<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1392</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1392</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bueno-Diaz, C.</style></author><author><style face="normal" font="default" size="100%">Martin-Pedraza, L.</style></author><author><style face="normal" font="default" size="100%">Leon, L.</style></author><author><style face="normal" font="default" size="100%">Haroun-Diaz, E.</style></author><author><style face="normal" font="default" size="100%">Pastor-Vargas, C.</style></author><author><style face="normal" font="default" size="100%">Munoz-Garcia, E.</style></author><author><style face="normal" font="default" size="100%">de Las Heras, M.</style></author><author><style face="normal" font="default" size="100%">Batanero, E.</style></author><author><style face="normal" font="default" size="100%">Cuesta-Herranz, J.</style></author><author><style face="normal" font="default" size="100%">Villalba, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, Universidad Complutense de Madrid, Madrid, Spain.&#xD;Allergy Service, Hospital Universitario Infanta Leonor, Madrid, Spain.&#xD;Hospital Universitario Fundacion Jimenez Diaz, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD, UAM), RETIC ARADyAL, Instituto de Salud Carlos III, Madrid, Spain.&#xD;Hospital Universitario de Getafe, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">2S albumins and 11S globulins, two storage proteins involved in pumpkin seeds allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">383-386</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Albumins</style></keyword><keyword><style face="normal" font="default" size="100%">*Cucurbita</style></keyword><keyword><style face="normal" font="default" size="100%">*Globulins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Seeds</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32706416</style></accession-num><notes><style face="normal" font="default" size="100%">Bueno-Diaz, Cristina&#xD;Martin-Pedraza, Laura&#xD;Leon, Laura&#xD;Haroun-Diaz, Elisa&#xD;Pastor-Vargas, Carlos&#xD;Munoz-Garcia, Esther&#xD;de Las Heras, Manuel&#xD;Batanero, Eva&#xD;Cuesta-Herranz, Javier&#xD;Villalba, Mayte&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):383-386. doi: 10.1111/all.14518. Epub 2020 Aug 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32706416</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14518</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2812</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2812</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brzoza, P.</style></author><author><style face="normal" font="default" size="100%">Camacho, M.</style></author><author><style face="normal" font="default" size="100%">Tyshchenko, M.</style></author><author><style face="normal" font="default" size="100%">Morytko, A.</style></author><author><style face="normal" font="default" size="100%">Kwitniewski, M.</style></author><author><style face="normal" font="default" size="100%">Pastuszczak, M.</style></author><author><style face="normal" font="default" size="100%">Stepinska, P.</style></author><author><style face="normal" font="default" size="100%">Migaczewski, M.</style></author><author><style face="normal" font="default" size="100%">Cichy, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.&#xD;Doctoral School of Exact and Natural Sciences, Jagiellonian University, Krakow, Poland.&#xD;Department of Dermatology, Medical University of Silesia, Zabrze, Poland.&#xD;2nd Department of General Surgery, Jagiellonian University Collegium Medicum, Krakow, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">3D Model of Human Epidermis Exposed to Staphylococci Reveals Keratinocyte Responses Unique to Atopy-Associated S. aureus Challenge</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2388-2391</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/03/13</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40079221</style></accession-num><notes><style face="normal" font="default" size="100%">Brzoza, Piotr&#xD;Camacho, Michelle&#xD;Tyshchenko, Mariia&#xD;Morytko, Agnieszka&#xD;Kwitniewski, Mateusz&#xD;Pastuszczak, Maciej&#xD;Stepinska, Paulina&#xD;Migaczewski, Marcin&#xD;Cichy, Joanna&#xD;eng&#xD;N19/MNS/000020/Jagiellonian University/&#xD;UMO-2014/12/W/NZ6/00454/Narodowe Centrum Nauki/&#xD;2019/35/B/NZ6/03357/Narodowe Centrum Nauki/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2388-2391. doi: 10.1111/all.16524. Epub 2025 Mar 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40079221</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368736</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16524</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>261</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">261</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nakamura, T.</style></author><author><style face="normal" font="default" size="100%">Tachibana, Y.</style></author><author><style face="normal" font="default" size="100%">Murata, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Animal Radiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">12-HETE promotes late-phase responses in a murine model of allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">574-577</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">12-Hydroxy-5,8,10,14-eicosatetraenoic Acid</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36208108</style></accession-num><notes><style face="normal" font="default" size="100%">Nakamura, Tatsuro&#xD;Tachibana, Yuri&#xD;Murata, Takahisa&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):574-577. doi: 10.1111/all.15547. Epub 2022 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36208108</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15547</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2120</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2120</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brustad, N.</style></author><author><style face="normal" font="default" size="100%">Kim, M.</style></author><author><style face="normal" font="default" size="100%">Skov, F.</style></author><author><style face="normal" font="default" size="100%">Schoos, A. M.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Chawes, B. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Pediatrics, Slagelse Hospital, Slagelse, Denmark.&#xD;Section of Microbiology and Fermentation, Department of Food Science, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">25-hydroxyvitamin D and risk of atopic diseases and infections in early childhood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2770-2773</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/05/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37129456</style></accession-num><notes><style face="normal" font="default" size="100%">Brustad, Nicklas&#xD;Kim, Min&#xD;Skov, Frederikke&#xD;Schoos, Ann-Marie&#xD;Stokholm, Jakob&#xD;Bonnelykke, Klaus&#xD;Chawes, Bo L&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2770-2773. doi: 10.1111/all.15759. Epub 2023 May 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37129456</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15759</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>431</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">431</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Louvrier, C.</style></author><author><style face="normal" font="default" size="100%">Awad, F.</style></author><author><style face="normal" font="default" size="100%">Amselem, S.</style></author><author><style face="normal" font="default" size="100%">Lipsker, D.</style></author><author><style face="normal" font="default" size="100%">Giurgea, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sorbonne Universite, Inserm, Childhood Genetic Disorders and Departement de Genetique Medicale, Assistance Publique-Hopitaux de Paris (APHP), Hopital Armand-Trousseau, Paris, France.&#xD;Service de Dermatologie, Hopitaux Universitaires de Strasbourg, Hopital Civil, Strasbourg, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Absence of NLRP3 somatic mutations and VEXAS-related UBA1 mutations in a large cohort of patients with Schnitzler syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3435-3436</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/06/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">NLR Family, Pyrin Domain-Containing 3 Protein/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Schnitzler Syndrome/diagnosis/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35713654</style></accession-num><notes><style face="normal" font="default" size="100%">Louvrier, Camille&#xD;Awad, Fawaz&#xD;Amselem, Serge&#xD;Lipsker, Dan&#xD;Giurgea, Irina&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3435-3436. doi: 10.1111/all.15411. Epub 2022 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35713654</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15411</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>366</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">366</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sasaki, M.</style></author><author><style face="normal" font="default" size="100%">Schwab, C.</style></author><author><style face="normal" font="default" size="100%">Ramirez Garcia, A.</style></author><author><style face="normal" font="default" size="100%">Li, Q.</style></author><author><style face="normal" font="default" size="100%">Ferstl, R.</style></author><author><style face="normal" font="default" size="100%">Bersuch, E.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Lauener, R.</style></author><author><style face="normal" font="default" size="100%">Ck-Care study group</style></author><author><style face="normal" font="default" size="100%">Frei, R.</style></author><author><style face="normal" font="default" size="100%">Roduit, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Children&apos;s Hospital Zurich, Zurich, Switzerland.&#xD;Department of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.&#xD;Laboratory of Food Biotechnology, Institute of Food, Nutrition and Health, ETH Zurich, Zurich, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Children&apos;s Hospital of Eastern Switzerland, St Gallen, Switzerland.&#xD;Division of Respiratory Medicine, Department of Paediatrics, Inselspital, University of Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The abundance of Ruminococcus bromii is associated with faecal butyrate levels and atopic dermatitis in infancy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3629-40</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/08/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">butyrate</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">resistant starch</style></keyword><keyword><style face="normal" font="default" size="100%">short chain fatty acid</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 2</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35917214</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Impaired microbial development and decreased levels of short chain fatty acids, particularly butyrate, is suggested to have a role in the development of atopic dermatitis (AD). METHODS: Faecal microbiota composition, abundance of selected bacterial groups and fermentation metabolites were compared at 90, 180 and 360 days of life between 27 children who developed AD by age one (AD group), and 39 controls (non-AD group) among the CARE (Childhood AlleRgy, nutrition and Environment) study cohort. RESULTS: Diversity within the Firmicutes and Bacteroidetes phylum in the faecal microbiota was lower in the AD group compared to the non-AD group. Longitudinal analysis showed multiple amplicon sequence variants (ASV) within the same bacterial family to be differentially abundant. Namely, Ruminococcus bromii, a keystone primary starch degrader, and Akkermansia muciniphila, a mucin-utilizer, had lower abundance among the AD group. Children with AD were less likely to have high levels of faecal butyrate at 360 days compared to those without AD (11.5% vs 34.2%). At 360 days, children with high abundance of R. bromii had higher level of butyrate as well as lower proportion of children with AD compared to children with low abundance of R. bromii (11.1-12.5% vs 44.4-52.5%), which was independent of the abundance of the major butyrate producers. CONCLUSION: Our results suggested that R. bromii and other primary degraders might play an important role in the differences in microbial cross-feeding and metabolite formation between children with and without AD, which may influence the risk of developing the disease.</style></abstract><notes><style face="normal" font="default" size="100%">Sasaki, Mari&#xD;Schwab, Clarissa&#xD;Ramirez Garcia, Alejandro&#xD;Li, Qing&#xD;Ferstl, Ruth&#xD;Bersuch, Eugen&#xD;Akdis, Cezmi A&#xD;Lauener, Roger&#xD;Frei, Remo&#xD;Roduit, Caroline&#xD;eng&#xD;Denmark&#xD;Allergy. 2022 Aug 2;77(12):3629-40. doi: 10.1111/all.15440.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35917214</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087690</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15440</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2851</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2851</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baichoo, N.</style></author><author><style face="normal" font="default" size="100%">Fishbein, J.</style></author><author><style face="normal" font="default" size="100%">Ponda, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy &amp; Immunology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, New Hyde Park, New York, USA.&#xD;Biostatistics Unit, Office of Academic Affairs, Northwell Health, New Hyde Park, New York, USA.&#xD;Division of Allergy and Immunology, Children&apos;s Hospital at Montefiore Einstein, Bronx, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Access to Epinephrine Autoinjectors, the Patient Perspective</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2879-2881</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/03/29</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40156482</style></accession-num><notes><style face="normal" font="default" size="100%">Baichoo, Nadia&#xD;Fishbein, Joanna&#xD;Ponda, Punita&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2879-2881. doi: 10.1111/all.16534. Epub 2025 Mar 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40156482</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16534</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>998</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">998</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suarez-Farinas, M.</style></author><author><style face="normal" font="default" size="100%">Suprun, M.</style></author><author><style face="normal" font="default" size="100%">Kearney, P.</style></author><author><style face="normal" font="default" size="100%">Getts, R.</style></author><author><style face="normal" font="default" size="100%">Grishina, G.</style></author><author><style face="normal" font="default" size="100%">Hayward, C.</style></author><author><style face="normal" font="default" size="100%">Luta, D.</style></author><author><style face="normal" font="default" size="100%">Porter, A.</style></author><author><style face="normal" font="default" size="100%">Witmer, M.</style></author><author><style face="normal" font="default" size="100%">du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Population Health Science and Policy and Department of Genetics and Genomics, Icahn School of Medicine, New York, NY, USA.&#xD;Department of Pediatrics, Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;AllerGenis LLC, Hatfield, PA, USA.&#xD;Data Incites LLC, Seattle, WA, USA.&#xD;King&apos;s College London, London, UK.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA, USA.&#xD;Departments of Pathology and Microbiology &amp; Immunology, Stanford University, Stanford, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Accurate and reproducible diagnosis of peanut allergy using epitope mapping</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3789-3797</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Epitope Mapping</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Bbea</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">peanut</style></keyword><keyword><style face="normal" font="default" size="100%">AllerGenis LLC. Ms. Suprun and Grishinahave nothing to disclose. Dr. Kearney, Mr.</style></keyword><keyword><style face="normal" font="default" size="100%">Hayward, Mr. Luta, Dr. Porter, Mr. Witmerare employees or paid consultants to</style></keyword><keyword><style face="normal" font="default" size="100%">AllerGenis. Dr. Getts is an employee of Genisphere LLC and scientific consultant</style></keyword><keyword><style face="normal" font="default" size="100%">of AllerGenis LLC</style></keyword><keyword><style face="normal" font="default" size="100%">in addition, Dr. Getts has a patent PCT/US15/020715 (WO)</style></keyword><keyword><style face="normal" font="default" size="100%">pending. Dr. du Toit has received research support from the NIAID (NO1-AI-15416</style></keyword><keyword><style face="normal" font="default" size="100%">[contract] and UM1AI109565 [grant], covering salary) and the UK Food Standards</style></keyword><keyword><style face="normal" font="default" size="100%">Agency</style></keyword><keyword><style face="normal" font="default" size="100%">has received a contribution to NIAID contract/grant from the Food Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Research &amp; Education</style></keyword><keyword><style face="normal" font="default" size="100%">has received a contribution to KCL Division of Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy &amp;Lung Biology from Medical Research Council (MRC) &amp; Asthma UK Centre</style></keyword><keyword><style face="normal" font="default" size="100%">has</style></keyword><keyword><style face="normal" font="default" size="100%">received the Biomedical Research Centre (BRC) award to Guy&apos;s and St Thomas&apos;</style></keyword><keyword><style face="normal" font="default" size="100%">National Health Service (NHS) Foundation from the UK Department of Health through</style></keyword><keyword><style face="normal" font="default" size="100%">the National Institute for Health Research (NIHR)</style></keyword><keyword><style face="normal" font="default" size="100%">and has received support for</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric allergy clinical trial&apos;s unit from the National Peanut Board. Dr. Lack</style></keyword><keyword><style face="normal" font="default" size="100%">has received research support from the NIAID (NO1-AI-15416 [contract] and</style></keyword><keyword><style face="normal" font="default" size="100%">UM1AI109565 [grant]), and UK Food Standards Agency</style></keyword><keyword><style face="normal" font="default" size="100%">is on the DBV Technologies</style></keyword><keyword><style face="normal" font="default" size="100%">scientific advisory board</style></keyword><keyword><style face="normal" font="default" size="100%">has received a contribution to NIAID contract/grant</style></keyword><keyword><style face="normal" font="default" size="100%">from Food Allergy Research and Education</style></keyword><keyword><style face="normal" font="default" size="100%">has received a contribution to KCL</style></keyword><keyword><style face="normal" font="default" size="100%">Division of Asthma Allergy &amp; Lung Biology from MRC &amp; Asthma UK Centre</style></keyword><keyword><style face="normal" font="default" size="100%">has</style></keyword><keyword><style face="normal" font="default" size="100%">received the BRC award to Guy&apos;s and St Thomas&apos; NHS Foundation from the UK</style></keyword><keyword><style face="normal" font="default" size="100%">Department of Health through NIHR</style></keyword><keyword><style face="normal" font="default" size="100%">has received support for pediatric allergy</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial&apos;s unit from the National Peanut Board</style></keyword><keyword><style face="normal" font="default" size="100%">has received discounted</style></keyword><keyword><style face="normal" font="default" size="100%">Bamba peanut snack from Osem</style></keyword><keyword><style face="normal" font="default" size="100%">and has stock/stock options in DBV Technologies.</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Chinthrajah reports grants from NIAID, CoFAR, Aimmune, DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">Astellas, Regeneron, FARE, and is an Advisory Board member for Alladapt,</style></keyword><keyword><style face="normal" font="default" size="100%">Genentech, Novartis, Sanofi, and received personal fees from Nutricia. Dr. Nadeau</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from National Institute of Allergy and Infectious Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">(NIAID), National Heart, Lung, and Blood Institute (NHLBI), and National</style></keyword><keyword><style face="normal" font="default" size="100%">Institute of Environmental Health Sciences (NIEHS)</style></keyword><keyword><style face="normal" font="default" size="100%">Food Allergy Research &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Education (FARE), Director of World Allergy Organization (WAO) Center of</style></keyword><keyword><style face="normal" font="default" size="100%">Excellence at Stanford</style></keyword><keyword><style face="normal" font="default" size="100%">Advisor at Cour Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">Co-founder of Before Brands,</style></keyword><keyword><style face="normal" font="default" size="100%">Alladapt, Latitude, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">National Scientific Committee member at Immune</style></keyword><keyword><style face="normal" font="default" size="100%">Tolerance Network (ITN) and National Institutes of Health (NIH) clinical research</style></keyword><keyword><style face="normal" font="default" size="100%">centers</style></keyword><keyword><style face="normal" font="default" size="100%">DSMB member for NHLBI, US patents for basophil testing, multifood</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and prevention, monoclonal antibody from plasmoblasts, and device</style></keyword><keyword><style face="normal" font="default" size="100%">for diagnostics. Dr. Galli reports grants from NIH, including NIAID U19AI104209.</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Sampson reports grants from Immune Tolerance Network</style></keyword><keyword><style face="normal" font="default" size="100%">NIAID/NIH, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from N-Fold Therapeutics and DBV Technologies, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and Mount Sinai has licensed the technology for a bead-based epitope assay for</style></keyword><keyword><style face="normal" font="default" size="100%">food-allergen epitope analyses to AllerGenis LLC. Dr. Sampson serves as an unpaid</style></keyword><keyword><style face="normal" font="default" size="100%">Board of Directors member and advisor to AllerGenis LLC.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33991353</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Accurate diagnosis of peanut allergy is a significant clinical challenge. Here, a novel diagnostic blood test using the peanut bead-based epitope assay (&quot;peanut BBEA&quot;) was developed utilizing the LEAP cohort and then validated using two independent cohorts. METHODS: The development of the peanut BBEA diagnostic test followed the National Academy of Medicine&apos;s established guidelines with discovery performed on 133 subjects from the non-interventional arm of the LEAP trial and an independent validation performed on 82 subjects from the CoFAR2 and 84 subjects from the POISED study. All samples were analyzed using the peanut BBEA methodology, which measures levels of IgE to two Ara h 2 sequential (linear) epitopes and compares their combination to a threshold pre-specified in the model development phase. When a patient has an inconclusive outcome by skin prick testing (or sIgE), IgE antibody levels to this combination of two epitopes can distinguish whether the patient is &quot;Allergic&quot; or &quot;Not Allergic.&quot; Diagnoses of peanut allergy in all subjects were confirmed by double-blind placebo-controlled food challenge and subjects&apos; ages were 7-55 years. RESULTS: In the validation using CoFAR2 and POISED cohorts, the peanut BBEA diagnostic test correctly diagnosed 93% of the subjects, with a sensitivity of 92%, specificity of 94%, a positive predictive value of 91%, and negative predictive value of 95%. CONCLUSIONS: In validation of the peanut BBEA diagnostic test, the overall accuracy was found to be superior to existing diagnostic tests for peanut allergy including skin prick testing, peanut sIgE, and peanut component sIgE testing.</style></abstract><notes><style face="normal" font="default" size="100%">Suarez-Farinas, Mayte&#xD;Suprun, Maria&#xD;Kearney, Paul&#xD;Getts, Robert&#xD;Grishina, Galina&#xD;Hayward, Clive&#xD;Luta, David&#xD;Porter, Alex&#xD;Witmer, Marc&#xD;du Toit, George&#xD;Lack, Gideon&#xD;Chinthrajah, Rebecca Sharon&#xD;Galli, Stephen J&#xD;Nadeau, Kari&#xD;Sampson, Hugh A&#xD;eng&#xD;T32 GM062754/GM/NIGMS NIH HHS/&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;Randomized Controlled Trial&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3789-3797. doi: 10.1111/all.14905. Epub 2021 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33991353</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8607840</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14905</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>999</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">999</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marin, C.</style></author><author><style face="normal" font="default" size="100%">Tubita, V.</style></author><author><style face="normal" font="default" size="100%">Langdon, C.</style></author><author><style face="normal" font="default" size="100%">Fuentes, M.</style></author><author><style face="normal" font="default" size="100%">Rojas-Lechuga, M. J.</style></author><author><style face="normal" font="default" size="100%">Valero, A.</style></author><author><style face="normal" font="default" size="100%">Alobid, I.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical &amp; Experimental Respiratory Immunoallergy (IRCE), Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.&#xD;Centre for Biomedical Investigation in Respiratory Diseases (CIBERES), Barcelona, Spain.&#xD;Universitat de Barcelona, Barcelona, Spain.&#xD;Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">ACE2 downregulation in olfactory mucosa: Eosinophilic rhinosinusitis as COVID-19 protective factor?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2904-2907</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Down-Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Olfactory Mucosa/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Peptidyl-Dipeptidase A/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Protective Factors</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Ace2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Tmprss2</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">olfactory neuroepithelium</style></keyword><keyword><style face="normal" font="default" size="100%">Mylan. Dr. Mullol has participated in advisory boards for, has received research</style></keyword><keyword><style face="normal" font="default" size="100%">grants from, or participated in speakers&apos; bureaus for AstraZeneca, Genentech,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Glenmark, Menarini, Mitsubishi-TanabePharma, MSD, Viatris</style></keyword><keyword><style face="normal" font="default" size="100%">(Mylan-Meda Pharmaceuticals), Novartis, Procter &amp; Gamble, Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Inc., Sanofi-Genzyme, UCB Pharma, and UriachGroup. Dr. Marin,</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Tubita, Dr. Langdon, M. Fuentes, M.J. Rojas-Lechuga, and Dr. Valero declare</style></keyword><keyword><style face="normal" font="default" size="100%">that they have no relevant conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33987850</style></accession-num><notes><style face="normal" font="default" size="100%">Marin, Concepcio&#xD;Tubita, Valeria&#xD;Langdon, Cristobal&#xD;Fuentes, Mireya&#xD;Rojas-Lechuga, Maria Jesus&#xD;Valero, Antonio&#xD;Alobid, Isam&#xD;Mullol, Joaquim&#xD;eng&#xD;FIS PI19/00806/Ministerio de Ciencia, Innovacion y Universidades/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2904-2907. doi: 10.1111/all.14904. Epub 2021 May 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33987850</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8222895</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14904</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1610</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1610</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marin, C.</style></author><author><style face="normal" font="default" size="100%">Tubita, V.</style></author><author><style face="normal" font="default" size="100%">Langdon, C.</style></author><author><style face="normal" font="default" size="100%">Fuentes, M.</style></author><author><style face="normal" font="default" size="100%">Rojas-Lechuga, M. J.</style></author><author><style face="normal" font="default" size="100%">Valero, A.</style></author><author><style face="normal" font="default" size="100%">Alobid, I.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical &amp; Experimental Respiratory Immunoallergy (IRCE), Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.&#xD;Centre for Biomedical Investigation in Respiratory Diseases (CIBERES), Barcelona, Spain.&#xD;Universitat de Barcelona, Barcelona, Spain.&#xD;Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">ACE2 downregulation in olfactory mucosa: Eosinophilic rhinosinusitis as COVID-19 protective factor?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2904-2907</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Down-Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Olfactory Mucosa/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Peptidyl-Dipeptidase A/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Protective Factors</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Ace2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Tmprss2</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">olfactory neuroepithelium</style></keyword><keyword><style face="normal" font="default" size="100%">Mylan. Dr. Mullol has participated in advisory boards for, has received research</style></keyword><keyword><style face="normal" font="default" size="100%">grants from, or participated in speakers&apos; bureaus for AstraZeneca, Genentech,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Glenmark, Menarini, Mitsubishi-TanabePharma, MSD, Viatris</style></keyword><keyword><style face="normal" font="default" size="100%">(Mylan-Meda Pharmaceuticals), Novartis, Procter &amp; Gamble, Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Inc., Sanofi-Genzyme, UCB Pharma, and UriachGroup. Dr. Marin,</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Tubita, Dr. Langdon, M. Fuentes, M.J. Rojas-Lechuga, and Dr. Valero declare</style></keyword><keyword><style face="normal" font="default" size="100%">that they have no relevant conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33987850</style></accession-num><notes><style face="normal" font="default" size="100%">Marin, Concepcio&#xD;Tubita, Valeria&#xD;Langdon, Cristobal&#xD;Fuentes, Mireya&#xD;Rojas-Lechuga, Maria Jesus&#xD;Valero, Antonio&#xD;Alobid, Isam&#xD;Mullol, Joaquim&#xD;eng&#xD;FIS PI19/00806/Ministerio de Ciencia, Innovacion y Universidades/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2904-2907. doi: 10.1111/all.14904. Epub 2021 May 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33987850</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8222895</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14904</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3081</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3081</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, B.</style></author><author><style face="normal" font="default" size="100%">Lu, T.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Xiong, P.</style></author><author><style face="normal" font="default" size="100%">Zeng, J.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Jiang, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Shu, L.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Gu, Y.</style></author><author><style face="normal" font="default" size="100%">Guan, D.</style></author><author><style face="normal" font="default" size="100%">Li, C.</style></author><author><style face="normal" font="default" size="100%">Zhao, L.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Ke, X.</style></author><author><style face="normal" font="default" size="100%">Shen, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Upper Airway Inflammation and Tumor Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.&#xD;Centre for Lipid Research &amp; Chongqing Key Laboratory of Metabolism on Lipid and Glucose, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.&#xD;Institute of Life Sciences, School of Basic Medicine, Chongqing Medical University, Chongqing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Acetylcholine From Solitary Chemosensory Cell, Not Neuron, Regulates Basal Cell Fate Driving Eosinophilic Chronic Rhinosinusitis With Nasal Polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">acetylcholine</style></keyword><keyword><style face="normal" font="default" size="100%">basal cell</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">solitary chemosensory cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40951952</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Basal cells (BCs) play a crucial role in epithelial remodeling, a hallmark of eosinophilic chronic rhinosinusitis with nasal polyps (eCRSwNP). Single-cell sequencing has revealed an increased number of solitary chemosensory cells (SCCs) alongside BC hyperplasia in eCRSwNP, yet the underlying mechanism of BC hyperplasia in eCRSwNP remains unclear. This study aimed to investigate the role of SCC-derived acetylcholine (Ach) in determining BC fate. METHODS: Tissue samples from healthy individuals, patients with eCRSwNP, and those with non-eCRSwNP (neCRSwNP) were analyzed to investigate BC proliferation, differentiation abnormalities, and the prevalence of SCCs. The relationship between SCC-derived Ach, BC dysfunction, and disease severity was examined. Ach sources and receptor expression patterns were characterized. In vitro studies using submerged cell cultures and air-liquid interface cultures, along with in vivo murine models, were employed to elucidate the mechanisms by which Ach influences BC fate. The inhibitory effects of tiotropium bromide (TB) on Ach-driven processes were also evaluated. RESULTS: Our results indicated that SCC-derived Ach, rather than by parasympathetic nerves, contributed to abnormal BC proliferation and differentiation through muscarinic acetylcholine receptors (mAChRs) and had potential impact on the development of eCRSwNP. These effects were associated with the activation of YAP and could be partially reversed both in vitro and in vivo by blocking mAChRs with TB. CONCLUSION: These results demonstrate that SCC-derived Ach plays a critical role in eCRSwNP by regulating BC fate. This provides a potential translational framework for developing prevention and treatment strategies targeting the cholinergic pathway.</style></abstract><notes><style face="normal" font="default" size="100%">Zheng, Bowen&#xD;Lu, Tao&#xD;Wang, Ji&#xD;Zhang, Yalan&#xD;Xiong, Panhui&#xD;Zeng, Jieyu&#xD;Li, Shuman&#xD;Jiang, Yu&#xD;Liu, Yijun&#xD;Shu, Longlan&#xD;Chen, Yuan&#xD;Zhou, Yin&#xD;Gu, Yue&#xD;Guan, Dayu&#xD;Li, Chenxi&#xD;Zhao, Lei&#xD;Wang, Shujin&#xD;Liu, Jie&#xD;Ke, Xia&#xD;Shen, Yang&#xD;Yang, Yucheng&#xD;eng&#xD;China Postdoctoral Science Foundation/&#xD;The National Natural Science Foundation of China/&#xD;Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau)/&#xD;National Key Research and Development Program of China/&#xD;Foundation of State Key Laboratory of Ultrasound in Medicine and Engineering/&#xD;The Natural Science Foundation of Chongqing, China/&#xD;Denmark&#xD;Allergy. 2025 Sep 15. doi: 10.1111/all.70048.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40951952</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70048</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3267</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3267</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Ruikun</style></author><author><style face="normal" font="default" size="100%">Xu, Ziying</style></author><author><style face="normal" font="default" size="100%">Zhang, Yimin</style></author><author><style face="normal" font="default" size="100%">Wang, Qian</style></author><author><style face="normal" font="default" size="100%">Li, Mengyao</style></author><author><style face="normal" font="default" size="100%">Liang, Jieqiong</style></author><author><style face="normal" font="default" size="100%">Zhan, Xiaojun</style></author><author><style face="normal" font="default" size="100%">Lu, YinXia</style></author><author><style face="normal" font="default" size="100%">Yuan, Jing</style></author><author><style face="normal" font="default" size="100%">Wang, Shan</style></author><author><style face="normal" font="default" size="100%">Gu, Qinglong</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Acetylome Analyses Provide New Insights Into the Effects of Childhood Allergic Rhinitis on Olfactory Bulb-Dependent Olfactory Impairment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70254</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70254</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2376</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2376</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yanagisawa, R.</style></author><author><style face="normal" font="default" size="100%">Koike, Y.</style></author><author><style face="normal" font="default" size="100%">Usami, Y.</style></author><author><style face="normal" font="default" size="100%">Kanai, A.</style></author><author><style face="normal" font="default" size="100%">Tokunaga, M.</style></author><author><style face="normal" font="default" size="100%">Tozuka, M.</style></author><author><style face="normal" font="default" size="100%">Ito, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Blood Transfusion, Shinshu University Hospital, Matsumoto, Japan.&#xD;Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan.&#xD;Life Science Research Center, Nagano Children&apos;s Hospital, Azumino, Japan.&#xD;Department of Allergy, Nagano Children&apos;s Hospital, Azumino, Japan.&#xD;Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Activation of basophils in children with food allergies by blood from donors ingesting the corresponding food</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1602-1605</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/01/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Donors</style></keyword><keyword><style face="normal" font="default" size="100%">Food/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology/administration &amp; dosage</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38205723</style></accession-num><notes><style face="normal" font="default" size="100%">Yanagisawa, Ryu&#xD;Koike, Yumi&#xD;Usami, Yoko&#xD;Kanai, Ayako&#xD;Tokunaga, Mai&#xD;Tozuka, Minoru&#xD;Ito, Yasunori&#xD;eng&#xD;Japan Society for the Promotion of Science/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1602-1605. doi: 10.1111/all.16013. Epub 2024 Jan 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38205723</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16013</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>617</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">617</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tang, X.</style></author><author><style face="normal" font="default" size="100%">Ronnberg, E.</style></author><author><style face="normal" font="default" size="100%">Safholm, J.</style></author><author><style face="normal" font="default" size="100%">Thulasingam, M.</style></author><author><style face="normal" font="default" size="100%">Trauelsen, M.</style></author><author><style face="normal" font="default" size="100%">Schwartz, T. W.</style></author><author><style face="normal" font="default" size="100%">Wheelock, C. E.</style></author><author><style face="normal" font="default" size="100%">Dahlen, S. E.</style></author><author><style face="normal" font="default" size="100%">Nilsson, G.</style></author><author><style face="normal" font="default" size="100%">Haeggstrom, J. Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.&#xD;Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, and Karolinska University Hospital, Solna, Sweden.&#xD;Unit of Experimental Asthma and Allergy Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Respiratory Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.&#xD;Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Activation of succinate receptor 1 boosts human mast cell reactivity and allergic bronchoconstriction</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2677-2687</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/02/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoconstriction</style></keyword><keyword><style face="normal" font="default" size="100%">Guinea Pigs</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Succinates/metabolism/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Sucnr1</style></keyword><keyword><style face="normal" font="default" size="100%">allergic bronchoconstriction</style></keyword><keyword><style face="normal" font="default" size="100%">eicosanoid</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell hyper-reactivity</style></keyword><keyword><style face="normal" font="default" size="100%">succinate</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35122266</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: SUCNR1 is a sensor of extracellular succinate, a Krebs cycle intermediate generated in excess during oxidative stress and has been linked to metabolic regulation and inflammation. While mast cells express SUCNR1, its role in mast cell reactivity and allergic conditions such as asthma remains to be elucidated. METHODS: Cord blood-derived mast cells and human mast cell line LAD-2 challenged by SUCNR1 ligands were analyzed for the activation and mediator release. Effects on mast cell-dependent bronchoconstriction were assessed in guinea pig trachea and isolated human small bronchi challenged with antigen and anti-IgE, respectively. RESULTS: SUCNR1 is abundantly expressed on human mast cells. Challenge with succinate, or the synthetic non-metabolite agonist cis-epoxysuccinate, renders mast cells hypersensitive to IgE-dependent activation, resulting in augmented degranulation and histamine release, de novo biosynthesis of eicosanoids and cytokine secretion. The succinate-potentiated mast cell reactivity was attenuated by SUCNR1 knockdown and selective SUCNR1 antagonists and could be tuned by pharmacologically targeting protein kinase C and extracellular signal-regulated kinase. Both succinate and cis-epoxysuccinate dose-dependently potentiated antigen-induced contraction in a mast cell-dependent guinea pig airway model, associated with increased generation of cysteinyl-leukotrienes and histamine in trachea. Similarly, cis-epoxysuccinate aggravated IgE-receptor-induced contraction of human bronchi, which was blocked by SUCNR1 antagonism. CONCLUSION: SUCNR1 amplifies IgE-receptor-induced mast cell activation and allergic bronchoconstriction, suggesting a role for this pathway in aggravation of allergic asthma, thus linking metabolic perturbations to mast cell-dependent inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Tang, Xiao&#xD;Ronnberg, Elin&#xD;Safholm, Jesper&#xD;Thulasingam, Madhuranayaki&#xD;Trauelsen, Mette&#xD;Schwartz, Thue W&#xD;Wheelock, Craig E&#xD;Dahlen, Sven-Erik&#xD;Nilsson, Gunnar&#xD;Haeggstrom, Jesper Z&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2677-2687. doi: 10.1111/all.15245. Epub 2022 Feb 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35122266</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9545225</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15245</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>857</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">857</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhong, B.</style></author><author><style face="normal" font="default" size="100%">Du, J.</style></author><author><style face="normal" font="default" size="100%">Liu, F.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, S.</style></author><author><style face="normal" font="default" size="100%">Xie, L.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Ba, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Upper Airways Research Laboratory, Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, China.&#xD;Department of Otolaryngology, People&apos;s Hospital of Tibet Autonomous Region, Lhasa, China.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Activation of the mTOR/HIF-1alpha/VEGF axis promotes M1 macrophage polarization in non-eosinophilic chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">643-646</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/08/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">TOR Serine-Threonine Kinases</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-induced factor-1alpha</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">macrophage</style></keyword><keyword><style face="normal" font="default" size="100%">mammalian target of rapamycin</style></keyword><keyword><style face="normal" font="default" size="100%">vascular endothelial growth factor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34390596</style></accession-num><notes><style face="normal" font="default" size="100%">Zhong, Bing&#xD;Du, Jintao&#xD;Liu, Feng&#xD;Liu, Yafeng&#xD;Liu, Shixi&#xD;Xie, Lifeng&#xD;Wang, De Yun&#xD;Ba, Luo&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):643-646. doi: 10.1111/all.15050. Epub 2021 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34390596</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15050</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1953</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1953</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sampath, V.</style></author><author><style face="normal" font="default" size="100%">Shalakhti, O.</style></author><author><style face="normal" font="default" size="100%">Veidis, E.</style></author><author><style face="normal" font="default" size="100%">Efobi, J. A. I.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Skevaki, C.</style></author><author><style face="normal" font="default" size="100%">Renz, H.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy and Asthma Research at Stanford University, California, Stanford, USA.&#xD;Center for Innovation in Global Health, Stanford University, California, Stanford, USA.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Institute of Laboratory Medicine, Member of the German Center for Lung Research (DZL), Philipps-University Marburg, Marburg, Germany.&#xD;German Center for Lung Research (DZL), Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg, Marburg, Germany.&#xD;Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia.&#xD;Kilimanjaro Christian Medical University College (KCMUCo), Moshi, Tanzania.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Acute and chronic impacts of heat stress on planetary health</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2109-2120</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Heat-Shock Response</style></keyword><keyword><style face="normal" font="default" size="100%">*Photosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidants</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Physiological</style></keyword><keyword><style face="normal" font="default" size="100%">climate change</style></keyword><keyword><style face="normal" font="default" size="100%">global warming</style></keyword><keyword><style face="normal" font="default" size="100%">health</style></keyword><keyword><style face="normal" font="default" size="100%">heat stress</style></keyword><keyword><style face="normal" font="default" size="100%">planetary health</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36883412</style></accession-num><abstract><style face="normal" font="default" size="100%">Heat waves are increasing in intensity, frequency, and duration causing significant heat stress in all living organisms. Heat stress has multiple negative effects on plants affecting photosynthesis, respiration, growth, development, and reproduction. It also impacts animals leading to physiological and behavioral alterations, such as reduced caloric intake, increased water intake, and decreased reproduction and growth. In humans, epidemiological studies have shown that heat waves are associated with increased morbidity and mortality. There are many biological effects of heat stress (structural changes, enzyme function disruption, damage through reactive oxygen or nitrogen species). While plants and animals can mitigate some of these effects through adaptive mechanisms such as the generation of heat shock proteins, antioxidants, stress granules, and others, these mechanisms may likely be inadequate with further global warming. This review summarizes the effects of heat stress on plants and animals and the adaptative mechanisms that have evolved to counteract this stress.</style></abstract><notes><style face="normal" font="default" size="100%">Sampath, Vanitha&#xD;Shalakhti, Omar&#xD;Veidis, Erika&#xD;Efobi, Jo Ann Ifeoma&#xD;Shamji, Mohamed H&#xD;Agache, Ioana&#xD;Skevaki, Chrysanthi&#xD;Renz, Harald&#xD;Nadeau, Kari C&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2109-2120. doi: 10.1111/all.15702. Epub 2023 Apr 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36883412</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15702</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1002</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1002</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Centonze, A.</style></author><author><style face="normal" font="default" size="100%">Capillo, S.</style></author><author><style face="normal" font="default" size="100%">Mazzei, A.</style></author><author><style face="normal" font="default" size="100%">Salerno, D.</style></author><author><style face="normal" font="default" size="100%">Sinopoli, D.</style></author><author><style face="normal" font="default" size="100%">Prosperi Porta, I.</style></author><author><style face="normal" font="default" size="100%">Baldassarre, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatric Surgery, Pugliese-Ciaccio Hospital, Catanzaro, Italia.&#xD;Department of Emergency Medicine, ASL Valle d&apos;Aosta, Aosta, Italia.&#xD;Department of Andrology and Paediatric Urology, ASL Valle d&apos;Aosta, Aosta, Italia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Acute scrotum in a 8-year-old Italian child caused by extraintestinal anisakiasis in a seaside area</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1601-1602</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/05/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Anisakiasis</style></keyword><keyword><style face="normal" font="default" size="100%">*Anisakis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Italy</style></keyword><keyword><style face="normal" font="default" size="100%">Japan</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Scrotum</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33983662</style></accession-num><notes><style face="normal" font="default" size="100%">Centonze, Antonella&#xD;Capillo, Stellario&#xD;Mazzei, Aurelio&#xD;Salerno, Domenico&#xD;Sinopoli, Domenico&#xD;Prosperi Porta, Ilaria&#xD;Baldassarre, Emanuele&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1601-1602. doi: 10.1111/all.14779.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33983662</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14779</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>967</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">967</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;CK-CARE, Christine Kuhne Center for Allergy Research and Education, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adding the variable of environmental complexity into the COVID-19 pandemic equation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">331-333</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV</style></keyword><keyword><style face="normal" font="default" size="100%">aerobiology</style></keyword><keyword><style face="normal" font="default" size="100%">pollen</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34047383</style></accession-num><notes><style face="normal" font="default" size="100%">Damialis, Athanasios&#xD;Gilles, Stefanie&#xD;Traidl-Hoffmann, Claudia&#xD;eng&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):331-333. doi: 10.1111/all.14966. Epub 2021 Jun 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34047383</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8222880</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14966</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1891</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1891</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;CK-CARE, Christine Kuhne Center for Allergy Research and Education, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adding the variable of environmental complexity into the COVID-19 pandemic equation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">331-333</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV</style></keyword><keyword><style face="normal" font="default" size="100%">aerobiology</style></keyword><keyword><style face="normal" font="default" size="100%">pollen</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34047383</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract In a recently published data-orientedstudyin March 2021, a relationship between SARS-CoV-2 infection rates and airborne pollen concentrationswas detected [1]. The studyincluded a data compilation of airborne pollen concentrations and SARS-CoV-2 infection numbers across 31 countries from both hemispheres and all inhabited continents from an inter-disciplinary team consisting of 154 scientists. The salient finding wasa significant and positive correlation between SARS-CoV-2 infection rates and airborne pollen concentrations in the spring of 2020 for the majority of examined countries, in synergy with air temperature and/or relative humidity (Fig. 1).</style></abstract><notes><style face="normal" font="default" size="100%">Damialis, Athanasios&#xD;Gilles, Stefanie&#xD;Traidl-Hoffmann, Claudia&#xD;eng&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):331-333. doi: 10.1111/all.14966. Epub 2021 Jun 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34047383</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8222880</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14966</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2223</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2223</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Esposito, G.</style></author><author><style face="normal" font="default" size="100%">Fergadiotou, I.</style></author><author><style face="normal" font="default" size="100%">Goroncy, C.</style></author><author><style face="normal" font="default" size="100%">Guitton, P.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Erotokritou, K.</style></author><author><style face="normal" font="default" size="100%">Jartti, T.</style></author><author><style face="normal" font="default" size="100%">Murray, C.</style></author><author><style face="normal" font="default" size="100%">Nenes, A.</style></author><author><style face="normal" font="default" size="100%">Nikoletseas, S.</style></author><author><style face="normal" font="default" size="100%">Finotto, S.</style></author><author><style face="normal" font="default" size="100%">Pandis, S. N.</style></author><author><style face="normal" font="default" size="100%">Ramiconi, V.</style></author><author><style face="normal" font="default" size="100%">Simpson, A.</style></author><author><style face="normal" font="default" size="100%">Soudunsaari, A.</style></author><author><style face="normal" font="default" size="100%">Starbrost, A.</style></author><author><style face="normal" font="default" size="100%">Staiano, M.</style></author><author><style face="normal" font="default" size="100%">Varriale, A.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">SynAir, G. Consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland, Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Ecology, School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Bio Check Up (BCU), Naples, Italy.&#xD;INLECOM INNOVATION, Kifissia, Greece.&#xD;DIN Deutsches Institut fuer Normung EV, Berlin, Germany.&#xD;TEQOYA Company, Paris, France.&#xD;Center for Allergy and Immunology Research (CAIR), Tbilisi, Georgia.&#xD;CY.R.I.C Cyprus Research and Innovation Center Ltd, Nicosia, Cyprus.&#xD;PEDEGO Research Unit, University of Oulu, Oulu, Finland.&#xD;Department of Pediatrics, Oulu University Hospital, Oulu, Finland.&#xD;Department of Pediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.&#xD;Laboratory of Atmospheric Processes and their Impacts, School of Architecture, Civil and Environmental Engineering, Swiss Institute of Technology, Lausanne, Switzerland.&#xD;Computer Engineering and Informatics Department, University of Patras, Patras, Greece.&#xD;Molecular Pneumology Department, University Hospital of Erlangen, Erlangen, Germany.&#xD;Institute of Chemical Engineering Sciences (ICEHT), Foundation for Research and Technology Hellas (FORTH), Patras, Greece.&#xD;The European Federation of Allergy and Airways Diseases Patients&apos; Association (EFA), Brussels, Belgium.&#xD;NAAVA, Helsinki, Finland.&#xD;Lulea University of Technology, Lulea, Sweden.&#xD;Institute of Food Science, CNR Italy, Avellino, Italy.&#xD;URT-ISA, CNR at Department of Biology, University of Naples Federico II, Naples, Italy.&#xD;Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Global Allergy &amp; Asthma European Network of Excellence-GA2LEN, Berlin, Germany.&#xD;Department of Allergic and Respiratory Disease, Institut Desbrest of Epidemiology and Public Health, University of Montpellier and INSERM, Montpellier University Hospital, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Addressing adverse synergies between chemical and biological pollutants at schools-The &apos;SynAir-G&apos; hypothesis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">294-301</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/09/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution, Indoor/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Pollutants</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Particulate Matter</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">aerobiology</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">artificial intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biosensors</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">school</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword><keyword><style face="normal" font="default" size="100%">volatile organic compounds</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37654007</style></accession-num><abstract><style face="normal" font="default" size="100%">While the number and types of indoor air pollutants is rising, much is suspected but little is known about the impact of their potentially synergistic interactions, upon human health. Gases, particulate matter, organic compounds but also allergens and viruses, fall within the &apos;pollutant&apos; definition. Distinct populations, such as children and allergy and asthma sufferers are highly susceptible, while a low socioeconomic background is a further susceptibility factor; however, no specific guidance is available. We spend most of our time indoors; for children, the school environment is of paramount importance and potentially amenable to intervention. The interactions between some pollutant classes have been studied. However, a lot is missing with respect to understanding interactions between specific pollutants of different classes in terms of concentrations, timing and sequence, to improve targeting and upgrade standards. SynAir-G is a European Commission-funded project aiming to reveal and quantify synergistic interactions between different pollutants affecting health, from mechanisms to real life, focusing on the school setting. It will develop a comprehensive and responsive multipollutant monitoring system, advance environmentally friendly interventions, and disseminate the generated knowledge to relevant stakeholders in accessible and actionable formats. The aim of this article it to put forward the SynAir-G hypothesis, and describe its background and objectives.</style></abstract><notes><style face="normal" font="default" size="100%">Papadopoulos, Nikolaos G&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Damialis, Athanasios&#xD;Esposito, Giuseppina&#xD;Fergadiotou, Ioana&#xD;Goroncy, Christian&#xD;Guitton, Pierre&#xD;Gotua, Maia&#xD;Erotokritou, Kleanthis&#xD;Jartti, Tuomas&#xD;Murray, Clare&#xD;Nenes, Athanasios&#xD;Nikoletseas, Sotirios&#xD;Finotto, Susetta&#xD;Pandis, Spyros N&#xD;Ramiconi, Valeria&#xD;Simpson, Angela&#xD;Soudunsaari, Aki&#xD;Starbrost, Anna&#xD;Staiano, Maria&#xD;Varriale, Antonio&#xD;Xepapadaki, Paraskevi&#xD;Zuberbier, Torsten&#xD;Annesi-Maesano, Isabella&#xD;eng&#xD;101057271/HORIZON EUROPE Health/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):294-301. doi: 10.1111/all.15857. Epub 2023 Aug 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37654007</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15857</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>544</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">544</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Phillips, E. J.</style></author><author><style face="normal" font="default" size="100%">Demoly, P.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Institute for Immunology &amp; Infectious Diseases, Murdoch University, Murdoch, WA, Australia.&#xD;Division of Allergy, Department of Pulmonology, University Hospital of Montepellier, and IDESP, Univ. Montpellier - Inserm, Montpellier, France.&#xD;Departmento de Medicina, Allergy Unit, Hospital Regional Universitario de Malaga-IBIMA-BIONAND-ARADyAL, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Addressing beta-lactam allergy: A time for action</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1091-1093</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/03/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*beta-Lactams/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35344217</style></accession-num><notes><style face="normal" font="default" size="100%">Phillips, Elizabeth J&#xD;Demoly, Pascal&#xD;Torres, Maria J&#xD;eng&#xD;P50 GM115305/GM/NIGMS NIH HHS/&#xD;R01 HG010863/HG/NHGRI NIH HHS/&#xD;R01 AI152183/AI/NIAID NIH HHS/&#xD;U01 AI154659/AI/NIAID NIH HHS/&#xD;Editorial&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1091-1093. doi: 10.1111/all.15135.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35344217</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15135</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2964</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2964</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alves, P. B.</style></author><author><style face="normal" font="default" size="100%">Pablo-Torres, C.</style></author><author><style face="normal" font="default" size="100%">Karavelia, A.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Vecillas, L. L.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy and Clinical Immunology Department, ULS Coimbra, Coimbra, Portugal.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;ENT Department, General Hospital of Kalamata, Kalamata, Greece.&#xD;Immunology Department, IIS-Fundacion Jimenez Diaz, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Allergy Unit, Department of Medicine and Dermatology, UMA, Hospital Regional Universitario de Malaga-IBIMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Addressing the Growing Role of Junior Members in EAACI</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2682-2685</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/07/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">education</style></keyword><keyword><style face="normal" font="default" size="100%">ethics</style></keyword><keyword><style face="normal" font="default" size="100%">personlized medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40726202</style></accession-num><notes><style face="normal" font="default" size="100%">Alves, Pedro Botelho&#xD;Pablo-Torres, Carmela&#xD;Karavelia, Aspasia&#xD;Fernandez-Santamaria, Ruben&#xD;Giovannini, Mattia&#xD;Vecillas, Leticia de Las&#xD;Shamji, Mohammed&#xD;Torres, Maria Jose&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2682-2685. doi: 10.1111/all.16681. Epub 2025 Jul 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40726202</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16681</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1993</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1993</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Schmitt, J.</style></author><author><style face="normal" font="default" size="100%">Demoly, P.</style></author><author><style face="normal" font="default" size="100%">Hilberg, O.</style></author><author><style face="normal" font="default" size="100%">DuBuske, L.</style></author><author><style face="normal" font="default" size="100%">Hass, N.</style></author><author><style face="normal" font="default" size="100%">Klok, T.</style></author><author><style face="normal" font="default" size="100%">Beutner, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Laboratoire de Pharmacologie Respiratoire - VIM Suresnes, Hopital Foch, Suresnes Universite Paris Saclay, Gif-sur-Yvette, France.&#xD;Center for Evidence-based Healthcare, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.&#xD;IDESP, UMR UA11 University Hospital of Montpellier - INSERM, Montpellier, France.&#xD;Department of Internal Medicine, Lillebaelt Hospital, Vejle, Denmark.&#xD;George Washington University Hospital, Washington, District of Columbia, USA.&#xD;Global Allergy and Airways Patient Platform (GAAPP), Vienna, Austria.&#xD;Paediatric Allergy Treatment Centre, Deventer Hospital, Deventer, The Netherlands.&#xD;Department of Dermatology, Venereology and Allergology, University Medical Center Gottingen, Gottingen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adherence and persistence in allergen immunotherapy (APAIT): A reporting checklist for retrospective studies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2277-2289</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/03/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Checklist</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">checklist</style></keyword><keyword><style face="normal" font="default" size="100%">compliance</style></keyword><keyword><style face="normal" font="default" size="100%">medication adherence</style></keyword><keyword><style face="normal" font="default" size="100%">persistence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36971779</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Adherence is essential for the long-term efficacy of allergen immunotherapy (AIT) and has been evaluated in numerous retrospective studies. However, there are no published guidelines for best practice in measuring and reporting adherence or persistence to AIT, which has resulted in substantial heterogeneity among existing studies. The &apos;adherence and persistence in AIT (APAIT)&apos; checklist has been developed to guide the reporting, design and interpretation of retrospective studies that evaluate adherence or persistence to AIT in clinical practice. METHODS: Five existing checklists, focussing on study protocol design, the use of retrospective databases/patient registries, and the appraisal and reporting of observational studies, were identified and merged. Relevant items were selected and tailored to be specific to AIT. The content of the checklist was discussed by 11 experts from Europe, the United States and Canada, representing allergy, healthcare and life sciences, and health technology appraisal. RESULTS: The APAIT checklist presents a set of items that should either be included or at least considered, when reporting retrospective studies that assess adherence or persistence to AIT. Items are organized into four categories comprising study objective, design and methods, data analysis, and results and discussion. The checklist highlights the need for clarity and transparency in reporting and emphasizes the importance of considering potential sources of bias in retrospective studies evaluating adherence or persistence to AIT. CONCLUSIONS: The APAIT checklist provides a pragmatic guide for reporting retrospective adherence and persistence studies in AIT. Importantly, it identifies potential sources of bias and discusses how these influence outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Devillier, Philippe&#xD;Schmitt, Jochen&#xD;Demoly, Pascal&#xD;Hilberg, Ole&#xD;DuBuske, Lawrence&#xD;Hass, Nicole&#xD;Klok, Ted&#xD;Beutner, Caroline&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2277-2289. doi: 10.1111/all.15723. Epub 2023 Apr 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36971779</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15723</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1198</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1198</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">d&apos;Ancona, G.</style></author><author><style face="normal" font="default" size="100%">Kavanagh, J. E.</style></author><author><style face="normal" font="default" size="100%">Dhariwal, J.</style></author><author><style face="normal" font="default" size="100%">Hearn, A. P.</style></author><author><style face="normal" font="default" size="100%">Roxas, C.</style></author><author><style face="normal" font="default" size="100%">Fernandes, M.</style></author><author><style face="normal" font="default" size="100%">Green, L.</style></author><author><style face="normal" font="default" size="100%">Thomson, L.</style></author><author><style face="normal" font="default" size="100%">Nanzer, A. M.</style></author><author><style face="normal" font="default" size="100%">Jackson, D. J.</style></author><author><style face="normal" font="default" size="100%">Kent, B. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Guy&apos;s Severe Asthma Centre, Guy&apos;s and St Thomas&apos; Hospitals, London, UK.&#xD;Asthma UK Centre, King&apos;s College London, London, UK.&#xD;Department of Respiratory Medicine, St James&apos; Hospital, Dublin, Ireland.&#xD;School of Medicine, Trinity College Dublin, Dublin, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2238-2241</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Eosinophilia/drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33432682</style></accession-num><notes><style face="normal" font="default" size="100%">d&apos;Ancona, Grainne&#xD;Kavanagh, Joanne E&#xD;Dhariwal, Jaideep&#xD;Hearn, Andrew P&#xD;Roxas, Cris&#xD;Fernandes, Mariana&#xD;Green, Linda&#xD;Thomson, Louise&#xD;Nanzer, Alexandra M&#xD;Jackson, David J&#xD;Kent, Brian D&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2238-2241. doi: 10.1111/all.14737. Epub 2021 Jan 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33432682</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14737</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3083</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3083</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vassilopoulou, E.</style></author><author><style face="normal" font="default" size="100%">Karastogiannidou, C.</style></author><author><style face="normal" font="default" size="100%">Comotti, A.</style></author><author><style face="normal" font="default" size="100%">Agostoni, C.</style></author><author><style face="normal" font="default" size="100%">Maragkou, M. K.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Pasioti, M.</style></author><author><style face="normal" font="default" size="100%">Lithoxopoulou, M.</style></author><author><style face="normal" font="default" size="100%">Feketea, G.</style></author><author><style face="normal" font="default" size="100%">Tsabouri, S.</style></author><author><style face="normal" font="default" size="100%">Milani, G. P.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nutritional Sciences and Dietetics, School of Health Sciences, International Hellenic University, Thessaloniki, Greece.&#xD;Department of Clinical Sciences and Community Health, Universita degli Studi di Milano, Milan, Italy.&#xD;Nous Therapy Center, Thessaloniki, Greece.&#xD;Department of Life Sciences, School of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus.&#xD;Pediatric Unit, Fondazione IRCCS Ca&apos; Granda-Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Occupational Health Unit, Foundation IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;2nd Department of Neonatology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Department of Pharmacology, &quot;Luliu Hatieganu&quot; University of Medicine and Pharmacy, Cluj-Napoca, Romania.&#xD;&quot;Karamandaneio&quot; Children&apos;s Hospital of Patra, Patra, Greece.&#xD;Department of Pediatrics, School of Medicine, University of Ioannina, Ioannina, Greece.&#xD;Section of Allergy &amp; Immunology, Department of Pediatrics, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adherence to Mediterranean Diet During Pregnancy, Breastfeeding, and Development of Food Allergy in the Offspring: Results From the MEDALLION Cohort Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mediterranean diet</style></keyword><keyword><style face="normal" font="default" size="100%">allergy prevention</style></keyword><keyword><style face="normal" font="default" size="100%">dietary patterns</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">fruit</style></keyword><keyword><style face="normal" font="default" size="100%">full-fat dairy</style></keyword><keyword><style face="normal" font="default" size="100%">infant health</style></keyword><keyword><style face="normal" font="default" size="100%">maternal diet</style></keyword><keyword><style face="normal" font="default" size="100%">traditional diet</style></keyword><keyword><style face="normal" font="default" size="100%">vegetables</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40944444</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Prevention is a key strategy for reducing the burden of food allergies (FA). The maternal diet during pregnancy and breastfeeding is increasingly recognized as a factor contributing to FA risk. METHODS: We analyzed data from a sub-cohort of the MEDALLION study to evaluate the association between maternal adherence to the Mediterranean Diet (MedDiet) and the development of FA in offsprings. Maternal dietary intake during pregnancy and lactation was assessed using a validated scale, i.e., the MedDiet Score, along with individual food group consumption. Multiple logistic regression models were performed. RESULTS: A total of 430 mother-offspring dyads were included in the analysis. Higher maternal adherence to the MedDiet was associated with reduced odds of FA in offspring during both pregnancy (adjusted OR 0.94, 95% CI 0.89-1.00) and lactation (adjusted OR 0.94, 95% CI 0.88-1.00). Increased weekly consumption of fruits and full-fat dairy products during pregnancy, and vegetables during breastfeeding, was associated with reduced likelihood of FA in the offspring. Conversely, higher intake of poultry and red meat (&gt; 3 servings/week) during both periods, and fish consumption during pregnancy (&gt; 1 serving/week), were associated with increased odds of FA. CONCLUSIONS: This study points out that the MedDiet and, especially, some specific components, such as fruits, vegetables, and full-fat dairy products, may contribute to lowering the risk of FA in infants, whereas a higher intake of poultry, red meat, and fish may increase it. These findings support the potential of maternal nutrition to reduce childhood FA.</style></abstract><notes><style face="normal" font="default" size="100%">Vassilopoulou, Emilia&#xD;Karastogiannidou, Calliope&#xD;Comotti, Anna&#xD;Agostoni, Carlo&#xD;Maragkou, Myrto-Kalliopi&#xD;Papadopoulos, Nikolaos G&#xD;Pasioti, Maria&#xD;Lithoxopoulou, Maria&#xD;Feketea, Gavriela&#xD;Tsabouri, Sophia&#xD;Milani, Gregorio Paolo&#xD;Venter, Carina&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Sep 13. doi: 10.1111/all.70054.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40944444</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70054</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1033</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1033</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yegit, O. O.</style></author><author><style face="normal" font="default" size="100%">Demir, S.</style></author><author><style face="normal" font="default" size="100%">Unal, D.</style></author><author><style face="normal" font="default" size="100%">Olgac, M.</style></author><author><style face="normal" font="default" size="100%">Terzioglu, K.</style></author><author><style face="normal" font="default" size="100%">Eyice Karabacak, D.</style></author><author><style face="normal" font="default" size="100%">Tuzer, C.</style></author><author><style face="normal" font="default" size="100%">Ayhan, V.</style></author><author><style face="normal" font="default" size="100%">Colakoglu, B.</style></author><author><style face="normal" font="default" size="100%">Buyukozturk, S.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Adult Immunology and Allergy Clinic, Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey.&#xD;Adult Immunology and Allergy Clinic, Sisli Hamidiye Etfal Education and Research Hospital, Istanbul, Turkey.&#xD;Adult Immunology and Allergy Clinic, Kartal Dr Lutfi Kirdar Education and Research Hospital, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adherence to subcutaneous immunotherapy with aeroallergens in real-life practice during the COVID-19 pandemic</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">197-206</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/04/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Subcutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">adherence</style></keyword><keyword><style face="normal" font="default" size="100%">pandemic</style></keyword><keyword><style face="normal" font="default" size="100%">real-life study</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33904166</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The success of subcutaneous immunotherapy (SCIT) mostly depends on regular injections. Our aim was to investigate adherence to SCIT with aeroallergens during the COVID-19 pandemic and demonstrate clinical consequences of treatment disruptions in real life. METHODS: Visual analogue scale for quality of life (VAS-QoL), VAS for symptom scores (VAS-symptom), medication scores (MSs), and total symptom scores (TSS-6) were recorded during the pandemic in 327 adult allergic rhinitis and/or asthmatic patients receiving maintenance SCIT, and these scores were compared with the pre-pandemic data. Patients were grouped according to SCIT administration intervals; no delay (Group 1), &lt;2 months (Group 2), and &gt;/=2-month intervals (Group 3). RESULTS: A total of 104 (31.8%) patients (Group 3) were considered as nonadherent which was mostly related to receiving SCIT with HDMs and using public transportation for reaching the hospital. Median MS, VAS-symptom, and TSS-6 scores of Group 3 patients during the pandemic were higher than the pre-pandemic scores (p = 0.005, p &lt; 0.001, p &lt; 0.001, respectively), whereas median VAS-QoL scores of Group 3 during the pandemic were lower than the pre-pandemic scores (p &lt; 0.001). Median TSS-6 and VAS-symptom scores were the highest in Group 3 compared with other groups (p &lt; 0.001 for each comparison). Median VAS-QoL scores were the lowest in Group 3 compared with Group 1 and Group 2 (p &lt; 0.001, p = 0.043, respectively). CONCLUSION: When precautions in allergy clinics are carefully applied, adherence to SCIT can be high during a pandemic. Patients must be encouraged to regularly adhere to SCIT injections since delays in SCIT administration can deteriorate clinical symptoms.</style></abstract><notes><style face="normal" font="default" size="100%">Yegit, Osman Ozan&#xD;Demir, Semra&#xD;Unal, Derya&#xD;Olgac, Muge&#xD;Terzioglu, Kadriye&#xD;Eyice Karabacak, Deniz&#xD;Tuzer, Can&#xD;Ayhan, Vehbi&#xD;Colakoglu, Bahattin&#xD;Buyukozturk, Suna&#xD;Gelincik, Asli&#xD;eng&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):197-206. doi: 10.1111/all.14876. Epub 2021 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33904166</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8222885</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14876</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>981</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">981</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wiehn, E.</style></author><author><style face="normal" font="default" size="100%">Ricci, C.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Perea, A.</style></author><author><style face="normal" font="default" size="100%">Perkin, M. R.</style></author><author><style face="normal" font="default" size="100%">Jones, C. J.</style></author><author><style face="normal" font="default" size="100%">Akdis, C.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Eigenmann, P.</style></author><author><style face="normal" font="default" size="100%">Grattan, C.</style></author><author><style face="normal" font="default" size="100%">Apfelbacher, C. J.</style></author><author><style face="normal" font="default" size="100%">Genuneit, J.</style></author><author><style face="normal" font="default" size="100%">Task Force &apos;Adherence to reporting guidelines in articles published in, Eaaci Journals a systematic review&apos; of the Eaaci Working Group on Epidemiology</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.&#xD;Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany.&#xD;Allergy Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain.&#xD;Population Health Research Institute, St George&apos;s, University of London, London, UK.&#xD;Faculty of Health &amp; Medical Sciences, School of Psychology, University of Surrey, Guildford, UK.&#xD;Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.&#xD;University Hospital, Montpellier, France.&#xD;University Hospital Pediatrics, Geneva, Switzerland.&#xD;St John&apos;s Institute of Dermatology, Guy&apos;s Hospital, London, UK.&#xD;Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.&#xD;Institute of Social Medicine and Health Systems Research, Otto von Guericke University Magdeburg, Magdeburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adherence to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist in articles published in EAACI Journals: A bibliographic study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3581-3588</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Checklist</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Periodicals as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34022062</style></accession-num><abstract><style face="normal" font="default" size="100%">Research data derived from observational studies are accumulating quickly in the field of allergy and immunology and a large amount of observational studies are published every year. The aim of the present study was to evaluate the adherence to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist by papers published in the three European Academy of Allergy and Clinical Immunology journals, during the period 2009-2018. To this end, we conducted a bibliographic study of up to eight randomly selected papers per year per Journal. Our literature search resulted in 223 papers. Amongst those, 80, 80 and 63 records were from Paediatric Allergy and Immunology, Allergy and Clinical and Translational Allergy, respectively; the latter was published only from 2011 on. Prospective, case control and cross-sectional designs were described in 88, 43 and 92 papers, respectively. Full reporting of all STROBE items was present in 47.4%, 45.6% and 41.2% for the cohort, cross-sectional and case-control studies, respectively. Generally, no time trend in adherence of reporting STROBE items was observed, apart from reporting funding, which increased from 60% in 2009/2010 to more than 90% in 2018. We identified a cluster of STROBE items with low proportions of full reporting constituted by the items on reporting study design in the title and methods, variables types along with their measurement/assessment, bias and confounding, study size, and grouping of variables. It appears that the STROBE checklist is a suitable tool in observational allergy epidemiology. However, adherence to the STROBE checklist appeared suboptimal.</style></abstract><notes><style face="normal" font="default" size="100%">Wiehn, Elena&#xD;Ricci, Cristian&#xD;Alvarez-Perea, Alberto&#xD;Perkin, Michael R&#xD;Jones, Christina J&#xD;Akdis, Cezmi&#xD;Bousquet, Jean&#xD;Eigenmann, Philippe&#xD;Grattan, Clive&#xD;Apfelbacher, Christian J&#xD;Genuneit, Jon&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3581-3588. doi: 10.1111/all.14951.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34022062</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14951</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>573</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">573</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bizjak, M.</style></author><author><style face="normal" font="default" size="100%">Kosnik, M.</style></author><author><style face="normal" font="default" size="100%">Dinevski, D.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author><author><style face="normal" font="default" size="100%">Fomina, D.</style></author><author><style face="normal" font="default" size="100%">Borzova, E.</style></author><author><style face="normal" font="default" size="100%">Kulthanan, K.</style></author><author><style face="normal" font="default" size="100%">Meshkova, R.</style></author><author><style face="normal" font="default" size="100%">Aarestrup, F. M.</style></author><author><style face="normal" font="default" size="100%">Ahsan, D. M.</style></author><author><style face="normal" font="default" size="100%">Al-Ahmad, M.</style></author><author><style face="normal" font="default" size="100%">Altrichter, S.</style></author><author><style face="normal" font="default" size="100%">Bauer, A.</style></author><author><style face="normal" font="default" size="100%">Brockstadt, M.</style></author><author><style face="normal" font="default" size="100%">Costa, C.</style></author><author><style face="normal" font="default" size="100%">Demir, S.</style></author><author><style face="normal" font="default" size="100%">Criado, R. F.</style></author><author><style face="normal" font="default" size="100%">Ensina, L. F.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A. M.</style></author><author><style face="normal" font="default" size="100%">Goncalo, M.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Holm, J. G.</style></author><author><style face="normal" font="default" size="100%">Inomata, N.</style></author><author><style face="normal" font="default" size="100%">Kasperska-Zajac, A.</style></author><author><style face="normal" font="default" size="100%">Khoshkhui, M.</style></author><author><style face="normal" font="default" size="100%">Klyucharova, A.</style></author><author><style face="normal" font="default" size="100%">Kocaturk, E.</style></author><author><style face="normal" font="default" size="100%">Lu, R.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Maltseva, N.</style></author><author><style face="normal" font="default" size="100%">Pasali, M.</style></author><author><style face="normal" font="default" size="100%">Paulino, M.</style></author><author><style face="normal" font="default" size="100%">Pesque, D.</style></author><author><style face="normal" font="default" size="100%">Peter, J.</style></author><author><style face="normal" font="default" size="100%">Ramon, G. D.</style></author><author><style face="normal" font="default" size="100%">Ritchie, C.</style></author><author><style face="normal" font="default" size="100%">Rodrigues Valle, S. O.</style></author><author><style face="normal" font="default" size="100%">Rudenko, M.</style></author><author><style face="normal" font="default" size="100%">Sikora, A.</style></author><author><style face="normal" font="default" size="100%">Wagner, N.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Xue, X.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z.</style></author><author><style face="normal" font="default" size="100%">Terhorst-Molawi, D.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Urticaria Center of Reference and Excellence (UCARE), University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.&#xD;Faculty of Medicine, University of Maribor, Maribor, Slovenia.&#xD;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Center of Allergy and Immunology, Urticaria Center of Reference and Excellence (UCARE), Clinical State Hospital 52, Moscow Ministry of Healthcare, Moscow, Russian Federation.&#xD;Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;Department of Clinical Genetics, Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University, Moscow, Russian Federation.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Clinical Immunology and Allergology, Urticaria Center of Reference and Excellence (UCARE), Smolensk State Medical University, Smolensk, Russian Federation.&#xD;Faculdade de Ciencias, Medicas e da Saude de Juiz de Fora (SUPREMA), Urticaria Center of Reference and Excellence (UCARE), Hospital Maternidade Therezinha de Jesus, Minas Gerais, Brazil.&#xD;Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charite -Universitatsmedizin Berlin, Corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Microbiology Department, Faculty of Medicine, Urticaria Center of Reference and Excellence (UCARE), Kuwait University, Safat, Kuwait.&#xD;Department of Dermatology and Venerology, Urticaria Center of Reference and Excellence (UCARE), Comprehensive Allergy Center, Kepler University Hospital, Linz, Austria.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), University Allergy Center, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.&#xD;Immunoallergology Department, Urticaria Center of Reference and Excellence (UCARE), Hospital de Santa Maria, CHULN, Lisbon, Portugal.&#xD;Division of Allergy, Department of Internal Medicine, Istanbul Faculty of Medicine, Urticaria Center of Reference and Excellence (UCARE), Istanbul University, Istanbul, Turkey.&#xD;Faculdade de Medicina do ABC (FMABC), Urticaria Center of Reference and Excellence (UCARE), Santo Andre, Brazil.&#xD;Division of Allergy, Department of Pediatrics, Clinical Immunology and Rheumatology, Urticaria Center of Reference and Excellence (UCARE), Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), Hospital del Mar, IMIM, Universitat Autonoma, Barcelona, Spain.&#xD;Clinic of Dermatology, Urticaria Center of Reference and Excellence (UCARE), University Hospital and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Center of Allergy and Immunology, Urticaria Center of Reference and Excellence (UCARE), Tbilsi, Georgia.&#xD;Department of Environmental Immuno-Dermatology, Urticaria Center of Reference and Excellence (UCARE), Yokohama City University Graduate School of Medicine, Yokohama, Japan.&#xD;European Center for Diagnosis and Treatment of Urticaria/Angioedema (GA2LEN UCARE /ACARE Network) &amp; Department of Clinical Allergology and Urticaria of Medical University of Silesia, Bytom, Poland.&#xD;Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.&#xD;Department of Clinical Immunology and Allergology, Republican Center of Clinical Immunology and Allergology, Urticaria Center of Reference and Excellence (UCARE), Republican Clinical Hospital, Kazan State Medical University, Kazan, Russian Federation.&#xD;Department of Internal Diseases, Institute of Fundamental Medicine and Biology (IFMB) of Kazan Federal University, Kazan, Russian Federation.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), Koc University School of Medicine, Istanbul, Turkey.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.&#xD;Allergy Unit, Second Department of Dermatology and Venereology, Urticaria Center of Reference and Excellence (UCARE), National and Kapodistrian University of Athens, University General Hospital &quot;Attikon&quot;, Athens, Greece.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Urticaria Center of Reference and Excellence (UCARE), University of Cape Town, Cape Town, South Africa.&#xD;Allergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa.&#xD;Instituto de Alergia e Inmunologia del Sur, Urticaria Center of Reference and Excellence (UCARE), Buenos Aires, Argentina.&#xD;Adults and Pediatrics Allergy Unit, Urticaria Center of Reference and Excellence (UCARE), Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.&#xD;Department of Internal Medicine, Immunology Service, Urticaria Center of Reference and Excellence (UCARE), Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.&#xD;London Allergy and Immunology Centre, Urticaria Center of Reference and Excellence (UCARE), London, UK.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), University Hospital of Erlangen, University of Erlangen-Nuremberg (FAU), Germany.&#xD;Allergy Unit, 2nd Pediatric Clinic, Urticaria Center of Reference and Excellence (UCARE), National and Kapodistrian University of Athens, Athens, Greece.&#xD;Department of General Practice, Urticaria Center of Reference and Excellence (UCARE), Community Health Service Center, Guangzhou City, China.&#xD;Department of Dermatology and Venerology, Urticaria Center of Reference and Excellence (UCARE), Beijing Key Laboratory of Molecular Diagnosis on Dermatoses and National Clinical Research Center for Skin and Immune Diseases, Peking University First Hospital, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adrenaline autoinjector is underprescribed in typical cold urticaria patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2224-2229</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/03/09</style></edition><section><style face="normal" font="default" size="100%">2224</style></section><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cold Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cold-ce</style></keyword><keyword><style face="normal" font="default" size="100%">adrenaline autoinjector</style></keyword><keyword><style face="normal" font="default" size="100%">cold urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">cold-induced anaphylaxis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35258111</style></accession-num><notes><style face="normal" font="default" size="100%">Bizjak, Mojca&#xD;Kosnik, Mitja&#xD;Dinevski, Dejan&#xD;Thomsen, Simon Francis&#xD;Fomina, Daria&#xD;Borzova, Elena&#xD;Kulthanan, Kanokvalai&#xD;Meshkova, Raisa&#xD;Aarestrup, Fernando Monteiro&#xD;Ahsan, Dalia Melina&#xD;Al-Ahmad, Mona&#xD;Altrichter, Sabine&#xD;Bauer, Andrea&#xD;Brockstadt, Maxi&#xD;Costa, Celia&#xD;Demir, Semra&#xD;Criado, Roberta Fachini&#xD;Ensina, Luis Felipe&#xD;Gelincik, Asli&#xD;Gimenez-Arnau, Ana Maria&#xD;Goncalo, Margarida&#xD;Gotua, Maia&#xD;Holm, Jesper Gronlund&#xD;Inomata, Naoko&#xD;Kasperska-Zajac, Alicja&#xD;Khoshkhui, Maryam&#xD;Klyucharova, Aliya&#xD;Kocaturk, Emek&#xD;Lu, Rongbiao&#xD;Makris, Michael&#xD;Maltseva, Natalya&#xD;Pasali, Maria&#xD;Paulino, Marisa&#xD;Pesque, David&#xD;Peter, Jonny&#xD;Ramon, German Dario&#xD;Ritchie, Carla&#xD;Rodrigues Valle, Solange Oliveira&#xD;Rudenko, Michael&#xD;Sikora, Agnieszka&#xD;Wagner, Nicola&#xD;Xepapadaki, Paraskevi&#xD;Xue, Xiaoyang&#xD;Zhao, Zuotao&#xD;Terhorst-Molawi, Dorothea&#xD;Maurer, Marcus&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2224-2229. doi: 10.1111/all.15274. Epub 2022 Mar 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35258111</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15274</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1963</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1963</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gu, B. H.</style></author><author><style face="normal" font="default" size="100%">Choi, J. P.</style></author><author><style face="normal" font="default" size="100%">Park, T.</style></author><author><style face="normal" font="default" size="100%">Kim, A. S.</style></author><author><style face="normal" font="default" size="100%">Jung, H. Y.</style></author><author><style face="normal" font="default" size="100%">Choi, D. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, S. J.</style></author><author><style face="normal" font="default" size="100%">Chang, Y. S.</style></author><author><style face="normal" font="default" size="100%">Kim, M.</style></author><author><style face="normal" font="default" size="100%">Park, H. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Life and Industry Convergence Research Institute, Pusan National University, Miryang-si, South Korea.&#xD;Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea.&#xD;Department of Animal Science and Technology, Chung-Ang University, Anseong-si, South Korea.&#xD;Department of Family Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Deagu, South Korea.&#xD;Division of Allergy and Clinical Immunology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea.&#xD;Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.&#xD;Department of Animal Science, College of Natural Resources and Life Science, Pusan National University, Miryang-si, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adult asthma with symptomatic eosinophilic inflammation is accompanied by alteration in gut microbiome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1909-1921</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Metagenome</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">gut microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36847620</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Accumulating evidence suggests that the gut microbiome is associated with asthma. However, altered gut microbiome in adult asthma is not yet well established. We aimed to investigate the gut microbiome profiles of adult asthmatic patients with symptomatic eosinophilic inflammation. METHODS: The 16 s rRNA gene metagenomic analysis of feces in the symptomatic eosinophilic asthma group (EA, n = 28) was compared with the healthy control (HC, n = 18) and the chronic cough control (CC, n = 13). A correlation analysis between individual taxa and clinical markers was performed within the EA group. Changes in the gut microbiome were examined in patients with significant symptom improvement in the EA group. RESULTS: The relative abundances of Lachnospiraceae and Oscillospiraceae significantly decreased and Bacteroidetes increased in the EA group. Within EA group, Lachnospiraceae was negatively correlated with indicators of type 2 inflammation and lung function decline. Enterobacteriaceae and Prevotella was positively associated with type 2 inflammation and lung function decline, respectively. The abundance of predicted genes associated with amino acid metabolism and secondary bile acid biosynthesis was diminished in the EA group. These functional gene family alterations could be related to gut permeability, and the serum lipopolysaccharide concentration was actually high in the EA group. EA patients with symptom improvement after 1 month did not show a significant change in the gut microbiome. CONCLUSIONS: Symptomatic eosinophilic adult asthma patients showed altered the gut microbiome composition. Specifically, a decrease in commensal clostridia was observed, and a decrease in Lachnospiraceae was correlated with blood eosinophilia and lung function decline.</style></abstract><notes><style face="normal" font="default" size="100%">Gu, Bon-Hee&#xD;Choi, Jun-Pyo&#xD;Park, Tansol&#xD;Kim, A-Sol&#xD;Jung, Ho Young&#xD;Choi, Doo Young&#xD;Lee, Sang Jin&#xD;Chang, Yoon-Seok&#xD;Kim, Myunghoo&#xD;Park, Han-Ki&#xD;eng&#xD;NRF-2022R1C1C1003256/Korea Government/&#xD;NRF-2020R1C1C1011678/Korea Government/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1909-1921. doi: 10.1111/all.15691. Epub 2023 Mar 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36847620</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15691</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>861</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">861</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Lan, F.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Advances and highlights in allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3383-3389</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/08/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">dual allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">real-world evidence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34379805</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic rhinitis (AR) is a growing public health, medical and economic problem worldwide. The current review describes the major discoveries related to AR during the past 2 years, including risk factors for the prevalence of AR, the corresponding diagnostic strategy, precise underlying immunological mechanisms, and efficient therapies for AR during the ongoing global &quot;coronavirus disease 2019&quot; (COVID-19) pandemic. The review further attempts to highlight future research perspectives. Increasing evidence suggests that environmental exposures, climate changes, and lifestyle are important risk factors for AR. Consequently, detailed investigation of the exposome and the connection between environmental exposures and health in the future should provide better risk profiles instead of single predictors, and also help mitigate adverse health outcomes in allergic diseases. Although patients with dual AR, a newly defined AR phenotype, display perennial and seasonal allergens-related nasal symptoms, they are only allergic to seasonal allergens, indicating the importance of measuring inflammation at the local sites. Herein, we suggest that a combination of precise diagnosis in local sites and traditional diagnostic methods may enhance the precision medicine-based approach for management of AR; however, this awaits further investigations. Apart from traditional treatments, social distancing, washing hands, and disinfection are also required to better manage AR patients in the ongoing global COVID-19 pandemic. Despite recent advances in understanding the immune mechanisms underlying the effects of allergen immunotherapy (AIT), further understanding changes of cell profiles after AIT and accurately evaluate the efficacy of AIT are required.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Yuan&#xD;Lan, Feng&#xD;Zhang, Luo&#xD;eng&#xD;2016YFC0905200/National key R&amp;amp;D program of China/&#xD;IRT13082/Changjiang scholars and innovative research team/&#xD;81630023/National natural science foundation of China/&#xD;82071022/National natural science foundation of China/&#xD;Z181100001618002/Beijing municipal science and technology project/&#xD;2018000021223ZK14/Beijing talents foundation/&#xD;2018000021223ZK12/Beijing talents foundation/&#xD;Z191100001119117/Beijing Nova Program of Science and Technology/&#xD;2019-I2M-5-022/CAMS Innovation Fund for Medical Sciences/&#xD;Public Welfare Development and Reform Pilot Project/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3383-3389. doi: 10.1111/all.15044. Epub 2021 Aug 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34379805</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15044</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>853</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">853</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Cojanu, C.</style></author><author><style face="normal" font="default" size="100%">Laculiceanu, A.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Zemelka-Wiacek, M.</style></author><author><style face="normal" font="default" size="100%">Kosowska, A.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Allergy Unit, IBIMA-Regional University Hospital of Malaga, UMA, RETICS ARADyAL, BIONAND, Malaga, Spain.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;All-MED Medical Research Institute, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Advances and highlights in asthma in 2021</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3390-3407</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/08/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Artificial Intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbations</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34392546</style></accession-num><abstract><style face="normal" font="default" size="100%">Last year brought a significant advance in asthma management, unyielding to the pressure of the pandemics. Novel key findings in asthma pathogenesis focus on the resident cell compartment, epigenetics and the innate immune system. The precision immunology unbiased approach was supplemented with novel tools and greatly facilitated by the use of artificial intelligence. Several randomised clinical trials and good quality real-world evidence shed new light on asthma treatment and supported the revision of several asthma guidelines (GINA, Expert Panel Report 3, ERS/ATS guidelines on severe asthma) and the conception of new ones (EAACI Guidelines for the use of biologicals in severe asthma). Integrating asthma management within the broader context of Planetary Health has been put forward. In this review, recently published articles and clinical trials are summarised and discussed with the goal to provide clinicians and researchers with a concise update on asthma research from a translational perspective.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Eguiluz-Gracia, Ibon&#xD;Cojanu, Catalina&#xD;Laculiceanu, Alexandru&#xD;Del Giacco, Stefano&#xD;Zemelka-Wiacek, Magdalena&#xD;Kosowska, Anna&#xD;Akdis, Cezmi A&#xD;Jutel, Marek&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3390-3407. doi: 10.1111/all.15054. Epub 2021 Aug 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34392546</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15054</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>817</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">817</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Ardicli, O.</style></author><author><style face="normal" font="default" size="100%">Barletta, E.</style></author><author><style face="normal" font="default" size="100%">Cevhertas, L.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Huang, M.</style></author><author><style face="normal" font="default" size="100%">Bel Imam, M.</style></author><author><style face="normal" font="default" size="100%">Koch, J.</style></author><author><style face="normal" font="default" size="100%">Ma, S.</style></author><author><style face="normal" font="default" size="100%">Maurer, D. J.</style></author><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Peng, Y.</style></author><author><style face="normal" font="default" size="100%">Radzikowska, U.</style></author><author><style face="normal" font="default" size="100%">Rinaldi, A. O.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Coira, J.</style></author><author><style face="normal" font="default" size="100%">Satitsuksanoa, P.</style></author><author><style face="normal" font="default" size="100%">Schneider, S. R.</style></author><author><style face="normal" font="default" size="100%">Wallimann, A.</style></author><author><style face="normal" font="default" size="100%">Zhakparov, D.</style></author><author><style face="normal" font="default" size="100%">Ziadlou, R.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Baerenfaller, K.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Division of Pediatric Allergy and Immunology, School of Medicine, Marmara University, Istanbul, Turkey.&#xD;Department of Medical Microbiology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin, Turkey.&#xD;Department of Microbiology, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey.&#xD;Swiss Institute of Bioinformatics (SIB), Davos, Switzerland.&#xD;Department of Medical Immunology, Institute of Health Sciences, Bursa Uludag University, Bursa, Turkey.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Universidad de Malaga, Malaga, Spain.&#xD;Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Basic Medical Sciences, Facultad de Medicana, Institute of Applied Molecular Medicine (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Department of Chemistry and Biochemistry, Facultad de Farmacia, Centre for Metabolomics and Bioanalysis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;AO Research Institute Davos, Davos Platz, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Department of Otolaryngology Head and Neck Surgery and Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Advances and highlights in biomarkers of allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3659-3686</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/09/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Fernandez-Santamaria, Mengting Huang, Manal Bel Imam, Jana Koch, Siyuan Ma,</style></keyword><keyword><style face="normal" font="default" size="100%">Debbie J. Maurer, Yaqi Peng, Urszula Radzikowska, Arturo O. Rinaldi, Juan</style></keyword><keyword><style face="normal" font="default" size="100%">Rodriguez-Coira, Pattraporn Satitsuksanoa, Stephan R. Schneider, Alexandra</style></keyword><keyword><style face="normal" font="default" size="100%">Wallimann, Damir Zhakparov, Reihane Ziadlou, Marie-Charlotte Bruggen, Katja</style></keyword><keyword><style face="normal" font="default" size="100%">Baerenfaller, Luo Zhang, Mubeccel Akdis declare no conflict of interest. Yasutaka</style></keyword><keyword><style face="normal" font="default" size="100%">Mitamura and Willem van de Veen report grants from Novartis. Milena Sokolowska</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from Swiss National Science Foundation, GSK and Novartis. Cezmi</style></keyword><keyword><style face="normal" font="default" size="100%">Akdis reports grants from Allergopharma, Idorsia, Swiss National Science</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, Christine Kuhne-Center for Allergy Research and Education, European</style></keyword><keyword><style face="normal" font="default" size="100%">Commission&apos;s Horison&apos;s 2020 Framework Programme, Cure, Novartis Research</style></keyword><keyword><style face="normal" font="default" size="100%">Institutes, Basel, Astra Zeneca, Switzerland, Scibase, Stockholm, advisory role</style></keyword><keyword><style face="normal" font="default" size="100%">for Sanofi/Regeneron, Glaxo Smith-Kline, Novartis.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34519063</style></accession-num><abstract><style face="normal" font="default" size="100%">During the past years, there has been a global outbreak of allergic diseases, presenting a considerable medical and socioeconomical burden. A large fraction of allergic diseases is characterized by a type 2 immune response involving Th2 cells, type 2 innate lymphoid cells, eosinophils, mast cells, and M2 macrophages. Biomarkers are valuable parameters for precision medicine as they provide information on the disease endotypes, clusters, precision diagnoses, identification of therapeutic targets, and monitoring of treatment efficacies. The availability of powerful omics technologies, together with integrated data analysis and network-based approaches can help the identification of clinically useful biomarkers. These biomarkers need to be accurately quantified using robust and reproducible methods, such as reliable and point-of-care systems. Ideally, samples should be collected using quick, cost-efficient and noninvasive methods. In recent years, a plethora of research has been directed toward finding novel biomarkers of allergic diseases. Promising biomarkers of type 2 allergic diseases include sputum eosinophils, serum periostin and exhaled nitric oxide. Several other biomarkers, such as pro-inflammatory mediators, miRNAs, eicosanoid molecules, epithelial barrier integrity, and microbiota changes are useful for diagnosis and monitoring of allergic diseases and can be quantified in serum, body fluids and exhaled air. Herein, we review recent studies on biomarkers for the diagnosis and treatment of asthma, chronic urticaria, atopic dermatitis, allergic rhinitis, chronic rhinosinusitis, food allergies, anaphylaxis, drug hypersensitivity and allergen immunotherapy. In addition, we discuss COVID-19 and allergic diseases within the perspective of biomarkers and recommendations on the management of allergic and asthmatic patients during the COVID-19 pandemic.</style></abstract><notes><style face="normal" font="default" size="100%">Ogulur, Ismail&#xD;Pat, Yagiz&#xD;Ardicli, Ozge&#xD;Barletta, Elena&#xD;Cevhertas, Lacin&#xD;Fernandez-Santamaria, Ruben&#xD;Huang, Mengting&#xD;Bel Imam, Manal&#xD;Koch, Jana&#xD;Ma, Siyuan&#xD;Maurer, Debbie J&#xD;Mitamura, Yasutaka&#xD;Peng, Yaqi&#xD;Radzikowska, Urszula&#xD;Rinaldi, Arturo O&#xD;Rodriguez-Coira, Juan&#xD;Satitsuksanoa, Pattraporn&#xD;Schneider, Stephan R&#xD;Wallimann, Alexandra&#xD;Zhakparov, Damir&#xD;Ziadlou, Reihane&#xD;Bruggen, Marie-Charlotte&#xD;van de Veen, Willem&#xD;Sokolowska, Milena&#xD;Baerenfaller, Katja&#xD;Zhang, Luo&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3659-3686. doi: 10.1111/all.15089. Epub 2021 Sep 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34519063</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9292545</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15089</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>750</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">750</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Ariza, A.</style></author><author><style face="normal" font="default" size="100%">Fernandez, T. D.</style></author><author><style face="normal" font="default" size="100%">Cespedes, J. A.</style></author><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA-ARADyAL, Malaga, Spain.&#xD;Departamento de Biologia Celular, Genetica y Fisiologia, Universidad de Malaga, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-ARADyAL, Malaga, Spain.&#xD;Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.&#xD;Departamento de Medicina, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Advances and highlights in T and B cell responses to drug antigens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1129-1138</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/10/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">HLA Antigens/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">B cell</style></keyword><keyword><style face="normal" font="default" size="100%">T cell</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34617287</style></accession-num><abstract><style face="normal" font="default" size="100%">The immunological mechanisms involved in drug hypersensitivity reactions (DHRs) are complex, and despite important advances, multiple aspects remain poorly understood. These not fully known aspects are mainly related to the factors that drive towards either a tolerant or a hypersensitivity response and specifically regarding the role of B and T cells. In this review, we focus on recent findings on this knowledge area within the last 2 years. We highlight new evidences of covalent and non-covalent interactions of drug antigen with proteins, as well as the very first characterization of naturally processed flucloxacillin-haptenated human leukocyte antigen (HLA) ligands. Moreover, we have analysed new insights into the identification of risk factors associated with the development of DHRs, such as the role of oxidative metabolism of drugs in the activation of the immune system and the discovery of new associations between DHRs and HLA variants. Finally, evidence of IgG-mediated anaphylaxis in humans and the involvement of specific subpopulations of effector cells associated with different clinical entities are also topics explored in this review. All these recent findings are relevant for the underlying pathology mechanisms and advance the field towards a more precise diagnosis, management and treatment approach for DHRs.</style></abstract><notes><style face="normal" font="default" size="100%">Fernandez-Santamaria, Ruben&#xD;Ariza, Adriana&#xD;Fernandez, Tahia D&#xD;Cespedes, Jose A&#xD;Labella, Marina&#xD;Mayorga, Cristobalina&#xD;Torres, Maria J&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1129-1138. doi: 10.1111/all.15126. Epub 2021 Oct 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34617287</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15126</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1640</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1640</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Han, X.</style></author><author><style face="normal" font="default" size="100%">Krempski, J. W.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Advances and novel developments in mechanisms of allergic inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3100-3111</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2020/10/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33068299</style></accession-num><abstract><style face="normal" font="default" size="100%">In the past decade, research in the molecular and cellular underpinnings of basic and clinical immunology has significantly advanced our understanding of allergic disorders, allowing scientists and clinicians to diagnose and treat disorders such as asthma, allergic and nonallergic rhinitis, and food allergy. In this review, we discuss several significant recent developments in basic and clinical research as well as important future research directions in allergic inflammation. Certain key regulatory cytokines, genes and molecules have recently been shown to play key roles in allergic disorders. For example, interleukin-33 (IL-33) plays an important role in refractory disorders such as asthma, allergic rhinitis and food allergy, mainly by inducing T helper (Th) 2 immune responses and clinical trials with IL-33 inhibitors are underway in food allergy. We discuss interleukin 4 receptor pathways, which recently have been shown to play a critical role among the allergic inflammatory pathways that drive allergic disorders and pathogenesis. Further, the cytokine thymic stromal lymphopoietin (TSLP) has recently been shown as a factor in maintaining immune homeostasis and regulating type 2 inflammatory responses at mucosal barriers in allergic inflammation and targeting TSLP-mediated signalling is considered an attractive therapeutic strategy. In addition, new findings establish an important T cell-intrinsic role of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) proteolytic activity in the suppression of autoimmune responses. We have seen how mutations in the filaggrin gene are a significant risk factor for allergic diseases such as atopic dermatitis, asthma, allergic rhinitis, food allergy, contact allergy, and hand eczema. We are only beginning to understand the mechanisms by which the human microbiota may be regulating the immune system, and how sudden changes in the composition of the microbiota may have profound effects, linked with an increased risk of developing chronic inflammatory disorders, including allergies. New research has shown the important but complex role monocytes play in disorders such as food allergies. Finally, we discuss some of the new directions of research in this area, particularly the important use of biologicals in oral immunotherapy, advances in gene therapy, multifood therapy, novel diagnostics in diagnosing allergic disorders and the central role that omics play in creating molecular signatures and biomarkers of allergic disorders such as food allergy. Such exciting new developments and advances have significantly moved forth our ability to understand the mechanisms underlying allergic diseases for improved patient care.</style></abstract><notes><style face="normal" font="default" size="100%">Han, Xiaorui&#xD;Krempski, James W&#xD;Nadeau, Kari&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2020 Dec;75(12):3100-3111. doi: 10.1111/all.14632. Epub 2020 Nov 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33068299</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14632</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>870</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">870</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van Zelm, M. C.</style></author><author><style face="normal" font="default" size="100%">McKenzie, C. I.</style></author><author><style face="normal" font="default" size="100%">Varese, N.</style></author><author><style face="normal" font="default" size="100%">Rolland, J. M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.&#xD;Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University, and Alfred Hospital, Melbourne, VIC, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Advances in allergen-specific immune cell measurements for improved detection of allergic sensitization and immunotherapy responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3374-3382</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">B cell</style></keyword><keyword><style face="normal" font="default" size="100%">T cell</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">flowcytometry</style></keyword><keyword><style face="normal" font="default" size="100%">tetramer</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34355403</style></accession-num><abstract><style face="normal" font="default" size="100%">Over the past two decades, precision medicine has advanced diagnostics and treatment of allergic diseases. Component-resolved analysis of allergen sensitization facilitates stratification of patients. Furthermore, new formulations of allergen immunotherapy (AIT) products can more effectively deliver the relevant components. Molecular insights from the identification of allergen component sensitization and clinical outcomes of treatment with new AIT formulations can now be utilized for a deeper understanding of the nature of the pathogenic immune response in allergy and how this can be corrected by AIT. Fundamental in these processes are the allergen-specific B and T cells. Within the large B- and T-cell compartments, only those that specifically recognize the allergen with their immunoglobulin (Ig) or T-cell receptor (TCR), respectively, are of clinical relevance. With peripheral blood allergen-specific B- and T-cell frequencies below 1%, bulk cell analysis is typically insufficiently sensitive. We here review the latest technologies to detect allergen-specific B and T cells, as well as new developments in utilizing these tools for diagnostics and therapy monitoring to advance precision medicine for allergic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">van Zelm, Menno C&#xD;McKenzie, Craig I&#xD;Varese, Nirupama&#xD;Rolland, Jennifer M&#xD;O&apos;Hehir, Robyn E&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3374-3382. doi: 10.1111/all.15036. Epub 2021 Aug 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34355403</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15036</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>551</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">551</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruano-Zaragoza, M.</style></author><author><style face="normal" font="default" size="100%">Casas-Saucedo, R.</style></author><author><style face="normal" font="default" size="100%">De la Cruz Martinez, C. A.</style></author><author><style face="normal" font="default" size="100%">Araujo-Sanchez, G.</style></author><author><style face="normal" font="default" size="100%">Gelis, S.</style></author><author><style face="normal" font="default" size="100%">Gonzalez, M. F.</style></author><author><style face="normal" font="default" size="100%">San Bartolome, C.</style></author><author><style face="normal" font="default" size="100%">Pascal, M.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Rodriguez, T. W.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Delgado, P.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Sanchez, J.</style></author><author><style face="normal" font="default" size="100%">Munoz-Cano, R.</style></author><author><style face="normal" font="default" size="100%">Bartra, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, Hospital Clinic, Barcelona, Spain.&#xD;Clinical &amp; Experimental Respiratory Immunoallergy, Institut Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.&#xD;Asma, Reacciones Adversas y Alergia (ARADyAL), Instituto de Salud Carlos III, Madrid, Spain.&#xD;Immunology Department, Centre de Diagnostic Biomedic (CDB), Hospital Clinic de Barcelona, Barcelona, Spain.&#xD;Allergy Section, Alicante University Hospital, Alicante, Spain.&#xD;UMH-ISABIAL, Alicante University Hospital, Alicante, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Advances in the understanding of the cofactor effect in lipid transfer protein food allergy: From phenotype description to clinical management</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1924-1926</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/03/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Carrier Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Pru p 3</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">cofactor</style></keyword><keyword><style face="normal" font="default" size="100%">lipid transfer protein</style></keyword><keyword><style face="normal" font="default" size="100%">risk factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35322440</style></accession-num><notes><style face="normal" font="default" size="100%">Ruano-Zaragoza, Maria&#xD;Casas-Saucedo, Rocio&#xD;De la Cruz Martinez, Cinthia Aracelis&#xD;Araujo-Sanchez, Giovanna&#xD;Gelis, Sonia&#xD;Gonzalez, Maria Fernanda&#xD;San Bartolome, Clara&#xD;Pascal, Mariona&#xD;Jimenez-Rodriguez, Teodorikez Wilfox&#xD;Gonzalez-Delgado, Purificacion&#xD;Fernandez-Sanchez, Javier&#xD;Munoz-Cano, Rosa&#xD;Bartra, Joan&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1924-1926. doi: 10.1111/all.15291. Epub 2022 Apr 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35322440</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15291</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2134</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2134</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, E.</style></author><author><style face="normal" font="default" size="100%">Cao, G.</style></author><author><style face="normal" font="default" size="100%">Yang, Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Si, Y.</style></author><author><style face="normal" font="default" size="100%">Singh, K.</style></author><author><style face="normal" font="default" size="100%">Jude, J.</style></author><author><style face="normal" font="default" size="100%">An, S. S.</style></author><author><style face="normal" font="default" size="100%">Koziol-White, C. J.</style></author><author><style face="normal" font="default" size="100%">Panettieri, R. A., Jr.</style></author><author><style face="normal" font="default" size="100%">Yang, Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.&#xD;Rutgers Institute for Translational Medicine and Science, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.&#xD;Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adventitial stromal cells and myofibroblasts recruit pro- and anti-inflammatory immune cells in allergic airway inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2994-2997</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/05/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Myofibroblasts</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Stromal Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37171245</style></accession-num><notes><style face="normal" font="default" size="100%">Xu, En&#xD;Cao, Gaoyuan&#xD;Yang, Zhi&#xD;Zhang, Yuanyue&#xD;Si, Youwen&#xD;Singh, Kunal&#xD;Jude, Joseph&#xD;An, Steven S&#xD;Koziol-White, Cynthia J&#xD;Panettieri, Reynold A Jr&#xD;Yang, Qi&#xD;eng&#xD;RF1 AG078459/AG/NIA NIH HHS/&#xD;UL1 TR003017/TR/NCATS NIH HHS/&#xD;R01 HL137813/HL/NHLBI NIH HHS/&#xD;P01 HL114471/HL/NHLBI NIH HHS/&#xD;R01 AG057782/AG/NIA NIH HHS/&#xD;R01 HL155021/HL/NHLBI NIH HHS/&#xD;P30 ES005022/ES/NIEHS NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2994-2997. doi: 10.1111/all.15766. Epub 2023 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37171245</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10640656</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15766</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>881</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">881</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karakoc Aydiner, E.</style></author><author><style face="normal" font="default" size="100%">Bilgic Eltan, S.</style></author><author><style face="normal" font="default" size="100%">Babayeva, R.</style></author><author><style face="normal" font="default" size="100%">Aydiner, O.</style></author><author><style face="normal" font="default" size="100%">Kepenekli, E.</style></author><author><style face="normal" font="default" size="100%">Kolukisa, B.</style></author><author><style face="normal" font="default" size="100%">Sefer, A. P.</style></author><author><style face="normal" font="default" size="100%">Yalcin Gungoren, E.</style></author><author><style face="normal" font="default" size="100%">Karabiber, E.</style></author><author><style face="normal" font="default" size="100%">Yucel, E. O.</style></author><author><style face="normal" font="default" size="100%">Ozdemir, O.</style></author><author><style face="normal" font="default" size="100%">Kiykim, A.</style></author><author><style face="normal" font="default" size="100%">Artac, H.</style></author><author><style face="normal" font="default" size="100%">Yakici, N.</style></author><author><style face="normal" font="default" size="100%">Yalcin, K.</style></author><author><style face="normal" font="default" size="100%">Cokugras, H.</style></author><author><style face="normal" font="default" size="100%">Celkan, T. T.</style></author><author><style face="normal" font="default" size="100%">Orhan, F.</style></author><author><style face="normal" font="default" size="100%">Yesilipek, M. A.</style></author><author><style face="normal" font="default" size="100%">Baris, S.</style></author><author><style face="normal" font="default" size="100%">Ozen, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Division of Pediatric Allergy-Immunology, Marmara University, Istanbul, Turkey.&#xD;Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey.&#xD;The Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.&#xD;Department of Interventional Radiology, Kartal Research and Training Hospital, Istanbul, Turkey.&#xD;Faculty of Medicine, Division of Pediatric Infectious Diseases, Marmara University, Istanbul, Turkey.&#xD;Faculty of Medicine, Department of Chest Diseases, Division of Adult Allergy-Immunology Marmara University, Istanbul, Turkey.&#xD;Faculty of Medicine, Division of Pediatric Allergy-Immunology, Istanbul University, Istanbul, Turkey.&#xD;Faculty of Medicine, Division of Pediatric Allergy-Immunology, Sakarya University, Sakarya, Turkey.&#xD;Faculty of Medicine, Division of Pediatric Allergy-Immunology, Istanbul Cerrahpasa University, Istanbul, Turkey.&#xD;Faculty of Medicine, Division of Pediatric Allergy-Immunology, Selcuk University, Konya, Turkey.&#xD;Faculty of Medicine, Division of Pediatric Allergy-Immunology, Karadeniz Teknik University, Trabzon, Turkey.&#xD;Pediatric Hematology/Oncology and Stem Cell Transplantation Department, Medical Park Goztepe Hospital, Istanbul, Turkey.&#xD;Faculty of Medicine, Division of Pediatric Hematology and Oncology, Istanbul Cerrahpasa, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">282-295</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/07/28</style></edition><section><style face="normal" font="default" size="100%">282</style></section><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunologic Deficiency Syndromes</style></keyword><keyword><style face="normal" font="default" size="100%">*Primary Immunodeficiency Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">inborn errors of immunity</style></keyword><keyword><style face="normal" font="default" size="100%">outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34314546</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Genetic deficiencies of immune system, referred to as inborn errors of immunity (IEI), serve as a valuable model to study human immune responses. In a multicenter prospective cohort, we evaluated the outcome of SARS-CoV-2 infection among IEI subjects and analyzed genetic and immune characteristics that determine adverse COVID-19 outcomes. METHODS: We studied 34 IEI patients (19M/15F, 12 [min: 0.6-max: 43] years) from six centers. We diagnosed COVID-19 infection by finding a positive SARS-CoV-2 PCR test (n = 25) and/or a lung tomography scoring (CORADS) &gt;/=4 (n = 9). We recorded clinical and laboratory findings prospectively, fitted survival curves, and calculated fatality rates for the entire group and each IEI subclass. RESULTS: Nineteen patients had combined immune deficiency (CID), six with predominantly antibody deficiency (PAD), six immune dysregulation (ID), two innate immune defects, and one in the autoinflammatory class. Overall, 23.5% of cases died, with disproportionate fatality rates among different IEI categories. PAD group had a relatively favorable outcome at any age, but CIDs and IDs were particularly vulnerable. At admission, presence of dyspnea was an independent risk for COVID-related death (OR: 2.630, 95% CI; 1.198-5.776, p &lt; .001). Concerning predictive roles of laboratory markers at admission, deceased subjects compared to survived had significantly higher CRP, procalcitonin, Troponin-T, ferritin, and total-lung-score (p = .020, p = .003, p = .014, p = .013, p = .020; respectively), and lower absolute lymphocyte count, albumin, and trough IgG (p = .012, p = .022, p = .011; respectively). CONCLUSION: Our data disclose a highly vulnerable IEI subgroup particularly disadvantaged for COVID-19 despite their youth. Future studies should address this vulnerability and consider giving priority to these subjects in SARS-Cov-2 therapy trials.</style></abstract><notes><style face="normal" font="default" size="100%">Karakoc Aydiner, Elif&#xD;Bilgic Eltan, Sevgi&#xD;Babayeva, Royale&#xD;Aydiner, Omer&#xD;Kepenekli, Eda&#xD;Kolukisa, Burcu&#xD;Sefer, Asena Pinar&#xD;Yalcin Gungoren, Ezgi&#xD;Karabiber, Esra&#xD;Yucel, Esra Ozek&#xD;Ozdemir, Oner&#xD;Kiykim, Ayca&#xD;Artac, Hasibe&#xD;Yakici, Nalan&#xD;Yalcin, Koray&#xD;Cokugras, Haluk&#xD;Celkan, Tulin Tiraje&#xD;Orhan, Fazil&#xD;Yesilipek, Mehmet Akif&#xD;Baris, Safa&#xD;Ozen, Ahmet&#xD;eng&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):282-295. doi: 10.1111/all.15025. Epub 2021 Aug 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34314546</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441734</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15025</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2881</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2881</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tsao, C. L.</style></author><author><style face="normal" font="default" size="100%">Chan, S. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, M. H.</style></author><author><style face="normal" font="default" size="100%">Hsieh, T. Y. J.</style></author><author><style face="normal" font="default" size="100%">Phipatanakul, W.</style></author><author><style face="normal" font="default" size="100%">Ruran, H. B.</style></author><author><style face="normal" font="default" size="100%">Ma, K. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;School of Medicine, Chung Shan Medical University, Taichung, Taiwan.&#xD;Department of Internal Medicine, Weiss Memorial Hospital, Chicago, Illinois, USA.&#xD;Department of Internal Medicine, Maimonides Medical Center, Brooklyn, New York, USA.&#xD;Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Immunology, Boston Children&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adverse Outcomes Associated With Short-Acting Beta-Agonist Overuse in Asthma: A Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1629-1646</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/06/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">*Adrenergic beta-Agonists/adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40491263</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: The 2019 Global Initiative for Asthma (GINA) report no longer recommended short-acting beta-agonists (SABA) monotherapy due to associated complications and a lack of anti-inflammatory properties. This systematic review and meta-analysis aimed to evaluate adverse outcomes associated with SABA overuse in patients with asthma. METHODS: PubMed, Cochrane Library, EMBASE, and Web of Science databases were searched for studies on SABA overuse (&gt;/= 3 SABA canisters/year) in patients with asthma, from 1981 to November 2023. Randomized controlled trials (RCTs), cohort studies, and cross-sectional studies were included. Pooled risk ratios (RRs) were calculated for dichotomous measures of all-cause mortality and acute exacerbations using random-effects models and Mantel-Haenszel weighting. Subgroup analyses were conducted based on study design. RESULTS: Out of 626 records, 27 studies (2 RCTs, 1 prospective cohort study, 12 retrospective cohort studies, and 12 cross-sectional studies) were included. SABA overuse (&gt;/= 3 SABA canisters/year) was associated with significantly higher mortality (2743 of 130,629 in the overuse group versus 3534 of 300,451 in controls; RR = 2.04, 95% confidence interval, CI = 1.37-3.04; p &lt; 0.001) and a significantly higher rate of acute exacerbations (60,320 of 165,271 in the overuse group versus 84,439 of 376,845 in controls; RR = 1.93, 95% CI = 1.24-3.03; p &lt; 0.001). An increased risk of acute exacerbations was observed in retrospective cohort studies (RR = 1.88, 95% CI = 1.43-2.47; p &lt; 0.001) and cross-sectional studies (RR = 2.23, 95% CI = 1.04-4.77; p &lt; 0.001). CONCLUSIONS: SABA overuse was associated with increased rates of mortality and acute exacerbations in patients with asthma, supporting guidelines that advise against SABA monotherapy in asthma management.</style></abstract><notes><style face="normal" font="default" size="100%">Tsao, Chia-Ling&#xD;Chan, Shu-Yen&#xD;Lee, Meng-Hsun&#xD;Hsieh, Tina Yi Jin&#xD;Phipatanakul, Wanda&#xD;Ruran, Hana B&#xD;Ma, Kevin Sheng-Kai&#xD;eng&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1629-1646. doi: 10.1111/all.16538. Epub 2025 Jun 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40491263</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186600</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16538</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2905</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2905</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kazadzis, S.</style></author><author><style face="normal" font="default" size="100%">Fountoulakis, I.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Masoom, A.</style></author><author><style face="normal" font="default" size="100%">Papachristopoulou, K.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Coen, M. C.</style></author><author><style face="normal" font="default" size="100%">Tummon, F.</style></author><author><style face="normal" font="default" size="100%">Crouzy, B.</style></author><author><style face="normal" font="default" size="100%">Clot, B.</style></author><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">Nyeki, S.</style></author><author><style face="normal" font="default" size="100%">Raptis, I. P.</style></author><author><style face="normal" font="default" size="100%">Solomos, S.</style></author><author><style face="normal" font="default" size="100%">Gkikas, A.</style></author><author><style face="normal" font="default" size="100%">Moustaka, A.</style></author><author><style face="normal" font="default" size="100%">Kouremeti, N.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Physikalisch-Meteorologisches Observatorium Davos, World Radiation Center, Davos Dorf, Switzerland.&#xD;Research Centre for Atmospheric Physics and Climatology, Academy of Athens, Athens, Greece.&#xD;Terrestrial Ecology and Climate Change, Department of Ecology, School of Biology, Faculty of Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Federal Office of Meteorology and Climatology, MeteoSwiss, Chemin de L&apos;aerologie, Payerne, Switzerland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), Davos Dorf, Switzerland.&#xD;Faculty of Medicine, University Zurich, Zurich, Switzerland.&#xD;Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Institute for Astronomy, Astrophysics, Space Applications and Remote Sensing, National Observatory of Athens, Athens, Greece.&#xD;Institute of Environmental Research and Sustainable Development, National Observatory of Athens, Athens, Greece.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Aerosol Measurements and Decadal Changes: The Role of Climatic Changes and How It Reflects in Respiratory Allergies and Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1613-1628</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/05/31 22:29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Aerosols/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Climate Change</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Hypersensitivity/etiology/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Air Pollutants/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">aerobiology</style></keyword><keyword><style face="normal" font="default" size="100%">aerosols</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">climate change</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40448467</style></accession-num><abstract><style face="normal" font="default" size="100%">The causative agents of respiratory allergies are bioaerosols, such as house dust mite feces, pollen grains, and fungal spores. Climate change and urbanization are considered to lead to an increase in the load of allergenic bioaerosols due to impacts on plant phenophases and allergenicity. Continuous and efficient monitoring of the atmospheric composition worldwide is essential, given the major changes involved and their impact on climate change. The complexity of the exposome, evolving from single to multiple complex exposures, is explored in this work. Acquiring information from interdisciplinary scientific disciplines, such as aerobiology (for airborne particles of biological origin), aerosol science (for airborne particles of chemical or inorganic material), and integrating this with the actual reactome of patients with respiratory diseases, we aim to provide evidence of the multifactorial nature of this interaction in real life. The objective of this review is to present how we can monitor aerosols and mostly monitor the exposome, especially the biological one, i.e., pollen and fungal spores, and what their impact is, or could be, on respiratory allergies. A huge technological advancement has been required, as traditional methods of particle collection and identification have been based on tedious laboratory procedures, with delays of more than a week. This has limited their practical use to allergic patients and their treating physicians. Automation, real-time high temporal resolution, and the use of artificial intelligence are being increasingly used in medicine. Likewise, this overview summarizes the current aerosol measurement and modeling capabilities and discusses the classification of various aerosol particles and their impact on respiratory allergies. Satellite remote sensing is highlighted as a solution to the gaps in global aerosol representation by examining aerosol load in the atmospheric column in major cities worldwide. We also discuss potential novel threats, such as pioneer bioaerosols and the respiratory epithelial barrier, as well as future insights into the impact of climate change on allergy and asthma. We conclude with a discussion of emerging co-exposures and co-diseases resulting from the ongoing climate change.</style></abstract><notes><style face="normal" font="default" size="100%">Kazadzis, Stelios&#xD;Fountoulakis, Illias&#xD;Damialis, Athanasios&#xD;Masoom, Akriti&#xD;Papachristopoulou, Kyriakoula&#xD;Gilles, Stefanie&#xD;Coen, Martine Collaud&#xD;Tummon, Fiona&#xD;Crouzy, Benoit&#xD;Clot, Bernard&#xD;Pat, Yagiz&#xD;Bruggen, Marie-Charlotte&#xD;Nyeki, Stephan&#xD;Raptis, Ioannis-Panagiotis&#xD;Solomos, Stavros&#xD;Gkikas, Antonis&#xD;Moustaka, Anna&#xD;Kouremeti, Natalia&#xD;Akdis, Cezmi A&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1613-1628. doi: 10.1111/all.16602. Epub 2025 May 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40448467</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186611</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16602</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2116</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Facheris, P.</style></author><author><style face="normal" font="default" size="100%">Da Rosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Pagan, A. D.</style></author><author><style face="normal" font="default" size="100%">Angelov, M.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Rabinowitz, G.</style></author><author><style face="normal" font="default" size="100%">Gomez-Arias, P. J.</style></author><author><style face="normal" font="default" size="100%">Rothenberg-Lausell, C.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y. D.</style></author><author><style face="normal" font="default" size="100%">Bose, S.</style></author><author><style face="normal" font="default" size="100%">Chowdhury, M.</style></author><author><style face="normal" font="default" size="100%">Shemer, A.</style></author><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Icahn School of Medicine at Mount Sinai, New York City, New York, USA.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Ponce Health Sciences University School of Medicine, Ponce, Puerto Rico.&#xD;Reina Sofia University Hospital, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.&#xD;University of Puerto Rico, School of Medicine, San Juan, Puerto Rico.&#xD;Department of Dermatology, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Age of onset defines two distinct profiles of atopic dermatitis in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2202-2214</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/04/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Age of Onset</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">adult-onset atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">endotype</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric-onset atopic dermatitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37032461</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The incidence of adult-onset atopic dermatitis (AOAD) is increasing. However, the unique characteristics of AOAD compared to pediatric-onset AD persisting into adulthood (POAD) are underexplored, hampering the development of targeted-therapeutics for this growing population. We thus assessed the profile of AOAD in skin and blood compared to that of POAD. METHODS: We collected skin biopsies and blood from adults with AOAD, POAD, and healthy controls (n = 15 in each group). Skin samples were analyzed by RNA sequencing, qRT-PCR, and immunohistochemistry, and Olink Proseek multiplex assay was used to identify the serum proteomic profile. RESULTS: Compared to healthy controls, both AOAD and POAD showed cutaneous immune and barrier dysregulations with a shared Th2/Th22 hyperactivation. Overall, POAD showed greater inflammation in lesional skin, with more prominent expression of Th2/Th17/Th22 markers (CCL17/22, S100A8/9, IL-36A, PI3/Elafin, DEFB4) in POAD compared to AOAD (p-value &lt; .05). In contrast, higher Th1-(IFN-gamma, IL-2, IL-15, CCL5) upregulation and Th1-skewing were seen in AOAD. The epidermal barrier was also more compromised in POAD, with greater epidermal hyperplasia and lower expression of markers related to terminal differentiation, lipids, and cell adhesion. In parallel with increased rates of cardiovascular comorbidities, AOAD demonstrated many more significantly dysregulated proteins in serum (n = 148) compared to POAD (n = 86), including pro-inflammatory and cardiovascular-risk markers. Th1-related products showed significant correlations between their skin and blood expressions only in AOAD subjects. CONCLUSION: Age-of-onset delineates two distinct endophenotypes in adult AD potentially suggesting the need for broader (beyond Th2) therapeutic targeting in AOAD.</style></abstract><notes><style face="normal" font="default" size="100%">Facheris, Paola&#xD;Da Rosa, Joel Correa&#xD;Pagan, Angel D&#xD;Angelov, Michael&#xD;Del Duca, Ester&#xD;Rabinowitz, Grace&#xD;Gomez-Arias, Pedro Jesus&#xD;Rothenberg-Lausell, Camille&#xD;Estrada, Yeriel D&#xD;Bose, Swaroop&#xD;Chowdhury, Mashkura&#xD;Shemer, Avner&#xD;Pavel, Ana B&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2202-2214. doi: 10.1111/all.15741. Epub 2023 Apr 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37032461</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15741</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3055</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3055</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brigger, D.</style></author><author><style face="normal" font="default" size="100%">Steinmann, M.</style></author><author><style face="normal" font="default" size="100%">Roos, N.</style></author><author><style face="normal" font="default" size="100%">Guntern, P.</style></author><author><style face="normal" font="default" size="100%">Wurgler, O. M.</style></author><author><style face="normal" font="default" size="100%">Balsiger, L. M.</style></author><author><style face="normal" font="default" size="100%">Eggel, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department for BioMedical Research, University of Bern, Bern, Switzerland.&#xD;Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Age-Related Increase in Anaphylaxis Severity Is Associated With Enhanced Sensitivity to Allergic Mediators</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/29</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41020414</style></accession-num><notes><style face="normal" font="default" size="100%">Brigger, Daniel&#xD;Steinmann, Melanie&#xD;Roos, Nadine&#xD;Guntern, Pascal&#xD;Wurgler, Oliver M&#xD;Balsiger, Lukas Michaja&#xD;Eggel, Alexander&#xD;eng&#xD;219361/SNSF_/Swiss National Science Foundation/Switzerland&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep 29. doi: 10.1111/all.70082.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41020414</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70082</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2982</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2982</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kamphuis, J. B. J.</style></author><author><style face="normal" font="default" size="100%">Loste, A.</style></author><author><style face="normal" font="default" size="100%">Worrall, W. P. M.</style></author><author><style face="normal" font="default" size="100%">Serhan, N.</style></author><author><style face="normal" font="default" size="100%">Villeneuve, T.</style></author><author><style face="normal" font="default" size="100%">Apoil, P. A.</style></author><author><style face="normal" font="default" size="100%">Trouche-Estival, B.</style></author><author><style face="normal" font="default" size="100%">I. H. U. HealthAge INSPIRE/Open Science group</style></author><author><style face="normal" font="default" size="100%">Guilleminault, L.</style></author><author><style face="normal" font="default" size="100%">Gaudenzio, N.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), INSERM UMR1291, CNRS UMR5051, University of Toulouse, Toulouse, France.&#xD;Institut Federatif de Biologie, University Hospital Centre of Toulouse, Toulouse, France.&#xD;Department of Respiratory Medicine, University Hospital Centre of Toulouse, Toulouse, France.&#xD;Genoskin SAS, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Aging Increases the Severity of Anaphylaxis Through Changes in Mast Cell Numbers and Histamine Sensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2904-2908</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">histamine</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">research funding from ArgenX, Novartis, Ceva, and Neovacs, and is an inventor on</style></keyword><keyword><style face="normal" font="default" size="100%">patents issued or pending relating to IgE detection and anti-IgE therapies:</style></keyword><keyword><style face="normal" font="default" size="100%">EP2021/060829, EP20315224-4, WO2019197607 (A1). N.G. is (or was) collaborating,</style></keyword><keyword><style face="normal" font="default" size="100%">consulting, or a member of the scientific advisory board for Genoskin (CSO,</style></keyword><keyword><style face="normal" font="default" size="100%">shareholder), Escient Pharmaceuticals, Aikium, CEVA, MaxiVax, Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, Novartis, Sanofi, and ArgenX. The rest of the authors declare no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40654257</style></accession-num><notes><style face="normal" font="default" size="100%">Kamphuis, Jasper B J&#xD;Loste, Alexia&#xD;Worrall, William P M&#xD;Serhan, Nadine&#xD;Villeneuve, Thomas&#xD;Apoil, Pol Andre&#xD;Trouche-Estival, Benjamin&#xD;Guilleminault, Laurent&#xD;Gaudenzio, Nicolas&#xD;Reber, Laurent L&#xD;eng&#xD;Institut National de la Sante et de la Recherche Medicale/&#xD;SPF202005011962/Fondation pour la Recherche Medicale/&#xD;EQU202103012566/Fondation pour la Recherche Medicale/&#xD;ANR-23-IAHU-0011/Agence Nationale de la Recherche/&#xD;MP0022856/European Regional Development Fund/&#xD;1901175/Region Occitanie/Pyrenees-Mediterranee/&#xD;ERC-2021-CoG 101043749/ERC_/European Research Council/International&#xD;ERC-2023-COG 101124255/ERC_/European Research Council/International&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2904-2908. doi: 10.1111/all.16650. Epub 2025 Jul 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40654257</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486355</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16650</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2980</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2980</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ordak, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">AI-Assisted Statistical Review: Could It Have Averted Retractions? A Case-Based Perspective From Immunology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3441-3443</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/07/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">artificial intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">immunology</style></keyword><keyword><style face="normal" font="default" size="100%">retractions</style></keyword><keyword><style face="normal" font="default" size="100%">statistical reviews</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40673433</style></accession-num><notes><style face="normal" font="default" size="100%">Ordak, Michal&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3441-3443. doi: 10.1111/all.16669. Epub 2025 Jul 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40673433</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16669</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2907</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2907</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Okata-Karigane, U.</style></author><author><style face="normal" font="default" size="100%">Hirota, M.</style></author><author><style face="normal" font="default" size="100%">Takahashi, C.</style></author><author><style face="normal" font="default" size="100%">Miyagawa, A.</style></author><author><style face="normal" font="default" size="100%">Ako, R.</style></author><author><style face="normal" font="default" size="100%">Nakajima, S.</style></author><author><style face="normal" font="default" size="100%">Futamura, M.</style></author><author><style face="normal" font="default" size="100%">Yonekura, S.</style></author><author><style face="normal" font="default" size="100%">Ogawa, Y.</style></author><author><style face="normal" font="default" size="100%">Inomata, T.</style></author><author><style face="normal" font="default" size="100%">Ishikawa, T.</style></author><author><style face="normal" font="default" size="100%">Ito, Y.</style></author><author><style face="normal" font="default" size="100%">Masaki, K.</style></author><author><style face="normal" font="default" size="100%">Sato, S.</style></author><author><style face="normal" font="default" size="100%">Katoh, N.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author><author><style face="normal" font="default" size="100%">Adachi, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.&#xD;Allergy Center, Keio University Hospital, Shinjuku-ku, Tokyo, Japan.&#xD;Department of Orthoptics, Teikyo University, Tokyo, Japan.&#xD;Department of Medical Innovation and Translational Medical Science, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.&#xD;Atopiyo LLC, Ichikawa, Japan.&#xD;Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;ENGAGE Task Force, Tokyo, Japan.&#xD;Department of Pediatrics, NHO Nagoya Medical Center, Aichi, Japan.&#xD;Department of Advanced Medicine, Nagoya University Hospital, Aichi, Japan.&#xD;Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Department of Extended Intelligence for Medicine, The Ishii-Ishibashi Laboratory, Keio University School of Medicine.&#xD;Advanced Data Science Project, RIKEN Information R&amp;D and Strategy Headquarters, RIKEN, Yokohama, Japan.&#xD;Collective Intelligence Research Laboratory, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan.&#xD;Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.&#xD;Department of Allergy, Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Kanagawa, Japan.&#xD;North Campus, Kyoto Prefectural University of Medicine, Kyoto, Japan.&#xD;Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">AI-Based Objective Severity Assessment of Atopic Dermatitis Using Patient Photos in a Real-World Setting: A Digital Biomarker Approach</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3185-3189</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/05/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword><keyword><style face="normal" font="default" size="100%">personalized medicine</style></keyword><keyword><style face="normal" font="default" size="100%">quality-of-Life</style></keyword><keyword><style face="normal" font="default" size="100%">Iwasa Educational and Cultural Foundation and Himawari Venture Development</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation. M.H. has received grants from TAKEDA Science Foundation, Bayer Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">Co. Ltd., Topcon Corp., and Tokai Optical Holdings. S.N. has served as a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant and/or speaker (received honoraria) for Sanofi, Maruho, and Pfizer.</style></keyword><keyword><style face="normal" font="default" size="100%">S.N. is a member of an industry-academia collaboration course with Maruho. T.In.</style></keyword><keyword><style face="normal" font="default" size="100%">reports non-financial support from Lion Corporation and Sony Network</style></keyword><keyword><style face="normal" font="default" size="100%">Communications Inc.</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Yuimedi Inc., ROHTO Pharmaceutical Co. Ltd.,</style></keyword><keyword><style face="normal" font="default" size="100%">Kobayashi Pharmaceutical Co. Ltd., and Kandenko Co. Ltd.</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Santen Pharmaceutical Co. Ltd. and InnoJin Inc., outside the submitted work. N.K.</style></keyword><keyword><style face="normal" font="default" size="100%">has received honoraria as a speaker/consultant for Sanofi, Maruho, Abbvie,</style></keyword><keyword><style face="normal" font="default" size="100%">Ely-Lilly Japan, Torii Pharmaceutical, and Otsuka Pharmaceutical, and has</style></keyword><keyword><style face="normal" font="default" size="100%">received grants as an investigator from Maruho, Sun Pharma, and Leo Pharma. T.A.</style></keyword><keyword><style face="normal" font="default" size="100%">has received grants from SECOM Science and Technology Foundation and Nakayama</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation for Human Science. Other authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40390173</style></accession-num><notes><style face="normal" font="default" size="100%">Okata-Karigane, Utako&#xD;Hirota, Masakazu&#xD;Takahashi, Chiaki&#xD;Miyagawa, Akihiro&#xD;Ako, Ryotaro&#xD;Nakajima, Saeko&#xD;Futamura, Masaki&#xD;Yonekura, Satoru&#xD;Ogawa, Yasushi&#xD;Inomata, Takenori&#xD;Ishikawa, Tetsuo&#xD;Ito, Yoshihiro&#xD;Masaki, Katsunori&#xD;Sato, Sakura&#xD;Katoh, Norito&#xD;Morita, Hideaki&#xD;Adachi, Takeya&#xD;eng&#xD;JP22ek0410090/AMED/&#xD;21FE2001/The Scientific Research Fund of the Ministry of Health, Labour and Welfare, Japan/&#xD;SECOM Science and Technology Foundation/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3185-3189. doi: 10.1111/all.16586. Epub 2025 May 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40390173</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590331</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16586</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2402</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2402</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Devilliers, M. A.</style></author><author><style face="normal" font="default" size="100%">Brisebarre, A.</style></author><author><style face="normal" font="default" size="100%">Petit, L. M. G.</style></author><author><style face="normal" font="default" size="100%">Polette, M.</style></author><author><style face="normal" font="default" size="100%">Deslee, G.</style></author><author><style face="normal" font="default" size="100%">Djukanovic, R.</style></author><author><style face="normal" font="default" size="100%">Dormoy, V.</style></author><author><style face="normal" font="default" size="100%">Perotin, J. M.</style></author><author><style face="normal" font="default" size="100%">U. Biopred consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Inserm UMR-S 1250, University of Reims Champagne-Ardenne (URCA), SFR Cap-Sante, Reims, France.&#xD;Department of Biopathology, University Hospital of Reims, Reims, France.&#xD;Department of Respiratory Diseases, University Hospital of Reims, Reims, France.&#xD;NIHR Southampton Biomedical Research Centre, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Airway epithelial cell cilia transcriptomic dysregulation is associated with the inflammatory phenotype in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1982-1988</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/02/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Cilia/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Mucosa/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38372076</style></accession-num><notes><style face="normal" font="default" size="100%">Devilliers, Maeva A&#xD;Brisebarre, Audrey&#xD;Petit, Laure M G&#xD;Polette, Myriam&#xD;Deslee, Gaetan&#xD;Djukanovic, Ratko&#xD;Dormoy, Valerian&#xD;Perotin, Jeanne-Marie&#xD;eng&#xD;Universite de Reims Champagne-Ardenne/&#xD;Reims Metropole/&#xD;Institut National de la Sante et de la Recherche Medicale/&#xD;Region Champagne-Ardenne/&#xD;Fondation du Souffle/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1982-1988. doi: 10.1111/all.16063. Epub 2024 Feb 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38372076</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16063</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1275</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1275</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carlsson, C. J.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, M. A.</style></author><author><style face="normal" font="default" size="100%">Pedersen, S. B.</style></author><author><style face="normal" font="default" size="100%">Wang, N.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Chawes, B. L.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Bisgaard, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Food Science, University of Copenhagen, Frederiksberg, Denmark.&#xD;Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Airway immune mediator levels during asthma-like symptoms in young children and their possible role in response to azithromycin</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1754-1764</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/11/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Azithromycin/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">allergy and immunology</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">chemokines</style></keyword><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33150590</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma-like symptoms in young children are orchestrated by the local airway immune response, but current knowledge largely relies on in vitro airway models. Azithromycin has been shown to reduce the duration of episodes with asthma-like symptoms, but efficacy may depend on the individual child&apos;s immune response. OBJECTIVES: To investigate in vivo upper airway immune mediator levels during episodes with asthma-like symptoms in young children and their ability to predict the clinical response to azithromycin treatment. METHODS: A total of 535 children aged 0-3 years from the Copenhagen Prospective Studies of Asthma in Childhood-2010 mother-child cohort were examined for immune mediator levels in samples of nasal epithelial lining fluid during episodes with asthma-like symptoms as well as in the asymptomatic state. In a sub-study, children with recurrent asthma-like symptoms were randomized to either a 3-day course of oral azithromycin (10 mg/kg; n = 32) or placebo (n = 38). In the current study, we compared the pretreatment immune mediator levels with the clinical response to treatment with azithromycin in an exploratory post hoc analysis. RESULTS: The immune mediator concentrations during vs outside episodes were significantly upregulated for IFN-ɣ (ratio 1.73), TNF-alpha (ratio 2.05), IL-1beta (ratio 1.45), IL-10 (ratio 1.97), while CCL22 (ratio 0.65) was downregulated. Low levels of TNF-alpha and IL-10 and high levels of CCL22 predicted better treatment response to azithromycin (P-values &lt; .05). CONCLUSION: Upper airway immune mediator levels were altered during episodes of asthma-like symptoms, and levels of TNF-alpha, CCL22, and IL-10 may predict the response to azithromycin treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Carlsson, Christian J&#xD;Rasmussen, Morten A&#xD;Pedersen, Susanne B&#xD;Wang, Ni&#xD;Stokholm, Jakob&#xD;Chawes, Bo L&#xD;Bonnelykke, Klaus&#xD;Bisgaard, Hans&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1754-1764. doi: 10.1111/all.14651. Epub 2020 Nov 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33150590</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14651</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>843</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">843</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Su, Z. Q.</style></author><author><style face="normal" font="default" size="100%">Zhou, Z. Q.</style></author><author><style face="normal" font="default" size="100%">Guan, W. J.</style></author><author><style face="normal" font="default" size="100%">Fan, M. Y.</style></author><author><style face="normal" font="default" size="100%">Rao, W. Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, X. B.</style></author><author><style face="normal" font="default" size="100%">Zhong, C. H.</style></author><author><style face="normal" font="default" size="100%">Tang, C. L.</style></author><author><style face="normal" font="default" size="100%">Li, S. Y.</style></author><author><style face="normal" font="default" size="100%">Zhong, N. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.&#xD;Department of Thoracic Surgery, Guangzhou Institute for Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Airway remodeling and bronchodilator responses in asthma assessed by endobronchial optical coherence tomography</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">646-649</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/08/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Airway Remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Bronchodilator Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, Optical Coherence/methods</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchodilation</style></keyword><keyword><style face="normal" font="default" size="100%">optical coherence tomography</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34437708</style></accession-num><notes><style face="normal" font="default" size="100%">Su, Zhu-Quan&#xD;Zhou, Zi-Qing&#xD;Guan, Wei-Jie&#xD;Fan, Ming-Yue&#xD;Rao, Wan-Yuan&#xD;Chen, Yu&#xD;Chen, Xiao-Bo&#xD;Zhong, Chang-Hao&#xD;Tang, Chun-Li&#xD;Li, Shi-Yue&#xD;Zhong, Nan-Shan&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):646-649. doi: 10.1111/all.15062. Epub 2021 Aug 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34437708</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15062</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>479</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">479</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khalfaoui, L.</style></author><author><style face="normal" font="default" size="100%">Symon, F. A.</style></author><author><style face="normal" font="default" size="100%">Couillard, S.</style></author><author><style face="normal" font="default" size="100%">Hargadon, B.</style></author><author><style face="normal" font="default" size="100%">Chaudhuri, R.</style></author><author><style face="normal" font="default" size="100%">Bicknell, S.</style></author><author><style face="normal" font="default" size="100%">Mansur, A. H.</style></author><author><style face="normal" font="default" size="100%">Shrimanker, R.</style></author><author><style face="normal" font="default" size="100%">Hinks, T. S. C.</style></author><author><style face="normal" font="default" size="100%">Pavord, I. D.</style></author><author><style face="normal" font="default" size="100%">Fowler, S. J.</style></author><author><style face="normal" font="default" size="100%">Brown, V.</style></author><author><style face="normal" font="default" size="100%">McGarvey, L. P.</style></author><author><style face="normal" font="default" size="100%">Heaney, L. G.</style></author><author><style face="normal" font="default" size="100%">Austin, C. D.</style></author><author><style face="normal" font="default" size="100%">Howarth, P. H.</style></author><author><style face="normal" font="default" size="100%">Arron, J. R.</style></author><author><style face="normal" font="default" size="100%">Choy, D. F.</style></author><author><style face="normal" font="default" size="100%">Bradding, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Sciences, Leicester Respiratory NIHR BRC, Glenfield Hospital, University of Leicester, Leicester, UK.&#xD;NIHR Oxford Respiratory BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK.&#xD;Gartnavel General Hospital, Glasgow, and Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.&#xD;University of Birmingham and Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.&#xD;School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, University of Manchester, Manchester, UK.&#xD;Wellcome-Wolfson- Centre for Experimental Medicine, Queen&apos;s University Belfast School of Medicine Dentistry and Biomedical Sciences, Belfast, UK.&#xD;Genentech, Inc., South San Francisco, California, USA.&#xD;School of Clinical and Experimental Sciences, NIHR Southampton Biomedical Research Centre, University of Southampton, Southampton, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2974-2986</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/05/18</style></edition><section><style face="normal" font="default" size="100%">2974</style></section><keywords><keyword><style face="normal" font="default" size="100%">Airway Remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilia/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-5/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">FeNO</style></keyword><keyword><style face="normal" font="default" size="100%">Th2</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genzyme and the Quebec Respiratory Health Research Network</style></keyword><keyword><style face="normal" font="default" size="100%">he is the</style></keyword><keyword><style face="normal" font="default" size="100%">holder of the Association Pulmonaire du Quebec&apos;s Research Chair in Respiratory</style></keyword><keyword><style face="normal" font="default" size="100%">medicine</style></keyword><keyword><style face="normal" font="default" size="100%">he received speaker honoraria from AstraZeneca, GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Regeneron and Valeo Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">he received consultancy fees for FirstThought</style></keyword><keyword><style face="normal" font="default" size="100%">he has received sponsorship to attend international scientific meetings by</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca. He is an advisory board member for Biometry Inc-a company which is</style></keyword><keyword><style face="normal" font="default" size="100%">developing a FeNO device (myBiometry)</style></keyword><keyword><style face="normal" font="default" size="100%">the contract will be remunerated by stock</style></keyword><keyword><style face="normal" font="default" size="100%">options. RC has received lecture fees from GSK, AstraZeneca, Teva, Chiesi and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria for Advisory Board Meetings from GSK, AstraZeneca, Teva, Chiesi</style></keyword><keyword><style face="normal" font="default" size="100%">and Novarti</style></keyword><keyword><style face="normal" font="default" size="100%">sponsorship to attend international scientific meetings from Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">Napp, Sanofi, Boehringer, GSK and AstraZeneca and a research grant to her</style></keyword><keyword><style face="normal" font="default" size="100%">Institute from AstraZeneca for a UK multi-centre study. AHM has received personal</style></keyword><keyword><style face="normal" font="default" size="100%">and institutional payment for talks, advisory board meetings, education and</style></keyword><keyword><style face="normal" font="default" size="100%">research funding from GSK, AstraZeneca, Teva, Chiesi, NAPP, Sanofi, Novartis, PI.</style></keyword><keyword><style face="normal" font="default" size="100%">TSCH has received grants from Pfizer Inc., the University of Oxford, the Wellcome</style></keyword><keyword><style face="normal" font="default" size="100%">Trust, The Guardians of the Beit Fellowship, the NIHR Oxford Biomedical Research</style></keyword><keyword><style face="normal" font="default" size="100%">Centre, Sensyne Health and Kymab during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">and personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from AstraZeneca, TEVA and Peer Voice outside the submitted work. IDP, In</style></keyword><keyword><style face="normal" font="default" size="100%">the last 5 years, IDP has received speaker&apos;s honoraria for speaking at sponsored</style></keyword><keyword><style face="normal" font="default" size="100%">meetings from Astra Zeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK, and payments for organizing</style></keyword><keyword><style face="normal" font="default" size="100%">educational events from AstraZeneca, GSK, Sanofi/Regeneron and Teva. He has</style></keyword><keyword><style face="normal" font="default" size="100%">received honoraria for attending advisory panels with Genentech,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck,</style></keyword><keyword><style face="normal" font="default" size="100%">Circassia, Chiesi and Knopp, and payments to support FDA approval meetings from</style></keyword><keyword><style face="normal" font="default" size="100%">GSK. He has received sponsorship to attend international scientific meetings from</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, GSK, AstraZeneca, Teva and Chiesi. He has received a grant</style></keyword><keyword><style face="normal" font="default" size="100%">from Chiesi to support a phase 2 clinical trial in Oxford. In 2014-5 and 2019-20,</style></keyword><keyword><style face="normal" font="default" size="100%">he was an expert witness for a patent dispute involving AstraZeneca and Teva. SJF</style></keyword><keyword><style face="normal" font="default" size="100%">has received grants from Boehringer Ingelheim and fees from AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Novartis, Teva and Chiesi. LPM declares Research funding</style></keyword><keyword><style face="normal" font="default" size="100%">from Chiesi and Merck</style></keyword><keyword><style face="normal" font="default" size="100%">consultancies for Chiesi, Glaxo Smith Kline, Merck,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, Genentech and support to attend scientific meetings from Chiesi, Merck</style></keyword><keyword><style face="normal" font="default" size="100%">and Bayer. LGH reports grants from Genentech/Hoffman la Roche, during the conduct</style></keyword><keyword><style face="normal" font="default" size="100%">of the study</style></keyword><keyword><style face="normal" font="default" size="100%">other from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, personal fees from Novartis, Hoffman la Roche/Genentech Inc,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, Evelo Biosciences, Glaxo Smith Kline, Astra Zeneca, Teva, Theravance,</style></keyword><keyword><style face="normal" font="default" size="100%">Circassia, grants from Medimmune, Novartis UK, Roche/Genentech Inc and Glaxo</style></keyword><keyword><style face="normal" font="default" size="100%">Smith Kline, Amgen, Genentech/Hoffman la Roche, Astra Zeneca, Medimmune, Glaxo</style></keyword><keyword><style face="normal" font="default" size="100%">Smith Kline, Aerocrine and Vitalograph, outside the submitted work. CDA is an</style></keyword><keyword><style face="normal" font="default" size="100%">employee of Genentech. PHH is an employee of GSK. JRA is an employee of</style></keyword><keyword><style face="normal" font="default" size="100%">Genentech. DC is an employee of Genentech. PB has received research funding from</style></keyword><keyword><style face="normal" font="default" size="100%">Genentech via the University Hospitals of Leicester NHS Trust</style></keyword><keyword><style face="normal" font="default" size="100%">consultancies for</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Genentech and Celldex Therapeutics via the University of</style></keyword><keyword><style face="normal" font="default" size="100%">Leicester. Support to attend scientific meetings from Chiesi, Teva and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genzyme. BH, LC, FAS, SB, RS, VB no conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35579040</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The most recognizable phenotype of severe asthma comprises people who are blood eosinophil and FeNO-high, driven by type 2 (T2) cytokine biology, which responds to targeted biological therapies. However, in many people with severe asthma, these T2 biomarkers are suppressed but poorly controlled asthma persists. The mechanisms driving asthma in the absence of T2 biology are poorly understood. OBJECTIVES: To explore airway pathology in T2 biomarker-high and -low severe asthma. METHODS: T2 biomarker-high severe asthma (T2-high, n = 17) was compared with biomarker-intermediate (T2-intermediate, n = 21) and biomarker-low (T2-low, n = 20) severe asthma and healthy controls (n = 28). Bronchoscopy samples were processed for immunohistochemistry, and sputum for cytokines, PGD(2) and LTE(4) measurements. RESULTS: Tissue eosinophil, neutrophil and mast cell counts were similar across severe asthma phenotypes and not increased when compared to healthy controls. In contrast, the remodelling features of airway smooth muscle mass and MUC5AC expression were increased in all asthma groups compared with health, but similar across asthma subgroups. Submucosal glands were increased in T2-intermediate and T2-low asthma. In spite of similar tissue cellular inflammation, sputum IL-4, IL-5 and CCL26 were increased in T2-high versus T2-low asthma, and several further T2-associated cytokines, PGD(2) and LTE(4) , were increased in T2-high and T2-intermediate asthma compared with healthy controls. CONCLUSIONS: Eosinophilic tissue inflammation within proximal airways is suppressed in T2 biomarker-high and T2-low severe asthma, but inflammatory and structural cell activation is present, with sputum T2-associated cytokines highest in T2 biomarker-high patients. Airway remodelling persists and may be important for residual disease expression beyond eosinophilic exacerbations. Registered at ClincialTrials.gov: NCT02883530.</style></abstract><notes><style face="normal" font="default" size="100%">Khalfaoui, Latifa&#xD;Symon, Fiona A&#xD;Couillard, Simon&#xD;Hargadon, Beverley&#xD;Chaudhuri, Rekha&#xD;Bicknell, Steve&#xD;Mansur, Adel H&#xD;Shrimanker, Rahul&#xD;Hinks, Timothy S C&#xD;Pavord, Ian D&#xD;Fowler, Stephen J&#xD;Brown, Vanessa&#xD;McGarvey, Lorcan P&#xD;Heaney, Liam G&#xD;Austin, Cary D&#xD;Howarth, Peter H&#xD;Arron, Joseph R&#xD;Choy, David F&#xD;Bradding, Peter&#xD;eng&#xD;211050/Z/18/Z/WT_/Wellcome Trust/United Kingdom&#xD;MR/M016579/1/MRC_/Medical Research Council/United Kingdom&#xD;DH_/Department of Health/United Kingdom&#xD;Clinical Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):2974-2986. doi: 10.1111/all.15376. Epub 2022 May 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35579040</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9790286</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15376</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2652</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2652</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rhee, H.</style></author><author><style face="normal" font="default" size="100%">Henderson, L. M.</style></author><author><style face="normal" font="default" size="100%">Bauer, R. N.</style></author><author><style face="normal" font="default" size="100%">Wong, K.</style></author><author><style face="normal" font="default" size="100%">Staton, T. L.</style></author><author><style face="normal" font="default" size="100%">Choy, D. F.</style></author><author><style face="normal" font="default" size="100%">Banerjee, P.</style></author><author><style face="normal" font="default" size="100%">Poon, V.</style></author><author><style face="normal" font="default" size="100%">Yoshida, K.</style></author><author><style face="normal" font="default" size="100%">Chen, C.</style></author><author><style face="normal" font="default" size="100%">Long, K.</style></author><author><style face="normal" font="default" size="100%">Sperinde, G.</style></author><author><style face="normal" font="default" size="100%">Laing, S. T.</style></author><author><style face="normal" font="default" size="100%">Jones, N. S.</style></author><author><style face="normal" font="default" size="100%">Glickstein, S. B.</style></author><author><style face="normal" font="default" size="100%">Dayal, P.</style></author><author><style face="normal" font="default" size="100%">Fong, A.</style></author><author><style face="normal" font="default" size="100%">Dash, A.</style></author><author><style face="normal" font="default" size="100%">Pulka, G.</style></author><author><style face="normal" font="default" size="100%">Leaker, B.</style></author><author><style face="normal" font="default" size="100%">Singh, D.</style></author><author><style face="normal" font="default" size="100%">Bradding, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Early Clinical Development, Ophthalmology, Metabolism, Neurology, Immunology (OMNI), Genentech, Inc., South San Francisco, California, USA.&#xD;Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.&#xD;Department of Translational Medicine, Genentech, Inc., South San Francisco, California, USA.&#xD;Human Pathobiology and OMNI Reverse Translation, Genentech, Inc., South San Francisco, California, USA.&#xD;Data and Statistical Sciences, Genentech, Inc., South San Francisco, California, USA.&#xD;Department of BioAnalytical Sciences, Genentech, Inc., South San Francisco, California, USA.&#xD;Safety Assessment Pathology, Genentech, Inc., South San Francisco, California, USA.&#xD;Real World Data Science Enabling Platform, Product Development Data Sciences, Genentech, Inc., South San Francisco, California, USA.&#xD;Portfolio Clinical Safety, Genentech, Inc., South San Francisco, California, USA.&#xD;Early Development Safety, Genentech, Inc., South San Francisco, California, USA.&#xD;Centrum Medyczne All-Med, Krakow, Poland.&#xD;Respiratory Clinical Trials Ltd., Queen Anne Street Medical Center, London, UK.&#xD;Medicines Evaluations Unit, Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK.&#xD;Department of Respiratory Sciences, University of Leicester, Leicester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2993-3004</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/09/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Tryptases/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Asthmatic Agents/therapeutic use/pharmacokinetics/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">antibody</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trials</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">tryptase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39250147</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tryptase, a mast cell protease, has been identified as a potential therapeutic target in managing patients with refractory asthma. We assessed the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTPS9579A, an anti-tryptase antibody, in a phase 2a randomized trial for patients with uncontrolled asthma and a phase 1c trial to understand activity within the lower respiratory tract. METHODS: Phase 2a patients (n = 134) received 1800 mg MTPS9579A or placebo intravenously every 4 weeks for 48 weeks. The primary endpoint was time to the first composite exacerbation event. Phase 1c patients (n = 27) received one intravenous dose of 300 or 1800 mg MTPS9579A or placebo. Both trials measured MTPS9579A concentrations and effects on tryptase in serum and nasal lining fluid; phase 1c also analyzed bronchial lining fluid. RESULTS: MTPS9579A did not meet the primary endpoint (hazard ratio = 0.90; 95% CI: 0.55-1.47; p = 0.6835); exacerbation rates in the placebo group were low. Serum and nasal MTPS9579A pharmacokinetics and tryptase levels were consistent with data from healthy volunteers. However, in phase 1c patients, compared to nasal levels, MTPS9579A bronchial concentrations were 6.8-fold lower, and bronchial active and total tryptase levels were higher (119-fold and 30-fold, respectively). Pharmacokinetic/pharmacodynamic modeling predicted intravenous doses of 3800 mg every 4 weeks would be necessary to achieve 95% active tryptase inhibition from baseline. CONCLUSIONS: The MTPS9579A dose tested in the phase 2a study was insufficient to inhibit tryptase in bronchial lining fluid, likely contributing to the observed lack of efficacy.</style></abstract><notes><style face="normal" font="default" size="100%">Rhee, Horace&#xD;Henderson, Lindsay M&#xD;Bauer, Rebecca N&#xD;Wong, Kit&#xD;Staton, Tracy L&#xD;Choy, David F&#xD;Banerjee, Prajna&#xD;Poon, Victor&#xD;Yoshida, Kenta&#xD;Chen, Chen&#xD;Long, Keyi&#xD;Sperinde, Gizette&#xD;Laing, Steven T&#xD;Jones, Nicholas S&#xD;Glickstein, Sara B&#xD;Dayal, Parul&#xD;Fong, Alice&#xD;Dash, Ajit&#xD;Pulka, Grazyna&#xD;Leaker, Brian&#xD;Singh, Dave&#xD;Bradding, Peter&#xD;eng&#xD;Genentech/&#xD;National Institute for Health Research/&#xD;Clinical Trial, Phase II&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):2993-3004. doi: 10.1111/all.16309. Epub 2024 Sep 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39250147</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16309</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>354</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">354</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salvati, L.</style></author><author><style face="normal" font="default" size="100%">Mazzoni, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Alarming inflammation: The TGFbeta1-Nrp1 pathway upregulates the IL-33 axis in lung ILC2s</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3471-3472</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/08/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-33/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35960644</style></accession-num><notes><style face="normal" font="default" size="100%">Salvati, Lorenzo&#xD;Mazzoni, Alessio&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3471-3472. doi: 10.1111/all.15478. Epub 2022 Aug 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35960644</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15478</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1882</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1882</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salvati, L.</style></author><author><style face="normal" font="default" size="100%">Mazzoni, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Alarming inflammation: The TGFbeta1-Nrp1 pathway upregulates the IL-33 axis in lung ILC2s</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3471-3472</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/08/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-33/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35960644</style></accession-num><notes><style face="normal" font="default" size="100%">Salvati, Lorenzo&#xD;Mazzoni, Alessio&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3471-3472. doi: 10.1111/all.15478. Epub 2022 Aug 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35960644</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15478</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2993</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2993</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chaker, A.</style></author><author><style face="normal" font="default" size="100%">Kauppi, P.</style></author><author><style face="normal" font="default" size="100%">Bavbek, S.</style></author><author><style face="normal" font="default" size="100%">Bossios, A.</style></author><author><style face="normal" font="default" size="100%">Chatzipetrou, A.</style></author><author><style face="normal" font="default" size="100%">Firinu, D.</style></author><author><style face="normal" font="default" size="100%">Rogala, B.</style></author><author><style face="normal" font="default" size="100%">Matucci, A.</style></author><author><style face="normal" font="default" size="100%">Vultaggio, A.</style></author><author><style face="normal" font="default" size="100%">Panzner, P.</style></author><author><style face="normal" font="default" size="100%">Feleszko, W.</style></author><author><style face="normal" font="default" size="100%">Eliashar, R.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Torres, M.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Kolios, A. G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">TUM School of Medicine and Health, Department of Otolaryngology and Center of Allergy and Environment, TUM University Hospital, Technical University of Munich, Munich, Germany.&#xD;Pulmonary Department and University of Helsinki, Helsinki University Hospital, Heart and Lung Center, Helsinki, Finland.&#xD;School of Medicine, Department of Chest Diseases, Division of Immunology and Allergy, Ankara University, Ankara, Turkey.&#xD;Karolinska Severe Asthma Center, Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.&#xD;Division of Lung and Airway Research, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.&#xD;Lung Laboratory, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.&#xD;Allergy Unit &quot;D. Kalogeromitros&quot;, 2nd Dpt. of Dermatology and Venereology, University General Hospital Attikon, Athens, Greece.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.&#xD;Univestity Medical Centre Medical University of Silesia, Katowice, Poland.&#xD;Immunoallergology Unit, Careggi University Hospital, Florence, Italy.&#xD;Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.&#xD;Dept. of Immunology and Allergology, Medical Faculty in Pilsen, Charles University in Prague, Praha, Czechia.&#xD;Department of Pediatric Pulmonology and Allergy, The Medical University of Warsaw, Warsaw, Poland.&#xD;Hadassah Medical Center, Hebrew University School of Medicine, Jerusalem, Israel.&#xD;Transylvania University, Brasov, Romania.&#xD;Center for Rhinology and Allergy, Wiesbaden, Germany.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga; Allergy Research Group, IBIMA-Plataforma BIONAND, Malaga University, Malaga, Spain.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Biochemistry and Molecular Biology, School of Pharmacy, Complutense University of Madrid, Madrid, Spain.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St.Polten, Austria.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Department of Dermatology, University of Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Alert Card for Patients on Biologicals and Immunosuppressives: An EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3233-3236</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">biological</style></keyword><keyword><style face="normal" font="default" size="100%">biologicals</style></keyword><keyword><style face="normal" font="default" size="100%">educational material</style></keyword><keyword><style face="normal" font="default" size="100%">immunosuppressive</style></keyword><keyword><style face="normal" font="default" size="100%">patient adherence</style></keyword><keyword><style face="normal" font="default" size="100%">patient alert card</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">research support and other, all via Technical University of Munich from</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, ALK Abello, Astra Zeneca, Bencard/Allergen Therapeutics, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Hippo Dx, LETI, Roche, Zeller, Sanofi, Regeneron, Thermo Fisher,</style></keyword><keyword><style face="normal" font="default" size="100%">European Institute of Technology (EIT Health) and Federal Ministery of Research</style></keyword><keyword><style face="normal" font="default" size="100%">and Education Germany. Consultancy or speaker honoria GSK, Swedish Orphan</style></keyword><keyword><style face="normal" font="default" size="100%">Biovitrum, Sanofi, AstraZeneca. Principal investigator: Theravance, MSD. Other:</style></keyword><keyword><style face="normal" font="default" size="100%">Chair of the Finnish Respiratory Society. speaker honoraria, consultancy or</style></keyword><keyword><style face="normal" font="default" size="100%">advisory fees and/or research support from GSK, AstraZeneca and Novartis. A.B.</style></keyword><keyword><style face="normal" font="default" size="100%">reports a grant from AstraZeneca, honoraria, and lecture fees from AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, and GSK paid to his institution outside the submitted work. A.C. reports</style></keyword><keyword><style face="normal" font="default" size="100%">speaker honoraria from Astra Zeneca, Pfizer, GSK. Advisory fees and/or research</style></keyword><keyword><style face="normal" font="default" size="100%">support from Takeda, CSL Behring, GSK and Novartis. B.R. and A.M. declare no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest for this work. A.V. received speaker honoraria, consultancy</style></keyword><keyword><style face="normal" font="default" size="100%">or advisory fees from GSK, AstraZeneca, Sanofi Genzyme. P.P. declares no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest for this work. W.F. received speaker&apos;s honoraria from Astra</style></keyword><keyword><style face="normal" font="default" size="100%">Zeneca. R.E. declares no conflict of interests for this work. I.A. Deputy editor</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy journal. L.K., M.T. and O.P. declare no conflicts of interest for this</style></keyword><keyword><style face="normal" font="default" size="100%">work. O.P. received research grants from MINECO, Ministerio de Ciencia e</style></keyword><keyword><style face="normal" font="default" size="100%">Innovacion, Inmunotek S.L., Novartis, and AstraZeneca and fees for giving</style></keyword><keyword><style face="normal" font="default" size="100%">scientific lectures or participation in Advisory Boards from: AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, GlaxoSmithKline, Inmunotek S.L, Novartis, Sanofi-Genzyme and Regeneron.</style></keyword><keyword><style face="normal" font="default" size="100%">M.S. declares no conflict of interests for this work. T. Eiwegger reports to</style></keyword><keyword><style face="normal" font="default" size="100%">act/recently acted as local PI for company sponsored trials by DBV Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">Greer Stallergens, Novartis, and sub-investigator for Regeneron and ALK-Abello.</style></keyword><keyword><style face="normal" font="default" size="100%">He/his lab received unconditional/in-kind contributions from Macro Array.</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostics and ALK-Abello and he is co-I in an investigator-initiated trial with</style></keyword><keyword><style face="normal" font="default" size="100%">in-kind support from Novartis. He holds advisory board roles for ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi and Nutricia/Danone. T.E. reports lecture fees from Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">ThermoFisher, Nutricia/Danone, MADX, ALK-Abello. A.G.A.K. declares no conflict of</style></keyword><keyword><style face="normal" font="default" size="100%">interests for this work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40632138</style></accession-num><abstract><style face="normal" font="default" size="100%">[Image: see text]</style></abstract><notes><style face="normal" font="default" size="100%">Chaker, Adam&#xD;Kauppi, Paula&#xD;Bavbek, Sevim&#xD;Bossios, Apostolos&#xD;Chatzipetrou, Alexia&#xD;Firinu, Davide&#xD;Rogala, Barbara&#xD;Matucci, Andrea&#xD;Vultaggio, Alessandra&#xD;Panzner, Petr&#xD;Feleszko, Wojciech&#xD;Eliashar, Ron&#xD;Agache, Ioanna&#xD;Klimek, Ludger&#xD;Torres, Maria&#xD;Pfaar, Oliver&#xD;Palomares, Oscar&#xD;Shamji, Mohamed&#xD;Eiwegger, Thomas&#xD;Kolios, Antonios G A&#xD;eng&#xD;This Position Paper was supported by the European Academy of Allergy and Clinical Immunology (EAACI) under the EAACI IG Biologicals and Task force &quot;Patient Card Biologicals/Immunsuppressives&quot; (#40243, 2017-2018)/&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3233-3236. doi: 10.1111/all.16656. Epub 2025 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40632138</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666755</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16656</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1512</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1512</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Romano, A.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Allergy Unit, Presidio Columbus, Rome, Italy.&#xD;Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.&#xD;Departamento de Medicina, Facultad de Medicina, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Algorithm for betalactam allergy diagnosis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1817-1819</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2019/04/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Hypersensitivity/*diagnosis/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">beta-Lactams/*adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31034613</style></accession-num><notes><style face="normal" font="default" size="100%">Dona, Inmaculada&#xD;Romano, Antonino&#xD;Torres, Maria Jose&#xD;eng&#xD;PI-0241-2016/Andalusian Government/International&#xD;RD16/0006/0001/Institute of Health Carlos III of Ministry of Economy and Competitiveness (cofounded by European Regional Development Fund)/International&#xD;PI15-01206/Institute of Health Carlos III of Ministry of Economy and Competitiveness (cofounded by European Regional Development Fund)/International&#xD;PI18-00095/Institute of Health Carlos III of Ministry of Economy and Competitiveness (cofounded by European Regional Development Fund)/International&#xD;B-0001-2017/Consejeria de Salud of Junta de Andalucia/International&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2019 Sep;74(9):1817-1819. doi: 10.1111/all.13844. Epub 2019 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31034613</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13844</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2642</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2642</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Skypala, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Division of Immunology and Allergy, The Hospital for Sick Children and the SickKids Food Allergy and Anaphylaxis Program, Toronto, Ontario, Canada.&#xD;Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Royal Brompton &amp; Harefield Hospitals, part of Guys &amp; St Thomas NHS Foundation Trust, London, UK.&#xD;Department of Inflammation and Repair, Imperial College, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An algorithm for the diagnosis and management of IgE-mediated food allergy, 2024 update</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">629-632</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/09/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">adrenaline</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword><keyword><style face="normal" font="default" size="100%">skin prick test</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39302341</style></accession-num><notes><style face="normal" font="default" size="100%">Santos, Alexandra F&#xD;Riggioni, Carmen&#xD;Du Toit, George&#xD;Skypala, Isabel&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):629-632. doi: 10.1111/all.16321. Epub 2024 Sep 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39302341</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16321</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3018</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3018</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hamelmann, E.</style></author><author><style face="normal" font="default" size="100%">Schaub, B.</style></author><author><style face="normal" font="default" size="100%">Lau, S.</style></author><author><style face="normal" font="default" size="100%">Bacharier, L. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Children&apos;s Center Bethel, Bielefeld, University Hospital OWL, University of Bielefeld, Germany.&#xD;Department of Pulmonary and Allergy, Dept. of Paediatrics, Dr von Hauner Children&apos;s Hospital, University Children&apos;s Hospital, Ludwig-Maximilians-University, Munich, Germany.&#xD;Comprehensive Pneumology Center (CPC-M), LMU Munich, Member of the German Center for Lung Research (DZL), and German Center for Child and Adolescent Health (DZKJ), Dr von Hauner Children&apos;s Hospital, LMU Munich, Germany.&#xD;Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Pediatrics, Monroe Carell Jr. Children&apos;s Hospital at Vanderbilt University Medical Center, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An Algorithm for the Diagnosis and Management of Severe Asthma in Children and Adolescents</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">307-310</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">paediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals Inc., Sanofi-speaker/consultant fees</style></keyword><keyword><style face="normal" font="default" size="100%">BMBF, BMG, MAGS,</style></keyword><keyword><style face="normal" font="default" size="100%">G-BA-research support</style></keyword><keyword><style face="normal" font="default" size="100%">Wolff-data and safety monitoring board. Bianca Schaub:</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, Novartis, AstraZeneca, Sanofi-speaker/consultant fees</style></keyword><keyword><style face="normal" font="default" size="100%">German Center for</style></keyword><keyword><style face="normal" font="default" size="100%">Child and Adolescent Health (DZKJ</style></keyword><keyword><style face="normal" font="default" size="100%">LMU/LMU Klinikum: 01GL2406A), DFG-research</style></keyword><keyword><style face="normal" font="default" size="100%">support</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Data Safety Monitoring Board. Susanne Lau: Received honoraria for</style></keyword><keyword><style face="normal" font="default" size="100%">lectures and advisory boards from Sanofi-Aventis, AstraZeneca, Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">ALK, GSK, Leo Pharma, Leti, Viatris, Lilly, and DBV. Leonard B. Bacharier:</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GSK, OM Pharma, Regeneron Pharmaceuticals Inc.,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-speaker/consultant fees</style></keyword><keyword><style face="normal" font="default" size="100%">NIH, OM Pharma, Sanofi, Vectura-research support</style></keyword><keyword><style face="normal" font="default" size="100%">Aravax, AstraZeneca, Cystic Fibrosis Foundation, DBV Technologies-data and safety</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring board.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40879251</style></accession-num><abstract><style face="normal" font="default" size="100%">Severe asthma (SA) in childhood is infrequent ( approximately 2% of all paediatric asthma), yet it drives a disproportionate share of morbidity and cost. A clear algorithm is required to distinguish difficult-to-treat asthma (DTA) from true SA and to guide phenotype-driven diagnosis and therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Hamelmann, Eckard&#xD;Schaub, Bianca&#xD;Lau, Susanne&#xD;Bacharier, Leonard B&#xD;eng&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):307-310. doi: 10.1111/all.70027. Epub 2025 Aug 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40879251</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773671</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70027</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2552</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2552</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Bonnekoh, H.</style></author><author><style face="normal" font="default" size="100%">Grekowitz, E.</style></author><author><style face="normal" font="default" size="100%">Kiefer, L.</style></author><author><style face="normal" font="default" size="100%">Munoz, M.</style></author><author><style face="normal" font="default" size="100%">Pereira, M. P.</style></author><author><style face="normal" font="default" size="100%">Terhorst-Molawi, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An algorithm for the diagnosis and treatment of chronic inducible urticaria, 2024 update</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2573-2576</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/07/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Urticaria/diagnosis/etiology/drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39056446</style></accession-num><notes><style face="normal" font="default" size="100%">Maurer, Marcus&#xD;Bonnekoh, Hanna&#xD;Grekowitz, Eva&#xD;Kiefer, Lea&#xD;Munoz, Melba&#xD;Pereira, Manuel P&#xD;Terhorst-Molawi, Dorothea&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2573-2576. doi: 10.1111/all.16250. Epub 2024 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39056446</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16250</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2604</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2604</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfefferle, M.</style></author><author><style face="normal" font="default" size="100%">Greuter, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Limmattalspital, Schlieren, Switzerland.&#xD;Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Division of Gastroenterology and Hepatology, University Hospital Lausanne - CHUV, Lausanne, Switzerland.&#xD;Division of Gastroenterology and Hepatology, GZO -Zurich Regional Health Center, Wetzikon, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An algorithm for the diagnosis and treatment of eosinophilic esophagitis in adults, 2024 update</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3546-3549</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/08/21</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39166414</style></accession-num><notes><style face="normal" font="default" size="100%">Pfefferle, Marc&#xD;Greuter, Thomas&#xD;eng&#xD;Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3546-3549. doi: 10.1111/all.16279. Epub 2024 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39166414</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16279</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2756</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2756</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beaudoin, M.</style></author><author><style face="normal" font="default" size="100%">Mehra, A.</style></author><author><style face="normal" font="default" size="100%">Wong, L. S. Y.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Ortiz, M.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Delgado, P.</style></author><author><style face="normal" font="default" size="100%">Nowak-Wegrzyn, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, NYU Grossman School of Medicine, Hassenfeld Children&apos;s Hospital, New York, New York, USA.&#xD;Department of Pediatrics, National University of Singapore, Singapore, Singapore.&#xD;Paediatric Allergy, Imperial College NHS Healthcare Trust, London, UK.&#xD;Allergy Service, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.&#xD;Clinical Medicine Department, University Miguel Hernandez, Alicante, Spain.&#xD;Allergy Section, Alicante General University Hospital Dr. Balmis, Alicante, Spain.&#xD;Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An Algorithm for the Diagnosis and Treatment of Food Protein-Induced Enterocolitis Syndrome (FPIES), 2024 Update</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">362-365</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/12/10</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39655844</style></accession-num><notes><style face="normal" font="default" size="100%">Beaudoin, Michele&#xD;Mehra, Ashna&#xD;Wong, Lydia Su Yin&#xD;Vazquez-Ortiz, Marta&#xD;Gonzalez-Delgado, Purificacion&#xD;Nowak-Wegrzyn, Anna&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):362-365. doi: 10.1111/all.16432. Epub 2024 Dec 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39655844</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16432</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2584</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2584</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sturm, G. J.</style></author><author><style face="normal" font="default" size="100%">Arzt-Gradwohl, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An algorithm for the diagnosis and treatment of Hymenoptera venom allergy, 2024 update</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2298-2301</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hymenoptera/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthropod Venoms/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Insect Bites and Stings/therapy/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38978291</style></accession-num><notes><style face="normal" font="default" size="100%">Sturm, Gunter J&#xD;Arzt-Gradwohl, Lisa&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2298-2301. doi: 10.1111/all.16219. Epub 2024 Jul 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38978291</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16219</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2697</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2697</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Saenz de Santa Maria, R.</style></author><author><style face="normal" font="default" size="100%">Moreno, E. M.</style></author><author><style face="normal" font="default" size="100%">Bartra, J.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;RICORS de Enfermedades Inflamatorias, Instituto de Salud Carlos III, Madrid, Spain.&#xD;Departamento de Medicina, Universidad de Malaga-UMA, Malaga, Spain.&#xD;Allergy Service, Hospital Universitario de Salamanca, Salamanca, Spain.&#xD;Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.&#xD;Department of Biomedical and Diagnostic Sciences, Salamanca Medical School, University of Salamanca, Salamanca, Spain.&#xD;Clinical and Experimental Respiratory Immunoallergy (IRCE), Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.&#xD;Allergy Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.&#xD;Medicine Department, Faculty of Medicine, University of Barcelona, Barcelona, Spain.&#xD;Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An algorithm for the diagnosis and treatment of nonsteroidal antiinflammatory drugs hypersensitivity, 2024 update</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1183-1186</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/10/04</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39365158</style></accession-num><notes><style face="normal" font="default" size="100%">Dona, Inmaculada&#xD;Saenz de Santa Maria, Rocio&#xD;Moreno, Esther Maria&#xD;Bartra, Joan&#xD;Torres, Maria Jose&#xD;eng&#xD;Instituto de Salud Carlos III/&#xD;News&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1183-1186. doi: 10.1111/all.16349. Epub 2024 Oct 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39365158</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16349</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2696</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2696</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Moreno, E.</style></author><author><style face="normal" font="default" size="100%">Ferrer, M.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;RICORS de Enfermedades Inflamatorias, Instituto de Salud Carlos III, Madrid, Spain.&#xD;Allergy Service, Hospital Universitario de Salamanca, Salamanca, Spain.&#xD;Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.&#xD;Department of Biomedical and Diagnostic Sciences, Salamanca Medical School, University of Salamanca, Salamanca, Spain.&#xD;Department of Allergy, Clinica Universidad de Navarra, Pamplona, Spain.&#xD;Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.&#xD;Departamento de Medicina, Universidad de Malaga-UMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An algorithm for the diagnosis of beta-lactam allergy, 2024 update</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">633-637</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/10/05</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39367663</style></accession-num><notes><style face="normal" font="default" size="100%">Dona, Inmaculada&#xD;Salas, Maria&#xD;Moreno, Esther&#xD;Ferrer, Marta&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;eng&#xD;Instituto de Salud Carlos III/&#xD;News&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):633-637. doi: 10.1111/all.16348. Epub 2024 Oct 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39367663</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16348</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2430</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2430</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kaplan, A. P.</style></author><author><style face="normal" font="default" size="100%">Ferrer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, The Medical University of South Carolina, Charleston, South Carolina, USA.&#xD;Department of Allergy, Clinica Universidad de Navarra, Pamplona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An algorithm for the diagnosis, pathogenesis and treatment of chronic spontaneous urticaria, 2024 update</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2567-2569</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/04/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/diagnosis/etiology/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">histamine</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38558416</style></accession-num><notes><style face="normal" font="default" size="100%">Kaplan, Allen P&#xD;Ferrer, Marta&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2567-2569. doi: 10.1111/all.16113. Epub 2024 Apr 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38558416</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16113</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2760</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2760</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">de Corso, E.</style></author><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author><author><style face="normal" font="default" size="100%">Harvey, R. J.</style></author><author><style face="normal" font="default" size="100%">Hopkins, C.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolarynogology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Unit of Otorhinolaryngology and Head-Neck Surgery, &apos;A. Gemelli&apos; University Hospital Foundation IRCCS, Rome, Italy.&#xD;Department of Otorhinolaryngology, University of Leuven, Leuven, Belgium.&#xD;The European Forum for Research and Education in Allergy and Airway Diseases Scientific Expert Team Members, Brussels, Belgium.&#xD;Rhinology and Skull Base Research Group, St Vincent&apos;s Centre for Applied Medical Research, University of New South Wales, Sydney, Australia.&#xD;Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.&#xD;King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Algorithm for the Management of Primary Diffuse Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">359-361</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/12/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword><keyword><style face="normal" font="default" size="100%">primary diffuse chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">received grants for research in Rhinology from: Novartis, EU, GSK and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Aventis. Wytske Fokkens received consultation and/or speaker fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Dianosic, GSK, Novartis, Sanofi-Aventis/Regeneron and AstraZeneca. Eugenio de</style></keyword><keyword><style face="normal" font="default" size="100%">Corso received lecture fees and participations on expert board meeting of GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Sanofi, Firma and AstraZeneca. Richard J Harvey is consultant/advisory</style></keyword><keyword><style face="normal" font="default" size="100%">board with Medtronic, Novartis, Glaxo-Smith-Kline and Neil Med Pharmaceuticals.</style></keyword><keyword><style face="normal" font="default" size="100%">He has been on the speakers&apos; bureau for Sanofi, Viatris, Proctor and Gamble,</style></keyword><keyword><style face="normal" font="default" size="100%">Glaxo-Smith-Kline, Astra-Zeneca, Meda Pharmaceuticals and Seqirus. He is research</style></keyword><keyword><style face="normal" font="default" size="100%">grant recipient Glaxo-Smith-Kline, Sanofi and Stallergenes. Peter Hellings has</style></keyword><keyword><style face="normal" font="default" size="100%">received honoraria and/or research grants from Sanofi/Regeneron, GSK, Vialtris</style></keyword><keyword><style face="normal" font="default" size="100%">and ALK. Claire Hopkins is an advisory board member of AstraZeneca, BioInspire</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Dianosic, GlaxoSmithKline and Sanofi. Sietze Reitsma reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants, consulting fees and honoraria from Sanofi and Novartis and GSK.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39641626</style></accession-num><notes><style face="normal" font="default" size="100%">Fokkens, W J&#xD;de Corso, E&#xD;Hellings, P W&#xD;Harvey, R J&#xD;Hopkins, C&#xD;Reitsma, S&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):359-361. doi: 10.1111/all.16417. Epub 2024 Dec 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39641626</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724224</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16417</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2532</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2532</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brockow, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Biederstein, School of Medicine and Health, Technical University of Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An algorithm for the management of radiocontrast media hypersensitivity, 2024 update</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2570-2572</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/06/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Contrast Media/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Hypersensitivity/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/etiology/drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38887890</style></accession-num><notes><style face="normal" font="default" size="100%">Brockow, Knut&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2570-2572. doi: 10.1111/all.16191. Epub 2024 Jun 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38887890</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16191</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1499</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1499</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Angier, E.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Halken, S.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Primary Care and Population Sciences, University of Southampton, Southampton, UK.&#xD;Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy.&#xD;Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Odense, Denmark.&#xD;Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Isle of Wight, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Algorithms in allergen immunotherapy in allergic rhinoconjunctivitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2411-2414</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2020/03/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">algorithm</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical recommendations</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32163594</style></accession-num><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Angier, Elizabeth&#xD;Muraro, Antonella&#xD;Halken, Susanne&#xD;Roberts, Graham&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2020 Sep;75(9):2411-2414. doi: 10.1111/all.14270. Epub 2020 Apr 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32163594</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14270</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2602</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2602</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Darsow, U.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author><author><style face="normal" font="default" size="100%">Jappe, U.</style></author><author><style face="normal" font="default" size="100%">Platts-Mills, T. A.</style></author><author><style face="normal" font="default" size="100%">Unal, D.</style></author><author><style face="normal" font="default" size="100%">Biedermann, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Biederstein, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.&#xD;Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Division of Clinical and Molecular Allergology, Research Center Borstel, Airway Research, Center North (ARCN), Member of the German Center for Lung Research, Borstel, Germany.&#xD;Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University of Luebeck, Luebeck, Germany.&#xD;School of Medicine, Department of Medicine, Division of Asthma, Allergy, and Immunology, University of Virginia, Charlottesville, Virginia, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Algorithms in allergy: An algorithm for alpha-Gal syndrome diagnosis and treatment, 2024 update</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3169-3172</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/08/23</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39175257</style></accession-num><notes><style face="normal" font="default" size="100%">Darsow, U&#xD;Gelincik, A&#xD;Jappe, U&#xD;Platts-Mills, T A&#xD;Unal, D&#xD;Biedermann, T&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3169-3172. doi: 10.1111/all.16291. Epub 2024 Aug 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39175257</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16291</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2747</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2747</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Zemelka-Wiacek, M.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Immunology, Faculty of Medicine of Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Algorithms in Allergy: Assessment of Rhinitis Using Allergen Exposure Chambers</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">904-907</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/12/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergen exposure chamber</style></keyword><keyword><style face="normal" font="default" size="100%">allergen provocation test</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39688144</style></accession-num><notes><style face="normal" font="default" size="100%">Jutel, Marek&#xD;Zemelka-Wiacek, Magdalena&#xD;Okamoto, Yoshitaka&#xD;Pfaar, Oliver&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):904-907. doi: 10.1111/all.16444. Epub 2024 Dec 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39688144</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16444</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2651</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2651</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hren, M. G.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">He, H.</style></author><author><style face="normal" font="default" size="100%">Ji, A. L.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Algorithms in allergy: Diagnosis and management of atopic dermatitis in adulthood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3550-3552</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/09/11</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39258454</style></accession-num><notes><style face="normal" font="default" size="100%">Hren, M Grace&#xD;Del Duca, Ester&#xD;He, Helen&#xD;Ji, Andrew L&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;K08 CA263187/CA/NCI NIH HHS/&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3550-3552. doi: 10.1111/all.16315. Epub 2024 Sep 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39258454</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12641416</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16315</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2996</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2996</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Traidl, S.</style></author><author><style face="normal" font="default" size="100%">Heratizadeh, A.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Algorithms in Allergy: Diagnosis and Treatment of Atopic Dermatitis Complicated by Eczema Herpeticum</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2417-2420</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/07/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Hsv</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">eczema herpeticum</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 immune response</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword><keyword><style face="normal" font="default" size="100%">consultant and lecturer for AbbVie, ALK, Galderma, Incyte, Lilly Pharma, Leo</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Janssen, Novartis, and Sanofi. A.H. declares consulting fees and/or</style></keyword><keyword><style face="normal" font="default" size="100%">travel grants from Janssen, AbbVie, Almirall, Lilly, Novartis, Pierre Fabre,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, Beiersdorf, Leo Pharma, Nutricia, Hans Karrer, Meda, Klinge Pharma, ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">and Pfizer.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40600392</style></accession-num><notes><style face="normal" font="default" size="100%">Traidl, Stephan&#xD;Heratizadeh, Annice&#xD;Werfel, Thomas&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2417-2420. doi: 10.1111/all.16632. Epub 2025 Jul 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40600392</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368745</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16632</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3323</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3323</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Asero, R.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Pravettoni, V.</style></author><author><style face="normal" font="default" size="100%">Scala, E.</style></author><author><style face="normal" font="default" size="100%">Villalta, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.&#xD;Allergy and Clinical Immunology Unit, San Giovanni di Dio Hospital, Firenze, Italy.&#xD;SC Medicina Generale-Immunologia e Allergologia, IRCCS Ca&apos; Granda, Ospedale Maggiore Policlinico, Milano, Italy.&#xD;Fondazione Luigi Maria Monti, IDI-IRCCS, Roma, Italy.&#xD;S.C. di Immunologia e Allergologia di Laboratorio, PO S. Maria degli Angeli, Pordenone, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Algorithms in Allergy: Diagnosis and Treatment of Pollen Food Syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/03/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pollen</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41792853</style></accession-num><notes><style face="normal" font="default" size="100%">Asero, R&#xD;Cecchi, L&#xD;Pravettoni, V&#xD;Scala, E&#xD;Villalta, D&#xD;eng&#xD;Denmark&#xD;Allergy. 2026 Mar 6. doi: 10.1111/all.70286.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41792853</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70286</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3327</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3327</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, H. J.</style></author><author><style face="normal" font="default" size="100%">Trifonova, D.</style></author><author><style face="normal" font="default" size="100%">Gattinger, P.</style></author><author><style face="normal" font="default" size="100%">Dramburg, S.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P. M.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Center for Molecular Allergology, Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Life Improvement by Future Technologies (LIFT) Center, Moscow, Russia.&#xD;Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Clinical Immunology, Faculty of Medicine of Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Institute of Allergology, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Algorithms in Allergy: General Allergen Molecule-Based Algorithm for Allergen-Specific Immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/03/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">immunologic tests</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 2</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41771548</style></accession-num><notes><style face="normal" font="default" size="100%">Huang, Huey-Jy&#xD;Trifonova, Daria&#xD;Gattinger, Pia&#xD;Dramburg, Stephanie&#xD;Jutel, Marek&#xD;Matricardi, Paolo Maria&#xD;Valenta, Rudolf&#xD;eng&#xD;Russian Science Foundation/&#xD;Danube Allergy Research Cluster, Country of Lower Austria/&#xD;Denmark&#xD;Allergy. 2026 Mar 2. doi: 10.1111/all.70278.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41771548</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70278</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3281</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3281</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bork, K.</style></author><author><style face="normal" font="default" size="100%">Magerl, M.</style></author><author><style face="normal" font="default" size="100%">Aygoren-Pursun, E.</style></author><author><style face="normal" font="default" size="100%">Farkas, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, University Medical Center, Johannes Gutenberg University, Mainz, Germany.&#xD;Institute of Allergology, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany.&#xD;Department for Children and Adolescents, Goethe-University Frankfurt, Frankfurt, Germany.&#xD;Hungarian Angioedema Centre of Reference and Excellence, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Algorithms in Allergy: Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/02/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 2</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41629755</style></accession-num><notes><style face="normal" font="default" size="100%">Bork, Konrad&#xD;Magerl, Markus&#xD;Aygoren-Pursun, Emel&#xD;Farkas, Henriette&#xD;eng&#xD;Denmark&#xD;Allergy. 2026 Feb 2. doi: 10.1111/all.70241.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41629755</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70241</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2663</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2663</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Johnson, M.</style></author><author><style face="normal" font="default" size="100%">Kline, O.</style></author><author><style face="normal" font="default" size="100%">Torres Jaen, M. J.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA Plataforma Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Algorithms in allergy: Management of allergic reactions to COVID-19 vaccines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">638-640</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/10/30</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39475414</style></accession-num><notes><style face="normal" font="default" size="100%">Johnson, Mary&#xD;Kline, Olivia&#xD;Torres Jaen, Maria Jose&#xD;Nadeau, Kari C&#xD;eng&#xD;U54 CA260517/CA/NCI NIH HHS/&#xD;anonymous donor/&#xD;NH/NIH HHS/&#xD;Sunshine Foundation/&#xD;News&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):638-640. doi: 10.1111/all.16358. Epub 2024 Oct 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39475414</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11805645</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16358</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3219</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3219</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hilger, C.</style></author><author><style face="normal" font="default" size="100%">Sekerel, B. E.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Hemmer, W.</style></author><author><style face="normal" font="default" size="100%">Konradsen, J. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infection &amp; Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Pediatric Allergy and Asthma Division, School of Medicine, Hacettepe University, Ankara, Turkiye.&#xD;Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.&#xD;Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.&#xD;Floridsdorf Allergy Center, Vienna, Austria.&#xD;Astrid Lindgren Children&apos;s Hospital, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Women&apos;s and Children&apos;s Health, Karolinska Institutet, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Algorithms in Allergy: Molecular Allergology in the Context of Animal Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41582700</style></accession-num><notes><style face="normal" font="default" size="100%">Hilger, Christiane&#xD;Sekerel, Bulent E&#xD;van Hage, Marianne&#xD;Hemmer, Wolfgang&#xD;Konradsen, Jon R&#xD;eng&#xD;2021/16734157/Luxembourg National Research Fund (FNR)/&#xD;20240563/Swedish Heart-Lung Foundation/&#xD;FoUI-986234/Region Stockholm/&#xD;FoUI-1002791/Region Stockholm/&#xD;F2022-0011/The Swedish Asthma and Allergy Association&apos;s Research Foundation/&#xD;The Swedish Cancer and Allergy Foundation/&#xD;The Hesselman Foundation/&#xD;Foundation &quot;Frimurare Barnhuset in Stockholm,&quot;/&#xD;240018/Konsul Th. C. Bergh&apos;s Foundation/&#xD;Denmark&#xD;Allergy. 2026 Jan 26. doi: 10.1111/all.70234.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41582700</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70234</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2601</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2601</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Asllani, J.</style></author><author><style face="normal" font="default" size="100%">Mitsias, D.</style></author><author><style face="normal" font="default" size="100%">Konstantinou, G.</style></author><author><style face="normal" font="default" size="100%">Qirko, E.</style></author><author><style face="normal" font="default" size="100%">Hitaj, M.</style></author><author><style face="normal" font="default" size="100%">Musollari, S.</style></author><author><style face="normal" font="default" size="100%">Christoff, G.</style></author><author><style face="normal" font="default" size="100%">Novakova, S.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Radulovic Pevec, M.</style></author><author><style face="normal" font="default" size="100%">Pevec, B.</style></author><author><style face="normal" font="default" size="100%">Muntean, A.</style></author><author><style face="normal" font="default" size="100%">Tomic-Spiric, V.</style></author><author><style face="normal" font="default" size="100%">Stosovic, R.</style></author><author><style face="normal" font="default" size="100%">Kosnik, M.</style></author><author><style face="normal" font="default" size="100%">Mungan, D.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Calderon, M.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Ader Study Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, University of Medicine, Tirana, Albania.&#xD;Allergy and Asthma Medical Clinic, Tirana, Albania.&#xD;Allergy Department 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.&#xD;University Hospital Center &quot;Mother Teresa&quot;, Tirana, Albania.&#xD;Ambulatory Polyclinic of Specialties, Tirana, Albania.&#xD;Musollari Allergy Clinic, Tirana, Albania.&#xD;Medical University-Sofia, Faculty of Public Health, Sofia, Bulgaria.&#xD;Internal Consulting Department, Allergy Unit University hospital &quot;Sv. Georgi&quot;, Plovdiv, Bulgaria.&#xD;Immunotherapy Outpatient Clinic, Allergy Unit, 2nd Department Dermatology and Venereology, National and Kapodistrian University of Athens, University General Hospital &apos;Attikon&apos;, Athens, Greece.&#xD;Clinic for Lung Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia.&#xD;Immunology and Allergology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.&#xD;Allergology and Immunology Ambulatory, Professor Doctor Octavian Fodor Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.&#xD;Clinic of Allergology and Immunology, University Clinical Center of Serbia, Belgrade, Serbia.&#xD;Faculty of Medicine, University of Belgrade, Belgrade, Serbia.&#xD;University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.&#xD;Department of Allergy and Immunology, Ankara University School of Medicine, Ankara, Turkey.&#xD;University Hospital &quot;Sv Ivan Rilski&quot;, Sofia, Bulgaria.&#xD;Section of Allergy and Clinical Immunology, Imperial College London-NHLI, London, UK.&#xD;Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergen immunotherapy adverse events in adults with respiratory allergies-data from ADER: An EAACI task force report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">775-784</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/08/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/adverse effects/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Hypersensitivity/therapy/immunology/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">adverse reactions</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">real-world data</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39175252</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Registries can yield important insights on allergen immunotherapy (AIT) outcomes in daily clinical practice. However, systematic recordings of adverse events (AE) due to AIT in real-life are lacking. METHODS: The Allergen Immunotherapy Adverse Events Registry (ADER) is a prospective, multicenter registry on real-life AIT safety. Data on adults (&gt;18 years old) with respiratory allergies receiving AIT with mites, pollens, epithelia, and/or molds were retrieved and analyzed from ADER. The frequency, characteristics and risk factors of AE were investigated. The MedDRA terminology was used to record AE. RESULTS: A total of 1545 individuals with a mean age of 33 +/- 10 years receiving 1815 AIT courses (n = 1060 sublingual (SLIT); n = 755 subcutaneous (SCIT)) in centers from eight countries were included. Patients had allergic rhinitis (65%) or, asthma only (3.7%) or rhinitis with asthma (31.2%). Grass was the most frequent specific sensitizer (60.7%), followed by mites (45.5%), birch pollen (20.6%), epithelia (16.1%), and molds (8%). There were 296 AE recorded in 115 patients (7.4%). A higher frequency of AE occurred during up-dosing (59%) compared to maintenance. Severe reactions were rare (0.2%), all in the context of SCIT. After 6 weeks of maintenance only one moderate AE was recorded. The most frequently reported symptoms were from the respiratory system and the skin. Having asthma, doing SCIT, AIT with mugwort, cat, or birch were associated with higher risk for AE while the use of allergoids induced lower risk. CONCLUSION: In real life clinical practice, AIT-associated AE occur in a minority of patients, while severe reactions are rare. The presence of asthma and use of SCIT are risk factors, while the use of modified allergens lowers the risk.</style></abstract><notes><style face="normal" font="default" size="100%">Asllani, Julijana&#xD;Mitsias, Dimitrios&#xD;Konstantinou, George&#xD;Qirko, Etleva&#xD;Hitaj, Mirela&#xD;Musollari, Sybi&#xD;Christoff, George&#xD;Novakova, Silviya&#xD;Makris, Michael&#xD;Radulovic Pevec, Mira&#xD;Pevec, Branko&#xD;Muntean, Adriana&#xD;Tomic-Spiric, Vesna&#xD;Stosovic, Rajica&#xD;Kosnik, Mitja&#xD;Mungan, Dilsad&#xD;Popov, Todor A&#xD;Calderon, Moises&#xD;Papadopoulos, Nikolaos G&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Stallergenes/&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):775-784. doi: 10.1111/all.16286. Epub 2024 Aug 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39175252</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16286</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>647</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">647</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">de Silva, D.</style></author><author><style face="normal" font="default" size="100%">Rodriguez Del Rio, P.</style></author><author><style face="normal" font="default" size="100%">de Jong, N. W.</style></author><author><style face="normal" font="default" size="100%">Khaleva, E.</style></author><author><style face="normal" font="default" size="100%">Singh, C.</style></author><author><style face="normal" font="default" size="100%">Nowak-Wegrzyn, A.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Begin, P.</style></author><author><style face="normal" font="default" size="100%">Pajno, G.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author><author><style face="normal" font="default" size="100%">Sanchez, A.</style></author><author><style face="normal" font="default" size="100%">Jones, C.</style></author><author><style face="normal" font="default" size="100%">Nilsson, C.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Wong, G.</style></author><author><style face="normal" font="default" size="100%">Sampson, H.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Marchisotto, M. J.</style></author><author><style face="normal" font="default" size="100%">Fernandez Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Meyer, R.</style></author><author><style face="normal" font="default" size="100%">Lau, S.</style></author><author><style face="normal" font="default" size="100%">Nurmatov, U.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Ga Len Food Allergy Guidelines Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Evidence Centre, London, UK.&#xD;Nino Jesus University Children&apos;s Hospital, Madrid, Spain.&#xD;University Medical Centre Rotterdam, Rotterdam, The Netherlands.&#xD;University of Southampton, London, UK.&#xD;The Evidence Centre, Wellington, New Zealand.&#xD;NYU Langone Health, New York, New York, USA.&#xD;Padua University Hospital, Padua, Italy.&#xD;Univerisite de Montreal, Montreal, QC, Canada.&#xD;Policlinico Hospital-University of Messina, Messina, Italy.&#xD;Bambino Gesu Childrens&apos; Hospital IRCCS, Rome, Italy.&#xD;AEPNAA Spanish Association for People with Food and Latex Allergy, Madrid, Spain.&#xD;Allergy UK, London, UK.&#xD;Karolinska Institutet and Sachs Children and Youth Hospital, Stockholm, Sweden.&#xD;Odense University Hospital, Odense, Denmark.&#xD;Chinese University of Hong Kong, Hong Kong, Hong Kong.&#xD;Mount Sinai School of Medicine, New York, New York, USA.&#xD;Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;EAACI Patient Organisation Committee Chair, New York, New York, USA.&#xD;Hospital Clinico San Carlos, Madrid, Spain.&#xD;Imperial College, London, UK.&#xD;Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Cardiff University, Cardiff, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1852-1862</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/01/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Chickens</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/adverse effects/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Egg Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-mediated</style></keyword><keyword><style face="normal" font="default" size="100%">biological</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut</style></keyword><keyword><style face="normal" font="default" size="100%">review process. Pablo Rodriguez del Rio, Personal fees: Aimmune, Nicolette W. de</style></keyword><keyword><style face="normal" font="default" size="100%">Jong, none declared. Ekaterina Khaleva, none declared. Chris Singh, none</style></keyword><keyword><style face="normal" font="default" size="100%">declared. Organisation received GA(2)LEN funding to support review process. Anna</style></keyword><keyword><style face="normal" font="default" size="100%">Nowak-Wegrzyn, Personal fees: Nestle, Novartis, Sanofil. Antonella Muraro,</style></keyword><keyword><style face="normal" font="default" size="100%">Personal fees: Aimmune, DVB, Mylan, ALK, Nestle, Novartis, Nutricia Research.</style></keyword><keyword><style face="normal" font="default" size="100%">Grant: Aimmune, Sanofil. Philippe Begin, Personal fees: ALK, DBV, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofil, Giovanni Pajno, none declared. Alessandro Fiocchi, Personal fees:</style></keyword><keyword><style face="normal" font="default" size="100%">Ferrero. Grant: Danone, HIPP. Angel Sanchez, none declared. Carla Jones, none</style></keyword><keyword><style face="normal" font="default" size="100%">declared. Organisation received funding to support projects. Caroline Nilsson,</style></keyword><keyword><style face="normal" font="default" size="100%">Grant: Aimmune, Thermofisher. Carsten Bindslev-Jensen, Personal fees: Allakos,</style></keyword><keyword><style face="normal" font="default" size="100%">CEV SA. Grant: Novartis. Gary Wong, none declared. Hugh Sampson, Personal fees:</style></keyword><keyword><style face="normal" font="default" size="100%">DBV, N-fold, Siolta. Kirsten Beyer, Personal fees: Aimmune, Bencard, Danone, DBV,</style></keyword><keyword><style face="normal" font="default" size="100%">HIPP, Hycor, Infectopharm, Jenapharma, Mylan/Meda, Nestle, Novartis, Nutricia</style></keyword><keyword><style face="normal" font="default" size="100%">Research, Thermofisher. Grants: Aimmune, Danone/Nutricia/Milipa, DBV, Hipp,</style></keyword><keyword><style face="normal" font="default" size="100%">Hycor, Infectopharm. Mary-Jane Marchisotto, none declared. Montserrat Fernandez</style></keyword><keyword><style face="normal" font="default" size="100%">Rivas, Personal fees: Therapeutics, ALK, Allergy Therapeutics, DBV, Diater, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Thermofisher Scientific, SPRIM. Rosan Meyer, Personal fees: Abbott, Danone,</style></keyword><keyword><style face="normal" font="default" size="100%">Nestle, Mead Johnson. Susanne Lau, none declared. Ulugbek Nurmatov, none</style></keyword><keyword><style face="normal" font="default" size="100%">declared. Graham Roberts, Grant: UK Food Standards Agency, DBV, European Union.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35001400</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: There is substantial interest in immunotherapy and biologicals in IgE-mediated food allergy. METHODS: We searched six databases for randomized controlled trials about immunotherapy alone or with biologicals (to April 2021) or biological monotherapy (to September 2021) in food allergy confirmed by oral food challenge. We pooled the data using random-effects meta-analysis. RESULTS: We included 36 trials about immunotherapy with 2126 mainly child participants. Oral immunotherapy increased tolerance whilst on therapy for peanut (RR 9.9, 95% CI 4.5.-21.4, high certainty); cow&apos;s milk (RR 5.7, 1.9-16.7, moderate certainty) and hen&apos;s egg allergy (RR 8.9, 4.4-18, moderate certainty). The number needed to treat to increase tolerance to a single dose of 300 mg or 1000 mg peanut protein was 2. Oral immunotherapy did not increase adverse reactions (RR 1.1, 1.0-1.2, low certainty) or severe reactions in peanut allergy (RR 1,6, 0.7-3.5, low certainty), but may increase (mild) adverse reactions in cow&apos;s milk (RR 3.9, 2.1-7.5, low certainty) and hen&apos;s egg allergy (RR 7.0, 2.4-19.8, moderate certainty). Epicutaneous immunotherapy increased tolerance whilst on therapy for peanut (RR 2.6, 1.8-3.8, moderate certainty). Results were unclear for other allergies and administration routes. There were too few trials of biologicals alone (3) or with immunotherapy (1) to draw conclusions. CONCLUSIONS: Oral immunotherapy improves tolerance whilst on therapy and is probably safe in peanut, cow&apos;s milk and hen&apos;s egg allergy. More research is needed about quality of life, cost and biologicals.</style></abstract><notes><style face="normal" font="default" size="100%">de Silva, Debra&#xD;Rodriguez Del Rio, Pablo&#xD;de Jong, Nicolette W&#xD;Khaleva, Ekaterina&#xD;Singh, Chris&#xD;Nowak-Wegrzyn, Anna&#xD;Muraro, Antonella&#xD;Begin, Philippe&#xD;Pajno, Giovanni&#xD;Fiocchi, Alessandro&#xD;Sanchez, Angel&#xD;Jones, Carla&#xD;Nilsson, Caroline&#xD;Bindslev-Jensen, Carsten&#xD;Wong, Gary&#xD;Sampson, Hugh&#xD;Beyer, Kirsten&#xD;Marchisotto, Mary-Jane&#xD;Fernandez Rivas, Montserrat&#xD;Meyer, Rosan&#xD;Lau, Susanne&#xD;Nurmatov, Ulugbek&#xD;Roberts, Graham&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1852-1862. doi: 10.1111/all.15211. Epub 2022 Jan 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35001400</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9303769</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15211</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>545</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">545</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Farraia, M.</style></author><author><style face="normal" font="default" size="100%">Paciencia, I.</style></author><author><style face="normal" font="default" size="100%">Castro Mendes, F.</style></author><author><style face="normal" font="default" size="100%">Cavaleiro Rufo, J.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">EPIUnit - Institute of Public Health, University of Porto, Porto, Portugal.&#xD;Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal.&#xD;Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Sao Joao University Hospital Center, Porto, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergen immunotherapy for asthma prevention: A systematic review and meta-analysis of randomized and non-randomized controlled studies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1719-1735</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/03/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35342949</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated diseases. Randomized controlled trials (RCTs) support AIT&apos;s potential role in asthma prevention but evidence from non-randomized studies of interventions (NRSI) and longitudinal observational studies has been poorly addressed. Therefore, we aimed to conduct a systematic review and meta-analysis to assess clinical data from all study types to evaluate quantitatively the preventive role of AIT in asthma onset. METHODS: We search three databases. Studies were screened, selected and evaluated for quality using risk-of-bias (ROB) tools. Data were descriptively summarized and meta-analysed using random effects. We performed a sensitivity, influence and subgroup analyses. Publication bias and heterogeneity were assessed. RESULTS: From the 4549 identified studies, 24 (12 RCTs and 12 NRSI) were included in the qualitative synthesis and 18 underwent meta-analysis. One study was at low ROB, seven had moderate ROB, and 15 were proven of high ROB. Random-effects analysis showed a significant decrease in the risk of developing asthma following AIT by 25% (RR, 95% CI: 0.75, 0.64-0.88). This effect was not significant in the sensitivity analysis. Publication bias raised concerns, together with the moderate heterogeneity between studies (I(2) = 58%). Subgroup analysis showed a remarkable preventive effect of AIT in children (RR, 95% CI: 0.71, 0.53-0.96), when completing 3 years of therapy (RR, 95% CI: 0.64, 0.47-0.88), and in mono-sensitized patients (RR, 95% CI: 0.49, 0.39-0.61). CONCLUSIONS: Our findings support a possible preventive effect of AIT in asthma onset and suggest an enhanced effect when administered in children, mono-sensitized, and for at least 3 years, independently of allergen type.</style></abstract><notes><style face="normal" font="default" size="100%">Farraia, Mariana&#xD;Paciencia, Ines&#xD;Castro Mendes, Francisca&#xD;Cavaleiro Rufo, Joao&#xD;Shamji, Mohamed&#xD;Agache, Ioana&#xD;Moreira, Andre&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1719-1735. doi: 10.1111/all.15295. Epub 2022 Apr 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35342949</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15295</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1163</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1163</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paoletti, G.</style></author><author><style face="normal" font="default" size="100%">Di Bona, D.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Firinu, D.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">DunnGalvin, A.</style></author><author><style face="normal" font="default" size="100%">Genuneit, J.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, H. J.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS and Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari - Aldo Moro, Bari, Italy.&#xD;Division of Immunology and Allergy, Department of Health Research Methods, Evidence and Impact, Department of Medicine, McMaster University, Hamilton, ON, Canada.&#xD;The Research Institute of St. Joe&apos;s Hamilton, Hamilton, ON, Canada.&#xD;Department of Clinical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Department of Allergy and Clinical Immunology, Faculty of Medicine, Transylvania University of Brasov, Brasov, Romania.&#xD;Department of Clinical Immunology, Wroclaw Medical University and &quot;ALLMED&quot;Medical Research Institute, Wroclaw, Poland.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Faculty of Medicine, Institute of Medical Statistics and Computational Biology (IMSB), University of Cologne and CRI - Clinical Research International Limited, Cologne, Germany.&#xD;School of Applied Psychology and Department of Paediatrics &amp; Child Health, University College Cork, Cork, Ireland.&#xD;Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.&#xD;Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany.&#xD;Department of Clinical Medicine, Aarhus University and Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergen immunotherapy: The growing role of observational and randomized trial &quot;Real-World Evidence&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2663-2672</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/02/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">real-world evidence</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33583050</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Although there is a considerable body of knowledge about allergen immunotherapy (AIT), there is a lack of data on the reliability of real-world evidence (RWE) in AIT, and consequently, a lack of information on how AIT effectively works in real life. METHODS: To address the current unmet need for an appraisal of the quality of RWE in AIT, the European Academy of Allergy and Clinical Immunology Methodology Committee recently initiated a systematic review of observational studies of AIT, which will use the RELEVANT tool and the Grading of Recommendations Assessment, Development and Evaluation approach (GRADE) to rate the quality of the evidence base as a whole. The next step will be to develop a broadly applicable, pragmatic &quot;real-world&quot; database using systematic data collection. Based on the current RWE base, and perspectives and recommendations of authorities and scientific societies, a hierarchy of RWE in AIT is proposed, which places pragmatic trials and registry data at the positions of highest level of evidence. KEY RESULTS: There is a need to establish more AIT registries that collect data in a cohesive way, using standardized protocols. CONCLUSIONS: This will provide an essential source of real-world data that can be easily shared, promoting evidence-based research and quality improvement in study design and clinical decision-making.</style></abstract><notes><style face="normal" font="default" size="100%">Paoletti, Giovanni&#xD;Di Bona, Danilo&#xD;Chu, Derek K&#xD;Firinu, Davide&#xD;Heffler, Enrico&#xD;Agache, Ioana&#xD;Jutel, Marek&#xD;Klimek, Ludger&#xD;Pfaar, Oliver&#xD;Mosges, Ralph&#xD;DunnGalvin, Audrey&#xD;Genuneit, Jon&#xD;Hoffmann, Hans Jurgen&#xD;Canonica, Giorgio Walter&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2663-2672. doi: 10.1111/all.14773.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33583050</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14773</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>294</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">294</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lozano-Ojalvo, D.</style></author><author><style face="normal" font="default" size="100%">Tyler, S. R.</style></author><author><style face="normal" font="default" size="100%">Aranda, C. J.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Sicherer, S.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author><author><style face="normal" font="default" size="100%">Wood, R. A.</style></author><author><style face="normal" font="default" size="100%">Burks, A. W.</style></author><author><style face="normal" font="default" size="100%">Jones, S. M.</style></author><author><style face="normal" font="default" size="100%">Leung, D. Y. M.</style></author><author><style face="normal" font="default" size="100%">de Lafaille, M. C.</style></author><author><style face="normal" font="default" size="100%">Berin, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Icahn School of Medicine at Mount Sinai, Jaffe Food Allergy Institute, New York, New York, USA.&#xD;Icahn School of Medicine at Mount Sinai, Precision Immunology Institute, New York, New York, USA.&#xD;Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.&#xD;Department of Medicine and Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.&#xD;Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children&apos;s Hospital, Little Rock, Arkansas, USA.&#xD;Department of Pediatrics, National Jewish Health, Denver, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergen recognition by specific effector Th2 cells enables IL-2-dependent activation of regulatory T-cell responses in humans</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">697-713</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/09/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Il-2</style></keyword><keyword><style face="normal" font="default" size="100%">antigen-specific T cell</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">oral tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">peanut</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cell</style></keyword><keyword><style face="normal" font="default" size="100%">Infectious Diseases, Aimmune, DBV Technologies, and Regeneron, and consultancy</style></keyword><keyword><style face="normal" font="default" size="100%">fees from ALK Abello and Jubilant HollisterStier. S. Sicherer reports royalty</style></keyword><keyword><style face="normal" font="default" size="100%">payments from UpToDate and from Johns Hopkins University Press</style></keyword><keyword><style face="normal" font="default" size="100%">grants to his</style></keyword><keyword><style face="normal" font="default" size="100%">institution from the National Institute of Allergy and Infectious Diseases, from</style></keyword><keyword><style face="normal" font="default" size="100%">Food Allergy Research and Education, and from Pfizer</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from the</style></keyword><keyword><style face="normal" font="default" size="100%">American Academy of Allergy, Asthma and Immunology as Deputy Editor of the</style></keyword><keyword><style face="normal" font="default" size="100%">Journal of Allergy and Clinical Immunology: In Practice, outside of the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. H.A. Sampson receives consultancy fees from N-Fold, LLC, DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">and Siolta Therapeutics, grant funding from the National Institutes of Health</style></keyword><keyword><style face="normal" font="default" size="100%">(NIH)/National Institute of Allergy and Infectious Diseases (NIAID), and</style></keyword><keyword><style face="normal" font="default" size="100%">royalties from Elsevier. R.A. Wood receives research support from NIH, Aimmune,</style></keyword><keyword><style face="normal" font="default" size="100%">DBV, Genentech, Novartis, Regeneron, and Siolta, and Royalties from UpToDate.</style></keyword><keyword><style face="normal" font="default" size="100%">S.M. Jones reports grants to her institution from the National Institute of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Infectious Diseases and from Food Allergy Research and Education</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trials funding to her institution from Aimmune Therapeutics, Inc., DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Inc., Regeneron Pharmaceuticals, Inc., Astellas Pharma, Inc.,</style></keyword><keyword><style face="normal" font="default" size="100%">Genentech, Inc.</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from Aimmune Therapeutics, Inc. as a member of</style></keyword><keyword><style face="normal" font="default" size="100%">the scientific advisory board and FDA advisory consultant, from Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Inc. as a research advisory consultant, and from Astellas</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Inc. as scientific advisory consultant. D.Y.M. Leung receives research</style></keyword><keyword><style face="normal" font="default" size="100%">support from NIH and Sanofi-Genzyme Pharma and acts as a Consultant/Advisory</style></keyword><keyword><style face="normal" font="default" size="100%">Board Member for Boeheringer Ingelheim, Evommune Inc., Genentech Inc., Leo</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, and Incyte Corporation. M. Curotto de Lafaille received advisory</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Genentech. Wesley Burks receives grant support to his institution from</style></keyword><keyword><style face="normal" font="default" size="100%">the National Institutes of Health and the Burroughs Wellcome Fund</style></keyword><keyword><style face="normal" font="default" size="100%">royalties from</style></keyword><keyword><style face="normal" font="default" size="100%">UpToDate, Elsevier, and Wolter Kluwer</style></keyword><keyword><style face="normal" font="default" size="100%">consulting honorariums from Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics Ltd and DBV Technologies, as well as honorariums from Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Consortia TX, and Ukko for his service on their respective</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific Advisory Boards. The rest of the authors have nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36089900</style></accession-num><abstract><style face="normal" font="default" size="100%">Type 2 allergen-specific T cells are essential for the induction and maintenance of allergies to foods, and Tregs specific for these allergens are assumed to be involved in their resolution. However, it has not been convincingly demonstrated whether allergen-specific Treg responses are responsible for the generation of oral tolerance in humans. We observed that sustained food allergen exposure in the form of oral immunotherapy resulted in increased frequency of Tregs only in individuals with lasting clinical tolerance. We sought to identify regulatory components of the CD4(+) T-cell response to food allergens by studying their functional activation over time in vitro and in vivo. Two subsets of Tregs expressing CD137 or CD25/OX40 were identified with a delayed kinetics of activation compared with clonally enriched pathogenic effector Th2 cells. Treg activation was dependent on IL-2 derived from effector T cells. In vivo exposure to peanut in the form of an oral food challenge of allergic subjects induced a delayed and persistent activation of Tregs after initiation of the allergen-specific Th2 response. The novel finding of our work is that a sustained wave of Treg activation is induced by the release of IL-2 from Th2 effector cells, with the implication that therapeutic administration of IL-2 could improve current OIT approaches.</style></abstract><notes><style face="normal" font="default" size="100%">Lozano-Ojalvo, Daniel&#xD;Tyler, Scott R&#xD;Aranda, Carlos J&#xD;Wang, Julie&#xD;Sicherer, Scott&#xD;Sampson, Hugh A&#xD;Wood, Robert A&#xD;Burks, A Wesley&#xD;Jones, Stacie M&#xD;Leung, Donald Y M&#xD;de Lafaille, Maria Curotto&#xD;Berin, M Cecilia&#xD;eng&#xD;R01 AI130343/AI/NIAID NIH HHS/&#xD;UM1 AI130570/AI/NIAID NIH HHS/&#xD;K99 HG011270/HG/NHGRI NIH HHS/&#xD;R01 AI151707/AI/NIAID NIH HHS/&#xD;U19 AI136053/AI/NIAID NIH HHS/&#xD;UM1 AI130781/AI/NIAID NIH HHS/&#xD;R01 AI153708/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):697-713. doi: 10.1111/all.15512. Epub 2022 Sep 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36089900</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10111618</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15512</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2777</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2777</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Kim, E. H.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Ortiz, M.</style></author><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart and Lung Institute, Imperial College, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Franklin-Kay Allergy Centre, Imperial College, London, UK.&#xD;Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergen-Specific B Cell Responses Following Desensitisation and Natural Tolerance to Cow&apos;s Milk Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">12-13</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/12/23</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39711083</style></accession-num><notes><style face="normal" font="default" size="100%">Shamji, Mohamed H&#xD;Kim, Edwin H&#xD;Vazquez-Ortiz, Marta&#xD;Turner, Paul J&#xD;Layhadi, Janice A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):12-13. doi: 10.1111/all.16443. Epub 2024 Dec 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39711083</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16443</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2577</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2577</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Satitsuksanoa, P.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Lopez, J. F.</style></author><author><style face="normal" font="default" size="100%">Wirz, O.</style></author><author><style face="normal" font="default" size="100%">Jansen, K.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Mirer, D.</style></author><author><style face="normal" font="default" size="100%">Globinska, A.</style></author><author><style face="normal" font="default" size="100%">Boonpiyathad, T.</style></author><author><style face="normal" font="default" size="100%">Schneider, S. R.</style></author><author><style face="normal" font="default" size="100%">Barletta, E.</style></author><author><style face="normal" font="default" size="100%">Spits, H.</style></author><author><style face="normal" font="default" size="100%">Chang, I.</style></author><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">Tahrali, I.</style></author><author><style face="normal" font="default" size="100%">Deniz, G.</style></author><author><style face="normal" font="default" size="100%">Yucel, E. O.</style></author><author><style face="normal" font="default" size="100%">Kiykim, A.</style></author><author><style face="normal" font="default" size="100%">Boyd, S. D.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Functional Genomics Center Zurich, ETH Zurich, Zurich, Switzerland.&#xD;Department of Pathology, Stanford University, Stanford, California, USA.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Swiss Institute of Bioinformatics, Laussane, Switzerland.&#xD;Department of Experimental Immunology, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford, California, USA.&#xD;Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.&#xD;Division of Pediatrics, Department of Pediatric Allergy and Immunology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Department of Pediatric Allergy and Immunology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergen-specific B cell responses in oral immunotherapy-induced desensitization, remission, and natural outgrowth in cow&apos;s milk allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">161-180</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/07/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity/immunology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">*B-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Remission Induction</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Bos d 9 (Bos taurus domestic 9 or alphaS1-casein)</style></keyword><keyword><style face="normal" font="default" size="100%">RNA sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific B cells</style></keyword><keyword><style face="normal" font="default" size="100%">cow&apos;s milk allergy</style></keyword><keyword><style face="normal" font="default" size="100%">natural tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy (OIT)</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis Research Institutes, AstraZeneca, Swiss National Science Foundation,</style></keyword><keyword><style face="normal" font="default" size="100%">Christine Kuhne-Center for Allergy Research and Education, grant from European</style></keyword><keyword><style face="normal" font="default" size="100%">Commission Horizon 2020 Framework Programme, Cure, advisory role in</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron, and SciBase, Sweden. M.S. reports research grants from the</style></keyword><keyword><style face="normal" font="default" size="100%">Swiss National Science Foundation (No. 310030_189334/1), GSK and Novartis and a</style></keyword><keyword><style face="normal" font="default" size="100%">speaker&apos;s fee from AstraZeneca. S.D.B. has consulted for Regeneron, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Genent and Novartis on topics unrelated to this study, owns stock in Ab Cellera</style></keyword><keyword><style face="normal" font="default" size="100%">Biologics, has received grant support from the U.S. National Institutes of Health</style></keyword><keyword><style face="normal" font="default" size="100%">and the Bill and Melinda Gates Foundation, and has an endowment from the Crown</style></keyword><keyword><style face="normal" font="default" size="100%">Family Foundation. M.A has received research grants from the Swiss National</style></keyword><keyword><style face="normal" font="default" size="100%">Science Foundation (310,030_201,053/1), European Union (EU CURE, EU Syn-Air-G),</style></keyword><keyword><style face="normal" font="default" size="100%">is the Co-Chair for EAACI Scientific Program</style></keyword><keyword><style face="normal" font="default" size="100%">is on the Advisory Boards of</style></keyword><keyword><style face="normal" font="default" size="100%">Stanford University Sean Parker Asthma Allergy Center (CA, USA), LEO Foundation</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Immunology Research Center Copenhagen, Denmark. W.V. has consulted for</style></keyword><keyword><style face="normal" font="default" size="100%">Mabylon AG on topics unrelated to this study and has received grant support from</style></keyword><keyword><style face="normal" font="default" size="100%">the Promedica foundation, Novartis Freenovation and the EoE foundation.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38989779</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Antigen-specific memory B cells play a key role in the induction of desensitization and remission to food allergens in oral immunotherapy and in the development of natural tolerance (NT). Here, we characterized milk allergen Bos d 9-specific B cells in oral allergen-specific immunotherapy (OIT) and in children spontaneously outgrowing cow&apos;s milk allergy (CMA) due to NT. METHODS: Samples from children with CMA who received oral OIT (before, during, and after), children who naturally outgrew CMA (NT), and healthy individuals were received from Stanford biobank. Bos d 9-specific B cells were isolated by flow cytometry and RNA-sequencing was performed. Protein profile of Bos d 9-specific B cells was analyzed by proximity extension assay. RESULTS: Increased frequencies of circulating milk allergen Bos d 9-specific B cells were observed after OIT and NT. Milk-desensitized subjects showed the partial acquisition of phenotypic features of remission, suggesting that desensitization is an earlier stage of remission. Within these most significantly expressed genes, IL10RA and TGFB3 were highly expressed in desensitized OIT patients. In both the remission and desensitized groups, B cell activation-, Breg cells-, BCR-signaling-, and differentiation-related genes were upregulated. In NT, pathways associated with innate immunity characteristics, development of marginal zone B cells, and a more established suppressor function of B cells prevail that may play a role in long-term tolerance. The analyses of immunoglobulin heavy chain genes in specific B cells demonstrated that IgG2 in desensitization, IgG1, IgA1, IgA2, IgG4, and IgD in remission, and IgD in NT were predominating. Secreted proteins from allergen-specific B cells revealed higher levels of regulatory cytokines, IL-10, and TGF-beta after OIT and NT. CONCLUSION: Allergen-specific B cells are essential elements in regulating food allergy towards remission in OIT-received and naturally resolved individuals.</style></abstract><notes><style face="normal" font="default" size="100%">Satitsuksanoa, Pattraporn&#xD;van de Veen, Willem&#xD;Tan, Ge&#xD;Lopez, Juan-Felipe&#xD;Wirz, Oliver&#xD;Jansen, Kirstin&#xD;Sokolowska, Milena&#xD;Mirer, David&#xD;Globinska, Anna&#xD;Boonpiyathad, Tadech&#xD;Schneider, Stephan R&#xD;Barletta, Elena&#xD;Spits, Hergen&#xD;Chang, Iris&#xD;Babayev, Huseyn&#xD;Tahrali, Ilhan&#xD;Deniz, Gunnur&#xD;Yucel, Esra Ozek&#xD;Kiykim, Ayca&#xD;Boyd, Scott D&#xD;Akdis, Cezmi A&#xD;Nadeau, Kari&#xD;Akdis, Mubeccel&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):161-180. doi: 10.1111/all.16220. Epub 2024 Jul 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38989779</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724240</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16220</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3149</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3149</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, Z.</style></author><author><style face="normal" font="default" size="100%">Yan, S.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Wu, Z.</style></author><author><style face="normal" font="default" size="100%">Cheng, L.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Zhan, H.</style></author><author><style face="normal" font="default" size="100%">Xu, H.</style></author><author><style face="normal" font="default" size="100%">Feng, F.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Feng, X.</style></author><author><style face="normal" font="default" size="100%">Yin, C.</style></author><author><style face="normal" font="default" size="100%">Peng, L.</style></author><author><style face="normal" font="default" size="100%">Zhou, J.</style></author><author><style face="normal" font="default" size="100%">Fei, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, W.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.&#xD;Department of Laboratory Medicine, Gene Diagnosis Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.&#xD;Department of Rheumatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.&#xD;Beijing Protein Innovation, B-8, Airport Industrial Zone, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergen-Specific IgE and IgG4 Signatures in IgG4-Related Disease Revealed by a Large-Scale PhIP-Seq Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4-RD</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41267614</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: Immunoglobulin G4-related disease (IgG4-RD) is frequently accompanied by allergic/atopic manifestations, yet its allergen-specific antibody landscape remains poorly defined. Therefore, we detected allergen-specific IgE and IgG4 levels in patients with IgG4-RD to clarify their contribution to IgG4-RD pathogenesis. METHODS: In total, 826 plasma samples from 370 patients with IgG4-RD and 354 healthy controls were used to perform Phage Immunoprecipitation Sequencing. Follow-up samples from 102 patients (median 3 years) captured temporal dynamics. Machine learning (XGBoost) was used to identify key allergen peptides. ELISA was used for validation in 51 IgG4-RD patients and 24 healthy controls, including an independent cohort of 20 treatment-naive patients. RESULTS: Abnormal IgE and IgG4 allergen reactivity was observed in IgG4-RD patients. Enhanced responses to Apis mellifera and Arachis hypogaea were particularly prominent and correlated with lacrimal gland, parotid gland, paranasal, pulmonary, renal (A. mellifera) and pancreatic (A. hypogaea) involvement. XGBoost achieved an AUC of 0.91-0.96 and consistently ranked 10 peptides, mainly from bee, peanut, vespid-venom and fish allergens. ELISA confirmed significantly elevated Ara h 1-specific IgG4 in IgG4-RD. Follow-up sampling showed a global decline in reactivity to most top allergens and an IgE-to-IgG4 shift to Staphylococcus aureus peptides, suggesting therapy-associated modulation and emerging tolerance. CONCLUSIONS: Comprehensive pan-allergen profiling suggests distinct IgE and IgG4 signatures in IgG4-RD and links specific environmental antigens to organ-selective disease patterns. These findings support a contributory role for aberrant allergen responses in IgG4-RD pathogenesis and provide a foundation for biomarker development and targeted allergen-based interventions, especially for future mechanistic investigations.</style></abstract><notes><style face="normal" font="default" size="100%">Li, Zhan&#xD;Yan, Songxin&#xD;Zhang, Jialei&#xD;Li, Haolong&#xD;Wu, Ziyan&#xD;Cheng, Linlin&#xD;Liu, Yongmei&#xD;Zhan, Haoting&#xD;Xu, Honglin&#xD;Feng, Futai&#xD;Zhang, Jingdi&#xD;Wang, Siyu&#xD;Feng, Xinxin&#xD;Yin, Changcheng&#xD;Peng, Linyi&#xD;Zhou, Jiaxin&#xD;Fei, Yunyun&#xD;Zhang, Wen&#xD;Li, Yongzhe&#xD;eng&#xD;2024YFA1307604/the National Key Research and Development Program of China/&#xD;2022YFC2703104/the National Key Research and Development Program of China/&#xD;82472348/the National Natural Science Foundation of China/&#xD;82471829/the National Natural Science Foundation of China/&#xD;82271848/the National Natural Science Foundation of China/&#xD;M23008/Beijing Natural Science Foundation/&#xD;7232113/Beijing Natural Science Foundation/&#xD;2022-PUMCH-B-124/the National High Level Hospital Clinical Research Funding/&#xD;2022-PUMCH-C-006/the National High Level Hospital Clinical Research Funding/&#xD;Denmark&#xD;Allergy. 2025 Nov 21. doi: 10.1111/all.70162.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41267614</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70162</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2771</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2771</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ashley, S. E.</style></author><author><style face="normal" font="default" size="100%">Lloyd, M.</style></author><author><style face="normal" font="default" size="100%">Loke, P.</style></author><author><style face="normal" font="default" size="100%">Orsini, F.</style></author><author><style face="normal" font="default" size="100%">Lozinsky, A. C.</style></author><author><style face="normal" font="default" size="100%">O&apos;Sullivan, M. D.</style></author><author><style face="normal" font="default" size="100%">Quinn, P.</style></author><author><style face="normal" font="default" size="100%">Gold, M.</style></author><author><style face="normal" font="default" size="100%">Tang, M. L. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Murdoch Children&apos;s Research Institute, Parkville, Australia.&#xD;The University of Melbourne, Parkville, Australia.&#xD;The Royal Children&apos;s Hospital Melbourne, Parkville, Australia.&#xD;Monash University Parkville Campus, Parkville, Australia.&#xD;Monash Children&apos;s Hospital, Clayton, Australia.&#xD;Telethon Kids Institute, Nedlands, Australia.&#xD;Perth Children&apos;s Hospital, Nedlands, Australia.&#xD;The University of Western Australia, Perth, Australia.&#xD;The University of Adelaide, Adelaide, Australia.&#xD;Women&apos;s and Children&apos;s Health Network, North Adelaide, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergen-Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1-10 Years</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">843-848</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/12/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Arachis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Remission Induction</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">paediatric OIT</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut-specific IgE</style></keyword><keyword><style face="normal" font="default" size="100%">remission</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39723600</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Remission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high-quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut-specific IgE (sIgE) levels which is closely correlated with age. METHODS: This study examined relationships between peanut sIgE and age at baseline and remission, in children aged 1-10 who completed 18 months of OIT in the PPOIT-003 RCT (n = 162). Remission was defined as absence of clinical reactivity to peanut after 8 weeks of allergen avoidance/treatment discontinuation. Age and sIgE were examined as continuous variables in univariate and multivariate regression models. RESULTS: Higher peanut sIgE was consistently predictive of lower likelihood of remission, independent of age. In contrast, there was no independent association between age and remission after adjusting for baseline sIgE (OR 0.94 [0.79-1.12], p = 0.5). CONCLUSIONS: Findings do not support age as an independent predictor of remission following OIT. Additional studies examining safety and efficacy of OIT in infants and younger children are urgently needed, ahead of widespread adoption of early intervention.</style></abstract><notes><style face="normal" font="default" size="100%">Ashley, Sarah E&#xD;Lloyd, Melanie&#xD;Loke, Paxton&#xD;Orsini, Francesca&#xD;Lozinsky, Adriana C&#xD;O&apos;Sullivan, Michael D&#xD;Quinn, Patrick&#xD;Gold, Michael&#xD;Tang, Mimi L K&#xD;eng&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):843-848. doi: 10.1111/all.16451. Epub 2024 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39723600</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16451</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2763</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2763</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martin-Cruz, L.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Chemistry, Department of Biochemistry and Molecular Biology, Complutense University, Madrid, Spain.&#xD;School of Pharmacy, Department of Biochemistry and Molecular Biology, Complutense University, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergen-Specific Immunotherapy and Trained Immunity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">677-689</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/12/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Memory</style></keyword><keyword><style face="normal" font="default" size="100%">Trained Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">metabolic and epigenetic rewiring</style></keyword><keyword><style face="normal" font="default" size="100%">trained immunity-based allergen vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">trained immunity-based vaccines (TIbV)</style></keyword><keyword><style face="normal" font="default" size="100%">Innovacion, CAM, Inmunotek S.L., Novartis, and AstraZeneca, and fees for giving</style></keyword><keyword><style face="normal" font="default" size="100%">scientific lectures or participation in Advisory Boards from: AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, GlaxoSmithKline, Inmunotek S.L, Novartis, and Sanofi-Genzyme. O.P.</style></keyword><keyword><style face="normal" font="default" size="100%">received research grants from MICINN, MINECO, CAM, Inmunotek S.L., Novartis, and</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca and fees for giving scientific lectures or participation in Advisory</style></keyword><keyword><style face="normal" font="default" size="100%">Boards from: AstraZeneca, Pfizer, GlaxoSmithKline, Inmunotek S.L, Novartis and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genzyme. L. M.-C. declares no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39641571</style></accession-num><abstract><style face="normal" font="default" size="100%">The high prevalence of allergic diseases reached over the last years is attributed to the complex interplay of genetic factors, lifestyle changes, and environmental exposome. Allergen-specific immunotherapy (AIT) is the single therapeutic strategy for allergic diseases with the potential capacity to modify the course of the disease. Our knowledge of the mechanisms involved in allergy and successful AIT has significantly improved. Recent findings indicate that long-term allergen tolerance upon AIT discontinuation not only relies on the generation of proper adaptive immune responses by the generation of allergen-specific regulatory T and B cells enabling the induction of different isotypes of blocking antibodies but also relies on the restoration of proper innate immune responses. Trained immunity (TRIM) is the process by which innate immune cells acquire memory by mechanisms depending on metabolic and epigenetic reprogramming, thus conferring the host with increased broad protection against infection. This concept was initially explored for infectious diseases, as well as for vaccination against infections, but compelling experimental evidence suggests that TRIM might also play a role in allergy and AIT. Hyperinflammatory innate immune responses in early life, likely due to TRIM maladaptations, lead to aberrant type 2 inflammation-enhancing allergy. However, exposure to farming environments and specific microbes prevents recurrent infections and allergy development, likely due to mechanisms partially depending on TRIM. TRIM-based vaccines and next-generation AIT vaccines inducing metabolic and epigenetic reprogramming in innate immune cells and their precursors have shown protective antiallergic effects. A better understanding of the factors involved in early-life TRIM mechanisms in the context of allergy and the identification and characterization of novel tolerance inducers might well enable the design of alternative TRIM-based allergen vaccines for allergic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Martin-Cruz, Leticia&#xD;Palomares, Oscar&#xD;eng&#xD;Ministerio de Educacion y Ciencias/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):677-689. doi: 10.1111/all.16423. Epub 2024 Dec 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39641571</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891420</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16423</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1179</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1179</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zissler, U. M.</style></author><author><style face="normal" font="default" size="100%">Jakwerth, C. A.</style></author><author><style face="normal" font="default" size="100%">Guerth, F.</style></author><author><style face="normal" font="default" size="100%">Lewitan, L.</style></author><author><style face="normal" font="default" size="100%">Rothkirch, S.</style></author><author><style face="normal" font="default" size="100%">Davidovic, M.</style></author><author><style face="normal" font="default" size="100%">Ulrich, M.</style></author><author><style face="normal" font="default" size="100%">Oelsner, M.</style></author><author><style face="normal" font="default" size="100%">Garn, H.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Chaker, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Allergy &amp; Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany.&#xD;Member of the German Center for Lung Research (DZL), Munich, Germany.&#xD;Member of the Helmholtz I&amp;I Initiative, Munich, Germany.&#xD;Department of Otorhinolaryngology and Head and Neck Surgery, Medical School, Technical University of Munich, Munich, Germany.&#xD;Institute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg, Medical Faculty, Member of the German Center of Lung Research, Marburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergen-specific immunotherapy induces the suppressive secretoglobin 1A1 in cells of the lower airways</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2461-2474</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/02/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal</style></keyword><keyword><style face="normal" font="default" size="100%">Uteroglobin/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">induced sputum</style></keyword><keyword><style face="normal" font="default" size="100%">tolerance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33528894</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: While several systemic immunomodulatory effects of allergen-specific immunotherapy (AIT) have been discovered, local anti-inflammatory mechanisms in the respiratory tract are largely unknown. We sought to elucidate local and epithelial mechanisms underlying allergen-specific immunotherapy in a genome-wide approach. METHODS: We induced sputum in hay fever patients and healthy controls during the pollen peak season and stratified patients by effective allergen immunotherapy or as untreated. Sputum was directly processed after induction and subjected to whole transcriptome RNA microarray analysis. Nasal secretions were analyzed for Secretoglobin1A1 (SCGB1A1) and IL-24 protein levels in an additional validation cohort at three defined time points during the 3-year course of AIT. Subsequently, RNA was extracted and subjected to an array-based whole transcriptome analysis. RESULTS: Allergen-specific immunotherapy inhibited pro-inflammatory CXCL8, IL24, and CCL26mRNA expression, while SCGB1A1, IL7, CCL5, CCL23, and WNT5BmRNAs were induced independently of the asthma status and allergen season. In our validation cohort, local increase of SCGB1A1 occurred concomitantly with the reduction of local IL-24 in upper airways during the course of AIT. Additionally, SCGB1A1 was identified as a suppressor of epithelial gene expression. CONCLUSIONS: Allergen-specific immunotherapy induces a yet unknown local gene expression footprint in the lower airways that on one hand appears to be a result of multiple regulatory pathways and on the other hand reveals SCGB1A1 as novel anti-inflammatory mediator of long-term allergen-specific therapeutic intervention in the local environment.</style></abstract><notes><style face="normal" font="default" size="100%">Zissler, Ulrich M&#xD;Jakwerth, Constanze A&#xD;Guerth, Ferdinand&#xD;Lewitan, Larissa&#xD;Rothkirch, Sandra&#xD;Davidovic, Miodrag&#xD;Ulrich, Moritz&#xD;Oelsner, Madlen&#xD;Garn, Holger&#xD;Schmidt-Weber, Carsten B&#xD;Chaker, Adam M&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2461-2474. doi: 10.1111/all.14756. Epub 2021 Mar 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33528894</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14756</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1124</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1124</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Novak, N.</style></author><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Department of Dermatology and Allergy, University Hospital, Bonn, Germany.&#xD;Department of Allergy, Research Institute Hospital 12 de Octubre, Madrid, Spain.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Poland, ALL-MED Medical research Institute, Wroclaw, Poland.&#xD;Comprehensive Allergy Center, Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health, Berlin, Germany.&#xD;MACVIA-France, Montpellier, France.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF, University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3307-3313</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/03/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">2019-nCoV Vaccine mRNA-1273</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Complement Activation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Polyethylene Glycols/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, Christine Kuhne-Center for Allergy Research and Education, European</style></keyword><keyword><style face="normal" font="default" size="100%">Commission&apos;s Horison&apos;s 2020 Framework Programme, Cure, Novartis Research</style></keyword><keyword><style face="normal" font="default" size="100%">Institutes, Astra Zeneca, Scibase, advisory role in Sanofi/Regeneron, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Glakso Smith-Kline, advisory role in Scibase. Dr. Bousquet reports personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Aventis, Takeda, Teva, Uriach, other from KYomed Innov, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. Dr. Jutel reports personal fees from ALK-Abello, Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes, Anergis, Allergy Therapeutics, Circassia, Leti, Biomay, HAL, during</style></keyword><keyword><style face="normal" font="default" size="100%">the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">Astra-Zeneka, GSK, Novartis, Teva, Vectura, UCB,</style></keyword><keyword><style face="normal" font="default" size="100%">Takeda, Roche, Janssen, Medimmune, Chiesi, outside the submitted work. Dr. Klimek</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants and/or personal fees from Allergopharma, MEDA/Mylan, HAL Allergie,</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, from LETI Pharma, Stallergenes, Quintiles, Sanofi, ASIT biotech,</style></keyword><keyword><style face="normal" font="default" size="100%">Lofarma, Allergy Therapeut., AstraZeneca, GSK, Inmunotk, Cassella med, outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and reports Membership: AeDA, DGHNO, Deutsche Akademie fur</style></keyword><keyword><style face="normal" font="default" size="100%">Allergologie und klinischeImmunologie, HNO-BV, GPA, EAACI. Dr. Novak reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants and/or personal fees from ALK-Abello, HAL Allergy, Stallergenes Geer, Leti</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Novartis, Leo Pharma, Abbvie, Sanofi Genzmye, Lofarma, Bencard Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, outside the submitted work. Dr. Cabanillas has nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33657648</style></accession-num><abstract><style face="normal" font="default" size="100%">Following the emergency use authorization of the mRNA-1273 vaccine on the 18(th) of December 2020, two mRNA vaccines are in current use for the prevention of coronavirus disease 2019 (COVID-19). For both mRNA vaccines, the phase III pivotal trials excluded individuals with a history of allergy to vaccine components. Immediately after the initiation of vaccination in the United Kingdom, Canada, and the United States, anaphylactic reactions were reported. While the culprit trigger requires investigation, initial reports suggested the excipient polyethylene glycol 2000 (PEG-2000)-contained in both vaccines as the PEG-micellar carrier system-as the potential culprit. Surface PEG chains form a hydrate shell to increase stability and prevent opsonization. Allergic reactions to such PEGylated lipids can be IgE-mediated, but may also result from complement activation-related pseudoallergy (CARPA) that has been described in similar liposomes. In addition, mRNA-1273 also contains tromethamine (trometamol), which has been reported to cause anaphylaxis to substances such as gadolinium-based contrast media. Skin prick, intradermal and epicutaneous tests, in vitro sIgE assessment, evaluation of sIgG/IgM, and basophil activation tests are being used to demonstrate allergic reactions to various components of the vaccines.</style></abstract><notes><style face="normal" font="default" size="100%">Klimek, Ludger&#xD;Novak, Natalija&#xD;Cabanillas, Beatriz&#xD;Jutel, Marek&#xD;Bousquet, Jean&#xD;Akdis, Cezmi A&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3307-3313. doi: 10.1111/all.14794. Epub 2021 Jun 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33657648</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8013891</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14794</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2569</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2569</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perusko, M.</style></author><author><style face="normal" font="default" size="100%">Grundstrom, J.</style></author><author><style face="normal" font="default" size="100%">Eldh, M.</style></author><author><style face="normal" font="default" size="100%">Reinhardt, A.</style></author><author><style face="normal" font="default" size="100%">Fuhrmann, V.</style></author><author><style face="normal" font="default" size="100%">Duzakin, M.</style></author><author><style face="normal" font="default" size="100%">Hamsten, C.</style></author><author><style face="normal" font="default" size="100%">Starkhammar, M.</style></author><author><style face="normal" font="default" size="100%">Apostolovic, D.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.&#xD;Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Innovative Centre of the Faculty of Chemistry, University of Belgrade, Belgrade, Serbia.&#xD;Department of Internal Medicine, Sodersjukhuset, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergenic potency of various foods of mammalian origin in patients with alpha-Gal syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">181-192</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/07/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Meat/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Mammals</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">allergenic potency</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation</style></keyword><keyword><style face="normal" font="default" size="100%">milk</style></keyword><keyword><style face="normal" font="default" size="100%">pork kidney</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-Gal syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. The rest of the authors report no conflict of</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39007417</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The alpha-Gal syndrome (AGS) is an emerging allergy to mammalian food caused by IgE-mediated reactions to the carbohydrate galactose-alpha-1,3-galactose (alpha-Gal). Mammalian food sources contain alpha-Gal, but the amount differs. The objective of this study was to investigate the allergenic potency of various foods of mammalian origin among AGS patients. METHODS: Twenty-six AGS patients were included. Food extracts from innards, lean meats, processed meat products, milk, and whey were analyzed. Immunoblot, ELISA, immunofluorescence, and basophil activation test were used to determine the alpha-Gal content, characterize IgE binding, and assess foods&apos; allergenicity. RESULTS: The determined amount of alpha-Gal, IgE reactivity to food extracts, and food extract potencies to activate patients&apos; basophils correlated well with each other. Pork and beef kidney showed the highest allergenicity. Beef liver and bacon showed allergenicity comparable to that of lean meats. Game meat seemed to have a higher allergenic potency than meats from farm-raised animals. The processed meat products liver pate and black pudding, despite lower alpha-Gal content, demonstrated moderate allergenicity. Milk showed the lowest allergenicity. IgE reactivity to food extracts was highly similar for all patients and strongly dominated by the alpha-Gal epitope. CONCLUSIONS: The allergenic potency of mammalian meat depends on the origin of the meat, the different cuts, and type of processing, with innards posing the greatest risk to AGS patients. Even processed mammalian meat constitutes a risk. Dairy products show the lowest risk. This study highlights the importance of analyzing even more foods to improve the management of AGS.</style></abstract><notes><style face="normal" font="default" size="100%">Perusko, Marija&#xD;Grundstrom, Jeanette&#xD;Eldh, Maria&#xD;Reinhardt, Annika&#xD;Fuhrmann, Verena&#xD;Duzakin, Meltem&#xD;Hamsten, Carl&#xD;Starkhammar, Maria&#xD;Apostolovic, Danijela&#xD;van Hage, Marianne&#xD;eng&#xD;2019-01060/The Swedish Research Council/&#xD;F2022-0011/The Swedish Asthma and Allergy Association&apos;s Research Foundation/&#xD;20210424/The Swedish Heart-Lung Foundation/&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):181-192. doi: 10.1111/all.16235. Epub 2024 Jul 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39007417</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724243</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16235</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1041</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1041</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chruszcz, M.</style></author><author><style face="normal" font="default" size="100%">Chew, F. T.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Hurlburt, B. K.</style></author><author><style face="normal" font="default" size="100%">Mueller, G. A.</style></author><author><style face="normal" font="default" size="100%">Pomes, A.</style></author><author><style face="normal" font="default" size="100%">Rouvinen, J.</style></author><author><style face="normal" font="default" size="100%">Villalba, M.</style></author><author><style face="normal" font="default" size="100%">Wohrl, B. M.</style></author><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC, USA.&#xD;Department of Biological Sciences, National University of Singapore, Singapore.&#xD;Division of Medical Biotechnology, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Agricultural Research Service, Southern Regional Research Center, US Department of Agriculture, New Orleans, LA, USA.&#xD;National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA.&#xD;Indoor Biotechnologies, Inc., Charlottesville, VA, USA.&#xD;Department of Chemistry, University of Eastern Finland, Joensuu, Finland.&#xD;Department of Biochemistry and Molecular Biology, Universidad Complutense de Madrid, Madrid, Spain.&#xD;Biochemie IV - Biopolymere, Universitat Bayreuth, Bayreuth, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergens and their associated small molecule ligands-their dual role in sensitization</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2367-2382</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/04/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Ligands</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Binding</style></keyword><keyword><style face="normal" font="default" size="100%">Pr-10</style></keyword><keyword><style face="normal" font="default" size="100%">group 2 house dust mite allergens</style></keyword><keyword><style face="normal" font="default" size="100%">lipocalin</style></keyword><keyword><style face="normal" font="default" size="100%">nsLTP</style></keyword><keyword><style face="normal" font="default" size="100%">serum albumin</style></keyword><keyword><style face="normal" font="default" size="100%">Ministry of Education Academic Research Fund, Singapore Immunology Network,</style></keyword><keyword><style face="normal" font="default" size="100%">National Medical Research Council (NMRC) (Singapore), Biomedical Research Council</style></keyword><keyword><style face="normal" font="default" size="100%">(BMRC) (Singapore), and the Agency for Science Technology and Research (A*STAR)</style></keyword><keyword><style face="normal" font="default" size="100%">(Singapore), during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">and consulting fees from Sime Darby</style></keyword><keyword><style face="normal" font="default" size="100%">Technology Centre</style></keyword><keyword><style face="normal" font="default" size="100%">First Resources Ltd</style></keyword><keyword><style face="normal" font="default" size="100%">Genting Plantation, and Olam</style></keyword><keyword><style face="normal" font="default" size="100%">International, outside the submitted work. Dr. Pomes is employed by Indoor</style></keyword><keyword><style face="normal" font="default" size="100%">Biotechnologies, Inc. and is the contact PI of the 2R01AI077653-10A1 Award from</style></keyword><keyword><style face="normal" font="default" size="100%">the NIH/NIAID that funds research presented in this article. She declares that</style></keyword><keyword><style face="normal" font="default" size="100%">her research was conducted in the absence of any commercial or financial</style></keyword><keyword><style face="normal" font="default" size="100%">relationships that could be construed as a potential conflict of interest. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Rouvinen reports contract research between University of Eastern Finland and</style></keyword><keyword><style face="normal" font="default" size="100%">Desentum Ltd, outside the submitted work. Dr Rouvinen is also a shareholder in</style></keyword><keyword><style face="normal" font="default" size="100%">Desentum Ltd. All other authors declare that they have no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33866585</style></accession-num><abstract><style face="normal" font="default" size="100%">Many allergens feature hydrophobic cavities that allow the binding of primarily hydrophobic small-molecule ligands. Ligand-binding specificities can be strict or promiscuous. Serum albumins from mammals and birds can assume multiple conformations that facilitate the binding of a broad spectrum of compounds. Pollen and plant food allergens of the family 10 of pathogenesis-related proteins bind a variety of small molecules such as glycosylated flavonoid derivatives, flavonoids, cytokinins, and steroids in vitro. However, their natural ligand binding was reported to be highly specific. Insect and mammalian lipocalins transport odorants, pheromones, catecholamines, and fatty acids with a similar level of specificity, while the food allergen beta-lactoglobulin from cow&apos;s milk is notably more promiscuous. Non-specific lipid transfer proteins from pollen and plant foods bind a wide variety of lipids, from phospholipids to fatty acids, as well as sterols and prostaglandin B2, aided by the high plasticity and flexibility displayed by their lipid-binding cavities. Ligands increase the stability of allergens to thermal and/or proteolytic degradation. They can also act as immunomodulatory agents that favor a Th2 polarization. In summary, ligand-binding allergens expose the immune system to a variety of biologically active compounds whose impact on the sensitization process has not been well studied thus far.</style></abstract><notes><style face="normal" font="default" size="100%">Chruszcz, Maksymilian&#xD;Chew, Fook Tim&#xD;Hoffmann-Sommergruber, Karin&#xD;Hurlburt, Barry K&#xD;Mueller, Geoffrey A&#xD;Pomes, Anna&#xD;Rouvinen, Juha&#xD;Villalba, Mayte&#xD;Wohrl, Birgitta M&#xD;Breiteneder, Heimo&#xD;eng&#xD;R01 AI077653/AI/NIAID NIH HHS/&#xD;Z99 ES999999/ImNIH/Intramural NIH HHS/&#xD;ZIA ES102906/ImNIH/Intramural NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, N.I.H., Intramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2367-2382. doi: 10.1111/all.14861. Epub 2021 May 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33866585</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8286345</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14861</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>260</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">260</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Poli, A.</style></author><author><style face="normal" font="default" size="100%">Oudin, A.</style></author><author><style face="normal" font="default" size="100%">Muller, A.</style></author><author><style face="normal" font="default" size="100%">Salvato, I.</style></author><author><style face="normal" font="default" size="100%">Scafidi, A.</style></author><author><style face="normal" font="default" size="100%">Hunewald, O.</style></author><author><style face="normal" font="default" size="100%">Domingues, O.</style></author><author><style face="normal" font="default" size="100%">Nazarov, P. V.</style></author><author><style face="normal" font="default" size="100%">Puard, V.</style></author><author><style face="normal" font="default" size="100%">Baus, V.</style></author><author><style face="normal" font="default" size="100%">Azuaje, F.</style></author><author><style face="normal" font="default" size="100%">Dittmar, G.</style></author><author><style face="normal" font="default" size="100%">Zimmer, J.</style></author><author><style face="normal" font="default" size="100%">Michel, T.</style></author><author><style face="normal" font="default" size="100%">Michelucci, A.</style></author><author><style face="normal" font="default" size="100%">Niclou, S. P.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Cancer Research, Luxembourg Institute of Health, Neuro-Immunology Group, Luxembourg, Luxembourg.&#xD;Department of Cancer Research, NORLUX Neuro-Oncology Laboratory, Luxembourg Institute of Health, Luxembourg, Luxembourg.&#xD;Luxembourg Institute of Health, Bioinformatics Platform, Strassen, Luxembourg.&#xD;Institut Curie Centre de Recherche, PSL Research University, RPPA platform, Paris, France.&#xD;Department of Biomedicine, University of Bergen, Bergen, Norway.&#xD;Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic airway inflammation delays glioblastoma progression and reinvigorates systemic and local immunity in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">682-696</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Glioblastoma/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Brain Neoplasms/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Glioma/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">T-lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">glioma-induced immunosuppression</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin-E</style></keyword><keyword><style face="normal" font="default" size="100%">microglia</style></keyword><keyword><style face="normal" font="default" size="100%">tumor microenvironment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36210648</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Numerous patient-based studies have highlighted the protective role of immunoglobulin E-mediated allergic diseases on glioblastoma (GBM) susceptibility and prognosis. However, the mechanisms behind this observation remain elusive. Our objective was to establish a preclinical model able to recapitulate this phenomenon and investigate the role of immunity underlying such protection. METHODS: An immunocompetent mouse model of allergic airway inflammation (AAI) was initiated before intracranial implantation of mouse GBM cells (GL261). RAG1-KO mice served to assess tumor growth in a model deficient for adaptive immunity. Tumor development was monitored by MRI. Microglia were isolated for functional analyses and RNA-sequencing. Peripheral as well as tumor-associated immune cells were characterized by flow cytometry. The impact of allergy-related microglial genes on patient survival was analyzed by Cox regression using publicly available datasets. RESULTS: We found that allergy establishment in mice delayed tumor engraftment in the brain and reduced tumor growth resulting in increased mouse survival. AAI induced a transcriptional reprogramming of microglia towards a pro-inflammatory-like state, uncovering a microglia gene signature, which correlated with limited local immunosuppression in glioma patients. AAI increased effector memory T-cells in the circulation as well as tumor-infiltrating CD4(+) T-cells. The survival benefit conferred by AAI was lost in mice devoid of adaptive immunity. CONCLUSION: Our results demonstrate that AAI limits both tumor take and progression in mice, providing a preclinical model to study the impact of allergy on GBM susceptibility and prognosis, respectively. We identify a potentiation of local and adaptive systemic immunity, suggesting a reciprocal crosstalk that orchestrates allergy-induced immune protection against GBM.</style></abstract><notes><style face="normal" font="default" size="100%">Poli, Aurelie&#xD;Oudin, Anais&#xD;Muller, Arnaud&#xD;Salvato, Ilaria&#xD;Scafidi, Andrea&#xD;Hunewald, Oliver&#xD;Domingues, Olivia&#xD;Nazarov, Petr V&#xD;Puard, Vincent&#xD;Baus, Virginie&#xD;Azuaje, Francisco&#xD;Dittmar, Gunnar&#xD;Zimmer, Jacques&#xD;Michel, Tatiana&#xD;Michelucci, Alessandro&#xD;Niclou, Simone P&#xD;Ollert, Markus&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):682-696. doi: 10.1111/all.15545. Epub 2022 Oct 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36210648</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15545</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>570</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">570</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ryan, D.</style></author><author><style face="normal" font="default" size="100%">Flokstra-de Blok, B. M. J.</style></author><author><style face="normal" font="default" size="100%">Clark, E.</style></author><author><style face="normal" font="default" size="100%">Gaudin, C.</style></author><author><style face="normal" font="default" size="100%">Mamodaly, M.</style></author><author><style face="normal" font="default" size="100%">Kocks, J.</style></author><author><style face="normal" font="default" size="100%">van der Velde, J. L.</style></author><author><style face="normal" font="default" size="100%">Angier, L.</style></author><author><style face="normal" font="default" size="100%">Romberg, K.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Demoly, P.</style></author><author><style face="normal" font="default" size="100%">Tanno, L. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Usher Institute, University of Edinburgh, Edinburgh, UK.&#xD;General Practitioners Research Institute (GPRI), Groningen, The Netherlands.&#xD;University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, The Netherlands.&#xD;Department of Pediatric Pulmonology and Pediatric Allergology, University of Groningen, University Medical Center Groningen, Beatrix Children&apos;s Hospital, Groningen, The Netherlands.&#xD;University Hospital of Montpellier, Montpellier, France.&#xD;University Hospital of Nantes, Nantes, France.&#xD;Observational and Pragmatic Research Institute, Singapore, Singapore.&#xD;Department of General Practice, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Primary Care and Population Sciences, University of Southampton, Southampton, UK.&#xD;Health Care Centre, Nasets Lakargrupp, Hollviken, Sweden.&#xD;Respiratory Medicine and Allergology, Clinical Sciences Lund, Lund University, Lund, Sweden.&#xD;Department of Internal Medicine, Allergology and Clinical Immunology, Silesian University of Medicine, Katowice, Poland.&#xD;IDESP, INSERM - University, Montpellier, France.&#xD;WHO Collaborating Centre on Scientific Classification Support, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic and hypersensitivity conditions in non-specialist care: Flow diagrams to support clinical practice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2618-2633</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/03/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy/hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">flow-diagram</style></keyword><keyword><style face="normal" font="default" size="100%">non-specialist care</style></keyword><keyword><style face="normal" font="default" size="100%">primary care</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, Viatris, GSK, AZ, Trudell, Regeneron, Novartis. PD: Has received</style></keyword><keyword><style face="normal" font="default" size="100%">remuneration for board and/or speaker bureau from Chiesi, IQVIA, Menarini,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, Regeneron, AstraZeneca, Bausch &amp; Lomb, ThermoFisher Scientific, Mylan,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis. KR: received remuneration for educational initiatives or speaker</style></keyword><keyword><style face="normal" font="default" size="100%">fees from: Astra Zeneca, ALK, Boehrinrer Ingelheim, Chiesi, GSK, Mylan,</style></keyword><keyword><style face="normal" font="default" size="100%">Mundipharma and Novartis. JK: reports grants, personal fees and non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support from AstraZeneca, grants, personal fees and non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, grants and personal fees from Chiesi, grants, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">and non-financial support from GSK, non-financial support from Mundi Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from Teva, personal fees from MSD, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">COVIS Pharma, grants from Valneva outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and Janwillem Kocks</style></keyword><keyword><style face="normal" font="default" size="100%">holds &lt;5% shares of Lothar Medtec GmbH and 72.5% of shares in the General</style></keyword><keyword><style face="normal" font="default" size="100%">Practitioners Research Institute. BFB: was employed by General Practitioners</style></keyword><keyword><style face="normal" font="default" size="100%">Research Institute (GPRI) at the time of the study. In the past 3 years</style></keyword><keyword><style face="normal" font="default" size="100%">(2019-2021), GPRI conducted investigator- and sponsor-initiated research funded</style></keyword><keyword><style face="normal" font="default" size="100%">by non-commercial organizations, academic institutes, and pharmaceutical</style></keyword><keyword><style face="normal" font="default" size="100%">companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, and Teva). All other authors declare no COI.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35266160</style></accession-num><abstract><style face="normal" font="default" size="100%">Most patients presenting with allergies are first seen by primary care health professionals. The perceived knowledge gaps and educational needs were recently assessed in response to which the LOGOGRAM Task Force was established with the remit of constructing pragmatic flow diagrams for common allergic conditions in line with an earlier EAACI proposal to develop simplified pathways for the diagnosis and management of allergic diseases in primary care. To address the lack of accessible and pragmatic guidance, we designed flow diagrams for five major clinical allergy conditions: asthma, anaphylaxis, food allergy, drug allergy, and urticaria. Existing established allergy guidelines were collected and iteratively distilled to produce five pragmatic and accessible tools to aid diagnosis and management of these common allergic problems. Ultimately, they should now be validated prospectively in primary care settings.</style></abstract><notes><style face="normal" font="default" size="100%">Ryan, Dermot&#xD;Flokstra-de Blok, Bertine M J&#xD;Clark, Evangeline&#xD;Gaudin, Clara&#xD;Mamodaly, Myriam&#xD;Kocks, Janwillem&#xD;van der Velde, Jantina Lucia&#xD;Angier, Liz&#xD;Romberg, Kerstin&#xD;Gawlik, Radek&#xD;Demoly, Pascal&#xD;Tanno, Luciana Kase&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2618-2633. doi: 10.1111/all.15273. Epub 2022 Mar 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35266160</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9543313</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15273</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2192</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2192</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Okada, N.</style></author><author><style face="normal" font="default" size="100%">Yamamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Oguma, T.</style></author><author><style face="normal" font="default" size="100%">Tanaka, J.</style></author><author><style face="normal" font="default" size="100%">Tomomatsu, K.</style></author><author><style face="normal" font="default" size="100%">Shiraishi, Y.</style></author><author><style face="normal" font="default" size="100%">Matsuse, H.</style></author><author><style face="normal" font="default" size="100%">Shimoda, T.</style></author><author><style face="normal" font="default" size="100%">Kimura, H.</style></author><author><style face="normal" font="default" size="100%">Watai, K.</style></author><author><style face="normal" font="default" size="100%">Harada, T.</style></author><author><style face="normal" font="default" size="100%">Fujita, Y.</style></author><author><style face="normal" font="default" size="100%">Obase, Y.</style></author><author><style face="normal" font="default" size="100%">Suzukawa, M.</style></author><author><style face="normal" font="default" size="100%">Suzuki, J.</style></author><author><style face="normal" font="default" size="100%">Takayanagi, N.</style></author><author><style face="normal" font="default" size="100%">Ishiguro, T.</style></author><author><style face="normal" font="default" size="100%">Masaki, K.</style></author><author><style face="normal" font="default" size="100%">Fukunaga, K.</style></author><author><style face="normal" font="default" size="100%">Asano, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan.&#xD;Department of Mathematics, School of Science, Tokai University, Kanagawa, Japan.&#xD;Division of Respiratory Medicine, Department of Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.&#xD;Department of Allergy, Clinical Research Center, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.&#xD;Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.&#xD;Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan.&#xD;Center for Immunology and Allergy, Shonan Kamakura General Hospital, Kanagawa, Japan.&#xD;Center for Respiratory Diseases, Japan Community Healthcare Organization Hokkaido Hospital, Sapporo, Japan.&#xD;Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan.&#xD;Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.&#xD;Clinical Research Center, National Hospital Organization Tokyo National Hospital, Kiyose, Japan.&#xD;Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Kiyose, Japan.&#xD;Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Kumagaya, Japan.&#xD;Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic bronchopulmonary aspergillosis with atopic, nonatopic, and sans asthma-Factor analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2933-2943</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/07/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Aspergillosis, Allergic Bronchopulmonary/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/complications/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">factor analysis</style></keyword><keyword><style face="normal" font="default" size="100%">fungal component</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37458287</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) develops in the presence or absence of asthma, either atopic or nonatopic. We have tried to explore the essential components in the pathogenesis of the disease, which are either consistent and variable according to the presence and type of asthma. METHODS: Non-cystic fibrosis ABPA cases satisfying Asano&apos;s criteria were extracted from a prospective registry of ABPA and related diseases in Japan between 2013 and 2023. According to the type of preceding asthma, ABPA was classified into three groups: ABPA sans asthma (no preceding asthma), ABPA with atopic asthma, and ABPA with nonatopic asthma. Exploratory and confirmatory factor analyses were performed to identify the components that determined the clinical characteristics of ABPA. RESULTS: Among 106 cases of ABPA, 25 patients (24%) had ABPA sans asthma, whereas 57 (54%) and 24 (23%) had ABPA with atopic and nonatopic asthma, respectively. Factor analysis identified three components: allergic, eosinophilic, and fungal. Patients with atopic asthma showed the highest scores for the allergic component (p &lt; .001), defined by total and allergen-specific IgE titers and lung opacities, and the lowest scores for the fungal component defined by the presence of specific precipitin/IgG or positive culture for A. fumigatus. Eosinophilic components, including peripheral blood eosinophil counts and presence of mucus plugs/high attenuation mucus in the bronchi, were consistent among the three groups. CONCLUSION: The eosinophilic component of ABPA is considered as the cardinal feature of ABPA regardless of the presence of preceding asthma or atopic predisposition.</style></abstract><notes><style face="normal" font="default" size="100%">Okada, Naoki&#xD;Yamamoto, Yoshiro&#xD;Oguma, Tsuyoshi&#xD;Tanaka, Jun&#xD;Tomomatsu, Katsuyoshi&#xD;Shiraishi, Yoshiki&#xD;Matsuse, Hiroto&#xD;Shimoda, Terufumi&#xD;Kimura, Hirokazu&#xD;Watai, Kentaro&#xD;Harada, Toshiyuki&#xD;Fujita, Yuka&#xD;Obase, Yasushi&#xD;Suzukawa, Maho&#xD;Suzuki, Junko&#xD;Takayanagi, Noboru&#xD;Ishiguro, Takashi&#xD;Masaki, Katsunori&#xD;Fukunaga, Koichi&#xD;Asano, Koichiro&#xD;eng&#xD;Japan Agency for Medical Research and Development/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2933-2943. doi: 10.1111/all.15820. Epub 2023 Jul 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37458287</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15820</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>324</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">324</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kilanowski, A.</style></author><author><style face="normal" font="default" size="100%">Thiering, E.</style></author><author><style face="normal" font="default" size="100%">Wang, G.</style></author><author><style face="normal" font="default" size="100%">Kumar, A.</style></author><author><style face="normal" font="default" size="100%">Kress, S.</style></author><author><style face="normal" font="default" size="100%">Flexeder, C.</style></author><author><style face="normal" font="default" size="100%">Bauer, C. P.</style></author><author><style face="normal" font="default" size="100%">Berdel, D.</style></author><author><style face="normal" font="default" size="100%">von Berg, A.</style></author><author><style face="normal" font="default" size="100%">Bergstrom, A.</style></author><author><style face="normal" font="default" size="100%">Gappa, M.</style></author><author><style face="normal" font="default" size="100%">Heinrich, J.</style></author><author><style face="normal" font="default" size="100%">Herberth, G.</style></author><author><style face="normal" font="default" size="100%">Koletzko, S.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Schikowski, T.</style></author><author><style face="normal" font="default" size="100%">Peters, A.</style></author><author><style face="normal" font="default" size="100%">Standl, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Epidemiology, Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Institute for Medical Information Processing, Biometry, and Epidemiology, Pettenkofer School of Public Health, LMU Munich, Munich, Germany.&#xD;Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children&apos;s Hospital, University of Munich Medical Center, Munich, Germany.&#xD;Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.&#xD;Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Leibniz Research Institute for Environmental Medicine, Dusseldorf, Germany.&#xD;Medical Research School Dusseldorf, Heinrich Heine University, Dusseldorf, Germany.&#xD;German Center for Lung Research (DZL), Munich, Germany.&#xD;Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany.&#xD;Department of Pediatrics, Technical University of Munich, Munich, Germany.&#xD;Research Institute, Department of Pediatrics, Marien-Hospital Wesel, Wesel, Germany.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Centre for Occupational and Environmental Medicine, Stockholm, Sweden.&#xD;Evangelisches Krankenhaus Dusseldorf, Children&apos;s Hospital, Dusseldorf, Germany.&#xD;Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.&#xD;Department of Environmental Immunology, Helmholtz Centre for Environmental Research-UFZ, Leipzig, Germany.&#xD;Department of Pediatrics, Dr. von Hauner Children&apos;s Hospital, University Hospital, LMU Munich, Munich, Germany.&#xD;Department of Pediatrics, Gastroenterology and Nutrition, School of Medicine Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.&#xD;Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Sachs Children&apos;s and Youth Hospital, Stockholm, Sweden.&#xD;Chair of Epidemiology, Ludwig-Maximilians University, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic disease trajectories up to adolescence: Characteristics, early-life, and genetic determinants</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">836-850</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">longitudinal clustering</style></keyword><keyword><style face="normal" font="default" size="100%">polygenic risk score</style></keyword><keyword><style face="normal" font="default" size="100%">trajectories</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36069615</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic diseases often develop jointly during early childhood but differ in timing of onset, remission, and progression. Their disease course over time is often difficult to predict and determinants are not well understood. OBJECTIVES: We aimed to identify trajectories of allergic diseases up to adolescence and to investigate their association with early-life and genetic determinants and clinical characteristics. METHODS: Longitudinal k-means clustering was used to derive trajectories of allergic diseases (asthma, atopic dermatitis, and rhinitis) in two German birth cohorts (GINIplus/LISA). Associations with early-life determinants, polygenic risk scores, food and aeroallergen sensitization, and lung function were estimated by multinomial models. The results were replicated in the independent Swedish BAMSE cohort. RESULTS: Seven allergic disease trajectories were identified: &quot;Intermittently allergic,&quot; &quot;rhinitis,&quot; &quot;early-resolving dermatitis,&quot; &quot;mid-persisting dermatitis,&quot; &quot;multimorbid,&quot; &quot;persisting dermatitis plus rhinitis,&quot; and &quot;early-transient asthma.&quot; Family history of allergies was more prevalent in all allergic disease trajectories compared the non-allergic controls with stronger effect sizes for clusters comprising more than one allergic disease (e.g., RRR = 5.0, 95% CI = [3.1-8.0] in the multimorbid versus 1.8 [1.4-2.4] in the mild intermittently allergic cluster). Specific polygenic risk scores for single allergic diseases were significantly associated with their relevant trajectories. The derived trajectories and their association with genetic effects and clinical characteristics showed similar results in BAMSE. CONCLUSION: Seven robust allergic clusters were identified and showed associations with early life and genetic factors as well as clinical characteristics.</style></abstract><notes><style face="normal" font="default" size="100%">Kilanowski, Anna&#xD;Thiering, Elisabeth&#xD;Wang, Gang&#xD;Kumar, Ashish&#xD;Kress, Sara&#xD;Flexeder, Claudia&#xD;Bauer, Carl-Peter&#xD;Berdel, Dietrich&#xD;von Berg, Andrea&#xD;Bergstrom, Anna&#xD;Gappa, Monika&#xD;Heinrich, Joachim&#xD;Herberth, Gunda&#xD;Koletzko, Sibylle&#xD;Kull, Inger&#xD;Melen, Erik&#xD;Schikowski, Tamara&#xD;Peters, Annette&#xD;Standl, Marie&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):836-850. doi: 10.1111/all.15511. Epub 2022 Sep 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36069615</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15511</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>407</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">407</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gangneux, J. P.</style></author><author><style face="normal" font="default" size="100%">Godet, C.</style></author><author><style face="normal" font="default" size="100%">Denning, D. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Univ Rennes, CHU Rennes, Inserm, EHESP, IRSET (Institut de recherche en sante, environnement et travail) - UMR_S 1085, Rennes, France.&#xD;Service de Pneumologie, Assistance Publique - Hopitaux de Paris, Hopital Bichat, Paris, France.&#xD;Manchester Fungal Infection Group, Core Technology Facility, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic diseases and fungal exposome: Prevention is better than cure</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3182-3184</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Exposome</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35822920</style></accession-num><notes><style face="normal" font="default" size="100%">Gangneux, Jean-Pierre&#xD;Godet, Cendrine&#xD;Denning, David W&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3182-3184. doi: 10.1111/all.15436.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35822920</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15436</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>753</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">753</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eskandarpour, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Micera, A.</style></author><author><style face="normal" font="default" size="100%">Zaher, S.</style></author><author><style face="normal" font="default" size="100%">Larkin, F. D. P.</style></author><author><style face="normal" font="default" size="100%">Nunn, M.</style></author><author><style face="normal" font="default" size="100%">Bonini, S.</style></author><author><style face="normal" font="default" size="100%">Weston-Davies, W.</style></author><author><style face="normal" font="default" size="100%">Calder, V. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ocular Immunology Group, UCL Institute of Ophthalmology, London, UK.&#xD;UOSD Research Laboratories, IRCCS-fondazione Bietti, University Campus Bio-Medico, Rome, Italy.&#xD;NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, London, UK.&#xD;NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust &amp;, UCL Institute of Ophthalmology, London, UK.&#xD;Akari Therapeutics plc, London, UK.&#xD;Ophthalmology Operative Complex Unit, University Campus Bio-Medico, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic eye disease: Blocking LTB4/C5 in vivo suppressed disease and Th2 &amp; Th9 cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">660-664</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Eye Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Leukotriene B4</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Helper-Inducer</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34614221</style></accession-num><notes><style face="normal" font="default" size="100%">Eskandarpour, Malihe&#xD;Zhang, Xiaozhe&#xD;Micera, Alessandra&#xD;Zaher, Sarah&#xD;Larkin, Frank D P&#xD;Nunn, Miles&#xD;Bonini, Stefano&#xD;Weston-Davies, Wynne&#xD;Calder, Virginia L&#xD;eng&#xD;DH_/Department of Health/United Kingdom&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):660-664. doi: 10.1111/all.15128. Epub 2021 Oct 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34614221</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9292376 Weston-Davies, who are both employees of Akari Therapeutics Inc.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15128</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2538</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2538</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Gallego, N.</style></author><author><style face="normal" font="default" size="100%">Castillo-Gonzalez, R.</style></author><author><style face="normal" font="default" size="100%">Moreno-Serna, L.</style></author><author><style face="normal" font="default" size="100%">Garcia-Civico, A. J.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Martinez, E.</style></author><author><style face="normal" font="default" size="100%">Lopez-Sanz, C.</style></author><author><style face="normal" font="default" size="100%">Fontes, A. L.</style></author><author><style face="normal" font="default" size="100%">Pimentel, L. L.</style></author><author><style face="normal" font="default" size="100%">Gradillas, A.</style></author><author><style face="normal" font="default" size="100%">Obeso, D.</style></author><author><style face="normal" font="default" size="100%">Neuhaus, R.</style></author><author><style face="normal" font="default" size="100%">Ramirez-Huesca, M.</style></author><author><style face="normal" font="default" size="100%">Ruiz-Fernandez, I.</style></author><author><style face="normal" font="default" size="100%">Nunez-Borque, E.</style></author><author><style face="normal" font="default" size="100%">Carrasco, Y. R.</style></author><author><style face="normal" font="default" size="100%">Ibanez, B.</style></author><author><style face="normal" font="default" size="100%">Martin, P.</style></author><author><style face="normal" font="default" size="100%">Blanco, C.</style></author><author><style face="normal" font="default" size="100%">Barbas, C.</style></author><author><style face="normal" font="default" size="100%">Barber, D.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Alcala, L. M.</style></author><author><style face="normal" font="default" size="100%">Villasenor, A.</style></author><author><style face="normal" font="default" size="100%">Esteban, V.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Madrid, F.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.&#xD;Department of Immunology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Universidad Autonoma de Madrid (UAM), Madrid, Spain.&#xD;Department of Immunology, Ophthalmology and Ear, Nose and Throat (ENT), Universidad Complutense de Madrid, Madrid, Spain.&#xD;Department of Basic Medical Sciences, Faculty of Medicine, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Centro de Metabolomica y Bioanalisis (CEMBIO), Faculty of Pharmacy, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;CBQF-Centro de Biotecnologia e Quimica Fina-Laboratorio Associado, Escola Superior de Biotecnologia, Universidade Catolica Portuguesa, Porto, Portugal.&#xD;Department of Allergy and Immunology, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma de Madrid (UAM), Madrid, Spain.&#xD;Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;Department of Cardiology, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD), Madrid, Spain.&#xD;CIBER de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.&#xD;Department of Allergy, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Madrid, Spain.&#xD;Faculty of Medicine and Biomedicine, Universidad Alfonso X El Sabio, Madrid, Spain.&#xD;Department of Medicine, McMaster Immunology Research Centre (MIRC), Schroeder Allergy and Immunology Research Institute (SAIRI), McMaster University, Hamilton, Ontario, Canada.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic inflammation triggers dyslipidemia via IgG signalling</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2680-2699</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Dyslipidemias/metabolism/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin G/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology/metabolism/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Lipid Metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Triglycerides/blood/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Adipose Tissue/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Liver/metabolism/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">IgG</style></keyword><keyword><style face="normal" font="default" size="100%">allergic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular risk</style></keyword><keyword><style face="normal" font="default" size="100%">dyslipidemia</style></keyword><keyword><style face="normal" font="default" size="100%">lipidomics</style></keyword><keyword><style face="normal" font="default" size="100%">metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38864116</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic diseases begin early in life and are often chronic, thus creating an inflammatory environment that may precede or exacerbate other pathologies. In this regard, allergy has been associated to metabolic disorders and with a higher risk of cardiovascular disease, but the underlying mechanisms remain incompletely understood. METHODS: We used a murine model of allergy and atherosclerosis, different diets and sensitization methods, and cell-depleting strategies to ascertain the contribution of acute and late phase inflammation to dyslipidemia. Untargeted lipidomic analyses were applied to define the lipid fingerprint of allergic inflammation at different phases of allergic pathology. Expression of genes related to lipid metabolism was assessed in liver and adipose tissue at different times post-allergen challenge. Also, changes in serum triglycerides (TGs) were evaluated in a group of 59 patients &gt;/=14 days after the onset of an allergic reaction. RESULTS: We found that allergic inflammation induces a unique lipid signature that is characterized by increased serum TGs and changes in the expression of genes related to lipid metabolism in liver and adipose tissue. Alterations in blood TGs following an allergic reaction are independent of T-cell-driven late phase inflammation. On the contrary, the IgG-mediated alternative pathway of anaphylaxis is sufficient to induce a TG increase and a unique lipid profile. Lastly, we demonstrated an increase in serum TGs in 59 patients after undergoing an allergic reaction. CONCLUSION: Overall, this study reveals that IgG-mediated allergic inflammation regulates lipid metabolism.</style></abstract><notes><style face="normal" font="default" size="100%">Fernandez-Gallego, Nieves&#xD;Castillo-Gonzalez, Raquel&#xD;Moreno-Serna, Lucia&#xD;Garcia-Civico, Antonio J&#xD;Sanchez-Martinez, Elisa&#xD;Lopez-Sanz, Celia&#xD;Fontes, Ana Luiza&#xD;Pimentel, Ligia L&#xD;Gradillas, Ana&#xD;Obeso, David&#xD;Neuhaus, Rene&#xD;Ramirez-Huesca, Marta&#xD;Ruiz-Fernandez, Ignacio&#xD;Nunez-Borque, Emilio&#xD;Carrasco, Yolanda R&#xD;Ibanez, Borja&#xD;Martin, Pilar&#xD;Blanco, Carlos&#xD;Barbas, Coral&#xD;Barber, Domingo&#xD;Rodriguez-Alcala, Luis M&#xD;Villasenor, Alma&#xD;Esteban, Vanesa&#xD;Sanchez-Madrid, Francisco&#xD;Jimenez-Saiz, Rodrigo&#xD;eng&#xD;CP20/00043/Instituto de Salud Carlos III/&#xD;PI22/00236/Instituto de Salud Carlos III/&#xD;CD23/00125/Instituto de Salud Carlos III/&#xD;CM23/00019/Instituto de Salud Carlos III/&#xD;PI21/00158/Instituto de Salud Carlos III/&#xD;PI22/01759/Instituto de Salud Carlos III/&#xD;PMPTA22/00090/Instituto de Salud Carlos III/&#xD;AEI/SEV-2017-0712/Ministerio de Ciencia e Innovacion/&#xD;FJC2021-047282-I/Ministerio de Ciencia e Innovacion/&#xD;PID2020-120412RB-I00/Ministerio de Ciencia e Innovacion/&#xD;AEI/10.13039/501100011033/Ministerio de Ciencia e Innovacion/&#xD;09-PIN1-00015.6/2022/Plan de Recuperacion, Transformacion y Resiliencia and NextGenerationEU/&#xD;2022-C23.I01.P03.S0020-0000031/Plan de Recuperacion, Transformacion y Resiliencia and NextGenerationEU/&#xD;NRF-2021-13/The Nutricia Research Foundation/&#xD;NFRFE-2019-00083/New Frontiers in Research Fund/&#xD;BECA20A9/SEAIC/&#xD;FPU16/03953/Ministerio de Universidades/&#xD;FPU20/05176/Ministerio de Universidades/&#xD;P2022/BMD7209/Comunidad de Madrid/&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2680-2699. doi: 10.1111/all.16187. Epub 2024 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38864116</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16187</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1200</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1200</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Mahler, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Paul-Ehrlich-Institut, Langen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic reactions to COVID-19 vaccinations-unveiling the secret(s)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1621-1623</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/01/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33432606</style></accession-num><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Mahler, Vera&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1621-1623. doi: 10.1111/all.14734.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33432606</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8013986 Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, grants from Biomay, grants from Circassia, grants and personal fees from ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, personal fees from MEDA Pharma/MYLAN, grants and personal fees from Anergis S.A., personal fees from Mobile Chamber Experts (a GA2LEN Partner), personal fees from Indoor Biotechnologies, grants and personal fees from Glaxo Smith Kline, personal fees from Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi-Aventis and Sanofi Genzyme, Med Update Europe GmbH, streamedup! GmbH, grants from Pohl-Boskamp, Inmunotek S.L., personal fees from John Wiley and Sons AS, Paul-Martini-Stiftung (PMS). Vera Mahler indicates that the views expressed in this editorial are the personal views of the author as an expert in the field of allergology and may not be understood or quoted as being made on behalf of or reflecting the position of the respective national competent authority, the European Medicines Agency, or one of its committees or working parties. She has no conflict of interest to disclose.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14734</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2638</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2638</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cosi, V.</style></author><author><style face="normal" font="default" size="100%">Wildner, S.</style></author><author><style face="normal" font="default" size="100%">Kapfhammer, C.</style></author><author><style face="normal" font="default" size="100%">Eichhorn, S.</style></author><author><style face="normal" font="default" size="100%">Briza, P.</style></author><author><style face="normal" font="default" size="100%">Hemmer, W.</style></author><author><style face="normal" font="default" size="100%">Gadermaier, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biosciences and Medical Biology, Paris Lodron University Salzburg, Salzburg, Austria.&#xD;Floridsdorf Allergy Center, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic reactions to horse chestnut seeds are caused by mugwort pollen Art v 1-sensitization and represent a novel type of defensin-related allergy syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">611-614</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/09/24</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39314061</style></accession-num><notes><style face="normal" font="default" size="100%">Cosi, Valentina&#xD;Wildner, Sabrina&#xD;Kapfhammer, Christine&#xD;Eichhorn, Stephanie&#xD;Briza, Peter&#xD;Hemmer, Wolfgang&#xD;Gadermaier, Gabriele&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):611-614. doi: 10.1111/all.16335. Epub 2024 Sep 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39314061</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804300</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16335</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1224</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1224</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Novak, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Research Institute Hospital Doce de Octubre, Madrid, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1617-1618</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Polyethylene Glycols/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33320974</style></accession-num><notes><style face="normal" font="default" size="100%">Cabanillas, Beatriz&#xD;Akdis, Cezmi A&#xD;Novak, Natalija&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1617-1618. doi: 10.1111/all.14711.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33320974</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14711</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2801</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2801</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koenig, J. F. E.</style></author><author><style face="normal" font="default" size="100%">Wade-Vallance, A. K.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author><author><style face="normal" font="default" size="100%">Bruton, K.</style></author><author><style face="normal" font="default" size="100%">Gadkar, S.</style></author><author><style face="normal" font="default" size="100%">Grydziuszko, E.</style></author><author><style face="normal" font="default" size="100%">Walker, T. D.</style></author><author><style face="normal" font="default" size="100%">Gordon, M. E.</style></author><author><style face="normal" font="default" size="100%">Gillgrass, A. E.</style></author><author><style face="normal" font="default" size="100%">Taylor, J. J.</style></author><author><style face="normal" font="default" size="100%">Waserman, S.</style></author><author><style face="normal" font="default" size="100%">Jordana, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Schroeder Allergy and Immunology Research Institute, Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Canada.&#xD;McMaster Immunology Research Centre, Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Canada.&#xD;Department of Immunology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Universidad Autonoma de Madrid (UAM), Madrid, Spain.&#xD;Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain.&#xD;Beirne B. Carter Immunology Center, University of Virginia, Charlottesville, Virginia, USA.&#xD;Division of Infectious Diseases &amp; International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.&#xD;Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic Reactivity and Memory Occur Independently of Sequential Switching Through IgG1</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2141-2157</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/01/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin G/immunology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunologic Memory</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin Class Switching/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">B-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Anaphylaxis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">IgG1</style></keyword><keyword><style face="normal" font="default" size="100%">memory</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">sequential switching</style></keyword><keyword><style face="normal" font="default" size="100%">to ALK Abello A/S.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39803817</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic reactions to foods are primarily driven by allergen-binding immunoglobulin (Ig)E antibodies. IgE-expressing cells can be generated through direct switching from IgM to IgE or a sequential class switching pathway where activated B cells first switch to an intermediary isotype, most frequently IgG1, and then to IgE. It has been proposed that sequential class switch recombination is involved in augmenting the severity of allergic reactions, generating high affinity IgE, differentiation of IgE plasma cells, and in holding the memory of IgE responses. We directly tested these possibilities by comparing the allergic immunity of wild-type and IgG1-deficient (hMT) mice. We found that sequential switching through IgG1 was not required to maintain the binding capacity of IgE nor for its ability to promote degranulation and elicit anaphylaxis against bona fide food allergens. Furthermore, the absence of sequential switching modestly impacted IgE affinity and clinical reactivity against hapten antigens, suggesting that the nature of the antigen impacts the requirement for sequential switching. At a cellular level, the capacity to undergo sequential switching through IgG1 provided no competitive advantage for subsequent IgE expression among germinal center B cells or plasma cells. Furthermore, the recall of allergic immunity at memory timepoints was preserved in the absence of sequential switching through IgG1, a finding that corresponded with intact type 2 memory B cell polarization. Together, these data demonstrate that sequential switching through IgG1 is redundant in sensitization, anaphylaxis, and the persistence of allergy, ultimately revealing that IgE derived from any switching source should be targeted by novel therapeutics seeking to ameliorate allergic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Koenig, Joshua F E&#xD;Wade-Vallance, Adam K&#xD;Jimenez-Saiz, Rodrigo&#xD;Bruton, Kelly&#xD;Gadkar, Siyon&#xD;Grydziuszko, Emily&#xD;Walker, Tina D&#xD;Gordon, Melissa E&#xD;Gillgrass, Amy E&#xD;Taylor, Justin J&#xD;Waserman, Susan&#xD;Jordana, Manel&#xD;eng&#xD;Instituto de Salud Carlos III/&#xD;European Social Fund/&#xD;CAPMC/CIHR/Canada&#xD;Canadian Society of Allergy and Clinical Immunology/&#xD;Canadian Allergy, Asthma and Immunology Foundation/&#xD;ALK Abello A/S/&#xD;Food Allergy Canada/&#xD;Schroeder Foundation/&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2141-2157. doi: 10.1111/all.16460. Epub 2025 Jan 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39803817</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368767</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16460</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3214</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3214</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Vieira, R. J.</style></author><author><style face="normal" font="default" size="100%">Schunemann, H. J.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Bognanni, A.</style></author><author><style face="normal" font="default" size="100%">Togias, A.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Williams, S.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Vecillas, L. L.</style></author><author><style face="normal" font="default" size="100%">Dykewicz, M. S.</style></author><author><style face="normal" font="default" size="100%">Jacomelli, C.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Leemann, L.</style></author><author><style face="normal" font="default" size="100%">Lourenco, O.</style></author><author><style face="normal" font="default" size="100%">Palamarchuk, Y.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Pereira, A. M.</style></author><author><style face="normal" font="default" size="100%">Savoure, M.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S. K.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Yepes-Nunez, J. J.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Ciprandi, G.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Gradauskiene, B.</style></author><author><style face="normal" font="default" size="100%">Jartti, T.</style></author><author><style face="normal" font="default" size="100%">Jesenak, M.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Latiff, A. H.</style></author><author><style face="normal" font="default" size="100%">Mohammad, Y.</style></author><author><style face="normal" font="default" size="100%">Ohta, K.</style></author><author><style face="normal" font="default" size="100%">Mahesh, P. A.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Roche, N.</style></author><author><style face="normal" font="default" size="100%">Taborda-Barata, L.</style></author><author><style face="normal" font="default" size="100%">Ulrik, C. S.</style></author><author><style face="normal" font="default" size="100%">Rostan, M. V.</style></author><author><style face="normal" font="default" size="100%">Viegi, G.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Cherrez-Ojeda, I.</style></author><author><style face="normal" font="default" size="100%">Carlos Ivancevich, J.</style></author><author><style face="normal" font="default" size="100%">Khaltaev, N.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Abdullah, B.</style></author><author><style face="normal" font="default" size="100%">Al-Ahmad, M.</style></author><author><style face="normal" font="default" size="100%">Al-Nesf, M. A.</style></author><author><style face="normal" font="default" size="100%">Amaral, R.</style></author><author><style face="normal" font="default" size="100%">Asllani, J.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Blaiss, M. S.</style></author><author><style face="normal" font="default" size="100%">Braido, F.</style></author><author><style face="normal" font="default" size="100%">Camargos, P.</style></author><author><style face="normal" font="default" size="100%">Carreiro-Martins, P.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author><author><style face="normal" font="default" size="100%">Giuliano, A. F. M.</style></author><author><style face="normal" font="default" size="100%">Christoff, G.</style></author><author><style face="normal" font="default" size="100%">Cirule, I.</style></author><author><style face="normal" font="default" size="100%">de Sousa, J. C.</style></author><author><style face="normal" font="default" size="100%">Costa, E. M.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Dokic, D.</style></author><author><style face="normal" font="default" size="100%">Hossny, E.</style></author><author><style face="normal" font="default" size="100%">Iinuma, T.</style></author><author><style face="normal" font="default" size="100%">Irani, C.</style></author><author><style face="normal" font="default" size="100%">Ispayeva, Z.</style></author><author><style face="normal" font="default" size="100%">Julge, K.</style></author><author><style face="normal" font="default" size="100%">Kaidashev, I.</style></author><author><style face="normal" font="default" size="100%">Bennoor, K. S.</style></author><author><style face="normal" font="default" size="100%">Kraxner, H.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Kulus, M.</style></author><author><style face="normal" font="default" size="100%">Kupczyk, M.</style></author><author><style face="normal" font="default" size="100%">Kurchenko, A.</style></author><author><style face="normal" font="default" size="100%">La Grutta, S.</style></author><author><style face="normal" font="default" size="100%">Miculinic, N.</style></author><author><style face="normal" font="default" size="100%">Tuyet, L. L. T.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Milenkovic, B.</style></author><author><style face="normal" font="default" size="100%">Lee, S. M.</style></author><author><style face="normal" font="default" size="100%">Montefort, S.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Nadif, R.</style></author><author><style face="normal" font="default" size="100%">Nakonechna, A.</style></author><author><style face="normal" font="default" size="100%">Neffen, H. E.</style></author><author><style face="normal" font="default" size="100%">Niedoszytko, M.</style></author><author><style face="normal" font="default" size="100%">Nyembue, D.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Olze, H.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Panzner, P.</style></author><author><style face="normal" font="default" size="100%">Patella, V.</style></author><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Pitsios, C.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Puggioni, F.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Ramonaite, A.</style></author><author><style face="normal" font="default" size="100%">Recto, M.</style></author><author><style face="normal" font="default" size="100%">Repka-Ramirez, M. S.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Robles-Velasco, K.</style></author><author><style face="normal" font="default" size="100%">Rottem, M.</style></author><author><style face="normal" font="default" size="100%">Salapatas, M.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Scichilone, N.</style></author><author><style face="normal" font="default" size="100%">Sisul, J. C.</style></author><author><style face="normal" font="default" size="100%">Sole, D.</style></author><author><style face="normal" font="default" size="100%">Soto-Martinez, M. E.</style></author><author><style face="normal" font="default" size="100%">Sova, M.</style></author><author><style face="normal" font="default" size="100%">Tantilipikorn, P.</style></author><author><style face="normal" font="default" size="100%">Todo-Bom, A.</style></author><author><style face="normal" font="default" size="100%">Tsaryk, V.</style></author><author><style face="normal" font="default" size="100%">Tsiligianni, I.</style></author><author><style face="normal" font="default" size="100%">Urrutia-Pereira, M.</style></author><author><style face="normal" font="default" size="100%">Valovirta, E.</style></author><author><style face="normal" font="default" size="100%">Vasankari, T.</style></author><author><style face="normal" font="default" size="100%">Wallace, D.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Yusuf, O. M.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author><author><style face="normal" font="default" size="100%">Gil-Mata, S.</style></author><author><style face="normal" font="default" size="100%">Marques-Cruz, M.</style></author><author><style face="normal" font="default" size="100%">Mahboub, B.</style></author><author><style face="normal" font="default" size="100%">Ansotegui, I. J.</style></author><author><style face="normal" font="default" size="100%">Romano, A.</style></author><author><style face="normal" font="default" size="100%">Aberer, W.</style></author><author><style face="normal" font="default" size="100%">Artesani, M. C.</style></author><author><style face="normal" font="default" size="100%">Azzolini, E.</style></author><author><style face="normal" font="default" size="100%">Barreto, B.</style></author><author><style face="normal" font="default" size="100%">Bartra, J.</style></author><author><style face="normal" font="default" size="100%">Becker, S.</style></author><author><style face="normal" font="default" size="100%">Beghe, B.</style></author><author><style face="normal" font="default" size="100%">Boner, A.</style></author><author><style face="normal" font="default" size="100%">Borowiack, E.</style></author><author><style face="normal" font="default" size="100%">Bouchard, J.</style></author><author><style face="normal" font="default" size="100%">Bourgoin-Heck, M.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Buhl, R.</style></author><author><style face="normal" font="default" size="100%">Castillo-Vizuete, J. A.</style></author><author><style face="normal" font="default" size="100%">Charpin, D.</style></author><author><style face="normal" font="default" size="100%">Chavannes, N. H.</style></author><author><style face="normal" font="default" size="100%">Chelminska, M.</style></author><author><style face="normal" font="default" size="100%">Cheng, L.</style></author><author><style face="normal" font="default" size="100%">Chkhartishvili, E.</style></author><author><style face="normal" font="default" size="100%">Cho, S. H.</style></author><author><style face="normal" font="default" size="100%">Chong-Neto, H. J.</style></author><author><style face="normal" font="default" size="100%">Choudhury, D.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Cingi, C.</style></author><author><style face="normal" font="default" size="100%">Compalati, E.</style></author><author><style face="normal" font="default" size="100%">Costa, R. A.</style></author><author><style face="normal" font="default" size="100%">Cunha, O. M.</style></author><author><style face="normal" font="default" size="100%">Cvetkovski, B.</style></author><author><style face="normal" font="default" size="100%">Cardona-Dahl, V.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">Davies, J.</style></author><author><style face="normal" font="default" size="100%">Di Bona, D.</style></author><author><style face="normal" font="default" size="100%">Gonzalez Diaz, S. N.</style></author><author><style face="normal" font="default" size="100%">Dimou, M. V.</style></author><author><style face="normal" font="default" size="100%">Doulaptsi, M.</style></author><author><style face="normal" font="default" size="100%">Ferreira-da-Silva, R.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Calvo-Gil, M.</style></author><author><style face="normal" font="default" size="100%">Goksel, O.</style></author><author><style face="normal" font="default" size="100%">Gomez, M. R.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Grigoreas, C.</style></author><author><style face="normal" font="default" size="100%">Grisle, I.</style></author><author><style face="normal" font="default" size="100%">Guzman, M. A.</style></author><author><style face="normal" font="default" size="100%">Tan, R. H.</style></author><author><style face="normal" font="default" size="100%">Hyland, M.</style></author><author><style face="normal" font="default" size="100%">Ierodiakonou, D.</style></author><author><style face="normal" font="default" size="100%">Karavelia, A.</style></author><author><style face="normal" font="default" size="100%">Keith, P.</style></author><author><style face="normal" font="default" size="100%">Kisiel, M.</style></author><author><style face="normal" font="default" size="100%">Kosak, T. S.</style></author><author><style face="normal" font="default" size="100%">Kosnik, M.</style></author><author><style face="normal" font="default" size="100%">Koyuncu, I. V.</style></author><author><style face="normal" font="default" size="100%">Kritikos, V.</style></author><author><style face="normal" font="default" size="100%">Litynska, J.</style></author><author><style face="normal" font="default" size="100%">Lombardi, C.</style></author><author><style face="normal" font="default" size="100%">Louis, G.</style></author><author><style face="normal" font="default" size="100%">Martini, M.</style></author><author><style face="normal" font="default" size="100%">Meco, C.</style></author><author><style face="normal" font="default" size="100%">Mesonjesi, E.</style></author><author><style face="normal" font="default" size="100%">Mihaltan, F.</style></author><author><style face="normal" font="default" size="100%">Moniuszko, M.</style></author><author><style face="normal" font="default" size="100%">Naclerio, R. N.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Neisinger, S.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Ordak, M.</style></author><author><style face="normal" font="default" size="100%">Paoletti, G.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author><author><style face="normal" font="default" size="100%">Parmelli, E.</style></author><author><style face="normal" font="default" size="100%">Perdomo-Flores, E. A.</style></author><author><style face="normal" font="default" size="100%">Perez, J. M. F.</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, N.</style></author><author><style face="normal" font="default" size="100%">Prokopakis, E.</style></author><author><style face="normal" font="default" size="100%">Ribeiro-Vaz, I.</style></author><author><style face="normal" font="default" size="100%">Rolla, G.</style></author><author><style face="normal" font="default" size="100%">Romantowski, J.</style></author><author><style face="normal" font="default" size="100%">Rombaux, P.</style></author><author><style face="normal" font="default" size="100%">Rouadi, P. W.</style></author><author><style face="normal" font="default" size="100%">Rukhadze, M.</style></author><author><style face="normal" font="default" size="100%">Ryan, D.</style></author><author><style face="normal" font="default" size="100%">Sadowska, E.</style></author><author><style face="normal" font="default" size="100%">Sakurai, D.</style></author><author><style face="normal" font="default" size="100%">Salameh, L.</style></author><author><style face="normal" font="default" size="100%">Sarquis, F. S.</style></author><author><style face="normal" font="default" size="100%">Serrano, E.</style></author><author><style face="normal" font="default" size="100%">Da Silva, J.</style></author><author><style face="normal" font="default" size="100%">Soyka, M.</style></author><author><style face="normal" font="default" size="100%">Specjalski, K.</style></author><author><style face="normal" font="default" size="100%">Tomic-Spiric, V.</style></author><author><style face="normal" font="default" size="100%">Stevanovic, K.</style></author><author><style face="normal" font="default" size="100%">Subramaniam, A.</style></author><author><style face="normal" font="default" size="100%">Teixeira, M. D. C.</style></author><author><style face="normal" font="default" size="100%">Thomander, T.</style></author><author><style face="normal" font="default" size="100%">Vachova, M.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Vichyanond, P.</style></author><author><style face="normal" font="default" size="100%">Wagenmann, M.</style></author><author><style face="normal" font="default" size="100%">Ko, F. W. S.</style></author><author><style face="normal" font="default" size="100%">Werminghaus, P.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P. V.</style></author><author><style face="normal" font="default" size="100%">Xiang, Y. K.</style></author><author><style face="normal" font="default" size="100%">Yang, Q.</style></author><author><style face="normal" font="default" size="100%">Yeverino, D. R.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, J.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE-Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;ARIA (Allergic Rhinitis and Its Impact on Asthma), Montpellier, France.&#xD;Department of Health Research Methods, Evidence, and Impact &amp; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, Italy.&#xD;Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.&#xD;Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland.&#xD;Institute of Clinical Medicine and Institute of Health Sciences, Medical Faculty of Vilnius University, Vilnius, Lithuania.&#xD;Clinic of Asthma, Allergy and Chronic Lung Diseases, Vilnius, Lithuania.&#xD;International Primary Care Respiratory Group IPCRG, Edinburgh, UK.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;Allergy Unit, Malaga Regional University Hospital of Malaga, Malaga University, ARADyAL, Malaga, Spain.&#xD;Immunomodulation and Tolerance Group and Allergy and Clinical Immunology, Imperial College London, London, UK.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;Asthma &amp; Allergy Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.&#xD;Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.&#xD;Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.&#xD;&quot;Respiriamo Insieme&quot; Association, Asthma &amp; Allergy Center, Padova, Italy.&#xD;Department of Otolaryngology, Head &amp; Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Allergology &amp; Rhinology Department, Wiesbaden, Germany.&#xD;Department of Political Science, University of Zurich, Zurich, Switzerland.&#xD;RISE-Health, Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal.&#xD;Finnish Meteorological Institute (FMI), Atmospheric Composition Research, Helsinki, Finland.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;PaCeIT-Patient Centered Innovation and Technologies, Center for Health Technology and Services Research (CINTESIS), Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Allergy Unit, Instituto and Hospital CUF, Porto, Portugal.&#xD;Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Department of Allergy, Skin and Allergy Hospital, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Otorhinolaryngology, University of Eastern Finland and the North Savo Wellbeing Services County, Kuopio, Finland.&#xD;University of Bari Medical School, Bari, Italy.&#xD;Institute of Sciences of Food Production, National Research Council (ISPA-CNR), Bari, Italy.&#xD;School of Medicine, Universidad de los Andes, Bogota, D. C., Colombia.&#xD;Pulmonology Service, Internal Medicine Section, Fundacion Santa Fe de Bogota, University Hospital, Bogota, D. C., Colombia.&#xD;Fundacao ProAR and (Faculdade de Medicina da), Universidade Federal da Bahia, Salvador, Bahia, Brazil.&#xD;Casa di Cura Villa Montallegro, Allergology Department, Genova, Italy.&#xD;Department of Pulmonary Diseases and Institute of Pulmonology and Tuberculosis, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Immunology and Allergology, Lithuanian University of Health Sciences, Kaunas, Lithuania.&#xD;Department of Pediatrics and Adolescent Medicine, University of Turku, Turku University Hospital, Turku, Finland.&#xD;Institute of Clinical Immunology and Medical Genetics, Department of Paediatrics and Adolescent Medicine, Department of Pulmonology and Phthisiology, Jessenius Faculty of Medicine, Martin, Slovakia.&#xD;Comenius University, Bratislava, Slovakia.&#xD;University Teaching Hospital Martin, Martin, Slovakia.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;Allergy &amp; Immunology Centre, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.&#xD;National Center for Research in Chronic Respiratory Diseases, Collaborating With WHO-EMRO Tishreen University School of Medicine, Latakia, Syria.&#xD;Al-Sham Private University, Pharmacy Department, Damascus, Syria.&#xD;Japan Antituberculosis Association (JATA), Fukujuji Hospital, Tokyo, Japan.&#xD;Department of Respiratory Medicine, JSS Medical College, JSSAHER Mysuru, Mysore, Karnataka, India.&#xD;Departement of Biological Sciences and Pathophysiology, University of Veterinary Medicine, Vienna, Austria.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Allergy and Clinical Immunology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saude de Coimbra, Coimbra, Portugal.&#xD;Center for Innovative Biomedicine and Biotechnology (CIBB), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;UBIAir-Clinical &amp; Experimental Lung Centre and CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Pneumologie, AP-HP Centre Universite de Paris Cite, Hopital Cochin, Paris, France.&#xD;UMR 1016, Institut Cochin, Paris, France.&#xD;Inserm, Equipe D&apos;epidemiologie Respiratoire Integrative, CESP, Villejuif, France.&#xD;Department of Immunoallergology, Cova da Beira University Hospital Centre, Covilha, Portugal.&#xD;Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Copenhagen, Denmark.&#xD;Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Pediatrics, Allergy &amp; Immunology, Latin American Society of Allergy, Asthma &amp; Immunology (SLAAi), Montevideo, Uruguay.&#xD;Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy.&#xD;Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital and Beijing Institute of Otolaryngology, Beijing, China.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.&#xD;Universidad Espiritu Santo, Samborondon, Ecuador.&#xD;Department of Allergology &amp; Pulmonology, Respiralab Research Group, Guayaquil, Guayas, Ecuador.&#xD;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;Global NCD Platform, Geneva, Switzerland.&#xD;Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.&#xD;Microbiology Department, College of Medicine, Kuwait University, Kuwait City, Kuwait.&#xD;Adult Allergy and Immunology Division-Hamad Medical Corporation, Doha, Qatar.&#xD;Department of Cardiovascular and Respiratory Sciences, Porto Health School, Polytechnic Institute of Porto, Porto, Portugal.&#xD;Department of Women&apos;s and Children&apos;s Health, Paediatric Research, Uppsala University, Uppsala, Sweden.&#xD;Department of Internal Medicine, University of Medicine, Tirana, Albania.&#xD;Division of Immunology, Allergy and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.&#xD;Department of Internal Medicine (DIMI), University of Genoa, Genoa, Italy.&#xD;Respiratory &amp; Allergy Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.&#xD;Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil.&#xD;NOVA Medical School/Comprehensive Health Research Centre (CHRC), Lisbon, Portugal.&#xD;Servico de Imunoalergologia, Centro Hospitalar Universitario de Lisboa Central/ULS Sao Jose, Lisbon, Portugal.&#xD;Division of Allergy/Immunology, University of South Florida, Tampa, Florida, USA.&#xD;SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Allergy, Bambino Gesu Children&apos;s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.&#xD;Department of Internal Medicine &apos;A. Murri&apos; and Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.&#xD;Faculty of Public Health, Sofia Medical University, Sofia, Bulgaria.&#xD;Latvian Association of Allergists, University Children Hospital, Riga, Latvia.&#xD;Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.&#xD;CINTESIS@RISE, Biochemistry Lab, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing, University of Porto, Porto, Portugal.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, University of Cagliari, Cagliari, Italy.&#xD;VIM Suresnes, UMR 0892, Pole Des Maladies Des Voies Respiratoires, Hopital Foch, Universite Paris-Saclay, Suresnes, France.&#xD;Medical Faculty Skopje, University Clinic of Pulmology and Allergy, Skopje, Republic of North Macedonia.&#xD;Pediatric Allergy, Immunology and Rheumatology Unit, Children&apos;s Hospital, Ain Shams University, Cairo, Egypt.&#xD;Department of Otorhinolaryngology, Chiba University, Chiba, Japan.&#xD;Department of Internal Medicine and Infectious Diseases, St Joseph University, Hotel Dieu de France Hospital, Beirut, Lebanon.&#xD;Department of Allergology and Clinical Immunology, Kazakhstan Association of Allergology and Clinical Immunology, Kazakh National Medical University, Almaty, Kazakhstan.&#xD;Institute of Clinical Medicine, Children&apos;s Clinic, Tartu University, Tartu, Estonia.&#xD;Poltava State Medical University, Immunology &amp; Allergology Department, Poltava, Ukraine.&#xD;Department of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary.&#xD;Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Sach&apos;s Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Department of Pediatric Respiratory Diseases and Allergology, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Clinical and Laboratory Immunology, Allergology and Medical Genetics, Bogomolets National Medical University, Kyiv, Ukraine.&#xD;Institute of Translational Pharmacology (IFT)-National Research Council (CNR), Palermo, Italy.&#xD;Croatian Pulmonary Society, Clinical Center for Pulmonary Diseases, Zagreb, Croatia.&#xD;Asthma, COPD Outpatient Care Unit, University Medical Center, Ho-Chi-Minh City, Vietnam.&#xD;Allergy Unit &quot;D Kalogeromitros&quot;, 2nd Department of Dermatology and Venereology, National &amp; Kapodistrian University of Athens, &quot;Attikon&quot; University Hospital, Athens, Greece.&#xD;Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia.&#xD;Division of Respiratory Disease and Allergy, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea.&#xD;Department of Medicine, Faculty of Medicine and Surgery, University of Malta, Msida, Malta.&#xD;EPIUnit-Institute of Public Health, University of Porto, and Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal.&#xD;Servico de Imunoalergologia, Centro Hospitalar Universitario Sao Joao, Porto, Portugal.&#xD;Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Rhinology Unit &amp; Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain.&#xD;Clinical &amp; Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.&#xD;Universite Paris-Saclay, UVSQ, Universite Paris-Sud, Villejuif, France.&#xD;Imperial College Healthcare NHS Trust, London, UK.&#xD;University of Liverpool, Liverpool, UK.&#xD;Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina.&#xD;Department of Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;ENT Department, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo.&#xD;Allergy, Asthma and Clinical Immunology, Alfred Health and Department of Immunology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Chiba Rosai Hospital, ENT Department, Chiba, Japan.&#xD;Chiba University Hospital, Department of Otolaryngology, Head and Neck Surgery, Chiba, Japan.&#xD;Department of Otorhinolaryngology, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, &quot;Santa Maria della Speranza&quot; Hospital, Battipaglia, Salerno, Italy.&#xD;Agency of Health ASL, Division of Allergy and Clinical Immunology, Department of Medicine, Salerno, Italy.&#xD;Postgraduate Programme in Allergy and Clinical Immunology, University of Naples Federico II, Naples, Italy.&#xD;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Medical School, University of Cyprus, Nicosia, Cyprus.&#xD;Clinic of Occupational Diseases, University Hospital Sveti Ivan Rilski, Sofia, Bulgaria.&#xD;IRCCS Humanitas Research Center, Personalized Medicine Asthma &amp; Allergy, Rozzano, Milan, Italy.&#xD;Department of Pulmonology and Allergology, Klaipeda National Hospital, Klaipeda, Lithuania.&#xD;Vilnius University Medical Faculty, Vilnius, Lithuania.&#xD;Division of Adult and Pediatric Allergy and Immunology, University of the Philippines-Philippines General Hospital, Manila, Philippines.&#xD;Department of Allergy, Clinics Hospital, National University, San Lorenzo, Paraguay.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;The David Hide Asthma and Allergy Centre, St Mary&apos;s Hospital, Newport, Isle of Wight, UK.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;LEADER Research Inc., Hamilton, Ontario, Canada.&#xD;Division of Allergy, Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel.&#xD;Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.&#xD;Aria, Asthma, Rhinitis, Immunology &amp; Allergy Department, Athens, Greece.&#xD;Allergy Service, Fundacion Jimenez Diaz, Autonoma University of Madrid, CIBERES-ISCIII, Madrid, Spain.&#xD;PROMISE Department, University of Palermo, Palermo, Italy.&#xD;Allergy &amp; Asthma, Medical Director, CLINICA SISUL, FACAAI, SPAAI, Asuncion, Paraguay.&#xD;Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;Division of Respiratory Medicine, Department of Pediatrics, Hospital Nacional de Ninos, Universidad de Costa Rica, San Jose, Costa Rica.&#xD;Department of Respiratory Medicine and Tuberculosis, University Hospital, Brno, Czech Republic.&#xD;Department of Otolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Imunoalergologia, Centro Hospitalar Universitario de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;International Primary Care Respiratory Group IPCRG, Aberdeen, UK.&#xD;Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece.&#xD;Federal University of Pampa, Department of Medicine, Uruguaiana, Brazil.&#xD;Department of Lung Diseases and Clinical Immunology, University of Turku, Turku, Finland.&#xD;FiLHA, Finnish Lung Health Association, Helsinki, Finland.&#xD;Department of Clinical Medicine, Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland.&#xD;Nova Southeastern University, College of Allopathic Medicine, Fort Lauderdale, Florida, USA.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore.&#xD;Division of Allergy and Immunology, Department of Dermatology, Allergy and Venerology, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;The Allergy and Asthma Institute, Allergy &amp; Asthma Department, Islamabad, Pakistan.&#xD;University Clinic of Respiratory and Allergic Diseases, Pulmonary &amp; Allergy Department, Golnik, Slovenia.&#xD;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.&#xD;Pulmonary Department, Rashid Hospital, DUBAI Health, Dubai, UAE.&#xD;Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, UAE.&#xD;Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.&#xD;Oasi Research Institute-IRCCS, Troina, Italy.&#xD;BIOS S.P.A. Societa Benefit, Rome, Italy.&#xD;Department of Dermatology, Medical University of Graz, Graz, Austria.&#xD;Department of Allergy and Immunology, Para State University Center-CESUPA, Belem, Brazil.&#xD;Allergy Department, Hospital Clinic and IDIBAPS. Universitat de Barcelona, Barcelona, Spain.&#xD;RICORS de Enfermedades Inflamatorias (ISCIII), Madrid, Spain.&#xD;Department for Otorhinolaryngology, Head and Neck Surgery, University of Tubingen, Tubingen, Germany.&#xD;Respiratory Medicine, University of Modena &amp; Reggio Emilia, Azienda Ospedaliera-Universitaria di Modena, Modena, Italy.&#xD;Pediatric Unit, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy.&#xD;Evidence Prime, Krakow, Poland.&#xD;Evidence Prime, Hamilton, Ontario, Canada.&#xD;Laval University, Quebec City, Quebec, Canada.&#xD;Department of Pediatric Allergology, Armand Trousseau University Hospital, Sorbonne University, AP-HP, Paris, France.&#xD;French National Reference Center for Angioedema (CREAK), Saint-Antoine University Hospital, Paris, France.&#xD;CRESS, Inserm, INRAE, HERA Team, Paris Cite University, Paris, France.&#xD;Department of Medical Sciences, University of Turin, Turin, Italy.&#xD;Allergy and Clinical Immunology Unit, Mauriziano Hospital, Torino, Italy.&#xD;Department of Pulmonary Medicine, Mainz University Hospital, Mainz, Germany.&#xD;Pneumology Department, Hospital Universitari Dexeus, Barcelona, Spain.&#xD;CIBER of Respiratory Diseases, Group of Rhinitis, Rhinosinusitis and Nasal Polyps, Area of Asthma, SEPAR, Barcelona, Spain.&#xD;Clinique Des Bronches, Allergie et Sommeil, Hopital Nord, Marseille, France.&#xD;Department of Public Health and Primary Care, Leiden University Medical Centre, Leiden, the Netherlands.&#xD;National eHealth Living Lab, Leiden, the Netherlands.&#xD;Department of Pulmonology and Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;Department of Allergology and Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.&#xD;Allergist, David Tvildiani Medical University, Tbilisi, Georgia.&#xD;University of South Florida, College of Medicine, Division of Allergy-Immunology, Department of Internal Medicine, Tampa, Florida, USA.&#xD;Associate Professor of Pediatrics, Division of Allergy and Immunology, Federal University of Parana, Curitiba, Brazil.&#xD;Paediatric Allergy Clinic, Department of Dermatology, Amersham Hospital, NHS Hospital Trust, Amersham, UK.&#xD;Evidence in Allergy Group, McMaster University and the Research Institute of St. Joe&apos;s Hamilton, Hamilton, Canada.&#xD;Eskisehir Osmangazi University, Medical Faculty, ENT Department, Eskisehir, Turkey.&#xD;Scientific &amp; Medical Department, Lofarma S.p.A, Milan, Italy.&#xD;LAQV@REQUIMTE, Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.&#xD;Woolcock Institute of Medical Research, Sydney, Australia.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall D&apos;hebron, Barcelona, Spain.&#xD;ARADyAL Research Network, Barcelona, Spain.&#xD;Division of Respiratory and Allergic Diseases, High Specialty Hospital &apos;A Cardarelli&apos;, and Respiratory Allergy School of Specialization in Respiratory Diseases, Federico II University of Naples, Naples, Italy.&#xD;Centre for Immunology and Infection Control, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia.&#xD;Office of Research, Metro North Hospital and Health Service, Brisbane, Australia.&#xD;University of Foggia, Department of Medical and Surgical Science, Foggia, Italy.&#xD;Allergy and Clinical Immunology Centro Regional, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University of Crete, School of Medicine, Heraklion, Crete, Greece.&#xD;Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia in Katowice, Katowice, Poland.&#xD;Pediatrics Department, Universidad Austral de Chile, Valvidia, Chile.&#xD;Department of Pulmonary Medicine, Division of Immunology, Allergy and Asthma, Laboratory of Occupational and Environmental Respiratory Diseases, Faculty of Medicine, Ege University, EgeSAM (Ege University Translational Pulmonary Research Center), Bornova, Izmir, Turkiye.&#xD;Faculty of Health Sciences, Catholic University of Salta, Salta, Argentina.&#xD;Center of Allergy and Immunology, and Georgian Academy of Allergy, Asthma, and Clinical Immunology, Tbilisi, Georgia.&#xD;Former President of the Hellenic Society of Allergology and Clinical Immunology, Department of Allergy and Clinical Immunology, Air Force General Hospital, Athens, Greece.&#xD;Riga East University Hospital, Riga, Latvia.&#xD;Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile.&#xD;Quality Use of Research Medicines Group, Woolcock Institute of Medical Research, Macquarie Park, New South Wales, Australia.&#xD;Macquarie University, Macquarie Park, New South Wales, Australia.&#xD;Faculty of Health, University of Plymouth, Plymouth, UK.&#xD;Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.&#xD;Otolaryngology Department, General Hospital of Kalamata, Kalamata City, Greece.&#xD;Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;Occupational and Environmental Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.&#xD;ORL SOKLIC KOSAK, Ljubljana, Slovenia.&#xD;University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.&#xD;Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.&#xD;Bagcilar Research and Training Hospital, Department of Chest Diseases, Istanbul, Turkey.&#xD;Clinical Management Group, Woolcock Institute of Medical Research, Macquarie University, Sydney, New South Wales, Australia.&#xD;Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.&#xD;Departmental Unit of Allergology, Clinical Immunology &amp; Pneumology, Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy.&#xD;Department of Public Health, University of Liege, Liege, Belgium.&#xD;Department of Pneumology, GIGA I3 Research Group, University of Liege, Liege, Belgium.&#xD;Allergy Unit, Department of Internal Medicine, University Hospital AOU Delle Marche, Ancona, Italy.&#xD;Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Ankara University Medical School, Ankara, Turkey.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Salzburg Paracelsus Medical University, Salzburg, Austria.&#xD;Department of Otolaryngology, Head and Neck Surgery, Cornell University, Weill Cornell Medical College, New York, New York, USA.&#xD;Allergy &amp; Clinical Immunology Department, University Hospital Center &quot;Mother Teresa&quot;, Tirana, Albania.&#xD;UMF-University of Medicine and Pharmacy &apos;Carol Davila&apos;, Pneumology Department, National Institute of Pneumology &apos;Marius Nasta&apos;, Bucharest, Romania.&#xD;Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland, USA.&#xD;Department of Environmental Health, Harvard TH Chan School of Public Health and Department of Medicine, Division of Allergy and Inflammation, Beth Israel Deaconess Hospital, Boston, Massachusetts, USA.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.&#xD;Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Republic of Korea.&#xD;Clinical Epidemiology and Research Center, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.&#xD;Otorhinolaryngology and Neck Surgery Unit, San Juan de Dios National Hospital, San Miguel, El Salvador.&#xD;Allergist, Private Practice, Mexico City, Mexico.&#xD;Ecole Polytechnique de Palaiseau, Palaiseau, France.&#xD;IRBA (Institut de Recherche Bio-Medicale Des Armees), Bretigny sur Orge, France.&#xD;Universite Paris Cite, Paris, France.&#xD;Department of Otorhinolaryngology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.&#xD;Department of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Dar Al Shifa Hospital, Salmiya, Kuwait.&#xD;Center Allergy &amp; Immunology/Geomedi Teaching University, Faculty of Medicine, Tbilisi, Georgia.&#xD;Usher Institute, University of Edinburgh, Edinburgh, UK.&#xD;Department of Otorhinolaryngology, Yamanashi University, Yamanashi, Japan.&#xD;Mohammed Bin Rashid University (MBRU), Dubai Health, Dubai, UAE.&#xD;Asthma Reference Center-School of Medicine of Santa Casa de Misericordia of Vitoria, Espirito Santo, Brazil.&#xD;Department of Otorhinolaryngology and Head &amp; Neck Surgery, CHU Rangueil-Larrey, Toulouse, France.&#xD;Allergy Service, University Hospital Professor Polydoro Ernani de Sao Thiago (HU-UFSC/EBSERH), Florianopolis, Brazil.&#xD;Department of Internal Medicine, Federal University of Santa Catarina (UFSC), Florianopolis, Brazil.&#xD;Otolaryngology-HNS, University of Zurich, University Hospital of Zurich, Zurich, Switzerland.&#xD;Clinic of Allergology and Immunology, University Clinical Center of Serbia, Belgrade, Serbia.&#xD;Faculty of Medicine, University of Belgrade, Belgrade, Serbia.&#xD;Department of Respiratory Medicine, Medical Professorial Unit, Tallaght University Hospital &amp; Trinity College, Dublin, Ireland.&#xD;Dr Agostinho Neto University Hospital, Praia, Cabo Verde.&#xD;Immunology, Cabo Verde University, Faculty of Medicine, Praia, Cabo Verde.&#xD;The Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Department of Immunology and Allergology, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.&#xD;Charles University, Prague, Czech Republic.&#xD;Department of Medicine Solna, Division of Immunology and Respiratory Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.&#xD;Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.&#xD;Samitivej Allergy Institute, Bangkok, Thailand.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Siriraj Hospital, Mahidol University, Faculty of Medicine, Bangkok, Thailand.&#xD;Department of Otorhinolaryngology, Heinrich Heine University Dusseldorf, Medical Faculty and University Hospital Dusseldorf, Dusseldorf, Germany.&#xD;The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, China.&#xD;ENT and Allergology, Dusseldorf, Germany.&#xD;Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.&#xD;The Third Affiliated Hospital of sun Yat-Sen University, Guangzhou, China.&#xD;Servicio de Alergia e Inmunologia clinica, Hospital Universitario de Puebla, Puebla, Mexico.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">intranasal antihistamines</style></keyword><keyword><style face="normal" font="default" size="100%">intranasal corticosteroids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41324154</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI-endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024-2025). This manuscript presents the ARIA 2024-2025 recommendations for intranasal treatments, one of the mainstays for AR management. METHODS: The ARIA 2024-2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgments and recommendations, including systematic reviews, evaluation of mHealth and pharmacovigilance data, as well as a survey of experts on costs. RESULTS: Eleven guideline questions concerning intranasal treatments for AR were prioritized, leading to recommendations. Overall, these questions concern the choice between different classes of intranasal medications-most notably, intranasal corticosteroids (INCS), antihistamines (INAH), fixed combinations of INAH+INCS and decongestants-or between different individual medications within each class. Four questions had not been evaluated in previous ARIA guidelines, while for the other three there was a change in the strength or directionality of recommendations. Overall, recommendations point to the suggested use of INAH+INCS over INAH or INCS and INCS over INAH. CONCLUSION: This ARIA 2024-2025 article supports patients, their caregivers, and healthcare professionals in choosing an intranasal treatment. However, decisions on AR treatment should consider the clinical variability of the disease, patients&apos; values, and the affordability of medications.</style></abstract><notes><style face="normal" font="default" size="100%">Sousa-Pinto, Bernardo&#xD;Bousquet, Jean&#xD;Vieira, Rafael Jose&#xD;Schunemann, Holger J&#xD;Zuberbier, Torsten&#xD;Bognanni, Antonio&#xD;Togias, Alkis&#xD;Samolinski, Boleslaw&#xD;Valiulis, Arunas&#xD;Williams, Sian&#xD;Bedbrook, Anna&#xD;Czarlewski, Wienczyslawa&#xD;Torres, Maria Jose&#xD;Shamji, Mohamed H&#xD;Morais-Almeida, Mario&#xD;Canonica, G Walter&#xD;Vecillas, Leticia de Las&#xD;Dykewicz, Mark S&#xD;Jacomelli, Cristina&#xD;Klimek, Ludger&#xD;Leemann, Lucas&#xD;Lourenco, Olga&#xD;Palamarchuk, Yuliia&#xD;Papadopoulos, Nikolaos G&#xD;Pereira, Ana Margarida&#xD;Savoure, Marine&#xD;Toppila-Salmi, Sanna K&#xD;Ventura, Maria Teresa&#xD;Yepes-Nunez, Juan Jose&#xD;Cruz, Alvaro A&#xD;Ciprandi, Giorgio&#xD;Gemicioglu, Bilun&#xD;Giovannini, Mattia&#xD;Gradauskiene, Brigita&#xD;Jartti, Tuomas&#xD;Jesenak, Milos&#xD;Kuna, Piotr&#xD;Kvedariene, Violeta&#xD;Larenas-Linnemann, Desiree E&#xD;Latiff, Amir Ha&#xD;Mohammad, Yousser&#xD;Ohta, Ken&#xD;Mahesh, Padukudru A&#xD;Pali-Scholl, Isabella&#xD;Pfaar, Oliver&#xD;Regateiro, Frederico S&#xD;Roche, Nicolas&#xD;Taborda-Barata, Luis&#xD;Ulrik, Charlotte Suppli&#xD;Rostan, Marylin Valentin&#xD;Viegi, Giovanni&#xD;Zhang, Luo&#xD;Haahtela, Tari&#xD;Cherrez-Ojeda, Ivan&#xD;Carlos Ivancevich, Juan&#xD;Khaltaev, Nikolai&#xD;Yorgancioglu, Arzu&#xD;Abdullah, Baharudin&#xD;Al-Ahmad, Mona&#xD;Al-Nesf, Maryam Ali&#xD;Amaral, Rita&#xD;Asllani, Julijana&#xD;Bergmann, Karl-C&#xD;Bernstein, Jonathan A&#xD;Blaiss, Michael S&#xD;Braido, Fulvio&#xD;Camargos, Paulo&#xD;Carreiro-Martins, Pedro&#xD;Casale, Thomas&#xD;Cecchi, Lorenzo&#xD;Fiocchi, Alessandro&#xD;Giuliano, Antonio F M&#xD;Christoff, George&#xD;Cirule, Ieva&#xD;de Sousa, Jaime Correia&#xD;Costa, Elisio M&#xD;Del Giacco, Stefano&#xD;Devillier, Philippe&#xD;Dokic, Dejan&#xD;Hossny, Elham&#xD;Iinuma, Tomohisa&#xD;Irani, Carla&#xD;Ispayeva, Zhanat&#xD;Julge, Kaja&#xD;Kaidashev, Igor&#xD;Bennoor, Kazi S&#xD;Kraxner, Helga&#xD;Kull, Inger&#xD;Kulus, Marek&#xD;Kupczyk, Maciej&#xD;Kurchenko, Andriy&#xD;La Grutta, Stefania&#xD;Miculinic, Neven&#xD;Tuyet, Lan Le Thi&#xD;Makris, Michael&#xD;Milenkovic, Branislava&#xD;Lee, Sang Min&#xD;Montefort, Stephen&#xD;Moreira, Andre&#xD;Mullol, Joaquim&#xD;Nadif, Rachel&#xD;Nakonechna, Alla&#xD;Neffen, Hugo E&#xD;Niedoszytko, Marek&#xD;Nyembue, Dieudonne&#xD;O&apos;Hehir, Robyn E&#xD;Ogulur, Ismail&#xD;Okamoto, Yoshitaka&#xD;Olze, Heidi&#xD;Palomares, Oscar&#xD;Panzner, Petr&#xD;Patella, Vincenzo&#xD;Pawankar, Ruby&#xD;Pitsios, Constantinos&#xD;Popov, Todor A&#xD;Puggioni, Francesca&#xD;Quirce, Santiago&#xD;Ramonaite, Agne&#xD;Recto, Marysia&#xD;Repka-Ramirez, Maria Susana&#xD;Roberts, Graham&#xD;Robles-Velasco, Karla&#xD;Rottem, Menachem&#xD;Salapatas, Marianella&#xD;Sastre, Joaquin&#xD;Scichilone, Nicola&#xD;Sisul, Juan-Carlos&#xD;Sole, Dirceu&#xD;Soto-Martinez, Manuel E&#xD;Sova, Milan&#xD;Tantilipikorn, Pongsakorn&#xD;Todo-Bom, Ana&#xD;Tsaryk, Vladyslav&#xD;Tsiligianni, Ioanna&#xD;Urrutia-Pereira, Marilyn&#xD;Valovirta, Erkka&#xD;Vasankari, Tuula&#xD;Wallace, Dana&#xD;Wang, De Yun&#xD;Worm, Margitta&#xD;Yusuf, Osman M&#xD;Zidarn, Mihaela&#xD;Gil-Mata, Sara&#xD;Marques-Cruz, Manuel&#xD;Mahboub, Bassam&#xD;Ansotegui, Ignacio J&#xD;Romano, Antonino&#xD;Aberer, Werner&#xD;Artesani, Maria Cristina&#xD;Azzolini, Elena&#xD;Barreto, Bruno&#xD;Bartra, Joan&#xD;Becker, Sven&#xD;Beghe, Bianca&#xD;Boner, Attilio&#xD;Borowiack, Ewa&#xD;Bouchard, Jacques&#xD;Bourgoin-Heck, Melisande&#xD;Brussino, Luisa&#xD;Buhl, Roland&#xD;Castillo-Vizuete, Jose Antonio&#xD;Charpin, Denis&#xD;Chavannes, Niels H&#xD;Chelminska, Marta&#xD;Cheng, Lei&#xD;Chkhartishvili, Ekaterine&#xD;Cho, Seong H&#xD;Chong-Neto, Herberto Jose&#xD;Choudhury, Deepa&#xD;Chu, Derek K&#xD;Cingi, Cemal&#xD;Compalati, Enrico&#xD;Costa, Raquel Albuquerque&#xD;Cunha, Olga Mariana&#xD;Cvetkovski, Biljana&#xD;Cardona-Dahl, Victoria&#xD;D&apos;Amato, Gennaro&#xD;Davies, Janet&#xD;Di Bona, Danilo&#xD;Gonzalez Diaz, Sandra N&#xD;Dimou, Maria V&#xD;Doulaptsi, Maria&#xD;Ferreira-da-Silva, Renato&#xD;Gawlik, Radoslaw&#xD;Calvo-Gil, Mario&#xD;Goksel, Ozlem&#xD;Gomez, Maximiliano R&#xD;Gotua, Maia&#xD;Grigoreas, Christos&#xD;Grisle, Ineta&#xD;Guzman, Maria Antonieta&#xD;Tan, Rachel House&#xD;Hyland, Michael&#xD;Ierodiakonou, Despo&#xD;Karavelia, Aspasia&#xD;Keith, Paul&#xD;Kisiel, Marta&#xD;Kosak, Tanja Soklic&#xD;Kosnik, Mitja&#xD;Koyuncu, Ilgim Vardaloglu&#xD;Kritikos, Vicky&#xD;Litynska, Justyna&#xD;Lombardi, Carlo&#xD;Louis, Gilles&#xD;Martini, Matteo&#xD;Meco, Cem&#xD;Mesonjesi, Eris&#xD;Mihaltan, Florin&#xD;Moniuszko, Marcin&#xD;Naclerio, Robert N&#xD;Nadeau, Kari C&#xD;Neisinger, Sophia&#xD;Ollert, Markus&#xD;Ordak, Michal&#xD;Paoletti, Giovanni&#xD;Park, Hae-Sim&#xD;Parmelli, Elena&#xD;Perdomo-Flores, Edgar Arturo&#xD;Perez, Jose Miguel Fuentes&#xD;Pham-Thi, Nhan&#xD;Prokopakis, Emmanuel&#xD;Ribeiro-Vaz, Ines&#xD;Rolla, Giovanni&#xD;Romantowski, Jan&#xD;Rombaux, Philippe&#xD;Rouadi, Philip W&#xD;Rukhadze, Maia&#xD;Ryan, Dermot&#xD;Sadowska, Ewelina&#xD;Sakurai, Daiju&#xD;Salameh, Laila&#xD;Sarquis, Faradiba Serpa&#xD;Serrano, Elie&#xD;Da Silva, Jane&#xD;Soyka, Michael&#xD;Specjalski, Krzysztof&#xD;Tomic-Spiric, Vesna&#xD;Stevanovic, Katarina&#xD;Subramaniam, Abirami&#xD;Teixeira, Maria Do Ceu&#xD;Thomander, Tuuli&#xD;Vachova, Martina&#xD;van Hage, Marianne&#xD;Vichyanond, Pakit&#xD;Wagenmann, Martin&#xD;Ko, Fanny Wai San&#xD;Werminghaus, Pascal&#xD;Xepapadaki, Paraskevi Vicky&#xD;Xiang, Yi-Kui&#xD;Yang, Qintai&#xD;Yeverino, Daniela Rivero&#xD;Zuberbier, Jaron&#xD;Fonseca, Joao A&#xD;eng&#xD;ARIA (Allergic Rhinitis and its Impact on Asthma), Montpellier, France/&#xD;Denmark&#xD;Allergy. 2025 Dec 1. doi: 10.1111/all.70131.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41324154</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70131</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3293</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3293</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vieira, Rafael José</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, Bernardo</style></author><author><style face="normal" font="default" size="100%">Bousquet, Jean</style></author><author><style face="normal" font="default" size="100%">Schünemann, Holger J.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, Torsten</style></author><author><style face="normal" font="default" size="100%">Bognanni, Antonio</style></author><author><style face="normal" font="default" size="100%">Togias, Alkis</style></author><author><style face="normal" font="default" size="100%">Samolinski, Boleslaw</style></author><author><style face="normal" font="default" size="100%">Valiulis, Arunas</style></author><author><style face="normal" font="default" size="100%">Williams, Sian</style></author><author><style face="normal" font="default" size="100%">Bedbrook, Anna</style></author><author><style face="normal" font="default" size="100%">Czarlewski, Wienczyslawa</style></author><author><style face="normal" font="default" size="100%">Torres, Maria Jose</style></author><author><style face="normal" font="default" size="100%">Shamji, Mohamed H.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, Mário</style></author><author><style face="normal" font="default" size="100%">Canonica, G. Walter</style></author><author><style face="normal" font="default" size="100%">Vecillas, Leticia de las</style></author><author><style face="normal" font="default" size="100%">Dykewicz, Mark S.</style></author><author><style face="normal" font="default" size="100%">Jacomelli, Cristina</style></author><author><style face="normal" font="default" size="100%">Klimek, Ludger</style></author><author><style face="normal" font="default" size="100%">Leemann, Lucas</style></author><author><style face="normal" font="default" size="100%">Lourenço, Olga</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, Nikolaos G.</style></author><author><style face="normal" font="default" size="100%">Pereira, Ana Margarida</style></author><author><style face="normal" font="default" size="100%">Savouré, Marine</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, Sanna K.</style></author><author><style face="normal" font="default" size="100%">Ventura, Maria Teresa</style></author><author><style face="normal" font="default" size="100%">Yepes-Nuñez, Juan José</style></author><author><style face="normal" font="default" size="100%">Cruz, Alvaro A.</style></author><author><style face="normal" font="default" size="100%">Ciprandi, Giorgio</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, Bilun</style></author><author><style face="normal" font="default" size="100%">Giovannini, Mattia</style></author><author><style face="normal" font="default" size="100%">Gradauskiene, Brigita</style></author><author><style face="normal" font="default" size="100%">Jartti, Tuomas</style></author><author><style face="normal" font="default" size="100%">Jeseňák, Miloš</style></author><author><style face="normal" font="default" size="100%">Kuna, Piotr</style></author><author><style face="normal" font="default" size="100%">Kvedariene, Violeta</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, Désirée E.</style></author><author><style face="normal" font="default" size="100%">Latiff, Amir H. A.</style></author><author><style face="normal" font="default" size="100%">Mohammad, Yousser</style></author><author><style face="normal" font="default" size="100%">Ohta, Ken</style></author><author><style face="normal" font="default" size="100%">Mahesh, Padukudru A.</style></author><author><style face="normal" font="default" size="100%">Pali-Schöll, Isabella</style></author><author><style face="normal" font="default" size="100%">Pfaar, Oliver</style></author><author><style face="normal" font="default" size="100%">Regateiro, Frederico S.</style></author><author><style face="normal" font="default" size="100%">Roche, Nicolas</style></author><author><style face="normal" font="default" size="100%">Taborda-Barata, Luís</style></author><author><style face="normal" font="default" size="100%">Ulrik, Charlotte Suppli</style></author><author><style face="normal" font="default" size="100%">Viegi, Giovanni</style></author><author><style face="normal" font="default" size="100%">Zhang, Luo</style></author><author><style face="normal" font="default" size="100%">Haahtela, Tari</style></author><author><style face="normal" font="default" size="100%">Cherrez-Ojeda, Ivan</style></author><author><style face="normal" font="default" size="100%">Ivancevich, Juan Carlos</style></author><author><style face="normal" font="default" size="100%">Khaltaev, Nikolai</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, Arzu</style></author><author><style face="normal" font="default" size="100%">Abdullah, Baharudin</style></author><author><style face="normal" font="default" size="100%">Al-Ahmad, Mona</style></author><author><style face="normal" font="default" size="100%">Al-Nesf, Maryam Ali</style></author><author><style face="normal" font="default" size="100%">Amaral, Rita</style></author><author><style face="normal" font="default" size="100%">Asllani, Julijana</style></author><author><style face="normal" font="default" size="100%">Bergmann, Karl-C.</style></author><author><style face="normal" font="default" size="100%">Bernstein, Jonathan A.</style></author><author><style face="normal" font="default" size="100%">Blaiss, Michael S.</style></author><author><style face="normal" font="default" size="100%">Toskala, Elina</style></author><author><style face="normal" font="default" size="100%">Carreiro-Martins, Pedro</style></author><author><style face="normal" font="default" size="100%">Casale, Thomas</style></author><author><style face="normal" font="default" size="100%">Cecchi, Lorenzo</style></author><author><style face="normal" font="default" size="100%">Fiocchi, Alessandro</style></author><author><style face="normal" font="default" size="100%">Giuliano, Antonio F. M.</style></author><author><style face="normal" font="default" size="100%">Christoff, George</style></author><author><style face="normal" font="default" size="100%">Cirule, Ieva</style></author><author><style face="normal" font="default" size="100%">de Sousa, Jaime Correia</style></author><author><style face="normal" font="default" size="100%">Costa, Elisio M.</style></author><author><style face="normal" font="default" size="100%">Devillier, Philippe</style></author><author><style face="normal" font="default" size="100%">Hossny, Elham</style></author><author><style face="normal" font="default" size="100%">Iinuma, Tomohisa</style></author><author><style face="normal" font="default" size="100%">Ispayeva, Zhanat</style></author><author><style face="normal" font="default" size="100%">Julge, Kaja</style></author><author><style face="normal" font="default" size="100%">Kaidashev, Igor</style></author><author><style face="normal" font="default" size="100%">Bennoor, Kazi S.</style></author><author><style face="normal" font="default" size="100%">Kraxner, Helga</style></author><author><style face="normal" font="default" size="100%">Kull, Inger</style></author><author><style face="normal" font="default" size="100%">Kulus, Marek</style></author><author><style face="normal" font="default" size="100%">Kupczyk, Maciej</style></author><author><style face="normal" font="default" size="100%">Kurchenko, Andriy</style></author><author><style face="normal" font="default" size="100%">La Grutta, Stefania</style></author><author><style face="normal" font="default" size="100%">Miculinic, Neven</style></author><author><style face="normal" font="default" size="100%">Tuyet, Lan Le Thi</style></author><author><style face="normal" font="default" size="100%">Lee, Sang Min</style></author><author><style face="normal" font="default" size="100%">Montefort, Stephen</style></author><author><style face="normal" font="default" size="100%">Moreira, Andre</style></author><author><style face="normal" font="default" size="100%">Mullol, Joaquim</style></author><author><style face="normal" font="default" size="100%">Nadif, Rachel</style></author><author><style face="normal" font="default" size="100%">Nakonechna, Alla</style></author><author><style face="normal" font="default" size="100%">Neffen, Hugo E.</style></author><author><style face="normal" font="default" size="100%">Niedoszytko, Marek</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, Robyn E.</style></author><author><style face="normal" font="default" size="100%">Ogulur, Ismail</style></author><author><style face="normal" font="default" size="100%">Okamoto, Yoshitaka</style></author><author><style face="normal" font="default" size="100%">Olze, Heidi</style></author><author><style face="normal" font="default" size="100%">Palomares, Oscar</style></author><author><style face="normal" font="default" size="100%">Panzner, Petr</style></author><author><style face="normal" font="default" size="100%">Patella, Vincenzo</style></author><author><style face="normal" font="default" size="100%">Pitsios, Constantinos</style></author><author><style face="normal" font="default" size="100%">Puggioni, Francesca</style></author><author><style face="normal" font="default" size="100%">Quirce, Santiago</style></author><author><style face="normal" font="default" size="100%">Ramonaité, Agné</style></author><author><style face="normal" font="default" size="100%">Repka-Ramirez, Maria Susana</style></author><author><style face="normal" font="default" size="100%">Roberts, Graham</style></author><author><style face="normal" font="default" size="100%">Robles-Velasco, Karla</style></author><author><style face="normal" font="default" size="100%">Rottem, Menachem</style></author><author><style face="normal" font="default" size="100%">Salapatas, Marianella</style></author><author><style face="normal" font="default" size="100%">Sastre, Joaquin</style></author><author><style face="normal" font="default" size="100%">Scichilone, Nicola</style></author><author><style face="normal" font="default" size="100%">Sisul, Juan-Carlos</style></author><author><style face="normal" font="default" size="100%">Solé, Dirceu</style></author><author><style face="normal" font="default" size="100%">Soto-Martinez, Manuel E.</style></author><author><style face="normal" font="default" size="100%">Sova, Milan</style></author><author><style face="normal" font="default" size="100%">Tantilipikorn, Pongsakorn</style></author><author><style face="normal" font="default" size="100%">Todo-Bom, Ana</style></author><author><style face="normal" font="default" size="100%">Tsaryk, Vladyslav</style></author><author><style face="normal" font="default" size="100%">Tsiligianni, Ioanna</style></author><author><style face="normal" font="default" size="100%">Urrutia-Pereira, Marilyn</style></author><author><style face="normal" font="default" size="100%">Valovirta, Erkka</style></author><author><style face="normal" font="default" size="100%">Vasankari, Tuula</style></author><author><style face="normal" font="default" size="100%">Wallace, Dana</style></author><author><style face="normal" font="default" size="100%">Wang, De Yun</style></author><author><style face="normal" font="default" size="100%">Worm, Margitta</style></author><author><style face="normal" font="default" size="100%">Yusuf, Osman M.</style></author><author><style face="normal" font="default" size="100%">Gil-Mata, Sara</style></author><author><style face="normal" font="default" size="100%">Marques-Cruz, Manuel</style></author><author><style face="normal" font="default" size="100%">Mahboub, Bassam</style></author><author><style face="normal" font="default" size="100%">Romano, Antonino</style></author><author><style face="normal" font="default" size="100%">Aberer, Werner</style></author><author><style face="normal" font="default" size="100%">Artesani, Maria Cristina</style></author><author><style face="normal" font="default" size="100%">Azzolini, Elena</style></author><author><style face="normal" font="default" size="100%">Barreto, Bruno</style></author><author><style face="normal" font="default" size="100%">Bartra, Joan</style></author><author><style face="normal" font="default" size="100%">Becker, Sven</style></author><author><style face="normal" font="default" size="100%">Beghe, Bianca</style></author><author><style face="normal" font="default" size="100%">Boner, Attilio</style></author><author><style face="normal" font="default" size="100%">Borowiack, Ewa</style></author><author><style face="normal" font="default" size="100%">Bouchard, Jacques</style></author><author><style face="normal" font="default" size="100%">Brussino, Luisa</style></author><author><style face="normal" font="default" size="100%">Buhl, Roland</style></author><author><style face="normal" font="default" size="100%">Catamerò, Francesco</style></author><author><style face="normal" font="default" size="100%">Charpin, Denis</style></author><author><style face="normal" font="default" size="100%">Chavannes, Niels H.</style></author><author><style face="normal" font="default" size="100%">Chełmińska, Marta</style></author><author><style face="normal" font="default" size="100%">Cheng, Lei</style></author><author><style face="normal" font="default" size="100%">Chkhartishvili, Ekaterine</style></author><author><style face="normal" font="default" size="100%">Cho, Seong H.</style></author><author><style face="normal" font="default" size="100%">Chong-Neto, Herberto Jose</style></author><author><style face="normal" font="default" size="100%">Chu, Derek K.</style></author><author><style face="normal" font="default" size="100%">Cingi, Cemal</style></author><author><style face="normal" font="default" size="100%">Compalati, Enrico</style></author><author><style face="normal" font="default" size="100%">Costa, Raquel Albuquerque</style></author><author><style face="normal" font="default" size="100%">Cvetkovski, Biljana</style></author><author><style face="normal" font="default" size="100%">Cardona, Victoria</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, Gennaro</style></author><author><style face="normal" font="default" size="100%">Davies, Janet M.</style></author><author><style face="normal" font="default" size="100%">Di Bona, Danilo</style></author><author><style face="normal" font="default" size="100%">Gonzalez Diaz, Sandra N.</style></author><author><style face="normal" font="default" size="100%">Dimou, Maria V.</style></author><author><style face="normal" font="default" size="100%">Doulaptsi, Maria</style></author><author><style face="normal" font="default" size="100%">Ferreira-da-Silva, Renato</style></author><author><style face="normal" font="default" size="100%">Gawlik, Radoslaw</style></author><author><style face="normal" font="default" size="100%">Calvo-Gil, Mario</style></author><author><style face="normal" font="default" size="100%">Gómez, Maximiliano R.</style></author><author><style face="normal" font="default" size="100%">Gotua, Maia</style></author><author><style face="normal" font="default" size="100%">Grigoreas, Christos</style></author><author><style face="normal" font="default" size="100%">Guzman, Maria Antonieta</style></author><author><style face="normal" font="default" size="100%">House, Rachel</style></author><author><style face="normal" font="default" size="100%">Hyland, Michael</style></author><author><style face="normal" font="default" size="100%">Ierodiakonou, Despo</style></author><author><style face="normal" font="default" size="100%">Karavelia, Aspasia</style></author><author><style face="normal" font="default" size="100%">Keith, Paul</style></author><author><style face="normal" font="default" size="100%">Kisiel, Marta</style></author><author><style face="normal" font="default" size="100%">Kosak, Tanja Soklic</style></author><author><style face="normal" font="default" size="100%">Kosnik, Mitja</style></author><author><style face="normal" font="default" size="100%">Koyuncu, Ilgim Vardaloglu</style></author><author><style face="normal" font="default" size="100%">Kritikos, Vicky</style></author><author><style face="normal" font="default" size="100%">Litynska, Justyna</style></author><author><style face="normal" font="default" size="100%">Lombardi, Carlo</style></author><author><style face="normal" font="default" size="100%">Louis, Gilles</style></author><author><style face="normal" font="default" size="100%">Luo, Xin</style></author><author><style face="normal" font="default" size="100%">Martini, Matteo</style></author><author><style face="normal" font="default" size="100%">Meço, Cem</style></author><author><style face="normal" font="default" size="100%">Mesonjesi, Eris</style></author><author><style face="normal" font="default" size="100%">Mihaltan, Florin</style></author><author><style face="normal" font="default" size="100%">Moniuszko, Marcin</style></author><author><style face="normal" font="default" size="100%">Naclerio, Robert N.</style></author><author><style face="normal" font="default" size="100%">Neisinger, Sophia</style></author><author><style face="normal" font="default" size="100%">Ollert, Markus</style></author><author><style face="normal" font="default" size="100%">Ordak, Michal</style></author><author><style face="normal" font="default" size="100%">Paoletti, Giovanni</style></author><author><style face="normal" font="default" size="100%">Parmelli, Elena</style></author><author><style face="normal" font="default" size="100%">Perdomo-Flores, Edgar Arturo</style></author><author><style face="normal" font="default" size="100%">Pereira, Henrique</style></author><author><style face="normal" font="default" size="100%">Pérez, José Miguel Fuentes</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, Nhan</style></author><author><style face="normal" font="default" size="100%">Prokopakis, Emmanuel</style></author><author><style face="normal" font="default" size="100%">Ribeiro-Vaz, Inês</style></author><author><style face="normal" font="default" size="100%">Rolla, Giovanni</style></author><author><style face="normal" font="default" size="100%">Romantowski, Jan</style></author><author><style face="normal" font="default" size="100%">Rombaux, Philippe</style></author><author><style face="normal" font="default" size="100%">Rouadi, Philip W.</style></author><author><style face="normal" font="default" size="100%">Ryan, Dermot</style></author><author><style face="normal" font="default" size="100%">Sadowska, Ewelina</style></author><author><style face="normal" font="default" size="100%">Sakurai, Daiju</style></author><author><style face="normal" font="default" size="100%">Salameh, Laila</style></author><author><style face="normal" font="default" size="100%">Serrano, Elie</style></author><author><style face="normal" font="default" size="100%">Da Silva, Jane</style></author><author><style face="normal" font="default" size="100%">Soyka, Michael B.</style></author><author><style face="normal" font="default" size="100%">Specjalski, Krzysztof</style></author><author><style face="normal" font="default" size="100%">Tomic-Spiric, Vesna</style></author><author><style face="normal" font="default" size="100%">Stevanovic, Katarina</style></author><author><style face="normal" font="default" size="100%">Subramaniam, Abirami</style></author><author><style face="normal" font="default" size="100%">Thomander, Tuuli</style></author><author><style face="normal" font="default" size="100%">Tong, Wu</style></author><author><style face="normal" font="default" size="100%">Vachova, Martina</style></author><author><style face="normal" font="default" size="100%">van Hage, Marianne</style></author><author><style face="normal" font="default" size="100%">Wagenmann, Martin</style></author><author><style face="normal" font="default" size="100%">Ko, Fanny Wai San</style></author><author><style face="normal" font="default" size="100%">Werminghaus, Pascal</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, Paraskevi Vicky</style></author><author><style face="normal" font="default" size="100%">Xiang, Yi-Kui</style></author><author><style face="normal" font="default" size="100%">Yang, Qintai</style></author><author><style face="normal" font="default" size="100%">Zhang, He</style></author><author><style face="normal" font="default" size="100%">Zuberbier, Jaron</style></author><author><style face="normal" font="default" size="100%">Fonseca, João A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines—2024–2025 Revision: Part II—Guidelines on Oral and Ocular Treatments</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)-EAACI guidelines, this manuscript presents the ARIA-EAACI 2024–2025 recommendations for oral and ocular treatments. Methods The ARIA-EAACI 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgements and recommendations, including systematic reviews, mHealth and pharmacovigilance data as well as a survey on costs. Results Eight guideline questions concerning oral treatments for AR and three questions concerning ocular treatments were addressed. These questions led to the recommendations. Overall, these questions concern the choice between different classes of medication. They also discuss the role of oral antihistamines (OAH), leukotriene receptor antagonists (LTRA), ocular antihistamines (OcAH) and ocular mast cell stabilisers. Four questions had not been previously evaluated in ARIA guidelines, while, for the other four, there was a change in the strength or directionality of the recommendations. Overall, these guidelines recommend using intranasal corticosteroids over OAH and using OAH over LTRA. Moreover, they suggest using OAH over OcAH and suggest being against adding LTRA to OAH. Finally, considerations for choosing between different individual OAHs are presented. Conclusion This ARIA-EAACI 2024–2025 article supports patients, their caregivers and healthcare professionals in choosing oral and ocular treatments for AR. Decisions on treatment should consider the clinical variability of the disease, patients&apos; values and the affordability of medications.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70305</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70305</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3224</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3224</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grimsholm, O.</style></author><author><style face="normal" font="default" size="100%">Zghaebi, M.</style></author><author><style face="normal" font="default" size="100%">Hambrecht, B.</style></author><author><style face="normal" font="default" size="100%">Kalic, T.</style></author><author><style face="normal" font="default" size="100%">Udoye, C. C.</style></author><author><style face="normal" font="default" size="100%">Manz, R.</style></author><author><style face="normal" font="default" size="100%">Bohle, B.</style></author><author><style face="normal" font="default" size="100%">Sitnik, K. M.</style></author><author><style face="normal" font="default" size="100%">Eckl-Dorna, J.</style></author><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Vienna Airway Lab, Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.&#xD;Department of Dermatology, University Hospital St. Polten, Karl Landsteiner University of Health Sciences, St. Polten, Austria.&#xD;Institute for Systemic Inflammation Research, University of Lubeck, Lubeck, Germany.&#xD;Department of Biomedical Sciences and Pathobiology, University of Veterinary Medicine Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract-the B Cell Side</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">B cells</style></keyword><keyword><style face="normal" font="default" size="100%">IgE plasma cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergen transport</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">nasal mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">organoids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41578632</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic diseases are on the rise worldwide, driven by respiratory epithelial barrier dysfunction that promotes sensitization to inhalant allergens such as pollen, dust mites, pet dander, and fungal spores. These antigens trigger IgE-mediated immune responses that lead to diseases such as allergic rhinitis (AR) and asthma. B cells play a central role by producing allergen-specific IgE, presenting antigens, releasing cytokines, and forming memory B cells (MBCs). Their differentiation into IgE-secreting plasma cells (PCs) mainly relies on T cell help, germinal center (GC) reactions, and/or extrafollicular responses and class switch recombination (CSR), which makes them important therapeutic targets. The nasal mucosa, as the first point of contact for allergens, acts both as a barrier and as an immunological site. In AR, IL-13-driven goblet cell hyperplasia and overproduction of mucus compromise the integrity of the barrier. Although the nasal microbiome can influence the immune response, its role in atopy remains unclear. Local B cell activity, including extrafollicular IgE production and ectopic GCs, enhances mucosal immunity. Epithelial cells detect allergens via pattern recognition receptors (PRRs) and release alarmins (IL-25, IL-33, TSLP), which can trigger type 2 inflammation. Proteases from allergens such as house dust mites (HDM) disrupt epithelial junctions, while pollutants, smoke, microplastics, and allergen-derived metabolites further modulate immune activation. Allergens are transported to the lymph nodes by the passive flow to follicular dendritic cells (FDCs) or by active uptake by interferon regulatory factor (IRF) 4-dependent conventional type 2 DCs, which activate T follicular helper (TFH) cells to drive IgE responses. Advanced lymphoid organoids that mimic the microenvironment of GCs offer promising models for the study of allergic sensitization but require improved standardization.</style></abstract><notes><style face="normal" font="default" size="100%">Grimsholm, Ola&#xD;Zghaebi, Mohammed&#xD;Hambrecht, Bita&#xD;Kalic, Tanja&#xD;Udoye, Christopher C&#xD;Manz, Rudolf&#xD;Bohle, Barbara&#xD;Sitnik, Katarzyna M&#xD;Eckl-Dorna, Julia&#xD;Breiteneder, Heimo&#xD;eng&#xD;10.55776/PAT3959823(OG)/Austrian Science Fund/&#xD;P32953andI4437(BB)/Austrian Science Fund/&#xD;P36664(KMS)/Austrian Science Fund/&#xD;10.55776/KLP4891723(JED)/Austrian Science Fund/&#xD;Danube-ARCP03(BB)/Federal State of Lower Austria/&#xD;P04(HB)/Federal State of Lower Austria/&#xD;P10(TK)/Federal State of Lower Austria/&#xD;EXC22167-390884018(RAM)/Deutsche Forschungsgemeinschaft/&#xD;MA2273/16-1(CCU)/Deutsche Forschungsgemeinschaft/&#xD;J06/2024(CCU)/Junior Program of the Medical Section of the University of Lubeck/&#xD;Review&#xD;Denmark&#xD;Allergy. 2026 Jan 23. doi: 10.1111/all.70229.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41578632</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70229</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2807</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2807</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Do, D.</style></author><author><style face="normal" font="default" size="100%">Bertolotti, L.</style></author><author><style face="normal" font="default" size="100%">Mosnier, A.</style></author><author><style face="normal" font="default" size="100%">Facile, A.</style></author><author><style face="normal" font="default" size="100%">Bourdenet, V.</style></author><author><style face="normal" font="default" size="100%">Poletto, N.</style></author><author><style face="normal" font="default" size="100%">Guironnet-Paquet, A.</style></author><author><style face="normal" font="default" size="100%">Hacard, F.</style></author><author><style face="normal" font="default" size="100%">Nosbaum, A.</style></author><author><style face="normal" font="default" size="100%">Berard, F.</style></author><author><style face="normal" font="default" size="100%">Nicolas, J. F.</style></author><author><style face="normal" font="default" size="100%">Vocanson, M.</style></author><author><style face="normal" font="default" size="100%">Lefevre, M. A.</style></author><author><style face="normal" font="default" size="100%">Tauber, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Hospices Civils de Lyon, Lyon Sud Hospital, Lyon, France.&#xD;CIRI-International Center for Infectiology Research (Team Epidermal Immunity and Allergy) Inserm U1111, Lyon, France.&#xD;Hospices Civils de Lyon, Service Hospitalo-Universitaire de Pharmacotoxicologie, Lyon, France.&#xD;Pharmacy Department, Hospices Civils de Lyon, Lyon Sud Hospital, Lyon, France.&#xD;Department of Dermatology and Allergy, Centre Hospitalier Universitaire de St Etienne, Saint-Priest, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergic Signature in Delayed Cross-Hypersensitivity to all Iodinated Contrast Media</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3178-3180</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/03/22 20:45</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunologic tests</style></keyword><keyword><style face="normal" font="default" size="100%">iodinated contrast media</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40119608</style></accession-num><notes><style face="normal" font="default" size="100%">Do, D&#xD;Bertolotti, L&#xD;Mosnier, A&#xD;Facile, A&#xD;Bourdenet, V&#xD;Poletto, N&#xD;Guironnet-Paquet, A&#xD;Hacard, F&#xD;Nosbaum, A&#xD;Berard, F&#xD;Nicolas, J-F&#xD;Vocanson, M&#xD;Lefevre, M-A&#xD;Tauber, M&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3178-3180. doi: 10.1111/all.16533. Epub 2025 Mar 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40119608</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590332</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16533</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>621</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">621</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barbaud, A.</style></author><author><style face="normal" font="default" size="100%">Garvey, L. H.</style></author><author><style face="normal" font="default" size="100%">Arcolaci, A.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Mori, F.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Atanaskovic-Markovic, M.</style></author><author><style face="normal" font="default" size="100%">Moral, L.</style></author><author><style face="normal" font="default" size="100%">Zanoni, G.</style></author><author><style face="normal" font="default" size="100%">Pagani, M.</style></author><author><style face="normal" font="default" size="100%">Soria, A.</style></author><author><style face="normal" font="default" size="100%">Jost, M.</style></author><author><style face="normal" font="default" size="100%">Caubet, J. C.</style></author><author><style face="normal" font="default" size="100%">Carmo, A.</style></author><author><style face="normal" font="default" size="100%">Mona, A. A.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Perea, A.</style></author><author><style face="normal" font="default" size="100%">Bavbek, S.</style></author><author><style face="normal" font="default" size="100%">Benedetta, B.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Blanca-Lopez, N.</style></author><author><style face="normal" font="default" size="100%">Bogas, H. G.</style></author><author><style face="normal" font="default" size="100%">Buonomo, A.</style></author><author><style face="normal" font="default" size="100%">Calogiuri, G.</style></author><author><style face="normal" font="default" size="100%">Carli, G.</style></author><author><style face="normal" font="default" size="100%">Cernadas, J.</style></author><author><style face="normal" font="default" size="100%">Cortellini, G.</style></author><author><style face="normal" font="default" size="100%">Celik, G.</style></author><author><style face="normal" font="default" size="100%">Demir, S.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Dursun, A. B.</style></author><author><style face="normal" font="default" size="100%">Eberlein, B.</style></author><author><style face="normal" font="default" size="100%">Faria, E.</style></author><author><style face="normal" font="default" size="100%">Fernandes, B.</style></author><author><style face="normal" font="default" size="100%">Garcez, T.</style></author><author><style face="normal" font="default" size="100%">Garcia-Nunez, I.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author><author><style face="normal" font="default" size="100%">Gomes, E.</style></author><author><style face="normal" font="default" size="100%">Gooi, J. H. C.</style></author><author><style face="normal" font="default" size="100%">Grosber, M.</style></author><author><style face="normal" font="default" size="100%">Gulen, T.</style></author><author><style face="normal" font="default" size="100%">Hacard, F.</style></author><author><style face="normal" font="default" size="100%">Hoarau, C.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Johnston, S. L.</style></author><author><style face="normal" font="default" size="100%">Joerg, L.</style></author><author><style face="normal" font="default" size="100%">Kepil Ozdemir, S.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Kosnik, M.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author><author><style face="normal" font="default" size="100%">Kuyucu, S.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Laguna, J. J.</style></author><author><style face="normal" font="default" size="100%">Lombardo, C.</style></author><author><style face="normal" font="default" size="100%">Marinho, S.</style></author><author><style face="normal" font="default" size="100%">Merk, H.</style></author><author><style face="normal" font="default" size="100%">Meucci, E.</style></author><author><style face="normal" font="default" size="100%">Morisset, M.</style></author><author><style face="normal" font="default" size="100%">Munoz-Cano, R.</style></author><author><style face="normal" font="default" size="100%">Murzilli, F.</style></author><author><style face="normal" font="default" size="100%">Nakonechna, A.</style></author><author><style face="normal" font="default" size="100%">Popescu, F. D.</style></author><author><style face="normal" font="default" size="100%">Porebski, G.</style></author><author><style face="normal" font="default" size="100%">Radice, A.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Rockmann, H.</style></author><author><style face="normal" font="default" size="100%">Romano, A.</style></author><author><style face="normal" font="default" size="100%">Sargur, R.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Scherer Hofmeier, K.</style></author><author><style face="normal" font="default" size="100%">Sedlackova, L.</style></author><author><style face="normal" font="default" size="100%">Sobotkova, M.</style></author><author><style face="normal" font="default" size="100%">Terreehorst, I.</style></author><author><style face="normal" font="default" size="100%">Treudler, R.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Wedi, B.</style></author><author><style face="normal" font="default" size="100%">Wohrl, S.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sorbonne Universite, INSERM, Institut Pierre Louis d&apos;Epidemiologie et de Sante Publique, AP-HP.Sorbonne Universite, Hopital Tenon, Departement de dermatologie et allergologie, Paris, France.&#xD;Allergy Clinic, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Denmark.&#xD;Immunology Unit, University Hospital of Verona, Policlinico G.B. Rossi, Verona, Italy.&#xD;Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich, Germany.&#xD;Allergy Unit, Department of Pediatrics, Meyer Children&apos;s University Hospital.&#xD;Allergy Clinical Unit, Hospital Regional Universitario de Malaga-Instituto de Investigacion Biomedica de Malaga-IBIMA, ARADyAL, Malaga, Spain.&#xD;Allergy Unit, Verona University Hospital, Verona, Italy.&#xD;Faculty of Medicine, University of Belgrade, University Children&apos;s Hospital, Belgrade, Serbia.&#xD;Moral Luis. Pediatric Allergy and Respiratory Unit, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.&#xD;Giovanna Zanoni, Immunology Unit, Policlinico G.B. Rossi, Azienda Ospedaliera Universitaria Integrata Verona, Italy.&#xD;Medicine Department, Medicine Ward Mantova Hospital, ASST di Mantova, Italy.&#xD;Sorbonne Universite, INSERM 1135 Cimi-Paris, Hopital Tenon, Assistance Publique-Hopitaux de Paris, Departement de dermatologie et d&apos;allergologie, Paris, France.&#xD;University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.&#xD;Department of Women-Children-Teenagers, University Hospital of Geneva, Geneva, Switzerland.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar de Tras-os-Montes e Alto Douro, Vila Real and Allergy and Clinical Immunology Unit, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal.&#xD;Microbiology Department, Faculty of Medicine, Kuwait University, Kuwait.&#xD;Allergy Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain.&#xD;School of Medicine, Department of Pulmonary Diseases, Division of Allergy, FAAAI, Ankara University, Ankara, Turkey.&#xD;Division of Internal Medicine, Hepatobiliary and Immunoallergic Disease, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.&#xD;Department of Clinical and Molecular Sciences, Universita Politecnica delle Marche, Ancona, Italy.&#xD;Allergy Unit - Department of Internal Medicine, University Hospital Ospedali Riuniti di Ancona, Italy.&#xD;Infanta Leonor University Hospital, Madrid, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, and Allergy Unit, Hospital Regional Universitario de Malaga-HRUM, Malaga, Spain.&#xD;Allergy Unit - Fondazione Policlinico Gemelli IRCCS - Largo Gemelli, Rome, Italy.&#xD;Hospital Vito Fazzi, Lecce, Italy.&#xD;SOS Allergologia e Immunologia, Azienda USL Toscana Centro, Ospedale S. Stefano, Prato, Italy.&#xD;Allergy and Clinical Immunology Department, Centro Hospitalar Universitario de S. Joao, Porto and Allergy Unit, Hospital Lusiadas, Porto, Portugal.&#xD;Allergy Unit, Departments of Internal Medicine, Azienda Sanitaria della Romagna, Rimini, Hospital, Rimini, Italy.&#xD;Department of Chest Diseases, Division of Immunology and allergy, Ankara University School of Medicine cebeci Hospital, Ankara, Turkey.&#xD;Istanbul University, Istanbul Faculty of Medicine, Internal Medicine, Immunology and Allergic Diseases, Istanbul, Turkey.&#xD;Allergy Research Group, Allergy Unit, Hospital Regional Universitario de Malaga, Instituto de Investigacion Biomedica de Malaga-IBIMA, Plaza del Hospital Civil s/n, Malaga, Spain.&#xD;Department of Adult Allergy, Memorial Ankara Hospital, Ankara, Turkey.&#xD;Faculty of Medicine, Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar E Universitario de Coimbra, Coimbra, Portugal.&#xD;Barts Health NHS Trust, St Bartholomew&apos;s Hospital, London, UK.&#xD;Immunology Department, Manchester University NHS Foundation Trust, Manchester, UK.&#xD;Hospital Quironsalud Cordoba, Cordoba, Spain.&#xD;Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, Katowice, Poland.&#xD;Allergy Department, Centro Hospitalar Universitario do Porto, Porto, Portugal.&#xD;Department of Clinical Immunology, King&apos;s College Hospital, London, UK.&#xD;Department of Dermatology, Universitair Ziekenhuis, Vrije Universiteit Brussel, Brussel, Belgium.&#xD;Department of Respiratory Medicine and Allergy, Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden.&#xD;Allergology and Clinical Immunology Department, Centre Hospitalier Lyon-Sud, Pierre-Benite, France.&#xD;Service transversal d&apos;allergologie et immunologie clinique, CHR de Tours, Tours, France.&#xD;Department of Medical Sciences, Uppsala university, Sweden.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Division of Allergology and Clinical Immunology, Department of Pneumology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Department of Chest Diseases, Division of Allergy and Immunology, Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;University Clinic Golnik, Slovenia.&#xD;Department of Immunology and Allergy, Medical University of Lodz, Poland.&#xD;Faculty of Medicine, Dpt of Pediatric Allergy and Immunology, Mersin University, Mersin, Turkey.&#xD;Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Institute of Clinical Medicine, Clinic of Chest diseases, Immunology and Allergology, Faculty of Medicine, Vilnius, Lithuania.&#xD;Allergy Unit, Allergo-Anaesthesia Unit, Faculty of Medicine, Hospital Central de la Cruz Roja, Alfonso X El Sabio University, Madrid, Spain.&#xD;Allergy Unit, Trento, Italy.&#xD;Allergy Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust and University of Manchester, Manchester, UK.&#xD;Dohlenfeld, Muelheim, Germany.&#xD;SOS Allergologia ed Immunologia clinica, Azienda USL Toscana Centro, Ospedale San Giovanni di Dio, Firenze, Italy.&#xD;Allergy Unit, Angers University Hospital, Angers, France.&#xD;C/Villarroel, Barcelona, Spain.&#xD;Allergy Unit, S,S, Filippo and Nicola, Avezzano, Italy.&#xD;Allergy and Clinical Immunology Department, University of Liverpool, Royal Preston Hospital, Lancashire Teaching Hospitals, NHS Foundation Trust, UK.&#xD;Department of Allergology, Carol Davila University of Medicine and Pharmacy, Nicolae Malaxa Clinical Hospital, Bucharest, Romania.&#xD;Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Krakow, Poland.&#xD;Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;ICBR - Coimbra Institute for Clinical and Biomedical Research, CIBB, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Department of Dermatology, University Medical Centre Utrecht-Heidelberglaan 100, Utrecht, The Netherlands.&#xD;Oasi Research Institute-IRCCS, Troina, Italy.&#xD;Clinical Immunology and Allergy Unit, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.&#xD;Allergy Department, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, CIBERES, Instituto de Salud Carlos III, Spain.&#xD;Department of Dermatology and Allergy, Cantonal Hospital Aarau, Aarau, Switzerland.&#xD;Gennet s.r.o., Allergy and Clinical Immunology, Czech Republic.&#xD;Department of Immunology, Motol University Hospital and 2nd Faculty of Medicine Charles University, Prague, Czech Republic.&#xD;Department of ENT, AUMC, Amsterdam, The Netherlands.&#xD;Department of Dermatology, Venerology and Allergology, Universitatsmedizin Leipzig, Leipzig, Germany.&#xD;Department of Occupational Diseases and Environmental Health, Walusiak-Skorupa Jolanta, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;Department of Dermatology &amp; Allergy, OE6600, Comprehensive Allergy Center, Hannover Medical School, Hannover, Germany.&#xD;Floridsdorf Allergy Center (FAZ), Vienna, Austria.&#xD;University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, and Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.&#xD;Charite - Universitatsmedizin Berlin, Klinik fur Dermatologie, Berlin, Germany.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Allergy Unit, Regional University Hospital of Malaga, IBIMA-UMA-ARADyAL, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2292-2312</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/02/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines, Synthetic</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">allergy test</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35112371</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its management is not standardized. METHOD: Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre-vaccination screening and management of allergic reactions to COVID-19 vaccines, and literature was analysed. RESULTS: No death due to anaphylaxis to COVID-19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine are excipients. The authors propose allergy evaluation of persons with the following histories: 1-anaphylaxis to injectable drug or vaccine containing PEG or derivatives; 2-anaphylaxis to oral/topical PEG containing products; 3-recurrent anaphylaxis of unknown cause; 4-suspected or confirmed allergy to any mRNA vaccine; and 5-confirmed allergy to PEG or derivatives. We recommend a prick-to-prick skin test with the left-over solution in the suspected vaccine vial to avoid waste. Prick test panel should include PEG 4000 or 3500, PEG 2000 and polysorbate 80. The value of in vitro test is arguable. CONCLUSIONS: These recommendations will lead to a better knowledge of the management and mechanisms involved in anaphylaxis to COVID-19 vaccines and enable more people with history of allergy to be vaccinated.</style></abstract><notes><style face="normal" font="default" size="100%">Barbaud, Annick&#xD;Garvey, Lene Heise&#xD;Arcolaci, Alessandra&#xD;Brockow, Knut&#xD;Mori, Francesca&#xD;Mayorga, Cristobalina&#xD;Bonadonna, Patrizia&#xD;Atanaskovic-Markovic, Marina&#xD;Moral, Luis&#xD;Zanoni, Giovanna&#xD;Pagani, Mauro&#xD;Soria, Angele&#xD;Jost, Maja&#xD;Caubet, Jean-Christoph&#xD;Carmo, Abreu&#xD;Mona, Al-Ahmad&#xD;Alvarez-Perea, Alberto&#xD;Bavbek, Sevim&#xD;Benedetta, Biagioni&#xD;Bilo, M Beatrice&#xD;Blanca-Lopez, Natalia&#xD;Bogas, Herrera Gador&#xD;Buonomo, Alessandro&#xD;Calogiuri, Gianfranco&#xD;Carli, Giulia&#xD;Cernadas, Josefina&#xD;Cortellini, Gabriele&#xD;Celik, Gulfem&#xD;Demir, Semra&#xD;Dona, Inmaculada&#xD;Dursun, Adile Berna&#xD;Eberlein, Bernadette&#xD;Faria, Emilia&#xD;Fernandes, Bryan&#xD;Garcez, Tomaz&#xD;Garcia-Nunez, Ignacio&#xD;Gawlik, Radoslaw&#xD;Gelincik, Asli&#xD;Gomes, Eva&#xD;Gooi, Jimmy H C&#xD;Grosber, Martine&#xD;Gulen, Theo&#xD;Hacard, Florence&#xD;Hoarau, Cyrille&#xD;Janson, Christer&#xD;Johnston, Sebastian L&#xD;Joerg, Lukas&#xD;Kepil Ozdemir, Secil&#xD;Klimek, Ludger&#xD;Kosnik, Mitja&#xD;Kowalski, Marek L&#xD;Kuyucu, Semanur&#xD;Kvedariene, Violeta&#xD;Laguna, Jose Julio&#xD;Lombardo, Carla&#xD;Marinho, Susana&#xD;Merk, Hans&#xD;Meucci, Elisa&#xD;Morisset, Martine&#xD;Munoz-Cano, Rosa&#xD;Murzilli, Francesco&#xD;Nakonechna, Alla&#xD;Popescu, Florin-Dan&#xD;Porebski, Grzegorz&#xD;Radice, Anna&#xD;Regateiro, Frederico S&#xD;Rockmann, Heike&#xD;Romano, Antonino&#xD;Sargur, Ravishankar&#xD;Sastre, Joaquin&#xD;Scherer Hofmeier, Kathrin&#xD;Sedlackova, Lenka&#xD;Sobotkova, Marta&#xD;Terreehorst, Ingrid&#xD;Treudler, Regina&#xD;Walusiak-Skorupa, Jolanta&#xD;Wedi, Bettina&#xD;Wohrl, Stefan&#xD;Zidarn, Mihael&#xD;Zuberbier, Torsten&#xD;Agache, Ioana&#xD;Torres, Maria J&#xD;eng&#xD;Consensus Development Conference&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2292-2312. doi: 10.1111/all.15241. Epub 2022 Mar 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35112371</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15241</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>760</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">760</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benito-Villalvilla, C.</style></author><author><style face="normal" font="default" size="100%">Perez-Diego, M.</style></author><author><style face="normal" font="default" size="100%">Subiza, J. L.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.&#xD;Inmunotek, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergoid-mannan conjugates imprint tolerogenic features in human macrophages</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">320-323</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/10/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Allergoids</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">*Mannans</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergoid-mannan conjugates</style></keyword><keyword><style face="normal" font="default" size="100%">human macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">immune regulation</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34601743</style></accession-num><notes><style face="normal" font="default" size="100%">Benito-Villalvilla, Cristina&#xD;Perez-Diego, Mario&#xD;Subiza, Jose Luis&#xD;Palomares, Oscar&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):320-323. doi: 10.1111/all.15118. Epub 2021 Oct 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34601743</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15118</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2275</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2275</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caballero, M. L.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, La Paz University Hospital, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergological reappraisal of the Annex to the European Commission guideline on excipients (SANTE-2017-11,668)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">735-739</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/10/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Excipients/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37815171</style></accession-num><notes><style face="normal" font="default" size="100%">Caballero, Maria Luisa&#xD;Quirce, Santiago&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):735-739. doi: 10.1111/all.15913. Epub 2023 Oct 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37815171</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15913</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3163</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3163</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Ghilarducci, A.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Schiappoli, M.</style></author><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Dama, A.</style></author><author><style face="normal" font="default" size="100%">Olivieri, E.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;Allergy Unit and Asthma Center, Verona University Hospital, Verona, Italy.&#xD;Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.&#xD;Departamento de Medicina, Facultad de Medicina, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergological Work-Up in Cephalosporin Allergy Diagnosis and Delabelling: The Experience From Two European Allergy Centres</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">betalactam</style></keyword><keyword><style face="normal" font="default" size="100%">cephalosporin</style></keyword><keyword><style face="normal" font="default" size="100%">drug provocation test</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default" size="100%">skin test</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 12</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41221718</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Diagnostic strategies for cephalosporin allergy are not well defined due to differences in inclusion criteria among studies and a lack of standardised diagnostic tests. Our aim was to describe the characteristics of patients with a suspicion of cephalosporin allergy and to analyse the role of in vivo tests. METHODS: Patients with suspected cephalosporin allergy were prospectively evaluated (2019-2023). Diagnosis was achieved using clinical history, skin tests (STs) and, if negative, drug provocation tests (DPTs). A randomised group of patients who tolerated DPT were retested by STs at 2-8 weeks. RESULTS: 211 patients were evaluated, with 55.4% reporting IRs and 44.5% NIRs. Skin was involved in half of the patients reporting IRs and in all reporting NIRs (p &lt; 0.0001). Anaphylaxis was experienced by 18% and shock by 7.1%. The cephalosporin most commonly involved was cefuroxime (63.6%) (p &lt; 0.0001) in the Spanish cohort and cefazolin (51%) (p &lt; 0.0001) in the Italian one. Allergy was confirmed in 57.2% of patients reporting IRs (47% by STs and 9.4% by DPT) and 14.9% of NIRs (5.3% by STs and 8.5% by DPT). In the positive-ST group, the percentage of grade II and III reactions was higher (p = 0.02) and the interval reaction-study shorter (p = 0.0007) than in negative-ST. Of the 48 patients retested, 1 (2.9%) who reported an IR and 1 (7.1%) who reported NIR resulted positive. CONCLUSIONS: The patterns of cephalosporin allergy may differ across different regions, being STs and DPT useful for diagnosis. Further studies are needed to confirm the role of retesting, as well as to identify which patients would benefit most from this procedure.</style></abstract><notes><style face="normal" font="default" size="100%">Salas, Maria&#xD;Ghilarducci, Alessandro&#xD;Dona, Inmaculada&#xD;Schiappoli, Michele&#xD;Labella, Marina&#xD;Dama, Annarita&#xD;Olivieri, Elisa&#xD;Torres, Maria Jose&#xD;Bonadonna, Patrizia&#xD;eng&#xD;Universidad de Malaga/&#xD;Instituto de Salud Carlos III/&#xD;Denmark&#xD;Allergy. 2025 Nov 12. doi: 10.1111/all.70120.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41221718</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70120</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2361</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2361</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turner, M. C.</style></author><author><style face="normal" font="default" size="100%">Radzikowska, U.</style></author><author><style face="normal" font="default" size="100%">Ferastraoaru, D. E.</style></author><author><style face="normal" font="default" size="100%">Pascal, M.</style></author><author><style face="normal" font="default" size="100%">Wesseling, P.</style></author><author><style face="normal" font="default" size="100%">McCraw, A.</style></author><author><style face="normal" font="default" size="100%">Backes, C.</style></author><author><style face="normal" font="default" size="100%">Bax, H. J.</style></author><author><style face="normal" font="default" size="100%">Bergmann, C.</style></author><author><style face="normal" font="default" size="100%">Bianchini, R.</style></author><author><style face="normal" font="default" size="100%">Cari, L.</style></author><author><style face="normal" font="default" size="100%">de Las Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Izquierdo, E.</style></author><author><style face="normal" font="default" size="100%">Lind-Holm Mogensen, F.</style></author><author><style face="normal" font="default" size="100%">Michelucci, A.</style></author><author><style face="normal" font="default" size="100%">Nazarov, P. V.</style></author><author><style face="normal" font="default" size="100%">Niclou, S. P.</style></author><author><style face="normal" font="default" size="100%">Nocentini, G.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Preusser, M.</style></author><author><style face="normal" font="default" size="100%">Rohr-Udilova, N.</style></author><author><style face="normal" font="default" size="100%">Scafidi, A.</style></author><author><style face="normal" font="default" size="100%">Toth, R.</style></author><author><style face="normal" font="default" size="100%">Van Hemelrijck, M.</style></author><author><style face="normal" font="default" size="100%">Weller, M.</style></author><author><style face="normal" font="default" size="100%">Jappe, U.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Karagiannis, S. N.</style></author><author><style face="normal" font="default" size="100%">Poli, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.&#xD;Immunology Department, Centre de Diagnostic Biomedic, Hospital Clinic de Barcelona, Barcelona, Spain.&#xD;Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.&#xD;Department of Medicine, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.&#xD;Department of Pathology, Amsterdam University Medical Centers/VUmc, Amsterdam, The Netherlands.&#xD;Laboratory for Childhood Cancer Pathology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.&#xD;St. John&apos;s Institute of Dermatology, School of Basic &amp; Medical Biosciences, King&apos;s College London, Guy&apos;s Hospital, London, UK.&#xD;National Cancer Registry (Registre National du Cancer (RNC)), Luxembourg Institute of Health (LIH), Strassen, Luxembourg.&#xD;Public Health Expertise Unit, Department of Precision Health, Cancer Epidemiology and Prevention (EPI CAN), Luxembourg Institute of Health, Strassen, Luxembourg.&#xD;Department of Otorhinolaryngology, RKM740 Interdisciplinary Clinics, Dusseldorf, Germany.&#xD;Center of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;The Interuniversity Messerli Research Institute Vienna, University of Veterinary Medecine Vienna, Medical University Vienna, University Vienna, Vienna, Austria.&#xD;Section of Pharmacology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.&#xD;Department of Allergy, La Paz University Hospital - IdiPAZ, Madrid, Spain.&#xD;Institute of Applied Molecular Medicine Instituto de Medicina Molecular Aplicada Nemesio Diez (IMMA), Department of Basic Medical Sciences, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Neuro-Immunology Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.&#xD;Faculty of Sciences, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.&#xD;Multiomics Data Science, Department of Cancer Research, Luxembourg Institute of Health, Strassen, Luxembourg.&#xD;NORLUX Neuro-Oncology laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-Sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.&#xD;Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.&#xD;Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.&#xD;Liver Cancer (HCC) Study Group Vienna, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.&#xD;Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King&apos;s College London, London, UK.&#xD;Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.&#xD;Division of Clinical and Molecular Allergology, Priority Research Area Chronic Lung Diseases, Research Center Borstel, Leibniz Lung Center, German Center for Lung Research (DZL), Airway Research Center North (ARCN), Borstel, Germany.&#xD;Department of Pneumology, Interdisciplinary Allergy Outpatient Clinic, University of Luebeck, Luebeck, Germany.&#xD;Breast Cancer Now Research Unit, School of Cancer &amp; Pharmaceutical Sciences, King&apos;s College London, Innovation Hub, Guy&apos;s Cancer Centre, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus-A joint EAACI-EANO position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1419-1439</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Glioma/immunology/etiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Neoplasms/immunology/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">brain cancer</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">neuroimmunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38263898</style></accession-num><abstract><style face="normal" font="default" size="100%">Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE-mediated diseases and glioma. Allergic disease stems from a Th2-biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour-immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro-Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult-type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune-glioma interactions to ultimately improve patient prognosis and survival.</style></abstract><notes><style face="normal" font="default" size="100%">Turner, Michelle C&#xD;Radzikowska, Urszula&#xD;Ferastraoaru, Denisa E&#xD;Pascal, Mariona&#xD;Wesseling, Pieter&#xD;McCraw, Alexandra&#xD;Backes, Claudine&#xD;Bax, Heather J&#xD;Bergmann, Christoph&#xD;Bianchini, Rodolfo&#xD;Cari, Luigi&#xD;de Las Vecillas, Leticia&#xD;Izquierdo, Elena&#xD;Lind-Holm Mogensen, Frida&#xD;Michelucci, Alessandro&#xD;Nazarov, Petr V&#xD;Niclou, Simone P&#xD;Nocentini, Giuseppe&#xD;Ollert, Markus&#xD;Preusser, Matthias&#xD;Rohr-Udilova, Nataliya&#xD;Scafidi, Andrea&#xD;Toth, Reka&#xD;Van Hemelrijck, Mieke&#xD;Weller, Michael&#xD;Jappe, Uta&#xD;Escribese, Maria M&#xD;Jensen-Jarolim, Erika&#xD;Karagiannis, Sophia N&#xD;Poli, Aurelie&#xD;eng&#xD;573/CU/CSP VA/&#xD;Action LIONS Vaincre le Cancer/&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Televie/&#xD;Fonds De La Recherche Scientifique - FNRS/&#xD;Fonds National de la Recherche Luxembourg/&#xD;Action Lions Vaincre le Cancer association/&#xD;PDR-TLV 2023 RESTAGE/FNRS-Televie/&#xD;PRIDE/14254520/I2TRON/Luxembourg National Research Fund/&#xD;RYC-2017-01892/Ramon y Cajal fellowship/&#xD;AP177712021/Fundacion Mutua Madrilena/&#xD;PCI2018-092930/Ministerio de Ciencia, Innovacion y Universidades/&#xD;RD21/0002/0008/Instituto de Salud Carlos III-European Regional Development/&#xD;RD16/0006/0015/Instituto de Salud Carlos III-European Regional Development/&#xD;National Institute for Health and Care Research/&#xD;IS-BRC-1215-20006/Biomedical Research Centre/&#xD;MR/R015643/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/V049445/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/L023091/1/MRC_/Medical Research Council/United Kingdom&#xD;BB/T008709/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom&#xD;KCL-BCN-Q3/BBC_/Breast Cancer Now/United Kingdom&#xD;C604/A25135/Cancer Research UK King&apos;s Health Partners Centre at King&apos;s College London/&#xD;463087/Innovate UK/&#xD;006/R/22/British Skin Foundation/&#xD;C30122/A15774/CRUK_/Cancer Research UK/United Kingdom&#xD;C30122/A11527/CRUK_/Cancer Research UK/United Kingdom&#xD;JA 1007/2-3/German Research Foundation/&#xD;Federal Ministry of Education and Science/&#xD;Federal Ministry of Food and Agriculture/&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1419-1439. doi: 10.1111/all.15994. Epub 2024 Jan 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38263898</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15994</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>606</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">606</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bergmann, C.</style></author><author><style face="normal" font="default" size="100%">Poli, A.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Bianchini, R.</style></author><author><style face="normal" font="default" size="100%">Bax, H. J.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author><author><style face="normal" font="default" size="100%">Crescioli, S.</style></author><author><style face="normal" font="default" size="100%">Dombrowicz, D.</style></author><author><style face="normal" font="default" size="100%">Ferastraoaru, D.</style></author><author><style face="normal" font="default" size="100%">Fiebiger, E.</style></author><author><style face="normal" font="default" size="100%">Gould, H. J.</style></author><author><style face="normal" font="default" size="100%">Hartmann, K.</style></author><author><style face="normal" font="default" size="100%">Izquierdo, E.</style></author><author><style face="normal" font="default" size="100%">Jordakieva, G.</style></author><author><style face="normal" font="default" size="100%">Josephs, D. H.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Levi-Schaffer, F.</style></author><author><style face="normal" font="default" size="100%">de Las Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Lotze, M. T.</style></author><author><style face="normal" font="default" size="100%">Osborn, G.</style></author><author><style face="normal" font="default" size="100%">Pascal, M.</style></author><author><style face="normal" font="default" size="100%">Redegeld, F.</style></author><author><style face="normal" font="default" size="100%">Rosenstreich, D.</style></author><author><style face="normal" font="default" size="100%">Roth-Walter, F.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author><author><style face="normal" font="default" size="100%">Steveling, E. H.</style></author><author><style face="normal" font="default" size="100%">Turner, M. C.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Karagiannis, S. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, RKM740 Interdisciplinary Clinics, Dusseldorf, Germany.&#xD;Neuro-Immunology Group, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.&#xD;Faculty of Medicine, Transylania University Brasov, Brasov, Romania.&#xD;Comparative Medicine, The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna, University of Vienna, Vienna, Austria.&#xD;St. John&apos;s Institute of Dermatology, School of Basic &amp; Medical Biosciences, Guy&apos;s Hospital, King&apos;s College London, London, United Kindgom.&#xD;School of Cancer and Pharmaceutical Sciences, Guy&apos;s Hospital, King&apos;s College London, London, United Kingdom.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille U1011-EGID, Lille, France.&#xD;Department of Internal Medicine/Allergy and Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.&#xD;Division of Gastroenterology, Hepatology and Nutrition Research, Department of Medicine Research, Children&apos;s University Hospital Boston, Boston, Massachusetts, USA.&#xD;Randall Centre for Cell and Molecular Biophysics, School of Basic &amp; Medical Biosciences, King&apos;s College London, New Hunt&apos;s House, London, United Kingdom.&#xD;Medical Research Council &amp; Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom.&#xD;Department of Dermatology, University of Basel, Basel, Switzerland.&#xD;IMMA, School of Medicine, Institute of Applied Molecular Medicine, CEU San Pablo University, Madrid, Spain.&#xD;Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Vienna, Austria.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.&#xD;G.27A Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.&#xD;Department of Immunology, CDB, Hospital Clinic de Barcelona, Institut d&apos;Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.&#xD;Division of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.&#xD;Center of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University Vienna, Vienna, Austria.&#xD;Center of Allergy &amp; Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany.&#xD;German Center for Lung Research (DZL), Munich, Germany.&#xD;Immunomodulation and Tolerance Group, Imperial College London, and Allergy and Clinical Immunology, Imperial College London, London, United Kingdom.&#xD;Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.&#xD;Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King&apos;s College London, Guy&apos;s Hospital,, London, SE1 9RT, United Kindgom.</style></auth-address><titles><title><style face="normal" font="default" size="100%">AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2594-2617</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/02/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Neoplasms/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Aamp</style></keyword><keyword><style face="normal" font="default" size="100%">Alr</style></keyword><keyword><style face="normal" font="default" size="100%">Damp</style></keyword><keyword><style face="normal" font="default" size="100%">Nlr</style></keyword><keyword><style face="normal" font="default" size="100%">Pamp</style></keyword><keyword><style face="normal" font="default" size="100%">Rlr</style></keyword><keyword><style face="normal" font="default" size="100%">Tlr</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">cancer</style></keyword><keyword><style face="normal" font="default" size="100%">danger signals</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">interest are listed here: CB: Christoph Bergmann received honoraria for</style></keyword><keyword><style face="normal" font="default" size="100%">presentations from Allergy Theraypeutics, Bencard, HAL Allergy and SCS. CSW:</style></keyword><keyword><style face="normal" font="default" size="100%">Carsten Schmidt-Weber has received speaker honoraria from Bencard and</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma and has a patent a patent on nasal secretions that is pending. EJJ:</style></keyword><keyword><style face="normal" font="default" size="100%">Erika Jensen-Jarolim declares inventorship in patents on allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">formulation with Biomedical International R+D, Vienna, Austria, of which she is</style></keyword><keyword><style face="normal" font="default" size="100%">shareholder. She received honoraria for presentations from Allergy Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">AllergoPharma, Bencard, Meda, Roxall, ThermoFisher, and consulted previously for</style></keyword><keyword><style face="normal" font="default" size="100%">MediGene, Germany, Novartis, for Allergy Therapeutics and Dr. Schar. EHS: Esther</style></keyword><keyword><style face="normal" font="default" size="100%">Steveling has received funds from Bencard and ALK. HJB: Heather J. Bax is</style></keyword><keyword><style face="normal" font="default" size="100%">employed through a fund provided by Epsilogen Ltd. (formerly IGEM Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">Ltd.) and holds patents on anti-tumour IgE antibodies. DHJ: Debra H Josephs holds</style></keyword><keyword><style face="normal" font="default" size="100%">patents on anti-tumour IgE antibodies. GJ: Galateja Jordakieva has received</style></keyword><keyword><style face="normal" font="default" size="100%">lecture honoraria by Bencard Allergie GmbH and Thermo Fisher Scientific. KH:</style></keyword><keyword><style face="normal" font="default" size="100%">Karin Hartmann has received research funding from Thermo Fisher and consultancy</style></keyword><keyword><style face="normal" font="default" size="100%">or lecture fees from Allergopharma, ALK-Abello, Blueprint, Deciphera, Leo Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Menarini, Novartis, Pfizer, Takeda and Thermo Fisher. MC: Marianna Castells is</style></keyword><keyword><style face="normal" font="default" size="100%">Principal Investigator for BluePrint PIONEER and HARBOR clinical trials,</style></keyword><keyword><style face="normal" font="default" size="100%">Editorial Board Annals Of Allergy Asthma and Immunology, Author UpToDate, Board</style></keyword><keyword><style face="normal" font="default" size="100%">of Directors ABAI. MTL: Michael Lotze is currently Chief Cell Therapy Officer at</style></keyword><keyword><style face="normal" font="default" size="100%">Nurix Biotherapeutics and has an invention disclosure with the University of</style></keyword><keyword><style face="normal" font="default" size="100%">Pittsburgh relating IgE to gammadelta T cells. FRW: Franziska Roth-Walter declares main</style></keyword><keyword><style face="normal" font="default" size="100%">inventorship on patent EP2894478 (applicant Biomedical International R+D GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">Vienna, Austria) and received research funding from Biomedical International R+D</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, Vienna, Austria and Bencard Allergie GmbH, Munich, Germany. Moreover, she</style></keyword><keyword><style face="normal" font="default" size="100%">received lecture honoraria by FOMF, VAEM, Bencard Allergie GmbH, Munich, Germany</style></keyword><keyword><style face="normal" font="default" size="100%">and Vienna, Austria, and Allergy Therapeutics, Worthing, UK. SNK: Sophia N.</style></keyword><keyword><style face="normal" font="default" size="100%">Karagiannis is founder and shareholder of Epsilogen Ltd. (formerly IGEM</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics Ltd.) and has received funds from IGEM Therapeutics Ltd/Epsilogen</style></keyword><keyword><style face="normal" font="default" size="100%">Ltd. Sophia N. Karagiannis holds patents on anti-tumour IgE antibodies. AP, DD,</style></keyword><keyword><style face="normal" font="default" size="100%">DR, DHJ, DF, EF, EI, EU, FLS, FR, GO, HJG, IA, LV, MJ, MP, MCT, MS, RB and SC</style></keyword><keyword><style face="normal" font="default" size="100%">declare no conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35152450</style></accession-num><abstract><style face="normal" font="default" size="100%">The immune system interacts with many nominal &apos;danger&apos; signals, endogenous danger-associated (DAMP), exogenous pathogen (PAMP) and allergen (AAMP)-associated molecular patterns. The immune context under which these are received can promote or prevent immune activating or inflammatory mechanisms and may orchestrate diverse immune responses in allergy and cancer. Each can act either by favouring a respective pathology or by supporting the immune response to confer protective effects, depending on acuity or chronicity. In this Position Paper under the collective term danger signals or DAMPs, PAMPs and AAMPs, we consider their diverse roles in allergy and cancer and the connection between these in AllergoOncology. We focus on their interactions with different immune cells of the innate and adaptive immune system and how these promote immune responses with juxtaposing clinical outcomes in allergy and cancer. While danger signals present potential targets to overcome inflammatory responses in allergy, these may be reconsidered in relation to a history of allergy, chronic inflammation and autoimmunity linked to the risk of developing cancer, and with regard to clinical responses to anti-cancer immune and targeted therapies. Cross-disciplinary insights in AllergoOncology derived from dissecting clinical phenotypes of common danger signal pathways may improve allergy and cancer clinical outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Bergmann, Christoph&#xD;Poli, Aurelie&#xD;Agache, Ioana&#xD;Bianchini, Rodolfo&#xD;Bax, Heather J&#xD;Castells, Mariana&#xD;Crescioli, Silvia&#xD;Dombrowicz, David&#xD;Ferastraoaru, Denisa&#xD;Fiebiger, Edda&#xD;Gould, Hannah J&#xD;Hartmann, Karin&#xD;Izquierdo, Elena&#xD;Jordakieva, Galateja&#xD;Josephs, Debra H&#xD;Jutel, Marek&#xD;Levi-Schaffer, Francesca&#xD;de Las Vecillas, Leticia&#xD;Lotze, Michael T&#xD;Osborn, Gabriel&#xD;Pascal, Mariona&#xD;Redegeld, Frank&#xD;Rosenstreich, David&#xD;Roth-Walter, Franziska&#xD;Schmidt-Weber, Carsten&#xD;Shamji, Mohamed&#xD;Steveling, Esther H&#xD;Turner, Michelle C&#xD;Untersmayr, Eva&#xD;Jensen-Jarolim, Erika&#xD;Karagiannis, Sophia N&#xD;eng&#xD;MR/L023091/1/MRC_/Medical Research Council/United Kingdom&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2594-2617. doi: 10.1111/all.15255. Epub 2022 Mar 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35152450</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9545837</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15255</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2667</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2667</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schneider, S.</style></author><author><style face="normal" font="default" size="100%">Satitsuksanoa, P.</style></author><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author><author><style face="normal" font="default" size="100%">Chang, I.</style></author><author><style face="normal" font="default" size="100%">Yang, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.&#xD;Department of Medical Microbiology, Abant Izzet Baysal University Hospital, Bolu, Turkiye.&#xD;Department of Pediatrics/Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Environmental Health, Harvard TH Chan School of Public Health, Boston, Mass, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergy discordant twins do not exhibit differences in gene expression in non-switched and switched B cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">342-345</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/10/29</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39470621</style></accession-num><notes><style face="normal" font="default" size="100%">Schneider, Stephan&#xD;Satitsuksanoa, Pattraporn&#xD;Babayev, Huseyn&#xD;van de Veen, Willem&#xD;Chang, Iris&#xD;Yang, Minglin&#xD;Akdis, Cezmi A&#xD;Nadeau, Kari&#xD;Akdis, Mubeccel&#xD;eng&#xD;Novartis Stiftung fur Medizinisch-Biologische Forschung/&#xD;Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):342-345. doi: 10.1111/all.16376. Epub 2024 Oct 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39470621</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724222</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16376</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2131</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2131</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sturm, G. J.</style></author><author><style face="normal" font="default" size="100%">Boni, E.</style></author><author><style face="normal" font="default" size="100%">Antolin-Amerigo, D.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Breynaert, C.</style></author><author><style face="normal" font="default" size="100%">Fassio, F.</style></author><author><style face="normal" font="default" size="100%">Spriggs, K.</style></author><author><style face="normal" font="default" size="100%">Vega, A.</style></author><author><style face="normal" font="default" size="100%">Ricciardi, L.</style></author><author><style face="normal" font="default" size="100%">Arzt-Gradwohl, L.</style></author><author><style face="normal" font="default" size="100%">Hemmer, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.&#xD;Allergy and Immunology Department, Metropolitan Laboratory AUSL Bologna, Maggiore Hospital, Bologna, Italy.&#xD;Allergy Department, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Madrid, Spain.&#xD;Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.&#xD;Allergy Unit, Department of Internal Medicine, Ospedali Riuniti Ancona University Hospital, Ancona, Italy.&#xD;Department of General Internal Medicine - Allergy and Clinical Immunology, University Hospitals Leuven, Leuven, Belgium.&#xD;KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, Leuven, Belgium.&#xD;Allergy and Clinical Immunology Unit, Ospedale San Giovanni di Dio, Azienda USL Toscana Centro, Florence, Italy.&#xD;Department of Allergy &amp; Immunology, Monash Medical Centre, Clayton, Victoria, Australia.&#xD;Department of Allergy &amp; Immunology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.&#xD;Department of Medicine, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Allergy Department, University Hospital of Guadalajara, Guadalajara, Spain.&#xD;ARADyAL Spanish Thematic Network and Co-operative Research Centre RD16/0006/0023, Madrid, Spain.&#xD;Allergy and Clinical Immunology Unit, AOU Policlinico G. Martino, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.&#xD;FAZ - Floridsdorf Allergy Center, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergy to stings and bites from rare or locally important arthropods: Worldwide distribution, available diagnostics and treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2089-2108</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/05/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bees</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthropods</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hymenoptera</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthropod Venoms/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Insect Bites and Stings/diagnosis/therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Bee Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">ants</style></keyword><keyword><style face="normal" font="default" size="100%">arthropods</style></keyword><keyword><style face="normal" font="default" size="100%">insects</style></keyword><keyword><style face="normal" font="default" size="100%">saliva allergy</style></keyword><keyword><style face="normal" font="default" size="100%">venom allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37191880</style></accession-num><abstract><style face="normal" font="default" size="100%">Insect venom allergy is the most frequent cause of anaphylaxis in Europe and possibly worldwide. The majority of systemic allergic reactions after insect stings are caused by Hymenoptera, and among these, vespid genera induce most of the systemic sting reactions (SSR). Honey bees are the second leading cause of SSR. Depending on the global region, other Hymenoptera such as different ant genera are responsible for SSR. Widely distributed hornets and bumblebees or local vespid or bee genera rarely induce SSR. Hematophagous insects such as mosquitoes and horse flies usually cause (large) local reactions while SSR occasionally occur. This position paper aimed to identify either rare or locally important insects causing SSR as well as rarely occurring SSR after stings or bites of widely distributed insects. We summarized relevant venom or saliva allergens and intended to identify possible cross-reactivities between the insect allergens. Moreover, we aimed to locate diagnostic tests for research and routine diagnosis, which are sometimes only regionally available. Finally, we gathered information on available immunotherapies. Major allergens of most insects were identified, and cross-reactivity between insects was frequently observed. While some diagnostics and immunotherapies are locally available, standardized skin tests and immunotherapies are generally lacking in rare insect allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Sturm, Gunter Johannes&#xD;Boni, Elisa&#xD;Antolin-Amerigo, Dario&#xD;Bilo, Maria Beatrice&#xD;Breynaert, Christine&#xD;Fassio, Filippo&#xD;Spriggs, Kymble&#xD;Vega, Arantza&#xD;Ricciardi, Luisa&#xD;Arzt-Gradwohl, Lisa&#xD;Hemmer, Wolfgang&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2089-2108. doi: 10.1111/all.15769. Epub 2023 May 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37191880</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15769</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1524</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1524</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Traina, G.</style></author><author><style face="normal" font="default" size="100%">Martelli, A. G.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A. G.</style></author><author><style face="normal" font="default" size="100%">Franco, V.</style></author><author><style face="normal" font="default" size="100%">Ronchi, B.</style></author><author><style face="normal" font="default" size="100%">Betti, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ASST-Melegnano Martesana, Melzo, Italy.&#xD;ASST Rohodense, Garbagnate Milanese, Italy.&#xD;Bambino Gesu Hospital, Rome, Italy.&#xD;Bambino Gesu Hospital, Vatican City, Vatican City.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergy...No more fear of needles!</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2277-2279</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2019/05/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Subcutaneous/*instrumentation/*methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31124154</style></accession-num><abstract><style face="normal" font="default" size="100%">Needleless injection systems are nowadays widespread and are mainly used to overcome the common problems of needle injection systems, such as pain, hematoma, scar tissue formation, infection or abscess, possibility of accidentally injecting into a venous vessel, and transmission of infectious diseases. All these problems are independent of the type of drug injected and are exclusively related to the needle devices. Current needleless injection systems are a valuable tool, which is especially available for the administration of vaccines to large numbers of patients. Our experience focused in particular on the so-called &quot;jet injectors,&quot; of which one of the most valid representatives is Injex(R). Our patent essentially concerns a medical needleless device, suitable to inject a subcutaneous AIT (allergy immunotherapy). The mechanism at the base of our device works with compressed air by means of a spring: It is very simple and similar to that of compressed air guns. Once the syringe has been filled, it is placed perpendicular to the skin, and then, the device is activated. The pressure vaporizes the drug, without changing or altering its chemical structure; it makes it pass through the epidermis, until it quickly reaches the subcutaneous layer, at a depth between 3.2 and 9.1 mm, without the patient feeling any pain. The entrance hole made by the needleless device in the epidermis is 0.17 mm rather than 0.39 mm of a normal needle. This type of administration also allows a uniform and spray diffusion of the drug, without causing localized inflammation, as it sometimes happens with normal syringe.</style></abstract><notes><style face="normal" font="default" size="100%">Traina, Giovanni&#xD;Martelli, Alberto G&#xD;Fiocchi, Alessandro Giovanni&#xD;Franco, Valentina&#xD;Ronchi, Barbara&#xD;Betti, Federica&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Nov;74(11):2277-2279. doi: 10.1111/all.13926. Epub 2019 Jul 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31124154</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13926</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2195</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2195</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mifsud, N. A.</style></author><author><style face="normal" font="default" size="100%">Illing, P. T.</style></author><author><style face="normal" font="default" size="100%">Ho, R.</style></author><author><style face="normal" font="default" size="100%">Tuomisto, J. E.</style></author><author><style face="normal" font="default" size="100%">Fettke, H.</style></author><author><style face="normal" font="default" size="100%">Mullan, K. A.</style></author><author><style face="normal" font="default" size="100%">McCluskey, J.</style></author><author><style face="normal" font="default" size="100%">Rossjohn, J.</style></author><author><style face="normal" font="default" size="100%">Vivian, J.</style></author><author><style face="normal" font="default" size="100%">Reantragoon, R.</style></author><author><style face="normal" font="default" size="100%">Purcell, A. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.&#xD;Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.&#xD;Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.&#xD;Immunology Division, Department of Microbiology, Department of Microbiology, Chulalongkorn University, Bangkok, Thailand.&#xD;Center of Excellence in Immunology and Immune-mediated Disease, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The allopurinol metabolite, oxypurinol, drives oligoclonal expansions of drug-reactive T cells in resolved hypersensitivity cases and drug-naive healthy donors</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2980-2993</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/07/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allopurinol/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Oxypurinol/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Stevens-Johnson Syndrome/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">HLA-B Antigens/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">T-cell receptor</style></keyword><keyword><style face="normal" font="default" size="100%">allopurinol</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default" size="100%">oxypurinol</style></keyword><keyword><style face="normal" font="default" size="100%">commercial or financial relationships that could be construed as a potential</style></keyword><keyword><style face="normal" font="default" size="100%">conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37452515</style></accession-num><abstract><style face="normal" font="default" size="100%">Allopurinol (ALP) is a successful drug used in the treatment of gout. However, this drug has been implicated in hypersensitivity reactions that can cause severe to life-threatening reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Individuals who carry the human leukocyte antigen (HLA)-B*58:01 allotype are at higher risk of experiencing a hypersensitivity reaction (odds ratios ranging from 5.62 to 580.3 for mild to severe reactions, respectively). In addition to the parent drug, the metabolite oxypurinol (OXP) is implicated in triggering T cell-mediated immunopathology via a labile interaction with HLA-B*58:01. To date, there has been limited information regarding the T-cell receptor (TCR) repertoire usage of reactive T cells in patients with ALP-induced SJS or TEN and, in particular, there are no reports examining paired alphabetaTCRs. Here, using in vitro drug-treated PBMCs isolated from both resolved ALP-induced SJS/TEN cases and drug-naive healthy donors, we show that OXP is the driver of CD8(+) T cell-mediated responses and that drug-exposed memory T cells can exhibit a proinflammatory immunophenotype similar to T cells described during active disease. Furthermore, this response supported the pharmacological interaction with immune receptors (p-i) concept by showcasing (i) the labile metabolite interaction with peptide/HLA complexes, (ii) immunogenic complex formation at the cell surface, and (iii) lack of requirement for antigen processing to elicit drug-induced T cell responsiveness. Examination of paired OXP-induced alphabetaTCR repertoires highlighted an oligoclonal and private clonotypic profile in both resolved ALP-induced SJS/TEN cases and drug-naive healthy donors.</style></abstract><notes><style face="normal" font="default" size="100%">Mifsud, Nicole A&#xD;Illing, Patricia T&#xD;Ho, Rebecca&#xD;Tuomisto, Johanna E&#xD;Fettke, Heidi&#xD;Mullan, Kerry A&#xD;McCluskey, James&#xD;Rossjohn, Jamie&#xD;Vivian, Julian&#xD;Reantragoon, Rangsima&#xD;Purcell, Anthony W&#xD;eng&#xD;Monash University/&#xD;National Health and Medical Research Council of Australia/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2980-2993. doi: 10.1111/all.15814. Epub 2023 Jul 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37452515</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10952278</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15814</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2841</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2841</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Otten, J. J.</style></author><author><style face="normal" font="default" size="100%">Elzinga, H. E.</style></author><author><style face="normal" font="default" size="100%">van der Lans, R. J. L.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Poly, R. E. G. Consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Amsterdam Rhinology Team (ART), Department of Otorhinolaryngology and Head/Neck Surgery, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Almost Half of the Dupilumab-Treated Patients With Severe Chronic Rhinosinusitis With Nasal Polyps Achieve Remission in One Year</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1166-1168</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/02/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">remission</style></keyword><keyword><style face="normal" font="default" size="100%">is an advisory board member of Sanofi, GSK, and Dianosic. S.R. has acted as a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant and/or advisory board member for Sanofi, GSK, and Novartis. The</style></keyword><keyword><style face="normal" font="default" size="100%">department of Otorhinolaryngology and Head/Neck Surgery of the Amsterdam UMC has</style></keyword><keyword><style face="normal" font="default" size="100%">received research funding from Sanofi, GSK, and Novartis. M.E.C. has acted as a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant and/or advisory board member for Sanofi, GSK, ALK, Mylan, and</style></keyword><keyword><style face="normal" font="default" size="100%">Medtronic. A.R. has acted as a consultant and/or advisory board member for</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi. J.J.O., H.E.E., I.J.K., I.K., G.F.J.P.M.A., L.B.L.B., and R.H. have no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39912310</style></accession-num><notes><style face="normal" font="default" size="100%">Otten, Josje J&#xD;Elzinga, Hester E&#xD;van der Lans, Rik J L&#xD;Fokkens, Wytske J&#xD;Reitsma, Sietze&#xD;eng&#xD;Stichting AERO/&#xD;GlaxoSmithKline/&#xD;Sanofi/&#xD;Novartis/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1166-1168. doi: 10.1111/all.16496. Epub 2025 Feb 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39912310</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969297</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16496</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2619</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2619</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, M.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Dahabreh, D.</style></author><author><style face="normal" font="default" size="100%">Lozano-Ojalvo, D.</style></author><author><style face="normal" font="default" size="100%">Carroll, B.</style></author><author><style face="normal" font="default" size="100%">Manson, M.</style></author><author><style face="normal" font="default" size="100%">Bose, S.</style></author><author><style face="normal" font="default" size="100%">Gour, D.</style></author><author><style face="normal" font="default" size="100%">NandyMazumdar, M.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Yu Ekey, M.</style></author><author><style face="normal" font="default" size="100%">Chowdhury, A.</style></author><author><style face="normal" font="default" size="100%">Angelov, M.</style></author><author><style face="normal" font="default" size="100%">Ungar, B.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3401-3414</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Alopecia Areata/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, OX40/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/metabolism/pathology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Scalp/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">Ox40</style></keyword><keyword><style face="normal" font="default" size="100%">Ox40l</style></keyword><keyword><style face="normal" font="default" size="100%">Th2</style></keyword><keyword><style face="normal" font="default" size="100%">alopecia areata</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39115359</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Alopecia areata (AA) is a chronic, nonscarring hair-loss disorder associated with significant quality-of-life impairment and limited treatment options. AA has been recently linked to atopy and shown to exhibit both Th1- and Th2-driven inflammation. However, a comprehensive molecular and cellular characterization across blood and scalp compartments in both atopic and nonatopic patients is lacking. METHODS: Lesional and nonlesional scalp biopsies obtained from AA patients with (n = 16) or without (n = 20) atopic history, and 17 demographically matched healthy controls were analyzed with RNA-seq, RT-PCR, and immunohistochemistry. Flow cytometry was also performed on peripheral blood mononuclear cells (PBMCs) from a subset of patients. Differential expression was defined using |fold-change| &gt; 1.5 and false-discovery rate &lt;0.05. RESULTS: AA scalp exhibited robust upregulation of Th1- (IFNG, CXCL9, CXCL10, CXCL11) and Th2-related products (CCL26, CCR4, IL10, IL13, TSLP, TNFRSF4/OX40) and shared downregulation of hair keratins, regardless of atopic background, with variable Th17/Th22 modulation. AA patients with atopy exhibited greater inflammatory tone and Th2-skewing (IL10, IL13, IL33, CCR4, CCL26). Disease severity correlated significantly with immune and hair keratin biomarkers and with perifollicular cellular infiltrates. Cutaneous OX40/OX40L upregulation was paralleled by increases in circulating OX40(+) and OX40L(+) leukocytes, regardless of atopic background. CONCLUSION: Our results suggest some atopy-associated immune differences in AA and highlight the OX40 axis as a potential novel therapeutic target that may broadly benefit AA patients.</style></abstract><notes><style face="normal" font="default" size="100%">Kim, Madeline&#xD;Del Duca, Ester&#xD;Dahabreh, Dante&#xD;Lozano-Ojalvo, Daniel&#xD;Carroll, Britta&#xD;Manson, Meredith&#xD;Bose, Swaroop&#xD;Gour, Digpal&#xD;NandyMazumdar, Monali&#xD;Liu, Ying&#xD;Yu Ekey, Mitchelle&#xD;Chowdhury, Amira&#xD;Angelov, Michael&#xD;Ungar, Benjamin&#xD;Estrada, Yeriel&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;Mount Sinai Alopecia Areata Center of Excellence/&#xD;Kyowa Kirin Pharmaceutical Development/&#xD;TR/NCATS NIH HHS/&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3401-3414. doi: 10.1111/all.16268. Epub 2024 Aug 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39115359</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16268</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>619</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">619</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fieten, K. B.</style></author><author><style face="normal" font="default" size="100%">Drijver-Messelink, M. T.</style></author><author><style face="normal" font="default" size="100%">Cogo, A.</style></author><author><style face="normal" font="default" size="100%">Charpin, D.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Taborda-Barata, L. M.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Braunstahl, G. J.</style></author><author><style face="normal" font="default" size="100%">Seys, S. F.</style></author><author><style face="normal" font="default" size="100%">van den Berge, M.</style></author><author><style face="normal" font="default" size="100%">Bloch, K. E.</style></author><author><style face="normal" font="default" size="100%">Ulrich, S.</style></author><author><style face="normal" font="default" size="100%">Cardoso-Vigueros, C.</style></author><author><style face="normal" font="default" size="100%">Kappen, J. H.</style></author><author><style face="normal" font="default" size="100%">Brinke, A. T.</style></author><author><style face="normal" font="default" size="100%">Koch, M.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">da Mata, P.</style></author><author><style face="normal" font="default" size="100%">Prins, D. J.</style></author><author><style face="normal" font="default" size="100%">Pasmans, Sgma</style></author><author><style face="normal" font="default" size="100%">Bendien, S.</style></author><author><style face="normal" font="default" size="100%">Rukhadze, M.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Couto, M.</style></author><author><style face="normal" font="default" size="100%">Oude Elberink, H.</style></author><author><style face="normal" font="default" size="100%">Peroni, D. G.</style></author><author><style face="normal" font="default" size="100%">Piacentini, G.</style></author><author><style face="normal" font="default" size="100%">Weersink, E. J. M.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Rijssenbeek-Nouwens, L. H. M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos Wolfgang, Switzerland.&#xD;Dutch Asthma Center Davos, Davos, Switzerland.&#xD;Center for Exercise and Sport Science, University of Ferrara, Ferrara, Italy.&#xD;Institute Pio XII, Misurina, Italy.&#xD;Department of Pulmonology and Allergy, Faculty of Medicine, North Hospital, Aix-Marseille University, Marseille, France.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;NuESP-Planetary Health Study Unit, Faculty of Health Sciences &amp; CICS-Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Department of Immunoallergology, Cova da Beira University Hospital Center, Covilha, Portugal.&#xD;Allergy Unit and Research Group, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Instituto de Investigacion Biomedica de Malaga (IBIMA) and ARADyAL, Malaga, Spain.&#xD;Department of Pulmonology, STZ Centre of Excellence for Asthma and COPD, Franciscus Group, Rotterdam, The Netherlands.&#xD;Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology &amp; Transplantation, KU Leuven, Leuven, Belgium.&#xD;Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;Department of Respiratory Medicine, University and University Hospital of Zurich, Zurich, Switzerland.&#xD;Department of Allergology, University Hospital of Zurich, Zurich, Switzerland.&#xD;Hochgebirgsklinik Davos, Davos, Switzerland.&#xD;Allergy and Clinical Immunology, Immunomodulation and Tolerance Group, Inflammation Repair and Development, Imperial College, National Heart and Lung Institute, London, United Kingdom.&#xD;Department of Pulmonary Diseases, Medical Center Leeuwarden, Leeuwarden, The Netherlands.&#xD;Alpenklinik Santa-Maria, Oberjoch- Bad Hindelang, Germany.&#xD;Department of Environmental Medicine, Medical Faculty, University Augsburg, Augsburg, Germany.&#xD;Instituto Clinico de Allergologia, Lisbon, Portugal.&#xD;Department of Dermatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.&#xD;Department of Pulmonology, HAGA Teaching Hospital, The Hague, The Netherlands.&#xD;Center of Allergy &amp; Immunology, Tbilisi, Georgia.&#xD;Faculty of Medicine, Teaching University Geomedi LLC, Tbilisi, Georgia.&#xD;Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Allergy Unit, Hospital CUF Descobertas, Lisbon, Portugal.&#xD;Department of Allergology, Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Pediatric Section, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, Verona, Italy.&#xD;Department of Pulmonology, Location AMC, Amsterdam University Medical Center, Amsterdam, The Netherlands.&#xD;Department of Cardiovascular and Thoracic Sciences, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;Department of Clinical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.&#xD;National Heart and Lung Institute (NHLI), Imperial College London, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Alpine altitude climate treatment for severe and uncontrolled asthma: An EAACI position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1991-2024</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/02/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Altitude</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Climate</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">altitude</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">pulmonary rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">Christine Kuhne-Center for Allergy Research and Education, European Commission</style></keyword><keyword><style face="normal" font="default" size="100%">Horizon&apos;s 2020 Framework Programme &quot;CURE,&quot; Novartis Research Institutes,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline and AstraZeneca. He took part in the advisory board and received</style></keyword><keyword><style face="normal" font="default" size="100%">research grants from GlaxoSmithKline, Sanofi/Regeneron, SciBase, and Novartis. He</style></keyword><keyword><style face="normal" font="default" size="100%">is the Editor-in-Chief of Allergy. IA has received payments from Sanofi, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, AZN, Mylan and participated on advisory boards from Sanofi, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, AZN. She is Associate Editor of Allergy and CTA. MS has received</style></keyword><keyword><style face="normal" font="default" size="100%">research grants from the Swiss National Science Foundation, GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, and AstraZeneca speaker fee. MC is currently employed by Roche, with no</style></keyword><keyword><style face="normal" font="default" size="100%">relation to this work. GJB received research grants from AstraZeneca and received</style></keyword><keyword><style face="normal" font="default" size="100%">payments for consultations and/or speaking at conferences from Novartis, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, AstraZeneca, ALK, TEVA, and Chiesi. AC is health director at the Institute</style></keyword><keyword><style face="normal" font="default" size="100%">Pio XII, Misurina, Italy since June 1, 2020. GP serves on the scientific advisory</style></keyword><keyword><style face="normal" font="default" size="100%">board to the owner of the Institute Pio XII, Misurina since the beginning of 2020</style></keyword><keyword><style face="normal" font="default" size="100%">and received payments for advisory board participation and or speaker fees from</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Novartis, Sanofi, Regeneron, Chiesi, Omron, NOOS, Angelini,</style></keyword><keyword><style face="normal" font="default" size="100%">Recordati, Pediatrica, OMPharma, MSD. AtB received research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GSK, TEVA and received payments for consultations and/or speaking at</style></keyword><keyword><style face="normal" font="default" size="100%">conferences from AstraZeneca, GSK, Novartis, SanofiGenzyme, and TEVA. SS is</style></keyword><keyword><style face="normal" font="default" size="100%">currently employed by Galenus Health, with no relation to this work. The other</style></keyword><keyword><style face="normal" font="default" size="100%">authors declare they have no conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35113452</style></accession-num><abstract><style face="normal" font="default" size="100%">Currently available European Alpine Altitude Climate Treatment (AACT) programs combine the physical characteristics of altitude with the avoidance of environmental triggers in the alpine climate and a personalized multidisciplinary pulmonary rehabilitation approach. The reduced barometric pressure, oxygen pressure, and air density, the relatively low temperature and humidity, and the increased UV radiation at moderate altitude induce several physiological and immunological adaptation responses. The environmental characteristics of the alpine climate include reduced aeroallergens such as house dust mites (HDM), pollen, fungi, and less air pollution. These combined factors seem to have immunomodulatory effects controlling pathogenic inflammatory responses and favoring less neuro-immune stress in patients with different asthma phenotypes. The extensive multidisciplinary treatment program may further contribute to the observed clinical improvement by AACT in asthma control and quality of life, fewer exacerbations and hospitalizations, reduced need for oral corticosteroids (OCS), improved lung function, decreased airway hyperresponsiveness (AHR), improved exercise tolerance, and improved sinonasal outcomes. Based on observational studies and expert opinion, AACT represents a valuable therapy for those patients irrespective of their asthma phenotype, who cannot achieve optimal control of their complex condition despite all the advances in medical science and treatment according to guidelines, and therefore run the risk of falling into a downward spiral of loss of physical and mental health. In the light of the observed rapid decrease in inflammation and immunomodulatory effects, AACT can be considered as a natural treatment that targets biological pathways.</style></abstract><notes><style face="normal" font="default" size="100%">Fieten, Karin B&#xD;Drijver-Messelink, Marieke T&#xD;Cogo, Annalisa&#xD;Charpin, Denis&#xD;Sokolowska, Milena&#xD;Agache, Ioana&#xD;Taborda-Barata, Luis Manuel&#xD;Eguiluz-Gracia, Ibon&#xD;Braunstahl, Gerrit J&#xD;Seys, Sven F&#xD;van den Berge, Maarten&#xD;Bloch, Konrad E&#xD;Ulrich, Silvia&#xD;Cardoso-Vigueros, Carlos&#xD;Kappen, Jasper H&#xD;Brinke, Anneke Ten&#xD;Koch, Markus&#xD;Traidl-Hoffmann, Claudia&#xD;da Mata, Pedro&#xD;Prins, David J&#xD;Pasmans, Suzanne G M A&#xD;Bendien, Sarah&#xD;Rukhadze, Maia&#xD;Shamji, Mohamed H&#xD;Couto, Mariana&#xD;Oude Elberink, Hanneke&#xD;Peroni, Diego G&#xD;Piacentini, Giorgio&#xD;Weersink, Els J M&#xD;Bonini, Matteo&#xD;Rijssenbeek-Nouwens, Lucia H M&#xD;Akdis, Cezmi A&#xD;eng&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):1991-2024. doi: 10.1111/all.15242. Epub 2022 Feb 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35113452</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9305916</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15242</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2576</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2576</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fieten, K. B.</style></author><author><style face="normal" font="default" size="100%">Drijver-Messelink, M. T.</style></author><author><style face="normal" font="default" size="100%">Wolters, R.</style></author><author><style face="normal" font="default" size="100%">Hilvering, B.</style></author><author><style face="normal" font="default" size="100%">Vijverberg, S. J. H.</style></author><author><style face="normal" font="default" size="100%">Weersink, E. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Dutch Asthma Centre Davos, Davos, Switzerland.&#xD;Department of Pulmonary Medicine, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Alpine altitude climate treatment improves asthma control, irrespective of biologics use</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2864-2867</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/07/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Altitude</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Climate</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38993120</style></accession-num><notes><style face="normal" font="default" size="100%">Fieten, Karin B&#xD;Drijver-Messelink, Marieke T&#xD;Wolters, Rolf&#xD;Hilvering, Bart&#xD;Vijverberg, Susanne J H&#xD;Weersink, Els J&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2864-2867. doi: 10.1111/all.16233. Epub 2024 Jul 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38993120</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16233</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2893</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2893</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Park, H. K.</style></author><author><style face="normal" font="default" size="100%">Her, Y.</style></author><author><style face="normal" font="default" size="100%">Choi, D. Y.</style></author><author><style face="normal" font="default" size="100%">Park, T.</style></author><author><style face="normal" font="default" size="100%">Kwon, J. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea.&#xD;Department of Dermatology, Kangwon National University School of Medicine, Chuncheon, Korea.&#xD;Department of Animal Science and Technology, Chung-Ang University, Anseong, Korea.&#xD;Department of Allergy and Clinical Immunology, Kangwon National University School of Medicine, Chuncheon, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Alterations in Gut Microbiota Composition Are Related to Disease Severity and Systemic Inflammation in Patients With Chronic Urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2369-2372</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/05/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">chronic urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">gut microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40403172</style></accession-num><notes><style face="normal" font="default" size="100%">Park, Han-Ki&#xD;Her, Young&#xD;Choi, Doo Young&#xD;Park, Tansol&#xD;Kwon, Jae-Woo&#xD;eng&#xD;National Research Foundation of Korea/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2369-2372. doi: 10.1111/all.16601. Epub 2025 May 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40403172</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368743</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16601</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2593</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2593</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ferrara, A. L.</style></author><author><style face="normal" font="default" size="100%">Palestra, F.</style></author><author><style face="normal" font="default" size="100%">Piscitelli, F.</style></author><author><style face="normal" font="default" size="100%">Petraroli, A.</style></author><author><style face="normal" font="default" size="100%">Suffritti, C.</style></author><author><style face="normal" font="default" size="100%">Firinu, D.</style></author><author><style face="normal" font="default" size="100%">Lopez-Lera, A.</style></author><author><style face="normal" font="default" size="100%">Caballero, T.</style></author><author><style face="normal" font="default" size="100%">Bork, K.</style></author><author><style face="normal" font="default" size="100%">Spadaro, G.</style></author><author><style face="normal" font="default" size="100%">Marone, G.</style></author><author><style face="normal" font="default" size="100%">Di Marzo, V.</style></author><author><style face="normal" font="default" size="100%">Bova, M.</style></author><author><style face="normal" font="default" size="100%">Loffredo, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medical Sciences, Center for Basic and Clinical Immunology Research, University of Naples Federico II, WAO Center of Excellence, Naples, Italy.&#xD;Endocannabinoid Research Group, Istituto di Chimica Biomolecolare-Consiglio Nazionale delle Ricerche, Pozzuoli, Italy.&#xD;Italian Network for Hereditary and Acquired Angioedema, Napoli, Italy.&#xD;Fondazione IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.&#xD;Internal Medicine, Allergy and Clinical Immunology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Hospital La Paz Institute for Health Research (IdiPAZ), CIBERER (U754), Madrid, Spain.&#xD;Allergy Department, Hospital Universitario La Paz, Hospital La Paz Institute for Health Research (IdiPAZ), CIBERER (U754), Madrid, Spain.&#xD;Department of Dermatology, University Medical Center, Johannes Gutenberg University, Mainz, Germany.&#xD;Institute of Experimental Endocrinology and Oncology &quot;G. Salvatore&quot;, National Research Council, Naples, Italy.&#xD;Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health, Centre de Recherche de l&apos;Institut Universitaire de Cardiologie et Pneumologie de Quebec, and Centre NUTRISS, Institut sur la Nutrition et les Aliments Fonctionnels, Universite Laval, Quebec City, Canada.&#xD;Department of Internal Medicine, A.O.R.N. Antonio Cardarelli, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Altered levels of phospholipases C, diacylglycerols, endocannabinoids, and N-acylethanolamines in patients with hereditary angioedema due to FXII mutation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">287-296</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">*Endocannabinoids/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Ethanolamines/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Factor XII/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/blood/genetics/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Type C Phospholipases/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">2-arachidonoylglycerol</style></keyword><keyword><style face="normal" font="default" size="100%">anandamide</style></keyword><keyword><style face="normal" font="default" size="100%">diacylglycerols</style></keyword><keyword><style face="normal" font="default" size="100%">oleoylethanolamide</style></keyword><keyword><style face="normal" font="default" size="100%">palmitoylethanolamide</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38935036</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hereditary angioedema (HAE) is a rare genetic disorder characterized by local, self-limiting edema due to temporary increase in vascular permeability. HAE with normal C1 esterase inhibitor (C1INH) activity includes the form with mutations in the F12 gene encoding for coagulation factor XII (FXII-HAE) causing an overproduction of bradykinin (BK) leading to angioedema attack. BK binding to B2 receptors (BK2R) leads to an activation of phospholipase C (PLC) and subsequent generation of second messengers: diacylglycerols (DAGs) and possibly the endocannabinoids (eCBs), 2-arachidonoylglycerol (2-AG) and anandamide (AEA), and eCB-related N-acylethanolamines [palmitoylethanolamide (PEA) and oleoylethanolamide (OEA)]. To date, there are no data on the role of these lipid mediators in FXII-HAE. METHODS: Here, we analyzed plasma levels of PLC, DAGs, and eCBs in 40 patients with FXII-HAE and 40 sex- and age-matched healthy individuals. RESULTS: Plasma PLC activity was increased in FXII-HAE patients compared to controls. Concentrations of DAG 18:1-20:4, a lipid second messenger produced by PLC, were higher in FXII-HAE compared to controls, and positively correlated with PLC activity and cleaved high molecular kininogen (cHK). Also the concentrations of the DAG metabolite, 2-AG were altered in FXII-HAE. AEA and OEA were decreased in FXII-HAE patients compared to controls; by contrast, PEA, was increased. The levels of all tested mediators did not differ between symptomatic and asymptomatic patients. Moreover, C1INH-HAE patients had elevated plasma levels of PLC, which correlated with cHK, but the levels of DAGs and eCBs were the same as controls. CONCLUSIONS: BK overproduction and BKR2 activation are linked to alteration of PLCs and their metabolites in patients with FXII-HAE. Our results may pave way to investigations on the functions of these mediators in the pathophysiology of FXII-HAE, and provide new potential biomarkers and therapeutic targets.</style></abstract><notes><style face="normal" font="default" size="100%">Ferrara, Anne Lise&#xD;Palestra, Francesco&#xD;Piscitelli, Fabiana&#xD;Petraroli, Angelica&#xD;Suffritti, Chiara&#xD;Firinu, Davide&#xD;Lopez-Lera, Alberto&#xD;Caballero, Teresa&#xD;Bork, Konrad&#xD;Spadaro, Giuseppe&#xD;Marone, Gianni&#xD;Di Marzo, Vincenzo&#xD;Bova, Maria&#xD;Loffredo, Stefania&#xD;eng&#xD;IIR-ITA-002138/&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):287-296. doi: 10.1111/all.16197. Epub 2024 Jun 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38935036</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16197</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3045</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3045</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baek, M. G.</style></author><author><style face="normal" font="default" size="100%">Park, S.</style></author><author><style face="normal" font="default" size="100%">Kim, Y. C.</style></author><author><style face="normal" font="default" size="100%">Sohn, K. H.</style></author><author><style face="normal" font="default" size="100%">Kim, J. W.</style></author><author><style face="normal" font="default" size="100%">Lee, K. J.</style></author><author><style face="normal" font="default" size="100%">Cho, S. H.</style></author><author><style face="normal" font="default" size="100%">Kang, H. R.</style></author><author><style face="normal" font="default" size="100%">Yi, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Biomaterials, Korea University, Seoul, Korea.&#xD;Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.&#xD;Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea.&#xD;Division of Zoonotic and Vector Borne Diseases Research, Center for Infectious Disease Research, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Korea.&#xD;School of Biosystems and Biomedical Sciences, Korea University, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Altered Phage-Related Gene Profiles in Asthmatic Airways</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">252-255</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40772646</style></accession-num><notes><style face="normal" font="default" size="100%">Baek, Min-Gyung&#xD;Park, Sangcheol&#xD;Kim, Young-Chan&#xD;Sohn, Kyoung-Hee&#xD;Kim, Jung Wook&#xD;Lee, Kwang Jun&#xD;Cho, Sang-Heon&#xD;Kang, Hye-Ryun&#xD;Yi, Hana&#xD;eng&#xD;2022R1A2C1007966/Korean Government/&#xD;RS-2023-00217157/Korean Government/&#xD;2024-ER2105-00/National Institute of Health/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):252-255. doi: 10.1111/all.70009. Epub 2025 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40772646</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773677</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70009</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>819</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">819</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fricker, M.</style></author><author><style face="normal" font="default" size="100%">Qin, L.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Ovando, S.</style></author><author><style face="normal" font="default" size="100%">Simpson, J. L.</style></author><author><style face="normal" font="default" size="100%">Baines, K. J.</style></author><author><style face="normal" font="default" size="100%">Riveros, C.</style></author><author><style face="normal" font="default" size="100%">Scott, H. A.</style></author><author><style face="normal" font="default" size="100%">Wood, L. G.</style></author><author><style face="normal" font="default" size="100%">Wark, P. A.</style></author><author><style face="normal" font="default" size="100%">Kermani, N. Z.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Gibson, P. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medicine and Public Health, Faculty of Health and Medicine and Priority Research Centre for Healthy Lungs, The University of Newcastle, Callaghan, NSW, Australia.&#xD;National Health and Medical Research Council Centre for Excellence in Severe Asthma, Newcastle, NSW, Australia.&#xD;Hunter Medical Research Institute, Newcastle, NSW, Australia.&#xD;Department of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, China.&#xD;Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW, Australia.&#xD;Statistical services (CReDITSS), Hunter Medical Research Institute, Newcastle, NSW, Australia.&#xD;School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, Priority Research Centre for Healthy Lungs, The University of Newcastle, Newcastle, NSW, Australia.&#xD;Data Science Institute, Imperial College London, London, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An altered sputum macrophage transcriptome contributes to the neutrophilic asthma endotype</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1204-1215</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/09/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">*Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">endotype</style></keyword><keyword><style face="normal" font="default" size="100%">macrophage</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophil</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">and New Zealand, during the conduct of the study, and grants from GlaxoSmithKline</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. Dr. Baines reports grants from NHMRC, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Australian Lung Foundation, grants from HMRI, outside the submitted work. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Gibson reports personal fees from AstraZeneca, GlaxoSmithKline, Novartis, grants</style></keyword><keyword><style face="normal" font="default" size="100%">from AstraZeneca, GlaxoSmithKline, outside the submitted work. L.Q., S.S-O.,</style></keyword><keyword><style face="normal" font="default" size="100%">J.L.S., C.R., H.A.S. and L.W. have nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34510493</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Neutrophilic asthma (NA) is a clinically important asthma phenotype, the cellular and molecular basis of which is not completely understood. Airway macrophages are long-lived immune cells that exert important homeostatic and inflammatory functions which are dysregulated in asthma. Unique transcriptomic programmes reflect varied macrophage phenotypes in vitro. We aimed to determine whether airway macrophages are transcriptomically altered in NA. METHODS: We performed RNASeq analysis on flow cytometry-isolated sputum macrophages comparing NA (n = 7) and non-neutrophilic asthma (NNA, n = 13). qPCR validation of RNASeq results was performed (NA n = 13, NNA n = 23). Pathway analysis (PANTHER, STRING) of differentially expressed genes (DEGs) was performed. Gene set variation analysis (GSVA) was used to test for enrichment of NA macrophage transcriptomic signatures in whole sputum microarray (cohort 1 - controls n = 16, NA n = 29, NNA n = 37; cohort 2 U-BIOPRED - controls n = 16, NA n = 47, NNA n = 57). RESULTS: Flow cytometry-sorting significantly enriched sputum macrophages (99.4% post-sort, 44.9% pre-sort, p &lt; .05). RNASeq analysis confirmed macrophage purity and identified DEGs in NA macrophages. Selected DEGs (SLAMF7, DYSF, GPR183, CSF3, PI3, CCR7, all p &lt; .05 NA vs. NNA) were confirmed by qPCR. Pathway analysis of NA macrophage DEGs was consistent with responses to bacteria, contribution to neutrophil recruitment and increased expression of phagocytosis and efferocytosis factors. GSVA demonstrated neutrophilic macrophage gene signatures were significantly enriched in whole sputum microarray in NA vs. NNA and controls in both cohorts. CONCLUSIONS: We demonstrate a pathophysiologically relevant sputum macrophage transcriptomic programme in NA. The finding that there is transcriptional activation of inflammatory programmes in cell types other than neutrophils supports the concept of NA as a specific endotype.</style></abstract><notes><style face="normal" font="default" size="100%">Fricker, Michael&#xD;Qin, Ling&#xD;Sanchez-Ovando, Stephany&#xD;Simpson, Jodie L&#xD;Baines, Katherine J&#xD;Riveros, Carlos&#xD;Scott, Hayley A&#xD;Wood, Lisa G&#xD;Wark, Peter Ab&#xD;Kermani, Nazanin Z&#xD;Chung, Kian Fan&#xD;Gibson, Peter G&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1204-1215. doi: 10.1111/all.15087. Epub 2021 Sep 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34510493</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9541696</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15087</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1952</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1952</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, C. H.</style></author><author><style face="normal" font="default" size="100%">Kabak, E.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Translational Medicine Program, Hospital for Sick Children, Research Institute, Toronto, Ontario, Canada.&#xD;Temerty Faculty of Medicine, Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An alternative path to oral tolerance</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2058-2060</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">T cell</style></keyword><keyword><style face="normal" font="default" size="100%">dendritic cell</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36883354</style></accession-num><notes><style face="normal" font="default" size="100%">Li, Carmen H&#xD;Kabak, Ekaterina&#xD;Eiwegger, Thomas&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2058-2060. doi: 10.1111/all.15701. Epub 2023 Mar 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36883354</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15701</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2484</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2484</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Becker, S.</style></author><author><style face="normal" font="default" size="100%">Deshmukh, S.</style></author><author><style face="normal" font="default" size="100%">De Looze, F.</style></author><author><style face="normal" font="default" size="100%">Francardo, V.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author><author><style face="normal" font="default" size="100%">McGirr, A.</style></author><author><style face="normal" font="default" size="100%">Nathan, Z.</style></author><author><style face="normal" font="default" size="100%">Rook, C.</style></author><author><style face="normal" font="default" size="100%">Meyer, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center of Eberhard-Karls University Tubingen, Tubingen, Germany.&#xD;Clinical Trial Unit, Griffith University, Southport, Queensland, Australia.&#xD;Austrials, Brisbane Health Connect, Brisbane, Queensland, Australia.&#xD;Altamira Medica AG, Basel, Switzerland.&#xD;Department of Immunology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.&#xD;Holdsworth House Medical Practice, Sydney, New South Wales, Australia.&#xD;Northern Beaches Clinical Research, Brookvale, New South Wales, Australia.&#xD;Hatherley Medical, Winthrop, Western Australia, Australia.&#xD;CMAX, Adelaide, South Australia, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1858-1867</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/04/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Sprays</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Intranasal</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Saline Solution/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Am-301</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">drug-free</style></keyword><keyword><style face="normal" font="default" size="100%">nasal spray</style></keyword><keyword><style face="normal" font="default" size="100%">saline</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38581259</style></accession-num><abstract><style face="normal" font="default" size="100%">RATIONALE: Saline nasal sprays are frequently used in the management of seasonal allergic rhinitis (SAR) for the cleansing and clearing of aeroallergens from the nasal cavity. Also using a drug-free approach, AM-301 nasal spray is forming a thin film barrier on the nasal mucosa to prevent contact with allergens, trap them, and facilitate their discharge. A clinical trial compared the efficacy, safety, and tolerability of AM-301 and saline spray in SAR. METHODS: A total of 100 patients were randomized 1:1 to self-administer AM-301 or saline 3 x daily for 2 weeks. Primary efficacy endpoint: reduction in mean daily reflective Total Nasal Symptom Score (rTNSS). Secondary efficacy endpoints: reduction in mean instantaneous TNSS and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), global impression of efficacy. Safety and tolerability: adverse events, relief medication use, symptom-free days, global impression of tolerability. RESULTS: AM-301-treated patients achieved a significantly lower rTNSS than the saline group (LS square means difference -1.1, 95% CI -1.959 to -0.241, p = .013) with improvement observed across all individual nasal symptoms. Likewise, all secondary endpoints showed statistical significance in favor of AM-301; for example, quality of life was significantly improved overall (p &lt; .001) as well as for each individual RQLQ domain. Both treatments showed similarly good safety and tolerability. With AM-301, fewer patients used relief medication and more enjoyed symptom-free days compared to saline treatment. CONCLUSIONS: AM-301 was more effective than saline in improving SAR nasal symptoms and related quality of life while offering similar tolerability, demonstrating the benefits of a barrier approach.</style></abstract><notes><style face="normal" font="default" size="100%">Becker, Sven&#xD;Deshmukh, Sachin&#xD;De Looze, Ferdinandus&#xD;Francardo, Veronica&#xD;Lee, Jessie&#xD;McGirr, Anthony&#xD;Nathan, Zachary&#xD;Rook, Christopher&#xD;Meyer, Thomas&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1858-1867. doi: 10.1111/all.16116. Epub 2024 Apr 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38581259</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16116</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2472</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2472</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Luyten, A.</style></author><author><style face="normal" font="default" size="100%">Burgler, A.</style></author><author><style face="normal" font="default" size="100%">Glick, S.</style></author><author><style face="normal" font="default" size="100%">Kwiatkowski, M.</style></author><author><style face="normal" font="default" size="100%">Gehrig, R.</style></author><author><style face="normal" font="default" size="100%">Beigi, M.</style></author><author><style face="normal" font="default" size="100%">Hartmann, K.</style></author><author><style face="normal" font="default" size="100%">Eeftens, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Tropical and Public Health Institute, Allschwil, Switzerland.&#xD;University of Basel, Basel, Switzerland.&#xD;Federal Office of Meteorology and Climatology MeteoSwiss, Zurich, Switzerland.&#xD;Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ambient pollen exposure and pollen allergy symptom severity in the EPOCHAL study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1908-1920</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/04/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/immunology/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Seasons</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Symptom Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">exposure-response modeling</style></keyword><keyword><style face="normal" font="default" size="100%">hay fever</style></keyword><keyword><style face="normal" font="default" size="100%">pollen allergy</style></keyword><keyword><style face="normal" font="default" size="100%">symptom severity</style></keyword><keyword><style face="normal" font="default" size="100%">symptoms</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38659216</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Ambient pollen exposure causes nasal, ocular, and pulmonary symptoms in allergic individuals, but the shape of the exposure-response association is not well characterized. We evaluated this association and determined (1) whether symptom severity differs between subpopulations; (2) how the association changes over the course of the pollen season; and (3) which pollen exposure time lags affect symptoms. METHODS: Adult study participants (n = 396) repeatedly scored severity of nasal, ocular, and pulmonary allergic symptoms, resulting in three composite symptom scores. We calculated hourly individually relevant pollen exposure to seven allergenic plants (alder, ash, birch, hazel, grasses, mugwort, and ragweed) considering personal sensitization and exposure time lags of up to 96 h. We fitted generalized additive mixed models, with a random personal intercept, adjusting for weather and air pollution as potential time-varying confounders. RESULTS: We identified a clear nonlinear positive association between pollen exposure and ocular and nasal symptom severity in the pollen allergy group: Symptom severity increased steeply with increasing exposure initially, but attenuated beyond approximately 80 pollen/m(3). We found no evidence of an exposure threshold, below which no symptoms occur. While recent pollen exposure in the last approximately 5 h affected symptoms most, associations lingered for up to 60 h. Grass pollen exposure (compared to tree pollen) and younger age (18-30 years, as opposed to 30-65 years) were both associated with higher nasal and ocular symptom severity. CONCLUSIONS: The lack of a threshold and attenuated dose-response curve may have implications for pollen warning systems, which may be revised to include multiday pollen concentrations in the future.</style></abstract><notes><style face="normal" font="default" size="100%">Luyten, Axel&#xD;Burgler, Alexandra&#xD;Glick, Sarah&#xD;Kwiatkowski, Marek&#xD;Gehrig, Regula&#xD;Beigi, Minaya&#xD;Hartmann, Karin&#xD;Eeftens, Marloes&#xD;eng&#xD;185864/Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;853568/HORIZON EUROPE European Research Council/&#xD;ERC_/European Research Council/International&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1908-1920. doi: 10.1111/all.16130. Epub 2024 Apr 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38659216</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16130</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2939</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2939</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, L.</style></author><author><style face="normal" font="default" size="100%">Zhang, S.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Guo, Y.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, Q.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author><author><style face="normal" font="default" size="100%">Qu, Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, N.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Lan, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology Head and Neck Surgery, Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of New Medicine and Diagnostic Technology Research for Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, University Hospital of Munster, Munster, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Amphiregulin Mediates Epithelial Cell-Eosinophil Interactions and Amplifies Inflammation in Chronic Rhinosinusitis With Nasal Polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1335-1347</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/05/03 22:26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Amphiregulin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/metabolism/immunology/complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/metabolism/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/metabolism/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Epithelial Cells/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Cell Communication/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">amphiregulin</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyp</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40317745</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophils easily accumulate in the intra-epithelial layer and subepithelial regions in eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP). While several factors influence the migration of eosinophils from peripheral blood to extravascular tissues, the triggers and role of eosinophils near the epithelial layer in CRSwNP remain unclear. METHODS: We examined interactions between eosinophils and epithelial cells using co-culture systems. We assessed the expression of amphiregulin (AREG) in CRSwNP epithelial cells and investigated its impact on epithelial barrier function, eosinophil activation, and migration. These effects were further validated in a CRSwNP mouse model treated with an AREG-blocking antibody. RESULTS: Co-culturing blood eosinophils and primary epithelial cells from CRSwNP patients decreased tight junction expression and increased eosinophil activation. Epithelial cells from ECRSwNP patients expressed higher levels of AREG than those from non-eosinophilic CRSwNP (non-ECRSwNP) patients, particularly in basal cells. As measured in the culture medium by ELISA, both blood eosinophils and primary epithelial cells automatically secreted AREG. Our in vitro experiments demonstrated that AREG impaired epithelial barrier function and facilitated eosinophil migration and activation. Confirmatory studies in a CRSwNP mouse model indicated that blocking AREG reduced the number of nasal polyp-like lesions, mucosal thickness, and eosinophil infiltration, while restoring the expression of tight junction proteins. CONCLUSION: The upregulation of AREG triggers eosinophil migration and mediates the interaction between epithelial cells and eosinophils, thereby enhancing chronic inflammation in CRSwNP. Our study highlights the therapeutic potential of anti-AREG antibodies in CRSwNP, offering a promising strategy for treating human eosinophilic sinus diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Zhao, Limin&#xD;Zhang, Shujian&#xD;Zhang, Yuling&#xD;Liu, Yingyue&#xD;Guo, Yushi&#xD;Li, Yan&#xD;Wang, Qiqi&#xD;Wang, Zaichuan&#xD;Qu, Zhennan&#xD;Zhang, Nan&#xD;Bachert, Claus&#xD;Wang, Chengshuo&#xD;Zhang, Luo&#xD;Lan, Feng&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1335-1347. doi: 10.1111/all.16582. Epub 2025 May 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40317745</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16582</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2586</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2586</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tontini, C.</style></author><author><style face="normal" font="default" size="100%">Bahri, R.</style></author><author><style face="normal" font="default" size="100%">Simpson, A.</style></author><author><style face="normal" font="default" size="100%">Bulfone-Paus, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.&#xD;Manchester University NHS Foundation Trust, Manchester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anaphylaxis and desensitization differently activate and induce IL-8 release by mast cells in a human peanut allergy in vitro model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2289-2292</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/07/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-8/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38972006</style></accession-num><notes><style face="normal" font="default" size="100%">Tontini, Chiara&#xD;Bahri, Rajia&#xD;Simpson, Angela&#xD;Bulfone-Paus, Silvia&#xD;eng&#xD;MRC_/Medical Research Council/United Kingdom&#xD;WT_/Wellcome Trust/United Kingdom&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2289-2292. doi: 10.1111/all.16222. Epub 2024 Jul 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38972006</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16222</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1354</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1354</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choe, Y. J.</style></author><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Choi, W. S.</style></author><author><style face="normal" font="default" size="100%">Shin, J. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Social and Preventive Medicine, Hallym University College of Medicine, Chuncheon, South Korea.&#xD;School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.&#xD;Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Ansan Hospital, Ansan, South Korea.&#xD;Samsung Advanced Institute for Health Sciences &amp; Technology (SAIHST), Sungkyunkwan University, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anaphylaxis following vaccination among children in Asia: A large-linked database study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1246-1249</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/08/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Asia/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32790924</style></accession-num><notes><style face="normal" font="default" size="100%">Choe, Young June&#xD;Lee, Hyesung&#xD;Kim, Ju Hwan&#xD;Choi, Won Suk&#xD;Shin, Ju-Young&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1246-1249. doi: 10.1111/all.14562. Epub 2020 Sep 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32790924</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14562</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2506</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2506</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Chen, H.</style></author><author><style face="normal" font="default" size="100%">Huang, N.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Ma, D.</style></author><author><style face="normal" font="default" size="100%">Demoly, P.</style></author><author><style face="normal" font="default" size="100%">Zhu, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Allergy Unit, Pulmonology Department, Hopital Arnaud de Villeneuve and IDESP, University of Montpellier-Inserm, Montpellier, France.&#xD;Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anaphylaxis in outpatients: A 5-year retrospective study on incidence and clinical characteristics at a university hospital in Wuhan, China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1501-1505</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/05/11</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38733203</style></accession-num><notes><style face="normal" font="default" size="100%">Li, Le&#xD;Chen, Hao&#xD;Huang, Nan&#xD;Li, Wenjing&#xD;Yang, Yaqi&#xD;Ma, Dongxia&#xD;Demoly, Pascal&#xD;Zhu, Rongfei&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1501-1505. doi: 10.1111/all.16152. Epub 2024 May 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38733203</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105061</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16152</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1029</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1029</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pur Ozyigit, L.</style></author><author><style face="normal" font="default" size="100%">Khalil, G.</style></author><author><style face="normal" font="default" size="100%">Choudhry, T.</style></author><author><style face="normal" font="default" size="100%">Williams, M.</style></author><author><style face="normal" font="default" size="100%">Khan, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Adult Allergy Service, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK.&#xD;Emergency Decisions Unit, University Hospitals of Leicester NHS Trust, Leicester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anaphylaxis in the Emergency Department Unit: Before and during COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2624-2626</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/04/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">*Emergency Medical Services</style></keyword><keyword><style face="normal" font="default" size="100%">Emergency Service, Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33905546</style></accession-num><notes><style face="normal" font="default" size="100%">Pur Ozyigit, Leyla&#xD;Khalil, Ghayyur&#xD;Choudhry, Taimour&#xD;Williams, Mark&#xD;Khan, Nasreen&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2624-2626. doi: 10.1111/all.14873. Epub 2021 May 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33905546</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8222882</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14873</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2935</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2935</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pouessel, G.</style></author><author><style face="normal" font="default" size="100%">Vaia, E. S.</style></author><author><style face="normal" font="default" size="100%">Chatain, C.</style></author><author><style face="normal" font="default" size="100%">Liabeuf, V.</style></author><author><style face="normal" font="default" size="100%">Braun, C.</style></author><author><style face="normal" font="default" size="100%">Correard, A. K.</style></author><author><style face="normal" font="default" size="100%">Bradatan, E.</style></author><author><style face="normal" font="default" size="100%">Dumond, P.</style></author><author><style face="normal" font="default" size="100%">Karaca-Altintas, Y.</style></author><author><style face="normal" font="default" size="100%">Beaumont, P.</style></author><author><style face="normal" font="default" size="100%">Delalande, D.</style></author><author><style face="normal" font="default" size="100%">Tscheiller, S.</style></author><author><style face="normal" font="default" size="100%">Van der Brempt, X.</style></author><author><style face="normal" font="default" size="100%">Metz-Favre, C.</style></author><author><style face="normal" font="default" size="100%">Divaret-Chauveau, A.</style></author><author><style face="normal" font="default" size="100%">Sabouraud-Leclerc, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CH Roubaix, Department of Pediatrics, Children&apos;s Hospital, Roubaix, France.&#xD;CHU Lille, Pediatric Pulmonology and Allergy Department, Pole Enfant, Hopital Jeanne de Flandre, Lille, France.&#xD;University of Lille, ULR 2694: Metrics, Lille, France.&#xD;Allergy-Vigilance Network, Vandoeuvre-les-Nancy, France.&#xD;CH Jules Niel, Valreas, France.&#xD;Department of Dermatology, Allergology and Photobiology, University Hospital Center Grenoble Alpes, Grenoble, France.&#xD;Department of Pediatrics, University Hospital Center Grenoble Alpes, Grenoble, France.&#xD;Department of Dermatology, University Hospital Center La Timone, Aix-Marseille University, Marseille, France.&#xD;Pediatric Pulmonology and Allergology Department, Pediatric Cystic Fibrosis Center, Hopital Femme Mere Enfant, Hospices Civils de Lyon, Bron, France.&#xD;Centre International de Recherche en Infectiologie, INSERM U1111, Lyon, France.&#xD;Department of Paediatrics, CHRU Namur, Vandoeuvre-les-Nancy, Belgium.&#xD;Paediatric Allergy Unit, Children&apos;s Hospital, CHRU Vandoeuvre-Les-Nancy, Vandoeuvre-Les-Nancy, France.&#xD;University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.&#xD;Medical Office, Saint Maur des Fosses, Saint Maur des Fosses, France.&#xD;Departement of Pediatrics, Centre Hospitalier Intercommunal de Creteil, Creteil, France.&#xD;Allergopole, Clinique Saint-Luc, Namur, Belgium.&#xD;Department of Pneumology and Allergology, Strasbourg University Hospital Center, Strasbourg, France.&#xD;UR 3450 DevAH, Health Faculty, Vandoeuvre Les Nancy, France.&#xD;General and Specialized Pediatrics Department, American Hospital, Reims University Hospital Center, Reims, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anaphylaxis Induced by Goat&apos;s and Sheep&apos;s Milk: An Allergen That We Should Keep Under Surveillance</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">300-303</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/05/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">adrenaline</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">goat&apos;s milk</style></keyword><keyword><style face="normal" font="default" size="100%">sheep&apos;s milk</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40326788</style></accession-num><notes><style face="normal" font="default" size="100%">Pouessel, Guillaume&#xD;Vaia, Elleni-Sofia&#xD;Chatain, Catharina&#xD;Liabeuf, Valerie&#xD;Braun, Camille&#xD;Correard, Anne-Karine&#xD;Bradatan, Elena&#xD;Dumond, Pascale&#xD;Karaca-Altintas, Yasemin&#xD;Beaumont, Pascale&#xD;Delalande, Delphine&#xD;Tscheiller, Selina&#xD;Van der Brempt, Xavier&#xD;Metz-Favre, Carine&#xD;Divaret-Chauveau, Amandine&#xD;Sabouraud-Leclerc, Dominique&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):300-303. doi: 10.1111/all.16581. Epub 2025 May 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40326788</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16581</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1357</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1357</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pichler, W. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ADR-AC, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anaphylaxis to drugs: Overcoming mast cell unresponsiveness by fake antigens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1340-1349</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/08/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Drug-Related Side Effects and Adverse Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Pharmaceutical Preparations</style></keyword><keyword><style face="normal" font="default" size="100%">adducts</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">covalent bonds</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">fake antigen</style></keyword><keyword><style face="normal" font="default" size="100%">hapten</style></keyword><keyword><style face="normal" font="default" size="100%">immediate drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">non-covalent bindings</style></keyword><keyword><style face="normal" font="default" size="100%">specific IgE</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32780486</style></accession-num><abstract><style face="normal" font="default" size="100%">Our understanding of IgE-mediated drug allergy relies on the hapten concept, which is well established in inducing adaptive reactions of the immune system to small molecules like drugs. The role of hapten-carrier adducts in re-challenge reactions leading to mast cell degranulation and anaphylaxis is unclear. Based on clinical observations, the speed of adduct formation, skin and in vitro tests to inert drug molecules, a different explanation of IgE-mediated reactions to drugs is proposed: These are (a) A natural role of reduced mast cell (MC) reactivity in developing IgE-mediated reactions to drugs. This MC unresponsiveness is antigen-specific and covers the serum drug concentrations, but allows reactivity to locally higher concentrations. (b) Some non-covalent drug-protein complexes rely on rather affine bindings and have a similar appearance as covalent hapten-protein adducts. Such drug-protein complexes represent so-called &quot;fake antigens,&quot; as they are unable to induce immunity, but may react with and cross-link preformed drug-specific IgE. As they are formed very rapidly and in high concentrations, they may cause fulminant MC degranulation and anaphylaxis. (c) The generation of covalent hapten-protein adducts requires hours, either because the formation of covalent bonds requires time or because first a metabolic step for forming a reactive metabolite is required. This slow process of stable adduct formation has the advantage that it may give time to desensitize mast cells, even in already sensitized individuals. The consequences of this new interpretation of IgE-mediated reactions to drugs are potentially wide-reaching for IgE-mediated drug allergy but also allergy in general.</style></abstract><notes><style face="normal" font="default" size="100%">Pichler, Werner J&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1340-1349. doi: 10.1111/all.14554. Epub 2020 Sep 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32780486</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8247404</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14554</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>979</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">979</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Krantz, M. S.</style></author><author><style face="normal" font="default" size="100%">Bruusgaard-Mouritsen, M. A.</style></author><author><style face="normal" font="default" size="100%">Koo, G.</style></author><author><style face="normal" font="default" size="100%">Phillips, E. J.</style></author><author><style face="normal" font="default" size="100%">Stone, C. A., Jr.</style></author><author><style face="normal" font="default" size="100%">Garvey, L. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.&#xD;Department of Dermatology and Allergy, Allergy Clinic, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.&#xD;Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don&apos;t give up on the second dose!</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2916-2920</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34028041</style></accession-num><notes><style face="normal" font="default" size="100%">Krantz, Matthew S&#xD;Bruusgaard-Mouritsen, Maria A&#xD;Koo, Grace&#xD;Phillips, Elizabeth J&#xD;Stone, Cosby A Jr&#xD;Garvey, Lene H&#xD;eng&#xD;K12 HS026395/HS/AHRQ HHS/&#xD;R01 HG010863/HG/NHGRI NIH HHS/&#xD;National Health and Medical Research Foundation of Australia/&#xD;R21 AI139021/AI/NIAID NIH HHS/&#xD;R21AI139021/NH/NIH HHS/&#xD;1P50GM115305-01/NH/NIH HHS/&#xD;1K12HS026395-01/HS/AHRQ HHS/&#xD;P50 GM115305/GM/NIGMS NIH HHS/&#xD;R34 AI136815/AI/NIAID NIH HHS/&#xD;1 R01 HG010863-01/NH/NIH HHS/&#xD;R34AI136815/NH/NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2916-2920. doi: 10.1111/all.14958. Epub 2021 Jun 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34028041</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8222898</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14958</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2555</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2555</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Voisin, T.</style></author><author><style face="normal" font="default" size="100%">Labit, E.</style></author><author><style face="normal" font="default" size="100%">Gaudenzio, N.</style></author><author><style face="normal" font="default" size="100%">Basso, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 - CNRS UMR5051, University Toulouse III, Toulouse, France.&#xD;Genoskin SAS, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anaplastic lymphoma kinase as a new therapeutic target in inflammatory itch</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3537-3539</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/07/26</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39056456</style></accession-num><notes><style face="normal" font="default" size="100%">Voisin, Tiphaine&#xD;Labit, Elodie&#xD;Gaudenzio, Nicolas&#xD;Basso, Lilian&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3537-3539. doi: 10.1111/all.16260. Epub 2024 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39056456</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657048 for Genoskin (CSO, shareholder), Escient Pharmaceuticals, Aikium, CEVA, MaxiVax, Boehringer Ingelheim, Novartis, Sanofi, ArgenX.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16260</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2849</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2849</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Haase, P.</style></author><author><style face="normal" font="default" size="100%">Perima, A.</style></author><author><style face="normal" font="default" size="100%">Ramnarayan, V. R.</style></author><author><style face="normal" font="default" size="100%">England, P.</style></author><author><style face="normal" font="default" size="100%">Iannascoli, B.</style></author><author><style face="normal" font="default" size="100%">Limnander, A.</style></author><author><style face="normal" font="default" size="100%">Asrat, S.</style></author><author><style face="normal" font="default" size="100%">Vecchione, A.</style></author><author><style face="normal" font="default" size="100%">Orengo, J. M.</style></author><author><style face="normal" font="default" size="100%">Sleeman, M. A.</style></author><author><style face="normal" font="default" size="100%">Bruhns, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit of Antibodies in Therapy and Pathology, Inserm UMR1222, Institut Pasteur, Universite de Paris, Paris, France.&#xD;Plateforme de Biophysique Moleculaire, Institut Pasteur, CNRS UMR3528, Paris, France.&#xD;Regeneron Pharmaceuticals, Tarrytown, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anatomical Distribution and Quantification of IgE Secretion in Mouse Models of House Dust Mite Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2059-2062</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/03/31 21:16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">b cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40162560</style></accession-num><notes><style face="normal" font="default" size="100%">Haase, Paul&#xD;Perima, Angga&#xD;Ramnarayan, Venkat Raman&#xD;England, Patrick&#xD;Iannascoli, Bruno&#xD;Limnander, Andre&#xD;Asrat, Seblewongel&#xD;Vecchione, Andrea&#xD;Orengo, Jamie M&#xD;Sleeman, Matthew A&#xD;Bruhns, Pierre&#xD;eng&#xD;Agence Nationale de la Recherche/&#xD;Fondation pour la Recherche Medicale/&#xD;Institut National de la Sante et de la Recherche Medicale/&#xD;Institut Pasteur/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2059-2062. doi: 10.1111/all.16546. Epub 2025 Mar 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40162560</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16546</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1455</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1455</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sanak, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Jagiellonian University Medical College, Krakow, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Andrew Szczeklik: From fine art, music and literature to front science</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3000-3002</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2020/03/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aspirin</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma, Aspirin-Induced</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Music</style></keyword><keyword><style face="normal" font="default" size="100%">Publications</style></keyword><keyword><style face="normal" font="default" size="100%">Aerd</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">challenge tests</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32171025</style></accession-num><notes><style face="normal" font="default" size="100%">Sanak, Marek&#xD;eng&#xD;Denmark&#xD;Allergy. 2020 Nov;75(11):3000-3002. doi: 10.1111/all.14274. Epub 2020 Apr 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32171025</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14274</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">25</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, P. H.</style></author><author><style face="normal" font="default" size="100%">Choi, S.</style></author><author><style face="normal" font="default" size="100%">An, M.</style></author><author><style face="normal" font="default" size="100%">Hwang, D.</style></author><author><style face="normal" font="default" size="100%">Park, S.</style></author><author><style face="normal" font="default" size="100%">Baek, A. R.</style></author><author><style face="normal" font="default" size="100%">Jang, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Angiomotin and angiostatin as asthma biomarkers: Implications for the regulation of airway remodeling and inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1674-1677</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Angiostatins</style></keyword><keyword><style face="normal" font="default" size="100%">Angiomotins</style></keyword><keyword><style face="normal" font="default" size="100%">Airway Remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">Microfilament Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Intercellular Signaling Peptides and Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36602260</style></accession-num><notes><style face="normal" font="default" size="100%">Lee, Pureun-Haneul&#xD;Choi, SeonMuk&#xD;An, MinHyeok&#xD;Hwang, DaYeon&#xD;Park, Shinhee&#xD;Baek, Ae Rin&#xD;Jang, An-Soo&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1674-1677. doi: 10.1111/all.15637. Epub 2023 Jan 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36602260</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15637</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1344</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1344</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Song, J.</style></author><author><style face="normal" font="default" size="100%">Yao, Y.</style></author><author><style face="normal" font="default" size="100%">Deng, Y. K.</style></author><author><style face="normal" font="default" size="100%">Wang, Z. C.</style></author><author><style face="normal" font="default" size="100%">Liao, B.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">He, C.</style></author><author><style face="normal" font="default" size="100%">Pan, L.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Xie, J. G.</style></author><author><style face="normal" font="default" size="100%">Zeng, M.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Key Laboratory of Respiratory Diseases of Ministry of Health, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Angiotensin-converting enzyme II expression and its implication in the association between COVID-19 and allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">906-910</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*enzymology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinitis, Allergic/complications/*enzymology/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">angiotensin-converting enzyme II</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus disease 2019</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32851645</style></accession-num><notes><style face="normal" font="default" size="100%">Wang, Hai&#xD;Song, Jia&#xD;Yao, Yin&#xD;Deng, Yi-Ke&#xD;Wang, Zhi-Chao&#xD;Liao, Bo&#xD;Ma, Jin&#xD;He, Chao&#xD;Pan, Li&#xD;Liu, Yang&#xD;Xie, Jun-Gang&#xD;Zeng, Ming&#xD;Liu, Zheng&#xD;eng&#xD;81630024/National Natural Science Foundation of China/&#xD;81920108011/National Natural Science Foundation of China/&#xD;81900925/National Natural Science Foundation of China/&#xD;2018CFB602/National Natural Science Foundation of China/&#xD;Natural Science Foundation of Hubei Province/&#xD;2018YFC0116800/National Key R&amp;amp;D Program/&#xD;2018YFC0116800/of China/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):906-910. doi: 10.1111/all.14569. Epub 2020 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32851645</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7461276</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14569</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1591</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1591</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Song, J.</style></author><author><style face="normal" font="default" size="100%">Yao, Y.</style></author><author><style face="normal" font="default" size="100%">Deng, Y. K.</style></author><author><style face="normal" font="default" size="100%">Wang, Z. C.</style></author><author><style face="normal" font="default" size="100%">Liao, B.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">He, C.</style></author><author><style face="normal" font="default" size="100%">Pan, L.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Xie, J. G.</style></author><author><style face="normal" font="default" size="100%">Zeng, M.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Key Laboratory of Respiratory Diseases of Ministry of Health, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Angiotensin-converting enzyme II expression and its implication in the association between COVID-19 and allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">906-910</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*enzymology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinitis, Allergic/complications/*enzymology/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">angiotensin-converting enzyme II</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus disease 2019</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32851645</style></accession-num><notes><style face="normal" font="default" size="100%">Wang, Hai&#xD;Song, Jia&#xD;Yao, Yin&#xD;Deng, Yi-Ke&#xD;Wang, Zhi-Chao&#xD;Liao, Bo&#xD;Ma, Jin&#xD;He, Chao&#xD;Pan, Li&#xD;Liu, Yang&#xD;Xie, Jun-Gang&#xD;Zeng, Ming&#xD;Liu, Zheng&#xD;eng&#xD;81630024/National Natural Science Foundation of China/&#xD;81920108011/National Natural Science Foundation of China/&#xD;81900925/National Natural Science Foundation of China/&#xD;2018CFB602/National Natural Science Foundation of China/&#xD;Natural Science Foundation of Hubei Province/&#xD;2018YFC0116800/National Key R&amp;amp;D Program/&#xD;2018YFC0116800/of China/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):906-910. doi: 10.1111/all.14569. Epub 2020 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32851645</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7461276</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14569</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3332</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3332</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Fang</style></author><author><style face="normal" font="default" size="100%">Sun, Shi-Ran</style></author><author><style face="normal" font="default" size="100%">Wu, Xing-Liang</style></author><author><style face="normal" font="default" size="100%">Ma, Jing-Yi</style></author><author><style face="normal" font="default" size="100%">Yu, Di</style></author><author><style face="normal" font="default" size="100%">Liu, Zheng</style></author><author><style face="normal" font="default" size="100%">Yao, Yin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Animal Models of Allergen Immunotherapy for Allergic Airway Inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Allergen immunotherapy (AIT) is currently the only disease-modifying therapy for allergic airway inflammation. However, its underlying mechanisms remain incompletely understood, which in turn impede the development of more effective and durable treatment strategies. Although animal models are indispensable for mechanistic dissection and therapeutic innovation, they are limited by significant translational gaps arising from fundamental interspecies immunological differences, variability in modeling protocols, and the frequent conflation of short-term desensitization with durable clinical tolerance. This review critically evaluates current animal models of AIT, particularly murine models, by systematically comparing their immunological parameters and treatment paradigms with human clinical pathophysiology. We analyze the effects of animal strain, allergen type, intervention timing, and administration route on the observed mechanisms of tolerance. Furthermore, we assess the utility of these models in optimizing next-generation strategies, including adjuvants and combination biologics. We conclude by proposing a conceptual framework to enhance translational relevance, emphasizing the need for standardized and clinically aligned protocols, integration of chronic and humanized models, and the synergistic use of emerging technologies such as organoids and artificial intelligence. This framework aims to guide the development of predictive preclinical models that can accelerate the rational design of novel AIT therapies.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70323</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70323</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2167</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2167</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Almeida, M. S.</style></author><author><style face="normal" font="default" size="100%">Tahara-Hanaoka, S.</style></author><author><style face="normal" font="default" size="100%">Shibagaki, S.</style></author><author><style face="normal" font="default" size="100%">Niizuma, K.</style></author><author><style face="normal" font="default" size="100%">Hitomi, K.</style></author><author><style face="normal" font="default" size="100%">Shinkai, Y.</style></author><author><style face="normal" font="default" size="100%">Shibayama, S.</style></author><author><style face="normal" font="default" size="100%">Shibuya, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.&#xD;R&amp;D Center for Innovative Drug Discovery, University of Tsukuba, Tsukuba, Japan.&#xD;Life Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance (TARA), Tsukuba, Japan.&#xD;Environmental Biology Laboratory, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.&#xD;Research Center of Immunology, Tsukuba Institute, ONO Pharmaceutical Company, Ltd., Tsukuba, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Annexin A5 inhibits mast cell activation via Allergin-1 immunoreceptor</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3258-3260</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/08/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Annexin A5</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Apoptosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37568278</style></accession-num><notes><style face="normal" font="default" size="100%">Almeida, Mariana Silva&#xD;Tahara-Hanaoka, Satoko&#xD;Shibagaki, Shohei&#xD;Niizuma, Kouta&#xD;Hitomi, Kaori&#xD;Shinkai, Yasuhiro&#xD;Shibayama, Shiro&#xD;Shibuya, Akira&#xD;eng&#xD;Japan Society for the Promotion of Science (KAKENHI)/&#xD;Ono Pharmaceutical/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3258-3260. doi: 10.1111/all.15851. Epub 2023 Aug 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37568278</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15851</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1989</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1989</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sethi, G. S.</style></author><author><style face="normal" font="default" size="100%">Gracias, D. T.</style></author><author><style face="normal" font="default" size="100%">Gupta, R. K.</style></author><author><style face="normal" font="default" size="100%">Carr, D.</style></author><author><style face="normal" font="default" size="100%">Miki, H.</style></author><author><style face="normal" font="default" size="100%">Da Silva Antunes, R.</style></author><author><style face="normal" font="default" size="100%">Croft, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.&#xD;Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.&#xD;Department of Medicine, University of California San Diego, La Jolla, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-CD3 inhibits circulatory and tissue-resident memory CD4 T cells that drive asthma exacerbations in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2168-2180</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/03/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Memory T Cells</style></keyword><keyword><style face="normal" font="default" size="100%">CD4-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">anti-CD3</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">circulatory memory T cells</style></keyword><keyword><style face="normal" font="default" size="100%">tissue-resident memory T cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36951658</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Exacerbations of asthma are thought to be strongly dependent on reactivation of allergen-induced lung tissue-resident and circulatory memory CD4 T cells. Strategies that broadly inhibit multiple T cell populations might then be useful to limit asthma. Accordingly, we tested whether targeting CD3 during exposure to inhaled allergen could prevent the accumulation of lung-localized effector memory CD4 T cells and block exacerbations of asthmatic inflammation. METHODS: House dust mite-sensitized and repetitively challenged BL/6 mice were transiently treated therapeutically with F(ab&apos;)2 anti-CD3epsilon and memory T cell responses and lung inflammation were assessed. PBMCs from HDM-allergic donors were examined for the effect of anti-CD3 on expansion of allergen-reactive T cells. RESULTS: Allergen-sensitized mice undergoing exacerbations of asthma were protected from lung inflammation by transient therapeutic treatment with F(ab&apos;)2 anti-CD3. Regardless of whether sensitized mice underwent a secondary or tertiary recall response to inhaled allergen, anti-CD3 inhibited all phenotypes of effector memory CD4 T cells in the lung tissue and lung vasculature by 80%-90%, including those derived from tissue-resident and circulatory memory T cells. This did not depend on Treg cells suggesting it was primarily a blocking effect on memory T cell signaling. Correspondingly, anti-CD3 also strongly inhibited proliferation of human allergen-reactive memory CD4 T cells from allergic individuals. In contrast, the number of surviving tissue-resident memory CD4 T cells that were maintained in the lungs at later times was not robustly reduced by anti-CD3. CONCLUSION: Anti-CD3 F(ab&apos;)2 administration at the time of allergen exposure represents a viable strategy for limiting the immediate activity of allergen-responding memory T cells and asthma exacerbations.</style></abstract><notes><style face="normal" font="default" size="100%">Sethi, Gurupreet S&#xD;Gracias, Donald T&#xD;Gupta, Rinkesh K&#xD;Carr, Daniel&#xD;Miki, Haruka&#xD;Da Silva Antunes, Ricardo&#xD;Croft, Michael&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2168-2180. doi: 10.1111/all.15722. Epub 2023 Apr 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36951658</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15722</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>578</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">578</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Worrall, W. P. M.</style></author><author><style face="normal" font="default" size="100%">Kamphuis, J. B. J.</style></author><author><style face="normal" font="default" size="100%">Stackowicz, J.</style></author><author><style face="normal" font="default" size="100%">Mougel, A.</style></author><author><style face="normal" font="default" size="100%">Maure, E.</style></author><author><style face="normal" font="default" size="100%">Pecalvel, C.</style></author><author><style face="normal" font="default" size="100%">Brule, S.</style></author><author><style face="normal" font="default" size="100%">Bruhns, P.</style></author><author><style face="normal" font="default" size="100%">Guilleminault, L.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), UMR 1291, University of Toulouse, INSERM, CNRS, Toulouse, France.&#xD;Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Universite de Paris, Inserm UMR1222, Paris, France.&#xD;Sorbonne University, Paris, France.&#xD;Plateforme de Biophysique Moleculaire, Institut Pasteur, Universite de Paris, UMR 3528 CNRS, Paris, France.&#xD;Department of Respiratory Medicine, University Hospital Centre of Toulouse, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The anti-FcepsilonRI antibody MAR-1 depletes basophils and cross-reacts with myeloid cells through its Fc portion</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1903-1906</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/03/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Degranulation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, IgE</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35244223</style></accession-num><notes><style face="normal" font="default" size="100%">Worrall, William P M&#xD;Kamphuis, Jasper B J&#xD;Stackowicz, Julien&#xD;Mougel, Aurelie&#xD;Maure, Emilie&#xD;Pecalvel, Cyprien&#xD;Brule, Sebastien&#xD;Bruhns, Pierre&#xD;Guilleminault, Laurent&#xD;Reber, Laurent L&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1903-1906. doi: 10.1111/all.15269. Epub 2022 Mar 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35244223</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15269</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2205</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2205</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, B. Y.</style></author><author><style face="normal" font="default" size="100%">Yang, E. M.</style></author><author><style face="normal" font="default" size="100%">Jung, H. W.</style></author><author><style face="normal" font="default" size="100%">Shin, M. K.</style></author><author><style face="normal" font="default" size="100%">Jo, J.</style></author><author><style face="normal" font="default" size="100%">Cha, H. Y.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author><author><style face="normal" font="default" size="100%">Kang, H. C.</style></author><author><style face="normal" font="default" size="100%">Ye, Y. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea.&#xD;Department of Pharmacology, Ajou University School of Medicine, Suwon, South Korea.&#xD;Center for Convergence Research of Neurological Disorders, Ajou University School of Medicine, Suwon, South Korea.&#xD;Department of Physiology, Ajou University School of Medicine, Suwon, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-heat shock protein 10 IgG in chronic spontaneous urticaria: Relation with miRNA-101-5p and platelet-activating factor</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3166-3177</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/07/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Activating Factor</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Autoantibodies</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Hsp10</style></keyword><keyword><style face="normal" font="default" size="100%">Interlukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">anti-HSP10 antibody</style></keyword><keyword><style face="normal" font="default" size="100%">degranulation</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">microRNA</style></keyword><keyword><style face="normal" font="default" size="100%">platelet-activating factor</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37415527</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Anti-heat shock protein (HSP) autoantibodies are detected in autoimmune diseases. We sought to ascertain whether anti-HSP10 IgG is present in patients with CSU and to elucidate the role of HSP10 in CSU pathogenesis. METHOD: Using a human proteome microarray, six potential autoantibodies had higher expression in 10 CSU samples compared with 10 normal controls (NCs). Among them, HSP10 IgG autoantibody was quantified by immune dot-blot assay in sera from 86 CSU patients and 44 NCs. The serum levels of HSP10 and microRNA-101-5p were measured in CSU patients and NCs. The effects of HSP10 and miR-101-5p on mast cell degranulation in response to IgE, compound 48/80, and platelet-activating factor (PAF) were investigated. RESULTS: CSU patients had higher IgG positivity to HSP10 (40.7% vs. 11.4%, p = .001), lower serum HSP10 levels (5.8 +/- 3.6 vs. 12.2 +/- 6.6 pg/mL, p &lt; .001) than in NCs, and their urticaria severity was associated with anti-HSP10 IgG positivity, while HSP10 levels were related to urticaria control status. MiR-101-5p was increased in CSU patients. PAF enhanced IL4 production in PBMCs from CSU patients. IL-4 upregulated miR-101-5p and reduced HSP10 expression in keratinocytes. Transfection of miR-101-5p reduced HSP10 expression in keratinocytes. MiR-101-5p promoted PAF-induced mast cell degranulation, while HSP10 specifically prevented it. CONCLUSION: A new autoantibody, anti-HSP10 IgG was detected in CSU patients, which showed a significant correlation with UAS7 scores. A decreased serum HSP10 level was associated with upregulation of miR-101-5p due to increased IL-4 and PAF in CSU patients. Modulation of miR-101-5p and HSP10 may be a novel therapeutic approach for CSU.</style></abstract><notes><style face="normal" font="default" size="100%">Choi, Bo Youn&#xD;Yang, Eun-Mi&#xD;Jung, Hae-Won&#xD;Shin, Min-Kyoung&#xD;Jo, Junghyun&#xD;Cha, Hyun-Young&#xD;Park, Hae-Sim&#xD;Kang, Ho-Chul&#xD;Ye, Young-Min&#xD;eng&#xD;HR16C0001/Korea Health Technology R&amp;amp;D Project/&#xD;NRF-2018R1A2B6006199/National Research Foundation of Korea/&#xD;NRF-2022R1A2C2006607/National Research Foundation of Korea/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3166-3177. doi: 10.1111/all.15810. Epub 2023 Jul 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37415527</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15810</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3030</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3030</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jebbawi, F.</style></author><author><style face="normal" font="default" size="100%">Olomski, F.</style></author><author><style face="normal" font="default" size="100%">Inversini, V.</style></author><author><style face="normal" font="default" size="100%">Keller, G.</style></author><author><style face="normal" font="default" size="100%">Rhiner, T.</style></author><author><style face="normal" font="default" size="100%">Waldern, N.</style></author><author><style face="normal" font="default" size="100%">Lam, J.</style></author><author><style face="normal" font="default" size="100%">Pantelyushin, S.</style></author><author><style face="normal" font="default" size="100%">Canonica, F.</style></author><author><style face="normal" font="default" size="100%">Birkmann, K.</style></author><author><style face="normal" font="default" size="100%">Johansen, P.</style></author><author><style face="normal" font="default" size="100%">Kundig, T. M.</style></author><author><style face="normal" font="default" size="100%">Fettelschoss-Gabriel, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, University Hospital Zurich, Schlieren, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Evax AG, Guntershausen, Switzerland.&#xD;Equine Department, Veterinary Faculty, Ludwig Maximilians University Munich LMU, Oberschleissheim, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-IL-5 Vaccination Dampens Allergen-Specific IgE Levels and Modulates IL-4 and IL-5 Th2 Cytokines in Skin Allergy of Mice and Horses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3377-3390</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/08/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Horses</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-5/immunology/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-4/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Horse Diseases/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Insect Bites and Stings/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Il-4</style></keyword><keyword><style face="normal" font="default" size="100%">Il-5</style></keyword><keyword><style face="normal" font="default" size="100%">IgE allergen-specific</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">equine</style></keyword><keyword><style face="normal" font="default" size="100%">insect bite hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">in the development of therapeutic equine vaccines. F.O., S.P., and P.J. have no</style></keyword><keyword><style face="normal" font="default" size="100%">financial or personal conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40838325</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Skin allergies are among the most frequent types of allergies, where continuous investigation of the pathological immune mechanisms is required for a better understanding and a more effective treatment of the disease. In this study, we aimed to investigate the effect of interleukin (IL)-5 vaccination on allergen-specific IgE antibodies as well as T cell cytokine modulation in skin allergy using a mouse model and a naturally occurring disease in horses. METHODS: Ovalbumin (OVA)-sensitized mice, as well as horses affected by equine insect bite hypersensitivity (IBH) were administered an anti-IL-5 vaccination, and allergen-specific IgE and IgG were quantified in the blood. Additionally, mRNA and protein expression of T cell cytokines of in vitro allergen re-stimulated murine splenocytes and equine peripheral blood mononuclear cells (PBMCs), as well as in IBH lesional skin biopsies, were investigated using qPCR and ELISA. Clinical signs were recorded by ear swelling in mice. RESULTS: Our data showed a significant decrease in allergen-specific immunoglobulins (Igs) in IL-5-vaccinated mice, as well as a reduction in allergen-specific IgE in horses. Furthermore, protein production of T cell cytokines IL-4 and IFNgamma in mice, as well as mRNA expression of IL-4, IL-5, IL-13, and IFNgamma in lesional skin of the horses, was significantly decreased upon vaccination when compared to the placebo group. Furthermore, we demonstrated that CD4(+) cells in IBH-affected horses are highly enriched with the GATA3 transcription factor, responsible for IL-5 mRNA production and differentiation of Th2 cells. Additionally, increased IL-4 mRNA expression in IBH horses was shown to be CD4(-)MHC-II(-)cell dependent. CONCLUSION: IL-5 vaccination significantly decreased allergen-specific IgE in both the murine skin allergy model and horses with naturally occurring allergic skin disease, as well as alleviated clinical signs of the diseases. We suggest that the IL-5 depletion may modulate the IL-4 levels originating from non-T cell sources. This is the first study showing that an IL-5 vaccination leads to a decrease in allergen-specific IgE levels, potentially suggesting its use in prophylactic settings for high-risk patients.</style></abstract><notes><style face="normal" font="default" size="100%">Jebbawi, Fadi&#xD;Olomski, Florian&#xD;Inversini, Victoria&#xD;Keller, Giulia&#xD;Rhiner, Tanya&#xD;Waldern, Nina&#xD;Lam, Juwela&#xD;Pantelyushin, Stanislav&#xD;Canonica, Fabia&#xD;Birkmann, Katharina&#xD;Johansen, Pal&#xD;Kundig, Thomas M&#xD;Fettelschoss-Gabriel, Antonia&#xD;eng&#xD;EVAX AG (CH)/&#xD;Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;Kommission fur Technologie und Innovation (KTI)/&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3377-3390. doi: 10.1111/all.70020. Epub 2025 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40838325</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666748</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70020</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3120</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3120</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mougel, A.</style></author><author><style face="normal" font="default" size="100%">Lemdani, K.</style></author><author><style face="normal" font="default" size="100%">Serhan, N.</style></author><author><style face="normal" font="default" size="100%">Hateb, C.</style></author><author><style face="normal" font="default" size="100%">Bonnefoy, J.</style></author><author><style face="normal" font="default" size="100%">Hamdi, S.</style></author><author><style face="normal" font="default" size="100%">Worrall, W. P. M.</style></author><author><style face="normal" font="default" size="100%">Kamphuis, J. B. J.</style></author><author><style face="normal" font="default" size="100%">Andrieux, L.</style></author><author><style face="normal" font="default" size="100%">Colaone, F.</style></author><author><style face="normal" font="default" size="100%">Vieira, R.</style></author><author><style face="normal" font="default" size="100%">Zahm, M.</style></author><author><style face="normal" font="default" size="100%">Chaubet, A.</style></author><author><style face="normal" font="default" size="100%">Lachambre, S.</style></author><author><style face="normal" font="default" size="100%">Ekren, R.</style></author><author><style face="normal" font="default" size="100%">Leveque, E.</style></author><author><style face="normal" font="default" size="100%">Guilleminault, L.</style></author><author><style face="normal" font="default" size="100%">Gaudenzio, N.</style></author><author><style face="normal" font="default" size="100%">Drouet, B.</style></author><author><style face="normal" font="default" size="100%">Serra, V.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neovacs SA, Suresnes, France.&#xD;University of Toulouse, Infinity, Inserm, CNRS, Toulouse, France.&#xD;Department of Respiratory Medicine, University Hospital Centre of Toulouse, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An Anti-IL-13 Vaccine Reduces Atopic Dermatitis in Humanized Mice and Induces Neutralizing Antibodies in Nonhuman Primates</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3465-3468</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">active immunization</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">antibody</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin</style></keyword><keyword><style face="normal" font="default" size="100%">(A1)) licensed to Neovacs. A.M., F.C., J.B., S.H., R.V., B.D., K.L., V.S, L.L.R.</style></keyword><keyword><style face="normal" font="default" size="100%">are employees of Neovacs and/or company stock owners. Outside of the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work, L.G. has been an investigator in clinical trials for AstraZeneca, Bayer,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, MSD, and Novartis, reports grants or fees for consulting from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GlaxoSmithKline, Novartis, and Sanofi-Regeneron, and fees for</style></keyword><keyword><style face="normal" font="default" size="100%">consulting from ALK, Bayer, Chiesi, and MSD. L.L.R. is or recently was a speaker</style></keyword><keyword><style face="normal" font="default" size="100%">and/or advisor for and/or has received research funding from Argenx, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Ceva, Merus, and CSL Behring. The other authors declare no competing interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41117068</style></accession-num><notes><style face="normal" font="default" size="100%">Mougel, Aurelie&#xD;Lemdani, Katia&#xD;Serhan, Nadine&#xD;Hateb, Charlotte&#xD;Bonnefoy, Jonathan&#xD;Hamdi, Samir&#xD;Worrall, William P M&#xD;Kamphuis, Jasper B J&#xD;Andrieux, Lena&#xD;Colaone, Fabien&#xD;Vieira, Remi&#xD;Zahm, Margot&#xD;Chaubet, Adeline&#xD;Lachambre, Simon&#xD;Ekren, Ruchan&#xD;Leveque, Edouard&#xD;Guilleminault, Laurent&#xD;Gaudenzio, Nicolas&#xD;Drouet, Beatrice&#xD;Serra, Vincent&#xD;Reber, Laurent L&#xD;eng&#xD;NEOVACS/&#xD;Agence Nationale de la Recherche/&#xD;Fondation pour la Recherche Medicale/&#xD;Institut National de la Sante et de la Recherche Medicale/&#xD;ERC_/European Research Council/International&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3465-3468. doi: 10.1111/all.70110. Epub 2025 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41117068</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666736</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70110</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>505</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">505</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shilovskiy, I.</style></author><author><style face="normal" font="default" size="100%">Nikonova, A.</style></author><author><style face="normal" font="default" size="100%">Barvinskaia, E.</style></author><author><style face="normal" font="default" size="100%">Kaganova, M.</style></author><author><style face="normal" font="default" size="100%">Nikolskii, A.</style></author><author><style face="normal" font="default" size="100%">Vishnyakova, L.</style></author><author><style face="normal" font="default" size="100%">Kovchina, V.</style></author><author><style face="normal" font="default" size="100%">Yumashev, K.</style></author><author><style face="normal" font="default" size="100%">Korneev, A.</style></author><author><style face="normal" font="default" size="100%">Petukhova, O.</style></author><author><style face="normal" font="default" size="100%">Kudlay, D.</style></author><author><style face="normal" font="default" size="100%">Smirnov, V.</style></author><author><style face="normal" font="default" size="100%">Andreev, S.</style></author><author><style face="normal" font="default" size="100%">Kozhikhova, K.</style></author><author><style face="normal" font="default" size="100%">Shatilov, A.</style></author><author><style face="normal" font="default" size="100%">Shatilova, A.</style></author><author><style face="normal" font="default" size="100%">Maerle, A.</style></author><author><style face="normal" font="default" size="100%">Sergeev, I.</style></author><author><style face="normal" font="default" size="100%">Trofimov, D.</style></author><author><style face="normal" font="default" size="100%">Khaitov, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">NRC Institute of Immunology FMBA, Moscow, Russia.&#xD;RUDN University, Moscow, Russia.&#xD;I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.&#xD;Pirogov Russian National Research Medical University, Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-inflammatory effect of siRNAs targeted il-4 and il-13 in a mouse model of allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2829-2832</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/05/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">Il-4</style></keyword><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">siRNA</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35538848</style></accession-num><notes><style face="normal" font="default" size="100%">Shilovskiy, Igor&#xD;Nikonova, Alexandra&#xD;Barvinskaia, Ekaterina&#xD;Kaganova, Mariya&#xD;Nikolskii, Aleksandr&#xD;Vishnyakova, Lyudmila&#xD;Kovchina, Valeriia&#xD;Yumashev, Kirill&#xD;Korneev, Artem&#xD;Petukhova, Olga&#xD;Kudlay, Dmitry&#xD;Smirnov, Valeriy&#xD;Andreev, Sergey&#xD;Kozhikhova, Ksenia&#xD;Shatilov, Artem&#xD;Shatilova, Anastasiia&#xD;Maerle, Artem&#xD;Sergeev, Ilya&#xD;Trofimov, Dmitry&#xD;Khaitov, Musa&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2829-2832. doi: 10.1111/all.15366. Epub 2022 May 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35538848</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15366</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>87</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">87</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Terhorst-Molawi, D.</style></author><author><style face="normal" font="default" size="100%">Hawro, T.</style></author><author><style face="normal" font="default" size="100%">Grekowitz, E.</style></author><author><style face="normal" font="default" size="100%">Kiefer, L.</style></author><author><style face="normal" font="default" size="100%">Merchant, K.</style></author><author><style face="normal" font="default" size="100%">Alvarado, D.</style></author><author><style face="normal" font="default" size="100%">Thomas, L. J.</style></author><author><style face="normal" font="default" size="100%">Hawthorne, T.</style></author><author><style face="normal" font="default" size="100%">Crowley, E.</style></author><author><style face="normal" font="default" size="100%">Heath-Chiozzi, M.</style></author><author><style face="normal" font="default" size="100%">Metz, M.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Department of Dermatology, Allergology and Venereology, Institute and Comprehensive Center for Inflammation Medicine, University Medical Center Schleswig-Holstein, Lubeck, Germany.&#xD;Celldex Therapeutics, Hampton, New Jersey, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1269-1279</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/11/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Inducible Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptases</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-kit</style></keyword><keyword><style face="normal" font="default" size="100%">Cdx-0159</style></keyword><keyword><style face="normal" font="default" size="100%">barzolvolimab</style></keyword><keyword><style face="normal" font="default" size="100%">cold urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">symptomatic dermographism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36385701</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chronic inducible urticaria (CIndU) is characterized by mast cell (MC)-mediated wheals in response to triggers: cold in cold urticaria (ColdU) and friction in symptomatic dermographism (SD). KIT receptor activation by stem cell factor (SCF) is essential for MC function. Barzolvolimab (CDX-0159) is a humanized antibody that inhibits KIT activation by SCF and was well tolerated in healthy volunteers with dose-dependent plasma tryptase suppression indicative of systemic mast cell ablation. METHODS: This is an open-label, trial in patients with antihistamine refractory ColdU or SD, receiving one IV dose of barzolvolimab (3 mg/kg), with a 12-week follow-up. Primary endpoint was safety/tolerability; pharmacodynamic (PD)/clinical endpoints included serum tryptase, plasma SCF, skin MC histology, provocation tests, urticaria control test (UCT), and dermatology life quality index (DLQI). RESULTS: Analysis populations were safety (n = 21) and pharmacodynamics/clinical activity (n = 20). Barzolvolimab was well tolerated; most adverse events were mild and resolved. Treatment resulted in significant depletion of skin MCs, decreased tryptase (&lt;limit of detection), and increased soluble SCF through Week 12. Complete responses (negative provocation test) occurred in 95% (n = 19/20) of patients (n = 10/10 ColdU; n = 9/10 SD), and all (n = 20/20) showed improvement in urticaria control (UCT &gt;/= 12). The kinetics of clinical activity mirrored that of MC and tryptase reduction. DLQI-measured impairment significantly decreased to minimal/none in 93% of patients on study. CONCLUSION: In CIndU patients, barzolvolimab was well tolerated, demonstrated marked, rapid, durable depletion of skin MCs, circulating tryptase, and reductions in clinical activity with significant improvements in disease control and quality of life (QoL) demonstrating potential therapeutic effects for MC-mediated disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Terhorst-Molawi, Dorothea&#xD;Hawro, Tomasz&#xD;Grekowitz, Eva&#xD;Kiefer, Lea&#xD;Merchant, Kunal&#xD;Alvarado, Diego&#xD;Thomas, Lawrence J&#xD;Hawthorne, Thomas&#xD;Crowley, Elizabeth&#xD;Heath-Chiozzi, Margo&#xD;Metz, Martin&#xD;Maurer, Marcus&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1269-1279. doi: 10.1111/all.15585. Epub 2022 Dec 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36385701</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15585</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2892</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2892</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Metz, M.</style></author><author><style face="normal" font="default" size="100%">Anderson, J.</style></author><author><style face="normal" font="default" size="100%">Talreja, N.</style></author><author><style face="normal" font="default" size="100%">Young, D.</style></author><author><style face="normal" font="default" size="100%">Crowley, E.</style></author><author><style face="normal" font="default" size="100%">Heath-Chiozzi, M.</style></author><author><style face="normal" font="default" size="100%">Ma, R.</style></author><author><style face="normal" font="default" size="100%">Paradise, E.</style></author><author><style face="normal" font="default" size="100%">Hawthorne, T.</style></author><author><style face="normal" font="default" size="100%">Alvarado, D.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology, Immunology and Allergology, Berlin, Germany.&#xD;Clinical Research Center of Alabama, AllerVie Health, University of Alabama, Birmingham, and VA Medical Center, Birmingham, Alabama, USA.&#xD;The Allergy Group and Treasure Valley Medical Research, Boise, Idaho, USA.&#xD;Celldex Therapeutics, Hampton, New Jersey, USA.&#xD;University of Cincinnati, Cincinnati, Ohio, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-KIT Barzolvolimab for Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2178-2186</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/05/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Proto-Oncogene Proteins c-kit/antagonists &amp; inhibitors/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">anti-KIT</style></keyword><keyword><style face="normal" font="default" size="100%">chronic urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">hives</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">monoclonal antibody</style></keyword><keyword><style face="normal" font="default" size="100%">stem cell factor</style></keyword><keyword><style face="normal" font="default" size="100%">Hawthorne, and Margo Heath-Chiozzi are full-time employees of Celldex</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics and may hold stock and/or stock options. Martin Metz reports being a</style></keyword><keyword><style face="normal" font="default" size="100%">speaker and/or advisor for AbbVie, Advanz, ALK Abello, Allegria, Almirall, Amgen,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Argenx, Astria, Attovia, Berlin-Chemie, Celldex, Celltrion,</style></keyword><keyword><style face="normal" font="default" size="100%">DeepApple, Escient, Galderma, GSK, Incyte, Jasper, Lilly, Novartis, Pfizer,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Sanofi, Santa Ana Bio, Septerna, Teva, ThirdHarmonic Bio, and Vifor.</style></keyword><keyword><style face="normal" font="default" size="100%">John Anderson is a speaker bureau member for CSL Behring, Pharming, BioCryst,</style></keyword><keyword><style face="normal" font="default" size="100%">Takeda, AstraZeneca, and GSK</style></keyword><keyword><style face="normal" font="default" size="100%">has received consulting fees from CSL Behring,</style></keyword><keyword><style face="normal" font="default" size="100%">Pharming, BioCryst, Pharvaris, Ionis, Takeda, and Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">and is a clinical</style></keyword><keyword><style face="normal" font="default" size="100%">trial investigator for BioCryst, CSL Behring, Pharvaris, Kalvista, Biomarin,</style></keyword><keyword><style face="normal" font="default" size="100%">Astria, Takeda, Novartis, and Celldex. Neetu Talreja has been an investigator for</style></keyword><keyword><style face="normal" font="default" size="100%">9Meters, AbbVie, Allakos, Amgen, Anaptybio Inc., Arena, ARS, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Biohaven, Braintree, Celldex, Eli Lilly, Escient, GlaxoSmithKline, Gossamer,</style></keyword><keyword><style face="normal" font="default" size="100%">Incyte, Janssen, Knopp, Nerre, Novartis, Pearl Therapeutics, Pfizer, Phathom,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Sanofi, Teva, and Upstream. She has also sat on advisory board(s) and</style></keyword><keyword><style face="normal" font="default" size="100%">been a medical consultant for Celldex, Novartis, and Regeneron. Jonathan A.</style></keyword><keyword><style face="normal" font="default" size="100%">Bernstein has been a PI, consultant, and speaker for Novartis, Genentech,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Sanofi, Regeneron, BioCryst, CSL Behring, Takeda/Shire, Pharming,</style></keyword><keyword><style face="normal" font="default" size="100%">and GSK</style></keyword><keyword><style face="normal" font="default" size="100%">PI and consultant for Celldex, Cogent, Escient, Jasper, Amgen, Roche,</style></keyword><keyword><style face="normal" font="default" size="100%">Ionis, Kalvista, Allakos, Biomarin, and Blueprint Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">PI for Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Telios, Intellia, Aretrea, Pharvaris, Astria</style></keyword><keyword><style face="normal" font="default" size="100%">PI for Teva</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">consultant for Incyte, Astria, ONO, Cycle, Escient, Pharvaris, and TLL.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40415544</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chronic spontaneous urticaria (CSU) is characterized by mast cell (MC)-mediated wheals and/or angioedema without identifiable triggers and is driven by MC activation. Barzolvolimab-a monoclonal anti-KIT antibody-depletes MCs by inhibiting activation of KIT by stem cell factor. We evaluated multiple ascending doses in patients with CSU. METHODS: Phase 1b double-blind placebo-controlled trial (NCT04538794) in adults with moderate-to-severe (urticaria activity score over 7 days [UAS7] &gt;/= 16) antihistamine-refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12-week follow-up in four sequentially enrolled cohorts (randomized 4:1 barzolvolimab:placebo): 0.5 mg/kg, Q4W (n = 9); 1.5 mg/kg, Q4W (n = 8); 3 mg/kg, Q8W (n = 9); and 4.5 mg/kg, Q8W (n = 9). Primary and secondary objectives were safety and disease activity (UAS7 and urticaria control test [UCT]). Pharmacokinetics and pharmacodynamics were assessed. RESULTS: Patients had high mean (range) baseline CSU activity, with UAS7 = 29.6 (16.3-42.0) for barzolvolimab-treated, UAS7 = 35.8 (19.0-42.0) for placebo-treated, and 44% prior omalizumab use. Multiple doses of barzolvolimab were well tolerated. Hair color change was the commonest adverse event in barzolvolimab-treated patients. Across barzolvolimab doses, rapid symptom reduction within 1 week was observed and sustained during 12 weeks; 71% of patients achieved a well-controlled (UAS7 &lt;/= 6) response and 57% a complete response (UAS7 = 0). Additionally, 77% of barzolvolimab-treated patients achieved a well-controlled response (UCT &gt;/= 12) and 43% a complete response (UCT = 16) by Week 12. The kinetics of disease activity paralleled tryptase suppression, indicative of MC inhibition. Patients with and without prior omalizumab treatment responded similarly. CONCLUSIONS: This study supports barzolvolimab as a promising treatment for CSU.</style></abstract><notes><style face="normal" font="default" size="100%">Maurer, Marcus&#xD;Metz, Martin&#xD;Anderson, John&#xD;Talreja, Neetu&#xD;Young, Diane&#xD;Crowley, Elizabeth&#xD;Heath-Chiozzi, Margo&#xD;Ma, Rick&#xD;Paradise, Elsa&#xD;Hawthorne, Thomas&#xD;Alvarado, Diego&#xD;Bernstein, Jonathan A&#xD;eng&#xD;Celldex Therapeutics/&#xD;Clinical Trial, Phase I&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2178-2186. doi: 10.1111/all.16598. Epub 2025 May 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40415544</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368744</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16598</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>586</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">586</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alvarado, D.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Gedrich, R.</style></author><author><style face="normal" font="default" size="100%">Seibel, S. B.</style></author><author><style face="normal" font="default" size="100%">Murphy, M. B.</style></author><author><style face="normal" font="default" size="100%">Crew, L.</style></author><author><style face="normal" font="default" size="100%">Goldstein, J.</style></author><author><style face="normal" font="default" size="100%">Crocker, A.</style></author><author><style face="normal" font="default" size="100%">Vitale, L. A.</style></author><author><style face="normal" font="default" size="100%">Morani, P. A.</style></author><author><style face="normal" font="default" size="100%">Thomas, L. J.</style></author><author><style face="normal" font="default" size="100%">Hawthorne, T. R.</style></author><author><style face="normal" font="default" size="100%">Keler, T.</style></author><author><style face="normal" font="default" size="100%">Young, D.</style></author><author><style face="normal" font="default" size="100%">Crowley, E.</style></author><author><style face="normal" font="default" size="100%">Kankam, M.</style></author><author><style face="normal" font="default" size="100%">Heath-Chiozzi, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Celldex Therapeutics, Hampton, New Jersey, USA.&#xD;Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite - Universtatsmedizin Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Altasciences Clinical Kansas, Overland Park, Kansas, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2393-2403</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/02/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal/adverse effects/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Healthy Volunteers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Proto-Oncogene Proteins c-kit/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Factor</style></keyword><keyword><style face="normal" font="default" size="100%">Cdx-0159</style></keyword><keyword><style face="normal" font="default" size="100%">Kit</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">monoclonal antibody</style></keyword><keyword><style face="normal" font="default" size="100%">employees of Celldex Therapeutics. SBS is a full-time employee of</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer-Ingelheim. MM reports grants and/or personal fees from Allakos, Amgen,</style></keyword><keyword><style face="normal" font="default" size="100%">Aralez, ArgenX, AstraZeneca, Celldex, Centogene, CSL Behring, FAES, Genentech,</style></keyword><keyword><style face="normal" font="default" size="100%">GIInnovation, Innate Pharma, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Roche, Sanofi/Regeneron, Third HarmonicBio, UCB, and Uriach. MK is a</style></keyword><keyword><style face="normal" font="default" size="100%">full-time employee of Altasciences, which has received research grant/funding</style></keyword><keyword><style face="normal" font="default" size="100%">(institution) from Actelion Pharmaceuticals, Acurx Pharmaceuticals, Bioxcel</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Grifols, Jazz Pharmaceuticals, Novus Therapeutics, Pfizer, DynPort</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccine Company, Novo Nordisk, FDA/NIH, and ViroDefense. MK holds a leadership</style></keyword><keyword><style face="normal" font="default" size="100%">role at Altasciences. JG and RG are inventors in patent applications No:</style></keyword><keyword><style face="normal" font="default" size="100%">63/140,642 and 63/140,621.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35184297</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Mast cells (MC) are powerful inflammatory immune sentinel cells that drive numerous allergic, inflammatory, and pruritic disorders when activated. MC-targeted therapies are approved in several disorders, yet many patients have limited benefit suggesting the need for approaches that more broadly inhibit MC activity. MCs require the KIT receptor and its ligand stem cell factor (SCF) for differentiation, maturation, and survival. Here we describe CDX-0159, an anti-KIT monoclonal antibody that potently suppresses MCs in human healthy volunteers. METHODS: CDX-0159-mediated KIT inhibition was tested in vitro using KIT-expressing immortalized cells and primary human mast cells. CDX-0159 safety and pharmacokinetics were evaluated in a 13-week good laboratory practice (GLP)-compliant cynomolgus macaque study. A single ascending dose (0.3, 1, 3, and 9 mg/kg), double-blinded placebo-controlled phase 1a human healthy volunteer study (n = 32) was conducted to evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX-0159. RESULTS: CDX-0159 inhibits SCF-dependent KIT activation in vitro. Fc modifications in CDX-0159 led to elimination of effector function and reduced serum clearance. In cynomolgus macaques, multiple high doses were safely administered without a significant impact on hematology, a potential concern for KIT inhibitors. A single dose of CDX-0159 in healthy human subjects was generally well tolerated and demonstrated long antibody exposure. Importantly, CDX-0159 led to dose-dependent, profound suppression of plasma tryptase, a MC-specific protease associated with tissue MC burden, indicative of systemic MC suppression or ablation. CONCLUSION: CDX-0159 administration leads to systemic mast cell ablation and may represent a safe and novel approach to treat mast cell-driven disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Alvarado, Diego&#xD;Maurer, Marcus&#xD;Gedrich, Richard&#xD;Seibel, Scott B&#xD;Murphy, Michael B&#xD;Crew, Linda&#xD;Goldstein, Joel&#xD;Crocker, Andrea&#xD;Vitale, Laura A&#xD;Morani, Pamela A&#xD;Thomas, Lawrence J&#xD;Hawthorne, Thomas R&#xD;Keler, Tibor&#xD;Young, Diane&#xD;Crowley, Elizabeth&#xD;Kankam, Martin&#xD;Heath-Chiozzi, Margo&#xD;eng&#xD;Clinical Trial, Phase I&#xD;Controlled Clinical Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2393-2403. doi: 10.1111/all.15262. Epub 2022 Mar 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35184297</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9544977</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15262</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2122</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2122</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grandits, M.</style></author><author><style face="normal" font="default" size="100%">Chauhan, J.</style></author><author><style face="normal" font="default" size="100%">Bax, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">St. John&apos;s Institute of Dermatology, School of Basic &amp; Medical Biosciences, King&apos;s College London, London, UK.&#xD;School of Cancer &amp; Pharmaceutical Sciences, King&apos;s College London, Guy&apos;s Hospital, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-PD1 therapy outcome can be predicted by pre-therapy IFN-I responsiveness of T(eff) cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2562-2564</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/04/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interferon Type I</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon-gamma</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">*Immune Checkpoint Inhibitors/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37119458</style></accession-num><notes><style face="normal" font="default" size="100%">Grandits, Melanie&#xD;Chauhan, Jitesh&#xD;Bax, Heather J&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2562-2564. doi: 10.1111/all.15756. Epub 2023 May 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37119458</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15756</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2581</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2581</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hollstein, M. M.</style></author><author><style face="normal" font="default" size="100%">Dierks, S.</style></author><author><style face="normal" font="default" size="100%">Schon, M. P.</style></author><author><style face="normal" font="default" size="100%">Gross, U.</style></author><author><style face="normal" font="default" size="100%">Thiele, K.</style></author><author><style face="normal" font="default" size="100%">Leha, A.</style></author><author><style face="normal" font="default" size="100%">Zautner, A. E.</style></author><author><style face="normal" font="default" size="100%">Fischer, A.</style></author><author><style face="normal" font="default" size="100%">Erpenbeck, L.</style></author><author><style face="normal" font="default" size="100%">Schnelle, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Venereology and Allergology, University Medical Center Gottingen, Gottingen, Germany.&#xD;Department of Clinical Chemistry, University Medical Center Gottingen, Gottingen, Germany.&#xD;Interdisciplinary UMG Laboratory, University Medical Center Gottingen, Gottingen, Germany.&#xD;Lower Saxony Institute of Occupational Dermatology, University Medical Center Gottingen, Gottingen, Germany.&#xD;Institute of Medical Microbiology and Virology, University Medical Center Gottingen, Gottingen, Germany.&#xD;Department of Medical Statistics, University Medical Center Gottingen, Gottingen, Germany.&#xD;Institute of Medical Microbiology and Hospital Hygiene, Medical Faculty, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.&#xD;Center for Health and Medical Prevention (CHaMP), Otto-von-Guericke University Magdeburg, Magdeburg, Germany.&#xD;Department of Dermatology, University of Munster, Munster, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-rubella IgG serum levels predict risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infections</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3154-3156</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/07/09</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38979807</style></accession-num><notes><style face="normal" font="default" size="100%">Hollstein, Moritz M&#xD;Dierks, Sascha&#xD;Schon, Michael P&#xD;Gross, Uwe&#xD;Thiele, Karin&#xD;Leha, Andreas&#xD;Zautner, Andreas E&#xD;Fischer, Andreas&#xD;Erpenbeck, Luise&#xD;Schnelle, Moritz&#xD;eng&#xD;ER723/3-1/German Research Foundation Deutsche Forschungsgemeinschaft/&#xD;TRR332/German Research Foundation Deutsche Forschungsgemeinschaft/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3154-3156. doi: 10.1111/all.16232. Epub 2024 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38979807</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16232</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2557</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2557</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buhre, J. S.</style></author><author><style face="normal" font="default" size="100%">Pongracz, T.</style></author><author><style face="normal" font="default" size="100%">Geisen, U. M.</style></author><author><style face="normal" font="default" size="100%">Schubert, M.</style></author><author><style face="normal" font="default" size="100%">Wang, W.</style></author><author><style face="normal" font="default" size="100%">Nouta, J.</style></author><author><style face="normal" font="default" size="100%">Obara, M.</style></author><author><style face="normal" font="default" size="100%">Lehrian, S.</style></author><author><style face="normal" font="default" size="100%">Rahmoller, J.</style></author><author><style face="normal" font="default" size="100%">Petry, J.</style></author><author><style face="normal" font="default" size="100%">Tran, F.</style></author><author><style face="normal" font="default" size="100%">Schreiber, S.</style></author><author><style face="normal" font="default" size="100%">Sumbul, M.</style></author><author><style face="normal" font="default" size="100%">Berner, D.</style></author><author><style face="normal" font="default" size="100%">Gerdes, S.</style></author><author><style face="normal" font="default" size="100%">Schirmer, J.</style></author><author><style face="normal" font="default" size="100%">Longardt, A. C.</style></author><author><style face="normal" font="default" size="100%">Hoff, P.</style></author><author><style face="normal" font="default" size="100%">Kalinke, U.</style></author><author><style face="normal" font="default" size="100%">Ludwig, R. J.</style></author><author><style face="normal" font="default" size="100%">Bartsch, Y. C.</style></author><author><style face="normal" font="default" size="100%">Hoyer, B. F.</style></author><author><style face="normal" font="default" size="100%">Wuhrer, M.</style></author><author><style face="normal" font="default" size="100%">Ehlers, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratories of Immunology and Antibody Glycan Analysis, Institute of Nutritional Medicine, University of Lubeck and University Medical Center Schleswig-Holstein, Lubeck, Germany.&#xD;Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.&#xD;Medical Department 1, Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein, Kiel, Germany.&#xD;Laboratory of Anti-viral antibody-omics, TWINCORE-Institute for Experimental Infection Research, Helmholtz Center for Infection Research (HZI) and Medical School Hannover (MHH), Hannover, Germany.&#xD;Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Hannover Medical School, Hannover, Germany.&#xD;Institute of Clinical Molecular Biology, Christian-Albrecht University of Kiel, Kiel, Germany.&#xD;Department for Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, Germany.&#xD;Department for Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany.&#xD;Department of Pediatrics, University Medical Center Schleswig-Holstein, Kiel, Germany.&#xD;Department of Rheumatology, Endokrinologikum-Gruppe, Berlin, Germany.&#xD;Lubeck Institute of Experimental Dermatology, University of Lubeck, Lubeck, Germany.&#xD;Department of Dermatology, University Medical Center Schleswig-Holstein, Lubeck, Germany.&#xD;Airway Research Center North (ARCN), University of Lubeck, German Center for Lung Research (DZL), Lubeck, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-TNF therapy impairs both short- and long-term IgG responses after repeated vaccination</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">423-439</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/07/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin G/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/prevention &amp; control/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Glycosylation</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">*Tumor Necrosis Factor Inhibitors/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Viral/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Tumor Necrosis Factor-alpha/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization, Secondary</style></keyword><keyword><style face="normal" font="default" size="100%">B-Lymphocytes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">IgG</style></keyword><keyword><style face="normal" font="default" size="100%">IgG glycosylation</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">TriNetX</style></keyword><keyword><style face="normal" font="default" size="100%">antibody</style></keyword><keyword><style face="normal" font="default" size="100%">anti-TNF treatment</style></keyword><keyword><style face="normal" font="default" size="100%">germinal center</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory diseases</style></keyword><keyword><style face="normal" font="default" size="100%">long-lived plasma cell</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">memory B cell</style></keyword><keyword><style face="normal" font="default" size="100%">short-lived plasma cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39049686</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Recently, it has been questioned whether vaccination of patients with inflammatory (auto)immune diseases under anti-tumor necrosis factor (TNF) treatment leads to impaired vaccine-induced immune responses and protection against breakthrough infections. However, the effects of TNF blockade on short- and long-term immune responses after repeated vaccination remain unclear. Vaccination studies have shown that initial short-term IgG antibodies (Abs) carry highly galactosylated and sialylated Fc glycans, whilst long-term IgG Abs have low levels of galactosylation and sialylation and are most likely generated by long-lived plasma cells (PCs) derived primarily from the germinal center (GC) response. Thus, IgG Fc glycosylation patterns may be applicable to distinguish short- and long-term vaccine responses after repeated vaccination under the influence of anti-TNF treatment. METHODS: We used COVID-19 vaccination as a model to investigate vaccine-induced IgG subclass levels and Fc glycosylation patterns, B cell subsets, and effector functions of short- and long-term Ab responses after up to three vaccinations in patients on anti-TNF or other immunosuppressive treatments and in healthy individuals. Using TriNetX, a global healthcare database, we determined the risk of SARS-CoV-2 breakthrough infections in vaccinated patients treated with anti-TNF or other immunosuppressive drugs. RESULTS: Anti-TNF treatment reduced the long-term abundance of all anti-S IgG subclasses with low levels of galactosylation and sialylation. Re-activation of potential memory B cells initially generated highly galactosylated and sialylated IgG antibodies, which were progressively reduced after each booster dose in anti-TNF-treated patients, especially in the elderly. The reduced short- and long-term IgG (1) levels in anti-TNF-treated patients correlated with diminished functional activity and an increased risk for the development of COVID-19. CONCLUSIONS: The data suggest that anti-TNF treatment reduces both GC-dependent long-lived PCs and GC-dependent memory B cell-derived short-lived PCs, hence both the long- and short-term IgG subclass responses, respectively, after repeated vaccination. We propose that anti-TNF therapy, especially in the elderly, reduces the benefit of booster vaccination.</style></abstract><notes><style face="normal" font="default" size="100%">Buhre, Jana Sophia&#xD;Pongracz, Tamas&#xD;Geisen, Ulf Martin&#xD;Schubert, Mareike&#xD;Wang, Wenjun&#xD;Nouta, Jan&#xD;Obara, Maureen&#xD;Lehrian, Selina&#xD;Rahmoller, Johann&#xD;Petry, Janina&#xD;Tran, Florian&#xD;Schreiber, Stefan&#xD;Sumbul, Melike&#xD;Berner, Dennis&#xD;Gerdes, Sascha&#xD;Schirmer, Jan&#xD;Longardt, Ann Carolin&#xD;Hoff, Paula&#xD;Kalinke, Ulrich&#xD;Ludwig, Ralf J&#xD;Bartsch, Yannic C&#xD;Hoyer, Bimba F&#xD;Wuhrer, Manfred&#xD;Ehlers, Marc&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):423-439. doi: 10.1111/all.16241. Epub 2024 Jul 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39049686</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804311</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16241</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1651</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1651</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alhasan, M. M.</style></author><author><style face="normal" font="default" size="100%">Cait, A. M.</style></author><author><style face="normal" font="default" size="100%">Heimesaat, M. M.</style></author><author><style face="normal" font="default" size="100%">Blaut, M.</style></author><author><style face="normal" font="default" size="100%">Klopfleisch, R.</style></author><author><style face="normal" font="default" size="100%">Wedel, A.</style></author><author><style face="normal" font="default" size="100%">Conlon, T. M.</style></author><author><style face="normal" font="default" size="100%">Yildirim, A. O.</style></author><author><style face="normal" font="default" size="100%">Sodemann, E. B.</style></author><author><style face="normal" font="default" size="100%">Mohn, W. W.</style></author><author><style face="normal" font="default" size="100%">Bereswill, S.</style></author><author><style face="normal" font="default" size="100%">Conrad, M. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Microbiology, Infectious Diseases and Immunology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health, Berlin, Germany.&#xD;Division of Psychosomatic Medicine, Department of Internal Medicine, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health, Berlin, Germany.&#xD;Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada.&#xD;Department of Gastrointestinal Microbiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.&#xD;Department of Veterinary Medicine, Freie Universitat Berlin, Berlin, Germany.&#xD;Department of Educational Psychology, Institute of Education, Technische Universitat Berlin, Berlin, Germany.&#xD;Comprehensive Pneumology Center (CPC), Institute of Lung Biology and Disease, Helmholtz Zentrum Munchen, Member of the German Center for Lung Research (DZL), Neuherberg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotic use during pregnancy increases offspring asthma severity in a dose-dependent manner</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1979-1990</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Ovalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">*Prenatal Exposure Delayed Effects</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">short-chain fatty acid</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32064643</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The use of antibiotics during pregnancy is associated with increased allergic asthma risk in the offspring, and given that approximately 25% of pregnant women are prescribed antibiotics, it is important to understand the mechanisms contributing to this phenomenon. Currently, there are no studies that directly test this association experimentally. Our objective was to develop a mouse model in which antibiotic treatment during pregnancy results in increased offspring asthma susceptibility. METHODS: Pregnant mice were treated daily from gestation day 8-17 with an oral solution of the antibiotic vancomycin, and three concentrations were tested. At weaning, offspring were subjected to an adjuvant-free experimental asthma protocol using ovalbumin as an allergen. The composition of the gut microbiome was determined in mothers and offspring with samples collected from five different time points; short-chain fatty acids were also analyzed in allergic offspring. RESULTS: We found that maternal antibiotic treatment during pregnancy was associated with increased offspring asthma severity in a dose-dependent manner. Furthermore, maternal vancomycin treatment during pregnancy caused marked changes in the gut microbiome composition in both mothers and pups at several different time points. The increased asthma severity and intestinal microbiome changes in pups were also associated with significantly decreased cecal short-chain fatty acid concentrations. CONCLUSION: Consistent with the &quot;Developmental Origins Hypothesis,&quot; our results confirm that exposure to antibiotics during pregnancy shapes the neonatal intestinal environment and increases offspring allergic lung inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Alhasan, Moumen M&#xD;Cait, Alissa M&#xD;Heimesaat, Markus M&#xD;Blaut, Michael&#xD;Klopfleisch, Robert&#xD;Wedel, Alexander&#xD;Conlon, Thomas M&#xD;Yildirim, Ali O&#xD;Sodemann, Elisa B&#xD;Mohn, William W&#xD;Bereswill, Stefan&#xD;Conrad, Melanie L&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Aug;75(8):1979-1990. doi: 10.1111/all.14234. Epub 2020 Mar 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32064643</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14234</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3132</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3132</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Redel, A. L.</style></author><author><style face="normal" font="default" size="100%">Feleszko, W.</style></author><author><style face="normal" font="default" size="100%">Atanaskovic-Markovic, M.</style></author><author><style face="normal" font="default" size="100%">Arcolaci, A.</style></author><author><style face="normal" font="default" size="100%">Beigelman, A.</style></author><author><style face="normal" font="default" size="100%">Boccabella, C.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Braunstahl, G. J.</style></author><author><style face="normal" font="default" size="100%">Cefaloni, F.</style></author><author><style face="normal" font="default" size="100%">Karavelia, A.</style></author><author><style face="normal" font="default" size="100%">Tramper-Stranders, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonology, Franciscus Gasthuis &amp; Vlietland, Rotterdam, the Netherlands.&#xD;Department of Pulmonology, Erasmus Medical Centre, Rotterdam, the Netherlands.&#xD;Department of Paediatric Allergy and Pneumonology, Medical University of Warsaw, Warsaw, Poland.&#xD;Faculty of Medicine, University of Belgrade, University Children&apos;s Hospital, Belgrade, Serbia.&#xD;Immunology Unit, University of Verona and General Hospital Borgo Roma Hospital, Verona, Italy.&#xD;Kipper Institute of Allergy and Immunology, Schneider Children&apos;s Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel.&#xD;Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;Department of Cardiovascular and Thoracic Sciences, Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.&#xD;National Heart and Lung Institute, Royal Brompton Hospital &amp; Imperial College London, London, UK.&#xD;Department of ear-Nose-Throat Surgery, General Hospital of Nafplio, Nafplio, Greece.&#xD;Department of Pediatrics, Franciscus Gasthuis &amp; Vlietland, Rotterdam, the Netherlands.&#xD;Department of Paediatrics, Division of Neonatal and Paediatric Intensive Care, Erasmus University Medical Centre - Sophia Children&apos;s Hospital, Rotterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotics for Acute Wheezing and Asthma Exacerbations: An EAACI Position Paper and Systematic Review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3237-3250</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/10/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Bacterial Agents/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Sounds/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41078060</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Antibiotics are frequently prescribed in preschool wheezing episodes and acute asthma exacerbations (AAEs), even though antibiotics are not recommended as standard AAE treatment. OBJECTIVE: To systematically present relevant literature about the clinical effects of antibiotics for AAE and conclude with recommendations. METHODS: Systematic search was conducted in Medline ALL, Embase, Web of Science Core Collection, and Cochrane Central Register of Controlled Trials. Primary outcomes included AAE duration and length of hospital stay, while secondary outcomes incorporated AAE severity, treatment failure, AAE recurrence risk, spirometry, health costs, and adverse events. SELECTION CRITERIA: Randomised controlled trials and cohort studies were included if they investigated the clinical effect of antibiotics in AAE compared to placebo/standard care. RESULTS: Fifteen studies were included. Evidence for clinical effects of antibiotics in AAE treatment is scarce. Macrolides seem to shorten AAE duration in children; for adults, there is a lack of data. Antibiotics were associated with a longer hospital admission in retrospective observational studies, without evidence in randomised trials. Procalcitonin-guided treatment led to a reduction of antibiotic prescriptions without adverse outcomes. CONCLUSION: Limited evidence is available that macrolides shorten AAE duration in preschool wheezers. For other age groups, there is no clear evidence of beneficial effects of antibiotics.</style></abstract><notes><style face="normal" font="default" size="100%">Redel, Anne-Lotte&#xD;Feleszko, Wojciech&#xD;Atanaskovic-Markovic, Marina&#xD;Arcolaci, Alessandra&#xD;Beigelman, Avraham&#xD;Boccabella, Cristina&#xD;Bonini, Matteo&#xD;Braunstahl, Gert-Jan&#xD;Cefaloni, Francesca&#xD;Karavelia, Aspasia&#xD;Tramper-Stranders, Gerdien&#xD;eng&#xD;EAACI Funding/&#xD;Consensus Development Conference&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3237-3250. doi: 10.1111/all.70091. Epub 2025 Oct 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41078060</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70091</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2264</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2264</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Libera, D. D.</style></author><author><style face="normal" font="default" size="100%">Fortier, S.</style></author><author><style face="normal" font="default" size="100%">Koenig, J. F. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Clinical Immunology and Allergy, Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.&#xD;McMaster Immunology Research Centre, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.&#xD;Schroeder Allergy and Immunology Research Institute, Faculty of Health Sciences, McMaster University, Ontario, Hamilton, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antigens localized to B-cell follicles are protected from proteases: Implications for allergy and allergen immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">537-539</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/10/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peptide Hydrolases</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37861065</style></accession-num><notes><style face="normal" font="default" size="100%">Libera, Danielle Della&#xD;Fortier, Sara&#xD;Koenig, Joshua F E&#xD;eng&#xD;ALK Abello/&#xD;Food Allergy Canada/&#xD;Schroeder Foundation/&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):537-539. doi: 10.1111/all.15928. Epub 2023 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37861065</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15928</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2293</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2293</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Libera, D. D.</style></author><author><style face="normal" font="default" size="100%">Fortier, S.</style></author><author><style face="normal" font="default" size="100%">Koenig, J. F. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Clinical Immunology and Allergy, Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.&#xD;McMaster Immunology Research Centre, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.&#xD;Schroeder Allergy and Immunology Research Institute, Faculty of Health Sciences, McMaster University, Ontario, Hamilton, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antigens localized to B-cell follicles are protected from proteases: Implications for allergy and allergen immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">537-539</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/10/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peptide Hydrolases</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37861065</style></accession-num><notes><style face="normal" font="default" size="100%">Libera, Danielle Della&#xD;Fortier, Sara&#xD;Koenig, Joshua F E&#xD;eng&#xD;ALK Abello/&#xD;Food Allergy Canada/&#xD;Schroeder Foundation/&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):537-539. doi: 10.1111/all.15928. Epub 2023 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37861065</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15928</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>856</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">856</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leonardi, A.</style></author><author><style face="normal" font="default" size="100%">Rosani, U.</style></author><author><style face="normal" font="default" size="100%">Cavarzeran, F.</style></author><author><style face="normal" font="default" size="100%">Daull, P.</style></author><author><style face="normal" font="default" size="100%">Garrigue, J. S.</style></author><author><style face="normal" font="default" size="100%">Paola, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroscience, Ophthalmology Unit, University of Padua, Padova, Italy.&#xD;Department of Biology, University of Padova, Padova, Italy.&#xD;Santen SAS, Evry, France.&#xD;Department of Molecular Medicine, Histology Unit, University of Padova, Padova, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antiviral response in vernal keratoconjunctivitis may be protective against COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">298-300</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/08/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antiviral Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Peptidyl-Dipeptidase A</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Ace2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">antiviral factors</style></keyword><keyword><style face="normal" font="default" size="100%">vernal keratoconjuntivitis</style></keyword><keyword><style face="normal" font="default" size="100%">Garrigue are employees of Santen SAS.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34390598</style></accession-num><notes><style face="normal" font="default" size="100%">Leonardi, Andrea&#xD;Rosani, Umberto&#xD;Cavarzeran, Fabiano&#xD;Daull, Philippe&#xD;Garrigue, Jean-Sebastien&#xD;Paola, Brun&#xD;eng&#xD;Santen SAS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):298-300. doi: 10.1111/all.15048. Epub 2021 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34390598</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441822</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15048</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3311</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3311</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chang, Hui-Chin</style></author><author><style face="normal" font="default" size="100%">Wu, Meng-Che</style></author><author><style face="normal" font="default" size="100%">Zuberbier, Torsten</style></author><author><style face="normal" font="default" size="100%">Gau, Shuo-Yan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Anxiety, Depression, Schizophrenia, and Bipolar Disorder in Eosinophilic Esophagitis Patients: A Global Federated Cohort Analysis of Bidirectional Risks</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70288</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70288</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1947</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1947</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Valdelvira, R.</style></author><author><style face="normal" font="default" size="100%">Garcia-Medina, G.</style></author><author><style face="normal" font="default" size="100%">Galleani, C.</style></author><author><style face="normal" font="default" size="100%">Kralova, V.</style></author><author><style face="normal" font="default" size="100%">Crespo, J. F.</style></author><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Instituto de Investigacion Biosanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ara h 1 but not Ara h 2 strongly adheres to oral epithelium and remains in the oral area upon peanut release</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2024-2028</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">2S Albumins, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36794969</style></accession-num><notes><style face="normal" font="default" size="100%">Valdelvira, Rafael&#xD;Garcia-Medina, Guadalupe&#xD;Galleani, Celine&#xD;Kralova, Vera&#xD;Crespo, Jesus F&#xD;Cabanillas, Beatriz&#xD;eng&#xD;2019-T1/BIO-12690/Talento Investigador Program. Regional Ministry of Science, Universities, and Innovation, Madrid/&#xD;PI20/00351/Spanish Ministry of Science and Innovation (Co-funded by the European Union)/&#xD;FI21/00037/Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2024-2028. doi: 10.1111/all.15677. Epub 2023 Mar 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36794969</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15677</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>541</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">541</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bonini, S.</style></author><author><style face="normal" font="default" size="100%">Fiorito, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Translational Pharmacology, Italian National Research Council, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Are health care policies for COVID-19 evidence-based?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2290-2291</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/03/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Delivery of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Health Policy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword><keyword><style face="normal" font="default" size="100%">evidence-based medicine</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35353906</style></accession-num><abstract><style face="normal" font="default" size="100%">-</style></abstract><notes><style face="normal" font="default" size="100%">Bonini, Sergio&#xD;Fiorito, Silvana&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2290-2291. doi: 10.1111/all.15297.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35353906</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9111449</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15297</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1123</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1123</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alessandri, C.</style></author><author><style face="normal" font="default" size="100%">Giangrieco, I.</style></author><author><style face="normal" font="default" size="100%">Tuppo, L.</style></author><author><style face="normal" font="default" size="100%">Ferrara, R.</style></author><author><style face="normal" font="default" size="100%">Zennaro, D.</style></author><author><style face="normal" font="default" size="100%">Bernardi, M. L.</style></author><author><style face="normal" font="default" size="100%">Ciancamerla, M.</style></author><author><style face="normal" font="default" size="100%">Rafaiani, C.</style></author><author><style face="normal" font="default" size="100%">Rafaiani, C.</style></author><author><style face="normal" font="default" size="100%">Tamburrini, M.</style></author><author><style face="normal" font="default" size="100%">Mari, A.</style></author><author><style face="normal" font="default" size="100%">Ciardiello, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Associated Centers for Molecular Allergology (CAAM), Rome, Italy.&#xD;Allergy Data Laboratories s.r.l. (ADL), Latina, Italy.&#xD;Institute of Biosciences and BioResources (IBBR), CNR, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Are peas a safe food for lipid transfer protein allergic patients?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2587-2589</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Carrier Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Pisum sativum/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ltp</style></keyword><keyword><style face="normal" font="default" size="100%">Pis s 3</style></keyword><keyword><style face="normal" font="default" size="100%">multiplex testing system</style></keyword><keyword><style face="normal" font="default" size="100%">pea</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33657652</style></accession-num><notes><style face="normal" font="default" size="100%">Alessandri, Claudia&#xD;Giangrieco, Ivana&#xD;Tuppo, Lisa&#xD;Ferrara, Rosetta&#xD;Zennaro, Danila&#xD;Bernardi, Maria L&#xD;Ciancamerla, Michela&#xD;Rafaiani, Claudia&#xD;Rafaiani, Chiara&#xD;Tamburrini, Maurizio&#xD;Mari, Adriano&#xD;Ciardiello, Maria A&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2587-2589. doi: 10.1111/all.14801. Epub 2021 Mar 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33657652</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14801</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1313</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1313</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kow, C. S.</style></author><author><style face="normal" font="default" size="100%">Capstick, T.</style></author><author><style face="normal" font="default" size="100%">Hasan, S. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.&#xD;Leeds Teaching Hospitals NHS Trust, St. James&apos;s University Hospital, Leeds, United Kingdom.&#xD;Department of Pharmacy, University of Huddersfield, Huddersfield, United Kingdom.&#xD;School of Biomedical Sciences &amp; Pharmacy, The University of Newcastle, Callaghan, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">959-960</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/10/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Italy</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33006777</style></accession-num><notes><style face="normal" font="default" size="100%">Kow, Chia Siang&#xD;Capstick, Toby&#xD;Hasan, Syed Shahzad&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):959-960. doi: 10.1111/all.14589. Epub 2020 Oct 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33006777</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7537068</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14589</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1425</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1425</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Bosnic-Anticevich, S.</style></author><author><style face="normal" font="default" size="100%">Walter Canonica, G.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">Costa, E.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Erhola, M.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Illario, M.</style></author><author><style face="normal" font="default" size="100%">Ivancevich, J. C.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Le, L.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Laune, D.</style></author><author><style face="normal" font="default" size="100%">Lourenco, O. M.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Niedoszytko, M.</style></author><author><style face="normal" font="default" size="100%">Odemyr, M.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Patella, V.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, N.</style></author><author><style face="normal" font="default" size="100%">Rolland, C.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Sofiev, M.</style></author><author><style face="normal" font="default" size="100%">Suppli Ulrik, C.</style></author><author><style face="normal" font="default" size="100%">Todo-Bom, A.</style></author><author><style face="normal" font="default" size="100%">Tomazic, P. V.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Tsiligianni, I.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Valovirta, E.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Walker, S.</style></author><author><style face="normal" font="default" size="100%">Williams, S.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Almeida, R.</style></author><author><style face="normal" font="default" size="100%">Ansotegui, I. J.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Arnavielhe, S.</style></author><author><style face="normal" font="default" size="100%">Basagana, X.</style></author><author><style face="normal" font="default" size="100%">D. Bateman E</style></author><author><style face="normal" font="default" size="100%">Bedard, A.</style></author><author><style face="normal" font="default" size="100%">Bedolla-Barajas, M.</style></author><author><style face="normal" font="default" size="100%">Becker, S.</style></author><author><style face="normal" font="default" size="100%">Bennoor, K. S.</style></author><author><style face="normal" font="default" size="100%">Benveniste, S.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Bewick, M.</style></author><author><style face="normal" font="default" size="100%">Bialek, S.</style></author><author><style face="normal" font="default" size="100%">E. Billo N</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Bjermer, L.</style></author><author><style face="normal" font="default" size="100%">Blain, H.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Bonniaud, P.</style></author><author><style face="normal" font="default" size="100%">Bosse, I.</style></author><author><style face="normal" font="default" size="100%">Bouchard, J.</style></author><author><style face="normal" font="default" size="100%">Boulet, L. P.</style></author><author><style face="normal" font="default" size="100%">Bourret, R.</style></author><author><style face="normal" font="default" size="100%">Boussery, K.</style></author><author><style face="normal" font="default" size="100%">Braido, F.</style></author><author><style face="normal" font="default" size="100%">Briedis, V.</style></author><author><style face="normal" font="default" size="100%">Briggs, A.</style></author><author><style face="normal" font="default" size="100%">Brightling, C. E.</style></author><author><style face="normal" font="default" size="100%">Brozek, J.</style></author><author><style face="normal" font="default" size="100%">Brusselle, G.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Buhl, R.</style></author><author><style face="normal" font="default" size="100%">Buonaiuto, R.</style></author><author><style face="normal" font="default" size="100%">Calderon, M. A.</style></author><author><style face="normal" font="default" size="100%">Camargos, P.</style></author><author><style face="normal" font="default" size="100%">Camuzat, T.</style></author><author><style face="normal" font="default" size="100%">Caraballo, L.</style></author><author><style face="normal" font="default" size="100%">Carriazo, A. M.</style></author><author><style face="normal" font="default" size="100%">Carr, W.</style></author><author><style face="normal" font="default" size="100%">Cartier, C.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Cepeda Sarabia, A. M.</style></author><author><style face="normal" font="default" size="100%">H. Chavannes N</style></author><author><style face="normal" font="default" size="100%">Chkhartishvili, E.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Cingi, C.</style></author><author><style face="normal" font="default" size="100%">Correia de Sousa, J.</style></author><author><style face="normal" font="default" size="100%">Costa, D. J.</style></author><author><style face="normal" font="default" size="100%">Courbis, A. L.</style></author><author><style face="normal" font="default" size="100%">Custovic, A.</style></author><author><style face="normal" font="default" size="100%">Cvetkosvki, B.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">da Silva, J.</style></author><author><style face="normal" font="default" size="100%">Dantas, C.</style></author><author><style face="normal" font="default" size="100%">Dokic, D.</style></author><author><style face="normal" font="default" size="100%">Dauvilliers, Y.</style></author><author><style face="normal" font="default" size="100%">De Feo, G.</style></author><author><style face="normal" font="default" size="100%">De Vries, G.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Di Capua, S.</style></author><author><style face="normal" font="default" size="100%">Dray, G.</style></author><author><style face="normal" font="default" size="100%">Dubakiene, R.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Dykewicz, M.</style></author><author><style face="normal" font="default" size="100%">Ebisawa, M.</style></author><author><style face="normal" font="default" size="100%">Gaga, M.</style></author><author><style face="normal" font="default" size="100%">El-Gamal, Y.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Emuzyte, R.</style></author><author><style face="normal" font="default" size="100%">Farrell, J.</style></author><author><style face="normal" font="default" size="100%">Fauquert, J. L.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author><author><style face="normal" font="default" size="100%">Fink-Wagner, A.</style></author><author><style face="normal" font="default" size="100%">Fontaine, J. F.</style></author><author><style face="normal" font="default" size="100%">Fuentes Perez, J. M.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Gamkrelidze, A.</style></author><author><style face="normal" font="default" size="100%">Garcia-Aymerich, J.</style></author><author><style face="normal" font="default" size="100%">Gevaert, P.</style></author><author><style face="normal" font="default" size="100%">Gomez, R. M.</style></author><author><style face="normal" font="default" size="100%">Gonzalez Diaz, S.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Guldemond, N. A.</style></author><author><style face="normal" font="default" size="100%">Guzman, M. A.</style></author><author><style face="normal" font="default" size="100%">Hajjam, J.</style></author><author><style face="normal" font="default" size="100%">Huerta Villalobos, Y. R.</style></author><author><style face="normal" font="default" size="100%">Humbert, M.</style></author><author><style face="normal" font="default" size="100%">Iaccarino, G.</style></author><author><style face="normal" font="default" size="100%">Ierodiakonou, D.</style></author><author><style face="normal" font="default" size="100%">Iinuma, T.</style></author><author><style face="normal" font="default" size="100%">Jassem, E.</style></author><author><style face="normal" font="default" size="100%">Joos, G.</style></author><author><style face="normal" font="default" size="100%">Jung, K. S.</style></author><author><style face="normal" font="default" size="100%">Kaidashev, I.</style></author><author><style face="normal" font="default" size="100%">Kalayci, O.</style></author><author><style face="normal" font="default" size="100%">Kardas, P.</style></author><author><style face="normal" font="default" size="100%">Keil, T.</style></author><author><style face="normal" font="default" size="100%">Khaitov, M.</style></author><author><style face="normal" font="default" size="100%">Khaltaev, N.</style></author><author><style face="normal" font="default" size="100%">Kleine-Tebbe, J.</style></author><author><style face="normal" font="default" size="100%">Kouznetsov, R.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author><author><style face="normal" font="default" size="100%">Kritikos, V.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">La Grutta, S.</style></author><author><style face="normal" font="default" size="100%">Leonardini, L.</style></author><author><style face="normal" font="default" size="100%">Ljungberg, H.</style></author><author><style face="normal" font="default" size="100%">Lieberman, P.</style></author><author><style face="normal" font="default" size="100%">Lipworth, B.</style></author><author><style face="normal" font="default" size="100%">Lodrup Carlsen, K. C.</style></author><author><style face="normal" font="default" size="100%">Lopes-Pereira, C.</style></author><author><style face="normal" font="default" size="100%">Loureiro, C. C.</style></author><author><style face="normal" font="default" size="100%">Louis, R.</style></author><author><style face="normal" font="default" size="100%">Mair, A.</style></author><author><style face="normal" font="default" size="100%">Mahboub, B.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Malva, J.</style></author><author><style face="normal" font="default" size="100%">Manning, P.</style></author><author><style face="normal" font="default" size="100%">Marshall, G. D.</style></author><author><style face="normal" font="default" size="100%">Masjedi, M. R.</style></author><author><style face="normal" font="default" size="100%">Maspero, J. F.</style></author><author><style face="normal" font="default" size="100%">Carreiro-Martins, P.</style></author><author><style face="normal" font="default" size="100%">Makela, M.</style></author><author><style face="normal" font="default" size="100%">Mathieu-Dupas, E.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">De Manuel Keenoy, E.</style></author><author><style face="normal" font="default" size="100%">Melo-Gomes, E.</style></author><author><style face="normal" font="default" size="100%">Meltzer, E. O.</style></author><author><style face="normal" font="default" size="100%">Menditto, E.</style></author><author><style face="normal" font="default" size="100%">Mercier, J.</style></author><author><style face="normal" font="default" size="100%">Micheli, Y.</style></author><author><style face="normal" font="default" size="100%">Miculinic, N.</style></author><author><style face="normal" font="default" size="100%">Mihaltan, F.</style></author><author><style face="normal" font="default" size="100%">Milenkovic, B.</style></author><author><style face="normal" font="default" size="100%">Mitsias, D. I.</style></author><author><style face="normal" font="default" size="100%">Moda, G.</style></author><author><style face="normal" font="default" size="100%">Mogica-Martinez, M. D.</style></author><author><style face="normal" font="default" size="100%">Mohammad, Y.</style></author><author><style face="normal" font="default" size="100%">Montefort, S.</style></author><author><style face="normal" font="default" size="100%">Monti, R.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Munter, L.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Murray, R.</style></author><author><style face="normal" font="default" size="100%">Naclerio, R.</style></author><author><style face="normal" font="default" size="100%">Napoli, L.</style></author><author><style face="normal" font="default" size="100%">Namazova-Baranova, L.</style></author><author><style face="normal" font="default" size="100%">Neffen, H.</style></author><author><style face="normal" font="default" size="100%">Nekam, K.</style></author><author><style face="normal" font="default" size="100%">Neou, A.</style></author><author><style face="normal" font="default" size="100%">Nordlund, B.</style></author><author><style face="normal" font="default" size="100%">Novellino, E.</style></author><author><style face="normal" font="default" size="100%">Nyembue, D.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R.</style></author><author><style face="normal" font="default" size="100%">Ohta, K.</style></author><author><style face="normal" font="default" size="100%">Okubo, K.</style></author><author><style face="normal" font="default" size="100%">Onorato, G. L.</style></author><author><style face="normal" font="default" size="100%">Orlando, V.</style></author><author><style face="normal" font="default" size="100%">Ouedraogo, S.</style></author><author><style face="normal" font="default" size="100%">Palamarchuk, J.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Panzner, P.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author><author><style face="normal" font="default" size="100%">Passalacqua, G.</style></author><author><style face="normal" font="default" size="100%">Pepin, J. L.</style></author><author><style face="normal" font="default" size="100%">Paulino, E.</style></author><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Phillips, J.</style></author><author><style face="normal" font="default" size="100%">Picard, R.</style></author><author><style face="normal" font="default" size="100%">Pinnock, H.</style></author><author><style face="normal" font="default" size="100%">Plavec, D.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Portejoie, F.</style></author><author><style face="normal" font="default" size="100%">Price, D.</style></author><author><style face="normal" font="default" size="100%">Prokopakis, E. P.</style></author><author><style face="normal" font="default" size="100%">Psarros, F.</style></author><author><style face="normal" font="default" size="100%">Pugin, B.</style></author><author><style face="normal" font="default" size="100%">Puggioni, F.</style></author><author><style face="normal" font="default" size="100%">Quinones-Delgado, P.</style></author><author><style face="normal" font="default" size="100%">Raciborski, F.</style></author><author><style face="normal" font="default" size="100%">Rajabian-Soderlund, R.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Rivero-Yeverino, D.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Roche, N.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Zagal, E.</style></author><author><style face="normal" font="default" size="100%">Rolland, C.</style></author><author><style face="normal" font="default" size="100%">Roller-Wirnsberger, R. E.</style></author><author><style face="normal" font="default" size="100%">Rosario, N.</style></author><author><style face="normal" font="default" size="100%">Romano, A.</style></author><author><style face="normal" font="default" size="100%">Rottem, M.</style></author><author><style face="normal" font="default" size="100%">Ryan, D.</style></author><author><style face="normal" font="default" size="100%">Salimaki, J.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Borges, M. M.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Scadding, G. K.</style></author><author><style face="normal" font="default" size="100%">Scheire, S.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Schunemann, H. J.</style></author><author><style face="normal" font="default" size="100%">Sarquis Serpa, F.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author><author><style face="normal" font="default" size="100%">Sisul, J. C.</style></author><author><style face="normal" font="default" size="100%">Sofiev, M.</style></author><author><style face="normal" font="default" size="100%">Sole, D.</style></author><author><style face="normal" font="default" size="100%">Somekh, D.</style></author><author><style face="normal" font="default" size="100%">Sooronbaev, T.</style></author><author><style face="normal" font="default" size="100%">Sova, M.</style></author><author><style face="normal" font="default" size="100%">Spertini, F.</style></author><author><style face="normal" font="default" size="100%">Spranger, O.</style></author><author><style face="normal" font="default" size="100%">Stellato, C.</style></author><author><style face="normal" font="default" size="100%">Stelmach, R.</style></author><author><style face="normal" font="default" size="100%">Thibaudon, M.</style></author><author><style face="normal" font="default" size="100%">To, T.</style></author><author><style face="normal" font="default" size="100%">Toumi, M.</style></author><author><style face="normal" font="default" size="100%">Usmani, O.</style></author><author><style face="normal" font="default" size="100%">Valero, A. A.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Valentin-Rostan, M.</style></author><author><style face="normal" font="default" size="100%">Pereira, M. U.</style></author><author><style face="normal" font="default" size="100%">van der Kleij, R.</style></author><author><style face="normal" font="default" size="100%">Van Eerd, M.</style></author><author><style face="normal" font="default" size="100%">Vandenplas, O.</style></author><author><style face="normal" font="default" size="100%">Vasankari, T.</style></author><author><style face="normal" font="default" size="100%">Vaz Carneiro, A.</style></author><author><style face="normal" font="default" size="100%">Vezzani, G.</style></author><author><style face="normal" font="default" size="100%">Viart, F.</style></author><author><style face="normal" font="default" size="100%">Viegi, G.</style></author><author><style face="normal" font="default" size="100%">Wallace, D.</style></author><author><style face="normal" font="default" size="100%">Wagenmann, M.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Waserman, S.</style></author><author><style face="normal" font="default" size="100%">Wickman, M.</style></author><author><style face="normal" font="default" size="100%">Williams, D. M.</style></author><author><style face="normal" font="default" size="100%">Wong, G.</style></author><author><style face="normal" font="default" size="100%">Wroczynski, P.</style></author><author><style face="normal" font="default" size="100%">Yiallouros, P. K.</style></author><author><style face="normal" font="default" size="100%">Yusuf, O. M.</style></author><author><style face="normal" font="default" size="100%">Zar, H. J.</style></author><author><style face="normal" font="default" size="100%">Zeng, S.</style></author><author><style face="normal" font="default" size="100%">Zernotti, M. E.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Shan Zhong, N.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MACVIA-France and CHU, Montpellier, France.&#xD;INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, Universite Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, and Charite, Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany.&#xD;ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.&#xD;IMIM (Hospital del Mar Research Institute), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium and Sun Yat-sen University, International Airway Research Center, First Affiliated Hospital Guangzou, China, and Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm and Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.&#xD;Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Uniersitat zu Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and Allergy, Member of GA2LEN, Berlin, Germany.&#xD;Medical Consulting Czarlewski, Levallois, and MASK-air, Montpellier, France.&#xD;Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia.&#xD;Personalized Medicine Clinic Asthma &amp; Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano and Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall d&apos;Hebron &amp; ARADyAL research network, Barcelona, Spain.&#xD;UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), Porto, Portugal.&#xD;ProAR-Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Brazil.&#xD;National Insitute for Health and Welfare, Helsinki, Finland.&#xD;Department of Otorhinolaryngology, Academic Medical Centres, AMC, Amsterdam, the Netherlands, and Euforea, Brussels, Belgium.&#xD;CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto; and Medida, Lda Porto, Portugal.&#xD;Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&amp;D and DISMET), Naples, Italy.&#xD;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;Department of Clinical Immunology, Wroclaw Medical University and ALL-MED Medical Research Institute, Warsaw, Poland.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland.&#xD;Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University and Institute of Clinical Medicine, Clinic of Chest diseases and Allergology, Faculty of Medicine, Vilnius, Lithuania.&#xD;University of Medicine and Pharmacy, Hochiminh City, Vietnam.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;KYomed INNOV, Montpellier, France.&#xD;Faculty of Health Sciences and CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Rhinology Unit &amp; Smell Clinic, ENT Department, Hospital Clinic; Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Spain.&#xD;Department of Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;EFA European Federation of Allergy and Airways Diseases Patients&apos; Associations, Brussels, Belgium.&#xD;Dept of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, Royal Manchester Children&apos;s Hospital, University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Pediatric Clinic, Athens General Children&apos;s Hospital &quot;P&amp;A Kyriakou&quot;, University of Athens, Athens, Greece.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, &quot;Santa Maria della Speranza&quot; Hospital, Salerno, Italy.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Ecole polytechnique, Palaiseau, IRBA (Institut de Recherche bio-Medicale des Armees, Bretigny), France.&#xD;Association Asthme et Allergie, Paris, France.&#xD;Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.&#xD;The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.&#xD;Finnish Meteorological Institute (FMI), Helsinki, Finland.&#xD;Department of Respiratory Medicine, Hvidovre Hospital &amp; University of Copenhagen, Copenhagen, Denmark.&#xD;Allergy and Clinical Immunology Unit, Institute of Immunology, Faculty of Medicine, University of Coimbra, ICBR - Coimbra Institute for Clinical and Biomedical Research, CIBB, Coimbra, Portugal.&#xD;Department of General ORL, H&amp;NS, Medical University of Graz, Graz, Austria.&#xD;Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece and International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland.&#xD;Vilnius University Faculty of Medicine, Institute of Clinical Medicine &amp; Institute of Health Sciences, Vilnius, Lithuania.&#xD;Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo Allergy Clinic, Turku, Finland.&#xD;University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy.&#xD;Asthma UK, London, UK.&#xD;International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland.&#xD;Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Allergy and Immunology, Hospital Quiron Bizkaia, Erandio, Spain.&#xD;Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Universites, Medical School Saint Antoine, Paris, France.&#xD;Department of Medicine, University of Cape Town, Cape Town, South Africa.&#xD;Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalarara, Mexico.&#xD;Department of Otolaryngology, Head and Neck Surgery, University of Mainz, Mainz, Germany.&#xD;Dept of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.&#xD;National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France.&#xD;Mines ParisTech CRI-PSL Research University, Fontainebleau, France.&#xD;iQ4U Consultants Ltd, London, UK.&#xD;Department of Biochemistry and Clinical Chemistry, Faculty of Pharmacy with the Division of Laboratory Medicine, Warsaw Medical University, Warsaw, Poland.&#xD;Independent Consultant, Joensuu, Finland.&#xD;Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.&#xD;Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden.&#xD;Department of Geriatrics, Montpellier University hospital, Montpellier, France.&#xD;EA 2991, Euromov, University Montpellier, Montpellier, France.&#xD;UOC Pneumologia, Istituto di Medicina Interna, F Policlinico Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy, and National Heart and Lung Institute, Royal Brompton Hospital &amp; Imperial College London, London, UK.&#xD;CHU Dijon, Dijon, France.&#xD;Allergist, La Rochelle, France.&#xD;Laval&apos;s University, Quebec, QC, Canada.&#xD;Quebec Heart and Lung Institute, Laval University, Quebec, QC, Canada.&#xD;Centre Hospitalier Valenciennes, Valenciennes, France.&#xD;Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.&#xD;University of Genoa, Department of Internal Medicine (DiMI) and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.&#xD;Department of Clinical Pharmacy of Lithuanian, University of Health, Kaunas, Lithuania.&#xD;Health Economics and Health Technology Assessment, Institute of Health &amp; Wellbeing, University of Glasgow, Glasgow, UK.&#xD;Institute of Lung Health, Respiratory Biomedical Unit, University Hospitals of Leicester NHS Trust, Leicestershire, UK; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.&#xD;Department of Health Research Methods, Evidence and Impact, Division of Immunology and Allergy, McMaster University, Hamilton, ON, Canada.&#xD;Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.&#xD;Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino &amp; Mauriziano Hospital, Torino, Italy.&#xD;Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Germany.&#xD;Municipality Pharmacy, Sarno, Italy.&#xD;Imperial College London-National Heart and Lung Institute, London, UK.&#xD;Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil.&#xD;Assitant Director General, Montpellier, Region Occitanie, Montpellier, France.&#xD;Institute for Immunological Research, University of Cartagena, Campus de Zaragocilla, Edificio Biblioteca Primer Piso, Cartagena, Colombia, and Foundation for the Development of Medical and Biological Sciences (Fundemeb), Cartagena, Colombia.&#xD;Regional Ministry of Health of Andalusia, Seville, Spain.&#xD;Allergy and Asthma Associates of Southern California, Mission Viejo, CA, USA.&#xD;ASA-Advanced Solutions Accelerator, Clapiers, France.&#xD;Division of Allergy/Immunology, University of South Florida, Tampa, FL, USA.&#xD;SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Allergy and Immunology Laboratory, Metropolitan University, Simon Bolivar University, Barranquilla, Colombia and SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia, Branquilla, Colombia.&#xD;Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands.&#xD;Chachava Clinic, David Tvildiani Medical University-AIETI Medical School, Grigol Robakidze University, Tbilisi, Georgia.&#xD;ENT Department, Eskisehir Osmangazi University, Eskisehir, Turkey.&#xD;Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; ICVS/3B&apos;s, PT Government Associate Laboratory, Guimaraes, Portugal.&#xD;General Practice, Nimes, France.&#xD;IMT Mines Ales, Universite Montpellier, Montpellier, France.&#xD;Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester and University Hospital of South Manchester, Manchester, UK.&#xD;Division of Respiratory and Allergic Diseases, Department of Respiratory Diseases, High Specialty Hospital ACardarelli, Napoli, Italy.&#xD;Department of Internal Medicine and Allergy Clinic of Professor Polydoro Ernani de Sao, Thiago University Hospital, Federal University of Santa Catarina (UFSC), Florianopolis-SC, Brazil.&#xD;Caritas Diocesana de Coimbra, Coimbra, Portugal, Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal.&#xD;Medical Faculty Skopje, University Clinic of Pulmology and Allergy, Skopje, Republic of Macedonia.&#xD;Sleep Unit, Department of Neurology, Hopital Gui-de-Chauliac Montpellier, Inserm U1061, Montpellier, France.&#xD;Department of Medicine, Surgery and Dentistry &quot;Scuola Medica Salernitana&quot;, University of Salerno, Salerno, Italy.&#xD;Peercode BV, Geldermalsen, The Netherlands.&#xD;UPRES EA220, Pole des Maladies des Voies Respiratoires, Hopital Foch, Universite Paris-Saclay, Suresnes, France.&#xD;Farmacie Dei Golfi Group, Massa Lubrense, Italy.&#xD;Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania.&#xD;Allergy and Clinical Immunology Section, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, USA.&#xD;Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan.&#xD;ERS President 2017-2018, Athens Chest Hospital, 7th Resp Med Dept and Asthma Center, Athens, Greece.&#xD;Pediatric Allergy and Immunology Unit, Children&apos;s hospital, Ain Shams University, Cairo, Egypt.&#xD;Clinic of Children&apos;s Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Department of Health, Social Services and Public Safety, Northern Ireland Belfast, UK.&#xD;CHU Clermont-Ferrand, Unite d&apos;allergologie de l&apos;enfant, pole pediatrique, Hopital Estaing, Clermont-Ferrand, France.&#xD;Division of Allergy, Department of Pediatric Medicine-The Bambino Gesu Children&apos;s Research Hospital Holy See, Rome, Italy.&#xD;Global Allergy and Airways Patient Platform GAAPP, Vienna, Austria.&#xD;Allergist, Reims, France.&#xD;Hospital General Regional 1 &quot;Dr Carlos Mc Gregor Sanchez Navarro&quot; IMSS, Mexico City, Mexico.&#xD;Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.&#xD;Gamkrelidze National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia.&#xD;Allergy &amp; Asthma Unit, Hospital San Bernardo Salta, Salta, Argentina.&#xD;Universidad Autonoma de Nuevo Leon, San Nicolas de los Garza, Mexico.&#xD;Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia.&#xD;Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, The Netherlands.&#xD;Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile.&#xD;Centich: Centre d&apos;Expertise National des Technologies de l&apos;Information et de la communication pour l&apos;autonomie, Groupe VyV, Conseil Regional des Pays de la Loire, Centre d&apos;expertise PartenariatEuropeen d&apos;Innovation pour un vieillissement actif et en bonne sante, Nantes, France.&#xD;IMSS Hospital General Region 1, Dr Carlos Mc Gregor Sanchez Navarro, Mexico City, Mexico.&#xD;Universite Paris-Sud; Service de Pneumologie, Hopital Bicetre; Inserm UMR_S999, Le Kremlin Bicetre, France.&#xD;Department of Advanced Biomedical Sciences, Federico II University, Napoli, Italy.&#xD;Department of Social Medicine, Faculty of Medicine, University of Crete, and International Primary Care Respiratory Group, Crete, Greece.&#xD;Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Gyeonggi-do, South Korea.&#xD;Ukrainina Medical Stomatological Academy, Poltava, Ukraine.&#xD;Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey.&#xD;First Department of Family Medicine, Medical University of Lodz, Poland.&#xD;Institute of Social Medicine, Epidemiology and Health Economics, Charite-Universitatsmedizin Berlin, Berlin, and Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, and Institute of Health Resort Medicine and Health Promotion, Bavarian Health and Food Safety Authority, Bad Kissingen, Germany.&#xD;National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular immunology, Moscow, Russian Federation.&#xD;GARD Chairman, Geneva, Switzerland.&#xD;Allergy &amp; Asthma Center Westend, Berlin, Germany.&#xD;Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Lodz, Poland.&#xD;Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, and Sach&apos;s Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), Palermo, Italy.&#xD;Veneto Region, Mattone Internazionale Program, Venise, Italy.&#xD;Lung-Allergy Department at Astrid Lindgren Children&apos;s Hospital, Karolinska University Hospital, &amp; Department of Women&apos;s and Children&apos;s Health, Karolinska Institutet, Stockholm, Sweden.&#xD;Departments of Internal Medicine and Pediatrics (Divisions of Allergy and Immunology), University of Tennessee College of Medicine, Germantown, TN, USA.&#xD;Scottish Centre for Respiratory Research, Cardiovascular &amp; Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, Dundee, UK.&#xD;Oslo University Hospital, Department of Paediatrics, Oslo, and University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway.&#xD;Market Access Senior Manager, Medicines for Europe, Brussels, Belgium.&#xD;Pneumology Department, Hospitais da Universidade de Coimbra, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.&#xD;Department of Pulmonary Medicine, CHU Sart-Tilman, and GIGA I3 Research Group, Liege, Belgium.&#xD;DG for Health and Social Care, Scottish Government, Edinburgh, UK.&#xD;Department of Pulmonary Medicine, Rashid Hospital, Dubai, UAE.&#xD;Allergy Unit &quot;D Kalogeromitros&quot;, 2nd Department of Dermatology and Venereology, National &amp; Kapodistrian University of Athens, &quot;Attikon&quot; University Hospital, Chaidari, Greece.&#xD;Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra; Coimbra, and Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal.&#xD;Department of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland.&#xD;Division of Clinical Immunology and Allergy, Laboratory of Behavioral Immunology Research, The University of Mississippi Medical Center, Jackson, MS, USA.&#xD;Tobacco Control Research Centre; Iranian Anti Tobacco Association, Tehran, Iran.&#xD;Argentine Association of Allergy and Clinical Immunology, Buenos Aires, Argentina.&#xD;Servico de Immunologia, Hospital de Dona Estefania, Centro Hospitalar de Lisboa Central, Lisbon, Portugal and Nova Medical School/Comprehensive Health Research Center (CHRC), Universidade Nova de Lisboa, Lisboa, Portugal.&#xD;Kronikgune, International Centre of Excellence in Chronicity Research Barakaldo, Bizkaia, Spain.&#xD;PNDR, Portuguese National Programme for Respiratory Diseases, Faculdade de Medicina de Lisboa, Lisbon, Portugal.&#xD;Allergy and Asthma Medical Group and Research Center, San Diego, CA, USA.&#xD;CIRFF, Federico II University, Naples, Italy.&#xD;Department of Physiology, CHRU, University Montpellier, Vice President for Research, PhyMedExp, INSERM U1046, CNRS UMR 9214, Montpellier, France.&#xD;Croatian Pulmonary Society, Zagreb, Croatia.&#xD;National Institute of Pneumology M Nasta, Bucharest, Romania.&#xD;Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia.&#xD;Regione Piemonte, Torino, Italy.&#xD;Col Jardines de Sta Monica, Tlalnepantla, Mexico.&#xD;National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, and Syrian Private University-Damascus, Damascus, Syria.&#xD;Lead Respiratory Physician Mater Dei Hospital Malta, Academic Head of Department and Professor of Medicine, University of Malta, Deputy Dean Faculty of Medicine and Surgery, University of Medicine, La Valette, Malta.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;CRI-Clinical Research International-Ltd, Hamburg, Germany.&#xD;Danish Committee for Health Education, Copenhagen East, Denmark.&#xD;Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy.&#xD;Research Fellow, OPC, Cambridge, UK and Director Medscript, Paraparaumu, New Zealand.&#xD;Johns Hopkins School of Medicine, Baltimore, MD, USA.&#xD;Director, Consortium of Pharmacies and Services COSAFER, Salerno, Italy.&#xD;Scientific Centre of Children&apos;s Health under the PoH, Russian National Research Medical University named Pirogov, Moscow, Russia.&#xD;Director of Center of Allergy, Immunology and Respiratory Diseases, Center for Allergy and Immunology, Santa Fe, Argentina.&#xD;Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.&#xD;Die Hautambulanz and Rothhaar study center, Berlin, Germany.&#xD;Director of Department of Pharmacy of University of Naples Federico II, Naples, Italy.&#xD;ENT Department, University Hospital of Kinshasa, Kinshasa, Congo.&#xD;Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Vic., Australia; Department of Immunology, Monash University, Melbourne, Vic., Australia.&#xD;Department of Otolaryngology, Nippon Medical School, Tokyo, Japan.&#xD;Centre Hospitalier Universitaire Pediatrique Charles de Gaulle, Ouagadougou, Burkina Faso.&#xD;Department of Comparative Medicine, Messerli Research Institute of the University of Veterinary Medicine and Medical University, Vienna, Austria.&#xD;Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.&#xD;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea.&#xD;Allergy and Respiratory Diseases, Ospedale Policlino San Martino-University of Genoa, Genoa, Italy.&#xD;Universite Grenoble Alpes, Laboratoire HP2, Grenoble, INSERM, U1042 and CHU de Grenoble, Grenoble, France.&#xD;Ezfy, Lisbon, Portugal.&#xD;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Centre for Empowering Patients and Communities, Faulkland, UK.&#xD;Conseil General de l&apos;Economie Ministere de l&apos;Economie, de l&apos;Industrie et du Numerique, Paris, France.&#xD;Children&apos;s Hospital Srebrnjak, Zagreb, School of Medicine, University JJ Strossmayer, Osijek, Croatia.&#xD;University Hospital &quot;Sv Ivan Rilski&quot;, Sofia, Bulgaria.&#xD;Observational and Pragmatic Research Institute Singapore, Singapore City, Singapore.&#xD;Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece.&#xD;Allergy Department, Athens Naval Hospital, Athens, Greece.&#xD;European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium.&#xD;Agency for Social Services and Dependency, Regional Government for Equality, Social Policies and Conciliation of Andalucia, Seville, Spain.&#xD;Department of Nephrology and Endocrinology, Karolinska University Hospital, Stockholm, Sweden.&#xD;Allergist, Mexico City, Mexico.&#xD;David Hide Centre, St Mary&apos;s Hospital, Isle of Wight and University of Southampton, Southampton, UK.&#xD;Pneumologie et Soins Intensifs Respiratoires, Centre Hopital Cochin, Hopitaux Universitaires Paris, Paris, France.&#xD;Department of Internal Medicine, Medical University of Graz, Graz, Austria.&#xD;Hospital de Clinicas, University of Parana, Parana, Brazil.&#xD;Allergy Unit, Presidio Columbus, Rome, Catholic University of Sacred Heart, Rome and IRCCS Oasi Maria SS, Troina, Italy.&#xD;Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel.&#xD;Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, The University of Edinburgh, Edinburgh, UK.&#xD;Association of Finnish Pharmacists, Helsinki, Finland.&#xD;Allergy and Clinical Immunology Department, Centro Medico-Docente la, Trinidad and Clinica El Avila, Caracas, Venezuela.&#xD;Faculty of Medicine, Autnonous University of Madrid, Madrid, Spain.&#xD;The Royal National TNE Hospital, University College, London, UK.&#xD;Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.&#xD;Asthma Reference Center, School of Medicine of Santa Casa de Misericordia of Vitoria-Esperito Santo, Vitoria, Brazil.&#xD;Immunomodulation and Tolerance Group, Imperial College London, and Allergy and Clinical Immunology, Imperial College London, London, UK.&#xD;Sociedad Paraguaya de Alergia Asma e Inmunologi&apos;a, Paraguay.&#xD;Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;European Health Futures Forum (EHFF), Dromahair, UK.&#xD;Kyrgyzstan National Centre of Cardiology and Internal Medicine, Euro-Asian Respiratory Society, Bishkek, Kyrgyzstan.&#xD;Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic.&#xD;Service Immunologie et Allergie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.&#xD;Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.&#xD;RNSA (Reseau National de Surveillance Aerobiologique), Brussieu, France.&#xD;Sidkkids Hospitala and Institute of Health Policy, Management and Evaluation, Toronto, Canada.&#xD;Public Health, Aix-marseille University, Marseille, France.&#xD;National Heart and Lung Institute (NHLI), Imperial College London &amp; Royal Brompton Hospital, Airways Disease Section, London, UK.&#xD;Pneumology and Allergy Department CIBERES and Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;NRC Institute of Immunology FMBA of Russia, Moscow, Russia and Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Allergist, Montevideo, Uruguay.&#xD;PIPA Pediatric Program on Asthma Prevention, Uruguaiana, Brazil.&#xD;Department of Public Health &amp; Primary Care, Leiden University Medical Center (LUMC), Leiden, The Netherlands, Erasmus MC, Department of Obstetrics and Gynaecology, University Medical Center, Rotterdam, The Netherlands.&#xD;Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Universite Catholique de Louvain, Yvoir, Belgium.&#xD;FILHA, Finnish Lung Association, Helsinki, and Turku University, Turku, Finland.&#xD;Instituto de Medicina Preventiva e Saude Publica, Instituto de Saude Ambiental, Centro de Estudos de Medicina Baseada na Evidencia, Cochrane, Portugal.&#xD;Pulmonary Unit, Department of Medical Specialties, Arcispedale SMaria Nuova/IRCCS, AUSL di Reggio Emilia, Reggio Emilia, Italy.&#xD;Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa (Italy), Via Trieste 41, 56126, Pisa, Italy; and CNR Institute of Biomedicine and Molecular Immunology &quot;A Monroy&quot;, Palermo, Italy.&#xD;Nova Southeastern University, Fort Lauderdale, FL, USA.&#xD;Department of Otorhinolaryngology, HNO-Klinik, Universitatsklinikum Dusseldorf, Dusseldorf, Germany.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.&#xD;Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada.&#xD;Centre for Clinical Research Sormland, Uppsala University, Eskilstuna, Sweden.&#xD;Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.&#xD;Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China.&#xD;Department of Physical Pharmacy and Bioanalysis, Faculty of Pharmacy with the Laboratory Medicine Division, Medical University of Warsaw, Warsaw, Poland.&#xD;Cyprus International Institute for Environmental &amp; Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus; Department of Pediatrics, Hospital &quot;Archbishop Makarios III&quot;, Nicosia, Cyprus.&#xD;The Allergy and Asthma Institute, Pakistan.&#xD;Department of Paediatrics and Child Health, Red Cross Children&apos;s Hospital, and MRC Unit on Child &amp; Adolescent Health, University of Cape Town, Cape Town, South Africa.&#xD;Bull DSAS, Echirolles, France.&#xD;Universidad Catolica de Cordoba, Cordoba, Argentina.&#xD;Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital and Beijing Institute of Otolaryngology, Beijing, China.&#xD;State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.&#xD;University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">168-190</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/06/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiration Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Aria</style></keyword><keyword><style face="normal" font="default" size="100%">Carat</style></keyword><keyword><style face="normal" font="default" size="100%">Mask</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">digital transformation of health and care</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32512619</style></accession-num><abstract><style face="normal" font="default" size="100%">Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed.</style></abstract><notes><style face="normal" font="default" size="100%">Bousquet, Jean&#xD;Anto, Josep M&#xD;Bachert, Claus&#xD;Haahtela, Tari&#xD;Zuberbier, Torsten&#xD;Czarlewski, Wienczyslawa&#xD;Bedbrook, Anna&#xD;Bosnic-Anticevich, Sinthia&#xD;Walter Canonica, G&#xD;Cardona, Victoria&#xD;Costa, Elisio&#xD;Cruz, Alvaro A&#xD;Erhola, Marina&#xD;Fokkens, Wytske J&#xD;Fonseca, Joao A&#xD;Illario, Maddalena&#xD;Ivancevich, Juan-Carlos&#xD;Jutel, Marek&#xD;Klimek, Ludger&#xD;Kuna, Piotr&#xD;Kvedariene, Violeta&#xD;Le, Ltt&#xD;Larenas-Linnemann, Desiree E&#xD;Laune, Daniel&#xD;Lourenco, Olga M&#xD;Melen, Erik&#xD;Mullol, Joaquim&#xD;Niedoszytko, Marek&#xD;Odemyr, Mikaela&#xD;Okamoto, Yoshitaka&#xD;Papadopoulos, Nikos G&#xD;Patella, Vincenzo&#xD;Pfaar, Oliver&#xD;Pham-Thi, Nhan&#xD;Rolland, Christine&#xD;Samolinski, Boleslaw&#xD;Sheikh, Aziz&#xD;Sofiev, Mikhail&#xD;Suppli Ulrik, Charlotte&#xD;Todo-Bom, Ana&#xD;Tomazic, Peter-Valentin&#xD;Toppila-Salmi, Sanna&#xD;Tsiligianni, Ioanna&#xD;Valiulis, Arunas&#xD;Valovirta, Erkka&#xD;Ventura, Maria-Teresa&#xD;Walker, Samantha&#xD;Williams, Sian&#xD;Yorgancioglu, Arzu&#xD;Agache, Ioana&#xD;Akdis, Cezmi A&#xD;Almeida, Rute&#xD;Ansotegui, Ignacio J&#xD;Annesi-Maesano, Isabella&#xD;Arnavielhe, Sylvie&#xD;Basagana, Xavier&#xD;D Bateman, Eric&#xD;Bedard, Annabelle&#xD;Bedolla-Barajas, Martin&#xD;Becker, Sven&#xD;Bennoor, Kazi S&#xD;Benveniste, Samuel&#xD;Bergmann, Karl C&#xD;Bewick, Michael&#xD;Bialek, Slawomir&#xD;E Billo, Nils&#xD;Bindslev-Jensen, Carsten&#xD;Bjermer, Leif&#xD;Blain, Hubert&#xD;Bonini, Matteo&#xD;Bonniaud, Philippe&#xD;Bosse, Isabelle&#xD;Bouchard, Jacques&#xD;Boulet, Louis-Philippe&#xD;Bourret, Rodolphe&#xD;Boussery, Koen&#xD;Braido, Fluvio&#xD;Briedis, Vitalis&#xD;Briggs, Andrew&#xD;Brightling, Christopher E&#xD;Brozek, Jan&#xD;Brusselle, Guy&#xD;Brussino, Luisa&#xD;Buhl, Roland&#xD;Buonaiuto, Roland&#xD;Calderon, Moises A&#xD;Camargos, Paulo&#xD;Camuzat, Thierry&#xD;Caraballo, Luis&#xD;Carriazo, Ana-Maria&#xD;Carr, Warner&#xD;Cartier, Christine&#xD;Casale, Thomas&#xD;Cecchi, Lorenzo&#xD;Cepeda Sarabia, Alfonso M&#xD;H Chavannes, Niels&#xD;Chkhartishvili, Ekaterine&#xD;Chu, Derek K&#xD;Cingi, Cemal&#xD;Correia de Sousa, Jaime&#xD;Costa, David J&#xD;Courbis, Anne-Lise&#xD;Custovic, Adnan&#xD;Cvetkosvki, Biljana&#xD;D&apos;Amato, Gennaro&#xD;da Silva, Jane&#xD;Dantas, Carina&#xD;Dokic, Dejan&#xD;Dauvilliers, Yves&#xD;De Feo, Giulia&#xD;De Vries, Govert&#xD;Devillier, Philippe&#xD;Di Capua, Stefania&#xD;Dray, Gerard&#xD;Dubakiene, Ruta&#xD;Durham, Stephen R&#xD;Dykewicz, Mark&#xD;Ebisawa, Motohiro&#xD;Gaga, Mina&#xD;El-Gamal, Yehia&#xD;Heffler, Enrico&#xD;Emuzyte, Regina&#xD;Farrell, John&#xD;Fauquert, Jean-Luc&#xD;Fiocchi, Alessandro&#xD;Fink-Wagner, Antje&#xD;Fontaine, Jean-Francois&#xD;Fuentes Perez, Jose M&#xD;Gemicioglu, Bilun&#xD;Gamkrelidze, Amiran&#xD;Garcia-Aymerich, Judith&#xD;Gevaert, Philippe&#xD;Gomez, Rene Maximiliano&#xD;Gonzalez Diaz, Sandra&#xD;Gotua, Maia&#xD;Guldemond, Nick A&#xD;Guzman, Maria-Antonieta&#xD;Hajjam, Jawad&#xD;Huerta Villalobos, Yunuen R&#xD;Humbert, Marc&#xD;Iaccarino, Guido&#xD;Ierodiakonou, Despo&#xD;Iinuma, Tomohisa&#xD;Jassem, Ewa&#xD;Joos, Guy&#xD;Jung, Ki-Suck&#xD;Kaidashev, Igor&#xD;Kalayci, Omer&#xD;Kardas, Przemyslaw&#xD;Keil, Thomas&#xD;Khaitov, Musa&#xD;Khaltaev, Nikolai&#xD;Kleine-Tebbe, Jorg&#xD;Kouznetsov, Rostislav&#xD;Kowalski, Marek L&#xD;Kritikos, Vicky&#xD;Kull, Inger&#xD;La Grutta, Stefania&#xD;Leonardini, Lisa&#xD;Ljungberg, Henrik&#xD;Lieberman, Philip&#xD;Lipworth, Brian&#xD;Lodrup Carlsen, Karin C&#xD;Lopes-Pereira, Catarina&#xD;Loureiro, Claudia C&#xD;Louis, Renaud&#xD;Mair, Alpana&#xD;Mahboub, Bassam&#xD;Makris, Michael&#xD;Malva, Joao&#xD;Manning, Patrick&#xD;Marshall, Gailen D&#xD;Masjedi, Mohamed R&#xD;Maspero, Jorge F&#xD;Carreiro-Martins, Pedro&#xD;Makela, Mika&#xD;Mathieu-Dupas, Eve&#xD;Maurer, Marcus&#xD;De Manuel Keenoy, Esteban&#xD;Melo-Gomes, Elisabete&#xD;Meltzer, Eli O&#xD;Menditto, Enrica&#xD;Mercier, Jacques&#xD;Micheli, Yann&#xD;Miculinic, Neven&#xD;Mihaltan, Florin&#xD;Milenkovic, Branislava&#xD;Mitsias, Dimitirios I&#xD;Moda, Giuliana&#xD;Mogica-Martinez, Maria-Dolores&#xD;Mohammad, Yousser&#xD;Montefort, Steve&#xD;Monti, Ricardo&#xD;Morais-Almeida, Mario&#xD;Mosges, Ralph&#xD;Munter, Lars&#xD;Muraro, Antonella&#xD;Murray, Ruth&#xD;Naclerio, Robert&#xD;Napoli, Luigi&#xD;Namazova-Baranova, Leyla&#xD;Neffen, Hugo&#xD;Nekam, Kristoff&#xD;Neou, Angelo&#xD;Nordlund, Bjorn&#xD;Novellino, Ettore&#xD;Nyembue, Dieudonne&#xD;O&apos;Hehir, Robyn&#xD;Ohta, Ken&#xD;Okubo, Kimi&#xD;Onorato, Gabrielle L&#xD;Orlando, Valentina&#xD;Ouedraogo, Solange&#xD;Palamarchuk, Julia&#xD;Pali-Scholl, Isabella&#xD;Panzner, Peter&#xD;Park, Hae-Sim&#xD;Passalacqua, Gianni&#xD;Pepin, Jean-Louis&#xD;Paulino, Ema&#xD;Pawankar, Ruby&#xD;Phillips, Jim&#xD;Picard, Robert&#xD;Pinnock, Hilary&#xD;Plavec, Davor&#xD;Popov, Todor A&#xD;Portejoie, Fabienne&#xD;Price, David&#xD;Prokopakis, Emmanuel P&#xD;Psarros, Fotis&#xD;Pugin, Benoit&#xD;Puggioni, Francesca&#xD;Quinones-Delgado, Pablo&#xD;Raciborski, Filip&#xD;Rajabian-Soderlund, Rojin&#xD;Regateiro, Frederico S&#xD;Reitsma, Sietze&#xD;Rivero-Yeverino, Daniela&#xD;Roberts, Graham&#xD;Roche, Nicolas&#xD;Rodriguez-Zagal, Erendira&#xD;Roller-Wirnsberger, Regina E&#xD;Rosario, Nelson&#xD;Romano, Antonino&#xD;Rottem, Menachem&#xD;Ryan, Dermot&#xD;Salimaki, Johanna&#xD;Sanchez-Borges, Mario M&#xD;Sastre, Joaquin&#xD;Scadding, Glenis K&#xD;Scheire, Sophie&#xD;Schmid-Grendelmeier, Peter&#xD;Schunemann, Holger J&#xD;Sarquis Serpa, Faradiba&#xD;Shamji, Mohamed&#xD;Sisul, Juan-Carlos&#xD;Sole, Dirceu&#xD;Somekh, David&#xD;Sooronbaev, Talant&#xD;Sova, Milan&#xD;Spertini, Francois&#xD;Spranger, Otto&#xD;Stellato, Cristiana&#xD;Stelmach, Rafael&#xD;Thibaudon, Michel&#xD;To, Teresa&#xD;Toumi, Mondher&#xD;Usmani, Omar&#xD;Valero, Antonio A&#xD;Valenta, Rudolph&#xD;Valentin-Rostan, Marylin&#xD;Pereira, Marilyn Urrutia&#xD;van der Kleij, Rianne&#xD;Van Eerd, Michiel&#xD;Vandenplas, Olivier&#xD;Vasankari, Tuula&#xD;Vaz Carneiro, Antonio&#xD;Vezzani, Giorgio&#xD;Viart, Frederic&#xD;Viegi, Giovanni&#xD;Wallace, Dana&#xD;Wagenmann, Martin&#xD;Wang, De Yun&#xD;Waserman, Susan&#xD;Wickman, Magnus&#xD;Williams, Dennis M&#xD;Wong, Gary&#xD;Wroczynski, Piotr&#xD;Yiallouros, Panayiotis K&#xD;Yusuf, Osman M&#xD;Zar, Heather J&#xD;Zeng, Stephane&#xD;Zernotti, Mario E&#xD;Zhang, Luo&#xD;Shan Zhong, Nan&#xD;Zidarn, Mihaela&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):168-190. doi: 10.1111/all.14422. Epub 2020 Oct 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32512619</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14422</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1415</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1415</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Ansotegui, I. J.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Bateman, E. D.</style></author><author><style face="normal" font="default" size="100%">Bennoor, K. S.</style></author><author><style face="normal" font="default" size="100%">Berghea, E. C.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Blain, H.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Bosnic-Anticevich, S.</style></author><author><style face="normal" font="default" size="100%">Boulet, L. P.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Buhl, R.</style></author><author><style face="normal" font="default" size="100%">Camargos, P.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, S.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Christoff, G.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Du, H.</style></author><author><style face="normal" font="default" size="100%">El-Gamal, Y.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Gao, Y.</style></author><author><style face="normal" font="default" size="100%">Gaga, M.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Halpin, D.</style></author><author><style face="normal" font="default" size="100%">Hamelmann, E.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Humbert, M.</style></author><author><style face="normal" font="default" size="100%">Ilina, N.</style></author><author><style face="normal" font="default" size="100%">Ivancevich, J. C.</style></author><author><style face="normal" font="default" size="100%">Joos, G.</style></author><author><style face="normal" font="default" size="100%">Khaitov, M.</style></author><author><style face="normal" font="default" size="100%">Kirenga, B.</style></author><author><style face="normal" font="default" size="100%">Knol, E. F.</style></author><author><style face="normal" font="default" size="100%">Ko, F. W.</style></author><author><style face="normal" font="default" size="100%">Koskinen, S.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author><author><style face="normal" font="default" size="100%">Kraxner, H.</style></author><author><style face="normal" font="default" size="100%">Kudlay, D.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Kupczyk, M.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Abdul Latiff, A. H.</style></author><author><style face="normal" font="default" size="100%">Le, L. T.</style></author><author><style face="normal" font="default" size="100%">Levin, M.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D.</style></author><author><style face="normal" font="default" size="100%">Louis, R.</style></author><author><style face="normal" font="default" size="100%">Masjedi, M. R.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Mihaltan, F.</style></author><author><style face="normal" font="default" size="100%">Milenkovic, B.</style></author><author><style face="normal" font="default" size="100%">Mohammad, Y.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Namazova, L.</style></author><author><style face="normal" font="default" size="100%">Neffen, H.</style></author><author><style face="normal" font="default" size="100%">Nunes, E.</style></author><author><style face="normal" font="default" size="100%">O&apos;Byrne, P.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Ohta, K.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Onorato, G. L.</style></author><author><style face="normal" font="default" size="100%">Panzner, P.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Passalacqua, G.</style></author><author><style face="normal" font="default" size="100%">Patella, V.</style></author><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, N.</style></author><author><style face="normal" font="default" size="100%">Pigearias, B.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Puggioni, F.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Rolla, G.</style></author><author><style face="normal" font="default" size="100%">Rottem, M.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Scichilone, N.</style></author><author><style face="normal" font="default" size="100%">Soto-Quiros, M.</style></author><author><style face="normal" font="default" size="100%">Soto-Martinez, M.</style></author><author><style face="normal" font="default" size="100%">Sova, M.</style></author><author><style face="normal" font="default" size="100%">Nicola, S.</style></author><author><style face="normal" font="default" size="100%">Stelmach, R.</style></author><author><style face="normal" font="default" size="100%">Suppli-Ulrik, C.</style></author><author><style face="normal" font="default" size="100%">Taborda-Barata, L.</style></author><author><style face="normal" font="default" size="100%">To, T.</style></author><author><style face="normal" font="default" size="100%">Tomazic, P. V.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Tsiligianni, I.</style></author><author><style face="normal" font="default" size="100%">Usmani, O.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Viegi, G.</style></author><author><style face="normal" font="default" size="100%">Vontetsianos, T.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Williams, S.</style></author><author><style face="normal" font="default" size="100%">Wong, G. W. K.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Zernotti, M.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Charite, Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin Institute of Health, Berlin, Germany.&#xD;University Hospital Montpellier, Montpellier, France.&#xD;MACVIA-France, Montpellier, France.&#xD;Department of Clinical Immunology, Wroclaw Medical University and ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Akdis M. Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Stanford University School of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford, CA, USA.&#xD;The Hospital for Sick Children, Department of Paediatrics, Division of Clinical Immunology and Allergy, Food allergy and Anaphylaxis Program, The University of Toronto, Toronto, ON, Canada.&#xD;Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Erandio, Spain.&#xD;Centre for Research in Environmental Epidemiology (CREAL), ISGlobAL, Barcelona, Spain.&#xD;IMIM (Hospital del Mar Research Institute), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium.&#xD;International Airway Research Center, First Affiliated Hospital Guangzou, Sun Yat-sen University, Guangzou, China.&#xD;Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Medicine, University of Cape Town, Cape Town, South Africa.&#xD;Department of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.&#xD;Allergology and Clinical Immunology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.&#xD;Clinical Emergency Hospital for Children MS Curie, Bucharest, Romania.&#xD;Department of Geriatrics, Montpellier University Hospital, Montpellier, France.&#xD;EA:2991, Euromov, University Montpellier, Montpellier, France.&#xD;Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;National Heart and Lung Institute, Royal Brompton Hospital and Imperial College London, London, UK.&#xD;Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.&#xD;Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia.&#xD;Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada.&#xD;Allergy and Clinical Immunology Unit, Department of Medical Sciences, University of Torino and Mauriziano Hospital, Torino, Italy.&#xD;Department of Pulmonary Medicine, Mainz University Hospital, Mainz, Germany.&#xD;Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil.&#xD;Personalized Medicine Asthma and Allergy Clinic-Humanitas University and Research Hospital, IRCCS-Milano, Milano, Italy.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall d&apos;Hebron and ARADyAL research network, Barcelona, Spain.&#xD;Division of Allergy/immunology, University of South Florida, Tampa, FL, USA.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Faculty of Public Health, Medical University - Sofia, Sofia, Bulgaria.&#xD;Fundacao ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Brazil.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, University of Cagliari, Cagliari, Italy.&#xD;Department of Respiratory Medicine, Wuhan Children&apos;s Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan, Hubei, China.&#xD;Pediatric Allergy and Immunology Unit, Children&apos;s Hospital, Ain Shams University, Cairo, Egypt.&#xD;Department of Otorhinolaryngology, Academic Medical Centers, AMC, Amsterdam, The Netherlands.&#xD;EUFOREA, Brussels, Belgium.&#xD;Center for Research in Health Technologies and Information Systems, CINTESIS, Universidade do Porto, Porto, Portugal.&#xD;Allergy Unit, Instituto CUF Porto e Hospital CUF Porto, Porto, Portugal.&#xD;Health Information and Decision Sciences Department - CIDES, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.&#xD;Faculdade de Medicina da Universidade do Porto, Porto, Portugal.&#xD;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;7th Respiratory Medicine Department and Asthma Center, Athens Chest Hospital, Athens, Greece.&#xD;Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.&#xD;Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.&#xD;College of Medicine and Health, University of Exeter Medical School, University of Exeter, Exeter, UK.&#xD;Klinik fur Kinder- und Jugendmedizin, Kinderzentrum Bethel, Evangelisches Klinikum Bethel EvKB, University Bielefeld, Bielefeld, Germany.&#xD;Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Service de Pneumologie, Hopital Bicetrem, Inserm UMR_S999, Universite Paris-Sud, Le Kremlin Bicetre, France.&#xD;National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow, Russia.&#xD;IServicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.&#xD;Makerere University Lung Institute, Kampala, Uganda.&#xD;Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong.&#xD;Finnish Institute for Health and Welfare, Helsinki, Finland.&#xD;Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Lodz, Poland.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania.&#xD;Clinic of Chest diseases and Allergology, Faculty of Medicine, Institute of Clinical medicine, Vilnius University, Vilnius, Lithuania.&#xD;Allergy and Immunology Centre, Pantai Hospital, Kuala Lumpur, Malaysia.&#xD;University of Medicine and Pharmacy, Hochiminh City, Vietnam.&#xD;Division Paediatric Allergology, University of Cape Town, Cape Town, South Africa.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;Department of Pulmonary Medicine, CHU Sart-Tilman, and GIGA I3 Research Group, Liege, Belgium.&#xD;Tobacco Control Research Centre, Iranian Anti Tobacco Association, Tehran, Iran.&#xD;Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;National Institute of Pneumology M Nasta, Bucharest, Romania.&#xD;Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, Serbian Association for Asthma and COPD, University of Belgrade, Belgrade, Serbia.&#xD;National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, Syria.&#xD;Syrian Private University-Damascus, Damas, Syria.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain.&#xD;Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.&#xD;Scientific Centre of Children&apos;s Health Under the MoH, Moscow, Russia.&#xD;Russian National Research Medical University Named Pirogov, Moscow, Russia.&#xD;Director of Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina.&#xD;Argentina Center for Allergy and Immunology, Santa Fe, Argentina.&#xD;Servico de Pneumologia Hospital Central and Faculdade de Medicina Dr Eduardo Mondelane, Maputo, Mozambique.&#xD;Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON, Canada.&#xD;Firestone Institute for Respiratory Health, St Joseph&apos;s Healthcare, Hamilton, ON, Canada.&#xD;Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University, and Alfred Health, Melbourne, Vic., Australia.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;National Hospital Organization, Tokyo National Hospital, Tokyo, Japan.&#xD;Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.&#xD;Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic.&#xD;Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children&apos;s Hospital, University of Manchester, Manchester, UK.&#xD;Allergy and Respiratory Diseases, Ospedale Policlino San Martino -University of Genoa, Genoa, Italy.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, &quot;Santa Maria della Speranza&quot; Hospital, Salerno, Italy.&#xD;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Ecole Polytechnique Palaiseau, IRBA (Institut de Recherche bio-Medicale des Armees),, Bretigny, France.&#xD;Societe de Pneumologie de Langue Francaise, Espace Francophone de Pneumologie, Paris, France.&#xD;University Hospital &apos;Sv Ivan Rilski&apos;&quot;, Sofia, Bulgaria.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.&#xD;Faculty of Medicine, Institute of Immunology, University of Coimbra, Coimbra, Portugal.&#xD;Faculty of Medicine, ICBR - Coimbra Institute for Clinical and Biomedical Research, CIBB, University of Coimbra, Coimbra, Portugal.&#xD;Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel.&#xD;Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.&#xD;Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.&#xD;Faculty of Medicine, Fundacion Jimenez Diaz, CIBERES, Autonoma University of Madrid, Madrid, Spain.&#xD;Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.&#xD;The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.&#xD;PROMISE Department, University of Palermo, Palermo, Italy.&#xD;Department of Pediatrics, Hospital Nacional de Ninos, San Jose, Costa Rica.&#xD;Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic.&#xD;Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.&#xD;Department of Respiratory Medicine, Hvidovre Hospital and University of Copenhagen, Copenhagen, Denmark.&#xD;Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal.&#xD;Department of Immunoallergology, Cova da Beira University Hospital Centre, Covilha, Portugal.&#xD;The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.&#xD;Department of General ORL, H&amp;NS, Medical University of Graz, ENT-University Hospital Graz, Graz, Austria.&#xD;Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece.&#xD;International Primary Care Respiratory Group International Primary Care Respiratory Group, (IPCRG), Aberdeen, Scotland.&#xD;Airways Disease Section, National Heart and Lung Institute (NHLI), Imperial College London and Royal Brompton Hospital, London, UK.&#xD;Faculty of Medicine, Institute of Clinical Medicine and Institute of Health Sciences, Vilnius University, Vilnius, Lithuania.&#xD;European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium.&#xD;Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.&#xD;Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy.&#xD;CNR Institute for Biomedical Research and Innovation, Palermo, Italy.&#xD;Sotiria Hospital, Athens, Greece.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland.&#xD;Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.&#xD;Department of Pulmonology, Celal Bayar University, Manisa, Turkey.&#xD;Universidad Nacional de Villa Maria, Universidad Catolica de Cordoba, Cordoba, Argentina.&#xD;University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.&#xD;Transylvania University Brasov, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">689-697</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/*complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32588922</style></accession-num><notes><style face="normal" font="default" size="100%">Bousquet, Jean&#xD;Jutel, Marek&#xD;Akdis, Cezmi A&#xD;Klimek, Ludger&#xD;Pfaar, Oliver&#xD;Nadeau, Kari C&#xD;Eiwegger, Thomas&#xD;Bedbrook, Anna&#xD;Ansotegui, Ignacio J&#xD;Anto, Josep M&#xD;Bachert, Claus&#xD;Bateman, Eric D&#xD;Bennoor, Kazi S&#xD;Berghea, Elena Camelia&#xD;Bergmann, Karl-Christian&#xD;Blain, Hubert&#xD;Bonini, Mateo&#xD;Bosnic-Anticevich, Sinthia&#xD;Boulet, Louis-Philippe&#xD;Brussino, Luisa&#xD;Buhl, Roland&#xD;Camargos, Paulo&#xD;Canonica, Giorgio Walter&#xD;Cardona, Victoria&#xD;Casale, Thomas&#xD;Chinthrajah, Sharon&#xD;Akdis, Mubeccel&#xD;Chivato, Tomas&#xD;Christoff, George&#xD;Cruz, Alvaro A&#xD;Czarlewski, Wienczyslawa&#xD;Del Giacco, Stefano&#xD;Du, Hui&#xD;El-Gamal, Yehia&#xD;Fokkens, Wytske J&#xD;Fonseca, Joao A&#xD;Gao, Yadong&#xD;Gaga, Mina&#xD;Gemicioglu, Bilun&#xD;Gotua, Maia&#xD;Haahtela, Tari&#xD;Halpin, David&#xD;Hamelmann, Eckard&#xD;Hoffmann-Sommergruber, Karin&#xD;Humbert, Marc&#xD;Ilina, Nataliya&#xD;Ivancevich, Juan-Carlos&#xD;Joos, Guy&#xD;Khaitov, Musa&#xD;Kirenga, Bruce&#xD;Knol, Edward F&#xD;Ko, Fanny W&#xD;Koskinen, Seppo&#xD;Kowalski, Marek L&#xD;Kraxner, Helga&#xD;Kudlay, Dmitry&#xD;Kuna, Piotr&#xD;Kupczyk, Maciej&#xD;Kvedariene, Violeta&#xD;Abdul Latiff, Amir H&#xD;Le, Lan T&#xD;Levin, Michael&#xD;Larenas-Linnemann, Desiree&#xD;Louis, Renaud&#xD;Masjedi, Mohammad R&#xD;Melen, Erik&#xD;Mihaltan, Florin&#xD;Milenkovic, Branislava&#xD;Mohammad, Yousser&#xD;Morais-Almeida, Mario&#xD;Mullol, Joaquim&#xD;Namazova, Leyla&#xD;Neffen, Hugo&#xD;Nunes, Elisabete&#xD;O&apos;Byrne, Paul&#xD;O&apos;Hehir, Robyn&#xD;O&apos;Mahony, Liam&#xD;Ohta, Ken&#xD;Okamoto, Yoshitaka&#xD;Onorato, Gabrielle L&#xD;Panzner, Petr&#xD;Papadopoulos, Nikos G&#xD;Passalacqua, Gianni&#xD;Patella, Vincenzo&#xD;Pawankar, Ruby&#xD;Pham-Thi, Nhan&#xD;Pigearias, Bernard&#xD;Popov, Todor A&#xD;Puggioni, Francesca&#xD;Regateiro, Frederico S&#xD;Rolla, Giovanni&#xD;Rottem, Menachem&#xD;Samolinski, Boleslaw&#xD;Sastre, Joaquin&#xD;Schwarze, Jurgen&#xD;Sheikh, Aziz&#xD;Scichilone, Nicola&#xD;Soto-Quiros, Manuel&#xD;Soto-Martinez, Manuel&#xD;Sova, Milan&#xD;Nicola, Stefania&#xD;Stelmach, Rafael&#xD;Suppli-Ulrik, Charlotte&#xD;Taborda-Barata, Luis&#xD;To, Teresa&#xD;Tomazic, Peter-Valentin&#xD;Toppila-Salmi, Sanna&#xD;Tsiligianni, Ioanna&#xD;Usmani, Omar&#xD;Valiulis, Arunas&#xD;Ventura, Maria Teresa&#xD;Viegi, Giovanni&#xD;Vontetsianos, Theodor&#xD;Wang, De Yun&#xD;Williams, Sian&#xD;Wong, Gary W K&#xD;Yorgancioglu, Arzu&#xD;Zernotti, Mario&#xD;Zidarn, Mihaela&#xD;Zuberbier, Torsten&#xD;Agache, Ioana&#xD;eng&#xD;N/A/ARIA/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):689-697. doi: 10.1111/all.14471. Epub 2020 Sep 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32588922</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7361514 Idorsia, Swiss National Science Foundation, Christine Kuhne-Center for Allergy Research and Education, European Commission&apos;s Horison&apos;s 2020 Framework Programme, Cure, Novartis Research Institutes, Astra Zeneca, Scibase, advisory role in Sanofi/Regeneron. IA reports personal fees from Mundipharma, Roxall, Sanofi, MSD, Faes Farma, Hikma, UCB, Astra Zeneca, Stallergenes, Abbott, Bial. EB is a member of the Science Committee and Board of the Global Initiative for Asthma (GINA). SBA reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan. JPB reports grants from AstraZeneca, Boston Scientific, GSK, Hoffman La Roche, Ono Pharma, Novartis, Sanofi, Takeda, Boehringer-Ingelheim, Merck, personal fees from AstraZeneca, GSK, Merck, Metapharm, Novartis, Takeda, other from AstraZeneca, Boehringer-Ingelheim, GSK, Merck, Novartis. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach, other from KYomed-Innov. RB reports grants to Mainz University and personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche, as well as personal fees from AstraZeneca, Chiesi, Cipla, Sanofi, and Teva. VC reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermo Fisher, Stallergenes. RSC reports grants from NIAID, CoFAR, Aimmune, DBV Technologies, Astellas, Regeneron, an Advisory member for Alladapt, Genentech, Novartis, and receives personal fees from Before Brands. AC reports grants and personal fees from GSK, SANOFI, Boehringer-Ingelheim, Astrazeneca, Mantecorp, MYLAN, Novartis, personal fees and non-financial support from CHIESI. SdG reports personal fees from AstraZeneca, Chiesi, Menarini, grants and personal fees from GSK, Novartis. DH reports personal fees from AstraZeneca, Chiesi, GSK, Pfizer, personal fees and non-financial support from Boehringer Ingelheim, Novartis. TE reports other from DBV, Regeneron, grants from Innovation fund Denmark and Co-I or scientific lead in three investigator initiated oral immunotherapy trials supported by the Allergy and Anaphylaxis Program Sickkids and serve as associate editor for Allergy. Advisory board ALK. JF reports personal fees from AstraZeneca, GSK, undipharma, grants and personal fees from Novartis. MG reports grants and personal fees from Elpen, Novartis, Menarini, grants from Galapagos, personal fees from BMS, MSD. TH reports personal fees from GSK, Mundipharma, OrionPharma. MH reports personal fees and non-financial support from GlaxoSmithKline, personal fees from Astrazeneca, Novartis, Roche, Sanofi, Teva. JCI reports personal fees from Faes Farma, Eurofarma Argentina, other from Laboratorios Casasco, Sanofi. GJ reports grants from AstraZeneca, Chiesi, personal fees from Bayer, Eureca vzw, Teva, grants and personal fees from GlaxoSmithKline. MJ reports personal fees from ALK-Abello, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, Leti, Biomay, from HAL, Astra-Zeneka, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, Medimmune, Chiesi, LK reports grants and personal fees from Allergopharma, LETI Pharma, MEDA/Mylan, Sanofi, personal fees from HAL Allergie, Allergy Therapeut., grants from ALK Abello, Stallergenes, Quintiles, ASIT biotech, grants from Lofarma, AstraZeneca, GSK, Inmunotk and Membership: AeDA, DGHNO,Deutsche Akademie fur Allergologie und klinische Immunologie, HNO-BV GPA,EAACI. PK reports personal fees from Astra, Boehringer Ingelheim, Berlin Chemie Menarini, GSK, Lekam, Novartis, Polpharma, Mylan, Orion, Teva, Adamed. VK reports personal fees from GSK, non-financial support from StallergenGreer, AstraZeneca, Norameda, DIMUNA. DLL reports personal fees from Allakos, Amstrong, Astrazeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Novartis, Sanofi, Siegfried, UCB, Alakos, Gossamer, grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Boehringer Ingelheim, Chiesi, Purina institute. RL reports grants and personal fees from AZ, GSK, Novartis, grants from Chiesi, JM reports personal fees and other from SANOFI-GENZYME &amp; REGENERON, NOVARTIS, ALLAKOS, grants and personal fees from MYLAN Pharma, URIACH Group, personal fees from Mitsubishi-Tanabe, Menarini, UCB, AstraZeneca, GSK, from MSD, outside the submitted work. KN reports grants and other from NIAID, FARE, personal fees and other from Regeneron, grants from EAT, other from Sanofi, Astellas, Nestle, BeforeBrands, Alladapt, ForTra, Genentech, AImmune Therapeutics, DBV Technologies, personal fees from Astrazeneca, ImmuneWorks, Cour Pharmaceuticals, grants from Allergenis, Ukko Pharma, Novartis,AnaptysBio, Adare Pharmaceuticals, Stallergenes-Greer, NHLBI, NIEHS, EPA, WAO Center of Excellence, Iggenix, Probio, Vedanta, Centecor, Seed, Immune Tolerance Network, NIH,; In addition, Dr Nadeau has a patent Inhibition of Allergic Reaction to Peanut Allergen using an IL-33 Inhibitor pending, a patent Special Oral Formula for Decreasing Food Allergy Risk and Treatment for Food Allergy pending, a patent Basophil Activation Based Diagnostic Allergy Test pending, a patent Granulocyte-based methods for detecting and monitoring immune system disorders pending, a patent Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders pending, a patent Mixed Allergen Compositions and Methods for Using the Same pending, and a patent Microfluidic Device and Diagnostic Methods for Allergy Testing Based on Detection of Basophil Activation pending. YO reports personal fees from Shionogi Co., Ltd., Torii Co., Ltd., GSK, MSD, Eizai Co.,Ltd., grants and personal fees from Kyorin Co., Ltd., Tiho Co., Ltd., grants from Yakuruto Co., Ltd., Yamada Bee Farm. ROB reports grants and personal fees from AstraZeneca, GSK, grants from Novartis, Medimmune, Bayer. YO reports personal fees from Shionogi Co., Ltd., Torii Co., Ltd., GSK, MSD, Eizai Co.,Ltd., grants and personal fees from Kyorin Co., Ltd., Tiho Co., Ltd., grants from Yakuruto Co., Ltd., Yamada Bee Farm, outside the submitted work. NP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. OP reports grants and personal fees from Anergis SA, ALK-Abello, Allergopharma, Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools SA, Laboratorios LETI/LETI Pharma, grants from Biomay, Glaxo Smith Kline Circassia, personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA(2)LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL, NOVARTIS, SANOFI AVENTIS, Med Update Europe GmbH, streamedup! GmbH. FP reports sanofi, novartis, teva, astrazeneca, glaxosmithkline, menarini, mundipharma, guidotti, malesci, chiesi, valeas, allergy therapeutics, almirall, personal fees from boehringer Ingelheim. FR reports personal fees from AstraZeneca, Novartis, Lusomedicamenta, Sanofi, GSK. JS reports other from MEDA, grants and personal fees from SANOFI, personal fees from GSK, NOVARTIS, ASTRA ZENECA, MUNDIPHARMA, FAES FARMA. JSchwarze reports personal fees from MYLAN, outside the submitted work. ASheikh reports support of the Asthma UK Centre for Applied Research. RS reports grants from Sao Paulo Research Foundation, MSD,grants and personal fees from Novartis, grants, personal fees and non-financial support from AstraZeneca, Chiesi, Boehringer Ingelheim. IT reports grants from GSK Hellas, ELPEN, personal fees from Boehringer Ingelheim, Novartis, Astra Zeneca, GSK. TZ reports Organizational affiliations: Committee member: WHO-Initiative &quot;Allergic Rhinitis and Its Impact on Asthma&quot; (ARIA); Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI); Head: European Centre for Allergy Research Foundation (ECARF); President: Global Allergy and Asthma European Network (GA(2)LEN); Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). The other authors have no COI to declare.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14471</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1209</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1209</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Ring, J.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Knol, E.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF, University of Zurich, Davos, Switzerland.&#xD;Department of Dermatology and Allergy, Comprehensive Allergy Center, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Charite, Universitatsmedizin Berlin, Berlin, Germany.&#xD;University Hospital Montpellier, Montpellier, France.&#xD;MACVIA-France, Montpellier, France.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-UMA-ARADyAL, Malaga, Spain.&#xD;Transylvania University Brasov, Brasov, Romania.&#xD;Personalized Medicine Clinic Asthma &amp; Allergy, Humanitas Research Hospital-IRCCS, Milan, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, University of Cagliari, Cagliari, Italy.&#xD;Department of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Child Life and Health and Centre for Inflammation Research, Queen&apos;s Medical Research Institute, The University of Edinburgh, Edinburgh, UK.&#xD;Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Dermatology and Allergy, TUM, Munich, Germany.&#xD;Departments of Immuno and Dermatology/Allergology, University Medical Center, Utrecht, Netherlands.&#xD;School of medicine. University CEU San Pablo, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1624-1628</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">BNT162b2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA</style></keyword><keyword><style face="normal" font="default" size="100%">severe allergic reactions</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33378789</style></accession-num><abstract><style face="normal" font="default" size="100%">Further to the approval of the Coronavirus disease 2019 (COVID-19) vaccine BNT162b2, several severe anaphylaxis cases occured within the first few days of public vaccination. An investigation is taking place to understand the cases and their triggers. The vaccine will be administered to a large number of individuals worldwide and there are raising concerns that severe adverse events might occur. With the current information, the European Academy of Allergy and Clinical Immunology (EAACI) states its position for the following preliminary recommendations that are to be revised as soon as more data emerge. To minimize the risk of severe allergic reactions in vaccinated individuals, it is urgently required to understand the specific nature of the reported severe allergic reactions, including the background medical history of the individuals affected and the mechanisms involved. To achieve this goal, all clinical and laboratory information should be collected and reported. Mild and moderate allergic patients should not be excluded from the vaccine as this could have a significant impact on reaching the goal of population immunity. Healthcare practitioners vaccinating against COVID-19 are required to be sufficiently prepared to recognize and treat anaphylaxis properly with the ability to administer adrenaline. Further to vaccine administration, a mandatory observation period of at least 15 minutes should be followed for all individuals. The current data have not shown any higher risk for patients suffering from allergic rhinitis or asthma, and this message should be clearly stated by physicians to enable our patients to trust the vaccine. More than 30% of the population suffers from allergic diseases and the benefit of the vaccination clearly outweighs the risk of severe COVID-19 development.</style></abstract><notes><style face="normal" font="default" size="100%">Klimek, Ludger&#xD;Jutel, Marek&#xD;Akdis, Cezmi A&#xD;Bousquet, Jean&#xD;Akdis, Mubeccel&#xD;Torres, Maria J&#xD;Agache, Ioana&#xD;Canonica, G Walter&#xD;Del Giacco, Stefano&#xD;O&apos;Mahony, Liam&#xD;Shamji, Mohamed H&#xD;Schwarze, Jurgen&#xD;Untersmayr, Eva&#xD;Ring, Johannes&#xD;Bedbrook, Anna&#xD;Worm, Margitta&#xD;Zuberbier, Torsten&#xD;Knol, Edward&#xD;Hoffmann-Sommergruber, Karin&#xD;Chivato, Tomas&#xD;eng&#xD;Consensus Development Conference&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1624-1628. doi: 10.1111/all.14726.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33378789</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14726</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2119</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2119</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, X.</style></author><author><style face="normal" font="default" size="100%">Xiao, Y.</style></author><author><style face="normal" font="default" size="100%">Jing, D.</style></author><author><style face="normal" font="default" size="100%">Huang, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, S.</style></author><author><style face="normal" font="default" size="100%">Huang, Z.</style></author><author><style face="normal" font="default" size="100%">Yang, G.</style></author><author><style face="normal" font="default" size="100%">Duan, Y.</style></author><author><style face="normal" font="default" size="100%">He, M.</style></author><author><style face="normal" font="default" size="100%">Su, J.</style></author><author><style face="normal" font="default" size="100%">Chen, M.</style></author><author><style face="normal" font="default" size="100%">Chen, X.</style></author><author><style face="normal" font="default" size="100%">Shen, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.&#xD;Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.&#xD;Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, Hunan, China.&#xD;Hunan Engineering Research Center of Skin Health and Disease, Changsha, Hunan, China.&#xD;Furong Laboratory, Changsha, Hunan, China.&#xD;National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Changsha, Hunan, China.&#xD;Department of Dermatology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.&#xD;Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.&#xD;Department of Environmental and Occupational Health, Xiangya School of Public Health, Central South University, Changsha, Hunan, China.&#xD;Department of Environmental and Occupational Health, Tongji School of Public Health, Huazhong University of Science and Technology, Wuhan, Hubei, China.&#xD;Department of Social Medicine and Health Management, Xiangya School of Public Health, Central South University, Changsha, Hunan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Arsenic exposure and pruritus: Evidence from observational, interventional, and mendelian randomization studies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1585-1594</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/05/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Arsenic/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">*Arsenites/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">beta-Endorphin/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Mendelian Randomization Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Naloxone/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">arsenic exposure</style></keyword><keyword><style face="normal" font="default" size="100%">chronic pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">beta-Endorphin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37129453</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Pruritus is identified as an adverse drug reaction to arsenic trioxide, but the association of arsenic exposure with pruritus has not been investigated. METHODS: A cross-sectional study was conducted in Shimen, China. A Mendelian randomization analysis was conducted to confirm the causal relationship between genetically predicted percentages of monomethylated arsenic (MMA%) and dimethylated arsenic (DMA%) in urine with chronic pruritus in UK Biobank. A case-control study was then conducted to determine the biomarker for pruritus. Arsenite-treated mice were used to confirm the biomarker, and von Frey test was used to induce scratching bouts. Last, a randomized, double-blind, placebo-controlled trial was conducted to test the efficacy of naloxone in arsenic-exposed patients with pruritus in Shimen. RESULTS: Hair arsenic (mug/g) showed a dose-response relationship with the intensity of itch in 1079 participants, with odds ratios (OR) of 1.11 for moderate-to-severe itch (p = 0.012). The Mendelian randomization analysis confirmed the causal relationship, with ORs of 1.043 for MMA% (p = 0.029) and 0.904 for DMA% (p = 0.077) above versus under median. Serum beta-endorphin was identified as a significant biomarker for the intensity of itch (p &lt; 0.001). Consistently, treatment with arsenite upregulated the level of beta-endorphin (p = 0.002) and induced scratching bouts (p &lt; 0.001) in mice. The randomized controlled trial in 126 participants showed that treatment with sublingual naloxone significantly relieved the intensity of itch in arsenic-exposed participants in 2 weeks (beta = -0.98, p = 0.04). CONCLUSION: Arsenic exposure is associated with pruritus, and beta-endorphin serves as a biomarker of pruritus. Naloxone relieves pruritus in patients with arseniasis.</style></abstract><notes><style face="normal" font="default" size="100%">Huang, Xiaoyan&#xD;Xiao, Yi&#xD;Jing, Danrong&#xD;Huang, Yuzhou&#xD;Yang, Songchun&#xD;Huang, Zhijun&#xD;Yang, Guoping&#xD;Duan, Yanying&#xD;He, Meian&#xD;Su, Juan&#xD;Chen, Mingliang&#xD;Chen, Xiang&#xD;Shen, Minxue&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1585-1594. doi: 10.1111/all.15758. Epub 2023 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37129453</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15758</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3190</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scala, E.</style></author><author><style face="normal" font="default" size="100%">Cusa, G.</style></author><author><style face="normal" font="default" size="100%">Villella, V.</style></author><author><style face="normal" font="default" size="100%">Abeni, D.</style></author><author><style face="normal" font="default" size="100%">Giani, M.</style></author><author><style face="normal" font="default" size="100%">Guerra, E. C.</style></author><author><style face="normal" font="default" size="100%">Locanto, M.</style></author><author><style face="normal" font="default" size="100%">Meneguzzi, G.</style></author><author><style face="normal" font="default" size="100%">Pirrotta, L.</style></author><author><style face="normal" font="default" size="100%">Quaratino, D.</style></author><author><style face="normal" font="default" size="100%">Zaffiro, A.</style></author><author><style face="normal" font="default" size="100%">Caprini, E.</style></author><author><style face="normal" font="default" size="100%">Barrale, M.</style></author><author><style face="normal" font="default" size="100%">Brusca, I.</style></author><author><style face="normal" font="default" size="100%">Pravettoni, V.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Villalta, D.</style></author><author><style face="normal" font="default" size="100%">Aumayr, M.</style></author><author><style face="normal" font="default" size="100%">Mittermann, I.</style></author><author><style face="normal" font="default" size="100%">Lupinek, C.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fondazione Luigi Maria Monti, IDI-IRCCS, Rome, Italy.&#xD;U.O.C of Clinical Pathology, Buccheri La Ferla Hospital, Palermo, Italy.&#xD;Department of Internal Medicine, Fondazione IRCCS ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Allergy and Clinical Immunology Unit, San Giovanni di Dio Hospital, Florence, Italy.&#xD;S.C. di Immunologia e Allergologia di Laboratorio, PO S. Maria Degli Angeli, Pordenone, Italy.&#xD;Macro Array Diagnostics, Vienna, Austria.&#xD;Ambulatorio di Allergologia, Clinica San Carlo, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Art v 1 and Amb a 4 Co-Sensitization Identifies Italian Patients at Risk for Mugwort-Celery-Spice Syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41424259</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Pollen defensins such as Art v 1 (mugwort) and Amb a 4 (ragweed) are pivotal allergens in pollen-food syndromes, but their clinical role in Southern Europe is poorly defined. OBJECTIVE: To characterize sensitization to defensins and related allergens in Italy and its association with clinical phenotypes. METHODS: Between 2021 and 2025, 7176 patients underwent molecular testing in three Italian centers. Sensitization to the pollen defensins Art v 1 and Amb a 4 was evaluated, together with celery allergens representing different protein families: the PR-10 Api g 1, the nsLTPs Api g 2, Api g 6, and the defensin Api g 7 (tested in a subset). Panallergens were also assessed. RESULTS: Defensin sensitization occurred in 272 patients (3.8%). Art v 1 mono-sensitization (64.7%) was largely confined to respiratory disease. Dual Art v 1-Amb a 4 sensitization (30.5%) identified a distinct subgroup at high risk of food reactions (OR = 6.9; p &lt; 0.0001). Amb a 4 sensitization followed a clear northward gradient. Among 90 patients tested for Api g 7, 82.7% were positive, all co-sensitized to Art v 1, and one-third also to Amb a 4. IgE inhibition confirmed Art v 1 as the primary sensitizer driving defensin cross-reactivity. In contrast, Api g 2 nsLTP sensitization was strongly associated with severe systemic reactions. CONCLUSIONS: Defensin sensitization in Italy reveals distinct molecular and geographic signatures. Isolated Art v 1 sensitization dominates and marks respiratory allergy, while co-sensitization to Amb a 4-often associated with Api g 7 co-recognition-defines patients at high risk for systemic food reactions.</style></abstract><notes><style face="normal" font="default" size="100%">Scala, Enrico&#xD;Cusa, Gabriella&#xD;Villella, Valeria&#xD;Abeni, Damiano&#xD;Giani, Mauro&#xD;Guerra, Emma Cristina&#xD;Locanto, Maria&#xD;Meneguzzi, Giorgia&#xD;Pirrotta, Lia&#xD;Quaratino, Donato&#xD;Zaffiro, Alessandra&#xD;Caprini, Elisabetta&#xD;Barrale, Maria&#xD;Brusca, Ignazio&#xD;Pravettoni, Valerio&#xD;Cecchi, Lorenzo&#xD;Villalta, Danilo&#xD;Aumayr, Martina&#xD;Mittermann, Irene&#xD;Lupinek, Christian&#xD;Asero, Riccardo&#xD;eng&#xD;Ministero della Salute/&#xD;Denmark&#xD;Allergy. 2025 Dec 22. doi: 10.1111/all.70195.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41424259</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70195</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2401</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2401</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tang, L.</style></author><author><style face="normal" font="default" size="100%">Wang, P.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Zhao, J.</style></author><author><style face="normal" font="default" size="100%">Pang, C.</style></author><author><style face="normal" font="default" size="100%">Xiang, L.</style></author><author><style face="normal" font="default" size="100%">Ge, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing Children&apos;s Hospital, Capital Medical University, National Center for Children&apos;s Health, Beijing, China.&#xD;Department of Otorhinolaryngology, The Fourth Hospital of Baotou, Baotou, China.&#xD;Department of Otolaryngology Head and Neck Surgery, Children&apos;s Hospital Attached to the Capital Institute of Pediatrics, Beijing, China.&#xD;Department of Allergy, Beijing Children&apos;s Hospital, Capital Medical University, National Center for Children&apos;s Health, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Artemisia annua sublingual immunotherapy in children with seasonal allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1376-1379</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Artemisia annua</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts/administration &amp; dosage</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38375928</style></accession-num><notes><style face="normal" font="default" size="100%">Tang, Lixing&#xD;Wang, Pengpeng&#xD;Yang, Xiaojian&#xD;Zhao, Jinchi&#xD;Pang, Chong&#xD;Xiang, Li&#xD;Ge, Wentong&#xD;eng&#xD;Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd./&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1376-1379. doi: 10.1111/all.16073. Epub 2024 Feb 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38375928</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16073</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1375</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1375</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xian, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Artemisia annua-sublingual immunotherapy: First step to cross the chasm</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">425-427</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/08/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Artemisia annua</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32740960</style></accession-num><notes><style face="normal" font="default" size="100%">Xian, Mu&#xD;Zhang, Luo&#xD;eng&#xD;Editorial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):425-427. doi: 10.1111/all.14539.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32740960</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14539</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2149</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2149</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Zemelka-Wiacek, M.</style></author><author><style face="normal" font="default" size="100%">Ordak, M.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Rechenmacher, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The artificial intelligence (AI) revolution: How important for scientific work and its reliable sharing</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2085-2088</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/06/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Artificial Intelligence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37278131</style></accession-num><notes><style face="normal" font="default" size="100%">Jutel, Marek&#xD;Zemelka-Wiacek, Magdalena&#xD;Ordak, Michal&#xD;Pfaar, Oliver&#xD;Eiwegger, Thomas&#xD;Rechenmacher, Maximilian&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2085-2088. doi: 10.1111/all.15778. Epub 2023 Jun 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37278131</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15778</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>30</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">30</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shim, J. S.</style></author><author><style face="normal" font="default" size="100%">Kim, M. H.</style></author><author><style face="normal" font="default" size="100%">Lee, S. M.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Kwon, J. W.</style></author><author><style face="normal" font="default" size="100%">Song, C.</style></author><author><style face="normal" font="default" size="100%">Ahn, K. M.</style></author><author><style face="normal" font="default" size="100%">Kang, S. Y.</style></author><author><style face="normal" font="default" size="100%">Park, H. K.</style></author><author><style face="normal" font="default" size="100%">Park, H. W.</style></author><author><style face="normal" font="default" size="100%">Kim, B. K.</style></author><author><style face="normal" font="default" size="100%">Yang, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.&#xD;Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.&#xD;Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Republic of Korea.&#xD;Soundable Health, Inc., California, San Francisco, USA.&#xD;Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea.&#xD;Division of Allergy and Clinical Immunology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.&#xD;Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.&#xD;Division of Pulmonology, Allergy and Critical Care Medicine, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An artificial intelligence algorithm-based smartphone application for daily cough monitoring</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1378-1380</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/01/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Artificial Intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">*Cough/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Smartphone</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36588171</style></accession-num><notes><style face="normal" font="default" size="100%">Shim, Ji-Su&#xD;Kim, Min-Hye&#xD;Lee, Sang Min&#xD;Kim, Sae-Hoon&#xD;Kwon, Jae-Woo&#xD;Song, Catherine&#xD;Ahn, Kyung-Min&#xD;Kang, Sung-Yoon&#xD;Park, Han-Ki&#xD;Park, Heung-Woo&#xD;Kim, Byung-Keun&#xD;Yang, Min-Suk&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1378-1380. doi: 10.1111/all.15632. Epub 2023 Jan 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36588171</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15632</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3321</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3321</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Luo, Xin</style></author><author><style face="normal" font="default" size="100%">Li, Hansheng</style></author><author><style face="normal" font="default" size="100%">Chen, Jianning</style></author><author><style face="normal" font="default" size="100%">Zhou, Zhihao</style></author><author><style face="normal" font="default" size="100%">Liang, Guixian</style></author><author><style face="normal" font="default" size="100%">Chao, Manhou</style></author><author><style face="normal" font="default" size="100%">Yuan, Tian</style></author><author><style face="normal" font="default" size="100%">Zhang, He</style></author><author><style face="normal" font="default" size="100%">Kang, Ning</style></author><author><style face="normal" font="default" size="100%">Xu, Zhaofeng</style></author><author><style face="normal" font="default" size="100%">Sun, Yueqi</style></author><author><style face="normal" font="default" size="100%">Hong, Haiyu</style></author><author><style face="normal" font="default" size="100%">Xu, Yuanteng</style></author><author><style face="normal" font="default" size="100%">Zhang, Ya</style></author><author><style face="normal" font="default" size="100%">Zheng, Guoxi</style></author><author><style face="normal" font="default" size="100%">Lv, Mei</style></author><author><style face="normal" font="default" size="100%">Wang, Song</style></author><author><style face="normal" font="default" size="100%">Zhang, Hua</style></author><author><style face="normal" font="default" size="100%">Zhao, Chuanliang</style></author><author><style face="normal" font="default" size="100%">Yu, Shaoqing</style></author><author><style face="normal" font="default" size="100%">Shen, Yang</style></author><author><style face="normal" font="default" size="100%">Yang, Yucheng</style></author><author><style face="normal" font="default" size="100%">Cheng, Fengli</style></author><author><style face="normal" font="default" size="100%">Zhao, Changqing</style></author><author><style face="normal" font="default" size="100%">Peng, Zican</style></author><author><style face="normal" font="default" size="100%">Liu, Zheng</style></author><author><style face="normal" font="default" size="100%">Wei, Xin</style></author><author><style face="normal" font="default" size="100%">Ba, Luo</style></author><author><style face="normal" font="default" size="100%">Wang, Zhenlin</style></author><author><style face="normal" font="default" size="100%">Qin, Long</style></author><author><style face="normal" font="default" size="100%">Qin, Zili</style></author><author><style face="normal" font="default" size="100%">Mo, Binyu</style></author><author><style face="normal" font="default" size="100%">Lin, Haoran</style></author><author><style face="normal" font="default" size="100%">Li, Yuming</style></author><author><style face="normal" font="default" size="100%">Xu, Lei</style></author><author><style face="normal" font="default" size="100%">Shen, Zhanhua</style></author><author><style face="normal" font="default" size="100%">Lai, Ming</style></author><author><style face="normal" font="default" size="100%">Pan, Jigui</style></author><author><style face="normal" font="default" size="100%">Yang, Yani</style></author><author><style face="normal" font="default" size="100%">Li, Gang</style></author><author><style face="normal" font="default" size="100%">Hu, Guowen</style></author><author><style face="normal" font="default" size="100%">Qin, Yong</style></author><author><style face="normal" font="default" size="100%">Kong, Weifeng</style></author><author><style face="normal" font="default" size="100%">Wu, Shuo</style></author><author><style face="normal" font="default" size="100%">Shi, Zhaohui</style></author><author><style face="normal" font="default" size="100%">Zhang, Yana</style></author><author><style face="normal" font="default" size="100%">Cheng, Na</style></author><author><style face="normal" font="default" size="100%">Zhang, Nana</style></author><author><style face="normal" font="default" size="100%">Shao, Chunkui</style></author><author><style face="normal" font="default" size="100%">Liu, Zifeng</style></author><author><style face="normal" font="default" size="100%">Wang, Xun</style></author><author><style face="normal" font="default" size="100%">Lin, Haotian</style></author><author><style face="normal" font="default" size="100%">Cui, Lei</style></author><author><style face="normal" font="default" size="100%">Yang, Lin</style></author><author><style face="normal" font="default" size="100%">Yang, Qintai</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Artificial Intelligence-Based Pathological Subtype Diagnosis of Nasal Polyps: A Multidimensional and Micro-Visualization Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Nasal polyps (NP) are common upper respiratory conditions with diverse inflammatory subtypes influencing clinical features and prognosis. Manual counting of inflammatory cells in microscopic images (MI) is laborious and subjective, limiting diagnostic precision and treatment decisions. Methods A total of 2457 slides from 20 hospitals were used to develop an AI-based NP subtype diagnosis system (NPSS). NPSS-MI was built using 1047 slides (15,705 MIs) annotated by pathologists. NPSS-WSI was trained on 1410 slides (21,150 images) combining PA-P2PNet for cell detection and U-KAN for region segmentation. Three-dimensional reconstruction (3DNP) using registration and point cloud analysis enabled spatial quantification of inflammatory cells. Twelve pathologists evaluated NPSS accuracy and efficiency on 200 slides, and recurrence prediction models were developed using logistic regression in a 131-patient cohort. Results NPSS achieved performance with a weighted average F1-score of 0.809 for cell detection and an intersection over union (IoU) of 0.827 for region segmentation with an internal dataset. External dataset performance showed an F1-score of 0.792 and an IoU of 0.815. Forty randomly accumulated MIs were approximated WSI results. NPSS-MI and NPSS-WSI reached accuracies of 90% and 91%, reducing diagnostic time from 193 to 8 s and from 10,450 to 250 s, respectively. Junior pathologists using NPSS improved accuracy from 50% to 89%. Inflammatory cells showed distinct spatial patterns in 3DNP. NPSS-WSI prognostic model outperformed the MI-based model (AUC 86.64% vs. 79.81%, p = 0.039). Conclusions NPSS integrates MI, WSI, and 3DNP to enable accurate and efficient NP subtype diagnosis and prognosis prediction, greatly enhancing diagnostic precision and clinical utility.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70282</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70282</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1014</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1014</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Thong, B. Y.</style></author><author><style face="normal" font="default" size="100%">Tiongco-Recto, M.</style></author><author><style face="normal" font="default" size="100%">Wang, J. Y.</style></author><author><style face="normal" font="default" size="100%">Abdul Latiff, A. H.</style></author><author><style face="normal" font="default" size="100%">Thien, F.</style></author><author><style face="normal" font="default" size="100%">Oh, J. W.</style></author><author><style face="normal" font="default" size="100%">Kamchaisatian, W.</style></author><author><style face="normal" font="default" size="100%">Rengganis, I.</style></author><author><style face="normal" font="default" size="100%">Udwadia, Z. F.</style></author><author><style face="normal" font="default" size="100%">Dhar, R.</style></author><author><style face="normal" font="default" size="100%">Munkhbayarlakh, S.</style></author><author><style face="normal" font="default" size="100%">Narantsetseg, L.</style></author><author><style face="normal" font="default" size="100%">Le Pham, D.</style></author><author><style face="normal" font="default" size="100%">Leung, T. F.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Apaaaci Covid- Working Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore City, Singapore.&#xD;Division of Allergy and Immunology, Department of Pediatrics, University of the Philippines-Philippine General Hospital, Manila, Philippines.&#xD;Centre of Allergy and Clinical Immunology Research (ACIR), Department of Paediatrics, National Cheng Kung University Hospital, Tainan, Taiwan.&#xD;Allergy &amp; Immunology Centre Pantai Hospital, Kuala Lumpur, Malaysia.&#xD;Department of Paediatrics, Universiti Putra Malaysia Teaching Hospital, Kuala Lumpur, Malaysia.&#xD;Eastern Health, Monash University, Melbourne, Vic, Australia.&#xD;Department of Pediatrics, Hanyang University Guri Hospital, Guri, Gyunggi-Do, Korea.&#xD;Pediatric Allergy and Immunology Division, Samitivej Children&apos;s Hospital, Bangkok, Thailand.&#xD;Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, CiptoMangunkusumo General Hopsital, Jakarta, Indonesia.&#xD;P.D. Hinduja National Hospital and Medical Research Centre and the Breach Candy Hospital, Mumbai, India.&#xD;Department of Pulmonology, C K BIRLA Group of Hospitals, CMRI, Kolkata, India.&#xD;Department of Pulmonology and Allergology, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.&#xD;Department of Biochemistry, School of Biomedicine, MongolianNational University of Medical Sciences, Ulaanbaatar, Mongolia.&#xD;Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.&#xD;Department of Pediatrics, Chinese University of Hong Kong, Hong Kong City, Hong Kong.&#xD;Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asia-Pacific perspectives on the COVID-19 pandemic</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2998-2901</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Asia/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33948966</style></accession-num><notes><style face="normal" font="default" size="100%">Pawankar, Ruby&#xD;Thong, Bernard Yu-Hor&#xD;Tiongco-Recto, Marysia&#xD;Wang, Jiu-Yao&#xD;Abdul Latiff, Amir Hamzah&#xD;Thien, Francis&#xD;Oh, Jae-Won&#xD;Kamchaisatian, Wasu&#xD;Rengganis, Iris&#xD;Udwadia, Zarir F&#xD;Dhar, Raja&#xD;Munkhbayarlakh, Sonomjamts&#xD;Narantsetseg, Logii&#xD;Le Pham, Duy&#xD;Leung, Ting Fan&#xD;Zhang, Luo&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2998-2901. doi: 10.1111/all.14894. Epub 2021 May 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33948966</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8222936</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14894</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>241</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">241</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caminati, M.</style></author><author><style face="normal" font="default" size="100%">Feleszko, W.</style></author><author><style face="normal" font="default" size="100%">Michel, M.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Vitte, J.</style></author><author><style face="normal" font="default" size="100%">Eaaci Task Force Diagnosis, Management of Abpa</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University of Verona, Verona, Italy.&#xD;Department of Pediatric Pulmonology and Allergy, Medical University of Warsaw, Warsaw, Poland.&#xD;Laboratoire d&apos;Immunologie, CHU de Nimes, Nimes, France.&#xD;Aix-Marseille Univ, IRD, APHM, MEPHI, IHU Mediterranee Infection, Marseille, France.&#xD;IDESP, INSERM UMR UA11, University of Montpellier, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Aspergillus fumigatus and personalized medicine: Toward a clinically reliable algorithm</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3476-3477</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/10/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="default" size="100%">*Precision Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36305471</style></accession-num><notes><style face="normal" font="default" size="100%">Caminati, Marco&#xD;Feleszko, Wojciech&#xD;Michel, Moise&#xD;Annesi-Maesano, Isabella&#xD;Vitte, Joana&#xD;eng&#xD;Comment&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3476-3477. doi: 10.1111/all.15299.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36305471</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15299</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2600</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2600</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mastalerz, L.</style></author><author><style face="normal" font="default" size="100%">Trad, G.</style></author><author><style face="normal" font="default" size="100%">Szatkowski, P.</style></author><author><style face="normal" font="default" size="100%">Cmiel, A.</style></author><author><style face="normal" font="default" size="100%">Gielicz, A.</style></author><author><style face="normal" font="default" size="100%">Kacorzyk, R.</style></author><author><style face="normal" font="default" size="100%">Plutecka, H.</style></author><author><style face="normal" font="default" size="100%">Szaleniec, J.</style></author><author><style face="normal" font="default" size="100%">Gawlewicz-Mroczka, A.</style></author><author><style face="normal" font="default" size="100%">Jakiela, B.</style></author><author><style face="normal" font="default" size="100%">Sanak, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.&#xD;Doctoral School of Medical and Health Sciences, Jagiellonian University, Krakow, Poland.&#xD;Department of Applied Mathematics, AGH University of Science and Technology, Krakow, Poland.&#xD;Department of Otolaryngology, Jagiellonian University Medical College, Krakow, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Aspirin hypersensitivity diagnostic index (AHDI): In vitro test for diagnosing of N-ERD based on urinary 15-oxo-ETE and LTE(4) excretion</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">534-544</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/08/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Leukotriene E4/urine</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Aspirin/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/urine</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma, Aspirin-Induced/diagnosis/urine</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/urine</style></keyword><keyword><style face="normal" font="default" size="100%">*Arachidonic Acids/urine/blood</style></keyword><keyword><style face="normal" font="default" size="100%">ROC Curve</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Inflammatory Agents, Non-Steroidal/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxyeicosatetraenoic Acids</style></keyword><keyword><style face="normal" font="default" size="100%">15-oxo-eicosatetraenoic acid</style></keyword><keyword><style face="normal" font="default" size="100%">NSAID-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default" size="100%">aspirin hypersensitivity diagnostic index</style></keyword><keyword><style face="normal" font="default" size="100%">in-vitro diagnostic test</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39180224</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: 15-oxo-eicosatetraenoic acid (15-oxo-ETE), is a product of arachidonic acid (AA) metabolism in the 15-lipoxygenase-1 (15-LOX-1) pathway. 15-oxo-ETE was overproduced in the nasal polyps of patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD). In this study we investigated the systemic biosynthesis of 15-oxo-ETE and leukotriene E(4) (LTE(4)) and assessed their diagnostic value to identify patients with N-ERD. METHODS: The study included 64 patients with N-ERD, 59 asthmatics who tolerated aspirin well (ATA), and 51 healthy controls. A thorough clinical characteristics of asthmatics included computed tomography of paranasal sinuses. Plasma and urinary 15-oxo-ETE levels, and urinary LTE(4) excretion were measured using high-performance liquid chromatography and tandem mass spectrometry. Repeatability and precision of the measurements were tested. RESULTS: Plasma 15-oxo-ETE levels were the highest in N-ERD (p &lt; .001). A receiver operator characteristic (ROC) revealed that 15-oxo-ETE had certain sensitivity (64.06% in plasma, or 88.24% in urine) for N-ERD discrimination, while the specificity was rather limited. Modeling of variables allowed to construct the Aspirin Hypersensitivity Diagnostic Index (AHDI) based on urinary LTE(4)-to-15-oxo-ETE excretion corrected for sex and the Lund-Mackay score of chronic rhinosinusitis. AHDI outperformed single measurements in discrimination of N-ERD among asthmatics with an area under ROC curve of 0.889, sensitivity of 81.97%, specificity of 87.23%, and accuracy of 86.87%. CONCLUSIONS: We confirmed 15-oxo-ETE as a second to cysteinyl leukotrienes biomarker of N-ERD. An index based on these eicosanoids corrected for sex and Lund-Mackay score has a similar diagnostic value as gold standard oral aspirin challenge in the studied group of patients with asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Mastalerz, Lucyna&#xD;Trad, Gabriela&#xD;Szatkowski, Piotr&#xD;Cmiel, Adam&#xD;Gielicz, Anna&#xD;Kacorzyk, Radoslaw&#xD;Plutecka, Hanna&#xD;Szaleniec, Joanna&#xD;Gawlewicz-Mroczka, Agnieszka&#xD;Jakiela, Bogdan&#xD;Sanak, Marek&#xD;eng&#xD;Narodowe Centrum Nauki/&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):534-544. doi: 10.1111/all.16281. Epub 2024 Aug 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39180224</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804310</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16281</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2728</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2728</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pecalvel, C.</style></author><author><style face="normal" font="default" size="100%">Mougel, A.</style></author><author><style face="normal" font="default" size="100%">Leveque, E.</style></author><author><style face="normal" font="default" size="100%">Lemdani, K.</style></author><author><style face="normal" font="default" size="100%">Serra, V.</style></author><author><style face="normal" font="default" size="100%">Guilleminault, L.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), UMR 1291, University of Toulouse, INSERM, CNRS, Toulouse, France.&#xD;Neovacs SA, Suresnes, France.&#xD;Department of Respiratory Medicine, University Hospital Centre of Toulouse, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Assessing IgE and basophil activity in blood samples from nonhuman primates</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">338-341</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/11/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">FcepsilonRI</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">cynomolgus monkey</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">research funding from Argenx, Novartis and Ceva, and is inventor on patents</style></keyword><keyword><style face="normal" font="default" size="100%">issued or pending relating to IgE detection (WO2021/219544) and anti-IgE</style></keyword><keyword><style face="normal" font="default" size="100%">therapies (WO2019/197607). V.S and L.L.R are inventors on a patent relating to</style></keyword><keyword><style face="normal" font="default" size="100%">anti-IgE therapy (WO2022/058571)</style></keyword><keyword><style face="normal" font="default" size="100%">A.M, K.L, V.S, and L.L.R are currently or were</style></keyword><keyword><style face="normal" font="default" size="100%">previously employees of NEOVACS and/or company stock owners. L.G. has been an</style></keyword><keyword><style face="normal" font="default" size="100%">investigator in clinical trials for AstraZeneca, Bayer, GlaxoSmithKline, MSD, and</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, reports grants or fees for consulting from AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Novartis, and Sanofi-Regeneron, and fees for consulting from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK, Bayer, Chiesi, MSD, not related to the submitted work. The rest of the</style></keyword><keyword><style face="normal" font="default" size="100%">authors declare no competing interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39495093</style></accession-num><notes><style face="normal" font="default" size="100%">Pecalvel, Cyprien&#xD;Mougel, Aurelie&#xD;Leveque, Edouard&#xD;Lemdani, Katia&#xD;Serra, Vincent&#xD;Guilleminault, Laurent&#xD;Reber, Laurent L&#xD;eng&#xD;Agence Nationale de la Recherche/&#xD;NEOVACS/&#xD;Institut National de la Sante et de la Recherche Medicale (INSERM)/&#xD;ERC_/European Research Council/International&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):338-341. doi: 10.1111/all.16367. Epub 2024 Nov 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39495093</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724247</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16367</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2775</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2775</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cihanbeylerden, M.</style></author><author><style face="normal" font="default" size="100%">Teixeira, J.</style></author><author><style face="normal" font="default" size="100%">Kayikci, H.</style></author><author><style face="normal" font="default" size="100%">Tuccar, C.</style></author><author><style face="normal" font="default" size="100%">Kalyoncu, A. F.</style></author><author><style face="normal" font="default" size="100%">Damadoglu, E.</style></author><author><style face="normal" font="default" size="100%">Goncalo, M.</style></author><author><style face="normal" font="default" size="100%">Karakaya, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonology, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey.&#xD;Department of Dermatology and Venereology, University Hospital, Coimbra Local Health Unit, Coimbra, Portugal.&#xD;Faculty of Medicine, University of Coimbra, Coimbra, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1495-1497</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/12/26</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39723594</style></accession-num><notes><style face="normal" font="default" size="100%">Cihanbeylerden, Melek&#xD;Teixeira, Joao&#xD;Kayikci, Hazal&#xD;Tuccar, Cise&#xD;Kalyoncu, Ali Fuat&#xD;Damadoglu, Ebru&#xD;Goncalo, Margarida&#xD;Karakaya, Gul&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1495-1497. doi: 10.1111/all.16458. Epub 2024 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39723594</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16458</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1306</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1306</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yuan, S.</style></author><author><style face="normal" font="default" size="100%">Vithayathil, M.</style></author><author><style face="normal" font="default" size="100%">Kar, S.</style></author><author><style face="normal" font="default" size="100%">Carter, P.</style></author><author><style face="normal" font="default" size="100%">Mason, A. M.</style></author><author><style face="normal" font="default" size="100%">Xie, S. H.</style></author><author><style face="normal" font="default" size="100%">Burgess, S.</style></author><author><style face="normal" font="default" size="100%">Larsson, S. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;MRC Cancer Unit, University of Cambridge, Cambridge, UK.&#xD;MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK.&#xD;Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.&#xD;British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.&#xD;National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK.&#xD;Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.&#xD;MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.&#xD;Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Assessing the protective role of allergic disease in gastrointestinal tract cancers using Mendelian randomization analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1559-1562</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Neoplasms/epidemiology/genetics/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mendelian Randomization Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33031565</style></accession-num><notes><style face="normal" font="default" size="100%">Yuan, Shuai&#xD;Vithayathil, Mathew&#xD;Kar, Siddhartha&#xD;Carter, Paul&#xD;Mason, Amy M&#xD;Xie, Shao-Hua&#xD;Burgess, Stephen&#xD;Larsson, Susanna C&#xD;eng&#xD;19169/CRUK_/Cancer Research UK/United Kingdom&#xD;204623/Z/16/Z/WT_/Wellcome Trust/United Kingdom&#xD;MC_UU_00002/7/MRC_/Medical Research Council/United Kingdom&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1559-1562. doi: 10.1111/all.14616. Epub 2020 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33031565</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8411419 (BigData@Heart) and the National Institute for Health Research (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust).</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14616</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>731</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">731</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andersson, A. M.</style></author><author><style face="normal" font="default" size="100%">Solberg, J.</style></author><author><style face="normal" font="default" size="100%">Koch, A.</style></author><author><style face="normal" font="default" size="100%">Skov, L.</style></author><author><style face="normal" font="default" size="100%">Jakasa, I.</style></author><author><style face="normal" font="default" size="100%">Kezic, S.</style></author><author><style face="normal" font="default" size="100%">Thyssen, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.&#xD;University of Greenland, Nuuk, Greenland.&#xD;Copenhagen Research Group for Inflammatory Skin (CORGIS), Hellerup, Denmark.&#xD;Department of Dermatology and Allergy, Herlev and Gentofte Hospital, The National Allergy Research Centre, University of Copenhagen, Hellerup, Denmark.&#xD;Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.&#xD;Department of Infectious Diseases, Rigshospitalet University Hospital, Copenhagen, Denmark.&#xD;Laboratory for Analytical Chemistry, Department of Chemistry and Biochemistry, Faculty of Food Technology and Biotechnology, University of Zagreb, Pieottijeva, Zagreb, Croatia.&#xD;Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.&#xD;Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Assessment of biomarkers in pediatric atopic dermatitis by tape strips and skin biopsies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1499-1509</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/10/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biomarkers/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-18/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-8/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">filaggrin</style></keyword><keyword><style face="normal" font="default" size="100%">immunotype</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34695223</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The cytokine profile of atopic dermatitis (AD) depends on age, ethnicity, and disease severity. This study examined biomarkers in children with AD collected by tape strips and skin biopsies, and examined whether the levels differed with filaggrin genotype, disease severity, and food allergy. METHODS: Twenty-five children aged 2-14 years with AD were clinically examined. Skin biopsies were collected from lesional skin and tape strips were collected from lesional and non-lesional skin. We analyzed natural moisturizing factor (NMF) and 17 immune markers represented by mRNA levels in skin biopsies and protein levels in tape strips. Common filaggrin gene mutations were examined in all children. RESULTS: The cytokine profile in lesional skin was dominated by a T helper (Th) 2 response in skin biopsies, and by a general increase in innate inflammation markers (interleukin (IL)-1alpha, IL-1beta, IL-8, IL-18) along with TARC and CTACK in tape strips. The levels of TARC, CTACK, IL-8, IL-18 showed significant correlation with AD severity in both lesional and non-lesional tape stripped skin, while no significant correlations were observed in skin biopsy data. In tape strips from lesional and non-lesional skin, the levels of NMF and selected cytokines differed significantly between children with and without FLG mutations and food allergy. CONCLUSION: Sampling of the stratum corneum with non-invasive tape strips can be used to identify biomarkers that are associated with disease severity, food allergy and FLG mutations. Skin biopsies showed robust Th2 signature but was inferior for association analysis regarding severity.</style></abstract><notes><style face="normal" font="default" size="100%">Andersson, Anna Maria&#xD;Solberg, Julie&#xD;Koch, Anders&#xD;Skov, Lone&#xD;Jakasa, Ivone&#xD;Kezic, Sanja&#xD;Thyssen, Jacob Pontoppidan&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1499-1509. doi: 10.1111/all.15153. Epub 2021 Nov 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34695223</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15153</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2685</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2685</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Oka, A.</style></author><author><style face="normal" font="default" size="100%">Kanai, K.</style></author><author><style face="normal" font="default" size="100%">Matsune, S.</style></author><author><style face="normal" font="default" size="100%">Hosoya, K.</style></author><author><style face="normal" font="default" size="100%">Komachi, T.</style></author><author><style face="normal" font="default" size="100%">Murakami, R.</style></author><author><style face="normal" font="default" size="100%">Okubo, K.</style></author><author><style face="normal" font="default" size="100%">Hirano, K.</style></author><author><style face="normal" font="default" size="100%">Suzaki, I.</style></author><author><style face="normal" font="default" size="100%">Shimura, T.</style></author><author><style face="normal" font="default" size="100%">Tokudome, T.</style></author><author><style face="normal" font="default" size="100%">Kanzaki, S.</style></author><author><style face="normal" font="default" size="100%">Wakabayashi, K. I.</style></author><author><style face="normal" font="default" size="100%">Ozawa, H.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Kondo, K.</style></author><author><style face="normal" font="default" size="100%">Nishijima, H.</style></author><author><style face="normal" font="default" size="100%">Nishijima, A.</style></author><author><style face="normal" font="default" size="100%">Okano, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, International University of Health and Welfare School of Medicine, Narita, Japan.&#xD;Department of Otorhinolaryngology, Nippon Medical School Musashikosugi Hospital, Kawasaki, Japan.&#xD;Nose and Smell Clinic Ikebukuro, Tokyo, Japan.&#xD;Department of Otorhinolaryngology, Nippon Medical School Chibahokusoh Hospital, Inzai, Japan.&#xD;Department of Otorhinolaryngology, Nippon Medical School, Tokyo, Japan.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, School of Medicine, Showa University, Tokyo, Japan.&#xD;Department of Otorhinolaryngology, Showa University Fujigaoka Hospital, Yokohama, Japan.&#xD;Department of Otorhinolaryngology, Showa University Northern Yokohama Hospital Yokohama, Japan.&#xD;Department of Otolaryngology, Head and Neck Surgery, Keio University of Medicine, Tokyo, Japan.&#xD;Laboratory of Auditory Disorders, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.&#xD;Musashikoyama WAKABA ENT Clinic, Tokyo, Japan.&#xD;Department of Otorhinolaryngology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.&#xD;Department of Otolaryngology and Head and Neck Surgery, University of Tokyo Graduate School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Assessment of patient satisfaction with dupilumab for chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">614-616</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/10/16</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39412479</style></accession-num><notes><style face="normal" font="default" size="100%">Oka, Aiko&#xD;Kanai, Kengo&#xD;Matsune, Shoji&#xD;Hosoya, Kei&#xD;Komachi, Taro&#xD;Murakami, Ryosuke&#xD;Okubo, Kimihiro&#xD;Hirano, Kojiro&#xD;Suzaki, Isao&#xD;Shimura, Tomotaka&#xD;Tokudome, Takatoshi&#xD;Kanzaki, Sho&#xD;Wakabayashi, Ken-Ichiro&#xD;Ozawa, Hiroyuki&#xD;Okamoto, Yasuhide&#xD;Kondo, Kenji&#xD;Nishijima, Hironobu&#xD;Nishijima, Ami&#xD;Okano, Mitsuhiro&#xD;eng&#xD;This work was supported by a Health and Labour Sciences Research Grant (21FC1013) from the Ministry of Health, Labour and Welfare of Japan (to SM, KenK and MO), Grants-in-Aid for Scientific Research (24K12659) from Japan Society for the Promotion of Science (to SM), Translational Research Program (B-099, Pre F to SM) and Adopting Sustainable Partnerships for Innovative Research Ecosystem (24jf0126005h0001 to MO) from Japan Agency for Medical Research and Development./&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):614-616. doi: 10.1111/all.16355. Epub 2024 Oct 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39412479</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16355</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2617</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2617</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martin-Garcia, C.</style></author><author><style face="normal" font="default" size="100%">Murillo-Casas, A. D.</style></author><author><style face="normal" font="default" size="100%">Lazaro-Sastre, M.</style></author><author><style face="normal" font="default" size="100%">Estravis, M.</style></author><author><style face="normal" font="default" size="100%">Munoz-Bellido, F. J.</style></author><author><style face="normal" font="default" size="100%">Mazoteras-Martinez, E.</style></author><author><style face="normal" font="default" size="100%">Davila, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, University Hospital of Salamanca, Salamanca, Spain.&#xD;Instituto de Investigacion Biomedica de Salamanca (IBSAL), Salamanca, Spain.&#xD;Allergy Service, Fundacion Valle de Lili, ICESI University of Cali, Cali, Colombia.&#xD;Red de Enfermedades Inflamatorias (REI), Instituto de Salud Carlos III, Madrid, Spain.&#xD;Biomedical and Diagnostic Sciences Department, University of Salamanca, Salamanca, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Assessment of sIgE to rLep d 2 for detecting Lepidoglyphus destructor sensitization</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3540-3542</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/08/11</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39127909</style></accession-num><notes><style face="normal" font="default" size="100%">Martin-Garcia, Cristina&#xD;Murillo-Casas, Andrea Dionelly&#xD;Lazaro-Sastre, Milagros&#xD;Estravis, Miguel&#xD;Munoz-Bellido, Francisco Javier&#xD;Mazoteras-Martinez, Elena&#xD;Davila, Ignacio&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3540-3542. doi: 10.1111/all.16272. Epub 2024 Aug 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39127909</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657039</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16272</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3181</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Du, C. W.</style></author><author><style face="normal" font="default" size="100%">Wang, J. H.</style></author><author><style face="normal" font="default" size="100%">Pereda, J.</style></author><author><style face="normal" font="default" size="100%">Jakasa, I.</style></author><author><style face="normal" font="default" size="100%">Christensen, M. O.</style></author><author><style face="normal" font="default" size="100%">Kezic, S.</style></author><author><style face="normal" font="default" size="100%">Dervillez, A.</style></author><author><style face="normal" font="default" size="100%">Thyssen, J. P.</style></author><author><style face="normal" font="default" size="100%">Hwu, E. E.</style></author><author><style face="normal" font="default" size="100%">Chu, C. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.&#xD;Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.&#xD;Division of Computational Science and Technology, Science for Life Laboratory, KTH Royal University of Technology, Stockholm, Sweden.&#xD;Laboratory for Analytical Chemistry, Department of Chemistry and Biochemistry, Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.&#xD;Department of Dermatology, Bispebjerg and Frederiksberg Hospital, University Hospitals of Copenhagen, Copenhagen, Denmark.&#xD;Department of Public and Occupational Health, Amsterdam University Medical Center, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Assessment of the Severity of Atopic Dermatitis Using Atomic Force Microscopy Analysis of Skin Tape Strips</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41292407</style></accession-num><notes><style face="normal" font="default" size="100%">Du, Ching-Wen&#xD;Wang, Jen-Hung&#xD;Pereda, Jorge&#xD;Jakasa, Ivone&#xD;Christensen, Maria Oberlander&#xD;Kezic, Sanja&#xD;Dervillez, Arthur&#xD;Thyssen, Jacob P&#xD;Hwu, Edwin En-Te&#xD;Chu, Chia-Yu&#xD;eng&#xD;LF-OC-20-000370/LEO Foundation/&#xD;LF-OC-24-001760/LEO Foundation/&#xD;NNF22OC0076607/Novo Nordisk Foundation/&#xD;NSTC 112-2314-B-002-074-MY3/National Science and Technology Council of Taiwan/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov 26. doi: 10.1111/all.70170.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41292407</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70170</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2921</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2921</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Y. W.</style></author><author><style face="normal" font="default" size="100%">Yen, T. H.</style></author><author><style face="normal" font="default" size="100%">Kao, C. M.</style></author><author><style face="normal" font="default" size="100%">Chao, W. C.</style></author><author><style face="normal" font="default" size="100%">Chen, D. Y.</style></author><author><style face="normal" font="default" size="100%">Chen, H. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Division of General Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Department of Animal Science and Biotechnology, Tunghai University, Taichung, Taiwan.&#xD;Division of Translational Medicine, Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Big Data Center, Chung Hsing University, Taichung, Taiwan.&#xD;Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.&#xD;Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan.&#xD;College of Medicine, China Medical University, Taichung, Taiwan.&#xD;Translational Medicine Laboratory, Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan.&#xD;Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.&#xD;Faculty of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan.&#xD;Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine and Big Data Center, Chung Hsing University, Taichung, Taiwan.&#xD;Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan.&#xD;Division of Clinical Informatics, Taichung Veterans General Hospital, Taichung, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association Between a History of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and the Risk of Systemic Autoimmune Rheumatic Diseases: A Nationwide, Population-Based Case-Control Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2373-2375</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/05/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Stevens-Johnson syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">claims data</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">systemic autoimmune rheumatic disease (SARD)</style></keyword><keyword><style face="normal" font="default" size="100%">toxic epidermal necrolysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40346987</style></accession-num><notes><style face="normal" font="default" size="100%">Chen, Yun-Wen&#xD;Yen, Tsai-Hung&#xD;Kao, Chung-Mao&#xD;Chao, Wen-Cheng&#xD;Chen, Der-Yuan&#xD;Chen, Hsin-Hua&#xD;eng&#xD;TCVGH-1123801A/Taichung Veterans General Hospital, Taiwan/&#xD;TCVGH-1133801A/Taichung Veterans General Hospital, Taiwan/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2373-2375. doi: 10.1111/all.16584. Epub 2025 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40346987</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16584</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2930</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2930</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Y. W.</style></author><author><style face="normal" font="default" size="100%">Yen, T. H.</style></author><author><style face="normal" font="default" size="100%">Kao, C. M.</style></author><author><style face="normal" font="default" size="100%">Chao, W. C.</style></author><author><style face="normal" font="default" size="100%">Chen, D. Y.</style></author><author><style face="normal" font="default" size="100%">Chen, H. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Division of General Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Department of Animal Science and Biotechnology, Tunghai University, Taichung, Taiwan.&#xD;Division of Translational Medicine, Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Big Data Center, Chung Hsing University, Taichung, Taiwan.&#xD;Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.&#xD;Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan.&#xD;College of Medicine, China Medical University, Taichung, Taiwan.&#xD;Translational Medicine Laboratory, Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan.&#xD;Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.&#xD;Faculty of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan.&#xD;Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine and Big Data Center, Chung Hsing University, Taichung, Taiwan.&#xD;Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan.&#xD;Division of Clinical Informatics, Taichung Veterans General Hospital, Taichung, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association Between a History of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and the Risk of Systemic Autoimmune Rheumatic Diseases: A Nationwide, Population-Based Case-Control Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2373-2375</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/05/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Stevens-Johnson syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">claims data</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">systemic autoimmune rheumatic disease (SARD)</style></keyword><keyword><style face="normal" font="default" size="100%">toxic epidermal necrolysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40346987</style></accession-num><notes><style face="normal" font="default" size="100%">Chen, Yun-Wen&#xD;Yen, Tsai-Hung&#xD;Kao, Chung-Mao&#xD;Chao, Wen-Cheng&#xD;Chen, Der-Yuan&#xD;Chen, Hsin-Hua&#xD;eng&#xD;TCVGH-1123801A/Taichung Veterans General Hospital, Taiwan/&#xD;TCVGH-1133801A/Taichung Veterans General Hospital, Taiwan/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2373-2375. doi: 10.1111/all.16584. Epub 2025 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40346987</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16584</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2188</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2188</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Zhao, J.</style></author><author><style face="normal" font="default" size="100%">Sima, Y.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.&#xD;Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The association between allergic rhinitis and the risk of coronavirus disease 2019 (COVID-19): A national survey in China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2783-2786</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/07/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37476953</style></accession-num><notes><style face="normal" font="default" size="100%">Yang, Xiaozhe&#xD;Zhao, Jinming&#xD;Sima, Yutong&#xD;Zhao, Yan&#xD;Zhang, Jing&#xD;Wang, Xiangdong&#xD;Zhang, Luo&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2783-2786. doi: 10.1111/all.15823. Epub 2023 Jul 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37476953</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15823</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1142</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1142</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lopez, D. J.</style></author><author><style face="normal" font="default" size="100%">Lodge, C. J.</style></author><author><style face="normal" font="default" size="100%">Bui, D. S.</style></author><author><style face="normal" font="default" size="100%">Waidyatillake, N. T.</style></author><author><style face="normal" font="default" size="100%">Su, J. C.</style></author><author><style face="normal" font="default" size="100%">Perret, J. L.</style></author><author><style face="normal" font="default" size="100%">Knibbs, L. D.</style></author><author><style face="normal" font="default" size="100%">Erbas, B.</style></author><author><style face="normal" font="default" size="100%">Thomas, P. S.</style></author><author><style face="normal" font="default" size="100%">Hamilton, G. S.</style></author><author><style face="normal" font="default" size="100%">Thompson, B. R.</style></author><author><style face="normal" font="default" size="100%">Abramson, M. J.</style></author><author><style face="normal" font="default" size="100%">Walters, E. H.</style></author><author><style face="normal" font="default" size="100%">Dharmage, S. C.</style></author><author><style face="normal" font="default" size="100%">Bowatte, G.</style></author><author><style face="normal" font="default" size="100%">Lowe, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy and Lung Health Unit, The University of Melbourne, Melbourne, Vic, Australia.&#xD;Department of Dermatology, Eastern Health and the Population allergy group, Monash University, Clayton, Vic, Australia.&#xD;Murdoch Children&apos;s Research Institute, University of Melbourne, Melbourne, Vic, Australia.&#xD;Faculty of Medicine, School of Public Health, The University of Queensland, Herston, Qld, Australia.&#xD;School of Psychology and Public Health, La Trobe University, Melbourne, Vic, Australia.&#xD;Prince of Wales&apos; Clinical School, and Mechanisms of Disease and Translational Research, Faculty of Medicine, UNSW and Prince of Wales&apos; Hospital, Sydney, NSW, Australia.&#xD;Department of Lung and Sleep Medicine, Monash Health, Melbourne, Vic, Australia.&#xD;School of Clinical Sciences, Monash University, Melbourne, Vic, Australia.&#xD;School of Heath Sciences, Swinburne University of Technology, Melbourne, Vic, Australia.&#xD;School of Public Health &amp; Preventive Medicine, Monash University, Melbourne, Vic, Australia.&#xD;Medicine, University of Tasmania, Hobart, TAS, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association between ambient air pollution and development and persistence of atopic and non-atopic eczema in a cohort of adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2524-2534</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/02/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Particulate Matter/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">adults</style></keyword><keyword><style face="normal" font="default" size="100%">ambient air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">middle age</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33598994</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: There is limited information on risk factors for eczema in adults. Recent evidence suggests that air pollution may be associated with increased incidence of eczema in adults. We aimed to assess this possible association. METHODS: Ambient air pollution exposures (distance from a major road, nitrogen dioxide [NO(2) ], fine particulate matter with an aerodynamic diameter &lt;/=2.5 microm [PM(2.5) ]) were assessed for the residential address of Tasmanian Longitudinal Health Study participants at ages 43 and 53 years. Eczema incidence (onset after age 43 years), prevalence (at 53 years), and persistence were assessed from surveys, while IgE sensitization was assessed using skin prick tests. The presence or absence of eczema and sensitization was classified into four groups: no atopy or eczema, atopy alone, non-atopic eczema, and atopic eczema. Adjusted logistic and multinomial regression models were fitted to estimate associations between ambient air pollution and eczema, and interaction by sex was assessed. RESULTS: Of 3153 participants in both follow-ups, 2369 had valid skin prick tests. For males, a 2.3 ppb increase in baselineNO(2) was associated with increased odds of prevalent eczema (OR = 1.15 [95% CI 0.98-1.36]) and prevalent atopic eczema (OR = 1.26 [1.00-1.59]). These associations were not seen in females (p for interaction = 0.08, &lt;0.01). For both sexes, a 1.6 microg/m(3) increase in PM(2.5) exposure at follow-up was associated with increased odds of aeroallergen sensitization (OR = 1.15 [1.03-1.30]). CONCLUSION: Increased exposure to residential ambient air pollutants was associated with an increased odds of eczema, only in males, and aeroallergen sensitization in both genders.</style></abstract><notes><style face="normal" font="default" size="100%">Lopez, Diego J&#xD;Lodge, Caroline J&#xD;Bui, Dinh S&#xD;Waidyatillake, Nilakshi T&#xD;Su, John C&#xD;Perret, Jenny L&#xD;Knibbs, Luke D&#xD;Erbas, Bircan&#xD;Thomas, Paul S&#xD;Hamilton, Garun S&#xD;Thompson, Bruce R&#xD;Abramson, Michael J&#xD;Walters, E Haydn&#xD;Dharmage, Shyamali C&#xD;Bowatte, Gayan&#xD;Lowe, Adrian J&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2524-2534. doi: 10.1111/all.14783. Epub 2021 Mar 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33598994</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14783</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2468</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2468</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Halvard Hansen, E. S.</style></author><author><style face="normal" font="default" size="100%">Kaiser, H.</style></author><author><style face="normal" font="default" size="100%">Hansen, K. T.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Chawes, B.</style></author><author><style face="normal" font="default" size="100%">Backer, V.</style></author><author><style face="normal" font="default" size="100%">Torp-Pedersen, C.</style></author><author><style face="normal" font="default" size="100%">Ulrik, C. S.</style></author><author><style face="normal" font="default" size="100%">Brustad, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Respiratory Research Unit Hvidovre, Copenhagen University Hospital - Hvidovre, Hvidovre, Denmark.&#xD;Department of Respiratory Medicine, Slagelse Hospital, Slagelse, Denmark.&#xD;Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, Denmark.&#xD;Department of Child and Adolescent Psychiatry, Roskilde, Denmark.&#xD;Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark.&#xD;Department of Otorhinolaryngology Head &amp; Neck Surgery and audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.&#xD;Department of Cardiology, North Zealand Hospital, Hillerod, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association between Apgar scores within normal range and development of asthma, allergic rhinitis and eczema in childhood: A Danish nationwide register study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2847-2849</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/04/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Registries</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Apgar Score</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38676401</style></accession-num><notes><style face="normal" font="default" size="100%">Halvard Hansen, Erik Soren&#xD;Kaiser, Hannah&#xD;Hansen, Kristine Tronier&#xD;Bonnelykke, Klaus&#xD;Chawes, Bo&#xD;Backer, Vibeke&#xD;Torp-Pedersen, Christian&#xD;Ulrik, Charlotte Suppli&#xD;Brustad, Nicklas&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2847-2849. doi: 10.1111/all.16143. Epub 2024 Apr 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38676401</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16143</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1254</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1254</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, H. G.</style></author><author><style face="normal" font="default" size="100%">Wee, J. H.</style></author><author><style face="normal" font="default" size="100%">Kim, S. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Il Kim, H.</style></author><author><style face="normal" font="default" size="100%">Park, J. Y.</style></author><author><style face="normal" font="default" size="100%">Park, S.</style></author><author><style face="normal" font="default" size="100%">Il Hwang, Y.</style></author><author><style face="normal" font="default" size="100%">Jang, S. H.</style></author><author><style face="normal" font="default" size="100%">Jung, K. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Otorhinolaryngology-Head &amp; Neck Surgery, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.&#xD;Department of Otorhinolaryngology-Head &amp; Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.&#xD;Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association between asthma and clinical mortality/morbidity in COVID-19 patients using clinical epidemiologic data from Korean Disease Control and Prevention</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">921-924</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/11/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/*complications</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33249591</style></accession-num><notes><style face="normal" font="default" size="100%">Choi, Hyo-Geun&#xD;Wee, Jee Hye&#xD;Kim, So Young&#xD;Kim, Joo-Hee&#xD;Il Kim, Hwan&#xD;Park, Ji-Young&#xD;Park, Sunghoon&#xD;Il Hwang, Yong&#xD;Jang, Seung Hun&#xD;Jung, Ki-Suck&#xD;eng&#xD;2017R1C1B5076565/National Research Foundation of Korea/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):921-924. doi: 10.1111/all.14675. Epub 2020 Dec 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33249591</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7753771</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14675</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2283</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2283</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, B. X.</style></author><author><style face="normal" font="default" size="100%">Ma, J. J.</style></author><author><style face="normal" font="default" size="100%">Lai, H.</style></author><author><style face="normal" font="default" size="100%">Li, C. G.</style></author><author><style face="normal" font="default" size="100%">Huang, L. X.</style></author><author><style face="normal" font="default" size="100%">Huang, H. N.</style></author><author><style face="normal" font="default" size="100%">Liu, X. Q.</style></author><author><style face="normal" font="default" size="100%">Zhou, Z. R.</style></author><author><style face="normal" font="default" size="100%">Xie, Y. C.</style></author><author><style face="normal" font="default" size="100%">Kuang, P. P.</style></author><author><style face="normal" font="default" size="100%">Ou, C. Q.</style></author><author><style face="normal" font="default" size="100%">Fu, Q. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Otorhinolaryngology Hospital and Department of Allergy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.&#xD;State Key Laboratory of Organ Failure Research, Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China.&#xD;Department of Allergy, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association between daily 1-km resolution levels of ambient air pollution and hospital visits for allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1336-1338</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/10/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/etiology/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Particulate Matter/adverse effects/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Air Pollutants/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37787017</style></accession-num><notes><style face="normal" font="default" size="100%">He, Bi-Xin&#xD;Ma, Jia-Jun&#xD;Lai, He&#xD;Li, Chan-Gu&#xD;Huang, Long-Xin&#xD;Huang, Hao-Neng&#xD;Liu, Xiao-Qing&#xD;Zhou, Zhi-Rou&#xD;Xie, Ying-Chun&#xD;Kuang, Peng-Peng&#xD;Ou, Chun-Quan&#xD;Fu, Qing-Ling&#xD;eng&#xD;Guangzhou Key R&amp;amp;D Program (No. 2023B03J1233)/&#xD;National Natural Science Foundation of China (No. 82271144，No.81970863 to Q. L. F and No. 81573249 to C.Q.O.)/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1336-1338. doi: 10.1111/all.15904. Epub 2023 Oct 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37787017</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15904</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3175</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3175</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, M. J.</style></author><author><style face="normal" font="default" size="100%">Lee, S. H.</style></author><author><style face="normal" font="default" size="100%">Kim, S. J.</style></author><author><style face="normal" font="default" size="100%">Song, H. E.</style></author><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Kang, M. J.</style></author><author><style face="normal" font="default" size="100%">Yang, S. I.</style></author><author><style face="normal" font="default" size="100%">Kim, H. B.</style></author><author><style face="normal" font="default" size="100%">Lee, S. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Im, H.</style></author><author><style face="normal" font="default" size="100%">Seong, H. J.</style></author><author><style face="normal" font="default" size="100%">Park, Y. J.</style></author><author><style face="normal" font="default" size="100%">Yeom, J.</style></author><author><style face="normal" font="default" size="100%">Oh, J. H.</style></author><author><style face="normal" font="default" size="100%">Choi, E. J.</style></author><author><style face="normal" font="default" size="100%">Suh, D. I.</style></author><author><style face="normal" font="default" size="100%">Kim, K. W.</style></author><author><style face="normal" font="default" size="100%">Ahn, K.</style></author><author><style face="normal" font="default" size="100%">Shin, Y. H.</style></author><author><style face="normal" font="default" size="100%">Hong, S. J.</style></author><author><style face="normal" font="default" size="100%">Yoo, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Convergence Medicine and Department of Digital Medicine, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.&#xD;Department of Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Humidifier Disinfectant Health Center, National Medical Center, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea.&#xD;Department of Pediatrics, Inha University Hospital, Inha University College of Medicine, Incheon, Republic of Korea.&#xD;PHI Digital Healthcare, Seoul, Republic of Korea.&#xD;Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Republic of Korea.&#xD;Institute for Life &amp; Environmental Technology, Smartive Corporation, Hanam-si, Republic of Korea.&#xD;Department of Biological Science, Kunsan National University, Gunsan, Republic of Korea.&#xD;College of Pharmacy, Kyungsung University, Gyeongsan-si, Gyeongsangbuk-do, Republic of Korea.&#xD;Prometabio Research Institute, Prometabio Co. Ltd., Hanam-si, Republic of Korea.&#xD;Bioinformatics Core Laboratory, Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.&#xD;Department of Pediatrics, CHA Medical Center, CHA University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Kyunghee University College of Medicine, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association Between Di-(2-Ethylhexyl) Phthalate and Childhood Asthma Through Plasma Metabolome Alterations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">304-306</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/11/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41184991</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Mi Jeong&#xD;Lee, Seung Hwa&#xD;Kim, Su Jung&#xD;Song, Ha Eun&#xD;Lee, Hyoyeong&#xD;Kang, Mi Jin&#xD;Yang, Song-I&#xD;Kim, Hyo-Bin&#xD;Lee, So Yeon&#xD;Kim, Jeong-Hyun&#xD;Im, Hosub&#xD;Seong, Hoon Je&#xD;Park, Yong Joo&#xD;Yeom, Jeonghun&#xD;Oh, Ji-Hye&#xD;Choi, Eom Ji&#xD;Suh, Dong In&#xD;Kim, Kyung Won&#xD;Ahn, Kangmo&#xD;Shin, Youn Ho&#xD;Hong, Soo-Jong&#xD;Yoo, Hyun Ju&#xD;eng&#xD;RS-2021-KE001380/Ministry of Environment/&#xD;RS-2022-KE002048/Ministry of Environment/&#xD;RS-2024-00399341/National Research Foundation/&#xD;RS-2022-NR069411/National Research Foundation/&#xD;2008-E33030-00/Korea National Institute of Health/&#xD;2009-E33033-00/Korea National Institute of Health/&#xD;2011-E33021-00/Korea National Institute of Health/&#xD;2012-E33012-00/Korea National Institute of Health/&#xD;2013-E51003-00/Korea National Institute of Health/&#xD;2014-E51004-00/Korea National Institute of Health/&#xD;2014-E51004-01/Korea National Institute of Health/&#xD;2014-E51004-02/Korea National Institute of Health/&#xD;2017-E67002-00/Korea National Institute of Health/&#xD;2017-E67002-01/Korea National Institute of Health/&#xD;2017-E67002-02/Korea National Institute of Health/&#xD;2020E670200/Korea National Institute of Health/&#xD;2020E670201/Korea National Institute of Health/&#xD;2020E670202/Korea National Institute of Health/&#xD;2023ER120300/Korea National Institute of Health/&#xD;2023ER120301/Korea National Institute of Health/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):304-306. doi: 10.1111/all.70143. Epub 2025 Nov 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41184991</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773664</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70143</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3235</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3235</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, Q.</style></author><author><style face="normal" font="default" size="100%">Sun, Y.</style></author><author><style face="normal" font="default" size="100%">Messerlian, C.</style></author><author><style face="normal" font="default" size="100%">Dong, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Mustieles, V.</style></author><author><style face="normal" font="default" size="100%">Liu, C.</style></author><author><style face="normal" font="default" size="100%">Si, K.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Yu, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, Y. X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Environmental Health, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, Shanghai Jiao Tong University Affiliated Sixth People&apos;s Hospital, Shanghai, China.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.&#xD;School of Environmental Science and Engineering, Shanghai Jiao Tong University, Shanghai, China.&#xD;Center for Biomedical Research, University of Granada, Granada, Spain.&#xD;Instituto de Investigacion Biosanitaria de Granada (ibs GRANADA), Granada, Spain.&#xD;Consortium for Biomedical Research in Epidemiology and Public Health, Granada, Spain.&#xD;Department of Preventive Medicine, School of Public Health, Zunyi Medical University, Zunyi, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association Between Fluoride Exposure and Asthma Among US Children and Adolescents</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">adolescents</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">fluoride</style></keyword><keyword><style face="normal" font="default" size="100%">tobacco smoke</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 16</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41542951</style></accession-num><notes><style face="normal" font="default" size="100%">Xu, Qingqing&#xD;Sun, Yang&#xD;Messerlian, Carmen&#xD;Dong, Chenyin&#xD;Zhang, Yu&#xD;Mustieles, Vicente&#xD;Liu, Chong&#xD;Si, Keyi&#xD;Liu, Jun&#xD;Yu, Yunjiang&#xD;Wang, Yi-Xin&#xD;eng&#xD;82473581/National Natural Science Foundation of China/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan 16. doi: 10.1111/all.70214.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41542951</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70214</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2453</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2453</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Korpela, K.</style></author><author><style face="normal" font="default" size="100%">Hurley, S.</style></author><author><style face="normal" font="default" size="100%">Ford, S. A.</style></author><author><style face="normal" font="default" size="100%">Franklin, R.</style></author><author><style face="normal" font="default" size="100%">Byrne, S.</style></author><author><style face="normal" font="default" size="100%">Lunjani, N.</style></author><author><style face="normal" font="default" size="100%">Forde, B.</style></author><author><style face="normal" font="default" size="100%">Neogi, U.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Walter, J.</style></author><author><style face="normal" font="default" size="100%">Hourihane, J.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Coral Study Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.&#xD;APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Paediatrics and Child Health, Royal College of Surgeons in Ireland, Dublin, Ireland.&#xD;Children&apos;s Health Ireland, Dublin, Ireland.&#xD;School of Microbiology, University College Cork, Cork, Ireland.&#xD;The Systems Virology Lab, Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.&#xD;Section of Allergy &amp; Immunology, Department of Pediatrics, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Department of Medicine, University College Cork, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association between gut microbiota development and allergy in infants born during pandemic-related social distancing restrictions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1938-1951</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/02/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Feces/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Physical Distancing</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">infants</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38419554</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Several hypotheses link reduced microbial exposure to increased prevalence of allergies. Here we capitalize on the opportunity to study a cohort of infants (CORAL), raised during COVID-19 associated social distancing measures, to identify the environmental exposures and dietary factors that contribute to early life microbiota development and to examine their associations with allergic outcomes. METHODS: Fecal samples were sequenced from infants at 6 (n = 351) and repeated at 12 (n = 343) months, using 16S sequencing. Published 16S data from pre-pandemic cohorts were included for microbiota comparisons. Online questionnaires collected epidemiological information on home environment, healthcare utilization, infant health, allergic diseases, and diet. Skin prick testing (SPT) was performed at 12 (n = 343) and 24 (n = 320) months of age, accompanied by atopic dermatitis and food allergy assessments. RESULTS: The relative abundance of bifidobacteria was higher, while environmentally transmitted bacteria such as Clostridia was lower in CORAL infants compared to previous cohorts. The abundance of multiple Clostridia taxa correlated with a microbial exposure index. Plant based foods during weaning positively impacted microbiota development. Bifidobacteria levels at 6 months of age, and relative abundance of butyrate producers at 12 months of age, were negatively associated with AD and SPT positivity. The prevalence of allergen sensitization, food allergy, and AD did not increase over pre-pandemic levels. CONCLUSIONS: Environmental exposures and dietary components significantly impact microbiota community assembly. Our results also suggest that vertically transmitted bacteria and appropriate dietary supports may be more important than exposure to environmental microbes alone for protection against allergic diseases in infancy.</style></abstract><notes><style face="normal" font="default" size="100%">Korpela, Katri&#xD;Hurley, Sadhbh&#xD;Ford, Sinead Ahearn&#xD;Franklin, Ruth&#xD;Byrne, Susan&#xD;Lunjani, Nonhlanhla&#xD;Forde, Brian&#xD;Neogi, Ujjwal&#xD;Venter, Carina&#xD;Walter, Jens&#xD;Hourihane, Jonathan&#xD;O&apos;Mahony, Liam&#xD;eng&#xD;SFI_/Science Foundation Ireland/Ireland&#xD;Childrens Health Ireland/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1938-1951. doi: 10.1111/all.16069. Epub 2024 Feb 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38419554</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16069</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2845</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2845</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nawa, N.</style></author><author><style face="normal" font="default" size="100%">Nishimura, H.</style></author><author><style face="normal" font="default" size="100%">Fushimi, K.</style></author><author><style face="normal" font="default" size="100%">Fujiwara, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Public Health, Institute of Science Tokyo, Tokyo, Japan.&#xD;Department of Health Policy and Informatics, Institute of Science Tokyo, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association Between Heat Exposure and Anaphylaxis in Japan: A Time-Stratified Case-Crossover Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2640-2642</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/02/01 20:44</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">climate change</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">global warming</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39891474</style></accession-num><notes><style face="normal" font="default" size="100%">Nawa, Nobutoshi&#xD;Nishimura, Hisaaki&#xD;Fushimi, Kiyohide&#xD;Fujiwara, Takeo&#xD;eng&#xD;Science and Technology Research Partnership for Sustainable Development/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2640-2642. doi: 10.1111/all.16488. Epub 2025 Feb 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39891474</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16488</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2794</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2794</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, J. L.</style></author><author><style face="normal" font="default" size="100%">Zhao, C. Y.</style></author><author><style face="normal" font="default" size="100%">Xu, X. H.</style></author><author><style face="normal" font="default" size="100%">Shi, C.</style></author><author><style face="normal" font="default" size="100%">Huang, H. N.</style></author><author><style face="normal" font="default" size="100%">Tao, Y. M.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Ou, C. Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Organ Failure Research, Department of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association Between Long-Term Exposure to Ambient Air Pollution and the Risk of Recurrent Asthma Hospitalizations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1452-1454</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/01/24</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39853743</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Jin-Lun&#xD;Zhao, Chong-Ye&#xD;Xu, Xiao-Han&#xD;Shi, Chen&#xD;Huang, Hao-Neng&#xD;Tao, Yi-Ming&#xD;Li, Li&#xD;Ou, Chun-Quan&#xD;eng&#xD;82373679/National Natural Science Foundation of China/&#xD;2024A1515011404/Basic and Applied Basic Research Foundation of Guangdong Province/&#xD;2024A1515011957/Basic and Applied Basic Research Foundation of Guangdong Province/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1452-1454. doi: 10.1111/all.16476. Epub 2025 Jan 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39853743</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16476</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>973</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">973</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tuli, J. F.</style></author><author><style face="normal" font="default" size="100%">Ramezanpour, M.</style></author><author><style face="normal" font="default" size="100%">Cooksley, C.</style></author><author><style face="normal" font="default" size="100%">Psaltis, A. J.</style></author><author><style face="normal" font="default" size="100%">Wormald, P. J.</style></author><author><style face="normal" font="default" size="100%">Vreugde, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Surgery-Otolaryngology, Head and Neck Surgery, University of Adelaide, Adelaide, South Australia, Australia.&#xD;Central Adelaide Local Health Network, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association between mucosal barrier disruption by Pseudomonas aeruginosa exoproteins and asthma in patients with chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3459-3469</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/05/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">exoproteins</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal barrier</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34033126</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chronic rhinosinusitis (CRS) is a common chronic respiratory condition, frequently associated with asthma and affecting the majority of cystic fibrosis (CF) patients. Pseudomonas aeruginosa infections and biofilms have been implicated in recalcitrant CRS. One of the mechanisms of action for bacteria in CRS and CF is mucosal barrier disruption by secreted products that contribute to the inflammation. However, the role of biofilm and planktonic forms of P. aeruginosa in this process is not known. The aim is to determine the effect of P. aeruginosa exoproteins isolated from CF and non-CF CRS patients on the mucosal barrier. METHODS: Exoproteins from 40 P. aeruginosa isolates were collected in planktonic and biofilm forms and applied to air-liquid interface (ALI) cultures of primary human nasal epithelial cells (HNECs). Mucosal barrier integrity was evaluated by transepithelial electrical resistance (TEER), passage of FITC-dextrans and immunofluorescence of tight junction proteins. Cytotoxicity assays were performed to measure cell viability, and IL-6 ELISA was carried out to evaluate pro-inflammatory effects. RESULTS: Planktonic exoproteins from 20/40 (50%) clinical isolates had a significant detrimental effect on the barrier and significantly increased IL-6 production. Barrier disruption was characterized by a reduced TEER, increased permeability of FITC-dextrans and discontinuous immunolocalization of tight junction proteins and was significantly more prevalent in isolates harvested from patients with comorbid asthma (P &lt; .05). CONCLUSION: Exoproteins from planktonic P. aeruginosa clinical isolates from asthmatic CRS patients have detrimental effects on the mucosal barrier and induce IL-6 production potentially contributing to the mucosal inflammation in CRS patients.</style></abstract><notes><style face="normal" font="default" size="100%">Tuli, Jannatul Ferdoush&#xD;Ramezanpour, Mahnaz&#xD;Cooksley, Clare&#xD;Psaltis, Alkis James&#xD;Wormald, Peter-John&#xD;Vreugde, Sarah&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3459-3469. doi: 10.1111/all.14959. Epub 2021 Jun 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34033126</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14959</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2868</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2868</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vansteelant, G.</style></author><author><style face="normal" font="default" size="100%">Dietz de Loos, D. A. E.</style></author><author><style face="normal" font="default" size="100%">Ronsmans, S.</style></author><author><style face="normal" font="default" size="100%">Samaha, M.</style></author><author><style face="normal" font="default" size="100%">Langer, D.</style></author><author><style face="normal" font="default" size="100%">Keirsbilck, S.</style></author><author><style face="normal" font="default" size="100%">Rombaux, P.</style></author><author><style face="normal" font="default" size="100%">Huart, C.</style></author><author><style face="normal" font="default" size="100%">Jorissen, M.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W.</style></author><author><style face="normal" font="default" size="100%">Nemery, B.</style></author><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author><author><style face="normal" font="default" size="100%">Hox, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, Location AMC, Amsterdam, the Netherlands.&#xD;Department of Public Health and Primary Care, Centre for Environment and Health, KU Leuven, Leuven, Belgium.&#xD;Department of Otorhinolaryngology, Centre Hospitalier Universitaire de Liege, Liege, Belgium.&#xD;Respiratory Rehabilitation and Respiratory Division, University Hospitals Leuven, Leuven, Belgium.&#xD;IDEWE, External Service for Prevention and Protection at Work, Leuven, Belgium.&#xD;Department of Otorhinolaryngology - Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.&#xD;Upper Airways Research Laboratory - University of Ghent, Ghent, Belgium.&#xD;Clinic of Occupational and Environmental Medicine, University Hospitals Leuven, Leuven, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association Between Occupational Exposure and Sinus Surgery Outcomes in Chronic Rhinosinusitis: A Prospective Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2063-2067</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/04/10</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40207711</style></accession-num><notes><style face="normal" font="default" size="100%">Vansteelant, G&#xD;Dietz de Loos, D A E&#xD;Ronsmans, S&#xD;Samaha, M&#xD;Langer, D&#xD;Keirsbilck, S&#xD;Rombaux, P&#xD;Huart, C&#xD;Jorissen, M&#xD;Fokkens, W&#xD;Nemery, B&#xD;Hellings, P W&#xD;Hox, V&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2063-2067. doi: 10.1111/all.16555. Epub 2025 Apr 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40207711</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16555</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2834</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2834</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, M. S.</style></author><author><style face="normal" font="default" size="100%">Lee, H. W.</style></author><author><style face="normal" font="default" size="100%">Choi, M. S.</style></author><author><style face="normal" font="default" size="100%">Lee, H. S.</style></author><author><style face="normal" font="default" size="100%">Park, H. W.</style></author><author><style face="normal" font="default" size="100%">Rhew, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">College of Pharmacy, Dongduk Women&apos;s University, Seoul, Republic of Korea.&#xD;Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.&#xD;Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association Between Prevalence of Anemia and Asthma Severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1782-1784</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/02/18</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39963775</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Mi-So&#xD;Lee, Hye-Won&#xD;Choi, Min Sik&#xD;Lee, Hyun Seung&#xD;Park, Heung-Woo&#xD;Rhew, Kiyon&#xD;eng&#xD;the National Research Foundation (NRF) funded by the Ministry of Science and ICT (MSIT), Republic of Korea./&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1782-1784. doi: 10.1111/all.16506. Epub 2025 Feb 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39963775</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16506</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2953</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2953</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, D. K.</style></author><author><style face="normal" font="default" size="100%">Chang, H. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of General Medicine, Taipei Medical University Hospital, Taipei, Taiwan.&#xD;Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Dermatology, Taipei Medical University Hospital, Taipei, Taiwan.&#xD;Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association of Atopic Dermatitis or Allergic Rhinitis With Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">248-251</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/06/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">irritable bowel syndrome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40560692</style></accession-num><notes><style face="normal" font="default" size="100%">Lin, Daniel Keng-Hsien&#xD;Chang, Hua-Ching&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):248-251. doi: 10.1111/all.16630. Epub 2025 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40560692</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16630</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2655</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2655</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Seastedt, H.</style></author><author><style face="normal" font="default" size="100%">Han, X.</style></author><author><style face="normal" font="default" size="100%">Fernandes, A.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author><author><style face="normal" font="default" size="100%">Boyd, S. D.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Manohar, M.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association of cytotoxic effector memory CD8(+) T cells with sustained unresponsiveness after peanut oral immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">319-322</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/09/08 22:43</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39244697</style></accession-num><notes><style face="normal" font="default" size="100%">Seastedt, Hana&#xD;Han, Xiaorui&#xD;Fernandes, Andrea&#xD;Galli, Stephen J&#xD;Boyd, Scott D&#xD;Nadeau, Kari C&#xD;Manohar, Monali&#xD;Chinthrajah, Sharon&#xD;eng&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University/&#xD;National Institute of Allergy and Infectious Diseases/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):319-322. doi: 10.1111/all.16307. Epub 2024 Sep 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39244697</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724757</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16307</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1202</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1202</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abdel-Aziz, M. I.</style></author><author><style face="normal" font="default" size="100%">Kermani, N. Z.</style></author><author><style face="normal" font="default" size="100%">Neerincx, A. H.</style></author><author><style face="normal" font="default" size="100%">Vijverberg, S. J. H.</style></author><author><style face="normal" font="default" size="100%">Guo, Y.</style></author><author><style face="normal" font="default" size="100%">Howarth, P.</style></author><author><style face="normal" font="default" size="100%">Dahlen, S. E.</style></author><author><style face="normal" font="default" size="100%">Djukanovic, R.</style></author><author><style face="normal" font="default" size="100%">Sterk, P. J.</style></author><author><style face="normal" font="default" size="100%">Kraneveld, A. D.</style></author><author><style face="normal" font="default" size="100%">Maitland-van der Zee, A. H.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">On behalf the, U. Biopred Consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, Egypt.&#xD;Data Science Institute, Imperial College London, London, UK.&#xD;NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, University of Southampton, Southampton, UK.&#xD;Centre for Allergy Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Division of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.&#xD;Faculty of Veterinary Medicine, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.&#xD;Department of Pediatric Respiratory Medicine, Emma Children&apos;s Hospital, Amsterdam UMC, Amsterdam, The Netherlands.&#xD;National Heart and Lung Institute, Imperial College London, and Royal Brompton and Harefield NHS Trust, London, UK.&#xD;National Heart and Lung Institute, Imperial College London and the NIHR Imperial Biomedical Research Centre, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association of endopeptidases, involved in SARS-CoV-2 infection, with microbial aggravation in sputum of severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1917-1921</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Endopeptidases</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33411967</style></accession-num><notes><style face="normal" font="default" size="100%">Abdel-Aziz, Mahmoud I&#xD;Kermani, Nazanin Zounemat&#xD;Neerincx, Anne H&#xD;Vijverberg, Susanne J H&#xD;Guo, Yike&#xD;Howarth, Peter&#xD;Dahlen, Sven-Erik&#xD;Djukanovic, Ratko&#xD;Sterk, Peter J&#xD;Kraneveld, Aletta D&#xD;Maitland-van der Zee, Anke H&#xD;Chung, Kian Fan&#xD;Adcock, Ian M&#xD;eng&#xD;115010/Innovative Medicines Initiative/&#xD;European Federation of Pharmaceutical Industries and Associations/&#xD;FP7/2007-2013/Seventh Framework Programme/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1917-1921. doi: 10.1111/all.14731. Epub 2021 Jan 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33411967</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14731</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>23</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">23</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kwon, R.</style></author><author><style face="normal" font="default" size="100%">Shin, Y. H.</style></author><author><style face="normal" font="default" size="100%">Shin, J. I.</style></author><author><style face="normal" font="default" size="100%">Kang, S. M.</style></author><author><style face="normal" font="default" size="100%">Hwang, J.</style></author><author><style face="normal" font="default" size="100%">Shin, J. U.</style></author><author><style face="normal" font="default" size="100%">Noh, H.</style></author><author><style face="normal" font="default" size="100%">Heo, C. Y.</style></author><author><style face="normal" font="default" size="100%">Koyanagi, A.</style></author><author><style face="normal" font="default" size="100%">Jacob, L.</style></author><author><style face="normal" font="default" size="100%">Smith, L.</style></author><author><style face="normal" font="default" size="100%">Ludvigsson, J. F.</style></author><author><style face="normal" font="default" size="100%">Turner, S.</style></author><author><style face="normal" font="default" size="100%">Shin, J. Y.</style></author><author><style face="normal" font="default" size="100%">Jeong, H. E.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Rhee, S. Y.</style></author><author><style face="normal" font="default" size="100%">Min, C.</style></author><author><style face="normal" font="default" size="100%">Suh, D. I.</style></author><author><style face="normal" font="default" size="100%">Koo, M. J.</style></author><author><style face="normal" font="default" size="100%">Abuabara, K.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Lee, S. W.</style></author><author><style face="normal" font="default" size="100%">Yon, D. K.</style></author><author><style face="normal" font="default" size="100%">Cho, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biomedical Engineering, University of Michigan, Michigan, Ann Arbor, USA.&#xD;Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Pediatrics, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea.&#xD;Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.&#xD;Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Maryland, Baltimore, USA.&#xD;Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.&#xD;Department of Dermatology, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea.&#xD;Department of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.&#xD;Research and Development Unit, Parc Sanitari Sant Joan de Deu, CIBERSAM, Barcelona, Spain.&#xD;Catalan Institution for Research and Advanced Studies (ICREA), Pg. Lluis Companys, Barcelona, Spain.&#xD;Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France.&#xD;Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.&#xD;Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden.&#xD;Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA.&#xD;Department of Paediatrics, Orebro University Hospital, Orebro, Sweden.&#xD;Maternity and Child Health Division, NHS Grampian Aberdeen, Aberdeen, UK.&#xD;School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.&#xD;Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea.&#xD;Department of Allergy and Clinical Immunology, Korean Armed Forces Capital Hospital, Seongnam, South Korea.&#xD;Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, South Korea.&#xD;Department of Pediatrics, Seoul National University Children&apos;s Hospital, Seoul National University College of Medicine, Seoul, South Korea.&#xD;Department of Human Biology, University of Toronto, Ontario, Toronto, Canada.&#xD;Department of Dermatology, University of California San Francisco, California, San Francisco, USA.&#xD;Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, South Korea.&#xD;Department of Pediatrics, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Division of Allergy-Immunology, University of South Florida Morsani College of Medicine, Florida, Tampa, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association of fracture incidence in children with the development of food allergy: A Korean nationwide birth cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">858-862</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/01/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Republic of Korea/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36602289</style></accession-num><notes><style face="normal" font="default" size="100%">Kwon, Rosie&#xD;Shin, Youn Ho&#xD;Shin, Jae Il&#xD;Kang, So Min&#xD;Hwang, Jimin&#xD;Shin, Jung U&#xD;Noh, Hyungrye&#xD;Heo, Chan Yeong&#xD;Koyanagi, Ai&#xD;Jacob, Louis&#xD;Smith, Lee&#xD;Ludvigsson, Jonas F&#xD;Turner, Stephen&#xD;Shin, Ju-Young&#xD;Jeong, Han Eol&#xD;Kim, Jung-Hyun&#xD;Rhee, Sang Youl&#xD;Min, Chanyang&#xD;Suh, Dong In&#xD;Koo, Min Ji&#xD;Abuabara, Katrina&#xD;Kim, Sunyeup&#xD;Lee, Seung Won&#xD;Yon, Dong Keon&#xD;Cho, Seong Ho&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):858-862. doi: 10.1111/all.15639. Epub 2023 Jan 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36602289</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15639</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3264</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3264</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, Min Seong</style></author><author><style face="normal" font="default" size="100%">Kim, Kyeongeun</style></author><author><style face="normal" font="default" size="100%">Byun, Seungjae</style></author><author><style face="normal" font="default" size="100%">Yim, Yesol</style></author><author><style face="normal" font="default" size="100%">Nehs, Christa J.</style></author><author><style face="normal" font="default" size="100%">Pizzol, Damiano</style></author><author><style face="normal" font="default" size="100%">Kim, Tae</style></author><author><style face="normal" font="default" size="100%">Yon, Dong Keon</style></author><author><style face="normal" font="default" size="100%">Kang, Jiseung</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Association of Sleep Duration With Asthma and Allergic Rhinitis in South Korea: A Nationwide Representative Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70257</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70257</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3046</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3046</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Delaunay, E.</style></author><author><style face="normal" font="default" size="100%">Esnault, S.</style></author><author><style face="normal" font="default" size="100%">Dendooven, A.</style></author><author><style face="normal" font="default" size="100%">Stoup, T.</style></author><author><style face="normal" font="default" size="100%">Vanderhaegen, T.</style></author><author><style face="normal" font="default" size="100%">Jan, L.</style></author><author><style face="normal" font="default" size="100%">Cadart, L.</style></author><author><style face="normal" font="default" size="100%">Chenivesse, C.</style></author><author><style face="normal" font="default" size="100%">Mortuaire, G.</style></author><author><style face="normal" font="default" size="100%">Lefevre, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Univ. Lille, INSERM, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, France.&#xD;CHU Lille, Institut D&apos;immunologie, Medecine Interne et Immunologie Clinique, Lille, France.&#xD;Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.&#xD;Univ. Lille, CHU Lille, Service de Pneumologie et Immuno-Allergologie, U1286 Inserm INFINITE, Univ. Lille, Institute for Translational Research in Inflammation, Lille, France.&#xD;Univ. Lille, CHU Lille, Service D&apos;otorhinolaryngologie, U1286 Inserm INFINITE, Univ. Lille, Institute for Translational Research in Inflammation, Lille, France.&#xD;CHU Lille, Service de Biostatistique, Lille, France.&#xD;Univ. Lille, CHU Lille, CNRS, Inserm, Institut Pasteur Lille, U1019-UMR9017-CIIL-Centre D&apos;infection et D&apos;immunite de Lille, Lille, France.&#xD;CRISALIS (Clinical Research Initiative in Severe Asthma: A Lever for Innovation &amp; Science), Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Associations Between Blood Eosinophil Surface Proteins and Clinical Traits in Severe Asthma and Chronic Rhinosinusitis With Nasal Polyposis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3454-3457</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">surface protein expression</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from ALK-Abello, AstraZeneca, Boehringer-Ingelheim,</style></keyword><keyword><style face="normal" font="default" size="100%">Celtrion, Chiesi, Sanofi, and GSK</style></keyword><keyword><style face="normal" font="default" size="100%">and congress support from AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Chiesi, Sanofi, and Novartis. G. Lefevre received</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees, personal fees for advisory boards or meetings, and research</style></keyword><keyword><style face="normal" font="default" size="100%">funding from AstraZeneca and GSK. The rest of the authors declare that they have</style></keyword><keyword><style face="normal" font="default" size="100%">no relevant conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40751399</style></accession-num><notes><style face="normal" font="default" size="100%">Delaunay, Emeline&#xD;Esnault, Stephane&#xD;Dendooven, Arnaud&#xD;Stoup, Thomas&#xD;Vanderhaegen, Thibaut&#xD;Jan, Louison&#xD;Cadart, Laurine&#xD;Chenivesse, Cecile&#xD;Mortuaire, Geoffrey&#xD;Lefevre, Guillaume&#xD;eng&#xD;AstraZeneca France/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3454-3457. doi: 10.1111/all.70001. Epub 2025 Aug 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40751399</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666750</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70001</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1089</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1089</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gheerbrant, H.</style></author><author><style face="normal" font="default" size="100%">Guillien, A.</style></author><author><style face="normal" font="default" size="100%">Vernet, R.</style></author><author><style face="normal" font="default" size="100%">Lupinek, C.</style></author><author><style face="normal" font="default" size="100%">Pison, C.</style></author><author><style face="normal" font="default" size="100%">Pin, I.</style></author><author><style face="normal" font="default" size="100%">Demenais, F.</style></author><author><style face="normal" font="default" size="100%">Nadif, R.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Pickl, W. F.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Bouzigon, E.</style></author><author><style face="normal" font="default" size="100%">Siroux, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Service Hospitalier Universitaire Pneumologie Physiologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.&#xD;Inserm, CNRS, IAB, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, University Grenoble Alpes, Grenoble, France.&#xD;UMRS 1124, INSERM, Group of Genomic Epidemiology of Multifactorial Diseases, Universite de Paris, Paris, France.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Inserm 1055, Laboratoire de Bioenergetique Fondamentale et Appliquee, Grenoble, France.&#xD;Department of Pediatrics, Grenoble-Alpes University Hospital, Grenoble, France.&#xD;Universite Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Equipe d&apos;Epidemiologie respiratoire integrative, CESP, Villejuif, France.&#xD;Arnaud de Villeneuve University Hospital and Inserm, Montpellier, France.&#xD;Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;NRC Institute of Immunology FMBA of Russia, Moscow, Russia.&#xD;Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Associations between specific IgE sensitization to 26 respiratory allergen molecules and HLA class II alleles in the EGEA cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2575-2586</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Phleum</style></keyword><keyword><style face="normal" font="default" size="100%">HLA class-II genes</style></keyword><keyword><style face="normal" font="default" size="100%">MeDALL allergen-chip</style></keyword><keyword><style face="normal" font="default" size="100%">genetic epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory allergen</style></keyword><keyword><style face="normal" font="default" size="100%">specific IgE</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33742477</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergy, the most frequent immune disorder affecting 30% of the world&apos;s population, is the consequence of immunoglobin E (IgE) sensitization to allergens. Among the genetic factors suspected to be involved in allergy, the HLA class-II genomic region is a strong candidate. OBJECTIVE: To assess the association between HLA class-II alleles and specific IgE (sIgE) sensitization to a large number of respiratory allergen molecules. METHODS: The analysis relied on 927 participants of the EGEA cohort, including 497 asthmatics. The study focuses on 26 aeroallergens recognized by sIgE in at least 5% of the study population (determined with the MEDALL chip with sIgE &gt;/= 0.3 ISU) and 23 imputed HLA class-II alleles. For each sIgE sensitization and HLA class-II allele, we fitted a logistic regression model accounting for familial dependence and adjusted for gender, age, and genetic principal components. p-values were corrected for multiple comparisons (False Discovery Rate). RESULTS: Most of the 19 statistically significant associations observed regard pollen allergens (mugwort Art v 1, olive tree Ole e 1, timothy grass Phl p 2, Phl p 5 and plantain Pla l 1), three were mold allergen (Alternaria Alt a 1), and a single one regards house dust mite allergen (Der p 7). No association was observed with pet allergens. The strongest associations were found with mugwort Art v 1 (OR = 5.42 (95%CI, 3.30; 8.88), 4.14 (2.65; 6.47), 3.16 (1.88; 5.31) with DQB1*05:01, DQA1*01:01 and DRB1*01:01, respectively). CONCLUSION: Our results support the important role of HLA class-II alleles as immune response genes predisposing their carriers for sensitization to various major pollen allergens.</style></abstract><notes><style face="normal" font="default" size="100%">Gheerbrant, Hubert&#xD;Guillien, Alicia&#xD;Vernet, Raphael&#xD;Lupinek, Christian&#xD;Pison, Christophe&#xD;Pin, Isabelle&#xD;Demenais, Florence&#xD;Nadif, Rachel&#xD;Bousquet, Jean&#xD;Pickl, Winfried F&#xD;Valenta, Rudolf&#xD;Bouzigon, Emmanuelle&#xD;Siroux, Valerie&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2575-2586. doi: 10.1111/all.14820. Epub 2021 Apr 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33742477</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14820</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3315</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3315</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, Shenglong</style></author><author><style face="normal" font="default" size="100%">Wan, Zhaoman</style></author><author><style face="normal" font="default" size="100%">Zhang, Xinlei</style></author><author><style face="normal" font="default" size="100%">Zhang, Peng</style></author><author><style face="normal" font="default" size="100%">Zhang, Luo</style></author><author><style face="normal" font="default" size="100%">Zhao, Yan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Associations of Chronic Rhinosinusitis and Nasal Polyps With Elevated Venous Thromboembolism Risk: Evidence From the UK Biobank</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70295</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70295</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2370</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2370</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Meng, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, N.</style></author><author><style face="normal" font="default" size="100%">Jiao, J.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, M.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Upper Airways Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent University Hospital, Ghent, Belgium.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University of Muenster, Muenster, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Associations of tenascin C with Th2 response, edema degree, and disease severity in patients with chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1357-1361</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/01/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Edema</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/immunology/metabolism/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinosinusitis/complications/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">*Tenascin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells/immunology/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38230820</style></accession-num><notes><style face="normal" font="default" size="100%">Wang, Min&#xD;Meng, Haiyang&#xD;Zhang, Nan&#xD;Jiao, Jian&#xD;Wang, Yifei&#xD;Liu, Mengdi&#xD;Li, Ying&#xD;Wang, Xiangdong&#xD;Zhang, Luo&#xD;Bachert, Claus&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1357-1361. doi: 10.1111/all.16015. Epub 2024 Jan 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38230820</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16015</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2860</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2860</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, S.</style></author><author><style face="normal" font="default" size="100%">Yoo, S. A.</style></author><author><style face="normal" font="default" size="100%">Ji, K. Y.</style></author><author><style face="normal" font="default" size="100%">Jung, D. H.</style></author><author><style face="normal" font="default" size="100%">Lee, S.</style></author><author><style face="normal" font="default" size="100%">Lee, K. G.</style></author><author><style face="normal" font="default" size="100%">Kim, K. M.</style></author><author><style face="normal" font="default" size="100%">Lee, J. Y.</style></author><author><style face="normal" font="default" size="100%">Jung, M. A.</style></author><author><style face="normal" font="default" size="100%">Pyun, B. J.</style></author><author><style face="normal" font="default" size="100%">Hur, J.</style></author><author><style face="normal" font="default" size="100%">Choi, J. Y.</style></author><author><style face="normal" font="default" size="100%">Rhee, C. K.</style></author><author><style face="normal" font="default" size="100%">Kim, W. U.</style></author><author><style face="normal" font="default" size="100%">Kim, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">KM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.&#xD;Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.&#xD;Center for Integrative Rheumatoid Transcriptomics and Dynamics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.&#xD;Department of Plastic and Reconstructive Surgery, Seoul National University College of Medicine, Seoul National University Boramae Hospital, Seoul, Republic of Korea.&#xD;Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, The Catholic University of Korea, Seoul, Republic of Korea.&#xD;Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary&apos;s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea.&#xD;Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary&apos;s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.&#xD;Department of Biomedicine &amp; Health Sciences, The Catholic University of Korea, Seoul, Republic of Korea.&#xD;Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary&apos;s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asthma Alleviation by Ginsenoside Rb1 via Promotion of Treg Proliferation and Inflammatory T Cell Inhibition</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1647-1668</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/04/19 22:12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Ginsenosides/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory/immunology/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Activation/drug effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocyte Subsets/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Panax ginseng</style></keyword><keyword><style face="normal" font="default" size="100%">Treg</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">ginsenoside Rb1</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">screening</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40251907</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Regulatory T cells (Tregs) are living drugs with feasibility, tolerability, and therapeutic benefits. Although Tregs are linked to asthma prognosis through inflammation regulation, no therapeutic agents specifically designed to manage asthma by upregulating Tregs have been developed to date. METHODS: We screened a library of 250 natural products using a cytometric bead array. Among the selected candidates, gRb1 was identified for further investigation. The effects of gRb1 on Treg and Th17 populations were evaluated in mouse asthma models and human PBMCs from both healthy donors and asthma patients using flow cytometry and cytokine analysis. RESULTS: In inflammatory conditions, ginsenoside Rb1 (gRb1, a major ginseng component) increased IL-10- and TGF-beta-expressing Treg populations and decreased the Th17 population; activated phospho-STAT5 and NFAT1 in Tregs; inhibited NFAT1 activation in conventional T cells (Tconvs); increased Treg proliferation and Tconv-Treg differentiation, inhibiting Tconv proliferation; and reduced inflammatory cytokine secretion by Tconvs. In asthma model mice, suppression of asthma symptoms by gRb1 was associated with elevated Treg and lower Th17, Th1, and Th2 counts. gRb1 treatment of stimulated PBMCs from patients with asthma and healthy donors increased IL-10- and TGF-beta-expressing Treg populations and decreased IL-17A-, IL-22-, IFN-gamma-, and TNF-alpha-expressing T-cell populations. CONCLUSIONS: gRb1 alleviate asthma by shifting the Treg-inflammatory T cell balance. These findings suggest a strategy for enhancing Treg activity through treatment with gRb1. This may provide a novel therapeutic approach for asthma and related disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Choi, Susanna&#xD;Yoo, Seung-Ah&#xD;Ji, Kon-Young&#xD;Jung, Dong Ho&#xD;Lee, Saseong&#xD;Lee, Kang-Gu&#xD;Kim, Ki-Myo&#xD;Lee, Joo Young&#xD;Jung, Myung-A&#xD;Pyun, Bo-Jeong&#xD;Hur, Jung&#xD;Choi, Joon Young&#xD;Rhee, Chin Kook&#xD;Kim, Wan-Uk&#xD;Kim, Taesoo&#xD;eng&#xD;Korea Institute of Oriental Medicine/&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1647-1668. doi: 10.1111/all.16551. Epub 2025 Apr 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40251907</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186593</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16551</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2816</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2816</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, K.</style></author><author><style face="normal" font="default" size="100%">Liu, M.</style></author><author><style face="normal" font="default" size="100%">Wang, W.</style></author><author><style face="normal" font="default" size="100%">Shi, H.</style></author><author><style face="normal" font="default" size="100%">Shi, C.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Bateman, E. D.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Feng, X.</style></author><author><style face="normal" font="default" size="100%">Shen, H.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.&#xD;Department of Medicine, University of Cape Town, Cape Town, South Africa.&#xD;Department of Pulmonary and Critical Care Medicine, Beijing Hospital, Beijing, China.&#xD;Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.&#xD;National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.&#xD;Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asthma Control and Risk Factors for Poor Asthma Outcomes in Chinese Asthma Patients: Baseline Analysis of a Multi-Centre, Single-Arm Study (CARE4ALL)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1487-1490</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/03/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma control</style></keyword><keyword><style face="normal" font="default" size="100%">inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default" size="100%">quality improvement programme</style></keyword><keyword><style face="normal" font="default" size="100%">risk factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40059338</style></accession-num><notes><style face="normal" font="default" size="100%">Huang, Kewu&#xD;Liu, Meishan&#xD;Wang, Wenjun&#xD;Shi, Honglei&#xD;Shi, Chenxi&#xD;Wang, Ying&#xD;Bateman, Eric D&#xD;Li, Yanming&#xD;Feng, Xiaokai&#xD;Shen, Huahao&#xD;Wang, Chen&#xD;eng&#xD;AstraZeneca/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1487-1490. doi: 10.1111/all.16522. Epub 2025 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40059338</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105054</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16522</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1327</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1327</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chang, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Dong, F.</style></author><author><style face="normal" font="default" size="100%">Liang, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Shang, Y.</style></author><author><style face="normal" font="default" size="100%">Abulikemu, M.</style></author><author><style face="normal" font="default" size="100%">Sun, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asthma control, self-management, and healthcare access during the COVID-19 epidemic in Beijing</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">586-588</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/09/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Beijing</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Delivery of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Services Accessibility</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Self-Management</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32946594</style></accession-num><notes><style face="normal" font="default" size="100%">Chang, Chun&#xD;Zhang, Linlin&#xD;Dong, Fawu&#xD;Liang, Ying&#xD;Chen, Yahong&#xD;Shang, Ying&#xD;Abulikemu, Mairipaiti&#xD;Sun, Yongchang&#xD;eng&#xD;81970028/National Natural Science Foundation of China/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):586-588. doi: 10.1111/all.14591. Epub 2020 Sep 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32946594</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7537259</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14591</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2656</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2656</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Melgaard, M. E.</style></author><author><style face="normal" font="default" size="100%">Jensen, S. K.</style></author><author><style face="normal" font="default" size="100%">Eliasen, A.</style></author><author><style face="normal" font="default" size="100%">Pedersen, C. T.</style></author><author><style face="normal" font="default" size="100%">Thorsen, J.</style></author><author><style face="normal" font="default" size="100%">Mikkelsen, M.</style></author><author><style face="normal" font="default" size="100%">Vahman, N.</style></author><author><style face="normal" font="default" size="100%">Schoos, A. M.</style></author><author><style face="normal" font="default" size="100%">Gern, J.</style></author><author><style face="normal" font="default" size="100%">Brix, S.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Chawes, B. L.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Health Technology, Section for Bioinformatics, Technical University of Denmark, Kgs. Lyngby, Denmark.&#xD;Department of Pediatrics, Slagelse Sygehus, Slagelse, Denmark.&#xD;Department of Pediatrics and Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.&#xD;Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark.&#xD;Department of Food Science, University of Copenhagen, Frederiksberg C, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asthma development is associated with low mucosal IL-10 during viral infections in early life</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2981-2992</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/09/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/immunology/virology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Virus Diseases/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-10/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Tract Infections/immunology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa/immunology/virology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">preschool child</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">viruses</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39221476</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Viral infection is a common trigger of severe respiratory illnesses in early life and a risk factor for later asthma development. The mechanism leading to asthma could involve an aberrant airway immune response to viral infections, but this has rarely been studied in a human setting. OBJECTIVES: To investigate in situ virus-specific differences in upper airway immune mediator levels during viral episodes of respiratory illnesses and the association with later asthma. METHODS: We included 493 episodes of acute respiratory illnesses in 277 children aged 0-3 years from the COPSAC(2010) mother-child cohort. Levels of 18 different immune mediators were assessed in nasal epithelial lining fluid using high-sensitivity MesoScale Discovery kits and compared between children with and without viral PCR-identification in nasopharyngeal samples. Finally, we investigated whether the virus-specific immune response was associated with asthma by age 6 years. RESULTS: Viral detection were associated with upregulation of several Type 1 and regulatory immune mediators, including IFN-ɣ, TNF-alpha, CCL4, CXCL10 and IL-10 and downregulation of Type 2 and Type 17 immune mediators, including CCL13, and CXCL8 (FDR &lt;0.05). Children developing asthma had decreased levels of IL-10 (FDR &lt;0.05) during viral episodes compared to children not developing asthma. CONCLUSION: We described the airway immune mediator profile during viral respiratory illnesses in early life and showed that children developing asthma by age 6 years have a reduced regulatory (IL-10) immune mediator level. This provides insight into the interplay between early-life viral infections, airway immunity and asthma development.</style></abstract><notes><style face="normal" font="default" size="100%">Melgaard, Mathias Elsner&#xD;Jensen, Signe Kjeldgaard&#xD;Eliasen, Anders&#xD;Pedersen, Casper-Emil Tingskov&#xD;Thorsen, Jonathan&#xD;Mikkelsen, Marianne&#xD;Vahman, Nilofar&#xD;Schoos, Ann-Marie Malby&#xD;Gern, James&#xD;Brix, Susanne&#xD;Stokholm, Jakob&#xD;Chawes, Bo Lund&#xD;Bonnelykke, Klaus&#xD;eng&#xD;Novo Nordisk Fonden/&#xD;Herlev-Gentofte Hospital&apos;s local foundation/&#xD;The Children&apos;s Lung foundation/&#xD;Region Hovedstaden/&#xD;Strategiske Forskningsraring;d/&#xD;The Danish Ministry of Health/&#xD;Lundbeck Foundation/&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):2981-2992. doi: 10.1111/all.16276. Epub 2024 Sep 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39221476</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16276</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>527</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">527</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rasmussen, S. M.</style></author><author><style face="normal" font="default" size="100%">Halvard Hansen, E. S.</style></author><author><style face="normal" font="default" size="100%">Stensrud, T.</style></author><author><style face="normal" font="default" size="100%">Radon, K.</style></author><author><style face="normal" font="default" size="100%">Wolfarth, B.</style></author><author><style face="normal" font="default" size="100%">Kurowski, M.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Bonini, S.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Delgado, L.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Drobnic, F.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Vakali, S.</style></author><author><style face="normal" font="default" size="100%">Gratziou, C.</style></author><author><style face="normal" font="default" size="100%">Malmberg, L. P.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Backer, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Physical Activity Research (CFAS), Rigshospitalet, Copenhagen, Denmark.&#xD;Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre Hospital, Hvidovre, Denmark.&#xD;Norwegian School of Sport Sciences, Oslo, Norway.&#xD;Institute for Occupational, Social and Environmental Medicine, Hospital of the Ludwig-Maximilian-University, Munich, Germany.&#xD;Department of Sports Medicine, Humboldt University and Charite University School of Medicine, Berlin, Germany.&#xD;Department of Immunology and Allergy, Chair of Pulmonology, Rheumatology and Clinical Immunology, Medical University of Lodz, Lodz, Poland.&#xD;University Hospital and INSERM, Hopital Arnaud de Villeneuve, Montpellier, France.&#xD;CNR, Institute of Neurobiology and Molecular Medicine, Rome, Italy.&#xD;Fondazione Policlinico Universitario A. Gemelli - IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;National Heart and Lung Institute (NHLI), Imperial College London, London, UK.&#xD;Basic &amp; Clinical Immunology, Department of Pathology, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.&#xD;Center for Health Technology and Services Research, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.&#xD;EPIUnit - Institute of Public Health, University of Porto, Porto, Portugal.&#xD;Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal.&#xD;Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Imunoalergologia, Sao Joao University Hospital Center, Porto, Portugal.&#xD;Medical Department, Shanghai Shenhau FC, Shanghai, China.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.&#xD;Department of ENT, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asthma endotypes in elite athletes: A cross-sectional study of European athletes participating in the Olympic Games</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2250-2253</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/04/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Athletes</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sports</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35426975</style></accession-num><notes><style face="normal" font="default" size="100%">Rasmussen, Soren Malte&#xD;Halvard Hansen, Erik Soren&#xD;Stensrud, Trine&#xD;Radon, Katja&#xD;Wolfarth, Bernd&#xD;Kurowski, Marcin&#xD;Bousquet, Jean&#xD;Bonini, Sergio&#xD;Bonini, Matteo&#xD;Delgado, Luis&#xD;Moreira, Andre&#xD;Drobnic, Franchek&#xD;Papadopoulos, Nikolaos G&#xD;Vakali, Sofia&#xD;Gratziou, Christina&#xD;Malmberg, Leo Pekka&#xD;Haahtela, Tari&#xD;Backer, Vibeke&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2250-2253. doi: 10.1111/all.15313. Epub 2022 May 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35426975</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15313</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1362</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1362</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Poznanski, S. M.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Zhao, N.</style></author><author><style face="normal" font="default" size="100%">Huang, C.</style></author><author><style face="normal" font="default" size="100%">Radford, K.</style></author><author><style face="normal" font="default" size="100%">Ashkar, A. A.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.&#xD;Division of Respirology, Department of Medicine, McMaster University, Hamilton &amp; Firestone Institute for Respiratory Health, St Joseph&apos;s Healthcare, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asthma exacerbations on benralizumab are largely non-eosinophilic</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">375-379</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/08/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">airway infections</style></keyword><keyword><style face="normal" font="default" size="100%">benralizumab</style></keyword><keyword><style face="normal" font="default" size="100%">natural killer cells</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">sputum</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32767484</style></accession-num><notes><style face="normal" font="default" size="100%">Poznanski, Sophie M&#xD;Mukherjee, Manali&#xD;Zhao, Nan&#xD;Huang, Chynna&#xD;Radford, Katherine&#xD;Ashkar, Ali A&#xD;Nair, Parameswaran&#xD;eng&#xD;CIHR/Canada&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):375-379. doi: 10.1111/all.14514. Epub 2020 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32767484</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14514</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>826</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">826</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Viiu, B.</style></author><author><style face="normal" font="default" size="100%">Christer, J.</style></author><author><style face="normal" font="default" size="100%">Fredrik, S.</style></author><author><style face="normal" font="default" size="100%">Magnus, P. B.</style></author><author><style face="normal" font="default" size="100%">Jenny, H.</style></author><author><style face="normal" font="default" size="100%">Nikolaos, T.</style></author><author><style face="normal" font="default" size="100%">Kjell, A.</style></author><author><style face="normal" font="default" size="100%">Andrei, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Sciences, Respiratory, Allergy and Sleep Research Unit, Uppsala University, Uppsala, Sweden.&#xD;Women&apos;s and Children&apos;s Health, Uppsala University, Uppsala, Sweden.&#xD;Thermo Fisher Scientific, Uppsala, Sweden.&#xD;Department of Medical Biochemistry and Microbiology, Uppsala, Sweden.&#xD;Department of Medical Sciences, Clinical Physiology, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asthma in combination with rhinitis and eczema is associated with a higher degree of type-2 inflammation and symptom burden than asthma alone</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3827-3829</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/09/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34486733</style></accession-num><notes><style face="normal" font="default" size="100%">Viiu, Blondal&#xD;Christer, Janson&#xD;Fredrik, Sundbom&#xD;Magnus P, Borres&#xD;Jenny, Hallgren&#xD;Nikolaos, Tsolakis&#xD;Kjell, Alving&#xD;Andrei, Malinovschi&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3827-3829. doi: 10.1111/all.15082. Epub 2021 Sep 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34486733</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15082</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3143</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3143</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Denton, E.</style></author><author><style face="normal" font="default" size="100%">Jensen, M. E.</style></author><author><style face="normal" font="default" size="100%">Brew, B. K.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author><author><style face="normal" font="default" size="100%">Murphy, V. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Asthma, Allergy and Clinical Immunology, The Alfred Hospital, Melbourne, Victoria, Australia.&#xD;School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.&#xD;Asthma and Breathing Program, Hunter Medical Research Institute, School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asthma in Pregnancy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">84-108</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/10/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/drug therapy/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Pregnancy Complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">treatable traits</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41051000</style></accession-num><abstract><style face="normal" font="default" size="100%">Asthma is one of the most common chronic diseases affecting pregnant women with variable prevalence around the world. Hormonally mediated and physical changes to the respiratory system occur during pregnancy and can impact asthma status unpredictably-some women improve, some worsen and some are stable. Increased maternal and foetal adverse outcomes are observed with uncontrolled asthma. Medication non-adherence increases in pregnancy, often because of concerns regarding the effect of medications on the developing foetus and is a major contributor to loss of asthma control. Certain comorbidities, particularly metabolic comorbidities, are more common in pregnant women with asthma and are increasingly understood to impact asthma and pregnancy outcomes. There is reassuring observational data to suggest the safety of omalizumab and dupilumab in pregnancy, but more studies are needed. This review highlights the current evidence regarding epidemiology, pregnancy-related respiratory changes, comorbidities and treatment of asthma in pregnancy.</style></abstract><notes><style face="normal" font="default" size="100%">Denton, Eve&#xD;Jensen, Megan E&#xD;Brew, Bronwyn K&#xD;Hew, Mark&#xD;Murphy, Vanessa E&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):84-108. doi: 10.1111/all.70087. Epub 2025 Oct 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41051000</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70087</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>959</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">959</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eggert, L. E.</style></author><author><style face="normal" font="default" size="100%">He, Z.</style></author><author><style face="normal" font="default" size="100%">Collins, W.</style></author><author><style face="normal" font="default" size="100%">Lee, A. S.</style></author><author><style face="normal" font="default" size="100%">Dhondalay, G.</style></author><author><style face="normal" font="default" size="100%">Jiang, S. Y.</style></author><author><style face="normal" font="default" size="100%">Fitzpatrick, J.</style></author><author><style face="normal" font="default" size="100%">Snow, T. T.</style></author><author><style face="normal" font="default" size="100%">Pinsky, B. A.</style></author><author><style face="normal" font="default" size="100%">Artandi, M.</style></author><author><style face="normal" font="default" size="100%">Barman, L.</style></author><author><style face="normal" font="default" size="100%">Puri, R.</style></author><author><style face="normal" font="default" size="100%">Wittman, R.</style></author><author><style face="normal" font="default" size="100%">Ahuja, N.</style></author><author><style face="normal" font="default" size="100%">Blomkalns, A.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hara, R.</style></author><author><style face="normal" font="default" size="100%">Cao, S.</style></author><author><style face="normal" font="default" size="100%">Desai, M.</style></author><author><style face="normal" font="default" size="100%">Sindher, S. B.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University, Stanford, CA, USA.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA, USA.&#xD;Division of Hospital Medicine, Stanford University, Stanford, CA, USA.&#xD;Department of Internal Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA.&#xD;Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA.&#xD;Medicine/Primary Care and Population Health, Stanford University, Stanford, CA, USA.&#xD;Graduate School, Medicine, Stanford University, Stanford, CA, USA.&#xD;Department of Emergency Medicine, Stanford University, Stanford, CA, USA.&#xD;Psychiatry/Public Mental Health &amp; Population Sciences, Stanford University, Stanford, CA, USA.&#xD;Medicine, Biomedical Informatics Research, Stanford University, Stanford, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">173-185</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/06/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Testing</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest. WC reports research support from Regeneron.MD reports</style></keyword><keyword><style face="normal" font="default" size="100%">receiving grant funding from the Ping Li and Kim Li Endowment and the NIH. SS</style></keyword><keyword><style face="normal" font="default" size="100%">reports receiving grant funding from the NIH, Regeneron, DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune, Novartis, and CoFAR. KN reports grant funding from NIAID, NHLBI, NIEHS,</style></keyword><keyword><style face="normal" font="default" size="100%">and FARE, and support from the Sunshine Foundation, Parker Foundation, and Crown</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation.SC receives grant funding from NIAID, CoFAR, Aimmune, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Astellas, Regeneron, and FARE and support from the Maternal Child</style></keyword><keyword><style face="normal" font="default" size="100%">Health Research Institute, Sunshine Foundation, Parker Foundation, and Crown</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34080210</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: It is unclear whether asthma and its allergic phenotype are risk factors for hospitalization or severe disease from SARS-CoV-2. METHODS: All patients over 28 days old testing positive for SARS-CoV-2 between March 1 and September 30, 2020, were retrospectively identified and characterized through electronic analysis at Stanford. A sub-cohort was followed prospectively to evaluate long-term COVID-19 symptoms. RESULTS: 168,190 patients underwent SARS-CoV-2 testing, and 6,976 (4.15%) tested positive. In a multivariate analysis, asthma was not an independent risk factor for hospitalization (OR 1.12 [95% CI 0.86, 1.45], p = .40). Among SARS-CoV-2-positive asthmatics, allergic asthma lowered the risk of hospitalization and had a protective effect compared with non-allergic asthma (OR 0.52 [0.28, 0.91], p = .026); there was no association between baseline medication use as characterized by GINA and hospitalization risk. Patients with severe COVID-19 disease had lower eosinophil levels during hospitalization compared with patients with mild or asymptomatic disease, independent of asthma status (p = .0014). In a patient sub-cohort followed longitudinally, asthmatics and non-asthmatics had similar time to resolution of COVID-19 symptoms, particularly lower respiratory symptoms. CONCLUSIONS: Asthma is not a risk factor for more severe COVID-19 disease. Allergic asthmatics were half as likely to be hospitalized with COVID-19 compared with non-allergic asthmatics. Lower levels of eosinophil counts (allergic biomarkers) were associated with a more severe COVID-19 disease trajectory. Recovery was similar among asthmatics and non-asthmatics with over 50% of patients reporting ongoing lower respiratory symptoms 3 months post-infection.</style></abstract><notes><style face="normal" font="default" size="100%">Eggert, Lauren E&#xD;He, Ziyuan&#xD;Collins, William&#xD;Lee, Alexandra S&#xD;Dhondalay, Gopal&#xD;Jiang, Shirley Y&#xD;Fitzpatrick, Jessica&#xD;Snow, Theo T&#xD;Pinsky, Benjamin A&#xD;Artandi, Maja&#xD;Barman, Linda&#xD;Puri, Rajan&#xD;Wittman, Richard&#xD;Ahuja, Neera&#xD;Blomkalns, Andra&#xD;O&apos;Hara, Ruth&#xD;Cao, Shu&#xD;Desai, Manisha&#xD;Sindher, Sayantani B&#xD;Nadeau, Kari&#xD;Chinthrajah, R Sharon&#xD;eng&#xD;Sean N. Parker Center for Allergy and Asthma Research/&#xD;Stanford University School of Medicine/&#xD;Sunshine Foundation/&#xD;Crown Foundation/&#xD;Parker Foundation/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):173-185. doi: 10.1111/all.14972. Epub 2021 Jun 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34080210</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8222896</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14972</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1345</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1345</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carli, G.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Stebbing, J.</style></author><author><style face="normal" font="default" size="100%">Parronchi, P.</style></author><author><style face="normal" font="default" size="100%">Farsi, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">SOS Allergy and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Department of Surgery and Cancer, Imperial College London, London, UK.&#xD;Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asthma phenotypes, comorbidities, and disease activity in COVID-19: The need of risk stratification</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">955-956</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">infections</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword><keyword><style face="normal" font="default" size="100%">Prof. Stebbing&apos;s conflicts of interest can be found at</style></keyword><keyword><style face="normal" font="default" size="100%">https://www.nature.com/onc/editors, and none are relevant here.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32830862</style></accession-num><notes><style face="normal" font="default" size="100%">Carli, Giulia&#xD;Cecchi, Lorenzo&#xD;Stebbing, Justin&#xD;Parronchi, Paola&#xD;Farsi, Alessandro&#xD;eng&#xD;NIHR-RP-011-053/DH_/Department of Health/United Kingdom&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):955-956. doi: 10.1111/all.14537. Epub 2020 Aug 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32830862</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7461536</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14537</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3129</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3129</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abohalaka, R.</style></author><author><style face="normal" font="default" size="100%">Ercan, S.</style></author><author><style face="normal" font="default" size="100%">Lehtimaki, L.</style></author><author><style face="normal" font="default" size="100%">Lisik, D.</style></author><author><style face="normal" font="default" size="100%">Ozuygur Ermis, S. S.</style></author><author><style face="normal" font="default" size="100%">Ekerljung, L.</style></author><author><style face="normal" font="default" size="100%">Backman, H.</style></author><author><style face="normal" font="default" size="100%">Radinger, M.</style></author><author><style face="normal" font="default" size="100%">Nwaru, B. I.</style></author><author><style face="normal" font="default" size="100%">Kankaanranta, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Krefting Research Centre, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.&#xD;Allergy Centre, Tampere University Hospital, Tampere, Finland.&#xD;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.&#xD;Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.&#xD;Department of Internal Medicine/Respiratory Medicine and Allergology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.&#xD;Department of Respiratory Medicine, Seinajoki Central Hospital, Seinajoki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asthma Remission in Adults: Role of Age at Asthma Onset, Smoking, Obesity, and Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">288-291</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/10/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">personlized medicine</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword><keyword><style face="normal" font="default" size="100%">quality-of-life</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Society (ERS), the Swedish Heart and Lung Foundation (HLF), and the</style></keyword><keyword><style face="normal" font="default" size="100%">Adlerbertska foundations, outside the current work. H.B. reports personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">for Advisory Board work for Chiesi. H.K. reports fees for lectures and/or</style></keyword><keyword><style face="normal" font="default" size="100%">consulting from AstraZeneca, Boehringer-Ingelheim, Chiesi Pharma, Covis Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, MSD, Orion Pharma, and Sanofi outside the current study. The rest of the</style></keyword><keyword><style face="normal" font="default" size="100%">authors have no conflicts of interest to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41090708</style></accession-num><notes><style face="normal" font="default" size="100%">Abohalaka, Reshed&#xD;Ercan, Selin&#xD;Lehtimaki, Lauri&#xD;Lisik, Daniil&#xD;Ozuygur Ermis, Saliha Selin&#xD;Ekerljung, Linda&#xD;Backman, Helena&#xD;Radinger, Madeleine&#xD;Nwaru, Bright I&#xD;Kankaanranta, Hannu&#xD;eng&#xD;ALF agreement/&#xD;Tampereen Tuberkuloosisaatio/&#xD;Astma- och Allergiforbundet/&#xD;Hjart-Lungfonden/&#xD;Vetenskapsradet/&#xD;VBG Group Herman Krefting Foundation/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):288-291. doi: 10.1111/all.70106. Epub 2025 Oct 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41090708</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773658</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70106</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1119</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1119</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alberca, R. W.</style></author><author><style face="normal" font="default" size="100%">Yendo, T.</style></author><author><style face="normal" font="default" size="100%">Aoki, V.</style></author><author><style face="normal" font="default" size="100%">Sato, M. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de Dermatologia, Faculdade de Medicina FMUSP, Laboratorio de Dermatologia e Imunodeficiencias (LIM-56), Universidade de Sao Paulo, Sao Paulo, SP, Brazil.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asthmatic patients and COVID-19: Different disease course?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">963-965</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/03/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">systemic arterial hypertension</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33675252</style></accession-num><notes><style face="normal" font="default" size="100%">Alberca, Ricardo Wesley&#xD;Yendo, Tatiana&#xD;Aoki, Valeria&#xD;Sato, Maria Notomi&#xD;eng&#xD;88887.503842/2020-00/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/&#xD;17/18199-9/Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)/&#xD;19/02679-7/Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)/&#xD;Comment&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):963-965. doi: 10.1111/all.14601.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33675252</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8250961</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14601</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3172</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3172</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Matzner, L.</style></author><author><style face="normal" font="default" size="100%">Denkena, J.</style></author><author><style face="normal" font="default" size="100%">Messingschlager, M.</style></author><author><style face="normal" font="default" size="100%">Seegebarth, A.</style></author><author><style face="normal" font="default" size="100%">Engelhardt, R.</style></author><author><style face="normal" font="default" size="100%">Peng, Z.</style></author><author><style face="normal" font="default" size="100%">Kheiroddin, P.</style></author><author><style face="normal" font="default" size="100%">Mackowiak, S. D.</style></author><author><style face="normal" font="default" size="100%">Brenner, H.</style></author><author><style face="normal" font="default" size="100%">Rothenbacher, D.</style></author><author><style face="normal" font="default" size="100%">Ishaque, N.</style></author><author><style face="normal" font="default" size="100%">Kabesch, M.</style></author><author><style face="normal" font="default" size="100%">Eils, R.</style></author><author><style face="normal" font="default" size="100%">Genuneit, J.</style></author><author><style face="normal" font="default" size="100%">Trump, S.</style></author><author><style face="normal" font="default" size="100%">Lehmann, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular Epidemiology Unit, Berlin Institute of Health at Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Center of Digital Health, Berlin Institute of Health (BIH) at Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany.&#xD;University Children&apos;s Hospital Regensburg (KUNO-Clinics), University of Regensburg, Clinic St. Hedwig, Regensburg, Germany.&#xD;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.&#xD;Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.&#xD;German Center of Child and Adolescent Health (DZKJ) Partner Site, Ulm, Germany.&#xD;Member of the Research and Development Campus Regensburg (WECARE) at the Clinic St. Hedwig, Regensburg, Germany.&#xD;German Center of Child and Adolescent Health (DZKJ) Partner Site, Berlin, Germany.&#xD;German Center for Lung Research (DZL), Associated Partner Site, Berlin, Germany.&#xD;Intelligent Medicine Institute, Fudan University, Shanghai, China.&#xD;German Center of Child and Adolescent Health (DZKJ) Partner Site, Leipzig, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Atopic Dermatitis (AD) Related Cord Blood DNA Methylation Patterns Are Linked to Maternal AD</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetics</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 4</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41189447</style></accession-num><notes><style face="normal" font="default" size="100%">Matzner, Laura&#xD;Denkena, Johanna&#xD;Messingschlager, Marey&#xD;Seegebarth, Anke&#xD;Engelhardt, Rosa&#xD;Peng, Zhuoxin&#xD;Kheiroddin, Parastoo&#xD;Mackowiak, Sebastian D&#xD;Brenner, Hermann&#xD;Rothenbacher, Dietrich&#xD;Ishaque, Naveed&#xD;Kabesch, Michael&#xD;Eils, Roland&#xD;Genuneit, Jon&#xD;Trump, Saskia&#xD;Lehmann, Irina&#xD;eng&#xD;NAMIBIO: 01EA2108C/German Federal Ministry of Education and Research (BMBF)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov 4. doi: 10.1111/all.70130.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41189447</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70130</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1977</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1977</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maintz, L.</style></author><author><style face="normal" font="default" size="100%">Schmitz, M. T.</style></author><author><style face="normal" font="default" size="100%">Herrmann, N.</style></author><author><style face="normal" font="default" size="100%">Muller, S.</style></author><author><style face="normal" font="default" size="100%">Havenith, R.</style></author><author><style face="normal" font="default" size="100%">Brauer, J.</style></author><author><style face="normal" font="default" size="100%">Rhyner, C.</style></author><author><style face="normal" font="default" size="100%">Dreher, A.</style></author><author><style face="normal" font="default" size="100%">Bersuch, E.</style></author><author><style face="normal" font="default" size="100%">Fehr, D.</style></author><author><style face="normal" font="default" size="100%">Hammel, G.</style></author><author><style face="normal" font="default" size="100%">Reiger, M.</style></author><author><style face="normal" font="default" size="100%">Luschkova, D.</style></author><author><style face="normal" font="default" size="100%">Neumann, A.</style></author><author><style face="normal" font="default" size="100%">Lang, C. C. V.</style></author><author><style face="normal" font="default" size="100%">Renner, E. D.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Lauener, R.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">Schmid, M.</style></author><author><style face="normal" font="default" size="100%">Bieber, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), Davos, Switzerland.&#xD;DavosBioSciences, Davos, Switzerland.&#xD;Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Augsburg, Germany.&#xD;Translational Immunology of Environmental Medicine, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Department of Pediatrics, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Children&apos;s Hospital of Eastern Switzerland, St. Gallen, Switzerland.&#xD;Hochgebirgsklinik Davos, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Atopic dermatitis: Correlation of distinct risk factors with age of onset in adulthood compared to childhood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2181-2201</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/03/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/etiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Age of Onset</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/complications</style></keyword><keyword><style face="normal" font="default" size="100%">adult-onset</style></keyword><keyword><style face="normal" font="default" size="100%">associated factor</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">childhood-onset</style></keyword><keyword><style face="normal" font="default" size="100%">phenotype</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36946297</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) has long been regarded as a primarily pediatric disease. However, there is growing evidence for a high rate of adult-onset AD. We aimed to characterize factors associated with adult-onset versus childhood-onset AD and controls. METHODS: We analyzed cross-sectional data of the CK-CARE-ProRaD cohorts Bonn, Augsburg, Davos, Zurich of 736 adult patients stratified by age of AD onset (childhood-onset &lt;18 years: 76.4% (subsets: 0 to 2; &gt;/=2 to 6; &gt;/=7 to 11; &gt;/=12 to 18); adult-onset &gt;/=18 years: 23.6% (subsets: &gt;/=18 to 40; &gt;/=41 to 60; &gt;/=61) and 167 controls (91 atopic, 76 non-atopic)). RESULTS: We identified active smoking to be associated with adult-onset AD versus controls (adjusted Odds Ratio (aOR) = 5.54 [95% Confidence Interval: 1.06-29.01] vs. controls(non-atopic) , aOR = 4.03 [1.20-13.45] vs. controls(atopic) ). Conjunctivitis showed a negative association versus controls(atopic) (aOR = 0.36 [0.14-0.91]). Food allergy (aOR = 2.93 [1.44-5.96]), maternal food allergy (aOR = 9.43 [1.10-80.95]), palmar hyperlinearity (aOR = 2.11 [1.05-4.25]), and academic background (aOR = 2.14 [1.00-4.54]) increased the odds of childhood-onset AD versus controls(atopic) . Shared AD-associated factors were maternal AD (4-34x), increased IgE (2-20x), atopic stigmata (2-3x) with varying effect sizes depending on AD onset and control group. Patients with adult-compared to childhood-onset had doubled odds of allergic rhinitis (aOR = 2.15 [1.12-4.13]), but reduced odds to feature multiple (3-4) atopic comorbidities (aOR = 0.34 [0.14-0.84]). Adult-onset AD, particularly onset &gt;/=61 years, grouped mainly in clusters with low contributions of personal and familial atopy and high frequencies of physical inactivity, childhood-onset AD, particularly infant-onset, mainly in &quot;high-atopic&quot;-clusters. CONCLUSIONS: The identified associated factors suggest partly varying endo- and exogeneous mechanisms underlying adult-onset versus childhood-onset AD. Our findings might contribute to better assessment of the individual risk to develop AD throughout life and encourage prevention by non-smoking and physical activity as modifiable lifestyle factors.</style></abstract><notes><style face="normal" font="default" size="100%">Maintz, Laura&#xD;Schmitz, Marie-Therese&#xD;Herrmann, Nadine&#xD;Muller, Svenja&#xD;Havenith, Regina&#xD;Brauer, Juliette&#xD;Rhyner, Claudio&#xD;Dreher, Anita&#xD;Bersuch, Eugen&#xD;Fehr, Danielle&#xD;Hammel, Gertrud&#xD;Reiger, Matthias&#xD;Luschkova, Daria&#xD;Neumann, Avidan&#xD;Lang, Claudia C V&#xD;Renner, Ellen D&#xD;Schmid-Grendelmeier, Peter&#xD;Traidl-Hoffmann, Claudia&#xD;Akdis, Cezmi A&#xD;Lauener, Roger&#xD;Bruggen, Marie-Charlotte&#xD;Schmid, Matthias&#xD;Bieber, Thomas&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2181-2201. doi: 10.1111/all.15721. Epub 2023 Apr 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36946297</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15721</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>59</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">59</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fehr, D.</style></author><author><style face="normal" font="default" size="100%">Lang, C.</style></author><author><style face="normal" font="default" size="100%">Masenga, J.</style></author><author><style face="normal" font="default" size="100%">Mavura, D.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Regional Dermatology Training Centre, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Atopic dermatitis: The importance of future research in Africa</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">327-328</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/12/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Africa/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36468335</style></accession-num><notes><style face="normal" font="default" size="100%">Fehr, Danielle&#xD;Lang, Claudia&#xD;Masenga, John&#xD;Mavura, Daudi&#xD;Schmid-Grendelmeier, Peter&#xD;Bruggen, Marie-Charlotte&#xD;eng&#xD;Comment&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):327-328. doi: 10.1111/all.15422. Epub 2022 Dec 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36468335</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15422</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2808</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2808</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Colas, L.</style></author><author><style face="normal" font="default" size="100%">Lorent, M.</style></author><author><style face="normal" font="default" size="100%">Feuillet, F.</style></author><author><style face="normal" font="default" size="100%">Kerleau, C.</style></author><author><style face="normal" font="default" size="100%">Papuchon, E.</style></author><author><style face="normal" font="default" size="100%">Hemont, C.</style></author><author><style face="normal" font="default" size="100%">Braudeau, C.</style></author><author><style face="normal" font="default" size="100%">Delbos, F.</style></author><author><style face="normal" font="default" size="100%">Renaudin, K. M.</style></author><author><style face="normal" font="default" size="100%">Giral, M.</style></author><author><style face="normal" font="default" size="100%">Brouard, S.</style></author><author><style face="normal" font="default" size="100%">Divat Consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CHU Nantes, Nantes Universite, Clinique dermatologique, Plateforme Transversale d&apos;Allergologie, Nantes, France.&#xD;Nantes Universite, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000, Nantes, France.&#xD;CHU Nantes, Nantes Universite, Service de nephrologique, Institut de Transplantation Uro-Nephrologique, Nantes, France.&#xD;CHU de Nantes, Laboratoire d&apos;Immunologie, Nantes, France.&#xD;CHU de Nantes, Laboratoire d&apos;Immunologie, CIMNA, Nantes, France.&#xD;Etablissement Francais du Sang (EFS), Centre Pays de la Loire, Laboratoire HLA, Nantes, France.&#xD;Nantes Universite, CHU Nantes, Service d&apos;anatomie et Cytologie Pathologique, Nantes, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Atopic Status Is Associated With Kidney Transplanted Recipients&apos; Outcomes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2874-2878</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/03/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">kidney transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">transplant rejection</style></keyword><keyword><style face="normal" font="default" size="100%">transplant survival</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40110882</style></accession-num><notes><style face="normal" font="default" size="100%">Colas, Luc&#xD;Lorent, Marine&#xD;Feuillet, Fanny&#xD;Kerleau, Clarisse&#xD;Papuchon, Emmanuelle&#xD;Hemont, Caroline&#xD;Braudeau, Cecile&#xD;Delbos, Florent&#xD;Renaudin, Karine M&#xD;Giral, Magali&#xD;Brouard, Sophie&#xD;eng&#xD;Fondation Centaure/&#xD;ANR-10-IBHU-005/Agence Nationale de la Recherche/&#xD;Appel d&apos;Offre Interne du CHU de Nantes/&#xD;Programme PULSAR/&#xD;ANR-11-LABX-0016-01/Labex IGO/&#xD;AGIPI grant (AXA program)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2874-2878. doi: 10.1111/all.16529. Epub 2025 Mar 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40110882</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486361</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16529</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1351</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1351</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scala, E.</style></author><author><style face="normal" font="default" size="100%">Abeni, D.</style></author><author><style face="normal" font="default" size="100%">Tedeschi, A.</style></author><author><style face="normal" font="default" size="100%">Manzotti, G.</style></author><author><style face="normal" font="default" size="100%">Yang, B.</style></author><author><style face="normal" font="default" size="100%">Borrelli, P.</style></author><author><style face="normal" font="default" size="100%">Marra, A.</style></author><author><style face="normal" font="default" size="100%">Giani, M.</style></author><author><style face="normal" font="default" size="100%">Sgadari, A.</style></author><author><style face="normal" font="default" size="100%">Saltalamacchia, F.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Istituto Dermopatico dell&apos;Immacolata, IRCCS FLMM, Roma, Italia.&#xD;UO Medicina Generale, Ospedale Bolognini ASST Bergamo Est, Seriate, Italia.&#xD;Casa di Cura Palazzolo, Bergamo, Italia.&#xD;ASST Carlo Poma, Mantova, Italy.&#xD;SSD Dermatologia e Allergologia, Ospedale Beauregard, Aosta, Italia.&#xD;UOC Medicina, ASST Rhodense - P.O. Rho (Milano), Rho, Italia.&#xD;Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Atopic status protects from severe complications of COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">899-902</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*complications</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Logistic Models</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32799364</style></accession-num><notes><style face="normal" font="default" size="100%">Scala, Enrico&#xD;Abeni, Damiano&#xD;Tedeschi, Alberto&#xD;Manzotti, Giuseppina&#xD;Yang, Baoran&#xD;Borrelli, Paolo&#xD;Marra, Alessandro&#xD;Giani, Mauro&#xD;Sgadari, Antonio&#xD;Saltalamacchia, Francesca&#xD;Asero, Riccardo&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):899-902. doi: 10.1111/all.14551. Epub 2020 Sep 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32799364</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7461535</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14551</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3240</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3240</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cohen, C. G.</style></author><author><style face="normal" font="default" size="100%">Toscano-Rivero, D.</style></author><author><style face="normal" font="default" size="100%">Ahmed, E. A.</style></author><author><style face="normal" font="default" size="100%">Al Ali, A.</style></author><author><style face="normal" font="default" size="100%">Zhao, W.</style></author><author><style face="normal" font="default" size="100%">Ke, D.</style></author><author><style face="normal" font="default" size="100%">Lejtenyi, D.</style></author><author><style face="normal" font="default" size="100%">Beaudette, L.</style></author><author><style face="normal" font="default" size="100%">Chazbey, H.</style></author><author><style face="normal" font="default" size="100%">Alrafiaah, A. S.</style></author><author><style face="normal" font="default" size="100%">Li, C. H.</style></author><author><style face="normal" font="default" size="100%">Dejgaard, K.</style></author><author><style face="normal" font="default" size="100%">Berghuis, A. M.</style></author><author><style face="normal" font="default" size="100%">Jean-Claude, B. J.</style></author><author><style face="normal" font="default" size="100%">McCusker, C.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Ben-Shoshan, M.</style></author><author><style face="normal" font="default" size="100%">Mazer, B. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Experimental Medicine, Department of Medicine, McGill University and the Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.&#xD;Department of Pediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Montreal Children&apos;s Hospital, McGill University Health Centre, Montreal, Canada.&#xD;Department of Pediatrics, College of Medicine, Majmaah University, Al Majma&apos;ah, Saudi Arabia.&#xD;Translational Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Canada.&#xD;Department of Biochemistry, McGill University, Montreal, Canada.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Autoclaved Peanuts Exhibit Reduced Immunoglobulin E Binding and Improved Oral Tolerability</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE binding</style></keyword><keyword><style face="normal" font="default" size="100%">autoclave</style></keyword><keyword><style face="normal" font="default" size="100%">oral food challenge</style></keyword><keyword><style face="normal" font="default" size="100%">oral tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41493009</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Major peanut allergens are stable and resistant to denaturation under standard cooking conditions, contributing to allergenicity and low rates of developing natural tolerance in allergic individuals. We evaluated the effects of heat and pressure autoclaving on peanut proteins, IgE binding, and oral tolerability. METHODS: Raw, roasted, and autoclaved peanut protein extracts were evaluated by Bradford assay, ELISA, and mass spectrometry-proteomics to compare relative amounts of protein, specific IgE binding, and allergen fragmentation. To assess changes in clinical reactivity, we performed skin prick testing (SPT) in 41 subjects using standard and autoclaved peanut extracts. We also performed double-blind oral food challenges (OFC) in 10 peanut-allergic subjects with standard and autoclaved peanuts. RESULTS: Autoclaving at 130 degrees C, 2.4 atm, for 30 min significantly degraded allergens Ara h 1 and 2, and completely degraded Ara h 8. Mass spectrometry-proteomics analysis of size-filtered extracts (&lt; 10 kDa) showed greater numbers and diversity of peptides from peanut proteins and allergens in autoclaved extracts. Autoclaving fragmented proteins into shorter peptides, against which sera from highly allergic patients exhibited a 74% reduction in IgE binding compared to raw peanuts. SPT demonstrated significant decreases in wheal diameters using autoclaved peanut extract (median [IQR] = 5 mm [2, 9]) compared to commercial extract (10 mm [6, 15]; p &lt; 0.001). All OFC subjects tolerated the maximum cumulative autoclaved peanut dose (444 mg) versus standard peanut (median: 9 mg, range: [1, 44]). CONCLUSIONS: Autoclaving peanuts induces important chemical changes including fragmentation, leading to decreased peanut allergenicity and consequently increased tolerability. This has the potential for novel immunotherapeutic approaches with more favorable side effect profiles.</style></abstract><notes><style face="normal" font="default" size="100%">Cohen, Casey G&#xD;Toscano-Rivero, Diana&#xD;Ahmed, Eisha A&#xD;Al Ali, Adnan&#xD;Zhao, Wei&#xD;Ke, Danbing&#xD;Lejtenyi, Duncan&#xD;Beaudette, Liane&#xD;Chazbey, Hana&#xD;Alrafiaah, Abdulaziz S&#xD;Li, Carmen H&#xD;Dejgaard, Kurt&#xD;Berghuis, Albert M&#xD;Jean-Claude, Bertrand J&#xD;McCusker, Christine&#xD;Eiwegger, Thomas&#xD;Ben-Shoshan, Moshe&#xD;Mazer, Bruce D&#xD;eng&#xD;Fondation de l&apos;Hopital de Montreal pour enfants/&#xD;McGill University Health Centre/&#xD;AllerGEN NCE/&#xD;CAPMC/CIHR/Canada&#xD;Children&apos;s Hospital Foundation/&#xD;Denmark&#xD;Allergy. 2026 Jan 6. doi: 10.1111/all.70208.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41493009</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70208</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>27</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">27</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Keren, A.</style></author><author><style face="normal" font="default" size="100%">Reich, K.</style></author><author><style face="normal" font="default" size="100%">Bertolini, M.</style></author><author><style face="normal" font="default" size="100%">Moga, A.</style></author><author><style face="normal" font="default" size="100%">Riethmuller, C.</style></author><author><style face="normal" font="default" size="100%">Ullmann, Y.</style></author><author><style face="normal" font="default" size="100%">Paus, R.</style></author><author><style face="normal" font="default" size="100%">Gilhar, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Skin Research Laboratory, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.&#xD;Translational Research in Inflammatory Skin Diseases, Institute for Health Care Research in Dermatology and Nursing, University Medical Center Hamburg - Eppendorf, Hamburg, Germany.&#xD;Monasterium Laboratory, Munster, Germany.&#xD;QIMA Life Sciences, Poitiers, France.&#xD;Serendip GmbH, Munster, Germany.&#xD;Dr Phillip Frost Department of Dermatology &amp; Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.&#xD;CUTANEON, Hamburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Autologous Th2-polarized lymphocytes induce atopic dermatitis lesions in non-atopic human skin xenotransplants</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1538-1553</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, SCID</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Il-2</style></keyword><keyword><style face="normal" font="default" size="100%">Il-4</style></keyword><keyword><style face="normal" font="default" size="100%">Lps</style></keyword><keyword><style face="normal" font="default" size="100%">SCID mice</style></keyword><keyword><style face="normal" font="default" size="100%">perceived stress</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36597714</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The key signals that suffice to induce atopic dermatitis (AD) in human skin remain incompletely understood. Also, current mouse models reflect human AD only unsatisfactorily. Therefore, we have asked whether a humanized AD mouse model can be developed that reflects human AD more faithfully and permit to identify key signals that suffice to induce AD lesions in previously healthy human skin in vivo. METHODS: Healthy human skin from non-atopic donors was transplanted onto SCID/beige mice. After xenotransplant reinnervation by mouse sensory nerve fibers had occurred, mixed autologous human Th2 CD4+ and Tc2 CD8+ T cells that had been pretreated in vitro with IL-2, IL-4, and LPS were injected intradermally into the xenotransplants without skin barrier disruption. RESULTS: Injected non-atopic xenotransplants rapidly developed a morphological, functional, and immunological phenocopy of human AD lesions regarding skin barrier defects, immunopathology including intraepidermal eosinophils, mast cell activation, increase of thymic stromal lymphopoietin, eotaxin-1 and type 2 cytokine circuits, and even showed characteristic neuroimmunological abnormalities such as ss2-adrenergic receptor downregulation. The experimentally induced AD lesions in human skin responded to standard AD therapy (topical dexamethasone or tacrolimus; systemic anti-IL-4Ralpha antibody [dupilumab]), and relapsed when neurogenic skin inflammation was induced by exposing mice to perceived stress. CONCLUSIONS: This new animal model uniquely mimics the complexity of human AD and its clinical response to standard therapy and psychoemotional stressors in vivo, and shows that Th2-polarized lymphocytes associated with excessive IL-4Ralpha-mediated signaling suffice to induce human AD skin lesions, while atopy and epidermal barrier disruption are dispensable.</style></abstract><notes><style face="normal" font="default" size="100%">Keren, Aviad&#xD;Reich, Kristian&#xD;Bertolini, Marta&#xD;Moga, Alain&#xD;Riethmuller, Christoph&#xD;Ullmann, Yehuda&#xD;Paus, Ralf&#xD;Gilhar, Amos&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1538-1553. doi: 10.1111/all.15635. Epub 2023 Mar 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36597714</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15635</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>736</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">736</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Haya, L. K.</style></author><author><style face="normal" font="default" size="100%">Mehri, R.</style></author><author><style face="normal" font="default" size="100%">Somers-Neal, S.</style></author><author><style face="normal" font="default" size="100%">Van de Mosselaer, S.</style></author><author><style face="normal" font="default" size="100%">Spence, A.</style></author><author><style face="normal" font="default" size="100%">Kelly, S. M.</style></author><author><style face="normal" font="default" size="100%">Matida, E. A.</style></author><author><style face="normal" font="default" size="100%">Yang, W. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Red Maple Trials, Inc., Ottawa, ON, Canada.&#xD;Carleton University, Ottawa, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Automated dander dispersal in a cat Naturalistic Exposure Chamber (NEC)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">685-687</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Cats</style></keyword><keyword><style face="normal" font="default" size="100%">*Dander</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">aerobiology</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">challenge tests</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34687051</style></accession-num><notes><style face="normal" font="default" size="100%">Haya, Laura Kilford&#xD;Mehri, Rym&#xD;Somers-Neal, Shawn&#xD;Van de Mosselaer, Stefan&#xD;Spence, Ashley&#xD;Kelly, Suzanne Marie&#xD;Matida, Edgar Akio&#xD;Yang, William H&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):685-687. doi: 10.1111/all.15146. Epub 2021 Nov 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34687051</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15146</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>844</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">844</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anto, A.</style></author><author><style face="normal" font="default" size="100%">Maurer, R.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A.</style></author><author><style face="normal" font="default" size="100%">Cherrez-Ojeda, I.</style></author><author><style face="normal" font="default" size="100%">Hawro, T.</style></author><author><style face="normal" font="default" size="100%">Magerl, M.</style></author><author><style face="normal" font="default" size="100%">Metz, M.</style></author><author><style face="normal" font="default" size="100%">Weller, K.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MASK-air, Montpellier, France.&#xD;Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health, Berlin, Germany.&#xD;Department of Dermatology, Hospital del Mar, Institut Mar d&apos;Investigacions Mediques, Universitat Pompeu Fabra, Barcelona, Spain.&#xD;Universidad Espiritu Santo, Samborondon, Ecuador.&#xD;Comprehensive Allergy Centre Charite, Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health, Berlin, Germany.&#xD;Centre Hospitalier Universitaire, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3810-3813</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/08/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedema/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostic Self Evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">apple</style></keyword><keyword><style face="normal" font="default" size="100%">automatic search</style></keyword><keyword><style face="normal" font="default" size="100%">google</style></keyword><keyword><style face="normal" font="default" size="100%">itch</style></keyword><keyword><style face="normal" font="default" size="100%">javascript</style></keyword><keyword><style face="normal" font="default" size="100%">swelling</style></keyword><keyword><style face="normal" font="default" size="100%">wheals</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34437706</style></accession-num><notes><style face="normal" font="default" size="100%">Anto, Aram&#xD;Maurer, Rasmus&#xD;Gimenez-Arnau, Ana&#xD;Cherrez-Ojeda, Ivan&#xD;Hawro, Tomasz&#xD;Magerl, Markus&#xD;Metz, Martin&#xD;Weller, Karsten&#xD;Zuberbier, Torsten&#xD;Bousquet, Jean&#xD;Maurer, Marcus&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3810-3813. doi: 10.1111/all.15061. Epub 2021 Sep 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34437706</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15061</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2169</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2169</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Charles, N.</style></author><author><style face="normal" font="default" size="100%">Kortekaas-Krohn, I.</style></author><author><style face="normal" font="default" size="100%">Kocaturk, E.</style></author><author><style face="normal" font="default" size="100%">Scheffel, J.</style></author><author><style face="normal" font="default" size="100%">Altrichter, S.</style></author><author><style face="normal" font="default" size="100%">Steinert, C.</style></author><author><style face="normal" font="default" size="100%">Xiang, Y. K.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculte de Medecine site Bichat, Centre de Recherche sur l&apos;Inflammation, INSERM UMR1149, CNRS EMR8252, Universite Paris Cite, Paris, France.&#xD;Laboratoire d&apos;Excellence Inflamex, Universite Paris Cite, Paris, France.&#xD;Vrije Universiteit Brussel (VUB), Skin Immunology &amp; Immune Tolerance (SKIN) Research Group, Brussels, Belgium.&#xD;Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.&#xD;Department of Dermatology, Koc University School of Medicine, Istanbul, Turkey.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Departement of Dermatology and Venerology, Kepler University Hospital, Linz, Austria.&#xD;Freie Universitat Berlin, Department of Biology, Chemistry and Pharmacy, Berlin, Germany.&#xD;Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), UMR 1291, University of Toulouse, INSERM, CNRS, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Autoreactive IgE: Pathogenic role and therapeutic target in autoimmune diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3118-3135</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/08/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Autoimmune Diseases/etiology/therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">Autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgE/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ub-221</style></keyword><keyword><style face="normal" font="default" size="100%">antibody-mediated autoimmune diseases</style></keyword><keyword><style face="normal" font="default" size="100%">autoallergy</style></keyword><keyword><style face="normal" font="default" size="100%">autoreactive IgE</style></keyword><keyword><style face="normal" font="default" size="100%">ligelizumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37555488</style></accession-num><abstract><style face="normal" font="default" size="100%">Autoimmunity is the break of tolerance to self-antigens that leads to organ-specific or systemic diseases often characterized by the presence of pathogenic autoreactive antibodies (AAb) produced by plasmablast and/or plasma cells. AAb are prevalent in the general population and not systematically associated with clinical symptoms. In contrast, in some individuals, these AAb are pathogenic and drive the development of signs and symptoms of antibody-mediated autoimmune diseases (AbAID). AAb production, isotype profiles, and glycosylations are promoted by pro-inflammatory triggers linked to genetic, environmental, and hormonal parameters. Recent evidence supports a role for pathogenic AAb of the IgE isotype in a number of AbAID. Autoreactive IgE can drive the activation of mast cells, basophils, and other types of FcepsilonRI-bearing cells and may play a role in promoting autoantibody production and other pro-inflammatory pathways. In this review, we discuss the current knowledge on the pathogenicity of autoreactive IgE in AbAID and their status as therapeutic targets. We also highlight unresolved issues including the need for assays that reproducibly quantify IgE AAbs, to validate their diagnostic and prognostic value, and to further study their pathophysiological contributions to AbAID.</style></abstract><notes><style face="normal" font="default" size="100%">Charles, Nicolas&#xD;Kortekaas-Krohn, Inge&#xD;Kocaturk, Emek&#xD;Scheffel, Jorg&#xD;Altrichter, Sabine&#xD;Steinert, Carolin&#xD;Xiang, Yi-Kui&#xD;Gutermuth, Jan&#xD;Reber, Laurent L&#xD;Maurer, Marcus&#xD;eng&#xD;ERC_/European Research Council/International&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3118-3135. doi: 10.1111/all.15843. Epub 2023 Aug 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37555488</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15843</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3248</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3248</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moschetti, Giorgia</style></author><author><style face="normal" font="default" size="100%">Vasco, Chiara</style></author><author><style face="normal" font="default" size="100%">Clemente, Francesca</style></author><author><style face="normal" font="default" size="100%">Larghi, Paola</style></author><author><style face="normal" font="default" size="100%">Maioli, Sara</style></author><author><style face="normal" font="default" size="100%">Scarpa, Edoardo</style></author><author><style face="normal" font="default" size="100%">Carelli, Elena</style></author><author><style face="normal" font="default" size="100%">Pulvirenti, Nadia</style></author><author><style face="normal" font="default" size="100%">Sarnicola, Maria Lucia</style></author><author><style face="normal" font="default" size="100%">Crosti, Mariacristina</style></author><author><style face="normal" font="default" size="100%">Bel Imam, Manal</style></author><author><style face="normal" font="default" size="100%">van de Veen, Willem</style></author><author><style face="normal" font="default" size="100%">Rizzello, Loris</style></author><author><style face="normal" font="default" size="100%">Abrignani, Sergio</style></author><author><style face="normal" font="default" size="100%">Baselli, Lucia A.</style></author><author><style face="normal" font="default" size="100%">Dellepiane, Rosa Maria</style></author><author><style face="normal" font="default" size="100%">Carrabba, Maria</style></author><author><style face="normal" font="default" size="100%">Fabio, Giovanna</style></author><author><style face="normal" font="default" size="100%">Geginat, Jens</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Autosomal Dominant Hyper-IgE Syndrome Patients Retain IL10-Producing preTh17-Cells That Are Activated by Opportunistic Pathogens and Support IgE Production</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Autosomal Dominant-Hyper-IgE Syndrome (AD-HIES) is caused by dominant-negative (DN) STAT3 mutations and characterized by high IgE levels, a lack of Th17-cells, and recurrent infections with extracellular pathogens. We previously identified an enigmatic population of IL-10 producing CCR6+B-helper T-cells and investigated here their relationship to Th17-cells and STAT3 signaling requirements. Methods Human blood lymphocytes were analyzed by multiparametric flow cytometry in healthy donors and AD-HIES patients. Analysis was performed by conventional gating or with bioinformatic tools. FACS-purified T-cell subsets were activated in vitro and Th17 differentiation assessed. T-cell antigen specificities were assessed by activation with heat-killed pathogens or antigenic peptide pools. B helper capacities were determined according to antibody secretion in B-T co-cultures by ELISA. Results CCR6+Th-cells that lacked subset-defining differentiation markers (“CCR6SP”) were mostly non-polarized central memory T-cells (TCM) that produced IL-10 and expressed RORγt. They were pre-committed to a Th17 fate, since TCR stimulation in the absence of polarizing cytokines induced efficient Th17 differentiation. The latter was promoted by an autocrine loop of STAT3-activating cytokines. CCR6+Th-cells were reduced in patients with DN-STAT3 mutations but contained activated CCR6SPT-cells that produced IL-10 and responded vigorously to AD-HIES-associated pathogens. These residual CCR6+Th-cells provided B-cell help for IgG and IgE production. Conclusions Th17 differentiation in AD-HIES patients was not completely impaired but arrested at an intermediate stage of IL-10-producing “pre-Th17”-cells. Surprisingly, DN-STAT3 mutations did not inhibit IL-10 production by CD4+T-cells. Pre-Th17-cells were activated by AD-HIES-associated pathogens and possessed B-helper functions, suggesting that they are not protective but may promote aberrant IgE production.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70266</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70266</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1319</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1319</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perkins, T. N.</style></author><author><style face="normal" font="default" size="100%">Donnell, M. L.</style></author><author><style face="normal" font="default" size="100%">Oury, T. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The axis of the receptor for advanced glycation endproducts in asthma and allergic airway disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1350-1366</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/09/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptor for Advanced Glycation End Products</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">signal transduction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32976640</style></accession-num><abstract><style face="normal" font="default" size="100%">Asthma is a generalized term that describes a scope of distinct pathologic phenotypes of variable severity, which share a common complication of reversible airflow obstruction. Asthma is estimated to affect almost 400 million people worldwide, and nearly ten percent of asthmatics have what is considered &quot;severe&quot; disease. The majority of moderate to severe asthmatics present with a &quot;type 2-high&quot; (T2-hi) phenotypic signature, which pathologically is driven by the type 2 cytokines Interleukin-(IL)-4, IL-5, and IL-13. However, &quot;type 2-low&quot; (T2-lo) phenotypic signatures are often associated with more severe, steroid-refractory neutrophilic asthma. A wide range of clinical and experimental studies have found that the receptor for advanced glycation endproducts (RAGE) plays a significant role in the pathogenesis of asthma and allergic airway disease (AAD). Current experimental data indicates that RAGE is a critical mediator of the type 2 inflammatory reactions which drive the development of T2-hi AAD. However, clinical studies demonstrate that increased RAGE ligands and signaling strongly correlate with asthma severity, especially in severe neutrophilic asthma. This review presents an overview of the current understandings of RAGE in asthma pathogenesis, its role as a biomarker of disease, and future implications for mechanistic studies, and potential therapeutic intervention strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Perkins, Timothy N&#xD;Donnell, Mason L&#xD;Oury, Tim D&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1350-1366. doi: 10.1111/all.14600. Epub 2020 Oct 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32976640</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14600</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3166</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3166</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gill, K. K.</style></author><author><style face="normal" font="default" size="100%">Moore, C.</style></author><author><style face="normal" font="default" size="100%">Nwogu, O.</style></author><author><style face="normal" font="default" size="100%">Kroner, J. W.</style></author><author><style face="normal" font="default" size="100%">Chang, W. C.</style></author><author><style face="normal" font="default" size="100%">Burkle, J.</style></author><author><style face="normal" font="default" size="100%">Virolainen, S. J.</style></author><author><style face="normal" font="default" size="100%">Stevens, M. L.</style></author><author><style face="normal" font="default" size="100%">Baatyrbek, A.</style></author><author><style face="normal" font="default" size="100%">Miraldi, E. R.</style></author><author><style face="normal" font="default" size="100%">Biagini, J. M.</style></author><author><style face="normal" font="default" size="100%">Devonshire, A. L.</style></author><author><style face="normal" font="default" size="100%">Kottyan, L.</style></author><author><style face="normal" font="default" size="100%">Schwartz, J. T.</style></author><author><style face="normal" font="default" size="100%">Assa&apos;ad, A. H.</style></author><author><style face="normal" font="default" size="100%">Martin, L. J.</style></author><author><style face="normal" font="default" size="100%">Andorf, S.</style></author><author><style face="normal" font="default" size="100%">Khurana Hershey, G. K.</style></author><author><style face="normal" font="default" size="100%">Roskin, K. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Biomedical Informatics, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Division of Asthma Research, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Division of Human Genetics, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Division of Immunobiology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Center for Autoimmune Genomics and Etiology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA.&#xD;Division of Allergy and Immunology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Division of Biostatistics and Epidemiology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">B-Cell Repertoire of Children With Atopic Dermatitis Exhibits Altered IgE Maturation Associated With Allergic Food Sensitization</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">BCR repertoire sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">B-cell maturation</style></keyword><keyword><style face="normal" font="default" size="100%">IgE antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">food allergen sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">pets</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41216705</style></accession-num><abstract><style face="normal" font="default" size="100%">IgE B cells produce antibodies responsible for the inappropriate specificity seen in allergic disease. In this study, we sequence antibody gene repertoires from a large, well-characterized early life cohort at risk for developing food allergy. We found that food allergen sensitization was associated with lower IgE mutation frequencies that was abrogated in children living with a pet dog, suggesting potential molecular mechanisms underlying the hygiene hypothesis (i.e., protective effects of pet ownership and non-antiseptic environs reported for allergic disease). We also observed increased IgE diversity and increased isotype-switching to IgE, suggesting that B-cell development is altered in those with food allergen sensitizations relative to those without. IgE diversity was even more extreme in subjects who were highly likely to be peanut allergic. Unlike food sensitization, we detected no effect of aeroallergen sensitization on IgE mutation levels and diversity. Consistent patterns of antibody rearrangement were associated with food allergen sensitization. These results have important implications for the allergic response driven by mast cells and basophils and the underlying drivers of the atopic march.</style></abstract><notes><style face="normal" font="default" size="100%">Gill, Kirandeep K&#xD;Moore, Carolina&#xD;Nwogu, Onyekachi&#xD;Kroner, John W&#xD;Chang, Wan-Chi&#xD;Burkle, Jeffrey&#xD;Virolainen, Samuel J&#xD;Stevens, Mariana L&#xD;Baatyrbek, Asel&#xD;Miraldi, Emily R&#xD;Biagini, Jocelyn M&#xD;Devonshire, Ashley L&#xD;Kottyan, Leah&#xD;Schwartz, Justin T&#xD;Assa&apos;ad, Amal H&#xD;Martin, Lisa J&#xD;Andorf, Sandra&#xD;Khurana Hershey, Gurjit K&#xD;Roskin, Krishna M&#xD;eng&#xD;NH/NIH HHS/&#xD;Cincinnati Children&apos;s Hospital Medical Center/&#xD;Denmark&#xD;Allergy. 2025 Nov 11. doi: 10.1111/all.70150.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41216705</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70150</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1383</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1383</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ventura, L.</style></author><author><style face="normal" font="default" size="100%">Vitali, M.</style></author><author><style face="normal" font="default" size="100%">Romano Spica, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Economy and Law, Sapienza University of Rome, Rome, Italy.&#xD;Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.&#xD;Department of Movement, Human and Health Sciences, University of Rome Foro Italico, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bacillus Calmette-Guerin vaccination and socioeconomic variables vs COVID-19 global features: Clearing up a controversial issue</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">884-887</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">BCG Vaccine/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*epidemiology/mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Socioeconomic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">infections</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32726479</style></accession-num><notes><style face="normal" font="default" size="100%">Ventura, Luigi&#xD;Vitali, Matteo&#xD;Romano Spica, Vincenzo&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):884-887. doi: 10.1111/all.14524. Epub 2020 Aug 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32726479</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14524</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>422</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">422</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pittet, L. F.</style></author><author><style face="normal" font="default" size="100%">Curtis, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infectious Diseases Group, Murdoch Children&apos;s Research Institute, Parkville, VIC, Australia.&#xD;Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia.&#xD;Infectious Diseases, The Royal Children&apos;s Hospital Melbourne, Parkville, VIC, Australia.&#xD;Infectious Diseases Unit, Department of Paediatrics, Gynaecology and Obstetrics, Faculty of Medicine, University of Geneva and University Hospitals of Geneva, Geneva, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bacillus Calmette-Guerin vaccination to prevent childhood asthma: A revised meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2262-2263</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/07/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adjuvants, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*BCG Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35770814</style></accession-num><notes><style face="normal" font="default" size="100%">Pittet, Laure F&#xD;Curtis, Nigel&#xD;eng&#xD;Comment&#xD;Letter&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2262-2263. doi: 10.1111/all.15200.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35770814</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15200</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>723</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">723</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Castillo-Gonzalez, R.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Delgado, I.</style></author><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Vascular Pathophysiology Department, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.&#xD;Department of Immunology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-IP), Madrid, Spain.&#xD;Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bacteriotherapy with human skin commensals in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1331-1333</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">S. aureus</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">bacteriotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">skin microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34713451</style></accession-num><notes><style face="normal" font="default" size="100%">Castillo-Gonzalez, Raquel&#xD;Fernandez-Delgado, Irene&#xD;Comberiati, Pasquale&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1331-1333. doi: 10.1111/all.15162. Epub 2021 Nov 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34713451</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15162</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1623</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1623</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Castillo-Gonzalez, R.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Delgado, I.</style></author><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Vascular Pathophysiology Department, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.&#xD;Department of Immunology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-IP), Madrid, Spain.&#xD;Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bacteriotherapy with human skin commensals in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1331-1333</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">S. aureus</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">bacteriotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">skin microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34713451</style></accession-num><notes><style face="normal" font="default" size="100%">Castillo-Gonzalez, Raquel&#xD;Fernandez-Delgado, Irene&#xD;Comberiati, Pasquale&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1331-1333. doi: 10.1111/all.15162. Epub 2021 Nov 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34713451</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15162</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1893</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1893</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Castillo-Gonzalez, R.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Delgado, I.</style></author><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Vascular Pathophysiology Department, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.&#xD;Department of Immunology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-IP), Madrid, Spain.&#xD;Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bacteriotherapy with human skin commensals in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1331-1333</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">S. aureus</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">bacteriotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">skin microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34713451</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Atopic dermatitis (AD) is a common chronic inflammatory skin disease, whose pathophysiology involves a complex interplay of genetic predisposition, environmental factors, immune dysregulation, and altered skin barrier function. Emerging evidence suggests that dysbiosis of the skin microbiome plays a key role in epidermal barrier impairment and inflammation, which are hallmarks of AD1,2.</style></abstract><notes><style face="normal" font="default" size="100%">Castillo-Gonzalez, Raquel&#xD;Fernandez-Delgado, Irene&#xD;Comberiati, Pasquale&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1331-1333. doi: 10.1111/all.15162. Epub 2021 Nov 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34713451</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15162</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2690</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2690</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wong, L. S. Y.</style></author><author><style face="normal" font="default" size="100%">Groetch, M.</style></author><author><style face="normal" font="default" size="100%">Bahnson, H. T.</style></author><author><style face="normal" font="default" size="100%">Strong, E.</style></author><author><style face="normal" font="default" size="100%">Nowak-Wegrzyn, A.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Hassenfeld Children&apos;s Hospital, NYU Grossman School of Medicine, New York City, New York, USA.&#xD;Department of Pediatrics, National University of Singapore, Singapore City, Singapore.&#xD;Khoo Teck Puat-National University Children&apos;s Medical Institute, National University Health System, Singapore City, Singapore.&#xD;Jaffe Food Allergy Institute, Icahn School of Medicine, New York City, New York, USA.&#xD;Bahnson Analytics, LLC, Seattle, Washington, USA.&#xD;Columbia Doctors, New York-Presbyterian, New York City, New York, USA.&#xD;Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Baked milk diet is associated with improved quality of life and growth parameters in milk-allergic children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">323-326</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/10/09</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39382844</style></accession-num><notes><style face="normal" font="default" size="100%">Wong, Lydia Su Yin&#xD;Groetch, Marion&#xD;Bahnson, Henry T&#xD;Strong, Elizabeth&#xD;Nowak-Wegrzyn, Anna&#xD;Sampson, Hugh A&#xD;eng&#xD;the NIAID and the National Center for Advancing Translational Sciences (NCATS)/&#xD;AI 44236/AI/NIAID NIH HHS/&#xD;UL1 TR-000067/the National Center for Advancing Translational Sciences (NCATS)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):323-326. doi: 10.1111/all.16330. Epub 2024 Oct 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39382844</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16330</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2879</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2879</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Loli-Ausejo, D.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Matamala, M. F.</style></author><author><style face="normal" font="default" size="100%">Marti, D.</style></author><author><style face="normal" font="default" size="100%">Ruano-Zaragoza, M.</style></author><author><style face="normal" font="default" size="100%">Mir-Ihara, P.</style></author><author><style face="normal" font="default" size="100%">Solis-Ynga, K.</style></author><author><style face="normal" font="default" size="100%">Lara, R.</style></author><author><style face="normal" font="default" size="100%">Bartra, J.</style></author><author><style face="normal" font="default" size="100%">Pascal, M.</style></author><author><style face="normal" font="default" size="100%">Munoz-Cano, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Hospital Clinic Barcelona, Universitat de Barcelona (UB), Barcelona, Spain.&#xD;Clinical and Experimental Respiratory Immunoallergy (IRCE), Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.&#xD;Redes de Investigacion Cooperativa Orientadas a Resultados en Salud (RICORS), red de Enfermedades Inflamatorias (REI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.&#xD;Department of Immunology, Hospital Clinic Barcelona, Universitat de Barcelona (UB), Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basal Serum Tryptase Outperforms Hereditary Alpha Tryptasemia as a Biomarker of Food Allergy Severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2376-2378</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40503609</style></accession-num><notes><style face="normal" font="default" size="100%">Loli-Ausejo, D&#xD;Gonzalez-Matamala, M F&#xD;Marti, D&#xD;Ruano-Zaragoza, M&#xD;Mir-Ihara, P&#xD;Solis-Ynga, K&#xD;Lara, R&#xD;Bartra, J&#xD;Pascal, M&#xD;Munoz-Cano, R&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2376-2378. doi: 10.1111/all.16623. Epub 2025 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40503609</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368740</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16623</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2135</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2135</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Francois, F.</style></author><author><style face="normal" font="default" size="100%">Mauff, B. L.</style></author><author><style face="normal" font="default" size="100%">Waeckel, L.</style></author><author><style face="normal" font="default" size="100%">de Chaisemartin, L.</style></author><author><style face="normal" font="default" size="100%">Tabary, T.</style></author><author><style face="normal" font="default" size="100%">Dumontet, E.</style></author><author><style face="normal" font="default" size="100%">Lecron, J. C.</style></author><author><style face="normal" font="default" size="100%">Delamare, B.</style></author><author><style face="normal" font="default" size="100%">Boumediene, A.</style></author><author><style face="normal" font="default" size="100%">Chauvineau-Grenier, A.</style></author><author><style face="normal" font="default" size="100%">Pescarmona, R.</style></author><author><style face="normal" font="default" size="100%">Garnier, L.</style></author><author><style face="normal" font="default" size="100%">Lambert, C.</style></author><author><style face="normal" font="default" size="100%">French Network of Hospital Biologist in, Allergology</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratoire d&apos;Immunologie, Pole de Biologie, CHU Saint-Etienne, Saint-Etienne, France.&#xD;Laboratoire Immunologie CHU Caen, Caen, France.&#xD;APHP, Laboratoire d&apos;Immunologie, Hopital Bichat, Paris, France.&#xD;Laboratoire d&apos;Immunologie CHU Reims, Pole de Biologie Territoriale, Reims, France.&#xD;Laboratoire Immunologie CHU Rennes, Rennes, France.&#xD;Laboratoire Immunologie CHU Poitiers, Poitiers, France.&#xD;Laboratoire Biochimie CHR Orleans, Orleans, France.&#xD;Laboratoire Immunologie CHU Limoges, Limoges, France.&#xD;Service de Biologie Medicale CH Aulnay-sous-Bois, Aulnay-sous-Bois, France.&#xD;Laboratoire Immunologie CH Lyon Sud, Lyon, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basal serum tryptase: A critical reconsideration of reference values</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3003-3006</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptases</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Values</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">basal serum tryptase</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary alpha tryptasemia</style></keyword><keyword><style face="normal" font="default" size="100%">mastocytosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37357803</style></accession-num><abstract><style face="normal" font="default" size="100%">Basal serum tryptase in 681 healthy adults. Mathematical analysis reveals a double population of low (2-8 mug/L) or high producers (8-11.4 mug/L) with a threshold at 8 mug/L.</style></abstract><notes><style face="normal" font="default" size="100%">Francois, Fabien&#xD;Mauff, Brigitte Le&#xD;Waeckel, Louis&#xD;de Chaisemartin, Luc&#xD;Tabary, Thierry&#xD;Dumontet, Erwan&#xD;Lecron, Jean Claude&#xD;Delamare, Benoit&#xD;Boumediene, Ahmed&#xD;Chauvineau-Grenier, Angelique&#xD;Pescarmona, Remi&#xD;Garnier, Lorna&#xD;Lambert, Claude&#xD;(AllergoBioNet)&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):3003-3006. doi: 10.1111/all.15790. Epub 2023 Jun 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37357803</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15790</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3067</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3067</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chantran, Y.</style></author><author><style face="normal" font="default" size="100%">Novakowski, H.</style></author><author><style face="normal" font="default" size="100%">Vial-Dupuy, A.</style></author><author><style face="normal" font="default" size="100%">Bouz, C.</style></author><author><style face="normal" font="default" size="100%">Apoil, P. A.</style></author><author><style face="normal" font="default" size="100%">Choi, S.</style></author><author><style face="normal" font="default" size="100%">Fromentin, E.</style></author><author><style face="normal" font="default" size="100%">Goret, J.</style></author><author><style face="normal" font="default" size="100%">Mathieu, P.</style></author><author><style face="normal" font="default" size="100%">Michel, M.</style></author><author><style face="normal" font="default" size="100%">Nemni, A.</style></author><author><style face="normal" font="default" size="100%">Seve, E.</style></author><author><style face="normal" font="default" size="100%">Roda, C.</style></author><author><style face="normal" font="default" size="100%">Ranciere, F.</style></author><author><style face="normal" font="default" size="100%">Vitte, J.</style></author><author><style face="normal" font="default" size="100%">Momas, I.</style></author><author><style face="normal" font="default" size="100%">Klingebiel, C.</style></author><author><style face="normal" font="default" size="100%">Gtba of the SFA</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environmental Risk Assessment (HERA) Team, UMR261 MERIT, IRD, Inserm 1344, Universite Paris Cite, Paris, France.&#xD;Molecular Platform for the Analysis of cKIT Mutations and Other Gene Defects, ECNM Reference Center, Saint-Antoine Hospital, Centre National de Reference des Mastocytoses CEREMAST, Filiere MaRIH, Paris, France.&#xD;Department of Biological Immunology, Saint-Antoine Hospital, DMU BioGeMH, AP-HP, Sorbonne University, Paris, France.&#xD;Reims Champagne Ardennes University, Reims, France.&#xD;Synlab Provence Laboratory, Marseille, France.&#xD;Parot Medical Center, Lyon, France.&#xD;Eurofins-Biomnis Laboratory, Lyon, France.&#xD;Institut Federatif de Biologie, University Hospital Centre of Toulouse, Toulouse, France.&#xD;French Society of Allergology, France.&#xD;Immunology Laboratory, CHU de Bordeaux, Bordeaux, France.&#xD;Inovie Biofutur Laboratories, Conflans-Sainte-Honorine, France.&#xD;Immunology Laboratory, University Hospital of Nimes, Nimes, France.&#xD;Children and Adult Allergology Department, Robert Ballanger Hospital, Aulnay-sous-Bois, France.&#xD;Service de Pediatrie Generale, Centre Hospitalier de Fontainebleau, Fontainebleau, France.&#xD;Immunology Laboratory, Faculty of Medicine, and INSERM UMR1250 P3CELL; University Hospital of Reims, University of Reims Champagne-Ardenne, Reims, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Baseline Serum Tryptase: Sex- and Age-Specific Reference Intervals in the Pediatric and Adult Population</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3217-3221</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/09/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">age</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">elderly</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary alpha-tryptasemia</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell disorders</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">reference intervals</style></keyword><keyword><style face="normal" font="default" size="100%">sex</style></keyword><keyword><style face="normal" font="default" size="100%">tryptase</style></keyword><keyword><style face="normal" font="default" size="100%">received honoraria from Thermo Fisher Scientific, and research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Blueprint Medicines and Thermo Fisher Scientific. M. Michel received honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">from Thermo Fisher Scientific. J. Vitte reports speaker and consultancy fees in</style></keyword><keyword><style face="normal" font="default" size="100%">the past 5 years from Astra Zeneca, HpVac, L&apos;Oreal, Novartis, Sanofi, Thermo</style></keyword><keyword><style face="normal" font="default" size="100%">Fisher Scientific, Zambon, and travel support from Stallergenes-Greer, outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work. C. Klingebiel received honoraria from Thermo Fisher</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific. J.G. reports speaker and travel support in the past 5 years from ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes-Greer, Thermo Fisher Scientific, and Menarini, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. Eric Fromentin-ALK-Abello, Menarini, Stallergenes Greer, Thermo Fisher, and</style></keyword><keyword><style face="normal" font="default" size="100%">Viatris. The other authors declare that they have no relevant conflicts of</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40990097</style></accession-num><notes><style face="normal" font="default" size="100%">Chantran, Yannick&#xD;Novakowski, Helene&#xD;Vial-Dupuy, Amandine&#xD;Bouz, Christine&#xD;Apoil, Pol Andre&#xD;Choi, Simone&#xD;Fromentin, Eric&#xD;Goret, Julien&#xD;Mathieu, Patricia&#xD;Michel, Moise&#xD;Nemni, Ariane&#xD;Seve, Edouard&#xD;Roda, Celine&#xD;Ranciere, Fanny&#xD;Vitte, Joana&#xD;Momas, Isabelle&#xD;Klingebiel, Caroline&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3217-3221. doi: 10.1111/all.70069. Epub 2025 Sep 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40990097</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590325</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70069</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>664</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">664</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Corren, J.</style></author><author><style face="normal" font="default" size="100%">Pham, T. H.</style></author><author><style face="normal" font="default" size="100%">Garcia Gil, E.</style></author><author><style face="normal" font="default" size="100%">Salapa, K.</style></author><author><style face="normal" font="default" size="100%">Ren, P.</style></author><author><style face="normal" font="default" size="100%">Parnes, J. R.</style></author><author><style face="normal" font="default" size="100%">Colice, G.</style></author><author><style face="normal" font="default" size="100%">Griffiths, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, USA.&#xD;Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, Maryland, USA.&#xD;Global Medical Respiratory, BioPharmaceuticals R&amp;D, AstraZeneca, Barcelona, Spain.&#xD;Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, Warsaw, Poland.&#xD;Early Biostats and Statistical Innovation, Early-stage Development, Respiratory and Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, Maryland, USA.&#xD;Translational Medicine, Amgen, Thousand Oaks, California, USA.&#xD;Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Baseline type 2 biomarker levels and response to tezepelumab in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1786-1796</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/12/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-5</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">has also received grants from Genentech, Novartis, Optinose, Regeneron, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">and Teva, and has received personal fees from AstraZeneca, Genentech, Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">and Sanofi. Ms Pham, Dr. Ren, Dr. Colice, and Dr. Griffiths are employees of</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca and own stock and stock options in AstraZeneca. Dr. Garcia Gil was an</style></keyword><keyword><style face="normal" font="default" size="100%">employee of AstraZeneca at the time of this study</style></keyword><keyword><style face="normal" font="default" size="100%">she is a present employee of</style></keyword><keyword><style face="normal" font="default" size="100%">Almirall. Ms Salapa is an employee of AstraZeneca. Dr. Parnes is an employee of</style></keyword><keyword><style face="normal" font="default" size="100%">Amgen Inc., and owns stock and stock options in Amgen Inc.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34913186</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks activity of thymic stromal lymphopoietin (TSLP). In the phase IIb PATHWAY study (NCT02054130), tezepelumab significantly reduced annualized asthma exacerbation rates (AAERs) versus placebo in adults with severe, uncontrolled asthma. We evaluated the effects of tezepelumab in reducing type 2 (T2) inflammatory biomarker levels in the PATHWAY population, and the relationship between baseline T2 biomarker levels and AAER. METHODS: Adults with severe, uncontrolled asthma (n = 550) were randomized to tezepelumab (70 mg or 210 mg every 4 weeks, or 280 mg every 2 weeks) or placebo for 52 weeks. Blood eosinophil count, fractional exhaled nitric oxide (FeNO), and serum total immunoglobulin (Ig)E, interleukin (IL)-5, IL-13, periostin, thymus and activation-regulated chemokine (TARC), and TSLP were measured at baseline and over 52 weeks. AAERs were analyzed by baseline threshold (high/low) biomarker levels. RESULTS: Positive correlations were observed between T2 inflammatory biomarkers (blood eosinophil count, FeNO, IL-5, IL-13 and periostin) at baseline. At Week 52, treatment with tezepelumab 210 mg reduced all biomarker levels measured from baseline versus placebo. Exacerbations were reduced by 55-83% in the pooled tezepelumab cohort versus placebo, irrespective of baseline blood eosinophil count, FeNO, or serum total IgE, IL-5, IL-13, periostin, TARC, or TSLP, when these biomarkers were assessed individually. CONCLUSION: At baseline, positive correlations between specific T2 inflammatory biomarkers were observed. Tezepelumab reduced multiple T2 inflammatory biomarkers, which indicates decreased airway inflammation, and reduced exacerbations irrespective of baseline T2 biomarker profiles in patients with severe asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Corren, Jonathan&#xD;Pham, Tuyet-Hang&#xD;Garcia Gil, Esther&#xD;Salapa, Kinga&#xD;Ren, Pin&#xD;Parnes, Jane R&#xD;Colice, Gene&#xD;Griffiths, Janet M&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1786-1796. doi: 10.1111/all.15197. Epub 2022 Feb 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34913186</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9306691</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15197</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1285</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1285</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caruso, C.</style></author><author><style face="normal" font="default" size="100%">Colantuono, S.</style></author><author><style face="normal" font="default" size="100%">Tolusso, B.</style></author><author><style face="normal" font="default" size="100%">Di Mario, C.</style></author><author><style face="normal" font="default" size="100%">Pentassuglia, A.</style></author><author><style face="normal" font="default" size="100%">Rumi, G.</style></author><author><style face="normal" font="default" size="100%">Gremese, E.</style></author><author><style face="normal" font="default" size="100%">Romano, A.</style></author><author><style face="normal" font="default" size="100%">Gasbarrini, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.&#xD;Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.&#xD;Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.&#xD;Division of Rheumatology, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;San Giovanni Battista Hospital, Rome, Italy.&#xD;IRCCS Oasi Maria S.S., Troina, Italy.&#xD;Fondazione Mediterranea G.B. Morgagni, Catania, Italy.&#xD;UOC Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil activation and serum IL-5 levels as possible monitor biomarkers in severe eosinophilic asthma patients treated with anti-IL-5 drugs</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1569-1571</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-5/*antagonists &amp; inhibitors/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Pharmaceutical Preparations</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">interleukins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33099778</style></accession-num><notes><style face="normal" font="default" size="100%">Caruso, Cristiano&#xD;Colantuono, Stefania&#xD;Tolusso, Barbara&#xD;Di Mario, Clara&#xD;Pentassuglia, Antonella&#xD;Rumi, Gabriele&#xD;Gremese, Elisa&#xD;Romano, Antonino&#xD;Gasbarrini, Antonio&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1569-1571. doi: 10.1111/all.14643. Epub 2020 Nov 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33099778</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14643</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3194</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3194</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boyd, H.</style></author><author><style face="normal" font="default" size="100%">Bartha, I.</style></author><author><style face="normal" font="default" size="100%">Foong, R. X.</style></author><author><style face="normal" font="default" size="100%">Krawiec, M.</style></author><author><style face="normal" font="default" size="100%">Marques-Mejias, A.</style></author><author><style face="normal" font="default" size="100%">Marshall, H. F.</style></author><author><style face="normal" font="default" size="100%">Radulovic, S.</style></author><author><style face="normal" font="default" size="100%">Harrison, F.</style></author><author><style face="normal" font="default" size="100%">Antoneria, G.</style></author><author><style face="normal" font="default" size="100%">Jama, Z.</style></author><author><style face="normal" font="default" size="100%">Kwok, M.</style></author><author><style face="normal" font="default" size="100%">Pietraszewicz, E.</style></author><author><style face="normal" font="default" size="100%">Eghleilib, M.</style></author><author><style face="normal" font="default" size="100%">Ricci, C.</style></author><author><style face="normal" font="default" size="100%">Marrs, T.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Africa Unit for Transdisciplinary Health Research (AUTHeR), North-West University, Potchefstroom, South Africa.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil Activation Test as Biomarker of Severity and Threshold of Allergic Reactions to Cow&apos;s Milk During Oral Food Challenges</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">cow&apos;s milk allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">severity</style></keyword><keyword><style face="normal" font="default" size="100%">skin prick test</style></keyword><keyword><style face="normal" font="default" size="100%">specific IgE</style></keyword><keyword><style face="normal" font="default" size="100%">threshold</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41410184</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cow&apos;s milk allergy is the most common food allergy worldwide and the top cause of food anaphylaxis fatalities. Identifying patients at higher risk of severe symptoms as well as patients with a lower threshold of reactivity would improve their management. We aimed to assess the utility of putative biomarkers to identify these high-risk patients. METHODS: The severity of allergic reactions to baked milk (BM) and to fresh milk (FM) during oral food challenges (OFC) was assessed prospectively during the BAT2 study (NCT03309488), according to the Practall guidelines. Demographic, clinical and immunological parameters were compared between severe/non-severe and higher/lower threshold reactors to BM or FM. Receiver Operating Characteristic curve analyses were performed to measure the accuracy of biomarkers with discriminative ability. RESULTS: Seventy-one children reacted to cow&apos;s milk: 22 (15%) to BM and 49 (43%) to FM. Seven (32%) and 12 (24%) reactors had severe symptoms during OFC to BM and FM, respectively. The median cumulative dose of milk protein tolerated was 0.44 g for BM and 0.143 g for FM. The basophil activation test (BAT) was the only biomarker that could distinguish severity and threshold groups. BAT optimal cut-offs had 71% sensitivity and 100% specificity to identify severe reactors to BM and 96% sensitivity and 41% specificity to identify children reacting to 0.143 g or less of FM. CONCLUSIONS: BAT was the only biomarker for severity and threshold of allergic reactions to BM and FM, respectively. Once applied to clinical practice, BAT can help risk-stratify cow&apos;s milk allergic patients and improve their management.</style></abstract><notes><style face="normal" font="default" size="100%">Boyd, Holly&#xD;Bartha, Irene&#xD;Foong, Ru-Xin&#xD;Krawiec, Marta&#xD;Marques-Mejias, Andreina&#xD;Marshall, Hannah F&#xD;Radulovic, Suzana&#xD;Harrison, Faye&#xD;Antoneria, Grammatiki&#xD;Jama, Zainab&#xD;Kwok, Matthew&#xD;Pietraszewicz, Ewa&#xD;Eghleilib, Malak&#xD;Ricci, Cristian&#xD;Marrs, Tom&#xD;Lack, Gideon&#xD;Du Toit, George&#xD;Santos, Alexandra F&#xD;eng&#xD;MRC_/Medical Research Council/United Kingdom&#xD;King&apos;s College London/&#xD;King&apos;s College Hospital NHS Foundation Trust/&#xD;Denmark&#xD;Allergy. 2025 Dec 18. doi: 10.1111/all.70175.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41410184</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70175</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2252</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2252</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Radulovic, S.</style></author><author><style face="normal" font="default" size="100%">Foong, R. X.</style></author><author><style face="normal" font="default" size="100%">Bartha, I.</style></author><author><style face="normal" font="default" size="100%">Marques-Mejias, A.</style></author><author><style face="normal" font="default" size="100%">Krawiec, M.</style></author><author><style face="normal" font="default" size="100%">Kwok, M.</style></author><author><style face="normal" font="default" size="100%">Jama, Z.</style></author><author><style face="normal" font="default" size="100%">Harrison, F.</style></author><author><style face="normal" font="default" size="100%">Ricci, C.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Africa Unit for Transdisciplinary Health Research (AUTHeR), North-West University, Potchefstroom, South Africa.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil activation test as predictor of severity and threshold of allergic reactions to egg</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">419-431</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophil Degranulation Test</style></keyword><keyword><style face="normal" font="default" size="100%">*Egg Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Ovomucin</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">baked egg allergy</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">egg allergy</style></keyword><keyword><style face="normal" font="default" size="100%">severity</style></keyword><keyword><style face="normal" font="default" size="100%">threshold</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Infectious Diseases (NIAID, NIH). Dr Lack reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">National Institute of Allergy and Infectious Diseases (NIAID, NIH), other from</style></keyword><keyword><style face="normal" font="default" size="100%">Food Allergy &amp; Research Education (FARE), other from MRC &amp; Asthma UK Centre,</style></keyword><keyword><style face="normal" font="default" size="100%">other from UK Dept of Health through NIHR, other from National Peanut Board</style></keyword><keyword><style face="normal" font="default" size="100%">(NPB), other from The Davis Foundation, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">shareholder in DBV Technologies, and Mighty Mission Me, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, personal fees from Sanofi-Genyzme, personal fees from Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from ALK-Abello, personal fees from Lurie Children&apos;s Hospital,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. Dr Du Toit reports grants from National Institute of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Infectious Diseases (NIAID, NIH), Food Allergy &amp; Research Education</style></keyword><keyword><style face="normal" font="default" size="100%">(FARE), MRC &amp; Asthma UK Centre, UK Dept of Health through NIHR, Action Medical</style></keyword><keyword><style face="normal" font="default" size="100%">Research and National Peanut Board. Scientific Advisory Board member Aimmune.</style></keyword><keyword><style face="normal" font="default" size="100%">Investigator on pharma-sponsored allergy studies (Aimmune, and DBV Technologies).</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific advisor to Aimmune, DBV and Novartis. Dr Santos reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Medical Research Council (MR/M008517/1</style></keyword><keyword><style face="normal" font="default" size="100%">MC/PC/18052</style></keyword><keyword><style face="normal" font="default" size="100%">MR/T032081/1), Food Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Research and Education (FARE), the Immune Tolerance Network/National Institute of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Infectious Diseases (NIAID, NIH), Asthma UK (AUK-BC-2015-01), BBSRC,</style></keyword><keyword><style face="normal" font="default" size="100%">Rosetrees Trust and the NIHR through the Biomedical Research Centre (BRC) award</style></keyword><keyword><style face="normal" font="default" size="100%">to Guy&apos;s and St Thomas&apos; NHS Foundation Trust, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Thermo Scientific, Nutricia, Infomed, Novartis, Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Buhlmann, as well as research support from Buhlmann and Thermo</style></keyword><keyword><style face="normal" font="default" size="100%">Fisher Scientific through a collaboration agreement with King&apos;s College London.</style></keyword><keyword><style face="normal" font="default" size="100%">The other authors have nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37680143</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Identifying patients at risk of severe allergic reactions and/or low threshold of reactivity is very important, particularly for staple foods like egg. METHODS: One hundred and fifty children underwent double-blind placebo-controlled food challenge (DBPCFC) to baked egg (BE), skin prick testing and blood collection for serology and basophil activation test (BAT). Patients who passed BE DBPCFC underwent loosely cooked egg (LCE) DBPCFC. Severity of allergic reactions was classified following Practall guidelines and threshold dose was determined during DBPCFC. RESULTS: Sixty out of 150 (40%) children reacted to BE and 16 out of 77 (21%) to LCE on DBPCFC. Considering DBPCFC to BE, 23 children (38%) had severe reactions and 33 (55%) reacted to 0.13 g or less of egg protein (low threshold group). Two children (2 out of 16 = 12%) had severe reactions to LCE. Demographic, clinical and most immunological features were not significantly different between severe/non-severe BE reactors or low/high threshold groups. Severe BE reactors had higher ovomucoid-sIgE (p = .009) and higher BAT to BE (p = .001). Patients with lower threshold to BE had higher IgE-specific activity (p = .027) and BAT to egg (p = .007) but lower severity score (p = .008). Optimal cut-offs for ovomucoid-sIgE had 100% sensitivity, 35% specificity and 60% accuracy and for BAT 76% sensitivity, 74% specificity and 75% accuracy to identify BE severe reactors. Optimal cut-offs for specific activity had 70% sensitivity, 68% specificity and 69% accuracy and for BAT 70% sensitivity, 72% specificity and 71% accuracy to identify low threshold patients. CONCLUSIONS: BAT was the best biomarker to predict severity and threshold of allergic reactions to BE and can be useful when making decisions about management of egg allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Radulovic, Suzana&#xD;Foong, Ru-Xin&#xD;Bartha, Irene&#xD;Marques-Mejias, Andreina&#xD;Krawiec, Marta&#xD;Kwok, Matthew&#xD;Jama, Zainab&#xD;Harrison, Faye&#xD;Ricci, Cristian&#xD;Lack, Gideon&#xD;Du Toit, George&#xD;Santos, Alexandra F&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MC_PC_18052/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):419-431. doi: 10.1111/all.15875. Epub 2023 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37680143</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10952485</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15875</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2658</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2658</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Ariza, A.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Revuelta, P.</style></author><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Madrigal-Burgaleta, R.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Calvo-Serrano, S.</style></author><author><style face="normal" font="default" size="100%">Villar-Chamorro, E.</style></author><author><style face="normal" font="default" size="100%">Martin-Clavo, S.</style></author><author><style face="normal" font="default" size="100%">Lebron-Martin, C.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Drug Desensitization Centre, Catalan Institute of Oncology (Institut Catala d&apos;oncologia-ICO), Barcelona, Spain.&#xD;Allergy Department, Hospital Universitari de Bellvitge, Barcelona, Spain.&#xD;Allergy and Severe Asthma Service, St Bartholomew&apos;s Hospital, Barts Health NHS Trust, London, UK.&#xD;Departamento de Medicina, Universidad de Malaga, Malaga, Spain.&#xD;UGCI Oncologia Medica, Hospital Regional Universitario de Malaga y Virgen de la Victoria, Malaga, Spain.&#xD;Servicio de Farmacia Hospitalaria, Hospital Regional Universitario de Malaga, Hospital Materno Infantil, Malaga, Spain.&#xD;Departamento de Biologia Molecular y Bioquimica, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">271-286</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/08/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophil Degranulation Test/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Taxoids/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Platinum Compounds/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Antineoplastic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">drug provocation tests</style></keyword><keyword><style face="normal" font="default" size="100%">endophenotype</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39215539</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Delabelling pathways offer confirmatory diagnosis and can prevent unnecessary second-line therapies or drug desensitization procedures after chemotherapeutic hypersensitivity reactions (CHT-HSRs). However, these pathways rely on risky in vivo tests. Data on whether in vitro tests could be helpful are scarce. We assessed the role of basophil activation test (BAT) in the diagnosis of HSRs to platin salts (PSs) and taxanes (TXs) in a well-defined population featuring varied endophenotypes and severities of HSRs. METHODS: We conducted a 3-year-long multicentric, prospective study with 121 suspected-immediate CHT-HSR patients. The allergy workup included clinical history (initial reaction based on Type I, cytokine release syndrome, and mixed phenotype&apos;s symptoms and if unable to fit in any of these, as &quot;indeterminate&quot;), skin testing (ST), and drug provocation testing (DPT), provided risk assessment was favorable. Final diagnosis classified patients as &quot;hypersensitive,&quot; &quot;non-hypersensitive,&quot; or &quot;inconclusive.&quot; We performed BAT using CD63 and CD203c as activation markers in patients and controls. Patients underwent DPT regardless of BAT results to prevent bias. RESULTS: ST positivity significantly correlated with skin involvement, Type I phenotype, cancer recurrence, and lifetime exposures before reactions. DPTs were negative in all indeterminate phenotype patients (p = .02) and those considered low-risk, whereas they were negative in 62% moderate-risk patients. 55% were confirmed as hypersensitive (mainly Type I reactions, p &lt; .0001), 24% as non-hypersensitive (mainly TXs and indeterminate phenotypes), and 21% as inconclusive. BAT showed 79% sensitivity in Type I IgE-mediated reactions to PSs with a high correlation to ST. CONCLUSIONS: BAT is a promising tool for delabelling and endotyping CHT-HSRs, especially Type I reactions to PSs, possibly identifying patients at risk of positive DPT. ST seems useful in confirming CHT-HSRs, especially PS-induced reactions, and DPT remains the gold standard, being essential even in moderate-risk patients.</style></abstract><notes><style face="normal" font="default" size="100%">Bogas, Gador&#xD;Ariza, Adriana&#xD;Vazquez-Revuelta, Paula&#xD;Labella, Marina&#xD;Madrigal-Burgaleta, Ricardo&#xD;Fernandez-Santamaria, Ruben&#xD;Calvo-Serrano, Silvia&#xD;Villar-Chamorro, Esther&#xD;Martin-Clavo, Susana&#xD;Lebron-Martin, Clara&#xD;Mayorga, Cristobalina&#xD;Dona, Inmaculada&#xD;Torres, Maria J&#xD;eng&#xD;RC-0004-2021/Andalusian Regional Ministry Health/&#xD;PI-0076-2019/Andalusian Regional Ministry Health/&#xD;RH-0099-2020/Andalusian Regional Ministry Health/&#xD;B-0007-2022/Andalusian Regional Ministry Health/&#xD;C1-0007-2023/Andalusian Regional Ministry Health/&#xD;PREDOC_01545/Andalusian Regional Goverment/&#xD;RICORSREI(RD21/0002/0008)/Instituto de Salud Carlos III (ISCIII) of the Ministry of Economy and Competitiveness (MINECO)/&#xD;RETICSARADYALRD16/0006/0001/Instituto de Salud Carlos III (ISCIII) of the Ministry of Economy and Competitiveness (MINECO) and co-funded by Fondo Europeo de Desarrollo Regional-FEDER/&#xD;Ministerio de Economia y Competitividad/&#xD;PI18/00095|FI23/00027|PI22/01119/Instituto de Salud Carlos III (ISCIII) of the Ministry of Economy and Competitiveness (MINECO)/&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):271-286. doi: 10.1111/all.16296. Epub 2024 Aug 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39215539</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724245</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16296</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3037</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3037</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bartha, I.</style></author><author><style face="normal" font="default" size="100%">Boyd, H.</style></author><author><style face="normal" font="default" size="100%">Foong, R. X.</style></author><author><style face="normal" font="default" size="100%">Krawiec, M.</style></author><author><style face="normal" font="default" size="100%">Marques-Mejias, A.</style></author><author><style face="normal" font="default" size="100%">Marshall, H. F.</style></author><author><style face="normal" font="default" size="100%">Radulovic, S.</style></author><author><style face="normal" font="default" size="100%">Harrison, F.</style></author><author><style face="normal" font="default" size="100%">Antoneria, G.</style></author><author><style face="normal" font="default" size="100%">Jama, Z.</style></author><author><style face="normal" font="default" size="100%">Kwok, M.</style></author><author><style face="normal" font="default" size="100%">Pietraszewicz, E.</style></author><author><style face="normal" font="default" size="100%">Eghleilib, M.</style></author><author><style face="normal" font="default" size="100%">Ricci, C.</style></author><author><style face="normal" font="default" size="100%">Marrs, T.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Africa Unit for Transdisciplinary Health Research (AUTHeR), North-West University, Potchefstroom, South Africa.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Basophil Activation Test Is the Most Accurate Test in Predicting Allergic Reactions to Baked and Fresh Cow&apos;s Milk During Oral Food Challenges</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2861-2873</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/08/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophil Degranulation Test/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk/adverse effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">ROC Curve</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">baked milk</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">cow&apos;s milk allergy</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">fresh milk</style></keyword><keyword><style face="normal" font="default" size="100%">oral food challenges</style></keyword><keyword><style face="normal" font="default" size="100%">skin prick test</style></keyword><keyword><style face="normal" font="default" size="100%">specific IgE</style></keyword><keyword><style face="normal" font="default" size="100%">National Institute of Allergy and Infectious Diseases (NIAID, NIH). Dr. Lack</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from the National Institute of Allergy and Infectious Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">(NIAID, NIH), others from Food Allergy &amp; Research Education (FARE), others from</style></keyword><keyword><style face="normal" font="default" size="100%">the MRC &amp; Asthma UK Centre, others from the UK Dept of Health through NIHR,</style></keyword><keyword><style face="normal" font="default" size="100%">others from the National Peanut Board (NPB), others from The Davis Foundation,</style></keyword><keyword><style face="normal" font="default" size="100%">during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">he is a shareholder in DBV Technologies and</style></keyword><keyword><style face="normal" font="default" size="100%">Mighty Mission Me, and he receives personal fees from Novartis, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Sanofi-Genzyme, personal fees from Regeneron, personal fees from ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from Lurie Children&apos;s Hospital, outside the submitted work. Dr</style></keyword><keyword><style face="normal" font="default" size="100%">Du Toit reports grants from National Institute of Allergy and Infectious Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">(NIAID, NIH), Food Allergy &amp; Research Education (FARE), MRC &amp; Asthma UK Centre,</style></keyword><keyword><style face="normal" font="default" size="100%">UK Dept of Health through NIHR, Action Medical Research, and National Peanut</style></keyword><keyword><style face="normal" font="default" size="100%">Board. Scientific Advisory Board member Aimmune. Investigator on pharma-sponsored</style></keyword><keyword><style face="normal" font="default" size="100%">allergy studies (Aimmune, and DBV Technologies). Scientific advisor to Aimmune,</style></keyword><keyword><style face="normal" font="default" size="100%">DBV, and Novartis. Dr. Santos reports grants from Medical Research Council</style></keyword><keyword><style face="normal" font="default" size="100%">(MR/M008517/1</style></keyword><keyword><style face="normal" font="default" size="100%">MC/PC/18052</style></keyword><keyword><style face="normal" font="default" size="100%">MR/T032081/1), Food Allergy Research and Education</style></keyword><keyword><style face="normal" font="default" size="100%">(FARE), the Immune Tolerance Network/National Institute of Allergy and Infectious</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases (NIAID, NIH), Asthma UK (AUK-BC-2015-01), BBSRC, Rosetrees Trust, and</style></keyword><keyword><style face="normal" font="default" size="100%">the NIHR through the Biomedical Research Centre (BRC) award to Guy&apos;s and St</style></keyword><keyword><style face="normal" font="default" size="100%">Thomas&apos; NHS Foundation Trust, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Thermo Scientific, Novartis, Allergy Therapeutics, DBV, Sanofi/Regeneron and</style></keyword><keyword><style face="normal" font="default" size="100%">Parexel as well as research support from Buhlmann and Thermo Fisher Scientific</style></keyword><keyword><style face="normal" font="default" size="100%">through a collaboration agreement with King&apos;s College London. The other authors</style></keyword><keyword><style face="normal" font="default" size="100%">declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40808324</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cow&apos;s milk is the most common cause of food allergy and related fatalities. Consumption of baked milk (BM) has been associated with better prognosis, nutrition and quality-of-life. METHODS: The BAT 2 milk study (NCT03309488) was a diagnostic study of cow&apos;s milk allergy designed according to STARD guidelines. All children had an oral food challenge (OFC) to BM, and those who tolerated BM were offered an OFC to fresh milk (FM). The diagnostic performance of the basophil activation test (BAT), skin prick test (SPT) and specific IgE (sIgE) was assessed in comparison with OFC. RESULTS: Out of the 150 children studied, 85% tolerated BM and 56% also tolerated FM. BAT had the best diagnostic accuracy (area under the receiver operator characteristic curve 0.90 for BM and 0.81 for FM) compared with the other tests for both BM (sIgE: 0.79 and SPT: 0.70) and FM (sIgE: 0.74 and SPT: 0.78) allergies. Using 100% sensitivity and 100% specificity cut-offs to select patients for OFC would have led to the following proportion of children having OFC (and positive OFC) to BM: 99% (13%) for SPT to baked milk, 82% (17%) for sIgE to boiled milk, and 49% (24%) for BAT to baked milk. In children younger than 2 years, only 27% required an OFC following BAT to BM (compared to 100% and 81% following SPT or sIgE to milk extract, respectively), with 100% diagnostic accuracy. CONCLUSIONS: BAT was the best test to identify children who reacted on OFC to BM or FM. Using 100% sensitivity and 100% specificity cut-offs, BAT ensured the lowest need for OFC and 100% diagnostic accuracy. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT03309488.</style></abstract><notes><style face="normal" font="default" size="100%">Bartha, Irene&#xD;Boyd, Holly&#xD;Foong, Ru-Xin&#xD;Krawiec, Marta&#xD;Marques-Mejias, Andreina&#xD;Marshall, Hannah F&#xD;Radulovic, Suzana&#xD;Harrison, Faye&#xD;Antoneria, Grammatiki&#xD;Jama, Zainab&#xD;Kwok, Matthew&#xD;Pietraszewicz, Ewa&#xD;Eghleilib, Malak&#xD;Ricci, Cristian&#xD;Marrs, Tom&#xD;Lack, Gideon&#xD;Du Toit, George&#xD;Santos, Alexandra F&#xD;eng&#xD;MRC_/Medical Research Council/United Kingdom&#xD;Observational Study&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2861-2873. doi: 10.1111/all.16675. Epub 2025 Aug 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40808324</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486342</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16675</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2736</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2736</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Ariza, A.</style></author><author><style face="normal" font="default" size="100%">Jimenez, M. A.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Mendiola, M. R.</style></author><author><style face="normal" font="default" size="100%">Sanchez, M. L.</style></author><author><style face="normal" font="default" size="100%">Boteanu, C.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Fernandez, T. D.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Laguna, J. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-ARADyAL, Malaga, Spain.&#xD;Departamento de Medicina, Universidad de Malaga-UMA, Malaga, Spain.&#xD;Allergy Department, Hospital Universitario Cruz Roja, Faculty of Medicine, Alfonso X el Sabio University, Madrid, Spain.&#xD;Allergy-Anaesthesia Unit, Allergy Department, Hospital Universitario Cruz Roja, Faculty of Medicine, Alfonso X el Sabio University, Madrid, Spain.&#xD;Departamento de Biologia Celular, Genetica y Fisiologia, Universidad de Malaga-UMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil Activation Test Positivity Decreases With Time in Immediate Allergic Reactions to Proton Pump Inhibitors</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1111-1114</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/11/27</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39601607</style></accession-num><notes><style face="normal" font="default" size="100%">Fernandez-Santamaria, Ruben&#xD;Salas, Maria&#xD;Ariza, Adriana&#xD;Jimenez, Maria A&#xD;Gonzalez-Mendiola, Maria R&#xD;Sanchez, Maria L&#xD;Boteanu, Cosmin&#xD;Mayorga, Cristobalina&#xD;Fernandez, Tahia D&#xD;Torres, Maria J&#xD;Laguna, Jose J&#xD;eng&#xD;Instituto de Salud Carlos III/&#xD;European Regional Development Fund/&#xD;Ministerio de Economia y Competitividad/&#xD;Fundacion IDIPAZ/&#xD;Fundacion de la Sociedad Espanola de Alergologia e Inmunologia Clinica/&#xD;Fundacion Universidad Alfonso X el Sabio/&#xD;Consejeria de Salud y Familias, Junta de Andalucia/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1111-1114. doi: 10.1111/all.16406. Epub 2024 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39601607</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969308</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16406</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2741</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2741</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Ariza, A.</style></author><author><style face="normal" font="default" size="100%">Jimenez, M. A.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Mendiola, M. R.</style></author><author><style face="normal" font="default" size="100%">Sanchez, M. L.</style></author><author><style face="normal" font="default" size="100%">Boteanu, C.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Fernandez, T. D.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Laguna, J. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-ARADyAL, Malaga, Spain.&#xD;Departamento de Medicina, Universidad de Malaga-UMA, Malaga, Spain.&#xD;Allergy Department, Hospital Universitario Cruz Roja, Faculty of Medicine, Alfonso X el Sabio University, Madrid, Spain.&#xD;Allergy-Anaesthesia Unit, Allergy Department, Hospital Universitario Cruz Roja, Faculty of Medicine, Alfonso X el Sabio University, Madrid, Spain.&#xD;Departamento de Biologia Celular, Genetica y Fisiologia, Universidad de Malaga-UMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil Activation Test Positivity Decreases With Time in Immediate Allergic Reactions to Proton Pump Inhibitors</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1111-1114</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/11/27</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39601607</style></accession-num><notes><style face="normal" font="default" size="100%">Fernandez-Santamaria, Ruben&#xD;Salas, Maria&#xD;Ariza, Adriana&#xD;Jimenez, Maria A&#xD;Gonzalez-Mendiola, Maria R&#xD;Sanchez, Maria L&#xD;Boteanu, Cosmin&#xD;Mayorga, Cristobalina&#xD;Fernandez, Tahia D&#xD;Torres, Maria J&#xD;Laguna, Jose J&#xD;eng&#xD;Instituto de Salud Carlos III/&#xD;European Regional Development Fund/&#xD;Ministerio de Economia y Competitividad/&#xD;Fundacion IDIPAZ/&#xD;Fundacion de la Sociedad Espanola de Alergologia e Inmunologia Clinica/&#xD;Fundacion Universidad Alfonso X el Sabio/&#xD;Consejeria de Salud y Familias, Junta de Andalucia/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1111-1114. doi: 10.1111/all.16406. Epub 2024 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39601607</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969308</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16406</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1239</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1239</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Duan, L.</style></author><author><style face="normal" font="default" size="100%">Celik, A.</style></author><author><style face="normal" font="default" size="100%">Hoang, J. A.</style></author><author><style face="normal" font="default" size="100%">Schmidthaler, K.</style></author><author><style face="normal" font="default" size="100%">So, D.</style></author><author><style face="normal" font="default" size="100%">Yin, X.</style></author><author><style face="normal" font="default" size="100%">Ditlof, C. M.</style></author><author><style face="normal" font="default" size="100%">Ponce, M.</style></author><author><style face="normal" font="default" size="100%">Upton, J. E. M.</style></author><author><style face="normal" font="default" size="100%">Lee, J. S.</style></author><author><style face="normal" font="default" size="100%">Hung, L.</style></author><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author><author><style face="normal" font="default" size="100%">Palladino, C.</style></author><author><style face="normal" font="default" size="100%">Atkinson, A. R.</style></author><author><style face="normal" font="default" size="100%">Kim, V. H. D.</style></author><author><style face="normal" font="default" size="100%">Berenjy, A.</style></author><author><style face="normal" font="default" size="100%">Asper, M.</style></author><author><style face="normal" font="default" size="100%">Hummel, D.</style></author><author><style face="normal" font="default" size="100%">Wong, S.</style></author><author><style face="normal" font="default" size="100%">Alexanian-Farr, M.</style></author><author><style face="normal" font="default" size="100%">Magder, A.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, S. R.</style></author><author><style face="normal" font="default" size="100%">Mukai, K.</style></author><author><style face="normal" font="default" size="100%">Tsai, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author><author><style face="normal" font="default" size="100%">Ramani, A. K.</style></author><author><style face="normal" font="default" size="100%">Szepfalusi, Z.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Translational Medicine, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Division of Immunology and Allergy, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.&#xD;Centre for Computational Medicine, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatric and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.&#xD;Department of Immunology, University of Toronto, Toronto, ON, Canada.&#xD;Division of Medical Biotechnology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Division of Allergy, Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, USA.&#xD;Departments of Pathology and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil activation test shows high accuracy in the diagnosis of peanut and tree nut allergy: The Markers of Nut Allergy Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1800-1812</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Austria</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Canada</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nut Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Nuts</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">challenge tests</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">molecular allergology</style></keyword><keyword><style face="normal" font="default" size="100%">multiple nut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33300157</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Peanut and tree nut allergies are the most important causes of anaphylaxis. Co-reactivity to more than one nut is frequent, and co-sensitization in the absence of clinical data is often obtained. Confirmatory oral food challenges (OFCs) are inconsistently performed. OBJECTIVE: To investigate the utility of the basophil activation test (BAT) in diagnosing peanut and tree nut allergies. METHODS: The Markers Of Nut Allergy Study (MONAS) prospectively enrolled patients aged 0.5-17 years with confirmed peanut and/or tree nut (almond, cashew, hazelnut, pistachio, walnut) allergy or sensitization from Canadian (n = 150) and Austrian (n = 50) tertiary pediatric centers. BAT using %CD63(+) basophils (SSClow/CCR3pos) as outcome was performed with whole blood samples stimulated with allergen extracts of each nut (0.001-1000 ng/mL protein). BAT results were assessed against confirmed allergic status in a blinded fashion to develop a generalizable statistical model for comparison to extract and marker allergen-specific IgE. RESULTS: A mixed effect model integrating BAT results for 10 and 100 ng/mL of peanut and individual tree nut extracts was optimal. The area under the ROC curve (AUROC) was 0.98 for peanut, 0.97 for cashew, 0.92 for hazelnut, 0.95 for pistachio, and 0.97 for walnut. The BAT outperformed sIgE testing for peanut or hazelnut and was comparable for walnut (AUROC 0.95, 0.94, 0.92) in a sub-analysis in sensitized patients undergoing OFC. CONCLUSIONS: Basophil activation test can predict allergic clinical status to peanut and tree nuts in multi-nut-sensitized children and may reduce the need for high-risk OFCs in patients.</style></abstract><notes><style face="normal" font="default" size="100%">Duan, Lucy&#xD;Celik, Alper&#xD;Hoang, Jennifer A&#xD;Schmidthaler, Klara&#xD;So, Delvin&#xD;Yin, Xiaojun&#xD;Ditlof, Christina M&#xD;Ponce, Marta&#xD;Upton, Julia E M&#xD;Lee, Jean-Soo&#xD;Hung, Lisa&#xD;Breiteneder, Heimo&#xD;Palladino, Chiara&#xD;Atkinson, Adelle R&#xD;Kim, Vy H D&#xD;Berenjy, Alireza&#xD;Asper, Maria&#xD;Hummel, David&#xD;Wong, Samantha&#xD;Alexanian-Farr, Mara&#xD;Magder, Ahuva&#xD;Chinthrajah, Sharon R&#xD;Mukai, Kaori&#xD;Tsai, Mindy&#xD;Nadeau, Kari&#xD;Galli, Stephen J&#xD;Ramani, Arun K&#xD;Szepfalusi, Zsolt&#xD;Eiwegger, Thomas&#xD;eng&#xD;5U01 AI140498-03/T cell Reagents for Allergy/&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;U01 AI147462/AI/NIAID NIH HHS/&#xD;U01 AI140498/AI/NIAID NIH HHS/&#xD;5U19 AI104209-07/Integrated Genomic and Functional Studies of Immunotherapy for Multi-Food Allergy/&#xD;R01 AI140134/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1800-1812. doi: 10.1111/all.14695. Epub 2020 Dec 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33300157</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8608143</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14695</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1328</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1328</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alpan, O.</style></author><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Ulrik Sonder, S.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Amerimmune, Fairfax, VA, USA.&#xD;Immunomodulation and Tolerance Group, Allergy &amp; Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London, UK.&#xD;Institute for Asthma and Allergy, Wheaton, MD, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil activation test: A diagnostic, predictive and monitoring assay for allergen immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1321-1324</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/09/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Poaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">immunological tests</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32909281</style></accession-num><notes><style face="normal" font="default" size="100%">Alpan, Oral&#xD;Layhadi, Janice A&#xD;Ulrik Sonder, Soren&#xD;Li, Henry&#xD;Shamji, Mohamed H&#xD;eng&#xD;Comment&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1321-1324. doi: 10.1111/all.14585.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32909281</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14585</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2876</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2876</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pascal, M.</style></author><author><style face="normal" font="default" size="100%">Chauhan, J.</style></author><author><style face="normal" font="default" size="100%">Knol, E.</style></author><author><style face="normal" font="default" size="100%">Bianchini, R.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author><author><style face="normal" font="default" size="100%">De Las Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Hartmann, K.</style></author><author><style face="normal" font="default" size="100%">Izquierdo, E.</style></author><author><style face="normal" font="default" size="100%">Jappe, U.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Rodriguez, T. W.</style></author><author><style face="normal" font="default" size="100%">Levi-Schaffer, F.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Poli, A.</style></author><author><style face="normal" font="default" size="100%">Redegeld, F.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Bergmann, C.</style></author><author><style face="normal" font="default" size="100%">Karagiannis, S. N.</style></author><author><style face="normal" font="default" size="100%">Bax, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunology Department, CDB, Hospital Clinic de Barcelona; Institut D&apos;investigacio Biomedica August pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.&#xD;Department of Medicine, Universitat de Barcelona, Barcelona, Spain.&#xD;RETICS Asma, Reacciones Adversas y alergicas (ARADYAL) and RICORS Red De Enfermedades Inflamatorias (REI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.&#xD;School of Basic &amp; Medical Biosciences &amp; KHP Centre for Translational Medicine, St. John&apos;s Institute of Dermatology, King&apos;s College London, London, UK.&#xD;Center of Translational Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, Vienna, Austria.&#xD;The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna, and University Vienna, Vienna, Austria.&#xD;Division of Allergy and Clinical Immunology, Drug Hypersensitivity and Desensitization Center, Mastocytosis Center, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Allergy, La Paz University Hospital, Madrid, Spain.&#xD;Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Departamento de Ciencias Medicas Basicas, Facultad de Medicina, Instituto de Medicina Molecular Aplicada - Nemesio Diez (IMMA-ND), Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain.&#xD;Division of Clinical and Molecular Allergology, Priority Research Area Chronic Lung Diseases, Research Center Borstel, Leibniz Lung Center, German Center for Lung Research (DZL), Airway Research Center North (ARCN), Borstel, Germany.&#xD;Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University of Luebeck, Luebeck, Germany.&#xD;Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.&#xD;Pharmacology and Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.&#xD;Allergy Unit and Research Laboratory, Hospital Regional Universitario de Malaga-HRUM, Instituto de Investigacion Biomedica de Malaga-IBIMA-Plataforma BIONAND, Malaga, Spain.&#xD;Neuro-Immunology Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.&#xD;Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.&#xD;Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Department of Otorhinolaryngology, RKM740 Interdisciplinary Clinics, Dusseldorf, Germany.&#xD;Breast Cancer Now Research Unit, School of Cancer &amp; Pharmaceutical Sciences, King&apos;s College London, Guy&apos;s Cancer Centre, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology: An EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2097-2112</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophil Degranulation Test/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Medical Oncology/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms/diagnosis/immunology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">AllergoOncology</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test (BAT)</style></keyword><keyword><style face="normal" font="default" size="100%">cancer immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword><keyword><style face="normal" font="default" size="100%">T.W.J.R., F.L.S., and C.M. declare no conflicts of interest. A.F.S. reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Medical Research Council (MR/M008517/1</style></keyword><keyword><style face="normal" font="default" size="100%">MC/PC/18052</style></keyword><keyword><style face="normal" font="default" size="100%">MR/T032081/1),</style></keyword><keyword><style face="normal" font="default" size="100%">Food Allergy Research and Education (FARE), the Immune Tolerance Network/National</style></keyword><keyword><style face="normal" font="default" size="100%">Institute of Allergy and Infectious Diseases (NIAID, NIH), Asthma UK</style></keyword><keyword><style face="normal" font="default" size="100%">(AUK-BC-2015-01), BBSRC, Rosetrees Trust, and the NIHR through the Biomedical</style></keyword><keyword><style face="normal" font="default" size="100%">Research Centre (BRC) award to Guy&apos;s and St Thomas&apos; NHS Foundation Trust, during</style></keyword><keyword><style face="normal" font="default" size="100%">the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Thermo Scientific, Nestle, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics, IgGenix, and Mabylon, as well as research support from</style></keyword><keyword><style face="normal" font="default" size="100%">Thermo Fisher Scientific through a collaboration agreement with King&apos;s College</style></keyword><keyword><style face="normal" font="default" size="100%">London. S.N.K. is the academic founder and shareholder of Epsilogen Ltd.</style></keyword><keyword><style face="normal" font="default" size="100%">(formerly IGEM Therapeutics Ltd.) and has received funds from IGEM Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">Ltd/Epsilogen Ltd. H.J.B. is employed through a fund provided by Epsilogen Ltd.</style></keyword><keyword><style face="normal" font="default" size="100%">S.N.K. and H.J.B. are inventors of patents on antibody technologies. J.C. has</style></keyword><keyword><style face="normal" font="default" size="100%">been employed through a fund provided by Epsilogen Ltd. C.B. received honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">for presentations from Allergy Therapeutics, Bencard, HAL Allergy, and SCS.</style></keyword><keyword><style face="normal" font="default" size="100%">E.J.J. declares inventorship in patents on immunoBON, owned by Biomedical</style></keyword><keyword><style face="normal" font="default" size="100%">International R + D, Vienna, Austria, of which she is a shareholder. She received</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria for presentations from Allergy Therapeutics, AllergoPharma, Bencard</style></keyword><keyword><style face="normal" font="default" size="100%">Allergie, Meda, Menarini, Roxall, Santen, Sanofi, and ThermoFisher. U.J. has</style></keyword><keyword><style face="normal" font="default" size="100%">received a hotel accommodation and catering for a lecture and chairing of a</style></keyword><keyword><style face="normal" font="default" size="100%">workshop organized by ALK Abello. The honorarium went to her institution, the</style></keyword><keyword><style face="normal" font="default" size="100%">R.C.B. Her research on molecular allergology is funded by the Federal Ministry of</style></keyword><keyword><style face="normal" font="default" size="100%">Education and Science, the Federal Ministries of Technology, Economy and</style></keyword><keyword><style face="normal" font="default" size="100%">Technology, Food and Agriculture (BMEL), the German Research Foundation, and the</style></keyword><keyword><style face="normal" font="default" size="100%">Kanert Foundation. F.R. received a Pathways in Type 2 Inflammation Research Grant</style></keyword><keyword><style face="normal" font="default" size="100%">from Sanofi/Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">he is Editor-in-Chief of the European Journal of</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacology (Elsevier). M.P. received honoraria for presentations from</style></keyword><keyword><style face="normal" font="default" size="100%">ThermoFisher Scientific and LETI Pharma SLU. KH has received consultancy or</style></keyword><keyword><style face="normal" font="default" size="100%">lecture fees from ALK-Abello, Allergopharma, Blueprint, Cogent, KalVista, LEO</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Menarini, Novartis, Pfizer, Sanofi, Takeda, and Thermo Fisher, travel</style></keyword><keyword><style face="normal" font="default" size="100%">support from Allergopharma and Blueprint, and research funding from Thermo</style></keyword><keyword><style face="normal" font="default" size="100%">Fisher. M.C. declares Telios: TL-895 Trial PI BWH, AAAAI Foundation Research</style></keyword><keyword><style face="normal" font="default" size="100%">Chair, Editor in Chief of Current Allergy and Asthma Reports, UpToDate: Author,</style></keyword><keyword><style face="normal" font="default" size="100%">NIH: Allergy Data and Safety Monitoring Board (DSMB), BluePrint: BLU-285 and</style></keyword><keyword><style face="normal" font="default" size="100%">BLU-263 Studies PI BWH, Consultant for Daiichi Sankyo, and Cogent Biosciences:</style></keyword><keyword><style face="normal" font="default" size="100%">SUMMIT Trials. EFK received honoraria for presentations for Thermo Fisher</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific, Glaxo Smith Kline, Astra Zeneca, and Sanofi.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40503572</style></accession-num><abstract><style face="normal" font="default" size="100%">The basophil activation test (BAT) is gaining increasing relevance as an ex vivo functional assay in allergy to evaluate IgE-mediated hypersensitivity reactions to food allergens, venoms, and drugs and to monitor tolerance induction. Establishing universal standard operating protocols has been difficult, due to several challenges including variable activation markers, positive control selection, the need for processing fresh blood samples, and the existence of non-releasing individuals. In oncology, BAT is also an emerging promising diagnostic and management tool to assess hypersensitivity reactions to biologics and chemotherapy agents, monitor drug tolerance in desensitisation, and predict and address the safety of novel anti-cancer IgE-based therapeutics. This position paper highlights the emerging significance of BAT in AllergoOncology, in facilitating therapy monitoring, biomarker discovery, and risk stratification. Capitalising on long-acquired expertise in the development of BAT for allergy, we propose research directions and routes to clinical applications of this highly promising tool in AllergoOncology. We advocate the need for enhanced focus on addressing standardisation challenges and leveraging outputs for precision medicine. By linking allergy and oncology, the key remaining limitations can be addressed, with the aim of realising the significant promise of BAT as a robust tool to enhance personalised care in allergy and AllergoOncology.</style></abstract><notes><style face="normal" font="default" size="100%">Pascal, Mariona&#xD;Chauhan, Jitesh&#xD;Knol, Edward&#xD;Bianchini, Rodolfo&#xD;Castells, Mariana&#xD;De Las Vecillas, Leticia&#xD;Hartmann, Karin&#xD;Izquierdo, Elena&#xD;Jappe, Uta&#xD;Jimenez-Rodriguez, Teodorikez-Wilfox&#xD;Levi-Schaffer, Francesca&#xD;Mayorga, Cristobalina&#xD;Poli, Aurelie&#xD;Redegeld, Frank&#xD;Santos, Alexandra F&#xD;Jensen-Jarolim, Erika&#xD;Bergmann, Christoph&#xD;Karagiannis, Sophia N&#xD;Bax, Heather J&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Consensus Development Conference&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2097-2112. doi: 10.1111/all.16607. Epub 2025 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40503572</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368759</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16607</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2725</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2725</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bezinge, L.</style></author><author><style face="normal" font="default" size="100%">Vogt, D.</style></author><author><style face="normal" font="default" size="100%">Melone, A.</style></author><author><style face="normal" font="default" size="100%">Lartigue, M.</style></author><author><style face="normal" font="default" size="100%">Giegelmann, C.</style></author><author><style face="normal" font="default" size="100%">Schuster, T.</style></author><author><style face="normal" font="default" size="100%">Schneider, M.</style></author><author><style face="normal" font="default" size="100%">Romano, M.</style></author><author><style face="normal" font="default" size="100%">Gerhold, C. B.</style></author><author><style face="normal" font="default" size="100%">Gerspach, M. A.</style></author><author><style face="normal" font="default" size="100%">Bauer, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">BUHLMANN Laboratories AG, Schonenbuch, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil activation test: How many basophils are enough?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">351-353</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/11/06</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39503250</style></accession-num><notes><style face="normal" font="default" size="100%">Bezinge, Leonard&#xD;Vogt, Dominik&#xD;Melone, Anna&#xD;Lartigue, Maximilien&#xD;Giegelmann, Cedric&#xD;Schuster, Thomas&#xD;Schneider, Michael&#xD;Romano, Michele&#xD;Gerhold, Christian-Benedikt&#xD;Gerspach, Michael A&#xD;Bauer, Christina&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):351-353. doi: 10.1111/all.16391. Epub 2024 Nov 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39503250</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724242 for basophil activation testing.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16391</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1192</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1192</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Alpan, O.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Amerimmune, Fairfax, VA, USA.&#xD;Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.&#xD;Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2420-2432</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/01/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Basophil Degranulation Test</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Flow Cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Tetraspanin 30</style></keyword><keyword><style face="normal" font="default" size="100%">Cd63</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33475181</style></accession-num><abstract><style face="normal" font="default" size="100%">The basophil activation test (BAT) is a functional assay that measures the degree of degranulation following stimulation with allergen or controls by flow cytometry. It correlates directly with histamine release. From the dose-response curve resulting from BAT in allergic patients, basophil reactivity (%CD63(+) basophils) and basophil sensitivity (EC(50) or similar) are the main outcomes of the test. BAT takes into account all characteristics of IgE and allergen and thus can be more specific than sensitization tests in the diagnosis of allergic disease. BAT reduces the need for in vivo procedures, such as intradermal tests and allergen challenges, which can cause allergic reactions of unpredictable severity. As it closely reflects the patients&apos; phenotype in most cases, it may be used to support the diagnosis of food, venom and drug allergies and chronic urticaria, to monitor the natural resolution of food allergies and to predict and monitor clinical the response to immunomodulatory treatments, such as allergen-specific immunotherapy and biologicals. Clinical application of BAT requires analytical validation, clinical validation, standardization of procedures and quality assurance to ensure reproducibility and reliability of results. Currently, efforts are ongoing to establish a platform that could be used by laboratories in Europe and in the USA for quality assurance and certification.</style></abstract><notes><style face="normal" font="default" size="100%">Santos, Alexandra F&#xD;Alpan, Oral&#xD;Hoffmann, Hans-Jurgen&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MC_PC_18052/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2420-2432. doi: 10.1111/all.14747. Epub 2021 Feb 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33475181</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14747</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>69</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">69</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perkins, G. B.</style></author><author><style face="normal" font="default" size="100%">Hurtado, P. R.</style></author><author><style face="normal" font="default" size="100%">Hissaria, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Biological Sciences, University of Adelaide, Adelaide, South Australia, Australia.&#xD;SA Pathology, Adelaide, South Australia, Australia.&#xD;Renal Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia.&#xD;Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.&#xD;Immunology Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil reactivity to BNT162b2 in COVID-19 convalescence</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3704-3705</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Convalescence</style></keyword><keyword><style face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36441594</style></accession-num><notes><style face="normal" font="default" size="100%">Perkins, Griffith B&#xD;Hurtado, Plinio R&#xD;Hissaria, Pravin&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3704-3705. doi: 10.1111/all.15472.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36441594</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9877828</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15472</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1435</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1435</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmid, J. M.</style></author><author><style face="normal" font="default" size="100%">Wurtzen, P. A.</style></author><author><style face="normal" font="default" size="100%">Siddhuraj, P.</style></author><author><style face="normal" font="default" size="100%">Jogdand, P.</style></author><author><style face="normal" font="default" size="100%">Petersen, C. G.</style></author><author><style face="normal" font="default" size="100%">Dahl, R.</style></author><author><style face="normal" font="default" size="100%">Erjefalt, J. S.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.&#xD;Global Research, ALK, Horsholm, Denmark.&#xD;Unit of Airway Inflammation, Lund University, Lund, Sweden.&#xD;Department of Otorhinolaryngology, Aarhus University Hospital, Aarhus, Denmark.&#xD;Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1528-1538</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/03/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Poaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-blocking factor</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific IgE</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">basophil sensitivity measurement</style></keyword><keyword><style face="normal" font="default" size="100%">facilitated antigen binding</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32145088</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic rhinoconjunctivitis is a public health problem. Allergen Immunotherapy is an effective and safe treatment, that modifies the natural course of allergic disease and induces long-term tolerance. OBJECTIVE: To correlate basophil and antibody biomarkers of subcutaneous immunotherapy to clinical outcomes and cellular changes in target tissue. METHODS: Adults suffering from allergic rhinoconjunctivitis due to grass pollen allergy were randomized to receive subcutaneous immunotherapy (n = 18) or to an open control group (n = 6). Patients reported daily symptom and medication scores and weekly rhinitis related quality of life scores during four pollen seasons. Biomarkers were measured every 3 months for three years treatment and every 6 months in the follow-up year. Nasal and cutaneous allergen challenge tests were performed annually. Leukocyte subsets were assessed in nasal mucosa biopsies at baseline and after treatment. RESULTS: Subcutaneous immunotherapy led to a 447-fold decrease in basophil sensitivity during the first treatment year. This remained 100-fold lower than baseline during the 3 year-treatment period and 10-fold lower during the follow-up year (n = 18, P = .03). Decrease in basophil sensitivity after three weeks of treatment predicted long-term improvement in seasonal combined symptom and medication scores (ῥ=-0.69, P = .0027) during three years of treatment. AUC of IgE-blocking factor correlated to nasal allergen challenge (ῥ = 0.63, P = .0012) and SPT (ῥ = 0.45, P = .03). Plasma cell numbers in the nasal mucosa increased during treatment (P = .02). CONCLUSION: Decrease in basophil sensitivity after three weeks of subcutaneous allergen immunotherapy predicted the clinical outcome of this treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Schmid, Johannes M&#xD;Wurtzen, Peter A&#xD;Siddhuraj, Premkumar&#xD;Jogdand, Prajakta&#xD;Petersen, Claus G&#xD;Dahl, Ronald&#xD;Erjefalt, Jonas S&#xD;Hoffmann, Hans Jurgen&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1528-1538. doi: 10.1111/all.14264. Epub 2020 Mar 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32145088</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14264</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1268</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1268</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Miyake, K.</style></author><author><style face="normal" font="default" size="100%">Shibata, S.</style></author><author><style face="normal" font="default" size="100%">Yoshikawa, S.</style></author><author><style face="normal" font="default" size="100%">Karasuyama, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Inflammation, Infection and Immunity Laboratory, TMDU Advanced Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.&#xD;Department of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.&#xD;Department of Cell Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophils and their effector molecules in allergic disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1693-1706</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/11/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Parasitic Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Il-4</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33205439</style></accession-num><abstract><style face="normal" font="default" size="100%">Basophils are the rarest granulocytes which represent &lt;1% of peripheral blood leukocytes. Basophils bear several phenotypic similarities to tissue-resident mast cells and therefore had been erroneously considered as blood-circulating mast cells. However, recent researches have revealed that basophils play nonredundant roles in allergic inflammation, protective immunity against parasitic infections and regulation of innate and acquired immunity. Basophils are recruited to inflamed tissues and activated in an IgE-dependent or IgE-independent manner to release a variety of effector molecules. Such molecules, including IL-4, act on various types of cells and play versatile roles, including the induction and termination of allergic inflammation and the regulation of immune responses. Recent development of novel therapeutic agents has enabled us to gain further insights into basophil biology in human disorders. In this review, we highlight the recent advances in the field of basophil biology with a particular focus on the role of basophils in allergic inflammation. Further studies on basophils and their effector molecules will help us identify novel therapeutic targets for treating allergic disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Miyake, Kensuke&#xD;Shibata, Sho&#xD;Yoshikawa, Soichiro&#xD;Karasuyama, Hajime&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1693-1706. doi: 10.1111/all.14662. Epub 2020 Nov 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33205439</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14662</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3136</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3136</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, E. D.</style></author><author><style face="normal" font="default" size="100%">Voehringer, D.</style></author><author><style face="normal" font="default" size="100%">Radtke, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infection Biology, University Hospital Erlangen and Friedrich-Alexander University Erlangen-Nuremberg (FAU), Erlangen, Germany.&#xD;FAU Profile Center Immunomedicine (FAU I-MED), Erlangen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Basophils in Skin-Mediated Sensitization Drive Subsequent Lung Inflammation in Airway-Challenged Mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">220-231</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Pneumonia/immunology/etiology/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style face="normal" font="default" size="100%">Anaphylaxis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Ovalbumin/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">lung</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41074677</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) and asthma are observed as epidemiologically linked allergic comorbidities, both characterized by elevated systemic IgE levels and type 2 immunity. Basophils play a pivotal role in these responses by producing interleukin-4 (IL-4), which is essential for IgE synthesis and allergic inflammation. However, their specific impact on the progression from AD to asthma remains unclear. METHODS: We utilized an AD model in basophil-deficient Mcpt8Cre mice and temporarily basophil-depleted mice, where topical application of the vitamin D analog MC903 induced the alarmin TSLP, resulting in AD-like symptoms. In addition, we topically applied ovalbumin (OVA) as a model allergen to trace the allergen-specific immune response. We determined allergen-specific antibody formation by analysis of the germinal center reaction and measured serum antibody concentrations and IgE loading of basophils in the spleen and lung. We further challenged mice sensitized via the skin in anaphylaxis and allergic lung inflammation models. RESULTS: Our results demonstrate that basophils promote loss of skin barrier integrity, allergen-specific IgE formation, and subsequent allergic responses. Basophil depletion selectively during sensitization significantly reduced IgE-dependent anaphylaxis and lung inflammation. In challenged lungs, reduced inflammation and eosinophilia were accompanied by lower levels of chemokines CCL17 and CCL24, which attract Th2 cells and eosinophils, respectively. Notably, Il4 and Il13 were not affected by basophil depletion during sensitization but were reduced in mice that permanently lack basophils. CONCLUSION: We find that basophils promote IgE formation and lung sensitization to skin-encountered allergens and drive secondary allergen-induced lung inflammation. We separate the role of basophils in sensitization from their effector function during anaphylaxis or lung inflammation relevant to envision novel strategies to prevent the development of allergic comorbidities.</style></abstract><notes><style face="normal" font="default" size="100%">Choi, E Da&#xD;Voehringer, David&#xD;Radtke, Daniel&#xD;eng&#xD;Deutsche Forschungsgemeinschaft/&#xD;Interdisziplinares Zentrum fur Klinische Forschung, Universitatsklinikum Erlangen/&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):220-231. doi: 10.1111/all.70093. Epub 2025 Oct 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41074677</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773652</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70093</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>574</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">574</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Sa-Sousa, A.</style></author><author><style face="normal" font="default" size="100%">Vieira, R. J.</style></author><author><style face="normal" font="default" size="100%">Amaral, R.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Ansotegui, I. J.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">Carreiro-Martins, P.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Cingi, C.</style></author><author><style face="normal" font="default" size="100%">Costa, E. M.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">De Feo, G.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Gaga, M.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Ivancevich, J. C.</style></author><author><style face="normal" font="default" size="100%">Ispayeva, Z.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Kaidashev, I.</style></author><author><style face="normal" font="default" size="100%">Kraxner, H.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Laune, D.</style></author><author><style face="normal" font="default" size="100%">Lipworth, B.</style></author><author><style face="normal" font="default" size="100%">Louis, R.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Monti, R.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Odemyr, M.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Patella, V.</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, N.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Rouadi, P. W.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Sova, M.</style></author><author><style face="normal" font="default" size="100%">Todo-Bom, A.</style></author><author><style face="normal" font="default" size="100%">Taborda-Barata, L.</style></author><author><style face="normal" font="default" size="100%">Tomazic, P. V.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Tsiligianni, I.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Vandenplas, O.</style></author><author><style face="normal" font="default" size="100%">Wallace, D.</style></author><author><style face="normal" font="default" size="100%">Waserman, S.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS - Center for Health Technology and Services Research, University of Porto, Porto, Portugal.&#xD;RISE - Health Research Network; University of Porto, Porto, Portugal.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;MASK-air, Montpellier, France.&#xD;ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.&#xD;IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University and Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy.&#xD;Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino &amp; Mauriziano Hospital, Torino, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall d&apos;Hebron &amp; ARADyAL Research Network, Barcelona, Spain.&#xD;Servico de Imunoalergologia, Hospital de Dona Estefania, Centro Hospitalar Universitario de Lisboa Central, Lisbon, Portugal.&#xD;NOVA Medical School/Comprehensive Health Research Center (CHRC), Lisbon, Portugal.&#xD;Division of Allergy/Immunology, University of South Florida, Tampa, Florida, USA.&#xD;SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Department of Medicine and Health Research Methods, Evidence &amp; Impact, McMaster University, Hamilton, ON, Canada.&#xD;Eskisehir Osmangazi University, Medical Faculty, ENT Department, Eskisehir, Turkey.&#xD;UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), Porto, Portugal.&#xD;Fundacao ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Brazil.&#xD;Department of Medicine, Surgery and Dentistry &quot;Scuola Medica Salernitana&quot;, University of Salerno, Salerno, Italy.&#xD;VIM Suresnes, UMR_0892, Pole des Maladies des Voies Respiratoires, Hopital Foch, Universite Paris-Saclay, Suresnes, France.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, Location AMC, Amsterdam, The Netherlands.&#xD;ERS President 2017-2018, 7th Resp Med Department and Asthma Center, Athens Chest Hospital, Athens, Greece.&#xD;Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;Department of Allergology and Clinical Immunology of the Kazakh National Medical University, Almaty, Kazakhstan.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Department of Clinical Immunology, ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Poltava State Medical University, Poltava, Ukraine.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;KYomed INNOV, Montpellier, France.&#xD;Scottish Centre for Respiratory Research, Cardiovascular &amp; Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, Dundee, UK.&#xD;Department of Pulmonary Medicine, CHU Sart-Tilman, and GIGA I3 Research Group, Liege, Belgium.&#xD;Allergy Unit &quot;D Kalogeromitros&quot;, 2nd Department of Dermatology and Venereology, National &amp; Kapodistrian University of Athens, &quot;Attikon&quot; University Hospital, Athens, Greece.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;IMSB, Medical Faculty, University of Cologne, and ClinCompetence Cologne GmbH, Cologne, Germany.&#xD;Rhinology Unit &amp; Smell Clinic, ENT Department, Hospital Clinic, Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.&#xD;EFA European Federation of Allergy and Airways Diseases Patients&apos; Associations, Brussels, Belgium.&#xD;Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, &quot;Santa Maria della Speranza&quot; Hospital, Battipaglia, Salerno, Italy.&#xD;Ecole Polytechnique Palaiseau, IRBA (Institut de Recherche bio-Medicale des Armees), Bretigny, France.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitario de Coimbra, and Institute of Immunology, Faculty of Medicine, University of Coimbra, and Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Department of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon, and ENT Department, Dar Al Shifa Hospital, Salmiya, Kuwait.&#xD;Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Pulmonary medicine and tuberculosis, University Hospital Brno, Brno, Czech Republic.&#xD;Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal.&#xD;UBIAir - Clinical &amp; Experimental Lung Centre, University of Beira Interior, Covilha, Portugal.&#xD;Department of Immunoallergology, Cova da Beira University Hospital Centre, Covilha, Portugal.&#xD;Department of General ORL, H&amp;NS, Medical University of Graz, ENT-University Hospital Graz, Graz, Austria.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.&#xD;Fundacion Jimenez Diaz, CIBERES, Faculty of Medicine, Autonoma University of Madrid, Madrid, Spain.&#xD;Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece, and International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland.&#xD;Institute of Clinical Medicine and Institute of Health Sciences, Medical Faculty of Vilnius University, Vilnius, Lithuania.&#xD;Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Universite Catholique de Louvain, Yvoir, Belgium.&#xD;Nova Southeastern University, Fort Lauderdale, Florida, USA.&#xD;Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Pulmonology, Celal Bayar University, Manisa, Turkey.&#xD;University Clinic of Respiratory and Allergic Diseases, Golnick, and University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia.&#xD;University Hospital Montpellier, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air((R)) real-world data</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2699-2711</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Habits</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine Antagonists/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Co-medication</style></keyword><keyword><style face="normal" font="default" size="100%">MASK-air</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">visual analogue scale</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35258105</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. METHODS: We analysed 2015-2020 MASK-air((R)) European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms (&apos;VAS Global Symptoms&apos;) and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year. RESULTS: We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median &apos;VAS Global Symptoms&apos; was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p &lt; .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H(1) -antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more. CONCLUSIONS: Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity.</style></abstract><notes><style face="normal" font="default" size="100%">Sousa-Pinto, Bernardo&#xD;Sa-Sousa, Ana&#xD;Vieira, Rafael Jose&#xD;Amaral, Rita&#xD;Klimek, Ludger&#xD;Czarlewski, Wienczyslawa&#xD;Anto, Josep M&#xD;Pfaar, Oliver&#xD;Bedbrook, Anna&#xD;Kvedariene, Violeta&#xD;Ventura, Maria Teresa&#xD;Ansotegui, Ignacio J&#xD;Bergmann, Karl-Christian&#xD;Brussino, Luisa&#xD;Canonica, G Walter&#xD;Cardona, Victoria&#xD;Carreiro-Martins, Pedro&#xD;Casale, Tomas&#xD;Cecchi, Lorenzo&#xD;Chivato, Tomas&#xD;Chu, Derek K&#xD;Cingi, Cemal&#xD;Costa, Elisio M&#xD;Cruz, Alvaro A&#xD;De Feo, Giulia&#xD;Devillier, Philippe&#xD;Fokkens, Wytske J&#xD;Gaga, Mina&#xD;Gemicioglu, Bilun&#xD;Haahtela, Tari&#xD;Ivancevich, Juan Carlos&#xD;Ispayeva, Zhanat&#xD;Jutel, Marek&#xD;Kuna, Piotr&#xD;Kaidashev, Igor&#xD;Kraxner, Helga&#xD;Larenas-Linnemann, Desiree E&#xD;Laune, Daniel&#xD;Lipworth, Brian&#xD;Louis, Renaud&#xD;Makris, Michael&#xD;Monti, Riccardo&#xD;Morais-Almeida, Mario&#xD;Mosges, Ralph&#xD;Mullol, Joaquim&#xD;Odemyr, Mikaela&#xD;Okamoto, Yoshitaka&#xD;Papadopoulos, Nikolaos G&#xD;Patella, Vincenzo&#xD;Pham-Thi, Nhan&#xD;Regateiro, Frederico S&#xD;Reitsma, Sietze&#xD;Rouadi, Philip W&#xD;Samolinski, Boleslaw&#xD;Sova, Milan&#xD;Todo-Bom, Ana&#xD;Taborda-Barata, Luis&#xD;Tomazic, Peter Valentin&#xD;Toppila-Salmi, Sanna&#xD;Sastre, Joaquin&#xD;Tsiligianni, Ioanna&#xD;Valiulis, Arunas&#xD;Vandenplas, Olivier&#xD;Wallace, Dana&#xD;Waserman, Susan&#xD;Yorgancioglu, Arzu&#xD;Zidarn, Mihaela&#xD;Zuberbier, Torsten&#xD;Fonseca, Joao A&#xD;Bousquet, Jean&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2699-2711. doi: 10.1111/all.15275. Epub 2022 Mar 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35258105</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15275</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>734</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">734</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Forkel, S.</style></author><author><style face="normal" font="default" size="100%">Schubert, S.</style></author><author><style face="normal" font="default" size="100%">Dickel, H.</style></author><author><style face="normal" font="default" size="100%">Gina, M.</style></author><author><style face="normal" font="default" size="100%">Schroder-Kraft, C.</style></author><author><style face="normal" font="default" size="100%">Vieluf, D.</style></author><author><style face="normal" font="default" size="100%">Brans, R.</style></author><author><style face="normal" font="default" size="100%">Kreft, B.</style></author><author><style face="normal" font="default" size="100%">Wurpts, G.</style></author><author><style face="normal" font="default" size="100%">Geier, J.</style></author><author><style face="normal" font="default" size="100%">Buhl, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Venereology and Allergology, University Medical Center Gottingen, Gottingen, Germany.&#xD;Information Network of Departments of Dermatology, Institute at the University Medical Center Gottingen, Gottingen, Germany.&#xD;Department of Dermatology, Venereology and Allergology, St. Josef Hospital, University Medical Center of the Ruhr University Bochum (UK RUB), Bochum, Germany.&#xD;Department of Occupational Dermatology, BG Hospital Falkenstein, Falkenstein, Germany.&#xD;Institute for Interdisciplinary Dermatological Prevention and Rehabilitation (iDerm), BG Hospital Hamburg, Hamburg, Germany.&#xD;Department of Allergology, Photodermatology and Occupational Dermatology, Dermatologikum Hamburg, Hamburg, Germany.&#xD;Institute for Interdisciplinary Dermatological Prevention and Rehabilitation (iDerm) at the University of Osnabruck, Osnabruck, Germany.&#xD;Department of Dermatology, Environmental Medicine and Health Theory, University of Osnabruck, Osnabruck, Germany.&#xD;Lower Saxony Institute of Occupational Dermatology, University of Osnabruck, Osnabruck, Germany.&#xD;Department of Dermatology, Venereology and Allergology, University Medical Center Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.&#xD;Department of Dermatology, Venereology and Allergology, University Medical Center Aachen, Aachen, Germany.&#xD;Lower Saxony Institute of Occupational Dermatology, University of Gottingen, Gottingen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The benefit of late readings in patch testing depends both on allergen and patient characteristics</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1477-1485</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/10/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Patch Tests/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">day 7 reading</style></keyword><keyword><style face="normal" font="default" size="100%">late patch test reaction</style></keyword><keyword><style face="normal" font="default" size="100%">reaction pattern</style></keyword><keyword><style face="normal" font="default" size="100%">sodium lauryl sulfate</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34687560</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Patch test (PT) readings are recommended after 48 h and 72 h (D3). An additional day 7 (D7) reading has been suggested by some, although data on efficient patient selection are scarce. We investigated positive D7 reactions regarding (i) allergens in the baseline series and additional PT series of the German Contact Dermatitis Research Group (DKG) and (ii) characteristics of the patients tested. METHODS: Retrospective, multicentre analysis of 190 allergens derived from 17 DKG test series in 4687 patients with an additional D7 reading. Patients were patch tested with the baseline series and additional series, if required. Occurrence of novel D7 reactions as well as increasing skin reactions from D3 to D7 was analysed separately. RESULTS: Depending on the allergen tested, waiving D7 readings would have missed 4.4-26.8% of positive PT results. Patch test series with the highest number of novel D7 reactions were baseline series, metal series, and leather/shoe series. New positive reactions on D7 were associated with age over 50 years and with a negative irritant control containing sodium lauryl sulphate. Of note, application of the PT allergens for 48 h instead of 24 h was positively associated with late PT reactions. CONCLUSION: Within the most frequently tested allergens, without late readings, on average 11.7% of sensitizations would have been missed. Novel late reacting allergens were identified. This study comprehensively dissects patient-, allergen- and test-dependent parameters in support for D7 readings. We propose to always consider late readings individually based on effort-benefit considerations.</style></abstract><notes><style face="normal" font="default" size="100%">Forkel, Susann&#xD;Schubert, Steffen&#xD;Dickel, Heinrich&#xD;Gina, Michal&#xD;Schroder-Kraft, Claudia&#xD;Vieluf, Dieter&#xD;Brans, Richard&#xD;Kreft, Burkhard&#xD;Wurpts, Gerda&#xD;Geier, Johannes&#xD;Buhl, Timo&#xD;eng&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1477-1485. doi: 10.1111/all.15149. Epub 2021 Oct 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34687560</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15149</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1238</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1238</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kavanagh, J. E.</style></author><author><style face="normal" font="default" size="100%">Hearn, A. P.</style></author><author><style face="normal" font="default" size="100%">d&apos;Ancona, G.</style></author><author><style face="normal" font="default" size="100%">Dhariwal, J.</style></author><author><style face="normal" font="default" size="100%">Roxas, C.</style></author><author><style face="normal" font="default" size="100%">Green, L.</style></author><author><style face="normal" font="default" size="100%">Thomson, L.</style></author><author><style face="normal" font="default" size="100%">Fernandes, M.</style></author><author><style face="normal" font="default" size="100%">Kent, B. D.</style></author><author><style face="normal" font="default" size="100%">Nanzer, A. M.</style></author><author><style face="normal" font="default" size="100%">Jackson, D. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Guy&apos;s Severe Asthma Centre, Guy&apos;s Hospital, Guy&apos;s &amp; St Thomas&apos; NHS Trust, London, UK.&#xD;School of Immunology &amp; Microbial Sciences, King&apos;s College London, London, UK.&#xD;Department of Respiratory Medicine, St James&apos; Hospital, Dublin, Ireland.&#xD;School of Medicine, Trinity College Dublin, Dublin, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1890-1893</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33300186</style></accession-num><notes><style face="normal" font="default" size="100%">Kavanagh, Joanne E&#xD;Hearn, Andrew P&#xD;d&apos;Ancona, Grainne&#xD;Dhariwal, Jaideep&#xD;Roxas, Cris&#xD;Green, Linda&#xD;Thomson, Louise&#xD;Fernandes, Mariana&#xD;Kent, Brian D&#xD;Nanzer, Alexandra M&#xD;Jackson, David J&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1890-1893. doi: 10.1111/all.14693. Epub 2020 Dec 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33300186</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14693</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1005</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1005</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Harrison, T. W.</style></author><author><style face="normal" font="default" size="100%">Chanez, P.</style></author><author><style face="normal" font="default" size="100%">Menzella, F.</style></author><author><style face="normal" font="default" size="100%">Louis, R.</style></author><author><style face="normal" font="default" size="100%">Cosio, B. G.</style></author><author><style face="normal" font="default" size="100%">Lugogo, N. L.</style></author><author><style face="normal" font="default" size="100%">Mohan, A.</style></author><author><style face="normal" font="default" size="100%">Burden, A.</style></author><author><style face="normal" font="default" size="100%">Garcia Gil, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;IRCCS Humanitas Research Hospital, Personalized Medicine, Asthma and Allergy, Milan, Italy.&#xD;Respiratory Research Unit, Nottingham NIHR BRC, University of Nottingham, Nottingham City Hospital, Nottingham, UK.&#xD;Department of Respiratory CIC Nord INSERMINRAE C2VN, Aix Marseille University, Marseille, France.&#xD;Pneumology Unit, Azienda USL di Reggio Emilia-IRCCS, Reggio Emilia, Italy.&#xD;University and CHU of Liege, Liege, Belgium.&#xD;Hospital Son Espases-IdISBa and Ciberes, Palma de Mallorca, Spain.&#xD;University of Michigan Medical Center, Ann Arbor, Michigan, USA.&#xD;East Carolina University Brody School of Medicine, Greenville, North Carolina, USA.&#xD;AstraZeneca, Cambridge, UK.&#xD;AstraZeneca, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">150-161</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/05/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/chemically induced/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Eosinophilia/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33978983</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Clinically meaningful improvement in the Sino-Nasal Outcome Test-22 (SNOT-22) was observed in patients with severe, eosinophilic asthma, and nasal polyposis (NP) treated with benralizumab in the ANDHI trial. A post hoc assessment of the effects of benralizumab on SNOT-22 response and asthma efficacy measures in these patients was conducted for further characterization of the efficacy and safety of benralizumab for patients with severe asthma and NP. METHODS: Adults with severe, eosinophilic asthma who had experienced &gt;/=2 prior-year exacerbations despite high-dosage inhaled corticosteroid plus additional controller[s] were randomized to 24 weeks of benralizumab or placebo. Patients with physician-diagnosed chronic rhinosinusitis with NP of any severity ongoing at baseline who consented to participate were included in the current ANDHI NP substudy population. Effect on NP symptoms was assessed by the SNOT-22, with an improvement of at least 8.9 defined as clinically significant (responder). Effects on chronic asthma outcomes were assessed by means of annualized asthma exacerbation rate (AER), St. George&apos;s Respiratory Questionnaire (SGRQ) total score, forced expiratory volume in one second (FEV(1) ), and Asthma Control Questionnaire-6 (ACQ-6). All p-values were nominal. RESULTS: Of the ANDHI population (n = 656), 23% (n = 153) participated in the NP substudy (n = 96 benralizumab; n = 57 placebo). Patients were 50% female, with mean age of 53 years, had prior-year AER = 3.3; mean pre-bronchodilator FEV(1) = 55% predicted; and median blood eosinophil count ​= 510 cells/microl. For patients with high baseline SNOT-22 scores (&gt;30), benralizumab treatment improved symptoms of NP as measured by SNOT-22 from baseline to Week 24 compared with placebo (Week 24: -10.44 [p = .0176]). Percentage of responders to SNOT-22 was greater for benralizumab vs. placebo (71.3% vs. 45.5%; p = .0036), and effect was enhanced for patients with high baseline SNOT-22 scores (&gt;30). A 69% reduction vs. placebo in annualized AER (0.77 vs. 2.47; p &lt; .0001) and greater clinically meaningful improvements from baseline in SGRQ total score (-16.7), FEV(1) (+0.32 L), and ACQ-6 (-0.88) were observed (p &lt; .0001). Benralizumab was well-tolerated. Frequency of adverse events (AEs) was similar for benralizumab (76.0%) and placebo (73.7%) groups. Most common AEs (frequency &gt;/=5%) reported at a greater frequency in benralizumab vs. placebo included headache, sinusitis, pyrexia, and influenza. CONCLUSIONS: These substudy data from ANDHI demonstrated the efficacy profile of benralizumab for patients with severe, eosinophilic asthma and NP, with improvement in SNOT-22 and asthma outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Canonica, Giorgio Walter&#xD;Harrison, Tim W&#xD;Chanez, Pascal&#xD;Menzella, Francesco&#xD;Louis, Renaud&#xD;Cosio, Borja G&#xD;Lugogo, Njira L&#xD;Mohan, Arjun&#xD;Burden, Annie&#xD;Garcia Gil, Esther&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):150-161. doi: 10.1111/all.14902. Epub 2021 Jun 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33978983</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14902</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2545</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2545</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gil-Martinez, M.</style></author><author><style face="normal" font="default" size="100%">Rodrigo-Munoz, J. M.</style></author><author><style face="normal" font="default" size="100%">Lorente-Sorolla, C.</style></author><author><style face="normal" font="default" size="100%">de Castro, Z. G.</style></author><author><style face="normal" font="default" size="100%">Minguez, P.</style></author><author><style face="normal" font="default" size="100%">Canas, J. A.</style></author><author><style face="normal" font="default" size="100%">Valverde-Monge, M.</style></author><author><style face="normal" font="default" size="100%">Bernaola, J.</style></author><author><style face="normal" font="default" size="100%">Pinillos-Robles, E. J.</style></author><author><style face="normal" font="default" size="100%">Betancor, D.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Nieto, M.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Nieto, M. J.</style></author><author><style face="normal" font="default" size="100%">Del Pozo, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunoallergy Laboratory, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD, UAM), Madrid, Spain.&#xD;CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.&#xD;Department of Genetics, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD, UAM), Madrid, Spain.&#xD;Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.&#xD;Bioinformatics Unit, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD, UAM), Madrid, Spain.&#xD;Allergy Department, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.&#xD;Pulmonology Unit, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.&#xD;Hospital Universitario General de Villalba, Madrid, Spain.&#xD;Universidad Autonoma de Madrid, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2551-2553</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/06/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/drug effects/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Cell Degranulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">benralizumab</style></keyword><keyword><style face="normal" font="default" size="100%">immunology</style></keyword><keyword><style face="normal" font="default" size="100%">severe eosinophilic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38841822</style></accession-num><notes><style face="normal" font="default" size="100%">Gil-Martinez, Marta&#xD;Rodrigo-Munoz, Jose Manuel&#xD;Lorente-Sorolla, Clara&#xD;de Castro, Zahara Garcia&#xD;Minguez, Pablo&#xD;Canas, Jose Antonio&#xD;Valverde-Monge, Marcela&#xD;Bernaola, Jaime&#xD;Pinillos-Robles, Erwin Javier&#xD;Betancor, Diana&#xD;Fernandez-Nieto, Mar&#xD;Sastre, Joaquin&#xD;Rodriguez-Nieto, Maria Jesus&#xD;Del Pozo, Victoria&#xD;eng&#xD;ISCIII - Instituto de Salud Carlos III and co-funded by the European Union, FIS (Fondo de Investigacion Sanitaria - Spanish Health Research Fund) grants PI21/00896 and FI19/00067; Miguel Servet Program (CP23/00017); CIBER de Enfermedades Respiratorias (CIBERES); BASEAS STUDY (Basophils in Eosinophilic Asthma) Study Code ESR-20-20764 AstraZeneca Farmaceutica Spain, S.A.; and FEDER funds (Fondo Europeo de Desarrollo Regional)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2551-2553. doi: 10.1111/all.16190. Epub 2024 Jun 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38841822</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16190</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1090</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1090</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hirai, K.</style></author><author><style face="normal" font="default" size="100%">Uehara, S.</style></author><author><style face="normal" font="default" size="100%">Shirai, T.</style></author><author><style face="normal" font="default" size="100%">Rachi, Y.</style></author><author><style face="normal" font="default" size="100%">Kimura, T.</style></author><author><style face="normal" font="default" size="100%">Akamatsu, T.</style></author><author><style face="normal" font="default" size="100%">Itoh, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Pharmacology &amp; Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.&#xD;Laboratory of Clinical Pharmacogenomics, Shizuoka General Hospital, Shizuoka, Japan.&#xD;Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Benralizumab restores gene and microRNA expression involved in steroid sensitivity in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2589-2592</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Steroids/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">benralizumab</style></keyword><keyword><style face="normal" font="default" size="100%">glucocorticoids</style></keyword><keyword><style face="normal" font="default" size="100%">microRNAs</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33738833</style></accession-num><notes><style face="normal" font="default" size="100%">Hirai, Keita&#xD;Uehara, Sekiko&#xD;Shirai, Toshihiro&#xD;Rachi, Yuuka&#xD;Kimura, Tomoki&#xD;Akamatsu, Taisuke&#xD;Itoh, Kunihiko&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2589-2592. doi: 10.1111/all.14819. Epub 2021 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33738833</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14819</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>21</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">21</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ahuja, M.</style></author><author><style face="normal" font="default" size="100%">Dorr, A.</style></author><author><style face="normal" font="default" size="100%">Bode, E.</style></author><author><style face="normal" font="default" size="100%">Boulton, A. P. R.</style></author><author><style face="normal" font="default" size="100%">Buckland, M.</style></author><author><style face="normal" font="default" size="100%">Chee, S.</style></author><author><style face="normal" font="default" size="100%">Dalley, C.</style></author><author><style face="normal" font="default" size="100%">Denman, S.</style></author><author><style face="normal" font="default" size="100%">Ekbote, A.</style></author><author><style face="normal" font="default" size="100%">Elkhalifa, S.</style></author><author><style face="normal" font="default" size="100%">El-Shanawany, T.</style></author><author><style face="normal" font="default" size="100%">Eren, E.</style></author><author><style face="normal" font="default" size="100%">Herwadkar, A.</style></author><author><style face="normal" font="default" size="100%">Garcez, T.</style></author><author><style face="normal" font="default" size="100%">Ghanta, H.</style></author><author><style face="normal" font="default" size="100%">Grammatikos, A.</style></author><author><style face="normal" font="default" size="100%">Grigoriadou, S.</style></author><author><style face="normal" font="default" size="100%">Jain, R.</style></author><author><style face="normal" font="default" size="100%">Lorenzo, L.</style></author><author><style face="normal" font="default" size="100%">Manson, A.</style></author><author><style face="normal" font="default" size="100%">Moon, E.</style></author><author><style face="normal" font="default" size="100%">Murng, S.</style></author><author><style face="normal" font="default" size="100%">Murphy, A.</style></author><author><style face="normal" font="default" size="100%">Mutlu, L.</style></author><author><style face="normal" font="default" size="100%">Peters, N.</style></author><author><style face="normal" font="default" size="100%">Sooriyakumar, K.</style></author><author><style face="normal" font="default" size="100%">Stroud, C.</style></author><author><style face="normal" font="default" size="100%">Townsend, K.</style></author><author><style face="normal" font="default" size="100%">Yellon, R. L.</style></author><author><style face="normal" font="default" size="100%">Yong, P.</style></author><author><style face="normal" font="default" size="100%">Kiani-Alikhan, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Royal Victoria Infirmary, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.&#xD;Barts Health NHS Trust, London, UK.&#xD;Leeds Teaching Hospitals, NHFT, Leeds, UK.&#xD;Cambridge University Hospitals NHSFT, Cambridge, UK.&#xD;Manchester University NHS Foundation Trust, Manchester, UK.&#xD;Gloucestershire Hospitals NHSFT, Gloucester, UK.&#xD;Leeds Teaching Hospitals, NHSF, Leeds, UK.&#xD;University Hospitals Birmingham NHSFT, Birmingham, UK.&#xD;Cardiff and Vale UHB, Cardiff, UK.&#xD;University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Northern Care Alliance NHS Foundation Trust, Manchester, UK.&#xD;North Bristol Hospitals NHSFT, Bristol, UK.&#xD;Oxford University Hospitals, Oxford, UK.&#xD;St Helier University Hospitals, Carshalton, Morden, UK.&#xD;Newcastle upon Tyne Hospitals NHSFT, Newcastle upon Tyne, UK.&#xD;Frimley Health NHSFT, Frimley, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Berotralstat for the prophylaxis of hereditary angioedema-Real-world evidence data from the United Kingdom</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1380-1383</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/drug therapy/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrazoles/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedema/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36609839</style></accession-num><notes><style face="normal" font="default" size="100%">Ahuja, Manisha&#xD;Dorr, Anthony&#xD;Bode, Eniola&#xD;Boulton, Anne P R&#xD;Buckland, Matthew&#xD;Chee, Samuel&#xD;Dalley, Claire&#xD;Denman, Sarah&#xD;Ekbote, Anjali&#xD;Elkhalifa, Shuayb&#xD;El-Shanawany, Tariq&#xD;Eren, Efrem&#xD;Herwadkar, Archana&#xD;Garcez, Tomaz&#xD;Ghanta, Harichandana&#xD;Grammatikos, Alexandros&#xD;Grigoriadou, Sofia&#xD;Jain, Rashmi&#xD;Lorenzo, Lorena&#xD;Manson, Ania&#xD;Moon, Emily&#xD;Murng, Sai&#xD;Murphy, Aveen&#xD;Mutlu, Leman&#xD;Peters, Nicholas&#xD;Sooriyakumar, Kavitha&#xD;Stroud, Catherine&#xD;Townsend, Katie&#xD;Yellon, Robert L&#xD;Yong, Patrick&#xD;Kiani-Alikhan, Sorena&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1380-1383. doi: 10.1111/all.15641. Epub 2023 Jan 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36609839</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15641</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>652</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">652</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cabrera, A.</style></author><author><style face="normal" font="default" size="100%">Foo, A. C. Y.</style></author><author><style face="normal" font="default" size="100%">Fitzgerald, M. C.</style></author><author><style face="normal" font="default" size="100%">Mueller, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemistry, Duke University, Durham, North Carolina, USA.&#xD;Genome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, Durham, North Carolina, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bet v 1 and other birch allergens are more resistant to proteolysis and more abundant than other birch pollen proteins</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1307-1309</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">*Betula</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Proteolysis</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34995370</style></accession-num><notes><style face="normal" font="default" size="100%">Cabrera, Aurora&#xD;Foo, Alexander C Y&#xD;Fitzgerald, Michael C&#xD;Mueller, Geoffrey A&#xD;eng&#xD;Z01-ES102906/ES/NIEHS NIH HHS/&#xD;R01GM134716/GM/NIGMS NIH HHS/&#xD;R01 GM134716/GM/NIGMS NIH HHS/&#xD;Z99 ES999999/ImNIH/Intramural NIH HHS/&#xD;ZIA ES102906/ImNIH/Intramural NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, N.I.H., Intramural&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1307-1309. doi: 10.1111/all.15209. Epub 2022 Jan 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34995370</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9132243</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15209</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>852</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">852</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hufnagl, K.</style></author><author><style face="normal" font="default" size="100%">Kromp, L.</style></author><author><style face="normal" font="default" size="100%">Bianchini, R.</style></author><author><style face="normal" font="default" size="100%">Afify, S. M.</style></author><author><style face="normal" font="default" size="100%">Wiederstein, M.</style></author><author><style face="normal" font="default" size="100%">Redegeld, F. A.</style></author><author><style face="normal" font="default" size="100%">Zuvalova, I.</style></author><author><style face="normal" font="default" size="100%">Dvorak, Z.</style></author><author><style face="normal" font="default" size="100%">Hofstetter, G.</style></author><author><style face="normal" font="default" size="100%">Roth-Walter, F.</style></author><author><style face="normal" font="default" size="100%">Pacios, L. F.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Comparative Medicine, The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna, University of Vienna, Vienna, Austria.&#xD;Laboratory Medicine and Immunology Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt.&#xD;Department of Biosciences, Center of Applied Molecular Engineering, University of Salzburg, Salzburg, Austria.&#xD;Division of Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands.&#xD;Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Olomouc, Czech Republic.&#xD;Center for Plant Biotechnology and Genomics and Department of Biotechnology-Vegetal Biology, ETSIAAB, Technical University of Madrid, Madrid, Spain.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, Vienna, Austria.&#xD;Biomedical Int. R+D GmbH, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bet v 1 from birch pollen is a hypoallergen with vitamin D3 in the pocket</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3801-3804</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/08/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">*Betula</style></keyword><keyword><style face="normal" font="default" size="100%">*Cholecalciferol</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Bet v 1</style></keyword><keyword><style face="normal" font="default" size="100%">birch pollen allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">lipocalin-like</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34392548</style></accession-num><notes><style face="normal" font="default" size="100%">Hufnagl, Karin&#xD;Kromp, Livia&#xD;Bianchini, Rodolfo&#xD;Afify, Sheriene Moussa&#xD;Wiederstein, Markus&#xD;Redegeld, Frank A&#xD;Zuvalova, Iveta&#xD;Dvorak, Zdenek&#xD;Hofstetter, Gerlinde&#xD;Roth-Walter, Franziska&#xD;Pacios, Luis F&#xD;Jensen-Jarolim, Erika&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3801-3804. doi: 10.1111/all.15052. Epub 2021 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34392548</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15052</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>78</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">78</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Polak, D.</style></author><author><style face="normal" font="default" size="100%">Vollmann, U.</style></author><author><style face="normal" font="default" size="100%">Grilo, J.</style></author><author><style face="normal" font="default" size="100%">Bogdanov, I. V.</style></author><author><style face="normal" font="default" size="100%">Aglas, L.</style></author><author><style face="normal" font="default" size="100%">Ovchinnikova, T. V.</style></author><author><style face="normal" font="default" size="100%">Ferreira, F.</style></author><author><style face="normal" font="default" size="100%">Bohle, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Science-Educational Center, M. M. Shemyakin &amp; Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, The Russian Academy of Sciences, Moscow, Russia.&#xD;Department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bet v 1-independent sensitization to major allergens in Fagales pollen: Evidence at the T-cell level</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">743-751</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/11/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Fagales</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides</style></keyword><keyword><style face="normal" font="default" size="100%">Epitopes, T-Lymphocyte</style></keyword><keyword><style face="normal" font="default" size="100%">Betula</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Medical University of Vienna, during the conduct of the study and personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from AllergenOnline outside the submitted work. The other authors have nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36424884</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In birch-dominated areas, allergies to pollen from trees of the order Fagales are considered to be initiated by the major birch pollen allergen Bet v 1. However, the sensitizing activity of Bet v 1-homologs in Fagales pollen might be underestimated. Allergen-specific T-cells are crucial in the sensitization process. The T-cell response to major allergens from alder, hazel, oak, hornbeam, chestnut, beech, and chestnut pollen has not yet been analyzed. Here, we characterized the cellular cross-reactivity of major allergens in Fagales pollen with Bet v 1. METHODS: T-cell-lines (TCL) were established from allergic individuals with Aln g 1, Car b 1, Ost c 1, Cor a 1, Fag s 1, Cas s 1, and Que a 1, and tested for reactivity with Bet v 1 and synthetic overlapping 12-mer peptides representing its primary sequence. Aln g 1-specific TCL was additionally tested with Aln g 1-derived peptides and all allergens. IgE-competition experiments with Aln g 1 and Bet v 1 were performed. RESULTS: T-cell-lines initiated with Fagales pollen allergens varied strongly in their reactivity with Bet v 1 and by the majority responded stronger to the original stimulus. Cross-reactivity was mostly restricted to the epitope Bet v 1(142-153) . No distinct cross-reactivity of Aln g 1-specific T-cells with Bet v 1 was detected. Among 22 T-cell epitopes, Aln g 1 contained two immunodominant epitopes. Bet v 1 inhibited IgE-binding to Aln g 1 less potently than Aln g 1 itself. CONCLUSION: The cellular cross-reactivity of major Fagales pollen allergens with Bet v 1 was unincisive, particularly for Aln g 1, most akin to Bet v 1. Our results indicate that humoral and cellular responses to these allergens are not predominantly based on cross-reactivity with the major birch pollen allergen but suggest a Bet v 1-independent sensitization in individuals from birch tree-dominated areas.</style></abstract><notes><style face="normal" font="default" size="100%">Polak, Dominika&#xD;Vollmann, Ute&#xD;Grilo, Joao&#xD;Bogdanov, Ivan V&#xD;Aglas, Lorenz&#xD;Ovchinnikova, Tatiana V&#xD;Ferreira, Fatima&#xD;Bohle, Barbara&#xD;eng&#xD;P 32953/FWF_/Austrian Science Fund FWF/Austria&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):743-751. doi: 10.1111/all.15594. Epub 2022 Dec 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36424884</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11497339</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15594</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2165</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2165</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, C.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Schulke, S.</style></author><author><style face="normal" font="default" size="100%">Nishio, S.</style></author><author><style face="normal" font="default" size="100%">Guo, Y.</style></author><author><style face="normal" font="default" size="100%">Rainer, H.</style></author><author><style face="normal" font="default" size="100%">Maren, K.</style></author><author><style face="normal" font="default" size="100%">Cheng, T. Y.</style></author><author><style face="normal" font="default" size="100%">Nochi, T.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author><author><style face="normal" font="default" size="100%">Scheurer, S.</style></author><author><style face="normal" font="default" size="100%">Matsuda, T.</style></author><author><style face="normal" font="default" size="100%">Toda, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Food and Biomolecular Science, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan.&#xD;Molecular Allergology, Paul-Ehrlich-Institut, Langen, Germany.&#xD;Faculty of Food and Agricultural Sciences, Institute of Fermentation Sciences (IFeS), Fukushima University, Fukushima, Japan.&#xD;Laboratory of Animal Functional Morphology, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">beta-1,3-glucan, but not beta-1,3/1,6-glucan, exacerbates experimental food allergy, while both increase IgA induction</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">503-506</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/08/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Glucans</style></keyword><keyword><style face="normal" font="default" size="100%">*beta-Glucans/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin A</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37565258</style></accession-num><notes><style face="normal" font="default" size="100%">He, Chaoqi&#xD;Liu, Yunhui&#xD;Schulke, Stefan&#xD;Nishio, Shunsuke&#xD;Guo, Yingnan&#xD;Rainer, Hannah&#xD;Maren, Krause&#xD;Cheng, Ting-Yu&#xD;Nochi, Tomonori&#xD;Vieths, Stefan&#xD;Scheurer, Stephan&#xD;Matsuda, Tsukasa&#xD;Toda, Masako&#xD;eng&#xD;Japan Society for the Promotion of Science/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):503-506. doi: 10.1111/all.15841. Epub 2023 Aug 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37565258</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15841</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1139</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1139</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sturm, G. J.</style></author><author><style face="normal" font="default" size="100%">Herzog, S. A.</style></author><author><style face="normal" font="default" size="100%">Aberer, W.</style></author><author><style face="normal" font="default" size="100%">Alfaya Arias, T.</style></author><author><style face="normal" font="default" size="100%">Antolin-Amerigo, D.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Boni, E.</style></author><author><style face="normal" font="default" size="100%">Bozek, A.</style></author><author><style face="normal" font="default" size="100%">Chelminska, M.</style></author><author><style face="normal" font="default" size="100%">Ernst, B.</style></author><author><style face="normal" font="default" size="100%">Frelih, N.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author><author><style face="normal" font="default" size="100%">Hawranek, T.</style></author><author><style face="normal" font="default" size="100%">Hoetzenecker, W.</style></author><author><style face="normal" font="default" size="100%">Jimenez Blanco, A.</style></author><author><style face="normal" font="default" size="100%">Kita, K.</style></author><author><style face="normal" font="default" size="100%">Kendirlinan, R.</style></author><author><style face="normal" font="default" size="100%">Kosnik, M.</style></author><author><style face="normal" font="default" size="100%">Laipold, K.</style></author><author><style face="normal" font="default" size="100%">Lang, R.</style></author><author><style face="normal" font="default" size="100%">Marchi, F.</style></author><author><style face="normal" font="default" size="100%">Mauro, M.</style></author><author><style face="normal" font="default" size="100%">Nittner-Marszalska, M.</style></author><author><style face="normal" font="default" size="100%">Poziomkowska-Gesicka, I.</style></author><author><style face="normal" font="default" size="100%">Pravettoni, V.</style></author><author><style face="normal" font="default" size="100%">Preziosi, D.</style></author><author><style face="normal" font="default" size="100%">Quercia, O.</style></author><author><style face="normal" font="default" size="100%">Reider, N.</style></author><author><style face="normal" font="default" size="100%">Rosiek-Biegus, M.</style></author><author><style face="normal" font="default" size="100%">Ruiz-Leon, B.</style></author><author><style face="normal" font="default" size="100%">Schrautzer, C.</style></author><author><style face="normal" font="default" size="100%">Serrano, P.</style></author><author><style face="normal" font="default" size="100%">Sin, A.</style></author><author><style face="normal" font="default" size="100%">Sin, B. A.</style></author><author><style face="normal" font="default" size="100%">Stoevesandt, J.</style></author><author><style face="normal" font="default" size="100%">Trautmann, A.</style></author><author><style face="normal" font="default" size="100%">Vachova, M.</style></author><author><style face="normal" font="default" size="100%">Arzt-Gradwohl, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.&#xD;Center for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine &amp; Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.&#xD;Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz, Graz, Austria.&#xD;Allergy Unit, Hospital General Universitario de Ciudad Real &amp; Hospital Universitario Fundacion Alcorcon, Madrid, Spain.&#xD;Servicio de Enfermedades del Sistema Inmune-Alergia, Hospital Universitario Principe de Asturias, Departamento de Medicina y EspecialidadesMedicas, Universidad de Alcala, Madrid, Spain.&#xD;Servicio de Alergia, Hospital Universitario Ramon y Cajal (IRYCIS, Madrid, Spain.&#xD;Allergy Unit, Verona General Hospital, Verona, Italy.&#xD;Laboratorio Unico Metropolitano, Maggiore Hospital, Bologna, Italy.&#xD;Clinical Department of Internal Diseases, Dermatology, and Allergology, Medical University of Silesia, Zabrze, Poland.&#xD;Allergology Department, Medical University of Gdansk, Gdansk, Poland.&#xD;Department of Dermatology, General Hospital Ordensklinikum Linz GmbH Elisabethinen, Linz, Austria.&#xD;University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.&#xD;Department of Internal Medicine, Allergy, and Clinical Immunology, Silesian University of Medicine, Katowice, Poland.&#xD;Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Department of Dermatology and Allergology, Paracelsus Medical University Salzburg, Salzburg, Austria.&#xD;Department of Dermatology, Kepler University Hospital and Medical Faculty, Johannes Kepler University, Linz, Austria.&#xD;Allergy Unit, Hospital Central de la Cruz Roja, Faculty of Medicine, Alfonso X El Sabio University, ARADyAL, Madrid, Spain.&#xD;Department of Pulmonary Diseases, Division of Immunology and Allergy, Faculty of Medicine, Ankara University, Ankara, Turkey.&#xD;University Clinic of Respiratory and Allergic Diseases, Golnik and Medical Faculty Ljubljana, Ljubljana, Slovenia.&#xD;SD Allergologia Clinica, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.&#xD;Allergy Unit, Sant&apos;Anna Hospital, Como, Italy.&#xD;Department of Internal Diseases, Pulmonology and Allergology, Medical University of Wroclaw, Wroclaw, Poland.&#xD;Clinical Allergology Department, Pomeranian Medical University, Szczecin, Poland.&#xD;UOC General Medicine, Immunology and Allergology, IRCCS Foundation Ca, Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;High Specialization Unit of Allergology, Hospital of Faenza, AUSL (Local Health Unit) of Romagna, Romagna, Italy.&#xD;Department of Dermatology, Venereology, and Allergology, Medical University of Innsbruck, Innsbruck, Austria.&#xD;Maimonides Biomedical Research Institute of Cordoba (IMIBIC, Avenida Menendez Pidal S/N, Cordoba, Spain.&#xD;9Unidad de GestionClinica de Inmunoalergia &amp; ARADyAL Research Network, Reina Sofia University Hospital, Cordoba, Spain.&#xD;Department of Internal Medicine, Division of Allergy and Immunology, Medical Faculty, Ege University, Izmir, Turkey.&#xD;Department of Dermatology and Allergy, University Hospital Wurzburg, Wurzburg, Germany.&#xD;Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.</style></auth-address><titles><title><style face="normal" font="default" size="100%">beta-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2166-2176</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Bee Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Insect Bites and Stings</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">ACE inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">adverse event</style></keyword><keyword><style face="normal" font="default" size="100%">beta-blocker</style></keyword><keyword><style face="normal" font="default" size="100%">systemic insect sting reaction</style></keyword><keyword><style face="normal" font="default" size="100%">venom immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Allergopharma, personal fees from Novartis, personal fees from Mylan,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Stallergenes, personal fees from Bencard, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. Dr. Herzog has nothing to disclose. Dr. Aberer has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr. Alfaya reports personal fees from ALK-Abello, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. Dr. Antolin-Amerigo reports personal fees from Astra-Zeneca, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from GSK, personal fees from MSD, personal fees from Novartis, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">MEDA-Mylan, personal fees from FAES, personal fees from Leti, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genzyme, personal fees from ALK-Abello, outside the submitted work. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Bonadonna has nothing to disclose. Dr. Boni has nothing to disclose. Dr. Bozek</style></keyword><keyword><style face="normal" font="default" size="100%">has nothing to disclose. Dr. Chelminska has nothing to disclose. Dr. Ernst has</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose. Dr. Frelih has nothing to disclose. Dr. Gawlik has nothing</style></keyword><keyword><style face="normal" font="default" size="100%">to disclose. Dr. Gelincik has nothing to disclose. Dr. Hawranek reports personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from ALK-Abello, personal fees from Novartis, personal fees from Takeda,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Bencard, personal fees from Lofarma, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. Dr. Hoetzenecker has nothing to disclose. Dr. Jimenez Blanco has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr. Kita has nothing to disclose. Dr. Kendirlinan has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr. Kosnik has nothing to disclose. Dr. Laipold has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr. Lang reports non-financial support from Bencard, non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support from ALK-Abello, non-financial support from Thermo Fisher Scientific,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. Dr. Marchi has nothing to disclose. Dr. Mauro has</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose. Dr. Nittner-Marszalska has nothing to disclose. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Poziomkowska-Gesicka has nothing to disclose. Dr. Pravettoni has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr. Preziosi has nothing to disclose. Dr. Quercia has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr. Reider has nothing to disclose. Dr. Rosiek-Biegus has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr. Ruiz-Leon has nothing to disclose. Dr. Schrautzer has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr. Serrano has nothing to disclose. Dr. Sin A. has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr. Sin B.A. has nothing to disclose. Dr. Stoevesandt has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr. Trautmann reports personal fees from ALK-Abello, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. Dr. Vachova has nothing to disclose. Dr. Arzt-Gradwohl has</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33605465</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: There is controversy whether taking beta-blockers or ACE inhibitors (ACEI) is a risk factor for more severe systemic insect sting reactions (SSR) and whether it increases the number or severity of adverse events (AE) during venom immunotherapy (VIT). METHODS: In this open, prospective, observational, multicenter trial, we recruited patients with a history of a SSR and indication for VIT. The primary objective of this study was to evaluate whether patients taking beta-blockers or ACEI show more systemic AE during VIT compared to patients without such treatment. RESULTS: In total, 1,425 patients were enrolled and VIT was performed in 1,342 patients. Of all patients included, 388 (27.2%) took antihypertensive (AHT) drugs (10.4% took beta-blockers, 11.9% ACEI, 5.0% beta-blockers and ACEI). Only 5.6% of patients under AHT treatment experienced systemic AE during VIT as compared with 7.4% of patients without these drugs (OR: 0.74, 95% CI: 0.43-1.22, p = 0.25). The severity of the initial sting reaction was not affected by the intake of beta-blockers or ACEI (OR: 1.14, 95% CI: 0.89-1.46, p = 0.29). In total, 210 (17.7%) patients were re-stung during VIT and 191 (91.0%) tolerated the sting without systemic symptoms. Of the 19 patients with VIT treatment failure, 4 took beta-blockers, none an ACEI. CONCLUSIONS: This trial provides robust evidence that taking beta-blockers or ACEI does neither increase the frequency of systemic AE during VIT nor aggravate SSR. Moreover, results suggest that these drugs do not impair effectiveness of VIT. (Funded by Medical University of Graz, Austria; Clinicaltrials.gov number, NCT04269629).</style></abstract><notes><style face="normal" font="default" size="100%">Sturm, Gunter Johannes&#xD;Herzog, Sereina Annik&#xD;Aberer, Werner&#xD;Alfaya Arias, Teresa&#xD;Antolin-Amerigo, Dario&#xD;Bonadonna, Patrizia&#xD;Boni, Elisa&#xD;Bozek, Andrzej&#xD;Chelminska, Marta&#xD;Ernst, Barbara&#xD;Frelih, Nina&#xD;Gawlik, Radoslaw&#xD;Gelincik, Asli&#xD;Hawranek, Thomas&#xD;Hoetzenecker, Wolfram&#xD;Jimenez Blanco, Aranzazu&#xD;Kita, Karolina&#xD;Kendirlinan, Resat&#xD;Kosnik, Mitja&#xD;Laipold, Karin&#xD;Lang, Roland&#xD;Marchi, Francesco&#xD;Mauro, Marina&#xD;Nittner-Marszalska, Marita&#xD;Poziomkowska-Gesicka, Iwona&#xD;Pravettoni, Valerio&#xD;Preziosi, Donatella&#xD;Quercia, Oliviero&#xD;Reider, Norbert&#xD;Rosiek-Biegus, Marta&#xD;Ruiz-Leon, Berta&#xD;Schrautzer, Christoph&#xD;Serrano, Pilar&#xD;Sin, Aytul&#xD;Sin, Betul Ayse&#xD;Stoevesandt, Johanna&#xD;Trautmann, Axel&#xD;Vachova, Martina&#xD;Arzt-Gradwohl, Lisa&#xD;eng&#xD;Clinical Trial&#xD;Multicenter Study&#xD;Observational Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2166-2176. doi: 10.1111/all.14785. Epub 2021 Mar 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33605465</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8359427</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14785</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1197</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1197</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hostrup, M.</style></author><author><style face="normal" font="default" size="100%">Jessen, S.</style></author><author><style face="normal" font="default" size="100%">Backer, V.</style></author><author><style face="normal" font="default" size="100%">Bangsbo, J.</style></author><author><style face="normal" font="default" size="100%">Jacobson, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Integrative Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of ENT and Center for Physical Activity, Rigshospitalet, Copenhagen, Denmark.&#xD;School of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Beta(2) -adrenergic agonists can enhance intense performance and muscle strength in healthy individuals</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2318-2319</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic Agonists</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Muscle Strength</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Adrenergic, beta-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33440033</style></accession-num><notes><style face="normal" font="default" size="100%">Hostrup, Morten&#xD;Jessen, Soren&#xD;Backer, Vibeke&#xD;Bangsbo, Jens&#xD;Jacobson, Glenn A&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2318-2319. doi: 10.1111/all.14735.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33440033</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14735</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>918</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">918</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lourenco, O.</style></author><author><style face="normal" font="default" size="100%">Cardoso, A.</style></author><author><style face="normal" font="default" size="100%">Monico, B.</style></author><author><style face="normal" font="default" size="100%">Gama, J. M. R.</style></author><author><style face="normal" font="default" size="100%">Neiva, H. P.</style></author><author><style face="normal" font="default" size="100%">Marinho, D. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal.&#xD;CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Centre of Mathematics and Applications (CMA-UBI), University of Beira Interior, Covilha, Portugal.&#xD;Department of Sport Sciences, University of Beira Interior, Covilha, Portugal.&#xD;Research Center in Sports Sciences, Health Sciences and Human Development, CIDESD, Covilha, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">beta2-adrenergic agonists and doping: Where do we stand?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2320-2321</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/07/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-2 Receptor Agonists/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">*Doping in Sports</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Sympathomimetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34192372</style></accession-num><notes><style face="normal" font="default" size="100%">Lourenco, Olga&#xD;Cardoso, Ana&#xD;Monico, Beatriz&#xD;Gama, Jorge M R&#xD;Neiva, Henrique P&#xD;Marinho, Daniel A&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2320-2321. doi: 10.1111/all.14830.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34192372</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14830</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1330</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1330</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cardoso, A.</style></author><author><style face="normal" font="default" size="100%">Monico, B.</style></author><author><style face="normal" font="default" size="100%">Gama, J. M. R.</style></author><author><style face="normal" font="default" size="100%">Neiva, H. P.</style></author><author><style face="normal" font="default" size="100%">Marinho, D. A.</style></author><author><style face="normal" font="default" size="100%">Lourenco, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal.&#xD;Centre of Mathematics and Applications (CMA-UBI), University of Beira Interior, Covilha, Portugal.&#xD;Department of Sport Sciences, University of Beira Interior, Covilha, Portugal.&#xD;Research Center in Sports Sciences, Health Sciences and Human Development, CIDESD, Covilha, Portugal.&#xD;CICS - UBI Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">beta2-adrenergic agonists do not improve physical performance in healthy individuals</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2201-2203</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/09/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">*Adrenergic beta-2 Receptor Agonists</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Physical Functional Performance</style></keyword><keyword><style face="normal" font="default" size="100%">doping</style></keyword><keyword><style face="normal" font="default" size="100%">performance</style></keyword><keyword><style face="normal" font="default" size="100%">sport</style></keyword><keyword><style face="normal" font="default" size="100%">beta2-agonists</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32901942</style></accession-num><notes><style face="normal" font="default" size="100%">Cardoso, Ana&#xD;Monico, Beatriz&#xD;Gama, Jorge M R&#xD;Neiva, Henrique P&#xD;Marinho, Daniel A&#xD;Lourenco, Olga&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2201-2203. doi: 10.1111/all.14588. Epub 2020 Sep 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32901942</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14588</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3209</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3209</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruiz-Sanchez, A.</style></author><author><style face="normal" font="default" size="100%">Nunez-Borque, E.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Madrid, Spain.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain.&#xD;Department of Medicine, McMaster Immunology Research Centre (MIRC), Schroeder Allergy and Immunology Research Institute (SAIRI), McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Between Healing and Harm: The Two Faces of Acetylcholine in Lung Immunity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">acetylcholine</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">immunopathology</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">nicotinic receptor alpha7</style></keyword><keyword><style face="normal" font="default" size="100%">virus infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41351461</style></accession-num><notes><style face="normal" font="default" size="100%">Ruiz-Sanchez, Alessandra&#xD;Nunez-Borque, Emilio&#xD;Jimenez-Saiz, Rodrigo&#xD;eng&#xD;POP24-11435/Weston Family Foundation/&#xD;FDM2025/Fundacion Domingo Martinez/&#xD;CNS2024-154194/Ministerio de Ciencia e Innovacion/&#xD;950.690/UAX Foundation/&#xD;PIM-011/IIS-Princesa/&#xD;CP20/00043/Instituto de Salud Carlos III/&#xD;PI22/00236/Instituto de Salud Carlos III/&#xD;PI25/00477/Instituto de Salud Carlos III/&#xD;RD24/0007/0037/Instituto de Salud Carlos III/&#xD;IND2024/BMD-33910/Comunidad de Madrid/&#xD;PEJ-2024-AI/SAL-GL-32172/Comunidad de Madrid/&#xD;Denmark&#xD;Allergy. 2025 Dec 6. doi: 10.1111/all.70185.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41351461</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70185</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3105</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3105</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meng, S.</style></author><author><style face="normal" font="default" size="100%">Berna, R.</style></author><author><style face="normal" font="default" size="100%">Takeshita, J.</style></author><author><style face="normal" font="default" size="100%">Hoffstad, O.</style></author><author><style face="normal" font="default" size="100%">Shin, D.</style></author><author><style face="normal" font="default" size="100%">Mitra, N.</style></author><author><style face="normal" font="default" size="100%">Margolis, D. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bidirectional Associations Between Seborrheic Dermatitis and Epithelial Barrier Diseases: A Retrospective Cohort Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic disease</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier theory</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory diseases</style></keyword><keyword><style face="normal" font="default" size="100%">seborrheic dermatitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41144761</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Seborrheic dermatitis (SD) is a common skin disease characterized by epithelial barrier breakdown. The epithelial barrier theory (EBT) implicates epithelial barrier disruption in the development of epithelial barrier diseases (EBDs). We hypothesized that SD is associated with an increased risk of EBDs and investigated the bidirectional association between SD and EBDs. METHODS: Retrospective cohort study of 5,083,689 patients using a large US administrative claims database from January 1, 2016, to June 30, 2022. The mean (standard deviation) follow-up was 3.25 (1.75) years with a total follow-up of over 16 million person-years. The outcomes were a diagnosis of (i) SD after an EBD and (ii) EBD after SD, analyzed using a multivariable Cox proportional hazards model (hazard ratio [95% confidence interval]). RESULTS: The risk of SD was increased after EBD diagnosis for multiple diseases, including atopic dermatitis [2.46 (2.40, 2.53)], alopecia areata [3.47 (3.24, 3.71)], contact dermatitis [1.92 (1.88, 1.96)], psoriasis [2.62 (2.54, 2.69)], rosacea [2.84 (2.78, 2.90)], hidradenitis suppurativa [1.79 (1.63, 1.97)], rhinosinusitis [1.34 (1.32, 1.35)], food allergy [1.47 (1.42, 1.54)], celiac disease [1.55 (1.43, 1.68)], ocular allergy [1.55 (1.49, 1.61)], and dry eye [1.54 (1.52, 1.56)]. The risk of EBD after SD diagnosis followed similar trends, with the largest effect estimates being psoriasis [3.52 (3.42, 3.61)], rosacea [2.85 (2.79, 2.92)], and alopecia areata [2.81 (2.61, 3.03)]. CONCLUSIONS: Our results support the EBT as a shared driver of EBD pathogenesis at not only local (e.g., skin) barriers but also at non-local sites, including the respiratory, gastrointestinal, and ocular epithelial barriers.</style></abstract><notes><style face="normal" font="default" size="100%">Meng, Sabrina&#xD;Berna, Ronald&#xD;Takeshita, Junko&#xD;Hoffstad, Ole&#xD;Shin, Daniel&#xD;Mitra, Nandita&#xD;Margolis, David J&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Oct 27. doi: 10.1111/all.70112.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41144761</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70112</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3048</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3048</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shao, H.</style></author><author><style face="normal" font="default" size="100%">Min, F.</style></author><author><style face="normal" font="default" size="100%">Bai, T.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, F.</style></author><author><style face="normal" font="default" size="100%">Li, Z.</style></author><author><style face="normal" font="default" size="100%">Di, C.</style></author><author><style face="normal" font="default" size="100%">Lin, M.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Chen, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, Jiangxi, China.&#xD;College of Food Science and Technology, Nanchang University, Nanchang, Jiangxi, China.&#xD;Jiangxi Province Key Laboratory of Food Allergy, Nanchang University, Nanchang, Jiangxi, China.&#xD;BYHEALTH Institute of Nutrition &amp; Health, Guangzhou, Guangdong, China.&#xD;Department of Dermatology, Jiangxi Provincial Children&apos;s Hospital, Nanchang, Jiangxi, China.&#xD;Sino-German Joint Research Institute, Nanchang University, Nanchang, Jiangxi, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bifidobacterium breve M-16V Alleviates Cow&apos;s Milk Allergy in a Mouse Model via Gut Microbiota-Derived Indole-3-Propionic Acid-Aryl Hydrocarbon Receptor Signaling Axis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bifidobacterium breve M-16V</style></keyword><keyword><style face="normal" font="default" size="100%">aryl hydrocarbon receptor</style></keyword><keyword><style face="normal" font="default" size="100%">cow&apos;s milk allergy</style></keyword><keyword><style face="normal" font="default" size="100%">indole-3-propionic acid</style></keyword><keyword><style face="normal" font="default" size="100%">tryptophan metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40751356</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Gut microbiota plays a crucial role in the development of food allergy (FA), and probiotic intervention is a promising therapeutic strategy targeting the gut microbiota. Previous investigations have reported that some Bifidobacterium species mitigate FA by regulating the microbial composition and metabolic functions. However, the key metabolites and potential mechanisms remain poorly understood. We aim to investigate the alleviating effect of Bifidobacterium breve (B. breve) M-16V on cow&apos;s milk allergy (CMA) and elucidate the underlying molecular mechanism. METHODS: We evaluated the mitigation effect of B. breve M-16V on CMA using a BALB/c mouse model, combined with 16S rRNA sequencing, transcriptome sequencing, and metabolomics to determine the key metabolites and explore their molecular mechanisms. RESULTS: B. breve M-16V supplementation was found to alleviate CMA symptoms, reverse Th2-biased immune response, and enhance intestinal barrier function. It was demonstrated that these positive effects of B. breve M-16V depended upon its cooperation with the original gut microbes. This contributed to promoting the expansion of tryptophan-metabolizing bacteria, regulating the tryptophan metabolism function of the host and the indole derivatives production by intestinal microbiota, especially increasing indole-3-propionic acid (IPA) level. Moreover, the results further indicated that IPA improved CMA through activating the aryl hydrocarbon receptor (AhR) signaling pathway, and consistently, the AhR activation was necessary for B. breve M-16V to alleviate CMA. CONCLUSIONS: B. breve M-16V ameliorates CMA depending on the activation of AhR signaling by an increase in microbiota-derived IPA, presenting a potential approach for the management of FA.</style></abstract><notes><style face="normal" font="default" size="100%">Shao, Huming&#xD;Min, Fangfang&#xD;Bai, Tianliang&#xD;Wang, Zhongliang&#xD;Liu, Yan&#xD;Yang, Fan&#xD;Li, Zhongxia&#xD;Di, Can&#xD;Lin, Min&#xD;Li, Xin&#xD;Chen, Hongbing&#xD;eng&#xD;Jiangxi Provincial Health Technology Project/&#xD;Jiangxi Medicine Academy of Nutrition and Health Management Cultivation Project/&#xD;Nutrition Scientific Research Foundation of BYHEALTH/&#xD;Denmark&#xD;Allergy. 2025 Aug 1. doi: 10.1111/all.16684.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40751356</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16684</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>866</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">866</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, R.</style></author><author><style face="normal" font="default" size="100%">Yuan, X.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Ma, N.</style></author><author><style face="normal" font="default" size="100%">Jiang, H.</style></author><author><style face="normal" font="default" size="100%">Tang, H.</style></author><author><style face="normal" font="default" size="100%">Xu, G.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Inflammation &amp; Allergic Diseases Research Unit, Affiliated Hospital of Southwest Medical University, Sichuan, China.&#xD;Model Animal Research Center, Nanjing University, Nanjing, China.&#xD;The School of Basic Medical Sciences, Southwest Medical University, Sichuan, China.&#xD;State Key Laboratory of Respiratory Disease for Allergy at, Shenzhen University, Shenzhen University School of Medicine, Shenzhen, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The bile acid-activated retinoic acid response in dendritic cells is involved in food allergen sensitization</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">483-498</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/08/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Bile Acids and Salts/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Chromatography, Liquid</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">*Tretinoin/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34365653</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Alteration of commensal microbiota is highly correlated with the prevalence of allergic reactions to food in the gastrointestinal tract. The mechanisms by which microbiota modulate food allergen sensitization in the mucosal site are not fully understood. METHODS: We generate DCs specific knockout of retinoic acid receptor alpha (Rara) gene mice (DC KO Rara) to evaluate food sensitization. The bile acid-activated retinoic acid response was evaluated by flow cytometry, real-time RT-PCR and Illumina transcriptome sequencing. The global effect of Abx treatment on BA profiles in the mucosal lymph tissue mLN in mice was examined by UPLC-MS analysis. RESULTS: In this study, we demonstrate that depletion of commensal gut bacteria leads to enhanced retinoic acid (RA) signaling in mucosal dendritic cells (DCs). RA signaling in DCs is required for the production of food allergen-specific IgE and IgG1. Antibiotics induced an enlarged bile acid (BA) pool, and dysregulated BA profiles contributed to enhanced RA signaling in mucosal DCs. BA-activated RA signaling promoted DC upregulation of interferon I signature, RA signature, OX40L, and PDL2, which may lead to T helper 2 differentiation of CD4+ T cells. BA-activated RA signaling involved the farnesoid X receptor and RA receptor alpha (RARa) interaction. Depletion of bile acid reduces food allergen specific IgE and IgG1 levels in mice. CONCLUSION: Our research unveils a mechanism of food sensitization modulated by BA-RA signaling in DCs, which suggests a potential new approach for the intervention of food allergic reactions.</style></abstract><notes><style face="normal" font="default" size="100%">Wu, Renlan&#xD;Yuan, Xiefang&#xD;Li, Xingjie&#xD;Ma, Ning&#xD;Jiang, Hongyu&#xD;Tang, Hongmei&#xD;Xu, Guofeng&#xD;Liu, Zhigang&#xD;Zhang, Zongde&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):483-498. doi: 10.1111/all.15039. Epub 2021 Aug 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34365653</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15039</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1577</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1577</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, R.</style></author><author><style face="normal" font="default" size="100%">Yuan, X.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Ma, N.</style></author><author><style face="normal" font="default" size="100%">Jiang, H.</style></author><author><style face="normal" font="default" size="100%">Tang, H.</style></author><author><style face="normal" font="default" size="100%">Xu, G.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Inflammation &amp; Allergic Diseases Research Unit, Affiliated Hospital of Southwest Medical University, Sichuan, China.&#xD;Model Animal Research Center, Nanjing University, Nanjing, China.&#xD;The School of Basic Medical Sciences, Southwest Medical University, Sichuan, China.&#xD;State Key Laboratory of Respiratory Disease for Allergy at, Shenzhen University, Shenzhen University School of Medicine, Shenzhen, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The bile acid-activated retinoic acid response in dendritic cells is involved in food allergen sensitization</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">483-498</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/08/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Bile Acids and Salts/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Chromatography, Liquid</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">*Tretinoin/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34365653</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Alteration of commensal microbiota is highly correlated with the prevalence of allergic reactions to food in the gastrointestinal tract. The mechanisms by which microbiota modulate food allergen sensitization in the mucosal site are not fully understood. METHODS: We generate DCs specific knockout of retinoic acid receptor alpha (Rara) gene mice (DC KO Rara) to evaluate food sensitization. The bile acid-activated retinoic acid response was evaluated by flow cytometry, real-time RT-PCR and Illumina transcriptome sequencing. The global effect of Abx treatment on BA profiles in the mucosal lymph tissue mLN in mice was examined by UPLC-MS analysis. RESULTS: In this study, we demonstrate that depletion of commensal gut bacteria leads to enhanced retinoic acid (RA) signaling in mucosal dendritic cells (DCs). RA signaling in DCs is required for the production of food allergen-specific IgE and IgG1. Antibiotics induced an enlarged bile acid (BA) pool, and dysregulated BA profiles contributed to enhanced RA signaling in mucosal DCs. BA-activated RA signaling promoted DC upregulation of interferon I signature, RA signature, OX40L, and PDL2, which may lead to T helper 2 differentiation of CD4+ T cells. BA-activated RA signaling involved the farnesoid X receptor and RA receptor alpha (RARa) interaction. Depletion of bile acid reduces food allergen specific IgE and IgG1 levels in mice. CONCLUSION: Our research unveils a mechanism of food sensitization modulated by BA-RA signaling in DCs, which suggests a potential new approach for the intervention of food allergic reactions.</style></abstract><notes><style face="normal" font="default" size="100%">Wu, Renlan&#xD;Yuan, Xiefang&#xD;Li, Xingjie&#xD;Ma, Ning&#xD;Jiang, Hongyu&#xD;Tang, Hongmei&#xD;Xu, Guofeng&#xD;Liu, Zhigang&#xD;Zhang, Zongde&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):483-498. doi: 10.1111/all.15039. Epub 2021 Aug 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34365653</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15039</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2717</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2717</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kamide, Y.</style></author><author><style face="normal" font="default" size="100%">Sonehara, K.</style></author><author><style face="normal" font="default" size="100%">Sekiya, K.</style></author><author><style face="normal" font="default" size="100%">Ueki, S.</style></author><author><style face="normal" font="default" size="100%">Nakamura, Y.</style></author><author><style face="normal" font="default" size="100%">Okada, Y.</style></author><author><style face="normal" font="default" size="100%">Taniguchi, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.&#xD;Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan.&#xD;Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.&#xD;Research Center for Immunology and Allergology, Shonan-Kamakura General Hospital, Kamakura, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bioactive Mediator Profile of Mepolizumab-Treated Eosinophilic Granulomatosis With Polyangiitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">882-885</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/11/13</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39526755</style></accession-num><notes><style face="normal" font="default" size="100%">Kamide, Yosuke&#xD;Sonehara, Kyuto&#xD;Sekiya, Kiyoshi&#xD;Ueki, Shigeharu&#xD;Nakamura, Yuto&#xD;Okada, Yukinori&#xD;Taniguchi, Masami&#xD;eng&#xD;UMIN000040163/GlaxoSmithKline/&#xD;JP22ek0410097/Japan Agency for Medical Research and Development/&#xD;22K08598/Japan Society for the Promotion of Science (JSPS) KAKENHI/&#xD;24K11593/Japan Society for the Promotion of Science (JSPS) KAKENHI/&#xD;202213003A/Ministry of Health, Labour and Welfare/&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):882-885. doi: 10.1111/all.16395. Epub 2024 Nov 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39526755</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16395</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1404</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1404</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gonzalez, T.</style></author><author><style face="normal" font="default" size="100%">Stevens, M. L.</style></author><author><style face="normal" font="default" size="100%">Baatyrbek Kyzy, A.</style></author><author><style face="normal" font="default" size="100%">Alarcon, R.</style></author><author><style face="normal" font="default" size="100%">He, H.</style></author><author><style face="normal" font="default" size="100%">Kroner, J. W.</style></author><author><style face="normal" font="default" size="100%">Spagna, D.</style></author><author><style face="normal" font="default" size="100%">Grashel, B.</style></author><author><style face="normal" font="default" size="100%">Sidler, E.</style></author><author><style face="normal" font="default" size="100%">Martin, L. J.</style></author><author><style face="normal" font="default" size="100%">Biagini Myers, J. M.</style></author><author><style face="normal" font="default" size="100%">Khurana Hershey, G. K.</style></author><author><style face="normal" font="default" size="100%">Herr, A. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunobiology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH, USA.&#xD;Division of Asthma Research, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH, USA.&#xD;Division of Human Genetics, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH, USA.&#xD;Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.&#xD;Division of Allergy and Immunology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH, USA.&#xD;Division of Infectious Diseases, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biofilm propensity of Staphylococcus aureus skin isolates is associated with increased atopic dermatitis severity and barrier dysfunction in the MPAACH pediatric cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">302-313</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Biofilms</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">*Staphylococcal Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus epidermidis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">S100a8/s100a9</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">filaggrin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32640045</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) patients are often colonized with Staphylococcus aureus, and staphylococcal biofilms have been reported on adult AD skin lesions. The commensal S epidermidis can antagonize S aureus, although its role in AD is unclear. We sought to characterize S aureus and S epidermidis colonization and biofilm propensity and determine their associations with AD severity, barrier function, and epidermal gene expression in the first US early-life cohort of children with AD, the Mechanisms of Progression of Atopic Dermatitis to Asthma in Children (MPAACH). METHODS: The biofilm propensity of staphylococcal isolates was assessed by crystal violet assays. Gene expression of filaggrin and antimicrobial alarmins S100A8 and S100A9 was measured in keratinocyte RNA extracted from skin tape strips. Staphylococcal biofilms sampled from MPAACH skin were visualized using scanning electron microscopy. RESULTS: Sixty-two percent of staphylococcal isolates (sampled from 400 subjects) formed moderate/strong biofilms. Sixty-eight percent of subjects co-colonized with both staphylococcal species exhibited strains that formed cooperative mixed-species biofilms. Scanning electron microscopy verified the presence of staphylococcal biofilms on the skin of MPAACH children. Staphylococcus aureus strains showing higher relative biofilm propensity compared with S epidermidis were associated with increased AD severity (P = .03) and increased lesional and nonlesional transepidermal water loss (P = .01, P = .03). CONCLUSIONS: Our data suggest a pathogenic role for S aureus biofilms in AD. We found that strain-level variation in staphylococcal isolates governs the interactions between S epidermidis and S aureus and that the balance between these two species, and their biofilm propensity, has important implications for AD.</style></abstract><notes><style face="normal" font="default" size="100%">Gonzalez, Tammy&#xD;Stevens, Mariana L&#xD;Baatyrbek Kyzy, Asel&#xD;Alarcon, Rosario&#xD;He, Hua&#xD;Kroner, John W&#xD;Spagna, Daniel&#xD;Grashel, Brittany&#xD;Sidler, Elaine&#xD;Martin, Lisa J&#xD;Biagini Myers, Jocelyn M&#xD;Khurana Hershey, Gurjit K&#xD;Herr, Andrew B&#xD;eng&#xD;R01 AI127392/AI/NIAID NIH HHS/&#xD;T32 GM063483/GM/NIGMS NIH HHS/&#xD;U19 AI070235/AI/NIAID NIH HHS/&#xD;UL1 TR001425/TR/NCATS NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):302-313. doi: 10.1111/all.14489. Epub 2020 Aug 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32640045</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8561741</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14489</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>338</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">338</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ghosh, D.</style></author><author><style face="normal" font="default" size="100%">Karim, R.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Singh, U.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Department of Electrical Engineering and Computer Science, University of Cincinnati College of Engineering and Applied Science, Cincinnati, Ohio, USA.&#xD;Department of Environmental &amp; Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biologic pathways for chronic spontaneous urticaria and their regulation by benralizumab</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3687-3689</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/08/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36004497</style></accession-num><notes><style face="normal" font="default" size="100%">Ghosh, Debajyoti&#xD;Karim, Rashid&#xD;Zhang, Xiang&#xD;Singh, Umesh&#xD;Bernstein, Jonathan A&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3687-3689. doi: 10.1111/all.15493. Epub 2022 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36004497</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15493</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>976</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">976</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Palmer, E.</style></author><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Moraes, T. J.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biological treatment in allergic disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2934-2937</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34028048</style></accession-num><notes><style face="normal" font="default" size="100%">Shamji, Mohamed H&#xD;Palmer, Elizabeth&#xD;Layhadi, Janice A&#xD;Moraes, Theo J&#xD;Eiwegger, Thomas&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2934-2937. doi: 10.1111/all.14954. Epub 2021 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34028048</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14954</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1653</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1653</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Palmer, E.</style></author><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Moraes, T. J.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biological treatment in allergic disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2934-2937</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34028048</style></accession-num><notes><style face="normal" font="default" size="100%">Shamji, Mohamed H&#xD;Palmer, Elizabeth&#xD;Layhadi, Janice A&#xD;Moraes, Theo J&#xD;Eiwegger, Thomas&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2934-2937. doi: 10.1111/all.14954. Epub 2021 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34028048</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14954</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2985</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2985</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stryjewska-Makuch, G.</style></author><author><style face="normal" font="default" size="100%">Humeniuk-Arasiewicz, M.</style></author><author><style face="normal" font="default" size="100%">Onyszczuk, M.</style></author><author><style face="normal" font="default" size="100%">Kokoszka, M.</style></author><author><style face="normal" font="default" size="100%">Niemiec-Urbanczyk, M.</style></author><author><style face="normal" font="default" size="100%">Michalak-Kolarz, M.</style></author><author><style face="normal" font="default" size="100%">Scierski, W.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Gluck, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Laryngology and Laryngological Oncology, Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University, Katowice, Poland.&#xD;Department and Chair of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.&#xD;Department of Pathomorphology, Leszek Giec Upper-Silesian Medical, Centre of the Medical University of Silesia, Katowice, Poland.&#xD;Department of Pediatric Otolaryngology, Department of Pediatric Surgery, Head and Neck Surgery, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland.&#xD;Department of Otorhinolaryngology and Laryngological Oncology in Zabrze, Medical University of Silesia, Katowice, Poland.&#xD;Clinical Department of Internal Diseases, Allergology and Clinical Immunology in Katowice, Medical University of Silesia, Katowice, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biological Treatment of Chronic Rhinosinusitis With Polyps Increases Number of Nasal Ciliated Cells-Real-Life Experience</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3434-3437</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/07/10</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40637250</style></accession-num><notes><style face="normal" font="default" size="100%">Stryjewska-Makuch, Grazyna&#xD;Humeniuk-Arasiewicz, Maria&#xD;Onyszczuk, Magdalena&#xD;Kokoszka, Magdalena&#xD;Niemiec-Urbanczyk, Marcelina&#xD;Michalak-Kolarz, Marta&#xD;Scierski, Wojciech&#xD;Gawlik, Radoslaw&#xD;Gluck, Joanna&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3434-3437. doi: 10.1111/all.16636. Epub 2025 Jul 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40637250</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666753 presentations for AstraZeneca, GlaxoSmithKline, and Chiesi and received support for attending meetings from Sanofi Poland.&quot;</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16636</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1434</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1434</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaller, B.</style></author><author><style face="normal" font="default" size="100%">Jose Yepes-Nunez, J.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Alsalamah, M.</style></author><author><style face="normal" font="default" size="100%">Bavbek, S.</style></author><author><style face="normal" font="default" size="100%">Bossios, A.</style></author><author><style face="normal" font="default" size="100%">Boyman, O.</style></author><author><style face="normal" font="default" size="100%">Chaker, A.</style></author><author><style face="normal" font="default" size="100%">Chan, S.</style></author><author><style face="normal" font="default" size="100%">Chatzipetrou, A.</style></author><author><style face="normal" font="default" size="100%">du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Kauppi, P.</style></author><author><style face="normal" font="default" size="100%">Kolios, A.</style></author><author><style face="normal" font="default" size="100%">Li, C.</style></author><author><style face="normal" font="default" size="100%">Matucci, A.</style></author><author><style face="normal" font="default" size="100%">Marson, A.</style></author><author><style face="normal" font="default" size="100%">Bendien, S.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Rogala, B.</style></author><author><style face="normal" font="default" size="100%">Szepfalusi, Z.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Vultaggio, A.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Cardiology, Department of Medicine, University of Toronto Pregnancy and Heart Disease Research Program, Mount Sinai and Toronto General Hospitals, Toronto, ON, Canada.&#xD;School of Medicine, Universidad de los Andes, Bogota, D.C., Colombia.&#xD;Faculty of Medicine, Department of Allergy and Clinical Immunology, Transylvania University Brasov, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), Davos, Switzerland.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Toronto, ON, Canada.&#xD;College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.&#xD;Clinical Immunology and Allergy Division, Pediatrics Department, King Abdullah Specialists Children&apos;s Hospital, Riyadh, Saudi Arabia.&#xD;Division of Immunology and Allergy, Department of Chest Disease, School of Medicine, Ankara University, Ankara, Turkey.&#xD;Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Huddinge, Sweden.&#xD;Department of Medicine, Huddinge, Stockholm, Sweden.&#xD;Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Immunology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Department of Otolaryngology and Center for Allergy and Environment, Technical University of Munich, TUM School of Medicine, Klinikum rechts der Isar, Munich, Germany.&#xD;Guy&apos;s and St. Thomas&apos; NHS Foundation Trust, London, UK.&#xD;King&apos;s College London School of Life Course Sciences, School of Immunology, Microbial Sciences, King&apos;s Health Partners, UK.&#xD;Allergy Unit &quot;D. Kalogeromitros, Department of Dermatology and Venereology, Medical School, Attikon&quot; University Hospital, University of Athens, Athens, Greece.&#xD;Paediatric Allergy Group, Department of Women and Children&apos;s Health, King&apos;s College London, London, UK.&#xD;Paediatric Allergy Group, Peter Gorer Dept of Immunobiology, School of Immunology &amp; Microbial Sciences, King&apos;s College London, Guys&apos; Hospital, London, UK.&#xD;Children&apos;s Allergy Service, Evelina Children&apos;s Hospital, Guy&apos;s and St, Thomas&apos; Hospital NHS Foundation Trust, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Allergy, Skin and Allergy Hospital, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Immunoallergology Unit, Careggi University Hospital, Florence, Italy.&#xD;Department of respiratory medicine, Haga Teaching Hospital, The Hague, The Netherlands.&#xD;Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Internal Diseases, Allergology &amp; Clinical Immunology Medical, University of Silesia, Katowice, Poland.&#xD;Division of Ped. Pulmonology, Allergology and Endocrinology, Dpt. of Pediatrics, Medical University of Vienna, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Immunology, University of Toronto, Toronto, ON, Canada.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biologicals in atopic disease in pregnancy: An EAACI position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">71-89</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/03/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Multicenter Studies as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biologicals</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32189356</style></accession-num><abstract><style face="normal" font="default" size="100%">Biologicals have transformed the management of severe disease phenotypes in asthma, atopic dermatitis, and chronic spontaneous urticaria. As a result, the number of approved biologicals for the treatment of atopic diseases is continuously increasing. Although atopic diseases are among the most common diseases in the reproductive age, investigations, and information on half-life, pharmacokinetics defining the neonatal Fc receptors (FcRn) and most important safety of biologicals in pregnancy are lacking. Given the complex sequence of immunological events that regulate conception, fetal development, and the intrauterine and postnatal maturation of the immune system, this information is of utmost importance. We conducted a systematic review on biologicals in pregnancy for indications of atopic diseases. Evidence in this field is scarce and mainly reserved to reports on the usage of omalizumab. This lack of evidence demands the establishment of a multidisciplinary approach for the management of pregnant women who receive biologicals and multicenter registries for long-term follow-up, drug trial designs suitable for women in the reproductive age, and better experimental models that represent the human situation. Due to the very long half-life of biologicals, preconception counseling and healthcare provider education are crucial to offer the best care for mother and fetus. This position paper integrates available data on safety of biologicals during pregnancy in atopic diseases via a systematic review with a detailed review on immunological considerations how inhibition of different pathways may impact pregnancy.</style></abstract><notes><style face="normal" font="default" size="100%">Pfaller, Birgit&#xD;Jose Yepes-Nunez, Juan&#xD;Agache, Ioana&#xD;Akdis, Cezmi A&#xD;Alsalamah, Mohammad&#xD;Bavbek, Sevim&#xD;Bossios, Apostolos&#xD;Boyman, Onur&#xD;Chaker, Adam&#xD;Chan, Susan&#xD;Chatzipetrou, Alexia&#xD;du Toit, George&#xD;Jutel, Marek&#xD;Kauppi, Paula&#xD;Kolios, Antonios&#xD;Li, Carmen&#xD;Matucci, Andrea&#xD;Marson, Alanna&#xD;Bendien, Sarah&#xD;Palomares, Oscar&#xD;Rogala, Barbara&#xD;Szepfalusi, Zsolt&#xD;Untersmayr, Eva&#xD;Vultaggio, Alessandra&#xD;Eiwegger, Thomas&#xD;eng&#xD;Consensus Development Conference&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):71-89. doi: 10.1111/all.14282.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32189356</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14282</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2234</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2234</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thomas, D.</style></author><author><style face="normal" font="default" size="100%">McDonald, V. M.</style></author><author><style face="normal" font="default" size="100%">Stevens, S.</style></author><author><style face="normal" font="default" size="100%">Harvey, E. S.</style></author><author><style face="normal" font="default" size="100%">Baraket, M.</style></author><author><style face="normal" font="default" size="100%">Bardin, P.</style></author><author><style face="normal" font="default" size="100%">Bowden, J. J.</style></author><author><style face="normal" font="default" size="100%">Bowler, S.</style></author><author><style face="normal" font="default" size="100%">Chien, J.</style></author><author><style face="normal" font="default" size="100%">Chung, L. P.</style></author><author><style face="normal" font="default" size="100%">Gillman, A.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author><author><style face="normal" font="default" size="100%">Hodge, S.</style></author><author><style face="normal" font="default" size="100%">James, A.</style></author><author><style face="normal" font="default" size="100%">Jenkins, C.</style></author><author><style face="normal" font="default" size="100%">Katelaris, C. H.</style></author><author><style face="normal" font="default" size="100%">Katsoulotos, G. P.</style></author><author><style face="normal" font="default" size="100%">Langton, D.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author><author><style face="normal" font="default" size="100%">Marks, G.</style></author><author><style face="normal" font="default" size="100%">Peters, M.</style></author><author><style face="normal" font="default" size="100%">Radhakrishna, N.</style></author><author><style face="normal" font="default" size="100%">Reynolds, P. N.</style></author><author><style face="normal" font="default" size="100%">Rimmer, J.</style></author><author><style face="normal" font="default" size="100%">Sivakumaran, P.</style></author><author><style face="normal" font="default" size="100%">Upham, J. W.</style></author><author><style face="normal" font="default" size="100%">Wark, P.</style></author><author><style face="normal" font="default" size="100%">Yang, I. A.</style></author><author><style face="normal" font="default" size="100%">Gibson, P. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre of Excellence in Treatable Traits, College of Health, Medicine and Wellbeing, University of Newcastle, Hunter Medical Research Institute Asthma and Breathing Programme, Newcastle, New South Wales, Australia.&#xD;Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia.&#xD;South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia.&#xD;Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia.&#xD;Lung and Sleep Medicine, Monash University and Medical Centre and Hudson Institute, Clayton, Victoria, Australia.&#xD;Respiratory and Sleep Services, Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia.&#xD;Department of Respiratory Medicine, Mater Hospital, Brisbane, Queensland, Australia.&#xD;Department of Sleep and Respiratory Medicine, Westmead Hospital, Westmead, New South Wales, Australia.&#xD;School of Medicine, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.&#xD;Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia.&#xD;School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.&#xD;Lung Research Laboratory, Hanson Institute, Adelaide, South Australia, Australia.&#xD;Department of Thoracic Medicine, Royal Adelaide Hospital, Lung Research, University of Adelaide, Adelaide, South Australia, Australia.&#xD;Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.&#xD;Medcial School, The University of Western Australia, Perth, Western Australia, Australia.&#xD;Department of Thoracic Medicine, Concord Hospital, Concord, New South Wales, Australia.&#xD;Concord Clinical School, University of Sydney, Concord, New South Wales, Australia.&#xD;School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.&#xD;Immunology and Allergy Unit, Campbelltown Hospital, Campbelltown, New South Wales, Australia.&#xD;Woolcock Institute of Medical Research, University of Sydney, Glebe, New South Wales, Australia.&#xD;The University of Notre Dame, Sydney, Western Australia, Australia.&#xD;St George Specialist Centre, Kogarah, New South Wales, Australia.&#xD;St Vincent&apos;s Clinic, Darlinghurst, New South Wales, Australia.&#xD;Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.&#xD;Department of Thoracic Medicine, Frankston Hospital, Frankston, Victoria, Australia.&#xD;Austin Health, Melbourne, Victoria, Australia.&#xD;Respiratory Department, St Vincent&apos;s Hospital, Melbourne, Victoria, Australia.&#xD;Department of Respiratory Medicine, Gold Coast University Hospital, Gold Coast, Queensland, Australia.&#xD;Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.&#xD;Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.&#xD;Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">384-392</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/08/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchodilator Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Australia/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">remission</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37632144</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma remission has emerged as a potential treatment goal. This study evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving asthma remission. METHODS: This observational study included 453 severe asthma patients (41% male; mean age +/- SD 55.7 +/- 14.7 years) from two real-world drug registries: the Australian Mepolizumab Registry and the Australian Xolair Registry. The composite outcome clinical remission was defined as zero exacerbations and zero oral corticosteroids during the previous 6 months assessed at 12 months and 5-item Asthma Control Questionnaire (ACQ-5) &lt;/=1 at 12 months. We also assessed clinical remission plus optimization (post-bronchodilator FEV1 &gt;/=80%) or stabilization (post-bronchodilator FEV1 not greater than 5% decline from baseline) of lung function at 12 months. Sensitivity analyses explored various cut-offs of ACQ-5/FEV1 scores. The predictors of clinical remission were identified. RESULTS: 29.3% (73/249) of AMR and 22.8% (37/162) of AXR cohort met the criteria for clinical remission. When lung function criteria were added, the remission rates were reduced to 25.2% and 19.1%, respectively. Sensitivity analyses identified that the remission rate ranged between 18.1% and 34.9% in the AMR cohort and 10.6% and 27.2% in the AXR cohort. Better lung function, lower body mass index, mild disease and absence of comorbidities such as obesity, depression and osteoporosis predicted the odds of achieving clinical remission. CONCLUSION: Biologic treatment with mepolizumab or omalizumab for severe asthma-induced asthma remission in a subgroup of patients. Remission on treatment may be an achievable treatment target and future studies should consider remission as an outcome measure.</style></abstract><notes><style face="normal" font="default" size="100%">Thomas, Dennis&#xD;McDonald, Vanessa M&#xD;Stevens, Sean&#xD;Harvey, Erin S&#xD;Baraket, Melissa&#xD;Bardin, Philip&#xD;Bowden, Jeffrey J&#xD;Bowler, Simon&#xD;Chien, Jimmy&#xD;Chung, Li Ping&#xD;Gillman, Andrew&#xD;Hew, Mark&#xD;Hodge, Sandra&#xD;James, Alan&#xD;Jenkins, Christine&#xD;Katelaris, Constance H&#xD;Katsoulotos, Gregory P&#xD;Langton, David&#xD;Lee, Joy&#xD;Marks, Guy&#xD;Peters, Matthew&#xD;Radhakrishna, Naghmeh&#xD;Reynolds, Paul N&#xD;Rimmer, Janet&#xD;Sivakumaran, Pathmanathan&#xD;Upham, John W&#xD;Wark, Peter&#xD;Yang, Ian A&#xD;Gibson, Peter G&#xD;eng&#xD;GlaxoSmithKline Australia/&#xD;Novartis Australia/&#xD;Observational Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):384-392. doi: 10.1111/all.15867. Epub 2023 Aug 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37632144</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15867</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2719</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2719</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Varricchi, G.</style></author><author><style face="normal" font="default" size="100%">Poto, R.</style></author><author><style face="normal" font="default" size="100%">Lommatzsch, M.</style></author><author><style face="normal" font="default" size="100%">Brusselle, G.</style></author><author><style face="normal" font="default" size="100%">Braido, F.</style></author><author><style face="normal" font="default" size="100%">Virchow, J. C.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.&#xD;Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.&#xD;World Allergy Organization (WAO) Center of Excellence, Naples, Italy.&#xD;Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council, Naples, Italy.&#xD;Department of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.&#xD;Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.&#xD;Respiratory Diseases and Allergy Department, IRCCS Polyclinic Hospital San Martino, Genoa, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Asthma &amp; Allergy Unit-IRCCS Humanitas Research Hospital, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biologics and airway remodeling in asthma: early, late, and potential preventive effects</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">408-422</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/11/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/prevention &amp; control/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Airway Remodeling/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">interest to declare. ML has received consulting fees or honoraria, or both for</style></keyword><keyword><style face="normal" font="default" size="100%">lectures from ALK, Allergopharma, AstraZeneca, Berlin-Chemie, Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, Chiesi, GSK, HAL Allergy, Leti, Novartis, MSD, Sanofi, and TEVA</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">grants for research or clinical trials, or both from Deutsche</style></keyword><keyword><style face="normal" font="default" size="100%">Forschungsgemeinschaft, AstraZeneca, and GSK. GB reports personal fees from Astra</style></keyword><keyword><style face="normal" font="default" size="100%">Zeneca, personal fees from Boehringer-Ingelheim, personal fees from Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from GSK, personal fees from Novartis, personal fees from Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from MSD, outside the submitted work. G.W.C. has received consulting fees</style></keyword><keyword><style face="normal" font="default" size="100%">or honoraria, or both for lectures from AstraZeneca, Chiesi, Novartis, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Menarini, Stallergenes Greer, GSK, and HAL Allergy. FB has been on the scientific</style></keyword><keyword><style face="normal" font="default" size="100%">Board for AZ, BI, Chiesi, GSK, Menarini group, Sanofi and P&amp;G</style></keyword><keyword><style face="normal" font="default" size="100%">received honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">from AZ, BI, Chiesi, GSK, Menarini group and Sanofi. JCV is a full time employee</style></keyword><keyword><style face="normal" font="default" size="100%">of the University of Rostock as a full time professor and chair of the</style></keyword><keyword><style face="normal" font="default" size="100%">Departments of Pneumology and Intensive Care Medicine has given independent</style></keyword><keyword><style face="normal" font="default" size="100%">advice, lectured for and received honoraria from AstraZeneca, Avontec, Bayer,</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard, Bionorica, Boehringer-Ingelheim, Chiesi, Essex/Schering-Plough, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Janssen-Cilag, Leti, MEDA, Merck, MSD, Mundipharma, Novartis, Nycomed/Altana,</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, Revotar, Sandoz-Hexal, Stallergens, TEVA, UCB/Schwarz-Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Zydus/Cadila, has participated in advisory boards for Avontec,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer-Ingelheim, Chiesi, Essex/Schering-Plough, GSK, Janssen-Cilag, MEDA,</style></keyword><keyword><style face="normal" font="default" size="100%">MSD, Mundipharma, Novartis, Regeneron, Revotar, Roche, Sanofi-Aventis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sandoz-Hexal, TEVA, UCB/Schwarz-Pharma and has received research grants from the</style></keyword><keyword><style face="normal" font="default" size="100%">Deutsche Forschungsgesellschaft, Land Mecklenburg-Vorpommern, GSK, MSD. G.W.C.</style></keyword><keyword><style face="normal" font="default" size="100%">received honoraria for lectures, presentations, speakers from AstraZeneca, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Sanofi, Stallergenes, Greer, Hal Allergy, Menarini, Chiesi, Mylan,</style></keyword><keyword><style face="normal" font="default" size="100%">Valeas, Faes.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39520155</style></accession-num><abstract><style face="normal" font="default" size="100%">Although airway remodeling in severe and/or fatal asthma is still considered irreversible, its individual components as a cause of clinical symptoms and/or lung function changes remain largely unknown. While inhaled glucocorticoids have not consistently been shown to affect airway remodeling, biologics targeting specific pathways of airway inflammation have been shown to improve lung function, mucus plugging, and airway structural changes that can exceed those seen with glucocorticoids. This superiority of biologic treatment, which cannot be solely explained by insufficient doses or limited durations of glucocorticoid therapies, needs to be further explored. For this field of research, we propose a novel classification of the potential effects of biologics on airway remodeling into three temporal effects: early effects (days to weeks, primarily modulating inflammatory processes), late effects (months to years, predominantly affecting structural changes), and potential preventive effects (outcomes of early treatment with biologics). For the identification of potential preventive effects of biologics, we call for studies exploring the impact of early biological treatment on airway remodeling in patients with moderate-to-severe asthma, which should be accompanied by a long-term evaluation of clinical parameters, biomarkers, treatment burden, and socioeconomic implications.</style></abstract><notes><style face="normal" font="default" size="100%">Varricchi, G&#xD;Poto, R&#xD;Lommatzsch, M&#xD;Brusselle, G&#xD;Braido, F&#xD;Virchow, J C&#xD;Canonica, G W&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):408-422. doi: 10.1111/all.16382. Epub 2024 Nov 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39520155</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804314</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16382</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>356</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">356</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Varricchi, G.</style></author><author><style face="normal" font="default" size="100%">Ferri, S.</style></author><author><style face="normal" font="default" size="100%">Pepys, J.</style></author><author><style face="normal" font="default" size="100%">Poto, R.</style></author><author><style face="normal" font="default" size="100%">Spadaro, G.</style></author><author><style face="normal" font="default" size="100%">Nappi, E.</style></author><author><style face="normal" font="default" size="100%">Paoletti, G.</style></author><author><style face="normal" font="default" size="100%">Virchow, J. C.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Canonica, W. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.&#xD;Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.&#xD;World Allergy Organization (WAO) Center of Excellence, Naples, Italy.&#xD;Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council, Naples, Italy.&#xD;Personalized Medicine Asthma and Allergy Unit - IRCCS Humanitas Research Hospital, Milan, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Departments of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biologics and airway remodeling in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3538-3552</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/08/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Airway Remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">*Airway Obstruction</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapies</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">declare. J.C.V. is a full time employee of the University of Rostock as a full</style></keyword><keyword><style face="normal" font="default" size="100%">time professor and chair of the Departments of Pneumology and Intensive Care</style></keyword><keyword><style face="normal" font="default" size="100%">Medicine has given independent advice, lectured for and received honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Avontec, Bayer, Bencard, Bionorica, Boehringer-Ingelheim, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">Essex/Schering-Plough, GSK, Janssen-Cilag, Leti, MEDA, Merck, MSD, Mundipharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Nycomed/Altana, Pfizer, Revotar, Sandoz-Hexal, Stallergens, TEVA,</style></keyword><keyword><style face="normal" font="default" size="100%">UCB/Schwarz-Pharma, Zydus/Cadila, has participated in advisory boards for</style></keyword><keyword><style face="normal" font="default" size="100%">Avontec, Boehringer-Ingelheim, Chiesi, Essex/Schering-Plough, GSK, Janssen-Cilag,</style></keyword><keyword><style face="normal" font="default" size="100%">MEDA, MSD, Mundipharma, Novartis, Regeneron, Revotar, Roche, Sanofi-Aventis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sandoz-Hexal, TEVA, UCB/Schwarz-Pharma and has received research grants from the</style></keyword><keyword><style face="normal" font="default" size="100%">Deutsche Forschungsgesellschaft, Land Mecklenburg-Vorpommern, GSK, MSD. E.H.</style></keyword><keyword><style face="normal" font="default" size="100%">received grants and personal fees from AstraZeneca, Sanofi, Regeneron, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, Circassia, Nestle Purina, Stallergenes-Greer outside the submitted work.</style></keyword><keyword><style face="normal" font="default" size="100%">G.W.C. received honoraria for lectures, presentations, speakers from AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, Novartis, Sanofi, Stallergenes, Greer, Hal Allergy, Menarini, Chiesi, Mylan,</style></keyword><keyword><style face="normal" font="default" size="100%">Valeas, Faes.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35950646</style></accession-num><abstract><style face="normal" font="default" size="100%">Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in part can become irreversible to conventional therapies, defining the concept of airway remodeling. The introduction of biologics in severe asthma has led in some patients to the complete normalization of previously considered irreversible airflow obstruction. This highlights the need to distinguish a &quot;fixed&quot; airflow obstruction due to structural changes unresponsive to current therapies, from a &quot;reversible&quot; one as demonstrated by lung function normalization during biological therapies not previously obtained even with high-dose systemic glucocorticoids. The mechanisms by which exposure to environmental factors initiates the inflammatory responses that trigger airway remodeling are still incompletely understood. Alarmins represent epithelial-derived cytokines that initiate immunologic events leading to inflammatory airway remodeling. Biological therapies can improve airflow obstruction by addressing these airway inflammatory changes. In addition, biologics might prevent and possibly even revert &quot;fixed&quot; remodeling due to structural changes. Hence, it appears clinically important to separate the therapeutic effects (early and late) of biologics as a new paradigm to evaluate the effects of these drugs and future treatments on airway remodeling in severe asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Varricchi, Gilda&#xD;Ferri, Sebastian&#xD;Pepys, Jack&#xD;Poto, Remo&#xD;Spadaro, Giuseppe&#xD;Nappi, Emanuele&#xD;Paoletti, Giovanni&#xD;Virchow, Johann Christian&#xD;Heffler, Enrico&#xD;Canonica, Walter G&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3538-3552. doi: 10.1111/all.15473. Epub 2022 Aug 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35950646</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087445</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15473</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1565</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1565</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Alvaro-Lozano, M.</style></author><author><style face="normal" font="default" size="100%">Alsina, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Deu, Barcelona, Spain.&#xD;Institut de Recerca Sant Joan de Deu, Barcelona, Spain.&#xD;Clinical Immunology and Primary Immunodeficiencies Unit, Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Deu Barcelona Spain, Barcelona, Spain.&#xD;Universitat de Barcelona, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biologics as a therapeutic approach for a Th17-mediated severe dermatitis in skin barrier disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3007-3008</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2020/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biological Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Psoriasis</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Th17 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">SAM-like syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">T helper 17</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">secukinumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32583554</style></accession-num><notes><style face="normal" font="default" size="100%">Riggioni, Carmen&#xD;Alvaro-Lozano, Montserrat&#xD;Alsina, Laia&#xD;eng&#xD;Denmark&#xD;Allergy. 2020 Nov;75(11):3007-3008. doi: 10.1111/all.14475. Epub 2020 Aug 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32583554</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14475</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3065</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3065</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">de Bruin-Weller, M. S.</style></author><author><style face="normal" font="default" size="100%">Boesjes, C. M.</style></author><author><style face="normal" font="default" size="100%">Achten, R. A.</style></author><author><style face="normal" font="default" size="100%">Beck, L. A.</style></author><author><style face="normal" font="default" size="100%">Irvine, A. D.</style></author><author><style face="normal" font="default" size="100%">Vestergaard, C.</style></author><author><style face="normal" font="default" size="100%">de Graaf, M.</style></author><author><style face="normal" font="default" size="100%">van Wijk, F.</style></author><author><style face="normal" font="default" size="100%">Bakker, D. S.</style></author><author><style face="normal" font="default" size="100%">Weidinger, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.&#xD;Department of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.&#xD;Department of Clinical Medicine, Trinity College, Dublin, Ireland.&#xD;Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.&#xD;Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.&#xD;Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40990093</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. The clinical presentation of AD is heterogeneous and is characterized by a relapsing and remitting course. Most patients suffer from mild AD while approximately 5% to 20% experience severe disease activity, which often requires systemic treatment. Before 2017, systemic treatment options were limited to broad immunosuppressants, which often had significant toxicity and limited effectiveness. Advances in understanding AD pathophysiology have led to the development of targeted biologic therapies, including dupilumab, tralokinumab, lebrikizumab, and nemolizumab. These monoclonal antibodies specifically block key pro-inflammatory cytokines involved in AD, improving disease control and symptom relief. Dupilumab, the first approved biologic, inhibits IL-4 and IL-13 signaling, while tralokinumab and lebrikizumab selectively block IL-13. Nemolizumab targets IL-31, which plays a crucial role in pruritus. This review summarizes primarily real-world data on the effectiveness and safety of these biologics, providing clinical guidance for their use and management of side effects. It also briefly discusses promising therapeutic targets currently in phase 3 trials.</style></abstract><notes><style face="normal" font="default" size="100%">de Bruin-Weller, Marjolein S&#xD;Boesjes, Celeste M&#xD;Achten, Roselie A&#xD;Beck, Lisa A&#xD;Irvine, Alan D&#xD;Vestergaard, Christian&#xD;de Graaf, Marlies&#xD;van Wijk, Femke&#xD;Bakker, Daphne S&#xD;Weidinger, Stephan&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Sep 24. doi: 10.1111/all.70061.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40990093</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70061</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1249</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1249</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Satitsuksanoa, P.</style></author><author><style face="normal" font="default" size="100%">Daanje, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Boyd, S. D.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biology and dynamics of B cells in the context of IgE-mediated food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1707-1717</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Biology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">B cells</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33274454</style></accession-num><abstract><style face="normal" font="default" size="100%">An increasing number of people suffer from IgE-mediated food allergies. The immunological mechanisms that cause IgE-mediated food allergy have been extensively studied. B cells play a key role in the development of IgE-mediated food allergies through the production of allergen-specific antibodies. While this particular function of B cells has been known for many years, we still do not fully understand the mechanisms that regulate the induction and maintenance of allergen-specific IgE production. It is still not fully understood where in the body IgE class switch recombination of food allergen-specific B cells occurs, and what processes are involved in the immunological memory of allergen-specific IgE responses. B cells can also contribute to the regulation of allergen-specific immune responses through other mechanisms such as antigen presentation and cytokine production. Recent technological advances have enabled highly detailed analysis of small subsets of B cells down to the single-cell level. In this review, we provide an overview of the current knowledge on the biology of B cells in relation to IgE-mediated food allergies.</style></abstract><notes><style face="normal" font="default" size="100%">Satitsuksanoa, Pattraporn&#xD;Daanje, Monique&#xD;Akdis, Mubeccel&#xD;Boyd, Scott D&#xD;van de Veen, Willem&#xD;eng&#xD;R01AI125567/AI/NIAID NIH HHS/&#xD;U19AI104209/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1707-1717. doi: 10.1111/all.14684. Epub 2020 Dec 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33274454</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14684</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3061</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3061</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vijendra, A.</style></author><author><style face="normal" font="default" size="100%">Shobnam, N.</style></author><author><style face="normal" font="default" size="100%">Jordan, J.</style></author><author><style face="normal" font="default" size="100%">Thota, P.</style></author><author><style face="normal" font="default" size="100%">Myles, I. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Epithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biomarkers Are Consistent With Patient-Reported Allergic Sensitization in Topical Steroid Withdrawal</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">topical steroid withdrawal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 25</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40995891</style></accession-num><notes><style face="normal" font="default" size="100%">Vijendra, Aditi&#xD;Shobnam, Nadia&#xD;Jordan, Jalin&#xD;Thota, Pranav&#xD;Myles, Ian A&#xD;eng&#xD;NH/NIH HHS/&#xD;Division of Intramural Research of the NIAID/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep 25. doi: 10.1111/all.70068.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40995891</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70068</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>108</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">108</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Broderick, C.</style></author><author><style face="normal" font="default" size="100%">Ziehfreund, S.</style></author><author><style face="normal" font="default" size="100%">van Bart, K.</style></author><author><style face="normal" font="default" size="100%">Arents, B.</style></author><author><style face="normal" font="default" size="100%">Eyerich, K.</style></author><author><style face="normal" font="default" size="100%">Weidinger, S.</style></author><author><style face="normal" font="default" size="100%">Rastrick, J.</style></author><author><style face="normal" font="default" size="100%">Zink, A.</style></author><author><style face="normal" font="default" size="100%">Flohr, C.</style></author><author><style face="normal" font="default" size="100%">Biomap Consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit for Population-Based Dermatology Research, School of Basic and Medical Biosciences, St John&apos;s Institute of Dermatology, King&apos;s College London, London, UK.&#xD;Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Royal College of Physicians, National Guideline Centre, London, UK.&#xD;Dutch Association for People with Atopic Dermatitis, Nijkerk, The Netherlands.&#xD;Division of Dermatology and Venerology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.&#xD;Immunology Research, New Medicines UCB Pharma, Slough, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biomarkers associated with the development of comorbidities in patients with atopic dermatitis: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">84-120</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/11/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidities</style></keyword><keyword><style face="normal" font="default" size="100%">work. KE has received grants and personal fees from AbbVie, Almirall, BMS, Lilly,</style></keyword><keyword><style face="normal" font="default" size="100%">Leo, Janssen, Novartis, UCB, and Sanofi. SW has received institutional research</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Sanofi Deutschland GmbH, LEO Pharma, and La Roche Posay, has</style></keyword><keyword><style face="normal" font="default" size="100%">performed consultancies for Abbvie, Eli Lilly, Galderma, Kymab, LEO Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, Novartis, Sanofi-Genzyme, and Regeneron, he has also lectured at</style></keyword><keyword><style face="normal" font="default" size="100%">educational events sponsored by Abbvie, Eli Lilly, LEO Pharma, Sanofi-Genzyme,</style></keyword><keyword><style face="normal" font="default" size="100%">and Regeneron, and is involved in performing clinical trials with many</style></keyword><keyword><style face="normal" font="default" size="100%">pharmaceutical industries that manufacture drugs used for the treatment of</style></keyword><keyword><style face="normal" font="default" size="100%">psoriasis and atopic dermatitis. JR is an employee of UCB and holds shares in</style></keyword><keyword><style face="normal" font="default" size="100%">UCB. AZ has been an advisor and/or received speaker&apos;s honoraria and/or received</style></keyword><keyword><style face="normal" font="default" size="100%">grants and/or participated in clinical trials of the following companies: AbbVie,</style></keyword><keyword><style face="normal" font="default" size="100%">Almirall, Amgen, Beiersdorf Dermo Medical, Bencard Allergie, BMS, Celgene, Eli</style></keyword><keyword><style face="normal" font="default" size="100%">Lilly, GSK, Janssen Cilag, Leo Pharma, Miltenyi Biotec, Novartis, Pfizer,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Aventis, Takeda Pharma, UCB Pharma. CF is chief investigator of the UK</style></keyword><keyword><style face="normal" font="default" size="100%">National Institute for Health Research-funded TREAT (ISRCTN15837754) and SOFTER</style></keyword><keyword><style face="normal" font="default" size="100%">(ClinicalTrials.gov: NCT03270566) trials and the UK-Irish Atopic Eczema Systemic</style></keyword><keyword><style face="normal" font="default" size="100%">Therapy Register (A-STAR</style></keyword><keyword><style face="normal" font="default" size="100%">ISRCTN11210918) and is a principal investigator in the</style></keyword><keyword><style face="normal" font="default" size="100%">European Union Horizon 2020-funded BIOMAP Consortium (http://www.biomap-imi.eu/).</style></keyword><keyword><style face="normal" font="default" size="100%">He is also the CI of the EU Joint Programme Initiative-funded TRANS-FOODS</style></keyword><keyword><style face="normal" font="default" size="100%">consortium. His department has also received funding from Sanofi-Genzyme.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36366871</style></accession-num><abstract><style face="normal" font="default" size="100%">Biomarkers associated with the development of comorbidities in atopic dermatitis (AD) patients have been reported, but have not yet been systematically reviewed. Seven electronic databases were searched, from database inception to September 2021. English language randomized controlled trials, prospective and retrospective cohort, and case-control studies that investigated the association between a biomarker and the development of comorbidities in AD patients were included. Two authors independently screened the records for eligibility, one extracted all data, and critically appraised the quality of studies and risk of bias. Fifty six articles met the inclusion criteria, evaluating 146 candidate biomarkers. The most frequently reported biomarkers were filaggrin mutations and allergen specific-IgE. Promising biomarkers include specific-IgE and/or skin prick tests predicting the development of asthma, and genetic polymorphisms predicting the occurrence of eczema herpeticum. The identified studies and biomarkers were highly heterogeneous, and associated with predominately moderate-to-high risk of bias across multiple domains. Overall, findings were inconsistent. High-quality studies assessing biomarkers associated with the development of comorbidities in people with AD are lacking. Harmonized datasets and independent validation studies are urgently needed.</style></abstract><notes><style face="normal" font="default" size="100%">Broderick, Conor&#xD;Ziehfreund, Stefanie&#xD;van Bart, Karin&#xD;Arents, Bernd&#xD;Eyerich, Kilian&#xD;Weidinger, Stephan&#xD;Rastrick, Joseph&#xD;Zink, Alexander&#xD;Flohr, Carsten&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):84-120. doi: 10.1111/all.15578. Epub 2022 Dec 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36366871</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10107168</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15578</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>271</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">271</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Okada, N.</style></author><author><style face="normal" font="default" size="100%">Yazu, H.</style></author><author><style face="normal" font="default" size="100%">Shimizu, E.</style></author><author><style face="normal" font="default" size="100%">Fukagawa, K.</style></author><author><style face="normal" font="default" size="100%">Nunomura, S.</style></author><author><style face="normal" font="default" size="100%">Saito, H.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, K.</style></author><author><style face="normal" font="default" size="100%">Kawaguchi, A.</style></author><author><style face="normal" font="default" size="100%">Izuhara, K.</style></author><author><style face="normal" font="default" size="100%">Fujishima, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmaceutical Sciences, Nihon Pharmaceutical University, Saitama, Japan.&#xD;Department of Ophthalmology, Tsurumi University School of Dental Medicine, Yokohama, Japan.&#xD;Keio Allergy Center, Keio University School of Medicine, Tokyo, Japan.&#xD;Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.&#xD;Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development Laboratory, Tokyo, Japan.&#xD;Education and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biomarkers enable prediction of tacrolimus resistance in patients with severe allergic conjunctivitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">319-321</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Tacrolimus/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36178061</style></accession-num><notes><style face="normal" font="default" size="100%">Okada, Naoko&#xD;Yazu, Hiroyuki&#xD;Shimizu, Eisuke&#xD;Fukagawa, Kazumi&#xD;Nunomura, Satoshi&#xD;Saito, Hirohisa&#xD;Matsumoto, Kenji&#xD;Kawaguchi, Atsushi&#xD;Izuhara, Kenji&#xD;Fujishima, Hiroshi&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):319-321. doi: 10.1111/all.15535. Epub 2022 Oct 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36178061</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15535</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2609</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2609</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thulin, H.</style></author><author><style face="normal" font="default" size="100%">Mansouri, L.</style></author><author><style face="normal" font="default" size="100%">Altman, M.</style></author><author><style face="normal" font="default" size="100%">Merid, S. K.</style></author><author><style face="normal" font="default" size="100%">Lundahl, J.</style></author><author><style face="normal" font="default" size="100%">Nilsson, C.</style></author><author><style face="normal" font="default" size="100%">Safholm, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Science and Education, South Hospital, Karolinska Institutet, Stockholm, Sweden.&#xD;Astrid Lindgren Children&apos;s Hospital, Karolinska University Hospital, Stockholm, Sweden.&#xD;Clinical Epidemiology Division, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Medical Diagnostics, Karolinska University Hospital, Stockholm, Sweden.&#xD;Sachs Children and Youth Hospital, South Hospital, Stockholm, Sweden.&#xD;Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biomarkers for a less invasive strategy to predict children with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3464-3474</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/08/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">ROC Curve</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Saliva/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G/blood</style></keyword><keyword><style face="normal" font="default" size="100%">15(s)-hete</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4</style></keyword><keyword><style face="normal" font="default" size="100%">cutoff values</style></keyword><keyword><style face="normal" font="default" size="100%">panel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39157867</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Noninvasive biomarkers for diagnosing and monitoring eosinophilic esophagitis (EoE) are currently lacking. This study evaluates 20 biomarkers in serum and saliva, aiming to assess their diagnostic potential in pediatric EoE patients and healthy individuals. METHODS: Blood and saliva from children undergoing upper endoscopy were analyzed for biomarkers, including absolute eosinophil count (AEC), eosinophil-derived neurotoxin (EDN), total and specific IgG(4)-antibodies (sIgG(4)), specific IgE-antibodies (sIgE) and 15-hydroxyeicosatetraenoic acid (15(S)-HETE). Some patients participated twice, forming a longitudinal cohort. The ability to use the biomarkers to predict the EoE diagnosis was evaluated. RESULTS: Analysis from 105 children divided into active EoE, remission, and healthy, revealed elevated levels of serum biomarkers (AEC, EDN, 15(S)-HETE, sIgG(4), and sIgE) in active EoE compared to healthy individuals. A combination of biomarkers (AEC, EDN, sIgE to egg white and wheat) and symptoms showed an AUC of 0.92 in distinguishing between the three groups. We further showed that optimal cutoff values for these biomarkers could discriminate between active EoE and healthy with a sensitivity of 88% and a specificity of 100% in distinguishing EoE (active and in remission) from healthy. Longitudinally, levels of EDN, sIgG(4) to Bos d 4, Bos d 5, Bos d 8, gliadin, and birch, and sIgE to milk decreased in patients progressing from active EoE to remission (p &lt;.05). CONCLUSIONS: This study identified novel biomarkers associated with EoE and proposes a panel, together with symptoms, for effective discrimination between active EoE, EoE in remission, and healthy individuals. The findings may contribute to a less invasive diagnostic method and may be a potential surveillance tool for pediatric EoE patients.</style></abstract><notes><style face="normal" font="default" size="100%">Thulin, Helena&#xD;Mansouri, Ladan&#xD;Altman, Maria&#xD;Merid, Simon Kebede&#xD;Lundahl, Joachim&#xD;Nilsson, Caroline&#xD;Safholm, Jesper&#xD;eng&#xD;Astma- och Allergiforbundet/&#xD;Mjolkdroppen/&#xD;Stiftelsen Lars Hiertas Minne/&#xD;Cayman Biomedical Research Institute/&#xD;Ake Wibergs foundation/&#xD;Magnus Bergvalls foundation/&#xD;Hjart-Lungfonden/&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3464-3474. doi: 10.1111/all.16275. Epub 2024 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39157867</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657037</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16275</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>242</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">242</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tan, D. J.</style></author><author><style face="normal" font="default" size="100%">Lodge, C. J.</style></author><author><style face="normal" font="default" size="100%">Walters, E. H.</style></author><author><style face="normal" font="default" size="100%">Lowe, A. J.</style></author><author><style face="normal" font="default" size="100%">Bui, D. S.</style></author><author><style face="normal" font="default" size="100%">Bowatte, G.</style></author><author><style face="normal" font="default" size="100%">Kandane-Rathnayake, R.</style></author><author><style face="normal" font="default" size="100%">Aldakheel, F. M.</style></author><author><style face="normal" font="default" size="100%">Erbas, B.</style></author><author><style face="normal" font="default" size="100%">Hamilton, G. S.</style></author><author><style face="normal" font="default" size="100%">Thomas, P. S.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author><author><style face="normal" font="default" size="100%">Tang, M. L. K.</style></author><author><style face="normal" font="default" size="100%">Abramson, M. J.</style></author><author><style face="normal" font="default" size="100%">Perret, J. L.</style></author><author><style face="normal" font="default" size="100%">Dharmage, S. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.&#xD;School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.&#xD;Department of Basic Sciences, Faculty of Allied Health Sciences, University of Peradeniya, Peradeniya, Sri Lanka.&#xD;School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.&#xD;Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.&#xD;School of Psychology and Public Health, La Trobe University, Melbourne, Victoria, Australia.&#xD;Violet Vines Marshman Centre for Rural Health Research, La Trobe University, Bendigo, Victoria, Australia.&#xD;Monash Lung, Sleep, Allergy and Immunology, Monash Health, Melbourne, Victoria, Australia.&#xD;Prince of Wales&apos; Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.&#xD;School of Public Health &amp; Preventive Medicine, Monash University, Melbourne, Victoria, Australia.&#xD;The Alfred Hospital, Melbourne, Victoria, Australia.&#xD;Murdoch Children&apos;s Research Institute, Melbourne, Victoria, Australia.&#xD;Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.&#xD;Institute for Breathing and Sleep, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biomarkers of asthma relapse and lung function decline in adults with spontaneous asthma remission: A population-based cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">957-967</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/10/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Remission, Spontaneous</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline for unrelated research. SCD holds an investigator-initiated grant</style></keyword><keyword><style face="normal" font="default" size="100%">from AstraZeneca for unrelated research. MJA holds investigator-initiated grants</style></keyword><keyword><style face="normal" font="default" size="100%">from Pfizer, Boehringer-Ingelheim and Sanofi for unrelated research</style></keyword><keyword><style face="normal" font="default" size="100%">has</style></keyword><keyword><style face="normal" font="default" size="100%">undertaken an unrelated consultancy for and received assistance with conference</style></keyword><keyword><style face="normal" font="default" size="100%">attendance from Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and received a speaker&apos;s fee from GlaxoSmithKline. AJL</style></keyword><keyword><style face="normal" font="default" size="100%">has received non-financial support from Primus Pharmaceuticals for unrelated</style></keyword><keyword><style face="normal" font="default" size="100%">research. MH has received unrestricted grants, speaker fees, and consulted for</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, AstraZeneca, Novartis, Teva, Sanofi and Seqirus</style></keyword><keyword><style face="normal" font="default" size="100%">with all</style></keyword><keyword><style face="normal" font="default" size="100%">payments to his employer Alfred Health. All other authors declare no competing</style></keyword><keyword><style face="normal" font="default" size="100%">interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36301194</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The extent to which biomarkers of asthma activity persist in spontaneous asthma remission and whether such markers are associated with future respiratory outcomes remained unclear. We investigated the association between sub-clinical inflammation in adults with spontaneous asthma remission and future asthma relapse and lung function decline. METHODS: The Tasmanian Longitudinal Health Study is a population-based cohort (n = 8583). Biomarkers of systemic inflammation were measured on participants at age 45, and latent profile analysis was used to identify cytokine profiles. Bronchial hyperresponsiveness (BHR) and nitric oxide products in exhaled breath condensate (EBC NOx) were measured at age 50. Participants with spontaneous asthma remission at ages 45 (n = 466) and 50 (n = 318) were re-evaluated at age 53, and associations between baseline inflammatory biomarkers and subsequent asthma relapse and lung function decline were assessed. RESULTS: We identified three cytokine profiles in adults with spontaneous asthma remission: average (34%), Th2-high (42%) and Th2-low (24%). Compared to the average profile, a Th2-high profile was associated with accelerated decline in post-BD FEV(1) /FVC (MD -0.18% predicted per-year; 95% CI -0.33, -0.02), while a Th2-low profile was associated with accelerated decline in both post-BD FEV(1) (-0.41%; -0.75, -0.06) and post-BD FVC (-0.31%; -0.62, 0.01). BHR and high TNF-alpha during spontaneous remission were associated with an increased risk of asthma relapse. In contrast, we found no evidence of association between EBC NOx and either asthma relapse or lung function decline. CONCLUSION: BHR and serum inflammatory cytokines have prognostic value in adults with spontaneous asthma remission. At-risk individuals with BHR, Th2-high or Th2-low cytokine profiles may benefit from closer monitoring and on-going follow-up.</style></abstract><notes><style face="normal" font="default" size="100%">Tan, Daniel J&#xD;Lodge, Caroline J&#xD;Walters, Eugene Haydn&#xD;Lowe, Adrian J&#xD;Bui, Dinh S&#xD;Bowatte, Gayan&#xD;Kandane-Rathnayake, Rangi&#xD;Aldakheel, Fahad M&#xD;Erbas, Bircan&#xD;Hamilton, Garun S&#xD;Thomas, Paul S&#xD;Hew, Mark&#xD;Tang, Mimi L K&#xD;Abramson, Michael J&#xD;Perret, Jennifer L&#xD;Dharmage, Shyamali C&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):957-967. doi: 10.1111/all.15566. Epub 2022 Nov 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36301194</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10953440</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15566</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2313</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2313</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Ariza, A.</style></author><author><style face="normal" font="default" size="100%">Munoz-Cano, R.</style></author><author><style face="normal" font="default" size="100%">Sabato, V.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina - IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-HRUM, Malaga, Spain.&#xD;Allergy Department, Hospital Clinic, Institut d&apos;Investigacions Biomediques August Pi i Sunyer - IDIBAPS, University of Barcelona, Barcelona, Spain.&#xD;Department of Immunology, Allergology, Rheumatology, Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.&#xD;Medicine Department, Universidad de Malaga-UMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biomarkers of immediate drug hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">601-612</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/11/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, G-Protein-Coupled/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Degranulation</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Neuropeptide</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">drug</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">immediate</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37947156</style></accession-num><abstract><style face="normal" font="default" size="100%">Immediate drug hypersensitivity reactions (IDHRs) are a burden for patients and the health systems. This problem increases when taking into account that only a small proportion of patients initially labelled as allergic are finally confirmed after an allergological workup. The diverse nature of drugs involved will imply different interactions with the immunological system. Therefore, IDHRs can be produced by a wide array of mechanisms mediated by the drug interaction with specific antibodies or directly on effector target cells. These heterogeneous mechanisms imply an enhanced complexity for an accurate diagnosis and the identification of the phenotype and endotype at early stages of the reaction is of vital importance. Currently, several endophenotypic categories (type I IgE/non-IgE, cytokine release, Mast-related G-protein coupled receptor X2 (MRGPRX2) or Cyclooxygenase-1 (COX-1) inhibition and their associated biomarkers have been proposed. A precise knowledge of endotypes will permit to discriminate patients within the same phenotype, which is crucial in order to personalise diagnosis, future treatment and prevention to improve the patient&apos;s quality of life.</style></abstract><notes><style face="normal" font="default" size="100%">Mayorga, Cristobalina&#xD;Ariza, Adriana&#xD;Munoz-Cano, Rosa&#xD;Sabato, Vito&#xD;Dona, Inmaculada&#xD;Torres, Maria J&#xD;eng&#xD;PI20/01734/Institute of Health &apos;Carlos III&apos; (ISCIII) of the Ministry of Economy and Competitiveness (MINECO) (co-funded by European Regional Development Fund)/&#xD;PI22/01119/Institute of Health &apos;Carlos III&apos; (ISCIII) of the Ministry of Economy and Competitiveness (MINECO) (co-funded by European Regional Development Fund)/&#xD;REI-RICORSRD21/0002/0008 and RD21/0002/0058/Institute of Health &apos;Carlos III&apos; (ISCIII) of the Ministry of Economy and Competitiveness (MINECO) (co-funded by European Regional Development Fund)/&#xD;PI-0076-2019/Andalusian Regional Ministry of Health/&#xD;PI-0127-2020/Andalusian Regional Ministry of Health/&#xD;PI-0129-2021/Andalusian Regional Ministry of Health/&#xD;PI21/00329/Andalusian Regional Ministry of Health/&#xD;RH-0099-2020(co-fundedbyEuropeanSocialFund)/Andalusian Regional Ministry of Health/&#xD;RC-0004-2021/Andalusian Regional Ministry of Health/&#xD;AC19/00082/ISCIII thorough AES 2019 within the ERANET-EuroNanoMed-III framework (DrNanoDall project)/&#xD;1804523N/Flemish Research Council/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):601-612. doi: 10.1111/all.15933. Epub 2023 Nov 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37947156</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15933</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2533</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2533</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Foong, R. X.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Bahnson, H. T.</style></author><author><style face="normal" font="default" size="100%">Radulovic, S.</style></author><author><style face="normal" font="default" size="100%">Craven, J.</style></author><author><style face="normal" font="default" size="100%">Kwok, M.</style></author><author><style face="normal" font="default" size="100%">Jama, Z.</style></author><author><style face="normal" font="default" size="100%">Versteeg, S. A.</style></author><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Logan, K.</style></author><author><style face="normal" font="default" size="100%">Perkin, M. R.</style></author><author><style face="normal" font="default" size="100%">Flohr, C.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.&#xD;Immune Tolerance Network, Benaroya Research Institute, Seattle, Washington, USA.&#xD;Department of Women and Children&apos;s Health, School of Life Course and Population Sciences, King&apos;s College London, London, UK.&#xD;Population Health Research Institute. St George&apos;s, University of London, London, UK.&#xD;St John&apos;s Institute of Dermatology, King&apos;s College London and Guy&apos;s &amp; St Thomas&apos; NHS Foundation Trust, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biomarkers of peanut allergy in children over time</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2775-2786</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/06/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis/blood/immunology/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis/immunology/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">England/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Wales/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell activation test</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">(NIAID, NIH), Food Allergy &amp; Research Education (FARE), MRC &amp; Asthma UK Centre,</style></keyword><keyword><style face="normal" font="default" size="100%">UK Department of Health through NIHR, Action Medical Research and National Peanut</style></keyword><keyword><style face="normal" font="default" size="100%">Board. Scientific Advisory Board member Aimmune. Investigator on pharma-sponsored</style></keyword><keyword><style face="normal" font="default" size="100%">allergy studies (Aimmune, and DBV Technologies). Scientific advisor to Aimmune,</style></keyword><keyword><style face="normal" font="default" size="100%">DBV and Novartis. RvR consults for HAL Allergy BV, Citeq BV, Angany Inc, Reacta</style></keyword><keyword><style face="normal" font="default" size="100%">Healthcare, Mission MightyMe and has equity in Angany Inc. SR reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">National Institute of Allergy and Infectious Diseases (NIAID, NIH) to cover parts</style></keyword><keyword><style face="normal" font="default" size="100%">of a research salary. HAB reports grants from National Institute of Allergy and</style></keyword><keyword><style face="normal" font="default" size="100%">Infectious Diseases (NIAID, NIH), and speaker fees from DBV Technologies, outside</style></keyword><keyword><style face="normal" font="default" size="100%">of the submitted work. CF is Chief Investigator of the UK National Institute for</style></keyword><keyword><style face="normal" font="default" size="100%">Health Research-funded TREAT. (ISRCTN15837754) and SOFTER (Clinicaltrials.gov:</style></keyword><keyword><style face="normal" font="default" size="100%">NCT03270566) trials as well as the UK-Irish Atopic eczema Systemic Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Register (A-STAR</style></keyword><keyword><style face="normal" font="default" size="100%">ISRCTN11210918) and a Principle Investigator in the European</style></keyword><keyword><style face="normal" font="default" size="100%">Union (EU) Horizon 2020-funded BIOMAP Consortium (http://www.biomap-imi.eu/). He</style></keyword><keyword><style face="normal" font="default" size="100%">also leads the EU Trans-Foods consortium and directs the Global Atopic Dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">Atlas (www.atopicdermatitisatlas.org). His department has received funding from</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genzyme and Pfizer for skin microbiome work. He has also received</style></keyword><keyword><style face="normal" font="default" size="100%">compensation from the British Journal of Dermatology (reviewer and Section</style></keyword><keyword><style face="normal" font="default" size="100%">Editor) and EuroGuiDerm (guidelines lead). GL reports grants from National</style></keyword><keyword><style face="normal" font="default" size="100%">Institute of Allergy and Infectious Diseases (NIAID, NIH), other from Food</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy &amp; Research Education (FARE), other from MRC &amp; Asthma UK Centre, other</style></keyword><keyword><style face="normal" font="default" size="100%">from UK Department of Health through NIHR, other from National Peanut Board</style></keyword><keyword><style face="normal" font="default" size="100%">(NPB), other from The Davis Foundation, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">shareholder in DBV Technologies, and Mighty Mission Me, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, personal fees from Sanofi-Genyzme, personal fees from Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from ALK-Abello, personal fees from Lurie Children&apos;s Hospital,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. AFS reports grants from Medical Research Council</style></keyword><keyword><style face="normal" font="default" size="100%">(MR/M008517/1</style></keyword><keyword><style face="normal" font="default" size="100%">MC/PC/18052</style></keyword><keyword><style face="normal" font="default" size="100%">MR/T032081/1), Food Allergy Research and Education</style></keyword><keyword><style face="normal" font="default" size="100%">(FARE), the Immune Tolerance Network/National Institute of Allergy and Infectious</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases (NIAID, NIH), Asthma UK (AUK-BC-2015-01), BBSRC, Rosetrees Trust and the</style></keyword><keyword><style face="normal" font="default" size="100%">NIHR through the Biomedical Research Centre (BRC) award to Guy&apos;s and St Thomas&apos;</style></keyword><keyword><style face="normal" font="default" size="100%">NHS Foundation Trust, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Thermo</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific, Nestle, Novartis, Allergy Therapeutics, Buhlmann, IgGenix, as well as</style></keyword><keyword><style face="normal" font="default" size="100%">research support from Buhlmann, IgGenix and Thermo Fisher Scientific through a</style></keyword><keyword><style face="normal" font="default" size="100%">collaboration agreement with King&apos;s College London. All the other authors have</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38887787</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Various biomarkers are used to define peanut allergy (PA). We aimed to observe changes in PA resolution and persistence over time comparing biomarkers in PA and peanut sensitised but tolerant (PS) children in a population-based cohort. METHODS: Participants were recruited from the EAT and EAT-On studies, conducted across England and Wales, and were exclusively breastfeed babies recruited at 3 months old and followed up until 7-12 years old. Clinical characteristics, skin prick test (SPT), sIgE to peanut and peanut components and mast cell activation tests (MAT) were assessed at 12 months, 36 months and 7-12 years. PA status was determined at the 7-12 year time point. RESULTS: The prevalence of PA was 2.1% at 7-12 years. Between 3 and 7-12 year, two children developed PA and one outgrew PA. PA children had larger SPT, higher peanut-sIgE, Ara h 2-sIgE and MAT (all p &lt; .001) compared to PS children from 12 months onwards. SPT, peanut-sIgE, Ara h 2-sIgE and MAT between children with persistent PA, new PA, outgrown PA and PS were statistically significant from 12 months onwards (p &lt; .001). Those with persistent PA had SPT, peanut-sIgE and Ara h 2-sIgE that increased over time and MAT which was highest at 36 months. New PA children had increased SPT and peanut-sIgE from 36 months to 7-12 years, but MAT remained low. PS children had low biomarkers across time. CONCLUSIONS: In this cohort, few children outgrow or develop new PA between 36 months and 7-12 years. Children with persistent PA have raised SPT, peanut-sIgE, Ara h 2-sIgE and MAT evident from infancy that consistently increase over time.</style></abstract><notes><style face="normal" font="default" size="100%">Foong, Ru-Xin&#xD;Du Toit, George&#xD;van Ree, Ronald&#xD;Bahnson, Henry T&#xD;Radulovic, Suzana&#xD;Craven, Jo&#xD;Kwok, Matthew&#xD;Jama, Zainab&#xD;Versteeg, Serge A&#xD;Brough, Helen A&#xD;Logan, Kirsty&#xD;Perkin, Michael R&#xD;Flohr, Carsten&#xD;Lack, Gideon&#xD;Santos, Alexandra F&#xD;eng&#xD;MC_G1001205/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2775-2786. doi: 10.1111/all.16193. Epub 2024 Jun 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38887787</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11875691</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16193</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>369</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">369</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ordak, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacodynamics, Centre for Preclinical, Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biostatistics in allergy - recommendations for authors</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3493-3495</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/08/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Biostatistics</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35916056</style></accession-num><notes><style face="normal" font="default" size="100%">Ordak, Michal&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3493-3495. doi: 10.1111/all.15463.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35916056</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15463</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>333</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">333</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fneish, Z.</style></author><author><style face="normal" font="default" size="100%">Becker, J.</style></author><author><style face="normal" font="default" size="100%">Mulenge, F.</style></author><author><style face="normal" font="default" size="100%">Costa, B.</style></author><author><style face="normal" font="default" size="100%">Krajewski, L.</style></author><author><style face="normal" font="default" size="100%">Duran, V.</style></author><author><style face="normal" font="default" size="100%">Ziegler, A.</style></author><author><style face="normal" font="default" size="100%">Sommer, V.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Kalinke, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Hannover Medical School, Hannover, Germany.&#xD;AYOXXA Biosystems GmbH, BioCampus Cologne, Koln, Germany.&#xD;Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Christine-Kuhne Center for Allergy Research and Education (CK-Care), Davos, Switzerland.&#xD;Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Birch pollen extract enhances human cytomegalovirus replication in monocyte-derived dendritic cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">543-546</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/08/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Betula</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytomegalovirus</style></keyword><keyword><style face="normal" font="default" size="100%">Monocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Trees</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36038150</style></accession-num><notes><style face="normal" font="default" size="100%">Fneish, Zeinab&#xD;Becker, Jennifer&#xD;Mulenge, Felix&#xD;Costa, Bibiana&#xD;Krajewski, Luise&#xD;Duran, Veronica&#xD;Ziegler, Annett&#xD;Sommer, Vivien&#xD;Traidl-Hoffmann, Claudia&#xD;Gilles, Stefanie&#xD;Kalinke, Ulrich&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):543-546. doi: 10.1111/all.15497. Epub 2022 Sep 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36038150</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15497</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>912</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">912</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Galati, D.</style></author><author><style face="normal" font="default" size="100%">Zanotta, S.</style></author><author><style face="normal" font="default" size="100%">Capitelli, L.</style></author><author><style face="normal" font="default" size="100%">Bocchino, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology and Developmental Therapeutics, Istituto Nazionale Tumori- IRCCS- Fondazione G. Pascale, Napoli, Italy.&#xD;Department of Clinical Medicine and Surgery, Universita degli Studi di Napoli Federico II, Napoli, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A bird&apos;s eye view on the role of dendritic cells in SARS-CoV-2 infection: Perspectives for immune-based vaccines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">100-110</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/07/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">immune-therapies</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34245591</style></accession-num><abstract><style face="normal" font="default" size="100%">Coronavirus disease-19 (COVID-19) is a complex disorder caused by the pandemic diffusion of a novel coronavirus named SARS-CoV-2. Clinical manifestations vary from silent infection to severe pneumonia, disseminated thrombosis, multi-organ failure, and death. COVID-19 pathogenesis is still not fully elucidated, while increasing evidence suggests that disease phenotypes are strongly related to the virus-induced immune system&apos;s dysregulation. Indeed, when the virus-host cross talk is out of control, the occurrence of an aberrant systemic inflammatory reaction, named &quot;cytokine storm,&quot; leads to a detrimental impairment of the adaptive immune response. Dendritic cells (DCs) are the most potent antigen-presenting cells able to support innate immune and promote adaptive responses. Besides, DCs play a key role in the anti-viral defense. The aim of this review is to focus on DC involvement in SARS-CoV-2 infection to better understand pathogenesis and clinical behavior of COVID-19 and explore potential implications for immune-based therapy strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Galati, Domenico&#xD;Zanotta, Serena&#xD;Capitelli, Ludovica&#xD;Bocchino, Marialuisa&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):100-110. doi: 10.1111/all.15004. Epub 2021 Jul 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34245591</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441836</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15004</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2766</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2766</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sharma, R.</style></author><author><style face="normal" font="default" size="100%">Wu, K.</style></author><author><style face="normal" font="default" size="100%">Han, K.</style></author><author><style face="normal" font="default" size="100%">Russo, A. C.</style></author><author><style face="normal" font="default" size="100%">Dagur, P. K.</style></author><author><style face="normal" font="default" size="100%">Combs, C. A.</style></author><author><style face="normal" font="default" size="100%">Yao, X.</style></author><author><style face="normal" font="default" size="100%">Levine, S. J.</style></author><author><style face="normal" font="default" size="100%">Sack, M. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Mitochondrial Biology and Metabolism, NHLBI, NIH, Bethesda, Maryland, USA.&#xD;Cardiovascular Branch, NHLBI, NIH, Bethesda, Maryland, USA.&#xD;Flow Cytometry Core, NHLBI, NIH, Bethesda, Maryland, USA.&#xD;Light Microscopy Core, NHLBI, NIH, Bethesda, Maryland, USA.&#xD;Critical Care Medicine and Pulmonary Branch, Bethesda, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">BLOC1S1 Control of Vacuolar Organelle Fidelity Modulates Murine T(H)2 Cell Immunity and Allergy Susceptibility</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2128-2140</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/12/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/metabolism/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">*Vacuoles/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">NF-kappa B/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39737471</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The levels of biogenesis of lysosome organelles complex 1 subunit 1 (BLOC1S1) control mitochondrial and endolysosome organelle homeostasis and function. Reduced fidelity of these vacuolar organelles is increasingly being recognized as important in instigating cell-autonomous immune cell activation. We reasoned that exploring the role of BLOC1S1 in CD4(+) T cells may further advance our understanding of regulatory events linked to mitochondrial and/or endolysosomal function in adaptive immunity. METHODS: CD4(+) T cells were analyzed from control and CD4(+) T-cell-specific BLOC1S1 knockout mice. Polarization profiles were assayed using biochemical and molecular signatures, and signaling pathways were disrupted pharmacologically or via siRNA. Mouse models of airway and skin inflammation were generated by Ovalbumin and MC903 exposure, respectively. RESULTS: T(H)2 regulator GATA3 and phosphorylated STAT6 were preferentially induced in BLOC1S1-depleted primary CD4(+) T (TKO) cells. The levels of IL-4, IL-5, and IL-13 were markedly induced in the absence of BLOC1S1. At the organelle level, mitochondrial DNA leakage evoked cGAS-STING and NF-kappaB pathway activation with subsequent T(H)2 polarization. The induction of autophagy with rapamycin reduced cytosolic mtDNA and reversed these T(H)2 signatures. Furthermore, genetic knockdown of STING and NF-kappaB inhibition ameliorated this immune regulatory cascade in TKO cells. Finally, at a functional level, TKO mice displayed an increased susceptibility to allergic conditions, including dermatitis and allergic asthma. CONCLUSIONS: BLOC1S1 depletion in mouse CD4(+) T cells mediated disruption of mitochondrial integrity to initiate a predominant T(H)2-responsive phenotype via STING-NF-kappaB-driven signaling of the canonical T(H)2 regulatory program.</style></abstract><notes><style face="normal" font="default" size="100%">Sharma, Rahul&#xD;Wu, Kaiyuan&#xD;Han, Kim&#xD;Russo, Anna Chiara&#xD;Dagur, Pradeep K&#xD;Combs, Christian A&#xD;Yao, Xianglan&#xD;Levine, Stewart J&#xD;Sack, Michael N&#xD;eng&#xD;Z01 HL005199/ImNIH/Intramural NIH HHS/&#xD;ZIA HL005102/ImNIH/Intramural NIH HHS/&#xD;NHLBI Division of Intramural Research/&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2128-2140. doi: 10.1111/all.16461. Epub 2024 Dec 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39737471</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12206928</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16461</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1942</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1942</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jeong, M.</style></author><author><style face="normal" font="default" size="100%">Kim, S. J.</style></author><author><style face="normal" font="default" size="100%">Koo, K.</style></author><author><style face="normal" font="default" size="100%">Lee, A. R.</style></author><author><style face="normal" font="default" size="100%">Pyo, M. J.</style></author><author><style face="normal" font="default" size="100%">Shim, H. J.</style></author><author><style face="normal" font="default" size="100%">Moon, K. A.</style></author><author><style face="normal" font="default" size="100%">Lee, J. H.</style></author><author><style face="normal" font="default" size="100%">Hong, C. H.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Cho, H.</style></author><author><style face="normal" font="default" size="100%">Koh, E. H.</style></author><author><style face="normal" font="default" size="100%">Lee, K. U.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Yoon, S. Y.</style></author><author><style face="normal" font="default" size="100%">Cho, Y. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Department of Medical Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.&#xD;College of Pharmacy, Seoul National University, Seoul, Korea.&#xD;Department of Internal Medicine, Biomedical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Department of Convergence Medicine, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Department of Allergy and Pulmonology in Internal Medicine, Chungnam National University, Chungnam National University Sejong Hospital, Sejong, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blockade of sphingosine-1-phosphate receptor 4 pathway has anti-inflammatory effects in a murine model of allergic airway inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2033-2036</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Sphingosine-1-Phosphate Receptors/metabolism/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Lung/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Sphingosine</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Lysophospholipids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36802060</style></accession-num><notes><style face="normal" font="default" size="100%">Jeong, Mini&#xD;Kim, Sin-Jeong&#xD;Koo, Kyomoon&#xD;Lee, A Ryang&#xD;Pyo, Min Ju&#xD;Shim, Hyun Jae&#xD;Moon, Keun-Ai&#xD;Lee, Ji-Hyang&#xD;Hong, Chung Hwan&#xD;Kim, Jae Hyun&#xD;Cho, Hyunkyung&#xD;Koh, Eun Hee&#xD;Lee, Ki-Up&#xD;Kim, Sanghee&#xD;Yoon, Sun-Young&#xD;Cho, You-Sook&#xD;eng&#xD;NRF-2019R1G1A1100521/korean ministry of science and ICT/&#xD;ministry of health and welfare, Republic of korea/&#xD;HR21C0198/Ministry of Health &amp;amp; Welfare, Republic of Korea/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2033-2036. doi: 10.1111/all.15682. Epub 2023 Mar 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36802060</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15682</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2670</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2670</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Zheng, G.</style></author><author><style face="normal" font="default" size="100%">Wang, T.</style></author><author><style face="normal" font="default" size="100%">Sun, H.</style></author><author><style face="normal" font="default" size="100%">Huang, Z.</style></author><author><style face="normal" font="default" size="100%">He, J.</style></author><author><style face="normal" font="default" size="100%">Qiu, J.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z.</style></author><author><style face="normal" font="default" size="100%">Guo, Y.</style></author><author><style face="normal" font="default" size="100%">He, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Intensive Care Unit, Guangdong Provincial People&apos;s Hospital (Guangdong Academy of Medical Sciences); Department of Immunology, School of Basic Medical Sciences; Department of Clinical Laboratory, The Third Affiliated Hospital of Southern Medical University, Southern Medical University, Guangzhou, China.&#xD;Department of Clinical Laboratory, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China.&#xD;Department of Immunology; Guangdong Provincial Key Laboratory of Single Cell Technology and Application, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.&#xD;Pediatric Intensive Care Unit, Guangdong Provincial People&apos;s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University; Guangdong Provincial Cardiovascular Institute, Guangdong Provincial People&apos;s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.&#xD;CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.&#xD;Medical Research Institute, Guangdong Provincial People&apos;s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blocking the HIF-1alpha/glycolysis axis inhibits allergic airway inflammation by reducing ILC2 metabolism and function</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1309-1334</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/10/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypoxia-Inducible Factor 1, alpha Subunit/metabolism/antagonists &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Glycolysis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Hypersensitivity/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">HIF-1alpha</style></keyword><keyword><style face="normal" font="default" size="100%">allergic lung inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">glycolysis</style></keyword><keyword><style face="normal" font="default" size="100%">group 2 innate lymphoid cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39462230</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The role of lung group 2 innate lymphoid cell (ILC2) activation in allergic asthma is increasingly established. However, the regulatory mechanisms underlying hypoxia-inducible factor-1alpha (HIF-1alpha)-mediated glycolysis in ILC2-mediated allergic airway inflammation remain unclear. OBJECTIVE: To investigate the role of the HIF-1alpha/glycolysis axis in ILC2-mediated allergic airway inflammation. METHODS: Glycolysis and HIF-1alpha inhibitors were used to identify their effect on the function and glucose metabolism of mouse and human ILC2s in vivo and vitro. Blocking glycolysis and HIF-1alpha in mice under interleukin-33 (IL-33) stimulation were performed to test ILC2 responses. Conditional HIF-1alpha-deficient mice were used to confirm the specific role of HIF-1alpha in ILC2-driven airway inflammation models. Transcriptomic, metabolic, and chromatin immunoprecipitation analyses were performed to elucidate the underlying mechanism. RESULTS: HIF-1alpha is involved in ILC2 metabolism and is crucial in allergic airway inflammation. Single-cell sequencing data analysis and qPCR confirmation revealed a significant upregulation of glycolysis-related genes, particularly HIF-1alpha, in murine lung ILC2s after IL-33 intranasal administration or injection. Treatment with the glycolysis inhibitor 2-deoxy-D-glucose (2-DG) and the HIF-1alpha inhibitor 2-methoxyestradiol (2-ME) abrogated inflammation by suppressing ILC2s function. Conditional HIF-1alpha-deficient mice showed reduced ILC2 response and airway inflammation induced upon IL-33 or house dust mite (HDM) stimulation. Transcriptome and metabolic analyses revealed significantly impaired glycolysis in lung ILC2s in conditional HIF-1alpha knockout mice compared to that in their littermate controls. Chromatin immunoprecipitation results confirmed the transcriptional downregulation of glycolysis-related genes in HIF-1alpha-knockout and 2-DG-treated mice. Furthermore, impaired HIF-1alpha/glycolysis axis activation is correlated with downregulated ILC2 in patients with asthma. CONCLUSION: The HIF-1alpha/glycolysis axis is critical for controlling ILC2 responses in allergic airway inflammation and has potential immunotherapeutic value in asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Xiaogang&#xD;Liu, Jingping&#xD;Li, Xinyao&#xD;Zheng, Guilang&#xD;Wang, Tianci&#xD;Sun, Hengbiao&#xD;Huang, Zhengcong&#xD;He, Junyu&#xD;Qiu, Ju&#xD;Zhao, Zhibin&#xD;Guo, Yuxiong&#xD;He, Yumei&#xD;eng&#xD;YKY-KF202209/the Open Fund Project of Guangdong Academy of Medical Sciences/&#xD;2022A1515012427;2022A1515140172;2024A1515012897/National Natural Science Foundation of China-Guangdong Joint Fund/&#xD;82171706;81991511/National Natural Science Foundation of China/&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1309-1334. doi: 10.1111/all.16361. Epub 2024 Oct 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39462230</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16361</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2458</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2458</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nadif, R.</style></author><author><style face="normal" font="default" size="100%">Henny, J.</style></author><author><style face="normal" font="default" size="100%">Tsiavia, T.</style></author><author><style face="normal" font="default" size="100%">Ribet, C.</style></author><author><style face="normal" font="default" size="100%">Goldberg, M.</style></author><author><style face="normal" font="default" size="100%">Zins, M.</style></author><author><style face="normal" font="default" size="100%">Orsi, L.</style></author><author><style face="normal" font="default" size="100%">Roche, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Equipe d&apos;Epidemiologie respiratoire integrative, CESP, Villejuif, France.&#xD;Universite de Paris Cite, Universite Paris-Saclay, UVSQ, Inserm, UMS 11, Cohortes Epidemiologiques en population, Villejuif, France.&#xD;Faculty of Medicine, University of Paris, Paris, France.&#xD;APHP Centre-Universite de Paris, Hopital et Institut Cochin, Service de Pneumologie, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blood basophils and asthma among participants from CONSTANCES, the French population-based cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2527-2531</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">France/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38425050</style></accession-num><notes><style face="normal" font="default" size="100%">Nadif, Rachel&#xD;Henny, Joseph&#xD;Tsiavia, Tajidine&#xD;Ribet, Celine&#xD;Goldberg, Marcel&#xD;Zins, Marie&#xD;Orsi, Laurent&#xD;Roche, Nicolas&#xD;eng&#xD;French national health insurance fund/&#xD;ANR-11-INBS-0002/French national agency for research:/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2527-2531. doi: 10.1111/all.16093. Epub 2024 Feb 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38425050</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16093</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2282</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2282</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vultaggio, A.</style></author><author><style face="normal" font="default" size="100%">Accinno, M.</style></author><author><style face="normal" font="default" size="100%">Vivarelli, E.</style></author><author><style face="normal" font="default" size="100%">Mecheri, V.</style></author><author><style face="normal" font="default" size="100%">Maggiore, G.</style></author><author><style face="normal" font="default" size="100%">Cosmi, L.</style></author><author><style face="normal" font="default" size="100%">Parronchi, P.</style></author><author><style face="normal" font="default" size="100%">Rossi, O.</style></author><author><style face="normal" font="default" size="100%">Maggi, E.</style></author><author><style face="normal" font="default" size="100%">Gallo, O.</style></author><author><style face="normal" font="default" size="100%">Matucci, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.&#xD;Immunology and Cellular Therapy Unit, Careggi University Hospital, Florence, Italy.&#xD;Department of Clinical and Experimental Medicine, Otolaryngology Clinic, University of Florence, Florence, Italy.&#xD;Immunoallergology Unit, Careggi University Hospital, Florence, Italy.&#xD;Translational Immunology Unit, Immunology Area, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blood CD62L(low) inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3154-3165</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/10/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-5</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Eosinophilia/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cd62l</style></keyword><keyword><style face="normal" font="default" size="100%">Il-5</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37792721</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophils have been divided into different subpopulations with distinct phenotypes based on CD62L expression. No data are available regarding the correlation between eosinophils subphenotypes and clinical severity of asthma, as well as the effect of anti-IL-5 therapy on these cells. The study investigates the correlation between blood CD62L(low) inflammatory eosinophils (iEos) and clinical severity of severe eosinophilic asthma (SEA) and evaluates the impact of mepolizumab on iEos. METHODS: 112 patients were screened and were divided in two groups: biological-naive (n = 51) and biological-treated patients (n = 61). The Biological-naive patients were analyzed before treatment (Group A) and 19 out of 51 patients, were longitudinally analyzed before and after treatment with mepolizumab 100 mg s.c/4 weeks (Group B); 32 patients were excluded because they were being treated with other biological therapies. Blood eosinophils were analyzed by FACS and correlated with clinical scores. In vitro effect of IL-5 and mepolizumab on CD62L expression was assessed. RESULTS: A significant correlation between blood CD62L(low) cells and clinical scores of asthma and nasal polyps, as well as the number of asthma exacerbations in the last year was shown in untreated patients. In longitudinally studied patients we observed a marked reduction of CD62L(low) cells paralleled by an increase in the proportion of CD62L(bright) cells, associated with clinical improvement of asthma control. In vitro, CD62L expression on eosinophils is modulated by IL-5 and anti-IL-5. CONCLUSION: A positive correlation between CD62L(low) iEos and the baseline clinical features of SEA with CRSwNP was shown. Furthermore mepolizumab restores the healthy balance among eosinophils sub-phenotypes in SEA patients.</style></abstract><notes><style face="normal" font="default" size="100%">Vultaggio, Alessandra&#xD;Accinno, Matteo&#xD;Vivarelli, Emanuele&#xD;Mecheri, Valentina&#xD;Maggiore, Giandomenico&#xD;Cosmi, Lorenzo&#xD;Parronchi, Paola&#xD;Rossi, Olivero&#xD;Maggi, Enrico&#xD;Gallo, Oreste&#xD;Matucci, Andrea&#xD;eng&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3154-3165. doi: 10.1111/all.15909. Epub 2023 Oct 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37792721</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15909</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1373</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1373</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gueant, J. L.</style></author><author><style face="normal" font="default" size="100%">Fromonot, J.</style></author><author><style face="normal" font="default" size="100%">Gueant-Rodriguez, R. M.</style></author><author><style face="normal" font="default" size="100%">Lacolley, P.</style></author><author><style face="normal" font="default" size="100%">Guieu, R.</style></author><author><style face="normal" font="default" size="100%">Regnault, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department INSERM UMR_S1256, Nutrition-Genetics-Environmental Risk Exposure University of Lorraine, Nancy, France.&#xD;Center for CardioVascular and Nutrition Research, INSERM, INRA and Aix-Marseille University, Marseille, France.&#xD;Department INSERM, UMR_S1116 Defaillance cardiovasculaire aigue et chronique, University of Lorraine, Nancy, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blood myeloperoxidase-DNA, a biomarker of early response to SARS-CoV-2 infection?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">892-896</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">DNA/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Extracellular Traps</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Histones/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Peroxidase/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">myeloperoxidase</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophil extra-cellular traps (NETs)</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophils</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32743884</style></accession-num><notes><style face="normal" font="default" size="100%">Gueant, Jean-Louis&#xD;Fromonot, Julien&#xD;Gueant-Rodriguez, Rosa-Maria&#xD;Lacolley, Patrick&#xD;Guieu, Regis&#xD;Regnault, Veronique&#xD;eng&#xD;ANR-15-IDEX-04-LUE/ANR/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):892-896. doi: 10.1111/all.14533. Epub 2020 Aug 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32743884</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7436665</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14533</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1229</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1229</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Choi, H.</style></author><author><style face="normal" font="default" size="100%">Nam, H.</style></author><author><style face="normal" font="default" size="100%">Yang, B.</style></author><author><style face="normal" font="default" size="100%">Hwangbo, B.</style></author><author><style face="normal" font="default" size="100%">Kong, S. Y.</style></author><author><style face="normal" font="default" size="100%">Chung, S. J.</style></author><author><style face="normal" font="default" size="100%">Yeo, Y.</style></author><author><style face="normal" font="default" size="100%">Park, T. S.</style></author><author><style face="normal" font="default" size="100%">Park, D. W.</style></author><author><style face="normal" font="default" size="100%">Moon, J. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, T. H.</style></author><author><style face="normal" font="default" size="100%">Sohn, J. W.</style></author><author><style face="normal" font="default" size="100%">Yoon, H. J.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.&#xD;Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.&#xD;Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Korea.&#xD;Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.&#xD;Division of Pulmonology, Center of Lung Cancer, National Cancer Center, Goyang, Korea.&#xD;Department of Laboratory Medicine, Hospital, National Cancer Center, Goyang, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Body mass index change and incident asthma in adults: A nationwide cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1896-1899</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33319354</style></accession-num><notes><style face="normal" font="default" size="100%">Lee, Hyun&#xD;Choi, Hayoung&#xD;Nam, Hyewon&#xD;Yang, Bumhee&#xD;Hwangbo, Bin&#xD;Kong, Sun-Young&#xD;Chung, Sung Jun&#xD;Yeo, Yoomi&#xD;Park, Tai Sun&#xD;Park, Dong Won&#xD;Moon, Ji-Yong&#xD;Kim, Tae-Hyung&#xD;Sohn, Jang Won&#xD;Yoon, Ho Joo&#xD;Kim, Sang-Heon&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1896-1899. doi: 10.1111/all.14703. Epub 2020 Dec 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33319354</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14703</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1018</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1018</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perusko, M.</style></author><author><style face="normal" font="default" size="100%">Apostolovic, D.</style></author><author><style face="normal" font="default" size="100%">Kiewiet, M. B. G.</style></author><author><style face="normal" font="default" size="100%">Grundstrom, J.</style></author><author><style face="normal" font="default" size="100%">Hamsten, C.</style></author><author><style face="normal" font="default" size="100%">Starkhammar, M.</style></author><author><style face="normal" font="default" size="100%">Cirkovic Velickovic, T.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.&#xD;Innovative Centre Faculty of Chemistry, Belgrade, Serbia.&#xD;Department of Internal Medicine, Sodersjukhuset, Stockholm, Sweden.&#xD;Department of Biochemistry, Center of Excellence for Molecular Food Sciences, University of Belgrade-Faculty of Chemistry, Belgrade, Serbia.&#xD;Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium.&#xD;Ghent University Global Campus, Yeonsu-Gu, Incheon, South Korea.&#xD;Serbian Academy of Sciences and Arts, Belgrade, Serbia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bovine gamma-globulin, lactoferrin, and lactoperoxidase are relevant bovine milk allergens in patients with alpha-Gal syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3766-3775</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Lactoferrin/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Lactoperoxidase/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*gamma-Globulins/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">bovine gamma-globulin</style></keyword><keyword><style face="normal" font="default" size="100%">lactoferrin</style></keyword><keyword><style face="normal" font="default" size="100%">lactoperoxidase</style></keyword><keyword><style face="normal" font="default" size="100%">milk</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-Gal syndrome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33938008</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Mammalian meat is the most common trigger of the allergic reactions in patients with alpha-Gal syndrome (AGS). Milk and dairy, although less often, also cause a significant number of allergic manifestations. The aim of this study was to identify alpha-Gal-containing bovine milk proteins with allergenic properties among AGS patients. METHODS: Thirty-eight AGS patients with IgE to milk were included in the study. Milk proteins were analyzed for the presence of alpha-Gal and for binding by patients&apos; IgE using immunoblot, ImmunoCAP, and inhibition ELISA. Allergenicity of milk and milk proteins was assessed by basophil activation test. RESULTS: More than half of the AGS patients reported allergic reactions to milk or dairy products. Bovine gamma-globulin (BGG), lactoferrin (LF), and lactoperoxidase (LPO) were identified as alpha-Gal carrying proteins which were recognized by AGS patients&apos; IgE. Whey mirrored the anti-alpha-Gal and IgE reactivity of BGG, LF, and LPO. Eighty-nine percent of the patients displayed IgE to BGG, 91% to LF, and 57% to LPO. Inhibition of alpha-Gal-specific IgE binding was achieved by BGG, LF, LPO, and whey. These proteins also activated AGS patients&apos; basophils. Interestingly, at lower concentrations, LF was the most potent inhibitor of IgE binding, and the most potent activator of basophils. CONCLUSION: BGG, LF, and LPO were all found to be relevant milk alpha-Gal-containing glycoproteins that bound AGS patients&apos; IgE antibodies and activated their basophils. These proteins are probably involved in the allergic reactions to milk in AGS patients. LPO was for the first time shown to be an allergen.</style></abstract><notes><style face="normal" font="default" size="100%">Perusko, Marija&#xD;Apostolovic, Danijela&#xD;Kiewiet, Mensiena Berentje Geertje&#xD;Grundstrom, Jeanette&#xD;Hamsten, Carl&#xD;Starkhammar, Maria&#xD;Cirkovic Velickovic, Tanja&#xD;van Hage, Marianne&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3766-3775. doi: 10.1111/all.14889. Epub 2021 May 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33938008</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14889</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1246</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1246</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Callebaut, I.</style></author><author><style face="normal" font="default" size="100%">Steelant, B.</style></author><author><style face="normal" font="default" size="100%">Backaert, W.</style></author><author><style face="normal" font="default" size="100%">Peeters, R.</style></author><author><style face="normal" font="default" size="100%">Sunaert, S.</style></author><author><style face="normal" font="default" size="100%">Van Oudenhove, L.</style></author><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, Leuven, Belgium.&#xD;Department of Imaging &amp; Pathology, KU Leuven, Leuven, Belgium.&#xD;Department of Radiology, University Hospitals Leuven, Leuven, Belgium.&#xD;Laboratory for Brain-Gut Axis Studies (LaBGAS), Department of Chronic Diseases, Metabolism, and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven, Belgium.&#xD;Cognitive and Affective Neuroscience Laboratory (CANlab), Center for Cognitive Neuroscience, Department of Psychological and Brain Sciences, Dartmouth College, Hanover, NH, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Brain activation after nasal histamine provocation in house dust mite allergic rhinitis patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1879-1882</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mites</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33283291</style></accession-num><notes><style face="normal" font="default" size="100%">Callebaut, Ina&#xD;Steelant, Brecht&#xD;Backaert, Wout&#xD;Peeters, Ronald&#xD;Sunaert, Stefan&#xD;Van Oudenhove, Lukas&#xD;Hellings, Peter W&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1879-1882. doi: 10.1111/all.14677. Epub 2020 Dec 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33283291</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246755</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14677</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2743</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2743</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Bentabol-Ramos, G.</style></author><author><style face="normal" font="default" size="100%">van den Berge, M.</style></author><author><style face="normal" font="default" size="100%">Boccabella, C.</style></author><author><style face="normal" font="default" size="100%">Canonica, W. G.</style></author><author><style face="normal" font="default" size="100%">Caruso, C.</style></author><author><style face="normal" font="default" size="100%">Couto, M.</style></author><author><style face="normal" font="default" size="100%">Davila, I.</style></author><author><style face="normal" font="default" size="100%">Drummond, D.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J.</style></author><author><style face="normal" font="default" size="100%">Gherasim, A.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Jackson, D. J.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Licari, A.</style></author><author><style face="normal" font="default" size="100%">Loukides, S.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Ojanguren, I.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Papi, A.</style></author><author><style face="normal" font="default" size="100%">Perez de Llano, L.</style></author><author><style face="normal" font="default" size="100%">Price, O. J.</style></author><author><style face="normal" font="default" size="100%">Rukhazde, M.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Shaw, D.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Garcia, S.</style></author><author><style face="normal" font="default" size="100%">Testera-Montes, A.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Pulmonology Unit, Hospital Regional Universitario de Malaga and IBIMA-Plataforma BIONAND, Malaga, Spain.&#xD;Department of Pulmonary Diseases, Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Department of Cardiovascular and Thoracic Sciences, Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.&#xD;Personalized Medicine, Asthma and Allergy, Humanitas Clinical &amp; Research Center, IRCCS, Rozzano, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.&#xD;UOSD DH Internal Medicine and Digestive Disease, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy.&#xD;Immunoallergology, Hospital CUF Trindade, Porto, Portugal.&#xD;Allergy Service, Salamanca University Hospital, Faculty of Medicine, University of Salamanca, Salamanca, Spain.&#xD;Department of Pediatric Pulmonology and Allergology, University Hospital Necker-Enfants Malades, AP-HP, Faculte de Medecine, Universite Paris Cite, Inserm UMR 1138, HeKAteam, Centre de Recherche des Cordeliers, Paris, France.&#xD;MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Centre for Health Technology and Services Research, Health Research Network (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;ALYATEC Clinical Research Center, Strasbourg University Hospital, Strasbourg, France.&#xD;Unit of Allergy and Clinical Immunology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Guy&apos;s Severe Asthma Centre, School of Immunology &amp; Microbial Sciences, Guy&apos;s Hospital, King&apos;s College London, London, UK.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.&#xD;2nd Respiratory Medicine Department, &quot;Attikon&quot; University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.&#xD;Department of Allergy and Clinical Immunology, Centro Hospitalar Universitario de Sao Joao, Porto, Portugal.&#xD;EPIUnit - Institute of Public Health, University of Porto, Porto, Portugal.&#xD;Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal.&#xD;Department of Medicine, McMaster University &amp; St Joseph&apos;s Healthcare, Hamilton, Ontario, Canada.&#xD;Pneumology Service, University Hospital Vall d&apos;Hebron, VHIR, CIBERES, Autonomous University of Barcelona, Barcelona, Spain.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.&#xD;Respiratory Medicine, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.&#xD;Pneumology Service, Lucus Augusti University Hospital, EOXI Lugo, Monforte, Cervo, Psychiatry, Radiology, Public Health, Nursing and Medicine Department of the Santiago de Compostela University, Santiago de Compostela, Spain.&#xD;School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, UK.&#xD;Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.&#xD;Center Allergy&amp;Immunology, Tbilisi, Georgia.&#xD;Faculty of Medicine, Geomedi Teaching University, Tbilisi, Georgia.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Respiratory Research Unit, University of Nottingham, Nottingham, UK.&#xD;Allergy Unit, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, IBIMA-Plataforma BIONAND, RICORS Inflammatory Diseases, Department of Medicine and Dermatology, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">380-394</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/12/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Acetylcholine/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Inflammatory Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/complications/drug therapy/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Bronchodilator Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Muscarine/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Muscarinic Antagonists/adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Disease, Chronic Obstructive/ethnology</style></keyword><keyword><style face="normal" font="default" size="100%">Societies, Medical</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">acetylcholine</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchodilator</style></keyword><keyword><style face="normal" font="default" size="100%">endotype</style></keyword><keyword><style face="normal" font="default" size="100%">long-acting muscarinic antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39676750</style></accession-num><abstract><style face="normal" font="default" size="100%">As cholinergic innervation is a major contributor to increased vagal tone and mucus secretion, inhaled long-acting muscarinic antagonists (LAMA) are a pillar for the treatment of chronic obstructive pulmonary disease and asthma. By blocking the muscarinic receptors expressed in the lung, LAMA improve lung function and reduce exacerbations in asthma patients who remained poorly controlled despite treatment with inhaled corticosteroids and long-acting beta2 agonists. Asthma guidelines recommend LAMA as a third controller to be added on before the initiation of biologicals. In addition to bronchodilation, LAMA also exert anti-inflammatory and anti-fibrotic effects by inhibiting muscarinic receptors present in neutrophils, macrophages, fibroblasts and airway smooth muscle cells. Thus, besides bronchodilation, LAMA might provide additional therapeutic effects, thereby supporting an endotype-driven approach to asthma management. The Position Paper, developed by the Asthma Section of the European Academy of Allergy and Clinical Immunology, discusses the main cholinergic pathways in the lung, reviews the findings of significant clinical trials and real-life studies on LAMA use in asthma, examines the placement of these drugs in asthma clinical guidelines, and considers the potential for personalised medicine with LAMA in both adult and paediatric asthma patients.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, I&#xD;Adcock, I M&#xD;Akdis, C A&#xD;Akdis, M&#xD;Bentabol-Ramos, G&#xD;van den Berge, M&#xD;Boccabella, C&#xD;Canonica, W G&#xD;Caruso, C&#xD;Couto, M&#xD;Davila, I&#xD;Drummond, D&#xD;Fonseca, J&#xD;Gherasim, A&#xD;Del Giacco, S&#xD;Jackson, D J&#xD;Jutel, M&#xD;Licari, A&#xD;Loukides, S&#xD;Moreira, A&#xD;Mukherjee, M&#xD;Ojanguren, I&#xD;Palomares, O&#xD;Papi, A&#xD;Perez de Llano, L&#xD;Price, O J&#xD;Rukhazde, M&#xD;Shamji, M H&#xD;Shaw, D&#xD;Sanchez-Garcia, S&#xD;Testera-Montes, A&#xD;Torres, M J&#xD;Eguiluz-Gracia, I&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Consensus Development Conference&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):380-394. doi: 10.1111/all.16436. Epub 2024 Dec 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39676750</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16436</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>588</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">588</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mendes-Bastos, P.</style></author><author><style face="normal" font="default" size="100%">Brasileiro, A.</style></author><author><style face="normal" font="default" size="100%">Kolkhir, P.</style></author><author><style face="normal" font="default" size="100%">Frischbutter, S.</style></author><author><style face="normal" font="default" size="100%">Scheffel, J.</style></author><author><style face="normal" font="default" size="100%">Monino-Romero, S.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dermatology Center, Hospital CUF Descobertas, Lisbon, Portugal.&#xD;Department of Dermatology, Hospital Santo Antonio dos Capuchos, Centro Hospitalar Universitario Lisboa Central, Lisbon, Portugal.&#xD;NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal.&#xD;Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;Division of Immune-Mediated Skin Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bruton&apos;s tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2355-2366</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Agammaglobulinaemia Tyrosine Kinase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pemphigus/drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Kinase Inhibitors/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Bruton&apos;s tyrosine kinase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">fenebrutinib</style></keyword><keyword><style face="normal" font="default" size="100%">pemphigus</style></keyword><keyword><style face="normal" font="default" size="100%">remibrutinib</style></keyword><keyword><style face="normal" font="default" size="100%">AbbVie, Janssen, Novartis, LEO Pharma, Almirall, Sanofi, Viatris, L&apos;Oreal, and</style></keyword><keyword><style face="normal" font="default" size="100%">Cantabria Labs and served as a principal investigator in clinical trials</style></keyword><keyword><style face="normal" font="default" size="100%">supported by AbbVie, Sanofi, and Novartis. AB received honoraria for lectures and</style></keyword><keyword><style face="normal" font="default" size="100%">educational events for LEO Pharma, Janssen-Cilag, AbbVie, and Novartis. PK</style></keyword><keyword><style face="normal" font="default" size="100%">received payment/honoraria for lectures/presentations outside of submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">for Novartis and Roche.. SM-R received funding from GA(2)LEN Global Allergy and</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma European Network. MM served as a speaker and/or advisor for and/or has</style></keyword><keyword><style face="normal" font="default" size="100%">received research funding from Allakos, Amgen, Aralez, ArgenX, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Blueprint, Celldex, Centogene, CSL Behring, FAES, Genentech, Gilead,</style></keyword><keyword><style face="normal" font="default" size="100%">GIInnovation, Innate Pharma, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Roche, Sanofi/Regeneron, Third Harmonic Bio, UCB, and Uriach. SF and JS</style></keyword><keyword><style face="normal" font="default" size="100%">have no conflicts of interest to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35175630</style></accession-num><abstract><style face="normal" font="default" size="100%">Bruton&apos;s tyrosine kinase (BTK), a member of the Tec kinase family, is critically involved in a range of immunological pathways. The clinical application of BTK inhibitors for B-cell malignancies has proven successful, and there is strong rationale for the potential benefits of BTK inhibitors in some autoimmune and allergic conditions, including immune-mediated dermatological diseases. However, the established risk-to-benefit profile of &quot;first-generation&quot; BTK inhibitors cannot be extrapolated to these emerging, non-oncological, indications. &quot;Next-generation&quot; BTK inhibitors such as remibrutinib and fenebrutinib entered clinical development for chronic spontaneous urticaria (CSU); rilzabrutinib and tirabrutinib are being studied as potential treatments for pemphigus. Promising data from early-phase clinical trials in CSU suggest potential for these agents to achieve strong pathway inhibition, which may translate into measurable clinical benefits, as well as other effects such as the disruption of autoantibody production. BTK inhibitors may help to overcome some of the shortcomings of monoclonal antibody treatments for immune-mediated dermatological conditions such as CSU, pemphigus, and systemic lupus erythematosus. In addition, the use of BTK inhibitors may improve understanding of the pathophysiological roles of mast cells, basophils, and B cells in such conditions.</style></abstract><notes><style face="normal" font="default" size="100%">Mendes-Bastos, Pedro&#xD;Brasileiro, Ana&#xD;Kolkhir, Pavel&#xD;Frischbutter, Stefan&#xD;Scheffel, Jorg&#xD;Monino-Romero, Sherezade&#xD;Maurer, Marcus&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2355-2366. doi: 10.1111/all.15261. Epub 2022 Feb 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35175630</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9545595</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15261</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1970</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1970</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hsu, Y. T.</style></author><author><style face="normal" font="default" size="100%">Wu, C. C.</style></author><author><style face="normal" font="default" size="100%">Wang, C. C.</style></author><author><style face="normal" font="default" size="100%">Chung, W. Y.</style></author><author><style face="normal" font="default" size="100%">Sheu, C. C.</style></author><author><style face="normal" font="default" size="100%">Yang, Y. H.</style></author><author><style face="normal" font="default" size="100%">Cheng, M. Y.</style></author><author><style face="normal" font="default" size="100%">Lai, R. S.</style></author><author><style face="normal" font="default" size="100%">Leung, S. Y.</style></author><author><style face="normal" font="default" size="100%">Lin, C. C.</style></author><author><style face="normal" font="default" size="100%">Wei, Y. F.</style></author><author><style face="normal" font="default" size="100%">Lin, C. H.</style></author><author><style face="normal" font="default" size="100%">Lin, S. H.</style></author><author><style face="normal" font="default" size="100%">Hsu, J. Y.</style></author><author><style face="normal" font="default" size="100%">Huang, W. C.</style></author><author><style face="normal" font="default" size="100%">Tseng, C. C.</style></author><author><style face="normal" font="default" size="100%">Lai, Y. F.</style></author><author><style face="normal" font="default" size="100%">Cheng, M. H.</style></author><author><style face="normal" font="default" size="100%">Chen, H. C.</style></author><author><style face="normal" font="default" size="100%">Yang, C. J.</style></author><author><style face="normal" font="default" size="100%">Su, C. H.</style></author><author><style face="normal" font="default" size="100%">Wang, C. J.</style></author><author><style face="normal" font="default" size="100%">Hsu, S. C.</style></author><author><style face="normal" font="default" size="100%">Hung, C. H.</style></author><author><style face="normal" font="default" size="100%">Lee, C. L.</style></author><author><style face="normal" font="default" size="100%">Huang, M. S.</style></author><author><style face="normal" font="default" size="100%">Huang, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Institute of Environmental Health Sciences, National Health Research Institutes, Miaoli, Taiwan.&#xD;Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.&#xD;Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Department of Computer Science and Information Engineering, National Kaohsiung University of Science and Technology, Kaohsiung, Taiwan.&#xD;Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.&#xD;Department of Mathematics, Hong Kong Baptist University, Hong Kong, China.&#xD;Division of Chest Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.&#xD;Department of Internal Medicine, Chest Division, Antai Medical Care Cooperation Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan.&#xD;Department of Internal Medicine, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.&#xD;Department of Internal Medicine, Division of Chest Medicine, Changhua Christian Hospital, Changhua, Taiwan.&#xD;Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung, Taiwan.&#xD;Department of Recreation and Holistic Wellness, MingDao University, Changhua, Taiwan.&#xD;Department of Medical Research, Division of Clinical Research, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Department of Internal Medicine, Division of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan.&#xD;School of Medicine, Chung Shan Medical University, Taichung, Taiwan.&#xD;Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.&#xD;Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.&#xD;Department of Internal Medicine, Division of Chest Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.&#xD;Department of Respiratory Therapy, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Emergency Department, Taipei Municipal Wan-Fang Hospital, Taipei, Taiwan.&#xD;Department of Emergency, Taipei Medical University School of Medicine, Taipei, Taiwan.&#xD;Department of Pediatrics, Kaohsiung Medical University Hospital and College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Department of Pediatrics, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Department of Marine Environment and Engineering, National Sun Yat-Sen University, Kaohsiung, Taiwan.&#xD;Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">BTEX exposure and its body burden pose differential risks for asthma and its phenotypic clusters</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2036-2040</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Body Burden</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36853070</style></accession-num><notes><style face="normal" font="default" size="100%">Hsu, Yuan-Ting&#xD;Wu, Chao-Chien&#xD;Wang, Chin-Chou&#xD;Chung, Wen-Yu&#xD;Sheu, Chau-Chyun&#xD;Yang, Yi-Hsin&#xD;Cheng, Ming-Yen&#xD;Lai, Ruay-Sheng&#xD;Leung, Sum-Yee&#xD;Lin, Chi-Cheng&#xD;Wei, Yu-Feng&#xD;Lin, Ching-Hsiung&#xD;Lin, Sheng-Hao&#xD;Hsu, Jeng-Yuan&#xD;Huang, Wei-Chang&#xD;Tseng, Chia-Cheng&#xD;Lai, Yung-Fa&#xD;Cheng, Meng-Hsuan&#xD;Chen, Huang-Chi&#xD;Yang, Chih-Jen&#xD;Su, Chian-Heng&#xD;Wang, Chien-Jen&#xD;Hsu, Shih-Chang&#xD;Hung, Chih-Hsing&#xD;Lee, Chon-Lin&#xD;Huang, Ming-Shyan&#xD;Huang, Shau-Ku&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2036-2040. doi: 10.1111/all.15683. Epub 2023 Mar 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36853070</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15683</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2129</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2129</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Janarthanam, R.</style></author><author><style face="normal" font="default" size="100%">Kuang, F. L.</style></author><author><style face="normal" font="default" size="100%">Zalewski, A.</style></author><author><style face="normal" font="default" size="100%">Amsden, K.</style></author><author><style face="normal" font="default" size="100%">Wang, M. Y.</style></author><author><style face="normal" font="default" size="100%">Ostilla, L.</style></author><author><style face="normal" font="default" size="100%">Keeley, K.</style></author><author><style face="normal" font="default" size="100%">Hirano, I.</style></author><author><style face="normal" font="default" size="100%">Kagalwalla, A.</style></author><author><style face="normal" font="default" size="100%">Wershil, B. K.</style></author><author><style face="normal" font="default" size="100%">Gonsalves, N.</style></author><author><style face="normal" font="default" size="100%">Wechsler, J. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Gastroenterology, Hepatology &amp; Nutrition, Ann &amp; Robert H. Lurie Children&apos;s Hospital of Chicago, Northwestern University Feinberg school of Medicine, Chicago, Illinois, USA.&#xD;Division of Allergy-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Department of Pediatrics, John H. Stroger Cook County Hospital of Chicago, Chicago, Illinois, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bulk T-cell receptor sequencing confirms clonality in pediatric eosinophilic esophagitis and identifies a food-specific repertoire</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2487-2496</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/05/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Food/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Antigen, T-Cell/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">EoE</style></keyword><keyword><style face="normal" font="default" size="100%">Tcr</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">diet elimination</style></keyword><keyword><style face="normal" font="default" size="100%">food trigger</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Genzyme, AstraZeneca, and Invea Therapeutics. JBW receives clinical</style></keyword><keyword><style face="normal" font="default" size="100%">trial/research funding from Allakos and Sanofi-Regeneron. FLK receives research</style></keyword><keyword><style face="normal" font="default" size="100%">funding from AstraZeneca and is a consultant for GlaxoSmithKline. NG is a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant for Allakos, Sanofi-Regeneron, AstraZeneca, Abbvie, Knopp, Nutritia.</style></keyword><keyword><style face="normal" font="default" size="100%">NG receives royalties from Up-to-date. IH is a consultant for Adare/Ellodi, Arena</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, AstraZeneca, Celgene/Receptos/BMS, Regeneron/Sanofi, Esocap,</style></keyword><keyword><style face="normal" font="default" size="100%">Gossamer Bio, Lilly, Shire/Takeda, Allakos. IH receives research funding from</style></keyword><keyword><style face="normal" font="default" size="100%">Allakos, Celgene/Bristol Meyers Squibb, Regeneron/Sanofi, Shire/Takeda,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Arena, Adare/Ellodi.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37203302</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophilic esophagitis (EoE) involves a chronic immune-mediated response to dietary antigens. Recent work identifies T-cell clonality in children with EoE, however, it is unknown whether this is true in adults or whether there is a restricted food-specific T-cell repertoire. We sought to confirm T-cell receptor (TCR) clonality in EoE and assess for differences with specific food triggers. METHODS: Bulk TCR sequencing was performed on mRNA isolated from esophageal biopsies obtained from adults and children with EoE (n = 15) who had food triggers confirmed by endoscopic evaluation. Non-EoE adult and pediatric controls (n = 10) were included. Differences in TCR clonality by disease and treatment status were assessed. Shared and similar V-J-CDR3s were assessed based on specific food triggers. RESULTS: Active EoE biopsies from children but not adults displayed decreased unique TCRalpha/beta clonotypes and increased relative abundance of TCRs comprising &gt;1% of the total compared to non-EoE controls and paired inactive EoE samples. Among patients in which baseline, post diet elimination, and food trigger reintroduction samples (n = 6) were obtained, we observed ~1% of TCRs were shared only between pre-diet elimination and trigger reintroduction. Patients with a shared EoE trigger (milk) had a greater degree of shared and similar TCRs compared to patients with differing triggers (seafood, wheat, egg, soy). CONCLUSION: We confirmed relative clonality in children but not adults with active EoE and identified potential food-specific TCRs, particularly for milk-triggered EoE. Further studies are needed to better identify the broad TCR repertoire relevant to food triggers.</style></abstract><notes><style face="normal" font="default" size="100%">Janarthanam, Rethavathi&#xD;Kuang, Fei Li&#xD;Zalewski, Angelika&#xD;Amsden, Katie&#xD;Wang, Ming-Yu&#xD;Ostilla, Lorena&#xD;Keeley, Kaitlyn&#xD;Hirano, Ikuo&#xD;Kagalwalla, Amir&#xD;Wershil, Barry K&#xD;Gonsalves, Nirmala&#xD;Wechsler, Joshua B&#xD;eng&#xD;K23 AI171085/AI/NIAID NIH HHS/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2487-2496. doi: 10.1111/all.15773. Epub 2023 May 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37203302</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10768854</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15773</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2955</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2955</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Porsbjerg, C.</style></author><author><style face="normal" font="default" size="100%">Price, D. B.</style></author><author><style face="normal" font="default" size="100%">Wechsler, M. E.</style></author><author><style face="normal" font="default" size="100%">Heaney, L. G.</style></author><author><style face="normal" font="default" size="100%">Hanania, N. A.</style></author><author><style face="normal" font="default" size="100%">Gall, R.</style></author><author><style face="normal" font="default" size="100%">Pandit-Abid, N.</style></author><author><style face="normal" font="default" size="100%">Jacob-Nara, J. A.</style></author><author><style face="normal" font="default" size="100%">Sacks, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.&#xD;Personalized Medicine Center: Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.&#xD;Department of Respiratory Medicine and Infectious Diseases, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.&#xD;Observational and Pragmatic Research Institute, Midview City, Singapore.&#xD;Division of Applied Health Sciences, Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK.&#xD;Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado, USA.&#xD;Wellcome-Wolfson Institute for Experimental Medicine, Queen&apos;s University Belfast, Belfast, UK.&#xD;Department of Medicine, Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas, USA.&#xD;Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.&#xD;Sanofi, Bridgewater, New Jersey, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2113-2127</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/06/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Adrenal Cortex Hormones/administration &amp; dosage/adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/administration &amp; dosage/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cost of Illness</style></keyword><keyword><style face="normal" font="default" size="100%">OCS stewardship</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">dose sparing</style></keyword><keyword><style face="normal" font="default" size="100%">oral corticosteroid</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">board fees from A Menarini, Allergy Therapeutics, AstraZeneca, Chiesi</style></keyword><keyword><style face="normal" font="default" size="100%">Farmaceutici, Genentech, GSK, Guidotti-Malesci, HAL Allergy, INNOVACAREMD,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, OM Pharma, Red MAPLE, Regeneron Pharmaceuticals Inc., Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes Greer, and Uriach Pharma. Celeste Porsbjerg has received research</style></keyword><keyword><style face="normal" font="default" size="100%">grants and consultancy and/or speaker fees from ALK, AstraZeneca, Chiesi, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Sanofi, and Teva</style></keyword><keyword><style face="normal" font="default" size="100%">and advisory board fees from ALK, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Sanofi, and Teva. David B. Price has or had advisory board membership</style></keyword><keyword><style face="normal" font="default" size="100%">with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Viatris, and Teva Pharmaceuticals</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy agreements with AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, and Teva</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals</style></keyword><keyword><style face="normal" font="default" size="100%">grants and unrestricted funding for investigator-initiated</style></keyword><keyword><style face="normal" font="default" size="100%">studies (conducted through Observational and Pragmatic Research Institute Pte</style></keyword><keyword><style face="normal" font="default" size="100%">Ltd) from AstraZeneca, Chiesi, Novartis, Regeneron Pharmaceuticals Inc., Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">Genzyme, UK National Health Service, and Viatris</style></keyword><keyword><style face="normal" font="default" size="100%">payment for lectures/speaking</style></keyword><keyword><style face="normal" font="default" size="100%">engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Inside</style></keyword><keyword><style face="normal" font="default" size="100%">Practice, GlaxoSmithKline, Medscape, Novartis, Regeneron Pharmaceuticals Inc.,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi Genzyme, Teva Pharmaceuticals, and Viatris</style></keyword><keyword><style face="normal" font="default" size="100%">payment for</style></keyword><keyword><style face="normal" font="default" size="100%">travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Medscape, and Teva Pharmaceuticals</style></keyword><keyword><style face="normal" font="default" size="100%">owns 74% of the social enterprise</style></keyword><keyword><style face="normal" font="default" size="100%">Optimum Patient Care Ltd. (Australia and UK) and 92.61% of Observational and</style></keyword><keyword><style face="normal" font="default" size="100%">Pragmatic Research Institute Pte Ltd. (Singapore)</style></keyword><keyword><style face="normal" font="default" size="100%">is peer reviewer for grant</style></keyword><keyword><style face="normal" font="default" size="100%">committees of the UK Efficacy and Mechanism Evaluation Programme and Health</style></keyword><keyword><style face="normal" font="default" size="100%">Technology Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">and he was an expert witness for GlaxoSmithKline. Michael</style></keyword><keyword><style face="normal" font="default" size="100%">E. Wechsler has received consulting and/or advisory honoraria from Allakos,</style></keyword><keyword><style face="normal" font="default" size="100%">Areteia Therapeutics, Arrowhead Pharmaceutical, Avalo Therapeutics, Belenos Bio,</style></keyword><keyword><style face="normal" font="default" size="100%">Celldex, Connect Biopharma, Eli Lilly, Equillium, Incyte, Jasper Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">Kinaset, Kymera, Merck, MyBiometry, Pharming, Phylaxis, Pulmatrix, Rapt</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, recludix Pharma, Roche/Genentech, Sentien, Sound Biologics,</style></keyword><keyword><style face="normal" font="default" size="100%">Tetherex Pharmaceuticals, Uniquity Bio, Verona Pharma, and Zurabio</style></keyword><keyword><style face="normal" font="default" size="100%">consulting/advising/speaking honoraria from AstraZeneca, Amgen, GlaxoSmith Kline,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals Inc., and Sanofi/Genzyme and is doing research</style></keyword><keyword><style face="normal" font="default" size="100%">sponsored by them</style></keyword><keyword><style face="normal" font="default" size="100%">has received consulting honoraria and stock options and is</style></keyword><keyword><style face="normal" font="default" size="100%">doing research sponsored by Upstream Bio. Liam G. Heaney has received grant</style></keyword><keyword><style face="normal" font="default" size="100%">funding, participated in advisory boards, and given lectures at meetings</style></keyword><keyword><style face="normal" font="default" size="100%">supported by Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Evelo</style></keyword><keyword><style face="normal" font="default" size="100%">Biosciences, GSK, Hoffman-La Roche, Novartis, Sanofi, Teva, and Theravance</style></keyword><keyword><style face="normal" font="default" size="100%">Biopharma</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Aerocrine, Amgen, AstraZeneca, Genentech/Hoffman-La Roche,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, MedImmune, Novartis, Roche-Genentech, and Vitalograph</style></keyword><keyword><style face="normal" font="default" size="100%">sponsorship to attend</style></keyword><keyword><style face="normal" font="default" size="100%">international scientific meetings from AstraZeneca, Boehringer Ingelheim, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, and Napp Pharmaceuticals</style></keyword><keyword><style face="normal" font="default" size="100%">and institutional remuneration for participation</style></keyword><keyword><style face="normal" font="default" size="100%">in asthma clinical trials sponsored by AstraZeneca, Boehringer Ingelheim, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">and Hoffman-La Roche</style></keyword><keyword><style face="normal" font="default" size="100%">and is academic lead for the Medical Research Council</style></keyword><keyword><style face="normal" font="default" size="100%">Stratified Medicine UK Consortium in Severe Asthma, which involves industrial</style></keyword><keyword><style face="normal" font="default" size="100%">partnerships with a number of pharmaceutical companies, including Amgen,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Boehringer Ingelheim, GSK, Hoffman-La Roche, and Janssen. Nicola A.</style></keyword><keyword><style face="normal" font="default" size="100%">Hanania has received consultancy or advisor honoraria from Amgen, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, GSK, Novartis, Sanofi, and Teva</style></keyword><keyword><style face="normal" font="default" size="100%">and grant support to the</style></keyword><keyword><style face="normal" font="default" size="100%">institution from AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Novartis, and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi. Rebecca Gall is an employee of and shareholder in Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals Inc. Nami Pandit-Abid is an employee of Sanofi and may hold stock</style></keyword><keyword><style face="normal" font="default" size="100%">and/or stock options in the company. Juby A. Jacob-Nara is a former employee of</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi and may hold stock and/or stock options in the company. Harry J. Sacks is</style></keyword><keyword><style face="normal" font="default" size="100%">an employee of Regeneron Pharmaceuticals Inc. and may hold stock and/or stock</style></keyword><keyword><style face="normal" font="default" size="100%">options in the company. He has also been a shareholder of Optinose Inc.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40548588</style></accession-num><abstract><style face="normal" font="default" size="100%">Over the past 70 years, oral corticosteroids (OCS) have played an important role in the management of acute and chronic asthma; however, their use is associated with an increased incidence of adverse events, chronic diseases such as osteoporosis and diabetes, and mortality, as well as increased healthcare resource utilization and costs. Despite a consensus that the use of OCS should be minimized in asthma treatment strategies, many patients still routinely receive long-term or frequent short courses of OCS. Add-on biologics can help to improve asthma control in patients with severe asthma and evidence of type 2 inflammation; in clinical trials and real-world studies, both short- and long-term OCS-sparing effects have been demonstrated. In this review, we discuss the benefits and burdens of OCS in patients with severe asthma from the perspective of both patients and healthcare providers and outline potential methods for reducing reliance on OCS. Given the risk of adrenal insufficiency or crisis upon cessation of OCS, we discuss the need for clear guidance and algorithms for the tapering of OCS together with the requirement for multidisciplinary patient-provider interactions as part of an effective OCS stewardship scheme.</style></abstract><notes><style face="normal" font="default" size="100%">Canonica, G Walter&#xD;Porsbjerg, Celeste&#xD;Price, David B&#xD;Wechsler, Michael E&#xD;Heaney, Liam G&#xD;Hanania, Nicola A&#xD;Gall, Rebecca&#xD;Pandit-Abid, Nami&#xD;Jacob-Nara, Juby A&#xD;Sacks, Harry J&#xD;eng&#xD;Regeneron Pharmaceuticals/&#xD;Sanofi/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2113-2127. doi: 10.1111/all.16569. Epub 2025 Jun 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40548588</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368757</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16569</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>838</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">838</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kleuskens, M. T. A.</style></author><author><style face="normal" font="default" size="100%">Haasnoot, M. L.</style></author><author><style face="normal" font="default" size="100%">Herpers, B. M.</style></author><author><style face="normal" font="default" size="100%">Ampting, Mtjv</style></author><author><style face="normal" font="default" size="100%">Bredenoord, A. J.</style></author><author><style face="normal" font="default" size="100%">Garssen, J.</style></author><author><style face="normal" font="default" size="100%">Redegeld, F. A.</style></author><author><style face="normal" font="default" size="100%">van Esch, Bcam</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.&#xD;Department of Gastroenterology &amp; Hepatology, Amsterdam UMC, location AMC, Amsterdam, The Netherlands.&#xD;Danone Nutricia Research, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Butyrate and propionate restore interleukin 13-compromised esophageal epithelial barrier function</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1510-1521</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/08/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Butyrates/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acids, Volatile/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-13/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Propionates/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">barrier function</style></keyword><keyword><style face="normal" font="default" size="100%">dietary intervention</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 13</style></keyword><keyword><style face="normal" font="default" size="100%">short-chain fatty acids</style></keyword><keyword><style face="normal" font="default" size="100%">does not depend on the outcomes of this study. All other authors report no</style></keyword><keyword><style face="normal" font="default" size="100%">conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34458999</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophilic esophagitis (EoE) is a food allergen driven disease that is accompanied by interleukin (IL) 13 overexpression and esophageal barrier dysfunction allowing transepithelial food allergen permeation. Nutraceuticals, such as short-chain fatty acids (SCFAs) that restore barrier function and increase immune fitness may be a promising tool in the management of EoE. Here, we investigated the effects of the SCFAs acetate, propionate, and butyrate on an IL-13-compromised human esophageal epithelial barrier, including the mechanisms involved. METHODS: An air-liquid interface culture model of differentiated human EPC2-hTERT (EPC2) was used to study whether SCFAs could restore barrier function after IL-13-induced impairment. Esophageal epithelial barrier function was monitored by transepithelial electrical resistance (TEER) and FITC-dextran paracellular flux, and was further examined by qPCR and immunohistochemical analysis. G protein-coupled receptor (GPR) GPR41, GPR43, GPR109a, or histone deacetylase (HDAC) (ant)agonists were used to assess mechanisms of action of SCFAs. RESULTS: IL-13 stimulation decreased TEER and increased FITC flux, which was counteracted by butyrate and propionate, but not acetate treatment. Barrier proteins FLG and DSG1 mRNA expression was upregulated following butyrate and propionate treatment, whereas expression of eosinophil chemoattractant CCL26 and protease CAPN14 was downregulated. Similarly, butyrate and propionate restored FLG and DSG1 protein expression. Similar effects were observed with an HDAC antagonist but not with GPR agonists. CONCLUSION: Nutraceuticals butyrate and propionate restore the barrier function of esophageal epithelial cells after an inflammatory insult and may be of therapeutic benefit in the management of EoE.</style></abstract><notes><style face="normal" font="default" size="100%">Kleuskens, Mirelle T A&#xD;Haasnoot, Maria L&#xD;Herpers, Bart M&#xD;Ampting, Marleen T J van&#xD;Bredenoord, Albert J&#xD;Garssen, Johan&#xD;Redegeld, Frank A&#xD;van Esch, Betty C A M&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1510-1521. doi: 10.1111/all.15069. Epub 2021 Sep 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34458999</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9293003</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15069</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1298</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1298</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paparo, L.</style></author><author><style face="normal" font="default" size="100%">Nocerino, R.</style></author><author><style face="normal" font="default" size="100%">Ciaglia, E.</style></author><author><style face="normal" font="default" size="100%">Di Scala, C.</style></author><author><style face="normal" font="default" size="100%">De Caro, C.</style></author><author><style face="normal" font="default" size="100%">Russo, R.</style></author><author><style face="normal" font="default" size="100%">Trinchese, G.</style></author><author><style face="normal" font="default" size="100%">Aitoro, R.</style></author><author><style face="normal" font="default" size="100%">Amoroso, A.</style></author><author><style face="normal" font="default" size="100%">Bruno, C.</style></author><author><style face="normal" font="default" size="100%">Di Costanzo, M.</style></author><author><style face="normal" font="default" size="100%">Passariello, A.</style></author><author><style face="normal" font="default" size="100%">Messina, F.</style></author><author><style face="normal" font="default" size="100%">Agangi, A.</style></author><author><style face="normal" font="default" size="100%">Napolitano, M.</style></author><author><style face="normal" font="default" size="100%">Voto, L.</style></author><author><style face="normal" font="default" size="100%">Gatta, G. D.</style></author><author><style face="normal" font="default" size="100%">Pisapia, L.</style></author><author><style face="normal" font="default" size="100%">Montella, F.</style></author><author><style face="normal" font="default" size="100%">Mollica, M. P.</style></author><author><style face="normal" font="default" size="100%">Calignano, A.</style></author><author><style face="normal" font="default" size="100%">Puca, A.</style></author><author><style face="normal" font="default" size="100%">Berni Canani, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medical Science, University of Naples Federico II, Naples, Italy.&#xD;ImmunoNutritionLab at the CEINGE-Biotecnologie Avanzate s.c.ar.l Research Center, University of Naples Federico II, Naples, Italy.&#xD;European Laboratory for the Investigation of Food-Induced Diseases, University of Naples Federico II, Naples, Italy.&#xD;Department of Medicine, Surgery and Dentistry &quot;Scuola Medica Salernitana&quot;, University of Salerno, Fisciano, Italy.&#xD;Department of Pharmacy, University of Naples Federico II, Naples, Italy.&#xD;Department of Biology, University of Naples Federico II, Naples, Italy.&#xD;Department of Pediatric Cardiology, Monaldi Hospital, Naples, Italy.&#xD;Neonatal Intensive Care Unit, &quot;Betania&quot; Evangelical Hospital, Naples, Italy.&#xD;Cardiovascular Research Unit, IRCCS MultiMedica, Milan, Italy.&#xD;Task Force for Microbiome Studies, University of Naples Federico II, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Butyrate as a bioactive human milk protective component against food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1398-1415</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Butyrates</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Milk, Human</style></keyword><keyword><style face="normal" font="default" size="100%">breast milk</style></keyword><keyword><style face="normal" font="default" size="100%">short-chain fatty acids</style></keyword><keyword><style face="normal" font="default" size="100%">tolerogenic mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">content of this manuscript, which remains their sole responsibility.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33043467</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food allergy (FA) is a growing health problem worldwide. Effective strategies are advocated to limit the disease burden. Human milk (HM) could be considered as a protective factor against FA, but its mechanisms remain unclear. Butyrate is a gut microbiota-derived metabolite able to exert several immunomodulatory functions. We aimed to define the butyrate concentration in HM, and to see whether the butyrate concentration detected in HM is able to modulate the mechanisms of immune tolerance. METHODS: HM butyrate concentration from 109 healthy women was assessed by GS-MS. The effect of HM butyrate on tolerogenic mechanisms was assessed in in vivo and in vitro models. RESULTS: The median butyrate concentration in mature HM was 0.75 mM. This butyrate concentration was responsible for the maximum modulatory effects observed in all experimental models evaluated in this study. Data from mouse model show that in basal condition, butyrate up-regulated the expression of several biomarkers of gut barrier integrity, and of tolerogenic cytokines. Pretreatment with butyrate significantly reduced allergic response in three animal models of FA, with a stimulation of tolerogenic cytokines, inhibition of Th2 cytokines production and a modulation of oxidative stress. Data from human cell models show that butyrate stimulated human beta defensin-3, mucus components and tight junctions expression in human enterocytes, and IL-10, IFN-gamma and FoxP3 expression through epigenetic mechanisms in PBMCs from FA children. Furthermore, it promoted the precursors of M2 macrophages, DCs and regulatory T cells. CONCLUSION: The study&apos;s findings suggest the importance of butyrate as a pivotal HM compound able to protect against FA.</style></abstract><notes><style face="normal" font="default" size="100%">Paparo, Lorella&#xD;Nocerino, Rita&#xD;Ciaglia, Elena&#xD;Di Scala, Carmen&#xD;De Caro, Carmen&#xD;Russo, Roberto&#xD;Trinchese, Giovanna&#xD;Aitoro, Rosita&#xD;Amoroso, Antonio&#xD;Bruno, Cristina&#xD;Di Costanzo, Margherita&#xD;Passariello, Annalisa&#xD;Messina, Francesco&#xD;Agangi, Annalisa&#xD;Napolitano, Marcello&#xD;Voto, Luana&#xD;Gatta, Giusy Della&#xD;Pisapia, Laura&#xD;Montella, Francesco&#xD;Mollica, Maria Pina&#xD;Calignano, Antonio&#xD;Puca, Annibale&#xD;Berni Canani, Roberto&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1398-1415. doi: 10.1111/all.14625. Epub 2020 Nov 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33043467</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8247419</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14625</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1604</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1604</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paparo, L.</style></author><author><style face="normal" font="default" size="100%">Nocerino, R.</style></author><author><style face="normal" font="default" size="100%">Ciaglia, E.</style></author><author><style face="normal" font="default" size="100%">Di Scala, C.</style></author><author><style face="normal" font="default" size="100%">De Caro, C.</style></author><author><style face="normal" font="default" size="100%">Russo, R.</style></author><author><style face="normal" font="default" size="100%">Trinchese, G.</style></author><author><style face="normal" font="default" size="100%">Aitoro, R.</style></author><author><style face="normal" font="default" size="100%">Amoroso, A.</style></author><author><style face="normal" font="default" size="100%">Bruno, C.</style></author><author><style face="normal" font="default" size="100%">Di Costanzo, M.</style></author><author><style face="normal" font="default" size="100%">Passariello, A.</style></author><author><style face="normal" font="default" size="100%">Messina, F.</style></author><author><style face="normal" font="default" size="100%">Agangi, A.</style></author><author><style face="normal" font="default" size="100%">Napolitano, M.</style></author><author><style face="normal" font="default" size="100%">Voto, L.</style></author><author><style face="normal" font="default" size="100%">Gatta, G. D.</style></author><author><style face="normal" font="default" size="100%">Pisapia, L.</style></author><author><style face="normal" font="default" size="100%">Montella, F.</style></author><author><style face="normal" font="default" size="100%">Mollica, M. P.</style></author><author><style face="normal" font="default" size="100%">Calignano, A.</style></author><author><style face="normal" font="default" size="100%">Puca, A.</style></author><author><style face="normal" font="default" size="100%">Berni Canani, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medical Science, University of Naples Federico II, Naples, Italy.&#xD;ImmunoNutritionLab at the CEINGE-Biotecnologie Avanzate s.c.ar.l Research Center, University of Naples Federico II, Naples, Italy.&#xD;European Laboratory for the Investigation of Food-Induced Diseases, University of Naples Federico II, Naples, Italy.&#xD;Department of Medicine, Surgery and Dentistry &quot;Scuola Medica Salernitana&quot;, University of Salerno, Fisciano, Italy.&#xD;Department of Pharmacy, University of Naples Federico II, Naples, Italy.&#xD;Department of Biology, University of Naples Federico II, Naples, Italy.&#xD;Department of Pediatric Cardiology, Monaldi Hospital, Naples, Italy.&#xD;Neonatal Intensive Care Unit, &quot;Betania&quot; Evangelical Hospital, Naples, Italy.&#xD;Cardiovascular Research Unit, IRCCS MultiMedica, Milan, Italy.&#xD;Task Force for Microbiome Studies, University of Naples Federico II, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Butyrate as a bioactive human milk protective component against food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1398-1415</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Butyrates</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Milk, Human</style></keyword><keyword><style face="normal" font="default" size="100%">breast milk</style></keyword><keyword><style face="normal" font="default" size="100%">short-chain fatty acids</style></keyword><keyword><style face="normal" font="default" size="100%">tolerogenic mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">content of this manuscript, which remains their sole responsibility.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33043467</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food allergy (FA) is a growing health problem worldwide. Effective strategies are advocated to limit the disease burden. Human milk (HM) could be considered as a protective factor against FA, but its mechanisms remain unclear. Butyrate is a gut microbiota-derived metabolite able to exert several immunomodulatory functions. We aimed to define the butyrate concentration in HM, and to see whether the butyrate concentration detected in HM is able to modulate the mechanisms of immune tolerance. METHODS: HM butyrate concentration from 109 healthy women was assessed by GS-MS. The effect of HM butyrate on tolerogenic mechanisms was assessed in in vivo and in vitro models. RESULTS: The median butyrate concentration in mature HM was 0.75 mM. This butyrate concentration was responsible for the maximum modulatory effects observed in all experimental models evaluated in this study. Data from mouse model show that in basal condition, butyrate up-regulated the expression of several biomarkers of gut barrier integrity, and of tolerogenic cytokines. Pretreatment with butyrate significantly reduced allergic response in three animal models of FA, with a stimulation of tolerogenic cytokines, inhibition of Th2 cytokines production and a modulation of oxidative stress. Data from human cell models show that butyrate stimulated human beta defensin-3, mucus components and tight junctions expression in human enterocytes, and IL-10, IFN-gamma and FoxP3 expression through epigenetic mechanisms in PBMCs from FA children. Furthermore, it promoted the precursors of M2 macrophages, DCs and regulatory T cells. CONCLUSION: The study&apos;s findings suggest the importance of butyrate as a pivotal HM compound able to protect against FA.</style></abstract><notes><style face="normal" font="default" size="100%">Paparo, Lorella&#xD;Nocerino, Rita&#xD;Ciaglia, Elena&#xD;Di Scala, Carmen&#xD;De Caro, Carmen&#xD;Russo, Roberto&#xD;Trinchese, Giovanna&#xD;Aitoro, Rosita&#xD;Amoroso, Antonio&#xD;Bruno, Cristina&#xD;Di Costanzo, Margherita&#xD;Passariello, Annalisa&#xD;Messina, Francesco&#xD;Agangi, Annalisa&#xD;Napolitano, Marcello&#xD;Voto, Luana&#xD;Gatta, Giusy Della&#xD;Pisapia, Laura&#xD;Montella, Francesco&#xD;Mollica, Maria Pina&#xD;Calignano, Antonio&#xD;Puca, Annibale&#xD;Berni Canani, Roberto&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1398-1415. doi: 10.1111/all.14625. Epub 2020 Nov 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33043467</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8247419</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14625</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2366</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2366</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cruz-Amaya, A.</style></author><author><style face="normal" font="default" size="100%">Martin-Astorga, M. D. C.</style></author><author><style face="normal" font="default" size="100%">Lebron-Martin, C.</style></author><author><style face="normal" font="default" size="100%">Paris, J. L.</style></author><author><style face="normal" font="default" size="100%">Cespedes, J. A.</style></author><author><style face="normal" font="default" size="100%">Nunez, R.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Aranda, C. J.</style></author><author><style face="normal" font="default" size="100%">Canas, J. A.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Malaga, Spain.&#xD;Universidad de Malaga (UMA), Malaga, Spain.&#xD;Allergy Clinical Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Butyrate dietary supplementation promotes tolerant responses in a Pru p 3-anaphylactic mouse model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1605-1608</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">*Butyrates/pharmacology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38263770</style></accession-num><notes><style face="normal" font="default" size="100%">Cruz-Amaya, Anyith&#xD;Martin-Astorga, Maria Del Carmen&#xD;Lebron-Martin, Clara&#xD;Paris, Juan Luis&#xD;Cespedes, Jose Antonio&#xD;Nunez, Rafael&#xD;Torres, Maria Jose&#xD;Aranda, Carlos Jose&#xD;Canas, Jose Antonio&#xD;Mayorga, Cristobalina&#xD;eng&#xD;European Regional Development Fund/&#xD;Consejeria de Salud y Bienestar Social, Junta de Andalucia/&#xD;Instituto de Salud Carlos III/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1605-1608. doi: 10.1111/all.16033. Epub 2024 Jan 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38263770</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16033</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1936</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1936</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wiese, A. V.</style></author><author><style face="normal" font="default" size="100%">Duhn, J.</style></author><author><style face="normal" font="default" size="100%">Korkmaz, R. U.</style></author><author><style face="normal" font="default" size="100%">Quell, K. M.</style></author><author><style face="normal" font="default" size="100%">Osman, I.</style></author><author><style face="normal" font="default" size="100%">Ender, F.</style></author><author><style face="normal" font="default" size="100%">Schroder, T.</style></author><author><style face="normal" font="default" size="100%">Lewkowich, I.</style></author><author><style face="normal" font="default" size="100%">Hogan, S.</style></author><author><style face="normal" font="default" size="100%">Huber-Lang, M.</style></author><author><style face="normal" font="default" size="100%">Gumprecht, F.</style></author><author><style face="normal" font="default" size="100%">Konig, P.</style></author><author><style face="normal" font="default" size="100%">Kohl, J.</style></author><author><style face="normal" font="default" size="100%">Laumonnier, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Systemic Inflammation Research, University of Lubeck, Lubeck, Germany.&#xD;Institute of Nutritional Medicine, University Hospital of Schleswig-Holstein &amp; University of Lubeck, Lubeck, Germany.&#xD;Division of Immunobiology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Mary H. Weiser Food Allergy Center, Experimental Pathology, Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.&#xD;Institute of Clinical and Experimental Trauma-Immunology (ITI), University of Ulm, Ulm, Germany.&#xD;Institute for Anatomy, University of Lubeck, Lubeck, Germany.&#xD;Airway Research Center North, Member of the German Center for Lung Research (DZL), Lubeck, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">C5aR1 activation in mice controls inflammatory eosinophil recruitment and functions in allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1893-1908</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36757006</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Pulmonary eosinophils comprise at least two distinct populations of resident eosinophils (rEOS) and inflammatory eosinophils (iEOS), the latter recruited in response to pulmonary inflammation. Here, we determined the impact of complement activation on rEOS and iEOS trafficking and function in two models of pulmonary inflammation. METHODS: BALB/c wild-type and C5ar1(-/-) mice were exposed to different allergens or IL-33. Eosinophil populations in the airways, lung, or mediastinal lymph nodes (mLN) were characterized by FACS or immunohistochemistry. rEOS and iEOS functions were determined in vivo and in vitro. RESULTS: HDM and IL-33 exposure induced a strong accumulation of iEOS but not rEOS in the airways, lungs, and mLNs. rEOS and iEOS expressed C3/C5 and C5aR1, which were significantly higher in iEOS. Initial pulmonary trafficking of iEOS was markedly reduced in C5ar1(-/-) mice and associated with less IL-5 production from ILC2 cells. Functionally, adoptively transferred pulmonary iEOS from WT but not from C5ar1(-/-) mice-induced airway hyperresponsiveness (AHR), which was associated with significantly reduced C5ar1(-/-) iEOS degranulation. Pulmonary iEOS but not rEOS were frequently associated with T cells in lung tissue. After HDM or IL-33 exposure, iEOS but not rEOS were found in mLNs, which were significantly reduced in C5ar1(-/-) mice. C5ar1(-/-) iEOS expressed less costimulatory molecules, associated with a decreased potency to drive antigen-specific T cell proliferation and differentiation into memory T cells. CONCLUSIONS: We uncovered novel roles for C5aR1 in iEOS trafficking and activation, which affects key aspects of allergic inflammation such as AHR, ILC2, and T cell activation.</style></abstract><notes><style face="normal" font="default" size="100%">Wiese, Anna V&#xD;Duhn, Jannis&#xD;Korkmaz, Rabia Ulku&#xD;Quell, Katharina M&#xD;Osman, Ibrahim&#xD;Ender, Fanny&#xD;Schroder, Torsten&#xD;Lewkowich, Ian&#xD;Hogan, Simon&#xD;Huber-Lang, Markus&#xD;Gumprecht, Franziska&#xD;Konig, Peter&#xD;Kohl, Jorg&#xD;Laumonnier, Yves&#xD;eng&#xD;EXC306/2/Deutsche Forschungsgemeinschaft (DFG)/&#xD;EXC 2167/Deutsche Forschungsgemeinschaft (DFG)/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1893-1908. doi: 10.1111/all.15670. Epub 2023 Feb 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36757006</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15670</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1117</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1117</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soriano, J. B.</style></author><author><style face="normal" font="default" size="100%">Ancochea, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pneumology, Hospital Universitario de la Princesa, Madrid, Spain.&#xD;School of Medicine, Universidad Autonoma de Madrid, Madrid, Spain.&#xD;Centro de Investigacion en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cabbage and COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">966-967</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/03/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Brassica</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">Vegetables</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33675254</style></accession-num><notes><style face="normal" font="default" size="100%">Soriano, Joan B&#xD;Ancochea, Julio&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):966-967. doi: 10.1111/all.14654.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33675254</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8251406</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14654</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1364</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1364</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Fonseca, S. C.</style></author><author><style face="normal" font="default" size="100%">Iaccarino, G.</style></author><author><style face="normal" font="default" size="100%">Blain, H.</style></author><author><style face="normal" font="default" size="100%">Vidal, A.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Aria group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Charite, Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany.&#xD;MACVIA-France and CHU, Montpellier, France.&#xD;Centre for Research in Environmental Epidemiology (CREAL), ISGlobAL, Barcelona, Spain.&#xD;IMIM (Hospital del Mar Research Institute), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;MASK-Air, Montpellier, France.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Finland.&#xD;Faculty of Sciences, GreenUPorto - Sustainable Agrifood Production Research Centre, DGAOT, University of Porto, Porto, Portugal.&#xD;Department of Advanced Biomedical Sciences, Federico II University, Napoli, Italy.&#xD;Department of Geriatrics, Montpellier University hospital and MUSE, Montpellier, France.&#xD;World Business Council for Sustainable Development (WBCSD), Geneva, Switzerland.&#xD;AgroParisTech - Paris Institute of Technology for Life, Food and Environmental Sciences, Paris, France.&#xD;Usher Institute, University of Edinburgh, Scotland, UK.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">735-750</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidants/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Brassica</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/epidemiology/*mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Ecology</style></keyword><keyword><style face="normal" font="default" size="100%">*Fermentation</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillales/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">NF-E2-Related Factor 2/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Vegetables</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">angiotensin-converting enzyme 2</style></keyword><keyword><style face="normal" font="default" size="100%">cabbage</style></keyword><keyword><style face="normal" font="default" size="100%">fermented vegetable</style></keyword><keyword><style face="normal" font="default" size="100%">kimchi</style></keyword><keyword><style face="normal" font="default" size="100%">sulforaphane</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32762135</style></accession-num><abstract><style face="normal" font="default" size="100%">Large differences in COVID-19 death rates exist between countries and between regions of the same country. Some very low death rate countries such as Eastern Asia, Central Europe, or the Balkans have a common feature of eating large quantities of fermented foods. Although biases exist when examining ecological studies, fermented vegetables or cabbage have been associated with low death rates in European countries. SARS-CoV-2 binds to its receptor, the angiotensin-converting enzyme 2 (ACE2). As a result of SARS-CoV-2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT(1) R) axis associated with oxidative stress. This leads to insulin resistance as well as lung and endothelial damage, two severe outcomes of COVID-19. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is the most potent antioxidant in humans and can block in particular the AT(1) R axis. Cabbage contains precursors of sulforaphane, the most active natural activator of Nrf2. Fermented vegetables contain many lactobacilli, which are also potent Nrf2 activators. Three examples are: kimchi in Korea, westernized foods, and the slum paradox. It is proposed that fermented cabbage is a proof-of-concept of dietary manipulations that may enhance Nrf2-associated antioxidant effects, helpful in mitigating COVID-19 severity.</style></abstract><notes><style face="normal" font="default" size="100%">Bousquet, Jean&#xD;Anto, Josep M&#xD;Czarlewski, Wienczyslawa&#xD;Haahtela, Tari&#xD;Fonseca, Susana C&#xD;Iaccarino, Guido&#xD;Blain, Hubert&#xD;Vidal, Alain&#xD;Sheikh, Aziz&#xD;Akdis, Cezmi A&#xD;Zuberbier, Torsten&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):735-750. doi: 10.1111/all.14549. Epub 2020 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32762135</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7436771</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14549</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1624</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1624</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Fonseca, S. C.</style></author><author><style face="normal" font="default" size="100%">Iaccarino, G.</style></author><author><style face="normal" font="default" size="100%">Blain, H.</style></author><author><style face="normal" font="default" size="100%">Vidal, A.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Aria group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Charite, Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany.&#xD;MACVIA-France and CHU, Montpellier, France.&#xD;Centre for Research in Environmental Epidemiology (CREAL), ISGlobAL, Barcelona, Spain.&#xD;IMIM (Hospital del Mar Research Institute), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;MASK-Air, Montpellier, France.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Finland.&#xD;Faculty of Sciences, GreenUPorto - Sustainable Agrifood Production Research Centre, DGAOT, University of Porto, Porto, Portugal.&#xD;Department of Advanced Biomedical Sciences, Federico II University, Napoli, Italy.&#xD;Department of Geriatrics, Montpellier University hospital and MUSE, Montpellier, France.&#xD;World Business Council for Sustainable Development (WBCSD), Geneva, Switzerland.&#xD;AgroParisTech - Paris Institute of Technology for Life, Food and Environmental Sciences, Paris, France.&#xD;Usher Institute, University of Edinburgh, Scotland, UK.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">735-750</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidants/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Brassica</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/epidemiology/*mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Ecology</style></keyword><keyword><style face="normal" font="default" size="100%">*Fermentation</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillales/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">NF-E2-Related Factor 2/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Vegetables</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">angiotensin-converting enzyme 2</style></keyword><keyword><style face="normal" font="default" size="100%">cabbage</style></keyword><keyword><style face="normal" font="default" size="100%">fermented vegetable</style></keyword><keyword><style face="normal" font="default" size="100%">kimchi</style></keyword><keyword><style face="normal" font="default" size="100%">sulforaphane</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32762135</style></accession-num><abstract><style face="normal" font="default" size="100%">Large differences in COVID-19 death rates exist between countries and between regions of the same country. Some very low death rate countries such as Eastern Asia, Central Europe, or the Balkans have a common feature of eating large quantities of fermented foods. Although biases exist when examining ecological studies, fermented vegetables or cabbage have been associated with low death rates in European countries. SARS-CoV-2 binds to its receptor, the angiotensin-converting enzyme 2 (ACE2). As a result of SARS-CoV-2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT(1) R) axis associated with oxidative stress. This leads to insulin resistance as well as lung and endothelial damage, two severe outcomes of COVID-19. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is the most potent antioxidant in humans and can block in particular the AT(1) R axis. Cabbage contains precursors of sulforaphane, the most active natural activator of Nrf2. Fermented vegetables contain many lactobacilli, which are also potent Nrf2 activators. Three examples are: kimchi in Korea, westernized foods, and the slum paradox. It is proposed that fermented cabbage is a proof-of-concept of dietary manipulations that may enhance Nrf2-associated antioxidant effects, helpful in mitigating COVID-19 severity.</style></abstract><notes><style face="normal" font="default" size="100%">Bousquet, Jean&#xD;Anto, Josep M&#xD;Czarlewski, Wienczyslawa&#xD;Haahtela, Tari&#xD;Fonseca, Susana C&#xD;Iaccarino, Guido&#xD;Blain, Hubert&#xD;Vidal, Alain&#xD;Sheikh, Aziz&#xD;Akdis, Cezmi A&#xD;Zuberbier, Torsten&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):735-750. doi: 10.1111/all.14549. Epub 2020 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32762135</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7436771</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14549</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>847</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">847</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Atwoli, L.</style></author><author><style face="normal" font="default" size="100%">Baqui, A. H.</style></author><author><style face="normal" font="default" size="100%">Benfield, T.</style></author><author><style face="normal" font="default" size="100%">Bosurgi, R.</style></author><author><style face="normal" font="default" size="100%">Godlee, F.</style></author><author><style face="normal" font="default" size="100%">Hancocks, S.</style></author><author><style face="normal" font="default" size="100%">Horton, R.</style></author><author><style face="normal" font="default" size="100%">Laybourn-Langton, L.</style></author><author><style face="normal" font="default" size="100%">Monteiro, C. A.</style></author><author><style face="normal" font="default" size="100%">Norman, I.</style></author><author><style face="normal" font="default" size="100%">Patrick, K.</style></author><author><style face="normal" font="default" size="100%">Praities, N.</style></author><author><style face="normal" font="default" size="100%">Olde Rikkert, M. G. M.</style></author><author><style face="normal" font="default" size="100%">Rubin, E. J.</style></author><author><style face="normal" font="default" size="100%">Sahni, P.</style></author><author><style face="normal" font="default" size="100%">Smith, R.</style></author><author><style face="normal" font="default" size="100%">Talley, N. J.</style></author><author><style face="normal" font="default" size="100%">Turale, S.</style></author><author><style face="normal" font="default" size="100%">Vazquez, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">East African Medical Journal.&#xD;Journal of Health, Population and Nutrition.&#xD;Danish Medical Journal.&#xD;PLOS Medicine.&#xD;The BMJ.&#xD;British Dental Journal.&#xD;The Lancet.&#xD;UK Health Alliance on Climate Change.&#xD;Revista de Saude Publica.&#xD;International Journal of Nursing Studies.&#xD;Cmaj.&#xD;Pharmaceutical Journal.&#xD;Dutch Journal of Medicine.&#xD;Nejm.&#xD;National Medical Journal of India.&#xD;Medical Journal of Australia.&#xD;International Nursing Review.&#xD;Pan American Journal of Public Health.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Call for emergency action to limit global temperature increases, restore biodiversity and protect health: Wealthy nations must do much more, much faster: Wealthy nations must do much more, much faster</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">730-733</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/08/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Biodiversity</style></keyword><keyword><style face="normal" font="default" size="100%">*Global Health</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Temperature</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34418118</style></accession-num><notes><style face="normal" font="default" size="100%">Atwoli, Lukoye&#xD;Baqui, Abdullah H&#xD;Benfield, Thomas&#xD;Bosurgi, Raffaella&#xD;Godlee, Fiona&#xD;Hancocks, Stephen&#xD;Horton, Richard&#xD;Laybourn-Langton, Laurie&#xD;Monteiro, Carlos Augusto&#xD;Norman, Ian&#xD;Patrick, Kirsten&#xD;Praities, Nigel&#xD;Olde Rikkert, Marcel G M&#xD;Rubin, Eric J&#xD;Sahni, Peush&#xD;Smith, Richard&#xD;Talley, Nicholas J&#xD;Turale, Sue&#xD;Vazquez, Damian&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):730-733. doi: 10.1111/all.15059. Epub 2021 Sep 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34418118</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15059</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1949</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1949</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pointner, L.</style></author><author><style face="normal" font="default" size="100%">Adamkova, V.</style></author><author><style face="normal" font="default" size="100%">Bethanis, A.</style></author><author><style face="normal" font="default" size="100%">Gerkhardt, S.</style></author><author><style face="normal" font="default" size="100%">Moelter, L.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Aglas, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria.&#xD;Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Zentrum Munchen, Neuherberg, Germany.&#xD;Christine-Kuhne-Center for Allergy Research and Education (CK-Care), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Can birch pollen directly influence the IL-4/IL-4R interaction to modulate Th2 responses?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2022-2024</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Betula</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36789457</style></accession-num><notes><style face="normal" font="default" size="100%">Pointner, Lisa&#xD;Adamkova, Vanda&#xD;Bethanis, Athanasios&#xD;Gerkhardt, Swetlana&#xD;Moelter, Leopold&#xD;Traidl-Hoffmann, Claudia&#xD;Gilles, Stefanie&#xD;Aglas, Lorenz&#xD;eng&#xD;I5312/Austrian Science Fund/&#xD;W1213/Austrian Science Fund/&#xD;Deutsche Forschungsgemeinschaft/&#xD;Allergy-Cancer-BioNano Research Centre/&#xD;University of Salzburg/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2022-2024. doi: 10.1111/all.15673. Epub 2023 Mar 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36789457</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15673</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>584</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">584</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, M.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Coira, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.&#xD;Instituto de Medicina Molecular Aplicada, Grupo Hospital Madrid, Universidad San Pablo-CEU, CEU Universities, Madrid, Espana.&#xD;Centro de Metabolomica y Bioanalisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Espana.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Can polyamine metabolism in T helper cell lineage commitment be a new target in allergy research?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1929-1930</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/02/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Lineage</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Polyamines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Helper-Inducer/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">T cell lineage</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">hypusine</style></keyword><keyword><style face="normal" font="default" size="100%">immunometabolism</style></keyword><keyword><style face="normal" font="default" size="100%">polyamine metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35191039</style></accession-num><notes><style face="normal" font="default" size="100%">Huang, Mengting&#xD;Rodriguez-Coira, Juan&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1929-1930. doi: 10.1111/all.15265. Epub 2022 Mar 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35191039</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15265</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1539</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1539</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, M.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Coira, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.&#xD;Instituto de Medicina Molecular Aplicada, Grupo Hospital Madrid, Universidad San Pablo-CEU, CEU Universities, Madrid, Espana.&#xD;Centro de Metabolomica y Bioanalisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Espana.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Can polyamine metabolism in T helper cell lineage commitment be a new target in allergy research?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1929-1930</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/02/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Lineage</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Polyamines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Helper-Inducer/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">T cell lineage</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">hypusine</style></keyword><keyword><style face="normal" font="default" size="100%">immunometabolism</style></keyword><keyword><style face="normal" font="default" size="100%">polyamine metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35191039</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract -</style></abstract><notes><style face="normal" font="default" size="100%">Huang, Mengting&#xD;Rodriguez-Coira, Juan&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1929-1930. doi: 10.1111/all.15265. Epub 2022 Mar 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35191039</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15265</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1227</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1227</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Angelina, A.</style></author><author><style face="normal" font="default" size="100%">Martin-Fontecha, M.</style></author><author><style face="normal" font="default" size="100%">Ruckert, B.</style></author><author><style face="normal" font="default" size="100%">Wawrzyniak, P.</style></author><author><style face="normal" font="default" size="100%">Perez-Diego, M.</style></author><author><style face="normal" font="default" size="100%">Lopez-Abente, J.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Organic Chemistry, School of Chemistry, Complutense University of Madrid, Madrid, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The cannabinoid WIN55212-2 restores rhinovirus-induced epithelial barrier disruption</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1900-1902</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Benzoxazines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Cannabinoids</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Morpholines</style></keyword><keyword><style face="normal" font="default" size="100%">Naphthalenes</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Cannabinoid, CB1</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinovirus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33319366</style></accession-num><notes><style face="normal" font="default" size="100%">Angelina, Alba&#xD;Martin-Fontecha, Mar&#xD;Ruckert, Beate&#xD;Wawrzyniak, Paulina&#xD;Perez-Diego, Mario&#xD;Lopez-Abente, Jacobo&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;Palomares, Oscar&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1900-1902. doi: 10.1111/all.14707. Epub 2020 Dec 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33319366</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14707</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>722</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">722</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Angelina, A.</style></author><author><style face="normal" font="default" size="100%">Perez-Diego, M.</style></author><author><style face="normal" font="default" size="100%">Maldonado, A.</style></author><author><style face="normal" font="default" size="100%">Ruckert, B.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Martin-Fontecha, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Organic Chemistry, School of Optics and Optometry, Complutense University of Madrid, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The cannabinoid WIN55212-2 suppresses effector T-cell responses and promotes regulatory T cells in human tonsils</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1029-1032</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Benzoxazines</style></keyword><keyword><style face="normal" font="default" size="100%">*Cannabinoids/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Morpholines</style></keyword><keyword><style face="normal" font="default" size="100%">Naphthalenes</style></keyword><keyword><style face="normal" font="default" size="100%">Palatine Tonsil</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Cannabinoid, CB1</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">cannabinoids</style></keyword><keyword><style face="normal" font="default" size="100%">effector T cells</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cells</style></keyword><keyword><style face="normal" font="default" size="100%">tonsils</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34713459</style></accession-num><notes><style face="normal" font="default" size="100%">Angelina, Alba&#xD;Perez-Diego, Mario&#xD;Maldonado, Angel&#xD;Ruckert, Beate&#xD;Akdis, Mubeccel&#xD;Martin-Fontecha, Mar&#xD;Akdis, Cezmi A&#xD;Palomares, Oscar&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1029-1032. doi: 10.1111/all.15160. Epub 2021 Nov 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34713459</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15160</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>624</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">624</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Skypala, I. J.</style></author><author><style face="normal" font="default" size="100%">Jeimy, S.</style></author><author><style face="normal" font="default" size="100%">Brucker, H.</style></author><author><style face="normal" font="default" size="100%">Nayak, A. P.</style></author><author><style face="normal" font="default" size="100%">Decuyper,, II</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Connors, L.</style></author><author><style face="normal" font="default" size="100%">Kanani, A.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Lo, S. C. R.</style></author><author><style face="normal" font="default" size="100%">Murphy, K. R.</style></author><author><style face="normal" font="default" size="100%">Nanda, A.</style></author><author><style face="normal" font="default" size="100%">Poole, J. A.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Sussman, G.</style></author><author><style face="normal" font="default" size="100%">Zeiger, J. S.</style></author><author><style face="normal" font="default" size="100%">Goodman, R. E.</style></author><author><style face="normal" font="default" size="100%">Ellis, A. K.</style></author><author><style face="normal" font="default" size="100%">Silvers, W. S.</style></author><author><style face="normal" font="default" size="100%">Ebo, D. G.</style></author><author><style face="normal" font="default" size="100%">International Cannabis Allergy, Collaboration</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy &amp; Clinical Immunology, Royal Brompton &amp; Harefield Hospitals, and Imperial College, London, UK.&#xD;Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, Ontario, Canada.&#xD;Southdale Allergy and Asthma Clinic, Minneapolis, Minnesota, USA.&#xD;Center for Translational Medicine and Division of Pulmonary Allergy and Critical Care Medicine, Department of Medicine, Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.&#xD;Department of Pediatrics, Faculty of Medicine and Health Sciences, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium.&#xD;Division of Immunology/Allergy Section, Department of Internal Medicine, University of Cincinnati College of Medicine and Bernstein Allergy Group; Bernstein Clinical Research Center, Cincinnati, Ohio, USA.&#xD;Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.&#xD;Division of Allergy and Immunology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.&#xD;Center for Rhinology and Allergy, Wiesbaden, Germany.&#xD;Division of Allergy, Asthma and Pediatric Pulmonology, Department of Pediatrics, Boys Town National Research Hospital, Omaha, Nebraska, USA.&#xD;Asthma and Allergy Center, Lewisville and Flower Mound, Dallas, Texas, USA.&#xD;Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.&#xD;Division of Allergy and Immunology, Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.&#xD;Department of Occupational Medicine and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;Department of Medicine and Division of Clinical Immunology &amp; Allergy, University of Toronto, Toronto, Ontario, Canada.&#xD;Canna Research Foundation, Boulder, Colorado, USA.&#xD;Food Allergy Research and Resource Program, University of Nebraska-Lincoln, Lincoln, Nebraska, USA.&#xD;Division of Allergy &amp; Immunology, Department of Medicine, Queen&apos;s University, Kingston, Ontario, Canada.&#xD;Division of Allergy Clinical Immunology, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Faculty of Medicine and Health Sciences, Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium.&#xD;Department of Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium.&#xD;Department of Immunology and Allergology, AZ Jan Palfijn Gent, Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cannabis-related allergies: An international overview and consensus recommendations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2038-2052</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/02/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">*Cannabis/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">cannabis allergy</style></keyword><keyword><style face="normal" font="default" size="100%">occupational allergies</style></keyword><keyword><style face="normal" font="default" size="100%">interest in relation to this paper</style></keyword><keyword><style face="normal" font="default" size="100%">Hannelore Brucker, Didier Ebo, Richard</style></keyword><keyword><style face="normal" font="default" size="100%">Goodman, Ine Decuyper, Jolanta Walusiak-Skorupa, Anil Nanda, Amin Kanani, and</style></keyword><keyword><style face="normal" font="default" size="100%">Shun Chi Ryan Lo. The following authors have institutional positions or honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">to declare</style></keyword><keyword><style face="normal" font="default" size="100%">Isabel Skypala has received honoraria from ThermoFisher and is a</style></keyword><keyword><style face="normal" font="default" size="100%">member of the Executive Committee of the European Academy of Allergy &amp; Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Immunology (EAACI)</style></keyword><keyword><style face="normal" font="default" size="100%">Ajay P. Nayak&apos;s institution has received grant funding from</style></keyword><keyword><style face="normal" font="default" size="100%">National Institutes of Health (NIH/NIAID R21AI140411) and National Institute of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy &amp; Infectious Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Samira Jeimy has received honoraria for speaking</style></keyword><keyword><style face="normal" font="default" size="100%">engagements from Sanofi Regeneron, AstraZeneca, Novartis, Aralez, Medexus</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals Inc and registration fees for the European Academy of Allergy &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Immunology annual meetings in 2020, 2021 reimbursed by Medexus</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals Inc</style></keyword><keyword><style face="normal" font="default" size="100%">Jonathan Bernstein has received PI, consultant, and speaker</style></keyword><keyword><style face="normal" font="default" size="100%">fees from-Sanofi Regeneron, AstraZeneca, Novartis, Genentech, Takeda/Shire, CSL</style></keyword><keyword><style face="normal" font="default" size="100%">Behring, Pharming, Biocryst, GSK</style></keyword><keyword><style face="normal" font="default" size="100%">ALK</style></keyword><keyword><style face="normal" font="default" size="100%">PI, consultant-Amgen, Biomarin, Kalvista</style></keyword><keyword><style face="normal" font="default" size="100%">Jill Poole has received grants from NIH, Department of Defense, National</style></keyword><keyword><style face="normal" font="default" size="100%">Institute for Occupational Safety and Health, AstraZeneca and Takeda, is</style></keyword><keyword><style face="normal" font="default" size="100%">co-editor/board member of the journal Current Allergy and Asthma Reports,</style></keyword><keyword><style face="normal" font="default" size="100%">receiving ~$300/year for editorial role and has had a waived registration fee for</style></keyword><keyword><style face="normal" font="default" size="100%">speaking at the American Academy of Asthma, Allergy and Immunology (AAAAI)</style></keyword><keyword><style face="normal" font="default" size="100%">William Silvers is Chief Scientific Officer of the Canna Research Foundation</style></keyword><keyword><style face="normal" font="default" size="100%">Joanna S. Zeiger is the CEO of Canna Research Foundation and has received</style></keyword><keyword><style face="normal" font="default" size="100%">payments from EAACI, Canadian Society of Allergy &amp; Clinical Immunology and the</style></keyword><keyword><style face="normal" font="default" size="100%">American College of Asthma, Allergy and Immunology for other projects run by the</style></keyword><keyword><style face="normal" font="default" size="100%">Cannabis Allergy Interest Group</style></keyword><keyword><style face="normal" font="default" size="100%">Lori Connors has received honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, ALK, Novartis, has participated on advisory boards of AbbVie, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Sanofi and is the CPD Chair of the CSACI</style></keyword><keyword><style face="normal" font="default" size="100%">Anne Ellis is vice president</style></keyword><keyword><style face="normal" font="default" size="100%">of CSACI, has participated in advisory boards for Abbvie, ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Aralez, Bausch Health, Circassia, GSK, LEO Pharma, Merck, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, and has been a speaker for ALK-Abello, Aralez, AstraZeneca, CSL Behring,</style></keyword><keyword><style face="normal" font="default" size="100%">Medexus, Novartis, Mylan, Pfizer, Sanofi and Takeda, and her institution has</style></keyword><keyword><style face="normal" font="default" size="100%">received research grants from ALK Abelo, Aralez, AstraZeneca, Bayer LLC,</style></keyword><keyword><style face="normal" font="default" size="100%">Circassia, Green Cross, Merck, Medexus, Pfizer, Novartis, Sanofi and Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">she has also served as an independent consultant to Bayer LLC and Regeneron and</style></keyword><keyword><style face="normal" font="default" size="100%">Ludger Klimek reports grants and personal fees from Allergopharma, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from MEDA/Mylan, personal fees from HAL Allergie, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, grants and personal fees from LETI Pharma, grants from Stallergenes,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Quintiles, grants and personal fees from Sanofi, grants from ASIT</style></keyword><keyword><style face="normal" font="default" size="100%">biotech, grants from Lofarma, personal fees from Allergy Therapeutic, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, grants from GSK, grants from Inmunotk, personal fees from Cassella</style></keyword><keyword><style face="normal" font="default" size="100%">med, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and Membership of the following organisations:</style></keyword><keyword><style face="normal" font="default" size="100%">AeDA DGHNO, Deutsche Akademie fur Allergologie und klinische Immunologie, HNO-BV,</style></keyword><keyword><style face="normal" font="default" size="100%">GPA and EAACI. Gordon Sussman has received research support from Aimmune, ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">Amgen, AstraZeneca, DBV technologies, Genentech, Leo Pharma Inc., Novartis, and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi. He is a medical advisor and/or has received payment for lectures from</style></keyword><keyword><style face="normal" font="default" size="100%">AbbVie, Novartis, CSL Behring, Pfizer, and the Allergy and Immunology Society of</style></keyword><keyword><style face="normal" font="default" size="100%">Ontario</style></keyword><keyword><style face="normal" font="default" size="100%">Kevin Murphy reports receiving consulting fees from AstraZeneca, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Genzyme, Genentech, Novartis, speaker honoraria from AstraZeneca, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Genzyme, Genentech, Novartis, GlaxoSmithKline, TEVA, Amgen, participates on Data</style></keyword><keyword><style face="normal" font="default" size="100%">Safety Monitoring Board or Advisory Boards for AstraZeneca and TAKEDA, and is a</style></keyword><keyword><style face="normal" font="default" size="100%">Board Member of the ACAAI.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35102560</style></accession-num><abstract><style face="normal" font="default" size="100%">Cannabis is the most widely used recreational drug in the world. Cannabis sativa and Cannabis indica have been selectively bred to develop their psychoactive properties. The increasing use in many countries has been accelerated by the COVID-19 pandemic. Cannabis can provoke both type 1 and type 4 allergic reactions. Officially recognized allergens include a pathogenesis-related class 10 allergen, profilin, and a nonspecific lipid transfer protein. Other allergens may also be relevant, and recognition of allergens may vary between countries and continents. Cannabis also has the potential to provoke allergic cross-reactions to plant foods. Since cannabis is an illegal substance in many countries, research has been hampered, leading to challenges in diagnosis since no commercial extracts are available for testing. Even in countries such as Canada, where cannabis is legalized, diagnosis may rely solely on the purchase of cannabis for prick-to-prick skin tests. Management consists of avoidance, with legal issues hindering the development of other treatments such as immunotherapy. Education of healthcare professionals is similarly lacking. This review aimed to summarize the current status of cannabis allergy and proposes recommendations for the future management of this global issue.</style></abstract><notes><style face="normal" font="default" size="100%">Skypala, Isabel J&#xD;Jeimy, Samira&#xD;Brucker, Hannelore&#xD;Nayak, Ajay P&#xD;Decuyper, Ine I&#xD;Bernstein, Jonathan A&#xD;Connors, Lori&#xD;Kanani, Amin&#xD;Klimek, Ludger&#xD;Lo, Shun Chi Ryan&#xD;Murphy, Kevin R&#xD;Nanda, Anil&#xD;Poole, Jill A&#xD;Walusiak-Skorupa, Jolanta&#xD;Sussman, Gordon&#xD;Zeiger, Joanna S&#xD;Goodman, Richard E&#xD;Ellis, Anne K&#xD;Silvers, William S&#xD;Ebo, Didier G&#xD;eng&#xD;R21 AI140411/AI/NIAID NIH HHS/&#xD;Consensus Statement&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2038-2052. doi: 10.1111/all.15237. Epub 2022 Feb 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35102560</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9871863</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15237</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2936</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2936</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rossi, F.</style></author><author><style face="normal" font="default" size="100%">Fernandez Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Castagnoli, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Unit, Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.&#xD;Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.&#xD;Immunology Department, IIS-Fundacion Jimenez Diaz, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CAR-T Cell Therapy in Autoimmune Setting: A New Appealing Approach Extendable to Allergy?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2421-2422</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/05/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">B cells</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">cellular therapy</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">personlized medicine</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40326855</style></accession-num><notes><style face="normal" font="default" size="100%">Rossi, Federico&#xD;Fernandez Santamaria, Ruben&#xD;Castagnoli, Riccardo&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2421-2422. doi: 10.1111/all.16585. Epub 2025 May 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40326855</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368754</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16585</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1125</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1125</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Platts-Mills, T. A.</style></author><author><style face="normal" font="default" size="100%">Hilger, C.</style></author><author><style face="normal" font="default" size="100%">Jappe, U.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Gadermaier, G.</style></author><author><style face="normal" font="default" size="100%">Spillner, E.</style></author><author><style face="normal" font="default" size="100%">Lidholm, J.</style></author><author><style face="normal" font="default" size="100%">Keshavarz, B.</style></author><author><style face="normal" font="default" size="100%">Aalberse, R. C.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Goodman, R. E.</style></author><author><style face="normal" font="default" size="100%">Pomes, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">WHO/IUIS Allergen Nomenclature Sub-Committee.&#xD;Division of Allergy and Immunology, University of Virginia, Charlottesville, Virginia, USA.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Division of Clinical and Molecular Allergology, Research Center Borstel, AirwayResearch Center North (ARCN), German Center for Lung Research, Borstel, Germany.&#xD;Interdisciplinary Allergy Outpatient Clinic, Department of Internal Medicine and Pneumology, University of Lubeck, Lubeck, Germany.&#xD;Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet &amp; Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Biosciences, Paris Lodron University of Salzburg, Salzburg, Austria.&#xD;Department of Biological and Chemical Engineering, Aarhus University, Denmark.&#xD;Thermo Fisher Scientific, Uppsala, Sweden.&#xD;Department of Immunopathology, Sanquin, Amsterdam, The Netherlands.&#xD;Departments of Experimental Immunology and of Otorhinolaryngology, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, The Netherlands.&#xD;Food Allergy Research &amp; Resource Program, University of Nebraska, Lincoln, Nebraska, USA.&#xD;Basic Research, Indoor Biotechnologies, Inc., Charlottesville, Virginia, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Carbohydrate epitopes currently recognized as targets for IgE antibodies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2383-2394</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Carbohydrates</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">Epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Mmxf</style></keyword><keyword><style face="normal" font="default" size="100%">Muxf3</style></keyword><keyword><style face="normal" font="default" size="100%">O-glycans</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-gal</style></keyword><keyword><style face="normal" font="default" size="100%">clinical relevance</style></keyword><keyword><style face="normal" font="default" size="100%">cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="default" size="100%">hapten</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33655520</style></accession-num><abstract><style face="normal" font="default" size="100%">Until recently, glycan epitopes have not been documented by the WHO/IUIS Allergen Nomenclature Sub-Committee. This was in part due to scarce or incomplete information on these oligosaccharides, but also due to the widely held opinion that IgE to these epitopes had little or no relevance to allergic symptoms. Most IgE-binding glycans recognized up to 2008 were considered to be &quot;classical&quot; cross-reactive carbohydrate determinants (CCD) that occur in insects, some helminths and throughout the plant kingdom. Since 2008, the prevailing opinion on lack of clinical relevance of IgE-binding glycans has been subject to a reevaluation. This was because IgE specific for the mammalian disaccharide galactose-alpha-1,3-galactose (alpha-gal) was identified as a cause of delayed anaphylaxis to mammalian meat in the United States, an observation that has been confirmed by allergists in many parts of the world. Several experimental studies have shown that oligosaccharides with one or more terminal alpha-gal epitopes can be attached as a hapten to many different mammalian proteins or lipids. The classical CCDs also behave like haptens since they can be expressed on proteins from multiple species. This is the explanation for extensive in vitro cross-reactivity related to CCDs. Because of these developments, the Allergen Nomenclature Sub-Committee recently decided to include glycans as potentially allergenic epitopes in an adjunct section of its website (www.allergen.org). In this article, the features of the main glycan groups known to be involved in IgE recognition are revisited, and their characteristic structural, functional, and clinical features are discussed.</style></abstract><notes><style face="normal" font="default" size="100%">Platts-Mills, Thomas A&#xD;Hilger, Christiane&#xD;Jappe, Uta&#xD;van Hage, Marianne&#xD;Gadermaier, Gabriele&#xD;Spillner, Edzard&#xD;Lidholm, Jonas&#xD;Keshavarz, Behnam&#xD;Aalberse, Rob C&#xD;van Ree, Ronald&#xD;Goodman, Richard E&#xD;Pomes, Anna&#xD;eng&#xD;R37 AI020565/AI/NIAID NIH HHS/&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2383-2394. doi: 10.1111/all.14802.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33655520</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8489568</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14802</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1206</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1206</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Waern, I.</style></author><author><style face="normal" font="default" size="100%">Taha, S.</style></author><author><style face="normal" font="default" size="100%">Lorenzo, J.</style></author><author><style face="normal" font="default" size="100%">Montpeyo, D.</style></author><author><style face="normal" font="default" size="100%">Covaleda-Cortes, G.</style></author><author><style face="normal" font="default" size="100%">Aviles, F. X.</style></author><author><style face="normal" font="default" size="100%">Wernersson, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden.&#xD;Institut de Biotecnologia i de Biomedicina (IBB) and Departament de Bioquimica i de Biologia Molecular, Universitat Autonoma de Barcelona, Bellaterra, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Carboxypeptidase inhibition by NvCI suppresses airway hyperreactivity in a mouse asthma model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2234-2237</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="default" size="100%">Carboxypeptidases</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">NvCI carboxypeptidase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">carboxypeptidase activity</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33387397</style></accession-num><notes><style face="normal" font="default" size="100%">Waern, Ida&#xD;Taha, Sowsan&#xD;Lorenzo, Julia&#xD;Montpeyo, David&#xD;Covaleda-Cortes, Giovanni&#xD;Aviles, Francesc Xavier&#xD;Wernersson, Sara&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2234-2237. doi: 10.1111/all.14730. Epub 2021 Jan 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33387397</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14730</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2268</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2268</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Lee, E.</style></author><author><style face="normal" font="default" size="100%">Ha, E. K.</style></author><author><style face="normal" font="default" size="100%">Shin, J.</style></author><author><style face="normal" font="default" size="100%">Lee, G. C.</style></author><author><style face="normal" font="default" size="100%">Rha, Y. H.</style></author><author><style face="normal" font="default" size="100%">Han, M. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Kyung Hee University School of Medicine, Seoul, Korea.&#xD;Department of Pediatrics, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.&#xD;Department of Pediatrics, Kangnam Sacred Heart Hospital, Seoul, Korea.&#xD;Department of Pediatrics, Bundang CHA Medical Center, CHA University School of Medicine, Seongnam, Korea.&#xD;Department of Computer Science and Engineering, Konkuk University, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cascade of atopic dermatitis comorbidities in children after birth for 15 years</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">153-163</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/10/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">childhood diseases</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37843069</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Individuals with atopic dermatitis often develop other conditions. OBJECTIVE: This study aimed to determine how atopic dermatitis comorbidities develop in children over time. METHODS: This population-based administrative cohort study used national health insurance data. We traced individuals born in Korea between 2002 and 2003 to 2018. The date of initial atopic dermatitis diagnosis was set as the index date. Fifty-three childhood comorbidities of atopic dermatitis were identified as outcomes of interest by performing a comprehensive literature search and comparing the prevalence of diagnostic codes in children with and without atopic dermatitis. Four control children per individual in the atopic dermatitis group were randomly matched based on sex and index date. The association between atopic dermatitis and the development of each specified disease was assessed using proportional hazard assumption, followed by mapping of the temporal sequences of interconnected comorbidities. RESULTS: The atopic dermatitis and control groups contained 67,632 and 270,528 individuals, respectively. The median age at the index date was 10 months, whereas the median follow-up period was 15 years. Twenty diseases that were associated with a higher risk of atopic dermatitis were identified and a chain of interconnected conditions created. The progression began in childhood with febrile seizures, constipation, and asthma, and was later associated with the emergence of food allergy, allergic rhinitis, psychiatric disorders, and autoimmune diseases. CONCLUSION: Our study highlights the temporal nature of atopic dermatitis comorbidities in children, and indicates that an understanding of the comorbidities may inform its clinical management and treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Kim, Ju Hee&#xD;Lee, Eun&#xD;Ha, Eun Kyo&#xD;Shin, Jeewon&#xD;Lee, Gi Chun&#xD;Rha, Yeong Ho&#xD;Han, Man Yong&#xD;eng&#xD;Korea Health Technology R&amp;amp;D/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):153-163. doi: 10.1111/all.15917. Epub 2023 Oct 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37843069</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15917</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3312</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3312</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Engeroff, Paul</style></author><author><style face="normal" font="default" size="100%">Gharailoo, Zahra</style></author><author><style face="normal" font="default" size="100%">Vogel, Monique</style></author><author><style face="normal" font="default" size="100%">Bachmann, Martin F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A Case for Anti-IgE Vaccination</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high-affinity receptor FcεRI on mast cells and basophils, where allergen-induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research. Nevertheless, monoclonal anti-IgE therapy with omalizumab has transformed allergy treatment and proven to be safe and effective in various allergic indications. A remaining limitation of omalizumab is its high cost and requirement for repeated dosing, which limits accessibility. Vaccination against IgE theoretically offers a promising, cost-effective alternative, but long-standing safety concerns have slowed its development. Here, we review emerging concepts in IgE biology and therapeutic IgE neutralization. Recent research demonstrates that vaccine-induced anti-IgE antibodies can selectively neutralize free IgE while sparing FcεRI-bound IgE, thereby avoiding effector cell activation. This mechanism mirrors the behavior of natural anti-IgE autoantibodies, which may regulate physiological IgE homeostasis. Together, these novel insights indicate that anti-IgE vaccination is safe, biologically grounded, and a compelling strategy for the long-term control of IgE-mediated allergic disease.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70287</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70287</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>648</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">648</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elizur, A.</style></author><author><style face="normal" font="default" size="100%">Appel, M. Y.</style></author><author><style face="normal" font="default" size="100%">Nachshon, L.</style></author><author><style face="normal" font="default" size="100%">Levy, M. B.</style></author><author><style face="normal" font="default" size="100%">Epstein-Rigbi, N.</style></author><author><style face="normal" font="default" size="100%">Koren, Y.</style></author><author><style face="normal" font="default" size="100%">Holmqvist, M.</style></author><author><style face="normal" font="default" size="100%">Porsch, H.</style></author><author><style face="normal" font="default" size="100%">Lidholm, J.</style></author><author><style face="normal" font="default" size="100%">Goldberg, M. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Yitzhak Shamir Medical Center, Institute of Allergy, Immunology and Pediatric Pulmonology, Zerifin, Israel.&#xD;Department of Pediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.&#xD;Department of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Israel.&#xD;Thermo Fisher Scientific, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cashew oral immunotherapy for desensitizing cashew-pistachio allergy (NUT CRACKER study)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1863-1872</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/01/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Anacardium/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunotherapy/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Nut Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Pistacia/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">cashew</style></keyword><keyword><style face="normal" font="default" size="100%">cross-reactivity</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">tree nuts</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35000223</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Oral immunotherapy (OIT) is a treatment option for patients with milk, egg, and peanut allergy, but data on the efficacy and safety of cashew OIT are limited. METHODS: A cohort of 50 cashew-allergic patients aged &gt;/=4 years, who were consecutively enrolled into cashew OIT (target dose 4000 mg protein) between 4/2016 and 12/2019. Fifteen cashew-allergic patients who continued cashew elimination served as observational controls. Co-allergy to pistachio and walnut was determined. Full desensitization rate and associated immunological changes in both groups were compared. Patients fully desensitized to cashew were instructed to consume a dose of 1200 mg cashew protein for 6 months and were then challenged to a full dose. Patients with co-allergy to pistachio or walnut were challenged to the respective nut. RESULTS: Forty-four of 50 OIT-treated patients (88%) compared to 0% in controls tolerated a dose of 4000 mg cashew protein at the end of the study (odds ratio 8.3, 95% CI 3.9-17.7, p &lt; 0.001). An additional three patients were desensitized to 1200 mg cashew protein, and three patients stopped treatment. Three patients (6%) were treated with injectable epinephrine for home reactions. Desensitized patients had decreased SPT, sIgE, basophil reactivity, and increased sIgG4, following treatment. Following cashew desensitization, all pistachio (n = 35) and four of eight walnut co-allergic patients were cross-desensitized to the respective nut. All (n = 44) patients consuming a low cashew dose for &gt;/=6 months following desensitization passed a full-dose cashew OFC. CONCLUSIONS: Cashew OIT desensitizes most cashew-allergic patients and cross-desensitizes to pistachio. Safety is similar to OIT for other foods.</style></abstract><notes><style face="normal" font="default" size="100%">Elizur, Arnon&#xD;Appel, Michael Y&#xD;Nachshon, Liat&#xD;Levy, Michael B&#xD;Epstein-Rigbi, Naama&#xD;Koren, Yael&#xD;Holmqvist, Marie&#xD;Porsch, Helena&#xD;Lidholm, Jonas&#xD;Goldberg, Michael R&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1863-1872. doi: 10.1111/all.15212. Epub 2022 Jan 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35000223</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15212</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>997</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">997</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Plassmeyer, M.</style></author><author><style face="normal" font="default" size="100%">Alpan, O.</style></author><author><style face="normal" font="default" size="100%">Corley, M. J.</style></author><author><style face="normal" font="default" size="100%">Premeaux, T. A.</style></author><author><style face="normal" font="default" size="100%">Lillard, K.</style></author><author><style face="normal" font="default" size="100%">Coatney, P.</style></author><author><style face="normal" font="default" size="100%">Vaziri, T.</style></author><author><style face="normal" font="default" size="100%">Michalsky, S.</style></author><author><style face="normal" font="default" size="100%">Pang, A. P. S.</style></author><author><style face="normal" font="default" size="100%">Bukhari, Z.</style></author><author><style face="normal" font="default" size="100%">Yeung, S. T.</style></author><author><style face="normal" font="default" size="100%">Evering, T. H.</style></author><author><style face="normal" font="default" size="100%">Naughton, G.</style></author><author><style face="normal" font="default" size="100%">Latterich, M.</style></author><author><style face="normal" font="default" size="100%">Mudd, P.</style></author><author><style face="normal" font="default" size="100%">Spada, A.</style></author><author><style face="normal" font="default" size="100%">Rindone, N.</style></author><author><style face="normal" font="default" size="100%">Loizou, D.</style></author><author><style face="normal" font="default" size="100%">Ulrik Sonder, S.</style></author><author><style face="normal" font="default" size="100%">Ndhlovu, L. C.</style></author><author><style face="normal" font="default" size="100%">Gupta, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Amerimmune, Fairfax, VA, USA.&#xD;Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York City, NY, USA.&#xD;S.U.N.Y. Downstate Health Sciences University, Brooklyn, NY, USA.&#xD;Histogen, Inc, San Diego, CA, USA.&#xD;Department of Emergency Medicine, Washington University School of Medicine, Saint Louis, MO, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS-CoV-2 infection and long COVID</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">118-129</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/05/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">CD4-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 1</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 3</style></keyword><keyword><style face="normal" font="default" size="100%">Caspase 7</style></keyword><keyword><style face="normal" font="default" size="100%">*Caspase Inhibitors/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Caspases/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Post-Acute COVID-19 Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Drug Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">T-helper cell</style></keyword><keyword><style face="normal" font="default" size="100%">caspase</style></keyword><keyword><style face="normal" font="default" size="100%">emricasan</style></keyword><keyword><style face="normal" font="default" size="100%">red blood cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33993490</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: COVID-19 can present with lymphopenia and extraordinary complex multiorgan pathologies that can trigger long-term sequela. AIMS: Given that inflammasome products, like caspase-1, play a role in the pathophysiology of a number of co-morbid conditions, we investigated caspases across the spectrum of COVID-19 disease. MATERIALS &amp; METHODS: We assessed transcriptional states of multiple caspases and using flow cytometry, the expression of active caspase-1 in blood cells from COVID-19 patients in acute and convalescent stages of disease. Non-COVID-19 subject presenting with various comorbid conditions served as controls. RESULTS: Single-cell RNA-seq data of immune cells from COVID-19 patients showed a distinct caspase expression pattern in T cells, neutrophils, dendritic cells, and eosinophils compared with controls. Caspase-1 was upregulated in CD4+ T-cells from hospitalized COVID-19 patients compared with unexposed controls. Post-COVID-19 patients with lingering symptoms (long-haulers) also showed upregulated caspase-1activity in CD4+ T-cells that ex vivo was attenuated with a select pan-caspase inhibitor. We observed elevated caspase-3/7levels in red blood cells from COVID-19 patients compared with controls that was reduced following caspase inhibition. DISCUSSION: Our preliminary results suggest an exuberant caspase response in COVID-19 that may facilitate immune-related pathological processes leading to severe outcomes. Further clinical correlations of caspase expression in different stages of COVID-19 will be needed. CONCLUSION: Pan-caspase inhibition could emerge as a therapeutic strategy to ameliorate or prevent severe COVID-19.</style></abstract><notes><style face="normal" font="default" size="100%">Plassmeyer, Matthew&#xD;Alpan, Oral&#xD;Corley, Michael J&#xD;Premeaux, Thomas A&#xD;Lillard, Kimberleigh&#xD;Coatney, Paige&#xD;Vaziri, Tina&#xD;Michalsky, Suzan&#xD;Pang, Alina P S&#xD;Bukhari, Zaheer&#xD;Yeung, Stephen T&#xD;Evering, Teresa H&#xD;Naughton, Gail&#xD;Latterich, Martin&#xD;Mudd, Philip&#xD;Spada, Alfred&#xD;Rindone, Nicole&#xD;Loizou, Denise&#xD;Ulrik Sonder, Soren&#xD;Ndhlovu, Lishomwa C&#xD;Gupta, Raavi&#xD;eng&#xD;K01 HL140271/HL/NHLBI NIH HHS/&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):118-129. doi: 10.1111/all.14907. Epub 2021 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33993490</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8222863</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14907</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2753</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2753</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Deng, L.</style></author><author><style face="normal" font="default" size="100%">Yao, Y.</style></author><author><style face="normal" font="default" size="100%">Lu, Z.</style></author><author><style face="normal" font="default" size="100%">Xia, P.</style></author><author><style face="normal" font="default" size="100%">Yu, T.</style></author><author><style face="normal" font="default" size="100%">Shen, H.</style></author><author><style face="normal" font="default" size="100%">Ji, J.</style></author><author><style face="normal" font="default" size="100%">Jiao, Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Suzhou Wuzhong People&apos;s Hospital, Suzhou, China.&#xD;Department of Dermatology, The Second Affiliated Hospital of Soochow University, Suzhou, China.&#xD;Department of Traditional Chinese Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.&#xD;Department of Dermatology, TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, China.&#xD;Central Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, China.&#xD;Department of Dermatology, The First Affiliated Hospital of Soochow University, Suzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Causal Associations Between Chronic Spontaneous Urticaria and Thyroid Function Indicators on Different Ethnic Groups: A Bidirectional Two-Sample Mendelian Randomization Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1498-1500</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/12/13</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39670504</style></accession-num><notes><style face="normal" font="default" size="100%">Deng, Lijun&#xD;Yao, Yuxu&#xD;Lu, Zhenzhong&#xD;Xia, Ping&#xD;Yu, Tingting&#xD;Shen, Hui&#xD;Ji, Jiang&#xD;Jiao, Qingqing&#xD;eng&#xD;MS2023102/Jiangsu Province Traditional Chinese Medicine Science and Technology Development Project/&#xD;KJXW2021065/Suzhou Municipal Health Commission, &quot;Science, Education and Health&quot; Youth Science and Technology Project/&#xD;MS2021098/Jiangsu Provincial Bureau of Chinese Medicine and Technology/&#xD;ZD202209/Key Project of TCM Science and Technology Development plan of Jiangsu Province/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1498-1500. doi: 10.1111/all.16400. Epub 2024 Dec 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39670504</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105073</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16400</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3284</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3284</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sun, Shuomin</style></author><author><style face="normal" font="default" size="100%">Meng, Ruogu</style></author><author><style face="normal" font="default" size="100%">Wang, Qi</style></author><author><style face="normal" font="default" size="100%">Hao, Xingjie</style></author><author><style face="normal" font="default" size="100%">Wang, Xin</style></author><author><style face="normal" font="default" size="100%">Shen, Chen</style></author><author><style face="normal" font="default" size="100%">Chung, Wen-Hung</style></author><author><style face="normal" font="default" size="100%">Miao, Xiaoping</style></author><author><style face="normal" font="default" size="100%">Li, Danqi</style></author><author><style face="normal" font="default" size="100%">Tao, Juan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Causal Associations Between Interleukin-13 Inhibitors and Atopic Dermatitis Related Neuropsychiatric Comorbidities</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70242</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70242</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2217</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2217</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Kim, S. P.</style></author><author><style face="normal" font="default" size="100%">Song, J. I.</style></author><author><style face="normal" font="default" size="100%">Kim, Z.</style></author><author><style face="normal" font="default" size="100%">Kim, J. Y.</style></author><author><style face="normal" font="default" size="100%">Yoon, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.&#xD;Interdisciplinary Program of Medical Informatics, Seoul National University College of Medicine, Seoul, South Korea.&#xD;Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea.&#xD;Department of Future &amp; Smart Construction Research, Korea Institute of Civil Engineering and Building Technology (KICT), Goyang-si, South Korea.&#xD;Interdisciplinary Program of Bioengineering, Seoul National University College of Engineering, Seoul, South Korea.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Ilsan Hospital, Dongguk University, Goyang, South Korea.&#xD;Medical Big Data Research Center, Seoul National University College of Medicine, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Causal relationship between asthma outpatient visits and air pollution with instrumental variable approach</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3007-3009</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Outpatients</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Particulate Matter/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">China</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37357713</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Su Hwan&#xD;Kim, Seong Pyo&#xD;Song, Jae-In&#xD;Kim, Zio&#xD;Kim, Jin Youp&#xD;Yoon, Hyung-Jin&#xD;eng&#xD;National Research Foundation of Korea/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):3007-3009. doi: 10.1111/all.15791. Epub 2023 Jun 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37357713</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15791</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>689</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">689</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ito, N.</style></author><author><style face="normal" font="default" size="100%">Sakata, F.</style></author><author><style face="normal" font="default" size="100%">Hachisu, M.</style></author><author><style face="normal" font="default" size="100%">Nagata, K.</style></author><author><style face="normal" font="default" size="100%">Ito, T.</style></author><author><style face="normal" font="default" size="100%">Nomura, K.</style></author><author><style face="normal" font="default" size="100%">Nagaoka, M.</style></author><author><style face="normal" font="default" size="100%">Inaba, K.</style></author><author><style face="normal" font="default" size="100%">Hara, M.</style></author><author><style face="normal" font="default" size="100%">Nakano, N.</style></author><author><style face="normal" font="default" size="100%">Nakajima, T.</style></author><author><style face="normal" font="default" size="100%">Yashiro, T.</style></author><author><style face="normal" font="default" size="100%">Nishiyama, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biological Science and Technology, Faculty of Advanced Engineering, Tokyo University of Science, Tokyo, Japan.&#xD;Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Ccl17 gene encoding TARC is synergistically transactivated by PU.1 and IRF4 driven by the mammalian common promoter in dendritic cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1054-1059</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/11/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Chemokine CCL17/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Dendritic Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mammals/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Promoter Regions, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Ccl17</style></keyword><keyword><style face="normal" font="default" size="100%">Irf4</style></keyword><keyword><style face="normal" font="default" size="100%">Pu.1</style></keyword><keyword><style face="normal" font="default" size="100%">Tarc</style></keyword><keyword><style face="normal" font="default" size="100%">dendritic cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34807993</style></accession-num><notes><style face="normal" font="default" size="100%">Ito, Naoto&#xD;Sakata, Fumiya&#xD;Hachisu, Masakazu&#xD;Nagata, Kazuki&#xD;Ito, Tomoka&#xD;Nomura, Kurumi&#xD;Nagaoka, Masanori&#xD;Inaba, Keito&#xD;Hara, Mutsuko&#xD;Nakano, Nobuhiro&#xD;Nakajima, Tadaaki&#xD;Yashiro, Takuya&#xD;Nishiyama, Chiharu&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1054-1059. doi: 10.1111/all.15184. Epub 2021 Dec 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34807993</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15184</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2948</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2948</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Seok, S. H.</style></author><author><style face="normal" font="default" size="100%">Han, S. H.</style></author><author><style face="normal" font="default" size="100%">Jeong, M. R.</style></author><author><style face="normal" font="default" size="100%">Song, Y.</style></author><author><style face="normal" font="default" size="100%">Park, Y. J.</style></author><author><style face="normal" font="default" size="100%">Choi, D. Y.</style></author><author><style face="normal" font="default" size="100%">Shin, N.</style></author><author><style face="normal" font="default" size="100%">Park, S.</style></author><author><style face="normal" font="default" size="100%">Kim, J.</style></author><author><style face="normal" font="default" size="100%">Ahn, Y.</style></author><author><style face="normal" font="default" size="100%">Kim, H. Y.</style></author><author><style face="normal" font="default" size="100%">Ahn, J.</style></author><author><style face="normal" font="default" size="100%">Kim, K.</style></author><author><style face="normal" font="default" size="100%">Hong, J. J.</style></author><author><style face="normal" font="default" size="100%">Na, Y. R.</style></author><author><style face="normal" font="default" size="100%">Park, M. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology and Immunology, and Institute of Endemic Disease, Seoul National University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.&#xD;Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.&#xD;Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, Republic of Korea.&#xD;Immunology Core Facility, Department of Translational Research Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.&#xD;Interdisciplinary Program in Neuroscience, College of Natural Sciences, Seoul National University, Seoul, South Korea.&#xD;Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.&#xD;Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, South Korea.&#xD;Korea Research Institute of Bioscience and Biotechnology National Primate Research Center, Ochang, South Korea.&#xD;University of Science and Technology, Daejeon, South Korea.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul, Republic of Korea.&#xD;Sensory Organ Research Institute, Medical Research Center, Seoul National University, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CCR2-Dependent Monocyte Recruitment Accelerates Allergic Airway Inflammation in Diesel Exhaust-Exposed Mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3430-3433</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40569169</style></accession-num><notes><style face="normal" font="default" size="100%">Seok, Seung Hyeok&#xD;Han, Seung Hee&#xD;Jeong, Mi Reu&#xD;Song, Youngmin&#xD;Park, Yeon Ji&#xD;Choi, Da Yeon&#xD;Shin, Nayeon&#xD;Park, Sohyeon&#xD;Kim, Jihyun&#xD;Ahn, Yoojin&#xD;Kim, Hye Young&#xD;Ahn, Jiyoung&#xD;Kim, Kwangsoo&#xD;Hong, Jung Joo&#xD;Na, Yi Rang&#xD;Park, Moo Kyun&#xD;eng&#xD;National Research Foundation of Korea/&#xD;SNUH research fund/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3430-3433. doi: 10.1111/all.16626. Epub 2025 Jun 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40569169</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16626</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3275</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3275</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Balaji, Anishaa</style></author><author><style face="normal" font="default" size="100%">Karagiannis, Sophia N.</style></author><author><style face="normal" font="default" size="100%">McCraw, Alexandra J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">CD4+ T Cell-Intrinsic Arg1 Regulates Th1 Dynamics in Influenza: Functional and Translational Implications for Infection and Cancer Inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70249</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70249</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>928</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">928</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Funch, A. B.</style></author><author><style face="normal" font="default" size="100%">Mraz, V.</style></author><author><style face="normal" font="default" size="100%">Gadsboll, A. O.</style></author><author><style face="normal" font="default" size="100%">Jee, M. H.</style></author><author><style face="normal" font="default" size="100%">Weber, J. F.</style></author><author><style face="normal" font="default" size="100%">Odum, N.</style></author><author><style face="normal" font="default" size="100%">Woetmann, A.</style></author><author><style face="normal" font="default" size="100%">Johansen, J. D.</style></author><author><style face="normal" font="default" size="100%">Geisler, C.</style></author><author><style face="normal" font="default" size="100%">Bonefeld, C. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, The LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Dermatology and Allergy, National Allergy Research Center, Copenhagen University Hospital Gentofte, Hellerup, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CD8(+) tissue-resident memory T cells recruit neutrophils that are essential for flare-ups in contact dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">513-524</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Memory</style></keyword><keyword><style face="normal" font="default" size="100%">Memory T Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">Cxcl1</style></keyword><keyword><style face="normal" font="default" size="100%">Cxcl2</style></keyword><keyword><style face="normal" font="default" size="100%">allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">epidermal-resident T cells</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophils</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34169536</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic contact dermatitis (ACD) is classically described as a delayed-type hypersensitivity reaction. However, patients often experience flare-ups characterized by itching erythema, edema, and often vesicles occurring within hours after re-exposure of previously sensitized skin to the specific contact allergen. Recent studies have indicated that skin-resident memory T (T(RM) ) cells play a central role in ACD. However, the pathogenic role of T(RM) cells in allergen-induced flare-ups is not known. METHODS: By the use of various mouse models and cell depletion protocols, we investigated the role of epidermal T(RM) cells in flare-up reactions to the experimental contact allergen 1-fluoro-2,4-dinitrobenzene. The inflammatory response was measured by changes in ear thickness, and the cellular composition in epidermis was determined by flow cytometry and confocal microscopy. Finally, adaptive transfer and inhibitors were used to determine the role of T(RM) cells, neutrophils, and CXCL1/CXCL2 in the response. RESULTS: We show that CD8(+) T(RM) cells initiate massive infiltration of neutrophils in the epidermis within 12 h after re-exposure to the contact allergen. Depletion of neutrophils before re-exposure to the allergen abrogated the flare-up reactions. Furthermore, we demonstrate that CD8(+) T(RM) cells mediate neutrophil recruitment by inducing CXCL1 and CXCL2 production in the skin, and that blockage of the C-X-C chemokine receptor type 1 and 2 inhibits flare-up reactions and neutrophil infiltration. CONCLUSION: As the first, we show that epidermal CD8(+) T(RM) cells cause ACD flare-ups by rapid recruitment of neutrophils to the epidermis.</style></abstract><notes><style face="normal" font="default" size="100%">Funch, Anders B&#xD;Mraz, Veronika&#xD;Gadsboll, Anne-Sofie O&#xD;Jee, Mia H&#xD;Weber, Julie F&#xD;Odum, Niels&#xD;Woetmann, Anders&#xD;Johansen, Jeanne D&#xD;Geisler, Carsten&#xD;Bonefeld, Charlotte M&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):513-524. doi: 10.1111/all.14986. Epub 2021 Jul 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34169536</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14986</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2499</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2499</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Piperakis, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CD8+ T-cell efficiency is affected by the form of membrane lipids in lipid rafts</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2577-2579</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/05/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*CD8-Positive T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Membrane Lipids/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Membrane Microdomains/metabolism/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38794855</style></accession-num><notes><style face="normal" font="default" size="100%">Piperakis, Artemios&#xD;eng&#xD;Letter&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2577-2579. doi: 10.1111/all.16176. Epub 2024 May 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38794855</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16176</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>739</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">739</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tagkareli, S.</style></author><author><style face="normal" font="default" size="100%">Salagianni, M.</style></author><author><style face="normal" font="default" size="100%">Galani, I. E.</style></author><author><style face="normal" font="default" size="100%">Manioudaki, M.</style></author><author><style face="normal" font="default" size="100%">Pavlos, E.</style></author><author><style face="normal" font="default" size="100%">Thanopoulou, K.</style></author><author><style face="normal" font="default" size="100%">Andreakos, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.&#xD;Airway Disease Infection Section, National Heart and Lung Institute, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CD103 integrin identifies a high IL-10-producing FoxP3(+) regulatory T-cell population suppressing allergic airway inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1150-1164</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/10/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Forkhead Transcription Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Integrin alpha Chains/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Integrins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-10/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Cd103</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">th-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34658046</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Although FoxP3(+) regulatory T (Treg) cells constitute a highly heterogeneous population, with different regulatory potential depending on the disease context, distinct subsets or phenotypes remain poorly defined. This hampers the development of immunotherapy for allergic and autoimmune disorders. The present study aimed at characterizing distinct FoxP3(+) Treg subpopulations involved in the suppression of Th2-mediated allergic inflammation in the lung. METHODS: We used an established mouse model of allergic airway disease based on ovalbumin sensitization and challenge to analyze FoxP3(+) Tregs during the induction and resolution of inflammation, and identify markers that distinguish their most suppressive phenotypes. We also developed a new knock-in mouse model (Foxp3(cre) Cd103(dtr) ) enabling the specific ablation of CD103(+) FoxP3(+) Tregs for functional studies. RESULTS: We found that during resolution of allergic airway inflammation in mice &gt;50% of FoxP3(+) Treg cells expressed the integrin CD103 which marks FoxP3(+) Treg cells of high IL-10 production, increased expression of immunoregulatory molecules such as KLRG1, ICOS and CD127, and enhanced suppressive capacity for Th2-mediated inflammatory responses. CD103(+) FoxP3(+) Tregs were essential for keeping allergic inflammation under control as their specific depletion in Foxp3(cre) Cd103(dtr) mice lead to severe alveocapillary damage, eosinophilic pneumonia, and markedly reduced lifespan of the animals. Conversely, adoptive transfer of CD103(+) FoxP3(+) Tregs effectively treated disease, attenuating Th2 responses and allergic inflammation in an IL-10-dependent manner. CONCLUSIONS: Our study identifies a novel regulatory T-cell population, defined by CD103 expression, programmed to prevent exuberant type 2 inflammation and keep homeostasis in the respiratory tract under control. This has important therapeutic implications.</style></abstract><notes><style face="normal" font="default" size="100%">Tagkareli, Sofia&#xD;Salagianni, Maria&#xD;Galani, Ioanna-Evdokia&#xD;Manioudaki, Maria&#xD;Pavlos, Eleftherios&#xD;Thanopoulou, Kalliopi&#xD;Andreakos, Evangelos&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1150-1164. doi: 10.1111/all.15144. Epub 2021 Oct 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34658046</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15144</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>368</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">368</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mumby, S.</style></author><author><style face="normal" font="default" size="100%">Kermani, N. Z.</style></author><author><style face="normal" font="default" size="100%">Garnett, J. P.</style></author><author><style face="normal" font="default" size="100%">Pavlidis, S.</style></author><author><style face="normal" font="default" size="100%">Wilson, S. J.</style></author><author><style face="normal" font="default" size="100%">Howarth, P. J.</style></author><author><style face="normal" font="default" size="100%">Thomas, M. J.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Lopez-Garcia, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Airway Disease Section, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Computing, Data Science Institute, Imperial College London, London, UK.&#xD;Immunology and Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH and Co KG Biberach, Biberach, Germany.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CEACAM5 is an IL-13-regulated epithelial gene that mediates transcription in type-2 (T2) high severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3463-3466</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/08/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-13/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Carcinoembryonic Antigen</style></keyword><keyword><style face="normal" font="default" size="100%">GPI-Linked Proteins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35916059</style></accession-num><notes><style face="normal" font="default" size="100%">Mumby, Sharon&#xD;Kermani, Nazanin Zounemat&#xD;Garnett, James P&#xD;Pavlidis, Stelios&#xD;Wilson, Susan J&#xD;Howarth, Peter J&#xD;Thomas, Matthew J&#xD;Adcock, Ian M&#xD;Lopez-Garcia, Carlos&#xD;eng&#xD;CRUK_/Cancer Research UK/United Kingdom&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3463-3466. doi: 10.1111/all.15465. Epub 2022 Aug 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35916059</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15465</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3041</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3041</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, Y.</style></author><author><style face="normal" font="default" size="100%">Kang, M.</style></author><author><style face="normal" font="default" size="100%">Seo, J.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Rha, M. S.</style></author><author><style face="normal" font="default" size="100%">Kim, C. H.</style></author><author><style face="normal" font="default" size="100%">Cho, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biomedical Sciences, Yonsei University College of Medicine, Seoul, Korea.&#xD;Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.&#xD;Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea.&#xD;The Airway Mucus Institute, Yonsei University College of Medicine, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cell Type-Specific IL-5Ralpha Distribution and IL-5-Induced CCL11 Expression in Human Nasal Epithelium</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2654-2659</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/08/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Ccl11</style></keyword><keyword><style face="normal" font="default" size="100%">Ccl26</style></keyword><keyword><style face="normal" font="default" size="100%">Ciliated epithelial cell</style></keyword><keyword><style face="normal" font="default" size="100%">Goblet cell</style></keyword><keyword><style face="normal" font="default" size="100%">Il-4r</style></keyword><keyword><style face="normal" font="default" size="100%">Il-5</style></keyword><keyword><style face="normal" font="default" size="100%">Il-5r</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40785590</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Yosep&#xD;Kang, Miran&#xD;Seo, Juhee&#xD;Kim, Subin&#xD;Rha, Min-Seok&#xD;Kim, Chang-Hoon&#xD;Cho, Hyung-Ju&#xD;eng&#xD;RS-2023-00220853/National Research Foundation of Korea/&#xD;NRF2021R1A2C2010811/National Research Foundation of Korea/&#xD;6-2021-0005/Team Science Award of Yonsei University College of Medicine/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2654-2659. doi: 10.1111/all.70003. Epub 2025 Aug 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40785590</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444812</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70003</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>434</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">434</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qi, C.</style></author><author><style face="normal" font="default" size="100%">Berg, M.</style></author><author><style face="normal" font="default" size="100%">Chu, X.</style></author><author><style face="normal" font="default" size="100%">Timens, W.</style></author><author><style face="normal" font="default" size="100%">Kole, T.</style></author><author><style face="normal" font="default" size="100%">van den Berge, M.</style></author><author><style face="normal" font="default" size="100%">Xu, C. J.</style></author><author><style face="normal" font="default" size="100%">Koppelman, G. H.</style></author><author><style face="normal" font="default" size="100%">Nawijn, M. C.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Pulmonology and Pediatric Allergology, University of Groningen, University Medical Center Groningen, Beatrix Children&apos;s Hospital, University of Groningen, Groningen, The Netherlands.&#xD;University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, The Netherlands.&#xD;Microbiome Medicine Center, Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.&#xD;Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.&#xD;Centre for Individualized Infection Medicine (CiiM), a Joint Venture Between Hannover Medical School and Helmholtz Centre for Infection Research, Hannover, Germany.&#xD;Department of Pathology &amp; Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;TWINCORE, Centre for Experimental and Clinical Infection Research, a Joint Venture Between Hannover Medical School and Helmholtz Centre for Infection Research, Hannover, Germany.&#xD;Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cell-type eQTL deconvolution of bronchial epithelium through integration of single-cell and bulk RNA-seq</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3663-3666</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/06/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">RNA-Seq</style></keyword><keyword><style face="normal" font="default" size="100%">Sequence Analysis, RNA</style></keyword><keyword><style face="normal" font="default" size="100%">*Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35708915</style></accession-num><notes><style face="normal" font="default" size="100%">Qi, Cancan&#xD;Berg, Marijn&#xD;Chu, Xiaojing&#xD;Timens, Wim&#xD;Kole, Tessa&#xD;van den Berge, Maarten&#xD;Xu, Cheng-Jian&#xD;Koppelman, Gerard H&#xD;Nawijn, Martijn C&#xD;Li, Yang&#xD;eng&#xD;ZONMW_/ZonMw/Netherlands&#xD;ERC_/European Research Council/International&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3663-3666. doi: 10.1111/all.15410. Epub 2022 Jun 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35708915</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15410</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3110</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3110</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Zeyneloglu, C.</style></author><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">Ardicli, S.</style></author><author><style face="normal" font="default" size="100%">Garci-Sanchez, A.</style></author><author><style face="normal" font="default" size="100%">Bu, X.</style></author><author><style face="normal" font="default" size="100%">Heider, A.</style></author><author><style face="normal" font="default" size="100%">Viscardi, O. G.</style></author><author><style face="normal" font="default" size="100%">Chang, L.</style></author><author><style face="normal" font="default" size="100%">Simmons, S.</style></author><author><style face="normal" font="default" size="100%">Almada, A.</style></author><author><style face="normal" font="default" size="100%">Avena, C.</style></author><author><style face="normal" font="default" size="100%">Jensen, T.</style></author><author><style face="normal" font="default" size="100%">Dhir, R.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Biomedical and Diagnostic Sciences, University of Salamanca, Salamanca, Spain.&#xD;SEED Health, Venice, USA.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cellular Stress, Inflammation and Barrier Damage in Gut Epithelial Cells Caused by Aspartame</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">aspartame</style></keyword><keyword><style face="normal" font="default" size="100%">barrier</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">gut-on-a-chip</style></keyword><keyword><style face="normal" font="default" size="100%">organoid</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41137210</style></accession-num><abstract><style face="normal" font="default" size="100%">Aspartame has been widely used as a sweetener in foods and beverages since the 1980s. In this study, we aimed to assess its effects on gut epithelial cell biology, inflammation and the epithelial barrier. We found that aspartame induces cytotoxic effects, disrupts the epithelial barrier and triggers proinflammatory cytokine release in gastrointestinal epithelial cells, organoids and gut-on-a-chip models at concentrations corresponding to daily consumed doses in food products. Cellular cytotoxicity was observed at doses as low as 1.25 mg/mL. RNA sequencing analysis revealed that aspartame significantly alters the transcriptome in gut-on-a-chip models, with upregulation of pathways involved in the unfolded protein response, pro-apoptotic and inflammatory processes and downregulation of those related to DNA repair and replication. Aspartame exposure upregulated proinflammatory genes, particularly in the TNF signalling pathway, and induced multiple chemokine responses. It also activated the NF-kappaB pathway via oxidative stress, promoting inflammation in NF-kappaB reporter monocyte cells and leading to gut epithelial cell death. Additionally, aspartame affected genes involved in tight and adherens junctions, disrupting gut epithelial barrier integrity in a dose-dependent manner. It further suppressed key DNA repair and replication genes associated with double-strand break repair, mismatch repair and DNA replication. Overall, our findings indicate that, at commonly consumed levels, aspartame induces cellular stress, inflammation and epithelial barrier damage in gastrointestinal epithelial cells. These results underscore the biological relevance of our study and raise concerns that daily dietary intake of aspartame may pose previously underappreciated risks to gut health.</style></abstract><notes><style face="normal" font="default" size="100%">Pat, Yagiz&#xD;Yazici, Duygu&#xD;Zeyneloglu, Can&#xD;Babayev, Huseyn&#xD;Ardicli, Sena&#xD;Garci-Sanchez, Asuncion&#xD;Bu, Xiangting&#xD;Heider, Anja&#xD;Viscardi, Oliva Giannelli&#xD;Chang, Lihong&#xD;Simmons, Sheri&#xD;Almada, Anthony&#xD;Avena, Christine&#xD;Jensen, Tye&#xD;Dhir, Raja&#xD;Ogulur, Ismail&#xD;Akdis, Cezmi A&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Oct 24. doi: 10.1111/all.70095.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41137210</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70095</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1039</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1039</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Matsuo, S.</style></author><author><style face="normal" font="default" size="100%">Hashimoto, T.</style></author><author><style face="normal" font="default" size="100%">Matsuura, F.</style></author><author><style face="normal" font="default" size="100%">Imamura, O.</style></author><author><style face="normal" font="default" size="100%">Endo, S.</style></author><author><style face="normal" font="default" size="100%">Satoh, Y.</style></author><author><style face="normal" font="default" size="100%">Satoh, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, National Defense Medical College, Tokorozawa, Japan.&#xD;Department of Anesthesiology, National Defense Medical College, Tokorozawa, Japan.&#xD;Department of Biochemistry, National Defense Medical College, Tokorozawa, Japan.&#xD;Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Central, but not peripheral, nervous system ERK2 is essential for itch signals in murine allergic skin inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3422-3432</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*MAP Kinase Signaling System</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">*Mitogen-Activated Protein Kinase 1/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Peripheral Nervous System</style></keyword><keyword><style face="normal" font="default" size="100%">*Pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Erk2</style></keyword><keyword><style face="normal" font="default" size="100%">Il-31</style></keyword><keyword><style face="normal" font="default" size="100%">alloknesis</style></keyword><keyword><style face="normal" font="default" size="100%">mechanical itch</style></keyword><keyword><style face="normal" font="default" size="100%">urocortin3</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33884632</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Itch is a common cutaneous symptom in a variety of dermatological diseases, but detailed neuropathological mechanisms remain to be fully elucidated. This study aimed to assess in vivo ERK2 functions in the nervous system for itch responses. METHODS: We generated conditional knockout mice deficient in ERK2 of the central nervous system (CNS) or peripheral nervous system (PNS), respectively, and assessed chemical and mechanical itch responses in vivo. RESULTS: Chemical itch responses to histamine, but not to BAM8-22, were alleviated in CNS Erk2-deficient mice. In contrast, both histamine- and BAM8-22-induced mechanical itch (alloknesis) were alleviated in CNS Erk2-deficient mice. Neither chemical itch nor mechanical itch induced by these pruritogens was affected by PNS ERK2 deficiency. Spontaneous scratching behaviors during acute and chronic contact hypersensitivity were impaired in CNS Erk2-deficient mice, but not PNS Erk2-deficient mice. In addition, CNS ERK2 deficiency attenuated mechanical itch responses during chronic contact hypersensitivity. Again, PNS Erk2-deficient mice showed comparable responses of mechanical itch to control mice. In addition, alleviated mechanical itch in CNS Erk2-deficient mice was observed in IgE-mediated prurigo-like allergic skin inflammation. Mechanical itch induced by IL-31 was also alleviated by CNS ERK2 deficiency. Phosphorylated ERK1/2 was detected in neurokinin B-expressing cells of the spinal dorsal horn of control mice; these cells accumulated during the induction of chronic contact hypersensitivity. Notably, phosphorylated ERK1/2 was also localized in spinal urocortin3-expressing neurons that are known to transmit mechanical itch. CONCLUSIONS: Spinal cord ERK2 could be a potential therapeutic target for intractable itch in pruritic skin diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Matsuo, Shinsuke&#xD;Hashimoto, Takashi&#xD;Matsuura, Fumhiro&#xD;Imamura, Osamu&#xD;Endo, Shogo&#xD;Satoh, Yasushi&#xD;Satoh, Takahiro&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3422-3432. doi: 10.1111/all.14867. Epub 2021 May 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33884632</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14867</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2257</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2257</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Eller, E.</style></author><author><style face="normal" font="default" size="100%">Garvik, O. S.</style></author><author><style face="normal" font="default" size="100%">Kjaer, H. F.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark, Odense C, Denmark.&#xD;Center for Clinical Epidemiology, Odense University Hospital, and Research Unit of Clinical Epidemiology, University of Southern Denmark, Odense, Denmark.&#xD;Charite-Universitatsmedizin Berlin, Institute of Allergology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Allergology and Immunology Paul-Ehrlich-Haus Hindenburgdamm 27, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Challenge-verified thresholds for allergens mandatory for labeling: How little is too much for the most sensitive patient?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1306-1316</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/09/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">allergen labeling</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">severity of symptoms</style></keyword><keyword><style face="normal" font="default" size="100%">threshold value</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37661296</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: It is mandatory to label food products with the 14 main allergens in the EU. Reasonable allergen labeling requires knowledge of population-based thresholds derived from food challenges. The aim of this study was to evaluate the threshold-distribution in clinically verified food allergic patients for allergens mandatory for labeling. METHODS: All positive open oral food challenges and double-blind placebo-controlled food challenges (DBPCFC) performed at the Allergy Center, Odense University Hospital, Denmark (2000-2022) were included. For each included challenge, the cumulative threshold (LOAEL) was obtained and NOAEL estimated. Data were modelled as an interval censored log-normal distribution. RESULTS: Overall, 38 of all 2612 challenges (1.5%) in 1229 patients (717 male, 986 children) reacted to &lt;5 mg protein. The majority of the most sensitive patients reacted with a Sampson severity score of 2-3. Using interval censored log-normal models only five groups (hens egg, fish, peanut, milk, tree-nuts) elicited reactions after ingestion of 0.5 mg protein and in low frequencies of the population. Hen&apos;s egg was the most potent allergen, with reactivity to &lt;0.5 mg protein in 0.24% [0.13-0.44%] of egg allergic patients while the estimated fraction of allergic patients reacting to a eliciting dose on 0.5 mg protein for most other allergens were below 0.04%. CONCLUSION: Our data demonstrates that the majority of food allergic patients as expected tolerating traces of allergenic foods without developing severe allergic symptoms and signs. Hen&apos;s egg appears to be the food most likely to elicit reactions in the most sensitive individuals at very low doses.</style></abstract><notes><style face="normal" font="default" size="100%">Mortz, Charlotte G&#xD;Eller, Esben&#xD;Garvik, Olav Sivertsen&#xD;Kjaer, Henrik Fomsgaard&#xD;Zuberbier, Torsten&#xD;Bindslev-Jensen, Carsten&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1306-1316. doi: 10.1111/all.15870. Epub 2023 Sep 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37661296</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15870</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2305</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2305</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pinto, Msdn</style></author><author><style face="normal" font="default" size="100%">Gil, Sjrca</style></author><author><style face="normal" font="default" size="100%">Ramio-Lluch, L.</style></author><author><style face="normal" font="default" size="100%">Schmidt, V. M.</style></author><author><style face="normal" font="default" size="100%">Pereira, H. M. L.</style></author><author><style face="normal" font="default" size="100%">Fernandes, B. A. P.</style></author><author><style face="normal" font="default" size="100%">Camoes, A. F. B.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Sao Braz, Bmff</style></author><author><style face="normal" font="default" size="100%">Marto, J. M.</style></author><author><style face="normal" font="default" size="100%">Lourenco, Amgxf</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Veterinary Medicine, Centre for Interdisciplinary Research in Animal Health (CIISA), University of Lisbon, Lisbon, Portugal.&#xD;Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), Lisbon, Portugal.&#xD;LETI Pharma S.L.U, Barcelona, Spain.&#xD;Department of Small Animal Clinical Science, Institute of Infection Veterinary and Ecological Sciences (IVES), The University of Liverpool, Liverpool, UK.&#xD;Allergy Centre, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), University of Lisbon, Lisbon, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Challenging the norm: Epicutaneous immunotherapy for canine atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">255-257</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37984458</style></accession-num><notes><style face="normal" font="default" size="100%">Pinto, Marta Sofia das Neves&#xD;Gil, Solange Judite Roque Coelho Alves&#xD;Ramio-Lluch, Laura&#xD;Schmidt, Vanessa Merta&#xD;Pereira, Hugo Miguel Lino&#xD;Fernandes, Beatriz Amaral Pinto&#xD;Camoes, Ana Filipa Bizarro&#xD;Morais-Almeida, Mario&#xD;Sao Braz, Berta Maria Fernandes Ferreira&#xD;Marto, Joana Marques&#xD;Lourenco, Ana Mafalda Goncalves Xavier Felix&#xD;eng&#xD;LA/P/0059/2020/Associate Laboratory for Animal and Veterinary Sciences/&#xD;UIDB/00276/2020/Centre for Interdisciplinary Research in Animal Health/&#xD;UI/BD/153072/2022/Foundation for Science and Technology/&#xD;UIDB/04138/2020/Foundation for Science and Technology/&#xD;UIDP/04138/2020/Foundation for Science and Technology/&#xD;CEECINST/00145/2018/Foundation for Science and Technology/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):255-257. doi: 10.1111/all.15946. Epub 2023 Nov 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37984458</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15946</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>290</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">290</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhou, B.</style></author><author><style face="normal" font="default" size="100%">Liang, S.</style></author><author><style face="normal" font="default" size="100%">Shang, S.</style></author><author><style face="normal" font="default" size="100%">Xiang, L.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The changes of eosinophil counts in patients after treatment of Dupilumab: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3690-3694</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/09/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36107699</style></accession-num><notes><style face="normal" font="default" size="100%">Zhou, Boyang&#xD;Liang, Surong&#xD;Shang, Shuai&#xD;Xiang, Lujing&#xD;Li, Linfeng&#xD;eng&#xD;Letter&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3690-3694. doi: 10.1111/all.15517. Epub 2022 Sep 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36107699</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15517</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2124</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2124</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Denton, E.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy, Asthma &amp; Clinical Immunology, The Alfred Hospital, Melbourne, Victoria, Australia.&#xD;Department of Immunology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.&#xD;Public Health &amp; Preventive Medicine, Monash University, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The changing global prevalence of asthma and atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2079-2080</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/04/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37102759</style></accession-num><notes><style face="normal" font="default" size="100%">Denton, Eve&#xD;O&apos;Hehir, Robyn E&#xD;Hew, Mark&#xD;eng&#xD;Comment&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2079-2080. doi: 10.1111/all.15754. Epub 2023 Jun 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37102759</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15754</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2342</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2342</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Celik, G.</style></author><author><style face="normal" font="default" size="100%">Phillips, E.</style></author><author><style face="normal" font="default" size="100%">Tanno, L. K.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Departamento de Medicina, Universidad de Malaga, Malaga, Spain.&#xD;Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey.&#xD;Department of Medicine, Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.&#xD;Division of Allergy, Department of Pulmonology, Allergy and Thoracic Oncology, University Hospital of Montpellier, Montpellier, France.&#xD;Desbrest Institute of Epidemiology and Public Health, UMR UA11 University of Montpellier-INSERM, Montpellier, France.&#xD;WHO Collaborating Centre on Scientific Classification Support, Montpellier, France.&#xD;Division of Allergy and Immunology, Department of Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Changing patterns in the epidemiology of drug allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">613-628</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/12/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillins/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">drug-induced anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">risk factors</style></keyword><keyword><style face="normal" font="default" size="100%">trends</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38084822</style></accession-num><abstract><style face="normal" font="default" size="100%">Drug allergy (DA) remains a complex and unaddressed problem worldwide that often deprives patients of optimal medication choices and places them at risk for life-threatening reactions. Underdiagnosis and overdiagnosis are common and due to the lack of standardized definitions and biomarkers. The true burden of DA is unknown, and recent efforts in data gathering through electronic medical records are starting to provide emerging patterns around the world. Ten percent of the general population engaged in health care claim to have a DA, and the most common label is penicillin allergy. Up to 20% of emergency room visits for anaphylaxis are due to DA and 15%-20% of hospitalized patients report DA. It is estimated that DA will increase based on the availability and use of new and targeted antibiotics, vaccines, chemotherapies, biologicals, and small molecules, which are aimed at improving patient&apos;s options and quality of life. Global and regional variations in the prevalence of diseases such as human immunodeficiency virus and mycobacterial diseases, and the drugs used to treat these infections have an impact on DA. The aim of this review is to provide an update on the global impact of DA by presenting emerging data on drug epidemiology in adult and pediatric populations.</style></abstract><notes><style face="normal" font="default" size="100%">Dona, Immaculada&#xD;Torres, Maria Jose&#xD;Celik, Gulfem&#xD;Phillips, Elizabeth&#xD;Tanno, Luciana Kase&#xD;Castells, Mariana&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):613-628. doi: 10.1111/all.15970. Epub 2023 Dec 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38084822</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15970</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2558</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2558</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Connell, J. T.</style></author><author><style face="normal" font="default" size="100%">Bouras, G.</style></author><author><style face="normal" font="default" size="100%">Yeo, K.</style></author><author><style face="normal" font="default" size="100%">Fenix, K.</style></author><author><style face="normal" font="default" size="100%">Cooksley, C.</style></author><author><style face="normal" font="default" size="100%">Bassiouni, A.</style></author><author><style face="normal" font="default" size="100%">Vreugde, S.</style></author><author><style face="normal" font="default" size="100%">Wormald, P. J.</style></author><author><style face="normal" font="default" size="100%">Psaltis, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Surgery-Otolaryngology Head and Neck Surgery, University of Adelaide and the Basil Hetzel Institute for Translational Health Research, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.&#xD;Department of Otolaryngology, Head and Neck Surgery, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characterising the allergic fungal rhinosinusitis microenvironment using full-length 16S rRNA gene amplicon sequencing and fungal ITS sequencing</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3082-3094</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/07/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/microbiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*RNA, Ribosomal, 16S/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Fungi/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinitis, Allergic/microbiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Mycoses/microbiology/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Allergic Fungal Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">mycobiome</style></keyword><keyword><style face="normal" font="default" size="100%">sequence analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39044721</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Allergic fungal rhinosinusitis (AFRS) is a severe phenotype of chronic rhinosinusitis with nasal polyposis (CRSwNP), characterised by localised and exaggerated type 2 inflammation. While fungal antigenic stimulation of unregulated Th2-mediated inflammation is the core pathophysiological mechanism, the direct and synergistic role of bacteria in disease modification is a pervasive hypothesis. We set out to define the microenvironment of AFRS to elucidate virulent organisms that may be implicated in the pathophysiology of AFRS. METHODOLOGY: We undertook a cross-sectional study of AFRS patients and non-fungal CRSwNP patients. Demographics, disease severity, culture and microbiome sequences were analysed. Multimodality microbiome sequencing included short-read next-generation sequencing (NGS) on the Illumina Miseq (16S rRNA and ITS) and full-length 16S rRNA sequencing on the Oxford Nanopore Technologies GridION (ONT). RESULTS: Thirty-two AFRS and 29 non-fungal CRSwNP patients (NF) were included in this study. Staphylococcus aureus was the dominant organism cultured and sequenced in both AFRS and NF groups (AFRS 27.54%; NF 18.04%; p = .07). Streptococcus pneumoniae (AFRS 12.31%; NF 0.98%; p = .03) and Haemophilus influenzae (AFRS 15.03%; NF 0.24%; p = .005) were significantly more abundant in AFRS. Bacterial diversity (Shannon&apos;s index) was considerably lower in AFRS relative to NF (AFRS 0.6; NF 1.0, p = .008). Aspergillus was the most cultured fungus in AFRS (10/32, 31.3%). The AFRS sequenced mycobiome was predominantly represented by Malassezia (43.6%), Curvularia (18.5%) and Aspergillus (16.8%), while the NF mycobiome was nearly exclusively Malassezia (84.2%) with an absence of Aspergillus or dematiaceous fungi. CONCLUSION: A low diversity, dysbiotic microenvironment dominated by Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae characterised the bacterial microbiome of AFRS, with a mycobiome abundant in Malassezia, Aspergillus and Curvularia. While Staphylococcus aureus has been previously implicated in AFRS through enterotoxin superantigen potential, Streptococcus pneumoniae and Haemophilus influenzae are novel findings that may represent alternate cross-kingdom pathophysiological mechanisms.</style></abstract><notes><style face="normal" font="default" size="100%">Connell, J T&#xD;Bouras, G&#xD;Yeo, K&#xD;Fenix, K&#xD;Cooksley, C&#xD;Bassiouni, A&#xD;Vreugde, S&#xD;Wormald, P J&#xD;Psaltis, A J&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3082-3094. doi: 10.1111/all.16240. Epub 2024 Jul 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39044721</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16240</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3103</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3103</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wanin, S.</style></author><author><style face="normal" font="default" size="100%">Taam, R. A.</style></author><author><style face="normal" font="default" size="100%">Chami, L. G.</style></author><author><style face="normal" font="default" size="100%">Marguet, C.</style></author><author><style face="normal" font="default" size="100%">Just, J.</style></author><author><style face="normal" font="default" size="100%">Da Silva, C.</style></author><author><style face="normal" font="default" size="100%">Msihid, J.</style></author><author><style face="normal" font="default" size="100%">Ledanois, O.</style></author><author><style face="normal" font="default" size="100%">Gall, R.</style></author><author><style face="normal" font="default" size="100%">Sacks, H. J.</style></author><author><style face="normal" font="default" size="100%">Jacob-Nara, J. A.</style></author><author><style face="normal" font="default" size="100%">Daridon, C.</style></author><author><style face="normal" font="default" size="100%">Deschildre, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Allergology, Armand Trousseau University Hospital, Groupe Hospitalier Universitaire, AP-HP Sorbonne University, Paris, France.&#xD;CRESS, Inserm, INRAE, HERA Team, Universite Paris Cite, Paris, France.&#xD;Service de Pneumologie et Allergologie Pediatriques, Hopital Necker-Enfants Malades, APHP, Universite de Paris, Paris, France.&#xD;Service de Pneumo-Allergologie Pediatrique, Hopitaux Pediatriques de Nice CHU-Lenval, Nice, France.&#xD;Department Pediatrics and Adolescent Medicine, Pulmonology, Allergy and CF, UnivRouen Normandie, UMR 1311 Dynamycure, FHU Respire, CHU Rouen, Rouen, France.&#xD;Unite d&apos;Allergologie, Hopital Americain de Paris, Neuilly sur Seine, France.&#xD;Sanofi, Gentilly, France.&#xD;Sanofi, Paris, France.&#xD;Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.&#xD;Sanofi, Bridgewater, New Jersey, USA.&#xD;Service de Pneumologie et Allergologie Pediatriques, Hopital Jeanne de Flandre, Universite de Lille, CHU Lille, Lille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characteristics of Adolescents With Uncontrolled Severe Asthma Starting Dupilumab: The PEDIASTHMA Registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">292-296</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">interleukins</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">quality-of-life</style></keyword><keyword><style face="normal" font="default" size="100%">fees. R.A.T.: ALK, AstraZeneca, GSK, Novartis, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes-speaker/consulting fees. L.G.C.: ALK, AstraZeneca, Novartis, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes-speaker/consulting fees. C.M.: ALK, GSK, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-speaker/consulting fees. J.J.: ALK-Abello, AstraZeneca, GSK, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, Stallergenes, Zambon-speaker/consulting fees. C.D.S., J.M., O.L.,</style></keyword><keyword><style face="normal" font="default" size="100%">J.A.J.-N., C.D.: Sanofi-employees, may hold stock and/or stock options in the</style></keyword><keyword><style face="normal" font="default" size="100%">company. R.G.: Regeneron Pharmaceuticals Inc.-employee and shareholder. H.J.S.:</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals Inc.-employee</style></keyword><keyword><style face="normal" font="default" size="100%">Optinose-shareholder. A.D.: Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, ALK, AstraZeneca, Celltrion, DBV Technologies, GSK, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals Inc., Sanofi, Stallergenes Greer,</style></keyword><keyword><style face="normal" font="default" size="100%">Viatris-speaker/consulting fees.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41163372</style></accession-num><notes><style face="normal" font="default" size="100%">Wanin, Stephanie&#xD;Taam, Rola Abou&#xD;Chami, Lisa Giovannini&#xD;Marguet, Christophe&#xD;Just, Jocelyne&#xD;Da Silva, Christele&#xD;Msihid, Jerome&#xD;Ledanois, Olivier&#xD;Gall, Rebecca&#xD;Sacks, Harry J&#xD;Jacob-Nara, Juby A&#xD;Daridon, Capucine&#xD;Deschildre, Antoine&#xD;eng&#xD;Sanofi/&#xD;Regeneron Pharmaceuticals Inc./&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):292-296. doi: 10.1111/all.70119. Epub 2025 Oct 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41163372</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773651</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70119</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1203</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1203</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Kim, B. K.</style></author><author><style face="normal" font="default" size="100%">Lee, Y.</style></author><author><style face="normal" font="default" size="100%">Lee, H. Y.</style></author><author><style face="normal" font="default" size="100%">Ban, G. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, M. H.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Kwon, J. W.</style></author><author><style face="normal" font="default" size="100%">Park, S. Y.</style></author><author><style face="normal" font="default" size="100%">Jung, J. W.</style></author><author><style face="normal" font="default" size="100%">Park, S. Y.</style></author><author><style face="normal" font="default" size="100%">Park, C. S.</style></author><author><style face="normal" font="default" size="100%">Rhee, C. K.</style></author><author><style face="normal" font="default" size="100%">Lee, T.</style></author><author><style face="normal" font="default" size="100%">Lee, J. H.</style></author><author><style face="normal" font="default" size="100%">Kim, S. R.</style></author><author><style face="normal" font="default" size="100%">Park, J. S.</style></author><author><style face="normal" font="default" size="100%">Park, H. W.</style></author><author><style face="normal" font="default" size="100%">Yoo, K. H.</style></author><author><style face="normal" font="default" size="100%">Oh, Y. M.</style></author><author><style face="normal" font="default" size="100%">Koh, Y. I.</style></author><author><style face="normal" font="default" size="100%">Lee, B. J.</style></author><author><style face="normal" font="default" size="100%">Jang, A. S.</style></author><author><style face="normal" font="default" size="100%">Cho, S. H.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author><author><style face="normal" font="default" size="100%">Park, C. S.</style></author><author><style face="normal" font="default" size="100%">Cho, Y. S.</style></author><author><style face="normal" font="default" size="100%">Yoon, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, Korea University Medical Center Anam Hospital, Seoul, Korea.&#xD;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.&#xD;Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St Mary&apos;s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.&#xD;Department of Pulmonary, Allergy and Critical Care Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.&#xD;Department of Internal Medicine, Hallym University College of Medicine, Anyang, Korea.&#xD;Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.&#xD;Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, Eulji University School of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, Inje University, Haeundae Paik Hospital, Busan, Korea.&#xD;Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.&#xD;Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.&#xD;Division of Respiratory Medicine and Allergy, Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea.&#xD;Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.&#xD;Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.&#xD;Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characteristics of Specialist-Diagnosed Asthma-COPD Overlap in Severe Asthma: Observations from the Korean Severe Asthma Registry (KoSAR)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">223-232</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">Republic of Korea/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Specialization</style></keyword><keyword><style face="normal" font="default" size="100%">asthma-COPD overlap</style></keyword><keyword><style face="normal" font="default" size="100%">registry</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33411398</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: While the clinical characteristics and outcomes of asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) have been frequently compared with those of COPD or asthma, the prevalence and features of ACO in patients with severe asthma are unclear. OBJECTIVES: Evaluation of the prevalence and clinical features of ACO using the Korean severe asthma registry. METHODS: At the time of registration, ACO was determined in patients with severe asthma by attending specialists. Patients were classified into ACO and non-ACO groups, and the demographic and clinical characteristics of these two groups were compared. RESULTS: Of 482 patients with severe asthma, 23.7% had ACO. Patients in the ACO group were more likely to be male (P &lt; .001), older (P &lt; .001), and ex- or current smokers (P &lt; .001) compared with those in the non-ACO group. Patients in the ACO group had lower mean forced expiratory volume in 1 second (P &lt; .001) and blood eosinophil percentage (P = .006), but higher blood neutrophil percentage (P = .027) than those in the non-ACO group. The ACO group used more inhaled long-acting muscarinic antagonist (P &lt; .001), methylxanthine (P = .001), or sustained systemic corticosteroid (P = .002). In addition, unscheduled emergency department visits due to exacerbation were more frequent in the ACO group (P = .006). CONCLUSION: Among patients with severe asthma, those with ACO were older, predominantly male, and were more likely to have a smoking history than those with asthma only. Patients with ACO used more systemic corticosteroid and had more frequent exacerbations related to emergency department visits than those with severe asthma only.</style></abstract><notes><style face="normal" font="default" size="100%">Lee, Hyun&#xD;Kim, Sang-Heon&#xD;Kim, Byung-Keun&#xD;Lee, Youngsoo&#xD;Lee, Hwa Young&#xD;Ban, Ga-Young&#xD;Kim, Min-Hye&#xD;Kim, Joo-Hee&#xD;Kwon, Jae-Woo&#xD;Park, So-Young&#xD;Jung, Jae-Woo&#xD;Park, So Young&#xD;Park, Chan Sun&#xD;Rhee, Chin Kook&#xD;Lee, Taehoon&#xD;Lee, Jae-Hyun&#xD;Kim, So Ri&#xD;Park, Jong-Sook&#xD;Park, Heung-Woo&#xD;Yoo, Kwang Ha&#xD;Oh, Yeon-Mok&#xD;Koh, Young-Il&#xD;Lee, Byung-Jae&#xD;Jang, An-Soo&#xD;Cho, Sang-Heon&#xD;Park, Hae-Sim&#xD;Park, Choon-Sik&#xD;Cho, You Sook&#xD;Yoon, Ho Joo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):223-232. doi: 10.1111/all.14483. Epub 2020 Jul 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33411398</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14483</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1040</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1040</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Orimo, K.</style></author><author><style face="normal" font="default" size="100%">Tamari, M.</style></author><author><style face="normal" font="default" size="100%">Saito, H.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, K.</style></author><author><style face="normal" font="default" size="100%">Nakae, S.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Graduate School of Integrated Sciences for Life, Hiroshima University, Hiroshima, Japan.&#xD;Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Saitama, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characteristics of tissue-resident ILCs and their potential as therapeutic targets in mucosal and skin inflammatory diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3332-3348</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/04/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adaptive Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">heterogeneity</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cells</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">therapeutic target</style></keyword><keyword><style face="normal" font="default" size="100%">tissue-resident</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33866593</style></accession-num><abstract><style face="normal" font="default" size="100%">Discovery of innate lymphoid cells (ILCs), which are non-T and non-B lymphocytes that have no antigen-specific receptors, changed the classical concept of the mechanism of allergy, which had been explained mainly as antigen-specific acquired immunity based on IgE and Th2 cells. The discovery led to dramatic improvement in our understanding of the mechanism of non-IgE-mediated allergic inflammation. Numerous studies conducted in the past decade have elucidated the characteristics of each ILC subset in various organs and tissues and their ontogeny. We now know that each ILC subset exhibits heterogeneity. Moreover, the functions and activating/suppressing factors of each ILC subset were found to differ among both organs and types of tissue. Therefore, in this review, we summarize our current knowledge of ILCs by focusing on the organ/tissue-specific features of each subset to understand their roles in various organs. We also discuss ILCs&apos; involvement in human inflammatory diseases in various organs and potential therapeutic/preventive strategies that target ILCs.</style></abstract><notes><style face="normal" font="default" size="100%">Orimo, Keisuke&#xD;Tamari, Masato&#xD;Saito, Hirohisa&#xD;Matsumoto, Kenji&#xD;Nakae, Susumu&#xD;Morita, Hideaki&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3332-3348. doi: 10.1111/all.14863. Epub 2021 May 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33866593</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14863</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1311</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1311</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Jung, C. G.</style></author><author><style face="normal" font="default" size="100%">Lee, J. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, G.</style></author><author><style face="normal" font="default" size="100%">Choi, S. W.</style></author><author><style face="normal" font="default" size="100%">Jin, H. J.</style></author><author><style face="normal" font="default" size="100%">Park, H. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.&#xD;Division of Allergy and Clinical Immunology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.&#xD;Division of Infectious Disease, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.&#xD;Division of Allergy and Rheumatology, Department of Internal Medicine, Fatima Hospital, Daegu, Korea.&#xD;Office of Hospital Information, Seoul National University Hospital, Seoul, Korea.&#xD;Department of internal medicine, Medical school of Yeungnam University, Daegu, Korea.&#xD;Division of Allergy and Clinical Immunology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characterization of asthma and risk factors for delayed SARS-CoV-2 clearance in adult COVID-19 inpatients in Daegu</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">918-921</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/10/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/*complications</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/mortality/*virology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Virus Shedding</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">negative conversion</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33012003</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Sujeong&#xD;Jung, Chang-Gyu&#xD;Lee, Ji Yeon&#xD;Kim, Gunwoo&#xD;Choi, Sae Won&#xD;Jin, Hyun Jung&#xD;Park, Han-Ki&#xD;eng&#xD;COVID19_DM05/the Research Program of Medicity Daegu Council funded by Daegu Metropolitan City/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):918-921. doi: 10.1111/all.14609. Epub 2020 Oct 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33012003</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7675236</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14609</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1290</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1290</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liang, Q.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, S.</style></author><author><style face="normal" font="default" size="100%">Liao, Y.</style></author><author><style face="normal" font="default" size="100%">Guo, S.</style></author><author><style face="normal" font="default" size="100%">Liang, J.</style></author><author><style face="normal" font="default" size="100%">Deng, X.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Zou, B.</style></author><author><style face="normal" font="default" size="100%">Wen, X.</style></author><author><style face="normal" font="default" size="100%">Liang, L.</style></author><author><style face="normal" font="default" size="100%">Wei, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characterization of conjunctival microbiome dysbiosis associated with allergic conjunctivitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">596-600</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Conjunctiva</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">allergic conjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">ocular surface</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33080059</style></accession-num><notes><style face="normal" font="default" size="100%">Liang, Qiaoxing&#xD;Li, Jing&#xD;Zhang, Shiyao&#xD;Liao, Yinglin&#xD;Guo, Shixin&#xD;Liang, Juanran&#xD;Deng, Xiuli&#xD;Liu, Yu&#xD;Zou, Bin&#xD;Wen, Xiaofeng&#xD;Liang, Lingyi&#xD;Wei, Lai&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):596-600. doi: 10.1111/all.14635. Epub 2020 Nov 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33080059</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14635</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>626</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">626</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Greuter, T.</style></author><author><style face="normal" font="default" size="100%">Straumann, A.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Marrero, Y.</style></author><author><style face="normal" font="default" size="100%">Germic, N.</style></author><author><style face="normal" font="default" size="100%">Hosseini, A.</style></author><author><style face="normal" font="default" size="100%">Yousefi, S.</style></author><author><style face="normal" font="default" size="100%">Simon, D.</style></author><author><style face="normal" font="default" size="100%">Collins, M. H.</style></author><author><style face="normal" font="default" size="100%">Bussmann, C.</style></author><author><style face="normal" font="default" size="100%">Chehade, M.</style></author><author><style face="normal" font="default" size="100%">Dellon, E. S.</style></author><author><style face="normal" font="default" size="100%">Furuta, G. T.</style></author><author><style face="normal" font="default" size="100%">Gonsalves, N.</style></author><author><style face="normal" font="default" size="100%">Hirano, I.</style></author><author><style face="normal" font="default" size="100%">Moawad, F. J.</style></author><author><style face="normal" font="default" size="100%">Biedermann, L.</style></author><author><style face="normal" font="default" size="100%">Safroneeva, E.</style></author><author><style face="normal" font="default" size="100%">Schoepfer, A. M.</style></author><author><style face="normal" font="default" size="100%">Simon, H. U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Division of Gastroenterology and Hepatology, University Hospital Lausanne - Centre Hopitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.&#xD;Institute of Pharmacology, University of Bern, Bern, Switzerland.&#xD;Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Division of Pathology, Cincinnati Children;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Pathology Viollier AG, Basel, Switzerland.&#xD;Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Division of Gastroenterology and Hepatology, UNC Hospital, Chapel Hill, North Carolina, USA.&#xD;Department of Pediatrics, Gastrointestinal Eosinophilic Diseases Program, Digestive Health Institute, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Division of Gastroenterology and Hepatology, Northwestern University, Chicago, Illinois, USA.&#xD;Division of Gastroenterology, Scripps Clinic, La Jolla, California, USA.&#xD;Insitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.&#xD;Institute of Biochemistry, Brandenburg Medical School, Neuruppin, Germany.&#xD;Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia.&#xD;Laboratory of Molecular Immunology, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A cross-sectional multi-center study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2520-2533</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/01/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Enteritis</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gastritis</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastroesophageal Reflux/diagnosis/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">dysphagia</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">esophageal eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocytic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">next generation rna sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">travel grants from Falk Pharma GmbH and Vifor, and an unrestricted research grant</style></keyword><keyword><style face="normal" font="default" size="100%">from Novartis. AS has consulting contracts with Actelion, Celgene-Receptos, Falk</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma GmbH, Roche-Genentech, GSK, Novartis, Nutricia, and Sanofi-Regeneron. ES</style></keyword><keyword><style face="normal" font="default" size="100%">is a consultant for Celgene Corp., Regeneron Pharmaceuticals Inc., and Novartis.</style></keyword><keyword><style face="normal" font="default" size="100%">AMS is a consultant for Falk Pharma GmbH, Adare Pharmaceuticals Inc,</style></keyword><keyword><style face="normal" font="default" size="100%">Celgene-Receptos, and Sanofi-Regeneron. MHC is a consultant for Astra Zeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Allakos, Arena, Celgene, Esocap, GlaxoSmithKline, Regeneron and Shire, and has</style></keyword><keyword><style face="normal" font="default" size="100%">received research funds from Regeneron and Shire. LB has received consulting fees</style></keyword><keyword><style face="normal" font="default" size="100%">and/or speaker fees from Falk Pharma GmbH, Esocap AG, Sanofi-Aventis AG, and</style></keyword><keyword><style face="normal" font="default" size="100%">Calypso Biotech SA. GTF is a consultant for Takeda and Arena and has received</style></keyword><keyword><style face="normal" font="default" size="100%">research support from Holoclara. MC received research support from hire,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron and Allakos, consulting fees from Shire, Regeneron, Allakos, Adare and</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia, and lecture honoraria from Nutricia, Medscape, and the Annenberg Center</style></keyword><keyword><style face="normal" font="default" size="100%">for Health Sciences at Eisenhower. IH has received consulting fees from Receptos,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Shire, and Roche. ESD has received research funding from Adare,</style></keyword><keyword><style face="normal" font="default" size="100%">Allakos, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos, Regeneron, Shire</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Adare, Aimmune, Alivio, Allakos, AstraZeneca, Banner,</style></keyword><keyword><style face="normal" font="default" size="100%">Biorasi, Calypso, Celgene/Receptos, Enumeral, EsoCap, Gossamer Bio, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Robarts, Salix, Shire</style></keyword><keyword><style face="normal" font="default" size="100%">and educational grants from Allakos, Banner,</style></keyword><keyword><style face="normal" font="default" size="100%">Holoclara. HUS is a consultant for AstraZeneca, GlaxoSmithKline, and Esocap. The</style></keyword><keyword><style face="normal" font="default" size="100%">other authors have no competing interests to declare. No company representative</style></keyword><keyword><style face="normal" font="default" size="100%">was involved in conception, writing, or financing of this study.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35094416</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Physicians are increasingly confronted with patients presenting with symptoms of esophageal dysfunction resembling eosinophilic esophagitis (EoE), but absence of significant esophageal eosinophilia. The purpose of this study was to characterize and classify this group of EoE variants. DESIGN: Patients from six EoE-centers with symptoms of esophageal dysfunction, but peak eosinophil counts of &lt;60/mm(2) (&lt;15/hpf) in esophageal biopsies and absence of gastro-esophageal reflux disease (GERD) were included. Clinical, endoscopic, (immuno)-histological, and molecular features were determined and compared with EoE, GERD, and healthy controls. RESULTS: We included 69 patients with EoE variants. Endoscopic abnormalities were found in 53.6%. We identified three histological subtypes: EoE-like esophagitis (36/69, 52.2%), lymphocytic esophagitis (14/69, 20.3%), and non-specific esophagitis (19/69, 27.5%). Immunohistochemistry revealed-in contrast to EoE-no significant increase in inflammatory cell infiltrates compared with GERD and healthy controls, except for lymphocytes in lymphocytic esophagitis. EoE-typical Th2-response was absent in all EoE variants. However, considerable structural changes were detected based on histology and protein expression. Using next generation mRNA sequencing, we found the three EoE variants to have distinct molecular fingerprints partially sharing pronounced traits of EoE. Hierarchical sample clustering of RNA sequencing data confirmed the presence of an EoE-like (characterized by eotaxin-3 expression), non-specific, and lymphocytic variant cluster (characterized by CD3 cells and TSLP expression). CONCLUSION: All EoE variants are clinically and histologically active conditions despite the absence of esophageal eosinophilia. EoE variants appear to be part of a disease spectrum, where classical EoE represents the most common and apparent phenotype.</style></abstract><notes><style face="normal" font="default" size="100%">Greuter, Thomas&#xD;Straumann, Alex&#xD;Fernandez-Marrero, Yuniel&#xD;Germic, Nina&#xD;Hosseini, Aref&#xD;Yousefi, Shida&#xD;Simon, Dagmar&#xD;Collins, Margaret H&#xD;Bussmann, Christian&#xD;Chehade, Mirna&#xD;Dellon, Evan S&#xD;Furuta, Glenn T&#xD;Gonsalves, Nirmala&#xD;Hirano, Ikuo&#xD;Moawad, Fouad J&#xD;Biedermann, Luc&#xD;Safroneeva, Ekaterina&#xD;Schoepfer, Alain M&#xD;Simon, Hans-Uwe&#xD;eng&#xD;U54 AI117804/AI/NIAID NIH HHS/&#xD;U54AI117804/National Institutes of Health (NIH): Consortium of Eosinophilic Gastrointestinal Diseases Researchers CEGIR/&#xD;Multicenter Study&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2520-2533. doi: 10.1111/all.15233. Epub 2022 Feb 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35094416</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9545458</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15233</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3184</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peng, Y. Q.</style></author><author><style face="normal" font="default" size="100%">Zhang, T.</style></author><author><style face="normal" font="default" size="100%">Liu, X. Q.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Sun, Q.</style></author><author><style face="normal" font="default" size="100%">Ruckert, B.</style></author><author><style face="normal" font="default" size="100%">He, B. X.</style></author><author><style face="normal" font="default" size="100%">Chen, D. H.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author><author><style face="normal" font="default" size="100%">Ye, H. J.</style></author><author><style face="normal" font="default" size="100%">Fu, Q. L.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Otorhinolaryngology, Department of Allergy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People&apos;s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.&#xD;Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characterization of Human Group 9 Innate Lymphoid Cells in Response to Allergen Immunotherapy in Patients With Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Il-9</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cells</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">transforming growth factor beta</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41451507</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Innate lymphoid cells (ILCs) are classically divided into three groups: ILC1, ILC2, and ILC3 to reflect their functional analogy to Th1, Th2, and Th17. There is also an IL-9 single-producing T cell subset, namely the Th9 cell, which plays a dominant role in the onset of allergic diseases compared with traditional Th2 cells. Although a corresponding cell subset of ILCs to different Th cell subsets exists, so far the counterpart of Th9 cells in ILCs has not been reported. OBJECTIVE: In this study, we aimed to report the existence of group 9 innate lymphoid cells (ILC9s) and characterize them in allergic rhinitis (AR) and in response to allergen immunotherapy. METHODS: The expressions and characterization of ILC9s were investigated in purified ILCs cultures, PBMCs from patients with AR and responder subcutaneous immunotherapy (SCIT) patients by flow cytometry, scRNA-seq transcriptome, qRT-PCR, siRNA knockdown, and immunofluorescence staining. RESULTS: IL-9-expressing cells were observed in the nasal mucosa of patients with AR without the co-expression of IL-5 and IL-13. IL-4 and TGF-beta induce IL-9 secretion by human ILCs. scRNA-seq of whole ILCs defines an H1R(+)OX-40L(-)ILC subset as ILC9 expressing high levels of IL-9 and low levels of the ILC2 transcription factor GATA3. Instead, this new ILC9 subset displays Bach2 as a transcription factor, and IL-9 expression decreases after siRNA inhibition of Bach2. Histamine is an important regulator of ILC9 because ILC9 production increases in response to histamine, and IL-9 levels in ILCs positively correlate with the expression of histamine 1R. An up-regulation of PPARgamma was observed in ILCs in response to IL-4 and TGF-beta, and ILC9 differentiation was suppressed by the PPARgamma antagonist. CONCLUSION: ILC9s are highly expressed in the nasal mucosa and PBMCs of patients with AR and were decreased in response to house dust mite-SCIT. Our study sheds light on the newly discovered ILC9 subset and demonstrates a potential target in allergen immunotherapy.</style></abstract><notes><style face="normal" font="default" size="100%">Peng, Ya-Qi&#xD;Zhang, Te&#xD;Liu, Xiao-Qing&#xD;Ogulur, Ismail&#xD;Sun, Qi&#xD;Ruckert, Beate&#xD;He, Bi-Xin&#xD;Chen, De-Hua&#xD;Morita, Hideaki&#xD;Ye, Hui-Jing&#xD;Fu, Qing-Ling&#xD;Akdis, Cezmi A&#xD;eng&#xD;National Natural Science Foundation of China/&#xD;Guangdong Provincial People&apos;s Hospital/&#xD;Sun Yat-sen University/&#xD;Denmark&#xD;Allergy. 2025 Dec 26. doi: 10.1111/all.70202.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41451507</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70202</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3243</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3243</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peng, Y. Q.</style></author><author><style face="normal" font="default" size="100%">Zhang, T.</style></author><author><style face="normal" font="default" size="100%">Liu, X. Q.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Sun, Q.</style></author><author><style face="normal" font="default" size="100%">Ruckert, B.</style></author><author><style face="normal" font="default" size="100%">He, B. X.</style></author><author><style face="normal" font="default" size="100%">Chen, D. H.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author><author><style face="normal" font="default" size="100%">Ye, H. J.</style></author><author><style face="normal" font="default" size="100%">Fu, Q. L.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Otorhinolaryngology, Department of Allergy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People&apos;s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.&#xD;Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characterization of Human Group 9 Innate Lymphoid Cells in Response to Allergen Immunotherapy in Patients With Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Il-9</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cells</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">transforming growth factor beta</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41451507</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Innate lymphoid cells (ILCs) are classically divided into three groups: ILC1, ILC2, and ILC3 to reflect their functional analogy to Th1, Th2, and Th17. There is also an IL-9 single-producing T cell subset, namely the Th9 cell, which plays a dominant role in the onset of allergic diseases compared with traditional Th2 cells. Although a corresponding cell subset of ILCs to different Th cell subsets exists, so far the counterpart of Th9 cells in ILCs has not been reported. OBJECTIVE: In this study, we aimed to report the existence of group 9 innate lymphoid cells (ILC9s) and characterize them in allergic rhinitis (AR) and in response to allergen immunotherapy. METHODS: The expressions and characterization of ILC9s were investigated in purified ILCs cultures, PBMCs from patients with AR and responder subcutaneous immunotherapy (SCIT) patients by flow cytometry, scRNA-seq transcriptome, qRT-PCR, siRNA knockdown, and immunofluorescence staining. RESULTS: IL-9-expressing cells were observed in the nasal mucosa of patients with AR without the co-expression of IL-5 and IL-13. IL-4 and TGF-beta induce IL-9 secretion by human ILCs. scRNA-seq of whole ILCs defines an H1R(+)OX-40L(-)ILC subset as ILC9 expressing high levels of IL-9 and low levels of the ILC2 transcription factor GATA3. Instead, this new ILC9 subset displays Bach2 as a transcription factor, and IL-9 expression decreases after siRNA inhibition of Bach2. Histamine is an important regulator of ILC9 because ILC9 production increases in response to histamine, and IL-9 levels in ILCs positively correlate with the expression of histamine 1R. An up-regulation of PPARgamma was observed in ILCs in response to IL-4 and TGF-beta, and ILC9 differentiation was suppressed by the PPARgamma antagonist. CONCLUSION: ILC9s are highly expressed in the nasal mucosa and PBMCs of patients with AR and were decreased in response to house dust mite-SCIT. Our study sheds light on the newly discovered ILC9 subset and demonstrates a potential target in allergen immunotherapy.</style></abstract><notes><style face="normal" font="default" size="100%">Peng, Ya-Qi&#xD;Zhang, Te&#xD;Liu, Xiao-Qing&#xD;Ogulur, Ismail&#xD;Sun, Qi&#xD;Ruckert, Beate&#xD;He, Bi-Xin&#xD;Chen, De-Hua&#xD;Morita, Hideaki&#xD;Ye, Hui-Jing&#xD;Fu, Qing-Ling&#xD;Akdis, Cezmi A&#xD;eng&#xD;National Natural Science Foundation of China/&#xD;Guangdong Provincial People&apos;s Hospital/&#xD;Sun Yat-sen University/&#xD;Denmark&#xD;Allergy. 2025 Dec 26. doi: 10.1111/all.70202.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41451507</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70202</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2554</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2554</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pierrard, G.</style></author><author><style face="normal" font="default" size="100%">Bernier, C.</style></author><author><style face="normal" font="default" size="100%">Du-Thanh, A.</style></author><author><style face="normal" font="default" size="100%">Bara, C.</style></author><author><style face="normal" font="default" size="100%">Soria, A.</style></author><author><style face="normal" font="default" size="100%">Castelain, F.</style></author><author><style face="normal" font="default" size="100%">Boccon-Gibod, I.</style></author><author><style face="normal" font="default" size="100%">Hacard, F.</style></author><author><style face="normal" font="default" size="100%">Delaunay, J.</style></author><author><style face="normal" font="default" size="100%">de Montjoye, L.</style></author><author><style face="normal" font="default" size="100%">Staumont-Salle, D.</style></author><author><style face="normal" font="default" size="100%">Dezoteux, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CHU Lille, University Lille, Service de Dermatologie, Lille, France.&#xD;French Chronic Urticaria Study Group (GUS), Paris, France.&#xD;CHU Nantes, Service de Dermatologie, Nantes, France.&#xD;CHU Montpellier, Service de Dermatologie, Montpellier, France.&#xD;CHU Le Mans, Service de Dermatologie, Le Mans, France.&#xD;Sorbonne Universite, Service de Dermatologie et d&apos;Allergologie, Hopital Tenon, Paris, France.&#xD;CHU Besancon, Service de Dermatologie, Besancon, France.&#xD;CHU Grenoble, Service de Medecine Interne et Immunologie Clinique, Centre de Reference des Angioedemes, Grenoble, France.&#xD;CHU Lyon, Service Allergologie et Immunologie Clinique, Lyon, France.&#xD;CHU Angers, Service de Dermatologie Angers, Angers, France.&#xD;Department of Dermatology, Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium.&#xD;U1286 Inserm INFINITE Institute for Translational Research in Inflammation, Lille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2448-2457</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/07/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">updosing</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39056480</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Limited information is available on the use of omalizumab (OMA) updosing since its introduction as a second-line therapy in chronic spontaneous urticaria (CSU) in 2014. Practical guidelines from health authorities are lacking, and the specific characteristics of patients requiring higher doses remain unknown. Our objectives were to characterize the patterns of OMA updosing (defined as changes in dose and/or injection intervals), to identify the predictive factors associated with updosing, and to improve CSU management. METHODS: We conducted a prospective, multicentric, real-life observational study, including patients diagnosed with CSU and starting OMA. The data were collected at 0, 3, 6, and 9 months. The primary endpoint was the frequency of OMA updosing at 3 months. The secondary endpoints included an analysis of updosed patients&apos; profile, and an assessment of OMA efficacy and safety. RESULTS: We included 153 patients. Twenty percent of patients were updosed at 3 months, and 27% in total during the 9-month follow-up. Practitioners mainly chose to increase the frequency of injections (66%). At baseline, the updosed patients were more likely to have more severe CSU (UCT &lt; 4, p &lt; 0.030), a lower lymphocyte count (&lt;2000/mm(3), p = 0.037), and low IgE levels (&lt;70 UI/mL, p = 0.024). The side effects of OMA were not more frequent after updosing. CONCLUSION: One in five patient underwent updosing within just 3 months. OMA updosing is frequent in particular in cases of severe disease and low IgE blood levels.</style></abstract><notes><style face="normal" font="default" size="100%">Pierrard, Guillaume&#xD;Bernier, Claire&#xD;Du-Thanh, Aurelie&#xD;Bara, Corina&#xD;Soria, Angele&#xD;Castelain, Florence&#xD;Boccon-Gibod, Isabelle&#xD;Hacard, Florence&#xD;Delaunay, Juliette&#xD;de Montjoye, Laurence&#xD;Staumont-Salle, Delphine&#xD;Dezoteux, Frederic&#xD;eng&#xD;Multicenter Study&#xD;Observational Study&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2448-2457. doi: 10.1111/all.16256. Epub 2024 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39056480</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16256</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1034</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1034</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jeong, K. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author><author><style face="normal" font="default" size="100%">Yuk, J. E.</style></author><author><style face="normal" font="default" size="100%">Park, J. H.</style></author><author><style face="normal" font="default" size="100%">Ferreira, F.</style></author><author><style face="normal" font="default" size="100%">Sang, M. K.</style></author><author><style face="normal" font="default" size="100%">Lee, Y. S.</style></author><author><style face="normal" font="default" size="100%">Vogel, L.</style></author><author><style face="normal" font="default" size="100%">Park, K. H.</style></author><author><style face="normal" font="default" size="100%">Park, J. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea.&#xD;Department of Medicine, Yonsei University College of Medicine, Seoul, Korea.&#xD;Department of Bioscience, University of Salzburg, Salzburg, Austria.&#xD;Department of Biology, College of Natural Sciences, Soonchunhyang University, Asan, Korea.&#xD;Paul Ehrlich Institut, Federal Agency of Sera and Vaccines, Langen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characterization of the major allergen, Que ac 1, from sawtooth oak pollen</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2626-2629</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/04/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Quercus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33896022</style></accession-num><notes><style face="normal" font="default" size="100%">Jeong, Kyoung Yong&#xD;Lee, Jongsun&#xD;Yuk, Ji Eun&#xD;Park, Jong Han&#xD;Ferreira, Fatima&#xD;Sang, Min Kyu&#xD;Lee, Yong Seok&#xD;Vogel, Lothar&#xD;Park, Kyung Hee&#xD;Park, Jung-Won&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2626-2629. doi: 10.1111/all.14875. Epub 2021 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33896022</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14875</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>511</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">511</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arroyo-Hornero, R.</style></author><author><style face="normal" font="default" size="100%">Aegerter, H.</style></author><author><style face="normal" font="default" size="100%">Hamad, I.</style></author><author><style face="normal" font="default" size="100%">Corte-Real, B.</style></author><author><style face="normal" font="default" size="100%">Staes, K.</style></author><author><style face="normal" font="default" size="100%">van der Woning, B.</style></author><author><style face="normal" font="default" size="100%">Verstraete, K.</style></author><author><style face="normal" font="default" size="100%">Savvides, S. N.</style></author><author><style face="normal" font="default" size="100%">Lambrecht, B. N.</style></author><author><style face="normal" font="default" size="100%">Kleinewietfeld, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">VIB Laboratory of Translational Immunomodulation, VIB Center for Inflammation Research (IRC), Hasselt University, Diepenbeek, Belgium.&#xD;Department of Immunology, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium.&#xD;Immunoregulation Unit, VIB Center for Inflammation Research, Ghent, Belgium.&#xD;Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.&#xD;Transgenic Core Facility, VIB Center for Inflammation Research, Ghent, Belgium.&#xD;Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.&#xD;argenx BV, Zwijnaarde, Belgium.&#xD;Unit for Structural Biology, VIB Center for Inflammation Research, Ghent, Belgium.&#xD;Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.&#xD;Department of Pulmonary Medicine, ErasmusMC, Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Charcot-Leyden crystal protein galectin-10 is not a major determinant of human regulatory T-cell function</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2818-2821</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/05/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Eosinophils/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Galectins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Glycoproteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Lysophospholipase/chemistry/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35491437</style></accession-num><notes><style face="normal" font="default" size="100%">Arroyo-Hornero, Rebeca&#xD;Aegerter, Helena&#xD;Hamad, Ibrahim&#xD;Corte-Real, Beatriz&#xD;Staes, Katrien&#xD;van der Woning, Bas&#xD;Verstraete, Kenneth&#xD;Savvides, Savvas N&#xD;Lambrecht, Bart N&#xD;Kleinewietfeld, Markus&#xD;eng&#xD;ERC_/European Research Council/International&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2818-2821. doi: 10.1111/all.15332. Epub 2022 May 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35491437</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15332</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1215</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1215</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huber, S.</style></author><author><style face="normal" font="default" size="100%">van der Kleij, H.</style></author><author><style face="normal" font="default" size="100%">Wildner, S.</style></author><author><style face="normal" font="default" size="100%">Wolf, M.</style></author><author><style face="normal" font="default" size="100%">Wallner, M.</style></author><author><style face="normal" font="default" size="100%">Hofer, H.</style></author><author><style face="normal" font="default" size="100%">Asam, C.</style></author><author><style face="normal" font="default" size="100%">Briza, P.</style></author><author><style face="normal" font="default" size="100%">Ferreira, F.</style></author><author><style face="normal" font="default" size="100%">Hauser, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biosciences, University of Salzburg, Salzburg, Austria.&#xD;HAL Allergy B.V., Leiden, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chemical modification of ragweed extract results in an increased safety profile while maintaining immunogenicity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2226-2229</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/12/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Allergoids</style></keyword><keyword><style face="normal" font="default" size="100%">*Ambrosia</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergoid</style></keyword><keyword><style face="normal" font="default" size="100%">immunogenicity</style></keyword><keyword><style face="normal" font="default" size="100%">pollen extract</style></keyword><keyword><style face="normal" font="default" size="100%">ragweed immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">member of Scientific Advisory Boards (HAL Allergy, NL</style></keyword><keyword><style face="normal" font="default" size="100%">SIAF, Davos, CH</style></keyword><keyword><style face="normal" font="default" size="100%">AllergenOnline, USA) and has been supported by the Austrian Science Funds (FWF).</style></keyword><keyword><style face="normal" font="default" size="100%">Martin Wolf, Michael Hauser, Sara Huber, Sabrina Wildner, Claudia Asam, Heidi</style></keyword><keyword><style face="normal" font="default" size="100%">Hofer, Peter Briza, and Michael Wallner have no conflict of interest to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33368383</style></accession-num><notes><style face="normal" font="default" size="100%">Huber, Sara&#xD;van der Kleij, Hanneke&#xD;Wildner, Sabrina&#xD;Wolf, Martin&#xD;Wallner, Michael&#xD;Hofer, Heidi&#xD;Asam, Claudia&#xD;Briza, Peter&#xD;Ferreira, Fatima&#xD;Hauser, Michael&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2226-2229. doi: 10.1111/all.14721. Epub 2021 Jan 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33368383</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8359213</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14721</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2436</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2436</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guiddir, T.</style></author><author><style face="normal" font="default" size="100%">Senechal, H.</style></author><author><style face="normal" font="default" size="100%">Selva, M. A.</style></author><author><style face="normal" font="default" size="100%">Couderc, R.</style></author><author><style face="normal" font="default" size="100%">Swoboda, I.</style></author><author><style face="normal" font="default" size="100%">Hilger, C.</style></author><author><style face="normal" font="default" size="100%">Kuehn, A.</style></author><author><style face="normal" font="default" size="100%">Chantran, Y.</style></author><author><style face="normal" font="default" size="100%">Yen-Nicolay, S.</style></author><author><style face="normal" font="default" size="100%">Vrai, T.</style></author><author><style face="normal" font="default" size="100%">Ruellou, G.</style></author><author><style face="normal" font="default" size="100%">Baudin, B.</style></author><author><style face="normal" font="default" size="100%">Poncet, P.</style></author><author><style face="normal" font="default" size="100%">Nemni, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Paris-Saclay University, AP-HP, Bicetre Hospital, Pediatric Pulmonology and Allergology Unit, Le Kremlin Bicetre, France.&#xD;Sorbonne University, AP-HP, Armand Trousseau Children Hospital, Biochemistry Department, Allergy &amp; Environment Team, Paris, France.&#xD;Sorbonne University, AP-HP, Armand Trousseau Children Hospital, Immunology Department, Allergology Sector, Paris, France.&#xD;The Molecular Biotechnology Section, FH Campus Wien, University of Applied Sciences, Vienna, Austria.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Proteomic Facility-UMS IPSIT, Paris-Saclay University, Orsay, France.&#xD;Immunology Department, Institut Pasteur, Paris, France.&#xD;Children-Adult Allergology Department, Robert Ballanger Hospital, Aulnay-sous-Bois, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chicken meat allergy in children: Complex sensitization profiles with newly described allergen candidates</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2262-2266</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/03/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Chickens</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Meat/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38523510</style></accession-num><notes><style face="normal" font="default" size="100%">Guiddir, T&#xD;Senechal, H&#xD;Selva, M A&#xD;Couderc, R&#xD;Swoboda, I&#xD;Hilger, C&#xD;Kuehn, A&#xD;Chantran, Y&#xD;Yen-Nicolay, S&#xD;Vrai, T&#xD;Ruellou, G&#xD;Baudin, B&#xD;Poncet, P&#xD;Nemni, A&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2262-2266. doi: 10.1111/all.16106. Epub 2024 Mar 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38523510</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16106</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3038</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3038</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Husain, I.</style></author><author><style face="normal" font="default" size="100%">Mukhopadhyay, S.</style></author><author><style face="normal" font="default" size="100%">Eccles, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK.&#xD;Royal Alexandra Children&apos;s Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.&#xD;Department of Clinical Neuroscience, Brighton and Sussex Medical School, Brighton, UK.&#xD;Sussex Partnership NHS Foundation Trust, Worthing, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Childhood Allergy and Neurodivergence: A Cross-Sectional Analysis in a UK-Birth Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3452-3453</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/08/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">paediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">personlized medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40801173</style></accession-num><notes><style face="normal" font="default" size="100%">Husain, Isra&#xD;Mukhopadhyay, Somnath&#xD;Eccles, Jessica&#xD;eng&#xD;WT_/Wellcome Trust/United Kingdom&#xD;MR/K002643/1/MRC_/Medical Research Council/United Kingdom&#xD;217065/Z/19/Z/Wellcome/&#xD;University of Bristol/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3452-3453. doi: 10.1111/all.70000. Epub 2025 Aug 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40801173</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666756</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70000</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2929</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2929</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leskien, M.</style></author><author><style face="normal" font="default" size="100%">Thiering, E.</style></author><author><style face="normal" font="default" size="100%">Yu, Z.</style></author><author><style face="normal" font="default" size="100%">Huels, A.</style></author><author><style face="normal" font="default" size="100%">Yao, Y.</style></author><author><style face="normal" font="default" size="100%">Merid, S. K.</style></author><author><style face="normal" font="default" size="100%">Gruzieva, O.</style></author><author><style face="normal" font="default" size="100%">Weidinger, S.</style></author><author><style face="normal" font="default" size="100%">Waldenberger, M.</style></author><author><style face="normal" font="default" size="100%">Peters, A.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Standl, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Epidemiology, Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Medical Faculty, Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany.&#xD;German Center for Child and Adolescent Health (DZKJ), Munich, Germany.&#xD;Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children&apos;s Hospital, University of Munich Medical Center, Munich, Germany.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.&#xD;Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.&#xD;Department of Clinical Sciences and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Centre for Occupational and Environmental Medicine, Stockholm, Sweden.&#xD;Department of Dermatology, Venereology, and Allergology, University Hospital Schleswig-Holstein, Kiel, Germany.&#xD;Research Unit Molecular Epidemiology, Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Chair of Epidemiology, Ludwig-Maximilians University, Munich, Germany.&#xD;German Center for Lung Research (DZL), Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Childhood Asthma and Allergy Are Related to Accelerated Epigenetic Aging</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1912-1922</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/05/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/genetics/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Aging/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Germany/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetic aging</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetic clock</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40346984</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Few studies showed associations of childhood allergic diseases with epigenetic aging using traditional clocks trained mainly on adults. Tracking DNA methylation variation early in life has suggested poor performance of these clocks in children. Therefore, we aim to elucidate the association between allergic diseases and epigenetic age using a pediatric clock. METHODS: We used data from the German LISA birth cohort study at six (N = 234) and ten (N = 227) years. DNA methylation was measured in blood using the Infinium Methylation EPIC BeadChip. We calculated epigenetic age using the pediatric clock developed by Wu et al. (Aging 2019) (median absolute error = 0.04 years, Spearman correlation with chronological age r = 0.75). Linear mixed models were used to examine longitudinal associations of epigenetic age acceleration with doctor-diagnosed asthma, rhinitis, and eczema, or a combination thereof (&quot;any allergy&quot;) as well as aeroallergen sensitization. Replication was performed in BAMSE at the 8-year follow-up (N = 625) using linear models. Additionally, epigenetic age in adults from KORA F4 was estimated using Horvath&apos;s clocks and associations with allergic diseases were tested applying linear models. RESULTS: Having any allergy was significantly associated with a mean epigenetic age acceleration of 0.34 years (95% CI = [0.06; 0.63]) using Wu&apos;s clock in LISA. Associations with consistent effect directions were found for allergic rhinitis, asthma, and eczema. No associations with aeroallergen sensitization were observed. In BAMSE, an inverse association of epigenetic age acceleration with eczema was found (-0.52 years, 95% CI = [-0.97; -0.07]). In KORA, hay fever was significantly associated with accelerated epigenetic age when using the Horvath pan-tissue clock (1.05 years, 95% CI = [0.21; 1.89]). CONCLUSIONS: We found an increase in epigenetic age in children with allergic diseases from LISA. Our results suggest that epigenetic age acceleration seems to be related to the persistent burden of allergic diseases, but not to non-symptomatic aeroallergen sensitization.</style></abstract><notes><style face="normal" font="default" size="100%">Leskien, Miriam&#xD;Thiering, Elisabeth&#xD;Yu, Zhebin&#xD;Huels, Anke&#xD;Yao, Yueli&#xD;Merid, Simon Kebede&#xD;Gruzieva, Olena&#xD;Weidinger, Stephan&#xD;Waldenberger, Melanie&#xD;Peters, Annette&#xD;Melen, Erik&#xD;Standl, Marie&#xD;eng&#xD;Helmholtz Zentrum Munchen/&#xD;Karolinska Institutet/&#xD;Swedish Research Council for Health, Working Life and Welfare/&#xD;Hjart-Lungfonden/&#xD;Swedish Research Council/&#xD;Bundesministerium fur Bildung und Forschung/&#xD;ERC_/European Research Council/International&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1912-1922. doi: 10.1111/all.16583. Epub 2025 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40346984</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261877</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16583</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1138</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1138</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Mathioudakis, A. G.</style></author><author><style face="normal" font="default" size="100%">Custovic, A.</style></author><author><style face="normal" font="default" size="100%">Deschildre, A.</style></author><author><style face="normal" font="default" size="100%">Phipatanakul, W.</style></author><author><style face="normal" font="default" size="100%">Wong, G.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Abou-Taam, R.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Castro-Rodriguez, J. A.</style></author><author><style face="normal" font="default" size="100%">Chen, Z.</style></author><author><style face="normal" font="default" size="100%">Cros, P.</style></author><author><style face="normal" font="default" size="100%">Dubus, J. C.</style></author><author><style face="normal" font="default" size="100%">El-Sayed, Z. A.</style></author><author><style face="normal" font="default" size="100%">El-Owaidy, R.</style></author><author><style face="normal" font="default" size="100%">Feleszko, W.</style></author><author><style face="normal" font="default" size="100%">Fierro, V.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author><author><style face="normal" font="default" size="100%">Garcia-Marcos, L.</style></author><author><style face="normal" font="default" size="100%">Goh, A.</style></author><author><style face="normal" font="default" size="100%">Hossny, E. M.</style></author><author><style face="normal" font="default" size="100%">Huerta Villalobos, Y. R.</style></author><author><style face="normal" font="default" size="100%">Jartti, T.</style></author><author><style face="normal" font="default" size="100%">Le Roux, P.</style></author><author><style face="normal" font="default" size="100%">Levina, J.</style></author><author><style face="normal" font="default" size="100%">Lopez Garcia, A. I.</style></author><author><style face="normal" font="default" size="100%">Ramos, A. M.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Murray, C.</style></author><author><style face="normal" font="default" size="100%">Nagaraju, K.</style></author><author><style face="normal" font="default" size="100%">Nagaraju, M. K.</style></author><author><style face="normal" font="default" size="100%">Navarrete Rodriguez, E. M.</style></author><author><style face="normal" font="default" size="100%">Namazova-Baranova, L.</style></author><author><style face="normal" font="default" size="100%">Nieto Garcia, A.</style></author><author><style face="normal" font="default" size="100%">Pozo Beltran, C. F.</style></author><author><style face="normal" font="default" size="100%">Ratchataswan, T.</style></author><author><style face="normal" font="default" size="100%">Rivero Yeverino, D.</style></author><author><style face="normal" font="default" size="100%">Rodriguez Zagal, E.</style></author><author><style face="normal" font="default" size="100%">Schweitzer, C. E.</style></author><author><style face="normal" font="default" size="100%">Tulkki, M.</style></author><author><style face="normal" font="default" size="100%">Wasilczuk, K.</style></author><author><style face="normal" font="default" size="100%">Xu, D.</style></author><author><style face="normal" font="default" size="100%">PeArl collaborators, on behalf of the PeARL Think Tank</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.&#xD;Imperial College London, London, UK.&#xD;INSERM Unit 1019, CNRS UMR 8204, Center for infection and immunity of Lille, Institut Pasteur de Lille, Univ. Lille, Lille cedex, France.&#xD;Department of Allergy and Immunology, Boston Children&apos;s Hospital, Boston, MA, USA.&#xD;Department of Pediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.&#xD;Pediatric Pulmonology and Allergy DepartmentHopital Necker-Enfants Malades, Paris, France.&#xD;Allergy &amp; Clinical Immunology, Transylvania University, Brasov, Romania.&#xD;Department of Pediatric Pulmonology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.&#xD;Department of Pulmonology, The Children&apos;s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.&#xD;Department of Pediatrics, University Hospital Morvan, Brest, France.&#xD;Centre de Ressources et de Competences pour la Mucoviscidose Pneumo-Allergologie, Ventilation, Maladies RespiratoiresRares de l&apos;Enfant CHU Timone-Enfants, Marseille, France.&#xD;Pediatric Allergy and Immunology Unit, Children&apos;s Hospital, Ain Shams University, Cairo, Egypt.&#xD;Department of Pediatric Pneumonology and Allergy, The Medical University of Warsaw, Warsaw, Poland.&#xD;Allergy Department, Bambino Gesu Children&apos;s Hospital IRCCS, Roma, Italy.&#xD;Pediatric Respiratory and Allergy Units, &quot;Virgen de la Arrixaca&quot; Children&apos;s University Clinical Hospital, University of Murcia, Murcia, Spain.&#xD;Institute for Biomedical Research of Murcia, IMIB-Arrixaca; &amp; Network of Asthma and Adverse and Allergic Reactions ARADyAL, Murcia, Spain.&#xD;Department of Internal Medicine, Rush Medical College, Chicago.&#xD;Hospital General Regional 1 &quot;Dr. Carlos Mac Gregor Sanchez Navarro&quot; IMSS, Mexico, Mexico.&#xD;Department of Pediatrics and Adolescent Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland.&#xD;Department of Pediatrics, Groupe Hospitalier Le Havre, Le Havre, France.&#xD;Pediatric and Child Health Research Institute of the Central Clinical Hospital of the Russian Academy of Sciences, Moskva, Russia.&#xD;Allergy and Clinical Immunology Service of the University Hospital of Puebla, Puebla, Mexico.&#xD;Pediatric Pulmonology &amp; Allergy Unit Children&apos;s Hospital la Fe, Valencia, Spain.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;VN Allergy &amp; Asthma Research Centre, Chennai, India.&#xD;Department of Allergy &amp; Clinical Immunology, Saveetha Medical College, Chennai, India.&#xD;Pediatric Allergy and Clinical Immunology Service, Hospital Infantil, til de Mexico Federico Gomez, Mexico City, Mexico.&#xD;Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia.&#xD;Teaching and Research Department and Paediatric Allergy Department, Hospital with Specialties Juan Maria de Salvatierra, La Paz, Mexico.&#xD;Allergy &amp; immunology Department Hospital Infantil de Medico Federico Gomez, Mexico City, Mexico.&#xD;Allergy and Clinical Immunology Department, Hospital Universitario de Puebla, Puebla, Mexico.&#xD;CHRU de Nancy, Hopitald&apos;Enfants, Vandoeuvre, France.&#xD;Department of Pediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1765-1775</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/02/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">childhood asthma</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus</style></keyword><keyword><style face="normal" font="default" size="100%">received support from AstraZeneca, Novartis, and Sanofi for continued work on</style></keyword><keyword><style face="normal" font="default" size="100%">PeARL. TJ reports grants from The Paulo Foundation, Helsinki, Finland. MT reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from The Sigrid Juselius Foundation, Helsinki, Finland, during the conduct</style></keyword><keyword><style face="normal" font="default" size="100%">of the study. None of the other authors had any conflicts of interest directly</style></keyword><keyword><style face="normal" font="default" size="100%">related to this work. AND, AF, KN,EH, LN-B, WP, ZC, WF, GW, LG-M, ZAW-S, YRHV,</style></keyword><keyword><style face="normal" font="default" size="100%">CFPB, DRY, CS, PLR, PS, RA-T, J-CD, JL, TR, DY, AMR, KW, RE-O, JAC-R, AG, CM,</style></keyword><keyword><style face="normal" font="default" size="100%">AILG, MM-A, EMNR, MKN, VF, and ER-Z do not declare any conflicts of interest</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work either. NGP reports personal fees from ALK, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia, HAL, Menarini/FAES Farma, Sanofi, Mylan/MEDA, Biomay, AstraZeneca, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">MSD, ASIT BIOTECH, and Boehringer Ingelheim</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Gerolymatos</style></keyword><keyword><style face="normal" font="default" size="100%">International SA and Capricare outside the submitted work. AGM reports grants</style></keyword><keyword><style face="normal" font="default" size="100%">from Boehringer Ingelheim outside the submitted work. AC reports personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Novartis, Thermo Fisher Scientific, Philips, Sanofi, Stallergenes Greer,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, outside the submitted work. AD reports personal fees and other from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, ALK, MYLAN, GSK,CHIESI, Astra Zeneca, DBV technologies, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Stallergenes Greer, personal fees from AImmune, Zambon,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Nestle HealthScience, other from Nutricia, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. IA reports and Associate Editor Allergy journal. PXreports</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Nutricia, Nestle, Menarini, Uriach, Novartis PharmaAG, and</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithkline outside the submitted work. CM reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, GSK, ThermoFisher, Boehringer Ingelheim, outside the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33608919</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The interplay between COVID-19 pandemic and asthma in children is still unclear. We evaluated the impact of COVID-19 pandemic on childhood asthma outcomes. METHODS: The PeARL multinational cohort included 1,054 children with asthma and 505 non-asthmatic children aged between 4 and 18 years from 25 pediatric departments, from 15 countries globally. We compared the frequency of acute respiratory and febrile presentations during the first wave of the COVID-19 pandemic between groups and with data available from the previous year. In children with asthma, we also compared current and historical disease control. RESULTS: During the pandemic, children with asthma experienced fewer upper respiratory tract infections, episodes of pyrexia, emergency visits, hospital admissions, asthma attacks, and hospitalizations due to asthma, in comparison with the preceding year. Sixty-six percent of asthmatic children had improved asthma control while in 33% the improvement exceeded the minimal clinically important difference. Pre-bronchodilatation FEV(1) and peak expiratory flow rate were improved during the pandemic. When compared to non-asthmatic controls, children with asthma were not at increased risk of LRTIs, episodes of pyrexia, emergency visits, or hospitalizations during the pandemic. However, an increased risk of URTIs emerged. CONCLUSION: Childhood asthma outcomes, including control, were improved during the first wave of the COVID-19 pandemic, probably because of reduced exposure to asthma triggers and increased treatment adherence. The decreased frequency of acute episodes does not support the notion that childhood asthma may be a risk factor for COVID-19. Furthermore, the potential for improving childhood asthma outcomes through environmental control becomes apparent.</style></abstract><notes><style face="normal" font="default" size="100%">Papadopoulos, Nikolaos G&#xD;Mathioudakis, Alexander G&#xD;Custovic, Adnan&#xD;Deschildre, Antoine&#xD;Phipatanakul, Wanda&#xD;Wong, Gary&#xD;Xepapadaki, Paraskevi&#xD;Abou-Taam, Rola&#xD;Agache, Ioana&#xD;Castro-Rodriguez, Jose A&#xD;Chen, Zhimin&#xD;Cros, Pierrick&#xD;Dubus, Jean-Christophe&#xD;El-Sayed, Zeinab Awad&#xD;El-Owaidy, Rasha&#xD;Feleszko, Wojciech&#xD;Fierro, Vincenzo&#xD;Fiocchi, Alessandro&#xD;Garcia-Marcos, Luis&#xD;Goh, Anne&#xD;Hossny, Elham M&#xD;Huerta Villalobos, Yunuen R&#xD;Jartti, Tuomas&#xD;Le Roux, Pascal&#xD;Levina, Julia&#xD;Lopez Garcia, Aida Ines&#xD;Ramos, Angel Mazon&#xD;Morais-Almeida, Mario&#xD;Murray, Clare&#xD;Nagaraju, Karthik&#xD;Nagaraju, Major K&#xD;Navarrete Rodriguez, Elsy Maureen&#xD;Namazova-Baranova, Leyla&#xD;Nieto Garcia, Antonio&#xD;Pozo Beltran, Cesar Fireth&#xD;Ratchataswan, Thanaporn&#xD;Rivero Yeverino, Daniela&#xD;Rodriguez Zagal, Erendira&#xD;Schweitzer, Cyril E&#xD;Tulkki, Marleena&#xD;Wasilczuk, Katarzyna&#xD;Xu, Dan&#xD;eng&#xD;MR/S025340/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1765-1775. doi: 10.1111/all.14787. Epub 2021 Mar 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33608919</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8013557</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14787</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>688</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">688</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jansson, M. K.</style></author><author><style face="normal" font="default" size="100%">Neuber, K.</style></author><author><style face="normal" font="default" size="100%">Rudolf, H.</style></author><author><style face="normal" font="default" size="100%">Podbielski, A.</style></author><author><style face="normal" font="default" size="100%">Virchow, J. C.</style></author><author><style face="normal" font="default" size="100%">Warnke, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Medical Microbiology, Virology and Hygiene, University Medicine Rostock, Rostock, Germany.&#xD;Gesundheitsamt Rostock (Rostock Public Health Authority), Rostock, Germany.&#xD;Institute for Biostatistics and Informatics in Medicine and Ageing Research, University Medicine Rostock, Rostock, Germany.&#xD;Departments of Pneumology and Critical Care Medicine, University Medicine Rostock, Rostock, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Childhood Bacille Calmette-Guerin vaccination seems to selectively protect adult males from COVID-19 infection</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1285-1287</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/11/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">BCG Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Bcg</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">tuberculosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34812526</style></accession-num><notes><style face="normal" font="default" size="100%">Jansson, Moritz K&#xD;Neuber, Kerstin&#xD;Rudolf, Henrik&#xD;Podbielski, Andreas&#xD;Virchow, J Christian&#xD;Warnke, Philipp&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1285-1287. doi: 10.1111/all.15186. Epub 2021 Dec 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34812526</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9011414</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15186</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3316</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3316</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Chin-Hung</style></author><author><style face="normal" font="default" size="100%">Huang, Jing-Long</style></author><author><style face="normal" font="default" size="100%">Tsai, Hui-Ju</style></author><author><style face="normal" font="default" size="100%">Huang, Hsin-Yi</style></author><author><style face="normal" font="default" size="100%">Tseng, Yu-Lun</style></author><author><style face="normal" font="default" size="100%">Yao, Tsung-Chieh</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Childhood Fractional Exhaled Nitric Oxide Predicts Incident Allergic Rhinitis in Adolescence and Young Adulthood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70296</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70296</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2578</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2578</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perret, J. L.</style></author><author><style face="normal" font="default" size="100%">Idrose, N. S.</style></author><author><style face="normal" font="default" size="100%">Walters, E. H.</style></author><author><style face="normal" font="default" size="100%">Bui, D. S.</style></author><author><style face="normal" font="default" size="100%">Lowe, A. J.</style></author><author><style face="normal" font="default" size="100%">Lodge, C. J.</style></author><author><style face="normal" font="default" size="100%">Fernandez, A. R.</style></author><author><style face="normal" font="default" size="100%">Yao, V.</style></author><author><style face="normal" font="default" size="100%">Feather, I.</style></author><author><style face="normal" font="default" size="100%">Zeng, X. W.</style></author><author><style face="normal" font="default" size="100%">Thompson, B. R.</style></author><author><style face="normal" font="default" size="100%">Erbas, B.</style></author><author><style face="normal" font="default" size="100%">Abramson, M. J.</style></author><author><style face="normal" font="default" size="100%">Dharmage, S. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy and Lung Health Unit, Centre of Epidemiology and Biostatistics, The University of Melbourne, Melbourne, Victoria, Australia.&#xD;The Institute for Breathing and Sleep (IBAS), Melbourne, Victoria, Australia.&#xD;Department of Respiratory and Sleep Medicine, Austin Hospital, Melbourne, Victoria, Australia.&#xD;School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.&#xD;School of Medicine, Deakin University, Geelong, Victoria, Australia.&#xD;Gold Coast University Hospital, Southport, Queensland, Australia.&#xD;Department of Occupational and Environmental Health, School of Public Health, Sun Yat-sen University, Guangzhou, China.&#xD;School of Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.&#xD;School of Psychology and Public Health, La Trobe University, Melbourne, Victoria, Australia.&#xD;School of Public Health &amp; Preventive Medicine, Monash University, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Childhood infections, asthma and allergy trajectories, and chronic rhinosinusitis in middle age: A prospective cohort study across six decades</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2717-2731</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/07/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/epidemiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/epidemiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Tasmania/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Tract Infections/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergies</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">head colds</style></keyword><keyword><style face="normal" font="default" size="100%">tonsillitis</style></keyword><keyword><style face="normal" font="default" size="100%">trajectories</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38987868</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Evidence on the early life risk factors of adult CRS, and the history of asthma and allergies across the life course, is limited. AIM: To investigate relationships between respiratory infective/allergic conditions in childhood, and asthma and allergies across the life course and CRS in middle age. METHODS: Data were from the population-based Tasmanian Longitudinal Health Study (TAHS) cohort, first studied in 1968 when aged 6-7 years (n = 8583) and serially followed into middle age (n = 3609). Using a well-accepted epidemiological definition, participants were assigned a CRS-severity subtype at age 53: no sinusitis/CRS (reference); past doctor diagnosis only; current symptoms without doctor diagnosis; and doctor-diagnosed CRS with current symptoms. Relationships with infective/allergic respiratory illnesses at age 7, and previously published asthma-allergy trajectories from 7 to 53 years, were examined using multinominal regression. RESULTS: In middle age, 5.8% reported current CRS symptoms with 2.5% doctor-diagnosed. Childhood conditions associated with symptomatic doctor-diagnosed CRS included frequent head colds (multinomial odds ratio [mOR] = 2.04 (95% confidence interval [95% CI]: 1.24, 3.37)), frequent tonsillitis (mOR = 1.61 [95% CI: 1.00, 2.59]) and current childhood asthma (mOR = 2.23 [95% CI: 1.25, 3.98]). Life course trajectories that featured late-onset or persistent asthma and allergies were associated with all CRS subtypes in middle age; early-onset persistent asthma and allergies (mOR = 6.74, 95% CI: 2.76, 16.4); late-onset asthma allergies (mOR = 15.9, 95% CI: 8.06, 31.4), and late-onset hayfever (mOR = 3.02, 95% CI: 1.51, 6.06) were associated with symptomatic doctor-diagnosed CRS. CONCLUSION: Current asthma, frequent head colds and tonsillitis at age 7 could signal a susceptible child who is at higher risk for CRS in mid-adult life and who might benefit from closer monitoring and/or proactive management. Concurrent asthma and allergies were strongly associated and are potential treatable traits of adult CRS.</style></abstract><notes><style face="normal" font="default" size="100%">Perret, Jennifer L&#xD;Idrose, N Sabrina&#xD;Walters, E Haydn&#xD;Bui, Dinh S&#xD;Lowe, Adrian J&#xD;Lodge, Caroline J&#xD;Fernandez, Anne R&#xD;Yao, Vivian&#xD;Feather, Iain&#xD;Zeng, Xiao-Wen&#xD;Thompson, Bruce R&#xD;Erbas, Bircan&#xD;Abramson, Michael J&#xD;Dharmage, Shyamali C&#xD;eng&#xD;GlaxoSmithKline/&#xD;Royal Hobart Hospital Research Foundation/&#xD;Helen MacPherson Smith Trust/&#xD;Asthma Foundation of Queensland/&#xD;Clifford Craig Medical Research Trust of Tasmania/&#xD;University of Melbourne/&#xD;Asthma Foundation of Tasmania/&#xD;Asthma Foundation of Victoria/&#xD;299901/National Health and Medical Research Council (NHMRC) of Australia/&#xD;566931/National Health and Medical Research Council (NHMRC) of Australia/&#xD;1021275/National Health and Medical Research Council (NHMRC) of Australia/&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2717-2731. doi: 10.1111/all.16184. Epub 2024 Jul 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38987868</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16184</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1168</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1168</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Navaratna, S.</style></author><author><style face="normal" font="default" size="100%">Estcourt, M. J.</style></author><author><style face="normal" font="default" size="100%">Burgess, J.</style></author><author><style face="normal" font="default" size="100%">Waidyatillake, N.</style></author><author><style face="normal" font="default" size="100%">Enoh, E.</style></author><author><style face="normal" font="default" size="100%">Lowe, A. J.</style></author><author><style face="normal" font="default" size="100%">Peters, R.</style></author><author><style face="normal" font="default" size="100%">Koplin, J.</style></author><author><style face="normal" font="default" size="100%">Dhamage, S. C.</style></author><author><style face="normal" font="default" size="100%">Lodge, C. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Department of Community Medicine, University of Peradeniya, Kandy, Sri Lanka.&#xD;Wesfarmers Centre of Vaccines &amp; Infectious Diseases, Telethon Kids Institute, Perth Children&apos;s Hospital, Nedlands, Australia.&#xD;Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Vic., Australia.&#xD;Reproductive Health Programme, United Nations Population Fund (UNFPA), Yaounde, Cameroon.&#xD;Murdoch Children&apos;s Research Institute, Royal Children&apos;s Hospital, Parkville, Vic., Australia.&#xD;Department of Paediatrics, The University of Melbourne, Parkville, Vic., Australia.&#xD;Centre for Food and Allergy Research (CFAR), Murdoch Children&apos;s Research Institute, Parkville, Vic., Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Childhood vaccination and allergy: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2135-2152</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">BCG Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33569761</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND OBJECTIVE: As the rise in prevalence of allergic diseases worldwide corresponds in time with increasing infant vaccination, it has been hypothesized that childhood vaccination may increase the risk of allergic disease. We aimed to synthesize the literature on the association between childhood vaccination and allergy. DESIGN: We searched the electronic databases PubMed and EMBASE (January 1946-January 2018) using vaccination and allergy terms. METHODS: Two authors selected papers according to the inclusion criteria. Pooled effects across studies were estimated using random-effects meta-analysis. Due to inadequate number of homogeneous publications on newer and underused vaccines, meta-analysis was limited to allergic outcomes following administration of (Bacillus Calmette-Guerin) BCG, measles or pertussis vaccination. The review was prospectively registered in the PROSPERO systematic review registry (NO: CRD42017071009). RESULTS: A total of 35 publications based on cohort studies and 7 publications based on randomized controlled trials (RCTs) met the inclusion criteria. RCTs: From 2 studies, early vaccination with BCG vaccine was associated with a reduced risk of eczema (RR = 0.83; 95% CI = 0.73-0.93; I(2) = 0%) but not food allergy or asthma. No association was found between pertussis vaccine and any allergic outcome based on a single RCT. COHORT STUDIES: Childhood measles vaccination was associated with a reduced risk of eczema (RR = 0.65; 95% CI = 0.47-0.90, I(2) = 0.0%), asthma (RR = 0.78; 95% CI = 0.62-0.98, I(2) = 93.9%) and, with a similar, statistically non-significant reduction in sensitization (RR = 0.78; 95% CI = 0.61-1.01, I(2) = 19.4%). CONCLUSIONS: We found no evidence that childhood vaccination with commonly administered vaccines was associated with increased risk of later allergic disease. Our results from pooled analysis of both RCTs and cohort studies suggest that vaccination with BCG and measles vaccines were associated with a reduced risk of eczema.</style></abstract><notes><style face="normal" font="default" size="100%">Navaratna, Samidi&#xD;Estcourt, Marie J&#xD;Burgess, John&#xD;Waidyatillake, Nilakshi&#xD;Enoh, Elizabeth&#xD;Lowe, Adrian J&#xD;Peters, Rachel&#xD;Koplin, Jennifer&#xD;Dhamage, Shyamali C&#xD;Lodge, Caroline J&#xD;eng&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2135-2152. doi: 10.1111/all.14771. Epub 2021 Mar 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33569761</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14771</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1086</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1086</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suaini, N. H. A.</style></author><author><style face="normal" font="default" size="100%">Loo, E. X.</style></author><author><style face="normal" font="default" size="100%">Peters, R. L.</style></author><author><style face="normal" font="default" size="100%">Yap, G. C.</style></author><author><style face="normal" font="default" size="100%">Allen, K. J.</style></author><author><style face="normal" font="default" size="100%">Van Bever, H.</style></author><author><style face="normal" font="default" size="100%">Martino, D. J.</style></author><author><style face="normal" font="default" size="100%">Goh, A. E. N.</style></author><author><style face="normal" font="default" size="100%">Dharmage, S. C.</style></author><author><style face="normal" font="default" size="100%">Colega, M. T.</style></author><author><style face="normal" font="default" size="100%">Chong, M. F. F.</style></author><author><style face="normal" font="default" size="100%">Ponsonby, A. L.</style></author><author><style face="normal" font="default" size="100%">Tan, K. H.</style></author><author><style face="normal" font="default" size="100%">Tang, M. L. K.</style></author><author><style face="normal" font="default" size="100%">Godfrey, K. M.</style></author><author><style face="normal" font="default" size="100%">Lee, B. W.</style></author><author><style face="normal" font="default" size="100%">Shek, L. P.</style></author><author><style face="normal" font="default" size="100%">Koplin, J. J.</style></author><author><style face="normal" font="default" size="100%">Tham, E. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Food and Allergy Research, Murdoch Children&apos;s Research Institute, Parkville, Vic, Australia.&#xD;Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.&#xD;Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore City, Singapore.&#xD;Department of Paediatrics, University of Melbourne, Parkville, Vic, Australia.&#xD;Department of Allergy and Clinical Immunology, Royal Children&apos;s Hospital, Parkville, Vic, Australia.&#xD;Institute of Inflammation and Repair, University of Manchester, Manchester, UK.&#xD;Khoo Teck Puat-National University Children&apos;s Medical Institute, National University Health System (NUHS), Singapore City, Singapore.&#xD;Telethon Kids Institute, University of Western Australia, Perth, Australia.&#xD;Allergy Service, Department of Paediatrics, KK Women&apos;s and Children&apos;s Hospital (KKH), Singapore City, Singapore.&#xD;The School of Population and Global Health, University of Melbourne, Carlton, Vic, Australia.&#xD;Saw Swee Hock School of Public Health, National University of Singapore, Singapore City, Singapore.&#xD;Neuroepidemiology Research Group, Florey Institute for Neuroscience and Mental Health, Parkville, Australia.&#xD;Department of Maternal Fetal Medicine, KK Women&apos;s and Children&apos;s Hospital (KKH), Singapore City, Singapore.&#xD;NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Medical Research Council Lifecourse Epidemiology Unit, Southampton, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Children of Asian ethnicity in Australia have higher risk of food allergy and early-onset eczema than those in Singapore</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3171-3182</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/03/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Australia/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Ethnicity</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Singapore/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Asian children</style></keyword><keyword><style face="normal" font="default" size="100%">Gusto</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">healthnuts</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33751595</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In Western countries, Asian children have higher food allergy risk than Caucasian children. The early-life environmental exposures for this discrepancy are unclear. We aimed to compare prevalence of food allergy and associated risk factors between Asian children in Singapore and Australia. METHODS: We studied children in the Growing Up in Singapore Towards healthy Outcomes (GUSTO) birth cohort (n = 878) and children of Asian ancestry in the HealthNuts cohort (n = 314). Food allergy was defined as a positive SPT &gt;/=3 mm to egg or peanut AND either a convincing history of IgE-mediated reaction at 18 months (GUSTO) or a positive oral food challenge at 14-18 months (HealthNuts). Eczema was defined as parent-reported doctor diagnosis. RESULTS: Food allergy prevalence was 1.1% in Singapore and 15.0% in Australia (P&lt;0.001). Egg introduction was more often delayed (&gt;10 months) in Singapore (63.5%) than Australia (16.3%; P&lt;0.001). Prevalence of early-onset eczema (&lt;6 months) was lower in Singapore (8.4%) than Australia (30.5%) (P&lt;0.001). Children with early-onset eczema were more likely to have food allergy than those without eczema in Australia [aOR 5.11 (2.34-11.14); P&lt;0.001] and Singapore [aOR4.00 (0.62-25.8); P = 0.145]. CONCLUSIONS: Among Asian children, prevalence of early-onset eczema and food allergy was higher in Australia than Singapore. Further research with larger sample sizes and harmonized definitions of food allergy between cohorts is required to confirm and extend these findings. Research on environmental factors influencing eczema onset in Australia and Singapore may aid understanding of food allergy pathogenesis in different parts of the world.</style></abstract><notes><style face="normal" font="default" size="100%">Suaini, Noor H A&#xD;Loo, Evelyn Xiu-Ling&#xD;Peters, Rachel L&#xD;Yap, Gaik Chin&#xD;Allen, Katrina J&#xD;Van Bever, Hugo&#xD;Martino, David J&#xD;Goh, Anne Eng Neo&#xD;Dharmage, Shyamali C&#xD;Colega, Marjorelee T&#xD;Chong, Mary Foong Fong&#xD;Ponsonby, Anne-Louise&#xD;Tan, Kok Hian&#xD;Tang, Mimi L K&#xD;Godfrey, Keith M&#xD;Lee, Bee Wah&#xD;Shek, Lynette Pei-Chi&#xD;Koplin, Jennifer J&#xD;Tham, Elizabeth Huiwen&#xD;eng&#xD;MC_PC_21000/MRC_/Medical Research Council/United Kingdom&#xD;MC_PC_21003/MRC_/Medical Research Council/United Kingdom&#xD;MC_PC_21001/MRC_/Medical Research Council/United Kingdom&#xD;IS-BRC-1215-20004/DH_/Department of Health/United Kingdom&#xD;NF-SI-0515-10042/DH_/Department of Health/United Kingdom&#xD;MC_UU_12011/4/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3171-3182. doi: 10.1111/all.14823. Epub 2021 Apr 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33751595</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14823</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2626</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2626</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tian, Y.</style></author><author><style face="normal" font="default" size="100%">Luo, X.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Rong, H.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Li, B.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">You, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.&#xD;National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science and Technology, Beijing, China.&#xD;State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.&#xD;Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.&#xD;School of Information Technology and Management, University of International Business and Economics, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Children with elevated wheat IgG4 antibody titer in autism spectrum disorder: Clinical presentation and findings associated with gut microbiota</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1482-1486</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/08/02</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39092541</style></accession-num><notes><style face="normal" font="default" size="100%">Tian, Yixiao&#xD;Luo, Xin&#xD;Chen, Jianxiong&#xD;Rong, Huiteng&#xD;Wang, Huinuo&#xD;Li, Bing&#xD;Li, Jing&#xD;You, Xin&#xD;eng&#xD;Autism Special Fund from Peking Union Medical Foundation/&#xD;2017-I2M-3-017/CAMS Innovation Fund for Medical Sciences (CIFMS)/&#xD;2023-I2M-C&amp;T-B-042/CAMS Innovation Fund for Medical Sciences (CIFMS)/&#xD;2019XK320030/Non-profit Central Research Institute Fund from Chinese Academy of Medical Sciences/&#xD;L222085/Peking Natural Science Foundation/&#xD;2022-PUMCH-A-006/National High Level Hospital Clinical Research Funding/&#xD;2022-PUMCH-C-068/National High Level Hospital Clinical Research Funding/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1482-1486. doi: 10.1111/all.16244. Epub 2024 Aug 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39092541</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105060</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16244</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2574</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2574</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hiremath, G.</style></author><author><style face="normal" font="default" size="100%">Choksi, Y.</style></author><author><style face="normal" font="default" size="100%">Correa, H.</style></author><author><style face="normal" font="default" size="100%">Jacobse, J.</style></author><author><style face="normal" font="default" size="100%">Das, S. R.</style></author><author><style face="normal" font="default" size="100%">Ma, S.</style></author><author><style face="normal" font="default" size="100%">Goettel, J. A.</style></author><author><style face="normal" font="default" size="100%">Rajagopala, S. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Gastroenterology, Hepatology and Nutrition, Vanderbilt Children&apos;s Hospital, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Tennesee Valley Health System, Veteran&apos;s Affairs, Nashville, Tennessee, USA.&#xD;Division of Pathology, Vanderbilt Children&apos;s Hospital, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Willem-Alexander Children&apos;s Hospital, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.&#xD;Department of Medicine, Division of Infectious Disease, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Department of Pathology, Microbiology and Immunology, Division of Molecular Pathogenesis, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Center for Mucosal Inflammation and Cancer, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Children with eosinophilic esophagitis non-responsive to combination therapy have distinct esophageal transcriptomic and microbiome profile</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2798-2811</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/07/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/drug therapy/microbiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Proton Pump Inhibitors/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Esophagus/microbiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Metatranscriptomics</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, and Sanofi. In addition, he has received speaker fees from Bristol</style></keyword><keyword><style face="normal" font="default" size="100%">Myer Squibb. All other authors declare that the research was conducted without</style></keyword><keyword><style face="normal" font="default" size="100%">commercial or financial relationships that could be construed as a potential</style></keyword><keyword><style face="normal" font="default" size="100%">conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38993131</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A combination of proton-pump inhibitors (PPI) and topical steroids (TS) is used to treat children with eosinophilic esophagitis (EoE). However, a subset of children do not respond to this combination therapy. We aimed to identify the esophageal transcriptional, cell composition, and microbial differences between the non-responders (EoE-PPI-TSnr; n = 7) and responders (EoE-PPI-TSr; n = 7) to the combination therapy for EoE and controls (n = 9) using metatranscriptomics. METHODS: Differential gene expression analysis was used to identify transcriptional differences, validated using the EoE diagnostic panel (EDP). Deconvolution analysis was performed to identify differences in their cell type composition. Microbiome analysis was conducted from esophageal biopsies RNAseq data, and microbial abundance was correlated with esophageal gene expression. RESULTS: In all, 3164 upregulated and 3154 downregulated genes distinguished EoE-PPI-TSnr from EoE-PPI-TSr. Eosinophilic inflammatory response, cytokine signaling, and collagen formation pathways were significantly upregulated in EoE-PPI-TSnr. There was a 56% overlap in dysregulated genes between EoE-PPI-TSnr and EDP, with a perfect agreement in the directionality of modulation. Eosinophils, dendritic cells (DCs), immature DCs, megakaryocytic-erythroid progenitors, and T helper type 1 cells were significantly higher in EoE-PPI-TSnr. There was no significant difference in microbiome diversity. The relative abundance of Fusobacterium sp. and Acinetobacter sp. notably differed in EoE-PPI-TSnr and correlated with the key pathways. CONCLUSION: Our results provide critical insights into the molecular, cellular, and microbial factors associated with the lack of response to PPI and TS combination therapy in children with EoE. This study advances our understanding of the pathobiology of EoE while guiding personalized treatment strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Hiremath, Girish&#xD;Choksi, Yash&#xD;Correa, Hernan&#xD;Jacobse, Justin&#xD;Das, Suman R&#xD;Ma, Siyuan&#xD;Goettel, Jeremy A&#xD;Rajagopala, Seesandra V&#xD;eng&#xD;IK2 BX004648/BX/BLRD VA/&#xD;K23 DK131341/DK/NIDDK NIH HHS/&#xD;P30 DK058404/DK/NIDDK NIH HHS/&#xD;R21 AI168832/AI/NIAID NIH HHS/&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2798-2811. doi: 10.1111/all.16208. Epub 2024 Jul 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38993131</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11528550</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16208</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3300</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3300</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Yuan</style></author><author><style face="normal" font="default" size="100%">Li, Jingyun</style></author><author><style face="normal" font="default" size="100%">Li, Xian</style></author><author><style face="normal" font="default" size="100%">Wang, Menglin</style></author><author><style face="normal" font="default" size="100%">Yang, Xiangli</style></author><author><style face="normal" font="default" size="100%">Shi, Li</style></author><author><style face="normal" font="default" size="100%">Cao, Zhiwei</style></author><author><style face="normal" font="default" size="100%">Feng, Yan</style></author><author><style face="normal" font="default" size="100%">Liu, Weiwei</style></author><author><style face="normal" font="default" size="100%">Xu, Zhendong</style></author><author><style face="normal" font="default" size="100%">Ma, Ruixia</style></author><author><style face="normal" font="default" size="100%">Gao, Xiaoping</style></author><author><style face="normal" font="default" size="100%">Liu, Wen</style></author><author><style face="normal" font="default" size="100%">Xue, Jinmei</style></author><author><style face="normal" font="default" size="100%">Ren, Xiaoyong</style></author><author><style face="normal" font="default" size="100%">Li, Xuezhong</style></author><author><style face="normal" font="default" size="100%">Song, Xicheng</style></author><author><style face="normal" font="default" size="100%">Yang, Yi</style></author><author><style face="normal" font="default" size="100%">Quan, Fang</style></author><author><style face="normal" font="default" size="100%">Cheng, Lei</style></author><author><style face="normal" font="default" size="100%">Jiang, Weihong</style></author><author><style face="normal" font="default" size="100%">Li, Huabin</style></author><author><style face="normal" font="default" size="100%">Li, Jian</style></author><author><style face="normal" font="default" size="100%">Liu, Huanhai</style></author><author><style face="normal" font="default" size="100%">Liu, Jianfeng</style></author><author><style face="normal" font="default" size="100%">Liu, Zheng</style></author><author><style face="normal" font="default" size="100%">Lv, Wei</style></author><author><style face="normal" font="default" size="100%">Qiu, Qianhui</style></author><author><style face="normal" font="default" size="100%">Wang, Xiangdong</style></author><author><style face="normal" font="default" size="100%">Xu, Yu</style></author><author><style face="normal" font="default" size="100%">Xu, Yuanteng</style></author><author><style face="normal" font="default" size="100%">Yang, Qintai</style></author><author><style face="normal" font="default" size="100%">Yang, Yucheng</style></author><author><style face="normal" font="default" size="100%">Ye, Jing</style></author><author><style face="normal" font="default" size="100%">Yu, Hongmeng</style></author><author><style face="normal" font="default" size="100%">Zhu, Dongdong</style></author><author><style face="normal" font="default" size="100%">Wang, Chengshuo</style></author><author><style face="normal" font="default" size="100%">Zhang, Luo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Chinese Position Paper on Biologic Therapy for Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to treat patients experiencing poorly controlled symptoms, despite standard-of-care (SoC) treatment. Although biological treatment options for AR remain limited worldwide, the recent approval of novel agents, such as stapokibart for seasonal allergic rhinitis (SAR), has accelerated clinical research and development in this field. Evidence for biologic therapy in the management of perennial allergic rhinitis (PAR) is currently sparse. To standardise the use of biologics in AR management and promote their evidence-based application, a multidisciplinary expert panel was convened. This position paper evaluates current evidence regarding the efficacy and safety of biologic agents for AR, incorporating data from both international and regional clinical studies. Here, we provide recommendations on appropriate indications for biologic therapy and emphasise its role in patients with uncontrolled SAR, supporting clinical decision-making and facilitating the integration of biologics into routine practice.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70312</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70312</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2822</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2822</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xian, M.</style></author><author><style face="normal" font="default" size="100%">Yan, B.</style></author><author><style face="normal" font="default" size="100%">Song, X.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Tang, J.</style></author><author><style face="normal" font="default" size="100%">Jiang, Y.</style></author><author><style face="normal" font="default" size="100%">Wan, L.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author><author><style face="normal" font="default" size="100%">Xue, J.</style></author><author><style face="normal" font="default" size="100%">Cao, Z.</style></author><author><style face="normal" font="default" size="100%">Yu, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Shi, L.</style></author><author><style face="normal" font="default" size="100%">Wang, G.</style></author><author><style face="normal" font="default" size="100%">Xu, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Ye, J.</style></author><author><style face="normal" font="default" size="100%">Jiang, L.</style></author><author><style face="normal" font="default" size="100%">Quan, F.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Liu, F.</style></author><author><style face="normal" font="default" size="100%">Xu, Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Su, L.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Fan, J.</style></author><author><style face="normal" font="default" size="100%">He, G.</style></author><author><style face="normal" font="default" size="100%">Zhu, L.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Shen, S.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Wei, X.</style></author><author><style face="normal" font="default" size="100%">Yu, H.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Ma, R.</style></author><author><style face="normal" font="default" size="100%">Liu, H.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Lv, W.</style></author><author><style face="normal" font="default" size="100%">Yang, Q.</style></author><author><style face="normal" font="default" size="100%">Zhu, D.</style></author><author><style face="normal" font="default" size="100%">Cheng, L.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of New Medicine and Diagnostic Technology Research for Nasal Disease, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China.&#xD;Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.&#xD;Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.&#xD;Otolaryngology Department, The First People&apos;s Hospital, Foshan, Guangdong, China.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.&#xD;Department of Otorhinolaryngology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, China.&#xD;Department of Otorhinolaryngology, Zibo Central Hospital, Zibo, Shandong, China.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.&#xD;Department of Otolaryngology Head &amp; Neck Surgery, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.&#xD;Department of Otolaryngology Head and Neck Surgery, Tianjin Union Medical Center, Tianjin, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, Shandong, China.&#xD;Department of Otolaryngology, Head and Neck Surgery, Henan Provincial People&apos;s Hospital, People&apos;s Hospital of Zhengzhou University, Zhengzhou, Henan, China.&#xD;Department of Rhinology and Allergy, Otolaryngology-Head and Neck Surgery Centre, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.&#xD;Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.&#xD;Department of Otorhinolaryngology, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.&#xD;Department of Otolaryngology Head and Neck Surgery, First Affiliated Hospital of Xi&apos;an Jiaotong University, Xi&apos;an, Shanxi, China.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, West China Hospital Sichuan University, Chengdu, Sichuan, China.&#xD;E.N.T. Department, Baotou Central Hospital, Baotou, Inner Mongolia Autonomous Region, China.&#xD;Department of Otolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.&#xD;Department of Otolaryngology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.&#xD;Department of Otolaryngology, Centre of Otolaryngology Head and Neck Surgery, Zhejiang Provincial People&apos;s Hospital, People&apos;s Hospital of Hangzhou Medical College, Zhejiang, Hangzhou, China.&#xD;Otolaryngology Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.&#xD;Department of Otolaryngology Head and Neck Surgery, Sichuan Provincial People&apos;s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.&#xD;Department of Otolaryngology Head and Neck Surgery, Peking University Third Hospital, Beijing, China.&#xD;Department of Otorhinolaryngology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.&#xD;Guangxi Hospital Division, Of the First Affiliated Hospital, Sun Yat-Sen University, Nanning, Guangxi, China.&#xD;Allergy Center, Department of Otolaryngology, Affiliated Eye and ENT Hospital, Fudan University, Shanghai, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.&#xD;ENT Institute and Department of Otolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.&#xD;Department of Otolaryngology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.&#xD;The Department of Otorhinolaryngology Head and Neck Surgery, The First People&apos;s Hospital of Yinchuan, Yinchuan, Ningxia, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, Second Affiliated Hospital of Naval Medical University, Naval Medical University, Shanghai, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, China-Japan Friendship Hospital, Beijing, China.&#xD;Department of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.&#xD;Department of Otolaryngology, Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.&#xD;Department of Otorhinolaryngology &amp; Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1208-1225</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/03/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Therapy/methods</style></keyword><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/therapy/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/therapy/complications/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/therapy/complications/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">monoclonal antibody</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40042059</style></accession-num><abstract><style face="normal" font="default" size="100%">Emerging biologics that selectively target key cytokines present a promising therapeutic alternative for patients suffering from severe, uncontrollable chronic rhinosinusitis with nasal polyps (CRSwNP). Despite the limited availability of registered biologics for CRSwNP treatment in China, the country is experiencing rapid development in this field. It is imperative to standardize the application of biologic agents in CRSwNP management in preparation for their future integration into the CRSwNP care pathway. The Rhinology Group, Chinese Society of Otorhinolaryngology-Head and Neck Surgery; the Rhinology Group, Chinese Medical Doctor Association of Otorhinolaryngology-Head and Neck Surgery; and the Nasal and Ocular Allergy Group, Chinese Society of Allergy have convened an expert panel consisting of principal investigators experienced in clinical trials of biologic treatment for CRSwNP. This expert panel was assembled to discuss the application of biologic agents in patients with CRSwNP in China. Additionally, the latest findings on the pathogenesis of CRSwNP, mechanisms of biologic agents, and efficacy and safety of biologic treatment in patients with CRSwNP were reviewed, with a special emphasis on research evidence from China. The expert panel reached a consensus on several critical issues, including criteria for the prescription, treatment course, and efficacy evaluation from a Chinese perspective. This position paper aims to guide Chinese physicians in the use of biologic agents for patients with CRSwNP. As our experience with biologic treatment continues to grow, this position paper will be further updated.</style></abstract><notes><style face="normal" font="default" size="100%">Xian, Mu&#xD;Yan, Bing&#xD;Song, Xicheng&#xD;Chen, Jianjun&#xD;Tang, Jun&#xD;Jiang, Yan&#xD;Wan, Lijia&#xD;Liu, Wen&#xD;Xue, Jinmei&#xD;Cao, Zhiwei&#xD;Yu, Yafeng&#xD;Yang, Xiangli&#xD;Shi, Li&#xD;Wang, Guangke&#xD;Xu, Yu&#xD;Yang, Yucheng&#xD;Ye, Jing&#xD;Jiang, Luyun&#xD;Quan, Fang&#xD;Tan, Guolin&#xD;Liu, Feng&#xD;Xu, Zhendong&#xD;Zhang, Xiaowen&#xD;Li, Jiping&#xD;Su, Lizhong&#xD;Yang, Yi&#xD;Fan, Jiangang&#xD;He, Gang&#xD;Zhu, Li&#xD;Wang, Xiangdong&#xD;Wang, Ming&#xD;Shen, Shen&#xD;Li, Jian&#xD;Li, Huabin&#xD;Wei, Xin&#xD;Yu, Hongmeng&#xD;Liu, Zheng&#xD;Ma, Ruixia&#xD;Liu, Huanhai&#xD;Liu, Jianfeng&#xD;Lv, Wei&#xD;Yang, Qintai&#xD;Zhu, Dongdong&#xD;Cheng, Lei&#xD;Wang, Chengshuo&#xD;Zhang, Luo&#xD;eng&#xD;2022YFC2504100/National Key R&amp;D Program of China/&#xD;82025010/National Natural Science Foundation of China/&#xD;82371115/National Natural Science Foundation of China/&#xD;82471135/National Natural Science Foundation of China/&#xD;82171111/National Natural Science Foundation of China/&#xD;Z221100007422009/Beijing Municipal Science and Technology Project/&#xD;Z211100002921057/Beijing Municipal Science and Technology Project/&#xD;CFH2022-1-1091/Capital&apos;s Funds for Health Improvement and Research/&#xD;JYY2023-1/Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes, Beijing Municipal Health Commission/&#xD;Consensus Development Conference&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1208-1225. doi: 10.1111/all.16519. Epub 2025 Mar 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40042059</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105070</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16519</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3322</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3322</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Declercq, Jozefien</style></author><author><style face="normal" font="default" size="100%">Aegerter, Helena</style></author><author><style face="normal" font="default" size="100%">Smole, Ursula</style></author><author><style face="normal" font="default" size="100%">Van Damme, Karel F. A.</style></author><author><style face="normal" font="default" size="100%">Ketelaere, Ellen</style></author><author><style face="normal" font="default" size="100%">Lammens, Inés</style></author><author><style face="normal" font="default" size="100%">Dewolf, Caroline</style></author><author><style face="normal" font="default" size="100%">Vergote, Karl</style></author><author><style face="normal" font="default" size="100%">Vanheerswynghels, Manon</style></author><author><style face="normal" font="default" size="100%">De Prijck, Sofie</style></author><author><style face="normal" font="default" size="100%">Holtappels, Gabriele</style></author><author><style face="normal" font="default" size="100%">De Ruyck, Natalie</style></author><author><style face="normal" font="default" size="100%">Hammad, Hamida</style></author><author><style face="normal" font="default" size="100%">Gevaert, Phillippe</style></author><author><style face="normal" font="default" size="100%">Vanhee, Stijn</style></author><author><style face="normal" font="default" size="100%">Lambrecht, Bart N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Chitin Is a Potent Inducer of Type 2 Airway Inflammation Independent of Endogenous Chitinolytic Activity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Chitin is highly abundant in organisms with allergenic potential such as house dust mites, fungi, nematodes, and arthropods. Several observations suggest a role for chitin in allergic disease, although the mechanism of action is poorly understood. Humans and mice express highly conserved chitin-degrading chitinases: acidic mammalian chitinase (AMCase; encoded by CHIA in humans and Chia in mice) and chitotriosidase (Chit1; encoded by CHIT1 in humans and Chit1 in mice), which have been suggested to modulate allergic responses through enzymatic degradation of chitins. Humans with nasal polyposis and mice with type 2 immune responses had increased chitinolytic activity in their airways, emanating from two different enzymes. Due to redundancy between both enzymes and lack of a mouse model completely devoid of all chitinolytic activity, their precise role in regulating type 2 immunity to chitin remains controversial. Using transgenic mice with single or combined deficiency of Chia and Chit1, we investigated the impact of chitin and chitinases on type 2 immunity. Our data demonstrate that chitin is a potent adjuvant for type 2 inflammation by triggering increased activation and migration of type 2 dendritic cells, with consequent increased polarization of T helper 2 cells. This adjuvant potential of chitin is however unaffected by the absence of endogenous chitinolytic activity in different models of allergic airway disease. Taken together, we here highlight the role of chitin as an allergenic adjuvant and question if the strength of this response is influenced by endogenous chitinases.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70276</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70276</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Klimov, P. B.</style></author><author><style face="normal" font="default" size="100%">Gu, X.</style></author><author><style face="normal" font="default" size="100%">Yu, Z.</style></author><author><style face="normal" font="default" size="100%">Cui, X.</style></author><author><style face="normal" font="default" size="100%">Li, Q.</style></author><author><style face="normal" font="default" size="100%">Pan, R.</style></author><author><style face="normal" font="default" size="100%">Yuan, C.</style></author><author><style face="normal" font="default" size="100%">Cai, F.</style></author><author><style face="normal" font="default" size="100%">Cui, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics Laboratory, The Affiliated Wuxi Children&apos;s Hospital of Nanjing Medical University, Wuxi, China.&#xD;Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA.&#xD;Department of Respiratory, The Affiliated Wuxi Children&apos;s Hospital of Nanjing Medical University, Wuxi, China.&#xD;Department of General Medicine, The Affiliated Wuxi People&apos;s Hospital of Nanjing Medical University, Wuxi, China.&#xD;Clinical Research Center, The Affiliated Wuxi People&apos;s Hospital of Nanjing Medical University, Wuxi, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chromosome-level genomic assembly and allergome inference reveal novel allergens in Tyrophagus putrescentiae</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1691-1695</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Acaridae</style></keyword><keyword><style face="normal" font="default" size="100%">*Mites</style></keyword><keyword><style face="normal" font="default" size="100%">Genomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36695039</style></accession-num><notes><style face="normal" font="default" size="100%">Zhou, Ying&#xD;Klimov, Pavel B&#xD;Gu, Xiaohong&#xD;Yu, Zhiwei&#xD;Cui, Xiaochuan&#xD;Li, Qingqing&#xD;Pan, Ruilin&#xD;Yuan, Cunyin&#xD;Cai, Fangfang&#xD;Cui, Yubao&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1691-1695. doi: 10.1111/all.15656. Epub 2023 Feb 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36695039</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15656</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1302</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1302</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carrard, J.</style></author><author><style face="normal" font="default" size="100%">Marquillies, P.</style></author><author><style face="normal" font="default" size="100%">Pichavant, M.</style></author><author><style face="normal" font="default" size="100%">Visez, N.</style></author><author><style face="normal" font="default" size="100%">Lanone, S.</style></author><author><style face="normal" font="default" size="100%">Tsicopoulos, A.</style></author><author><style face="normal" font="default" size="100%">Chenivesse, C.</style></author><author><style face="normal" font="default" size="100%">Scherpereel, A.</style></author><author><style face="normal" font="default" size="100%">de Nadai, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Center for Infection and Immunity of Lille, Universite de Lille, Lille, France.&#xD;CNRS, UMR 8522-PC2A-Physicochimie des Processus de Combustion et de l&apos;Atmosphere, Universite de Lille, Lille, France.&#xD;INSERM, IMRB, Universite Paris-Est Creteil, Creteil, France.&#xD;CHU Lille, Service de Pneumologie et Immuno-allergologie, Centre Constitutif Des Maladies Pulmonaires Rares, Lille, France.&#xD;CRISALIS/F-CRIN network, Lille, France.&#xD;Pulmonary and Thoracic Oncology Department, CHU Lille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chronic exposure to benzo(a)pyrene-coupled nanoparticles worsens inflammation in a mite-induced asthma mouse model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1562-1565</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Benzo(a)pyrene</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Mites</style></keyword><keyword><style face="normal" font="default" size="100%">*Nanoparticles</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33037642</style></accession-num><notes><style face="normal" font="default" size="100%">Carrard, Julie&#xD;Marquillies, Philippe&#xD;Pichavant, Muriel&#xD;Visez, Nicolas&#xD;Lanone, Sophie&#xD;Tsicopoulos, Anne&#xD;Chenivesse, Cecile&#xD;Scherpereel, Arnaud&#xD;de Nadai, Patricia&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1562-1565. doi: 10.1111/all.14619. Epub 2020 Oct 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33037642</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14619</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>538</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">538</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ko, Y. G.</style></author><author><style face="normal" font="default" size="100%">Kim, M. H.</style></author><author><style face="normal" font="default" size="100%">Park, J. Y.</style></author><author><style face="normal" font="default" size="100%">Gil, C. H.</style></author><author><style face="normal" font="default" size="100%">Kim, T. S.</style></author><author><style face="normal" font="default" size="100%">Choi, J. Y.</style></author><author><style face="normal" font="default" size="100%">Chung, D. H.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author><author><style face="normal" font="default" size="100%">Kim, D. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, H. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.&#xD;Laboratory of Behavioral Systems Epidemiology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.&#xD;Department of Life Science, Ewha Women University, Seoul, Republic of Korea.&#xD;Institute of Health Policy and Management, Seoul National University Medical Research Center, Seoul, Republic of Korea.&#xD;Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.&#xD;Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea.&#xD;Laboratory of Immune Regulation, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.&#xD;Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chronic rhinosinusitis endotypes associate with distinct local cytokine milieus that shape the distribution of innate lymphoid cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2246-2250</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/04/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35357717</style></accession-num><notes><style face="normal" font="default" size="100%">Ko, Young Gyun&#xD;Kim, Min Ho&#xD;Park, Joo Yong&#xD;Gil, Chan Hee&#xD;Kim, Tae Soo&#xD;Choi, Ji-Yeob&#xD;Chung, Doo Hyun&#xD;Kim, Hyun Jik&#xD;Kim, Dong Young&#xD;Kim, Hye Young&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2246-2250. doi: 10.1111/all.15300. Epub 2022 Apr 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35357717</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15300</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>67</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">67</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kaplan, A.</style></author><author><style face="normal" font="default" size="100%">Lebwohl, M.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A. M.</style></author><author><style face="normal" font="default" size="100%">Hide, M.</style></author><author><style face="normal" font="default" size="100%">Armstrong, A. W.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.&#xD;Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Dermatology, Hospital del Mar, Institut Mar D&apos;Investigacions Mediques, Universitat Autonoma and Universitat Pompeu Fabra, Barcelona, Spain.&#xD;Department of Dermatology, Hiroshima Citizens Hospital and Department of Dermatology, Hiroshima University, Hiroshima, Japan.&#xD;Department of Dermatology, University of Southern California, Los Angeles, California, USA.&#xD;Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">389-401</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/12/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36448493</style></accession-num><abstract><style face="normal" font="default" size="100%">Chronic spontaneous urticaria (CSU) is a debilitating skin disease characterized by intensely itchy wheals, angioedema, or both. Symptoms recur spontaneously, on a near-daily basis, over &gt;6 weeks; many patients experience flare-ups over several years and, consequently, reduced quality of life. Differences between the inflammatory profiles of the skin of CSU patients (wheals and nonlesional sites) and healthy controls indicate that key drivers such as mast cells, eosinophils, and basophils interact, release vasoactive mediators, and prime the skin, leaving patients predisposed to symptoms. Many cytokines and chemokines involved in these inflammatory networks and their corresponding intracellular signaling cascades have been identified. These insights informed the development of therapies such as omalizumab, dupilumab, and Bruton&apos;s tyrosine kinase (BTK) inhibitors, marking a renewed focus on pathogenesis in CSU clinical research. Despite progress, current therapies provide symptomatic control but do not appear to redress the inflammatory balance in the skin permanently. A deeper understanding of CSU pathogenesis will permit a more targeted approach to developing novel treatments with curative intent. Here, we review what is known about the pathogenesis of CSU and consider how this can be used to identify rational targets to improve patient care further.</style></abstract><notes><style face="normal" font="default" size="100%">Kaplan, Allen&#xD;Lebwohl, Mark&#xD;Gimenez-Arnau, Ana M&#xD;Hide, Michihiro&#xD;Armstrong, April W&#xD;Maurer, Marcus&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):389-401. doi: 10.1111/all.15603. Epub 2022 Dec 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36448493</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15603</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>528</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">528</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Miyake, T.</style></author><author><style face="normal" font="default" size="100%">Egawa, G.</style></author><author><style face="normal" font="default" size="100%">Chow, Z.</style></author><author><style face="normal" font="default" size="100%">Asahina, R.</style></author><author><style face="normal" font="default" size="100%">Otsuka, M.</style></author><author><style face="normal" font="default" size="100%">Nakajima, S.</style></author><author><style face="normal" font="default" size="100%">Nomura, T.</style></author><author><style face="normal" font="default" size="100%">Shibuya, R.</style></author><author><style face="normal" font="default" size="100%">Ishida, Y.</style></author><author><style face="normal" font="default" size="100%">Nakamizo, S.</style></author><author><style face="normal" font="default" size="100%">Murata, T.</style></author><author><style face="normal" font="default" size="100%">Kitoh, A.</style></author><author><style face="normal" font="default" size="100%">Kabashima, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Singapore Immunology Network (SIgN) and Skin Research Institute of Singapore (SRIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Circadian rhythm affects the magnitude of contact hypersensitivity response in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2748-2759</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/04/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Albuterol</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Circadian Rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact</style></keyword><keyword><style face="normal" font="default" size="100%">Dinitrofluorobenzene</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">adrenal hormone</style></keyword><keyword><style face="normal" font="default" size="100%">circadian rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">contact hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35426135</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The circadian rhythm controls multiple biological processes, including immune responses; however, its impact on cutaneous adaptive immune response remains unclear. METHODS: We used a well-established cutaneous type IV allergy model, contact hypersensitivity (CHS). We induced CHS using dinitrofluorobenzene (DNFB). Mice were sensitized and elicited with DNFB in the daytime or at night. RESULTS: In mice, a nocturnally active animal, we found that ear swelling increased when mice were sensitized at night compared with in the daytime. In addition, cell proliferation and cytokine production in the draining lymph nodes (LNs) were promoted when sensitized at night. We hypothesized that these differences were due to the oscillation of leukocyte distribution in the body through the circadian production of adrenergic hormones. Administration of a beta2-adrenergic receptor (beta2AR) agonist salbutamol in the daytime decreased the number of immune cells in blood and increased the number of immune cells in LNs. In contrast, a beta2AR antagonist ICI18551 administration at night increased the number of immune cells in blood and decreased the number of immune cells in LNs. Accordingly, the severity of CHS response was exacerbated by salbutamol administration in the daytime and attenuated by ICI18551 administration at night. CONCLUSION: Our study demonstrated that the magnitude of adaptive CHS response depends on the circadian rhythm and this knowledge may improve the management of allergic contact dermatitis (ACD) in humans.</style></abstract><notes><style face="normal" font="default" size="100%">Miyake, Toshiya&#xD;Egawa, Gyohei&#xD;Chow, Zachary&#xD;Asahina, Ryota&#xD;Otsuka, Masayuki&#xD;Nakajima, Saeko&#xD;Nomura, Takashi&#xD;Shibuya, Rintaro&#xD;Ishida, Yoshihiro&#xD;Nakamizo, Satoshi&#xD;Murata, Teruasa&#xD;Kitoh, Akihiko&#xD;Kabashima, Kenji&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2748-2759. doi: 10.1111/all.15314. Epub 2022 Apr 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35426135</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15314</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>292</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">292</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liang, Q.</style></author><author><style face="normal" font="default" size="100%">Fu, J.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Liu, L.</style></author><author><style face="normal" font="default" size="100%">Xiao, W.</style></author><author><style face="normal" font="default" size="100%">Gao, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Yu, H.</style></author><author><style face="normal" font="default" size="100%">Xie, X.</style></author><author><style face="normal" font="default" size="100%">Tu, Z.</style></author><author><style face="normal" font="default" size="100%">Huang, S.</style></author><author><style face="normal" font="default" size="100%">Han, X.</style></author><author><style face="normal" font="default" size="100%">Qian, L.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pediatrics, Children&apos;s Hospital of Fudan University, National Children&apos;s Medical Center, and the Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.&#xD;National Health Commission (NHC) Key Laboratory of Neonatal Diseases, Fudan University, Shanghai, China.&#xD;Department of General Medicine, Children&apos;s Hospital of Fudan University, Shanghai, China.&#xD;Department of Respiratory Medicine, Children&apos;s Hospital of Fudan University, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">circS100A11 enhances M2a macrophage activation and lung inflammation in children with asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1459-1472</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/09/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Circular</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophage Activation</style></keyword><keyword><style face="normal" font="default" size="100%">RNA/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Cycle Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">S100a11</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">circRNA</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36104951</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dysregulation of circRNAs is associated with a variety of human diseases; however, its role in childhood asthma is undefined. METHODS: The differential expression profiles of circRNAs were analyzed by microarray. The effects and mechanisms by which circRNAs influence macrophage activation were detected by quantitative real-time PCR, RNA immunoprecipitation assay, and chromatin immunoprecipitation assay, among others. The roles of circRNA and its host gene in asthma were tested in a cockroach allergen extract (CRE)-induced murine asthma model. RESULTS: We identified 372 circRNAs that were differentially expressed in PBMCs of children with asthma as compared with healthy controls. A circRNA with unknown function, circS100A11, was dominantly expressed in monocytes and significantly upregulated in children with asthma. circS100A11 facilitated M2a macrophage activation by enhancing translation of its host gene, S100A11, and exacerbated lung inflammation in a CRE-induced murine asthma model with macrophage-specific overexpression of circS100A11. Mechanistically, circS100A11 promoted S100A11 translation by competitively binding to CAPRIN1 to decrease the suppression of CAPRIN1 upon S100A11 translation. Then, S100A11 liberated SP3 from nucleolin and promoted SP3 binding to the STAT6 promoter to enhance STAT6 expression and M2a macrophage activation. Macrophage-specific knockdown of S100A11 could alleviate lung inflammation in a CRE-induced murine asthma model in vivo. CONCLUSIONS: circS100A11 and S100A11 promote M2a macrophage activation and lung inflammation in asthma model and may serve as potential therapeutic and diagnostic targets in children with asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Liang, Qiuyan&#xD;Fu, Jinrong&#xD;Wang, Xiang&#xD;Liu, Lijuan&#xD;Xiao, Wenfeng&#xD;Gao, Yajing&#xD;Yang, Lan&#xD;Yu, Hongmiao&#xD;Xie, Xueru&#xD;Tu, Zikun&#xD;Huang, Saihua&#xD;Han, Xiao&#xD;Qian, Liling&#xD;Zhou, Yufeng&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1459-1472. doi: 10.1111/all.15515. Epub 2022 Sep 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36104951</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15515</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2861</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2861</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fricker, M.</style></author><author><style face="normal" font="default" size="100%">Harrington, J.</style></author><author><style face="normal" font="default" size="100%">Hiles, S. A.</style></author><author><style face="normal" font="default" size="100%">Gibson, P. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.&#xD;Asthma and Breathing Research Program, Hunter Medical Research Institute, Newcastle, New South Wales, Australia.&#xD;Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia.&#xD;School of Psychological Sciences, University of Newcastle, Newcastle, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Circulating Mast Cell Progenitors Are Depleted by Benralizumab in Severe Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1797-1800</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/04/19 22:12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">benralizumab</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">progenitors</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, and Novartis. S.A.H. declares no conflicts of interest. P.G.G.</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees from AstraZeneca, Chiesi, GSK, Novartis, and Sanofi and</style></keyword><keyword><style face="normal" font="default" size="100%">grants from AstraZeneca and GSK.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40251899</style></accession-num><notes><style face="normal" font="default" size="100%">Fricker, Michael&#xD;Harrington, John&#xD;Hiles, Sarah A&#xD;Gibson, Peter G&#xD;eng&#xD;GlaxoSmithKline/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1797-1800. doi: 10.1111/all.16553. Epub 2025 Apr 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40251899</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186583</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16553</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2236</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2236</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alvarado-Vazquez, P. A.</style></author><author><style face="normal" font="default" size="100%">Mendez-Enriquez, E.</style></author><author><style face="normal" font="default" size="100%">Salomonsson, M.</style></author><author><style face="normal" font="default" size="100%">Waern, I.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Wernersson, S.</style></author><author><style face="normal" font="default" size="100%">Malinovschi, A.</style></author><author><style face="normal" font="default" size="100%">Hallgren, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.&#xD;Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden.&#xD;Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Circulating mast cell progenitors increase during natural birch pollen exposure in allergic asthma patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2959-2968</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/08/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Betula</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Betula</style></keyword><keyword><style face="normal" font="default" size="100%">FcepsilonRI</style></keyword><keyword><style face="normal" font="default" size="100%">asthma control</style></keyword><keyword><style face="normal" font="default" size="100%">asthma symptoms</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37615432</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Mast cells (MCs) develop from a rare population of peripheral blood circulating MC progenitors (MCps). Here, we investigated whether the frequency of circulating MCps is altered in asthma patients sensitized to birch pollen during pollen season, compared to out of season. METHODS: Asthma patients were examined during birch pollen season in late April to early June (May), and out of season in November-January. Spirometry measurements, asthma and allergy-related symptoms, asthma control questionnaire (ACQ), and asthma control test (ACT) scores were assessed at both time points. The MCp frequency was determined by flow cytometry in ficoll-separated blood samples from patients with positive birch pollen-specific IgE, and analyzed in relation to basic and disease parameters. RESULTS: The frequency of MCps per liter of blood was higher in May than in November (p = .004), particularly in women (p = .009). Patients that reported moderate to severe asthma symptoms (&lt;.0001), nose or eye symptoms (p = .02; p = .01), or reduced asthma control (higher ACQ, p = .01) had higher MCp frequency in May than those that did not report this. These associations remained significant after adjusting for sex and BMI. The change in asthma control to a lower ACT score in May correlated with an increase in MCp frequency in May (p = .006, rho = 0.46). CONCLUSIONS: The data suggest that the frequency of MCps increases in symptomatic patients with allergic asthma. Our results unravel a link between asthma symptoms and circulating MCps, and bring new insight into the impact of natural allergen exposure on the expansion of MCs.</style></abstract><notes><style face="normal" font="default" size="100%">Alvarado-Vazquez, P Abigail&#xD;Mendez-Enriquez, Erika&#xD;Salomonsson, Maya&#xD;Waern, Ida&#xD;Janson, Christer&#xD;Wernersson, Sara&#xD;Malinovschi, Andrei&#xD;Hallgren, Jenny&#xD;eng&#xD;Astma- och Allergiforbundet/&#xD;Hans von Kantzows Stiftelse/&#xD;20200625/Hjart-Lungfonden/&#xD;20170479/Hjart-Lungfonden/&#xD;Cancer- och Allergifonden/&#xD;2017.0022/Knut och Alice Wallenbergs Stiftelse/&#xD;Konsul Th C Berghs Stiftelse/&#xD;Svenska Foreningen for Allergologi/&#xD;2016-00803/Vetenskapsradet/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2959-2968. doi: 10.1111/all.15860. Epub 2023 Aug 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37615432</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15860</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1390</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1390</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hirai, K.</style></author><author><style face="normal" font="default" size="100%">Shirai, T.</style></author><author><style face="normal" font="default" size="100%">Shimoshikiryo, T.</style></author><author><style face="normal" font="default" size="100%">Ueda, M.</style></author><author><style face="normal" font="default" size="100%">Gon, Y.</style></author><author><style face="normal" font="default" size="100%">Maruoka, S.</style></author><author><style face="normal" font="default" size="100%">Itoh, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Pharmacology &amp; Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.&#xD;Laboratory of Clinical Pharmacogenomics, Shizuoka General Hospital, Shizuoka, Japan.&#xD;Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.&#xD;Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Circulating microRNA-15b-5p as a biomarker for asthma-COPD overlap</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">766-774</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Circulating MicroRNA</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma-COPD overlap</style></keyword><keyword><style face="normal" font="default" size="100%">chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default" size="100%">miR-15b-5p</style></keyword><keyword><style face="normal" font="default" size="100%">microRNA</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32713026</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: It remains unclear how to characterize different subtypes of asthma and chronic obstructive pulmonary disease (COPD). We previously described serum periostin and chitinase-3-like protein 1 (YKL-40) as useful markers for asthma-COPD overlap (ACO). MicroRNAs (miRNAs) are now recognized as markers for identifying the pathophysiological features in several diseases. This study aimed to identify circulating miRNAs that could discriminate patients with ACO from patients with asthma or COPD. METHODS: This study included two independent cohorts. First, we screened 84 miRNAs for expression levels in patients with ACO (n = 6) or asthma (n = 6) using a quantitative real-time PCR array. The miRNAs showing at least a 2-fold difference in the discovery phase were analyzed in 30 patients each with asthma, COPD, or ACO in the replication phase. The diagnostic accuracy was evaluated using the area under the receiver operating characteristic curve (AUROC). RESULTS: Nine miRNAs were identified in the discovery phase. Five of these miRNAs (miR-148a-3p, miR-15b-5p, miR-223-3p, miR-23a-3p, and miR-26b-5p) had lower levels in ACO patients and could discriminate between ACO patients and patients with either asthma or COPD. miR-15b-5p was the most accurate miRNA for the discrimination of patients with ACO (AUROC, 0.71). Moreover, the combined assessment of miR-15b-5p, serum periostin, and YKL-40 (AUROC, 0.80) improved diagnostic accuracy for ACO compared with the combined model of periostin and YKL-40 (AUROC, 0.69). CONCLUSIONS: Circulating miR-15b-5p is a potential marker for identifying patients with ACO. By elucidating the molecular pathways controlled by miRNAs, we may better understand the pathophysiology of ACO.</style></abstract><notes><style face="normal" font="default" size="100%">Hirai, Keita&#xD;Shirai, Toshihiro&#xD;Shimoshikiryo, Takayuki&#xD;Ueda, Megumi&#xD;Gon, Yasuhiro&#xD;Maruoka, Shuichiro&#xD;Itoh, Kunihiko&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):766-774. doi: 10.1111/all.14520. Epub 2020 Aug 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32713026</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14520</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2784</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2784</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Freeman, A.</style></author><author><style face="normal" font="default" size="100%">Minnion, M.</style></author><author><style face="normal" font="default" size="100%">Lee, P. H.</style></author><author><style face="normal" font="default" size="100%">Haitchi, H. M.</style></author><author><style face="normal" font="default" size="100%">Kurukulaaratchy, R.</style></author><author><style face="normal" font="default" size="100%">Wilkinson, T.</style></author><author><style face="normal" font="default" size="100%">Feelisch, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.&#xD;The David Hide Asthma &amp; Allergy Research Centre, St Mary&apos;s Hospital, Newport, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Circulating Nitrite in Severe Asthma: Just Another Biomarker or Novel Treatment Target?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1146-1149</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/19</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39698749</style></accession-num><notes><style face="normal" font="default" size="100%">Freeman, Anna&#xD;Minnion, Magdalena&#xD;Lee, Paul H&#xD;Haitchi, Hans Michael&#xD;Kurukulaaratchy, Ramesh&#xD;Wilkinson, Tom&#xD;Feelisch, Martin&#xD;eng&#xD;University Hospital Southampton NHS Foundation Trust/&#xD;National Institute for Health Research Southampton Biomedical Research Centre/&#xD;Novartis/&#xD;AAIR Charity/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1146-1149. doi: 10.1111/all.16435. Epub 2024 Dec 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39698749</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969320</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16435</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3234</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3234</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ma, Y.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Ye, L.</style></author><author><style face="normal" font="default" size="100%">Qiu, L.</style></author><author><style face="normal" font="default" size="100%">Wu, J.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Feng, X.</style></author><author><style face="normal" font="default" size="100%">Qian, W.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Lou, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, P.R. China.&#xD;Clinical Research Center, Eye &amp; ENT Hospital, Fudan University, Shanghai, P.R. China.&#xD;Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, P.R. China.&#xD;The Second Affiliated Hospital, Guangdong Key Provincial Laboratory of Allergy &amp; Clinical Immunology, Guangzhou Medical University, Guangdong, P.R. China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Circulating Type 2 Memory B Cell Frequency Is a Biomarker for Allergen Immunotherapy Efficacy in Patients With Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword><keyword><style face="normal" font="default" size="100%">interleukins</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41549585</style></accession-num><notes><style face="normal" font="default" size="100%">Ma, Yue&#xD;Li, Shuying&#xD;Ye, Lei&#xD;Qiu, Lin&#xD;Wu, Jiayu&#xD;Li, Jiaying&#xD;Feng, Xian&#xD;Qian, Wei&#xD;Yang, Xiangping&#xD;Li, Huabin&#xD;Lou, Hongfei&#xD;eng&#xD;82271139/National Natural Science Foundation of China/&#xD;82271138/National Natural Science Foundation of China/&#xD;82000955/National Natural Science Foundation of China/&#xD;82521001/National Natural Science Foundation of China/&#xD;2022YFC2504100/National Key Research and Development Program of China/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan 18. doi: 10.1111/all.70221.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41549585</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70221</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2198</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2198</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nicolas, L. S. S.</style></author><author><style face="normal" font="default" size="100%">Czarnowicki, T.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Pujol, R. M.</style></author><author><style face="normal" font="default" size="100%">Lozano-Ojalvo, D.</style></author><author><style face="normal" font="default" size="100%">Leung, D. Y. M.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Santamaria-Babi, L. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunologia Translacional, Departament de Biologia Cel.lular, Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona (UB), Parc Cientific de Barcelona (PCB), Barcelona, Spain.&#xD;Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos-Wolfgang, Switzerland.&#xD;Departament de Dermatologia, Hospital del Mar, Institut Hospital del Mar d&apos;Investigacions Mediques (IMIM), Universitat Autonoma de Barcelona (UAB), Barcelona, Spain.&#xD;Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Pediatrics, National Jewish Health, Denver, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CLA+ memory T cells in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">15-25</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/07/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Memory T Cells</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocyte Subsets</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Differentiation, T-Lymphocyte</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Glycoproteins</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Lymphocyte Homing</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">CLA+ T cells</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">skin-homing</style></keyword><keyword><style face="normal" font="default" size="100%">translational</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37439317</style></accession-num><abstract><style face="normal" font="default" size="100%">Circulating skin-homing cutaneous lymphocyte-associated antigen (CLA)(+) T cells constitute a small subset of human memory T cells involved in several aspects of atopic dermatitis: Staphylococcus aureus related mechanisms, the abnormal Th2 immune response, biomarkers, clinical aspects of the patients, pruritus, and the mechanism of action of targeted therapies. Superantigens, IL-13, IL-31, pruritus, CCL17 and early effects on dupilumab-treated patients have in common that they are associated with the CLA(+) T cell mechanisms in atopic dermatitis patients. The function of CLA(+) T cells corresponds with the role of T cells belonging to the skin-associated lymphoid tissue and could be a reason why they reflect different mechanisms of atopic dermatitis and many other T cell mediated skin diseases. The goal of this review is to gather all this translational information of atopic dermatitis pathology.</style></abstract><notes><style face="normal" font="default" size="100%">Nicolas, Lidia Sans-de San&#xD;Czarnowicki, Tali&#xD;Akdis, Mubeccel&#xD;Pujol, Ramon M&#xD;Lozano-Ojalvo, Daniel&#xD;Leung, Donald Y M&#xD;Guttman-Yassky, Emma&#xD;Santamaria-Babi, Luis F&#xD;eng&#xD;European Regional Development Fund/&#xD;Instituto de Salud Carlos III/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):15-25. doi: 10.1111/all.15816. Epub 2023 Jul 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37439317</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15816</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2738</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2738</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Iijima, A.</style></author><author><style face="normal" font="default" size="100%">Matsuda, K.</style></author><author><style face="normal" font="default" size="100%">Yamasaki, S.</style></author><author><style face="normal" font="default" size="100%">Shibuya, K.</style></author><author><style face="normal" font="default" size="100%">Shibuya, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.&#xD;Ph.D. Program in Human Biology, University of Tsukuba, Tsukuba, Ibaraki, Japan.&#xD;Life Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance, University of Tsukuba, Tsukuba, Ibaraki, Japan.&#xD;R&amp;D Center for Innovative Drug Discovery, University of Tsukuba, Tsukuba, Ibaraki, Japan.&#xD;Department of Cell Immunology, Research Institute for Microbial Diseases, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clec12b Alleviates Mite-Induced Dermatitis by Regulating P2RX7-Mediated Mast Cell Activation in Mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">625-628</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/11/28</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39606881</style></accession-num><notes><style face="normal" font="default" size="100%">Iijima, Ayana&#xD;Matsuda, Kenshiro&#xD;Yamasaki, Sho&#xD;Shibuya, Kazuko&#xD;Shibuya, Akira&#xD;eng&#xD;Takeda Foundation/&#xD;Japan Society for the Promotion of Science/&#xD;Ministry of Education, Culture, Sports, Science and Technology/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):625-628. doi: 10.1111/all.16401. Epub 2024 Nov 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39606881</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16401</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>634</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">634</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Sampath, V.</style></author><author><style face="normal" font="default" size="100%">Aguilera, J.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Barry, M.</style></author><author><style face="normal" font="default" size="100%">Bouagnon, A.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, S.</style></author><author><style face="normal" font="default" size="100%">Collins, W.</style></author><author><style face="normal" font="default" size="100%">Dulitzki, C.</style></author><author><style face="normal" font="default" size="100%">Erny, B.</style></author><author><style face="normal" font="default" size="100%">Gomez, J.</style></author><author><style face="normal" font="default" size="100%">Goshua, A.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Kizer, K. W.</style></author><author><style face="normal" font="default" size="100%">Kline, O.</style></author><author><style face="normal" font="default" size="100%">LaBeaud, A. D.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Perrett, K. P.</style></author><author><style face="normal" font="default" size="100%">Peters, R. L.</style></author><author><style face="normal" font="default" size="100%">Plaza, M. P.</style></author><author><style face="normal" font="default" size="100%">Prunicki, M.</style></author><author><style face="normal" font="default" size="100%">Sack, T.</style></author><author><style face="normal" font="default" size="100%">Salas, R. N.</style></author><author><style face="normal" font="default" size="100%">Sindher, S. B.</style></author><author><style face="normal" font="default" size="100%">Sokolow, S. H.</style></author><author><style face="normal" font="default" size="100%">Thiel, C.</style></author><author><style face="normal" font="default" size="100%">Veidis, E.</style></author><author><style face="normal" font="default" size="100%">Wray, B. D.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Witt, C.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, California, USA.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Center for Innovation in Global Health, Stanford University, Stanford, California, USA.&#xD;Department of Physiology, University of California San Francisco, San Francisco, California, USA.&#xD;Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, California, USA.&#xD;Division of Hospital Medicine, Stanford University, Stanford, California, USA.&#xD;Department of Internal Medicine, Division of Med/Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA.&#xD;Stanford School of Medicine, Stanford, California, USA.&#xD;Stanford Graduate School of Business, Stanford, California, USA.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;&quot;ALL-MED&quot; Medical Research Institute, Wroclaw, Poland.&#xD;Atlas Research, LLC, Washington, District of Columbia, USA.&#xD;Department of Pediatrics, Division of Infectious Disease, Stanford University, Stanford, California, USA.&#xD;Comparative Medicine, Interuniversity Messerli Research Institute, University of Veterinary Medicine/Medical University/University Vienna, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Immunology and Infectiology, Medical University of Vienna, Vienna, Austria.&#xD;Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;Department of Pediatrics, University of Melbourne, Parkville, Victoria, Australia.&#xD;Royal Children&apos;s Hospital, Parkville, Victoria, Australia.&#xD;Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Center Munich, German Research Center for Environmental Health, Augsburg, Germany.&#xD;My Green Doctor Foundation, Jacksonville, Florida, USA.&#xD;Harvard Global Health Institute, Cambridge, Massachusetts, USA.&#xD;Center for Climate, Health, and the Global Environment, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Woods Institute for the Environment, Stanford University, Stanford, California, USA.&#xD;Marine Science Institute, University of California Santa Barbara, Santa Barbara, California, USA.&#xD;Department of Population Health, NYU Grossman School of Medicine, NY, USA.&#xD;London School of Hygiene and Tropical Medicine Centre on Climate Change and Planetary Health, London, UK.&#xD;Christine Kuhne Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Institute of Physiology, Division of Pneumology, Charite-Universitatsmedizin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Climate change and global health: A call to more research and more action</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1389-1407</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/01/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Climate Change</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Pollution</style></keyword><keyword><style face="normal" font="default" size="100%">*Global Health</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">climate change</style></keyword><keyword><style face="normal" font="default" size="100%">greenhouse gases</style></keyword><keyword><style face="normal" font="default" size="100%">health</style></keyword><keyword><style face="normal" font="default" size="100%">pollution</style></keyword><keyword><style face="normal" font="default" size="100%">Genentech, Takeda, and Chiesi</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Stallergenesm Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">and Chiesi</style></keyword><keyword><style face="normal" font="default" size="100%">Payment or honoraria from Stallergenesm Allergopharma, and ALK</style></keyword><keyword><style face="normal" font="default" size="100%">Participated on DSMB or Advisory board for Stallergenesm and Allergopharma</style></keyword><keyword><style face="normal" font="default" size="100%">president of EAACI</style></keyword><keyword><style face="normal" font="default" size="100%">Unrelated to this publication, Dr. Thiel is a paid consultant</style></keyword><keyword><style face="normal" font="default" size="100%">for Becton Dickenson, a paid advisor to The Sean N. Parker Center for Allergy and</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma Research at Stanford University, an unpaid member of the Mass General</style></keyword><keyword><style face="normal" font="default" size="100%">Center for Climate and Health advisory board, a member of the advisory board for</style></keyword><keyword><style face="normal" font="default" size="100%">Zabble, Inc. for which she has received stock options and a paid consultant for</style></keyword><keyword><style face="normal" font="default" size="100%">the Stryker Corporation and received honoraria for lectures hosted by 3M. All</style></keyword><keyword><style face="normal" font="default" size="100%">other authors indicate no conflict of interest. Dr Cezmi Akdis reports research</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine</style></keyword><keyword><style face="normal" font="default" size="100%">Kuhne-Center for Allergy Research and Education, European Commission&apos;s Horison&apos;s</style></keyword><keyword><style face="normal" font="default" size="100%">2020 Framework Programme &quot;Cure&quot;, Novartis Research Institutes, Astra Zeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">research grants and advisory board from Glaxo Smith-Kline, Sanofi/Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">Scibase, Novartis, and is Editor-in-Chief of Allergy. Dr. Agache is Associate</style></keyword><keyword><style face="normal" font="default" size="100%">Editor of Allergy. All other authors report no COI.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35073410</style></accession-num><abstract><style face="normal" font="default" size="100%">There is increasing understanding, globally, that climate change and increased pollution will have a profound and mostly harmful effect on human health. This review brings together international experts to describe both the direct (such as heat waves) and indirect (such as vector-borne disease incidence) health impacts of climate change. These impacts vary depending on vulnerability (i.e., existing diseases) and the international, economic, political, and environmental context. This unique review also expands on these issues to address a third category of potential longer-term impacts on global health: famine, population dislocation, and environmental justice and education. This scholarly resource explores these issues fully, linking them to global health in urban and rural settings in developed and developing countries. The review finishes with a practical discussion of action that health professionals around the world in our field can yet take.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Sampath, Vanitha&#xD;Aguilera, Juan&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Barry, Michele&#xD;Bouagnon, Aude&#xD;Chinthrajah, Sharon&#xD;Collins, William&#xD;Dulitzki, Coby&#xD;Erny, Barbara&#xD;Gomez, Jason&#xD;Goshua, Anna&#xD;Jutel, Marek&#xD;Kizer, Kenneth W&#xD;Kline, Olivia&#xD;LaBeaud, A Desiree&#xD;Pali-Scholl, Isabella&#xD;Perrett, Kirsten P&#xD;Peters, Rachel L&#xD;Plaza, Maria Pilar&#xD;Prunicki, Mary&#xD;Sack, Todd&#xD;Salas, Renee N&#xD;Sindher, Sayantani B&#xD;Sokolow, Susanne H&#xD;Thiel, Cassandra&#xD;Veidis, Erika&#xD;Wray, Brittany Delmoro&#xD;Traidl-Hoffmann, Claudia&#xD;Witt, Christian&#xD;Nadeau, Kari C&#xD;eng&#xD;P01 HL152953/HL/NHLBI NIH HHS/&#xD;R01 ES032253/ES/NIEHS NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1389-1407. doi: 10.1111/all.15229. Epub 2022 Feb 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35073410</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12039856</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15229</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2255</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2255</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Climate change and the epithelial barrier theory in allergic diseases: A One Health approach to a green environment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2829-2834</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/09/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">chronic noncommunicable diseases</style></keyword><keyword><style face="normal" font="default" size="100%">climate change</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barriers</style></keyword><keyword><style face="normal" font="default" size="100%">global warming</style></keyword><keyword><style face="normal" font="default" size="100%">microbial biodiversity</style></keyword><keyword><style face="normal" font="default" size="100%">one health</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37675628</style></accession-num><notes><style face="normal" font="default" size="100%">Pawankar, Ruby&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2829-2834. doi: 10.1111/all.15885. Epub 2023 Sep 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37675628</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15885</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3191</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Augustin, J.</style></author><author><style face="normal" font="default" size="100%">Gilge, S.</style></author><author><style face="normal" font="default" size="100%">Appel, H.</style></author><author><style face="normal" font="default" size="100%">Dauert, U.</style></author><author><style face="normal" font="default" size="100%">Endler, C.</style></author><author><style face="normal" font="default" size="100%">Heesen, R.</style></author><author><style face="normal" font="default" size="100%">Hoflich, C.</style></author><author><style face="normal" font="default" size="100%">Kuttler, W.</style></author><author><style face="normal" font="default" size="100%">Schlunzen, K. H.</style></author><author><style face="normal" font="default" size="100%">Straff, W.</style></author><author><style face="normal" font="default" size="100%">Werchan, B.</style></author><author><style face="normal" font="default" size="100%">Werchan, M.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.&#xD;German Meteorological Service, Climate and Environment Division, Research Center Human Biometeorology, Freiburg, Germany.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Ulm University Medical Center (UKU), Ulm, Germany.&#xD;Section II 4.2, Air Quality Assessment, German Environment Agency, Dessau-Rosslau, Germany.&#xD;VDI - The Association of German Engineers, VDI/DIN-Commission on Air Pollution Prevention (KRdL) - Standards Committee, Dusseldorf, Germany.&#xD;Section II 1.5 Environmental Medicine and Health Effects Assessment, German Environment Agency, Berlin, Germany.&#xD;Faculty of Biology, Applied Climatology and Landscape Ecology, University of Duisburg-Essen, Essen, Germany.&#xD;Meteorological Institute, University of Hamburg, Hamburg, Germany.&#xD;German Pollen Information Service Foundation (PID), Berlin, Germany.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Environmental Health Center, Helmholtz Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Climate Change, Air Quality, and Pollen Allergies-State of the Art and Recommendations for Research and Public Health</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">airborne pollen</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">meteorology</style></keyword><keyword><style face="normal" font="default" size="100%">policy</style></keyword><keyword><style face="normal" font="default" size="100%">stakeholder</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 20</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41420513</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergies are one of the major health challenges of our time, associated with a high individual burden of disease and high costs for the healthcare system. Given their prevalence, allergies are also highly relevant from a public health perspective. The development of allergic diseases is multifactorial. In addition to individual factors (e.g., genetic predisposition), environmental factors are particularly important. These include climate (including climate change), weather, and air pollution, which affect the biosphere and biodiversity. Pollen-associated allergic rhinitis is one of the most common allergies. Airborne pollen is strongly connected with climate (change) and air pollution. For example, interannual climate variability and climate change affect phenology, pollen production, and pollen transport, and air pollutants affect pollen allergenicity. Climate change also affects air quality as meteorological conditions influence relevant processes such as the emission, transport, chemistry, and deposition of air pollutants, which affect the occurrence, intensity, and duration of allergy symptoms. The aims of this position paper are: (a) to provide an overview of the current state of scientific knowledge on the effects of climate change and air quality on pollen allergies, (b) to discuss conflicting objectives in the fight against pollen allergies, and (c) to provide recommendations for policy makers, health professionals, public health measures, and future research.</style></abstract><notes><style face="normal" font="default" size="100%">Augustin, Jobst&#xD;Gilge, Stefan&#xD;Appel, Heike&#xD;Dauert, Ute&#xD;Endler, Christina&#xD;Heesen, Ruth&#xD;Hoflich, Conny&#xD;Kuttler, Wilhelm&#xD;Schlunzen, Katharina Heinke&#xD;Straff, Wolfgang&#xD;Werchan, Barbora&#xD;Werchan, Matthias&#xD;Zuberbier, Torsten&#xD;Traidl-Hoffmann, Claudia&#xD;eng&#xD;Universitatsklinikum Hamburg-Eppendorf/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Dec 20. doi: 10.1111/all.70159.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41420513</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70159</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>829</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">829</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Annesi Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Sampath, V.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy and Asthma Research at Stanford University and Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, California, USA.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;All-MED Medical Research Institute, Wroclaw, Poland.&#xD;Desbrest Institute of Epidemiology and Public Health, INSERM, and Montpellier University, Montpellier, France.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Division of Respiratory and Allergic Diseases, Department of Chest Diseases, High Specialty A, Cardarelli Hospital, and Medical School of Specialization in Respiratory Diseases, University of Naples Federico II, Naples, Italy.&#xD;Centre of Bioclimatology, University of Florence, Florence, Italy.&#xD;Department of Environmental Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Center Munich - German Research Center for Environmental Health, Augsburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Climate change: A call to action for the United Nations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1087-1090</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/09/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Climate Change</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*United Nations</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34476822</style></accession-num><notes><style face="normal" font="default" size="100%">Nadeau, Kari C&#xD;Agache, Ioana&#xD;Jutel, Marek&#xD;Annesi Maesano, Isabella&#xD;Akdis, Mubeccel&#xD;Sampath, Vanitha&#xD;D&apos;Amato, Gennaro&#xD;Cecchi, Lorenzo&#xD;Traidl-Hoffmann, Claudia&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1087-1090. doi: 10.1111/all.15079. Epub 2021 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34476822</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15079</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2450</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Orasche, J.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Schuster, A.</style></author><author><style face="normal" font="default" size="100%">Rockstrom, J.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Mountain View, California, USA.&#xD;Potsdam Institute for Climate Impact Research, Potsdam, Germany.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Climate crisis paralysis: Accelerating global action for health resilience in a changing world</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1653-1655</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/03/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Climate Change</style></keyword><keyword><style face="normal" font="default" size="100%">*Global Health</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38436208</style></accession-num><notes><style face="normal" font="default" size="100%">Orasche, Jurgen&#xD;Nadeau, Kari C&#xD;Schuster, Antonia&#xD;Rockstrom, Johan&#xD;Akdis, Cezmi A&#xD;Traidl-Hoffmann, Claudia&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1653-1655. doi: 10.1111/all.16096. Epub 2024 Mar 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38436208</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16096</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2917</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2917</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gates, J.</style></author><author><style face="normal" font="default" size="100%">Haris, F.</style></author><author><style face="normal" font="default" size="100%">Cefaloni, F.</style></author><author><style face="normal" font="default" size="100%">Khooshemehri, P.</style></author><author><style face="normal" font="default" size="100%">Green, L.</style></author><author><style face="normal" font="default" size="100%">Fernandes, M.</style></author><author><style face="normal" font="default" size="100%">Thomson, L.</style></author><author><style face="normal" font="default" size="100%">Roxas, C.</style></author><author><style face="normal" font="default" size="100%">Lam, J.</style></author><author><style face="normal" font="default" size="100%">d&apos;Ancona, G.</style></author><author><style face="normal" font="default" size="100%">Nanzer, A. M.</style></author><author><style face="normal" font="default" size="100%">Dhariwal, J.</style></author><author><style face="normal" font="default" size="100%">Jackson, D. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Guy&apos;s Severe Asthma Centre, Guy&apos;s and St Thomas&apos; NHS Trust, London, UK.&#xD;School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical and Biological Remission With Tezepelumab: The Real-World Response in Severe Uncontrolled Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1669-1676</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/05/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Remission Induction</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">Zeneca and Sanofi. A.M.N. reports payment or honoraria for lectures and</style></keyword><keyword><style face="normal" font="default" size="100%">educational events from Astra Zeneca, Glaxo Smith Kline, and Sanofi and support</style></keyword><keyword><style face="normal" font="default" size="100%">for attending conferences from Astra Zeneca, Chiesi, and Napp. L.T. reports</style></keyword><keyword><style face="normal" font="default" size="100%">payment or honoraria for lectures and educational events and travel support from</style></keyword><keyword><style face="normal" font="default" size="100%">Astra Zeneca and Teva. GdA reports advisory board work for, been engaged to</style></keyword><keyword><style face="normal" font="default" size="100%">provide training to HCPs on behalf of, received research grants from, and/or been</style></keyword><keyword><style face="normal" font="default" size="100%">sponsored to attend an educational meeting by: AstraZeneca, Boehringer-Ingleheim,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, GlaxoSmithKline, NAPP, Novartis, Pfizer, Sanofi, Teva. J.D. reports</style></keyword><keyword><style face="normal" font="default" size="100%">support to attend conferences from Sanofi. C.R. reports honoraria for lectures</style></keyword><keyword><style face="normal" font="default" size="100%">and conference support from Astra Zeneca. D.J.J. reports research grants to the</style></keyword><keyword><style face="normal" font="default" size="100%">department from Astra Zeneca, consulting fees from Astra Zeneca, GSK, and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, payments or honoraria for lectures and educational events from Astra</style></keyword><keyword><style face="normal" font="default" size="100%">Zeneca, GSK, and Sanofi.FC is a recipient of the European Academy of Allergy and</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Immunology (EAACI) Research Fellowship 2024 and has received honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">from Astra Zeneca, GSK, Sanofi, Chiesi, and Doxa Pharma. L.G., M.F., J.L.L.,</style></keyword><keyword><style face="normal" font="default" size="100%">T.M., F.H., and P.K. report no COI.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40365686</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Tezepelumab is an anti-TSLP monoclonal antibody approved for the treatment of severe asthma. It has broad downstream anti-T2 effects, offering the prospect of biological remission. Real-world data on clinical remission rates with tezepelumab is lacking, and the relationship between clinical and biological remission is unclear. Finally, the effectiveness of tezepelumab in patients who have failed to respond to existing biologic therapies is unknown. METHODS: Clinical and biomarker data from adults with severe asthma treated with tezepelumab in a real-world setting was analyzed. Clinical outcome measures including clinical remission were recorded along with rates of biological remission (defined as blood eosinophil count &lt; 300 cells/mcL and FeNO &lt; 25 ppb). RESULTS: One hundred seventy-five patients were included. 98/175 (56%) had switched from another biologic. Following tezepelumab initiation, the exacerbation rate decreased from 3.1 (2.5) to 0.8 (1.4), with 59% of patients remaining exacerbation-free at 1 year. 54% achieved an ACQ score &lt; 1.5. Clinical remission at 1 year was observed in 36%, with a rate of 55% in T2-high patients versus 19% in T2 low patients. The clinical response in biologic-naive and biologic switch patients was similar. FeNO declined from 41 ppb (24-76) to 24 ppb (16-38) and BEC fell from 300 cells/muL (60-610) to 180 cells/muL (105-320) (both p &lt; 0.001). 38% achieved biological remission. 15% attained both clinical and biological remission. CONCLUSION: Tezepelumab led to substantial clinical improvements and clinical remission in up to 55% of T2-high patients with severe asthma. A disconnect between clinical and biological remission was observed. The long-term significance of residual T2 inflammation on tezepelumab is unknown.</style></abstract><notes><style face="normal" font="default" size="100%">Gates, Jessica&#xD;Haris, Faizan&#xD;Cefaloni, Francesca&#xD;Khooshemehri, Paniz&#xD;Green, Linda&#xD;Fernandes, Mariana&#xD;Thomson, Louise&#xD;Roxas, Cris&#xD;Lam, Jodie&#xD;d&apos;Ancona, Grainne&#xD;Nanzer, Alexandra M&#xD;Dhariwal, Jaideep&#xD;Jackson, David J&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1669-1676. doi: 10.1111/all.16590. Epub 2025 May 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40365686</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186586</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16590</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>871</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">871</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hashimura, C.</style></author><author><style face="normal" font="default" size="100%">Kiyohara, C.</style></author><author><style face="normal" font="default" size="100%">Fukushi, J. I.</style></author><author><style face="normal" font="default" size="100%">Hirose, T.</style></author><author><style face="normal" font="default" size="100%">Ohsawa, I.</style></author><author><style face="normal" font="default" size="100%">Tahira, T.</style></author><author><style face="normal" font="default" size="100%">Horiuchi, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.&#xD;Center for Research, Education, and Treatment of angioEdema, a specified Non-profit Corporation, Fukuoka, Japan.&#xD;Department of Preventive Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.&#xD;Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.&#xD;Department of Nephrology, Internal Medicine, Saiyu Soka Hospital, Saitama, Japan.&#xD;College of Pharmacy, Kinjo Gakuin University, Nagoya, Japan.&#xD;Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical and genetic features of hereditary angioedema with and without C1-inhibitor (C1-INH) deficiency in Japan</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3529-3534</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/08/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Factor XII</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Japan/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Japanese</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema with normal C1-inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">plasminogen</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr. Fukushi has nothing to disclose. Dr. Hirose is a consultant for</style></keyword><keyword><style face="normal" font="default" size="100%">Takeda Pharmaceutical Company (without salary). Dr. Ohsawa reports personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Takeda Pharmaceutical Company, personal fees from CSL Behring, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Torii Pharmaceutical Company, personal fees from BioCryst Pharmaceuticals,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. Dr. Tahira has nothing to disclose. Dr. Horiuchi</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees from Takeda Pharmaceutical Company, personal fees from CSL</style></keyword><keyword><style face="normal" font="default" size="100%">Behring, personal fees from Torii Pharmaceutical Company, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34343365</style></accession-num><notes><style face="normal" font="default" size="100%">Hashimura, Chinami&#xD;Kiyohara, Chikako&#xD;Fukushi, Jun-Ichi&#xD;Hirose, Tomoya&#xD;Ohsawa, Isao&#xD;Tahira, Tomoko&#xD;Horiuchi, Takahiko&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3529-3534. doi: 10.1111/all.15034. Epub 2021 Aug 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34343365</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9291306</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15034</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>268</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">268</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Binder, A. M.</style></author><author><style face="normal" font="default" size="100%">Cherry-Brown, D.</style></author><author><style face="normal" font="default" size="100%">Biggerstaff, B. J.</style></author><author><style face="normal" font="default" size="100%">Jones, E. S.</style></author><author><style face="normal" font="default" size="100%">Amelio, C. L.</style></author><author><style face="normal" font="default" size="100%">Beard, C. B.</style></author><author><style face="normal" font="default" size="100%">Petersen, L. R.</style></author><author><style face="normal" font="default" size="100%">Kersh, G. J.</style></author><author><style face="normal" font="default" size="100%">Commins, S. P.</style></author><author><style face="normal" font="default" size="100%">Armstrong, P. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.&#xD;University of North Carolina, Chapel Hill, North Carolina, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical and laboratory features of patients diagnosed with alpha-gal syndrome-2010-2019</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">477-487</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Tick Bites/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Galactose</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-gal syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="default" size="100%">red meat allergy</style></keyword><keyword><style face="normal" font="default" size="100%">tick bite</style></keyword><keyword><style face="normal" font="default" size="100%">Cherry-Brown, Brad J. Biggerstaff, Emma S. Jones, Claire L. Amelio, Charles B.</style></keyword><keyword><style face="normal" font="default" size="100%">Beard, Lyle R. Petersen, Gilbert J. Kersh, and Paige A. Armstrong report no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36178236</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Alpha-gal syndrome (AGS) is an IgE-mediated allergy to galactose-alpha-1,3-galactose. Clinical presentation ranges from hives to anaphylaxis; episodes typically occur 2-6 h after exposure to alpha-gal-containing products. In the United States, lone star tick bites are associated with the development of AGS. To characterize features of AGS, we evaluated a cohort of patients presenting for care at the University of North Carolina, focusing on symptoms, severity, and identifying features unique to specific alpha-gal-containing product exposures. METHODS: We performed a chart review and descriptive analysis of 100 randomly selected patients with AGS during 2010-2019. RESULTS: Median age at onset was 53 years, 56% were female, 95% reported White race, 86% reported a history of tick bite, and 75% met the criteria for anaphylaxis based on the involvement of &gt;/=2 organ systems. Those reporting dairy reactions were significantly less likely to report isolated mucocutaneous symptoms (3% vs. 24%; ratio [95% CI]: 0.1 [0.1, 0.3]) than those who tolerated dairy, and were more likely to report gastrointestinal symptoms (79% vs. 59%; ratio [95% CI]: 1.3 [0.7, 2.6]), although this difference was not statistically significant. Dairy-tolerant patients demonstrated higher alpha-gal sIgE titers (as a percentage of total IgE) than dairy-reactive patients (GM 4.1 [95% CI: 2.7, 6.1] vs. GM 2.5 [95% CI: 1.3, 4.8], respectively; ratio -1.6 [95% CI: -1.0, 3.9]). CONCLUSION: While tick exposure is common in the southern United States, nearly all AGS patients reported a tick bite. Gastrointestinal symptoms were prominent among those reporting reactions to dairy. Anaphylaxis was common, underscoring the severity and need to raise awareness of AGS among patients and providers.</style></abstract><notes><style face="normal" font="default" size="100%">Binder, Alison M&#xD;Cherry-Brown, Dena&#xD;Biggerstaff, Brad J&#xD;Jones, Emma S&#xD;Amelio, Claire L&#xD;Beard, Charles B&#xD;Petersen, Lyle R&#xD;Kersh, Gilbert J&#xD;Commins, Scott P&#xD;Armstrong, Paige A&#xD;eng&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):477-487. doi: 10.1111/all.15539. Epub 2022 Oct 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36178236</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10092820</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15539</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3193</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3193</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ellis, J.</style></author><author><style face="normal" font="default" size="100%">Fortunato, L.</style></author><author><style face="normal" font="default" size="100%">Wajdner, H.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Barnard, J.</style></author><author><style face="normal" font="default" size="100%">Betts, J. C.</style></author><author><style face="normal" font="default" size="100%">Bose, S.</style></author><author><style face="normal" font="default" size="100%">Browning, J.</style></author><author><style face="normal" font="default" size="100%">Buil-Bruna, N.</style></author><author><style face="normal" font="default" size="100%">Van Buren, S.</style></author><author><style face="normal" font="default" size="100%">David, E.</style></author><author><style face="normal" font="default" size="100%">Dinehart, S.</style></author><author><style face="normal" font="default" size="100%">Dhawan, P.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y.</style></author><author><style face="normal" font="default" size="100%">Ghafoori, P.</style></author><author><style face="normal" font="default" size="100%">Gumireddy, K.</style></author><author><style face="normal" font="default" size="100%">Li, Z.</style></author><author><style face="normal" font="default" size="100%">Loo, W. J.</style></author><author><style face="normal" font="default" size="100%">Lovegrove, F.</style></author><author><style face="normal" font="default" size="100%">Lowe, J.</style></author><author><style face="normal" font="default" size="100%">Parish, L. C.</style></author><author><style face="normal" font="default" size="100%">Powley, W.</style></author><author><style face="normal" font="default" size="100%">Prasad, N.</style></author><author><style face="normal" font="default" size="100%">Da Rosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Ruseva, M.</style></author><author><style face="normal" font="default" size="100%">Shokrian, N.</style></author><author><style face="normal" font="default" size="100%">Syed, F.</style></author><author><style face="normal" font="default" size="100%">Tang, C. H.</style></author><author><style face="normal" font="default" size="100%">Wong, G. K.</style></author><author><style face="normal" font="default" size="100%">Kelly, J. B.</style></author><author><style face="normal" font="default" size="100%">Wisniacki, N.</style></author><author><style face="normal" font="default" size="100%">Uings, I.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">GSK, Stevenage, UK.&#xD;GSK, Rueil-Malmaison, France.&#xD;Mount Sinai Medical Center, New York, USA.&#xD;University of Texas Health San Antonio, San Antonio, Texas, USA.&#xD;GSK, Collegeville, Pennsylvania, USA.&#xD;Arkansas Dermatology, Little Rock, Arkansas, USA.&#xD;Western University, London, Ontario, Canada.&#xD;Probity Medical Research Inc, Waterloo, Ontario, Canada.&#xD;DermEffects, London, Ontario, Canada.&#xD;Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical and Molecular Effect of the Anti-IL-18 Antibody Aletekitug in Adults With Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">interleukins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41410194</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Interleukin-18 (IL-18) is a pleiotropic cytokine implicated in atopic dermatitis (AD), affecting both type (T)1 and T2 immune pathways. An anti-IL-18 monoclonal antibody, aletekitug, was evaluated for its clinical and molecular effects in patients with moderate to severe AD. METHODS: This randomised, double-blind, parallel-group, placebo-controlled, 24-week study assessed adults with moderate-to-severe AD who were biologic-naive or dupilumab-inadequate responders/intolerant. Participants received a single intravenous (IV) infusion of aletekitug 2 mg/kg or placebo. The primary endpoint was percentage change from baseline (PCFB) in Eczema Area and Severity Index (EASI) score at Week 12. Other endpoints included safety, patient-reported outcomes (PROs) and transcriptomics. RESULTS: Thirty-four participants (aletekitug, n = 23; placebo, n = 11) were randomised. A greater reduction in the PCFB in EASI score at Week 12 was demonstrated for patients who received aletekitug versus placebo (posterior median PCFB [95% credible intervals]: aletekitug, -68.3% [-79.68, -56.68]; placebo, -32.9% [-45.74, -21.10]), with effects still apparent at Week 24. Aletekitug improved PRO measures of itch, sleep disturbance, fatigue and quality of life versus placebo up to Week 24. Transcriptome analysis suggested aletekitug modulated lesional skin towards a non-lesional profile and exerted broad immunomodulatory effects, impacting several AD-associated signalling pathways, not limited to T2 immunity. Aletekitug was well tolerated, with no serious adverse events reported. CONCLUSION: A single 2 mg/kg IV dose of aletekitug was associated with improved outcomes at Week 12, which were sustained to Week 24, and modulated immune mechanisms beyond T2 inflammation. These results support IL-18 as a potential therapeutic target in moderate-to-severe AD.</style></abstract><notes><style face="normal" font="default" size="100%">Ellis, Joanne&#xD;Fortunato, Lea&#xD;Wajdner, Hannah&#xD;Del Duca, Ester&#xD;Barnard, Joanna&#xD;Betts, Joanna C&#xD;Bose, Swaroop&#xD;Browning, John&#xD;Buil-Bruna, Nuria&#xD;Van Buren, Scott&#xD;David, Eden&#xD;Dinehart, Scott&#xD;Dhawan, Puneet&#xD;Estrada, Yeriel&#xD;Ghafoori, Parima&#xD;Gumireddy, Kiranmai&#xD;Li, Zhenghong&#xD;Loo, Wei Jing&#xD;Lovegrove, Fiona&#xD;Lowe, Jenny&#xD;Parish, Lawrence Charles&#xD;Powley, Will&#xD;Prasad, Naveen&#xD;Da Rosa, Joel Correa&#xD;Ruseva, Marieta&#xD;Shokrian, Neda&#xD;Syed, Farhat&#xD;Tang, Chun-Hang&#xD;Wong, Gabriel K&#xD;Kelly, John B&#xD;Wisniacki, Nicolas&#xD;Uings, Iain&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;This study (GSK Study 215253; NCT04975438) was funded by GSK. Medical writing support was provided by Eleri Ashworth, PhD, &amp; Nicholas Thomas, PhD, at Fishawack Indicia Ltd, part of Avalere Health, and was funded by GSK./&#xD;GSK/&#xD;Denmark&#xD;Allergy. 2025 Dec 18. doi: 10.1111/all.70172.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41410194</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70172</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2306</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2306</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bissonnette, R.</style></author><author><style face="normal" font="default" size="100%">DuBois, J.</style></author><author><style face="normal" font="default" size="100%">Facheris, P.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Kim, M.</style></author><author><style face="normal" font="default" size="100%">Correa Da Rosa, J.</style></author><author><style face="normal" font="default" size="100%">Trujillo, D. L.</style></author><author><style face="normal" font="default" size="100%">Bose, S.</style></author><author><style face="normal" font="default" size="100%">Pagan, A. D.</style></author><author><style face="normal" font="default" size="100%">Wustrow, D.</style></author><author><style face="normal" font="default" size="100%">Brockstedt, D. G.</style></author><author><style face="normal" font="default" size="100%">Wong, B.</style></author><author><style face="normal" font="default" size="100%">Kassner, P. D.</style></author><author><style face="normal" font="default" size="100%">Jankicevic, J.</style></author><author><style face="normal" font="default" size="100%">Ho, W.</style></author><author><style face="normal" font="default" size="100%">Cheng, L. E.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Innovaderm Research Inc., Montreal, Quebec, Canada.&#xD;DermResearch, P.A., Austin, Texas, USA.&#xD;Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;RAPT Therapeutics, Inc., South San Francisco, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">924-936</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, CCR4/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">chemokines</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37984453</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: RPT193 is an orally administered small molecule antagonist of the human C-C motif chemokine receptor 4 (CCR4) that inhibits the migration and downstream activation of T-helper Type 2 (Th2) cells. We investigated single- and multiple-ascending doses of RPT193 in healthy subjects, and multiple doses of RPT193 in subjects with moderate-to-severe atopic dermatitis (AD). METHODS: This was a first-in-human randomized, placebo-controlled Phase 1a/1b monotherapy study (NCT04271514) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and CCR4 surface receptor occupancy in eligible healthy subjects and subjects with moderate-to-severe AD. Clinical efficacy and skin biomarker effects of RPT193 monotherapy were assessed as exploratory endpoints in AD subjects. RESULTS: In healthy (n = 72) and AD subjects (n = 31), once-daily RPT193 treatment was generally well tolerated, with no serious adverse events reported and all treatment-emergent adverse events reported as mild/moderate. In AD subjects, numerically greater improvements in clinical efficacy endpoints were observed with RPT193 monotherapy versus placebo up to the end of the treatment period (Day 29), with statistically significant improvement, compared to Day 29 and placebo, observed 2 weeks after the end of treatment (Day 43) on several endpoints (p &lt; .05). Moreover, significant changes in the transcriptional profile were seen in skin biopsies of RPT193-treated versus placebo-treated subjects at Day 29, which were also significantly correlated with improvements in clinical efficacy measures. CONCLUSIONS: To our knowledge, this is the first clinical study with an oral CCR4 antagonist that showed clinical improvement coupled with modulation of the cutaneous transcriptomic profile in an inflammatory skin disease.</style></abstract><notes><style face="normal" font="default" size="100%">Bissonnette, Robert&#xD;DuBois, Janet&#xD;Facheris, Paola&#xD;Del Duca, Ester&#xD;Kim, Madeline&#xD;Correa Da Rosa, Joel&#xD;Trujillo, Damian L&#xD;Bose, Swaroop&#xD;Pagan, Angel D&#xD;Wustrow, David&#xD;Brockstedt, Dirk G&#xD;Wong, Brian&#xD;Kassner, Paul D&#xD;Jankicevic, Jasmina&#xD;Ho, William&#xD;Cheng, Laurence E&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;RAPT Therapeutics, Inc./&#xD;Clinical Trial, Phase I&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):924-936. doi: 10.1111/all.15949. Epub 2023 Nov 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37984453</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15949</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2513</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2513</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stolzl, D.</style></author><author><style face="normal" font="default" size="100%">Sander, N.</style></author><author><style face="normal" font="default" size="100%">Siegels, D.</style></author><author><style face="normal" font="default" size="100%">Harder, I.</style></author><author><style face="normal" font="default" size="100%">Kind, B.</style></author><author><style face="normal" font="default" size="100%">Fonfara, M.</style></author><author><style face="normal" font="default" size="100%">Heinrich, L.</style></author><author><style face="normal" font="default" size="100%">Ott, H.</style></author><author><style face="normal" font="default" size="100%">Abraham, S.</style></author><author><style face="normal" font="default" size="100%">Neustadter, I.</style></author><author><style face="normal" font="default" size="100%">Kleinheinz, A.</style></author><author><style face="normal" font="default" size="100%">Gerdes, S.</style></author><author><style face="normal" font="default" size="100%">Wollenberg, A.</style></author><author><style face="normal" font="default" size="100%">Lau, S.</style></author><author><style face="normal" font="default" size="100%">Nemat, K.</style></author><author><style face="normal" font="default" size="100%">Heratizadeh, A.</style></author><author><style face="normal" font="default" size="100%">Gellhaus, I.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Schmitt, J.</style></author><author><style face="normal" font="default" size="100%">Weidinger, S.</style></author><author><style face="normal" font="default" size="100%">T. REATgermany study group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Germany.&#xD;Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.&#xD;Department of Pediatric Dermatology, Children&apos;s Hospital Auf Der Bult, Academic Hospital, Hannover, Germany.&#xD;Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.&#xD;Cnopfsche Children&apos;s Hospital/Neonatology, Pediatrics, DIAKONEO KdoR, Nuremberg, Germany.&#xD;Clinics for Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany.&#xD;Clinics and Outpatient Clinics for Dermatology and Allergy, LMU Munich, Munich, Germany.&#xD;Department of Dermatology and Allergy, University Hospital Augsburg, Augsburg, Germany.&#xD;Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Praxis fur Kinderpneumologie/Allergologie, Kinderzentrum Dresden-Friedrichstadt, Dresden, Germany.&#xD;Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Rehaforschung Nord e.V, Sylt, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: Results of the German TREATkids registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2849-2852</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/05/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Registries</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Germany</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38712730</style></accession-num><notes><style face="normal" font="default" size="100%">Stolzl, D&#xD;Sander, N&#xD;Siegels, D&#xD;Harder, I&#xD;Kind, B&#xD;Fonfara, M&#xD;Heinrich, L&#xD;Ott, Hagen&#xD;Abraham, S&#xD;Neustadter, I&#xD;Kleinheinz, A&#xD;Gerdes, S&#xD;Wollenberg, A&#xD;Lau, S&#xD;Nemat, K&#xD;Heratizadeh, A&#xD;Gellhaus, I&#xD;Werfel, T&#xD;Schmitt, J&#xD;Weidinger, S&#xD;eng&#xD;Funding sources: TREATgermany is an academic, investigator-initiated clinical disease registry that is fi nancially supported by AbbVie Deutschland GmbH &amp; Co. KG, Almirall Hermal GmbH, Galderma S.A., LEO Pharma GmbH, Lilly Deutschland GmbH, Pfizer Inc. and Sanofi./&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2849-2852. doi: 10.1111/all.16147. Epub 2024 May 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38712730</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16147</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3218</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3218</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Watanabe, S.</style></author><author><style face="normal" font="default" size="100%">Sato, A.</style></author><author><style face="normal" font="default" size="100%">Seki, H.</style></author><author><style face="normal" font="default" size="100%">Negi, M.</style></author><author><style face="normal" font="default" size="100%">Yauchi, T.</style></author><author><style face="normal" font="default" size="100%">Yamamoto-Hanada, K.</style></author><author><style face="normal" font="default" size="100%">Fukuie, T.</style></author><author><style face="normal" font="default" size="100%">Ohya, Y.</style></author><author><style face="normal" font="default" size="100%">Nomura, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gastroenterology, Soka Municipal Hospital, Saitama, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.&#xD;Department of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.&#xD;Department of Pathology, Soka Municipal Hospital, Saitama, Japan.&#xD;Department of Environmental and Occupational Health, Nagoya City University Graduate School of Medicine, Nagoya, Aichi, Japan.&#xD;Division of General Allergy, Bantane Hospital, Fujita Health University, Toyoake, Aichi, Japan.&#xD;Division of Eosinophilic Gastrointestinal Disorders, National Research Institute for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical and Mucosal Transcriptomic Profiling of Adult Food Protein-Induced Enterocolitis Syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">adult FPIES</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">gastric mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">neuroimmunology</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41582712</style></accession-num><notes><style face="normal" font="default" size="100%">Watanabe, Sho&#xD;Sato, Ayako&#xD;Seki, Hiroto&#xD;Negi, Mariko&#xD;Yauchi, Tsunehito&#xD;Yamamoto-Hanada, Kiwako&#xD;Fukuie, Tatsuki&#xD;Ohya, Yukihiro&#xD;Nomura, Ichiro&#xD;eng&#xD;Japanese Society of Allergology/&#xD;JP25K19282/Japan Society for the Promotion of Science (JSPS)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan 26. doi: 10.1111/all.70233.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41582712</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70233</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3286</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3286</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Watanabe, S.</style></author><author><style face="normal" font="default" size="100%">Sato, A.</style></author><author><style face="normal" font="default" size="100%">Seki, H.</style></author><author><style face="normal" font="default" size="100%">Negi, M.</style></author><author><style face="normal" font="default" size="100%">Yauchi, T.</style></author><author><style face="normal" font="default" size="100%">Yamamoto-Hanada, K.</style></author><author><style face="normal" font="default" size="100%">Fukuie, T.</style></author><author><style face="normal" font="default" size="100%">Ohya, Y.</style></author><author><style face="normal" font="default" size="100%">Nomura, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gastroenterology, Soka Municipal Hospital, Saitama, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.&#xD;Department of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.&#xD;Department of Pathology, Soka Municipal Hospital, Saitama, Japan.&#xD;Department of Environmental and Occupational Health, Nagoya City University Graduate School of Medicine, Nagoya, Aichi, Japan.&#xD;Division of General Allergy, Bantane Hospital, Fujita Health University, Toyoake, Aichi, Japan.&#xD;Division of Eosinophilic Gastrointestinal Disorders, National Research Institute for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical and Mucosal Transcriptomic Profiling of Adult Food Protein-Induced Enterocolitis Syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">adult FPIES</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">gastric mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">neuroimmunology</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41582712</style></accession-num><notes><style face="normal" font="default" size="100%">Watanabe, Sho&#xD;Sato, Ayako&#xD;Seki, Hiroto&#xD;Negi, Mariko&#xD;Yauchi, Tsunehito&#xD;Yamamoto-Hanada, Kiwako&#xD;Fukuie, Tatsuki&#xD;Ohya, Yukihiro&#xD;Nomura, Ichiro&#xD;eng&#xD;Japanese Society of Allergology/&#xD;JP25K19282/Japan Society for the Promotion of Science (JSPS)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan 26. doi: 10.1111/all.70233.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41582712</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70233</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2471</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2471</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ueta, M.</style></author><author><style face="normal" font="default" size="100%">Watanabe, Y.</style></author><author><style face="normal" font="default" size="100%">Melby-Thompson, C.</style></author><author><style face="normal" font="default" size="100%">Sotozono, C.</style></author><author><style face="normal" font="default" size="100%">Kinoshita, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.&#xD;AI Inside Inc., Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical applicability of AI-based prognosis prediction for a rare ocular surface disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2542-2543</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/04/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Artificial Intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Eye Diseases/diagnosis/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38660745</style></accession-num><notes><style face="normal" font="default" size="100%">Ueta, Mayumi&#xD;Watanabe, Yasuhito&#xD;Melby-Thompson, Charles&#xD;Sotozono, Chie&#xD;Kinoshita, Shigeru&#xD;eng&#xD;Japan Agency for Medical Research and Development/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2542-2543. doi: 10.1111/all.16136. Epub 2024 Apr 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38660745</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16136</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2312</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2312</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, D. G.</style></author><author><style face="normal" font="default" size="100%">Sorensen, J. A.</style></author><author><style face="normal" font="default" size="100%">Ghazanfar, M. N.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.&#xD;Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical applicability of the urticaria control test in patients with chronic urticaria: Further evidence from 622 adult and pediatric patients with different disease subtypes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">263-264</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/11/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37966905</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Ditte Georgina&#xD;Sorensen, Jennifer Astrup&#xD;Ghazanfar, Misbah Noshela&#xD;Thomsen, Simon Francis&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):263-264. doi: 10.1111/all.15955. Epub 2023 Nov 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37966905</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15955</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2867</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2867</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Holzmann, C.</style></author><author><style face="normal" font="default" size="100%">Karg, J.</style></author><author><style face="normal" font="default" size="100%">Reiger, M.</style></author><author><style face="normal" font="default" size="100%">Kharbal, R.</style></author><author><style face="normal" font="default" size="100%">Romano, P.</style></author><author><style face="normal" font="default" size="100%">Scheiwein, S.</style></author><author><style face="normal" font="default" size="100%">Khalfi, C.</style></author><author><style face="normal" font="default" size="100%">Muzalyova, A.</style></author><author><style face="normal" font="default" size="100%">Brunner, J. O.</style></author><author><style face="normal" font="default" size="100%">Hammel, G.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Plaza, M. P.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University Hospital Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Munich-German Research Center for Environmental Health, Augsburg, Germany.&#xD;Outpatient Clinic for Environmental Medicine, University Hospital Augsburg, Augsburg, Germany.&#xD;Institute for Digital Medicine, University Hospital Augsburg, Augsburg, Germany.&#xD;Department of Technology, Management, and Economics, Technical University of Denmark, Copenhagen, Denmark.&#xD;Next Generation Technology, Region Zealand, Denmark.&#xD;Health Care Operations/Health Information Management, Faculty of Business and Economics, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Terrestrial Ecology and Climate Change, Department of Ecology, School of Biology, Faculty of Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Christine-Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1945-1955</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/04/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/diagnosis/therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen/immunology/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Mobile Applications</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Poaceae/immunology/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy app</style></keyword><keyword><style face="normal" font="default" size="100%">clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">pollen forecast</style></keyword><keyword><style face="normal" font="default" size="100%">symptom forecast</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40242867</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Symptom monitoring can improve adherence to daily medication. However, controlled clinical trials on multi-modular allergy apps and their various functions have been difficult to implement. The objective of this study was to assess the clinical benefit of an allergy app with varying numbers of functions in reducing symptoms and improving quality of (QoL) life in grass pollen allergic individuals. The secondary objective was to develop a symptom forecast based on patient-derived and environmental data. METHODS: We performed a stratified, controlled intervention study (May-August 2023) with grass pollen allergic participants (N = 167) in Augsburg, Germany. Participants were divided into three groups, each receiving the same allergy app, but with increasing numbers of functions. PRIMARY ENDPOINT: rhinitis-related QoL; Secondary endpoints: symptom scores, relevant behavior, self-reported usefulness of the app, symptom forecast. RESULTS: Rhinitis-related QoL was increased after the intervention, with no statistical inter-group differences. However, participants with access to the full app version, including a pollen forecast, took more medication and reported lower symptoms and social activity impairment than participants with access to a reduced-function app. Using an XGBoost multiclass classification model, we achieved promising results for predicting nasal (accuracy: 0.79; F1-score: 0.78) and ocular (accuracy: 0.82; F1-score: 0.76) symptom levels and derived feature importance using SHAP as a guidance for future approaches. CONCLUSION: Our allergy app with its high-performance pollen forecast, symptom diary, and general allergy-related information provides a clinical benefit for allergy sufferers. Reliable symptom forecasts may be created given high-quality and high-resolution data.</style></abstract><notes><style face="normal" font="default" size="100%">Holzmann, Caroline&#xD;Karg, Johannes&#xD;Reiger, Matthias&#xD;Kharbal, Rajiv&#xD;Romano, Paola&#xD;Scheiwein, Sabrina&#xD;Khalfi, Claudia&#xD;Muzalyova, Anna&#xD;Brunner, Jens O&#xD;Hammel, Gertrud&#xD;Damialis, Athanasios&#xD;Traidl-Hoffmann, Claudia&#xD;Plaza, Maria P&#xD;Gilles, Stefanie&#xD;eng&#xD;K1-2499-KuHeMo-21-V4/Bayerisches Landesamt fur Gesunheit und Lebensmittelsicherheit (LGL)/&#xD;01LN2202AIMPACCT/German Ministry of Research and Education (BMBF)/&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1945-1955. doi: 10.1111/all.16558. Epub 2025 Apr 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40242867</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261868</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16558</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1424</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1424</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Du, H.</style></author><author><style face="normal" font="default" size="100%">Dong, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, J. J.</style></author><author><style face="normal" font="default" size="100%">Cao, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Huang, P. Q.</style></author><author><style face="normal" font="default" size="100%">Chen, H. W.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, G. H.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Lu, X. X.</style></author><author><style face="normal" font="default" size="100%">Gao, Y. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, Wuhan Children&apos;s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">510-532</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*complications/*immunology/*pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia, Viral/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocyte subsets</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, Christine Kuhne-Center for Allergy Research and Education, European</style></keyword><keyword><style face="normal" font="default" size="100%">Commission&apos;s Horizon 2020 Framework Programme, Cure, Novartis Research</style></keyword><keyword><style face="normal" font="default" size="100%">Institutes, Astra Zeneca, and Scibase, and for advisory role in Sanofi/Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. Dr Cao, Dr Li, Dr Liu, Dr Chen, Dr Du, Dr Zhang,</style></keyword><keyword><style face="normal" font="default" size="100%">Prof. Akdis M, Dr Huang, Dr Dong, Dr Lu, and Dr Gao have nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32524611</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has made widespread impact recently. We aim to investigate the clinical characteristics of COVID-19 children with different severities and allergic status. METHODS: Data extracted from the electronic medical records, including demographics, clinical manifestations, comorbidities, laboratory and immunological results, and radiological images of 182 hospitalized COVID-19 children, were summarized and analyzed. RESULTS: The median age was 6 years, ranging from 3 days to 15 years, and there were more boys (male-female ratio about 2:1) within the studied 182 patients. Most of the children were infected by family members. Fever (43.4%) and dry cough (44.5%) were common symptoms, and gastrointestinal manifestations accounted for 11.0%, including diarrhea, abdominal discomfort, and vomiting. 71.4% had abnormal chest computed tomography (CT) scan images, and typical signs of pneumonia were ground-glass opacity and local patchy shadowing on admission. Laboratory results were mostly within normal ranges, and only a small ratio of lymphopenia (3.9%) and eosinopenia (29.5%) were observed. The majority (97.8%) of infected children were not severe, and 24 (13.2%) of them had asymptomatic infections. Compared to children without pneumonia (manifested as asymptomatic and acute upper respiratory infection), children with pneumonia were associated with higher percentages of the comorbidity history, symptoms of fever and cough, and increased levels of serum procalcitonin, alkaline phosphatase, and serum interleukins (IL)-2, IL-4, IL-6, IL-10, and TNF-alpha. There were no differences in treatments, duration of hospitalization, time from first positive to first negative nucleic acid testing, and outcomes between children with mild pneumonia and without pneumonia. All the hospitalized COVID-19 children had recovered except one death due to intussusception and sepsis. In 43 allergic children with COVID-19, allergic rhinitis (83.7%) was the major disease, followed by drug allergy, atopic dermatitis, food allergy, and asthma. Demographics and clinical features were not significantly different between allergic and nonallergic groups. Allergic patients showed less increase in acute phase reactants, procalcitonin, D-dimer, and aspartate aminotransferase levels compared with all patients. Immunological profiles including circulating T, B, and NK lymphocyte subsets, total immunoglobulin and complement levels, and serum cytokines did not show any difference in allergic and pneumonia groups. Neither eosinophil counts nor serum total immunoglobulin E (IgE) levels showed a significant correlation with other immunological measures, such as other immunoglobulins, complements, lymphocyte subset numbers, and serum cytokine levels. CONCLUSION: Pediatric COVID-19 patients tended to have a mild clinical course. Patients with pneumonia had higher proportion of fever and cough and increased inflammatory biomarkers than those without pneumonia. There was no difference between allergic and nonallergic COVID-19 children in disease incidence, clinical features, and laboratory and immunological findings. Allergy was not a risk factor for developing and severity of SARS-CoV-2 infection and hardly influenced the disease course of COVID-19 in children.</style></abstract><notes><style face="normal" font="default" size="100%">Du, Hui&#xD;Dong, Xiang&#xD;Zhang, Jin-Jin&#xD;Cao, Yi-Yuan&#xD;Akdis, Mubeccel&#xD;Huang, Pei-Qi&#xD;Chen, Hong-Wei&#xD;Li, Ying&#xD;Liu, Guang-Hui&#xD;Akdis, Cezmi A&#xD;Lu, Xiao-Xia&#xD;Gao, Ya-Dong&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):510-532. doi: 10.1111/all.14452. Epub 2020 Sep 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32524611</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7307120</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14452</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1195</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1195</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, M.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">She, W.</style></author><author><style face="normal" font="default" size="100%">Cheng, L.</style></author><author><style face="normal" font="default" size="100%">Lu, M.</style></author><author><style face="normal" font="default" size="100%">Xing, Z.</style></author><author><style face="normal" font="default" size="100%">Ma, F.</style></author><author><style face="normal" font="default" size="100%">Zhu, L.</style></author><author><style face="normal" font="default" size="100%">Chen, L.</style></author><author><style face="normal" font="default" size="100%">Lin, X.</style></author><author><style face="normal" font="default" size="100%">Jiang, X.</style></author><author><style face="normal" font="default" size="100%">Zhu, D.</style></author><author><style face="normal" font="default" size="100%">Xu, G.</style></author><author><style face="normal" font="default" size="100%">Wen, W.</style></author><author><style face="normal" font="default" size="100%">Kong, W.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Tao, Z.</style></author><author><style face="normal" font="default" size="100%">Xu, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, D.</style></author><author><style face="normal" font="default" size="100%">Liu, S.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Jiang, W.</style></author><author><style face="normal" font="default" size="100%">Sun, J.</style></author><author><style face="normal" font="default" size="100%">Zhao, C.</style></author><author><style face="normal" font="default" size="100%">Suo, L.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key laboratory of Nasal Diseases, Beijing Institute of Otorhinolaryngology, Beijing, China.&#xD;Department of Otorhinolaryngology &amp; Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Peking University People&apos;s Hospital, Beijing, China.&#xD;Department of Otorhinolaryngology, Peking University Third Hospital, Beijing, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Beijing, China.&#xD;Department of Allergy, General Hospital of Northern Theater Command, Shenyang, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, The First Hospital, China Medical University, Shenyang, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.&#xD;Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.&#xD;Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Renmin Hospital, Wuhan University, Wuhan, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Eye &amp; ENT Hospital of Fudan University, Shanghai, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Second Hospital of Shanxi Medical University, Taiyuan, China.&#xD;Department of Otorhinolaryngology, The First Affiliated Hospital, Xinjiang Medical University, Urumqi, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical characteristics of allergic rhinitis patients in 13 metropolitan cities of China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">577-581</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/01/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Air Pollution/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cities/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33460167</style></accession-num><notes><style face="normal" font="default" size="100%">Zheng, Ming&#xD;Wang, Xiangdong&#xD;Wang, Meng&#xD;She, Wenyu&#xD;Cheng, Lei&#xD;Lu, Meiping&#xD;Xing, Zhimin&#xD;Ma, Furong&#xD;Zhu, Li&#xD;Chen, Lei&#xD;Lin, Xiaoping&#xD;Jiang, Xuejun&#xD;Zhu, Dongdong&#xD;Xu, Geng&#xD;Wen, Weiping&#xD;Kong, Weijia&#xD;Chen, Jianjun&#xD;Tao, Zezhang&#xD;Xu, Yu&#xD;Wang, Dehui&#xD;Liu, Shixi&#xD;Wang, Shenqing&#xD;Jiang, Weihong&#xD;Sun, Jingwu&#xD;Zhao, Changqing&#xD;Suo, Limin&#xD;Zhang, Hua&#xD;Zhang, Luo&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):577-581. doi: 10.1111/all.14561. Epub 2020 Oct 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33460167</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14561</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2937</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2937</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tanaka, J.</style></author><author><style face="normal" font="default" size="100%">Oguma, T.</style></author><author><style face="normal" font="default" size="100%">Ishiguro, T.</style></author><author><style face="normal" font="default" size="100%">Taniguchi, H.</style></author><author><style face="normal" font="default" size="100%">Nishiuma, T.</style></author><author><style face="normal" font="default" size="100%">Tateno, H.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, H.</style></author><author><style face="normal" font="default" size="100%">Koshimizu, N.</style></author><author><style face="normal" font="default" size="100%">Ito, Y.</style></author><author><style face="normal" font="default" size="100%">Matsunaga, K.</style></author><author><style face="normal" font="default" size="100%">Matsushima, H.</style></author><author><style face="normal" font="default" size="100%">Uchida, Y.</style></author><author><style face="normal" font="default" size="100%">Yokomura, K.</style></author><author><style face="normal" font="default" size="100%">Yasuba, H.</style></author><author><style face="normal" font="default" size="100%">Suzuki, J.</style></author><author><style face="normal" font="default" size="100%">Hattori, S.</style></author><author><style face="normal" font="default" size="100%">Okada, N.</style></author><author><style face="normal" font="default" size="100%">Tomomatsu, K.</style></author><author><style face="normal" font="default" size="100%">Asano, K.</style></author><author><style face="normal" font="default" size="100%">Abpm Research Program</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.&#xD;Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, Japan.&#xD;Division of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Japan.&#xD;Department of Respiratory Medicine, Kakogawa Central City Hospital, Kakogawa, Japan.&#xD;Department of Pulmonary Medicine, Saitama City Hospital, Saitama, Japan.&#xD;Department of Respiratory Medicine and Allergology, Kindai University School of Medicine, Osaka, Japan.&#xD;Deparment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Division of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan.&#xD;Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.&#xD;Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube, Japan.&#xD;Department of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.&#xD;Department of Respiratory Medicine, Saitama Medical University Hospital, Saitama, Japan.&#xD;Division of Respiratory Medicine, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Japan.&#xD;Department of Airway Medicine, Mitsubishi Kyoto Hospital, Kyoto, Japan.&#xD;Department of Respiratory Medicine, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical Characteristics of Difficult-To-Treat Allergic Bronchopulmonary Aspergillosis and Its Prediction Score</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2531-2540</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/05/03 22:26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Aspergillosis, Allergic Bronchopulmonary/drug therapy/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Antifungal Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Japan/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="default" size="100%">allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical remission</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceutical. K.M. received lecture fees from AstraZeneca K.K., GlaxoSmithKline</style></keyword><keyword><style face="normal" font="default" size="100%">plc, Kyorin Pharmaceutical, and Sanofi. K.A. received lecture fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca K.K., GlaxoSmithKline plc, and Sanofi. The rest of the authors have</style></keyword><keyword><style face="normal" font="default" size="100%">no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40317973</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND OBJECTIVE: Administration of oral corticosteroids and/or azole antifungals for 4-6 months remains the standard treatment for allergic bronchopulmonary aspergillosis (ABPA). This study investigated the clinical characteristics of patients with difficult-to-treat ABPA who failed to achieve clinical remission within 6 months. METHODS: Among the participants of a nationwide survey conducted in Japan in 2020, treatment-naive patients with ABPA who satisfied Asano&apos;s criteria were enrolled in this study. Clinical remission was defined as stable disease without exacerbation for &gt;/= 6 months under minimal treatment (oral prednisolone: &lt;/= 5 mg/day and no antifungal medication). A risk prediction score for difficult-to-treat ABPA was developed and validated in an independent cohort comprising patients with ABPA from a prospective registration study in Japan. RESULTS: In total, 316 treatment-naive patients with ABPA were enrolled in the study. The median time to minimal treatment status was 4.8 months in the group receiving standard treatment. The clinical remission rate at 6 months after standard treatment was 51%. Age &lt;/= 50 years at onset of ABPA (p = 0.04), serum A. fumigatus-specific IgE titer of &gt;/= 20 U(A)/mL (p = 0.006), positive culture for Aspergillus spp. in the sputum/bronchial lavage fluid (p = 0.05), and presence of high attenuation mucus (HAM; p = 0.10) were associated with difficult-to-treat ABPA. The number of positive indicators indicated the risk of failure of standard treatment to yield clinical remission within 6 months in the derivation (n = 87, p &lt; 0.001) and validation (n = 64, p = 0.009) cohorts. CONCLUSION: Multiple components, including age at onset, allergic sensitization, airway fungal burden, and HAM, were associated with difficult-to-treat ABPA.</style></abstract><notes><style face="normal" font="default" size="100%">Tanaka, Jun&#xD;Oguma, Tsuyoshi&#xD;Ishiguro, Takashi&#xD;Taniguchi, Hirokazu&#xD;Nishiuma, Teruaki&#xD;Tateno, Hiroki&#xD;Matsumoto, Hisako&#xD;Koshimizu, Naoki&#xD;Ito, Yutaka&#xD;Matsunaga, Kazuto&#xD;Matsushima, Hidekazu&#xD;Uchida, Yoshitaka&#xD;Yokomura, Koshi&#xD;Yasuba, Hirotaka&#xD;Suzuki, Junko&#xD;Hattori, Shigeaki&#xD;Okada, Naoki&#xD;Tomomatsu, Katsuyoshi&#xD;Asano, Koichiro&#xD;eng&#xD;Japan Agency for Medical Research and Development/&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2531-2540. doi: 10.1111/all.16559. Epub 2025 May 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40317973</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444840</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16559</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1409</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1409</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jartti, T.</style></author><author><style face="normal" font="default" size="100%">Liimatainen, U.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Vahlberg, T.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Finotto, S.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author><author><style face="normal" font="default" size="100%">Sobanska, A.</style></author><author><style face="normal" font="default" size="100%">Lukkarinen, H.</style></author><author><style face="normal" font="default" size="100%">Pasioti, M.</style></author><author><style face="normal" font="default" size="100%">Vuorinen, T.</style></author><author><style face="normal" font="default" size="100%">Zhang, N.</style></author><author><style face="normal" font="default" size="100%">Zimmermann, T.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.&#xD;Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Department of Biostatistics, University of Turku, Turku, Finland.&#xD;Upper Airway Research Laboratory, Ghent University Hospital, Ghent, Belgium.&#xD;Department of Molecular Pneumology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Universitatsklinikum Erlangen, Erlangen, Germany.&#xD;Department of Immunology, Rheumatology and Allergy, Central University Hospital, Lodz, Poland.&#xD;Department of Clinical Microbiology, Turku University Hospital and Institute of Biomedicine, University of Turku, Turku, Finland.&#xD;Department of Pediatrics and Adolescent Medicine, Department of Allergy and Pneumology, Children&apos;s Hospital, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Universitatsklinikum Erlangen, Erlangen, Germany.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, University of Manchester, Manchester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical correlates of rhinovirus infection in preschool asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">247-254</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">preschool</style></keyword><keyword><style face="normal" font="default" size="100%">rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32621330</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Investigation of preschool asthma is important since not all children outgrow their illness during this age. Data are scarce on the role of rhinovirus (RV) infections in this patient group. OBJECTIVES: To investigate the role of RV infections in preschool asthma: (i) susceptibility factors, (ii) clinical course, and (iii) medium-term outcome. METHODS: A total of 130 asthmatic children aged 4-6 years from the multinational PreDicta cohort were prospectively followed for a 12-month period. Allergy tests and a standard health questionnaire were carried out at study entry. Respiratory virus presence in nasopharyngeal washes was studied at illness visits and at 3 scheduled visits. RESULTS: At study entry, mean age of the children was 5.3 years. Of 571 visits, 54% were positive for any virus and 39% for RV. Patient characteristics were only assessed with RV infection due to low number of other viruses. The use of supplementary vitamin D was inversely associated with RV infection (P &lt; .05). RV infection was associated with more severe course of acute illness in terms of more severe nighttime coughing, more sleep disturbances, and more days with runny nose (all P &lt; .05). RV infection was also associated with more severe disease course during the 12-month follow-up in terms of more nights with awakenings and more days of exercise-related symptoms (both P &lt; .05). CONCLUSIONS: Vitamin D supplementation may have an anti-rhinovirus effect. Both short- and medium-term outcomes suggest RV infection to be an important clinical marker of instable preschool asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Jartti, Tuomas&#xD;Liimatainen, Unna&#xD;Xepapadaki, Paraskevi&#xD;Vahlberg, Tero&#xD;Bachert, Claus&#xD;Finotto, Susetta&#xD;Kowalski, Marek L&#xD;Sobanska, Anna&#xD;Lukkarinen, Heikki&#xD;Pasioti, Maria&#xD;Vuorinen, Tytti&#xD;Zhang, Nan&#xD;Zimmermann, Theodor&#xD;Papadopoulos, Nikolaos G&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):247-254. doi: 10.1111/all.14479. Epub 2020 Jul 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32621330</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7818397</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14479</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2562</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2562</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chin-See-Chong, T. C. T.</style></author><author><style face="normal" font="default" size="100%">Valk, Jpmjv</style></author><author><style face="normal" font="default" size="100%">Layhadi, J. A. J.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H. M.</style></author><author><style face="normal" font="default" size="100%">Kappen, J. H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary Diseases, Franciscus Gasthuis &amp; Vlietland, Rotterdam, The Netherlands.&#xD;Department of Pulmonary Diseases, Erasmus Medical Centrum, Rotterdam, The Netherlands.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical efficacy of tezepelumab in pre-selected non-type 2 asthma patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2867-2870</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/07/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39034850</style></accession-num><notes><style face="normal" font="default" size="100%">Chin-See-Chong, T C Timothy&#xD;Valk, J P M Johanna van der&#xD;Layhadi, J A Janice&#xD;Shamji, M H Mohamed&#xD;Kappen, J H Jasper&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2867-2870. doi: 10.1111/all.16237. Epub 2024 Jul 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39034850</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16237</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2270</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2270</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gonzalez-de-Olano, D.</style></author><author><style face="normal" font="default" size="100%">Navarro-Navarro, P.</style></author><author><style face="normal" font="default" size="100%">Munoz-Gonzalez, J. I.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Munoz, L.</style></author><author><style face="normal" font="default" size="100%">Henriques, A.</style></author><author><style face="normal" font="default" size="100%">de-Andres-Martin, A.</style></author><author><style face="normal" font="default" size="100%">Peralta-Arjonilla, D.</style></author><author><style face="normal" font="default" size="100%">Mayado, A.</style></author><author><style face="normal" font="default" size="100%">Jara-Acevedo, M.</style></author><author><style face="normal" font="default" size="100%">Garcia-Montero, A. C.</style></author><author><style face="normal" font="default" size="100%">Orfao, A.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Twose, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Hospital Ramon y Cajal, IRYCIS, Madrid, Spain.&#xD;Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Salamanca, Spain.&#xD;Department of Medicine and Citometry Service (NUCLEUS), Cancer Research Center (IBMCC, USAL-CSIC), Universidad de Salamanca, Salamanca, Spain.&#xD;Sequencing Service (NUCLEUS), Universidad de Salamanca, Salamanca, Spain.&#xD;Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.&#xD;Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Virgen del Valle Hospital, Toledo, Spain.&#xD;Department of Immunology, Hospital Ramon y Cajal, IRYCIS, Madrid, Spain.&#xD;Instituto de Investigacion Biomedica de Salamanca (IBSAL), Salamanca, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">711-723</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/epidemiology/genetics/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis/diagnosis/epidemiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptases/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cell Activation Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Hat</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">copy number mutation</style></keyword><keyword><style face="normal" font="default" size="100%">frequency</style></keyword><keyword><style face="normal" font="default" size="100%">mastocytosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37818990</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A close association between hereditary alpha-tryptasemia (HAT) and mast cell (MC) disorders has been previously reported. However, the relationship between HAT and the diagnostic subtypes and clinical features of MC disorders still remains to be established. OBJECTIVE: To determine the prevalence of HAT in healthy donors (HD) vs patients with different diagnostic subtypes of MC activation syndromes (MCAS) and mastocytosis, and its relationship with the clinical behavior of the disease. METHODS: A total of 959 subjects were studied including 346 healthy donors (HD), 464 mastocytosis, and 149 non-clonal MCAS patients. Molecular studies to assess the TPSAB1 genotype were performed, and data on serum baseline tryptase (sBT) and basal MC-mediator release episodes and triggers of anaphylaxis were collected. RESULTS: HAT was detected in 15/346 (4%) HD versus 43/149 (29%) non-clonal MCAS and 84/464 (18%) mastocytosis cases. Among mastocytosis, HAT was more frequently found in patients with MC-restricted KIT(D816V) (21% vs. 10% among multilineage KIT(D816V) patients; p = .008). Overall, median sBT was higher in cases presenting with HAT (28.9 vs. 24.5 ng/mL; p = .008), while no significant differences in sBT were observed among HAT(+) mastocytosis patients depending on the presence of 1 vs. &gt;/=2 extra copies of the alpha-tryptase gene (44.1 vs. 35.2 ng/mL, p &gt; .05). In turn, anaphylaxis was more frequently observed in HAT(+) versus HAT(-) mastocytosis patients (76% vs. 65%; p = .018), while HAT(+) and HAT(-) patients who did not refer anaphylaxis as the presenting symptom (n = 308) showed a similar prevalence of subsequent anaphylaxis (35% vs. 36%, respectively). CONCLUSION: The frequency of HAT in MC disorders varies according to the diagnostic subtype of the disease. HAT does not imply a higher risk (and severity) of anaphylaxis in mastocytosis patients in whom anaphylaxis is not part of the presenting symptoms of the disease.</style></abstract><notes><style face="normal" font="default" size="100%">Gonzalez-de-Olano, David&#xD;Navarro-Navarro, Paula&#xD;Munoz-Gonzalez, Javier I&#xD;Sanchez-Munoz, Laura&#xD;Henriques, Ana&#xD;de-Andres-Martin, Ana&#xD;Peralta-Arjonilla, Dolores&#xD;Mayado, Andrea&#xD;Jara-Acevedo, Maria&#xD;Garcia-Montero, Andres C&#xD;Orfao, Alberto&#xD;Alvarez-Twose, Ivan&#xD;eng&#xD;Fundacion Espanola de Mastocitosis/&#xD;Fundacion para la investigacion Biomedica del Hospital Ramon y Cajal IRYCIS/&#xD;Fundacion Sociedad Espanola de Alergologia e Inmunologia Clinica/&#xD;Instituto de Salud Carlos III (reference PI22/01657)/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):711-723. doi: 10.1111/all.15911. Epub 2023 Oct 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37818990</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15911</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1140</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1140</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ullberg, J.</style></author><author><style face="normal" font="default" size="100%">Fech-Bormann, M.</style></author><author><style face="normal" font="default" size="100%">Fagerberg, U. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Vastmanland Hospital, Vasteras, Sweden.&#xD;Center for Clinical Research, Region Vastmanland/Uppsala University, Vastmanland hospital, Vasteras, Sweden.&#xD;Department of Women&apos;s and Children&apos;s Health, Karolinska Institutet, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical presentation and management of food protein-induced enterocolitis syndrome in 113 Swedish children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2115-2122</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Enterocolitis/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Sweden/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Fpies</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">milk allergy</style></keyword><keyword><style face="normal" font="default" size="100%">non-IgE-mediated food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33605459</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated food allergy causing severe acute gastrointestinal symptoms and lethargy, mainly affecting infants and young children. There are geographic variations in its clinical features. This study aimed to describe the clinical characteristics and management of FPIES in Swedish children. METHODS: The study included children who presented with acute FPIES during 2008-2017. All Swedish pediatric departments (n = 32) were invited to report their known patients. Data were collected through chart reviews and interviews with parents. RESULTS: Eighteen pediatric departments contributed, and 113 patients were included. Most had a family history of atopy (74%), and 51% had an atopic disease. Common trigger foods were cow&apos;s milk (26%), fish (25%), oat (22%), and rice (8%). Most patients (85%) reacted to a single food. The median age at first reaction was 3.9 months for cow&apos;s milk and 6.0 months for other foods (p &lt; 0.001, range 1.0 month to 9 years). Repetitive vomiting (100%), lethargy (86%), and pallor (61%) were common symptoms; 40% had diarrhea. Sixty percent visited the emergency department, and 27% of all patients were hospitalized. Most patients were diagnosed clinically (81%). Specific IgE for the trigger food was positive in 4/89 tested patients (4%), and skin prick test for the trigger food was positive in 1/53 tested patients (2%). CONCLUSIONS: In our Swedish study of 113 children, cow&apos;s milk, fish, and oat were the commonest trigger foods. Most patients reacted to a single food, and IgE sensitization was rare.</style></abstract><notes><style face="normal" font="default" size="100%">Ullberg, Josefin&#xD;Fech-Bormann, Mareike&#xD;Fagerberg, Ulrika L&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2115-2122. doi: 10.1111/all.14784. Epub 2021 Mar 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33605459</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14784</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2703</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2703</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bachmeier-Zbaren, N.</style></author><author><style face="normal" font="default" size="100%">Celik, A.</style></author><author><style face="normal" font="default" size="100%">van Brummelen, R.</style></author><author><style face="normal" font="default" size="100%">Roos, N.</style></author><author><style face="normal" font="default" size="100%">Steinmann, M.</style></author><author><style face="normal" font="default" size="100%">Hoang, J. A.</style></author><author><style face="normal" font="default" size="100%">Yin, X.</style></author><author><style face="normal" font="default" size="100%">Ditlof, C. M.</style></author><author><style face="normal" font="default" size="100%">Duan, L.</style></author><author><style face="normal" font="default" size="100%">Upton, J. E. M.</style></author><author><style face="normal" font="default" size="100%">Kaufmann, T.</style></author><author><style face="normal" font="default" size="100%">Eggel, A.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Monas working group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland.&#xD;Centre for Computational Medicine, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department for BioMedical Research, Lung Precision Medicine (LPM), University of Bern, Bern, Switzerland.&#xD;Translational Medicine, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Division of Immunology and Allergy, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Institute of Pharmacology, University of Bern, Bern, Switzerland.&#xD;Department Pediatric and Adolescent Medicine, University Hospital St. Poelten, St. Poelten, Austria.&#xD;Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">215-226</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/09/28 22:45</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Homeodomain Proteins/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Degranulation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Hoxb8 mast cell activation test</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">oral food challenge</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">specific IgE</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to declare. RvB is an employee of ATANIS Biotech AG. NR, MS, JAH, XY,</style></keyword><keyword><style face="normal" font="default" size="100%">CMD, and LD have nothing to disclose. JEMU reports grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello A/S, personal fees from Bausch Health, personal fees from Kaleo and</style></keyword><keyword><style face="normal" font="default" size="100%">Pharming Group N.V, grants from DBV Technologies, grants from Regeneron and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, and grants from Food Allergy Anaphylaxis Programme (SickKids), outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and Section Chair of Food Allergy and Anaphylaxis, Canadian</style></keyword><keyword><style face="normal" font="default" size="100%">Society of Allergy and Clinical Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Healthcare Advisory Board, Food</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Canada. TK is a cofounder, shareholder, and board member of ATANIS</style></keyword><keyword><style face="normal" font="default" size="100%">Biotech AG. AE is a cofounder, consultant, and shareholder of ATANIS Biotech AG</style></keyword><keyword><style face="normal" font="default" size="100%">and Excellergy, Inc. AE received grants from ATANIS Biotech AG, Nestle, Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">AG, and BUHLMANN Laboratories AG. TE reports grants from CIHR, FWF, Food Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">and Anaphylaxis Program Sickkids, ALK. He is site PI of company sponsored trials</style></keyword><keyword><style face="normal" font="default" size="100%">by DBV, Novartis and Stallergenes Greer, EFSA and FARE. Personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Danone/Nutricia/Milupa, ThermoFisher, Aimmune, Stallergenes Greer, ALK, MADx and</style></keyword><keyword><style face="normal" font="default" size="100%">Nonfinancial support from Novartis and MADx, all outside the submitted work. He</style></keyword><keyword><style face="normal" font="default" size="100%">is an associate editor of Allergy.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39340441</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Peanut allergy is among the most severe and common food allergies. The diagnosis has a significant impact on the quality of life for patients and their families. An effective management approach depends on accurate, safe, and easily implementable diagnostic methods. We previously developed a cell-based assay using Hoxb8 mast cells (Hoxb8 MCs) aimed at improving clinical allergy diagnosis. In this study, we assessed its diagnostic performance by measuring blinded sera from a prospectively enrolled and pre-validated peanut allergy cohort. METHODS: Hoxb8 MCs were passively sensitized with sera from peanut-allergic and peanut tolerant children and adolescents (n = 112). Degranulation of Hoxb8 MCs was quantified upon stimulation with dose-titrated peanut extract by means of flow cytometry, using CD107a as activation marker. The results from the Hoxb8 mast cell activation test (Hoxb8 MAT) were compared to established diagnostic assays such as the skin prick test (SPT), specific IgE (sIgE) levels, and the basophil activation test (BAT). Additionally, serum samples from BAT nonresponders were assessed with the Hoxb8 MAT. RESULTS: Hoxb8 MAT displayed a robust dose-dependent activation to peanut extract, with a cutoff value of &lt;/=5.2% CD107a positive cells. The diagnostic accuracy was highest at allergen concentrations &gt;/=100 ng/mL, with an area under the receiver operating characteristic curve (AUROC) of 0.97, 93% sensitivity, and 96% specificity, outperforming traditional SPT and sIgE tests. When compared to BAT, Hoxb8 MAT exhibited comparable diagnostic efficacy. Moreover, sera from BAT nonresponders were accurately classified into allergics and nonallergics by the Hoxb8 MAT. CONCLUSIONS: The Hoxb8 MAT demonstrated a very good diagnostic precision in patients prospectively assessed for peanut allergy comparable to the fresh whole blood-based BAT. Additionally, it demonstrated its value for accurate classification of BAT nonresponders into allergic and nonallergic individuals. Further investigations into its utility in the routine clinical setting are warranted.</style></abstract><notes><style face="normal" font="default" size="100%">Bachmeier-Zbaren, Noemi&#xD;Celik, Alper&#xD;van Brummelen, Robin&#xD;Roos, Nadine&#xD;Steinmann, Melanie&#xD;Hoang, Jennifer A&#xD;Yin, Xiaojun&#xD;Ditlof, Christina M&#xD;Duan, Lucy&#xD;Upton, Julia E M&#xD;Kaufmann, Thomas&#xD;Eggel, Alexander&#xD;Eiwegger, Thomas&#xD;eng&#xD;Food Allergy and Anaphylaxis Program at the Hospital for Sick Children/&#xD;Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;Innosuisse - Schweizerische Agentur fur Innovationsforderung/&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):215-226. doi: 10.1111/all.16341. Epub 2024 Sep 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39340441</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724244</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16341</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2853</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2853</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hu, H.</style></author><author><style face="normal" font="default" size="100%">Zheng, Y.</style></author><author><style face="normal" font="default" size="100%">Ruan, L.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Tong, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Liang, K.</style></author><author><style face="normal" font="default" size="100%">Zhou, L.</style></author><author><style face="normal" font="default" size="100%">Chen, W.</style></author><author><style face="normal" font="default" size="100%">Hu, Y.</style></author><author><style face="normal" font="default" size="100%">Song, W.</style></author><author><style face="normal" font="default" size="100%">Lv, F.</style></author><author><style face="normal" font="default" size="100%">Ping, Y.</style></author><author><style face="normal" font="default" size="100%">Fang, K.</style></author><author><style face="normal" font="default" size="100%">Zhang, N.</style></author><author><style face="normal" font="default" size="100%">Wei, H.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Ma, P.</style></author><author><style face="normal" font="default" size="100%">Gao, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacy, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, China.&#xD;Hubei Micro-Explore Innovative Pharmaceutical Research Co., Ltd, Wuhan, Hubei, China.&#xD;Suzhou Organ-On-a-Chip System Science and Technology Co., Ltd, Suzhou, Jiangsu, China.&#xD;Department of Allergy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.&#xD;Department of Infectious Diseases, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.&#xD;Tianjin Second People&apos;s Hospital, Tianjin Institute of Hepatology, Clinical School of the Second People&apos;s Hospital, Tianjin Medical University, Nankai, Tianjin, China.&#xD;Institute of Infectious Diseases, Hubei Center of Diseases Control and Prevention, Wuhan, China.&#xD;Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.&#xD;Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;School of Basic Medical Sciences, Wuhan University Taikang Medical School, Wuhan, China.&#xD;Yichang Third People&apos;s Hospital, Yichang, China.&#xD;School of Pharmaceutical Sciences, Wuhan University, Wuhan, China.&#xD;Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.&#xD;Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pharmacy, Peking University Cancer Hospital &amp; Institute, Beijing, China.&#xD;Department of Infectious Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical, Epidemiological, Virological Characteristics and Outcomes of 286 Patients Infected With Monkeypox Virus in China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1436-1451</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/03/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Mpox, Monkeypox/epidemiology/virology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Monkeypox virus</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">Hiv</style></keyword><keyword><style face="normal" font="default" size="100%">Mpox (monkeypox)</style></keyword><keyword><style face="normal" font="default" size="100%">hospital-based</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, European Union (EU CURE, EU Syn-Air-G), Novartis Research Institutes</style></keyword><keyword><style face="normal" font="default" size="100%">(Basel, Switzerland), Stanford University (Redwood City, Calif), Seed Health</style></keyword><keyword><style face="normal" font="default" size="100%">(Boston, USA) and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">is the Co-Chair for EAACI</style></keyword><keyword><style face="normal" font="default" size="100%">Guidelines on Environmental Science in Allergic diseases and Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Chair of the</style></keyword><keyword><style face="normal" font="default" size="100%">EAACI Epithelial Cell Biology Working Group</style></keyword><keyword><style face="normal" font="default" size="100%">is on the Advisory Boards of</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron (Bern, Switzerland, New York, USA), Stanford University Sean</style></keyword><keyword><style face="normal" font="default" size="100%">Parker Asthma Allergy Center (CA, USA), Novartis (Basel, Switzerland), Glaxo</style></keyword><keyword><style face="normal" font="default" size="100%">Smith Kline (Zurich, Switzerland), Bristol-Myers Squibb (New York, USA), Seed</style></keyword><keyword><style face="normal" font="default" size="100%">Health (Boston, USA) and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">and is the Editor-in-Chief</style></keyword><keyword><style face="normal" font="default" size="100%">of Allergy. The other authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40156486</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Monkeypox virus (mpox) outbreak since 2022 has already constituted a public health emergency of international concern. A comprehensive study on epidemiological features, symptoms and signs, complications, sequelae, and clinical outcomes has been lacking. Accordingly, we performed a large-scale multicenter study to comprehensively summarize the clinical, epidemiological, behavioral, laboratory, virological characteristics, and treatment-related outcomes of mpox in China. METHOD: In this multicenter hospital-based retrospective study, demographic information, clinical characteristics, laboratory results, hospitalization records, prescribed medications, and clinical outcomes were extracted from the electronic medical records of 286 confirmed mpox cases from five regions of China. RESULT: An approximately 1:1 ratio of HIV-positive (52.1%) and HIV-negative was found, with an overall median age of 32 years (IQR 27-37). Most patients were male (99.3%), lived in urban areas (86.0%), single (72.6%), and had a college degree or higher (62.0%). Men having sex with men (MSM) was the predominant sexual orientation (83.0%), and sexual contact was the most likely mode of exposure (85.4%). 17 (9.6%) patients reported a history of smallpox vaccination. Hundered and seven patients had at least one co-morbid other sexually transmitted infection. Fourteen patients had a self-reported history of allergy. Significant differences were found between HIV-negative and HIV-positive mpox in the proportion of MSM, anal and perianal pain, levels of AST, CRP, CD4+ T-cell, CD8+ T-cell, NK-cell levels, and clinical outcomes. CONCLUSION: MSM individuals with an interquartile age range of 27-37 years, particularly from coastal or developed regions of China, were identified as &quot;main affected population&quot; for mpox prevention and control. HIV infection may contribute to more severe mpox manifestations, characterized by elevated AST and CRP levels, reduced CD4 + T-cell and NK-cell counts, and unfavorable clinical outcomes with increased mortality.</style></abstract><notes><style face="normal" font="default" size="100%">Hu, Hankun&#xD;Zheng, Yang&#xD;Ruan, Lianguo&#xD;Liu, Yamin&#xD;Tong, Yeqing&#xD;Chen, Yaokai&#xD;Liang, Ke&#xD;Zhou, Li&#xD;Chen, Wu&#xD;Hu, Yixin&#xD;Song, Wei&#xD;Lv, Feng&#xD;Ping, Yaodong&#xD;Fang, Kaiwen&#xD;Zhang, Nan&#xD;Wei, Hongxia&#xD;Akdis, Cezmi A&#xD;Ma, Ping&#xD;Gao, Yadong&#xD;eng&#xD;Wuhan University Degree and Graduate Education Teaching Reform Research Project/&#xD;National Natural Science Foundation of China/&#xD;Zhejiang Provincial Natural Science Foundation of China/&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1436-1451. doi: 10.1111/all.16540. Epub 2025 Mar 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40156486</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105066</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16540</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1398</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1398</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, J. J.</style></author><author><style face="normal" font="default" size="100%">Cao, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Dong, X.</style></author><author><style face="normal" font="default" size="100%">Wang, B. C.</style></author><author><style face="normal" font="default" size="100%">Lin, J.</style></author><author><style face="normal" font="default" size="100%">Yan, Y. Q.</style></author><author><style face="normal" font="default" size="100%">Liu, G. H.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Gao, Y. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland.&#xD;Functional Genomics Center Zurich, ETH Zurich/University of Zurich, Zurich, Switzerland.&#xD;Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Department of Infectious Disease, No.7 Hospital of Wuhan, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">533-550</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/07/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*blood/*mortality/*pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">clinical characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus disease 2019</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">severity</style></keyword><keyword><style face="normal" font="default" size="100%">Christine Kuhne-Center for Allergy Research and Education, European Commission&apos;s</style></keyword><keyword><style face="normal" font="default" size="100%">Horizon&apos;s 2020 Framework Programme, Cure, Novartis Research Institutes,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Scibase, and advisory role in Sanofi/Regeneron. All other authors</style></keyword><keyword><style face="normal" font="default" size="100%">declare no conflict of interest outside the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32662525</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The coronavirus disease 2019 (COVID-19) has become a global pandemic, with 10%-20% of severe cases and over 508 000 deaths worldwide. OBJECTIVE: This study aims to address the risk factors associated with the severity of COVID-19 patients and the mortality of severe patients. METHODS: 289 hospitalized laboratory-confirmed COVID-19 patients were included in this study. Electronic medical records, including patient demographics, clinical manifestation, comorbidities, laboratory tests results, and radiological materials, were collected and analyzed. According to the severity and outcomes of the patients, they were divided into three groups: nonsurvived (n = 49), survived severe (n = 78), and nonsevere (n = 162) groups. Clinical, laboratory, and radiological data were compared among these groups. Principal component analysis (PCA) was applied to reduce the dimensionality and visualize the patients on a low-dimensional space. Correlations between clinical, radiological, and laboratory parameters were investigated. Univariate and multivariate logistic regression methods were used to determine the risk factors associated with mortality in severe patients. Longitudinal changes of laboratory findings of survived severe cases and nonsurvived cases during hospital stay were also collected. RESULTS: Of the 289 patients, the median age was 57 years (range, 22-88) and 155 (53.4%) patients were male. As of the final follow-up date of this study, 240 (83.0%) patients were discharged from the hospital and 49 (17.0%) patients died. Elder age, underlying comorbidities, and increased laboratory variables, such as leukocyte count, neutrophil count, neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), procalcitonin (PCT), D-dimer, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood urea nitrogen (BUN) on admission, were found in survived severe cases compared to nonsevere cases. According to the multivariate logistic regression analysis, elder age, a higher number of affected lobes, elevated CRP levels on admission, increased prevalence of chest tightness/dyspnea, and smoking history were independent risk factors for death of severe patients. A trajectory in PCA was observed from &quot;nonsevere&quot; toward &quot;nonsurvived&quot; via &quot;severe and survived&quot; patients. Strong correlations between the age of patients, the affected lobe numbers, and laboratory variables were identified. Dynamic changes of laboratory findings of survived severe cases and nonsurvived cases during hospital stay showed that continuing increase of leukocytes and neutrophil count, sustained lymphopenia and eosinopenia, progressing decrease in platelet count, as well as high levels of NLR, CRP, PCT, AST, BUN, and serum creatinine were associated with in-hospital death. CONCLUSIONS: Survived severe and nonsurvived COVID-19 patients had distinct clinical and laboratory characteristics, which were separated by principle component analysis. Elder age, increased number of affected lobes, higher levels of serum CRP, chest tightness/dyspnea, and smoking history were risk factors for mortality of severe COVID-19 patients. Longitudinal changes of laboratory findings may be helpful in predicting disease progression and clinical outcome of severe patients.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Jin-Jin&#xD;Cao, Yi-Yuan&#xD;Tan, Ge&#xD;Dong, Xiang&#xD;Wang, Bin-Chen&#xD;Lin, Jun&#xD;Yan, You-Qin&#xD;Liu, Guang-Hui&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;Gao, Ya-Dong&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):533-550. doi: 10.1111/all.14496. Epub 2020 Aug 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32662525</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7404752</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14496</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2470</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2470</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez-Moreno, A. M.</style></author><author><style face="normal" font="default" size="100%">Torres, P.</style></author><author><style face="normal" font="default" size="100%">Paris, J. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clovibactin: Discovery and antimicrobial mechanism of action</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2302-2304</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/04/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Infective Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Discovery</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial</style></keyword><keyword><style face="normal" font="default" size="100%">depsipeptide</style></keyword><keyword><style face="normal" font="default" size="100%">immutable molecular target</style></keyword><keyword><style face="normal" font="default" size="100%">mechanism of action</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38666369</style></accession-num><notes><style face="normal" font="default" size="100%">Perez-Moreno, Ana M&#xD;Torres, Pablo&#xD;Paris, Juan L&#xD;eng&#xD;Instituto de Salud Carlos III/&#xD;Agencia Estatal de Investigacion/&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2302-2304. doi: 10.1111/all.16144. Epub 2024 Apr 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38666369</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16144</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3114</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3114</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, Z. Q.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Ye, J.</style></author><author><style face="normal" font="default" size="100%">Sun, L. Y.</style></author><author><style face="normal" font="default" size="100%">Ong, H. H.</style></author><author><style face="normal" font="default" size="100%">Peng, Y.</style></author><author><style face="normal" font="default" size="100%">Lin, B. Q.</style></author><author><style face="normal" font="default" size="100%">Tu, J. H.</style></author><author><style face="normal" font="default" size="100%">Wang, K. S.</style></author><author><style face="normal" font="default" size="100%">Xiong, Y. S.</style></author><author><style face="normal" font="default" size="100%">Luo, Q.</style></author><author><style face="normal" font="default" size="100%">Thong, M.</style></author><author><style face="normal" font="default" size="100%">Xu, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, D. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China.&#xD;Department of Otolaryngology, Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Department of Allergy, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.&#xD;First School of Clinical Medicine, Renmin Hospital of Wuhan University, Wuhan, China.&#xD;State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.&#xD;Department of Otolaryngology, Head and Neck Surgery, National University Hospital, National University Health System, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Club Cells in Nasal Epithelial Repair: Insights From an IL-13-Induced Inflammatory Model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">club cells</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">nasal epithelial repair</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41123053</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Club cells, originating from basal cells, can differentiate into ciliated or goblet cells in the lower respiratory tract, but their role in nasal epithelium during chronic rhinosinusitis with nasal polyps (CRSwNP) is not well understood. We aim to investigate the role of club cells in CRSwNP and their biological mechanism in an IL-13-induced inflammation model of human nasal epithelial cells (HNECs). METHODS: CRSwNP was classified into four endotypes (N(-)E(-), N(+)E(-), N(-)E(+), and N(+)E(+)) based on neutrophil and eosinophil infiltration. The expression of basal (TP63(+)), club (SCGB1A1(+)), ciliated (betaIV-tubulin(+)), and goblet cells (MUC5AC(+)) was assessed in healthy controls (n = 23) and CRSwNP (n = 73) using RT-qPCR, western blot (WB), and immunofluorescence. The effects of IL-13, Dupilumab, and STAT6 inhibitor (AS1517499) on cell differentiation were investigated in HNECs (n = 9) through RT-qPCR, WB, and flow cytometry (FCM). RESULTS: Club and ciliated cells significantly decreased in four endotypes of CRSwNP (all p &lt; 0.001), while basal and goblet cells increased in neutrophilic and eosinophilic CRSwNP, respectively (all p &lt; 0.05). In vitro, IL-13-induced significant cilia loss and MUC5AC secretion compared to IFN-gamma and IL-17A (all p &lt; 0.05), and FCM revealed a shift from SCGB1A1(+)betaIV-tubulin(+) to SCGB1A1(+)MUC5AC(+) cells by IL-13-treated (all p &lt; 0.05). Furthermore, Dupilumab mitigated IL-13-induced changes more effectively than AS1517499 (all p &lt; 0.05). CONCLUSIONS: Club cells are crucial in nasal epithelial repair, which is notably compromised in CRSwNP. This impairment is highlighted in an IL-13-induced inflammation model of nasal epithelium and further underscored by the therapeutic effect of Dupilumab in restoring epithelial repair mechanisms.</style></abstract><notes><style face="normal" font="default" size="100%">Huang, Zhi-Qun&#xD;Liu, Jing&#xD;Ye, Jing&#xD;Sun, Li-Ying&#xD;Ong, Hsiao Hui&#xD;Peng, Yang&#xD;Lin, Bing-Qi&#xD;Tu, Jun-Hao&#xD;Wang, Ke-Shuang&#xD;Xiong, Yi-Shan&#xD;Luo, Qing&#xD;Thong, Mark&#xD;Xu, Yu&#xD;Wang, De-Yun&#xD;eng&#xD;8207101/National Natural Science Foundation of China/&#xD;202206270150/China Scholarship Council/&#xD;202510017/Science and Technology Project of Jiangxi Provincial Health Commission/&#xD;NMRC/CIRG/1458/2016/National Medical Research Council/&#xD;2025M772056/China Postdoctoral Science Foundation/&#xD;Denmark&#xD;Allergy. 2025 Oct 22. doi: 10.1111/all.70115.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41123053</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70115</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1230</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1230</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blazowski, L.</style></author><author><style face="normal" font="default" size="100%">Jerzynska, J.</style></author><author><style face="normal" font="default" size="100%">Kurzawa, R.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Majak, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergology, National Research Institute of Tuberculosis and Lung Diseases, Rabka-Zdroj, Poland.&#xD;Department of Pathophysiology, Institute of Medical Science, Medical College of Rzeszow University, Rzeszow, Poland.&#xD;Paediatric and Allergology Department, Specialty Hospital, Jaslo, Poland.&#xD;Department of Paediatrics and Allergy, Medical University of Lodz, Lodz, Poland.&#xD;N. Copernicus Memorial Hospital, Lodz, Poland.&#xD;Institute of Health Science, Podhale State College of Applied Sciences, Nowy Targ, Poland.&#xD;Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Poland.&#xD;Department of Paediatric Pulmonology, Medical University of Lodz, Lodz, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cluster analysis of 505 real-life food-induced anaphylaxis in children reveals two stable clinical phenotypes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1585-1588</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/12/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cluster Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">food</style></keyword><keyword><style face="normal" font="default" size="100%">phenotypes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33316107</style></accession-num><notes><style face="normal" font="default" size="100%">Blazowski, Lukasz&#xD;Jerzynska, Joanna&#xD;Kurzawa, Ryszard&#xD;Kuna, Piotr&#xD;Majak, Pawel&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1585-1588. doi: 10.1111/all.14705. Epub 2020 Dec 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33316107</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14705</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3167</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3167</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuks, P. J. M.</style></author><author><style face="normal" font="default" size="100%">Karp, T.</style></author><author><style face="normal" font="default" size="100%">Hartman, J. E.</style></author><author><style face="normal" font="default" size="100%">Kraft, M.</style></author><author><style face="normal" font="default" size="100%">Siddiqui, S.</style></author><author><style face="normal" font="default" size="100%">Fabbri, L. M.</style></author><author><style face="normal" font="default" size="100%">Beghe, B.</style></author><author><style face="normal" font="default" size="100%">Rabe, K. F.</style></author><author><style face="normal" font="default" size="100%">Papi, A.</style></author><author><style face="normal" font="default" size="100%">Brightling, C. E.</style></author><author><style face="normal" font="default" size="100%">Singh, D.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Kocks, J. W. H.</style></author><author><style face="normal" font="default" size="100%">Scaffidi-Argentina, U.</style></author><author><style face="normal" font="default" size="100%">Kerstjens, H. A. M.</style></author><author><style face="normal" font="default" size="100%">Heijink, I. H.</style></author><author><style face="normal" font="default" size="100%">Pouwels, S. D.</style></author><author><style face="normal" font="default" size="100%">Slebos, D. J.</style></author><author><style face="normal" font="default" size="100%">van den Berge, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.&#xD;Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.&#xD;Samuel Bronfman Department of Medicine, Icahn School of Medicine, Mount Sinai Medical Center, New York, New York, USA.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Morphology, Surgery and Experimental Medicine, Section of Respiratory Medicine, University of Ferrara, Ferrara, Italy.&#xD;Department of Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy.&#xD;Department of Medicine, Christian Albrechts University Kiel, Kiel, Germany.&#xD;LungenClinic, Grosshansdorf, Germany.&#xD;Section of Respiratory Medicine, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.&#xD;The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.&#xD;Centre for Respiratory Medicine and Allergy, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.&#xD;General Practitioners Research Institute, Groningen, the Netherlands.&#xD;Observational and Pragmatic Research Institute, Singapore, Singapore.&#xD;Global Medical Affairs, Chiesi Farmaceutici S.p.A., Parma, Italy.&#xD;Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cluster Analysis to Identify Distinct Asthma Phenotypes in the ATLANTIS Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">185-196</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/11/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Cluster Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Function Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">airway inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma phenotypes</style></keyword><keyword><style face="normal" font="default" size="100%">small airways dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">Health, American Lung Association, Areteia, AstraZeneca, and Sanofi (funds paid</style></keyword><keyword><style face="normal" font="default" size="100%">to the University of Arizona through June 2022 and now to the Icahn School of</style></keyword><keyword><style face="normal" font="default" size="100%">Medicine at Mount Sinai). They report personal fees for consultancies from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Sanofi, Chiesi, GSK, Kinaset, and Genentech</style></keyword><keyword><style face="normal" font="default" size="100%">speaker fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi and Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">travel support from the European Respiratory Society</style></keyword><keyword><style face="normal" font="default" size="100%">participation on the ALung Data Safety Monitoring Board (funds paid to them)</style></keyword><keyword><style face="normal" font="default" size="100%">equity in RaeSedo Inc. (a company developing therapeutics for asthma in the</style></keyword><keyword><style face="normal" font="default" size="100%">preclinical phase, with no human trials, IND, or revenue)</style></keyword><keyword><style face="normal" font="default" size="100%">one issued and two</style></keyword><keyword><style face="normal" font="default" size="100%">pending patents for the development of therapeutics for inflammatory lung disease</style></keyword><keyword><style face="normal" font="default" size="100%">(no funding)</style></keyword><keyword><style face="normal" font="default" size="100%">leadership roles in the National Heart, Lung and Blood Advisory</style></keyword><keyword><style face="normal" font="default" size="100%">Council (completed in 2022, funds paid to them) and the Association of Professors</style></keyword><keyword><style face="normal" font="default" size="100%">of Medicine (unpaid)</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees as a Section Editor for UpToDate. L.M.F.</style></keyword><keyword><style face="normal" font="default" size="100%">reports consulting fees from Chiesi, GSK, AstraZeneca, Novartis, Verona Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">and ICON</style></keyword><keyword><style face="normal" font="default" size="100%">speaker fees from Chiesi, GSK, Lusofarmaco, and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">participation</style></keyword><keyword><style face="normal" font="default" size="100%">on advisory boards for Chiesi, ICON, and Novartis. K.F.R. reports payments for</style></keyword><keyword><style face="normal" font="default" size="100%">lectures from AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Sanofi &amp; Regeneron, GlaxoSmithKline, Berlin Chemie, and Roche Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">participation on advisory boards for AstraZeneca, Boehringer Ingelheim, and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi &amp; Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">and leadership roles in the German Center for Lung Research</style></keyword><keyword><style face="normal" font="default" size="100%">(DZL), German Chest Society (DGP), and American Thoracic Society (ATS). A.P.</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants to their institution from Chiesi, AstraZeneca, GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Chiesi, AstraZeneca, GlaxoSmithKline, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, Iqvia, Avillion, Elpen Pharmaceuticals, Moderna, and Roche</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria for</style></keyword><keyword><style face="normal" font="default" size="100%">lectures from Chiesi, AstraZeneca, GlaxoSmithKline, Menarini, Zambon,</style></keyword><keyword><style face="normal" font="default" size="100%">Mundipharma, Sanofi, Edmond Pharma, Iqvia, Avillion, Sanofi, and Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">participation on advisory boards for Chiesi, AstraZeneca, GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Sanofi, Iqvia, Avillion, Elpen Pharmaceuticals, and Moderna</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">receipt of materials from Consorzio Futuro in Ricerca. C.B. reports grants and</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy fees paid to their institution from 4D Pharma, Areteia, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, Genentech, GlaxoSmithKline, Mologic, Novartis, Regeneron Pharmaceuticals,</style></keyword><keyword><style face="normal" font="default" size="100%">Roche, and Sanofi. D.S. reports consulting fees received from Aerogen,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, EpiEndo,</style></keyword><keyword><style face="normal" font="default" size="100%">Genentech, GlaxoSmithKline, Glenmark, Gossamer Bio, Kinaset Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">Menarini, Novartis, Orion, Pulmatrix, Sanofi, Synairgen, Teva, Theravance</style></keyword><keyword><style face="normal" font="default" size="100%">Biopharma, Verona Pharma. J.W.H.K. reports grants to their institution from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, and Valneva</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, TEVA, MSD, COVIS Pharma, and</style></keyword><keyword><style face="normal" font="default" size="100%">Jansen</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria for lectures from Mundi Pharma and ALK-Albello</style></keyword><keyword><style face="normal" font="default" size="100%">leadership</style></keyword><keyword><style face="normal" font="default" size="100%">roles as ERS group chair, President/board member of the International Primary</style></keyword><keyword><style face="normal" font="default" size="100%">Care Respiratory Group, member of the CAHAG scientific committee, and board</style></keyword><keyword><style face="normal" font="default" size="100%">member of the Inhalation Institute Netherlands</style></keyword><keyword><style face="normal" font="default" size="100%">stocks as Director of the General</style></keyword><keyword><style face="normal" font="default" size="100%">Practitioners Research Institute and &lt; 5% in Lothar Medtec. H.A.M.K. reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from GlaxoSmithKline and Novartis, and participation on advisory boards</style></keyword><keyword><style face="normal" font="default" size="100%">with GlaxoSmithKline, Novartis, AstraZeneca, and Sanofi. I.H.H. reports receiving</style></keyword><keyword><style face="normal" font="default" size="100%">research grants from Roche, Boehringer Ingelheim, Health Holland, Netherlands</style></keyword><keyword><style face="normal" font="default" size="100%">Lung Foundation, and NWO, outside the submitted work. M.v.d.B. reports receiving</style></keyword><keyword><style face="normal" font="default" size="100%">research grants paid to their institution from GlaxoSmithKline, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Novartis, Genentech, and Roche. All other authors declare no</style></keyword><keyword><style face="normal" font="default" size="100%">competing interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41212157</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Previous cluster analyses have identified subgroups of asthma. However, only a few studies included parameters of small airways dysfunction (SAD), or gene expression profiles reflecting underlying disease mechanisms. We aimed to identify clinically distinct asthma phenotypes, beyond GINA asthma severity, using available data from the ATLANTIS study which focused on identifying the prevalence of SAD in asthma and its role in asthma control, exacerbations and quality of life. METHODS: The ATLANTIS study included 773 asthma patients (mean age 44 years, 58% female, 76% never-smoker, GINA 1-5). Subjects were extensively characterized, including symptoms, parameters of large and small airways dysfunction, blood and sputum differential cell counts, and genome-wide gene expression profiling from nasal brushes. Clusters were generated using the Self-Organizing Map-Ward&apos;s method. RESULTS: Four distinct clusters were identified: A (N = 62; 8%) characterized by the most frequent exacerbations, lower post-bronchodilator FEV(1) % predicted, more small airways dysfunction, higher sputum and blood eosinophils, and high expression of asthma-related genes. B (N = 206; 27%) consisting of atopic patients with early-onset asthma, uncontrolled symptoms, and normal lung function and bronchial hyperresponsiveness, along with a high expression of asthma-related genes in the nasal epithelium. C (N = 277; 36%), predominantly male former smokers, with well-controlled asthma, mild obstructive lung disease, and relatively high neutrophil levels. D (N = 228; 29%), with normal lung function and low blood and sputum eosinophils. CONCLUSIONS: Four distinct clusters were identified, where the presence of SAD was associated with high type-2 inflammation, lower lung function, and frequent exacerbations. SAD may be a marker of poorly controlled asthma and should be considered as an important clinical trait.</style></abstract><notes><style face="normal" font="default" size="100%">Kuks, Pauline J M&#xD;Karp, Tatiana&#xD;Hartman, Jorine E&#xD;Kraft, Monica&#xD;Siddiqui, Salman&#xD;Fabbri, Leonardo M&#xD;Beghe, Bianca&#xD;Rabe, Klaus F&#xD;Papi, Alberto&#xD;Brightling, Christopher E&#xD;Singh, Dave&#xD;Li, Xingnan&#xD;Kocks, Janwillem W H&#xD;Scaffidi-Argentina, Ulrica&#xD;Kerstjens, Huib A M&#xD;Heijink, Irene H&#xD;Pouwels, Simon D&#xD;Slebos, Dirk-Jan&#xD;van den Berge, Maarten&#xD;eng&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):185-196. doi: 10.1111/all.70127. Epub 2025 Nov 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41212157</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773654</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70127</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2233</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2233</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Galdiero, M. R.</style></author><author><style face="normal" font="default" size="100%">Ciaglia, E.</style></author><author><style face="normal" font="default" size="100%">Dal Col, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.&#xD;WAO Center of Excellence, Naples, Italy.&#xD;Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council, Naples, Italy.&#xD;Department of Medicine, Surgery and Dentistry &quot;Scuola Medica Salernitana&quot;, University of Salerno, Salerno, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CMTM4 as a new partner for IL-17 receptor: Adding a piece in the puzzle of IL17-driven diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3282-3284</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/08/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Interleukin-17</style></keyword><keyword><style face="normal" font="default" size="100%">*MARVEL Domain-Containing Proteins/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37632159</style></accession-num><notes><style face="normal" font="default" size="100%">Galdiero, M R&#xD;Ciaglia, E&#xD;Dal Col, J&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3282-3284. doi: 10.1111/all.15862. Epub 2023 Aug 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37632159</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15862</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3259</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3259</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leung, Agnes Sze-yin</style></author><author><style face="normal" font="default" size="100%">Gu, Yanjun</style></author><author><style face="normal" font="default" size="100%">Au, Ann Wing-shan</style></author><author><style face="normal" font="default" size="100%">Leung, Rosetta Tsz-ching</style></author><author><style face="normal" font="default" size="100%">Tang, Vanessa Hiu-tung</style></author><author><style face="normal" font="default" size="100%">Fung, Kin Yi</style></author><author><style face="normal" font="default" size="100%">Li, Janice Min</style></author><author><style face="normal" font="default" size="100%">Wai, Christine Yee-yan</style></author><author><style face="normal" font="default" size="100%">Leung, Ting Fan</style></author><author><style face="normal" font="default" size="100%">Wong, Gary Wing-kin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Codfish Oral Immunotherapy in Children Aged 2–10: Randomized Placebo-Controlled Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background For young children with fish allergy, dietary avoidance is the current standard of care. We aimed to assess whether codfish oral immunotherapy (OIT) can induce desensitization or sustained unresponsiveness (SU) in this population. Methods We conducted a randomized, double-blind, placebo-controlled study in Hong Kong. Children aged 2–10 years reactive to codfish protein during DBPCFC were randomly assigned 1:1 to codfish OIT or placebo for 52 weeks (1000 mg daily maintenance) followed by 8 weeks avoidance. Primary outcome was desensitization at week 52; sustained unresponsiveness (SU) at week 60 was a key secondary outcome. Results Between November 2022–September 2023, 70 children (median age 5.6 years) were randomized to codfish OIT (n = 35) or placebo (n = 35). At the week 52 end-of-treatment challenges, 15 (43%) OIT participants versus 4 (11%) placebo achieved desensitization (risk difference 32%, 95% CI 9%–51%; p = 0.003), with significantly greater increases in cumulative tolerated protein [median 4330 mg vs. 0 mg, p &lt; 0.001]. At week 60, SU rates were 8 (23%) versus 3 (9%) (risk difference 14%, 95% CI −5% to 33%; p = 0.332). Codfish OIT significantly decreased codfish-specific IgE, rGad c1-specific IgE, and skin reactivity while increasing codfish-specific IgG4. The treatment demonstrated acceptable safety with minimal moderate-to-severe adverse events and epinephrine use (3% both groups), and immunological evidence of reduced cross-reactivity to salmon and catfish allergens. Conclusions In children with fish allergy, codfish OIT significantly increased desensitization rates compared to avoidance, though SU remained limited. The treatment demonstrated acceptable safety with predominantly mild reactions and reduced IgE cross-reactivity to other fish allergens. Trial Registration ClinicalTrials.gov identifier: NCT05590299</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70268</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70268</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1255</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1255</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maltseva, N.</style></author><author><style face="normal" font="default" size="100%">Borzova, E.</style></author><author><style face="normal" font="default" size="100%">Fomina, D.</style></author><author><style face="normal" font="default" size="100%">Bizjak, M.</style></author><author><style face="normal" font="default" size="100%">Terhorst-Molawi, D.</style></author><author><style face="normal" font="default" size="100%">Kosnik, M.</style></author><author><style face="normal" font="default" size="100%">Kulthanan, K.</style></author><author><style face="normal" font="default" size="100%">Meshkova, R.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Cold-Ce Steering Committee</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Allergy and Immunology, Clinical State Hospital 52, Moscow Ministry of Healthcare, Moscow, Russian Federation.&#xD;Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;Department of Clinical Immunology and Allergology, I.M.Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.&#xD;Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Smolensk State Medical University, Smolensk, Russian Federation.&#xD;Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cold urticaria - What we know and what we do not know</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1077-1094</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/11/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Cold Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">*Histamine H1 Antagonists, Non-Sedating</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">cold stimulation testing</style></keyword><keyword><style face="normal" font="default" size="100%">cold urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">cryoglobulinemic vasculitis</style></keyword><keyword><style face="normal" font="default" size="100%">cryoglobulins</style></keyword><keyword><style face="normal" font="default" size="100%">familial cold autoinflammatory syndrome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33249577</style></accession-num><abstract><style face="normal" font="default" size="100%">Cold urticaria (ColdU) is a common form of chronic inducible urticaria characterized by the development of wheals, angioedema or both in response to cold exposure. Recent research and guideline updates have advanced our understanding and management of ColdU. Today, its pathophysiology is thought to involve the cold-induced formation of autoallergens and IgE to these autoallergens, which provoke a release of proinflammatory mediators from skin mast cells. The classification of ColdU includes typical and atypical subtypes. We know that cold-induced wheals usually develop on rewarming and resolve within an hour and that anaphylaxis can occur. The diagnosis relies on the patient&apos;s history and cold stimulation testing. Additional diagnostic work-up, including a search for underlying infections, should only be done if indicated by the patient&apos;s history. The management of ColdU includes cold avoidance, the regular use of nonsedating antihistamines and the off-label use of omalizumab. However, many questions regarding ColdU remain unanswered. Here, we review what is known about ColdU, and we present important unanswered questions on the epidemiology, underlying pathomechanisms, clinical heterogeneity and treatment outcomes. Our aim is to guide future efforts that will close these knowledge gaps and advance the management of ColdU.</style></abstract><notes><style face="normal" font="default" size="100%">Maltseva, Natalya&#xD;Borzova, Elena&#xD;Fomina, Daria&#xD;Bizjak, Mojca&#xD;Terhorst-Molawi, Dorothea&#xD;Kosnik, Mitja&#xD;Kulthanan, Kanokvalai&#xD;Meshkova, Raisa&#xD;Thomsen, Simon Francis&#xD;Maurer, Marcus&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1077-1094. doi: 10.1111/all.14674. Epub 2020 Dec 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33249577</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14674</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1433</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1433</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shi, L. L.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">Deng, Y. K.</style></author><author><style face="normal" font="default" size="100%">Chen, C. L.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Cao, P. P.</style></author><author><style face="normal" font="default" size="100%">Long, X. B.</style></author><author><style face="normal" font="default" size="100%">Zeng, M.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cold-inducible RNA-binding protein contributes to tissue remodeling in chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">497-509</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/03/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">RNA-Binding Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">cold-inducible RNA-binding protein</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial cell</style></keyword><keyword><style face="normal" font="default" size="100%">macrophage</style></keyword><keyword><style face="normal" font="default" size="100%">matrix metalloproteinase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32198936</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cold-inducible RNA-binding protein (CIRP) is a newly identified damage-associated molecular pattern molecule. Its roles beyond promoting inflammation and in human diseases are poorly understood. This study aimed to investigate the involvement of CIRP in chronic rhinosinusitis with nasal polyps (CRSwNP). METHODS: Immunohistochemistry, quantitative RT-PCR, and ELISA were used to detect the expression of CIRP and matrix metalloproteinases (MMPs) in sinonasal mucosal samples and nasal secretions. Human nasal epithelial cells (HNECs) and THP-1 cells, a human monocytic/macrophage cell line, were cultured to explore the regulation of CIRP expression and MMP expression. RESULTS: Cytoplasmic CIRP expression in nasal epithelial cells and CD68(+) macrophages in sinonasal tissues, and CIRP levels in nasal secretions were significantly increased in both patients with eosinophilic and noneosinophilic CRSwNP as compared to those in control subjects. IL-4, IL-13, IL-10, IL-17A, TNF-alpha, Dermatophagoides pteronyssinus group 1, and lipopolysaccharide induced the production and secretion of CIRP from HNECs and macrophages differentiated from THP-1 cells. CIRP promoted MMP2, MMP7, MMP9, MMP12, and vascular endothelial growth factor A (VEGF-A) production from HNECs, macrophages differentiated from THP-1 cells, and polyp tissues, which was inhibited by the blocking antibody for Toll-like receptor 4, but not advanced glycation end products. The expression of MMPs and VEGF-A in tissues correlated with CIRP levels in nasal secretions in patients with CRSwNP. CONCLUSIONS: The upregulated production and release of CIRP from nasal epithelial cells and macrophages may contribute to the edema formation in both eosinophilic and noneosinophilic CRSwNP by inducing MMP and VEGF-A production from epithelial cells and macrophages.</style></abstract><notes><style face="normal" font="default" size="100%">Shi, Li-Li&#xD;Ma, Jin&#xD;Deng, Yi-Ke&#xD;Chen, Cai-Ling&#xD;Wang, Heng&#xD;Cao, Ping-Ping&#xD;Long, Xiao-Bo&#xD;Zeng, Ming&#xD;Liu, Zheng&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):497-509. doi: 10.1111/all.14287. Epub 2020 Apr 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32198936</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14287</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1597</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1597</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shi, L. L.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">Deng, Y. K.</style></author><author><style face="normal" font="default" size="100%">Chen, C. L.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Cao, P. P.</style></author><author><style face="normal" font="default" size="100%">Long, X. B.</style></author><author><style face="normal" font="default" size="100%">Zeng, M.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cold-inducible RNA-binding protein contributes to tissue remodeling in chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">497-509</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/03/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">RNA-Binding Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">cold-inducible RNA-binding protein</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial cell</style></keyword><keyword><style face="normal" font="default" size="100%">macrophage</style></keyword><keyword><style face="normal" font="default" size="100%">matrix metalloproteinase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32198936</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cold-inducible RNA-binding protein (CIRP) is a newly identified damage-associated molecular pattern molecule. Its roles beyond promoting inflammation and in human diseases are poorly understood. This study aimed to investigate the involvement of CIRP in chronic rhinosinusitis with nasal polyps (CRSwNP). METHODS: Immunohistochemistry, quantitative RT-PCR, and ELISA were used to detect the expression of CIRP and matrix metalloproteinases (MMPs) in sinonasal mucosal samples and nasal secretions. Human nasal epithelial cells (HNECs) and THP-1 cells, a human monocytic/macrophage cell line, were cultured to explore the regulation of CIRP expression and MMP expression. RESULTS: Cytoplasmic CIRP expression in nasal epithelial cells and CD68(+) macrophages in sinonasal tissues, and CIRP levels in nasal secretions were significantly increased in both patients with eosinophilic and noneosinophilic CRSwNP as compared to those in control subjects. IL-4, IL-13, IL-10, IL-17A, TNF-alpha, Dermatophagoides pteronyssinus group 1, and lipopolysaccharide induced the production and secretion of CIRP from HNECs and macrophages differentiated from THP-1 cells. CIRP promoted MMP2, MMP7, MMP9, MMP12, and vascular endothelial growth factor A (VEGF-A) production from HNECs, macrophages differentiated from THP-1 cells, and polyp tissues, which was inhibited by the blocking antibody for Toll-like receptor 4, but not advanced glycation end products. The expression of MMPs and VEGF-A in tissues correlated with CIRP levels in nasal secretions in patients with CRSwNP. CONCLUSIONS: The upregulated production and release of CIRP from nasal epithelial cells and macrophages may contribute to the edema formation in both eosinophilic and noneosinophilic CRSwNP by inducing MMP and VEGF-A production from epithelial cells and macrophages.</style></abstract><notes><style face="normal" font="default" size="100%">Shi, Li-Li&#xD;Ma, Jin&#xD;Deng, Yi-Ke&#xD;Chen, Cai-Ling&#xD;Wang, Heng&#xD;Cao, Ping-Ping&#xD;Long, Xiao-Bo&#xD;Zeng, Ming&#xD;Liu, Zheng&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):497-509. doi: 10.1111/all.14287. Epub 2020 Apr 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32198936</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14287</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1634</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1634</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moon, H. G.</style></author><author><style face="normal" font="default" size="100%">Kim, S. J.</style></author><author><style face="normal" font="default" size="100%">Lee, M. K.</style></author><author><style face="normal" font="default" size="100%">Kang, H.</style></author><author><style face="normal" font="default" size="100%">Choi, H. S.</style></author><author><style face="normal" font="default" size="100%">Harijith, A.</style></author><author><style face="normal" font="default" size="100%">Ren, J.</style></author><author><style face="normal" font="default" size="100%">Natarajan, V.</style></author><author><style face="normal" font="default" size="100%">Christman, J. W.</style></author><author><style face="normal" font="default" size="100%">Ackerman, S. J.</style></author><author><style face="normal" font="default" size="100%">Park, G. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.&#xD;Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.&#xD;Department of Pediatrics, University of Illinois at Chicago, IL, USA.&#xD;Center for Biomolecular Science, College of Pharmacy, University of Illinois at Chicago, IL, USA.&#xD;Department of Pharmacology, University of Illinois at Chicago, IL, USA.&#xD;Section of Pulmonary, Critical Care, and Sleep Medicine, Davis Heart and Lung, the Ohio State University, Columbus, OH, USA.&#xD;Department of Biochemistry and Molecular Genetics, and Medicine, University of Illinois at Chicago, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Colony-stimulating factor 1 and its receptor are new potential therapeutic targets for allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">357-369</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2019/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens/immunology/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anisoles/*administration &amp; dosage/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/chemically induced/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Delivery Systems/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophage Colony-Stimulating Factor/*antagonists &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors/genetics/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Nanostructures/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrimidines/*administration &amp; dosage/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Quaternary Ammonium Compounds/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/genetics/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonic Acids/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Csf1</style></keyword><keyword><style face="normal" font="default" size="100%">Csf1r</style></keyword><keyword><style face="normal" font="default" size="100%">airway epithelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">airway remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">asthma therapy</style></keyword><keyword><style face="normal" font="default" size="100%">chronic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">dendritic cells</style></keyword><keyword><style face="normal" font="default" size="100%">related to the submitted manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31385613</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A new approach targeting aeroallergen sensing in the early events of mucosal immunity could have greater benefit. The CSF1-CSF1R pathway has a critical role in trafficking allergens to regional lymph nodes through activating dendritic cells. Intervention in this pathway could prevent allergen sensitization and subsequent Th2 allergic inflammation. OBJECTIVE: To examine the therapeutic effectiveness of CSF1 and CSF1R inhibition for blocking the dendritic cell function of sensing aeroallergens. METHODS: We adopted a model of chronic asthma induced by a panel of three naturally occurring allergens and novel delivery system of CSF1R inhibitor encapsulated nanoprobe. RESULTS: Selective depletion of CSF1 in airway epithelial cells abolished the production of allergen-reactive IgE, resulting in prevention of new asthma development as well as reversal of established allergic lung inflammation. CDPL-GW nanoprobe containing GW2580, a selective CSF1R inhibitor, showed favorable pharmacokinetics for inhalational treatment and intranasal insufflation delivery of CDPL-GW nanoprobe ameliorated asthma pathologies including allergen-specific serum IgE production, allergic lung and airway inflammation and airway hyper-responsiveness (AHR) with minimal pulmonary adverse reaction. CONCLUSION: The inhibition of the CSF1-CSF1R signaling pathway effectively suppresses sensitization to aeroallergens and consequent allergic lung inflammation in a murine model of chronic asthma. CSF1R inhibition is a promising new target for the treatment of allergic asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Moon, Hyung-Geun&#xD;Kim, Seung-Jae&#xD;Lee, Myoung Kyu&#xD;Kang, Homan&#xD;Choi, Hak Soo&#xD;Harijith, Anantha&#xD;Ren, Jinhong&#xD;Natarajan, Viswanathan&#xD;Christman, John W&#xD;Ackerman, Steven J&#xD;Park, Gye Young&#xD;eng&#xD;I01 BX004981/BX/BLRD VA/&#xD;R01 HL126852/HL/NHLBI NIH HHS/&#xD;R01 HL137224/HL/NHLBI NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Feb;75(2):357-369. doi: 10.1111/all.14011. Epub 2019 Oct 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31385613</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7002247</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14011</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3074</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3074</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bhasin, M.</style></author><author><style face="normal" font="default" size="100%">Cooper, M.</style></author><author><style face="normal" font="default" size="100%">Macchiaverni, P.</style></author><author><style face="normal" font="default" size="100%">Joys, R. S.</style></author><author><style face="normal" font="default" size="100%">O&apos;Sullivan, T. A.</style></author><author><style face="normal" font="default" size="100%">Keelan, J. A.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Palmer, D. J.</style></author><author><style face="normal" font="default" size="100%">Lowe, A. J.</style></author><author><style face="normal" font="default" size="100%">Prescott, S. L.</style></author><author><style face="normal" font="default" size="100%">Silva, D.</style></author><author><style face="normal" font="default" size="100%">Verhasselt, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Larsson-Rosenquist Foundation Centre for Immunology and Breastfeeding, School of Medicine, University of Western Australia, Perth, Western Australia, Australia.&#xD;The Kids Research Institute Australia, Perth, Western Australia, Australia.&#xD;Department of Paediatrics, Joondalup Health Campus, Perth, Western Australia, Australia.&#xD;Nutrition &amp; Health Innovation Research Institute, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.&#xD;School of Medicine, University of Western Australia, Perth, Western Australia, Australia.&#xD;School of Biomedical Science, University of Western Australia, Perth, Western Australia, Australia.&#xD;Section of Allergy and Immunology, Department of Pediatrics, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Murdoch Children&apos;s Research Institute, Centre for Food Allergy Research, Melbourne, Victoria, Australia.&#xD;Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.&#xD;Nova Institute for Health, Baltimore, Maryland, USA.&#xD;Department of Family and Community Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.&#xD;School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Colostrum as a Protective Factor Against Peanut Allergy: Evidence From a Birth Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">paediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40968490</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food allergy affects families&apos; quality of life, can be lifelong and life-threatening, urging the identification of early modifiable risk factors. Formula feeding in the first days of life may increase the risk of cow&apos;s milk allergy, a risk often attributed to cow&apos;s milk allergens exposure. Early formula feeding also reduces the colostrum intake, the first 3 days&apos; milk, which is rich in bioactive compounds critical for immune and gut health. This study investigates whether partial colostrum feeding increases the risk of food allergy beyond cow&apos;s milk. METHODS: Data from 666 mother-infant pairs in the Australian ORIGINS cohort categorised neonates as exclusive colostrum-fed (ECF, only breastmilk) or partial colostrum-fed (PCF, formula plus breastmilk) within the first 3 days. IgE-mediated food allergy (egg, peanut, cow&apos;s milk, cashew) at 12-18 months was determined by skin prick tests and maternal-reported immediate reactions to allergens. RESULTS: PCF prevalence was 46%. PCF infants showed an increased risk of peanut allergy [aOR (95% CI) 4.47 (1.04-19.12)] and multiple food allergies [aOR 11.44 (1.48-88.55)] compared to ECF infants. Risk was greater in PCF infants with later (&gt; 7 M) peanut introduction [aOR 5.45 (1.18-25.11)], while ECF infants maintained a low risk regardless of timing. To disentangle the effect of reduced colostrum intake from formula feeding in PCF infants, we analysed the association between the number of colostrum feeds and allergic outcomes. No peanut allergy cases occurred in infants receiving nine or more colostrum feeds per day within their first 72 h, regardless of formula feeding. CONCLUSION: Partial colostrum feeding may be an overlooked risk factor for peanut and multiple food allergies. With over a third of neonates globally partially colostrum-fed, findings highlight the importance of promoting colostrum feeding and exploring colostrum-based therapies for high-risk infants.</style></abstract><notes><style face="normal" font="default" size="100%">Bhasin, Maheshwar&#xD;Cooper, Matthew&#xD;Macchiaverni, Patricia&#xD;Joys, Ravisha Srinivas&#xD;O&apos;Sullivan, Therese A&#xD;Keelan, Jeffrey A&#xD;Venter, Carina&#xD;Palmer, Debra J&#xD;Lowe, Adrian J&#xD;Prescott, Susan L&#xD;Silva, Desiree&#xD;Verhasselt, Valerie&#xD;eng&#xD;Channel 7 Telethon Trust/&#xD;Family Larsson-Rosenquist Foundation/&#xD;Denmark&#xD;Allergy. 2025 Sep 18. doi: 10.1111/all.70043.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40968490</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70043</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2410</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2410</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rekima, A.</style></author><author><style face="normal" font="default" size="100%">van den Elsen, L.</style></author><author><style face="normal" font="default" size="100%">Isnard, C.</style></author><author><style face="normal" font="default" size="100%">Smyth, D. J.</style></author><author><style face="normal" font="default" size="100%">Lynn, M. A.</style></author><author><style face="normal" font="default" size="100%">Yee, T.</style></author><author><style face="normal" font="default" size="100%">Stevens, N. E.</style></author><author><style face="normal" font="default" size="100%">Machado, S.</style></author><author><style face="normal" font="default" size="100%">Divakara, N.</style></author><author><style face="normal" font="default" size="100%">Bhasin, M.</style></author><author><style face="normal" font="default" size="100%">Tjiam, M. C.</style></author><author><style face="normal" font="default" size="100%">Rowel, C.</style></author><author><style face="normal" font="default" size="100%">Servant, F.</style></author><author><style face="normal" font="default" size="100%">Burcelin, R.</style></author><author><style face="normal" font="default" size="100%">Locksley, R.</style></author><author><style face="normal" font="default" size="100%">Maizels, R.</style></author><author><style face="normal" font="default" size="100%">Lynn, D. J.</style></author><author><style face="normal" font="default" size="100%">Egwang, T.</style></author><author><style face="normal" font="default" size="100%">Verhasselt, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Larsson-Rosenquist Centre for Immunology and Breastfeeding, School of Medicine, The University of Western Australia, Nedlands, Western Australia, Australia.&#xD;Telethon Kids Institute, Nedlands, Western Australia, Australia.&#xD;University of Nice, Nice, France.&#xD;Wellcome Centre for Integrative Parasitology, University of Glasgow, Glasgow, UK.&#xD;The South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.&#xD;Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia.&#xD;Centre for Child Health Research, The University of Western Australia, Perth, Western Australia, Australia.&#xD;Vector Control Division, Ministry of Health, Kampala, Uganda.&#xD;Vaiomer SAS, Toulouse-Labege, France.&#xD;I2MC, INSERM 1297, Toulouse, France.&#xD;Department of Medicine, University of California San Francisco, San Francisco, California, USA.&#xD;MedBiotech Laboratories, Kampala, Uganda.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Colostrum is required for the postnatal ontogeny of small intestine innate lymphoid type 2 cells and successful anti-helminth defences</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2247-2251</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/02/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Intestine, Small/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Colostrum/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Helminths/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Helminthiasis/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38348877</style></accession-num><notes><style face="normal" font="default" size="100%">Rekima, Akila&#xD;van den Elsen, Lieke&#xD;Isnard, Charlotte&#xD;Smyth, Danielle J&#xD;Lynn, Miriam A&#xD;Yee, Tee&#xD;Stevens, Natalie E&#xD;Machado, Savannah&#xD;Divakara, Nivedithaa&#xD;Bhasin, Maheshwar&#xD;Tjiam, M Christian&#xD;Rowel, Candia&#xD;Servant, Florence&#xD;Burcelin, Remy&#xD;Locksley, Richard&#xD;Maizels, Rick&#xD;Lynn, David J&#xD;Egwang, Thomas&#xD;Verhasselt, Valerie&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2247-2251. doi: 10.1111/all.16054. Epub 2024 Feb 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38348877</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16054</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1356</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1356</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hernandez-Pacheco, N.</style></author><author><style face="normal" font="default" size="100%">Gorenjak, M.</style></author><author><style face="normal" font="default" size="100%">Jurgec, S.</style></author><author><style face="normal" font="default" size="100%">Corrales, A.</style></author><author><style face="normal" font="default" size="100%">Jorgensen, A.</style></author><author><style face="normal" font="default" size="100%">Karimi, L.</style></author><author><style face="normal" font="default" size="100%">Vijverberg, S. J.</style></author><author><style face="normal" font="default" size="100%">Berce, V.</style></author><author><style face="normal" font="default" size="100%">Schieck, M.</style></author><author><style face="normal" font="default" size="100%">Acosta-Herrera, M.</style></author><author><style face="normal" font="default" size="100%">Kerick, M.</style></author><author><style face="normal" font="default" size="100%">Samedy-Bates, L. A.</style></author><author><style face="normal" font="default" size="100%">Tavendale, R.</style></author><author><style face="normal" font="default" size="100%">Villar, J.</style></author><author><style face="normal" font="default" size="100%">Mukhopadhyay, S.</style></author><author><style face="normal" font="default" size="100%">Pirmohamed, M.</style></author><author><style face="normal" font="default" size="100%">Verhamme, K. M. C.</style></author><author><style face="normal" font="default" size="100%">Kabesch, M.</style></author><author><style face="normal" font="default" size="100%">Hawcutt, D. B.</style></author><author><style face="normal" font="default" size="100%">Turner, S.</style></author><author><style face="normal" font="default" size="100%">Palmer, C. N.</style></author><author><style face="normal" font="default" size="100%">Burchard, E. G.</style></author><author><style face="normal" font="default" size="100%">Maitland-van der Zee, A. H.</style></author><author><style face="normal" font="default" size="100%">Flores, C.</style></author><author><style face="normal" font="default" size="100%">Potocnik, U.</style></author><author><style face="normal" font="default" size="100%">Pino-Yanes, M.</style></author><author><style face="normal" font="default" size="100%">PiCa,</style></author><author><style face="normal" font="default" size="100%">SysPharmPedia, consortia</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit, Hospital Universitario N.S. de Candelaria, Universidad de La Laguna, Santa Cruz de Tenerife, Spain.&#xD;Genomics and Health Group, Department of Biochemistry, Microbiology, Cell Biology and Genetics, Universidad de La Laguna, San Cristobal de La Laguna, Santa Cruz de Tenerife, Spain.&#xD;Center for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia.&#xD;Laboratory for Biochemistry, Molecular Biology and Genomics, Faculty for Chemistry and Chemical Engineering, University of Maribor, Maribor, Slovenia.&#xD;CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.&#xD;Department of Biostatistics, University of Liverpool, Liverpool, UK.&#xD;Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.&#xD;Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht University, Utrecht, The Netherlands.&#xD;Department of Pediatric Respiratory Medicine and Allergy, Emma&apos;s Children Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Pediatrics, University Medical Centre Maribor, Maribor, Slovenia.&#xD;Department of Pediatric Pneumology and Allergy, University Children&apos;s Hospital Regensburg (KUNO), Regensburg, Germany.&#xD;Department of Human Genetics, Hannover Medical School, Hannover, Germany.&#xD;Cellular Biology and Immunology, Institute of Parasitology and Biomedicine Lopez-Neyra (IPBLN), Consejo Superior de Investigaciones Cientificas (CSIC), Granada, Spain.&#xD;Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.&#xD;Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.&#xD;Population Pharmacogenetics Group, Biomedical Research Institute, Ninewells Hospital, Medical School, University of Dundee, Dundee, UK.&#xD;Multidisciplinary Organ Dysfunction Evaluation Research Network, Research Unit, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Spain.&#xD;Keenan Research Center for Biomedical Science at the Li Ka Shing Knowledge Institute, St Michael&apos;s Hospital, Toronto, ON, Canada.&#xD;Academic Department of Paediatrics, Brighton and Sussex Medical School, Royal Alexandra Children&apos;s Hospital, Brighton, UK.&#xD;Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.&#xD;Department of Women&apos;s and Children&apos;s Health, University of Liverpool, Liverpool, UK.&#xD;Alder Hey Children&apos;s Hospital, Liverpool, UK.&#xD;Child Health, University of Aberdeen, Aberdeen, UK.&#xD;Genomics Division, Instituto Tecnologico y de Energias Renovables (ITER), Santa Cruz de Tenerife, Spain.&#xD;Instituto de Tecnologias Biomedicas (ITB), Universidad de La Laguna, San Cristobal de La Laguna, Santa Cruz de Tenerife, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Combined analysis of transcriptomic and genetic data for the identification of loci involved in glucocorticosteroid response in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1238-1243</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/08/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">*Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">childhood asthma</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbations</style></keyword><keyword><style face="normal" font="default" size="100%">genetic polymorphism</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacogenomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32786158</style></accession-num><notes><style face="normal" font="default" size="100%">Hernandez-Pacheco, Natalia&#xD;Gorenjak, Mario&#xD;Jurgec, Stasa&#xD;Corrales, Almudena&#xD;Jorgensen, Andrea&#xD;Karimi, Leila&#xD;Vijverberg, Susanne J&#xD;Berce, Vojko&#xD;Schieck, Maximilian&#xD;Acosta-Herrera, Marialbert&#xD;Kerick, Martin&#xD;Samedy-Bates, Lesly-Anne&#xD;Tavendale, Roger&#xD;Villar, Jesus&#xD;Mukhopadhyay, Somnath&#xD;Pirmohamed, Munir&#xD;Verhamme, Katia M C&#xD;Kabesch, Michael&#xD;Hawcutt, Daniel B&#xD;Turner, Steve&#xD;Palmer, Colin N&#xD;Burchard, Esteban G&#xD;Maitland-van der Zee, Anke H&#xD;Flores, Carlos&#xD;Potocnik, Uros&#xD;Pino-Yanes, Maria&#xD;eng&#xD;R01 ES015794/ES/NIEHS NIH HHS/&#xD;099177/Z/12/Z/Wellcome Trust Biomedical Resource/&#xD;R01 HL117004/HL/NHLBI NIH HHS/&#xD;WT_/Wellcome Trust/United Kingdom&#xD;X01HL134589/National Heart, Lung, and Blood Institute of the National Institute of Health/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1238-1243. doi: 10.1111/all.14552. Epub 2020 Sep 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32786158</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7908891</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14552</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kratzer, B.</style></author><author><style face="normal" font="default" size="100%">Schlax, L. C.</style></author><author><style face="normal" font="default" size="100%">Gattinger, P.</style></author><author><style face="normal" font="default" size="100%">Waidhofer-Sollner, P.</style></author><author><style face="normal" font="default" size="100%">Trapin, D.</style></author><author><style face="normal" font="default" size="100%">Tauber, P. A.</style></author><author><style face="normal" font="default" size="100%">Sehgal, A. N. A.</style></author><author><style face="normal" font="default" size="100%">Kormoczi, U.</style></author><author><style face="normal" font="default" size="100%">Rottal, A.</style></author><author><style face="normal" font="default" size="100%">Feichter, M.</style></author><author><style face="normal" font="default" size="100%">Oberhofer, T.</style></author><author><style face="normal" font="default" size="100%">Grabmeier-Pfistershammer, K.</style></author><author><style face="normal" font="default" size="100%">Borochova, K.</style></author><author><style face="normal" font="default" size="100%">Dorofeeva, Y.</style></author><author><style face="normal" font="default" size="100%">Tulaeva, I.</style></author><author><style face="normal" font="default" size="100%">Weber, M.</style></author><author><style face="normal" font="default" size="100%">Muhl, B.</style></author><author><style face="normal" font="default" size="100%">Kropfmuller, A.</style></author><author><style face="normal" font="default" size="100%">Negrin, B.</style></author><author><style face="normal" font="default" size="100%">Kundi, M.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Pickl, W. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Vienna, Austria.&#xD;Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology, Department of Pathophysiology and Allergy Research, Vienna, Austria.&#xD;I. M. Sechenov First Moscow State Medical University (Sechenov University), Department of Clinical Immunology and Allergology, Laboratory for Immunopathology, Moscow, Russia.&#xD;Labors.at, Vienna, Austria.&#xD;Osterreichische Gesundheitskasse, Klinikum Peterhof, Baden, Austria.&#xD;Medical University of Vienna, Center for Public Health, Department for Environmental Health, Vienna, Austria.&#xD;NRC Institute of Immunology FMBA of Russia, Moscow, Russia.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Combined assessment of S- and N-specific IL-2 and IL-13 secretion and CD69 neo-expression for discrimination of post-infection and post-vaccination cellular SARS-CoV-2-specific immune response</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3408-3425</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/06/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Cellular</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Leukocytes, Mononuclear/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">would like to indicate that Winfried F. Pickl has received honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Astra Zeneca, and Roche. Rudolf Valenta has received research grants</style></keyword><keyword><style face="normal" font="default" size="100%">from HVD Life-Sciences, Vienna, Austria, WORG Pharmaceuticals, Hangzhou, China,</style></keyword><keyword><style face="normal" font="default" size="100%">and from Viravaxx, Vienna, Austria. He serves as consultant for Viravaxx and WORG</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals. The other authors have no conflict of interest to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35690994</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Antibody-based tests are available for measuring SARS-CoV-2-specific immune responses but fast T-cell assays remain scarce. Robust T cell-based tests are needed to differentiate specific cellular immune responses after infection from those after vaccination. METHODS: One hundred seventeen individuals (COVID-19 convalescent patients: n = 40; SARS-CoV-2 vaccinees: n = 41; healthy controls: n = 36) were evaluated for SARS-CoV-2-specific cellular immune responses (proliferation, Th1, Th2, Th17, and inflammatory cytokines, activation-induced marker [AIM] expression) by incubating purified peripheral blood mononuclear cells (PBMC) or whole blood (WB) with SARS-CoV-2 peptides (S, N, or M), vaccine antigens (tetanus toxoid, tick borne encephalitis virus) or polyclonal stimuli (Staphylococcal enterotoxin, phytohemagglutinin). RESULTS: N-peptide mix stimulation of WB identified the combination of IL-2 and IL-13 secretion as superior to IFN-gamma secretion to discriminate between COVID-19-convalescent patients and healthy controls (p &lt; .0001). Comparable results were obtained with M- or S-peptides, the latter almost comparably recalled IL-2, IFN-gamma, and IL-13 responses in WB of vaccinees. Analysis 10 months as opposed to 10 weeks after COVID-19, but not allergic disease status, positively correlated with IL-13 recall responses. WB cytokine responses correlated with cytokine and proliferation responses of PBMC. Antigen-induced neo-expression of the C-type lectin CD69 on CD4(+) (p &lt; .0001) and CD8(+) (p = .0002) T cells informed best about the SARS-CoV-2 exposure status with additional benefit coming from CD25 upregulation. CONCLUSION: Along with N- and S-peptide-induced IL-2 and CD69 neo-expression, we suggest to include the type 2 cytokine IL-13 as T-cellular recall marker for SARS-CoV-2 specific T-cellular immune responses after infection and vaccination.</style></abstract><notes><style face="normal" font="default" size="100%">Kratzer, Bernhard&#xD;Schlax, Larissa C&#xD;Gattinger, Pia&#xD;Waidhofer-Sollner, Petra&#xD;Trapin, Doris&#xD;Tauber, Peter A&#xD;Sehgal, Al Nasar Ahmed&#xD;Kormoczi, Ulrike&#xD;Rottal, Arno&#xD;Feichter, Melanie&#xD;Oberhofer, Teresa&#xD;Grabmeier-Pfistershammer, Katharina&#xD;Borochova, Kristina&#xD;Dorofeeva, Yulia&#xD;Tulaeva, Inna&#xD;Weber, Milena&#xD;Muhl, Bernhard&#xD;Kropfmuller, Anna&#xD;Negrin, Bettina&#xD;Kundi, Michael&#xD;Valenta, Rudolf&#xD;Pickl, Winfried F&#xD;eng&#xD;DKW1248/FWF_/Austrian Science Fund FWF/Austria&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3408-3425. doi: 10.1111/all.15406. Epub 2022 Jul 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35690994</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9348018</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15406</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2317</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2317</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Castano, N.</style></author><author><style face="normal" font="default" size="100%">Chua, K.</style></author><author><style face="normal" font="default" size="100%">Kaushik, A.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Cordts, S. C.</style></author><author><style face="normal" font="default" size="100%">Nafarzadegan, C. D.</style></author><author><style face="normal" font="default" size="100%">Hofmann, G. H.</style></author><author><style face="normal" font="default" size="100%">Seastedt, H.</style></author><author><style face="normal" font="default" size="100%">Schuetz, J. P.</style></author><author><style face="normal" font="default" size="100%">Dunham, D.</style></author><author><style face="normal" font="default" size="100%">Parsons, E. S.</style></author><author><style face="normal" font="default" size="100%">Tsai, M.</style></author><author><style face="normal" font="default" size="100%">Cao, S.</style></author><author><style face="normal" font="default" size="100%">Desai, M.</style></author><author><style face="normal" font="default" size="100%">Sindher, S. B.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Tang, S. K. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Mechanical Engineering, Stanford University, Stanford, California, USA.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, California, USA.&#xD;Department of Environmental Health, T. H. Chan School of Public Health, Harvard University, Cambridge, Massachusetts, USA.&#xD;Department of Microbiology and Immunology, Stanford University, Stanford, California, USA.&#xD;Department of Pathology, Stanford University, Stanford, California, USA.&#xD;Department of Medicine, Biomedical Informatics Research, Stanford University, Stanford, California, USA.&#xD;Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Stanford University, Stanford, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Combining avidin with CD63 improves basophil activation test accuracy in classifying peanut allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">445-455</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/11/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophil Degranulation Test</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Avidin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Flow Cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Tetraspanin 30/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cd63</style></keyword><keyword><style face="normal" font="default" size="100%">avidin</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">classification model</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">related to this work. The patent was filed jointly by Institut National de la</style></keyword><keyword><style face="normal" font="default" size="100%">Sante et de la Recherche Medicale, Universite Paul Sabatier Toulouse Iii, Centre</style></keyword><keyword><style face="normal" font="default" size="100%">National De La Recherche Scientifique, and Stanford University. KCN reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from National Institute of Allergy and Infectious Diseases (NIAID),</style></keyword><keyword><style face="normal" font="default" size="100%">National Heart, Lung, and Blood Institute (NHLBI), National Institute of</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Health Sciences (NIEHS), and Food Allergy Research &amp; Education</style></keyword><keyword><style face="normal" font="default" size="100%">(FARE)</style></keyword><keyword><style face="normal" font="default" size="100%">Stock options from IgGenix, Seed Health, ClostraBio, Cour, Alladapt</style></keyword><keyword><style face="normal" font="default" size="100%">Advisor at Cour Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">Consultant for Excellergy, Red tree ventures, Before</style></keyword><keyword><style face="normal" font="default" size="100%">Brands, Alladapt, Cour, Latitude, Regeneron, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">Co-founder of Before</style></keyword><keyword><style face="normal" font="default" size="100%">Brands, Alladapt, Latitude, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">National Scientific Committee member at</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance Network (ITN), and National Institutes of Health (NIH) clinical</style></keyword><keyword><style face="normal" font="default" size="100%">research centers</style></keyword><keyword><style face="normal" font="default" size="100%">patents include, &quot;Mixed allergen com-position and methods for</style></keyword><keyword><style face="normal" font="default" size="100%">using the same,&quot; &quot;Granulocyte-based methods for detecting and monitoring immune</style></keyword><keyword><style face="normal" font="default" size="100%">system disorders,&quot; and &quot;Methods and Assays for Detecting and Quantifying Pure</style></keyword><keyword><style face="normal" font="default" size="100%">Subpopulations of White Blood Cells in Immune System Disorders&quot;. The authors</style></keyword><keyword><style face="normal" font="default" size="100%">declare that they have no other competing interests, and all other authors</style></keyword><keyword><style face="normal" font="default" size="100%">declare they have no competing interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37916710</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Conventional basophil activation tests (BATs) measure basophil activation by the increased expression of CD63. Previously, fluorophore-labeled avidin, a positively-charged molecule, was found to bind to activated basophils, which tend to expose negatively charged granule constituents during degranulation. This study further compares avidin versus CD63 as basophil activation biomarkers in classifying peanut allergy. METHODS: Seventy subjects with either a peanut allergy (N = 47), a food allergy other than peanut (N = 6), or no food allergy (N = 17) were evaluated. We conducted BATs in response to seven peanut extract (PE) concentrations (0.01-10,000 ng/mL) and four control conditions (no stimulant, anti-IgE, fMLP (N-formylmethionine-leucyl-phenylalanine), and anti-FcepsilonRI). We measured avidin binding and CD63 expression on basophils with flow cytometry. We evaluated logistic regression and XGBoost models for peanut allergy classification and feature identification. RESULTS: Avidin binding was correlated with CD63 expression. Both markers discriminated between subjects with and without a peanut allergy. Although small by percentage, an avidin(+) /CD63(-) cell subset was found in all allergic subjects tested, indicating that the combination of avidin and CD63 could allow a more comprehensive identification of activated basophils. Indeed, we obtained the best classification accuracy (97.8% sensitivity, 96.7% specificity) by combining avidin and CD63 across seven PE doses. Similar accuracy was obtained by combining PE dose of 10,000 ng/mL for avidin and PE doses of 10 and 100 ng/mL for CD63. CONCLUSIONS: Avidin and CD63 are reliable BAT activation markers associated with degranulation. Their combination enhances the identification of activated basophils and improves the classification accuracy of peanut allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Castano, Nicolas&#xD;Chua, Kaiser&#xD;Kaushik, Abhinav&#xD;Kim, Sungu&#xD;Cordts, Seth C&#xD;Nafarzadegan, Ceena D&#xD;Hofmann, Grady H&#xD;Seastedt, Hana&#xD;Schuetz, Jackson P&#xD;Dunham, Diane&#xD;Parsons, Ella S&#xD;Tsai, Mindy&#xD;Cao, Shu&#xD;Desai, Manisha&#xD;Sindher, Sayantani B&#xD;Chinthrajah, R Sharon&#xD;Galli, Stephen J&#xD;Nadeau, Kari C&#xD;Tang, Sindy K Y&#xD;eng&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;R21 AI149277/AI/NIAID NIH HHS/&#xD;R21AI149277/NH/NIH HHS/&#xD;R21EB030643/NH/NIH HHS/&#xD;R21 EB030643/EB/NIBIB NIH HHS/&#xD;U19AI104209/NH/NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):445-455. doi: 10.1111/all.15930. Epub 2023 Nov 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37916710</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10842984</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15930</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>421</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">421</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Miceli Sopo, S.</style></author><author><style face="normal" font="default" size="100%">Sinatti, D.</style></author><author><style face="normal" font="default" size="100%">Mastellone, F.</style></author><author><style face="normal" font="default" size="100%">Bersani, G.</style></author><author><style face="normal" font="default" size="100%">Gelsomino, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Allergy Unit, Pediatrics Section, Department of Life Sciences and Public Health, Policlinico Gemelli Universitary Foundation IRCCS, Catholic University of Sacre Hearth, Rome, Italy.&#xD;Department of Life Sciences and Public Health, Post-Graduate School of Pediatrics, Policlinico Gemelli Universitary Foundation IRCCS, Catholic University of Sacre Hearth, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comment on EAACI guideline: Anaphylaxis (2021 update)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2268</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/07/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35770816</style></accession-num><notes><style face="normal" font="default" size="100%">Miceli Sopo, Stefano&#xD;Sinatti, Dario&#xD;Mastellone, Francesco&#xD;Bersani, Giulia&#xD;Gelsomino, Mariannita&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2268. doi: 10.1111/all.15256.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35770816</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15256</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1287</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1287</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martinez-Lourido, E.</style></author><author><style face="normal" font="default" size="100%">Otero, A.</style></author><author><style face="normal" font="default" size="100%">Armisen, M.</style></author><author><style face="normal" font="default" size="100%">Vidal, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, Complejo Hospitalario Universitario de Santiago, Faculty of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain.&#xD;Spanish Network for Addictive Disorders (Red de Trastornos Adictivos, RD16/0017/0018), Madrid, Spain.&#xD;Department of Medicine, Complejo Hospitalario Universitario de Santiago, Faculty of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comment on: Bilo MB, Pravettoni V, Mauro M, Bonadonna P. Treating venom allergy during COVID-19 pandemic: Management of venom allergen immunotherapy during the COVID-19 outbreak in Spain</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">951-952</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/10/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Spain/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Venoms</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33095922</style></accession-num><notes><style face="normal" font="default" size="100%">Martinez-Lourido, Emilia&#xD;Otero, Andrea&#xD;Armisen, Margarita&#xD;Vidal, Carmen&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):951-952. doi: 10.1111/all.14567. Epub 2020 Oct 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33095922</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14567</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2159</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2159</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruethers, T.</style></author><author><style face="normal" font="default" size="100%">Johnston, E. B.</style></author><author><style face="normal" font="default" size="100%">Karnaneedi, S.</style></author><author><style face="normal" font="default" size="100%">Nie, S.</style></author><author><style face="normal" font="default" size="100%">Nugraha, R.</style></author><author><style face="normal" font="default" size="100%">Taki, A. C.</style></author><author><style face="normal" font="default" size="100%">Kamath, S. D.</style></author><author><style face="normal" font="default" size="100%">Williamson, N. A.</style></author><author><style face="normal" font="default" size="100%">Mehr, S. S.</style></author><author><style face="normal" font="default" size="100%">Campbell, D. E.</style></author><author><style face="normal" font="default" size="100%">Lopata, A. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Tropical Futures Institute, James Cook University, Singapore, Singapore.&#xD;Molecular Allergy Research Laboratory, College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, Queensland, Australia.&#xD;Centre for Food and Allergy Research, Murdoch Children&apos;s Research Institute, Melbourne, Victoria, Australia.&#xD;Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia.&#xD;Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.&#xD;Department of Aquatic Product Technology, Faculty of Fisheries and Marine Science, IPB University, Bogor, Indonesia.&#xD;Melbourne Veterinary School, Faculty of Science, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Division of Medical Biotechnology, Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Allergy and Immunology, The Children&apos;s Hospital at Westmead, Sydney, New South Wales, Australia.&#xD;Epworth Allergy Specialists, Epworth Hospital, Richmond, Victoria, Australia.&#xD;Paediatric Allergy and Immunology Unit, The Royal Children&apos;s Hospital, Melbourne, Victoria, Australia.&#xD;Discipline of Child and Adolescent Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Commercial shellfish skin prick test extracts show critical variability in allergen repertoire</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3261-3265</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/08/21</style></edition><section><style face="normal" font="default" size="100%">3261</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Shellfish/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">non-standardized allergen extracts</style></keyword><keyword><style face="normal" font="default" size="100%">seafood allergens</style></keyword><keyword><style face="normal" font="default" size="100%">shellfish allergy</style></keyword><keyword><style face="normal" font="default" size="100%">tropomyosin</style></keyword><keyword><style face="normal" font="default" size="100%">presented in this manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37602511</style></accession-num><notes><style face="normal" font="default" size="100%">Ruethers, Thimo&#xD;Johnston, Elecia B&#xD;Karnaneedi, Shaymaviswanathan&#xD;Nie, Shuai&#xD;Nugraha, Roni&#xD;Taki, Aya C&#xD;Kamath, Sandip D&#xD;Williamson, Nicholas A&#xD;Mehr, Sam S&#xD;Campbell, Dianne E&#xD;Lopata, Andreas L&#xD;eng&#xD;GNT1134812/The Centre for Food and Allergy Research, NHMRC, Australia/&#xD;GNT1086656/The National Health and Medical Research Council (NHMRC), Australia/&#xD;GNT1124143/The National Health and Medical Research Council (NHMRC), Australia/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3261-3265. doi: 10.1111/all.15853. Epub 2023 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37602511</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10952831</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15853</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>388</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">388</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benamar, M.</style></author><author><style face="normal" font="default" size="100%">Harb, H.</style></author><author><style face="normal" font="default" size="100%">Chen, Q.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Chan, T. M. F.</style></author><author><style face="normal" font="default" size="100%">Fong, J.</style></author><author><style face="normal" font="default" size="100%">Phipatanakul, W.</style></author><author><style face="normal" font="default" size="100%">Cunningham, A.</style></author><author><style face="normal" font="default" size="100%">Ertem, D.</style></author><author><style face="normal" font="default" size="100%">Petty, C. R.</style></author><author><style face="normal" font="default" size="100%">Mousavi, A. J.</style></author><author><style face="normal" font="default" size="100%">Sioutas, C.</style></author><author><style face="normal" font="default" size="100%">Crestani, E.</style></author><author><style face="normal" font="default" size="100%">Chatila, T. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology, Boston Children&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Institute for Medical Microbiology and Virology, Technical University Dresden, Dresden, Germany.&#xD;Institutional Centers for Clinical and Translational Research, Boston Children&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Department of Civil and Environmental Engineering, University of Southern California, Los Angeles, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A common IL-4 receptor variant promotes asthma severity via a T(reg) cell GRB2-IL-6-Notch4 circuit</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3377-3387</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-6/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">*Pneumonia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Interleukin-4/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Grb2</style></keyword><keyword><style face="normal" font="default" size="100%">Notch4</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 4 receptor</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35841382</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The mechanisms by which genetic and environmental factors interact to promote asthma remain unclear. Both the IL-4 receptor alpha chain R576 (IL-4RalphaR576) variant and Notch4 license asthmatic lung inflammation by allergens and ambient pollutant particles by subverting lung regulatory T (T(reg) ) cells in an IL-6-dependent manner. OBJECTIVE: We examined the interaction between IL-4RalphaR576 and Notch4 in promoting asthmatic inflammation. METHODS: Peripheral blood mononuclear cells (PBMCs) of asthmatics were analyzed for T helper type 2 cytokine production and Notch4 expression on T(reg) cells as a function of IL4R(R576) allele. The capacity of IL-4RalphaR576 to upregulate Notch4 expression on T(reg) cells to promote severe allergic airway inflammation was further analyzed in genetic mouse models. RESULTS: Asthmatics carrying the IL4R(R576) allele had increased Notch4 expression on their circulating T(reg) cells as a function of disease severity and serum IL-6. Mice harboring the Il4ra(R576) allele exhibited increased Notch4-dependent allergic airway inflammation that was inhibited upon T(reg) cell-specific Notch4 deletion or treatment with an anti-Notch4 antibody. Signaling via IL-4RalphaR576 upregulated the expression in lung T(reg) cells of Notch4 and its downstream mediators Yap1 and beta-catenin, leading to exacerbated lung inflammation. This upregulation was dependent on growth factor receptor-bound protein 2 (GRB2) and IL-6 receptor. CONCLUSION: These results identify an IL-4RalphaR576-regulated GRB2-IL-6-Notch4 circuit that promotes asthma severity by subverting lung T(reg) cell function.</style></abstract><notes><style face="normal" font="default" size="100%">Benamar, Mehdi&#xD;Harb, Hani&#xD;Chen, Qian&#xD;Wang, Muyun&#xD;Chan, Tsz Man Fion&#xD;Fong, Jason&#xD;Phipatanakul, Wanda&#xD;Cunningham, Amparito&#xD;Ertem, Deniz&#xD;Petty, Carter R&#xD;Mousavi, Amirhosein J&#xD;Sioutas, Constantinos&#xD;Crestani, Elena&#xD;Chatila, Talal A&#xD;eng&#xD;U01 AI110397/AI/NIAID NIH HHS/&#xD;R01 HL137192/HL/NHLBI NIH HHS/&#xD;U01 AI143514/AI/NIAID NIH HHS/&#xD;R56 AI115699/AI/NIAID NIH HHS/&#xD;R01 AI065617/AI/NIAID NIH HHS/&#xD;NH/NIH HHS/&#xD;U01 AI160087/AI/NIAID NIH HHS/&#xD;K23 AI155940/AI/NIAID NIH HHS/&#xD;U01 AI152033/AI/NIAID NIH HHS/&#xD;R01 AI115699/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3377-3387. doi: 10.1111/all.15444. Epub 2022 Jul 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35841382</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9617759</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15444</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>849</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">849</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dendooven, E.</style></author><author><style face="normal" font="default" size="100%">Stappers, S.</style></author><author><style face="normal" font="default" size="100%">Lambert, J.</style></author><author><style face="normal" font="default" size="100%">Pieters, L.</style></author><author><style face="normal" font="default" size="100%">Foubert, K.</style></author><author><style face="normal" font="default" size="100%">Aerts, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, University Hospital Antwerp (UZA), and Infla-Med Centre of Excellence, Research group Immunology, University of Antwerp, Antwerp, Belgium.&#xD;Research Group Natural Products &amp; Food Research and Analysis (NatuRA), Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Commonly problematic medical devices and associated contact allergens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3517-3520</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/08/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Patch Tests</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34405418</style></accession-num><notes><style face="normal" font="default" size="100%">Dendooven, Ella&#xD;Stappers, Sofie&#xD;Lambert, Julien&#xD;Pieters, Luc&#xD;Foubert, Kenn&#xD;Aerts, Olivier&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3517-3520. doi: 10.1111/all.14023. Epub 2021 Aug 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34405418</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14023</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3272</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3272</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Toppila-Salmi, Sanna</style></author><author><style face="normal" font="default" size="100%">Reitsma, Sietze</style></author><author><style face="normal" font="default" size="100%">Hox, Valérie</style></author><author><style face="normal" font="default" size="100%">Gane, Simon</style></author><author><style face="normal" font="default" size="100%">Gevaert, Philippe</style></author><author><style face="normal" font="default" size="100%">Maza-Solano, Juan</style></author><author><style face="normal" font="default" size="100%">Helevä, Alma</style></author><author><style face="normal" font="default" size="100%">Sulku, Ida</style></author><author><style face="normal" font="default" size="100%">Santala, Kaisa</style></author><author><style face="normal" font="default" size="100%">Kangasniemi, Iiris</style></author><author><style face="normal" font="default" size="100%">Klimek, Ludger</style></author><author><style face="normal" font="default" size="100%">Chaker, Adam</style></author><author><style face="normal" font="default" size="100%">Karavelia, Aspasia</style></author><author><style face="normal" font="default" size="100%">Rudenko, Michael</style></author><author><style face="normal" font="default" size="100%">Pfaar, Oliver</style></author><author><style face="normal" font="default" size="100%">Van Gerven, Laura</style></author><author><style face="normal" font="default" size="100%">Ariana, Shaari</style></author><author><style face="normal" font="default" size="100%">Schiappoli, Michele</style></author><author><style face="normal" font="default" size="100%">Lundberg, Marie</style></author><author><style face="normal" font="default" size="100%">Hagemann, Jan</style></author><author><style face="normal" font="default" size="100%">Eguíluz-Gracia, Ibon</style></author><author><style face="normal" font="default" size="100%">Moreira, Andre</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Chronic rhinosinusitis (CRS) and asthma are prevalent conditions that often coexist. These diseases share common inflammatory mechanisms, such as T-helper cell 2 (T2)-high inflammation, driven by interleukin (IL)-4, IL-5, and IL-13 cytokines. The frequent comorbidity between CRS, especially CRS with nasal polyps (CRSwNP), and asthma exacerbates disease severity, impairs quality of life, and complicates treatment. Patients with NSAID-exacerbated respiratory disease (N-ERD) represent a severe phenotype of this disease, characterized by the coexistence of CRSwNP, asthma, and NSAID hypersensitivity, which poses unique therapeutic challenges. This EAACI Task Force explores the shared risk factors, including genetic predispositions, epithelial barrier dysfunction, microbiome dysbiosis, underlying CRS, and asthma. It also evaluates current therapeutic strategies such as biologics, aspirin therapy after desensitization (ATAD), and endoscopic sinus surgery (ESS). Biologics have shown their effectiveness and safety in the treatment of asthma and CRS. Dupilumab, mepolizumab, depemokimab, and omalizumab have emerged as transformative therapies, particularly for patients with severe type 2 inflammation. Tezepelulumab is effective for both T2-high and T2-low asthma and CRSwNP. Itepekimab has shown its effect in asthma and is under investigation for CRSwNP. Omalizumab is effective in allergic asthma and CRSwNP. ATAD provides an additional disease-modifying approach for N-ERD, though patient adherence and tolerability remain critical challenges. ESS significantly improves asthma control, reduces medication use, and enhances sinonasal outcomes, particularly in severe asthma cases; however, these patients often need recurring surgeries. Despite these advances, treatment outcomes vary based on individual phenotypes and endotypes, underscoring the need for personalized approaches. The report highlights gaps in the literature, such as the lack of head-to-head trials comparing biologics, ATAD, and surgery. Future research should focus on refining treatment algorithms, identifying biomarkers for treatment selection, and assessing long-term outcomes to optimize care for patients with CRS, asthma, and N-ERD.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70237</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70237</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1170</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1170</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pohlmeier, L.</style></author><author><style face="normal" font="default" size="100%">Sonar, S. S.</style></author><author><style face="normal" font="default" size="100%">Rodewald, H. R.</style></author><author><style face="normal" font="default" size="100%">Kopf, M.</style></author><author><style face="normal" font="default" size="100%">Tortola, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.&#xD;Division for Cellular Immunology, German Cancer Research Center, Heidelberg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparative analysis of the role of mast cells in murine asthma models using Kit-sufficient mast cell-deficient animals</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2030-2043</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Kit-sufficient</style></keyword><keyword><style face="normal" font="default" size="100%">allergic airway inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma models</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33559884</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma is a frequent chronic disease that can potentially severely affect the respiratory capacity and well-being of patients. Mast cells (MCs) are regarded as major players in human asthma due to their capacity to release crucial inflammatory mediators following allergen exposure. However, unambiguous characterization of their role in animal models has long been hindered by the unavailability of specific MC-deficient models lacking confounding MC-unrelated effects. This study aims to examine the role of MCs in Kit-sufficient MC-deficient Cpa3(Cre)(/+) mice. METHODS: We used a variety of models of acute and chronic asthma employing distinct routes and regimes of sensitization. These sensitizations were done via the peritoneal cavity, the skin, or the lung. Additionally, different allergens, i.e. ovalbumin and house dust mite extract, were used. RESULTS: Our results show that the absence of MCs had no impact on the severity of allergic airway inflammation in any of the tested mouse models, as measured by leukocyte infiltration in the airways, cytokine expression, antibody production, airway hyper-responsiveness and mucus production. CONCLUSION: This indicates that MCs do not play a major role in murine allergic airway inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Pohlmeier, Lea&#xD;Sonar, Sanchaita Sriwal&#xD;Rodewald, Hans-Reimer&#xD;Kopf, Manfred&#xD;Tortola, Luigi&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2030-2043. doi: 10.1111/all.14765. Epub 2021 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33559884</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14765</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>591</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">591</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hatziantoniou, S.</style></author><author><style face="normal" font="default" size="100%">Anastassopoulou, C.</style></author><author><style face="normal" font="default" size="100%">Lampropoulou, V.</style></author><author><style face="normal" font="default" size="100%">Maltezou, H. C.</style></author><author><style face="normal" font="default" size="100%">Andreakos, E.</style></author><author><style face="normal" font="default" size="100%">Poland, G. A.</style></author><author><style face="normal" font="default" size="100%">Tsakris, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece.&#xD;Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.&#xD;Directorate of Research, Studies and Documentation, National Public Health Organization, Athens, Greece.&#xD;Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparative assessment of allergic reactions to COVID-19 vaccines in Europe and the United States</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1630-1633</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*COVID-19/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35174502</style></accession-num><notes><style face="normal" font="default" size="100%">Hatziantoniou, Sophia&#xD;Anastassopoulou, Cleo&#xD;Lampropoulou, Vicky&#xD;Maltezou, Helena C&#xD;Andreakos, Evangelos&#xD;Poland, Gregory A&#xD;Tsakris, Athanasios&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1630-1633. doi: 10.1111/all.15257. Epub 2022 Feb 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35174502</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9111347 investigational vaccine trials being conducted by Merck Research Laboratories; holds patents related to vaccinia, influenza, and measles peptide vaccines; received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine; and provides consultative advice on vaccine development to Merck &amp; Co., Medicago, GlaxoSmithKline, Sanofi Pasteur, Johnson &amp; Johnson/Janssen Global Services LLC, Emergent Biosolutions, Dynavax, Genentech, Eli Lilly and Company, Kentucky Bioprocessing, Bavarian Nordic, AstraZeneca, Exelixis, Regeneron, Janssen, Vyriad, Moderna, and Genevant Sciences, Inc. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. SH, CA, VL, HM, EA, and AT declare no conflict of interest in relation to this work.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15257</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1982</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1982</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfeffer, P. E.</style></author><author><style face="normal" font="default" size="100%">Ali, N.</style></author><author><style face="normal" font="default" size="100%">Murray, R.</style></author><author><style face="normal" font="default" size="100%">Ulrik, C.</style></author><author><style face="normal" font="default" size="100%">Tran, T. N.</style></author><author><style face="normal" font="default" size="100%">Maspero, J.</style></author><author><style face="normal" font="default" size="100%">Peters, M.</style></author><author><style face="normal" font="default" size="100%">Christoff, G. C.</style></author><author><style face="normal" font="default" size="100%">Sadatsafavi, M.</style></author><author><style face="normal" font="default" size="100%">Torres-Duque, C. A.</style></author><author><style face="normal" font="default" size="100%">Altraja, A.</style></author><author><style face="normal" font="default" size="100%">Lehtimaki, L.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Salvi, S.</style></author><author><style face="normal" font="default" size="100%">Costello, R. W.</style></author><author><style face="normal" font="default" size="100%">Cushen, B.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Iwanaga, T.</style></author><author><style face="normal" font="default" size="100%">Al-Ahmad, M.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Al-Lehebi, R.</style></author><author><style face="normal" font="default" size="100%">Rhee, C. K.</style></author><author><style face="normal" font="default" size="100%">Perez-de-Llano, L.</style></author><author><style face="normal" font="default" size="100%">Perng Steve, D. W.</style></author><author><style face="normal" font="default" size="100%">Mahboub, B.</style></author><author><style face="normal" font="default" size="100%">Wang, E.</style></author><author><style face="normal" font="default" size="100%">Goh, C.</style></author><author><style face="normal" font="default" size="100%">Lyu, J.</style></author><author><style face="normal" font="default" size="100%">Newell, A.</style></author><author><style face="normal" font="default" size="100%">Alacqua, M.</style></author><author><style face="normal" font="default" size="100%">Belevskiy, A. S.</style></author><author><style face="normal" font="default" size="100%">Bhutani, M.</style></author><author><style face="normal" font="default" size="100%">Bjermer, L.</style></author><author><style face="normal" font="default" size="100%">Bjornsdottir, U.</style></author><author><style face="normal" font="default" size="100%">Bourdin, A.</style></author><author><style face="normal" font="default" size="100%">Bulow, A. V.</style></author><author><style face="normal" font="default" size="100%">Busby, J.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Cosio, B. G.</style></author><author><style face="normal" font="default" size="100%">Dorscheid, D. R.</style></author><author><style face="normal" font="default" size="100%">Munoz-Esquerre, M.</style></author><author><style face="normal" font="default" size="100%">FitzGerald, J. M.</style></author><author><style face="normal" font="default" size="100%">Gil, E. G.</style></author><author><style face="normal" font="default" size="100%">Gibson, P. G.</style></author><author><style face="normal" font="default" size="100%">Heaney, L. G.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author><author><style face="normal" font="default" size="100%">Hilberg, O.</style></author><author><style face="normal" font="default" size="100%">Hoyte, F.</style></author><author><style face="normal" font="default" size="100%">Jackson, D. J.</style></author><author><style face="normal" font="default" size="100%">Koh, M. S.</style></author><author><style face="normal" font="default" size="100%">Ko, H. B.</style></author><author><style face="normal" font="default" size="100%">Lee, J. H.</style></author><author><style face="normal" font="default" size="100%">Lehmann, S.</style></author><author><style face="normal" font="default" size="100%">Chaves Loureiro, C.</style></author><author><style face="normal" font="default" size="100%">Luethviksdottir, D.</style></author><author><style face="normal" font="default" size="100%">Menzies-Gow, A. N.</style></author><author><style face="normal" font="default" size="100%">Mitchell, P.</style></author><author><style face="normal" font="default" size="100%">Papaioannou, A. I.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Porsbjerg, C. M.</style></author><author><style face="normal" font="default" size="100%">Salameh, L.</style></author><author><style face="normal" font="default" size="100%">Sirena, C.</style></author><author><style face="normal" font="default" size="100%">Taille, C.</style></author><author><style face="normal" font="default" size="100%">Taube, C.</style></author><author><style face="normal" font="default" size="100%">Tohda, Y.</style></author><author><style face="normal" font="default" size="100%">Wechsler, M. E.</style></author><author><style face="normal" font="default" size="100%">Price, D. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, Barts Health NHS Trust, London, UK.&#xD;Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.&#xD;Observational and Pragmatic Research Institute, Singapore, Singapore.&#xD;Optimum Patient Care Global, Cambridge, UK.&#xD;Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark.&#xD;AstraZeneca, Gaithersburg, Maryland, USA.&#xD;Clinical Research for Allergy and Respiratory Medicine, CIDEA Foundation, Buenos Aires, Argentina.&#xD;University Career of Specialists in Allergy and Clinical Immunology at the Buenos Aires University School of Medicine, Buenos Aires, Argentina.&#xD;Department of Thoracic Medicine, Concord Hospital, Sydney, Australia.&#xD;Medical University-Sofia, Faculty of Public Health, Sofia, Bulgaria.&#xD;Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.&#xD;CINEUMO, Research Center, Fundacion Neumologica Colombiana, Bogota, Colombia.&#xD;Department of Pulmonology, University of Tartu and Lung Clinic, Tartu University Hospital, Tartu, Estonia.&#xD;Allergy Centre, Tampere University Hospital, Tampere, Finland.&#xD;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Pulmocare Research and Education Foundation, Pune, India.&#xD;Department of Respiratory Medicine, Clinical Research Centre, Smurfit Building Beaumont Hospital, Dublin, Ireland.&#xD;Department of Respiratory Medicine, Beaumont Hospital, Dublin, Ireland.&#xD;Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Milan, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Center for General Medical Education and Clinical Training, Kindai University Hospital, Osakasayama, Japan.&#xD;Microbiology Department, College of Medicine, Kuwait University, Kuwait, Al-Rashed Allergy Center, Kuwait, Kuwait.&#xD;Directora Centro de Excelencia en Asma y Alergia, Hospital Medica Sur, Ciudad de Mexico, Mexico.&#xD;Division of Internal Medicine, Asthma and Allergy Medical University of Lodz, Lodz, Poland.&#xD;Health Information and Decision Sciences Department (MEDCIDS), CINTESIS@RiSE, Faculty of Medicine of University of Porto, Porto, Portugal.&#xD;Department of Pulmonology, King Fahad Medical City, Riyadh, Saudi Arabia. Alfaisal University, Riyadh, Saudi Arabia.&#xD;Alfaisal University, Riyadh, Saudi Arabia.&#xD;Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Seoul St. Mary&apos;s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.&#xD;Pneumology Service, Lucus Augusti University Hospital, Cervo, Spain.&#xD;Biodiscovery Research Group, Health Research Institute of Santiago de Compostela, Santiago, Spain.&#xD;Division of Clinical Respiratory Physiology Chest Department, Taipei Veterans General Hospital, Taipei, Taiwan.&#xD;COPD Assembly of the Asian Pacific Society of Respirology, Hong Kong, China.&#xD;College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.&#xD;Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates.&#xD;Department of Medicine, Division of Allergy &amp; Clinical Immunology, National Jewish Health, Denver, Colorado, USA.&#xD;Department of Medicine, Division of Allergy &amp; Clinical Immunology, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Optimum Patient Care, Queensland, Australia.&#xD;CSL Behring SpA, Milan, Italy.&#xD;Department of Pulmonology, N.I. Pirogov Russian State National Research Medical University, Moscow, Russian Federation.&#xD;Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, Canada.&#xD;Department of Clinical Sciences, Respiratory Medicine and Allergology, Skane University Hospital, Lund University, Lund, Sweden.&#xD;Department of Allergy and Respiratory Medicine, University Hospital, Reykjavik, Iceland.&#xD;PhyMedExp, Univ Montpellier, CNRS, INSERM, Montpellier, France.&#xD;Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark.&#xD;Centre for Public Health, Queen&apos;s University Belfast, Belfast, UK.&#xD;Son Espases University Hospital-IdISBa-Ciberes, Mallorca, Spain.&#xD;Department of Medicine, Center for Heart, Lung Innovation, The University of British Columbia, Vancouver, Canada.&#xD;Department of Respiratory Medicine, Bellvitge University Hospital-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.&#xD;University of Barcelona, Barcelona, Spain.&#xD;Department of Medicine, The University of British Columbia, Vancouver, Canada.&#xD;AstraZeneca, Barcelona, Spain.&#xD;Australian Severe Asthma Network, Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, Australia.&#xD;Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, New Lambton Heights, Australia.&#xD;Wellcome-Wolfson Centre for Experimental Medicine, Queen&apos;s University Belfast, Belfast, UK.&#xD;Allergy, Asthma &amp; Clinical Immunology Service, Alfred Health, Melbourne, Australia.&#xD;Public Health and Preventive Medicine, Monash University, Melbourne, Australia.&#xD;Medical department, Vejle University Hospital, Vejle, Denmark.&#xD;UK Severe Asthma Network and National Registry, Guy&apos;s and St Thomas&apos; NHS Trust, London, England.&#xD;School of Immunology &amp; Microbial Sciences, King&apos;s College London, London, UK.&#xD;Respiratory &amp; Critical Care Medicine, Singapore General Hospital, Singapore, Singapore.&#xD;SingHealth Duke-NUS Lung Centre, Singapore, Singapore.&#xD;Department of Chest Medicine, Division of Respiratory Therapy, Taipei Veterans General Hospital, Taipei, Taiwan.&#xD;Department of Internal Medicine, Division of Pulmonology and Critical Care Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.&#xD;Department of Clinical Science, Section of Thoracic Medicine, University of Bergen, Bergen, Norway.&#xD;Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway.&#xD;Pulmonology Unit, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal &amp; Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Department of Allergy, University Hospital, Reykjavik, Iceland.&#xD;Department of Respiratory Medicine, University Hospital, Reykjavik, Iceland.&#xD;Royal Brompton &amp; Harefield Hospitals, London, UK.&#xD;School of Medicine, Trinity College Dublin, Dublin, Ireland.&#xD;2nd Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece.&#xD;University Hospital &quot;Sv. Ivan Rilski&quot;, Sofia, Bulgaria.&#xD;Department of Respiratory Medicine and Infections Diseases, Research Unit, Bispebjerg Hospital, Copenhagen, Denmark.&#xD;Severe Asthma Network Italy (SANI), Milan, Italy.&#xD;Department of Respiratory Diseases, Bichat Hospital, AP-HP Nord-Universite de Paris, Paris, France.&#xD;Department of Pulmonary Medicine, University Medical Center Essen-Ruhrlandklinik, Essen, Germany.&#xD;Kindai University Hospital, Osakasayama, Japan.&#xD;NJH Cohen Family Asthma Institute, Department of Medicine, National Jewish Health, Denver, Colorado, USA.&#xD;Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1934-1948</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/03/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Isar</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">oral corticosteroids</style></keyword><keyword><style face="normal" font="default" size="100%">real life</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36929509</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti-IgE and anti-IL5/5R and to compare the effectiveness of both classes of treatment in real life. METHODS: This was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti-IgE and anti-IL5/5R. The effectiveness of anti-IgE and anti-IL5/5R was compared in a 1:1 matched cohort. Exacerbation rate was the primary effectiveness endpoint. Secondary endpoints included long-term-oral corticosteroid (LTOCS) use, asthma-related emergency room (ER) attendance, and hospital admissions. RESULTS: In the matched analysis (n = 350/group), the mean annualized exacerbation rate decreased by 47.1% in the anti-IL5/5R group and 38.7% in the anti-IgE group. Patients treated with anti-IL5/5R were less likely to experience a future exacerbation (adjusted IRR 0.76; 95% CI 0.64, 0.89; p &lt; 0.001) and experienced a greater reduction in mean LTOCS dose than those treated with anti-IgE (37.44% vs. 20.55% reduction; p = 0.023). There was some evidence to suggest that patients treated with anti-IL5/5R experienced fewer asthma-related hospitalizations (IRR 0.64; 95% CI 0.38, 1.08), but not ER visits (IRR 0.94, 95% CI 0.61, 1.43). CONCLUSIONS: In real life, both anti-IgE and anti-IL5/5R improve asthma outcomes in patients eligible for both biologic classes; however, anti-IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use.</style></abstract><notes><style face="normal" font="default" size="100%">Pfeffer, Paul E&#xD;Ali, Nasloon&#xD;Murray, Ruth&#xD;Ulrik, Charlotte&#xD;Tran, Trung N&#xD;Maspero, Jorge&#xD;Peters, Matthew&#xD;Christoff, George C&#xD;Sadatsafavi, Mohsen&#xD;Torres-Duque, Carlos A&#xD;Altraja, Alan&#xD;Lehtimaki, Lauri&#xD;Papadopoulos, Nikolaos G&#xD;Salvi, Sundeep&#xD;Costello, Richard W&#xD;Cushen, Breda&#xD;Heffler, Enrico&#xD;Iwanaga, Takashi&#xD;Al-Ahmad, Mona&#xD;Larenas-Linnemann, Desiree&#xD;Kuna, Piotr&#xD;Fonseca, Joao A&#xD;Al-Lehebi, Riyad&#xD;Rhee, Chin Kook&#xD;Perez-de-Llano, Luis&#xD;Perng Steve, Diahn-Warng&#xD;Mahboub, Bassam&#xD;Wang, Eileen&#xD;Goh, Celine&#xD;Lyu, Juntao&#xD;Newell, Anthony&#xD;Alacqua, Marianna&#xD;Belevskiy, Andrey S&#xD;Bhutani, Mohit&#xD;Bjermer, Leif&#xD;Bjornsdottir, Unnur&#xD;Bourdin, Arnaud&#xD;Bulow, Anna von&#xD;Busby, John&#xD;Canonica, Giorgio Walter&#xD;Cosio, Borja G&#xD;Dorscheid, Delbert R&#xD;Munoz-Esquerre, Mariana&#xD;FitzGerald, J Mark&#xD;Gil, Esther Garcia&#xD;Gibson, Peter G&#xD;Heaney, Liam G&#xD;Hew, Mark&#xD;Hilberg, Ole&#xD;Hoyte, Flavia&#xD;Jackson, David J&#xD;Koh, Mariko Siyue&#xD;Ko, Hsin-Kuo Bruce&#xD;Lee, Jae Ha&#xD;Lehmann, Sverre&#xD;Chaves Loureiro, Claudia&#xD;Luethviksdottir, Dora&#xD;Menzies-Gow, Andrew N&#xD;Mitchell, Patrick&#xD;Papaioannou, Andriana I&#xD;Popov, Todor A&#xD;Porsbjerg, Celeste M&#xD;Salameh, Laila&#xD;Sirena, Concetta&#xD;Taille, Camille&#xD;Taube, Christian&#xD;Tohda, Yuji&#xD;Wechsler, Michael E&#xD;Price, David B&#xD;eng&#xD;AstraZeneca/&#xD;Optimum Patient Care Global/&#xD;Comparative Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1934-1948. doi: 10.1111/all.15711. Epub 2023 Mar 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36929509</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15711</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2815</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2815</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zemelka-Wiacek, M.</style></author><author><style face="normal" font="default" size="100%">Kosowska, A.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Kujawa, K.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Immunology, Faculty of Medicine of Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Statistical Analysis Centre, Wroclaw Medical University, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparative Evaluation of an Allergen Exposure Chamber and Nasal Allergen Challenge Versus In-Field Symptom Assessment in Patients With Allergic Rhinitis Triggered by Timothy Grass Pollen</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1286-1297</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/03/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Phleum/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Symptom Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Atmosphere Exposure Chambers</style></keyword><keyword><style face="normal" font="default" size="100%">Phleum pratense</style></keyword><keyword><style face="normal" font="default" size="100%">allergen exposure chamber</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">combined symptom medication score</style></keyword><keyword><style face="normal" font="default" size="100%">nasal allergen challenge</style></keyword><keyword><style face="normal" font="default" size="100%">timothy grass pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Deputy Editor. A.K. has nothing to disclose. O.P. reports grants and/or personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees and/or travel support from AEDA, Alfried Krupp Krankenhaus, ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, Almirall, Altamira Therapeutics, ASIT Biotech, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard Allergie GmbH/Allergy Therapeutics, Deutsche AllergieLiga e.V., Deutsche</style></keyword><keyword><style face="normal" font="default" size="100%">Forschungsgemeinschaft, Dustri-Verlag, ECM Expro &amp; Conference Management GmBH,</style></keyword><keyword><style face="normal" font="default" size="100%">Forum fur Medizinische Fortbildung, GSK, HAL Allergy Holding B.V./HAL Allergie</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, Immunotek, Ingress Health, Institut fur Disease Management (Essen,</style></keyword><keyword><style face="normal" font="default" size="100%">Germany), IQVIA Commercial, Japanese Society of Allergology, Koniglich Danisches</style></keyword><keyword><style face="normal" font="default" size="100%">Generalkonsulat, Laboratorios LETI/LETI Pharma, Lilly, Lofarma, Medizinische</style></keyword><keyword><style face="normal" font="default" size="100%">Hochschule Hannover, med update europe GmbH, Meinhardt Congress GmbH, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Paul-Ehrlich-Institut, Paul-Martini-Stiftung, PneumoLive, Pohl-Boskamp, Procter &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Gamble, Red Maple Trials Inc., Regeneron Pharmaceuticals, RG Arztefortbildung,</style></keyword><keyword><style face="normal" font="default" size="100%">ROXALL Medizin, Sanofi Aventis, Sanofi Genzyme, Springer GmbH, Stallergenes</style></keyword><keyword><style face="normal" font="default" size="100%">Greer, streamedup! GmbH, Technical University Dresden, Thieme Medical Publishers,</style></keyword><keyword><style face="normal" font="default" size="100%">Wiley Publishers, Wort &amp; Bild Verlag, Verlag ME</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work,</style></keyword><keyword><style face="normal" font="default" size="100%">Oliver Pfaar is Vice President of the European Academy of Allergy and Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Immunology (EAACI), a member of EAACI Excom as well as a member of the external</style></keyword><keyword><style face="normal" font="default" size="100%">board of directors of the German Society of Allergy and Clinical Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">(DGAKI)</style></keyword><keyword><style face="normal" font="default" size="100%">coordinator, main or co-author of different position papers and</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines in rhinology, allergology, and allergen-immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">and he is</style></keyword><keyword><style face="normal" font="default" size="100%">editor-in-chief of Clinical Translational Allergy and associate editor of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy. I.A. reports Deputy Editor of the Allergy journal. K.K. has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. M.J. reports personal fees from ALK-Abello, Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes, Anergis, Allergy Therapeutics, Leti, HAL, during the conduct of the</style></keyword><keyword><style face="normal" font="default" size="100%">study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from GSK, Novartis, Teva, Takeda, Chiesi outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and is the Allergy journal&apos;s deputy editor.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40059339</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: An allergen exposure chamber (AEC) is a specialized medical facility designed to expose individuals to allergens at precise and consistent concentrations within a controlled environment. This study aimed to correlate the assessment of clinical endpoints in patients with allergic rhinitis sensitized to timothy grass pollen (Phleum pratense) by comparing three different methods: AEC, nasal allergen challenge (NAC), and symptoms during natural exposure during the grass pollen season. METHODS: Fifteen allergic subjects and twelve healthy controls were evaluated in the ALLEC AEC; allergic symptoms were measured by subjective and objective methods, including total nasal symptom score (TNSS), acoustic rhinometry (AcR), peak nasal inspiratory flow (PNIF), and nasal discharge amount. For the in-field evaluation, a combined symptom medication score (EAACI-CSMS), as proposed by the European Academy of Allergy and Clinical Immunology (EAACI), was used, which was assessed for 14 days during the peak of the pollen season. The AcR, PNIF, and TNSS were used for the NAC assessment. RESULTS: Both in the AEC and NAC, all allergic individuals developed symptoms at the optimal pollen/allergen concentration across all the measured endpoints. Using Spearman&apos;s rank correlation coefficient (p &lt; 0.05), the analysis revealed significant correlations between symptoms assessed in AEC at 120 min of the challenge, as well as in NAC after 15 min with the EAACI-CSMS in-field. The correlations between in-field assessment and AEC were stronger than those with NAC, which showed weaker or no significant correlations. This indicates that the AEC challenge correlates better with in-field assessments than NAC. CONCLUSION: Clinical endpoints assessed to allergen exposure in the AEC and NAC significantly correspond to the efficacy analysis in-field (EAACI-CSMS during the peak of pollen exposure). The effect of NAC was not significant for all outcomes measured. Both methods might be considered to be an alternative to traditional assessment during natural exposure.</style></abstract><notes><style face="normal" font="default" size="100%">Zemelka-Wiacek, Magdalena&#xD;Kosowska, Anna&#xD;Pfaar, Oliver&#xD;Agache, Ioana&#xD;Kujawa, Krzysztof&#xD;Jutel, Marek&#xD;eng&#xD;Polish Ministry of Health subvention according to the number of SUB.A020.23.068 from the IT Simple system from Wroclaw Medical University/&#xD;Comparative Study&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1286-1297. doi: 10.1111/all.16518. Epub 2025 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40059339</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105075</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16518</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1237</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1237</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Darnhofer, B.</style></author><author><style face="normal" font="default" size="100%">Tomin, T.</style></author><author><style face="normal" font="default" size="100%">Liesinger, L.</style></author><author><style face="normal" font="default" size="100%">Schittmayer, M.</style></author><author><style face="normal" font="default" size="100%">Tomazic, P. V.</style></author><author><style face="normal" font="default" size="100%">Birner-Gruenberger, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.&#xD;Omics Center Graz, BiotechMed-Graz, Graz, Austria.&#xD;Faculty of Technical Chemistry, Institute of Chemical Technologies and Analytics, Technische Universitat Wien (TU Wien), Vienna, Austria.&#xD;Division of Phoniatrics, Department of Otorhinolaryngology, Medical University of Graz, Graz, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparative proteomics of common allergenic tree pollens of birch, alder, and hazel</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1743-1753</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Alnus</style></keyword><keyword><style face="normal" font="default" size="100%">Betula</style></keyword><keyword><style face="normal" font="default" size="100%">*Corylus</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Trees</style></keyword><keyword><style face="normal" font="default" size="100%">alder</style></keyword><keyword><style face="normal" font="default" size="100%">birch</style></keyword><keyword><style face="normal" font="default" size="100%">hazel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33301602</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In addition to known allergens, other proteins in pollen can aid the development of an immune response in allergic individuals. The contribution of the &quot;unknown&quot; protein allergens is apparent in phylogenetically related species where, despite of high homology of the lead allergens, the degree of allergenic potential can vary greatly. The aim of this study was to identify other potentially allergenic proteins in pollen of three common and highly related allergenic tree species: birch (Betula pendula), hazel (Corylus avellana) and alder (Alnus glutinosa). METHODS: For that purpose, we carried out a comprehensive, comparative proteomic screening of the pollen from the three species. In order to maximize protein recovery and coverage, different protein extraction and isolation strategies during sample preparation were employed. RESULTS: As a result, we report 2500-3000 identified proteins per each of the pollen species. Identified proteins were further used for a number of annotation steps, providing insight into differential distribution of peptidases, peptidase inhibitors and other potential allergenic proteins across the three species. Moreover, we carried out functional enrichment analyses that, interestingly, corroborated high species similarity in spite of their relatively distinct protein profiles. CONCLUSION: We provide to our knowledge first insight into proteomes of two very important allergenic pollen types, hazel and alder, where not even transcriptomics data are available, and compared them to birch. Datasets from this study can be readily used as protein databases and as such serve as basis for further functional studies.</style></abstract><notes><style face="normal" font="default" size="100%">Darnhofer, Barbara&#xD;Tomin, Tamara&#xD;Liesinger, Laura&#xD;Schittmayer, Matthias&#xD;Tomazic, Peter Valentin&#xD;Birner-Gruenberger, Ruth&#xD;eng&#xD;W 1226/FWF_/Austrian Science Fund FWF/Austria&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1743-1753. doi: 10.1111/all.14694. Epub 2021 Jan 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33301602</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8248232</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14694</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3228</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3228</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nakashima, D.</style></author><author><style face="normal" font="default" size="100%">Hirota, T.</style></author><author><style face="normal" font="default" size="100%">Inoue, N.</style></author><author><style face="normal" font="default" size="100%">Yoshikawa, M.</style></author><author><style face="normal" font="default" size="100%">Mori, E.</style></author><author><style face="normal" font="default" size="100%">Otori, N.</style></author><author><style face="normal" font="default" size="100%">Kojima, H.</style></author><author><style face="normal" font="default" size="100%">Sato, Y.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author><author><style face="normal" font="default" size="100%">Nakayama, T.</style></author><author><style face="normal" font="default" size="100%">Tamari, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Molecular Genetics, Research Center for Medical Science, The Jikei University School of Medicine, Tokyo, Japan.&#xD;Department of Otorhinolaryngology, The Jikei University School of Medicine, Tokyo, Japan.&#xD;Department of Otorhinolaryngology, Toho University Ohashi Medical Center, Tokyo, Japan.&#xD;Immunology and Allergy Research Unit, Division of Otorhinolaryngology, Head &amp; Neck Surgery, Faculty of Medicine, University of Fukui, Fukui, Japan.&#xD;Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Dokkyo Medical University, Tochigi, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparative Transcriptomic Analysis of Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Using Nasal Tissue and Brushing Samples</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/21</style></edition><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41562190</style></accession-num><notes><style face="normal" font="default" size="100%">Nakashima, Daiki&#xD;Hirota, Tomomitsu&#xD;Inoue, Natsuki&#xD;Yoshikawa, Mamoru&#xD;Mori, Eri&#xD;Otori, Nobuyoshi&#xD;Kojima, Hiromi&#xD;Sato, Yohei&#xD;Morita, Hideaki&#xD;Nakayama, Tsuguhisa&#xD;Tamari, Mayumi&#xD;eng&#xD;23K08923/Ministry of Education, Culture, Sports, Science and Technology/&#xD;21FE2001/Health, Labor and Welfare Sciences Research/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan 21. doi: 10.1111/all.70227.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41562190</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70227</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>656</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">656</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boechat, J. L.</style></author><author><style face="normal" font="default" size="100%">Silva, D.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Delgado, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Immunology Service, Internal Medicine Department, Faculty of Medicine, Fluminense Federal University, Niteroi, Brazil.&#xD;Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Center for Health Technology and Services Research (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Servico de Imunoalergologia, Centro Hospitalar de Sao Joao, E.P.E., Porto, Portugal.&#xD;MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparing biologicals for severe chronic rhinosinusitis with nasal polyps: A network meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1299-1306</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/01/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34981835</style></accession-num><notes><style face="normal" font="default" size="100%">Boechat, Jose Laerte&#xD;Silva, Diana&#xD;Sousa-Pinto, Bernardo&#xD;Delgado, Luis&#xD;eng&#xD;Comment&#xD;Letter&#xD;Network Meta-Analysis&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1299-1306. doi: 10.1111/all.15205. Epub 2022 Jan 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34981835</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15205</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>513</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">513</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Catak, M. C.</style></author><author><style face="normal" font="default" size="100%">Akcam, B.</style></author><author><style face="normal" font="default" size="100%">Bilgic Eltan, S.</style></author><author><style face="normal" font="default" size="100%">Babayeva, R.</style></author><author><style face="normal" font="default" size="100%">Karakus, I. S.</style></author><author><style face="normal" font="default" size="100%">Akgun, G.</style></author><author><style face="normal" font="default" size="100%">Baser, D.</style></author><author><style face="normal" font="default" size="100%">Bulutoglu, A.</style></author><author><style face="normal" font="default" size="100%">Bayram, F.</style></author><author><style face="normal" font="default" size="100%">Kasap, N.</style></author><author><style face="normal" font="default" size="100%">Kiykim, A.</style></author><author><style face="normal" font="default" size="100%">Hancioglu, G.</style></author><author><style face="normal" font="default" size="100%">Kokcu Karadag, S. I.</style></author><author><style face="normal" font="default" size="100%">Kendir Demirkol, Y.</style></author><author><style face="normal" font="default" size="100%">Ozen, S.</style></author><author><style face="normal" font="default" size="100%">Cekic, S.</style></author><author><style face="normal" font="default" size="100%">Ozcan, D.</style></author><author><style face="normal" font="default" size="100%">Edeer Karaca, N.</style></author><author><style face="normal" font="default" size="100%">Sasihuseyinoglu, A. S.</style></author><author><style face="normal" font="default" size="100%">Cansever, M.</style></author><author><style face="normal" font="default" size="100%">Ozek Yucel, E.</style></author><author><style face="normal" font="default" size="100%">Tamay, Z.</style></author><author><style face="normal" font="default" size="100%">Altintas, D. U.</style></author><author><style face="normal" font="default" size="100%">Aydogmus, C.</style></author><author><style face="normal" font="default" size="100%">Celmeli, F.</style></author><author><style face="normal" font="default" size="100%">Cokugras, H.</style></author><author><style face="normal" font="default" size="100%">Gulez, N.</style></author><author><style face="normal" font="default" size="100%">Genel, F.</style></author><author><style face="normal" font="default" size="100%">Metin, A.</style></author><author><style face="normal" font="default" size="100%">Guner, S. N.</style></author><author><style face="normal" font="default" size="100%">Kutukculer, N.</style></author><author><style face="normal" font="default" size="100%">Keles, S.</style></author><author><style face="normal" font="default" size="100%">Reisli, I.</style></author><author><style face="normal" font="default" size="100%">Kilic, S. S.</style></author><author><style face="normal" font="default" size="100%">Yildiran, A.</style></author><author><style face="normal" font="default" size="100%">Karakoc-Aydiner, E.</style></author><author><style face="normal" font="default" size="100%">Lo, B.</style></author><author><style face="normal" font="default" size="100%">Ozen, A.</style></author><author><style face="normal" font="default" size="100%">Baris, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Allergy and Immunology, Marmara University, School of Medicine, Istanbul, Turkey.&#xD;Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey.&#xD;The Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.&#xD;Marmara University, School of Medicine, Istanbul, Turkey.&#xD;Cerrahpasa Faculty of Medicine, Pediatric Allergy and Immunology, Istanbul University-Cerrahpasa, Istanbul, Turkey.&#xD;Division of Pediatric Allergy and Immunology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey.&#xD;Division of Pediatric Genetics, University of Health Sciences, Umraniye Education and Research Hospital, Istanbul, Turkey.&#xD;Division of Pediatric Allergy and Immunology, University of Health Sciences, Dr. Behcet Uz Children&apos;s Education and Research Hospital, Izmir, Turkey.&#xD;Faculty of Medicine, Pediatric Allergy and Immunology, Uludag University, Bursa, Turkey.&#xD;Division of Pediatric Allergy-Immunology, Faculty of Medicine, Cukurova University, Adana, Turkey.&#xD;Faculty of Medicine, Pediatric Allergy and Immunology, Ege University, Izmir, Turkey.&#xD;Ministry of Health, Sanliurfa Training and Research Hospital, Urfa, Turkey.&#xD;Faculty of Medicine, Pediatric Immunology, Erciyes University, Kayseri, Turkey.&#xD;Istanbul Faculty of Medicine, Pediatric Allergy and Immunology, Istanbul University, Istanbul, Turkey.&#xD;Pediatric Allergy and Immunology, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.&#xD;Ministry of Health, Antalya Training and Research Hospital, Antalya, Turkey.&#xD;Pediatric Immunology and Allergy, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.&#xD;Faculty of Medicine, Pediatric Allergy and Immunology, Necmettin Erbakan University, Konya, Turkey.&#xD;Division of Translational Medicine, Research Branch, Sidra Medicine, Doha, Qatar.&#xD;College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparing the levels of CTLA-4-dependent biological defects in patients with LRBA deficiency and CTLA-4 insufficiency</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3108-3123</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/05/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Abatacept/metabolism/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Adaptor Proteins, Signal Transducing/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">CTLA-4 Antigen/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Forkhead Transcription Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Lipopolysaccharides</style></keyword><keyword><style face="normal" font="default" size="100%">Ctla-4</style></keyword><keyword><style face="normal" font="default" size="100%">Lrba</style></keyword><keyword><style face="normal" font="default" size="100%">T follicular helper cells</style></keyword><keyword><style face="normal" font="default" size="100%">Treg</style></keyword><keyword><style face="normal" font="default" size="100%">inborn errors of immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35491430</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Lipopolysaccharide-responsive beige-like anchor protein (LRBA) deficiency and cytotoxic T-lymphocyte protein-4 (CTLA-4) insufficiency are recently described disorders that present with susceptibility to infections, autoimmunity, and lymphoproliferation. Clinical and immunological comparisons of the diseases with long-term follow-up have not been previously reported. We sought to compare the clinical and laboratory manifestations of both diseases and investigate the role of flow cytometry in predicting the genetic defect in patients with LRBA deficiency and CTLA-4 insufficiency. METHODS: Patients were evaluated clinically with laboratory assessments for lymphocyte subsets, T follicular helper cells (T(FH) ), LRBA expression, and expression of CD25, FOXP3, and CTLA4 in regulatory T cells (Tregs) at baseline and 16 h post-stimulation. RESULTS: LRBA-deficient patients (n = 29) showed significantly early age of symptom onset, higher rates of pneumonia, autoimmunity, chronic diarrhea, and failure to thrive compared to CTLA-4 insufficiency (n = 12). In total, 29 patients received abatacept with favorable responses and the overall survival probability was not different between transplanted versus non-transplanted patients in LRBA deficiency. Meanwhile, higher probability of survival was observed in CTLA-4-insufficient patients (p = 0.04). The T-cell subsets showed more deviation to memory cells in CTLA-4-insufficiency, accompanied by low percentages of Treg and dysregulated cT(FH) cells response in both diseases. Cumulative numbers of autoimmunities positively correlated with cT(FH) frequencies. Baseline CTLA-4 expression was significantly diminished in LRBA deficiency and CTLA-4 insufficiency, but significant induction in CTLA-4 was observed after short-term T-cell stimulation in LRBA deficiency and controls, while this elevation was less in CTLA-4 insufficiency, allowing to differentiate this disease from LRBA deficiency with high sensitivity (87.5%) and specificity (90%). CONCLUSION: This cohort provided detailed clinical and laboratory comparisons for LRBA deficiency and CTLA-4 insufficiency. The flow cytometric approach is useful in predicting the defective gene; thus, targeted sequencing can be conducted to provide rapid diagnosis and treatment for these diseases impacting the CTLA-4 pathway.</style></abstract><notes><style face="normal" font="default" size="100%">Catak, Mehmet C&#xD;Akcam, Bengu&#xD;Bilgic Eltan, Sevgi&#xD;Babayeva, Royala&#xD;Karakus, Ibrahim S&#xD;Akgun, Gamze&#xD;Baser, Dilek&#xD;Bulutoglu, Alper&#xD;Bayram, Feyza&#xD;Kasap, Nurhan&#xD;Kiykim, Ayca&#xD;Hancioglu, Gonca&#xD;Kokcu Karadag, Sefika I&#xD;Kendir Demirkol, Yasemin&#xD;Ozen, Selime&#xD;Cekic, Sukru&#xD;Ozcan, Dilek&#xD;Edeer Karaca, Neslihan&#xD;Sasihuseyinoglu, Ayse S&#xD;Cansever, Murat&#xD;Ozek Yucel, Esra&#xD;Tamay, Zeynep&#xD;Altintas, Derya U&#xD;Aydogmus, Cigdem&#xD;Celmeli, Fatih&#xD;Cokugras, Haluk&#xD;Gulez, Nesrin&#xD;Genel, Ferah&#xD;Metin, Ayse&#xD;Guner, Sukru N&#xD;Kutukculer, Necil&#xD;Keles, Sevgi&#xD;Reisli, Ismail&#xD;Kilic, Sara S&#xD;Yildiran, Alisan&#xD;Karakoc-Aydiner, Elif&#xD;Lo, Bernice&#xD;Ozen, Ahmet&#xD;Baris, Safa&#xD;eng&#xD;Comparative Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3108-3123. doi: 10.1111/all.15331. Epub 2022 May 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35491430</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15331</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3059</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3059</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Vieira, R. J.</style></author><author><style face="normal" font="default" size="100%">Bognanni, A.</style></author><author><style face="normal" font="default" size="100%">Martini, M.</style></author><author><style face="normal" font="default" size="100%">Ordak, M.</style></author><author><style face="normal" font="default" size="100%">Paoletti, G.</style></author><author><style face="normal" font="default" size="100%">Gil-Mata, S.</style></author><author><style face="normal" font="default" size="100%">Amaral, R.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Coutinho-Almeida, J.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Dykewicz, M.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Ivancevich, J. C.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Marques-Cruz, M.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Niedoszytko, M.</style></author><author><style face="normal" font="default" size="100%">Pereira, A. M.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, N.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S. K.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Taborda-Barata, L.</style></author><author><style face="normal" font="default" size="100%">Thomander, T.</style></author><author><style face="normal" font="default" size="100%">Koyuncu, I. V.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Vecillas, L. L.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Xiang, Y. K.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Schunemann, H. J.</style></author><author><style face="normal" font="default" size="100%">di Bona, D.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE-Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Department of Health Research Methods, Evidence, and Impact &amp; Department of Medicine, Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada.&#xD;Allergy Unit, Department of Internal Medicine, University Hospital AOU delle Marche, Ancona, Italy.&#xD;Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.&#xD;Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.&#xD;Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Italy.&#xD;Department of Cardiovascular and Respiratory Sciences, Porto Health School, Polytechnic Institute of Porto, Porto, Portugal.&#xD;Department of Women&apos;s and Children&apos;s Health, Paediatric Research, Uppsala University, Uppsala, Sweden.&#xD;ARIA, Montpellier, France.&#xD;MASK-air, Montpellier, France.&#xD;Allergy Unit and Asthma Center, Verona University Hospital, Verona, Italy.&#xD;Department of Medical Sciences, University of Torino, Torino, Italy.&#xD;Allergy and Clinical Immunology Unit, Mauriziano Hospital, Torino, Italy.&#xD;Fundacao ProAR, and (Faculdade de Medicina da) Universidade Federal da Bahia, Salvador, Bahia, Brazil.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.&#xD;Institute of Pulmonology and Tuberculosis, Istanbul University-Cerrahpasa, Istanbul, Turkey.&#xD;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;EPIUnit-Institute of Public Health, University of Porto, and Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal.&#xD;Servico de Imunoalergologia, Centro Hospitalar Universitario Sao Joao, Porto, Portugal.&#xD;Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Department of Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;Allergy Unit, Instituto and Hospital CUF, Porto, Portugal.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Ecole Polytechnique de Palaiseau, Palaiseau, France.&#xD;IRBA (Institut de Recherche Bio-Medicale des Armees), Bretigny Sur Orge, France.&#xD;Universite Paris Cite, Paris, France.&#xD;Allergy and Clinical Immunology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saude de Coimbra, Coimbra, Portugal.&#xD;Center for Innovative Biomedicine and Biotechnology (CIBB), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;UBIAir-Clinical &amp; Experimental Lung Centre and CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Department of Otorhinolaryngology, University of Eastern Finland and the North Savo Wellbeing Services County, Kuopio, Finland.&#xD;Department of Allergy, Skin and Allergy Hospital, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland.&#xD;Allergy Service, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, CIBERES-ISCIII, Madrid, Spain.&#xD;RISE-Health, Faculty of Health Sciences, and UBIAir-Clinical &amp; Experimental Lung Centre, University of Beira Interior, Covilha, Portugal.&#xD;Department of Immunoallergology, Cova da Beira University Hospital Center, Covilha, Portugal.&#xD;The Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Clinic of Asthma, Allergy and Chronic Lung Diseases, Vilnius, Lithuania.&#xD;Institute of Clinical Medicine and Institute of Health Sciences, Medical Faculty of Vilnius University, Vilnius, Lithuania.&#xD;Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.&#xD;University of Bari Medical School, Bari, Italy.&#xD;Institute of Sciences of Food Production, National Research Council (ISPA-CNR), Bari, Italy.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Michael G. DeGroote Cochrane Canada &amp; McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Medical and Surgical Science, University of Foggia, Foggia, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of Allergic Rhinitis Treatments on Patient Satisfaction: A MASK-air and EAACI Methodological Committee Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3319-3330</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/09/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient Satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine Antagonists/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Intranasal</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41001805</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Satisfaction with treatments may affect medication adherence and use patterns, including the use of co-medication. We aimed to compare different medications for allergic rhinitis (AR) on (i) patients&apos; satisfaction and (ii) co-medication use frequency. METHODS: We assessed data from the mHealth app MASK-air. We evaluated days on which users with self-reported AR had used-alone or in co-medication-intranasal corticosteroids (INCS), intranasal antihistamines (INAH), fixed combinations of INAH+INCS, or oral antihistamines (OAH). We built multivariable regression models to compare these different AR medication classes (as well as individual medications) on their (i) treatment satisfaction levels (measured using a specific daily visual analogue scale [&apos;VAS satisfaction&apos;]) and (ii) odds of being used in co-medication. RESULTS: We assessed 28,177 days reported by 1691 MASK-air users. For all medication classes, co-medication usage was associated with lower treatment satisfaction. When used in monotherapy, OAH were associated with lower VAS satisfaction than INCS (-1.7 points; 95% CI = -2.7; -0.7) or INAH+INCS (-2.1 points; 95% CI = -3.5; -0.7). INCS displayed higher odds of being used in co-medication than OAH (OR = 1.3; 95% CI = 1.0; 1.6) or INAH+INCS (OR = 1.3; 95% CI = 0.8; 1.8). When comparing individual intranasal medications, fluticasone furoate and fluticasone propionate tended to be more frequently used in co-medication. Among individual OAH, desloratadine and rupatadine were associated with higher satisfaction, while fexofenadine was more frequently used in co-medication. CONCLUSION: Using patient-reported data, we evaluated different medication classes and treatments in terms of satisfaction and co-medication frequency. These results provide key insights into the acceptability of AR treatments and will contribute to future treatment guidelines.</style></abstract><notes><style face="normal" font="default" size="100%">Sousa-Pinto, Bernardo&#xD;Vieira, Rafael Jose&#xD;Bognanni, Antonio&#xD;Martini, Matteo&#xD;Ordak, Michal&#xD;Paoletti, Giovanni&#xD;Gil-Mata, Sara&#xD;Amaral, Rita&#xD;Bedbrook, Anna&#xD;Bonadonna, Patrizia&#xD;Brussino, Luisa&#xD;Canonica, G Walter&#xD;Coutinho-Almeida, Joao&#xD;Cruz, Alvaro A&#xD;Czarlewski, Wienczyslawa&#xD;Dykewicz, Mark&#xD;Giovannini, Mattia&#xD;Gemicioglu, Bilun&#xD;Ivancevich, Juan Carlos&#xD;Klimek, Ludger&#xD;Kvedariene, Violeta&#xD;Larenas-Linnemann, Desiree E&#xD;Marques-Cruz, Manuel&#xD;Moreira, Andre&#xD;Niedoszytko, Marek&#xD;Pereira, Ana Margarida&#xD;Papadopoulos, Nikolaos G&#xD;Pham-Thi, Nhan&#xD;Regateiro, Frederico S&#xD;Toppila-Salmi, Sanna K&#xD;Samolinski, Boleslaw&#xD;Sastre, Joaquin&#xD;Taborda-Barata, Luis&#xD;Thomander, Tuuli&#xD;Koyuncu, Ilgim Vardaloglu&#xD;Valiulis, Arunas&#xD;Vecillas, Leticia de Las&#xD;Ventura, Maria Teresa&#xD;Walusiak-Skorupa, Jolanta&#xD;Xiang, Yi-Kui&#xD;Pfaar, Oliver&#xD;Fonseca, Joao A&#xD;Zuberbier, Torsten&#xD;Schunemann, Holger J&#xD;di Bona, Danilo&#xD;Bousquet, Jean&#xD;eng&#xD;MASK-air SAS/&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Comparative Study&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3319-3330. doi: 10.1111/all.70055. Epub 2025 Sep 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41001805</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666759 Sanofi-Aventis, Teva, Noucor, other from KYomed-Innov, other from MASK-air SAS, outside the submitted work. A. Cruz reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from Farmoquimica, personal fees from Eurofarma, personal fees from Ache, personal fees from GSK, personal fees from Sanofi, outside the submitted work. G. Paoletti reports other from LoFarma, GSK, Astrazeneca, outside the submitted work. J. C. Ivancevich reports personal fees from Laboratorios Casasco Argentina, outside the submitted work. N. Papadopoulos reports grants from Capricare, Nestle, Numil, Vianex, REG, other from Abbott, Abbvie, Astra Zeneca, GSK, HAL, Medscape, Menarini/Faes Farma, Mylan, Novartis, Nutricia, OM Pharma, Regeneron/Sanofi, outside the submitted work. O. Pfaar reports grants and personal fees from ALK-Abello, grants and personal fees from Allergopharma, grants and personal fees from Stallergenes Greer, grants and personal fees from HAL Allergy Holding B.V./HAL Allergie GmbH, grants and personal fees from Bencard Allergie GmbH/Allergy Therapeutics, grants and personal fees from Laboratorios LETI/LETI Pharma, grants and personal fees from GlaxoSmithKline, personal fees from ROXALL Medizin, personal fees from Novartis, grants and personal fees from Sanofi-Aventis and Sanofi-Genzyme, personal fees from Med Update Europe GmbH, personal fees from streamedup! GmbH, grants and personal fees from Pohl-Boskamp, grants from Inmunotek S.L., personal fees from John Wiley and Sons, AS, personal fees from Paul-Martini-Stiftung, personal fees from RG Aerztefortbildung, personal fees from Institut fur Disease Management, personal fees from Springer Publisher, grants and personal fees from AstraZeneca, personal fees from IQVIA Commercial, personal fees from Ingress Health, personal fees from Wort&amp;Bild Verlag, personal fees from Verlag ME, personal fees from Procter&amp;Gamble, personal fees from ALTAMIRA, personal fees from Meinhardt Congress GmbH, personal fees from Deutsche Forschungsgemeinschaft, personal fees from Thieme Publisher, grants from Deutsche AllergieLiga e.V., personal fees from AeDA, personal fees from Alfried-Krupp Krankenhaus, personal fees from Red Maple Trials Inc., personal fees from Koniglich Danisches Generalkonsulat, personal fees from Medizinische Hochschule Hannover, personal fees from ECM Expro&amp;Conference Management, personal fees from Technical University Dresden, grants and personal fees from Lilly, personal fees from Japanese Society of Allergy, personal fees from Forum fur Medizinische Fortbildung, personal fees from Dustri-Verlag, personal fees from Pneumolive, grants and personal fees from ASIT Biotech, grants and personal fees from LOFARMA, personal fees from Paul-Ehrlich-Institut, personal fees from Almirall, personal fees from Blueprint, personal fees from Cliantha, outside the submitted work; and Vice President and member of EAACI Excom, member of ext. board of directors DGAKI; coordinator, main- or co-author of different position papers and guidelines in rhinology, allergology and allergen immunotherapy; associate editor (AE) of Allergy and Editor-in-Chief (EIC) of Clinical Translational Allergy. J. Sastre reports grants and personal fees from SANOFI, personal fees from GSK, personal fees from NOVARTIS, personal fees from ASTRA ZENECA, personal fees from MUNDIPHARMA, personal fees from FAES FARMA, outside the submitted work. T. Thomander reports grants from The Finnish ORL-HNS Foundation, grants from The Research Foundation of the Pulmonary Diseases, grants from The Foundation of the Finnish Anti-Tuberculosis Association, during the conduct of the study. S. Toppila-Salmi reports other from ALK-Abello, grants and other from Sanofi, grants and other from GSK, Orion Pharma, Clario, AstraZeneca, outside the submitted work. T. Zuberbier reports honoraria for lectures from Amgen, AstraZeneca, AbbVie, ALK -Abello, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, FAES Farma, HAL Allergie GmbH, Henkel, Kryolan, Leti, L&apos;Oreal, Meda, Menarini, Merck Sharp &amp; Dohme, Novartis, Nuocor, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB, and Uriach; Fees for industry consulting were received from Abivax, Almirall, Bluprint, Celldex, Celltrion, Novartis, and Sanofi; in addition he declares non-paid organisational affiliations: Committee member, &apos;Allergic Rhinitis and its Impact on Asthma&apos; (ARIA), Member of the Board, German Society for Allergy and Clinical Immunology (DGAKI), Head, European Centre for Allergy Research Foundation (ECARF), President, Global Allergy and Asthma Excellence Network (GA(2)LEN), and Member, Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organisation (WAO). N. Pham-Thi reports other from ALK, Stallergenes, outside the submitted work. L. Taborda-Barata reports personal fees from LETI, personal fees from Sanofi, personal fees from Diater, outside the submitted work. D. Larenas Linnemann reports personal fees from ALK, Astrazeneca national and global, Bayer, Chiesi, Grunenthal, Grin, GSK national and global, Viatris, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, Carnot, Syneos Health, grants from Abbvie, Bayer, Lilly, Sanofi, Astrazeneca, Pfizer, Novartis, Pulmonair, GSK, Chiesi, outside the submitted work; and Editor in chief of Immune System (Karger); Member of asthma committee ACAAI; Subgroup chair of allergen immunotherapy Practice parameter update JTF AAAAI/ACAAI 2024; Member of allergen immunotherapy committee AAAAI; Chair of allergen immunotherapy committee CMICA; Member of allergic asthma task force EAACI. M. Giovannini reports fees from Sanofi, Thermo Fisher Scientific, outside the submitted work. The other authors have nothing to declare, outside the submitted work.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70055</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2705</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2705</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gupta, R. K.</style></author><author><style face="normal" font="default" size="100%">Figueroa, D. S.</style></author><author><style face="normal" font="default" size="100%">Ay, F.</style></author><author><style face="normal" font="default" size="100%">Causton, B.</style></author><author><style face="normal" font="default" size="100%">Abdollahi, S.</style></author><author><style face="normal" font="default" size="100%">Croft, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.&#xD;Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, California, USA.&#xD;Department of Pediatrics, University of California San Diego, La Jolla, California, USA.&#xD;Bristol Myers Squibb, Cambridge, Massachusetts, USA.&#xD;Department of Medicine, University of California San Diego, La Jolla, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">500-512</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/11/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/immunology/metabolism/drug therapy/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*OX40 Ligand/genetics/metabolism/antagonists &amp; inhibitors/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*CD30 Ligand/genetics/metabolism/antagonists &amp; inhibitors/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Ki-1 Antigen/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, OX40</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cd30</style></keyword><keyword><style face="normal" font="default" size="100%">Ox40</style></keyword><keyword><style face="normal" font="default" size="100%">Tnf</style></keyword><keyword><style face="normal" font="default" size="100%">dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39589186</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Blocking IL-13 is highly efficacious in patients with Th2-biased atopic dermatitis (AD), and recent clinical data have highlighted that targeting the T cell costimulatory molecules OX40 and OX40L (TNFSF4) holds promise for future treatment of AD. AIM: We asked whether targeting another T cell costimulatory molecule, CD30L (TNFSF8), might also be a possible treatment option in AD. METHODS: Single-cell RNA-seq data from human AD skin lesions was analyzed to identify pathogenic IL-13- or IL-22-producing T cells and assess expression of CD30 and its ligand in comparison to OX40 and its ligand. Additionally, a murine model of AD with repetitive exposure to house dust mite allergen was used to compare neutralizing antibodies against CD30L with those against IL-13 or OX40L. RESULTS: Analysis of several scRNA-seq datasets from skin lesions of AD patients showed that transcripts for CD30 or CD30L were found expressed with OX40 or OX40L in the primary T cell populations that also expressed mRNA for IL13 and/or IL22. Suggesting that this could be therapeutically relevant, mice treated prophylactically with a blocking CD30L antibody were protected from developing maximal allergen-induced AD features, including epidermal and dermal thickening, immune cell infiltration, and expression of AD-related genes, similar to mice treated with a blocking IL-13 antibody. Moreover, therapeutic neutralization of CD30L in mice with experimental AD also reduced all of the pathological skin lesion features to a comparable extent as blocking OX40L. CONCLUSION: These data suggest that targeting the CD30-CD30L axis might hold promise as a future therapeutic intervention in human AD, similar to targeting the OX40-OX40L axis.</style></abstract><notes><style face="normal" font="default" size="100%">Gupta, Rinkesh K&#xD;Figueroa, Daniela Salgado&#xD;Ay, Ferhat&#xD;Causton, Benjamin&#xD;Abdollahi, Shahla&#xD;Croft, Michael&#xD;eng&#xD;R35 GM128938/GM/NIGMS NIH HHS/&#xD;La Jolla Institute for Immunology/&#xD;Bristol-Myers Squibb/&#xD;Comparative Study&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):500-512. doi: 10.1111/all.16412. Epub 2024 Nov 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39589186</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12330979</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16412</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1396</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1396</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Testera-Montes, A.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Perez-Sanchez, N.</style></author><author><style face="normal" font="default" size="100%">Ariza, A.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Bartra, J.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA and ARADyAL, Malaga, Spain.&#xD;Universidad de Malaga (UMA), Malaga, Spain.&#xD;Allergy Section, Pulmonology Unit, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.&#xD;Clinical &amp; Experimental Respiratory Immunoallergy (IRCE), Instituto de Investigaciones Biomedicas August Pi i Sunyer (IDIBAPS)-ARADyAL, Barcelona, Spain.&#xD;Laboratory for Nanostructures for the Diagnosis and Treatment of Allergic Diseases, Andalusian Center for Nanomedicine and Biotechnology (BIONAND), Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of diagnostic accuracy of acoustic rhinometry and symptoms score for nasal allergen challenge monitoring</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">371-375</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Obstruction</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Perennial</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinometry, Acoustic</style></keyword><keyword><style face="normal" font="default" size="100%">acoustic rhinometry</style></keyword><keyword><style face="normal" font="default" size="100%">cutoff point</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostic accuracy</style></keyword><keyword><style face="normal" font="default" size="100%">nasal allergen challenge</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32687610</style></accession-num><notes><style face="normal" font="default" size="100%">Eguiluz-Gracia, Ibon&#xD;Testera-Montes, Almudena&#xD;Salas, Maria&#xD;Perez-Sanchez, Natalia&#xD;Ariza, Adriana&#xD;Bogas, Gador&#xD;Bartra, Joan&#xD;Torres, Maria Jose&#xD;Rondon, Carmen&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):371-375. doi: 10.1111/all.14499. Epub 2020 Aug 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32687610</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14499</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2752</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2752</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">de Weger, W. W.</style></author><author><style face="normal" font="default" size="100%">Sprikkelman, A. B.</style></author><author><style face="normal" font="default" size="100%">Herpertz, C. E. M.</style></author><author><style face="normal" font="default" size="100%">van der Meulen, G. N.</style></author><author><style face="normal" font="default" size="100%">Vonk, J. M.</style></author><author><style face="normal" font="default" size="100%">Koppelman, G. H.</style></author><author><style face="normal" font="default" size="100%">Kamps, A. W. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Martini Hospital, Groningen, The Netherlands.&#xD;Department of Pediatric Pulmonology and Pediatric Allergology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of Double-Blind and Open Food Challenges for the Diagnosis of Food Allergy in Childhood: The ALDORADO Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">248-257</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/12/14 20:07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Anacardium/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Corylus/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Oral food challenge</style></keyword><keyword><style face="normal" font="default" size="100%">allergy and immunology</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiologic methodes/statistics as a topic/sensitivity and specificity</style></keyword><keyword><style face="normal" font="default" size="100%">nut and peanut hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. Her institution received compensation for her</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy from Sanofi Netherlands and Nestle Research, Lausanne. G.H.K. reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from the Netherlands Lung Foundation, ZON-MW (VICI grant), European Union</style></keyword><keyword><style face="normal" font="default" size="100%">(H2020), Vertex, GSK, and TEVA in the Netherlands, outside the submitted work.</style></keyword><keyword><style face="normal" font="default" size="100%">His institution received compensation for participation in advisory board</style></keyword><keyword><style face="normal" font="default" size="100%">meetings for AZ and PURE IMS and for invited lectures from Sanofi, Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, and AZ. G.H.K. is the founder and chair of the exquAIro Foundation,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. The other authors report no proprietary or commercial</style></keyword><keyword><style face="normal" font="default" size="100%">interest in any product mentioned, concept discussed, or personal relationships</style></keyword><keyword><style face="normal" font="default" size="100%">with other people or organisations that could influence their work and</style></keyword><keyword><style face="normal" font="default" size="100%">conclusions in this article.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39673463</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Double-blind placebo-controlled food challenge (DBPCFC) is widely regarded as the &quot;gold standard&quot; to diagnose food allergy. Maximum efforts are made to reduce bias, yet DBPCFCs are costly, time-, and resource-intensive. Less demanding open food challenges are increasingly used in clinical practice. However, recommendations regarding the use of these challenges are based on low certainty of evidence, and no comparative studies have been performed using the most recent international food challenge guidelines. We hypothesised that the open food challenge is non-inferior to DBPCFC in children suspected of allergy to cashew nuts, hazelnuts or peanuts. METHODS: A total of 63 children, aged 4 years and older, were included if referred for suspected IgE-mediated allergy to cashew nut, hazelnut, or peanut. All study participants underwent DBPCFC first, followed by an open food challenge for the same food. Challenge outcomes were assessed by predefined criteria into positive, negative, or inconclusive. RESULTS: DBPCFC and open food challenge outcomes were the same for 36/41 (87.8%) patients. Sensitivity and specificity of the open food challenge were 0.91 (95% CI 0.79, 1.03) and 0.83 (95% CI 0.63, 1.01), respectively, with an AUC value of 0.87. Eliciting and stop doses were not significantly different between both food challenges. CONCLUSION: The Diagnostic accuracy of open food challenge is non-inferior to that of DBPCFC. This finding implies less demanding open food challenges can be implemented for children from the age of 4 years suspected to be cashew nut, hazelnut, or peanut allergic. Further research is necessary to validate our findings and to investigate the diagnostic accuracy for other major food allergens.</style></abstract><notes><style face="normal" font="default" size="100%">de Weger, Wouter W&#xD;Sprikkelman, Aline B&#xD;Herpertz, Catherina E M&#xD;van der Meulen, Gerbrich N&#xD;Vonk, Judith M&#xD;Koppelman, Gerard H&#xD;Kamps, Arvid W A&#xD;eng&#xD;Research Fund Martini Hospital/&#xD;Nutricia (the Netherlands)/&#xD;Comparative Study&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):248-257. doi: 10.1111/all.16428. Epub 2024 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39673463</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724221</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16428</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2177</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2177</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jessen, F. B.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Eller, E.</style></author><author><style face="normal" font="default" size="100%">Gudichsen, J. H.</style></author><author><style face="normal" font="default" size="100%">Baekdal, E. A.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A comparison of double-blind, placebo-controlled food challenge and open food challenge</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3204-3211</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/08/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Food</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">double-blind, placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">open food challenge</style></keyword><keyword><style face="normal" font="default" size="100%">severity of symptoms</style></keyword><keyword><style face="normal" font="default" size="100%">threshold values</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37539617</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Double-blind, placebo-controlled food challenge (DBPCFC) remains the gold standard for diagnosing food allergy, despite sparse comparisons to open food challenges (OpenFCs). The objective of this retrospective study was to compare severity of symptoms and threshold values (cumulative dose of food allergen eliciting a clinical reaction) in children and adults with peanut allergy, challenged in an open and/or double-blind, placebo-controlled protocol. METHODS: This study included patients from the Allergy Centre, Odense University Hospital with a positive oral food challenge, defined as strict objective signs, with peanut during the period 2001-2022. Severity of symptoms was graded using the Sampson&apos;s severity score. Distribution models of threshold values were calculated using log-normal interval-censored survival analysis, and the number of placebo reactions was evaluated. RESULTS: In total, 318 positive OpenFCs and 86 DBPCFCs were included. There was no difference in severity of symptoms nor threshold values comparing the two challenge types, neither when stratified for age groups. However, a higher proportion of children experienced Grade 3 symptoms in the double-blind group. Only one patient had a positive reaction to a placebo challenge. CONCLUSION: Our findings do not advocate for DBPCFC being superior to OpenFC, if the latter is performed with strict objective stop criteria by trained staff.</style></abstract><notes><style face="normal" font="default" size="100%">Jessen, Frederik Bloch&#xD;Mortz, Charlotte G&#xD;Eller, Esben&#xD;Gudichsen, Julie H&#xD;Baekdal, Emil A&#xD;Bindslev-Jensen, Carsten&#xD;eng&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3204-3211. doi: 10.1111/all.15834. Epub 2023 Aug 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37539617</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15834</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>738</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">738</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">de Lusignan, S.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS - Center for Health Technology and Services Research, University of Porto, Porto, Portugal.&#xD;ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.&#xD;Universitat Pompeu Fabra, Barcelona, Spain.&#xD;IMIM - Hospital del Mar Medical Research Institute, Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica - CIBERESP, Barcelona, Spain.&#xD;Usher Institute, University of Edinburgh, Edinburgh, UK.&#xD;Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.&#xD;Royal College of General Practitioners Research and Surveillance Centre, London, UK.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.&#xD;Charite, Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Department of Dermatology and Allergy, Comprehensive Allergy Center, Berlin Institute of Health, Berlin, Germany.&#xD;MACVIA-France, Montpellier, France.&#xD;University Hospital, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of epidemiologic surveillance and Google Trends data on asthma and allergic rhinitis in England</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">675-678</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">England/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiological Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Search Engine</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory infections</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">surveillance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34665881</style></accession-num><notes><style face="normal" font="default" size="100%">Sousa-Pinto, Bernardo&#xD;Anto, Josep M&#xD;Sheikh, Aziz&#xD;de Lusignan, Simon&#xD;Haahtela, Tari&#xD;Fonseca, Joao Almeida&#xD;Bousquet, Jean&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):675-678. doi: 10.1111/all.15139. Epub 2021 Oct 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34665881</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15139</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1187</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1187</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muddaluru, V.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Vrtala, S.</style></author><author><style face="normal" font="default" size="100%">Schlederer, T.</style></author><author><style face="normal" font="default" size="100%">Hindley, J.</style></author><author><style face="normal" font="default" size="100%">Hickey, P.</style></author><author><style face="normal" font="default" size="100%">Larche, M.</style></author><author><style face="normal" font="default" size="100%">Tonti, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Immunology &amp; Allergy Division, Department of Medicine, McMaster University, Hamilton, ON, Canada.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;NRC Institute of Immunology FMBA of Russia, Moscow, Russia.&#xD;Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Phadia Austria GmbH, Part of Thermo Fisher Scientific ImmunoDiagnostics, Vienna, Austria.&#xD;Indoor Biotechnologies Ltd., Cardiff, UK.&#xD;Adiga Life Sciences Inc., Hamilton, ON, Canada.&#xD;Aravax Pty Ltd, Melbourne, Victoria, Australia.&#xD;Firestone Institute of Respiratory Health, The Research Institute at St. Joe&apos;s, St. Joseph&apos;s Healthcare Hamilton, Hamilton, ON, Canada.&#xD;McMaster Immunology Research Institute, McMaster University, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of house dust mite sensitization profiles in allergic adults from Canada, Europe, South Africa and USA</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2177-2188</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">South Africa/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Der p 23</style></keyword><keyword><style face="normal" font="default" size="100%">Der p 7</style></keyword><keyword><style face="normal" font="default" size="100%">IgE sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">allergen exposure</style></keyword><keyword><style face="normal" font="default" size="100%">allergen microarray</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33484161</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Sensitization to house dust mite (HDM) is a leading cause of allergic rhinitis and asthma. Despite more than 30 HDM-derived allergens having been identified to date, specific therapeutic approaches do not yet take into account the local sensitization profiles of patients. This study aimed to identify patterns of HDM sensitization in HDM-allergic adults living in distinct geographic areas, to inform the development of targeted diagnostic and therapeutic tools. METHODS: Serum samples from 685 HDM-allergic subjects from Canada, Europe, South Africa, and the USA were tested for levels of IgE specific for 17 micro-arrayed HDM allergens by ImmunoCAP Immuno Solid-phase Allergen Chip (ISAC) technology. RESULTS: The results confirmed significant geographical variability in sensitization patterns and levels of IgE. In all areas, the major sensitizers were the group 1 and group 2 allergens and Der p 23. Der p 23 was a frequent sensitizer: 64% of the subjects had IgE specific for Der p 23, and 2.3% were monosensitized to it. In South Africa, Der p 23 was the dominant HDM allergen (86% prevalence) and Der p 7 achieved major allergen status (56%). IgE sensitization to HDM was influenced by asthmatic status, levels of allergen exposure, age, race-ethnicity and smoking status, but not by BMI. CONCLUSION: Sensitization profiles to HDM allergens differ considerably among distinct geographic areas, with Der p 7 and Der p 23 being major sensitizers in South Africa. Such heterogeneity should be taken into account in the diagnosis and treatment of HDM-allergic patients.</style></abstract><notes><style face="normal" font="default" size="100%">Muddaluru, Varun&#xD;Valenta, Rudolf&#xD;Vrtala, Susanne&#xD;Schlederer, Thomas&#xD;Hindley, James&#xD;Hickey, Pascal&#xD;Larche, Mark&#xD;Tonti, Elena&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2177-2188. doi: 10.1111/all.14749. Epub 2021 Mar 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33484161</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14749</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1326</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1326</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eifan, A. O.</style></author><author><style face="normal" font="default" size="100%">Fedina, A.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Scadding, G. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College, London, UK.&#xD;Allergy Department, Royal Brompton and Harefield Hospitals NHS Trust, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of nasal allergen challenges with dissolved Timothy grass pollen tablets and aqueous extract</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1543-1545</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/09/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Phleum</style></keyword><keyword><style face="normal" font="default" size="100%">Poaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">challenge</style></keyword><keyword><style face="normal" font="default" size="100%">grass</style></keyword><keyword><style face="normal" font="default" size="100%">nasal</style></keyword><keyword><style face="normal" font="default" size="100%">provocation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32946601</style></accession-num><notes><style face="normal" font="default" size="100%">Eifan, Aarif O&#xD;Fedina, Alexandra&#xD;Durham, Stephen R&#xD;Scadding, Guy W&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1543-1545. doi: 10.1111/all.14590. Epub 2020 Oct 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32946601</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14590</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>500</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">500</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Schunemann, H. J.</style></author><author><style face="normal" font="default" size="100%">Sa-Sousa, A.</style></author><author><style face="normal" font="default" size="100%">Vieira, R. J.</style></author><author><style face="normal" font="default" size="100%">Amaral, R.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Ansotegui, I. J.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Bosnic-Anticevich, S.</style></author><author><style face="normal" font="default" size="100%">Brozek, J.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">Carreiro-Martins, P.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Cingi, C.</style></author><author><style face="normal" font="default" size="100%">Costa, E. M.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Eklund, P.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Ivancevich, J. C.</style></author><author><style face="normal" font="default" size="100%">Ispayeva, Z.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Kaidashev, I.</style></author><author><style face="normal" font="default" size="100%">Khaitov, M.</style></author><author><style face="normal" font="default" size="100%">Kraxner, H.</style></author><author><style face="normal" font="default" size="100%">Laune, D.</style></author><author><style face="normal" font="default" size="100%">Lipworth, B.</style></author><author><style face="normal" font="default" size="100%">Louis, R.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Monti, R.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Niedoszytko, M.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Patella, V.</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, N.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Rouadi, P. W.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Sova, M.</style></author><author><style face="normal" font="default" size="100%">Todo-Bom, A.</style></author><author><style face="normal" font="default" size="100%">Taborda-Barata, L.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Tsiligianni, I.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Vandenplas, O.</style></author><author><style face="normal" font="default" size="100%">Wallace, D.</style></author><author><style face="normal" font="default" size="100%">Waserman, S.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS - Center for Health Technology and Services Research, University of Porto, Porto, Portugal.&#xD;RISE - Health Research Network, University of Porto, Porto, Portugal.&#xD;Department of Health Research Methods, Evidence, and Impact &amp; Department of Medicine, McMaster University, Hamilton, ON, Canada.&#xD;ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.&#xD;IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, and Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;Rhinology Unit &amp; Smell Clinic, ENT Department, Hospital Clinic, Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;ARIA, Montpellier, France.&#xD;Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino &amp; Mauriziano Hospital, Torino, Italy.&#xD;Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University and Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.&#xD;University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy.&#xD;Transylvania University Brasov, Brasov, Romania.&#xD;Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Quality Use of Respiratory Medicine Group, Woolcock Institute of Medical Research, The University of Sydney, and Sydney Local Health District, Sydney, NSW, Australia.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall d&apos;Hebron &amp; ARADyAL Research Network, Barcelona, Spain.&#xD;Servico de Imunoalergologia, Hospital de Dona Estefania, Centro Hospitalar Universitario de Lisboa Central, Lisbon, Portugal.&#xD;NOVA Medical School/Comprehensive Health Research Centre (CHRC), Lisbon, Portugal.&#xD;Division of Allergy/Immunology, University of South Florida, Tampa, Florida, USA.&#xD;SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Department of Medicine and Health Research Methods, Evidence &amp; Impact, McMaster University, Hamilton, ON, Canada.&#xD;ENT Department, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey.&#xD;UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), Porto, Portugal.&#xD;Fundacao ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Brazil.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, University of Cagliari, Cagliari, Italy.&#xD;VIM Suresnes, UMR_0892, Pole des Maladies des Voies Respiratoires, Hopital Foch, Universite Paris-Saclay, Suresnes, France.&#xD;Department of Computing Science, Umea University, Umea, Sweden.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, Location AMC, Amsterdam, The Netherlands.&#xD;Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;President of Kazakhstan Association of Allergology and Clinical Immunology, Department of Allergology and Clinical Immunology of the Kazakh National Medical University, Almaty, Kazakhstan.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Poltava State Medical University, Poltava, Ukraine.&#xD;National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular Immunology, Moscow, Russia and Pirogov Russian National Research Medical University, Moscow, Russia.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary.&#xD;KYomed INNOV, Montpellier, France.&#xD;Scottish Centre for Respiratory Research, Cardiovascular &amp; Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, Dundee, UK.&#xD;Department of Pulmonary Medicine, CHU Sart-Tilman, and GIGA I3 Research Group, Liege, Belgium.&#xD;Allergy Unit &quot;D Kalogeromitros&quot;, 2nd Department of Dermatology and Venereology, National &amp; Kapodistrian University of Athens, &quot;Attikon&quot; University Hospital, Athens, Greece.&#xD;Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;IMSB, Medical Faculty, University at Cologne, and ClinCompetence Cologne GmbH, Cologne, Germany.&#xD;Department of Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, &quot;Santa Maria della Speranza&quot; Hospital, Battipaglia, Italy.&#xD;Ecole Polytechnique Palaiseau, IRBA (Institut de Recherche bio-Medicale des Armees), Bretigny, France.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitario de Coimbra, Coimbra and Institute of Immunology, Faculty of Medicine, University of Coimbra, and Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, The Netherlands.&#xD;Department of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon.&#xD;ENT Department, Dar Al Shifa Hospital- Salmiya, Salmiya, Kuwait.&#xD;Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland.&#xD;Usher Institute, The University of Edinburgh, Edinburgh, UK.&#xD;Department of Pulmonary Medicine and Tuberculosis, University Hospital Brno, Brno, Czech Republic.&#xD;Imunoalergologia, Centro Hospitalar Universitario de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal.&#xD;UBIAir - Clinical &amp; Experimental Lung Centre, University of Beira Interior, Covilha, Portugal.&#xD;Department of Immunoallergology, Cova da Beira University Hospital Centre, Covilha, Portugal.&#xD;Fundacion Jimenez Diaz, CIBERES, Faculty of Medicine, Autonoma University of Madrid, Madrid, Spain.&#xD;Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Greece and International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland.&#xD;Institute of Clinical Medicine and Institute of Health Sciences, Medical Faculty of Vilnius University, Vilnius, Lithuania.&#xD;Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Universite Catholique de Louvain, Yvoir, Belgium.&#xD;Nova Southeastern University, Fort Lauderdale, Florida, USA.&#xD;Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada.&#xD;Celal Bayar University, Department of Pulmonology, Manisa, Turkey.&#xD;University Clinic of Respiratory and Allergic Diseases, Golnick, Slovenia.&#xD;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.&#xD;University Hospital Montpellier, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of rhinitis treatments using MASK-air(R) data and considering the minimal important difference</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3002-3014</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Fluticasone/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">co-medication</style></keyword><keyword><style face="normal" font="default" size="100%">multivariable mixed-effects model</style></keyword><keyword><style face="normal" font="default" size="100%">real-world data</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35567393</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., &quot;real-world data&quot;). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. METHODS: We assessed the MASK-air(R) app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. RESULTS: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80). CONCLUSION: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines.</style></abstract><notes><style face="normal" font="default" size="100%">Sousa-Pinto, Bernardo&#xD;Schunemann, Holger J&#xD;Sa-Sousa, Ana&#xD;Vieira, Rafael Jose&#xD;Amaral, Rita&#xD;Anto, Josep M&#xD;Klimek, Ludger&#xD;Czarlewski, Wienczyslawa&#xD;Mullol, Joaquim&#xD;Pfaar, Oliver&#xD;Bedbrook, Anna&#xD;Brussino, Luisa&#xD;Kvedariene, Violeta&#xD;Larenas-Linnemann, Desiree&#xD;Okamoto, Yoshitaka&#xD;Ventura, Maria Teresa&#xD;Agache, Ioana&#xD;Ansotegui, Ignacio J&#xD;Bergmann, Karl C&#xD;Bosnic-Anticevich, Sinthia&#xD;Brozek, Jan&#xD;Canonica, G Walter&#xD;Cardona, Victoria&#xD;Carreiro-Martins, Pedro&#xD;Casale, Thomas&#xD;Cecchi, Lorenzo&#xD;Chivato, Tomas&#xD;Chu, Derek K&#xD;Cingi, Cemal&#xD;Costa, Elisio M&#xD;Cruz, Alvaro A&#xD;Del Giacco, Stefano&#xD;Devillier, Philippe&#xD;Eklund, Patrik&#xD;Fokkens, Wytske J&#xD;Gemicioglu, Bilun&#xD;Haahtela, Tari&#xD;Ivancevich, Juan Carlos&#xD;Ispayeva, Zhanat&#xD;Jutel, Marek&#xD;Kuna, Piotr&#xD;Kaidashev, Igor&#xD;Khaitov, Musa&#xD;Kraxner, Helga&#xD;Laune, Daniel&#xD;Lipworth, Brian&#xD;Louis, Renaud&#xD;Makris, Michael&#xD;Monti, Riccardo&#xD;Morais-Almeida, Mario&#xD;Mosges, Ralph&#xD;Niedoszytko, Marek&#xD;Papadopoulos, Nikolaos G&#xD;Patella, Vincenzo&#xD;Pham-Thi, Nhan&#xD;Regateiro, Frederico S&#xD;Reitsma, Sietze&#xD;Rouadi, Philip W&#xD;Samolinski, Boleslaw&#xD;Sheikh, Aziz&#xD;Sova, Milan&#xD;Todo-Bom, Ana&#xD;Taborda-Barata, Luis&#xD;Toppila-Salmi, Sanna&#xD;Sastre, Joaquin&#xD;Tsiligianni, Ioanna&#xD;Valiulis, Arunas&#xD;Vandenplas, Olivier&#xD;Wallace, Dana&#xD;Waserman, Susan&#xD;Yorgancioglu, Arzu&#xD;Zidarn, Mihaela&#xD;Zuberbier, Torsten&#xD;Fonseca, Joao A&#xD;Bousquet, Jean&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3002-3014. doi: 10.1111/all.15371. Epub 2022 Jun 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35567393</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15371</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2641</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2641</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palazzo, S.</style></author><author><style face="normal" font="default" size="100%">Piarulli, C.</style></author><author><style face="normal" font="default" size="100%">Lerario, F.</style></author><author><style face="normal" font="default" size="100%">Cinquantasei, M.</style></author><author><style face="normal" font="default" size="100%">Albanesi, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">&quot;M. Albanesi&quot; Allergy and Immunology Unit, Bari, Italy.&#xD;The Allergist, Bari, Italy.&#xD;Faculty of Technological and Innovation Sciences, Universitas Mercatorum, Rome, Italy.&#xD;Department of Mechanics, Mathematics, and Management, Polytechnic of Bari, Bari, Italy.&#xD;Allergolys, Asnieres-sur-Seine, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of social network engagement performance between artificial intelligence-generated content and human experts: A study in the field of immunology and allergology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">326-328</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/09/22</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39306728</style></accession-num><notes><style face="normal" font="default" size="100%">Palazzo, Stefano&#xD;Piarulli, Cataldo&#xD;Lerario, Francesca&#xD;Cinquantasei, Marco&#xD;Albanesi, Marcello&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):326-328. doi: 10.1111/all.16331. Epub 2024 Sep 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39306728</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16331</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2612</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2612</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Bastl, M.</style></author><author><style face="normal" font="default" size="100%">Berger, M.</style></author><author><style face="normal" font="default" size="100%">Berger, U. E.</style></author><author><style face="normal" font="default" size="100%">Karatzas, K.</style></author><author><style face="normal" font="default" size="100%">Tasioulis, T.</style></author><author><style face="normal" font="default" size="100%">Werchan, B.</style></author><author><style face="normal" font="default" size="100%">Werchan, M.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Eaaci Task Force &quot;Definition of clinical relevant thresholds of allergen exposure for analysis of outcomes in AIT</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Otorhinolaryngology, Wiener Gesundheitsverbund, Hospital Hietzing, Vienna, Austria.&#xD;Department of Botany, University of Innsbruck, Innsbruck, Austria.&#xD;Environmental Informatics Research Group, School of Mechanical Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;German Pollen Information Service Foundation, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Institute of Allergology, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Charite-Universitatsmedizin Berlin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of two different pollen season definitions based on 10 years of birch and grass pollen data from two distant central European cities: An EAACI Task Force report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3161-3165</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/08/17</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39152560</style></accession-num><notes><style face="normal" font="default" size="100%">Pfaar, O&#xD;Bastl, M&#xD;Berger, M&#xD;Berger, U E&#xD;Karatzas, K&#xD;Tasioulis, T&#xD;Werchan, B&#xD;Werchan, M&#xD;Bergmann, K C&#xD;eng&#xD;40904/European Academy of Allergy and Clinical Immunology (EAACI)/&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3161-3165. doi: 10.1111/all.16252. Epub 2024 Aug 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39152560</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16252</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3159</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3159</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van Aarle, M.</style></author><author><style face="normal" font="default" size="100%">Kienhorst, S.</style></author><author><style face="normal" font="default" size="100%">Vitale, R.</style></author><author><style face="normal" font="default" size="100%">Bannier, M.</style></author><author><style face="normal" font="default" size="100%">Jobsis, Q.</style></author><author><style face="normal" font="default" size="100%">Vercammen, J.</style></author><author><style face="normal" font="default" size="100%">van Schayck, O.</style></author><author><style face="normal" font="default" size="100%">van Schooten, F. J.</style></author><author><style face="normal" font="default" size="100%">Smolinska, A.</style></author><author><style face="normal" font="default" size="100%">Dompeling, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Maastricht University Medical Centre+, MosaKids Children&apos;s Hospital, Maastricht, the Netherlands.&#xD;Universite de Lille, LASIRE CNRS (UMR 8516), Lille, France.&#xD;Interscience Expert Centre, IS-X, Louvain-la-Neuve, Belgium.&#xD;Industrial Catalysis and Adsorption Technology (INCAT), Department of Materials Textiles and Chemical Engineering (MaTCh), Ghent University, Ghent, Belgium.&#xD;Department of Family Medicine, School for Public Health and Primary Care, Maastricht University, Maastricht, the Netherlands.&#xD;Pharmacology and Toxicology, Maastricht University, Maastricht, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of Two Methods to Analyse Exhaled Breath for Accurate Asthma Detection in School-Aged Children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">281-283</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/11/14</style></edition><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41236030</style></accession-num><notes><style face="normal" font="default" size="100%">van Aarle, Moniek&#xD;Kienhorst, Sophie&#xD;Vitale, Raffaele&#xD;Bannier, Michiel&#xD;Jobsis, Quirijn&#xD;Vercammen, Joeri&#xD;van Schayck, Onno&#xD;van Schooten, Frederik-Jan&#xD;Smolinska, Agnieszka&#xD;Dompeling, Edward&#xD;eng&#xD;Health~Holland/&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):281-283. doi: 10.1111/all.70084. Epub 2025 Nov 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41236030</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773676</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70084</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2509</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2509</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ranjbar, M.</style></author><author><style face="normal" font="default" size="100%">Whetstone, C. E.</style></author><author><style face="normal" font="default" size="100%">Cusack, R. P.</style></author><author><style face="normal" font="default" size="100%">Al-Sajee, D.</style></author><author><style face="normal" font="default" size="100%">Omer, H.</style></author><author><style face="normal" font="default" size="100%">Alsaji, N.</style></author><author><style face="normal" font="default" size="100%">Ho, T.</style></author><author><style face="normal" font="default" size="100%">Duong, M.</style></author><author><style face="normal" font="default" size="100%">Mitchell, P.</style></author><author><style face="normal" font="default" size="100%">Satia, I.</style></author><author><style face="normal" font="default" size="100%">Keith, P. K.</style></author><author><style face="normal" font="default" size="100%">Xie, Y.</style></author><author><style face="normal" font="default" size="100%">MacLean, J.</style></author><author><style face="normal" font="default" size="100%">Sommer, D. D.</style></author><author><style face="normal" font="default" size="100%">O&apos;Byrne, P. M.</style></author><author><style face="normal" font="default" size="100%">Sehmi, R.</style></author><author><style face="normal" font="default" size="100%">Gauvreau, G. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.&#xD;Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, Canada.&#xD;Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Surgery, Otolaryngology, Head &amp; Neck Surgery Division, McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of upper and lower airway expression of SARS-CoV-2 receptors in allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2856-2858</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/05/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Serine Endopeptidases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38726474</style></accession-num><notes><style face="normal" font="default" size="100%">Ranjbar, Maral&#xD;Whetstone, Christiane E&#xD;Cusack, Ruth P&#xD;Al-Sajee, Dhuha&#xD;Omer, Hafsa&#xD;Alsaji, Nadia&#xD;Ho, Terence&#xD;Duong, MyLinh&#xD;Mitchell, Patrick&#xD;Satia, Imran&#xD;Keith, Paul K&#xD;Xie, Yanqing&#xD;MacLean, Jonathan&#xD;Sommer, Doron D&#xD;O&apos;Byrne, Paul M&#xD;Sehmi, Roma&#xD;Gauvreau, Gail M&#xD;eng&#xD;AstraZeneca Canada/&#xD;Comparative Study&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2856-2858. doi: 10.1111/all.16157. Epub 2024 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38726474</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16157</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>31</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">31</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author><author><style face="normal" font="default" size="100%">Murdaca, G.</style></author><author><style face="normal" font="default" size="100%">Guemari, A.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Azkur, A. K.</style></author><author><style face="normal" font="default" size="100%">Aksoy, E.</style></author><author><style face="normal" font="default" size="100%">Vitte, J.</style></author><author><style face="normal" font="default" size="100%">de Las Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Castagnoli, R.</style></author><author><style face="normal" font="default" size="100%">Orsi, A.</style></author><author><style face="normal" font="default" size="100%">Amato, R.</style></author><author><style face="normal" font="default" size="100%">Giberti, I.</style></author><author><style face="normal" font="default" size="100%">Catala, A.</style></author><author><style face="normal" font="default" size="100%">Ambrozej, D.</style></author><author><style face="normal" font="default" size="100%">Schaub, B.</style></author><author><style face="normal" font="default" size="100%">Tramper-Stranders, G. A.</style></author><author><style face="normal" font="default" size="100%">Novak, N.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Departments of Internal Medicine, University of Genova, Genova, Italy.&#xD;Aix-Marseille Univ, IRD, MEPHI, IHU Mediterranee Infection, Marseille, France.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-ARADyAL, Malaga, Spain.&#xD;Department of Virology, Faculty of Veterinary Medicine, Kirikkale University, Kirikkale, Turkey.&#xD;Montpellier University, IDESP INSERM UMR UA 11, Montpellier, France.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.&#xD;Allergy Unit, Department of Pediatrics, Meyer Children&apos;s Hospital, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.&#xD;Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.&#xD;Department of Health Sciences, University of Genova, Genova, Italy.&#xD;Dermatology Department, Sexually Transmitted Diseases Clinic, Hospital Clinic, Barcelona, Spain.&#xD;Department of Pediatric Pneumonology and Allergy, Medical University of Warsaw, Warsaw, Poland.&#xD;Doctoral School, Medical University of Warsaw, Warsaw, Poland.&#xD;Pediatric Allergology, Department of Pediatrics, Dr. von Hauner Children&apos;s Hospital, University Hospital, LMU, Munich, Germany.&#xD;Member of German Center for Lung Research - DZL, LMU, Munich, Germany.&#xD;Franciscus Gasthuis &amp; Vlietland, Rotterdam, The Netherlands.&#xD;Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.&#xD;Transylvania University, Brasov, Romania.&#xD;Theramed Medical Center, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A compilation answering 50 questions on monkeypox virus and the current monkeypox outbreak</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">639-662</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/01/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Outbreaks</style></keyword><keyword><style face="normal" font="default" size="100%">*Mpox, Monkeypox/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Monkeypox virus</style></keyword><keyword><style face="normal" font="default" size="100%">monkeypox</style></keyword><keyword><style face="normal" font="default" size="100%">orthopoxvirus</style></keyword><keyword><style face="normal" font="default" size="100%">outbreak</style></keyword><keyword><style face="normal" font="default" size="100%">viral infection</style></keyword><keyword><style face="normal" font="default" size="100%">zoonosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36587287</style></accession-num><abstract><style face="normal" font="default" size="100%">The current monkeypox disease (MPX) outbreak constitutes a new threat and challenge for our society. With more than 55,000 confirmed cases in 103 countries, World Health Organization declared the ongoing MPX outbreak a Public Health Emergency of International Concern (PHEIC) on July 23, 2022. The current MPX outbreak is the largest, most widespread, and most serious since the diagnosis of the first case of MPX in 1970 in the Democratic Republic of the Congo (DRC), a country where MPX is an endemic disease. Throughout history, there have only been sporadic and self-limiting outbreaks of MPX outside Africa, with a total of 58 cases described from 2003 to 2021. This figure contrasts with the current outbreak of 2022, in which more than 55,000 cases have been confirmed in just 4 months. MPX is, in most cases, self-limiting; however, severe clinical manifestations and complications have been reported. Complications are usually related to the extent of virus exposure and patient health status, generally affecting children, pregnant women, and immunocompromised patients. The expansive nature of the current outbreak leaves many questions that the scientific community should investigate and answer in order to understand this phenomenon better and prevent new threats in the future. In this review, 50 questions regarding monkeypox virus (MPXV) and the current MPX outbreak were answered in order to provide the most updated scientific information and to explore the potential causes and consequences of this new health threat.</style></abstract><notes><style face="normal" font="default" size="100%">Cabanillas, Beatriz&#xD;Murdaca, Giuseppe&#xD;Guemari, Amir&#xD;Torres, Maria Jose&#xD;Azkur, Ahmet Kursat&#xD;Aksoy, Emel&#xD;Vitte, Joana&#xD;de Las Vecillas, Leticia&#xD;Giovannini, Mattia&#xD;Fernandez-Santamaria, Ruben&#xD;Castagnoli, Riccardo&#xD;Orsi, Andrea&#xD;Amato, Rosa&#xD;Giberti, Irene&#xD;Catala, Alba&#xD;Ambrozej, Dominika&#xD;Schaub, Bianca&#xD;Tramper-Stranders, Gerdien A&#xD;Novak, Natalija&#xD;Nadeau, Kari C&#xD;Agache, Ioana&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):639-662. doi: 10.1111/all.15633. Epub 2023 Jan 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36587287</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15633</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2185</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2185</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adam, T.</style></author><author><style face="normal" font="default" size="100%">Divaret-Chauveau, A.</style></author><author><style face="normal" font="default" size="100%">Roduit, C.</style></author><author><style face="normal" font="default" size="100%">Adel-Patient, K.</style></author><author><style face="normal" font="default" size="100%">Deschildre, A.</style></author><author><style face="normal" font="default" size="100%">Raherison, C.</style></author><author><style face="normal" font="default" size="100%">Charles, M. A.</style></author><author><style face="normal" font="default" size="100%">Nicklaus, S.</style></author><author><style face="normal" font="default" size="100%">de Lauzon-Guillain, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergology, University Hospital of Nancy, Vandoeuvre-Les-Nancy, France.&#xD;Department of Pediatric Allergology, University Hospital of Nancy, Vandoeuvre-Les-Nancy, France.&#xD;EA3450 Developpement Adaptation et Handicap (DevAH), University of Lorraine, Nancy, France.&#xD;Division of Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, University of Bern, Bern, Switzerland.&#xD;Children&apos;s Hospital of Eastern Switzerland, St. Gallen, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Universite Paris-Saclay, CEA, INRAE, Departement Medicaments et Technologies pour la Sante (DMTS), Laboratoire d&apos;Immuno-Allergie Alimentaire, Gif-sur-Yvette, France.&#xD;University of Lille, CHU Lille, Pediatric Pulmonology and Allergy Department, Hopital Jeanne de Flandre, Lille, France.&#xD;Department of Pulmonology, CHU of Guadeloupe, French West Indies University, INSERM UMR 1219 EpiCene Team, Bordeaux, France.&#xD;Universite Paris Cite and Universite Sorbonne Paris Nord, Inserm, INRAE, CRESS, Paris, France.&#xD;Unite Mixte Inserm-Ined-EFS Elfe, Ined, Aubervilliers, France.&#xD;Centre des Sciences du Gout et de l&apos;Alimentation, CNRS, INRAE, Institut Agro, Universite Bourgogne Franche-Comte, Dijon, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Complementary feeding practices are related to the risk of food allergy in the ELFE cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2456-2466</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/07/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/complications/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Eggs</style></keyword><keyword><style face="normal" font="default" size="100%">*Feeding Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/etiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Infant Nutritional Physiological Phenomena/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">childhood</style></keyword><keyword><style face="normal" font="default" size="100%">complementary feeding</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37496192</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Conflicting results have been obtained when analyzing the relationship between complementary feeding (CF) practices and allergic diseases in childhood. This study aims to further explore the association between allergic diseases in early childhood (10.1016/j.jaci.2012.02.036) and the age at CF introduction (10.1016/S0140-6736(15)00149-X), food diversity in the first year of life (10.1016/j.ijporl.2019.109759) and the delayed introduction of major allergenic foods. METHODS: This analysis focused on 6662 children from the French nationwide ELFE cohort. Data on feeding practices were collected monthly from 3 to 10 months old. Their age at CF introduction was calculated alongside a diversity score, and the number of major allergenic foods (out of eggs, fish, wheat, and dairy products) not introduced at 8 and 10 months. Their associations with parent-reported allergy-related health events between 1 and 5.5 years were assessed using logistic regressions adjusted for confounding factors. A sensitivity analysis excluding early allergic cases (occurring between 2 months and 1 or 2 years) was conducted. RESULTS: Late CF (&gt;6 months) was related to a higher risk of food allergy (OR [95% CI] = 1.35 [1.02; 1.78]), a low diversity score at 8 months to a higher risk of asthma (OR [95% CI] = 1.22 [1.01; 1.48]), and two allergenic foods or more not being introduced at 10 months to a higher risk of rhinoconjunctivitis (OR [95% CI] = 1.20 [1.00; 1.44]) and food allergy (OR [95% CI] = 2.46 [1.77; 3.42]). Only this last association remained significant after the exclusion of early cases. CONCLUSION: The delayed introduction of major allergenic foods is related to a higher risk of food allergy, which supports the updated guidelines for allergy prevention.</style></abstract><notes><style face="normal" font="default" size="100%">Adam, T&#xD;Divaret-Chauveau, A&#xD;Roduit, C&#xD;Adel-Patient, K&#xD;Deschildre, A&#xD;Raherison, C&#xD;Charles, M-A&#xD;Nicklaus, S&#xD;de Lauzon-Guillain, B&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2456-2466. doi: 10.1111/all.15828. Epub 2023 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37496192</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15828</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3032</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3032</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shahbazi Khamas, S.</style></author><author><style face="normal" font="default" size="100%">Brinkman, P.</style></author><author><style face="normal" font="default" size="100%">Neerincx, A. H.</style></author><author><style face="normal" font="default" size="100%">Vijverberg, S. J. H.</style></author><author><style face="normal" font="default" size="100%">Hashimoto, S.</style></author><author><style face="normal" font="default" size="100%">Blankestijn, J. M.</style></author><author><style face="normal" font="default" size="100%">Duitman, J. W.</style></author><author><style face="normal" font="default" size="100%">Dekker, T.</style></author><author><style face="normal" font="default" size="100%">Smids, B. S.</style></author><author><style face="normal" font="default" size="100%">Terheggen-Lagro, S. W. J.</style></author><author><style face="normal" font="default" size="100%">Lutter, R.</style></author><author><style face="normal" font="default" size="100%">Metwally, N. K. A.</style></author><author><style face="normal" font="default" size="100%">Sondaal, F.</style></author><author><style face="normal" font="default" size="100%">Haarman, E. G.</style></author><author><style face="normal" font="default" size="100%">Sterk, P. J.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Auffray, C.</style></author><author><style face="normal" font="default" size="100%">Bang, C.</style></author><author><style face="normal" font="default" size="100%">Bansal, A. T.</style></author><author><style face="normal" font="default" size="100%">Buntrock-Dopke, H.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Bush, A.</style></author><author><style face="normal" font="default" size="100%">Chawes, B. L.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Corcuera-Elosegui, P.</style></author><author><style face="normal" font="default" size="100%">Dahlen, S. E.</style></author><author><style face="normal" font="default" size="100%">Djukanovic, R.</style></author><author><style face="normal" font="default" size="100%">Fleming, L. J.</style></author><author><style face="normal" font="default" size="100%">Fowler, S. J.</style></author><author><style face="normal" font="default" size="100%">Franke, A.</style></author><author><style face="normal" font="default" size="100%">Frey, U.</style></author><author><style face="normal" font="default" size="100%">Gorenjak, M.</style></author><author><style face="normal" font="default" size="100%">Brandstetter, S.</style></author><author><style face="normal" font="default" size="100%">Harner, S.</style></author><author><style face="normal" font="default" size="100%">Hedlin, G.</style></author><author><style face="normal" font="default" size="100%">Kabesch, M.</style></author><author><style face="normal" font="default" size="100%">Zounemat-Kermani, N.</style></author><author><style face="normal" font="default" size="100%">Kheirolldein, P.</style></author><author><style face="normal" font="default" size="100%">Kiefer, A.</style></author><author><style face="normal" font="default" size="100%">Konradsen, J. R.</style></author><author><style face="normal" font="default" size="100%">Kraneveld, A. D.</style></author><author><style face="normal" font="default" size="100%">Lopez-Fernandez, L.</style></author><author><style face="normal" font="default" size="100%">Murray, C. S.</style></author><author><style face="normal" font="default" size="100%">Nordlund, B.</style></author><author><style face="normal" font="default" size="100%">Pino-Yanes, M.</style></author><author><style face="normal" font="default" size="100%">Potocnik, U.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Sorensen, S. J.</style></author><author><style face="normal" font="default" size="100%">Sardon-Prado, O.</style></author><author><style face="normal" font="default" size="100%">Shaw, D. E.</style></author><author><style face="normal" font="default" size="100%">Singer, F.</style></author><author><style face="normal" font="default" size="100%">Sousa, A. R.</style></author><author><style face="normal" font="default" size="100%">Thorsen, J.</style></author><author><style face="normal" font="default" size="100%">Toncheva, A. A.</style></author><author><style face="normal" font="default" size="100%">Vissing, N. H.</style></author><author><style face="normal" font="default" size="100%">Wolff, C.</style></author><author><style face="normal" font="default" size="100%">Abdel-Aziz, M. I.</style></author><author><style face="normal" font="default" size="100%">Maitland-van der Zee, A. H.</style></author><author><style face="normal" font="default" size="100%">SysPharmPediA,</style></author><author><style face="normal" font="default" size="100%">U. Biopred Consortia</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Amsterdam UMC Location University of Amsterdam, Department of Pulmonary Medicine, Amsterdam, the Netherlands.&#xD;Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.&#xD;Amsterdam Public Health, Amsterdam, the Netherlands.&#xD;Department of Paediatric Pulmonary Medicine, Emma Children&apos;s Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.&#xD;Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Royal Brompton &amp; Harefield Hospital, London, UK.&#xD;European Institute for Systems Biology and Medicine, CIRI UMR5308, CNRS-ENS-UCBL-INSERM, Lyon, France.&#xD;Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.&#xD;Acclarogen Ltd., St. John&apos;s Innovation Centre, Cambridge, UK.&#xD;Science and Development Campus Regensburg (WECARE), university Children&apos;s Hospital Regensburg (KUNO) at the Hospital St. Hedwig of the Order of St. John, University of Regensburg, Regensburg, Germany.&#xD;COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.&#xD;Division of Pediatric Respiratory Medicine, Hospital Universitario Donostia, San Sebastian, Spain.&#xD;Clinical Lung and Allergy Research Unit, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.&#xD;Integrative Metabolomics Unit, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Respiratory Medicine and Allergology, Karolinska University Hospital, Stockholm, Sweden.&#xD;Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and Clinical and Experimental Sciences and Human Development and Health, University of Southampton, Southampton, UK.&#xD;Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.&#xD;Manchester Academic Health Science Centre and National Institute for Health and Care Research Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.&#xD;University Children&apos;s Hospital Basel UKBB, University of Basel, Basel, Switzerland.&#xD;Center for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia.&#xD;Department of Pediatric Pneumology and Allergy, University Children&apos;s Hospital Regensburg (KUNO) at the Hospital St.Hedwig of the Order of St. John, University of Regensburg, Regensburg, Germany.&#xD;Astrid Lindgren Children&apos;s Hospital, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Women&apos;s and Children&apos;s Health, Karolinska Institute, Stockholm, Sweden.&#xD;Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.&#xD;Genomics and Health Group, Department of Biochemistry, Microbiology, Cell Biology and Genetics, Universidad de La Laguna, La Laguna, Santa Cruz de Tenerife, Spain.&#xD;CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.&#xD;Instituto de Tecnologias Biomedicas (ITB), Universidad de La Laguna (ULL), La Laguna, Spain.&#xD;Laboratory for Biochemistry, Molecular Biology and Genomics, Faculty of Chemistry and Chemical Engineering, University of Maribor, Maribor, Slovenia.&#xD;Department for Science and Research, University Medical Centre Maribor, Maribor, Slovenia.&#xD;Department of Food Science, University of Copenhagen, Frederiksberg, Denmark.&#xD;Section of Microbiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Pediatrics, University of the Basque Country (UPV/EHU), San Sebastian, Spain.&#xD;Leicester NIHR Biomedical Research Centre and Department of Respiratory Sciences, University of Leicester, Leicester, UK.&#xD;Division of Paediatric Pulmonology and Allergology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.&#xD;Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Respiratory Therapeutic Unit, GlaxoSmithKline, London, UK.&#xD;Dept of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Complementary Predictors for Asthma Attack Prediction in Children: Salivary Microbiome, Serum Inflammatory Mediators, and Past Attack History</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/08/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">16S rRNA</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbations</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword><keyword><style face="normal" font="default" size="100%">saliva</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40823900</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Early identification of children at risk of asthma attacks is important for optimizing treatment strategies. We aimed to integrate salivary microbiome and serum inflammatory mediator profiles with asthma attacks history to develop a comprehensive predictive model for future attacks. METHODS: This study contained a discovery (SysPharmPediA) and a replication phase (U-BIOPRED). School-aged children with asthma were classified into at risk and no-risk groups, based on the presence or absence of one or more severe attacks during one-year follow-up. Prediction models were developed using random forest on the training set (70%) with data on past asthma attacks, microbiome composition, serum inflammatory mediator levels, and their combinations and then tested on the rest of the population (30%). Outcomes were replicated in a subset of children with severe asthma from U-BIOPRED. RESULTS: Complete data were available for 154 children (SysPharmPediA = 121, U-BIOPRED = 33). In discovery, the model based on past attacks resulted in an area under the receiving characteristic curve (AUROCC) ~ 0.7. Models including six salivary bacteria or six inflammatory mediators achieved similar results. The combined model incorporating seven features, past asthma attacks, Capnocytophaga, Corynebacterium, and Cardiobacterium, TIMP-4, VEGF, and MIP-3beta achieved the highest accuracy with AUROCC ~0.87. The combined model in the U-BIOPRED limited to available inflammatory mediators (VEGF), and incorporating past asthma attacks, Capnocytophaga, Corynebacterium, and Cardiobacterium, resulted in an AUROCC of 0.84. CONCLUSION: Serum inflammatory mediators and salivary microbiome complement asthma attacks history for predicting future attacks. These results highlight the imperative for continued investigation into oral microbiota and its interaction with the immune system.</style></abstract><notes><style face="normal" font="default" size="100%">Shahbazi Khamas, Shahriyar&#xD;Brinkman, Paul&#xD;Neerincx, Anne H&#xD;Vijverberg, Susanne J H&#xD;Hashimoto, Simone&#xD;Blankestijn, Jelle M&#xD;Duitman, Jan Willem&#xD;Dekker, Tamara&#xD;Smids, Barbara S&#xD;Terheggen-Lagro, Suzanne W J&#xD;Lutter, Rene&#xD;Metwally, Nariman K A&#xD;Sondaal, Fleur&#xD;Haarman, Eric G&#xD;Sterk, Peter J&#xD;Adcock, Ian M&#xD;Auffray, Charles&#xD;Bang, Corinna&#xD;Bansal, Aruna T&#xD;Buntrock-Dopke, Heike&#xD;Bonnelykke, Klaus&#xD;Bush, Andrew&#xD;Chawes, Bo Lund&#xD;Chung, Kian Fan&#xD;Corcuera-Elosegui, Paula&#xD;Dahlen, Sven-Erik&#xD;Djukanovic, Ratko&#xD;Fleming, Louise J&#xD;Fowler, Stephen J&#xD;Franke, Andre&#xD;Frey, Urs&#xD;Gorenjak, Mario&#xD;Brandstetter, Susanne&#xD;Harner, Susanne&#xD;Hedlin, Gunilla&#xD;Kabesch, Michael&#xD;Zounemat-Kermani, Nazanin&#xD;Kheirolldein, Parastoo&#xD;Kiefer, Alexander&#xD;Konradsen, Jon R&#xD;Kraneveld, Aletta D&#xD;Lopez-Fernandez, Leyre&#xD;Murray, Clare S&#xD;Nordlund, Bjorn&#xD;Pino-Yanes, Maria&#xD;Potocnik, Uros&#xD;Roberts, Graham&#xD;Stokholm, Jakob&#xD;Sorensen, Soren Johannes&#xD;Sardon-Prado, Olaia&#xD;Shaw, Dominick E&#xD;Singer, Florian&#xD;Sousa, Ana R&#xD;Thorsen, Jonathan&#xD;Toncheva, Antoaneta A&#xD;Vissing, Nadja H&#xD;Wolff, Christine&#xD;Abdel-Aziz, Mahmoud I&#xD;Maitland-van der Zee, Anke H&#xD;eng&#xD;Ministrstvo za visoko solstvo, znanost in inovacije (MVZI)/&#xD;ZONMW_/ZonMw/Netherlands&#xD;FP7/&#xD;ERACoSysMed/&#xD;ISCIII/&#xD;Bundesministerium fur Bildung und Forschung (BMBF)/&#xD;Denmark&#xD;Allergy. 2025 Aug 18. doi: 10.1111/all.70004.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40823900</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70004</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2790</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2790</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Szegedi, A.</style></author><author><style face="normal" font="default" size="100%">Komlosi, Z. I.</style></author><author><style face="normal" font="default" size="100%">Kapitany, A.</style></author><author><style face="normal" font="default" size="100%">Bata-Csorgo, Z.</style></author><author><style face="normal" font="default" size="100%">Koncz, G.</style></author><author><style face="normal" font="default" size="100%">Bacsi, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Centre of Excellence, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.&#xD;HUN-REN-DE Allergology Research Group, Debrecen, Hungary.&#xD;Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary.&#xD;HCEMM-USZ Skin Research Group, Szeged, Hungary.&#xD;Department of Dermatology and Allergology, Albert Szent-Gyorgyi Medical School, University of Szeged, Szeged, Hungary.&#xD;HUN-REN-SZTE Dermatological Research Group, Szeged, Hungary.&#xD;Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Complex Nomenclature of Allergic Diseases and Hypersensitivity Reactions: An Addendum to the EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1162-1165</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/01/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">addendum</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">complex nomenclature</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">p-i mechanism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39873245</style></accession-num><notes><style face="normal" font="default" size="100%">Szegedi, Andrea&#xD;Komlosi, Zsolt I&#xD;Kapitany, Aniko&#xD;Bata-Csorgo, Zsuzsanna&#xD;Koncz, Gabor&#xD;Bacsi, Attila&#xD;eng&#xD;K-135637/National Research, Development, and Innovation Office of Hungary (NKFIH) grants/&#xD;K-142348/National Research, Development, and Innovation Office of Hungary (NKFIH) grants/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1162-1165. doi: 10.1111/all.16486. Epub 2025 Jan 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39873245</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969293</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16486</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1359</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1359</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Clinical Unit, Hospital Regional Universitario de Malaga-UMA-ARADyAL, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The complexity of drug hypersensitivity reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">985-987</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/08/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunologic tests</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32780432</style></accession-num><notes><style face="normal" font="default" size="100%">Torres, Maria J&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):985-987. doi: 10.1111/all.14555.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32780432</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14555</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1428</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1428</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Goh, S. J. R.</style></author><author><style face="normal" font="default" size="100%">Tuomisto, J. E. E.</style></author><author><style face="normal" font="default" size="100%">Purcell, A. W.</style></author><author><style face="normal" font="default" size="100%">Mifsud, N. A.</style></author><author><style face="normal" font="default" size="100%">Illing, P. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Vic., Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The complexity of T cell-mediated penicillin hypersensitivity reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">150-167</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/05/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antigen Presentation</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Delayed/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillins/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">T cell</style></keyword><keyword><style face="normal" font="default" size="100%">beta-lactam</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">human leukocyte antigen</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32383256</style></accession-num><abstract><style face="normal" font="default" size="100%">Penicillin refers to a group of beta-lactam antibiotics that are the first-line treatment for a range of infections. However, they also possess the ability to form novel antigens, or neoantigens, through haptenation of proteins and can stimulate a range of immune-mediated adverse reactions-collectively known as drug hypersensitivity reactions (DHRs). IgE-mediated reactions towards these neoantigens are well studied; however, IgE-independent reactions are less well understood. These reactions usually manifest in a delayed manner as different forms of cutaneous eruptions or liver injury consistent with priming of an immune response. Ex vivo studies have confirmed the infiltration of T cells into the site of inflammation, and the subsets of T cells involved appear dependent on the nature of the reaction. Here, we review the evidence that has led to our current understanding of these immune-mediated reactions, discussing the nature of the lesional T cells, the characterization of drug-responsive T cells isolated from patient blood, and the potential mechanisms by which penicillins enter the antigen processing and presentation pathway to stimulate these deleterious responses. Thus, we highlight the need for a more comprehensive understanding of the underlying genetic and molecular basis of penicillin-induced DHRs.</style></abstract><notes><style face="normal" font="default" size="100%">Goh, Shawn J R&#xD;Tuomisto, Johanna E E&#xD;Purcell, Anthony W&#xD;Mifsud, Nicole A&#xD;Illing, Patricia T&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):150-167. doi: 10.1111/all.14355. Epub 2020 Jul 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32383256</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14355</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1358</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1358</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Novotny, E. N.</style></author><author><style face="normal" font="default" size="100%">White, S. J.</style></author><author><style face="normal" font="default" size="100%">Wilson, A. D.</style></author><author><style face="normal" font="default" size="100%">Stefansdottir, S. B.</style></author><author><style face="normal" font="default" size="100%">Tijhaar, E.</style></author><author><style face="normal" font="default" size="100%">Jonsdottir, S.</style></author><author><style face="normal" font="default" size="100%">Frey, R.</style></author><author><style face="normal" font="default" size="100%">Reiche, D.</style></author><author><style face="normal" font="default" size="100%">Rose, H.</style></author><author><style face="normal" font="default" size="100%">Rhyner, C.</style></author><author><style face="normal" font="default" size="100%">Schupbach-Regula, G.</style></author><author><style face="normal" font="default" size="100%">Torsteinsdottir, S.</style></author><author><style face="normal" font="default" size="100%">Alcocer, M.</style></author><author><style face="normal" font="default" size="100%">Marti, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Research and VPH, Vetsuisse Faculty, University of Bern, Bern, Switzerland.&#xD;School of Animal, Rural and Environmental Sciences, Nottingham Trent University, Brackenhurst Campus, Southwell, UK.&#xD;School of Biosciences, University of Nottingham, Loughborough, UK.&#xD;Division of Veterinary Pathology, Infection and Immunity, University of Bristol, Langford, UK.&#xD;Institute for Experimental Pathology, Biomedical Center, University of Iceland, Reykjavik, Iceland.&#xD;Cell Biology and Immunology Group, Wageningen University, Wageningen, The Netherlands.&#xD;AniCura Norsholms Djursjukhus, Norsholm, Sweden.&#xD;Boehringer Ingelheim Vetmedica GmbH, Rohrdorf, Germany.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Component-resolved microarray analysis of IgE sensitization profiles to Culicoides recombinant allergens in horses with insect bite hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1147-1157</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/08/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Ceratopogonidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Horse Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Horses</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Insect Bites and Stings/veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Microarray Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">culicoides allergens</style></keyword><keyword><style face="normal" font="default" size="100%">equine insect bite hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">microarray</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32780483</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergy to bites of blood-sucking insects, including biting midges, can affect both human and veterinary patients. Horses are often suffering from an IgE-mediated allergic dermatitis caused by bites of midges (Culicoides spp). With the aim to improve allergen immunotherapy (AIT), numerous Culicoides allergens have been produced as recombinant (r-) proteins. This study aimed to test a comprehensive panel of differently expressed Culicoides r-allergens on a cohort of IBH-affected and control horses using an allergen microarray. METHODS: IgE levels to 27 Culicoides r-allergens, including 8 previously unpublished allergens, of which 11 were expressed in more than one expression system, were determined in sera from 347 horses. ROC analyses were carried out, cut-offs selected using a specificity of 95% and seropositivity rates compared between horses affected with insect bite hypersensitivity (IBH) and control horses. The combination of r-allergens giving the best performing test was determined using logistic regression analysis. RESULTS: Seropositivity was significantly higher in IBH horses compared with controls for 25 r-allergens. Nine Culicoides r-allergens were major allergens for IBH with seven of them binding IgE in sera from &gt; 70% of the IBH-affected horses. Combination of these top seven r-allergens could diagnose &gt; 90% of IBH-affected horses with a specificity of &gt; 95%. Correlation between differently expressed r-allergens was usually high (mean = 0.69, range: 0.28-0.91). CONCLUSION: This microarray will be a powerful tool for the development of component-resolved, patient-tailored AIT for IBH and could be useful for the study of allergy to biting midges in humans and other species.</style></abstract><notes><style face="normal" font="default" size="100%">Novotny, Ella N&#xD;White, Samuel J&#xD;Wilson, A Douglas&#xD;Stefansdottir, Sara B&#xD;Tijhaar, Edwin&#xD;Jonsdottir, Sigridur&#xD;Frey, Rebekka&#xD;Reiche, Dania&#xD;Rose, Horst&#xD;Rhyner, Claudio&#xD;Schupbach-Regula, Gertraud&#xD;Torsteinsdottir, Sigurbjorg&#xD;Alcocer, Marcos&#xD;Marti, Eliane&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1147-1157. doi: 10.1111/all.14556. Epub 2020 Sep 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32780483</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246938</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14556</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>503</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">503</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wai, C. Y. Y.</style></author><author><style face="normal" font="default" size="100%">Leung, N. Y. H.</style></author><author><style face="normal" font="default" size="100%">Leung, A. S. Y.</style></author><author><style face="normal" font="default" size="100%">Ngai, S. M.</style></author><author><style face="normal" font="default" size="100%">Pacharn, P.</style></author><author><style face="normal" font="default" size="100%">Yau, Y. S.</style></author><author><style face="normal" font="default" size="100%">Rosa Duque, J. S. D.</style></author><author><style face="normal" font="default" size="100%">Kwan, M. Y. W.</style></author><author><style face="normal" font="default" size="100%">Jirapongsananuruk, O.</style></author><author><style face="normal" font="default" size="100%">Chan, W. H.</style></author><author><style face="normal" font="default" size="100%">Chua, G. T.</style></author><author><style face="normal" font="default" size="100%">Lee, Q. U.</style></author><author><style face="normal" font="default" size="100%">Piboonpocanun, S.</style></author><author><style face="normal" font="default" size="100%">Ho, P. K.</style></author><author><style face="normal" font="default" size="100%">Wong, J. S. C.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Xu, K. J. Y.</style></author><author><style face="normal" font="default" size="100%">Wong, G. W. K.</style></author><author><style face="normal" font="default" size="100%">Chu, K. H.</style></author><author><style face="normal" font="default" size="100%">Leung, P. S. C.</style></author><author><style face="normal" font="default" size="100%">Vichyanond, P.</style></author><author><style face="normal" font="default" size="100%">Leung, T. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.&#xD;State Key Laboratory of Agrobiotechnology, The Chinese University of Hong Kong, Hong Kong, China.&#xD;School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Paediatrics, Queen Elizabeth Hospital, Hong Kong, China.&#xD;Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.&#xD;Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital and Yan Chai Hospital, Hong Kong, China.&#xD;Institute of Molecular Biosciences, Mahidol University, Nakhonpathom, Thailand.&#xD;Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, California, USA.&#xD;Samitivej Allergy Institute, Samitivej Thonburi Hospital, Bangkok, Thailand.&#xD;Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comprehending the allergen repertoire of shrimp for precision molecular diagnosis of shrimp allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3041-3051</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acid-Binding Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Tropomyosin</style></keyword><keyword><style face="normal" font="default" size="100%">Troponin C</style></keyword><keyword><style face="normal" font="default" size="100%">Dbpcfc</style></keyword><keyword><style face="normal" font="default" size="100%">allergen profiling</style></keyword><keyword><style face="normal" font="default" size="100%">component-resolved diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">shellfish allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35567339</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Clinical management of shrimp allergy is hampered by the lack of accurate tests. Molecular diagnosis has been shown to more accurately reflect the clinical reactivity but the full spectrum of shrimp allergens and their clinical relevance are yet to be established. We therefore sought to comprehend the allergen repertoire of shrimp, investigate and compare the sensitization pattern and diagnostic value of the allergens in allergic subjects of two distinct populations. METHODS: Sera were collected from 85 subjects with challenge-proven or doctor-diagnosed shrimp allergy in Hong Kong and Thailand. The IgE-binding proteins of Penaeus monodon were probed by Western blotting and identified by mass spectrometry. Recombinant shrimp allergens were synthesized and analyzed for IgE sensitization by ELISA. RESULTS: Ten IgE-binding proteins were identified, and a comprehensive panel of 11 recombinant shrimp allergens was generated. The major shrimp allergens among Hong Kong subjects were troponin C (Pen m 6) and glycogen phosphorylase (Pen m 14, 47.1%), tropomyosin (Pen m 1, 41.2%) and sarcoplasmic-calcium binding protein (Pen m 4, 35.3%), while those among Thai subjects were Pen m 1 (68.8%), Pen m 6 (50.0%) and fatty acid-binding protein (Pen m 13, 37.5%). Component-based tests yielded significantly higher area under curve values (0.77-0.96) than shrimp extract-IgE test (0.70-0.75). Yet the best component test differed between populations; Pen m 1-IgE test added diagnostic value only in the Thai cohort, whereas sensitizations to other components were better predictors of shrimp allergy in Hong Kong patients. CONCLUSION: Pen m 14 was identified as a novel shrimp allergen predictive of challenge outcome. Molecular diagnosis better predicts shrimp allergy than conventional tests, but the relevant component is population dependent.</style></abstract><notes><style face="normal" font="default" size="100%">Wai, Christine Y Y&#xD;Leung, Nicki Y H&#xD;Leung, Agnes S Y&#xD;Ngai, Sai Ming&#xD;Pacharn, Punchama&#xD;Yau, Yat Sun&#xD;Rosa Duque, Jaime Sou Da&#xD;Kwan, Mike Y W&#xD;Jirapongsananuruk, Orathai&#xD;Chan, Wai Hung&#xD;Chua, Gilbert T&#xD;Lee, Qun Ui&#xD;Piboonpocanun, Surapon&#xD;Ho, Po Ki&#xD;Wong, Joshua S C&#xD;Li, Shanshan&#xD;Xu, Kary J Y&#xD;Wong, Gary W K&#xD;Chu, Ka Hou&#xD;Leung, Patrick S C&#xD;Vichyanond, Pakit&#xD;Leung, Ting Fan&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3041-3051. doi: 10.1111/all.15370. Epub 2022 May 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35567339</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9795902</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15370</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2928</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2928</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bozkurt, C.</style></author><author><style face="normal" font="default" size="100%">Cildir, G.</style></author><author><style face="normal" font="default" size="100%">Aba, U.</style></author><author><style face="normal" font="default" size="100%">Erdogan, R. K.</style></author><author><style face="normal" font="default" size="100%">Warnock, N. I. st</style></author><author><style face="normal" font="default" size="100%">Kok, C. H.</style></author><author><style face="normal" font="default" size="100%">Sefer, A. P.</style></author><author><style face="normal" font="default" size="100%">Haskologlu, S.</style></author><author><style face="normal" font="default" size="100%">Tekeoglu, S. D.</style></author><author><style face="normal" font="default" size="100%">Kilinc, G. M.</style></author><author><style face="normal" font="default" size="100%">Ipsir, C.</style></author><author><style face="normal" font="default" size="100%">Arikoglu, T.</style></author><author><style face="normal" font="default" size="100%">Ozhan, A. K.</style></author><author><style face="normal" font="default" size="100%">Esenboga, S.</style></author><author><style face="normal" font="default" size="100%">Ozen, A.</style></author><author><style face="normal" font="default" size="100%">Karakoc-Aydiner, E.</style></author><author><style face="normal" font="default" size="100%">Eltan, S. B.</style></author><author><style face="normal" font="default" size="100%">Aydogmus, C.</style></author><author><style face="normal" font="default" size="100%">Islamoglu, C.</style></author><author><style face="normal" font="default" size="100%">Baskin, K.</style></author><author><style face="normal" font="default" size="100%">Karaatmaca, B.</style></author><author><style face="normal" font="default" size="100%">Metin, A.</style></author><author><style face="normal" font="default" size="100%">Cagdas, D.</style></author><author><style face="normal" font="default" size="100%">Dogu, F.</style></author><author><style face="normal" font="default" size="100%">Ikinciogullari, A.</style></author><author><style face="normal" font="default" size="100%">Baris, S.</style></author><author><style face="normal" font="default" size="100%">Erman, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Can Sucak Research Laboratory for Translational Immunology, Hacettepe University, Ankara, Turkiye.&#xD;Department of Pediatric Immunology, Institute of Child Health, Hacettepe University, Ankara, Turkiye.&#xD;Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, South Australia, Australia.&#xD;Data and Bioinformatics Innovation, Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia.&#xD;Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.&#xD;Division of Pediatric Allergy and Immunology, School of Medicine, Recep Tayyip Erdogan University, Rize, Turkiye.&#xD;Department of Pediatric Immunology and Allergy, Ankara University Faculty of Medicine, Ankara, Turkiye.&#xD;Department of Bioinformatics, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkiye.&#xD;Department of Pediatric Allergy and Immunology, Faculty of Medicine, Mersin University, Mersin, Turkiye.&#xD;Ihsan Dogramaci Childrens Hospital, Hacettepe University Faculty of Medicine, Ankara, Turkiye.&#xD;Department of Pediatric Allergy and Immunology, Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, the Isil Berat Barlan Center for Translational Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkiye.&#xD;Department of Pediatric Allergy and Clinical Immunology, University of Health Sciences, Istanbul Basaksehir Cam and Sakura City Hospital, Istanbul, Turkiye.&#xD;Department of Pediatric Immunology and Allergy, Gazi University Faculty of Medicine, Ankara, Turkiye.&#xD;Department of Pediatric Allergy and Immunology, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkiye.&#xD;Department of Pediatric Immunology, Pediatric Basic Sciences, Institute of Child Health, Hacettepe University, Ankara, Turkiye.&#xD;Division of Pediatric Immunology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkiye.&#xD;Institute of Child Health, Hacettepe University, Ankara, Turkiye.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comprehensive alphabeta T-Cell Receptor Repertoire Analysis Reveals a Unique CD8+ TCR Landscape in DOCK8-Deficient Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2519-2530</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/05/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Guanine Nucleotide Exchange Factors/deficiency/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*CD8-Positive T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Antigen, T-Cell, alpha-beta/genetics/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">CD4-Positive T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Immunophenotyping</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">DOCK8 deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">T-cell receptor repertoire</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">immune repertoire sequencing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40346988</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dedicator of cytokinesis protein 8 (DOCK8) is a guanine nucleotide exchange factor highly expressed in, and critical for, the function of various innate and adaptive immune cells. DOCK8 deficiency leads to combined immunodeficiency characterized by susceptibility to infections, autoimmunity, and a severe Th2-type immune response. While dysfunction in various T cell subsets has been implicated in these phenotypes, a comprehensive analysis of the T-cell receptor (TCR) repertoire in these patients has not yet been documented. This study investigates the alphabeta TCR repertoire in DOCK8-deficient patients to identify features related to disease pathogenesis and explore the potential role of TCR repertoire alterations in disease development. METHODS: We compared immune repertoire profiles determined by high-throughput TCR sequencing of circulating CD4+ and CD8+ T cells from patients with DOCK8 deficiency (n = 10) to healthy controls (n = 7) and patients with ataxia-telangiectasia (AT) (n = 5). RESULTS: Different diversity analyses revealed a restricted TRA and TRB repertoire in both CD4+ and CD8+ T cells from DOCK8-deficient patients, with the restriction being more pronounced in CD8+ T cells. Skewed usage of individual variable (V) and joining (J) genes and potentially self-reactive CD8+ T cell clones, as determined by hydrophobicity and cysteine indices, were identified in DOCK8-deficient patients. CONCLUSION: Our study represents the most comprehensive immune repertoire analysis in DOCK8 deficiency. The identification of a significantly restricted alphabeta TCR repertoire, along with the detection of potentially autoreactive clones, highlights the crucial role of immune repertoire profiling in elucidating the pathogenesis of DOCK8 deficiency.</style></abstract><notes><style face="normal" font="default" size="100%">Bozkurt, Ceren&#xD;Cildir, Gokhan&#xD;Aba, Umran&#xD;Erdogan, Rahmi Kutay&#xD;Warnock, Nicholas I 1st&#xD;Kok, Chung Hoow&#xD;Sefer, Asena Pinar&#xD;Haskologlu, Sule&#xD;Tekeoglu, Sidem Didar&#xD;Kilinc, Gulsah Merve&#xD;Ipsir, Canberk&#xD;Arikoglu, Tugba&#xD;Ozhan, Aylin Kont&#xD;Esenboga, Saliha&#xD;Ozen, Ahmet&#xD;Karakoc-Aydiner, Elif&#xD;Eltan, Sevgi Bilgic&#xD;Aydogmus, Cigdem&#xD;Islamoglu, Candan&#xD;Baskin, Kubra&#xD;Karaatmaca, Betul&#xD;Metin, Ayse&#xD;Cagdas, Deniz&#xD;Dogu, Figen&#xD;Ikinciogullari, Aydan&#xD;Baris, Safa&#xD;Erman, Baran&#xD;eng&#xD;The Hospital Research Foundation/&#xD;Turkiye Bilimsel ve Teknolojik Arastirma Kurumu/&#xD;Hacettepe Universitesi/&#xD;121S667/The Scientific and Technological Research Council of Turkiye (TUBITAK)/&#xD;123S777/The Scientific and Technological Research Council of Turkiye (TUBITAK)/&#xD;THD-2022-20180/The Scientific Research Projects Coordination Unit of Hacettepe University/&#xD;TKB-2021-19539/The Scientific Research Projects Coordination Unit of Hacettepe University/&#xD;THD-2024-21191/The Scientific Research Projects Coordination Unit of Hacettepe University/&#xD;ADT-2025-11514/The Marmara University Scientific Research Project Coordination Unit/&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2519-2530. doi: 10.1111/all.16580. Epub 2025 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40346988</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444818</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16580</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3203</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3203</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kobayashi, Y.</style></author><author><style face="normal" font="default" size="100%">Inoue, T.</style></author><author><style face="normal" font="default" size="100%">Kageyama, I.</style></author><author><style face="normal" font="default" size="100%">Iwasaki, Y.</style></author><author><style face="normal" font="default" size="100%">Ito, R.</style></author><author><style face="normal" font="default" size="100%">Kodama, K.</style></author><author><style face="normal" font="default" size="100%">Akiyama, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Tokyo, Japan.&#xD;School of Informatics, University of Tsukuba, Ibaraki, Japan.&#xD;Ritsumeikan University, Osaka, Japan.&#xD;Center for Research and Education on Drug Discovery, The Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.&#xD;National Institute of Health Sciences, Kawasaki, Kanagawa, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comprehensive Analysis of Food Allergy Research Trends via Large Language Model-Assisted Text Mining (1980-2024)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory aspects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 9</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41366720</style></accession-num><notes><style face="normal" font="default" size="100%">Kobayashi, Yoshiyuki&#xD;Inoue, Takahiro&#xD;Kageyama, Itsuki&#xD;Iwasaki, Yusuke&#xD;Ito, Rie&#xD;Kodama, Kota&#xD;Akiyama, Hiroshi&#xD;eng&#xD;23KA1007/Ministry of Health, Labour and Welfare/&#xD;JP25K18320/Japan Society for the Promotion of Science/&#xD;23K07902/Japan Society for the Promotion of Science/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec 9. doi: 10.1111/all.70169.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41366720</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70169</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>110</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">110</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heeb, L. E. M.</style></author><author><style face="normal" font="default" size="100%">Boyman, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comprehensive analysis of human IL-4 receptor subunits shows compartmentalization in steady state and dupilumab treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1073-1087</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/11/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Interleukin-4/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">B-Lymphocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine receptors</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">intracellular</style></keyword><keyword><style face="normal" font="default" size="100%">patients</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36334079</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Insight into the pathomechanism of atopic diseases demonstrated a pivotal role of the cytokines interleukin-4 (IL-4) and IL-13, which has spurred the development of tailored therapeutics targeting their common IL-4 receptor (IL-4R). However, several aspects of the IL-4R system remain ill-defined in humans. METHODS: We used multicolor spectral flow cytometry to characterize IL-4R subunit expression in 28 human immune cell subsets on protein and mRNA levels and assessed their subcellular distribution by applying a specifically adapted protocol that avoided influence of fixation and permeabilization on fluorochrome and antibody performance. In patients, we investigated possible changes in IL-4Ralpha distribution before and during treatment with dupilumab, a monoclonal antibody-targeting IL-4Ralpha. RESULTS: Whereas all immune cell subsets investigated expressed IL-4Ralpha and common gamma chain protein and mRNA, expression of IL-13Ralpha1 was restricted to myeloid and B cells. Interestingly, some cells contained considerably more intracellular IL-4R protein than on their surface. Naive B cells were found to carry the highest levels of IL-4Ralpha distributed evenly between surface and intracellular space, whereas IL-4Ralpha was found predominantly in intracellular pools in neutrophils. In patients with atopic diseases treated with dupilumab, we observed that engagement of IL-4Ralpha by dupilumab resulted in internalization of the antibody and decreased total IL-4Ralpha expression. Notably, even after months of treatment not all intracellular IL-4Ralpha molecules were occupied by dupilumab, indicating the presence of a &quot;dormant&quot; intracellular IL-4Ralpha pool that could be mobilized upon certain extrinsic or intrinsic cues. CONCLUSION: Collectively, our findings suggest that distinct human immune cell subsets contain surface and intracellular IL-4R pools, which are differently affected by targeted biologic treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Heeb, Lukas E M&#xD;Boyman, Onur&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):1073-1087. doi: 10.1111/all.15576. Epub 2022 Nov 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36334079</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15576</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2536</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2536</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Goksel, O.</style></author><author><style face="normal" font="default" size="100%">Sipahi, M. I.</style></author><author><style face="normal" font="default" size="100%">Yanasik, S.</style></author><author><style face="normal" font="default" size="100%">Saglam-Metiner, P.</style></author><author><style face="normal" font="default" size="100%">Benzer, S.</style></author><author><style face="normal" font="default" size="100%">Sabour-Takanlou, L.</style></author><author><style face="normal" font="default" size="100%">Sabour-Takanlou, M.</style></author><author><style face="normal" font="default" size="100%">Biray-Avci, C.</style></author><author><style face="normal" font="default" size="100%">Yesil-Celiktas, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary Medicine, Division of Immunology and Allergy, Laboratory of Occupational &amp; Environmental Respiratory Diseases and Asthma, Faculty of Medicine, Ege University, Izmir, Turkey.&#xD;Translational Pulmonary Research Center (EgeSAM), Ege University, Izmir, Turkey.&#xD;Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.&#xD;Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Turkey.&#xD;Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey.&#xD;METU MEMS Center, Ankara, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comprehensive analysis of resilience of human airway epithelial barrier against short-term PM2.5 inorganic dust exposure using in vitro microfluidic chip and ex vivo human airway models</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2953-2965</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/06/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Particulate Matter/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Epithelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Dust</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Mucosa/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Lab-On-A-Chip Devices</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">Pm2.5</style></keyword><keyword><style face="normal" font="default" size="100%">airway epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">microfluidic systems</style></keyword><keyword><style face="normal" font="default" size="100%">particulate matter</style></keyword><keyword><style face="normal" font="default" size="100%">silica particles</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38868934</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND OBJECTIVE: The updated World Health Organization (WHO) air quality guideline recommends an annual mean concentration of fine particulate matter (PM2.5) not exceeding 5 or 15 mug/m(3) in the short-term (24 h) for no more than 3-4 days annually. However, more than 90% of the global population is currently exposed to daily concentrations surpassing these limits, especially during extreme weather conditions and due to transboundary dust transport influenced by climate change. Herein, the effect of respirable &lt;PM2.5 inorganic silica particle exposures on epithelial barrier integrity was simultaneously evaluated within the biomimetic microfluidic platform-based airway epithelial barrier (AEB)-on-a-chip and human bronchoscopic ex vivo airway tissue models, comparatively. METHODS: Silica particles at an average size of 1 mum, referred to as &lt;PM2.5, dose-dependently tested by MTT and LDH analyses. The elicited dose of 800 mug/mL was applied to human airway epithelial cells (Calu-3) seeded to the membrane at air-liquid interface in the AEB-on-a-chip platform, which is operated under static and dynamic conditions and to ex vivo human bronchoscopy bronchial tissue slices for 72 h. For both models, healthy and exposed groups were comparatively investigated. Computational fluid dynamics simulations were performed to assess shear stress profiles under different flow conditions. Qualitative and quantitative analyses were carried out to evaluate the resilience of the epithelial barrier via cell survivability, morphology, barrier integrity, permeability, and inflammation. RESULTS: In the AEB-on-a-chip platform, short-term exposure to 800 mug/mL PM2.5 disrupted AEB integrity via increasing barrier permeability, decreasing cell adhesion-barrier markers such as ZO-1, Vinculin, ACE2, and CD31, impaired cell viability and increased the expression levels of proinflammatory markers; IFNs, IL-6, IL-1s, TNF-alpha, CD68, CD80, and Inos, mostly under dynamic conditions. Besides, decreased tissue viability, impaired tissue integrity via decreasing of Vinculin, ACE2, beta-catenin, and E-cadherin, and also proinflammatory response with elevated CD68, IL-1alpha, IL-6, IFN-Ɣ, Inos, and CD80 markers, were observed after PM2.5 exposure in ex vivo tissue. CONCLUSION: The duration and concentration of PM2.5 that can be exposed during extreme weather conditions and natural events aligns with our exposure model (0-800 mug/mL 72 h). At this level of exposure, the resilience of the epithelial barrier is demonstrated by both AEB-on-a-chip platform emulating dynamic forces in the body and ex vivo bronchial biopsy slices. Lung-on-a-chip models will serve as reliable exposure models in this context.</style></abstract><notes><style face="normal" font="default" size="100%">Goksel, Ozlem&#xD;Sipahi, Meryem Irem&#xD;Yanasik, Sena&#xD;Saglam-Metiner, Pelin&#xD;Benzer, Sema&#xD;Sabour-Takanlou, Leila&#xD;Sabour-Takanlou, Maryam&#xD;Biray-Avci, Cigir&#xD;Yesil-Celiktas, Ozlem&#xD;eng&#xD;2019K12-149080/Presidency of the Republic of Turkey Strategy and Budget Department/&#xD;1139B412102522/Scientific and Technological Research Council of Turkey (TUBITAK)/&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):2953-2965. doi: 10.1111/all.16179. Epub 2024 Jun 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38868934</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16179</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3063</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3063</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nishimura, M.</style></author><author><style face="normal" font="default" size="100%">Imai, Y.</style></author><author><style face="normal" font="default" size="100%">Matsushima, Y.</style></author><author><style face="normal" font="default" size="100%">Yamanaka, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Mie University Graduate School of Medicine, Tsu, Japan.&#xD;Inflammatory Skin Disease Research Center, Mie University Graduate School of Medicine, Tsu, Japan.&#xD;Imai Adult and Pediatric Dermatology Clinic, Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comprehensive Analysis of Type 2 Innate Lymphoid Cell (ILC2) Heterogeneity and Identification of CD81 as a Marker for Pathogenic IL-13(+) ILC2s in Atopic Dermatitis Skin</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cd81</style></keyword><keyword><style face="normal" font="default" size="100%">Il-18</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">caspase-1</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenic group 2 innate lymphoid cells</style></keyword><keyword><style face="normal" font="default" size="100%">single-cell RNA sequencing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 25</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40995882</style></accession-num><notes><style face="normal" font="default" size="100%">Nishimura, Mai&#xD;Imai, Yasutomo&#xD;Matsushima, Yoshiaki&#xD;Yamanaka, Keiichi&#xD;eng&#xD;24K11464forYI/Japan Society for the Promotion of Science (JSPS)/&#xD;25K11582forKY/Japan Society for the Promotion of Science (JSPS)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep 25. doi: 10.1111/all.70077.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40995882</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70077</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1219</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1219</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leonard, C.</style></author><author><style face="normal" font="default" size="100%">Montamat, G.</style></author><author><style face="normal" font="default" size="100%">Davril, C.</style></author><author><style face="normal" font="default" size="100%">Domingues, O.</style></author><author><style face="normal" font="default" size="100%">Hunewald, O.</style></author><author><style face="normal" font="default" size="100%">Revets, D.</style></author><author><style face="normal" font="default" size="100%">Guerin, C.</style></author><author><style face="normal" font="default" size="100%">Blank, S.</style></author><author><style face="normal" font="default" size="100%">Heckendorn, J.</style></author><author><style face="normal" font="default" size="100%">Jardon, G.</style></author><author><style face="normal" font="default" size="100%">Hentges, F.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Quantitative Biology Unit, National Cytometry Platform, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Member of the German Center of Lung Research (DZL), Munich, Germany.&#xD;National Unit of Immunology-Allergology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.&#xD;Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, Odense University Hospital, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comprehensive mapping of immune tolerance yields a regulatory TNF receptor 2 signature in a murine model of successful Fel d 1-specific immunotherapy using high-dose CpG adjuvant</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2153-2165</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/12/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cats</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Glycoproteins/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Tumor Necrosis Factor, Type II</style></keyword><keyword><style face="normal" font="default" size="100%">CpG-ODN</style></keyword><keyword><style face="normal" font="default" size="100%">Fel d 1</style></keyword><keyword><style face="normal" font="default" size="100%">Tnfr2</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">biTregs</style></keyword><keyword><style face="normal" font="default" size="100%">WO2019/076477Al pending. G. Montamat, C. Davril, O. Domingues, O. Hunewald, D.</style></keyword><keyword><style face="normal" font="default" size="100%">Revets and Dr. C. Guerin: nothing to disclose. Dr. S. Blank reports non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support from ALK-Abello, grants, personal fees and non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard Allergie GmbH, personal fees from Teomed AG, grants from Leti Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from Thermo Fischer Scientific, grants from Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, outside the submitted work. J. Heckendorn, G. Jardon and Dr. F.</style></keyword><keyword><style face="normal" font="default" size="100%">Hentges: nothing to disclose. Dr. M. Ollert reports that he is a cofounder of</style></keyword><keyword><style face="normal" font="default" size="100%">Tolerogenics SARL, Luxembourg, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Hycor Diagnostics, personal fees from Thermo Fischer/Phadia, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">In addition, Dr. Ollert has a patent WO2019/076478Al pending, and</style></keyword><keyword><style face="normal" font="default" size="100%">a patent WO2019/076477Al pending.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33345329</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The prevalence of allergy to cat is expanding worldwide. Allergen-specific immunotherapy (AIT) has advantages over symptomatic pharmacotherapy and promises long-lasting disease control in allergic patients. However, there is still a need to improve cat AIT regarding efficacy, safety, and adherence to the treatment. Here, we aim to boost immune tolerance to the major cat allergen Fel d 1 by increasing the anti-inflammatory activity of AIT with the established immunomodulatory adjuvant CpG, but at a higher dose than previously used in AIT. METHODS: Together with CpG, we used endotoxin-free Fel d 1 as therapeutic allergen throughout the study in a BALB/c model of allergy to Fel d 1, thus mimicking the conditions of human AIT trials. Multidimensional immune phenotyping including mass cytometry (CyTOF) was applied to analyze AIT-specific immune signatures. RESULTS: We show that AIT with high-dose CpG in combination with endotoxin-free Fel d 1 reverts all major hallmarks of allergy. High-dimensional CyTOF analysis of the immune cell signatures initiating and sustaining the AIT effect indicates the simultaneous engagement of both, the pDC-Treg and B-cell axis, with the emergence of a systemic GATA3(+) FoxP3(hi) biTreg population. The regulatory immune signature also suggests the involvement of the anti-inflammatory TNF/TNFR2 signaling cascade in NK and B cells at an early stage and in Tregs later during AIT. CONCLUSION: Our results highlight the potential of CpG adjuvant in a novel formulation to be further exploited for inducing allergen-specific tolerance in patients with cat allergy or other allergic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Leonard, Cathy&#xD;Montamat, Guillem&#xD;Davril, Caroline&#xD;Domingues, Olivia&#xD;Hunewald, Oliver&#xD;Revets, Dominique&#xD;Guerin, Coralie&#xD;Blank, Simon&#xD;Heckendorn, Justine&#xD;Jardon, Gauthier&#xD;Hentges, Francois&#xD;Ollert, Markus&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2153-2165. doi: 10.1111/all.14716. Epub 2021 Jan 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33345329</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8359185</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14716</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2108</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2108</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stackowicz, J.</style></author><author><style face="normal" font="default" size="100%">Gillis, C. M.</style></author><author><style face="normal" font="default" size="100%">Godon, O.</style></author><author><style face="normal" font="default" size="100%">Iannascoli, B.</style></author><author><style face="normal" font="default" size="100%">Conde, E.</style></author><author><style face="normal" font="default" size="100%">Leveque, E.</style></author><author><style face="normal" font="default" size="100%">Worrall, W. P. M.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author><author><style face="normal" font="default" size="100%">Bruhns, P.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author><author><style face="normal" font="default" size="100%">Jonsson, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit of Antibodies in Therapy and Pathology, INSERM UMR1222, Institut Pasteur, Universite de Paris Cite, Paris.&#xD;College Doctoral, Sorbonne Universite, Paris, France.&#xD;Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France.&#xD;Departments of Pathology and of Microbiology and Immunology, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.&#xD;CNRS, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Conditional neutrophil depletion challenges their contribution to mouse models of anaphylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2767-2770</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/04/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgG</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37022292</style></accession-num><notes><style face="normal" font="default" size="100%">Stackowicz, Julien&#xD;Gillis, Caitlin M&#xD;Godon, Ophelie&#xD;Iannascoli, Bruno&#xD;Conde, Eva&#xD;Leveque, Edouard&#xD;Worrall, William P M&#xD;Galli, Stephen J&#xD;Bruhns, Pierre&#xD;Reber, Laurent L&#xD;Jonsson, Friederike&#xD;eng&#xD;R01 AI165373/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2767-2770. doi: 10.1111/all.15738. Epub 2023 Apr 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37022292</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15738</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>842</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">842</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bakker, D. S.</style></author><author><style face="normal" font="default" size="100%">Ter Linde, J. J. M.</style></author><author><style face="normal" font="default" size="100%">Amini, M. M.</style></author><author><style face="normal" font="default" size="100%">Ariens, L. F. M.</style></author><author><style face="normal" font="default" size="100%">van Luijk, C. M.</style></author><author><style face="normal" font="default" size="100%">de Bruin-Weller, M. S.</style></author><author><style face="normal" font="default" size="100%">Thijs, J. L.</style></author><author><style face="normal" font="default" size="100%">Vercoulen, Y.</style></author><author><style face="normal" font="default" size="100%">van Wijk, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.&#xD;Department of Ophthalmology, University Medical Center Utrecht, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3814-3817</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/08/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34449906</style></accession-num><notes><style face="normal" font="default" size="100%">Bakker, Daphne S&#xD;Ter Linde, Jose J M&#xD;Amini, Mojtaba M&#xD;Ariens, Lieneke F M&#xD;van Luijk, Chantal M&#xD;de Bruin-Weller, Marjolein S&#xD;Thijs, Judith L&#xD;Vercoulen, Yvonne&#xD;van Wijk, Femke&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3814-3817. doi: 10.1111/all.15064. Epub 2021 Sep 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34449906</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9292644 Pharma, outside the submitted work. C.M. van Luijk reports personal fees from Sanofi Europe and Santen Europe, outside the submitted work. Dr. de Bruin-Weller reports grants and other from Sanofi-Genzyme, grants and other from Regeneron, grants and other from AbbVie, other from Arena, other from Almirall, grants and other from Eli-Lilly, other from Galderma, other from Janssen, grants and other from Leo Pharma, other from Pfizer, outside the submitted work. Dr. Thijs reports personal fees from Sanofi/Regeneron and Leo Pharma, outside the submitted work. Dr. Vercoulen reports grants from NWO Gravitation 024.001.028 cancergenomicscenter.nl, during the conduct of the study; grants from WKZ fund research grant, grants from TKI-Health Holland grant, grants and non-financial support from TigaTx B.V., grants from Vrienden van het UMC Utrecht, non-financial support from Life Science editors parental leave grant, outside the submitted work. Dr. van Wijk reports grants from Investigator initiated studies Regeneron and Leo Pharma, outside the submitted work. All other authors have nothing to disclose.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15064</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>112</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">112</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Schunemann, H. J.</style></author><author><style face="normal" font="default" size="100%">Sa-Sousa, A.</style></author><author><style face="normal" font="default" size="100%">Vieira, R. J.</style></author><author><style face="normal" font="default" size="100%">Amaral, R.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Ansotegui, I. J.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Bosnic-Anticevich, S.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">Carreiro-Martins, P.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Cingi, C.</style></author><author><style face="normal" font="default" size="100%">Costa, E. M.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Eklund, P.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Ivancevich, J. C.</style></author><author><style face="normal" font="default" size="100%">Ispayeva, Z.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Kaidashev, I.</style></author><author><style face="normal" font="default" size="100%">Khaitov, M.</style></author><author><style face="normal" font="default" size="100%">Kraxner, H.</style></author><author><style face="normal" font="default" size="100%">Laune, D.</style></author><author><style face="normal" font="default" size="100%">Lipworth, B.</style></author><author><style face="normal" font="default" size="100%">Louis, R.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Monti, R.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Niedoszytko, M.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Patella, V.</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, N.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Rouadi, P. W.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Sova, M.</style></author><author><style face="normal" font="default" size="100%">Todo-Bom, A.</style></author><author><style face="normal" font="default" size="100%">Taborda-Barata, L.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Tsiligianni, I.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Vandenplas, O.</style></author><author><style face="normal" font="default" size="100%">Wallace, D.</style></author><author><style face="normal" font="default" size="100%">Waserman, S.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS - Center for Health Technology and Services Research, University of Porto, Porto, Portugal.&#xD;RISE - Health Research Network, University of Porto, Porto, Portugal.&#xD;Department of Health Research Methods, Evidence, and Impact &amp; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.&#xD;IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;Rhinology Unit &amp; Smell Clinic, ENT Department, Hospital Clinic, Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;ARIA, Montpellier, France.&#xD;Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino &amp; Mauriziano Hospital, Torino, Italy.&#xD;Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Institute of Clinical medicine, Clinic of Chest diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;Chiba University Hospital and Chiba Rosai Hospital, Chiba, Japan.&#xD;Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.&#xD;Transylvania University Brasov, Brasov, Romania.&#xD;Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Quality Use of Respiratory Medicine Group, Woolcock Institute of Medical Research, The University of Sydney and Sydney Local Health District, Sydney, New South Wales, Australia.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall d&apos;Hebron &amp; ARADyAL research network, Barcelona, Spain.&#xD;Servico de Imunoalergologia, Hospital de Dona Estefania, Centro Hospitalar Universitario de Lisboa Central, Lisbon, Portugal.&#xD;NOVA Medical School/Comprehensive Health Research Centre (CHRC), Lisbon, Portugal.&#xD;Division of Allergy/immunology, University of South Florida, Tampa, Florida, USA.&#xD;SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;ENT Department, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey.&#xD;UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), Porto, Portugal.&#xD;Fundacao ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Brazil.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, University of Cagliari, Cagliari, Italy.&#xD;VIM Suresnes, UMR 0892, Pole des Maladies des Voies Respiratoires, Hopital Foch, Universite Paris-Saclay, Suresnes, France.&#xD;Department of Computing Science, Umea University, Umea, Sweden.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands.&#xD;Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;Kazakhstan Association of Allergology and Clinical Immunology, Department of Allergology and Clinical Immunology of the Kazakh National Medical University, Almaty, Kazakhstan.&#xD;Department of Clinical Immunology, Wroclaw Medical University, and ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Poltava State Medical University, Poltava, Ukraine.&#xD;Laboratory of Molecular immunology, National Research Center, Institute of Immunology, Federal Medicobiological Agency, Moscow, Russian Federation.&#xD;Pirogov Russian National Research Medical University, Moscow, Russian Federation.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary.&#xD;KYomed INNOV, Montpellier, France.&#xD;Scottish Centre for Respiratory Research, Cardiovascular &amp; Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, Dundee, UK.&#xD;Department of Pulmonary Medicine, CHU Liege and GIGA I3 research group, University of Liege, Liege, Belgium.&#xD;Allergy Unit &quot;D Kalogeromitros&quot;, 2nd Department of Dermatology and Venereology, &quot;Attikon&quot; University Hospital, National &amp; Kapodistrian University of Athens, Athens, Greece.&#xD;Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;IMSB, Medical Faculty, University at Cologne, and ClinCompetence Cologne GmbH, Cologne, Germany.&#xD;Department of Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, &quot;Santa Maria della Speranza&quot; Hospital, Battipaglia and Agency of Health ASL, Salerno, Italy.&#xD;Ecole Polytechnique Palaiseau, IRBA (Institut de Recherche bio-Medicale des Armees), Bretigny, France.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.&#xD;Faculty of Medicine, Institute of Immunology, University of Coimbra, Coimbra, Portugal.&#xD;Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, The Netherlands.&#xD;Department of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Dar Al Shifa Hospital, Salmiya, Kuwait.&#xD;Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland.&#xD;Usher Institute, The University of Edinburgh, Edinburgh, UK.&#xD;Department of Respiratory Medicine and Tuberculosis, University Hospital, Brno, Czech Republic.&#xD;Imunoalergologia, Centro Hospitalar Universitario de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;UBIAir - Clinical &amp; Experimental Lung Centre, University of Beira Interior, Covilha, Portugal.&#xD;Department of Immunoallergology, Cova da Beira University Hospital Centre, Covilha, Portugal.&#xD;Fundacion Jimenez Diaz, CIBERES, Faculty of Medicine, Autonoma University of Madrid, Madrid, Spain.&#xD;Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Iraklio, Greece.&#xD;International Primary Care Respiratory Group IPCRG, Aberdeen, UK.&#xD;Institute of Clinical Medicine and Institute of Health Sciences, Vilnius and Medical Faculty of Vilnius University, Vilnius, Lithuania.&#xD;Department of Chest Medicine, Centre Hospitalier Universitaire UCL, Namur, and Universite Catholique de Louvain, Yvoir, Belgium.&#xD;Nova Southeastern University, Fort Lauderdale, Florida, USA.&#xD;Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey.&#xD;University Clinic of Respiratory and Allergic Diseases, Golnick, Slovenia.&#xD;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.&#xD;University Hospital Montpellier, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air(R) longitudinal study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">968-983</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/11/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">*Telemedicine</style></keyword><keyword><style face="normal" font="default" size="100%">mobile health</style></keyword><keyword><style face="normal" font="default" size="100%">patient-reported outcomes</style></keyword><keyword><style face="normal" font="default" size="100%">real-world data</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36325824</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Data from mHealth apps can provide valuable information on rhinitis control and treatment patterns. However, in MASK-air(R), these data have only been analyzed cross-sectionally, without considering the changes of symptoms over time. We analyzed data from MASK-air(R) longitudinally, clustering weeks according to reported rhinitis symptoms. METHODS: We analyzed MASK-air(R) data, assessing the weeks for which patients had answered a rhinitis daily questionnaire on all 7 days. We firstly used k-means clustering algorithms for longitudinal data to define clusters of weeks according to the trajectories of reported daily rhinitis symptoms. Clustering was applied separately for weeks when medication was reported or not. We compared obtained clusters on symptoms and rhinitis medication patterns. We then used the latent class mixture model to assess the robustness of results. RESULTS: We analyzed 113,239 days (16,177 complete weeks) from 2590 patients (mean age +/- SD = 39.1 +/- 13.7 years). The first clustering algorithm identified ten clusters among weeks with medication use: seven with low variability in rhinitis control during the week and three with highly-variable control. Clusters with poorly-controlled rhinitis displayed a higher frequency of rhinitis co-medication, a more frequent change of medication schemes and more pronounced seasonal patterns. Six clusters were identified in weeks when no rhinitis medication was used, displaying similar control patterns. The second clustering method provided similar results. Moreover, patients displayed consistent levels of rhinitis control, reporting several weeks with similar levels of control. CONCLUSIONS: We identified 16 patterns of weekly rhinitis control. Co-medication and medication change schemes were common in uncontrolled weeks, reinforcing the hypothesis that patients treat themselves according to their symptoms.</style></abstract><notes><style face="normal" font="default" size="100%">Sousa-Pinto, Bernardo&#xD;Schunemann, Holger J&#xD;Sa-Sousa, Ana&#xD;Vieira, Rafael Jose&#xD;Amaral, Rita&#xD;Anto, Josep M&#xD;Klimek, Ludger&#xD;Czarlewski, Wienczyslawa&#xD;Mullol, Joaquim&#xD;Pfaar, Oliver&#xD;Bedbrook, Anna&#xD;Brussino, Luisa&#xD;Kvedariene, Violeta&#xD;Larenas-Linnemann, Desiree E&#xD;Okamoto, Yoshitaka&#xD;Ventura, Maria Teresa&#xD;Agache, Ioana&#xD;Ansotegui, Ignacio J&#xD;Bergmann, Karl C&#xD;Bosnic-Anticevich, Sinthia&#xD;Canonica, G Walter&#xD;Cardona, Victoria&#xD;Carreiro-Martins, Pedro&#xD;Casale, Thomas&#xD;Cecchi, Lorenzo&#xD;Chivato, Tomas&#xD;Chu, Derek K&#xD;Cingi, Cemal&#xD;Costa, Elisio M&#xD;Cruz, Alvaro A&#xD;Del Giacco, Stefano&#xD;Devillier, Philippe&#xD;Eklund, Patrik&#xD;Fokkens, Wytske J&#xD;Gemicioglu, Bilun&#xD;Haahtela, Tari&#xD;Ivancevich, Juan Carlos&#xD;Ispayeva, Zhanat&#xD;Jutel, Marek&#xD;Kuna, Piotr&#xD;Kaidashev, Igor&#xD;Khaitov, Musa&#xD;Kraxner, Helga&#xD;Laune, Daniel&#xD;Lipworth, Brian&#xD;Louis, Renaud&#xD;Makris, Michael&#xD;Monti, Riccardo&#xD;Morais-Almeida, Mario&#xD;Mosges, Ralph&#xD;Niedoszytko, Marek&#xD;Papadopoulos, Nikolaos G&#xD;Patella, Vincenzo&#xD;Pham-Thi, Nhan&#xD;Regateiro, Frederico S&#xD;Reitsma, Sietze&#xD;Rouadi, Philip W&#xD;Samolinski, Boleslaw&#xD;Sheikh, Aziz&#xD;Sova, Milan&#xD;Todo-Bom, Ana&#xD;Taborda-Barata, Luis&#xD;Toppila-Salmi, Sanna&#xD;Sastre, Joaquin&#xD;Tsiligianni, Ioanna&#xD;Valiulis, Arunas&#xD;Vandenplas, Olivier&#xD;Wallace, Dana&#xD;Waserman, Susan&#xD;Yorgancioglu, Arzu&#xD;Zidarn, Mihaela&#xD;Zuberbier, Torsten&#xD;Fonseca, Joao A&#xD;Bousquet, Jean&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):968-983. doi: 10.1111/all.15574. Epub 2022 Nov 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36325824</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15574</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2473</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2473</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Michils, A.</style></author><author><style face="normal" font="default" size="100%">Makhoul, J. P.</style></author><author><style face="normal" font="default" size="100%">Blekic, N.</style></author><author><style face="normal" font="default" size="100%">Haccuria, A.</style></author><author><style face="normal" font="default" size="100%">Perez-Bogerd, S.</style></author><author><style face="normal" font="default" size="100%">Malinovschi, A.</style></author><author><style face="normal" font="default" size="100%">Van Muylem, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Chest Department, Erasme University Hospital, Universite libre de Bruxelles, Brussels, Belgium.&#xD;Department of Medical Sciences: Clinical Physiology, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Continuous improvement of FEV(1) in severe eosinophilic asthmatics on anti-interleukin-5 therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2845-2847</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/04/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-5/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophilia/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38659210</style></accession-num><notes><style face="normal" font="default" size="100%">Michils, Alain&#xD;Makhoul, Jean-Pierre&#xD;Blekic, Nathan&#xD;Haccuria, Amaryllis&#xD;Perez-Bogerd, Silvia&#xD;Malinovschi, Andrei&#xD;Van Muylem, Alain&#xD;eng&#xD;Chiesi Pharmaceuticals/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2845-2847. doi: 10.1111/all.16139. Epub 2024 Apr 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38659210</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16139</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1632</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1632</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruokolainen, L.</style></author><author><style face="normal" font="default" size="100%">Parkkola, A.</style></author><author><style face="normal" font="default" size="100%">Karkman, A.</style></author><author><style face="normal" font="default" size="100%">Sinkko, H.</style></author><author><style face="normal" font="default" size="100%">Peet, A.</style></author><author><style face="normal" font="default" size="100%">Hamalainen, A. M.</style></author><author><style face="normal" font="default" size="100%">von Hertzen, L.</style></author><author><style face="normal" font="default" size="100%">Tillmann, V.</style></author><author><style face="normal" font="default" size="100%">Koski, K.</style></author><author><style face="normal" font="default" size="100%">Virtanen, S. M.</style></author><author><style face="normal" font="default" size="100%">Niemela, O.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Knip, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biosciences, University of Helsinki, Helsinki, Finland.&#xD;Pediatric Research Center, Children&apos;s Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.&#xD;Department of Microbiology, University of Helsinki, Helsinki, Finland.&#xD;Human Microbiome (HUMI) Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Paediatrics, Tartu University Hospital, University of Tartu, Tartu, Estonia.&#xD;Department of Paediatrics, Jorvi Hospital, Helsinki University Hospital, Espoo, Finland.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.&#xD;Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.&#xD;Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland.&#xD;Faculty of Social Sciences/Health Sciences, University of Tampere, Tampere, Finland.&#xD;Center for Child Health Research, Tampere University Hospital and Science Centre, Tampere University Hospital, University of Tampere, Tampere, Finland.&#xD;Department of Laboratory Medicine and Medical Research Unit, Seinajoki Central Hospital, University of Tampere, Tampere, Finland.&#xD;Folkhalsan Research Center, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Contrasting microbiotas between Finnish and Estonian infants: Exposure to Acinetobacter may contribute to the allergy gap</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2342-2351</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2020/02/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Acinetobacter</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Estonia/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Finland/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">atopic sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">intestine</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32108360</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic diseases are more common in Finland than in Estonia, which-according to the biodiversity hypothesis-could relate to differences in early microbial exposures. METHODS: We aimed at defining possible microbial perturbations preceding early atopic sensitization. Stool, nasal and skin samples of 6-month-old DIABIMMUNE study participants with HLA susceptibility to type 1 diabetes were collected. We compared microbiotas of sensitized (determined by specific IgE results at 18 months of age) and unsensitized Estonian and Finnish children. RESULTS: Sensitization was differentially targeted between populations, as egg-specific and birch pollen-specific IgE was more common in Finland. Microbial diversity and community composition also differed; the genus Acinetobacter was more abundant in Estonian skin and nasal samples. Particularly, the strain-level profile of Acinetobacter lwoffii was more diverse in Estonian samples. Early microbiota was not generally associated with later sensitization. Microbial composition tended to differ between children with or without IgE-related sensitization, but only in Finland. While land-use pattern (ie green areas vs. urban landscapes around the children&apos;s homes) was not associated with microbiota as a whole, it associated with the composition of the genus Acinetobacter. Breastfeeding affected gut microbial composition and seemed to protect from sensitization. CONCLUSIONS: In accordance with the biodiversity hypothesis, our results support disparate early exposure to environmental microbes between Finnish and Estonian children and suggest a significant role of the genus Acinetobacter in the allergy gap between the two populations. The significance of the observed differences for later allergic sensitization remains open.</style></abstract><notes><style face="normal" font="default" size="100%">Ruokolainen, Lasse&#xD;Parkkola, Anna&#xD;Karkman, Antti&#xD;Sinkko, Hanna&#xD;Peet, Aleksandr&#xD;Hamalainen, Anu-Maaria&#xD;von Hertzen, Leena&#xD;Tillmann, Vallo&#xD;Koski, Katriina&#xD;Virtanen, Suvi M&#xD;Niemela, Onni&#xD;Haahtela, Tari&#xD;Knip, Mikael&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Sep;75(9):2342-2351. doi: 10.1111/all.14250. Epub 2020 Mar 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32108360</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14250</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2245</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2245</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Haveri, H.</style></author><author><style face="normal" font="default" size="100%">Puggioni, F.</style></author><author><style face="normal" font="default" size="100%">Makela, M.</style></author><author><style face="normal" font="default" size="100%">Bourret, R.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;ARIA, Montpellier, France.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;MASK-air, Montpellier, France.&#xD;Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Health and Hospital Care Services, Wellbeing Services County of Paijat-Hame, Lahti, Finland.&#xD;Personalized Medicine Asthma &amp; Allergy, IRCCS Humanitas Research Center, Rozzano, Italy.&#xD;University Hospital of Nice, Nice, France.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.&#xD;IRCCS Humanitas Research Center, Rozzano, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The contribution of digital health to net zero patient care in allergic diseases: From concept to practice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">281-285</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/09/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Digital Health</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Care</style></keyword><keyword><style face="normal" font="default" size="100%">Finnish Allergy Programme</style></keyword><keyword><style face="normal" font="default" size="100%">MASK-air</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">planetary health</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37712588</style></accession-num><notes><style face="normal" font="default" size="100%">Bousquet, Jean&#xD;Haahtela, Tari&#xD;Anto, Josep M&#xD;Haveri, Hanna&#xD;Puggioni, Francesca&#xD;Makela, Mika&#xD;Bourret, Rodolphe&#xD;Canonica, G Walter&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):281-285. doi: 10.1111/all.15880. Epub 2023 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37712588</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15880</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>808</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">808</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bordas-Le Floch, V.</style></author><author><style face="normal" font="default" size="100%">Berjont, N.</style></author><author><style face="normal" font="default" size="100%">Batard, T.</style></author><author><style face="normal" font="default" size="100%">Varese, N.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">Canonica, W. G.</style></author><author><style face="normal" font="default" size="100%">van Zelm, M. C.</style></author><author><style face="normal" font="default" size="100%">Mascarell, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Innovation &amp; Science Department, Stallergenes Greer, Antony, France.&#xD;Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, Vic, Australia.&#xD;Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University, and Alfred Hospital, Melbourne, Vic, Australia.&#xD;Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1263-1273</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/09/23</style></edition><section><style face="normal" font="default" size="100%">1263</style></section><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">IgG2</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite</style></keyword><keyword><style face="normal" font="default" size="100%">humoral responses</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34551124</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IgG2 responses are associated with repeated antigen exposure and display highly mutated variable domains. A recent study highlighted a role of IgG2+ memory B cells and allergen-specific IgG2 levels after a 3rd consecutive pre-seasonal sublingual allergen immunotherapy (AIT) with grass pollen tablet. Herein, we aim to explore changes in allergen-specific IgG2 in individuals undergoing house dust mite immunotherapy (HDM-AIT) and explore whether the interrelationship with other humoral responses (i.e., IgG4 and IgE) may discriminate between high and low responders. METHODS: Levels of serum Dermatophagoides pteronyssinus and Dermatophagoides farinae-specific IgG2, IgG4, and IgE antibodies were measured by ELISA or ImmunoCap in a sub-group of individuals enrolled in a randomized, double-blind, placebo-controlled, sublingual AIT study evaluating the safety and efficacy of a 300 IR HDM tablet. RESULTS: After 1-year sublingual AIT, HDM-specific serum IgG2 responses increase mostly in high versus low responders and are distinctive according to the clinical benefit. Higher correlation between HDM-specific IgG2, IgE, and/or IgG4 responses is seen in subjects benefiting the most from HDM-AIT as indicated by changes in Average Total Combined Scores. More strikingly, statistically significant correlation between HDM-specific IgG2 and IgE responses is only observed in individuals stratified as high responders. CONCLUSIONS: We provide evidence for coordinated serum immune responses upon AIT in HDM-allergic subjects exhibiting high clinical benefit when compared with low responders. Assessing HDM-specific IgE, IgG2, and IgG4 in serum could be used as follow-up combined markers to support decision as to AIT continuation and/or adaptation.</style></abstract><notes><style face="normal" font="default" size="100%">Bordas-Le Floch, Veronique&#xD;Berjont, Nathalie&#xD;Batard, Thierry&#xD;Varese, Nirupama&#xD;O&apos;Hehir, Robyn E&#xD;Canonica, Walter G&#xD;van Zelm, Menno C&#xD;Mascarell, Laurent&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1263-1273. doi: 10.1111/all.15107. Epub 2021 Oct 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34551124</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15107</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>252</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">252</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Atwoli, L.</style></author><author><style face="normal" font="default" size="100%">Erhabor, G. E.</style></author><author><style face="normal" font="default" size="100%">Gbakima, A. A.</style></author><author><style face="normal" font="default" size="100%">Haileamlak, A.</style></author><author><style face="normal" font="default" size="100%">Ntumba, J. K.</style></author><author><style face="normal" font="default" size="100%">Kigera, J.</style></author><author><style face="normal" font="default" size="100%">Laybourn-Langton, L.</style></author><author><style face="normal" font="default" size="100%">Mash, B.</style></author><author><style face="normal" font="default" size="100%">Muhia, J.</style></author><author><style face="normal" font="default" size="100%">Mulaudzi, F. M.</style></author><author><style face="normal" font="default" size="100%">Ofori-Adjei, D.</style></author><author><style face="normal" font="default" size="100%">Okonofua, F.</style></author><author><style face="normal" font="default" size="100%">Rashidian, A.</style></author><author><style face="normal" font="default" size="100%">El-Adawy, M.</style></author><author><style face="normal" font="default" size="100%">Sidibe, S.</style></author><author><style face="normal" font="default" size="100%">Snouber, A.</style></author><author><style face="normal" font="default" size="100%">Tumwine, J.</style></author><author><style face="normal" font="default" size="100%">Yassien, M. S.</style></author><author><style face="normal" font="default" size="100%">Yonga, P.</style></author><author><style face="normal" font="default" size="100%">Zakhama, L.</style></author><author><style face="normal" font="default" size="100%">Zielinski, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">East African Medical Journal.&#xD;West African Journal of Medicine.&#xD;Sierra Leone Journal of Biomedical Research.&#xD;Ethiopian Journal of Health Sciences.&#xD;Annales Africaines de Medecine.&#xD;Annals of African Surgery.&#xD;University of Exeter.&#xD;African Journal of Primary Health Care &amp; Family Medicine.&#xD;London School of Medicine and Tropical Hygiene.&#xD;Curationis.&#xD;Ghana Medical Journal.&#xD;African Journal of Reproductive Health.&#xD;Eastern Mediterranean Health Journal.&#xD;Mali Medical.&#xD;Journal de la Faculte de Medecine d&apos;Oran.&#xD;African Health Sciences.&#xD;Evidence-Based Nursing Research.&#xD;La Tunisie Medicale.&#xD;University of Winchester.</style></auth-address><titles><title><style face="normal" font="default" size="100%">COP27 Climate Change Conference: Urgent action needed for Africa and the world</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">17-19</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/10/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Climate Change</style></keyword><keyword><style face="normal" font="default" size="100%">Africa/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36257669</style></accession-num><notes><style face="normal" font="default" size="100%">Atwoli, Lukoye&#xD;Erhabor, Gregory E&#xD;Gbakima, Aiah A&#xD;Haileamlak, Abraham&#xD;Ntumba, Jean-Marie Kayembe&#xD;Kigera, James&#xD;Laybourn-Langton, Laurie&#xD;Mash, Bob&#xD;Muhia, Joy&#xD;Mulaudzi, Fhumulani Mavis&#xD;Ofori-Adjei, David&#xD;Okonofua, Friday&#xD;Rashidian, Arash&#xD;El-Adawy, Maha&#xD;Sidibe, Siaka&#xD;Snouber, Abdelmadjid&#xD;Tumwine, James&#xD;Yassien, Mohammad Sahar&#xD;Yonga, Paul&#xD;Zakhama, Lilia&#xD;Zielinski, Chris&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):17-19. doi: 10.1111/all.15523. Epub 2022 Oct 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36257669</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15523</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2463</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2463</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Demidova, A.</style></author><author><style face="normal" font="default" size="100%">Drewitz, K. P.</style></author><author><style face="normal" font="default" size="100%">Kimkool, P.</style></author><author><style face="normal" font="default" size="100%">Banjanin, N.</style></author><author><style face="normal" font="default" size="100%">Barzylovich, V.</style></author><author><style face="normal" font="default" size="100%">Botjes, E.</style></author><author><style face="normal" font="default" size="100%">Capper, I.</style></author><author><style face="normal" font="default" size="100%">Castor, M. A. R.</style></author><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author><author><style face="normal" font="default" size="100%">Cook, E. E.</style></author><author><style face="normal" font="default" size="100%">Costa, J.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Epstein, M. M.</style></author><author><style face="normal" font="default" size="100%">Galvin, A. D.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Girard, F.</style></author><author><style face="normal" font="default" size="100%">Golding, M. A.</style></author><author><style face="normal" font="default" size="100%">Greenhawt, M.</style></author><author><style face="normal" font="default" size="100%">Ierodiakonou, D.</style></author><author><style face="normal" font="default" size="100%">Jones, C. J.</style></author><author><style face="normal" font="default" size="100%">Khaleva, E.</style></author><author><style face="normal" font="default" size="100%">Knibb, R. C.</style></author><author><style face="normal" font="default" size="100%">Macit-Celebi, M. S.</style></author><author><style face="normal" font="default" size="100%">Mack, D. P.</style></author><author><style face="normal" font="default" size="100%">Mafra, I.</style></author><author><style face="normal" font="default" size="100%">Marchisotto, M. J.</style></author><author><style face="normal" font="default" size="100%">Mijakoski, D.</style></author><author><style face="normal" font="default" size="100%">Nekliudov, N.</style></author><author><style face="normal" font="default" size="100%">Ozdemir, C.</style></author><author><style face="normal" font="default" size="100%">Patel, N.</style></author><author><style face="normal" font="default" size="100%">Pazukhina, E.</style></author><author><style face="normal" font="default" size="100%">Protudjer, J. L. P.</style></author><author><style face="normal" font="default" size="100%">Rodriguez Del Rio, P.</style></author><author><style face="normal" font="default" size="100%">Roomet, J.</style></author><author><style face="normal" font="default" size="100%">Sammut, P.</style></author><author><style face="normal" font="default" size="100%">Schoos, A. M.</style></author><author><style face="normal" font="default" size="100%">Schopfer, A. F.</style></author><author><style face="normal" font="default" size="100%">Schultz, F.</style></author><author><style face="normal" font="default" size="100%">Seylanova, N.</style></author><author><style face="normal" font="default" size="100%">Skypala, I.</style></author><author><style face="normal" font="default" size="100%">Sorensen, M.</style></author><author><style face="normal" font="default" size="100%">Stoleski, S.</style></author><author><style face="normal" font="default" size="100%">Stylianou, E.</style></author><author><style face="normal" font="default" size="100%">Upton, J.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author><author><style face="normal" font="default" size="100%">Genuneit, J.</style></author><author><style face="normal" font="default" size="100%">Boyle, R. J.</style></author><author><style face="normal" font="default" size="100%">Apfelbacher, C.</style></author><author><style face="normal" font="default" size="100%">Munblit, D.</style></author><author><style face="normal" font="default" size="100%">Comfa Consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Independent Researcher, Limassol, Cyprus.&#xD;Institute of Social Medicine and Health Systems Research, Medical Faculty, Otto von Guericke University, Magdeburg, Germany.&#xD;Department of Pediatric Allergy, Imperial College Healthcare NHS Trust, London, UK.&#xD;Institute of Hygiene and Medical Ecology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.&#xD;Department of Pediatrics, National Medical University named after O.O. Bogomolets, Kyiv, Ukraine.&#xD;Dutch Food Allergy SVA, Nijkerk, The Netherlands.&#xD;University of Nottingham, Nottingham, UK.&#xD;Division of Allergy and Immunology, Department of Pediatrics, College of Medicine-Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.&#xD;Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Modern Japanese Studies Program, Graduate School of Media and Communication, Hokkaido University, Sapporo, Japan.&#xD;REQUIMTE-LAQV, Faculdade de Farmacia, Universidade do Porto, Porto, Portugal.&#xD;Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.&#xD;Experimental Allergy Laboratory, Department of Dermatology, Medical University of Vienna, Vienna, Austria.&#xD;School of Applied Psychology, University College Cork, Cork, Ireland.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;DBV Technologies, Montrouge, France.&#xD;The Children&apos;s Hospital Research Institute of Manitoba, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.&#xD;Department of Pediatrics, Section of Allergy and Immunology, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.&#xD;School of Psychology, University of Surrey, Guildford, UK.&#xD;Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;School of Psychology, Aston Institute of Health and Neurodevelopment, Aston University, Birmingham, UK.&#xD;Department of Nutrition and Dietetics, Faculty of Health Sciences, Ondokuz Mayis University, Samsun, Turkey.&#xD;Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.&#xD;MJM Advisory, LLC, New York, New York, USA.&#xD;Department for Allergic Diseases, Institute of Occupational Health of R.N. Macedonia, WHO Collaborating Center, Skopje, North Macedonia.&#xD;Department of Occupational Medicine, Faculty of Medicine, Ss. Cyril and Methodius, University in Skopje, Skopje, North Macedonia.&#xD;Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA.&#xD;Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkey.&#xD;Heybeliada, Istanbul, Turkey.&#xD;Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.&#xD;Allergy department, Hospital Universitario Infantil Nino Jesus, Madrid, Spain.&#xD;Centre for Allergology and Immunology, East Tallinn Central Hospital, Tallinn, Estonia.&#xD;Department of Paediatrics, Mater Dei Hospital, Msida, Malta.&#xD;COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Copenhagen University Hospital-Herlev and Gentofte, Gentofte, Denmark.&#xD;Department of Pediatrics, Slagelse Sygehus, Slagelse, Denmark.&#xD;Allergissima Association, Crissier, Switzerland.&#xD;International FPIES Association (IFPIES), Point Pleasant Beach, New Jersey, USA.&#xD;Independent Researcher, London, UK.&#xD;Department of Inflammation and Repair, Imperial College London, London, UK.&#xD;Regional center for asthma, allergy and hypersensitivity, University Hospital of North Norway, Tromso, Norway.&#xD;Department of Pulmonary Medicine, Regional Centre for Asthma, Allergy and Hypersensitivity, Oslo University Hospital, Oslo, Norway.&#xD;The Hospital for Sick Children, Divison of Immunology and Allergy, Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany.&#xD;Care for Long Term Conditions Division, Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King&apos;s College London, London, UK.&#xD;Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child&apos;s Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Core Outcome Set for IgE-mediated food allergy clinical trials and observational studies of interventions: International Delphi consensus study &apos;COMFA&apos;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">977-989</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/03/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Delphi Technique</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment, Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Observational Studies as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">allergic symptoms</style></keyword><keyword><style face="normal" font="default" size="100%">core outcome set</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38433402</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IgE-mediated food allergy (FA) is a global health concern with substantial individual and societal implications. While diverse intervention strategies have been researched, inconsistencies in reported outcomes limit evaluations of FA treatments. To streamline evaluations and promote consistent reporting, the Core Outcome Measures for Food Allergy (COMFA) initiative aimed to establish a Core Outcome Set (COS) for FA clinical trials and observational studies of interventions. METHODS: The project involved a review of published clinical trials, trial protocols and qualitative literature. Outcomes found as a result of review were categorized and classified, informing a two-round online-modified Delphi process followed by hybrid consensus meeting to finalize the COS. RESULTS: The literature review, taxonomy mapping and iterative discussions with diverse COMFA group yielded an initial list of 39 outcomes. The iterative online and in-person meetings reduced the list to 13 outcomes for voting in the formal Delphi process. One more outcome was added based on participant suggestions after the first Delphi round. A total of 778 participants from 52 countries participated, with 442 participating in both Delphi rounds. No outcome met a priori criteria for inclusion, and one was excluded as a result of the Delphi. Thirteen outcomes were brought to the hybrid consensus meeting as a result of Delphi and two outcomes, &apos;allergic symptoms&apos; and &apos;quality of life&apos; achieved consensus for inclusion as &apos;core&apos; outcomes. CONCLUSION: In addition to the mandatory reporting of adverse events for FA clinical trials or observational studies of interventions, allergic symptoms and quality of life should be measured as core outcomes. Future work by COMFA will define how best to measure these core outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Demidova, Anastasia&#xD;Drewitz, Karl Philipp&#xD;Kimkool, Parisut&#xD;Banjanin, Nikolina&#xD;Barzylovich, Vladyslava&#xD;Botjes, Erna&#xD;Capper, India&#xD;Castor, Mary Anne R&#xD;Comberiati, Pasquale&#xD;Cook, Emma E&#xD;Costa, Joana&#xD;Chu, Derek K&#xD;Epstein, Michelle M&#xD;Galvin, Audrey Dunn&#xD;Giovannini, Mattia&#xD;Girard, Frederic&#xD;Golding, Michael A&#xD;Greenhawt, Matthew&#xD;Ierodiakonou, Despo&#xD;Jones, Christina J&#xD;Khaleva, Ekaterina&#xD;Knibb, Rebecca C&#xD;Macit-Celebi, Melahat Sedanur&#xD;Mack, Douglas P&#xD;Mafra, Isabel&#xD;Marchisotto, Mary Jane&#xD;Mijakoski, Dragan&#xD;Nekliudov, Nikita&#xD;Ozdemir, Cevdet&#xD;Patel, Nandinee&#xD;Pazukhina, Ekaterina&#xD;Protudjer, Jennifer L P&#xD;Rodriguez Del Rio, Pablo&#xD;Roomet, Jelena&#xD;Sammut, Patrick&#xD;Schoos, Ann-Marie Malby&#xD;Schopfer, Anita Fossaluzza&#xD;Schultz, Fallon&#xD;Seylanova, Nina&#xD;Skypala, Isabel&#xD;Sorensen, Martin&#xD;Stoleski, Sasho&#xD;Stylianou, Eva&#xD;Upton, Julia&#xD;van de Veen, Willem&#xD;Genuneit, Jon&#xD;Boyle, Robert J&#xD;Apfelbacher, Christian&#xD;Munblit, Daniel&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):977-989. doi: 10.1111/all.16023. Epub 2024 Mar 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38433402</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16023</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2280</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2280</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leonardi, A.</style></author><author><style face="normal" font="default" size="100%">Cavarzeran, F.</style></author><author><style face="normal" font="default" size="100%">Rosani, U.</style></author><author><style face="normal" font="default" size="100%">Righetti, G.</style></author><author><style face="normal" font="default" size="100%">Garrigue, J. S.</style></author><author><style face="normal" font="default" size="100%">Brun, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy.&#xD;Department of Biology, University of Padova, Padova, Italy.&#xD;Santen SAS, Geneva, France.&#xD;Department of Molecular Medicine, Histology Unit, University of Padova, Padova, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Correlation between gene expression and clinical scores in vernal keratoconjunctivitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">513-515</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/10/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37792793</style></accession-num><notes><style face="normal" font="default" size="100%">Leonardi, Andrea&#xD;Cavarzeran, Fabiano&#xD;Rosani, Umberto&#xD;Righetti, Giuseppe&#xD;Garrigue, Jean-Sebastien&#xD;Brun, Paola&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):513-515. doi: 10.1111/all.15903. Epub 2023 Oct 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37792793</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15903</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2840</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2840</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alvarez, J.</style></author><author><style face="normal" font="default" size="100%">Parody, N.</style></author><author><style face="normal" font="default" size="100%">Calzada, D.</style></author><author><style face="normal" font="default" size="100%">Aranda, T.</style></author><author><style face="normal" font="default" size="100%">Renshaw, A.</style></author><author><style face="normal" font="default" size="100%">Serna, S.</style></author><author><style face="normal" font="default" size="100%">Reichardt, N.</style></author><author><style face="normal" font="default" size="100%">Beitia, J. M.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-de-Olano, D.</style></author><author><style face="normal" font="default" size="100%">Dominguez-Ortega, J.</style></author><author><style face="normal" font="default" size="100%">Carnes, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">R&amp;D Unit. Allergy &amp; Immunology, LETI Pharma SLU, Madrid, Spain.&#xD;Centro de Biologia Molecular Severo Ochoa, Madrid, Spain.&#xD;Glycotechnology Group, CICbiomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.&#xD;Asparia Glycomics, San Sebastian, Spain.&#xD;Hospital Universitario de Guadalajara, Guadalajara, Spain.&#xD;Hospital Universitario Ramon y Cajal, Madrid, Spain.&#xD;Department of Allergy, Hospital Universitario La Paz. Institute for Health Research (IdiPAZ), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Correlation Between N-Glycan GnGnXF3 and the Allergic Immune Response Against Juniperus ashei Pollen</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1935-1944</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/02/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Polysaccharides/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Juniperus/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Plant/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Glycosylation</style></keyword><keyword><style face="normal" font="default" size="100%">Juniperus ashei</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Cupressaceae</style></keyword><keyword><style face="normal" font="default" size="100%">GnGnXF3</style></keyword><keyword><style face="normal" font="default" size="100%">N-glycan</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39912313</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cupressaceae pollen increasingly causes respiratory allergies worldwide. Carbohydrates are abundant in extracts of these pollens, and the associated allergens are highly glycosylated. However, the contribution of saccharides to the allergenicity of these species remains unknown. METHODS: Juniperus ashei pollen extract was deglycosylated and characterised using SDS-PAGE and immunoblotting. Additionally, N- and O-glycans were purified from the extract, identified, used as inhibitors in IgE-immunoblotting and further analysed via basophil activation tests. The interactions between IgE and J. ashei glycans were analysed using a glycan array. Purified Jun a 1 was treated with beta-N-acetylglucosaminidase S and analysed using immunoblotting. The native pollen extract was used to immunise rabbits, and the IgG response was analysed using ELISA and glycan array. RESULTS: Deglycosylation of J. ashei proteins abolished the interaction between IgE and allergens. This effect primarily depends on N-glycans. Purified N-glycans triggered basophil activation in some patients. A biantennary N-glycan with terminal GlcNAc, beta-1,2 xylose and core alpha-1,3 fucose (GnGnXF3) was the most abundant glycan identified. The glycan array confirmed its interaction with IgE. The contribution of terminal N-acetylglucosamines (GlcNAc) to IgE-Jun a 1 interaction was validated. Moreover, effective immunisation of rabbits with the native extract confirmed the immunogenicity of their N-glycans. CONCLUSIONS: The IgE-J. ashei allergen interaction is broadly controlled through N-glycans different from MUXF3. GnGnXF3 exerts an immunogenic effect in humans and rabbits; terminal GlcNAc residues influence its recognition by IgE. These discoveries reinforce the role of N-glycans in the allergic response to J. ashei.</style></abstract><notes><style face="normal" font="default" size="100%">Alvarez, Javier&#xD;Parody, Nuria&#xD;Calzada, David&#xD;Aranda, Tamara&#xD;Renshaw, Ana&#xD;Serna, Sonia&#xD;Reichardt, Niels&#xD;Beitia, Juan Maria&#xD;Gonzalez-de-Olano, David&#xD;Dominguez-Ortega, Javier&#xD;Carnes, Jeronimo&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1935-1944. doi: 10.1111/all.16475. Epub 2025 Feb 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39912313</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16475</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1242</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1242</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bertolini, F.</style></author><author><style face="normal" font="default" size="100%">Carriero, V.</style></author><author><style face="normal" font="default" size="100%">Bullone, M.</style></author><author><style face="normal" font="default" size="100%">Sprio, A. E.</style></author><author><style face="normal" font="default" size="100%">Defilippi, I.</style></author><author><style face="normal" font="default" size="100%">Sorbello, V.</style></author><author><style face="normal" font="default" size="100%">Gani, F.</style></author><author><style face="normal" font="default" size="100%">Di Stefano, A.</style></author><author><style face="normal" font="default" size="100%">Ricciardolo, F. L. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical and Biological Sciences, Rare Lung Disease Unit and Severe Asthma Centre, San Luigi Gonzaga University Hospital, University of Turin, Orbassano, Turin, TO, Italy.&#xD;Department of Veterinary Sciences, University of Turin, Grugliasco, Turin, TO, Italy.&#xD;Allergy Service, AOU San Luigi Gonzaga Hospital, Turin, TO, Italy.&#xD;Department of Pneumology and Laboratory of Cytoimmunopathology of the Heart and Lung, Istituti Clinici Scientifici Maugeri, IRCCS, Veruno, NO, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Correlation of matrix-related airway remodeling and bradykinin B1 receptor expression with fixed airflow obstruction in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1886-1890</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Airway Obstruction/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Airway Remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Bradykinin B1</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33284471</style></accession-num><notes><style face="normal" font="default" size="100%">Bertolini, Francesca&#xD;Carriero, Vitina&#xD;Bullone, Michela&#xD;Sprio, Andrea Elio&#xD;Defilippi, Ilaria&#xD;Sorbello, Valentina&#xD;Gani, Federica&#xD;Di Stefano, Antonino&#xD;Ricciardolo, Fabio Luigi Massimo&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1886-1890. doi: 10.1111/all.14691. Epub 2020 Dec 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33284471</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14691</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2352</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cheng, I.</style></author><author><style face="normal" font="default" size="100%">Yii, C. Y.</style></author><author><style face="normal" font="default" size="100%">Shih, L. C.</style></author><author><style face="normal" font="default" size="100%">Wang, J. Y.</style></author><author><style face="normal" font="default" size="100%">Yong, S. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medicine, Chung Shan Medical University, Taichung, Taiwan.&#xD;Division of Gastroenterology and Hepatology, Department of Internal Medicine, Landseed International Hospital, Taoyuan, Taiwan.&#xD;Department of Biomedical Sciences and Engineering, National Central University, Taoyuan, Taiwan.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung, Taiwan.&#xD;Center for Allergy, Immunology and Microbiome (AIM), China Medical University Hospital, Taichung, Taiwan.&#xD;Department of Allergy, Immunology and Rheumatology (AIR), China Medical University Children&apos;s Hospital, Taichung, Taiwan.&#xD;Department of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Correspondence to &apos;association between chronic rhinosinusitis and new onset asthma implications for prevention&apos;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1392-1393</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/12/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/prevention &amp; control/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinosinusitis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">new onset asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38037748</style></accession-num><notes><style face="normal" font="default" size="100%">Cheng, Iressa&#xD;Yii, Chin-Yuan&#xD;Shih, Liang-Chun&#xD;Wang, Jiu Yao&#xD;Yong, Su-Boon&#xD;eng&#xD;DMR-113-137/China Medical University Hospital/&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1392-1393. doi: 10.1111/all.15965. Epub 2023 Dec 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38037748</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15965</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>462</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">462</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kelleher, M. M.</style></author><author><style face="normal" font="default" size="100%">Cro, S.</style></author><author><style face="normal" font="default" size="100%">Phillips, R.</style></author><author><style face="normal" font="default" size="100%">Williams, H. C.</style></author><author><style face="normal" font="default" size="100%">Lowe, A. J.</style></author><author><style face="normal" font="default" size="100%">Boyle, R. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart Lung Institute, Imperial College London, London, UK.&#xD;Imperial Clinical Trials Unit, Imperial College London, London, UK.&#xD;Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.&#xD;Allergy and Lung Health Unit, Melbourne School of Population and Global Health, Carlton, Vic, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Correspondence to &quot; Emollients in infancy to prevent atopic dermatitis: A systematic review and meta-analysis&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1931-1933</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/06/02</style></edition><section><style face="normal" font="default" size="100%">1931</style></section><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Emollients/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Systematic Reviews as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Meta-Analysis as Topic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35643983</style></accession-num><notes><style face="normal" font="default" size="100%">Kelleher, Maeve M&#xD;Cro, Suzie&#xD;Phillips, Rachel&#xD;Williams, Hywel C&#xD;Lowe, Adrian J&#xD;Boyle, Robert J&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1931-1933. doi: 10.1111/all.15238.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35643983</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15238</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2307</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2307</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ebo, D. G.</style></author><author><style face="normal" font="default" size="100%">Elst, J.</style></author><author><style face="normal" font="default" size="100%">Van Gasse, A. L.</style></author><author><style face="normal" font="default" size="100%">Mertens, C.</style></author><author><style face="normal" font="default" size="100%">Sabato, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine and Health Sciences, Department of Immunology, Allergology, Rheumatology, The Infla-Med Centre of Excellence, University of Antwerp and Antwerp University Hospital, Antwerpen, Belgium.&#xD;Faculty of Medicine and Health Sciences, Department of Paediatrics, The Infla-Med Centre of Excellence, University of Antwerp and Antwerp University Hospital, Antwerpen, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Correspondence to &quot;Basophil activation test as predictor of severity and threshold of allergic reactions to egg&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1386-1388</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Egg Hypersensitivity/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Basophil Degranulation Test/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37985443</style></accession-num><notes><style face="normal" font="default" size="100%">Ebo, Didier G&#xD;Elst, Jessy&#xD;Van Gasse, Athina L&#xD;Mertens, Christel&#xD;Sabato, Vito&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1386-1388. doi: 10.1111/all.15950. Epub 2023 Nov 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37985443</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15950</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>360</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">360</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Smith, P. K.</style></author><author><style face="normal" font="default" size="100%">Lesslar, O.</style></author><author><style face="normal" font="default" size="100%">Price, D. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Griffith University, Southport, Qld, Australia.&#xD;Observational and Pragmatic Research Institute, Singapore City, Singapore.&#xD;Division of Applied Health Sciences, Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Correspondence to &quot;Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2571-2573</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*COVID-19/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Common Cold/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Consensus</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Perennial/diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35932253</style></accession-num><notes><style face="normal" font="default" size="100%">Smith, Peter K&#xD;Lesslar, Olivia&#xD;Price, David B&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2571-2573. doi: 10.1111/all.15281.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35932253</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9537924 conflicts of interest related to this letter. He has current researcher-initiated funding in mucosal and skin immunology supported by GSK and Sanofi respectively. DBP has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Thermofisher; has consultancy agreements with Airway Vista Secretariat, AstraZeneca, Boehringer Ingelheim, Chiesi, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, GlaxoSmithKline, Mylan, Mundipharma, Novartis, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc, Strategic North Limited, Synapse Research Management Partners S.L., Talos Health Solutions, Theravance and WebMD Global LLC; has grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service; has payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme; has payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis, Thermofisher; has stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals, owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and has 5% shareholding in Timestamp, which develops adherence monitoring technology, is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment, and was an expert witness for GlaxoSmithKline.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15281</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>580</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">580</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maher, E.</style></author><author><style face="normal" font="default" size="100%">Martiniuk, F.</style></author><author><style face="normal" font="default" size="100%">Levis, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, NYU Langone, New York City, New York, USA.&#xD;JME Group, Inc and Psychogenics Center, Parasmus, New Jersey, USA.&#xD;Department of Dermatology, Bellevue Hospital, New York City, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Correspondence to: Phase 2a randomized clinical trial of dupilumab (anti-IL-4Ralpha) for alopecia areata patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1073-1074</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/02/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Alopecia Areata/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35218045</style></accession-num><notes><style face="normal" font="default" size="100%">Maher, Eamonn&#xD;Martiniuk, Frank&#xD;Levis, William&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1073-1074. doi: 10.1111/all.15185.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35218045</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15185</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3072</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3072</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Takefuji, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Data Science, Musashino University, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Correspondence: Accuracy Is Not Enough: Stability-Aware Feature Selection for Reproducible Biomarker Discovery</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">biomarker discovery</style></keyword><keyword><style face="normal" font="default" size="100%">feature selection</style></keyword><keyword><style face="normal" font="default" size="100%">random forest</style></keyword><keyword><style face="normal" font="default" size="100%">reproducibility</style></keyword><keyword><style face="normal" font="default" size="100%">stability</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40985317</style></accession-num><abstract><style face="normal" font="default" size="100%">Random forest (RF) models can achieve high predictive accuracy, yet their model-specific feature importances may be unstable and misleading. Using an allergy benchmark dataset (10,000 instances, 11 features), we compared five selection strategies-RF, logistic regression, feature agglomeration (FA), highly variable gene selection (HVGS), and Spearman correlation-evaluating cross-validated accuracy with the top five features and after removing the top two (reselecting the top three). RF attained 0.9999 accuracy with the top five but fell to 0.8836 and showed unstable rankings; logistic regression maintained 0.9116 but was also unstable. FA, HVGS, and Spearman achieved near-perfect accuracy (0.9999) with the top five and modest declines (0.9076-0.9116) with stable rankings. Results underscore that accuracy does not imply reliable importance; stability-aware, model-agnostic, or unsupervised methods better support reproducible biomarker discovery.</style></abstract><notes><style face="normal" font="default" size="100%">Takefuji, Yoshiyasu&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep 23. doi: 10.1111/all.70075.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40985317</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70075</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3064</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3064</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cichocka-Jarosz, E.</style></author><author><style face="normal" font="default" size="100%">Dolle-Bierke, S.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Pulmonology-Allergology-Dermatology Clinic, Jagiellonian University Medical College, Krakow, Poland.&#xD;Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;Department of Allergy, 2nd Paediatric Clinic, University of Athens, Athens, Greece.&#xD;University of Manchester, Manchester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Correspondence: Anaphylaxis Induced by Goat&apos;s and Sheep&apos;s Milk-A Rare Entity in Europe</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">311-313</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/09/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40990253</style></accession-num><notes><style face="normal" font="default" size="100%">Cichocka-Jarosz, Ewa&#xD;Dolle-Bierke, Sabine&#xD;Papadopoulos, Nikolaos G&#xD;Worm, Margitta&#xD;eng&#xD;NORA e.V/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):311-313. doi: 10.1111/all.70051. Epub 2025 Sep 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40990253</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70051</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>520</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">520</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Farraia, M.</style></author><author><style face="normal" font="default" size="100%">Paciencia, I.</style></author><author><style face="normal" font="default" size="100%">Castro Mendes, F.</style></author><author><style face="normal" font="default" size="100%">Cavaleiro Rufo, J.</style></author><author><style face="normal" font="default" size="100%">H. Shamji M</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">EPIUnit-Institute of Public Health, University of Porto, Porto, Portugal.&#xD;Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal.&#xD;Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Sao Joao University Hospital Center, Porto, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2688-2698</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy/methods</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">cost effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mites</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35451128</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cost-effectiveness studies evaluating allergen immunotherapy (AIT) in children are limited but needed to drive clinical and policy-making decisions such as reimbursement of new interventions. In this study, we compared the cost effectiveness of subcutaneous (SCIT) and sublingual immunotherapy (SLIT) tablets to the standard of care (SOC) treatment in children with house dust mite-driven (HDM) allergic asthma. METHODS: We developed a hypothetical Markov model based on the Global Initiative for Asthma (GINA) severity steps to compare the three strategies over a 10-year horizon divided by cycles of 6 months. SOC was used as a reference to calculate the incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses were used to assess models&apos; uncertainty. Other scenarios were evaluated to strengthen the presentation of results. RESULTS: The ICER for SCIT and SLIT tablets was 1281euro and 7717euro, respectively. The cost-effectiveness threshold for Portugal was 18,482.80euro; both treatment approaches were below this limit. The major contributors to these results were the AIT effects on reducing moderate and severe exacerbations and asthma controller medication. In the sensitivity analysis, SCIT revealed a higher probability of cost-effectiveness than SLIT. When including allergic rhinitis as comorbidity, ICER values reduced markedly, especially for SCIT intervention. CONCLUSIONS: AIT was cost effective in children with HDM-driven allergic asthma, especially when given by the subcutaneous route. The high probability of cost effectiveness, especially for SCIT, may drive future policy decisions and AIT-prescribing habits. AIT adherence greatly influenced the results highlighting the value of implementing strategies to promote adherence rates.</style></abstract><notes><style face="normal" font="default" size="100%">Farraia, Mariana&#xD;Paciencia, Ines&#xD;Castro Mendes, Francisca&#xD;Cavaleiro Rufo, Joao&#xD;H Shamji, Mohamed&#xD;Agache, Ioana&#xD;Moreira, Andre&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2688-2698. doi: 10.1111/all.15321. Epub 2022 May 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35451128</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15321</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1212</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1212</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parra-Padilla, D.</style></author><author><style face="normal" font="default" size="100%">Zakzuk, J.</style></author><author><style face="normal" font="default" size="100%">Carrasquilla, M.</style></author><author><style face="normal" font="default" size="100%">Alvis-Guzman, N.</style></author><author><style face="normal" font="default" size="100%">Dennis, R.</style></author><author><style face="normal" font="default" size="100%">Rojas, M. X.</style></author><author><style face="normal" font="default" size="100%">Rondon, M.</style></author><author><style face="normal" font="default" size="100%">Perez, A.</style></author><author><style face="normal" font="default" size="100%">Penaranda, A.</style></author><author><style face="normal" font="default" size="100%">Barragan, A. M.</style></author><author><style face="normal" font="default" size="100%">Caraballo, L.</style></author><author><style face="normal" font="default" size="100%">Garcia, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Health Economics Research Group, University of Cartagena, Cartagena, Colombia.&#xD;ALZAK Foundation, Cartagena, Colombia.&#xD;Institute for Immunological Research, University of Cartagena, Cartagena, Colombia.&#xD;Department of Research, Fundacion Cardioinfantil, Bogota, Colombia.&#xD;School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.&#xD;Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogota, Colombia.&#xD;Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston-UTHealth, Austin, TX, USA.&#xD;Department of Otolaryngology, Fundacion Santa Fe de Bogota, Bogota, Colombia.&#xD;School of Medicine, Universidad de los Andes, Bogota, Colombia.&#xD;Public Health Research Group, School of Medicine, Universidad del Rosario, Bogota, Colombia.&#xD;Department Pediatric Allergology, Fundacion Santa Fe de Bogota, Bogota, Colombia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cost-effectiveness of the subcutaneous house dust mite allergen immunotherapy plus pharmacotherapy for allergic asthma: A mathematical model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2229-2233</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/12/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Theoretical</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33377199</style></accession-num><notes><style face="normal" font="default" size="100%">Parra-Padilla, Devian&#xD;Zakzuk, Josefina&#xD;Carrasquilla, Maria&#xD;Alvis-Guzman, Nelson&#xD;Dennis, Rodolfo&#xD;Rojas, Maria X&#xD;Rondon, Martin&#xD;Perez, Adriana&#xD;Penaranda, Augusto&#xD;Barragan, Ana M&#xD;Caraballo, Luis&#xD;Garcia, Elizabeth&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2229-2233. doi: 10.1111/all.14723. Epub 2021 Jan 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33377199</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14723</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3195</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3195</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sturm, G.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Vidal, C.</style></author><author><style face="normal" font="default" size="100%">Oude Elberink, J. N. G.</style></author><author><style face="normal" font="default" size="100%">Schmitt, J.</style></author><author><style face="normal" font="default" size="100%">Slaettanes, A. K.</style></author><author><style face="normal" font="default" size="100%">Jakob, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.&#xD;Department of Clinical and Molecular Sciences, Universita Politecnica Delle Marche, Ancona, Italy.&#xD;Allergy Unit, Department of Internal Medicine, University Hospital Ospedali Riuniti di Ancona, Ancona, Italy.&#xD;Allergy Department, Complejo Hospitalario Universitario de Santiago, Faculty of Medicine USC, Santiago de Compostela, Spain.&#xD;Department of Allergology, University Medical Center Groningen, University of Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.&#xD;Center for Evidence-Based Healthcare, TU Dresden, Dresden, Germany.&#xD;ALK-Abello A/S, Horsholm, Denmark.&#xD;Department of Dermatology and Allergy, University Medical Center, Justus-Liebig University, Giessen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cost-Effectiveness of Venom Immunotherapy in Preventing Severe Bee and Wasp Sting Reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">immunotherapy vaccines and mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">venom and insect allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41410197</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Systemic sting reactions (SSRs) from bee and wasp stings can cause severe symptoms, including anaphylaxis and potentially lead to fatal outcomes. These reactions can significantly affect individuals&apos; daily lives due to the fear and anxiety associated with the risk of stings. Venom immunotherapy (VIT) has been shown to be an effective preventive treatment for SSRs, offering a viable alternative to emergency treatments like adrenaline auto-injectors (AAIs). METHODS: We created a decision tree framework with a Danish payer perspective designed to evaluate the cost-effectiveness of VIT with Alutard((R)) SQ in individuals with bee and/or wasp venom allergies. Input in the model was identified from a structured literature review and expert consensus. The incremental cost-effectiveness ratio (ICER) of Hymenoptera venom depot immunotherapy (HVDI) compared to AAIs over a 10-year time horizon was estimated. The impact of uncertainty associated with key assumptions was investigated using univariate deterministic sensitivity analyses (DSA). RESULTS: In the base case, the incremental cost of HVDI was euro7428, while the incremental quality-adjusted life years (QALYs) gained were 0.48. Consequently, the ICER (cost per QALY) of HVDI compared to AAIs after 10 years was estimated at euro15,550. CONCLUSION: VIT is a cost-effective treatment for the prevention of severe reactions to wasp and/or bee stings when compared to AAIs.</style></abstract><notes><style face="normal" font="default" size="100%">Sturm, Gunter&#xD;Bilo, Maria Beatrice&#xD;Vidal, Carmen&#xD;Oude Elberink, Joanna N G&#xD;Schmitt, Jochen&#xD;Slaettanes, Andreas Kallsoy&#xD;Jakob, Thilo&#xD;eng&#xD;ALK-Abello/&#xD;Denmark&#xD;Allergy. 2025 Dec 18. doi: 10.1111/all.70176.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41410197</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70176</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1416</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1416</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patella, V.</style></author><author><style face="normal" font="default" size="100%">Florio, G.</style></author><author><style face="normal" font="default" size="100%">Brancaccio, R.</style></author><author><style face="normal" font="default" size="100%">Delfino, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, &quot;Santa Maria della Speranza&quot; Hospital, Salerno, Italy.&#xD;Postprogram in Allergy and Clinical Immunology, School of Medicine, University of Naples Federico II, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Could anti-tubercular vaccination protect against COVID-19 infection?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">942-945</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/06/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">BCG Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mycobacterium tuberculosis</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32578215</style></accession-num><notes><style face="normal" font="default" size="100%">Patella, Vincenzo&#xD;Florio, Giovanni&#xD;Brancaccio, Raffaele&#xD;Delfino, Gabriele&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):942-945. doi: 10.1111/all.14443. Epub 2020 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32578215</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7361449 financial associations that could have influenced the outcome of the findings here detailed.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14443</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1411</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1411</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J. Y.</style></author><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Tsai, H. J.</style></author><author><style face="normal" font="default" size="100%">Wu, L. S.</style></author><author><style face="normal" font="default" size="100%">Kuo, W. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Allergy and Clinical Immunology Research, College of Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.&#xD;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Division of Biostatistics and Bioinformatics, Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan.&#xD;Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.&#xD;School of Chemistry and Materials Science, Nanjing University of Information Science and Technology, Nanjing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">COVID-19 and asthma, the good or the bad?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">565-567</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Asthma/*epidemiology/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*complications/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32621304</style></accession-num><notes><style face="normal" font="default" size="100%">Wang, Jiu-Yao&#xD;Pawankar, Ruby&#xD;Tsai, Hui-Ju&#xD;Wu, Lawrence Shih-Hsin&#xD;Kuo, Wen-Shuo&#xD;eng&#xD;Center for Allergy and Clinical Immunology Research (ACIR)/&#xD;National Cheng Kung University/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):565-567. doi: 10.1111/all.14480. Epub 2020 Jul 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32621304</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7362161</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14480</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1381</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1381</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Detoraki, A.</style></author><author><style face="normal" font="default" size="100%">Contoli, M.</style></author><author><style face="normal" font="default" size="100%">Papi, A.</style></author><author><style face="normal" font="default" size="100%">Paoletti, G.</style></author><author><style face="normal" font="default" size="100%">Malipiero, G.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Crimi, C.</style></author><author><style face="normal" font="default" size="100%">Morrone, D.</style></author><author><style face="normal" font="default" size="100%">Padovani, M.</style></author><author><style face="normal" font="default" size="100%">Guida, G.</style></author><author><style face="normal" font="default" size="100%">Gerli, A. G.</style></author><author><style face="normal" font="default" size="100%">Centanni, S.</style></author><author><style face="normal" font="default" size="100%">Senna, G.</style></author><author><style face="normal" font="default" size="100%">Paggiaro, P.</style></author><author><style face="normal" font="default" size="100%">Blasi, F.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Sani Working Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Department of Internal Medicine, Clinical Immunology, Clinical Pathology and Infectious Disease, Azienda Ospedaliera Universitaria Federico II, Napoli, Italy.&#xD;Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.&#xD;Department of Medical Sciences, AO Ordine Mauriziano Umberto I, University of Torino, Torino, Italy.&#xD;Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.&#xD;Severe Asthma Network in Italy (SANI) Infrastructure, Milano, Italy.&#xD;Allergy and Pneumology Unit, A.O. S. Croce e Carle, Cuneo, Italy.&#xD;Management Engineering Tourbillon Tech srl, Padova, Italy.&#xD;Respiratory Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, San Paolo Hospital, University of Milano, Milano, Italy.&#xD;Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy.&#xD;Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Pisa, Italy.&#xD;Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, Italy.&#xD;Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">887-892</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/*complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32738147</style></accession-num><notes><style face="normal" font="default" size="100%">Heffler, Enrico&#xD;Detoraki, Aikaterini&#xD;Contoli, Marco&#xD;Papi, Alberto&#xD;Paoletti, Giovanni&#xD;Malipiero, Giacomo&#xD;Brussino, Luisa&#xD;Crimi, Claudia&#xD;Morrone, Daniela&#xD;Padovani, Marianna&#xD;Guida, Giuseppe&#xD;Gerli, Alberto Giovanni&#xD;Centanni, Stefano&#xD;Senna, Gianenrico&#xD;Paggiaro, Pierluigi&#xD;Blasi, Francesco&#xD;Canonica, Giorgio Walter&#xD;eng&#xD;Unrestricted grant/Sanofi Genzyme/&#xD;Unrestricted grant/AstraZeneca/&#xD;Unrestricted grant/Novartis/&#xD;Unrestricted grant/GlaxoSmithKline/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):887-892. doi: 10.1111/all.14532. Epub 2020 Aug 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32738147</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7436509 AstraZeneca, Sanofi, GSK, Novartis, Circassia, Nestle Purina, Boheringer Ingheleim, Valeas, outside the submitted work. Aikaterini Detoraki does not have any conflict of interest to report. Marco Contoli reports grants from Chiesi, University of Ferrara-Italy, personal fees from Chiesi, AstraZeneca, Boehringer Ingelheim, Alk-Abello, GlaxoSmithKline, Novartis, Zambon, outside the submitted work. Alberto Papi reports grants,, personal fees and non-financial support from AstraZeneca, Menarini, grants, personal fees, nonfinancial support and other from Boehringer Ingelheim, Chiesi Farmaceutici, TEVA, personal fees, nonfinancial support and other from GlaxoSmithKline, Mundipharma, Zambon, Novartis, Sanofi/Regeneron, personal fees from Roche, Edmondpharma, grants from Fondazione Maugeri, Fondazione Chiesi, outside the submitted work. Giovanni Paoletti does not have any conflict of interest to report. Giacomo Malipiero does not have any conflict of interest to report. Luisa Brussino does not have any conflict of interest to report. Claudia Crimi reports personal fees from Menarini. Daniela Morrone does not have any conflict of interest to report. Marianna Padovani does not have any conflict of interest to report. Giuseppe Guida does not have any conflict of interest to report. Alberto Giovanni Gerli does not have any conflict of interest to report. Stefano Centanni reports personal fees from GLAXOSMITHKLINE, NOVARTIS, MENARINI SPA, GUIDOTTI MALESCI, and grants and personal fees from CHIESI SPA, ASTRA ZENECA, VALEAS, BOEHRINGER INGELHEIM, outside the submitted work. Gianenrico Senna does not have any conflict of interest to report. Pierluigi Paggiaro reports grants and personal fees from AstraZeneca, Chiesi, Novartis and Sanofi, and personal fees from GlaxoSmithKline, Guidotti, Mundipharma, outside the submitted work. Francesco Blasi reports grants and personal fees from Astrazeneca, Chiesi, GSK, Pfizer and Insmed, grants from Bayer, and personal fees from Guidotti, Grifols, Menarini, Mundipharma, Novartis and Zambon, outside the submitted work. Giorgio Walter Canonica reports grants as well as lecture or advisory board fees from: A. Menarini, Alk-Abello, Allergy Therapeutics, AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, Glaxo Smith Kline, Hal Allergy, Mylan, Merck, Mundipharma, Novartis, Regeneron, Sanofi-Aventis, Sanofi-Genzyme, StallergenesGreer, UCB pharma, Uriach Pharma, Valeas, ViborPharma.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14532</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2354</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2354</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S. R.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Knol, E. F.</style></author><author><style face="normal" font="default" size="100%">Lauerma, A.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Skypala, I.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Chaker, A.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Quecchia, C.</style></author><author><style face="normal" font="default" size="100%">Sandoval-Ruballos, M.</style></author><author><style face="normal" font="default" size="100%">Sahiner, U.</style></author><author><style face="normal" font="default" size="100%">Tomic Spiric, V.</style></author><author><style face="normal" font="default" size="100%">Alvaro-Lozano, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Transylvania University, Brasov, Romania.&#xD;Theramed Medical Center, Brasov, Romania.&#xD;Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;National Heart and Lung Institute (NHLI), Imperial College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina Children&apos;s Hospital, Guy&apos;s and St, Thomas, Hospital NHS Foundation Trust, London, UK.&#xD;Paediatric Allergy Group, Department of Women and Children&apos;s Health, School of Life Course Sciences, King&apos;s College London, London, UK.&#xD;School of Medicine, University CEU San Pablo Madrid, Spain.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Department of Internal Medicine, Allergology, Clinical Immunology, Medical University of Silesia, Katowice, Poland.&#xD;Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Department of Dermatology and Allergology, Helsinki University Hospital Inflammation Centre, University of Helsinki, Helsinki, Finland.&#xD;Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark, Odense, Denmark.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.&#xD;Allergy and Clinical Immunology, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.&#xD;Institut de Recerca Sant Joan de Deu, Barcelona, Spain.&#xD;Centre for Inflammation Research and Child Life and Heath, the University of Edinburgh, Edinburgh, UK.&#xD;Royal Brompton and Harefield NHS Foundation Trust, London, UK.&#xD;Allergy Unit, Malaga Regional University Hospital-UMA-ARADyAL, Malaga, Spain.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;Department of Otolaryngology and Center of Allergy and Environment, TUM School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Allergy Unit, Department of Pediatrics, Meyer Children&apos;s University Hospital, Florence, Italy.&#xD;Personalized Medicine, Asthma and Allergy - Humanitas Clinical and Research Hospital IRCCS, Rozzano, MI, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.&#xD;The Interuniversity Messerli Research Institute, University of Veterinary Medicine, Vienna, Medical University Vienna, Vienna, Austria.&#xD;&quot;Io e l&apos;Asma&quot; Center, Children&apos;s Hospital, ASST Spedali Civili, Brescia, Italy.&#xD;Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Deu, Barcelona, Spain.&#xD;Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Turkey.&#xD;Faculty of Medicine, University of Belgrade, Belgrade, Serbia.&#xD;Clinic of Allergology and Immunology, Clinical Centre of Serbia, Belgrade, Serbia.&#xD;Universitat de Barcelona, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">COVID-19 pandemic and allergen immunotherapy-an EAACI survey</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3504-3516</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/03/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy (AIT)</style></keyword><keyword><style face="normal" font="default" size="100%">pandemic</style></keyword><keyword><style face="normal" font="default" size="100%">survey</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Allergopharma, grants and personal fees from Stallergenes Greer, grants</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from HAL Allergy Holding B.V./HAL Allergie GmbH, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Bencard Allergie GmbH/Allergy Therapeutics, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Lofarma, grants from Biomay, grants from Circassia, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from ASIT Biotech Tools S.A., grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Laboratorios LETI/LETI Pharma, personal fees from MEDA Pharma/MYLAN, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Anergis S.A., personal fees from Mobile Chamber Experts (a</style></keyword><keyword><style face="normal" font="default" size="100%">GA2LEN Partner), personal fees from Indoor Biotechnologies, grants and personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from GlaxoSmithKline, personal fees from Astellas Pharma Global, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from EUFOREA, personal fees from ROXALL Medizin, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, personal fees from Sanofi-Aventis and Sanofi-Genzyme, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Med Update Europe GmbH, personal fees from streamedup! GmbH, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Pohl-Boskamp, grants from Inmunotek S.L., personal fees from John Wiley and Sons</style></keyword><keyword><style face="normal" font="default" size="100%">AS, personal fees from Paul-Martini-Stiftung (PMS), all outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. Dr. Brough discloses personal speaker fees from DBV Technologies and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">outside of the submitted work. Dr. Ollert reports personal fees from Hycor</style></keyword><keyword><style face="normal" font="default" size="100%">Biomedical, other from Tolerogenics SarL, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">In</style></keyword><keyword><style face="normal" font="default" size="100%">addition, Dr. Ollert has a patent WO2019/076478Al pending, and a patent</style></keyword><keyword><style face="normal" font="default" size="100%">WO2019/076477Al pending. Dr. Palomares reports research grants from Inmunotek</style></keyword><keyword><style face="normal" font="default" size="100%">S.L., Novartis and MINECO. Dr. Palomares has received fees for giving scientific</style></keyword><keyword><style face="normal" font="default" size="100%">lectures or participation in Advisory Boards from Allergy Therapeutics, Amgen,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Diater, GlaxoSmithKline, S.A, Inmunotek S.L, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genzyme and Stallergenes. Dr. Schwarze reports personal fees from MYLAN,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and as EAACI Secretary General involved in</style></keyword><keyword><style face="normal" font="default" size="100%">acquisition of industrial sponsorship as listed on EAACI website. Dr. Chaker</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants for clinical studies and research and other from Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">ALK Abello, AstraZeneca, Bencard / Allergen Therapeutics, ASIT Biotech,</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotek, Lofarma, GSK, Novartis, LETI, Roche, Sanofi Genzyme, Zeller and from</style></keyword><keyword><style face="normal" font="default" size="100%">the European Institute of Technology (EIT)</style></keyword><keyword><style face="normal" font="default" size="100%">has received travel support from the</style></keyword><keyword><style face="normal" font="default" size="100%">European Academy of Allergy and Clinical Immunology (EAACI) and DGAKI, all</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. In addition, Dr. Chaker has a patent A ratio of</style></keyword><keyword><style face="normal" font="default" size="100%">immune cells as prognostic indicator of therapeutic success in allergen-specific</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy: 17 177 681.8 not licensed at present. Dr. Heffler reports personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Sanofi, personal fees from AstraZeneca, personal fees from GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Novartis, personal fees from Circassia, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes Greer, personal fees from Nestle Purina, outside the submitted work.</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Quecchia reports personal fees from Stallergenes Greer, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. Dr. Agache reports Associate Editor Allergy and PAI. Dr. Radoslaw reports</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from Allergopharma, HAL Allergy, ALK-Abello. Dr. Jensen-Jarolim</style></keyword><keyword><style face="normal" font="default" size="100%">reports other from Biomedical Int. R + D, Vienna, grants, personal fees and other</style></keyword><keyword><style face="normal" font="default" size="100%">from Bencard Allergie, Germany, other from AllergyTherapeutics, UK, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">and other from Vifor Pharma, personal fees from Meda Pharma, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, personal fees from Dr. Schar, outside the submitted work. Dr. Jutel</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees from ALK-Abello, personal fees from Allergopharma, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Stallergenes, personal fees from Anergis, personal fees from Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, personal fees from Circassia, personal fees from Leti, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Biomay, personal fees from HAL, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Astra-Zeneka, personal fees from GSK, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, personal fees from Teva, personal fees from Vectura, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">UCB, personal fees from Takeda, personal fees from Roche, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Janssen, personal fees from Medimmune, personal fees from Chiesi, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. Dr. Klimek reports grants and personal fees from Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from MEDA/Mylan, personal fees from HAL Allergie,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from ALK Abello, grants and personal fees from LETI Pharma, grants</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from Stallergenes, grants from Quintiles, grants and personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Sanofi, grants from ASIT biotech, grants from Lofarma, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Allergy Therapeut., grants from AstraZeneca, grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, grants from Inmunotek, personal fees from Cassella med, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and Membership: AeDA, DGHNO, Deutsche</style></keyword><keyword><style face="normal" font="default" size="100%">Akademie fur Allergologie und klinische Immunologie, HNO-BV, GPA, EAACI. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Torres reports personal fees from Diater, Aimmune Therapeutics and Leti</style></keyword><keyword><style face="normal" font="default" size="100%">laboratories, grants from European Commission, MINECO and ISCIII of Spanish</style></keyword><keyword><style face="normal" font="default" size="100%">Government and SEAIC, outside the submitted work. Dr. Bonini, Dr. Chivato, Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Del Giacco, Dr. Gawlik, Dr. Gelincik, Dr. Hoffmann-Sommergruber, Dr. Knol, Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Lauerma, Dr. O&apos;Mahony, Dr. Mortz, Dr. Riggioni, Dr. Skypala, Dr. Untersmayr, Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Walusiak-Skorupa, Dr. Giovannini, Dr. Sandoval-Ruballos, Dr. Sahiner, Dr. Tomic</style></keyword><keyword><style face="normal" font="default" size="100%">Spiric, Dr. Alvaro-Lozano have nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33655519</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: As in many fields of medical care, the coronavirus disease 2019 (COVID-19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT. METHODS: Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set-up a web-based retrospective survey (SurveyMonkey((R)) ) including 27 standardized questions on practical and safety aspects on AIT in worldwide clinical routine. RESULTS: 417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID-19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID-19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). CONCLUSIONS: This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID-19 pandemic and gave no concerns regarding reduced tolerability under real-life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long-lasting negative impact on the clinical care of allergic patients.</style></abstract><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Agache, Ioana&#xD;Bonini, Matteo&#xD;Brough, Helen Annaruth&#xD;Chivato, Tomas&#xD;Del Giacco, Stefano R&#xD;Gawlik, Radoslaw&#xD;Gelincik, Asli&#xD;Hoffmann-Sommergruber, Karin&#xD;Jutel, Marek&#xD;Klimek, Ludger&#xD;Knol, Edward F&#xD;Lauerma, Antti&#xD;Ollert, Markus&#xD;O&apos;Mahony, Liam&#xD;Mortz, Charlotte G&#xD;Palomares, Oscar&#xD;Riggioni, Carmen&#xD;Schwarze, Jurgen&#xD;Skypala, Isabel&#xD;Torres, Maria Jose&#xD;Untersmayr, Eva&#xD;Walusiak-Skorupa, Jolanta&#xD;Chaker, Adam&#xD;Giovannini, Mattia&#xD;Heffler, Enrico&#xD;Jensen-Jarolim, Erika&#xD;Quecchia, Cristina&#xD;Sandoval-Ruballos, Monica&#xD;Sahiner, Umit&#xD;Tomic Spiric, Vesna&#xD;Alvaro-Lozano, Montserrat&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3504-3516. doi: 10.1111/all.14793. Epub 2021 Aug 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33655519</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8013670</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14793</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2978</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2978</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">You, S. H.</style></author><author><style face="normal" font="default" size="100%">Lee, J. W.</style></author><author><style face="normal" font="default" size="100%">Kim, E.</style></author><author><style face="normal" font="default" size="100%">Kim, Y.</style></author><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Jung, S. Y.</style></author><author><style face="normal" font="default" size="100%">Moon, J. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.&#xD;College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.&#xD;Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of Korea.&#xD;Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea.&#xD;Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">COVID-19 Pandemic and Decrease in New-Onset Asthma Incidence: National Data From Korea</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3201-3204</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/07/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">covid</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40673622</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Sang Hyuk&#xD;You, Seung-Hun&#xD;Lee, Ju Won&#xD;Kim, Eunji&#xD;Kim, Youlim&#xD;Lee, Hyun&#xD;Jung, Sun-Young&#xD;Moon, Ji-Yong&#xD;eng&#xD;6400-6431-303/National Immunization Program/&#xD;Korea Disease Control and Prevention Agency/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3201-3204. doi: 10.1111/all.16658. Epub 2025 Jul 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40673622</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590324</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16658</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>70</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">70</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caminati, M.</style></author><author><style face="normal" font="default" size="100%">Guarnieri, G.</style></author><author><style face="normal" font="default" size="100%">Marchetti, P.</style></author><author><style face="normal" font="default" size="100%">Furci, F.</style></author><author><style face="normal" font="default" size="100%">Senna, G.</style></author><author><style face="normal" font="default" size="100%">Vianello, A.</style></author><author><style face="normal" font="default" size="100%">Poli, A.</style></author><author><style face="normal" font="default" size="100%">Marchese-Ragona, R.</style></author><author><style face="normal" font="default" size="100%">Ottaviano, G.</style></author><author><style face="normal" font="default" size="100%">Marcon, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Asthma, Allergy and Clinical Immunology Section, Department of Medicine, University of Verona, Verona, Italy.&#xD;Respiratory Pathophysiology Unit, Department of Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy.&#xD;Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.&#xD;Immunology Unit University Hospital, Verona, Italy.&#xD;Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy.&#xD;Section of Hygiene and Preventive Medicine, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.&#xD;Otolaryngology Section, Department of Neuroscience, University of Padova, Padova, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">COVID-19 pandemic and environment: Not only air pollution</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3699-3701</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">pandemic</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">population density</style></keyword><keyword><style face="normal" font="default" size="100%">disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36441593</style></accession-num><notes><style face="normal" font="default" size="100%">Caminati, Marco&#xD;Guarnieri, Gabriella&#xD;Marchetti, Pierpaolo&#xD;Furci, Fabiana&#xD;Senna, Gianenrico&#xD;Vianello, Andrea&#xD;Poli, Albino&#xD;Marchese-Ragona, Rosario&#xD;Ottaviano, Giancarlo&#xD;Marcon, Alessandro&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3699-3701. doi: 10.1111/all.15394.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36441593</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9878037</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15394</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>953</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">953</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Novak, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Research Institute Hospital Doce de Octubre, Madrid, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: &quot;COVID-19 vaccine anaphylaxis: PEG or not?&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1938-1940</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/06/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34128561</style></accession-num><notes><style face="normal" font="default" size="100%">Cabanillas, Beatriz&#xD;Akdis, Cezmi A&#xD;Novak, Natalija&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1938-1940. doi: 10.1111/all.14725.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34128561</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441702</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14725</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>952</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">952</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Krantz, M. S.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Phillips, E. J.</style></author><author><style face="normal" font="default" size="100%">Stone, C. A., Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.&#xD;Pharmaceutical Sciences Department, St. Jude Children&apos;s Research Hospital, Memphis, TN, USA.&#xD;Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.&#xD;Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">COVID-19 vaccine anaphylaxis: PEG or not?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1934-1937</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/06/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Polyethylene Glycols</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34128562</style></accession-num><notes><style face="normal" font="default" size="100%">Krantz, Matthew S&#xD;Liu, Yiwei&#xD;Phillips, Elizabeth J&#xD;Stone, Cosby A Jr&#xD;eng&#xD;K12 HS026395/HS/AHRQ HHS/&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1934-1937. doi: 10.1111/all.14722.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34128562</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441754</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14722</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>951</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">951</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Novak, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Research Institute Hospital Doce de Octubre, Madrid, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF, University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">COVID-19 vaccines and the role of other potential allergenic components different from PEG. A reply to: &quot;Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1943-1944</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/06/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Excipients/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34128563</style></accession-num><notes><style face="normal" font="default" size="100%">Cabanillas, Beatriz&#xD;Akdis, Cezmi A&#xD;Novak, Natalija&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1943-1944. doi: 10.1111/all.14761.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34128563</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441644 Christine Kuhne-Center for Allergy Research and Education, European Commission Horizon 2020 Framework Programme, Cure, Novartis Research Institutes, AstraZeneca, SciBase, advisory role for Sanofi/Regeneron, GlaxoSmithKline, SciBase, and Novartis, outside the submitted work. NN and BC declare no conflicts of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14761</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>695</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">695</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Banerji, A.</style></author><author><style face="normal" font="default" size="100%">Wolfson, A. R.</style></author><author><style face="normal" font="default" size="100%">Robinson, L. B.</style></author><author><style face="normal" font="default" size="100%">McMahon, A. E.</style></author><author><style face="normal" font="default" size="100%">Cogan, A. S.</style></author><author><style face="normal" font="default" size="100%">Saff, R. R.</style></author><author><style face="normal" font="default" size="100%">Blumenthal, K. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">COVID-19 vaccines tolerated in patients with paclitaxel and docetaxel allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1048-1051</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/11/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Docetaxel/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Paclitaxel/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">Peg</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV</style></keyword><keyword><style face="normal" font="default" size="100%">docetaxel</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">paclitaxel</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Massachusetts General Hospital Department of Medicine Transformative Scholar</style></keyword><keyword><style face="normal" font="default" size="100%">Program.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34779000</style></accession-num><notes><style face="normal" font="default" size="100%">Banerji, Aleena&#xD;Wolfson, Anna R&#xD;Robinson, Lacey B&#xD;McMahon, Aubree E&#xD;Cogan, Amelia S&#xD;Saff, Rebecca R&#xD;Blumenthal, Kimberly G&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1048-1051. doi: 10.1111/all.15178. Epub 2021 Nov 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34779000</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8652939</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15178</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1414</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1414</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Allergy Clinical Unit, Hospital Regional Universitario de Malaga-UMA-ARADyAL, Malaga, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">622-625</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">COVID-19/*etiology/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32589296</style></accession-num><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Torres, Maria J&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):622-625. doi: 10.1111/all.14472.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32589296</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7361446 Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biomay, Circassia, ASIT Biotech Tools SA, Laboratorios LETI/LETI Pharma, MEDA Pharma/MYLAN, Anergis SA, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, GSK, Astellas Pharma Global, EUFOREA, ROXALL, NOVARTIS, SANOFI AVENTIS, Med Update Europe GmbH, and streamedup! GmbH. Dr Torres has no conflict of interest in relation to this work. Dr Akdis reports grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kuhne-Center for Allergy Research and Education, European Commission&apos;s Horizon&apos;s 2020 Framework Programme, Cure, Novartis Research Institutes, AstraZeneca, SciBase, GSK, and other from Sanofi and Regeneron.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14472</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1208</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1208</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pajno, G. B.</style></author><author><style face="normal" font="default" size="100%">Szajewska, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Human Pathology in Adult and Development Age, Pediatric Unit, University of Messina, Messina, Italy.&#xD;Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cow&apos;s milk allergy guidelines promote over-diagnosis of cow&apos;s milk disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1929-1931</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/01/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Medical Overuse</style></keyword><keyword><style face="normal" font="default" size="100%">Milk</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Milk Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33382106</style></accession-num><notes><style face="normal" font="default" size="100%">Pajno, Giovanni B&#xD;Szajewska, Hania&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1929-1931. doi: 10.1111/all.14729. Epub 2021 Jan 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33382106</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14729</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1654</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1654</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pajno, G. B.</style></author><author><style face="normal" font="default" size="100%">Szajewska, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Human Pathology in Adult and Development Age, Pediatric Unit, University of Messina, Messina, Italy.&#xD;Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cow&apos;s milk allergy guidelines promote over-diagnosis of cow&apos;s milk disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Allergy</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></alt-periodical><pages><style face="normal" font="default" size="100%">1929-1931</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/01/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Medical Overuse</style></keyword><keyword><style face="normal" font="default" size="100%">Milk</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Milk Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33382106</style></accession-num><notes><style face="normal" font="default" size="100%">Pajno, Giovanni B&#xD;Szajewska, Hania&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1929-1931. doi: 10.1111/all.14729. Epub 2021 Jan 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33382106</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14729</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>458</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">458</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Valluzzi, R. L.</style></author><author><style face="normal" font="default" size="100%">Riccardi, C.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Piscitelli, A. L.</style></author><author><style face="normal" font="default" size="100%">Calandrelli, V.</style></author><author><style face="normal" font="default" size="100%">Dahdah, L.</style></author><author><style face="normal" font="default" size="100%">Fierro, V.</style></author><author><style face="normal" font="default" size="100%">Mennini, M.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Translational Research in Paediatric Specialities Area, Allergy Unit, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cow&apos;s milk and egg protein threshold dose distributions in children tolerant to beef, baked milk, and baked egg</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3052-3060</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/06/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Egg Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Milk/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">challenge tests</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35652800</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The use of eliciting doses (EDs) for food allergens is necessary to inform individual dietary advice and food allergen risk-management. The Eliciting Dose 01 (ED01) for milk and egg, calculated from populations of allergic subjects undergoing oral food challenges (OFCs), are 0.2 mg total protein. The respective Eliciting Dose 05 (ED05) is 2.4 mg for milk and 2.3 mg for egg. As about 70% children allergic to such foods may tolerate them when baked, we sought to verify the EDs of that subpopulation of milk and egg-allergic children. METHODS: We retrospectively assessed consecutive OFC for fresh milk and egg between January 2018 and December 2020 in a population of baked food-tolerant children. RESULTS: Among 288 children (median age 56 - IQR 36-92.5 months, 67.1% male) included, 87 (30.2%) returned positive OFC results, 38 with milk and 49 with egg. The most conservative ED01 was 0.3 mg total protein (IQR 0.03-2.9) for milk and 14.4 mg total protein (IQR 3.6-56.9) for egg. The respective ED05 was 4.2 (IQR 0.9-19.6) mg for milk and 87.7 (IQR 43-179) mg for egg. Such thresholds are, respectively, 1.5 (milk ED01), 1.75 (milk ED05), 72 (egg ED01), and 38.35 (egg ED05) times higher than the currently used thresholds. CONCLUSIONS: The subpopulation of children allergic to milk and egg, but tolerant to baked proteins, displays higher reactivity thresholds than the general population of children allergic to milk and egg. Their risk stratification, in both individual and population terms, should consider this difference. In baked milk-tolerant children, milk causes reactions at lower doses than egg in our group of egg-tolerant children. This could be associated with the relative harmlessness of egg compared with milk in the determinism of fatal anaphylactic reactions in children.</style></abstract><notes><style face="normal" font="default" size="100%">Valluzzi, Rocco Luigi&#xD;Riccardi, Carla&#xD;Arasi, Stefania&#xD;Piscitelli, Anna Lucia&#xD;Calandrelli, Veronica&#xD;Dahdah, Lamia&#xD;Fierro, Vincenzo&#xD;Mennini, Maurizio&#xD;Fiocchi, Alessandro&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3052-3060. doi: 10.1111/all.15397. Epub 2022 Jun 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35652800</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9796240</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15397</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2368</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2368</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Tan, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Inflammation and Allergic Diseases Research Unit, Affiliated Hospital of Southwest Medical University, Luzhou, China.&#xD;The School of Basic Medical Sciences, Southwest Medical University, Luzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">cRARalpha: Derailleur nuclear retinoic acid chain to TCR</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1383-1385</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/01/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Antigen, T-Cell/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Tretinoin</style></keyword><keyword><style face="normal" font="default" size="100%">Retinoic acid</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">signal transduction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38240138</style></accession-num><notes><style face="normal" font="default" size="100%">Li, Xingjie&#xD;Tan, Jinzhuo&#xD;Zhang, Zongde&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1383-1385. doi: 10.1111/all.16034. Epub 2024 Jan 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38240138</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16034</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>433</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">433</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Awan, S. F.</style></author><author><style face="normal" font="default" size="100%">Haque, T. T.</style></author><author><style face="normal" font="default" size="100%">Kubala, S. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CRISPR screening reveals mechanisms of IgE+ B-cell constraint</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3163-3164</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/06/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">*Clustered Regularly Interspaced Short Palindromic Repeats</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Plasma Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgE</style></keyword><keyword><style face="normal" font="default" size="100%">B cell</style></keyword><keyword><style face="normal" font="default" size="100%">Crispr</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">plasma cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35708917</style></accession-num><notes><style face="normal" font="default" size="100%">Awan, Seemal F&#xD;Haque, Tamara T&#xD;Kubala, Stephanie A&#xD;eng&#xD;Comment&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3163-3164. doi: 10.1111/all.15409. Epub 2022 Jun 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35708917</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15409</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1898</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1898</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Awan, S. F.</style></author><author><style face="normal" font="default" size="100%">Haque, T. T.</style></author><author><style face="normal" font="default" size="100%">Kubala, S. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CRISPR screening reveals mechanisms of IgE+ B-cell constraint</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3163-3164</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/06/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">*Clustered Regularly Interspaced Short Palindromic Repeats</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Plasma Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgE</style></keyword><keyword><style face="normal" font="default" size="100%">B cell</style></keyword><keyword><style face="normal" font="default" size="100%">Crispr</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">plasma cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35708917</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract -</style></abstract><notes><style face="normal" font="default" size="100%">Awan, Seemal F&#xD;Haque, Tamara T&#xD;Kubala, Stephanie A&#xD;eng&#xD;Comment&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3163-3164. doi: 10.1111/all.15409. Epub 2022 Jun 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35708917</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15409</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2639</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2639</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Demir, H.</style></author><author><style face="normal" font="default" size="100%">Radauer, C.</style></author><author><style face="normal" font="default" size="100%">Strobl, M. R.</style></author><author><style face="normal" font="default" size="100%">Scheurer, S.</style></author><author><style face="normal" font="default" size="100%">Kinaciyan, T.</style></author><author><style face="normal" font="default" size="100%">Bohle, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Molecular Allergology, Paul-Ehrlich-Institute, Langen, Germany.&#xD;Department of Dermatology, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cross-protection of allergen immunotherapy-induced antibodies to related allergens requires a high degree of structural identity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">785-794</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/09/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cross Reactions/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Plant/immunology/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">*Plant Proteins/immunology/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Research Cluster, Country of Lower Austria, and Medical University of</style></keyword><keyword><style face="normal" font="default" size="100%">Vienna, Austria, during the conduct of the study and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AllergenOnline outside the submitted work. The other authors have nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39311416</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In contrast to sublingual immunotherapy (SLIT) with recombinant Mal d 1 (rMal d 1-SLIT), SLIT with rBet v 1 (rBet v 1-SLIT) induced Mal d 1-cross-reactive antibodies without IgE-blocking activity. To elucidate whether the development of cross-protective IgG responses depends on the degree of molecular identity of allergens we compared the cross-reactivity, cross-blocking activity, and affinity of SLIT-induced antibodies with allergens of varying amino acid sequence identities to Bet v 1 and Mal d 1, namely Cor a 1.04 (hazelnut), Pru av 1 (cherry), and Dau c 1 (carrot). METHODS: Allergen-specific antibodies were quantified by ELISA. IgE blocking was analyzed by inhibition of allergen-induced basophil activation and IgE-facilitated allergen-presentation to T cells. The affinity of SLIT-induced antibodies was studied by acidic dissociation ELISA and competition ELISA. Identical surface areas on allergens were predicted using an in-house designed script based on structural alignments. RESULTS: rBet v 1-SLIT-induced IgG antibodies cross-reacted with all allergens except Dau c 1. rMal d 1-SLIT-induced antibodies predominantly cross-reacted with Pru av 1 and displayed significantly higher IgE blocking to Pru av 1 than rBet v 1-SLIT-induced antibodies. rMal d 1-SLIT-induced IgG1 showed higher affinity to Mal d 1 and Pru av 1. Surface analysis revealed 84% identical area on Mal d 1 and Pru av 1. Furthermore, we identified two surface areas potentially containing epitopes present on these allergens and absent on Bet v 1. CONCLUSION: In summary, our findings suggest that a relatively high threshold of similarity is required to establish effective cross-blocking antibodies to related allergens. Apparently, the structural identity between Bet v 1 and Mal d 1 is below this threshold. Therefore, this study may explain why immunotherapy with birch pollen allergen often fails to reduce birch pollen-related apple allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Demir, Hilal&#xD;Radauer, Christian&#xD;Strobl, Maria R&#xD;Scheurer, Stephan&#xD;Kinaciyan, Tamar&#xD;Bohle, Barbara&#xD;eng&#xD;Austrian Science Fund/&#xD;Danube Allergy Research Cluster/&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):785-794. doi: 10.1111/all.16323. Epub 2024 Sep 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39311416</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891415</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16323</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1418</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1418</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nkurunungi, G.</style></author><author><style face="normal" font="default" size="100%">Mpairwe, H.</style></author><author><style face="normal" font="default" size="100%">Versteeg, S. A.</style></author><author><style face="normal" font="default" size="100%">van Diepen, A.</style></author><author><style face="normal" font="default" size="100%">Nassuuna, J.</style></author><author><style face="normal" font="default" size="100%">Kabagenyi, J.</style></author><author><style face="normal" font="default" size="100%">Nambuya, I.</style></author><author><style face="normal" font="default" size="100%">Sanya, R. E.</style></author><author><style face="normal" font="default" size="100%">Nampijja, M.</style></author><author><style face="normal" font="default" size="100%">Serna, S.</style></author><author><style face="normal" font="default" size="100%">Reichardt, N. C.</style></author><author><style face="normal" font="default" size="100%">Hokke, C. H.</style></author><author><style face="normal" font="default" size="100%">Webb, E. L.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Yazdanbakhsh, M.</style></author><author><style face="normal" font="default" size="100%">Elliott, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, Uganda.&#xD;Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.&#xD;Departments of Experimental Immunology and of Otorhinolaryngology, Amsterdam University Medical Centers (AMC), Amsterdam, The Netherlands.&#xD;Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.&#xD;College of Health Sciences, Makerere University, Kampala, Uganda.&#xD;Glycotechnology Laboratory, Centro de Investigacion Cooperativa en Biomateriales (CIC biomaGUNE), San Sebastian, Spain.&#xD;Centro de Investigacion Biomedica en Red en Bioingenieria, Biomateriales y Nanomedicina (CIBER-BBN), San Sebastian, Spain.&#xD;Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, MRC Tropical Epidemiology Group, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cross-reactive carbohydrate determinant-specific IgE obscures true atopy and exhibits ⍺-1,3-fucose epitope-specific inverse associations with asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">233-246</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/06/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Carbohydrates</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">Epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">*Fucose</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Schistosoma mansoni</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">cross-reactive carbohydrate determinant</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-1,3-fucose</style></keyword><keyword><style face="normal" font="default" size="100%">beta-1,2-xylose</style></keyword><keyword><style face="normal" font="default" size="100%">for Chronic Disease Research, Royal Society of Tropical Medicine and Hygiene and</style></keyword><keyword><style face="normal" font="default" size="100%">European Academy of Allergy and Clinical Immunology, during the conduct of the</style></keyword><keyword><style face="normal" font="default" size="100%">study. Harriet Mpairwe reports a grant from the Wellcome Trust, during the</style></keyword><keyword><style face="normal" font="default" size="100%">conduct of the study. Alison Elliott reports grants from the Wellcome Trust and</style></keyword><keyword><style face="normal" font="default" size="100%">the Medical research Council, UK, during the conduct of the study. Richard Sanya</style></keyword><keyword><style face="normal" font="default" size="100%">reports a grant from Alliance for Accelerating Excellence in Science in Africa</style></keyword><keyword><style face="normal" font="default" size="100%">(AESA), outside the submitted work. Ronald van Ree reports personal fees from HAL</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy BV and Thermo Fisher Scientific, outside the submitted work, and has</style></keyword><keyword><style face="normal" font="default" size="100%">consultant agreements with HAL Allergy BV, Citeq BV and Angany Inc The rest of</style></keyword><keyword><style face="normal" font="default" size="100%">the authors declare that they have no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32568414</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In high-income, temperate countries, IgE to allergen extracts is a risk factor for, and mediator of, allergy-related diseases (ARDs). In the tropics, positive IgE tests are also prevalent, but rarely associated with ARD. Instead, IgE responses to ubiquitous cross-reactive carbohydrate determinants (CCDs) on plant, insect and parasite glycoproteins, rather than to established major allergens, are dominant. Because anti-CCD IgE has limited clinical relevance, it may impact ARD phenotyping and assessment of contribution of atopy to ARD. METHODS: Using an allergen extract-based test, a glycan and an allergen (glyco)protein microarray, we mapped IgE fine specificity among Ugandan rural Schistosoma mansoni (Sm)-endemic communities, proximate urban communities, and importantly in asthmatic and nonasthmatic schoolchildren. RESULTS: Overall, IgE sensitization to extracts was highly prevalent (43%-73%) but allergen arrays indicated that this was not attributable to established major allergenic components of the extracts (0%-36%); instead, over 40% of all participants recognized CCD-bearing components. Using glycan arrays, we dissected IgE responses to specific glycan moieties and found that reactivity to classical CCD epitopes (core beta-1,2-xylose, alpha-1,3-fucose) was positively associated with sensitization to extracts, rural environment and Sm infection, but not with skin reactivity to extracts or sensitization to their major allergenic components. Interestingly, we discovered that reactivity to only a subset of core alpha-1,3-fucose-carrying N-glycans was inversely associated with asthma. CONCLUSIONS: CCD reactivity is not just an epiphenomenon of parasite exposure hampering specificity of allergy diagnostics; mechanistic studies should investigate whether specific CCD moieties identified here are implicated in the protective effect of certain environmental exposures against asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Nkurunungi, Gyaviira&#xD;Mpairwe, Harriet&#xD;Versteeg, Serge A&#xD;van Diepen, Angela&#xD;Nassuuna, Jacent&#xD;Kabagenyi, Joyce&#xD;Nambuya, Irene&#xD;Sanya, Richard E&#xD;Nampijja, Margaret&#xD;Serna, Sonia&#xD;Reichardt, Niels-Christian&#xD;Hokke, Cornelis H&#xD;Webb, Emily L&#xD;van Ree, Ronald&#xD;Yazdanbakhsh, Maria&#xD;Elliott, Alison M&#xD;eng&#xD;MC_UU_00027/5/MRC_/Medical Research Council/United Kingdom&#xD;102512/WT_/Wellcome Trust/United Kingdom&#xD;095778/WT_/Wellcome Trust/United Kingdom&#xD;107743/WT_/Wellcome Trust/United Kingdom&#xD;102512/Z/13/Z/WT_/Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):233-246. doi: 10.1111/all.14469. Epub 2020 Jul 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32568414</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7610925</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14469</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3197</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3197</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Port, H.</style></author><author><style face="normal" font="default" size="100%">Ghazanfar, M. N.</style></author><author><style face="normal" font="default" size="100%">Zhang, D. G.</style></author><author><style face="normal" font="default" size="100%">Borg, B.</style></author><author><style face="normal" font="default" size="100%">Egeberg, A.</style></author><author><style face="normal" font="default" size="100%">Thyssen, J. P.</style></author><author><style face="normal" font="default" size="100%">Nielsen, S. H.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ImmunoScience, Nordic Bioscience, Herlev, Denmark.&#xD;Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Crosslinked Fibrin Fragment (X-FIB) as a Biomarker for Endotype Differentiation and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41410205</style></accession-num><notes><style face="normal" font="default" size="100%">Port, Helena&#xD;Ghazanfar, Misbah Noshela&#xD;Zhang, Ditte Georgina&#xD;Borg, Bea&#xD;Egeberg, Alexander&#xD;Thyssen, Jacob Pontoppidan&#xD;Nielsen, Signe Holm&#xD;Thomsen, Simon Francis&#xD;eng&#xD;Innovationsfonden/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec 18. doi: 10.1111/all.70196.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41410205</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70196</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3169</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3169</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jensen, R. K.</style></author><author><style face="normal" font="default" size="100%">Miehe, M.</style></author><author><style face="normal" font="default" size="100%">Gandini, R.</style></author><author><style face="normal" font="default" size="100%">Jorgensen, M. H.</style></author><author><style face="normal" font="default" size="100%">Spillner, E.</style></author><author><style face="normal" font="default" size="100%">Andersen, G. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.&#xD;Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.&#xD;Immunological Biotechnology, Department of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cryo-EM Structure of FcepsilonRI Bound IgE Reveals Multiple Defined Conformations of the Fab-Fc Hinge</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">FcepsilonRI</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergen recognition</style></keyword><keyword><style face="normal" font="default" size="100%">antibody hinge</style></keyword><keyword><style face="normal" font="default" size="100%">structure</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41199488</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IgE is the central driver of allergic responses. Prior studies have defined the conformation of the IgE Fc fragment bound to the FcepsilonRIalpha ectodomain and the dynamic properties of the IgE Fc. It remains unknown, how these prior studies translate to the complex of a full antibody including the Fab arms with the receptor. METHODS: For structural analysis, crystallography, cryo-EM and negative stain EM (ns-EM) were combined. IgE variants were analyzed by mediator release and CD23 binding assays. RESULTS: An ensemble of 10 cryo-EM structures of the full-size IgE FcepsilonRIalpha complex was obtained revealing that the receptor bound IgE adopts a pronounced T-like conformation. Either Fab arm may rotate up to 40 degrees . Two additional conformations with different arrangements of the Fab arms were captured in ns-EM. The introduction of additional flexibility into the Fab-Fc hinge does not compromise the biological activity of IgE, suggesting that the observed conformations of the IgE Fab-Fc hinge exhibit equivalent biological function. Comparison of the full IgE receptor complex with recent cryo-EM structures of the intact receptor reveals that FcepsilonRI conformations differ markedly by the orientation of the ectodomain. Hence, our ensemble of IgE FcepsilonRIalpha structures including the Fab arms enabled critical evaluation of FcepsilonRI conformations. CONCLUSION: Our data reveal the architecture of a full-size IgE antibody bound to its receptor and a new layer of dynamics in FcepsilonRIalpha bound IgE on top of the well-established IgE Fc conformations. Development of novel anti-IgE therapeutics may take into account these properties of FcepsilonRIalpha bound IgE.</style></abstract><notes><style face="normal" font="default" size="100%">Jensen, Rasmus K&#xD;Miehe, Michaela&#xD;Gandini, Rosaria&#xD;Jorgensen, Martin H&#xD;Spillner, Edzard&#xD;Andersen, Gregers R&#xD;eng&#xD;Danmarks Frie Forskningsfond/&#xD;Denmark&#xD;Allergy. 2025 Nov 6. doi: 10.1111/all.70132.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41199488</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70132</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3009</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3009</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Castaing-Lasvignottes, M. E.</style></author><author><style face="normal" font="default" size="100%">Bourgoin, P.</style></author><author><style face="normal" font="default" size="100%">Carsin, A.</style></author><author><style face="normal" font="default" size="100%">Dubus, J. C.</style></author><author><style face="normal" font="default" size="100%">Busnel, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Global Research Organization, Beckman Coulter Life Sciences, Marseille, France.&#xD;C2VN, INSERM 1263, INRAE 1260, Aix-Marseille Universite, Marseille, France.&#xD;Department of Pediatric Emergency Medicine, Saint Joseph Hospital, Marseille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cryopreservation Between Sample Processing and Analysis in Streamlined Basophil Activation Test</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3205-3208</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/09/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40899471</style></accession-num><notes><style face="normal" font="default" size="100%">Castaing-Lasvignottes, Marie-Elise&#xD;Bourgoin, Penelope&#xD;Carsin, Ania&#xD;Dubus, Jean-Christophe&#xD;Busnel, Jean-Marc&#xD;eng&#xD;Beckman Coulter Foundation/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3205-3208. doi: 10.1111/all.70029. Epub 2025 Sep 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40899471</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70029</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3100</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3100</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Castaing-Lasvignottes, M. E.</style></author><author><style face="normal" font="default" size="100%">Bourgoin, P.</style></author><author><style face="normal" font="default" size="100%">Carsin, A.</style></author><author><style face="normal" font="default" size="100%">Dubus, J. C.</style></author><author><style face="normal" font="default" size="100%">Busnel, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Global Research Organization, Beckman Coulter Life Sciences, Marseille, France.&#xD;C2VN, INSERM 1263, INRAE 1260, Aix-Marseille Universite, Marseille, France.&#xD;Department of Pediatric Emergency Medicine, Saint Joseph Hospital, Marseille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cryopreservation Between Sample Processing and Analysis in Streamlined Basophil Activation Test</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3205-3208</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/09/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40899471</style></accession-num><notes><style face="normal" font="default" size="100%">Castaing-Lasvignottes, Marie-Elise&#xD;Bourgoin, Penelope&#xD;Carsin, Ania&#xD;Dubus, Jean-Christophe&#xD;Busnel, Jean-Marc&#xD;eng&#xD;Beckman Coulter Foundation/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3205-3208. doi: 10.1111/all.70029. Epub 2025 Sep 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40899471</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70029</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1950</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1950</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, S.</style></author><author><style face="normal" font="default" size="100%">Kim, Y.</style></author><author><style face="normal" font="default" size="100%">Kim, Y. S.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Noh, M.</style></author><author><style face="normal" font="default" size="100%">Kwon, Y. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea.&#xD;R&amp;D Department, Curacle Co. Ltd, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CU06-1004 alleviates vascular hyperpermeability in a murine model of hereditary angioedema by protecting the endothelium</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1333-1346</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/02/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/drug therapy/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/genetics/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bradykinin/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium</style></keyword><keyword><style face="normal" font="default" size="100%">Cu06-1004</style></keyword><keyword><style face="normal" font="default" size="100%">bradykinin</style></keyword><keyword><style face="normal" font="default" size="100%">endothelial cell</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">vascular</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36789476</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Over-release of the vasoactive peptide bradykinin (BK) due to mutation in the SERPING1 gene is the leading cause of hereditary angioedema (HAE). BK directly activates endothelial cells and increases vascular permeability by disrupting the endothelial barrier, leading to angioedema affecting face, lips, extremities, gastrointestinal tract, and larynx. Although various pharmacological treatment options for HAE became available during the last decade, they are presently limited and pose a major economic burden on patients. To identify additional therapeutic options for HAE, we evaluated the effect of CU06-1004, an endothelial dysfunction blocker, on BK-induced vascular hyperpermeability and the HAE murine model. METHODS: To investigate the effect of CU06-1004 on BK-induced vascular hyperpermeability in vivo, we pre-administrated WT mice with the drug and then induced vascular leakage through intravenous injection of BK and observed vascular alternation. Then, SERPING1 deficient mice were used for a HAE murine model. For an in vitro model, the HUVEC monolayer was pre-treated with CU06-1004 and then stimulated with BK. RESULTS: Bradykinin disrupted the endothelial barrier and formed interendothelial cell gaps, leading to hyperpermeability in vivo and in vitro. However, CU06-1004 treatment protected the endothelial barrier by suppressing Src and myosin light chain activation via BK and alleviated hyperpermeability. CONCLUSION: Our study shows that CU06-1004 oral administration significantly reduced vascular hyperpermeability in the HAE murine model by protecting the endothelial barrier function against BK stimulation. Therefore, protecting endothelium against BK with CU06-1004 could serve as a potential prophylactic/therapeutic approach for HAE patients.</style></abstract><notes><style face="normal" font="default" size="100%">Lee, Sunghye&#xD;Kim, Yeomyeong&#xD;Kim, Ye-Seul&#xD;Zhang, Haiying&#xD;Noh, Minyoung&#xD;Kwon, Young-Guen&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1333-1346. doi: 10.1111/all.15674. Epub 2023 Mar 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36789476</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15674</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>821</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">821</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cabrera, M.</style></author><author><style face="normal" font="default" size="100%">Ryan, D.</style></author><author><style face="normal" font="default" size="100%">Angier, E.</style></author><author><style face="normal" font="default" size="100%">Losappio, L.</style></author><author><style face="normal" font="default" size="100%">Flokstra-de Blok, B. M. J.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Purushotam, D.</style></author><author><style face="normal" font="default" size="100%">Bosnic-Anticevich, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, Hospital los Madronos, Brunete, Madrid, Spain.&#xD;Usher Institute, University of Edinburgh, UK.&#xD;Primary Care and Population Sciences, University of Southampton, Southampton, UK.&#xD;Allergy and Immunology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.&#xD;General Practitioners Research Institute, Groningen, the Netherlands.&#xD;GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;Department of Pediatric Pulmonology and Pediatric Allergology, University Medical Center Groningen, Beatrix Children&apos;s Hospital, University of Groningen, Groningen, The Netherlands.&#xD;Department of Internal Medicine, Allergology and Clinical Immunology, Silesian University of Medicine, Katowice, Poland.&#xD;Mandore Sattelite Hospital, Jodhpur, India.&#xD;Quality Use of Respiratory Medicines Group, Woolcock Institute of Medical Research, University of Sydney, NSW, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current allergy educational needs in primary care. Results of the EAACI working group on primary care survey exploring the confidence to manage and the opportunity to refer patients with allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">378-387</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/09/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Referral and Consultation</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword><keyword><style face="normal" font="default" size="100%">learning methods</style></keyword><keyword><style face="normal" font="default" size="100%">primary care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34498282</style></accession-num><abstract><style face="normal" font="default" size="100%">The aim of this survey was to explore the specific educational needs of a cohort of European GPs with regards to allergy training so that future educational initiatives may better support the delivery of allergy services in primary care. METHOD: This study took the form of a cross-sectional observational study in which a structured electronic questionnaire was distributed to primary care providers, in eight languages, across 8 European countries between September 2019 and November 2019. Data associated with demographic parameters, professional qualifications, type of employment, level of confidence regarding competencies for diagnosis and treatment of allergic diseases, referral of patients to allergist and preferred method of learning and assessment were collected. A 5-point Likert scale was used to assess level of confidence. Exploratory analysis was carried out. RESULTS: A total of 687 responses were available for analysis, with 99.3% of responders working within Europe. 70.1% of participants were female; and 48.0% and 48.0% of participants respectively had received some undergraduate and/or postgraduate allergy education. Confidence in dealing with different aspect of allergy management differed between countries. The main reason for specialist referral was a perceived need for tertiary assessment (54.3%), and the main barrier for referral was the consideration that the patient&apos;s condition could be appropriately diagnosed and treated in a primary care facility. Up to 44.7% and 55.3% of participants reported that they preferred e-Learning over traditional learning. CONCLUSIONS: This study identified the specific areas of skills training and educational needs of GPs in managing allergic conditions in primary care, and provided insights into possible strategies for more feasible and cost-effective approaches.</style></abstract><notes><style face="normal" font="default" size="100%">Cabrera, Martha&#xD;Ryan, Dermot&#xD;Angier, Elisabeth&#xD;Losappio, Laura&#xD;Flokstra-de Blok, Bertine M J&#xD;Gawlik, Radoslaw&#xD;Purushotam, Dan&#xD;Bosnic-Anticevich, Sinthia&#xD;eng&#xD;Observational Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):378-387. doi: 10.1111/all.15084. Epub 2021 Sep 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34498282</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15084</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1431</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1431</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Rovati, G. E.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Lukasik, Z.</style></author><author><style face="normal" font="default" size="100%">Sava, F.</style></author><author><style face="normal" font="default" size="100%">Angelina, A.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Sanak, M.</style></author><author><style face="normal" font="default" size="100%">Dahlen, S. E.</style></author><author><style face="normal" font="default" size="100%">Woszczek, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Pharmaceutical Sciences, University of Milan, Milan, Italy.&#xD;Department of Respiratory Medicine &amp; Allergology, Skane University Hospital, Lund, Sweden.&#xD;Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.&#xD;Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Child Life and Health and Centre for Inflammation Research, The University of Edinburgh, Edinburgh, UK.&#xD;London North Genomic Laboratory Hub, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Department of Medicine, Jagiellonian University Medical College, Krakow, Poland.&#xD;Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.&#xD;Centre for Allergy Research, Karolinska Institute, Stockholm, Sweden.&#xD;MRC/Asthma UK Centre in Allergic Mechanisms of Asthma, School of Immunology &amp; Microbial Sciences, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">114-130</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/04/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Eicosanoids</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Leukotrienes</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">lipid mediators</style></keyword><keyword><style face="normal" font="default" size="100%">prostaglandins</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32279330</style></accession-num><abstract><style face="normal" font="default" size="100%">Eicosanoids are biologically active lipid mediators, comprising prostaglandins, leukotrienes, thromboxanes, and lipoxins, involved in several pathophysiological processes relevant to asthma, allergies, and allied diseases. Prostaglandins and leukotrienes are the most studied eicosanoids and established inducers of airway pathophysiology including bronchoconstriction and airway inflammation. Drugs inhibiting the synthesis of lipid mediators or their effects, such as leukotriene synthesis inhibitors, leukotriene receptors antagonists, and more recently prostaglandin D(2) receptor antagonists, have been shown to modulate features of asthma and allergic diseases. This review, produced by an European Academy of Allergy and Clinical Immunology (EAACI) task force, highlights our current understanding of eicosanoid biology and its role in mediating human pathology, with a focus on new findings relevant for clinical practice, development of novel therapeutics, and future research opportunities.</style></abstract><notes><style face="normal" font="default" size="100%">Sokolowska, Milena&#xD;Rovati, G Enrico&#xD;Diamant, Zuzana&#xD;Untersmayr, Eva&#xD;Schwarze, Jargen&#xD;Lukasik, Zuzanna&#xD;Sava, Florentina&#xD;Angelina, Alba&#xD;Palomares, Oscar&#xD;Akdis, Cezmi A&#xD;O&apos;Mahony, Liam&#xD;Sanak, Marek&#xD;Dahlen, Sven-Erik&#xD;Woszczek, Grzegorz&#xD;eng&#xD;G0900536/MRC_/Medical Research Council/United Kingdom&#xD;G1000758/MRC_/Medical Research Council/United Kingdom&#xD;MC_PC_15031/MRC_/Medical Research Council/United Kingdom&#xD;Consensus Statement&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):114-130. doi: 10.1111/all.14295.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32279330</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14295</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2162</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2162</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van Breugel, M.</style></author><author><style face="normal" font="default" size="100%">Fehrmann, R. S. N.</style></author><author><style face="normal" font="default" size="100%">Bugel, M.</style></author><author><style face="normal" font="default" size="100%">Rezwan, F. I.</style></author><author><style face="normal" font="default" size="100%">Holloway, J. W.</style></author><author><style face="normal" font="default" size="100%">Nawijn, M. C.</style></author><author><style face="normal" font="default" size="100%">Fontanella, S.</style></author><author><style face="normal" font="default" size="100%">Custovic, A.</style></author><author><style face="normal" font="default" size="100%">Koppelman, G. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children&apos;s Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.&#xD;Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.&#xD;MIcompany, Amsterdam, the Netherlands.&#xD;Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.&#xD;Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Department of Computer Science, Aberystwyth University, Aberystwyth, UK.&#xD;National Institute for Health and Care Research Southampton Biomedical Research Centre, University Hospitals Southampton NHS Foundation Trust, Southampton, UK.&#xD;Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;National Institute for Health and Care Research Imperial Biomedical Research Centre (BRC), London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current state and prospects of artificial intelligence in allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2623-2643</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/08/16</style></edition><section><style face="normal" font="default" size="100%">2623</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Artificial Intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">Machine Learning</style></keyword><keyword><style face="normal" font="default" size="100%">Precision Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">artificial intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">deep learning</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37584170</style></accession-num><abstract><style face="normal" font="default" size="100%">The field of medicine is witnessing an exponential growth of interest in artificial intelligence (AI), which enables new research questions and the analysis of larger and new types of data. Nevertheless, applications that go beyond proof of concepts and deliver clinical value remain rare, especially in the field of allergy. This narrative review provides a fundamental understanding of the core concepts of AI and critically discusses its limitations and open challenges, such as data availability and bias, along with potential directions to surmount them. We provide a conceptual framework to structure AI applications within this field and discuss forefront case examples. Most of these applications of AI and machine learning in allergy concern supervised learning and unsupervised clustering, with a strong emphasis on diagnosis and subtyping. A perspective is shared on guidelines for good AI practice to guide readers in applying it effectively and safely, along with prospects of field advancement and initiatives to increase clinical impact. We anticipate that AI can further deepen our knowledge of disease mechanisms and contribute to precision medicine in allergy.</style></abstract><notes><style face="normal" font="default" size="100%">van Breugel, Merlijn&#xD;Fehrmann, Rudolf S N&#xD;Bugel, Marnix&#xD;Rezwan, Faisal I&#xD;Holloway, John W&#xD;Nawijn, Martijn C&#xD;Fontanella, Sara&#xD;Custovic, Adnan&#xD;Koppelman, Gerard H&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2623-2643. doi: 10.1111/all.15849. Epub 2023 Aug 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37584170</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15849</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>931</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">931</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Schulz, D.</style></author><author><style face="normal" font="default" size="100%">Oro, S.</style></author><author><style face="normal" font="default" size="100%">Li, N.</style></author><author><style face="normal" font="default" size="100%">Kolm, I.</style></author><author><style face="normal" font="default" size="100%">Lang, C.</style></author><author><style face="normal" font="default" size="100%">Ziadlou, R.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Bodenmiller, B.</style></author><author><style face="normal" font="default" size="100%">Steiger, P.</style></author><author><style face="normal" font="default" size="100%">Marzano, A.</style></author><author><style face="normal" font="default" size="100%">de Prost, N.</style></author><author><style face="normal" font="default" size="100%">Caudin, O.</style></author><author><style face="normal" font="default" size="100%">Levesque, M.</style></author><author><style face="normal" font="default" size="100%">Stoffel, C.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Maverakis, E.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute for Allergy Research (SIAF) Davos, Davos, Switzerland.&#xD;Institute for Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.&#xD;Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, Henri Mondor Hospital, Paris, France.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University Zurich, Zurich, Switzerland.&#xD;Department of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland.&#xD;Dermatology Unit, Fondazione IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Department of Pathophysiology and Transplantation, Universita degli Studi di Milano, Milan, Italy.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Dermatology, University of California, Davis, Sacramento, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID-19 patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">595-608</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/06/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">*Exanthema</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pharmaceutical Preparations</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus</style></keyword><keyword><style face="normal" font="default" size="100%">drug-induced maculopapular exanthema</style></keyword><keyword><style face="normal" font="default" size="100%">Christine Kuhne-Center for Allergy Research and Education, European Commission</style></keyword><keyword><style face="normal" font="default" size="100%">Horizon 2020 Framework Programme, Novartis Research Institutes, Astra Zeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">SciBase, Glaxo Smith-Kline, and is on the board of Sanofi/Regeneron, Scibase, and</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis. PS-G reports lecture honorarium from Astra Zeneca and Glaxo</style></keyword><keyword><style face="normal" font="default" size="100%">Smith-Kline, YM, DS, SO, NL, IK, CL, RZ, GT, BB, PS, MA, NDP, OC, ML, CS, EM and</style></keyword><keyword><style face="normal" font="default" size="100%">M-CB have nothing to declare within the scope of this work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34157151</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Coronavirus disease-2019 (COVID-19) has been associated with cutaneous findings, some being the result of drug hypersensitivity reactions such as maculopapular drug rashes (MDR). The aim of this study was to investigate whether COVID-19 may impact the development of the MDR. METHODS: Blood and skin samples from COVID-19 patients (based on a positive nasopharyngeal PCR) suffering from MDR (COVID-MDR), healthy controls, non-COVID-19-related patients with drug rash with eosinophilia and systemic symptoms (DRESS), and MDR were analyzed. We utilized imaging mass cytometry (IMC) to characterize the cellular infiltrate in skin biopsies. Furthermore, RNA sequencing transcriptome of skin biopsy samples and high-throughput multiplexed proteomic profiling of serum were performed. RESULTS: IMC revealed by clustering analyses a more prominent, phenotypically shifted cytotoxic CD8(+) T cell population and highly activated monocyte/macrophage (Mo/Mac) clusters in COVID-MDR. The RNA sequencing transcriptome demonstrated a more robust cytotoxic response in COVID-MDR skin. However, severe acute respiratory syndrome coronavirus 2 was not detected in skin biopsies at the time point of MDR diagnosis. Serum proteomic profiling of COVID-MDR patients revealed upregulation of various inflammatory mediators (IL-4, IL-5, IL-6, TNF, and IFN-gamma), eosinophil and Mo/Mac -attracting chemokines (MCP-2, MCP-3, MCP-4 and CCL11). Proteomics analyses demonstrated a massive systemic cytokine storm in COVID-MDR compared with the relatively milder cytokine storm observed in DRESS, while MDR did not exhibit such features. CONCLUSION: A systemic cytokine storm may promote activation of Mo/Mac and cytotoxic CD8(+) T cells in severe COVID-19 patients, which in turn may impact the development of MDR.</style></abstract><notes><style face="normal" font="default" size="100%">Mitamura, Yasutaka&#xD;Schulz, Daniel&#xD;Oro, Saskia&#xD;Li, Nick&#xD;Kolm, Isabel&#xD;Lang, Claudia&#xD;Ziadlou, Reihane&#xD;Tan, Ge&#xD;Bodenmiller, Bernd&#xD;Steiger, Peter&#xD;Marzano, Angelo&#xD;de Prost, Nicolas&#xD;Caudin, Olivier&#xD;Levesque, Mitchell&#xD;Stoffel, Corinne&#xD;Schmid-Grendelmeier, Peter&#xD;Maverakis, Emanual&#xD;Akdis, Cezmi A&#xD;Bruggen, Marie-Charlotte&#xD;eng&#xD;K24 AR077313/AR/NIAMS NIH HHS/&#xD;COVID-19 solidarity funds of the University Zurich/&#xD;Christine Kuhne Center for Allergy Research and education (CK Care) -Foundation/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):595-608. doi: 10.1111/all.14983. Epub 2021 Jul 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34157151</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441838</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14983</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2695</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2695</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Galleani, C.</style></author><author><style face="normal" font="default" size="100%">Penalver, M. J.</style></author><author><style face="normal" font="default" size="100%">Barranco, R.</style></author><author><style face="normal" font="default" size="100%">Garcia-Moguel, I.</style></author><author><style face="normal" font="default" size="100%">Crespo, J. F.</style></author><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain.&#xD;Instituto de Investigacion Sanitaria del Hospital 12 de Octubre (imas12), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cutaneous reactions during Helicobacter pylori eradication therapy referred to an allergy department</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">329-331</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/10/05</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39367670</style></accession-num><notes><style face="normal" font="default" size="100%">Galleani, Celine&#xD;Penalver, Maria Jose&#xD;Barranco, Ruth&#xD;Garcia-Moguel, Ismael&#xD;Crespo, Jesus F&#xD;Cabanillas, Beatriz&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):329-331. doi: 10.1111/all.16344. Epub 2024 Oct 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39367670</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16344</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3106</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3106</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ding, J.</style></author><author><style face="normal" font="default" size="100%">Cui, L.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Wei, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Piao, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Head and Neck Molecular Pathological Diagnosis, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Department of Rheumatology and Immunology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of Nasal Diseases, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The CXCL12-CXCR4 Axis Mediates Lymphocyte Immune Overactivation in IgG4-Related Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cxcl12</style></keyword><keyword><style face="normal" font="default" size="100%">Cxcr4</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4-CRS</style></keyword><keyword><style face="normal" font="default" size="100%">ScRNA-seq</style></keyword><keyword><style face="normal" font="default" size="100%">immune overactivation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41144786</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IgG4-related chronic rhinosinusitis (IgG4-CRS) is a new clinical entity characterized by nasal lesions; however, its pathogenesis remains unclear. This study aimed to reveal single-cell transcriptomic changes in patients with IgG4-CRS via single-cell RNA sequencing (scRNA-seq) and illustrate its pathogenesis at the single-cell level. METHODS: Nasal mucosal tissues from five patients with IgG4-CRS were used for unbiased scRNA-seq. Bioinformatic analysis was performed using these five samples and three published control samples. Immunohistochemical and multicolor immunofluorescence analyses were performed to validate the sequencing results. RESULTS: A total of 49,063 cells and 11 sub-clusters were identified. CXCL12 secretion increased in endothelial cells and fibroblasts, and CXCR4 was upregulated in the immune cells of IgG4-CRS. Enhanced chemotaxis mediated by the CXCL12-CXCR4 axis recruits excess immune cells and overactivation. Compared with those in the control group, the immunocompetence of CD4+ T cells and cytotoxicity of CD8+ T cells were enhanced in the IgG4-CRS group, and B cells were more differentiated to secrete IgG-type plasma cells. CONCLUSIONS: Chemotaxis of the CXCL12-CXCR4 axis plays a role in the pathogenesis of IgG4-CRS by influencing both the immune and nonimmune cells of IgG4-CRS.</style></abstract><notes><style face="normal" font="default" size="100%">Ding, Jing&#xD;Cui, Li&#xD;Wang, Chengshuo&#xD;Wei, Ming&#xD;Zhang, Yuan&#xD;Zhang, Luo&#xD;Piao, Yingshi&#xD;eng&#xD;2022-2-2054/Capital Funds for Health Improvement and Research/&#xD;Denmark&#xD;Allergy. 2025 Oct 27. doi: 10.1111/all.70124.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41144786</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70124</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2357</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2357</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ding, J.</style></author><author><style face="normal" font="default" size="100%">Hillig, C.</style></author><author><style face="normal" font="default" size="100%">White, C. W.</style></author><author><style face="normal" font="default" size="100%">Fernandopulle, N. A.</style></author><author><style face="normal" font="default" size="100%">Anderton, H.</style></author><author><style face="normal" font="default" size="100%">Kern, J. S.</style></author><author><style face="normal" font="default" size="100%">Menden, M. P.</style></author><author><style face="normal" font="default" size="100%">Mackay, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Helmholtz Zentrum Munchen-German Research Centre for Environmental Health, Institute of Computational Biology, Neuherberg, Germany.&#xD;Australian Research Council, Centre for Personalised Therapeutics Technologies, Melbourne, Victoria, Australia.&#xD;Division of Inflammation, Walter and Elisa Hall Institute, Melbourne, Victoria, Australia.&#xD;Central Clinical School, Monash University, The Alfred Hospital, Melbourne, Victoria, Australia.&#xD;Department of Dermatology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CXCL17 induces activation of human mast cells via MRGPRX2</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1609-1612</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/01/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Nerve Tissue Proteins/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, G-Protein-Coupled/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Neuropeptide/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38279626</style></accession-num><notes><style face="normal" font="default" size="100%">Ding, Jie&#xD;Hillig, Christina&#xD;White, Carl W&#xD;Fernandopulle, Nithya A&#xD;Anderton, Holly&#xD;Kern, Johannes S&#xD;Menden, Michael P&#xD;Mackay, Graham A&#xD;eng&#xD;Australian and New Zealand College of Anaesthetists/&#xD;Deutsche Forschungsgemeinschaft/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1609-1612. doi: 10.1111/all.16036. Epub 2024 Jan 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38279626</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16036</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>522</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">522</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van der Burg, N.</style></author><author><style face="normal" font="default" size="100%">Stenberg, H.</style></author><author><style face="normal" font="default" size="100%">Bjermer, L.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author><author><style face="normal" font="default" size="100%">Tufvesson, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Sciences Lund, Respiratory Medicine and Allergology, Lund University, Lund, Sweden.&#xD;Center for Primary Health Care Research, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden.&#xD;Department of Microbiology Immunology &amp; Transplantation, KU Leuven, Catholic University of Leuven, Leuven, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cysteinyl-leukotriene and prostaglandin pathways in bronchial versus alveolar lavage in allergic asthmatics</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2549-2551</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchial Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default" size="100%">Cysteine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Leukotrienes</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutic Irrigation</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchial lavage</style></keyword><keyword><style face="normal" font="default" size="100%">allergen bronchoprovocation test</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">cysteinyl-leukotriene pathway</style></keyword><keyword><style face="normal" font="default" size="100%">prostaglandin pathway</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35451080</style></accession-num><notes><style face="normal" font="default" size="100%">van der Burg, Nicole&#xD;Stenberg, Henning&#xD;Bjermer, Leif&#xD;Diamant, Zuzana&#xD;Tufvesson, Ellen&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2549-2551. doi: 10.1111/all.15319. Epub 2022 Apr 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35451080</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9546403</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15319</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1078</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1078</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McKenzie, C. I.</style></author><author><style face="normal" font="default" size="100%">Varese, N.</style></author><author><style face="normal" font="default" size="100%">Aui, P. M.</style></author><author><style face="normal" font="default" size="100%">Wines, B. D.</style></author><author><style face="normal" font="default" size="100%">Hogarth, P. M.</style></author><author><style face="normal" font="default" size="100%">Thien, F.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author><author><style face="normal" font="default" size="100%">Rolland, J. M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">van Zelm, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.&#xD;Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University, Melbourne, VIC, Australia.&#xD;Immune Therapies Group, Burnet Institute, Melbourne, Australia.&#xD;Department of Pathology, The University of Melbourne, Parkville, VIC, Australia.&#xD;Respiratory Medicine, Eastern Health, Box Hill and Monash University, Melbourne, VIC, Australia.&#xD;School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.&#xD;Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, VIC, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">CytoBas: Precision component-resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3028-3040</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/03/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Flow Cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Staining and Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">allergen tetramers</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">component-resolved diagnostics</style></keyword><keyword><style face="normal" font="default" size="100%">surface IgE</style></keyword><keyword><style face="normal" font="default" size="100%">All the other authors declare that they have no relevant conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33772805</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Diagnostic tests for allergy rely on detecting allergen-specific IgE. Component-resolved diagnostics incorporate multiple defined allergen components to improve the quality of diagnosis and patient care. OBJECTIVE: To develop a new approach for determining sensitization to specific allergen components that utilizes fluorescent protein tetramers for direct staining of IgE on blood basophils by flow cytometry. METHODS: Recombinant forms of Lol p 1 and Lol p 5 proteins from ryegrass pollen (RGP) and Api m 1 from honeybee venom (BV) were produced, biotinylated, and tetramerized with streptavidin-fluorochrome conjugates. Blood samples from 50 RGP-allergic, 41 BV-allergic, and 26 controls were incubated with fluorescent protein tetramers for flow cytometric evaluation of basophil allergen binding and activation. RESULTS: Allergen tetramers bound to and activated basophils from relevant allergic patients but not controls. Direct fluorescence staining of Api m 1 and Lol p 1 tetramers had greater positive predictive values than basophil activation for BV and RGP allergy, respectively, as defined with receiver operator characteristics (ROC) curves. Staining intensities of allergen tetramers correlated with allergen-specific IgE levels in serum. Inclusion of multiple allergens coupled with distinct fluorochromes in a single-tube assay enabled rapid detection of sensitization to both Lol p 1 and Lol p 5 in RGP-allergic patients and discriminated between controls, BV-allergic, and RGP-allergic patients. CONCLUSION: Our novel flow cytometric assay, termed CytoBas, enables rapid and reliable detection of clinically relevant allergic sensitization. The intensity of fluorescent allergen tetramer staining of basophils has a high positive predictive value for disease, and the assay can be multiplexed for a component-resolved and differential diagnostic test for allergy.</style></abstract><notes><style face="normal" font="default" size="100%">McKenzie, Craig I&#xD;Varese, Nirupama&#xD;Aui, Pei M&#xD;Wines, Bruce D&#xD;Hogarth, Philip Mark&#xD;Thien, Francis&#xD;Hew, Mark&#xD;Rolland, Jennifer M&#xD;O&apos;Hehir, Robyn E&#xD;van Zelm, Menno C&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3028-3040. doi: 10.1111/all.14832. Epub 2021 May 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33772805</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8518718</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14832</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2854</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2854</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gonzalez-Delgado, P.</style></author><author><style face="normal" font="default" size="100%">Anvari, S.</style></author><author><style face="normal" font="default" size="100%">Jimenez, A. I.</style></author><author><style face="normal" font="default" size="100%">Gallego-Velez, P.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Fortun, C.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Rodriguez, T. W.</style></author><author><style face="normal" font="default" size="100%">de la Calle, F. M.</style></author><author><style face="normal" font="default" size="100%">Fernandez, J.</style></author><author><style face="normal" font="default" size="100%">Barrachina, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Service, Alicante General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.&#xD;Clinical Medicine Department, University Miguel Hernandez, Alicante, Spain.&#xD;Division of Immunology, Allergy and Retrovirology, Department of Pediatrics, Baylor College of Medicine, Texas Children&apos;s Hospital, Houston, Texas, USA.&#xD;William T. Shearer Center for Human Immunobiology, Texas Children&apos;s Hospital, Houston, Texas, USA.&#xD;Immunology Service, Alicante General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.&#xD;Gastroenterology Service, Alicante General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cytokine Variations After Positive Oral Food Challenges in Adult-Onset Food Protein-Induced Enterocolitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2882-2885</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/03/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">adult FPIES</style></keyword><keyword><style face="normal" font="default" size="100%">adult food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">non-IgE mediated food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40145371</style></accession-num><notes><style face="normal" font="default" size="100%">Gonzalez-Delgado, Purificacion&#xD;Anvari, Sara&#xD;Jimenez, Ana I&#xD;Gallego-Velez, Paulina&#xD;Sanchez-Fortun, Cristina&#xD;Jimenez-Rodriguez, Teodorikez-Wilfox&#xD;de la Calle, Francisco Marco&#xD;Fernandez, Javier&#xD;Barrachina, Jordi&#xD;eng&#xD;ISABIAL/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2882-2885. doi: 10.1111/all.16539. Epub 2025 Mar 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40145371</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486349</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16539</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2208</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2208</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tharakan, A.</style></author><author><style face="normal" font="default" size="100%">Kumar, A.</style></author><author><style face="normal" font="default" size="100%">Allegood, J.</style></author><author><style face="normal" font="default" size="100%">Cowart, L. A.</style></author><author><style face="normal" font="default" size="100%">Conrad, D. H.</style></author><author><style face="normal" font="default" size="100%">Martin, R. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, Virginia, USA.&#xD;Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia, USA.&#xD;Hunter Holmes McGuire Veteran&apos;s Affairs Medical Center, Richmond, Virginia, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">D-2-hydroxyglutarate suppresses allergic sensitization in a murine model of experimental asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3014-3016</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Glutarates</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37408337</style></accession-num><notes><style face="normal" font="default" size="100%">Tharakan, Anuj&#xD;Kumar, Ankit&#xD;Allegood, Jeremy&#xD;Cowart, Lauren Ashley&#xD;Conrad, Daniel H&#xD;Martin, Rebecca K&#xD;eng&#xD;R01 HL151243/HL/NHLBI NIH HHS/&#xD;IK6 BX006315/BX/BLRD VA/&#xD;I01 BX000200/BX/BLRD VA/&#xD;P30 CA016059/CA/NCI NIH HHS/&#xD;UL1 TR002649/TR/NCATS NIH HHS/&#xD;T32 GM144294/GM/NIGMS NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):3014-3016. doi: 10.1111/all.15809. Epub 2023 Jul 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37408337</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10732592</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15809</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>810</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">810</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Majumdar, S.</style></author><author><style face="normal" font="default" size="100%">Bhattacharjee, S.</style></author><author><style face="normal" font="default" size="100%">Jana, T.</style></author><author><style face="normal" font="default" size="100%">Saha, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Bioinformatics, Bose Institute, Kolkata, India.&#xD;Department of Computer Science and Engineering, University of Calcutta, Kolkata, India.</style></auth-address><titles><title><style face="normal" font="default" size="100%">DAAB-V2: Updated database of allergy and asthma biomarkers</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3829-3832</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/09/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">p-Dimethylaminoazobenzene/analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default" size="100%">allergy and asthma</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory network</style></keyword><keyword><style face="normal" font="default" size="100%">relational database</style></keyword><keyword><style face="normal" font="default" size="100%">single nucleotide polymorphisms</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34543446</style></accession-num><notes><style face="normal" font="default" size="100%">Majumdar, Sreyashi&#xD;Bhattacharjee, Sudipto&#xD;Jana, Tanmoy&#xD;Saha, Sudipto&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3829-3832. doi: 10.1111/all.15100. Epub 2021 Sep 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34543446</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15100</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>858</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">858</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tramper-Stranders, G.</style></author><author><style face="normal" font="default" size="100%">Ambrozej, D.</style></author><author><style face="normal" font="default" size="100%">Arcolaci, A.</style></author><author><style face="normal" font="default" size="100%">Atanaskovic-Markovic, M.</style></author><author><style face="normal" font="default" size="100%">Boccabella, C.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Karavelia, A.</style></author><author><style face="normal" font="default" size="100%">Mingomataj, E.</style></author><author><style face="normal" font="default" size="100%">O&apos; Mahony L</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Feleszko, W.</style></author><author><style face="normal" font="default" size="100%">Eaaci Task Force on Conscious</style></author><author><style face="normal" font="default" size="100%">Rational use of Antibiotics in Allergic, Diseases</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Franciscus Gasthuis &amp; Vlietland, Rotterdam, the Netherlands.&#xD;Department of Neonatology, Erasmus Medical Center, Sophia Children&apos;s Hospital, Rotterdam, the Netherlands.&#xD;Department of Pediatric Pneumonology and Allergy, Medical University of Warsaw, Warsaw, Poland.&#xD;Doctoral School, Medical University of Warsaw, Warsaw, Poland.&#xD;Immunology Unit, University of Verona and General Hospital Borgo Roma Hospital, Verona, Italy.&#xD;Faculty of Medicine, University of Belgrade, University Children&apos;s Hospital, Belgrade, Serbia.&#xD;Department of Cardiovascular and Thoracic Sciences, Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.&#xD;National Heart and Lung Institute (NHLI), Imperial College London, London, UK.&#xD;Department of Ear-Nose-Throat surgery, General Hospital of Kozani, Kozani, Greece.&#xD;Department of Allergology &amp; Clinical Immunology &apos;Mother Theresa&apos; School of Medicine, Tirana, Albania.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland.&#xD;Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dangerous liaisons: Bacteria, antimicrobial therapies, and allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3276-3291</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/08/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial lysates</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">probiotics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34390006</style></accession-num><abstract><style face="normal" font="default" size="100%">Microbiota composition and associated metabolic activities are essential for the education and development of a healthy immune system. Microbial dysbiosis, caused by risk factors such as diet, birth mode, or early infant antimicrobial therapy, is associated with the inception of allergic diseases. In turn, allergic diseases increase the risk for irrational use of antimicrobial therapy. Microbial therapies, such as probiotics, have been studied in the prevention and treatment of allergic diseases, but evidence remains limited due to studies with high heterogeneity, strain-dependent effectiveness, and variable outcome measures. In this review, we sketch the relation of microbiota with allergic diseases, the overuse and rationale for the use of antimicrobial agents in allergic diseases, and current knowledge concerning the use of bacterial products in allergic diseases. We urgently recommend 1) limiting antibiotic therapy in pregnancy and early childhood as a method contributing to the reduction of the allergy epidemic in children and 2) restricting antibiotic therapy in exacerbations and chronic treatment of allergic diseases, mainly concerning asthma and atopic dermatitis. Future research should be aimed at antibiotic stewardship implementation strategies and biomarker-guided therapy, discerning those patients that might benefit from antibiotic therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Tramper-Stranders, Gerdien&#xD;Ambrozej, Dominika&#xD;Arcolaci, Alessandra&#xD;Atanaskovic-Markovic, Marina&#xD;Boccabella, Cristina&#xD;Bonini, Matteo&#xD;Karavelia, Aspasia&#xD;Mingomataj, Ervin&#xD;O&apos; Mahony, Liam&#xD;Sokolowska, Milena&#xD;Untersmayr, Eva&#xD;Feleszko, Wojciech&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3276-3291. doi: 10.1111/all.15046. Epub 2021 Aug 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34390006</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15046</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3170</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3170</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">King, J.</style></author><author><style face="normal" font="default" size="100%">Woodcock, A.</style></author><author><style face="normal" font="default" size="100%">Anzueto, A.</style></author><author><style face="normal" font="default" size="100%">Wilkinson, A. J. K.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Henderson, R.</style></author><author><style face="normal" font="default" size="100%">Fulmali, S.</style></author><author><style face="normal" font="default" size="100%">Plank, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environment, Health, Safety and Sustainability, GSK, London, UK.&#xD;University of Manchester, Manchester, UK.&#xD;South Texas Veterans Health Care System, University of Texas Health San Antonio, San Antonio, Texas, USA.&#xD;Department of Respiratory Medicine, East and North Hertfordshire NHS Trust, Stevenage, UK.&#xD;Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.&#xD;GSK, General Medicines, Mumbai, India.&#xD;Global Medical Affairs, General Medicines, GSK, Gold Coast, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Decarbonising Respiratory Care: The Impact of a Low-Carbon Salbutamol Pressurised Metered-Dose Inhalers</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">dry-powder inhaler</style></keyword><keyword><style face="normal" font="default" size="100%">greenhouse gas emissions</style></keyword><keyword><style face="normal" font="default" size="100%">metered-dose inhaler</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41199473</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Rapid reductions in greenhouse gas (GHG) emissions are vital to combat climate change. Healthcare systems contribute ~5% of global GHG emissions, with pressurised metered-dose inhalers (pMDIs) a significant contributor owing to their hydrofluorocarbon propellants. This study compared GHG emissions of a salbutamol pMDI using a low-carbon propellant in clinical development, hydrofluoroalkane (HFA)-152a, against current salbutamol inhalers. METHODS: Three &apos;cradle-to-grave&apos; lifecycle analyses compared GHG emissions of salbutamol pMDIs with HFA-152a and HFA-134a, and salbutamol dry-powder inhaler (DPI). Over 600 individual emission factors were calculated from &gt; 2000 data points, and categorised into Active Pharmaceutical Ingredients Manufacture, Micronisation, Device, Formulation/Packaging, Use, Distribution and End-of-Life stages. 2023 manufacturing and supply data were collected from Algeria, Australia, Canada, France, Poland, Romania and Saudi Arabia. Carbon footprints were independently verified by the Carbon Trust. RESULTS: Mean total carbon footprint per salbutamol inhaler (based on 100-year global warming potential [GWP100]) was 26.91, 2.06 and 0.69 kgCO(2)e for HFA-134a pMDI, HFA-152a pMDI and DPI, respectively. This equated to a 92% reduction in total emissions for HFA-152a versus HFA-134a. Most pMDI emissions came from the Use stage (HFA-134a: 21.48 kgCO(2)e; HFA-152a: 1.45 kgCO(2)e). Per actuation, emissions were 135, 10 and 11 gCO(2)e, respectively. For each pMDI, GHG emissions were similar across countries. CONCLUSIONS: The low-GWP propellant, HFA-152a is expected to achieve &gt; 90% reduction in the carbon footprint of salbutamol pMDI versus the currently used HFA-134a. The development of salbutamol pMDI with HFA-152a is a crucial step towards ensuring future patient access to salbutamol in a pMDI.</style></abstract><notes><style face="normal" font="default" size="100%">King, James&#xD;Woodcock, Ashley&#xD;Anzueto, Antonio&#xD;Wilkinson, Alexander J K&#xD;Janson, Christer&#xD;Henderson, Richard&#xD;Fulmali, Sourabh&#xD;Plank, Maximilian&#xD;eng&#xD;GSK/&#xD;Denmark&#xD;Allergy. 2025 Nov 6. doi: 10.1111/all.70141.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41199473</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70141</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2788</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2788</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kang, S. J.</style></author><author><style face="normal" font="default" size="100%">Gong, J. R.</style></author><author><style face="normal" font="default" size="100%">Jin, S. P.</style></author><author><style face="normal" font="default" size="100%">Oh, J. M.</style></author><author><style face="normal" font="default" size="100%">Jin, H.</style></author><author><style face="normal" font="default" size="100%">Lee, Y.</style></author><author><style face="normal" font="default" size="100%">Moon, Y.</style></author><author><style face="normal" font="default" size="100%">Kim, D.</style></author><author><style face="normal" font="default" size="100%">Nam, H. J.</style></author><author><style face="normal" font="default" size="100%">Choi, H. S.</style></author><author><style face="normal" font="default" size="100%">Hwang, S.</style></author><author><style face="normal" font="default" size="100%">Huh, Y. J.</style></author><author><style face="normal" font="default" size="100%">Han, K. Y.</style></author><author><style face="normal" font="default" size="100%">Moon, J.</style></author><author><style face="normal" font="default" size="100%">Chung, J.</style></author><author><style face="normal" font="default" size="100%">Park, W. Y.</style></author><author><style face="normal" font="default" size="100%">Park, C. G.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author><author><style face="normal" font="default" size="100%">Kim, J. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea.&#xD;Department of Basic Research, PB Immune Therapeutics, Seoul, Republic of Korea.&#xD;Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.&#xD;Department of Bio and Brain Engineering, KAIST, Daejeon, Republic of Korea.&#xD;Department of Dermatology, Seoul National University Hospital, Seoul, Republic of Korea.&#xD;Medical Research Center, Institute of Human-Environmental Interface Biology, Seoul National University, Seoul, Republic of Korea.&#xD;Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea.&#xD;Transplantation Research Institute, Medical Research Center, Seoul National University, Seoul, Republic of Korea.&#xD;Department of Dermatology, Hanyang University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Digital Health, Sungkyunkwan University, Seoul, Republic of Korea.&#xD;GENINUS Inc., Seoul, Republic of Korea.&#xD;Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea.&#xD;Interdisciplinary Program in Artificial Intelligence (IPAI), Seoul National University, Seoul, Republic of Korea.&#xD;Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Deciphering Dysfunctional Regulatory T Cells in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1473-1477</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/12/18</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39692151</style></accession-num><notes><style face="normal" font="default" size="100%">Kang, Seong-Jun&#xD;Gong, Jeong-Ryeol&#xD;Jin, Seon-Pil&#xD;Oh, Jin-Mi&#xD;Jin, Hyunjin&#xD;Lee, Yuji&#xD;Moon, Yewon&#xD;Kim, Dongjun&#xD;Nam, Hyo Jeong&#xD;Choi, Hyun Seung&#xD;Hwang, Sanha&#xD;Huh, Yun Jung&#xD;Han, Kyung Yeon&#xD;Moon, Jihwan&#xD;Chung, Jongsuk&#xD;Park, Woong-Yang&#xD;Park, Chung-Gyu&#xD;Kim, Hyun Je&#xD;Kim, Jeong Eun&#xD;eng&#xD;Ministry of Science and ICT, South Korea/&#xD;National Research Foundation of Korea/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1473-1477. doi: 10.1111/all.16439. Epub 2024 Dec 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39692151</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16439</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2956</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2956</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">von Wachter, C.</style></author><author><style face="normal" font="default" size="100%">Ameri, M.</style></author><author><style face="normal" font="default" size="100%">Chimbetete, T.</style></author><author><style face="normal" font="default" size="100%">Pedretti, S.</style></author><author><style face="normal" font="default" size="100%">Ziadlou, R.</style></author><author><style face="normal" font="default" size="100%">Selim, R.</style></author><author><style face="normal" font="default" size="100%">Nageli, M.</style></author><author><style face="normal" font="default" size="100%">Fehr, D.</style></author><author><style face="normal" font="default" size="100%">Mohrenschlager, M.</style></author><author><style face="normal" font="default" size="100%">White, A.</style></author><author><style face="normal" font="default" size="100%">Li, N.</style></author><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Peter, J.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Division of Allergology and Clinical Immunology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.&#xD;Allergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF) Davos, Davos, Switzerland.&#xD;Combined Drug Allergy Clinic, Groote Schuur Hospital, Cape Town, South Africa.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Deciphering Immune Endotypes Within Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2332-2347</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/06/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity Syndrome/immunology/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation Mediators</style></keyword><keyword><style face="normal" font="default" size="100%">Dress</style></keyword><keyword><style face="normal" font="default" size="100%">DRESS systemic immune profiles</style></keyword><keyword><style face="normal" font="default" size="100%">Drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default" size="100%">drug reaction with eosinophilia and systemic symptoms (DRESS)</style></keyword><keyword><style face="normal" font="default" size="100%">immune ednotypes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40551570</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a rare, severe delayed-type drug hypersensitivity reaction. It can range from mild reactions with little or no organ involvement to severe, potentially life-threatening forms. It is unclear whether these distinct clinical phenotypes are associated with different immune signatures and, ultimately, distinct pathomechanisms. AIMS: The aim of this study was to explore systemic immune profiles of DRESS patients. Our hypothesis was that different grades of DRESS severity would be associated with distinct inflammatory profiles. METHODS: In this multicentric study, we included a total of 26 DRESS patients from Switzerland and South Africa. Serum samples were obtained at the time of diagnosis. 6 healthy controls (HC) were included. Serum levels of inflammation-/immune response-associated proteins were measured by two panels [180 proteins] of a targeted high-throughput proteomics assay (OLINK). RESULTS: Our targeted proteomics findings from serum show immune activation in DRESS. Type 2-/eosinophil-axis associated cytokines (e.g., IL4, IL5 and IL13) were increased in all DRESS patients compared to HC. In addition, we saw an upregulation of proinflammatory mediators like IL6, IL10, CXCL9, and IFN-gamma and of immune regulatory proteins such as PSIP1, ADA, and SH2D1A. Regarding disease severity, all grades showed overlap in inflammation-related upregulated proteins, including chemokines (CXCL9, CXCL10), interferon signaling (IFN-gamma), and immune checkpoint molecules (LAG3, PD-L1). Strikingly, there was a heterogeneous expression of immune proteins in DRESS patients regardless of the severity grade. We identified three immune clusters based on unsupervised clustering. Group 1 was characterized by the upregulation of IL7 and milder immune activation. Group 1 patients were older, had shorter drug latency, and longer hospitalizations. Group 2 displayed features of a pronounced type 3 immune response. This was marked by increased levels of Th17-related cytokines and proteins involved in Toll-like receptor signaling, contributing to a more inflammatory profile. There was a significantly higher rate of HIV-positive patients in this group 2. Group 3 was defined by high eosinophil counts and elevated eosinophil-associated mediator expression, namely elevated levels of like, for example, MCP-4 (CCL13), which is highly effective at recruiting eosinophils, along with a predominant type 2 cytokine response. CONCLUSION: Our targeted serum proteomics findings suggest a systemic immune activation, particularly of the type 2-/eosinophil axis. Our findings of different DRESS immune profiles could, if further validated, pave the way for patient stratification and more targeted treatment approaches.</style></abstract><notes><style face="normal" font="default" size="100%">von Wachter, Camilla&#xD;Ameri, Milad&#xD;Chimbetete, Tafadzwa&#xD;Pedretti, Sarah&#xD;Ziadlou, Reihane&#xD;Selim, Rose&#xD;Nageli, Mirjam&#xD;Fehr, Danielle&#xD;Mohrenschlager, Matthias&#xD;White, Anna&#xD;Li, Nick&#xD;Mitamura, Yasutaka&#xD;Peter, Jonny&#xD;Bruggen, Marie-Charlotte&#xD;eng&#xD;Christine Kuhne - Center for Allergy Research and Education/&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2332-2347. doi: 10.1111/all.16615. Epub 2025 Jun 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40551570</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16615</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2908</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2908</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fehr, D.</style></author><author><style face="normal" font="default" size="100%">Huynh-Tran, V. H.</style></author><author><style face="normal" font="default" size="100%">Maintz, L.</style></author><author><style face="normal" font="default" size="100%">Niederseer, D.</style></author><author><style face="normal" font="default" size="100%">Ameri, M.</style></author><author><style face="normal" font="default" size="100%">Dreher, A.</style></author><author><style face="normal" font="default" size="100%">Study Group, C. C.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Lauener, R.</style></author><author><style face="normal" font="default" size="100%">Rhyner, C.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Bieber, T.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Dermatology and Allergy, University of Bonn, Bonn, Germany.&#xD;Department of Cardiology, Hochgebirgsklinik Davos, Davos, Switzerland.&#xD;Center of Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Heart Center Zurich, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Children&apos;s Hospital of Eastern Switzerland, St. Gallen, Switzerland.&#xD;Faculty of Medicine, University of Augsburg and University Hospital Augsburg, Institute for Environmental Medicine, and Integrative Health, Environmental Medicine, Augsburg, Germany.&#xD;Helmholtz Munich - German Research Center for Environmental Health, Institute of Environmental Medicine, Augsburg, Germany.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Deciphering the Connection Between Atopic Dermatitis and Cardiovascular Diseases: Analysis of Clinical Associations and Cardiometabolic Proteins</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2187-2200</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/05/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/complications/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Cardiovascular Diseases/epidemiology/etiology/blood/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular diseases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40386898</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: There are conflicting data on a potential association between atopic dermatitis (AD) and cardiovascular diseases (CVD). The aim of this study was to further explore this connection and whether there are biomarkers indicating the risk for CVD in AD patients. METHODS: We included 677 AD patients and 79 nonatopic controls from an observational multicenter case-control study (ProRaD: Prospective longitudinal study investigating the remission phase in patients with atopic dermatitis and other allergy-associated diseases). AD severity and atopic, metabolic, and cardiovascular conditions as well as risk factors were assessed. Serum samples were analyzed with targeted proteomics (cardiometabolics panel, Olink). RESULTS: We did not find an overall association between AD and CVD. However, AD patients without atopic comorbidities (pure AD) showed a significantly higher CVD prevalence than AD patients with atopic comorbidities (ADAC) (28.2% [37/131] vs. 14.7% [80/546], p &lt; 0.001). Yet, this association could not be confirmed when controlling for cardiovascular risk factors. In pure AD, patients with CVD showed a more severe AD than those without CVD (median EASI [Eczema Area and Severity Index] 12.9 vs. 4.0, p &lt; 0.001). In this subgroup of patients, EASI remained a significant predictor of CVD even in the adjusted model (adjusted odds ratio [aOR] = 1.05, p = 0.040). Forty serum cardiometabolic proteins were upregulated in AD patients compared with nonatopic controls. CC-chemokine ligand 18 (CCL18) was upregulated in both AD (p &lt; 0.001) and CVD (p &lt; 0.001) and its increase correlated with AD severity. CONCLUSIONS: Our study does not suggest an overall association between AD and CVD, but a more complex relation between the two conditions. Disease severity may be a risk factor for CVD in pure AD patients, but not in those with atopic comorbidities. CCL18 may be a biomarker for CVD.</style></abstract><notes><style face="normal" font="default" size="100%">Fehr, Danielle&#xD;Huynh-Tran, Van Hung&#xD;Maintz, Laura&#xD;Niederseer, David&#xD;Ameri, Milad&#xD;Dreher, Anita&#xD;Study Group, Ck-Care&#xD;Akdis, Cezmi A&#xD;Lauener, Roger&#xD;Rhyner, Claudio&#xD;Traidl-Hoffmann, Claudia&#xD;Schmid-Grendelmeier, Peter&#xD;Bieber, Thomas&#xD;Bruggen, Marie-Charlotte&#xD;eng&#xD;Christine Kuhne - Center for Allergy Research and Education/&#xD;Multicenter Study&#xD;Observational Study&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2187-2200. doi: 10.1111/all.16588. Epub 2025 May 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40386898</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16588</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2332</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2332</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benito-Villalvilla, C.</style></author><author><style face="normal" font="default" size="100%">Angelina, A.</style></author><author><style face="normal" font="default" size="100%">Martin-Cruz, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Deciphering the factors determining the differentiation of autoreactive thymocytes into regulatory T cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1068-1070</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/12/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Thymocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">Autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">Thymus Gland</style></keyword><keyword><style face="normal" font="default" size="100%">TGF-beta</style></keyword><keyword><style face="normal" font="default" size="100%">autoreactive thymocytes</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cells</style></keyword><keyword><style face="normal" font="default" size="100%">thymic selection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38130078</style></accession-num><notes><style face="normal" font="default" size="100%">Benito-Villalvilla, Cristina&#xD;Angelina, Alba&#xD;Martin-Cruz, Leticia&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):1068-1070. doi: 10.1111/all.15993. Epub 2023 Dec 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38130078</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15993</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>51</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">51</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pablo-Torres, C.</style></author><author><style face="normal" font="default" size="100%">Izquierdo, E.</style></author><author><style face="normal" font="default" size="100%">Tan, T. J.</style></author><author><style face="normal" font="default" size="100%">Obeso, D.</style></author><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Solares, J.</style></author><author><style face="normal" font="default" size="100%">Mera-Berriatua, L.</style></author><author><style face="normal" font="default" size="100%">Bueno-Cabrera, J. L.</style></author><author><style face="normal" font="default" size="100%">Del Mar Reano-Martos, M.</style></author><author><style face="normal" font="default" size="100%">Iglesias-Cadarso, A.</style></author><author><style face="normal" font="default" size="100%">Barbas, C.</style></author><author><style face="normal" font="default" size="100%">Gomez-Casado, C.</style></author><author><style face="normal" font="default" size="100%">Villasenor, A.</style></author><author><style face="normal" font="default" size="100%">Barber, D.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de Ciencias Medicas Basicas, Instituto de Medicina Molecular Aplicada (IMMA) Nemesio Diez, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Espana.&#xD;National Heart and Lung Institute, Allergy and Clinical Immunology, Imperial College NIHR Biomedical Research Centre, Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Centro de Metabolomica y Bioanalisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Espana.&#xD;Department of Hematology and Hemotherapy, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain.&#xD;Department of Allergy and Immunology, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Deciphering the role of platelets in severe allergy by an integrative omics approach</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1319-1332</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/12/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Blood Platelets/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNAseq</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">lipidomics</style></keyword><keyword><style face="normal" font="default" size="100%">metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">platelets</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36527294</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Mechanisms causing the onset and perpetuation of inflammation in severe allergic patients remain unknown. Our previous studies suggested that severe allergic inflammation is linked to platelet dysfunction. METHODS: Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) samples were obtained by platelet-apheresis from severe (n = 7) and mild (n = 10) allergic patients and nonallergic subjects (n = 9) to perform platelet lipidomics by liquid chromatography coupled to mass spectrometry (LC-MS) and RNA-seq analysis. Significant metabolites and transcripts were used to identify compromised biological pathways in the severe phenotype. Platelet and inflammation-related proteins were quantified by Luminex. RESULTS: Platelets from severe allergic patients were characterized by high levels of ceramides, phosphoinositols, phosphocholines, and sphingomyelins. In contrast, they showed a decrease in eicosanoid precursor levels. Biological pathway analysis performed with the significant lipids revealed the alteration of phospholipases, calcium-dependent events, and linolenic metabolism. RNAseq confirmed mRNA overexpression of genes related to platelet activation and arachidonic acid metabolism in the severe phenotypes. Pathway analysis indicated the alteration of NOD, MAPK, TLR, TNF, and IL-17 pathways in the severe phenotype. P-Selectin and IL-17AF proteins were increased in the severe phenotype. CONCLUSIONS: This study demonstrates that platelet lipid, mRNA, and protein content is different according to allergy severity. These findings suggest that platelet load is a potential source of biomarkers and a new chance for therapeutic targets in severe inflammatory pathologies.</style></abstract><notes><style face="normal" font="default" size="100%">Pablo-Torres, Carmela&#xD;Izquierdo, Elena&#xD;Tan, Tiak Ju&#xD;Obeso, David&#xD;Layhadi, Janice A&#xD;Sanchez-Solares, Javier&#xD;Mera-Berriatua, Leticia&#xD;Bueno-Cabrera, Jose Luis&#xD;Del Mar Reano-Martos, Maria&#xD;Iglesias-Cadarso, Alfredo&#xD;Barbas, Coral&#xD;Gomez-Casado, Cristina&#xD;Villasenor, Alma&#xD;Barber, Domingo&#xD;Shamji, Mohamed H&#xD;Escribese, Maria M&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1319-1332. doi: 10.1111/all.15621. Epub 2023 Jan 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36527294</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15621</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3244</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3244</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moya, B.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain.&#xD;Instituto de Investigacion Sanitaria, Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Division of Immunology and Allergy, The Hospital for Sick Children and the SickKids Food Allergy and Anaphylaxis Program, Toronto, Ontario, Canada.&#xD;Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Decoding Resistin-Like Molecule Beta (RELMbeta): A Key Modulator in Food Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">gut microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">oral tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cells</style></keyword><keyword><style face="normal" font="default" size="100%">resistin-like molecule beta</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 28</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41604349</style></accession-num><notes><style face="normal" font="default" size="100%">Moya, Beatriz&#xD;Riggioni, Carmen&#xD;Cabanillas, Beatriz&#xD;eng&#xD;Denmark&#xD;Allergy. 2026 Jan 28. doi: 10.1111/all.70238.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41604349</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70238</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1940</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1940</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stikker, B. S.</style></author><author><style face="normal" font="default" size="100%">Hendriks, R. W.</style></author><author><style face="normal" font="default" size="100%">Stadhouders, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.&#xD;Department of Cell Biology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Decoding the genetic and epigenetic basis of asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">940-956</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/02/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Epigenomics</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Ewas</style></keyword><keyword><style face="normal" font="default" size="100%">Gwas</style></keyword><keyword><style face="normal" font="default" size="100%">Prs</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36727912</style></accession-num><abstract><style face="normal" font="default" size="100%">Asthma is a complex and heterogeneous chronic inflammatory disease of the airways. Alongside environmental factors, asthma susceptibility is strongly influenced by genetics. Given its high prevalence and our incomplete understanding of the mechanisms underlying disease susceptibility, asthma is frequently studied in genome-wide association studies (GWAS), which have identified thousands of genetic variants associated with asthma development. Virtually all these genetic variants reside in non-coding genomic regions, which has obscured the functional impact of asthma-associated variants and their translation into disease-relevant mechanisms. Recent advances in genomics technology and epigenetics now offer methods to link genetic variants to gene regulatory elements embedded within non-coding regions, which have started to unravel the molecular mechanisms underlying the complex (epi)genetics of asthma. Here, we provide an integrated overview of (epi)genetic variants associated with asthma, focusing on efforts to link these disease associations to biological insight into asthma pathophysiology using state-of-the-art genomics methodology. Finally, we provide a perspective as to how decoding the genetic and epigenetic basis of asthma has the potential to transform clinical management of asthma and to predict the risk of asthma development.</style></abstract><notes><style face="normal" font="default" size="100%">Stikker, Bernard S&#xD;Hendriks, Rudi W&#xD;Stadhouders, Ralph&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):940-956. doi: 10.1111/all.15666. Epub 2023 Feb 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36727912</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15666</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3042</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3042</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Granger, V.</style></author><author><style face="normal" font="default" size="100%">Nadif, R.</style></author><author><style face="normal" font="default" size="100%">Orsi, L.</style></author><author><style face="normal" font="default" size="100%">Chollet Martin, S.</style></author><author><style face="normal" font="default" size="100%">de Chaisemartin, L.</style></author><author><style face="normal" font="default" size="100%">Taille, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunology Department, Assistance Publique-Hopitaux de Paris (APHP), Bichat Hospital, Paris, France.&#xD;Centre for Research in Inflammation, INSERM UMR 1149, Universite Paris Cite, Team InnaLung, Paris, France.&#xD;Universite Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Equipe d&apos;Epidemiologie Respiratoire Integrative, CESP, Villejuif, France.&#xD;Inserm, Inflammation, Microbiome and Immunosurveillance, Universite Paris-Saclay, Orsay, France.&#xD;Pneumology Department, Reference Center for Rare Pulmonary Diseases, Bichat Hospital, Assistance Publique-Hopitaux de Paris, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Decrease in Eosinophil-Derived-Neurotoxin With Mepolizumab Is Associated With Asthma Improvement</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2663-2666</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/08/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil-derived neurotoxin</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Sanofi, GSK, Chiesi, Stallergenes Greer, and Novartis. The other</style></keyword><keyword><style face="normal" font="default" size="100%">authors have no conflicts to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40785372</style></accession-num><notes><style face="normal" font="default" size="100%">Granger, Vanessa&#xD;Nadif, Rachel&#xD;Orsi, Laurent&#xD;Chollet Martin, Sylvie&#xD;de Chaisemartin, Luc&#xD;Taille, Camille&#xD;eng&#xD;Thermo Fisher Scientific/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2663-2666. doi: 10.1111/all.70008. Epub 2025 Aug 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40785372</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444817</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70008</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1128</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1128</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yamagishi, M.</style></author><author><style face="normal" font="default" size="100%">Akagawa, S.</style></author><author><style face="normal" font="default" size="100%">Akagawa, Y.</style></author><author><style face="normal" font="default" size="100%">Nakai, Y.</style></author><author><style face="normal" font="default" size="100%">Yamanouchi, S.</style></author><author><style face="normal" font="default" size="100%">Kimata, T.</style></author><author><style face="normal" font="default" size="100%">Hashiyada, M.</style></author><author><style face="normal" font="default" size="100%">Akane, A.</style></author><author><style face="normal" font="default" size="100%">Tsuji, S.</style></author><author><style face="normal" font="default" size="100%">Kaneko, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Kansai Medical University, Osaka, Japan.&#xD;Department of Legal Medicine, Kansai Medical University, Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Decreased butyric acid-producing bacteria in gut microbiota of children with egg allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2279-2282</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/03/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacteria</style></keyword><keyword><style face="normal" font="default" size="100%">Butyric Acid</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Egg Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">paediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33650199</style></accession-num><notes><style face="normal" font="default" size="100%">Yamagishi, Mitsuru&#xD;Akagawa, Shohei&#xD;Akagawa, Yuko&#xD;Nakai, Yoko&#xD;Yamanouchi, Sohsaku&#xD;Kimata, Takahisa&#xD;Hashiyada, Masaki&#xD;Akane, Atsushi&#xD;Tsuji, Shoji&#xD;Kaneko, Kazunari&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2279-2282. doi: 10.1111/all.14795. Epub 2021 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33650199</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14795</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1586</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1586</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yamagishi, M.</style></author><author><style face="normal" font="default" size="100%">Akagawa, S.</style></author><author><style face="normal" font="default" size="100%">Akagawa, Y.</style></author><author><style face="normal" font="default" size="100%">Nakai, Y.</style></author><author><style face="normal" font="default" size="100%">Yamanouchi, S.</style></author><author><style face="normal" font="default" size="100%">Kimata, T.</style></author><author><style face="normal" font="default" size="100%">Hashiyada, M.</style></author><author><style face="normal" font="default" size="100%">Akane, A.</style></author><author><style face="normal" font="default" size="100%">Tsuji, S.</style></author><author><style face="normal" font="default" size="100%">Kaneko, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Kansai Medical University, Osaka, Japan.&#xD;Department of Legal Medicine, Kansai Medical University, Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Decreased butyric acid-producing bacteria in gut microbiota of children with egg allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2279-2282</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/03/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacteria</style></keyword><keyword><style face="normal" font="default" size="100%">Butyric Acid</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Egg Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">paediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33650199</style></accession-num><notes><style face="normal" font="default" size="100%">Yamagishi, Mitsuru&#xD;Akagawa, Shohei&#xD;Akagawa, Yuko&#xD;Nakai, Yoko&#xD;Yamanouchi, Sohsaku&#xD;Kimata, Takahisa&#xD;Hashiyada, Masaki&#xD;Akane, Atsushi&#xD;Tsuji, Shoji&#xD;Kaneko, Kazunari&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2279-2282. doi: 10.1111/all.14795. Epub 2021 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33650199</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14795</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3151</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3151</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Epstein-Rigbi, N.</style></author><author><style face="normal" font="default" size="100%">Elkan, M.</style></author><author><style face="normal" font="default" size="100%">Tzarfati, Y.</style></author><author><style face="normal" font="default" size="100%">Levy, M. B.</style></author><author><style face="normal" font="default" size="100%">Nachshon, L.</style></author><author><style face="normal" font="default" size="100%">Koren, Y.</style></author><author><style face="normal" font="default" size="100%">Katz, Y.</style></author><author><style face="normal" font="default" size="100%">Elizur, A.</style></author><author><style face="normal" font="default" size="100%">Goldberg, M. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergy, Immunology and Pediatric Pulmonology, Shamir (Assaf Harofeh) Medical Center, Be&apos;er Ya&apos;akov, Israel.&#xD;Allergy and Immunology Unit, Assuta Ashdod Medical Center, Ashdod, Israel.&#xD;Faculty of Health Science, Ben Gurion University, Be&apos;er Sheva, Israel.&#xD;Department of Medicine Gray Faculty of Medical &amp; Health Sciences, Tel Aviv University, Tel Aviv, Israel.&#xD;Department of Pediatrics, Gray Faculty of Medical &amp; Health Sciences, Tel Aviv University, Tel Aviv, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Decreased Severity of Oral Immunotherapy Induced Gastrointestinal Eosinophilic Reactions Following Revisions in Milk-Treatment Protocol</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy induced gastrointestinal eosinophilic reaction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 20</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41263053</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: OIT-induced gastrointestinal eosinophilic reactions (OITIGER) is comprised of abdominal pain/vomiting unrelated to the timing of dose administration, typically associated with increased absolute eosinophil counts (AEC). Previously described risk factors during milk OIT included higher baseline AEC, higher OIT starting dose (SD) and faster dose increase. The effect of a revised milk OIT protocol (lower SD and slower dose escalations), on the rate and severity of OITIGER, was examined. METHODS: Milk OIT patients treated with a revised protocol between 2017 and 2021 (n = 269) were compared to a milk cohort from 2010 to 2015 (n = 604) who were treated with the previous protocol. OITIGER rate, severity, and treatment outcomes were compared. RESULTS: Patients in the revised protocol were slightly older (p &lt; 0.001), but other demographics and baseline AEC were similar. The rates for OITIGER were comparable (8.2% vs. 9.1%). However, there was a significant reduction in the rate of severe presentation, defined by vomiting &gt;/= 3 times/month (45.5% vs. 72.7%, p = 0.023) among OITIGER patients undergoing the revised protocol. Upon multivariate logistic regression, baseline AEC &gt; 600/muL was a risk factor [OR 2.16 (CI 1.30-3.60), p = 0.003] for OITIGER, while the revised protocol was protective for severe OITIGER [OR 0.30 (CI 0.10-0.89), p = 0.031]. Older age was associated with less OITIGER [OR 0.92 (CI 0.85-0.99), p = 0.018] and borderline less severe OITIGER [OR 0.85 (CI 0.72-1.00), p = 0.050]. A lower fold increase in AEC was observed in OITIGER patients in the revised protocol (2.25 [1.63-3.45] vs. 1.79 [1.34-2.11], p = 0.009). CONCLUSIONS: A revised protocol was associated with reduced AEC increase, and ameliorated the severity of OITIGER during OIT.</style></abstract><notes><style face="normal" font="default" size="100%">Epstein-Rigbi, Na&apos;ama&#xD;Elkan, Matan&#xD;Tzarfati, Yair&#xD;Levy, Michael B&#xD;Nachshon, Liat&#xD;Koren, Yael&#xD;Katz, Yitzhak&#xD;Elizur, Arnon&#xD;Goldberg, Michael R&#xD;eng&#xD;Ministry of Health, Israel/&#xD;Leon Alcalay Chair in Pediatric Immunology, Tel Aviv University/&#xD;Denmark&#xD;Allergy. 2025 Nov 20. doi: 10.1111/all.70165.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41263053</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70165</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2253</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2253</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jia, M.</style></author><author><style face="normal" font="default" size="100%">Fu, H.</style></author><author><style face="normal" font="default" size="100%">Jiang, X.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Xu, J.</style></author><author><style face="normal" font="default" size="100%">Barnes, P. J.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">He, S.</style></author><author><style face="normal" font="default" size="100%">Zhang, F.</style></author><author><style face="normal" font="default" size="100%">Yao, L.</style></author><author><style face="normal" font="default" size="100%">Sun, P.</style></author><author><style face="normal" font="default" size="100%">Yao, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory &amp; Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.&#xD;Airway Disease Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK.&#xD;Department of Allergy, Pulmonary and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.&#xD;Shandong Key Laboratory of Infections Respiratory Disease, Medical Science and Technology Innovation Center, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.&#xD;Department of Respiratory Medicine, Nanjing Red Cross Hospital, Nanjing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">DEL-1, as an anti-neutrophil transepithelial migration molecule, inhibits airway neutrophilic inflammation in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1180-1194</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Calcium-Binding Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">*Cell Adhesion Molecules/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Neutrophils/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Transendothelial and Transepithelial Migration</style></keyword><keyword><style face="normal" font="default" size="100%">Del-1</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchial epithelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophil transepithelial migration</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37681299</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Neutrophil migration into the airways is a key process in neutrophilic asthma. Developmental endothelial locus-1 (DEL-1), an extracellular matrix protein, is a neutrophil adhesion inhibitor that attenuates neutrophilic inflammation. METHODS: Levels of DEL-1 were measured in exhaled breath condensate (EBC) and serum in asthma patients by ELISA. DEL-1 modulation of neutrophil adhesion and transepithelial migration was examined in a co-culture model in vitro. The effects of DEL-1-adenoviral vector-mediated overexpression on ovalbumin/lipopolysaccharide (OVA/LPS)-induced neutrophilic asthma were studied in mice in vivo. RESULTS: DEL-1 was primarily expressed in human bronchial epithelial cells and was decreased in asthma patients. Serum DEL-1 concentrations were reduced in patients with severe asthma compared with normal subjects (567.1 +/- 75.3 vs. 276.8 +/- 29.36 pg/mL, p &lt; .001) and were negatively correlated to blood neutrophils (r = -0.2881, p = .0384) and neutrophil-to-lymphocyte ratio (NLR) (r = -0.5469, p &lt; .0001). DEL-1 concentrations in the EBC of severe asthmatic patients (113.2 +/- 8.09 pg/mL) were also lower than normal subjects (193.0 +/- 7.61 pg/mL, p &lt; .001) and were positively correlated with the asthma control test (ACT) score (r = 0.3678, p = .0035) and negatively related to EBC IL-17 (r = -0.3756, p = .0131), myeloperoxidase (MPO) (r = -0.5967, p = .0055), and neutrophil elastase (NE) (r = -0.5488, p = .0009) expression in asthma patients. Neutrophil adhesion and transepithelial migration in asthma patients were associated with LFA-1 binding to ICAM-1 and inhibited by DEL-1. DEL-1 mRNA and protein expression in human bronchial epithelial cells were regulated by IL-17. Exogenous DEL-1 inhibited IL-17-enhanced neutrophil adhesion and migration. DEL-1 expression was decreased while neutrophil infiltration was increased in the airway of a murine model of neutrophilic asthma. This was prevented by DEL-1 overexpression. CONCLUSIONS: DEL-1 down-regulation leads to increased neutrophil migration across bronchial epithelial cells and is associated with neutrophilic airway inflammation in asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Jia, Man&#xD;Fu, Heng&#xD;Jiang, Xinyu&#xD;Wang, Lina&#xD;Xu, Jiayan&#xD;Barnes, Peter J&#xD;Adcock, Ian M&#xD;Liu, Yi&#xD;He, Shujuan&#xD;Zhang, Fan&#xD;Yao, Lei&#xD;Sun, Peng&#xD;Yao, Xin&#xD;eng&#xD;82200035/National Natural Science Foundation of China/&#xD;82170040/National Natural Science Foundation of China/&#xD;BK20210957/Natural Science Foundation of Jiangsu Province/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1180-1194. doi: 10.1111/all.15882. Epub 2023 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37681299</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15882</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>946</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">946</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shin, E.</style></author><author><style face="normal" font="default" size="100%">Bae, S.</style></author><author><style face="normal" font="default" size="100%">Jung, J.</style></author><author><style face="normal" font="default" size="100%">Song, W. J.</style></author><author><style face="normal" font="default" size="100%">Kwon, H. S.</style></author><author><style face="normal" font="default" size="100%">Kim, H. S.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Kim, T. B.</style></author><author><style face="normal" font="default" size="100%">Cho, Y. S.</style></author><author><style face="normal" font="default" size="100%">Lee, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Delayed local reactions after the first administration of the ChAdOx1 nCoV-19 vaccine</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3520-3522</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/06/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">ChAdOx1 nCoV-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization, Secondary</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34129694</style></accession-num><notes><style face="normal" font="default" size="100%">Shin, Eunyong&#xD;Bae, Seongman&#xD;Jung, Jiwon&#xD;Song, Woo-Jung&#xD;Kwon, Hyouk-Soo&#xD;Kim, Hee-Sung&#xD;Kim, Sung-Han&#xD;Kim, Tae-Bum&#xD;Cho, You Sook&#xD;Lee, Ji-Hyang&#xD;eng&#xD;2019M3E5D3073365/National Research Foundation/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3520-3522. doi: 10.1111/all.14978. Epub 2021 Jun 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34129694</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441908</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14978</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>269</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">269</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Cheng, J.</style></author><author><style face="normal" font="default" size="100%">Wu, J.</style></author><author><style face="normal" font="default" size="100%">Ungar, B.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y. D.</style></author><author><style face="normal" font="default" size="100%">Jack, C.</style></author><author><style face="normal" font="default" size="100%">Maari, C.</style></author><author><style face="normal" font="default" size="100%">Proulx, E. S.</style></author><author><style face="normal" font="default" size="100%">Ramirez-Valle, F.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author><author><style face="normal" font="default" size="100%">Bissonnette, R.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Dermatology, University of Magna Graecia, Catanzaro, Italy.&#xD;Innovaderm Research Inc, Montreal, Quebec, Canada.&#xD;Bristol Myers Squibb, New York, New York, USA.&#xD;Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">178-191</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-17</style></keyword><keyword><style face="normal" font="default" size="100%">Nickel/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">*Psoriasis</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Th17 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory skin disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36178084</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Treatment of inflammatory skin diseases, including atopic dermatitis (AD) and psoriasis, is undergoing transformative changes, highlighting the need to develop experimental models of skin inflammation in humans to predict treatment responses. METHODS: We topically or intradermally administered four common sensitizers (dust mite (DM), diphencyprone (DPCP), nickel (Ni), and purified protein derivative (PPD)) to the backs of 40 healthy patients and the skin hypersensitivity response was biopsied and evaluated using immunohistochemistry, RNA-seq, and RT-PCR. RESULTS: All agents induced strong increases in cellular infiltrates (T-cells and dendritic cells) as compared to untreated skin (p &lt; .05), with variable T helper polarization. Overall, DPCP induced the strongest immune responses across all pathways, including innate immunity (IL-1alpha, IL-8), Th1 (IFNgamma, CXCL10), Th2 (IL-5, CCL11), and Th17 (CAMP/LL37) products, as well as the highest regulatory tone (FOXP3, IL-34, IL-37) (FDR &lt;0.01). Nickel induced Th17 (IL-17A), Th1 (CXCL10) and Th2 (IL-4R) immune responses to a lesser extent than DPCP (p &lt; .05). PPD induced predominantly Th1 (IFNgamma, CXCL10, STAT1) and Th17 inflammation (IL-17A) (p &lt; .05). DM induced modulation of Th2 (IL-13, CCL17, CCL18), Th22 (IL-22), and Th17/Th22 (S100A7/9/12) pathways (p &lt; .05). Barrier defects that characterize both AD and psoriasis were best modeled by DPCP and Ni, followed by PPD, including downregulation of terminal differentiation (FLG, FLG2, LOR, LCEs), tight junction (CLDN1/CLDN8), and lipid metabolism (FA2H, FABP7)-related markers. CONCLUSION: Our data imply that DPCP induced the strongest immune response across all pathways, and barrier defects characteristic of AD and psoriasis.</style></abstract><notes><style face="normal" font="default" size="100%">Pavel, Ana B&#xD;Del Duca, Ester&#xD;Cheng, Julia&#xD;Wu, Jianni&#xD;Ungar, Benjamin&#xD;Estrada, Yeriel D&#xD;Jack, Carolyn&#xD;Maari, Catherine&#xD;Proulx, Etienne Saint-Cyr&#xD;Ramirez-Valle, Francisco&#xD;Krueger, James G&#xD;Bissonnette, Robert&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):178-191. doi: 10.1111/all.15538. Epub 2022 Oct 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36178084</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15538</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2981</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2981</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cancian, M.</style></author><author><style face="normal" font="default" size="100%">Accardo, P.</style></author><author><style face="normal" font="default" size="100%">Arcoleo, F.</style></author><author><style face="normal" font="default" size="100%">Giardino, F.</style></author><author><style face="normal" font="default" size="100%">Nicola, S.</style></author><author><style face="normal" font="default" size="100%">Senter, R.</style></author><author><style face="normal" font="default" size="100%">Triggianese, P.</style></author><author><style face="normal" font="default" size="100%">Danese, S.</style></author><author><style face="normal" font="default" size="100%">Ulloa, J.</style></author><author><style face="normal" font="default" size="100%">Desai, V.</style></author><author><style face="normal" font="default" size="100%">Frade, J. P.</style></author><author><style face="normal" font="default" size="100%">Audhya, P. K.</style></author><author><style face="normal" font="default" size="100%">Zanichelli, A.</style></author><author><style face="normal" font="default" size="100%">Itaca Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Azienda Ospedale Universita di Padova, Padova, Italy.&#xD;A.O. &quot;Ospedali Riuniti Villa Sofia-Cervello&quot;-Presidio Ospedaliero Cervello, Palermo, Italy.&#xD;A.O.U. Policlinico &quot;G.Rodolico-San Marco&quot;, Catania, Italy.&#xD;Allergy and Immunology Unit-AO Ordine Mauriziano di Torino and Department of Medical Sciences, University of Turin, Turin, Italy.&#xD;Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.&#xD;Outcomes Insights, Agoura Hills, California, USA.&#xD;KalVista Pharmaceuticals, Cambridge, Massachusetts, USA.&#xD;Operative Unit of Medicine, Angioedema Center, IRCCS Policlinico San Donato Milanese, Milan, Italy.&#xD;Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Delays and Barriers Related to the Treatment of Hereditary Angioedema Attacks in Italy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3198-3200</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/07/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Itaca</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">on-demand treatment</style></keyword><keyword><style face="normal" font="default" size="100%">treatment barriers</style></keyword><keyword><style face="normal" font="default" size="100%">treatment delay</style></keyword><keyword><style face="normal" font="default" size="100%">Behring, KalVista Pharmaceuticals, Novartis, Pharvaris, Sanofi, SOBI, and Takeda.</style></keyword><keyword><style face="normal" font="default" size="100%">F.G. has served on advisory boards/seminars funded by BioCryst, CSL Behring,</style></keyword><keyword><style face="normal" font="default" size="100%">KalVista Pharmaceuticals, and Takeda and has received funding from CSL Behring</style></keyword><keyword><style face="normal" font="default" size="100%">and Takeda to attend conferences/educational events. R.S. has served as a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant for BioCryst, KalVista Pharmaceuticals, and Takeda and has received</style></keyword><keyword><style face="normal" font="default" size="100%">travel grants from Alk Abello, BioCryst, CSL Behring, Novartis, and Takeda. P.T.</style></keyword><keyword><style face="normal" font="default" size="100%">was a speaker/consultant for and received honoraria and/or meeting/travel support</style></keyword><keyword><style face="normal" font="default" size="100%">from AbbVie, Janssen, BioCryst, CSL Behring, KalVista Pharmaceuticals, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">and Takeda. S.D. and J.U. have received consulting fees from KalVista</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals. V.D. is a former salaried employee of KalVista Pharmaceuticals.</style></keyword><keyword><style face="normal" font="default" size="100%">J.P.F. and P.K.A. are salaried employees of KalVista Pharmaceuticals. P.A., F.A.,</style></keyword><keyword><style face="normal" font="default" size="100%">S.N., and A.Z. have nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40671362</style></accession-num><notes><style face="normal" font="default" size="100%">Cancian, Mauro&#xD;Accardo, Pietro&#xD;Arcoleo, Francesco&#xD;Giardino, Francesco&#xD;Nicola, Stefania&#xD;Senter, Riccardo&#xD;Triggianese, Paola&#xD;Danese, Sherry&#xD;Ulloa, Julie&#xD;Desai, Vibha&#xD;Frade, Joao P&#xD;Audhya, Paul K&#xD;Zanichelli, Andrea&#xD;eng&#xD;This study was funded by KalVista Pharmaceuticals./&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3198-3200. doi: 10.1111/all.16643. Epub 2025 Jul 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40671362</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590309</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16643</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>725</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">725</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, Y.</style></author><author><style face="normal" font="default" size="100%">Tian, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Peng, H.</style></author><author><style face="normal" font="default" size="100%">Lei, Q.</style></author><author><style face="normal" font="default" size="100%">Yuan, X.</style></author><author><style face="normal" font="default" size="100%">Liu, S.</style></author><author><style face="normal" font="default" size="100%">Xiong, Y.</style></author><author><style face="normal" font="default" size="100%">Lin, X.</style></author><author><style face="normal" font="default" size="100%">Jo-Lewis, B. N.</style></author><author><style face="normal" font="default" size="100%">Yao, Z.</style></author><author><style face="normal" font="default" size="100%">Fu, H.</style></author><author><style face="normal" font="default" size="100%">Fan, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Human Body Anatomy, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Deletion of BCG_2432c from the Bacillus Calmette-Guerin vaccine enhances autophagy-mediated immunity against tuberculosis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">619-632</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Autophagy</style></keyword><keyword><style face="normal" font="default" size="100%">BCG Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Mycobacterium bovis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Mycobacterium tuberculosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Tuberculosis/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">BCG_2432c</style></keyword><keyword><style face="normal" font="default" size="100%">recombinant BCG</style></keyword><keyword><style face="normal" font="default" size="100%">tuberculosis</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34706102</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Mycobacterium bovis bacillus Calmette-Guerin (BCG) is an attenuated live vaccine that provides insufficient protection against tuberculosis (TB), the underlying mechanisms for which remain unknown. Assuming that the BCG vaccine inherits immune evasive strategies from virulent parent M. bovis strains, we aimed to identify the associated genes and assess their effects on the vaccine efficacy. METHODS: Three genes, BCG_3174, BCG_1782, and BCG_2432c, associated with immune evasion were first identified via bioinformatics analysis and then confirmed in the genome of M. bovis and 12 commercial BCG vaccine substrains using Polymerase Chain Reaction (PCR) and DNA sequencing. These genes were disrupted to develop mutant strains, and their effects on autophagy and their protective efficacy were further compared with the BCG vaccine in vitro and in vivo. RESULTS: Of the three identified genes, only the disruption of BCG_2432c, namely DeltaBCG_2432c, conferred stronger protection against intranasal TB in vaccinated mice, when compared with the BCG vaccine. DeltaBCG_2432c showed a stronger ability to trigger intracellular ROS-mediated complete autophagic flux in infected THP-1 cells that resulted in higher antigen presentation. The improved protection could be attributed to early and increased IFN-gamma(+) CD4(+) T(EM) and IL-2(+) CD4(+) T(CM) cells in the spleens and lungs of DeltaBCG_2432c-vaccinated mice. CONCLUSIONS: The insufficient efficacy of the BCG vaccine is attributable to the important autophagy-inhibition gene BCG_2432c that blocks the autophagosome-lysosome pathway of antigen presentation. DeltaBCG_2432c provides a promising platform to either replace the current BCG vaccine or develop vaccines that are more effective against TB.</style></abstract><notes><style face="normal" font="default" size="100%">Wu, Yaqi&#xD;Tian, Maopeng&#xD;Zhang, Yandi&#xD;Peng, Huiming&#xD;Lei, Qing&#xD;Yuan, Xuefeng&#xD;Liu, Shijie&#xD;Xiong, Yulong&#xD;Lin, Xiaosong&#xD;Jo-Lewis, Banga Ndzouboukou&#xD;Yao, Zongjie&#xD;Fu, Hui&#xD;Fan, Xionglin&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):619-632. doi: 10.1111/all.15158. Epub 2021 Nov 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34706102</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15158</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>459</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">459</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rose, R.</style></author><author><style face="normal" font="default" size="100%">Neumann, F.</style></author><author><style face="normal" font="default" size="100%">Muller, S.</style></author><author><style face="normal" font="default" size="100%">Baumler, C.</style></author><author><style face="normal" font="default" size="100%">Schafer, M.</style></author><author><style face="normal" font="default" size="100%">Schon, F.</style></author><author><style face="normal" font="default" size="100%">Rompke, J.</style></author><author><style face="normal" font="default" size="100%">Schulze, S.</style></author><author><style face="normal" font="default" size="100%">Weyer, D.</style></author><author><style face="normal" font="default" size="100%">Grobe, O.</style></author><author><style face="normal" font="default" size="100%">Lorentz, T.</style></author><author><style face="normal" font="default" size="100%">Fickenscher, H.</style></author><author><style face="normal" font="default" size="100%">Krumbholz, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut fur Infektionsmedizin, Christian-Albrechts-Universitat zu Kiel und Universitatsklinikum Schleswig Holstein, Kiel, Germany.&#xD;Labor Dr. Krause und Kollegen MVZ GmbH, Kiel, Germany.&#xD;Stadtisches Krankenhaus Kiel, Kiel, Germany.&#xD;Stadt Flensburg, Flensburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3130-3133</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/06/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antibodies, Neutralizing</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Viral</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35652740</style></accession-num><notes><style face="normal" font="default" size="100%">Rose, Ruben&#xD;Neumann, Franziska&#xD;Muller, Sina&#xD;Baumler, Carina&#xD;Schafer, Miriam&#xD;Schon, Frieda&#xD;Rompke, Janine&#xD;Schulze, Simone&#xD;Weyer, Dirk&#xD;Grobe, Olaf&#xD;Lorentz, Thomas&#xD;Fickenscher, Helmut&#xD;Krumbholz, Andi&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3130-3133. doi: 10.1111/all.15395. Epub 2022 Jun 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35652740</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9347669</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15395</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3262</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3262</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ayane, Amene Tesfaye</style></author><author><style face="normal" font="default" size="100%">Salas, Maria</style></author><author><style face="normal" font="default" size="100%">Benede, Sara</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Sanchez, Maria J.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Sojo, Maria J.</style></author><author><style face="normal" font="default" size="100%">Jiménez-Sánchez, Isabel M.</style></author><author><style face="normal" font="default" size="100%">Bogas, Gador</style></author><author><style face="normal" font="default" size="100%">Perez-Inestrosa, Ezequiel</style></author><author><style face="normal" font="default" size="100%">Mayorga, Cristobalina</style></author><author><style face="normal" font="default" size="100%">Paris, Juan L.</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Nogales, Alba</style></author><author><style face="normal" font="default" size="100%">Torres, María J.</style></author><author><style face="normal" font="default" size="100%">Montañez, María I.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Dendrimeric Antigens for Passive Mast Cell Activation in the Evaluation of Amoxicillin Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Amoxicillin (AX) is frequently implicated in immediate IgE-mediated allergic reactions. Diagnosis is challenging, highlighting the need for new approaches enhancing in vitro sensitivity and specificity. Engineered nanostructures can mimic immunological recognition of hapten-carrier conjugates, offering a strategy to improve diagnostic accuracy. Methods Dendrimeric Antigens (DeAns), with controlled size (1st–5th generation) and multivalent AX determinants (8–128 units, respectively), were synthesized for in vitro immunological evaluation. In vitro IgE recognition was studied by competitive radio-immunoassay. Allergenic activity was evaluated in mouse bone marrow-derived mast cells (MC) sensitized with mouse anti-AX IgE monoclonal antibody and humanized RBL-2H3 (huRBL-2H3) and LUVA cells sensitized with sera from β-lactam-allergic subjects and tolerant controls, measuring degranulation in response to DeAns stimulation. Results Five different DeAns were obtained as pure compounds. All DeAns were recognized by AX-sIgE. A clear size-dependent activation pattern was observed in the three cell models: lower-generation (1st–2nd) DeAns failed to induce degranulation, whereas DeAns of bigger size (3rd–5th generation) triggered significant, dose-dependent activation. Notably, no activation was observed in tolerants and unsensitized cells or with blank dendrimers. In patient-sera assays, the passive MC activation test (pMAT) with DeAns provided complete diagnostic discrimination, with activation restricted to AX-allergic patients. Conclusions DeAns are effective platforms for investigating effector cell activation in AX allergy. By fine-tuning structural attributes—size and multivalence—we reveal the promising utility of DeAns in pMAT that leverage commercial cell lines and patient sera. This approach could address key limitations of β-lactam allergy diagnostics, enabling more reliable and standardized in vitro testing.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70250</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70250</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1180</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1180</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Palomares, F.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Fernandez, T. D.</style></author><author><style face="normal" font="default" size="100%">Jimenez, I.</style></author><author><style face="normal" font="default" size="100%">Barrionuevo, E.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-HRUM, Malaga, Spain.&#xD;Allergy Unit, Hospital 12 de Octubre, Madrid, Spain.&#xD;Medicine Department, Universidad de Malaga-UMA, Malaga, Spain.&#xD;Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Centro Andaluz de Nanomedicina y Biotecnologia-BIONAND, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dendritic cells inclusion and cell-subset assessment improve flow-cytometry-based proliferation test in non-immediate drug hypersensitivity reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2123-2134</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Activation</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default" size="100%">in vitro tests</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">non-immediate reactions</style></keyword><keyword><style face="normal" font="default" size="100%">proliferation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33523478</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Lymphocyte transformation test (LTT) has been widely used to evaluate non-immediate drug hypersensitivity reactions (NIDHRs). However, the lack of standardization and the low sensitivity have limited its routine diagnostic use. The drug presentation by dendritic cells (DCs) and the assessment of proliferation on effector cells have shown promising results. Flow-cytometry-based methods can help apply these improvements. We aimed to assess the added value of using drug-primed-DCs and the determination of the proliferative response of different lymphocyte subpopulations in NIDHRs. METHODS: Patients with confirmed NIDHR were evaluated by both conventional (C-LTT) and with drug-primed-DCs LTT (dDC-LTT)analysing the proliferative response in T cells and other effector cell subpopulations by using the fluorescent molecule, carboxyfluorescein diacetate succinimidyl ester (CFSE). RESULTS: The C-LTT showed a significantly lower sensitivity (29.4%) compared with dDC-LTT (61.8%), which was confirmed analysing each particular clinical entity: SJS-TEN (62.5% vs 87.5%), MPE (15% vs 47.4%) and AGEP (33% vs 80%). When including the effector cell subpopulations involved in each clinical entity, CD3(+) +CD4(+) T(h) 1 or CD3(+) +NK cells in SJS-TEN, CD3(+) +CD4(+) T(h) 1+NK cells in MPE and CD3(+) +NK cells in AGEP, we could significantly increase the sensitivity of the in vitro test to 100%, 68.4% and 100%, respectively, with an overall sensitivity of 87% and 85% of specificity in NIDHR. CONCLUSIONS: The use of a flow-cytometry-based test, DCs as drug presenting cells, and focusing on effector cell subpopulations for each clinical entity significantly improved the drug-specific proliferative response in NIDHRs with a unique cellular in vitro test.</style></abstract><notes><style face="normal" font="default" size="100%">Fernandez-Santamaria, Ruben&#xD;Bogas, Gador&#xD;Palomares, Francisca&#xD;Salas, Maria&#xD;Fernandez, Tahia D&#xD;Jimenez, Isabel&#xD;Barrionuevo, Esther&#xD;Dona, Inmaculada&#xD;Torres, Maria Jose&#xD;Mayorga, Cristobalina&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2123-2134. doi: 10.1111/all.14755. Epub 2021 Feb 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33523478</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14755</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>74</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">74</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alvarado-Vazquez, P. A.</style></author><author><style face="normal" font="default" size="100%">Cardenas, E. I.</style></author><author><style face="normal" font="default" size="100%">Das, A.</style></author><author><style face="normal" font="default" size="100%">Hallgren, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.&#xD;Division of Lung and Airway Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Depletion of Mcpt8-expressing cells reduces lung mast cells in mice with experimental asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1363-1366</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/11/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36435992</style></accession-num><notes><style face="normal" font="default" size="100%">Alvarado-Vazquez, P Abigail&#xD;Cardenas, Eduardo I&#xD;Das, Avijit&#xD;Hallgren, Jenny&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1363-1366. doi: 10.1111/all.15596. Epub 2022 Dec 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36435992</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15596</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2241</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2241</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carucci, L.</style></author><author><style face="normal" font="default" size="100%">Berni Canani, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medical Science, University of Naples Federico II, Naples, Italy.&#xD;ImmunoNutritionLab at the CEINGE Advanced Biotechnologies Research Center, University of Naples Federico II, Naples, Italy.&#xD;Task Force on Microbiome Studies, University of Naples Federico II, Naples, Italy.&#xD;European Laboratory for the Investigation of Food-Induced Diseases, University of Naples Federico II, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Derived cholesterol metabolites and sIgA production: A novel intriguing link</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">260-262</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/09/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin A, Secretory</style></keyword><keyword><style face="normal" font="default" size="100%">*Cholesterol/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">antibody</style></keyword><keyword><style face="normal" font="default" size="100%">duodenum epithelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">oxysterols</style></keyword><keyword><style face="normal" font="default" size="100%">plasma cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37746772</style></accession-num><notes><style face="normal" font="default" size="100%">Carucci, Laura&#xD;Berni Canani, Roberto&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):260-262. doi: 10.1111/all.15896. Epub 2023 Sep 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37746772</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15896</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>465</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">465</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Respiratory and Allergic Diseases, Department of Chest Diseases, High Specialty A. Cardarelli Hospital, Naples, Italy.&#xD;Medical School of Specialization in Respiratory Diseases, University of Naples Federico II, Naples, Italy.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Christine Kuhne - Center for Allergy Research and Education, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Desert dust and respiratory diseases: Further insights into the epithelial barrier hypothesis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3490-3492</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiration Disorders</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35633073</style></accession-num><notes><style face="normal" font="default" size="100%">D&apos;Amato, Gennaro&#xD;Akdis, Cezmi A&#xD;eng&#xD;Comment&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3490-3492. doi: 10.1111/all.15392.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35633073</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15392</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>855</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">855</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cass, S. P.</style></author><author><style face="normal" font="default" size="100%">McGrath, J. J. C.</style></author><author><style face="normal" font="default" size="100%">Son, K.</style></author><author><style face="normal" font="default" size="100%">Radford, K.</style></author><author><style face="normal" font="default" size="100%">LaVigne, N.</style></author><author><style face="normal" font="default" size="100%">Klein, D. K.</style></author><author><style face="normal" font="default" size="100%">Ditlev, S. B.</style></author><author><style face="normal" font="default" size="100%">Porsbjerg, C.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author><author><style face="normal" font="default" size="100%">Stampfli, M. R.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical Sciences Graduate Program, McMaster University, Hamilton, ON, Canada.&#xD;Firestone Institute of Respiratory Health at St. Joseph&apos;s Healthcare, Department of Medicine, McMaster University, Hamilton, ON, Canada.&#xD;Respiratory Research Unit, Department of Respiratory Medicine, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark.&#xD;Copenhagen Center for Translational Research, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark.&#xD;Department of Medicine, McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Detecting immunoglobulins in processed sputa</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3798-3800</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/08/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulins</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Sputum</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34390600</style></accession-num><notes><style face="normal" font="default" size="100%">Cass, Steven P&#xD;McGrath, Joshua J C&#xD;Son, Kiho&#xD;Radford, Katherine&#xD;LaVigne, Nicola&#xD;Klein, Ditte K&#xD;Ditlev, Sisse B&#xD;Porsbjerg, Celeste&#xD;Nair, Parameswaran&#xD;Stampfli, Martin R&#xD;Mukherjee, Manali&#xD;eng&#xD;PJT-159792/CIHR/Canada&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3798-3800. doi: 10.1111/all.15049. Epub 2021 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34390600</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15049</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1960</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1960</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parsons, E. S.</style></author><author><style face="normal" font="default" size="100%">Liu, F.</style></author><author><style face="normal" font="default" size="100%">Kaushik, A.</style></author><author><style face="normal" font="default" size="100%">Lee, A.</style></author><author><style face="normal" font="default" size="100%">Schuetz, J.</style></author><author><style face="normal" font="default" size="100%">Dunham, D.</style></author><author><style face="normal" font="default" size="100%">Seastedt, H.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Heider, A.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Shah, A.</style></author><author><style face="normal" font="default" size="100%">Cao, S.</style></author><author><style face="normal" font="default" size="100%">Smith, E.</style></author><author><style face="normal" font="default" size="100%">Kost, L.</style></author><author><style face="normal" font="default" size="100%">Acharya, S.</style></author><author><style face="normal" font="default" size="100%">Prunicki, M.</style></author><author><style face="normal" font="default" size="100%">Rothenberg, M.</style></author><author><style face="normal" font="default" size="100%">Sindher, S.</style></author><author><style face="normal" font="default" size="100%">Leib, R.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Lejeune, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Palo Alto, California, USA.&#xD;Mass Spectrometry Center, Stanford University, Palo Alto, California, USA.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Pediatrics, Department of Allergy and Immunology, Cincinnati Children&apos;s Hospital, Cincinnati, Ohio, USA.&#xD;Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University, Stanford, California, USA.&#xD;Department of Environmental Health Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;INSERM U1019, CNRS UMR 9017, Center for infection and immunity of Lille (CIIL), Univ. Lille, CHU Lille, Institut Pasteur de Lille, Lille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Detection of gut and mucosal peptides through TOMAHAQ in healthy individuals</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2052-2055</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/03/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peptides</style></keyword><keyword><style face="normal" font="default" size="100%">*Mucous Membrane</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36872560</style></accession-num><notes><style face="normal" font="default" size="100%">Parsons, E S&#xD;Liu, F&#xD;Kaushik, A&#xD;Lee, A&#xD;Schuetz, J&#xD;Dunham, D&#xD;Seastedt, H&#xD;Ogulur, I&#xD;Heider, A&#xD;Tan, G&#xD;Shah, A&#xD;Cao, S&#xD;Smith, E&#xD;Kost, L&#xD;Acharya, S&#xD;Prunicki, M&#xD;Rothenberg, M&#xD;Sindher, S&#xD;Leib, R&#xD;Akdis, C A&#xD;Nadeau, K&#xD;Lejeune, S&#xD;eng&#xD;S10 OD030473/OD/NIH HHS/&#xD;R01 HL 118612/HL/NHLBI NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2052-2055. doi: 10.1111/all.15698. Epub 2023 Mar 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36872560</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15698</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1082</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1082</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thieme, C. J.</style></author><author><style face="normal" font="default" size="100%">Abou-El-Enein, M.</style></author><author><style face="normal" font="default" size="100%">Fritsche, E.</style></author><author><style face="normal" font="default" size="100%">Anft, M.</style></author><author><style face="normal" font="default" size="100%">Paniskaki, K.</style></author><author><style face="normal" font="default" size="100%">Skrzypczyk, S.</style></author><author><style face="normal" font="default" size="100%">Doevelaar, A.</style></author><author><style face="normal" font="default" size="100%">Elsallab, M.</style></author><author><style face="normal" font="default" size="100%">Brindle, N.</style></author><author><style face="normal" font="default" size="100%">Blazquez-Navarro, A.</style></author><author><style face="normal" font="default" size="100%">Seibert, F. S.</style></author><author><style face="normal" font="default" size="100%">Meister, T. L.</style></author><author><style face="normal" font="default" size="100%">Pfaender, S.</style></author><author><style face="normal" font="default" size="100%">Steinmann, E.</style></author><author><style face="normal" font="default" size="100%">Witzke, O.</style></author><author><style face="normal" font="default" size="100%">Westhoff, T. H.</style></author><author><style face="normal" font="default" size="100%">Stervbo, U.</style></author><author><style face="normal" font="default" size="100%">Heine, G.</style></author><author><style face="normal" font="default" size="100%">Roch, T.</style></author><author><style face="normal" font="default" size="100%">Babel, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Berlin Institute of Health at Charite - Universitatsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), and Institute of Medical Immunology, Berlin, Germany.&#xD;Division of Medical Oncology, Department of Medicine, and Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.&#xD;Joint USC/CHLA Cell Therapy Program, University of Southern California, and Children&apos;s Hospital Los Angeles, Los Angeles, CA, USA.&#xD;Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.&#xD;Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany.&#xD;Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.&#xD;Department of Molecular and Medical Virology, Ruhr-University Bochum, Bochum, Germany.&#xD;Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Detection of SARS-CoV-2-specific memory B cells to delineate long-term COVID-19 immunity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2595-2599</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Memory</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Spike Glycoprotein, Coronavirus</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">long-term immunity</style></keyword><keyword><style face="normal" font="default" size="100%">memory B cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33764510</style></accession-num><notes><style face="normal" font="default" size="100%">Thieme, Constantin J&#xD;Abou-El-Enein, Mohamed&#xD;Fritsche, Enrico&#xD;Anft, Moritz&#xD;Paniskaki, Krystallenia&#xD;Skrzypczyk, Sarah&#xD;Doevelaar, Adrian&#xD;Elsallab, Magdi&#xD;Brindle, Nicola&#xD;Blazquez-Navarro, Arturo&#xD;Seibert, Felix S&#xD;Meister, Toni L&#xD;Pfaender, Stephanie&#xD;Steinmann, Eike&#xD;Witzke, Oliver&#xD;Westhoff, Timm H&#xD;Stervbo, Ulrik&#xD;Heine, Guido&#xD;Roch, Toralf&#xD;Babel, Nina&#xD;eng&#xD;Mercator Foundation/&#xD;01ZX1612A/German Federal Ministry of Education and Research (BMBF)/&#xD;FKZ 13GW0338B/German Federal Ministry of Education and Research (BMBF)/&#xD;01DL20003/German Federal Ministry of Education and Research (BMBF)/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2595-2599. doi: 10.1111/all.14827. Epub 2021 May 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33764510</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8251309</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14827</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>375</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">375</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Doyle, A. D.</style></author><author><style face="normal" font="default" size="100%">Masuda, M. Y.</style></author><author><style face="normal" font="default" size="100%">Pyon, G. C.</style></author><author><style face="normal" font="default" size="100%">Luo, H.</style></author><author><style face="normal" font="default" size="100%">Putikova, A.</style></author><author><style face="normal" font="default" size="100%">LeSuer, W. E.</style></author><author><style face="normal" font="default" size="100%">Flashner, S.</style></author><author><style face="normal" font="default" size="100%">Rank, M. A.</style></author><author><style face="normal" font="default" size="100%">Nakagawa, H.</style></author><author><style face="normal" font="default" size="100%">Kita, H.</style></author><author><style face="normal" font="default" size="100%">Wright, B. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.&#xD;Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA.&#xD;Division of Pulmonology, Section of Allergy and Immunology, Phoenix Children&apos;s Hospital, Phoenix, Arizona, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Detergent exposure induces epithelial barrier dysfunction and eosinophilic inflammation in the esophagus</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">192-201</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/07/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Detergents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperplasia/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">detergent</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35899466</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic allergic disease associated with type 2 inflammation and epithelial barrier dysfunction. The etiology is unknown, however, genetic heritability studies suggest environmental factors play a key role in pathogenesis. Detergents, such as sodium dodecyl sulfate (SDS), are common ingredients in household products such as dish soap and toothpaste. We hypothesized detergent exposure decreases epithelial barrier function and induces esophageal inflammation. METHODS: Immortalized esophageal epithelial cells (EPC2) were cultured in air-liquid interface (ALI) and exposed to SDS. Barrier function/activity was assessed by transepithelial electrical resistance (TEER), FITC-dextran flux, and RT-PCR. Additionally, SDS-treated mouse esophageal organoids were evaluated for morphology. To investigate the effects of SDS in vivo, mice were treated with 0.5% SDS in drinking water for 14 days. Esophagi were assessed by gross morphology, histopathology, protein expression, and bulk RNA sequencing. RESULTS: When EPC2 cells were exposed to SDS (5 mug/ml) for 96 h, TEER decreased (p = 0.03), and FITC-dextran flux increased (p = 0.0002). mRNA expression of IL-33 increased 4.5-fold (p = 0.02) at 6 h and DSG1 decreased (p &lt; 0.0001) by 72 h. Disrupted epithelial integrity was noted in SDS-treated esophageal organoids. When mice were exposed to SDS, they showed increased esophageal width, chemokine, and metalloprotease levels. Mice treated with SDS also showed increased IL-33 protein expression, basal zone hyperplasia, CD4(+) cell infiltration, and esophageal eosinophilia. RNA sequencing revealed upregulation of immune response pathway genes. CONCLUSION: Exposure to SDS decreases esophageal barrier integrity, stimulates IL-33 production, and promotes epithelial hyperplasia and tissue eosinophilia. Detergents may be a key environmental trigger in EoE pathogenesis.</style></abstract><notes><style face="normal" font="default" size="100%">Doyle, Alfred D&#xD;Masuda, Mia Y&#xD;Pyon, Grace C&#xD;Luo, Huijun&#xD;Putikova, Arina&#xD;LeSuer, William E&#xD;Flashner, Samuel&#xD;Rank, Matthew A&#xD;Nakagawa, Hiroshi&#xD;Kita, Hirohito&#xD;Wright, Benjamin L&#xD;eng&#xD;R01 DK114436/DK/NIDDK NIH HHS/&#xD;R37 AI071106/AI/NIAID NIH HHS/&#xD;P30 DK132710/DK/NIDDK NIH HHS/&#xD;R01 AI128729/AI/NIAID NIH HHS/&#xD;R01 HL117823/HL/NHLBI NIH HHS/&#xD;R01 AA026297/AA/NIAAA NIH HHS/&#xD;U2C TR002818/TR/NCATS NIH HHS/&#xD;U54 AI117804/AI/NIAID NIH HHS/&#xD;L30 CA264714/CA/NCI NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):192-201. doi: 10.1111/all.15457. Epub 2022 Aug 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35899466</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9797443</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15457</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">16</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Detergent-induced eosinophilic inflammation in the esophagus: A key evidence for the epithelial barrier theory</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1422-1424</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Detergents</style></keyword><keyword><style face="normal" font="default" size="100%">Esophagus</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Sds</style></keyword><keyword><style face="normal" font="default" size="100%">detergent</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier theory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36645729</style></accession-num><notes><style face="normal" font="default" size="100%">Yazici, Duygu&#xD;Pat, Yagiz&#xD;Mitamura, Yasutaka&#xD;Akdis, Cezmi A&#xD;Ogulur, Ismail&#xD;eng&#xD;Comment&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1422-1424. doi: 10.1111/all.15646. Epub 2023 Mar 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36645729</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15646</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1958</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1958</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols-Vinueza, D. X.</style></author><author><style face="normal" font="default" size="100%">Mateja, A.</style></author><author><style face="normal" font="default" size="100%">Hatzimemos, A.</style></author><author><style face="normal" font="default" size="100%">Michael, M.</style></author><author><style face="normal" font="default" size="100%">Rasooly, M.</style></author><author><style face="normal" font="default" size="100%">Dempsey, C.</style></author><author><style face="normal" font="default" size="100%">Magnani, A.</style></author><author><style face="normal" font="default" size="100%">Brittain, E.</style></author><author><style face="normal" font="default" size="100%">Boyce, A. M.</style></author><author><style face="normal" font="default" size="100%">Frischmeyer-Guerrerio, P. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Laboratory of Allergic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.&#xD;Clinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, USA.&#xD;Nutrition Department, NIH Clinical Center, Bethesda, Maryland, USA.&#xD;Biostatistics Research Branch (BRB), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.&#xD;Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Determinants of bone density in children with immunoglobulin E-mediated food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2048-2051</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/03/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Bone Density</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36871185</style></accession-num><notes><style face="normal" font="default" size="100%">Nichols-Vinueza, Diana Ximena&#xD;Mateja, Allyson&#xD;Hatzimemos, Aristides&#xD;Michael, Madeline&#xD;Rasooly, Marjohn&#xD;Dempsey, Caeden&#xD;Magnani, Alaina&#xD;Brittain, Erica&#xD;Boyce, Alison M&#xD;Frischmeyer-Guerrerio, Pamela A&#xD;eng&#xD;DE/NIDCR NIH HHS/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2048-2051. doi: 10.1111/all.15696. Epub 2023 Mar 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36871185</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15696</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>728</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">728</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aliee, H.</style></author><author><style face="normal" font="default" size="100%">Massip, F.</style></author><author><style face="normal" font="default" size="100%">Qi, C.</style></author><author><style face="normal" font="default" size="100%">Stella de Biase, M.</style></author><author><style face="normal" font="default" size="100%">van Nijnatten, J.</style></author><author><style face="normal" font="default" size="100%">Kersten, E. T. G.</style></author><author><style face="normal" font="default" size="100%">Kermani, N. Z.</style></author><author><style face="normal" font="default" size="100%">Khuder, B.</style></author><author><style face="normal" font="default" size="100%">Vonk, J. M.</style></author><author><style face="normal" font="default" size="100%">Vermeulen, R. C. H.</style></author><author><style face="normal" font="default" size="100%">U. Biopred study group</style></author><author><style face="normal" font="default" size="100%">Cambridge Lung Cancer Early Detection, Programme</style></author><author><style face="normal" font="default" size="100%">I. NER-Ciencias Mexican Lung Program</style></author><author><style face="normal" font="default" size="100%">Neighbors, M.</style></author><author><style face="normal" font="default" size="100%">Tew, G. W.</style></author><author><style face="normal" font="default" size="100%">Grimbaldeston, M. A.</style></author><author><style face="normal" font="default" size="100%">Ten Hacken, N. H. T.</style></author><author><style face="normal" font="default" size="100%">Hu, S.</style></author><author><style face="normal" font="default" size="100%">Guo, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Sun, K.</style></author><author><style face="normal" font="default" size="100%">Hiemstra, P. S.</style></author><author><style face="normal" font="default" size="100%">Ponder, B. A.</style></author><author><style face="normal" font="default" size="100%">Makela, M. J.</style></author><author><style face="normal" font="default" size="100%">Malmstrom, K.</style></author><author><style face="normal" font="default" size="100%">Rintoul, R. C.</style></author><author><style face="normal" font="default" size="100%">Reyfman, P. A.</style></author><author><style face="normal" font="default" size="100%">Theis, F. J.</style></author><author><style face="normal" font="default" size="100%">Brandsma, C. A.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Timens, W.</style></author><author><style face="normal" font="default" size="100%">Xu, C. J.</style></author><author><style face="normal" font="default" size="100%">van den Berge, M.</style></author><author><style face="normal" font="default" size="100%">Schwarz, R. F.</style></author><author><style face="normal" font="default" size="100%">Koppelman, G. H.</style></author><author><style face="normal" font="default" size="100%">Nawijn, M. C.</style></author><author><style face="normal" font="default" size="100%">Faiz, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Computational Biology, Helmholtz Centre, Munich, Germany.&#xD;Berlin Institute for Medical Systems Biology, Max Delbruck Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.&#xD;University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.&#xD;Department of Pediatric Pulmonology and Pediatric Allergy, University of Groningen, University Medical Center Groningen, Beatrix Children&apos;s Hospital, Groningen, the Netherlands.&#xD;Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.&#xD;Respiratory Bioinformatics and Molecular Biology (RBMB), School of Life Sciences, University of Technology Sydney, Sydney, New South Wales, Australia.&#xD;Department of computing, Data Science Institute, Imperial College London, London, UK.&#xD;Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.&#xD;Division of Environmental Epidemiology (EEPI), Institute for Risk Assessment Science (IRAS), Utrecht University, Utrecht, The Netherlands.&#xD;OMNI Biomarker Development, Genentech Inc., South San Francisco, California, USA.&#xD;Product Development Immunology, Infectious Disease &amp; Opthalmology, Genentech Inc., South San Francisco, California, USA.&#xD;Department of statistics, University of Oxford, Oxford, UK.&#xD;Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.&#xD;Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.&#xD;Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.&#xD;Department of Allergy, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.&#xD;Royal Papworth Hospital, Cambridge, UK.&#xD;Department of Mathematics, Technical University of Munich, Munich, Germany.&#xD;Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;National Heart and Lung Institute, London, UK.&#xD;Research group Bioinformatics and Computational Genomics, Centre for Individualised Infection Medicine, CiiM, Hannover Medical School, Helmholtz Centre for Infection Research, Hannover, Germany.&#xD;Department of Gastroenterology, Hepatology and Endocrinology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover Medical School, Helmholtz Centre for Infection Research, Hannover, Germany.&#xD;Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Determinants of expression of SARS-CoV-2 entry-related genes in upper and lower airways</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">690-694</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Serine Endopeptidases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34698405</style></accession-num><notes><style face="normal" font="default" size="100%">Aliee, Hananeh&#xD;Massip, Florian&#xD;Qi, Cancan&#xD;Stella de Biase, Maria&#xD;van Nijnatten, Jos&#xD;Kersten, Elin T G&#xD;Kermani, Nazanin Z&#xD;Khuder, Basil&#xD;Vonk, Judith M&#xD;Vermeulen, Roel C H&#xD;Neighbors, Margaret&#xD;Tew, Gaik W&#xD;Grimbaldeston, Michele A&#xD;Ten Hacken, Nick H T&#xD;Hu, Sile&#xD;Guo, Yike&#xD;Zhang, Xiaoyu&#xD;Sun, Kai&#xD;Hiemstra, Pieter S&#xD;Ponder, Bruce A&#xD;Makela, Mika J&#xD;Malmstrom, Kristiina&#xD;Rintoul, Robert C&#xD;Reyfman, Paul A&#xD;Theis, Fabian J&#xD;Brandsma, Corry-Anke&#xD;Adcock, Ian M&#xD;Timens, Wim&#xD;Xu, Cheng-Jian&#xD;van den Berge, Maarten&#xD;Schwarz, Roland F&#xD;Koppelman, Gerard H&#xD;Nawijn, M C&#xD;Faiz, Alen&#xD;eng&#xD;115010/Innovative Medicines Initiative Joint/&#xD;The Netherlands Organization for Health Research and Development/&#xD;MR/T010371/1/MRC_/Medical Research Council/United Kingdom&#xD;Cancer Research UK Cambridge Centre/&#xD;K08 HL146943/HL/NHLBI NIH HHS/&#xD;874656/European Union&apos;s H2020 Research and Innovation Program/&#xD;AF 4.1.14.001/The Netherlands Lung Foundation/&#xD;Cambridge Bioresource/&#xD;Parker B. Francis Fellowship/&#xD;The Netherlands Organization for Scientific Research/&#xD;The Netherlands Ministry of Spatial Planning, Housing, and the Environment/&#xD;FP7/2007-2013/European Union&apos;s Seventh Framework Programme/&#xD;Longfonds Junior Fellowship/&#xD;NIH K08HL146943/Helmholtz Association/&#xD;The Netherlands Ministry of Health, Welfare, and Sport/&#xD;Chan Zuckerberg Initiative/&#xD;China Scholarship Council/&#xD;ATS Foundation/Boehringer Ingelheim Pharmaceuticals Inc. Research Fellowship/&#xD;Cambridge NIHR Biomedical Research Centre/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):690-694. doi: 10.1111/all.15152. Epub 2021 Nov 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34698405</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8652715 work.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15152</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>654</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">654</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blaiss, M. S.</style></author><author><style face="normal" font="default" size="100%">Gronskyte Juhl, R.</style></author><author><style face="normal" font="default" size="100%">Siew, L. Q. C.</style></author><author><style face="normal" font="default" size="100%">Hammerby, E.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical College of Georgia at Augusta University, Augusta, Georgia, USA.&#xD;ALK-Abello A/S, Horsholm, Denmark.&#xD;Department of Adult Allergy, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, United Kingdom.&#xD;Laboratoire de Pharmacologie Respiratoire - VIM Suresnes, Hopital Foch, Suresnes Universite Paris Saclay, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Determining the minimal important differences in the RQLQ score with grass and tree allergy immunotherapy versus placebo in adults with moderate-to-severe allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1843-1851</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/01/06</style></edition><section><style face="normal" font="default" size="100%">1843</style></section><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Poaceae/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/drug therapy/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy/adverse effects/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Trees</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinoconjunctivitis Quality of Life Questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">minimal important difference</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">Merck, speaker/writing fees from ALK-Abello and Merck, and has participated on a</style></keyword><keyword><style face="normal" font="default" size="100%">Data Safety Monitoring Board/Advisory Board for ALK-Abello and Merck. LS has no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest to declare. PD has received personal fees, speaker/writing</style></keyword><keyword><style face="normal" font="default" size="100%">fees, and meeting attendance support from ALK-Abello, consulting fees from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, Stallergenes Greer, GlaxoSmithKline, AstraZeneca, Chiesi, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">and Mylan/Meda Pharma. RGJ and EH are employees of ALK-Abello.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34986506</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Pollen from grasses and trees can trigger allergic rhinitis (AR), where the symptoms and associated consequences can negatively affect quality of life (QoL). The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) is frequently used in clinical trials of AR to assess QoL. To help interpret RQLQ data, the minimal important difference (MID) can be used to assess whether a mean difference in QoL between treatment groups is clinically meaningful. In seasonal allergy, an MID differs according to the allergen, pollen exposure, symptom severity, patient age and treatment; the same MID cannot be applied to all scenarios. METHODS: Using data from four Phase III clinical trials of SQ sublingual immunotherapy-tablets in adults with moderate-to-severe allergy, between-group MIDs were derived for the RQLQ in grass pollen allergy (during the peak [n = 501] and entire [n = 514] pollen seasons), and in tree pollen allergy (during the birch [n = 516] and tree [n = 518] pollen seasons), using anchor-based methodology, supported by distribution-based methods. RESULTS: For grass pollen allergy, anchor-based derived between-group MIDs were 0.22 for the entire pollen season (n = 343) and 0.10 for the peak pollen season (n = 335). For tree pollen allergy, anchor-based derived between-group MIDs were 0.26 for the tree pollen season (n = 306) and 0.16 for the birch pollen season (n = 305) (representative of peak season). Distribution-based derived MIDs were supportive of the anchor-based values. CONCLUSIONS: This analysis has derived between-group MIDs specific to the trial populations evaluated and to the conditions under which the data were obtained, and highlights the need for a range of MIDs to reflect the unique nature of seasonal allergic disease.</style></abstract><notes><style face="normal" font="default" size="100%">Blaiss, Michael S&#xD;Gronskyte Juhl, Ruta&#xD;Siew, Leonard Q C&#xD;Hammerby, Eva&#xD;Devillier, Philippe&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1843-1851. doi: 10.1111/all.15207. Epub 2022 Jan 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34986506</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9306835</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15207</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2691</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2691</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van Duuren, I. C.</style></author><author><style face="normal" font="default" size="100%">van Hengel, O. R. J.</style></author><author><style face="normal" font="default" size="100%">Penders, J.</style></author><author><style face="normal" font="default" size="100%">Duijts, L.</style></author><author><style face="normal" font="default" size="100%">Smits, H. H.</style></author><author><style face="normal" font="default" size="100%">Tramper-Stranders, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Franciscus Gasthuis &amp; Vlietland, Rotterdam, The Netherlands.&#xD;Department of Pediatrics, Division of Respiratory Medicine and Allergology, Sophia Children&apos;s Hospital - Erasmus MC, Rotterdam, The Netherlands.&#xD;Leiden University Center of Infectious Disease (LU-CID), Leiden, The Netherlands.&#xD;Department of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center+, Maastricht, The Netherlands.&#xD;Department of Neonatal and Pediatric Intensive Care, Division of Neonatology, Sophia Children&apos;s Hospital, ErasmusMC, Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The developing immune system in preterm born infants: From contributor to potential solution for respiratory tract infections and wheezing</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2924-2942</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Sounds/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Infant, Premature</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Tract Infections/immunology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">*Immune System/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">Microbiota/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">immune system</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">preterm</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory morbidity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39382056</style></accession-num><abstract><style face="normal" font="default" size="100%">Moderate-late preterm-born infants experience more frequent and severe respiratory tract infections and wheezing compared to term-born infants. Decreasing the risk on respiratory tract infections and wheezing in this group is vital to improve quality of life and reduce medical consumption during infancy, but also to reduce the risk on asthma and COPD later in life. Until now, moderate-late preterm infants are underrepresented in research and mechanisms underlying their morbidity are largely unknown, although they represent 80% of all preterm-born infants. In order to protect these infants effectively, it is essential to understand the role of the immune system in early life respiratory health and to identify strategies to optimize immune development and respiratory health. This review elaborates on risk factors and preventative measures concerning respiratory tract infections and wheezing in preterm-born infants, exploring their impact on the immune system and microbiome. Factors discussed are early life antibiotic use, birth mode, feeding type and living environment. Further, differences in adaptive and innate immune maturation between term and preterm infants are discussed, as well as differences in local immune reactions in the lungs. Finally, preventative strategies are being explored, including microbiota transplantation, immune modulation (through pre-, pro-, syn- and postbiotics, bacterial lysates, vaccinations, and monoclonal antibodies) and antibiotic prophylaxis.</style></abstract><notes><style face="normal" font="default" size="100%">van Duuren, Inger C&#xD;van Hengel, Oscar R J&#xD;Penders, John&#xD;Duijts, Liesbeth&#xD;Smits, Hermelijn H&#xD;Tramper-Stranders, Gerdien A&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):2924-2942. doi: 10.1111/all.16342. Epub 2024 Oct 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39382056</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16342</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2633</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2633</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anagnostou, A.</style></author><author><style face="normal" font="default" size="100%">Abrams, E. M.</style></author><author><style face="normal" font="default" size="100%">Carver, M.</style></author><author><style face="normal" font="default" size="100%">Chan, E. S.</style></author><author><style face="normal" font="default" size="100%">Eftekhari, S.</style></author><author><style face="normal" font="default" size="100%">Greiwe, J.</style></author><author><style face="normal" font="default" size="100%">Jaffee, H.</style></author><author><style face="normal" font="default" size="100%">Lieberman, J. A.</style></author><author><style face="normal" font="default" size="100%">Mack, D. P.</style></author><author><style face="normal" font="default" size="100%">Mustafa, S. S.</style></author><author><style face="normal" font="default" size="100%">Shaker, M. S.</style></author><author><style face="normal" font="default" size="100%">Stukus, D.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Greenhawt, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Immunology, Texas Children&apos;s Hospital, Houston, Texas, USA.&#xD;Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.&#xD;Department of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, Winnipeg, Manitoba, Canada.&#xD;The Asthma and Allergy Foundation of America, Arlington, Virginia, USA.&#xD;Division of Allergy, Department of Pediatrics, BC Children&apos;s Hospital, University of British Columbia, Vancouver, British Columbia, Canada.&#xD;Bernstein Allergy Group, Inc., Cincinnati, Ohio, USA.&#xD;Division of Immunology/Allergy Section, Department of Internal Medicine, The University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;The University of Tennessee Health Science Center, Memphis, Tennessee, USA.&#xD;Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.&#xD;Rochester Regional Health, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.&#xD;Dartmouth Hitchcock Medical Center, Section of Allergy and Clinical Immunology, Lebanon, New Hampshire, USA.&#xD;Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.&#xD;Division of Allergy and Immunology, Nationwide Children&apos;s Hospital, Columbus, Ohio, USA.&#xD;The Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, Jaffe Food Allergy Institute, New York, New York, USA.&#xD;Section of Allergy and Clinical Immunology, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development and acceptability of a decision-aid for food allergy oral immunotherapy in children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">205-214</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/09/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Decision Support Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Acceptance of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">allergen avoidance</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">decisional acceptability</style></keyword><keyword><style face="normal" font="default" size="100%">decisional conflict</style></keyword><keyword><style face="normal" font="default" size="100%">decisional self-efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">decision-aid</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">shared decision-making</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39324369</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Limited decision-support tools are available to help shared decision-making (SDM) regarding food oral immunotherapy (OIT) initiation. No current tool covers all foods, forms, and pediatric ages for which OIT is offered. METHODS: In compliance with International Patient Decision Aid Standards criteria, this pediatric decision-aid comparing OIT versus avoidance was developed in three stages. Nested qualitative data assessing OIT decisional needs were supplemented with evidence-synthesis from the OIT literature to create the prototype decision-aid content. This underwent iterative development with food allergy experts and patient advocacy stakeholders until unanimous consensus was reached regarding content, bias, readability, and utility in making a choice. Lastly, the tool underwent validated assessment of decisional acceptability, decisional conflict, and decisional self-efficacy. RESULTS: The decision-aid underwent 5 iterations, resulting in a 4-page written aid (Flesch-Kincaid reading level 6.1) explaining therapy choices, risks and benefits, providing self-rating for attribute importance for the options and self-assessment regarding how adequate the information was in decision-making. A total of n = 135 caregivers of food-allergic children assessed the decision-aid, noting good acceptability, high decisional self-efficacy (mean score 85.9/100) and low decisional conflict (mean score 20.9/100). Information content was rated adequate and sufficient, the therapy choices wording balanced, and presented without bias for a &quot;best choice.&quot; Lower decisional conflict was associated with caregiver-reported anaphylaxis. CONCLUSIONS: This first pediatric OIT decision-aid, agnostic to product, allergen, and age has good acceptability, limited bias, and is associated with low decisional conflict and high decisional self-efficacy. It supports SDM in navigating the decision to start OIT or continue allergen avoidance.</style></abstract><notes><style face="normal" font="default" size="100%">Anagnostou, Aikaterini&#xD;Abrams, Elissa M&#xD;Carver, Melanie&#xD;Chan, Edmond S&#xD;Eftekhari, Sanaz&#xD;Greiwe, Justin&#xD;Jaffee, Hannah&#xD;Lieberman, Jay A&#xD;Mack, Douglas P&#xD;Mustafa, S Shahzad&#xD;Shaker, Marcus S&#xD;Stukus, David&#xD;Wang, Julie&#xD;Greenhawt, Matthew&#xD;eng&#xD;R13 AI112228/AI/NIAID NIH HHS/&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):205-214. doi: 10.1111/all.16332. Epub 2024 Sep 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39324369</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11934854</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16332</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3016</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3016</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Battut, L.</style></author><author><style face="normal" font="default" size="100%">Kamphuis, J.</style></author><author><style face="normal" font="default" size="100%">Serhan, N.</style></author><author><style face="normal" font="default" size="100%">Reber, L.</style></author><author><style face="normal" font="default" size="100%">Cenac, N.</style></author><author><style face="normal" font="default" size="100%">Dietrich, G.</style></author><author><style face="normal" font="default" size="100%">Espinosa, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut de Recherche en Sante Digestive (IRSD), INSERM U1220, INRA, INP-ENVT, University of Toulouse, Toulouse, France.&#xD;Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), UMR 1291, INSERM, CNRS, University of Toulouse, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development and Characterisation of a New In Vitro Murine Mucosal Mast Cell Model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2926-2930</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal mast cell model</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40878968</style></accession-num><notes><style face="normal" font="default" size="100%">Battut, Louise&#xD;Kamphuis, Jasper&#xD;Serhan, Nadine&#xD;Reber, Laurent&#xD;Cenac, Nicolas&#xD;Dietrich, Gilles&#xD;Espinosa, Eric&#xD;eng&#xD;Institut National de la Sante et de la Recherche Medicale/&#xD;Fondation pour la Recherche Medicale/&#xD;Universite de Toulouse/&#xD;Agence Nationale de la Recherche/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2926-2930. doi: 10.1111/all.70022. Epub 2025 Aug 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40878968</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486343</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70022</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>915</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">915</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Conde, E.</style></author><author><style face="normal" font="default" size="100%">Bruhns, P.</style></author><author><style face="normal" font="default" size="100%">Serra, V.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut Pasteur, Unit of Antibodies in Therapy and Pathology, UMR 1222 INSERM, Paris, France.&#xD;Neovacs SA, Paris, France.&#xD;Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development and preclinical evaluation of a vaccine targeting IL-4 and IL-13 for the treatment of allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3553-3555</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34224596</style></accession-num><notes><style face="normal" font="default" size="100%">Conde, Eva&#xD;Bruhns, Pierre&#xD;Serra, Vincent&#xD;Reber, Laurent L&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3553-3555. doi: 10.1111/all.14998. Epub 2021 Jul 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34224596</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14998</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1925</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1925</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Conde, E.</style></author><author><style face="normal" font="default" size="100%">Bruhns, P.</style></author><author><style face="normal" font="default" size="100%">Serra, V.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut Pasteur, Unit of Antibodies in Therapy and Pathology, UMR 1222 INSERM, Paris, France.&#xD;Neovacs SA, Paris, France.&#xD;Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development and preclinical evaluation of a vaccine targeting IL-4 and IL-13 for the treatment of allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3553-3555</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34224596</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Asthma is the most prevalent chronic respiratory disease, affecting more than 300 million people worldwide1. Although asthma is a heterogenous disease that presents with various phenotypes, around 50 % of the patients suffer from type 2 inflammation, characterized by elevated levels of IgE, type 2 cytokines such as IL-4 and IL-13 and eosinophilia1.</style></abstract><notes><style face="normal" font="default" size="100%">Conde, Eva&#xD;Bruhns, Pierre&#xD;Serra, Vincent&#xD;Reber, Laurent L&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3553-3555. doi: 10.1111/all.14998. Epub 2021 Jul 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34224596</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14998</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>662</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">662</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Azevedo, L. F.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Laune, D.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Anto, A.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Eklund, P.</style></author><author><style face="normal" font="default" size="100%">Almeida, R.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Bosnic-Anticevich, S.</style></author><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Charpin, D.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Costa, E. M.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Dramburg, S.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">De Feo, G.</style></author><author><style face="normal" font="default" size="100%">Gerth van Wijk, R.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Illario, M.</style></author><author><style face="normal" font="default" size="100%">Ivancevich, J. C.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Mathieu-Dupas, E.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, N.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Stellato, C.</style></author><author><style face="normal" font="default" size="100%">Todo-Bom, A.</style></author><author><style face="normal" font="default" size="100%">Tomazic, P. V.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Valero, A.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Wallace, D.</style></author><author><style face="normal" font="default" size="100%">Waserman, S.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">De Vries, G.</style></author><author><style face="normal" font="default" size="100%">van Eerd, M.</style></author><author><style face="normal" font="default" size="100%">Zieglmayer, P.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Almeida Fonseca, J.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS - Center for Health Technology and Services Research, University of Porto, Porto, Portugal.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Personalized Medicine, Asthma &amp; Allergy -Humanitas Clinical &amp; Research Centre, IRCCS, Rozzano, Italy.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;ARIA, Montpellier, France.&#xD;Allergy Department, 2nd Pediatric Clinic, Athens General Children&apos;s Hospital &quot;P&amp;A Kyriakou&quot;, University of Athens, Athens, Greece.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Institute for Allergology, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;UPRES EA220, Pole des Maladies des Voies Respiratoires, Hopital Foch, Universite Paris-Saclay, Suresnes, France.&#xD;KYomed INNOV, Montpellier, France.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;ISGlobAL, Barcelona Institute for Global Health, Barcelona, Spain.&#xD;IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Computing Science Department, Umea University, Umea, Finland.&#xD;MACVIA-France, Montpellier, France.&#xD;Quality Use of Respiratory Medicine Group, Woolcock Institute of Medical Research, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Sydney Local Health District, Sydney, New South Wales, Australia.&#xD;Division of Allergy/Immunology, University of South Florida, Tampa, Florida, USA.&#xD;Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino &amp; Mauriziano Hospital, Torino, Italy.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall d&apos;Hebron &amp; ARADyAL Research Network, Barcelona, Spain.&#xD;SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Clinique des Bronches, Allergie et Sommeil, Hopital Nord, Marseille, France.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Faculty of Pharmacy and Competence Center on Active and Healthy Ageing, University of Porto (Porto4Ageing), UCIBIO, REQUINTE, Porto, Portugal.&#xD;Fundacao ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Brazil.&#xD;Department of Pediatric Pneumology, Immunology and Intensive Care Medicine, Charite Medical University, Berlin, Germany.&#xD;Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Medicine, Surgery and Dentistry &quot;Scuola Medica Salernitana&quot;, University of Salerno, Salerno, Italy.&#xD;Section of Allergology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.&#xD;Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Department of Public Health and Research and Development Unit, Federico II University and Hospital, Naples, Italy.&#xD;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania.&#xD;Faculty of Medicine, Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Vilnius University, Vilnius, Lithuania.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;Allergy Unit &quot;D Kalogeromitros&quot;, 2nd Department of Dermatology and Venereology, National &amp; Kapodistrian University of Athens, &quot;Attikon&quot; University Hospital, Athens, Greece.&#xD;Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;CRI-Clinical Research International-Ltd, Hamburg, Germany.&#xD;Rhinology Unit &amp; Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain.&#xD;Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.&#xD;IRBA (Institut de Recherche bio-Medicale des Armees), Ecole Polytechnique Palaiseau, Bretigny, France.&#xD;Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University and Alfred Health, Melbourne, Victoria, Australia.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.&#xD;Institute of Immunology, Faculty of Medicine, University of Coimbra, Portugal.&#xD;ICBR - Coimbra Institute for Clinical and Biomedical Research, CIBB, Coimbra, Portugal.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, The Netherlands.&#xD;Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland.&#xD;Usher Institute, The University of Edinburgh, Edinburgh, UK.&#xD;Imunoalergologia, Centro Hospitalar Universitario de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Department of General ORL, H&amp;NS, Medical University of Graz, ENT-University Hospital Graz, Austria.&#xD;Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Pneumology and Allergy Department CIBERES and Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Spain.&#xD;Faculty of Medicine, Institute of Clinical Medicine &amp; Institute of Health Sciences, Vilnius University, Vilnius, Lithuania.&#xD;European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium.&#xD;Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.&#xD;Nova Southeastern University, Fort Lauderdale, Florida, USA.&#xD;Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.&#xD;Peercode BV, Geldermalsen, The Netherlands.&#xD;Vienna Challenge Chamber, Vienna, Austria.&#xD;Competence Center for Allergology and Immunology, Karl Landsteiner University, Krems, Austria.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Departamento Medicina da Comunidade, Informacao e Decisao em Saude (MEDCIDS), Faculdada de Medicina da Universidade do Porto, Porto, Portugal.&#xD;Medicina, EDucacao, I&amp;D e Avaliacao, Lda (MEDIDA), Porto, Portugal.&#xD;Imunoalergologia, CUF, Porto, Portugal.&#xD;University Hospital Montpellier, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development and validation of combined symptom-medication scores for allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2147-2162</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/12/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">medication score</style></keyword><keyword><style face="normal" font="default" size="100%">quality-of-life</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">symptom score</style></keyword><keyword><style face="normal" font="default" size="100%">work</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34932829</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air((R)) app to generate and validate hypothesis- and data-driven CSMSs. METHODS: We used MASK-air((R)) data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air((R)) data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air((R)) , and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT]). RESULTS: We assessed 317,176 days of MASK-air((R)) use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820). CONCLUSION: The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials.</style></abstract><notes><style face="normal" font="default" size="100%">Sousa-Pinto, Bernardo&#xD;Azevedo, Luis Filipe&#xD;Jutel, Marek&#xD;Agache, Ioana&#xD;Canonica, G Walter&#xD;Czarlewski, Wienczyslawa&#xD;Papadopoulos, Nikolaos G&#xD;Bergmann, Karl-Christian&#xD;Devillier, Philippe&#xD;Laune, Daniel&#xD;Klimek, Ludger&#xD;Anto, Aram&#xD;Anto, Josep M&#xD;Eklund, Patrik&#xD;Almeida, Rute&#xD;Bedbrook, Anna&#xD;Bosnic-Anticevich, Sinthia&#xD;Brough, Helen A&#xD;Brussino, Luisa&#xD;Cardona, Victoria&#xD;Casale, Thomas&#xD;Cecchi, Lorenzo&#xD;Charpin, Denis&#xD;Chivato, Tomas&#xD;Costa, Elisio M&#xD;Cruz, Alvaro A&#xD;Dramburg, Stephanie&#xD;Durham, Stephen R&#xD;De Feo, Giulia&#xD;Gerth van Wijk, Roy&#xD;Fokkens, Wystke J&#xD;Gemicioglu, Bilun&#xD;Haahtela, Tari&#xD;Illario, Maddalena&#xD;Ivancevich, Juan Carlos&#xD;Kvedariene, Violeta&#xD;Kuna, Piotr&#xD;Larenas-Linnemann, Desiree E&#xD;Makris, Michael&#xD;Mathieu-Dupas, Eve&#xD;Melen, Erik&#xD;Morais-Almeida, Mario&#xD;Mosges, Ralph&#xD;Mullol, Joaquim&#xD;Nadeau, Kari C&#xD;Pham-Thi, Nhan&#xD;O&apos;Hehir, Robyn&#xD;Regateiro, Frederico S&#xD;Reitsma, Sietze&#xD;Samolinski, Boleslaw&#xD;Sheikh, Aziz&#xD;Stellato, Cristiana&#xD;Todo-Bom, Ana&#xD;Tomazic, Peter Valentin&#xD;Toppila-Salmi, Sanna&#xD;Valero, Antonio&#xD;Valiulis, Arunas&#xD;Ventura, Maria Teresa&#xD;Wallace, Dana&#xD;Waserman, Susan&#xD;Yorgancioglu, Arzu&#xD;De Vries, Govert&#xD;van Eerd, Michiel&#xD;Zieglmayer, Petra&#xD;Zuberbier, Torsten&#xD;Pfaar, Oliver&#xD;Almeida Fonseca, Joao&#xD;Bousquet, Jean&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2147-2162. doi: 10.1111/all.15199. Epub 2022 Jan 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34932829</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15199</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>718</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">718</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Gomez Garcia, I.</style></author><author><style face="normal" font="default" size="100%">Gonzalo-Fernandez, A.</style></author><author><style face="normal" font="default" size="100%">Fuentes Ferrer, M.</style></author><author><style face="normal" font="default" size="100%">Dolle-Bierke, S.</style></author><author><style face="normal" font="default" size="100%">Marco-Martin, G.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B. K.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author><author><style face="normal" font="default" size="100%">Belohlavkova, S.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">de Blay, F.</style></author><author><style face="normal" font="default" size="100%">Clausen, M.</style></author><author><style face="normal" font="default" size="100%">Datema, M. R.</style></author><author><style face="normal" font="default" size="100%">Dubakiene, R.</style></author><author><style face="normal" font="default" size="100%">Grimshaw, K. E. C.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Hourihane, J. O.</style></author><author><style face="normal" font="default" size="100%">Jedrzejczak-Czechowicz, M.</style></author><author><style face="normal" font="default" size="100%">Knulst, A. C.</style></author><author><style face="normal" font="default" size="100%">Kralimarkova, T.</style></author><author><style face="normal" font="default" size="100%">Le, T. M.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Poulsen, L. K.</style></author><author><style face="normal" font="default" size="100%">Purohit, A.</style></author><author><style face="normal" font="default" size="100%">Seneviratne, S. L.</style></author><author><style face="normal" font="default" size="100%">Simpson, A.</style></author><author><style face="normal" font="default" size="100%">Sinaniotis, A.</style></author><author><style face="normal" font="default" size="100%">Turkalji, M.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Cortes, S.</style></author><author><style face="normal" font="default" size="100%">Vera-Berrios, R. N.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Perez, C.</style></author><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author><author><style face="normal" font="default" size="100%">Mills, E. N. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, Hospital Clinico San Carlos, Facultad de Medicina, Universidad Complutense (UCM), IdISSC, ARADyAL, Madrid, Spain.&#xD;Grupo de Investigacion en Alergia, IdISSC, Madrid, Spain.&#xD;Unidad de Apoyo a la Investigacion, Preventive Medicine Department, Hospital Clinico San Carlos, IdISSC, Universidad Alfonso X El Sabio, Madrid, Spain.&#xD;Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;Allergy Department, Hospital Clinico San Carlos, IdISSC, ARADyAL, Madrid, Spain.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Clinic for Dermatology and Allergology, Kantonsspital St Gallen, St Gallen, Switzerland.&#xD;Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Milan, Italy.&#xD;Medical Faculty and Faculty Hospital Pilsen, Pilsen, Czech Republic.&#xD;Department of Pediatric Respiratory Medicine, Immunology and Intensive Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Chest Diseases Department, Strasbourg University Hospital, Federation of Translational Medicine, University of Strasbourg, Strasbourg, France.&#xD;Children&apos;s Hospital and Department of Allergy, Landspitali University Hospital, Reykjavik, Iceland.&#xD;Department of Experimental Immunology, and Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Center, Amsterdam, The Netherlands.&#xD;Medical Faculty, Vilnius University, Vilnius, Lithuania.&#xD;Department of Dietetics, Salford Royal NHS Foundation Trust, Salford, UK.&#xD;Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Royal College of Surgeons in Ireland, Children&apos;s Health Ireland at Temple Street, Dublin, Ireland.&#xD;Department of Allergy and Immunology, Medical University of Lodz, Lodz, Poland.&#xD;Dept. Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.&#xD;Clinic of Allergy and Asthma, Medical University in Sofia, Sofia, Bulgaria.&#xD;Allergy Dpt, 2nd Pediatric clinic, University of Athens, Athens, Greece.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, University of Manchester, Manchester, UK.&#xD;University Hospital Sv. Ivan Rilski, Sofia, Bulgaria.&#xD;Allergy Clinic, Copenhagen University Hospital at Herlev-Gentofte, Copenhagen, Denmark.&#xD;Allergy Division, Chest Disease Department, University Hospital of Strasbourg, Strasbourg, France.&#xD;Department of Clinical Immunology and Allergy, Central Manchester and Manchester Children&apos;s University Hospitals NHS Trust, Manchester, UK.&#xD;Institute of Immunity and Transplantation, Royal Free Hospital and University College London, London, UK.&#xD;Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, and Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Allergy Department, Sotiria Chest Diseases Hospital, Athens, Greece.&#xD;Srebrnjak Children&apos;s Hospital Zagreb, Catholic University of Croatia Zagreb, and Medical Faculty Osijek, J.J.Strossmayer University, Osijek, Croatia.&#xD;Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Clinical and Experimental Sciences and Human Development in Health, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;Departments of Experimental Immunology and of Otorhinoraryngology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.&#xD;Preventive Medicine Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.&#xD;Preventive Medicine Department, Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain.&#xD;National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Sciences Centre, Manchester Institute of Biotechnology, University of Manchester, Manchester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development and validation of the food allergy severity score</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1545-1558</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/10/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Area Under Curve</style></keyword><keyword><style face="normal" font="default" size="100%">Food</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">ROC Curve</style></keyword><keyword><style face="normal" font="default" size="100%">allergic reactions</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">score</style></keyword><keyword><style face="normal" font="default" size="100%">severity</style></keyword><keyword><style face="normal" font="default" size="100%">iFAAM project related to the work reported in this manuscript</style></keyword><keyword><style face="normal" font="default" size="100%">research grants to</style></keyword><keyword><style face="normal" font="default" size="100%">her institution from Spanish Government (MINECO, ISCIII), and Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics and Diater, consultancy fees from Aimmune Therapeutics, Novartis and</style></keyword><keyword><style face="normal" font="default" size="100%">SPRIM, fees for participation in DSMB from DBV, lecture fees from Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, ALK, Allergy Therapeutics, Diater, GSK, HAL Allergy and Thermo</style></keyword><keyword><style face="normal" font="default" size="100%">Fisher Scientific, outside the submitted work. Dr. Beyer reports grants/research</style></keyword><keyword><style face="normal" font="default" size="100%">supports from Aimmune Therapeutics, Danone/Nutricia/Milupa, DBV, Hipp, Hycor,</style></keyword><keyword><style face="normal" font="default" size="100%">Infectopharm and honoraria or consultation fees from Aimmune Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard, Danone/Nutricia/Milupa, DBV, Hipp, Hycor, Infectopharm, Jenapharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Mylan/Meda, Nestle, Novartis, Thermo Fisher outside of the submitted work. Dr de</style></keyword><keyword><style face="normal" font="default" size="100%">Blay reports advisory board membership of Aimmune Therapeutics, Stallergenes</style></keyword><keyword><style face="normal" font="default" size="100%">Greer, Mundipharma, Novartis, Regeneron, DVB, Sanofi, ALK, Boehringer, and</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, outside the submitted work. Dr Hourihane reports research funding</style></keyword><keyword><style face="normal" font="default" size="100%">from Aimmune Therapeutics, DBV Technologies, Johnson&amp;Johnson, Dublin Skin and</style></keyword><keyword><style face="normal" font="default" size="100%">Cancer Hospital Charity, National Children&apos;s Research Centre, Dublin, Ireland,</style></keyword><keyword><style face="normal" font="default" size="100%">Temple St Hospital Foundation Charity and Clemens von Pirquet Foundation</style></keyword><keyword><style face="normal" font="default" size="100%">advisory board membership of Aimmune Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">speaker bureaux of Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, DBV Technologies and Danone-Nutricia, outside the submitted work.</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Papadopoulos reports research Support from Gerolymatos Int, Capricare,</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia, Vian</style></keyword><keyword><style face="normal" font="default" size="100%">Speaker/Chairperson fees from HAL, Menarini/Faes Farma, MSD,</style></keyword><keyword><style face="normal" font="default" size="100%">Biomay, Novartis, Nutricia, Sanofi, Boehringer Ingelheim, Mylan/Meda, Asit</style></keyword><keyword><style face="normal" font="default" size="100%">Biotech</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory board fees from HAL, Menarini/Faes Farma, Novartis, Nutricia,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, AstraZeneca, Mylan/Meda, outside the submitted work. Prof. Worm declares the</style></keyword><keyword><style face="normal" font="default" size="100%">receipt of honoraria or consultation fees by the following companies: ALK-Abello</style></keyword><keyword><style face="normal" font="default" size="100%">Arzneimittel GmbH, Mylan Germany GmbH, Leo Pharma GmbH, Sanofi-Aventis</style></keyword><keyword><style face="normal" font="default" size="100%">Deutschland GmbH, Regeneron Pharmaceuticals, DBV Technologies S.A, Stallergenes</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, HAL Allergie GmbH, Allergopharma GmbH &amp; Co.KG, Bencard Allergie GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis AG, Biotest AG., AbbVie Deutschland GmbH &amp; Co. KG and Lilly Deutschland</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, outside the submitted work. Prof. Roberts reports funding to his</style></keyword><keyword><style face="normal" font="default" size="100%">institution by the European Commission and the UK Food Standards Agency to</style></keyword><keyword><style face="normal" font="default" size="100%">undertake research as part of iFAAM, for the reported work in this manuscript. Dr</style></keyword><keyword><style face="normal" font="default" size="100%">van Ree reports research grant from EU FP7 for the iFAAM Project for the reported</style></keyword><keyword><style face="normal" font="default" size="100%">work in this manuscript</style></keyword><keyword><style face="normal" font="default" size="100%">research grants from EU FP7, Dutch Science Foundation,</style></keyword><keyword><style face="normal" font="default" size="100%">and Health Holland, a research contract from Agany Inc., consulting fees from HAL</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy BV, Citeq BV, Angany Inc., lecture fees from HAL Allergy BV, ALK and</style></keyword><keyword><style face="normal" font="default" size="100%">Thermo Fisher Scientific, support for attending meetings from HAL Allergy BV,</style></keyword><keyword><style face="normal" font="default" size="100%">advisory board fees from HAL Allergy BV and Agany Inc., stock options from Agany</style></keyword><keyword><style face="normal" font="default" size="100%">Inc., outside the submitted work. Dr Turner reports grants from European</style></keyword><keyword><style face="normal" font="default" size="100%">Commission H2020 iFAAM collaboration for the reported work in this manuscript</style></keyword><keyword><style face="normal" font="default" size="100%">grants from UK Medical Research Council, NIHR/Imperial BRC, and UK Food Standards</style></keyword><keyword><style face="normal" font="default" size="100%">Agency</style></keyword><keyword><style face="normal" font="default" size="100%">advisory board fees from ILSI Europe, Aimmune Therapeutics, and</style></keyword><keyword><style face="normal" font="default" size="100%">AllerGenis, outside the submitted work. Dr. Mills owns founder shares in Reacta</style></keyword><keyword><style face="normal" font="default" size="100%">Biotech Ltd, a company developing oral food challenge diagnostics for food</style></keyword><keyword><style face="normal" font="default" size="100%">allergy. Funding for research and consultancy is received from the company</style></keyword><keyword><style face="normal" font="default" size="100%">through the University of Manchester. All other authors declare no conflicts of</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34716996</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The heterogeneity and lack of validation of existing severity scores for food allergic reactions limit standardization of case management and research advances. We aimed to develop and validate a severity score for food allergic reactions. METHODS: Following a multidisciplinary experts consensus, it was decided to develop a food allergy severity score (FASS) with ordinal (oFASS) and numerical (nFASS) formats. oFASS with 3 and 5 grades were generated through expert consensus, and nFASS by mathematical modeling. Evaluation was performed in the EuroPrevall outpatient clinic cohort (8232 food reactions) by logistic regression with request of emergency care and medications used as outcomes. Discrimination, classification, and calibration were calculated. Bootstrapping internal validation was followed by external validation (logistic regression) in 5 cohorts (3622 food reactions). Correlation of nFASS with the severity classification done by expert allergy clinicians by Best-Worst Scaling of 32 food reactions was calculated. RESULTS: oFASS and nFASS map consistently, with nFASS having greater granularity. With the outcomes emergency care, adrenaline and critical medical treatment, oFASS and nFASS had a good discrimination (receiver operating characteristic area under the curve [ROC-AUC]&gt;0.80), classification (sensitivity 0.87-0.92, specificity 0.73-0.78), and calibration. Bootstrapping over ROC-AUC showed negligible biases (1.0 x 10(-6) -1.23 x 10(-3) ). In external validation, nFASS performed best with higher ROC-AUC. nFASS was strongly correlated (R 0.89) to best-worst scoring of 334 expert clinicians. CONCLUSION: FASS is a validated and reliable method to measure severity of food allergic reactions. The ordinal and numerical versions that map onto each other are suitable for use by different stakeholders in different settings.</style></abstract><notes><style face="normal" font="default" size="100%">Fernandez-Rivas, Montserrat&#xD;Gomez Garcia, Ismael&#xD;Gonzalo-Fernandez, Alejandro&#xD;Fuentes Ferrer, Manuel&#xD;Dolle-Bierke, Sabine&#xD;Marco-Martin, Guadalupe&#xD;Ballmer-Weber, Barbara K&#xD;Asero, Riccardo&#xD;Belohlavkova, Simona&#xD;Beyer, Kirsten&#xD;de Blay, Frederic&#xD;Clausen, Michael&#xD;Datema, Mareen R&#xD;Dubakiene, Ruta&#xD;Grimshaw, Kate E C&#xD;Hoffmann-Sommergruber, Karin&#xD;Hourihane, Jonathan O&apos;B&#xD;Jedrzejczak-Czechowicz, Monika&#xD;Knulst, Andre C&#xD;Kralimarkova, Tanya&#xD;Le, Thuy-My&#xD;Papadopoulos, Nikolaos G&#xD;Popov, Todor A&#xD;Poulsen, Lars K&#xD;Purohit, Ashok&#xD;Seneviratne, Suranjith L&#xD;Simpson, Angela&#xD;Sinaniotis, Atanasios&#xD;Turkalji, Mirjana&#xD;Vazquez-Cortes, Sonia&#xD;Vera-Berrios, Rosialzira N&#xD;Muraro, Antonella&#xD;Worm, Margitta&#xD;Roberts, Graham&#xD;van Ree, Ronald&#xD;Fernandez-Perez, Cristina&#xD;Turner, Paul J&#xD;Mills, Elizabeth N Clare&#xD;eng&#xD;MR/K010468/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1545-1558. doi: 10.1111/all.15165. Epub 2021 Nov 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34716996</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9298738</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15165</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2291</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2291</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muller, S.</style></author><author><style face="normal" font="default" size="100%">Welchowski, T.</style></author><author><style face="normal" font="default" size="100%">Schmid, M.</style></author><author><style face="normal" font="default" size="100%">Maintz, L.</style></author><author><style face="normal" font="default" size="100%">Herrmann, N.</style></author><author><style face="normal" font="default" size="100%">Wilsmann-Theis, D.</style></author><author><style face="normal" font="default" size="100%">Royeck, T.</style></author><author><style face="normal" font="default" size="100%">Havenith, R.</style></author><author><style face="normal" font="default" size="100%">Bieber, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.&#xD;Christine Kuhne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.&#xD;Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the &quot;Flip-Flop&quot; phenomenon)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">164-173</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Psoriasis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Cutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">Germany/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">differential diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword><keyword><style face="normal" font="default" size="100%">psoriasis</style></keyword><keyword><style face="normal" font="default" size="100%">validation study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37864390</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) and psoriasis vulgaris (PV) are almost mutually exclusive diseases with different immune polarizations, mechanisms and therapeutic targets. Switches to the other disease (&quot;Flip-Flop&quot; [FF] phenomenon) can occur with or without systemic treatment and are often referred to as paradoxical reactions under biological therapy. METHODS: The objective was to develop a diagnostic algorithm by combining clinical criteria of AD and PV to identify FF patients. The algorithm was prospectively validated in patients enrolled in the CK-CARE registry in Bonn, Germany. Afterward, algorithm refinements were implemented based on machine learning. RESULTS: Three hundred adult Caucasian patients were included in the validation study (n = 238 with AD, n = 49 with PV, n = 13 with FF; mean age 41.2 years; n = 161 [53.7%] female). The total FF scores of the PV and AD groups differed significantly from the FF group in the validation data (p &lt; .001). The predictive mean generalized Youden-Index of the initial model was 78.9% [95% confidence interval 72.0%-85.6%] and the accuracy was 89.7%. Disease group-specific sensitivity was 100% (FF), 95.0% (AD), and 61.2% (PV). The specificity was 89.2% (FF), 100% (AD), and 100% (PV), respectively. CONCLUSION: The FF algorithm represents the first validated tool to identify FF patients.</style></abstract><notes><style face="normal" font="default" size="100%">Muller, Svenja&#xD;Welchowski, Thomas&#xD;Schmid, Matthias&#xD;Maintz, Laura&#xD;Herrmann, Nadine&#xD;Wilsmann-Theis, Dagmar&#xD;Royeck, Thorben&#xD;Havenith, Regina&#xD;Bieber, Thomas&#xD;eng&#xD;Christine Kuhne-Center for Allergy Research and Education/&#xD;Lilly Deutschland/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):164-173. doi: 10.1111/all.15921. Epub 2023 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37864390</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15921</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3210</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3210</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Serra, V.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neovacs SA, Suresnes, France.&#xD;Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University of Toulouse, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development of a Conjugate Vaccine Targeting Human IgE for Long-Term Prevention of Anaphylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 4</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41342239</style></accession-num><notes><style face="normal" font="default" size="100%">Serra, Vincent&#xD;Reber, Laurent L&#xD;eng&#xD;Agence Nationale de la Recherche/&#xD;ERC_/European Research Council/International&#xD;Denmark&#xD;Allergy. 2025 Dec 4. doi: 10.1111/all.70099.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41342239</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70099</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3230</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3230</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Nunez, R.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">de Guzman, J. R.</style></author><author><style face="normal" font="default" size="100%">Moreno, E.</style></author><author><style face="normal" font="default" size="100%">Garvey, L. H.</style></author><author><style face="normal" font="default" size="100%">Laguna, J. J.</style></author><author><style face="normal" font="default" size="100%">Barbaud, A.</style></author><author><style face="normal" font="default" size="100%">Bonnadona, P.</style></author><author><style face="normal" font="default" size="100%">Boel, J. B.</style></author><author><style face="normal" font="default" size="100%">Mosbech, H.</style></author><author><style face="normal" font="default" size="100%">Sfriso, G.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author><author><style face="normal" font="default" size="100%">Phillips, E.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina- IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;Departamento de Medicina, Facultad de Medicina, Universidad de Malaga, Malaga, Spain.&#xD;Allergy Service, University Hospital of Salamanca, Salamanca, Spain Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.&#xD;Allergy Clinic, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.&#xD;Allergy Unit, Allergo- Anaesthesia Unit, Faculty of Medicine, Hospital Central de la Cruz Roja, Alfonso X El Sabio University, Madrid, Spain.&#xD;Sorbonne Universite, INSERM, Institut Pierre Louis D&apos;epidemiologie et de Sante Publique, AP- HP. Sorbonne Universite, Hopital Tenon, Service de Dermatologie et Allergologie, Paris, France.&#xD;Allergy Unit, Ospedale San Bortolo, Vicenza, Italy.&#xD;Department of Clinical Microbiology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Allergy Unit, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Infectious Diseases, Vanderbilt University Medical Centre, Nashville, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development of Betalactam-Predictor: A Clinical Decision Tool for Delabeling Low-Risk Betalactam Allergy Patients. Initial Validation in Penicillin Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">challenge tests</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 19</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41549873</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A label of betalactam (BL) allergy is estimated in around 10% of the population in their medical records. Second-line choices carry significant negative consequences, including reduced efficacy, effectiveness, and safety. This study aimed to develop a new highly specific score constructed by selecting variables assisted by artificial intelligence to identify low-risk BL-allergic patients. METHODS: In this study, derivation and validation of the BL-predictor score were performed on a retrospective cohort of 2207 patients who underwent penicillin allergy testing at Malaga University Hospital (Spain). The development of the BL-predictor encompassed expert drafting and a two-step variable selection process consisting of univariate analysis and variable filtering, followed by stepwise logistic regression with resampling. To assess the efficiency, a multicentric retrospective external validation was performed in 4261 patients from six populations: Salamanca and Madrid, Spain; Nashville, United States of America; Verona, Italy; Paris, France; and Copenhagen, Denmark. RESULTS: The definitive questionnaire consisted of eight items and risk points were computed from the logistic regression model as follows: +1 for reactions after first dose or in less than 1 h (ITEM-1), +2 for anaphylaxis (ITEM-2); +1 for previous reaction with the culprit (ITEM-3); -1 for resolution in &gt; 24 h (ITEM-4); +2 for spontaneous resolution (ITEM-5); -2 for unknown symptoms (ITEM-6); -2 for reaction occurred &gt; 5 years (ITEM-7), and -1 for another reported drug allergy (ITEM-8). After establishing a threshold of &lt;/= 0 points to classify individuals with low risk, internal validation showed a specificity of 86% and a negative predictive value (NPV) of 83%. Overall multicenter external validation showed a specificity of 93%, which implies a 25% increase in specificity compared to the previously published BL decision tool. CONCLUSION: This score would simplify diagnostic procedures in low-risk patients, enabling rapid delabeling, potentially in non-specialty settings, and reducing diagnostic costs and the negative consequences associated with incorrect antibiotic allergy labels.</style></abstract><notes><style face="normal" font="default" size="100%">Labella, Marina&#xD;Nunez, Rafael&#xD;Dona, Inmaculada&#xD;de Guzman, Julia Rodriguez&#xD;Moreno, Esther&#xD;Garvey, Lene Heise&#xD;Laguna, Jose Julio&#xD;Barbaud, Annick&#xD;Bonnadona, Patrizia&#xD;Boel, Jonas Bredtoft&#xD;Mosbech, Holger&#xD;Sfriso, Giovanna&#xD;Castells, Mariana&#xD;Phillips, Elizabeth&#xD;Torres, Maria Jose&#xD;eng&#xD;This Project was supported by the European Academy of Allergy and Clinical Immunology (EAACI) under the EAACI Committee, 43309./&#xD;Denmark&#xD;Allergy. 2026 Jan 19. doi: 10.1111/all.70222.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41549873</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70222</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>117</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">117</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tedner, S. G.</style></author><author><style face="normal" font="default" size="100%">Klevebro, S.</style></author><author><style face="normal" font="default" size="100%">Bergstrom, A.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Andersson, N.</style></author><author><style face="normal" font="default" size="100%">Borres, M. P.</style></author><author><style face="normal" font="default" size="100%">Ballardini, N.</style></author><author><style face="normal" font="default" size="100%">Westman, M.</style></author><author><style face="normal" font="default" size="100%">Konradsen, J. R.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Nilsson, C.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Asarnoj, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women&apos;s and Children&apos;s Health, Karolinska Institutet, Stockholm, Sweden.&#xD;Pediatric Allergy and Pulmonology Unit at Astrid Lindgren Children&apos;s Hospital, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Clinical Science and Education Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Centre for Occupational and Environmental Medicine, Region Stockholm, Stockholm, Sweden.&#xD;Department of Women&apos;s and Children&apos;s Health, Uppsala University and Thermo Fisher Scientific, Uppsala, Sweden.&#xD;Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and University Hospital, Stockholm, Sweden.&#xD;S:t Goran Asthma and Allergy Clinic, Praktikertjanst, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development of sensitization to peanut and storage proteins and relation to markers of airway and systemic inflammation: A 24-year follow-up</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">488-499</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Betula</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts</style></keyword><keyword><style face="normal" font="default" size="100%">Feno</style></keyword><keyword><style face="normal" font="default" size="100%">Olink</style></keyword><keyword><style face="normal" font="default" size="100%">birth cohort</style></keyword><keyword><style face="normal" font="default" size="100%">molecular allergology</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">work. MvH has received lecture fees from Thermo Fisher Scientific outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. CN reports Advisory board fee from Aimmune Therapeutics, a Nestle</style></keyword><keyword><style face="normal" font="default" size="100%">Health Science company outside the submitted work. SK reports Advisory board fee</style></keyword><keyword><style face="normal" font="default" size="100%">from Novartis and payment for lecture from AstraZeneca outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. AA reports Advisory board fees from Aimmune Therapeutics, Nestle Health</style></keyword><keyword><style face="normal" font="default" size="100%">Science, Sanofi and Novartis and lecture fees from Orion Pharma, Nestle and</style></keyword><keyword><style face="normal" font="default" size="100%">Semper outside the submitted work. ST reports Advisory board fees from ALK and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi outside the submitted work. None of the authors has any conflict of</style></keyword><keyword><style face="normal" font="default" size="100%">interest in relation to the current study.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36315061</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Long-time data of peanut allergy over time is sparse. We aimed to study the longitudinal development of sensitization to peanut extract and storage protein allergen molecules and associations with asthma status, airway and systemic inflammation markers. METHODS: The Swedish birth cohort BAMSE followed 4089 participants with questionnaires, clinical investigations and blood sampling between 0 and 24 years. Information on (i) background factors at 2 months, (ii) peanut allergy symptoms and IgE data (ImmunoCAP) at 4, 8, 16, and 24 years, and (iii) IgE to storage proteins, lung function data including exhaled nitric oxide (FENO) as well as systemic inflammatory markers at 24 years of age were collected. RESULTS: The prevalence of peanut extract sensitization, defined as IgE &gt;/= 0.35 kU(A) /L, was 5.4%, 8.0%, 7.5%, and 6.2% at 4, 8, 16, and 24 years of age, respectively. Between 8 and 24 years of age, (33/1565) participants developed IgE-ab to peanut extract (median 1,4, range 0.7-2.6 kU(A) /L), and among those 85% were also sensitized to birch. Only six individuals developed sensitization to Ara h 2 (&gt;/=0.1 kU(A) /L) between 8 and 24 years of age, of whom three had an IgE-ab level between 0.1-0.12 kU(A) /L. Storage protein sensitization was associated with elevated FENO, blood eosinophils and type 2 inflammation-related systemic proteins. CONCLUSION: Sensitization to peanut extract after 4 years of age is mainly induced by birch cross-sensitization and IgE to Ara h 2 rarely emerges after eight years of age. Storage protein sensitization is associated with respiratory and systemic inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Tedner, Sandra G&#xD;Klevebro, Susanna&#xD;Bergstrom, Anna&#xD;Kull, Inger&#xD;Andersson, Niklas&#xD;Borres, Magnus P&#xD;Ballardini, Natalia&#xD;Westman, Marit&#xD;Konradsen, Jon R&#xD;van Hage, Marianne&#xD;Nilsson, Caroline&#xD;Melen, Erik&#xD;Asarnoj, Anna&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):488-499. doi: 10.1111/all.15568. Epub 2022 Nov 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36315061</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10098493</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15568</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>530</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">530</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ahsan, D. M.</style></author><author><style face="normal" font="default" size="100%">Altrichter, S.</style></author><author><style face="normal" font="default" size="100%">Gutsche, A.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Altunergil, T.</style></author><author><style face="normal" font="default" size="100%">Brockstaedt, M.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Weller, K.</style></author><author><style face="normal" font="default" size="100%">Terhorst-Molawi, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.&#xD;Department of Dermatology and Venerology, Kepler University Hospital, Linz, Austria.&#xD;Division of Immunology and Allergy, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.&#xD;Institute of Clinical Physiology/Nutritional Medicine, Medical Department, Division of Gastroenterology, Infectiology, Rheumatology, Charite - Universitatsmedizin Berlin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development of the Cold Urticaria Activity Score</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2509-2519</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/04/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedema/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">chronic inducible urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">cold urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">disease activity</style></keyword><keyword><style face="normal" font="default" size="100%">patient-reported outcome measures</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria activity score</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35403217</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cold urticaria (ColdU) is a form of inducible urticaria where cold induces wheals and/or angioedema. The burden of disease is high and linked to trigger thresholds, exposure, and avoidance. There are presently no validated patient-reported outcome measures (PROMs) to assess and monitor disease activity. Our objective was to develop a disease-specific activity score for ColdU that is easy to administer and evaluate. METHODS: A Cold Urticaria Activity Score (ColdUAS) questionnaire was developed, directed by PROM developing guidelines. After the generation of a conceptional framework, the item generation phase included the literature research on ColdU signs and symptoms and on comparable tools for similar diseases and 47 ColdU patient interviews. Subsequently, an impact analysis for content validity was performed. The final selection of items underwent expert review for face validity and cognitive debriefing. RESULTS: The ColdUAS, a self-administered questionnaire for the prospective assessment of disease activity in patients with ColdU, consists of 4 items: 1. the frequency and severity of the signs (wheals and/or angioedema), 2. the frequency and severity of the symptoms (e.g., itch and burn), 3. the exposure to specific triggers, and 4. the avoidance of these triggers. The recall period for each item is the last 24 h. CONCLUSIONS: The ColdUAS is the first disease-specific PROM to assess ColdU disease activity. It may help to better assess patients&apos; disease status in routine clinical practice as well as in clinical trials. Anchor-based approaches are currently used to validate the ColdUAS.</style></abstract><notes><style face="normal" font="default" size="100%">Ahsan, Dalia Melina&#xD;Altrichter, Sabine&#xD;Gutsche, Annika&#xD;Bernstein, Jonathan A&#xD;Altunergil, Tatjana&#xD;Brockstaedt, Maxi&#xD;Maurer, Marcus&#xD;Weller, Karsten&#xD;Terhorst-Molawi, Dorothea&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2509-2519. doi: 10.1111/all.15310. Epub 2022 Apr 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35403217</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15310</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>620</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">620</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bastl, M.</style></author><author><style face="normal" font="default" size="100%">Berger, M.</style></author><author><style face="normal" font="default" size="100%">Bastl, K.</style></author><author><style face="normal" font="default" size="100%">Dirr, L.</style></author><author><style face="normal" font="default" size="100%">Zwingers, T.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Bruffaerts, N.</style></author><author><style face="normal" font="default" size="100%">Magyar, D.</style></author><author><style face="normal" font="default" size="100%">Majkowska-Wojciechowska, B.</style></author><author><style face="normal" font="default" size="100%">Mitrovic Josipovic, M.</style></author><author><style face="normal" font="default" size="100%">Rybnicek, O.</style></author><author><style face="normal" font="default" size="100%">Stjepanovic, B.</style></author><author><style face="normal" font="default" size="100%">Werchan, M.</style></author><author><style face="normal" font="default" size="100%">Berger, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department for Oto-Rhino-Laryngology, Head and Neck Surgery; Medical University of Vienna, Vienna, Austria.&#xD;Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology; Medical University of Vienna, Vienna, Austria.&#xD;Allergy Therapeutics, Worthing, UK.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Institute for Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Mycology &amp; Aerobiology Service of Sciensano, Brussels, Belgium.&#xD;National Public Health Center, Budapest, Hungary.&#xD;Depatment of Immunology and Allergy Medical University of Lodz, Lodz, Poland.&#xD;Ministry of Environmental Protection, Environmental Protection Agency, Belgrade, Serbia.&#xD;Paediatric Department, Allergy Unit, Masaryk University and University Hospital Brno, Brno, Czech Republic.&#xD;Andrija Stampar Teaching Institute of Public Health, Zagreb, Croatia.&#xD;German Pollen Information Service Foundation, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development of the EAACI% season definition a backup for a global application</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1315-1317</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/02/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Seasons</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35112730</style></accession-num><notes><style face="normal" font="default" size="100%">Bastl, Maximilian&#xD;Berger, Markus&#xD;Bastl, Katharina&#xD;Dirr, Lukas&#xD;Zwingers, Thomas&#xD;Bergmann, Karl-Christian&#xD;Pfaar, Oliver&#xD;Bruffaerts, Nicolas&#xD;Magyar, Donat&#xD;Majkowska-Wojciechowska, Barbara&#xD;Mitrovic Josipovic, Mirjana&#xD;Rybnicek, Ondrej&#xD;Stjepanovic, Barbara&#xD;Werchan, Matthias&#xD;Berger, Uwe&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1315-1317. doi: 10.1111/all.15220. Epub 2022 Feb 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35112730</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9305171</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15220</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1325</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1325</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andreakos, E.</style></author><author><style face="normal" font="default" size="100%">Papadaki, M.</style></author><author><style face="normal" font="default" size="100%">Serhan, C. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.&#xD;Airway Disease Infection Section, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Center for Experimental Therapeutics and Reperfusion Injury, Boston, MA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">626-628</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/09/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">COVID-19/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Dexamethasone/*pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Docosahexaenoic Acids/*physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acids, Unsaturated/*physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Drug Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">dexamethasone</style></keyword><keyword><style face="normal" font="default" size="100%">hyperinflammation</style></keyword><keyword><style face="normal" font="default" size="100%">proresolving lipids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32956495</style></accession-num><notes><style face="normal" font="default" size="100%">Andreakos, Evangelos&#xD;Papadaki, Maria&#xD;Serhan, Charles N&#xD;eng&#xD;P01 GM095467/GM/NIGMS NIH HHS/&#xD;INTERFLU / No 1574/Hellenic Foundation for Research and Innovation/&#xD;IMMUNAID / No 779295/H2020 Societal Challenges/&#xD;CURE / No. 767015/H2020 Future and Emerging Technologies/&#xD;Editorial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):626-628. doi: 10.1111/all.14595.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32956495</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7537007</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14595</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1337</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1337</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">de Silva, D.</style></author><author><style face="normal" font="default" size="100%">Singh, C.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Alviani, C.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">DunnGlvin, A.</style></author><author><style face="normal" font="default" size="100%">Garvey, L. H.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Angier, E.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Bellou, A.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Bijlhout, D.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Halken, S.</style></author><author><style face="normal" font="default" size="100%">Jensen, B.</style></author><author><style face="normal" font="default" size="100%">Khaleva, E.</style></author><author><style face="normal" font="default" size="100%">Michaelis, L. J.</style></author><author><style face="normal" font="default" size="100%">Oude Elberink, H.</style></author><author><style face="normal" font="default" size="100%">Regent, L.</style></author><author><style face="normal" font="default" size="100%">Sanchez, A.</style></author><author><style face="normal" font="default" size="100%">Vlieg-Boerstra, B.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">European Academy of, Allergy</style></author><author><style face="normal" font="default" size="100%">Clinical Immunology Food, Allergy</style></author><author><style face="normal" font="default" size="100%">Anaphylaxis Guidelines, Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Evidence Centre Ltd, London, UK.&#xD;Department of Women and Child Health, Food Allergy Referral Centre Veneto Region, Padua General University Hospital, Padua, Italy.&#xD;Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charite Universitatsmedizin, Berlin, Germany.&#xD;Faculty of Medicine, Clinical and Experimental Sciences and Human Development in Health, University of Southampton, Southampton, UK.&#xD;Department of Internal Medicine, Allergy Section, Hospital Vall d&apos;Hebron, Barcelona, Spain.&#xD;ARADyAL Research Network, Caceres, Spain.&#xD;University College Cork, Cork, UK.&#xD;Sechnov University Moscow, Moscow, Russia.&#xD;Department of Dermatology and Allergy, Allergy Clinic, Gentofte Hospital, Hellerup, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Paediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Deu and Sant Joan de Deu Research Foundation, Barcelona, Spain.&#xD;Primary Care and Population Sciences, University of Southampton, Southampton, UK.&#xD;Predictive and Preventive Medicine Research Unit, Multifactorial and Systemic Diseases Research Area, Bambino Gesu Hospital IRCCS, Rome, Italy.&#xD;European Society for Emergency Medicine, Brussels, Belgium.&#xD;Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Association for Teacher Education in Europe (ATEE), Brussels, Belgium.&#xD;Allergy Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.&#xD;Department of Internal Medicine, University Hospital of Ancona, Ancona, Italy.&#xD;Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.&#xD;Allergy Department, Hospital Clinico San Carlos, Facultad Medicina Universidad Complutense, IdISSC, ARADyAL, Madrid, Spain.&#xD;Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Odense, Denmark.&#xD;Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.&#xD;Paediatric Allergy Research, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.&#xD;Department of Allergology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands.&#xD;Anaphylaxis Campaign, Farnborough, UK.&#xD;AEPNAA Spanish Association for People with Food and Latex Allergy, Madrid, Spain.&#xD;Department of Paediatrics, OLVG, Amsterdam, The Netherlands.&#xD;Department of Nutrition &amp; Dietetics, Hanze University of Applied Sciences, Groningen, The Netherlands.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Isle of Wight, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnosing, managing and preventing anaphylaxis: Systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1493-1506</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/09/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchodilator Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pharmaceutical Preparations</style></keyword><keyword><style face="normal" font="default" size="100%">adrenaline</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32880997</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: This systematic review used the GRADE approach to compile evidence to inform the European Academy of Allergy and Clinical Immunology&apos;s (EAACI) anaphylaxis guideline. METHODS: We searched five bibliographic databases from 1946 to 20 April 2020 for studies about the diagnosis, management and prevention of anaphylaxis. We included 50 studies with 18 449 participants: 29 randomized controlled trials, seven controlled clinical trials, seven consecutive case series and seven case-control studies. Findings were summarized narratively because studies were too heterogeneous to conduct meta-analysis. RESULTS: It is unclear whether the NIAID/FAAN criteria or Brighton case definition are valid for immediately diagnosing anaphylaxis due to the very low certainty of evidence. There was also insufficient evidence about the impact of most anaphylaxis management and prevention strategies. Adrenaline is regularly used for first-line emergency management of anaphylaxis but little robust research has assessed its effectiveness. Newer models of adrenaline autoinjectors may slightly increase the proportion of people correctly using the devices and reduce time to administration. Face-to-face training for laypeople may slightly improve anaphylaxis knowledge and competence in using autoinjectors. We searched for but found little or no comparative effectiveness evidence about strategies such as fluid replacement, oxygen, glucocorticosteroids, methylxanthines, bronchodilators, management plans, food labels, drug labels and similar. CONCLUSIONS: Anaphylaxis is a potentially life-threatening condition but, due to practical and ethical challenges, there is a paucity of robust evidence about how to diagnose and manage it.</style></abstract><notes><style face="normal" font="default" size="100%">de Silva, Debra&#xD;Singh, Chris&#xD;Muraro, Antonella&#xD;Worm, Margitta&#xD;Alviani, Cherry&#xD;Cardona, Victoria&#xD;DunnGlvin, Audrey&#xD;Garvey, Lene Heise&#xD;Riggioni, Carmen&#xD;Angier, Elizabeth&#xD;Arasi, Stefania&#xD;Bellou, Abdelouahab&#xD;Beyer, Kirsten&#xD;Bijlhout, Diola&#xD;Bilo, M Beatrice&#xD;Brockow, Knut&#xD;Fernandez-Rivas, Montserrat&#xD;Halken, Susanne&#xD;Jensen, Britt&#xD;Khaleva, Ekaterina&#xD;Michaelis, Louise J&#xD;Oude Elberink, Hanneke&#xD;Regent, Lynne&#xD;Sanchez, Angel&#xD;Vlieg-Boerstra, Berber&#xD;Roberts, Graham&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1493-1506. doi: 10.1111/all.14580. Epub 2020 Sep 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32880997</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14580</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1127</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1127</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Skypala, I. J.</style></author><author><style face="normal" font="default" size="100%">Bartra, J.</style></author><author><style face="normal" font="default" size="100%">Ebo, D. G.</style></author><author><style face="normal" font="default" size="100%">Antje Faber, M.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Gomez, F.</style></author><author><style face="normal" font="default" size="100%">Luengo, O.</style></author><author><style face="normal" font="default" size="100%">Till, S. J.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author><author><style face="normal" font="default" size="100%">Barber, D.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Diaz Perales, A.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Anna Pastorello, E.</style></author><author><style face="normal" font="default" size="100%">Swoboda, I.</style></author><author><style face="normal" font="default" size="100%">Konstantinopoulos, A. P.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Scala, E.</style></author><author><style face="normal" font="default" size="100%">European Academy of, Allergy</style></author><author><style face="normal" font="default" size="100%">Clinical Immunology Task Force: Non-specific Lipid Transfer Protein Allergy Across, Europe</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Royal Brompton &amp; Harefield NHS Foundation Trust, London, UK.&#xD;Department of Allergy and Clinical Immunology, Imperial College, London, UK.&#xD;Hospital Clinic, Barcelona, Spain.&#xD;IDIBAPS, Universitat de Barcelona, ARADyAL, Barcelona, Spain.&#xD;Department of Immunology, Allergology, Rheumatology, Faculty of Medicine and Health Sciences, Infla-Med Centre of Excellence, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.&#xD;Jan Palfijn Ziekenhuis Ghent, Ghent, Belgium.&#xD;Faculty of Medicine and Health Sciences, Department of Immunology, Allergology, Rheumatology, Infla-Med Centre of Excellence, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.&#xD;Department of Allergy, Hospital Clinico San Carlos, Universidad Complutense de Madrid, IdISSC, ARADyAL, Madrid, Spain.&#xD;Allergy Unit, IBIMA-Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Spanish Network for Allergy - RETICS de Asma, Reaccionesadversas y Alergicas (ARADyAL, Madrid, Spain.&#xD;Allergy Unit, Internal Medicine Department, Vall d&apos;Hebron University Hospital, Universitat Autonoma de Barcelona, ARADyAL, Barcelona, Spain.&#xD;Peter Gorer Department of Immunobiology, King&apos;s College London, London, UK.&#xD;Department of Allergy, Guy&apos;s &amp; St Thomas&apos; NHS Foundation Trust, London, UK.&#xD;Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.&#xD;IMMA, School of Medicine, Universidad San Pablo CEU, Universities, Madrid, Spain.&#xD;RETIC ARADYAL RD16/0006/0015, Instituto de Salud Carlos III, Madrid, Spain.&#xD;SOS Allergy and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Centro de Biotecnologia y Genomica de Plantas, Universidad Politecnica, Madrid, Spain.&#xD;Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Unit of Allergology and Immunology, ASST Grande Ospedale Metropolitano Niguarda, University of Milan, Milan, Italy.&#xD;Biotechnology Section, Campus Vienna Biocenter, FH Campus Wien, University of Applied Sciences, Vienna, Austria.&#xD;Allergy Department, 2nd Paediatric Clinic, University of Athens, Athens, Greece.&#xD;Department of Experimental Immunology, Amsterdam University Medical Centers, location AMC, Amsterdam, The Netherlands.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centers, location AMC, Amsterdam, The Netherlands.&#xD;Experimental Allergy Unit, Istituto Dermopatico dell&apos;Immacolata - IRCCS, FLMM, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The diagnosis and management of allergic reactions in patients sensitized to non-specific lipid transfer proteins</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2433-2446</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Lipids</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">cofactors</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">lipid transfer protein</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33655502</style></accession-num><abstract><style face="normal" font="default" size="100%">Sensitization to one or more non-specific lipid transfer proteins (nsLTPs), initially thought to exist mainly in southern Europe, is becoming accepted as a cause of allergic reactions to plant foods across Europe and beyond. The peach nsLTP allergen Pru p 3 is a dominant sensitizing allergen and peaches a common food trigger, although multiple foods can be involved. A frequent feature of reactions is the requirement for a cofactor (exercise, alcohol, non-steroidal anti-inflammatory drugs, Cannabis sativa) to be present for a food to elicit a reaction. The variability in the food and cofactor triggers makes it essential to include an allergy-focused diet and clinical history in the diagnostic workup. Testing on suspected food triggers should also establish whether sensitization to nsLTP is present, using purified or recombinant nsLTP allergens such as Pru p 3. The avoidance of known trigger foods and advice on cofactors is currently the main management for this condition. Studies on immunotherapy are promising, but it is unknown whether such treatments will be useful in populations where Pru p 3 is not the primary sensitizing allergen. Future research should focus on the mechanisms of cofactors, improving diagnostic accuracy and establishing the efficacy of immunotherapy.</style></abstract><notes><style face="normal" font="default" size="100%">Skypala, Isabel J&#xD;Bartra, Joan&#xD;Ebo, Didier G&#xD;Antje Faber, Margaretha&#xD;Fernandez-Rivas, Montserrat&#xD;Gomez, Francisca&#xD;Luengo, Olga&#xD;Till, Stephen J&#xD;Asero, Riccardo&#xD;Barber, Domingo&#xD;Cecchi, Lorenzo&#xD;Diaz Perales, Araceli&#xD;Hoffmann-Sommergruber, Karin&#xD;Anna Pastorello, Elide&#xD;Swoboda, Ines&#xD;Konstantinopoulos, Anastasios P&#xD;van Ree, Ronald&#xD;Scala, Enrico&#xD;(EAACI)&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2433-2446. doi: 10.1111/all.14797. Epub 2021 Mar 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33655502</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14797</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>410</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">410</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Price, O. J.</style></author><author><style face="normal" font="default" size="100%">Walsted, E. S.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Brannan, J. D.</style></author><author><style face="normal" font="default" size="100%">Bougault, V.</style></author><author><style face="normal" font="default" size="100%">Carlsen, K. H.</style></author><author><style face="normal" font="default" size="100%">Couto, M.</style></author><author><style face="normal" font="default" size="100%">Kippelen, P.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Pite, H.</style></author><author><style face="normal" font="default" size="100%">Rukhadze, M.</style></author><author><style face="normal" font="default" size="100%">Hull, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, UK.&#xD;Leeds Institute of Medical Research at St James&apos;s, University of Leeds, Leeds, UK.&#xD;Department of Respiratory Medicine, Royal Brompton Hospital, London, UK.&#xD;Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark.&#xD;Fondazione Policlinico Universitario A. Gemelli - IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;National Heart and Lung Institute (NHLI), Imperial College London, London, UK.&#xD;University of Newcastle, Callaghan, Australia.&#xD;Universite Cote d&apos;Azur, LAMHESS, Nice, France.&#xD;Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.&#xD;Faculty of Medicine, University of Oslo, Institute of Clinical Medicine, Oslo, Norway.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;Division of Sport, Health and Exercise Sciences, College of Health, Medicine and Life Sciences, Brunel University London, UK.&#xD;Centro Hospitalar Universitario de Sao Joao, Porto, Portugal.&#xD;Epidemiology Unit (EPIUnit), Laboratory for Integrative and Translational Research in Population Health (ITR), Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Allergy Center, CUF Descobertas Hospital and CUF Tejo Hospital, CEDOC, NOVA University, Universidade NOVA de Lisboa, Lisbon, Portugal.&#xD;Centre of Allergy and Immunology, Tbilisi, Georgia.&#xD;Institute of Sport, Exercise and Health (ISEH), Division of Surgery and Interventional Science, University College London (UCL), London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnosis and management of allergy and respiratory disorders in sport: An EAACI task force position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2909-2923</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/07/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Advisory Committees</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiration Disorders/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Tract Diseases/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sports</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunology</style></keyword><keyword><style face="normal" font="default" size="100%">physiology</style></keyword><keyword><style face="normal" font="default" size="100%">sport</style></keyword><keyword><style face="normal" font="default" size="100%">interest in respect to this manuscript. JB receives 10% of royalties for the sale</style></keyword><keyword><style face="normal" font="default" size="100%">of the mannitol bronchial provocation test (AridolTM/OsmohaleTM) in jurisdictions</style></keyword><keyword><style face="normal" font="default" size="100%">other than Australia.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35809082</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergy and respiratory disorders are common in young athletic individuals. In the context of elite sport, it is essential to secure an accurate diagnosis in order to optimize health and performance. It is also important, however, to consider the potential impact or consequences of these disorders, in recreationally active individuals engaging in structured exercise and/or physical activity to maintain health and well-being across the lifespan. This EAACI Task Force was therefore established, to develop an up-to-date, research-informed position paper, detailing the optimal approach to the diagnosis and management of common exercise-related allergic and respiratory conditions. The recommendations are informed by a multidisciplinary panel of experts including allergists, pulmonologists, physiologists and sports physicians. The report is structured as a concise, practically focussed document, incorporating diagnostic and treatment algorithms, to provide a source of reference to aid clinical decision-making. Throughout, we signpost relevant learning resources to consolidate knowledge and understanding and conclude by highlighting future research priorities and unmet needs.</style></abstract><notes><style face="normal" font="default" size="100%">Price, Oliver J&#xD;Walsted, Emil S&#xD;Bonini, Matteo&#xD;Brannan, John D&#xD;Bougault, Valerie&#xD;Carlsen, Kai-Hakon&#xD;Couto, Mariana&#xD;Kippelen, Pascale&#xD;Moreira, Andre&#xD;Pite, Helena&#xD;Rukhadze, Maia&#xD;Hull, James H&#xD;eng&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):2909-2923. doi: 10.1111/all.15431. Epub 2022 Jul 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35809082</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9796481</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15431</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2967</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2967</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cortellini, G.</style></author><author><style face="normal" font="default" size="100%">Nakonechna, A.</style></author><author><style face="normal" font="default" size="100%">Barbaud, A.</style></author><author><style face="normal" font="default" size="100%">Bavbek, S.</style></author><author><style face="normal" font="default" size="100%">Calogiuri, G.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Laguna Martinez, J. J.</style></author><author><style face="normal" font="default" size="100%">Liberati, S.</style></author><author><style face="normal" font="default" size="100%">Pagani, M.</style></author><author><style face="normal" font="default" size="100%">Romano, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Azienda Sanitaria Della Romagna, Rimini, Italy.&#xD;Chest and Allergy Clinic, Imperial College Healthcare NHS Foundation Trust, London, UK.&#xD;Departement de Dermatologie et Allergologie, Sorbonne Universite, INSERM, Institut Pierre Louis d&apos;Epidemiologie et de Sante Publique, AP-HP, Sorbonne Universite, Hopital Tenon, Paris, France.&#xD;Division of Allergy and Immunology, Department of Chest Diseases, Faculty of Medicine, Ankara University, Ankara, Turkey.&#xD;Dermatology and Allergy Interdivisional Service, Ospedale Civile Vito Fazzi, Lecce, Italy.&#xD;Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Bari, Italy.&#xD;Allergy Unit and Research Group, Hospital Regional Universitario de Malaga, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, ARADyAL, Malaga, Spain.&#xD;Institute of Biomedical Sciences and Institute of Clinical Medicine, Faculty of Medicine, Vilnius, Lithuania.&#xD;Institute of Clinical Medicine, Vilnius University Hospital Santariskiu Klinikos, Innovative Allergology Center, Vilnius, Lithuania.&#xD;Allergy Unit, Allergo-Anaesthesia Unit, Faculty of Medicine, Hospital Central de la Cruz Roja, Alfonso X El Sabio University, ARADyAL, REI, Madrid, Spain.&#xD;Medicine Department, Medicine Ward Mantova Hospital, ASST di Mantova, Mantova, Italy.&#xD;Oasi Research Institute-IRCCS, Troina, Italy.&#xD;BIOS S.p.A. Societa Benefit, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2973-2987</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/07/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Aspirin/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Clopidogrel</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Platelet Aggregation Inhibitors/adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">antiplatelet drugs hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">aspirin</style></keyword><keyword><style face="normal" font="default" size="100%">challenge</style></keyword><keyword><style face="normal" font="default" size="100%">desensitization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40704552</style></accession-num><abstract><style face="normal" font="default" size="100%">Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs). The most common reported reactions to these drugs are cutaneous, such as exanthemas associated with thienopyridine and urticaria/angioedema by aspirin, which can also induce respiratory symptoms. APDs other than aspirin, particularly ticlopidine, can also cause hematologic reactions consisting mainly of isolated thrombocytopenia, agranulocytosis, and leukopenia. Immune-mediated reactions to aspirin are very rare. Few data suggest the usefulness of skin testing in patients with cutaneous reactions to APDs other than aspirin, particularly clopidogrel. Therefore, the drug provocation test is the gold standard for diagnosing hypersensitivity to APDs. Low-dose aspirin challenge (i.e., up to 150-180 mg) and aspirin desensitization have emerged as effective and safe approaches in patients with suspected or confirmed aspirin hypersensitivity who require aspirin therapy. Both, a short course of oral glucocorticoids without interruption of clopidogrel treatment and desensitization, appears to be effective and safe options in patients with cutaneous HSRs to clopidogrel. This position paper provides data and recommendations regarding the characteristics of HSRs to APDs and related diagnostic procedures in order to make them as safe and effective as possible. Management and treatment options, including desensitization protocols, are also provided.</style></abstract><notes><style face="normal" font="default" size="100%">Cortellini, Gabriele&#xD;Nakonechna, Alla&#xD;Barbaud, Annick&#xD;Bavbek, Sevim&#xD;Calogiuri, Gianfranco&#xD;Dona, Inmaculada&#xD;Kvedariene, Violeta&#xD;Laguna Martinez, Jose Julio&#xD;Liberati, Serena&#xD;Pagani, Mauro&#xD;Romano, Antonino&#xD;eng&#xD;EAACI/&#xD;Funding for open access charge: Universidad de Malaga/CBUA/&#xD;Consensus Development Conference&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):2973-2987. doi: 10.1111/all.16663. Epub 2025 Jul 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40704552</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590344</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16663</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1508</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1508</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Hawro, T.</style></author><author><style face="normal" font="default" size="100%">Krause, K.</style></author><author><style face="normal" font="default" size="100%">Magerl, M.</style></author><author><style face="normal" font="default" size="100%">Metz, M.</style></author><author><style face="normal" font="default" size="100%">Siebenhaar, F.</style></author><author><style face="normal" font="default" size="100%">Terhorst-Molawi, D.</style></author><author><style face="normal" font="default" size="100%">Weller, K.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Altrichter, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Allergie-Centrum-Charite, Charite - Universitatsmedizin Berlin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnosis and treatment of chronic inducible urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2550-2553</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2019/05/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Urticaria/*diagnosis/etiology/*therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31102545</style></accession-num><notes><style face="normal" font="default" size="100%">Maurer, Marcus&#xD;Hawro, Tomasz&#xD;Krause, Karoline&#xD;Magerl, Markus&#xD;Metz, Martin&#xD;Siebenhaar, Frank&#xD;Terhorst-Molawi, Dorothea&#xD;Weller, Karsten&#xD;Zuberbier, Torsten&#xD;Altrichter, Sabine&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Dec;74(12):2550-2553. doi: 10.1111/all.13878. Epub 2019 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31102545</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13878</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1500</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1500</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kaplan, A. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, The Medical University of South Carolina, Charleston, South Carolina.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnosis and treatment of chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1830-1832</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine Release</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">histamine</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32073151</style></accession-num><notes><style face="normal" font="default" size="100%">Kaplan, Allen P&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2020 Jul;75(7):1830-1832. doi: 10.1111/all.14192. Epub 2020 Feb 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32073151</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14192</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>56</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">56</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cespedes, J. A.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Ariza, A.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Frecha, C.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Fernandez, T. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;RICORS Red De Enfermedades Inflamatorias (REI), Madrid, Spain.&#xD;RETICS Asma, Reacciones Adversas y Alergicas (ARADYAL), Madrid, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-ARADyAL, Malaga, Spain.&#xD;Departamento de Medicina y Dermatologia, Universidad de Malaga, Malaga, Spain.&#xD;Departamento de Biologia Celular, Genetica y Fisiologia, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnosis of immediate reactions to amoxicillin: Comparison of basophil activation markers CD63 and CD203c in a prospective study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2745-2755</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/12/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Amoxicillin/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Basophil Degranulation Test/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Clavulanic Acid</style></keyword><keyword><style face="normal" font="default" size="100%">Tetraspanin 30</style></keyword><keyword><style face="normal" font="default" size="100%">amoxicillin</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immediate reactions</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36478407</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Amoxicillin (AX) combined or not with clavulanic acid (CLV) is frequently involved in IgE-mediated reactions. Drug provocation test (DPT) is considered as the gold standard for diagnosis, although contraindicated in high-risk patients. Basophil activation test (BAT) can help diagnose immediate reactions to beta-lactams, although controversy exists regarding the best activation marker. We have performed a real-life study in a prospective cohort to analyze the real value of BAT as diagnostic tool and the best activation marker, CD63 and CD203c, for the evaluation of immediate reactions to these drugs. METHODS: We prospectively evaluated patients with a clinical suspicion of immediate reactions after AX or AX-CLV administration during a 6-year period. The allergological work-up was done following the EAACI recommendations. BAT was performed in all patients using CD63 and CD203c as activation markers. RESULTS: In AX-allergic patients, both activation markers, CD63 and CD203c, showed similar SE values (48.6% and 46.7%, respectively); however, specificity was of 81.1% and 94.6%, respectively, with CD203c showing good positive predictive value and like-hood ratio. In CLV-allergic patients, CD203c showed higher SE (50%) than CD63 (42.9%), maintaining the same value of SP (80%). Combining the results of both markers can slightly increase the sensitivity (51.4% for AX and 54.8% for CLV), although decreasing the specificity (79.7% and 73%, respectively). Interestingly, all patients with an anaphylactic shock showed a positive BAT to CLV using CD203c. CONCLUSIONS: BAT using CD203c showed a good confirmatory power, especially for AX allergy. Placing BAT as a first step in the diagnostic procedure can help reduce the need of performing a complete allergological work-up in 46.6% of patients, diminishing the risk of reinducing allergic reactions.</style></abstract><notes><style face="normal" font="default" size="100%">Cespedes, Jose A&#xD;Fernandez-Santamaria, Ruben&#xD;Ariza, Adriana&#xD;Bogas, Gador&#xD;Dona, Inmaculada&#xD;Rondon, Carmen&#xD;Salas, Maria&#xD;Labella, Marina&#xD;Frecha, Cecilia&#xD;Mayorga, Cristobalina&#xD;Torres, Maria J&#xD;Fernandez, Tahia D&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2745-2755. doi: 10.1111/all.15610. Epub 2022 Dec 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36478407</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15610</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3086</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3086</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Celik, G. E.</style></author><author><style face="normal" font="default" size="100%">Demir, S.</style></author><author><style face="normal" font="default" size="100%">Dona Diaz, I.</style></author><author><style face="normal" font="default" size="100%">Ebo, D. G.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Sabato, V.</style></author><author><style face="normal" font="default" size="100%">Jaen, M. J. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul, Turkiye.&#xD;Department of Dermatology and Allergy Biederstein, Faculty of Medicine and Health, TUM University Hospital, Munich, Germany.&#xD;Department of Immunology and Allergy (Retired), Ankara University School of Medicine and Private Practise, Ankara, Turkiye.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;RICORS de Enfermedades Inflamatorias, Instituto de Salud Carlos III, Madrid, Spain.&#xD;Immunology-Allergology-Rheumatology, Faculty of Medicine and Health Sciences, Infla-Med Centre of Excellence, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.&#xD;Immunology-Allergology, AZ Jan Palfijn Ghent, Ghent, Belgium.&#xD;Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.&#xD;Departamento de Medicina, Universidad de Malaga-UMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnosis of Quinolone Hypersensitivity: An EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2988-3011</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/09/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Bacterial Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/etiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Quinolones/adverse effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">drug provocation test</style></keyword><keyword><style face="normal" font="default" size="100%">fluoroquinolone</style></keyword><keyword><style face="normal" font="default" size="100%">in vitro tests</style></keyword><keyword><style face="normal" font="default" size="100%">quinolone</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40931617</style></accession-num><abstract><style face="normal" font="default" size="100%">Hypersensitivity reactions to quinolones (QHRs) have been increasing in frequency, thus classifying them as the second most frequently implicated class of antibiotics in hypersensitivity reactions (HRs). It is noteworthy that quinolones (Qs) have been observed to predominantly trigger immediate hypersensitivity reactions (IHRs). These reactions are categorized as either IgE-mediated or non-IgE-mediated, attributable to the off-target occupation of the recently described receptor, Mas-related G-protein coupled receptor member X2 (MRGPRX2), on effector cells. The increasing trend of HRs underscores the necessity for enhanced diagnostic and management strategies. The present position paper aims to shed light on the key mechanisms involved in immediate and non-immediate QHRs. The clinical spectrum of these reactions is discussed, as well as the utility of skin tests, in vitro diagnostic tests, and drug provocation tests in diagnosis. A further focal point of this study is the analysis of cross-reactivity between various Qs. The paper concludes with the presentation of diagnostic algorithms for both immediate and non-immediate QHRs. The paper&apos;s findings aid clinical practice for QHRs and address unmet needs, which should stimulate more in-depth investigations into the mechanisms and clinical practice of QHRs.</style></abstract><notes><style face="normal" font="default" size="100%">Gelincik, Asli&#xD;Brockow, Knut&#xD;Celik, Gulfem E&#xD;Demir, Semra&#xD;Dona Diaz, Inmaculada&#xD;Ebo, Didier G&#xD;Mayorga, Cristobalina&#xD;Labella, Marina&#xD;Sabato, Vito&#xD;Jaen, Maria Jose Torres&#xD;eng&#xD;Consensus Development Conference&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):2988-3011. doi: 10.1111/all.70037. Epub 2025 Sep 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40931617</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70037</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>115</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">115</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Greenhawt, M.</style></author><author><style face="normal" font="default" size="100%">Shaker, M.</style></author><author><style face="normal" font="default" size="100%">Golden, D. B. K.</style></author><author><style face="normal" font="default" size="100%">Abrams, E. M.</style></author><author><style face="normal" font="default" size="100%">Blumenthal, K. G.</style></author><author><style face="normal" font="default" size="100%">Wolfson, A. R.</style></author><author><style face="normal" font="default" size="100%">Stone, C. A., Jr.</style></author><author><style face="normal" font="default" size="100%">Krantz, M. S.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Dwamena, B. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Allergy and Clinical Immunology, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Lebanon, New Hampshire, USA.&#xD;Dartmouth Geisel School of Medicine, Hanover, New Hampshire, USA.&#xD;Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.&#xD;Department of Pediatrics and Child Health, Section of Allergy and Immunology, The University of Manitoba, Winnipeg, Manitoba, Canada.&#xD;Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.&#xD;Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Health Research Methods, Evidence &amp; Impact, McMaster University, Hamilton, Ontario, Canada.&#xD;The Research Institute of St. Joe&apos;s Hamilton, Hamilton, Ontario, Canada.&#xD;Evidence in Allergy Group, Hamilton, Ontario, Canada.&#xD;Division of Nuclear Medicine, Department of Radiology, Michigan Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnostic accuracy of vaccine and vaccine excipient testing in the setting of allergic reactions to COVID-19 vaccines: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">71-83</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/11/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Bayes Theorem</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/diagnosis/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Excipients/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Polysorbates/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccine Excipients</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergic reactions</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA COVID-19 vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">test sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">test specificity</style></keyword><keyword><style face="normal" font="default" size="100%">physician/medical advisory boards for DBV Technologies, Sanofi/Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia, Novartis, Acquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">and Prota, with all activity unrelated to vacines/vaccine development or COVID-19</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword><keyword><style face="normal" font="default" size="100%">is an unpaid member of the scientific advisory council for the</style></keyword><keyword><style face="normal" font="default" size="100%">National Peanut Board and medical advisory board of the International Food</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Induced Enterocolitis Syndrome Association</style></keyword><keyword><style face="normal" font="default" size="100%">is a member of the Brighton</style></keyword><keyword><style face="normal" font="default" size="100%">Collaboration Criteria Vaccine Anaphylaxis 2.0 working group</style></keyword><keyword><style face="normal" font="default" size="100%">is the senior</style></keyword><keyword><style face="normal" font="default" size="100%">associate editor for the Annals of Allergy, Asthma, and Immunology, and is member</style></keyword><keyword><style face="normal" font="default" size="100%">of the Joint Taskforce on Allergy Practice Parameters. He has received honorarium</style></keyword><keyword><style face="normal" font="default" size="100%">for lectures from ImSci, MedLearningGroup, RMEI Medical Education and multiple</style></keyword><keyword><style face="normal" font="default" size="100%">state/local allergy societies. He received past research support ending in 2020</style></keyword><keyword><style face="normal" font="default" size="100%">from the Agency for Healthcare Quality and Research (K08-HS024599). Elissa</style></keyword><keyword><style face="normal" font="default" size="100%">Abrams: is a collaborator with the Institute for Health Metrics and Evaluation.</style></keyword><keyword><style face="normal" font="default" size="100%">She is na employee of Public Health Agency of Canada (PHAC) but the views</style></keyword><keyword><style face="normal" font="default" size="100%">expressed are her own and not that of PHAC. Marcus Shaker: member of the Joint</style></keyword><keyword><style face="normal" font="default" size="100%">Taskforce on Allergy Practice Parameters</style></keyword><keyword><style face="normal" font="default" size="100%">has a family member who is CEO of</style></keyword><keyword><style face="normal" font="default" size="100%">Altrix Medical</style></keyword><keyword><style face="normal" font="default" size="100%">is an associate editor for the Annals of Allergy, Asthma, and</style></keyword><keyword><style face="normal" font="default" size="100%">Immunology, and serves on the editorial boards of the Journal of Allergy and</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Immunology In Practice and the Journal of Food Allergy. Kimberly</style></keyword><keyword><style face="normal" font="default" size="100%">Blumenthal: receives grant support from the NIH/NIAID (R01AI150295,</style></keyword><keyword><style face="normal" font="default" size="100%">2UM1AI109565-08), Phadia Ab (Thermo Fisher Scientific), and the Massachusetts</style></keyword><keyword><style face="normal" font="default" size="100%">General Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees for legal case review from Weekley Shulte Valdes</style></keyword><keyword><style face="normal" font="default" size="100%">Murman Tonelli, Piedmont Liability Trust, Vasios Kelly and Strollo PA, and Publix</style></keyword><keyword><style face="normal" font="default" size="100%">Supermarkets</style></keyword><keyword><style face="normal" font="default" size="100%">and royalties from UpToDate, outside the submitted work. Anna</style></keyword><keyword><style face="normal" font="default" size="100%">Wolfson: no conflicts to declare. Cosby Stone: receives research support from the</style></keyword><keyword><style face="normal" font="default" size="100%">AAAAI Foundation Faculty Development Award. Matthew Krantz: no conflicts to</style></keyword><keyword><style face="normal" font="default" size="100%">declare. David Golden: Speakers bureau honoraria from Genentech, Kaleo</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">trial support from Genentech, Thermo Fisher, Novartis, Pfizer, GSK, and</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, all unrelated to vaccine/vaccine development or COVID-19 treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Consulting fees from Aquestive, Novartis, ALK</style></keyword><keyword><style face="normal" font="default" size="100%">Royalties from UpToDate (section</style></keyword><keyword><style face="normal" font="default" size="100%">editor). Derek Chu: no conflicts to declare. Ben Dwamena: no conflicts to report.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36321821</style></accession-num><abstract><style face="normal" font="default" size="100%">For persons with immediate allergic reactions to mRNA COVID-19 vaccines, skin testing (ST) to the vaccine/excipients (polyethylene glycol[PEG] and polysorbate 80 [PS]) has been recommended, but has unknown accuracy. To assess vaccine/excipient ST accuracy in predicting all-severity immediate allergic reactions upon re-vaccination, systematic review was performed searching Medline, EMBASE, Web of Science, and the WHO global coronavirus database (inception-Oct 4, 2021) for studies addressing immediate (&lt;/=4 h post-vaccination) all-severity allergic reactions to 2nd mRNA COVID-19 vaccination in persons with 1st dose immediate allergic reactions. Cases evaluating delayed reactions, change of vaccine platform, or revaccination without vaccine/excipient ST were excluded. Meta-analysis of diagnostic testing accuracy was performed using Bayesian methods. The GRADE approach evaluated certainty of the evidence, and QUADAS-2 assessed risk of bias. Among 20 studies of mRNA COVID-19 first dose vaccine reactions, 317 individuals underwent 578 ST to any one or combination of vaccine, PEG, or PS, and were re-vaccinated with the same vaccine. Test sensitivity for either mRNA vaccine was 0.2 (95%CrI 0.01-0.52) and specificity 0.97 (95%CrI 0.9-1). PEG test sensitivity was 0.02 (95%CrI 0.00-0.07) and specificity 0.99 (95%CrI 0.96-1). PS test sensitivity was 0.03 (95%CrI 0.00-0.0.11) and specificity 0.97 (95%CrI 0.91-1). Combined for use of any of the 3 testing agents, sensitivity was 0.03 (95%CrI 0.00-0.08) and specificity was 0.98 (95%CrI 0.95-1.00). Certainty of evidence was moderate. ST has low sensitivity but high specificity in predicting all-severity repeat immediate allergic reactions to the same agent, among persons with 1st dose immediate allergic reactions to mRNA COVID-19 vaccines. mRNA COVID-19 vaccine or excipient ST has limited risk assessment utility.</style></abstract><notes><style face="normal" font="default" size="100%">Greenhawt, Matthew&#xD;Shaker, Marcus&#xD;Golden, David B K&#xD;Abrams, Elissa M&#xD;Blumenthal, Kimberly G&#xD;Wolfson, Anna R&#xD;Stone, Cosby A Jr&#xD;Krantz, Matthew S&#xD;Chu, Derek K&#xD;Dwamena, Ben A&#xD;eng&#xD;T32 HL087738/HL/NHLBI NIH HHS/&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):71-83. doi: 10.1111/all.15571. Epub 2022 Nov 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36321821</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9878056</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15571</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2203</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2203</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Krawiec, M.</style></author><author><style face="normal" font="default" size="100%">Radulovic, S.</style></author><author><style face="normal" font="default" size="100%">Foong, R. X.</style></author><author><style face="normal" font="default" size="100%">Marques-Mejias, A.</style></author><author><style face="normal" font="default" size="100%">Bartha, I.</style></author><author><style face="normal" font="default" size="100%">Kwok, M.</style></author><author><style face="normal" font="default" size="100%">Jama, Z.</style></author><author><style face="normal" font="default" size="100%">Harrison, F.</style></author><author><style face="normal" font="default" size="100%">Ricci, C.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Africa Unit for Transdisciplinary Health Research (AUTHeR), North-West University, Potchefstroom, South Africa.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnostic utility of allergy tests to predict baked egg and lightly cooked egg allergies compared to double-blind placebo-controlled food challenges</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2510-2522</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/07/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Basophil Degranulation Test</style></keyword><keyword><style face="normal" font="default" size="100%">*Egg Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">baked egg allergy</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">egg allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">ovalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">skin prick test</style></keyword><keyword><style face="normal" font="default" size="100%">specific IgE</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Infectious Diseases (NIAID, NIH). Dr Lack reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">National Institute of Allergy and Infectious Diseases (NIAID, NIH), other from</style></keyword><keyword><style face="normal" font="default" size="100%">Food Allergy &amp; Research Education (FARE), other from MRC &amp; Asthma UK Centre,</style></keyword><keyword><style face="normal" font="default" size="100%">other from UK Dept of Health through NIHR, other from National Peanut Board</style></keyword><keyword><style face="normal" font="default" size="100%">(NPB), other from The Davis Foundation, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">shareholder in DBV Technologies, and Mighty Mission Me, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, personal fees from Sanofi-Genyzme, personal fees from Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from ALK-Abello, personal fees from Lurie Children&apos;s Hospital,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. Dr Du Toit reports grants from National Institute of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Infectious Diseases (NIAID, NIH), Food Allergy &amp; Research Education</style></keyword><keyword><style face="normal" font="default" size="100%">(FARE), MRC &amp; Asthma UK Centre, UK Dept of Health through NIHR, Action Medical</style></keyword><keyword><style face="normal" font="default" size="100%">Research and National Peanut Board. Scientific Advisory Board member Aimmune.</style></keyword><keyword><style face="normal" font="default" size="100%">Investigator on pharma-sponsored allergy studies (Aimmune, and DBV Technologies).</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific advisor to Aimmune, DBV and Novartis. Dr. Santos reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Medical Research Council (MR/M008517/1</style></keyword><keyword><style face="normal" font="default" size="100%">MC/PC/18052</style></keyword><keyword><style face="normal" font="default" size="100%">MR/T032081/1), Food Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Research and Education (FARE), the Immune Tolerance Network/National Institute of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Infectious Diseases (NIAID, NIH), Asthma UK (AUK-BC-2015-01), BBSRC,</style></keyword><keyword><style face="normal" font="default" size="100%">Rosetrees Trust and the NIHR through the Biomedical Research Centre (BRC) award</style></keyword><keyword><style face="normal" font="default" size="100%">to Guy&apos;s and St Thomas&apos; NHS Foundation Trust, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Thermo Scientific, Nutricia, Infomed, Novartis, Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Buhlmann, as well as research support from Buhlmann and Thermo</style></keyword><keyword><style face="normal" font="default" size="100%">Fisher Scientific through a collaboration agreement with King&apos;s College London.</style></keyword><keyword><style face="normal" font="default" size="100%">The other authors have nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37417650</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Double-blind placebo-controlled food challenges (DBPCFC) are the gold-standard to diagnose food allergy. However, they can cause allergic reactions of unpredictable severity. We assessed accuracy of current and new diagnostic tests compared to DBPCFC to baked egg (BE) and to lightly cooked egg (LCE). METHODS: Children aged 6 months to 15 years were assessed for possible egg allergy as part of the BAT2 study (NCT03309488). They underwent clinical assessment, skin prick test (SPT), specific IgE (sIgE) and basophil activation test (BAT). The results of the tests were compared with DBPCFC outcomes to both BE and LCE. RESULTS: A total of 150 children underwent DBPCFC to BE, 60 (40%) reacted to and 85 (57%) tolerated BE and 5 (3%) had inconclusive oral food challenges (OFC). Seventy-seven children tolerant to BE had DBPCFC to LCE and 16 reacted. The test within each modality with the best diagnostic performance for BE allergy was as follows: SPT to egg white (EW) (AUC = 0.726), sIgE to EW (AUC = 0.776) and BAT to egg (AUC = 0.783). BAT (AUC = 0.867) was the best test in the younger than 2 years age group. Applying 100% sensitivity and 100% specificity cut-offs, followed by OFC, resulted in 100% diagnostic accuracy. BAT enabled the greatest reduction in OFC (41%). Using sIgE followed by BAT allowed to reduce the number of BATs performed by about 30% without significantly increasing the number of OFC. CONCLUSIONS: The best diagnostic test was BAT to egg in terms of diagnostic accuracy and reduction in number of OFC. Using sIgE to EW followed by BAT required fewer BATs with sustained OFC reduction and diagnostic accuracy.</style></abstract><notes><style face="normal" font="default" size="100%">Krawiec, Marta&#xD;Radulovic, Suzana&#xD;Foong, Ru-Xin&#xD;Marques-Mejias, Andreina&#xD;Bartha, Irene&#xD;Kwok, Matthew&#xD;Jama, Zainab&#xD;Harrison, Faye&#xD;Ricci, Cristian&#xD;Lack, Gideon&#xD;Du Toit, George&#xD;Santos, Alexandra F&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MC_PC_18052/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2510-2522. doi: 10.1111/all.15797. Epub 2023 Jul 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37417650</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10790315</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15797</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>282</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">282</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sverrild, A.</style></author><author><style face="normal" font="default" size="100%">Carruthers, J.</style></author><author><style face="normal" font="default" size="100%">Murthee, K. G.</style></author><author><style face="normal" font="default" size="100%">Moore, A.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">Puy, R.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author><author><style face="normal" font="default" size="100%">Zubrinich, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia.&#xD;Anaesthesiology and Perioperative Medicine, Alfred Health, Melbourne, Victoria, Australia.&#xD;Department of Internal Medicine, Singapore General Hospital, Singapore, Singapore.&#xD;Department of Immunology and pathology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.&#xD;Department of Medicine, Central Clinical School, Monash University, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnostic value of a medical algorithm for investigation of perioperative hypersensitivity reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">225-232</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/09/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptases</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">anaesthetic allergy</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">perioperative hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">skin testing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36136057</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Evaluation of perioperative hypersensitivity (POH) is challenging, and accurate screening tools are needed to optimize the diagnostic process. We aimed to assess and validate the diagnostic value of a published algorithm (using tryptase and clinical presentation) to identify appropriate individuals for further testing for IgE-mediated POH. METHODS: We analysed the clinical presentation (tryptase elevation, cardiovascular, respiratory, skin involvement) of patients proceeding to testing for possible IgE-mediated POH at a single tertiary referral centre, relative to subsequent skin testing and specific IgE results. Clinical presentations by drug class were also determined. RESULTS: In 293 consecutive patients, the use of a published algorithm based on one or more of; (i) defined increase in serum tryptase, (ii) involvement of at least two-organ systems, or (iii) presentation with new urticaria and/or angioedema; was highly sensitive [98.8% (CI95: 95.7-99.9%)] but less specific [34.6% (CI95: 25.7-44.4%)] in identifying patients testing positive on skin testing and/or specific IgE. Presentation with cardiovascular symptoms was also sensitive [89.8%(CI95: 84.2-94.0%)], while the combination of respiratory symptoms and increased tryptase was most specific [85.9%(CI95:76.6-92.5%)]. Respiratory involvement was more common in neuromuscular blocking agent allergy, while urticaria/angioedema was more common in antibiotic allergy. CONCLUSION: The published algorithm (of tryptase rise, two-organ involvement or new urticaria/angioedema) is highly sensitive, and appropriate as a screening tool to identify patients suitable for testing for IgE-mediated POH.</style></abstract><notes><style face="normal" font="default" size="100%">Sverrild, Asger&#xD;Carruthers, John&#xD;Murthee, Kavitha Garuna&#xD;Moore, Alice&#xD;O&apos;Hehir, Robyn Elizabeth&#xD;Puy, Robert&#xD;Hew, Mark&#xD;Zubrinich, Celia&#xD;eng&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):225-232. doi: 10.1111/all.15526. Epub 2022 Oct 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36136057</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15526</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1367</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1367</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beyaz, S.</style></author><author><style face="normal" font="default" size="100%">Akdeniz, N.</style></author><author><style face="normal" font="default" size="100%">Yilmaz, A.</style></author><author><style face="normal" font="default" size="100%">Demir, S.</style></author><author><style face="normal" font="default" size="100%">Oztop, N.</style></author><author><style face="normal" font="default" size="100%">Colakoglu, B.</style></author><author><style face="normal" font="default" size="100%">Buyukozturk, S.</style></author><author><style face="normal" font="default" size="100%">Deniz, G.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnostic workup including CD203c-based basophil activation test in immediate hypersensitivity due to metronidazole and ornidazole and evaluation of cross-reactivity in between</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">842-852</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Basophil Degranulation Test</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/chemically induced/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Metronidazole/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Ornidazole/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Single-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">5-Nitroimidazole antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">immediate drug hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default" size="100%">metronidazole</style></keyword><keyword><style face="normal" font="default" size="100%">ornidazole</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32761620</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Little is known about the diagnostic approaches for immediate hypersensitivity reactions (IHRs) due to 5-nitroimidazole antibiotics. The aim was to evaluate the usefulness of in vivo tests and basophil activation test (BAT) for the diagnosis of IHRs due to metronidazole and ornidazole and to determine possible cross-reactivity in between. METHODS: Forty-nine patients with a clear history of IHRs due to these drugs and 20 healthy subjects who were known to tolerate these drugs were included. Skin tests (STs) and single-blind placebo-controlled drug provocation tests (SBPCDPTs) were performed with both drugs whereas BAT was applied only with the culprit drug. RESULTS: The most and least common reaction types were urticaria/angioedema (34.7%) and anaphylaxis (14.3%), respectively. SBPCDPTs were positive in 15 out of 47 patients, and only 7 had positive STs. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of STs for metronidazole/ornidazole were 33.3%/16.6%, 94.2%/97.3%, 60%/50%, and 84.6%/88.1%, respectively. BAT was positive in 12 out of 15 patients and negative in 10 control subjects, giving a sensitivity rate of 71.4% (CI, 29.0%-96.3%) for metronidazole and 83.3% (CI, 35.8%-99.5%) for ornidazole. The optimal concentration of both drugs for BAT was determined as 5 mg/mL. No cross-reactivity among two drugs was observed according to in vivo tests. CONCLUSIONS: Our study showed that SBPCDPT and BAT are both useful diagnostic tools for IHRs due to 5-nitroimidazole antibiotics and can be used as supplementary to each other. No cross-reactivity between metronidazole and ornidazole in IHRs exists.</style></abstract><notes><style face="normal" font="default" size="100%">Beyaz, Sengul&#xD;Akdeniz, Nilgun&#xD;Yilmaz, Abdullah&#xD;Demir, Semra&#xD;Oztop, Nida&#xD;Colakoglu, Bahauddin&#xD;Buyukozturk, Suna&#xD;Deniz, Gunnur&#xD;Gelincik, Asli&#xD;eng&#xD;Controlled Clinical Trial&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):842-852. doi: 10.1111/all.14542. Epub 2020 Aug 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32761620</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14542</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>79</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">79</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Musiol, S.</style></author><author><style face="normal" font="default" size="100%">Harris, C. P.</style></author><author><style face="normal" font="default" size="100%">Karlina, R.</style></author><author><style face="normal" font="default" size="100%">Gostner, J. M.</style></author><author><style face="normal" font="default" size="100%">Rathkolb, B.</style></author><author><style face="normal" font="default" size="100%">Schnautz, B.</style></author><author><style face="normal" font="default" size="100%">Schneider, E.</style></author><author><style face="normal" font="default" size="100%">Mair, L.</style></author><author><style face="normal" font="default" size="100%">Vergara, E. E.</style></author><author><style face="normal" font="default" size="100%">Flexeder, C.</style></author><author><style face="normal" font="default" size="100%">Koletzko, S.</style></author><author><style face="normal" font="default" size="100%">Bauer, C. P.</style></author><author><style face="normal" font="default" size="100%">Schikowski, T.</style></author><author><style face="normal" font="default" size="100%">Berdel, D.</style></author><author><style face="normal" font="default" size="100%">von Berg, A.</style></author><author><style face="normal" font="default" size="100%">Herberth, G.</style></author><author><style face="normal" font="default" size="100%">Rozman, J.</style></author><author><style face="normal" font="default" size="100%">Hrabe de Angelis, M.</style></author><author><style face="normal" font="default" size="100%">Standl, M.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Ussar, S.</style></author><author><style face="normal" font="default" size="100%">Alessandrini, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Allergy &amp; Environment (ZAUM), Technical University of Munich (TUM) and Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Munich, Germany.&#xD;Institute of Epidemiology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Dr. von Hauner Children&apos;s Hospital, University Hospital, LMU of Munich, Munich, Germany.&#xD;RG Adipocytes &amp; Metabolism, Institute for Diabetes &amp; Obesity, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany.&#xD;German Center for Diabetes Research (DZD), Neuherberg, Germany.&#xD;Institute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.&#xD;Institute of Experimental Genetics, German Mouse Clinic, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Institute of Molecular Animal Breeding and Biotechnology, Gene Center, Ludwig-Maximilians-University Munich, Munich, Germany.&#xD;Institute of Lung Biology and Disease, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany.&#xD;German Center of Lung Research (DZL), Munich, Germany.&#xD;Department of Pediatrics, Gastroenterology and Nutrition, School of Medicine Collegium Medicum University of Warmia and Mazury, Olsztyn, Poland.&#xD;Department of Pediatrics, Technical University of Munich, Munich, Germany.&#xD;IUF-Leibniz Research Institute for Environmental Medicine, Dusseldorf, Germany.&#xD;Research Institute, Department of Pediatrics, Marien-Hospital Wesel, Wesel, Germany.&#xD;Department of Environmental Immunology, Helmholtz Centre for Environmental Research-UFZ, Leipzig, Germany.&#xD;Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prumyslova 595, 252 50 Vestec, Czech Republic.&#xD;Chair of Experimental Genetics, TUM School of Life Sciences (SoLS), Technische Universitat Munchen, Freising, Germany.&#xD;Department of Medicine, Technical University of Munich (TUM), Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dietary digestible carbohydrates are associated with higher prevalence of asthma in humans and with aggravated lung allergic inflammation in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1218-1233</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/11/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Carbohydrates/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">*Pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Starch/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Sucrose/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">allergic airway inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">carbohydrates</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36424672</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dietary carbohydrates and fats are intrinsically correlated within the habitual diet. We aimed to disentangle the associations of starch and sucrose from those of fat, in relation to allergic sensitization, asthma and rhinoconjuctivitis prevalence in humans, and to investigate underlying mechanisms using murine models. METHODS: Epidemiological data from participants of two German birth cohorts (age 15) were used in logistic regression analyses testing cross-sectional associations of starch and sucrose (and their main dietary sources) with aeroallergen sensitization, asthma and rhinoconjunctivitis, adjusting for correlated fats (saturated, monounsaturated, omega-6 and omega-3 polyunsaturated) and other covariates. For mechanistic insights, murine models of aeroallergen-induced allergic airway inflammation (AAI) fed with a low-fat-high-sucrose or -high-starch versus a high-fat diet were used to characterize and quantify disease development. Metabolic and physiologic parameters were used to track outcomes of dietary interventions and cellular and molecular responses to monitor the development of AAI. Oxidative stress biomarkers were measured in murine sera or lung homogenates. RESULTS: We demonstrate a direct association of dietary sucrose with asthma prevalence in males, while starch was associated with higher asthma prevalence in females. In mice, high-carbohydrate feeding, despite scant metabolic effects, aggravated AAI compared to high-fat in both sexes, as displayed by humoral response, mucus hypersecretion, lung inflammatory cell infiltration and T(H) 2-T(H) 17 profiles. Compared to high-fat, high-carbohydrate intake was associated with increased pulmonary oxidative stress, signals of metabolic switch to glycolysis and decreased systemic anti-oxidative capacity. CONCLUSION: High consumption of digestible carbohydrates is associated with an increased prevalence of asthma in humans and aggravated lung allergic inflammation in mice, involving oxidative stress-related mechanisms.</style></abstract><notes><style face="normal" font="default" size="100%">Musiol, Stephanie&#xD;Harris, Carla P&#xD;Karlina, Ruth&#xD;Gostner, Johanna M&#xD;Rathkolb, Birgit&#xD;Schnautz, Benjamin&#xD;Schneider, Evelyn&#xD;Mair, Lisa&#xD;Vergara, Ernesto Elorduy&#xD;Flexeder, Claudia&#xD;Koletzko, Sibylle&#xD;Bauer, Carl-Peter&#xD;Schikowski, Tamara&#xD;Berdel, Dietrich&#xD;von Berg, Andrea&#xD;Herberth, Gunda&#xD;Rozman, Jan&#xD;Hrabe de Angelis, Martin&#xD;Standl, Marie&#xD;Schmidt-Weber, Carsten B&#xD;Ussar, Siegfried&#xD;Alessandrini, Francesca&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1218-1233. doi: 10.1111/all.15589. Epub 2022 Dec 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36424672</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15589</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>504</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">504</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Losol, P.</style></author><author><style face="normal" font="default" size="100%">Barcik, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.&#xD;Medical Research Center, Seoul National University, Seoul, Korea.&#xD;Department of Molecular Biology and Genetics, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.&#xD;Genetics of Cognition Laboratory, Neuroscience Area, Istituto Italiano di Tecnologia, Genoa, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dietary fiber and fermented food consumption and its link to allergic responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2568-2570</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/05/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Dietary Fiber</style></keyword><keyword><style face="normal" font="default" size="100%">*Fermented Foods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35553445</style></accession-num><notes><style face="normal" font="default" size="100%">Losol, Purevsuren&#xD;Barcik, Weronika&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2568-2570. doi: 10.1111/all.15367. Epub 2022 May 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35553445</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15367</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1885</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1885</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Losol, P.</style></author><author><style face="normal" font="default" size="100%">Barcik, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.&#xD;Medical Research Center, Seoul National University, Seoul, Korea.&#xD;Department of Molecular Biology and Genetics, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.&#xD;Genetics of Cognition Laboratory, Neuroscience Area, Istituto Italiano di Tecnologia, Genoa, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dietary fiber and fermented food consumption and its link to allergic responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2568-2570</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/05/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Dietary Fiber</style></keyword><keyword><style face="normal" font="default" size="100%">*Fermented Foods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35553445</style></accession-num><notes><style face="normal" font="default" size="100%">Losol, Purevsuren&#xD;Barcik, Weronika&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2568-2570. doi: 10.1111/all.15367. Epub 2022 May 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35553445</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15367</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2278</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2278</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Immormino, R. M.</style></author><author><style face="normal" font="default" size="100%">Smeekens, J. M.</style></author><author><style face="normal" font="default" size="100%">Mathai, P. I.</style></author><author><style face="normal" font="default" size="100%">Clough, K. M.</style></author><author><style face="normal" font="default" size="100%">Nguyen, J. T.</style></author><author><style face="normal" font="default" size="100%">Ghio, A. J.</style></author><author><style face="normal" font="default" size="100%">Cook, D. N.</style></author><author><style face="normal" font="default" size="100%">Kulis, M. D.</style></author><author><style face="normal" font="default" size="100%">Moran, T. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.&#xD;Center for Environmental Medicine, Asthma, and Lung Biology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.&#xD;UNC Food Allergy Initiative, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.&#xD;University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.&#xD;Human Studies Facility, United States Environmental Protection Agency, Chapel Hill, North Carolina, USA.&#xD;Division of Intramural Research, Immunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, NIH, North Carolina, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Different airborne particulates trigger distinct immune pathways leading to peanut allergy in a mouse model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">432-444</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/10/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Particulate Matter/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">T follicular helper cells</style></keyword><keyword><style face="normal" font="default" size="100%">air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">exposome</style></keyword><keyword><style face="normal" font="default" size="100%">particulate matter</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">remaining authors have no relevant conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37804001</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Environmental exposure to peanut through non-oral routes is a risk factor for peanut allergy. Early-life exposure to air pollutants, including particulate matter (PM), is associated with sensitization to foods through unknown mechanisms. We investigated whether PM promotes sensitization to environmental peanut and the development of peanut allergy in a mouse model. METHODS: C57BL/6J mice were co-exposed to peanut and either urban particulate matter (UPM) or diesel exhaust particles (DEP) via the airways and assessed for peanut sensitization and development of anaphylaxis following peanut challenge. Peanut-specific CD4(+) T helper (Th) cell responses were characterized by flow cytometry and Th cytokine production. Mice lacking select innate immune signaling genes were used to study mechanisms of PM-induced peanut allergy. RESULTS: Airway co-exposure to peanut and either UPM- or DEP-induced systemic sensitization to peanut and anaphylaxis following peanut challenge. Exposure to UPM or DEP triggered activation and migration of lung dendritic cells to draining lymph nodes and induction of peanut-specific CD4(+) Th cells. UPM- and DEP-induced distinct Th responses, but both stimulated expansion of T follicular helper (Tfh) cells essential for peanut allergy development. MyD88 signaling was critical for UPM- and DEP-induced peanut allergy, whereas TLR4 signaling was dispensable. DEP-induced peanut allergy and Tfh-cell differentiation depended on IL-1 but not IL-33 signaling, whereas neither cytokine alone was necessary for UPM-mediated sensitization. CONCLUSION: Environmental co-exposure to peanut and PM induces peanut-specific Tfh cells and peanut allergy in mice.</style></abstract><notes><style face="normal" font="default" size="100%">Immormino, Robert M&#xD;Smeekens, Johanna M&#xD;Mathai, Priscilla I&#xD;Clough, Katelyn M&#xD;Nguyen, Jackqueline T&#xD;Ghio, Andrew J&#xD;Cook, Donald N&#xD;Kulis, Michael D&#xD;Moran, Timothy P&#xD;eng&#xD;P30 CA016086/CA/NCI NIH HHS/&#xD;P30 ES010126/ES/NIEHS NIH HHS/&#xD;R01 ES032544/ES/NIEHS NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):432-444. doi: 10.1111/all.15908. Epub 2023 Oct 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37804001</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11017991</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15908</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>365</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">365</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caruso, C.</style></author><author><style face="normal" font="default" size="100%">Colantuono, S.</style></author><author><style face="normal" font="default" size="100%">Ciasca, G.</style></author><author><style face="normal" font="default" size="100%">Basile, U.</style></author><author><style face="normal" font="default" size="100%">Di Santo, R.</style></author><author><style face="normal" font="default" size="100%">Bagnasco, D.</style></author><author><style face="normal" font="default" size="100%">Passalacqua, G.</style></author><author><style face="normal" font="default" size="100%">Caminati, M.</style></author><author><style face="normal" font="default" size="100%">Michele, S.</style></author><author><style face="normal" font="default" size="100%">Senna, G.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Crimi, N.</style></author><author><style face="normal" font="default" size="100%">Intravaia, R.</style></author><author><style face="normal" font="default" size="100%">De Corso, E.</style></author><author><style face="normal" font="default" size="100%">Firinu, D.</style></author><author><style face="normal" font="default" size="100%">Gasbarrini, A.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universita Cattolica Sacro Cuore, Rome, Italy.&#xD;Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.&#xD;Dipartimento di Neuroscienze, Sezione di Fisica, Universita Cattolica Del Sacro Cuore, Roma, Italy.&#xD;Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy.&#xD;Area Diagnostica di Laboratorio, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.&#xD;Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, Genoa, Italy.&#xD;Department of Medicine, University of Verona and Verona University Hospital, Verona, Italy.&#xD;Asthma Center and Allergy Unit, University of Verona and General Hospital, Verona, Italy.&#xD;Personalized Medicine, Asthma and Allergy - Humanitas Clinical and Research Hospital IRCCS, Milan, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Respiratory Medicine Unit, A.O.U. &quot;Policlinico-Vittorio Emanuele&quot;, Catania, Italy.&#xD;Department of Clinical and Experimental Medicine, Section of Respiratory Medicine, A.O.U. &quot;Policlinico-Vittorio Emanuele&quot;, University of Catania, Catania, Italy.&#xD;Department of Clinical and Experimental Medicine, Section of Respiratory Medicine, University of Catania, Catania, Italy.&#xD;Otolaryngology Institute-Department of Head and Neck, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">131-140</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/08/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Enterotoxins</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Acuity</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus enterotoxins</style></keyword><keyword><style face="normal" font="default" size="100%">biologicals</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyposis</style></keyword><keyword><style face="normal" font="default" size="100%">severe eosinophilic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35922152</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma, with several phenotypes and endotypes, is considered particularly suited for precision medicine. The identification of different non-invasive biomarkers may facilitate diagnosis and treatment. Recently, Staphylococcus aureus and its enterotoxins (SE) have been found to have a role in inducing persistent type 2 airway inflammation in severe asthma, but also in such comorbidities as chronic rhinosinusitis with nasal polyposis (CRSwNP). METHODS: The aim of this retrospective study was to evaluate the prevalence of SE-IgE sensitization in a multicentric Italian cohort of severe asthmatic patients and correlate it with demographic and clinical characteristics. RESULTS: A total of 249 patients were included in the analysis, out of which 25.3% were staphylococcal enterotoxin B (SEB)-IgE positive. We found a meaningful association between SEB-IgE and female gender, a positive association was also measured between CRS and CRSwNP. No significant association was found between SEB-IgE sensitization and atopy, the occurrence of exacerbations and corticosteroid dosages. In the SEB-IgE-positive patient, blood eosinophil count does not appear to be correlated with the severity of the disease. Patients with SEB-IgE sensitization are, on average, younger and with an earlier disease onset, thus confirming the possibility to consider SEB-IgE sensitization as an independent risk factor for developing asthma. CONCLUSIONS: Our data confirm that the search for SE in the initial screening phase of these patients is helpful to better phenotype them, may predict the evolution of comorbidities and lead to a targeted therapeutic choice; in this point of view this represents a goal of precision medicine.</style></abstract><notes><style face="normal" font="default" size="100%">Caruso, Cristiano&#xD;Colantuono, Stefania&#xD;Ciasca, Gabriele&#xD;Basile, Umberto&#xD;Di Santo, Riccardo&#xD;Bagnasco, Diego&#xD;Passalacqua, Giovanni&#xD;Caminati, Marco&#xD;Michele, Schiappoli&#xD;Senna, Gianenrico&#xD;Heffler, Enrico&#xD;Canonica, G Walter&#xD;Crimi, Nunzio&#xD;Intravaia, Rossella&#xD;De Corso, Eugenio&#xD;Firinu, Davide&#xD;Gasbarrini, Antonio&#xD;Del Giacco, Stefano R&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):131-140. doi: 10.1111/all.15466. Epub 2022 Aug 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35922152</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15466</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2151</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2151</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sohn, K. H.</style></author><author><style face="normal" font="default" size="100%">Choi, S.</style></author><author><style face="normal" font="default" size="100%">Jung, J. W.</style></author><author><style face="normal" font="default" size="100%">Choi, J. H.</style></author><author><style face="normal" font="default" size="100%">Cho, S. H.</style></author><author><style face="normal" font="default" size="100%">Yi, H.</style></author><author><style face="normal" font="default" size="100%">Kang, H. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul, South Korea.&#xD;Division of Pulmonology and Allergy, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, South Korea.&#xD;Interdisciplinary Program in Precision Public Health, Korea University, Seoul, South Korea.&#xD;Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.&#xD;Department of Pulmonology and Allergy, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, South Korea.&#xD;Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.&#xD;School of Biosystems and Biomedical Sciences, Korea University, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Different inflammatory features of asthma according to gut microbiome enterotype</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2997-3001</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/05/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Feces</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37199247</style></accession-num><notes><style face="normal" font="default" size="100%">Sohn, Kyoung-Hee&#xD;Choi, Sungmi&#xD;Jung, Jae-Woo&#xD;Choi, Jeong-Hee&#xD;Cho, Sang-Heon&#xD;Yi, Hana&#xD;Kang, Hye-Ryun&#xD;eng&#xD;Korea Centers for Disease Control and Prevention/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2997-3001. doi: 10.1111/all.15768. Epub 2023 Jun 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37199247</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15768</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2183</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2183</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Oh, H. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Yeom, J.</style></author><author><style face="normal" font="default" size="100%">Nam, M. H.</style></author><author><style face="normal" font="default" size="100%">Park, Y. M.</style></author><author><style face="normal" font="default" size="100%">Lee, S. Y.</style></author><author><style face="normal" font="default" size="100%">Hong, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Seoul Center, Korea Basic Science Institute, Seoul, Korea.&#xD;Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Department of Pediatrics, Childhood Asthma Atopy Center, Humidifier Disinfectant Health Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Different mechanisms distinguishing childhood allergic diseases including allergic march</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2786-2789</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/07/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37497847</style></accession-num><notes><style face="normal" font="default" size="100%">Oh, Hea Young&#xD;Kim, Jeong-Hyun&#xD;Yeom, Jeonghun&#xD;Nam, Myung Hee&#xD;Park, Yoon Mee&#xD;Lee, So-Yeon&#xD;Hong, Soo-Jong&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2786-2789. doi: 10.1111/all.15831. Epub 2023 Jul 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37497847</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15831</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>55</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">55</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hanschmann, T.</style></author><author><style face="normal" font="default" size="100%">Francuzik, W.</style></author><author><style face="normal" font="default" size="100%">Dolle-Bierke, S.</style></author><author><style face="normal" font="default" size="100%">Hofmeier, K. S.</style></author><author><style face="normal" font="default" size="100%">Grabenhenrich, L.</style></author><author><style face="normal" font="default" size="100%">Rueff, F.</style></author><author><style face="normal" font="default" size="100%">Renaudin, J. M.</style></author><author><style face="normal" font="default" size="100%">Pfohler, C.</style></author><author><style face="normal" font="default" size="100%">Treudler, R.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Lang, R.</style></author><author><style face="normal" font="default" size="100%">Ensina, L. F.</style></author><author><style face="normal" font="default" size="100%">Christoff, G.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">Wagner, N.</style></author><author><style face="normal" font="default" size="100%">Reider, N.</style></author><author><style face="normal" font="default" size="100%">Muller, S.</style></author><author><style face="normal" font="default" size="100%">Dickel, H.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health, Berlin, Germany.&#xD;Allergy Unit, Department of Dermatology, University Hospital Basel, Basel, Switzerland.&#xD;Allergy Unit, Cantonal Hospital Aarau, Aarau, Switzerland.&#xD;Department for Methodology and Research Infrastructure, Robert Koch-Institut, Berlin, Germany.&#xD;Department of Dermatology and Allergology, Ludwig-Maximilian-University, Munich, Germany.&#xD;Allergy Vigilance Network, Vandoeuvre les Nancy, France.&#xD;Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany.&#xD;Department of Dermatology, Venereology and Allergology and Leipzig Interdisciplinary Center of Allergology (LICA) Comprehensive Allergy Center, University Leipzig Medical Faculty, Leipzig, Germany.&#xD;Department of Clinical and Molecular Sciences, Universita Politecnica delle Marche, Ancona, Italy.&#xD;Department of Internal Medicine/Allergy Unit, University Hospital Ospedali Riuniti, Ancona, Italy.&#xD;Department of Dermatology and Allergology, Paracelsus Medizinische Privatuniversitat Salzburg, Salzburg, Austria.&#xD;Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;Faculty of Public Health, Medical University - Sofia, Sofia, Bulgaria.&#xD;Allergy Out-patient Department, Acibadem City Clinic, Tokuda Medical Centre, Sofia, Bulgaria.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall d&apos;Hebron, Barcelona, Spain.&#xD;ARADyAL Research Network, Barcelona, Spain.&#xD;Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany.&#xD;Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.&#xD;Department of Dermatology, Medical Center - University of Freiburg, Freiburg, Germany.&#xD;Faculty of Medicine, University of Freiburg, Freiburg, Germany.&#xD;Department of Dermatology, Venereology and Allergology, St. Josef Hospital, University Medical Center, Ruhr University Bochum, Bochum, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Different phenotypes of drug-induced anaphylaxis-Data from the European Anaphylaxis Registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1615-1627</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/12/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">drugs</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36479710</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Drugs are a frequent cause of severe anaphylactic reactions. Here, we analyze a large dataset on drug induced anaphylaxis regarding elicitors, risk factors, symptoms, and treatment. METHODS: Data from the European Anaphylaxis Registry (2007-2019) with 1815 reported cases of drug-induced anaphylaxis were studied accordingly. RESULTS: Drugs are the third most frequent cause of anaphylaxis reported in the Anaphylaxis Registry. Among the eliciting groups of drugs analgesics and antibiotics were far most often reported. Female and senior patients were more frequently affected, while the number of children with DIA was low. DIA patients had symptoms affecting the skin and mucous membranes (n = 1525, 84.02%), the respiratory (n = 1300, 71.63%), the cardiovascular (n = 1251, 68.93%) and the gastrointestinal system (n = 549, 30.25%). Drugs caused significant more severe reactions, occurred more often in medical facilities and led to increased hospitalization rates in comparison to food and insect venom induced anaphylaxis. Adrenaline was used more often in patients with DIA than in anaphylaxis due to other causes. Patients with skin symptoms received more antihistamines and corticosteroids in the acute treatment, while gastrointestinal symptoms led to less adrenaline use. CONCLUSION: The study contributes to a better understanding of DIA, with a large number of cases from Europe supporting previous data, e.g., analgesics and antibiotics being the most frequent culprits for DIA. Female gender and higher age are relevant risk factors and despite clear recommendations, the emergency treatment of DIA is not administered according to the guidelines.</style></abstract><notes><style face="normal" font="default" size="100%">Hanschmann, Theresa&#xD;Francuzik, Wojciech&#xD;Dolle-Bierke, Sabine&#xD;Hofmeier, Kathrin Scherer&#xD;Grabenhenrich, Linus&#xD;Rueff, Franziska&#xD;Renaudin, Jean-Marie&#xD;Pfohler, Claudia&#xD;Treudler, Regina&#xD;Bilo, M Beatrice&#xD;Lang, Roland&#xD;Ensina, Luis Felipe&#xD;Christoff, George&#xD;Cardona, Victoria&#xD;Wagner, Nicola&#xD;Reider, Norbert&#xD;Muller, Sabine&#xD;Dickel, Heinrich&#xD;Worm, Margitta&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1615-1627. doi: 10.1111/all.15612. Epub 2022 Dec 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36479710</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15612</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2570</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2570</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kratzer, B.</style></author><author><style face="normal" font="default" size="100%">Gattinger, P.</style></author><author><style face="normal" font="default" size="100%">Trapin, D.</style></author><author><style face="normal" font="default" size="100%">Ettel, P.</style></author><author><style face="normal" font="default" size="100%">Kormoczi, U.</style></author><author><style face="normal" font="default" size="100%">Rottal, A.</style></author><author><style face="normal" font="default" size="100%">Stieger, R. B.</style></author><author><style face="normal" font="default" size="100%">Sehgal, A. N. A.</style></author><author><style face="normal" font="default" size="100%">Feichter, M.</style></author><author><style face="normal" font="default" size="100%">Borochova, K.</style></author><author><style face="normal" font="default" size="100%">Tulaeva, I.</style></author><author><style face="normal" font="default" size="100%">Grabmeier-Pfistershammer, K.</style></author><author><style face="normal" font="default" size="100%">Tauber, P. A.</style></author><author><style face="normal" font="default" size="100%">Perkmann, T.</style></author><author><style face="normal" font="default" size="100%">Fae, I.</style></author><author><style face="normal" font="default" size="100%">Wenda, S.</style></author><author><style face="normal" font="default" size="100%">Kundi, M.</style></author><author><style face="normal" font="default" size="100%">Fischer, G. F.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Pickl, W. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Center for Pathophysiology, Infectiology and Immunology, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Laboratory for Immunopathology, Department of Clinical Immunology and Allergology, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.&#xD;Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.&#xD;Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria.&#xD;Center for Public Health, Department for Environmental Health, Medical University of Vienna, Vienna, Austria.&#xD;NRC Institute of Immunology FMBA of Russia, Moscow, Russia.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Differential decline of SARS-CoV-2-specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2482-2501</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Viral/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Adaptive Immunity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">*Th1 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Spike Glycoprotein, Coronavirus/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Coronavirus Nucleocapsid Proteins/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">CD19+CD27+ B memory cells</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Th1/Th2 cytokine shift</style></keyword><keyword><style face="normal" font="default" size="100%">leukopenia</style></keyword><keyword><style face="normal" font="default" size="100%">long-term effect</style></keyword><keyword><style face="normal" font="default" size="100%">recent thymic emigrants</style></keyword><keyword><style face="normal" font="default" size="100%">specific antibody decline</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39003594</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: SARS-CoV-2 has triggered a pandemic and contributes to long-lasting morbidity. Several studies have investigated immediate cellular and humoral immune responses during acute infection. However, little is known about long-term effects of COVID-19 on the immune system. METHODS: We performed a longitudinal investigation of cellular and humoral immune parameters in 106 non-vaccinated subjects ten weeks (10 w) and ten months (10 m) after their first SARS-CoV-2 infection. Peripheral blood immune cells were analyzed by multiparametric flow cytometry, serum cytokines were examined by multiplex technology. Antibodies specific for the Spike protein (S), the receptor-binding domain (RBD) and the nucleocapsid protein (NC) were determined. All parameters measured 10 w and 10 m after infection were compared with those of a matched, noninfected control group (n = 98). RESULTS: Whole blood flow cytometric analyses revealed that 10 m after COVID-19, convalescent patients compared to controls had reduced absolute granulocyte, monocyte, and lymphocyte counts, involving T, B, and NK cells, in particular CD3(+)CD45RA(+)CD62L(+)CD31(+) recent thymic emigrant T cells and non-class-switched CD19(+)IgD(+)CD27(+) memory B cells. Cellular changes were associated with a reversal from Th1- to Th2-dominated serum cytokine patterns. Strong declines of NC- and S-specific antibody levels were associated with younger age (by 10.3 years, p &lt; .01) and fewer CD3(-)CD56(+) NK and CD19(+)CD27(+) B memory cells. Changes of T-cell subsets at 10 m such as normalization of effector and Treg numbers, decline of RTE, and increase of central memory T cell numbers were independent of antibody decline pattern. CONCLUSIONS: COVID-19 causes long-term reduction of innate and adaptive immune cells which is associated with a Th2 serum cytokine profile. This may provide an immunological mechanism for long-term sequelae after COVID-19.</style></abstract><notes><style face="normal" font="default" size="100%">Kratzer, Bernhard&#xD;Gattinger, Pia&#xD;Trapin, Doris&#xD;Ettel, Paul&#xD;Kormoczi, Ulrike&#xD;Rottal, Arno&#xD;Stieger, Robert B&#xD;Sehgal, Al Nasar Ahmed&#xD;Feichter, Melanie&#xD;Borochova, Kristina&#xD;Tulaeva, Inna&#xD;Grabmeier-Pfistershammer, Katharina&#xD;Tauber, Peter A&#xD;Perkmann, Thomas&#xD;Fae, Ingrid&#xD;Wenda, Sabine&#xD;Kundi, Michael&#xD;Fischer, Gottfried F&#xD;Valenta, Rudolf&#xD;Pickl, Winfried F&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2482-2501. doi: 10.1111/all.16210. Epub 2024 Jul 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39003594</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16210</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2864</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2864</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">An, J.</style></author><author><style face="normal" font="default" size="100%">Park, J.</style></author><author><style face="normal" font="default" size="100%">Do, A. R.</style></author><author><style face="normal" font="default" size="100%">Seo, S.</style></author><author><style face="normal" font="default" size="100%">Shin, E.</style></author><author><style face="normal" font="default" size="100%">Lee, J. E.</style></author><author><style face="normal" font="default" size="100%">Cho, Y. S.</style></author><author><style face="normal" font="default" size="100%">Won, S.</style></author><author><style face="normal" font="default" size="100%">Kim, T. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary, Allergy and Critical Care Medicine, College of Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University, Seoul, South Korea.&#xD;Interdisciplinary Program of Bioinformatics, Seoul National University, Seoul, South Korea.&#xD;DNA Link, Seoul, South Korea.&#xD;Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.&#xD;Department of Public Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, South Korea.&#xD;Interdisciplinary Program of Bioinformatics, College of Natural Science, Seoul National University, Seoul, South Korea.&#xD;Institute of Health and Environment, Seoul National University, Seoul, South Korea.&#xD;Department of Public Health Sciences, Seoul National University, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Differential DNA Methylation in Peripheral Blood Mononuclear Cells Reflects Asthma Control Status in Adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1773-1775</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/04/19 22:11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetics</style></keyword><keyword><style face="normal" font="default" size="100%">personlized medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40251921</style></accession-num><notes><style face="normal" font="default" size="100%">An, Jin&#xD;Park, Jaehyun&#xD;Do, Ah Ra&#xD;Seo, Sujin&#xD;Shin, Eunsoon&#xD;Lee, Jong Eun&#xD;Cho, You Sook&#xD;Won, Sungho&#xD;Kim, Tae-Bum&#xD;eng&#xD;10.13039/501100003725/National Research Foundation of Korea/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1773-1775. doi: 10.1111/all.16566. Epub 2025 Apr 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40251921</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16566</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>637</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">637</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karlina, R.</style></author><author><style face="normal" font="default" size="100%">Flexeder, C.</style></author><author><style face="normal" font="default" size="100%">Musiol, S.</style></author><author><style face="normal" font="default" size="100%">Bhattacharyya, M.</style></author><author><style face="normal" font="default" size="100%">Schneider, E.</style></author><author><style face="normal" font="default" size="100%">Altun, I.</style></author><author><style face="normal" font="default" size="100%">Gschwendtner, S.</style></author><author><style face="normal" font="default" size="100%">Neumann, A. U.</style></author><author><style face="normal" font="default" size="100%">Nano, J.</style></author><author><style face="normal" font="default" size="100%">Schloter, M.</style></author><author><style face="normal" font="default" size="100%">Peters, A.</style></author><author><style face="normal" font="default" size="100%">Schulz, H.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Standl, M.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Alessandrini, F.</style></author><author><style face="normal" font="default" size="100%">Ussar, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">RG Adipocytes &amp; Metabolism, Institute for Diabetes &amp; Obesity, Helmholtz Zentrum Munchen, Munich, Germany.&#xD;German Center for Diabetes Research (DZD), Munich, Germany.&#xD;Institute of Epidemiology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Munich, Germany.&#xD;Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany.&#xD;German Center for Lung Research (DZL), Munich, Germany.&#xD;Center of Allergy &amp; Environment (ZAUM), Technical University of Munich and Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Munich, Germany.&#xD;Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Research Unit for Comparative Microbiome Analysis, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Augsburg, Germany.&#xD;Environmental Medicine, Technical University Munich, Munich, Germany.&#xD;Department of Medicine, Technical University of Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Differential effects of lung inflammation on insulin resistance in humans and mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2482-2497</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/01/22</style></edition><section><style face="normal" font="default" size="100%">2482</style></section><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Body Weight</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, High-Fat/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Insulin Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mites</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">insulin sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">obesity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35060125</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The rates of obesity, its associated diseases, and allergies are raising at alarming rates in most countries. House dust mites (HDM) are highly allergenic and exposure often associates with an urban sedentary indoor lifestyle, also resulting in obesity. The aim of this study was to investigate the epidemiological association and physiological impact of lung inflammation on obesity and glucose homeostasis. METHODS: Epidemiological data from 2207 adults of the population-based KORA FF4 cohort were used to test associations between asthma and rhinitis with metrics of body weight and insulin sensitivity. To obtain functional insights, C57BL/6J mice were intranasally sensitized and challenged with HDM and simultaneously fed with either low-fat or high-fat diet for 12 weeks followed by a detailed metabolic and biochemical phenotyping of the lung, liver, and adipose tissues. RESULTS: We found a direct association of asthma with insulin resistance but not body weight in humans. In mice, co-development of obesity and HDM-induced lung inflammation attenuated inflammation in lung and perigonadal fat, with little impact on body weight, but small shifts in the composition of gut microbiota. Exposure to HDM improved glucose tolerance, reduced hepatosteatosis, and increased energy expenditure and basal metabolic rate. These effects associate with increased activity of thermogenic adipose tissues independent of uncoupling protein 1. CONCLUSIONS: Asthma associates with insulin resistance in humans, but HDM challenge results in opposing effects on glucose homeostasis in mice due to increased energy expenditure, reduced adipose inflammation, and hepatosteatosis.</style></abstract><notes><style face="normal" font="default" size="100%">Karlina, Ruth&#xD;Flexeder, Claudia&#xD;Musiol, Stephanie&#xD;Bhattacharyya, Madhumita&#xD;Schneider, Evelyn&#xD;Altun, Irem&#xD;Gschwendtner, Silvia&#xD;Neumann, Avidan U&#xD;Nano, Jana&#xD;Schloter, Michael&#xD;Peters, Annette&#xD;Schulz, Holger&#xD;Schmidt-Weber, Carsten B&#xD;Standl, Marie&#xD;Traidl-Hoffmann, Claudia&#xD;Alessandrini, Francesca&#xD;Ussar, Siegfried&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2482-2497. doi: 10.1111/all.15226. Epub 2022 Feb 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35060125</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15226</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2356</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2356</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wipperman, M. F.</style></author><author><style face="normal" font="default" size="100%">Gayvert, K. M.</style></author><author><style face="normal" font="default" size="100%">Atanasio, A.</style></author><author><style face="normal" font="default" size="100%">Wang, C. Q.</style></author><author><style face="normal" font="default" size="100%">Corren, J.</style></author><author><style face="normal" font="default" size="100%">Covarrubias, A.</style></author><author><style face="normal" font="default" size="100%">Setliff, I.</style></author><author><style face="normal" font="default" size="100%">Chio, E.</style></author><author><style face="normal" font="default" size="100%">Laws, E.</style></author><author><style face="normal" font="default" size="100%">Wolfe, K.</style></author><author><style face="normal" font="default" size="100%">Harel, S.</style></author><author><style face="normal" font="default" size="100%">Maloney, J.</style></author><author><style face="normal" font="default" size="100%">Herman, G.</style></author><author><style face="normal" font="default" size="100%">Orengo, J. M.</style></author><author><style face="normal" font="default" size="100%">Lim, W. K.</style></author><author><style face="normal" font="default" size="100%">Hamon, S. C.</style></author><author><style face="normal" font="default" size="100%">Hamilton, J. D.</style></author><author><style face="normal" font="default" size="100%">O&apos;Brien, M. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.&#xD;Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, California, USA.&#xD;Clinical Research Division, Jonathan Corren, MD. Inc., Los Angeles, California, USA.&#xD;Sanofi, Bridgewater, New Jersey, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">894-907</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/01/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Phleum</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Rna</style></keyword><keyword><style face="normal" font="default" size="100%">Scit</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38279910</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Nasal epithelial cells are important regulators of barrier function and immune signaling; however, in allergic rhinitis (AR) these functions can be disrupted by inflammatory mediators. We aimed to better discern AR disease mechanisms using transcriptome data from nasal brushing samples from individuals with and without AR. METHODS: Data were drawn from a feasibility study of individuals with and without AR to Timothy grass and from a clinical trial evaluating 16 weeks of treatment with the following: dupilumab, a monoclonal antibody that binds interleukin (IL)-4Ralpha and inhibits type 2 inflammation by blocking signaling of both IL-4/IL-13; subcutaneous immunotherapy with Timothy grass (SCIT), which inhibits allergic responses through pleiotropic effects; SCIT + dupilumab; or placebo. Using nasal brushing samples from these studies, we defined distinct gene signatures in nasal tissue of AR disease and after nasal allergen challenge (NAC) and assessed how these signatures were modulated by study drug(s). RESULTS: Treatment with dupilumab (normalized enrichment score [NES] = -1.73, p = .002) or SCIT + dupilumab (NES = -2.55, p &lt; .001), but not SCIT alone (NES = +1.16, p = .107), significantly repressed the AR disease signature. Dupilumab (NES = -2.55, p &lt; .001), SCIT (NES = -2.99, p &lt; .001), and SCIT + dupilumab (NES = -3.15, p &lt; .001) all repressed the NAC gene signature. CONCLUSION: These results demonstrate type 2 inflammation is an important contributor to the pathophysiology of AR disease and that inhibition of the type 2 pathway with dupilumab may normalize nasal tissue gene expression.</style></abstract><notes><style face="normal" font="default" size="100%">Wipperman, Matthew F&#xD;Gayvert, Kaitlyn M&#xD;Atanasio, Amanda&#xD;Wang, Claire Q&#xD;Corren, Jonathan&#xD;Covarrubias, Angelica&#xD;Setliff, Ian&#xD;Chio, Erica&#xD;Laws, Elizabeth&#xD;Wolfe, Kelley&#xD;Harel, Sivan&#xD;Maloney, Jennifer&#xD;Herman, Gary&#xD;Orengo, Jamie M&#xD;Lim, Wei Keat&#xD;Hamon, Sara C&#xD;Hamilton, Jennifer D&#xD;O&apos;Brien, Meagan P&#xD;eng&#xD;Regeneron Pharmaceuticals/&#xD;Sanofi/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):894-907. doi: 10.1111/all.16001. Epub 2024 Jan 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38279910</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16001</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2319</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2319</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jimenez-Rodriguez, T. W.</style></author><author><style face="normal" font="default" size="100%">de Las Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Lynch, D. M.</style></author><author><style face="normal" font="default" size="100%">Besz, K. M.</style></author><author><style face="normal" font="default" size="100%">Marquis, K.</style></author><author><style face="normal" font="default" size="100%">Burgos, A.</style></author><author><style face="normal" font="default" size="100%">Soriano Gomis, V.</style></author><author><style face="normal" font="default" size="100%">Lozano, I.</style></author><author><style face="normal" font="default" size="100%">Anton, R. A. M.</style></author><author><style face="normal" font="default" size="100%">de la Calle, F. M.</style></author><author><style face="normal" font="default" size="100%">Gonzalez Delgado, M. P.</style></author><author><style face="normal" font="default" size="100%">Gutierrez, A.</style></author><author><style face="normal" font="default" size="100%">Montenegro, E.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, F.</style></author><author><style face="normal" font="default" size="100%">Fernandez Sanchez, F. J.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.&#xD;ARADyAL Spanish Network (RD16/0006), Instituto de Salud Carlos III (ISCIII), Fundacion Espanola para la Ciencia y la Tecnologia (FECyT), Madrid, Spain.&#xD;Allergy Section, Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.&#xD;Allergy Clinical Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Pharmacy Department, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.&#xD;Department of Clinical Medicine, Miguel Hernandez University, Alicante, Spain.&#xD;Oncology Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.&#xD;Oncology Day Hospital Nursing Service, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.&#xD;Immunology Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">679-689</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/11/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Oxaliplatin/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Carboplatin/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Antineoplastic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">carboplatin</style></keyword><keyword><style face="normal" font="default" size="100%">desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">endophenotype</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">oxaliplatin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37916741</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Drug hypersensitivity reactions (DHRs) to platinum-based drugs are heterogenous and restrict their access, and drug desensitization (DD) has provided a ground-breaking procedure for their re-introduction, although the response is heterogeneous. We aimed to identify the phenotypes, endotypes, and biomarkers of reactions to carboplatin and oxaliplatin and their response to DD. METHODS: Seventy-nine patients presenting with DHRs to oxaliplatin (N = 46) and carboplatin (N = 33) were evaluated at the Allergy Departments of two tertiary care hospitals in Spain. Patient symptoms, skin testing, biomarkers, and outcomes of 267 DDs were retrospectively analyzed. RESULTS: Oxaliplatin-reactive patients presented with type I (74%), cytokine release reaction (CRR) (11%), and mixed (Mx) (15%) phenotypes. In contrast, carboplatin reactive patients presented with predominantly type I (85%) and Mx (15%) but no CRRs. Out of 267 DDs, breakthrough reactions (BTRs) to oxaliplatin occurred twice as frequently as carboplatin (32% vs. 15%; p &lt; .05). Phenotype switching from type I to another phenotype was observed in 46% of oxaliplatin DDs compared to 21% of carboplatin DDs. Tryptase was elevated in type I and Mx reactions, and IL-6 in CRR and Mx, indicating different mechanisms and endotypes. CONCLUSION: Carboplatin and oxaliplatin induced three different types of reactions with defined phenotypes and endotypes amendable to DD. Although most of the initial reactions for both were type I, oxaliplatin presented with unique CRR reactions. During DD, carboplatin reactive patients presented mostly type I BTR, while oxaliplatin-reactive patients frequently switched from type I to CRR, providing a critical difference and the need for personalized DD protocols.</style></abstract><notes><style face="normal" font="default" size="100%">Jimenez-Rodriguez, Teodorikez-Wilfox&#xD;de Las Vecillas, Leticia&#xD;Labella, Marina&#xD;Lynch, Donna-Marie&#xD;Besz, Kylie Marie&#xD;Marquis, Kathleen&#xD;Burgos, Amparo&#xD;Soriano Gomis, Victor&#xD;Lozano, Inmaculada&#xD;Anton, Rosa Ana Montoyo&#xD;de la Calle, Francisco Marco&#xD;Gonzalez Delgado, Maria Purificacion&#xD;Gutierrez, Aurora&#xD;Montenegro, Estefania&#xD;Rodriguez, Fernando&#xD;Fernandez Sanchez, Francisco Javier&#xD;Castells, Mariana&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):679-689. doi: 10.1111/all.15940. Epub 2023 Nov 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37916741</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15940</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2835</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2835</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hsu, Y. T.</style></author><author><style face="normal" font="default" size="100%">Wu, C. C.</style></author><author><style face="normal" font="default" size="100%">Wang, C. C.</style></author><author><style face="normal" font="default" size="100%">Sheu, C. C.</style></author><author><style face="normal" font="default" size="100%">Yang, Y. H.</style></author><author><style face="normal" font="default" size="100%">Cheng, M. Y.</style></author><author><style face="normal" font="default" size="100%">Lai, R. S.</style></author><author><style face="normal" font="default" size="100%">Cheng, M. H.</style></author><author><style face="normal" font="default" size="100%">Chen, H. C.</style></author><author><style face="normal" font="default" size="100%">Yang, C. J.</style></author><author><style face="normal" font="default" size="100%">Wang, C. J.</style></author><author><style face="normal" font="default" size="100%">Liu, H. J.</style></author><author><style face="normal" font="default" size="100%">Chen, H. L.</style></author><author><style face="normal" font="default" size="100%">Hung, C. H.</style></author><author><style face="normal" font="default" size="100%">Lee, C. L.</style></author><author><style face="normal" font="default" size="100%">Huang, M. S.</style></author><author><style face="normal" font="default" size="100%">Huang, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Institute of Environmental Health Sciences, National Health Research Institutes, Miaoli, Taiwan.&#xD;National Center for Geriatrics and Welfare Research, National Health Research Institutes, Miaoli, Taiwan.&#xD;Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.&#xD;Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.&#xD;Department of Mathematics, Hong Kong Baptist University, Hong Kong, China.&#xD;Division of Chest Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.&#xD;Department of Respiratory Therapy, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Department of Pediatrics, Kaohsiung Medical University Hospital and College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Department of Pediatrics, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Department of Marine Environment and Engineering, National sun Yat-Sen University, Kaohsiung, Taiwan.&#xD;Division of Chest Medicine, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.&#xD;Department of Respirology and Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China.&#xD;Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Differential Risks of Exposure to Acrylamide in Adult Asthma Clusters</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1173-1175</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/02/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">acrylamide</style></keyword><keyword><style face="normal" font="default" size="100%">asthma phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">clustering analysis</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">urinary metabolites</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39953833</style></accession-num><notes><style face="normal" font="default" size="100%">Hsu, Yuan-Ting&#xD;Wu, Chao-Chien&#xD;Wang, Chin-Chou&#xD;Sheu, Chau-Chyun&#xD;Yang, Yi-Hsin&#xD;Cheng, Ming-Yen&#xD;Lai, Ruay-Sheng&#xD;Cheng, Meng-Hsuan&#xD;Chen, Huang-Chi&#xD;Yang, Chih-Jen&#xD;Wang, Chien-Jen&#xD;Liu, Huei-Ju&#xD;Chen, Hua-Ling&#xD;Hung, Chih-Hsing&#xD;Lee, Chon-Lin&#xD;Huang, Ming-Shyan&#xD;Huang, Shau-Ku&#xD;eng&#xD;Academia Sinica/&#xD;Ministry of Health and Welfare/&#xD;National Health Research Institutes/&#xD;Ministry of Science and Technology/&#xD;National Science Council/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1173-1175. doi: 10.1111/all.16503. Epub 2025 Feb 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39953833</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16503</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2778</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2778</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khalmuratova, R.</style></author><author><style face="normal" font="default" size="100%">Kim, Y. S.</style></author><author><style face="normal" font="default" size="100%">Kim, D. W.</style></author><author><style face="normal" font="default" size="100%">Shin, H. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Obstructive Upper Airway Research (OUaR) Laboratory, Department of Pharmacology, Seoul National University College of Medicine, Seoul, South Korea.&#xD;Ischemic/Hypoxic Disease Institute, Seoul National University Medical Research Center, Seoul, South Korea.&#xD;Sensory Organ Research Institute, Seoul National University Medical Research Center, Seoul, South Korea.&#xD;Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, South Korea.&#xD;Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine, Seoul National University Boramae Medical Center, Seoul, South Korea.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Differentiated Epithelial Layer Graft Improves Fibrosis and Survival in Airway Stenosis via IL-37</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1468-1472</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/12/23</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39711088</style></accession-num><notes><style face="normal" font="default" size="100%">Khalmuratova, Roza&#xD;Kim, Yi Sook&#xD;Kim, Dae Woo&#xD;Shin, Hyun-Woo&#xD;eng&#xD;National Research Foundation of Korea/&#xD;Korea Health Industry Development Institute (KHIDI)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1468-1472. doi: 10.1111/all.16452. Epub 2024 Dec 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39711088</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105059 technique. Other author has declared that no conflicts of interest exist.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16452</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>568</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">568</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Ruckert, B.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Perez-Diego, M.</style></author><author><style face="normal" font="default" size="100%">Kucukkase, O. C.</style></author><author><style face="normal" font="default" size="100%">Li, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Medical Microbiology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin, Turkey.&#xD;Division of Pediatric Allergy and Immunology, School of Medicine, Marmara University, Istanbul, Turkey.&#xD;Research Center for Translational Medicine (KUTTAM), Koc University School of Medicine, Istanbul, Turkey.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Differentiation of bronchial epithelial spheroids in the presence of IL-13 recapitulates characteristic features of asthmatic airway epithelia</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2229-2233</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/03/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchi</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">barrier</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">interleukins</style></keyword><keyword><style face="normal" font="default" size="100%">European Union (EU CURE), Novartis Research Institutes (Basel, Switzerland),</style></keyword><keyword><style face="normal" font="default" size="100%">Stanford University (Redwood City, Calif) and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">he is</style></keyword><keyword><style face="normal" font="default" size="100%">the Co-Chair for EAACI Guidelines on Environmental Science in Allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">and Asthma and serves on the Advisory Boards of Sanofi/Regeneron, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline and SciBase, and is the Editor-in-Chief of Allergy. All other</style></keyword><keyword><style face="normal" font="default" size="100%">authors have no conflicts to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35266577</style></accession-num><notes><style face="normal" font="default" size="100%">Pat, Yagiz&#xD;Ruckert, Beate&#xD;Ogulur, Ismail&#xD;Yazici, Duygu&#xD;Perez-Diego, Mario&#xD;Kucukkase, Ozan C&#xD;Li, Manru&#xD;Akdis, Cezmi A&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2229-2233. doi: 10.1111/all.15279. Epub 2022 Mar 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35266577</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9311728</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15279</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1092</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1092</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hagemann, J.</style></author><author><style face="normal" font="default" size="100%">Onorato, G. L.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Bennoor, K. S.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Braido, F.</style></author><author><style face="normal" font="default" size="100%">Camargos, P.</style></author><author><style face="normal" font="default" size="100%">Caraballo, L.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Cingi, C.</style></author><author><style face="normal" font="default" size="100%">Correia-de-Sousa, J.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Dokic, D.</style></author><author><style face="normal" font="default" size="100%">Dykewicz, M.</style></author><author><style face="normal" font="default" size="100%">Ebisawa, M.</style></author><author><style face="normal" font="default" size="100%">El-Gamal, Y.</style></author><author><style face="normal" font="default" size="100%">Emuzyte, R.</style></author><author><style face="normal" font="default" size="100%">Fauquert, J. L.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Gomez, R. M.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Hamelmann, E.</style></author><author><style face="normal" font="default" size="100%">Iinuma, T.</style></author><author><style face="normal" font="default" size="100%">Ivancevich, J. C.</style></author><author><style face="normal" font="default" size="100%">Jassem, E.</style></author><author><style face="normal" font="default" size="100%">Kalayci, O.</style></author><author><style face="normal" font="default" size="100%">Kardas, P.</style></author><author><style face="normal" font="default" size="100%">Khaitov, M.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Lipworth, B.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Maspero, J. F.</style></author><author><style face="normal" font="default" size="100%">Miculinic, N.</style></author><author><style face="normal" font="default" size="100%">Mihaltan, F.</style></author><author><style face="normal" font="default" size="100%">Mohammad, Y.</style></author><author><style face="normal" font="default" size="100%">Montefort, S.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Naclerio, R.</style></author><author><style face="normal" font="default" size="100%">Neffen, H.</style></author><author><style face="normal" font="default" size="100%">Niedoszytko, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">Ohta, K.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Okubo, K.</style></author><author><style face="normal" font="default" size="100%">Panzner, P.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Passalacqua, G.</style></author><author><style face="normal" font="default" size="100%">Patella, V.</style></author><author><style face="normal" font="default" size="100%">Pereira, A.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Plavec, D.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Prokopakis, E. P.</style></author><author><style face="normal" font="default" size="100%">Puggioni, F.</style></author><author><style face="normal" font="default" size="100%">Raciborski, F.</style></author><author><style face="normal" font="default" size="100%">Reijula, J.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Romano, A.</style></author><author><style face="normal" font="default" size="100%">Rosario, N.</style></author><author><style face="normal" font="default" size="100%">Rottem, M.</style></author><author><style face="normal" font="default" size="100%">Ryan, D.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Sole, D.</style></author><author><style face="normal" font="default" size="100%">Sova, M.</style></author><author><style face="normal" font="default" size="100%">Stellato, C.</style></author><author><style face="normal" font="default" size="100%">Suppli-Ulrik, C.</style></author><author><style face="normal" font="default" size="100%">Tsiligianni, I.</style></author><author><style face="normal" font="default" size="100%">Valero, A.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Valovirta, E.</style></author><author><style face="normal" font="default" size="100%">Vasankari, T.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Wallace, D.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Williams, S.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Yusuf, O. M.</style></author><author><style face="normal" font="default" size="100%">Zernotti, M.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;MACVIA-France, Montpellier, France.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Transylvania University Brasov, Brasov, Romania.&#xD;Comprehensive Allergy Center, Department of Dermatology and Allergy, Charite, Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;Rhinology Unit &amp; Smell Clinic, ENT Department, Hospital Clinic; Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.&#xD;MASK-air, Montpellier, France.&#xD;Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium.&#xD;Sun Yat-sen University, International Airway Research Center, First Affiliated Hospital Guangzou, Guangzou, China.&#xD;Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.&#xD;Department of Internal Medicine (DiMI) and IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy.&#xD;Department of Pediatrics, Federal University of Minas Gerais, Medical School, Belo Horizonte, Brazil.&#xD;Institute for Immunological Research, University of Cartagena, Campus de Zaragocilla, Edificio Biblioteca Primer piso, Cartagena, Colombia.&#xD;Foundation for the Development of Medical and Biological Sciences (Fundemeb), Cartagena, Colombia.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall d&apos;Hebron &amp; ARADyAL Research Network, Barcelona, Spain.&#xD;Division of Allergy/immunology, University of South Florida, Tampa, FL, USA.&#xD;SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Departments of Medicine and Health Research Methods, Evidence &amp; Impact, McMaster University, Hamilton, ON, Canada.&#xD;ENT Department, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey.&#xD;Life and Health Sciences Research Institute (ICVS, School of Medicine, University of Minho, Braga, Portugal.&#xD;PT Government Associate Laboratory, Braga/Guimaraes, Portugal.&#xD;International Primary Care Respiratory Group IPCRG, London, UK.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &apos;Duilio Casula&apos;, University of Cagliari, Cagliari, Italy.&#xD;University Clinic of Pulmology and Allergy, Medical Faculty Skopje, Skopje, Republic of Macedonia.&#xD;Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, USA.&#xD;Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.&#xD;Pediatric Allergy and Immunology Unit, Children&apos;s hospital, Ain Shams University, Cairo, Egypt.&#xD;Clinic of Children&apos;s Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;CHU Clermont-Ferrand, Unite d&apos;Allergologie de l&apos;Enfant, Pole pediatrique, Hopital Estaing, Clermont-Ferrand, France.&#xD;Division of Allergy, Department of Pediatric Medicine, The Bambino Gesu Children&apos;s Research Hospital Holy see, IRCCS, Rome, Italy.&#xD;Department of Otorhinolaryngology, Academic Medical Centers, AMC, Amsterdam, The Netherlands.&#xD;EUFOREA, Brussels, Belgium.&#xD;CINTESIS, Center for Health Technology and Services Research, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.&#xD;Allergy Unit, CUF Porto, Porto, Portugal.&#xD;Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.&#xD;Fundacion Ayre-Instituto Medico ALAS, Salta, Argentina.&#xD;Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.&#xD;University Hospital Bielefeld, Children&apos;s Center Bethel, EvKB, Bielefeld, Germany.&#xD;Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.&#xD;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;Department of Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey.&#xD;Department of Family Medicine, Medical University of Lodz, Lodz, Poland.&#xD;National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular Immunology, Moscow, Russian Federation.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University and Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;Scottish Centre for Respiratory Research, Cardiovascular &amp; Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, Dundee, UK.&#xD;Allergy Unit &apos;D Kalogeromitros&apos;, 2nd Department of Dermatology and Venereology, National &amp; Kapodistrian University of Athens, &apos;Attikon&apos; University Hospital, Athens, Greece.&#xD;Argentine Association of Allergy and Clinical Immunology, Buenos Aires, Argentina.&#xD;Croatian Pulmonary Society, Zagreb, Croatia.&#xD;National Institute of Pneumology M Nasta, Bucharest, Romania.&#xD;National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia and Syrian Private University-Damascus, Damascus, Syria.&#xD;Respiratory Physician Mater Dei Hospital Malta, Medicine University of Malta, Faculty of Medicine and Surgery University of Medicine, La Valette, Malta.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;CRI-Clinical Research International-Ltd, Hamburg, Germany.&#xD;Johns Hopkins School of Medicine, Baltimore, MD, USA.&#xD;Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina.&#xD;Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Vic., Australia.&#xD;Department of Immunology, Monash University, Melbourne, Vic., Australia.&#xD;National Hospital Organization, Tokyo National Hospital, Tokyo, Japan.&#xD;Department of Otolaryngology, Nippon Medical School, Tokyo, Japan.&#xD;Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, Royal Manchester Children&apos;s Hospital, University of Manchester, Manchester, UK.&#xD;Allergy and Respiratory Diseases, Ospedale Policlino San Martino -University of Genoa, Genoa, Italy.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, &apos;Santa Maria della Speranza&apos; Hospital, Salerno, Italy.&#xD;Center for Research in Health Technologies and Information Systems- CINTESIS, University of Porto, Porto, Portugal.&#xD;Allergy Unit, Instituto CUF Porto and Hospital CUF Porto, Porto, Portugal.&#xD;Department of Community Medicine, Health Information and Decision - MEDCIDsS, Faculty of Medicina, University of Porto, Porto, Portugal.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Children&apos;s Hospital Srebrnjak, Zagreb, School of Medicine, University J.J. Strossmayer, Osijek, Croatia.&#xD;University Hospital &apos;Sv Ivan Rilski&apos;&quot;, Sofia, Bulgaria.&#xD;Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece.&#xD;Personalized Medicine Clinic Asthma &amp; Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, and Department of Biomedical Sciences, Humanitas University Pieve Emanuele, Milan, Italy.&#xD;Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Pulmonology, Helsinki University Central Hospital, Helsinki, Department of Public Health, University of Helsinki, Helsinki, Finland.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitario de Coimbra, Coimbra and Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, The Netherlands.&#xD;Oasi Research Institute-IRCCS, Troina, Italy.&#xD;bFondazione Mediterranea GB Morgagni, Catania, Italy.&#xD;Hospital de Clinicas, University of Parana, Curitiba, Brazil.&#xD;Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel.&#xD;Usher Institute, University of Edinburgh, Edinburgh, UK.&#xD;Fundacion Jimenez Diaz, CIBERES, Faculty of Medicine, Autonoma University of Madrid, Madrid, Spain.&#xD;Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic.&#xD;Department of Medicine, Surgery and Dentistry &apos;Scuola Medica Salernitana&apos;, University of Salerno, Salerno, Italy.&#xD;Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, and Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Greece and International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland.&#xD;Pneumology and Allergy Department CIBERES and Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain.&#xD;Vilnius University Faculty of Medicine, Institute of Clinical Medicine &amp; Institute of Health Sciences, Vilnius, Lithuania.&#xD;European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium.&#xD;Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo allergy clinic, Turku, Finland.&#xD;Filha, Finnish Lung Health Association, Helsinki, Finland.&#xD;University of Turku, Turku, Finland.&#xD;University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy.&#xD;Nova Southeastern University, Fort Lauderdale, FL, USA.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Celal Bayar University Department of Pulmonology, Manisa, Turkey.&#xD;The Allergy and Asthma Institute, Pakistan, Pakistan.&#xD;Universidad Catolica de Cordoba, Universidad Nacional de Villa Maria, Cordoba, Argentina.&#xD;University Hospital Montpellier, Montpellier, France.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA(2) LEN consensus</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2354-2366</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">*Common Cold</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">common cold</style></keyword><keyword><style face="normal" font="default" size="100%">cough</style></keyword><keyword><style face="normal" font="default" size="100%">smell</style></keyword><keyword><style face="normal" font="default" size="100%">Christine Kuhne-Center for Allergy Research and Education, European Commission&apos;s</style></keyword><keyword><style face="normal" font="default" size="100%">Horison&apos;s 2020 Framework Programme, Cure, Novartis Research Institutes, Astra</style></keyword><keyword><style face="normal" font="default" size="100%">Zeneca, Scibase, advisory role in Sanofi/Regeneron, grants from Glakso</style></keyword><keyword><style face="normal" font="default" size="100%">Smith-Kline, advisory role in Scibase. JB reports personal fees from Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis,</style></keyword><keyword><style face="normal" font="default" size="100%">Takeda, Teva, Uriach, other from KYomed-Innov. VC reports personal fees from ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics, LETI, Thermofisher, Merck, Astrazeneca, GSK. JCS reports</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Board from Boheringer Ingelheim, personal fees and Advisory Board from</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, Bial, grants, personal fees and Advisory Board from AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from Mundipharma, personal fees from Sanofi, Advisory Board</style></keyword><keyword><style face="normal" font="default" size="100%">from Novartis. JCI reports personal fees from Faes Farma, Abbott Ecuador,</style></keyword><keyword><style face="normal" font="default" size="100%">Laboratorios Casasco, Laboratorios Bago Bolivia, Eurofarma Argentina, Sanofi. PK</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees from Adamed, AstraZeneca, Berlin Chemie Menarini,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Hal Allergy, Lekam, Mylan, Novartis, Polpharma, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Teva, Chiesi, USP Pharmacia. VK reports personal fees from GSK, non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support from AstraZeneca, DIMUNA, DLL reports personal fees from Allakos,</style></keyword><keyword><style face="normal" font="default" size="100%">Amstrong, Astrazeneca, Boehringer Ingelheim, Chiesi, DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">Grunenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Novartis, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Siegfried, UCB, Alakos, Gossamer, grants from Sanofi, Astrazeneca, Novartis, UCB,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, TEVA, Boehringer Ingelheim, Chiesi, Purina institute. BL reports grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Mylan, Glenmark. JM reports personal fees and other from</style></keyword><keyword><style face="normal" font="default" size="100%">SANOFI-GENZYME &amp; REGENERON, NOVARTIS, ALLAKOS, grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">MYLAN-MEDA Pharma, URIACH Group, personal fees from MITSUBISHI-TANABE, MENARINI,</style></keyword><keyword><style face="normal" font="default" size="100%">UCB, ASTRAZENECA, personal fees from GSK, MSD. NP reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Gerolymatos International SA, Capricare. OP reports grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL</style></keyword><keyword><style face="normal" font="default" size="100%">Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech</style></keyword><keyword><style face="normal" font="default" size="100%">Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., Glaxo Smith Kline,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Aventis and Sanofi-Genzyme, Med Update Europe GmbH, streamedup! GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Pohl-Boskamp, Inmunotek S.L.,personal fees from John Wiley and Sons,</style></keyword><keyword><style face="normal" font="default" size="100%">AS, personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA(2)LEN</style></keyword><keyword><style face="normal" font="default" size="100%">Partner), Indoor Biotechnologies. DP reports grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, personal fees from Menarini, Pliva, Belupo, AbbVie, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">MSD, Chiesi, Revenio, AbbVie, Novartis, MSD, Chiesi, Revenio, non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support from Philips, personal fees and non-financial support from Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, FP reports personal fees from SANOFI, ASTRAZENECA, NOVARTIS, GLAXO</style></keyword><keyword><style face="normal" font="default" size="100%">SMITHKLINE, STALLERGENES, ALLERGY THERAPEUTICS, HAL ALLERGY, MENARINI, MALESCI,</style></keyword><keyword><style face="normal" font="default" size="100%">GUIDOTTI, VALEAS, BOEHRINGER INGELHEIM, ALMIRALL, MUNDIPHARMA. NR reports and</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Board: Sanofi, Mylan, AstraZeneca, Speaker: Sanofi, Mylan, Chiesi. JS</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants and personal fees from SANOFI, personal fees from GSK, NOVARTIS,</style></keyword><keyword><style face="normal" font="default" size="100%">ASTRA ZENECA, MUNDIPHARMA, FAES FARMA. Dr. Tsiligianni reports grants from GSK</style></keyword><keyword><style face="normal" font="default" size="100%">Hellas, ELPEN, Astra Zeneca Hellas, personal fees from GSK, Boehringer Ingelheim,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Astra Zeneca. DW reports personal fees from Optinose, ALK, Sanofi, and</style></keyword><keyword><style face="normal" font="default" size="100%">was co-chair of Joint Task Force on Practice Parameters until July 2020. author</style></keyword><keyword><style face="normal" font="default" size="100%">of Rhinitis GRADE document (2017) and Rhinitis practice parameter update (2020).</style></keyword><keyword><style face="normal" font="default" size="100%">TZ reports personal fees from Bayer Health Care, FAES, Novartis, Henkel,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin</style></keyword><keyword><style face="normal" font="default" size="100%">Chemie, HAL, Leti, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes, Takeda, Teva, UCB, Kryolan L&apos;Oreal.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33730365</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Although there are many asymptomatic patients, one of the problems of COVID-19 is early recognition of the disease. COVID-19 symptoms are polymorphic and may include upper respiratory symptoms. However, COVID-19 symptoms may be mistaken with the common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate upper respiratory symptoms between the three diseases. METHODS: A modified Delphi process was used. The ARIA members who were seeing COVID-19 patients were asked to fill in a questionnaire on the upper airway symptoms of COVID-19, common cold and allergic rhinitis. RESULTS: Among the 192 ARIA members who were invited to respond to the questionnaire, 89 responded and 87 questionnaires were analysed. The consensus was then reported. A two-way ANOVA revealed significant differences in the symptom intensity between the three diseases (p &lt; .001). CONCLUSIONS: This modified Delphi approach enabled the differentiation of upper respiratory symptoms between COVID-19, the common cold and allergic rhinitis. An electronic algorithm will be devised using the questionnaire.</style></abstract><notes><style face="normal" font="default" size="100%">Hagemann, Jan&#xD;Onorato, Gabrielle L&#xD;Jutel, Marek&#xD;Akdis, Cezmi A&#xD;Agache, Ioana&#xD;Zuberbier, Torsten&#xD;Czarlewski, Wienczyslawa&#xD;Mullol, Joaquim&#xD;Bedbrook, Anna&#xD;Bachert, Claus&#xD;Bennoor, Kazi S&#xD;Bergmann, Karl-Christian&#xD;Braido, Fulvio&#xD;Camargos, Paulo&#xD;Caraballo, Luis&#xD;Cardona, Victoria&#xD;Casale, Thomas&#xD;Cecchi, Lorenzo&#xD;Chivato, Tomas&#xD;Chu, Derek K&#xD;Cingi, Cemal&#xD;Correia-de-Sousa, Jaime&#xD;Del Giacco, Stefano&#xD;Dokic, Dejan&#xD;Dykewicz, Mark&#xD;Ebisawa, Motohiro&#xD;El-Gamal, Yehia&#xD;Emuzyte, Regina&#xD;Fauquert, Jean-Luc&#xD;Fiocchi, Alessandro&#xD;Fokkens, Wytske J&#xD;Fonseca, Joao A&#xD;Gemicioglu, Bilun&#xD;Gomez, Rene-Maximiliano&#xD;Gotua, Maia&#xD;Haahtela, Tari&#xD;Hamelmann, Eckard&#xD;Iinuma, Tomohisa&#xD;Ivancevich, Juan Carlos&#xD;Jassem, Ewa&#xD;Kalayci, Omer&#xD;Kardas, Przemyslaw&#xD;Khaitov, Musa&#xD;Kuna, Piotr&#xD;Kvedariene, Violeta&#xD;Larenas-Linnemann, Desiree E&#xD;Lipworth, Brian&#xD;Makris, Michael&#xD;Maspero, Jorge F&#xD;Miculinic, Neven&#xD;Mihaltan, Florin&#xD;Mohammad, Yousser&#xD;Montefort, Stephen&#xD;Morais-Almeida, Mario&#xD;Mosges, Ralph&#xD;Naclerio, Robert&#xD;Neffen, Hugo&#xD;Niedoszytko, Marek&#xD;O&apos;Hehir, Robyn E&#xD;Ohta, Ken&#xD;Okamoto, Yoshitaka&#xD;Okubo, Kimi&#xD;Panzner, Petr&#xD;Papadopoulos, Nikolaos G&#xD;Passalacqua, Giovanni&#xD;Patella, Vincenzo&#xD;Pereira, Ana&#xD;Pfaar, Oliver&#xD;Plavec, Davor&#xD;Popov, Todor A&#xD;Prokopakis, Emmanuel P&#xD;Puggioni, Francesca&#xD;Raciborski, Filip&#xD;Reijula, Jere&#xD;Regateiro, Frederico S&#xD;Reitsma, Sietze&#xD;Romano, Antonino&#xD;Rosario, Nelson&#xD;Rottem, Menachem&#xD;Ryan, Dermot&#xD;Samolinski, Boleslaw&#xD;Sastre, Joaquin&#xD;Sole, Dirceu&#xD;Sova, Milan&#xD;Stellato, Cristiana&#xD;Suppli-Ulrik, Charlotte&#xD;Tsiligianni, Ioanna&#xD;Valero, Antonio&#xD;Valiulis, Arunas&#xD;Valovirta, Erkka&#xD;Vasankari, Tuula&#xD;Ventura, Maria Teresa&#xD;Wallace, Dana&#xD;Wang, De Yun&#xD;Williams, Sian&#xD;Yorgancioglu, Arzu&#xD;Yusuf, Osman M&#xD;Zernotti, Mario&#xD;Bousquet, Jean&#xD;Klimek, Ludger&#xD;eng&#xD;Consensus Statement&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2354-2366. doi: 10.1111/all.14815. Epub 2021 May 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33730365</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8250633</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14815</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1297</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1297</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sala-Cunill, A.</style></author><author><style face="normal" font="default" size="100%">Luengo, O.</style></author><author><style face="normal" font="default" size="100%">Curran, A.</style></author><author><style face="normal" font="default" size="100%">Moreno, N.</style></author><author><style face="normal" font="default" size="100%">Labrador-Horrillo, M.</style></author><author><style face="normal" font="default" size="100%">Guilarte, M.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Medina, M.</style></author><author><style face="normal" font="default" size="100%">Galvan-Blasco, P.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Section, Vall d&apos;Hebron University Hospital, Barcelona, Spain.&#xD;ARADyAL Research Network, Institute of health Carlos III (ISCIII), Madrin, Spain.&#xD;Vall d&apos;Hebron Research Institute, Barcelona, Spain.&#xD;Autonomous University of Barcelona, Barcelona, Spain.&#xD;Adan Medical Innovation S.A, Barcelona, Spain.&#xD;Internal Medicine Department, Vall d&apos; Hebron University Hospital, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Digital technology for anaphylaxis management impact on patient behaviour: A randomized clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1507-1516</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Digital Technology</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Injections</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">adrenaline</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">autoinjector</style></keyword><keyword><style face="normal" font="default" size="100%">digital health</style></keyword><keyword><style face="normal" font="default" size="100%">epinephrine</style></keyword><keyword><style face="normal" font="default" size="100%">mhealth</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33043475</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Epinephrine is the first-line treatment for anaphylaxis. Patients at risk should always carry an epinephrine autoinjector (EAI). Several EAI gaps have been identified. We sought to evaluate satisfaction using a medical device (digital technology comprising an EAI smart case connected to a mobile APP) with functions that overcome most of the EAI limitations and to determine whether patient behaviour and anaphylaxis management improve with its use. METHODS: This was a randomized, open-label, crossover clinical trial in a tertiary hospital involving patients with history of anaphylaxis carrying an EAI. The study was conducted in two three-month periods, one with and one without the medical device. The primary endpoint was satisfaction with the medical device. Usability, adherence, anxiety and anaphylaxis episodes were evaluated as secondary endpoints. RESULTS: A total of 100 patients were included (mean age 38.1 years, 74% female), and 95 completed the trial. The satisfaction visual analogue scale (VAS) after using the medical device was higher than before its use (89.1 [95% CI, 60.2-99.1] vs 56.3 [95% CI, 48.1-81.4]; P &lt; .0001). The adherence VAS improved from 59.7 (95% CI, 54.0-65.3) to 88.6 (95% CI, 84.2-92.9) (P &lt; .0001). Overall, 90% patients found the medical device easy to use. Patients&apos; anxiety decreased from 52.2% to 29.3% (P &lt; .001). Seven episodes of anaphylaxis occurred during the study, all in patients without the medical device (P = .025). Eighty-eight per cent of patients felt more involved in the management of anaphylaxis when using the medical device. CONCLUSION: This is the first clinical trial evaluating digital technology for EAIs, showing a change of behaviour in patients at risk of anaphylaxis, increasing satisfaction, improving adherence, and reducing anxiety, with good usability.</style></abstract><notes><style face="normal" font="default" size="100%">Sala-Cunill, Anna&#xD;Luengo, Olga&#xD;Curran, Adrian&#xD;Moreno, Nuria&#xD;Labrador-Horrillo, Moises&#xD;Guilarte, Mar&#xD;Gonzalez-Medina, Monica&#xD;Galvan-Blasco, Paula&#xD;Cardona, Victoria&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1507-1516. doi: 10.1111/all.14626. Epub 2020 Nov 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33043475</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14626</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2516</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2516</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Ordak, M.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P. M.</style></author><author><style face="normal" font="default" size="100%">Berger, U. E.</style></author><author><style face="normal" font="default" size="100%">Berger, M.</style></author><author><style face="normal" font="default" size="100%">Dramburg, S.</style></author><author><style face="normal" font="default" size="100%">Mahler, V.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S. K.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Tripodi, S.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Sofiev, M.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE-Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, IBIMA-Plataforma BIONAND, Universidad de Malaga, RICORS de Enfermedades Inflamatorias, Malaga, Spain.&#xD;Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany.&#xD;ClinCompetence Cologne GmbH, Cologne, Germany.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite-Universitatsmedizin - Berlin, Berlin, Germany.&#xD;Department of Botany, University of Innsbruck, Innsbruck, Austria.&#xD;European Aeroallergen Network (EAN), Vienna, Austria.&#xD;Department of Oto-Rhino-Laryngology, Klinik Hietzing, Wiener Gesundheitsverbund, Vienna, Austria.&#xD;Paul-Ehrlich-Institut, Langen, Germany.&#xD;Department of Otorhinolaryngology, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland.&#xD;Department of Allergy, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.&#xD;Allergy Unit, Policlinico Casilino, Roma, Italy.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Faculty of Medicine, Transylvania University of Brasov, Brasov, Romania.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Asthma and Allergy Unit, IRCCS Humanitas Research Hospital, Milan, Italy.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Finnish Meteorological Institute (FMI), Helsinki, Finland.&#xD;National Heart and Lung Institute, Imperial College, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;MASK-air, Montpellier, France.&#xD;ARIA, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Digitally-enabled, person-centred care (PCC) in allergen immunotherapy: An ARIA-EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2037-2050</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/05/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient-Centered Care</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Telemedicine</style></keyword><keyword><style face="normal" font="default" size="100%">Mobile Applications</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinitis, Allergic/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">AllergyMonitor(R)</style></keyword><keyword><style face="normal" font="default" size="100%">MASK-air(R)</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">digital biomarkers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38700063</style></accession-num><abstract><style face="normal" font="default" size="100%">In rhinitis and asthma, several mHealth apps have been developed but only a few have been validated. However, these apps have a high potential for improving person-centred care (PCC), especially in allergen immunotherapy (AIT). They can provide support in AIT initiation by selecting the appropriate patient and allergen shared decision-making. They can also help in (i) the evaluation of (early) efficacy, (ii) early and late stopping rules and (iii) the evaluation of (carried-over) efficacy after cessation of the treatment course. Future perspectives have been formulated in the first report of a joint task force (TF)-Allergic Rhinitis and Its Impact on Asthma (ARIA) and the European Academy of Allergy and Clinical Immunology (EAACI)-on digital biomarkers. The TF on AIT now aims to (i) outline the potential of the clinical applications of mHealth solutions, (ii) express their current limitations, (iii) make proposals regarding further developments for both clinical practice and scientific purpose and (iv) suggest which of the tools might best comply with the purpose of digitally-enabled PCC in AIT.</style></abstract><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Sousa-Pinto, Bernardo&#xD;Papadopoulos, Nikolaos G&#xD;Larenas-Linnemann, Desiree E&#xD;Ordak, Michal&#xD;Torres, Maria J&#xD;Mosges, Ralph&#xD;Klimek, Ludger&#xD;Zuberbier, Torsten&#xD;Matricardi, Paolo M&#xD;Berger, Uwe E&#xD;Berger, Markus&#xD;Dramburg, Stephanie&#xD;Mahler, Vera&#xD;Toppila-Salmi, Sanna K&#xD;Bergmann, Karl-Christian&#xD;Ollert, Markus&#xD;Tripodi, Salvatore&#xD;Jutel, Marek&#xD;Agache, Ioana&#xD;Eguiluz-Gracia, Ibon&#xD;Canonica, G Walter&#xD;Akdis, Cezmi A&#xD;Sokolowska, Milena&#xD;Sofiev, Mikhail&#xD;Shamji, Mohamed H&#xD;Czarlewski, Wienczyslawa&#xD;Fonseca, Joao A&#xD;Bedbrook, Anna&#xD;Bousquet, Jean&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology (EAACI)/&#xD;101086109/EU Horizon project SYLVA/&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2037-2050. doi: 10.1111/all.16135. Epub 2024 May 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38700063</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16135</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1194</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1194</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boute, M.</style></author><author><style face="normal" font="default" size="100%">Ait Yahia, S.</style></author><author><style face="normal" font="default" size="100%">Nanou, J.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Simon, D.</style></author><author><style face="normal" font="default" size="100%">Audousset, C.</style></author><author><style face="normal" font="default" size="100%">Vorng, H.</style></author><author><style face="normal" font="default" size="100%">Balsamelli, J.</style></author><author><style face="normal" font="default" size="100%">Ying, F.</style></author><author><style face="normal" font="default" size="100%">Marquillies, P.</style></author><author><style face="normal" font="default" size="100%">Werkmeister, E.</style></author><author><style face="normal" font="default" size="100%">de Nadai, P.</style></author><author><style face="normal" font="default" size="100%">Chenivesse, C.</style></author><author><style face="normal" font="default" size="100%">Tsicopoulos, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d&apos;Infection et d&apos;Immunite de Lille, Lille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Direct activation of the aryl hydrocarbon receptor by dog allergen participates in airway neutrophilic inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2245-2249</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Aryl Hydrocarbon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33465835</style></accession-num><notes><style face="normal" font="default" size="100%">Boute, Melodie&#xD;Ait Yahia, Saliha&#xD;Nanou, Julie&#xD;Alvarez-Simon, Daniel&#xD;Audousset, Camille&#xD;Vorng, Han&#xD;Balsamelli, Joanne&#xD;Ying, Fan&#xD;Marquillies, Philippe&#xD;Werkmeister, Elisabeth&#xD;de Nadai, Patricia&#xD;Chenivesse, Cecile&#xD;Tsicopoulos, Anne&#xD;eng&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2245-2249. doi: 10.1111/all.14740. Epub 2021 Feb 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33465835</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14740</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1272</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1272</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blais, C. M.</style></author><author><style face="normal" font="default" size="100%">Davis, B. E.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author><author><style face="normal" font="default" size="100%">Cockcroft, D. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.&#xD;Firestone Institute for Respiratory Health, St. Joseph&apos;s Healthcare &amp; Department of Medicine, McMaster University, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Direct and indirect bronchoprovocation tests in dose-response studies of inhaled corticosteroids: Past, present, and future directions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1679-1692</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/11/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchoprovocation</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">inhaled corticosteroid</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33185888</style></accession-num><abstract><style face="normal" font="default" size="100%">Inhaled corticosteroids (ICS) are a mainstay of treatment in eosinophilic asthma. Many studies have explored the dose-response effect of different formulations of ICS through direct or indirect bronchoprovocation testing. Such studies are important for investigating efficacy and identifying the relative potency between formulations. However, lack of consistency in methods and designs has hindered the comparability of study findings. This review discusses current knowledge of the dose-response, or lack thereof, of different formulations of ICS through direct and indirect bronchoprovocation testing. The strengths and weaknesses of past studies inform recommendations for future methodological considerations in this field, such as utilizing a randomized double-blind crossover design, enrolling participants likely to respond to ICS therapy, and carefully selecting treatment durations and washout periods to assess incremental improvement in airway hyperresponsiveness while reducing the likelihood of a carryover effect.</style></abstract><notes><style face="normal" font="default" size="100%">Blais, Christianne M&#xD;Davis, Beth E&#xD;Nair, Parameswaran&#xD;Cockcroft, Donald W&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1679-1692. doi: 10.1111/all.14658. Epub 2020 Nov 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33185888</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14658</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2833</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2833</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Domingo, C.</style></author><author><style face="normal" font="default" size="100%">Busse, W. W.</style></author><author><style face="normal" font="default" size="100%">Hanania, N. A.</style></author><author><style face="normal" font="default" size="100%">Ertugrul, M.</style></author><author><style face="normal" font="default" size="100%">Millette, L. A.</style></author><author><style face="normal" font="default" size="100%">Maio-Twofoot, T.</style></author><author><style face="normal" font="default" size="100%">Jaumont, X.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary Medicine, Parc Tauli Hospital Universitari, Institut d&apos;Investigacio i Innovacio Parc Tauli (I3PT-CERCA), Universitat Autonoma de Barcelona, Sabadell, Spain.&#xD;Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.&#xD;Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, Texas, USA.&#xD;Novartis Pharma, Istanbul, Turkey.&#xD;Genentech Inc, San Francisco, California, USA.&#xD;Novartis Pharma AG, Basel, Switzerland.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Direct and Indirect Role of IgE on Airway Epithelium in Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">919-931</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Mucosa/immunology/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">bureaus from Novartis, Sanofi, GSK, TEVA, MSD, Esteve, Almirall, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, Menarini, Pfizer, Ferrer, Stallergenes, ALK-Abello, Allergy therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">Hall Allergy, Inmunotek and Roxall. W.W.B. has received consulting fees and</style></keyword><keyword><style face="normal" font="default" size="100%">payment/honoraria for lectures, presentations, speakers bureaus, or education</style></keyword><keyword><style face="normal" font="default" size="100%">events from GlaxoSmithKline, Sanofi and Regeneron. W.W.B. has also received</style></keyword><keyword><style face="normal" font="default" size="100%">support for attending meetings and/or travel from GlaxoSmithKline, Sanofi and</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, and royalties from Elsevier. N.A.H has received advisory board</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria from Sanofi, Genentech, AstraZeneca, GlaxoSmithKline, Amgen and Verona.</style></keyword><keyword><style face="normal" font="default" size="100%">N.A.H. has also received lecture honoraria from Sanofi and Regeneron. N.A.H.</style></keyword><keyword><style face="normal" font="default" size="100%">institution has received grants from GlaxoSmithKline, AstraZeneca, Roche and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi. M.E. has no conflicts of interest to disclose. L.M. is an employee of and</style></keyword><keyword><style face="normal" font="default" size="100%">holds stock in Genentech. T.M.T. is an employee of and holds stock in Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma AG. X.J is an employee of Novartis. O.P. has received consulting fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Pfizer, Novartis, Sanofi-Genezyme and Regeneron. O.P. has received</style></keyword><keyword><style face="normal" font="default" size="100%">payment for lectures from AstraZeneca, GlaxoSmithKline, Pfizer, Immunotek SL,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Sanofi-Genezyme and Regeneron.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39963805</style></accession-num><abstract><style face="normal" font="default" size="100%">Asthma is a chronic airway inflammatory disorder, affecting over 350 million people worldwide, with allergic asthma being the most common form of the disease. Allergic asthma is characterized by a type 2 (T2) inflammatory response triggered by numerous allergens beginning in the airway epithelium, which acts as a physical barrier to allergens as well as other external irritants including infectious agents, and atmospheric pollutants. T2 inflammation is propagated by several key cell types including T helper 2 (Th2) cells, eosinophils, mast cells, and B cells. Immunoglobulin E (IgE), produced by B cells, is a key molecule in allergic airway disease and plays an important role in T2 inflammation, as well as being central to remodeling processes within the airway epithelium. Blocking IgE with omalizumab has been shown to be efficacious in treating allergic asthma however, the role of IgE on airway epithelial cells is less communicated. Developing a deeper explanation of the complex network of interactions between IgE and the airway epithelium will facilitate an improved understanding of asthma pathophysiology. This review discusses the indirect and direct roles of IgE on airway epithelial cells, with a focus on allergic asthma disease.</style></abstract><notes><style face="normal" font="default" size="100%">Domingo, Christian&#xD;Busse, William W&#xD;Hanania, Nicola A&#xD;Ertugrul, Muyesser&#xD;Millette, Lauren A&#xD;Maio-Twofoot, Tina&#xD;Jaumont, Xavier&#xD;Palomares, Oscar&#xD;eng&#xD;Novartis Pharma/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):919-931. doi: 10.1111/all.16459. Epub 2025 Feb 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39963805</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969325</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16459</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1611</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1611</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mannweiler, R.</style></author><author><style face="normal" font="default" size="100%">Bergmann, S.</style></author><author><style face="normal" font="default" size="100%">Vidal, Y. Sy S.</style></author><author><style face="normal" font="default" size="100%">Brandner, J. M.</style></author><author><style face="normal" font="default" size="100%">Gunzel, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Clinical Physiology/Nutritional Medicine, Medical Department, Division of Gastroenterology, Infectiology, Rheumatology, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Dermatology and Venerology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Direct assessment of individual skin barrier components by electrical impedance spectroscopy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3094-3106</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/04/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">*Dielectric Spectroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Epidermal Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Epidermis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Tight Junctions</style></keyword><keyword><style face="normal" font="default" size="100%">impedance spectroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">reconstructed human epidermis</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier</style></keyword><keyword><style face="normal" font="default" size="100%">transepithelial electrical resistance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33844311</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Expression of the tight junction proteins Cldn1 and 4 is altered in skin diseases such as atopic dermatitis, and Cldn1 deficiency affects skin barrier formation. Impedance spectroscopy (IS) has been proven to allow detection of alterations in the skin barrier but is currently unable to separate effects on viable epidermis (VE) and stratum corneum (SC). METHODS: Effects of siRNA-mediated Cldn1 and 4 knockdown in reconstructed human epidermis (RHE) on VE and SC barrier function were investigated with Ussing chamber-based IS. Barrier components were sequentially altered, employing iron oxide nanoparticles and EGTA, to identify their contribution to the impedance spectrum. Resistance changes due to apically applied hyperosmolar electrolyte were used to identify barrier defects non-invasively. RESULTS: IS of RHE yielded two relaxation frequencies, representing the barrier properties of the SC (~1000 Hz) and VE (~100 Hz). As proof of concept, it was shown that the Cldn1 knockdown-induced resistance drop arises from the impairment of both SC and VE, indicated by a shift of both relaxation frequencies. Hyperosmolar electrolyte penetration allowed non-invasive detection of Cldn1 knockdown via time-dependent frequency shifts. The absence of Cldn4 knockdown-induced changes revealed the weaknesses of transepithelial electrical resistance analysis. CONCLUSION: In conclusion, the present technique allows to separately measure the barrier properties of SC and VE and further evaluate the Cldn1 and 4 knockdown impact on the skin barrier. As the measurement with agarose-embedded electrolyte allowed non-invasive identification of the Cldn1 knockdown, this opens the way to detailed in vivo skin barrier assessment.</style></abstract><notes><style face="normal" font="default" size="100%">Mannweiler, Roman&#xD;Bergmann, Sophia&#xD;Vidal-Y-Sy, Sabine&#xD;Brandner, Johanna M&#xD;Gunzel, Dorothee&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3094-3106. doi: 10.1111/all.14851. Epub 2021 May 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33844311</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14851</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1324</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1324</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Canziani, K. E.</style></author><author><style face="normal" font="default" size="100%">Pucci Molineris, M.</style></author><author><style face="normal" font="default" size="100%">Guzman, L.</style></author><author><style face="normal" font="default" size="100%">Bernedo, V.</style></author><author><style face="normal" font="default" size="100%">Garcia, M.</style></author><author><style face="normal" font="default" size="100%">Altamirano, E. M.</style></author><author><style face="normal" font="default" size="100%">Muglia, C. I.</style></author><author><style face="normal" font="default" size="100%">Docena, G. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Instituto de Estudios Inmunologicos y Fisiopatologicos-IIFP, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), La Plata, Argentina.&#xD;Departamento de Ciencias Biologicas, Instituto de Estudios Inmunologicos y Fisiopatologicos (IIFP), UNLP, CONICET, asociado a CIC PBA, Facultad de Ciencias Exactas, La Plata, Argentina.&#xD;Servicio de Gastroenterologia, Hospital de Ninos Sor Maria Ludovica, La Plata, Argentina.&#xD;Servicio de Alergia, Hospital de Ninos Sor Maria Ludovica, La Plata, Argentina.&#xD;Servicio de Anatomia Patologica, Hospital de Ninos Sor Maria Ludovica, La Plata, Argentina.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Direct evidence for local IgE production in the human colonic mucosa</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1545-1549</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/09/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">IgE synthesis</style></keyword><keyword><style face="normal" font="default" size="100%">allergic sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">food allergens</style></keyword><keyword><style face="normal" font="default" size="100%">germinal center</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32960459</style></accession-num><notes><style face="normal" font="default" size="100%">Canziani, Karina Eva&#xD;Pucci Molineris, Melisa&#xD;Guzman, Luciana&#xD;Bernedo, Viviana&#xD;Garcia, Marcela&#xD;Altamirano, Eugenia Margarita&#xD;Muglia, Cecilia Isabel&#xD;Docena, Guillermo Horacio&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1545-1549. doi: 10.1111/all.14594. Epub 2020 Nov 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32960459</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14594</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>713</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">713</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Trubiano, J. A.</style></author><author><style face="normal" font="default" size="100%">Vogrin, S.</style></author><author><style face="normal" font="default" size="100%">Copaescu, A.</style></author><author><style face="normal" font="default" size="100%">Nasra, M.</style></author><author><style face="normal" font="default" size="100%">Douglas, A.</style></author><author><style face="normal" font="default" size="100%">Holmes, N. E.</style></author><author><style face="normal" font="default" size="100%">Chua, K. Y. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infectious Diseases, Centre for Antibiotic Allergy and Research, Austin Health, Heidelberg, VIC, Australia.&#xD;Department of Medicine, The University of Melbourne, Fitzroy, VIC, Australia.&#xD;Department of Clinical Immunology and Allergy, McGill University Health Center, Montreal, QC, Canada.&#xD;Department of Infectious Diseases, The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, VIC, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Direct oral penicillin challenge for penicillin allergy delabeling as a health services intervention: A multicenter cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1038-1042</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Health Services</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Penicillins/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic allergy</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial stewardship</style></keyword><keyword><style face="normal" font="default" size="100%">direct provocation</style></keyword><keyword><style face="normal" font="default" size="100%">oral challenge</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34735748</style></accession-num><notes><style face="normal" font="default" size="100%">Trubiano, Jason A&#xD;Vogrin, Sara&#xD;Copaescu, Ana&#xD;Nasra, Mohamed&#xD;Douglas, Abby&#xD;Holmes, Natasha E&#xD;Chua, Kyra Y L&#xD;eng&#xD;Letter&#xD;Multicenter Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1038-1042. doi: 10.1111/all.15169. Epub 2021 Nov 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34735748</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15169</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>850</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">850</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Orimo, K.</style></author><author><style face="normal" font="default" size="100%">Tamari, M.</style></author><author><style face="normal" font="default" size="100%">Takeda, T.</style></author><author><style face="normal" font="default" size="100%">Kubo, T.</style></author><author><style face="normal" font="default" size="100%">Ruckert, B.</style></author><author><style face="normal" font="default" size="100%">Motomura, K.</style></author><author><style face="normal" font="default" size="100%">Sugiyama, H.</style></author><author><style face="normal" font="default" size="100%">Yamada, A.</style></author><author><style face="normal" font="default" size="100%">Saito, K.</style></author><author><style face="normal" font="default" size="100%">Arae, K.</style></author><author><style face="normal" font="default" size="100%">Kuriyama, M.</style></author><author><style face="normal" font="default" size="100%">Hara, M.</style></author><author><style face="normal" font="default" size="100%">Soyka, M. B.</style></author><author><style face="normal" font="default" size="100%">Ikutani, M.</style></author><author><style face="normal" font="default" size="100%">Yamaguchi, S.</style></author><author><style face="normal" font="default" size="100%">Morimoto, N.</style></author><author><style face="normal" font="default" size="100%">Nakabayashi, K.</style></author><author><style face="normal" font="default" size="100%">Hata, K.</style></author><author><style face="normal" font="default" size="100%">Matsuda, A.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Sudo, K.</style></author><author><style face="normal" font="default" size="100%">Saito, H.</style></author><author><style face="normal" font="default" size="100%">Nakae, S.</style></author><author><style face="normal" font="default" size="100%">Tamaoki, J.</style></author><author><style face="normal" font="default" size="100%">Tagaya, E.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, K.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Department of Respiratory Medicine, Tokyo Women&apos;s Medical University, Tokyo, Japan.&#xD;Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan.&#xD;Department of Health Science, Kansai University of Health Sciences, Osaka, Japan.&#xD;Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, University of Fukui, Fukui, Japan.&#xD;Department of Immunology, Faculty of Health Sciences, Kyorin University, Tokyo, Japan.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland.&#xD;Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima City, Japan.&#xD;Department of Immune Regulation, Research Institute, National Center for Global Health and Medicine, Ichikawa, Japan.&#xD;Division of Otolaryngology, Department of Surgical Specialties, National Center for Child Health and Development, Tokyo, Japan.&#xD;Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Animal Research Center, Tokyo Medical University, Tokyo, Japan.&#xD;Laboratory of Systems Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.&#xD;Precursory Research for Embryonic Science and Technology (PRESTO, Japan Science and Technology Agency, Saitama, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Direct platelet adhesion potentiates group 2 innate lymphoid cell functions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">843-855</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/08/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-33/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">T2 cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">group 2 innate lymphoid cells</style></keyword><keyword><style face="normal" font="default" size="100%">platelets</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34402091</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Platelets are thought to be involved in the pathophysiology of asthma, presumably through direct adhesion to inflammatory cells, including group 2 innate lymphoid cells (ILC2s). Here, we tried to elucidate the effects of platelet adhesion to ILC2s in vitro and in vivo, as well as the mechanisms involved. METHODS: Alternaria-induced ILC2-dependent airway inflammation models using wild-type and c-mpl(-/-) mice were evaluated. Both purified CD41(+) and CD41(-) ILC2s were cultured with IL-2 and IL-33 to determine in vitro Type 2 (T2) cytokine production and cell proliferation. RNA-seq data of flow-cytometry-sorted CD41(+) and CD41(-) ILC2s were used to isolate ILC2-specific genes. Flow cytometry was performed to determine the expression of CD41 and adhesion-related molecules on ILC2s in both mouse and human tissues. RESULTS: T2 inflammation and T2 cytokine production from ILC2s were significantly reduced in the c-mpl(-/-) mice compared to wild-type mice. Platelet-adherent ILC2s underwent significant proliferation and showed enhanced T2 cytokine production when exposed to IL-2 and IL-33. The functions of ILC2-specific genes were related to cell development and function. Upstream regulator analysis identified 15 molecules, that are thought to be involved in ILC2 activation. CD41 expression levels were higher in ILC2s from human PBMCs and mouse lung than in those from secondary lymphoid tissues, but they did not correlate with the P-selectin glycoprotein ligand-1 or CD24 expression level. CONCLUSION: Platelets spontaneously adhere to ILC2s, probably in the peripheral blood and airways, thereby potentiating ILC2s to enhance their responses to IL-33.</style></abstract><notes><style face="normal" font="default" size="100%">Orimo, Keisuke&#xD;Tamari, Masato&#xD;Takeda, Tomohiro&#xD;Kubo, Terufumi&#xD;Ruckert, Beate&#xD;Motomura, Kenichiro&#xD;Sugiyama, Hiroki&#xD;Yamada, Ayako&#xD;Saito, Kyoko&#xD;Arae, Ken&#xD;Kuriyama, Motohiro&#xD;Hara, Mariko&#xD;Soyka, Michael B&#xD;Ikutani, Masashi&#xD;Yamaguchi, Sota&#xD;Morimoto, Noriko&#xD;Nakabayashi, Kazuhiko&#xD;Hata, Kenichiro&#xD;Matsuda, Akio&#xD;Akdis, Cezmi A&#xD;Sudo, Katsuko&#xD;Saito, Hirohisa&#xD;Nakae, Susumu&#xD;Tamaoki, Jun&#xD;Tagaya, Etsuko&#xD;Matsumoto, Kenji&#xD;Morita, Hideaki&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):843-855. doi: 10.1111/all.15057. Epub 2021 Aug 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34402091</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15057</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2911</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2911</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Rodriguez de Guzman, J.</style></author><author><style face="normal" font="default" size="100%">Diez-Echave, P.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;Departamento de Medicina, Facultad de Medicina, Universidad de Malaga, Malaga, Spain.&#xD;Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Direct Single-Dose Drug-Provocation Test Is Safe for Delabelling Penicillin Low-Risk Reactions in Adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3127-3139</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/05/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/etiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Penicillins/adverse effects/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Bacterial Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">betalactam</style></keyword><keyword><style face="normal" font="default" size="100%">delabelling</style></keyword><keyword><style face="normal" font="default" size="100%">drug-provocation test</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin</style></keyword><keyword><style face="normal" font="default" size="100%">single dose</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40377255</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Penicillins (PENs) are the most frequent drug-allergic reactions trigger. However, diagnostic work-up is complex and time-consuming: it requires skin testing (ST) and drug-provocation test (DPT), needing faster delabelling strategies. Although direct DPT without previous STs has shown to be safe, most of the studies are performed in children or in North American, Asian, or Oceanian adults, with few studies in the European adult population. We explored its safety in European adult patients with low-risk PEN allergy history and, additionally, analysed ST role and T-cell involvement by lymphocyte transformation test (LTT). METHODS: We prospectively evaluated &gt; 16 years of PEN-allergic labelled patients referred to Malaga Regional University Hospital during 2023. They reported non-immediate reactions without alarm signs and unknown reactions. Direct-single-dose DPT was performed in all patients. If positive, ST and LTT were carried out after reaction resolution. RESULTS: We included 269 patients with the culprits being an unidentified PEN (36%), amoxicillin (AX) (32%), and AX-clavulanic acid (AX-CLV) (31%); and the symptoms maculopapular exanthema (MPE) (34%) and unknown reaction during childhood (23%). Only 16 (5.9%) had positive DPT, being 56% for AX and 44% for AX-CLV, 81% developing MPE, none severe. Most DPT-reacting patients reported cutaneous non-immediate reactions in the index reaction, and only one had an unknown childhood reaction. The mean day interval between drug administration and symptom development was lower (p = 0.002) in positive DPT than in the index reaction (2 vs 5 days). Moreover, ST was positive in only 19% and LTTs in 86.7% of positive DPT patients. CONCLUSIONS: Direct-single-dose DPT is safe for delabelling PEN allergy in non-immediate reactions without alarm signs and unknown reactions. ST had a poor diagnostic value and LTT had a high one, confirming a T-cell involvement.</style></abstract><notes><style face="normal" font="default" size="100%">Labella, Marina&#xD;Rodriguez de Guzman, Julia&#xD;Diez-Echave, Patricia&#xD;Salas, Maria&#xD;Fernandez-Santamaria, Ruben&#xD;Mayorga, Cristobalina&#xD;Dona, Inmaculada&#xD;Torres, Maria Jose&#xD;eng&#xD;PI21/00329/Institute of Health &quot;Carlos III&quot;/&#xD;RD21/0002/0008/Redes de Investigacion Cooperativa Orientadas al Resultado en Salud (RICORS): Enfermedades Inflamatorias/&#xD;JR23/0039/Redes de Investigacion Cooperativa Orientadas al Resultado en Salud (RICORS): Enfermedades Inflamatorias/&#xD;CD22/00112/Redes de Investigacion Cooperativa Orientadas al Resultado en Salud (RICORS): Enfermedades Inflamatorias/&#xD;RC-0004-2021/Andalusian Regional Ministry Health/&#xD;Universidad de Malaga/ CBUA/&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3127-3139. doi: 10.1111/all.16567. Epub 2025 May 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40377255</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590346</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16567</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2371</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2371</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peng, Z.</style></author><author><style face="normal" font="default" size="100%">Apfelbacher, C.</style></author><author><style face="normal" font="default" size="100%">Brandstetter, S.</style></author><author><style face="normal" font="default" size="100%">Eils, R.</style></author><author><style face="normal" font="default" size="100%">Kabesch, M.</style></author><author><style face="normal" font="default" size="100%">Lehmann, I.</style></author><author><style face="normal" font="default" size="100%">Trump, S.</style></author><author><style face="normal" font="default" size="100%">Wellmann, S.</style></author><author><style face="normal" font="default" size="100%">Genuneit, J.</style></author><author><style face="normal" font="default" size="100%">Namibio App Consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany.&#xD;Institute of Social Medicine and Health Systems Research, Otto von Guericke University Magdeburg, Magdeburg, Germany.&#xD;Member of the Research and Development Campus Regensburg (WECARE) at the Clinic St. Hedwig, Regensburg, Germany.&#xD;University Children&apos;s Hospital Regensburg (KUNO-Clinics), University of Regensburg, Clinic St. Hedwig, Regensburg, Germany.&#xD;Center for Digital Health, Berlin Institute of Health (BIH) at Charite-Universitatsmedizin Berlin, Corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;German Center for Lung Research (DZL), Associated Partner Site, Berlin, Germany.&#xD;German Center of Child and Youth Health (DZKJ), Germany.&#xD;Molecular Epidemiology Unit, Berlin Institute of Health at Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Neonatology, University Children&apos;s Hospital Regensburg (KUNO), Hospital St. Hedwig of the Order of St. John, University of Regensburg, Regensburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Directed acyclic graph for epidemiological studies in childhood food allergy: Construction, user&apos;s guide, and application</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2051-2064</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/01/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiologic Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Causality</style></keyword><keyword><style face="normal" font="default" size="100%">causal inference</style></keyword><keyword><style face="normal" font="default" size="100%">confounding bias</style></keyword><keyword><style face="normal" font="default" size="100%">directed acyclic graph</style></keyword><keyword><style face="normal" font="default" size="100%">early life</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38234010</style></accession-num><abstract><style face="normal" font="default" size="100%">Understanding modifiable prenatal and early life causal determinants of food allergy is important for the prevention of the disease. Randomized clinical trials studying environmental and dietary determinants of food allergy may not always be feasible. Identifying risk/protective factors for early-life food allergy often relies on observational studies, which may be affected by confounding bias. The directed acyclic graph (DAG) is a causal diagram useful to guide causal inference from observational epidemiological research. To date, research on food allergy has made little use of this promising method. We performed a literature review of existing evidence with a systematic search, synthesized 32 known risk/protective factors, and constructed a comprehensive DAG for early-life food allergy development. We present an easy-to-use online tool for researchers to re-construct, amend, and modify the DAG along with a user&apos;s guide to minimize confounding bias. We estimated that adjustment strategies in 57% of previous observational studies on modifiable factors of childhood food allergy could be improved if the researchers determined their adjustment sets by DAG. Future researchers who are interested in the causal inference of food allergy development in early life can apply the DAG to identify covariates that should and should not be controlled in observational studies.</style></abstract><notes><style face="normal" font="default" size="100%">Peng, Zhuoxin&#xD;Apfelbacher, Christian&#xD;Brandstetter, Susanne&#xD;Eils, Roland&#xD;Kabesch, Michael&#xD;Lehmann, Irina&#xD;Trump, Saskia&#xD;Wellmann, Sven&#xD;Genuneit, Jon&#xD;eng&#xD;German Federal Ministry for Education and Research/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2051-2064. doi: 10.1111/all.16025. Epub 2024 Jan 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38234010</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16025</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2539</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2539</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, R.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Qin, X.</style></author><author><style face="normal" font="default" size="100%">Cui, Y.</style></author><author><style face="normal" font="default" size="100%">Corrigan, C. J.</style></author><author><style face="normal" font="default" size="100%">Ying, S.</style></author><author><style face="normal" font="default" size="100%">Wang, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Division of Asthma, Allergy &amp; Lung Biology, MRC &amp; Asthma UK Centre in Allergic Mechanisms of Asthma, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Discovery of ILC2 extracellular traps and ILC2 ETosis: A novel feature of group 2 innate lymphoid cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2283-2286</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Extracellular Traps/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38864159</style></accession-num><notes><style face="normal" font="default" size="100%">Xu, Yingjie&#xD;Zhou, Ruonan&#xD;Yang, Yiran&#xD;Zhang, Hanxiao&#xD;Li, Yan&#xD;Qin, Xiaofeng&#xD;Cui, Ye&#xD;Corrigan, Chris J&#xD;Ying, Sun&#xD;Wang, Wei&#xD;eng&#xD;81971510/National Natural Science Foundation of China/&#xD;82090013/National Natural Science Foundation of China/&#xD;82071805/National Natural Science Foundation of China/&#xD;82350710228/National Natural Science Foundation of China/&#xD;IS23094/Beijing Municipal Natural Science Foundation/&#xD;KZ20231002541/R&amp;amp;D Program of Beijing Municipal Education Commission/&#xD;Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2283-2286. doi: 10.1111/all.16192. Epub 2024 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38864159</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16192</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2828</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2828</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hutten, E. M.</style></author><author><style face="normal" font="default" size="100%">Bulatovic Calasan, M.</style></author><author><style face="normal" font="default" size="100%">Trubiano, J. A.</style></author><author><style face="normal" font="default" size="100%">Pleijhuis, R. G.</style></author><author><style face="normal" font="default" size="100%">Terreehorst, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine and Allergology, University Medical Center Groningen, Groningen, the Netherlands.&#xD;Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.&#xD;Laboratory Specialised Diagnostics &amp; Research, Department of Laboratory Medicine, Amsterdam, the Netherlands.&#xD;Centre for Antibiotic Allergy and Research, Department of Infectious Diseases and Immunology, Heidelberg, Victoria, Australia.&#xD;Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.&#xD;ENT Department, Amsterdam University Medical Centre, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Discrepancies in Beta-Lactam Antibiotics Cross-Reactivity: Implications for Clinical Practice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3108-3114</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/02/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*beta-Lactams/adverse effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Bacterial Agents/adverse effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/etiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">beta Lactam Antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial stewardship</style></keyword><keyword><style face="normal" font="default" size="100%">beta-lactam antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">cross-reactivity</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39981703</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In patients with a beta-lactam antibiotic (BA) allergy label, avoidance of the whole group of BAs leads to displacement of first-line therapies potentially influencing patient outcomes and antimicrobial resistance. Studies previously published on BA cross-reactivity use different sets of BA and seem to contain conflicting recommendations on safe BA alternatives in case of (suspected) BA allergy. METHODS: The objectives were (i) to identify discrepancies between studies regarding cross-allergy in BA and (ii) to identify research gaps. The tables and errata of 4 studies (Romano et al., Trubiano et al., Zagursky et al., SWAB-guideline by Wijnakker et al.) were evaluated and compared head-to-head. RESULTS: A total of 51 antibiotics were covered by the four authors, theoretically leading to 2550 potential recommendations regarding alternatives in case of specific allergies. Internal discrepancies existed in 2 tables. Since none of the tables included all 51 BAs, in 356 situations data were lacking regarding specific alternatives. In 1104 situations, only one author gave advice about a specific alternative. Harmony and disharmony between authors could be evaluated in 1090 cases. The advice regarding alternative BAs was 696 times in harmony (482 safe, 214 unsafe), while discrepancies were found in 394 cases. This led to a different advice (safe vs. unsafe) in 272 cases or 69%. CONCLUSION: Disharmony between authors was identified in 36% of the cases. In 69%, this led to a clinically relevant, different advice. This indicates the need for synchronisation of cross-reactivity tables and answering remaining research gaps.</style></abstract><notes><style face="normal" font="default" size="100%">Hutten, Evelien Maria&#xD;Bulatovic Calasan, Maja&#xD;Trubiano, Jason Anthony&#xD;Pleijhuis, Rick Gert-Jan&#xD;Terreehorst, Ingrid&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3108-3114. doi: 10.1111/all.16485. Epub 2025 Feb 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39981703</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590330</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16485</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2941</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2941</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bilgic-Eltan, S.</style></author><author><style face="normal" font="default" size="100%">Karakurt, T.</style></author><author><style face="normal" font="default" size="100%">Yuksel, R. G.</style></author><author><style face="normal" font="default" size="100%">Yalaki, A. I.</style></author><author><style face="normal" font="default" size="100%">Durankus, F.</style></author><author><style face="normal" font="default" size="100%">Dut, R.</style></author><author><style face="normal" font="default" size="100%">Altun, E. Z.</style></author><author><style face="normal" font="default" size="100%">Aygun, B.</style></author><author><style face="normal" font="default" size="100%">Kacar, D.</style></author><author><style face="normal" font="default" size="100%">Senkal, E.</style></author><author><style face="normal" font="default" size="100%">Sefer Arinc, A. P.</style></author><author><style face="normal" font="default" size="100%">Gurel, B. A.</style></author><author><style face="normal" font="default" size="100%">Baris, S.</style></author><author><style face="normal" font="default" size="100%">Arga, M.</style></author><author><style face="normal" font="default" size="100%">Ozen, A. O.</style></author><author><style face="normal" font="default" size="100%">Karakoc-Aydiner, E.</style></author><author><style face="normal" font="default" size="100%">Cavkaytar, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Jeffrey Modell Primary Immunodeficiency Diagnosis Center, Isil Barlan Translational Medicine Center, Immunodeficiency Application and Research Center, Marmara University Faculty of Medicine, Istanbul, Turkey.&#xD;Department of Pediatric Allergy and Immunology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.&#xD;Faculty of Medicine, Marmara University, Istanbul, Turkey.&#xD;Division of Pediatric Allergy and Immunology, Faculty of Medicine, Marmara University, Istanbul, Turkey.&#xD;Division of Pediatric Allergy and Immunology, Faculty of Medicine, Mersin University, Mersin, Turkey.&#xD;Department of Pediatrics, Faculty of Medicine, Goztepe Prof Dr Suleyman Yalcin City Hospital, Istanbul Medeniyet University, Istanbul, Turkey.&#xD;Istanbul Training and Research Hospital, Suleymaniye Obstetrics and Gynecology Hospital, Adolesan Clinic, Istanbul, Turkey.&#xD;Department of Pediatrics, Pendik Training and Research Hospital, Marmara University, Istanbul, Turkey.&#xD;Department of Pediatrics, Institute of Health Sciences, Social Pediatrics PhD Program, Pendik Training and Research Hospital, Marmara University, Istanbul, Turkey.&#xD;Department of Pediatric Allergy and Immunology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Discrepancy Between Perceived and Proven Drug Hypersensitivity in a Well-Defined Cohort of Patients With Inborn Errors of Immunity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3140-3150</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/04/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Enda</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">inborn errors of immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40298338</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Inborn errors of immunity (IEI) are genetic disorders characterized by recurrent and/or severe infections, autoimmunity, autoinflammation, allergies, and cancer. Despite frequent drug exposures due to recurrent infections and comorbidities, the prevalence and characteristics of drug hypersensitivity reactions (DHR) in pediatric patients with IEI remain understudied. METHODS: This multicenter, cross-sectional study evaluated 264 pediatric patients with IEI along with a control group (CG) comprising 443 age-matched controls using a stepwise diagnostic approach, including the patient-reported Study Questionnaire (Study-Q), the European Network for Drug Allergy Questionnaire (ENDA-Q), and confirmatory diagnostic testing, including skin testing and drug provocation tests (DPT). The demographic, clinical, and allergic profiles of the IEI patients and CG were compared. RESULTS: IEI patients (57.6% male) had a median current age of 10 years, with combined immunodeficiencies being the most common phenotype (53.4%). The number of courses for antibiotic use and hospitalization was more frequent in IEI patients compared to CG (p &lt; 0.001). DHR was more common in IEI patients according to Study-Q (p &lt; 0.001) and ENDA-Q (p = 0.002), although proven DHR as a result of confirmatory testing was comparable with CG (1.1% vs. 0.4%, p = 0.368). Despite the fact that suspected DHR in IEI patients was most frequently associated with beta-lactams (47.6%), with 73.9% presenting with urticaria, proven DHR mainly included reactions to radiocontrast agents (n = 2) and ibuprofen (n = 1). CONCLUSION: Although drug hypersensitivity is often suspected in patients with IEI, proven cases are rare. Standardized protocols, including DPT in drug allergy centers, are essential to differentiate proven allergies from nonallergic reactions, ensure effective treatment, and avoid unnecessary drug restrictions in this unique population.</style></abstract><notes><style face="normal" font="default" size="100%">Bilgic-Eltan, Sevgi&#xD;Karakurt, Tuba&#xD;Yuksel, Rozerin Goze&#xD;Yalaki, Aysu Ilhan&#xD;Durankus, Ferit&#xD;Dut, Raziye&#xD;Altun, Ekin Zeynep&#xD;Aygun, Burcu&#xD;Kacar, Dilek&#xD;Senkal, Evrim&#xD;Sefer Arinc, Asena Pinar&#xD;Gurel, Burak Ahmet&#xD;Baris, Safa&#xD;Arga, Mustafa&#xD;Ozen, Ahmet Oguzhan&#xD;Karakoc-Aydiner, Elif&#xD;Cavkaytar, Ozlem&#xD;eng&#xD;Multicenter Study&#xD;Observational Study&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3140-3150. doi: 10.1111/all.16570. Epub 2025 Apr 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40298338</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16570</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1248</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1248</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jakobsen, L. S.</style></author><author><style face="normal" font="default" size="100%">Pilegaard, K.</style></author><author><style face="normal" font="default" size="100%">Pires, S. M.</style></author><author><style face="normal" font="default" size="100%">Bogh, K. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Food Institute, Technical University of Denmark, Kgs. Lyngby, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The disease burden of peanut allergy in Denmark measured by disability-adjusted life years (DALYs)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1583-1585</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cost of Illness</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Persons with Disabilities</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Quality-Adjusted Life Years</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33274476</style></accession-num><notes><style face="normal" font="default" size="100%">Jakobsen, Lea S&#xD;Pilegaard, Kirsten&#xD;Pires, Sara M&#xD;Bogh, Katrine L&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1583-1585. doi: 10.1111/all.14682. Epub 2020 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33274476</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14682</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2559</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2559</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Kolkhir, P.</style></author><author><style face="normal" font="default" size="100%">Pereira, M. P.</style></author><author><style face="normal" font="default" size="100%">Siebenhaar, F.</style></author><author><style face="normal" font="default" size="100%">Witte-Handel, E.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Bonnekoh, H.</style></author><author><style face="normal" font="default" size="100%">Buttgereit, T.</style></author><author><style face="normal" font="default" size="100%">Fluhr, J. W.</style></author><author><style face="normal" font="default" size="100%">Frischbutter, S.</style></author><author><style face="normal" font="default" size="100%">Grekowitz, E. M.</style></author><author><style face="normal" font="default" size="100%">Herzog, L.</style></author><author><style face="normal" font="default" size="100%">Kiefer, L. A.</style></author><author><style face="normal" font="default" size="100%">Krause, K.</style></author><author><style face="normal" font="default" size="100%">Magerl, M.</style></author><author><style face="normal" font="default" size="100%">Munoz, M.</style></author><author><style face="normal" font="default" size="100%">Neisinger, S.</style></author><author><style face="normal" font="default" size="100%">Nojarov, N.</style></author><author><style face="normal" font="default" size="100%">Prins, S.</style></author><author><style face="normal" font="default" size="100%">Pyatilova, P.</style></author><author><style face="normal" font="default" size="100%">Ramanauskaite, A.</style></author><author><style face="normal" font="default" size="100%">Scheffel, J.</style></author><author><style face="normal" font="default" size="100%">Terhorst-Molawi, D.</style></author><author><style face="normal" font="default" size="100%">Treudler, R.</style></author><author><style face="normal" font="default" size="100%">Weller, K.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Metz, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Disease modification in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2396-2413</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/07/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">disease modification</style></keyword><keyword><style face="normal" font="default" size="100%">disease-driving signals</style></keyword><keyword><style face="normal" font="default" size="100%">disease-modifying treatments</style></keyword><keyword><style face="normal" font="default" size="100%">therapy-free clinical remission</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39044706</style></accession-num><abstract><style face="normal" font="default" size="100%">Chronic spontaneous urticaria (CSU) is a debilitating, inflammatory skin condition characterized by infiltrating immune cells. Available treatments are limited to improving the signs and symptoms. There is an unmet need to develop therapies that target disease-driving pathways upstream of mast cell activation to inhibit or delay the progression of CSU and associated comorbidities. Here, we aim to define disease modification due to a treatment intervention and criteria that disease-modifying treatments (DMTs) must meet in CSU. We have defined disease modification in CSU as a favorable treatment-induced change in the underlying pathophysiology and, therefore, the disease course, which is clinically beneficial and enduring. A DMT must fulfil the following criteria: (1) prevents or delays the progression of CSU, (2) induces long-term, therapy-free clinical remission, which is the sustained absence of CSU signs and symptoms without the need for treatment, and (3) affects the underlying mechanism of CSU, as demonstrated by an effect on disease-driving signals and/or a biomarker. DMTs in CSU should slow disease progression, achieve long-lasting disease remission, target disease-driving mechanisms, reduce mast cell-activating IgE autoantibodies, target cytokine profile polarization, and normalize the gut microbiome and barrier. Treating CSU at the immune system level could provide valuable alternatives to pharmacotherapy in CSU management. Specific DMTs in CSU are yet to be developed, but some show potential benefits, such as inhibitors of Bruton&apos;s Tyrosine Kinase, IL-4 and IL-13. Future therapies could prevent CSU signs and symptoms, achieve long-term clinical benefits after discontinuing treatment, and prevent associated concomitant disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Maurer, Marcus&#xD;Kolkhir, Pavel&#xD;Pereira, Manuel P&#xD;Siebenhaar, Frank&#xD;Witte-Handel, Ellen&#xD;Bergmann, Karl-Christian&#xD;Bonnekoh, Hanna&#xD;Buttgereit, Thomas&#xD;Fluhr, Joachim W&#xD;Frischbutter, Stefan&#xD;Grekowitz, Eva Maria&#xD;Herzog, Leonie&#xD;Kiefer, Lea Alice&#xD;Krause, Karoline&#xD;Magerl, Markus&#xD;Munoz, Melba&#xD;Neisinger, Sophia&#xD;Nojarov, Nicole&#xD;Prins, Samantha&#xD;Pyatilova, Polina&#xD;Ramanauskaite, Aiste&#xD;Scheffel, Jorg&#xD;Terhorst-Molawi, Dorothea&#xD;Treudler, Regina&#xD;Weller, Karsten&#xD;Zuberbier, Torsten&#xD;Metz, Martin&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2396-2413. doi: 10.1111/all.16243. Epub 2024 Jul 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39044706</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16243</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1990</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1990</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, P. H.</style></author><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Thong, B. Y. H.</style></author><author><style face="normal" font="default" size="100%">Mak, H. W. F.</style></author><author><style face="normal" font="default" size="100%">Chan, G.</style></author><author><style face="normal" font="default" size="100%">Chung, W. H.</style></author><author><style face="normal" font="default" size="100%">Juan, M.</style></author><author><style face="normal" font="default" size="100%">Kang, H. R.</style></author><author><style face="normal" font="default" size="100%">Kim, B. K.</style></author><author><style face="normal" font="default" size="100%">Lobo, R. C. M.</style></author><author><style face="normal" font="default" size="100%">Lucas, M.</style></author><author><style face="normal" font="default" size="100%">Pham, D. L.</style></author><author><style face="normal" font="default" size="100%">Ranasinghe, T.</style></author><author><style face="normal" font="default" size="100%">Rengganis, I.</style></author><author><style face="normal" font="default" size="100%">Rerkpattanapipat, T.</style></author><author><style face="normal" font="default" size="100%">Sonomjamts, M.</style></author><author><style face="normal" font="default" size="100%">Tsai, Y. G.</style></author><author><style face="normal" font="default" size="100%">Wang, J. Y.</style></author><author><style face="normal" font="default" size="100%">Yamaguchi, M.</style></author><author><style face="normal" font="default" size="100%">Yun, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong City, Hong Kong.&#xD;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore City, Singapore.&#xD;Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.&#xD;Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Department of Internal Medicine, Seoul National University College of Medicine, Drug Safety Center, Seoul National University Hospital, Seoul, South Korea.&#xD;Department of Internal Medicine, Korea University Medical Center Anam Hospital, Seoul, South Korea.&#xD;Philippine Childrens Medical Center Hospital of Infant Jesus Medical Center, Fe del Mundo Medical Center, Quezon City, Philippines.&#xD;Department of Clinical Immunology, Sir Charles Gairdner Hospital, Perth Children&apos;s Hospital, Perth, Western Australia, Australia.&#xD;Medical School, University of Western Australia, Nedlands, Western Australia, Australia.&#xD;Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.&#xD;Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.&#xD;Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, CiptoMangunkusumo General Hopsital, Jakarta, Indonesia.&#xD;Allergy, Immunology and Rheumatology Division, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Pulmonology and Allergology, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.&#xD;Department of Pediatrics, Changhua Christian Children Hospital, Changhua, Taiwan.&#xD;Allergy, Immunology, and Microbiome (A.I.M.) Research Centre, China Medical University Children&apos;s Hospital, Taichung, Taiwan.&#xD;Third Department of Medicine, Teikyo University Chiba Medical Center, Chiba, Japan.&#xD;Faculty of Medicine and Health, University of Sydney, Sydney, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Disparities and inequalities of penicillin allergy in the Asia-Pacific region</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2529-2532</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/03/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Status Disparities</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillins/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Asia/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36951669</style></accession-num><notes><style face="normal" font="default" size="100%">Li, Philip H&#xD;Pawankar, Ruby&#xD;Thong, Bernard Y H&#xD;Mak, Hugo W F&#xD;Chan, Grace&#xD;Chung, Wen-Hung&#xD;Juan, Meng&#xD;Kang, Hye-Ryun&#xD;Kim, Byung-Keun&#xD;Lobo, Rommel Crisenio M&#xD;Lucas, Michaela&#xD;Pham, Duy Le&#xD;Ranasinghe, Thushali&#xD;Rengganis, Iris&#xD;Rerkpattanapipat, Ticha&#xD;Sonomjamts, Munkhbayarlakh&#xD;Tsai, Yi-Giien&#xD;Wang, Jiu-Yao&#xD;Yamaguchi, Masao&#xD;Yun, James&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2529-2532. doi: 10.1111/all.15725. Epub 2023 Mar 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36951669</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15725</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2441</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2441</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leung, A. S. Y.</style></author><author><style face="normal" font="default" size="100%">Tham, E. H.</style></author><author><style face="normal" font="default" size="100%">Pacharn, P.</style></author><author><style face="normal" font="default" size="100%">Xing, Y.</style></author><author><style face="normal" font="default" size="100%">Trinh, H. K. T.</style></author><author><style face="normal" font="default" size="100%">Lee, S.</style></author><author><style face="normal" font="default" size="100%">Ahn, K.</style></author><author><style face="normal" font="default" size="100%">Chatchatee, P.</style></author><author><style face="normal" font="default" size="100%">Sato, S.</style></author><author><style face="normal" font="default" size="100%">Ebisawa, M.</style></author><author><style face="normal" font="default" size="100%">Lee, B. W.</style></author><author><style face="normal" font="default" size="100%">Wong, G. W. K.</style></author><author><style face="normal" font="default" size="100%">Asia-Pacific Research Network for, Anaphylaxis</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Prince of Wales Hospital, Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Shatin, Hong Kong.&#xD;Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Paediatrics, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.&#xD;Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.&#xD;Department of Pediatrics, Ajou University School of Medicine, Suwon, Republic of Korea.&#xD;Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Division of Allergy and Immunology, Faculty of Medicine, HAUS IAQ Research Unit, King Chulalongkorn Memorial Hospital, Chulalongkorn University, The Thai Red Cross Society, Bangkok, Thailand.&#xD;Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Kanagawa, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Disparities in pediatric anaphylaxis triggers and management across Asia</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1317-1328</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/03/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/epidemiology/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Asia/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Food Hypersensitivity/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">Asia</style></keyword><keyword><style face="normal" font="default" size="100%">adrenaline</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">nuts</style></keyword><keyword><style face="normal" font="default" size="100%">prospective</style></keyword><keyword><style face="normal" font="default" size="100%">registry</style></keyword><keyword><style face="normal" font="default" size="100%">shellfish</style></keyword><keyword><style face="normal" font="default" size="100%">wheat</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38462795</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The epidemiology and management of anaphylaxis are not well-reported in Asia. METHODS: A regional pediatric anaphylaxis registry was established by the Asia-Pacific Research Network for Anaphylaxis (APRA), using standardized protocols for prospective data collection, to evaluate the triggers and management of anaphylaxis in the Asia-Pacific region. Pediatric patients below 18 years presenting with anaphylaxis across four Asian countries/cities (Thailand, Singapore, Hong Kong (HK), and Qingdao) were included. Allergen triggers, symptoms, anaphylaxis severity, and management were compared. RESULTS: Between 2019 and 2022, 721 anaphylaxis episodes in 689 patients from 16 centers were identified. The mean age at anaphylaxis presentation was 7.0 years (SD = 5.2) and 60% were male. Food was the most common trigger (62%), particularly eggs and cow&apos;s milk in children aged 3 years and below. In school-age children, nut anaphylaxis was most common in HK and Singapore, but was rare in the other countries, and wheat was the top allergen in Bangkok. Shellfish anaphylaxis was most common in children aged 7-17. Adrenaline was administered in 60% of cases, with 9% given adrenaline before hospital arrival. Adrenaline devices were prescribed in up to 82% of cases in Thailand but none in Qingdao. CONCLUSIONS: The APRA identified food as the main trigger of anaphylaxis in children, but causative allergens differed even across Asian countries. Fewer than two-thirds of cases received adrenaline treatment, pre-hospital adrenaline usage was low, and adrenaline device prescription remained suboptimal. The registry recognizes an unmet need to strengthen anaphylaxis care and research in Asia-Pacific.</style></abstract><notes><style face="normal" font="default" size="100%">Leung, Agnes Sze Yin&#xD;Tham, Elizabeth Huiwen&#xD;Pacharn, Punchama&#xD;Xing, Yuhan&#xD;Trinh, Hoang Kim Tu&#xD;Lee, Sooyoung&#xD;Ahn, Kangmo&#xD;Chatchatee, Pantipa&#xD;Sato, Sakura&#xD;Ebisawa, Motohiro&#xD;Lee, Bee Wah&#xD;Wong, Gary Wing Kin&#xD;(APRA)&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1317-1328. doi: 10.1111/all.16098. Epub 2024 Mar 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38462795</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16098</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>286</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">286</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chiang, V.</style></author><author><style face="normal" font="default" size="100%">Kan, A. K. C.</style></author><author><style face="normal" font="default" size="100%">Yim, J. S. H.</style></author><author><style face="normal" font="default" size="100%">Lee, E.</style></author><author><style face="normal" font="default" size="100%">Au, E. Y. L.</style></author><author><style face="normal" font="default" size="100%">Li, P. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Clinical Immunology, Department of Pathology, Queen Mary Hospital, Hong Kong, Hong Kong.&#xD;Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Disproportionate rate of female referrals for suspected COVID-19 vaccine allergies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">308-310</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/09/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Referral and Consultation</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">sex</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36125309</style></accession-num><notes><style face="normal" font="default" size="100%">Chiang, Valerie&#xD;Kan, Andy Ka Chun&#xD;Yim, Jackie S H&#xD;Lee, Elaine&#xD;Au, Elaine Y L&#xD;Li, Philip H&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):308-310. doi: 10.1111/all.15522. Epub 2022 Sep 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36125309</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9538670</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15522</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2201</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2201</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Cagan, E.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Li, M.</style></author><author><style face="normal" font="default" size="100%">Do, E.</style></author><author><style face="normal" font="default" size="100%">Kucukkase, O. C.</style></author><author><style face="normal" font="default" size="100%">Simsek, A.</style></author><author><style face="normal" font="default" size="100%">Kizmaz, M. A.</style></author><author><style face="normal" font="default" size="100%">Bozkurt, T.</style></author><author><style face="normal" font="default" size="100%">Aydin, T.</style></author><author><style face="normal" font="default" size="100%">Heider, A.</style></author><author><style face="normal" font="default" size="100%">Ruckert, B.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">Dhir, R.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Budak, F.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Immunology, Bursa Uludag University School of Medicine, Bursa, Turkey.&#xD;Department of Pediatric Infectious Diseases, Bursa Yuksek Ihtisas Training and Research Hospital, University of Health Sciences, Bursa, Turkey.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;SEED Inc. Co., Los Angeles, California, USA.&#xD;Department of Medicine and School of Microbiology, University College Cork, Cork, Ireland.&#xD;APC Microbiome Ireland, Cork, Ireland.&#xD;Department of Environmental Health, T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Disrupted epithelial permeability as a predictor of severe COVID-19 development</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2644-2658</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">DNA, Bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">*Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Permeability</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Glycoproteins</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Lectins, C-Type</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial DNA</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">zonulin family peptides</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37422701</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: An impaired epithelial barrier integrity in the gastrointestinal tract is important to the pathogenesis of many inflammatory diseases. Accordingly, we assessed the potential of biomarkers of epithelial barrier dysfunction as predictive of severe COVID-19. METHODS: Levels of bacterial DNA and zonulin family peptides (ZFP) as markers of bacterial translocation and intestinal permeability and a total of 180 immune and inflammatory proteins were analyzed from the sera of 328 COVID-19 patients and 49 healthy controls. RESULTS: Significantly high levels of circulating bacterial DNA were detected in severe COVID-19 cases. In mild COVID-19 cases, serum bacterial DNA levels were significantly lower than in healthy controls suggesting epithelial barrier tightness as a predictor of a mild disease course. COVID-19 patients were characterized by significantly elevated levels of circulating ZFP. We identified 36 proteins as potential early biomarkers of COVID-19, and six of them (AREG, AXIN1, CLEC4C, CXCL10, CXCL11, and TRANCE) correlated strongly with bacterial translocation and can be used to predict and discriminate severe cases from healthy controls and mild cases (area under the curve (AUC): 1 and 0.88, respectively). Proteomic analysis of the serum of 21 patients with moderate disease at admission which progressed to severe disease revealed 10 proteins associated with disease progression and mortality (AUC: 0.88), including CLEC7A, EIF4EBP1, TRANCE, CXCL10, HGF, KRT19, LAMP3, CKAP4, CXADR, and ITGB6. CONCLUSION: Our results demonstrate that biomarkers of intact or defective epithelial barriers are associated with disease severity and can provide early information on the prediction at the time of hospital admission.</style></abstract><notes><style face="normal" font="default" size="100%">Yazici, Duygu&#xD;Cagan, Eren&#xD;Tan, Ge&#xD;Li, Manru&#xD;Do, Evan&#xD;Kucukkase, Ozan C&#xD;Simsek, Abdurrahman&#xD;Kizmaz, Muhammed Ali&#xD;Bozkurt, Tugce&#xD;Aydin, Tamer&#xD;Heider, Anja&#xD;Ruckert, Beate&#xD;Bruggen, Marie-Charlotte&#xD;Dhir, Raja&#xD;O&apos;Mahony, Liam&#xD;Akdis, Mubeccel&#xD;Nadeau, Kari C&#xD;Budak, Ferah&#xD;Akdis, Cezmi A&#xD;Ogulur, Ismail&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2644-2658. doi: 10.1111/all.15800. Epub 2023 Jul 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37422701</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15800</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2896</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2896</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Feng, X.</style></author><author><style face="normal" font="default" size="100%">Xue, Y.</style></author><author><style face="normal" font="default" size="100%">Bao, R.</style></author><author><style face="normal" font="default" size="100%">Chen, S.</style></author><author><style face="normal" font="default" size="100%">Yang, H.</style></author><author><style face="normal" font="default" size="100%">Xie, F.</style></author><author><style face="normal" font="default" size="100%">Sun, J.</style></author><author><style face="normal" font="default" size="100%">Su, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Endoscopy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.&#xD;Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.&#xD;Shanghai Engineering Research Center of Respiratory Endoscopy, Shanghai, China.&#xD;Unit of Respiratory Infection and Immunity, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.&#xD;State Key Laboratory of Oncogenes and Related Genes, Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.&#xD;Shanghai Key Laboratory of Lung Inflammation and Injury, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Disruption of the Vagal TRPA1-Pulmonary Neuroendocrine Cell Axis Reduces Asthma Severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1715-1736</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/06/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism/etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*TRPA1 Cation Channel/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Neuroendocrine Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Vagus Nerve/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Lung/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchial Thermoplasty</style></keyword><keyword><style face="normal" font="default" size="100%">Nrg1-erbb</style></keyword><keyword><style face="normal" font="default" size="100%">Pnec</style></keyword><keyword><style face="normal" font="default" size="100%">Trpa1</style></keyword><keyword><style face="normal" font="default" size="100%">alpha7 nAChR</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">vagus nerve</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40491289</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Pulmonary neuroendocrine cells (PNECs) are adjacent to the vagus nerve, which innervates the lungs, and have been implicated in asthma pathogenesis. However, the neuroimmunomodulatory role of vagal-PNEC signaling in asthma remains poorly understood. METHODS: We developed an asthma model of C-fiber photoactivation and vagotomy to investigate the changes in PNECs. RNA sequencing (RNA-seq) was performed on flow cytometry-sorted PNECs to explore how vagus nerve C fibers affect the function of PNECs, with further validation in an in vitro cell model. Single-nucleus RNA sequencing (snRNA-seq) was conducted on airway samples of patients before and after bronchial thermoplasty (BT) treatment, and the changes of neural signals in different airway cell types and their crosstalk with PNEC after BT were analyzed in depth. RESULTS: Vagotomy reduced photoactivated TRPA1-mediated PNEC activation and allergic inflammation, inhibited the number and function of PNEC, and attenuated PNEC-mediated asthma response. PNEC RNA-seq results showed that photoactivation of TRPA1 in lung could promote the migration, aggregation, and synaptic transmission of PNECs and increase the synthesis and secretion of neuropeptides, which could also be activated by alpha7 nAChR of PNECs. BT therapy significantly reduced or interrupted NRG1-ERBB signaling between PNECs and other cells by interfering with PNEC secretion, synapse formation, and signaling, thereby alleviating the condition of asthma patients. CONCLUSIONS: We found that the vagal TRPA1-PNEC axis contributes to asthma severity. BT can disrupt this pathway through NRG1-ERBB signaling between PNECs and other cells to attenuate the inflammatory response in asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Feng, Xintong&#xD;Xue, Yue&#xD;Bao, Rujuan&#xD;Chen, Si&#xD;Yang, Han&#xD;Xie, Fangfang&#xD;Sun, Jiayuan&#xD;Su, Xiao&#xD;eng&#xD;National Key Research and Development Program of China/&#xD;National Natural Science Foundation of China/&#xD;Science and Technology Commission of Shanghai Municipality/&#xD;Shanghai Municipal Education Commission/&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1715-1736. doi: 10.1111/all.16599. Epub 2025 Jun 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40491289</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16599</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1035</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1035</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Higgs, J.</style></author><author><style face="normal" font="default" size="100%">Styles, K.</style></author><author><style face="normal" font="default" size="100%">Bowyer, S.</style></author><author><style face="normal" font="default" size="100%">Warner, A.</style></author><author><style face="normal" font="default" size="100%">Dunn Galvin, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Food To Fit Limited, London, UK.&#xD;Allergy UK, Kent, UK.&#xD;University College Cork, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dissemination of EAACI food allergy guidelines using a flexible, practical, whole school allergy awareness toolkit</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3479-3488</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/04/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Epinephrine</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Schools</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">participatory action research</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">self-efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from American Pistachio Growers, personal fees from Frucom, outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">KS reports personal fees from Food To Fit Limited, during the</style></keyword><keyword><style face="normal" font="default" size="100%">conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">SB reports personal fees from Food To Fit Ltd, during the</style></keyword><keyword><style face="normal" font="default" size="100%">conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">AW has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">ADG has nothing to disclose. ​</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33894060</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Essential training for emergency adrenaline auto-injector administration alone provides an inadequate safeguard in school environments. Recent UK deaths have reinforced the urgency for embedding whole school (WS) allergy awareness to minimise risk. We documented the development of a practical, flexible WS Food Allergy Awareness Toolkit for UK secondary schools. METHODS: We used a multidisciplinary participatory action research methodology, involving successive modification and retesting of a pragmatic toolkit in 3 case study schools. A School Allergy Action Group drives WS risk assessment, helping schools gradually implement best practice policy in line with their particular needs. Additional schools self-piloted the resulting toolkit with only remote monitoring. School surveys, based on EAACI guidelines were developed to identify priorities and assess change. RESULTS: Effectiveness of the resulting process toolkit, now available online, was independently demonstrated via pre/post-intervention questionnaires from 24/10 pupils with food allergy (FA) and 97/6 pupils without FA, respectively. Pearson correlational analysis showed strong negative relationships between Food Allergy Quality of Life Questionnaire (FAQLQ) at T0 and School Support (SS) at T0 (r = -0.8, P&lt;0.01), and between SS and Self-Efficacy (SE) (r = 0.73, P&lt;0.05). Mean FAQLQ scores improved between T0 (3.3) and T1 (2.5). SE improved for those with FA (mean difference = 1.0). In those without FA, SE (mean difference = 0.9) and Attitudes and Knowledge (mean difference = 0.7) also improved. CONCLUSIONS: Full stakeholder involvement in toolkit development encourages usage and, therefore, improves WS community awareness; reduces risk of reactions; fosters a more accepting societal attitude and empowers pupils with/without allergies to self-manage effectively.</style></abstract><notes><style face="normal" font="default" size="100%">Higgs, Jennette&#xD;Styles, Kathryn&#xD;Bowyer, Sarah&#xD;Warner, Amena&#xD;Dunn Galvin, Audrey&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3479-3488. doi: 10.1111/all.14871. Epub 2021 May 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33894060</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8596703</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14871</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2235</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2235</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chang, I.</style></author><author><style face="normal" font="default" size="100%">Kaushik, A.</style></author><author><style face="normal" font="default" size="100%">Satitsuksanoa, P.</style></author><author><style face="normal" font="default" size="100%">Yang, M.</style></author><author><style face="normal" font="default" size="100%">Buergi, L.</style></author><author><style face="normal" font="default" size="100%">Schneider, S. R.</style></author><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University, Palo Alto, California, USA.&#xD;Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.&#xD;Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Department of Microbiology, Institute of Graduate Studies, Bolu Abant Izzet Baysal University, Bolu, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distinct and mutually exclusive Ca(2+) flux- and adenylyl cyclase-inducing gene expression profiles of G-protein-coupled receptors on human antigen-specific B cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3016-3019</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/08/24</style></edition><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37615338</style></accession-num><notes><style face="normal" font="default" size="100%">Chang, Iris&#xD;Kaushik, Abhinav&#xD;Satitsuksanoa, Pattraporn&#xD;Yang, Minglin&#xD;Buergi, Laura&#xD;Schneider, Stephan R&#xD;Babayev, Huseyn&#xD;Akdis, Cezmi A&#xD;Nadeau, Kari&#xD;van de Veen, Willem&#xD;Akdis, Mubeccel&#xD;eng&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;U01 AI140498/AI/NIAID NIH HHS/&#xD;R01 AI140134/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):3016-3019. doi: 10.1111/all.15858. Epub 2023 Aug 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37615338</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15858</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2375</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2375</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Won, J.</style></author><author><style face="normal" font="default" size="100%">Jo, A.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Shin, H.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Korea.&#xD;Seoul National University Hospital, Seoul, Korea.&#xD;Sensory Organ Research Institute, Seoul National University Medical Research Center, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distinct dampening of IL-33 following inhalation of interferon-lambda in the respiratory epithelium of in vivo asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2241-2244</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/01/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-33/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Mucosa/metabolism/immunology/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Interferons</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38205738</style></accession-num><notes><style face="normal" font="default" size="100%">Won, Jina&#xD;Jo, Ara&#xD;Kim, Sujin&#xD;Shin, Haeun&#xD;Kim, Hyun Jik&#xD;eng&#xD;2022R1A2C2011867/Ministry of Education/&#xD;RS-2023-00222762/Ministry of Science and ICT, Korea/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2241-2244. doi: 10.1111/all.16010. Epub 2024 Jan 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38205738</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16010</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1136</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1136</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Kolmert, J.</style></author><author><style face="normal" font="default" size="100%">Safholm, J.</style></author><author><style face="normal" font="default" size="100%">Johnsson, A. K.</style></author><author><style face="normal" font="default" size="100%">Zurita, J.</style></author><author><style face="normal" font="default" size="100%">Wheelock, C. E.</style></author><author><style face="normal" font="default" size="100%">Dahlen, S. E.</style></author><author><style face="normal" font="default" size="100%">Nilsson, G.</style></author><author><style face="normal" font="default" size="100%">Adner, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Experimental Asthma and Allergy Research Unit, Institute of Environmental Medicine (IMM), Karolinska Institutet, Stockholm, Sweden.&#xD;Division of Physiological Chemistry 2, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.&#xD;Division of Immunology and Allergy, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distinct effects of antigen and compound 48/80 in the guinea pig trachea</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2270-2273</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens</style></keyword><keyword><style face="normal" font="default" size="100%">Guinea Pigs</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine Release</style></keyword><keyword><style face="normal" font="default" size="100%">*Trachea</style></keyword><keyword><style face="normal" font="default" size="100%">*p-Methoxy-N-methylphenethylamine</style></keyword><keyword><style face="normal" font="default" size="100%">&quot;omics&quot; and systems biology</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33619732</style></accession-num><notes><style face="normal" font="default" size="100%">Liu, Jielu&#xD;Kolmert, Johan&#xD;Safholm, Jesper&#xD;Johnsson, Anna-Karin&#xD;Zurita, Javier&#xD;Wheelock, Craig E&#xD;Dahlen, Sven-Erik&#xD;Nilsson, Gunnar&#xD;Adner, Mikael&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2270-2273. doi: 10.1111/all.14789. Epub 2021 Mar 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33619732</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14789</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1387</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1387</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Song, J.</style></author><author><style face="normal" font="default" size="100%">Zeng, M.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Qin, C.</style></author><author><style face="normal" font="default" size="100%">Hou, H. Y.</style></author><author><style face="normal" font="default" size="100%">Sun, Z. Y.</style></author><author><style face="normal" font="default" size="100%">Xu, S. P.</style></author><author><style face="normal" font="default" size="100%">Wang, G. P.</style></author><author><style face="normal" font="default" size="100%">Guo, C. L.</style></author><author><style face="normal" font="default" size="100%">Deng, Y. K.</style></author><author><style face="normal" font="default" size="100%">Wang, Z. C.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">Pan, L.</style></author><author><style face="normal" font="default" size="100%">Liao, B.</style></author><author><style face="normal" font="default" size="100%">Du, Z. H.</style></author><author><style face="normal" font="default" size="100%">Feng, Q. M.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Xie, J. G.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;The Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Key Laboratory of Respiratory Diseases of Ministry of Health, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">483-496</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/*epidemiology/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*complications/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Disease, Chronic Obstructive/*epidemiology/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">angiotensin-converting enzyme II</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine</style></keyword><keyword><style face="normal" font="default" size="100%">immune cell</style></keyword><keyword><style face="normal" font="default" size="100%">severe acute respiratory syndrome coronavirus 2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32716553</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The impacts of chronic airway diseases on coronavirus disease 2019 (COVID-19) are far from understood. OBJECTIVE: To explore the influence of asthma and chronic obstructive pulmonary disease (COPD) comorbidity on disease expression and outcomes, and the potential underlying mechanisms in COVID-19 patients. METHODS: A total of 961 hospitalized COVID-19 patients with a definite clinical outcome (death or discharge) were retrospectively enrolled. Demographic and clinical information were extracted from the medical records. Lung tissue sections from patients suffering from lung cancer were used for immunohistochemistry study of angiotensin-converting enzyme II (ACE2) expression. BEAS-2B cell line was stimulated with various cytokines. RESULTS: In this cohort, 21 subjects (2.2%) had COPD and 22 (2.3%) had asthma. After adjusting for confounding factors, COPD patients had higher risk of developing severe illness (OR: 23.433; 95% CI 1.525-360.135; P &lt; .01) and acute respiratory distress syndrome (OR: 19.762; 95% CI 1.461-267.369; P = .025) than asthmatics. COPD patients, particularly those with severe COVID-19, had lower counts of CD4(+) T and CD8(+) T cells and B cells and higher levels of TNF-alpha, IL-2 receptor, IL-10, IL-8, and IL-6 than asthmatics. COPD patients had increased, whereas asthmatics had decreased ACE2 protein expression in lower airways, compared with that in control subjects without asthma and COPD. IL-4 and IL-13 downregulated, but TNF-alpha, IL-12, and IL-17A upregulated ACE2 expression in BEAS-2B cells. CONCLUSION: Patients with asthma and COPD likely have different risk of severe COVID-19, which may be associated with different ACE2 expression.</style></abstract><notes><style face="normal" font="default" size="100%">Song, Jia&#xD;Zeng, Ming&#xD;Wang, Hai&#xD;Qin, Chuan&#xD;Hou, Hong-Yan&#xD;Sun, Zi-Yong&#xD;Xu, San-Peng&#xD;Wang, Guo-Ping&#xD;Guo, Cui-Lian&#xD;Deng, Yi-Ke&#xD;Wang, Zhi-Chao&#xD;Ma, Jin&#xD;Pan, Li&#xD;Liao, Bo&#xD;Du, Zhi-Hui&#xD;Feng, Qi-Miao&#xD;Liu, Yang&#xD;Xie, Jun-Gang&#xD;Liu, Zheng&#xD;eng&#xD;2018CFB602/Natural Science Foundation of Hubei Province of China/&#xD;81570033/National Natural Science Foundation of China/&#xD;81630024/National Natural Science Foundation of China/&#xD;81770982/National Natural Science Foundation of China/&#xD;81900925/National Natural Science Foundation of China/&#xD;81920108011/National Natural Science Foundation of China/&#xD;81973986/National Natural Science Foundation of China/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):483-496. doi: 10.1111/all.14517. Epub 2020 Aug 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32716553</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14517</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1264</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1264</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Bu, X.</style></author><author><style face="normal" font="default" size="100%">Fang, G.</style></author><author><style face="normal" font="default" size="100%">Luan, G.</style></author><author><style face="normal" font="default" size="100%">Huang, Y.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Department of Otolaryngology, Head and Neck Surgery, Beijing Ditan Hospital, Capital Medical University, Beijing, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne - Center for Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distinct expression of SARS-CoV-2 receptor ACE2 correlates with endotypes of chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">789-803</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/11/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation, Enzymologic</style></keyword><keyword><style face="normal" font="default" size="100%">Glucocorticoids/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Polyps/*enzymology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Coronavirus/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinitis/*enzymology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Serine Endopeptidases/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Sinusitis/*enzymology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Ace2</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Tmprss2</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory endotype</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33210729</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry factors, ACE2 and TMPRSS2, are highly expressed in nasal epithelial cells. However, the association between SARS-CoV-2 and nasal inflammation in chronic rhinosinusitis with nasal polyps (CRSwNP) has not been investigated. We thus investigated the expression of SARS-CoV-2 entry factors in nasal tissues of CRSwNP patients, and their associations with inflammatory endotypes of CRSwNP. METHODS: The expression of ACE2 and TMPRSS2 was assessed in nasal tissues of control subjects and eosinophilic CRSwNP (ECRSwNP) and nonECRSwNP patients. The correlations between ACE2/TMPRSS2 expression and inflammatory indices of CRSwNP endotypes were evaluated. Regulation of ACE2/TMPRSS2 expression by inflammatory cytokines and glucocorticoids was investigated. RESULTS: ACE2 expression was significantly increased in nasal tissues of nonECRSwNP patients compared to ECRSwNP patients and control subjects, and positively correlated with the expression of IFN-gamma, but negatively correlated with tissue infiltrated eosinophils, and expression of IL5 and IL13. IFN-gamma up-regulated ACE2 expression while glucocorticoid attenuated this increase in cultured nasal epithelial cells. Genes co-expressed with ACE2 were enriched in pathways relating to defence response to virus in nasal tissue. TMPRSS2 expression was decreased in nasal tissues of CRSwNP patients compared to control subjects and not correlated with the inflammatory endotypes of CRSwNP. Glucocorticoid treatment decreased ACE2 expression in nasal tissues of nonECRSwNP patients, but not in ECRSwNP patients, whereas TMPRSS2 expression was not affected. CONCLUSION: These findings indicate that ACE2 expression, regulated by IFN-gamma, is increased in nasal tissues of nonECRSwNP patients and positively correlates with type 1 inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Ming&#xD;Bu, Xiangting&#xD;Fang, Gaoli&#xD;Luan, Ge&#xD;Huang, Yanran&#xD;Akdis, Cezmi A&#xD;Wang, Chengshuo&#xD;Zhang, Luo&#xD;eng&#xD;81800882/National Natural Science Foundation of China/&#xD;81630023/National Natural Science Foundation of China/&#xD;81870698/National Natural Science Foundation of China/&#xD;SML20150203/Beijing municipal administration of hospitals&apos; mission plan/&#xD;2018YFC0116800/national key R&amp;amp;D program of China/&#xD;2016YFC0905200/national key R&amp;amp;D program of China/&#xD;IRT13082/program for the Changjiang scholars and innovative research team/&#xD;DFL20190202/Beijing municipal administration of hospitals&apos; Dengfeng plan/&#xD;XMLX201816/Beijing municipal administration of hospitals clinical medicine development of special funding support/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):789-803. doi: 10.1111/all.14665. Epub 2020 Nov 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33210729</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7753806</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14665</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2839</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2839</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gueguen, E.</style></author><author><style face="normal" font="default" size="100%">Morsy, Y.</style></author><author><style face="normal" font="default" size="100%">Biedermann, L.</style></author><author><style face="normal" font="default" size="100%">Straumann, A.</style></author><author><style face="normal" font="default" size="100%">Swiss Eo, E. Cohort Study Group</style></author><author><style face="normal" font="default" size="100%">Scharl, M.</style></author><author><style face="normal" font="default" size="100%">Wawrzyniak, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Distinct Genetic Signature Differentiates Inflamed and Noninflamed Fibrotic Tissues in Eosinophilic Esophagitis Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2043-2046</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/02/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">EoE</style></keyword><keyword><style face="normal" font="default" size="100%">fibrosis</style></keyword><keyword><style face="normal" font="default" size="100%">genetic signature</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39921325</style></accession-num><notes><style face="normal" font="default" size="100%">Gueguen, Emilie&#xD;Morsy, Yasser&#xD;Biedermann, Luc&#xD;Straumann, Alex&#xD;Scharl, Michael&#xD;Wawrzyniak, Marcin&#xD;eng&#xD;2021-09/EoE Foundation Switzerland/&#xD;32003B_204751/1/SNSF_/Swiss National Science Foundation/Switzerland&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2043-2046. doi: 10.1111/all.16497. Epub 2025 Feb 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39921325</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16497</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2965</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2965</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dsilva, A.</style></author><author><style face="normal" font="default" size="100%">Wagner, A.</style></author><author><style face="normal" font="default" size="100%">Itan, M.</style></author><author><style face="normal" font="default" size="100%">Rhone, N.</style></author><author><style face="normal" font="default" size="100%">Avlas, S.</style></author><author><style face="normal" font="default" size="100%">Gordon, Y.</style></author><author><style face="normal" font="default" size="100%">Davidian, N.</style></author><author><style face="normal" font="default" size="100%">Sharma, S.</style></author><author><style face="normal" font="default" size="100%">Razravina, E.</style></author><author><style face="normal" font="default" size="100%">Zan-Bar, I.</style></author><author><style face="normal" font="default" size="100%">Parnes, J. R.</style></author><author><style face="normal" font="default" size="100%">Gorski, K. S.</style></author><author><style face="normal" font="default" size="100%">Sherrill, J. D.</style></author><author><style face="normal" font="default" size="100%">Varol, C.</style></author><author><style face="normal" font="default" size="100%">Ziegler, S. F.</style></author><author><style face="normal" font="default" size="100%">Rothenberg, M. E.</style></author><author><style face="normal" font="default" size="100%">Munitz, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Microbiology and Immunology, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.&#xD;Early Development, Amgen, Thousand Oaks, California, USA.&#xD;Clinical Biomarkers and Diagnostics, Amgen, South San Francisco, California, USA.&#xD;Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, Maryland, USA.&#xD;Research Center for Digestive Tract and Liver Diseases, Sourasky Medical Center, Tel Aviv, Israel.&#xD;Center for Fundamental Immunology, Benaroya Research Institute, Seattle, Washington, USA.&#xD;Division of Allergy/Immunology, Department of Pediatrics, Cincinnati Children&apos;s Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distinct Roles for Thymic Stromal Lymphopoietin (TSLP) and IL-33 in Experimental Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3095-3107</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/07/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Interleukin-33/metabolism/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/metabolism/etiology/pathology/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Thymic Stromal Lymphopoietin</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines/metabolism/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Cytokine/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">Tslp</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">Sartorious and is an inventor of patents owned by the Tel Aviv University. Marc</style></keyword><keyword><style face="normal" font="default" size="100%">E. Rothenberg is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm,</style></keyword><keyword><style face="normal" font="default" size="100%">Celldex, Uniquity Bio, EnZen Therapeutics, Bristol Myers Squibb, Astra Zeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, Glaxo Smith Kline, and Regeneron/Sanofi, and Guidepoint and has an equity</style></keyword><keyword><style face="normal" font="default" size="100%">interest in the first seven listed plus in Allakos and Santa Ana Bio, and</style></keyword><keyword><style face="normal" font="default" size="100%">royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust),</style></keyword><keyword><style face="normal" font="default" size="100%">and UpToDate. Marc E. Rothenberg is an inventor of patents owned by Cincinnati</style></keyword><keyword><style face="normal" font="default" size="100%">Children&apos;s Hospital Medical Center. The remaining authors disclose no conflicts.</style></keyword><keyword><style face="normal" font="default" size="100%">Jane R. Parnes and Kevin S. Gorski are employees of Amgen and may own stock or</style></keyword><keyword><style face="normal" font="default" size="100%">stock options in Amgen. Joseph D. Sherrill is an employee of AstraZeneca and may</style></keyword><keyword><style face="normal" font="default" size="100%">own stock or stock options in AstraZeneca.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40726298</style></accession-num><abstract><style face="normal" font="default" size="100%">RATIONALE: Thymic stromal lymphopoietin (TSLP) and IL-33 are alarmins implicated in eosinophilic esophagitis (EoE) pathogenesis by activating multiple cells, including mast cells (MCs). Whether TSLP or IL-33 have a role in EoE and whether their activities are distinct requires further investigation. METHODS: Experimental EoE was induced in wild type (WT) Il33(-/-) and Crlf2(-/-) mice. TSLP or IL-5 were neutralized using antibodies. Esophageal histopathology was determined by H&amp;E, anti-Ki67, anti-CD31, and anti-MBP staining. Esophageal RNA was subjected to RNA sequencing. Bone marrow-derived MCs were activated with TSLP and IL-13 was determined (ELISA). RESULTS: TSLP and IL-33 were overexpressed in human and experimental EoE. Human and mouse esophageal MCs displayed the highest level of Crlf2 (TSLPR) compared to other immune cells. Crlf2(-/-) mice were nearly completely protected from EoE, and TSLP neutralization resulted in decreased basal cell proliferation, eosinophilia, lamina propria thickening, and vascularization. Induction of experimental EoE in Il33(-/-) mice resulted in reduced eosinophilia, but no alterations in tissue remodeling were observed compared to WT mice. RNA sequencing revealed that TSLP regulates the expression of key genes associated with human EoE (e.g., eotaxins, Il19, Klk5, Flg, Il36rn, Il1r2) and suggests a role for TSLP in regulating IL-1 signaling, barrier integrity, and epithelial cell differentiation. Experimental EoE was characterized by a MC-associated gene signature and elevated MCs. Activation of MCs with TSLP resulted in the secretion of IL-13. CONCLUSION: TSLP and IL-33 have non-redundant functions in experimental EoE. This study highlights TSLP as an upstream regulator of IL-13 and a potential therapeutic target for EoE.</style></abstract><notes><style face="normal" font="default" size="100%">Dsilva, Anish&#xD;Wagner, Ariel&#xD;Itan, Michal&#xD;Rhone, Natalie&#xD;Avlas, Shmulik&#xD;Gordon, Yaara&#xD;Davidian, Natalie&#xD;Sharma, Shraddha&#xD;Razravina, Elizaveta&#xD;Zan-Bar, Israel&#xD;Parnes, Jane R&#xD;Gorski, Kevin S&#xD;Sherrill, Joseph D&#xD;Varol, Chen&#xD;Ziegler, Steven F&#xD;Rothenberg, Marc E&#xD;Munitz, Ariel&#xD;eng&#xD;Israel Science Foundation/&#xD;US-Israel Bi-national Science Foundation/&#xD;AstraZeneca/&#xD;Israel Cancer Research Fund/&#xD;Israel Cancer Association USA/&#xD;Azrieli Foundation Canada-Israel/&#xD;Campaign Urging Research for Eosinophilic Disease/&#xD;P30 DK078392/DK/NIDDK NIH HHS/&#xD;R37 AI045898/AI/NIAID NIH HHS/&#xD;NH/NIH HHS/&#xD;U19 AI070235/AI/NIAID NIH HHS/&#xD;Sunshine Charitable Foundation/&#xD;R01 AI124355/AI/NIAID NIH HHS/&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3095-3107. doi: 10.1111/all.16682. Epub 2025 Jul 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40726298</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590318</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16682</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3069</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3069</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">D&apos;Avino, P.</style></author><author><style face="normal" font="default" size="100%">Kim, J.</style></author><author><style face="normal" font="default" size="100%">Li, M.</style></author><author><style face="normal" font="default" size="100%">Gessner, P.</style></author><author><style face="normal" font="default" size="100%">Westermann, P.</style></author><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Beha, C.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Bost, J.</style></author><author><style face="normal" font="default" size="100%">Gaudenzio, N.</style></author><author><style face="normal" font="default" size="100%">Messner, C. B.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;CK CARE - Christine Kuhne Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Zentrum Munchen, Augsburg, Germany.&#xD;SciBase AB, Sundbyberg, Sweden.&#xD;Toulouse Institute for Infectious and Inflammatory Disease (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France.&#xD;Genoskin SAS, Toulouse, France.&#xD;Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distinct Roles of IL-4, IL-13, and IL-22 in Human Skin Barrier Dysfunction and Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab (anti-IL4Ralpha antibody)</style></keyword><keyword><style face="normal" font="default" size="100%">electrical impedance spectroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">ex vivo human skin</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-22</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40985485</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is a chronic type-2 inflammatory skin disease characterized by eczema and epithelial barrier dysfunction. Along with the type-2 cytokines IL-4 and IL-13, IL-22 contributes to AD pathogenesis. To date, most skin studies rely on reconstructed keratinocytes, which do not represent the real skin response. OBJECTIVE: Here, we report the distinct effects of IL-4, IL-13, and IL-22 on bio-stabilized human skin with intact barriers and immune cells. METHODS: Spatial transcriptomics on AD-lesions and non-lesional skin was performed. Ex vivo skin barrier integrity was evaluated using electrical impedance spectroscopy (EIS), RNA-sequencing, and untargeted proteomics, complemented by analyses of skin biopsies from dupilumab-treated AD patients. RESULTS: Spatial transcriptomics demonstrated that AD lesions showed reduced expression of key barrier genes, including CLDN1, FLG, and FLG2. IL-4, IL-13, and IL-22 disrupted the skin barrier in the ex vivo human skin. Combining type-2 cytokines and IL-22 alone downregulated genes critical for barrier function and keratinization. In addition, IL-4 and IL-13 downregulated antimicrobial peptides, while IL-22 upregulated them. Interestingly, IL-4 and IL-13 reduced IL-22Ralpha1, and IL-22 upregulated IL-4Ralpha, suggesting immune cross-regulation. Proteomic analysis confirmed that all three cytokines (IL-4, IL-13, and IL-22) reduced the expression of key skin barrier proteins, particularly filaggrin and claudin-1. Dupilumab treatment of AD patients for 3 months restored IL-4/IL-13-dysregulated genes, whereas it had limited effect on IL22-associated pathways. CONCLUSION: This comprehensive study provides insights into the distinct immune profiles following IL-4, IL-13, and IL-22 stimulation on human skin, highlighting their complex interplay in disrupting skin barrier function and modulating innate immune responses.</style></abstract><notes><style face="normal" font="default" size="100%">D&apos;Avino, Paolo&#xD;Kim, Juno&#xD;Li, Manru&#xD;Gessner, Philipp&#xD;Westermann, Patrick&#xD;Pat, Yagiz&#xD;Beha, Carina&#xD;Traidl-Hoffmann, Claudia&#xD;Bost, Jeremy&#xD;Gaudenzio, Nicolas&#xD;Messner, Christoph B&#xD;Akdis, Cezmi A&#xD;Mitamura, Yasutaka&#xD;eng&#xD;This work was funded by SciBase AB, GenoSkin SAS, and the Swiss National Foundation. SciBase AB contributed EIS instruments and electrodes for the study and contributed toward study funding. Genoskin SAS provided NativeSkin samples for the study with special discounts./&#xD;Denmark&#xD;Allergy. 2025 Sep 23. doi: 10.1111/all.70060.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40985485</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70060</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2589</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2589</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sasaki, H.</style></author><author><style face="normal" font="default" size="100%">Miyata, J.</style></author><author><style face="normal" font="default" size="100%">Kawashima, Y.</style></author><author><style face="normal" font="default" size="100%">Konno, R.</style></author><author><style face="normal" font="default" size="100%">Ishikawa, M.</style></author><author><style face="normal" font="default" size="100%">Hasegawa, Y.</style></author><author><style face="normal" font="default" size="100%">Onozato, R.</style></author><author><style face="normal" font="default" size="100%">Otsu, Y.</style></author><author><style face="normal" font="default" size="100%">Matsuyama, E.</style></author><author><style face="normal" font="default" size="100%">Sunata, K.</style></author><author><style face="normal" font="default" size="100%">Masaki, K.</style></author><author><style face="normal" font="default" size="100%">Kabata, H.</style></author><author><style face="normal" font="default" size="100%">Kimizuka, Y.</style></author><author><style face="normal" font="default" size="100%">Ueki, S.</style></author><author><style face="normal" font="default" size="100%">Asano, K.</style></author><author><style face="normal" font="default" size="100%">Kawana, A.</style></author><author><style face="normal" font="default" size="100%">Arita, M.</style></author><author><style face="normal" font="default" size="100%">Fukunaga, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan.&#xD;Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.&#xD;Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences, Tokyo, Kanagawa, Japan.&#xD;Department of Applied Genomics, Kazusa DNA Research Institute, Chiba, Japan.&#xD;Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.&#xD;Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.&#xD;Graduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan.&#xD;Division of Physiological Chemistry and Metabolism, Keio University Faculty of Pharmacy, Tokyo, Japan.&#xD;Human Biology-Microbiome-Quantum Research Center (WPI-Bio2Q), Keio University, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distinct roles of types 1 and 2 interferons in human eosinophil regulation: A multi-omics analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3141-3145</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/07/03</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38958441</style></accession-num><notes><style face="normal" font="default" size="100%">Sasaki, Hisashi&#xD;Miyata, Jun&#xD;Kawashima, Yusuke&#xD;Konno, Ryo&#xD;Ishikawa, Masaki&#xD;Hasegawa, Yoshinori&#xD;Onozato, Ryuta&#xD;Otsu, Yo&#xD;Matsuyama, Emiko&#xD;Sunata, Keeya&#xD;Masaki, Katsunori&#xD;Kabata, Hiroki&#xD;Kimizuka, Yoshifumi&#xD;Ueki, Shigeharu&#xD;Asano, Koichiro&#xD;Kawana, Akihiko&#xD;Arita, Makoto&#xD;Fukunaga, Koichi&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3141-3145. doi: 10.1111/all.16215. Epub 2024 Jul 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38958441</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16215</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3157</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3157</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chantran, Y.</style></author><author><style face="normal" font="default" size="100%">Choi, S.</style></author><author><style face="normal" font="default" size="100%">Roda, C.</style></author><author><style face="normal" font="default" size="100%">Barete, S.</style></author><author><style face="normal" font="default" size="100%">Hirsch, P.</style></author><author><style face="normal" font="default" size="100%">Hermine, O.</style></author><author><style face="normal" font="default" size="100%">Polivka, L.</style></author><author><style face="normal" font="default" size="100%">Rossignol, J.</style></author><author><style face="normal" font="default" size="100%">Arock, M.</style></author><author><style face="normal" font="default" size="100%">Ranciere, F.</style></author><author><style face="normal" font="default" size="100%">Momas, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environmental Risk Assessment (HERA) Team, UMR261 MERIT, IRD, Inserm 1344, Universite Paris Cite, Paris, France.&#xD;Molecular Platform for the Analysis of cKIT Mutations and Other Gene Defects, ECNM Reference Center, Reference Centre for Mastocytosis (CEREMAST), Saint-Antoine Hospital, AP-HP Sorbonne University, Paris, France.&#xD;Department of Biological Immunology, Saint-Antoine Hospital, AP-HP Sorbonne University, Paris, France.&#xD;Unit of Dermatology, Reference Centre for Mastocytosis (CEREMAST), Pitie-Salpetriere Hospital, AP-HP Sorbonne University, Paris, France.&#xD;Sorbonne Universite, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hopital Saint-Antoine, Hematologie Biologique, Paris, France.&#xD;CEREMAST, Imagine Institute, INSERM U1163, AP-HP, Necker Children&apos;s Hospital, Paris Centre University, Paris, France.&#xD;Department of Biological Hematology, Groupe Hospitalier Pitie-Salpetriere-C. Foix, DMU BioGeMH, AP-HP Sorbonne University, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distinct Tryptase Gene Copy Number Variations Correlate With Tryptase Levels in a Population-Based Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">birth cohort</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary alpha-tryptasemia</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">teenagers</style></keyword><keyword><style face="normal" font="default" size="100%">tryptase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41246864</style></accession-num><notes><style face="normal" font="default" size="100%">Chantran, Yannick&#xD;Choi, Simone&#xD;Roda, Celine&#xD;Barete, Stephane&#xD;Hirsch, Pierre&#xD;Hermine, Olivier&#xD;Polivka, Laura&#xD;Rossignol, Julien&#xD;Arock, Michel&#xD;Ranciere, Fanny&#xD;Momas, Isabelle&#xD;eng&#xD;Paris Municipal Department of Social Action, Childhood, and Health (DASES)/&#xD;Societe Francaise d&apos;Allergologie/&#xD;FP7-261357/European collaborative program MeDALL/&#xD;Universite Paris Descartes/&#xD;16-CE36-0007-01/Agence Nationale pour la Recherche (ANR)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov 17. doi: 10.1111/all.70160.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41246864</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70160</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1009</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1009</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ehlers, A. M.</style></author><author><style face="normal" font="default" size="100%">den Hartog Jager, C. F.</style></author><author><style face="normal" font="default" size="100%">Knulst, A. C.</style></author><author><style face="normal" font="default" size="100%">Otten, H. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.&#xD;Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distinction between peanut allergy and tolerance by characterization of B cell receptor repertoires</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2753-2764</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">2S Albumins, Plant/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Antigen, B-Cell</style></keyword><keyword><style face="normal" font="default" size="100%">VH family gene usage</style></keyword><keyword><style face="normal" font="default" size="100%">clinically irrelevant sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy diagnostics</style></keyword><keyword><style face="normal" font="default" size="100%">monoclonal antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Germany. Other authors have no conflicts of interest to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33969502</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Specific IgE against a peanut 2S albumin (Ara h 2 or 6) is the best predictor of clinically relevant peanut sensitization. However, sIgE levels of peanut allergic and those of peanut sensitized but tolerant patients partly overlap, highlighting the need for improved diagnostics to prevent incorrect diagnosis and consequently unnecessary food restrictions. Thus, we sought to explore differences in V(D)J gene transcripts coding for peanut 2S albumin-specific monoclonal antibodies (mAbs) from allergic and sensitized but tolerant donors. METHODS: 2S albumin-binding B-cells were single-cell sorted from peripheral blood of peanut allergic (n=6) and tolerant (n=6) donors sensitized to Ara h2 and/or 6 (&gt;/= 0.1 kU/l) and non-atopic controls (n=5). h 2 and/or 6 (&gt;/= 0.1 kU/l). Corresponding h heavy and light chain gene transcripts were heterologously expressed as mAbs and tested for specificity to native Ara h2 and 6. HCDR3 sequence motifs were identified by Levenshtein distances and hierarchically clustering. RESULTS: The frequency of 2S albumin-binding B cells was increased in allergic (median: 0.01%) compared to tolerant (median: 0.006%) and non-atopic donors (median: 0.0015%, p = 0.008). The majority of mAbs (74%, 29/39) bound specifically to Ara h 2 and/or 6. Non-specific mAbs (9/10) were mainly derived from non-atopic controls. In allergic donors, 89% of heavy chain gene transcripts consisted of VH3 family genes, compared with only 54% in sensitized but tolerant and 63% of non-atopic donors. Additionally, certain HCDR3 sequence motifs were associated with allergy (n = 4) or tolerance (n = 3) upon hierarchical clustering of their Levenshtein distances. CONCLUSIONS: Peanut allergy is associated with dominant VH3 family gene usage and certain public antibody sequences (HCDR3 motifs).</style></abstract><notes><style face="normal" font="default" size="100%">Ehlers, Anna M&#xD;den Hartog Jager, Constance F&#xD;Knulst, Andre C&#xD;Otten, Henny G&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2753-2764. doi: 10.1111/all.14897. Epub 2021 May 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33969502</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8453529</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14897</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2704</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2704</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Radzikowska, U.</style></author><author><style face="normal" font="default" size="100%">Ding, M.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Zhakparov, D.</style></author><author><style face="normal" font="default" size="100%">Peng, Y.</style></author><author><style face="normal" font="default" size="100%">Wawrzyniak, P.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author><author><style face="normal" font="default" size="100%">Altunbulakli, C.</style></author><author><style face="normal" font="default" size="100%">Reiger, M.</style></author><author><style face="normal" font="default" size="100%">Neumann, A. U.</style></author><author><style face="normal" font="default" size="100%">Lunjani, N.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Akdis, C.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne - Center for Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Functional Genomic Centre Zurich, ETH Zurich/University of Zurich, Zurich, Switzerland.&#xD;Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.&#xD;Division of Clinical Chemistry and Biochemistry, University Children;s Hospital Zurich, Zurich, Switzerland.&#xD;Children;s Research Center, University Children;s Hospital Zurich, Zurich, Switzerland.&#xD;Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University and the Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.&#xD;Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum Munchen, Augsburg, Germany.&#xD;Institute of Computational Biology (ICB), Helmholtz Zentrum Munchen, Munich, Germany.&#xD;Institute of Experimental Medicine (IEM), Czech Academy of Sciences, Prague, Czech Republic.&#xD;Sean N Parker Centre for Allergy and Asthma Research at Stanford University, Department of Medicine, Stanford University School of Medicine, Stanford, USA.&#xD;Department of Medicine and School of Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2829-2845</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2020/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2/genetics/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/epidemiology/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Basigin/genetics/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*epidemiology/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease/*epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Dipeptidyl Peptidase 4/genetics/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension/epidemiology/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity/epidemiology/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Disease, Chronic Obstructive/epidemiology/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2/genetics/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Copd</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 children</style></keyword><keyword><style face="normal" font="default" size="100%">SARS receptor</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">obesity</style></keyword><keyword><style face="normal" font="default" size="100%">has nothing to disclose. Dr Zhakparov has nothing to disclose. Dr Peng has</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose. Dr Wawrzyniak has nothing to disclose. Dr Wang has nothing</style></keyword><keyword><style face="normal" font="default" size="100%">to disclose. Dr LI has nothing to disclose. Dr Morita has nothing to disclose. Dr</style></keyword><keyword><style face="normal" font="default" size="100%">Altunbulakli has nothing to disclose. Dr Reiger reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard, Germany, personal fees from Roche-Posay, Germany, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Galderma, Germany, personal fees from Sebapharma, Germany, grants from CLR,</style></keyword><keyword><style face="normal" font="default" size="100%">Germany, outside the submitted work. Dr Neumann has nothing to disclose. Dr</style></keyword><keyword><style face="normal" font="default" size="100%">Lunjani has nothing to disclose. Dr Traidl-Hoffmann reports grants and personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Topfer, personal fees from Sanofi, personal fees from Novartis, grants</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from Sebapharma, grants and personal fees from Danone Nutricia,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from La Roche Posay, personal fees from Lilly Pharma, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Mylan, outside the submitted work. Dr Nadeau reports grants and other from</style></keyword><keyword><style face="normal" font="default" size="100%">NIAID, other from Novartis, personal fees and other from Regeneron, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">other from FARE, grants from EAT, other from Sanofi, other from Astellas, other</style></keyword><keyword><style face="normal" font="default" size="100%">from Nestle, other from BeforeBrands, other from Alladapt, other from ForTra,</style></keyword><keyword><style face="normal" font="default" size="100%">other from Genentech, other from AImmune Therapeutics, other from DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, personal fees from Astrazeneca, personal fees from ImmuneWorks,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Cour Pharmaceuticals, grants from Allergenis, grants from Ukko</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, other from AnaptysBio, other from Adare Pharmaceuticals, other from</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes-Greer, other from NHLBI, other from NIEHS, other from EPA, other</style></keyword><keyword><style face="normal" font="default" size="100%">from WAO Center of Excellence, other from Iggenix, other from Probio, other from</style></keyword><keyword><style face="normal" font="default" size="100%">Vedanta, other from Centecor, other from Seed, from Immune Tolerance Network,</style></keyword><keyword><style face="normal" font="default" size="100%">from NIH, outside the submitted work. In addition, Dr Nadeau has a patent</style></keyword><keyword><style face="normal" font="default" size="100%">Inhibition of Allergic Reaction to Peanut Allergen using an IL-33 Inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">pending, a patent Special Oral Formula for Decreasing Food Allergy Risk and</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment for Food Allergy pending, a patent Basophil Activation Based Diagnostic</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Test pending, a patent Granulocyte-based methods for detecting and</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring immune system disorders pending, a patent Methods and Assays for</style></keyword><keyword><style face="normal" font="default" size="100%">Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune</style></keyword><keyword><style face="normal" font="default" size="100%">System Disorders pending, a patent Mixed Allergen Compositions and Methods for</style></keyword><keyword><style face="normal" font="default" size="100%">Using the Same pending, and a patent Microfluidic Device and Diagnostic Methods</style></keyword><keyword><style face="normal" font="default" size="100%">for Allergy Testing Based on Detection of Basophil Activation pending. Dr</style></keyword><keyword><style face="normal" font="default" size="100%">O&apos;Mahony reports personal fees from AHL, grants from GSK, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. Dr Akdis reports grants from Allergopharma, Idorsia, Swiss National Science</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, Christine Kuhne-Center for Allergy Research and Education, European</style></keyword><keyword><style face="normal" font="default" size="100%">Commission&apos;s Horison&apos;s 2020 Framework Programme, Cure, Novartis Research</style></keyword><keyword><style face="normal" font="default" size="100%">Institutes, Astra Zeneca, Scibase, Glakso Smith-Kline and other from Sanofi &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron. Dr Sokolowska reports grants from SNSF, grants from GSK, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32496587</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Morbidity and mortality from COVID-19 caused by novel coronavirus SARS-CoV-2 is accelerating worldwide, and novel clinical presentations of COVID-19 are often reported. The range of human cells and tissues targeted by SARS-CoV-2, its potential receptors and associated regulating factors are still largely unknown. The aim of our study was to analyze the expression of known and potential SARS-CoV-2 receptors and related molecules in the extensive collection of primary human cells and tissues from healthy subjects of different age and from patients with risk factors and known comorbidities of COVID-19. METHODS: We performed RNA sequencing and explored available RNA-Seq databases to study gene expression and co-expression of ACE2, CD147 (BSG), and CD26 (DPP4) and their direct and indirect molecular partners in primary human bronchial epithelial cells, bronchial and skin biopsies, bronchoalveolar lavage fluid, whole blood, peripheral blood mononuclear cells (PBMCs), monocytes, neutrophils, DCs, NK cells, ILC1, ILC2, ILC3, CD4(+) and CD8(+) T cells, B cells, and plasmablasts. We analyzed the material from healthy children and adults, and from adults in relation to their disease or COVID-19 risk factor status. RESULTS: ACE2 and TMPRSS2 were coexpressed at the epithelial sites of the lung and skin, whereas CD147 (BSG), cyclophilins (PPIA andPPIB), CD26 (DPP4), and related molecules were expressed in both epithelium and in immune cells. We also observed a distinct age-related expression profile of these genes in the PBMCs and T cells from healthy children and adults. Asthma, COPD, hypertension, smoking, obesity, and male gender status generally led to the higher expression of ACE2- and CD147-related genes in the bronchial biopsy, BAL, or blood. Additionally, CD147-related genes correlated positively with age and BMI. Interestingly, we also observed higher expression of CD147-related genes in the lesional skin of patients with atopic dermatitis. CONCLUSIONS: Our data suggest different receptor repertoire potentially involved in the SARS-CoV-2 infection at the epithelial barriers and in the immune cells. Altered expression of these receptors related to age, gender, obesity and smoking, as well as with the disease status, might contribute to COVID-19 morbidity and severity patterns.</style></abstract><notes><style face="normal" font="default" size="100%">Radzikowska, Urszula&#xD;Ding, Mei&#xD;Tan, Ge&#xD;Zhakparov, Damir&#xD;Peng, Yaqi&#xD;Wawrzyniak, Paulina&#xD;Wang, Ming&#xD;Li, Shuo&#xD;Morita, Hideaki&#xD;Altunbulakli, Can&#xD;Reiger, Matthias&#xD;Neumann, Avidan U&#xD;Lunjani, Nonhlanhla&#xD;Traidl-Hoffmann, Claudia&#xD;Nadeau, Kari C&#xD;O&apos;Mahony, Liam&#xD;Akdis, Cezmi&#xD;Sokolowska, Milena&#xD;eng&#xD;Denmark&#xD;Allergy. 2020 Nov;75(11):2829-2845. doi: 10.1111/all.14429. Epub 2020 Aug 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32496587</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7300910</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14429</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3261</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3261</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Angkeow, Julia W.</style></author><author><style face="normal" font="default" size="100%">Hong, Xiumei</style></author><author><style face="normal" font="default" size="100%">Thakar, Manjusha</style></author><author><style face="normal" font="default" size="100%">Frischmeyer-Guerrerio, Pamela A.</style></author><author><style face="normal" font="default" size="100%">Wang, Xiaobin</style></author><author><style face="normal" font="default" size="100%">Larman, H. Benjamin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Diverse Food Allergen IgG Reactivities Are Associated With Food Allergies in the Boston Birth Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Food allergies in children represent a growing clinical and public health concern worldwide, yet their causes remain poorly understood. Objective To investigate the role of circulating IgG antibodies to food allergens and viral antigens at birth and during early childhood in the development of food allergies, using data from a prospective birth cohort. Methods This study included 458 children composed of 80 with food allergies, 151 with food sensitization, and 227 who were non-allergic and non-sensitized to these food allergens and had no other allergic diseases (asthma, atopic dermatitis, and allergic rhinitis). Phage ImmunoPrecipitation Sequencing (PhIP-Seq) was used to profile the IgG antibody reactome against thousands of environmental antigens (including allergens and viruses) in matched cord blood and childhood plasma samples from these children. We then investigated whether IgG profiles were associated with allergies to egg, milk, and peanut. Results Children with food allergies had a significantly elevated diversity of IgG reactivity to thousands of allergen peptides in early childhood compared to non-allergic controls. No such associations were found in cord blood at birth. We identified that peanut-allergic children have higher IgG reactivity to 24 peanut peptides, and egg-allergic children had higher IgG reactivity to 17 egg peptides compared to non-allergic controls. Additionally, patterns of shared IgG reactivity to wheat peptides were observed across different food allergy groups in early childhood. Notably, milk-allergic children exhibited lower magnitudes of IgG reactivities to eight milk peptides in cord blood and reduced IgG reactivities to enteroviral peptides during childhood (all FDR &lt; 0.05), relative to non-allergic controls. Conclusion These results suggest that unbiased IgG reactome profiling in a prospective birth cohort provides new insights into early life immune regulation and its influence on childhood allergic phenotypes.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70246</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70246</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1045</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1045</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mindaye, S. T.</style></author><author><style face="normal" font="default" size="100%">Sun, C.</style></author><author><style face="normal" font="default" size="100%">Esfahani, S. A. Z.</style></author><author><style face="normal" font="default" size="100%">Matsui, E. C.</style></author><author><style face="normal" font="default" size="100%">Sheehan, M. J.</style></author><author><style face="normal" font="default" size="100%">Rabin, R. L.</style></author><author><style face="normal" font="default" size="100%">Slater, J. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Immunobiochemistry, Division of Bacterial, Parasitic, and Allergenic Products, Food and Drug Administration, Silver Spring, MD, USA.&#xD;Department of Population Health and Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.&#xD;Department of Neurobiology and Behavior, Cornell University, Ithaca, NY, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diversity and complexity of mouse allergens in urine, house dust, and allergen extracts assessed with an immuno-allergomic approach</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3723-3732</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/04/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Proteome</style></keyword><keyword><style face="normal" font="default" size="100%">Urine</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy vaccines and mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">occupational allergies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33864689</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Mouse allergy is an important cause of indoor asthma and allergic rhinoconjunctivitis. The major mouse allergen, Mus m 1, is a complex of homologous pheromone-binding lipocalins called major urinary proteins (MUPs). METHODS: We analyzed the proteome of MUPs in mouse urine, commercial mouse epithelial extracts, and environmental samples using several approaches. These include as follows: two-dimensional electrophoresis and immunoblotting; liquid chromatography-high-resolution mass spectrometry (LC/HRMS); multiple reaction monitoring (MRM) mass spectrometry; and LC/HRMS analysis of glycans at the N-66 residue of MUP3. RESULTS: Albumin is predominant in the extracts, while MUPs are predominant in urine. LC/HRMS of 4 mouse allergen extracts revealed surprising heterogeneity. Of 22 known mouse MUPs, only 6 (MUP3, MUP4, MUP5, MUP13, MUP20, and MUP21) could be identified with MRM using unique peptides. Assessment of MUP content in urine, extracts, and dust samples showed good correlation between MRM and other methods working with different detection principles. All 6 identifiable MUPs were found in electrophoretically separated urine bands, but only MUP3 and MUP20 were above LOQ in unseparated mouse urine, and only MUP3, MUP4, and MUP20 were found in mouse epithelial extracts. Glycan heterogeneity was noted among 4 individual inbred mice: of 13 glycan structures detected, 8 were unique to one mouse, and only 2 glycan modifications were present in all 4 mice. CONCLUSIONS: Using mass spectrometry and MRM, mouse allergen extracts and urine samples are shown to be complex and heterogeneous. The efficacy and safety of commercial mouse allergen extracts will be improved with better controls of allergen content.</style></abstract><notes><style face="normal" font="default" size="100%">Mindaye, Samuel T&#xD;Sun, Carl&#xD;Esfahani, Sayyed Amin Zarkesh&#xD;Matsui, Elizabeth C&#xD;Sheehan, Michael J&#xD;Rabin, Ronald L&#xD;Slater, Jay E&#xD;eng&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3723-3732. doi: 10.1111/all.14860.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33864689</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14860</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3087</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3087</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite Universitatsmedizin, Berlin, Corporate Member of Freie Universitat Berlin and Humboldt Universitat Zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diversity and Dosage Determine the Efficacy of the Probiotic SYN-53 in Allergic Rhinoconjunctivitis: A Randomized, Double-Blind, Placebo-Controlled Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3310-3318</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/09/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Probiotics/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">allergen exposure chamber</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial diversity</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">multi-strain probiotic</style></keyword><keyword><style face="normal" font="default" size="100%">reimbursement for participating as a study center. K.-C.B. received honoraria for</style></keyword><keyword><style face="normal" font="default" size="100%">lectures from ALK, Allergopharma, Almirall, AstraZeneca, Bencard, Berlin-Chemie,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, GSK, HAL, Mundipharma, Novartis, Sanofi, and Stallergenes during the last</style></keyword><keyword><style face="normal" font="default" size="100%">5 years. T.Z. has received institutional funding for research and/or honoria for</style></keyword><keyword><style face="normal" font="default" size="100%">lectures and/or consulting from Amgen, AstraZeneca, AbbVie, ALK, Almirall,</style></keyword><keyword><style face="normal" font="default" size="100%">Astellas, Bayer Health Care, Bencard, Berlin Chemie, FAES, HAL, Henkel, Kryolan,</style></keyword><keyword><style face="normal" font="default" size="100%">Leti, L&apos;Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes, Takeda, Teva, and UCB, Uriach</style></keyword><keyword><style face="normal" font="default" size="100%">in addition, he is a member of</style></keyword><keyword><style face="normal" font="default" size="100%">ARIA/WHO, DGAKI, ECARF, GA2LEN, and WAO. The remaining authors declare no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40931615</style></accession-num><abstract><style face="normal" font="default" size="100%">SYN-53, a multi-strain probiotic food supplement, was recently shown to significantly alleviate allergic rhinoconjunctivitis (ARC) and its symptoms. The diversity and dosage of bacterial strains administered via SYN-53 have been proposed as key drivers of its efficacy. The aim of this study was to assess the role of bacterial diversity and dosage by comparing SYN-53 to a low dose variant (SYN-53-LD), a low diversity variant (SYN-4), and a placebo in the management of ARC. This double-blind, parallel-group, placebo-controlled clinical trial included subjects with moderate-to-severe grass pollen allergy. Following baseline exposure in an allergen exposure chamber (AEC), 166 subjects were randomized to undergo three weekly 3-day intake cycles of SYN-53, SYN-53-LD, SYN-4, or placebo, followed by a final allergen exposure. During AEC exposure, symptoms were continuously measured via assessment of the Total Symptom Score (TSS). SYN-53 was significantly superior in reducing TSS(MAX) compared with its low dose variant SYN-53-LD (∆TSS(MAX) [Mean +/- SE]: -5.19 +/- 0.80 vs. -2.27 +/- 0.65; p = 0.0372), its low diversity variant SYN-4 (-3.41 +/- 0.52; p = 0.0482), and placebo (-2.82 +/- 0.78; p = 0.0329). No significant differences to placebo were seen for either SYN-53-LD (p = 0.7377) or SYN-4 (p = 0.5152). SYN-53 and its variants were well tolerated, and adverse events were not different from placebo. Our findings reaffirm the efficacy of SYN-53 in the management of ARC and demonstrate that the effectiveness of this multi-strain probiotic is intricately linked to the diversity of bacterial strains and dosage administered.</style></abstract><notes><style face="normal" font="default" size="100%">Bergmann, Karl-Christian&#xD;Zuberbier, Torsten&#xD;eng&#xD;Synformulas/&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3310-3318. doi: 10.1111/all.70045. Epub 2025 Sep 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40931615</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666746</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70045</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2724</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2724</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, B.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Huang, N.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Meng, Q.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Chen, R.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Public Health, Capital Medical University, Beijing, People&apos;s Republic of China.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, P. R. China.&#xD;Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing, P. R. China.&#xD;Laboratory for Environmental Health and Allergic Nasal Diseases, Laboratory for Clinical Medicine, Capital Medical University, Beijing, P. R. China.&#xD;Department of Occupational and Environmental Health, Fourth Military Medical University, Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Xi&apos;an, P. R. China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">DNA hypomethylation of Th17 cells by ambient particulate pollutants enhances neutrophil recruitment in murine models of allergic airway inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1509-1513</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/11/13</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39508385</style></accession-num><notes><style face="normal" font="default" size="100%">Li, Bin&#xD;Zhang, Yuan&#xD;Huang, Nannan&#xD;Wang, Jing&#xD;Zhang, Xianan&#xD;Meng, Qingtao&#xD;Wang, Jiajia&#xD;Wang, Chengshuo&#xD;Li, Xiaobo&#xD;Chen, Rui&#xD;Zhang, Luo&#xD;eng&#xD;2022YFC2504100and2022YFC2504101/National Key Research and Development Program of China/&#xD;2023YFC3708300and2023YFC3708303/National Key Research and Development Program of China/&#xD;82025031/the National Science Fund for Distinguished Young Scholars/&#xD;JWZQ20240101024/the Beijing Outstanding Young Scientist Program/&#xD;the Youth Beijing Scholar Program/&#xD;CX23YZ01/the Chinese Institutes for Medical Research, Beijing/&#xD;the Beijing Outstanding Young Scientist Program/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1509-1513. doi: 10.1111/all.16389. Epub 2024 Nov 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39508385</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16389</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>569</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">569</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eberlein, B.</style></author><author><style face="normal" font="default" size="100%">Mathes, S.</style></author><author><style face="normal" font="default" size="100%">Fischer, J.</style></author><author><style face="normal" font="default" size="100%">Darsow, U.</style></author><author><style face="normal" font="default" size="100%">Biedermann, T.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Department of Dermatology, Eberhard Karls University, Tubingen, Germany.&#xD;Division of Experimental Allergy and Immunodermatology, University of Oldenburg, Oldenburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Do basophil activation tests help elucidate allergic reactions to the ingredients in COVID-19 vaccines?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2924-2936</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/03/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Basophil Degranulation Test</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Polyethylene Glycols</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">basophil histamine release test</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">polyethylene glycol (PEG)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35266570</style></accession-num><abstract><style face="normal" font="default" size="100%">The worldwide use of COVID-19 vaccines has shown that immediate allergic reactions to the ingredients are rare but should be clarified by means of an allergological work-up. This review aims to highlight the current state of knowledge and possible pathogenesis based on the literature published to date. In addition to recording a detailed history and performing skin tests, cellular tests (basophil activation or basophil histamine release test) by using the vaccines or modified compounds containing polyethylene glycol (PEG), rather than unmodified PEGs, have proven to be particularly helpful. Negative results with vaccines seem to indicate tolerance. Details of the performance of these cellular tests with different vaccines, PEGs of different molecular weights, other ingredients of the vaccines, as well as other PEGylated drugs, and the results in the context of COVID-19 vaccination of various working groups worldwide are summarized.</style></abstract><notes><style face="normal" font="default" size="100%">Eberlein, Bernadette&#xD;Mathes, Sonja&#xD;Fischer, Jorg&#xD;Darsow, Ulf&#xD;Biedermann, Tilo&#xD;Brockow, Knut&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):2924-2936. doi: 10.1111/all.15278. Epub 2022 Mar 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35266570</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9111482</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15278</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1349</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1349</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">SoRelle, J. A.</style></author><author><style face="normal" font="default" size="100%">Chen, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Yue, T.</style></author><author><style face="normal" font="default" size="100%">Choi, J. H.</style></author><author><style face="normal" font="default" size="100%">Wang, K. W.</style></author><author><style face="normal" font="default" size="100%">Zhong, X.</style></author><author><style face="normal" font="default" size="100%">Hildebrand, S.</style></author><author><style face="normal" font="default" size="100%">Russell, J.</style></author><author><style face="normal" font="default" size="100%">Scott, L.</style></author><author><style face="normal" font="default" size="100%">Xu, D.</style></author><author><style face="normal" font="default" size="100%">Zhan, X.</style></author><author><style face="normal" font="default" size="100%">Bu, C. H.</style></author><author><style face="normal" font="default" size="100%">Wang, T.</style></author><author><style face="normal" font="default" size="100%">Choi, M.</style></author><author><style face="normal" font="default" size="100%">Tang, M.</style></author><author><style face="normal" font="default" size="100%">Ludwig, S.</style></author><author><style face="normal" font="default" size="100%">Zhan, X.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Moresco, E. M. Y.</style></author><author><style face="normal" font="default" size="100%">Beutler, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for the Genetics of Host Defense, University of Texas Southwestern Medical Center, Dallas, TX, USA.&#xD;Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.&#xD;Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.&#xD;Department of Population and Data Sciences, Quantitative Biomedical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dominant atopy risk mutations identified by mouse forward genetic analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1095-1108</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/08/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">IgG1</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">papain</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32810290</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopy, the overall tendency to become sensitized to an allergen, is heritable but seldom ascribed to mutations within specific genes. Atopic individuals develop abnormally elevated IgE responses to immunization with potential allergens. To gain insight into the genetic causes of atopy, we carried out a forward genetic screen for atopy in mice. METHODS: We screened mice carrying homozygous and heterozygous N-ethyl-N-nitrosourea (ENU)-induced germline mutations for aberrant antigen-specific IgE and IgG1 production in response to immunization with the model allergen papain. Candidate genes were validated by independent gene mutation. RESULTS: Of 31 candidate genes selected for investigation, the effects of mutations in 23 genes on papain-specific IgE or IgG1 were verified. Among the 20 verified genes influencing the IgE response, eight were necessary for the response, while 12 repressed IgE. Nine genes were not previously implicated in the IgE response. Fifteen genes encoded proteins contributing to IgE class switch recombination or B-cell receptor signaling. The precise roles of the five remaining genes (Flcn, Map1lc3b, Me2, Prkd2, and Scarb2) remain to be determined. Loss-of-function mutations in nine of the 12 genes limiting the IgE response were dominant or semi-dominant for the IgE phenotype but did not cause immunodeficiency in the heterozygous state. Using damaging allele frequencies for the corresponding human genes and in silico simulations (Monte Carlo) of undiscovered atopy mutations, we estimated the percentage of humans with heterozygous atopy risk mutations. CONCLUSIONS: Up to 37% of individuals may be heterozygous carriers for at least one dominant atopy risk mutation.</style></abstract><notes><style face="normal" font="default" size="100%">SoRelle, Jeffrey A&#xD;Chen, Zhe&#xD;Wang, Jianhui&#xD;Yue, Tao&#xD;Choi, Jin Huk&#xD;Wang, Kuan-Wen&#xD;Zhong, Xue&#xD;Hildebrand, Sara&#xD;Russell, Jamie&#xD;Scott, Lindsay&#xD;Xu, Darui&#xD;Zhan, Xiaowei&#xD;Bu, Chun Hui&#xD;Wang, Tao&#xD;Choi, Mihwa&#xD;Tang, Miao&#xD;Ludwig, Sara&#xD;Zhan, Xiaoming&#xD;Li, Xiaohong&#xD;Moresco, Eva Marie Y&#xD;Beutler, Bruce&#xD;eng&#xD;R01 AI125581/AI/NIAID NIH HHS/&#xD;U19 AI100627/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1095-1108. doi: 10.1111/all.14564. Epub 2020 Sep 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32810290</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7889751</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14564</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2806</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2806</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Silva, G.</style></author><author><style face="normal" font="default" size="100%">Alves, P. B.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Public Health, University of Porto, Porto, Portugal.&#xD;Allergy and Clinical Immunology Department, Coimbra University Hospital, Coimbra, Portugal.&#xD;Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dopamine as a Potential Modulator of ILC2-Driven Lung Inflammation via Mitochondrial Regulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1540-1542</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/03/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory aspects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40129222</style></accession-num><notes><style face="normal" font="default" size="100%">Silva, Goncalo&#xD;Alves, Pedro Botelho&#xD;Regateiro, Frederico&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1540-1542. doi: 10.1111/all.16536. Epub 2025 Mar 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40129222</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16536</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2706</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2706</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Song, J.</style></author><author><style face="normal" font="default" size="100%">Zhao, C.</style></author><author><style face="normal" font="default" size="100%">Wang, E.</style></author><author><style face="normal" font="default" size="100%">Yuan, J.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Key Laboratory of Otolaryngology Head and Neck Surgery, Beijing Laboratory of Allergic Diseases, Ministry of Education, Beijing Institute of Otolaryngology, Capital Medical University, Beijing, China.&#xD;Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Downregulation of Tight Junction Protein MAGI1 by Interferon-gamma Contributes to Barrier Dysfunction in Chronic Rhinosinusitis With Nasal Polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1491-1494</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/11/23</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39578990</style></accession-num><notes><style face="normal" font="default" size="100%">Song, Jing&#xD;Zhao, Chaoran&#xD;Wang, Enhao&#xD;Yuan, Jing&#xD;Wang, Chengshuo&#xD;Wang, Ming&#xD;Zhang, Luo&#xD;eng&#xD;IRT13082/Program for Changjiang Scholars and Innovative Research Team/&#xD;82171109/National Natural Science Foundation of China/&#xD;82025010/National Natural Science Foundation of China/&#xD;2022YFC2504100/National Key Research and Development Program of China/&#xD;JYY2023-1/Beijing municipal public welfare development and reform pilot project for medical research institutes/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1491-1494. doi: 10.1111/all.16405. Epub 2024 Nov 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39578990</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16405</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2210</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2210</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pichler, W. J.</style></author><author><style face="normal" font="default" size="100%">Thoo, L.</style></author><author><style face="normal" font="default" size="100%">Yerly, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ADR-AC GmbH, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drug hypersensitivity and eosinophilia: The decisive role of p-i stimulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2596-2605</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/07/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Antigen, T-Cell/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-5</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">CD8 Antigens/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">CD4 Antigens/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">CD4/CD8 co-receptors</style></keyword><keyword><style face="normal" font="default" size="100%">Il-5</style></keyword><keyword><style face="normal" font="default" size="100%">TCR signalosome</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">p-i concept</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37395496</style></accession-num><abstract><style face="normal" font="default" size="100%">Eosinophilia is a common finding in drug hypersensitivity reactions (DHR). Its cause is unclear, as neither antigen/allergen-driven inflammation nor clonal expansion is involved. Most delayed-DHRs are due to p-i (pharmacologic interaction of drugs with immune receptors). These are off-target activities of drugs with immune receptors that result in various types of T-cell stimulation, some of which involve excessive IL-5 production. Functional and phenotypic studies of T-cell clones and their TCR-transfected hybridoma cell lines revealed that some p-i-induced drug stimulations occur without CD4/ CD8 co-receptor engagement. The CD4/CD8 co-receptors link Lck (lymphocyte-specific protein tyrosine kinase) and LAT (linker for activation of T cells) to the TCR. Alteration of Lck or LAT can result in a TCR signalosome with enhanced IL-5 production. Thus, if a more affine TCR-[drug/peptide/HLA] interaction allows bypassing the CD4 co-receptor, a modified Lck/LAT activation may lead to a TCR signalosome with elevated IL-5 production. This &quot;IL-5-TCR-signalosome&quot; hypothesis could also explain eosinophilia in superantigen or allo-stimulation (graft-versus-host disease), in which evasion of CD4/CD8 co-receptors has also been described. It may open new therapeutic possibilities in certain eosinophilic diseases by directly targeting the IL-5-TCR signalosome.</style></abstract><notes><style face="normal" font="default" size="100%">Pichler, Werner J&#xD;Thoo, Lester&#xD;Yerly, Daniel&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2596-2605. doi: 10.1111/all.15795. Epub 2023 Jul 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37395496</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15795</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>371</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">371</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palomares, F.</style></author><author><style face="normal" font="default" size="100%">Paris, J. L.</style></author><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA-ARADyAL, Malaga, Spain.&#xD;Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-ARADyAL, Malaga, Spain.&#xD;Departamento de Medicina, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drug hypersensitivity, in vitro tools, biomarkers, and burden with COVID-19 vaccines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3527-3537</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default" size="100%">in vitro test</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35912413</style></accession-num><abstract><style face="normal" font="default" size="100%">Hypersensitivity reactions to drugs are increasing worldwide. They display a large degree of variability in the immunological mechanisms involved, which impacts both disease severity and the optimal diagnostic procedure. Therefore, drug hypersensitivity diagnosis relies on both in vitro and in vivo assessments, although most of the methods are not well standardized. Moreover, several biomarkers can be used as valuable parameters for precision medicine that provide information on the endotypes, diagnosis, prognosis, and prediction of drug hypersensitivity development, as well on the identification of therapeutic targets and treatment efficacy monitoring. Furthermore, in the last 2 years, the SARS-CoV-2 (severe acute respiratory syndrome-coronavirus) pandemic has had an important impact on health system, leading us to update approaches on how to manage hypersensitivity reactions to drugs used for its treatment and on COVID-19 (Coronavirus disease) vaccines used for its prevention. This article reviews recent advances in these 3 areas regarding drug hypersensitivity: in vitro tools for drug hypersensitivity diagnosis, recently identified biomarkers that could guide clinical decision making and management of hypersensitivity reactions to drugs and vaccines used for COVID-19.</style></abstract><notes><style face="normal" font="default" size="100%">Palomares, Francisca&#xD;Paris, Juan L&#xD;Labella, Marina&#xD;Dona, Inmaculada&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3527-3537. doi: 10.1111/all.15461. Epub 2022 Aug 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35912413</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9537799</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15461</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2408</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2408</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, IBIMA-Regional University Hospital of Malaga, UMA, RETICS ARADyAL, BIONAND, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drug hypersensitivity: Past, present and future</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">549-551</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/02/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Basophil Degranulation Test</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">drug provocation test</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38363030</style></accession-num><notes><style face="normal" font="default" size="100%">Torres, Maria J&#xD;Dona, Inmaculada&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):549-551. doi: 10.1111/all.16050. Epub 2024 Feb 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38363030</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16050</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3204</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3204</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van der Gang, L. F.</style></author><author><style face="normal" font="default" size="100%">Boesjes, C. M.</style></author><author><style face="normal" font="default" size="100%">Zuithoff, N. P. A.</style></author><author><style face="normal" font="default" size="100%">Haeck, I.</style></author><author><style face="normal" font="default" size="100%">Bacos-Cosma, O.</style></author><author><style face="normal" font="default" size="100%">Loman, L.</style></author><author><style face="normal" font="default" size="100%">Atash, K.</style></author><author><style face="normal" font="default" size="100%">Harbers, V.</style></author><author><style face="normal" font="default" size="100%">Stadhouders, S.</style></author><author><style face="normal" font="default" size="100%">Oosting, A. J.</style></author><author><style face="normal" font="default" size="100%">van Lynden-van Nes, A. M. T.</style></author><author><style face="normal" font="default" size="100%">Politiek, K.</style></author><author><style face="normal" font="default" size="100%">Gostynski, A.</style></author><author><style face="normal" font="default" size="100%">Christoffers, W. A.</style></author><author><style face="normal" font="default" size="100%">Garritsen, F. M.</style></author><author><style face="normal" font="default" size="100%">Flinterman, A.</style></author><author><style face="normal" font="default" size="100%">Touwslager, W. R. H.</style></author><author><style face="normal" font="default" size="100%">Velstra, B.</style></author><author><style face="normal" font="default" size="100%">Stewart, S. M.</style></author><author><style face="normal" font="default" size="100%">van Erp, F. C.</style></author><author><style face="normal" font="default" size="100%">Galimont-Collen, A. F. S.</style></author><author><style face="normal" font="default" size="100%">Schuttelaar, M. A.</style></author><author><style face="normal" font="default" size="100%">de Graaf, M.</style></author><author><style face="normal" font="default" size="100%">de Bruin-Weller, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Expertise Centre for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Centre Utrecht, Utrecht, the Netherlands.&#xD;Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.&#xD;Department of Dermatology, University Medical Centre Groningen, Groningen, the Netherlands.&#xD;Department of Dermatology, Radboud University Medical Centre, Nijmegen, the Netherlands.&#xD;Department of Dermatology, Reinier de Graaf Hospital, Delft, the Netherlands.&#xD;Department of Dermatology, Spaarne Gasthuis, Hoofddorp, the Netherlands.&#xD;Department of Dermatology, Meander Medical Centre, Amersfoort, the Netherlands.&#xD;Department of Dermatology, Frisius Medical Centre, Leeuwarden, the Netherlands.&#xD;Department of Dermatology, Maastricht University Medical Centre+, Maastricht, the Netherlands.&#xD;GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.&#xD;Department of Dermatology, Isala Hospital, Zwolle, the Netherlands.&#xD;Department of Dermatology, Haga Hospital, Den Haag, the Netherlands.&#xD;Department of Dermatolog, Diakonessenhuis, Utrecht, the Netherlands.&#xD;Department of Dermatology, Catharina Hospital, Eindhoven, the Netherlands.&#xD;Department of Dermatology, St Antonius Hospital, Nieuwegein, the Netherlands.&#xD;Department of Dermatology, IJsselland Hospital, Capelle aan den IJssel, the Netherlands.&#xD;Department of Dermatology, TerGooi Medical Centre, Hilversum, the Netherlands.&#xD;Department of Dermatology, Bravis Hospital, Bergen op Zoom, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">personlized medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 9</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41363469</style></accession-num><notes><style face="normal" font="default" size="100%">van der Gang, Lian F&#xD;Boesjes, Celeste M&#xD;Zuithoff, Nicolaas P A&#xD;Haeck, Inge&#xD;Bacos-Cosma, Octavian&#xD;Loman, Laura&#xD;Atash, Keneshka&#xD;Harbers, Veroniek&#xD;Stadhouders, Simone&#xD;Oosting, Albert J&#xD;van Lynden-van Nes, Anneke M T&#xD;Politiek, Klaziena&#xD;Gostynski, Antoni&#xD;Christoffers, Wianda A&#xD;Garritsen, Floor M&#xD;Flinterman, Annebeth&#xD;Touwslager, Wouter R H&#xD;Velstra, Berit&#xD;Stewart, Shiarra M&#xD;van Erp, Francine C&#xD;Galimont-Collen, Annemie F S&#xD;Schuttelaar, Marie-Louise A&#xD;de Graaf, Marlies&#xD;de Bruin-Weller, Marjolein S&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec 9. doi: 10.1111/all.70187.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41363469</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70187</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1567</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1567</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology &amp; Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;McMaster Immunology Research Centre (MIRC), Department of Pathology &amp; Molecular Medicine, McMaster University, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drug-induced IgG-neutrophil-mediated anaphylaxis in humans: Uncovered!</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">484-485</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2019/11/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anaphylaxis/blood/*complications</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Hypersensitivity/blood/*complications/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G/blood/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Neuromuscular Blocking Agents/*adverse effects/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophils/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgG/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31736087</style></accession-num><notes><style face="normal" font="default" size="100%">Jimenez-Saiz, Rodrigo&#xD;eng&#xD;IJCI-2016-27619/Ministerio de Economia y Competitividad/International&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Feb;75(2):484-485. doi: 10.1111/all.14118. Epub 2019 Dec 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31736087</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14118</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3052</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3052</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leonardi, A.</style></author><author><style face="normal" font="default" size="100%">Bozkurt, B.</style></author><author><style face="normal" font="default" size="100%">Silva, D.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Baudouin, C.</style></author><author><style face="normal" font="default" size="100%">Atanaskovic-Markovic, M.</style></author><author><style face="normal" font="default" size="100%">Sharma, V.</style></author><author><style face="normal" font="default" size="100%">Doan, S.</style></author><author><style face="normal" font="default" size="100%">Agarwal, S.</style></author><author><style face="normal" font="default" size="100%">Perez-Formigo, D.</style></author><author><style face="normal" font="default" size="100%">Vasconcelos, M. J.</style></author><author><style face="normal" font="default" size="100%">Baudouin, F. B.</style></author><author><style face="normal" font="default" size="100%">Chorzepa, G.</style></author><author><style face="normal" font="default" size="100%">Fauquert, J. L.</style></author><author><style face="normal" font="default" size="100%">Calder, V.</style></author><author><style face="normal" font="default" size="100%">Demoly, P.</style></author><author><style face="normal" font="default" size="100%">Delgado, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ophthalmology Unit, Department of Neuroscience, University of Padova, Padova, Italy.&#xD;Department of Ophthalmology, Selcuk University Faculty of Medicine, Konya, Turkiye.&#xD;Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Immunoallergology Service, Department of Medicine, ULS Sao Joao, Porto, Portugal.&#xD;Laboratory for Integrative and Translational Research in Population Health (ITR), EPIUnit-Institute of Public Health, University of Porto, Porto, Portugal.&#xD;Departement of Dermatology and Allergy Center, Odense University Hospital, University of Southern Denmark, Odense, Denmark.&#xD;Hopital National de la Vision des 15-20, INSERM-DGOS CIC 1423, IHU FOReSIGHT, Paris, France.&#xD;University Paris Saclay, Versailles St Quentin, Paris, France.&#xD;Faculty of Medicine, University Children&apos;s Hospital of Belgrade, University of Belgrade, Belgrade, Serbia.&#xD;Royal Manchester Children&apos;s Hospital, Manchester, UK.&#xD;Lydia Becker Institute of Immunology, and Inflammation, University of Manchester, Manchester, UK.&#xD;Ophthalmology, Fondation A de Rothschild and Hopital Bichat, Paris, France.&#xD;CJ Shah Cornea Services/Dr G Sitalakshmi Memorial Clinic for Ocular Surface Disorders, Medical Research Foundation, Chennai, Tamil Nadu, India.&#xD;Department of Ophthalmology, Hospital Universitario de Torrejon, Madrid, Spain.&#xD;Unidade de Imunoalergologia, Hospital Lusiadas Porto, Lusiadas Saude, Porto, Portugal.&#xD;Faculte de Pharmacie de Paris, Universite Paris Cite, Paris, France.&#xD;Sanatorio Parque, Rosario, Argentina.&#xD;Pediatric Allergy Unit, University Hospital Center Estaing, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.&#xD;UCL Institute of Ophthalmology, London, UK.&#xD;Division of Allergy, Department of Pulmonology, Allergy and Thoracic Oncology, University Hospital of Montpellier, Montpellier, France.&#xD;Allergy Unit, CUF Porto Hospital &amp; Institute, Porto, Portugal.&#xD;RISE-Health, Department of Pathology, Faculty of Medicine, Alameda Prof. Hernani Monteiro, University of Porto, Porto, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drug-Induced Periocular and Ocular Surface Disorders: An EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2953-2972</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/09/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eye Diseases/diagnosis/etiology/therapy/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug-Related Side Effects and Adverse Reactions/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Dry Eye Syndromes</style></keyword><keyword><style face="normal" font="default" size="100%">biological treatments</style></keyword><keyword><style face="normal" font="default" size="100%">drug related blepharoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">ocular allergy</style></keyword><keyword><style face="normal" font="default" size="100%">ocular drug hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default" size="100%">severe cutaneous adverse reactions</style></keyword><keyword><style face="normal" font="default" size="100%">Thea, SIFI. Christophe Baudouin: Consultancy for Bausch &amp; Lomb, Glaukos, Horus</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Oculis, Santen, and Thea. Vibha Sharma: Consultancy for DBV, Novartis.</style></keyword><keyword><style face="normal" font="default" size="100%">Jasper Therapeutics. Serge Doan: Received honoraria from Alcon, Almirall, Bausch</style></keyword><keyword><style face="normal" font="default" size="100%">&amp; Lomb, Horus, Leo Pharma, Sanofi, Santen, Thea. All other authors declare no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41025570</style></accession-num><abstract><style face="normal" font="default" size="100%">Various systemic and topical medications can induce ocular and periocular cutaneous adverse effects (AEs), ranging from mild to severe. These AEs may lead to ocular surface (OS) damage and, in some cases, life-threatening complications. Drug-induced ocular adverse reactions are generally classified into two primary categories: toxic reactions and/or allergic hypersensitivity reactions, which can be IgE or non-IgE-mediated. Systemic antibiotics, antivirals, and anticonvulsants can trigger adverse reactions that may involve the OS. Drugs like antihistamines, beta-blockers, antipsychotics, antidepressants, and isotretinoin are linked to dry eye disease. Topical treatments-including antibiotics, antiglaucoma medications, preservatives, contact lens solutions, and cosmetics-may elicit allergic or toxic ocular diseases. Recent evidence implicates ocular surface AEs in patients undergoing biological treatments for oncological diseases and atopic dermatitis. Epidermal growth factor receptor inhibitors, used in the treatment of several cancers, have been associated with conjunctivitis, meibomitis, dry eye, periocular skin changes, and trichomegaly. Similarly, dupilumab, the first biologic approved for treating moderate-to-severe atopic dermatitis, has also been linked to OS disease with blepharoconjunctivitis. This position paper provides a comprehensive overview of the clinical presentations, diagnostic approaches, and treatment strategies for drug-induced ocular AEs, integrating the latest literature and clinical guidelines.</style></abstract><notes><style face="normal" font="default" size="100%">Leonardi, Andrea&#xD;Bozkurt, Banu&#xD;Silva, Diana&#xD;Mortz, Charlotte G&#xD;Baudouin, Christophe&#xD;Atanaskovic-Markovic, Marina&#xD;Sharma, Vibha&#xD;Doan, Serge&#xD;Agarwal, Shweta&#xD;Perez-Formigo, Daniel&#xD;Vasconcelos, Maria Joao&#xD;Baudouin, Francoise-Brignole&#xD;Chorzepa, Gonzalo&#xD;Fauquert, Jean-Luc&#xD;Calder, Virginia&#xD;Demoly, Pascal&#xD;Delgado, Luis&#xD;eng&#xD;EAACI ExCom/&#xD;Consensus Development Conference&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):2953-2972. doi: 10.1111/all.70074. Epub 2025 Sep 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41025570</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590328</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70074</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1276</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1276</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thomson, P. J.</style></author><author><style face="normal" font="default" size="100%">Kafu, L.</style></author><author><style face="normal" font="default" size="100%">Meng, X.</style></author><author><style face="normal" font="default" size="100%">Snoeys, J.</style></author><author><style face="normal" font="default" size="100%">De Bondt, A.</style></author><author><style face="normal" font="default" size="100%">De Maeyer, D.</style></author><author><style face="normal" font="default" size="100%">Wils, H.</style></author><author><style face="normal" font="default" size="100%">Leclercq, L.</style></author><author><style face="normal" font="default" size="100%">Vinken, P.</style></author><author><style face="normal" font="default" size="100%">Naisbitt, D. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.&#xD;Drug Metabolism and Pharmacokinetics, Janssen R&amp;D, Beerse, Belgium.&#xD;Discovery Sciences, Janssen R&amp;D, Beerse, Belgium.&#xD;Non-Clinical Safety, Janssen R&amp;D, Beerse, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drug-specific T-cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1825-1835</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/11/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">CD4-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Clone Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear</style></keyword><keyword><style face="normal" font="default" size="100%">Liver</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Activation</style></keyword><keyword><style face="normal" font="default" size="100%">*Pharmaceutical Preparations</style></keyword><keyword><style face="normal" font="default" size="100%">Pyridines</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Thiazines</style></keyword><keyword><style face="normal" font="default" size="100%">T-lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">drug-induced liver injury</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune system</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33150583</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atabecestat is an orally administered BACE inhibitor developed to treat Alzheimer&apos;s disease. Elevations in hepatic enzymes were detected in a number of in trial patients, which resulted in termination of the drug development programme. Immunohistochemical characterization of liver tissue from an index case of atabecestat-mediated liver injury revealed an infiltration of T-lymphocytes in areas of hepatocellular damage. This coupled with the fact that liver injury had a delayed onset suggests that the adaptive immune system may be involved in the pathogenesis. The aim of this study was to generate and characterize atabecestat(metabolite)-responsive T-cell clones from patients with liver injury. METHODS: Peripheral blood mononuclear cells were cultured with atabecestat and its metabolites (diaminothiazine [DIAT], N-acetyl DIAT &amp; epoxide) and cloning was attempted in a number of patients. Atabecestat(metabolite)-responsive clones were analysed in terms of T-cell phenotype, function, pathways of T-cell activation and cross-reactivity with structurally related compounds. RESULTS: CD4(+) T-cell clones activated with the DIAT metabolite were detected in 5 out of 8 patients (up to 4.5% cloning efficiency). Lower numbers of CD4(+) and CD8(+) clones displayed reactivity against atabecestat. Clones proliferated and secreted IFN-gamma, IL-13 and cytolytic molecules following atabecestat or DIAT stimulation. Certain atabecestat and DIAT-responsive clones cross-reacted with N-acetyl DIAT; however, no cross-reactivity was observed between atabecestat and DIAT. CD4(+) clones were activated through a direct, reversible compound-HLA class II interaction with no requirement for protein processing. CONCLUSION: The detection of atabecestat metabolite-responsive T-cell clones activated via a pharmacological interactions pathway in patients with liver injury is indicative of an immune-based mechanism for the observed hepatic enzyme elevations.</style></abstract><notes><style face="normal" font="default" size="100%">Thomson, Paul J&#xD;Kafu, Laila&#xD;Meng, Xiaoli&#xD;Snoeys, Jan&#xD;De Bondt, An&#xD;De Maeyer, Dries&#xD;Wils, Hans&#xD;Leclercq, Laurent&#xD;Vinken, Petra&#xD;Naisbitt, Dean J&#xD;eng&#xD;G0700654/MRC_/Medical Research Council/United Kingdom&#xD;MR/R009635/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1825-1835. doi: 10.1111/all.14652. Epub 2020 Nov 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33150583</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14652</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>262</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">262</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vijeyakumaran, M.</style></author><author><style face="normal" font="default" size="100%">Jawhri, M. A.</style></author><author><style face="normal" font="default" size="100%">Fortunato, J.</style></author><author><style face="normal" font="default" size="100%">Solomon, L.</style></author><author><style face="normal" font="default" size="100%">Shrestha Palikhe, N.</style></author><author><style face="normal" font="default" size="100%">Vliagoftis, H.</style></author><author><style face="normal" font="default" size="100%">Cameron, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology and Laboratory Medicine, Schulich School of Medicine &amp; Dentistry, Western University, London, Ontario, Canada.&#xD;Division of Pulmonary Medicine, Department of Medicine and Alberta Respiratory Centre, University of Alberta, Edmonton, Alberta, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dual activation of estrogen receptor alpha and glucocorticoid receptor upregulate CRTh2-mediated type 2 inflammation; mechanism driving asthma severity in women?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">767-779</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/10/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Glucocorticoid/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Estrogen Receptor alpha/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Immunologic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Prostaglandin/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Glucocorticoids/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandin D2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 cells</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">estrogen</style></keyword><keyword><style face="normal" font="default" size="100%">glucocorticoid</style></keyword><keyword><style face="normal" font="default" size="100%">sex differences</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36207765</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Type 2-high asthma is characterized by elevated levels of circulating Th2 cells and eosinophils, cells that express chemoattractant-homologous receptor expressed on Th2 cells (CRTh2). Severe asthma is more common in women than men; however, the underlying mechanism(s) remain elusive. Here we examined whether the relationship between severe asthma and type 2 inflammation differs by sex and if estrogen influences Th2 cell response to glucocorticoid (GC). METHODS: Type 2 inflammation and the proportion of blood Th2 cells (CD4(+) CRTh2(+) ) were assessed in whole blood from subjects with asthma (n = 66). The effects of GC and estrogen receptor alpha (ERalpha) agonist on in vitro differentiated Th2 cells were examined. Expression of CRTh2, type 2 cytokines and degree of apoptosis (Annexin V(+) , 7-AAD) were determined by flow cytometry, qRT-PCR, western blot and ELISA. RESULTS: In severe asthma, the proportion of circulating Th2 cells and hospitalizations were higher in women than men. Women with severe asthma also had more Th2 cells and serum IL-13 than women with mild/moderate asthma. Th2 cells, eosinophils and CRTh2 mRNA correlated with clinical characteristics associated with asthma control in women but not men. In vitro, GC and ERalpha agonist treated Th2 cells exhibited less apoptosis, more CRTh2 as well as IL-5 and IL-13 following CRTh2 activation than Th2 cells treated with GC alone. CONCLUSION: Women with severe asthma had higher levels of circulating Th2 cells than men, which may be due to estrogen modifying the effects of GC, enhancing Th2 cell survival and type 2 cytokine production.</style></abstract><notes><style face="normal" font="default" size="100%">Vijeyakumaran, Meerah&#xD;Jawhri, MohdWessam Al&#xD;Fortunato, Jenna&#xD;Solomon, Lauren&#xD;Shrestha Palikhe, Nami&#xD;Vliagoftis, Harissios&#xD;Cameron, Lisa&#xD;eng&#xD;CIHR/Canada&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):767-779. doi: 10.1111/all.15543. Epub 2022 Oct 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36207765</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15543</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3078</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3078</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scala, E.</style></author><author><style face="normal" font="default" size="100%">Villella, V.</style></author><author><style face="normal" font="default" size="100%">Abeni, D.</style></author><author><style face="normal" font="default" size="100%">Giani, M.</style></author><author><style face="normal" font="default" size="100%">Guerra, E. C.</style></author><author><style face="normal" font="default" size="100%">Locanto, M.</style></author><author><style face="normal" font="default" size="100%">Meneguzzi, G.</style></author><author><style face="normal" font="default" size="100%">Pirrotta, L.</style></author><author><style face="normal" font="default" size="100%">Quaratino, D.</style></author><author><style face="normal" font="default" size="100%">Zaffiro, A.</style></author><author><style face="normal" font="default" size="100%">Caprini, E.</style></author><author><style face="normal" font="default" size="100%">Barrale, M.</style></author><author><style face="normal" font="default" size="100%">Brusca, I.</style></author><author><style face="normal" font="default" size="100%">Pravettoni, V.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Villalta, D.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fondazione Luigi Maria Monti, IDI-IRCCS, Rome, Italy.&#xD;U.O.C of Clinical Pathology, Buccheri La Ferla Hospital Palermo, Palermo, Italy.&#xD;Department of Internal Medicine, Fondazione IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Allergy and Clinical Immunology Unit, San Giovanni di Dio Hospital, Florence, Italy.&#xD;S.C. di Immunologia e Allergologia di Laboratorio, PO S. Maria degli Angeli, Pordenone, Italy.&#xD;Ambulatorio di Allergologia, Clinica San Carlo, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Dual Face of Wheat and Cereal Reactivity: Molecular Divergence Between Soluble and Gluten-Derived Allergens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40960211</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cereal allergy comprises a heterogeneous spectrum of sensitization patterns directed toward water-soluble and gluten-derived proteins. The role of molecular cross-reactivity with homologous allergens from other cereals remains only partially understood. OBJECTIVE: To investigate IgE reactivity to major wheat allergens (Tri a 14, Tri a 19, Tri a 30) and their homologs across cereals and pseudocereals, integrating bioinformatic, epidemiological, and clinical data. METHODS: Sequence homology was assessed using BLAST analysis across cereal and pseudocereal proteomes. IgE reactivity was evaluated in 17,510 patients using two multiplex platforms (ImmunoCAP ISAC and ALEX2). Clinical data were available for 7201 individuals. RESULTS: Tri a 14 displayed high sequence identity with multiple cereal nsLTPs, including a hitherto undefined maize-derived protein (72%), suggesting broad cross-reactivity, whereas Zea m 14 showed higher identity with Pru p 3 than with Tri a 14. Homologs of Tri a 30 and Tri a 19 were found in spelt and durum wheat. Sensitization to wheat allergens was rare (3.9%); Tri a 14 was the most frequent (64%), followed by Tri a 30 (23%) and Tri a 19 (18%). The limited cases of Tri a 14 or Tri a 19 were specifically associated with severe reactions and WDEIA. Limited co-sensitization indicated distinct IgE pathways to soluble and gluten-related proteins. CONCLUSIONS: IgE profiling revealed distinct cross-reactivity patterns across cereals. Tri a 14 frequently co-sensitized with nsLTPs from both gluten-containing and gluten-free cereals, while Tri a 19 was exclusive to gluten-containing species. These findings support the need to expand molecular diagnostic panels to enhance clinical accuracy and guide dietary recommendations.</style></abstract><notes><style face="normal" font="default" size="100%">Scala, Enrico&#xD;Villella, Valeria&#xD;Abeni, Damiano&#xD;Giani, Mauro&#xD;Guerra, Emma Cristina&#xD;Locanto, Maria&#xD;Meneguzzi, Giorgia&#xD;Pirrotta, Lia&#xD;Quaratino, Donato&#xD;Zaffiro, Alessandra&#xD;Caprini, Elisabetta&#xD;Barrale, Maria&#xD;Brusca, Ignazio&#xD;Pravettoni, Valerio&#xD;Cecchi, Lorenzo&#xD;Villalta, Danilo&#xD;Asero, Riccardo&#xD;eng&#xD;Ministero della Salute/&#xD;Denmark&#xD;Allergy. 2025 Sep 17. doi: 10.1111/all.70062.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40960211</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70062</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2832</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2832</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Murphy, M. B.</style></author><author><style face="normal" font="default" size="100%">Vitale, L.</style></author><author><style face="normal" font="default" size="100%">O&apos;Neill, T.</style></author><author><style face="normal" font="default" size="100%">Maurer, D. M.</style></author><author><style face="normal" font="default" size="100%">Malenchek, L.</style></author><author><style face="normal" font="default" size="100%">Crocker, A.</style></author><author><style face="normal" font="default" size="100%">Patterson, C.</style></author><author><style face="normal" font="default" size="100%">Mills-Chen, L.</style></author><author><style face="normal" font="default" size="100%">Saley, V.</style></author><author><style face="normal" font="default" size="100%">Antczak, N. M.</style></author><author><style face="normal" font="default" size="100%">Boyer, J. M.</style></author><author><style face="normal" font="default" size="100%">McManus, K. M.</style></author><author><style face="normal" font="default" size="100%">Montanari, N. R.</style></author><author><style face="normal" font="default" size="100%">Hammond, R. A.</style></author><author><style face="normal" font="default" size="100%">Goldstein, J.</style></author><author><style face="normal" font="default" size="100%">Thomas, L. J.</style></author><author><style face="normal" font="default" size="100%">Keler, T.</style></author><author><style face="normal" font="default" size="100%">Alvarado, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Celldex Therapeutics, Inc., Hampton, New Jersey, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX-622</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3115-3126</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Cytokines/antagonists &amp; inhibitors/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Thymic Stromal Lymphopoietin</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Bispecific/pharmacology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cell Factor/immunology/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Macaca fascicularis</style></keyword><keyword><style face="normal" font="default" size="100%">Cdx-622</style></keyword><keyword><style face="normal" font="default" size="100%">Scf</style></keyword><keyword><style face="normal" font="default" size="100%">Tslp</style></keyword><keyword><style face="normal" font="default" size="100%">bispecific antibody</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">K.M.M., N.R.M., R.A.H., J.G., L.J.T., T.K., and D.A. are full-time employees of</style></keyword><keyword><style face="normal" font="default" size="100%">Celldex Therapeutics.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39976188</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Mast cells (MCs) respond to an array of allergens that drive allergic and inflammatory diseases. Stem cell factor (SCF), the ligand for the receptor KIT, is required for MC survival and function. Thymic stromal lymphopoietin (TSLP) is an alarmin that promotes Type 2 inflammation in asthma and other inflammatory diseases. We describe CDX-622, a bispecific antibody (bsAb), that targets both SCF and TSLP to neutralize these distinct cytokines. METHODS: The bsAb CDX-622 was developed from novel antagonist monoclonal antibodies (mAbs) to SCF (SCF-12) and TSLP (1D10). CDX-622 encodes the full-length 1D10 mAb and the single-chain variable fragment of SCF-12, linked to the C-terminus of the 1D10 heavy chain. CDX-622 was modified to prevent Fcgamma receptor interactions and enhance FcRn binding. CDX-622 was tested using in vitro assays of MC and dendritic cell (DC) activation, an ex vivo human skin model, and in vivo studies in nonhuman primates. RESULTS: Novel SCF and TSLP mAbs with neutralizing activity were generated. The bsAb CDX-622 potently inhibited SCF-driven MC degranulation and TSLP-mediated CCL17 release by DCs. In human skin samples treated with SCF and TSLP, CDX-622 markedly reduced proinflammatory, MC, and DC-related RNA signatures. Additionally, CDX-622 and SCF-12 mAb administered to cynomolgus macaques (Macaca fascicularis) had a profound effect on MCs without any observed toxicity. CONCLUSIONS: CDX-622 is a potent inhibitor of MCs through the neutralization of SCF and effectively blocks Type 2 inflammatory responses driven by TSLP. Dual inhibition of these cytokines may lead to improved clinical outcomes in certain inflammatory disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Murphy, Michael B&#xD;Vitale, Laura&#xD;O&apos;Neill, Thomas&#xD;Maurer, Deena M&#xD;Malenchek, Linda&#xD;Crocker, Andrea&#xD;Patterson, Colleen&#xD;Mills-Chen, Laura&#xD;Saley, Virginia&#xD;Antczak, Nicole M&#xD;Boyer, James M&#xD;McManus, Kelly M&#xD;Montanari, Noe Rico&#xD;Hammond, Russell A&#xD;Goldstein, Joel&#xD;Thomas, Lawrence J&#xD;Keler, Tibor&#xD;Alvarado, Diego&#xD;eng&#xD;Celldex Therapeutics/&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3115-3126. doi: 10.1111/all.16509. Epub 2025 Feb 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39976188</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590333</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16509</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2897</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2897</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Portacci, A.</style></author><author><style face="normal" font="default" size="100%">Poto, R.</style></author><author><style face="normal" font="default" size="100%">Varricchi, G.</style></author><author><style face="normal" font="default" size="100%">Carpagnano, G. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University &quot;Aldo Moro&quot;, Bari, Italy.&#xD;Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, World Allergy Organization (WAO) Center of Excellence, Naples, Italy.&#xD;Istituti Clinici Scientifici Maugeri-IRCCS Scientific Institute of Telese Terme, Benevento, Italy.&#xD;Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab and Blood Eosinophilia: A Disease-Specific Phenomenon?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1811-1814</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/06/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Copd</style></keyword><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">Dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">hypereosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">speakers&apos; bureaus, manuscript writing, or educational events from Astrazeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Chiesi, Sanofi. Remo Poto reported personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Astrazeneca and GSK. Gilda Varricchi reported research support from Astrazeneca.</style></keyword><keyword><style face="normal" font="default" size="100%">Giovanna Elisiana Carpagnano reported grants or contracts from Astrazeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, GlaxoSmithKline, Sanofi, Grifols</style></keyword><keyword><style face="normal" font="default" size="100%">payment or honoraria for lectures,</style></keyword><keyword><style face="normal" font="default" size="100%">presentations, speakers, bureaus, manuscript writing, or educational events from</style></keyword><keyword><style face="normal" font="default" size="100%">Astrazeneca, GlaxoSmithKline, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">support for attending meetings and/or</style></keyword><keyword><style face="normal" font="default" size="100%">travel from Astrazeneca, Menarini, Chiesi.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40492692</style></accession-num><notes><style face="normal" font="default" size="100%">Portacci, Andrea&#xD;Poto, Remo&#xD;Varricchi, Gilda&#xD;Carpagnano, Giovanna Elisiana&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1811-1814. doi: 10.1111/all.16610. Epub 2025 Jun 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40492692</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186584</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16610</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2749</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2749</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author><author><style face="normal" font="default" size="100%">Sindher, S. B.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Leflein, J. G.</style></author><author><style face="normal" font="default" size="100%">Spergel, J. M.</style></author><author><style face="normal" font="default" size="100%">Petroni, D. H.</style></author><author><style face="normal" font="default" size="100%">Jones, S. M.</style></author><author><style face="normal" font="default" size="100%">Casale, T. B.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Carr, W. W.</style></author><author><style face="normal" font="default" size="100%">Shreffler, W. G.</style></author><author><style face="normal" font="default" size="100%">Wood, R. A.</style></author><author><style face="normal" font="default" size="100%">Wambre, E.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Akinlade, B.</style></author><author><style face="normal" font="default" size="100%">Atanasio, A.</style></author><author><style face="normal" font="default" size="100%">Orengo, J. M.</style></author><author><style face="normal" font="default" size="100%">Hamilton, J. D.</style></author><author><style face="normal" font="default" size="100%">Kamal, M. A.</style></author><author><style face="normal" font="default" size="100%">Hooper, A. T.</style></author><author><style face="normal" font="default" size="100%">Patel, K.</style></author><author><style face="normal" font="default" size="100%">Laws, E.</style></author><author><style face="normal" font="default" size="100%">Mannent, L. P.</style></author><author><style face="normal" font="default" size="100%">Adelman, D. C.</style></author><author><style face="normal" font="default" size="100%">Ratnayake, A.</style></author><author><style face="normal" font="default" size="100%">Radin, A. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.&#xD;Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.&#xD;Allergy &amp; Immunology Association of Michigan, Ypsilanti, Michigan, USA.&#xD;Children&apos;s Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;Seattle Allergy &amp; Asthma Research Institute, Seattle, Washington, USA.&#xD;Department of Pediatrics, Division of Allergy and Immunology, University of Arkansas for Medical Sciences and Arkansas Children&apos;s Hospital, Little Rock, Arkansas, USA.&#xD;Division of Allergy &amp; Immunology, University of South Florida, Tampa, Florida, USA.&#xD;Department of Pediatrics, Division of Allergy &amp; Immunology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Allergy &amp; Asthma Associates of Southern California, Food Allergy Center of Southern California, Southern California Research, Mission Viejo, California, USA.&#xD;Food Allergy Center and Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Pediatric Allergy &amp; Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.&#xD;Benaroya Research Institute, Seattle, Washington, USA.&#xD;Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.&#xD;Former Employee, Sanofi, Cambridge, Massachusetts, USA.&#xD;Sanofi, Bridgewater, New Jersey, USA.&#xD;Sanofi, Chilly-Mazarin, France.&#xD;Department of Medicine, Allergy/Immunology, University of California, San Francisco, California, USA.&#xD;Aimmune Therapeutics, Brisbane, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">827-842</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/12/14 20:07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Oit</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Consortium for Food Allergy Research, DBV Technologies, Food Allergy Research &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Education, National Institute of Allergy and Infectious Disease, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, and has been an advisory board member for Alladapt, Allergenis,</style></keyword><keyword><style face="normal" font="default" size="100%">Intrommune Therapeutics, Genentech, Novartis, Sanofi. S.B.S. reports research</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Aimmune, the Consortium for Food Allergy Research (CoFAR), FARE, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, the National Institute of Allergy and Infectious Diseases (NIAID),</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Regeneron Pharmaceuticals Inc., and Sanofi, and is an advisory board</style></keyword><keyword><style face="normal" font="default" size="100%">member for DBV Technologies and a consultant for Genentech. K.C.N. has received</style></keyword><keyword><style face="normal" font="default" size="100%">research grants from Food Allergy Research &amp; Education, National Heart, Lung, and</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Institute, National Institute of Allergy and Infectious Diseases, National</style></keyword><keyword><style face="normal" font="default" size="100%">Institute of Environmental Health Sciences, holds stock options in ClostraBio,</style></keyword><keyword><style face="normal" font="default" size="100%">IgGenix, ImmuneID, Seed Health, is involved in directorship for World Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Organization Center of Excellence for Stanford, is an advisor for Cour Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">receives consultancy fees from Eli Lilly, Excellergy, Phylaxis, Red Tree</style></keyword><keyword><style face="normal" font="default" size="100%">Ventures, is a co-founder of Alladapt, Before Brands, ClostraBio, IgGenix,</style></keyword><keyword><style face="normal" font="default" size="100%">ImmuneID, Latitude, Seed Health, is a National Scientific Committee member for</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance Network, National Institutes of Health clinical research</style></keyword><keyword><style face="normal" font="default" size="100%">centers, has issued patents (US12/686,121 and US12/610,94), and is a licensee</style></keyword><keyword><style face="normal" font="default" size="100%">(US15/048,609). J.G.L. has no conflicts to disclose. J.M.S. has received research</style></keyword><keyword><style face="normal" font="default" size="100%">grants from National Institutes of Health, Regeneron/Sanofi, has received</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy fees from Allakos, Celgene, Regeneron/Sanofi, and has received</style></keyword><keyword><style face="normal" font="default" size="100%">royalties from UpToDate. D.H.P. has received speakers&apos; bureau fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca and is a consultant for HollisterStier. S.M.J. has received grants</style></keyword><keyword><style face="normal" font="default" size="100%">and/or contracts for the conduct of research and clinical trials from Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, ALK-Abello Inc., Aravax, PTY, Astellas Pharma Inc., DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Genentech, Novartis, Regeneron, and Food Allergy Research and</style></keyword><keyword><style face="normal" font="default" size="100%">Education (FARE), NIH-NIAID, Immune Tolerance Network, and she serves on the</style></keyword><keyword><style face="normal" font="default" size="100%">board of directors for LAmAb Bio Inc. T.B.C. has received research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">American Lung Association, Genentech, National Institutes of Health, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Patient-Centered Outcomes Research Institute, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Boehringer Ingelheim, Genentech, Novartis, Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">and speakers&apos;</style></keyword><keyword><style face="normal" font="default" size="100%">bureau fees from Genentech, Sanofi. J.W. has received research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune, DBV Technologies, National Institute of Allergy and Infectious Diseases,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron and is a consultant for ALK Abello, Jubilant HollisterStier. WWC has</style></keyword><keyword><style face="normal" font="default" size="100%">received speaker&apos;s fees from AstraZeneca, Boehringer Ingelheim, Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, Teva, and consultancy fees from Aerocrine, Alcon Laboratories,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Baxalta, Boehringer Ingelheim, Circassia, CSL Behring, Genentech,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Greer Laboratories, Grifols, Horizon Pharma, Kaleo, Meda, Mylan,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Pfizer, Regeneron, Sanofi, Shire, Teva, Valeant Pharmaceuticals. WGS</style></keyword><keyword><style face="normal" font="default" size="100%">has received research grants from National Institutes of Health,</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune/NestleAngany, Allergy Therapeutics, Celgene, Food Allergy Science</style></keyword><keyword><style face="normal" font="default" size="100%">Initiative, Genentech, Novartis, Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy fees from Aimmune, Food</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Research &amp; Education, Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">and royalties from UpToDate. R.A.W. has</style></keyword><keyword><style face="normal" font="default" size="100%">received research grants from Aimmune, DBV Technologies, Food Allergy Research &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Education, Genentech, National Institutes of Health, Novartis, Regeneron, Siolta,</style></keyword><keyword><style face="normal" font="default" size="100%">and royalties from UpToDate. E.W. has received grant support from Aimmune,</style></keyword><keyword><style face="normal" font="default" size="100%">AnaptysBio, Astellas, Cour Pharma, Food Allergy Research &amp; Education, Immune</style></keyword><keyword><style face="normal" font="default" size="100%">Tolerance Network, National Institute of Allergy and Infectious Disease, and</style></keyword><keyword><style face="normal" font="default" size="100%">research sponsorship from Regeneron. J.L., B.A., M.A.K., A.A., and A.R.R. are</style></keyword><keyword><style face="normal" font="default" size="100%">employees of, and may hold stock and/or stock options in, Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals Inc. J.D.H. is an employee of, and may hold stock and/or stock</style></keyword><keyword><style face="normal" font="default" size="100%">options in, Regeneron Pharmaceuticals Inc. and has a patent pending</style></keyword><keyword><style face="normal" font="default" size="100%">(PCT/US2020/044958) with Regeneron Pharmaceuticals Inc. J.M.O. is an officer and</style></keyword><keyword><style face="normal" font="default" size="100%">employee at Regeneron Pharmaceuticals Inc., may hold stock and/or stock options,</style></keyword><keyword><style face="normal" font="default" size="100%">has a patent pending (PCT/US2020/0345843, PCT/US2022/0220211), and has issued</style></keyword><keyword><style face="normal" font="default" size="100%">patents (US patent numbers 10,392,439, 10,676,530, and 11,485,788). K.P., E.L.,</style></keyword><keyword><style face="normal" font="default" size="100%">and L.P.M. are employees of, and may hold stock and/or stock options in, Sanofi.</style></keyword><keyword><style face="normal" font="default" size="100%">A.T.H. is an employee of, and may hold stock and/or stock options in, Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals Inc. D.C.A. has received consultancy fees from Aimmune and has a</style></keyword><keyword><style face="normal" font="default" size="100%">patent pending (US 16/542,198</style></keyword><keyword><style face="normal" font="default" size="100%">PCT/US2019/046706</style></keyword><keyword><style face="normal" font="default" size="100%">US 16/721,805</style></keyword><keyword><style face="normal" font="default" size="100%">PCT/US2019/067634). A.R. is an employee of, and may hold stock and/or stock</style></keyword><keyword><style face="normal" font="default" size="100%">options in, Aimmune.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39673367</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Peanut allergy is a common, life-threatening food allergy in children. We evaluated whether dupilumab, which blocks the activity of interleukin (IL)-4/IL-13, enhances the efficacy of oral immunotherapy (OIT) AR101 in pediatric patients with peanut allergy. METHODS: A Phase II, multicenter, randomized, double-blind study was conducted in the USA (NCT03682770) in pediatric patients (6-&lt;/= 17 years old) with confirmed peanut allergy. Patients were randomized 2:1 to receive dupilumab + OIT or placebo + OIT during a 28-40-week up-dosing period. Patients in the dupilumab + OIT group were re-randomized 1:1 and received dupilumab + OIT or placebo + OIT during 24-week OIT maintenance, undergoing a 2044 mg (cumulative) of peanut protein double-blind, placebo-controlled food challenge (DBPCFC) following up-dosing, maintenance, and at 12-week post-treatment follow-up. RESULTS: The study enrolled 148 patients, 123 of whom were included in the modified full analysis set, with a mean age of 11.1 years. Dupilumab + OIT treatment (n = 84) led to a 20.2% increase (p &lt; 0.05) in the number of patients who passed a DBPCFC to 2044 mg (cumulative) of peanut protein following the up-dosing period versus placebo (OIT alone, n = 39). Following the OIT maintenance period, continuous dupilumab treatment improved the number of patients who passed a DBPCFC to 2044 mg (cumulative) of peanut protein versus patients continuously on OIT alone (16.6% difference [95% CI -9.7, 42.8], p = 0.2123). Safety was consistent with known dupilumab safety profile. CONCLUSIONS: Dupilumab provided a modest increase efficacy of OIT in children and adolescents with peanut allergy, though it did not provide protection against OIT-related anaphylaxis. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03793608.</style></abstract><notes><style face="normal" font="default" size="100%">Chinthrajah, R Sharon&#xD;Sindher, Sayantani B&#xD;Nadeau, Kari C&#xD;Leflein, Jeffrey G&#xD;Spergel, Jonathan M&#xD;Petroni, Daniel H&#xD;Jones, Stacie M&#xD;Casale, Thomas B&#xD;Wang, Julie&#xD;Carr, Warner W&#xD;Shreffler, Wayne G&#xD;Wood, Robert A&#xD;Wambre, Erik&#xD;Liu, Jinzhong&#xD;Akinlade, Bolanle&#xD;Atanasio, Amanda&#xD;Orengo, Jamie M&#xD;Hamilton, Jennifer D&#xD;Kamal, Mohamed A&#xD;Hooper, Andrea T&#xD;Patel, Kiran&#xD;Laws, Elizabeth&#xD;Mannent, Leda P&#xD;Adelman, Daniel C&#xD;Ratnayake, Anoshie&#xD;Radin, Allen R&#xD;eng&#xD;Sanofi and Regeneron Pharmaceuticals Inc./&#xD;Clinical Trial, Phase II&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):827-842. doi: 10.1111/all.16420. Epub 2024 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39673367</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891407</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16420</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2104</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2104</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hartmann, J.</style></author><author><style face="normal" font="default" size="100%">Moitinho-Silva, L.</style></author><author><style face="normal" font="default" size="100%">Sander, N.</style></author><author><style face="normal" font="default" size="100%">Harder, I.</style></author><author><style face="normal" font="default" size="100%">Hasler, R.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, E.</style></author><author><style face="normal" font="default" size="100%">Haufe, E.</style></author><author><style face="normal" font="default" size="100%">Kleinheinz, A.</style></author><author><style face="normal" font="default" size="100%">Abraham, S.</style></author><author><style face="normal" font="default" size="100%">Heratizadeh, A.</style></author><author><style face="normal" font="default" size="100%">Weisshaar, E.</style></author><author><style face="normal" font="default" size="100%">Schakel, K.</style></author><author><style face="normal" font="default" size="100%">Handrick, C.</style></author><author><style face="normal" font="default" size="100%">Augustin, M.</style></author><author><style face="normal" font="default" size="100%">Wollenberg, A.</style></author><author><style face="normal" font="default" size="100%">Staubach-Renz, P.</style></author><author><style face="normal" font="default" size="100%">Ertner, K.</style></author><author><style face="normal" font="default" size="100%">Sticherling, M.</style></author><author><style face="normal" font="default" size="100%">Schwarz, B.</style></author><author><style face="normal" font="default" size="100%">Quist, S.</style></author><author><style face="normal" font="default" size="100%">Wiemers, F.</style></author><author><style face="normal" font="default" size="100%">Schenck, F.</style></author><author><style face="normal" font="default" size="100%">Wildberger, J.</style></author><author><style face="normal" font="default" size="100%">Tittmann, L.</style></author><author><style face="normal" font="default" size="100%">Lieb, W.</style></author><author><style face="normal" font="default" size="100%">Schmitt, J.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Weidinger, S.</style></author><author><style face="normal" font="default" size="100%">T. REATgermany Study Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Inflammatory Skin Diseases, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.&#xD;Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany.&#xD;Center of Evidence-Based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.&#xD;Clinics for Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany.&#xD;Department of Dermatology, Medical Faculty Carl Gustav Carus, University Allergy Center, TU Dresden, Dresden, Germany.&#xD;Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Division of Occupational Dermatology, Department of Dermatology, Ruprecht-Karls University Heidelberg, Heidelberg, Germany.&#xD;Department of Dermatology, Ruprecht-Karls University Heidelberg, Heidelberg, Germany.&#xD;Practice Dr. med. Christiane Handrick, Berlin, Germany.&#xD;Institute for Health Services Research in Dermatology Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.&#xD;Clinics and Outpatient Clinics for Dermatology and Allergy, LMU Munich, Munich, Germany.&#xD;Department of Dermatology and Allergy, University Medical Center Mainz, Mainz, Germany.&#xD;Practice Dr. med. Konstantin Ertner, Nuremberg, Germany.&#xD;Department of Dermatology, University Hospital, Friedrich Alexander University Erlangen-Nuernberg, Erlangen, Germany.&#xD;Practice Dr. med. Beate Schwarz, Langenau, Germany.&#xD;Dermatology Clinic, Helix Medical Excellence Center Mainz, Mainz, Germany.&#xD;Practice Dr. med. Franca Wiemers, Leipzig, Germany.&#xD;Dermatology Center, Hannover, Germany.&#xD;Practice Dr. med. Julia Wildberger, Hautmedizin Bad Soden, Bad Soden, Germany.&#xD;Biobank PopGen and Institute of Epidemiology, Kiel University, Kiel, Germany.&#xD;Institute of Epidemiology, Kiel University, Kiel, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2290-2300</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/04/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cyclosporine/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4 Receptor alpha Subunit/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">*Staphylococcus aureus/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus hominis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37032440</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) patients display an altered skin microbiome which may not only be an indicator but also a driver of inflammation. We aimed to investigate associations among AD patients&apos; skin microbiome, clinical data, and response to systemic therapy in patients of the TREATgermany registry. METHODS: Skin swabs of 157 patients were profiled with 16S rRNA gene amplicon sequencing before and after 3 months of treatment with dupilumab or cyclosporine. For comparison, 16s microbiome data from 258 population-based healthy controls were used. Disease severity was assessed using established instruments such as the Eczema Area and Severity Index (EASI). RESULTS: We confirmed the previously shown correlation of Staphylococcus aureus abundance and bacterial alpha diversity with AD severity as measured by EASI. Therapy with Dupilumab shifted the bacterial community toward the pattern seen in healthy controls. The relative abundance of Staphylococci and in particular S. aureus significantly decreased on both lesional and non-lesional skin, whereas the abundance of Staphylococcus hominis increased. These changes were largely independent from the degree of clinical improvement and were not observed for cyclosporine. CONCLUSIONS: Systemic treatment with dupilumab but not cyclosporine tends to restore a healthy skin microbiome largely independent of the clinical response indicating potential effects of IL-4RA blockade on the microbiome.</style></abstract><notes><style face="normal" font="default" size="100%">Hartmann, Jan&#xD;Moitinho-Silva, Lucas&#xD;Sander, Nicole&#xD;Harder, Inken&#xD;Hasler, Robert&#xD;Rodriguez, Elke&#xD;Haufe, Eva&#xD;Kleinheinz, Andreas&#xD;Abraham, Susanne&#xD;Heratizadeh, Annice&#xD;Weisshaar, Elke&#xD;Schakel, Knut&#xD;Handrick, Christiane&#xD;Augustin, Matthias&#xD;Wollenberg, Andreas&#xD;Staubach-Renz, Petra&#xD;Ertner, Konstantin&#xD;Sticherling, Michael&#xD;Schwarz, Beate&#xD;Quist, Sven&#xD;Wiemers, Franca&#xD;Schenck, Florian&#xD;Wildberger, Julia&#xD;Tittmann, Lukas&#xD;Lieb, Wolfgang&#xD;Schmitt, Jochen&#xD;Werfel, Thomas&#xD;Weidinger, Stephan&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2290-2300. doi: 10.1111/all.15742. Epub 2023 Apr 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37032440</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15742</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3187</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3187</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moermans, C.</style></author><author><style face="normal" font="default" size="100%">Sabbe, M.</style></author><author><style face="normal" font="default" size="100%">Onssels, A.</style></author><author><style face="normal" font="default" size="100%">Bricmont, N.</style></author><author><style face="normal" font="default" size="100%">Bonhiver, R.</style></author><author><style face="normal" font="default" size="100%">Regnier, F.</style></author><author><style face="normal" font="default" size="100%">Graff, S.</style></author><author><style face="normal" font="default" size="100%">Gerday, S.</style></author><author><style face="normal" font="default" size="100%">Njock, M. S.</style></author><author><style face="normal" font="default" size="100%">Rosu, A.</style></author><author><style face="normal" font="default" size="100%">Paulus, V.</style></author><author><style face="normal" font="default" size="100%">Guissard, F.</style></author><author><style face="normal" font="default" size="100%">Ziant, S.</style></author><author><style face="normal" font="default" size="100%">Sanchez, C.</style></author><author><style face="normal" font="default" size="100%">Ernst, M.</style></author><author><style face="normal" font="default" size="100%">Desmet, C.</style></author><author><style face="normal" font="default" size="100%">Louis, R.</style></author><author><style face="normal" font="default" size="100%">Schleich, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Giga I3, Pneumology Research Group, Liege University, Liege, Belgium.&#xD;Department of Pneumology-Allergology, CHU of Liege, Liege, Belgium.&#xD;Biostatistics and Research Method Center, CHU of Liege, University of Liege, Liege, Belgium.&#xD;Laboratory of Cellular and Molecular Immunology, GIGA Institute and Faculty of Veterinary Medicine, Liege University, Liege, Belgium.&#xD;Exercise Physiology Lab, Department of Physical Activity and Rehabilitation Sciences, University of Liege, Liege, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab Effectiveness in Biologic-Naive and Switched Severe Asthma in Real Life</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41437843</style></accession-num><notes><style face="normal" font="default" size="100%">Moermans, Catherine&#xD;Sabbe, Mare&#xD;Onssels, Adrien&#xD;Bricmont, Noemie&#xD;Bonhiver, Romane&#xD;Regnier, France&#xD;Graff, Sophie&#xD;Gerday, Sara&#xD;Njock, Makon-Sebastien&#xD;Rosu, Adeline&#xD;Paulus, Virginie&#xD;Guissard, Francoise&#xD;Ziant, Stephanie&#xD;Sanchez, Carole&#xD;Ernst, Marie&#xD;Desmet, Christophe&#xD;Louis, Renaud&#xD;Schleich, Florence&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec 24. doi: 10.1111/all.70205.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41437843</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70205</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2543</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2543</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Gevaert, P.</style></author><author><style face="normal" font="default" size="100%">Lipworth, B.</style></author><author><style face="normal" font="default" size="100%">Mustafa, S. S.</style></author><author><style face="normal" font="default" size="100%">Lane, A. P.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Rowe, P.</style></author><author><style face="normal" font="default" size="100%">Deniz, Y.</style></author><author><style face="normal" font="default" size="100%">Kamat, S.</style></author><author><style face="normal" font="default" size="100%">Khan, A. H.</style></author><author><style face="normal" font="default" size="100%">Jacob-Nara, J.</style></author><author><style face="normal" font="default" size="100%">Siddiqui, S.</style></author><author><style face="normal" font="default" size="100%">Ruddy, M.</style></author><author><style face="normal" font="default" size="100%">Laws, E.</style></author><author><style face="normal" font="default" size="100%">Msihid, J.</style></author><author><style face="normal" font="default" size="100%">Harel, S.</style></author><author><style face="normal" font="default" size="100%">Jagerschmidt, A.</style></author><author><style face="normal" font="default" size="100%">Amin, N.</style></author><author><style face="normal" font="default" size="100%">Mannent, L.</style></author><author><style face="normal" font="default" size="100%">Rout, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Hospital of Munster, Munster, Germany.&#xD;Sun Yat-sen University, The First Affiliated Hospital, Guangzhou, China.&#xD;Ghent University, Ghent, Belgium.&#xD;University of Dundee, Dundee, UK.&#xD;Rochester Regional Health, Rochester, New York, USA.&#xD;Johns Hopkins School of Medicine, Baltimore, Maryland, USA.&#xD;Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Catalonia, Spain.&#xD;Sanofi, Bridgewater, New Jersey, USA.&#xD;Regeneron Pharmaceuticals, Tarrytown, New York, USA.&#xD;Sanofi, Gentilly, France.&#xD;Sanofi, Chilly-Mazarin, France.&#xD;Sanofi, Reading, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2858-2861</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/06/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/drug therapy/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38850227</style></accession-num><notes><style face="normal" font="default" size="100%">Bachert, Claus&#xD;Gevaert, Philippe&#xD;Lipworth, Brian&#xD;Mustafa, Syed Shahzad&#xD;Lane, Andrew P&#xD;Mullol, Joaquim&#xD;Rowe, Paul&#xD;Deniz, Yamo&#xD;Kamat, Siddhesh&#xD;Khan, Asif H&#xD;Jacob-Nara, Juby&#xD;Siddiqui, Shahid&#xD;Ruddy, Marcella&#xD;Laws, Elizabeth&#xD;Msihid, Jerome&#xD;Harel, Sivan&#xD;Jagerschmidt, Alexandre&#xD;Amin, Nikhil&#xD;Mannent, Leda&#xD;Rout, Raj&#xD;eng&#xD;Sanofi/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2858-2861. doi: 10.1111/all.16189. Epub 2024 Jun 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38850227</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16189</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1030</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1030</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maspero, J. F.</style></author><author><style face="normal" font="default" size="100%">FitzGerald, J. M.</style></author><author><style face="normal" font="default" size="100%">Pavord, I. D.</style></author><author><style face="normal" font="default" size="100%">Rice, M. S.</style></author><author><style face="normal" font="default" size="100%">Maroni, J.</style></author><author><style face="normal" font="default" size="100%">Rowe, P. J.</style></author><author><style face="normal" font="default" size="100%">Pirozzi, G.</style></author><author><style face="normal" font="default" size="100%">Amin, N.</style></author><author><style face="normal" font="default" size="100%">Ruddy, M.</style></author><author><style face="normal" font="default" size="100%">Graham, N. M. H.</style></author><author><style face="normal" font="default" size="100%">Teper, A.</style></author><author><style face="normal" font="default" size="100%">Hardin, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">FundacionCIDEA, Buenos Aires, Argentina.&#xD;University of British Columbia, Vancouver, BC, Canada.&#xD;Respiratory Medicine Unit and Oxford Respiratory, National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK.&#xD;Sanofi, Cambridge, MA, USA.&#xD;Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.&#xD;Sanofi, Bridgewater, NJ, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2621-2624</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/04/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">interleukins</style></keyword><keyword><style face="normal" font="default" size="100%">Uriach-speaker fees</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis-research grants. FitzGerald JM: AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Novartis, Teva-advisory board</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals, Inc., Sanofi-research funding paid directly to UBC</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline-unrestricted grants</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis-speaker honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">Vancouver Coastal Health-educational material. Pavord</style></keyword><keyword><style face="normal" font="default" size="100%">ID: Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Teva-speakers&apos; honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Teva-organization of educational</style></keyword><keyword><style face="normal" font="default" size="100%">events</style></keyword><keyword><style face="normal" font="default" size="100%">Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Dey</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Genentech, GlaxoSmithKline, Knopp Biosciences, Merck, Merck Sharp &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Dohme, Napp Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, Inc.,</style></keyword><keyword><style face="normal" font="default" size="100%">RespiVert, Sanofi, Schering-Plough, Teva-advisory boards</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, Chiesi, GlaxoSmithKline, Napp Pharmaceuticals, Teva-traveling grants</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi-clinical trial support. Rice MS, Rowe P, Hardin M: Sanofi-employees, may</style></keyword><keyword><style face="normal" font="default" size="100%">hold stock and/or stock options in the company. Maroni J, Amin N, Ruddy M:</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals, Inc.-employees and shareholders. Pirozzi G, Teper A:</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-former employees, may hold stock and/or stock options in the company.</style></keyword><keyword><style face="normal" font="default" size="100%">Graham NMH: Regeneron Pharmaceuticals, Inc.-former employee and shareholder.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33905544</style></accession-num><notes><style face="normal" font="default" size="100%">Maspero, Jorge F&#xD;FitzGerald, John Mark&#xD;Pavord, Ian D&#xD;Rice, Megan S&#xD;Maroni, Jaman&#xD;Rowe, Paul J&#xD;Pirozzi, Gianluca&#xD;Amin, Nikhil&#xD;Ruddy, Marcella&#xD;Graham, Neil M H&#xD;Teper, Ariel&#xD;Hardin, Megan&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2621-2624. doi: 10.1111/all.14872. Epub 2021 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33905544</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8360078</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14872</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>996</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">996</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fujieda, S.</style></author><author><style face="normal" font="default" size="100%">Matsune, S.</style></author><author><style face="normal" font="default" size="100%">Takeno, S.</style></author><author><style face="normal" font="default" size="100%">Ohta, N.</style></author><author><style face="normal" font="default" size="100%">Asako, M.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Inoue, T.</style></author><author><style face="normal" font="default" size="100%">Takahashi, Y.</style></author><author><style face="normal" font="default" size="100%">Fujita, H.</style></author><author><style face="normal" font="default" size="100%">Deniz, Y.</style></author><author><style face="normal" font="default" size="100%">Rowe, P.</style></author><author><style face="normal" font="default" size="100%">Ortiz, B.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Mannent, L. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology-Head &amp; Neck Surgery, Fukui, Japan.&#xD;Nippon Medical School, Musashi Kosugi Hospital, Kanagawa, Japan.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.&#xD;Department of Otolaryngology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.&#xD;Department of Otolaryngology, Kansai Medical University, Osaka, Japan.&#xD;Department of Ear, Nose, and Throat Science, Ghent University, Ghent, Belgium.&#xD;Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.&#xD;Sanofi K.K., Tokyo, Japan.&#xD;Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.&#xD;Sanofi, Bridgewater, NJ, USA.&#xD;Sanofi France, Chilly-Mazarin, Ile-de-France, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">186-196</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/05/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">ENT (rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps)</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">board member</style></keyword><keyword><style face="normal" font="default" size="100%">Kyorin, Mitsubishi Tanabe Pharma, and Taiho Pharma - speaker fees.</style></keyword><keyword><style face="normal" font="default" size="100%">Matsune S: Sanofi - advisory board member</style></keyword><keyword><style face="normal" font="default" size="100%">Kyorin, Meiji Seika Pharma, Mitsubishi</style></keyword><keyword><style face="normal" font="default" size="100%">Tanabe Pharma, Sanofi, Taiho Pharma, and Tanabe Pharma - speaker fees. Takeno S:</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi - advisory board member</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi - speaker fees. Ohta N: Mitsubishi Tanabe</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Sanofi, and Taiho Pharma- speaker fees. Asako M: AstraZeneca, Sanofi, and</style></keyword><keyword><style face="normal" font="default" size="100%">Taiho Pharma - speaker fees. Bachert C: ALK, ASIT Biotech, AstraZeneca, Intrexon</style></keyword><keyword><style face="normal" font="default" size="100%">Actobiotics, Novartis, Sanofi, Stallergenes Greer - advisory board member. Inoue</style></keyword><keyword><style face="normal" font="default" size="100%">T, Takahashi Y, Fujita H, Rowe P, Li Y, Mannent LP: Sano fi - employees, may hold</style></keyword><keyword><style face="normal" font="default" size="100%">stock and/or stock options in the company. Deniz Y, Ortiz B: Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Inc. - employees and shareholders.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33993501</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The human monoclonal antibody dupilumab blocks interleukin (IL)-4 andIL-13, key and central drivers of type 2 inflammation. Dupilumab, on background mometasone furoate nasal spray (MFNS), improved outcomes in the phase III SINUS-52 study (NCT02898454) in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). This posthoc analysis of SINUS-52 examined whether eosinophilic status of CRSwNP was a predictor of dupilumab efficacy. METHODS: Patients were randomized 1:1:1 to dupilumab 300 mg every 2 weeks (q2w) until week 52; dupilumab 300 mg q2w until Week 24, then 300 mg every 4 weeks until week 52; or placebo (MFNS) until week 52. Coprimary endpoints were change from baseline in nasal polyps score (NPS), nasal congestion (NC), and Lund-Mackay score assessed by CT (LMK-CT) at week 24. Patients (n = 438) were stratified by eosinophilic chronic rhinosinusitis (ECRS) status according to the Japanese Epidemiological Survey of Refractory Eosinophilic Rhinosinusitis algorithm. RESULTS: Dupilumab significantly improved NPS, NC, and LMK-CT scores versus placebo at week 24 in all ECRS subgroups (p &lt; 0.001), with improvements maintained or increased at week 52 (p &lt; 0.001). There was no significant interaction between ECRS subgroup (non-/mild or moderate/severe) and dupilumab treatment effect for all endpoints at weeks 24 and 52 (p &gt; 0.05), except LMK-CT at week 24 (p = 0.0275). Similar results were seen for the secondary endpoints. Dupilumab was well tolerated across all ECRS subgroups. CONCLUSION: Dupilumab produced consistent improvement in symptoms of severe CRSwNP irrespective of ECRS status. Therefore, blood eosinophil level may not be a suitable biomarker for dupilumab efficacy in CRSwNP.</style></abstract><notes><style face="normal" font="default" size="100%">Fujieda, Shigeharu&#xD;Matsune, Shoji&#xD;Takeno, Sachio&#xD;Ohta, Nobuo&#xD;Asako, Mikiya&#xD;Bachert, Claus&#xD;Inoue, Tomoyuki&#xD;Takahashi, Yoshinori&#xD;Fujita, Hiroyuki&#xD;Deniz, Yamo&#xD;Rowe, Paul&#xD;Ortiz, Benjamin&#xD;Li, Yongtao&#xD;Mannent, Leda P&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):186-196. doi: 10.1111/all.14906. Epub 2021 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33993501</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9290136</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14906</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>82</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">82</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spekhorst, L. S.</style></author><author><style face="normal" font="default" size="100%">van der Rijst, L. P.</style></author><author><style face="normal" font="default" size="100%">de Graaf, M.</style></author><author><style face="normal" font="default" size="100%">van Megen, M.</style></author><author><style face="normal" font="default" size="100%">Zuithoff, N. P. A.</style></author><author><style face="normal" font="default" size="100%">Knulst, A. C.</style></author><author><style face="normal" font="default" size="100%">de Bruin-Weller, M. S.</style></author><author><style face="normal" font="default" size="100%">Le, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">875-878</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/11/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36420598</style></accession-num><notes><style face="normal" font="default" size="100%">Spekhorst, Lotte S&#xD;van der Rijst, Lisa P&#xD;de Graaf, Marlies&#xD;van Megen, Maxime&#xD;Zuithoff, Nicolaas P A&#xD;Knulst, Andre C&#xD;de Bruin-Weller, Marjolein S&#xD;Le, Thuy-My&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):875-878. doi: 10.1111/all.15591. Epub 2022 Dec 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36420598</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15591</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>642</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">642</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, S. E.</style></author><author><style face="normal" font="default" size="100%">Hopkins, C.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Msihid, J.</style></author><author><style face="normal" font="default" size="100%">Guillemin, I.</style></author><author><style face="normal" font="default" size="100%">Amin, N.</style></author><author><style face="normal" font="default" size="100%">Mannent, L. P.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Siddiqui, S.</style></author><author><style face="normal" font="default" size="100%">Chuang, C. C.</style></author><author><style face="normal" font="default" size="100%">Kamat, S.</style></author><author><style face="normal" font="default" size="100%">Khan, A. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Otolaryngology-Head &amp; Neck Surgery, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;ENT Department, Guy&apos;s and St Thomas&apos; Hospitals, King&apos;s College London, London, UK.&#xD;Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Spain.&#xD;Sanofi, Chilly-Mazarin, France.&#xD;Sanofi, Lyon, France.&#xD;Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.&#xD;Sanofi, Bridgewater, New Jersey, USA.&#xD;Sanofi, Cambridge, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2211-2221</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/01/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">HRQoL</style></keyword><keyword><style face="normal" font="default" size="100%">Snot-22</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidities</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">trial funding</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals,</style></keyword><keyword><style face="normal" font="default" size="100%">Inc., Sanofi - advisory board member. Claire Hopkins: GSK, Optinose,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genzyme, Smith and Nephew - advisory board member. Joaquim Mullol: ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Genentech, GSK, Menarini, Mitsubishi Tanabe Pharma, MSD, Mylan-Meda</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, UCB, Uriach -</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial funding, advisory board member, or speaker fees</style></keyword><keyword><style face="normal" font="default" size="100%">Mylan-Meda</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Uriach - research grants. Jerome Msihid, Leda P. Mannent,</style></keyword><keyword><style face="normal" font="default" size="100%">Yongtao Li, Chien-Chia Chuang, Asif H. Khan: Sanofi - employees, may hold stock</style></keyword><keyword><style face="normal" font="default" size="100%">and/or stock options in the company. Isabelle Guillemin: Sanofi - employee at the</style></keyword><keyword><style face="normal" font="default" size="100%">time of manuscript development. Nikhil Amin, Shahid Siddiqui, Siddhesh Kamat:</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals, Inc. - employees and shareholders.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35034364</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2-mediated inflammatory disease with high symptom burden and reduced health-related quality of life (HRQoL). This report aimed to comprehensively understand the effects of dupilumab on domains of HRQoL, their individual elements, and health status in patients with severe CRSwNP from phase 3 SINUS-24 (NCT02912468) and SINUS-52 (NCT02898454) trials. METHODS: Patients were randomized to dupilumab (n = 438) or placebo (n = 286) for 24 weeks (SINUS-24), or 52 weeks (SINUS-52). Disease-specific HRQoL using 22-item sino-nasal outcome test (SNOT-22), and health status using EuroQoL-visual analog scale (EQ-VAS) was evaluated in the pooled intention-to-treat (ITT) population (Week 24), SINUS-52 ITT (Week 52) and in the subgroups with/without asthma; non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD); and prior sinus surgery. RESULTS: At baseline, patients had poor disease-specific HRQoL and general health status and identified &quot;Decreased sense of smell/taste&quot; and &quot;Nasal blockage&quot; as the most important symptoms. Dupilumab significantly improved SNOT-22 total, domain (Nasal, Sleep, Function, Emotion, and Ear/facial), and 22-item scores, and EQ-VAS, at Week 24 vs placebo (all p &lt; .0001), with continued improvements to Week 52 in SINUS-52. Improvements occurred irrespective of comorbid asthma, NSAID-ERD, or prior surgery. A significantly greater proportion of dupilumab-treated patients exceeded clinically meaningful thresholds for SNOT-22 total score and EQ-VAS vs placebo (all subgroups p &lt; .05 except patients without surgery at Week 24). CONCLUSIONS: Dupilumab treatment led to significant clinically meaningful improvements across all aspects of disease-specific HRQoL, and general health status in patients with severe CRSwNP.</style></abstract><notes><style face="normal" font="default" size="100%">Lee, Stella E&#xD;Hopkins, Claire&#xD;Mullol, Joaquim&#xD;Msihid, Jerome&#xD;Guillemin, Isabelle&#xD;Amin, Nikhil&#xD;Mannent, Leda P&#xD;Li, Yongtao&#xD;Siddiqui, Shahid&#xD;Chuang, Chien-Chia&#xD;Kamat, Siddhesh&#xD;Khan, Asif H&#xD;eng&#xD;Clinical Trial, Phase III&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2211-2221. doi: 10.1111/all.15222. Epub 2022 Feb 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35034364</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9305228</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15222</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2112</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2112</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rabe, K. F.</style></author><author><style face="normal" font="default" size="100%">Pavord, I. D.</style></author><author><style face="normal" font="default" size="100%">Busse, W. W.</style></author><author><style face="normal" font="default" size="100%">Chupp, G. L.</style></author><author><style face="normal" font="default" size="100%">Izuhara, K.</style></author><author><style face="normal" font="default" size="100%">Altincatal, A.</style></author><author><style face="normal" font="default" size="100%">Gall, R.</style></author><author><style face="normal" font="default" size="100%">Pandit-Abid, N.</style></author><author><style face="normal" font="default" size="100%">Deniz, Y.</style></author><author><style face="normal" font="default" size="100%">Rowe, P. J.</style></author><author><style face="normal" font="default" size="100%">Jacob-Nara, J. A.</style></author><author><style face="normal" font="default" size="100%">Radwan, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">LungenClinic Grosshansdorf (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany.&#xD;Christian-Albrechts University (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Kiel, Germany.&#xD;NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.&#xD;University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.&#xD;Yale School of Medicine, New Haven, Connecticut, USA.&#xD;Saga Medical School, Saga, Japan.&#xD;Sanofi, Cambridge, Massachusetts, USA.&#xD;Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.&#xD;Sanofi, Bridgewater, New Jersey, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab improves long-term outcomes in patients with uncontrolled, moderate-to-severe GINA-based type 2 asthma, irrespective of allergic status</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2148-2156</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/04/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchodilator Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37073882</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Previous research has shown greater efficacy of dupilumab in patients with uncontrolled asthma and type 2 inflammation. We analyzed dupilumab&apos;s efficacy in patients from the TRAVERSE study with or without evidence of allergic asthma and type 2 inflammation per current GINA guidelines (&gt;/=150 eosinophils/muL or FeNO &gt;/=20 ppb). METHODS: All patients aged &gt;/=12 years who rolled over from the placebo-controlled QUEST study (NCT02414854) to TRAVERSE (NCT02134028) received add-on dupilumab 300 mg every 2 weeks for up to 96 weeks. We assessed annualized severe asthma exacerbation rates (AERs) and changes from parent-study baseline (PSBL) in pre-bronchodilator FEV(1) and 5-item asthma control questionnaire (ACQ-5) score in patients with moderate-to-severe type 2 asthma with and without evidence of allergic asthma at PSBL. RESULTS: In TRAVERSE, dupilumab consistently reduced AER across all subgroups. By Week 96, dupilumab increased pre-bronchodilator FEV(1) from PSBL by 0.35-0.41 L in patients receiving placebo during QUEST (placebo/dupilumab) and 0.34-0.44 L in those receiving dupilumab during QUEST (dupilumab/dupilumab) with an allergic phenotype at baseline. In patients without evidence of allergic asthma, pre-bronchodilator FEV(1) improved by 0.38-0.41 L and 0.33-0.37 L, respectively. By Week 48, ACQ-5 scores decreased from PSBL by 1.63-1.69 (placebo/dupilumab) and 1.74-1.81 (dupilumab/dupilumab) points across subgroups with allergic asthma, and 1.75-1.83 (placebo/dupilumab) and 1.78-1.86 (dupilumab/dupilumab) in those without. CONCLUSIONS: Long-term treatment with dupilumab reduced exacerbation rates and improved lung function and asthma control in patients with asthma with type 2 inflammation as per current GINA guidance and irrespective of evidence of allergic asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Rabe, Klaus F&#xD;Pavord, Ian D&#xD;Busse, William W&#xD;Chupp, Geoffrey L&#xD;Izuhara, Kenji&#xD;Altincatal, Arman&#xD;Gall, Rebecca&#xD;Pandit-Abid, Nami&#xD;Deniz, Yamo&#xD;Rowe, Paul J&#xD;Jacob-Nara, Juby A&#xD;Radwan, Amr&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2148-2156. doi: 10.1111/all.15747. Epub 2023 May 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37073882</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15747</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2954</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2954</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Levine, J.</style></author><author><style face="normal" font="default" size="100%">Islam, R. K.</style></author><author><style face="normal" font="default" size="100%">Mo, L.</style></author><author><style face="normal" font="default" size="100%">Kim, B. S.</style></author><author><style face="normal" font="default" size="100%">Talia, J.</style></author><author><style face="normal" font="default" size="100%">Lipner, S. R.</style></author><author><style face="normal" font="default" size="100%">Ungar, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Louisiana State University Health Sciences Center New Orleans School of Medicine, New Orleans, Louisiana, USA.&#xD;Department of Dermatology, Weill Cornell Medicine, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab in Atopic Dermatitis Linked to Reduced Irritable Bowel Syndrome Risk: A Real-World Cohort Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2667-2670</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/06/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptoms</style></keyword><keyword><style face="normal" font="default" size="100%">irritable bowel syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell dysfunction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40560741</style></accession-num><notes><style face="normal" font="default" size="100%">Levine, Jasmine&#xD;Islam, Rahib K&#xD;Mo, Lillian&#xD;Kim, Brian S&#xD;Talia, Jordan&#xD;Lipner, Shari R&#xD;Ungar, Benjamin&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2667-2670. doi: 10.1111/all.16637. Epub 2025 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40560741</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16637</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3142</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3142</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Pi, J.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Tan, Q.</style></author><author><style face="normal" font="default" size="100%">Zhou, X.</style></author><author><style face="normal" font="default" size="100%">Jiang, J.</style></author><author><style face="normal" font="default" size="100%">Yang, H.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Luo, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Children&apos;s Hospital of Chongqing Medical University, Chongqing, China.&#xD;National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab in Children Under 6 Years With Moderate-to-Severe Atopic Dermatitis: A 16-Week Real-World Prospective Study on Efficacy, Safety, and Local-Systemic Immune Responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">proteomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 7</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41055300</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Real-world data on the clinical and molecular impacts of dupilumab in young children with moderate-to-severe atopic dermatitis (AD) remain limited. OBJECTIVES: To evaluate 16-week clinical outcomes, cutaneous proteomic changes, and systemic immune responses to dupilumab in children aged 6 months to 5 years. METHODS: This prospective cohort study enrolled 110 participants, with clinical evaluations performed at weeks 2, 4, 8, 12, and 16. Longitudinal biomarker profiling included skin tape strip (STS) proteomics, flow cytometric analysis of T-cell subsets, and serum cytokine multiplex assays. RESULTS: Of the 96 participants who completed the study, 70.8% achieved EASI-75, 41.7% attained IGA 0/1, and 84.4% reported a &gt;/= 4-point improvement in PP-NRS, with comparable outcomes and adverse events observed across age subgroups (6 months to &lt; 2 years vs. &gt;/= 2 to 5 years). Marked reductions in CLA(+) IL-4(+)/IL-13(+) Th2 cells (p &lt; 0.001) and an expansion of CLA(+) Tregs (p &lt; 0.01) were noted in peripheral blood. However, serum Th2/Th1/Th17 cytokine levels remained unchanged or were elevated posttreatment, particularly IL-4 (p &lt; 0.001), despite declines in CCL13/17/22. STS proteomics indicated a restoration of proteins associated with the skin barrier, while markers related to epidermal hyperplasia, innate immune activation, and antimicrobial defense remained unchanged. Utilizing machine-learning algorithms, PON2 and PRDX1, both involved in anti-oxidative processes, were identified as predictive biomarkers for treatment response. CONCLUSIONS: Short-term dupilumab exhibited favorable outcomes in young children with AD, primarily through the remodeling of CLA(+)Th2 cells and the restoration of skin barrier functions. Although circulating Th2 inflammation was not completely normalized within a 16-week period, the significant reductions in TARC and MDC indicate systemic improvement and underscore the importance of maintenance therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Yunxuan&#xD;Pi, Jiangshan&#xD;Wang, Lingling&#xD;Chen, Jingsi&#xD;Tan, Qingqing&#xD;Zhou, Xiaoying&#xD;Jiang, Jingqiu&#xD;Yang, Huan&#xD;Wang, Hua&#xD;Luo, Xiaoyan&#xD;eng&#xD;82173402/National Natural Science Foundation of China/&#xD;82273522/National Natural Science Foundation of China/&#xD;82473515/National Natural Science Foundation of China/&#xD;Denmark&#xD;Allergy. 2025 Oct 7. doi: 10.1111/all.70090.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41055300</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70090</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2152</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2152</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">De Corso, E.</style></author><author><style face="normal" font="default" size="100%">Pasquini, E.</style></author><author><style face="normal" font="default" size="100%">Trimarchi, M.</style></author><author><style face="normal" font="default" size="100%">La Mantia, I.</style></author><author><style face="normal" font="default" size="100%">Pagella, F.</style></author><author><style face="normal" font="default" size="100%">Ottaviano, G.</style></author><author><style face="normal" font="default" size="100%">Garzaro, M.</style></author><author><style face="normal" font="default" size="100%">Pipolo, C.</style></author><author><style face="normal" font="default" size="100%">Torretta, S.</style></author><author><style face="normal" font="default" size="100%">Seccia, V.</style></author><author><style face="normal" font="default" size="100%">Cantone, E.</style></author><author><style face="normal" font="default" size="100%">Ciofalo, A.</style></author><author><style face="normal" font="default" size="100%">Lucidi, D.</style></author><author><style face="normal" font="default" size="100%">Fadda, G. L.</style></author><author><style face="normal" font="default" size="100%">Pafundi, P. C.</style></author><author><style face="normal" font="default" size="100%">Settimi, S.</style></author><author><style face="normal" font="default" size="100%">Montuori, C.</style></author><author><style face="normal" font="default" size="100%">Anastasi, F.</style></author><author><style face="normal" font="default" size="100%">Pagliuca, G.</style></author><author><style face="normal" font="default" size="100%">Ghidini, A.</style></author><author><style face="normal" font="default" size="100%">Cavaliere, C.</style></author><author><style face="normal" font="default" size="100%">Maffei, M.</style></author><author><style face="normal" font="default" size="100%">Bussu, F.</style></author><author><style face="normal" font="default" size="100%">Gallo, S.</style></author><author><style face="normal" font="default" size="100%">Canevari, F. R. M.</style></author><author><style face="normal" font="default" size="100%">Paludetti, G.</style></author><author><style face="normal" font="default" size="100%">Galli, J.</style></author><author><style face="normal" font="default" size="100%">Dupireal Italian Study, Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Otorhinolaryngology Unit, A.Gemelli University Hospital Foundation IRCCS, Rome, Italy.&#xD;Otorhinolaryngology Unit, Ospedale Bellaria Dip Chirurgie Specialistiche AUSL, Bologna, Italy.&#xD;Otorhinolaryngology Unit, Head and Neck Department, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.&#xD;Department of Medical-Surgical Sciences and Advanced Technologies, E.N.T. Unit, P.O. &quot;G. Rodolico&quot;, University of Catania, Catania, Italy.&#xD;Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.&#xD;Department of Neurosciences, Otolaryngology Section, University of Padova, Padova, Italy.&#xD;Department of Otorhinolaryngology, Rhinology Unit, Eastern Piedmont University, Maggiore Hospital, Novara, Italy.&#xD;Otorhinolaryngology Unit, Department of Health Sciences, ASST Santi Paolo e Carlo Hospital, Universita degli Studi di Milano, Milan, Italy.&#xD;Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico&quot;, University of Milan, Milan, Italy.&#xD;Otolaryngology, Audiology and Phoniatric Operative Unit, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Pisa, Italy.&#xD;Department of Neuroscience, Reproductive and Odontostomatological Sciences-ENT Section, Head and Neck Department-ENT Section, University of Naples Federico II, AOU Federico II, Naples, Italy.&#xD;Rhinology Unit, Department of Sensory Organs, Sapienza University of Rome, Rome, Italy.&#xD;Department of Otolaryngology-Head and Neck Surgery, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.&#xD;Department of Otorhinolaryngology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.&#xD;Epidemiology and Biostatistics Core Facility, Gemelli Science and Technology park, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.&#xD;Department of Head, Neck and Sensory Organs, Catholic University of The Sacred Heart, Rome, Italy.&#xD;Otorhinolaryngology Unit, Ospedale San Giovanni Evangelista, Tivoli, Italy.&#xD;Otolaryngology University Unit, &quot;S. M. Goretti Hospital&quot;, Latina, Italy.&#xD;ENT Department, Azienda USL Reggio Emilia-IRCCS, Reggio Emilia, Italy.&#xD;Department of Sensory Organs, Sapienza University of Rome, Rome, Italy.&#xD;Otolaryngology Head and Neck Surgery Unit, AORN Ospedali della Colli, Naples, Italy.&#xD;Division of Otorhinolaryngology, Department of Medicine, Surgery and Pharmacy, Azienda Ospedaliera Universitaria di Sassari, University of Sassary, Sassari, Italy.&#xD;Otorinolaryngology Unit, Head and Neck Department, ASST Sette Laghi and UPLOAD Research Center, University of Insubria, Varese, Italy.&#xD;Otorhinolaryngology Unit, Dipartimento DISC, IRCCS Policlinico San Martino, Universita di Genova, Genoa, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2669-2683</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/05/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">smell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37203259</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and reduced health-related quality of life. Findings from clinical trials have demonstrated the effectiveness of dupilumab in CRSwNP, although real-world evidence is still limited. METHODS: This Phase IV real-life, observational, multicenter study assessed the effectiveness and safety of dupilumab in patients with severe uncontrolled CRSwNP (n = 648) over the first year of treatment. We collected data at baseline and after 1, 3, 6, 9, and 12 months of follow-up. We focused on nasal polyps score (NPS), symptoms, and olfactory function. We stratified outcomes by comorbidities, previous surgery, and adherence to intranasal corticosteroids, and examined the success rates based on current guidelines, as well as potential predictors of response at each timepoint. RESULTS: We observed a significant decrease in NPS from a median value of 6 (IQR 5-6) at baseline to 1.0 (IQR 0.0-2.0) at 12 months (p &lt; .001), and a significant decrease in Sino-Nasal Outcomes Test-22 (SNOT-22) from a median score of 58 (IQR 49-70) at baseline to 11 (IQR 6-21; p &lt; .001) at 12 months. Sniffin&apos; Sticks scores showed a significant increase over 12 months (p &lt; .001) compared to baseline. The results were unaffected by concomitant diseases, number of previous surgeries, and adherence to topical steroids, except for minor differences in rapidity of action. An excellent-moderate response was observed in 96.9% of patients at 12 months based on EPOS 2020 criteria. CONCLUSIONS: Our findings from this large-scale real-life study support the effectiveness of dupilumab as an add-on therapy in patients with severe uncontrolled CRSwNP in reducing polyp size and improving the quality of life, severity of symptoms, nasal congestion, and smell.</style></abstract><notes><style face="normal" font="default" size="100%">De Corso, Eugenio&#xD;Pasquini, Ernesto&#xD;Trimarchi, Matteo&#xD;La Mantia, Ignazio&#xD;Pagella, Fabio&#xD;Ottaviano, Giancarlo&#xD;Garzaro, Massimiliano&#xD;Pipolo, Carlotta&#xD;Torretta, Sara&#xD;Seccia, Veronica&#xD;Cantone, Elena&#xD;Ciofalo, Andrea&#xD;Lucidi, Daniela&#xD;Fadda, Gian Luca&#xD;Pafundi, Pia Clara&#xD;Settimi, Stefano&#xD;Montuori, Claudio&#xD;Anastasi, Francesca&#xD;Pagliuca, Giulio&#xD;Ghidini, Angelo&#xD;Cavaliere, Carlo&#xD;Maffei, Marianna&#xD;Bussu, Francesco&#xD;Gallo, Stefania&#xD;Canevari, Frank Rikki Mauritz&#xD;Paludetti, Gaetano&#xD;Galli, Jacopo&#xD;eng&#xD;Multicenter Study&#xD;Observational Study&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2669-2683. doi: 10.1111/all.15772. Epub 2023 May 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37203259</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15772</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1312</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1312</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bourdin, A.</style></author><author><style face="normal" font="default" size="100%">Papi, A. A.</style></author><author><style face="normal" font="default" size="100%">Corren, J.</style></author><author><style face="normal" font="default" size="100%">Virchow, J. C.</style></author><author><style face="normal" font="default" size="100%">Rice, M. S.</style></author><author><style face="normal" font="default" size="100%">Deniz, Y.</style></author><author><style face="normal" font="default" size="100%">Djandji, M.</style></author><author><style face="normal" font="default" size="100%">Rowe, P.</style></author><author><style face="normal" font="default" size="100%">Pavord, I. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Diseases, INSERM U1046, University of Montpellier, Montpellier, France.&#xD;Universita degli Studi di Ferrara, Ferrara, Italy.&#xD;David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.&#xD;Universitatsmedizin Rostock, Rostock, Germany.&#xD;Sanofi, Cambridge, MA, USA.&#xD;Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.&#xD;Sanofi, Bridgewater, NJ, USA.&#xD;University of Oxford, Oxford, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">269-280</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/10/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">asthma control</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbations</style></keyword><keyword><style face="normal" font="default" size="100%">inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default" size="100%">moderate-to-severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">prebronchodilator FEV1</style></keyword><keyword><style face="normal" font="default" size="100%">the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from AstraZeneca, grants and personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Boehringer Ingelheim, Chiesi, GSK, Novartis, and Sanofi-Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">other from Acceleron, Actelion, Galapagos, MSD, Nuvaira, Pulmonx, United</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutic, and Vertex, outside the submitted work. Alberto A. Papi reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants, personal fees, non-financial support and other from GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Chiesi Farmaceutici, and TEVA</style></keyword><keyword><style face="normal" font="default" size="100%">grants, personal fees and</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from AstraZeneca and Menarini</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees, non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support and other from Mundipharma, Zambon, Novartis, and Sanofi/Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Roche and Edmondpharma</style></keyword><keyword><style face="normal" font="default" size="100%">and grants from Fondazione Maugeri and</style></keyword><keyword><style face="normal" font="default" size="100%">Fondazione Chiesi</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. Jonathan Corren reports research</style></keyword><keyword><style face="normal" font="default" size="100%">support from Sanofi outside the submitted work. J. Christian Virchow reports</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from AstraZeneca, Avontec, Bayer, Bencard, Bionorica, Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, Chiesi, Essex/Schering-Plough, GSK, Janssen-Cilag, Leti, MEDA, Merck,</style></keyword><keyword><style face="normal" font="default" size="100%">MSD, Mundipharma, Novartis, Nycomed/Altana, Pfizer, Revotar, Sandoz-Hexal,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergens, Teva, UCB/Schwarz-Pharma, Zydus/Cadila, and possibly others</style></keyword><keyword><style face="normal" font="default" size="100%">other</style></keyword><keyword><style face="normal" font="default" size="100%">for Avontec, Boehringer Ingelheim, Chiesi, Essex/Schering-Plough, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Janssen-Cilag, MEDA, MSD, Mundipharma, Novartis, Regeneron, Revotar, Roche,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Aventis, Sandoz-Hexal, Teva, UCB/Schwarz-Pharma, and possibly others</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">research grants from Deutsche Forschungsgesellschaft, Land</style></keyword><keyword><style face="normal" font="default" size="100%">Mecklenburg-Vorpommern, GSK, and MSD. Megan S. Rice reports personal fees and</style></keyword><keyword><style face="normal" font="default" size="100%">other from Sanofi, outside the submitted work. Yamo Deniz reports personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">and other from Regeneron Pharmaceuticals, Inc, outside the submitted work. Michel</style></keyword><keyword><style face="normal" font="default" size="100%">Djandji reports personal fees and other from Sanofi, outside the submitted work.</style></keyword><keyword><style face="normal" font="default" size="100%">Paul Rowe reports personal fees and other from Sanofi, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. Ian D. Pavord reports personal fees from AstraZeneca, Boehringer Ingelheim,</style></keyword><keyword><style face="normal" font="default" size="100%">Aerocrine, Almirall, Novartis, GlaxoSmithKline, Genentech, and Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">other</style></keyword><keyword><style face="normal" font="default" size="100%">from Teva, Chiesi, Sanofi, Circassia, and Knopp</style></keyword><keyword><style face="normal" font="default" size="100%">grants from NIHR, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33010038</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)-4/IL-13, key drivers of type 2 inflammation. In phase 2b (NCT01854047) and phase 3 LIBERTY ASTHMA QUEST (NCT02414854), add-on dupilumab 200/300 mg every 2 weeks (q2w) reduced severe exacerbations, improved prebronchodilator (pre-BD) forced expiratory volume in 1 second (FEV(1) ) and quality of life measures, and it was generally well tolerated in patients with uncontrolled, persistent (phase 2b), or moderate-to-severe (phase 3) asthma. METHODS: In patients on high-dose inhaled corticosteroids (ICS) with type 2-high asthma (subgroups including baseline blood eosinophils &gt;/=150/300 cells/microL and/or fractional exhaled nitric oxide [FeNO] &gt;/=25 ppb), annualized severe exacerbation rates over the treatment period, changes from baseline in pre-BD FEV(1) and asthma control (5-item asthma control questionnaire [ACQ-5]) were analyzed. RESULTS: In high-dose ICS type 2-high subgroups, dupilumab 200/300 mg q2w vs placebo in the phase 2b (24 weeks) and phase 3 (52 weeks) studies significantly reduced severe exacerbations by 55%-69%/57%-60% (all P&lt;.05) and 53%-69%/48%-66% (all P &lt; .001), respectively, except in patients with &gt;/= 300 eosinophils/microL in phase 2b study (24%/50% (P = .52/0.15). Across subgroups, pre-BD FEV(1) improved by 0.18-0.22 L/0.19-0.24 L (all P &lt; .05) and 0.23-0.36 L/0.15-0.25 L (all P &lt; .01) and ACQ-5 scores were reduced by 0.46-0.55/0.47-0.85 (all P &lt; .05) and 0.38-0.50/0.24-0.30 (all P &lt; .05), respectively, except dupilumab 200 mg q2w in phase 2b in patients with FeNO &gt;/= 25 ppb (0.41; P = .09). Dupilumab was also effective in patients taking medium-dose ICS. CONCLUSION: Dupilumab significantly reduced severe exacerbations and improved lung function and asthma control in patients with type 2-high asthma on high-dose ICS at baseline.</style></abstract><notes><style face="normal" font="default" size="100%">Bourdin, Arnaud&#xD;Papi, Alberto A&#xD;Corren, Jonathan&#xD;Virchow, J Christian&#xD;Rice, Megan S&#xD;Deniz, Yamo&#xD;Djandji, Michel&#xD;Rowe, Paul&#xD;Pavord, Ian D&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):269-280. doi: 10.1111/all.14611. Epub 2020 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33010038</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7820970</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14611</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>374</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">374</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Papi, A.</style></author><author><style face="normal" font="default" size="100%">Corren, J.</style></author><author><style face="normal" font="default" size="100%">Castro, M.</style></author><author><style face="normal" font="default" size="100%">Domingo, C.</style></author><author><style face="normal" font="default" size="100%">Rogers, L.</style></author><author><style face="normal" font="default" size="100%">Chapman, K. R.</style></author><author><style face="normal" font="default" size="100%">Jackson, D. J.</style></author><author><style face="normal" font="default" size="100%">Daizadeh, N.</style></author><author><style face="normal" font="default" size="100%">Pandit-Abid, N.</style></author><author><style face="normal" font="default" size="100%">Gall, R.</style></author><author><style face="normal" font="default" size="100%">Jacob-Nara, J. A.</style></author><author><style face="normal" font="default" size="100%">Rowe, P. J.</style></author><author><style face="normal" font="default" size="100%">Deniz, Y.</style></author><author><style face="normal" font="default" size="100%">Ortiz, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Respiratory Medicine, University of Ferrara and Emergency Department, University Hospital, Ferrara, Italy.&#xD;David Geffen School of Medicine at UCLA, Los Angeles, California, USA.&#xD;University of Kansas School of Medicine, Kansas City, Kansas, USA.&#xD;Pulmonary Service, Corporacio Sanitaria Parc Tauli, Autonomous University of Barcelona, Sabadell, Barcelona, Spain.&#xD;Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;University of Toronto, Toronto, Ontario, Canada.&#xD;University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.&#xD;Sanofi, Cambridge, Massachusetts, USA.&#xD;Sanofi, Bridgewater Township, New Jersey, USA.&#xD;Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">233-243</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/07/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Fev1</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">severe exacerbations</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GSK, Mundipharma</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, Teva Pharmaceuticals</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees and non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">Menarini, Novartis, Zambon</style></keyword><keyword><style face="normal" font="default" size="100%">and grants from Sanofi. JC reports research grants,</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy fees for AstraZeneca, Genentech, Novartis, Regeneron Pharmaceuticals,</style></keyword><keyword><style face="normal" font="default" size="100%">Inc., Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and has received speaker fees from AstraZeneca, Genentech,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis. MC has received research support from American Lung Association,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GSK, NIH, Novartis, PCORI, Pulmatrix, Inc., Sanofi-Aventis,</style></keyword><keyword><style face="normal" font="default" size="100%">Shionogi</style></keyword><keyword><style face="normal" font="default" size="100%">is a consultant for Genentech, Novartis, Sanofi-Aventis, Teva</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals</style></keyword><keyword><style face="normal" font="default" size="100%">has received speaker fees from AstraZeneca, Genentech, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals, Inc., Sanofi, Teva Pharmaceuticals</style></keyword><keyword><style face="normal" font="default" size="100%">and reports</style></keyword><keyword><style face="normal" font="default" size="100%">royalties from Elsevier. CD has received travel and speaker fees from ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi</style></keyword><keyword><style face="normal" font="default" size="100%">Farmaceutici, Esteve, Ferrer Pharma, GSK, HAL Allergy Group, ImmunoTek, Menarini,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Pfizer, Sanofi-Aventis, Stallergenes Greer PLC, Takeda, Teva</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals. LR reports research support from Lung Association, NIH, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">is a consultant for AstraZeneca, Genentech, Novartis, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and has received</style></keyword><keyword><style face="normal" font="default" size="100%">payments for organizing educational events from AstraZeneca, Genentech. KRC has</style></keyword><keyword><style face="normal" font="default" size="100%">received grants and personal fees from AstraZeneca, Boehringer Ingelheim, CSL</style></keyword><keyword><style face="normal" font="default" size="100%">Behring, Genentech, Grifols Ltd., Kamada Ltd., Mereo BioPharma Group, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Roche, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from Amgen, Baxter, GSK</style></keyword><keyword><style face="normal" font="default" size="100%">and has received personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from CIHR-GSK Research Chair in Respiratory Health Care Delivery, Merck,</style></keyword><keyword><style face="normal" font="default" size="100%">UHN. DJJ is a consultant for AstraZeneca, Boehringer Ingelheim, GSK, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals, Inc., Sanofi, Vifor Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">and reports membership of</style></keyword><keyword><style face="normal" font="default" size="100%">the data and safety monitoring board for Pfizer. ND is a former employee of</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi and may hold stock and/or stock options in the company. NP, JAJ, and PJR</style></keyword><keyword><style face="normal" font="default" size="100%">are Sanofi employees and may hold stock and/or stock options in the company. RG,</style></keyword><keyword><style face="normal" font="default" size="100%">YD, and BO are employees and shareholders of Regeneron Pharmaceuticals, Inc.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35899469</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Severe asthma exacerbations increase the risk of accelerated lung function decline. This analysis examined the effect of dupilumab on forced expiratory volume in 1 s (FEV(1) ) in patients with moderate-to-severe asthma and elevated type 2 biomarkers from phase 3 LIBERTY ASTHMA QUEST (NCT02414854). METHODS: Changes from baseline in pre- and post-bronchodilator (BD) FEV(1) and 5-item Asthma Control Questionnaire (ACQ-5) scores were assessed in patients with elevated type 2 biomarkers at baseline (type 2-150/25: eosinophils &gt;/=150 cells/mul and/or fractional exhaled nitric oxide [FeNO] &gt;/=25 ppb; type 2-300/25: eosinophils &gt;/=300 cells/mul and/or FeNO &gt;/=25 ppb), stratified as exacerbators (&gt;/=1 severe exacerbation during the study) or non-exacerbators. RESULTS: In exacerbators and non-exacerbators, dupilumab increased pre-BD FEV(1) by Week 2 vs placebo; differences were maintained to Week 52 (type 2-150/25: LS mean difference (LSMD) vs placebo: 0.17 L (95% CI: 0.10-0.24) and 0.17 L (0.12-0.23); type 2-300/25: 0.22 L (0.13-0.30) and 0.21 L (0.15-0.28)), in exacerbators and non-exacerbators, respectively (p &lt; .0001). Similar trends were seen for post-BD FEV(1) . Dupilumab vs placebo also showed significantly greater improvements in post-BD FEV(1) 0-42 days after first severe exacerbation in type 2-150/25 (LSMD vs placebo: 0.13 L [0.06-0.20]; p = .006) and type 2-300/25 (0.14 L [0.06-0.22]; p = .001) patients. ACQ-5 improvements were greater with dupilumab vs placebo in both groups. CONCLUSION: Dupilumab treatment led to improvements in lung function independent of exacerbations and appeared to reduce the impact of exacerbations on lung function in patients who experienced a severe exacerbation during the study.</style></abstract><notes><style face="normal" font="default" size="100%">Papi, Alberto&#xD;Corren, Jonathan&#xD;Castro, Mario&#xD;Domingo, Christian&#xD;Rogers, Linda&#xD;Chapman, Kenneth R&#xD;Jackson, Daniel J&#xD;Daizadeh, Nadia&#xD;Pandit-Abid, Nami&#xD;Gall, Rebecca&#xD;Jacob-Nara, Juby A&#xD;Rowe, Paul J&#xD;Deniz, Yamo&#xD;Ortiz, Benjamin&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):233-243. doi: 10.1111/all.15456. Epub 2022 Aug 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35899469</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087924</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15456</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1263</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1263</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rohner, M. H.</style></author><author><style face="normal" font="default" size="100%">Thormann, K.</style></author><author><style face="normal" font="default" size="100%">Cazzaniga, S.</style></author><author><style face="normal" font="default" size="100%">Yousefi, S.</style></author><author><style face="normal" font="default" size="100%">Simon, H. U.</style></author><author><style face="normal" font="default" size="100%">Schlapbach, C.</style></author><author><style face="normal" font="default" size="100%">Simon, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Centro Studi GISED, Bergamo, Italy.&#xD;Institute of Pharmacology, University of Bern, Bern, Switzerland.&#xD;Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1268-1270</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/11/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">epidermal barrier</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33210741</style></accession-num><notes><style face="normal" font="default" size="100%">Rohner, Maria Helena&#xD;Thormann, Kathrin&#xD;Cazzaniga, Simone&#xD;Yousefi, Shida&#xD;Simon, Hans-Uwe&#xD;Schlapbach, Christoph&#xD;Simon, Dagmar&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1268-1270. doi: 10.1111/all.14664. Epub 2020 Dec 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33210741</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14664</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">9</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Campion, N. J.</style></author><author><style face="normal" font="default" size="100%">Doralt, A.</style></author><author><style face="normal" font="default" size="100%">Lupinek, C.</style></author><author><style face="normal" font="default" size="100%">Berger, M.</style></author><author><style face="normal" font="default" size="100%">Poglitsch, K.</style></author><author><style face="normal" font="default" size="100%">Brugger, J.</style></author><author><style face="normal" font="default" size="100%">Quint, T.</style></author><author><style face="normal" font="default" size="100%">Gangl, K.</style></author><author><style face="normal" font="default" size="100%">Sinz, C.</style></author><author><style face="normal" font="default" size="100%">Bartosik, T.</style></author><author><style face="normal" font="default" size="100%">Liu, D. T.</style></author><author><style face="normal" font="default" size="100%">Landegger, L. D.</style></author><author><style face="normal" font="default" size="100%">Tu, A.</style></author><author><style face="normal" font="default" size="100%">Stanek, V.</style></author><author><style face="normal" font="default" size="100%">Berger, U.</style></author><author><style face="normal" font="default" size="100%">Bangert, C.</style></author><author><style face="normal" font="default" size="100%">Schneider, S.</style></author><author><style face="normal" font="default" size="100%">Eckl-Dorna, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, General Hospital and Medical University of Vienna, Vienna, Austria.&#xD;MacroArray Diagnostics, Vienna, Austria.&#xD;Department of Otorhinolaryngology, Wiener Gesundheitsverbund, Hospital Hietzing, Vienna, Austria.&#xD;Department of Dermatology, General Hospital and Medical University of Vienna, Vienna, Austria.&#xD;Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab reduces symptom burden in allergic rhinitis and suppresses allergen-specific IgE production</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1687-1691</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">birch pollen</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">grass pollen</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36691369</style></accession-num><notes><style face="normal" font="default" size="100%">Campion, Nicholas James&#xD;Doralt, Anna&#xD;Lupinek, Christian&#xD;Berger, Markus&#xD;Poglitsch, Katharina&#xD;Brugger, Jonas&#xD;Quint, Tamara&#xD;Gangl, Katharina&#xD;Sinz, Christoph&#xD;Bartosik, Tina&#xD;Liu, David Tianxiang&#xD;Landegger, Lukas David&#xD;Tu, Aldine&#xD;Stanek, Victoria&#xD;Berger, Uwe&#xD;Bangert, Christine&#xD;Schneider, Sven&#xD;Eckl-Dorna, Julia&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1687-1691. doi: 10.1111/all.15653. Epub 2023 Feb 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36691369</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15653</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>409</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">409</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Berdyshev, E.</style></author><author><style face="normal" font="default" size="100%">Goleva, E.</style></author><author><style face="normal" font="default" size="100%">Bissonnette, R.</style></author><author><style face="normal" font="default" size="100%">Bronova, I.</style></author><author><style face="normal" font="default" size="100%">Bronoff, A. S.</style></author><author><style face="normal" font="default" size="100%">Richers, B. N.</style></author><author><style face="normal" font="default" size="100%">Garcia, S.</style></author><author><style face="normal" font="default" size="100%">Ramirez-Gama, M.</style></author><author><style face="normal" font="default" size="100%">Taylor, P.</style></author><author><style face="normal" font="default" size="100%">Praestgaard, A.</style></author><author><style face="normal" font="default" size="100%">Agueusop, I.</style></author><author><style face="normal" font="default" size="100%">Jurvilliers, P.</style></author><author><style face="normal" font="default" size="100%">Boguniewicz, M.</style></author><author><style face="normal" font="default" size="100%">Levit, N. A.</style></author><author><style face="normal" font="default" size="100%">Rossi, A. B.</style></author><author><style face="normal" font="default" size="100%">Zhang, A.</style></author><author><style face="normal" font="default" size="100%">Leung, D. Y. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Jewish Health, Denver, Colorado, USA.&#xD;Innovaderm Research, Montreal, Quebec, Canada.&#xD;Sanofi, Cambridge, Massachusetts, USA.&#xD;Sanofi, Frankfurt, Germany.&#xD;Sanofi, Chilly-Mazarin, France.&#xD;Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3388-3397</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">Ceramides</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acids/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">EOS-ceramides</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35815904</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is characterized by abnormal skin lipids that are largely driven by hyperactivated type 2 immune responses. The antibody to the alpha-subunit of interleukin (IL)-4 receptor, dupilumab, was recently approved to treat AD and demonstrated strong efficacy. However, the role of dupilumab therapy in the regulation of skin barrier structure and function has not been fully explored. METHODS: We have evaluated the content of lipids and transepidermal water loss (TEWL) in lesional and non-lesional skin of adults and adolescents with moderate-to-severe AD over the course of 16-week treatment with dupilumab and compared those values with that of matched healthy volunteers. RESULTS: Dupilumab treatment provided a significant decrease in TEWL in AD lesions, lowering it almost to the levels seen in the skin of healthy subjects. Blocking IL-4/IL-13 signaling with dupilumab normalized lipid composition (decreased levels of ceramides with non-hydroxy fatty acids and C18-sphingosine and increased the level of esterified omega-hydroxy fatty acid-containing ceramides) and increased ceramide chain length in lesional as well as non-lesional stratum corneum of AD patients. Partial changes for these parameters were already observed after 2 weeks, with a full response achieved after 8 weeks of dupilumab treatment. CONCLUSIONS: Inhibition of IL-4/IL-13 signaling by dupilumab allows restoration of skin lipid composition and barrier function in patients with moderate-to-severe AD.</style></abstract><notes><style face="normal" font="default" size="100%">Berdyshev, Evgeny&#xD;Goleva, Elena&#xD;Bissonnette, Robert&#xD;Bronova, Irina&#xD;Bronoff, Anna Sofia&#xD;Richers, Brittany N&#xD;Garcia, Shannon&#xD;Ramirez-Gama, Marco&#xD;Taylor, Patricia&#xD;Praestgaard, Amy&#xD;Agueusop, Inoncent&#xD;Jurvilliers, Pauline&#xD;Boguniewicz, Mark&#xD;Levit, Noah A&#xD;Rossi, Ana B&#xD;Zhang, Annie&#xD;Leung, Donald Y M&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3388-3397. doi: 10.1111/all.15432. Epub 2022 Jul 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35815904</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15432</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2199</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2199</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pavord, I. D.</style></author><author><style face="normal" font="default" size="100%">Bourdin, A.</style></author><author><style face="normal" font="default" size="100%">Papi, A.</style></author><author><style face="normal" font="default" size="100%">Domingo, C.</style></author><author><style face="normal" font="default" size="100%">Corren, J.</style></author><author><style face="normal" font="default" size="100%">Altincatal, A.</style></author><author><style face="normal" font="default" size="100%">Radwan, A.</style></author><author><style face="normal" font="default" size="100%">Pandit-Abid, N.</style></author><author><style face="normal" font="default" size="100%">Jacob-Nara, J. A.</style></author><author><style face="normal" font="default" size="100%">Deniz, Y.</style></author><author><style face="normal" font="default" size="100%">Rowe, P. J.</style></author><author><style face="normal" font="default" size="100%">Laws, E.</style></author><author><style face="normal" font="default" size="100%">Lederer, D. J.</style></author><author><style face="normal" font="default" size="100%">Hardin, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.&#xD;Department of Respiratory Diseases, University of Montpellier, Montpellier, France.&#xD;Respiratory Medicine Unit, University of Ferrara, S. Anna University Hospital, Ferrara, Italy.&#xD;Pulmonary Service, Corporacio Sanitaria Parc Tauli, Sabadell, Autonomous University of Barcelona, Barcelona, Spain.&#xD;David Geffen School of Medicine at UCLA, Los Angeles, California, USA.&#xD;Sanofi, Cambridge, Massachusetts, USA.&#xD;Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.&#xD;Sanofi, Bridgewater, New Jersey, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2921-2932</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/07/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">asthma control</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbations</style></keyword><keyword><style face="normal" font="default" size="100%">inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default" size="100%">moderate-to-severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">pre-bronchodilator FEV1</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37431558</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dupilumab, a human monoclonal antibody, blocks the shared receptor component for interleukins-4/13, key and central drivers of type 2 inflammation. The TRAVERSE (NCT02134028) open-label extension study demonstrated the long-term safety and efficacy of dupilumab in patients &gt;/=12 years who completed a previous dupilumab asthma study. The safety profile was consistent with that observed in the parent studies. Here, we assess whether dupilumab sustains long-term efficacy in patients regardless of inhaled corticosteroid (ICS) dose at parent study baseline (PSBL). METHODS: Patients from phase 2b (NCT01854047) or phase 3 (QUEST; NCT02414854) studies receiving high- or medium-dose ICS at PSBL and enrolled in TRAVERSE were included. We analyzed unadjusted annualized severe exacerbation rates, change from PSBL in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV(1) ), 5-item asthma control questionnaire, and type 2 biomarkers in patients with type 2 asthma at baseline (blood eosinophils &gt;/=150 cells/muL or fractional exhaled nitric oxide [FeNO] &gt;/=25 ppb), and subgroups defined by baseline blood eosinophils or FeNO. RESULTS: Of patients with type 2 asthma (n = 1666), 891 (53.5%) were receiving high-dose ICS at PSBL. In this subgroup, unadjusted exacerbation rates for dupilumab versus placebo were 0.517 versus 1.883 (phase 2b) and 0.571 versus 1.300 (QUEST) over the parent study (52 weeks) and remained low throughout TRAVERSE (0.313-0.494). Improvements in pre-BD FEV(1) were sustained throughout TRAVERSE. Similar clinical efficacy was observed among patients receiving medium-dose ICS at PSBL and biomarker subgroups. CONCLUSIONS: Dupilumab showed sustained efficacy for up to 3 years in patients with uncontrolled, moderate-to-severe type 2 asthma on high- or medium-dose ICS.</style></abstract><notes><style face="normal" font="default" size="100%">Pavord, Ian D&#xD;Bourdin, Arnaud&#xD;Papi, Alberto&#xD;Domingo, Christian&#xD;Corren, Jonathan&#xD;Altincatal, Arman&#xD;Radwan, Amr&#xD;Pandit-Abid, Nami&#xD;Jacob-Nara, Juby A&#xD;Deniz, Yamo&#xD;Rowe, Paul J&#xD;Laws, Elizabeth&#xD;Lederer, David J&#xD;Hardin, Megan&#xD;eng&#xD;Regeneron Pharmaceuticals Inc./&#xD;Sanofi/&#xD;Clinical Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2921-2932. doi: 10.1111/all.15792. Epub 2023 Jul 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37431558</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15792</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1954</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1954</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lommatzsch, M.</style></author><author><style face="normal" font="default" size="100%">Dost, M.</style></author><author><style face="normal" font="default" size="100%">Jaishankar, N.</style></author><author><style face="normal" font="default" size="100%">Weise, M.</style></author><author><style face="normal" font="default" size="100%">Stoll, P.</style></author><author><style face="normal" font="default" size="100%">Virchow, J. C.</style></author><author><style face="normal" font="default" size="100%">Bratke, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab treatment increases transitional B cells in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2055-2057</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Precursor Cells, B-Lymphoid</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/pharmacology/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36883436</style></accession-num><notes><style face="normal" font="default" size="100%">Lommatzsch, Marek&#xD;Dost, Marieke&#xD;Jaishankar, Neeraja&#xD;Weise, Martin&#xD;Stoll, Paul&#xD;Virchow, J Christian&#xD;Bratke, Kai&#xD;eng&#xD;Ministerium fur Bildung, Wissenschaft und Kultur Mecklenburg-Vorpommern/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2055-2057. doi: 10.1111/all.15703. Epub 2023 Mar 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36883436</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15703</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2903</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2903</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ryser, F. S.</style></author><author><style face="normal" font="default" size="100%">Demeter, T.</style></author><author><style face="normal" font="default" size="100%">Pijuan, J. B.</style></author><author><style face="normal" font="default" size="100%">Shambat, S. M.</style></author><author><style face="normal" font="default" size="100%">Bruhlmann, C.</style></author><author><style face="normal" font="default" size="100%">Mauthe, T.</style></author><author><style face="normal" font="default" size="100%">Hilty, M.</style></author><author><style face="normal" font="default" size="100%">Soyka, M. B.</style></author><author><style face="normal" font="default" size="100%">Steiner, U. C.</style></author><author><style face="normal" font="default" size="100%">Brugger, S. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Graduate School for Health Sciences, University of Bern, Bern, Switzerland.&#xD;Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Institute for Infectious Diseases, University of Bern, Bern, Switzerland.&#xD;Department of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab Treatment Is Associated With Clinical Improvement and a Shift Toward a Health-Associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1746-1756</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/06/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy/microbiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy/microbiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Polyps/drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Microbiome/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">biologicals</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">to this study. U.C.S. is a consultant for Sanofi, GSK, and Astra Zeneca unrelated</style></keyword><keyword><style face="normal" font="default" size="100%">to this study. The other authors reported no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40452334</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Nasal microbiota composition of patients with diffuse type 2 chronic rhinosinusitis with nasal polyps (CRSwNP) is altered compared to healthy individuals. Dupilumab, an anti-IL-4Ralpha-mAb, modulates type 2 inflammation, but the effect on microbiota composition in CRSwNP is unknown. The aim of this study was to investigate longitudinal effects of dupilumab on the nasal passage and gastrointestinal microbiota in patients with diffuse type 2 CRSwNP. METHODS: Twenty-seven patients with diffuse type 2 CRSwNP treated with dupilumab 300 mg subcutaneously every 2 weeks, 10 untreated patients with CRSwNP, and 11 healthy controls were included. Nasal and stool samples were collected at Days 0, 28, 90, and 180 posttreatment of the treated CRSwNP group and at Days 0 and 28 of untreated CRSwNP and healthy controls. The samples were analyzed using 16S rRNA gene amplicon sequencing (V3/V4). RESULTS: In CRSwNP patients, the most abundant genera in nasal passage microbiota were Corynebacterium and Staphylococcus. Cutibacterium and Lawsonella were less abundant in CRSwNP at baseline compared to healthy controls. Dupilumab treatment was associated with increased relative abundances in the nasal passage of genera such as Lawsonella, Corynebacterium, and Dolosigranulum. Microbial diversity of the gastrointestinal microbiota in CRSwNP at baseline was significantly higher than in healthy controls. There were no changes in gastrointestinal microbiota during dupilumab treatment. CONCLUSION: Dupilumab treatment was associated with a shift in the nasal passage bacterial microbiota toward that of healthy controls, whereas the composition of gastrointestinal microbiota did not change. These findings suggest that nasal passage microbiota composition is influenced by the underlying inflammatory endotype.</style></abstract><notes><style face="normal" font="default" size="100%">Ryser, Fabio S&#xD;Demeter, Tomas&#xD;Pijuan, Judith Bergada&#xD;Shambat, Srikanth Mairpady&#xD;Bruhlmann, Catrin&#xD;Mauthe, Tina&#xD;Hilty, Markus&#xD;Soyka, Michael B&#xD;Steiner, Urs C&#xD;Brugger, Silvio D&#xD;eng&#xD;211422/Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;Urs C Steiner (UCS)/&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1746-1756. doi: 10.1111/all.16600. Epub 2025 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40452334</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186592</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16600</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1979</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1979</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Achten, R.</style></author><author><style face="normal" font="default" size="100%">Thijs, J.</style></author><author><style face="normal" font="default" size="100%">van der Wal, M.</style></author><author><style face="normal" font="default" size="100%">van Luijk, C.</style></author><author><style face="normal" font="default" size="100%">de Graaf, M.</style></author><author><style face="normal" font="default" size="100%">Bakker, D.</style></author><author><style face="normal" font="default" size="100%">de Boer, J.</style></author><author><style face="normal" font="default" size="100%">van Wijk, F.</style></author><author><style face="normal" font="default" size="100%">de Bruin-Weller, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands.&#xD;Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.&#xD;Department of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2266-2276</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/03/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/drug therapy/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Goblet Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Eye Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab-associated ocular surface disease</style></keyword><keyword><style face="normal" font="default" size="100%">goblet cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36934403</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dupilumab-associated ocular surface disease (DAOSD) is frequently reported as side effect in atopic dermatitis (AD) patients. Therefore, the aim of this study was to investigate the frequency and severity of DAOSD, ophthalmic treatment response and to learn more about the effect of dupilumab on conjunctival goblet cells (GC). METHODS: This prospective study included dupilumab-treated AD patients between February 2020 and June 2022 from the University Medical Centre Utrecht. Patients were examined by an ophthalmologist and a dermatologist before start (baseline), and after 4 and 28 weeks of dupilumab treatment. Ophthalmological examination was assessed by the Utrecht Ophthalmic Inflammatory and Allergic disease (UTOPIA) score. DAOSD was defined as an increase in UTOPIA score of &gt;/=3 points from baseline. To quantify conjunctival GCs and to investigate the percentage of Cytokeratin 19 (CK19)-CD45-Mucin 5 AC (MUC5AC)+ cells, conjunctival impression cytology samples were analysed. RESULTS: Ocular surface disease (OSD) was present in 91.3% (n = 63/69) patients at baseline. DAOSD was observed in 28.9% (n = 20/69) patients, in whom GC numbers remained stable and the percentage of CK19-CD45-MUC5AC+ cells decreased at onset of DAOSD compared with baseline. After 28 weeks of dupilumab treatment, DAOSD was seen in 14.5% (n = 10/69) patients. Of the 85.5% (n = 59/69) patients without DAOSD or with controlled DAOSD at Week 28, 40.7% (n = 24/59) patients received anti-inflammatory ophthalmic drugs. CONCLUSIONS: Ocular surface disease is common in moderate-to-severe AD patients before starting dupilumab. During treatment with dupilumab DAOSD severity improves with early ophthalmic treatment. The decrease in percentage of CK19-CD45-MUC5AC+ cells during dupilumab treatment suggests an impairment of the GC function due to dupilumab treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Achten, Roselie&#xD;Thijs, Judith&#xD;van der Wal, Marlot&#xD;van Luijk, Chantal&#xD;de Graaf, Marlies&#xD;Bakker, Daphne&#xD;de Boer, Joke&#xD;van Wijk, Femke&#xD;de Bruin-Weller, Marjolein&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2266-2276. doi: 10.1111/all.15717. Epub 2023 Mar 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36934403</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15717</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2417</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2417</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thormann, K.</style></author><author><style face="normal" font="default" size="100%">Luthi, A. S.</style></author><author><style face="normal" font="default" size="100%">Deniau, F.</style></author><author><style face="normal" font="default" size="100%">Heider, A.</style></author><author><style face="normal" font="default" size="100%">Cazzaniga, S.</style></author><author><style face="normal" font="default" size="100%">Radonjic-Hoesli, S.</style></author><author><style face="normal" font="default" size="100%">Lehmann, M.</style></author><author><style face="normal" font="default" size="100%">Schlapbach, C.</style></author><author><style face="normal" font="default" size="100%">Herzog, E. L.</style></author><author><style face="normal" font="default" size="100%">Kreuzer, M.</style></author><author><style face="normal" font="default" size="100%">Zinkernagel, M. S.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Zysset-Burri, D. C.</style></author><author><style face="normal" font="default" size="100%">Simon, H. U.</style></author><author><style face="normal" font="default" size="100%">Simon, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.&#xD;Centro Studi GISED, Bergamo, Italy.&#xD;Department for BioMedical Research, University of Bern, Bern, Switzerland.&#xD;Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.&#xD;Interfaculty Bioinformatics Unit and Swiss Institute of Bioinformatics, University of Bern, Bern, Switzerland.&#xD;Institute of Pharmacology, University of Bern, Bern, Switzerland.&#xD;Institute of Biochemistry, Brandenburg Medical School, Neuruppin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab-associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">937-948</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/02/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Eye Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrosis</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dry eye disease</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">ocular surface disease</style></keyword><keyword><style face="normal" font="default" size="100%">remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">type 1 inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38317432</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dupilumab is used for the treatment of atopic dermatitis (AD). Approximately one third of AD patients develop a dupilumab-associated ocular surface disease (DAOSD), of which the pathomechanism is poorly understood. This study aimed at investigating inflammatory markers in tear fluids of patients on dupilumab therapy. METHODS: Tear fluids were collected from AD patients with DAOSD (ADwDAOSD), AD patients without DAOSD (ADw/oDAOSD), and non-AD patients before and during dupilumab therapy, and analyzed using a specialized proteomic approach quantifying inflammatory markers. The ocular surface microbiome was determined by next generation sequencing technology. RESULTS: Upon dupilumab therapy, an upregulation of 31 inflammatory markers was observed in DAOSD tear fluids compared to baseline in AD patients. While IL-12B was upregulated in both ADwDAOSD and ADw/oDAOSD groups, the pattern of inflammatory markers significantly differed between groups and over time. In the ADwDAOSD group, a shift from a mixed Th2/Th17 pattern at baseline toward a Th1/Th17 profile under dupilumab was observed. Furthermore, an upregulation of remodeling and fibrosis markers was seen in DAOSD. Semantic map and hierarchical cluster analyses of baseline marker expression revealed four clusters distinguishing between AD and non-AD as well as ADwDAOSD and ADw/oDAOSD patient groups. In a pilot study, dupilumab therapy was associated with a decrease in richness of the ocular surface microbiome. CONCLUSIONS: DAOSD is characterized by a Th1/Th17 cytokine profile and an upregulation of markers known to promote remodeling and fibrosis. The expression pattern of inflammatory markers in tear fluids at baseline might serve as a prognostic factor for DAOSD.</style></abstract><notes><style face="normal" font="default" size="100%">Thormann, Kathrin&#xD;Luthi, Anne-Sophie&#xD;Deniau, Felix&#xD;Heider, Anja&#xD;Cazzaniga, Simone&#xD;Radonjic-Hoesli, Susanne&#xD;Lehmann, Mathias&#xD;Schlapbach, Christoph&#xD;Herzog, Elio L&#xD;Kreuzer, Marco&#xD;Zinkernagel, Martin S&#xD;Akdis, Cezmi A&#xD;Zysset-Burri, Denise C&#xD;Simon, Hans-Uwe&#xD;Simon, Dagmar&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):937-948. doi: 10.1111/all.16045. Epub 2024 Feb 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38317432</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16045</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2172</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2172</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ryser, F. S.</style></author><author><style face="normal" font="default" size="100%">Yalamanoglu, A.</style></author><author><style face="normal" font="default" size="100%">Valaperti, A.</style></author><author><style face="normal" font="default" size="100%">Bruhlmann, C.</style></author><author><style face="normal" font="default" size="100%">Mauthe, T.</style></author><author><style face="normal" font="default" size="100%">Traidl, S.</style></author><author><style face="normal" font="default" size="100%">Soyka, M. B.</style></author><author><style face="normal" font="default" size="100%">Steiner, U. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Rheumatology and Immunology, University Hospital Bern, University of Bern, Bern, Switzerland.&#xD;Faculty of Medicine, University of Bern, Bern, Switzerland.&#xD;Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Swiss Institute for Asthma and Allergy Research, Davos, Switzerland.&#xD;Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2712-2723</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Cell Adhesion Molecule-1/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">Vcam-1</style></keyword><keyword><style face="normal" font="default" size="100%">diffuse type 2 chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37548395</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dupilumab, a monoclonal anti-IL-4Ralpha antibody, is approved for several type 2 mediated inflammatory diseases like asthma, atopic dermatitis, and diffuse type 2 chronic rhinosinusitis (CRS). Clinical studies had reported a transient increase in blood eosinophils during dupilumab therapy. This study aimed to assess the impact of elevated blood eosinophils on clinical outcome and to investigate the cause of high blood eosinophil levels under dupilumab therapy. METHODS: Patients suffering from diffuse type 2 CRS treated with dupilumab were examined on days 0, 28, 90, and 180 after therapy start. Sino-Nasal-Outcome-Test Score (SNOT-22), Total Nasal Polyp Score (TNPS), and blood samples were collected. Cytokine measurements and proteomics analysis were conducted. Flow cytometry analysis measured receptor expression on eosinophils. RESULTS: Sixty-eighty patients were included. Baseline eosinophilia &gt;/=0.3G/L was observed in 63.2% of patients, and in 30.9% of patients, eosinophils increased by &gt;/=0.5G/L under dupilumab. Subjects with eosinophilia &gt;/=0.3G/L at baseline had the best SNOT-22 mean change compared to no eosinophilia. Eosinophil elevation during dupilumab therapy had no impact on clinical scores. The eosinophil adhesion molecule VCAM-1 decreased significantly during therapy in all patients. The chemokine receptor CXCR4 was significantly down- and IL-4 upregulated in subjects with eosinophil increase. CONCLUSION: Our findings suggest that increased eosinophils in type 2 CRS are associated with a good clinical response to dupilumab. Patients with elevated IL-4 at baseline developed dupilumab-induced transient eosinophilia. We identified the downregulation of VCAM-1 and surface markers CD49d and CXCR4 on eosinophils as possible explanations of dupilumab-induced eosinophilia.</style></abstract><notes><style face="normal" font="default" size="100%">Ryser, Fabio S&#xD;Yalamanoglu, Ayla&#xD;Valaperti, Alan&#xD;Bruhlmann, Catrin&#xD;Mauthe, Tina&#xD;Traidl, Stephan&#xD;Soyka, Michael B&#xD;Steiner, Urs C&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2712-2723. doi: 10.1111/all.15844. Epub 2023 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37548395</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15844</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3104</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3104</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tynecka, M.</style></author><author><style face="normal" font="default" size="100%">Tarasik, A.</style></author><author><style face="normal" font="default" size="100%">Hanczaruk, B.</style></author><author><style face="normal" font="default" size="100%">Janucik, A.</style></author><author><style face="normal" font="default" size="100%">Czolpinski, K.</style></author><author><style face="normal" font="default" size="100%">Walewska, A.</style></author><author><style face="normal" font="default" size="100%">Zbikowski, A.</style></author><author><style face="normal" font="default" size="100%">Zeller, A.</style></author><author><style face="normal" font="default" size="100%">Kulczynska-Przybik, A.</style></author><author><style face="normal" font="default" size="100%">Niemira, M.</style></author><author><style face="normal" font="default" size="100%">Reszec-Gielazyn, J.</style></author><author><style face="normal" font="default" size="100%">Mroczko, B.</style></author><author><style face="normal" font="default" size="100%">Kretowski, A.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Moniuszko, M.</style></author><author><style face="normal" font="default" size="100%">Karaaslan, C.</style></author><author><style face="normal" font="default" size="100%">Eljaszewicz, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre of Regenerative Medicine, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland.&#xD;Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland.&#xD;Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.&#xD;Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Biology, Molecular Biology Section, Hacettepe University, Ankara, Turkey.&#xD;Tissue and Cell Bank, Medical University of Bialystok Clinical Hospital, Bialystok, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dynamic Regulation of Collagens, Proteases, Their Inhibitors, and Cell Death in Experimental Asthma in Mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">170-184</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/10/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism/pathology/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Collagen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Airway Remodeling/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Peptide Hydrolases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Death</style></keyword><keyword><style face="normal" font="default" size="100%">Th17 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Protease Inhibitors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Extracellular Matrix/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/pathology/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">voluntary positions in the European Academy of Allergy and Clinical Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">(EAACI) as Genomic and Proteomics Working Group Board Member. Agnieszka</style></keyword><keyword><style face="normal" font="default" size="100%">Kulczynska-Przybik received consultation and/or lecture honoraria from Roche</style></keyword><keyword><style face="normal" font="default" size="100%">company. Barbara Mroczko reports consultation and/or lecture honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">Abbott, Wiener, Roche, Cormay, Biameditek, Biokom, and TK Biotech companies.</style></keyword><keyword><style face="normal" font="default" size="100%">Cezmi A. Akdis has received research grants from the Swiss National Science</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, European Union (EU CURE, EU Syn-Air-G), Novartis Research Institutes</style></keyword><keyword><style face="normal" font="default" size="100%">(Basel, Switzerland), Stanford University (Redwood City, Calif), Seed Health</style></keyword><keyword><style face="normal" font="default" size="100%">(Boston, USA), and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">is the Co-Chair for EAACI</style></keyword><keyword><style face="normal" font="default" size="100%">Guidelines on Environmental Science in Allergic diseases and Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Chair of the</style></keyword><keyword><style face="normal" font="default" size="100%">EAACI Epithelial Cell Biology Working Group</style></keyword><keyword><style face="normal" font="default" size="100%">is on the Advisory Boards of</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron (Bern, Switzerland, New York, USA), Stanford University Sean</style></keyword><keyword><style face="normal" font="default" size="100%">Parker Asthma Allergy Center (CA, USA), Novartis (Basel, Switzerland), Glaxo</style></keyword><keyword><style face="normal" font="default" size="100%">Smith Kline (Zurich, Switzerland), Bristol-Myers Squibb (New York, USA), Seed</style></keyword><keyword><style face="normal" font="default" size="100%">Health (Boston, USA), and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">and is the Editor-in-Chief</style></keyword><keyword><style face="normal" font="default" size="100%">of Allergy. Milena Sokolowska reports research grants from Swiss National Science</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation (nr 310030_189334/1, 320030E_224154 and 320030-236264), Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation for Medical-Biological Research, GSK, Stiftung vorm. Buendner</style></keyword><keyword><style face="normal" font="default" size="100%">Heilstaette Arosa, OM Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">speaker&apos;s fee from AstraZeneca and consultation fee</style></keyword><keyword><style face="normal" font="default" size="100%">from Roche</style></keyword><keyword><style face="normal" font="default" size="100%">voluntary positions in the European Academy of Allergy and Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Immunology (EAACI) as Executive Board member. Marcin Moniuszko has delivered in</style></keyword><keyword><style face="normal" font="default" size="100%">the past sponsored lectures and/or has received support for attending meetings</style></keyword><keyword><style face="normal" font="default" size="100%">and/or travel from Berlin-Chemie/Menarini, Astra Zeneca, GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Chiesi, Celon Pharma, Takeda, Polfarmex, CSL Behring, Teva, Glenmark</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Sanofi, and he was taking part (with no remuneration) in the</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial for KalVista Pharmaceuticals. Andrzej Eljaszewicz reports National</style></keyword><keyword><style face="normal" font="default" size="100%">Science Centre (grant no. 2020/37/N/NZ5/04144)</style></keyword><keyword><style face="normal" font="default" size="100%">ABM - Agencja Badan Medycznych</style></keyword><keyword><style face="normal" font="default" size="100%">(grant no. 2023/ABM/03/00057)</style></keyword><keyword><style face="normal" font="default" size="100%">voluntary positions in the European Academy of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Clinical Immunology (EAACI) as Basic and Clinical Immunology Section</style></keyword><keyword><style face="normal" font="default" size="100%">secretary. Agnieszka Tarasik, Bartosz Hanczaruk, Adrian Janucik, Krystian</style></keyword><keyword><style face="normal" font="default" size="100%">Czolpinski, Alicja Walewska, Arkadiusz Zbikowski, Anna Zeller, Magdalena Niemira,</style></keyword><keyword><style face="normal" font="default" size="100%">Joanna Reszec-Gielazyn, Adam Kretowski declare that the research was conducted in</style></keyword><keyword><style face="normal" font="default" size="100%">the absence of any commercial or financial relationships that could be construed</style></keyword><keyword><style face="normal" font="default" size="100%">as a potential conflict of interest. All authors read and accepted the</style></keyword><keyword><style face="normal" font="default" size="100%">manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41147134</style></accession-num><abstract><style face="normal" font="default" size="100%">Asthma is a complex airway disorder driven by diverse immunological pathways. While type 2 (T2)-mediated inflammation is well characterized, the mechanisms underlying T2-low (also referred to as mixed inflammatory phenotype) or non-T2-mediated asthma, often associated with Th1/Th17-driven immune responses and high pulmonary neutrophilic inflammation, remain poorly understood. This study investigates airway remodeling in acute and chronic experimental asthma models induced by house dust mite extract to elucidate inflammatory and structural changes. Two acute T2-low models demonstrated pronounced airway inflammation characterized by goblet cell hyperplasia, collagen deposition, and significant upregulation of extracellular matrix remodeling and fibroblast activation. In contrast, the chronic Th17-mediated model exhibited reduced ECM deposition, increased matrix metalloproteinase (MMP) activity, and a distinct molecular signature dominated by IL-17A-driven pathways, indicative of ECM degradation and structural instability. Furthermore, the acute models showed immune cell apoptosis as the predominant cell death mechanism. In contrast, the chronic inflammation model was marked by necroptosis localized to structural lung cells, contributing to persistent inflammation and remodeling. Our findings provide new insights into the distinct immunopathological mechanisms underlying airway remodeling and fibrosis in T2-low and Th17-mediated asthma phenotypes. The study emphasizes the need for advanced preclinical models and targeted therapeutic strategies to address ECM dysregulation and chronic inflammation to progress in airway remodeling treatment in asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Tynecka, Marlena&#xD;Tarasik, Agnieszka&#xD;Hanczaruk, Bartosz&#xD;Janucik, Adrian&#xD;Czolpinski, Krystian&#xD;Walewska, Alicja&#xD;Zbikowski, Arkadiusz&#xD;Zeller, Anna&#xD;Kulczynska-Przybik, Agnieszka&#xD;Niemira, Magdalena&#xD;Reszec-Gielazyn, Joanna&#xD;Mroczko, Barbara&#xD;Kretowski, Adam&#xD;Akdis, Cezmi A&#xD;Sokolowska, Milena&#xD;Moniuszko, Marcin&#xD;Karaaslan, Cagatay&#xD;Eljaszewicz, Andrzej&#xD;eng&#xD;POLTUR3/MT-REMOD/2/2019/Narodowe Centrum Badan i Rozwoju/&#xD;218S757/Turkiye Bilimsel ve Teknolojik Arastirma Kurumu/&#xD;Uniwersytet Medyczny w Bialymstoku/&#xD;the Foundation for Polish Science START 2023 scholarship/&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):170-184. doi: 10.1111/all.70126. Epub 2025 Oct 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41147134</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773674</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70126</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>119</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">119</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yin, H.</style></author><author><style face="normal" font="default" size="100%">Qiu, Z.</style></author><author><style face="normal" font="default" size="100%">Zhu, R.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Gu, C.</style></author><author><style face="normal" font="default" size="100%">Yao, X.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.&#xD;Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dysregulated lipidome of sebum in patients with atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1524-1537</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sebum/chemistry/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Chromatography, Liquid</style></keyword><keyword><style face="normal" font="default" size="100%">Lipidomics</style></keyword><keyword><style face="normal" font="default" size="100%">Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">Lipids</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">sebaceous glands</style></keyword><keyword><style face="normal" font="default" size="100%">sebum</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36308463</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Lipids are the major components of skin barrier, mainly produced by keratinocytes and sebaceous glands. Previous studies on barrier dysfunction of atopic dermatitis (AD) mainly focus on the lipids from keratinocytes, whereas the role of sebaceous gland-derived lipids in AD has long been underrecognized. METHODS: The sebum secreted on the skin surface of AD patients was measured using the Delfin Sebum Scale. Sebum was collected using Sebutape patches and subjected for liquid chromatography tandem-mass spectrometry (LC-MS/MS) analysis. Multivariate data analysis was applied to explore the relationship among the lipidome, clinical features, and sebaceous gland-related molecules. RESULTS: The amount of sebum secreted from sebaceous glands was decreased in AD patients and was negatively correlated with the barrier function and disease severity. LC-MS/MS revealed the lipidome of sebum, which clustered distinctly between AD patients and healthy individuals. Among the differential lipid subclasses, triglycerides (TG) were exclusively decreased in AD patients and correlated with disease severity. The first principal component scores of AD patients, which represented the main signature of the lipidome, were positively correlated with the SCORAD scores and were significantly different across the patient groups with differential clinical symptoms such as skin dryness and pruritus. Further analysis on the previously published transcriptome data revealed aberrant expression of lipid metabolism-related genes in non-lesional skin of AD patients, which was associated with skin inflammation and barrier dysfunction and mainly derived from inner root sheath keratinocytes and sebaceous gland cells. CONCLUSION: Atopic dermatitis patients demonstrated a deviated lipidome of sebum and aberrant lipid metabolism in sebaceous glands, indicating a possible role of lipids from sebaceous glands in the pathogenesis of AD.</style></abstract><notes><style face="normal" font="default" size="100%">Yin, Huibin&#xD;Qiu, Zhuoqiong&#xD;Zhu, Ronghui&#xD;Wang, Shangshang&#xD;Gu, Chaoying&#xD;Yao, Xu&#xD;Li, Wei&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1524-1537. doi: 10.1111/all.15569. Epub 2022 Nov 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36308463</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15569</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1631</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1631</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saunders, S. P.</style></author><author><style face="normal" font="default" size="100%">Floudas, A.</style></author><author><style face="normal" font="default" size="100%">Moran, T.</style></author><author><style face="normal" font="default" size="100%">Byrne, C. M.</style></author><author><style face="normal" font="default" size="100%">Rooney, M. D.</style></author><author><style face="normal" font="default" size="100%">Fahy, C. M. R.</style></author><author><style face="normal" font="default" size="100%">Geoghegan, J. A.</style></author><author><style face="normal" font="default" size="100%">Iwakura, Y.</style></author><author><style face="normal" font="default" size="100%">Fallon, P. G.</style></author><author><style face="normal" font="default" size="100%">Schwartz, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Trinity Biomedical Sciences Institute, School of Medicine, Trinity College Dublin, Dublin, Ireland.&#xD;National Children&apos;s Research Centre, Our Lady&apos;s Children&apos;s Hospital, Crumlin, Dublin, Ireland.&#xD;Dermatology, Our Lady&apos;s Children&apos;s Hospital Crumlin, Dublin, Ireland.&#xD;Department of Microbiology, Moyne Institute of Preventive Medicine, School of Genetics and Microbiology, Trinity College Dublin, Dublin, Ireland.&#xD;Research Institute for Biomedical Sciences, Tokyo University of Science, Yamazaki, Japan.&#xD;Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitatsklinikum Erlangen and Friedrich-Alexander Universitat (FAU) Erlangen-Nurnberg, Erlangen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dysregulated skin barrier function in Tmem79 mutant mice promotes IL-17A-dependent spontaneous skin and lung inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3216-3227</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2020/07/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-17/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Pneumonia/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Tmem79</style></keyword><keyword><style face="normal" font="default" size="100%">cutaneous inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-17A</style></keyword><keyword><style face="normal" font="default" size="100%">lung inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32644214</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is associated with a dysregulation of the skin barrier and may predispose to the development of secondary allergic conditions, such as asthma. Tmem79(ma/ma) mice harbor a mutation in the gene encoding Transmembrane Protein 79 (or Mattrin), which has previously been associated with AD. As a result of the Tmem79 gene mutation, these mice have a defective skin barrier and develop spontaneous skin inflammation. In this study, Tmem79(ma/ma) mice were assessed for the underlying immunological response in the development of spontaneous skin and lung inflammation. METHODS: Development of spontaneous skin and lung inflammation in Tmem79(ma/ma) mice was analyzed. We further investigated susceptibility to cutaneous Staphylococcus aureus infection. Tmem79(ma/ma) were crossed to IL-17A-deficient mice to address the contribution of IL-17A to spontaneous skin and lung disease. RESULTS: Tmem79(ma/ma) mice developed IL-17A-dependent spontaneous AD-like inflammation and were refractory to S aureus infection. Mutant mice progressed to airway inflammation subsequent to the occurrence of dermatitis. The progression from skin to lung disease is dependent on adaptive immunity and is facilitated by cutaneous expansion of Th17 and TCRgammadelta T cells. CONCLUSION: Mice lacking Tmem79/Mattrin expression have a defective skin barrier. In adulthood, these mice develop dermatitis with secondary progression to lung inflammation. The development of skin and lung inflammation is IL-17A-dependent and mediated by TCRgammadelta T cells.</style></abstract><notes><style face="normal" font="default" size="100%">Saunders, Sean P&#xD;Floudas, Achilleas&#xD;Moran, Tara&#xD;Byrne, Ciara M&#xD;Rooney, Michael D&#xD;Fahy, Caoimhe M R&#xD;Geoghegan, Joan A&#xD;Iwakura, Yoichiro&#xD;Fallon, Padraic G&#xD;Schwartz, Christian&#xD;eng&#xD;092530/Z/10/Z/WT_/Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Dec;75(12):3216-3227. doi: 10.1111/all.14488. Epub 2020 Jul 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32644214</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14488</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1178</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1178</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Eyerich, K.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Ogg, G.</style></author><author><style face="normal" font="default" size="100%">Ong, P. Y.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Warner, A.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine-Kuhne-Center for Allergy Research and Education (CK-CARE, Davos, Switzerland.&#xD;Department of Dermatology and Allergology Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Immunology, University of Toronto, Toronto, ON, Canada.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, Departments of Paediatrics and Immunology, The Hospital for Sick Children, University of Toronto, Toronto, Canada.&#xD;Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.&#xD;Department of Dermatology, Hospital del Mar- Institut Mar d&apos;InvestigacionsMediques, UniversitatAutonoma de Barcelona, Barcelona, Spain.&#xD;Department of Dermatology, VrijeUniversiteit Brussel (VUB), UniversitairZiekenhuis Brussel, Brussels, Belgium.&#xD;Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Dermatological Allergology, Department of Dermatology and Allergy, Allergie-Centrum-Charite, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;MRC Human Immunology Unit, Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular Medicine, Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.&#xD;Division of Clinical Immunology &amp; Allergy, Children&apos;s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.&#xD;Allergy UK, Kent, UK.&#xD;Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Clinical Immunology, University of Wroclaw, Wroclaw, Poland.&#xD;ALL-MED&quot; Medical Research Institute, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">988-1009</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/02/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Grade</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">guideline</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33538044</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based), its cost-effectiveness and long-term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Brockow, Knut&#xD;Chivato, Tomas&#xD;Del Giacco, Stefano&#xD;Eiwegger, Thomas&#xD;Eyerich, Kilian&#xD;Gimenez-Arnau, Ana&#xD;Gutermuth, Jan&#xD;Guttman-Yassky, Emma&#xD;Maurer, Marcus&#xD;Ogg, Graham&#xD;Ong, Peck Y&#xD;O&apos;Mahony, Liam&#xD;Schwarze, Jurgen&#xD;Warner, Amena&#xD;Werfel, Thomas&#xD;Palomares, Oscar&#xD;Jutel, Marek&#xD;eng&#xD;G116/150/MRC_/Medical Research Council/United Kingdom&#xD;MC_U137881017/MRC_/Medical Research Council/United Kingdom&#xD;MC_UU_00008/5/MRC_/Medical Research Council/United Kingdom&#xD;MC_UU_12010/5/MRC_/Medical Research Council/United Kingdom&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):988-1009. doi: 10.1111/all.14690. Epub 2020 Dec 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33538044</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14690</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>876</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">876</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Eyerich, K.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Ogg, G.</style></author><author><style face="normal" font="default" size="100%">Ong, P. Y.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Warner, A.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine-Kuhne-Center for Allergy Research and Education (CK-CARE, Davos, Switzerland.&#xD;Department of Dermatology and Allergology Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Immunology, University of Toronto, Toronto, ON, Canada.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Department of Paediatrics, University Hospital St. Polten, Polten, Austria.&#xD;Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.&#xD;Department of Dermatology, Hospital del Mar- Institut Mar d&apos;Investigacions Mediques, Universitat Autonoma de Barcelona, Barcelona, Spain.&#xD;Department of Dermatology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB, Brussels, Belgium.&#xD;Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford NIHR Biomedical Research Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.&#xD;Division of Clinical Immunology &amp; Allergy, Children&apos;s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.&#xD;Allergy UK, Kent, UK.&#xD;Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;All-MED Medical Research Institute, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">17-38</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Grade</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34324716</style></accession-num><abstract><style face="normal" font="default" size="100%">Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H(1) R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Brockow, Knut&#xD;Chivato, Tomas&#xD;Del Giacco, Stefano&#xD;Eiwegger, Thomas&#xD;Eyerich, Kilian&#xD;Gimenez-Arnau, Ana&#xD;Gutermuth, Jan&#xD;Guttman-Yassky, Emma&#xD;Maurer, Marcus&#xD;Ogg, Graham&#xD;Ong, Peck Y&#xD;O&apos;Mahony, Liam&#xD;Schwarze, Jurgen&#xD;Warner, Amena&#xD;Werfel, Thomas&#xD;Palomares, Oscar&#xD;Jutel, Marek&#xD;eng&#xD;MC_UU_00008/5/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):17-38. doi: 10.1111/all.15030. Epub 2021 Aug 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34324716</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15030</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1426</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1426</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Corren, J.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Flood, B.</style></author><author><style face="normal" font="default" size="100%">Firinu, D.</style></author><author><style face="normal" font="default" size="100%">Gern, J. E.</style></author><author><style face="normal" font="default" size="100%">Hamelmann, E.</style></author><author><style face="normal" font="default" size="100%">Hanania, N.</style></author><author><style face="normal" font="default" size="100%">Hernandez-Martin, I.</style></author><author><style face="normal" font="default" size="100%">Knibb, R.</style></author><author><style face="normal" font="default" size="100%">Makela, M.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Papi, A.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author><author><style face="normal" font="default" size="100%">Perez de Llano, L.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine-Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.&#xD;Division of Allergy and Immunology, University of South Florida Morsani College of Medicine, Tampa, FL, USA.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.&#xD;Department of Health Research Methods, Evidence and Impact, Division of Immunology and Allergy, and Department of Medicine, McMaster University, Hamilton, ON, Canada.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Immunology, University of Toronto, Toronto, ON, Canada.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Departments of Paediatrics and Immunology, University of Toronto, Toronto, ON, Canada.&#xD;European Federation of Allergy and Airway Diseases, Brussels, Belgium.&#xD;Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.&#xD;Children&apos;s Center Bethel, Evangelical Hospital Bethel, University of Bielefeld, Bielefeld, Germany.&#xD;Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA.&#xD;Department of Allergy, Hospital Universitario La Paz, Madrid, Spain.&#xD;Department of Psychology, School of Life and Health Sciences, Aston University, Birmingham, UK.&#xD;Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON, Canada.&#xD;Firestone Institute for Respiratory Health, St Joseph&apos;s Healthcare, Hamilton, ON, Canada.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Pediatric Clinic, National Kapodistrian University of Athens, Athens, Greece.&#xD;Research Center on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.&#xD;Department of Allergy and Clinical Immunology, Ajou University, Ajou, Korea.&#xD;Department of Respiratory Medicine, Hospital Lucus Augusti, Lugo, Spain.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, CIBER of Respiratory Diseases (CIBERES), Universidad Autonoma de Madrid, Madrid, Spain.&#xD;Facultad de Medicina, Universidad Autonoma de Madrid, Madrid, Spain.&#xD;Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair, Development, National Heart and Lung Institute, London, UK.&#xD;Imperial College NIHR Biomedical Research Centre, Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.&#xD;Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Clinical Immunology, University of Wroclaw, Wroclaw, Poland.&#xD;ALL-MED&quot; Medical Research Institute, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI Biologicals Guidelines-Recommendations for severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">14-44</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/06/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Grade</style></keyword><keyword><style face="normal" font="default" size="100%">biologicals</style></keyword><keyword><style face="normal" font="default" size="100%">cost-effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32484954</style></accession-num><abstract><style face="normal" font="default" size="100%">Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Canonica, Giorgio Walter&#xD;Casale, Thomas&#xD;Chivato, Tomas&#xD;Corren, Jonathan&#xD;Chu, Derek K&#xD;Del Giacco, Stefano&#xD;Eiwegger, Thomas&#xD;Flood, Breda&#xD;Firinu, Davide&#xD;Gern, James E&#xD;Hamelmann, Eckard&#xD;Hanania, Nicola&#xD;Hernandez-Martin, Irene&#xD;Knibb, Rebeca&#xD;Makela, Mika&#xD;Nair, Parameswaran&#xD;O&apos;Mahony, Liam&#xD;Papadopoulos, Nikolaos G&#xD;Papi, Alberto&#xD;Park, Hae-Sim&#xD;Perez de Llano, Luis&#xD;Pfaar, Oliver&#xD;Quirce, Santiago&#xD;Sastre, Joaquin&#xD;Shamji, Mohamed&#xD;Schwarze, Jurgen&#xD;Palomares, Oscar&#xD;Jutel, Marek&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):14-44. doi: 10.1111/all.14425. Epub 2020 Aug 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32484954</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14425</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2793</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2793</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Karavelia, A.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">De Las Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Walusiak Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunology Department, IIS-Fundacion Jimenez Diaz, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.&#xD;Department of Otolaryngology, General Hospital of Nafplio, Nafplio, Greece.&#xD;ENT Departent of General Hospital of Nafplio, Nafplio, Greece.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Department of Allergy, La Paz University Hospital; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.&#xD;Allergy Unit and Asthma Center, Verona University Hospital, Verona, Italy.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;EPIUnit - Institute of Public Health, University of Porto, Porto, Portugal.&#xD;Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Sao Joao University Hospital Center, Porto, Portugal.&#xD;Allergy Unit, Department of Medicine and Dermatology, UMA, Hospital Regional Universitario de Malaga-IBIMA, Malaga, Spain.&#xD;Child Life and Health, Centre for Inflammation Research, Institute for Regeneration and Repair, the University of Edinburgh, Edinburgh, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI Clinical and Research Fellowship Program: Shaping the Future of Allergy and Clinical Immunology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1565-1568</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/01/27</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39868865</style></accession-num><notes><style face="normal" font="default" size="100%">Fernandez Santamaria, Ruben&#xD;Karavelia, Aspasia&#xD;Giovannini, Mattia&#xD;De Las Vecillas, Leticia&#xD;Bonadonna, Patrizia&#xD;Del Giacco, Stefano&#xD;Pfaar, Oliver&#xD;Walusiak Skorupa, Jolanta&#xD;Moreira, Andre&#xD;Torres, Maria Jose&#xD;Shamji, Mohamed&#xD;Palomares, Oscar&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1565-1568. doi: 10.1111/all.16484. Epub 2025 Jan 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39868865</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16484</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2826</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2826</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Biagioni, B.</style></author><author><style face="normal" font="default" size="100%">Chung, F.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Dominguez Ortega, J.</style></author><author><style face="normal" font="default" size="100%">Galan, C.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Holgate, S.</style></author><author><style face="normal" font="default" size="100%">Jeebhay, M.</style></author><author><style face="normal" font="default" size="100%">Kazadzis, S.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Zemelka-Wiacek, M.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Institute Desbrest of Epidemiology and Public Health, University of Montpellier and INSERM, Montpellier, France.&#xD;Allergology and Clinical Immunology, S Giovanni di Dio Hospital, Florence, Italy.&#xD;Allergy and Clinical Immunology Unit, San Giovanni di Dio Hospital, Florence, Italy.&#xD;Imperial College, London, UK.&#xD;Respiratory Disease Department, Hospital Cardarelli, Naples, Italy.&#xD;Medical School of Respiratory Diseases, University of Naples Federico II, Naples, Italy.&#xD;Terrestrial Ecology and Climate Change, Department of Ecology, School of Biology, Faculty of Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, and CIBER of Respiratory Diseases (CIBERES), Madrid, Spain.&#xD;Inter-University Institute for Earth System Research (IISTA), international Campus of Excellence on Agrifood (ceiA3), University of Cordoba, Cordoba, Spain.&#xD;Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Allergy Service, Fundacion Jimenez Diaz, Faculty of Medicine Universidad Autonoma de Madrid and CIBERES, Instituto Carlos III, Ministry of Science and Innovation, Madrid, Spain.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Occupational Medicine Division and Centre for Environmental &amp; Occupational Health Research, University of Cape Town, Cape Town, South Africa.&#xD;Physikalisch-Meteorologisches Observatorium Davos, World Radiation Center, Davos, Switzerland.&#xD;John Rock Professor of Climate and Population Studies; Chair, Department of Environmental Health, Interim Director, Center for Climate, Health, and the Global Environment, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Department of Allergy, second Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Lydia Becker Institute, University of Manchester, Manchester, UK.&#xD;Insitute of Environmental Medicine, Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;Department of Clinical Immunology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI Guidelines on Environmental Science for Allergy and Asthma-Recommendations on the Impact of Indoor Air Pollutants on the Risk of New-Onset Asthma and on Asthma-Related Outcomes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">651-676</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2025/02/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">Academies and Institutes</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution, Indoor/adverse effects/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/adverse effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Consensus</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">environmental science</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">indoor air pollutants</style></keyword><keyword><style face="normal" font="default" size="100%">indoor environment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40018799</style></accession-num><abstract><style face="normal" font="default" size="100%">The EAACI Guidelines used the GRADE approach to evaluate the impact of major indoor air pollutants (dampness and mould, cleaning agents, volatile organic compounds and pesticides) on the risk of new-onset asthma and on asthma-related outcomes. The guideline also acknowledges the synergies among indoor air pollutants and other components of the indoor exposome (allergens, viruses, endotoxins). Very low to low certainty of evidence was found for the association between exposure to indoor pollutants and increased risk of new-onset asthma and asthma worsening. Only for mould exposure there was moderate certainty of evidence for new-onset asthma. Due to the quality of evidence, conditional recommendations were formulated on the risk of exposure to all indoor pollutants. Recommendations are provided for prevention, patient care and mitigation in a framework supporting rational decisions for healthcare professionals and patients to individualize and improve asthma management. For policymakers and regulators this evidence-informed guideline supports setting legally binding standards and goals for indoor air quality at international, national and local levels. Asthma management counselled by the current EAACI guidelines can improve asthma-related outcomes but community and governmental measures for improved indoor air quality are needed to achieve significant impact.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Annesi-Maesano, Isabella&#xD;Cecchi, Lorenzo&#xD;Biagioni, Benedetta&#xD;Chung, Fan&#xD;D&apos;Amato, Gennaro&#xD;Damialis, Athanasios&#xD;Del Giacco, Stefano&#xD;Dominguez Ortega, Javier&#xD;Galan, Carmen&#xD;Gilles, Stefanie&#xD;Holgate, Stephen&#xD;Jeebhay, Mohamed&#xD;Kazadzis, Stelios&#xD;Nadeau, Kari&#xD;Papadopoulos, Nikos G&#xD;Quirce, Santiago&#xD;Sastre, Joaquin&#xD;Traidl-Hoffmann, Claudia&#xD;Walusiak-Skorupa, Jolanta&#xD;Zemelka-Wiacek, Magdalena&#xD;Jutel, Marek&#xD;Akdis, Cezmi A&#xD;eng&#xD;Practice Guideline&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):651-676. doi: 10.1111/all.16502. Epub 2025 Feb 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40018799</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16502</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2489</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2489</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Biagioni, B.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Clot, B.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Dominguez-Ortega, J.</style></author><author><style face="normal" font="default" size="100%">Galan, C.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Holgate, S.</style></author><author><style face="normal" font="default" size="100%">Jeebhay, M.</style></author><author><style face="normal" font="default" size="100%">Kazadzis, S.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Tummon, F.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Institute Desbrest of Epidemiology and Public Health, University of Montpellier and INSERM, Montpellier, France.&#xD;Centre of Bioclimatology, University of Florence, Florence, Italy.&#xD;Allergy and Clinical Immunology Unit San Giovanni di Dio Hospital, Florence, Italy.&#xD;National Hearth &amp; Lung Institute, Imperial College London, London, UK.&#xD;Federal office of meteorology and climatology MeteoSwiss, Payerne, Switzerland.&#xD;Respiratory Disease Department, Hospital Cardarelli, Naples, Italy.&#xD;University of Naples Federico II Medical School of Respiratory Diseases, Naples, Italy.&#xD;Department of Ecology, School of Biology, Faculty of Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, and CIBER of Respiratory Diseases (CIBERES), Madrid, Spain.&#xD;Inter-University Institute for Earth System Research (IISTA), International Campus of Excellence on Agrifood (ceiA3), University of Cordoba, Cordoba, Spain.&#xD;Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Occupational Medicine Division and Centre for Environmental &amp; Occupational Health Research, University of Cape Town, Cape Town, South Africa.&#xD;Physikalisch-Meteorologisches Observatorium Davos, World Radiation Center, Davos, Switzerland.&#xD;John Rock Professor of Climate and Population Studies, Department of Environmental Health, Center for Climate, Health, and the Global Environment, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Allergy and Clinical Immunology Unit, Second Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK.&#xD;Allergy Service, Fundacion Jimenez Diaz, Faculty of Medicine Universidad Autonoma de Madrid and CIBERES, Instituto Carlos III, Ministry of Science and Innovation, Madrid, Spain.&#xD;Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Center Munich-German Research Center for Environmental Health, Augsburg, Germany.&#xD;Christine Kuhne Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;Department of Clinical Immunology, Wroclaw Medical University, and ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI guidelines on environmental science for allergy and asthma: The impact of short-term exposure to outdoor air pollutants on asthma-related outcomes and recommendations for mitigation measures</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1656-1686</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/04/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Air Pollution/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">environmental science</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">outdoor pollution</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38563695</style></accession-num><abstract><style face="normal" font="default" size="100%">The EAACI Guidelines on the impact of short-term exposure to outdoor pollutants on asthma-related outcomes provide recommendations for prevention, patient care and mitigation in a framework supporting rational decisions for healthcare professionals and patients to individualize and improve asthma management and for policymakers and regulators as an evidence-informed reference to help setting legally binding standards and goals for outdoor air quality at international, national and local levels. The Guideline was developed using the GRADE approach and evaluated outdoor pollutants referenced in the current Air Quality Guideline of the World Health Organization as single or mixed pollutants and outdoor pesticides. Short-term exposure to all pollutants evaluated increases the risk of asthma-related adverse outcomes, especially hospital admissions and emergency department visits (moderate certainty of evidence at specific lag days). There is limited evidence for the impact of traffic-related air pollution and outdoor pesticides exposure as well as for the interventions to reduce emissions. Due to the quality of evidence, conditional recommendations were formulated for all pollutants and for the interventions reducing outdoor air pollution. Asthma management counselled by the current EAACI guidelines can improve asthma-related outcomes but global measures for clean air are needed to achieve significant impact.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Annesi-Maesano, Isabella&#xD;Cecchi, Lorenzo&#xD;Biagioni, Benedetta&#xD;Chung, Kian Fan&#xD;Clot, Bernard&#xD;D&apos;Amato, Gennaro&#xD;Damialis, Athanasios&#xD;Del Giacco, Stefano&#xD;Dominguez-Ortega, Javier&#xD;Galan, Carmen&#xD;Gilles, Stefanie&#xD;Holgate, Stephen&#xD;Jeebhay, Mohamed&#xD;Kazadzis, Stelios&#xD;Nadeau, Kari&#xD;Papadopoulos, Nikolaos&#xD;Quirce, Santiago&#xD;Sastre, Joaquin&#xD;Tummon, Fiona&#xD;Traidl-Hoffmann, Claudia&#xD;Walusiak-Skorupa, Jolanta&#xD;Jutel, Marek&#xD;Akdis, Cezmi A&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1656-1686. doi: 10.1111/all.16103. Epub 2024 Apr 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38563695</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16103</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1939</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1939</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Bennett, O.</style></author><author><style face="normal" font="default" size="100%">Favaro, A.</style></author><author><style face="normal" font="default" size="100%">Sarama, R.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Custovic, A.</style></author><author><style face="normal" font="default" size="100%">Fontanella, S.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Zemelka-Wiacek, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), University of Southern Denmark, Odense, Denmark.&#xD;Faculty Science Limited, London, UK.&#xD;Pediatric Allergy and Clinical Immunology Service, Institut de Reserca Sant Joan de Deu, Barcelona, Spain.&#xD;Research Director and Deputy DIrector of Institut Desbrest of Epidemiology and Public Health (IDESP) French NIH (INSERM) and University of Montpellier, Montpellier, France.&#xD;Environmental Medicine Faculty of Medicine University of Augsburg, Augsburg, Germany.&#xD;CK-CARE, Christine Kuhne Center for Allergy Research and Education, Davos, Switzerland.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.&#xD;SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI guidelines on environmental science in allergic diseases and asthma - Leveraging artificial intelligence and machine learning to develop a causality model in exposomics</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1742-1757</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Artificial Intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Science</style></keyword><keyword><style face="normal" font="default" size="100%">Machine Learning</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">exposome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36740916</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic diseases and asthma are intrinsically linked to the environment we live in and to patterns of exposure. The integrated approach to understanding the effects of exposures on the immune system includes the ongoing collection of large-scale and complex data. This requires sophisticated methods to take full advantage of what this data can offer. Here we discuss the progress and further promise of applying artificial intelligence and machine-learning approaches to help unlock the power of complex environmental data sets toward providing causality models of exposure and intervention. We discuss a range of relevant machine-learning paradigms and models including the way such models are trained and validated together with examples of machine learning applied to allergic disease in the context of specific environmental exposures as well as attempts to tie these environmental data streams to the full representative exposome. We also discuss the promise of artificial intelligence in personalized medicine and the methodological approaches to healthcare with the final AI to improve public health.</style></abstract><notes><style face="normal" font="default" size="100%">Shamji, Mohamed H&#xD;Ollert, Markus&#xD;Adcock, Ian M&#xD;Bennett, Oscar&#xD;Favaro, Alberto&#xD;Sarama, Roudin&#xD;Riggioni, Carmen&#xD;Annesi-Maesano, Isabella&#xD;Custovic, Adnan&#xD;Fontanella, Sara&#xD;Traidl-Hoffmann, Claudia&#xD;Nadeau, Kari&#xD;Cecchi, Lorenzo&#xD;Zemelka-Wiacek, Magdalena&#xD;Akdis, Cezmi A&#xD;Jutel, Marek&#xD;Agache, Ioana&#xD;eng&#xD;MR/S002359/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/S025340/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/K002449/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/K002449/2/MRC_/Medical Research Council/United Kingdom&#xD;MR/T031565/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/W028352/1/MRC_/Medical Research Council/United Kingdom&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1742-1757. doi: 10.1111/all.15667. Epub 2023 Feb 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36740916</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15667</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2273</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2273</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Perea, A.</style></author><author><style face="normal" font="default" size="100%">Alvaro-Lozano, M.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B.</style></author><author><style face="normal" font="default" size="100%">Barni, S.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Buyuktiryaki, B.</style></author><author><style face="normal" font="default" size="100%">Chu, D.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Dunn-Galvin, A.</style></author><author><style face="normal" font="default" size="100%">Eberlein, B.</style></author><author><style face="normal" font="default" size="100%">Ebisawa, M.</style></author><author><style face="normal" font="default" size="100%">Eigenmann, P.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Feeney, M.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Fisher, H. R.</style></author><author><style face="normal" font="default" size="100%">Fleischer, D. M.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Gray, C.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Halken, S.</style></author><author><style face="normal" font="default" size="100%">Hourihane, J. O.</style></author><author><style face="normal" font="default" size="100%">Jones, C. J.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Knol, E.</style></author><author><style face="normal" font="default" size="100%">Konstantinou, G. N.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Lau, S.</style></author><author><style face="normal" font="default" size="100%">Marques Mejias, A.</style></author><author><style face="normal" font="default" size="100%">Marchisotto, M. J.</style></author><author><style face="normal" font="default" size="100%">Meyer, R.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Moya, B.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Nilsson, C.</style></author><author><style face="normal" font="default" size="100%">Lopes de Oliveira, L. C.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Perrett, K.</style></author><author><style face="normal" font="default" size="100%">Peters, R. L.</style></author><author><style face="normal" font="default" size="100%">Podesta, M.</style></author><author><style face="normal" font="default" size="100%">Poulsen, L. K.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Smith, P.</style></author><author><style face="normal" font="default" size="100%">Tham, E. H.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Vickery, B. P.</style></author><author><style face="normal" font="default" size="100%">Vlieg-Boerstra, B.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Skypala, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Pediatric Allergy), Faculty of Life Sciences and Medicine, School of Life Course Sciences, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Department of Allergy and Clinical Immunology, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Hospital General Universitario Gregorio Maranon, Madrid, Spain.&#xD;Gregorio Maranon Health Research Institute, Madrid, Spain.&#xD;Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Deu, Barcelona, Spain.&#xD;Institut de Recerca Sant Joan de Deu, Universitat de Barcelona, Barcelona, Spain.&#xD;Clinic for Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark, Odense, Denmark.&#xD;Division of Pediatric Allergy, Department of Pediatrics, Koc University School of Medicine, Istanbul, Turkey.&#xD;McMaster University, Ontario, Hamilton, Canada.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, University of Cagliari, Cagliari, Italy.&#xD;Paediatrics and Child Health, INFANT Centre, HRB-CRF, University College Cork, Cork, Ireland.&#xD;Paediatrics and Child Health, Royal College of Surgeons in Ireland, Children&apos;s Health Ireland, Dublin, Ireland.&#xD;Department of Dermatology and Allergy Biederstein, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.&#xD;Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan.&#xD;Department of Pediatrics, Gynecology and Obstetrics, University Hospitals of Geneva, Geneva, Switzerland.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Ontario, Toronto, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Ontario, Toronto, Canada.&#xD;Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St.Polten, Austria.&#xD;Allergy Department, Hospital Clinico San Carlos, Madrid, Spain.&#xD;Facultad de Medicina, IdISSC, ARADyAL, Universidad Complutense, Madrid, Spain.&#xD;Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Colorado, Aurora, USA.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Red Cross Children&apos;s Hospital and Kidsallergy Centre, Cape Town, South Africa.&#xD;Department of Paediatrics, University of Cape Town, Cape Town, South Africa.&#xD;Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Odense, Denmark.&#xD;Royal College of Surgeons in Ireland and Childrens Health Ireland, Dublin, Ireland.&#xD;Faculty of Medical Sciences, School of Psychology, University of Surrey, Surrey, UK.&#xD;Department of Clinical Immunology, Wroclaw Medical University, ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Dermatology/Allergology, Center of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.&#xD;EAACI Patient Organisation Committee, Zurich, Switzerland.&#xD;Department of Medicine, Imperial College, London, UK.&#xD;Department of Nutrition and Dietetics, Winchester University, Winchester, UK.&#xD;Department of Medicine, KU Leuven, Leuven, Belgium.&#xD;Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain.&#xD;Instituto de Investigacion Sanitaria, Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Food Allergy Referral Centre, Padua University Hospital, Padua, Italy.&#xD;Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden.&#xD;Sachs Children and Youth Hospital, South Hospital, Stockholm, Sweden.&#xD;Division of Allergy and Clinical Immunology, Department of Paediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;Department of Medicine, School of Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Lydia Becker Institute, University of Manchester, Manchester, UK.&#xD;Department of Paediatrics, University of Melbourne, Victoria, Parkville, Australia.&#xD;Department of Allergy and Immunology, Royal Children&apos;s Hospital, Victoria, Parkville, Australia.&#xD;Population Allergy Research Group, Murdoch Children&apos;s Research Institute, Victoria, Parkville, Australia.&#xD;EFA - European Federation of Allergy and Airways Diseases Patients&apos; Associations, Brussels, Belgium.&#xD;Allergy Clinic, Copenhagen University Hospital at Herlev-Gentofte, Copenhagen, Denmark.&#xD;Department of Paediatric Allergy and Respiratory Medicine, University of Southampton, Southampton, UK.&#xD;NIHR Southampton Biomedical Research Centre, Southampton, UK.&#xD;David Hide Asthma and Allergy Centre, St Mary Hospital, Isle of Wight, UK.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.&#xD;Child Life and Health, Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.&#xD;Clinical Medicine, Griffith University, Queensland, Southport, Australia.&#xD;Queensland Allergy Services Private Practice, Queensland, Southport, Australia.&#xD;Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Khoo Teck Puat-National University Children&apos;s Medical Institute, National University Health System (NUHS), Singapore, Singapore.&#xD;Human Potential Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Departments of Experimental Immunology and of Otorhinolaryngoloy, Amsterdam University Medical Centers, Amsterdam, The Netherlands.&#xD;Section of Allergy and Clinical Immunology, Children&apos;s Hospital Colorado, University of Colorado, Colorado, Aurora, USA.&#xD;Emory University School of Medicine and Children&apos;s Healthcare of Atlanta, Georgia, Atlanta, USA.&#xD;Department of Paediatrics, OLVG Hospital, Amsterdam, the Netherlands.&#xD;Rijnstate Allergy Centre, Rijnstate Hospital, Arnhem, The Netherlands.&#xD;Vlieg Dieticians, Private Practice for Dietary Management of Food Allergy, Arnhem, The Netherlands.&#xD;Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Division of Allergy and immunology, Department of Dermatology, Venerology and Allergology, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Royal Brompton &amp; Harefield Hospitals, Part of Guys &amp; St Thomas NHS Foundation Trust, London, UK.&#xD;Department of Inflammation and Repair, Imperial College, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI guidelines on the diagnosis of IgE-mediated food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3057-3076</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/10/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">oral food challenges</style></keyword><keyword><style face="normal" font="default" size="100%">skin prick test</style></keyword><keyword><style face="normal" font="default" size="100%">specific IgE</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37815205</style></accession-num><abstract><style face="normal" font="default" size="100%">This European Academy of Allergy and Clinical Immunology guideline provides recommendations for diagnosing IgE-mediated food allergy and was developed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Food allergy diagnosis starts with an allergy-focused clinical history followed by tests to determine IgE sensitization, such as serum allergen-specific IgE (sIgE) and skin prick test (SPT), and the basophil activation test (BAT), if available. Evidence for IgE sensitization should be sought for any suspected foods. The diagnosis of allergy to some foods, such as peanut and cashew nut, is well supported by SPT and serum sIgE, whereas there are less data and the performance of these tests is poorer for other foods, such as wheat and soya. The measurement of sIgE to allergen components such as Ara h 2 from peanut, Cor a 14 from hazelnut and Ana o 3 from cashew can be useful to further support the diagnosis, especially in pollen-sensitized individuals. BAT to peanut and sesame can be used additionally. The reference standard for food allergy diagnosis is the oral food challenge (OFC). OFC should be performed in equivocal cases. For practical reasons, open challenges are suitable in most cases. Reassessment of food allergic children with allergy tests and/or OFCs periodically over time will enable reintroduction of food into the diet in the case of spontaneous acquisition of oral tolerance.</style></abstract><notes><style face="normal" font="default" size="100%">Santos, Alexandra F&#xD;Riggioni, Carmen&#xD;Agache, Ioana&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Alvarez-Perea, Alberto&#xD;Alvaro-Lozano, Montserrat&#xD;Ballmer-Weber, Barbara&#xD;Barni, Simona&#xD;Beyer, Kirsten&#xD;Bindslev-Jensen, Carsten&#xD;Brough, Helen A&#xD;Buyuktiryaki, Betul&#xD;Chu, Derek&#xD;Del Giacco, Stefano&#xD;Dunn-Galvin, Audrey&#xD;Eberlein, Bernadette&#xD;Ebisawa, Motohiro&#xD;Eigenmann, Philippe&#xD;Eiwegger, Thomas&#xD;Feeney, Mary&#xD;Fernandez-Rivas, Montserrat&#xD;Fisher, Helen R&#xD;Fleischer, David M&#xD;Giovannini, Mattia&#xD;Gray, Claudia&#xD;Hoffmann-Sommergruber, Karin&#xD;Halken, Susanne&#xD;Hourihane, Jonathan O&apos;B&#xD;Jones, Christina J&#xD;Jutel, Marek&#xD;Knol, Edward&#xD;Konstantinou, George N&#xD;Lack, Gideon&#xD;Lau, Susanne&#xD;Marques Mejias, Andreina&#xD;Marchisotto, Mary Jane&#xD;Meyer, Rosan&#xD;Mortz, Charlotte G&#xD;Moya, Beatriz&#xD;Muraro, Antonella&#xD;Nilsson, Caroline&#xD;Lopes de Oliveira, Lucila Camargo&#xD;O&apos;Mahony, Liam&#xD;Papadopoulos, Nikolaos G&#xD;Perrett, Kirsten&#xD;Peters, Rachel L&#xD;Podesta, Marcia&#xD;Poulsen, Lars K&#xD;Roberts, Graham&#xD;Sampson, Hugh A&#xD;Schwarze, Jurgen&#xD;Smith, Peter&#xD;Tham, Elizabeth Huiwen&#xD;Untersmayr, Eva&#xD;Van Ree, Ronald&#xD;Venter, Carina&#xD;Vickery, Brian P&#xD;Vlieg-Boerstra, Berber&#xD;Werfel, Thomas&#xD;Worm, Margitta&#xD;Du Toit, George&#xD;Skypala, Isabel&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MC_PC_18052/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3057-3076. doi: 10.1111/all.15902. Epub 2023 Oct 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37815205</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15902</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3200</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3200</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Ceylan, O.</style></author><author><style face="normal" font="default" size="100%">Chaslaridis, P.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Lauerma, A.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Paciencia, I.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Renz, H.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Urrutia-Pereira, M.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Vercelli, D.</style></author><author><style face="normal" font="default" size="100%">Winders, T.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Department of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland.&#xD;Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;EAACI POC, The Patient Organisations Committee, Istanbul, Turkey.&#xD;European Federation of Allergy and Airways Diseases Patients&apos; Associations (EFA), Brussels, Belgium.&#xD;Department of Ecology, School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Allergologia e Immunologia Clinica, Dipartimento di Scienze Mediche e Sanita Pubblica, Universita Degli Studi di Cagliari, Cagliari, Italy.&#xD;John Rock Professor of Climate and Population Studies, Department of Environmental Health, Center for Climate, Health, and the Global Environment, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Center for Environmental and Respiratory Health Research, Research Unit of Population Health, University of Oulu, Oulu, Finland.&#xD;The Interuniversity Messerli Research Institute, University of Veterinary Medicine and Medical University Vienna, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology Medical University of Vienna, Vienna, Austria.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.&#xD;Institute of Laboratory Medicine, German Center for Lung Research (DZL) and the Lung Centre of the Universities of Giessen and Marburg (UGMLC), Philipps University Marburg, Marburg, Germany.&#xD;Kilimanjaro Christian Medical University College (KCMUCo), Moshi, Tanzania.&#xD;Tongji Medical School, Shanghai, China.&#xD;Child Life and Health, Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.&#xD;Federal University of Pampa, Uruguaiana, Brazil.&#xD;Brazilian Association for Allergy and Immunology, Sao Paulo, Brazil.&#xD;Section of Pediatric Allergy and Immunology, Children&apos;s Hospital Colorado, University of Colorado, Aurora, Colorado, USA.&#xD;Department of Cellular and Molecular Medicine, University of Arizona, Tucson, Arizona, USA.&#xD;Asthma and Airway Disease Research Center, University of Arizona, Tucson, Arizona, USA.&#xD;BIO5 Institute, University of Arizona, Tucson, Arizona, USA.&#xD;Arizona Center for the Biology of Complex Diseases, University of Arizona, Tucson, Arizona, USA.&#xD;Global Allergy and Airways Patient Platform, Vienna, Austria.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL- MED Medical Research Institute, Wroclaw, Poland.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI Guidelines on the Importance of Green Space in Urban Environments for Allergy and Asthma Prevention</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biodiversity</style></keyword><keyword><style face="normal" font="default" size="100%">climate change</style></keyword><keyword><style face="normal" font="default" size="100%">green space</style></keyword><keyword><style face="normal" font="default" size="100%">greenness</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">nature loss</style></keyword><keyword><style face="normal" font="default" size="100%">nature-based solutions</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41388798</style></accession-num><abstract><style face="normal" font="default" size="100%">The allergy and asthma epidemic in urban societies following World War II is mostly caused by changes in the environment, diet and lifestyle. Disconnection of urban populations from the wider environment has reduced the protective factors building up immunological resilience. The European Academy of Allergy and Clinical Immunology (EAACI) guidelines on greenness impact on allergy and asthma follow the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach and provide eight recommendations encouraging greenness exposure to support immune health. Controlled follow-up studies are still scarce, and the strength of evidence is generally low or moderate at best. For primary prevention of allergy and asthma, most of the evidence indicates beneficial effects. Exposure is also useful for secondary prevention. Asthma patients may feel better and need less medication by combining green space exposure with physical activity. During the high-pollen season, effective seasonal medication is necessary for patients with pollen allergy. In urban planning, implementing appropriate green infrastructure and easy access to green space promotes immune health and reduces risks of air pollution and heatwaves. These EAACI guidelines are the first recommendations highlighting the importance of urban green spaces on immune health and call for prioritising innovative research in this field.</style></abstract><notes><style face="normal" font="default" size="100%">Haahtela, Tari&#xD;O&apos;Mahony, Liam&#xD;Traidl-Hoffmann, Claudia&#xD;Akdis, Mubeccel&#xD;Ceylan, Ozlem&#xD;Chaslaridis, Panagiotis&#xD;Damialis, Athanasios&#xD;Del Giacco, Stefano&#xD;Lauerma, Antti&#xD;Nadeau, Kari C&#xD;Paciencia, Ines&#xD;Pali-Scholl, Isabella&#xD;Palomares, Oscar&#xD;Renz, Harald&#xD;Schwarze, Jurgen&#xD;Urrutia-Pereira, Marilyn&#xD;Venter, Carina&#xD;Vercelli, Donata&#xD;Winders, Tonya&#xD;Akdis, Cezmi A&#xD;Jutel, Marek&#xD;Agache, Ioana&#xD;eng&#xD;43205/European Academy of Allergy and Clinical Immunology/&#xD;Denmark&#xD;Allergy. 2025 Dec 13. doi: 10.1111/all.70182.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41388798</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70182</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2662</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2662</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Perea, A.</style></author><author><style face="normal" font="default" size="100%">Alvaro-Lozano, M.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B.</style></author><author><style face="normal" font="default" size="100%">Barni, S.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Buyuktiryaki, B.</style></author><author><style face="normal" font="default" size="100%">Chu, D.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Dunn-Galvin, A.</style></author><author><style face="normal" font="default" size="100%">Eberlein, B.</style></author><author><style face="normal" font="default" size="100%">Ebisawa, M.</style></author><author><style face="normal" font="default" size="100%">Eigenmann, P.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Feeney, M.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author><author><style face="normal" font="default" size="100%">Fisher, H. R.</style></author><author><style face="normal" font="default" size="100%">Fleischer, D. M.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Gray, C.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Halken, S.</style></author><author><style face="normal" font="default" size="100%">O&apos;B Hourihane J</style></author><author><style face="normal" font="default" size="100%">Jones, C. J.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Knol, E. F.</style></author><author><style face="normal" font="default" size="100%">Konstantinou, G. N.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Lau, S.</style></author><author><style face="normal" font="default" size="100%">Mejias, A. M.</style></author><author><style face="normal" font="default" size="100%">Marchisotto, M. J.</style></author><author><style face="normal" font="default" size="100%">Meyer, R.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Moya, B.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Nilsson, C.</style></author><author><style face="normal" font="default" size="100%">de Oliveira, L. C. L.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Perrett, K. P.</style></author><author><style face="normal" font="default" size="100%">Peters, R.</style></author><author><style face="normal" font="default" size="100%">Podesta, M.</style></author><author><style face="normal" font="default" size="100%">Poulsen, L. K.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Sampson, H.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Smith, P.</style></author><author><style face="normal" font="default" size="100%">Tham, E.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Vickery, B.</style></author><author><style face="normal" font="default" size="100%">Vlieg-Boerstra, B.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Skypala, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Division of Immunology and Allergy, The Hospital for Sick Children and the SickKids Food Allergy and Anaphylaxis Program, Toronto, Ontario, Canada.&#xD;Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Hospital General Universitario Gregorio Maranon, Madrid, Spain.&#xD;Gregorio Maranon Health Research Institute, Madrid, Spain.&#xD;Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Deu, Barcelona, Spain.&#xD;Institut de Recerca Sant Joan de Deu, Universitat de Barcelona, Barcelona, Spain.&#xD;Clinic for Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark, Odense, Denmark.&#xD;Department of Pediatrics, Division of Pediatric Allergy, Koc University School of Medicine, Istanbul, Turkiye.&#xD;McMaster University, Hamilton, Canada.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, University of Cagliari, Cagliari, Italy.&#xD;Paediatrics and Child Health, INFANT Centre, HRB-CRF, University College Cork, Cork, Ireland.&#xD;Paediatrics and Child Health, Royal College of Surgeons in Ireland, Children&apos;s Health Ireland, Dublin, Ireland.&#xD;Department of Dermatology and Allergy, Technical University of Munich, School of Medicine, Munich, Germany.&#xD;Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Kanagawa, Japan.&#xD;Department of Pediatrics, Gynecology and Obstetrics, University Hospitals of Geneva, Geneva, Switzerland.&#xD;Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St.Polten, Austria.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Allergy Department, Hospital Clinico San Carlos, Madrid, Spain.&#xD;Facultad de Medicina, Universidad Complutense, IdISSC, ARADyAL, Madrid, Spain.&#xD;Allergy Department, Pediatric Hospital Bambino Gesu IRCCS, Rome, Italy.&#xD;University of Colorado School of Medicine and Children&apos;s Hospital Colorado, Aurora, Colorado, USA.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Red Cross Children&apos;s Hospital and Kidsallergy Centre, Cape Town, South Africa.&#xD;Department of Paediatrics, University of Cape Town, Cape Town, South Africa.&#xD;Dept. of pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Odense, Denmark.&#xD;Royal College of Surgeons in Ireland and Childrens Health Ireland, Dublin, Ireland.&#xD;School of Psychology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.&#xD;Department of Clinical Immunology, Faculty of Medicine, Wroclaw Medical University; and ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department Center of Translational Immunology and Department Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.&#xD;EAACI Patient Organisation Committee, Zurich, Switzerland.&#xD;MJM Advisory, New York, New York, USA.&#xD;Dept. Nutrition and Dietetics, Winchester University, Winchester, UK.&#xD;Department of Medicine, KU Leuven, Leuven, Belgium.&#xD;Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain.&#xD;Instituto de Investigacion Sanitaria, Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Food Allergy Referral Centre, Padua University Hospital, Padua, Italy.&#xD;Department of Clinical Science and Education, Karolinska Institutet, Solna, Sweden.&#xD;Sachs Children and Youth Hospital, South Hospital, Stockholm, Sweden.&#xD;Division of Allergy and Clinical Immunology, Department of Paediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;Department of Medicine, School of Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Allergy Dpt, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Lydia Becker Institute, University of Manchester, Manchester, UK.&#xD;Population Allergy, Murdoch Children&apos;s Research Institute, Parkville, Australia.&#xD;Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia.&#xD;Department of Allergy and Immunology, Royal Children&apos;s Hospital, Parkville, Australia.&#xD;Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;Department of Paediatrics, the University of Melbourne, Parkville, Victoria, Australia.&#xD;European Federation of Allergy and Airways Diseases Patients&apos; Associations and the EAACI Patient Organisation Committee, Zurich, Switzerland.&#xD;Allergy Clinic, Copenhagen University Hospital at Herlev-Gentofte, Copenhagen, Denmark.&#xD;Paediatric Allergy and Respiratory Medicine, University of Southampton, NIHR Southampton Biomedical Research Centre and David Hide Asthma and Allergy Centre, St Mary Hospital, Isle of Wight, UK.&#xD;Department of Pediatrics, Division of Allergy and Immunology, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Child Life and Health, Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.&#xD;Clinical Medicine, Griffith University, Southport, Queensland, Australia.&#xD;Queensland Allergy Services Private Practice, Southport, Queensland, Australia.&#xD;Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Khoo Teck Puat-National University Children&apos;s Medical Institute, National University Health System (NUHS), Singapore, Singapore.&#xD;Human Potential Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Experimental Immunology and of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.&#xD;Section of Allergy and Clinical Immunology, Children&apos;s Hospital Colorado, University of Colorado, Boulder, Colorado, USA.&#xD;Emory University School of Medicine and Children&apos;s Healthcare of Atlanta, Atlanta, Georgia, USA.&#xD;Department of Paediatrics, OLVG Hospital, Amsterdam, the Netherlands.&#xD;Rijnstate Allergy Centre, Rijnstate Hospital, Arnhem, The Netherlands.&#xD;Vlieg Dieticians, Private Practice for dietary management of food allergy, Arnhem, the Netherlands.&#xD;Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Part of Guys and St Thomas NHS Foundation Trust, Royal Brompton and Harefield Hospitals, London, UK.&#xD;Department of Inflammation and Repair, Imperial College, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI guidelines on the management of IgE-mediated food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">14-36</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/therapy/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">biologicals</style></keyword><keyword><style face="normal" font="default" size="100%">diet</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword><keyword><style face="normal" font="default" size="100%">support the effort towards the systematic review of the literature and</style></keyword><keyword><style face="normal" font="default" size="100%">meta-analyses. All members of the steering committee and of the expert group</style></keyword><keyword><style face="normal" font="default" size="100%">worked voluntarily without compensation and filled in a declaration of conflicts</style></keyword><keyword><style face="normal" font="default" size="100%">ahead of the start of the project, which were reviewed by EAACI. A.F. Santos</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from Medical Research Council (MR/M008517/1</style></keyword><keyword><style face="normal" font="default" size="100%">MC/PC/18052</style></keyword><keyword><style face="normal" font="default" size="100%">MR/T032081/1), Food Allergy Research and Education (FARE), the Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Network/National Institute of Allergy and Infectious Diseases (NIAID, NIH),</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma UK (AUK-BC-2015-01), BBSRC, Rosetrees Trust and the NIHR through the</style></keyword><keyword><style face="normal" font="default" size="100%">Biomedical Research Centre (BRC) award to Guy&apos;s and St Thomas&apos; NHS Foundation</style></keyword><keyword><style face="normal" font="default" size="100%">Trust, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Thermo Scientific,</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia, Infomed, Novartis, Allergy Therapeutics, Buhlmann, as well as research</style></keyword><keyword><style face="normal" font="default" size="100%">support from Buhlmann and Thermo Fisher Scientific through a collaboration</style></keyword><keyword><style face="normal" font="default" size="100%">agreement with King&apos;s College London. C. Riggioni reports academic grants for the</style></keyword><keyword><style face="normal" font="default" size="100%">study of immunotherapy in food allergic children from the Spanish Society of</style></keyword><keyword><style face="normal" font="default" size="100%">Paediatric Allergy (SEICAP) and the National University of Singapore. H. A.</style></keyword><keyword><style face="normal" font="default" size="100%">Brough reports research grants from NIH (NAIAD), Aimmune and DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">and speaker honoraria fees from DBV Technologies, GSK and Sanofi outside of the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. I. Agache reports Deputy Editor Allergy and Associate Editor</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical and Translational Allergy. A. Fiocchi reports research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Ferrero, Hipp, Sanofi, Novartis, Astrazeneca and DBV, fees for presentations and</style></keyword><keyword><style face="normal" font="default" size="100%">advisory boards for Danone, Abbott, Ferrero, Stallergenes and Novartis. H. Fisher</style></keyword><keyword><style face="normal" font="default" size="100%">reports employment at Sanofi, outside of the submitted work. D. Fleischer reports</style></keyword><keyword><style face="normal" font="default" size="100%">research grants to institution from ARS Pharmaceuticals and DBV Technologies</style></keyword><keyword><style face="normal" font="default" size="100%">unpaid advisory board member for Food Allergy &amp; Anaphylaxis Connection Team and</style></keyword><keyword><style face="normal" font="default" size="100%">the National Peanut Board</style></keyword><keyword><style face="normal" font="default" size="100%">royalties from UpToDate</style></keyword><keyword><style face="normal" font="default" size="100%">consultation fees as a member</style></keyword><keyword><style face="normal" font="default" size="100%">of physician/medical advisory boards to Aquestive, ARS Pharmaceuticals, Bryn</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, DBV Technologies, Genentech, and Nasus</style></keyword><keyword><style face="normal" font="default" size="100%">and speaker fees from Genentech,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. B. Ballmer-Weber reports personal fees for</style></keyword><keyword><style face="normal" font="default" size="100%">presentations and advisory boards from Thermo Fisher Scientific, Novartis, ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, Menarini, Sanofi, MSD, Aiummune. S. Halken reports personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from ALK, personal fees from Mead Johnson, personal fees from Viatris, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from GSK, outside the submitted work. S. Lau receives grants from Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">DBV, Infectopharm as deputy PI and a grant from the German Research Foundation</style></keyword><keyword><style face="normal" font="default" size="100%">(DFG). SL received personal fees from Allergopharma, ALK, Viatris, Lilly, DBV,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, Leo Pharma and Sanofi-Aventis. P. Smith has received investigator initiated</style></keyword><keyword><style face="normal" font="default" size="100%">funding from GSK, Hyloris and Sanofi. C. G Mortz report research grant from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis and Thermo Fisher Scientific. B. Eberlein reports research support from</style></keyword><keyword><style face="normal" font="default" size="100%">Buhlmann. D. Fleisher reports Grant/research support: Aimmune Therapeutics, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technolgies. Consultant: Aquestive Therapeutics, ARS Pharma, DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">Nasus Pharma Genentech&apos; Royalties: UpToDate. M. Jutel reports: Personal fees form</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, ALK-Abello, Stallergenes, Anergis, Allergy Therapeutics, Leti,</style></keyword><keyword><style face="normal" font="default" size="100%">HAL, GSK, Novartis, Teva, Takeda, Chiesi, Pfizer, Regeneron, Astra-Zeneka,</style></keyword><keyword><style face="normal" font="default" size="100%">Lallemand, Shire, Celltrion Inc., Genentech, Roche, Verona, Lek Pharmaceuticals,</style></keyword><keyword><style face="normal" font="default" size="100%">Arcutis Biotherapeutics, FAES FARMA outside of submitted work. Deputy Editor in</style></keyword><keyword><style face="normal" font="default" size="100%">chief Allergy, Associate Editor CTA. C. Bindslev-Jensen reports material for IgE</style></keyword><keyword><style face="normal" font="default" size="100%">analyzes from Thermofisher</style></keyword><keyword><style face="normal" font="default" size="100%">Lecture fee from Alk-Abello</style></keyword><keyword><style face="normal" font="default" size="100%">advisory board fees from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK and Novartis research grants from Ionis, Allakos, Novartis. E. F. Knol</style></keyword><keyword><style face="normal" font="default" size="100%">reports Research grants from Stichting Astma Bestrijding and European Union.</style></keyword><keyword><style face="normal" font="default" size="100%">Research support from Euroimmune, speakers fee from Thermo Fisher Scientific,</style></keyword><keyword><style face="normal" font="default" size="100%">Hycor, Sanofi and GSK. C. Jones reports Research grants from the National</style></keyword><keyword><style face="normal" font="default" size="100%">Institute for Health and Care Research, Food Standards Agency and honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">National Institute for Health and Care Research, Allergy UK and Danone/Nutricia.</style></keyword><keyword><style face="normal" font="default" size="100%">C. Gray reports speaker or advisory board fees from Nutricia, Thermofisher,</style></keyword><keyword><style face="normal" font="default" size="100%">Kenvue, Viatris and Sanofi. G. Du Toit reports grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune, grants and personal fees from DBV, personal fees from FARE, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">NIH-NIAID, grants and personal fees from Novartis, outside the submitted work. G.</style></keyword><keyword><style face="normal" font="default" size="100%">Roberts reports Research funding from National Institute of Health and Food</style></keyword><keyword><style face="normal" font="default" size="100%">Standards Agency. President of British Society of Allergy and Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Immunology. H. Sampson reports funding to his institution for grants from</style></keyword><keyword><style face="normal" font="default" size="100%">NIH/NIAID and has received consulting fees from DBV Technologies, S. A., N-Fold</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, LLC, and Siolta, Inc., and stock options from DBV Technologies and</style></keyword><keyword><style face="normal" font="default" size="100%">N-Fold Therapeutics. S. Del Giacco has received speaker and consultancy fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Chiesi, CSL-Behring, GSK, Novartis, Sanofi, Stallergenes and</style></keyword><keyword><style face="normal" font="default" size="100%">unrestricted research grants from Novartis and GSK, all outside this work. G. N.</style></keyword><keyword><style face="normal" font="default" size="100%">Konstantinou is or recently was a speaker and/or advisor for and/or has received</style></keyword><keyword><style face="normal" font="default" size="100%">research funding from AstraZeneca, Chiesi, GSK, Menarini, Novartis, Nutricia,</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, Sanofi, Takeda, TEVA and Vianex. C. Nilsson reports grants to institution</style></keyword><keyword><style face="normal" font="default" size="100%">from Aimmune Therapeutics a Nestle Company, Lecture fees from ALK, Themofisher,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK. A. Muraro declared the receipt of consultation or speakers&apos; fees for</style></keyword><keyword><style face="normal" font="default" size="100%">Viatris, Aimmune, DVB Technologies, Nestle Health Sciences, ALK, Stallergenes,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Sanofi. Regeneron. E. Untersmayr reports grants from Desentum Oy</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">received personal speaker fees from Nutrica, AllergoPharma, MacroArray</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostics. B. P. Vickery reports grants from Abbott, grants and personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Aimmune, grants from Alladapt, personal fees from AllerGenis, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Aravax, grants and personal fees from DBV, grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">FARE, grants from Genentech, stock options from Moonlight Therapeutics, grants</style></keyword><keyword><style face="normal" font="default" size="100%">from NIH-NIAID, grants and personal fees from Novartis, personal fees from Reacta</style></keyword><keyword><style face="normal" font="default" size="100%">Biosciences, grants and personal fees from Regeneron, personal fees from Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Siolta, outside the submitted work. M. Worm declares the receipt of</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria or consultation fees by the following companies: Novartis Pharma GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Aventis Deutschland GmbH, DBV Technologies S.A, Aimmune Therapeutics UK</style></keyword><keyword><style face="normal" font="default" size="100%">Limited, Regeneron Pharmaceuticals, Inc., Leo Pharma GmbH, Boehringer Ingelheim</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma GmbH &amp;Co.KG, ALK-Abello Arzneimittel GmbH, Lilly Deutschland GmbH, Kymab</style></keyword><keyword><style face="normal" font="default" size="100%">Limited, Amgen GmbH, Abbvie Deutschland GmbH &amp; Co. KG, Pfizer Pharma GmbH, Mylan</style></keyword><keyword><style face="normal" font="default" size="100%">Germany GmbH (A Viatris Company), AstraZeneca GmbH, Lilly Deutschland GmbH and</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline GmbH &amp; Co. KG. B. Vlieg-Boerstra received research funding from</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia, consulting or speaker&apos;s fees from Marfo Food groups, Nestle, Abbott,</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia and Vinimini. J. Schwarze reports personal consulting fees from Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">and Sanofi, congress sponsorship from ALK, research grants from NIHR and</style></keyword><keyword><style face="normal" font="default" size="100%">UKRI-MRC. K. Hoffmann-Sommergruber reports grant support from Government of Lower</style></keyword><keyword><style face="normal" font="default" size="100%">Austria (DARC) and consultancy fees from COMPARE Database. K. Beyer reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from the German Research Foundation, the Federal Ministry of Education and</style></keyword><keyword><style face="normal" font="default" size="100%">Research, the Federal Ministry of Food and Agriculture as well as from Aimmune,</style></keyword><keyword><style face="normal" font="default" size="100%">Danone/Nutricia, DBV, Hipp, Hycor, Infectopharm and Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">she received</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Aimmune, Akademie Fresenius, Allergy Therapeutics, ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">Danone/Nutricia, Hipp, Hycor, Infectopharm, Kantar Health, Limbach Gruppe,</style></keyword><keyword><style face="normal" font="default" size="100%">Mylan/Meda/Mice, Nestle, Novartis, Sonic Health Care and ThermoFisher. K. P.</style></keyword><keyword><style face="normal" font="default" size="100%">Perrett has received research grants from National Health &amp; Medical Research</style></keyword><keyword><style face="normal" font="default" size="100%">Council of Australia, Immune Tolerance Network (NIH), Aravax, DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis and Siolta and consultant fees from Aravax, paid to their institution,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. L. O&apos;Mahony reports Consultancy with Precision</style></keyword><keyword><style face="normal" font="default" size="100%">BioticsAlimentary Health, grants from GlaxoSmithKline and Chiesi, and</style></keyword><keyword><style face="normal" font="default" size="100%">participation in speaker bureau for Nestle, Yakult, Reckitt and Abbott. L.</style></keyword><keyword><style face="normal" font="default" size="100%">Oliveira reports Speakers fee from Thermo Fisher Scientific, Nutricia, Sanofi and</style></keyword><keyword><style face="normal" font="default" size="100%">Takeda. Dunn-Galvin declares the receipt of honoraria or consultation fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, DBV, Aimmune, Nestle. M. Alvaro-Lozano reports Honoraria or</style></keyword><keyword><style face="normal" font="default" size="100%">consultation fees from ALK-Abello, FAES Pharma, LETI Pharma, Merck, Aimmune, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Allergy Therapeutics, Stallergenes, Diater, Novartis, Uriach,</style></keyword><keyword><style face="normal" font="default" size="100%">Nestle and Sanofi Genzyme. Grants from SEICAP, SCAIC. M. Fernandez-Rivas reports</style></keyword><keyword><style face="normal" font="default" size="100%">research support from Instituto de Salud Carlos III, Spanish Government, Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Diater and Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">Speaker and Advisory Board honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune Therapeutics, DBV, Diater, Ediciones Mayo, EPG Health, GSK, HAL Allergy,</style></keyword><keyword><style face="normal" font="default" size="100%">MEDSCAPE</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Reacta Healthcare, SPRIM. M. Ebisawa reports Speaker and</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Board honoraria from Viatris, Novartis, Sanofi, and ARS-Pharmaceuticals.</style></keyword><keyword><style face="normal" font="default" size="100%">M. Marshisotto reports advisory roles to IFPIES, National Peanut Board, Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Advisory Board, GA2LEN ANACare and University of Michigan. N.</style></keyword><keyword><style face="normal" font="default" size="100%">Papadoupoulos reports Research Support from Capricare, Nestle, Numil, REG,</style></keyword><keyword><style face="normal" font="default" size="100%">Vianex. Speaker and Advisory Board honoraria from Abbott, Abbvie, Astra Zeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, HAL, Medscape, Menarini/Faes Farma, Mylan, Novartis, Nutricia, OM Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron/Sanofi. P. Smith reports Speaker and advisory board honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">Nestle Nutrition Institute. Investigator initiated research funding from GSK and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi. Vitaris advisory board honoraria. P. Eigenmann reports Speaker and</style></keyword><keyword><style face="normal" font="default" size="100%">advisory board honoraria: DBV technologies, Novartis, ThermoFisher Scientific,</style></keyword><keyword><style face="normal" font="default" size="100%">Nestle Health Sciences, Synlab, GSK</style></keyword><keyword><style face="normal" font="default" size="100%">Stocks and Stock options: DBV technologies.</style></keyword><keyword><style face="normal" font="default" size="100%">R. Peters reports research grants from the National Health &amp; Medical Research</style></keyword><keyword><style face="normal" font="default" size="100%">Council of Australia, and research support from ThermoFisher, paid to their</style></keyword><keyword><style face="normal" font="default" size="100%">institution, outside the submitted work. R. van Ree reports Consultancies for HAL</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy, Citeq, Angany, Reacta Helathcare, Mission MightMe, AB Enzymes, The</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Brewery</style></keyword><keyword><style face="normal" font="default" size="100%">speaker&apos;s fees from HAL Allergy, ALK and Thermo Fisher</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific</style></keyword><keyword><style face="normal" font="default" size="100%">stock options from Angany. R. Meyer honoraria from academic lectures</style></keyword><keyword><style face="normal" font="default" size="100%">and consultancy fees from Nutricia/Danone, Abbott Laboratories, Nestle Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Nutrition, Reckitt Benckiser and Else Nutrition. T. Eiwegger reports to</style></keyword><keyword><style face="normal" font="default" size="100%">act/recently acted as local PI for company sponsored trials by DBV Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">Greer Stallergens, and sub-investigator for Regeneronand ALK-Abello. He/his lab</style></keyword><keyword><style face="normal" font="default" size="100%">received unconditional/in-kind contributions from Macro Array. Diagnostics and</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello and he is co-I in an investigator-initiated trial with in-kind support</style></keyword><keyword><style face="normal" font="default" size="100%">from Novartis. He holds advisory board roles for ALK-Abello, and Nutricia/Danone.</style></keyword><keyword><style face="normal" font="default" size="100%">TE reports lecture fees from Novartis, ThermoFisher, Nutricia/Danone, MADX,</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello. T. Werfel has received institutional grants from LEO Pharma and</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, has performed consultancies for Abbvie, Almirall, Janssen, Galderma,</style></keyword><keyword><style face="normal" font="default" size="100%">LEO, Lilly, Novartis, Pfizer, Sanofi-Regeneron and has lectured at events</style></keyword><keyword><style face="normal" font="default" size="100%">sponsored by Abbvie, Janssen, Celgene, Galderma, LEO Pharma, Lilly, Sanofi and</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis. I. Skypala-honoraria from ThermoFisher, Royal College of General</style></keyword><keyword><style face="normal" font="default" size="100%">Practitioners and Touch Independent Medical Education. JOBH declares research</style></keyword><keyword><style face="normal" font="default" size="100%">funding from DBV Technologies, Johnson&amp; Johnson, Consultancy with Camallergy,</style></keyword><keyword><style face="normal" font="default" size="100%">speaker fees from Nutricia. A. Alvarez-Perea declares the receipt of honoraria or</style></keyword><keyword><style face="normal" font="default" size="100%">consultation fees from ALK-Abello, Organon, Immunotek, DBV-technologies, GSK and</style></keyword><keyword><style face="normal" font="default" size="100%">PI and sub-investigator for company sponsored trials by Novartis, Leti, CEU-San</style></keyword><keyword><style face="normal" font="default" size="100%">Pablo, Aimmune. The other authors have nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39473345</style></accession-num><abstract><style face="normal" font="default" size="100%">This European Academy of Allergy and Clinical Immunology (EAACI) guideline provides recommendations for the management of IgE-mediated food allergy and was developed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Following the confirmation of IgE-mediated food allergy diagnosis, allergen avoidance and dietary advice (with support of a specialised dietitian, if possible) together with the provision of a written treatment plan, education on the recognition of allergic symptoms and prescription of medication including adrenaline using an auto-injector are essential. Patients with significant anxiety and requirement for coping strategies may benefit from support from a clinical psychologist. As immunomodulatory interventions, omalizumab is suggested for treatment of IgE-mediated food allergy in children from the age of 1 and adults; and oral allergen-specific immunotherapy is recommended for children and adolescents with peanut allergy and suggested for milk and egg allergies (generally after 4 years of age for milk and egg). Sublingual and epicutaneous immunotherapy are suggested for peanut allergy but are not yet available at the point of care. Future research into disease modifying treatments for IgE-mediated food allergy are highly needed, with standardised and patient-focused protocols and outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Santos, Alexandra F&#xD;Riggioni, Carmen&#xD;Agache, Ioana&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Alvarez-Perea, Alberto&#xD;Alvaro-Lozano, Montserrat&#xD;Ballmer-Weber, Barbara&#xD;Barni, Simona&#xD;Beyer, Kirsten&#xD;Bindslev-Jensen, Carsten&#xD;Brough, Helen A&#xD;Buyuktiryaki, Betul&#xD;Chu, Derek&#xD;Del Giacco, Stefano&#xD;Dunn-Galvin, Audrey&#xD;Eberlein, Bernadette&#xD;Ebisawa, Motohiro&#xD;Eigenmann, Philippe&#xD;Eiwegger, Thomas&#xD;Feeney, Mary&#xD;Fernandez-Rivas, Montserrat&#xD;Fiocchi, Alessandro&#xD;Fisher, Helen R&#xD;Fleischer, David M&#xD;Giovannini, Mattia&#xD;Gray, Claudia&#xD;Hoffmann-Sommergruber, Karin&#xD;Halken, Susanne&#xD;O&apos;B Hourihane, Jonathan&#xD;Jones, Christina J&#xD;Jutel, Marek&#xD;Knol, Edward F&#xD;Konstantinou, George N&#xD;Lack, Gideon&#xD;Lau, Susanne&#xD;Mejias, Andreina Marques&#xD;Marchisotto, Mary Jane&#xD;Meyer, Rosan&#xD;Mortz, Charlotte G&#xD;Moya, Beatriz&#xD;Muraro, Antonella&#xD;Nilsson, Caroline&#xD;de Oliveira, Lucila Camargo Lopes&#xD;O&apos;Mahony, Liam&#xD;Papadopoulos, Nikolaos G&#xD;Perrett, Kirsten P&#xD;Peters, Rachel&#xD;Podesta, Marcia&#xD;Poulsen, Lars K&#xD;Roberts, Graham&#xD;Sampson, Hugh&#xD;Schwarze, Jurgen&#xD;Smith, Peter&#xD;Tham, Elizabeth&#xD;Untersmayr, Eva&#xD;Van Ree, Ronald&#xD;Venter, Carina&#xD;Vickery, Brian&#xD;Vlieg-Boerstra, Berber&#xD;Werfel, Thomas&#xD;Worm, Margitta&#xD;Du Toit, George&#xD;Skypala, Isabel&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Practice Guideline&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):14-36. doi: 10.1111/all.16345. Epub 2024 Oct 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39473345</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724237</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16345</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>872</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">872</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Alviani, C.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">DunnGalvin, A.</style></author><author><style face="normal" font="default" size="100%">Garvey, L. H.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">de Silva, D.</style></author><author><style face="normal" font="default" size="100%">Angier, E.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Bellou, A.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Bijlhout, D.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Halken, S.</style></author><author><style face="normal" font="default" size="100%">Jensen, B.</style></author><author><style face="normal" font="default" size="100%">Khaleva, E.</style></author><author><style face="normal" font="default" size="100%">Michaelis, L. J.</style></author><author><style face="normal" font="default" size="100%">Oude Elberink, H. N. G.</style></author><author><style face="normal" font="default" size="100%">Regent, L.</style></author><author><style face="normal" font="default" size="100%">Sanchez, A.</style></author><author><style face="normal" font="default" size="100%">Vlieg-Boerstra, B. J.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">European Academy of, Allergy</style></author><author><style face="normal" font="default" size="100%">Clinical Immunology, Food Allergy Anaphylaxis Guidelines Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy.&#xD;Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charite Universitatsmedizin Berlin, Germany.&#xD;Clinical and Experimental Sciences and Human Development in Health, Faculty of Medicine, University of Southampton, UK.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall d&apos;Hebron &amp; ARADyAL Research Network, Barcelona, Spain.&#xD;University College Cork, Cork, Ireland.&#xD;Sechnov University Moscow, Moscow, Russia.&#xD;Allergy Clinic, Department of Dermatology and allergy, Copenhagen University Hospital Gentofte, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Allergy, Immunology and Rheumatology Division, Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.&#xD;The Evidence Centre Ltd, London, UK.&#xD;Primary Care, Population Science and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Allergy Unit - Area of Translational Research in Pediatric Specialities, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;European Society for Emergency Medicine, Brussels, Belgium.&#xD;Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA.&#xD;University of Rennes 1, Rennes, France.&#xD;Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Association for Teacher Education in Europe (ATEE, Brussels, Belgium.&#xD;Allergy Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.&#xD;Department of Internal Medicine, University Hospital of Ancona, Ancona, Italy.&#xD;Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.&#xD;Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.&#xD;Allergy Department, Hospital Clinico San Carlos, Facultad Medicina Universidad Complutense, IdISSC, ARADyAL, Madrid, Spain.&#xD;Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Odense, Denmark.&#xD;Department of Paediatric Immunology, Allergy, and Infectious Diseases, Great North Children&apos;s Hospital, Newcastle upon Tyne, UK.&#xD;Faculty of Medical Sciences, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.&#xD;Department of Allergology, University Medical Center Groningen, University of Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands.&#xD;Anaphylaxis Campaign, Farnborough, UK.&#xD;AEPNAA Spanish Association for People with Food and Latex Allergy, Madrid, Spain.&#xD;Department of Paediatrics, OLVG Hospital, Amsterdam, The Netherlands.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Isle of Wight, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI guidelines: Anaphylaxis (2021 update)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">357-377</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/08/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptases</style></keyword><keyword><style face="normal" font="default" size="100%">adults</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34343358</style></accession-num><abstract><style face="normal" font="default" size="100%">Anaphylaxis is a clinical emergency which all healthcare professionals need to be able to recognize and manage. The European Academy of Allergy and Clinical Immunology Anaphylaxis multidisciplinary Task Force has updated the 2014 guideline. The guideline was developed using the AGREE II framework and the GRADE approach. The evidence was systematically reviewed and recommendations were created by weighing up benefits and harms. The guideline was peer-reviewed by external experts and reviewed in a public consultation. The use of clinical criteria to identify anaphylaxis is suggested with blood sampling for the later measurement of tryptase. The prompt use of intramuscular adrenaline as first-line management is recommended with the availability of adrenaline autoinjectors to patients in the community. Pharmacokinetic data should be provided for adrenaline autoinjector devices. Structured, comprehensive training for people at risk of anaphylaxis is recommended. Simulation training and visual prompts for healthcare professionals are suggested to improve the management of anaphylaxis. It is suggested that school policies reflect anaphylaxis guidelines. The evidence for the management of anaphylaxis remains mostly at a very low level. There is an urgent need to prioritize clinical trials with the potential to improve the management of patients at risk of anaphylaxis.</style></abstract><notes><style face="normal" font="default" size="100%">Muraro, Antonella&#xD;Worm, Margitta&#xD;Alviani, Cherry&#xD;Cardona, Victoria&#xD;DunnGalvin, Audrey&#xD;Garvey, Lene Heise&#xD;Riggioni, Carmen&#xD;de Silva, Debra&#xD;Angier, Elizabeth&#xD;Arasi, Stefania&#xD;Bellou, Abdelouahab&#xD;Beyer, Kirsten&#xD;Bijlhout, Diola&#xD;Bilo, Maria Beatrice&#xD;Bindslev-Jensen, Carsten&#xD;Brockow, Knut&#xD;Fernandez-Rivas, Montserrat&#xD;Halken, Susanne&#xD;Jensen, Britt&#xD;Khaleva, Ekaterina&#xD;Michaelis, Louise J&#xD;Oude Elberink, Hanneke N G&#xD;Regent, Lynne&#xD;Sanchez, Angel&#xD;Vlieg-Boerstra, Berber J&#xD;Roberts, Graham&#xD;eng&#xD;Practice Guideline&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):357-377. doi: 10.1111/all.15032. Epub 2021 Sep 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34343358</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15032</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>657</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">657</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Antolin-Amerigo, D.</style></author><author><style face="normal" font="default" size="100%">de Blay, F.</style></author><author><style face="normal" font="default" size="100%">Boccabella, C.</style></author><author><style face="normal" font="default" size="100%">Caruso, C.</style></author><author><style face="normal" font="default" size="100%">Chanez, P.</style></author><author><style face="normal" font="default" size="100%">Couto, M.</style></author><author><style face="normal" font="default" size="100%">Covar, R.</style></author><author><style face="normal" font="default" size="100%">Doan, S.</style></author><author><style face="normal" font="default" size="100%">Fauquert, J. L.</style></author><author><style face="normal" font="default" size="100%">Gauvreau, G.</style></author><author><style face="normal" font="default" size="100%">Gherasim, A.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Lemiere, C.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author><author><style face="normal" font="default" size="100%">Ojanguren, I.</style></author><author><style face="normal" font="default" size="100%">Peden, D.</style></author><author><style face="normal" font="default" size="100%">Perez-de-Llano, L.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author><author><style face="normal" font="default" size="100%">Rukhazde, M.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Schulze, J.</style></author><author><style face="normal" font="default" size="100%">Silva, D.</style></author><author><style face="normal" font="default" size="100%">Tarlo, S.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Zielen, S.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Servicio de Alergia, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain.&#xD;ALYATEC Environmental Exposure Chamber, Chest Diseases Department, Strasbourg University Hospital, University of Strasbourg, Strasbourg, France.&#xD;Department of Cardiovascular and Thoracic Sciences, Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.&#xD;Allergy Unit, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy.&#xD;Department of Respiratory CIC Nord INSERMINRAE C2VN, Aix Marseille University, Marseille, France.&#xD;Centro de Alergia, Hospital CUF Descobertas, Lisboa, Portugal.&#xD;Pediatrics, National Jewish Health, Denver, Colorado, USA.&#xD;Fondation A de Rothschild, Paris, France.&#xD;University Hospital, Clermont-Ferrand, France.&#xD;Division of Respirology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;ALYATEC Environmental Exposure Chamber, Strasbourg, France.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Research Centre, Centre Integre Universitaire de sante et de services sociaux du Nord-de-l&apos;ile-de-Montreal, Montreal, Quebec, Canada.&#xD;Faculty of Medicine, Universite de Montreal, Montreal, Quebec, Canada.&#xD;Department of Medicine, Firestone Institute of Respiratory Health at St. Joseph&apos;s Healthcare, McMaster University, Hamilton, Ontario, Canada.&#xD;Departament de Medicina, Servei de Pneumologia, Hospital Universitari Valld Hebron, Universitat Autonoma de Barcelona (UAB), Institut de Recerca (VHIR), CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.&#xD;Division of Pediatric Allergy and Immunology, Center for Environmental Medicine, Asthma and Lung Biology, The School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.&#xD;Department of Respiratory Medicine, University Hospital Lucus Augusti, Lugo, Spain.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Instituto de Investigacion Biomedica de Malaga (IBIMA), Malaga, Spain.&#xD;Center of Allergy &amp; Immunology, Teaching University Geomedi LLC, Tbilisi, Georgia.&#xD;Allergy Unit, Hospital Universitario Fundacion Jimenez Diaz, Center for Biomedical Network of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.&#xD;Department for Children and Adolescents, Division of Allergology, Pulmonology and Cystic Fibrosis, Goethe-University Hospital, Frankfurt am Main, Germany.&#xD;Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto and Servico de Imunoalergologia, Centro Hospitalar Sao Joao, EPE, Porto, Portugal.&#xD;Respiratory Division, Department of Medicine, University Health Network, Toronto Western Hospital, University of Toronto Department of Medicine, and Dalla Lana Department of Public Health, Toronto, Ontario, Canada.&#xD;Haartman Institute, Medicum, Skin and Allergy Hospital, Hospital District of Helsinki and Uusimaa, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1667-1684</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/01/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/chemically induced/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchial Provocation Tests/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Research</style></keyword><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">bronchial allergen challenge</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mites</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34978085</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic asthma (AA) is a common asthma phenotype, and its diagnosis requires both the demonstration of IgE-sensitization to aeroallergens and the causative role of this sensitization as a major driver of asthma symptoms. Therefore, a bronchial allergen challenge (BAC) would be occasionally required to identify AA patients among atopic asthmatics. Nevertheless, BAC is usually considered a research tool only, with existing protocols being tailored to mild asthmatics and research needs (eg long washout period for inhaled corticosteroids). Consequently, existing BAC protocols are not designed to be performed in moderate-to-severe asthmatics or in clinical practice. The correct diagnosis of AA might help select patients for immunomodulatory therapies. Allergen sublingual immunotherapy is now registered and recommended for controlled or partially controlled patients with house dust mite-driven AA and with FEV1 &gt;/= 70%. Allergen avoidance is costly and difficult to implement for the management of AA, so the proper selection of patients is also beneficial. In this position paper, the EAACI Task Force proposes a methodology for clinical BAC that would need to be validated in future studies. The clinical implementation of BAC could ultimately translate into a better phenotyping of asthmatics in real life, and into a more accurate selection of patients for long-term and costly management pathways.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Antolin-Amerigo, Dario&#xD;de Blay, Frederic&#xD;Boccabella, Cristina&#xD;Caruso, Cristiano&#xD;Chanez, Pascal&#xD;Couto, Mariana&#xD;Covar, Ronina&#xD;Doan, Serge&#xD;Fauquert, Jean-Luc&#xD;Gauvreau, Gail&#xD;Gherasim, Alina&#xD;Klimek, Ludger&#xD;Lemiere, Catherine&#xD;Nair, Parameswaran&#xD;Ojanguren, Inigo&#xD;Peden, David&#xD;Perez-de-Llano, Luis&#xD;Pfaar, Oliver&#xD;Rondon, Carmen&#xD;Rukhazde, Maia&#xD;Sastre, Joaquin&#xD;Schulze, Johannes&#xD;Silva, Diana&#xD;Tarlo, Susan&#xD;Toppila-Salmi, Sanna&#xD;Walusiak-Skorupa, Jolanta&#xD;Zielen, Stefan&#xD;Eguiluz-Gracia, Ibon&#xD;eng&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1667-1684. doi: 10.1111/all.15203. Epub 2022 Jan 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34978085</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15203</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2161</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2161</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Hermuth-Kleinschmidt, K.</style></author><author><style face="normal" font="default" size="100%">Dramburg, S.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Mayerhofer, H.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Goshua, A.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria.&#xD;Center of Physiology, Pathophysiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University Vienna, Vienna, Austria.&#xD;NIUB Sustainability consulting, Freiburg im Breisgau, Germany.&#xD;Department of Pediatric Respiratory Care, Immunology and Intensive Care Medicine, Charite Universitatsmedizin - Berlin, Berlin, Germany.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An EAACI review: Go green in health care and research. Practical suggestions for sustainability in clinical practice, laboratories, and scientific meetings</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2606-2622</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/08/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Laboratories</style></keyword><keyword><style face="normal" font="default" size="100%">*Environment</style></keyword><keyword><style face="normal" font="default" size="100%">Delivery of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">lung diseases</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">sustainability</style></keyword><keyword><style face="normal" font="default" size="100%">in relation to the present article. Erika Jensen-Jarolim is a shareholder in</style></keyword><keyword><style face="normal" font="default" size="100%">Biomedical International R+D GmbH, Vienna, and co-inventor on patent EP 2894478</style></keyword><keyword><style face="normal" font="default" size="100%">A1 (Method and means for diagnosing and treating allergy), of Biomedical Int. R+D</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH. KHK is auditor for EGNATON-CERT. KN reports grants from National Institute</style></keyword><keyword><style face="normal" font="default" size="100%">of Allergy and Infectious Diseases (NIAID), National Heart, Lung, and Blood</style></keyword><keyword><style face="normal" font="default" size="100%">Institute (NHLBI), National Institute of Environmental Health Sciences (NIEHS),</style></keyword><keyword><style face="normal" font="default" size="100%">and Food Allergy Research &amp; Education (FARE)</style></keyword><keyword><style face="normal" font="default" size="100%">Stock options from IgGenix, Seed</style></keyword><keyword><style face="normal" font="default" size="100%">Health, ClostraBio, Cour, Alladapt, Clostrabio, and ImmuneID</style></keyword><keyword><style face="normal" font="default" size="100%">Director of the</style></keyword><keyword><style face="normal" font="default" size="100%">World Allergy Organization Center of Excellence for Stanford</style></keyword><keyword><style face="normal" font="default" size="100%">Advisor at Cour</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">Consultant for Excellergy, Red tree ventures, Before Brands, Alladapt,</style></keyword><keyword><style face="normal" font="default" size="100%">Cour, Latitude, Regeneron, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">Co-founder of Before Brands, Alladapt,</style></keyword><keyword><style face="normal" font="default" size="100%">Latitude, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">National Scientific Committee member at Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Network (ITN), and National Institutes of Health (NIH) clinical research centers</style></keyword><keyword><style face="normal" font="default" size="100%">patents include, &quot;Mixed allergen composition and methods for using the same,&quot;</style></keyword><keyword><style face="normal" font="default" size="100%">&quot;Granulocyte-based methods for detecting and monitoring immune system disorders,&quot;</style></keyword><keyword><style face="normal" font="default" size="100%">and &quot;Methods and Assays for Detecting and Quantifying Pure Subpopulations of</style></keyword><keyword><style face="normal" font="default" size="100%">White Blood Cells in Immune System Disorders.&quot;</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37584433</style></accession-num><abstract><style face="normal" font="default" size="100%">Health care professionals (HCPs) and researchers in the health care sector dedicate their professional life to maintaining and optimizing the health of their patients. To achieve this, significant amounts of resources are used and currently it is estimated that the health care sector contributes to more than 4% of net greenhouse gas (GHG) emissions. GHG emissions adversely impact planetary health and consequently human health, as the two are intricately linked. There are many factors of health care that contribute to these emissions. Hospitals and research labs also use high amounts of consumables which require large amounts of raw materials and energy to produce. They are further responsible for polluting the environment via disposal of plastics, drug products, and other chemicals. To maintain and develop state-of-the-art best practices and treatments, medical experts exchange and update their knowledge on methods and technologies in the respective fields at highly specialized scientific meetings. These meetings necessitate thousands of attendants traveling around the globe. Therefore, while the goal of HCPs is to care for the individual, current practices have an enormous (indirect) impact on the health of the patients by their negative environmental impacts. There is an urgent need for HCPs and researchers to mitigate these detrimental effects. The installation of a sustainability-manager at health care facilities and research organizations to implement sustainable practices while still providing quality health care is desirable. Increased use of telemedicine, virtual/hybrid conferences and green chemistry have recently been observed. The benefits of these practices need to be evaluated and implemented as appropriate. With this manuscript, we aim to increase the awareness about the negative impacts of the health care system (including health care research) on planetary and human health. We suggest some easy and highly impactful steps and encourage health care professionals and research scientists of all hierarchical levels to immediately implement them in their professional as well as private life to counteract the health care sector&apos;s detrimental effects on the environment.</style></abstract><notes><style face="normal" font="default" size="100%">Pali-Scholl, Isabella&#xD;Hermuth-Kleinschmidt, Kerstin&#xD;Dramburg, Stephanie&#xD;Agache, Ioana&#xD;Mayerhofer, Hanna&#xD;Jensen-Jarolim, Erika&#xD;Goshua, Anna&#xD;Nadeau, Kari C&#xD;eng&#xD;P01 HL152953/HL/NHLBI NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2606-2622. doi: 10.1111/all.15836. Epub 2023 Aug 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37584433</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10543587</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15836</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1196</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1196</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Barber, D.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Rabin, R. L.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF, University of Zurich, Zurich, Switzerland.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Toronto, ON, Canada.&#xD;Translational Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Immunology, University of Toronto, Toronto, ON, Canada.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, Odense University Hospital, University of Southern Denmark, Odense, Denmark.&#xD;AllergyClinical Unit, Hospital Regional Universitario de Malaga-UMA-ARADyAL, Malaga, Spain.&#xD;Departamento de Ciencias Medicas Basicas, Facultad de Medicina, Instituto de Medicina Molecular Aplicada (IMMA, Universidad San Pablo-CEU, CEU Universities, Madrid, Espana.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, USA.&#xD;Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, USA.&#xD;Department of Medicine, Division of Allergy, Immunology and Rheumatology, Stanford University, Stanford, CA, USA.&#xD;Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.&#xD;Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.&#xD;Allergy and Clinical Immunology, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Institut de Recerca Sant Joan de Deu, Barcelona, Spain.&#xD;Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, Langen, 63225, Germany.&#xD;Transylvania University, Brasov, Romania.&#xD;Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London. Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1629-1639</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/01/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation and GSK. Dr. Eiwegger reports to act as local PI for company sponsored</style></keyword><keyword><style face="normal" font="default" size="100%">trials by DBV and sub-investigator for Regeneron and holds grants from Innovation</style></keyword><keyword><style face="normal" font="default" size="100%">fund Denmark and CIHR. He is co-Investigator or scientific lead in three</style></keyword><keyword><style face="normal" font="default" size="100%">investigator initiated oral immunotherapy trials supported by the Food Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">and Anaphylaxis Program SickKids and serves as associate editor for Allergy.</style></keyword><keyword><style face="normal" font="default" size="100%">He/his laboratory received unconditional/kind contributions from Macro Array</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostics and ALK. He holds advisory board roles for ALK. Dr. Torres reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants or personal fees from European Commission, SEAIC, ISCIII, Diater</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory, Leti laboratory and Aimmune Therapeutics. Dr. Barber reports grants</style></keyword><keyword><style face="normal" font="default" size="100%">and/or personal fees from ALK and Aimmune. Dr. Nadeau reports grants from NIAID,</style></keyword><keyword><style face="normal" font="default" size="100%">NHLBI, NIEHS, FARE, and other from WAO, Cour Pharma, Before Brands, Alladapt,</style></keyword><keyword><style face="normal" font="default" size="100%">Latitude, IgGenix, ITN and NIH clinical research centres. In addition, Dr. Nadeau</style></keyword><keyword><style face="normal" font="default" size="100%">has the following pending patents: Inhibition of Allergic Reaction to Peanut</style></keyword><keyword><style face="normal" font="default" size="100%">Allergen using an IL-33 Inhibitor, Special Oral Formula for Decreasing Food</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Risk and Treatment for Food Allergy, Basophil Activation Based Diagnostic</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Test, Granulocyte-based Methods for Detecting and Monitoring Immune</style></keyword><keyword><style face="normal" font="default" size="100%">System Disorders, Methods and Assays for Detecting and Quantifying Pure</style></keyword><keyword><style face="normal" font="default" size="100%">Subpopulations of White Blood Cells in Immune System Disorders, Mixed Allergen</style></keyword><keyword><style face="normal" font="default" size="100%">Compositions and Methods for Using the Same, and Microfluidic Device and</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostic Methods for Allergy Testing Based on Detection of Basophil Activation.</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Palomares reports research grants from InmunoTek S.L., Novartis and Mineco.</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Palomares has received fees for giving scientific lectures or participation</style></keyword><keyword><style face="normal" font="default" size="100%">in Advisory Boards from: Allergy Therapeutics, Amgen, AstraZeneca, Diater, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Inmunotek S.L, Novartis, Sanofi-Genzyme and Stallergenes. Dr. Vieths reports</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Swiss Society for Allergy and Immunology, Schattauer</style></keyword><keyword><style face="normal" font="default" size="100%">Allergologie Handbuch, Elsevier Nahrungsmittelallergien und Intoleranzen, Karger</style></keyword><keyword><style face="normal" font="default" size="100%">Food Allergy: Molecular Basis and Clinical Practice, non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">German Research Foundation, European Directorate for the Quality of Medicines and</style></keyword><keyword><style face="normal" font="default" size="100%">Health Care, EAACI, GDCh, AKM Allergiekongress, International Union of</style></keyword><keyword><style face="normal" font="default" size="100%">Immunological Societies, and SEAIC. Dr. Agache serves as associate editor of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and CTA. Dr. Shamji, Dr. Jutel, Dr. Ollert, Dr. Rabin, Dr. Del Giacco and</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Riggioni declare no COI related to this paper.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33452689</style></accession-num><abstract><style face="normal" font="default" size="100%">The first approved COVID-19 vaccines include Pfizer/BioNTech BNT162B2, Moderna mRNA-1273 and AstraZeneca recombinant adenoviral ChAdOx1-S. Soon after approval, severe allergic reactions to the mRNA-based vaccines that resolved after treatment were reported. Regulatory agencies from the European Union, Unites States and the United Kingdom agree that vaccinations are contraindicated only when there is an allergy to one of the vaccine components or if there was a severe allergic reaction to the first dose. This position paper of the European Academy of Allergy and Clinical Immunology (EAACI) agrees with these recommendations and clarifies that there is no contraindication to administer these vaccines to allergic patients who do not have a history of an allergic reaction to any of the vaccine components. Importantly, as is the case for any medication, anaphylaxis may occur after vaccination in the absence of a history of allergic disease. Therefore, we provide a simplified algorithm of prevention, diagnosis and treatment of severe allergic reactions and a list of recommended medications and equipment for vaccine centres. We also describe potentially allergenic/immunogenic components of the approved vaccines and propose a workup to identify the responsible allergen. Close collaboration between academia, regulatory agencies and vaccine producers will facilitate approaches for patients at risks, such as incremental dosing of the second injection or desensitization. Finally, we identify unmet research needs and propose a concerted international roadmap towards precision diagnosis and management to minimize the risk of allergic reactions to COVID-19 vaccines and to facilitate their broader and safer use.</style></abstract><notes><style face="normal" font="default" size="100%">Sokolowska, Milena&#xD;Eiwegger, Thomas&#xD;Ollert, Markus&#xD;Torres, Maria J&#xD;Barber, Domingo&#xD;Del Giacco, Stefano&#xD;Jutel, Marek&#xD;Nadeau, Kari C&#xD;Palomares, Oscar&#xD;Rabin, Ronald L&#xD;Riggioni, Carmen&#xD;Vieths, Stefan&#xD;Agache, Ioana&#xD;Shamji, Mohamed H&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1629-1639. doi: 10.1111/all.14739.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33452689</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8013422</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14739</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2279</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2279</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pascal, M.</style></author><author><style face="normal" font="default" size="100%">Edelman, S. M.</style></author><author><style face="normal" font="default" size="100%">Nopp, A.</style></author><author><style face="normal" font="default" size="100%">Mobs, C.</style></author><author><style face="normal" font="default" size="100%">Geilenkeuser, W. J.</style></author><author><style face="normal" font="default" size="100%">Knol, E. F.</style></author><author><style face="normal" font="default" size="100%">Ebo, D. G.</style></author><author><style face="normal" font="default" size="100%">Mertens, C.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Patil, S.</style></author><author><style face="normal" font="default" size="100%">Eberlein, B.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunology Department, Centre de Diagnostic Biomedic, Hospital Clinic de Barcelona, Barcelona, Spain.&#xD;Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.&#xD;RETICS Asma reacciones adversas y alergicas (ARADYAL) and RICORS Red De Enfermedades Inflamatorias (REI), Madrid, Spain.&#xD;Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland.&#xD;Department of Clinical Science and Education, Karolinska Institutet, Sodersjukhuset, and Sachs Children and Youth Hospital, Stockholm, Sweden.&#xD;Department of Dermatology and Allergology, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Reference Institute for Bioanalytics, Bonn, Germany.&#xD;Center of Translational Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Faculty of Medicine and Health Sciences, Department of Immunology-Allergology- Rheumatology, University of Antwerp, Antwerp, Belgium.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Department of Women and Children&apos;s Health (Pediatric Allergy) &amp; Peter Gorer Department of Immunobiology, Faculty of Life Sciences and Medicine, King&apos;s College London, London, United Kingdom.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, United Kingdom.&#xD;Division of Allergy and Immunology, Departments of Medicine and Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States.&#xD;Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University Munich, Munich, Germany.&#xD;Allergy Clinical Unit, Hospital Regional Universitario de Malaga and Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA-BIONAND, Malaga, Spain.&#xD;Department of Clinical Medicine, Aarhus University, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI task force report: A consensus protocol for the basophil activation test for collaboration and external quality assurance</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">290-293</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/10/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophil Degranulation Test</style></keyword><keyword><style face="normal" font="default" size="100%">Consensus</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37795777</style></accession-num><notes><style face="normal" font="default" size="100%">Pascal, M&#xD;Edelman, S M&#xD;Nopp, A&#xD;Mobs, C&#xD;Geilenkeuser, W J&#xD;Knol, E F&#xD;Ebo, D G&#xD;Mertens, C&#xD;Shamji, M H&#xD;Santos, A F&#xD;Patil, S&#xD;Eberlein, B&#xD;Mayorga, C&#xD;Hoffmann, H J&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;R01 AI155630/AI/NIAID NIH HHS/&#xD;R21 AI159732/AI/NIAID NIH HHS/&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;MC_PC_18052/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):290-293. doi: 10.1111/all.15907. Epub 2023 Oct 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37795777</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10843141</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15907</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3233</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3233</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Ghiordanescu, I. M.</style></author><author><style face="normal" font="default" size="100%">Tontini, C.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Pichler, W. J.</style></author><author><style face="normal" font="default" size="100%">van Wijk, R. G.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C.</style></author><author><style face="normal" font="default" size="100%">Demoly, P.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Amerigo, D. A.</style></author><author><style face="normal" font="default" size="100%">Mulleneisen, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Odense Research Center for Anaphylaxis (ORCA), Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.&#xD;Laboratoire Inserm UMR1327 ISCHEMIA, University of Tours, Tours, France.&#xD;Department of Allergy and Clinical Immunology, University Hospital (CHRU) de Tours, Tours, France.&#xD;Division of Musculoskeletal and Dermatological Sciences, Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.&#xD;Medicine Campus Davos/Christine Kuhne Center for Allergy Research and Education CK-CARE, Davos, Switzerland.&#xD;Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.&#xD;ADR-AC GmbH, Bern, Switzerland.&#xD;Section of Allergology and Clinical Immunology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.&#xD;Center of Allergy and Environment (ZAUM), Technical University and Helmholtz Center Munich, Member of the German Center of Lung Research (DZL), Munich, Germany.&#xD;Allergy Unit, University Hospital of Montpellier, Montpellier, France.&#xD;UMR 1318 University of Montpellier - INSERM, Montpellier, France.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;Facultad de Medicina, Universidad CEU San Pablo, Madrid, Spain.&#xD;Department of Allergy, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Universidad de Alcala, Madrid, Spain.&#xD;Asthma-Allergie Zentrum Leverkusen, Leverkusen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The EAACI-UEMS Knowledge Examination: Certifying Standards in Allergy and Clinical Immunology Across Europe</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41549511</style></accession-num><notes><style face="normal" font="default" size="100%">Brockow, Knut&#xD;Ghiordanescu, Ileana M&#xD;Tontini, Chiara&#xD;Schmid-Grendelmeier, Peter&#xD;Pichler, Werner J&#xD;van Wijk, Roy Gerth&#xD;Schmidt-Weber, Carsten&#xD;Demoly, Pascal&#xD;Del Giacco, Stefano&#xD;Walusiak-Skorupa, Jolanta&#xD;Chivato, Tomas&#xD;Amerigo, Dario Antolin&#xD;Mulleneisen, Norbert&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;European Union of Medical Specialists (UEMS)/&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2026 Jan 18. doi: 10.1111/all.70213.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41549511</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70213</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2325</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2325</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barbaud, A.</style></author><author><style face="normal" font="default" size="100%">Garvey, L. H.</style></author><author><style face="normal" font="default" size="100%">Torres, M.</style></author><author><style face="normal" font="default" size="100%">Laguna, J. J.</style></author><author><style face="normal" font="default" size="100%">Arcolaci, A.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Scherer Hofmeier, K.</style></author><author><style face="normal" font="default" size="100%">Chiriac, A. M.</style></author><author><style face="normal" font="default" size="100%">Cernadas, J.</style></author><author><style face="normal" font="default" size="100%">Caubet, J. C.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sorbonne Universite, INSERM, Institut Pierre Louis d&apos;Epidemiologie et de Sante Publique, AP-HP. Sorbonne Universite, Hopital Tenon, Service de dermatologie et allergologie, Paris, France.&#xD;Allergy Clinic, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA-ARADyAL, Malaga, Spain.&#xD;Allergy Unit, Allergo-Anaesthesia Unit, Faculty of Medicine, Hospital Central de la Cruz Roja, Alfonso X El Sabio University, ARADyAL, REI, Madrid, Spain.&#xD;Immunology Unit, University Hospital of Verona, Policlinico G.B. Rossi, Verona, Italy.&#xD;Allergy Unit, University Hospital of Verona, Policlinico G.B. Rossi, Verona, Italy.&#xD;Allergy and Dermatology, Cantonal Hospital Aarau, Cantonal Hospital Aarau, Aarau, Switzerland.&#xD;Department of Biomedicine, University of Basel, Basel, Switzerland.&#xD;Allergy Unit, University Hospital of Montpellier and IDESP, UMR UA11, Univ. Montpellier - INSERM, Montpellier, France.&#xD;Hospital Lusiadas, Porto, Portugal.&#xD;Centro Hospitalar Universitario H. S. Joao, Porto, Portugal.&#xD;Department of Women-Children-Teenagers, University Hospital of Geneva, Geneva, Switzerland.&#xD;Department of Dermatology and Allergy Biederstein, Technical University of Munich, Faculty of Medicine and Health, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EAACI/ENDA position paper on drug provocation testing</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">565-579</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/12/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Contrast Media</style></keyword><keyword><style face="normal" font="default" size="100%">Monobactams</style></keyword><keyword><style face="normal" font="default" size="100%">beta Lactam Antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">beta-lactam antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">delabeling</style></keyword><keyword><style face="normal" font="default" size="100%">drug challenge</style></keyword><keyword><style face="normal" font="default" size="100%">drug provocation test</style></keyword><keyword><style face="normal" font="default" size="100%">risk stratification</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38155501</style></accession-num><abstract><style face="normal" font="default" size="100%">In drug hypersensitivity, drug provocation testing (DPT), also called drug challenge, is the gold standard for investigation. In recent years, risk stratification has become an important tool for adjusting the diagnostic strategy to the perceived risk, whilst still maintaining a high level of safety for the patient. Skin tests are recommended before DPT but may be omitted in low-risk patients. The task force suggests a strict definition of such low-risk patients in children and adults. Based on experience and evidence from studies of allergy to beta-lactam antibiotics, an algorithm on how to adjust DPT to the risk, and when to omit skin tests before DPT, is presented. For other antibiotics, non-steroidal anti-inflammatory drugs and other drugs, skin tests are poorly validated and DPT is frequently necessary. We recommend performing DPT with chemotherapeutics and biologicals to avoid unnecessary desensitization procedures and DPT with skin tests negative contrast media. We suggest DPT with anesthetics only in highly specialized centers. Specifics of DPT to proton pump inhibitors, anticonvulsants and corticosteroids are discussed. This position paper provides general recommendations and guidance on optimizing use of DPT, whilst balancing benefits with patient safety and optimizing the use of the limited available resources.</style></abstract><notes><style face="normal" font="default" size="100%">Barbaud, Annick&#xD;Garvey, Lene Heise&#xD;Torres, Maria&#xD;Laguna, Jose Julio&#xD;Arcolaci, Alessandra&#xD;Bonadonna, Patrizia&#xD;Scherer Hofmeier, Kathrin&#xD;Chiriac, Anca Mirela&#xD;Cernadas, Josefina&#xD;Caubet, Jean Christoph&#xD;Brockow, Knut&#xD;eng&#xD;40703/EAACI/&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):565-579. doi: 10.1111/all.15996. Epub 2023 Dec 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38155501</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15996</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3303</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3303</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Preis, S.</style></author><author><style face="normal" font="default" size="100%">Kaesler, S.</style></author><author><style face="normal" font="default" size="100%">Koeberle, M.</style></author><author><style face="normal" font="default" size="100%">Hils, M.</style></author><author><style face="normal" font="default" size="100%">Evers, B.</style></author><author><style face="normal" font="default" size="100%">Silva, R. L.</style></author><author><style face="normal" font="default" size="100%">Skabytska, Y.</style></author><author><style face="normal" font="default" size="100%">Schellenberger, L.</style></author><author><style face="normal" font="default" size="100%">Hufnagel, H.</style></author><author><style face="normal" font="default" size="100%">Schielein, M.</style></author><author><style face="normal" font="default" size="100%">Kuschel, B.</style></author><author><style face="normal" font="default" size="100%">Amar, Y.</style></author><author><style face="normal" font="default" size="100%">Zink, A.</style></author><author><style face="normal" font="default" size="100%">Biedermann, T.</style></author><author><style face="normal" font="default" size="100%">Kurgyis, Z.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Early Epidemiologic and Immune Predictors of Atopic Dermatitis: Reduced Cord Blood Regulatory B10 Cells in the Munich Atopy Prediction Study (MAPS)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background A complex interaction between environmental and lifestyle factors, immune dysregulation, and skin barrier integrity is believed to contribute to the development of atopic dermatitis (AD). However, the precise mechanisms underlying disease onset in infants remain largely unclear. Methods The “Munich Atopic Prediction Study” (MAPS) is a comprehensive clinical and biological investigation of a prospective birth cohort from Munich, Germany. Information on pregnancy, child development, environmental influences, parental exposure to potential allergens, as well as illnesses affecting both children and parents is gathered through questionnaires. This is complemented by thorough clinical examinations conducted by trained dermatologists, with a particular focus on allergies and skin health. Biomarker analyses were performed, for example, on cord blood immune cells using flow cytometry (FACS analysis). Results Maternal AD (aOR = 3.06, p = 0.020) and affected siblings (aOR = 4.80, p = 0.039) are associated with an increased risk of AD, whereas cold-remedy intake showed a protective association (aOR = 0.11, p = 0.047). Infants later diagnosed with AD (total 74 infants, AD n = 27, healthy n = 47) are characterized by reduced frequencies of CD4+ T cells (p = 0.0247) and increased B-cell counts (p = 0.0067). Moreover, for the first time, we could identify a significant reduction in regulatory B (Breg)-cell frequencies in these infants (p = 0.0015). Furthermore, our findings suggest that maternal allergen-specific immunotherapy may have a beneficial effect on the development and frequency of Breg cells (p = 0.0497). Conclusion Our study identifies early immune alterations, particularly a reduction in cord blood Breg cells, as potential contributors to AD pathogenesis. Incorporating Breg-cell measurements into neonatal immune panels, along with key perinatal and familial risk factors, may enhance early risk stratification and enable more personalized prevention of atopic diseases.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70306</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70306</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2388</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2388</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Voskamp, A. L.</style></author><author><style face="normal" font="default" size="100%">de Jong, N. W.</style></author><author><style face="normal" font="default" size="100%">Jochems, S. P.</style></author><author><style face="normal" font="default" size="100%">Ozir-Fazalalikhan, A.</style></author><author><style face="normal" font="default" size="100%">van Hengel, O. R. J.</style></author><author><style face="normal" font="default" size="100%">van der Vlugt, Lepm</style></author><author><style face="normal" font="default" size="100%">Stam, K. A.</style></author><author><style face="normal" font="default" size="100%">van den Berge, M.</style></author><author><style face="normal" font="default" size="100%">Nawijn, M. C.</style></author><author><style face="normal" font="default" size="100%">Braunstahl, G. J.</style></author><author><style face="normal" font="default" size="100%">Moller, G. M.</style></author><author><style face="normal" font="default" size="100%">van Wijk, R. G.</style></author><author><style face="normal" font="default" size="100%">Smits, H. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Parasitology, Leiden University Center for Infectious Diseases (LU-CID), Leiden University Medical Center, Leiden, The Netherlands.&#xD;Department of Internal Medicine, Section Allergology and Clinical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.&#xD;Department of Pulmonology, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Department of Pulmonology, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.&#xD;Department of Pulmonology, Erasmus Medical Center, Rotterdam, The Netherlands.&#xD;Netherlands Center of Clinical Occupational Medicine, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early expansion of allergen-responsive LAP(+) B regulatory cells in allergic rhinitis but not in allergic asthma subjects during allergen immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1060-1064</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/01/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38169044</style></accession-num><notes><style face="normal" font="default" size="100%">Voskamp, Astrid L&#xD;de Jong, Nicolette W&#xD;Jochems, Simon P&#xD;Ozir-Fazalalikhan, Arifa&#xD;van Hengel, Oscar R J&#xD;van der Vlugt, Lucien E P M&#xD;Stam, Koen Alexander&#xD;van den Berge, Maarten&#xD;Nawijn, Martijn C&#xD;Braunstahl, Gert-Jan&#xD;Moller, Gertrude M&#xD;van Wijk, Roy Gerth&#xD;Smits, Hermelijn H&#xD;eng&#xD;ZONMW_/ZonMw/Netherlands&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):1060-1064. doi: 10.1111/all.15973. Epub 2024 Jan 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38169044</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15973</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1968</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1968</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Berjont, N.</style></author><author><style face="normal" font="default" size="100%">Floch, V. V. B.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">Canonica, W. G.</style></author><author><style face="normal" font="default" size="100%">van Zelm, M. C.</style></author><author><style face="normal" font="default" size="100%">Batard, T.</style></author><author><style face="normal" font="default" size="100%">Mascarell, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Stallergenes Greer, Antony, France.&#xD;Department of Immunology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.&#xD;Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia.&#xD;Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early increase in serum specific IgG2 upon allergen immunotherapy with a 300 IR sublingual house dust mite tablet</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2040-2043</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36809660</style></accession-num><notes><style face="normal" font="default" size="100%">Berjont, Nathalie&#xD;Floch, Veronique V Bordas-Le&#xD;O&apos;Hehir, Robyn E&#xD;Canonica, Walter G&#xD;van Zelm, Menno C&#xD;Batard, Thierry&#xD;Mascarell, Laurent&#xD;eng&#xD;National Health and Medical Research Council/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2040-2043. doi: 10.1111/all.15685. Epub 2023 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36809660</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15685</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>18</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">18</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Su, K. W.</style></author><author><style face="normal" font="default" size="100%">Cetinbas, M.</style></author><author><style face="normal" font="default" size="100%">Martin, V. M.</style></author><author><style face="normal" font="default" size="100%">Virkud, Y. V.</style></author><author><style face="normal" font="default" size="100%">Seay, H.</style></author><author><style face="normal" font="default" size="100%">Ndahayo, R.</style></author><author><style face="normal" font="default" size="100%">Rosow, R.</style></author><author><style face="normal" font="default" size="100%">Elkort, M.</style></author><author><style face="normal" font="default" size="100%">Gupta, B.</style></author><author><style face="normal" font="default" size="100%">Kramer, E.</style></author><author><style face="normal" font="default" size="100%">Pronchick, T.</style></author><author><style face="normal" font="default" size="100%">Reuter, S.</style></author><author><style face="normal" font="default" size="100%">Sadreyev, R. I.</style></author><author><style face="normal" font="default" size="100%">Huang, J. L.</style></author><author><style face="normal" font="default" size="100%">Shreffler, W. G.</style></author><author><style face="normal" font="default" size="100%">Yuan, Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.&#xD;Department of Pediatrics, Chang Gung University, Taoyuan, Taiwan.&#xD;Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Harvard Medical School, Boston, Massachusetts, USA.&#xD;Food Allergy Center, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Department of Pediatrics, School of Medicine, University of North Carolina, North Carolina, USA.&#xD;Division of Pediatric Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Pediatrics at Newton Wellesley, P.C., Newton, Massachusetts, USA.&#xD;Department of Pediatrics, New Taipei Municipal TuCheng Hospital, New Taipei, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early infancy dysbiosis in food protein-induced enterocolitis syndrome: A prospective cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1595-1604</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Proteins/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Enterocolitis/epidemiology/etiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Fpies</style></keyword><keyword><style face="normal" font="default" size="100%">Stool microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">birth cohort study</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food protein-induced enterocolitis syndrome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36635218</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The microbiome associations of food protein-induced enterocolitis syndrome (FPIES) are understudied. We sought to prospectively define the clinical features of FPIES in a birth cohort, and investigate for the evidence of gut dysbiosis. METHODS: We identified children diagnosed with FPIES in the Gastrointestinal Microbiome and Allergic Proctocolitis Study, a healthy infant cohort. Children were assessed and stools were collected at each well child visit. The clinical features of the children with FPIES were summarized. Stool microbiome was analyzed using 16S rRNA sequencing comparing children with and without FPIES. RESULTS: Of the 874 children followed up for 3 years, 8 FPIES cases (4 male) were identified, yielding a cumulative incidence of 0.92%. The most common triggers were oat and rice (n = 3, each) followed by milk (n = 2). The children with FPIES were more likely to have family history of food allergy (50% vs. 15.9% among unaffected, p = .03). The average age of disease presentation was 6 months old. During the first 6 months of life, stool from children with FPIES contained significantly less Bifidobacterium adolescentis, but more pathobionts, including Bacteroides spp. (especially Bacteroides fragilis), Holdemania spp., Lachnobacterium spp., and Acinetobacter lwoffii. The short-chain fatty acid (SCFA)-producing Bifidobacterium shunt was expressed significantly less in the stool from FPIES children. CONCLUSIONS: In this cohort, the cumulative incidence over the 3-year study period was 0.92%. During the first 6 months of life, children with FPIES had evidence of dysbiosis and SCFA production pathway was expressed less in their stool, which may play an important role in the pathogenesis of FPIES.</style></abstract><notes><style face="normal" font="default" size="100%">Su, Kuan-Wen&#xD;Cetinbas, Murat&#xD;Martin, Victoria M&#xD;Virkud, Yamini V&#xD;Seay, Hannah&#xD;Ndahayo, Renata&#xD;Rosow, Rachael&#xD;Elkort, Michael&#xD;Gupta, Brinda&#xD;Kramer, Eileen&#xD;Pronchick, Tetiana&#xD;Reuter, Susan&#xD;Sadreyev, Ruslan I&#xD;Huang, Jing-Long&#xD;Shreffler, Wayne G&#xD;Yuan, Qian&#xD;eng&#xD;K23 AI130408/AI/NIAID NIH HHS/&#xD;K23 AI151556/AI/NIAID NIH HHS/&#xD;L40 AI120114/AI/NIAID NIH HHS/&#xD;P30 DK040561/DK/NIDDK NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1595-1604. doi: 10.1111/all.15644. Epub 2023 Jan 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36635218</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10534226</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15644</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>339</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">339</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ni Chaoimh, C.</style></author><author><style face="normal" font="default" size="100%">Lad, D.</style></author><author><style face="normal" font="default" size="100%">Nico, C.</style></author><author><style face="normal" font="default" size="100%">Puppels, G. J.</style></author><author><style face="normal" font="default" size="100%">Wong, Xfcc</style></author><author><style face="normal" font="default" size="100%">Common, J. E.</style></author><author><style face="normal" font="default" size="100%">Murray, D. M.</style></author><author><style face="normal" font="default" size="100%">Irvine, A. D.</style></author><author><style face="normal" font="default" size="100%">Hourihane, J. O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">INFANT Research Centre, University College Cork, Cork, Ireland.&#xD;Paediatrics and Child Health, University College Cork, Cork, Ireland.&#xD;River D International B.V., Rotterdam, The Netherlands.&#xD;Department of Dermatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.&#xD;A*STAR Skin Research Labs, Singapore, Singapore.&#xD;Clinical Medicine, Trinity College, Dublin, Ireland.&#xD;Paediatrics and Child Health, Royal College of Surgeons in Ireland, Dublin, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants-The STOP-AD randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">984-994</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/08/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Emollients/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">emollient</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier</style></keyword><keyword><style face="normal" font="default" size="100%">Johnson Sante Beaute France (JJSBF) as benefit-in-kind. JJSBF did not have any</style></keyword><keyword><style face="normal" font="default" size="100%">role in the trial design. JJSBF provided funding for a sub-study within this</style></keyword><keyword><style face="normal" font="default" size="100%">study, which includes the analysis of the microbiome and inflammatory biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">in a subgroup of the study. This is separate from the study&apos;s primary funding</style></keyword><keyword><style face="normal" font="default" size="100%">source. CNC, DL, DM, XFCCW, and JEC declare no conflicts of interest. CN and GJP</style></keyword><keyword><style face="normal" font="default" size="100%">are employees of RiverD International B.V., which produced the NMF-scan. GJP is</style></keyword><keyword><style face="normal" font="default" size="100%">the managing director and a shareholder of RiverD International B.V. JO&apos;BH</style></keyword><keyword><style face="normal" font="default" size="100%">receives research funding, speaker fees, and consultancy fees from Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, research funding and speaker fees from DBV Technologies, and</style></keyword><keyword><style face="normal" font="default" size="100%">research funding from Clemens von Pirquet Foundation and Temple St Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation. ADI is a consultant/on the advisory board for AbbVie, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Sanofi Genzyme, Pfizer, Eli Lilly, Amgen, Benevolent AI, LEO, Arena. A</style></keyword><keyword><style face="normal" font="default" size="100%">patent application has been submitted by Johnson &amp; Johnson based on these</style></keyword><keyword><style face="normal" font="default" size="100%">results, with JO&apos;BH and ADI named as inventors.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35997592</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Protecting the skin barrier in early infancy may prevent atopic dermatitis (AD). We investigated if daily emollient use from birth to 2 months reduced AD incidence in high-risk infants at 12 months. METHODS: This was a single-center, two-armed, investigator-blinded, randomized controlled clinical trial (NCT03871998). Term infants identified as high risk for AD (parental history of AD, asthma or allergic rhinitis) were recruited within 4 days of birth and randomised 1:1 to either twice-daily emollient application for the first 8 weeks of life (intervention group), using an emollient specifically formulated for very dry, AD-prone skin, or to standard routine skin care (control group). The primary outcome was cumulative AD incidence at 12 months. AD &lt;6 months was diagnosed based on clinical presence of AD. The UK Working Party Diagnostic Criteria were applied when diagnosing AD between 6 and 12 months. RESULTS: Three hundred twenty-one were randomised (161 intervention and 160 control), with 61 withdrawals (41 intervention, 20 control). The cumulative incidence of AD at 12 months was 32.8% in the intervention group vs. 46.4% in the control group, p = 0.036 [Relative risk (95%CI): 0.707 (0.516, 0.965)]. One infant in the intervention group was withdrawn from the study following development of a rash that had a potential relationship with the emollient. There was no significant difference in the incidence of skin infections between the intervention and control groups during the intervention period (5.0% vs. 5.7%, p &gt; 0.05). CONCLUSIONS: This study has demonstrated that early initiation of daily specialized emollient use until 2 months reduces the incidence of AD in the first year of life in high-risk infants.</style></abstract><notes><style face="normal" font="default" size="100%">Ni Chaoimh, Carol&#xD;Lad, Dhanis&#xD;Nico, Claudio&#xD;Puppels, Gerwin J&#xD;Wong, X F Colin C&#xD;Common, John E&#xD;Murray, Deirdre M&#xD;Irvine, Alan D&#xD;Hourihane, Jonathan O&apos;Brien&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):984-994. doi: 10.1111/all.15491. Epub 2022 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35997592</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10952678</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15491</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>910</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">910</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Lanser, B. J.</style></author><author><style face="normal" font="default" size="100%">Sindher, S. B.</style></author><author><style face="normal" font="default" size="100%">Teng, J. M. C.</style></author><author><style face="normal" font="default" size="100%">Leung, D. Y. M.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Chan, S. M.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Bahnson, H. T.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Gupta, R. S.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Ciaccio, C. E.</style></author><author><style face="normal" font="default" size="100%">Sampath, V.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Nagler, C. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina Children&apos;s Hospital, Guy&apos;s and St. Thomas&apos;s NHS Foundation Trust, London, UK.&#xD;Division of Pediatric Allergy-Immunology, Department of Pediatrics, National Jewish Health, Denver, CO, USA.&#xD;Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, USA.&#xD;Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.&#xD;Division of Allergy, Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, USA.&#xD;Department of Dermatology, Lucile Packard Children&apos;s Hospital at the Stanford University School of Medicine, Palo Alto, CA, USA.&#xD;Section of Allergy &amp; Immunology, School of Medicine, University of Colorado Denver, Children&apos;s Hospital Colorado, Aurora, CO, USA.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Benaroya Research Institute and Immune Tolerance Network, Seattle, WA, USA.&#xD;Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.&#xD;Center for Food Allergy and Asthma Research, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.&#xD;Ann &amp; Robert H. Lurie Children&apos;s Hospital of Chicago, Chicago, IL, USA.&#xD;Department of Pediatrics and Medicine, University of Chicago, Chicago, IL, USA.&#xD;Department of Pathology and Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early intervention and prevention of allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">416-441</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Mucous Membrane</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">barrier</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34255344</style></accession-num><abstract><style face="normal" font="default" size="100%">Food allergy (FA) is now one of the most common chronic diseases of childhood often lasting throughout life and leading to significant worldwide healthcare burden. The precise mechanisms responsible for the development of this inflammatory condition are largely unknown; however, a multifactorial aetiology involving both environmental and genetic contributions is well accepted. A precise understanding of the pathogenesis of FA is an essential first step to developing comprehensive prevention strategies that could mitigate this epidemic. As it is frequently preceded by atopic dermatitis and can be prevented by early antigen introduction, the development of FA is likely facilitated by the improper initial presentation of antigen to the developing immune system. Primary oral exposure of antigens allowing for presentation via a well-developed mucosal immune system, rather than through a disrupted skin epidermal barrier, is essential to prevent FA. In this review, we present the data supporting the necessity of (1) an intact epidermal barrier to prevent epicutaneous antigen presentation, (2) the presence of specific commensal bacteria to maintain an intact mucosal immune system and (3) maternal/infant diet diversity, including vitamins and minerals, and appropriately timed allergenic food introduction to prevent FA.</style></abstract><notes><style face="normal" font="default" size="100%">Brough, Helen A&#xD;Lanser, Bruce Joshua&#xD;Sindher, Sayantani B&#xD;Teng, Joyce M C&#xD;Leung, Donald Y M&#xD;Venter, Carina&#xD;Chan, Susan M&#xD;Santos, Alexandra F&#xD;Bahnson, Henry T&#xD;Guttman-Yassky, Emma&#xD;Gupta, Ruchi S&#xD;Lack, Gideon&#xD;Ciaccio, Christina E&#xD;Sampath, Vanitha&#xD;Nadeau, Kari C&#xD;Nagler, Cathryn R&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;U19AI070535/GF/NIH HHS/&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;R01AI140134/GF/NIH HHS/&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):416-441. doi: 10.1111/all.15006. Epub 2021 Sep 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34255344</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15006</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1583</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1583</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Lanser, B. J.</style></author><author><style face="normal" font="default" size="100%">Sindher, S. B.</style></author><author><style face="normal" font="default" size="100%">Teng, J. M. C.</style></author><author><style face="normal" font="default" size="100%">Leung, D. Y. M.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Chan, S. M.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Bahnson, H. T.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Gupta, R. S.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Ciaccio, C. E.</style></author><author><style face="normal" font="default" size="100%">Sampath, V.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Nagler, C. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina Children&apos;s Hospital, Guy&apos;s and St. Thomas&apos;s NHS Foundation Trust, London, UK.&#xD;Division of Pediatric Allergy-Immunology, Department of Pediatrics, National Jewish Health, Denver, CO, USA.&#xD;Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, USA.&#xD;Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.&#xD;Division of Allergy, Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, USA.&#xD;Department of Dermatology, Lucile Packard Children&apos;s Hospital at the Stanford University School of Medicine, Palo Alto, CA, USA.&#xD;Section of Allergy &amp; Immunology, School of Medicine, University of Colorado Denver, Children&apos;s Hospital Colorado, Aurora, CO, USA.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Benaroya Research Institute and Immune Tolerance Network, Seattle, WA, USA.&#xD;Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.&#xD;Center for Food Allergy and Asthma Research, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.&#xD;Ann &amp; Robert H. Lurie Children&apos;s Hospital of Chicago, Chicago, IL, USA.&#xD;Department of Pediatrics and Medicine, University of Chicago, Chicago, IL, USA.&#xD;Department of Pathology and Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early intervention and prevention of allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">416-441</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Mucous Membrane</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">barrier</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34255344</style></accession-num><abstract><style face="normal" font="default" size="100%">Food allergy (FA) is now one of the most common chronic diseases of childhood often lasting throughout life and leading to significant worldwide healthcare burden. The precise mechanisms responsible for the development of this inflammatory condition are largely unknown; however, a multifactorial aetiology involving both environmental and genetic contributions is well accepted. A precise understanding of the pathogenesis of FA is an essential first step to developing comprehensive prevention strategies that could mitigate this epidemic. As it is frequently preceded by atopic dermatitis and can be prevented by early antigen introduction, the development of FA is likely facilitated by the improper initial presentation of antigen to the developing immune system. Primary oral exposure of antigens allowing for presentation via a well-developed mucosal immune system, rather than through a disrupted skin epidermal barrier, is essential to prevent FA. In this review, we present the data supporting the necessity of (1) an intact epidermal barrier to prevent epicutaneous antigen presentation, (2) the presence of specific commensal bacteria to maintain an intact mucosal immune system and (3) maternal/infant diet diversity, including vitamins and minerals, and appropriately timed allergenic food introduction to prevent FA.</style></abstract><notes><style face="normal" font="default" size="100%">Brough, Helen A&#xD;Lanser, Bruce Joshua&#xD;Sindher, Sayantani B&#xD;Teng, Joyce M C&#xD;Leung, Donald Y M&#xD;Venter, Carina&#xD;Chan, Susan M&#xD;Santos, Alexandra F&#xD;Bahnson, Henry T&#xD;Guttman-Yassky, Emma&#xD;Gupta, Ruchi S&#xD;Lack, Gideon&#xD;Ciaccio, Christina E&#xD;Sampath, Vanitha&#xD;Nadeau, Kari C&#xD;Nagler, Cathryn R&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;U19AI070535/GF/NIH HHS/&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;R01AI140134/GF/NIH HHS/&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):416-441. doi: 10.1111/all.15006. Epub 2021 Sep 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34255344</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15006</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>75</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">75</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Logan, K.</style></author><author><style face="normal" font="default" size="100%">Bahnson, H. T.</style></author><author><style face="normal" font="default" size="100%">Ylescupidez, A.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Bellach, J.</style></author><author><style face="normal" font="default" size="100%">Campbell, D. E.</style></author><author><style face="normal" font="default" size="100%">Craven, J.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Clare Mills, E. N.</style></author><author><style face="normal" font="default" size="100%">Perkin, M. R.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health, School of Life Course and Population Sciences, King&apos;s College London, London, UK.&#xD;Immune Tolerance Network, Benaroya Research Institute, Seattle, Washington, USA.&#xD;Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Children&apos;s Hospital at Westmead, Westmead, New South Wales, Australia.&#xD;School of Biological Sciences, Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Science Centre, Manchester Institute of Biotechnology, University of Manchester, Manchester, UK.&#xD;The Population Health Research Institute, St George&apos;s University of London, London, UK.&#xD;University of Southampton and Southampton NIHR Biomedical Research Centre, Southampton, UK.&#xD;Departments of Experimental Immunology and of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1307-1318</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/11/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">causal inference analysis</style></keyword><keyword><style face="normal" font="default" size="100%">early introduction</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy prevention</style></keyword><keyword><style face="normal" font="default" size="100%">(NIAID, NIH) and consulting fees from DBV Technologies, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. KB reports institutional grants from the European Union during the conduct</style></keyword><keyword><style face="normal" font="default" size="100%">of the study and lecture fees from Aimmune, Allergopharma, Bencard,</style></keyword><keyword><style face="normal" font="default" size="100%">Danone/Nutrica, Infectopharm, Meda Pharma/Mylan, Nestle, ThermoFisher as well as</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Aimmune, ALK, Bausch &amp; Lomb, Bencard, Danone/Nutrica, DBV,</style></keyword><keyword><style face="normal" font="default" size="100%">Hipp, Hycor, Infectopharm, Mabylon, Meda Pharma/Mylan, Nestle, Novartis, outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work. DEC receives a part-time salary from the DBV Technologies as</style></keyword><keyword><style face="normal" font="default" size="100%">VP Clinical Development and Medical Affairs, receives institutional funding from</style></keyword><keyword><style face="normal" font="default" size="100%">the National Health and Medical Research Council of Australia and is on the</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Board of AllerGenis. The BEAT study was supported by the Ilhan Food</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Foundation and the Children&apos;s Hospital at Westmead Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Research Fund. GdT reports grants from the National Institute of Allergy and</style></keyword><keyword><style face="normal" font="default" size="100%">Infectious Diseases (NIAID, NIH), Food Allergy &amp; Research Education (FARE), MRC &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma UK Centre, UK Dept of Health through NIHR, Action Medical Research and</style></keyword><keyword><style face="normal" font="default" size="100%">National Peanut Board. Scientific Advisory Board member Aimmune, investigator on</style></keyword><keyword><style face="normal" font="default" size="100%">pharma-sponsored allergy studies (Aimmune and DBV Technologies), shareholder in</style></keyword><keyword><style face="normal" font="default" size="100%">DBV technologies, and scientific advisor to Aimmune, DBV and Novartis. ENM</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from European Union, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Reacta Biotech Ltd, other from Reacta Biotech Ltd, outside the submitted work. In</style></keyword><keyword><style face="normal" font="default" size="100%">addition, ENM has a patent Patents pending and Founder shares in Reacta Biotech</style></keyword><keyword><style face="normal" font="default" size="100%">Ltd. GR reports a grant from the European Union during the conduct of the study.</style></keyword><keyword><style face="normal" font="default" size="100%">RvR reports grants from the Dutch Science Foundation, Health Holland and the</style></keyword><keyword><style face="normal" font="default" size="100%">European Commission, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy for HAL Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">BV, Citeq BV and Angany Inc., speaker&apos;s fees from HAL Allergy BV and ThermoFisher</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific, outside the submitted work. GL reports grants from the National</style></keyword><keyword><style face="normal" font="default" size="100%">Institute of Allergy and Infectious Diseases (NIAID, NIH), Food Allergy &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Research Education (FARE), MRC &amp; Asthma UK Centre, UK Dept of Health through</style></keyword><keyword><style face="normal" font="default" size="100%">NIHR, National Peanut Board (NPB), UK Food Standards Agency (FSA), Action Medical</style></keyword><keyword><style face="normal" font="default" size="100%">Research, the Davis Foundation during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">shareholder in</style></keyword><keyword><style face="normal" font="default" size="100%">DBV Technologies and Mighty Mission Me, scientific advisor for Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genyzme, Regeneron, ALK-Abello, outside the submitted work. No other</style></keyword><keyword><style face="normal" font="default" size="100%">disclosures were reported.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36435990</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per-protocol (PP) analyses, which can be subject to bias. OBJECTIVE: The aim of this study was to combine individual-level data from the LEAP and EAT trials and provide robust evidence on the bias-corrected, causal effect of early peanut introduction. METHOD: As part of the European Union-funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods. RESULTS: An intention-to-treat (ITT) analysis of pooled data showed a 75% reduction in PA (p &lt; .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p &lt; .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p &lt; .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004). CONCLUSION: We demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction.</style></abstract><notes><style face="normal" font="default" size="100%">Logan, Kirsty&#xD;Bahnson, Henry T&#xD;Ylescupidez, Alyssa&#xD;Beyer, Kirsten&#xD;Bellach, Johanna&#xD;Campbell, Dianne E&#xD;Craven, Joanna&#xD;Du Toit, George&#xD;Clare Mills, E N&#xD;Perkin, Michael R&#xD;Roberts, Graham&#xD;van Ree, Ronald&#xD;Lack, Gideon&#xD;eng&#xD;MC_G1001205/MRC_/Medical Research Council/United Kingdom&#xD;N01AI15416/AI/NIAID NIH HHS/&#xD;UM1 AI109565/AI/NIAID NIH HHS/&#xD;HHSN272200800029C/AI/NIAID NIH HHS/&#xD;Randomized Controlled Trial&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1307-1318. doi: 10.1111/all.15597. Epub 2022 Dec 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36435990</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10202125</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15597</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2331</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2331</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, G.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Wan, J.</style></author><author><style face="normal" font="default" size="100%">Ji, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, C.</style></author><author><style face="normal" font="default" size="100%">Sweren, E.</style></author><author><style face="normal" font="default" size="100%">Reddy, S. K.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Garza, L. A.</style></author><author><style face="normal" font="default" size="100%">Hong, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Plastic and Aesthetic Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, China.&#xD;Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.&#xD;Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, Maryland, USA.&#xD;Center on the Early Life Origins of Disease, Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.&#xD;Department of Plastic and Reconstructive Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.&#xD;Division of General Pediatrics &amp; Adolescent Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.&#xD;Department of Cell Biology, Johns Hopkins University, Baltimore, Maryland, USA.&#xD;Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early life risk factors of Atopic March in a high-risk, minority, urban, low-income, prospective birth cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1351-1356</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/12/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Urban Population</style></keyword><keyword><style face="normal" font="default" size="100%">Poverty</style></keyword><keyword><style face="normal" font="default" size="100%">Minority Groups</style></keyword><keyword><style face="normal" font="default" size="100%">Birth Cohort</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38130146</style></accession-num><notes><style face="normal" font="default" size="100%">Wang, Gaofeng&#xD;Chen, Junjun&#xD;Wan, Joy&#xD;Ji, Yuelong&#xD;Zhang, Chunhua&#xD;Sweren, Evan&#xD;Reddy, Sashank K&#xD;Wang, Xiaobin&#xD;Garza, Luis A&#xD;Hong, Xiumei&#xD;eng&#xD;UG3 AR079376/AR/NIAMS NIH HHS/&#xD;R21 AI154233/AI/NIAID NIH HHS/&#xD;R01 HD098232/HD/NICHD NIH HHS/&#xD;R21 AI171059/AI/NIAID NIH HHS/&#xD;R01 AR074846/AR/NIAMS NIH HHS/&#xD;R01 ES031272/ES/NIEHS NIH HHS/&#xD;U01 ES034983/ES/NIEHS NIH HHS/&#xD;R01 HD041702/HD/NICHD NIH HHS/&#xD;P2C HD042854/HD/NICHD NIH HHS/&#xD;R01 ES031521/ES/NIEHS NIH HHS/&#xD;R24 HD042854/HD/NICHD NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1351-1356. doi: 10.1111/all.15990. Epub 2023 Dec 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38130146</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11062844</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15990</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2804</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2804</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chang, F. M.</style></author><author><style face="normal" font="default" size="100%">Lin, Y. F.</style></author><author><style face="normal" font="default" size="100%">Chuang, H. C.</style></author><author><style face="normal" font="default" size="100%">Hsu, J. W.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Medical Research, Taipei Medical University Hospital, Taipei, Taiwan.&#xD;School of Respiratory Therapy, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Family Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Family Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.&#xD;Nutrition Research Center, Taipei Medical University Hospital, Taipei, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early Puberty and Risk of Asthma: Meta-Analysis and Systematic Review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1794-1796</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/01/11</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39797581</style></accession-num><notes><style face="normal" font="default" size="100%">Chang, Fu-Min&#xD;Lin, Yung-Feng&#xD;Chuang, Hsiao-Chi&#xD;Hsu, Jhih-Wei&#xD;Chen, Yang-Ching&#xD;eng&#xD;113-2628-B-038-006-MY3/National Science and Technology Council/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1794-1796. doi: 10.1111/all.16471. Epub 2025 Jan 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39797581</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16471</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2751</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2751</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soendergaard, M. B.</style></author><author><style face="normal" font="default" size="100%">Hansen, S.</style></author><author><style face="normal" font="default" size="100%">Hakansson, K. E. J.</style></author><author><style face="normal" font="default" size="100%">von Bulow, A.</style></author><author><style face="normal" font="default" size="100%">Bjerrum, A. S.</style></author><author><style face="normal" font="default" size="100%">Schmid, J. M.</style></author><author><style face="normal" font="default" size="100%">Johansson, S. L.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, L. M.</style></author><author><style face="normal" font="default" size="100%">Johnsen, C. R.</style></author><author><style face="normal" font="default" size="100%">Bertelsen, B. B.</style></author><author><style face="normal" font="default" size="100%">Krogh, N. S.</style></author><author><style face="normal" font="default" size="100%">Hilberg, O.</style></author><author><style face="normal" font="default" size="100%">Ulrik, C. S.</style></author><author><style face="normal" font="default" size="100%">Porsbjerg, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, Copenhagen University Hospital-Bispebjerg, Copenhagen, Denmark.&#xD;Centre for Clinical Research and Prevention, Frederiksberg Hospital, Copenhagen, Denmark.&#xD;Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark.&#xD;Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.&#xD;Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark.&#xD;Allergy Clinic, Gentofte University Hospital, Hellerup, Denmark.&#xD;Department of Respiratory Diseases, Gentofte University Hospital, Hellerup, Denmark.&#xD;Zitelab ApS, Copenhagen, Denmark.&#xD;Department of Respiratory Medicine, Sygehus Lillebaelt-Vejle Sygehus, Vejle, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early Reduction of FeNO on Anti-IL5 Biologics Is Associated With Clinical Remission of Severe Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">986-995</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/14 20:05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/metabolism/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Nitric Oxide/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-5/antagonists &amp; inhibitors/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Remission Induction</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Fractional Exhaled Nitric Oxide Testing</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39673455</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In patients with severe asthma, treatment with anti-interleukin-5 (IL-5) biologics can lead to a reduction in fractional exhaled nitric oxide (FeNO) in some patients. The clinical implications of varying FeNO responses to anti-IL-5 biologics remain unclear. This study aims to categorise patients based on their FeNO response to anti-IL-5 biologics and evaluate the association of these categories with clinical outcomes. METHODS: We used the Danish Severe Asthma Register (DSAR) to identify the early FeNO response profiles in patients receiving anti-IL5 biologics. We defined FeNO responders as patients with elevated FeNO levels at baseline and a decrease corresponding to the minimal clinically important difference (MCID) at 4 months of follow-up and FeNO non-responders as those who did not experience a decrease. RESULTS: We identified 403 patients on anti-IL5 treatment in DSAR, and 265 (66%) had elevated FeNO levels at baseline. After 4 months of treatment, 151 (57%) patients showed a significant decrease in FeNO levels, and 114 (43%) did not. FeNO responders were more likely to achieve clinical remission of asthma (34% vs. 19%, p = 0.01, OR 2.11, CI 1.04, 5.18, p = 0.03) than FeNO non-responders after 12 months of treatment. The higher remission rates in FeNO responders mainly reflected a higher rate of normalisation of lung function. CONCLUSIONS: FeNO levels were reduced after anti-IL5 treatment in a significant proportion of patients treated with anti-IL5, and this was associated with clinical remission. Early FeNO response to anti-IL5 could potentially be used as a biomarker to guide management decisions with biologics towards remission of disease in severe asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Soendergaard, Marianne Baastrup&#xD;Hansen, Susanne&#xD;Hakansson, Kjell Erik Julius&#xD;von Bulow, Anna&#xD;Bjerrum, Anne-Sofie&#xD;Schmid, Johannes Martin&#xD;Johansson, Sofie Lock&#xD;Rasmussen, Linda Makowska&#xD;Johnsen, Claus Rikard&#xD;Bertelsen, Barbara Bonnesen&#xD;Krogh, Niels Steen&#xD;Hilberg, Ole&#xD;Ulrik, Charlotte Suppli&#xD;Porsbjerg, Celeste&#xD;eng&#xD;DSAR is funded by grants from GlaxoSmithKline, Novartis, AstraZeneca, Teva and Sanofi/&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):986-995. doi: 10.1111/all.16425. Epub 2024 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39673455</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16425</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3220</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3220</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hamelmann, E.</style></author><author><style face="normal" font="default" size="100%">Schaub, B.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Blumchen, K.</style></author><author><style face="normal" font="default" size="100%">Gerstlauer, M.</style></author><author><style face="normal" font="default" size="100%">Kopp, M. V.</style></author><author><style face="normal" font="default" size="100%">Lange, L.</style></author><author><style face="normal" font="default" size="100%">Lau, S.</style></author><author><style face="normal" font="default" size="100%">Maison, N.</style></author><author><style face="normal" font="default" size="100%">Ott, H.</style></author><author><style face="normal" font="default" size="100%">Schmidt, S. M.</style></author><author><style face="normal" font="default" size="100%">Spindler, T.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Vogelberg, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Children&apos;s Center Bethel, University Hospital OWL, University Bielefeld, Bielefeld, Germany.&#xD;Pediatric Allergology, Department of Pediatrics, Dr. Von Hauner Children&apos;s Hospital, University Hospital, Munich, Germany.&#xD;Member of German Center for Lung Research-DZL, LMU, Munich, Germany.&#xD;Member of German Center for Child and Adolescent Health-DZKJ, LMU, Munich, Germany.&#xD;Ludwig-Maximilians-Universitat Munich, Munich, Germany.&#xD;Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Member of German Center for Child and Adolescent Health (DZKJ)-Partner Site Berlin, Berlin, Germany.&#xD;Department of Pediatrics, Division of Pneumology, Allergology, Gastroenterology and Infectious Diseases, Goethe University, Frankfurt, Germany.&#xD;Paediatric and Adolescent Medicine, Department of Paediatric Pneumology and Allergology, University Medical Center Augsburg, Augsburg, Germany.&#xD;Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;GFO Kliniken Bonn, Bonn, Germany.&#xD;Institute of Asthma- and Allergy Prevention (IAP), Helmholtz Zentrum Munich, German Research Center for Environmental Health (GmbH), Neuherberg, Germany.&#xD;Section of Pediatric Dermatology, Munich University Center for Children With Medical and Developmental Complexity, Ludwig-Maximilians-University Hospital, Munich, Germany.&#xD;Department of Pediatrics, University Medicine, Greifswald, Germany.&#xD;Allergologisch-Pneumologische Ambulanz Padiatrie Medizincampus Bodensee, Friedrichshafen, Germany.&#xD;Departement of Pediatrics-Pneumology, Allergology, Klinikum Kempten, Kempten, Germany.&#xD;Medical Faculty, Institute of Environmental Medicine and Integrative Health, EMIH, University Augsburg, Augsburg, Germany.&#xD;Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitat Dresden, Dresden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early Risk Assessment and Recognition of Allergies in Children: Rationale, Methodology, and Proposed Algorithms</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">early allergy recognition</style></keyword><keyword><style face="normal" font="default" size="100%">predictive markers</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">risk factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 25</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41582428</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic diseases-including atopic dermatitis (AD), food allergy (FA), allergic rhinitis (AR), and asthma-are the most common chronic conditions in childhood and adolescence, affecting up to 30% of the global population. In Germany alone, more than 2.1 million children and adolescents are affected. These conditions frequently coexist and share common genetic, environmental, dietary, and microbial risk factors. METHODS: A comprehensive literature review was conducted, and a multidisciplinary Task Force of the German Society for Pediatric Allergology and Environmental Medicine (GPA) and the German Society for Allergology and Clinical Immunology (DGAKI) developed consensus-based algorithms for early risk assessment and recognition of allergies in children in already existing preventive medical check-ups. The approach emphasizes stepwise risk assessment, including family history, environmental exposures, and early clinical signs such as recurrent wheezing. RESULTS: For children identified as at risk for or with early clinical signs of atopy, targeted diagnostic steps are recommended that follow the national/international guidelines for the management of the suspected atopic disease. This may include general and specific recommendations for nutrition, measurement of specific sensitization and selected biomarkers, if indicated and recommended by the guidelines. Routine allergy testing in asymptomatic children is not recommended. The algorithms are designed to be embedded into routine pediatric check-ups, enabling systematic and early identification of children at increased risk or with early clinical signs of atopic diseases. Early recognition and management can reduce disease severity, improve quality of life, and decrease healthcare costs. CONCLUSION: Structured programs for early risk assessment and recognition of allergies in children are currently lacking but can provide substantial clinical and economic benefits. Integration into routine pediatric preventive examinations, supported by standardization, interdisciplinary collaboration, and sustainable funding, offers a promising strategy to improve long-term outcomes for affected children and their families.</style></abstract><notes><style face="normal" font="default" size="100%">Hamelmann, E&#xD;Schaub, B&#xD;Beyer, K&#xD;Blumchen, K&#xD;Gerstlauer, M&#xD;Kopp, M V&#xD;Lange, L&#xD;Lau, S&#xD;Maison, N&#xD;Ott, H&#xD;Schmidt, S M&#xD;Spindler, T&#xD;Traidl-Hoffmann, C&#xD;Vogelberg, C&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2026 Jan 25. doi: 10.1111/all.70224.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41582428</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70224</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2679</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2679</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Feleszko, W.</style></author><author><style face="normal" font="default" size="100%">Makrinioti, H.</style></author><author><style face="normal" font="default" size="100%">Nalej, M.</style></author><author><style face="normal" font="default" size="100%">Ooka, T.</style></author><author><style face="normal" font="default" size="100%">Zhu, Z.</style></author><author><style face="normal" font="default" size="100%">Sullivan, A. F.</style></author><author><style face="normal" font="default" size="100%">Jartti, T.</style></author><author><style face="normal" font="default" size="100%">Hasegawa, K.</style></author><author><style face="normal" font="default" size="100%">Camargo, C. A., Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Pediatric Respiratory Diseases and Allergy, The Medical University Children&apos;s Hospital, Medical University of Warsaw, Warsaw, Poland.&#xD;London School of Paediatrics, London, UK.&#xD;Institute of Urban Geography, Tourism Studies and Geoinformation, Faculty of Geographical Sciences, University of Lodz, Lodz, Poland.&#xD;Department of Health Sciences, University of Yamanashi, Chuo, Yamanashi, Japan.&#xD;Department of Paediatrics, Turku University Hospital and Turku University, Turku, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early-life exposure to residential greenness and risk of asthma in a U.S. bronchiolitis cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3036-3046</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Bronchiolitis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Residence Characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchiolitis</style></keyword><keyword><style face="normal" font="default" size="100%">chlorophyll index</style></keyword><keyword><style face="normal" font="default" size="100%">greenness</style></keyword><keyword><style face="normal" font="default" size="100%">vegetation</style></keyword><keyword><style face="normal" font="default" size="100%">this work</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39429165</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Severe bronchiolitis (i.e., bronchiolitis requiring hospitalization) is linked to childhood asthma development. Despite a growing understanding of risk factors for developing post-bronchiolitis asthma, protective factors remain unclear. In this study, we aimed to investigate whether exposure to residential greenness between birth and bronchiolitis hospitalization is associated with asthma and atopic asthma development by age 6 years. METHODS: We analyzed a US severe bronchiolitis cohort from hospitalization to age 6 years, investigating how the normalized difference vegetation index (NDVI) and chlorophyll index green (CI green), measured in small (100 m) and large (500 m) radiuses around homes, relate to asthma and atopic asthma by age 6 years. We also explored whether maternal antibiotic use, daycare attendance, and respiratory virus type during hospitalization act as effect modifiers. RESULTS: The study cohort included 861 infants, with 239 (28%) developing asthma by age 6 years-152 atopic, 17 nonatopic, and 70 unclassified. Early life residential exposure to high NDVI and CI green levels was associated with lower odds of asthma (OR(Adj) for NDVI within a 100 m radius, 0.18; 95% CI, 0.05-0.78; and OR(Adj) for CI green levels within a 100 m radius, 0.53; 95% CI, 0.31-0.90). Associations also were significant for the development of atopic asthma (OR(Adj) 0.16; 95% CI, 0.03-0.96; and OR(Adj) 0.46; 95% CI, 0.25-0.92; respectively). Results were similar for the 500 m radius exposures. No effect modification was noted. CONCLUSION: In a U.S. bronchiolitis cohort, exposure to residential greenness between birth and bronchiolitis hospitalization is linked to lower asthma and atopic asthma risk by age 6 years.</style></abstract><notes><style face="normal" font="default" size="100%">Feleszko, Wojciech&#xD;Makrinioti, Heidi&#xD;Nalej, Marta&#xD;Ooka, Tadao&#xD;Zhu, Zhaozhong&#xD;Sullivan, Ashley F&#xD;Jartti, Tuomas&#xD;Hasegawa, Kohei&#xD;Camargo, Carlos A Jr&#xD;eng&#xD;Fundacja Respira/&#xD;R01 AI148338/AI/NIAID NIH HHS/&#xD;UH3 OD023253/OD/NIH HHS/&#xD;K01 AI153558/AI/NIAID NIH HHS/&#xD;UG3 OD023253/OD/NIH HHS/&#xD;Lastentautien Tutkimussaatio/&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3036-3046. doi: 10.1111/all.16359. Epub 2024 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39429165</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11560528</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16359</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>66</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">66</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee-Sarwar, K. A.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. C.</style></author><author><style face="normal" font="default" size="100%">Lasky-Su, J.</style></author><author><style face="normal" font="default" size="100%">Kelly, R. S.</style></author><author><style face="normal" font="default" size="100%">Zeiger, R. S.</style></author><author><style face="normal" font="default" size="100%">O&apos;Connor, G. T.</style></author><author><style face="normal" font="default" size="100%">Bacharier, L. B.</style></author><author><style face="normal" font="default" size="100%">Jia, X.</style></author><author><style face="normal" font="default" size="100%">Beigelman, A.</style></author><author><style face="normal" font="default" size="100%">Gold, D. R.</style></author><author><style face="normal" font="default" size="100%">Laranjo, N.</style></author><author><style face="normal" font="default" size="100%">Bunyavanich, S.</style></author><author><style face="normal" font="default" size="100%">Weiss, S. T.</style></author><author><style face="normal" font="default" size="100%">Litonjua, A. A.</style></author><author><style face="normal" font="default" size="100%">Brennan, P. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Channing Division of Network Medicine, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Allergy &amp; Clinical Immunology, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Clinical Science Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.&#xD;Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.&#xD;Department of Pediatric Allergy, Immunology, and Pulmonary, Vanderbilt Children&apos;s Hospital, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Schneider Children&apos;s Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel.&#xD;Division of Pediatric Allergy, Immunology &amp; Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Division of Pediatric Pulmonary Medicine, Golisano Children&apos;s Hospital at Strong, University of Rochester Medical Center, Rochester, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early-life fecal metabolomics of food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">512-521</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/12/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Caffeine</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Milk, Human</style></keyword><keyword><style face="normal" font="default" size="100%">Sphingolipids</style></keyword><keyword><style face="normal" font="default" size="100%">bile acids</style></keyword><keyword><style face="normal" font="default" size="100%">caffeine</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">from UpToDate, Inc and has invested in Histolix. LBB reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">NIH/NIAID and NHLBI, personal fees from GlaxoSmithKline Genentech/Novartis, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Vectura, Circassia, Kinaset, Vertex, OM Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">and royalties from</style></keyword><keyword><style face="normal" font="default" size="100%">Elsevier outside the submitted work. AB holds stock from DBV Technologies, is a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant for AstraZeneca and Raffa, and received speaking honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZenica, Novartis and Sanofi. RSZ is a consultant for AstraZeneca, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Genentech, Inc., GlaxoSmithKline, Merck &amp; Co., Novartis, Quest</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostics, Regeneron/Sanofi, TEVA Pharmaceuticals, and has received research</style></keyword><keyword><style face="normal" font="default" size="100%">support from ALK Pharmaceuticals, AstraZeneca, Genentech, Inc., GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">NHLBI, MedImmune, Merck, and Teva Pharmaceuticals. GTO has been compensated for</style></keyword><keyword><style face="normal" font="default" size="100%">speaking at a conference supported by Menarini, Inc. and for serving on a Data</style></keyword><keyword><style face="normal" font="default" size="100%">and Safety Monitoring Committee for Dicerna, Inc. JL-S is a Scientific Advisor</style></keyword><keyword><style face="normal" font="default" size="100%">for Precion. KL-S, YCC, RSK, XJ, NL, SB, PJB and DRG have nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36448508</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Intestinal microenvironmental perturbations may increase food allergy risk. We hypothesize that children with clinical food allergy, those with food sensitization, and healthy children can be differentiated by intestinal metabolites in the first years of life. METHODS: In this ancillary analysis of the Vitamin D Antenatal Asthma Reduction Trial (VDAART), we performed untargeted metabolomic profiling in 824 stool samples collected at ages 3-6 months, 1 year and 3 years. Subjects included 23 with clinical food allergy at age 3 and/or 6 years, 151 with food sensitization but no clinical food allergy, and 220 controls. We identified modules of correlated, functionally related metabolites and sought associations of metabolite modules and individual metabolites with food allergy/sensitization using regression models. RESULTS: Several modules of functionally related intestinal metabolites were reduced among subjects with food allergy, including bile acids at ages 3-6 months and 1 year, amino acids at age 3-6 months, steroid hormones at 1 year, and sphingolipids at age 3 years. One module primarily containing diacylglycerols was increased in those with food allergy at age 3-6 months. Fecal caffeine metabolites at age 3-6 months, likely derived from breast milk, were increased in those with food allergy and/or sensitization (beta = 5.9, 95% CI 1.0-10.8, p = .02) and were inversely correlated with fecal bile acids and bilirubin metabolites, though maternal plasma caffeine levels were not associated with food allergy and/or sensitization. CONCLUSIONS: Several classes of bioactive fecal metabolites are associated with food allergy and/or sensitization including bile acids, steroid hormones, sphingolipids, and caffeine metabolites.</style></abstract><notes><style face="normal" font="default" size="100%">Lee-Sarwar, Kathleen A&#xD;Chen, Yih-Chieh&#xD;Lasky-Su, Jessica&#xD;Kelly, Rachel S&#xD;Zeiger, Robert S&#xD;O&apos;Connor, George T&#xD;Bacharier, Leonard B&#xD;Jia, Xiaojiong&#xD;Beigelman, Avraham&#xD;Gold, Diane R&#xD;Laranjo, Nancy&#xD;Bunyavanich, Supinda&#xD;Weiss, Scott T&#xD;Litonjua, Augusto A&#xD;Brennan, Patrick J&#xD;eng&#xD;R01 HL123915/HL/NHLBI NIH HHS/&#xD;R01 HL141826/HL/NHLBI NIH HHS/&#xD;R01 HL108818/HL/NHLBI NIH HHS/&#xD;U19 AI095219/AI/NIAID NIH HHS/&#xD;K08 HL148178/HL/NHLBI NIH HHS/&#xD;R01 AI143855/AI/NIAID NIH HHS/&#xD;UG3 OD023268/OD/NIH HHS/&#xD;T32 HL007427/HL/NHLBI NIH HHS/&#xD;U01 HL091528/HL/NHLBI NIH HHS/&#xD;R01 AI147028/AI/NIAID NIH HHS/&#xD;T32 AI007306/AI/NIAID NIH HHS/&#xD;P30 ES001247/ES/NIEHS NIH HHS/&#xD;UH3 OD023268/OD/NIH HHS/&#xD;K01 HL146980/HL/NHLBI NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):512-521. doi: 10.1111/all.15602. Epub 2022 Dec 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36448508</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10590492</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15602</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2862</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2862</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hu, Y.</style></author><author><style face="normal" font="default" size="100%">Zhao, J.</style></author><author><style face="normal" font="default" size="100%">Shen, Q.</style></author><author><style face="normal" font="default" size="100%">Yang, D.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Chen, Z.</style></author><author><style face="normal" font="default" size="100%">Ni, M.</style></author><author><style face="normal" font="default" size="100%">Li, B.</style></author><author><style face="normal" font="default" size="100%">Lin, Z.</style></author><author><style face="normal" font="default" size="100%">Cheng, C.</style></author><author><style face="normal" font="default" size="100%">Yao, D.</style></author><author><style face="normal" font="default" size="100%">Zhang, Q.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Huang, X.</style></author><author><style face="normal" font="default" size="100%">Tang, Z.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.&#xD;Shanghai Key Laboratory of Embryo Original Disease, Shanghai, China.&#xD;Shanghai Municipal Key Clinical Specialty, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early-Life Quarantine Increases the Development of Infant Atopic Dermatitis: A Birth Cohort Study in China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1526-1529</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/04/19 22:11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic Dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">environment and hygiene hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40251905</style></accession-num><notes><style face="normal" font="default" size="100%">Hu, Yi&#xD;Zhao, Jiuru&#xD;Shen, Qianwen&#xD;Yang, Dongjian&#xD;Li, Wei&#xD;Chen, Ze&#xD;Ni, Meng&#xD;Li, Baihe&#xD;Lin, Zhenying&#xD;Cheng, Chunyu&#xD;Yao, Dongting&#xD;Zhang, Qianqian&#xD;Liu, Xiaorui&#xD;Li, Hong&#xD;Huang, Xiaoyi&#xD;Tang, Zheng&#xD;Liu, Zhiwei&#xD;eng&#xD;2022YFC2702903/National Key R&amp;D Program of China/&#xD;82271742/National Natural Science Foundation of China/&#xD;SHDC22022303/Clinical Research Plan of SHDC/&#xD;21XD1403700/Program of Shanghai Academic Research Leader/&#xD;YG2021ZD29/Interdisciplinary Program of Shanghai Jiao Tong University/&#xD;20Z11900602/Shanghai Municipal Science and Technology Major Project/&#xD;23DZ1203006/Shanghai Municipal Science and Technology Major Project/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1526-1529. doi: 10.1111/all.16561. Epub 2025 Apr 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40251905</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16561</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3295</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3295</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ambrożej, Dominika</style></author><author><style face="normal" font="default" size="100%">Dumycz, Karolina</style></author><author><style face="normal" font="default" size="100%">Feleszko, Wojciech</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Early-Life Viral Infections as Architects of Asthma Susceptibility</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70315</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70315</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3183</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3183</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yin, X.</style></author><author><style face="normal" font="default" size="100%">Meng, J.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Li, P. H.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Translational Medical Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.&#xD;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Ajou University Medical Center, Suwon, Korea.&#xD;Allergy Unit, IBIMA-BIONAND, Regional University Hospital of Malaga, Malaga University, Malagia, Spain.&#xD;Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, SAR, China.&#xD;Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">East Meets West in Allergic Airway Disease: Insights From the EAACI Hong Kong Allergy School 2025</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy vaccines and mechanisms</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41454649</style></accession-num><notes><style face="normal" font="default" size="100%">Yin, Xiaoling&#xD;Meng, Juan&#xD;Durham, Stephen R&#xD;Del Giacco, Stefano&#xD;Li, Lisha&#xD;Park, Hae-Sim&#xD;Torres, Maria Jose&#xD;Li, Philip H&#xD;Shamji, Mohamed&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Dec 27. doi: 10.1111/all.70204.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41454649</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70204</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3217</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3217</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yin, X.</style></author><author><style face="normal" font="default" size="100%">Meng, J.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Li, P. H.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Translational Medical Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.&#xD;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Ajou University Medical Center, Suwon, Korea.&#xD;Allergy Unit, IBIMA-BIONAND, Regional University Hospital of Malaga, Malaga University, Malagia, Spain.&#xD;Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, SAR, China.&#xD;Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">East Meets West in Allergic Airway Disease: Insights From the EAACI Hong Kong Allergy School 2025</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy vaccines and mechanisms</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41454649</style></accession-num><notes><style face="normal" font="default" size="100%">Yin, Xiaoling&#xD;Meng, Juan&#xD;Durham, Stephen R&#xD;Del Giacco, Stefano&#xD;Li, Lisha&#xD;Park, Hae-Sim&#xD;Torres, Maria Jose&#xD;Li, Philip H&#xD;Shamji, Mohamed&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Dec 27. doi: 10.1111/all.70204.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41454649</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70204</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3242</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3242</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yin, X.</style></author><author><style face="normal" font="default" size="100%">Meng, J.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Li, P. H.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Translational Medical Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.&#xD;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Ajou University Medical Center, Suwon, Korea.&#xD;Allergy Unit, IBIMA-BIONAND, Regional University Hospital of Malaga, Malaga University, Malagia, Spain.&#xD;Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, SAR, China.&#xD;Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">East Meets West in Allergic Airway Disease: Insights From the EAACI Hong Kong Allergy School 2025</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy vaccines and mechanisms</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41454649</style></accession-num><notes><style face="normal" font="default" size="100%">Yin, Xiaoling&#xD;Meng, Juan&#xD;Durham, Stephen R&#xD;Del Giacco, Stefano&#xD;Li, Lisha&#xD;Park, Hae-Sim&#xD;Torres, Maria Jose&#xD;Li, Philip H&#xD;Shamji, Mohamed&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Dec 27. doi: 10.1111/all.70204.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41454649</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70204</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1401</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1401</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Azzano, P.</style></author><author><style face="normal" font="default" size="100%">Dufresne, E.</style></author><author><style face="normal" font="default" size="100%">Poder, T.</style></author><author><style face="normal" font="default" size="100%">Begin, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, CHU Sainte-Justine, Montreal, QC, Canada.&#xD;Department of Management, Evaluation and Health Policy, School of Public Health, University of Montreal, Montreal, QC, Canada.&#xD;Research Center of the Institut Universitaire en Sante Mentale de Montreal, Montreal, QC, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Economic considerations on the usage of biologics in the allergy clinic</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">191-209</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products</style></keyword><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">cost utility</style></keyword><keyword><style face="normal" font="default" size="100%">cost-effectiveness</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32656802</style></accession-num><abstract><style face="normal" font="default" size="100%">The advent of biologic therapies has transformed care for severe atopic disorders but their high cost poses new challenges with regard to long-term sustainability and fair allocation of resources. This article covers the basic concepts of cost-utility analyses and reviews the available literature on cost utility of biologic drugs in atopic disorders. When used within their limits as part of a multi-dimensional assessment, economic analyses can be extremely useful to guide decision-making and prioritization of care. Despite the good quality of most cost-utility analyses conducted for the use of biologics in asthma and other atopic diseases, their conclusions regarding cost-effectiveness are extremely variable. This is mainly due to the use of inconsistent estimates of health utility benefit with therapy. Development of reliable and validated instruments to measure disutility in atopic disorders and measure of indirect costs in atopic disease are identified as a priority for future research.</style></abstract><notes><style face="normal" font="default" size="100%">Azzano, Pauline&#xD;Dufresne, Elise&#xD;Poder, Thomas&#xD;Begin, Philippe&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):191-209. doi: 10.1111/all.14494. Epub 2020 Sep 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32656802</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14494</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2906</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2906</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Torres, M.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Bradatan, E.</style></author><author><style face="normal" font="default" size="100%">El Abd, K.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Rivolta, F.</style></author><author><style face="normal" font="default" size="100%">Sangalli, A.</style></author><author><style face="normal" font="default" size="100%">Bumbacea, R.</style></author><author><style face="normal" font="default" size="100%">Ali, S.</style></author><author><style face="normal" font="default" size="100%">Antolin, D.</style></author><author><style face="normal" font="default" size="100%">Cuenda, A. C. L.</style></author><author><style face="normal" font="default" size="100%">Albendiz, V.</style></author><author><style face="normal" font="default" size="100%">Oliveira, M. M.</style></author><author><style face="normal" font="default" size="100%">Nogueira, P. J.</style></author><author><style face="normal" font="default" size="100%">Carmona, L.</style></author><author><style face="normal" font="default" size="100%">Head Study Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy &amp; Clinical Immunology, Transylvania University, Brasov, Romania.&#xD;Allergy Unit and Research Group, Hospital Regional Universitario de Malaga and IBIMA-Plataforma BIONAND, RICORS Inflammatory Diseases, Malaga, Spain.&#xD;Pneumology-Allergology Unit, Pediatrics Department, Centre Hospitalier Regional de Namur, Namur, Belgium.&#xD;Centre Pediatrique d&apos;Allergologie, CHC MontLegia, Liege, Belgium.&#xD;Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.&#xD;Allergy Unit, Department of Internal Medicine, University Hospital of Anconai Riposo e Cura per Anziani (INCRA), Ancona, Italy.&#xD;Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale di Riposo e Cura per Anziani (INCRA), Ancona, Italy.&#xD;Allergy Unit, Department of Internal Medicine, Fondazione IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Allergology Department, &apos;Carol Davila&apos; University of Medicine and Pharmacy, Bucharest, Romania.&#xD;Department of Allergology and Clinical Immunology, &apos;Carol Davila&apos; Nephrology Clinical Hospital, Bucharest, Romania.&#xD;Allergy Department, Ramon y Cajal University Hospital, Ramon y Cajal Health Research Institute (IRyCIS), Universidad Alcala de Henares, Madrid, Spain.&#xD;Hospital de Merida, Merida, Badajoz, Spain.&#xD;ISAMB - Institute of Environmental Health, Associate Laboratory TERRA, Lisbon School of Medicine, University of Lisbon, Lisbon, Portugal.&#xD;Instituto de Salud Musculoesqueletica (Inmusc), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Economic Impact of Allergic Diseases and Asthma-The HEAD Pan-European Registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1677-1701</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/05/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/economics/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/economics/epidemiology/therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Care Costs</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Cost of Illness</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">economic impact</style></keyword><keyword><style face="normal" font="default" size="100%">registry</style></keyword><keyword><style face="normal" font="default" size="100%">COI.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40391774</style></accession-num><abstract><style face="normal" font="default" size="100%">The Health Economics of Allergic Diseases (HEAD) registry is a European-based registry developed by the European Academy of Allergy and Clinical Immunology in collaboration with national allergy societies to facilitate standardised allergic disease management. Using an observational design, this first registry-based study describes care patterns for allergic diseases and their impact on the healthcare system (diagnostic and management costs), society (missed work/school days and disability pension/support) and patients (out-of-pocket costs) in 778 adults and children with allergic rhinitis, asthma, atopic dermatitis and food allergy, from four countries (Belgium, Italy, Romania and Spain). The average total costs per patient and per year were euro1329.55 +/- 1947.39, with indirect costs of euro338.68 +/- 1629.61. Direct costs consisted of euro82.74 +/- 585.90 for hospitalisations, euro17.50 +/- 125.07 for the emergency department, euro172.94 +/- 323.17 for specialists, euro22.70 +/- 132.42 for primary care, euro4.85 +/- 136.84 for psychologists, euro21.24 +/- 82.47 for diagnosis and euro104.81 +/- 469.26 for treatments. Indirect costs were out-of-pocket consultation fees (euro16.24 +/- 106.40), medications (euro161.90 +/- 710.58), transportation (euro44.15 +/- 218.51), private insurance (euro16.77 +/- 157.91), avoidance (euro8.65 +/- 92.99) and environmental control (euro99.33 +/- 955.23). Adults missed 1.02 +/- 3.20 workdays, children missed 0.53 +/- 2.18 schooldays and burdened their families with 1.38 +/- 13.83 lost days. There was a high degree of heterogeneity across countries for management patterns and for costs. The significant burden of allergic diseases calls for immediate action for better management.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Torres, Maria&#xD;Eguiluz-Gracia, Ibon&#xD;Bradatan, Elena&#xD;El Abd, Kamal&#xD;Bilo, Maria Beatrice&#xD;Rivolta, Federica&#xD;Sangalli, Andrea&#xD;Bumbacea, Roxana&#xD;Ali, Selda&#xD;Antolin, Dario&#xD;Cuenda, Agueda Concepcion Lario&#xD;Albendiz, Vicente&#xD;Oliveira, Maria Miguel&#xD;Nogueira, Paulo Jorge&#xD;Carmona, Loreto&#xD;eng&#xD;Observational Study&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1677-1701. doi: 10.1111/all.16596. Epub 2025 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40391774</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186598</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16596</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1049</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1049</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Traidl, S.</style></author><author><style face="normal" font="default" size="100%">Roesner, L.</style></author><author><style face="normal" font="default" size="100%">Zeitvogel, J.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Eczema herpeticum in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3017-3027</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/04/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Kaposi Varicelliform Eruption</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">Hsv</style></keyword><keyword><style face="normal" font="default" size="100%">eczema herpeticum</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 immune response</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33844308</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases leading to pruritic skin lesions. A subset of AD patients exhibits a disseminated severe HSV infection called eczema herpeticum (EH) that can cause life-threatening complications. This review gives an overview of the clinical picture, and characteristics of the patients as well as the diagnosis and therapy of EH. A special focus lies on the pathophysiological hallmarks identified so far that predispose for EH. This aspect covers genetic aberrations, immunological changes, and environmental influences displaying a complex multifactorial situation, which is not completely understood. Type 2 skewing of virus-specific T cells in ADEH(+) patients has been implicated in immune profile abnormalities, along with impaired functions of dendritic cells and natural killer cells. Furthermore, aberrations in interferon pathway-related genes such as IFNG and IFNGR1 have been identified to increase the risk of EH. IL-4, IL-25, and thymic stromal lymphopoietin (TSLP) are overexpressed in EH, whereas antimicrobial peptides like human beta-defensins and LL-37 are reduced. Concerning the epidermal barrier, single nucleotide polymorphisms (SNPs) in skin barrier proteins such as filaggrin were identified in ADEH(+) patients. A dysbalance of the skin microbiome also contributes to EH due to an increase of Staphylococcus aureus, which provides a supporting role to the viral infection via secreted toxins such as alpha-toxin. The risk of EH is reduced in AD patients treated with dupilumab. Further research is needed to identify and specifically target risk factors for EH in AD patients.</style></abstract><notes><style face="normal" font="default" size="100%">Traidl, Stephan&#xD;Roesner, Lennart&#xD;Zeitvogel, Jana&#xD;Werfel, Thomas&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3017-3027. doi: 10.1111/all.14853. Epub 2021 May 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33844308</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14853</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>36</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">36</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Sindher, S.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine and Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service and Evelina Children&apos;s Hospital, Guy&apos;s and St Thomas&apos;s NHS Foundation Trust, London, UK.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford University, Stanford, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Editorial comments on &quot;Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants-The STOP-AD randomized controlled trial&quot;-Is emollient therapy enough?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">908-911</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/12/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Emollients/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36573442</style></accession-num><notes><style face="normal" font="default" size="100%">Brough, Helen A&#xD;Sindher, Sayantani&#xD;Nadeau, Kari C&#xD;eng&#xD;Comment&#xD;Editorial&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):908-911. doi: 10.1111/all.15626.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36573442</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15626</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2334</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2334</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Facheris, P.</style></author><author><style face="normal" font="default" size="100%">Gomez-Arias, P. J.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Da Rosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Weidinger, S.</style></author><author><style face="normal" font="default" size="100%">Bissonnette, R.</style></author><author><style face="normal" font="default" size="100%">Armstrong, A. W.</style></author><author><style face="normal" font="default" size="100%">Seneschal, J.</style></author><author><style face="normal" font="default" size="100%">Eyerich, K.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y. D.</style></author><author><style face="normal" font="default" size="100%">Bose, S. N.</style></author><author><style face="normal" font="default" size="100%">Xu, D.</style></author><author><style face="normal" font="default" size="100%">Chen, A.</style></author><author><style face="normal" font="default" size="100%">Tatulych, S.</style></author><author><style face="normal" font="default" size="100%">Guler, E.</style></author><author><style face="normal" font="default" size="100%">Chan, G.</style></author><author><style face="normal" font="default" size="100%">Page, K. M.</style></author><author><style face="normal" font="default" size="100%">Kerkmann, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, USA.&#xD;University Hospital Schleswig-Holstein, Kiel, Germany.&#xD;Innovaderm Research Inc., Montreal, Quebec, Canada.&#xD;University of Southern California, Los Angeles, California, USA.&#xD;Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andre, Bordeaux, France.&#xD;Bordeaux University, CNRS UMR 5164, Immunoconcept, Bordeaux, France.&#xD;University of Freiburg, Freiburg, Germany.&#xD;Pfizer Inc., San Diego, California, USA.&#xD;Pfizer Inc., Groton, Connecticut, USA.&#xD;Pfizer Inc., Istanbul, Turkey.&#xD;Pfizer Inc., Cambridge, Massachusetts, USA.&#xD;Pfizer Pharma GmbH, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1258-1270</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/12/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/pathology/metabolism/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Sulfonamides/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">*Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrimidines/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38108208</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: This is the first report on the effects of abrocitinib, a Janus kinase 1-selective inhibitor, on the expression of skin biomarkers in patients with moderate-to-severe atopic dermatitis (AD). METHODS: JADE MOA (NCT03915496) was a double-blind Phase 2a trial. Adults were randomly assigned 1:1:1 to receive monotherapy with once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 weeks. The primary endpoint was change from baseline in markers of inflammation (matrix metalloproteinase [MMP]-12), epidermal hyperplasia (keratin-16 [KRT16]), T-helper 2 (Th2) immune response (C-C motif chemokine ligand [CCL]17, CCL18, and CCL26), and Th22 immune response (S100 calcium binding protein A8, A9, and A12 [S100A8, S100A9, and S100A12]) in skin through 12 weeks. RESULTS: A total of 46 patients received abrocitinib 200 mg (n = 14), abrocitinib 100 mg (n = 16), or placebo (n = 16). Abrocitinib improved AD clinical signs and reduced itch. Gene expression of MMP-12, KRT16, S100A8, S100A9, and S100A12 was significantly decreased from baseline with abrocitinib 200 mg (at Weeks 2, 4, and 12) and abrocitinib 100 mg (at Weeks 4 and 12) in a dose-dependent manner. Abrocitinib 200 mg resulted in significant decreases from baseline in CCL17 expression at Week 12 and CCL18 expression at Weeks 2, 4, and 12; no significant decreases were observed for CCL26. CONCLUSIONS: Alongside improvements in clinical signs and symptoms of AD, 12 weeks of abrocitinib treatment resulted in downregulation of genes associated with inflammation, epidermal hyperplasia, and Th2 and Th22 immune responses in the skin of patients with moderate-to-severe AD.</style></abstract><notes><style face="normal" font="default" size="100%">Guttman-Yassky, Emma&#xD;Facheris, Paola&#xD;Gomez-Arias, Pedro Jesus&#xD;Del Duca, Ester&#xD;Da Rosa, Joel Correa&#xD;Weidinger, Stephan&#xD;Bissonnette, Robert&#xD;Armstrong, April W&#xD;Seneschal, Julien&#xD;Eyerich, Kilian&#xD;Estrada, Yeriel D&#xD;Bose, Swaroop N&#xD;Xu, Dan&#xD;Chen, Allshine&#xD;Tatulych, Svitlana&#xD;Guler, Erman&#xD;Chan, Gary&#xD;Page, Karen M&#xD;Kerkmann, Urs&#xD;eng&#xD;Pfizer Inc., New York, NY, USA/&#xD;Clinical Trial, Phase II&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1258-1270. doi: 10.1111/all.15969. Epub 2023 Dec 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38108208</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15969</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>977</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">977</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cusack, R. P.</style></author><author><style face="normal" font="default" size="100%">Huang, C.</style></author><author><style face="normal" font="default" size="100%">LaVigne, N.</style></author><author><style face="normal" font="default" size="100%">Satia, I.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author><author><style face="normal" font="default" size="100%">O&apos;Byrne, P. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, McMaster University, Hamilton, ON, Canada.&#xD;Department of Respirology, McMaster University, Hamilton, ON, Canada.&#xD;Firestone Institute of Respiratory Health, St. Joseph&apos;s Hospital, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of anti-IL-5 biologics on weight and body mass index</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2913-2916</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-5</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34028047</style></accession-num><notes><style face="normal" font="default" size="100%">Cusack, Ruth P&#xD;Huang, Chynna&#xD;LaVigne, Nicola&#xD;Satia, Imran&#xD;Nair, Parameswaran&#xD;O&apos;Byrne, Paul M&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2913-2916. doi: 10.1111/all.14956. Epub 2021 Jun 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34028047</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14956</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>540</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">540</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bogan, M.</style></author><author><style face="normal" font="default" size="100%">Kul, S.</style></author><author><style face="normal" font="default" size="100%">Al, B.</style></author><author><style face="normal" font="default" size="100%">Oktay, M. M.</style></author><author><style face="normal" font="default" size="100%">Akpinar Elci, M.</style></author><author><style face="normal" font="default" size="100%">Pinkerton, K. E.</style></author><author><style face="normal" font="default" size="100%">Bayram, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Emergency Medicine, University of Gaziantep, Gaziantep, Turkey.&#xD;Department of Emergency Medicine, Duzce University, Duzce, Turkey.&#xD;Department of Biostatistics, University of Gaziantep, Gaziantep, Turkey.&#xD;Vocational High School, Hasan Kalyoncu University, Gaziantep, Turkey.&#xD;School of Public, Health University of Nevada, Reno, Nevada, USA.&#xD;Center for Health and the Environment, University of California, Davis, California, USA.&#xD;Department of Chest Diseases, University of Gaziantep, Gaziantep, Turkey.&#xD;Koc University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of desert dust storms and meteorological factors on respiratory diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2243-2246</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/03/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Air Pollutants/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Meteorological Concepts</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiration Disorders</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35353917</style></accession-num><notes><style face="normal" font="default" size="100%">Bogan, Mustafa&#xD;Kul, Seval&#xD;Al, Behcet&#xD;Oktay, Mehmet Murat&#xD;Akpinar Elci, Muge&#xD;Pinkerton, Kent E&#xD;Bayram, Hasan&#xD;eng&#xD;T42 OH008429/OH/NIOSH CDC HHS/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2243-2246. doi: 10.1111/all.15298. Epub 2022 Apr 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35353917</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15298</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2240</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2240</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Svenningsen, S.</style></author><author><style face="normal" font="default" size="100%">Kjarsgaard, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, K.</style></author><author><style face="normal" font="default" size="100%">Serajeddini, H.</style></author><author><style face="normal" font="default" size="100%">Garrido, C. V.</style></author><author><style face="normal" font="default" size="100%">Bhalla, A.</style></author><author><style face="normal" font="default" size="100%">Radford, K.</style></author><author><style face="normal" font="default" size="100%">Huang, C.</style></author><author><style face="normal" font="default" size="100%">Ho, T.</style></author><author><style face="normal" font="default" size="100%">Ragunayakam, N.</style></author><author><style face="normal" font="default" size="100%">Thakar, A.</style></author><author><style face="normal" font="default" size="100%">Radadia, N.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada.&#xD;Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of dupilumab on sputum eosinophils in patients with moderate-to-severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">509-513</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/09/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37750593</style></accession-num><notes><style face="normal" font="default" size="100%">Svenningsen, Sarah&#xD;Kjarsgaard, Melanie&#xD;Zhang, Kayla&#xD;Serajeddini, Hana&#xD;Garrido, Carmen Venegas&#xD;Bhalla, Anurag&#xD;Radford, Katherine&#xD;Huang, Chynna&#xD;Ho, Terence&#xD;Ragunayakam, Nandhitha&#xD;Thakar, Ashutosh&#xD;Radadia, Nisarg&#xD;Mukherjee, Manali&#xD;Nair, Parameswaran&#xD;eng&#xD;Regeneron Pharmaceuticals/&#xD;Sanofi/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):509-513. doi: 10.1111/all.15901. Epub 2023 Sep 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37750593</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15901</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>255</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">255</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gao, Y. D.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Cui, Y. W.</style></author><author><style face="normal" font="default" size="100%">Stanic, B.</style></author><author><style face="normal" font="default" size="100%">Maurer, D. J.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, N.</style></author><author><style face="normal" font="default" size="100%">Finotto, S.</style></author><author><style face="normal" font="default" size="100%">Chalubinski, M.</style></author><author><style face="normal" font="default" size="100%">Lukkarinen, H.</style></author><author><style face="normal" font="default" size="100%">Passioti, M.</style></author><author><style face="normal" font="default" size="100%">Graser, A.</style></author><author><style face="normal" font="default" size="100%">Jartti, T.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Shi, Z. W.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Swiss Research Institute for Sports Medicine (SRISM), Davos, Switzerland.&#xD;Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland.&#xD;Upper Airway Research Laboratory, Ghent University Hospital, Ghent, Belgium.&#xD;Department of Molecular Pneumology, Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Universitatsklinikum Erlangen, Erlangen, Germany.&#xD;Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland.&#xD;Department of Pediatrics, Oulu University Hospital, Oulu, Finland.&#xD;PEDEGO Research Unit, University of Oulu, Oulu, Finland.&#xD;Department of Pediatrics and Adolescent Medicine, Oulu University Hospital, Oulu, Finland.&#xD;School of Public Health, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, University of Manchester, Manchester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of Haemophilus influenzae, Streptococcus pneumoniae and influenza vaccinations on infections, immune response and asthma control in preschool children with asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1473-1488</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/10/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">Haemophilus influenzae</style></keyword><keyword><style face="normal" font="default" size="100%">*Influenza, Human/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Tract Infections/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Haemophiluse influenzae</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">influenza</style></keyword><keyword><style face="normal" font="default" size="100%">pneumococcus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36229409</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Haemophilus influenzae (H. influenzae), Streptococcus pneumoniae (pneumococcus) and influenza vaccines are administered in children to prevent infections caused by these pathogens. The benefits of vaccination for asthma control in children and the elicited immune response are not fully understood. This study aimed to investigate the impact of these vaccinations on respiratory infections, asthma symptoms, asthma severity and control status, pathogen colonization and in vitro immune responses to different stimulants mimicking infections in asthmatic children. METHODS: Children aged 4-6 years were recruited into the multicentre prospective PreDicta study conducted across five European countries. Information about vaccination history, infections, antibiotic use, inhaled corticosteroid (ICS) use and asthma symptoms in the last 12 months were obtained from questionnaires of the study. Nasopharyngeal samples were collected at the first visit to assess bacterial and viral colonization, and venous blood for isolation of peripheral blood mononuclear cells (PBMCs). The PBMCs were stimulated with phytohemagglutinin, R848, Poly I:C and zymosan. The levels of 22 cytokines and chemokines were measured in cell culture supernatants using a luminometric multiplex assay. RESULTS: One-hundred and forty asthmatic preschool children (5.3 +/- 0.7 years) and 53 healthy children (5.0 +/- 0.8 years) from the PreDicta cohort were included in the current study. Asthmatic children were associated with more frequent upper and lower respiratory infections, and more frequent and longer duration of antibiotic use compared with healthy children. In asthmatic children, sufficient H. influenzae vaccination was associated with a shorter duration of upper respiratory infection (URI) and overall use and average dose of ICS. The airway colonization was characterized by less pneumococcus and more rhinovirus. Pneumococcal vaccination was associated with a reduction in the use rate and average dose of ICS, improved asthma control, and less human enterovirus and more H. influenzae and rhinovirus (RV) airway colonization. Influenza vaccination in the last 12 months was associated with a longer duration of URI, but with a decrease in the occurrence of lower respiratory infection (LRI) and the duration of gastrointestinal (GI) infection and antibiotic use. Asthmatic preschoolers vaccinated with H. influenzae, pneumococcus or influenza presented higher levels of Th1-, Th2-, Th17- and regulatory T cells (Treg)-related cytokines in unstimulated PBMCs. Under stimulation, PBMCs from asthmatic preschoolers with pneumococcal vaccination displayed a predominant anti-inflammatory immune response, whereas PBMCs from asthmatic children with sufficient H. influenzae or influenza vaccination were associated with both pro- and anti-inflammatory immune responses. CONCLUSION: In asthmatic preschoolers, the standard childhood vaccinations to common respiratory pathogens have beneficial effects on asthma control and may modulate immune responses relevant to asthma pathogenesis.</style></abstract><notes><style face="normal" font="default" size="100%">Gao, Ya-Dong&#xD;Xepapadaki, Paraskevi&#xD;Cui, Yan-Wen&#xD;Stanic, Barbara&#xD;Maurer, Debbie J&#xD;Bachert, Claus&#xD;Zhang, Nan&#xD;Finotto, Susetta&#xD;Chalubinski, Maciej&#xD;Lukkarinen, Heikki&#xD;Passioti, Maria&#xD;Graser, Anna&#xD;Jartti, Tuomas&#xD;Kowalski, Marek&#xD;Ogulur, Ismail&#xD;Shi, Zi-Wei&#xD;Akdis, Mubeccel&#xD;Papadopoulos, Nikolaos G&#xD;Akdis, Cezmi A&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1473-1488. doi: 10.1111/all.15551. Epub 2022 Oct 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36229409</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15551</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>287</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">287</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, J. H.</style></author><author><style face="normal" font="default" size="100%">Kang, B. T.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, College of Veterinary Medicine, Chonnam National University, Gwangju, South Korea.&#xD;BK 21 Project Team, College of Veterinary Medicine, Chonnam National University, Gwangju, South Korea.&#xD;Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of indoor air pollution on atopic dermatitis in dogs</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">862-864</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/09/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution, Indoor/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects/analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36125232</style></accession-num><notes><style face="normal" font="default" size="100%">Lee, Ji-Hye&#xD;Kang, Byeong-Teck&#xD;Kim, Ha-Jung&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):862-864. doi: 10.1111/all.15521. Epub 2022 Sep 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36125232</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15521</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3326</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3326</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weiss-Tessbach, Matthias</style></author><author><style face="normal" font="default" size="100%">Dizdarevic, Al Medina</style></author><author><style face="normal" font="default" size="100%">Bischof, Thorsten</style></author><author><style face="normal" font="default" size="100%">Firbas, Christa</style></author><author><style face="normal" font="default" size="100%">Taschner, Alexander</style></author><author><style face="normal" font="default" size="100%">Ritter-Hobl, Eva-Luise</style></author><author><style face="normal" font="default" size="100%">Steinlechner, Barbara</style></author><author><style face="normal" font="default" size="100%">Fischer, Eva</style></author><author><style face="normal" font="default" size="100%">Sonnberger, Lorenz</style></author><author><style face="normal" font="default" size="100%">Gelbenegger, Georg</style></author><author><style face="normal" font="default" size="100%">Siller-Matula, Jolanta M.</style></author><author><style face="normal" font="default" size="100%">Schoergenhofer, Christian</style></author><author><style face="normal" font="default" size="100%">Jilma, Bernd</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of Intramuscular Adrenaline on Histamine-Induced Hypotension: A Randomised Placebo-Controlled Pilot Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Intramuscular adrenaline (epinephrine) is the first-line treatment for anaphylaxis. This recommendation is based purely on consensus, not randomised controlled trials. In humans, hypotension and shock strongly correlate with plasma histamine concentrations. The efficacy of intramuscular adrenaline in reversing histamine-induced hypotension remains unproven. This trial evaluated whether intramuscular adrenaline reverses histamine-induced shock. Methods We conducted an exploratory open-label trial and a confirmatory randomised, double-blind, placebo-controlled, crossover trial. Healthy volunteers received a 15-min continuous intravenous histamine infusion to induce hypotension. At 5 min, participants received either intramuscular adrenaline (300–500 μg) or placebo. A second adrenaline dose was administered if the mean arterial pressure (MAP) remained below 60 mmHg at 10 min. The primary endpoint was area under the effect curve for change in MAP. Results During histamine-induced hypotension, intramuscular adrenaline failed to produce a pressor response and was indistinguishable from placebo in the majority of participants. Excluding two subjects who needed a simultaneous dose reduction of histamine, only 5 of 20 participants (25%; 95% CI 8.7%–49.1%) demonstrated a transient MAP recovery after a single dose. A second adrenaline dose administered to participants who did not reach a MAP &gt; 60 mmHg also failed to reverse hypotension. The primary outcome in the confirmatory cohort, excluding two subjects with histamine dose adjustments, was not different between treatments (adrenaline-placebo: 7 mmHg·min, 95% CI −2 to 25; p = 0.06). Conclusion In this study of a limited number of healthy human subjects, intramuscular adrenaline injections did not provide a sustained response in severe histamine-mediated hypotension in a majority of recipients. Trial Registration CTIS (2022–003591-16) and ISRCTN (Nr. 11335622; https://doi.org/10.1186/ISRCTN11335622)</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70277</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70277</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1073</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1073</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xie, Y.</style></author><author><style face="normal" font="default" size="100%">Ju, X.</style></author><author><style face="normal" font="default" size="100%">Beaudin, S.</style></author><author><style face="normal" font="default" size="100%">Wiltshire, L.</style></author><author><style face="normal" font="default" size="100%">Oliveria, J. P.</style></author><author><style face="normal" font="default" size="100%">MacLean, J.</style></author><author><style face="normal" font="default" size="100%">Sommer, D. D.</style></author><author><style face="normal" font="default" size="100%">Cusack, R.</style></author><author><style face="normal" font="default" size="100%">Li, O.</style></author><author><style face="normal" font="default" size="100%">Banerjee, P.</style></author><author><style face="normal" font="default" size="100%">Keith, P. K.</style></author><author><style face="normal" font="default" size="100%">O&apos;Byrne, P. M.</style></author><author><style face="normal" font="default" size="100%">Bauer, R. N.</style></author><author><style face="normal" font="default" size="100%">Staton, T.</style></author><author><style face="normal" font="default" size="100%">Gauvreau, G. M.</style></author><author><style face="normal" font="default" size="100%">Sehmi, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, McMaster University, Hamilton, ON, Canada.&#xD;State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.&#xD;Department of Pathology, Stanford University, Palo Alto, CA, USA.&#xD;Department of Surgery, Otolaryngology, Head &amp; Neck Surgery Division, McMaster University, Hamilton, ON, Canada.&#xD;Genentech Inc, South San Francisco, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of intranasal corticosteroid treatment on allergen-induced changes in group 2 innate lymphoid cells in allergic rhinitis with mild asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2797-2808</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/03/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Single-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cells</style></keyword><keyword><style face="normal" font="default" size="100%">nasal challenge</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33784411</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic rhinitis is characterized by rhinorrhea, nasal congestion, sneezing and nasal pruritus. Group 2 innate lymphoid cells (ILC2s), CD4(+) T cells and eosinophils in nasal mucosa are increased significantly after nasal allergen challenge (NAC). Effects of intranasal corticosteroids (INCS) on ILC2s remain to be investigated. METHODS: Subjects (n = 10) with allergic rhinitis and mild asthma were enrolled in a single-blind, placebo-controlled, sequential treatment study and treated twice daily with intranasal triamcinolone acetonide (220 microg) or placebo for 14 days, separated by a 7-day washout period. Following treatment, subjects underwent NAC and upper airway function was assessed. Cells from the nasal mucosa and blood, sampled 24 h post-NAC, underwent flow cytometric enumeration for ILC2s, CD4(+) T and eosinophil progenitor (EoPs) levels. Cell differentials and cytokine levels were assessed in nasal lavage. RESULTS: Treatment with INCS significantly attenuated ILC2s, IL-5(+) /IL-13(+) ILC2s, HLA-DR(+) ILC2s and CD4(+) T cells in the nasal mucosa, 24 h post-NAC. EoP in nasal mucosa was significantly increased, while mature eosinophils were significantly decreased, 24 h post-NAC in INCS versus placebo treatment arm. Following INCS treatment, IL-2, IL-4, IL-5 and IL-13 were significantly attenuated 24 h post-NAC accompanied by significant improvement in upper airway function. CONCLUSION: Pre-treatment with INCS attenuates allergen-induced increases in ILC2s, CD4(+) T cells and terminal differentiation of EoPs in the nasal mucosa of allergic rhinitis patients with mild asthma, with little systemic effect. Attenuation of HLA-DR expression by ILC2s may be an additional mechanism by which steroids modulate adaptive immune responses in the upper airways.</style></abstract><notes><style face="normal" font="default" size="100%">Xie, Yanqing&#xD;Ju, Xiaotian&#xD;Beaudin, Suzanne&#xD;Wiltshire, Lesley&#xD;Oliveria, John Paul&#xD;MacLean, Jonathan&#xD;Sommer, Doron D&#xD;Cusack, Ruth&#xD;Li, Olga&#xD;Banerjee, Prajna&#xD;Keith, Paul K&#xD;O&apos;Byrne, Paul M&#xD;Bauer, Rebecca N&#xD;Staton, Tracy&#xD;Gauvreau, Gail M&#xD;Sehmi, Roma&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2797-2808. doi: 10.1111/all.14835. Epub 2021 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33784411</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14835</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2830</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2830</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Newhouse, D.</style></author><author><style face="normal" font="default" size="100%">Klarner, T.</style></author><author><style face="normal" font="default" size="100%">Nucci, M.</style></author><author><style face="normal" font="default" size="100%">Ravanelli, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Kinesiology, Lakehead University, Thunder Bay, Ontario, Canada.&#xD;The Centre for Research in Occupational Safety &amp; Health, Sudbury, Ontario, Canada.&#xD;Northern Ontario School of Medicine University, Thunder Bay, Ontario, Canada.&#xD;Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Heat Resilience &amp; Performance Centre, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Human Potential Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Effect of Oral Antihistamines on the Sweating Response During Heat Stress in Adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2643-2645</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/02/20</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39976187</style></accession-num><notes><style face="normal" font="default" size="100%">Newhouse, Douglas&#xD;Klarner, Taryn&#xD;Nucci, Mario&#xD;Ravanelli, Nicholas&#xD;eng&#xD;Natural Sciences and Engineering Research Council of Canada/&#xD;Centre for Research in Occupational Safety &amp; Health/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2643-2645. doi: 10.1111/all.16507. Epub 2025 Feb 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39976187</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444814</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16507</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3071</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3071</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nolasco, S.</style></author><author><style face="normal" font="default" size="100%">Fagone, E.</style></author><author><style face="normal" font="default" size="100%">Campisi, R.</style></author><author><style face="normal" font="default" size="100%">Portacci, A.</style></author><author><style face="normal" font="default" size="100%">Scioscia, G.</style></author><author><style face="normal" font="default" size="100%">Pelaia, C.</style></author><author><style face="normal" font="default" size="100%">Maglio, A.</style></author><author><style face="normal" font="default" size="100%">Candia, C.</style></author><author><style face="normal" font="default" size="100%">Quaranta, V. N.</style></author><author><style face="normal" font="default" size="100%">Carrieri, I.</style></author><author><style face="normal" font="default" size="100%">Saglia, A.</style></author><author><style face="normal" font="default" size="100%">Vatrella, A.</style></author><author><style face="normal" font="default" size="100%">Pelaia, G.</style></author><author><style face="normal" font="default" size="100%">Vancheri, C.</style></author><author><style face="normal" font="default" size="100%">Foschino Barbaro, M. P.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, M.</style></author><author><style face="normal" font="default" size="100%">Carpagnano, G. E.</style></author><author><style face="normal" font="default" size="100%">Crimi, N.</style></author><author><style face="normal" font="default" size="100%">Crimi, C.</style></author><author><style face="normal" font="default" size="100%">Southern Italy Network on Severe Asthma, Therapy</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.&#xD;Respiratory Medicine Unit, Policlinico &quot;G. Rodolico-San Marco&quot; University Hospital, Catania, Italy.&#xD;Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University &quot;Aldo Moro&quot;, Bari, Italy.&#xD;Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.&#xD;Department of Health Sciences, University &quot;Magna Graecia&quot; of Catanzaro, Catanzaro, Italy.&#xD;Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.&#xD;Department of Respiratory Medicine, University &quot;Federico II&quot; of Naples, Naples, Italy.&#xD;Division of Allergy and Clinical Immunology, University of Salerno, Fisciano, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of the Arg16Gly beta(2)-Adrenergic Receptor Polymorphism on Long-Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype-Stratified, Multicenter Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Arg16Gly</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">remission</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">beta2-adrenergic receptor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40985517</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: beta(2)-adrenergic signaling promotes airway smooth muscle relaxation and limits the release of pro-inflammatory mediators by immune cells. The rs1042713 polymorphism encodes a glycine-to-arginine substitution (Arg16Gly) that enhances beta(2)-receptor downregulation. We investigated the association of this polymorphism with the risk of severe eosinophilic asthma and its impact on the long-term effectiveness of mepolizumab and clinical remission. METHODS: Genotypes from 102 patients with severe eosinophilic asthma receiving mepolizumab were compared with those from 31 individuals with mild asthma and 20 healthy controls. The severe-asthma cohort was followed for up to 24 months, and clinical data were collected at baseline and after 3, 6, 12, and 24 months of treatment. Analyses were stratified by Arg/Arg, Arg/Gly, and Gly/Gly genotypes. RESULTS: Each additional Arg16 allele increased the odds of severe eosinophilic asthma by 2.61-fold (95% CI 1.48-4.59; p = 0.0001) relative to mild asthma and by 3.61-fold (95% CI 1.78-7.35; p &lt; 0.0001) relative to healthy controls. Over 24 months of mepolizumab treatment, Arg/Arg patients had an increased risk of exacerbations (HR 2.3 [95% CI 1.03-5.20]; p = 0.0414) and poorer asthma control compared with Gly/Gly patients (ACT &gt;/= 20: 72.4% vs. 100%, p = 0.0308). Gly/Gly patients also experienced less decline in lung function. By month 24, each additional Gly16 allele increased the odds of achieving clinical remission by 2.86-fold (95% CI 1.20-6.81; p = 0.0170), defined as no annual exacerbations, no OCS, and ACT &gt;/= 20, and by 3.06-fold (95% CI 1.34-6.96; p = 0.0080) when including an FEV(1) decline &lt;/= 5% from baseline. CONCLUSIONS: The Arg16 allele of the rs1042713 polymorphism increases the risk of severe eosinophilic asthma and may reduce the long-term efficacy of mepolizumab, whereas the Gly16 allele appears to confer better outcomes and higher remission rates.</style></abstract><notes><style face="normal" font="default" size="100%">Nolasco, Santi&#xD;Fagone, Evelina&#xD;Campisi, Raffaele&#xD;Portacci, Andrea&#xD;Scioscia, Giulia&#xD;Pelaia, Corrado&#xD;Maglio, Angelantonio&#xD;Candia, Claudio&#xD;Quaranta, Vitaliano Nicola&#xD;Carrieri, Isabella&#xD;Saglia, Alessandro&#xD;Vatrella, Alessandro&#xD;Pelaia, Girolamo&#xD;Vancheri, Carlo&#xD;Foschino Barbaro, Maria Pia&#xD;D&apos;Amato, Maria&#xD;Carpagnano, Giovanna Elisiana&#xD;Crimi, Nunzio&#xD;Crimi, Claudia&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Sep 23. doi: 10.1111/all.70071.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40985517</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70071</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2946</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2946</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite Universitatsmedizin, Berlin, Germany.&#xD;Corporate Member of Freie Universitat Berlin, Humboldt Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of the Multi-Strain Probiotic SYN-53 in the Management of Allergic Rhinoconjunctivitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2158-2166</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Probiotics/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic/therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">allergen exposure chamber</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">probiotic</style></keyword><keyword><style face="normal" font="default" size="100%">reimbursement for participating as a study center. K.-C.B. received honoraria for</style></keyword><keyword><style face="normal" font="default" size="100%">lectures from ALK, Allergopharma, Almirall, AstraZeneca, Bencard, Berlin-Chemie,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, GSK, HAL, Mundipharma, Novartis, Sanofi, and Stallergenes during the last</style></keyword><keyword><style face="normal" font="default" size="100%">5 years. T.Z. has received institutional funding for research and/or honoria for</style></keyword><keyword><style face="normal" font="default" size="100%">lectures and/or consulting from Amgen, AstraZeneca, AbbVie, ALK, Almirall,</style></keyword><keyword><style face="normal" font="default" size="100%">Astellas, Bayer Health Care, Bencard, Berlin Chemie, Blueprint Medicines, FAES,</style></keyword><keyword><style face="normal" font="default" size="100%">HAL, Henkel, Kryolan, Leti, L&apos;Oreal, Meda, Menarini, Merck, MSD, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, Sanofi, Stallergenes, Takeda, Teva and UCB, Uriach</style></keyword><keyword><style face="normal" font="default" size="100%">in addition, he is a</style></keyword><keyword><style face="normal" font="default" size="100%">member of ARIA/WHO, DGAKI, ECARF, GA2LEN and WAO.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40577168</style></accession-num><abstract><style face="normal" font="default" size="100%">Dysbiosis is increasingly linked to allergy development. This study evaluates the efficacy of the multi-strain probiotic SYN-53 in the management of allergic rhinoconjunctivitis (ARC). Eighty-four subjects with confirmed grass pollen allergy underwent up to three bi-weekly 3-day intake cycles with SYN-53 or placebo. After each cycle, subjects were exposed to grass pollen in an allergen exposure chamber. ARC symptoms were assessed using the Total Symptom Score (TSS) before and after each use of SYN-53. After one intake cycle, SYN-53 already showed a trend towards greater efficacy over placebo, which became significant after two cycles (DeltaTSS(MAX): -3.44 +/- 0.42 vs. -1.87 +/- 0.37; p = 0.0067), with 38% vs. 24% symptom relief. In subjects with moderate to severe symptoms, SYN-53 was already significantly superior after one single intake cycle and improved further after two cycles (DeltaTSS(MAX): -4.78 +/- 0.51 vs. -2.43 +/- 0.47; p = 0.0014), with 45% vs. 26% symptom relief. SYN-53 is effective in the management of ARC, highlighting the role of bacterial diversity and dosage in probiotic nutritional supplements.</style></abstract><notes><style face="normal" font="default" size="100%">Bergmann, Karl-Christian&#xD;Zuberbier, Torsten&#xD;eng&#xD;Synformulas/&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2158-2166. doi: 10.1111/all.16634. Epub 2025 Jun 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40577168</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368763</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16634</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1318</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1318</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benitez, A. J.</style></author><author><style face="normal" font="default" size="100%">Tanes, C.</style></author><author><style face="normal" font="default" size="100%">Mattei, L.</style></author><author><style face="normal" font="default" size="100%">Hofstaedter, C. E.</style></author><author><style face="normal" font="default" size="100%">Kim, D. K.</style></author><author><style face="normal" font="default" size="100%">Gross, J.</style></author><author><style face="normal" font="default" size="100%">Ruffner, M. A.</style></author><author><style face="normal" font="default" size="100%">Albenberg, L.</style></author><author><style face="normal" font="default" size="100%">Spergel, J.</style></author><author><style face="normal" font="default" size="100%">Bittinger, K.</style></author><author><style face="normal" font="default" size="100%">Muir, A. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Gastroenterology, Hepatology, and Nutrition, Children&apos;s Hospital of Philadelphia, Philadelphia, PA, USA.&#xD;Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.&#xD;Division of Allergy and Immunology, Children&apos;s Hospital of Philadelphia, Philadelphia, PA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of topical swallowed steroids on the bacterial and fungal esophageal microbiota in eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1549-1552</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/09/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Fluticasone</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Steroids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32990947</style></accession-num><notes><style face="normal" font="default" size="100%">Benitez, Alain J&#xD;Tanes, Ceylan&#xD;Mattei, Lisa&#xD;Hofstaedter, Casey E&#xD;Kim, Dorothy K&#xD;Gross, Jonathan&#xD;Ruffner, Melanie A&#xD;Albenberg, Lindsey&#xD;Spergel, Jonathan&#xD;Bittinger, Kyle&#xD;Muir, Amanda B&#xD;eng&#xD;R03 DK118310/DK/NIDDK NIH HHS/&#xD;KL2 TR001879/TR/NCATS NIH HHS/&#xD;U54 AI117804/AI/NIAID NIH HHS/&#xD;K08 DK106444/DK/NIDDK NIH HHS/&#xD;R01 DK124266/DK/NIDDK NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1549-1552. doi: 10.1111/all.14602. Epub 2020 Oct 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32990947</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8130179</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14602</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2650</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2650</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spriggs, K.</style></author><author><style face="normal" font="default" size="100%">Leahy, E.</style></author><author><style face="normal" font="default" size="100%">Weibel, N.</style></author><author><style face="normal" font="default" size="100%">Barnes, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Department of Allergy and Immunology, Monash Health, Clayton, Victoria, Australia.&#xD;Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.&#xD;Department of Allergy and Clinical Immunology, Royal Melbourne Hospital, Parkville, Victoria, Australia.&#xD;Department of Medicine, Monash University, Clayton, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of venom immunotherapy and sting challenge on health-related quality of life measured by venom-allergy quality of life questionnaire (VQLQ) in Jack jumper ant allergic patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">864-866</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/09/12</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39264019</style></accession-num><notes><style face="normal" font="default" size="100%">Spriggs, Kymble&#xD;Leahy, Elizabeth&#xD;Weibel, Nicole&#xD;Barnes, Sara&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):864-866. doi: 10.1111/all.16319. Epub 2024 Sep 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39264019</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891408</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16319</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2345</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2345</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elbany, C.</style></author><author><style face="normal" font="default" size="100%">Braun, C.</style></author><author><style face="normal" font="default" size="100%">Lazizi, S.</style></author><author><style face="normal" font="default" size="100%">Paradis, L.</style></author><author><style face="normal" font="default" size="100%">Des Roches, A.</style></author><author><style face="normal" font="default" size="100%">Samaan, K.</style></author><author><style face="normal" font="default" size="100%">Labrosse, R.</style></author><author><style face="normal" font="default" size="100%">Graham, F.</style></author><author><style face="normal" font="default" size="100%">Begin, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Section of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.&#xD;AP-HP, Hopital Necker-Enfants Malades, Service de Pneumologie et Allergologie Pediatriques, Paris, France.&#xD;Service de Pediatrie, Centre Hospitalier Intercommunal de Creteil, Creteil, France.&#xD;Department of Pediatrics, Pneumology, Allergy, Cystic Fibrosis, Hopital Femme Mere Enfant, Hospices Civils de Lyon, Bron, France.&#xD;Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR 5308, Universite Lyon 1, ENS de Lyon, Lyon, France.&#xD;Department of Medicine, Section of Allergy and Clinical Immunology, Centre Hospitalier de l&apos;Universite de Montreal, Montreal, Quebec, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect-modifying impact of age on sex-based differences during oral immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">526-529</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/12/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">age</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">gender</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">sex</style></keyword><keyword><style face="normal" font="default" size="100%">sex-based differences</style></keyword><keyword><style face="normal" font="default" size="100%">tolerance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38087863</style></accession-num><notes><style face="normal" font="default" size="100%">Elbany, Charles&#xD;Braun, Camille&#xD;Lazizi, Selma&#xD;Paradis, Louis&#xD;Des Roches, Anne&#xD;Samaan, Kathryn&#xD;Labrosse, Roxane&#xD;Graham, Francois&#xD;Begin, Philippe&#xD;eng&#xD;Anaforcal/&#xD;Fondation du CHU Sainte-Justine/&#xD;Fonds de Recherche du Quebec - Sante/&#xD;Societe Francaise d&apos;Allergologie/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):526-529. doi: 10.1111/all.15980. Epub 2023 Dec 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38087863</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15980</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2797</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2797</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, Z.</style></author><author><style face="normal" font="default" size="100%">Song, X.</style></author><author><style face="normal" font="default" size="100%">Shang, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, L.</style></author><author><style face="normal" font="default" size="100%">Zheng, R.</style></author><author><style face="normal" font="default" size="100%">Xia, J.</style></author><author><style face="normal" font="default" size="100%">Liu, Q.</style></author><author><style face="normal" font="default" size="100%">Hao, G.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Geng, S.</style></author><author><style face="normal" font="default" size="100%">An, J.</style></author><author><style face="normal" font="default" size="100%">Wang, Q.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Tang, J.</style></author><author><style face="normal" font="default" size="100%">Xiao, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.&#xD;Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.&#xD;Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.&#xD;National Clinical Research Center for Skin and Immune Diseases, Beijing, China.&#xD;NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China.&#xD;Department of Dermatology and Venerology, General Hospital of Ningxia Medical University, Yinchuan, China.&#xD;Department of Dermatology, First Hospital of Hebei Medical University, Shijiazhuang, China.&#xD;Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.&#xD;Department of Dermatology, Second Hospital of Jilin University, Changchun, Jilin Province, China.&#xD;Department of Dermatology and Venerology, Second Hospital of Hebei Medical University, Shijiazhuang, China.&#xD;Department of Allergy, Tangshan Gongren Hospital, Tangshan, Hebei, China.&#xD;Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.&#xD;Department of Dermatology, Second Affiliated Hospital, School of Medicine, Xi&apos;an Jiaotong University, Xian, China.&#xD;Department of Dermatology, Seventh People&apos;s Hospital of Shenyang, Shenyang, China.&#xD;Department of Dermatology, Children&apos;s Hospital Affiliated to Capital Institute of Pediatrics, Beijing, China.&#xD;Department of Dermatology and Venerology, Hunan Children&apos;s Hospital, Changsha, China.&#xD;Department of Dermatology, Children&apos;s Hospital of Chongqing Medical University, Chongqing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effectiveness and Safety of Dupilumab for Prurigo Nodularis in China: A Multicentric and Observational Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1428-1435</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/01/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Prurigo/drug therapy/epidemiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">prurigo nodularis</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Pfizer, Astellas, Galderma, Janssen, GSK, BAYER, LEO, MEDA Pharma and</style></keyword><keyword><style face="normal" font="default" size="100%">ALK Pharma, outside the submitted work. The rest of the authors declare no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39835963</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The efficacy and safety of dupilumab in patients with refractory prurigo nodularis (PN) is well established in clinical trials, but there is a lack of multicenter data regarding its effectiveness and safety in real-world settings. METHODS: Patients with moderate-to-severe PN who initiated dupilumab treatment between July 2023 and January 2024, with a follow-up period of at least 16 weeks at 10 hospitals in China were included. We used peak pruritus numeric rating scale (PP-NRS), investigator global assessment (IGA) for PN, and dermatology life quality index for adults or children (DLQI/CDLQI) to assess disease control status and quality of life impairment, and monitored adverse events to assess the safety. RESULTS: A total of 73 PN patients (33 female, 40 male; mean age 45.9 +/- 21.5 years) were included. A clinically meaningful improvement of &gt;/= 4 points in PP-NRS (PP-NRS4) was achieved in 84.9% of patients at Week 12. The percentage of patients achieving IGA 0/1 significantly increasing from 0% to 37.0% and 46.6% at Week 12 and 16, respectively. Patient-reported quality of life outcomes showed substantial improvement, with decreasing from 16.6 +/- 6.8 at baseline to 7.2 +/- 4.9 at Week 12, 6.4 +/- 4.5 at Week 16. The safety profile of dupilumab was favorable, with one patient reporting dry eyes. CONCLUSION: Dupilumab can effectively improve the pruritus, nodular lesions and quality of life for PN in real-world settings.</style></abstract><notes><style face="normal" font="default" size="100%">Zhao, Zuotao&#xD;Song, Xiaoting&#xD;Shang, Yuanyuan&#xD;Liu, Lijuan&#xD;Zheng, Rui&#xD;Xia, Jianxin&#xD;Liu, Qiang&#xD;Hao, Guodong&#xD;Li, Jie&#xD;Geng, Songmei&#xD;An, Jingang&#xD;Wang, Qiang&#xD;Liu, Xiaoyan&#xD;Tang, Jianping&#xD;Xiao, Yizhu&#xD;Zhang, Litao&#xD;eng&#xD;National Natural Science Foundation of China (Grant number 82473512)/&#xD;82473512/National Natural Science Foundation of China/&#xD;Multicenter Study&#xD;Observational Study&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1428-1435. doi: 10.1111/all.16478. Epub 2025 Jan 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39835963</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105062</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16478</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2678</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2678</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuloglu, Z. E.</style></author><author><style face="normal" font="default" size="100%">Keske, S.</style></author><author><style face="normal" font="default" size="100%">Kuskucu, M. A.</style></author><author><style face="normal" font="default" size="100%">Can, F.</style></author><author><style face="normal" font="default" size="100%">Ergonul, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Koc University School of Medicine, Graduate School of Health Sciences, Istanbul, Turkey.&#xD;Koc University IsBank Research Center for Infectious Diseases (KUISCID), Istanbul, Turkey.&#xD;Department of Infectious Diseases and Clinical Microbiology, Koc University School of Medicine, Istanbul, Turkey.&#xD;Department of Medical Microbiology, Koc University School of Medicine, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effectiveness of CoronaVac versus BNT162b2 based on neutralizing antibody response: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">621-624</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/10/22</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39434632</style></accession-num><notes><style face="normal" font="default" size="100%">Kuloglu, Zeynep Ece&#xD;Keske, Siran&#xD;Kuskucu, Mert Ahmet&#xD;Can, Fusun&#xD;Ergonul, Onder&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):621-624. doi: 10.1111/all.16364. Epub 2024 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39434632</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16364</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2367</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2367</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bager, P.</style></author><author><style face="normal" font="default" size="100%">Poulsen, G.</style></author><author><style face="normal" font="default" size="100%">Wohlfahrt, J.</style></author><author><style face="normal" font="default" size="100%">Melbye, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.&#xD;Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.&#xD;Cancer Epidemiology and Surveillance, Danish Cancer Institute, Copenhagen, Denmark.&#xD;Danish Cancer Institute, Copenhagen, Denmark.&#xD;Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology, Trondheim, Norway.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The effectiveness of pollen allergen immunotherapy on allergic rhinitis over 18 years: A national cohort study in Denmark</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1028-1041</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/01/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">anti-allergic medication</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">grass pollen</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">nasal corticosteroids</style></keyword><keyword><style face="normal" font="default" size="100%">observational study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38247235</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Because long-term effectiveness of pollen allergen immune therapy (AIT) for allergic rhinitis (AR) is not well-described, we studied effectiveness over 18 years in Denmark. METHODS: A register-based cohort study using data on filled prescriptions, 1995-2016, Denmark. In a cohort of 1.1 million intranasal corticosteroid inhaler users (proxy for AR), we matched users treated with grass, birch or mugwort AIT 1:2 with non-treated users on baseline year and 24 characteristics in the 3 years prior to baseline. The primary outcome was the odds ratio (OR) of using anti-allergic nasal inhaler during the pollen season in the treated versus non-treated group by years since baseline. RESULTS: Among 7760 AR patients treated with pollen AIT, the OR of using nasal inhaler 0-5 years after baseline was reduced when compared with 15,520 non-treated AR individuals (0-2 years, OR 0.84 (0.81-0.88); 3-5 years, OR 0.88 (0.84-0.92)), but was close to unity or higher thereafter (6-9 years, OR 1.03 (0.97-1.08); 10-18 years, OR 1.18 (1.11-1.26)). In post hoc analyses, results were more consistent for those who already had 3 of 3 baseline years of use, and in patients using nasal inhaler in the latest pollen season (0-2 years, OR 0.76 (0.72-0.79); 3-5 years OR 0.86 (0.81-0.93); 6-9 years, OR 0.94 (0.87-1.02); 10-18 years, OR 0.94 (0.86-1.04)) as opposed to no such use. CONCLUSIONS: Patients treated with pollen AIT in routine care to a higher degree stopped using anti-allergic nasal inhaler 0-5 years after starting the standard 3 years of therapy, and not beyond 5 years. Post hoc analyses suggested effectiveness was more consistent among patients with persistent AR.</style></abstract><notes><style face="normal" font="default" size="100%">Bager, Peter&#xD;Poulsen, Gry&#xD;Wohlfahrt, Jan&#xD;Melbye, Mads&#xD;eng&#xD;Aase og Ejnar Danielsens Fond/&#xD;Fonden til Laegevidenskabens Fremme/&#xD;Dagmar Marshalls Fond/&#xD;Helsefonden/&#xD;Hartmann Fonden/&#xD;Oak Foundation/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):1028-1041. doi: 10.1111/all.16026. Epub 2024 Jan 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38247235</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16026</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>975</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">975</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Walter Canonica, G.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Center for Health Technology and Services Research (CINTESIS), Porto, Portugal.&#xD;Laboratory of Research in Respiratory Pharmacology, VIM Suresnes, UMR-0892, Hopital Foch, Universite Paris Saclay and Department of Airway Diseases, Suresnes, France.&#xD;Personalized Medicine Asthma &amp; Allergy Clinic-Humanitas University &amp; Research Hospital-IRCCS-Milano, Milano, Italy.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Department of Dermatology, Venerology and Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Patient-centred Innovation and Technologies group (PaCeIT), Center for Health Technology and Services Research (CINTESIS), Porto, Portugal.&#xD;Imunoalergologia, CUF, Porto, Portugal.&#xD;Department of Dermatology and Allergy, Comprehensive Allergy Center, Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;CHU Montpellier and MACVIA, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3212-3214</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/05/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34028052</style></accession-num><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Sousa-Pinto, Bernardo&#xD;Devillier, Philippe&#xD;Walter Canonica, Giorgio&#xD;Klimek, Ludger&#xD;Zuberbier, Torsten&#xD;Fonseca, Joao A&#xD;Bousquet, Jean&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3212-3214. doi: 10.1111/all.14955. Epub 2021 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34028052</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14955</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3153</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3153</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ni, D.</style></author><author><style face="normal" font="default" size="100%">Pinget, G.</style></author><author><style face="normal" font="default" size="100%">Santner-Nanan, B.</style></author><author><style face="normal" font="default" size="100%">Tan, J.</style></author><author><style face="normal" font="default" size="100%">Reyes, J. G. A.</style></author><author><style face="normal" font="default" size="100%">Lai, C. L.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Tran, C.</style></author><author><style face="normal" font="default" size="100%">Clarke, J. M.</style></author><author><style face="normal" font="default" size="100%">Macia, L.</style></author><author><style face="normal" font="default" size="100%">Campbell, D. E.</style></author><author><style face="normal" font="default" size="100%">Hsu, P.</style></author><author><style face="normal" font="default" size="100%">Nanan, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sydney Medical School Nepean, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Nepean Hospital, Nepean Blue Mountains Local Health District, Sydney, New South Wales, Australia.&#xD;Department of Allergy and Immunology, The Children&apos;s Hospital at Westmead, Westmead, New South Wales, Australia.&#xD;Centre for Food Allergy Research (CFAR), Melbourne, Victoria, Australia.&#xD;CSIRO Health and Biosecurity, Adelaide, South Australia, Australia.&#xD;CSIRO, Microbiomes for One Systems Health - Future Science Platform, Adelaide, South Australia, Australia.&#xD;The School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of Butyrylated High Amylose Maize Starch (HAMSB) as an Adjuvant for Oral Immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 19</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41258884</style></accession-num><notes><style face="normal" font="default" size="100%">Ni, Duan&#xD;Pinget, Gabriela&#xD;Santner-Nanan, Brigitte&#xD;Tan, Jian&#xD;Reyes, Julen Gabriel Araneta&#xD;Lai, Catherine L&#xD;Wang, Yanan&#xD;Tran, Cuong&#xD;Clarke, Julie M&#xD;Macia, Laurence&#xD;Campbell, Dianne E&#xD;Hsu, Peter&#xD;Nanan, Ralph&#xD;eng&#xD;National Health and Medical Research Council/&#xD;Norman Ernest Bequest Fund/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov 19. doi: 10.1111/all.70161.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41258884</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70161</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1629</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1629</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Taka, S.</style></author><author><style face="normal" font="default" size="100%">Nikopoulou, C.</style></author><author><style face="normal" font="default" size="100%">Polyzos, A.</style></author><author><style face="normal" font="default" size="100%">Megremis, S.</style></author><author><style face="normal" font="default" size="100%">Skevaki, C. L.</style></author><author><style face="normal" font="default" size="100%">Roumpedaki, E.</style></author><author><style face="normal" font="default" size="100%">Trochoutsou, A.</style></author><author><style face="normal" font="default" size="100%">Thanos, D.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Biomedical Research Foundation, Academy of Athens, Athens, Greece.&#xD;Division of Infection, Inflammation and Respiratory Medicine, University of Manchester, Manchester, UK.&#xD;Institute of Laboratory Medicine, Philipps Universitat Marburg, Marburg, Germany.&#xD;German Center for Lung Research (DZL) Marburg, Universities of Giessen and Marburg Lung Center (UGMLC), Philipps Universitat Marburg, Marburg, Germany.&#xD;German Center for Lung Research (DZL), Marburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of cryopreservation on antiviral responses of primary airway epithelial cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1486-1489</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2019/12/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antiviral Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Cryopreservation</style></keyword><keyword><style face="normal" font="default" size="100%">*Epithelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">airway epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">human rhinovirus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31879965</style></accession-num><notes><style face="normal" font="default" size="100%">Taka, Styliani&#xD;Nikopoulou, Chrysa&#xD;Polyzos, Alexandros&#xD;Megremis, Spyridon&#xD;Skevaki, Chrysanthi L&#xD;Roumpedaki, Eirini&#xD;Trochoutsou, Aikaterini&#xD;Thanos, Dimitris&#xD;Papadopoulos, Nikolaos G&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Jun;75(6):1486-1489. doi: 10.1111/all.14163. Epub 2020 Feb 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31879965</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14163</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2565</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2565</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stewart, K. E.</style></author><author><style face="normal" font="default" size="100%">Kuo, C. R.</style></author><author><style face="normal" font="default" size="100%">Chan, R.</style></author><author><style face="normal" font="default" size="100%">Lipworth, B. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Scottish Centre for Respiratory Research, School of Medicine, Ninewells Hospital, University of Dundee, Dundee, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of dupilumab on quality of life burden in refractory type 2 high unified airway disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2871-2873</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/07/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39033313</style></accession-num><notes><style face="normal" font="default" size="100%">Stewart, Kirsten E&#xD;Kuo, Chris RuiWen&#xD;Chan, Rory&#xD;Lipworth, Brian J&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2871-2873. doi: 10.1111/all.16249. Epub 2024 Jul 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39033313</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16249</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2701</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2701</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, N.</style></author><author><style face="normal" font="default" size="100%">Huang, Z.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Dong, J.</style></author><author><style face="normal" font="default" size="100%">Yan, X.</style></author><author><style face="normal" font="default" size="100%">Chen, Z.</style></author><author><style face="normal" font="default" size="100%">Xu, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nursing, Children&apos;s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.&#xD;Department of Pulmonology, Children&apos;s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of high-intensity interval training on exercise capacity and asthma-related outcomes in children: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1464-1467</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/09/30</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39347650</style></accession-num><notes><style face="normal" font="default" size="100%">Lin, Nan&#xD;Huang, Zhenzhen&#xD;Li, Jianping&#xD;Dong, Jiahui&#xD;Yan, Xiaofen&#xD;Chen, Zhimin&#xD;Xu, Hongzhen&#xD;eng&#xD;HL2024021/&quot; Double First-Class&quot; Construction Specialized Discipline Project at Zhejiang University/&#xD;Y202352389/Scientific Research Fund of Zhejiang Provincial Education Department/&#xD;2024C03177/Key Research and Development Program of Zhejiang Province/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1464-1467. doi: 10.1111/all.16336. Epub 2024 Sep 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39347650</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16336</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2465</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2465</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marchi, E.</style></author><author><style face="normal" font="default" size="100%">Hinks, T. S. C.</style></author><author><style face="normal" font="default" size="100%">Richardson, M.</style></author><author><style face="normal" font="default" size="100%">Khalfaoui, L.</style></author><author><style face="normal" font="default" size="100%">Symon, F. A.</style></author><author><style face="normal" font="default" size="100%">Rajasekar, P.</style></author><author><style face="normal" font="default" size="100%">Clifford, R.</style></author><author><style face="normal" font="default" size="100%">Hargadon, B.</style></author><author><style face="normal" font="default" size="100%">Austin, C. D.</style></author><author><style face="normal" font="default" size="100%">MacIsaac, J. L.</style></author><author><style face="normal" font="default" size="100%">Kobor, M. S.</style></author><author><style face="normal" font="default" size="100%">Siddiqui, S.</style></author><author><style face="normal" font="default" size="100%">Mar, J. S.</style></author><author><style face="normal" font="default" size="100%">Arron, J. R.</style></author><author><style face="normal" font="default" size="100%">Choy, D. F.</style></author><author><style face="normal" font="default" size="100%">Bradding, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">NIHR Oxford Respiratory BRC and Respiratory Medicine Unit, Experimental Medicine, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK.&#xD;Department of Respiratory Sciences, University of Leicester, Leicester Respiratory NIHR BRC, Glenfield Hospital, Leicester, UK.&#xD;Centre for Respiratory Research, Translational Medical Sciences, School of Medicine, Nottingham NIHR Biomedical Research Centre, Biodiscovery Institute, University Park, University of Nottingham, Nottingham, UK.&#xD;Genentech, Inc., South San Francisco, California, USA.&#xD;Edwin S.H. Leong Centre for Healthy Aging, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The effects of inhaled corticosteroids on healthy airways</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1831-1843</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/04/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Adrenal Cortex Hormones/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">*Healthy Volunteers</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Methylation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Mucosa/metabolism/immunology/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Fluticasone/administration &amp; dosage/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchial biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetics</style></keyword><keyword><style face="normal" font="default" size="100%">health</style></keyword><keyword><style face="normal" font="default" size="100%">inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">from Pfizer Inc., the University of Oxford, the Wellcome Trust, the Medical</style></keyword><keyword><style face="normal" font="default" size="100%">Research Council, Asthma UK+Lung, the NIHR Oxford Biomedical Research Centre,</style></keyword><keyword><style face="normal" font="default" size="100%">Sensyne Health, and Kymab during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AZ Pieris, and Kymab outside the submitted work. MR - none. LK - none. FAS -</style></keyword><keyword><style face="normal" font="default" size="100%">none. PR - none. RC - RC is supported by an Anne McLaren Fellowship. BH-none. CDA</style></keyword><keyword><style face="normal" font="default" size="100%">- CDA is an employee of Genentech. JLM - none. MSK - none. SS - SS has received</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees and honoraria from AstraZeneca, GSK, Roche, CSL Behring, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">Areteia Therapeutics, ERT Medical, Medscape, European Respiratory Society. JSM -</style></keyword><keyword><style face="normal" font="default" size="100%">JSM is an employee of Genentech. JRA - JRA is a former employee of Genentech and</style></keyword><keyword><style face="normal" font="default" size="100%">named inventor on granted and pending patents related to asthma diagnosis and</style></keyword><keyword><style face="normal" font="default" size="100%">treatment. DFC - DFC is an employee of Genentech, and is an inventor of filed and</style></keyword><keyword><style face="normal" font="default" size="100%">approved patents for the treatment and diagnosis of chronic lung diseases. As an</style></keyword><keyword><style face="normal" font="default" size="100%">employee of Genentech, DFC holds Roche shares and stock options. PB - PB has</style></keyword><keyword><style face="normal" font="default" size="100%">received research funding from Genentech via the University Hospitals of</style></keyword><keyword><style face="normal" font="default" size="100%">Leicester NHS Trust</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy for Genentech via the University of Leicester.</style></keyword><keyword><style face="normal" font="default" size="100%">Support to attend scientific meetings from Chiesi, GSK and Sanofi-Regeneron, and</style></keyword><keyword><style face="normal" font="default" size="100%">one honorarium from AstraZeneca.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38686450</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The effects of inhaled corticosteroids (ICS) on healthy airways are poorly defined. OBJECTIVES: To delineate the effects of ICS on gene expression in healthy airways, without confounding caused by changes in disease-related genes and disease-related alterations in ICS responsiveness. METHODS: Randomized open-label bronchoscopy study of high-dose ICS therapy in 30 healthy adult volunteers randomized 2:1 to (i) fluticasone propionate 500 mcg bd daily or (ii) no treatment, for 4 weeks. Laboratory staff were blinded to allocation. Biopsies and brushings were analysed by immunohistochemistry, bulk RNA sequencing, DNA methylation array and metagenomics. RESULTS: ICS induced small between-group differences in blood and lamina propria eosinophil numbers, but not in other immunopathological features, blood neutrophils, FeNO, FEV(1), microbiome or DNA methylation. ICS treatment upregulated 72 genes in brushings and 53 genes in biopsies, and downregulated 82 genes in brushings and 416 genes in biopsies. The most downregulated genes in both tissues were canonical markers of type-2 inflammation (FCER1A, CPA3, IL33, CLEC10A, SERPINB10 and CCR5), T cell-mediated adaptive immunity (TARP, TRBC1, TRBC2, PTPN22, TRAC, CD2, CD8A, HLA-DQB2, CD96, PTPN7), B-cell immunity (CD20, immunoglobulin heavy and light chains) and innate immunity, including CD48, Hobit, RANTES, Langerin and GFI1. An IL-17-dependent gene signature was not upregulated by ICS. CONCLUSIONS: In healthy airways, 4-week ICS exposure reduces gene expression related to both innate and adaptive immunity, and reduces markers of type-2 inflammation. This implies that homeostasis in health involves tonic type-2 signalling in the airway mucosa, which is exquisitely sensitive to ICS.</style></abstract><notes><style face="normal" font="default" size="100%">Marchi, Emanuele&#xD;Hinks, Timothy S C&#xD;Richardson, Matthew&#xD;Khalfaoui, Latifa&#xD;Symon, Fiona A&#xD;Rajasekar, Poojitha&#xD;Clifford, Rachel&#xD;Hargadon, Beverley&#xD;Austin, Cary D&#xD;MacIsaac, Julia L&#xD;Kobor, Michael S&#xD;Siddiqui, Salman&#xD;Mar, Jordan S&#xD;Arron, Joseph R&#xD;Choy, David F&#xD;Bradding, Peter&#xD;eng&#xD;Genentech/&#xD;211050/Z/18/z/WT_/Wellcome Trust/United Kingdom&#xD;National Institute for Health Research (NIHR): Leicester Biomedical Research Centre (Respiratory)/&#xD;211050/WT_/Wellcome Trust/United Kingdom&#xD;WADR22\100015/Asthma and Lung UK/&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1831-1843. doi: 10.1111/all.16146. Epub 2024 Apr 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38686450</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7616167</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16146</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>476</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">476</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, H. S.</style></author><author><style face="normal" font="default" size="100%">Noh, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biomedical Sciences, College of Natural Science, The Graduate School of Dong-A University, Busan, South Korea.&#xD;Department of Health Sciences, The Graduate School of Dong-A University, Busan, South Korea.&#xD;Department of Allergy and Clinical Immunology, Cheju Halla General Hospital, Jeju, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of the immunoglobulin/histamine complex in chronic spontaneous urticaria focusing on remission induction</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2846-2848</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/05/20</style></edition><section><style face="normal" font="default" size="100%">2846</style></section><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulins</style></keyword><keyword><style face="normal" font="default" size="100%">Remission Induction</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35587440</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Hyuk Soon&#xD;Noh, Geunwoong&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2846-2848. doi: 10.1111/all.15381. Epub 2022 May 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35587440</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15381</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1966</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1966</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gether, L.</style></author><author><style face="normal" font="default" size="100%">Storgaard, H.</style></author><author><style face="normal" font="default" size="100%">Kezic, S.</style></author><author><style face="normal" font="default" size="100%">Jakasa, I.</style></author><author><style face="normal" font="default" size="100%">Hartmann, B.</style></author><author><style face="normal" font="default" size="100%">Skov-Jeppesen, K.</style></author><author><style face="normal" font="default" size="100%">Holst, J. J.</style></author><author><style face="normal" font="default" size="100%">Pedersen, A. J.</style></author><author><style face="normal" font="default" size="100%">Forman, J.</style></author><author><style face="normal" font="default" size="100%">van Hall, G.</style></author><author><style face="normal" font="default" size="100%">Sorensen, O. E.</style></author><author><style face="normal" font="default" size="100%">Skov, L.</style></author><author><style face="normal" font="default" size="100%">Ropke, M. A.</style></author><author><style face="normal" font="default" size="100%">Knop, F. K.</style></author><author><style face="normal" font="default" size="100%">Thyssen, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.&#xD;Department of Dermatology and Allergy, Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.&#xD;LEO Pharma A/S, Ballerup, Denmark.&#xD;Steno Diabetes Center Copenhagen, Copenhagen, Denmark.&#xD;Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.&#xD;Department of Chemistry and Biochemistry, Laboratory for Analytical Chemistry, Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.&#xD;Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.&#xD;Clinical Metabolomics Core Facility, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Dermatology and Venereology, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of topical corticosteroid versus tacrolimus on insulin sensitivity and bone homeostasis in adults with atopic dermatitis-A randomized controlled study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1964-1979</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Tacrolimus/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">*Insulin Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">*Diabetes Mellitus, Type 2</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatologic Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Glucocorticoids</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Betamethasone</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">calcineurin inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroid</style></keyword><keyword><style face="normal" font="default" size="100%">osteoporosis</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 diabetes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36824052</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Topical corticosteroids (TCS), used to treat atopic dermatitis (AD), have been associated with type 2 diabetes and osteoporosis in epidemiological studies, possibly explained by systemic absorption. OBJECTIVES: We examined whether intensive daily whole-body TCS treatment over 2 weeks followed by twice weekly application for 4 weeks could elicit insulin resistance and increase bone resorption in adults with AD. METHODS: A randomized parallel-group double-blind double-dummy non-corticosteroid-based active comparator study design was completed in Copenhagen, Denmark. Thirty-six non-obese, non-diabetic adults with moderate-to-severe AD were randomized to whole-body treatment with betamethasone 17-valerate 0.1% plus a vehicle once daily or tacrolimus 0.1% twice daily after washout. Insulin sensitivity assessed by the hyperinsulinemic-euglycemic clamp combined with tracer infusions and biomarkers of bone formation (P1NP) and resorption (CTX) were evaluated at baseline, after 2 weeks of daily treatment and after further 4 weeks of twice-weekly maintenance treatment. RESULTS: AD severity improved with both treatments and systemic inflammation was reduced. After 2 weeks, we observed similar increase in peripheral insulin sensitivity with use of betamethasone (n = 18) and tacrolimus (n = 18). Bone resorption biomarker, CTX, was unchanged, while bone formation marker, P1NP, decreased after betamethasone treatment after both 2 and 6 weeks but remained unchanged in the tacrolimus arm. CONCLUSIONS: Whole-body treatment with TCS leads to systemic exposure but appears not to compromise glucose metabolism during short-term use, which may be a result of reduced systemic inflammatory activity. The negative impact on bone formation could be regarded an adverse effect of TCS.</style></abstract><notes><style face="normal" font="default" size="100%">Gether, Lise&#xD;Storgaard, Heidi&#xD;Kezic, Sanja&#xD;Jakasa, Ivone&#xD;Hartmann, Bolette&#xD;Skov-Jeppesen, Kirsa&#xD;Holst, Jens J&#xD;Pedersen, Anders J&#xD;Forman, Julie&#xD;van Hall, Gerrit&#xD;Sorensen, Ole E&#xD;Skov, Lone&#xD;Ropke, Mads A&#xD;Knop, Filip K&#xD;Thyssen, Jacob Pontoppidan&#xD;eng&#xD;Aage Bang&apos;s Foundation/&#xD;LEO Pharma A/S/&#xD;The Innovation Fund Denmark/&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1964-1979. doi: 10.1111/all.15690. Epub 2023 Mar 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36824052</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15690</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2454</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2454</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, Z.</style></author><author><style face="normal" font="default" size="100%">Wen, W.</style></author><author><style face="normal" font="default" size="100%">Shi, R.</style></author><author><style face="normal" font="default" size="100%">Chen, L.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Zheng, J.</style></author><author><style face="normal" font="default" size="100%">Zhu, H.</style></author><author><style face="normal" font="default" size="100%">Pan, M.</style></author><author><style face="normal" font="default" size="100%">Zhao, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety analysis of Dupilumab for atopic dermatitis of all ages in Chinese population: Real-world data from a single center</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1379-1382</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Asian People</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">East Asian People</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38425152</style></accession-num><notes><style face="normal" font="default" size="100%">Yang, Zijing&#xD;Wen, Wanting&#xD;Shi, Ruofei&#xD;Chen, Lihong&#xD;Wang, Hailun&#xD;Zheng, Jie&#xD;Zhu, Haiqin&#xD;Pan, Meng&#xD;Zhao, Xiaoqing&#xD;eng&#xD;National Natural Science Foundation of China/&#xD;Natural Science Foundation of Shanghai Municipality/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1379-1382. doi: 10.1111/all.16078. Epub 2024 Feb 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38425152</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16078</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2515</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2515</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kasternow, B.</style></author><author><style face="normal" font="default" size="100%">Kim, D. S.</style></author><author><style face="normal" font="default" size="100%">Yong, P. F. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Royal Surrey NHS Foundation Trust, Guildford, UK.&#xD;Frimley Health NHS Foundation Trust, Frimley, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of a 7-week immunotherapy protocol with aluminium hydroxide adsorbed hymenoptera venom</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2840-2842</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/05/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Hymenoptera/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Aluminum Hydroxide/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Arthropod Venoms/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Insect Bites and Stings/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38699933</style></accession-num><notes><style face="normal" font="default" size="100%">Kasternow, Bogusia&#xD;Kim, Da-In S&#xD;Yong, Patrick F K&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2840-2842. doi: 10.1111/all.16128. Epub 2024 May 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38699933</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16128</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2302</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2302</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Gooderham, M. J.</style></author><author><style face="normal" font="default" size="100%">Hartmann, K.</style></author><author><style face="normal" font="default" size="100%">Konstantinou, G. N.</style></author><author><style face="normal" font="default" size="100%">Fellmann, M.</style></author><author><style face="normal" font="default" size="100%">Koulias, C.</style></author><author><style face="normal" font="default" size="100%">Clibborn, C.</style></author><author><style face="normal" font="default" size="100%">Biswas, P.</style></author><author><style face="normal" font="default" size="100%">Brunner, P. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.&#xD;SKiN Centre for Dermatology, Queen&apos;s University, and Probity Medical Research, Peterborough, Ontario, Canada.&#xD;Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.&#xD;Pfizer Switzerland AG, Zurich, Switzerland.&#xD;Pfizer Hellas SA, Athens, Greece.&#xD;Pfizer Ltd., Surrey, United Kingdom.&#xD;Pfizer Inc., New York, New York, USA.&#xD;Icahn School of Medicine at Mount Sinai, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">174-183</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/complications/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin A</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">abrocitinib</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37988255</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Abrocitinib efficacy by comorbidity status in patients with moderate-to-severe atopic dermatitis (AD) has not been previously assessed. This post hoc analysis evaluated the efficacy and safety of abrocitinib in patients with AD and allergic comorbidities. METHODS: Data were pooled from patients who received abrocitinib 200 mg, 100 mg, or placebo in phase 2b (NCT02780167) and phase 3 (NCT03349060, NCT03575871) monotherapy trials. Patients with and without allergic comorbidities (allergic asthma, rhinitis, conjunctivitis, or food allergy) were evaluated for Investigator&apos;s Global Assessment (IGA) response (clear [0] or almost clear [1]), &gt;/=75% improvement in the Eczema Area and Severity Index (EASI-75), &gt;/=4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4), and Dermatology Life Quality Index (DLQI) response (&lt;2 with baseline score &gt;/=2). Other outcomes were Patient-Oriented Eczema Measure (POEM), SCORing Atopic Dermatitis (SCORAD), Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD), and treatment-emergent adverse events (TEAEs). RESULTS: Of 942 patients, 498 (53%) reported at least one allergic comorbidity (asthma only, 33%; conjunctivitis only or rhinitis only or both, 17%; food allergies only, 15%; &gt;1 allergic comorbidity, 34%). Regardless of comorbidity status, from Week 2 to Week 12, higher percentages of patients treated with either abrocitinib dose achieved IGA 0/1, EASI-75, PP-NRS4, or DLQI 0/1 versus placebo-treated patients. Changes from baseline in POEM, SCORAD, and PSAAD were greater with abrocitinib than with placebo in patients with and without allergic comorbidities. Most TEAEs were mild or moderate. CONCLUSIONS: Efficacy and safety data support abrocitinib use to manage AD in patients with or without allergic comorbidities.</style></abstract><notes><style face="normal" font="default" size="100%">Schmid-Grendelmeier, Peter&#xD;Gooderham, Melinda J&#xD;Hartmann, Karin&#xD;Konstantinou, George N&#xD;Fellmann, Marc&#xD;Koulias, Christopher&#xD;Clibborn, Claire&#xD;Biswas, Pinaki&#xD;Brunner, Patrick M&#xD;eng&#xD;Pfizer/&#xD;Clinical Trial, Phase II&#xD;Clinical Trial, Phase III&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):174-183. doi: 10.1111/all.15952. Epub 2023 Nov 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37988255</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15952</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2827</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2827</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cai, S.</style></author><author><style face="normal" font="default" size="100%">Xu, S.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, People&apos;s Republic of China.&#xD;Beijing Institute of Otorhinolaryngology, Beijing Key Laboratory of Nasal Diseases and Beijing Laboratory of Allergic Diseases, Beijing, People&apos;s Republic of China.&#xD;Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, People&apos;s Republic of China.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta-Analysis of Real-World Evidence</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1256-1270</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/02/22 20:11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/drug therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">meta-analysis</style></keyword><keyword><style face="normal" font="default" size="100%">real-world study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39985317</style></accession-num><abstract><style face="normal" font="default" size="100%">Dupilumab, omalizumab, mepolizumab, and benralizumab have demonstrated good efficacy and safety in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) in phase 3 randomised controlled trials (RCTs). With recent regulatory approvals, there has been a surge in real-world studies (RWSs). This systematic review and meta-analysis aimed to summarise the efficacy and safety of these four biologics in real-world settings. Primary outcomes were nasal polyp score and sino-nasal outcome test-22 score. Secondary outcomes included smell identification test score, loss of smell score, nasal congestion score, overall nasal symptom score, treatment response, and adverse events (AEs) prompting discontinuation. Efficacy outcomes at 4, 6, 12, and over 12 months were summarised, and meta-analyses of mean changes from baseline were conducted. Sixty-four RWSs involving 3921 patients were included. Significant improvements in clinical outcomes were observed at most follow-up time points, with dupilumab showing particularly notable effects. The efficacy observed in these RWSs was superior to that demonstrated in phase 3 RCTs. All biologics exhibited low discontinuation rates due to AEs. Overall, biologic treatments for CRSwNP in real-world settings demonstrate strong efficacy and good safety. However, the limitations in current RWSs highlight the need for long-term, high-quality multicentre prospective studies and comprehensive healthcare database analyses.</style></abstract><notes><style face="normal" font="default" size="100%">Cai, Shiru&#xD;Xu, Shenglong&#xD;Zhao, Yan&#xD;Zhang, Luo&#xD;eng&#xD;82371115/National Natural Science Foundation of China/&#xD;82471139/National Natural Science Foundation of China/&#xD;2022YFC2504100/National Key R&amp;D Program of China/&#xD;IRT13082/Program for Changjiang Scholars and Innovative Research Team/&#xD;20230484476/Beijing New-Star Plan of Science and Technology/&#xD;QML20230201/Beijing Hospitals Authority Youth Programme/&#xD;Lingjunrencai-02-09/High-Level Public Health Technical Talent Training Plan/&#xD;2019-I2M-5-022/CAMS Innovation Fund for Medical Sciences/&#xD;JYY2023-1/Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes/&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1256-1270. doi: 10.1111/all.16499. Epub 2025 Feb 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39985317</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105074</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16499</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1393</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1393</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Song, Y.</style></author><author><style face="normal" font="default" size="100%">Posso, M.</style></author><author><style face="normal" font="default" size="100%">Alonso-Coello, P.</style></author><author><style face="normal" font="default" size="100%">Rocha, C.</style></author><author><style face="normal" font="default" size="100%">Sola, I.</style></author><author><style face="normal" font="default" size="100%">Beltran, J.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Eyerich, K.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Ogg, G.</style></author><author><style face="normal" font="default" size="100%">Ong, P. Y.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Canelo-Aybar, C.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.&#xD;Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.&#xD;CIBER de Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Dermatology and Allergology Biederstein, Technical University of Munich, Munich, Germany.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Immunology, University of Toronto, Toronto, ON, Canada.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Departments of Paediatrics and Immunology, University of Toronto, Toronto, Canada.&#xD;Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.&#xD;Department of Dermatology, Hospital del Mar- Institut Mar d&apos;Investigacions Mediques, Universitat Autonoma de Barcelona, Bellaterra, Spain.&#xD;Department of Dermatology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium.&#xD;Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford NIHR Biomedical Research Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.&#xD;Division of Clinical Immunology &amp; Allergy, Children&apos;s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.&#xD;Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Clinical Immunology, Department of Clinical Immunology, University of Wroclaw, Wroclaw, Poland.&#xD;ALL-MED&quot; Medical Research Institute, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">45-58</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Easi</style></keyword><keyword><style face="normal" font="default" size="100%">Scorad</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">cost-effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32691892</style></accession-num><abstract><style face="normal" font="default" size="100%">This systematic review evaluates the efficacy, safety and economic impact of dupilumab compared to standard of care for uncontrolled moderate-to-severe atopic dermatitis (AD). Pubmed, EMBASE and Cochrane Library were searched for RCTs and health economic evaluations. Critical and important AD-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Seven RCTs including 1845 subjects &gt;12 years treated with dupilumab 16 to 52 weeks were evaluated. For adults, there is high certainty that dupilumab decreases SCORAD (MD -30,72; 95% CI -34,65% to -26,79%) and EASI-75 (RR 3.09; 95% CI 2.45 to 3.89), pruritus (RR 2.96; 95% CI 2.37 to 3.70), rescue medication (RR 3.46; 95% CI 2.79 to 4.30), sleep disturbance (MD -7.29; 95% CI -8.23 to -6.35) and anxiety/depression (MD -3.08; 95% CI -4.41 to -1.75) and improves quality of life (MD -4.80; 95% CI -5.55 to -4.06). The efficacy for adolescents is similar. Dupilumab-related adverse events (AEs) slightly increase (low certainty). The evidence for dupilumab-related serious AE is uncertain. The incremental cost-effectiveness ratio ranged from 28 500 pound (low certainty) to 124 541 US$ (moderate certainty). More data on long-term safety are needed both for children and for adults, together with more efficacy data in the paediatric population. Registration: PROSPERO (CRD42020153645).</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Song, Yang&#xD;Posso, Margarita&#xD;Alonso-Coello, Pablo&#xD;Rocha, Claudio&#xD;Sola, Ivan&#xD;Beltran, Jessica&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Brockow, Knut&#xD;Chivato, Tomas&#xD;Del Giacco, Stefano&#xD;Eiwegger, Thomas&#xD;Eyerich, Kilian&#xD;Gimenez-Arnau, Ana&#xD;Gutermuth, Jan&#xD;Guttman-Yassky, Emma&#xD;Maurer, Marcus&#xD;Ogg, Graham&#xD;Ong, Peck Y&#xD;O&apos;Mahony, Liam&#xD;Schwarze, Jurgen&#xD;Werfel, Thomas&#xD;Canelo-Aybar, Carlos&#xD;Palomares, Oscar&#xD;Jutel, Marek&#xD;eng&#xD;G116/150/MRC_/Medical Research Council/United Kingdom&#xD;MC_U137881017/MRC_/Medical Research Council/United Kingdom&#xD;MC_UU_00008/5/MRC_/Medical Research Council/United Kingdom&#xD;MC_UU_12010/5/MRC_/Medical Research Council/United Kingdom&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):45-58. doi: 10.1111/all.14510. Epub 2020 Oct 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32691892</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14510</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2744</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2744</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sindher, S. B.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author><author><style face="normal" font="default" size="100%">Leflein, J. G.</style></author><author><style face="normal" font="default" size="100%">Begin, P.</style></author><author><style face="normal" font="default" size="100%">Ohayon, J. A.</style></author><author><style face="normal" font="default" size="100%">Ponda, P.</style></author><author><style face="normal" font="default" size="100%">Wambre, E.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Khokhar, F. A.</style></author><author><style face="normal" font="default" size="100%">Akinlade, B.</style></author><author><style face="normal" font="default" size="100%">Maloney, J.</style></author><author><style face="normal" font="default" size="100%">Orengo, J. M.</style></author><author><style face="normal" font="default" size="100%">Hamilton, J. D.</style></author><author><style face="normal" font="default" size="100%">Kamal, M. A.</style></author><author><style face="normal" font="default" size="100%">Hooper, A. T.</style></author><author><style face="normal" font="default" size="100%">Patel, N.</style></author><author><style face="normal" font="default" size="100%">Patel, K.</style></author><author><style face="normal" font="default" size="100%">Laws, E.</style></author><author><style face="normal" font="default" size="100%">Mannent, L. P.</style></author><author><style face="normal" font="default" size="100%">Radin, A. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.&#xD;Harvard School of Public Health, Boston, Massachusetts, USA.&#xD;Allergy &amp; Immunology Association of Michigan, Ypsilanti, Michigan, USA.&#xD;Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.&#xD;Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.&#xD;Division of Allergy and Immunology, Children&apos;s Hospital at Montefiore, Bronx, New York, USA.&#xD;Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA.&#xD;Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.&#xD;Sanofi, Cambridge, Massachusetts, USA.&#xD;Sanofi, Bridgewater, New Jersey, USA.&#xD;Sanofi, Chilly-Mazarin, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">227-237</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/12/14 20:07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/drug therapy/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">peanut</style></keyword><keyword><style face="normal" font="default" size="100%">and Regeneron Pharmceuticals Inc.</style></keyword><keyword><style face="normal" font="default" size="100%">and is an advisory member at DBV Technlogies</style></keyword><keyword><style face="normal" font="default" size="100%">and Genentech. K.C.N. reports research grants from FARE, the National Heart,</style></keyword><keyword><style face="normal" font="default" size="100%">Lung, and Blood Institute, NIAID, and the National Institute of Environmental</style></keyword><keyword><style face="normal" font="default" size="100%">Health Sciences</style></keyword><keyword><style face="normal" font="default" size="100%">reports stock options from ClostraBio, IgGenix, ImmuneID, and</style></keyword><keyword><style face="normal" font="default" size="100%">Seed Health</style></keyword><keyword><style face="normal" font="default" size="100%">is the director of the World Allergy Organization Center of</style></keyword><keyword><style face="normal" font="default" size="100%">Excellence at Stanford University</style></keyword><keyword><style face="normal" font="default" size="100%">is an advisor for Cour Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">provides</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy to Eli Lilly, Excellergy, Phylaxis, and Red Tree Ventures</style></keyword><keyword><style face="normal" font="default" size="100%">is the</style></keyword><keyword><style face="normal" font="default" size="100%">co-founder of Alladapt, Before Brands, ClostraBio, IgGenix, ImmuneID, Latitude,</style></keyword><keyword><style face="normal" font="default" size="100%">and Seed Health</style></keyword><keyword><style face="normal" font="default" size="100%">is a National Scientific Committee member at the Immune</style></keyword><keyword><style face="normal" font="default" size="100%">Tolerance Network and the NIH clinical research centers</style></keyword><keyword><style face="normal" font="default" size="100%">has been issued patents</style></keyword><keyword><style face="normal" font="default" size="100%">(US12/686,121 and US12/610,94)</style></keyword><keyword><style face="normal" font="default" size="100%">and is a licensee (US15/048,609). R.S.C. receives</style></keyword><keyword><style face="normal" font="default" size="100%">grant support from CoFAR, FARE, and NIAID</style></keyword><keyword><style face="normal" font="default" size="100%">is an advisory board member for</style></keyword><keyword><style face="normal" font="default" size="100%">Alladapt Immunotherapeutics, Allergenis, Blueprint Therapeutics, Genentech,</style></keyword><keyword><style face="normal" font="default" size="100%">Intrommune Therapeutics, Novartis, and Phylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">and owns stock for Intrommune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics. J.G.L. declares no conflicts of interest. P.B. reports personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from ALK, Aralez, DBV Technologies, Novartis, Pfizer, and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">research grants from Novartis, Regeneron Pharmaceuticals Inc., and Sanofi. J.A.O.</style></keyword><keyword><style face="normal" font="default" size="100%">declares no conflicts of interest. P.P. is on the advisory board for dupilumab.</style></keyword><keyword><style face="normal" font="default" size="100%">E.W. reports grant support from Aimmune Therapeutics, AnaptysBio, Astellas, FARE,</style></keyword><keyword><style face="normal" font="default" size="100%">the Immune Tolerance Network, and NIAID</style></keyword><keyword><style face="normal" font="default" size="100%">and research sponsorship from Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals Inc. J.L., F.A.K., B.A., M.A.K., and A.R.R. are employees and may</style></keyword><keyword><style face="normal" font="default" size="100%">hold stock and/or stock options in Regeneron Pharmaceuticals Inc. J.M. and J.D.H.</style></keyword><keyword><style face="normal" font="default" size="100%">are officers and employees and may hold stock and/or stock options in Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals Inc., patent pending (PCT/US2020/044958). J.M.O. is an officer</style></keyword><keyword><style face="normal" font="default" size="100%">and employee at Regeneron Pharmaceuticals Inc.</style></keyword><keyword><style face="normal" font="default" size="100%">may hold stock and/or stock</style></keyword><keyword><style face="normal" font="default" size="100%">options in Regeneron Pharmaceuticals Inc.</style></keyword><keyword><style face="normal" font="default" size="100%">has a patent pending</style></keyword><keyword><style face="normal" font="default" size="100%">(PCT/US2020/0345843, PCT/US2022/0220211)</style></keyword><keyword><style face="normal" font="default" size="100%">and has been issued patents (US patent</style></keyword><keyword><style face="normal" font="default" size="100%">numbers 10,392,439, 10,676,530, and 11,485,788). A.T.H. is an employee of, and</style></keyword><keyword><style face="normal" font="default" size="100%">may hold stock and/or stock options in, Regeneron Pharmaceuticals Inc. N.P.,</style></keyword><keyword><style face="normal" font="default" size="100%">K.P., E.L., and L.P.M. are employees and may hold stock and/or stock options in</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39673452</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Peanut allergy is a potentially life-threatening food allergy in children. This study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks the activity of interleukin (IL)-4/IL-13, improved safety and desensitization to peanut exposure in children with peanut allergy. METHODS: A Phase II, 24-week, multicenter, single-arm, open-label, proof-of-concept study was conducted in the USA and Canada (NCT03793608). Children/adolescents with peanut allergy received subcutaneous dupilumab 300 mg (&gt;/= 60 kg) or 200 mg (&gt;/= 20 to &lt; 60 kg) every 2 weeks. The primary endpoint was the proportion of participants who passed a double-blind placebo-controlled food challenge (DBPCFC) with &gt;/= 444 mg (cumulative) of peanut protein at week 24. Secondary endpoints included safety measures (Consortium of Food Allergy Research grading system) and change from baseline in peanut-specific (ps)-IgG4, total IgE, and ps-IgE. RESULTS: Twenty-four participants enrolled and received dupilumab: 75.0% were male, 79.2% were white, mean (standard deviation) age was 11.7 (3.3) years. Most (95.8%) participants had not received allergen immunotherapy. Two participants (8.3%) achieved the primary endpoint and passed the DBPCFC at week 24. Fifteen participants (62.5%) reported 66 treatment-emergent adverse events, all being mild or in moderate intensity. At the week 24 DBPCFC, 8 participants (33.3%) had a grade 2 allergic reaction (no grade 3 or above); 10 (41.7%) used adrenaline as a rescue medication. Dupilumab treatment resulted in a median reduction of total and ps-IgE of -54% and -49%, respectively, and a 0% change in ps-IgG4. CONCLUSIONS: Dupilumab monotherapy treatment for 24 weeks did not improve desensitization to peanut exposure after food challenge.</style></abstract><notes><style face="normal" font="default" size="100%">Sindher, Sayantani B&#xD;Nadeau, Kari C&#xD;Chinthrajah, R Sharon&#xD;Leflein, Jeffrey G&#xD;Begin, Philippe&#xD;Ohayon, Jason A&#xD;Ponda, Punita&#xD;Wambre, Erik&#xD;Liu, Jinzhong&#xD;Khokhar, Faisal A&#xD;Akinlade, Bolanle&#xD;Maloney, Jennifer&#xD;Orengo, Jamie M&#xD;Hamilton, Jennifer D&#xD;Kamal, Mohamed A&#xD;Hooper, Andrea T&#xD;Patel, Naimish&#xD;Patel, Kiran&#xD;Laws, Elizabeth&#xD;Mannent, Leda P&#xD;Radin, Allen R&#xD;eng&#xD;Sanofi and Regeneron Pharmaceuticals Inc./&#xD;Clinical Trial, Phase II&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):227-237. doi: 10.1111/all.16404. Epub 2024 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39673452</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724241</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16404</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>837</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">837</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Laidlaw, T. M.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Mannent, L. P.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Han, J. K.</style></author><author><style face="normal" font="default" size="100%">Maspero, J. F.</style></author><author><style face="normal" font="default" size="100%">Picado, C.</style></author><author><style face="normal" font="default" size="100%">Daizadeh, N.</style></author><author><style face="normal" font="default" size="100%">Ortiz, B.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Ruddy, M.</style></author><author><style face="normal" font="default" size="100%">Laws, E.</style></author><author><style face="normal" font="default" size="100%">Amin, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Rhinology Unit &amp; Smell Clinic, ENT Department, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.&#xD;Division of Allergy and Clinical Immunology, Brigham and Women&apos;s Hospital, and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Upper Airways Research Laboratory and Department of Otorhinolaryngology, Ghent University, Ghent, Belgium.&#xD;Division of ENT Diseases, CLINTEX, Karolinska Institutet, Stockholm, Sweden.&#xD;First Affiliated Hosptial, Sun Yat-sen University, Guangzhou, China.&#xD;Global Clinical Development, Sanofi, Chilly-Mazarin, France.&#xD;Department of Biomedical Sciences, Humanitas University, Personalized Medicine Asthma &amp; Allergy Unit-IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.&#xD;Department of Otolaryngology &amp; Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, Virginia, USA.&#xD;Allergy and Respiratory Medicine, Fundacion CIDEA, Buenos Aires, Argentina.&#xD;Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.&#xD;Biostatistics, Sanofi, Cambridge, Massachusetts, USA.&#xD;Immunology and Allergy Medical Affairs, Regeneron Pharmaceuticals, Inc., New York, USA.&#xD;Global Medical Affairs Respiratory, Sanofi, Bridgewater, New Jersey, USA.&#xD;Clinical Sciences Global Development, Regeneron Pharmaceuticals, Inc., Tarrytown, New Jersey, USA.&#xD;Immunology and Inflammation, Sanofi, Bridgewater, New Jersey, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1231-1244</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/08/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials, Phase III as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiration Disorders/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">Il-4</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">non-steroidal anti-inflammatory drug-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, during the conduct of the study and grants, personal fees, and other from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, AstraZeneca, Genentech, GlaxoSmithKline, Glenmark, Menarini, Merck</style></keyword><keyword><style face="normal" font="default" size="100%">Sharp &amp; Dohme, Mitsubishi Tanabe Pharma, Mylan-Meda Pharmaceuticals (Viatris),</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Proctor &amp; Gamble, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, UCB</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, and Uriach Group, outside the submitted work. T.M. Laidlaw reports</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from Regeneron Pharmaceuticals, Inc. and Sanofi, during the</style></keyword><keyword><style face="normal" font="default" size="100%">conduct of the study and other from AstraZeneca, GlaxoSmithKline, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis, outside the submitted work.</style></keyword><keyword><style face="normal" font="default" size="100%">C. Bachert reports non-financial support from Regeneron Pharmaceuticals, Inc. and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, during the conduct of the study and personal fees and other from ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GlaxoSmithKline, Mylan, Novartis, Sanofi, and Stallergenes Greer,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. L.P. Mannent reports personal fees, non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support, and other from Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and non-financial support from Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Inc., during the conduct of the study. G.W. Canonica reports</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from Regeneron Pharmaceuticals, Inc. and Sanofi, during the</style></keyword><keyword><style face="normal" font="default" size="100%">conduct of the study and personal fees and other from ALK, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, GlaxoSmithKline, HAL Allergy, Menarini, Mundipharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, Stallergenes Greer, and Uriach</style></keyword><keyword><style face="normal" font="default" size="100%">Group, outside the submitted work. J.K. Han reports non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals, Inc. and Sanofi, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">other from Sanofi, outside the submitted work. J.F. Maspero reports non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support from Regeneron Pharmaceuticals, Inc. and Sanofi, during the conduct of</style></keyword><keyword><style face="normal" font="default" size="100%">the study</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GlaxoSmithKline, Menarini, Sanofi, Teva, and Uriach Group, outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work. C. Picado reports non-financial support from Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Inc. and Sanofi, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">grants,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees, and other from Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline and Menarini, outside the submitted work. N. Daizadeh reports</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees and non-financial support from Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and non-financial support</style></keyword><keyword><style face="normal" font="default" size="100%">from Regeneron Pharmaceuticals, Inc., during the conduct of the study. B. Ortiz</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees, non-financial support, and other from Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Inc.</style></keyword><keyword><style face="normal" font="default" size="100%">and non-financial support from Sanofi, during the conduct</style></keyword><keyword><style face="normal" font="default" size="100%">of the study. Y. Li reports personal fees, non-financial support, and other from</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and non-financial support from Regeneron Pharmaceuticals, Inc., during</style></keyword><keyword><style face="normal" font="default" size="100%">the conduct of the study. M. Ruddy reports personal fees, non-financial support,</style></keyword><keyword><style face="normal" font="default" size="100%">and other from Regeneron Pharmaceuticals, Inc.</style></keyword><keyword><style face="normal" font="default" size="100%">and non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, during the conduct of the study. E. Laws reports personal fees,</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support, and other from Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals, Inc., during the conduct of the study. N. Amin reports</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees, non-financial support, and other from Regeneron Pharmaceuticals,</style></keyword><keyword><style face="normal" font="default" size="100%">Inc.</style></keyword><keyword><style face="normal" font="default" size="100%">and non-financial support from Sanofi, during the conduct of the study.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34459002</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: About one-tenth of patients with difficult-to-treat chronic rhinosinusitis with nasal polyps (CRSwNP) have comorbid non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD). Dupilumab, a fully human monoclonal antibody that blocks the shared interleukin (IL)-4/IL-13 receptor component, is an approved add-on treatment in severe CRSwNP. This post hoc analysis evaluated dupilumab efficacy and safety in patients with CRSwNP with/without NSAID-ERD. METHODS: Data were pooled from the phase 3 SINUS-24 and SINUS-52 studies in adults with uncontrolled severe CRSwNP who received dupilumab 300 mg or placebo every 2 weeks. CRSwNP, nasal airflow, lung function, and asthma control outcomes at Week 24 were evaluated, and treatment-subgroup interactions were assessed for patients with and without NSAID-ERD. RESULTS: Of 724 patients, 204 (28.2%) had a diagnosis of NSAID-ERD. At Week 24, least squares mean treatment differences demonstrated significant improvements in nasal polyp score, nasal congestion (NC), Lund-Mackay computed tomography, 22-item Sinonasal Outcome Test (SNOT-22), Total Symptom Score (TSS), rhinosinusitis severity visual analog scale, peak nasal inspiratory flow (PNIF), six-item Asthma Control Questionnaire score, and improvement in smell with dupilumab versus placebo (all p &lt; .0001) in patients with NSAID-ERD. Treatment comparisons demonstrated significantly greater improvements with dupilumab in patients with versus without NSAID-ERD for NC (p = .0044), SNOT-22 (p = .0313), TSS (p = .0425), and PNIF (p = .0123). CONCLUSIONS: In patients with uncontrolled severe CRSwNP, dupilumab significantly improved objective measures and patient-reported symptoms to a greater extent in the presence of comorbid NSAID-ERD than without. Dupilumab was well tolerated in patients with/without NSAID-ERD.</style></abstract><notes><style face="normal" font="default" size="100%">Mullol, Joaquim&#xD;Laidlaw, Tanya M&#xD;Bachert, Claus&#xD;Mannent, Leda P&#xD;Canonica, G Walter&#xD;Han, Joseph K&#xD;Maspero, Jorge F&#xD;Picado, Cesar&#xD;Daizadeh, Nadia&#xD;Ortiz, Benjamin&#xD;Li, Yongtao&#xD;Ruddy, Marcella&#xD;Laws, Elizabeth&#xD;Amin, Nikhil&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1231-1244. doi: 10.1111/all.15067. Epub 2021 Oct 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34459002</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9292324</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15067</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>265</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">265</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Epstein-Rigbi, N.</style></author><author><style face="normal" font="default" size="100%">Levy, M. B.</style></author><author><style face="normal" font="default" size="100%">Nachshon, L.</style></author><author><style face="normal" font="default" size="100%">Koren, Y.</style></author><author><style face="normal" font="default" size="100%">Katz, Y.</style></author><author><style face="normal" font="default" size="100%">Goldberg, M. R.</style></author><author><style face="normal" font="default" size="100%">Elizur, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergy, Immunology and Pediatric Pulmonology, Shamir (former Assaf Harofeh) Medical Center, Zerifin, Israel.&#xD;Department of Pediatrics, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.&#xD;Department of Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of food allergy oral immunotherapy in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">803-811</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/10/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/adverse effects/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Milk</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">adults</style></keyword><keyword><style face="normal" font="default" size="100%">desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">maintenance dose</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36190349</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Oral immunotherapy (OIT) is an emerging method for treating food allergy in children. However, data regarding adults undergoing this process are lacking. METHODS: We retrospectively analyzed the medical records of patients with food allergy aged &gt;/=17 years who completed OIT treatment between April 2010 and December 2020 at Shamir Medical Center. Data were compared with that of children aged 4 to &lt;11 years and adolescents aged &gt;/=11 to 17 treated during the same time period. RESULTS: A total of 96 adults at a median age of 22.3 years who underwent OIT for milk (n = 53), peanut (n = 18), sesame (n = 7), egg (n = 5), and tree nuts (n = 13) were analyzed and compared with 1299 children and 309 adolescents. Adults experienced more adverse reactions requiring injectable epinephrine, both during in-clinic up-dosing (49% vs. 15.9% and 26.5% for children and adolescents, respectively, p &lt; 0.0001) and during home treatment (22.9% vs. 12.4%, p = 0.007 for children, and 17.5%, p = 0.23 for adolescents). Most adults (61.5%) were fully desensitized, but the rates of full desensitization were significantly lower than children (73.4%, p = 0.013). Significantly more adults (28.3%) undergoing milk OIT failed treatment than children (14.3%, p = 0.015) and adolescents (14.1%, p = 0.022), while failure rates in adults undergoing OIT for other foods were low (9.3%) and comparable with children and adolescents. CONCLUSIONS: OIT is successful in desensitizing most adults with IgE-mediated food allergy. Adults undergoing milk OIT are at increased risk for severe reactions and for OIT failure while failure rates in adults undergoing OIT for other foods are low.</style></abstract><notes><style face="normal" font="default" size="100%">Epstein-Rigbi, Na&apos;ama&#xD;Levy, Michael B&#xD;Nachshon, Liat&#xD;Koren, Yael&#xD;Katz, Yitzhak&#xD;Goldberg, Michael R&#xD;Elizur, Arnon&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):803-811. doi: 10.1111/all.15537. Epub 2022 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36190349</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15537</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2711</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2711</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Vieira, R. J.</style></author><author><style face="normal" font="default" size="100%">Bognanni, A.</style></author><author><style face="normal" font="default" size="100%">Gil-Mata, S.</style></author><author><style face="normal" font="default" size="100%">Ferreira-da-Silva, R.</style></author><author><style face="normal" font="default" size="100%">Ferreira, A.</style></author><author><style face="normal" font="default" size="100%">Cardoso-Fernandes, A.</style></author><author><style face="normal" font="default" size="100%">Ferreira-Cardoso, H.</style></author><author><style face="normal" font="default" size="100%">Marques-Cruz, M.</style></author><author><style face="normal" font="default" size="100%">Duarte, V. H.</style></author><author><style face="normal" font="default" size="100%">Castro-Teles, J.</style></author><author><style face="normal" font="default" size="100%">Campos-Lopes, M.</style></author><author><style face="normal" font="default" size="100%">Teixeira-Ferreira, A.</style></author><author><style face="normal" font="default" size="100%">Lourenco-Silva, N.</style></author><author><style face="normal" font="default" size="100%">Cherrez-Ojeda, I.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Nunez, J. J. Y.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Schunemann, H. J.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Aria guideline panel</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences; Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE-Health Research Network, MEDCIDS, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Clinical Epidemiology and Research Center (CERC), Humanitas University and Humanitas Research Hospital, Milan, Italy.&#xD;Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.&#xD;Unit of Anatomy, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Department of Ophthalmology, Centro Hospitalar Universitario do Porto, Porto, Portugal.&#xD;Universidad Espiritu Santo, Samborondon, Ecuador.&#xD;Respiralab Research Group, Guayaquil, Guayas, Ecuador.&#xD;MASK-air SAS, Montpellier, France.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;School of Medicine, Universidad de los Andes, Bogota, Colombia.&#xD;Fundacion Santa Fe de Bogota Hospital University, Bogota, Colombia.&#xD;Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;ARIA, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">94-105</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/11/16 20:04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Administration, Intranasal</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Histamine Antagonists/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">*Adrenal Cortex Hormones/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Allergic Agents/administration &amp; dosage/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">antihistamines</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroids</style></keyword><keyword><style face="normal" font="default" size="100%">intranasal medications</style></keyword><keyword><style face="normal" font="default" size="100%">network meta-analysis</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39548801</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Intranasal antihistamines (INAH), corticosteroids (INCS), and their fixed combinations (INAH+INCS) are one of the cornerstones of the treatment of allergic rhinitis (AR). We performed a systematic review and network-meta-analysis comparing the efficacy and safety of INAH, INCS, and INAH+INCS in patients with AR. METHODS: We searched four electronic bibliographic databases and three clinical trial databases for randomised controlled trials assessing the use of INAH, INCS, and INAH+INCS in adults with seasonal or perennial AR. We performed a network meta-analysis on the Total Nasal Symptom Score, Total Ocular Symptom Score, Rhinoconjunctivitis Quality-of-Life Questionnaire, development of adverse events, and withdrawals due to adverse events. Certainty of evidence was assessed using GRADE-NMA. RESULTS: We included 167 primary studies, most of which assessed patients with seasonal AR. Among individual medications, azelastine-fluticasone, and fluticasone furoate were the most frequently highest-ranked interventions for efficacy outcomes, being regularly associated with clinically meaningful larger improvements when compared to other active treatments. Considering drug classes, INAH+INCS were the highest-ranked interventions for all outcomes in which they were assessed, followed in most cases by INCS. In 105 out of 184 comparisons in seasonal AR, and 28 out of 97 comparisons in perennial AR, certainty of evidence was considered &quot;high&quot; or &quot;moderate&quot;. CONCLUSION: Intranasal medications for AR display clinically relevant differences in their efficacy, but all show a good safety profile. To our knowledge, this is the first network meta-analysis comparing INAH, INCS, and INAH+INCS in AR, providing relevant evidence for guideline developers and practising physicians on the most efficacious treatments.</style></abstract><notes><style face="normal" font="default" size="100%">Sousa-Pinto, Bernardo&#xD;Vieira, Rafael Jose&#xD;Bognanni, Antonio&#xD;Gil-Mata, Sara&#xD;Ferreira-da-Silva, Renato&#xD;Ferreira, Andre&#xD;Cardoso-Fernandes, Antonio&#xD;Ferreira-Cardoso, Henrique&#xD;Marques-Cruz, Manuel&#xD;Duarte, Vitor Henrique&#xD;Castro-Teles, Joao&#xD;Campos-Lopes, Miguel&#xD;Teixeira-Ferreira, Ana&#xD;Lourenco-Silva, Nuno&#xD;Cherrez-Ojeda, Ivan&#xD;Bedbrook, Anna&#xD;Klimek, Ludger&#xD;Nunez, Juan Jose Yepes&#xD;Zuberbier, Torsten&#xD;Fonseca, Joao A&#xD;Schunemann, Holger J&#xD;Bousquet, Jean&#xD;eng&#xD;Allergic Rhinitis and its Impact on Asthma/&#xD;Network Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):94-105. doi: 10.1111/all.16384. Epub 2024 Nov 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39548801</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16384</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3229</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3229</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Begin, P.</style></author><author><style face="normal" font="default" size="100%">Ebisawa, M.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Greenhawt, M.</style></author><author><style face="normal" font="default" size="100%">Rachid, R.</style></author><author><style face="normal" font="default" size="100%">Vickery, B. P.</style></author><author><style face="normal" font="default" size="100%">Anagnostou, A.</style></author><author><style face="normal" font="default" size="100%">Leflein, J.</style></author><author><style face="normal" font="default" size="100%">Perrett, K. P.</style></author><author><style face="normal" font="default" size="100%">Bottoli, I.</style></author><author><style face="normal" font="default" size="100%">Ortiz, B.</style></author><author><style face="normal" font="default" size="100%">Hosoe, M.</style></author><author><style face="normal" font="default" size="100%">Schlosser, E.</style></author><author><style face="normal" font="default" size="100%">Wang, W.</style></author><author><style face="normal" font="default" size="100%">Winkel, M.</style></author><author><style face="normal" font="default" size="100%">Gautier, A.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, CHU Sainte-Justine, Montreal, Quebec, Canada.&#xD;Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.&#xD;Food Allergy Department, University of Padua, Padua, Italy.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Department of Women and Childrens Health, School of Life Course Sciences, Kings College London, London, UK.&#xD;Asthma and Allergy Foundation of America, Arlington, Virginia, USA.&#xD;Division of Immunology, Boston Childrens Hospital and Department of Paediatrics, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Paediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.&#xD;Department of Allergy and Rheumatology, Texas Childrens Hospital Baylor College of Medicine, Houston, Texas, USA.&#xD;Allergy and Immunology Associates of Ann Arbor, Ann Arbor, Michigan, USA.&#xD;National Allergy Centre of Excellence, Murdoch Childrens Research Institute, Royal Childrens Hospital and Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Novartis Pharma AG, Basel, Switzerland.&#xD;Novartis Pharmaceutical Corporation, East Hannover, New Jersey, USA.&#xD;Novartis Institutes for BioMedical Research, Basel, Switzerland.&#xD;China Novartis Institutes for BioMedical Research Co. Ltd., Shanghai, China.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">early termination</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">ligelizumab</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 20</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41555809</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The growing burden of food allergy globally has been accompanied by increasing demand for effective treatments. Ligelizumab is a humanised anti-IgE monoclonal antibody that can strongly inhibit allergic pathways. This phase 3 study evaluated the efficacy and safety of ligelizumab in participants with confirmed IgE-mediated peanut allergy. METHODS: This was a 52-week, multicentre, randomised, double-blind, placebo-controlled study in adults and adolescents with confirmed peanut allergy. Participants received either ligelizumab 120 mg or 240 mg or placebo subcutaneously every 4 weeks. The primary endpoint was the proportion of participants tolerating &gt;/= 600 mg of peanut protein without dose-limiting symptoms during a double-blind, placebo-controlled, food challenge at week 12. Secondary endpoints included tolerance to higher doses of peanut protein. However, the study was terminated early due to evidence from blinded data reviews that the target efficacy would not be met. All participants enrolled at the time of termination could complete week 12 assessments. RESULTS: The primary endpoint was met in the ligelizumab 240 mg treatment arm, with 44.7% (21/47) of participants tolerating &gt;/= 600 mg of peanut protein versus 4.3% (1/23) for placebo. Numerically higher efficacy was observed in the ligelizumab 120 mg treatment arm (15.7% [8/51]) versus placebo. Positive dose-dependent trends were observed across the key secondary endpoints, but statistical significance, per the pre-planned testing strategy, was not achieved. Safety profiles were consistent with known data, with no new safety signals observed. CONCLUSIONS: Ligelizumab 240 mg demonstrated clinical superiority over placebo, with favourable tolerability, in treating IgE-mediated peanut allergy, despite early termination of the study.</style></abstract><notes><style face="normal" font="default" size="100%">Begin, Philippe&#xD;Ebisawa, Motohiro&#xD;Muraro, Antonella&#xD;Lack, Gideon&#xD;Greenhawt, Matthew&#xD;Rachid, Rima&#xD;Vickery, Brian P&#xD;Anagnostou, Aikaterini&#xD;Leflein, Jeffrey&#xD;Perrett, Kirsten P&#xD;Bottoli, Ivan&#xD;Ortiz, Benjamin&#xD;Hosoe, Motoi&#xD;Schlosser, Eva&#xD;Wang, Wei&#xD;Winkel, Munir&#xD;Gautier, Aurelie&#xD;Nadeau, Kari C&#xD;eng&#xD;Novartis Pharma AG, Basel, Switzerland/&#xD;Denmark&#xD;Allergy. 2026 Jan 20. doi: 10.1111/all.70206.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41555809</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70206</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2951</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2951</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spataro, F.</style></author><author><style face="normal" font="default" size="100%">Cacciapaglia, F.</style></author><author><style face="normal" font="default" size="100%">Carlucci, P.</style></author><author><style face="normal" font="default" size="100%">Solimando, A. G.</style></author><author><style face="normal" font="default" size="100%">Desantis, V.</style></author><author><style face="normal" font="default" size="100%">Di Girolamo, A.</style></author><author><style face="normal" font="default" size="100%">Montagnani, M.</style></author><author><style face="normal" font="default" size="100%">Di Bona, D.</style></author><author><style face="normal" font="default" size="100%">Vacca, A.</style></author><author><style face="normal" font="default" size="100%">Ria, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Precision and Regenerative Medicine and Ionian Area - DiMePRe-J, Post Graduate School in Allergology and Internal Medicine, Guido Baccelli Unit of Internal Medicine, School of Medicine, University of Bari Aldo Moro, Bari, Italy.&#xD;Department of Precision and Regenerative Medicine and Ionian Area - DiMePRe-J, Rheumatology Unit, University of Bari Aldo Moro, Bari, Italy.&#xD;Department of Precision and Regenerative Medicine and Ionian Area - DiMePRe-J, Guido Baccelli Unit of Internal Medicine, School of Medicine, University of Bari Aldo Moro, Bari, Italy.&#xD;Department of Precision and Regenerative Medicine and Ionian Area - DiMePRe-J, Section of Pharmacology, School of Medicine, University of Bari Aldo Moro, Bari, Italy.&#xD;Department of Medical and Surgical Sciences, University Centre for Liver Disease Research and Treatment - C.U.R.E., Internal Medicine, Liver Unit, University of Foggia, Foggia, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and Safety of Mepolizumab 300 mg in Eosinophilic Granulomatosis With Polyangiitis: A Meta-Analysis of Eight Retrospective Studies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2660-2662</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/06/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">vasculitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40560689</style></accession-num><notes><style face="normal" font="default" size="100%">Spataro, Federico&#xD;Cacciapaglia, Fabio&#xD;Carlucci, Palma&#xD;Solimando, Antonio Giovanni&#xD;Desantis, Vanessa&#xD;Di Girolamo, Attilio&#xD;Montagnani, Monica&#xD;Di Bona, Danilo&#xD;Vacca, Angelo&#xD;Ria, Roberto&#xD;eng&#xD;&quot;Fondo per il Programma Nazionale di Ricerca e Progetti di Rilevante Interesse Nazionale - PRIN&quot; (code 2022ZKKWLW to AGS)/&#xD;&quot;Societa Italiana di Medicina Interna-SIMI&quot; 2023 Research Award (CAMEL to AGS)/&#xD;postgraduate school of Allergy and Clinical Immunology Program, Bari Aldo Moro University/&#xD;&quot;Ministero della Salute&quot; with &quot;AmICA: Assistenza olistica Intelligente per l&apos;aCtive Ageing in ecosistemi indoor e outdoor&quot; project; Traiettoria 1 &quot;Active &amp; Healthy Ageing - Tecnologie per l&apos;invecchiamento attivo e l&apos;assistenza domiciliare&quot; - T1-MZ-09/&#xD;Complementary National Plan PNC-I.1 &quot;Research initiatives for innovative technologies and pathways in the health and welfare sector&quot; D.D. 931 of 06/06/2022, DARE - DigitAl lifelong pRevEntion initiative (code PNC0000002 to AV and RR)/&#xD;Italian network of excellence for advanced diagnosis -INNOVA-, &quot;Ministero della Salute&quot; (code PNC-E3-2022-23683266 PNC-HLS-DA, to AGS, VS and AV)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2660-2662. doi: 10.1111/all.16625. Epub 2025 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40560689</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16625</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2160</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2160</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weller, K.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A. M.</style></author><author><style face="normal" font="default" size="100%">Baron, J.</style></author><author><style face="normal" font="default" size="100%">Brehler, R.</style></author><author><style face="normal" font="default" size="100%">Ferrer, M.</style></author><author><style face="normal" font="default" size="100%">Groffik, A.</style></author><author><style face="normal" font="default" size="100%">Grundmann, S.</style></author><author><style face="normal" font="default" size="100%">Jakob, T.</style></author><author><style face="normal" font="default" size="100%">Labrador-Horrillo, M.</style></author><author><style face="normal" font="default" size="100%">Muller, S.</style></author><author><style face="normal" font="default" size="100%">Staubach, P.</style></author><author><style face="normal" font="default" size="100%">Wurpts, G.</style></author><author><style face="normal" font="default" size="100%">Metz, M.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Department of Dermatology, Hospital del Mar, IMIM, Universitat Pompeu Fabra, Barcelona, Spain.&#xD;Department of Dermatology and Allergy, University Hospital, RWTH Aachen, Aachen, Germany.&#xD;Department of Dermatology, University Hospital Muenster, Muenster, Germany.&#xD;Department of Allergy, Clinica Universidad de Navarra, Pamplona, Spain.&#xD;RICORS Red De Enfermedades Inflamatorias (REI)-RD21/0002/0028, Madrid, Spain.&#xD;Department of Dermatology, University Medical Center Mainz, Mainz, Germany.&#xD;Hospital of Dermatology, Bad Rothenfelde, Germany.&#xD;Department of Dermatology and Allergy, University Medical Center, Justus Liebig University Giessen, Giessen, Germany.&#xD;Allergy Department, Hospital Universitario Vall d&apos;Hebron, VHIR, Universitat Autonoma de Barcelona, Barcelona, Spain.&#xD;Department of Dermatology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.&#xD;Department of Dermatology and Allergy, University Medical Center, Mainz, Germany.&#xD;Clinic for Dermatology and Allergology, Aachen Comprehensive Allergy Center (ACAC), Uniklinik RWTH Aachen, Aachen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">93-103</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/08/19 20:42</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">disease activity</style></keyword><keyword><style face="normal" font="default" size="100%">on-demand</style></keyword><keyword><style face="normal" font="default" size="100%">rupatadine</style></keyword><keyword><style face="normal" font="default" size="100%">updosing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37597162</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Non-sedating H(1) -antihistamines (nsAH) are the most commonly used treatment for chronic spontaneous urticaria (CSU). Many patients use them as on-demand (OD) therapy rather than a maintenance treatment. Here, we compared OD versus daily maintenance treatment with the nsAH rupatadine, assessed the efficacy of rupatadine updosing, and investigated potential long-term disease-modifying effects. METHODS: This multicenter, randomized study consisted of 2 weeks of screening, 8 weeks of double-blind treatment, and 6 weeks of treatment-free follow-up (OD allowed). Adult patients were randomized to 10 mg rupatadine OD or 10 mg rupatadine daily. At Week 4, if patients did not have a complete response, they switched from 10 to 20 mg rupatadine daily or underwent sham updosing (patients on 10 mg rupatadine OD). The primary aim was to compare CSU disease activity at the end of follow-up between daily versus OD. Additionally, we assessed the efficacy of rupatadine updosing. Major outcomes were disease activity, CSU-related quality of life (QoL), and disease control. RESULTS: At Week 4, disease activity and QoL significantly improved in daily versus OD-treated patients. Updosing of rupatadine did not improve the mean disease activity, but the number of complete responders increased during updosing from 5% to 22%. At the end of follow-up, the disease activity of patients treated OD versus daily was not significantly different. CONCLUSIONS: Daily rupatadine treatment significantly improved CSU disease activity and QoL during treatment versus OD treatment but not after discontinuation of rupatadine, indicating the benefits of a daily maintenance nsAH schedule.</style></abstract><notes><style face="normal" font="default" size="100%">Weller, Karsten&#xD;Gimenez-Arnau, Ana Maria&#xD;Baron, Jens&#xD;Brehler, Randolf&#xD;Ferrer, Marta&#xD;Groffik, Adriane&#xD;Grundmann, Sonja&#xD;Jakob, Thilo&#xD;Labrador-Horrillo, Moises&#xD;Muller, Sabine&#xD;Staubach, Petra&#xD;Wurpts, Gerda&#xD;Metz, Martin&#xD;Maurer, Marcus&#xD;eng&#xD;Charite - Universitatsmedizin Berlin/&#xD;Uriach/&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):93-103. doi: 10.1111/all.15854. Epub 2023 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37597162</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15854</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2447</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2447</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, M. S.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author><author><style face="normal" font="default" size="100%">Kang, S. M.</style></author><author><style face="normal" font="default" size="100%">Heo, Y. M.</style></author><author><style face="normal" font="default" size="100%">Kang, J.</style></author><author><style face="normal" font="default" size="100%">Ryu, T. K.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author><author><style face="normal" font="default" size="100%">Choi, Y. B.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Nho, Y. H.</style></author><author><style face="normal" font="default" size="100%">Kang, S.</style></author><author><style face="normal" font="default" size="100%">Smith, L.</style></author><author><style face="normal" font="default" size="100%">Koyanagi, A.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Jo, H.</style></author><author><style face="normal" font="default" size="100%">Lee, D. G.</style></author><author><style face="normal" font="default" size="100%">Shin, J. U.</style></author><author><style face="normal" font="default" size="100%">Yon, D. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.&#xD;Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.&#xD;Research and Innovation Center, Cosmax BTI, Seoungnam, South Korea.&#xD;Department of Microbiology, Dankook University, Cheonan, South Korea.&#xD;Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Chemistry, Dankook University, Cheonan, South Korea.&#xD;Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.&#xD;Research and Development Unit, Parc Sanitari Sant Joan de Deu, Barcelona, Spain.&#xD;Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty or Biology, Medicine and Health, The University of Manchester, Manchester, UK.&#xD;Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.&#xD;Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of topical Streptococcus postbiotic emollient in adolescents and adults with mild-to-moderate atopic dermatitis: A randomized, double-blind, vehicle-controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1612-1616</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/03/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Emollients/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Topical</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38436460</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Min Seo&#xD;Kim, Hyeon Jin&#xD;Kang, So Min&#xD;Heo, Young Mok&#xD;Kang, Jiseung&#xD;Ryu, Tae Kyeong&#xD;Kim, Hyun Jeong&#xD;Choi, Young-Bong&#xD;Kim, Sol&#xD;Nho, Youn Hwa&#xD;Kang, Seunghyun&#xD;Smith, Lee&#xD;Koyanagi, Ai&#xD;Papadopoulos, Nikolaos G&#xD;Jo, Hyungwoo&#xD;Lee, Dong-Geol&#xD;Shin, Jung U&#xD;Yon, Dong Keon&#xD;eng&#xD;National Research Foundation of Korea/&#xD;Letter&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1612-1616. doi: 10.1111/all.16077. Epub 2024 Mar 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38436460</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16077</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1115</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1115</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Song, Y.</style></author><author><style face="normal" font="default" size="100%">Alonso-Coello, P.</style></author><author><style face="normal" font="default" size="100%">Vogel, Y.</style></author><author><style face="normal" font="default" size="100%">Rocha, C.</style></author><author><style face="normal" font="default" size="100%">Sola, I.</style></author><author><style face="normal" font="default" size="100%">Santero, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W.</style></author><author><style face="normal" font="default" size="100%">Georgalas, C.</style></author><author><style face="normal" font="default" size="100%">Gevaert, P.</style></author><author><style face="normal" font="default" size="100%">Hopkins, C.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Lund, V.</style></author><author><style face="normal" font="default" size="100%">Naclerio, R.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Palkonen, S.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Soyka, M. B.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Canelo-Aybar, C.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Transylvania University Brasov, Brasov, Romania.&#xD;Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.&#xD;CIBER de Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.&#xD;Furtwangen University, Furtwangen im Schwarzwald, Germany.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Personalized Medicine Asthma &amp; Allergy Clinic, IRCCS Research Hospital, Humanitas University, Milan, Italy.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Immunology, University of Toronto, Toronto, ON, Canada.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, Departments of Paediatrics and Immunology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.&#xD;Department of Otorhinolaryngology, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands.&#xD;Medical School, University of Nicosia, Nicosia, Cyprus.&#xD;Department of Otorhinolaryngology, Upper Airway Research Laboratory (URL), Ghent University Hospital, Ghent, Belgium.&#xD;Department of ENT, Guy&apos;s Hospital, London, UK.&#xD;Zentrum fur Rhinologie und Allergologie, Wiesbaden, Germany.&#xD;Royal National Throat, Nose and Ear Hospital, UCLH, London, UK.&#xD;Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, USA.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;European Federation of Allergy and Airways Diseases Patients&apos; Associations (EFA), Brussels, Belgium.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Department of Otolaryngology-Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Clinical Immunology, University of Wroclaw, Wroclaw, Poland.&#xD;&quot;ALL-MED&quot; Medical Research Institute, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2337-2353</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">reslizumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33683704</style></accession-num><abstract><style face="normal" font="default" size="100%">This systematic review evaluates the efficacy and safety of biologicals for chronic rhinosinusitis with nasal polyps (CRSwNP) compared with the standard of care. PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CRSwNP-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. RCTs evaluated (dupilumab-2, omalizumab-4, mepolizumab-2, and reslizumab-1) included 1236 adults, with follow-up of 20-64 weeks. Dupilumab reduces the need for surgery (NFS) or oral corticosteroid (OCS) use (RR 0.28; 95% CI 0.20-0.39, moderate certainty) and improves with high certainty smell evaluated with UPSIT score (mean difference (MD) +10.54; 95% CI +9.24 to +11.84) and quality of life (QoL) evaluated with SNOT-22 (MD -19.14; 95% CI -22.80 to -15.47), with fewer treatment-related adverse events (TAEs) (RR 0.95; 95% CI 0.89-1.02, moderate certainty). Omalizumab reduces NFS (RR 0.85; 95% CI 0.78-0.92, high certainty), decreases OCS use (RR 0.38; 95% CI 0.10-1.38, moderate certainty), and improves high certainty smell (MD +3.84; 95% CI +3.64 to +4.04) and QoL (MD -15.65; 95% CI -16.16 to -15.13), with increased TAE (RR 1.73; 95% CI 0.60-5.03, moderate certainty). There is low certainty for mepolizumab reducing NFS (RR 0.78; 95% CI 0.64-0.94) and improving QoL (MD -13.3; 95% CI -23.93 to -2.67) and smell (MD +0.7; 95% CI -0.48 to +1.88), with increased TAEs (RR 1.64; 95% CI 0.41-6.50). The evidence for reslizumab is very uncertain.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Song, Yang&#xD;Alonso-Coello, Pablo&#xD;Vogel, Yasmin&#xD;Rocha, Claudio&#xD;Sola, Ivan&#xD;Santero, Marilina&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Canonica, Giorgio Walter&#xD;Chivato, Tomas&#xD;Del Giacco, Stefano&#xD;Eiwegger, Thomas&#xD;Fokkens, Wytske&#xD;Georgalas, Christos&#xD;Gevaert, Philippe&#xD;Hopkins, Claire&#xD;Klimek, Ludger&#xD;Lund, Valerie&#xD;Naclerio, Robert&#xD;O&apos;Mahony, Liam&#xD;Palkonen, Susanna&#xD;Pfaar, Oliver&#xD;Schwarze, Jurgen&#xD;Soyka, Michael B&#xD;Wang, De Yun&#xD;Zhang, Luo&#xD;Canelo-Aybar, Carlos&#xD;Palomares, Oscar&#xD;Jutel, Marek&#xD;eng&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2337-2353. doi: 10.1111/all.14809. Epub 2021 Mar 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33683704</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14809</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1361</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1361</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Rocha, C.</style></author><author><style face="normal" font="default" size="100%">Pereira, A.</style></author><author><style face="normal" font="default" size="100%">Song, Y.</style></author><author><style face="normal" font="default" size="100%">Alonso-Coello, P.</style></author><author><style face="normal" font="default" size="100%">Sola, I.</style></author><author><style face="normal" font="default" size="100%">Beltran, J.</style></author><author><style face="normal" font="default" size="100%">Posso, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Eyerich, K.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Ogg, G.</style></author><author><style face="normal" font="default" size="100%">Ong, P.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Canelo-Aybar, C.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Iberoamerican Cochrane Centre - Department of Clinical Epidemiology and Public Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.&#xD;Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.&#xD;CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Dermatology and Allergology Biederstein, Technical University of Munich, Munich, Germany.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Immunology, University of Toronto, Toronto, ON, Canada.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Departments of Paediatrics and Immunology, University of Toronto, Toronto, ON, Canada.&#xD;Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.&#xD;Department of Dermatology, Hospital del Mar- Institut Mar d&apos;Investigacions Mediques, Universitat Autonoma de Barcelona, Barcelona, Spain.&#xD;Department of Dermatology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium.&#xD;Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;MRC Human Immunology Unit, Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, Radcliffe Oxford, UK.&#xD;Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.&#xD;Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Clinical Immunology, University of Wroclaw, Wroclaw, Poland.&#xD;&quot;ALL-MED&quot; Medical Research Institute, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">59-70</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/08/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">itch severity score</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria activity score</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32767573</style></accession-num><abstract><style face="normal" font="default" size="100%">This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU). PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CSU-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Ten RCTs including 1620 subjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated. Omalizumab 150 mg does not result in clinically meaningful improvement (high certainty) of the urticaria activity score (UAS)7 (mean difference (MD) -5; 95%CI -7.75 to -2.25), and the itch severity score (ISS)7 (MD -2.15; 95% CI -3.2 to -1.1) does not increase (moderate certainty) quality of life (QoL) (Dermatology Life Quality Index (DLQI); MD -2.01; 95%CI -3.22 to -0.81) and decreases (moderate certainty) rescue medication use (MD -1.68; 95%CI -2.95 to -0.4). Omalizumab 300 mg results in clinically meaningful improvements (moderate certainty) of the UAS7 (MD -11.05; 95%CI -12.87 to -9.24), the ISS7 (MD -4.45; 95%CI -5.39 to -3.51), and QoL (high certainty) (DLQI; MD -4.03; 95% CI -5.56 to -2.5) and decreases (moderate certainty) rescue medication use (MD -2.04; 95%CI -3.19 to -0.88) and drug-related serious AEs (RR 0.77; 95%CI 0.20 to 2.91).</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Rocha, Claudio&#xD;Pereira, Ana&#xD;Song, Yang&#xD;Alonso-Coello, Pablo&#xD;Sola, Ivan&#xD;Beltran, Jessica&#xD;Posso, Margarita&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Brockow, Knut&#xD;Chivato, Tomas&#xD;Del Giacco, Stefano&#xD;Eiwegger, Thomas&#xD;Eyerich, Kilian&#xD;Gimenez-Arnau, Ana&#xD;Gutermuth, Jan&#xD;Guttman-Yassky, Emma&#xD;Maurer, Marcus&#xD;Ogg, Graham&#xD;Ong, Peck&#xD;O&apos;Mahony, Liam&#xD;Schwarze, Jurgen&#xD;Werfel, Thomas&#xD;Canelo-Aybar, Carlos&#xD;Palomares, Oscar&#xD;Jutel, Marek&#xD;eng&#xD;G116/150/MRC_/Medical Research Council/United Kingdom&#xD;MC_U137881017/MRC_/Medical Research Council/United Kingdom&#xD;MC_UU_00008/5/MRC_/Medical Research Council/United Kingdom&#xD;MC_UU_12010/5/MRC_/Medical Research Council/United Kingdom&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):59-70. doi: 10.1111/all.14547. Epub 2020 Sep 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32767573</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14547</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2818</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2818</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, D. S.</style></author><author><style face="normal" font="default" size="100%">Kasternow, B.</style></author><author><style face="normal" font="default" size="100%">Grammatikos, A.</style></author><author><style face="normal" font="default" size="100%">Chin, Y. T.</style></author><author><style face="normal" font="default" size="100%">Whitfield, C.</style></author><author><style face="normal" font="default" size="100%">Jenkins, H.</style></author><author><style face="normal" font="default" size="100%">Yong, P. F. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Royal Surrey NHS Foundation Trust, Guildford, UK.&#xD;North Bristol NHS Trust, Bristol, UK.&#xD;University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Mid and South Essex NHS Foundation Trust, Southampton, UK.&#xD;Frimley Health NHS Foundation Trust, Frimley, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and Safety Profile of Animal Dander Immunotherapy: A Multicentre UK Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1770-1772</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/03/07</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40052461</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Da-In S&#xD;Kasternow, Bogusia&#xD;Grammatikos, Alexandros&#xD;Chin, Yoon Tak&#xD;Whitfield, Ciara&#xD;Jenkins, Huw&#xD;Yong, Patrick F K&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1770-1772. doi: 10.1111/all.16516. Epub 2025 Mar 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40052461</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16516</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2963</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2963</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heleva, A.</style></author><author><style face="normal" font="default" size="100%">Lyly, A.</style></author><author><style face="normal" font="default" size="100%">Salmi, V.</style></author><author><style face="normal" font="default" size="100%">Makela, M.</style></author><author><style face="normal" font="default" size="100%">Kauppi, P.</style></author><author><style face="normal" font="default" size="100%">Laulajainen-Hongisto, A.</style></author><author><style face="normal" font="default" size="100%">Hafren, L.</style></author><author><style face="normal" font="default" size="100%">Virkkula, P.</style></author><author><style face="normal" font="default" size="100%">Nuutinen, M.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;MD PhD Programme of the Faculty of Medicine, University of Helsinki, Helsinki, Finland.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Otorhinolaryngology, University of Eastern Finland, Kuopio, Finland.&#xD;Heart and Lung Center, Department of Pulmonary Diseases and Allergology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Otorhinolaryngology, Kuopio University Hospital, Wellbeing Services County of North Savo, Kuopio, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of Aspirin Therapy After Desensitization on Chronic Rhinosinusitis With Nasal Polyps Patients With Asthma and Non-steroidal Anti-inflammatory Drug Exacerbated Respiratory Disease -A Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3151-3164</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/07/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/complications/therapy/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Aspirin/therapeutic use/administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/complications/therapy/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma, Aspirin-Induced</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">Atad</style></keyword><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">N-erd</style></keyword><keyword><style face="normal" font="default" size="100%">Rdbct</style></keyword><keyword><style face="normal" font="default" size="100%">aspirin desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">Finnish Lung Health Association. A.L. was an employee of AstraZeneca. All are</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. A.L.-H. reports consultancies or lectures for</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline and Sanofi, a confidential post as European Rhinologic Society</style></keyword><keyword><style face="normal" font="default" size="100%">delegate, and chair of the Finnish Rhinologic Society, all outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. S.T.-S. reports consultancies for ALK-Abello, AstraZeneca, Clario, ERT,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Novartis, Sanofi Pharma, OrionPharma, Roche Products, and grants</style></keyword><keyword><style face="normal" font="default" size="100%">from GlaxoSmithKline and Sanofi. All are outside the submitted work. P.K. reports</style></keyword><keyword><style face="normal" font="default" size="100%">consultancies or education for Sanofi and AstraZeneca</style></keyword><keyword><style face="normal" font="default" size="100%">in addition, chair of the</style></keyword><keyword><style face="normal" font="default" size="100%">Finnish Respiratory Society. All are outside of the submitted work. P.V. reports</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy or lectures for Sanofi and GlaxoSmithKline. All are outside of the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. All other authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40726272</style></accession-num><abstract><style face="normal" font="default" size="100%">Non-steroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease (N-ERD) is a chronic inflammatory condition typically involving hypersensitivity to NSAIDs, asthma, and/or chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP). N-ERD increases the risk for severe hypersensitivity reactions, recurring sinonasal surgeries, or the need for systemic corticosteroid treatment. Aspirin (ASA) treatment after desensitization (ATAD) is a treatment option for N-ERD. Desensitization to ASA is reached with increasing ASA doses over a few days, followed by a long-term treatment. This study evaluated the efficacy of ATAD with an ASA dose of 250 mg in adult CRSwNP patients with asthma and N-ERD. Forty-one CRSwNP patients with comorbid asthma and N-ERD were recruited for this randomized double-blind clinical trial. Twenty-six patients had successful ASA desensitization, were randomized into placebo and ASA arms, and continued to 11 months of daily ASA, with a target dose of 250 mg. The outcome measures, including Sino-Nasal Outcome Test 22 (SNOT-22), nasal polyp score (NPS), Asthma Control Test (ACT), and EPOS 2012 CRS clinical control assessment, were evaluated at control visits at 1, 5, 11, and 12 months after the start of the treatment. In the linear mixed effects model, p-values for the combined effect of group and time showed no difference between placebo and ATAD for SNOT-22, ACT, and NPS, with p-values 0.17, 0.45, and 0.18, respectively. Neither group showed significant improvement in the EPOS 2012 CRS control assessment. In conclusion, no significant clinical difference was observed between ATAD and placebo in the treatment of CRSwNP patients with asthma and N-ERD.</style></abstract><notes><style face="normal" font="default" size="100%">Heleva, Alma&#xD;Lyly, Annina&#xD;Salmi, Viljami&#xD;Makela, Mika&#xD;Kauppi, Paula&#xD;Laulajainen-Hongisto, Anu&#xD;Hafren, Lena&#xD;Virkkula, Paula&#xD;Nuutinen, Mikko&#xD;Toppila-Salmi, Sanna&#xD;eng&#xD;Jalmari ja Rauha Ahokkaan Saatio/&#xD;Y243RWDTK1/State funding for university-level health research/&#xD;Y1209PDA04/State funding for university-level health research/&#xD;TYH2017146/State funding for university-level health research/&#xD;TYH2019322/State funding for university-level health research/&#xD;TYH2020249/State funding for university-level health research/&#xD;TYH2022331/State funding for university-level health research/&#xD;TYH2024309/State funding for university-level health research/&#xD;Investigator-Sponsored Study of Sanofi/&#xD;The Finnish Society of Allergology and Immunology/&#xD;MD PhD Programme of the Faculty of Medicine, University of Helsinki/&#xD;Suomen Tuberkuloosin Vastustamisyhdistyksen Saatio/&#xD;Allergiatutkimussaatio/&#xD;Orionin Tutkimussaatio/&#xD;Tampereen Tuberkuloosisaatio/&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3151-3164. doi: 10.1111/all.16679. Epub 2025 Jul 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40726272</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590337</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16679</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3133</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3133</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martini, M.</style></author><author><style face="normal" font="default" size="100%">Antonicelli, L.</style></author><author><style face="normal" font="default" size="100%">Garritani, M. S.</style></author><author><style face="normal" font="default" size="100%">Braschi, M. C.</style></author><author><style face="normal" font="default" size="100%">Di Vincenzo, A.</style></author><author><style face="normal" font="default" size="100%">Torresi, G.</style></author><author><style face="normal" font="default" size="100%">Gallifuoco, M.</style></author><author><style face="normal" font="default" size="100%">Claudi, I.</style></author><author><style face="normal" font="default" size="100%">Danieli, M. G.</style></author><author><style face="normal" font="default" size="100%">Mei, F.</style></author><author><style face="normal" font="default" size="100%">Moroncini, G.</style></author><author><style face="normal" font="default" size="100%">Piga, M. A.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, SOSD Allergologia, Marche University Hospital, Ancona, Italy.&#xD;Department of Clinical and Molecular Sciences, Universita Politecnica Delle Marche, Ancona, Italy.&#xD;Allergy and Asthma Outpatient Clinic, Ancona, Italy.&#xD;Department of Internal Medicine, SOS Immunologia Delle Malattie Rare e Dei Trapianti, SOD Clinica Medica, Marche University Hospital, Ancona, Italy.&#xD;Postgraduate School in Allergy and Clinical Immunology, Universita Politecnica Delle Marche, Ancona, Italy.&#xD;Department of Biomedical Sciences and Public Health, Universita Politecnica Delle Marche, Ancona, Italy.&#xD;Interstitial Lung Diseases, Pleural Diseases and Bronchiectasis Unit, Marche University Hospital, Ancona, Italy.&#xD;Department of Internal Medicine, Clinica Medica, Marche University Hospital, Ancona, Italy.&#xD;National PhD Course in Precision Medicine in Rare Diseases, University of Palermo, Palermo, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of Dupilumab in Asthma: Focus on Early, Progressive, and Long-Lasting Effects on Small Airways</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">284-287</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/10/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">oscillometry</style></keyword><keyword><style face="normal" font="default" size="100%">reactance</style></keyword><keyword><style face="normal" font="default" size="100%">small airway dysfunction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41078173</style></accession-num><notes><style face="normal" font="default" size="100%">Martini, Matteo&#xD;Antonicelli, Leonardo&#xD;Garritani, Maria Stella&#xD;Braschi, Maria Chiara&#xD;Di Vincenzo, Angelica&#xD;Torresi, Giada&#xD;Gallifuoco, Marco&#xD;Claudi, Ilaria&#xD;Danieli, Maria Giovanna&#xD;Mei, Federico&#xD;Moroncini, Gianluca&#xD;Piga, Mario Andrea&#xD;Bilo, Maria Beatrice&#xD;eng&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):284-287. doi: 10.1111/all.70097. Epub 2025 Oct 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41078173</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70097</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2381</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2381</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, Y. X.</style></author><author><style face="normal" font="default" size="100%">Chen, X. B.</style></author><author><style face="normal" font="default" size="100%">Wang, Z. Y.</style></author><author><style face="normal" font="default" size="100%">Cai, S. Q.</style></author><author><style face="normal" font="default" size="100%">Zheng, M.</style></author><author><style face="normal" font="default" size="100%">Koh, L. F.</style></author><author><style face="normal" font="default" size="100%">Common, J. E.</style></author><author><style face="normal" font="default" size="100%">Man, X. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.&#xD;A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of dupilumab in palmoplantar pustulosis treatment highlights the role of Th2 inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1361-1364</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/01/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Psoriasis/drug therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38193274</style></accession-num><abstract><style face="normal" font="default" size="100%">Palmoplantar pustulosis is a chronic, recurrent skin disorder characterized by sterile pustules and erythematous scaling on the palms and soles. In our study, dupilumab treatment showed efficacy and safety in PPP patients, potentially resulting from PPP patients&apos; serum Th2 signatures and the similarities between PPP and atopic dermatitis based on serum Olink proteomics.</style></abstract><notes><style face="normal" font="default" size="100%">Zheng, Yu-Xin&#xD;Chen, Xi-Bei&#xD;Wang, Zhao-Yuan&#xD;Cai, Sui-Qing&#xD;Zheng, Min&#xD;Koh, Li Fang&#xD;Common, John E&#xD;Man, Xiao-Yong&#xD;eng&#xD;(2022YFC2705300)/National Key R&amp;amp;D Program of China/&#xD;(82373466,82073426,82230104)/National Natural Science Foundation of China/&#xD;Agency for Science, Technology and Research (A*STAR) Biomedical Research Council (BMRC) Central Research Funds - Applied Translational Research/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1361-1364. doi: 10.1111/all.16019. Epub 2024 Jan 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38193274</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16019</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2647</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2647</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gijsen, C. E. W.</style></author><author><style face="normal" font="default" size="100%">Bogers, T. R. P.</style></author><author><style face="normal" font="default" size="100%">Muris, J. W. M.</style></author><author><style face="normal" font="default" size="100%">van van Horck, M. W. P.</style></author><author><style face="normal" font="default" size="100%">Dompeling, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CAPHRI-Care and Public Health Research Institute, Maastricht University Medical Centre+, Maastricht, The Netherlands.&#xD;Department of Paediatrics, Maastricht University Medical Centre+, Maastricht, The Netherlands.&#xD;Department of Paediatrics, Zuyderland Medical Centre, Heerlen/Sittard-Geleen, The Netherlands.&#xD;Department of General Practice, Maastricht University, Maastricht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of eHealth monitoring in pediatric asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">601-604</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/09/15 21:16</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39268613</style></accession-num><notes><style face="normal" font="default" size="100%">Gijsen, Casper E W&#xD;Bogers, Thijs R P&#xD;Muris, Jean W M&#xD;van van Horck, Marieke W P&#xD;Dompeling, Edward&#xD;eng&#xD;Zorginstituut Nederland/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):601-604. doi: 10.1111/all.16317. Epub 2024 Sep 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39268613</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804295</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16317</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>293</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">293</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ravanetti, L.</style></author><author><style face="normal" font="default" size="100%">Dekker, T.</style></author><author><style face="normal" font="default" size="100%">Guo, L.</style></author><author><style face="normal" font="default" size="100%">Dijkhuis, A.</style></author><author><style face="normal" font="default" size="100%">Dierdorp, B. S.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author><author><style face="normal" font="default" size="100%">Florquin, S.</style></author><author><style face="normal" font="default" size="100%">Lutter, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Center (Location AMC), Amsterdam, The Netherlands.&#xD;Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.&#xD;Department of Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.&#xD;Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.&#xD;Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.&#xD;Department of Pathology, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Center (Location AMC), Amsterdam, The Netherlands.&#xD;Department of Pulmonary Medicine, Amsterdam University Medical Center (Location AMC), Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of FP-025: A novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">559-562</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/09/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Matrix Metalloproteinase 12</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfur Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue Inhibitor of Metalloproteinase-1</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36094742</style></accession-num><notes><style face="normal" font="default" size="100%">Ravanetti, Lara&#xD;Dekker, Tamara&#xD;Guo, Lihui&#xD;Dijkhuis, Annemiek&#xD;Dierdorp, Barbara S&#xD;Diamant, Zuzana&#xD;Florquin, Sandrine&#xD;Lutter, Rene&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):559-562. doi: 10.1111/all.15513. Epub 2022 Sep 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36094742</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087922 received honoraria for serving on advisory boards or as a consultant with ALK, AstraZeneca, Boehringer-Ingelheim, GSK, HAL-Allergy, MSD, Sanofi-Genzyme. She acted as Research Director at QPS-NL: this institution has received research support from Foresee Pharmaceuticals, Novartis and Patara pharma. R.L. receives funding from Foresee Pharmaceuticals, Chiesi Farmaceutici, Astra Zeneca, MedImmune, GSK. The rest of the authors declare that they have no relevant conflicts of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15513</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3062</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3062</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, Q.</style></author><author><style face="normal" font="default" size="100%">Yuan, X.</style></author><author><style face="normal" font="default" size="100%">Liao, W.</style></author><author><style face="normal" font="default" size="100%">Chen, H.</style></author><author><style face="normal" font="default" size="100%">Jiang, Q.</style></author><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Huang, N.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Ma, D.</style></author><author><style face="normal" font="default" size="100%">Bai, J.</style></author><author><style face="normal" font="default" size="100%">Xie, Z.</style></author><author><style face="normal" font="default" size="100%">Zhu, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central South University, Changsha, China.&#xD;Department of Pediatrics, Foshan Maternity &amp; Child Healthcare Hospital, Foshan, China.&#xD;Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of House Dust Mite Immunotherapy in Chinese Allergic Rhinitis Patients With Diverse Sensitization Patterns: A Multicenter Study (COVER Study)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite</style></keyword><keyword><style face="normal" font="default" size="100%">molecular sensitization pattern</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 25</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40995889</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergen immunotherapy (AIT) is the only etiological treatment for allergic rhinitis (AR) patients, yet the impact of allergen sensitization patterns on AIT efficacy remains unclear. This study aimed to assess the effectiveness of subcutaneous immunotherapy (SCIT) using a native house dust mite (HDM) allergen extract in Chinese AR patients with diverse HDM sensitization patterns. METHODS: This prospective multicenter study across three allergy centers in China enrolled patients aged 5-65 diagnosed with HDM-induced AR. Serum-specific IgE testing for nine HDM components (Der p1, Der p2, Der p23, Der f1, Der f2, Der p5, Der p7, Der p10, Der p21) categorized patients into two groups: Group A with sensitization limited to major allergen components and Group B with sensitization to minor components with or without major components. Both groups underwent 1 year of HDM SCIT (Allergopharma, Germany), whose efficacy was assessed using the visual analogue scale (VAS) and combined symptom medication scores (CSMS). Serum IgE and IgG4 levels against the nine HDM components were measured pre- and post-treatment, and SCIT-related adverse reactions were recorded. RESULTS: The study enrolled 168 patients, with 75 in Group A and 93 in Group B. Group B patients had higher asthma prevalence and elevated baseline HDM sIgE and total IgE levels. After 1 year, Group B showed significantly greater CSMS reduction (67.70% vs. 59.09%, p = 0.03) and VAS improvement (66.67% vs. 50.00%, p = 0.01) compared to Group A. Group A had increased new sensitization risk to minor allergens (Der p5, Der p7, Der p21). No significant difference in SCIT efficacy was observed between patients with and without new sensitization. Both groups exhibited increased sIgG4 levels against all nine HDM allergens, with a more pronounced elevation of sIgG4 levels to Der p21 observed in Group B compared to Group A (p = 0.02). SCIT-related adverse reactions were comparable (p &gt; 0.05). CONCLUSIONS: The native HDM allergen extract demonstrates efficacy in Chinese AR patients with varying sensitization patterns. It offers enhanced benefits for patients sensitized to minor allergens with or without major allergens of HDM, positioning it as the preferred option for individuals with AR. TRIAL REGISTRATION: Chinese Clinical Trial Registry identifier: ChiCTR2300078642.</style></abstract><notes><style face="normal" font="default" size="100%">Xu, Qingxiu&#xD;Yuan, Xuan&#xD;Liao, Wang&#xD;Chen, Hao&#xD;Jiang, Qing&#xD;Yang, Lin&#xD;Liu, Jin&#xD;Li, Le&#xD;Huang, Nan&#xD;Li, Wenjing&#xD;Yang, Yaqi&#xD;Ma, Dongxia&#xD;Bai, Jun&#xD;Xie, Zhihai&#xD;Zhu, Rongfei&#xD;eng&#xD;National Key Research and Development Program of China/&#xD;Denmark&#xD;Allergy. 2025 Sep 25. doi: 10.1111/all.70072.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40995889</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70072</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2976</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2976</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turk, M.</style></author><author><style face="normal" font="default" size="100%">Yilmaz, I.</style></author><author><style face="normal" font="default" size="100%">Ertas, R.</style></author><author><style face="normal" font="default" size="100%">Kocaturk, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chest Diseases, Division of Allergy and Clinical Immunology, Erciyes University School of Medicine, Kayseri, Turkiye.&#xD;Department of Dermatology, Kayseri City Education and Research Hospital, University of Health Sciences, Kayseri, Turkiye.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;Department of Dermatology, School of Medicine, Bahcesehir University, Istanbul, Turkiye.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of Omalizumab, Dupilumab, and Remibrutinib in Chronic Spontaneous Urticaria: Phase Data and Placebo Response</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2410-2413</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/07/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">personalized medicine</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40682317</style></accession-num><notes><style face="normal" font="default" size="100%">Turk, Murat&#xD;Yilmaz, Insu&#xD;Ertas, Ragip&#xD;Kocaturk, Emek&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2410-2413. doi: 10.1111/all.16670. Epub 2025 Jul 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40682317</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16670</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2301</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2301</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Petersen, R. S.</style></author><author><style face="normal" font="default" size="100%">Fijen, L. M.</style></author><author><style face="normal" font="default" size="100%">Cohn, D. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy outcomes in trials with prophylactic hereditary angioedema therapy: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1345-1348</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/11/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38009479</style></accession-num><notes><style face="normal" font="default" size="100%">Petersen, Remy S&#xD;Fijen, Laure M&#xD;Cohn, Danny M&#xD;eng&#xD;Letter&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1345-1348. doi: 10.1111/all.15962. Epub 2023 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38009479</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15962</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>270</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">270</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mogensen, I.</style></author><author><style face="normal" font="default" size="100%">Flodstrom, C.</style></author><author><style face="normal" font="default" size="100%">Nopp, A.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Bergstrom, A.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Center for Occupational and Environmental Medicine, Region Stockholm, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Egg and milk exposure during pregnancy and food reactions in grandchildren</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">569-571</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Milk/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Egg Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">environment and hygiene hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work. None of the other authors have any conflicts of interests to</style></keyword><keyword><style face="normal" font="default" size="100%">report.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36178072</style></accession-num><notes><style face="normal" font="default" size="100%">Mogensen, Ida&#xD;Flodstrom, Charlotta&#xD;Nopp, Anna&#xD;Melen, Erik&#xD;Bergstrom, Anna&#xD;Kull, Inger&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):569-571. doi: 10.1111/all.15534. Epub 2022 Oct 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36178072</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10092286</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15534</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1186</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1186</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gueant, J. L.</style></author><author><style face="normal" font="default" size="100%">Gueant-Rodriguez, R. M.</style></author><author><style face="normal" font="default" size="100%">Fromonot, J.</style></author><author><style face="normal" font="default" size="100%">Oussalah, A.</style></author><author><style face="normal" font="default" size="100%">Louis, H.</style></author><author><style face="normal" font="default" size="100%">Chery, C.</style></author><author><style face="normal" font="default" size="100%">Gette, M.</style></author><author><style face="normal" font="default" size="100%">Gleye, S.</style></author><author><style face="normal" font="default" size="100%">Callet, J.</style></author><author><style face="normal" font="default" size="100%">Raso, J.</style></author><author><style face="normal" font="default" size="100%">Blanchecotte, F.</style></author><author><style face="normal" font="default" size="100%">Lacolley, P.</style></author><author><style face="normal" font="default" size="100%">Guieu, R.</style></author><author><style face="normal" font="default" size="100%">Regnault, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department Inserm, UMR_S 1256 Nutrition-Genetics-Environmental Risk Exposure, Universite de Lorraine and University Regional hospital of Nancy, Nancy, France.&#xD;Center for CardioVascular and Nutrition Research (RG, JF), INSERM, INRA and Aix-Marseille University, Marseille, France.&#xD;Department Inserm UMRS_1116 DCAC, Universite de Lorraine, Nancy, France.&#xD;Medical analysis laboratory L&apos;ABO+, Chambray-les-Tours, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Elastase and exacerbation of neutrophil innate immunity are involved in multi-visceral manifestations of COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1846-1858</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">*Extracellular Traps</style></keyword><keyword><style face="normal" font="default" size="100%">Histones</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">DNase</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">myeloperoxidase</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophil extracellular traps (NETs)</style></keyword><keyword><style face="normal" font="default" size="100%">immediate family/significant others.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33484168</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Many arguments suggest that neutrophils could play a prominent role in COVID-19. However, the role of key components of neutrophil innate immunity in severe forms of COVID-19 has deserved insufficient attention. We aimed to evaluate the involvement of neutrophil elastase, histone-DNA, and DNases in systemic and multi-organ manifestations of COVID-19. METHODS: We performed a multicenter study of markers of neutrophil innate immunity in 155 cases consecutively recruited in a screening center, local hospitals, and two regional university hospitals. The cases were evaluated according to clinical and biological markers of severity and multi-organ manifestations and compared to 35 healthy controls. RESULTS: Blood neutrophil elastase, histone-DNA, myeloperoxidase-DNA, and free dsDNA were dramatically increased, and DNase activity was decreased by 10-fold, compared with controls. Neutrophil elastase and histone-DNA were associated with intensive care admission, body temperature, lung damage, and markers of cardiovascular outcomes, renal failure, and increased interleukin-6 (IL-6), IL-8, and CXCR2. Neutrophil elastase was an independent predictor of the computed tomography score of COVID-19 lung damage and the number of affected organs, in multivariate analyses. The increased blood concentrations of NE and neutrophil extracellular traps were related to exacerbation of neutrophil stimulation through IL-8 and CXCR2 increased concentrations and increased serum DAMPs, and to impaired degradation of NETs as a consequence of the dramatic decrease in blood DNase activity. CONCLUSION: Our results point out the key role of neutrophil innate immunity exacerbation in COVID-19. Neutrophil elastase and DNase could be potential biomarkers and therapeutic targets of severe systemic manifestations of COVID-19.</style></abstract><notes><style face="normal" font="default" size="100%">Gueant, Jean-Louis&#xD;Gueant-Rodriguez, Rosa-Maria&#xD;Fromonot, Julien&#xD;Oussalah, Abderrahim&#xD;Louis, Huguette&#xD;Chery, Celine&#xD;Gette, Mickael&#xD;Gleye, Stanislas&#xD;Callet, Jonas&#xD;Raso, Jeremie&#xD;Blanchecotte, Francois&#xD;Lacolley, Patrick&#xD;Guieu, Regis&#xD;Regnault, Veronique&#xD;eng&#xD;FHU ARRIMAGE/&#xD;ANR-15-IDEX-04-LUE/Lorraine Universite d&apos;Excellence/&#xD;Multicenter Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1846-1858. doi: 10.1111/all.14746. Epub 2021 Feb 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33484168</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8014109</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14746</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2261</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2261</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sasaki, M.</style></author><author><style face="normal" font="default" size="100%">Sundberg, M.</style></author><author><style face="normal" font="default" size="100%">Frei, R.</style></author><author><style face="normal" font="default" size="100%">Ferstl, R.</style></author><author><style face="normal" font="default" size="100%">Heye, K. N.</style></author><author><style face="normal" font="default" size="100%">Willems, E. P.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Lauener, R.</style></author><author><style face="normal" font="default" size="100%">Ck-Care Study Group</style></author><author><style face="normal" font="default" size="100%">Roduit, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Children&apos;s Hospital Zurich, Zurich, Switzerland.&#xD;SciBase AB, Sundbyberg, Sweden.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Division of Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, University of Bern, Bern, Switzerland.&#xD;Department of Biomedical Research, University of Bern, Bern, Switzerland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Children&apos;s Hospital of Eastern Switzerland, St. Gallen, Switzerland.&#xD;Clinical Trials Unit, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Electrical impedance spectroscopy detects skin barrier dysfunction in childhood atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">142-152</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/09/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Dielectric Spectroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">electrical impedance spectroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">paediatric</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier assessment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37753955</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Skin barrier dysfunction is associated with the development of atopic dermatitis (AD), however methods to assess skin barrier function are limited. We investigated the use of electrical impedance spectroscopy (EIS) to detect skin barrier dysfunction in children with AD of the CARE (Childhood AlleRgy, nutrition, and Environment) cohort. METHODS: EIS measurements taken at multiple time points from 4 months to 3-year-old children, who developed AD (n = 66) and those who did not (n = 49) were investigated. Using only the EIS measurement and the AD status, we developed a machine learning algorithm that produces a score (EIS/AD score) which reflects the probability that a given measurement is from a child with active AD. We investigated the diagnostic ability of this score and its association with clinical characteristics and age. RESULTS: Based on the EIS/AD score, the EIS algorithm was able to clearly discriminate between healthy skin and clinically unaffected skin of children with active AD (area under the curve 0.92, 95% CI 0.85-0.99). It was also able to detect a difference between healthy skin and AD skin when the child did not have active AD. There was no clear association between the EIS/AD score and the severity of AD or sensitisation to the tested allergens. The performance of the algorithm was not affected by age. CONCLUSIONS: This study shows that EIS can detect skin barrier dysfunction and differentiate skin of children with AD from healthy skin and suggests that EIS may have the ability to predict future AD development.</style></abstract><notes><style face="normal" font="default" size="100%">Sasaki, Mari&#xD;Sundberg, Mathilda&#xD;Frei, Remo&#xD;Ferstl, Ruth&#xD;Heye, Kristina N&#xD;Willems, Erik P&#xD;Akdis, Cezmi A&#xD;Lauener, Roger&#xD;Roduit, Caroline&#xD;eng&#xD;Christine Kuhne - Center for Allergy Research and Education/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):142-152. doi: 10.1111/all.15895. Epub 2023 Sep 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37753955</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15895</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1060</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1060</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rinaldi, A. O.</style></author><author><style face="normal" font="default" size="100%">Korsfeldt, A.</style></author><author><style face="normal" font="default" size="100%">Ward, S.</style></author><author><style face="normal" font="default" size="100%">Burla, D.</style></author><author><style face="normal" font="default" size="100%">Dreher, A.</style></author><author><style face="normal" font="default" size="100%">Gautschi, M.</style></author><author><style face="normal" font="default" size="100%">Stolpe, B.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Bersuch, E.</style></author><author><style face="normal" font="default" size="100%">Melin, D.</style></author><author><style face="normal" font="default" size="100%">Askary Lord, N.</style></author><author><style face="normal" font="default" size="100%">Grant, S.</style></author><author><style face="normal" font="default" size="100%">Svedenhag, P.</style></author><author><style face="normal" font="default" size="100%">Tsekova, K.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Mohrenschlager, M.</style></author><author><style face="normal" font="default" size="100%">Renner, E. D.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF, Davos, Switzerland.&#xD;SciBase AB, Sundbyberg, Sweden.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Hochgebirgsklinik - High Altitude Clinic (HGK), Davos, Switzerland.&#xD;Functional Genomics Center Zurich, ETH Zurich/University of Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, University Hospital, Zurich, Switzerland.&#xD;Translational Immunology in Environmental Medicine, Technical University of Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Electrical impedance spectroscopy for the characterization of skin barrier in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3066-3079</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/04/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Dielectric Spectroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">electrical impedance spectroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier assessment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33830511</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic disorders such as atopic dermatitis (AD) are strongly associated with an impairment of the epithelial barrier, in which tight junctions and/or filaggrin expression can be defective. Skin barrier assessment shows potential to be clinically useful for prediction of disease development, improved and earlier diagnosis, lesion follow-up, and therapy evaluation. This study aimed to establish a method to directly assess the in vivo status of epithelial barrier using electrical impedance spectroscopy (EIS). METHODS: Thirty-six patients with AD were followed during their 3-week hospitalization and compared with 28 controls. EIS and transepidermal water loss (TEWL) were measured in lesional and non-lesional skin. Targeted proteomics by proximity extension assay in serum and whole-genome sequence were performed. RESULTS: Electrical impedance spectroscopy was able to assess epithelial barrier integrity, differentiate between patients and controls without AD, and characterize lesional and non-lesional skin of patients. It showed a significant negative correlation with TEWL, but a higher sensitivity to discriminate non-lesional atopic skin from controls. During hospitalization, lesions reported a significant increase in EIS that correlated with healing, decreased SCORAD and itch scores. Additionally, EIS showed a significant inverse correlation with serum biomarkers associated with inflammatory pathways that may affect the epithelial barrier, particularly chemokines such as CCL13, CCL3, CCL7, and CXCL8 and other cytokines, such as IRAK1, IRAK4, and FG2, which were significantly high at admission. Furthermore, filaggrin copy numbers significantly correlated with EIS on non-lesional skin of patients. CONCLUSIONS: Electrical impedance spectroscopy can be a useful tool to detect skin barrier dysfunction in vivo, valuable for the assessment of AD severity, progression, and therapy efficacy.</style></abstract><notes><style face="normal" font="default" size="100%">Rinaldi, Arturo O&#xD;Korsfeldt, Angelica&#xD;Ward, Siobhan&#xD;Burla, Daniel&#xD;Dreher, Anita&#xD;Gautschi, Marja&#xD;Stolpe, Britta&#xD;Tan, Ge&#xD;Bersuch, Eugen&#xD;Melin, David&#xD;Askary Lord, Nima&#xD;Grant, Simon&#xD;Svedenhag, Per&#xD;Tsekova, Kristina&#xD;Schmid-Grendelmeier, Peter&#xD;Mohrenschlager, Matthias&#xD;Renner, Ellen D&#xD;Akdis, Cezmi A&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3066-3079. doi: 10.1111/all.14842. Epub 2021 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33830511</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14842</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3265</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3265</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tossavainen, Tarleena</style></author><author><style face="normal" font="default" size="100%">Turunen, Tanja</style></author><author><style face="normal" font="default" size="100%">Martikainen, Maria-Viola</style></author><author><style face="normal" font="default" size="100%">Kankaanpää, Miisa</style></author><author><style face="normal" font="default" size="100%">Malinen, Marjo</style></author><author><style face="normal" font="default" size="100%">Roponen, Marjut</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Elevated CO2 and Temperature Alter Grass Pollen&apos;s Ability to Modify Transcriptome and Function of the Nasal Epithelium</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Climate change increases exposure to pollen, but the effects of climate-related factors on the potency of pollen to trigger early events in the epithelium are unknown, despite their significant impact on respiratory health. Objective We aimed to investigate whether climate change affects the capacity of grass pollen to mediate cell functions in human nasal epithelium. Methods Toxicological and immunological responses, and the transcriptomes were analyzed after exposing reconstituted human nasal epithelial tissues to pollen collected from grasses (timothy and meadow foxtail) grown under different climate change conditions (increasing temperature and CO2 levels). Results Pollen of both grass species grown under current climate conditions altered the expression of genes encoding for cytokines and chemokines, and similar patterns were observed at the protein level. Moreover, pollen exposure reduced epithelial barrier integrity and was associated with increased expression of genes related to tight junctions and tissue repair. Climate change-modified meadow foxtail pollen decreased the expression of genes related to vesicle-mediated transport and transcriptional and translational processes, whereas pollen of timothy grass inhibited the expression of genes related to cilium assembly and organization. Conclusions Future grass pollen potentially disrupts cilia function and vesicle-mediated (cytokine) signaling in human nasal epithelium more than pollen representing current climate. That may hinder appropriate immune reaction activation and foreign substance removal from the airways. Disrupted regulation of gene expression in turn potentially results in adverse system-level outcomes.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70251</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70251</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3017</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3017</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Chen, L.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Shuai, C.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Cao, H.</style></author><author><style face="normal" font="default" size="100%">Xue, F.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Pan, M.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Zheng, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.&#xD;Ruijin-Yatsen Joint Laboratory, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Elevated Cutaneous Interleukin-21 Links Eczematous Eruption to Interleukin-17A Inhibitor Treatment in Psoriasis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">eczematous eruption</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-17A inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-21</style></keyword><keyword><style face="normal" font="default" size="100%">janus kinase</style></keyword><keyword><style face="normal" font="default" size="100%">psoriasis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40879286</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eczematous eruption (EE) is an adverse effect observed in psoriasis patients undergoing interleukin (IL)-17A inhibitor therapy, with reported incidence rates ranging from 2.2% to 12.1%. In some cases, this reaction leads to discontinuation of treatment. However, the underlying mechanism of EE development remains unclear. Therefore, we aimed to elucidate the pathogenesis of EE associated with anti-IL-17A treatment and identify pathogenic molecules involved. METHODS: Skin samples were collected from psoriasis patients both before and after anti-IL-17A treatment, and the treated skin included those with and without EE. Transcriptomic profiling was performed using bulk RNA-seq and scRNA-seq, which were further validated by histopathological analysis and protein assay. In addition, in vitro experiments were conducted to explore the underlying mechanisms. RESULTS: Bulk RNA-seq analysis revealed significantly elevated IL-21 expression in EE lesions, along with marked enrichment of Th2/Th22 pathways and activation of JAK-STAT signaling compared to baseline and non-EE samples. Immunohistochemistry confirmed increased expression of IL-21, pJAK1, and pSTAT3 in EE lesions. ELISA and LEGENDplex assays detected higher levels of IL-21, IL-13, and IL-22, with positive correlations between IL-21 and the latter two cytokines. ScRNA-seq localized IL-21 expression predominantly to T cells within EE lesions, which co-expressed high levels of IL-13 and IL-22. In vitro, rhIL-21 stimulation activated JAK1/STAT3 signaling and increased IL-13 and IL-22 secretion, which were suppressed by JAK1 inhibition. These findings identify IL-21 as an important regulator of Th2/Th22 responses and JAK-STAT signaling in EE pathogenesis. CONCLUSION: IL-21 is an important inflammatory mediator contributing to the development of EE.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Li&#xD;Chen, Lihong&#xD;Wang, Hailun&#xD;Shuai, Ce&#xD;Wang, Youcong&#xD;Cao, Han&#xD;Xue, Feng&#xD;Zhang, Jiayi&#xD;Pan, Meng&#xD;Li, Xia&#xD;Zheng, Jie&#xD;eng&#xD;82404125/National Natural Science Foundation of China/&#xD;81830095/National Natural Science Foundation of China/&#xD;GZC20241061/Postdoctoral Fellowship Program of CPSF/&#xD;SHDC2020CR1014B/Clinical Research Plan of SHDC/&#xD;23PJ1408100/Science and Technology Commission of Shanghai Municipality, Shanghai Pujiang Program/&#xD;Denmark&#xD;Allergy. 2025 Aug 29. doi: 10.1111/all.70026.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40879286</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70026</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3221</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3221</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Marquis, K.</style></author><author><style face="normal" font="default" size="100%">McWhorter, O.</style></author><author><style face="normal" font="default" size="100%">Besz, K. M.</style></author><author><style face="normal" font="default" size="100%">Lynch, D. M.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Department of Pharmacy, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Elevated Tryptase and Hereditary Alpha Tryptasemia in Drug Hypersensitivity and Desensitization</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/26</style></edition><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 25</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41582297</style></accession-num><notes><style face="normal" font="default" size="100%">Labella, Marina&#xD;Marquis, Kathleen&#xD;McWhorter, Olivia&#xD;Besz, Kylie Marie&#xD;Lynch, Donna Marie&#xD;Castells, Mariana&#xD;eng&#xD;Ministry of Economy/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan 25. doi: 10.1111/all.70226.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41582297</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70226</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2564</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2564</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shah, M. M.</style></author><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Hourcade, D. E.</style></author><author><style face="normal" font="default" size="100%">Fulton, W. T.</style></author><author><style face="normal" font="default" size="100%">Tan, T. J.</style></author><author><style face="normal" font="default" size="100%">Dunham, D.</style></author><author><style face="normal" font="default" size="100%">Chang, I.</style></author><author><style face="normal" font="default" size="100%">Vel, M. S.</style></author><author><style face="normal" font="default" size="100%">Fernandes, A.</style></author><author><style face="normal" font="default" size="100%">Lee, A. S.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Arunachalam, P. S.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author><author><style face="normal" font="default" size="100%">Boyd, S. D.</style></author><author><style face="normal" font="default" size="100%">Pulendran, B.</style></author><author><style face="normal" font="default" size="100%">Davis, M. M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hara, R.</style></author><author><style face="normal" font="default" size="100%">Park, H.</style></author><author><style face="normal" font="default" size="100%">Mitchell, L. M.</style></author><author><style face="normal" font="default" size="100%">Akk, A.</style></author><author><style face="normal" font="default" size="100%">Patterson, A.</style></author><author><style face="normal" font="default" size="100%">Jerath, M. R.</style></author><author><style face="normal" font="default" size="100%">Monroy, J. M.</style></author><author><style face="normal" font="default" size="100%">Ren, Z.</style></author><author><style face="normal" font="default" size="100%">Kendall, P. L.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Fedina, A.</style></author><author><style face="normal" font="default" size="100%">Gibbs, B. F.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, S.</style></author><author><style face="normal" font="default" size="100%">Sindher, S. B.</style></author><author><style face="normal" font="default" size="100%">Heider, A.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Pham, C. T. N.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy &amp; Asthma Research, Stanford, California, USA.&#xD;Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, USA.&#xD;Stanford Health Library, Stanford, California, USA.&#xD;Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, California, USA.&#xD;Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Veteran&apos;s Administration and Dean&apos;s Office, Stanford University, Stanford, California, USA.&#xD;Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.&#xD;Department of Medicine, Division of Allergy and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.&#xD;Department of Human Medicine, School of Medicine and Health Sciences, Carl von Ossietzky University of Oldenburg, Oldenburg, Germany.&#xD;Canterbury Christ Church University, Canterbury, UK.&#xD;Faculty of Medicine, Transilvania University, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Harvard T.H. Chan School of Public Health, Harvard University, Cambridge, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Elucidating allergic reaction mechanisms in response to SARS-CoV-2 mRNA vaccination in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2502-2523</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/07/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/immunology/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/immunology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Complement Activation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA Vaccines/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">polyethylene glycol</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39033312</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: During the COVID-19 pandemic, novel nanoparticle-based mRNA vaccines were developed. A small number of individuals developed allergic reactions to these vaccines although the mechanisms remain undefined. METHODS: To understand COVID-19 vaccine-mediated allergic reactions, we enrolled 19 participants who developed allergic events within 2 h of vaccination and 13 controls, nonreactors. Using standard hemolysis assays, we demonstrated that sera from allergic participants induced stronger complement activation compared to nonallergic subjects following ex vivo vaccine exposure. RESULTS: Vaccine-mediated complement activation correlated with anti-polyethelyne glycol (PEG) IgG (but not IgM) levels while anti-PEG IgE was undetectable in all subjects. Depletion of total IgG suppressed complement activation in select individuals. To investigate the effects of vaccine excipients on basophil function, we employed a validated indirect basophil activation test that stratified the allergic populations into high and low responders. Complement C3a and C5a receptor blockade in this system suppressed basophil response, providing strong evidence for complement involvement in vaccine-mediated basophil activation. Single-cell multiome analysis revealed differential expression of genes encoding the cytokine response and Toll-like receptor (TLR) pathways within the monocyte compartment. Differential chromatin accessibility for IL-13 and IL-1B genes was found in allergic and nonallergic participants, suggesting that in vivo, epigenetic modulation of mononuclear phagocyte immunophenotypes determines their subsequent functional responsiveness, contributing to the overall physiologic manifestation of vaccine reactions. CONCLUSION: These findings provide insights into the mechanisms underlying allergic reactions to COVID-19 mRNA vaccines, which may be used for future vaccine strategies in individuals with prior history of allergies or reactions and reduce vaccine hesitancy.</style></abstract><notes><style face="normal" font="default" size="100%">Shah, Mihir M&#xD;Layhadi, Janice A&#xD;Hourcade, Dennis E&#xD;Fulton, William T&#xD;Tan, Tiak Ju&#xD;Dunham, Diane&#xD;Chang, Iris&#xD;Vel, Monica S&#xD;Fernandes, Andrea&#xD;Lee, Alexandra S&#xD;Liu, James&#xD;Arunachalam, Prabhu S&#xD;Galli, Stephen J&#xD;Boyd, Scott D&#xD;Pulendran, Bali&#xD;Davis, Mark M&#xD;O&apos;Hara, Ruth&#xD;Park, Helen&#xD;Mitchell, Lynne M&#xD;Akk, Antonina&#xD;Patterson, Alexander&#xD;Jerath, Maya R&#xD;Monroy, Jennifer M&#xD;Ren, Zhen&#xD;Kendall, Peggy L&#xD;Durham, Stephen R&#xD;Fedina, Aleksandra&#xD;Gibbs, Bernhard F&#xD;Agache, Ioana&#xD;Chinthrajah, Sharon&#xD;Sindher, Sayantani B&#xD;Heider, Anja&#xD;Akdis, Cezmi A&#xD;Shamji, Mohamed H&#xD;Pham, Christine T N&#xD;Nadeau, Kari C&#xD;eng&#xD;U19 AI057229/AI/NIAID NIH HHS/&#xD;UL1 TR002345/TR/NCATS NIH HHS/&#xD;U19 AI167903/AI/NIAID NIH HHS/&#xD;U54 CA260517/CA/NCI NIH HHS/&#xD;P30 AR073752/AR/NIAMS NIH HHS/&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2502-2523. doi: 10.1111/all.16231. Epub 2024 Jul 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39033312</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11368657</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16231</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1267</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1267</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kiewiet, M. B. G.</style></author><author><style face="normal" font="default" size="100%">Grundstrom, J.</style></author><author><style face="normal" font="default" size="100%">Apostolovic, D.</style></author><author><style face="normal" font="default" size="100%">Andersson, M.</style></author><author><style face="normal" font="default" size="100%">Borres, M. P.</style></author><author><style face="normal" font="default" size="100%">Hamsten, C.</style></author><author><style face="normal" font="default" size="100%">Starkhammar, M.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and University Hospital, Stockholm, Sweden.&#xD;Thermo Fisher Scientific, Uppsala, Sweden.&#xD;Department of Women&apos;s and Children&apos;s Health, Uppsala University, Uppsala, Sweden.&#xD;Department of Internal Medicine, Sodersjukhuset, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Elucidating the alpha-Gal syndrome at the molecular allergen level</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1576-1578</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/11/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33206401</style></accession-num><notes><style face="normal" font="default" size="100%">Kiewiet, Mensiena Berentje Geertje&#xD;Grundstrom, Jeanette&#xD;Apostolovic, Danijela&#xD;Andersson, Mats&#xD;Borres, Magnus P&#xD;Hamsten, Carl&#xD;Starkhammar, Maria&#xD;van Hage, Marianne&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1576-1578. doi: 10.1111/all.14660. Epub 2020 Dec 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33206401</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246984 Andersson and Prof. Borres are employed by Thermo Fisher Scientific (Sweden). Dr Hamsten declares no conflict of interest. Dr Starkhammar reports fees from Mylan, ALK and Chiesi. Prof. van Hage reports personal fees from Biomay AG, Vienna, Austria, and Hycor Biomedical LLC, CA, USA, personal fees from Thermo Fisher Scientific and ALK, outside the submitted work.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14660</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>697</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">697</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfeiffer, S.</style></author><author><style face="normal" font="default" size="100%">Raith, M.</style></author><author><style face="normal" font="default" size="100%">Pascal, M.</style></author><author><style face="normal" font="default" size="100%">Munoz-Cano, R. M.</style></author><author><style face="normal" font="default" size="100%">San Bartolome, C.</style></author><author><style face="normal" font="default" size="100%">Nobauer, K.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Razzazi-Fazeli, E.</style></author><author><style face="normal" font="default" size="100%">Focke-Tejkl, M.</style></author><author><style face="normal" font="default" size="100%">Sterflinger, K.</style></author><author><style face="normal" font="default" size="100%">Swoboda, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Molecular Biotechnology Section, FH Campus Wien, University of Applied Sciences, Vienna, Austria.&#xD;Hospital Clinic de Barcelona, Immunology Department, CDB, IDIBAPS, University of Barcelona, Barcelona, Spain.&#xD;Spanish Network for Allergy - RETIC de Asma, Reacciones adversas y Alergicas (ARADYAL), Madrid, Spain.&#xD;Hospital Clinic de Barcelona, Allergy Unit, IDIBAPS, University of Barcelona, ARADyAL, Barcelona, Spain.&#xD;VetCORE Facility for Research, University of Veterinary Medicine, Vienna, Austria.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, Universidad Autonoma de Madrid, Madrid, Spain.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Institute of Natural Sciences and Technology in the Arts, Academy of Fine Arts Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The emerging pathogen Paecilomyces variotii - a novel and important fungal allergen source</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1045-1048</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/11/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Byssochlamys</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Paecilomyces</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34773271</style></accession-num><notes><style face="normal" font="default" size="100%">Pfeiffer, Sandra&#xD;Raith, Marianne&#xD;Pascal, Mariona&#xD;Munoz-Cano, Rosa Maria&#xD;San Bartolome, Clara&#xD;Nobauer, Katharina&#xD;Quirce, Santiago&#xD;Razzazi-Fazeli, Ebrahim&#xD;Focke-Tejkl, Margarete&#xD;Sterflinger, Katja&#xD;Swoboda, Ines&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1045-1048. doi: 10.1111/all.15176. Epub 2021 Nov 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34773271</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9299467</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15176</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3213</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3213</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nishadhi, Dasm</style></author><author><style face="normal" font="default" size="100%">Sumiya, S.</style></author><author><style face="normal" font="default" size="100%">Tazaki, A.</style></author><author><style face="normal" font="default" size="100%">Kagawa, T.</style></author><author><style face="normal" font="default" size="100%">Abdelmoneim, M.</style></author><author><style face="normal" font="default" size="100%">Sakashita, M.</style></author><author><style face="normal" font="default" size="100%">Ogi, K.</style></author><author><style face="normal" font="default" size="100%">Fujieda, S.</style></author><author><style face="normal" font="default" size="100%">Iwasaki, S.</style></author><author><style face="normal" font="default" size="100%">Kato, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Occupational and Environmental Health, Nagoya University Graduate School of Medicine, Nagoya, Japan.&#xD;Voluntary Body for International Health Care in Universities, Nagoya, Japan.&#xD;Department of Otolaryngology-Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.&#xD;Institutes of Innovation for Future Society, Nagoya University, Nagoya, Japan.&#xD;Department of Microbiology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.&#xD;Division of Otorhinolaryngology-Head and Neck Surgery, Department of Sensory and Locomotor Medicine, University of Fukui, Fukui, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Emerging Risk: Intranasal Tin Exacerbates Allergic Rhinitis in Humans and Mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Ent</style></keyword><keyword><style face="normal" font="default" size="100%">environment and hygiene hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 2</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41328649</style></accession-num><notes><style face="normal" font="default" size="100%">Nishadhi, Delgama A S M&#xD;Sumiya, Shogo&#xD;Tazaki, Akira&#xD;Kagawa, Takumi&#xD;Abdelmoneim, Mohamed&#xD;Sakashita, Masafumi&#xD;Ogi, Kazuhiro&#xD;Fujieda, Shigeharu&#xD;Iwasaki, Shinichi&#xD;Kato, Masashi&#xD;eng&#xD;Japan Society for the Promotion of Science (JSPS)/&#xD;JST SPRING/&#xD;Kobayashi International Scholarship Foundation/&#xD;Asahi Glass Foundation/&#xD;Tojuro Iijima Foundation for Food Science and Technology/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec 2. doi: 10.1111/all.70180.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41328649</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70180</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>250</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">250</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bradshaw, L. E.</style></author><author><style face="normal" font="default" size="100%">Wyatt, L. A.</style></author><author><style face="normal" font="default" size="100%">Brown, S. J.</style></author><author><style face="normal" font="default" size="100%">Haines, R. H.</style></author><author><style face="normal" font="default" size="100%">Montgomery, A. A.</style></author><author><style face="normal" font="default" size="100%">Perkin, M. R.</style></author><author><style face="normal" font="default" size="100%">Lawton, S.</style></author><author><style face="normal" font="default" size="100%">Sach, T. H.</style></author><author><style face="normal" font="default" size="100%">Chalmers, J. R.</style></author><author><style face="normal" font="default" size="100%">Ridd, M. J.</style></author><author><style face="normal" font="default" size="100%">Flohr, C.</style></author><author><style face="normal" font="default" size="100%">Brooks, J.</style></author><author><style face="normal" font="default" size="100%">Swinden, R.</style></author><author><style face="normal" font="default" size="100%">Mitchell, E. J.</style></author><author><style face="normal" font="default" size="100%">Tarr, S.</style></author><author><style face="normal" font="default" size="100%">Jay, N.</style></author><author><style face="normal" font="default" size="100%">Thomas, K. S.</style></author><author><style face="normal" font="default" size="100%">Allen, H.</style></author><author><style face="normal" font="default" size="100%">Cork, M. J.</style></author><author><style face="normal" font="default" size="100%">Kelleher, M. M.</style></author><author><style face="normal" font="default" size="100%">Simpson, E. L.</style></author><author><style face="normal" font="default" size="100%">Lartey, S. T.</style></author><author><style face="normal" font="default" size="100%">Davies-Jones, S.</style></author><author><style face="normal" font="default" size="100%">Boyle, R. J.</style></author><author><style face="normal" font="default" size="100%">Williams, H. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.&#xD;Skin Research Group, School of Medicine, University of Dundee, Dundee, UK.&#xD;Department of Dermatology, Ninewells Hospital and Medical School, Dundee, UK.&#xD;Population Health Research Institute, St. George&apos;s University of London, London, UK.&#xD;Rotherham NHS Foundation Trust, UK.&#xD;Health Economics Group, Norwich Medical School, University of East Anglia, Norwich, UK.&#xD;Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.&#xD;Population Health Sciences, University of Bristol, Bristol, UK.&#xD;Unit for Population-Based Dermatology Research, St John&apos;s Institute of Dermatology, Guy&apos;s &amp; St Thomas&apos; NHS Foundation Trust and King&apos;s College London, London, UK.&#xD;Sheffield Children&apos;s Hospital, Sheffield, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Sheffield Dermatology Research, Department of Infection and Immunity, University of Sheffield, Sheffield, UK.&#xD;Department of Dermatology, Oregon Health &amp; Science University, Portland, Oregon, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Emollients for prevention of atopic dermatitis: 5-year findings from the BEEP randomized trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">995-1006</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Emollients/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36263451</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The effectiveness of emollients for preventing atopic dermatitis/eczema is controversial. The Barrier Enhancement for Eczema Prevention trial evaluated the effects of daily emollients during the first year of life on atopic dermatitis and atopic conditions to age 5 years. METHODS: 1394 term infants with a family history of atopic disease were randomized (1:1) to daily emollient plus standard skin-care advice (693 emollient group) or standard skin-care advice alone (701 controls). Long-term follow-up at ages 3, 4 and 5 years was via parental questionnaires. Main outcomes were parental report of a clinical diagnosis of atopic dermatitis and food allergy. RESULTS: Parents reported more frequent moisturizer application in the emollient group through to 5 years. A clinical diagnosis of atopic dermatitis between 12 and 60 months was reported for 188/608 (31%) in the emollient group and 178/631 (28%) in the control group (adjusted relative risk 1.10, 95% confidence interval 0.93 to 1.30). Although more parents in the emollient group reported food reactions in the previous year at 3 and 4 years, cumulative incidence of doctor-diagnosed food allergy by 5 years was similar between groups (92/609 [15%] emollients and 87/632 [14%] controls, adjusted relative risk 1.11, 95% confidence interval 0.84 to 1.45). Findings were similar for cumulative incidence of asthma and hay fever. CONCLUSIONS: Daily emollient application during the first year of life does not prevent atopic dermatitis, food allergy, asthma or hay fever.</style></abstract><notes><style face="normal" font="default" size="100%">Bradshaw, Lucy E&#xD;Wyatt, Laura A&#xD;Brown, Sara J&#xD;Haines, Rachel H&#xD;Montgomery, Alan A&#xD;Perkin, Michael R&#xD;Lawton, Sandra&#xD;Sach, Tracey H&#xD;Chalmers, Joanne R&#xD;Ridd, Matthew J&#xD;Flohr, Carsten&#xD;Brooks, Joanne&#xD;Swinden, Richard&#xD;Mitchell, Eleanor J&#xD;Tarr, Stella&#xD;Jay, Nicola&#xD;Thomas, Kim S&#xD;Allen, Hilary&#xD;Cork, Michael J&#xD;Kelleher, Maeve M&#xD;Simpson, Eric L&#xD;Lartey, Stella T&#xD;Davies-Jones, Susan&#xD;Boyle, Robert J&#xD;Williams, Hywel C&#xD;eng&#xD;12/67/12/DH_/Department of Health/United Kingdom&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):995-1006. doi: 10.1111/all.15555. Epub 2022 Nov 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36263451</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15555</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1277</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1277</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kothari, A.</style></author><author><style face="normal" font="default" size="100%">Locke, A.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Medicine, National University of Ireland, Galway, Ireland.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Emollients for the prevention of atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2641-2643</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Emollients</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Emollient</style></keyword><keyword><style face="normal" font="default" size="100%">atopic eczema</style></keyword><keyword><style face="normal" font="default" size="100%">infancy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33147358</style></accession-num><notes><style face="normal" font="default" size="100%">Kothari, Akash&#xD;Locke, Arielle&#xD;Eiwegger, Thomas&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2641-2643. doi: 10.1111/all.14650. Epub 2020 Nov 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33147358</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14650</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>767</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">767</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhong, Y.</style></author><author><style face="normal" font="default" size="100%">Samuel, M.</style></author><author><style face="normal" font="default" size="100%">van Bever, H.</style></author><author><style face="normal" font="default" size="100%">Tham, E. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore.&#xD;Khoo Teck Puat-National University Children&apos;s Medical Institute, National University Health System (NUHS), Singapore, Singapore.&#xD;Research Support Unit, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore.&#xD;Human Potential Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Emollients in infancy to prevent atopic dermatitis: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1685-1699</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Emollients/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">emollient</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">moisturizer</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34591995</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Several studies have evaluated prophylactic emollients as a preventive strategy against atopic dermatitis (AD) and food allergy (FA). We aimed to synthesize the evidence on efficacy and safety of prophylactic emollients started during the first 6 weeks of infancy for prevention of AD and FA. METHODS: MEDLINE, Embase, CINAHL, BIOSIS, and the Cochrane Library databases were searched systematically for randomized controlled trials published between January 2000 and July 2020, which assessed the effects of prophylactic emollients initiated within the first 6 weeks of life on the development of AD within 24 months of age, compared to no treatment. Risk of bias and certainty of evidence were assessed using the Cochrane Collaboration&apos;s tool and GRADE process, respectively. RESULTS: Of the 1486 articles identified, 10 studies fulfilled inclusion criteria. In infants given emollients, there was no significant reduction on the development of AD (risk ratio (RR) 0.84, 95% confidence interval (CI) 0.64, 1.10) compared to the control group. However, there was significant benefit of prophylactic emollients (RR 0.75, 95% CI 0.62-1.11) in the high-risk population (n = 8 studies). There was also significant benefit (RR 0.59, 95% CI 0.43, 0.81) in studies (n = 6) where emollients were used continuously to the point of AD assessment; but not when treatment was ceased for an interval before AD assessment. There were no protective effects on FA found. CONCLUSION: The prophylactic application of emollients initiated in early infancy may prevent AD, especially in high-risk populations and when used continuously. We hypothesize that emollients may delay rather than prevent AD.</style></abstract><notes><style face="normal" font="default" size="100%">Zhong, Youjia&#xD;Samuel, Miny&#xD;van Bever, Hugo&#xD;Tham, Elizabeth Huiwen&#xD;eng&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1685-1699. doi: 10.1111/all.15116. Epub 2021 Oct 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34591995</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15116</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2708</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2708</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Toki, S.</style></author><author><style face="normal" font="default" size="100%">Abney, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Rusznak, M.</style></author><author><style face="normal" font="default" size="100%">Warren, C. M.</style></author><author><style face="normal" font="default" size="100%">Newcomb, D. C.</style></author><author><style face="normal" font="default" size="100%">Cahill, K. N.</style></author><author><style face="normal" font="default" size="100%">Drucker, D. J.</style></author><author><style face="normal" font="default" size="100%">Niswender, K. D.</style></author><author><style face="normal" font="default" size="100%">Peebles, R. S., Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.&#xD;United States Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee, USA.&#xD;Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.&#xD;Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Endogenous Glucagon-Like Peptide-1 Receptor and Glucose-Dependent Insulinotropic Polypeptide Receptor Signaling Inhibits Aeroallergen-Induced Innate Airway Inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3373-3384</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/11/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">*Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">*Glucagon-Like Peptide-1 Receptor/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Gastrointestinal Hormone/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Alternaria/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage Fluid/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gipr</style></keyword><keyword><style face="normal" font="default" size="100%">Glp-1r</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">incretin</style></keyword><keyword><style face="normal" font="default" size="100%">past 12 months to Altimmune, Amgen, AstraZeneca Inc, Boehringer Ingelheim,</style></keyword><keyword><style face="normal" font="default" size="100%">Kallyope, Merck Research Laboratories, Novo Nordisk Inc., and Pfizer Inc. Neither</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Drucker nor his family members hold issued stock directly or indirectly in</style></keyword><keyword><style face="normal" font="default" size="100%">any of these companies. Dr. Cahill has served as an advisory board member for</style></keyword><keyword><style face="normal" font="default" size="100%">AztraZeneca, Sanofi, Genentech, Novartis, Regeneron, and as a consultant for</style></keyword><keyword><style face="normal" font="default" size="100%">Verantos and Clinical Key, receives royalties from UpToDate, and research support</style></keyword><keyword><style face="normal" font="default" size="100%">from NovoNordisk. All other authors have no financial conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39559998</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Anti-inflammatory effects of incretin signaling through the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR) in mice have been reported. Therefore, we hypothesized that signaling through the endogenous GLP-1R and the GIPR individually decreases allergic airway inflammation and that the combination of GLP-1R and GIPR signaling together additively inhibits allergen-induced lung and airway inflammation. METHODS: WT (C57BL/6J), GLP-1R knockout (KO), GIPR KO, and GLP-1R/GIPR double KO (DKO) mice were challenged intranasally with Alternaria alternata extract (Alt-Ext) or vehicle to evaluate the impact of signaling through these receptors on the innate allergen-induced inflammatory response that is primarily driven by group 2 innate lymphoid cells (ILC2). RESULTS: Alt-Ext-induced IL-33 release in the bronchoalveolar lavage fluid (BALF) was not different between the mouse strains, but thymic stromal lymphopoietin (TSLP) was significantly increased in GLP-1R/GIPR DKO mice challenged with Alt-Ext compared to the other strains. Furthermore, Alt-Ext-induced protein expression of IL-5, IL-13, CCL11, and CCL24 in the lung homogenates, the number of eosinophils, lymphocytes, and neutrophils in the BALF, and the number of lung GATA3+ ILC2 were significantly increased in GLP-1R/GIPR DKO mice compared to the other 3 strains. Furthermore, ICAM-1 expression on lung epithelial cells was increased in GLP-1R/GIPR DKO mice challenged with Alt-Ext compared to the other 3 strains. CONCLUSIONS: Deficiency of both GLP-1R and GIPR signaling together increased TSLP release, ILC2 activation, and early type 2 innate immune responses to aeroallergen exposure. Combined GLP-1R and GIPR signaling should be explored for the treatment of asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Toki, Shinji&#xD;Abney, Masako&#xD;Zhang, Jian&#xD;Rusznak, Mark&#xD;Warren, Christian M&#xD;Newcomb, Dawn C&#xD;Cahill, Katherine N&#xD;Drucker, Daniel J&#xD;Niswender, Kevin D&#xD;Peebles, Ray Stokes Jr&#xD;eng&#xD;5R21 AI145397/NH/NIH HHS/&#xD;R01 AI182159/AI/NIAID NIH HHS/&#xD;R21 AI145397/AI/NIAID NIH HHS/&#xD;5RO1 AI124456/NH/NIH HHS/&#xD;R01 AI124456/AI/NIAID NIH HHS/&#xD;5RO1 AI145265/NH/NIH HHS/&#xD;I01 BX004299/BX/BLRD VA/&#xD;U19 AI095227/AI/NIAID NIH HHS/&#xD;2U19 AI095227/NH/NIH HHS/&#xD;R01 AI145265/AI/NIAID NIH HHS/&#xD;5I01BX004299/U.S. Department of Veterans Affairs/&#xD;U01 AI155299/AI/NIAID NIH HHS/&#xD;154321/CIHR/&#xD;U01 AI155299/NH/NIH HHS/&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3373-3384. doi: 10.1111/all.16402. Epub 2024 Nov 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39559998</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11842020</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16402</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2865</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2865</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wong, L. S.</style></author><author><style face="normal" font="default" size="100%">Yang, J. L.</style></author><author><style face="normal" font="default" size="100%">Yen, Y. T.</style></author><author><style face="normal" font="default" size="100%">Lee, C. H.</style></author><author><style face="normal" font="default" size="100%">Yang, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Doctoral Program of Clinical and Experimental Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.&#xD;Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.&#xD;School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.&#xD;Institute for Translation Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.&#xD;Department of Dermatology, Fooyin University Hospital, Pingtung, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Endothelin-1 Participates in the Pathogenesis of Prurigo Nodularis by Promoting NGF Expression via Endothelial Receptor B in Epidermal Keratinocytes and Dorsal Root Ganglion Cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1530-1533</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/04/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">dorsal root ganglion neurons</style></keyword><keyword><style face="normal" font="default" size="100%">endothelin receptor B</style></keyword><keyword><style face="normal" font="default" size="100%">endothelin-1</style></keyword><keyword><style face="normal" font="default" size="100%">keratinocytes</style></keyword><keyword><style face="normal" font="default" size="100%">neuron growth factor</style></keyword><keyword><style face="normal" font="default" size="100%">prurigo nodularis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40249388</style></accession-num><notes><style face="normal" font="default" size="100%">Wong, Lai-San&#xD;Yang, Jenq-Lin&#xD;Yen, Yu-Ta&#xD;Lee, Chih-Hung&#xD;Yang, Jen-Hau&#xD;eng&#xD;Chang Gung Memorial Hospital/&#xD;Ministry of Science and Technology, Taiwan/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1530-1533. doi: 10.1111/all.16564. Epub 2025 Apr 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40249388</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105065</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16564</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2932</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2932</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Celik, G. E.</style></author><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Murdaca, G.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Naisbitt, D.</style></author><author><style face="normal" font="default" size="100%">Sabato, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga and Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;RICORS Red De Enfermedades Inflamatorias (REI), Madrid, Spain.&#xD;Immunology Department, IIS-Fundacion Jimenez Diaz, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.&#xD;Ankara University School of Medicine, Dept of Immunology and Allergy, Private clinic, Ankara, Turkey.&#xD;Department of Internal Medicine, University of Genova, Genova, Italy.&#xD;Allergology and Clinical Immunology Unit, San Bartolomeo Hospital, Sarzana, Italy.&#xD;Swiss Institute of Allergy and Asthma Reserch (SIAF), University of Zurich, Davos, Switzerland.&#xD;Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.&#xD;Department of Immunology, Allergology, Rheumatology, University of Antwerp and Antwerp University Hospital, Wilrijk, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Endotypes in Immune Mediated Drug Reactions: Present and Future of Relevant Biomarkers. An EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1831-1847</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/05/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">drug reactions</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">phenotypes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40329700</style></accession-num><abstract><style face="normal" font="default" size="100%">Drug-induced immune reactions are an important burden for patients and health systems. They can be classified into immediate-drug hypersensitivity reactions (IDHRs) and delayed-DHRs (DDHRs) based on their phenotype. Drugs do not always behave as allergens and need to bind to proteins, forming adducts. Therefore, IDHRs can be classified as antigenic (IgE, and IgG mediated) and nonantigenic immune responses (complement activation-[CARPA], mas-related G-protein coupled receptor member X2 [MRGPRX2], cyclooxygenase [COX]-1 and cytokine release reactions [CRRs]). DDHRs are even more complex due to the different cell subsets and mechanisms involved, showing both antigenic and nonantigenic immune responses too. Since different endotypes result in similar phenotypes, the establishment of specific biomarkers is essential for an accurate diagnosis, with important relevance for the management of patients, as well as for risk stratification. The biomarkers of clinical utility are skin tests, specific IgE (sIgE), tryptase, and some HLA-DR genotyping. The diagnostic performance depends on the responsible drug. This review highlights that, unfortunately, most biomarkers have not gone beyond analytic or clinical validity. It is therefore important to set up multicentre translational studies to advance the validation process towards reaching a clinical utility phase.</style></abstract><notes><style face="normal" font="default" size="100%">Mayorga, C&#xD;Fernandez-Santamaria, R&#xD;Celik, G E&#xD;Labella, M&#xD;Murdaca, G&#xD;Sokolowska, M&#xD;Naisbitt, D&#xD;Sabato, V&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1831-1847. doi: 10.1111/all.16576. Epub 2025 May 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40329700</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16576</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>830</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">830</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kato, A.</style></author><author><style face="normal" font="default" size="100%">Peters, A. T.</style></author><author><style face="normal" font="default" size="100%">Stevens, W. W.</style></author><author><style face="normal" font="default" size="100%">Schleimer, R. P.</style></author><author><style face="normal" font="default" size="100%">Tan, B. K.</style></author><author><style face="normal" font="default" size="100%">Kern, R. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.&#xD;Department of Otolaryngology - Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">812-826</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/09/03</style></edition><section><style face="normal" font="default" size="100%">812</style></section><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">endotype</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34473358</style></accession-num><abstract><style face="normal" font="default" size="100%">Chronic rhinosinusitis (CRS) is a common clinical syndrome that produces significant morbidity and costs to our health system. The study of CRS has progressed from an era focused on phenotype to include endotype-based information. Phenotypic classification has identified clinical heterogeneity in CRS based on endoscopically observed features such as presence of nasal polyps, presence of comorbid or systemic diseases, and timing of disease onset. More recently, laboratory-based findings have established CRS endotype based upon specific mechanisms or molecular biomarkers. Understanding the basis of widespread heterogeneity in the manifestations of CRS is advanced by findings that the three main endotypes, Type 1, 2, and 3, orchestrate the expression of three distinct large sets of genes. The development and use of improved methods of endotyping disease in the clinic are ushering in an expansion of the use of biological therapies targeting Type 2 inflammation now and perhaps other inflammatory endotypes in the near future. The purpose of this review is to discuss the phenotypic and endotypic heterogeneity of CRS from the perspective of advancing the understanding of the pathogenesis and improvement of treatment approaches and outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Kato, Atsushi&#xD;Peters, Anju T&#xD;Stevens, Whitney W&#xD;Schleimer, Robert P&#xD;Tan, Bruce K&#xD;Kern, Robert C&#xD;eng&#xD;R01 AI137174/AI/NIAID NIH HHS/&#xD;P01 AI145818/NH/NIH HHS/&#xD;U19 AI106683/AI/NIAID NIH HHS/&#xD;K23 AI141694/NH/NIH HHS/&#xD;P01 AI145818/AI/NIAID NIH HHS/&#xD;R01 AI137174/NH/NIH HHS/&#xD;U19 AI106683/NH/NIH HHS/&#xD;K23 AI141694/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):812-826. doi: 10.1111/all.15074. Epub 2021 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34473358</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9148187</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15074</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2761</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2761</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Hox, V.</style></author><author><style face="normal" font="default" size="100%">Gane, S.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author><author><style face="normal" font="default" size="100%">Maza-Solano, J.</style></author><author><style face="normal" font="default" size="100%">Jaaskelainen, B.</style></author><author><style face="normal" font="default" size="100%">Vaara, R.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author><author><style face="normal" font="default" size="100%">Chaker, A.</style></author><author><style face="normal" font="default" size="100%">Karavelia, A.</style></author><author><style face="normal" font="default" size="100%">Rudenko, M.</style></author><author><style face="normal" font="default" size="100%">Gevaert, P.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, University of Eastern Finland, Kuopio, Finland.&#xD;Department of Otorhinolaryngology, Wellbeing Services County of Pohjois-Savo, Kuopio, Finland.&#xD;Inflammation Center, Department of Allergology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Otorhinolaryngology/Head-Neck Surgery, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Cliniques Universitaires Saint-Luc, Brussels, Belgium.&#xD;Royal National Ear, Nose and Throat and Eastman Dental Hospital, University College London Hospitals NHS Trust, London, UK.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga. IBIMA-Plataforma BIONAND. RICORS Enfermedades Inflamatorias, Malaga, Spain.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Rhinology and Skull Base Unit, Department of Otolaryngology, University Hospital Virgen Macarena, Seville, Spain.&#xD;Department of Surgery, University of Seville, Seville, Spain.&#xD;Institute of Applied Molecular Medicine Instituto de Medicina Molecular Aplicada Nemesio Diez (IMMA), Department of Basic Medical Sciences, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Department of Otorhinolaryngology and Center for Allergy and Environment, Technische Universitat Munchen, Munchen, Germany.&#xD;Department of Otorhinolaryngology, General Hospital of Nafplio, Nafplio, Greece.&#xD;London Allergy and Immunology Centre, London, UK.&#xD;Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Endotyping in Chronic Rhinosinusitis-An EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">132-147</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/12/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Committees</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39641584</style></accession-num><abstract><style face="normal" font="default" size="100%">Chronic rhinosinusitis (CRS) is a clinical syndrome defined by typical sinonasal symptoms persisting for at least 12 weeks. CRS is divided into two distinct phenotypes, CRS with nasal polyps (CRSwNP) and without (CRSsNP). The aim of the review is to provide an update on the current knowledge in CRS endotypes. The prevailing hypothesis regarding the pathogenesis of CRS suggests that dysfunctional interactions between the host and environmental stressors at the mucosal surface drive the diverse inflammatory mechanisms. Genetic and epigenetic variations in the mucosal immune system are believed to play a significant role in the pathomechanisms of CRS. Various environmental agents (such as microbes and irritants) have been implicated in CRS. In a healthy state, the sinonasal mucosa acts as a barrier, modulating environmental stimulation and mounting appropriate immune responses against pathogens with minimal tissue damage. Different endotypes may exist based on the specific mechanistic pathways driving the chronic tissue inflammation of CRS. There is a need to understand endotypes in order to better predict, diagnose, and treat CRS. This literature review provides an update on the role of the endotypes in CRS and the limitations of endotyping CRS in clinical practice. Understanding of the pathogenesis and optimal management of CRS has progressed significantly in the last decades; however, there still are several unmet needs in endotype research.</style></abstract><notes><style face="normal" font="default" size="100%">Toppila-Salmi, Sanna&#xD;Reitsma, Sietze&#xD;Hox, Valerie&#xD;Gane, Simon&#xD;Eguiluz-Gracia, Ibon&#xD;Shamji, Mohamed&#xD;Maza-Solano, Juan&#xD;Jaaskelainen, Benjamin&#xD;Vaara, Risto&#xD;Escribese, Maria M&#xD;Chaker, Adam&#xD;Karavelia, Aspasia&#xD;Rudenko, Michael&#xD;Gevaert, Philippe&#xD;Klimek, Ludger&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):132-147. doi: 10.1111/all.16418. Epub 2024 Dec 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39641584</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724251 GlaxoSmithKline, Novartis, Sanofi Pharma, OrionPharma, Roche Products, and grants from GlaxoSmithKline and Sanofi. All are outside the submitted work. SR has acted as a consultant and/or advisory board member for GSK, Sanofi/Regeneron, Novartis, and Boehringer Ingelheim. The department of otorhinolaryngology/head-neck surgery had received research grants from GSK, Sanofi/Regeneron, Novartis. All are outside the submitted work. JMS has received honoraria for consultancy, projects, advisory boards, and talks from AstraZeneca, GlaxoSmithKline, MSD, Novartis and Sanofi. VH Has received consultancy fees from ALK-Albello, GSK, Sanofi, and Astra-Zeneca outside of the submitted work. SG has acted as a consultant and/or advisory board member for Sanofi, GSK, and Novartis, outside of the submitted work. AMC reports consultancy or advisory fees and/or research support and other, all via Technical University of Munich from ALK-Abello, AstraZeneca, Bencard/Allergen Therapeutics, ASIT Biotech, GSK, Hippo Dx, Novartis, LETI, Roche, Sanofi, Regeneron, Zeller, grants from the Federal German Ministry of Education and Research, German Lung Center, and the European Institute of Technology, all outside this submitted work. PG reports personal fees and non-financial support from Stallergenes Greer during the conduct of the study. LK has received research grants from Allergy Therapeutics/Bencard, Great Britain/Germany; ALK-Abello, Denmark; Allergopharma, Germany; Aimmune, USA; ASIT Biotech, Belgium; AstraZeneca, Sweden; Bionorica, Germany; Biomay, Austria; Boehringer Ingelheim, Germany, Circassia, USA; Chiesi, Italy; Cytos, Switzerland; Curalogic, Denmark; HAL, Netherlands; Lofarma, Italy; Menarini, Italy; Viatris/Mylan, USA; Novartis, Switzerland; Leti, Spain; ROXALL, Germany; GlaxoSmithKline (GSK), Great Britain; Sanofi, France; Stallergenes, France; Thermofisher, USA; and/or has served on the speaker&apos;s bureau or was consulting for the above-mentioned pharmaceutical companies. LK is the current President of German Society of Allergology AeDA, Vice-President of the European Academy for Allergy and Clinical Immunology (EAACI), Vice-President of the German Academy for Allergy and Environmental Medicine, and Editor-in-Chief of AllergoJournal and AllergoJournal International. All are outside of the submitted work. All other authors declare no conflicts of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16418</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1540</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1540</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Satitsuksanoa, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Allergy Research Group, Medicine Department, Instituto de Investigacion Biomedica de Malaga-IBIMA, Universidad de Malaga-UMA, Malaga, Spain.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Engineered IL-10: A matter of affinity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1067-1069</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/10/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*CD8-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-10/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Il-10</style></keyword><keyword><style face="normal" font="default" size="100%">allergic disease</style></keyword><keyword><style face="normal" font="default" size="100%">biotechnology</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">tolerance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34626499</style></accession-num><abstract><style face="normal" font="default" size="100%">Pleiotropic roles of IL-10. Immune cells including regulatory T cells and B cells, ILCregs, macrophages, and DCs produce IL-10, which exerts both anti-inflammatory and pro-inflammatory effects. In an anti-inflammatory state, IL-10 suppresses inflammatory signals from several immune cells. In a pro-inflammatory state, IL-10 can induce CD8(+) T cells to release IFN-gamma and granzyme B. The underlying mechanism that defines anti-inflammatory and pro-inflammatory activities of IL-10 depends on the binding affinity of IL-10 to its receptors (IL-10Ralpha and IL-10Rbeta). The dimerization of the IL-10 complex activates STAT1/STAT3 and diversifies the biological effects of IL-10. In hindsight, high-affinity to IL-10Rbeta leads to both anti-inflammatory and pro-inflammatory activities while low-affinity to IL-10Rbeta only induces anti-inflammatory functions.</style></abstract><notes><style face="normal" font="default" size="100%">Fernandez-Santamaria, Ruben&#xD;Satitsuksanoa, Pattraporn&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1067-1069. doi: 10.1111/all.15132. Epub 2021 Oct 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34626499</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15132</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>877</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">877</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klein, M.</style></author><author><style face="normal" font="default" size="100%">Misme-Aucouturier, B.</style></author><author><style face="normal" font="default" size="100%">Cheminant, M. A.</style></author><author><style face="normal" font="default" size="100%">De Carvalho, M.</style></author><author><style face="normal" font="default" size="100%">Wauters, M.</style></author><author><style face="normal" font="default" size="100%">Tranquet, O.</style></author><author><style face="normal" font="default" size="100%">Magnan, A.</style></author><author><style face="normal" font="default" size="100%">Bouchaud, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite de Nantes, CNRS, INSERM, l&apos;institut du thorax, Nantes, France.&#xD;Biopolymeres Interactions Assemblages (BIA), INRAE, Nantes, France.&#xD;GZA Hospital &amp; Health Care, Antwerpen, Belgium.&#xD;Universite de Nantes, CHU Nantes, CNRS, INSERM, l&apos;institut du thorax, Nantes, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Engineering a safe monoclonal anti-human IL-2 that is effective in a murine model of food allergy and asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">933-945</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-2</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Il-2</style></keyword><keyword><style face="normal" font="default" size="100%">T lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">antibody</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">dendritic cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34324715</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Regulatory T cells (Tregs) are known to protect against allergies. Moreover, the decrease in the frequency and efficiency of Tregs amplifies allergic symptoms. AIM: This study investigated whether expanding Tregs in vivo with an IL-2/IL-2 antibody complex could be safe, well tolerated and efficient in a therapeutic setting in allergies. METHODS: We produced an anti-IL-2 antibody (1C6) and demonstrated that when it is complexed to human IL-2, it increases IL-2 efficiency to induce Tregs in vivo without any detectable side effects. Furthermore, the IL-2/1C6 complex induces an increase in Helios expression by Tregs, suggesting that it not only elevated Treg numbers but also boosted their functions. Using mouse models of house-dust-mite-induced airway inflammation and wheat-gliadin-induced food allergies, we investigated the therapeutic potential of the IL-2/1C6 complex in allergies. RESULTS: IL-2/1C6 treatment significantly reduced allergic symptoms, specific IgE production, the adaptive immune response and tissue damage. Interestingly, IL-2/1C6 treatment modulated innate lymphoid cells by increasing ILC2s in asthma and decreasing ILC3s in food allergies. CONCLUSION: In conclusion,complexed IL-2/anti-IL-2 may restore Treg numbers and function in respiratory and food allergies, thereby improving allergic markers and symptoms. Our IL-2/anti-IL-2 complex offers new hope for reestablishing immune tolerance in patients with allergies.</style></abstract><notes><style face="normal" font="default" size="100%">Klein, Martin&#xD;Misme-Aucouturier, Barbara&#xD;Cheminant, Marie-Aude&#xD;De Carvalho, Marion&#xD;Wauters, Marie&#xD;Tranquet, Olivier&#xD;Magnan, Antoine&#xD;Bouchaud, Gregory&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):933-945. doi: 10.1111/all.15029. Epub 2021 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34324715</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15029</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2720</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2720</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bordas-Le Floch, V.</style></author><author><style face="normal" font="default" size="100%">Heider, A.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Luce, S.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Mascarell, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Innovation and Science Department, Stallergenes Greer, Antony, France.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Enhanced benefit from house dust mite immunotherapy in subjects with low serum levels of LILRA5 or CCL25</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">878-881</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/11/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">AIT efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite</style></keyword><keyword><style face="normal" font="default" size="100%">serum markers</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39520177</style></accession-num><notes><style face="normal" font="default" size="100%">Bordas-Le Floch, Veronique&#xD;Heider, Anja&#xD;Yazici, Duygu&#xD;Luce, Sonia&#xD;Akdis, Cezmi A&#xD;Mascarell, Laurent&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):878-881. doi: 10.1111/all.16386. Epub 2024 Nov 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39520177</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16386</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1241</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1241</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soleto, I.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author><author><style face="normal" font="default" size="100%">Carrasco, Y. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology &amp; Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;Department of Pathology &amp; Molecular Medicine, McMaster Immunology Research Centre (MIRC), McMaster University, Hamilton, ON, Canada.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Enlightening human B-cell diversity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2644-2646</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/12/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Genomics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">B cells</style></keyword><keyword><style face="normal" font="default" size="100%">cell atlas</style></keyword><keyword><style face="normal" font="default" size="100%">mass cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">multi-omic</style></keyword><keyword><style face="normal" font="default" size="100%">single cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33289101</style></accession-num><notes><style face="normal" font="default" size="100%">Soleto, Irene&#xD;Jimenez-Saiz, Rodrigo&#xD;Carrasco, Yolanda R&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2644-2646. doi: 10.1111/all.14685. Epub 2020 Dec 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33289101</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14685</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1554</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1554</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soleto, I.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author><author><style face="normal" font="default" size="100%">Carrasco, Y. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology &amp; Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;Department of Pathology &amp; Molecular Medicine, McMaster Immunology Research Centre (MIRC), McMaster University, Hamilton, ON, Canada.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Enlightening human B-cell diversity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2644-2646</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/12/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Genomics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">B cells</style></keyword><keyword><style face="normal" font="default" size="100%">cell atlas</style></keyword><keyword><style face="normal" font="default" size="100%">mass cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">multi-omic</style></keyword><keyword><style face="normal" font="default" size="100%">single cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33289101</style></accession-num><notes><style face="normal" font="default" size="100%">Soleto, Irene&#xD;Jimenez-Saiz, Rodrigo&#xD;Carrasco, Yolanda R&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2644-2646. doi: 10.1111/all.14685. Epub 2020 Dec 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33289101</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14685</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>748</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">748</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adjibade, M.</style></author><author><style face="normal" font="default" size="100%">Davisse-Paturet, C.</style></author><author><style face="normal" font="default" size="100%">Bernard, J. Y.</style></author><author><style face="normal" font="default" size="100%">Adel-Patient, K.</style></author><author><style face="normal" font="default" size="100%">Divaret-Chauveau, A.</style></author><author><style face="normal" font="default" size="100%">Lioret, S.</style></author><author><style face="normal" font="default" size="100%">Charles, M. A.</style></author><author><style face="normal" font="default" size="100%">de Lauzon-Guillain, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite de Paris, CRESS, Inserm, INRAE, Paris, France.&#xD;Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.&#xD;Universite Paris-Saclay, CEA, INRAE, DMTS, Gif-sur-Yvette, France.&#xD;EA3450, Universite de Lorraine, Vandoeuvre-les-Nancy, France.&#xD;Unite d&apos;allergologie pediatrique, Hopital d&apos;Enfants, CHRU de Nancy, Vandoeuvre-les-Nancy, France.&#xD;Unite mixte Inserm-Ined-EFS Elfe, Ined, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Enrichment of infant formula with long-chain polyunsaturated fatty acids and risk of infection and allergy in the nationwide ELFE birth cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1522-1533</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/10/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Arachidonic Acid</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Birth Cohort</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Docosahexaenoic Acids/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acids</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant Formula/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">LCPUFA enrichment</style></keyword><keyword><style face="normal" font="default" size="100%">allergies</style></keyword><keyword><style face="normal" font="default" size="100%">infant formula</style></keyword><keyword><style face="normal" font="default" size="100%">infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34626486</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The new European regulations require the enrichment of formulas with docosahexaenoic acid (DHA) because of the positive effects of long-chain polyunsaturated fatty acids (LCPUFAs) on neurodevelopment and visual acuity. In this observational study, we aimed to evaluate whether the consumption of LCPUFA-enriched formula was associated with the risk of infection and allergy in early childhood. METHODS: Analyses involved data from 8389 formula-fed infants from the ELFE birth cohort. Formula enrichment was identified from the list of ingredients of the formula consumed at 2 months. Infections (gastrointestinal, lower respiratory tract [LRTI], upper respiratory tract) and allergies (wheezing, itchy rash, asthma medication, food allergy) from age 2 months to 5.5 years were reported by parents during follow-up surveys. Multivariable logistic regression models were used to assess associations between the consumption of LCPUFA-enriched formula and the risk of infection and allergy. RESULTS: Among formula-fed infants at 2 months, 36% consumed formula enriched with DHA and arachidonic acid (ARA), and 11% consumed formula additionally enriched with eicosapentaenoic acid (EPA). Enriched formula consumption was not associated with infection or allergy, except for an association between consumption of DHA/ARA/EPA-enriched formula and lower use of asthma medications. Furthermore, as compared with non-DHA/ARA/EPA-enriched formula, consumption of formula with high EPA content (&gt;/=3.2 mg/100 kcal) was related to lower risk of LRTI and lower use of asthma medications. CONCLUSION: This study suggests that consumption of DHA/ARA/EPA-enriched formula (especially those with high EPA content) is associated with a lower risk of LRTI and lower use of asthma medications.</style></abstract><notes><style face="normal" font="default" size="100%">Adjibade, Moufidath&#xD;Davisse-Paturet, Camille&#xD;Bernard, Jonathan Y&#xD;Adel-Patient, Karine&#xD;Divaret-Chauveau, Amandine&#xD;Lioret, Sandrine&#xD;Charles, Marie-Aline&#xD;de Lauzon-Guillain, Blandine&#xD;eng&#xD;Observational Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1522-1533. doi: 10.1111/all.15137. Epub 2021 Oct 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34626486</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15137</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pessina, B.</style></author><author><style face="normal" font="default" size="100%">Guarnieri, V.</style></author><author><style face="normal" font="default" size="100%">Scarallo, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Health Sciences, Anna Meyer Children&apos;s University Hospital, Florence, Italy.&#xD;Gastroenterology and Nutrition Unit, Anna Meyer Children&apos;s University Hospital, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Entering the era of phage therapy: A &apos;happy hour&apos; for inflammatory bowel diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">889-891</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/01/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Phage Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammatory Bowel Diseases/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36600597</style></accession-num><notes><style face="normal" font="default" size="100%">Pessina, Benedetta&#xD;Guarnieri, Valentina&#xD;Scarallo, Luca&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):889-891. doi: 10.1111/all.15636. Epub 2023 Jan 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36600597</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15636</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1530</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1530</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pessina, B.</style></author><author><style face="normal" font="default" size="100%">Guarnieri, V.</style></author><author><style face="normal" font="default" size="100%">Scarallo, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Health Sciences, Anna Meyer Children&apos;s University Hospital, Florence, Italy.&#xD;Gastroenterology and Nutrition Unit, Anna Meyer Children&apos;s University Hospital, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Entering the era of phage therapy: A &apos;happy hour&apos; for inflammatory bowel diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">889-891</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/01/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Phage Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammatory Bowel Diseases/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36600597</style></accession-num><notes><style face="normal" font="default" size="100%">Pessina, Benedetta&#xD;Guarnieri, Valentina&#xD;Scarallo, Luca&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):889-891. doi: 10.1111/all.15636. Epub 2023 Jan 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36600597</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15636</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>958</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">958</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lunjani, N.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Dreher, A.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Groeger, D.</style></author><author><style face="normal" font="default" size="100%">Warwyzniak, M.</style></author><author><style face="normal" font="default" size="100%">Altunbulakli, C.</style></author><author><style face="normal" font="default" size="100%">Westermann, P.</style></author><author><style face="normal" font="default" size="100%">Basera, W.</style></author><author><style face="normal" font="default" size="100%">Hobane, L.</style></author><author><style face="normal" font="default" size="100%">Botha, M.</style></author><author><style face="normal" font="default" size="100%">Gray, C.</style></author><author><style face="normal" font="default" size="100%">Mankahla, A.</style></author><author><style face="normal" font="default" size="100%">Gray, C.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Hlela, C.</style></author><author><style face="normal" font="default" size="100%">Levin, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF, University of Zurich, Davos, Switzerland.&#xD;Department of Dermatology, University of Cape Town, Cape Town, South Africa.&#xD;APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Functional Genomics Center, University of Zurich, Zurich, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;PrecisionBiotics Ltd, Cork, Ireland.&#xD;Division of Paediatric Allergy, Department of Paediatrics and Child Health, University of Cape Town, South Africa.&#xD;The Division of Dermatology, Department of Medicine and Pharmacology, Walter Sisulu University, Eastern Cape, South Africa.&#xD;Division of Immunology, University of Cape Town, Cape Town, South Africa.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA, USA.&#xD;Department of Medicine, University College Cork, Cork, Ireland.&#xD;School of Microbiology, University College Cork, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Environment-dependent alterations of immune mediators in urban and rural South African children with atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">569-581</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Placenta Growth Factor</style></keyword><keyword><style face="normal" font="default" size="100%">Rural Population</style></keyword><keyword><style face="normal" font="default" size="100%">South Africa/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">personalized medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34086351</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In order to improve targeted therapeutic approaches for children with atopic dermatitis (AD), novel insights into the molecular mechanisms and environmental exposures that differentially contribute to disease phenotypes are required. We wished to identify AD immunological endotypes in South African children from rural and urban environments. METHODS: We measured immunological, socio-economic and environmental factors in healthy children (n = 74) and children with AD (n = 78), in rural and urban settings from the same ethno-linguistic AmaXhosa background in South Africa. RESULTS: Circulating eosinophils, monocytes, TARC, MCP-4, IL-16 and allergen-specific IgE levels were elevated, while IL-17A and IL-23 levels were reduced, in children with AD regardless of their location. Independent of AD, children living in a rural environment had the highest levels of TNFalpha, TNFbeta, IL-1alpha, IL-6, IL-8, IL-21, MCP-1, MIP-1alpha, MIP-1beta, MDC, sICAM1, sVCAM1, VEGFA, VEGFD and Tie2, suggesting a generalized microinflammation or a pattern of trained immunity without any specific T(H) polarization. In contrast, IL-15, IL-22, Flt1, PIGF and betaFGF were highest in urban children. Rural healthy children had the lowest levels of food allergen-specific IgG4. Early life nutritional factors, medications, animal exposures, indoor environment, sunlight exposure, household size, household income and parental education levels were associated with differences in circulating cytokine levels. CONCLUSIONS: This study highlights the immunological impact of environmental exposures and socio-economic status in the manifestation of immune endotypes in children with AD living in urban and rural areas, which are important in selecting appropriately matched immunological therapies for treatment of AD.</style></abstract><notes><style face="normal" font="default" size="100%">Lunjani, Nonhlanhla&#xD;Tan, Ge&#xD;Dreher, Anita&#xD;Sokolowska, Milena&#xD;Groeger, David&#xD;Warwyzniak, Marcin&#xD;Altunbulakli, Can&#xD;Westermann, Patrick&#xD;Basera, Wisdom&#xD;Hobane, Lelani&#xD;Botha, Maresa&#xD;Gray, Claudia&#xD;Mankahla, Avumile&#xD;Gray, Clive&#xD;Nadeau, Kari C&#xD;Hlela, Carol&#xD;Levin, Michael&#xD;O&apos;Mahony, Liam&#xD;Akdis, Cezmi A&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):569-581. doi: 10.1111/all.14974. Epub 2021 Jun 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34086351</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14974</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2105</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2105</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bayram, H.</style></author><author><style face="normal" font="default" size="100%">Rastgeldi Dogan, T.</style></author><author><style face="normal" font="default" size="100%">Sahin, U. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Koc University Research Centre for Translational Medicine (KUTTAM), Koc University, Istanbul, Turkey.&#xD;Department of Pulmonary Medicine, School of Medicine, Koc University, Istanbul, Turkey.&#xD;Department of Environmental Engineering, Faculty of Engineering, Harran University, Sanliurfa, Turkey.&#xD;Department of Environmental Engineering, Faculty of Engineering, Istanbul University-Cerrahpasa, Istanbul, Turkey.&#xD;Swiss Institute of Allergy and Asthma Research, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Environmental and health hazards by massive earthquakes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2081-2084</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/04/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Earthquakes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37026989</style></accession-num><notes><style face="normal" font="default" size="100%">Bayram, Hasan&#xD;Rastgeldi Dogan, Tuba&#xD;Sahin, Ulku Alver&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2081-2084. doi: 10.1111/all.15736. Epub 2023 Jun 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37026989</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15736</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2433</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2433</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Nasal Diseases, Beijing Laboratory of Allergic Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Environmental exposures drive the development of allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1081-1084</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/03/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38534020</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Luo&#xD;Akdis, Cezmi A&#xD;eng&#xD;2022YFC2504100/National Key R&amp;amp;D Program of China/&#xD;IRT13082/Program for Changjiang Scholars and Innovative Research Team/&#xD;JYY2023-1/Beijing municipal public welfare development and reform pilot project for medical research institutes/&#xD;Editorial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1081-1084. doi: 10.1111/all.16112. Epub 2024 Mar 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38534020</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16112</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1181</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fukuda, A.</style></author><author><style face="normal" font="default" size="100%">Toyoshima, S.</style></author><author><style face="normal" font="default" size="100%">Yamada, S.</style></author><author><style face="normal" font="default" size="100%">Kurosawa, Y.</style></author><author><style face="normal" font="default" size="100%">Okayama, Y.</style></author><author><style face="normal" font="default" size="100%">Maruoka, S.</style></author><author><style face="normal" font="default" size="100%">Gon, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Division of Respiratory Medicine, Nihon University School of Medicine, Tokyo, Japan.&#xD;Center for Allergy, Nihon University Itabashi Hospital, Tokyo, Japan.&#xD;Allergy and Immunology Research Project Team, Center for Medical Education, Nihon University School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Enzymatic activity of ACE2 regulates type 2 airway inflammation in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1913-1917</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/02/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">*Peptidyl-Dipeptidase A/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33521968</style></accession-num><notes><style face="normal" font="default" size="100%">Fukuda, Asami&#xD;Toyoshima, Shota&#xD;Yamada, Shiho&#xD;Kurosawa, Yusuke&#xD;Okayama, Yoshimichi&#xD;Maruoka, Shuichiro&#xD;Gon, Yasuhiro&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1913-1917. doi: 10.1111/all.14754. Epub 2021 Mar 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33521968</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8013183</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14754</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1420</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1420</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, L.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y. P.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Heart Center &amp; Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.&#xD;Department of Nephrology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R., China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Eosinopenia is associated with greater severity in patients with coronavirus disease 2019</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">562-564</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/06/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Agranulocytosis/*blood/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">infections</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32544252</style></accession-num><notes><style face="normal" font="default" size="100%">Zhao, Lei&#xD;Zhang, Ye-Ping&#xD;Yang, Xinchun&#xD;Liu, Xin&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):562-564. doi: 10.1111/all.14455. Epub 2020 Jul 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32544252</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7323424</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14455</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1643</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1643</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, Y.</style></author><author><style face="normal" font="default" size="100%">Kim, Y. M.</style></author><author><style face="normal" font="default" size="100%">Lee, H. R.</style></author><author><style face="normal" font="default" size="100%">Mun, J.</style></author><author><style face="normal" font="default" size="100%">Sim, S.</style></author><author><style face="normal" font="default" size="100%">Lee, D. H.</style></author><author><style face="normal" font="default" size="100%">Pham, D. L.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Shin, Y. S.</style></author><author><style face="normal" font="default" size="100%">Lee, S. W.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.&#xD;Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, Korea.&#xD;MD Healthcare Inc., Seoul, Korea.&#xD;Clinical Trial Center, Ajou University Medical Center, Suwon, Korea.&#xD;Faculty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh, Viet Nam.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Eosinophil extracellular traps activate type 2 innate lymphoid cells through stimulating airway epithelium in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">95-103</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2019/07/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Extracellular Traps/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Subsets/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Mucosa/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">extracellular traps</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cells</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31330043</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Activated eosinophils release extracellular traps (EETs), which contribute to airway inflammation in severe asthma (SA). However, the role of EETs in innate immunity has not yet been completely determined. The present study aimed to demonstrate the mechanism of airway inflammation in SA mediated by EETs. METHODS: Peripheral counts of EET(+) eosinophils and type 2 innate lymphoid cells (ILC2s) were evaluated in patients with SA (n = 13), nonsevere asthma (NSA, n = 17), and healthy control subjects (HC, n = 8). To confirm the effect of EETs, airway hyperresponsiveness (AHR) and adapted/innate immune responses were assessed in mice. Furthermore, the effects of anti-IL-33/TSLP antibody were tested. RESULTS: The numbers of EET(+) eosinophils and ILC2s were significantly elevated in SA, with a positive correlation between these two cells (r = .539, P &lt; .001). When mice were injected with EETs, we observed significant increases in epithelium-derived cytokines (IL-1alpha, IL-1beta, CXCL-1, CCL24, IL-33, and TSLP) and eosinophil/neutrophil count in bronchoalveolar lavage fluid (BALF) as well as an increased proportion of IL-5- or IL-13-producing ILC2s in the lungs. When Rag1(-/-) mice receiving ILC2s were treated with EETs, increased AHR and IL-5/IL-13 levels in BALF were noted, which were effectively suppressed by anti-IL-33 or anti-TSLP antibody. CONCLUSION: EETs could enhance innate and type 2 immune responses in SA, in which epithelium-targeting biologics (anti-IL-33/TSLP antibody) may have a potential benefit.</style></abstract><notes><style face="normal" font="default" size="100%">Choi, Youngwoo&#xD;Kim, Young-Min&#xD;Lee, Hee-Ra&#xD;Mun, Jiyeong&#xD;Sim, Soyoon&#xD;Lee, Dong-Hyun&#xD;Pham, Duy Le&#xD;Kim, Seung-Hyun&#xD;Shin, Yoo Seob&#xD;Lee, Seung-Woo&#xD;Park, Hae-Sim&#xD;eng&#xD;HI14C2628/Korean Health Technology R &amp;amp; D Project, Ministry of Health &amp;amp; Welfare, Republic of Korea/International&#xD;NRF-2017R1A5A1015366/The National Research Foundation of Korea (NRF), Korea Government (MSIT)/International&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Jan;75(1):95-103. doi: 10.1111/all.13997. Epub 2019 Nov 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31330043</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13997</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2173</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2173</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, W. W. L.</style></author><author><style face="normal" font="default" size="100%">Puan, K. J.</style></author><author><style face="normal" font="default" size="100%">Lee, B.</style></author><author><style face="normal" font="default" size="100%">Chua, C.</style></author><author><style face="normal" font="default" size="100%">Koh, S. M.</style></author><author><style face="normal" font="default" size="100%">Yusof, N.</style></author><author><style face="normal" font="default" size="100%">Tan, K. P.</style></author><author><style face="normal" font="default" size="100%">Luis, B. S.</style></author><author><style face="normal" font="default" size="100%">Ong, J.</style></author><author><style face="normal" font="default" size="100%">Merid, S. K.</style></author><author><style face="normal" font="default" size="100%">Ang, R.</style></author><author><style face="normal" font="default" size="100%">Chan, X. Y.</style></author><author><style face="normal" font="default" size="100%">Hui, L. J.</style></author><author><style face="normal" font="default" size="100%">Terenzani, E.</style></author><author><style face="normal" font="default" size="100%">Lum, J.</style></author><author><style face="normal" font="default" size="100%">Foo, S.</style></author><author><style face="normal" font="default" size="100%">Zolezzi, F.</style></author><author><style face="normal" font="default" size="100%">Yan, A. T. S.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Yi, S. J.</style></author><author><style face="normal" font="default" size="100%">Rotzschke, O.</style></author><author><style face="normal" font="default" size="100%">Andiappan, A. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.&#xD;Shanghai Junshi Biosciences Co Ltd, Shanghai, China.&#xD;Centre for Biomedical Informatics, Nanyang Technological University, Singapore, Singapore.&#xD;Institute of Molecular and Cell Biology (IMCB) A*STAR, Proteos, Singapore, Singapore.&#xD;Department of Clinical Science and Education Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Otolaryngology, National University Hospital, Singapore, Singapore.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Department of Paediatrics, Sachs&apos; Children&apos;s Hospital, Stockholm, Sweden.&#xD;Department of Paediatrics, National University Hospital, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Eosinophilic allergic rhinitis is strongly associated with the CD45RB(lo) subset of CD161(+) Th2 cells that secretes IL-2, IL-3, IL-4, IL-5, IL-9, and IL-13</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2794-2798</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-2</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-3</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-5</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-9/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Th1 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Leukocyte Common Antigens</style></keyword><keyword><style face="normal" font="default" size="100%">NK Cell Lectin-Like Receptor Subfamily B</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37551093</style></accession-num><notes><style face="normal" font="default" size="100%">Lee, Wendy W L&#xD;Puan, Kia Joo&#xD;Lee, Bernett&#xD;Chua, Celine&#xD;Koh, Ser Mei&#xD;Yusof, Nurhashikin&#xD;Tan, Kim Peng&#xD;Luis, Boris San&#xD;Ong, Jocelyn&#xD;Merid, Simon Kebede&#xD;Ang, Rachel&#xD;Chan, Xue Ying&#xD;Hui, Low Jing&#xD;Terenzani, Elisa&#xD;Lum, Josephine&#xD;Foo, Shihui&#xD;Zolezzi, Francesca&#xD;Yan, Annabelle Tay Sok&#xD;Melen, Erik&#xD;Yi, Soh Jian&#xD;Rotzschke, Olaf&#xD;Andiappan, Anand Kumar&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2794-2798. doi: 10.1111/all.15846. Epub 2023 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37551093</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15846</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2320</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2320</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caminati, M.</style></author><author><style face="normal" font="default" size="100%">Fassio, A.</style></author><author><style face="normal" font="default" size="100%">Alberici, F.</style></author><author><style face="normal" font="default" size="100%">Baldini, C.</style></author><author><style face="normal" font="default" size="100%">Bello, F.</style></author><author><style face="normal" font="default" size="100%">Cameli, P.</style></author><author><style face="normal" font="default" size="100%">Conticini, E.</style></author><author><style face="normal" font="default" size="100%">Cottin, V.</style></author><author><style face="normal" font="default" size="100%">Crimi, C.</style></author><author><style face="normal" font="default" size="100%">Dagna, L.</style></author><author><style face="normal" font="default" size="100%">Delvino, P.</style></author><author><style face="normal" font="default" size="100%">Deroux, A.</style></author><author><style face="normal" font="default" size="100%">Duran, E.</style></author><author><style face="normal" font="default" size="100%">Espigol-Frigole, G.</style></author><author><style face="normal" font="default" size="100%">Karadag, O.</style></author><author><style face="normal" font="default" size="100%">Maule, M.</style></author><author><style face="normal" font="default" size="100%">Moiseev, S.</style></author><author><style face="normal" font="default" size="100%">Monti, S.</style></author><author><style face="normal" font="default" size="100%">Moroni, L.</style></author><author><style face="normal" font="default" size="100%">Padoan, R.</style></author><author><style face="normal" font="default" size="100%">Pugnet, G.</style></author><author><style face="normal" font="default" size="100%">Taille, C.</style></author><author><style face="normal" font="default" size="100%">Toniati, P.</style></author><author><style face="normal" font="default" size="100%">Vaglio, A.</style></author><author><style face="normal" font="default" size="100%">Emmi, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Asthma Center and Allergy Unit, Department of Medicine, University and Integrated University Hospital of Verona, Verona, Italy.&#xD;Rheumatology Unit, Department of Medicine, University of Verona and Verona University Hospital, Verona, Italy.&#xD;Nephrology Unit, University of Brescia, Azienda Socio Sanitaria Territoriale Spedali Civili, Brescia, Italy.&#xD;Department of Internal Medicine, U.O. Rheumatology, University of Pisa, Pisa, Italy.&#xD;Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.&#xD;Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.&#xD;Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.&#xD;Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France.&#xD;Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.&#xD;Respiratory Medicine Unit, AOU Policlinico &quot;G. Rodolico-San Marco&quot;, Catania, Italy.&#xD;Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Vita-Salute San Raffaele University and San Raffaele Hospital, Milan, Italy.&#xD;Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.&#xD;Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.&#xD;Departement of Internal Medicine, CHU Grenoble-Alpes, Grenoble, France.&#xD;Division of Rheumatology, Department of Internal Medicine, Vasculitis Research Center, Hacettepe University School of Medicine, Ankara, Turkey.&#xD;Department of Autoimmune Diseases, Hospital Clinic, Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.&#xD;Allergy Unit and Asthma Center, Verona University Hospital, Verona, Italy.&#xD;Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Division of Rheumatology, Department of Medicine, University of Padova, Padova, Italy.&#xD;Service de Medecine Interne et Immunologie Clinique, CHU Rangueil, Toulouse, France.&#xD;Respiratory Diseases Department, Rare Pulmonary Diseases Reference Centre, Bichat Hospital, Paris Cite University, Paris, France.&#xD;Rheumatology and Clinical Immunology Unit, ASST Spedali Civili Brescia, Brescia, Italy.&#xD;Nephrology and Dialysis Unit, Meyer Children&apos;s University Hospital - IRCCS, Firenze, Italy.&#xD;Department of Biomedical, Experimental and Clinical Sciences &quot;Mario Serio&quot;, University of Firenze, Firenze, Italy.&#xD;Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">516-519</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/10/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal</style></keyword><keyword><style face="normal" font="default" size="100%">*Churg-Strauss Syndrome/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Granulomatosis with Polyangiitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Egpa</style></keyword><keyword><style face="normal" font="default" size="100%">T2 inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">benralizumab</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic granulomatosis with polyangiitis</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">monoclonal antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">reslizumab</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37904674</style></accession-num><notes><style face="normal" font="default" size="100%">Caminati, Marco&#xD;Fassio, Angelo&#xD;Alberici, Federico&#xD;Baldini, Chiara&#xD;Bello, Federica&#xD;Cameli, Paolo&#xD;Conticini, Edoardo&#xD;Cottin, Vincent&#xD;Crimi, Claudia&#xD;Dagna, Lorenzo&#xD;Delvino, Paolo&#xD;Deroux, Alban&#xD;Duran, Emine&#xD;Espigol-Frigole, Georgina&#xD;Karadag, Omer&#xD;Maule, Matteo&#xD;Moiseev, Sergey&#xD;Monti, Sara&#xD;Moroni, Luca&#xD;Padoan, Roberto&#xD;Pugnet, Gregory&#xD;Taille, Camille&#xD;Toniati, Paola&#xD;Vaglio, Augusto&#xD;Emmi, Giacomo&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):516-519. doi: 10.1111/all.15934. Epub 2023 Oct 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37904674</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15934</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>966</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">966</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lommatzsch, M.</style></author><author><style face="normal" font="default" size="100%">Stoll, P.</style></author><author><style face="normal" font="default" size="100%">Winkler, J.</style></author><author><style face="normal" font="default" size="100%">Zeise-Wehry, D.</style></author><author><style face="normal" font="default" size="100%">Tronnier, M.</style></author><author><style face="normal" font="default" size="100%">Weber, M. A.</style></author><author><style face="normal" font="default" size="100%">Virchow, J. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.&#xD;Outpatient Clinic for Pneumology and Allergology, Leipzig, Germany.&#xD;Stroke Unit, Department of Neurology, Helios-Klinikum Berlin-Buch, Berlin, Germany.&#xD;Department of Dermatology, Helios-Klinikum Hildesheim, Hildesheim, Germany.&#xD;Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, University of Rostock, Rostock, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab-induced hypereosinophilia</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2920-2923</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pleural Effusion</style></keyword><keyword><style face="normal" font="default" size="100%">*Stroke</style></keyword><keyword><style face="normal" font="default" size="100%">*Vasculitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34047387</style></accession-num><notes><style face="normal" font="default" size="100%">Lommatzsch, Marek&#xD;Stoll, Paul&#xD;Winkler, Jorg&#xD;Zeise-Wehry, Daniel&#xD;Tronnier, Michael&#xD;Weber, Marc-Andre&#xD;Virchow, J Christian&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2920-2923. doi: 10.1111/all.14964. Epub 2021 Jun 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34047387</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14964</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>995</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">995</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prenzler, F.</style></author><author><style face="normal" font="default" size="100%">Tschernig, T.</style></author><author><style face="normal" font="default" size="100%">Sewald, K.</style></author><author><style face="normal" font="default" size="100%">Veres, T. Z.</style></author><author><style face="normal" font="default" size="100%">Rittinghausen, S.</style></author><author><style face="normal" font="default" size="100%">Krug, N.</style></author><author><style face="normal" font="default" size="100%">Hohlfeld, J. M.</style></author><author><style face="normal" font="default" size="100%">Braun, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.&#xD;Institute for Cell Biology and Anatomy, Saarland University, Saarbrucken, Germany.&#xD;Member of the German Center for Lung Research (DZL), Biomedical Research in End-stage and Obstructive Lung Disease (BREATH) research network, Hannover, Germany.&#xD;Lymphocyte Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.&#xD;Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.&#xD;Institute of Immunology, Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Eosinophils and activation markers after allergen challenge - a pilot study for three-dimensional analysis in the bronchial mucosa</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2907-2910</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchi/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">*Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchial Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mucous Membrane</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">interleukins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33999418</style></accession-num><notes><style face="normal" font="default" size="100%">Prenzler, Frauke&#xD;Tschernig, Thomas&#xD;Sewald, Katherina&#xD;Veres, Tibor Z&#xD;Rittinghausen, Susanne&#xD;Krug, Norbert&#xD;Hohlfeld, Jens M&#xD;Braun, Armin&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2907-2910. doi: 10.1111/all.14909. Epub 2021 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33999418</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14909</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2123</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2123</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gigon, L.</style></author><author><style face="normal" font="default" size="100%">Fettrelet, T.</style></author><author><style face="normal" font="default" size="100%">Yousefi, S.</style></author><author><style face="normal" font="default" size="100%">Simon, D.</style></author><author><style face="normal" font="default" size="100%">Simon, H. U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pharmacology, University of Bern, Bern, Switzerland.&#xD;Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Institute of Biochemistry, Brandenburg Medical School, Neuruppin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Eosinophils from A to Z</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1810-1846</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/04/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Italy</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil subsets</style></keyword><keyword><style face="normal" font="default" size="100%">eosinopoiesis</style></keyword><keyword><style face="normal" font="default" size="100%">immunoregulation</style></keyword><keyword><style face="normal" font="default" size="100%">tissue homeostasis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37102676</style></accession-num><abstract><style face="normal" font="default" size="100%">Eosinophils are bone marrow-derived granulocytes and are found in low numbers in the peripheral blood of healthy subjects. In type 2 inflammatory diseases, eosinopoiesis in the bone marrow is increased, resulting in a rise in the number of mature eosinophils released in the circulation. From the blood, eosinophils can migrate in multiple tissues and organs under both physiological and pathological conditions. Eosinophils exert their various functions through the synthesis and release of a variety of granule proteins and pro-inflammatory mediators. Despite being present in all species of vertebrates, the functional role of eosinophils is still a matter of debate. Eosinophils may play a role in host defense against various pathogens. In addition, eosinophils have been reported to be involved in tissue homeostasis and exhibit immunomodulatory activities. In this review, we aim to provide a broad overview of eosinophil biology and eosinophilic diseases in a lexicon-style format using keywords starting from A until Z with cross-references to other chapters indicated in italics in the text or specified in parentheses.</style></abstract><notes><style face="normal" font="default" size="100%">Gigon, Lea&#xD;Fettrelet, Timothee&#xD;Yousefi, Shida&#xD;Simon, Dagmar&#xD;Simon, Hans-Uwe&#xD;eng&#xD;Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1810-1846. doi: 10.1111/all.15751. Epub 2023 May 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37102676</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15751</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2249</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2249</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jesenak, M.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author><author><style face="normal" font="default" size="100%">Simon, D.</style></author><author><style face="normal" font="default" size="100%">Tufvesson, E.</style></author><author><style face="normal" font="default" size="100%">Seys, S. F.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Lacy, P.</style></author><author><style face="normal" font="default" size="100%">Vijverberg, S.</style></author><author><style face="normal" font="default" size="100%">Slisz, T.</style></author><author><style face="normal" font="default" size="100%">Sediva, A.</style></author><author><style face="normal" font="default" size="100%">Simon, H. U.</style></author><author><style face="normal" font="default" size="100%">Striz, I.</style></author><author><style face="normal" font="default" size="100%">Plevkova, J.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Kosturiak, R.</style></author><author><style face="normal" font="default" size="100%">Alexis, N. E.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Vasakova, M. K.</style></author><author><style face="normal" font="default" size="100%">Knol, E.</style></author><author><style face="normal" font="default" size="100%">Koenderman, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Immunology and Allergology, University Teaching Hospital in Martin, Martin, Slovak Republic.&#xD;Department of Paediatrics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Teaching Hospital in Martin, Martin, Slovak Republic.&#xD;Department of Pulmonology and Phthisiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Teaching Hospital in Martin, Martin, Slovak Republic.&#xD;Department of Clinical Sciences Lund, Respiratory Medicine, Allergology and Palliative Medicine, Lund University, Lund, Sweden.&#xD;Department Microbiology Immunology &amp; Transplantation, KU Leuven, Catholic University of Leuven, Leuven, Belgium.&#xD;Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.&#xD;Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.&#xD;Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;The Firestone Institute for Respiratory Health, Research Institute of St. Joe&apos;s Hamilton, Hamilton, Ontario, Canada.&#xD;Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.&#xD;Amsterdam UMC Location University of Amsterdam, Pulmonary Diseases, Amsterdam, The Netherlands.&#xD;Department of Immunology, 2nd Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic.&#xD;Institute of Pharmacology, University of Bern, Bern, Switzerland.&#xD;Institute of Biochemistry, Brandenburg Medical School, Neuruppin, Germany.&#xD;Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.&#xD;Department of Pathophysiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.&#xD;Child Life and Health and Centre for Inflammation Research, The Queen&apos;s Medical Research Institute, University of Edinburgh, Edinburgh, UK.&#xD;Outpatient Clinic for Clinical Immunology and Allergology, Nitra, Slovak Republic.&#xD;Center for Environmental Medicine, Asthma and Lung Biology, Department of Paediatrics, University of North Carolina, Chapel Hill, North Carolina, USA.&#xD;Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department Center of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Department Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Department Pulmonary Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Eosinophils-from cradle to grave: An EAACI task force paper on new molecular insights and clinical functions of eosinophils and the clinical effects of targeted eosinophil depletion</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3077-3102</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/09/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">non-allergic diseases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37702095</style></accession-num><abstract><style face="normal" font="default" size="100%">Over the past years, eosinophils have become a focus of scientific interest, especially in the context of their recently uncovered functions (e.g. antiviral, anti-inflammatory, regulatory). These versatile cells display both beneficial and detrimental activities under various physiological and pathological conditions. Eosinophils are involved in the pathogenesis of many diseases which can be classified into primary (clonal) and secondary (reactive) disorders and idiopathic (hyper)eosinophilic syndromes. Depending on the biological specimen, the eosinophil count in different body compartments may serve as a biomarker reflecting the underlying pathophysiology and/or activity of distinct diseases and as a therapy-driving (predictive) and monitoring tool. Personalized selection of an appropriate therapeutic strategy directly or indirectly targeting the increased number and/or activity of eosinophils should be based on the understanding of eosinophil homeostasis including their interactions with other immune and non-immune cells within different body compartments. Hence, restoring as well as maintaining homeostasis within an individual&apos;s eosinophil pool is a goal of both specific and non-specific eosinophil-targeting therapies. Despite the overall favourable safety profile of the currently available anti-eosinophil biologics, the effect of eosinophil depletion should be monitored from the perspective of possible unwanted consequences.</style></abstract><notes><style face="normal" font="default" size="100%">Jesenak, Milos&#xD;Diamant, Zuzana&#xD;Simon, Dagmar&#xD;Tufvesson, Ellen&#xD;Seys, Sven F&#xD;Mukherjee, Manali&#xD;Lacy, Paige&#xD;Vijverberg, Susanne&#xD;Slisz, Tomas&#xD;Sediva, Anna&#xD;Simon, Hans-Uwe&#xD;Striz, Ilja&#xD;Plevkova, Jana&#xD;Schwarze, Jurgen&#xD;Kosturiak, Radovan&#xD;Alexis, Neil E&#xD;Untersmayr, Eva&#xD;Vasakova, Martina Koziar&#xD;Knol, Edward&#xD;Koenderman, Leo&#xD;eng&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3077-3102. doi: 10.1111/all.15884. Epub 2023 Sep 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37702095</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15884</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>956</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">956</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suzuki, Y.</style></author><author><style face="normal" font="default" size="100%">Yamaguchi, M.</style></author><author><style face="normal" font="default" size="100%">Mori, M.</style></author><author><style face="normal" font="default" size="100%">Sugimoto, N.</style></author><author><style face="normal" font="default" size="100%">Suzukawa, M.</style></author><author><style face="normal" font="default" size="100%">Iikura, M.</style></author><author><style face="normal" font="default" size="100%">Nagase, H.</style></author><author><style face="normal" font="default" size="100%">Ohta, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.&#xD;Division of Respiratory Medicine, Third Department of Medicine, Teikyo University Chiba Medical Center, Chiba, Japan.&#xD;Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.&#xD;Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.&#xD;Japan Anti-Tuberculosis Association Fukujuji Hospital, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Eotaxin (CCL11) enhances mediator release from human basophils</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3549-3552</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Chemokine CCL11</style></keyword><keyword><style face="normal" font="default" size="100%">*Histamine Release</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">eotaxin (CCL11)</style></keyword><keyword><style face="normal" font="default" size="100%">histamine</style></keyword><keyword><style face="normal" font="default" size="100%">leukotriene C4</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34086364</style></accession-num><notes><style face="normal" font="default" size="100%">Suzuki, Yuki&#xD;Yamaguchi, Masao&#xD;Mori, Miki&#xD;Sugimoto, Naoya&#xD;Suzukawa, Maho&#xD;Iikura, Motoyasu&#xD;Nagase, Hiroyuki&#xD;Ohta, Ken&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3549-3552. doi: 10.1111/all.14975. Epub 2021 Jun 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34086364</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14975</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2702</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2702</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ravindran, M.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author><author><style face="normal" font="default" size="100%">Kim, E. H.</style></author><author><style face="normal" font="default" size="100%">Bee, K. J.</style></author><author><style face="normal" font="default" size="100%">Green, T. D.</style></author><author><style face="normal" font="default" size="100%">Burks, A. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Allergy and Immunology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.&#xD;Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;DBV Technologies SA, Montrouge, France.&#xD;UPMC Children&apos;s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epicutaneous immunotherapy for the treatment of peanut allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">63-76</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/09/28 22:43</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Cutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Viaskin Peanut</style></keyword><keyword><style face="normal" font="default" size="100%">epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">LLC, DBV Technologies, AbbVie, Food Allergy Research and Education (FARE), and</style></keyword><keyword><style face="normal" font="default" size="100%">Siolta Therapeutics, stock options from N-Fold, LLC, and DBV Technologies, grants</style></keyword><keyword><style face="normal" font="default" size="100%">to his institution from the National Institute of Allergy and Infectious</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases, and FARE, royalties from Elsevier and Wiley, participated in a</style></keyword><keyword><style face="normal" font="default" size="100%">scientific advisory board for FARE and Siolta Therapeutics, received honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">for American Academy of Allergy, Asthma, and Immunology, American College of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy, Asthma, and Immunology, and Greater Washington Allergy, Asthma and</style></keyword><keyword><style face="normal" font="default" size="100%">Immunology Society, received support to attend meetings from DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">and has patents held by Mount Sinai. E.H.K. reports consulting fees from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, Ukko Inc., Cellergy Pharma, DBV Technologies, Genentech, Hanimune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Novartis, Nutricia, Phyalxis BioScience, and Revolo</style></keyword><keyword><style face="normal" font="default" size="100%">Biotherapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">safety review committee membership for Allergy Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">Ltd.</style></keyword><keyword><style face="normal" font="default" size="100%">royalties from UpToDate</style></keyword><keyword><style face="normal" font="default" size="100%">and has stock options for Cellergy Pharma. K.J.B.</style></keyword><keyword><style face="normal" font="default" size="100%">and T.D.G. are employees of DBV Technologies. A.W.B. reports consulting fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics, Aimmune Therapeutics, Consortia TX, DBV Technologies, Ukko,</style></keyword><keyword><style face="normal" font="default" size="100%">grants to his institution from Burroughs Wellcome Fund, research grant from the</style></keyword><keyword><style face="normal" font="default" size="100%">National Institutes of Health, and royalties from UpToDate.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39340442</style></accession-num><abstract><style face="normal" font="default" size="100%">Peanut allergy treatment options remain limited, but novel approaches are being studied, including epicutaneous immunotherapy (EPIT). EPIT uses the cutaneous immune system to promote tolerance to food allergens. Viaskin Peanut, an approach to EPIT in late-stage clinical development uses an occlusive patch with a condensation chamber that enables natural epidermal water loss to solubilize dry antigen on the patch, which is then absorbed and captured by skin Langerhans cells. This form of EPIT does not require disruption of the skin barrier, thus avoiding a proinflammatory cytokine response by targeting the nonvascularized epidermis and limiting systemic allergen exposure. Extensive preclinical research suggests that Viaskin Peanut has a distinct mechanism of desensitization, including the potential for disease modification, driven by a unique population of regulatory T cells. Numerous clinical studies of Viaskin Peanut have demonstrated desensitization and reductions in reaction severity, particularly in children aged 1 through 11 years, as well as a favorable safety profile with mostly mild-to-moderate skin reactions that were observed to decrease over time. EPIT with Viaskin Peanut may be a potential therapeutic option for peanut allergy that is clinically practical with long-term efficacy and tolerability.</style></abstract><notes><style face="normal" font="default" size="100%">Ravindran, Mayuran&#xD;Sampson, Hugh A&#xD;Kim, Edwin H&#xD;Bee, Katharine J&#xD;Green, Todd D&#xD;Burks, A Wesley&#xD;eng&#xD;DBV Technologies/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):63-76. doi: 10.1111/all.16324. Epub 2024 Sep 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39340442</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724258</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16324</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1316</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1316</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pelletier, B.</style></author><author><style face="normal" font="default" size="100%">Perrin, A.</style></author><author><style face="normal" font="default" size="100%">Assoun, N.</style></author><author><style face="normal" font="default" size="100%">Plaquet, C.</style></author><author><style face="normal" font="default" size="100%">Oreal, N.</style></author><author><style face="normal" font="default" size="100%">Gaulme, L.</style></author><author><style face="normal" font="default" size="100%">Bouzereau, A.</style></author><author><style face="normal" font="default" size="100%">Labernardiere, J. L.</style></author><author><style face="normal" font="default" size="100%">Ligouis, M.</style></author><author><style face="normal" font="default" size="100%">Dioszeghy, V.</style></author><author><style face="normal" font="default" size="100%">Wavrin, S.</style></author><author><style face="normal" font="default" size="100%">Matthews, K.</style></author><author><style face="normal" font="default" size="100%">Porcheray, F.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author><author><style face="normal" font="default" size="100%">Herve, P. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">DBV Technologies, Montrouge, France.&#xD;DBV Technologies, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epicutaneous immunotherapy protects cashew-sensitized mice from anaphylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1213-1222</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Anacardium</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Viaskin</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis mouse model</style></keyword><keyword><style face="normal" font="default" size="100%">cashew allergy</style></keyword><keyword><style face="normal" font="default" size="100%">epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Dioszeghy, Dr. Wavrin, Dr. Matthews, Dr. Sampson, and Dr. Herve report</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from DBV Technologies, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from DBV Technologies, outside the submitted work. Audrey Perrin, Noemie</style></keyword><keyword><style face="normal" font="default" size="100%">Assoun, Nathalie Oreal, Laetitia Gaulme, Adeline Bouzereau, and Dr. Porcheray</style></keyword><keyword><style face="normal" font="default" size="100%">report personal fees from DBV Technologies, during the conduct of the study.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32996148</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The prevalence of tree nut allergy has increased worldwide, and cashew has become one of the most common food allergens. More critically, cashew allergy is frequently associated with severe anaphylaxis. Despite the high medical need, no approved treatment is available and strict avoidance and preparedness for prompt treatment of allergic reactions are considered dual standard of care. In the meantime, Phase III study results suggest investigational epicutaneous immunotherapy (EPIT) may be a relevant and safe treatment for peanut allergy and may improve the quality of life for many peanut allergic children. OBJECTIVE: We aimed to evaluate the capacity of EPIT to provide protection against cashew-induced anaphylaxis in a relevant mouse model. METHODS: The efficacy of EPIT was evaluated by applying patches containing cashew allergens to cashew-sensitized mice. As negative control, sham mice received patches containing excipient. Following treatment, mice were challenged orally to cashew and anaphylactic symptoms, as well as plasmatic levels of mast-cell proteases (mMCP)-1/7, were quantified. RESULTS: Of 16 weeks of EPIT significantly protects against anaphylaxis by promoting a faster recovery of challenged mice. This protection was characterized by a significant reduction of temperature drop and clinical symptoms, 60 minutes after challenge. This was associated with a decrease in mast-cell reactivity as attested by the reduction of mMCP-1/7 in plasma, suggesting that EPIT specifically decrease IgE-mediated anaphylaxis. CONCLUSION: We demonstrate that EPIT markedly reduced IgE-mediated allergic reactions in a mouse model of cashew allergy, which suggests that EPIT may be a relevant approach to treating cashew allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Pelletier, Benjamin&#xD;Perrin, Audrey&#xD;Assoun, Noemie&#xD;Plaquet, Camille&#xD;Oreal, Nathalie&#xD;Gaulme, Laetitia&#xD;Bouzereau, Adeline&#xD;Labernardiere, Jean-Louis&#xD;Ligouis, Melanie&#xD;Dioszeghy, Vincent&#xD;Wavrin, Sophie&#xD;Matthews, Katie&#xD;Porcheray, Fabrice&#xD;Sampson, Hugh A&#xD;Herve, Pierre-Louis&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1213-1222. doi: 10.1111/all.14605. Epub 2020 Oct 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32996148</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246921</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14605</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2962</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2962</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Liu, L.</style></author><author><style face="normal" font="default" size="100%">Chang, B.</style></author><author><style face="normal" font="default" size="100%">Luo, W.</style></author><author><style face="normal" font="default" size="100%">Sun, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Laboratory, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.&#xD;Guangzhou Laboratory, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epidemiological Study of Common Allergens Sensitizing Hay Fever Patients in Different Regions of Mainland China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/07/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">pollen</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40726421</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Jiale&#xD;Liu, Li&#xD;Chang, Bo&#xD;Luo, Wenting&#xD;Sun, Baoqing&#xD;eng&#xD;SKLRD-L-202505/State Key Laboratory of Respiratory Disease/&#xD;GMUCR2024-01009/Guangzhou Medical University/&#xD;GMUCR2025-02009/Guangzhou Medical University/&#xD;2025SRP017/Guangzhou Medical University/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul 29. doi: 10.1111/all.16678.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40726421</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16678</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">475</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peng, C.</style></author><author><style face="normal" font="default" size="100%">Yu, N.</style></author><author><style face="normal" font="default" size="100%">Ding, Y.</style></author><author><style face="normal" font="default" size="100%">Shi, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.&#xD;Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epidemiological variations in global burden of atopic dermatitis: An analysis of trends from 1990 to 2019</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2843-2845</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/05/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35587441</style></accession-num><notes><style face="normal" font="default" size="100%">Peng, Chen&#xD;Yu, Ning&#xD;Ding, Yangfeng&#xD;Shi, Yuling&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2843-2845. doi: 10.1111/all.15380. Epub 2022 May 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35587441</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15380</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>537</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">537</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Starry, A.</style></author><author><style face="normal" font="default" size="100%">Hardtstock, F.</style></author><author><style face="normal" font="default" size="100%">Wilke, T.</style></author><author><style face="normal" font="default" size="100%">Weihing, J.</style></author><author><style face="normal" font="default" size="100%">Ultsch, B.</style></author><author><style face="normal" font="default" size="100%">Wernitz, M.</style></author><author><style face="normal" font="default" size="100%">Renninger, M.</style></author><author><style face="normal" font="default" size="100%">Maywald, U.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cytel/Ingress-Health, Wismar, Germany.&#xD;Institut fur Pharmakookonomie und Arzneimittellogistik e.V., Wismar, Germany.&#xD;GSK Deutschland, Munchen, Germany.&#xD;AOK PLUS, Dresden, Germany.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, Philipps-Universitat Marburg, University Hospital Marburg, Marburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epidemiology and treatment of patients with Chronic rhinosinusitis with nasal polyps in Germany-A claims data study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2725-2736</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/04/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Germany/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/surgery/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Germany</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">claims data</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">was financially supported by GSK. Thomas Wilke is an employee of IPAM and he has</style></keyword><keyword><style face="normal" font="default" size="100%">received honoraria from several pharmaceutical/consultancy companies (Novo</style></keyword><keyword><style face="normal" font="default" size="100%">Nordisk, Abbvie</style></keyword><keyword><style face="normal" font="default" size="100%">Merck</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, BMS, LEO Pharma, Astra Zeneca, Bayer, Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, Pharmerit). Julia Weihing, Bernhard Ultsch, Martin Wernitz and Marius</style></keyword><keyword><style face="normal" font="default" size="100%">Renninger are GSK employees and shareholders. Ulf Maywald has no potential</style></keyword><keyword><style face="normal" font="default" size="100%">conflict of interest, except those potentially related to his employer, AOK PLUS.</style></keyword><keyword><style face="normal" font="default" size="100%">Oliver Pfaar works at the University Hospital Marburg and is an associate editor</style></keyword><keyword><style face="normal" font="default" size="100%">of Allergy-European Journal of Allergy and Clinical Immunology. Dr. Pfaar reports</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Ingress-Health, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from ALK-Abello, grants and personal fees from Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from Stallergenes Greer, grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">HAL Allergy Holding B.V./HAL Allergie GmbH, grants and personal fees from Bencard</style></keyword><keyword><style face="normal" font="default" size="100%">Allergie GmbH/Allergy Therapeutics, grants and personal fees from Lofarma, grants</style></keyword><keyword><style face="normal" font="default" size="100%">from Biomay, grants from Circassia, grants and personal fees from ASIT Biotech</style></keyword><keyword><style face="normal" font="default" size="100%">Tools S.A., grants and personal fees from Laboratorios LETI/LETI Pharma, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from MEDA Pharma/MYLAN, grants and personal fees from Anergis S.A., personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Mobile Chamber Experts (a GA2LEN Partner), personal fees from Indoor</style></keyword><keyword><style face="normal" font="default" size="100%">Biotechnologies, grants and personal fees from GlaxoSmithKline, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Astellas Pharma Global, personal fees from EUFOREA, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">ROXALL Medizin, personal fees from Novartis, personal fees from Sanofi-Aventis</style></keyword><keyword><style face="normal" font="default" size="100%">and Sanofi-Genzyme, personal fees from Med Update Europe GmbH, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">streamedup! GmbH, grants from Pohl-Boskamp, grants from Inmunotek S.L., personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from John Wiley and Sons, AS, personal fees from Paul-Martini-Stiftung</style></keyword><keyword><style face="normal" font="default" size="100%">(PMS), personal fees from Regeneron Pharmaceuticals Inc., personal fees from RG</style></keyword><keyword><style face="normal" font="default" size="100%">Aerztefortbildung, personal fees from Institut fur Disease Management, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Springer GmbH, personal fees from AstraZeneca, personal fees from IQVIA</style></keyword><keyword><style face="normal" font="default" size="100%">Commercial, outside the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35357726</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: There are different levels of severity among patients who suffer from chronic rhinosinusitis with nasal polyps (CRSwNP). In this study, the epidemiology of CRSwNP and severe CRswNP was estimated. METHODS: A retrospective claim data analysis was conducted on adult CRSwNP patients (ICD-10: J33), and those classified as severe CRSwNP patients with inadequate disease control (based upon combinations of previous and current treatments) between 2015 and 2019. Prevalence and incidence figures were calculated and extrapolated to the German population. In addition, baseline characteristics and treatment outcomes were analysed. RESULTS: Overall, the 5-year prevalence of adult CRSwNP cases from 2015 to 2019 in Germany was 374,115 cases (about 5500 per million), with 12,989 (about 200 per million) patients being classified as severe CRSwNP with inadequate disease control, whereas 267,880 (about 3900 per million) patients were identified as having an incident CRSwNP diagnosis between 2016 and 2019. From the incident CRSwNP cohort, 80.55% had received at least one intranasal corticosteroid (INCS), 24.27% received at least 1 systemic corticosteroid (SCS), and 17.33% received at least one functional endoscopic sinus surgery (FESS) within 12 months after their incident diagnosis. CONCLUSION: Severe CRSwNP with inadequate disease control affects about 200 per million people in Germany. INCS is the first-choice treatment for most CRSwNP patients; however, for patients with severe CRSwNP, SCS are prescribed more frequently and long-term effects of these should be further investigated, especially if despite treatment, adequate disease control cannot be achieved.</style></abstract><notes><style face="normal" font="default" size="100%">Starry, Alexandra&#xD;Hardtstock, Fraence&#xD;Wilke, Thomas&#xD;Weihing, Julia&#xD;Ultsch, Bernhard&#xD;Wernitz, Martin&#xD;Renninger, Marius&#xD;Maywald, Ulf&#xD;Pfaar, Oliver&#xD;eng&#xD;214229/WT_/Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2725-2736. doi: 10.1111/all.15301. Epub 2022 Apr 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35357726</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9542419</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15301</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2850</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2850</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Day, C.</style></author><author><style face="normal" font="default" size="100%">Deetlefs, M.</style></author><author><style face="normal" font="default" size="100%">Mapahla, L.</style></author><author><style face="normal" font="default" size="100%">Jang, Y.</style></author><author><style face="normal" font="default" size="100%">Gusha-Mhlekude, Q.</style></author><author><style face="normal" font="default" size="100%">Ntuli, S.</style></author><author><style face="normal" font="default" size="100%">Hlungwani, B.</style></author><author><style face="normal" font="default" size="100%">Kannenberg, S.</style></author><author><style face="normal" font="default" size="100%">Kruger, E.</style></author><author><style face="normal" font="default" size="100%">Ambondo, N.</style></author><author><style face="normal" font="default" size="100%">Visser, W.</style></author><author><style face="normal" font="default" size="100%">Isaacs, T.</style></author><author><style face="normal" font="default" size="100%">Lehloenya, R.</style></author><author><style face="normal" font="default" size="100%">Peter, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergology and Clinical Immunology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.&#xD;Allergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa.&#xD;The Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Stellenbosch, South Africa.&#xD;The Modelling and Simulation Hub, Africa, Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa.&#xD;Faculty of Health Sciences, Division of Dermatology, Department of Medicine, University of Stellenbosch, Cape Town, South Africa.&#xD;Faculty of Health Sciences, Division of Dermatology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Epidemiology of Chronic Urticaria in Cape Town, South Africa: A Review of Two Tertiary Referral Centers</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2405-2409</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/03/31 21:16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">the South African Medical Council Division of Research Capacity Development</style></keyword><keyword><style face="normal" font="default" size="100%">Programme. The degree from which this study emanated was funded by the South</style></keyword><keyword><style face="normal" font="default" size="100%">African Medical Research Council through its Division of Research Capacity</style></keyword><keyword><style face="normal" font="default" size="100%">Development under the Clinician Researcher Development Programme with funding</style></keyword><keyword><style face="normal" font="default" size="100%">received from the South African National Department of Health. The content hereof</style></keyword><keyword><style face="normal" font="default" size="100%">is the sole responsibility of the authors and does not necessarily represent the</style></keyword><keyword><style face="normal" font="default" size="100%">official views of the SAMRC or the funders. J Peter has received speaker&apos;s fees</style></keyword><keyword><style face="normal" font="default" size="100%">or honoraria from CSL Behring, Novartis, Sanofi Regeneron, and Takeda. He has</style></keyword><keyword><style face="normal" font="default" size="100%">received educational grants from Astria, Cipla, Glenmark Pharmaceuticals,</style></keyword><keyword><style face="normal" font="default" size="100%">Kalvista, Pharvaris, and Takeda. He serves on the advisory board of Astria and</style></keyword><keyword><style face="normal" font="default" size="100%">Pharvaris.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40162584</style></accession-num><notes><style face="normal" font="default" size="100%">Day, Cascia&#xD;Deetlefs, Mimi&#xD;Mapahla, Lovemore&#xD;Jang, Yejin&#xD;Gusha-Mhlekude, Qiqa&#xD;Ntuli, Sicelo&#xD;Hlungwani, Balican&#xD;Kannenberg, Susanna&#xD;Kruger, Emma&#xD;Ambondo, Ndapewa&#xD;Visser, Willem&#xD;Isaacs, Thuraya&#xD;Lehloenya, Rannakoe&#xD;Peter, Jonny&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2405-2409. doi: 10.1111/all.16547. Epub 2025 Mar 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40162584</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368737</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16547</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2139</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2139</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schleich, F.</style></author><author><style face="normal" font="default" size="100%">Maury, E.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Hanon, S.</style></author><author><style face="normal" font="default" size="100%">Michel, O.</style></author><author><style face="normal" font="default" size="100%">Jansen, M.</style></author><author><style face="normal" font="default" size="100%">Gurdain, S.</style></author><author><style face="normal" font="default" size="100%">Van Schoor, J.</style></author><author><style face="normal" font="default" size="100%">Belgian Ig, E. Study Investigators</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, University Hospital Sart-Tilman, Liege, Belgium.&#xD;Medical Department, Novartis Pharma, Vilvoorde, Belgium.&#xD;Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium.&#xD;Respiratory Division, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.&#xD;Clinic of Immuno-Allergology, CHU Brugmann, Universite Libre de Bruxelles (ULB), Brussels, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epidemiology of sensitization to perennial aeroallergens in adults with severe asthma in Belgium. The BEIgE study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2774-2777</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/06/21</style></edition><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37340902</style></accession-num><notes><style face="normal" font="default" size="100%">Schleich, Florence&#xD;Maury, Eleonore&#xD;Bachert, Claus&#xD;Hanon, Shane&#xD;Michel, Olivier&#xD;Jansen, Mieke&#xD;Gurdain, Sandra&#xD;Van Schoor, Jan&#xD;(BEIgE)&#xD;eng&#xD;This research was sponsored by Novartis Pharma./&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2774-2777. doi: 10.1111/all.15785. Epub 2023 Jun 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37340902</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15785</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2384</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2384</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kimura, Y.</style></author><author><style face="normal" font="default" size="100%">Suzukawa, M.</style></author><author><style face="normal" font="default" size="100%">Jo, T.</style></author><author><style face="normal" font="default" size="100%">Hashimoto, Y.</style></author><author><style face="normal" font="default" size="100%">Kumazawa, R.</style></author><author><style face="normal" font="default" size="100%">Ishimaru, M.</style></author><author><style face="normal" font="default" size="100%">Matsui, H.</style></author><author><style face="normal" font="default" size="100%">Yokoyama, A.</style></author><author><style face="normal" font="default" size="100%">Tanaka, G.</style></author><author><style face="normal" font="default" size="100%">Yasunaga, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.&#xD;Clinical Research Center, National Hospital Organization Tokyo Hospital, Tokyo, Japan.&#xD;Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.&#xD;Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.&#xD;Save Sight Institute, The University of Sydney, Sydney, Australia.&#xD;Institute of Education, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epidemiology of severe childhood asthma in Japan: A nationwide descriptive study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1598-1602</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Japan/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38186054</style></accession-num><notes><style face="normal" font="default" size="100%">Kimura, Yuya&#xD;Suzukawa, Maho&#xD;Jo, Taisuke&#xD;Hashimoto, Yohei&#xD;Kumazawa, Ryosuke&#xD;Ishimaru, Miho&#xD;Matsui, Hiroki&#xD;Yokoyama, Akira&#xD;Tanaka, Goh&#xD;Yasunaga, Hideo&#xD;eng&#xD;Ministry of Health, Labour and Welfare/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1598-1602. doi: 10.1111/all.16008. Epub 2024 Jan 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38186054</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16008</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2397</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2397</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruchti, F.</style></author><author><style face="normal" font="default" size="100%">Zwicky, P.</style></author><author><style face="normal" font="default" size="100%">Becher, B.</style></author><author><style face="normal" font="default" size="100%">Dubrac, S.</style></author><author><style face="normal" font="default" size="100%">LeibundGut-Landmann, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Immunology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.&#xD;Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epidermal barrier impairment predisposes for excessive growth of the allergy-associated yeast Malassezia on murine skin</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1531-1547</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/02/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Malassezia/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/microbiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/microbiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Epidermis/microbiology/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/immunology/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Malassezia</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">epidermal barrier impairment</style></keyword><keyword><style face="normal" font="default" size="100%">fungal adaptation</style></keyword><keyword><style face="normal" font="default" size="100%">skin immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38385963</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The skin barrier is vital for protection against environmental threats including insults caused by skin-resident microbes. Dysregulation of this barrier is a hallmark of atopic dermatitis (AD) and ichthyosis, with variable consequences for host immune control of colonizing commensals and opportunistic pathogens. While Malassezia is the most abundant commensal fungus of the skin, little is known about the host control of this fungus in inflammatory skin diseases. METHODS: In this experimental study, MC903-treated mice were colonized with Malassezia spp. to assess the host-fungal interactions in atopic dermatitis. Additional murine models of AD and ichthyosis, including tape stripping, K5-Nrf2 overexpression and flaky tail mice, were employed to confirm and expand the findings. Skin fungal counts were enumerated. High parameter flow cytometry was used to characterize the antifungal response in the AD-like skin. Structural and functional alterations in the skin barrier were determined by histology and transcriptomics of bulk skin. Finally, differential expression of metabolic genes in Malassezia in atopic and control skin was quantified. RESULTS: Malassezia grows excessively in AD-like skin. Fungal overgrowth could, however, not be explained by the altered immune status of the atopic skin. Instead, we found that by upregulating key metabolic genes in the altered cutaneous niche, Malassezia acquired enhanced fitness to efficiently colonise the impaired skin barrier. CONCLUSIONS: This study provides evidence that structural and metabolic changes in the dysfunctional epidermal barrier environment provide increased accessibility and an altered lipid profile, to which the lipid-dependent yeast adapts for enhanced nutrient assimilation. Our findings reveal fundamental insights into the implication of the mycobiota in the pathogenesis of common skin barrier disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Ruchti, Fiorella&#xD;Zwicky, Pascale&#xD;Becher, Burkhard&#xD;Dubrac, Sandrine&#xD;LeibundGut-Landmann, Salome&#xD;eng&#xD;Universitat Zurich/&#xD;Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1531-1547. doi: 10.1111/all.16062. Epub 2024 Feb 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38385963</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16062</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3318</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3318</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, Jiahui</style></author><author><style face="normal" font="default" size="100%">Zhou, Lingxuan</style></author><author><style face="normal" font="default" size="100%">Wang, Chenyu</style></author><author><style face="normal" font="default" size="100%">Rao, Ziyan</style></author><author><style face="normal" font="default" size="100%">Yuan, Xiaohui</style></author><author><style face="normal" font="default" size="100%">Cui, Jun</style></author><author><style face="normal" font="default" size="100%">Zhao, Dongyu</style></author><author><style face="normal" font="default" size="100%">Sun, Ying</style></author><author><style face="normal" font="default" size="100%">Chen, Yan</style></author><author><style face="normal" font="default" size="100%">Li, Ruoyu</style></author><author><style face="normal" font="default" size="100%">Jing, Miao</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Epidermal PAR2-TRPV3-IL-33 Signaling Promotes Mast Cell Recruitment and Sensory Nerve-Mast Cell Interactions in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70284</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70284</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1004</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1004</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yong, H. M.</style></author><author><style face="normal" font="default" size="100%">Gour, N.</style></author><author><style face="normal" font="default" size="100%">Sharma, D.</style></author><author><style face="normal" font="default" size="100%">Khalil, S. M.</style></author><author><style face="normal" font="default" size="100%">Lane, A. P.</style></author><author><style face="normal" font="default" size="100%">Lajoie, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Johns Hopkins School of Medicine, Baltimore, MD, USA.&#xD;Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.&#xD;Solomon H. Snyder Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epigenetic regulation of epithelial dectin-1 through an IL-33-STAT3 axis in allergic disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">207-217</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/05/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">*Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/genetics/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-33/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lectins, C-Type/*genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">STAT3 Transcription Factor/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">dectin-1</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33982290</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic diseases arise in susceptible individuals in part because of decrements in protective pathways. The mechanism by which these anti-inflammatory molecules become repressed remains unclear. We have previously reported that epithelial dectin-1 prevents aberrant type 2 responses and is downregulated in the epithelium of allergic patients. Here, we report that dectin-1 is constitutively expressed by the respiratory epithelium in humans and that IL-33 specifically acts as a repressor of dectin-1. Mechanistically, this occurs via IL-33-dependent STAT3 activation and the subsequent repression of the dectin-1 gene, CLEC7A. We have identified a novel enhancer region upstream of the proximal promoter of CLEC7A that is only accessible in epithelial cells, but not in hematopoietic cells. Epigenetic repression of CLEC7A through this newly identified locus, downstream of an aberrant IL-33-STAT3 axis, occurs in the epithelium of allergic individuals. Collectively, our data identify a mechanism of epigenetic fine-tuning of dectin-1 expression in epithelial cells that may participate in allergenicity.</style></abstract><notes><style face="normal" font="default" size="100%">Yong, Hwan Mee&#xD;Gour, Naina&#xD;Sharma, Deepika&#xD;Khalil, Syed Muaz&#xD;Lane, Andrew P&#xD;Lajoie, Stephane&#xD;eng&#xD;R01 AI127644/AI/NIAID NIH HHS/&#xD;R01 AI132590/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):207-217. doi: 10.1111/all.14898. Epub 2021 May 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33982290</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10580706</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14898</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1576</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1576</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yong, H. M.</style></author><author><style face="normal" font="default" size="100%">Gour, N.</style></author><author><style face="normal" font="default" size="100%">Sharma, D.</style></author><author><style face="normal" font="default" size="100%">Khalil, S. M.</style></author><author><style face="normal" font="default" size="100%">Lane, A. P.</style></author><author><style face="normal" font="default" size="100%">Lajoie, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Johns Hopkins School of Medicine, Baltimore, MD, USA.&#xD;Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.&#xD;Solomon H. Snyder Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epigenetic regulation of epithelial dectin-1 through an IL-33-STAT3 axis in allergic disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">207-217</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/05/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">*Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/genetics/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-33/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lectins, C-Type/*genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">STAT3 Transcription Factor/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">dectin-1</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33982290</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic diseases arise in susceptible individuals in part because of decrements in protective pathways. The mechanism by which these anti-inflammatory molecules become repressed remains unclear. We have previously reported that epithelial dectin-1 prevents aberrant type 2 responses and is downregulated in the epithelium of allergic patients. Here, we report that dectin-1 is constitutively expressed by the respiratory epithelium in humans and that IL-33 specifically acts as a repressor of dectin-1. Mechanistically, this occurs via IL-33-dependent STAT3 activation and the subsequent repression of the dectin-1 gene, CLEC7A. We have identified a novel enhancer region upstream of the proximal promoter of CLEC7A that is only accessible in epithelial cells, but not in hematopoietic cells. Epigenetic repression of CLEC7A through this newly identified locus, downstream of an aberrant IL-33-STAT3 axis, occurs in the epithelium of allergic individuals. Collectively, our data identify a mechanism of epigenetic fine-tuning of dectin-1 expression in epithelial cells that may participate in allergenicity.</style></abstract><notes><style face="normal" font="default" size="100%">Yong, Hwan Mee&#xD;Gour, Naina&#xD;Sharma, Deepika&#xD;Khalil, Syed Muaz&#xD;Lane, Andrew P&#xD;Lajoie, Stephane&#xD;eng&#xD;R01 AI127644/AI/NIAID NIH HHS/&#xD;R01 AI132590/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):207-217. doi: 10.1111/all.14898. Epub 2021 May 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33982290</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10580706</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14898</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2164</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2164</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soliai, M. M.</style></author><author><style face="normal" font="default" size="100%">Kato, A.</style></author><author><style face="normal" font="default" size="100%">Naughton, K. A.</style></author><author><style face="normal" font="default" size="100%">Norton, J. E.</style></author><author><style face="normal" font="default" size="100%">Klinger, A. I.</style></author><author><style face="normal" font="default" size="100%">Kern, R. C.</style></author><author><style face="normal" font="default" size="100%">Tan, B. K.</style></author><author><style face="normal" font="default" size="100%">Nicolae, D. L.</style></author><author><style face="normal" font="default" size="100%">Schleimer, R. P.</style></author><author><style face="normal" font="default" size="100%">Ober, C.</style></author><author><style face="normal" font="default" size="100%">Pinto, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Committee on Genetics, Genomics and Systems Biology, The University of Chicago, Chicago, Illinois, USA.&#xD;Department of Human Genetics, The University of Chicago, Chicago, Illinois, USA.&#xD;Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Department of Statistics, The University of Chicago, Chicago, Illinois, USA.&#xD;Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, The University of Chicago, Chicago, Illinois, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epigenetic responses to rhinovirus exposure in airway epithelial cells are correlated with key transcriptional pathways in chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2698-2711</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/08/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">DNA methylation</style></keyword><keyword><style face="normal" font="default" size="100%">airway epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyposis</style></keyword><keyword><style face="normal" font="default" size="100%">competing interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37571876</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Viruses may drive immune mechanisms responsible for chronic rhinosinusitis with nasal polyposis (CRSwNP), but little is known about the underlying molecular mechanisms. OBJECTIVES: To identify epigenetic and transcriptional responses to a common upper respiratory pathogen, rhinovirus (RV), that are specific to patients with CRSwNP using a primary sinonasal epithelial cell culture model. METHODS: Airway epithelial cells were collected at surgery from patients with CRSwNP (cases) and from controls without sinus disease, cultured, and then exposed to RV or vehicle for 48 h. Differential gene expression and DNA methylation (DNAm) between cases and controls in response to RV were determined using linear mixed models. Weighted gene co-expression analysis (WGCNA) was used to identify (a) co-regulated gene expression and DNAm signatures, and (b) genes, pathways, and regulatory mechanisms specific to CRSwNP. RESULTS: We identified 5585 differential transcriptional and 261 DNAm responses (FDR &lt;0.10) to RV between CRSwNP cases and controls. These differential responses formed three co-expression/co-methylation modules that were related to CRSwNP and three that were related to RV (Bonferroni corrected p &lt; .01). Most (95%) of the differentially methylated CpGs (DMCs) were in modules related to CRSwNP, whereas the differentially expressed genes (DEGs) were more equally distributed between the CRSwNP- and RV-related modules. Genes in the CRSwNP-related modules were enriched in known CRS and/or viral response immune pathways. CONCLUSION: RV activates specific epigenetic programs and correlated transcriptional networks in the sinonasal epithelium of individuals with CRSwNP. These novel observations suggest epigenetic signatures specific to patients with CRSwNP modulate response to viral pathogens at the mucosal environmental interface. Determining how viral response pathways are involved in epithelial inflammation in CRSwNP could lead to therapeutic targets for this burdensome airway disorder.</style></abstract><notes><style face="normal" font="default" size="100%">Soliai, Marcus M&#xD;Kato, Atsushi&#xD;Naughton, Katherine A&#xD;Norton, James E&#xD;Klinger, Aiko I&#xD;Kern, Robert C&#xD;Tan, Bruce K&#xD;Nicolae, Dan L&#xD;Schleimer, Robert P&#xD;Ober, Carole&#xD;Pinto, Jayant M&#xD;eng&#xD;R01 AI137174/AI/NIAID NIH HHS/&#xD;R01 HL129735/HL/NHLBI NIH HHS/&#xD;U19 AI106683/NH/NIH HHS/&#xD;P01 AI145818/NH/NIH HHS/&#xD;U19 AI106683/AI/NIAID NIH HHS/&#xD;U19 AI162310/AI/NIAID NIH HHS/&#xD;P01 AI145818/AI/NIAID NIH HHS/&#xD;R01 AI104733/NH/NIH HHS/&#xD;T32 GM007197/GM/NIGMS NIH HHS/&#xD;R37 HL068546/HL/NHLBI NIH HHS/&#xD;R01 AI104733/AI/NIAID NIH HHS/&#xD;R01 HL129735/NH/NIH HHS/&#xD;T32 GM07197/NH/NIH HHS/&#xD;R01 AI137174/NH/NIH HHS/&#xD;R37 HL068546/NH/NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2698-2711. doi: 10.1111/all.15837. Epub 2023 Aug 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37571876</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10614423</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15837</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2722</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2722</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Risha, M. A.</style></author><author><style face="normal" font="default" size="100%">Reddy, K. D.</style></author><author><style face="normal" font="default" size="100%">Nemani, S. S. P.</style></author><author><style face="normal" font="default" size="100%">Jakwerth, C.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C.</style></author><author><style face="normal" font="default" size="100%">Bahmer, T.</style></author><author><style face="normal" font="default" size="100%">Hansen, G.</style></author><author><style face="normal" font="default" size="100%">von Mutius, E.</style></author><author><style face="normal" font="default" size="100%">Rabe, K. F.</style></author><author><style face="normal" font="default" size="100%">Dittrich, A. M.</style></author><author><style face="normal" font="default" size="100%">Grychtol, R.</style></author><author><style face="normal" font="default" size="100%">Maison, N.</style></author><author><style face="normal" font="default" size="100%">Schaub, B.</style></author><author><style face="normal" font="default" size="100%">Kopp, M. V.</style></author><author><style face="normal" font="default" size="100%">Brinkmann, F.</style></author><author><style face="normal" font="default" size="100%">Meiners, S.</style></author><author><style face="normal" font="default" size="100%">Jappe, U.</style></author><author><style face="normal" font="default" size="100%">Weckmann, M.</style></author><author><style face="normal" font="default" size="100%">Alliance Study Group as part of the German Centre for Lung Research</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Clinical and Molecular Allergology, PA Chronic Lung Diseases, Research Center Borstel, Borstel, Germany.&#xD;German Center for Lung Research (DZL), Airway Research Center North (ARCN), Borstel, Germany.&#xD;Department of Paediatric Pneumology &amp; Allergology, University Clinic Schleswig-Holstein (UKSH), Lubeck, Germany.&#xD;Division of Epigenetics of Chronic Lung Diseases, Priority Area Chronic Lung Diseases, Research Center Borstel - Leibniz Lung Center, Borstel, Germany.&#xD;Centre of Allergy and Environment (ZAUM), Technische Universitat and Helmholtz Centre Munich, Munich, Germany.&#xD;Comprehensive Pneumology Centre Munich (CPC-M), Member of The German Centre for Lung Research (DZL), Munich, Germany.&#xD;Department of Pneumology, LungenClinic Grosshansdorf, Grosshansdorf, Germany.&#xD;University Hospital Schleswig-Holstein Campus Kiel, Department for Internal Medicine I, Kiel, Germany.&#xD;Department of Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.&#xD;Biomedical Research in End stage and Obstructive Lung Disease Hannover (BREATH), Member of the German Centre of Lung Research (DZL), Munich, Germany.&#xD;Institute for Asthma and Allergy Prevention, Helmholtz Centre Munich, German Research Centre for Environmental Health, Neuherberg, Germany.&#xD;Department of Pulmonary and Allergy, Dr von Hauner Children&apos;s Hospital, University Children&apos;s Hospital, Ludwig Maximilian&apos;s University, Munich, Germany.&#xD;German Center for Child and Adolescent Health (DZKJ), Dr von Hauner Children&apos;s Hospital, LMU Munich, Munich, Germany.&#xD;Department of Paediatric Respiratory Medicine, Inselspital, University Children&apos;s Hospital of Bern, University of Bern, Bern, Switzerland.&#xD;Immunology and Cell Biology, PA Chronic Lung Diseases, Research Center Borstel, Borstel, Germany.&#xD;Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University of Lubeck, Lubeck, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epigenetic training of human bronchial epithelium cells by repeated rhinovirus infections</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3385-3400</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/11/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">*DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">*Picornaviridae Infections/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Epithelial Cells/metabolism/virology</style></keyword><keyword><style face="normal" font="default" size="100%">*Bronchi/cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Mucosa/virology/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">airway epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">human rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">trainable genes</style></keyword><keyword><style face="normal" font="default" size="100%">trained immunity</style></keyword><keyword><style face="normal" font="default" size="100%">conflict of interest regarding the content of this manuscript. MW reports grants</style></keyword><keyword><style face="normal" font="default" size="100%">from the COVID-19 Research Initiative Schleswig-Holstein, the Follow-Up of</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Infections in Schleswig-Holstein (FRISH), the German Center of Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Research (DZL, Funding No. 82DZL001B6), intramural funding of the</style></keyword><keyword><style face="normal" font="default" size="100%">Christian-Albrechts-University Kiel, the University of Lubeck, and the Leibniz</style></keyword><keyword><style face="normal" font="default" size="100%">Lung Center, Research Center Borstel. Funding institutions did not participate in</style></keyword><keyword><style face="normal" font="default" size="100%">the design and conduct of this study. MVK reports grant from the BMBF for the</style></keyword><keyword><style face="normal" font="default" size="100%">Deutsches Zentrum fur Lungenforschung (DZL) and received consultant fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi Aventis GmbH, Chiesi GmbH, Allergopharma GmbH along with payments or</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria for lectures, presentations, speakers&apos; bureaus, manuscript writing, or</style></keyword><keyword><style face="normal" font="default" size="100%">educational events from Sanofi Aventis GmbH, Infectopharm GmbH, Allergopharma</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH. KFR received personal payments or honoraria from AstraZeneca, Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, Chiesi Pharmaceuticals, CSL Behring, Sanofi &amp; Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKlfvine, Berlin Chemie, and Menarini</style></keyword><keyword><style face="normal" font="default" size="100%">K.F. Rabe also discloses</style></keyword><keyword><style face="normal" font="default" size="100%">participation on data safety monitoring boards/advisory boards for AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, and Sanofi Regeneron, and leadership or fiduciary role in</style></keyword><keyword><style face="normal" font="default" size="100%">the German Center for Lung Research (DZL), German Chest Society (DGP), and</style></keyword><keyword><style face="normal" font="default" size="100%">American Thoracic Society (ATS). BS reports grants from the BMBF (German center</style></keyword><keyword><style face="normal" font="default" size="100%">for lung research, CPC-Munich, DZL 82DZL033C2, Combat Lung diseases FP4), the</style></keyword><keyword><style face="normal" font="default" size="100%">German Center for Child and Adolescent Health (DZKJ</style></keyword><keyword><style face="normal" font="default" size="100%">LMU/LMU Klinikum:</style></keyword><keyword><style face="normal" font="default" size="100%">01GL2406A), from DFG (DFG-SCHA 997/8-1 (BS)</style></keyword><keyword><style face="normal" font="default" size="100%">DFG-SCHA 997/9-1, DFG-SCHA-997/10-1,</style></keyword><keyword><style face="normal" font="default" size="100%">DFG-SCHA-997/11-1). BS reports consulting fees from GlaxoSmithKline, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">payment/honoraria and participation on a Data Safety Monitoring Board</style></keyword><keyword><style face="normal" font="default" size="100%">or Advisory Board from Sanofi.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39513674</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Humans are subjected to various environmental stressors (bacteria, viruses, pollution) throughout life. As such, an inherent relationship exists between the effect of these exposures with age. The impact of these environmental stressors can manifest through DNA methylation (DNAm). However, whether these epigenetic effects selectively target genes, pathways, and biological regulatory mechanisms remains unclear. Due to the frequency of human rhinovirus (HRV) infections throughout life (particularly in early development), we propose the use of HRV under controlled conditions can model the effect of multiple exposures to environmental stressors. METHODS: We generated a prediction model by combining transcriptome and DNAm datasets from human epithelial cells after repeated HRV infections. We applied a novel experimental statistical design and method to systematically explore the multifaceted experimental space (number of infections, multiplicity of infections and duration). Our model included 35 samples, each characterized by the three parameters defining their infection status. RESULTS: Trainable genes were defined by a consistent linear directionality in DNAm and gene expression changes with successive infections. We identified 77 trainable genes which could be further explored in future studies. The identified methylation sites were tracked within a pediatric cohort to determine the relative changes in candidate-trained sites with disease status and age. CONCLUSIONS: Repeated viral infections induce an immune training response in bronchial epithelial cells. Training-sensitive DNAm sites indicate alternate divergent associations in asthma compared to healthy individuals. Our novel model presents a robust tool for identifying trainable genes, providing a foundation for future studies.</style></abstract><notes><style face="normal" font="default" size="100%">Risha, Marua Abu&#xD;Reddy, Karosham D&#xD;Nemani, Sai Sneha Priya&#xD;Jakwerth, Constanze&#xD;Schmidt-Weber, Carsten&#xD;Bahmer, Thomas&#xD;Hansen, Gesine&#xD;von Mutius, Erika&#xD;Rabe, Klaus F&#xD;Dittrich, Anna-Maria&#xD;Grychtol, Ruth&#xD;Maison, Nicole&#xD;Schaub, Bianca&#xD;Kopp, Matthias V&#xD;Brinkmann, Folke&#xD;Meiners, Silke&#xD;Jappe, Uta&#xD;Weckmann, Markus&#xD;(DZL)&#xD;eng&#xD;Federal Ministry of Education and Science: German Center for Lung Research / Deutsches Zentrum fur Lungenforschung (DZL) DZL 001C1/&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3385-3400. doi: 10.1111/all.16388. Epub 2024 Nov 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39513674</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657021</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16388</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2842</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2842</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martin-Gonzalez, E.</style></author><author><style face="normal" font="default" size="100%">Perez-Garcia, J.</style></author><author><style face="normal" font="default" size="100%">Herrera-Luis, E.</style></author><author><style face="normal" font="default" size="100%">Martin-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Kebede-Merid, S.</style></author><author><style face="normal" font="default" size="100%">Hernandez-Pacheco, N.</style></author><author><style face="normal" font="default" size="100%">Lorenzo-Diaz, F.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Perez, R.</style></author><author><style face="normal" font="default" size="100%">Sardon, O.</style></author><author><style face="normal" font="default" size="100%">Hernandez-Perez, J. M.</style></author><author><style face="normal" font="default" size="100%">Poza-Guedes, P.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Machin, I.</style></author><author><style face="normal" font="default" size="100%">Mederos-Luis, E.</style></author><author><style face="normal" font="default" size="100%">Corcuera, P.</style></author><author><style face="normal" font="default" size="100%">Lopez-Fernandez, L.</style></author><author><style face="normal" font="default" size="100%">Roman-Bernal, B.</style></author><author><style face="normal" font="default" size="100%">Toncheva, A. A.</style></author><author><style face="normal" font="default" size="100%">Harner, S.</style></author><author><style face="normal" font="default" size="100%">Wolff, C.</style></author><author><style face="normal" font="default" size="100%">Brandstetter, S.</style></author><author><style face="normal" font="default" size="100%">Abdel-Aziz, M. I.</style></author><author><style face="normal" font="default" size="100%">Hashimoto, S.</style></author><author><style face="normal" font="default" size="100%">Vijverberg, S. J. H.</style></author><author><style face="normal" font="default" size="100%">Kraneveld, A. D.</style></author><author><style face="normal" font="default" size="100%">Potocnik, U.</style></author><author><style face="normal" font="default" size="100%">Kabesch, M.</style></author><author><style face="normal" font="default" size="100%">Maitland-van der Zee, A. H.</style></author><author><style face="normal" font="default" size="100%">Villar, J.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Pino-Yanes, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Genomics and Health Group, Department of Biochemistry, Microbiology, Cell Biology, and Genetics, Universidad de La Laguna (ULL), La Laguna, Spain.&#xD;Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.&#xD;Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Instituto Universitario de Enfermedades Tropicales y Salud Publica de Canarias, Universidad de La Laguna (ULL), La Laguna, Spain.&#xD;Allergy Department, Hospital Universitario de Canarias, La Laguna, Spain.&#xD;Severe Asthma Unit, Allergy Department, Hospital Universitario de Canarias, La Laguna, Spain.&#xD;Division of Pediatric Respiratory Medicine, Hospital Universitario Donostia, San Sebastian, Spain.&#xD;Department of Pediatrics, University of the Basque Country (UPV/EHU), San Sebastian, Spain.&#xD;Department of Respiratory Medicine, Hospital Universitario de N.S de Candelaria, Santa Cruz de Tenerife, Spain.&#xD;Respiratory Medicine, Hospital Universitario de La Palma, Santa Cruz de Tenerife, Spain.&#xD;Respiratory Medicine, Hospital Dr. Jose Molina Orosa, Las Palmas, Spain.&#xD;University Children&apos;s Hospital Regensburg (KUNO), Hospital St. Hedwig of the Order of St. John, University of Regensburg, Regensburg, Germany.&#xD;Pulmonary Medicine, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.&#xD;Department of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, Egypt.&#xD;Pediatric Pulmonology, Emma&apos;s Childrens Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.&#xD;Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.&#xD;Faculty of Medicine, University of Maribor, Maribor, Slovenia.&#xD;Faculty of Chemistry and Chemical Engineering, University of Maribor, Maribor, Slovenia.&#xD;Department for Science and Research, University Medical Centre Maribor, Maribor, Slovenia.&#xD;Department of Pediatric Pneumology and Allergy, University Children&apos;s Hospital Regensburg (KUNO), Regensburg, Germany.&#xD;Research and Development Campus Regensburg (WECARE) at the Hospital St. Hedwig of the Order of St. John, Regensburg, Germany.&#xD;CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.&#xD;Research Unit, Hospital Universitario Dr. Negrin, Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias, Las Palmas de Gran Canaria, Spain.&#xD;Faculty of Health Sciences, Universidad del Atlantico Medio, Las Palmas, Spain.&#xD;Li Ka Shing Knowledge Institute at St Michael&apos;s Hospital, Toronto, Canada.&#xD;Instituto de Tecnologias Biomedicas (ITB), Universidad de La Laguna (ULL), San Cristobal de La Laguna, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epigenome-Wide Association Study of Asthma Exacerbations in Europeans</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1086-1099</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/02/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">*Epigenome</style></keyword><keyword><style face="normal" font="default" size="100%">CpG Islands</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Quantitative Trait Loci</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Epigenomics</style></keyword><keyword><style face="normal" font="default" size="100%">White People/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">European People</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Europeans</style></keyword><keyword><style face="normal" font="default" size="100%">epigenome-wide association study</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbations</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39907155</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma exacerbations (AEs) represent the major contributor to the global asthma burden. Although genetic and environmental factors have been associated with AEs, the role of epigenetics remains uncovered. OBJECTIVE: This study aimed to identify whole blood DNA methylation (DNAm) markers associated with AEs in Europeans. METHODS: DNAm was assessed in 406 blood samples from Spanish individuals using the Infinium MethylationEPIC microarray (Illumina). An epigenome-wide association study was conducted to test the association of DNAm with AEs at differentially methylated positions, regions, and epigenetic modules. CpGs suggestively associated with AEs (false discovery rate [FDR] &lt; 0.1) were followed up for replication in 222 European individuals, and the genome-wide significance (p &lt; 9 x 10(-8)) was declared after meta-analyzing the discovery and replication samples. Additional assessment was performed using nasal tissue DNAm data from 155 Spanish individuals. The effects of genetic variation on DNAm were assessed through cis-methylation quantitative trait loci (meQTL) analysis. Enrichment analyses of previous EWAS signals were conducted. RESULTS: Four CpGs were associated with AEs, and two were replicated and reached genomic significance in the meta-analysis (annotated to ZBTB16 and BAIAP2). Of those, CpG cg25345365 (ZBTB16) was cross-tissue validated in nasal epithelium (p= 0.003) and associated with five independent meQTLs (FDR &lt; 0.05). Additionally, four differentially methylated regions and one module were significantly associated with AEs. Enrichment analyses revealed an overrepresentation of prior epigenetic associations with prenatal and environmental exposures, immune-mediated diseases, and mortality. CONCLUSIONS: DNAm in whole blood and nasal samples may contribute to AEs in Europeans, capturing genetic and environmental risk factors.</style></abstract><notes><style face="normal" font="default" size="100%">Martin-Gonzalez, Elena&#xD;Perez-Garcia, Javier&#xD;Herrera-Luis, Esther&#xD;Martin-Almeida, Mario&#xD;Kebede-Merid, Simon&#xD;Hernandez-Pacheco, Natalia&#xD;Lorenzo-Diaz, Fabian&#xD;Gonzalez-Perez, Ruperto&#xD;Sardon, Olaia&#xD;Hernandez-Perez, Jose M&#xD;Poza-Guedes, Paloma&#xD;Sanchez-Machin, Inmaculada&#xD;Mederos-Luis, Elena&#xD;Corcuera, Paula&#xD;Lopez-Fernandez, Leyre&#xD;Roman-Bernal, Berta&#xD;Toncheva, Antoaneta A&#xD;Harner, Susanne&#xD;Wolff, Christine&#xD;Brandstetter, Susanne&#xD;Abdel-Aziz, Mahmoud Ibrahim&#xD;Hashimoto, Simone&#xD;Vijverberg, Susanne J H&#xD;Kraneveld, Aletta D&#xD;Potocnik, Uros&#xD;Kabesch, Michael&#xD;Maitland-van der Zee, Anke H&#xD;Villar, Jesus&#xD;Melen, Erik&#xD;Pino-Yanes, Maria&#xD;eng&#xD;PID2020-116274RB-I00/Ministerio de Ciencia, Innovacion y Universidades/&#xD;A21_05/Sociedad Espanola de Alergologia e Inmunologia Clinica (SEAIC)/&#xD;PIFIISC22/24/Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias (FIISC)/&#xD;1264-2022/Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR http://www.separ.es)/&#xD;CB06/06/1088/CIBER -Consorcio Centro de Investigacion Biomedica en Red- (CIBERES), Instituto de Salud Carlos III (ISCIII), and European Regional Development Fund/&#xD;European Academy of Allergy and Clinical Immunology (EAACI)/&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1086-1099. doi: 10.1111/all.16490. Epub 2025 Feb 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39907155</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16490</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>589</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">589</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Velasco, E.</style></author><author><style face="normal" font="default" size="100%">Delicado-Miralles, M.</style></author><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author><author><style face="normal" font="default" size="100%">Gallar, J.</style></author><author><style face="normal" font="default" size="100%">Van Gerven, L.</style></author><author><style face="normal" font="default" size="100%">Talavera, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Instituto de Neurociencias, Universidad Miguel Hernandez-CSIC, San Juan de Alicante, Spain.&#xD;The European University of Brain and Technology-Neurotech EU, San Juan de Alicante, Spain.&#xD;Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium.&#xD;Instituto de Investigacion Sanitaria y Biomedica de Alicante, San Juan de Alicante, Spain.&#xD;Department of Microbiology, Immunology and transplantation, Allergy and Clinical Immunology Research Unit, KU Leuven, Leuven, Belgium.&#xD;Department of Neurosciences, Experimental Otorhinolaryngology, Rhinology Research, KU Leuven, Leuven, Belgium.&#xD;Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, KU Leuven, VIB-KU Leuven Center for Brain &amp; Disease Research, Leuven, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelial and sensory mechanisms of nasal hyperreactivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1450-1463</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">TRP channel</style></keyword><keyword><style face="normal" font="default" size="100%">barrier function</style></keyword><keyword><style face="normal" font="default" size="100%">mucus secretion</style></keyword><keyword><style face="normal" font="default" size="100%">sensory nerve</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35174893</style></accession-num><abstract><style face="normal" font="default" size="100%">&quot;Nasal hyperreactivity&quot; is a key feature in various phenotypes of upper airway diseases, whereby reactions of the nasal epithelium to diverse chemical and physical stimuli are exacerbated. In this review, we illustrate how nasal hyperreactivity can result from at least three types of mechanisms: (1) impaired barrier function, (2) hypersensitivity to external and endogenous stimuli, and (3) potentiation of efferent systems. We describe the known molecular basis of hyperreactivity related to the functional impairment of epithelial cells and somatosensory innervation, and indicate that the thermal, chemical, and mechanical sensors determining hyperreactivity in humans remain to be identified. We delineate research directions that may provide new insights into nasal hyperreactivity associated with rhinitis/rhinosinusitis pathophysiology and therapeutics. The elucidation of the molecular mechanisms underlying nasal hyperreactivity is essential for the treatment of rhinitis according to the precepts of precision medicine.</style></abstract><notes><style face="normal" font="default" size="100%">Velasco, Enrique&#xD;Delicado-Miralles, Miguel&#xD;Hellings, Peter W&#xD;Gallar, Juana&#xD;Van Gerven, Laura&#xD;Talavera, Karel&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1450-1463. doi: 10.1111/all.15259. Epub 2022 Feb 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35174893</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15259</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1578</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1578</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Velasco, E.</style></author><author><style face="normal" font="default" size="100%">Delicado-Miralles, M.</style></author><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author><author><style face="normal" font="default" size="100%">Gallar, J.</style></author><author><style face="normal" font="default" size="100%">Van Gerven, L.</style></author><author><style face="normal" font="default" size="100%">Talavera, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Instituto de Neurociencias, Universidad Miguel Hernandez-CSIC, San Juan de Alicante, Spain.&#xD;The European University of Brain and Technology-Neurotech EU, San Juan de Alicante, Spain.&#xD;Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium.&#xD;Instituto de Investigacion Sanitaria y Biomedica de Alicante, San Juan de Alicante, Spain.&#xD;Department of Microbiology, Immunology and transplantation, Allergy and Clinical Immunology Research Unit, KU Leuven, Leuven, Belgium.&#xD;Department of Neurosciences, Experimental Otorhinolaryngology, Rhinology Research, KU Leuven, Leuven, Belgium.&#xD;Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, KU Leuven, VIB-KU Leuven Center for Brain &amp; Disease Research, Leuven, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelial and sensory mechanisms of nasal hyperreactivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1450-1463</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">TRP channel</style></keyword><keyword><style face="normal" font="default" size="100%">barrier function</style></keyword><keyword><style face="normal" font="default" size="100%">mucus secretion</style></keyword><keyword><style face="normal" font="default" size="100%">sensory nerve</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35174893</style></accession-num><abstract><style face="normal" font="default" size="100%">&quot;Nasal hyperreactivity&quot; is a key feature in various phenotypes of upper airway diseases, whereby reactions of the nasal epithelium to diverse chemical and physical stimuli are exacerbated. In this review, we illustrate how nasal hyperreactivity can result from at least three types of mechanisms: (1) impaired barrier function, (2) hypersensitivity to external and endogenous stimuli, and (3) potentiation of efferent systems. We describe the known molecular basis of hyperreactivity related to the functional impairment of epithelial cells and somatosensory innervation, and indicate that the thermal, chemical, and mechanical sensors determining hyperreactivity in humans remain to be identified. We delineate research directions that may provide new insights into nasal hyperreactivity associated with rhinitis/rhinosinusitis pathophysiology and therapeutics. The elucidation of the molecular mechanisms underlying nasal hyperreactivity is essential for the treatment of rhinitis according to the precepts of precision medicine.</style></abstract><notes><style face="normal" font="default" size="100%">Velasco, Enrique&#xD;Delicado-Miralles, Miguel&#xD;Hellings, Peter W&#xD;Gallar, Juana&#xD;Van Gerven, Laura&#xD;Talavera, Karel&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1450-1463. doi: 10.1111/all.15259. Epub 2022 Feb 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35174893</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15259</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2682</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2682</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ardicli, S.</style></author><author><style face="normal" font="default" size="100%">Ardicli, O.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">Xiong, P.</style></author><author><style face="normal" font="default" size="100%">Zeyneloglu, C.</style></author><author><style face="normal" font="default" size="100%">Garcia-Sanchez, A.</style></author><author><style face="normal" font="default" size="100%">Shi, L. L.</style></author><author><style face="normal" font="default" size="100%">Viscardi, O. G.</style></author><author><style face="normal" font="default" size="100%">Skolnick, S.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Dhir, R.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Janda, J.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Genetics, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkiye.&#xD;Division of Food Processing, Milk and Dairy Products Technology Program, Karacabey Vocational School, Bursa Uludag University, Bursa, Turkiye.&#xD;Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.&#xD;Department of Biomedical &amp; Diagnostic Sciences, Faculty of Medicine, University of Salamanca, Salamanca, Spain.&#xD;Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.&#xD;SEED Inc. Co., Los Angeles, California, USA.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Faculty of Medicine, Department of Allergy and Clinical Immunology, Transylvania University, Brasov, Romania.&#xD;Faculty of Science, Charles University, Prague, Czech Republic.&#xD;The Interuniversity Messerli Research Institute of the University of Veterinary Medicine and Medical University Vienna, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelial barrier dysfunction and associated diseases in companion animals: Differences and similarities between humans and animals and research needs</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3238-3268</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/10/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pets/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cats</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">companion animals</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetics</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">exposome</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword><keyword><style face="normal" font="default" size="100%">European Union (EU CURE, EU Syn-Air-G), Novartis Research Institutes, (Basel,</style></keyword><keyword><style face="normal" font="default" size="100%">Switzerland), Stanford University (Redwood City, Calif), Seed Health (Boston,</style></keyword><keyword><style face="normal" font="default" size="100%">USA) and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">is the Co-Chair for EAACI Guidelines on</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Science in Allergic diseases and Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Chair of the EAACI</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cell Biology Working Group is on the Advisory Boards of</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron (Bern, Switzerland, New York, USA), Stanford University Sean</style></keyword><keyword><style face="normal" font="default" size="100%">Parker Asthma Allergy Center (CA, USA), Novartis (Basel, Switzerland), Glaxo</style></keyword><keyword><style face="normal" font="default" size="100%">Smith Kline (Zurich, Switzerland), Bristol-Myers Squibb (New York, USA), Seed</style></keyword><keyword><style face="normal" font="default" size="100%">Health (Boston, USA) and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">and is the Editor-in-Chief</style></keyword><keyword><style face="normal" font="default" size="100%">of Allergy. MA has received research grants from Swiss National science</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, Bern</style></keyword><keyword><style face="normal" font="default" size="100%">research grant from the Stanford University</style></keyword><keyword><style face="normal" font="default" size="100%">Leading House for</style></keyword><keyword><style face="normal" font="default" size="100%">the Latin American Region, Seed Money Grant. She is in the Scientific Advisory</style></keyword><keyword><style face="normal" font="default" size="100%">Board member of Stanford University-Sean Parker Asthma Allergy Center, CA</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Board member of LEO Foundation Skin Immunology Research Center,</style></keyword><keyword><style face="normal" font="default" size="100%">Copenhagen</style></keyword><keyword><style face="normal" font="default" size="100%">and Scientific Co-Chair of World allergy Congress (WAC) Istanbul,</style></keyword><keyword><style face="normal" font="default" size="100%">2022, Scientific Programme Committee Chair, EAACI. RD is a co-founder and CEO in</style></keyword><keyword><style face="normal" font="default" size="100%">Seed Health. SS is currently a salaried employee of Seed Health, a probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">retailer. The rest of the authors declare that they have no relevant competing</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39417247</style></accession-num><abstract><style face="normal" font="default" size="100%">Since the 1960s, more than 350,000 new chemicals have been introduced into the lives of humans and domestic animals. Many of them have become part of modern life and some are affecting nature as pollutants. Yet, our comprehension of their potential health risks for both humans and animals remains partial. The &quot;epithelial barrier theory&quot; suggests that genetic predisposition and exposure to diverse factors damaging the epithelial barriers contribute to the emergence of allergic and autoimmune conditions. Impaired epithelial barriers, microbial dysbiosis, and tissue inflammation have been observed in a high number of mucosal inflammatory, autoimmune and neuropsychiatric diseases, many of which showed increased prevalence in the last decades. Pets, especially cats and dogs, share living spaces with humans and are exposed to household cleaners, personal care products, air pollutants, and microplastics. The utilisation of cosmetic products and food additives for pets is on the rise, unfortunately, accompanied by less rigorous safety regulations than those governing human products. In this review, we explore the implications of disruptions in epithelial barriers on the well-being of companion animals, drawing comparisons with humans, and endeavour to elucidate the spectrum of diseases that afflict them. In addition, future research areas with the interconnectedness of human, animal, and environmental well-being are highlighted in line with the &quot;One Health&quot; concept.</style></abstract><notes><style face="normal" font="default" size="100%">Ardicli, Sena&#xD;Ardicli, Ozge&#xD;Yazici, Duygu&#xD;Pat, Yagiz&#xD;Babayev, Huseyn&#xD;Xiong, Peng&#xD;Zeyneloglu, Can&#xD;Garcia-Sanchez, Asuncion&#xD;Shi, Li-Li&#xD;Viscardi, Oliva Giannelli&#xD;Skolnick, Stephen&#xD;Ogulur, Ismail&#xD;Dhir, Raja&#xD;Jutel, Marek&#xD;Agache, Ioana&#xD;Janda, Jozef&#xD;Pali-Scholl, Isabella&#xD;Nadeau, Kari C&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3238-3268. doi: 10.1111/all.16343. Epub 2024 Oct 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39417247</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657079</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16343</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1596</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1596</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Singh, N.</style></author><author><style face="normal" font="default" size="100%">Diebold, Y.</style></author><author><style face="normal" font="default" size="100%">Sahu, S. K.</style></author><author><style face="normal" font="default" size="100%">Leonardi, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ProCyto Labs Pvt. Ltd., KIIT-TBI, KIIT University, Patia, Bhubaneswar, India.&#xD;Ocular Surface Group, Instituto Universitario de Oftalmobiologia Aplicada (IOBA), Universidad de Valladolid, Valladolid, Spain.&#xD;Biomedical Research Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Valladolid, Spain.&#xD;LV Prasad Eye Institute, Cornea and Anterior Segment, MTC Campus, Patia, Bhubaneswar, India.&#xD;Ophthalmology Unit, Department of Neuroscience, University of Padova, Padova, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelial barrier dysfunction in ocular allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1360-1372</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/11/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">allergic conjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">glycocalyx</style></keyword><keyword><style face="normal" font="default" size="100%">ocular allergy</style></keyword><keyword><style face="normal" font="default" size="100%">tight junctions</style></keyword><keyword><style face="normal" font="default" size="100%">vernal keratoconjunctivitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34757631</style></accession-num><abstract><style face="normal" font="default" size="100%">The epithelial barrier is the first line of defense that forms a protective barrier against pathogens, pollutants, and allergens. Epithelial barrier dysfunction has been recently implicated in the development of allergic diseases such as asthma, atopic dermatitis, food allergy, and rhinitis. However, there is limited knowledge on epithelial barrier dysfunction in ocular allergy (OA). Since the ocular surface is directly exposed to the environment, it is important to understand the role of ocular epithelia and their dysfunction in OA. Impaired epithelial barrier enhances allergen uptake, which lead to activation of immune responses and development of chronic inflammation as seen in allergies. Abnormal expression of tight junction proteins that helps to maintain epithelial integrity has been reported in OA but sufficient data not available in chronic atopic (AKC) and vernal keratoconjunctivitis (VKC), the pathophysiology of which is not just complex, but also the current treatments are not completely effective. This review provides an overview of studies, which indicates the role of barrier dysfunction in OA, and highlights how ocular barrier dysfunction possibly contributes to the disease pathogenesis. The review also explores the potential of ocular epithelial barrier repair strategies as preventive and therapeutic approach.</style></abstract><notes><style face="normal" font="default" size="100%">Singh, Neera&#xD;Diebold, Yolanda&#xD;Sahu, Srikant K&#xD;Leonardi, Andrea&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1360-1372. doi: 10.1111/all.15174. Epub 2021 Nov 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34757631</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9300009</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15174</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1003</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1003</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF, University of Zurich, Davos, Switzerland.&#xD;Department of Medical Microbiology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin, Turkey.&#xD;Division of Pediatric Allergy and Immunology, School of Medicine, Marmara University, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The epithelial barrier hypothesis: a 20-year journey</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3560-3562</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/05/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial barrier hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmune diseases</style></keyword><keyword><style face="normal" font="default" size="100%">microbial dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">tissue microinflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33982305</style></accession-num><notes><style face="normal" font="default" size="100%">Pat, Yagiz&#xD;Ogulur, Ismail&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3560-3562. doi: 10.1111/all.14899. Epub 2021 May 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33982305</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14899</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1582</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1582</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Celebi Sozener, Z.</style></author><author><style face="normal" font="default" size="100%">Ozdel Ozturk, B.</style></author><author><style face="normal" font="default" size="100%">Cerci, P.</style></author><author><style face="normal" font="default" size="100%">Turk, M.</style></author><author><style face="normal" font="default" size="100%">Gorgulu Akin, B.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Altiner, S.</style></author><author><style face="normal" font="default" size="100%">Ozbey, U.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Yilmaz, I.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Ozdemir, C.</style></author><author><style face="normal" font="default" size="100%">Mungan, D.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinic of Immunology and Allergic Diseases, Ankara City Hospital, Ankara, Turkey.&#xD;School of Medicine, Department of Chest Diseases, Division of Immunology and Allergic Diseases, Ankara University, Ankara, Turkey.&#xD;Clinic of Immunology and Allergic Diseases, Eskisehir City Hospital, Eskisehir, Turkey.&#xD;Clinic of Immunology and Allergic Diseases, Kayseri City Hospital, Kayseri, Turkey.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Clinic of Internal Medicine Division of Immunology and Allergic Diseases, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey.&#xD;Department of Nutrition and Diet, Ankara University, Ankara, Turkey.&#xD;Department of Chest Diseases, Division of Immunology and Allergic Diseases, Erciyes University, Kayseri, Turkey.&#xD;Sean N. Parker Center for Allergy and Asthma Research at Stanford University School of Medicine, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, California, USA.&#xD;Institute of Child Health, Department of Pediatric Basic Sciences, Istanbul University, Istanbul, Turkey.&#xD;Istanbul Faculty of Medicine, Department of Pediatrics, Division of Pediatric Allergy and Immunology, Istanbul University, Istanbul, Turkey.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1418-1449</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Exposome</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Microplastics</style></keyword><keyword><style face="normal" font="default" size="100%">Plastics</style></keyword><keyword><style face="normal" font="default" size="100%">air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">climate change</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">exposome</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">Christine Kuhne-Center for Allergy Research and Education, European Commission&apos;s</style></keyword><keyword><style face="normal" font="default" size="100%">Horizon&apos;s 2020 Framework Programme, Cure, Novartis Research Institutes, Astra</style></keyword><keyword><style face="normal" font="default" size="100%">Zeneca, Glaxo Smith-Kline, Scibase, advisory role in Sanofi/Regeneron, Scibase,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Glaxo Smith Kline. Other authors declare no conflicts of interest in</style></keyword><keyword><style face="normal" font="default" size="100%">relation to this work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35108405</style></accession-num><abstract><style face="normal" font="default" size="100%">Environmental exposure plays a major role in the development of allergic diseases. The exposome can be classified into internal (e.g., aging, hormones, and metabolic processes), specific external (e.g., chemical pollutants or lifestyle factors), and general external (e.g., broader socioeconomic and psychological contexts) domains, all of which are interrelated. All the factors we are exposed to, from the moment of conception to death, are part of the external exposome. Several hundreds of thousands of new chemicals have been introduced in modern life without our having a full understanding of their toxic health effects and ways to mitigate these effects. Climate change, air pollution, microplastics, tobacco smoke, changes and loss of biodiversity, alterations in dietary habits, and the microbiome due to modernization, urbanization, and globalization constitute our surrounding environment and external exposome. Some of these factors disrupt the epithelial barriers of the skin and mucosal surfaces, and these disruptions have been linked in the last few decades to the increasing prevalence and severity of allergic and inflammatory diseases such as atopic dermatitis, food allergy, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis, and asthma. The epithelial barrier hypothesis provides a mechanistic explanation of how these factors can explain the rapid increase in allergic and autoimmune diseases. In this review, we discuss factors affecting the planet&apos;s health in the context of the &apos;epithelial barrier hypothesis,&apos; including climate change, pollution, changes and loss of biodiversity, and emphasize the changes in the external exposome in the last few decades and their effects on allergic diseases. In addition, the roles of increased dietary fatty acid consumption and environmental substances (detergents, airborne pollen, ozone, microplastics, nanoparticles, and tobacco) affecting epithelial barriers are discussed. Considering the emerging data from recent studies, we suggest stringent governmental regulations, global policy adjustments, patient education, and the establishment of individualized control measures to mitigate environmental threats and decrease allergic disease.</style></abstract><notes><style face="normal" font="default" size="100%">Celebi Sozener, Zeynep&#xD;Ozdel Ozturk, Betul&#xD;Cerci, Pamir&#xD;Turk, Murat&#xD;Gorgulu Akin, Begum&#xD;Akdis, Mubeccel&#xD;Altiner, Seda&#xD;Ozbey, Umus&#xD;Ogulur, Ismail&#xD;Mitamura, Yasutaka&#xD;Yilmaz, Insu&#xD;Nadeau, Kari&#xD;Ozdemir, Cevdet&#xD;Mungan, Dilsad&#xD;Akdis, Cezmi A&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1418-1449. doi: 10.1111/all.15240. Epub 2022 Feb 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35108405</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9306534</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15240</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2693</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2693</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sun, N.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Bu, X.</style></author><author><style face="normal" font="default" size="100%">Li, M.</style></author><author><style face="normal" font="default" size="100%">Zhu, X.</style></author><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">Ardicli, S.</style></author><author><style face="normal" font="default" size="100%">Ardicli, O.</style></author><author><style face="normal" font="default" size="100%">D&apos;Avino, P.</style></author><author><style face="normal" font="default" size="100%">Kiykim, A.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author><author><style face="normal" font="default" size="100%">Weidmann, L.</style></author><author><style face="normal" font="default" size="100%">Akdis, D.</style></author><author><style face="normal" font="default" size="100%">Ozdemir, B. G.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">Biedermann, L.</style></author><author><style face="normal" font="default" size="100%">Straumann, A.</style></author><author><style face="normal" font="default" size="100%">Kreienbuhl, A.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Jackson, D. J.</style></author><author><style face="normal" font="default" size="100%">Wang, D. Y.</style></author><author><style face="normal" font="default" size="100%">Lauerma, A.</style></author><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author><author><style face="normal" font="default" size="100%">Ozdemir, C.</style></author><author><style face="normal" font="default" size="100%">Kistler, W.</style></author><author><style face="normal" font="default" size="100%">Bayik, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;SKL of Marine Food Processing &amp; Safety Control, National Engineering Research Center of Seafood, School of Food Science and Technology, Dalian Polytechnic University, Dalian, P. R. China.&#xD;Department of Genetics, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey.&#xD;Division of Food Processing, Milk and Dairy Products Technology Program, Karacabey Vocational School, Bursa Uludag University, Bursa, Turkey.&#xD;Department of Pediatrics, Division of Pediatric Allergy and Immunology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.&#xD;Department of Nephrology, University Hospital Zurich, Zurich, Switzerland.&#xD;Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.&#xD;Obstetrician and Gynecologist, Nisantasi, Istanbul, Turkey.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St. Thomas&apos; Hospital, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Guy&apos;s Severe Asthma Centre, Guy&apos;s Hospital, Guy&apos;s &amp; St Thomas&apos; NHS Trust, London, UK.&#xD;School of Immunology &amp; Microbial Sciences, King&apos;s College London, London, UK.&#xD;Department of Otolaryngology, Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore City, Singapore.&#xD;Department of Dermatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Department of Medicine and School of Microbiology, University College Cork, Cork, Ireland.&#xD;APC Microbiome Ireland, Cork, Ireland.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Allergy, Asthma &amp; Clinical Immunology, The Alfred Hospital, Melbourne, Victoria, Australia.&#xD;Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.&#xD;Department of Otorhinolaryngology &amp; Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Allergy, Instituto de Investigacion Biosanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkey.&#xD;Istanbul Faculty of Medicine, Department of Pediatrics, Division of Pediatric Allergy and Immunology, Istanbul University, Istanbul, Turkey.&#xD;Department of Sports Medicine, Davos Hospital, Davos, Switzerland.&#xD;Swiss Research Institute for Sports Medicine (SRISM), Davos, Switzerland.&#xD;Medical Committee International Ice Hockey Federation (IIHF), Zurich, Switzerland.&#xD;Department of Internal Medicine and Hematology, Marmara University, Istanbul, Turkey.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Allergy Unit, IBIMA-Hospital Regional Universitario de Malaga-ARADyAL, UMA, Malaga, Spain.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Faculty of Medicine, Department of Allergy and Clinical Immunology, Transylvania University, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The epithelial barrier theory and its associated diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3192-3237</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/10/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">microbial dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">(SNSF no.: 310030_189334/1), GSK, Novartis, Stiftung vorm. Bundner Heilstatte</style></keyword><keyword><style face="normal" font="default" size="100%">Arosa and OM Pharma as well as speaker&apos;s fee from AstraZeneca. W.V. has received</style></keyword><keyword><style face="normal" font="default" size="100%">research grants from PROMEDICA Stiftung, Switzerland, and EoE Stiftung,</style></keyword><keyword><style face="normal" font="default" size="100%">Switzerland, and consulting fees form Mabylon AG, Switzerland. M.C.B. reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from the Swiss National Science Foundation, Christine Kuhne-Center for</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Research and Education, Leo Foundation, LEO Pharmacy, and Freenovation,</style></keyword><keyword><style face="normal" font="default" size="100%">advisory board fees from AstraZeneca, Almirall, LEO Pharma, lecture honorarium</style></keyword><keyword><style face="normal" font="default" size="100%">from Almirall and AstraZeneca, and patient education grant from AstraZeneca and</style></keyword><keyword><style face="normal" font="default" size="100%">GSK. A.S. has currently consultant contracts with Astra-Seneca, BMS-Receptos,</style></keyword><keyword><style face="normal" font="default" size="100%">Calypso, EsoCap, Falk-Pharma, GSK, and Sanofi-Regeneron. E.G.Y. is an employee of</style></keyword><keyword><style face="normal" font="default" size="100%">Mount Sinai and has received research grants from and/or is a consultant for:</style></keyword><keyword><style face="normal" font="default" size="100%">Research Grants (paid to the institution): Boehringer Ingelheim, Leo Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, Cara Therapeutics, UCB, Kyowa Kirin, RAPT, Amgen, GSK, Incyte, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Bristol Meyers Squibb, Aslan, Regeneron, Anaptysbio, Concert, Janssen.</style></keyword><keyword><style face="normal" font="default" size="100%">Consultant: Abbvie, Aclaris, Almirall, Amgen, AnaptysBio, Apogee Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">Apollo Therapeutics Limited, Artax Biopharma Inc., AstraZeneca, Bristol Meyers</style></keyword><keyword><style face="normal" font="default" size="100%">Squibb, Boerhinger-Ingelhiem, Cara Therapeutics, Centrexion Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">Corporation, Connect Biopharm, DBV TECHNOLOGIES, Eli Lilly, Enveda Biosciences,</style></keyword><keyword><style face="normal" font="default" size="100%">Escient Pharmaceuticals, Inc., Fairmount Funds Management LLC, Forest</style></keyword><keyword><style face="normal" font="default" size="100%">Laboratories Galderma, Gate Bio, Google Ventures (GV), GSK Immunology, Horizon</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics USA, Inc., Incyte, Inmagene, Janssen Biotech, JT Central</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceutical Research Institute, Jasper Therapeutics, Kyowa Kirin, Leo Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Merck, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, NUMAB</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics AG, OrbiMed Advisors LLC, OTSUKA, Pfizer, Pharmaxis Ltd, Pioneering</style></keyword><keyword><style face="normal" font="default" size="100%">Medicine VII, Inc., Proteologix US Inc, RAPT, Regeneron Pharmaceuticals,</style></keyword><keyword><style face="normal" font="default" size="100%">RibonTherapeutics, Inc., Sanofi, SATO, Schrodinger Inc., Sun Pharma Advanced</style></keyword><keyword><style face="normal" font="default" size="100%">Research Company (SPARC), Teva Branded Pharmaceutical Products R&amp;D, UCB. A.F.S.</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from the Medical Research Council (MR/M008517/1</style></keyword><keyword><style face="normal" font="default" size="100%">MC/PC/18052</style></keyword><keyword><style face="normal" font="default" size="100%">MR/T032081/1), Food Allergy Research and Education (FARE), the Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Network/National Institute of Allergy and Infectious Diseases (NIAID, NIH),</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma UK (AUK-BC-2015-01), BBSRC, Rosetrees Trust and the NIHR through the</style></keyword><keyword><style face="normal" font="default" size="100%">Biomedical Research Centre (BRC) award to Guy&apos;s and St Thomas&apos; NHS Foundation</style></keyword><keyword><style face="normal" font="default" size="100%">Trust, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Thermo Scientific,</style></keyword><keyword><style face="normal" font="default" size="100%">Nestle, Novartis, Allergy Therapeutics, IgGenix, Buhlmann, as well as research</style></keyword><keyword><style face="normal" font="default" size="100%">support from IgGenix, Buhlmann, and Thermo Fisher Scientific through a</style></keyword><keyword><style face="normal" font="default" size="100%">collaboration agreement with King&apos;s College London. S.D.G. reports speaker fees</style></keyword><keyword><style face="normal" font="default" size="100%">from AstraZeneca, Chiesi, GSK, Novartis, Sanofi, Stallergenes and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">advisory board fees from AstraZeneca, Chiesi, CSL-Behring, GSK, Novartis, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">unrestricted research grants from AstraZeneca, CSL-Behring, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, and Sanofi. O.P. reports grants and/or personal fees and/or travel</style></keyword><keyword><style face="normal" font="default" size="100%">support from ALK-Abello, Allergopharma, Stallergenes Greer, HAL Allergy Holding</style></keyword><keyword><style face="normal" font="default" size="100%">B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Laboratorios</style></keyword><keyword><style face="normal" font="default" size="100%">LETI/LETI Pharma, GlaxoSmithKline, ROXALL Medizin, Novartis, Sanofi-Aventis and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genzyme, Med Update Europe GmbH, streamedup! GmbH, Pohl-Boskamp, Inmunotek</style></keyword><keyword><style face="normal" font="default" size="100%">S.L., John Wiley and Sons/AS, Paul-Martini-Stiftung (PMS), Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals Inc., RG Aerztefortbildung, Institut fur Disease Management,</style></keyword><keyword><style face="normal" font="default" size="100%">Springer GmbH, AstraZeneca, IQVIA Commercial, Ingress Health, Wort&amp;Bild Verlag,</style></keyword><keyword><style face="normal" font="default" size="100%">Verlag ME, Procter&amp;Gamble, ALTAMIRA, Meinhardt Congress GmbH, Deutsche</style></keyword><keyword><style face="normal" font="default" size="100%">Forschungsgemeinschaft, Thieme, Deutsche AllergieLiga e.V., AeDA, Alfried-Krupp</style></keyword><keyword><style face="normal" font="default" size="100%">Krankenhaus, Red Maple Trials Inc., Koniglich Danisches Generalkonsulat,</style></keyword><keyword><style face="normal" font="default" size="100%">Medizinische Hochschule Hannover, ECM Expro&amp;Conference Management, Technical</style></keyword><keyword><style face="normal" font="default" size="100%">University Dresden, Lilly, Japanese Society of Allergy, Forum fur Medizinische</style></keyword><keyword><style face="normal" font="default" size="100%">Fortbildung, Dustri-Verlag, Pneumolive, ASIT Biotech, LOFARMA, Almirall,</style></keyword><keyword><style face="normal" font="default" size="100%">Paul-Ehrlich-Institut, outside the submitted work, and he is member of EAACI</style></keyword><keyword><style face="normal" font="default" size="100%">Excom, member of ext. board of directors DGAKI</style></keyword><keyword><style face="normal" font="default" size="100%">coordinator, main- or co-author</style></keyword><keyword><style face="normal" font="default" size="100%">of different position papers and guidelines in rhinology, allergology and</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">he is associate editor (AE) of Allergy and Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Translational Allergy. T.E. reports personal fees from Danone/Nutricia/Milupa,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from DBV, non-financial support from Novartis, personal fees from Thermo</style></keyword><keyword><style face="normal" font="default" size="100%">Fisher, personal fees from Aimmune, grants and personal fees from ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from MADX, personal fees from EFSA, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work, and I am the Co-I or scientific lead in three investigator-initiated oral</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy trials supported by the Food Allergy and Anaphylaxis Program</style></keyword><keyword><style face="normal" font="default" size="100%">Sickkids and serve as associate editor for Allergy. Site PI of company sponsored</style></keyword><keyword><style face="normal" font="default" size="100%">trials by DBV, Novartis, and Stallergen. C.O. is Assistant Editor of Allergy,</style></keyword><keyword><style face="normal" font="default" size="100%">EAACI Allied Health &amp; Primary Care Section chair. K.N. currently reports grants</style></keyword><keyword><style face="normal" font="default" size="100%">from National Institute of Allergy and Infectious Diseases (NIAID), National</style></keyword><keyword><style face="normal" font="default" size="100%">Heart, Lung, and Blood Institute (NHLBI), National Institute of Environmental</style></keyword><keyword><style face="normal" font="default" size="100%">Health Sciences (NIEHS)</style></keyword><keyword><style face="normal" font="default" size="100%">Stock options from IgGenix, Seed Health, ClostraBio,</style></keyword><keyword><style face="normal" font="default" size="100%">Cour, Alladapt</style></keyword><keyword><style face="normal" font="default" size="100%">Consultant for Excellergy, Red tree ventures, Regeneron, and</style></keyword><keyword><style face="normal" font="default" size="100%">IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">Co-founder of Alladapt, Latitude, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">National Scientific</style></keyword><keyword><style face="normal" font="default" size="100%">Committee member at Immune Tolerance Network (ITN), and National Institutes of</style></keyword><keyword><style face="normal" font="default" size="100%">Health (NIH) clinical research centers</style></keyword><keyword><style face="normal" font="default" size="100%">patents include, &quot;Mixed allergen</style></keyword><keyword><style face="normal" font="default" size="100%">com-position and methods for using the same,&quot; &quot;Granulocyte-based methods for</style></keyword><keyword><style face="normal" font="default" size="100%">detecting and monitoring immune system disorders,&quot; and &quot;Methods and Assays for</style></keyword><keyword><style face="normal" font="default" size="100%">Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune</style></keyword><keyword><style face="normal" font="default" size="100%">System Disorders.&quot; M.A. has received research grants from the Swiss National</style></keyword><keyword><style face="normal" font="default" size="100%">Science Foundation, Bern</style></keyword><keyword><style face="normal" font="default" size="100%">research grant from the Stanford University</style></keyword><keyword><style face="normal" font="default" size="100%">Leading</style></keyword><keyword><style face="normal" font="default" size="100%">House for the Latin American Region, Seed Money Grant. She is in the Scientific</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Board member of Stanford University Sean Parker Asthma Allergy Center,</style></keyword><keyword><style face="normal" font="default" size="100%">CA</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Board member of LEO Foundation Skin Immunology Research Center,</style></keyword><keyword><style face="normal" font="default" size="100%">Copenhagen</style></keyword><keyword><style face="normal" font="default" size="100%">and Scientific Co-Chair of World Allergy Congress (WAC) Istanbul,</style></keyword><keyword><style face="normal" font="default" size="100%">2022, Scientific Programme Committee Chair, EAACI. M.J. reports personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">outside of submitted work from Allergopharma, ALK-Abello, Stallergenes, Anergis,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics, Leti, HAL, GSK, Novartis, Teva, Takeda, Chiesi, Pfizer,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Astra-Zeneka, Lallemand, Shire, Celltrion Inc., Genentech, Roche,</style></keyword><keyword><style face="normal" font="default" size="100%">Verona, Lek Pharmaceuticals, Arcutis Biotherapeutics and FAES FARMA. I.A. reports</style></keyword><keyword><style face="normal" font="default" size="100%">Deputy Editor of Allergy journal. C.A.A. has received research grants from the</style></keyword><keyword><style face="normal" font="default" size="100%">Swiss National Science Foundation, European Union (EU CURE, EU Syn-Air-G),</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis Research Institutes (Basel, Switzerland), Stanford University (Redwood</style></keyword><keyword><style face="normal" font="default" size="100%">City, Calif), Seed Health (Boston, USA) and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">is the</style></keyword><keyword><style face="normal" font="default" size="100%">Co-Chair for EAACI Guidelines on Environmental Science in Allergic diseases and</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Chair of the EAACI Epithelial Cell Biology Working Group is on the</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Boards of Sanofi/Regeneron (Bern, Switzerland, New York, USA), Stanford</style></keyword><keyword><style face="normal" font="default" size="100%">University Sean Parker Asthma Allergy Center (CA, USA), Novartis (Basel,</style></keyword><keyword><style face="normal" font="default" size="100%">Switzerland), Glaxo Smith Kline (Zurich, Switzerland), Bristol-Myers Squibb (New</style></keyword><keyword><style face="normal" font="default" size="100%">York, USA), Seed Health (Boston, USA), and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">and is</style></keyword><keyword><style face="normal" font="default" size="100%">the Editor-in-Chief of Allergy. N.S., I.O., Y.M., D.Y., Y.P., X.B., M.L., X.Z.,</style></keyword><keyword><style face="normal" font="default" size="100%">H.B., S.A., O.A., P.D., A.K., L.W., D.A., B.G.O. L.B., A.K., C.T.H., D.J.J.,</style></keyword><keyword><style face="normal" font="default" size="100%">D.Y.W., A.L., H.B., L.Z., L.O.M., R.O.H., W.J.F., B.C., K.W., M.B., and M.J.T</style></keyword><keyword><style face="normal" font="default" size="100%">declare no relevant conflict of interest. N.S. reports grants from CSC</style></keyword><keyword><style face="normal" font="default" size="100%">scholarship program of China (No. 202008210164). D.A. reports grants and personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees, outside the submitted work, from the Swiss National Science Foundation, the</style></keyword><keyword><style face="normal" font="default" size="100%">Swiss Heart Foundation and Boehringer Ingelheim. L.B. reports advisory from</style></keyword><keyword><style face="normal" font="default" size="100%">Abbvie, Amgen, BMS, Falk, Janssen, Pfizer, Lilly, Takeda, Sanofi, Esocap, and</style></keyword><keyword><style face="normal" font="default" size="100%">speaker fees from Takeda, Sanofi, Abbvie, Lilly, Falk, BMS and Pfizer. D.J.J. has</style></keyword><keyword><style face="normal" font="default" size="100%">received speaker fees and consultancy fees from AZ, GSK and Sanofi. L.O.M. is a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant to PrecisionBiotics and has received research funding from GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, Reckitt and Fonterra. He has participated in speaker&apos;s bureau for Nestle,</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia, Reckitt and Abbott.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39370939</style></accession-num><abstract><style face="normal" font="default" size="100%">The prevalence of many chronic noncommunicable diseases has been steadily rising over the past six decades. During this time, over 350,000 new chemical substances have been introduced to the lives of humans. In recent years, the epithelial barrier theory came to light explaining the growing prevalence and exacerbations of these diseases worldwide. It attributes their onset to a functionally impaired epithelial barrier triggered by the toxicity of the exposed substances, associated with microbial dysbiosis, immune system activation, and inflammation. Diseases encompassed by the epithelial barrier theory share common features such as an increased prevalence after the 1960s or 2000s that cannot (solely) be accounted for by the emergence of improved diagnostic methods. Other common traits include epithelial barrier defects, microbial dysbiosis with loss of commensals and colonization of opportunistic pathogens, and circulating inflammatory cells and cytokines. In addition, practically unrelated diseases that fulfill these criteria have started to emerge as multimorbidities during the last decades. Here, we provide a comprehensive overview of diseases encompassed by the epithelial barrier theory and discuss evidence and similarities for their epidemiology, genetic susceptibility, epithelial barrier dysfunction, microbial dysbiosis, and tissue inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Sun, Na&#xD;Ogulur, Ismail&#xD;Mitamura, Yasutaka&#xD;Yazici, Duygu&#xD;Pat, Yagiz&#xD;Bu, Xiangting&#xD;Li, Manru&#xD;Zhu, Xueyi&#xD;Babayev, Huseyn&#xD;Ardicli, Sena&#xD;Ardicli, Ozge&#xD;D&apos;Avino, Paolo&#xD;Kiykim, Ayca&#xD;Sokolowska, Milena&#xD;van de Veen, Willem&#xD;Weidmann, Lukas&#xD;Akdis, Deniz&#xD;Ozdemir, Banu Goker&#xD;Bruggen, Marie Charlotte&#xD;Biedermann, Luc&#xD;Straumann, Alex&#xD;Kreienbuhl, Andrea&#xD;Guttman-Yassky, Emma&#xD;Santos, Alexandra F&#xD;Del Giacco, Stefano&#xD;Traidl-Hoffmann, Claudia&#xD;Jackson, David J&#xD;Wang, De-Yun&#xD;Lauerma, Antti&#xD;Breiteneder, Heimo&#xD;Zhang, Luo&#xD;O&apos;Mahony, Liam&#xD;Pfaar, Oliver&#xD;O&apos;Hehir, Robyn&#xD;Eiwegger, Thomas&#xD;Fokkens, Wytske J&#xD;Cabanillas, Beatriz&#xD;Ozdemir, Cevdet&#xD;Kistler, Walter&#xD;Bayik, Mahmut&#xD;Nadeau, Kari C&#xD;Torres, Maria J&#xD;Akdis, Mubeccel&#xD;Jutel, Marek&#xD;Agache, Ioana&#xD;Akdis, Cezmi A&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3192-3237. doi: 10.1111/all.16318. Epub 2024 Oct 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39370939</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657050</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16318</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2568</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2568</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kistler, W.</style></author><author><style face="normal" font="default" size="100%">Villiger, M.</style></author><author><style face="normal" font="default" size="100%">Villiger, B.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Ardicli, S.</style></author><author><style face="normal" font="default" size="100%">Skolnick, S.</style></author><author><style face="normal" font="default" size="100%">Dhir, R.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical Committee International Ice Hockey Federation, Zurich, Switzerland.&#xD;Swiss Research Institute for Sports Medicine (SRISM), Davos, Switzerland.&#xD;Department of Sports Medicine, Davos Hospital, Davos, Switzerland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Seed Health Inc., Los Angeles, California, USA.&#xD;Department of Environmental Health, T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelial barrier theory in the context of nutrition and environmental exposure in athletes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2912-2923</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/07/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Athletes</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nutritional Status</style></keyword><keyword><style face="normal" font="default" size="100%">air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">athletes</style></keyword><keyword><style face="normal" font="default" size="100%">cleaning agents</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barriers</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">processed food</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39011970</style></accession-num><abstract><style face="normal" font="default" size="100%">Exposure to toxic substances, introduced into our daily lives during industrialization and modernization, can disrupt the epithelial barriers in the skin, respiratory, and gastrointestinal systems, leading to microbial dysbiosis and inflammation. Athletes and physically active individuals are at increased risk of exposure to agents that damage the epithelial barriers and microbiome, and their extreme physical exercise exerts stress on many organs, resulting in tissue damage and inflammation. Epithelial barrier-damaging substances include surfactants and enzymes in cleaning products, laundry and dishwasher detergents, chlorine in swimming pools, microplastics, air pollutants such as ozone, particulate matter, and diesel exhaust. Athletes&apos; high-calorie diet often relies on processed foods that may contain food emulsifiers and other additives that may cause epithelial barrier dysfunction and microbial dysbiosis. The type of the material used in the sport equipment and clothing and their extensive exposure may increase the inflammatory effects. Excessive travel-related stress, sleep disturbances and different food and microbe exposure may represent additional factors. Here, we review the detrimental impact of toxic agents on epithelial barriers and microbiome; bring a new perspective on the factors affecting the health and performance of athletes and physically active individuals.</style></abstract><notes><style face="normal" font="default" size="100%">Kistler, Walter&#xD;Villiger, Michael&#xD;Villiger, Beat&#xD;Yazici, Duygu&#xD;Pat, Yagiz&#xD;Mitamura, Yasutaka&#xD;Ardicli, Sena&#xD;Skolnick, Stephen&#xD;Dhir, Raja&#xD;Akdis, Mubeccel&#xD;Nadeau, Kari&#xD;Ogulur, Ismail&#xD;Akdis, Cezmi A&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):2912-2923. doi: 10.1111/all.16221. Epub 2024 Jul 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39011970</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16221</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1639</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1639</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heijink, I. H.</style></author><author><style face="normal" font="default" size="100%">Kuchibhotla, V. N. S.</style></author><author><style face="normal" font="default" size="100%">Roffel, M. P.</style></author><author><style face="normal" font="default" size="100%">Maes, T.</style></author><author><style face="normal" font="default" size="100%">Knight, D. A.</style></author><author><style face="normal" font="default" size="100%">Sayers, I.</style></author><author><style face="normal" font="default" size="100%">Nawijn, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology &amp; Medical Biology, GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.&#xD;Department of Respiratory Medicine, Laboratory for Translational Research in Obstructive Pulmonary Diseases, Ghent University Hospital, Ghent University, Ghent, Belgium.&#xD;UBC Providence Health Care Research Institute, Vancouver, BC, Canada.&#xD;Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.&#xD;Division of Respiratory Medicine, National Institute for Health Research, Nottingham Biomedical Research Centre, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelial cell dysfunction, a major driver of asthma development</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1902-1917</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/05/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">(epi)genetics</style></keyword><keyword><style face="normal" font="default" size="100%">airway remodelling</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 responses</style></keyword><keyword><style face="normal" font="default" size="100%">Flanders (FWO</style></keyword><keyword><style face="normal" font="default" size="100%">G053516N, G041819N, FWO-EOS project G0G2318N), during the conduct</style></keyword><keyword><style face="normal" font="default" size="100%">of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from GlaxoSmithKline, outside the submitted work, and</style></keyword><keyword><style face="normal" font="default" size="100%">is shareholder of Oryzon Genomics and of Mendelion Lifesciences SL</style></keyword><keyword><style face="normal" font="default" size="100%">Prof. Nawijn</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from the Netherlands Lung Foundation (LF 14.020 and LF 18.226),</style></keyword><keyword><style face="normal" font="default" size="100%">during the conduct of the study. Outside of the submitted work, Prof. Sayers</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory reports grants from Asthma UK, British Lung Foundation Nottingham</style></keyword><keyword><style face="normal" font="default" size="100%">University Hospitals, National Institute for Health Research, Medical Research</style></keyword><keyword><style face="normal" font="default" size="100%">Council, GlaxoSmithKline and Boehringer Ingelheim</style></keyword><keyword><style face="normal" font="default" size="100%">Prof. Nawijn reports grants</style></keyword><keyword><style face="normal" font="default" size="100%">from GSK</style></keyword><keyword><style face="normal" font="default" size="100%">Prof. Heijink reports grants from the Netherlands Lung Foundation (LF</style></keyword><keyword><style face="normal" font="default" size="100%">15.017) and Boehringer Ingelheim.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32460363</style></accession-num><abstract><style face="normal" font="default" size="100%">Airway epithelial barrier dysfunction is frequently observed in asthma and may have important implications. The physical barrier function of the airway epithelium is tightly interwoven with its immunomodulatory actions, while abnormal epithelial repair responses may contribute to remodelling of the airway wall. We propose that abnormalities in the airway epithelial barrier play a crucial role in the sensitization to allergens and pathogenesis of asthma. Many of the identified susceptibility genes for asthma are expressed in the airway epithelium, supporting the notion that events at the airway epithelial surface are critical for the development of the disease. However, the exact mechanisms by which the expression of epithelial susceptibility genes translates into a functionally altered response to environmental risk factors of asthma are still unknown. Interactions between genetic factors and epigenetic regulatory mechanisms may be crucial for asthma susceptibility. Understanding these mechanisms may lead to identification of novel targets for asthma intervention by targeting the airway epithelium. Moreover, exciting new insights have come from recent studies using single-cell RNA sequencing (scRNA-Seq) to study the airway epithelium in asthma. This review focuses on the role of airway epithelial barrier function in the susceptibility to develop asthma and novel insights in the modulation of epithelial cell dysfunction in asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Heijink, Irene H&#xD;Kuchibhotla, Virinchi N S&#xD;Roffel, Mirjam P&#xD;Maes, Tania&#xD;Knight, Darryl A&#xD;Sayers, Ian&#xD;Nawijn, Martijn C&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2020 Aug;75(8):1902-1917. doi: 10.1111/all.14421. Epub 2020 Jun 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32460363</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7496351</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14421</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>322</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">322</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Avlas, S.</style></author><author><style face="normal" font="default" size="100%">Shani, G.</style></author><author><style face="normal" font="default" size="100%">Rhone, N.</style></author><author><style face="normal" font="default" size="100%">Itan, M.</style></author><author><style face="normal" font="default" size="100%">Dolitzky, A.</style></author><author><style face="normal" font="default" size="100%">Hazut, I.</style></author><author><style face="normal" font="default" size="100%">Grisaru-Tal, S.</style></author><author><style face="normal" font="default" size="100%">Gordon, Y.</style></author><author><style face="normal" font="default" size="100%">Shoda, T.</style></author><author><style face="normal" font="default" size="100%">Ballaban, A.</style></author><author><style face="normal" font="default" size="100%">Ben-Baruch, N. M.</style></author><author><style face="normal" font="default" size="100%">Rochman, M.</style></author><author><style face="normal" font="default" size="100%">Diesendruck, Y.</style></author><author><style face="normal" font="default" size="100%">Nahary, L.</style></author><author><style face="normal" font="default" size="100%">Bitton, A.</style></author><author><style face="normal" font="default" size="100%">Halpern, Z.</style></author><author><style face="normal" font="default" size="100%">Benhar, I.</style></author><author><style face="normal" font="default" size="100%">Varol, C.</style></author><author><style face="normal" font="default" size="100%">Rothenberg, M. E.</style></author><author><style face="normal" font="default" size="100%">Munitz, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.&#xD;Division of Allergy/Immunology, Department of Pediatrics, Cincinnati Children&apos;s Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.&#xD;Research Center for Digestive Tract and Liver Diseases, Sourasky Medical Center, Tel Aviv, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelial cell-expressed type II IL-4 receptor mediates eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">464-476</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13 Receptor alpha1 Subunit/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">IL-13 receptor alpha1</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">and Sartorious and is an inventor of patents owned by the Tel Aviv University.</style></keyword><keyword><style face="normal" font="default" size="100%">Itai Benhar and Almog Bitton are inventors of patents owned by the Tel Aviv</style></keyword><keyword><style face="normal" font="default" size="100%">University. Marc E. Rothenberg is a consultant for Pulm One, Spoon Guru,</style></keyword><keyword><style face="normal" font="default" size="100%">ClostraBio, Serpin Pharm, Allakos, Celgene, Astra Zeneca, Arena Pharmaceuticals,</style></keyword><keyword><style face="normal" font="default" size="100%">Glaxo Smith Kline, Revolo Biotherapeutics, and Guidepoint and has an equity</style></keyword><keyword><style face="normal" font="default" size="100%">interest in the Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, and Allakos and</style></keyword><keyword><style face="normal" font="default" size="100%">royalties from Reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust),</style></keyword><keyword><style face="normal" font="default" size="100%">and UpToDate and is an inventor of patents owned by Cincinnati Children&apos;s</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital. The remaining authors disclose no conflicts.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36070083</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic, food-driven allergic disease, characterized by eosinophil-rich inflammation in the esophagus. The histopathological and clinical features of EoE have been attributed to overproduction of the type 2 cytokines IL-4 and IL-13, which mediate profound alterations in the esophageal epithelium and neutralizing of their shared receptor component (IL-4Ralpha) with a human antibody drug (dupilumab) demonstrates clinical efficacy. Yet, the relative contribution of IL-4 and IL-13 and whether the type II IL-4 receptor (comprised of the IL-4Ralpha chain in association with IL-13Ralpha1) mediates this effect has not been determined. METHODS: Experimental EoE was induced in WT, Il13ra1(-/-) , and Krt14(Cre) /Il13ra1(fl/fl) mice by skin-sensitized using 4-ethoxymethylene-2-phenyl-2-oxazolin (OXA) followed by intraesophageal challenges. Esophageal histopathology was determined histologically. RNA was extracted and sequenced for transcriptome analysis and compared with human EoE RNAseq data. RESULTS: Induction of experimental EoE in mice lacking Il13ra1 and in vivo IL-13 antibody-based neutralization experiments blocked antigen-induced esophageal epithelial and lamina propria thickening, basal cell proliferation, eosinophilia, and tissue remodeling. In vivo targeted deletion of Il13ra1 in esophageal epithelial cells rendered mice protected from experimental EoE. Single-cell RNA sequencing analysis of human EoE biopsies revealed predominant expression of IL-13Ralpha1 in epithelial cells and that EoE signature genes correlated with IL-13 expression compared with IL-4. CONCLUSIONS: We demonstrate a definitive role for IL-13 signaling via IL-13Ralpha1 in EoE. These data provide mechanistic insights into the mode of action of current therapies in EoE and highlight the type II IL-4R as a future therapeutic target.</style></abstract><notes><style face="normal" font="default" size="100%">Avlas, Shmulik&#xD;Shani, Guy&#xD;Rhone, Natalie&#xD;Itan, Michal&#xD;Dolitzky, Avishay&#xD;Hazut, Inbal&#xD;Grisaru-Tal, Sharon&#xD;Gordon, Yaara&#xD;Shoda, Tetsuo&#xD;Ballaban, Adina&#xD;Ben-Baruch, Netali Morgenstern&#xD;Rochman, Mark&#xD;Diesendruck, Yael&#xD;Nahary, Limor&#xD;Bitton, Almog&#xD;Halpern, Zamir&#xD;Benhar, Itai&#xD;Varol, Chen&#xD;Rothenberg, Marc E&#xD;Munitz, Ariel&#xD;eng&#xD;R01 AI045898/AI/NIAID NIH HHS/&#xD;P30 DK078392/DK/NIDDK NIH HHS/&#xD;R37 AI045898/AI/NIAID NIH HHS/&#xD;R01 AI124355/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):464-476. doi: 10.1111/all.15510. Epub 2022 Sep 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36070083</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9892241</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15510</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1211</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1211</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, J.</style></author><author><style face="normal" font="default" size="100%">Meng, Y.</style></author><author><style face="normal" font="default" size="100%">Jia, M.</style></author><author><style face="normal" font="default" size="100%">Jiang, J.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Ou, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, Y.</style></author><author><style face="normal" font="default" size="100%">Yan, X.</style></author><author><style face="normal" font="default" size="100%">Huang, M.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Yao, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory &amp; Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.&#xD;Department of Respiratory &amp; Critical Care Medicine, Northern Jiangsu People&apos;s Hospital, Yangzhou, China.&#xD;Department of Respiratory &amp; Critical Care Medicine, Huai&apos;an First People&apos;s Hospital, Huai&apos;an, China.&#xD;Department of Respiratory &amp; Critical Care Medicine, Nanjing Jiangning People&apos;s Hospital, Nanjing, China.&#xD;Airway Disease Section, Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelial expression and role of secreted STC1 on asthma airway hyperresponsiveness through calcium channel modulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2475-2487</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/12/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchi</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channels</style></keyword><keyword><style face="normal" font="default" size="100%">Glycoproteins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Ovalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">calcium channel</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium- derived relaxing factor</style></keyword><keyword><style face="normal" font="default" size="100%">stanniocalcin-1</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33378582</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma is characterized by airway hyperresponsiveness (AHR), inflammation, and airway remodeling. Airway hyperresponsiveness results from enhanced airway smooth muscle (ASM) contraction potentially under the control of an epithelium-derived relaxing factor (EpDRF). However, relatively rare is known about EpDRF. We aimed to elucidate the role of epithelium-derived stanniocalcin-1 (STC1) on AHR and ASM contraction. METHODS: Stanniocalcin-1 levels in the serum of asthmatic patients and healthy volunteers and in bronchoalveolar lavage fluid (BALF) from ovalbumin (OVA)-challenged mice were measured by ELISA. The effects of exogenous STC1 on AHR and on inflammation were examined in mice. IL-13 modulation of STC1 mRNA and protein levels was studied in human bronchial epithelial cell lines (16HBE). The function of STC1 on Ca(2+) influx and ASM contraction was examined ex vivo. RESULTS: Serum STC1 was decreased in asthma (n = 93) compared with healthy volunteers (1071 +/- 30.4 vs 1414 +/- 75.1 pg/ml, p &lt; 0.0001, n = 23) and correlated with asthma control (p = 0.0270), lung function (FEV1, p = 0.0130), and serum IL-13 levels (p = 0.0009). Treatment of ten asthmatic subjects with inhaled corticosteroids/long-acting beta2-agonists (ICS/LABA) for 1 year enhanced STC1 expression which correlated with improved asthma control (p = 0.022). STC1 was mainly expressed in bronchial epithelium and intranasal administration of recombinant human STC1 (rhSTC1) reduced AHR and inflammation in mice. IL-13 suppressed STC1 release from 16HBE, whereas rhSTC1 blocked store-operated Ca(2+) entry (SOCE) by suppressing stromal interaction molecule 1 (STIM1) and further inhibited ASM cell contractility by suppressing Ca(2+) -dependent myosin light chain (MLC) phosphorylation. CONCLUSION: Our data indicate that STC1 deficiency in asthmatic airways promotes STIM1 hyperactivity, enhanced ASM contraction, and AHR. STC1 may be a candidate EpDRF.</style></abstract><notes><style face="normal" font="default" size="100%">Xu, Jiayan&#xD;Meng, Yaqi&#xD;Jia, Man&#xD;Jiang, Jie&#xD;Yang, Yi&#xD;Ou, Yingwei&#xD;Wu, Yunhui&#xD;Yan, Xiaoyi&#xD;Huang, Mao&#xD;Adcock, Ian M&#xD;Yao, Xin&#xD;eng&#xD;MR/T010371/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2475-2487. doi: 10.1111/all.14727. Epub 2021 Jun 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33378582</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14727</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1587</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1587</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, J.</style></author><author><style face="normal" font="default" size="100%">Meng, Y.</style></author><author><style face="normal" font="default" size="100%">Jia, M.</style></author><author><style face="normal" font="default" size="100%">Jiang, J.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Ou, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, Y.</style></author><author><style face="normal" font="default" size="100%">Yan, X.</style></author><author><style face="normal" font="default" size="100%">Huang, M.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Yao, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory &amp; Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.&#xD;Department of Respiratory &amp; Critical Care Medicine, Northern Jiangsu People&apos;s Hospital, Yangzhou, China.&#xD;Department of Respiratory &amp; Critical Care Medicine, Huai&apos;an First People&apos;s Hospital, Huai&apos;an, China.&#xD;Department of Respiratory &amp; Critical Care Medicine, Nanjing Jiangning People&apos;s Hospital, Nanjing, China.&#xD;Airway Disease Section, Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelial expression and role of secreted STC1 on asthma airway hyperresponsiveness through calcium channel modulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2475-2487</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/12/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchi</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channels</style></keyword><keyword><style face="normal" font="default" size="100%">Glycoproteins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Ovalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">calcium channel</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium- derived relaxing factor</style></keyword><keyword><style face="normal" font="default" size="100%">stanniocalcin-1</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33378582</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma is characterized by airway hyperresponsiveness (AHR), inflammation, and airway remodeling. Airway hyperresponsiveness results from enhanced airway smooth muscle (ASM) contraction potentially under the control of an epithelium-derived relaxing factor (EpDRF). However, relatively rare is known about EpDRF. We aimed to elucidate the role of epithelium-derived stanniocalcin-1 (STC1) on AHR and ASM contraction. METHODS: Stanniocalcin-1 levels in the serum of asthmatic patients and healthy volunteers and in bronchoalveolar lavage fluid (BALF) from ovalbumin (OVA)-challenged mice were measured by ELISA. The effects of exogenous STC1 on AHR and on inflammation were examined in mice. IL-13 modulation of STC1 mRNA and protein levels was studied in human bronchial epithelial cell lines (16HBE). The function of STC1 on Ca(2+) influx and ASM contraction was examined ex vivo. RESULTS: Serum STC1 was decreased in asthma (n = 93) compared with healthy volunteers (1071 +/- 30.4 vs 1414 +/- 75.1 pg/ml, p &lt; 0.0001, n = 23) and correlated with asthma control (p = 0.0270), lung function (FEV1, p = 0.0130), and serum IL-13 levels (p = 0.0009). Treatment of ten asthmatic subjects with inhaled corticosteroids/long-acting beta2-agonists (ICS/LABA) for 1 year enhanced STC1 expression which correlated with improved asthma control (p = 0.022). STC1 was mainly expressed in bronchial epithelium and intranasal administration of recombinant human STC1 (rhSTC1) reduced AHR and inflammation in mice. IL-13 suppressed STC1 release from 16HBE, whereas rhSTC1 blocked store-operated Ca(2+) entry (SOCE) by suppressing stromal interaction molecule 1 (STIM1) and further inhibited ASM cell contractility by suppressing Ca(2+) -dependent myosin light chain (MLC) phosphorylation. CONCLUSION: Our data indicate that STC1 deficiency in asthmatic airways promotes STIM1 hyperactivity, enhanced ASM contraction, and AHR. STC1 may be a candidate EpDRF.</style></abstract><notes><style face="normal" font="default" size="100%">Xu, Jiayan&#xD;Meng, Yaqi&#xD;Jia, Man&#xD;Jiang, Jie&#xD;Yang, Yi&#xD;Ou, Yingwei&#xD;Wu, Yunhui&#xD;Yan, Xiaoyi&#xD;Huang, Mao&#xD;Adcock, Ian M&#xD;Yao, Xin&#xD;eng&#xD;MR/T010371/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2475-2487. doi: 10.1111/all.14727. Epub 2021 Jun 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33378582</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14727</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2970</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2970</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moon, S.</style></author><author><style face="normal" font="default" size="100%">Moon, S.</style></author><author><style face="normal" font="default" size="100%">Lee, S.</style></author><author><style face="normal" font="default" size="100%">Kim, G.</style></author><author><style face="normal" font="default" size="100%">Koo, M. S.</style></author><author><style face="normal" font="default" size="100%">Cho, H. J.</style></author><author><style face="normal" font="default" size="100%">Kim, C. H.</style></author><author><style face="normal" font="default" size="100%">Rha, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea.&#xD;The Airway Mucus Institute, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelial Lining Fluid Cystatin SN is a Noninvasive Biomarker for Predicting Type 2 Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2572-2585</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/07/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/diagnosis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/diagnosis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Salivary Cystatins/metabolism/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Mucosa/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">ROC Curve</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">cystatin SN</style></keyword><keyword><style face="normal" font="default" size="100%">endotype</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40689541</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: As treatment responses differ according to the inflammatory endotype of chronic rhinosinusitis (CRS), identifying the endotype could facilitate personalized treatment. We aimed to identify a noninvasive epithelial lining fluid (ELF) biomarker for the type 2 (T2) endotype of CRS. METHODS: Nasal tissue and ELF samples were obtained from patients with CRS and control individuals. Single-cell RNA sequencing (scRNA-seq) data were analyzed. The expression of inflammatory mediators was measured using Luminex multiplex assays and enzyme-linked immunosorbent assays. RESULTS: Analysis of the scRNA-seq data revealed that CST1 was exclusively expressed in epithelial cells of T2 CRS, but not in those of non-T2 CRS, and this was confirmed by immunofluorescence staining. Cystatin SN expression was detected in ELF, and its levels were significantly higher in T2 CRS than in non-T2 CRS and controls. The expression level of cystatin SN in the ELF was positively correlated with the Lund-Mackay CT, SNOT-22, and JESREC scores, whereas it was inversely correlated with olfactory function. Furthermore, ELF cystatin SN levels correlated with the tissue/blood eosinophil count and nasal tissue expression of T2 inflammatory mediators, indicating that ELF cystatin SN is a reliable marker of nasal T2 inflammation. In the receiver operating characteristics curve analysis evaluating the predictive efficacy for T2 CRS, the AUC for ELF cystatin SN was 0.894 (0.936 in the validation cohort), which was higher than that of other markers, including blood eosinophil count, serum total IgE level, and the JESREC score. With a cut-off value of 112.5 ng/mg, ELF cystatin SN yielded a 75.0% sensitivity and 92.0% specificity. CONCLUSIONS: ELF cystatin SN is a clinically feasible, noninvasive biomarker with superior accuracy for predicting T2 CRS.</style></abstract><notes><style face="normal" font="default" size="100%">Moon, Seojin&#xD;Moon, Sungmin&#xD;Lee, Sol&#xD;Kim, Gyeongyeob&#xD;Koo, Min-Seok&#xD;Cho, Hyung-Ju&#xD;Kim, Chang-Hoon&#xD;Rha, Min-Seok&#xD;eng&#xD;Korea Health Industry Development Institute/&#xD;National Research Foundation of Korea/&#xD;Yonsei University College of Medicine/&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2572-2585. doi: 10.1111/all.16652. Epub 2025 Jul 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40689541</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444822</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16652</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3044</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3044</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Janas, P. P.</style></author><author><style face="normal" font="default" size="100%">T&apos;Jonck, W.</style></author><author><style face="normal" font="default" size="100%">Burgess, M. O.</style></author><author><style face="normal" font="default" size="100%">Reck, M.</style></author><author><style face="normal" font="default" size="100%">Chauche, C.</style></author><author><style face="normal" font="default" size="100%">Vermeren, M.</style></author><author><style face="normal" font="default" size="100%">Lucas, C. D.</style></author><author><style face="normal" font="default" size="100%">Bain, C.</style></author><author><style face="normal" font="default" size="100%">Illingworth, R.</style></author><author><style face="normal" font="default" size="100%">Roberts, E. W.</style></author><author><style face="normal" font="default" size="100%">McSorley, H. J.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Inflammation Research, Institute for Regeneration and Repair, the University of Edinburgh, Edinburgh, Scotland.&#xD;Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh, Scotland.&#xD;CRUK Scotland Institute, Glasgow, Scotland.&#xD;Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, Scotland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelial Memory After Respiratory Viral Infection in Mice Results in Prolonged Enhancement of Antigen Presentation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2501-2518</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigen Presentation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunologic Memory</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Syncytial Virus Infections/immunology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Epithelial Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Tract Infections/immunology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Syncytial Viruses/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Rsv</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetic imprinting</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial memory</style></keyword><keyword><style face="normal" font="default" size="100%">lung epithelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory viral infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40772364</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Viral lower respiratory tract infections (LRTIs) can reduce the severity of subsequent LRTIs but have also been linked to respiratory allergy development and exacerbation. Here, we show that viral LRTI can imprint lung epithelial cells (LECs), leading to prolonged phenotypic and functional changes. METHODS: Mice were infected via intranasal administration of respiratory syncytial virus (RSV). After 28 days, LECs were isolated using cold dispase digestion followed by magnetic-activated cell sorting. Epigenetic changes were assessed using Cleavage Under Targets and Release Using Nuclease (CUT&amp;RUN), while transcriptional changes were evaluated using NanoString and qPCR. Flow cytometry was employed to measure cell surface major histocompatibility complex (MHC) levels, antigen uptake and processing rates, and OT-I cell proliferation after antigen presentation. RESULTS: We identified epigenetic and transcriptomic changes in murine LECs 28 days after RSV infection, especially impacting genes associated with MHC. Lasting upregulation of MHC-I and MHC-II was further increased following in vivo LPS stimulation. Importantly, MHC upregulation was associated with increased antigen uptake and processing, as well as increased antigen presentation to T cells. CONCLUSIONS: Our data demonstrate that RSV can induce prolonged upregulation of antigen presentation by LECs, with the potential to facilitate local T cell responses to microbial antigens and allergens and to enhance immunity or in susceptible hosts respiratory allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Janas, Piotr P&#xD;T&apos;Jonck, Wouter&#xD;Burgess, Matthew O&#xD;Reck, Maximilian&#xD;Chauche, Caroline&#xD;Vermeren, Matthieu&#xD;Lucas, Christopher D&#xD;Bain, Calum&#xD;Illingworth, Robert&#xD;Roberts, Edward W&#xD;McSorley, Henry J&#xD;Schwarze, Jurgen&#xD;eng&#xD;British Lung Foundation/&#xD;MRC_/Medical Research Council/United Kingdom&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2501-2518. doi: 10.1111/all.16683. Epub 2025 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40772364</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444829</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16683</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3282</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3282</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fu, Heng</style></author><author><style face="normal" font="default" size="100%">Sun, Peng</style></author><author><style face="normal" font="default" size="100%">Yuan, Xijing</style></author><author><style face="normal" font="default" size="100%">Yao, Lei</style></author><author><style face="normal" font="default" size="100%">Hua, Qi</style></author><author><style face="normal" font="default" size="100%">Li, Yuebei</style></author><author><style face="normal" font="default" size="100%">Xuan, Shurui</style></author><author><style face="normal" font="default" size="100%">Zeng, Xiaoning</style></author><author><style face="normal" font="default" size="100%">Adcock, Ian M.</style></author><author><style face="normal" font="default" size="100%">Yao, Xin</style></author><author><style face="normal" font="default" size="100%">Jia, Man</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Epithelial-Associated CD207+ DCs Link Allergen Sensing and IL-25-Driven Th2 Inflammation in Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background IL-25 is a key epithelial-derived alarmin associated with T2-high asthma, yet its downstream mechanisms remain poorly defined. CD207 (Langerin)+ dendritic cells (DCs) are localized at the airway epithelial interface. However, whether these cells respond to epithelial-derived cytokines and contribute to the Th2 immune response in asthma remains unclear. Methods Single-cell RNA-seq from healthy human lungs was analyzed to define the transcriptomic features of CD207+ DCs. Their function was validated in a house dust mite (HDM)-induced asthma model using Cd207−/− mice. Flow cytometry was performed on lung and mediastinal lymph nodes. DC–T cell co-cultures were used to assess Th2 polarization. Epithelial–DC interactions were evaluated using transwell co-culture with ALI-differentiated tracheal epithelial cells. Clinical relevance was examined in airway samples from asthma patients in the U-BIOPRED cohort. Results CD207+ DCs were enriched in intraepithelial compartments and exhibited increased MHC-II and Claudin-1 expression. In asthma, their abundance correlated with T2 signatures and Th2 markers (CRTH2, ST2). CD207 deletion reduced HDM uptake, Th2 cytokines, airway inflammation, and Th2 differentiation. IL-25 induced CD207+ DCs and enhanced their Th2-polarizing capacity in vitro. An IL-25–CD207 co-expression score correlated with IL-4/IL-5/IL-13 levels and was higher in steroid-naïve patients with severe asthma. Conclusion Our study identifies CD207+ DCs as epithelial-associated antigen-presenting cells that bridge IL-25 signaling and Th2 polarization in allergic asthma. Targeting the IL-25–CD207 axis may offer therapeutic opportunities for T2-high asthma.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70244</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70244</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2106</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2106</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yao, L.</style></author><author><style face="normal" font="default" size="100%">Yuan, X.</style></author><author><style face="normal" font="default" size="100%">Fu, H.</style></author><author><style face="normal" font="default" size="100%">Guo, Q.</style></author><author><style face="normal" font="default" size="100%">Wu, Y.</style></author><author><style face="normal" font="default" size="100%">Xuan, S.</style></author><author><style face="normal" font="default" size="100%">Kermani, N. Z.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Zeng, X.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Xie, M.</style></author><author><style face="normal" font="default" size="100%">Yao, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.&#xD;Data Science Institute, Department of Computing, Imperial College London, London, UK.&#xD;Airway Disease Section, Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Allergy, Pulmonary and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.&#xD;Shandong Key Laboratory of Infections Respiratory Disease, Medical Science and Technology Innovation Center, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.&#xD;Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epithelium-derived cystatin SN inhibits house dust mite protease activity in allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1507-1523</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/04/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Salivary Cystatins</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">Peptide Hydrolases</style></keyword><keyword><style face="normal" font="default" size="100%">*Cysteine Proteases</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Cst1</style></keyword><keyword><style face="normal" font="default" size="100%">Hdm</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier function</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37026502</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergen source-derived proteases are a critical factor in the formation and development of asthma. The cysteine protease activity of house dust mite (HDM) disrupts the epithelial barrier function. The expression of cystatin SN (CST1) is elevated in asthma epithelium. CST1 inhibits the cysteine protease activity. We aimed to elucidate the role of epithelium-derived CST1 in the development of asthma caused by HDM. METHODS: CST1 protein levels in sputum supernatants and serum of patients with asthma and healthy volunteers were measured by ELISA. The ability of CST1 protein to suppress HDM-induced bronchial epithelial barrier function was examined in vitro. The effects of exogenous CST1 protein on abrogating HDM-induced epithelial barrier function and inflammation were examined in mice in vivo. RESULTS: CST1 protein levels were higher in sputum supernatants (142.4 +/- 8.95 vs 38.87 +/- 6.85 ng/mL, P &lt; 0.0001) and serum (1129 +/- 73.82 vs 703.1 +/- 57.02 pg/mL, P = 0.0035) in patients with asthma than in healthy subjects. The levels were significantly higher in patients with not well- and very poorly controlled asthma than those with well-controlled asthma. Sputum and serum CST1 protein levels were negatively correlated with lung function in asthma. CST1 protein levels were significantly lower in the serum of HDM-specific IgE (sIgE)-positive asthmatics than in sIgE-negative asthmatics. The HDM-induced epithelial barrier function disruption was suppressed by recombinant human CST1 protein (rhCST1) in vitro and in vivo. CONCLUSION: Our data indicated that human CST1 protein suppresses asthma symptoms by protecting the asthmatic bronchial epithelial barrier through inhibiting allergenic protease activity. CST1 protein may serve as a potential biomarker for asthma control.</style></abstract><notes><style face="normal" font="default" size="100%">Yao, Lei&#xD;Yuan, Xijing&#xD;Fu, Heng&#xD;Guo, Qinxing&#xD;Wu, Yunhui&#xD;Xuan, Shurui&#xD;Kermani, Nazanin Zounemat&#xD;Adcock, Ian M&#xD;Zeng, Xiaoning&#xD;Liu, Yi&#xD;Xie, Min&#xD;Yao, Xin&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1507-1523. doi: 10.1111/all.15739. Epub 2023 Apr 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37026502</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15739</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2523</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2523</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, D. F.</style></author><author><style face="normal" font="default" size="100%">Su, Z. Q.</style></author><author><style face="normal" font="default" size="100%">Luo, Y. L.</style></author><author><style face="normal" font="default" size="100%">Zhou, Z. Q.</style></author><author><style face="normal" font="default" size="100%">Guo, Z. Y.</style></author><author><style face="normal" font="default" size="100%">Yao, L. H.</style></author><author><style face="normal" font="default" size="100%">Liu, J. W.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Zhong, C. H.</style></author><author><style face="normal" font="default" size="100%">Chen, X. B.</style></author><author><style face="normal" font="default" size="100%">Tang, C. L.</style></author><author><style face="normal" font="default" size="100%">Li, S. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Respiratory Diseases, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.&#xD;Innovation Centre for Advanced Interdisciplinary Medicine, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.&#xD;National Heart &amp; Lung Institute, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Establishment of a novel severe asthma canine model: Feasible research platform of respiratory intervention therapies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1513-1517</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/06/26</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38922920</style></accession-num><notes><style face="normal" font="default" size="100%">Chen, Di-Fei&#xD;Su, Zhu-Quan&#xD;Luo, Yu-Long&#xD;Zhou, Zi-Qing&#xD;Guo, Zu-Yuan&#xD;Yao, Li-Hong&#xD;Liu, Jing-Wei&#xD;Chen, Yu&#xD;Chung, Kian Fan&#xD;Zhong, Chang-Hao&#xD;Chen, Xiao-Bo&#xD;Tang, Chun-Li&#xD;Li, Shi-Yue&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1513-1517. doi: 10.1111/all.16207. Epub 2024 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38922920</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105063</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16207</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2649</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2649</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Landgraf, A.</style></author><author><style face="normal" font="default" size="100%">Hein, S.</style></author><author><style face="normal" font="default" size="100%">Paulus-Tremel, K. E.</style></author><author><style face="normal" font="default" size="100%">Wolff, M. B.</style></author><author><style face="normal" font="default" size="100%">Arend, M.</style></author><author><style face="normal" font="default" size="100%">Junker, A. C.</style></author><author><style face="normal" font="default" size="100%">Strecker, D.</style></author><author><style face="normal" font="default" size="100%">Doring, S.</style></author><author><style face="normal" font="default" size="100%">Volker, E.</style></author><author><style face="normal" font="default" size="100%">Holzhauser, T.</style></author><author><style face="normal" font="default" size="100%">Schmidt, S.</style></author><author><style face="normal" font="default" size="100%">Kaul, S.</style></author><author><style face="normal" font="default" size="100%">Schulke, S.</style></author><author><style face="normal" font="default" size="100%">Mahler, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany.&#xD;Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Establishment of an ELISA-based in vitro test system to quantify the major honey bee venom allergen Api m 10 in crude bee venoms and therapy allergen products</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">861-864</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/09/12</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39264014</style></accession-num><notes><style face="normal" font="default" size="100%">Landgraf, Alisa&#xD;Hein, Sascha&#xD;Paulus-Tremel, Kathrin Elisabeth&#xD;Wolff, Michelle Beatrice&#xD;Arend, Meike&#xD;Junker, Ann-Christine&#xD;Strecker, Daniel&#xD;Doring, Sascha&#xD;Volker, Elke&#xD;Holzhauser, Thomas&#xD;Schmidt, Sandra&#xD;Kaul, Susanne&#xD;Schulke, Stefan&#xD;Mahler, Vera&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):861-864. doi: 10.1111/all.16313. Epub 2024 Sep 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39264014</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891423</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16313</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1403</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1403</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cephus, J. Y.</style></author><author><style face="normal" font="default" size="100%">Gandhi, V. D.</style></author><author><style face="normal" font="default" size="100%">Shah, R.</style></author><author><style face="normal" font="default" size="100%">Brooke Davis, J.</style></author><author><style face="normal" font="default" size="100%">Fuseini, H.</style></author><author><style face="normal" font="default" size="100%">Yung, J. A.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Kita, H.</style></author><author><style face="normal" font="default" size="100%">Polosukhin, V. V.</style></author><author><style face="normal" font="default" size="100%">Zhou, W.</style></author><author><style face="normal" font="default" size="100%">Newcomb, D. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, USA.&#xD;Allergic Diseases Research Laboratory, Mayo Clinic, Phoenix, Arizona, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Estrogen receptor-alpha signaling increases allergen-induced IL-33 release and airway inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">255-268</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Estrogen Receptor alpha</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-33</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">IL-33 release</style></keyword><keyword><style face="normal" font="default" size="100%">Ilc2</style></keyword><keyword><style face="normal" font="default" size="100%">allergic airway inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">estrogen receptor alpha</style></keyword><keyword><style face="normal" font="default" size="100%">sex disparity</style></keyword><keyword><style face="normal" font="default" size="100%">this work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32648964</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Group 2 innate lymphoid cells (ILC2) are stimulated by IL-33 to increase IL-5 and IL-13 production and airway inflammation. While sex hormones regulate airway inflammation, it remained unclear whether estrogen signaling through estrogen receptor-alpha (ER-alpha, Esr1) or ER-beta (Esr2) increased ILC2-mediated airway inflammation. We hypothesize that estrogen signaling increases allergen-induced IL-33 release, ILC2 cytokine production, and airway inflammation. METHODS: Female Esr1(-/-) , Esr2(-/-) , wild-type (WT), and IL33(fl/fl) eGFP mice were challenged with Alternaria extract (Alt Ext) or vehicle for 4 days. In select experiments, mice were administered tamoxifen or vehicle pellets for 21 days prior to challenge. Lung ILC2, IL-5 and IL-13 production, and BAL inflammatory cells were measured on day 5 of Alt Ext challenge model. Bone marrow from WT and Esr1(-/-) female mice was transferred (1:1 ratio) into WT female recipients for 6 weeks followed by Alt Ext challenge. hBE33 cells and normal human bronchial epithelial cells (NHBE) were pretreated with 17beta-estradiol (E2), propyl-pyrazole-triol (PPT, ER-alpha agonist), or diarylpropionitrile (DPN, ER-beta agonist) before allergen challenge to determine IL-33 gene expression and release, extracellular ATP release, DUOX-1 production, and necrosis. RESULTS: Alt Ext challenged Esr1(-/-) , but not Esr2(-/-) , mice had decreased IL-5 and IL-13 production, BAL eosinophils, and IL-33 release compared to WT mice. Tamoxifen decreased IL-5 and IL-13 production and BAL eosinophils. IL-33eGFP + epithelial cells were decreased in Alt Ext challenged Esr1(-/-) mice compared to WT mice. 17beta-E2 or PPT, but not DPN, increased IL-33 gene expression, release, and DUOX-1 production in hBE33 or NHBE cells. CONCLUSION: Estrogen receptor -alpha signaling increased IL-33 release and ILC2-mediated airway inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Cephus, Jacqueline-Yvonne&#xD;Gandhi, Vivek D&#xD;Shah, Ruchi&#xD;Brooke Davis, Jordan&#xD;Fuseini, Hubaida&#xD;Yung, Jeffrey A&#xD;Zhang, Jian&#xD;Kita, Hirohito&#xD;Polosukhin, Vasiliy V&#xD;Zhou, Weisong&#xD;Newcomb, Dawn C&#xD;eng&#xD;R01 HL122554/HL/NHLBI NIH HHS/&#xD;R21 AI121420/AI/NIAID NIH HHS/&#xD;UL1 TR000445/TR/NCATS NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):255-268. doi: 10.1111/all.14491. Epub 2020 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32648964</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7790897</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14491</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2336</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2336</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author><author><style face="normal" font="default" size="100%">Alobid, I.</style></author><author><style face="normal" font="default" size="100%">Anselmo-Lima, W. T.</style></author><author><style face="normal" font="default" size="100%">Bernal-Sprekelsen, M.</style></author><author><style face="normal" font="default" size="100%">Bjermer, L.</style></author><author><style face="normal" font="default" size="100%">Caulley, L.</style></author><author><style face="normal" font="default" size="100%">Chaker, A.</style></author><author><style face="normal" font="default" size="100%">Constantinidis, J.</style></author><author><style face="normal" font="default" size="100%">Conti, D. M.</style></author><author><style face="normal" font="default" size="100%">De Corso, E.</style></author><author><style face="normal" font="default" size="100%">Desrosiers, M.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author><author><style face="normal" font="default" size="100%">Gevaert, P.</style></author><author><style face="normal" font="default" size="100%">Han, J. K.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Hopkins, C.</style></author><author><style face="normal" font="default" size="100%">Landis, B. N.</style></author><author><style face="normal" font="default" size="100%">Lourenco, O.</style></author><author><style face="normal" font="default" size="100%">Lund, V.</style></author><author><style face="normal" font="default" size="100%">Luong, A. U.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Peters, A.</style></author><author><style face="normal" font="default" size="100%">Philpott, C.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Ryan, D.</style></author><author><style face="normal" font="default" size="100%">Scadding, G.</style></author><author><style face="normal" font="default" size="100%">Senior, B.</style></author><author><style face="normal" font="default" size="100%">Tomazic, P. V.</style></author><author><style face="normal" font="default" size="100%">Toskala, E.</style></author><author><style face="normal" font="default" size="100%">Van Zele, T.</style></author><author><style face="normal" font="default" size="100%">Viskens, A. S.</style></author><author><style face="normal" font="default" size="100%">Wagenmann, M.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology and Immunology, Allergy and Clinical Immunology Research unit, KU Leuven, Leuven, Belgium.&#xD;Clinical Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.&#xD;Department of Otorhinolaryngology, Upper airways research laboratory, Ghent University, Ghent, Belgium.&#xD;Rhinology and Skull Base Unit, ENT Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.&#xD;Clinical and Experimental Respiratory Immunoallergy, Institut d&apos;Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.&#xD;Center of Biomedical Research in Respiratory Diseases (CIBERES), Barcelona, Spain.&#xD;Division of Otorhinolaryngology, Department of Ophthalmology, Otorhinolaryngology, Head and Neck Surgery, Ribeirao Preto Medical School-University of Sao Paulo, Brazil.&#xD;Department of Otorhinolaryngology, University of Barcelona, Barcelona, Spain.&#xD;Department of Otorhinolaryngology, Hospital Clinic Barcelona, Barcelona, Spain.&#xD;Department of Respiratory Medicine &amp; Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.&#xD;Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, Ottawa, Ontario, Canada.&#xD;Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.&#xD;Institut for Klinisk Medicin, Aarhus University, Aarhus, Denmark.&#xD;Dept. of Otorhinolaryngology and Center for Allergy and Environment (ZAUM), TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.&#xD;1st Department of Otorhinolaryngology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;The European Forum for Research and Education in Allergy and Airway Diseases Scientific Expert Team Members, Brussels, Belgium.&#xD;Otolaryngology, Head and Neck Surgery, Rhinology, A. Gemelli University Hospital Foundation, IRCSS, Rome, Italy.&#xD;Department of ORL-HNS, Universite de Montreal, Montreal, Canada.&#xD;Department of Microbiology Immunology &amp; Transplantation, KU Leuven, Catholic University of Leuven, Leuven, Belgium.&#xD;Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.&#xD;Department of Clinical Pharmacy &amp; Pharmacology, University in Groningen, University Medical Center Groningen, Groningen, Netherlands.&#xD;Department of Otolaryngology &amp; Head and Neck Surgery, Eastern Virginia Medical School, Virginia, USA.&#xD;Personalized Medicine, Asthma and Allergy-IRCCS Humanitas Research Hospital, Rozzano, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Ear, Nose and Throat Department, Guys and St. Thomas Hospital, London, UK.&#xD;Rhinology-Olfactology Unit, Department of Otorhinolaryngology Head and Neck Surgery, University Hospital of Geneva, Geneva, Switzerland.&#xD;FCS-UBI, Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal.&#xD;CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Royal National Ear, Nose and Eastman Dental Hospital, London, UK.&#xD;Otolaryngology-HNS, McGovern Medical School of the University of Texas Health Science Center, Houston, Texas, USA.&#xD;Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, FRCB-IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Spain.&#xD;Division of Allergy and Immunology and Northwestern Sinus Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Rhinology &amp; ENT Research Group, Norwich Medical School, University of East Anglia, Norwich, UK.&#xD;Norfolk &amp; Waveney ENT Service, James Paget and Norfolk &amp; Norwich University Hospitals, Norfolk, UK.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.&#xD;Royal National ENT Hospital, London and Division of Immunity and Infection, University College, London, UK.&#xD;Department of Otolaryngology/Head and Neck Surgery, University of North Carolina, Chapel Hill, North Carolina, USA.&#xD;Department of General Otorhinolaryngology, H&amp;N Surgery, Medical University of Graz, Graz, Austria.&#xD;Otolaryngology-HNS, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.&#xD;Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.&#xD;Department of Otorhinolaryngology, Universitatsklinikum Dusseldorf, Dusseldorf, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1123-1133</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/12/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinosinusitis/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">aspirin intolerance</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroids</style></keyword><keyword><style face="normal" font="default" size="100%">sinus surgery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38108602</style></accession-num><abstract><style face="normal" font="default" size="100%">Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.</style></abstract><notes><style face="normal" font="default" size="100%">Hellings, Peter W&#xD;Alobid, Isam&#xD;Anselmo-Lima, Wilma T&#xD;Bernal-Sprekelsen, Manuel&#xD;Bjermer, Leif&#xD;Caulley, Lisa&#xD;Chaker, Adam&#xD;Constantinidis, Jannis&#xD;Conti, Diego M&#xD;De Corso, Eugenio&#xD;Desrosiers, Martin&#xD;Diamant, Zuzana&#xD;Gevaert, Philippe&#xD;Han, Joseph K&#xD;Heffler, Enrico&#xD;Hopkins, Claire&#xD;Landis, Basile N&#xD;Lourenco, Olga&#xD;Lund, Valerie&#xD;Luong, Amber U&#xD;Mullol, Joaquim&#xD;Peters, Anju&#xD;Philpott, Carl&#xD;Reitsma, Sietze&#xD;Ryan, Dermot&#xD;Scadding, Glenis&#xD;Senior, Brent&#xD;Tomazic, Peter Valentin&#xD;Toskala, Elina&#xD;Van Zele, Thibaut&#xD;Viskens, An-Sofie&#xD;Wagenmann, Martin&#xD;Fokkens, W J&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1123-1133. doi: 10.1111/all.15982. Epub 2023 Dec 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38108602</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15982</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">13</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gevaert, P.</style></author><author><style face="normal" font="default" size="100%">De Craemer, J.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Blauwblomme, M.</style></author><author><style face="normal" font="default" size="100%">Chaker, A.</style></author><author><style face="normal" font="default" size="100%">Cingi, C.</style></author><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author><author><style face="normal" font="default" size="100%">Hopkins, C.</style></author><author><style face="normal" font="default" size="100%">Hox, V.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Lund, V.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Scadding, G.</style></author><author><style face="normal" font="default" size="100%">Tomazic, P. V.</style></author><author><style face="normal" font="default" size="100%">Van Zele, T.</style></author><author><style face="normal" font="default" size="100%">Vlaminck, S.</style></author><author><style face="normal" font="default" size="100%">Wagenmann, M.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Alobid, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Upper Airways Research Laboratory, Department of Otorhinolaryngology, Ghent University, Ghent, Belgium.&#xD;First Affiliated Hospital, Sun Yat-sen University, International Airway Research Center, Guangzhou, China.&#xD;Division of ENT Diseases, CLINTEC, Karolinska Institute, University of Stockholm, Stockholm, Sweden.&#xD;Department of Otolaryngology and Center of Allergy and Environment (ZAUM), TUM School of Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.&#xD;Eskisehir Osmangazi University, Medical Faculty, Department of Otorhinolaryngology, Eskisehir, Turkey.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University of Leuven, Leuven, Belgium.&#xD;Department of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Guy&apos;s and St Thomas&apos; Hospitals, London, UK.&#xD;Department of Otorhinolaryngology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.&#xD;Institute of Experimental and Clinical Research, Pole of Pulmonology, ENT and Dermatology, UCLouvain, Brussels, Belgium.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Royal National Throat Nose and Ear Hospital, UCLH Foundation Trust, London, UK.&#xD;Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, and CRI-Clinical Research International, Hamburg, Germany.&#xD;Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Spain.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;RNENT Hospital, University College London Hospitals, London, UK.&#xD;Department of General Otorhinolaryngology, H&amp;N Surgery, Medical University of Graz, Graz, Austria.&#xD;Department of Otorhinolaryngology, AZ St-Johns Hospital, Bruges, Belgium.&#xD;Department of Otorhinolaryngology, HNO-Klinik, Universitatsklinikum Dusseldorf, Dusseldorf, Germany.&#xD;Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.&#xD;Rhinology and Skull Base Unit, ENT Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain; Clinical and Experimental Respiratory Immunoallergy, Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Center of Biomedical Research in Respiratory Diseases (CIBERES), Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">912-922</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/01/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Endoscopy/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">nasal endoscopy</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyposis</style></keyword><keyword><style face="normal" font="default" size="100%">scoring system</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36661567</style></accession-num><abstract><style face="normal" font="default" size="100%">Nasal endoscopy is not only used for the diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP), but also for monitoring the response to therapy playing an important role in both daily practice and research. In contrast to patient-reported outcomes, endoscopic nasal polyp scoring by independent blinded readers is an objective measurement, not influenced by the placebo effect. It is safer and cheaper compared with computed tomography imaging and therefore, better suited for regular assessments of the extent of the disease. Since the early 90s, a variety of endoscopic staging methods have been proposed and used in clinical research, making it hard to compare results from different studies. This paper resulted from a task force with experts in the field of CRSwNP, originated by the Ear, Nose and Throat section of the European Academy of Allergy and Clinical Immunology and aims to provide a unified endoscopic NP scoring system that can serve as a reference standard for researchers, but also as a useful tool for practitioners involved in the management of CRSwNP.</style></abstract><notes><style face="normal" font="default" size="100%">Gevaert, Philippe&#xD;De Craemer, Jarno&#xD;Bachert, Claus&#xD;Blauwblomme, Manon&#xD;Chaker, Adam&#xD;Cingi, Cemal&#xD;Hellings, Peter W&#xD;Hopkins, Claire&#xD;Hox, Valerie&#xD;Fokkens, Wytske J&#xD;Klimek, Ludger&#xD;Lund, Valerie&#xD;Mosges, Ralph&#xD;Mullol, Joaquim&#xD;Pfaar, Oliver&#xD;Scadding, Glenis&#xD;Tomazic, Peter Valentin&#xD;Van Zele, Thibaut&#xD;Vlaminck, Stephan&#xD;Wagenmann, Martin&#xD;Toppila-Salmi, Sanna&#xD;Alobid, Isam&#xD;eng&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):912-922. doi: 10.1111/all.15650. Epub 2023 Feb 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36661567</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15650</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2141</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2141</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kallen, E. J. J.</style></author><author><style face="normal" font="default" size="100%">Revers, A.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B.</style></author><author><style face="normal" font="default" size="100%">Barreales, L.</style></author><author><style face="normal" font="default" size="100%">Belohlavkova, S.</style></author><author><style face="normal" font="default" size="100%">de Blay, F.</style></author><author><style face="normal" font="default" size="100%">Clausen, M.</style></author><author><style face="normal" font="default" size="100%">Dubakiene, R.</style></author><author><style face="normal" font="default" size="100%">Ebisawa, M.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Perez, C.</style></author><author><style face="normal" font="default" size="100%">Fritsche, P.</style></author><author><style face="normal" font="default" size="100%">Fukutomi, Y.</style></author><author><style face="normal" font="default" size="100%">Gislason, D.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Jedrzejczak-Czechowicz, M.</style></author><author><style face="normal" font="default" size="100%">Knulst, A. C.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author><author><style face="normal" font="default" size="100%">Kralimarkova, T.</style></author><author><style face="normal" font="default" size="100%">Lidholm, J.</style></author><author><style face="normal" font="default" size="100%">Metzler, C.</style></author><author><style face="normal" font="default" size="100%">Mills, E. N. C.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Purohit, A.</style></author><author><style face="normal" font="default" size="100%">Reig, I.</style></author><author><style face="normal" font="default" size="100%">Seneviratne, S. L.</style></author><author><style face="normal" font="default" size="100%">Sinaniotis, A.</style></author><author><style face="normal" font="default" size="100%">Takei, M.</style></author><author><style face="normal" font="default" size="100%">Versteeg, S. A.</style></author><author><style face="normal" font="default" size="100%">Vassilopoulou, A. E.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author><author><style face="normal" font="default" size="100%">Welsing, P. M. J.</style></author><author><style face="normal" font="default" size="100%">Zwinderman, A. H.</style></author><author><style face="normal" font="default" size="100%">Le, T. M.</style></author><author><style face="normal" font="default" size="100%">Van Ree, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.&#xD;Epidemiology and Data Science (EDS), Amsterdam University Medical Center location University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Allergy, Hospital Clinico San Carlos, Universidad Complutense, IdISSC, ARADyAL, Madrid, Spain.&#xD;Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.&#xD;Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Clinic for Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland.&#xD;Medical Faculty Pilsen, Charles University Prague, Prague, Czech Republic.&#xD;Allergy Division, Chest Disease Department, Strasbourg University Hospital, Strasbourg, France.&#xD;Landspitali University Hospital, University of Iceland, Faculty of Medicine, Reykjavik, Iceland.&#xD;Clinic of Chest diseases, Allergology and Immunology Institute of Clinic al Medicine Medical Faculty Vilnius University, Vilnius, Lithuania.&#xD;Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Kanagawa, Japan.&#xD;Servicio de Medicina Preventiva, Area De Santiago de Compostela y Barbanza, Instituto de Investigacion Sanitaria de Santiago (IDIS) A Coruna, Santiago, Spain.&#xD;Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Department of Immunology and Allergy, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.&#xD;Clinic of Occupational Diseases, University Hospital Sv. Ivan Rilski, Sofia, Bulgaria.&#xD;Thermo Fisher Scientific, Uppsala, Sweden.&#xD;Division of Infection, Immunity and Respiratory Medicine, Manchester Institute of Biotechnology &amp; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Allergist and Pediatrician, Napoles y Sicilia Health Center, Valencia, Spain.&#xD;Institute of Immunity and Transplantation, University College London, London, UK.&#xD;Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece.&#xD;Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.&#xD;Departments of Experimental Immunology and of Otorhinolaryngology, Amsterdam University Medical Center, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A European-Japanese study on peach allergy: IgE to Pru p 7 associates with severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2497-2509</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/06/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Prunus persica/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Peach allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Pru p 3</style></keyword><keyword><style face="normal" font="default" size="100%">Pru p 7</style></keyword><keyword><style face="normal" font="default" size="100%">prediction</style></keyword><keyword><style face="normal" font="default" size="100%">severity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37334557</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Pru p 3 and Pru p 7 have been implicated as risk factors for severe peach allergy. This study aimed to establish sensitization patterns to five peach components across Europe and in Japan, to explore their relation to pollen and foods and to predict symptom severity. METHODS: In twelve European (EuroPrevall project) and one Japanese outpatient clinic, a standardized clinical evaluation was conducted in 1231 patients who reported symptoms to peach and/or were sensitized to peach. Specific IgE against Pru p 1, 2, 3, 4 and 7 and against Cup s 7 was measured in 474 of them. Univariable and multivariable Lasso regression was applied to identify combinations of parameters predicting severity. RESULTS: Sensitization to Pru p 3 dominated in Southern Europe but was also quite common in Northern and Central Europe. Sensitization to Pru p 7 was low and variable in the European centers but very dominant in Japan. Severity could be predicted by a model combining age of onset of peach allergy, probable mugwort, Parietaria pollen and latex allergy, and sensitization to Japanese cedar pollen, Pru p 4 and Pru p 7 which resulted in an AUC of 0.73 (95% CI 0.73-0.74). Pru p 3 tended to be a risk factor in South Europe only. CONCLUSIONS: Pru p 7 was confirmed as a significant risk factor for severe peach allergy in Europe and Japan. Combining outcomes from clinical and demographic background with serology resulted in a model that could better predict severity than CRD alone.</style></abstract><notes><style face="normal" font="default" size="100%">Kallen, E J J&#xD;Revers, A&#xD;Fernandez-Rivas, M&#xD;Asero, R&#xD;Ballmer-Weber, B&#xD;Barreales, L&#xD;Belohlavkova, S&#xD;de Blay, F&#xD;Clausen, M&#xD;Dubakiene, R&#xD;Ebisawa, M&#xD;Fernandez-Perez, C&#xD;Fritsche, P&#xD;Fukutomi, Y&#xD;Gislason, D&#xD;Hoffmann-Sommergruber, K&#xD;Jedrzejczak-Czechowicz, M&#xD;Knulst, A C&#xD;Kowalski, M L&#xD;Kralimarkova, T&#xD;Lidholm, J&#xD;Metzler, C&#xD;Mills, E N C&#xD;Papadopoulos, N G&#xD;Popov, T A&#xD;Purohit, A&#xD;Reig, I&#xD;Seneviratne, S L&#xD;Sinaniotis, A&#xD;Takei, M&#xD;Versteeg, S A&#xD;Vassilopoulou, A E&#xD;Vieths, S&#xD;Welsing, P M J&#xD;Zwinderman, A H&#xD;Le, T M&#xD;Van Ree, R&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2497-2509. doi: 10.1111/all.15783. Epub 2023 Jun 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37334557</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15783</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2535</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2535</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garate, D.</style></author><author><style face="normal" font="default" size="100%">Thang, C. J.</style></author><author><style face="normal" font="default" size="100%">Murphy, T. L.</style></author><author><style face="normal" font="default" size="100%">Sharma, D.</style></author><author><style face="normal" font="default" size="100%">Golovko, G.</style></author><author><style face="normal" font="default" size="100%">Wilkerson, M. G.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Gulati, N.</style></author><author><style face="normal" font="default" size="100%">Ungar, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">John Sealy School of Medicine, University of Texas Medical Branch, Galveston, Texas, USA.&#xD;Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA.&#xD;Department of Dermatology, University of Texas Medical Branch, Galveston, Texas, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluating alopecia areata risk among patients with seasonal and food allergies: A multicenter cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3525-3528</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/06/17</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38881038</style></accession-num><notes><style face="normal" font="default" size="100%">Garate, David&#xD;Thang, Christopher J&#xD;Murphy, Trevor L&#xD;Sharma, Divija&#xD;Golovko, George&#xD;Wilkerson, Michael G&#xD;Guttman-Yassky, Emma&#xD;Gulati, Nicholas&#xD;Ungar, Benjamin&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3525-3528. doi: 10.1111/all.16199. Epub 2024 Jun 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38881038</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16199</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2364</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2364</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rodriguez Del Rio, P.</style></author><author><style face="normal" font="default" size="100%">Alvaro-Lozano, M.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Bazire, R.</style></author><author><style face="normal" font="default" size="100%">Escudero, C.</style></author><author><style face="normal" font="default" size="100%">Patel, N.</style></author><author><style face="normal" font="default" size="100%">Sandoval-Ruballos, M.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Ortiz, M.</style></author><author><style face="normal" font="default" size="100%">Nowak-Wegrzyn, A.</style></author><author><style face="normal" font="default" size="100%">Blumchen, K.</style></author><author><style face="normal" font="default" size="100%">Dunn Galvin, A.</style></author><author><style face="normal" font="default" size="100%">Deschildre, A.</style></author><author><style face="normal" font="default" size="100%">Greenhawt, M.</style></author><author><style face="normal" font="default" size="100%">Schnadt, S.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Remington, B. C.</style></author><author><style face="normal" font="default" size="100%">Turner, P.</style></author><author><style face="normal" font="default" size="100%">Fernandez Rivas, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.&#xD;FibHNJ, ARADyAL-RETICs RD16 /0006/0026 Instituto de Salud Carlos III, Madrid, Spain.&#xD;IIS La Princesa, Madrid, Spain.&#xD;Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Deu, Barcelona, Spain.&#xD;Institut de Recerca Sant Joan de Deu, Barcelona, Spain.&#xD;Universitat de Barcelona, Barcelona, Spain.&#xD;Translational Research in Paediatric Specialities Area, Division of Allergy, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Department of Pediatrics, Hassenfeld Children&apos;s Hospital, NYU Grossman School of Medicine, New York City, New York, USA.&#xD;Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.&#xD;Division of Pneumology, Allergology and Cystic Fibrosis, Department of Paediatric and Adolescent Medicine, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.&#xD;University College Cork, Cork, Ireland.&#xD;Pediatric Pulmonology and Allergy Department, CHU Lille, Univ. Lille, Hopital Jeanne de Flandre, Lille, France.&#xD;Section of Allergy and Immunology, Department of Pediatrics, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurura, Colorado, USA.&#xD;German Allergy and Asthma Association (DAAB), Monchengladbach, Germany.&#xD;Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.&#xD;Khoo Teck Puat-National University Children&apos;s Medical Institute, National University Hospital, National University Health System, Singapore City, Singapore.&#xD;Food Allergy Research and Resource Program, Department of Food Science and Technology, University of Nebraska, Lincoln, Nebraska, USA.&#xD;Remington Consulting Group B.V, Utrecht, The Netherlands.&#xD;Allergy Department, Hospital Clinico San Carlos, Facultad de Medicina, Universidad Complutense (UCM), IdISSC, ARADyAL, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">793-822</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Committees</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38263695</style></accession-num><abstract><style face="normal" font="default" size="100%">Food allergy is a global public health problem that until recent years lacked any aetiological treatment supported by academy, industry and regulators. Food immunotherapy (AIT) is an evolving treatment option, supported by clinical practice and industry trial data. Recent AIT meta-analyses have highlighted the difficulty in pooling safety and efficacy data from AIT trials, due to secondary heterogeneity in the study. An EAACI task force (CO-FAITH) initiated by the Paediatric Section was created to focus on AIT efficacy outcomes for milk, egg and peanut allergy rather than in trial results. A systematic search and a narrative review of AIT controlled clinical trials and large case series was conducted. A total of 63 manuscripts met inclusion criteria, corresponding to 23, 21 and 22 studies of milk, egg and peanut AIT, respectively. The most common AIT efficacy outcome was desensitization, mostly defined as tolerating a maintenance phase dose, or reaching a particular dose upon successful exit oral food challenge (OFC). However, a large degree of heterogeneity was identified regarding the dose quantity defining this outcome. Sustained unresponsiveness and patient-reported outcomes (e.g. quality of life) were explored less frequently, and to date have been most rigorously described for peanut AIT versus other allergens. Change in allergen threshold assessed by OFC remains the most common efficacy measure, but OFC methods suffer from heterogeneity and methodological disparity. This review has identified multiple heterogeneous outcomes related to measuring the efficacy of AIT. Efforts to better standardize and harmonize which outcomes, and how to measure them must be carried out to help in the clinical development of safe and efficacious food allergy treatments.</style></abstract><notes><style face="normal" font="default" size="100%">Rodriguez Del Rio, Pablo&#xD;Alvaro-Lozano, Montserrat&#xD;Arasi, Stefania&#xD;Bazire, Raphaelle&#xD;Escudero, Carmelo&#xD;Patel, Nandinee&#xD;Sandoval-Ruballos, Monica&#xD;Vazquez-Ortiz, Marta&#xD;Nowak-Wegrzyn, Anna&#xD;Blumchen, Katharina&#xD;Dunn Galvin, Audrey&#xD;Deschildre, Antoine&#xD;Greenhawt, Matthew&#xD;Schnadt, Sabine&#xD;Riggioni, Carmen&#xD;Remington, Benjamin C&#xD;Turner, Paul&#xD;Fernandez Rivas, Montserrat&#xD;eng&#xD;MR/W025639/1/MRC_/Medical Research Council/United Kingdom&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):793-822. doi: 10.1111/all.16027. Epub 2024 Jan 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38263695</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16027</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2524</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2524</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chan, R.</style></author><author><style face="normal" font="default" size="100%">Stewart, K.</style></author><author><style face="normal" font="default" size="100%">Kuo, C. R.</style></author><author><style face="normal" font="default" size="100%">Lipworth, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Scottish Centre for Respiratory Research, School of Medicine, Ninewells Hospital, University of Dundee, Dundee, Scotland, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of dupilumab and benralizumab on peripheral airway resistance and reactance</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2862-2864</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38925542</style></accession-num><notes><style face="normal" font="default" size="100%">Chan, Rory&#xD;Stewart, Kirsten&#xD;Kuo, Chris RuiWen&#xD;Lipworth, Brian&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2862-2864. doi: 10.1111/all.16214. Epub 2024 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38925542</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16214</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2603</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2603</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tsai, S. Y.</style></author><author><style face="normal" font="default" size="100%">Gaffin, J. M.</style></author><author><style face="normal" font="default" size="100%">Hawryluk, E. B.</style></author><author><style face="normal" font="default" size="100%">Ruran, H. B.</style></author><author><style face="normal" font="default" size="100%">Bartnikas, L. M.</style></author><author><style face="normal" font="default" size="100%">Oyoshi, M. K.</style></author><author><style face="normal" font="default" size="100%">Schneider, L. C.</style></author><author><style face="normal" font="default" size="100%">Phipatanakul, W.</style></author><author><style face="normal" font="default" size="100%">Ma, K. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Pulmonary Medicine, Boston Children&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.&#xD;Division of Immunology, Department of Pediatrics, Boston Children&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Pediatric Allergy, Mucosal Immunology and Biology Research Center, Massachusetts General Hospital for Children, Charlestown, Massachusetts, USA.&#xD;Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population-based cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2748-2758</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/08/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cost of Illness</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Population Surveillance</style></keyword><keyword><style face="normal" font="default" size="100%">adolescents</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic march</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidities</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">infections</style></keyword><keyword><style face="normal" font="default" size="100%">mental health</style></keyword><keyword><style face="normal" font="default" size="100%">neurodevelopmental disorders</style></keyword><keyword><style face="normal" font="default" size="100%">receives royalty from UpToDate (author/reviewer), and reports conflicts with</style></keyword><keyword><style face="normal" font="default" size="100%">Apogee (advisory board) and Skin Analytics (consulting). Dr. Oyoshi was supported</style></keyword><keyword><style face="normal" font="default" size="100%">by grants NIH/NIAID R01 AI142872, R01 AI172938, and R21 AI151591. Dr. Schneider:</style></keyword><keyword><style face="normal" font="default" size="100%">Investigator - Regeneron, DBV Technologies. Advisory Boards - Sanofi, Triveni</style></keyword><keyword><style face="normal" font="default" size="100%">Bio, DBV, Alladapt Immunotherapeutics, BioThea Pharmaceuticals, Ukko, Leo</style></keyword><keyword><style face="normal" font="default" size="100%">pharmaceuticals, DAIT/NIAID, National Eczema Association Dr. Phipatanakul was</style></keyword><keyword><style face="normal" font="default" size="100%">supported by grant NIH/NIAID K24 AI106822. Dr. Tsai, Hana Ruran, Dr. Bartnikas,</style></keyword><keyword><style face="normal" font="default" size="100%">and Dr. Ma have no COI to report.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39166365</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed to evaluate the impact of dupilumab on the occurrence of comorbidities in pediatric patients with AD. METHODS: In this population-based cohort study, we utilized electronic health records from multiple healthcare organizations across the United States. Pediatric patients (&lt;18 years of age) with a diagnosis of AD initiating dupilumab were propensity-score matched 1:1 to those initiating other systemic agents (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, or systemic corticosteroids). The primary outcomes were new-onset comorbidities emerging during the study period measured by the risk ratio (RR) and its confidence interval (CI). Subgroup analyses were stratified by age (0-5 years, 6-11 years, and 12-17 years), sex, and race. RESULTS: A total of 3575 pediatric patients with AD treated with dupilumab were matched to 3575 patients treated with other systemic agents. The dupilumab cohort was associated with a lowered risk of new-onset atopic comorbidities (including asthma [RR, 0.72; 95% CI, 0.59-0.89] and allergic rhinitis [RR, 0.62; 95% CI, 0.52-0.74]), infections (e.g., skin and soft tissue infection [RR, 0.70; 95% CI, 0.63-0.76] and respiratory tract infection [RR = 0.56; 95% CI, 0.51-0.61]), psychiatric disorders (e.g., mood disorder [RR, 0.52; 95% CI, 0.39-0.70] and anxiety [RR, 0.57; 95% CI, 0.46-0.70], sleep disturbance [RR, 0.60; 95% CI, 0.47-0.77]), neurologic and developmental disorders (e.g., attention deficit hyperactivity disorder [RR, 0.54; 95% CI, 0.38-0.75]). Furthermore, the positive effects are found to be more pronounced in younger children (aged 0-5 years) with AD. CONCLUSIONS: Treatment with dupilumab compared to systemic agents resulted in reductions in AD-related comorbidities in pediatric patients.</style></abstract><notes><style face="normal" font="default" size="100%">Tsai, Serena Yun-Chen&#xD;Gaffin, Jonathan M&#xD;Hawryluk, Elena B&#xD;Ruran, Hana B&#xD;Bartnikas, Lisa M&#xD;Oyoshi, Michiko K&#xD;Schneider, Lynda C&#xD;Phipatanakul, Wanda&#xD;Ma, Kevin Sheng-Kai&#xD;eng&#xD;R01 AI142872/AI/NIAID NIH HHS/&#xD;R01 AI172938/AI/NIAID NIH HHS/&#xD;NH/NIH HHS/&#xD;R21 AI151591/AI/NIAID NIH HHS/&#xD;K24 AI106822/AI/NIAID NIH HHS/&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2748-2758. doi: 10.1111/all.16265. Epub 2024 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39166365</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11608558</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16265</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2636</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2636</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yong, H. J.</style></author><author><style face="normal" font="default" size="100%">Park, S. H.</style></author><author><style face="normal" font="default" size="100%">Lee, S. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Respiratory Disease and Allergy, Department of Internal Medicine, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Republic of Korea.&#xD;Department of Radiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.&#xD;Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of inguinal and axillary lymph node size distribution for intralymphatic injection</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">870-872</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/09/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">computed tomograph</style></keyword><keyword><style face="normal" font="default" size="100%">intralymphatic injection</style></keyword><keyword><style face="normal" font="default" size="100%">lymph nodes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39319596</style></accession-num><notes><style face="normal" font="default" size="100%">Yong, Ho Jin&#xD;Park, So Hyun&#xD;Lee, Sang Min&#xD;eng&#xD;Dankook University/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):870-872. doi: 10.1111/all.16325. Epub 2024 Sep 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39319596</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16325</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2802</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2802</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aktas, O. N.</style></author><author><style face="normal" font="default" size="100%">Mateja, A.</style></author><author><style face="normal" font="default" size="100%">Li, M. J.</style></author><author><style face="normal" font="default" size="100%">Chatman, L.</style></author><author><style face="normal" font="default" size="100%">Grieco, M. C.</style></author><author><style face="normal" font="default" size="100%">Baloh, C. H.</style></author><author><style face="normal" font="default" size="100%">Huffaker, M.</style></author><author><style face="normal" font="default" size="100%">Wheatley, L. M.</style></author><author><style face="normal" font="default" size="100%">du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Brittain, E.</style></author><author><style face="normal" font="default" size="100%">Frischmeyer-Guerrerio, P. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland, USA.&#xD;Division of Allergy and Immunology, Children&apos;s National Hospital, Washington, District of Columbia, USA.&#xD;Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.&#xD;Biostatistics Research Branch, NIAID, NIH, North Bethesda, Maryland, USA.&#xD;Division of Allergy and Clinical Immunology, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Immune Tolerance Network, Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA.&#xD;National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland, USA.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Pediatric Allergy Group, Department of Women and Children&apos;s Health, School of Life Course and Population Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of Intestinal Permeability Using Serum Biomarkers in Learning Early About Peanut Allergy Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2286-2296</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/01/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/immunology/blood/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Permeability</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Intestinal Mucosa/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Lipopolysaccharide Receptors/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acid-Binding Proteins/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Cholera Toxin/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Barrier Function</style></keyword><keyword><style face="normal" font="default" size="100%">Haptoglobins</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Precursors</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">intestinal permeability</style></keyword><keyword><style face="normal" font="default" size="100%">serum biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">to the current study.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39803811</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Intestinal barrier dysfunction may lead to a break in tolerance and development of food allergy (FA). There is contradictory evidence on whether intestinal permeability (IP) is altered in IgE-mediated FA. Thus, we sought to determine whether IP differed between children with eczema who did (FA group) or did not (atopic controls, ACs) develop FA and whether peanut sensitization, allergy, and early introduction impacted IP using serum biomarkers zonulin, soluble CD14, and Intestinal Fatty Acid Binding Protein among randomly selected participants enrolled in the Learning Early About Peanut allergy trial. METHODS: FA group was defined as having at least one FA at either baseline (4-11 months) or 60 months of age (V60). ACs had eczema at baseline and no FA at either visit. Serum IP markers (sIPMs) were measured by ELISA at baseline and V60, and their relationship with the clinical characteristics of participants was analyzed using parametric tests and linear regression models. RESULTS: We evaluated 237 FA subjects and 76 ACs. sIPM levels were similar in FA subjects and ACs at baseline and V60. Age when the child first developed any FA (&lt; 1 year vs. &gt; 1 year), eczema severity, peanut sensitization, peanut allergy, and early peanut introduction were not statistically significantly associated with sIPM levels. Total IgE and eosinophil levels, peanut-specific IgE, IgG4, and IgG4/IgE ratio were not correlated with sIPM levels. CONCLUSIONS: No differences in sIPMs were detected to support altered IP in infants with FA compared to ACs or following early peanut introduction among peanut-sensitized children.</style></abstract><notes><style face="normal" font="default" size="100%">Aktas, Ozge Nur&#xD;Mateja, Allyson&#xD;Li, Min Jenny&#xD;Chatman, Lindsay&#xD;Grieco, Megan C&#xD;Baloh, Carolyn H&#xD;Huffaker, Michelle&#xD;Wheatley, Lisa M&#xD;du Toit, George&#xD;Lack, Gideon&#xD;Brittain, Erica&#xD;Frischmeyer-Guerrerio, Pamela A&#xD;eng&#xD;UM1 AI109565/AI/NIAID NIH HHS/&#xD;75N91019D00024/CA/NCI NIH HHS/&#xD;National Institute of Allergy and Infectious Diseases/&#xD;Division of Intramural Research, National Institute of Allergy and Infectious Diseases/&#xD;Z99 AI999999/ImNIH/Intramural NIH HHS/&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2286-2296. doi: 10.1111/all.16464. Epub 2025 Jan 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39803811</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12255823</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16464</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2707</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2707</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Casanovas, N.</style></author><author><style face="normal" font="default" size="100%">Gruzelle, V.</style></author><author><style face="normal" font="default" size="100%">Broue-Chabbert, A.</style></author><author><style face="normal" font="default" size="100%">Pontcharraud, R.</style></author><author><style face="normal" font="default" size="100%">Kamphuis, J.</style></author><author><style face="normal" font="default" size="100%">Martin-Blondel, A.</style></author><author><style face="normal" font="default" size="100%">Guilleminault, L.</style></author><author><style face="normal" font="default" size="100%">Michelet, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pneumology Pediatric Allergology, CHU Toulouse Purpan, Toulouse, France.&#xD;Pediatric Clinical Research Unit/Pediatric multi-thematic module CIC 1436, CHU Toulouse Purpan, Centre d&apos;investigation clinique de Toulouse, Toulouse, France.&#xD;INSERM, Infinity, Asthme, Allergy and Immunotherapy, CHU Purpan, Toulouse, France.&#xD;Pneumology Allergology, CHU Toulouse Larrey, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of oral immunotherapy in hazelnut allergy: Pediatric experience in Toulouse</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">349-351</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/11/21</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39569706</style></accession-num><notes><style face="normal" font="default" size="100%">Casanovas, N&#xD;Gruzelle, V&#xD;Broue-Chabbert, A&#xD;Pontcharraud, R&#xD;Kamphuis, J&#xD;Martin-Blondel, A&#xD;Guilleminault, L&#xD;Michelet, M&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):349-351. doi: 10.1111/all.16385. Epub 2024 Nov 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39569706</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724246</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16385</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2242</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2242</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Philipp, M. S.</style></author><author><style face="normal" font="default" size="100%">Numm, T. J.</style></author><author><style face="normal" font="default" size="100%">Deng, Y.</style></author><author><style face="normal" font="default" size="100%">Iwamoto, K.</style></author><author><style face="normal" font="default" size="100%">Herrmann, N.</style></author><author><style face="normal" font="default" size="100%">Bieber, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, and Christine Kuhne Center for Allergy Research and Education Davos (CK-CARE), University Hospital Bonn, Bonn, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evidence for a restoration of TLR2 response in epidermal dendritic cells in atopic dermatitis by topical anti-inflammatory therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">249-252</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/09/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Langerhans Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 2</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Topical</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37746739</style></accession-num><notes><style face="normal" font="default" size="100%">Philipp, Marie-Sophie&#xD;Numm, Tim J&#xD;Deng, Yuxuan&#xD;Iwamoto, Kazumasa&#xD;Herrmann, Nadine&#xD;Bieber, Thomas&#xD;eng&#xD;Christine Kuhne - Center for Allergy Research and Education/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):249-252. doi: 10.1111/all.15899. Epub 2023 Sep 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37746739</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15899</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>383</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">383</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leonardi, A.</style></author><author><style face="normal" font="default" size="100%">Daull, P.</style></author><author><style face="normal" font="default" size="100%">Rosani, U.</style></author><author><style face="normal" font="default" size="100%">Cavarzeran, F.</style></author><author><style face="normal" font="default" size="100%">Salami, E.</style></author><author><style face="normal" font="default" size="100%">Garrigue, J. S.</style></author><author><style face="normal" font="default" size="100%">Paola, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ophthalmology Unit, Department of Neuroscience, University of Padua, Padova, Italy.&#xD;Santen SAS, Evry, France.&#xD;Department of Biology, University of Padova, Padova, Italy.&#xD;Histology Unit, Department of Molecular Medicine, University of Padova, Padova, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evidence of epithelial remodelling but not epithelial-mesenchymal transition by transcriptome profiling in vernal keratoconjunctivitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3460-3462</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35852814</style></accession-num><notes><style face="normal" font="default" size="100%">Leonardi, Andrea&#xD;Daull, Philippe&#xD;Rosani, Umberto&#xD;Cavarzeran, Fabiano&#xD;Salami, Elena&#xD;Garrigue, Jean-Sebastien&#xD;Paola, Brun&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3460-3462. doi: 10.1111/all.15450. Epub 2022 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35852814</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15450</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>892</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">892</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kolukisa, B.</style></author><author><style face="normal" font="default" size="100%">Baser, D.</style></author><author><style face="normal" font="default" size="100%">Akcam, B.</style></author><author><style face="normal" font="default" size="100%">Danielson, J.</style></author><author><style face="normal" font="default" size="100%">Bilgic Eltan, S.</style></author><author><style face="normal" font="default" size="100%">Haliloglu, Y.</style></author><author><style face="normal" font="default" size="100%">Sefer, A. P.</style></author><author><style face="normal" font="default" size="100%">Babayeva, R.</style></author><author><style face="normal" font="default" size="100%">Akgun, G.</style></author><author><style face="normal" font="default" size="100%">Charbonnier, L. M.</style></author><author><style face="normal" font="default" size="100%">Schmitz-Abe, K.</style></author><author><style face="normal" font="default" size="100%">Kendir Demirkol, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Gonzaga-Jauregui, C.</style></author><author><style face="normal" font="default" size="100%">Jimenez Heredia, R.</style></author><author><style face="normal" font="default" size="100%">Kasap, N.</style></author><author><style face="normal" font="default" size="100%">Kiykim, A.</style></author><author><style face="normal" font="default" size="100%">Ozek Yucel, E.</style></author><author><style face="normal" font="default" size="100%">Gok, V.</style></author><author><style face="normal" font="default" size="100%">Unal, E.</style></author><author><style face="normal" font="default" size="100%">Pac Kisaarslan, A.</style></author><author><style face="normal" font="default" size="100%">Nepesov, S.</style></author><author><style face="normal" font="default" size="100%">Baysoy, G.</style></author><author><style face="normal" font="default" size="100%">Onal, Z.</style></author><author><style face="normal" font="default" size="100%">Yesil, G.</style></author><author><style face="normal" font="default" size="100%">Celkan, T. T.</style></author><author><style face="normal" font="default" size="100%">Cokugras, H.</style></author><author><style face="normal" font="default" size="100%">Camcioglu, Y.</style></author><author><style face="normal" font="default" size="100%">Eken, A.</style></author><author><style face="normal" font="default" size="100%">Boztug, K.</style></author><author><style face="normal" font="default" size="100%">Lo, B.</style></author><author><style face="normal" font="default" size="100%">Karakoc-Aydiner, E.</style></author><author><style face="normal" font="default" size="100%">Su, H. C.</style></author><author><style face="normal" font="default" size="100%">Ozen, A.</style></author><author><style face="normal" font="default" size="100%">Chatila, T. A.</style></author><author><style face="normal" font="default" size="100%">Baris, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Pediatric Allergy and Immunology, Marmara University, Istanbul, Turkey.&#xD;Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey.&#xD;The Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.&#xD;Human Immunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, Maryland, USA.&#xD;Clinical Genomics Program, NIAID, NIH, Bethesda, Maryland, USA.&#xD;Department of Medical Biology, Erciyes University School of Medicine, Kayseri, Turkey.&#xD;Boston Children&apos;s Hospital and Department of Pediatrics, Division of Immunology, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Boston Children&apos;s Hospital, Division of Immunology and Newborn Medicine, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Genomic Laboratory (GLAB), Umraniye Teaching and Research Hospital, University of Health Sciences, Istanbul, Turkey.&#xD;Regeneron Genetics Center, Tarrytown, New York, USA.&#xD;Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria.&#xD;St. Anna Children&apos;s Cancer Research Institute (CCRI), Vienna, Austria.&#xD;Faculty of Medicine, Pediatric Allergy and Immunology, Istanbul University-Cerrahpasa, Istanbul, Turkey.&#xD;Istanbul Faculty of Medicine, Pediatric Allergy and Immunology, Istanbul University, Istanbul, Turkey.&#xD;Erciyes University School of Medicine, Pediatric Hematology and Oncology, Kayseri, Turkey.&#xD;Erciyes University School of Medicine, Pediatric Rheumatology, Kayseri, Turkey.&#xD;Department of Pediatric Allergy and Immunology, Medipol University Medical Faculty, Istanbul, Turkey.&#xD;Department of Pediatric Gastroenterology, Medipol University Medical Faculty, Istanbul, Turkey.&#xD;Department of Pediatric Gastroenterology, Hepatology and Nutrition, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Faculty of Medicine, Division of Pediatric Hematology and Oncology, Istanbul University-Cerrahpasa, Istanbul, Turkey.&#xD;Research Branch, Division of Translational Medicine, Sidra Medicine, Doha, Qatar.&#xD;College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evolution and long-term outcomes of combined immunodeficiency due to CARMIL2 deficiency</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1004-1019</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/07/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammatory Bowel Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Microfilament Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Primary Immunodeficiency Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Carmil2</style></keyword><keyword><style face="normal" font="default" size="100%">CD28 co-signaling</style></keyword><keyword><style face="normal" font="default" size="100%">combined immune deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default" size="100%">long-term follow-up</style></keyword><keyword><style face="normal" font="default" size="100%">Technological Research Council of Turkey (318S202). Dr. Chatila received grants</style></keyword><keyword><style face="normal" font="default" size="100%">from National Institutes of Health (R01AI065617 and R01AI128976). Dr. Su</style></keyword><keyword><style face="normal" font="default" size="100%">supported by Intramural Research Program of the National Institute of Allergy and</style></keyword><keyword><style face="normal" font="default" size="100%">Infectious Diseases. Dr. Lo received grant from the Sidra Precision Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Program, under project SDR400013. B.K, D.B, B.A, J.D, S.B.E, Y.H, A.P.S, R.B,</style></keyword><keyword><style face="normal" font="default" size="100%">G.A, L.M.C, K.S.A, Y.K.D, Y.Z, C.G.J, R.J.H, N.K, A.K, E.O.Y, V.G, E.U, A.P.K,</style></keyword><keyword><style face="normal" font="default" size="100%">S.N, G.B, Z.O, G.Y, T.T.C, H.C, Y.C, A.E, K.B, E.K.A, A.O have no conflict of</style></keyword><keyword><style face="normal" font="default" size="100%">interest to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34287962</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Biallelic loss-of-function mutations in CARMIL2 cause combined immunodeficiency associated with dermatitis, inflammatory bowel disease (IBD), and EBV-related smooth muscle tumors. Clinical and immunological characterizations of the disease with long-term follow-up and treatment options have not been previously reported in large cohorts. We sought to determine the clinical and immunological features of CARMIL2 deficiency and long-term efficacy of treatment in controlling different disease manifestations. METHODS: The presenting phenotypes, long-term outcomes, and treatment responses were evaluated prospectively in 15 CARMIL2-deficient patients, including 13 novel cases. Lymphocyte subpopulations, protein expression, regulatory T (Treg), and circulating T follicular helper (cT(FH) ) cells were analyzed. Three-dimensional (3D) migration assay was performed to determine T-cell shape. RESULTS: Mean age at disease onset was 38 +/- 23 months. Main clinical features were skin manifestations (n = 14, 93%), failure to thrive (n = 10, 67%), recurrent infections (n = 10, 67%), allergic symptoms (n = 8, 53%), chronic diarrhea (n = 4, 27%), and EBV-related leiomyoma (n = 2, 13%). Skin manifestations ranged from atopic and seborrheic dermatitis to psoriasiform rash. Patients had reduced proportions of memory CD4(+) T cells, Treg, and cT(FH) cells. Memory B and NK cells were also decreased. CARMIL2-deficient T cells exhibited reduced T-cell proliferation and cytokine production following CD28 co-stimulation and normal morphology when migrating in a high-density 3D collagen gel matrix. IBD was the most severe clinical manifestation, leading to growth retardation, requiring multiple interventional treatments. All patients were alive with a median follow-up of 10.8 years (range: 3-17 years). CONCLUSION: This cohort provides clinical and immunological features and long-term follow-up of different manifestations of CARMIL2 deficiency.</style></abstract><notes><style face="normal" font="default" size="100%">Kolukisa, Burcu&#xD;Baser, Dilek&#xD;Akcam, Bengu&#xD;Danielson, Jeffrey&#xD;Bilgic Eltan, Sevgi&#xD;Haliloglu, Yesim&#xD;Sefer, Asena Pinar&#xD;Babayeva, Royale&#xD;Akgun, Gamze&#xD;Charbonnier, Louis-Marie&#xD;Schmitz-Abe, Klaus&#xD;Kendir Demirkol, Yasemin&#xD;Zhang, Yu&#xD;Gonzaga-Jauregui, Claudia&#xD;Jimenez Heredia, Raul&#xD;Kasap, Nurhan&#xD;Kiykim, Ayca&#xD;Ozek Yucel, Esra&#xD;Gok, Veysel&#xD;Unal, Ekrem&#xD;Pac Kisaarslan, Aysenur&#xD;Nepesov, Serdar&#xD;Baysoy, Gokhan&#xD;Onal, Zerrin&#xD;Yesil, Gozde&#xD;Celkan, Tulin Tiraje&#xD;Cokugras, Haluk&#xD;Camcioglu, Yildiz&#xD;Eken, Ahmet&#xD;Boztug, Kaan&#xD;Lo, Bernice&#xD;Karakoc-Aydiner, Elif&#xD;Su, Helen C&#xD;Ozen, Ahmet&#xD;Chatila, Talal A&#xD;Baris, Safa&#xD;eng&#xD;R01 AI128976/AI/NIAID NIH HHS/&#xD;R01 AI065617/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, N.I.H., Intramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1004-1019. doi: 10.1111/all.15010. Epub 2021 Jul 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34287962</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9976932</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15010</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1343</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1343</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pritchard, D. I.</style></author><author><style face="normal" font="default" size="100%">Falcone, F. H.</style></author><author><style face="normal" font="default" size="100%">Mitchell, P. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Pharmacy, University of Nottingham, Nottingham, UK.&#xD;Institute for Parasitology, Justus-Liebig-University Giessen, Giessen, Germany.&#xD;Department of Archaeology, University of Cambridge, Cambridge, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The evolution of IgE-mediated type I hypersensitivity and its immunological value</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1024-1040</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/08/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">evolution</style></keyword><keyword><style face="normal" font="default" size="100%">parasites</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32852797</style></accession-num><abstract><style face="normal" font="default" size="100%">The allergic phenotype manifests itself in a spectrum of troublesome to life-threatening diseases, from seasonal hay fever, through the food allergies, atopic eczema, asthma, to anaphylaxis. Allergy, that is an overreaction to allergen in hypersensitive individuals, results from the production of IgE, mast cell and basophil sensitisation and degranulation, requiring a range of medications to manage the conditions. Yet it is highly likely that allergy evolved for a purpose and that allergic diseases are accidental consequences of an insufficiently regulated immune response. This article presents a viewpoint from which to restore the immunological reputation of the allergic phenotype. We consider the evolutionary origins of potential allergens, toxins and parasites, and how they might have influenced early-mammal species in existence when IgE first developed. We conclude that the allergic phenotype has likely saved the lives of many more mammals than have ever died from allergy, so justifying the positive role of IgE in our evolution.</style></abstract><notes><style face="normal" font="default" size="100%">Pritchard, David I&#xD;Falcone, Franco H&#xD;Mitchell, Piers D&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1024-1040. doi: 10.1111/all.14570. Epub 2020 Sep 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32852797</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14570</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2571</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2571</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Czarnowicki, T.</style></author><author><style face="normal" font="default" size="100%">David, E.</style></author><author><style face="normal" font="default" size="100%">Yamamura, K.</style></author><author><style face="normal" font="default" size="100%">Han, J.</style></author><author><style face="normal" font="default" size="100%">He, H.</style></author><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Glickman, J.</style></author><author><style face="normal" font="default" size="100%">Erickson, T.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author><author><style face="normal" font="default" size="100%">Rangel, S. M.</style></author><author><style face="normal" font="default" size="100%">Paller, A. S.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Icahn School of Medicine at Mount Sinai, Department of Dermatology and the Immunology Institute, New York, New York, USA.&#xD;Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.&#xD;Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA.&#xD;Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.&#xD;Department of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evolution of pathologic B-cell subsets and serum environment-specific sIgEs in patients with atopic dermatitis and controls, from infancy to adulthood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2732-2747</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*B-Lymphocyte Subsets/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Immunophenotyping</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Flow Cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">B-cells</style></keyword><keyword><style face="normal" font="default" size="100%">Cd23</style></keyword><keyword><style face="normal" font="default" size="100%">Il-9</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">Rafa, Sanofi. JGK has received research support (grants paid to his institution)</style></keyword><keyword><style face="normal" font="default" size="100%">and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon,</style></keyword><keyword><style face="normal" font="default" size="100%">Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, BiogenIdec, Delenex, AbbVie,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, Baxter, Paraxel, Xenoport, and Kineta. ASP is an investigator for AbbVie,</style></keyword><keyword><style face="normal" font="default" size="100%">Applied Pharma Research, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, and UCB</style></keyword><keyword><style face="normal" font="default" size="100%">(grants paid to Northwestern Univ.), a consultant for Aegerion Pharma, Azitra,</style></keyword><keyword><style face="normal" font="default" size="100%">BioCryst, Boehringer-Ingelheim, Bristol Myers Squibb, Castle Creek, Eli Lilly,</style></keyword><keyword><style face="normal" font="default" size="100%">Janssen, Krystal, LEO Pharma, Novartis, Regeneron, Sanofi/Genzyme, Seanergy, TWI</style></keyword><keyword><style face="normal" font="default" size="100%">Biotechnology, and UCB, and on the data safety monitoring board for AbbVie,</style></keyword><keyword><style face="normal" font="default" size="100%">Abeona, Catawba, Galderma, and InMed. EGY is an employee of Mount Sinai and has</style></keyword><keyword><style face="normal" font="default" size="100%">received research funds (grants paid to the institution) from Abbvie, Asana</style></keyword><keyword><style face="normal" font="default" size="100%">Biosciences, Celgene, Dermavant, DS Biopharma, Galderma, Glenmark, Innovaderm,</style></keyword><keyword><style face="normal" font="default" size="100%">Janssen Biotech, Leo Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron, and</style></keyword><keyword><style face="normal" font="default" size="100%">Union Therapeutics. EGY is also a consultant for Abbvie, Allergan, Amgen, Asana</style></keyword><keyword><style face="normal" font="default" size="100%">Biosciences, Celgene, Concert, DBV Technologies, Dermira, DS Biopharma, Eli</style></keyword><keyword><style face="normal" font="default" size="100%">Lilly, EMD Serono, Escalier, Flx Bio, Galderma, Glenmark, Kyowa Kirin, Leo</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Mitsubishi Tanabe, Novartis, Pfizer, Regeneron, Sanofi, and Union</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39003573</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: While B-cells have historically been implicated in allergy development, a growing body of evidence supports their role in atopic dermatitis (AD). B-cell differentiation across ages in AD, and its relation to disease severity scores, has not been well defined. OBJECTIVE: To compare the frequency of B-cell subsets in blood of 0-5, 6-11, 12-17, and &gt;/=18 years old patients with AD versus age-matched controls. METHODS: Flow cytometry was used to measure B-cell subset frequencies in the blood of 27 infants, 17 children, 11 adolescents, and 31 adults with moderate-to-severe AD and age-matched controls. IgD/CD27 and CD24/CD38 core gating systems and an 11-color flow cytometry panel were used to determine frequencies of circulating B-cell subsets. Serum total and allergen-specific IgE (sIgEs) levels were measured using ImmunoCAP(R). RESULTS: Adolescents with AD had lower frequencies of major B-cells subsets (p &lt; .03). CD23 expression increased with age and was higher in AD compared to controls across all age groups (p &lt; .04). In AD patients, multiple positive correlations were observed between IL-17-producing T-cells and B-cell subsets, most significantly non-switched memory (NSM) B-cells (r = .41, p = .0005). AD severity positively correlated with a list of B-cell subsets (p &lt; .05). IL-9 levels gradually increased during childhood, reaching a peak in adolescence, paralleling allergen sensitization, particularly in severe AD. Principal component analysis of the aggregated environmental sIgE data showed that while controls across all ages tightly clustered together, adolescents with AD demonstrated distinct clustering patterns relative to controls. CONCLUSIONS: Multiple correlations between B-cells and T-cells, as well as disease severity measures, suggest a complex interplay of immune pathways in AD. Unique B-cell signature during adolescence, with concurrent allergen sensitization and IL-9 surge, point to a potentially wider window of opportunity to implement interventions that may prevent the progression of the atopic march.</style></abstract><notes><style face="normal" font="default" size="100%">Czarnowicki, Tali&#xD;David, Eden&#xD;Yamamura, Kazuhiko&#xD;Han, Joseph&#xD;He, Helen&#xD;Pavel, Ana B&#xD;Glickman, Jacob&#xD;Erickson, Taylor&#xD;Estrada, Yeriel&#xD;Krueger, James G&#xD;Rangel, Stephanie M&#xD;Paller, Amy S&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;P30 AR075049/AR/NIAMS NIH HHS/&#xD;P30 AR079200/AR/NIAMS NIH HHS/&#xD;T32 AR082315/AR/NIAMS NIH HHS/&#xD;UL1 TR001422/TR/NCATS NIH HHS/&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2732-2747. doi: 10.1111/all.16225. Epub 2024 Jul 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39003573</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11449672</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16225</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3328</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3328</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Foong, Ru-Xin</style></author><author><style face="normal" font="default" size="100%">Du Toit, George</style></author><author><style face="normal" font="default" size="100%">Bahnson, Henry T.</style></author><author><style face="normal" font="default" size="100%">van Ree, Ronald</style></author><author><style face="normal" font="default" size="100%">Radulovic, Suzana</style></author><author><style face="normal" font="default" size="100%">Versteeg, Serge A.</style></author><author><style face="normal" font="default" size="100%">Craven, Joanna</style></author><author><style face="normal" font="default" size="100%">Kwok, Matthew</style></author><author><style face="normal" font="default" size="100%">Jama, Zainab</style></author><author><style face="normal" font="default" size="100%">Brough, Helen A.</style></author><author><style face="normal" font="default" size="100%">Logan, Kirsty</style></author><author><style face="normal" font="default" size="100%">Perkin, Michael R.</style></author><author><style face="normal" font="default" size="100%">Flohr, Carsten</style></author><author><style face="normal" font="default" size="100%">Santos, Alexandra F.</style></author><author><style face="normal" font="default" size="100%">Lack, Gideon</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Evolution of Sesame Seed Allergy Over Time</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background The prevalence of sesame allergy (SA) is increasing but little is known about how it changes over time. Our aims were to observe the natural history of sesame over time and the changes in biomarkers between sesame allergic and sesame sensitised but tolerant (SS) children. Methods Participants were recruited from the EAT and EAT-On studies in the UK who were exclusively breastfed babies seen at 3-months (m) old and followed up until 7–12 years (y) old. Clinical characteristics, skin prick test (SPT), sesame-specific IgE (sIgE), Ses i 1-sIgE and mast cell activation test (MAT) to sesame were assessed at 12 m, 36 m and 7–12 y. SA status was determined at 7–12 y. Results The period prevalence of SA increased from 0.5% (6/1170) between 12 and 36 m to 1.5% (14/947) between 7 and 12 y, with 71.4% of cases developing after 36 m. Longitudinal biomarker analyses were performed on SA and SS children (n = 301): 4 had persistent SA, 10 had new SA, 1 outgrew SA and 286 were SS. Children with SA at 7–12 y had larger SPT at 36 m and at 7–12 y, higher sesame-sIgE and Ses i 1-sIgE levels from 12 m onwards compared to SS children (p &lt; 0.001). There were small but significant differences in MAT. A larger increase of sesame-sIgE and Ses i 1-sIgE from 12 to 36 m was predictive of new SA at 7–12 y. Conclusion The period prevalence of SA increased from 0.5% between 12 and 36 m to 1.5% between 7 and 12 y in a general population. Sesame-sIgE and Ses i 1-sIgE are informative biomarkers in terms of SA development, persistence and resolution.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70281</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70281</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2944</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2944</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gao, Y. D.</style></author><author><style face="normal" font="default" size="100%">Wang, Z. J.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Li, S. J.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Li, X. H.</style></author><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Zheng, Y.</style></author><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">Zeyneloglu, C.</style></author><author><style face="normal" font="default" size="100%">Li, Y. C.</style></author><author><style face="normal" font="default" size="100%">Ardicli, S.</style></author><author><style face="normal" font="default" size="100%">Tian, W. Q.</style></author><author><style face="normal" font="default" size="100%">Ardicli, O.</style></author><author><style face="normal" font="default" size="100%">Chen, S. W.</style></author><author><style face="normal" font="default" size="100%">Bu, X. T.</style></author><author><style face="normal" font="default" size="100%">Lu, G.</style></author><author><style face="normal" font="default" size="100%">Chang, L. H.</style></author><author><style face="normal" font="default" size="100%">He, Y.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author><author><style face="normal" font="default" size="100%">Ozdemir, C.</style></author><author><style face="normal" font="default" size="100%">Kiykim, A.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.&#xD;Department of Dermatology, and Laboratory of Precision Dermatology and Molecular Immunology of the Biomaterials and Regenerative Medicine Institute, Shanghai Ninth People&apos;s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.&#xD;Swiss Institute for Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Department of Genetics, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey.&#xD;Division of Food Processing, Milk and Dairy Products Technology Program, Karacabey Vocational School, Bursa Uludag University, Bursa, Turkey.&#xD;Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Allergy, Instituto de Investigacion Biosanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkiye.&#xD;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkiye.&#xD;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkiye.&#xD;Child Life and Health, Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Allergy Unit, IBIMA-Hospital Regional Universitario de Malaga-ARADyAL, UMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Evolution, Immunopathogenesis and Biomarkers of Type 2 Inflammation in Common Allergic Disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1848-1877</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/07/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology/metabolism/etiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">inborn errors of immunity</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40586319</style></accession-num><abstract><style face="normal" font="default" size="100%">The prevalence of allergic diseases, including allergic rhinitis, chronic rhinosinusitis, asthma, eosinophilic esophagitis, food and drug allergies, and atopic dermatitis, has been increasing globally over the past few decades. Allergic diseases are closely linked to type 2 immunity, which is characterized by the coordinated interplay between innate and adaptive immune responses. Significant advancements have been achieved in elucidating the cellular and molecular mechanisms that govern type 2 immunity, chiefly mediated by type 2 cytokines, including IL-4, IL-5, IL-9, and IL-13, which are primarily secreted by T helper 2 cells and group 2 innate lymphoid cells. In addition, a diverse array of effector cells, including mast cells, basophils, eosinophils, regulatory T cells, B lymphocytes, dendritic cells, and natural killer cells, are critically involved in orchestrating and modulating type 2 inflammatory responses. The activation of epithelial cells, secretion of alarmins and multiple chemokines, impairment of epithelial barrier integrity, and disruption of microbial dysbiosis serve as crucial mechanisms underlying not only the pathogenesis of allergic disorders but also the development of various systemic conditions. Biologic therapies targeting type 2 pathways-specifically effector functions of IL-4, IL-13, IL-5, thymic stromal lymphopoietin, and immunoglobulin E have-demonstrated promising efficacy. However, a subset of patients with severe allergic diseases remains unresponsive to these treatments, underscoring the need for deeper mechanistic insights and personalized therapeutic approaches. This review addresses the definition, evolution, cellular and molecular basis, and regulation of type 2 immunity. It then examines the common allergic diseases associated with type 2 responses and concludes by exploring the associations between inborn errors of immunity and type 2 responses.</style></abstract><notes><style face="normal" font="default" size="100%">Gao, Ya-Dong&#xD;Wang, Zi-Jun&#xD;Ogulur, Ismail&#xD;Li, Sheng-Jie&#xD;Yazici, Duygu&#xD;Li, Xue-Hui&#xD;Pat, Yagiz&#xD;Zheng, Yang&#xD;Babayev, Huseyn&#xD;Zeyneloglu, Can&#xD;Li, Ya-Chun&#xD;Ardicli, Sena&#xD;Tian, Wen-Qu&#xD;Ardicli, Ozge&#xD;Chen, Shi-Wei&#xD;Bu, Xiang-Ting&#xD;Lu, Gan&#xD;Chang, Li-Hong&#xD;He, Ying&#xD;Guttman-Yassky, Emma&#xD;Cabanillas, Beatriz&#xD;Ozdemir, Cevdet&#xD;Kiykim, Ayca&#xD;Shamji, Mohamed&#xD;Nadeau, Kari&#xD;Torres, Maria J&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;eng&#xD;72204214/National Natural Science Foundation of China/&#xD;BQD 2306/Start-up Research fund by The First Affiliated Hospital of Zhejiang University School of Medicine/&#xD;LTGY24H260001/Zhejiang Provincial Natural Science Foundation of China/&#xD;LQN25H030006/Zhejiang Provincial Natural Science Foundation of China/&#xD;LQN25H020010/Zhejiang Provincial Natural Science Foundation of China/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1848-1877. doi: 10.1111/all.16620. Epub 2025 Jun 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40586319</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16620</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2999</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2999</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gao, Y. D.</style></author><author><style face="normal" font="default" size="100%">Wang, Z. J.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Li, S. J.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Li, X. H.</style></author><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Zheng, Y.</style></author><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">Zeyneloglu, C.</style></author><author><style face="normal" font="default" size="100%">Li, Y. C.</style></author><author><style face="normal" font="default" size="100%">Ardicli, S.</style></author><author><style face="normal" font="default" size="100%">Tian, W. Q.</style></author><author><style face="normal" font="default" size="100%">Ardicli, O.</style></author><author><style face="normal" font="default" size="100%">Chen, S. W.</style></author><author><style face="normal" font="default" size="100%">Bu, X. T.</style></author><author><style face="normal" font="default" size="100%">Lu, G.</style></author><author><style face="normal" font="default" size="100%">Chang, L. H.</style></author><author><style face="normal" font="default" size="100%">He, Y.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author><author><style face="normal" font="default" size="100%">Ozdemir, C.</style></author><author><style face="normal" font="default" size="100%">Kiykim, A.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.&#xD;Department of Dermatology, and Laboratory of Precision Dermatology and Molecular Immunology of the Biomaterials and Regenerative Medicine Institute, Shanghai Ninth People&apos;s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.&#xD;Swiss Institute for Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Department of Genetics, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey.&#xD;Division of Food Processing, Milk and Dairy Products Technology Program, Karacabey Vocational School, Bursa Uludag University, Bursa, Turkey.&#xD;Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Allergy, Instituto de Investigacion Biosanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkiye.&#xD;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkiye.&#xD;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkiye.&#xD;Child Life and Health, Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Allergy Unit, IBIMA-Hospital Regional Universitario de Malaga-ARADyAL, UMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Evolution, Immunopathogenesis and Biomarkers of Type 2 Inflammation in Common Allergic Disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1848-1877</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/07/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology/metabolism/etiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">inborn errors of immunity</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40586319</style></accession-num><abstract><style face="normal" font="default" size="100%">The prevalence of allergic diseases, including allergic rhinitis, chronic rhinosinusitis, asthma, eosinophilic esophagitis, food and drug allergies, and atopic dermatitis, has been increasing globally over the past few decades. Allergic diseases are closely linked to type 2 immunity, which is characterized by the coordinated interplay between innate and adaptive immune responses. Significant advancements have been achieved in elucidating the cellular and molecular mechanisms that govern type 2 immunity, chiefly mediated by type 2 cytokines, including IL-4, IL-5, IL-9, and IL-13, which are primarily secreted by T helper 2 cells and group 2 innate lymphoid cells. In addition, a diverse array of effector cells, including mast cells, basophils, eosinophils, regulatory T cells, B lymphocytes, dendritic cells, and natural killer cells, are critically involved in orchestrating and modulating type 2 inflammatory responses. The activation of epithelial cells, secretion of alarmins and multiple chemokines, impairment of epithelial barrier integrity, and disruption of microbial dysbiosis serve as crucial mechanisms underlying not only the pathogenesis of allergic disorders but also the development of various systemic conditions. Biologic therapies targeting type 2 pathways-specifically effector functions of IL-4, IL-13, IL-5, thymic stromal lymphopoietin, and immunoglobulin E have-demonstrated promising efficacy. However, a subset of patients with severe allergic diseases remains unresponsive to these treatments, underscoring the need for deeper mechanistic insights and personalized therapeutic approaches. This review addresses the definition, evolution, cellular and molecular basis, and regulation of type 2 immunity. It then examines the common allergic diseases associated with type 2 responses and concludes by exploring the associations between inborn errors of immunity and type 2 responses.</style></abstract><notes><style face="normal" font="default" size="100%">Gao, Ya-Dong&#xD;Wang, Zi-Jun&#xD;Ogulur, Ismail&#xD;Li, Sheng-Jie&#xD;Yazici, Duygu&#xD;Li, Xue-Hui&#xD;Pat, Yagiz&#xD;Zheng, Yang&#xD;Babayev, Huseyn&#xD;Zeyneloglu, Can&#xD;Li, Ya-Chun&#xD;Ardicli, Sena&#xD;Tian, Wen-Qu&#xD;Ardicli, Ozge&#xD;Chen, Shi-Wei&#xD;Bu, Xiang-Ting&#xD;Lu, Gan&#xD;Chang, Li-Hong&#xD;He, Ying&#xD;Guttman-Yassky, Emma&#xD;Cabanillas, Beatriz&#xD;Ozdemir, Cevdet&#xD;Kiykim, Ayca&#xD;Shamji, Mohamed&#xD;Nadeau, Kari&#xD;Torres, Maria J&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;eng&#xD;72204214/National Natural Science Foundation of China/&#xD;BQD 2306/Start-up Research fund by The First Affiliated Hospital of Zhejiang University School of Medicine/&#xD;LTGY24H260001/Zhejiang Provincial Natural Science Foundation of China/&#xD;LQN25H030006/Zhejiang Provincial Natural Science Foundation of China/&#xD;LQN25H020010/Zhejiang Provincial Natural Science Foundation of China/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1848-1877. doi: 10.1111/all.16620. Epub 2025 Jun 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40586319</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16620</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3056</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3056</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Minic-Pantic, D.</style></author><author><style face="normal" font="default" size="100%">Abela, B.</style></author><author><style face="normal" font="default" size="100%">Lehtimaki, J.</style></author><author><style face="normal" font="default" size="100%">Zink, A.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Fettelschoss-Gabriel, A.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Ring, J.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeir, P.</style></author><author><style face="normal" font="default" size="100%">Prelaud, P.</style></author><author><style face="normal" font="default" size="100%">Taieb, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Global WHO NTD Program, Geneva, Switzerland.&#xD;Finnish Environment Institute, Helsinki, Finland.&#xD;Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;AllergyCare, Private Clinic Doebling, Vienna, Austria.&#xD;Biomedical Int. R+D GmbH, Vienna, Austria.&#xD;Department of Dermatology, University of Zurich, Zurich, Switzerland.&#xD;Institute of Environmental Medicine and Integrative Health, Medical Faculty, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Augsburg, Germany.&#xD;CK-CARE, Christine-Kuhne Center for Allergy Research and Education (CK-Care), Davos, Switzerland.&#xD;Int Soc of Atopic Dermatitis, Davos, Switzerland.&#xD;ADVETIA Centre Hospitalier Veterinaire, Velizy Villacoublay, France.&#xD;University of Bordeaux, Bordeaux, France.&#xD;INSERM 1312, Bordeaux, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Examining Atopic Dermatitis Through the One Health Concept Lens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">canine atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">climate</style></keyword><keyword><style face="normal" font="default" size="100%">digital health</style></keyword><keyword><style face="normal" font="default" size="100%">one health</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41014009</style></accession-num><abstract><style face="normal" font="default" size="100%">This paper explores the application of the One Health framework to atopic dermatitis (AD), a complex, chronic skin disease, emphasizing interdisciplinary approaches to prevention and management. One Health integrates human, animal, environmental, and plant health, addressing challenges such as antimicrobial resistance, infectious diseases, and neglected tropical diseases (NTDs). In the context of AD, One Health principles are applied to explore etiological factors like urbanization, climate change, biodiversity loss, and environmental pollution. Key findings include the interplay between lifestyle and environmental exposures, as evidenced by studies on human-dog microbiota sharing, which reveal that rural environments confer protective effects against allergic conditions for both species. Historical observations of the &quot;old farm effect&quot; highlight the protective role of traditional rural living, including raw milk consumption, in preventing atopic diseases. However, modern urbanization and industrial farming have eroded these benefits. Climate change intensifies AD symptoms through extreme weather, proliferation of more and higher allergenic pollen, likely also of house dust mites, allergen proliferation, and pollution. Rising CO(2) levels exacerbate pollen allergenicity, prolong pollen seasons, and amplify allergic responses. The skin&apos;s microbiome and immune barrier are sensitive to pollutants like black carbon and traffic-related emissions, further influencing AD prevalence and severity. Innovative approaches to prevention, such as veterinary vaccination strategies targeting allergens or immunopathological key cytokines, illustrate cross-species solutions. Web data mining demonstrates potential for analyzing public interest and seasonal trends in AD, correlating search data with real-time monitored environmental factors and highlighting gaps in awareness and access to modern treatments. This integrative One Health lens provides a framework for reimagining AD prevention and management, emphasizing a return to environmental and lifestyle diversity, climate action, and leveraging digital and biomedical tools for personalized, sustainable care.</style></abstract><notes><style face="normal" font="default" size="100%">Minic-Pantic, Dijana&#xD;Abela, Bernadette&#xD;Lehtimaki, Jenni&#xD;Zink, Alexander&#xD;Jensen-Jarolim, Erika&#xD;Fettelschoss-Gabriel, Antonia&#xD;Traidl-Hoffmann, Claudia&#xD;Ring, Johannes&#xD;Schmid-Grendelmeir, Peter&#xD;Prelaud, Pascal&#xD;Taieb, Alain&#xD;eng&#xD;001/WHO_/World Health Organization/International&#xD;International Society of Atopic Dermatitis/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Sep 27. doi: 10.1111/all.70080.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41014009</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70080</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2274</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2274</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Halken, S.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Skypala, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Khoo Teck Puat-National University Children&apos;s Medical Institute, National University Hospital, National University Health System, Singapore, Singapore.&#xD;Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Odense, Denmark.&#xD;Food Allergy Referral Centre, Padua University Hospital, Padua, Italy.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Paediatric Allergy and Respiratory Medicine, University of Southampton, Southampton, UK.&#xD;NIHR Southampton Biomedical Research Centre, Southampton, UK.&#xD;David Hide Asthma and Allergy Centre, St Mary Hospital, Isle of Wight, UK.&#xD;Royal Brompton &amp; Harefield Hospitals, Part of Guys &amp; St Thomas NHS Foundation Trust, London, UK.&#xD;Department of Inflammation and Repair, Imperial College, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Executive summary of the EAACI guidelines on diagnosis of IgE-mediated food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3053-3056</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/10/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37815198</style></accession-num><notes><style face="normal" font="default" size="100%">Santos, Alexandra F&#xD;Riggioni, Carmen&#xD;Halken, Susanne&#xD;Muraro, Antonella&#xD;Akdis, Cezmi A&#xD;Roberts, Graham&#xD;Du Toit, George&#xD;Skypala, Isabel&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MC_PC_18052/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3053-3056. doi: 10.1111/all.15906. Epub 2023 Oct 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37815198</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15906</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2140</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2140</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Price, O. J.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Odemyr, M.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, UK.&#xD;Leeds Institute of Medical Research at St James&apos;s, University of Leeds, Leeds, UK.&#xD;Department of Respiratory Medicine, Leeds Teaching Hospital NHS Trust, Leeds, UK.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, University of Cagliari, Cagliari, Italy.&#xD;Silesian University School of Medicine, Zabrze, Poland.&#xD;Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.&#xD;EFA European Federation of Allergy and Airways Diseases Patients&apos; Associations, Brussels, Belgium.&#xD;Allergy Department, 2nd Pediatric Clinic, National Kapodistrian University of Athens, Athens, Greece.&#xD;Fondazione Policlinico Universitario A. Gemelli - IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;National Heart and Lung Institute (NHLI), Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exercise and physical activity for asthma management: The European Academy of Allergy and Clinical Immunology perspective</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2823-2825</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/06/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword><keyword><style face="normal" font="default" size="100%">physical activity</style></keyword><keyword><style face="normal" font="default" size="100%">rehabilitation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37340667</style></accession-num><notes><style face="normal" font="default" size="100%">Price, Oliver J&#xD;Del Giacco, Stefano&#xD;Gawlik, Radoslaw&#xD;Janson, Christer&#xD;Odemyr, Mikaela&#xD;Papadopoulos, Nikolaos G&#xD;Bonini, Matteo&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2823-2825. doi: 10.1111/all.15789. Epub 2023 Jun 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37340667</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15789</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2933</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2933</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Price, O. J.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Amerigo, D. A.</style></author><author><style face="normal" font="default" size="100%">Backer, V.</style></author><author><style face="normal" font="default" size="100%">Bougault, V.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">McDonald, V. M.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Simpson, A.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, UK.&#xD;Department of Respiratory Medicine, Leeds Teaching Hospital NHS Trust, Leeds, UK.&#xD;Allergy Department, 2nd Pediatric Clinic, National Kapodistrian University of Athens, Athens, Greece.&#xD;Lydia Becker Institute, University of Manchester, Manchester, UK.&#xD;Allergy Department, Ramon y Cajal University Hospital, Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Universidad de Alcala, Madrid, Spain.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, and Audiology, Rigshospitalet, Copenhagen, Denmark.&#xD;Universite Cote d&apos;Azur, LAMHESS, Nice, France.&#xD;Allergologia e Immunologia Clinica, Dipartimento di Scienze Mediche e Sanita Pubblica, Universita Degli Studi di Cagliari, Cagliari, Italy.&#xD;Silesian University School of Medicine, Zabrze, Poland.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, IBIMA-Plataforma BIONAND, RICORS Inflammatory Diseases, Malaga, Spain.&#xD;Personalized Medicine, Asthma and Allergy-IRCCS Humanitas Research Hospital, Rozzano, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.&#xD;Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.&#xD;School of Nursing and Midwifery, The University of Newcastle, Newcastle, New South Wales, Australia.&#xD;Department of Allergy and Clinical Immunology, Centro Hospitalar Universitario de Sao Joao, Porto, Portugal.&#xD;EPIUnit-Institute of Public Health, Laboratory for Integrative and Translational Research in Population Health (ITR), University of Porto, Porto, Portugal.&#xD;Department of Pathology, Basic and Clinical Immunology Unit, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;School of Sport, Exercise and Rehabilitation Sciences, University of Hull, Hull, UK.&#xD;Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.&#xD;National Heart and Lung Institute (NHLI), Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exercise Recommendations and Practical Considerations for Asthma Management-An EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1572-1591</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/05/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">*Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">*Exercise Therapy/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchoconstriction</style></keyword><keyword><style face="normal" font="default" size="100%">exercise</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword><keyword><style face="normal" font="default" size="100%">physical activity</style></keyword><keyword><style face="normal" font="default" size="100%">rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">EAACI task force members. O.J.P. reports grants from Merck and AstraZeneca</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. D.A.A. reports grants from the Spanish Society of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergology and Clinical Immunology (SEAIC), consulting fees from ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Chiesi, and Gebro, and speaker fees from AstraZeneca, Chiesi, Gebro,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Leti Pharma, Menarini, Novartis, Roxall, and Sanofi, all outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work. S.D.G. reports grants, advisory board, and speaker fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Chiesi, GSK, CSL-Behring, Novartis, Sanofi, and Takeda, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. V.M.M. reports grants from GlaxoSmithKline and advisory board and</style></keyword><keyword><style face="normal" font="default" size="100%">speaker fees from GlaxoSmithKline, Menarini, and Boehringer Ingelheim outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. M.B. reports grants, advisory board, and speaker fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Chiesi, Grifols, GlaxoSmithKline, Lallemand, Lusofarmaco, Menarini,</style></keyword><keyword><style face="normal" font="default" size="100%">Omron, and Sanofi outside the submitted work. N.G.P., Vibeke Backer, Valerie</style></keyword><keyword><style face="normal" font="default" size="100%">Bougault, R.G., I.E.G., E.H., C.J., A.M., and A.S. have declare no conflicts of</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40327018</style></accession-num><abstract><style face="normal" font="default" size="100%">Exercise is an important treatment for people with asthma and should be considered alongside pharmacological therapy when developing personalised asthma management plans. Despite this, there remains limited guidance concerning the practicalities of asthma-specific exercise prescription. This European Academy of Allergy and Clinical Immunology task force was therefore established to achieve three fundamental aims: first, to provide an up-to-date perspective concerning the role of exercise for asthma management (i.e., describe the disease modifying potential of exercise and associated impact on asthma-related extrapulmonary comorbidities); second, to develop pragmatic recommendations to facilitate safe and effective exercise prescription; and third, to identify key unmet needs and provide focused direction for future research. The position paper is structured as a practically focused document, with recommendations formulated according to best available scientific evidence and expert opinion, with an emphasis on providing healthcare providers with pragmatic advice that can be implemented during routine asthma review.</style></abstract><notes><style face="normal" font="default" size="100%">Price, Oliver J&#xD;Papadopoulos, Nikolaos G&#xD;Amerigo, Dario Antolin&#xD;Backer, Vibeke&#xD;Bougault, Valerie&#xD;Del Giacco, Stefano&#xD;Gawlik, Radoslaw&#xD;Eguiluz-Gracia, Ibon&#xD;Heffler, Enrico&#xD;Janson, Christer&#xD;McDonald, Vanessa M&#xD;Moreira, Andre&#xD;Simpson, Andrew&#xD;Bonini, Matteo&#xD;eng&#xD;This position paper was supported by the European Academy of Allergy and Clinical Immunology (EAACI) under the EAACI Research and Outreach Committee [budget code: 40009] (2023)/&#xD;Consensus Development Conference&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1572-1591. doi: 10.1111/all.16573. Epub 2025 May 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40327018</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186601</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16573</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2768</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2768</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Doyen, V.</style></author><author><style face="normal" font="default" size="100%">Migueres, N.</style></author><author><style face="normal" font="default" size="100%">van Kampen, V.</style></author><author><style face="normal" font="default" size="100%">Suojalehto, H.</style></author><author><style face="normal" font="default" size="100%">Mason, P.</style></author><author><style face="normal" font="default" size="100%">Munoz, X.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Svanes, C.</style></author><author><style face="normal" font="default" size="100%">Walters, G.</style></author><author><style face="normal" font="default" size="100%">Moore, V.</style></author><author><style face="normal" font="default" size="100%">Jacobsen, I. B.</style></author><author><style face="normal" font="default" size="100%">Folletti, I.</style></author><author><style face="normal" font="default" size="100%">Preisser, A. M.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Rifflart, C.</style></author><author><style face="normal" font="default" size="100%">de Blay, F.</style></author><author><style face="normal" font="default" size="100%">Vandenplas, O.</style></author><author><style face="normal" font="default" size="100%">European network for the, PHenotyping of OCcupational ASthma</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Service de Pneumologie, Centre Hospitalier Universitaire UCL Namur, Universite Catholique de Louvain, Yvoir, Belgium.&#xD;Service de Pneumologie et Allergologie, Pole de Pathologie Thoracique, University Hospital of Strasbourg, Strasbourg, France.&#xD;UMR 7357 Laboratory of Engineering, Computer Science and Imaging ICUBE, Strasbourg, France.&#xD;Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany.&#xD;Clinic of Occupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland.&#xD;Department of Cardiac, Thoracic, Vascular, Sciences Occupational and Public Health, University of Padova, Padova, Italy.&#xD;Servei Pneumologia, Hospital Vall d&apos;Hebron, Universitat Autonoma de Barcelona and CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.&#xD;Department of Allergy, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.&#xD;Department of Occupational Medicine, Haukeland University Hospital, Bergen, Norway.&#xD;Centre for International Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.&#xD;Occupational Lung Disease, Institute of Applied Health, University of Birmingham, Birmingham, UK.&#xD;Department of Pulmonary Medicine and Occupational Medicine, Odense University Hospital, Odense, Denmark.&#xD;Department of Medicine and Surgery, Section of Occupational Medicine, Respiratory Diseases and Occupational and Environmental Toxicology, University of Perugia, Perugia, Italy.&#xD;Institute for Occupational and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;EA 3072 Federation de Medecine Translationnelle, Strasbourg University, Strasbourg, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exhaled Nitric Oxide and Sputum Eosinophils Are Complementary Tools for Diagnosing Occupational Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1015-1024</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sputum/cytology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Nitric Oxide/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma, Occupational/diagnosis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">ROC Curve</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Exhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default" size="100%">occupational asthma</style></keyword><keyword><style face="normal" font="default" size="100%">specific inhalation challenge</style></keyword><keyword><style face="normal" font="default" size="100%">sputum eosinophils</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39726396</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Exposure-related changes in exhaled nitric oxide (FeNO) and sputum eosinophils have not been thoroughly compared in the investigation of occupational asthma. OBJECTIVE: This study aimed at comparing the accuracies of the changes in FeNO concentrations and sputum eosinophil counts in identifying asthmatic reactions induced by occupational agents during specific inhalation challenges (SICs). METHODS: This retrospective multicenter study included 321 subjects who completed an assessment of FeNO and sputum eosinophils before and 24 h after SICs with various occupational agents, of whom 156 showed a positive result. RESULTS: Post-challenge changes in FeNO and sputum eosinophils showed similar accuracies, with areas under the receiver operating characteristics curve of 0.78 (95% confidence interval [95% CI], 0.72-0.83) and 0.81 (95% CI, 0.76-0.86), respectively. Increases in FeNO level &gt;/= 13 ppb and sputum eosinophils &gt;/= 1.25% were identified as the optimal threshold values for differentiating positive from negative SICs. Using these thresholds, the changes in FeNO and sputum eosinophils each achieved a &gt;/= 95% specificity but a low sensitivity (55% and 62%, respectively). FeNO and sputum eosinophils showed discordant increases in 38% of subjects with a positive SIC. Combining either a rise in FeNO &gt;/= 13 ppb or an increase in sputum eosinophils &gt;/= 1.25% increased the sensitivity to 77%. CONCLUSIONS: Increases in FeNO concentration and/or sputum eosinophils after exposure to occupational agents strongly support a diagnosis of occupational asthma. The assessment of both markers of airway inflammation should be regarded as a reliable complementary tool to spirometry for identifying bronchial responses to occupational agents.</style></abstract><notes><style face="normal" font="default" size="100%">Doyen, Virginie&#xD;Migueres, Nicolas&#xD;van Kampen, Vera&#xD;Suojalehto, Hille&#xD;Mason, Paola&#xD;Munoz, Xavier&#xD;Sastre, Joaquin&#xD;Quirce, Santiago&#xD;Svanes, Cecilie&#xD;Walters, Gareth&#xD;Moore, Vicky&#xD;Jacobsen, Iben Brock&#xD;Folletti, Ilenia&#xD;Preisser, Alexandra M&#xD;Walusiak-Skorupa, Jolanta&#xD;Rifflart, Catherine&#xD;de Blay, Frederic&#xD;Vandenplas, Olivier&#xD;(E-PHOCAS)&#xD;eng&#xD;fondation mont godinne/&#xD;ADIRAL/&#xD;AstraZeneca/&#xD;chiesi/&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1015-1024. doi: 10.1111/all.16447. Epub 2024 Dec 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39726396</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16447</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3246</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3246</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sola-Martinez, Rosa Alba</style></author><author><style face="normal" font="default" size="100%">Zubiaga-Fernandez, Laura</style></author><author><style face="normal" font="default" size="100%">Figuerola, Marta</style></author><author><style face="normal" font="default" size="100%">Cruz-Amaya, Anyith</style></author><author><style face="normal" font="default" size="100%">Aranda, Carlos J.</style></author><author><style face="normal" font="default" size="100%">Torres, Maria J.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, Ibon</style></author><author><style face="normal" font="default" size="100%">Rondon, Carmen</style></author><author><style face="normal" font="default" size="100%">De Diego Puente, Teresa</style></author><author><style face="normal" font="default" size="100%">Testera-Montes, Almudena</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Exhaled Volatile Organic Compounds Identify Allergic Patients Among Individuals With Chronic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background The nasal allergen challenge (NAC) is the gold standard to diagnose allergic rhinitis (AR) and local allergic rhinitis (LAR), but its clinical use remains limited. We investigated whether volatile organic compounds (VOC) in exhaled breath could identify allergic individuals among patients with chronic rhinitis. Methods Exhaled breath samples were collected before and 24 h after NAC in participants with AR, LAR, non-allergic rhinitis (NAR), and healthy control (HC). Samples were analyzed using gas chromatography–mass spectrometry, focusing on saturated hydrocarbons. Associations with fractional exhaled nitric oxide (FeNO) and blood eosinophils were also assessed. Results We included 28 AR, 31 LAR, 29 NAR, and 14 HC individuals, divided into training and validation sets. A predictive model based on two VOCs (decane and nonadecane) discriminated allergic (AR + LAR) from non-allergic (NAR + HC) subjects (AUC 0.721, 95% CI: 0.506–0.936; permutation test p = 0.009), with moderate performance in the validation set (AUC 0.760, 95% CI: 0.585–0.935; 76.5% sensitivity, 69.2% specificity). Similarly, these two VOCs moderately differentiated LAR and NAR patients (AUC 0.737, 95% CI: 0.545–0.929; permutation test p = 0.011). At baseline, decane levels were higher in LAR than HC subjects (p = 0.007), nonadecane levels were higher in LAR than NAR individuals (p = 0.026), and decane, styrene, and nonanal levels were higher in patients with FeNO ≥ 25 ppb (all p ≤ 0.016). No associations were observed between VOCs and blood eosinophils. NAC induced a significant reduction in nonadecane in allergic patients (p = 0.012), but not in non-allergic subjects. Conclusion Exhaled decane and nonadecane might serve as non-invasive biomarkers of allergic inflammation in rhinitis patients, potentially supporting NAC indication. Elevated exhaled nonanal, decane, and styrene may reflect T2 airway inflammation. These exploratory findings require validation in larger, multicenter cohorts with accuracy-improving potential.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70273</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70273</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3330</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3330</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sola-Martinez, Rosa Alba</style></author><author><style face="normal" font="default" size="100%">Zubiaga-Fernandez, Laura</style></author><author><style face="normal" font="default" size="100%">Figuerola, Marta</style></author><author><style face="normal" font="default" size="100%">Cruz-Amaya, Anyith</style></author><author><style face="normal" font="default" size="100%">Aranda, Carlos J.</style></author><author><style face="normal" font="default" size="100%">Torres, Maria J.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, Ibon</style></author><author><style face="normal" font="default" size="100%">Rondon, Carmen</style></author><author><style face="normal" font="default" size="100%">De Diego Puente, Teresa</style></author><author><style face="normal" font="default" size="100%">Testera-Montes, Almudena</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Exhaled Volatile Organic Compounds Identify Allergic Patients Among Individuals With Chronic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background The nasal allergen challenge (NAC) is the gold standard to diagnose allergic rhinitis (AR) and local allergic rhinitis (LAR), but its clinical use remains limited. We investigated whether volatile organic compounds (VOC) in exhaled breath could identify allergic individuals among patients with chronic rhinitis. Methods Exhaled breath samples were collected before and 24 h after NAC in participants with AR, LAR, non-allergic rhinitis (NAR), and healthy control (HC). Samples were analyzed using gas chromatography–mass spectrometry, focusing on saturated hydrocarbons. Associations with fractional exhaled nitric oxide (FeNO) and blood eosinophils were also assessed. Results We included 28 AR, 31 LAR, 29 NAR, and 14 HC individuals, divided into training and validation sets. A predictive model based on two VOCs (decane and nonadecane) discriminated allergic (AR + LAR) from non-allergic (NAR + HC) subjects (AUC 0.721, 95% CI: 0.506–0.936; permutation test p = 0.009), with moderate performance in the validation set (AUC 0.760, 95% CI: 0.585–0.935; 76.5% sensitivity, 69.2% specificity). Similarly, these two VOCs moderately differentiated LAR and NAR patients (AUC 0.737, 95% CI: 0.545–0.929; permutation test p = 0.011). At baseline, decane levels were higher in LAR than HC subjects (p = 0.007), nonadecane levels were higher in LAR than NAR individuals (p = 0.026), and decane, styrene, and nonanal levels were higher in patients with FeNO ≥ 25 ppb (all p ≤ 0.016). No associations were observed between VOCs and blood eosinophils. NAC induced a significant reduction in nonadecane in allergic patients (p = 0.012), but not in non-allergic subjects. Conclusion Exhaled decane and nonadecane might serve as non-invasive biomarkers of allergic inflammation in rhinitis patients, potentially supporting NAC indication. Elevated exhaled nonanal, decane, and styrene may reflect T2 airway inflammation. These exploratory findings require validation in larger, multicenter cohorts with accuracy-improving potential.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70273</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70273</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1010</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1010</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, S. H.</style></author><author><style face="normal" font="default" size="100%">Zissler, U. M.</style></author><author><style face="normal" font="default" size="100%">Buettner, M.</style></author><author><style face="normal" font="default" size="100%">Heine, S.</style></author><author><style face="normal" font="default" size="100%">Heldner, A.</style></author><author><style face="normal" font="default" size="100%">Kotz, S.</style></author><author><style face="normal" font="default" size="100%">Pechtold, L.</style></author><author><style face="normal" font="default" size="100%">Kau, J.</style></author><author><style face="normal" font="default" size="100%">Plaschke, M.</style></author><author><style face="normal" font="default" size="100%">Ullmann, J. T.</style></author><author><style face="normal" font="default" size="100%">Guerth, F.</style></author><author><style face="normal" font="default" size="100%">Oelsner, M.</style></author><author><style face="normal" font="default" size="100%">Alessandrini, F.</style></author><author><style face="normal" font="default" size="100%">Blank, S.</style></author><author><style face="normal" font="default" size="100%">Chaker, A. M.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Jakwerth, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Allergy &amp; Environment (ZAUM), German Research Center for Environmental Health, Technical University of Munich and Helmholtz Center Munich, Munich, Germany.&#xD;Members of the German Center of Lung Research (DZL), CPC-M, Munich, Germany.&#xD;Member of the Helmholtz I&amp;I Initiative, Munich, Germany.&#xD;Institute of Computational Biology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Department of Otorhinolaryngology and Head and Neck Surgery, Medical School, Technical University of Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An exhausted phenotype of T(H) 2 cells is primed by allergen exposure, but not reinforced by allergen-specific immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2827-2839</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Leukocytes, Mononuclear</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Ait</style></keyword><keyword><style face="normal" font="default" size="100%">Ctla-4</style></keyword><keyword><style face="normal" font="default" size="100%">Pd-1</style></keyword><keyword><style face="normal" font="default" size="100%">T-cell exhaustion</style></keyword><keyword><style face="normal" font="default" size="100%">proallergic TH2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33969495</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Studies show that proallergic T(H) 2 cells decrease after successful allergen-specific immunotherapy (AIT). It is likely that iatrogenic administration of allergens drives these cells to exhaustion due to chronic T-cell receptor stimulation. This study aimed to investigate the exhaustion of T cells in connection with allergen exposure during AIT in mice and two independent patient cohorts. METHODS: OVA-sensitized C57BL/6J mice were challenged and treated with OVA, and the development of exhaustion in local and systemic T(H) 2 cells was analyzed. In patients, the expression of exhaustion-associated surface markers on T(H) 2 cells was evaluated using flow cytometry in a cross-sectional grass pollen allergy cohort with and without AIT. The treatment effect was further studied in PBMC collected from a prospective long-term AIT cohort. RESULTS: The exhaustion-associated surface markers CTLA-4 and PD-1 were significantly upregulated on T(H) 2 cells upon OVA aerosol exposure in OVA-allergic compared to non-allergic mice. CTLA-4 and PD-1 decreased after AIT, in particular on the surface of local lung T(H) 2 cells. Similarly, CTLA-4 and PD-1 expression was enhanced on T(H) 2 cells from patients with allergic rhinitis with an even stronger effect in those with concomitant asthma. Using an unbiased Louvain clustering analysis, we discovered a late-differentiated T(H) 2 population expressing both markers that decreased during up-dosing but persisted long term during the maintenance phase. CONCLUSIONS: This study shows that allergen exposure promotes CTLA-4 and PD-1 expression on T(H) 2 cells and that the dynamic change in frequencies of exhausted T(H) 2 cells exhibits a differential pattern during the up-dosing versus the maintenance phases of AIT.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Shu-Hung&#xD;Zissler, Ulrich M&#xD;Buettner, Maren&#xD;Heine, Sonja&#xD;Heldner, Alexander&#xD;Kotz, Sebastian&#xD;Pechtold, Lisa&#xD;Kau, Josephine&#xD;Plaschke, Mirjam&#xD;Ullmann, Julia T&#xD;Guerth, Ferdinand&#xD;Oelsner, Madlen&#xD;Alessandrini, Francesca&#xD;Blank, Simon&#xD;Chaker, Adam M&#xD;Schmidt-Weber, Carsten B&#xD;Jakwerth, Constanze A&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2827-2839. doi: 10.1111/all.14896. Epub 2021 May 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33969495</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14896</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>424</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">424</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prescott, S. L.</style></author><author><style face="normal" font="default" size="100%">Logan, A. C.</style></author><author><style face="normal" font="default" size="100%">Bristow, J.</style></author><author><style face="normal" font="default" size="100%">Rozzi, R.</style></author><author><style face="normal" font="default" size="100%">Moodie, R.</style></author><author><style face="normal" font="default" size="100%">Redvers, N.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Warber, S.</style></author><author><style face="normal" font="default" size="100%">Poland, B.</style></author><author><style face="normal" font="default" size="100%">Hancock, T.</style></author><author><style face="normal" font="default" size="100%">Berman, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical School, University of Western Australia, Nedlands, WA, Australia.&#xD;Nova Institute for Health, Baltimore, Maryland, USA.&#xD;ORIGINS Project, Telethon Kids Institute at Perth Children&apos;s Hospital, Nedlands, WA, Australia.&#xD;The Mindfulness Initiative, Sheffield, UK.&#xD;Cape Horn International Center (CHIC), University of Magallanes, Puerto Williams, Chile.&#xD;Philosophy and Religion, University of North Texas, Denton, Texas, USA.&#xD;School of Population and Global Health (MSPGH), University of Melbourne, Parkville, Vic., Australia.&#xD;School of Medicine and Health Sciences, University of North Dakota, Grand Forks, North Dakota, USA.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Department of Family Medicine, University of Michigan, Ann Arbor, Michigan, USA.&#xD;Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.&#xD;School of Public Health and Social Policy, University of Victoria, Victoria, BC, Canada.&#xD;Department of Family and Community Medicine, Center for Integrative Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exiting the Anthropocene: Achieving personal and planetary health in the 21st century</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3498-3512</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/06/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Ecosystem</style></keyword><keyword><style face="normal" font="default" size="100%">*Environment</style></keyword><keyword><style face="normal" font="default" size="100%">biodiversity hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">climate change</style></keyword><keyword><style face="normal" font="default" size="100%">nature-relatedness</style></keyword><keyword><style face="normal" font="default" size="100%">noncommunicable diseases (NCDs)</style></keyword><keyword><style face="normal" font="default" size="100%">planetary health</style></keyword><keyword><style face="normal" font="default" size="100%">Other authors have no conflicts of interest to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35748742</style></accession-num><abstract><style face="normal" font="default" size="100%">Planetary health provides a perspective of ecological interdependence that connects the health and vitality of individuals, communities, and Earth&apos;s natural systems. It includes the social, political, and economic ecosystems that influence both individuals and whole societies. In an era of interconnected grand challenges threatening health of all systems at all scales, planetary health provides a framework for cross-sectoral collaboration and unified systems approaches to solutions. The field of allergy is at the forefront of these efforts. Allergic conditions are a sentinel measure of environmental impact on human health in early life-illuminating how ecological changes affect immune development and predispose to a wider range of inflammatory noncommunicable diseases (NCDs). This shows how adverse macroscale ecology in the Anthropocene penetrates to the molecular level of personal and microscale ecology, including the microbial systems at the foundations of all ecosystems. It provides the basis for more integrated efforts to address widespread environmental degradation and adverse effects of maladaptive urbanization, food systems, lifestyle behaviors, and socioeconomic disadvantage. Nature-based solutions and efforts to improve nature-relatedness are crucial for restoring symbiosis, balance, and mutualism in every sense, recognizing that both personal lifestyle choices and collective structural actions are needed in tandem. Ultimately, meaningful ecological approaches will depend on placing greater emphasis on psychological and cultural dimensions such as mindfulness, values, and moral wisdom to ensure a sustainable and resilient future.</style></abstract><notes><style face="normal" font="default" size="100%">Prescott, Susan L&#xD;Logan, Alan C&#xD;Bristow, Jamie&#xD;Rozzi, Ricardo&#xD;Moodie, Rob&#xD;Redvers, Nicole&#xD;Haahtela, Tari&#xD;Warber, Sara&#xD;Poland, Blake&#xD;Hancock, Trevor&#xD;Berman, Brian&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3498-3512. doi: 10.1111/all.15419. Epub 2022 Jul 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35748742</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10083953</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15419</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3010</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3010</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cain, J.</style></author><author><style face="normal" font="default" size="100%">Hurrell, B.</style></author><author><style face="normal" font="default" size="100%">Akbari, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Microbiology and Immunology, University of Southern California, Los Angeles, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Expanding Role of ILC2s in Allergic Airways Disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">11-23</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/09/02 22:23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Hypersensitivity/immunology/metabolism/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cells and NK cells</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40891582</style></accession-num><abstract><style face="normal" font="default" size="100%">Group 2 innate lymphoid cells (ILC2s) play a pivotal role in the initiation and propagation of allergic airways disease. These cells, first discovered 15 years ago, respond to a range of stimuli in a non-antigen-dependent manner. ILC2s produce copious amounts of cytokines including IL-5 and IL-13, which are critical in the pathogenesis of allergic asthma. While allergic airways diseases have long been considered T-helper 2 cell-driven diseases, ILC2s are capable of inducing allergic-type pathologies in mice even in the absence of the adaptive immune system. The role of ILC2s in driving the pathology of allergic airways disease remains an expanding field of knowledge that may unlock novel therapeutic approaches in the management of asthma, a disease that affects up to 300 million people worldwide. In this review, we survey current knowledge of ILC2 immunobiology and present an overview of ILC2 phenotyping, concurrent with insights into ILC2 plasticity, and an exploration of the roles of costimulatory molecules, neuroendocrine signals, and diet-derived nutrients in modulating ILC2 activity.</style></abstract><notes><style face="normal" font="default" size="100%">Cain, Jafar&#xD;Hurrell, Benjamin&#xD;Akbari, Omid&#xD;eng&#xD;NH/NIH HHS/&#xD;Review&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):11-23. doi: 10.1111/all.70030. Epub 2025 Sep 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40891582</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70030</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3101</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3101</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cain, J.</style></author><author><style face="normal" font="default" size="100%">Hurrell, B.</style></author><author><style face="normal" font="default" size="100%">Akbari, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Microbiology and Immunology, University of Southern California, Los Angeles, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Expanding Role of ILC2s in Allergic Airways Disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">11-23</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/09/02 22:23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Hypersensitivity/immunology/metabolism/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cells and NK cells</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40891582</style></accession-num><abstract><style face="normal" font="default" size="100%">Group 2 innate lymphoid cells (ILC2s) play a pivotal role in the initiation and propagation of allergic airways disease. These cells, first discovered 15 years ago, respond to a range of stimuli in a non-antigen-dependent manner. ILC2s produce copious amounts of cytokines including IL-5 and IL-13, which are critical in the pathogenesis of allergic asthma. While allergic airways diseases have long been considered T-helper 2 cell-driven diseases, ILC2s are capable of inducing allergic-type pathologies in mice even in the absence of the adaptive immune system. The role of ILC2s in driving the pathology of allergic airways disease remains an expanding field of knowledge that may unlock novel therapeutic approaches in the management of asthma, a disease that affects up to 300 million people worldwide. In this review, we survey current knowledge of ILC2 immunobiology and present an overview of ILC2 phenotyping, concurrent with insights into ILC2 plasticity, and an exploration of the roles of costimulatory molecules, neuroendocrine signals, and diet-derived nutrients in modulating ILC2 activity.</style></abstract><notes><style face="normal" font="default" size="100%">Cain, Jafar&#xD;Hurrell, Benjamin&#xD;Akbari, Omid&#xD;eng&#xD;NH/NIH HHS/&#xD;Review&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):11-23. doi: 10.1111/all.70030. Epub 2025 Sep 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40891582</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70030</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1341</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1341</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruethers, T.</style></author><author><style face="normal" font="default" size="100%">Taki, A. C.</style></author><author><style face="normal" font="default" size="100%">Karnaneedi, S.</style></author><author><style face="normal" font="default" size="100%">Nie, S.</style></author><author><style face="normal" font="default" size="100%">Kalic, T.</style></author><author><style face="normal" font="default" size="100%">Dai, D.</style></author><author><style face="normal" font="default" size="100%">Daduang, S.</style></author><author><style face="normal" font="default" size="100%">Leeming, M.</style></author><author><style face="normal" font="default" size="100%">Williamson, N. A.</style></author><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author><author><style face="normal" font="default" size="100%">Mehr, S. S.</style></author><author><style face="normal" font="default" size="100%">Kamath, S. D.</style></author><author><style face="normal" font="default" size="100%">Campbell, D. E.</style></author><author><style face="normal" font="default" size="100%">Lopata, A. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular Allergy Research Laboratory, College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, Qld, Australia.&#xD;Centre for Food and Allergy Research, Murdoch Children&apos;s Research Institute, Melbourne, Vic., Australia.&#xD;Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Qld, Australia.&#xD;Centre for Sustainable Tropical Fisheries and Aquaculture, Faculty of Science and Engineering, James Cook University, Townsville, Qld, Australia.&#xD;Bio21 Mass Spectrometry and Proteomics Facility, The Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Vic., Australia.&#xD;Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Allergy and Immunology, Children&apos;s Hospital at Westmead, Sydney, NSW, Australia.&#xD;Division of Pharmacognosy and Toxicology, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand.&#xD;Protein and Proteomics Research Center for Commercial and Industrial Purposes (ProCCI), Khon Kaen University, Khon Kaen, Thailand.&#xD;Department of Allergy and Immunology, Royal Children&apos;s Hospital Melbourne, Melbourne, Vic., Australia.&#xD;Discipline of Paediatrics and Child Health, University of Sydney, Sydney, NSW, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Expanding the allergen repertoire of salmon and catfish</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1443-1453</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/08/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Catfishes</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Parvalbumins</style></keyword><keyword><style face="normal" font="default" size="100%">Salmon</style></keyword><keyword><style face="normal" font="default" size="100%">Pangasianodon hypophthalmus</style></keyword><keyword><style face="normal" font="default" size="100%">Salmo salar</style></keyword><keyword><style face="normal" font="default" size="100%">fish allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">triosephosphate isomerase</style></keyword><keyword><style face="normal" font="default" size="100%">tropomyosin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32860256</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Diagnostic tests for fish allergy are hampered by the large number of under-investigated fish species. Four salmon allergens are well-characterized and registered with the WHO/IUIS while no catfish allergens have been described so far. In 2008, freshwater-cultured catfish production surpassed that of salmon, the globally most-cultured marine species. We aimed to identify, quantify, and compare all IgE-binding proteins in salmon and catfish. METHODS: Seventy-seven pediatric patients with clinically confirmed fish allergy underwent skin prick tests to salmon and catfish. The allergen repertoire of raw and heated protein extracts was evaluated by immunoblotting using five allergen-specific antibodies and patients&apos; serum followed by mass spectrometric analyses. RESULTS: Raw and heated extracts from catfish displayed a higher frequency of IgE-binding compared to those from salmon (77% vs 70% and 64% vs 53%, respectively). The major fish allergen parvalbumin demonstrated the highest IgE-binding capacity (10%-49%), followed by triosephosphate isomerase (TPI; 19%-34%) in raw and tropomyosin (6%-32%) in heated extracts. Six previously unidentified fish allergens, including TPI, were registered with the WHO/IUIS. Creatine kinase from salmon and catfish was detected by IgE from 14% and 10% of patients, respectively. Catfish L-lactate dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase, pyruvate kinase, and glucose-6-phosphate isomerase showed IgE-binding for 6%-13% of patients. In salmon, these proteins could not be separated successfully. CONCLUSIONS: We detail the allergen repertoire of two highly farmed fish species. IgE-binding to fish tropomyosins and TPIs was demonstrated for the first time in a large patient cohort. Tropomyosins, in addition to parvalbumins, should be considered for urgently needed improved fish allergy diagnostics.</style></abstract><notes><style face="normal" font="default" size="100%">Ruethers, Thimo&#xD;Taki, Aya C&#xD;Karnaneedi, Shaymaviswanathan&#xD;Nie, Shuai&#xD;Kalic, Tanja&#xD;Dai, Danyi&#xD;Daduang, Sakda&#xD;Leeming, Michael&#xD;Williamson, Nicholas A&#xD;Breiteneder, Heimo&#xD;Mehr, Sam S&#xD;Kamath, Sandip D&#xD;Campbell, Dianne E&#xD;Lopata, Andreas L&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1443-1453. doi: 10.1111/all.14574. Epub 2020 Oct 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32860256</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14574</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2648</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2648</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">von Borstel, A.</style></author><author><style face="normal" font="default" size="100%">Reinwald, S.</style></author><author><style face="normal" font="default" size="100%">Aui, P. M.</style></author><author><style face="normal" font="default" size="100%">McKenzie, C. I.</style></author><author><style face="normal" font="default" size="100%">Varese, N.</style></author><author><style face="normal" font="default" size="100%">Hogarth, P. M.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">van Zelm, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.&#xD;Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia.&#xD;Immune Therapies Group, Burnet Institute, Melbourne, Victoria, Australia.&#xD;Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Expansion of phenotypically modified type 2 memory B cells after allergen immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">867-869</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/09/15 21:16</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39268605</style></accession-num><notes><style face="normal" font="default" size="100%">von Borstel, Anouk&#xD;Reinwald, Simone&#xD;Aui, Pei M&#xD;McKenzie, Craig I&#xD;Varese, Nirupama&#xD;Hogarth, P Mark&#xD;Hew, Mark&#xD;O&apos;Hehir, Robyn E&#xD;van Zelm, Menno C&#xD;eng&#xD;National Health and Medical Research Council/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):867-869. doi: 10.1111/all.16320. Epub 2024 Sep 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39268605</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891399 (PCT/AU2023/050439). All other authors declare no conflicts of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16320</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>691</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">691</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Mathes, S.</style></author><author><style face="normal" font="default" size="100%">Fischer, J.</style></author><author><style face="normal" font="default" size="100%">Volc, S.</style></author><author><style face="normal" font="default" size="100%">Darsow, U.</style></author><author><style face="normal" font="default" size="100%">Eberlein, B.</style></author><author><style face="normal" font="default" size="100%">Biedermann, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich, Germany.&#xD;Department of Dermatology, Eberhard Karls University, Tubingen, Germany.&#xD;Division of Experimental Allergy and Immunodermatology, University of Oldenburg, Oldenburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2200-2210</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/11/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Polyethylene Glycols/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Management</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy testing</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">polyethylene glycol</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34806775</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Polyethylene glycol (PEG) may elicit anaphylaxis to COVID-19 mRNA vaccines, and guidance for patients at risk is needed. METHODS: In retrospective patients with PEG allergy collected from 2006 till 2019, clinical, skin, and basophil activation test (BAT) characteristics discriminative for PEG allergy were analyzed and compared with the literature. In 421 prospective real-life patients asking for allergy workup for COVID-19 vaccine hypersensitivity in 2020/2021, risk assessment was performed and tolerance of the recommended vaccination approach was assessed. RESULTS: Ten patients with PEG allergy were found in the retrospective cohort. Patients reacted with immediate anaphylaxis (100%) not only to PEG-based laxatives/bowel preparations or injections, but also to cold medication, antiseptics, analgetics, or antibiotics. Skin tests +/- BAT with PEG +/- elicitors were positive in 10/10. Provocation tests were positive in 7/9 patients. From the prospective cohort, 370/421 patients self-reporting increased risk for vaccine allergy lacked criteria necessitating allergy workup and were recommended for routine vaccination. A total of 51/421 patients were tested, and three (6%) with PEG allergy were identified, whereas 48 patients remained negative in skin tests. Vaccination was recommended in all those patients. No hypersensitivity reactions were reported to vaccination including six PEG-allergic patients tolerating COVID-19 vaccination. CONCLUSIONS: Taking a detailed history excluded PEG allergy in most referred patients and enabled direct safe vaccination. Immediate urticaria/anaphylaxis to typical elicitors identified patients requiring PEG allergy workup. Skin tests +/- BAT identified PEG allergy and helped to select the vaccine and the vaccination approach. Even PEG-allergic patients can tolerate COVID-19 vaccines.</style></abstract><notes><style face="normal" font="default" size="100%">Brockow, Knut&#xD;Mathes, Sonja&#xD;Fischer, Jorg&#xD;Volc, Sebastian&#xD;Darsow, Ulf&#xD;Eberlein, Bernadette&#xD;Biedermann, Tilo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2200-2210. doi: 10.1111/all.15183. Epub 2021 Dec 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34806775</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9011687</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15183</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>638</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">638</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turk, M.</style></author><author><style face="normal" font="default" size="100%">Yilmaz, I.</style></author><author><style face="normal" font="default" size="100%">Sahiner, U. M.</style></author><author><style face="normal" font="default" size="100%">Kocaturk, E.</style></author><author><style face="normal" font="default" size="100%">Sekerel, B. E.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinic of Immunologic and Allergic Diseases, Kayseri City Education and Research Hospital, Kayseri, Turkey.&#xD;Division of Allergy and Clinical Immunology, Erciyes University School of Medicine, Kayseri, Turkey.&#xD;Pediatric Allergy Department, Hacettepe University School of Medicine, Ankara, Turkey.&#xD;Department of Dermatology, Koc University School of Medicine, Istanbul, Turkey.&#xD;Institute for Allergology, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Experience-based advice on stepping up and stepping down the therapeutic management of chronic spontaneous urticaria: Where is the guidance?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1626-1630</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/01/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedema/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">chronic urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">guideline</style></keyword><keyword><style face="normal" font="default" size="100%">treatment management</style></keyword><keyword><style face="normal" font="default" size="100%">wheals</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35048385</style></accession-num><notes><style face="normal" font="default" size="100%">Turk, Murat&#xD;Yilmaz, Insu&#xD;Sahiner, Umit Murat&#xD;Kocaturk, Emek&#xD;Sekerel, Bulent Enis&#xD;Zuberbier, Torsten&#xD;Maurer, Marcus&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1626-1630. doi: 10.1111/all.15227. Epub 2022 Jan 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35048385</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15227</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>927</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">927</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wirz, O. F.</style></author><author><style face="normal" font="default" size="100%">Jansen, K.</style></author><author><style face="normal" font="default" size="100%">Satitsuksanoa, P.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Mirer, D.</style></author><author><style face="normal" font="default" size="100%">Stanic, B.</style></author><author><style face="normal" font="default" size="100%">Message, S. D.</style></author><author><style face="normal" font="default" size="100%">Kebadze, T.</style></author><author><style face="normal" font="default" size="100%">Glanville, N.</style></author><author><style face="normal" font="default" size="100%">Mallia, P.</style></author><author><style face="normal" font="default" size="100%">Gern, J. E.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Johnston, S. L.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Functional Genomics Center Zurich, ETH Zurich/University of Zurich, Zurich, Switzerland.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Pediatrics, University of Wisconsin-Madison, Madison, USA.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, The University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University, Palo Alto, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Experimental rhinovirus infection induces an antiviral response in circulating B cells which is dysregulated in patients with asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">130-142</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antiviral Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interferons</style></keyword><keyword><style face="normal" font="default" size="100%">*Picornaviridae Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">B lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">interferon-stimulated genes (ISG)</style></keyword><keyword><style face="normal" font="default" size="100%">pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">rhinovirus infection</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Promedica Stiftung, outside the submitted work. Dr. Sokolowska</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from Swiss National Science Foundation, grants from GSK, and</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Novartis, outside the submitted work. Dr. Glanville has a patent</style></keyword><keyword><style face="normal" font="default" size="100%">US9937252B2 &apos;Induction of cross-reactive cellular response against rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">antigens&apos; pending. Dr. Gern reports grants from NIH, during the conduct of the</style></keyword><keyword><style face="normal" font="default" size="100%">study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Regeneron, personal fees and stock options from Meissa</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines Inc, and personal fees from MedImmune/AstraZeneca, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. In addition, Dr. Gern has patents for Methods of Propagating Rhinovirus C</style></keyword><keyword><style face="normal" font="default" size="100%">in Previously Unsusceptible Cell Lines, and for Adapted Rhinovirus C. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Papadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES</style></keyword><keyword><style face="normal" font="default" size="100%">FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, grants from Gerolymatos International SA, and grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Capricare, outside the submitted work. Dr. Akdis reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kuhne-Center</style></keyword><keyword><style face="normal" font="default" size="100%">for Allergy Research and Education, European Commission&apos;s Horizon&apos;s 2020</style></keyword><keyword><style face="normal" font="default" size="100%">Framework Programme, Cure, Novartis Research Institutes, Basel, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Switzerland, Scibase, Stockholm, advisory role for Sanofi/Regeneron, Glaxo</style></keyword><keyword><style face="normal" font="default" size="100%">Smith-Kline, Novartis. Dr. Johnston reports personal fees from Virtus Respiratory</style></keyword><keyword><style face="normal" font="default" size="100%">Research, personal fees from Myelo Therapeutics GmbH, personal fees from Bayer,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Novartis, personal fees from Boehringer Ingelheim, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Gerson Lehrman Group, personal fees from resTORbio, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Bioforce, personal fees from Lallemand Pharma, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">in</style></keyword><keyword><style face="normal" font="default" size="100%">addition, Dr. Johnston has a patent Wark PA, Johnston SL, Holgate ST, Davies DE</style></keyword><keyword><style face="normal" font="default" size="100%">&quot;Anti-virus therapy for respiratory diseases&quot;, UK patent application No. GB</style></keyword><keyword><style face="normal" font="default" size="100%">0405634.7, 12 March 2004, with royalties paid, a patent Wark PA, Johnston SL,</style></keyword><keyword><style face="normal" font="default" size="100%">Holgate ST, Davies DE &quot;Interferon-Beta for Anti-Virus Therapy for Respiratory</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases&quot;, International Patent Application No. PCT/GB05/50031, 12 March 2004,</style></keyword><keyword><style face="normal" font="default" size="100%">with royalties paid, and a patent Davies DE, Wark PA, Holgate ST, Johnston SL</style></keyword><keyword><style face="normal" font="default" size="100%">&quot;Interferon Lambda Therapy for the Treatment of Respiratory disease&quot;, UK Patent</style></keyword><keyword><style face="normal" font="default" size="100%">application No. 6779645.9, granted 15th August 2012, licensed. Dr. Nadeau reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from National Institute of Allergy and Infectious Diseases (NIAID),</style></keyword><keyword><style face="normal" font="default" size="100%">National Heart, Lung, and Blood Institute (NHLBI), National Institute of</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Health Sciences (NIEHS), and Food Allergy Research &amp; Education</style></keyword><keyword><style face="normal" font="default" size="100%">(FARE)</style></keyword><keyword><style face="normal" font="default" size="100%">Director of World Allergy Organization (WAO), Advisor at Cour Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">co-founder of Before Brands, Alladapt, Latitude, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">and National</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific Committee member at Immune Tolerance Network (ITN), and National</style></keyword><keyword><style face="normal" font="default" size="100%">Institutes of Health (NIH) clinical research centers, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">in addition, Dr. Nadeau has the following patents: &quot;Special Oral Formula for</style></keyword><keyword><style face="normal" font="default" size="100%">Decreasing Food Allergy Risk and Treatment for Food Allergy,&quot; (with royalties</style></keyword><keyword><style face="normal" font="default" size="100%">paid to Before Brands and Alladapt), &quot;Granulocyte-based methods for detecting and</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring immune system disorders,&quot; (issued), &quot;Methods and Assays for Detecting</style></keyword><keyword><style face="normal" font="default" size="100%">and Quantifying Pure Subpopulations of White Blood Cells in Immune System</style></keyword><keyword><style face="normal" font="default" size="100%">Disorders,&quot; (issued), &quot;Microfluidic Device and Diagnostic Methods for Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Testing Based on Detection of Basophil Activation,&quot; (pending). The other authors</style></keyword><keyword><style face="normal" font="default" size="100%">declare that they have no potential conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34169553</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Rhinoviruses are the predominant cause of respiratory viral infections and are strongly associated with asthma exacerbations. While humoral immunity plays an important role during virus infections, cellular aspects of this response are less well understood. Here, we investigated the antiviral response of circulating B cells upon experimental rhinovirus infection in healthy individuals and asthma patients. METHODS: We purified B cells from experimentally infected healthy individuals and patients with asthma and subjected them to total RNA-sequencing. Rhinovirus-derived RNA was measured in isolated B cells using a highly sensitive PCR. B cells were stimulated with rhinovirus in vitro to further study gene expression, expression of antiviral proteins and B-cell differentiation in response rhinovirus stimulation. Protein expression of pro-inflammatory cytokines in response to rhinovirus was assessed using a proximity extension assay. RESULTS: B cells isolated from experimentally infected subjects exhibited an antiviral gene profile linked to IFN-alpha, carried viral RNA in vivo and were transiently infected by rhinovirus in vitro. B cells rapidly differentiated into plasmablasts upon rhinovirus stimulation. While B cells lacked expression of interferons in response to rhinovirus exposure, co-stimulation with rhinovirus and IFN-alpha upregulated pro-inflammatory cytokine expression suggesting a potential new function of B cells during virus infections. Asthma patients showed extensive upregulation and dysregulation of antiviral gene expression. CONCLUSION: These findings add to the understanding of systemic effects of rhinovirus infections on B-cell responses in the periphery, show potential dysregulation in patients with asthma and might also have implications during infection with other respiratory viruses.</style></abstract><notes><style face="normal" font="default" size="100%">Wirz, Oliver F&#xD;Jansen, Kirstin&#xD;Satitsuksanoa, Pattraporn&#xD;van de Veen, Willem&#xD;Tan, Ge&#xD;Sokolowska, Milena&#xD;Mirer, David&#xD;Stanic, Barbara&#xD;Message, Simon D&#xD;Kebadze, Tatiana&#xD;Glanville, Nicholas&#xD;Mallia, Patrick&#xD;Gern, James E&#xD;Papadopoulos, Nikolaos&#xD;Akdis, Cezmi A&#xD;Johnston, Sebastian L&#xD;Nadeau, Kari&#xD;Akdis, Mubeccel&#xD;eng&#xD;WT_/Wellcome Trust/United Kingdom&#xD;G1000758/MRC_/Medical Research Council/United Kingdom&#xD;063717/WT_/Wellcome Trust/United Kingdom&#xD;083567/Z/07/Z/WT_/Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):130-142. doi: 10.1111/all.14985. Epub 2021 Jul 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34169553</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10138744</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14985</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2637</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2637</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vazquez-Mera, S.</style></author><author><style face="normal" font="default" size="100%">Martelo-Vidal, L.</style></author><author><style face="normal" font="default" size="100%">Miguens-Suarez, P.</style></author><author><style face="normal" font="default" size="100%">Bravo, S. B.</style></author><author><style face="normal" font="default" size="100%">Saavedra-Nieves, P.</style></author><author><style face="normal" font="default" size="100%">Arias, P.</style></author><author><style face="normal" font="default" size="100%">Ferreiro-Posse, A.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Lago, J.</style></author><author><style face="normal" font="default" size="100%">Salgado, F. J.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Barcala, F. J.</style></author><author><style face="normal" font="default" size="100%">Nieto-Fontarigo, J. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.&#xD;Translational Research In Airway Diseases Group (TRIAD), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.&#xD;Proteomic Unit, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.&#xD;Department of Statistics, Mathematical Analysis and Optimization, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.&#xD;Department of Respiratory Medicine, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.&#xD;Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.&#xD;Department of Medicine, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exploring CD26(-/lo) subpopulations of lymphocytes in asthma phenotype and severity: A novel CD4(+) T cell subset expressing archetypical granulocyte proteins</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3005-3021</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/09/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/immunology/metabolism/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Dipeptidyl Peptidase 4/metabolism/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*CD4-Positive T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocyte Subsets/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunophenotyping</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Granulocytes/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Flow Cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">Cd26</style></keyword><keyword><style face="normal" font="default" size="100%">CD26-/lo lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Dpp4</style></keyword><keyword><style face="normal" font="default" size="100%">T helper lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39319599</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma pathology may induce changes in naive/memory lymphocyte proportions assessable through the evaluation of surface CD26 (dipeptidyl peptidase 4/DPP4) levels. Our aim was to investigate the association of asthma phenotype/severity with the relative frequency of CD26(-/lo), CD26(int) and CD26(hi) subsets within different lymphocyte populations. METHODS: The proportion of CD26(-/lo), CD26(int) and CD26(hi) subsets within CD4(+) effector T cells (T(eff)), total CD4(-) lymphocytes, gammadelta-T cells, NK cells and NKT cells was measured in peripheral blood samples from healthy (N = 30) and asthma (N = 119) donors with different phenotypes/severities by flow cytometry. We performed K-means clustering analysis and further characterised the CD4(+)CD26(-/lo) T(eff) cell subset by LC-MS/MS and immunofluorescence. RESULTS: Cluster analysis including clinical and flow cytometry data resulted in four groups, two of them with opposite inflammatory profiles (neutrophilic vs. eosinophilic). Neutrophilic asthma presented reduced CD4(-)CD26(hi) cells, which negatively correlated with systemic inflammation. Eosinophilic asthma displayed a general expansion of CD26(-/lo) subsets. Specifically, CD4(+)CD26(-/lo) T(eff) expansion was confirmed in asthma, especially in atopic patients. Proteomic characterisation of this subset with a T(EM)/T(EMRA) phenotype revealed upregulated levels of innate (e.g. MPO and RNASE2) and cytoskeleton/extracellular matrix (e.g. MMP9 and ACTN1) proteins. Immunofluorescence assays confirmed the presence of atypical proteins for CD4(+) T cells, and an enrichment in &apos;flower-like&apos; nuclei and MMP9/RNASE2 levels in CD4(+)CD26(-/lo) T(eff) compared to CD4(+) T lymphocytes. CONCLUSION: There is an association between CD26 levels in different lymphocyte subsets and asthma phenotype/severity. CD4(+)CD26(-/lo)T(EMRA) cells expressing innate proteins specific to eosinophils/neutrophils could be determinant in sustaining long-term inflammation in adult allergic asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Vazquez-Mera, Sara&#xD;Martelo-Vidal, Laura&#xD;Miguens-Suarez, Pablo&#xD;Bravo, Susana Belen&#xD;Saavedra-Nieves, Paula&#xD;Arias, Pilar&#xD;Ferreiro-Posse, Antia&#xD;Vazquez-Lago, Juan&#xD;Salgado, Francisco Javier&#xD;Gonzalez-Barcala, Francisco Javier&#xD;Nieto-Fontarigo, Juan Jose&#xD;eng&#xD;NextGeneration EU/PRTR/&#xD;RYC2021-032676-I/European Union ERDF funds/&#xD;Instituto de Salud Carlos III/&#xD;MCIN/AEI/10.13039/501100011033(RYC2021-032676-I)/Agencia Estatal de Investigacion/&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3005-3021. doi: 10.1111/all.16327. Epub 2024 Sep 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39319599</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16327</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1348</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1348</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barker-Tejeda, T. C.</style></author><author><style face="normal" font="default" size="100%">Bazire, R.</style></author><author><style face="normal" font="default" size="100%">Obeso, D.</style></author><author><style face="normal" font="default" size="100%">Mera-Berriatua, L.</style></author><author><style face="normal" font="default" size="100%">Rosace, D.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Cortes, S.</style></author><author><style face="normal" font="default" size="100%">Ramos, T.</style></author><author><style face="normal" font="default" size="100%">Rico, M. D. P.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Barbas, C.</style></author><author><style face="normal" font="default" size="100%">Villasenor, A.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Blanco, C.</style></author><author><style face="normal" font="default" size="100%">Barber, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Facultad de Farmacia, Centro de Metabolomica y Bioanalisis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Urbanizacion Monteprincipe, Madrid, Espana.&#xD;Facultad de Medicina, Departamento de Ciencias Medicas Basicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, Espana.&#xD;Servicio de Alergia, Instituto de Investigacion Sanitaria Princesa (IP), Hospital Universitario de La Princesa, Madrid, Espana.&#xD;Servicio de Alergia, Hospital Infantil Universitario Nino Jesus, Fundacion para la Investigacion Biomedica del Hospital Nino Jesus, Madrid, Espana.&#xD;Servicio de Alergia, Hospital Clinico San Carlos, Universidad Complutense, IdISSC, Madrid, Espana.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1199-1212</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/08/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Poaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory allergy</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32813887</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Sublingual allergen-specific immunotherapy (SLIT) intervention improves the control of grass pollen allergy by maintaining allergen tolerance after cessation. Despite its widespread use, little is known about systemic effects and kinetics associated to SLIT, as well as the influence of the patient sensitization phenotype (Mono- or Poly-sensitized). In this quest, omics sciences could help to gain new insights to understand SLIT effects. METHODS: 47 grass-pollen-allergic patients were enrolled in a double-blind, placebo-controlled, multicenter trial using GRAZAX(R) during 2 years. Immunological assays (sIgE, sIgG4, and ISAC) were carried out to 31 patients who finished the trial. Additionally, serum and PBMCs samples were analyzed by metabolomics and transcriptomics, respectively. Based on their sensitization level, 22 patients were allocated in Mono- or Poly-sensitized groups, excluding patients allergic to epithelia. Individuals were compared based on their treatment (Active/Placebo) and sensitization level (Mono/Poly). RESULTS: Kinetics of serological changes agreed with those previously described. At two years of SLIT, there are scarce systemic changes that could be associated to improvement in systemic inflammation. Poly-sensitized patients presented a higher inflammation at inclusion, while Mono-sensitized patients presented a reduced activity of mast cells and phagocytes as an effect of the treatment. CONCLUSIONS: The most relevant systemic change detected after two years of SLIT was the desensitization of effector cells, which was only detected in Mono-sensitized patients. This change may be related to the clinical improvement, as previously reported, and, together with the other results, may explain why clinical effect is lost if SLIT is discontinued at this point.</style></abstract><notes><style face="normal" font="default" size="100%">Barker-Tejeda, Tomas Clive&#xD;Bazire, Raphaelle&#xD;Obeso, David&#xD;Mera-Berriatua, Leticia&#xD;Rosace, Domenico&#xD;Vazquez-Cortes, Sonia&#xD;Ramos, Tania&#xD;Rico, Maria Del Pilar&#xD;Chivato, Tomas&#xD;Barbas, Coral&#xD;Villasenor, Alma&#xD;Escribese, Maria M&#xD;Fernandez-Rivas, Montserrat&#xD;Blanco, Carlos&#xD;Barber, Domingo&#xD;eng&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1199-1212. doi: 10.1111/all.14565. Epub 2020 Sep 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32813887</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246889</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14565</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2742</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2742</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liao, T. C.</style></author><author><style face="normal" font="default" size="100%">Tsai, P. C.</style></author><author><style face="normal" font="default" size="100%">Lin, M. C.</style></author><author><style face="normal" font="default" size="100%">Wu, C. C.</style></author><author><style face="normal" font="default" size="100%">Chen, H. C.</style></author><author><style face="normal" font="default" size="100%">Chen, P. S.</style></author><author><style face="normal" font="default" size="100%">Lin, Y. C.</style></author><author><style face="normal" font="default" size="100%">Chen, K. S.</style></author><author><style face="normal" font="default" size="100%">Wang, T. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Public Health, College of Health Science, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Department of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan.&#xD;Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan.&#xD;Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.&#xD;Division of Pulmonary and Critical Care Medicine, Department of Medicine, Chang Gung, Memorial Hospital-Kaohsiung, Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.&#xD;Institute of Environmental Engineering, National Sun Yat-Sen University, Kaohsiung, Taiwan.&#xD;Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exploring Occupational Asthmagen-Related Asthma Phenotypes: A Cluster Analysis and Machine Learning Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1137-1142</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/16</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39676734</style></accession-num><notes><style face="normal" font="default" size="100%">Liao, Tzu-Ching&#xD;Tsai, Pei-Chien&#xD;Lin, Meng-Chih&#xD;Wu, Chao-Chien&#xD;Chen, Hung-Chen&#xD;Chen, Pei-Shih&#xD;Lin, Yuan-Chung&#xD;Chen, Kang-Shin&#xD;Wang, Tsu-Nai&#xD;eng&#xD;MOST103-2314-B-037-018-MY3/Ministry of Science and Technology, Taiwan/&#xD;MOST 107-2314-B-037-086-MY3/Ministry of Science and Technology, Taiwan/&#xD;MOST 110-2314-B-037-048-MY3/Ministry of Science and Technology, Taiwan/&#xD;NSYSUKMU 109-I006/National Sun Yat-sen University and Kaohsiung Medical University Joint Project/&#xD;112-I04/National Sun Yat-sen University and Kaohsiung Medical University Joint Project/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1137-1142. doi: 10.1111/all.16422. Epub 2024 Dec 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39676734</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16422</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3077</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3077</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adachi, T.</style></author><author><style face="normal" font="default" size="100%">Watanabe, S.</style></author><author><style face="normal" font="default" size="100%">Kuwabara, Y.</style></author><author><style face="normal" font="default" size="100%">Abe, Y.</style></author><author><style face="normal" font="default" size="100%">Futamura, M.</style></author><author><style face="normal" font="default" size="100%">Inomata, T.</style></author><author><style face="normal" font="default" size="100%">Ito, K.</style></author><author><style face="normal" font="default" size="100%">Kimura, M.</style></author><author><style face="normal" font="default" size="100%">Kan, O. K.</style></author><author><style face="normal" font="default" size="100%">Koguchi-Yoshioka, H.</style></author><author><style face="normal" font="default" size="100%">Kurashima, Y.</style></author><author><style face="normal" font="default" size="100%">Masaki, K.</style></author><author><style face="normal" font="default" size="100%">Matsunaga, M.</style></author><author><style face="normal" font="default" size="100%">Miki, H.</style></author><author><style face="normal" font="default" size="100%">Nakajima, S.</style></author><author><style face="normal" font="default" size="100%">Nakamura, Y.</style></author><author><style face="normal" font="default" size="100%">Ogawa, Y.</style></author><author><style face="normal" font="default" size="100%">Oka, A.</style></author><author><style face="normal" font="default" size="100%">Sakashita, M.</style></author><author><style face="normal" font="default" size="100%">Sato, S.</style></author><author><style face="normal" font="default" size="100%">Takahashi, K.</style></author><author><style face="normal" font="default" size="100%">Tamari, M.</style></author><author><style face="normal" font="default" size="100%">Tsuda, T.</style></author><author><style face="normal" font="default" size="100%">Yonekura, S.</style></author><author><style face="normal" font="default" size="100%">Tamari, M.</style></author><author><style face="normal" font="default" size="100%">Muto, K.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.&#xD;Allergy Center, Keio University Hospital, Tokyo, Japan.&#xD;Department of Medical Innovation and Translational Medical Science, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.&#xD;ENGAGE-Task Force, Tokyo, Japan.&#xD;NPO Cheiron Initiative, Tokyo, Japan.&#xD;Department of Public Policy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.&#xD;Institute for Clinical Research, NHO Mie National Hospital, Mie, Japan.&#xD;Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Hokkaido, Japan.&#xD;Department of Pediatrics, NHO Nagoya Medical Center, Aichi, Japan.&#xD;Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Department of Hospital Administration, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Department of Telemedicine and Mobile Health, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Data Science, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.&#xD;Department of Ophthalmology, Juntendo University Urayasu Hospital, Chiba, Japan.&#xD;Department of Respiratory Medicine, Tokyo Women&apos;s Medical University, Tokyo, Japan.&#xD;Department of Dermatology, Graduate School of Medicine, Osaka University, Osaka, Japan.&#xD;Department of Innovative Medicine, Graduate School of Medicine, Institute for Advanced Academic Research, Chiba University, Chiba, Japan.&#xD;Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.&#xD;Department of Pediatrics, Hamamatsu University School of Medicine, Shizuoka, Japan.&#xD;Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.&#xD;Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Cutaneous Allergy and Host Defense, Immunology Frontier Research Center, Osaka University, Osaka, Japan.&#xD;Department of Advanced Medicine, Nagoya University Hospital, Aichi, Japan.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, International University of Health and Welfare Narita Hospital, Chiba, Japan.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, University of Fukui, Fukui, Japan.&#xD;Department of Allergy, Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Kanagawa, Japan.&#xD;Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.&#xD;Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Division of Molecular Genetics, The Jikei University School of Medicine, Research Center for Medical Science, Tokyo, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exploring Patient and Public Involvement and Engagement in Allergy Research: Cross-Disease and Cross-Stakeholder Perspectives in Japan</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">cancer</style></keyword><keyword><style face="normal" font="default" size="100%">patient and public involvement</style></keyword><keyword><style face="normal" font="default" size="100%">patient engagement</style></keyword><keyword><style face="normal" font="default" size="100%">rare diseases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40964994</style></accession-num><notes><style face="normal" font="default" size="100%">Adachi, Takeya&#xD;Watanabe, Saori&#xD;Kuwabara, Yu&#xD;Abe, Yuki&#xD;Futamura, Masaki&#xD;Inomata, Takenori&#xD;Ito, Keima&#xD;Kimura, Meiko&#xD;Kan-O, Keiko&#xD;Koguchi-Yoshioka, Hanako&#xD;Kurashima, Yosuke&#xD;Masaki, Katsunori&#xD;Matsunaga, Mayumi&#xD;Miki, Haruka&#xD;Nakajima, Saeko&#xD;Nakamura, Yuumi&#xD;Ogawa, Yasushi&#xD;Oka, Aiko&#xD;Sakashita, Masafumi&#xD;Sato, Sakura&#xD;Takahashi, Kyohei&#xD;Tamari, Masato&#xD;Tsuda, Takeshi&#xD;Yonekura, Satoru&#xD;Tamari, Mayumi&#xD;Muto, Kaori&#xD;Morita, Hideaki&#xD;eng&#xD;Japan Society for the Promotion of Science/&#xD;the Scientific Research Fund of the Ministry of Health, Labour and Welfare of Japan/&#xD;Japanese Society of Allergology/&#xD;Secom Science and Technology Foundation/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep 18. doi: 10.1111/all.70064.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40964994</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70064</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2644</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2644</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cadot, R.</style></author><author><style face="normal" font="default" size="100%">Gery, P.</style></author><author><style face="normal" font="default" size="100%">Lenief, V.</style></author><author><style face="normal" font="default" size="100%">Nicolas, J. F.</style></author><author><style face="normal" font="default" size="100%">Vocanson, M.</style></author><author><style face="normal" font="default" size="100%">Tauber, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CIRI-Centre International de Recherche en Infectiologie, Lyon, France.&#xD;INSERM, U1111, Lyon, France.&#xD;Ecole Normale Superieure de Lyon, Universite Claude Bernard Lyon 1, Universite de Lyon, Lyon, France.&#xD;CNRS, UMR 5308, Lyon, France.&#xD;Allergology and Clinical Immunology Department, Lyon Sud University Hospital, Pierre Benite, France.&#xD;Reference center for toxic bullous dermatitis and severe cutaneous adverse reactions, Hospices Civils de Lyon, Lyon, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">47-62</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/09/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/etiology/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Eruptions/etiology/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Drug-Related Side Effects and Adverse Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">T-cell-mediated diseases</style></keyword><keyword><style face="normal" font="default" size="100%">delayed hypersensitivity classification</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunopathology</style></keyword><keyword><style face="normal" font="default" size="100%">severe cutaneous adverse reactions</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39295209</style></accession-num><abstract><style face="normal" font="default" size="100%">Severe cutaneous adverse reactions to drugs (SCARs) are rare but life-threatening delayed allergies. While they primarily affect the skin, they can also affect internal organs. Accordingly, they present with diverse clinical symptoms that vary not only between SCARs subtypes but also among patients. Despite the availability of topical and systemic treatments, these only address the symptoms and not the cause. To develop more effective therapies, it is necessary to elucidate the complexity of the pathophysiology of SCARs in relation to their severity. In line with the new type IV hypersensitivity reactions nomenclature proposed by the European Academy of Allergy and Clinical Immunology (EAACI), this review highlights the current insights into the intricate immune mechanisms engaged, the interplay between the culprit drug and genetic predisposition in drug presentation mechanisms, but also how external factors, such as viruses, are implicated in SCARs. Their relevance to the development of targeted medicine is also discussed.</style></abstract><notes><style face="normal" font="default" size="100%">Cadot, Romane&#xD;Gery, Perrine&#xD;Lenief, Vanina&#xD;Nicolas, Jean-Francois&#xD;Vocanson, Marc&#xD;Tauber, Marie&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):47-62. doi: 10.1111/all.16316. Epub 2024 Sep 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39295209</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724259</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16316</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2949</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2949</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ecrement, A.</style></author><author><style face="normal" font="default" size="100%">Spasovski, V.</style></author><author><style face="normal" font="default" size="100%">Rolin, G.</style></author><author><style face="normal" font="default" size="100%">Barnig, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, Besancon, France.&#xD;CHU Besancon, Inserm CIC 1431, Besancon, France.&#xD;Department of Chest Disease, CHU Besancon, Besancon, France.&#xD;INSERM, F-CRIN, Clinical Research Initiative in Severe Asthma: A Lever for Innovation and Science (CRISALIS), Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exploring the Diversity and Emerging Powers of Eosinophil Subpopulations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3012-3026</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">anti-IL5 therapies</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">iEOS</style></keyword><keyword><style face="normal" font="default" size="100%">phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">rEOS</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40568764</style></accession-num><abstract><style face="normal" font="default" size="100%">Eosinophils, once viewed as terminal effector cells of type 2 immunity, are now recognized as a heterogeneous population with context-dependent plasticity and diverse roles in tissue homeostasis, immune regulation, and disease. Emerging data from transcriptomic and functional studies, particularly in murine models, have identified distinct eosinophil subsets shaped by local environmental cues and systemic signals. These include regulatory and pro-inflammatory subsets in the gastrointestinal tract, lung, adipose tissue, synovium, and more, each defined by unique phenotypic and transcriptional signatures. In humans, eosinophil heterogeneity is increasingly evident in asthma, nasal polyposis, and eosinophilic esophagitis, although less well characterized than in mice. This review synthesizes recent advances that redefine eosinophil biology, emphasizing their functional diversity and context-dependent specialization across tissues and disease states, and how these subsets are regulated by anti-IL-5 therapies.</style></abstract><notes><style face="normal" font="default" size="100%">Ecrement, Alexandre&#xD;Spasovski, Vladimir&#xD;Rolin, Gwenael&#xD;Barnig, Cindy&#xD;eng&#xD;N degrees 2022-Y-13673/Region Bourgogne-Franche Comte/&#xD;N degrees 2023-10-30/Grand Besancon Metropole/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3012-3026. doi: 10.1111/all.16631. Epub 2025 Jun 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40568764</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16631</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2308</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2308</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ebo, D. G.</style></author><author><style face="normal" font="default" size="100%">Rihs, H. P.</style></author><author><style face="normal" font="default" size="100%">Mertens, C. H.</style></author><author><style face="normal" font="default" size="100%">Van Gasse, A. L.</style></author><author><style face="normal" font="default" size="100%">van der Poorten, M. L.</style></author><author><style face="normal" font="default" size="100%">Hagendorens, M. M.</style></author><author><style face="normal" font="default" size="100%">Sabato, V.</style></author><author><style face="normal" font="default" size="100%">Elst, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology-Allergology-Rheumatology and the Infla-med Centre of Excellence, University of Antwerp-University Hospital of Antwerp, Antwerp University, Antwerp, Belgium.&#xD;Department of Immunology-Allergology, AZ Jan Palfijn Ghent, Ghent, Belgium.&#xD;Ruhr-University Bochum, IPA-Institute for Prevention and Occupational Medicine, German Social Accident Insurance, Bochum, Germany.&#xD;Pediatrics, University of Antwerp-University Hospital of Antwerp, Antwerp, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exploring the thaumatin-like protein (TLP) as a candidate cannabis allergen in North-Western Europe</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">257-259</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Cannabis</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37984436</style></accession-num><notes><style face="normal" font="default" size="100%">Ebo, D G&#xD;Rihs, H P&#xD;Mertens, C H&#xD;Van Gasse, A L&#xD;van der Poorten, M L&#xD;Hagendorens, M M&#xD;Sabato, V&#xD;Elst, J&#xD;eng&#xD;Agentschap voor Innovatie door Wetenschap en Technologie/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):257-259. doi: 10.1111/all.15953. Epub 2023 Nov 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37984436</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15953</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1630</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1630</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stefanovic, N.</style></author><author><style face="normal" font="default" size="100%">Flohr, C.</style></author><author><style face="normal" font="default" size="100%">Irvine, A. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medicine, Trinity College Dublin, Dublin, Ireland.&#xD;Unit for Population-Based Dermatology Research, St John&apos;s Institute of Dermatology, Guy&apos;s &amp; St Thomas&apos; NHS Foundation Trust and King&apos;s College London, London, UK.&#xD;Department of Paediatric Dermatology, Our Lady&apos;s Children&apos;s Hospital Crumlin, Dublin, Ireland.&#xD;National Children&apos;s Research Centre, Crumlin and Clinical Medicine, Trinity College Dublin, Dublin, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The exposome in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">63-74</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2019/06/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Exposure</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">exposome</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31194890</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopic dermatitis (AD) is a complex inflammatory disorder with multiple interactions between genetic, immune and external factors. The sum of external factors that an individual is exposed to throughout their lifetime is termed the exposome. The exposome spans multiple domains from population to molecular levels and, in combination with genetic factors, holds the key to understanding the phenotypic diversity seen in AD patients. Exposomal domains are categorized into nonspecific (human and natural factors affecting populations), specific (eg humidity, ultraviolet radiation, diet, pollution, allergens, water hardness) and internal (cutaneous and gut microbiota and host cell interaction) exposures. The skin, as the organ that most directly interacts with and adapts to the external environment, is a prime target for exploration of exposomal influences on disease. Given the well-recognized physical environmental influences on AD, this condition could be much better understood through insightful exposomal research. In this narrative review, we examine each domain in turn, highlighting current understanding of the mechanisms by which exposomal influences modulate AD pathogenesis at distinct points in time. We highlight current approaches to exposome modification in AD and other allergic disease and propose future directions for exposome characterization and modification using novel research techniques.</style></abstract><notes><style face="normal" font="default" size="100%">Stefanovic, Nicholas&#xD;Flohr, Carsten&#xD;Irvine, Alan D&#xD;eng&#xD;CDF-2014-07-037/DH_/Department of Health/United Kingdom&#xD;CDF-2014-07-037/UK National Institute for Health Research (NIHR) Senior Career Development Fellowship/International&#xD;the NIHR Biomedical Research Centre at Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK/International&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2020 Jan;75(1):63-74. doi: 10.1111/all.13946. Epub 2019 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31194890</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7003958</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13946</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2773</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2773</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pacheco Da Silva, E.</style></author><author><style face="normal" font="default" size="100%">Weinmann, T.</style></author><author><style face="normal" font="default" size="100%">Gerlich, J.</style></author><author><style face="normal" font="default" size="100%">Weinmayr, G.</style></author><author><style face="normal" font="default" size="100%">Genuneit, J.</style></author><author><style face="normal" font="default" size="100%">Nowak, D.</style></author><author><style face="normal" font="default" size="100%">von Mutius, E.</style></author><author><style face="normal" font="default" size="100%">Vogelberg, C.</style></author><author><style face="normal" font="default" size="100%">Radon, K.</style></author><author><style face="normal" font="default" size="100%">Forster, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute and Clinic for Occupational, Social and Environmental Medicine, LMU University Hospital, LMU Munich, Munich, Germany.&#xD;Universite Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Equipe d&apos;Epidemiologie Respiratoire Integrative, CESP, Villejuif, France.&#xD;Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.&#xD;Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany.&#xD;Institute for Asthma and Allergy Prevention, Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany.&#xD;Department of Pediatrics, Dr. von Hauner Children&apos;s Hospital, LMU University Hospital, LMU Munich, Munich, Germany.&#xD;Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitat Dresden, Dresden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exposure Profiles for the Long-Term Use of Disinfectants and Cleaning Products and Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">996-1005</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Germany/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Disinfectants/analysis/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Latent Class Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/chemically induced/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Sounds/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Aerosols/analysis/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">*Detergents/analysis/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Exposure/adverse effects/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Household Products/analysis/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Logistic Models</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">disinfectants and cleaning products</style></keyword><keyword><style face="normal" font="default" size="100%">exposure profiles</style></keyword><keyword><style face="normal" font="default" size="100%">sprays</style></keyword><keyword><style face="normal" font="default" size="100%">payment or honoraria from ALK-Abello Arzneimittel GmbH, AstraZeneca, OM Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">and Abbott Laboratories</style></keyword><keyword><style face="normal" font="default" size="100%">support for attending meetings and/or travel from Fabio</style></keyword><keyword><style face="normal" font="default" size="100%">Luigi Massimo Ricciardolo/Contatto S.r.l., Karl-Landsteiner Private University</style></keyword><keyword><style face="normal" font="default" size="100%">for Health Sciences, Gordon Research Conferences, Arla, OM Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">participation</style></keyword><keyword><style face="normal" font="default" size="100%">on the BEAMS External Scientific Advisory Board (ESAB) and Abbott Allergy Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Reduction Advisory Board. E.vM. has Patent No. PCT/EP2019/085016 (barn dust</style></keyword><keyword><style face="normal" font="default" size="100%">extract for the prevention and treatment of diseases) pending, royalties paid to</style></keyword><keyword><style face="normal" font="default" size="100%">ProtectImmun for patent EP2361632 (Specific environmental bacteria for the</style></keyword><keyword><style face="normal" font="default" size="100%">protection from and/or the treatment of allergic, chronic inflammatory and/or</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmune disorders, granted on 19 March 2014), and patents EP1411977</style></keyword><keyword><style face="normal" font="default" size="100%">(composition containing bacterial antigens used for the prophylaxis and the</style></keyword><keyword><style face="normal" font="default" size="100%">treatment of allergic diseases, granted on April 18, 2007), EP1637147 (stable</style></keyword><keyword><style face="normal" font="default" size="100%">dust extract for allergy protection, granted on December 10, 2008), and EP1964570</style></keyword><keyword><style face="normal" font="default" size="100%">(pharmaceutical compound to protect against allergies and inflammatory diseases,</style></keyword><keyword><style face="normal" font="default" size="100%">granted on November 21, 2012) licensed to ProtectImmun. Patent EP21189353.2.</style></keyword><keyword><style face="normal" font="default" size="100%">2021. von Mutius E, Rankl B, Bracher F, Muller C, Walker A, Hauck SM, Merl-Pham</style></keyword><keyword><style face="normal" font="default" size="100%">J, and inventors</style></keyword><keyword><style face="normal" font="default" size="100%">PROTEINS IDENTIFIED FROM BARN DUST EXTRACT FOR THE PREVENTION</style></keyword><keyword><style face="normal" font="default" size="100%">AND TREATMENT OF DISEASES. Patent PCT/US2021/016918. 2021. Martinez FD, Vercelli</style></keyword><keyword><style face="normal" font="default" size="100%">D, Snyder SA, von Mutius E, Pivniouk V, Marques dos Santos M, and inventors</style></keyword><keyword><style face="normal" font="default" size="100%">THERAPEUTIC FRACTIONS AND PROTEINS FROM ASTHMA-PROTECTIVE FARM DUST. Patent</style></keyword><keyword><style face="normal" font="default" size="100%">EP21189353.2. 2021. von Mutius E, Rankl B, Bracher F, Muller C, Walker A, Hauck</style></keyword><keyword><style face="normal" font="default" size="100%">SM, Merl-Pham J, Adler H, Yildirim A.O., Sattler M, Santos Dias Mourao A,</style></keyword><keyword><style face="normal" font="default" size="100%">Borggrafe J, O&apos;Connor P.D., Plettenburg O, and inventors</style></keyword><keyword><style face="normal" font="default" size="100%">PROTEINS IDENTIFIED</style></keyword><keyword><style face="normal" font="default" size="100%">FROM BARN DUST EXTRACT FOR THE PREVENTION AND TREATMENT OF DISEASES. C.V. reports</style></keyword><keyword><style face="normal" font="default" size="100%">a research grant from Boehringer Ingelheim</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Sanofi Aventis</style></keyword><keyword><style face="normal" font="default" size="100%">and payment or honoraria from Sanofi Aventis, AstraZeneca, and Novartis Pharma.</style></keyword><keyword><style face="normal" font="default" size="100%">E.P.D.S., T.W., J. Gerlich, G.W., J. Genuneit, D.N., K.R., and F.F. declare no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39723603</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Using disinfectants and cleaning products (DCPs) at home and work is known to influence both the onset and course of asthma, but most epidemiological studies did not consider the multiplicity and correlations of exposures to DCPs. We aimed to identify exposure profiles for the long-term weekly use of DCPs by latent class analysis (LCA) and assess their associations with asthma. METHODS: LCA was conducted on data from 1143 young adults initially recruited in the German centers of Phase II of the International Study of Asthma and Allergies in Childhood (ISAAC) and followed up three times. In our LCA model, we included the use of cleaning sprays, disinfectant sprays, and nonspray disinfection methods, measured at ages 19-24 (first assessment) and 29-34 years (second assessment). Associations between identified exposure profiles and current as well as incident asthma/wheeze were evaluated by logistic regression. RESULTS: We identified five long-term exposure profiles to DCPs (latent classes): no weekly use of DCPs (55% of participants), use in first assessment (7%), use in second assessment (18%), persistent use (8%), and persistent cleaning sprays use (12%). Compared to &quot;no weekly use,&quot; being in the &quot;persistent use&quot; profile was associated with both current asthma (OR = 1.68, 95% CI = [0.48-5.88]) and current wheeze (OR = 1.71, 95% CI = [0.75-3.90]). For incident asthma/wheeze, interval estimates were very wide. CONCLUSIONS: Our study identified five distinct long-term exposure profiles to DCPs. Among those, only a persistent weekly use of multiple DCPs over time seemed to have an adverse effect on asthma. However, large confidence intervals indicate considerable uncertainty.</style></abstract><notes><style face="normal" font="default" size="100%">Pacheco Da Silva, Emilie&#xD;Weinmann, Tobias&#xD;Gerlich, Jessica&#xD;Weinmayr, Gudrun&#xD;Genuneit, Jon&#xD;Nowak, Dennis&#xD;von Mutius, Erika&#xD;Vogelberg, Christian&#xD;Radon, Katja&#xD;Forster, Felix&#xD;eng&#xD;European Respiratory Society/&#xD;Societe de Pneumologie de Langue Francaise/&#xD;German Ministry of Labour and Social Affairs/&#xD;Deutsche Forschungsgemeinschaft/&#xD;German Ministry for Economy and Labour/&#xD;German Federal Institute for Occupational Safety and Health/&#xD;01 EE 9411-3/German Ministry of Education and Research/&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):996-1005. doi: 10.1111/all.16456. Epub 2024 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39723603</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969305</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16456</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1096</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1096</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paciencia, I.</style></author><author><style face="normal" font="default" size="100%">Cavaleiro Rufo, J.</style></author><author><style face="normal" font="default" size="100%">Farraia, M.</style></author><author><style face="normal" font="default" size="100%">Leal, M.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servico de Imunologia Basica e Clinica, Departamento de Patologia, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.&#xD;EPIUnit - Instituto de Saude Publica, Universidade do Porto, Porto, Portugal.&#xD;Servico de Imunoalergologia, Centro Hospitalar Sao Joao, Porto, Portugal.&#xD;Faculdade de Ciencias da Nutricao, Alimentacao da Universidade do Porto, Porto, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exposure to indoor and airborne food allergens in commercial airplanes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2295-2296</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/03/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Air Pollution, Indoor/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Aircraft</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">airplanes</style></keyword><keyword><style face="normal" font="default" size="100%">exposure</style></keyword><keyword><style face="normal" font="default" size="100%">food allergens</style></keyword><keyword><style face="normal" font="default" size="100%">indoor allergens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33715190</style></accession-num><notes><style face="normal" font="default" size="100%">Paciencia, Ines&#xD;Cavaleiro Rufo, Joao&#xD;Farraia, Mariana&#xD;Leal, Mariana&#xD;Moreira, Andre&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2295-2296. doi: 10.1111/all.14813. Epub 2021 Mar 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33715190</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14813</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3211</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3211</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hartiala, M.</style></author><author><style face="normal" font="default" size="100%">Elenius, V.</style></author><author><style face="normal" font="default" size="100%">Pesquera, A. A.</style></author><author><style face="normal" font="default" size="100%">Androulakis, S.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Badyda, A.</style></author><author><style face="normal" font="default" size="100%">Brandsma, S.</style></author><author><style face="normal" font="default" size="100%">Chatziprodromidou, I.</style></author><author><style face="normal" font="default" size="100%">Gajski, G.</style></author><author><style face="normal" font="default" size="100%">Garcia-Aymerich, J.</style></author><author><style face="normal" font="default" size="100%">Giorio, C.</style></author><author><style face="normal" font="default" size="100%">Hugg, T.</style></author><author><style face="normal" font="default" size="100%">Jaakkola, J. J. K.</style></author><author><style face="normal" font="default" size="100%">Koch, S.</style></author><author><style face="normal" font="default" size="100%">Leonards, P. E. G.</style></author><author><style face="normal" font="default" size="100%">Matrali, A.</style></author><author><style face="normal" font="default" size="100%">Melymuk, L.</style></author><author><style face="normal" font="default" size="100%">Mueller, N.</style></author><author><style face="normal" font="default" size="100%">Muszynski, A.</style></author><author><style face="normal" font="default" size="100%">Opbroek, J.</style></author><author><style face="normal" font="default" size="100%">Paciencia, I.</style></author><author><style face="normal" font="default" size="100%">Pandis, S. N.</style></author><author><style face="normal" font="default" size="100%">Pozdniakova, S.</style></author><author><style face="normal" font="default" size="100%">Rantala, A. K.</style></author><author><style face="normal" font="default" size="100%">Sufuentes, S. R.</style></author><author><style face="normal" font="default" size="100%">Schenk, L.</style></author><author><style face="normal" font="default" size="100%">Sugeng, E.</style></author><author><style face="normal" font="default" size="100%">Sunyer-Caldu, A.</style></author><author><style face="normal" font="default" size="100%">Vantarakis, A.</style></author><author><style face="normal" font="default" size="100%">Zherebker, A.</style></author><author><style face="normal" font="default" size="100%">Alfaro-Moreno, E.</style></author><author><style face="normal" font="default" size="100%">Nizzetto, P. B.</style></author><author><style face="normal" font="default" size="100%">Dominguez, J. F.</style></author><author><style face="normal" font="default" size="100%">Karatzas, S.</style></author><author><style face="normal" font="default" size="100%">Mureddu, F.</style></author><author><style face="normal" font="default" size="100%">Salonen, H.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N.</style></author><author><style face="normal" font="default" size="100%">Jartti, T.</style></author><author><style face="normal" font="default" size="100%">Ideal Consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.&#xD;CARTIF Technology Center, Boecillo, Spain.&#xD;Foundation for Research and Technology Hellas (FORTH) and University of Patras, Patras, Greece.&#xD;Department of Chemical Engineering, University of Patras, Patras, Greece.&#xD;University Hospital Institute Immune4Cure, INSERM and University of Montpellier, Montpellier, France.&#xD;Division of Respiratory Medicine, Allergology, and Thoracic Oncology, University Hospital of Montpellier, Montpellier, France.&#xD;Warsaw University of Technology, Warsaw, Poland.&#xD;Amsterdam Institute for Life and Environment (A-LIFE), Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.&#xD;Department of Public Health, Medical School, University of Patras, Patras, Greece.&#xD;Division of Toxicology, Institute for Medical Research and Occupational Health, Zagreb, Croatia.&#xD;Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.&#xD;Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.&#xD;Center for Environmental and Respiratory Health Research (CERH), Research Unit of Population Health, University of Oulu, Oulu, Finland.&#xD;Finnish Meteorological Institute, Helsinki, Finland.&#xD;RECETOX, Faculty of Science, Masaryk University, Brno, Czechia.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Environmental Science, Exposure and Effects Unit, Science for Life Laboratory, Stockholm University, Stockholm, Sweden.&#xD;International Iberian Nanotechnology Laboratory, Braga, Portugal.&#xD;Department of Environmental Chemistry and Health Effects, NILU, Kjeller, Norway.&#xD;Department of Civil Engineering, University of Patras, Patras, Greece.&#xD;The Lisbon Council, Brussels, Belgium.&#xD;Department of Civil Engineering, Aalto University, Espoo, Finland.&#xD;International Laboratory for Air Quality and Health (WHO CC for Air Quality and Health), Queensland University of Technology (QUT), Brisbane, Australia.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Lydia Becker Institute of Immunology, University of Manchester, Manchester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exposures in Indoor Air Affecting Health</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">exposure</style></keyword><keyword><style face="normal" font="default" size="100%">health</style></keyword><keyword><style face="normal" font="default" size="100%">indoor air quality</style></keyword><keyword><style face="normal" font="default" size="100%">pollution</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 4</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41342236</style></accession-num><abstract><style face="normal" font="default" size="100%">Indoor air quality (IAQ) is influenced by a wide range of chemical, biological and physical agents that can negatively impact physical, immunological and mental health. Adverse health effects depend on the type and concentration of pollutants, duration of exposure, and individual susceptibility. The availability of data on IAQ is limited, as are standardized approaches for evaluating its health impact. This expert review aims to describe the most important indoor air determinants affecting health, and present the IDEAL cluster, which comprises seven EU-funded scientific projects on the topic of IAQ and human health. Across the IDEAL projects, knowledge is generated on exposure to a wide range of indoor air pollutants, including well-known hazards and more explorative chemical and microbiological determinants. The projects will also contribute to the implementation of low-cost and/or real-time sensors on IAQ, as well as advanced chemical and microbiological analyses, and evaluate various interventions to improve IAQ. Several of them focus on particularly vulnerable groups. Raising public awareness and implementing measures to reduce pollutant levels are essential for safeguarding health, particularly in urban areas with elevated pollution levels.</style></abstract><notes><style face="normal" font="default" size="100%">Hartiala, Maria&#xD;Elenius, Varpu&#xD;Pesquera, Alicia Aguado&#xD;Androulakis, Silas&#xD;Annesi-Maesano, Isabella&#xD;Badyda, Artur&#xD;Brandsma, Sicco&#xD;Chatziprodromidou, Ioanna&#xD;Gajski, Goran&#xD;Garcia-Aymerich, Judith&#xD;Giorio, Chiara&#xD;Hugg, Timo&#xD;Jaakkola, Jouni J K&#xD;Koch, Sarah&#xD;Leonards, Pim E G&#xD;Matrali, Angeliki&#xD;Melymuk, Lisa&#xD;Mueller, Natalie&#xD;Muszynski, Adam&#xD;Opbroek, Jet&#xD;Paciencia, Ines&#xD;Pandis, Spyros N&#xD;Pozdniakova, Sofya&#xD;Rantala, Aino K&#xD;Sufuentes, Sandra Rodriguez&#xD;Schenk, Linda&#xD;Sugeng, Eva&#xD;Sunyer-Caldu, Adria&#xD;Vantarakis, Apostolos&#xD;Zherebker, Alexander&#xD;Alfaro-Moreno, Ernesto&#xD;Nizzetto, Pernilla Bohlin&#xD;Dominguez, Jose Fermoso&#xD;Karatzas, Stylianos&#xD;Mureddu, Francesco&#xD;Salonen, Heidi&#xD;Papadopoulos, Nikolaos&#xD;Jartti, Tuomas&#xD;eng&#xD;Next Generation EU/&#xD;European Regional Development Fund/&#xD;Croatian Science Foundation/&#xD;UK Research and Innovation/&#xD;National Health and Medical Research Council/&#xD;State Secretariat for Education, Research and Innovation/&#xD;Horizon Europe/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Dec 4. doi: 10.1111/all.70179.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41342236</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70179</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>947</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">947</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mommert, S.</style></author><author><style face="normal" font="default" size="100%">Jahn, M.</style></author><author><style face="normal" font="default" size="100%">Schaper-Gerhardt, K.</style></author><author><style face="normal" font="default" size="100%">Gutzmer, R.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Department of Dermatology, Muhlenkreiskliniken AoR, Ruhr University Bochum, Campus Minden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Expression of histamine receptors H2R and H4R are predominantly regulated via the IL-4/IL-13 receptor type II on human M2 macrophages</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2886-2890</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/06/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Histamine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, G-Protein-Coupled</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Histamine</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Histamine H1</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Histamine H4</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34129684</style></accession-num><notes><style face="normal" font="default" size="100%">Mommert, Susanne&#xD;Jahn, Martin&#xD;Schaper-Gerhardt, Katrin&#xD;Gutzmer, Ralf&#xD;Werfel, Thomas&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2886-2890. doi: 10.1111/all.14979. Epub 2021 Jul 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34129684</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14979</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2991</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2991</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kanai, K.</style></author><author><style face="normal" font="default" size="100%">Kusano, H.</style></author><author><style face="normal" font="default" size="100%">Oka, A.</style></author><author><style face="normal" font="default" size="100%">Yamada, M.</style></author><author><style face="normal" font="default" size="100%">Takagi, R.</style></author><author><style face="normal" font="default" size="100%">Suzaki, I.</style></author><author><style face="normal" font="default" size="100%">Hirano, K.</style></author><author><style face="normal" font="default" size="100%">Bai, J.</style></author><author><style face="normal" font="default" size="100%">Shiomi, T.</style></author><author><style face="normal" font="default" size="100%">Okano, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology Head and Neck Surgery, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan.&#xD;Department of Anatomic Pathology, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, School of Medicine, Showa Medical University, Tokyo, Japan.&#xD;Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Expression of IL-4 Receptor Alpha in Ectopic Lymphoid Tissue in Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2671-2673</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">B cell</style></keyword><keyword><style face="normal" font="default" size="100%">IL-4 receptor alpha chain</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">ectopic lymphoid tissue</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40632021</style></accession-num><notes><style face="normal" font="default" size="100%">Kanai, Kengo&#xD;Kusano, Hiroyuki&#xD;Oka, Aiko&#xD;Yamada, Marie&#xD;Takagi, Ryo&#xD;Suzaki, Isao&#xD;Hirano, Kojiro&#xD;Bai, Junqin&#xD;Shiomi, Takayuki&#xD;Okano, Mitsuhiro&#xD;eng&#xD;International University of Health and Welfare/&#xD;Adopting Sustainable Partnerships for Innovative Research Ecosystem from Japan Agency for Medical Research and Development/&#xD;Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare of Japa/&#xD;Grants- in- Aid for Scientific Research from Japan Society for the Promotion of Science/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2671-2673. doi: 10.1111/all.16649. Epub 2025 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40632021</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444811</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16649</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1260</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1260</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Jiao, J.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Song, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.&#xD;Department of Otolaryngology, Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Expression of T helper cytokines associated with MUC5AC secretion in eosinophil-based endotypes of nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">604-609</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/11/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mucin 5AC</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">Muc5ac</style></keyword><keyword><style face="normal" font="default" size="100%">Th cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">endotype</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyp</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33245816</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Yu&#xD;Wang, Xiangdong&#xD;Jiao, Jian&#xD;Li, Ying&#xD;Song, Xicheng&#xD;Zhang, Luo&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):604-609. doi: 10.1111/all.14669. Epub 2020 Dec 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33245816</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14669</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1360</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1360</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jonstam, K.</style></author><author><style face="normal" font="default" size="100%">Alsharif, S.</style></author><author><style face="normal" font="default" size="100%">Bogaert, S.</style></author><author><style face="normal" font="default" size="100%">Suchonos, N.</style></author><author><style face="normal" font="default" size="100%">Holtappels, G.</style></author><author><style face="normal" font="default" size="100%">Jae-Hyun Park, J.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Ear, Nose and Throat Diseases, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Ear, Nose and Throat Diseases, Karolinska University Hospital, Stockholm, Sweden.&#xD;Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University, Ghent, Belgium.&#xD;Department of Otolaryngology, Supply Base, Saudi Royal Army, Taif, Saudi Arabia.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, St. Elisabeth-Hospital, Ruhr University Bochum, Bochum, Germany.&#xD;Ruhr University Bochum, Bochum, Germany.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Witten/Herdecke University, Hagen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Extent of inflammation in severe nasal polyposis and effect of sinus surgery on inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">933-936</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">*Paranasal Sinuses/surgery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32770835</style></accession-num><notes><style face="normal" font="default" size="100%">Jonstam, Karin&#xD;Alsharif, Saeed&#xD;Bogaert, Stijn&#xD;Suchonos, Nicole&#xD;Holtappels, Gabriele&#xD;Jae-Hyun Park, Jonas&#xD;Bachert, Claus&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):933-936. doi: 10.1111/all.14550. Epub 2020 Aug 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32770835</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7984056 grants from FWO Flanders, from Interuniversity Attraction Poles Grant, Ghent University, grants from the European Commission&apos;s Seventh Framework Program, and grants from Sanofi Belgium, during the conduct of the study; personal fees from Sanofi, personal fees from Novartis, personal fees from Astra-Zeneca, and personal fees from GSK, outside the submitted work; and is a member of advisory boards of Novartis, Sanofi, Astra-Zeneca and GSK.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14550</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2330</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2330</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sundar, I. K.</style></author><author><style face="normal" font="default" size="100%">Prasad, C.</style></author><author><style face="normal" font="default" size="100%">Duraisamy, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Division of Pulmonary Critical Care and Sleep Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Extracellular vesicle microRNA signatures as novel biomarkers in obese asthmatics</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1398-1400</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/12/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Extracellular Vesicles/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Obesity/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38126596</style></accession-num><notes><style face="normal" font="default" size="100%">Sundar, Isaac Kirubakaran&#xD;Prasad, Chandrashekar&#xD;Duraisamy, Santhosh Kumar&#xD;eng&#xD;P20 GM103418/GM/NIGMS NIH HHS/&#xD;R01 HL142543/HL/NHLBI NIH HHS/&#xD;Comment&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1398-1400. doi: 10.1111/all.15979. Epub 2023 Dec 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38126596</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11062842</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15979</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1234</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1234</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Al-Shaikhly, T.</style></author><author><style face="normal" font="default" size="100%">MacDonald, J. W.</style></author><author><style face="normal" font="default" size="100%">Bammler, T. K.</style></author><author><style face="normal" font="default" size="100%">Altman, M. C.</style></author><author><style face="normal" font="default" size="100%">Ayars, A. G.</style></author><author><style face="normal" font="default" size="100%">Petroni, D. H.</style></author><author><style face="normal" font="default" size="100%">Tilles, S. A.</style></author><author><style face="normal" font="default" size="100%">Henderson, W. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Infectious Diseases, Department of Medicine, School of Medicine, University of Washington, Seattle, WA, USA.&#xD;Interdisciplinary Center for Exposures, Diseases, Genomics &amp; Environment, Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, USA.&#xD;Seattle Allergy and Asthma Research Institute, Seattle, WA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1274-1277</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/12/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">*Extracellular Vesicles</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33314187</style></accession-num><notes><style face="normal" font="default" size="100%">Al-Shaikhly, Taha&#xD;MacDonald, James W&#xD;Bammler, Theo K&#xD;Altman, Matthew C&#xD;Ayars, Andrew G&#xD;Petroni, Daniel H&#xD;Tilles, Stephen A&#xD;Henderson, William R&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1274-1277. doi: 10.1111/all.14702. Epub 2020 Dec 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33314187</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14702</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3053</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3053</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prasad, C.</style></author><author><style face="normal" font="default" size="100%">Griffard, R.</style></author><author><style face="normal" font="default" size="100%">Pei, D.</style></author><author><style face="normal" font="default" size="100%">Haworth, S.</style></author><author><style face="normal" font="default" size="100%">Dhillon, N. K.</style></author><author><style face="normal" font="default" size="100%">Castro, M.</style></author><author><style face="normal" font="default" size="100%">Sundar, I. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Kansas City, Kansas, USA.&#xD;Department of Biostatistics &amp; Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Extracellular Vesicle miRNAs as Biomarkers of Asthma Severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">271-276</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/09/30</style></edition><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41025688</style></accession-num><notes><style face="normal" font="default" size="100%">Prasad, Chandrashekhar&#xD;Griffard, Rachel&#xD;Pei, Dong&#xD;Haworth, Steven&#xD;Dhillon, Navneet K&#xD;Castro, Mario&#xD;Sundar, Isaac Kirubakaran&#xD;eng&#xD;University of Kansas Medical Center, School of Medicine, Internal Medicine Start-Up Funds/&#xD;P30 CA168524/CA/NCI NIH HHS/&#xD;P20 GM103418/GM/NIGMS NIH HHS/&#xD;P20 GM130423/GM/NIGMS NIH HHS/&#xD;P30 GM122731/GM/NIGMS NIH HHS/&#xD;R01 HL142543/HL/NHLBI NIH HHS/&#xD;U10 HL109257/HL/NHLBI NIH HHS/&#xD;U01 HL146002/HL/NHLBI NIH HHS/&#xD;Lied Pre-clinical Grant-FY 2024/&#xD;UL1 TR002366/TR/NCATS NIH HHS/&#xD;U54 HD090216/HD/NICHD NIH HHS/&#xD;S10 OD036343/CD/ODCDC CDC HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):271-276. doi: 10.1111/all.70079. Epub 2025 Sep 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41025688</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70079</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2488</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2488</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hartung, F.</style></author><author><style face="normal" font="default" size="100%">Haimerl, P.</style></author><author><style face="normal" font="default" size="100%">Schindela, S.</style></author><author><style face="normal" font="default" size="100%">Mussack, V.</style></author><author><style face="normal" font="default" size="100%">Kirchner, B.</style></author><author><style face="normal" font="default" size="100%">Henkel, F. D. R.</style></author><author><style face="normal" font="default" size="100%">Bernhardt, U.</style></author><author><style face="normal" font="default" size="100%">Zissler, U. M.</style></author><author><style face="normal" font="default" size="100%">Santarella-Mellwig, R.</style></author><author><style face="normal" font="default" size="100%">Pfaffl, M.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Chaker, A. M.</style></author><author><style face="normal" font="default" size="100%">Esser-von Bieren, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Munich, Germany.&#xD;Division of Animal Physiology and Immunology, Technical University of Munich, Freising, Germany.&#xD;Member of the German Center of Lung Research (DZL), Munich, Germany.&#xD;EMBL Heidelberg, Heidelberg, Germany.&#xD;Department of Otorhinolaryngology and Head and Neck Surgery, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.&#xD;Department of Immunobiology, University of Lausanne, Epalinges, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Extracellular vesicle miRNAs drive aberrant macrophage responses in NSAID-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1893-1907</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/04/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Extracellular Vesicles/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Macrophages/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Inflammatory Agents, Non-Steroidal/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophage Activation/immunology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">extracellular vesicles</style></keyword><keyword><style face="normal" font="default" size="100%">macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38573073</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Extracellular vesicles (EVs) have been implicated in the pathogenesis of asthma, however, how EVs contribute to immune dysfunction and type 2 airway inflammation remains incompletely understood. We aimed to elucidate roles of airway EVs and their miRNA cargo in the pathogenesis of NSAID-exacerbated respiratory disease (N-ERD), a severe type 2 inflammatory condition. METHODS: EVs were isolated from induced sputum or supernatants of cultured nasal polyp or turbinate tissues of N-ERD patients or healthy controls by size-exclusion chromatography and characterized by particle tracking, electron microscopy and miRNA sequencing. Functional effects of EV miRNAs on gene expression and mediator release by human macrophages or normal human bronchial epithelial cells (NHBEs) were studied by RNA sequencing, LC-MS/MS and multiplex cytokine assays. RESULTS: EVs were highly abundant in secretions from the upper and lower airways of N-ERD patients. N-ERD airway EVs displayed profoundly altered immunostimulatory capacities and miRNA profiles compared to airway EVs of healthy individuals. Airway EVs of N-ERD patients, but not of healthy individuals induced inflammatory cytokine (GM-CSF and IL-8) production by NHBEs. In macrophages, N-ERD airway EVs exhibited an impaired potential to induce cytokine and prostanoid production, while enhancing M2 macrophage activation. Let-7 family miRNAs were highly enriched in sputum EVs from N-ERD patients and mimicked suppressive effects of N-ERD EVs on macrophage activation. CONCLUSION: Aberrant airway EV miRNA profiles may contribute to immune dysfunction and chronic type 2 inflammation in N-ERD. Let-7 family miRNAs represent targets for correcting aberrant macrophage activation and mediator responses in N-ERD.</style></abstract><notes><style face="normal" font="default" size="100%">Hartung, Franziska&#xD;Haimerl, Pascal&#xD;Schindela, Sonja&#xD;Mussack, Veronika&#xD;Kirchner, Benedikt&#xD;Henkel, Fiona D R&#xD;Bernhardt, Ulrike&#xD;Zissler, Ulrich M&#xD;Santarella-Mellwig, Rachel&#xD;Pfaffl, Michael&#xD;Schmidt-Weber, Carsten B&#xD;Chaker, Adam M&#xD;Esser-von Bieren, Julia&#xD;eng&#xD;Helmholtz Initiative and Networking/&#xD;Deutsche Forschungsgemeinschaft/&#xD;Else Kroner-Fresenius-Stiftung/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1893-1907. doi: 10.1111/all.16117. Epub 2024 Apr 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38573073</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16117</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1085</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1085</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tedner, S. G.</style></author><author><style face="normal" font="default" size="100%">Soderhall, C.</style></author><author><style face="normal" font="default" size="100%">Konradsen, J. R.</style></author><author><style face="normal" font="default" size="100%">Bains, K. E. S.</style></author><author><style face="normal" font="default" size="100%">Borres, M. P.</style></author><author><style face="normal" font="default" size="100%">Carlsen, K. H.</style></author><author><style face="normal" font="default" size="100%">Carlsen, K. C. L.</style></author><author><style face="normal" font="default" size="100%">Fardig, M.</style></author><author><style face="normal" font="default" size="100%">Gerdin, S. W.</style></author><author><style face="normal" font="default" size="100%">Gudmundsdottir, H. K.</style></author><author><style face="normal" font="default" size="100%">Haugen, G.</style></author><author><style face="normal" font="default" size="100%">Hedlin, G.</style></author><author><style face="normal" font="default" size="100%">Jonassen, C. M.</style></author><author><style face="normal" font="default" size="100%">Kreyberg, I.</style></author><author><style face="normal" font="default" size="100%">Magi, C. O.</style></author><author><style face="normal" font="default" size="100%">Nordhagen, L. S.</style></author><author><style face="normal" font="default" size="100%">Rehbinder, E. M.</style></author><author><style face="normal" font="default" size="100%">Rudi, K.</style></author><author><style face="normal" font="default" size="100%">Skjerven, H. O.</style></author><author><style face="normal" font="default" size="100%">Staff, A. C.</style></author><author><style face="normal" font="default" size="100%">Vettukattil, R.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Nordlund, B.</style></author><author><style face="normal" font="default" size="100%">Asarnoj, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Astrid Lindgren Children&apos;s Hospital, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Women&apos;s and Children&apos;s Health, Karolinska Institutet, Stockholm, Sweden.&#xD;Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.&#xD;Faculty of Medicine, University of Oslo, Institute of Clinical Medicine, Oslo, Norway.&#xD;Department of Women&apos;s and Children&apos;s Health, Uppsala University, Uppsala, Sweden.&#xD;Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway.&#xD;Genetic Unit, Centre for Laboratory Medicine, Ostfold Hospital Trust, Kalnes, Norway.&#xD;Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, As, Norway.&#xD;VID Specialized University, Oslo, Norway.&#xD;Department of Dermatology, Oslo University Hospital, Oslo, Norway.&#xD;Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and University Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Extract and molecular-based early infant sensitization and associated factors-A PreventADALL study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2730-2739</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/03/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Cats</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">birth cohort</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin E antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">molecular allergology</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33751598</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: More knowledge about sensitization patterns in early infancy, including impact of molecular allergology, is needed to help predict future allergy development more accurately. OBJECTIVE: We aimed to determine the prevalence and patterns of allergic sensitization at 3 months of age, and explore possible associated factors. METHODS: From the Scandinavian antenatally recruited PreventADALL mother-child cohort, we included 1110 3-month infants with available serum. Sensitization was defined as s-IgE of &gt;/=0.1 kU(A) /L by Phadiatop Infant((R)) (ThermoFisher Scientific) including birch, cat, grass, dog, milk, egg, peanut and wheat. Further ImmunoCAP analyses to ovomucoid, casein, Ara h 1-3, omega-5-gliadin were performed in food extract s-IgE-positive children. Maternal sensitization was defined as s-IgE &gt;/= 0.35 kU(A) /L to Phadiatop((R)) (inhalant allergen mix) and/or Fx5 (food allergen mix) at 18-week pregnancy. RESULTS: Overall 79 (7.3%) infants had specific sensitization, many with low s-IgE-levels (IQR 0.16-0.81 kU(A) /L), with 78 being sensitized to food extract allergens; 41 to egg, 27 to milk, 10 to peanut, and 25 to wheat. A total of 62/78 were further analysed, 18 (29%) had s-IgE to ovomucoid, casein, Ara h 1-3 and/or omega-5-gliadin. Eight infants (0.7%) were sensitized to inhalant allergens. Maternal sensitization to food allergens was associated with infant sensitization, odds ratio 3.64 (95% CI 1.53-8.68). CONCLUSION: Already at 3 months of age, 7% were sensitized to food, mostly without detectable s-IgE to food allergen molecules, and &lt;1% to inhalant allergens. Maternal food sensitization was associated with infants&apos; sensitization.</style></abstract><notes><style face="normal" font="default" size="100%">Tedner, Sandra G&#xD;Soderhall, Cilla&#xD;Konradsen, Jon R&#xD;Bains, Karen E S&#xD;Borres, Magnus P&#xD;Carlsen, Kai-Hakon&#xD;Carlsen, Karin C L&#xD;Fardig, Martin&#xD;Gerdin, Sabina W&#xD;Gudmundsdottir, Hrefna K&#xD;Haugen, Guttorm&#xD;Hedlin, Gunilla&#xD;Jonassen, Christine M&#xD;Kreyberg, Ina&#xD;Magi, Caroline-Aleksi O&#xD;Nordhagen, Live S&#xD;Rehbinder, Eva M&#xD;Rudi, Knut&#xD;Skjerven, Havard O&#xD;Staff, Anne C&#xD;Vettukattil, Riyas&#xD;van Hage, Marianne&#xD;Nordlund, Bjorn&#xD;Asarnoj, Anna&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2730-2739. doi: 10.1111/all.14805. Epub 2021 May 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33751598</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14805</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2254</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2254</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lu, C.</style></author><author><style face="normal" font="default" size="100%">Wang, F.</style></author><author><style face="normal" font="default" size="100%">Qiao, Z.</style></author><author><style face="normal" font="default" size="100%">Deng, M.</style></author><author><style face="normal" font="default" size="100%">Liu, Q.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">XiangYa School of Public Health, Central South University, Changsha, China.&#xD;Division of Animal and Human Health Engineering, Department of Biosystems, Leuven, Belgium.&#xD;Key Laboratory of Environmental Related Diseases and One Health, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Extreme temperatures exacerbated oxidative stress and airway inflammation in a mouse model of allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1333-1335</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Oxidative Stress</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/immunology/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37679862</style></accession-num><notes><style face="normal" font="default" size="100%">Lu, Chan&#xD;Wang, Faming&#xD;Qiao, Zipeng&#xD;Deng, Miaomiao&#xD;Liu, Qin&#xD;Yang, Xu&#xD;eng&#xD;National Natural Science Foundation of China (No. 42007391, 42277432, 21577045); Natural Science Foundation of Hunan Province (No. 2021JJ30813)./&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1333-1335. doi: 10.1111/all.15883. Epub 2023 Sep 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37679862</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15883</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1961</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1961</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez de Llano, L.</style></author><author><style face="normal" font="default" size="100%">Marina Malanda, N.</style></author><author><style face="normal" font="default" size="100%">Urrutia, I.</style></author><author><style face="normal" font="default" size="100%">Martinez-Moragon, E.</style></author><author><style face="normal" font="default" size="100%">Gullon-Blanco, J. A.</style></author><author><style face="normal" font="default" size="100%">Diaz-Campos, R.</style></author><author><style face="normal" font="default" size="100%">Esquerre, M. M.</style></author><author><style face="normal" font="default" size="100%">Mena, A. H.</style></author><author><style face="normal" font="default" size="100%">Cosio, B. G.</style></author><author><style face="normal" font="default" size="100%">Cisneros, C.</style></author><author><style face="normal" font="default" size="100%">Polo, F. J. L.</style></author><author><style face="normal" font="default" size="100%">Laorden, D.</style></author><author><style face="normal" font="default" size="100%">Dacal Rivas, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pneumology Service, Lucus Augusti University Hospital, EOXI Lugo, Cervo e Monforte, Lugo, Spain.&#xD;Pneumology Service, Cruces University Hospital, Barakaldo, Spain.&#xD;Pneumology Service, Galdakao-Usansolo University Hospital, Galdakao, Spain.&#xD;Pneumology Service, Doctor Peset University Hospital, Valencia, Spain.&#xD;Pneumology Service, San Agustin University Hospital, Aviles, Spain.&#xD;Pneumology Service, Doce de Octubre University Hospital, Madrid, Spain.&#xD;Pneumology Service, Bellvitge University Hospital, IBIDELL, Barcelona University, Barcelona, Spain.&#xD;Allergy Section, Internal Medicine Service, Complejo Hospitalario de Merida, Badajoz, Spain.&#xD;Pneumology Service, Son Espases University Hospital, IdISBa-Ciberes, Palma de Mallorca, Spain.&#xD;Pneumology Service, La Princesa University Hospital, Madrid, Spain.&#xD;Pneumology Service, Ciudad Real University Hospital, Ciudad Real, Spain.&#xD;Pneumology Service, La Paz University Hospital, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Factors associated with suboptimal response to monoclonal antibodies in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2305-2310</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/03/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36866939</style></accession-num><notes><style face="normal" font="default" size="100%">Perez de Llano, Luis&#xD;Marina Malanda, Nuria&#xD;Urrutia, Isabel&#xD;Martinez-Moragon, Eva&#xD;Gullon-Blanco, Jose Antonio&#xD;Diaz-Campos, Rocio&#xD;Esquerre, Mariana Munoz&#xD;Mena, Alicia Habernau&#xD;Cosio, Borja G&#xD;Cisneros, Carolina&#xD;Polo, Francisco Javier Lazaro&#xD;Laorden, Daniel&#xD;Dacal Rivas, David&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2305-2310. doi: 10.1111/all.15693. Epub 2023 Mar 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36866939</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15693</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2869</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2869</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Akagawa, S.</style></author><author><style face="normal" font="default" size="100%">Tsuji, S.</style></author><author><style face="normal" font="default" size="100%">Nakai, Y.</style></author><author><style face="normal" font="default" size="100%">Urakami, C.</style></author><author><style face="normal" font="default" size="100%">Yamagishi, M.</style></author><author><style face="normal" font="default" size="100%">Akagawa, Y.</style></author><author><style face="normal" font="default" size="100%">Kaneko, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Kansai Medical University, Osaka, Japan.&#xD;Allergy Center, Kansai Medical University Hospital, Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Faecalibacterium in the Gut Microbiota Predicts Tolerance Acquisition in Pediatric Hen&apos;s Egg Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2886-2889</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/04/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40211458</style></accession-num><notes><style face="normal" font="default" size="100%">Akagawa, Shohei&#xD;Tsuji, Shoji&#xD;Nakai, Yoko&#xD;Urakami, Chika&#xD;Yamagishi, Mitsuru&#xD;Akagawa, Yuko&#xD;Kaneko, Kazunari&#xD;eng&#xD;Nipponham Foundation for the Future of Food/&#xD;Kansai Medical University/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2886-2889. doi: 10.1111/all.16556. Epub 2025 Apr 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40211458</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486364</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16556</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3307</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3307</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nomura, Takayasu</style></author><author><style face="normal" font="default" size="100%">Tanida, Hisashi</style></author><author><style face="normal" font="default" size="100%">Inoue, Takeshi</style></author><author><style face="normal" font="default" size="100%">Kato, Sayaka</style></author><author><style face="normal" font="default" size="100%">Hiraoka, Daiki</style></author><author><style face="normal" font="default" size="100%">Ito, Yuki</style></author><author><style face="normal" font="default" size="100%">Sugiura-Ogasawara, Mayumi</style></author><author><style face="normal" font="default" size="100%">Saitoh, Shinji</style></author><author><style face="normal" font="default" size="100%">Kamijima, Michihiro</style></author><author><style face="normal" font="default" size="100%">Ohya, Yukihiro</style></author><author><style face="normal" font="default" size="100%">The Japan Environment</style></author><author><style face="normal" font="default" size="100%">Children&apos;s Study Group</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Family Size and Food Allergy in Early Childhood: The Japan Environment and Children&apos;s Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><notes><style face="normal" font="default" size="100%">(JECS)</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70303</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70303</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2687</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2687</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beerweiler, C. C.</style></author><author><style face="normal" font="default" size="100%">Salvermoser, M.</style></author><author><style face="normal" font="default" size="100%">Theodorou, J.</style></author><author><style face="normal" font="default" size="100%">Bock, A.</style></author><author><style face="normal" font="default" size="100%">Sattler, F.</style></author><author><style face="normal" font="default" size="100%">Kulig, P.</style></author><author><style face="normal" font="default" size="100%">Tosevski, V.</style></author><author><style face="normal" font="default" size="100%">Schaub, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Dr. von Hauner Children&apos;s Hospital, LMU University Hospital, LMU Munich, Munich, Germany.&#xD;Member of German Center for Lung Research - DZL, LMU Munich, Munich, Germany.&#xD;Member of German Center for Child and Adolescent Health-DZKJ, LMU, Munich, Germany.&#xD;Mass Cytometry Facility, University of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Farm-dust mediated protection of childhood asthma: Mass cytometry reveals novel cellular regulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3022-3035</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/10/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Farms</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunophenotyping</style></keyword><keyword><style face="normal" font="default" size="100%">Flow Cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">CyTOF</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">childhood</style></keyword><keyword><style face="normal" font="default" size="100%">farming</style></keyword><keyword><style face="normal" font="default" size="100%">protection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39400913</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Farm-dust mediated asthma protection in childhood was replicated in numerous epidemiological studies. Central immune mechanisms are not fully understood. This exploratory study aimed to disentangle underlying immunological regulation of farm-dust mediated protection in peripheral blood on a single-cell level. METHODS: Single-cell protein expression of in vitro farm-dust stimulated and unstimulated cells from allergic asthmatics and healthy controls were measured using mass cytometry. Analysis of innate and adaptive cellular proportions (linear regression) and T-cell proliferation was performed. Functional marker intensity was investigated using Earth Mover&apos;s Distance and the Monte Carlo permutation test. RESULTS: Farm-dust stimulation induced cell type-specific regulation: Key-features of farm-dust stimulation comprised opposing regulation of immune-cell frequencies (downregulated innate cell populations (monocytes/DCs (p &lt; .001), NK-cells (p &lt; .05)) and upregulated adaptive populations (B-cells, CD4(+) T-cells (both p &lt; .05)), reduced CD4(+) CD25(-) T-cell proliferation, and differential cell type-specific functional marker expression. Following stimulation, functional marker analysis revealed induced activation (CD25) in T-cells and NK-T-cells in both phenotypes even after correction for multiple testing. Cytotoxicity (GZMB) and inflammation (pERK1/2, pp38) related markers were reduced in T-cells exclusively in asthmatic children. Asthma-associated markers (Gata3, RORgamma, and HLA-DR) were reduced in T- and innate- cell populations of asthmatics following stimulation. B-cells displayed a phenotypically independent increase of diverse functional markers upon farm-dust stimulation. CONCLUSIONS: This study mimicking in vivo environmental exposure identified a novel profile of immune-regulatory markers using mass cytometry demonstrating decreased asthma-associated markers following farm-dust stimulation. These findings may be key for further studies on asthma prevention in childhood.</style></abstract><notes><style face="normal" font="default" size="100%">Beerweiler, Claudia Carina&#xD;Salvermoser, Michael&#xD;Theodorou, Johanna&#xD;Bock, Andreas&#xD;Sattler, Franziska&#xD;Kulig, Paulina&#xD;Tosevski, Vinko&#xD;Schaub, Bianca&#xD;eng&#xD;Friedrich-Baur-Stiftung/&#xD;Else Kroner-Fresenius-Stiftung/&#xD;SCHA997/7-1/Deutsche Forschungsgemeinschaft/&#xD;SCHA997/8-1/Deutsche Forschungsgemeinschaft/&#xD;SCHA997/11-1/Deutsche Forschungsgemeinschaft/&#xD;SCHA-997/9-1/Deutsche Forschungsgemeinschaft/&#xD;SCHA-997/10-1/Deutsche Forschungsgemeinschaft/&#xD;DZL2024-27/Bundesministerium fur Bildung und Forschung/&#xD;DZL82DZL033C2/Bundesministerium fur Bildung und Forschung/&#xD;LMU/LMUKlinikum01GL2406A/Deutsches Zentrum fur Kinder- und Jugendgesundheit (DZKJ)/&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3022-3035. doi: 10.1111/all.16347. Epub 2024 Oct 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39400913</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16347</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>416</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">416</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vega, F.</style></author><author><style face="normal" font="default" size="100%">Lopez-Raigada, A.</style></author><author><style face="normal" font="default" size="100%">Mugica, M. V.</style></author><author><style face="normal" font="default" size="100%">Blanco, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Instituto de Investigacion Sanitaria Princesa (IP), Hospital Universitario de la Princesa, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fast challenge tests with gadolinium-based contrast agents to search for an alternative contrast media in allergic patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3151-3153</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/07/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Contrast Media/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Gadolinium/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35775416</style></accession-num><notes><style face="normal" font="default" size="100%">Vega, Francisco&#xD;Lopez-Raigada, Azahara&#xD;Mugica, Maria Victoria&#xD;Blanco, Carlos&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3151-3153. doi: 10.1111/all.15420. Epub 2022 Jul 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35775416</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15420</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>17</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">17</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pouessel, G.</style></author><author><style face="normal" font="default" size="100%">Alonzo, S.</style></author><author><style face="normal" font="default" size="100%">Divaret-Chauveau, A.</style></author><author><style face="normal" font="default" size="100%">Dumond, P.</style></author><author><style face="normal" font="default" size="100%">Bradatan, E.</style></author><author><style face="normal" font="default" size="100%">Liabeuf, V.</style></author><author><style face="normal" font="default" size="100%">Beaumont, P.</style></author><author><style face="normal" font="default" size="100%">Tscheiller, S.</style></author><author><style face="normal" font="default" size="100%">Diesnis, R.</style></author><author><style face="normal" font="default" size="100%">Renaudin, J. M.</style></author><author><style face="normal" font="default" size="100%">Sabouraud-Leclerc, D.</style></author><author><style face="normal" font="default" size="100%">Allergy-Vigilance, Network</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, CH Roubaix, Roubaix, France.&#xD;Paediatric Pneumology and Allergology Unit, CHRU, Lille, France.&#xD;Paediatric Allergology, Children&apos;s Medicine, CHRU, Vandoeuvre-les-Nancy, France.&#xD;Department of Paediatrics, CHRU, Namur, Belgium.&#xD;Department of Dermatology, CHRU La Timone, Marseille, France.&#xD;Medical Practice, Paris, France.&#xD;Allergy-Vigilance Network, Vandoeuvre Les Nancy, France.&#xD;Adult Emergency - SMUR and Clinical Research Unit, Victor Provo Hospital, CH Roubaix, Roubaix, France.&#xD;Allergology Department, CH Durkheim, Epinal, France.&#xD;General and Specialized Pediatrics Department, American Hospital, Reims University Hospital, Reims, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fatal and near-fatal anaphylaxis: The Allergy-Vigilance(R) Network data (2002-2020)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1628-1638</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/etiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Food/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">adrenaline</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">death</style></keyword><keyword><style face="normal" font="default" size="100%">food</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36645170</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Having a better understanding of the risk factors of severe anaphylaxis is a crucial challenge for physicians. METHODS: To retrospectively analyse fatal/near-fatal anaphylaxis cases recorded by the Allergy-Vigilance(R) Network (2002-2020) and evaluate the characteristics associated with survival, age and allergens. RESULTS: Among the 3510 anaphylaxis cases documented in the network, 70 (2%) patients (males: 57%; mean age: 35.4 y) presented grade 4 (Ring-Messmer) anaphylaxis and 25 died (19 food-related); 33% had a history of asthma. The main allergens were food (60%; peanut, 20%; milks, 11%) involved in 25/26 cases in children and in 17/44 (39%) cases in adults. Non-food anaphylaxis was related to drugs/latex (24%; neuromuscular blocking agents, 10%; betalactamins, 6%), Hymenoptera (16%). Three food-related cases (one death) occurred during oral food challenge in children. Patients with a food allergy were younger (22.2 years vs. 55 years, p &lt; .001), had more likely a history of asthma (50% vs. 7%; p &lt; .001), a pre-existing allergy (62% vs. 18%; p &lt; .001) compared with other allergies. A cofactor was identified in 35 cases (50%) but predominantly in adults as opposed to children (64% vs. 27%; p = .01). The patients who died were younger (25.6 vs. 40.8 years; p = .01) than the survivors and mostly presented bronchospasm (56% vs. 29%; p = .05). Gaps in the prevention and management of anaphylaxis were noted in 15 cases (21%). CONCLUSIONS: Severe food anaphylaxis has specific features compared with other causes such as young age, asthma history and exercise. Food is also involved in severe anaphylaxis in adults that should not be underestimated.</style></abstract><notes><style face="normal" font="default" size="100%">Pouessel, Guillaume&#xD;Alonzo, Sabrina&#xD;Divaret-Chauveau, Amandine&#xD;Dumond, Pascale&#xD;Bradatan, Elena&#xD;Liabeuf, Valerie&#xD;Beaumont, Pascale&#xD;Tscheiller, Selina&#xD;Diesnis, Remy&#xD;Renaudin, Jean-Marie&#xD;Sabouraud-Leclerc, Dominique&#xD;(R)&#xD;eng&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1628-1638. doi: 10.1111/all.15645. Epub 2023 Jan 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36645170</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15645</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1288</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1288</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kobayashi, S.</style></author><author><style face="normal" font="default" size="100%">Phung, H. T.</style></author><author><style face="normal" font="default" size="100%">Kagawa, Y.</style></author><author><style face="normal" font="default" size="100%">Miyazaki, H.</style></author><author><style face="normal" font="default" size="100%">Takahashi, Y.</style></author><author><style face="normal" font="default" size="100%">Asao, A.</style></author><author><style face="normal" font="default" size="100%">Maruyama, T.</style></author><author><style face="normal" font="default" size="100%">Yoshimura, A.</style></author><author><style face="normal" font="default" size="100%">Ishii, N.</style></author><author><style face="normal" font="default" size="100%">Owada, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Organ Anatomy, Tohoku University Graduate School of Medicine, Sendai, Japan.&#xD;Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.&#xD;Mucosal Immunology Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.&#xD;Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fatty acid-binding protein 3 controls contact hypersensitivity through regulating skin dermal Vgamma4(+) gamma/delta T cell in a murine model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1776-1788</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/10/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Contact/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acid Binding Protein 3</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acid-Binding Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Antigen, T-Cell, gamma-delta/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Fabp3</style></keyword><keyword><style face="normal" font="default" size="100%">contact hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">skin inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">gamma/delta T-cell development</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33090507</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Fatty acid-binding protein 3 (FABP3) is a cytosolic carrier protein of polyunsaturated fatty acids (PUFAs) and regulates cellular metabolism. However, the physiological functions of FABP3 in immune cells and how FABP3 regulates inflammatory responses remain unclear. METHODS: Contact hypersensitivity (CHS) induced by 2,4-dinitrofluorobenzene (DNFB) and fluorescein isothiocyanate was applied to the skin wild-type and Fabp3(-/-) mice. Skin inflammation was assessed using FACS, histological, and qPCR analyses. The development of gamma/delta T cells was evaluated by a co-culture system with OP9/Dll1 cells in the presence or absence of transgene of FABP3. RESULTS: Fabp3-deficient mice exhibit a more severe phenotype of contact hypersensitivity (CHS) accompanied by infiltration of IL-17-producing Vgamma4(+) gamma/delta T cells that critically control skin inflammation. In Fabp3(-/-) mice, we found a larger proportion of Vgamma4(+) gamma/delta T cells in the skin, even though the percentage of total gamma/delta T cells did not change at steady state. Similarly, juvenile Fabp3(-/-) mice also contained a higher amount of Vgamma4(+) gamma/delta T cells not only in the skin but in the thymus when compared with wild-type mice. Furthermore, thymic double-negative (DN) cells expressed FABP3, and FABP3 negatively regulates the development of Vgamma4(+) gamma/delta T cells in the thymus. CONCLUSIONS: These findings suggest that FABP3 functions as a negative regulator of skin inflammation through limiting pathogenic Vgamma4(+) gamma/delta T-cell generation in the thymus.</style></abstract><notes><style face="normal" font="default" size="100%">Kobayashi, Shuhei&#xD;Phung, Hai The&#xD;Kagawa, Yoshiteru&#xD;Miyazaki, Hirofumi&#xD;Takahashi, Yu&#xD;Asao, Atsuko&#xD;Maruyama, Takashi&#xD;Yoshimura, Akihiko&#xD;Ishii, Naoto&#xD;Owada, Yuji&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1776-1788. doi: 10.1111/all.14630. Epub 2020 Nov 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33090507</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246717</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14630</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>577</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">577</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Babina, M.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author><author><style face="normal" font="default" size="100%">Li, Z.</style></author><author><style face="normal" font="default" size="100%">Franke, K.</style></author><author><style face="normal" font="default" size="100%">Guhl, S.</style></author><author><style face="normal" font="default" size="100%">Artuc, M.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Berlin Institute of Health, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Department of Dermatology, The Second Affiliated Hospital, Northwest Hospital, Xi&apos;an Jiaotong University, Xi&apos;an, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">FcepsilonRI- and MRGPRX2-evoked acute degranulation responses are fully additive in human skin mast cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1906-1909</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/03/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cell Degranulation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, G-Protein-Coupled</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, IgE</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Neuropeptide/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">FcepsilonRI</style></keyword><keyword><style face="normal" font="default" size="100%">Mrgprx2</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35246987</style></accession-num><notes><style face="normal" font="default" size="100%">Babina, Magda&#xD;Wang, Zhao&#xD;Li, Zhuoran&#xD;Franke, Kristin&#xD;Guhl, Sven&#xD;Artuc, Metin&#xD;Zuberbier, Torsten&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1906-1909. doi: 10.1111/all.15270. Epub 2022 Mar 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35246987</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15270</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>345</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">345</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blom, L. H.</style></author><author><style face="normal" font="default" size="100%">Bartko, E. A.</style></author><author><style face="normal" font="default" size="100%">Moller, T. K. R.</style></author><author><style face="normal" font="default" size="100%">Poulsen, L. K.</style></author><author><style face="normal" font="default" size="100%">Jensen, B. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Clinic, Department of Dermatology and Allergy, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">FcepsilonRI-activated basophils express CCR4, CCR8, CCR9, CCX-CKR and XCR1</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">539-543</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/08/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, IgE</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, CCR8</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, CCR4</style></keyword><keyword><style face="normal" font="default" size="100%">Ccr4</style></keyword><keyword><style face="normal" font="default" size="100%">Ccr8</style></keyword><keyword><style face="normal" font="default" size="100%">Ccr9</style></keyword><keyword><style face="normal" font="default" size="100%">Xcr1</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35986598</style></accession-num><notes><style face="normal" font="default" size="100%">Blom, Lars H&#xD;Bartko, Ewa A&#xD;Moller, Thea K R&#xD;Poulsen, Lars K&#xD;Jensen, Bettina M&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):539-543. doi: 10.1111/all.15488. Epub 2022 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35986598</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15488</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>111</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">111</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sun, W.</style></author><author><style face="normal" font="default" size="100%">Song, S.</style></author><author><style face="normal" font="default" size="100%">Li, G.</style></author><author><style face="normal" font="default" size="100%">Zhou, L.</style></author><author><style face="normal" font="default" size="100%">Xie, J.</style></author><author><style face="normal" font="default" size="100%">Guo, Y.</style></author><author><style face="normal" font="default" size="100%">Zeng, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">He, Y.</style></author><author><style face="normal" font="default" size="100%">Yan, J.</style></author><author><style face="normal" font="default" size="100%">Shuai, X.</style></author><author><style face="normal" font="default" size="100%">Tao, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Second Affiliated Hospital, The State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Allergy &amp; Clinical Immunology, Guangzhou Medical University, Guangzhou, China.&#xD;Department of Laboratory Medicine, The Seventh Affiliated Hospital of Southern Medical University, Foshan, China.&#xD;Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.&#xD;PCFM Lab of Ministry of Education, School of Materials Science and Engineering, Sun Yat-sen University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">FcRn-targeting and ROS-responsive Fedratinib-incorporated nanoparticles alleviate asthma by inducing eosinophil apoptosis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1659-1663</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/11/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Nanoparticles</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36325826</style></accession-num><notes><style face="normal" font="default" size="100%">Sun, Weimin&#xD;Song, Shijie&#xD;Li, Guangmeng&#xD;Zhou, Linghui&#xD;Xie, Junmou&#xD;Guo, Yuhe&#xD;Zeng, Jun&#xD;Zhang, Junyan&#xD;Li, Linmei&#xD;He, Ying&#xD;Yan, Jie&#xD;Shuai, Xintao&#xD;Tao, Ailin&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1659-1663. doi: 10.1111/all.15575. Epub 2022 Nov 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36325826</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15575</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1024</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1024</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Holbreich, M.</style></author><author><style face="normal" font="default" size="100%">Straumann, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy and Asthma Consultants, Indianapolis, IN, USA.&#xD;Swiss EoE Clinics and Research Network, Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Features of food-induced immediate response in the esophagus (FIRE) in a series of adult patients with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2893-2895</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/04/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33914936</style></accession-num><notes><style face="normal" font="default" size="100%">Holbreich, Mark&#xD;Straumann, Alex&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2893-2895. doi: 10.1111/all.14886. Epub 2021 May 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33914936</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14886</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2666</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2666</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Luo, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, X.</style></author><author><style face="normal" font="default" size="100%">Wu, M.</style></author><author><style face="normal" font="default" size="100%">Xu, X.</style></author><author><style face="normal" font="default" size="100%">Tian, J.</style></author><author><style face="normal" font="default" size="100%">Gao, Y.</style></author><author><style face="normal" font="default" size="100%">Zhu, J.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Lu, Q.</style></author><author><style face="normal" font="default" size="100%">Yao, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.&#xD;Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology, Shanghai, China.&#xD;01life Institute, Shenzhen, China.&#xD;Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fecal microbiota transplantation against moderate-to-severe atopic dermatitis: A randomized, double-blind controlled explorer trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1377-1388</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/10/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/therapy/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">*Fecal Microbiota Transplantation/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">fecal microbiota transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">gut microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">therapeutics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39470619</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Fecal microbiota transplantation (FMT) is a novel treatment for inflammatory diseases. Herein, we assess its safety, efficacy, and immunological impact in patients with moderate-to-severe atopic dermatitis (AD). METHODS: In this randomized, double-blind, placebo-controlled clinical trial, we performed the efficacy and safety assessment of FMT for moderate-to-severe adult patients with AD. All patients received FMT or placebo once a week for 3 weeks, in addition to their standard background treatments. Patients underwent disease severity assessments at weeks 0, 1, 2, 4, 8, 12, and 16, and blood and fecal samples were collected for immunologic analysis and metagenomic shotgun sequencing, respectively. Safety was monitored throughout the trial. RESULTS: Improvements in eczema area and severity index (EASI) scores and percentage of patients achieving EASI 50 (50% reduction in EASI score) were greater in patients treated with FMT than in placebo-treated patients. No serious adverse reactions occurred during the trial. FMT treatment decreased the Th2 and Th17 cell proportions among the peripheral blood mononuclear cells, and the levels of TNF-alpha, and total IgE in serum. By contrast, the expression levels of IL-12p70 and perforin on NK cells were increased. Moreover, FMT altered the abundance of species and functional pathways of the gut microbiota in the patients, especially the abundance of Megamonas funiformis and the pathway for 1,4-dihydroxy-6-naphthoate biosynthesis II. CONCLUSION: FMT was a safe and effective therapy in moderate-to-severe adult patients with AD; the treatment changed the gut microbiota compositions and functions.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Xiaochun&#xD;Luo, Yang&#xD;Chen, Xingyu&#xD;Wu, Mingyang&#xD;Xu, Xiaoqiang&#xD;Tian, Jingru&#xD;Gao, Yingxia&#xD;Zhu, Jun&#xD;Wang, Zhifeng&#xD;Zhou, Yuan&#xD;Zhang, Yu&#xD;Wang, Xiaokai&#xD;Li, Wei&#xD;Lu, Qianjin&#xD;Yao, Xu&#xD;eng&#xD;Nanjing Incubation Program for National Clinical Research Center/&#xD;National Key Research and Development Program of China/&#xD;CAMS Innovation Fund for Medical Sciences/&#xD;Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences/&#xD;National Natural Science Foundation of China/&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1377-1388. doi: 10.1111/all.16372. Epub 2024 Oct 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39470619</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16372</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2716</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2716</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sun, L.</style></author><author><style face="normal" font="default" size="100%">Zhao, Q.</style></author><author><style face="normal" font="default" size="100%">Ao, S.</style></author><author><style face="normal" font="default" size="100%">Liu, T.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author><author><style face="normal" font="default" size="100%">You, J.</style></author><author><style face="normal" font="default" size="100%">Mi, Z.</style></author><author><style face="normal" font="default" size="100%">Sun, Y.</style></author><author><style face="normal" font="default" size="100%">Xue, X.</style></author><author><style face="normal" font="default" size="100%">Ogese, M. O.</style></author><author><style face="normal" font="default" size="100%">Gardner, J.</style></author><author><style face="normal" font="default" size="100%">Meng, X.</style></author><author><style face="normal" font="default" size="100%">Naisbitt, D. J.</style></author><author><style face="normal" font="default" size="100%">Liu, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.&#xD;Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China.&#xD;MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutic, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.&#xD;School of Public Health, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.&#xD;Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Feedback regulation of VISTA and Treg by TNF-alpha controls T cell responses in drug allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1400-1416</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/11/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Tumor Necrosis Factor-alpha/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/immunology/metabolism/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Activation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Feedback, Physiological</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Tnfr</style></keyword><keyword><style face="normal" font="default" size="100%">TNF-alpha</style></keyword><keyword><style face="normal" font="default" size="100%">Vista</style></keyword><keyword><style face="normal" font="default" size="100%">dapsone hypersensitivity syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">severe cutaneous adverse reactions</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39526799</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Severe cutaneous adverse reactions (SCARs) mediated by cytotoxic T lymphocytes are a series of life-threatening conditions with a mortality of 4%-20%. The clinical application of tumor necrosis factor-alpha (TNF-alpha) antagonist improves the outcome of some SCARs patients; however, this is complicated by the elusive and varied immunopathogenesis. METHODS: To clarify the precise process and optimize the therapy regimen of SCARs, we performed single-cell sequencing, in vitro functional and clinical analysis of patients with SCARs. RESULTS: We observed that TNF-alpha breaks drug-specific T-cell tolerance by inhibiting the expression of V-type immunoglobulin domain-containing suppressor of T-cell activation (VISTA). Furthermore, TNF-alpha generated a positive feedback loop in the early phase of drug-specific T-cell activation, whereby B cells acted reciprocally on the corresponding T cells to reinforce TNF-alpha cytokine expression. In contrast, this pathway of TNF-alpha-VISTA signaling did not operate in memory effector T cells. Drug-specific memory effector T-cell responses were inhibited by increasing Treg cell expression in a negative feedback loop, with TNF-alpha antagonists preventing the inhibitory effect. These observations align with the clinical analysis that early but not late intervention with TNF-alpha antagonists significantly improved outcomes in SCARs patients. CONCLUSION: Our findings defining feedback regulation of VISTA and Treg cells by TNF-alpha in different stages of the drug-specific T-cell response and, indicate that a Treg agonists, instead of TNF-alpha antagonists, could be used for treatment of patients with progressive SCARs.</style></abstract><notes><style face="normal" font="default" size="100%">Sun, Lele&#xD;Zhao, Qing&#xD;Ao, Suiting&#xD;Liu, Tingting&#xD;Wang, Zhenzhen&#xD;You, Jiabao&#xD;Mi, Zihao&#xD;Sun, Yonghu&#xD;Xue, Xiaotong&#xD;Ogese, Monday O&#xD;Gardner, Joshua&#xD;Meng, Xiaoli&#xD;Naisbitt, Dean J&#xD;Liu, Hong&#xD;Zhang, Furen&#xD;eng&#xD;This work was financially supported by the Key research and development program of Shandong Province (2023CXGC010507), the National Natural Science Foundation of China (82103734, 82304033), Natural Science Foundation of Shandong Province (ZR2023MH269), the China Postdoctoral Science Foundation (2023M732128, 2023M742162), the Funded by Shandong Postdoctoral Science Foundation (SDCX-ZG-202301007), the Shandong Province Taishan Scholar Project (tsqn202211346), Joint Innovation Team for Clinical &amp; Basic Research (202410)./&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1400-1416. doi: 10.1111/all.16393. Epub 2024 Nov 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39526799</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105067</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16393</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>367</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">367</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Busold, S.</style></author><author><style face="normal" font="default" size="100%">Aglas, L.</style></author><author><style face="normal" font="default" size="100%">Menage, C.</style></author><author><style face="normal" font="default" size="100%">Auger, L.</style></author><author><style face="normal" font="default" size="100%">Desgagnes, R.</style></author><author><style face="normal" font="default" size="100%">Faye, L.</style></author><author><style face="normal" font="default" size="100%">Fitchette, A. C.</style></author><author><style face="normal" font="default" size="100%">de Jong, E. C.</style></author><author><style face="normal" font="default" size="100%">Martel, C.</style></author><author><style face="normal" font="default" size="100%">Stigler, M.</style></author><author><style face="normal" font="default" size="100%">Catala-Stordeur, V.</style></author><author><style face="normal" font="default" size="100%">Tropper, G.</style></author><author><style face="normal" font="default" size="100%">Vezina, L. P.</style></author><author><style face="normal" font="default" size="100%">Gomord, V.</style></author><author><style face="normal" font="default" size="100%">Geijtenbeek, T. B. H.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.&#xD;Amsterdam Institute for Infection and Immunity,Inflammatory Diseases, Amsterdam, The Netherlands.&#xD;Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.&#xD;Angany Inc., Quebec, Quebec, Canada.&#xD;Angany Innovation, Val-de-Reuil, France.&#xD;Department of Otorhinolaryngology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fel d 1 surface expression on plant-made eBioparticles combines potent immune activation and hypoallergenicity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3124-3126</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/08/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35916123</style></accession-num><notes><style face="normal" font="default" size="100%">Busold, Stefanie&#xD;Aglas, Lorenz&#xD;Menage, Charlotte&#xD;Auger, Lydia&#xD;Desgagnes, Rejean&#xD;Faye, Loic&#xD;Fitchette, Anne-Catherine&#xD;de Jong, Esther C&#xD;Martel, Caroline&#xD;Stigler, Maria&#xD;Catala-Stordeur, Virginie&#xD;Tropper, Guy&#xD;Vezina, Louis-Philippe&#xD;Gomord, Veronique&#xD;Geijtenbeek, Teunis B H&#xD;van Ree, Ronald&#xD;eng&#xD;FWF_/Austrian Science Fund FWF/Austria&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3124-3126. doi: 10.1111/all.15464. Epub 2022 Aug 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35916123</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10286754 material from Angany Inc. and the DC4Balance consortium. Lorenz Aglas and Maria Stigler received contract research funding and study material from Angany Inc. Louis-P Vezina is a cofounder, board member, and CEO of Angany Inc. Lydia Auger, Rejean Desgagnes, Loic Faye, Anne-Catherine Fitchette, Caroline Martel, Virginie Stordeur, Guy Tropper, and Veronique Gomord are employees of Angany Inc. Esther C. de Jong and Teunis B. H. Geijtenbeek received funding from the DC4Balance consortium. Ronald van Ree received contract research funding and research material from Angany Inc. and the DC4Balance consortium and besides received consulting fees and/or speaker&apos;s fees from Angany Inc., HAL Allergy BV, and Citeq BV, ThermoFisher Scientific, Reacta Healthcare Ltd., Mission MightyMe, and AB Enzymes and has stock options from Angany Inc.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15464</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3302</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3302</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Layhadi, Janice A.</style></author><author><style face="normal" font="default" size="100%">Gutierrez, Liliana Cifuentes</style></author><author><style face="normal" font="default" size="100%">Keane, Sean T.</style></author><author><style face="normal" font="default" size="100%">Fulton, William</style></author><author><style face="normal" font="default" size="100%">Samson, Nichell A.</style></author><author><style face="normal" font="default" size="100%">Wu, Lily Y. D.</style></author><author><style face="normal" font="default" size="100%">Filipaviciute, Paulina</style></author><author><style face="normal" font="default" size="100%">Hikmawati, Prista</style></author><author><style face="normal" font="default" size="100%">Fedina, Oleksandra</style></author><author><style face="normal" font="default" size="100%">Jimenez-Gil, Ana</style></author><author><style face="normal" font="default" size="100%">Durham, Stephen R.</style></author><author><style face="normal" font="default" size="100%">Scadding, Guy</style></author><author><style face="normal" font="default" size="100%">Tropper, Guy</style></author><author><style face="normal" font="default" size="100%">Vézina, Louis-Philippe</style></author><author><style face="normal" font="default" size="100%">Colin, Patrick</style></author><author><style face="normal" font="default" size="100%">Ree, Ronald van</style></author><author><style face="normal" font="default" size="100%">Shamji, Mohamed H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Fel d 1-Expressing Plant-Derived Bioparticle: A Novel Treatment for Cat Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Allergen immunotherapy (AIT) is the only disease-modifying therapeutic approach for cat allergy, though it requires at least three years of treatment and can potentially induce severe systemic reactions. Plant-derived bioparticles expressing Fel d 1 allergen (Fel d 1 eBP) have been developed as a novel therapeutic candidate for cat allergy. We aimed to investigate the allergenicity and immunogenicity profile of Fel d 1 eBP. Methods Fel d 1 eBP was synthesised in vivo in Nicotiana benthamiana and confirmed by cryo-electron microscopy and tomography. Immune modulatory properties of purified natural Fel d 1 (nFel d 1) and Fel d 1 eBP were assessed at T and B cells by flow cytometry in 12 cat-allergic subjects (CA) and 12 non-atopic controls (NAC). Single-cell RNA-seq was used to assess molecular mechanisms of Fel d 1 eBP immune skewing. The safety of Fel d 1 eBP was assessed by measuring basophil responsiveness in whole blood and further confirmed in vivo by its administration as a skin prick test (SPT) in 20 cat-allergic individuals. Results Fel d 1 eBP was shown to be a strong inducer of Th1 cells (p &lt; 0.05) and IL-10+ non-Th2 cells (p &lt; 0.05) in CA subjects. Fel d 1 eBP showed a stronger trend for inducing IL-10+ Breg cells compared to nFel d 1, peaking at 3 μg/mL. scRNA-seq analyses demonstrated that Fel d 1 eBP targets the induction of protective metallothionein genes, CCL18+ monocytes and naïve B cells that are interferon responsive and metabolically activated. Moreover, Fel d 1 eBP demonstrated reduced capacity to elicit basophil activation (p &lt; 0.001) and histamine release (p &lt; 0.01), indicating their hypoallergenic nature. Administration of titrated doses of Fel d 1 eBP through skin prick test revealed that they are well-tolerated with reduced mean wheal compared to native Fel d 1 in an open-label Phase 0 study (all, p &lt; 0.001). Conclusions We demonstrate that Fel d 1 eBP is hypoallergenic and demonstrates tolerogenic properties, making it a novel candidate for use in AIT for cat allergy.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70280</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70280</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>80</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">80</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carvallo, A.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Fernandez, S.</style></author><author><style face="normal" font="default" size="100%">Morales-Palacios, M. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fenebrutinib and BTK inhibition: Unveiling a new target for the treatment of chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">603-605</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/11/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines</style></keyword><keyword><style face="normal" font="default" size="100%">Pyridones</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36420759</style></accession-num><notes><style face="normal" font="default" size="100%">Carvallo, Alvaro&#xD;Sanchez-Fernandez, Sergio&#xD;Morales-Palacios, Maria de la Paz&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):603-605. doi: 10.1111/all.15592. Epub 2022 Dec 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36420759</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15592</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1879</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1879</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carvallo, A.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Fernandez, S.</style></author><author><style face="normal" font="default" size="100%">Morales-Palacios, M. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fenebrutinib and BTK inhibition: Unveiling a new target for the treatment of chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">603-605</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/11/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines</style></keyword><keyword><style face="normal" font="default" size="100%">Pyridones</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36420759</style></accession-num><notes><style face="normal" font="default" size="100%">Carvallo, Alvaro&#xD;Sanchez-Fernandez, Sergio&#xD;Morales-Palacios, Maria de la Paz&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):603-605. doi: 10.1111/all.15592. Epub 2022 Dec 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36420759</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15592</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>246</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">246</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Menard-Katcher, C.</style></author><author><style face="normal" font="default" size="100%">Liu, C.</style></author><author><style face="normal" font="default" size="100%">Galbraith, M. D.</style></author><author><style face="normal" font="default" size="100%">Benson, T.</style></author><author><style face="normal" font="default" size="100%">Burger, C.</style></author><author><style face="normal" font="default" size="100%">Dobias, D.</style></author><author><style face="normal" font="default" size="100%">Larsen, L.</style></author><author><style face="normal" font="default" size="100%">O&apos;Brien, C.</style></author><author><style face="normal" font="default" size="100%">Spencer, L. A.</style></author><author><style face="normal" font="default" size="100%">Furuta, G. T.</style></author><author><style face="normal" font="default" size="100%">Masterson, J. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Gastrointestinal Eosinophilic Diseases Program, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Digestive Health Institute, Children&apos;s Hospital Colorado, Aurora, Colorado, USA.&#xD;Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado-Denver Anschutz Medical Campus, Aurora, Colorado, USA.&#xD;Department of Pharmacology, Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.&#xD;Department of Biology, Allergy, Inflammation &amp; Remodeling Research Laboratory, Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fibrostenotic eosinophilic esophagitis phenotype is defined by a proliferative gene signature</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">579-583</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/10/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Enteritis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36273270</style></accession-num><notes><style face="normal" font="default" size="100%">Menard-Katcher, Calies&#xD;Liu, Cuining&#xD;Galbraith, Matthew D&#xD;Benson, Taylor&#xD;Burger, Cassandra&#xD;Dobias, Devin&#xD;Larsen, Leigha&#xD;O&apos;Brien, Carol&#xD;Spencer, Lisa A&#xD;Furuta, Glenn T&#xD;Masterson, Joanne C&#xD;eng&#xD;K23 DK109263/DK/NIDDK NIH HHS/&#xD;R01 AI121186/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):579-583. doi: 10.1111/all.15557. Epub 2022 Nov 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36273270</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9892276</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15557</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2966</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2966</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xie, Y. K.</style></author><author><style face="normal" font="default" size="100%">Xu, S. S.</style></author><author><style face="normal" font="default" size="100%">Li, Y. S.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, S. C.</style></author><author><style face="normal" font="default" size="100%">Xie, Y.</style></author><author><style face="normal" font="default" size="100%">Gao, Y. D.</style></author><author><style face="normal" font="default" size="100%">Zhang, X. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hubei Province Key Laboratory of Allergy and Immunology, Department of Allergy, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Department of Immunology, School of Basic Medical Sciences, State Key Laboratory of Virology, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, China.&#xD;The Sixth People&apos;s Hospital of Zhengzhou, Zhengzhou, China.&#xD;Department of Allergy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ficolin-A Protects Against Allergic Asthma via Suppressing ILC2-Drived Type 2 Inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/07/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">ficolin-2</style></keyword><keyword><style face="normal" font="default" size="100%">ficolin-a</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cell (ILC)2</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 25</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40708471</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Type 2 inflammation has emerged as a pivotal mechanism for asthma, which involves both innate and adaptive immunity. Human ficolin (FCN)-2 (L-ficolin, P35) and its mouse homolog FCN-A are one of the major pattern recognition molecules of plasma/serum, acting as important initiators of the lectin complement system and playing important roles in immunity, including respiratory immunity. However, little is known about the role of FCN-2/A in allergic asthma. METHODS: Serum FCN-2 and IgE levels in 90 allergic asthmatic patients and 48 healthy controls were measured by ELISA. Aeroallergen house dust mite (HDM)-induced mouse model of asthma was generated in both wild type (WT) and FCN-A knockout (KO) mice. Mouse serum and bronchoalveolar lavage fluid (BALF) IgE levels, lung innate lymphoid cells (ILC)1/2/3, the expression of transcription factors GATA3, T-bet, and RORgammat, and the concentrations of type 2 cytokines in serum and BALF were measured by FCM, RT-qPCR, Western blot, and ELISA. RESULTS: Serum FCN-2 concentrations in patients with allergic asthma were significantly lower than those in healthy controls. Similarly, lower serum and BALF FCN-A concentrations were observed in HDM-induced asthma mouse models compared to those of uninduced mice. In the asthma mouse model, FCN-A KO asthmatic mice had higher levels of total IgE and HDM-specific IgE (sIgE), beta-hexosaminidase (beta-HEX) and histamine secretion, as well as increased airway epithelial permeability with the release of FITC-dextran in sera, inflammatory cell infiltration and eosinophil counts, and displayed more severe disease symptoms with histological damage compared to WT asthmatic mice. FCN-A KO asthmatic mice showed decreased T-bet(+) ILC1 and increased IL-5(+)/IL-13(+) ILC2/ILC2 proportions, p-GATA3 expression, serum and BALF type 2 cytokines IL-4, IL-5, and IL-13, Th17 cytokine IL-17, and chemokines CCL2/4 production. Importantly, the administration of exogenous FCN-A protected against mouse allergic airway inflammation with decreased ILC2 proportions and type 2 cytokines expression, serum total and allergen-specific IgE production. These results suggest that FCN-A suppresses both ILC2 innate immunity and IgE-mediated adaptive immunity during asthma. CONCLUSION: Our findings provide previously unreported evidence that FCN-A protects against allergic asthma by suppressing lung ILC2-driven type 2 inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Xie, Yu-Ke&#xD;Xu, Shan-Shan&#xD;Li, Yong-Shuai&#xD;Li, Jiarong&#xD;Zhang, Shu-Chen&#xD;Xie, Yan&#xD;Gao, Ya-Dong&#xD;Zhang, Xiao-Lian&#xD;eng&#xD;82230078/National Natural Science Foundation of China/&#xD;91740120/National Natural Science Foundation of China/&#xD;22077097/National Natural Science Foundation of China/&#xD;21572173/National Natural Science Foundation of China/&#xD;2042022dx0003/The Fundamental Research Funds for the Central Universities/&#xD;2042023kf1011/The Fundamental Research Funds for the Central Universities/&#xD;ZNLH202212/Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University/&#xD;2022YFA1303500/National Key R&amp;D Program of China/&#xD;2018YFA0507603/National Key R&amp;D Program of China/&#xD;523-276003/Hubei Province&apos;s Outstanding Medical Academic Leader Program/&#xD;B2402031/Shenzhen Medical Research Fund/&#xD;Denmark&#xD;Allergy. 2025 Jul 25. doi: 10.1111/all.16661.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40708471</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16661</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1159</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1159</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koenig, J. F. E.</style></author><author><style face="normal" font="default" size="100%">Grydziuszko, E.</style></author><author><style face="normal" font="default" size="100%">Jordana, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, McMaster Immunology Research Centre (MIRC), McMaster University, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">First contact: Serum amyloid A and pattern recognition in Th2 immunity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2309-2311</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Serum Amyloid A Protein</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">aeroallergen</style></keyword><keyword><style face="normal" font="default" size="100%">group 13 mite allergen</style></keyword><keyword><style face="normal" font="default" size="100%">pattern recognition</style></keyword><keyword><style face="normal" font="default" size="100%">serum amyloid A</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33590523</style></accession-num><notes><style face="normal" font="default" size="100%">Koenig, Joshua F E&#xD;Grydziuszko, Emily&#xD;Jordana, Manel&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2309-2311. doi: 10.1111/all.14778. Epub 2021 Mar 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33590523</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14778</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1560</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1560</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koenig, J. F. E.</style></author><author><style face="normal" font="default" size="100%">Grydziuszko, E.</style></author><author><style face="normal" font="default" size="100%">Jordana, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, McMaster Immunology Research Centre (MIRC), McMaster University, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">First contact: Serum amyloid A and pattern recognition in Th2 immunity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2309-2311</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Serum Amyloid A Protein</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">aeroallergen</style></keyword><keyword><style face="normal" font="default" size="100%">group 13 mite allergen</style></keyword><keyword><style face="normal" font="default" size="100%">pattern recognition</style></keyword><keyword><style face="normal" font="default" size="100%">serum amyloid A</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33590523</style></accession-num><notes><style face="normal" font="default" size="100%">Koenig, Joshua F E&#xD;Grydziuszko, Emily&#xD;Jordana, Manel&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2309-2311. doi: 10.1111/all.14778. Epub 2021 Mar 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33590523</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14778</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2398</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2398</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The first plant allergen to be cloned-the story of the major birch pollen allergen Bet v 1</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1071-1072</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/02/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Betula</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38379457</style></accession-num><notes><style face="normal" font="default" size="100%">Breiteneder, Heimo&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):1071-1072. doi: 10.1111/all.16066. Epub 2024 Feb 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38379457</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16066</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>481</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">481</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nieto, A.</style></author><author><style face="normal" font="default" size="100%">Mazon, A.</style></author><author><style face="normal" font="default" size="100%">Nieto, M.</style></author><author><style face="normal" font="default" size="100%">Ibanez, E.</style></author><author><style face="normal" font="default" size="100%">Jang, D. T.</style></author><author><style face="normal" font="default" size="100%">Calaforra, S.</style></author><author><style face="normal" font="default" size="100%">Alba, P.</style></author><author><style face="normal" font="default" size="100%">Perez-Frances, C.</style></author><author><style face="normal" font="default" size="100%">Llusar, R.</style></author><author><style face="normal" font="default" size="100%">Montoro, J.</style></author><author><style face="normal" font="default" size="100%">de Mateo, A.</style></author><author><style face="normal" font="default" size="100%">Alamar, R.</style></author><author><style face="normal" font="default" size="100%">El-Qutob, D.</style></author><author><style face="normal" font="default" size="100%">Fernandez, J.</style></author><author><style face="normal" font="default" size="100%">Moral, L.</style></author><author><style face="normal" font="default" size="100%">Toral, T.</style></author><author><style face="normal" font="default" size="100%">Anton, M.</style></author><author><style face="normal" font="default" size="100%">Andreu, C.</style></author><author><style face="normal" font="default" size="100%">Ferrer, A.</style></author><author><style face="normal" font="default" size="100%">Flores, I. M.</style></author><author><style face="normal" font="default" size="100%">Cerda, N.</style></author><author><style face="normal" font="default" size="100%">Del Pozo, S.</style></author><author><style face="normal" font="default" size="100%">Caballero, R.</style></author><author><style face="normal" font="default" size="100%">Subiza, J. L.</style></author><author><style face="normal" font="default" size="100%">Casanovas, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit of Pediatric Allergy and Pneumology, Hospital Universitari i Politecnic la Fe, Valencia, Spain.&#xD;Department of Allergy, Hospital Universitari i Politecnic la Fe, Valencia, Spain.&#xD;Allergy Service, Hospital Manises, Valencia, Spain.&#xD;Allergy Service, University Hospital Doctor Peset, Valencia, Spain.&#xD;Allergy Service, University Hospital Arnau de Vilanova, Valencia, Spain.&#xD;Allergy Service, University Hospital, Castellon, Spain.&#xD;Allergy Service, University Hospital de la Plana, Castellon, Spain.&#xD;Allergy Service, Hospital General Universitario Dr. Balmis, ISABIAL, Alicante, Spain.&#xD;Pediatric Allergy and Respiratory Unit, Hospital Universitario Dr. Balmis, ISABIAL, Alicante, Spain.&#xD;Allergy Service, University Hospital Vinalopo, Elche, Alicante, Spain.&#xD;Allergy Service, Hospital Vega Baja, Orihuela, Alicante, Spain.&#xD;Allergy Service, Hospital Vithas, Alicante, Spain.&#xD;Allergy Service, Hospital Elche, Elche, Spain.&#xD;BioClever, Barcelona, Spain.&#xD;Inmunotek, S.L., Alcala de Henares, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3096-3107</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/05/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Allergoids</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mannans</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">allergoid</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">i</style></keyword><keyword><style face="normal" font="default" size="100%">mannan</style></keyword><keyword><style face="normal" font="default" size="100%">mmunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">polymerized</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, Stallergenes-Greer, Astra-Zeneca, Glaxo-Smith-kline, Roxall Medicine, and</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis. AM, MN, EI, DJ, SC, C P-F, JM, A de M, RA, JF, LM, MA, CA, and AF</style></keyword><keyword><style face="normal" font="default" size="100%">declare no conflict of interest. RC and SdP are employees of Inmunotek SL. JLS</style></keyword><keyword><style face="normal" font="default" size="100%">and MC are shareholders of Inmunotek SL.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35570712</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Polymerized allergens conjugated to non-oxidized mannan (PM-allergoids) are novel vaccines targeting dendritic cells (DCs). Previous experimental data indicate that PM-allergoids are readily taken up by DCs and induce Treg cells. This first-in-human study was aimed to evaluate safety and to find the optimal dose of house dust mite PM-allergoid (PM-HDM) administered subcutaneously (SC) or sublingually (SL). METHODS: In a randomized, double-blind, double-dummy, placebo-controlled trial, 196 subjects received placebo or PM-HDM at 500, 1000, 3000, or 5000 mannan-conjugated therapeutic units (mTU)/mL in 9-arm groups for 4 months. All subjects received 5 SC doses (0.5 ml each) every 30 days plus 0.2 ml SL daily. The primary efficacy outcome was the improvement of titrated nasal provocation tests (NPT) with D. pteronyssinus at baseline and at the end of the study. All adverse events and reactions were recorded and assessed. Secondary outcomes were the combination of symptom and medication scores (CSMS) and serological markers. RESULTS: No moderate or severe adverse reactions were reported. Subjects improving the NPT after treatment ranged from 45% to 62% in active SC, 44% to 61% in active SL and 16% in placebo groups. Statistical differences between placebo and active groups were all significant above 500 mTU, being the highest with 3000 mTU SL (p = 0.004) and 5000 mTU SC (p = 0.011). CSMS improvement over placebo reached 70% (p &lt; 0.001) in active 3000 mTU SC and 40% (p = 0.015) in 5000 mTU SL groups. CONCLUSIONS: PM-HDM immunotherapy was safe and successful in achieving primary and secondary clinical outcomes in SC and SL at either 3000 or 5000 mTU/ml.</style></abstract><notes><style face="normal" font="default" size="100%">Nieto, Antonio&#xD;Mazon, Angel&#xD;Nieto, Maria&#xD;Ibanez, Ethel&#xD;Jang, Dah-Tay&#xD;Calaforra, Susana&#xD;Alba, Pilar&#xD;Perez-Frances, Carmen&#xD;Llusar, Ruth&#xD;Montoro, Javier&#xD;de Mateo, Antonio&#xD;Alamar, Remedios&#xD;El-Qutob, David&#xD;Fernandez, Javier&#xD;Moral, Luis&#xD;Toral, Teresa&#xD;Anton, Monica&#xD;Andreu, Carmen&#xD;Ferrer, Angel&#xD;Flores, Isabel-Maria&#xD;Cerda, Neus&#xD;Del Pozo, Sandra&#xD;Caballero, Raquel&#xD;Subiza, Jose Luis&#xD;Casanovas, Miguel&#xD;eng&#xD;Clinical Trial, Phase II&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3096-3107. doi: 10.1111/all.15374. Epub 2022 May 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35570712</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9796063</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15374</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2858</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2858</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wai, C. Y. Y.</style></author><author><style face="normal" font="default" size="100%">Leung, N. Y. H.</style></author><author><style face="normal" font="default" size="100%">Leung, A. S. Y.</style></author><author><style face="normal" font="default" size="100%">Tang, M. F.</style></author><author><style face="normal" font="default" size="100%">Marknell DeWitt, A.</style></author><author><style face="normal" font="default" size="100%">Rosa Duque, J. S.</style></author><author><style face="normal" font="default" size="100%">Chua, G. T.</style></author><author><style face="normal" font="default" size="100%">Yau, Y. S.</style></author><author><style face="normal" font="default" size="100%">Chan, W. H.</style></author><author><style face="normal" font="default" size="100%">Ho, P. K.</style></author><author><style face="normal" font="default" size="100%">Kwan, M. Y. W.</style></author><author><style face="normal" font="default" size="100%">Lee, Q. U.</style></author><author><style face="normal" font="default" size="100%">Wong, J. S. C.</style></author><author><style face="normal" font="default" size="100%">Lam, I. C. S.</style></author><author><style face="normal" font="default" size="100%">Cheng, Jwch</style></author><author><style face="normal" font="default" size="100%">Luk, D. C. K.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Ngai, N. A.</style></author><author><style face="normal" font="default" size="100%">Chan, O. M.</style></author><author><style face="normal" font="default" size="100%">Leung, P. S. C.</style></author><author><style face="normal" font="default" size="100%">Wong, G. W. K.</style></author><author><style face="normal" font="default" size="100%">Leung, T. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Thermo Fisher Scientific, ImmunoDiagnostics, Uppsala, Sweden.&#xD;Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong SAR, China.&#xD;Allergy Centre, Union Hospital, Hong kong SAR, China.&#xD;Department of Paediatrics, Queen Elizabeth Hospital, Hong Kong SAR, China.&#xD;Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital and Yan Chai Hospital, Hong Kong SAR, China.&#xD;Department of Paediatrics and Adolescent Medicine, United Christian Hospital, Hong Kong SAR, China.&#xD;Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fish Allergenicity Ladder and Parvalbumin Epitopes for Predicting Clinical Cross-Reactivity and Reintroduction in Chinese Population</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2810-2823</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/04/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Epitope Mapping</style></keyword><keyword><style face="normal" font="default" size="100%">*Epitopes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Fish Proteins/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Fishes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Parvalbumins/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">East Asian People</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-mediated fish allergy</style></keyword><keyword><style face="normal" font="default" size="100%">clinical cross-reactivity</style></keyword><keyword><style face="normal" font="default" size="100%">food ladders</style></keyword><keyword><style face="normal" font="default" size="100%">home introduction</style></keyword><keyword><style face="normal" font="default" size="100%">manufacturer of the ImmunoCAP IgE assay system used in this study. The other</style></keyword><keyword><style face="normal" font="default" size="100%">authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40270099</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IgE-mediated fish allergy has long been considered an umbrella term due to the high cross-reactivity of parvalbumin, the major fish allergen. Yet, clinical tolerance to certain fish highlights allergenicity differences. In this study, we sought to construct a fish allergenicity ladder and identify fish parvalbumin epitopes to improve the diagnosis of fish allergy. METHODS: Reported clinical history and the serum-specific IgE (sIgE) responses of 200 Chinese subjects with suspected fish allergy were collected and analyzed, while the relative parvalbumin content in different fish was measured for the construction of a fish allergenicity ladder. Double-blind placebo-controlled food challenge (DBPCFC) and open challenge against salmon, grass carp, and grouper were performed in 58 selected patients for validation of the ladder. Epitope mapping was performed by peptide array against parvalbumins of salmon (both beta-1 and beta-2), cod, grouper, and grass carp with sera from fish allergic (n = 11), partial fish tolerant (n = 12), and complete fish tolerant (n = 5) patients diagnosed based on oral food challenge outcome. RESULTS: The distribution pattern of reported history of fish allergy and tolerance, sIgE and molecular data, as well as their strong positive correlation led to the construction of a 3-step fish allergenicity ladder comprising: step 1 of the least allergenic fishes (tuna, halibut, salmon and cod), steps 2 of moderately allergenic fishes (herring and grouper) to step 3 of highly allergenic fishes (catfish, grass carp and tilapia). Epitope mapping revealed one epitope from grouper parvalbumin (AA64-78) for diagnosing general fish allergy and one epitopic region from salmon parvalbumin (AA19-33) as a biomarker of specific fish tolerance. Only epitope-specific IgE differentiated these patients but not sIgE to fish extract or parvalbumin. CONCLUSION: The fish ladder and epitopes discovery can precisely differentiate fish-allergic and tolerant subjects and guide fish reintroduction by stepping up the ladder, which innovates fish allergy care in the next millennium.</style></abstract><notes><style face="normal" font="default" size="100%">Wai, Christine Y Y&#xD;Leung, Nicki Y H&#xD;Leung, Agnes S Y&#xD;Tang, Man Fung&#xD;Marknell DeWitt, Asa&#xD;Rosa Duque, Jaime S&#xD;Chua, Gilbert T&#xD;Yau, Yat Sun&#xD;Chan, Wai Hung&#xD;Ho, Po Ki&#xD;Kwan, Mike Y W&#xD;Lee, Qun Ui&#xD;Wong, Joshua S C&#xD;Lam, Ivan C S&#xD;Cheng, James W C H&#xD;Luk, David C K&#xD;Liu, Zhongyi&#xD;Ngai, Noelle Anne&#xD;Chan, Oi Man&#xD;Leung, Patrick S C&#xD;Wong, Gary W K&#xD;Leung, Ting Fan&#xD;eng&#xD;08191356/Health and Medical Research Fund/&#xD;09202866/Health and Medical Research Fund/&#xD;2024.078/Direct Grant for Research/&#xD;R4035-19/Research Impact Fund of the Research Grants Council, Hong Kong SAR Government/&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2810-2823. doi: 10.1111/all.16562. Epub 2025 Apr 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40270099</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486362</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16562</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2943</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2943</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wai, C. Y. Y.</style></author><author><style face="normal" font="default" size="100%">Leung, N. Y. H.</style></author><author><style face="normal" font="default" size="100%">Leung, A. S. Y.</style></author><author><style face="normal" font="default" size="100%">Tang, M. F.</style></author><author><style face="normal" font="default" size="100%">Marknell DeWitt, A.</style></author><author><style face="normal" font="default" size="100%">Rosa Duque, J. S.</style></author><author><style face="normal" font="default" size="100%">Chua, G. T.</style></author><author><style face="normal" font="default" size="100%">Yau, Y. S.</style></author><author><style face="normal" font="default" size="100%">Chan, W. H.</style></author><author><style face="normal" font="default" size="100%">Ho, P. K.</style></author><author><style face="normal" font="default" size="100%">Kwan, M. Y. W.</style></author><author><style face="normal" font="default" size="100%">Lee, Q. U.</style></author><author><style face="normal" font="default" size="100%">Wong, J. S. C.</style></author><author><style face="normal" font="default" size="100%">Lam, I. C. S.</style></author><author><style face="normal" font="default" size="100%">Cheng, Jwch</style></author><author><style face="normal" font="default" size="100%">Luk, D. C. K.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Ngai, N. A.</style></author><author><style face="normal" font="default" size="100%">Chan, O. M.</style></author><author><style face="normal" font="default" size="100%">Leung, P. S. C.</style></author><author><style face="normal" font="default" size="100%">Wong, G. W. K.</style></author><author><style face="normal" font="default" size="100%">Leung, T. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Thermo Fisher Scientific, ImmunoDiagnostics, Uppsala, Sweden.&#xD;Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong SAR, China.&#xD;Allergy Centre, Union Hospital, Hong kong SAR, China.&#xD;Department of Paediatrics, Queen Elizabeth Hospital, Hong Kong SAR, China.&#xD;Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital and Yan Chai Hospital, Hong Kong SAR, China.&#xD;Department of Paediatrics and Adolescent Medicine, United Christian Hospital, Hong Kong SAR, China.&#xD;Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fish Allergenicity Ladder and Parvalbumin Epitopes for Predicting Clinical Cross-Reactivity and Reintroduction in Chinese Population</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2810-2823</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/04/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Epitope Mapping</style></keyword><keyword><style face="normal" font="default" size="100%">*Epitopes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Fish Proteins/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Fishes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Parvalbumins/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">East Asian People</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-mediated fish allergy</style></keyword><keyword><style face="normal" font="default" size="100%">clinical cross-reactivity</style></keyword><keyword><style face="normal" font="default" size="100%">food ladders</style></keyword><keyword><style face="normal" font="default" size="100%">home introduction</style></keyword><keyword><style face="normal" font="default" size="100%">manufacturer of the ImmunoCAP IgE assay system used in this study. The other</style></keyword><keyword><style face="normal" font="default" size="100%">authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40270099</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IgE-mediated fish allergy has long been considered an umbrella term due to the high cross-reactivity of parvalbumin, the major fish allergen. Yet, clinical tolerance to certain fish highlights allergenicity differences. In this study, we sought to construct a fish allergenicity ladder and identify fish parvalbumin epitopes to improve the diagnosis of fish allergy. METHODS: Reported clinical history and the serum-specific IgE (sIgE) responses of 200 Chinese subjects with suspected fish allergy were collected and analyzed, while the relative parvalbumin content in different fish was measured for the construction of a fish allergenicity ladder. Double-blind placebo-controlled food challenge (DBPCFC) and open challenge against salmon, grass carp, and grouper were performed in 58 selected patients for validation of the ladder. Epitope mapping was performed by peptide array against parvalbumins of salmon (both beta-1 and beta-2), cod, grouper, and grass carp with sera from fish allergic (n = 11), partial fish tolerant (n = 12), and complete fish tolerant (n = 5) patients diagnosed based on oral food challenge outcome. RESULTS: The distribution pattern of reported history of fish allergy and tolerance, sIgE and molecular data, as well as their strong positive correlation led to the construction of a 3-step fish allergenicity ladder comprising: step 1 of the least allergenic fishes (tuna, halibut, salmon and cod), steps 2 of moderately allergenic fishes (herring and grouper) to step 3 of highly allergenic fishes (catfish, grass carp and tilapia). Epitope mapping revealed one epitope from grouper parvalbumin (AA64-78) for diagnosing general fish allergy and one epitopic region from salmon parvalbumin (AA19-33) as a biomarker of specific fish tolerance. Only epitope-specific IgE differentiated these patients but not sIgE to fish extract or parvalbumin. CONCLUSION: The fish ladder and epitopes discovery can precisely differentiate fish-allergic and tolerant subjects and guide fish reintroduction by stepping up the ladder, which innovates fish allergy care in the next millennium.</style></abstract><notes><style face="normal" font="default" size="100%">Wai, Christine Y Y&#xD;Leung, Nicki Y H&#xD;Leung, Agnes S Y&#xD;Tang, Man Fung&#xD;Marknell DeWitt, Asa&#xD;Rosa Duque, Jaime S&#xD;Chua, Gilbert T&#xD;Yau, Yat Sun&#xD;Chan, Wai Hung&#xD;Ho, Po Ki&#xD;Kwan, Mike Y W&#xD;Lee, Qun Ui&#xD;Wong, Joshua S C&#xD;Lam, Ivan C S&#xD;Cheng, James W C H&#xD;Luk, David C K&#xD;Liu, Zhongyi&#xD;Ngai, Noelle Anne&#xD;Chan, Oi Man&#xD;Leung, Patrick S C&#xD;Wong, Gary W K&#xD;Leung, Ting Fan&#xD;eng&#xD;08191356/Health and Medical Research Fund/&#xD;09202866/Health and Medical Research Fund/&#xD;2024.078/Direct Grant for Research/&#xD;R4035-19/Research Impact Fund of the Research Grants Council, Hong Kong SAR Government/&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2810-2823. doi: 10.1111/all.16562. Epub 2025 Apr 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40270099</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486362</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16562</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3185</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3185</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Didier, A.</style></author><author><style face="normal" font="default" size="100%">Juhl, R. G.</style></author><author><style face="normal" font="default" size="100%">Dalgaard, T.</style></author><author><style face="normal" font="default" size="100%">Chartier, A.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Service de Pneumologie Allergologie and Reseau CRISALIS/F-CRIN INSERM, Hopital Larrey, CHU de Toulouse, Toulouse, France.&#xD;ALK-Abellomicron A/S, Horsholm, Denmark.&#xD;ALK France, Paris la defense, France.&#xD;Department of Airway Diseases, Universite de Versailles Saint-Quentin, Hopital Foch, Suresnes, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Five-Grass-Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">5-grass-pollen mix</style></keyword><keyword><style face="normal" font="default" size="100%">adults</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">drops</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41444697</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tablet formulations of allergen extracts are widely recommended over other formulations for the sublingual immunotherapy (SLIT) of respiratory allergies. However, with adequate clinical trial evidence, SLIT (liquid) drop formulations may be a relevant allergy treatment option. METHODS: The RHAPSODY multinational, Phase III, parallel-group, double-blind, placebo-controlled, randomised clinical study of adults with moderate-to-severe, grass-pollen-induced allergic rhinoconjunctivitis (ARC) with or without asthma was conducted at 45 investigating centres in six European countries. Participants received 26 months of continuous treatment with active 5-grass-pollen SLIT drops or placebo. The primary efficacy endpoint was the average daily total combined score (TCS, comprising a symptom score and a rescue medication score) during the second peak grass pollen season (PGPS). RESULTS: Of the 445 randomised patients (mean +/- standard deviation (range) age: 32.6 +/- 9.9 (18-63); males: 55.1%), 389 completed the trial. The primary efficacy endpoint showed a statistically significant difference in favour of active treatment versus placebo (average difference in the daily TCS: 1.88 (95% CI: 0.60-3.17); relative difference 26.51% (95% CI: 9.42-40.55); p = 0.0036). The difference (0.17 points) in the average weekly Rhinitis Quality of Life Questionnaire score during the second PGPS in favour of the active treatment was clinically relevant but not statistically significant. The differences in efficacy were generally driven by the medication score, rather than the symptom score. Most adverse events were mild and local. CONCLUSIONS: RHAPSODY was the first well-powered clinical trial to show the positive risk-benefit ratio of 5-grass-pollen SLIT drops in adult participants with moderate-to-severe grass-pollen-induced ARC.</style></abstract><notes><style face="normal" font="default" size="100%">Didier, Alain&#xD;Juhl, Ruta Gronskyte&#xD;Dalgaard, Terrie&#xD;Chartier, Antoine&#xD;Devillier, Philippe&#xD;eng&#xD;ALK-Abellomicron/&#xD;Denmark&#xD;Allergy. 2025 Dec 24. doi: 10.1111/all.70191.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41444697</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70191</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3026</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3026</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Corcoran, A.</style></author><author><style face="normal" font="default" size="100%">d&apos;Art, Y.</style></author><author><style face="normal" font="default" size="100%">Byrne, A.</style></author><author><style face="normal" font="default" size="100%">Hourihane, J. O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Childrens Health Ireland, Dublin, Ireland.&#xD;Paediatrics and Child Health, Royal College of Surgeons in Ireland, Dublin, Ireland.&#xD;Trinity College Dublin, Dublin, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Five-Year Follow-Up Study of Single Dose Challenges in the Diagnosis and Management of Cow&apos;s Milk Allergy in Infants</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2931-2933</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/08/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Copd</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword><keyword><style face="normal" font="default" size="100%">paediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40847678</style></accession-num><notes><style face="normal" font="default" size="100%">Corcoran, Aoife&#xD;d&apos;Art, Yvonne&#xD;Byrne, Aideen&#xD;Hourihane, Jonathan O&apos;B&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2931-2933. doi: 10.1111/all.70024. Epub 2025 Aug 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40847678</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486360</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70024</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2873</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2873</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elst, J.</style></author><author><style face="normal" font="default" size="100%">Mertens, C.</style></author><author><style face="normal" font="default" size="100%">Van Houdt, M.</style></author><author><style face="normal" font="default" size="100%">van der Poorten, M. M.</style></author><author><style face="normal" font="default" size="100%">Van Gasse, A. L.</style></author><author><style face="normal" font="default" size="100%">Toscano, A.</style></author><author><style face="normal" font="default" size="100%">Beyens, M.</style></author><author><style face="normal" font="default" size="100%">Yerly, D.</style></author><author><style face="normal" font="default" size="100%">Hagendorens, M. M.</style></author><author><style face="normal" font="default" size="100%">Sabato, V.</style></author><author><style face="normal" font="default" size="100%">Hausmann, O.</style></author><author><style face="normal" font="default" size="100%">Ebo, D. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Allergology and Rheumatology and the Infla-Med Centre of Excellence, University Antwerp, Antwerp University Hospital, Antwerpen, Belgium.&#xD;Department of Paediatrics and the Infla-Med Centre of Excellence, University Antwerp, Antwerp University Hospital, Antwerpen, Belgium.&#xD;ADR-AC GmbH, Bern, Switzerland.&#xD;Loewenpraxis and Klinik St. Anna, Lucerne, Switzerland.&#xD;Department of Immunology and Allergology, AZ Jan Palfijn Gent, Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Flow Cytometry-Assisted Analyses of Individual Human Basophils, Mast Cells and T Cells in the Diagnosis of Immediate Drug Hypersensitivity: A Review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1242-1255</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/04/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Flow Cytometry/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunophenotyping</style></keyword><keyword><style face="normal" font="default" size="100%">Mas</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">immediate drug hypersensitivity reaction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40178393</style></accession-num><abstract><style face="normal" font="default" size="100%">Immediate drug hypersensitivity reactions (IDHRs) pose significant diagnostic challenges, often requiring potentially hazardous drug challenge testing (DCT). Flow cytometry-based cellular tests including the basophil activation test (BAT), the mast cell activation test (MAT) and the T cell activation test (TAT) offer promising alternatives to reduce DCT reliance. While these tests are still in development, they demonstrate potential to compete with skin tests by providing superior diagnostic performance and improved patient safety by reducing the need for DCT. Furthermore, it is encouraging that these flow cytometry-based tests are also suitable for challenging populations, such as children. Despite requiring specialised infrastructure, these tests have the potential to be cost-effective when performed in reference centres and may offer unique mechanistic insights into immediate drug hypersensitivity reactions. However, further research is needed to validate their reliability, address pharmaceutical-specific testing considerations, and potentially integrate them into clinical guidelines.</style></abstract><notes><style face="normal" font="default" size="100%">Elst, Jessy&#xD;Mertens, Christel&#xD;Van Houdt, Michel&#xD;van der Poorten, Marie-Line M&#xD;Van Gasse, Athina L&#xD;Toscano, Alessandro&#xD;Beyens, Michiel&#xD;Yerly, Daniel&#xD;Hagendorens, Margo M&#xD;Sabato, Vito&#xD;Hausmann, Oliver&#xD;Ebo, Didier G&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1242-1255. doi: 10.1111/all.16548. Epub 2025 Apr 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40178393</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16548</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2341</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2341</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Celik, G. E.</style></author><author><style face="normal" font="default" size="100%">Pascal, M.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, H. J.</style></author><author><style face="normal" font="default" size="100%">Eberlein, B.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Garvey, L. H.</style></author><author><style face="normal" font="default" size="100%">Barbaud, A.</style></author><author><style face="normal" font="default" size="100%">Madrigal-Burgaleta, R.</style></author><author><style face="normal" font="default" size="100%">Caubet, J. C.</style></author><author><style face="normal" font="default" size="100%">Ebo, D. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga and Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;RETICS Asma reacciones adversas y alergicas (ARADYAL) and RICORS Red De Enfermedades Inflamatorias (REI), Madrid, Spain.&#xD;Department of chest disease, Division of Allergy &amp; Immunology, Ankara University School of Medicine, Ankara, Turkey.&#xD;Immunology Department, Centre de Diagnostic Biomedic, Hospital Clinic de Barcelona, Barcelona, Spain.&#xD;Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.&#xD;Department of Clinical Medicine and Department of Clinical Immunology, Aarhus University and Aarhus University Hospital, Aarhus N, Denmark.&#xD;Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University Munich, Munich, Germany.&#xD;Medicine Department, Malaga University, Malaga, Spain.&#xD;Allergy Clinic, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen and Department of Clinical Medicine, University of Copenhagen, Kobenhavn, Denmark.&#xD;Sorbonne Universite, INSERM, Institut Pierre Louis d&apos;Epidemiologie et de Sante Publique, AP-HP.Sorbonne Universite, Hopital Tenon, Departement de dermatologie et allergologie, Paris, France.&#xD;Allergy &amp; Severe Asthma Service, St Bartholomew&apos;s Hospital, Barts Health NHS Trust, London, UK.&#xD;Department of Women-Children-Teenagers, University Hospital of Geneva, Geneva, Switzerland.&#xD;Faculty of Medicine and Health Sciences, Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Antwerp (Belgium) and Immunology, Allergology, Rheumatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.&#xD;Department of Immunology and Allergology, AZ Jan Palfijn Gent, Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">580-600</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/12/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Basophil Degranulation Test/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-mediated reactions</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">drug</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38084472</style></accession-num><abstract><style face="normal" font="default" size="100%">Diagnosing immediate drug hypersensitivity reactions (IDHRs) can pose a significant challenge and there is an urgent need for safe and reliable tests. Evidence has emerged that the basophil activation test (BAT), an in vitro assay that mirrors the in vivo response, can be a complementary test for many drugs. In this position paper, members of Task Force (TF) &quot;Basophil activation test in the evaluation of Drug Hypersensitivity Reactions&quot; from the European Academy of Allergy and Clinical Immunology (EAACI) present the data from a survey about the use and utility of BAT in IDHRs in Europe. The survey results indicate that there is a great interest for using BAT especially for diagnosing IDHRs. However, there are still main needs, mainly in the standardization of the protocols. Subsequently consensus-based recommendations were formulated for: (i) Technical aspects of BAT in IDHRs including type of sample, management of drugs, flow cytometry protocols, interpretation of the results; and (ii) Drug-specific aspects that should be taken into account when performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhexidine, opioids, radio contrast media, chemotherapeutics, biological agents, nonsteroidal anti-inflammatory drugs, COVID vaccine, and excipients. Moreover, aspects in the evaluation of pediatric population have also been considered. All this indicates that BAT offers the clinician and laboratory a complementary tool for a safe diagnostic for IDHRs, although its place in the diagnostic algorithm depends on the drug class and patient population (phenotype, geography, and age). The standardization of BAT is important for generalizing this method beyond the individual laboratory.</style></abstract><notes><style face="normal" font="default" size="100%">Mayorga, C&#xD;Celik, G E&#xD;Pascal, M&#xD;Hoffmann, H J&#xD;Eberlein, B&#xD;Torres, M J&#xD;Brockow, K&#xD;Garvey, L H&#xD;Barbaud, A&#xD;Madrigal-Burgaleta, R&#xD;Caubet, J C&#xD;Ebo, D G&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):580-600. doi: 10.1111/all.15957. Epub 2023 Dec 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38084472</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15957</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1566</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1566</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author><author><style face="normal" font="default" size="100%">Bruton, K.</style></author><author><style face="normal" font="default" size="100%">Jordana, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology &amp; Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;Department of Pathology &amp; Molecular Medicine, McMaster Immunology Research Centre (MIRC), McMaster University, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Follicular T cells: From stability to failure</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1006-1007</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2019/12/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Helper-Inducer</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31883377</style></accession-num><notes><style face="normal" font="default" size="100%">Jimenez-Saiz, Rodrigo&#xD;Bruton, Kelly&#xD;Jordana, Manel&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Apr;75(4):1006-1007. doi: 10.1111/all.14167. Epub 2020 Feb 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31883377</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14167</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2783</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2783</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arnau-Soler, A.</style></author><author><style face="normal" font="default" size="100%">Tremblay, B. L.</style></author><author><style face="normal" font="default" size="100%">Sun, Y.</style></author><author><style face="normal" font="default" size="100%">Madore, A. M.</style></author><author><style face="normal" font="default" size="100%">Simard, M.</style></author><author><style face="normal" font="default" size="100%">Kersten, E. T. G.</style></author><author><style face="normal" font="default" size="100%">Ghauri, A.</style></author><author><style face="normal" font="default" size="100%">Marenholz, I.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Simons, E.</style></author><author><style face="normal" font="default" size="100%">Chan, E. S.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Sampath, V.</style></author><author><style face="normal" font="default" size="100%">Mazer, B. D.</style></author><author><style face="normal" font="default" size="100%">Elliott, S.</style></author><author><style face="normal" font="default" size="100%">Hampson, C.</style></author><author><style face="normal" font="default" size="100%">Soller, L.</style></author><author><style face="normal" font="default" size="100%">Sandford, A.</style></author><author><style face="normal" font="default" size="100%">Begin, P.</style></author><author><style face="normal" font="default" size="100%">Hui, J.</style></author><author><style face="normal" font="default" size="100%">Wilken, B. F.</style></author><author><style face="normal" font="default" size="100%">Gerdts, J.</style></author><author><style face="normal" font="default" size="100%">Bourkas, A.</style></author><author><style face="normal" font="default" size="100%">Ellis, A. K.</style></author><author><style face="normal" font="default" size="100%">Vasileva, D.</style></author><author><style face="normal" font="default" size="100%">Clarke, A.</style></author><author><style face="normal" font="default" size="100%">Eslami, A.</style></author><author><style face="normal" font="default" size="100%">Ben-Shoshan, M.</style></author><author><style face="normal" font="default" size="100%">Martino, D.</style></author><author><style face="normal" font="default" size="100%">Daley, D.</style></author><author><style face="normal" font="default" size="100%">Koppelman, G. H.</style></author><author><style face="normal" font="default" size="100%">Laprise, C.</style></author><author><style face="normal" font="default" size="100%">Lee, Y. A.</style></author><author><style face="normal" font="default" size="100%">Asai, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Max Delbruck Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.&#xD;Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany.&#xD;Experimental and Clinical Research Center, a Joint Cooperation of Max Delbruck Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;German Center for Child and Adolescent Health (DZKJ), Berlin, Germany.&#xD;Departement Des Sciences Fondamentales, Universite du Quebec a Chicoutimi, Saguenay, Quebec, Canada.&#xD;Department of Pediatric Pulmonology and Pediatric Allergology, University Medical Center Groningen, Beatrix Children&apos;s Hospital, University of Groningen, Groningen, the Netherlands.&#xD;University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.&#xD;Department of Paediatrics, Division of Clinical Immunology and Allergy, Food Allergy and Anaphylaxis Program, the Hospital for Sick Children, The University of Toronto, Toronto, Ontario, Canada.&#xD;Section of Allergy &amp; Clinical Immunology, Department of Pediatrics &amp; Child Health, University of Manitoba, Children&apos;s Hospital Research Institute, Winnipeg, Manitoba, Canada.&#xD;Division of Allergy, Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada.&#xD;Department of Environmental Studies, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.&#xD;Department of Geography and Environmental Management, University of Waterloo, Waterloo, Ontario, Canada.&#xD;The Sandbox Project, Toronto, Ontario, Canada.&#xD;Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.&#xD;Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada.&#xD;Department of Pediatrics, Service of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.&#xD;Department of Medicine, Service of Allergy and Clinical Immunology, Centre Hospitalier de l&apos;Universite de Montreal, Montreal, Quebec, Canada.&#xD;School of Population Health, University of Western Australia, Perth, Western Australia, Australia.&#xD;School of Medicine, Department of Medicine, Queen&apos;s University, Kingston, Ontario, Canada.&#xD;Food Allergy Canada, Toronto, Ontario, Canada.&#xD;Division of Allergy &amp; Immunology, Department of Medicine, Queen&apos;s University, Kingston, Ontario, Canada.&#xD;Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.&#xD;Departement de medecine Sociale et preventive, Faculte de medecine, Universite Laval, Quebec, Canada.&#xD;Division of Allergy and Clinical Immunology, Department of Pediatrics, Montreal Children&apos;s Hospital, McGill University Health Centre, Montreal, Quebec, Canada.&#xD;Wal-Yan Respiratory Research Centre, Telethon Kids Institute, Perth, Australia.&#xD;Division of Dermatology, Department of Medicine, Queen&apos;s University, Kingston, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Food Allergy Genetics and Epigenetics: A Review of Genome-Wide Association Studies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">106-131</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/12/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">*Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">*Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Epigenomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetics</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">genetics</style></keyword><keyword><style face="normal" font="default" size="100%">inheritance</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases (NIAID), National Heart, Lung, and Blood Institute (NHLBI), National</style></keyword><keyword><style face="normal" font="default" size="100%">Institute of Environmental Health Sciences (NIEHS)</style></keyword><keyword><style face="normal" font="default" size="100%">Stock options from Phylaxis,</style></keyword><keyword><style face="normal" font="default" size="100%">IgGenix, Seed Health, ClostraBio, Cour</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory board for Aravax, Consultant for</style></keyword><keyword><style face="normal" font="default" size="100%">Excellergy, and Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Co-founder of IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">National Scientific Committee</style></keyword><keyword><style face="normal" font="default" size="100%">member at Immune Tolerance Network (ITN), and National Institutes of Health (NIH)</style></keyword><keyword><style face="normal" font="default" size="100%">clinical research centers</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific advisor for World Health Organization</style></keyword><keyword><style face="normal" font="default" size="100%">Patents include, &quot;Mixed allergen com-position and methods for using the same,&quot;</style></keyword><keyword><style face="normal" font="default" size="100%">&quot;Granulocyte-based methods for detecting and monitoring immune system disorders,&quot;</style></keyword><keyword><style face="normal" font="default" size="100%">and &quot;Methods and Assays for Detecting and Quantifying Pure Subpopulations of</style></keyword><keyword><style face="normal" font="default" size="100%">White Blood Cells in Immune System Disorders.&quot; PB reports grants from Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, and DBV technologies and honoraria from Prizer, Sanofi, Novartis, ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">DBV technologies, and Astra-Zeneca. JH has no conflicts of interest to declare.</style></keyword><keyword><style face="normal" font="default" size="100%">ESC has received research support from DBV Technologies</style></keyword><keyword><style face="normal" font="default" size="100%">and has been a member of</style></keyword><keyword><style face="normal" font="default" size="100%">advisory boards for Pfizer, Miravo, Medexus, Leo Pharma, Kaleo, DBV, AllerGenis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, Bausch Health, Avir Pharma, AstraZeneca, ALK, Alladapt. In the past, Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Anne K. Ellis has participated in advisory boards for ALK Abello, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Bausch Health, LEO Pharma, Miravo, Merck, Novartis, has been a speaker for ALK</style></keyword><keyword><style face="normal" font="default" size="100%">Abello, AstraZeneca, Bausch, Miravo, Medexus, Mylan, Novartis, Pfizer, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">StallergenesGreer and Regeneron. Her institution has received research grants</style></keyword><keyword><style face="normal" font="default" size="100%">from ALK Abello, Aralez, AstraZeneca, Bayer LLC, Medexus, Novartis, Sanofi, and</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron. She has also served as an independent consultant to Bayer LLC,</style></keyword><keyword><style face="normal" font="default" size="100%">Pharming, and Regeneron. YA reports grants from the Canadian Dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, the Eczema Society of Canada and unrestricted institutional research</style></keyword><keyword><style face="normal" font="default" size="100%">support from Sanofi, AbbVie, Pfizer, Novartis, Leo Pharma, performs clinical</style></keyword><keyword><style face="normal" font="default" size="100%">trials for Leo Pharma and Novartis, and has received speakers&apos; or advisory board</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria from Pfizer, Sun Pharma, Taro, Sanofi, Eli Lilly, Abbvie, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Searchlight Pharma, Leo Pharma, UCB, L&apos;Oreal, Boehringer Ingelheim, Kyowa Kirin,</style></keyword><keyword><style face="normal" font="default" size="100%">Arcutis, Bristol Myers Squibb, Incyte, and Recordati. GHK reports grants from the</style></keyword><keyword><style face="normal" font="default" size="100%">Netherlands Lung Foundation, ZON-MW, Ubbo Emmius Foundation, GSK, Vertex, TEVA</style></keyword><keyword><style face="normal" font="default" size="100%">the Netherlands</style></keyword><keyword><style face="normal" font="default" size="100%">all outside the submitted work. His institution has received</style></keyword><keyword><style face="normal" font="default" size="100%">speakers&apos; honoraria from the exquAIro foundation, Sanofi, Astra-Zeneca, and</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim. MBS is a member of advisory boards for Pfizer, Miravo,</style></keyword><keyword><style face="normal" font="default" size="100%">Medexus, Sanofi, Novartis, and reports speakers honoraria from Novartis, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Medexus, and StallergenesGreer. His institution has received research support</style></keyword><keyword><style face="normal" font="default" size="100%">from Novartis, Sanofi, and DBV Technologies. TE reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Danone/Nutricia/Milupa, grants from DBV, non-financial support from Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from ThermoFisher, personal fees from Aimmune, grants and personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from ALK, non-financial support from MADX, personal fees from EFSA, outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">he is Co-I or scientific lead in three investigator initiated</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy trials supported by the Food Allergy and Anaphylaxis Program</style></keyword><keyword><style face="normal" font="default" size="100%">Sickkids and serve as associate editor for Allergy. he recently was and is acting</style></keyword><keyword><style face="normal" font="default" size="100%">site PI of company sponsored trials by DBV, Novartis and Stallergen. LS, CL, MS,</style></keyword><keyword><style face="normal" font="default" size="100%">BLT, AMM, MBS, AEC, DV, CH, AJS, BFW, AB, AE, AAS, YS, ET, GK, DD, DM, SE, JG,</style></keyword><keyword><style face="normal" font="default" size="100%">VS, BDM, and YL report no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39698764</style></accession-num><abstract><style face="normal" font="default" size="100%">In this review, we provide an overview of food allergy genetics and epigenetics aimed at clinicians and researchers. This includes a brief review of the current understanding of genetic and epigenetic mechanisms, inheritance of food allergy, as well as a discussion of advantages and limitations of the different types of studies in genetic research. We specifically focus on the results of genome-wide association studies in food allergy, which have identified 16 genetic variants that reach genome-wide significance, many of which overlap with other allergic diseases, including asthma, atopic dermatitis, and allergic rhinitis. Identified genes for food allergy are mainly involved in epithelial barrier function (e.g., FLG, SERPINB7) and immune function (e.g., HLA, IL4). Epigenome-wide significant findings at 32 loci are also summarized as well as 14 additional loci with significance at a false discovery of &lt; 1 x 10(-4). Integration of epigenetic and genetic data is discussed in the context of disease mechanisms, many of which are shared with other allergic diseases. The potential utility of genetic and epigenetic discoveries is deliberated. In the future, genetic and epigenetic markers may offer ways to predict the presence or absence of clinical IgE-mediated food allergy among sensitized individuals, likelihood of development of natural tolerance, and response to immunotherapy.</style></abstract><notes><style face="normal" font="default" size="100%">Arnau-Soler, Aleix&#xD;Tremblay, Benedicte L&#xD;Sun, Yidan&#xD;Madore, Anne-Marie&#xD;Simard, Mathieu&#xD;Kersten, Elin T G&#xD;Ghauri, Ahla&#xD;Marenholz, Ingo&#xD;Eiwegger, Thomas&#xD;Simons, Elinor&#xD;Chan, Edmond S&#xD;Nadeau, Kari&#xD;Sampath, Vanitha&#xD;Mazer, Bruce D&#xD;Elliott, Susan&#xD;Hampson, Christine&#xD;Soller, Lianne&#xD;Sandford, Andrew&#xD;Begin, Philippe&#xD;Hui, Jennie&#xD;Wilken, Bethany F&#xD;Gerdts, Jennifer&#xD;Bourkas, Adrienn&#xD;Ellis, Anne K&#xD;Vasileva, Denitsa&#xD;Clarke, Ann&#xD;Eslami, Aida&#xD;Ben-Shoshan, Moshe&#xD;Martino, David&#xD;Daley, Denise&#xD;Koppelman, Gerard H&#xD;Laprise, Catherine&#xD;Lee, Young-Ae&#xD;Asai, Yuka&#xD;eng&#xD;Sanofi/&#xD;Novartis/&#xD;AbbVie Canada/&#xD;CAPMC/CIHR/Canada&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):106-131. doi: 10.1111/all.16429. Epub 2024 Dec 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39698764</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724255</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16429</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2150</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2150</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nemet, S.</style></author><author><style face="normal" font="default" size="100%">Mahlab-Guri, K.</style></author><author><style face="normal" font="default" size="100%">Elbirt, D.</style></author><author><style face="normal" font="default" size="100%">Bezalel-Rosenberg, S.</style></author><author><style face="normal" font="default" size="100%">Asher, I.</style></author><author><style face="normal" font="default" size="100%">Talmon, A.</style></author><author><style face="normal" font="default" size="100%">Rubin, L.</style></author><author><style face="normal" font="default" size="100%">Ribak, Y.</style></author><author><style face="normal" font="default" size="100%">Sergienko, R.</style></author><author><style face="normal" font="default" size="100%">Tal, Y.</style></author><author><style face="normal" font="default" size="100%">Shamriz, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy and Clinical Immunology Unit, Kaplan Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.&#xD;Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.&#xD;Department of Health Policy and Management, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.&#xD;The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Food allergy is associated with increased risk of developing psychological disorders: A nationwide study of 603,257 Israelis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2553-2555</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/05/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Israel/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37254847</style></accession-num><notes><style face="normal" font="default" size="100%">Nemet, Shay&#xD;Mahlab-Guri, Keren&#xD;Elbirt, Daniel&#xD;Bezalel-Rosenberg, Shira&#xD;Asher, Ilan&#xD;Talmon, Aviv&#xD;Rubin, Limor&#xD;Ribak, Yaarit&#xD;Sergienko, Ruslan&#xD;Tal, Yuval&#xD;Shamriz, Oded&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2553-2555. doi: 10.1111/all.15775. Epub 2023 May 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37254847</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15775</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>425</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">425</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sindher, S. B.</style></author><author><style face="normal" font="default" size="100%">Long, A.</style></author><author><style face="normal" font="default" size="100%">Chin, A. R.</style></author><author><style face="normal" font="default" size="100%">Hy, A.</style></author><author><style face="normal" font="default" size="100%">Sampath, V.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Food allergy, mechanisms, diagnosis and treatment: Innovation through a multi-targeted approach</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2937-2948</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/06/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Emollients</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Steroids</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostics</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35730331</style></accession-num><abstract><style face="normal" font="default" size="100%">The incidence of food allergy (FA) has continued to rise over the last several decades, posing significant burdens on health and quality of life. Significant strides into the advancement of FA diagnosis, prevention, and treatment have been made in recent years. In an effort to lower reliance on resource-intensive food challenges, the field has continued work toward the development of highly sensitive and specific assays capable of high-throughput analysis to assist in the diagnosis FA. In looking toward early infancy as a critical period in the development of allergy or acquisition of tolerance, evidence has increasingly suggested that early intervention via the early introduction of food allergens and maintenance of skin barrier function may decrease the risk of FA. As such, large-scale investigations are underway evaluating infant feeding and the impact of emollient and steroid use in infants with dry skin for the prevention of allergy. On the other end of the spectrum, the past few years have been witness to an explosive increase in clinical trials of novel and innovative therapeutic strategies aimed at the treatment of FA in those whom the disease has already manifested. A milestone in the field, 2020 marked the approval of the first drug, oral peanut allergen, for the indication of peanut allergy. With a foundation of promising data supporting the safety and efficacy of single- and multi-allergen oral immunotherapy, current efforts have turned toward the use of probiotics, biologic agents, and modified allergens to optimize and improve upon existing paradigms. Through these advancements, the field hopes to gain footing in the ongoing battle against FA.</style></abstract><notes><style face="normal" font="default" size="100%">Sindher, Sayantani B&#xD;Long, Andrew&#xD;Chin, Andrew R&#xD;Hy, Angela&#xD;Sampath, Vanitha&#xD;Nadeau, Kari C&#xD;Chinthrajah, R Sharon&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):2937-2948. doi: 10.1111/all.15418. Epub 2022 Jul 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35730331</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15418</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>889</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">889</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rodriguez Del Rio, P.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Perea, A.</style></author><author><style face="normal" font="default" size="100%">Blumchen, K.</style></author><author><style face="normal" font="default" size="100%">Caimmi, D.</style></author><author><style face="normal" font="default" size="100%">Caubet, J. C.</style></author><author><style face="normal" font="default" size="100%">Konstantinopoulos, A. P.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Fassio, F.</style></author><author><style face="normal" font="default" size="100%">Karakoc-Aydiner, E.</style></author><author><style face="normal" font="default" size="100%">Le, T. M.</style></author><author><style face="normal" font="default" size="100%">Patel, N.</style></author><author><style face="normal" font="default" size="100%">Savolainen, J.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Ortiz, M.</style></author><author><style face="normal" font="default" size="100%">Alvaro Lozano, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.&#xD;Health Research Institute Princesa, Madrid, Spain.&#xD;ARADyALRD16/0006/0026, Madrid, Spain.&#xD;Allergy Service, Hospital General Universitario Gregorio Maranon, Madrid, Spain.&#xD;Gregorio Maranon Health Research Institute, Madrid, Spain.&#xD;Department of Children and Adolescent Medicine, Division of Allergology, Pneumology and Cystic Fibrosis, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.&#xD;Department of Pulmonology, Division of Allergy, Arnaud de Villeneuve Hospital, University Hospital of Montpellier, Univ Montpellier, Montpellier, France.&#xD;UMR-S 1136, INSERM-Sorbonne Universite, Equipe EPAR - IPLESP, Paris, France.&#xD;Geneva University Hospital, Geneva, Switzerland.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Allergy, Immunology and Rheumatology Division, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Institut de Recerca Sant Joan de Deu, Barcelona, Spain.&#xD;Allergy and Clinical Immunology Unit, Ospedale San Giovanni di Dio, Azienda USL Toscana Centro, Florence, Italy.&#xD;Division of Pediatric Allergy and Immunology, Marmara University, Istanbul, Turkey.&#xD;Department of Dermatology/Allergology, University Medical Centre Utrecht, University Utrecht, Utrecht, The Netherlands.&#xD;Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Pulmonary Disease and Clinical Allergology, University of Turku and Turku University Hospital, Turku, Finland.&#xD;Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Deu, Barcelona, Spain.&#xD;Universitat de Barcelona, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Food immunotherapy practice: Nation differences across Europe, the FIND project</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">920-932</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/07/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">egg</style></keyword><keyword><style face="normal" font="default" size="100%">food immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">milk</style></keyword><keyword><style face="normal" font="default" size="100%">peanut</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34289131</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food allergen immunotherapy (FA-AIT) practice is known to vary globally. This project aims to identify and characterize European centres performing FA-AIT. METHODS: An EAACI task force conducted an online survey to gather relevant information regarding FA-AIT practice and setting-specific resources after reviewing the published literature and congress abstracts throughout Europe. RESULTS: We identified 102 FA-AIT centres in 18 countries; only Spain (n = 39) and France (n = 16) had &gt;/=10 such centres. Overall, most facilities were hospital-based (77.5%), publicly funded (80.4%) and delivered FA-AIT as routine clinical care (80.4%). On average, departments had 3 allergists/paediatric allergists and 2 nurses. Surveyed centres had provided FA-AIT for a median of 9 years [1-24] to a median of 105 [5-2415] patients. The estimated total number of treated patients was 24875, of whom 41.3% received AIT for milk, 34.2% egg, 12.8% peanut and 11.7% other foods. Anaphylaxis to AIT doses requiring over 4-6 h of observation was reported by 70.6% of centres, ICU admissions by 10.8% and eosinophilic esophagitis by 45.1%. Quality of life and sustained unresponsiveness were evaluated in 20.6% and 54.9% of centres, respectively. The main contraindications for food AIT were severe asthma (57%-63%), eosinophilic esophagitis (56%-48%) and age below 5 years (47%-41%). CONCLUSIONS: In Europe, FA-AIT is provided mostly in clinical practice. Significant variation is seen in the number of centres per country, facility characteristics and inclusion/exclusion criteria, and in certain aspects of protocols. Potential inequality in access to AIT has been identified as well as the need for education and guidance for treatment standardization.</style></abstract><notes><style face="normal" font="default" size="100%">Rodriguez Del Rio, Pablo&#xD;Alvarez-Perea, Alberto&#xD;Blumchen, Katharina&#xD;Caimmi, Davide&#xD;Caubet, Jean Christoph&#xD;Konstantinopoulos, Anastasios Panagiotis&#xD;Riggioni, Carmen&#xD;Fassio, Filippo&#xD;Karakoc-Aydiner, Elif&#xD;Le, Thuy May&#xD;Patel, Nandinee&#xD;Savolainen, Johannes&#xD;Vazquez-Ortiz, Marta&#xD;Alvaro Lozano, Montserrat&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):920-932. doi: 10.1111/all.15016. Epub 2021 Aug 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34289131</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15016</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1240</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1240</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sanchez-Lopez, J.</style></author><author><style face="normal" font="default" size="100%">Araujo, G.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">Garcia-Moral, A.</style></author><author><style face="normal" font="default" size="100%">Casas-Saucedo, R.</style></author><author><style face="normal" font="default" size="100%">Guilarte, M.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Picado, C.</style></author><author><style face="normal" font="default" size="100%">Pascal, M.</style></author><author><style face="normal" font="default" size="100%">Munoz-Cano, R.</style></author><author><style face="normal" font="default" size="100%">Bartra, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonology and Respiratory Allergy, Allergy Section, Hospital Clinic Barcelona, Barcelona, Spain.&#xD;Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.&#xD;Department of Internal medicine, Allergy Section, Hospital Universitari Vall d&apos;Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.&#xD;Vall d&apos;Hebron Research Institute, Allergy Research Unit, Barcelona, Spain.&#xD;Spanish Network for Allergy-RETIC de Asma, Reacciones adversas y Alergicas (ARADyAL), Madrid, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;CIBERES, CIBER of Respiratory Diseases, Madrid, Spain.&#xD;Immunology Department, Centre de Diagnostic Biomedic (CDB), Hospital Clinic de Barcelona, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Food-dependent NSAID-induced hypersensitivity (FDNIH) reactions: Unraveling the clinical features and risk factors</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1480-1492</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/12/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">non-steroidal anti-inflammatory drug</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33289951</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In up to 70%-80% of patients with a suspected non-steroidal anti-inflammatory drug hypersensitivity (NSAIDH), challenge tests with the culprit drug yield negative results. On the other hand, there could be a NSAIDH overdiagnosis when anaphylaxis is the clinical manifestation. We hypothesize that some negative NSAID challenge tests and an overdiagnosis of NSAIDH occur in patients with food-dependent NSAID-induced hypersensitivity (FDNIH). METHODS: We studied 328 patients with a suspected acute NSAIDH. FDNIH was diagnosed in patients meeting all the following: (1) tolerance to the food ingested more temporally closed before the reaction, later the episode, (2) respiratory or cutaneous symptoms or anaphylaxis related to NSAID, (3) positive skin prick test to foods and/or specific IgE to food allergens (Pru p 3, Tri a 19, Pen a 1) involved in the reaction, and (4) negative oral provocation test to the culprit NSAID. RESULTS: 199 patients (60%) were diagnosed with NSAIDH and 52 (16%) with FDNIH. Pru p 3 was involved in 44 cases (84.6%) and Tri a 19 in 6 cases (11%). FDNIH subjects were younger (p &lt; .001), with a higher prevalence of rhinitis (p &lt; .001) and previous food allergy (p &lt; .001), together with a higher proportion of subjects sensitized to pollens (p &lt; .001) and foods (p &lt; .001). Using just four variables (Pru p 3 sensitization, Tri a 19 sensitization, anaphylaxis, and any NSAID different from pyrazolones), 95.3% of cases were correctly classified, with a sensitivity of 92% and specificity of 96%. CONCLUSION: Evaluation of FDNIH should be included in the diagnostic workup of NSAIDH.</style></abstract><notes><style face="normal" font="default" size="100%">Sanchez-Lopez, Jaime&#xD;Araujo, Giovanna&#xD;Cardona, Victoria&#xD;Garcia-Moral, Alba&#xD;Casas-Saucedo, Rocio&#xD;Guilarte, Mar&#xD;Torres, Maria Jose&#xD;Dona, Inmaculada&#xD;Picado, Cesar&#xD;Pascal, Mariona&#xD;Munoz-Cano, Rosa&#xD;Bartra, Joan&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1480-1492. doi: 10.1111/all.14689. Epub 2020 Dec 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33289951</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14689</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2755</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2755</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pouessel, G.</style></author><author><style face="normal" font="default" size="100%">Divaret-Chauveau, A.</style></author><author><style face="normal" font="default" size="100%">Beaumont, P.</style></author><author><style face="normal" font="default" size="100%">Bradatan, E.</style></author><author><style face="normal" font="default" size="100%">Dumond, P.</style></author><author><style face="normal" font="default" size="100%">Karaca-Altintas, Y.</style></author><author><style face="normal" font="default" size="100%">Metz-Favre, C.</style></author><author><style face="normal" font="default" size="100%">Delalande, D.</style></author><author><style face="normal" font="default" size="100%">Correard, A. K.</style></author><author><style face="normal" font="default" size="100%">Tscheiller, S.</style></author><author><style face="normal" font="default" size="100%">Van der Brempt, X.</style></author><author><style face="normal" font="default" size="100%">Braun, C.</style></author><author><style face="normal" font="default" size="100%">Sabouraud-Leclerc, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CH Roubaix, Department of Pediatrics, Children&apos;s Hospital, Roubaix, France.&#xD;CHU Lille, Pediatric Pulmonology and Allergy Department, Pole Enfant, Hopital Jeanne de Flandre, Lille, France.&#xD;Univ Lille, ULR 2694: METRICS, Lille, France.&#xD;Allergy-Vigilance Network, Vandoeuvre-les-Nancy, France.&#xD;Paediatric Allergology, Children&apos;s Medicine, CHRU, Vandoeuvre-les-Nancy, France.&#xD;UR 3450 DevAH, Health Faculty, University of Lorraine, Vandoeuvre les Nancy, France.&#xD;Medical Office, Saint Maur des Fosses, France.&#xD;Department of Paediatrics, CHRU, Namur, Belgium.&#xD;Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.&#xD;Department of Pneumology and Allergology, Strasbourg University Hospital, Strasbourg, France.&#xD;Departement of Pediatrics, Centre Hospitalier Intercommunal de Creteil, Creteil, France.&#xD;Pediatric Pulmonology and Allergology Department, Pediatric Cystic Fibrosis Center, Hopital Femme Mere Enfant, Hospices Civils de Lyon, Bron, France.&#xD;Allergopole, Clinique Saint-Luc, Bouge (Namur), Belgium.&#xD;Centre International de Recherche en Infectiologie, INSERM U1111, Lyon, France.&#xD;Department of pediatrics, CHU de Reims, Reims, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Food-Induced Anaphylaxis Reactions at School: A Room for Improvement</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1132-1136</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">adrenaline auto-injector</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">individual healthcare plan</style></keyword><keyword><style face="normal" font="default" size="100%">school</style></keyword><keyword><style face="normal" font="default" size="100%">Bausch+Lomb, Stallergenes, Novartis, DVB technology, ALK-Abello</style></keyword><keyword><style face="normal" font="default" size="100%">serves as a</style></keyword><keyword><style face="normal" font="default" size="100%">medical consultant/advisor for Bioprojet, Theravia.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39660917</style></accession-num><notes><style face="normal" font="default" size="100%">Pouessel, Guillaume&#xD;Divaret-Chauveau, Amandine&#xD;Beaumont, Pascale&#xD;Bradatan, Elena&#xD;Dumond, Pascale&#xD;Karaca-Altintas, Yasemin&#xD;Metz-Favre, Carine&#xD;Delalande, Delphine&#xD;Correard, Anne-Karine&#xD;Tscheiller, Selina&#xD;Van der Brempt, Xavier&#xD;Braun, Camille&#xD;Sabouraud-Leclerc, Dominique&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1132-1136. doi: 10.1111/all.16427. Epub 2024 Dec 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39660917</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969322</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16427</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2248</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2248</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koken, G.</style></author><author><style face="normal" font="default" size="100%">Ertoy Karagol, H. I.</style></author><author><style face="normal" font="default" size="100%">Polat Terece, S.</style></author><author><style face="normal" font="default" size="100%">Cavdar, Z.</style></author><author><style face="normal" font="default" size="100%">Cetin, K.</style></author><author><style face="normal" font="default" size="100%">Egritas Gurkan, O.</style></author><author><style face="normal" font="default" size="100%">Sari, S.</style></author><author><style face="normal" font="default" size="100%">Dalgic, B.</style></author><author><style face="normal" font="default" size="100%">Bakirtas, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Allergy, Gazi University Faculty of Medicine, Ankara, Turkey.&#xD;Gazi University Pediatric Eosinophilic Gastrointestinal Diseases Working Group, Ankara, Turkey.&#xD;Department of Pediatric Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Food-induced immediate response of the esophagus in pediatric eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3235-3240</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/09/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Deglutition Disorders/etiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/complications/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">*Fluorocarbons</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis (EoE)</style></keyword><keyword><style face="normal" font="default" size="100%">food-induced immediate response of the esophagus (FIRE)</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">pollen-food allergy syndrome (PFAS)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37701950</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food-induced immediate response of the esophagus (FIRE) is a new phenomenon that has been described in eosinophilic esophagitis (EoE) patients. It is suspected when unpleasant symptoms occur suddenly on contact of the triggering food with the esophageal surface and recur with repeated exposures. It can often be mistaken for pollen-food allergy syndrome (PFAS) and solid food dysphagia. Data on FIRE is limited to one survey study and case reports, and there are no screening studies conducted on either adults or children with EoE. In this study, we aimed to screen children aged &gt;/=7 years old with EoE for FIRE. METHODS: Demographic data were collected from medical records. A questionnaire about FIRE was applied to all participants. Skin prick tests were done on suspected patients to identify the triggering foods. FIRE is defined as suitable clinical symptoms with suspected food allergen exposure. RESULTS: A total of 78 patients (74.4% male, median age: 13.5 years) were included. Unpleasant and recurrent symptoms distinct from dysphagia with specific foods were reported in 16.7% of the patients, all of whom had concomitant allergic rhinitis (AR). The symptoms described by almost all patients were oropharyngeal itching and tingling (PFAS: 15.3%) excluding only one patient reporting retrosternal narrowing and pressure after specific food consumption (FIRE: 1.2%). CONCLUSIONS: Although definitive conclusions regarding the true prevalence of FIRE cannot be made, it does not seem to be common as PFAS. However, it deserves questioning particularly in the presence of concurrent AR and/or PFAS in children with EoE.</style></abstract><notes><style face="normal" font="default" size="100%">Koken, Gizem&#xD;Ertoy Karagol, Hacer Ilbilge&#xD;Polat Terece, Sinem&#xD;Cavdar, Zeynep&#xD;Cetin, Kenan&#xD;Egritas Gurkan, Odul&#xD;Sari, Sinan&#xD;Dalgic, Buket&#xD;Bakirtas, Arzu&#xD;eng&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3235-3240. doi: 10.1111/all.15881. Epub 2023 Sep 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37701950</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15881</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1399</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1399</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Biedermann, L.</style></author><author><style face="normal" font="default" size="100%">Holbreich, M.</style></author><author><style face="normal" font="default" size="100%">Atkins, D.</style></author><author><style face="normal" font="default" size="100%">Chehade, M.</style></author><author><style face="normal" font="default" size="100%">Dellon, E. S.</style></author><author><style face="normal" font="default" size="100%">Furuta, G. T.</style></author><author><style face="normal" font="default" size="100%">Hirano, I.</style></author><author><style face="normal" font="default" size="100%">Gonsalves, N.</style></author><author><style face="normal" font="default" size="100%">Greuter, T.</style></author><author><style face="normal" font="default" size="100%">Gupta, S.</style></author><author><style face="normal" font="default" size="100%">Katzka, D. A.</style></author><author><style face="normal" font="default" size="100%">De Rooij, W.</style></author><author><style face="normal" font="default" size="100%">Safroneeva, E.</style></author><author><style face="normal" font="default" size="100%">Schoepfer, A.</style></author><author><style face="normal" font="default" size="100%">Schreiner, P.</style></author><author><style face="normal" font="default" size="100%">Simon, D.</style></author><author><style face="normal" font="default" size="100%">Simon, H. U.</style></author><author><style face="normal" font="default" size="100%">Warners, M.</style></author><author><style face="normal" font="default" size="100%">Bredenoord, A. J.</style></author><author><style face="normal" font="default" size="100%">Straumann, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Allergy and Asthma Consultant, Indianapolis, IN, USA.&#xD;Children&apos;s Hospital Colorado Anschutz Medical Campus Aurora, Aurora, CO, USA.&#xD;Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Divison of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.&#xD;Digestive Health Institute, Children&apos;s Hospital Colorado, Gastrointestinal Eosinophilic Diseases Program, University of Colorado School of Medicine, Aurora, CO, USA.&#xD;Feinberg School of Medicine, Nothwestern University, Chicago, IL, USA.&#xD;Department of Pediatrics, University of Illinois, Peoria, IL, USA.&#xD;Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.&#xD;Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands.&#xD;Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.&#xD;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.&#xD;Department of Dermatology, University Hospital Inselspital Bern, Bern, Switzerland.&#xD;Institute of Pharmacology, University of Bern, Bern, Switzerland.&#xD;Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Food-induced immediate response of the esophagus-A newly identified syndrome in patients with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">339-347</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Food/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">clinical symptoms</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis (EoE)</style></keyword><keyword><style face="normal" font="default" size="100%">food-induced immediate response of the esophagus (FIRE)</style></keyword><keyword><style face="normal" font="default" size="100%">immediate response</style></keyword><keyword><style face="normal" font="default" size="100%">oral allergy syndrome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32662110</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dysphagia is the main symptom of adult eosinophilic esophagitis (EoE). We describe a novel syndrome, referred to as &quot;food-induced immediate response of the esophagus&quot; (FIRE), observed in EoE patients. METHODS: Food-induced immediate response of the esophagus is an unpleasant/painful sensation, unrelated to dysphagia, occurring immediately after esophageal contact with specific foods. Eosinophilic esophagitis experts were surveyed to estimate the prevalence of FIRE, characterize symptoms, and identify food triggers. We also surveyed a large group of EoE patients enrolled in the Swiss EoE Cohort Study for FIRE. RESULTS: Response rates were 82% (47/57) for the expert and 65% (239/368) for the patient survey, respectively. Almost, 90% of EoE experts had observed the FIRE symptom complex in their patients. Forty percent of EoE patients reported experiencing FIRE, more commonly in patients who developed EoE symptoms at a younger age (mean age of 46.4 years vs 54.1 years without FIRE; P &lt; .01) and in those with high allergic comorbidity. Food-induced immediate response of the esophagus symptoms included narrowing, burning, choking, and pressure in the esophagus appearing within 5 minutes of ingesting a provoking food that lasted less than 2 hours. Symptom severity rated a median 7 points on a visual analogue scale from 1 to 10. Fresh fruits/vegetables and wine were the most frequent triggers. Endoscopic food removal was significantly more commonly reported in male patients with vs without FIRE (44.3% vs 27.6%; P = .03). CONCLUSIONS: Food-induced immediate response of the esophagus is a novel syndrome frequently reported in EoE patients, characterized by an intense, unpleasant/painful sensation occurring rapidly and reproducibly in 40% of surveyed EoE patients after esophageal contact with specific foods.</style></abstract><notes><style face="normal" font="default" size="100%">Biedermann, Luc&#xD;Holbreich, Mark&#xD;Atkins, Dan&#xD;Chehade, Mirna&#xD;Dellon, Evan S&#xD;Furuta, Glenn T&#xD;Hirano, Ikuo&#xD;Gonsalves, Nirmala&#xD;Greuter, Thomas&#xD;Gupta, Sandeep&#xD;Katzka, David A&#xD;De Rooij, Willemijn&#xD;Safroneeva, Ekaterina&#xD;Schoepfer, Alain&#xD;Schreiner, Philipp&#xD;Simon, Dagmar&#xD;Simon, Hans Uwe&#xD;Warners, Marijn&#xD;Bredenoord, Albert-Jan&#xD;Straumann, Alex&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):339-347. doi: 10.1111/all.14495. Epub 2020 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32662110</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14495</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>630</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">630</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Votto, M.</style></author><author><style face="normal" font="default" size="100%">Naso, M.</style></author><author><style face="normal" font="default" size="100%">De Filippo, M.</style></author><author><style face="normal" font="default" size="100%">Marseglia, A.</style></author><author><style face="normal" font="default" size="100%">Raffaele, A.</style></author><author><style face="normal" font="default" size="100%">Marseglia, G. L.</style></author><author><style face="normal" font="default" size="100%">Licari, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.&#xD;Pediatric Surgery Unit, Department of Maternal and Child Health, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.&#xD;Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Food-induced immediate response of the esophagus: A first report in the pediatric age</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">711-712</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/01/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Food/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">food-induced immediate response of the esophagus</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35094402</style></accession-num><notes><style face="normal" font="default" size="100%">Votto, Martina&#xD;Naso, Matteo&#xD;De Filippo, Maria&#xD;Marseglia, Alessia&#xD;Raffaele, Alessandro&#xD;Marseglia, Gian Luigi&#xD;Licari, Amelia&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):711-712. doi: 10.1111/all.15088.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35094402</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15088</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>887</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">887</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rondeau, L. E.</style></author><author><style face="normal" font="default" size="100%">De Palma, G.</style></author><author><style face="normal" font="default" size="100%">Caminero, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton Health Sciences, McMaster University Medical Center, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The food, the bug, and the ugly: A recipe for food-induced gut pain</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">334-336</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/07/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">Food/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Pain</style></keyword><keyword><style face="normal" font="default" size="100%">enteric infection</style></keyword><keyword><style face="normal" font="default" size="100%">food intolerance</style></keyword><keyword><style face="normal" font="default" size="100%">irritable bowel syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">visceral hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34293818</style></accession-num><notes><style face="normal" font="default" size="100%">Rondeau, Liam Emile&#xD;De Palma, Giada&#xD;Caminero, Alberto&#xD;eng&#xD;CIHR/Canada&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):334-336. doi: 10.1111/all.15018. Epub 2021 Jul 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34293818</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15018</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1883</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1883</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rondeau, L. E.</style></author><author><style face="normal" font="default" size="100%">De Palma, G.</style></author><author><style face="normal" font="default" size="100%">Caminero, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton Health Sciences, McMaster University Medical Center, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The food, the bug, and the ugly: A recipe for food-induced gut pain</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">334-336</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/07/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">Food/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Pain</style></keyword><keyword><style face="normal" font="default" size="100%">enteric infection</style></keyword><keyword><style face="normal" font="default" size="100%">food intolerance</style></keyword><keyword><style face="normal" font="default" size="100%">irritable bowel syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">visceral hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34293818</style></accession-num><notes><style face="normal" font="default" size="100%">Rondeau, Liam Emile&#xD;De Palma, Giada&#xD;Caminero, Alberto&#xD;eng&#xD;CIHR/Canada&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):334-336. doi: 10.1111/all.15018. Epub 2021 Jul 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34293818</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15018</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2575</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2575</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Makra, L.</style></author><author><style face="normal" font="default" size="100%">Coviello, L.</style></author><author><style face="normal" font="default" size="100%">Gobbi, A.</style></author><author><style face="normal" font="default" size="100%">Jurman, G.</style></author><author><style face="normal" font="default" size="100%">Furlanello, C.</style></author><author><style face="normal" font="default" size="100%">Brunato, M.</style></author><author><style face="normal" font="default" size="100%">Ziska, L. H.</style></author><author><style face="normal" font="default" size="100%">Hess, J. J.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Garcia, M. P. P.</style></author><author><style face="normal" font="default" size="100%">Tusnady, G.</style></author><author><style face="normal" font="default" size="100%">Czibolya, L.</style></author><author><style face="normal" font="default" size="100%">Ihasz, I.</style></author><author><style face="normal" font="default" size="100%">Deak, A. J.</style></author><author><style face="normal" font="default" size="100%">Miko, E.</style></author><author><style face="normal" font="default" size="100%">Dorner, Z.</style></author><author><style face="normal" font="default" size="100%">Harry, S. K.</style></author><author><style face="normal" font="default" size="100%">Bruffaerts, N.</style></author><author><style face="normal" font="default" size="100%">Packeu, A.</style></author><author><style face="normal" font="default" size="100%">Saarto, A.</style></author><author><style face="normal" font="default" size="100%">Toiviainen, L.</style></author><author><style face="normal" font="default" size="100%">Louna-Korteniemi, M.</style></author><author><style face="normal" font="default" size="100%">Patsi, S.</style></author><author><style face="normal" font="default" size="100%">Thibaudon, M.</style></author><author><style face="normal" font="default" size="100%">Oliver, G.</style></author><author><style face="normal" font="default" size="100%">Charalampopoulos, A.</style></author><author><style face="normal" font="default" size="100%">Vokou, D.</style></author><author><style face="normal" font="default" size="100%">Przedpelska-Wasowicz, E. M.</style></author><author><style face="normal" font="default" size="100%">Guethjohnsen, E. R.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Celenk, S.</style></author><author><style face="normal" font="default" size="100%">Ozaslan, C.</style></author><author><style face="normal" font="default" size="100%">Oh, J. W.</style></author><author><style face="normal" font="default" size="100%">Sullivan, K.</style></author><author><style face="normal" font="default" size="100%">Ford, L.</style></author><author><style face="normal" font="default" size="100%">Kelly, M.</style></author><author><style face="normal" font="default" size="100%">Levetin, E.</style></author><author><style face="normal" font="default" size="100%">Myszkowska, D.</style></author><author><style face="normal" font="default" size="100%">Severova, E.</style></author><author><style face="normal" font="default" size="100%">Gehrig, R.</style></author><author><style face="normal" font="default" size="100%">Calderon-Ezquerro, M. D. C.</style></author><author><style face="normal" font="default" size="100%">Guerra, C. G.</style></author><author><style face="normal" font="default" size="100%">Leiva-Guzman, M. A.</style></author><author><style face="normal" font="default" size="100%">Ramon, G. D.</style></author><author><style face="normal" font="default" size="100%">Barrionuevo, L. B.</style></author><author><style face="normal" font="default" size="100%">Peter, J.</style></author><author><style face="normal" font="default" size="100%">Berman, D.</style></author><author><style face="normal" font="default" size="100%">Katelaris, C. H.</style></author><author><style face="normal" font="default" size="100%">Davies, J. M.</style></author><author><style face="normal" font="default" size="100%">Burton, P.</style></author><author><style face="normal" font="default" size="100%">Beggs, P. J.</style></author><author><style face="normal" font="default" size="100%">Vergamini, S. M.</style></author><author><style face="normal" font="default" size="100%">Valencia-Barrera, R. M.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Economics and Rural Development, Faculty of Agriculture, University of Szeged, Hodmezovasarhely, Hungary.&#xD;University of Trento, Trento, Italy.&#xD;Enogis s.r.l., Trento, Italy.&#xD;Bruno Kessler Foundation, Trento, Italy.&#xD;HK3 Lab, Rovereto, Italy.&#xD;LIGHT Center, Brescia, Italy.&#xD;Department of Information Engineering and Computer Science, University of Trento, Trento, Italy.&#xD;Mailman School of Public Health, Columbia University, New York, New York, USA.&#xD;Department of Global Health, University of Washington, Seattle, State of Washington, USA.&#xD;Department of Ecology, School of Biology, Faculty of Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Environmental Medicine, Faculty of Medicine, University Clinic of Augsburg &amp; University of Augsburg, Augsburg, Germany.&#xD;Alfred Renyi Institute of Mathematics, Budapest, Hungary.&#xD;Hungarian Meteorological Service, Budapest, Hungary.&#xD;Institute of Animal Science and Wildlife Management, Faculty of Agriculture, University of Szeged, Hodmezovasarhely, Hungary.&#xD;Department of Integrated Plant Protection, Hungarian University of Agriculture and Life Science (MATE) (former SZIE), Plant Protection Institute, Godollo, Hungary.&#xD;Department of Veterinary Medicine, University of Alaska Fairbanks, Fairbanks, Alaska, USA.&#xD;Mycology &amp; Aerobiology Service, Brussels, Belgium.&#xD;Biodiversity Unit, University of Turku, Turku, Finland.&#xD;Reseau National de Surveillance Aerobiologique, Brussieu, France.&#xD;Icelandic Institute of Natural History, Garethabaer, Iceland.&#xD;Department of Hygiene and Health Prevention, ATS (Agency for Health Protection of Metropolitan Area of Milan), Hygiene and Public Health Service, Milan, Italy.&#xD;Science and Art Faculty, Biology Department, Aerobiology Laboratory, Uludag University, Bursa, Turkey.&#xD;Department of Plant Protection (Weed Science), Dicle University, Diyarbakir, Turkey.&#xD;Department of Pediatrics &amp; Adolescent, College of Medicine, Hanyang University, Medical Center, Guri Hospital, Seoul, South Korea.&#xD;Clinical Research Institute, Minneapolis, Minnesota, USA.&#xD;Asthma and Allergy Center, Bellevue, Nebraska, USA.&#xD;University of Tulsa, College of Engineering &amp; Natural Sciences, Department of Biological Science, Tulsa, Oklahoma, USA.&#xD;Jagiellonian University, Medical College, Department of Clinical and Environmental Allergology, Krakow, Poland.&#xD;Biological Faculty, Lomonosov Moscow State University, Moscow, Russia.&#xD;Federal Department of Home Affairs FDHA, Federal Office of Meteorology and Climatology MeteoSwiss, Zurich-Airport, Switzerland.&#xD;Centro de Ciencias de la Atmosfera, Universidad Nacional Autonoma de Mexico (UNAM), Circuito Exterior, Ciudad Universitaria, Mexico, Mexico.&#xD;Departamento de Quimica, Facultad de Ciencias, Universidad de Chile, Santiago, Chile.&#xD;Hospital Italiano Regional del Sur, Bahia Blanca, Argentina.&#xD;Instituto de Alergia e Inmunologia del Sur, AAAeIC Pollen Station, Bahia Blanca, Argentina.&#xD;Department of Medicine, Division of Allergy and Clinical Immunology, Groote Schuur Hospital, University of Cape Town, Groote Schuur, South Africa.&#xD;Allergy Immunology Department, University of Cape Town Lung Institute, Cape Town, South Africa.&#xD;Western Sydney University and Campbelltown Hospital, Campbelltown, New South Wales, Australia.&#xD;School of Biomedical Science, Queensland University of Technology, Herston, Queensland, Australia.&#xD;Office of Research, Metro North Hospital and Health Service, Herston, Queensland, Australia.&#xD;Department of Medicine, Immunology and Allergy, Campbelltown Hospital, Campbelltown, New South Wales, Australia.&#xD;School of Natural Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, New South Wales, Australia.&#xD;Centro de Ciencias Biologicas e da Saude, Museu de Ciencias Naturais, University of Caxias do Sul, Caxias do Sul, Brazil.&#xD;Departamento de Biologia Vegetal, Universidad de Leon, Leon, Spain.&#xD;Chair of Environmental Medicine, Technical University of Munich, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Centre, Munich, Augsburg, Germany.&#xD;Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Forecasting daily total pollen concentrations on a global scale</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2173-2185</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/07/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Forecasting/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Climate Change</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Theoretical</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Monitoring/methods</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">artificial intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">environmental variables</style></keyword><keyword><style face="normal" font="default" size="100%">feature importance cluster</style></keyword><keyword><style face="normal" font="default" size="100%">pollen forecast</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38995241</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: There is evidence that global anthropogenic climate change may be impacting floral phenology and the temporal and spatial characteristics of aero-allergenic pollen. Given the extent of current and future climate uncertainty, there is a need to strengthen predictive pollen forecasts. METHODS: The study aims to use CatBoost (CB) and deep learning (DL) models for predicting the daily total pollen concentration up to 14 days in advance for 23 cities, covering all five continents. The model includes the projected environmental parameters, recent concentrations (1, 2 and 4 weeks), and the past environmental explanatory variables, and their future values. RESULTS: The best pollen forecasts include Mexico City (R(2)(DL_7) approximately .7), and Santiago (R(2)(DL_7) approximately .8) for the 7th forecast day, respectively; while the weakest pollen forecasts are made for Brisbane (R(2)(DL_7) approximately .4) and Seoul (R(2)(DL_7) approximately .1) for the 7th forecast day. The global order of the five most important environmental variables in determining the daily total pollen concentrations is, in decreasing order: the past daily total pollen concentration, future 2 m temperature, past 2 m temperature, past soil temperature in 28-100 cm depth, and past soil temperature in 0-7 cm depth. City-related clusters of the most similar distribution of feature importance values of the environmental variables only slightly change on consecutive forecast days for Caxias do Sul, Cape Town, Brisbane, and Mexico City, while they often change for Sydney, Santiago, and Busan. CONCLUSIONS: This new knowledge of the ecological relationships of the most remarkable variables importance for pollen forecast models according to clusters, cities and forecast days is important for developing and improving the accuracy of airborne pollen forecasts.</style></abstract><notes><style face="normal" font="default" size="100%">Makra, Laszlo&#xD;Coviello, Luca&#xD;Gobbi, Andrea&#xD;Jurman, Giuseppe&#xD;Furlanello, Cesare&#xD;Brunato, Mauro&#xD;Ziska, Lewis H&#xD;Hess, Jeremy J&#xD;Damialis, Athanasios&#xD;Garcia, Maria Pilar Plaza&#xD;Tusnady, Gabor&#xD;Czibolya, Lilit&#xD;Ihasz, Istvan&#xD;Deak, Aron Jozsef&#xD;Miko, Edit&#xD;Dorner, Zita&#xD;Harry, Susan K&#xD;Bruffaerts, Nicolas&#xD;Packeu, Ann&#xD;Saarto, Annika&#xD;Toiviainen, Linnea&#xD;Louna-Korteniemi, Maria&#xD;Patsi, Sanna&#xD;Thibaudon, Michel&#xD;Oliver, Gilles&#xD;Charalampopoulos, Athanasios&#xD;Vokou, Despoina&#xD;Przedpelska-Wasowicz, Ewa Maria&#xD;Guethjohnsen, Elly Renee&#xD;Bonini, Maira&#xD;Celenk, Sevcan&#xD;Ozaslan, Cumali&#xD;Oh, Jae-Won&#xD;Sullivan, Krista&#xD;Ford, Linda&#xD;Kelly, Michelle&#xD;Levetin, Estelle&#xD;Myszkowska, Dorota&#xD;Severova, Elena&#xD;Gehrig, Regula&#xD;Calderon-Ezquerro, Maria Del Carmen&#xD;Guerra, Cesar Guerrero&#xD;Leiva-Guzman, Manuel Andres&#xD;Ramon, German Dario&#xD;Barrionuevo, Laura Beatriz&#xD;Peter, Jonny&#xD;Berman, Dilys&#xD;Katelaris, Connie H&#xD;Davies, Janet M&#xD;Burton, Pamela&#xD;Beggs, Paul J&#xD;Vergamini, Sandra Maria&#xD;Valencia-Barrera, Rosa Maria&#xD;Traidl-Hoffmann, Claudia&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2173-2185. doi: 10.1111/all.16227. Epub 2024 Jul 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38995241</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16227</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3139</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3139</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chiang, S.</style></author><author><style face="normal" font="default" size="100%">Jung, Y. S.</style></author><author><style face="normal" font="default" size="100%">Thorley, W.</style></author><author><style face="normal" font="default" size="100%">Yu, S.</style></author><author><style face="normal" font="default" size="100%">Banerjee, M.</style></author><author><style face="normal" font="default" size="100%">Rowe, E.</style></author><author><style face="normal" font="default" size="100%">Zou, J.</style></author><author><style face="normal" font="default" size="100%">Mejia, J.</style></author><author><style face="normal" font="default" size="100%">Peveri, E.</style></author><author><style face="normal" font="default" size="100%">Sumit, A.</style></author><author><style face="normal" font="default" size="100%">Bergmark, R.</style></author><author><style face="normal" font="default" size="100%">Maxfield, A.</style></author><author><style face="normal" font="default" size="100%">Roditi, R.</style></author><author><style face="normal" font="default" size="100%">Sampath, V.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Lee, S. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Otolaryngology-Head and Neck Surgery, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Tufts University School of Medicine, Boston, Massachusetts, USA.&#xD;Elson S. Floyd College of Medicine, Washington State University, Spokane, Massachusetts, USA.&#xD;University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.&#xD;Center for Surgery and Public Health, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Brown University, Providence, Rhode Island, USA.&#xD;University of Cincinnati, Cincinnati, Ohio, USA.&#xD;Division of Allergy and Inflammation, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Forever Chemicals: An Exploratory, Population-Based Analysis of Per- and Polyfluoroalkyl Substances Exposure and Effects on Sinonasal Health</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">alkanesulfonic acids</style></keyword><keyword><style face="normal" font="default" size="100%">environmental exposure</style></keyword><keyword><style face="normal" font="default" size="100%">fluorocarbons</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition surveys</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">smell</style></keyword><keyword><style face="normal" font="default" size="100%">sulfonic acids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41070772</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Per- and Polyfluoroalkyl Substances (PFAS) are widely used chemicals, notably in nonstick coatings, fire-fighting foams and equipment, and surfactants. These chemicals degrade slowly and accumulate in tissues and the environment, being detected in water, air, wildlife, and soil across the world. Initial studies have shown that these chemicals are associated with harmful health effects, but research in this area remains limited, especially in sinonasal diseases. METHODS: The National Health and Nutrition Examination Survey (NHANES) 2011-2014 was used to analyze the association between PFAS and taste and smell survey among adults (age &gt;/= 40) with complete data (n = 1911). The survey included self-reported sinonasal symptoms. Multivariable logistic regression adjusted for covariates was used to describe the relationship between serum PFAS concentrations and sinonasal health. Bayesian kernel machine regression (BKMR) was performed to consider the diverse chemical properties of PFAS and how real-life exposures involve multiple types of PFAS. RESULTS: The logistic regression model found that serum PFAS levels were not significantly associated with sinonasal health outcomes, except serum Me-PFOSA-AcOH (OR: 1.164; 95% CI: 1.020-1.308), which significantly increased the likelihood of reporting frequent nasal congestion in the past 12 months. The BKMR model identified exposure-response relationships on olfaction of Me-FPOSA-AcOH and PFHxS becoming more pronounced as the concentration of PFNA within the mixture increased. CONCLUSION: Our results explore potential relationships between PFAS and adverse sinonasal health effects. Exposure to Me-PFOSA-AcOH may be related to frequent nasal congestion, while other PFAS may have complex, mixture-dependent effects on olfaction.</style></abstract><notes><style face="normal" font="default" size="100%">Chiang, Simon&#xD;Jung, Youn Soo&#xD;Thorley, William&#xD;Yu, Sophie&#xD;Banerjee, Mitali&#xD;Rowe, Evelyn&#xD;Zou, Jonathan&#xD;Mejia, Jesus&#xD;Peveri, Emilio&#xD;Sumit, Advika&#xD;Bergmark, Regan&#xD;Maxfield, Alice&#xD;Roditi, Rachel&#xD;Sampath, Vanitha&#xD;Nadeau, Kari&#xD;Lee, Stella E&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Oct 10. doi: 10.1111/all.70092.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41070772</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70092</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>687</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">687</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author><author><style face="normal" font="default" size="100%">Novak, N.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Research Institute Hospital 12 de Octubre, Madrid, Spain.&#xD;Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The form of PEG matters: PEG conjugated with lipids and not PEG alone could be the specific form involved in allergic reactions to COVID-19 vaccines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1658-1660</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/11/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Lipids</style></keyword><keyword><style face="normal" font="default" size="100%">Polyethylene Glycols/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34816455</style></accession-num><notes><style face="normal" font="default" size="100%">Cabanillas, Beatriz&#xD;Novak, Natalija&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1658-1660. doi: 10.1111/all.15187.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34816455</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15187</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2353</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2353</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kwon, Y.</style></author><author><style face="normal" font="default" size="100%">Kang, Y. J.</style></author><author><style face="normal" font="default" size="100%">Kwon, J.</style></author><author><style face="normal" font="default" size="100%">Cho, S. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, J.</style></author><author><style face="normal" font="default" size="100%">Le, T. T.</style></author><author><style face="normal" font="default" size="100%">Hwang, H.</style></author><author><style face="normal" font="default" size="100%">Deshar, B.</style></author><author><style face="normal" font="default" size="100%">Kim, M.</style></author><author><style face="normal" font="default" size="100%">Kim, J. Y.</style></author><author><style face="normal" font="default" size="100%">Jung, J. H.</style></author><author><style face="normal" font="default" size="100%">Kim, H. S.</style></author><author><style face="normal" font="default" size="100%">Jung, S. H.</style></author><author><style face="normal" font="default" size="100%">Kwon, H. C.</style></author><author><style face="normal" font="default" size="100%">Kim, W. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Natural Product Research Center, Korea Institute of Science and Technology (KIST), Gangneung, Korea.&#xD;Division of Bio-Medical Science &amp; Technology, University of Science and Technology (UST), Daejeon, Korea.&#xD;Department of Marine Life Sciences, College of Life Science, Gangneung-Wonju National University, Gangneung, Korea.&#xD;Natural Product Informatics Research Center, Korea Institute of Science and Technology (KIST), Gangneung, Korea.&#xD;Department of Pharmacology, Department of Biomedicine &amp; Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Korea.&#xD;Department of Biology, Gangneung-Wonju National University, Gangneung, Korea.&#xD;Department of Tropical Medicine, Institute of Tropical Medicine, and Arthropods of Medical Importance Resource Bank, Yonsei University College of Medicine, Seoul, Korea.&#xD;Department of Urology, Yonsei University Wonju College of Medicine/Center of Evidence Based Medicine Institute of Convergence Science, Wonju, Korea.&#xD;Department of Oral Biochemistry, Dental and Life Science Institute, School of Dentistry, Pusan National University, Yangsan, Korea.&#xD;Department of Convergence Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Forsythia velutina Nakai extract: A promising therapeutic option for atopic dermatitis through multiple cell type modulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1242-1257</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/12/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Plant Extracts/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Forsythia/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">*Macrophages/drug effects/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Reactive Oxygen Species/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Keratinocytes/drug effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes/drug effects/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils/drug effects/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunomodulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Forsythia velutina Nakai</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">natural product</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38037751</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is a complex condition characterized by impaired epithelial barriers and dysregulated immune cells. In this study, we demonstrated Forsythia velutina Nakai extract (FVE) simultaneously inhibits basophils, macrophages, keratinocytes, and T cells that are closely interrelated in AD development. METHODS: We analyzed the effect of FVE on nitric oxide and reactive oxygen species (ROS) production in macrophages, basophil degranulation, T cell activation, and tight junctions in damaged keratinocytes. Expression of cell-type-specific inflammatory mediators was analyzed, and the underlying signaling pathways for anti-inflammatory effects of FVE were investigated. The anti-inflammatory effects of FVE were validated using a DNCB-induced mouse model of AD. Anti-inflammatory activity of compounds isolated from FVE was validated in each immune cell type. RESULTS: FVE downregulated the expression of inflammatory mediators and ROS production in macrophages through TLR4 and NRF2 pathways modulation. It significantly reduced basophil degranulation and expression of type 2 (T2) and pro-inflammatory cytokines by perturbing FcepsilonRI signaling. Forsythia velutina Nakai extract also robustly inhibited the expression of T2 cytokines in activated T cells. Furthermore, FVE upregulated the expression of tight junction molecules in damaged keratinocytes and downregulated leukocyte attractants, as well as IL-33, an inducer of T2 inflammation. In the AD mouse model, FVE showed superior improvement in inflammatory cell infiltration and skin structure integrity compared to dexamethasone. Dimatairesinol, a lignan dimer, was identified as the most potent anti-inflammatory FVE compound. CONCLUSION: Forsythia velutina Nakai extract and its constituent compounds demonstrate promising efficacy as a therapeutic option for prolonged AD treatment by independently inhibiting various cell types associated with AD and disrupting the deleterious link between them.</style></abstract><notes><style face="normal" font="default" size="100%">Kwon, Yujin&#xD;Kang, Yoon Jin&#xD;Kwon, Jaeyoung&#xD;Cho, Su-Yeon&#xD;Kim, Jiyoon&#xD;Le, Tam Thi&#xD;Hwang, Hoseong&#xD;Deshar, Barsha&#xD;Kim, Myungjun&#xD;Kim, Ju Yeong&#xD;Jung, Jae Hung&#xD;Kim, Hyung-Sik&#xD;Jung, Sang Hoon&#xD;Kwon, Hak Cheol&#xD;Kim, Won Kyu&#xD;eng&#xD;2E32641/Korea Institute of Science and Technology/&#xD;RS-2023-00223591 and 2022R1C1C1007059/National Research Foundation of Korea/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1242-1257. doi: 10.1111/all.15967. Epub 2023 Dec 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38037751</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15967</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2517</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2517</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, IBIMA-Regional University Hospital of Malaga, UMA, RETICS ARADyAL, BIONAND, Malaga, Spain.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;All-MED Medical Research Institute, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;NIHR Biomedical Research Centre, Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Four years into the COVID-19 pandemic: Timely published articles for patient care and EAACI&apos;s leadership role</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2031-2033</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/05/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*COVID-19/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Leadership</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient Care</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">Periodicals as Topic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38702913</style></accession-num><notes><style face="normal" font="default" size="100%">Torres, Maria Jose&#xD;Klimek, Ludger&#xD;Agache, Ioana&#xD;Jutel, Marek&#xD;Akdis, Mubeccel&#xD;Shamji, Mohamed H&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2031-2033. doi: 10.1111/all.16149. Epub 2024 May 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38702913</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16149</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>109</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">109</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, S. W.</style></author><author><style face="normal" font="default" size="100%">Shin, Y. H.</style></author><author><style face="normal" font="default" size="100%">Shin, J. I.</style></author><author><style face="normal" font="default" size="100%">Kang, S. M.</style></author><author><style face="normal" font="default" size="100%">Abuabara, K.</style></author><author><style face="normal" font="default" size="100%">Hwang, J.</style></author><author><style face="normal" font="default" size="100%">Shin, J. U.</style></author><author><style face="normal" font="default" size="100%">Noh, H.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Heo, C. Y.</style></author><author><style face="normal" font="default" size="100%">Koyanagi, A.</style></author><author><style face="normal" font="default" size="100%">Jacob, L.</style></author><author><style face="normal" font="default" size="100%">Smith, L.</style></author><author><style face="normal" font="default" size="100%">Ludvigsson, J. F.</style></author><author><style face="normal" font="default" size="100%">Turner, S.</style></author><author><style face="normal" font="default" size="100%">Shin, J. Y.</style></author><author><style face="normal" font="default" size="100%">Jeong, H. E.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Rhee, S. Y.</style></author><author><style face="normal" font="default" size="100%">Suh, D. I.</style></author><author><style face="normal" font="default" size="100%">Yon, D. K.</style></author><author><style face="normal" font="default" size="100%">Cho, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, South Korea.&#xD;Department of Pediatrics, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, South Korea.&#xD;Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea.&#xD;Research Administration Team, Seoul National University Bundang Hospital, Seongnam, South Korea.&#xD;H&amp;Bio Co., Ltd, Seongnam, South Korea.&#xD;Department of Dermatology, University of California San Francisco, California, San Francisco, USA.&#xD;Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Maryland, Baltimore, USA.&#xD;Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.&#xD;Department of Dermatology, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, South Korea.&#xD;Department of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.&#xD;Research and Development Unit, Parc Sanitari Sant Joan de Deu, CIBERSAM, Barcelona, Spain.&#xD;Catalan Institution for Research and Advanced Studies (ICREA), Pg. Lluis Companys, Barcelona, Spain.&#xD;Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France.&#xD;Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.&#xD;Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden.&#xD;Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA.&#xD;Department of Paediatrics, Orebro University Hospital, Orebro, Sweden.&#xD;Maternity and Child Health Division, NHS Grampian Aberdeen, Aberdeen, UK.&#xD;School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.&#xD;Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea.&#xD;Department of Allergy and Clinical Immunology, Korean Armed Forces Capital Hospital, Seongnam, South Korea.&#xD;Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Endocrinology and Metabolism, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Pediatrics, Seoul National University Children&apos;s Hospital, Seoul National University College of Medicine, Seoul, South Korea.&#xD;Department of Pediatrics, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Division of Allergy-Immunology, University of South Florida Morsani College of Medicine, Florida, Tampa, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fracture incidence in children after developing atopic dermatitis: A Korean nationwide birth cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">871-875</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/11/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Republic of Korea/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36353744</style></accession-num><notes><style face="normal" font="default" size="100%">Lee, Seung Won&#xD;Shin, Youn Ho&#xD;Shin, Jae Il&#xD;Kang, So Min&#xD;Abuabara, Katrina&#xD;Hwang, Jimin&#xD;Shin, Jung U&#xD;Noh, Hyungrye&#xD;Kim, Sunyeup&#xD;Heo, Chan Yeong&#xD;Koyanagi, Ai&#xD;Jacob, Louis&#xD;Smith, Lee&#xD;Ludvigsson, Jonas F&#xD;Turner, Stephen&#xD;Shin, Ju-Young&#xD;Jeong, Han Eol&#xD;Kim, Jung-Hyun&#xD;Rhee, Sang Youl&#xD;Suh, Dong In&#xD;Yon, Dong Keon&#xD;Cho, Seong Ho&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):871-875. doi: 10.1111/all.15577. Epub 2022 Nov 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36353744</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15577</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>924</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">924</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kopfnagel, V.</style></author><author><style face="normal" font="default" size="100%">Dreyer, S.</style></author><author><style face="normal" font="default" size="100%">Zeitvogel, J.</style></author><author><style face="normal" font="default" size="100%">Pieper, D. H.</style></author><author><style face="normal" font="default" size="100%">Buch, A.</style></author><author><style face="normal" font="default" size="100%">Sodeik, B.</style></author><author><style face="normal" font="default" size="100%">Rademacher, F.</style></author><author><style face="normal" font="default" size="100%">Harder, J.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.&#xD;Microbial Interactions and Processes Research Group, Helmholtz Centre for Infection Research, Braunschweig, Germany.&#xD;Institute of Virology, Hannover Medical School, Hannover, Germany.&#xD;DZIF - German Centre for Infection Research, Partner site Hannover-Braunschweig, Germany.&#xD;Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3145-3154</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/06/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial Cationic Peptides</style></keyword><keyword><style face="normal" font="default" size="100%">DNA</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pore Forming Cytotoxic Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Hsv-1</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial peptides</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34176149</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The high susceptibility of AD patients to microbial skin infections has been attributed to a deficient antimicrobial peptide (AMP) expression, which is contradicted by a growing amount of recent studies clearly demonstrating that AMP expression is not impaired in lesional skin of AD patients. The reasons for the high susceptibility of AD patients to microbial infections are still unknown. METHODS: The influence of self-DNA on the antimicrobial activity of RNase 7, LL-37, and hBD2 has been investigated using antibacterial and antiviral assays. The amount of self-DNA on skin has been analyzed by skin rinsings and subsequent quantification using dsDNA assays. DNA source was identified by qPCR. RESULTS: Complex formation of the AMPs with self-DNA significantly impaired their antibacterial activity against Staphylococcus aureus and their antiviral activity against HSV-1. The inhibition of the antibacterial activity was dependent on the DNA concentration but not on the length of the DNA molecules. Of note, we detected significant higher amounts of cell-free self-DNA in skin rinses taken from lesional AD skin compared to skin rinses from non-lesional skin and from normal skin of healthy donors. Consequently, rinse solution from AD lesional skin prevented antibacterial activity of LL-37. CONCLUSION: Our study indicates that extracellular self-DNA is released in considerable amounts in AD skin lesions and AMP-self-DNA-complex formation leads to a significant loss of antibacterial and antiviral activity in atopic dermatitis. Studies on strategies to reduce the amount of extracellular DNA in AD are needed to identify possible methods relevant in clinical settings.</style></abstract><notes><style face="normal" font="default" size="100%">Kopfnagel, Verena&#xD;Dreyer, Sylvia&#xD;Zeitvogel, Jana&#xD;Pieper, Dietmar H&#xD;Buch, Anna&#xD;Sodeik, Beate&#xD;Rademacher, Franziska&#xD;Harder, Jurgen&#xD;Werfel, Thomas&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3145-3154. doi: 10.1111/all.14992. Epub 2021 Jul 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34176149</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14992</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3298</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3298</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dölle-Bierke, Sabine</style></author><author><style face="normal" font="default" size="100%">Gonzalo-Fernández, Alejandro</style></author><author><style face="normal" font="default" size="100%">Sabouraud-Leclerc, Dominique</style></author><author><style face="normal" font="default" size="100%">Barreales-Tolosa, Laura</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, Barbara</style></author><author><style face="normal" font="default" size="100%">Belohlavkova, Simona</style></author><author><style face="normal" font="default" size="100%">Bilò, Maria B.</style></author><author><style face="normal" font="default" size="100%">Dubakiene, Ruta</style></author><author><style face="normal" font="default" size="100%">Hartmann, Karin</style></author><author><style face="normal" font="default" size="100%">Jedrzejczak-Czechowicz, Monika</style></author><author><style face="normal" font="default" size="100%">Le, Thuy-My</style></author><author><style face="normal" font="default" size="100%">Lange, Lars</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, Nikolaos G.</style></author><author><style face="normal" font="default" size="100%">Pouessel, Guillaume</style></author><author><style face="normal" font="default" size="100%">Reig, Isabel</style></author><author><style face="normal" font="default" size="100%">Sinaniotis, Athanasios</style></author><author><style face="normal" font="default" size="100%">Mills, E. N. Clare</style></author><author><style face="normal" font="default" size="100%">Worm, Margitta</style></author><author><style face="normal" font="default" size="100%">Fernández-Rivas, Montserrat</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Frequency and Severity of Allergic Reactions to Non-Mandatory Labelled Allergenic Foods—Data From Two Large European Cohorts</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background The consumption of plant-based food has lately largely increased, raising concerns about allergic reactions from ingredients which are currently not subject to mandatory labelling. Methods We analysed the frequency and severity of allergic reactions to non-mandatory labelled allergenic foods (pea, lentil, bean, chickpea, fenugreek, pine nut, sunflower-, poppy-, pumpkin seed, buckwheat) from two large European cohorts: The Anaphylaxis Registry (NORA) and EuroPrevall outpatient clinic study. Severity was assessed using the Food Allergy Severity Score (FASS) and compared with reactions to mandatory labelled allergenic foods. Results Among 589 reactions from both cohorts, sunflower seed was the most frequent trigger (n = 126). In NORA, pine nut (1.0% of food-induced allergic reactions) was most common followed by pea and buckwheat (0.7% each); in EuroPrevall, sunflower seed (1.2%), poppy seed (0.6%) and lentil (0.6%) predominated. After adjusting for age and sex, the severity of reactions to mandatory labelled seeds and legumes (excluding peanut) were not different (nFASS median: 4.39 vs. 4.43 and 4.56 vs. 4.49). Whereas, cereal-induced reactions (6.47) were significantly more severe than buckwheat (4.77). In Nora, the number of reactions to fenugreek and pumpkin seed were 7.4- and 3.7-fold higher in 2015–2022 versus 2007–2014. Conclusion Non-mandatory labelled allergenic foods were identified to cause severe allergic reactions in two large European cohorts. The frequent involvement of sunflower seed, pine nut, pea and lentil, but also rising numbers of reactions to fenugreek and pumpkin seed, indicates their potential risk. These allergenic foods warrant close monitoring and consideration in future allergen labelling revisions.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70308</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70308</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>248</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">248</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spolidoro, G. C. I.</style></author><author><style face="normal" font="default" size="100%">Amera, Y. T.</style></author><author><style face="normal" font="default" size="100%">Ali, M. M.</style></author><author><style face="normal" font="default" size="100%">Nyassi, S.</style></author><author><style face="normal" font="default" size="100%">Lisik, D.</style></author><author><style face="normal" font="default" size="100%">Ioannidou, A.</style></author><author><style face="normal" font="default" size="100%">Rovner, G.</style></author><author><style face="normal" font="default" size="100%">Khaleva, E.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Vlieg-Boerstra, B.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Nwaru, B. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.&#xD;School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.&#xD;Krefting Research Centre, University of Gothenburg, Gothenburg, Sweden.&#xD;ACT Institutet Sweden, Gothenburg, Sweden.&#xD;Division of Physiotherapy, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Section of Allergy and Immunology, School of Medicine, University of Colorado Denver, Children&apos;s Hospital Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.&#xD;Department of Experimental Immunology and Department of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.&#xD;Division of Allergy and Immunology, Department of Dermatology, Allergy and Venerology, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Pediatrics, OLVG Hospital, Amsterdam, the Netherlands.&#xD;Department of Pediatrics, Rijnstate Hospital, Arnhem, the Netherlands.&#xD;Usher Institute, University of Edinburgh, Edinburgh, UK.&#xD;Department of Mother and Child Health, The Referral Centre for Food Allergy Diagnosis and Treatment Veneto Region, University of Padua, Padua, Italy.&#xD;David Hide Asthma and Allergy Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Frequency of food allergy in Europe: An updated systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">351-368</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/10/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Food</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">Education, and National Peanut Board) and personal fees (Reckitt Benckiser,</style></keyword><keyword><style face="normal" font="default" size="100%">Nestle Nutrition Institute, Danone, Abbott Nutrition, Else Nutrition, Sifter, and</style></keyword><keyword><style face="normal" font="default" size="100%">Before Brands). Ronald van Ree reports: consultancies (HAL Allergy BV, Citeq BV,</style></keyword><keyword><style face="normal" font="default" size="100%">Angany Inc., Reacta Healthcare Ltd., Mission MightyMe, and AB Enzymes), speaker&apos;s</style></keyword><keyword><style face="normal" font="default" size="100%">fees (HAL Allergy BV, ThermoFisher Scientific, and ALK), and stock options</style></keyword><keyword><style face="normal" font="default" size="100%">(Angany Inc.). Margitta Worm reports: grants and personal fees (Stallergens, HAL</style></keyword><keyword><style face="normal" font="default" size="100%">Allergie, Bencard Allergie, Allergopharma, ALK-Abello, Mylan Germany, Actelion</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals Deutschland, Biotest, AbbVie Deutschland, Lilly Deutschland</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune, DBV Technologies SA, Regeneron Pharmaceuticals, Sanofi Aventis, Leo</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Novartis, and Viatris) outside of the submitted work and being past WAO</style></keyword><keyword><style face="normal" font="default" size="100%">co-chair of the anaphylaxis committee and past chair of the food allergy interest</style></keyword><keyword><style face="normal" font="default" size="100%">group of EAACI. Berber Vlieg-Boerstra reports: personal fees (Marfo Food Group,</style></keyword><keyword><style face="normal" font="default" size="100%">Nestle, and Nutricia) and grants (Nutricia). Antonella Muraro reports: grants and</style></keyword><keyword><style face="normal" font="default" size="100%">speaker&apos;s fees (Aimmune), speaker&apos;s fees (DVB Technologies SA, Viatris [Mylan],</style></keyword><keyword><style face="normal" font="default" size="100%">ALK, and Nestle), and being member of the Executive Committee of GA2LEN and past</style></keyword><keyword><style face="normal" font="default" size="100%">president of EAACI. Graham Roberts reports grants (Asthma UK and National</style></keyword><keyword><style face="normal" font="default" size="100%">Institutes of Health Research). Bright I, Nwaru reports unrestricted grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from DBV Technologies and AstraZeneca, respectively. Giulia C.I.</style></keyword><keyword><style face="normal" font="default" size="100%">Spolidoro, Yohannes Tesfaye Amera, Mohamed Mustafa Ali, Sungkutu Nyassi, Daniil</style></keyword><keyword><style face="normal" font="default" size="100%">Lisik, Athina Ioannidou report fee from ACT Institutet Sweden. The other authors</style></keyword><keyword><style face="normal" font="default" size="100%">report no conflicting interests related to this work. The funder played no role</style></keyword><keyword><style face="normal" font="default" size="100%">in the content and decision to submit this manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36271775</style></accession-num><abstract><style face="normal" font="default" size="100%">Food allergy (FA) is increasingly reported in Europe, however, the latest prevalence estimates were based on studies published a decade ago. The present work provides the most updated estimates of the prevalence and trends of FA in Europe. Databases were searched for studies published between 2012 and 2021, added to studies published up to 2012. In total, 110 studies were included in this update. Most studies were graded as moderate risk of bias. Pooled lifetime and point prevalence of self-reported FA were 19.9% (95% CI 16.6-23.3) and 13.1% (95% CI 11.3-14.8), respectively. The point prevalence of sensitization based on specific IgE (slgE) was 16.6% (95% CI 12.3-20.8), skin prick test (SPT) 5.7% (95% CI 3.9-7.4), and positive food challenge 0.8% (95% CI 0.5-0.9). While lifetime prevalence of self-reported FA and food challenge positivity only slightly changed, the point prevalence of self-reported FA, sIgE and SPT positivity increased from previous estimates. This may reflect a real increase, increased awareness, increased number of foods assessed, or increased number of studies from countries with less data in the first review. Future studies require rigorous designs and implementation of standardized methodology in diagnosing FA, including use of double-blinded placebo-controlled food challenge to minimize potential biases.</style></abstract><notes><style face="normal" font="default" size="100%">Spolidoro, Giulia C I&#xD;Amera, Yohannes Tesfaye&#xD;Ali, Mohamed Mustafa&#xD;Nyassi, Sungkutu&#xD;Lisik, Daniil&#xD;Ioannidou, Athina&#xD;Rovner, Graciela&#xD;Khaleva, Ekaterina&#xD;Venter, Carina&#xD;van Ree, Ronald&#xD;Worm, Margitta&#xD;Vlieg-Boerstra, Berber&#xD;Sheikh, Aziz&#xD;Muraro, Antonella&#xD;Roberts, Graham&#xD;Nwaru, Bright I&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):351-368. doi: 10.1111/all.15560. Epub 2022 Nov 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36271775</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10099188</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15560</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>86</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">86</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, S.</style></author><author><style face="normal" font="default" size="100%">Lin, Q.</style></author><author><style face="normal" font="default" size="100%">He, Q.</style></author><author><style face="normal" font="default" size="100%">Cui, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics Laboratory, The Affiliated Wuxi Children&apos;s Hospital of Nanjing Medical University, Wuxi, China.&#xD;Department of Pathology, The Affiliated Wuxi People&apos;s Hospital of Nanjing Medical University, Wuxi, China.&#xD;Digestive Department, The Affiliated Wuxi Children&apos;s Hospital of Nanjing Medical University, Wuxi, China.&#xD;Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA.&#xD;Clinical Research Center, The Affiliated Wuxi People&apos;s Hospital of Nanjing Medical University, Wuxi, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Frequent presence of major dust mite allergens in human digestive tissues of children with gastritis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">590-592</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/11/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastritis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36398462</style></accession-num><notes><style face="normal" font="default" size="100%">Zhou, Ying&#xD;Yang, Shudong&#xD;Lin, Qiong&#xD;He, Qixin&#xD;Cui, Yubao&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):590-592. doi: 10.1111/all.15587. Epub 2022 Nov 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36398462</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15587</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2560</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2560</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Consonni, F.</style></author><author><style face="normal" font="default" size="100%">Corsello, A.</style></author><author><style face="normal" font="default" size="100%">Pegoraro, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental and Clinical Biomedical Sciences &quot;Mario Serio&quot;, University of Florence, Florence, Italy.&#xD;Centre of Excellence, Division of Pediatric Oncology/Hematology, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Pediatric Hematology, Immunology and Rheumatology Unit, Assistance Publique Hopitaux de Paris (APHP), Necker Hospital for Sick Children, Paris, France.&#xD;Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.&#xD;Pediatric Unit, Fondazione IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">From allergy to oncology: Targeting IL-4 to boost cancer immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2890-2892</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/07/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/therapy/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunotherapy/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">*Neoplasms/therapy/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39044724</style></accession-num><notes><style face="normal" font="default" size="100%">Consonni, Filippo&#xD;Corsello, Antonio&#xD;Pegoraro, Francesco&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2890-2892. doi: 10.1111/all.16251. Epub 2024 Jul 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39044724</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16251</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1529</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1529</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blank, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Member of the German Center of Lung Research (DZL), Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">From basic science to diagnostics - History of a patent on a honeybee venom allergen</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">385-387</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2018/10/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/history</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Bee Venoms/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Bees/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*diagnosis/*immunology/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30353929</style></accession-num><notes><style face="normal" font="default" size="100%">Blank, Simon&#xD;eng&#xD;Historical Article&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Feb;74(2):385-387. doi: 10.1111/all.13643. Epub 2018 Nov 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30353929</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13643</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2672</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2672</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Houghton, V.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Florsheim, E. B.</style></author><author><style face="normal" font="default" size="100%">Knibb, R. C.</style></author><author><style face="normal" font="default" size="100%">Thuret, S.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King&apos;s College London, London, UK.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.&#xD;Translational Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Center for Health Through Microbiomes, Biodesign Institute Arizona State University Tempe, Arizona, USA.&#xD;School of Life Sciences, Arizona State University Tempe, Arizona, USA.&#xD;Institute of Health and Neurodevelopment, Aston University, Birmingham, UK.&#xD;Department of Women and Children&apos;s Health (Paediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Guy&apos;s and St. Thomas&apos; NHS Foundation Trust, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">From bite to brain: Neuro-immune interactions in food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3326-3340</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/10/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Neuroimmunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">neuro-immune interactions</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees from Danone/Nutricia/Milupa, ThermoFisher, MADX, ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Sanofi, EFSA outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial unconditional in</style></keyword><keyword><style face="normal" font="default" size="100%">kind support from MADX, Novartis and ALK, Co-I or scientific lead in three</style></keyword><keyword><style face="normal" font="default" size="100%">investigator initiated oral immunotherapy trials supported by the Food Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">and Anaphylaxis Program Sickkids and serves as associate editor for Allergy. Site</style></keyword><keyword><style face="normal" font="default" size="100%">PI of company sponsored trials by DBV, Novartis and Stallergen. RCK has received</style></keyword><keyword><style face="normal" font="default" size="100%">research funding from the National Institute for Health Research, Aimmune,</style></keyword><keyword><style face="normal" font="default" size="100%">National Peanut Board, Novartis and the Food Standards Agency and honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia, Viatris and DBV Technologies. RCK is also Chair of the British Society</style></keyword><keyword><style face="normal" font="default" size="100%">for Allergy and Clinical Immunology Psychology Special Interest Group for</style></keyword><keyword><style face="normal" font="default" size="100%">Psychology. AFS reports grants from Medical Research Council (MR/M008517/1</style></keyword><keyword><style face="normal" font="default" size="100%">MC/PC/18052</style></keyword><keyword><style face="normal" font="default" size="100%">MR/T032081/1), Food Allergy Research and Education (FARE), the</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance Network/National Institute of Allergy and Infectious Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">(NIAID, NIH), Asthma UK (AUK-BC-2015-01), BBSRC, Rosetrees Trust and the NIHR</style></keyword><keyword><style face="normal" font="default" size="100%">through the Biomedical Research Centre (BRC) award to Guy&apos;s and St Thomas&apos; NHS</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation Trust, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Thermo</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific, Nestle, Novartis, Allergy Therapeutics, IgGenix, Buhlmann, as well as</style></keyword><keyword><style face="normal" font="default" size="100%">research support from IgGenix, Buhlmann and Thermo Fisher Scientific through a</style></keyword><keyword><style face="normal" font="default" size="100%">collaboration agreement with King&apos;s College London.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39462229</style></accession-num><abstract><style face="normal" font="default" size="100%">Immunoglobulin E (IgE)-mediated food allergies are reported to affect around 3.5% of children and 2.4% of adults, with symptoms varying in range and severity. While being the gold standard for diagnosis, oral food challenges are burdensome, and diagnostic tools based on specific IgE can be flawed. Furthering our understanding of the mechanisms behind food allergy onset, severity and persistence could help reveal immune profiles associated with the disease, to ultimately aid in diagnosis. Alterations to cytokine levels and immune cell ratios have been identified, though further research is needed to fully capture the heterogenous nature of food allergy. Moreover, the existence of such immune alterations also raises the question of potential wider systemic effects. For example, recent research has emphasised the existence and impact of neuro-immune interactions and implicated behavioural and neurological changes associated with food allergy. This review will provide an overview of such food allergy-driven neuro-immune interactions, with the aim of emphasising the importance of furthering our understanding of the immune mechanisms underlying IgE-mediated food allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Houghton, Vikki&#xD;Eiwegger, Thomas&#xD;Florsheim, Esther Borges&#xD;Knibb, Rebecca C&#xD;Thuret, Sandrine&#xD;Santos, Alexandra F&#xD;eng&#xD;WT_/Wellcome Trust/United Kingdom&#xD;King&apos;s Health Partners/&#xD;King&apos;s College London/&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3326-3340. doi: 10.1111/all.16366. Epub 2024 Oct 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39462229</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657076</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16366</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1386</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1386</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Couffon, M.</style></author><author><style face="normal" font="default" size="100%">Stoneham, E.</style></author><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Patient within Paediatric Allergy Services, Imperial College Healthcare NHS Trust, London, UK.&#xD;Section of Inflammation, Repair and Development, National Heart &amp; Lung Institute, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">From child to adult: Putting the patient first and foremost</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">983-984</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Family</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32716563</style></accession-num><notes><style face="normal" font="default" size="100%">Couffon, Margaux&#xD;Stoneham, Ella&#xD;Turner, Paul J&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):983-984. doi: 10.1111/all.14515.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32716563</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14515</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3020</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3020</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bieber, T.</style></author><author><style face="normal" font="default" size="100%">Maintz, L.</style></author><author><style face="normal" font="default" size="100%">Phad, G. E.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Christine Kuhne-Center for Allergy Research and Education, Medicine Campus Davos, Davos, Switzerland.&#xD;Allergy Unit, Department of Dermatology, University Hospital, Zurich, Switzerland.&#xD;Bieber Dermatology Consulting, Feldafing, Germany.&#xD;Center for Skin Diseases, University Hospital of Bonn, Bonn, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">From Disease Control to Disease Modification: The Atopic Dermatitis Disease Activity Index</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">disease modification</style></keyword><keyword><style face="normal" font="default" size="100%">drug development</style></keyword><keyword><style face="normal" font="default" size="100%">remission</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40879255</style></accession-num><notes><style face="normal" font="default" size="100%">Bieber, Thomas&#xD;Maintz, Laura&#xD;Phad, Ganesh E&#xD;Bruggen, Marie-Charlotte&#xD;eng&#xD;Christine Kuhne - Center for Allergy Research and Education/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug 29. doi: 10.1111/all.70036.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40879255</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70036</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>851</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">851</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pavord, I. D.</style></author><author><style face="normal" font="default" size="100%">Bel, E. H.</style></author><author><style face="normal" font="default" size="100%">Bourdin, A.</style></author><author><style face="normal" font="default" size="100%">Chan, R.</style></author><author><style face="normal" font="default" size="100%">Han, J. K.</style></author><author><style face="normal" font="default" size="100%">Keene, O. N.</style></author><author><style face="normal" font="default" size="100%">Liu, M. C.</style></author><author><style face="normal" font="default" size="100%">Martin, N.</style></author><author><style face="normal" font="default" size="100%">Papi, A.</style></author><author><style face="normal" font="default" size="100%">Roufosse, F.</style></author><author><style face="normal" font="default" size="100%">Steinfeld, J.</style></author><author><style face="normal" font="default" size="100%">Wechsler, M. E.</style></author><author><style face="normal" font="default" size="100%">Yancey, S. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Nuffield Department of Medicine and Oxford Respiratory NIHR BRC, University of Oxford, Oxford, UK.&#xD;Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;INSERM 12, F-CRIN, Clinical Research Initiative In Severe Asthma: a Lever for Innovation &amp; Science (CRISALIS), France.&#xD;Service de Pneumologie and INSERM CNRS, CHU Montpellier, Universite de Montpellier, Montpellier, France.&#xD;Clinical Sciences, GSK R&amp;D, Stockley Park, UK.&#xD;Department of Otolaryngology, Head &amp; Neck Surgery, Eastern Virginia Medical School, Norfolk, Virginia, USA.&#xD;Biostatistics, GSK, Brentford, UK.&#xD;Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA.&#xD;Global Medical Affairs, GSK, Brentford, UK.&#xD;Institute for Lung Health, University of Leicester, Leicester, UK.&#xD;Research Center on Asthma and COPD, University of Ferrara, Ferrara, Italy.&#xD;Department of Internal Medicine, Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium.&#xD;Respiratory Research &amp; Development, GSK, Collegeville, PA, USA.&#xD;Department of Medicine, National Jewish Health Cohen Family Asthma Institute, Denver, CO, USA.&#xD;Respiratory Therapeutic Area Unit, GSK, Research Triangle Park, NC, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">778-797</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/08/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">*Churg-Strauss Syndrome/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">*Granulomatosis with Polyangiitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Eosinophilia/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trials</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-5</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">real-world data</style></keyword><keyword><style face="normal" font="default" size="100%">meetings from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Teva, Chiesi, Sanofi/Regeneron, and GSK</style></keyword><keyword><style face="normal" font="default" size="100%">and payments for organizing educational</style></keyword><keyword><style face="normal" font="default" size="100%">events from AstraZeneca, GSK, Sanofi/Regeneron, and Teva. He has received</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria for attending advisory panels with Genentech, Sanofi/Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">and Knopp</style></keyword><keyword><style face="normal" font="default" size="100%">and payments to support FDA approval meetings from GSK. He has</style></keyword><keyword><style face="normal" font="default" size="100%">received sponsorship to attend international scientific meetings from Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, GSK, AstraZeneca, Teva, and Chiesi. He has received a grant from</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi to support a Phase II clinical trial in Oxford. He is co-patent holder of</style></keyword><keyword><style face="normal" font="default" size="100%">the rights to the Leicester Cough Questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">and has received payments for</style></keyword><keyword><style face="normal" font="default" size="100%">its use in clinical trials from Merck, Bayer, and Insmed. In 2014-15, he was an</style></keyword><keyword><style face="normal" font="default" size="100%">expert witness for a patent dispute involving AstraZeneca and Teva. Elisabeth H</style></keyword><keyword><style face="normal" font="default" size="100%">Bel reports grants from GSK and Teva</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from AstraZeneca, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron, Sterna Biologicals, and Chiesi. Arnaud Bourdin has received</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Boehringer Ingelheim and AstraZeneca</style></keyword><keyword><style face="normal" font="default" size="100%">has participated in clinical</style></keyword><keyword><style face="normal" font="default" size="100%">research projects (as an investigator) with GSK, AstraZeneca, Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, Chiesi, Novartis, and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and has received personal fees from GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Regeneron-Sanofi, Novartis, and Chiesi. Robert Chan, Oliver N Keene,</style></keyword><keyword><style face="normal" font="default" size="100%">Jonathan Steinfeld, and Steven W Yancey are employees of GSK and own</style></keyword><keyword><style face="normal" font="default" size="100%">stocks/shares. Neil Martin is a former employee of GSK and owns stocks and</style></keyword><keyword><style face="normal" font="default" size="100%">shares. Joseph K Han has received consultancy fees from Sanofi Genzyme,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Genentech, Novartis, AstraZeneca, GSK, and Gossamer Bio. Mark C Liu</style></keyword><keyword><style face="normal" font="default" size="100%">reports funding for clinical trials or personal fees for advisory board</style></keyword><keyword><style face="normal" font="default" size="100%">participation from AstraZeneca, Boehringer Ingelheim, Gossamer Bio, GSK, and</style></keyword><keyword><style face="normal" font="default" size="100%">MedImmune. Alberto Papi has received grants, personal fees and non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support and other from AstraZeneca, Teva, Mundipharma, GSK, Chiesi, and</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim</style></keyword><keyword><style face="normal" font="default" size="100%">has received personal fees and non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Menarini, and Zambon</style></keyword><keyword><style face="normal" font="default" size="100%">and has received grants from Sanofi. Florence</style></keyword><keyword><style face="normal" font="default" size="100%">Roufosse reports consultancy fees from AstraZeneca and GSK</style></keyword><keyword><style face="normal" font="default" size="100%">and royalties from</style></keyword><keyword><style face="normal" font="default" size="100%">UpToDate. Michael E Wechsler has research grants with the National Institute of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute</style></keyword><keyword><style face="normal" font="default" size="100%">and is a consultant with GSK, Genentech, Sanofi, Regeneron, AstraZeneca, Teva,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Boehringer Ingelheim, Sentien, and Equillium.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34402066</style></accession-num><abstract><style face="normal" font="default" size="100%">Effective treatment of inflammatory diseases is often challenging owing to their heterogeneous pathophysiology. Understanding of the underlying disease mechanisms is improving and it is now clear that eosinophils play a complex pathophysiological role in a broad range of type 2 inflammatory diseases. Standard of care for these conditions often still includes oral corticosteroids (OCS) and/or cytotoxic immune therapies, which are associated with debilitating side effects. Selective, biological eosinophil-reducing agents provide treatment options that improve clinical symptoms associated with eosinophilic inflammation and reduce OCS use. Mepolizumab is a humanized monoclonal antibody that binds to and neutralizes interleukin-5, the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab is approved for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome. Additionally, the efficacy of add-on mepolizumab has been observed in patients with severe chronic rhinosinusitis with nasal polyposis and chronic obstructive pulmonary disease with an eosinophilic phenotype. Here, we review the development, approval, and real-world effectiveness of mepolizumab for the treatment of patients with severe eosinophilic asthma, from the DREAM to REALITI-A studies, and describe how knowledge from this journey extended to the use of mepolizumab and other biologics across a broad spectrum of eosinophilic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Pavord, Ian D&#xD;Bel, Elisabeth H&#xD;Bourdin, Arnaud&#xD;Chan, Robert&#xD;Han, Joseph K&#xD;Keene, Oliver N&#xD;Liu, Mark C&#xD;Martin, Neil&#xD;Papi, Alberto&#xD;Roufosse, Florence&#xD;Steinfeld, Jonathan&#xD;Wechsler, Michael E&#xD;Yancey, Steven W&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):778-797. doi: 10.1111/all.15056. Epub 2021 Sep 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34402066</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9293125</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15056</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>471</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">471</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andiappan, A. K.</style></author><author><style face="normal" font="default" size="100%">Puan, K. J.</style></author><author><style face="normal" font="default" size="100%">Sio, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Ally, F.</style></author><author><style face="normal" font="default" size="100%">Lee, B.</style></author><author><style face="normal" font="default" size="100%">Matta, S. A.</style></author><author><style face="normal" font="default" size="100%">Yusof, N.</style></author><author><style face="normal" font="default" size="100%">Larbi, A.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Chew, F. T.</style></author><author><style face="normal" font="default" size="100%">Rotzschke, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Singapore Immunology Network (SIgN), Singapore, Singapore.&#xD;Department of Biological Sciences, National University of Singapore, Singapore, Singapore.&#xD;Department of Otolaryngology, National University of Singapore, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Functional CTLA-4 variants associate to both allergic asthma and rhinitis potentially by modulating naive regulatory T cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2856-2858</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/05/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">CTLA-4 Antigen/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35607825</style></accession-num><notes><style face="normal" font="default" size="100%">Andiappan, Anand Kumar&#xD;Puan, Kia Joo&#xD;Sio, Yang Yie&#xD;Ally, Fauziah&#xD;Lee, Bernett&#xD;Matta, Sri Anusha&#xD;Yusof, Nurhashikin&#xD;Larbi, Anis&#xD;Wang, De Yun&#xD;Chew, Fook Tim&#xD;Rotzschke, Olaf&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2856-2858. doi: 10.1111/all.15386. Epub 2022 Jun 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35607825</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15386</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2212</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2212</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Limberg, M. M.</style></author><author><style face="normal" font="default" size="100%">Wiebe, D.</style></author><author><style face="normal" font="default" size="100%">Gray, N.</style></author><author><style face="normal" font="default" size="100%">Weihrauch, T.</style></author><author><style face="normal" font="default" size="100%">Brauer, A. U.</style></author><author><style face="normal" font="default" size="100%">Kremer, A. E.</style></author><author><style face="normal" font="default" size="100%">Homey, B.</style></author><author><style face="normal" font="default" size="100%">Raap, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Experimental Allergy and Immunodermatology, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.&#xD;Division of Anatomy, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.&#xD;Research Center for Neurosensory Science, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.&#xD;Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Department of Medicine 1, Friedrich-Alexander-University Erlangen-Nurnberg, Erlangen, Germany.&#xD;Department of Dermatology, University Hospital, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany.&#xD;University Clinic of Dermatology and Allergy, University of Oldenburg, Oldenburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Functional expression of TRPV1 in human peripheral blood basophils and its regulation in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">225-228</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/07/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">TRPV Cation Channels/genetics/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37392059</style></accession-num><notes><style face="normal" font="default" size="100%">Limberg, Maren M&#xD;Wiebe, Daniela&#xD;Gray, Natalie&#xD;Weihrauch, Tobias&#xD;Brauer, Anja U&#xD;Kremer, Andreas E&#xD;Homey, Bernhard&#xD;Raap, Ulrike&#xD;eng&#xD;Deutsche Forschungsgemeinschaft/&#xD;School of Medicine and Health Sciences, University of Oldenburg/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):225-228. doi: 10.1111/all.15802. Epub 2023 Jul 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37392059</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15802</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>970</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">970</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Petje, L. M.</style></author><author><style face="normal" font="default" size="100%">Jensen, S. A.</style></author><author><style face="normal" font="default" size="100%">Szikora, S.</style></author><author><style face="normal" font="default" size="100%">Sulzbacher, M.</style></author><author><style face="normal" font="default" size="100%">Bartosik, T.</style></author><author><style face="normal" font="default" size="100%">Pjevac, P.</style></author><author><style face="normal" font="default" size="100%">Hausmann, B.</style></author><author><style face="normal" font="default" size="100%">Hufnagl, K.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Fischer, L.</style></author><author><style face="normal" font="default" size="100%">Vyskocil, E.</style></author><author><style face="normal" font="default" size="100%">Eckl-Dorna, J.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Hofstetter, G.</style></author><author><style face="normal" font="default" size="100%">Afify, S. M.</style></author><author><style face="normal" font="default" size="100%">Krenn, C. G.</style></author><author><style face="normal" font="default" size="100%">Roth, G. A.</style></author><author><style face="normal" font="default" size="100%">Rivelles, E.</style></author><author><style face="normal" font="default" size="100%">Hann, S.</style></author><author><style face="normal" font="default" size="100%">Roth-Walter, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria.&#xD;Institute of Analytical Chemistry, Department of Chemistry, University of Natural Resources and Life Sciences (BOKU), Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.&#xD;Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria.&#xD;Centre for Microbiology and Environmental Systems Science, Department of Microbiology and Ecosystem Science Division of Microbial Ecology, University of Vienna, Vienna, Austria.&#xD;Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.&#xD;Biomedical International R+D GmbH, Vienna, Austria.&#xD;Laboratory Medicine and Immunology Department, Faculty of Medicine, Menoufia University, Shebien El-Kom, Egypt.&#xD;Department of Anesthesiology, General Intensive Care and Pain Medicine, Medical University of Vienna, Vienna, Austria.&#xD;Department of Anesthesiology and Intensive Care, Franziskus Spital, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Functional iron-deficiency in women with allergic rhinitis is associated with symptoms after nasal provocation and lack of iron-sequestering microbes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2882-2886</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Anemia, Iron-Deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Iron</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Nose</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">clinical reactivity</style></keyword><keyword><style face="normal" font="default" size="100%">functional iron deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">microbes</style></keyword><keyword><style face="normal" font="default" size="100%">and EJJ are inventors of EP2894478, owned by Biomedical International R+D GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">Vienna, Austria. The other authors declare no relevant conflict of interest in</style></keyword><keyword><style face="normal" font="default" size="100%">relation to this publication.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34037999</style></accession-num><notes><style face="normal" font="default" size="100%">Petje, Lisa-Marie&#xD;Jensen, Sebastian A&#xD;Szikora, Sebastian&#xD;Sulzbacher, Martin&#xD;Bartosik, Tina&#xD;Pjevac, Petra&#xD;Hausmann, Bela&#xD;Hufnagl, Karin&#xD;Untersmayr, Eva&#xD;Fischer, Lisa&#xD;Vyskocil, Erich&#xD;Eckl-Dorna, Julia&#xD;Jensen-Jarolim, Erika&#xD;Hofstetter, Gerlinde&#xD;Afify, Sheriene Moussa&#xD;Krenn, Claus G&#xD;Roth, Georg A&#xD;Rivelles, Elisa&#xD;Hann, Stephan&#xD;Roth-Walter, Franziska&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2882-2886. doi: 10.1111/all.14960. Epub 2021 Jun 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34037999</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8453563</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14960</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>341</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">341</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sanchez-Martinez, E.</style></author><author><style face="normal" font="default" size="100%">Garrido-Romero, M.</style></author><author><style face="normal" font="default" size="100%">Moreno, F. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa, (IIS-Princesa), Universidad Autonoma de Madrid (UAM), Madrid, Spain.&#xD;Department of Bioactivity and Food Analysis, Instituto de Investigacion en Ciencias de la Alimentacion, CIAL (CSIC-UAM), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Functional role of ST6GALNAC1-mediated sialylation of mucins in preserving intestinal barrier integrity and ameliorating inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3697-3698</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/08/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mucins</style></keyword><keyword><style face="normal" font="default" size="100%">*Intestines</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Muc2</style></keyword><keyword><style face="normal" font="default" size="100%">colitis</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">gut microbiota disruption</style></keyword><keyword><style face="normal" font="default" size="100%">intestinal mucus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35993845</style></accession-num><notes><style face="normal" font="default" size="100%">Sanchez-Martinez, Elisa&#xD;Garrido-Romero, Manuel&#xD;Moreno, Francisco Javier&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3697-3698. doi: 10.1111/all.15489. Epub 2022 Sep 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35993845</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15489</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>348</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">348</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vitte, J.</style></author><author><style face="normal" font="default" size="100%">Michel, M.</style></author><author><style face="normal" font="default" size="100%">Malinovschi, A.</style></author><author><style face="normal" font="default" size="100%">Caminati, M.</style></author><author><style face="normal" font="default" size="100%">Odebode, A.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Caimmi, D. P.</style></author><author><style face="normal" font="default" size="100%">Cassagne, C.</style></author><author><style face="normal" font="default" size="100%">Demoly, P.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Menu, E.</style></author><author><style face="normal" font="default" size="100%">Nwaru, B. I.</style></author><author><style face="normal" font="default" size="100%">Sereme, Y.</style></author><author><style face="normal" font="default" size="100%">Ranque, S.</style></author><author><style face="normal" font="default" size="100%">Raulf, M.</style></author><author><style face="normal" font="default" size="100%">Feleszko, W.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Galan, C.</style></author><author><style face="normal" font="default" size="100%">Eaaci Task Force on Allergic Bronchopulmonary Aspergillosis</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">IDESP, University of Montpellier and INSERM, Montpellier, France.&#xD;MEPHI, IHU Mediterranee Infection, IRD, APHM, Aix-Marseille Univ, Marseille, France.&#xD;Immunology Laboratory, University Hospital Nimes, Nimes, France.&#xD;Department of Medical Sciences Clinical Physiology, Uppsala University, Uppsala, Sweden.&#xD;Asthma, Allergy and Clinical Immunology Section, Department of Medicine, University of Verona, Verona, Italy.&#xD;Department of Basic Science, Kampala International University, Kampala, Uganda.&#xD;Departement of Pneumology, University Hospital of Montpellier, Montpellier, France.&#xD;VITROME, IHU Mediterranee Infection, IRD, APHM, Aix-Marseille Univ, Marseille, France.&#xD;Personalized Medicine, Asthma and Allergy Humanitas Clinical and Research Center IRCCS Rozzano, Rozzano, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.&#xD;Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.&#xD;Department of Immunology, Infectiology and Hematology, Institut Necker-Enfants Malades (INEM), INSERM U1151, CNRS UMR 8253, Universite Paris Descartes, Paris, France.&#xD;Department of Allergology and Immunology, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-Universitat Bochum (IPA), Bochum, Germany.&#xD;Department of Pediatric Pulmonology and Allergy, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Medical Sciences Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.&#xD;International Campus of Excellence on Agrifood (ceiA3), University of Cordoba, Cordoba, Spain.&#xD;Andalusian Inter-University Institute for Earth System Research (IISTA), University of Cordoba, Cordoba, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fungal exposome, human health, and unmet needs: A 2022 update with special focus on allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3199-3216</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/08/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Exposome</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">exposome</style></keyword><keyword><style face="normal" font="default" size="100%">fungus</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35976185</style></accession-num><abstract><style face="normal" font="default" size="100%">Humans inhale, ingest, and touch thousands of fungi each day. The ubiquity and diversity of the fungal kingdom, reflected by its complex taxonomy, are in sharp contrast with our scarce knowledge about its distribution, pathogenic effects, and effective interventions at the environmental and individual levels. Here, we present an overview of salient features of fungi as permanent players of the human exposome and key determinants of human health, through the lens of fungal allergy and other fungal hypersensitivity reactions. Improved understanding of the fungal exposome sheds new light on the epidemiology of fungal-related hypersensitivity diseases, their immunological substratum, the currently available methods, and biomarkers for environmental and medical fungi. Unmet needs are described and potential approaches are highlighted as perspectives.</style></abstract><notes><style face="normal" font="default" size="100%">Vitte, Joana&#xD;Michel, Moise&#xD;Malinovschi, Andrei&#xD;Caminati, Marco&#xD;Odebode, Adeyinka&#xD;Annesi-Maesano, Isabella&#xD;Caimmi, Davide Paolo&#xD;Cassagne, Carole&#xD;Demoly, Pascal&#xD;Heffler, Enrico&#xD;Menu, Estelle&#xD;Nwaru, Bright I&#xD;Sereme, Youssouf&#xD;Ranque, Stephane&#xD;Raulf, Monika&#xD;Feleszko, Wojciech&#xD;Janson, Christer&#xD;Galan, Carmen&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3199-3216. doi: 10.1111/all.15483. Epub 2022 Sep 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35976185</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15483</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2686</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2686</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Symon, F. A.</style></author><author><style face="normal" font="default" size="100%">Anees-Hill, S.</style></author><author><style face="normal" font="default" size="100%">Satchwell, J.</style></author><author><style face="normal" font="default" size="100%">Fairs, A.</style></author><author><style face="normal" font="default" size="100%">Edwards, R.</style></author><author><style face="normal" font="default" size="100%">Wardlaw, A. J.</style></author><author><style face="normal" font="default" size="100%">Cuthbertson, L.</style></author><author><style face="normal" font="default" size="100%">Hansell, A. L.</style></author><author><style face="normal" font="default" size="100%">Pashley, C. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Sciences, University of Leicester, Leicester, UK.&#xD;Centre for Environmental Health and Sustainability, University of Leicester, Leicester, UK.&#xD;Toxicology, UK Health Security Agency, Harwell Campus, Didcot, UK.&#xD;NIHR Health Protection Research Unit in Environmental Exposures and Health at the University of Leicester, Leicester, UK.&#xD;NIHR Leicester Biomedical Research Centre, Leicester General Hospital, Leicester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A fungal spore calendar for England: Analysis of 13 years of daily concentrations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">617-620</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/10/16</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39412478</style></accession-num><notes><style face="normal" font="default" size="100%">Symon, Fiona A&#xD;Anees-Hill, Samuel&#xD;Satchwell, Jack&#xD;Fairs, Abbie&#xD;Edwards, Richard&#xD;Wardlaw, Andrew J&#xD;Cuthbertson, Leah&#xD;Hansell, Anna L&#xD;Pashley, Catherine H&#xD;eng&#xD;University of Leicester/&#xD;Midlands Asthma and Allergy Research Association/&#xD;NIHR Leicester Biomedical Research Centre/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):617-620. doi: 10.1111/all.16356. Epub 2024 Oct 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39412478</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804307</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16356</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3049</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3049</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caminati, M.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Feleszko, W.</style></author><author><style face="normal" font="default" size="100%">Guida, G.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Hagg, S.</style></author><author><style face="normal" font="default" size="100%">Malinovschi, A.</style></author><author><style face="normal" font="default" size="100%">Tanno, L.</style></author><author><style face="normal" font="default" size="100%">Vitte, J.</style></author><author><style face="normal" font="default" size="100%">Ambrosani, F.</style></author><author><style face="normal" font="default" size="100%">Maule, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit and Asthma Center, Verona Integrated University Hospital, Verona, Italy.&#xD;Department of Medicine, University of Verona, Verona, Italy.&#xD;Institute Desbrest of Epidemiology and Public Health (IDESP), UMR1318, University of Montpellier and INSERM, Montpellier, France.&#xD;Department of Pulmonology, Allergy and Thoracic Oncology, University Hospital of Montpellier, Montpellier, France.&#xD;IHU Immun4Cure (INSERM University of Montpellier, CHUM), Montpellier, France.&#xD;Department of Paediatric Pneumonology and Allergy, Medical University of Warsaw Medical University Children&apos;s Hospital, Warsaw, Poland.&#xD;Rare Lung Disease and Respiratory Pathophysiology Unit, Severe Asthma, San Luigi Gonzaga University Hospital, Turin, Italy.&#xD;Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.&#xD;Allergy Unit, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France.&#xD;WHO Collaborating Centre on Scientific Classification Support, Montpellier, France.&#xD;Laboratory of Immunology, University Hospital of Reims, Reims, France.&#xD;INSERM UMR-S 1250 P3CELL, University of Reims, Reims, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fungal-Driven Airways Dis-Immunity From Asthma to Allergic Bronchopulmonary Aspergillosis: Dissecting Similarities and Differences. An EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3274-3289</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Aspergillosis, Allergic Bronchopulmonary/diagnosis/immunology/therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/immunology/therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Fungi/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis, Differential</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">Aspergillus</style></keyword><keyword><style face="normal" font="default" size="100%">allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">fungal sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40751367</style></accession-num><abstract><style face="normal" font="default" size="100%">Severe asthma and allergic bronchopulmonary aspergillosis (ABPA) do not rarely coexist and share several similarities in terms of pathobiological background, together with overlapping clinical manifestations, misleading the correct diagnosis. Within that scenario, severe asthma with fungal sensitization (SAFS) further complicates the correct pheno-endotyping, which still needs to be recognized in the light of the greater burden and higher risk of irreversible damage related to ABPA and SAFS when compared to asthma alone. The identification of pathobiological drivers underlying different conditions remains challenging; in fact, available biomarkers, although accurate when related to each specific condition, do not always fully support a clear-cut differential diagnosis. The opportunity for innovative targeted treatments, although needing further evidence, should further stimulate a precise endo-phenotyping of severe asthma patients presenting some hallmarks of fungal-related dis-immunity to provide them the best standard of care for preventing disease evolution and achieving complete remission. This review provides a comparative outline of the recent advances in terms of pathophysiology, clinical manifestations, biomarkers, and management of asthma and ABPA, including a focus on SAFS, with the aim of updating the practical approach to those conditions and supporting their correct recognition.</style></abstract><notes><style face="normal" font="default" size="100%">Caminati, Marco&#xD;Annesi-Maesano, Isabella&#xD;Feleszko, Wojciech&#xD;Guida, Giuseppe&#xD;Janson, Christer&#xD;Hagg, Shadi&#xD;Malinovschi, Andrei&#xD;Tanno, Luciana&#xD;Vitte, Joana&#xD;Ambrosani, Francesca&#xD;Maule, Matteo&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3274-3289. doi: 10.1111/all.16687. Epub 2025 Aug 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40751367</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666763</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16687</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>253</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">253</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gurdeniz, G.</style></author><author><style face="normal" font="default" size="100%">Kim, M.</style></author><author><style face="normal" font="default" size="100%">Brustad, N.</style></author><author><style face="normal" font="default" size="100%">Ernst, M.</style></author><author><style face="normal" font="default" size="100%">Russo, F.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Hougaard, D.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, M.</style></author><author><style face="normal" font="default" size="100%">Cohen, A.</style></author><author><style face="normal" font="default" size="100%">Chawes, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark.&#xD;Section of Chemometrics and Analytical Technologies, Department of Food Science, University of Copenhagen, Frederiksberg C, Denmark.&#xD;Section for Clinical Mass Spectrometry, Danish Center for Neonatal Screening, Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Furan fatty acid metabolite in newborns predicts risk of asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">429-438</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/10/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">*Fatty Acids</style></keyword><keyword><style face="normal" font="default" size="100%">*Fish Oils/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Furans</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">*Prenatal Nutritional Physiological Phenomena</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36254396</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Intake of fish-oil and fatty fish during pregnancy has been shown to reduce the risk of childhood asthma but biomarkers of such intake are lacking. OBJECTIVE: To establish biomarkers of prenatal fish-oil exposure from newborn dry blood spot metabolomics profiles and assess their relevance for childhood asthma risk stratification. METHODS: The Danish COPSAC(2010) mother-child cohort was utilized to investigate the effect of a double-blinded randomized controlled trial of fish-oil supplementation during pregnancy on dry blood spot liquid-chromatography mass spectrometry-based metabolomics profiles of 677 newborns. We thereafter investigated the association between fish-oil associated biomarkers in the newborn and development of asthma-related outcomes. Replication was sought in the independent observational COPSAC(2000) cohort with 387 newborn metabolomics profiles. RESULTS: The newborn metabolomics profiles differed between children in the fish-oil vs. placebo group in COPSAC(2010) (area under the receiver operator curve = 0.94 +/- 0.03, p &lt; .001). The fish-oil metabolomics profile and the top biomarker, 3-carboxy-4-methyl-5-propyl-2-furan propanoic acid (CMPF) were both associated with a decreased risk of asthma by age 6 years (HR = 0.89, p = .002 and HR = 0.67, p = .005, respectively). In COPSAC(2000) , newborn CMPF level was also inversely associated with asthma risk by age 6 years (HR = 0.69, p = .01). Troublesome lung symptoms and common infections in the first 3 years were also inversely associated with newborn CMPF levels in both cohorts. CONCLUSIONS: Newborn children&apos;s blood levels of the furan fatty acid metabolite CMPF reflect fish-oil and fatty fish intake during pregnancy and are associated with a lower risk of asthma across two cohorts, which could aid newborn screening for childhood asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Gurdeniz, Gozde&#xD;Kim, Min&#xD;Brustad, Nicklas&#xD;Ernst, Madeleine&#xD;Russo, Francesco&#xD;Stokholm, Jakob&#xD;Bonnelykke, Klaus&#xD;Hougaard, David&#xD;Rasmussen, Morten&#xD;Cohen, Arieh&#xD;Chawes, Bo&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):429-438. doi: 10.1111/all.15554. Epub 2022 Oct 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36254396</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15554</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2118</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2118</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anagnostou, A.</style></author><author><style face="normal" font="default" size="100%">Lieberman, J.</style></author><author><style face="normal" font="default" size="100%">Greenhawt, M.</style></author><author><style face="normal" font="default" size="100%">Mack, D. P.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Stukus, D.</style></author><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Section of Immunology, Allergy and Retrovirology, Texas Children&apos;s Hospital, Houston, Texas, USA.&#xD;Section of Allergy, Immunology &amp; Retrovirology, Baylor College of Medicine, Houston, Texas, USA.&#xD;Department of Pediatrics, The University of Tennessee Health Science Center, LeBonheur Children&apos;s Hospital, Memphis, Tennessee, USA.&#xD;Section of Allergy and Immunology, Food Challenge and Research Unit, Children&apos;s Hospital Colorado, Department of Pediatrics, University of Colorado School of Medicine, Denver, Colorado, USA.&#xD;Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Courses Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service and Children&apos;s Allergy Service, Evelina Children&apos;s Hospital, Guy&apos;s and St. Thomas&apos;s NHS Foundation Trust, London, UK.&#xD;Section of Allergy and Immunology, Children&apos;s Hospital Colorado, Department of Pediatrics, University of Colorado, Denver, Colorado, USA.&#xD;Nationwide Children&apos;s Hospital, The Ohio State University College of Medicine, Ohio, USA.&#xD;National Heart &amp; Lung Institute, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The future of food allergy: Challenging existing paradigms of clinical practice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1847-1865</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/05/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Food</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Allergists</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">novel diagnostics</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">shared decision-making</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37129472</style></accession-num><abstract><style face="normal" font="default" size="100%">The field of food allergy has seen tremendous change over the past 5-10 years with seminal studies redefining our approach to prevention and management and novel testing modalities in the horizon. Early introduction of allergenic foods is now recommended, challenging the previous paradigm of restrictive avoidance. The management of food allergy has shifted from a passive avoidance approach to active interventions that aim to provide protection from accidental exposures, decrease allergic reaction severity and improve the quality of life of food-allergic patients and their families. Additionally, novel diagnostic tools are making their way into clinical practice with the goal to reduce the need for food challenges and assist physicians in the-often complex-diagnostic process. With all the new developments and available choices for diagnosis, prevention and therapy, shared decision-making has become a key part of medical consultation, enabling patients to make the right choice for them, based on their values and preferences. Communication with patients has also become more complex over time, as patients are seeking advice online and through social media, but the information found online may be outdated, incorrect, or lacking in context. The role of the allergist has evolved to embrace all the above exciting developments and provide patients with the optimal care that fits their needs. In this review, we discuss recent developments as well as the evolution of the field of food allergy in the next decade.</style></abstract><notes><style face="normal" font="default" size="100%">Anagnostou, Aikaterini&#xD;Lieberman, Jay&#xD;Greenhawt, Matthew&#xD;Mack, Douglas Paul&#xD;Santos, Alexandra F&#xD;Venter, Carina&#xD;Stukus, David&#xD;Turner, Paul J&#xD;Brough, Helen A&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/W018616/1/MRC_/Medical Research Council/United Kingdom&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1847-1865. doi: 10.1111/all.15757. Epub 2023 May 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37129472</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15757</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>84</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">84</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, T. M.</style></author><author><style face="normal" font="default" size="100%">Hsu, H. C.</style></author><author><style face="normal" font="default" size="100%">Shen, Y. C.</style></author><author><style face="normal" font="default" size="100%">Chang, Y. S.</style></author><author><style face="normal" font="default" size="100%">Chen, W. S.</style></author><author><style face="normal" font="default" size="100%">Lee, H. Y.</style></author><author><style face="normal" font="default" size="100%">Chang, C. K.</style></author><author><style face="normal" font="default" size="100%">Kuo, T. T.</style></author><author><style face="normal" font="default" size="100%">Chen, S. C.</style></author><author><style face="normal" font="default" size="100%">Chen, J. H.</style></author><author><style face="normal" font="default" size="100%">Chang, C. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.&#xD;Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.&#xD;Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.&#xD;Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan.&#xD;Biostatistics Center, College of Management, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Mathematics and Statistics, Idaho State University, Pocatello, Idaho, USA.&#xD;Graduate Institute of Data Science, College of Management, Taipei Medical University, Taipei, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">GALTectomy increases the risk of allergic rhinitis: A nationwide population-based cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1663-1665</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/11/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36412075</style></accession-num><notes><style face="normal" font="default" size="100%">Lin, Tzu-Min&#xD;Hsu, Hui-Ching&#xD;Shen, Yu-Chuan&#xD;Chang, Yu-Sheng&#xD;Chen, Wei-Sheng&#xD;Lee, Hsiang-Yen&#xD;Chang, Ching-Kuei&#xD;Kuo, Tzu-Tung&#xD;Chen, Shu-Chuan&#xD;Chen, Jin-Hua&#xD;Chang, Chi-Ching&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1663-1665. doi: 10.1111/all.15588. Epub 2022 Nov 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36412075</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15588</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2916</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2916</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rohrhofer, J.</style></author><author><style face="normal" font="default" size="100%">Wolflehner, V.</style></author><author><style face="normal" font="default" size="100%">Schweighardt, J.</style></author><author><style face="normal" font="default" size="100%">Koidl, L.</style></author><author><style face="normal" font="default" size="100%">Stingl, M.</style></author><author><style face="normal" font="default" size="100%">Zehetmayer, S.</style></author><author><style face="normal" font="default" size="100%">Seneca, J.</style></author><author><style face="normal" font="default" size="100%">Pjevac, P.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Facharztzentrum Votivpark, Vienna, Austria.&#xD;Institute of Medical Statistics, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.&#xD;Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria.&#xD;Division of Microbial Ecology, Department of Microbiology and Ecosystem Science, University of Vienna, Vienna, Austria.&#xD;Division of Clinical Microbiology, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gastrointestinal Barrier Disruption in Post-COVID Syndrome Fatigue Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2610-2621</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Fatigue/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Tract/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Post-Acute COVID-19 Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal barrier function</style></keyword><keyword><style face="normal" font="default" size="100%">immune barrier</style></keyword><keyword><style face="normal" font="default" size="100%">post-COVID syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">post-viral fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">predictive phenotypes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40372110</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Post-COVID Syndrome (PCS) is the term for a condition with persistent symptoms in a proportion of COVID-19 patients after asymptomatic, mild, or severe disease courses. Numbers vary, but the current estimate is that after COVID-19 approximately 10% develop PCS. The aim of our study was to evaluate the impact of SARS-CoV-2 infection on the gastrointestinal (GI) tract and associations with the development of PCS with fatigue, post-exertional malaise (PEM), orthostatic dysregulation, autonomous dysregulation, and/or neurocognitive dysregulation. METHODS: By combining medical record data from a prospective observational study with symptom analysis before, during, and after SARS-CoV-2 infection, we aimed to identify potential risk factors and predictive markers for PCS. Additionally, we analyzed blood, saliva, and stool samples from this well-characterized PCS patient cohort to biologically validate our findings. RESULTS: We identified significant associations between pre-existing GI complaints and the development of PCS Fatigue. PCS patients showed higher LBP/sCD14 ratios, lower IL-33 levels, and higher IL-6 levels compared to control groups. Our results highlight the critical role of the GI tract in PCS development of post-viral Fatigue. CONCLUSION: We propose that the viral infection disrupts pathways related to the innate immune response and GI barrier function, evidenced by intestinal low-grade inflammation and GI barrier leakage. Monitoring GI symptoms and markers before, during, and after SARS-CoV-2 infection is crucial for identifying predictive clinical phenotypes in PCS. Understanding the interaction between viral infections, immune responses, and gut integrity could lead to more effective diagnostic and treatment strategies, ultimately reducing the burden on PCS patients.</style></abstract><notes><style face="normal" font="default" size="100%">Rohrhofer, Johanna&#xD;Wolflehner, Viktoria&#xD;Schweighardt, Johannes&#xD;Koidl, Larissa&#xD;Stingl, Michael&#xD;Zehetmayer, Sonja&#xD;Seneca, Joana&#xD;Pjevac, Petra&#xD;Untersmayr, Eva&#xD;eng&#xD;WE&amp;ME Foundation/&#xD;Medizinisch-Wissenschaftlicher Fond des Buergermeisters der Bundeshauptstadt Wien/&#xD;Observational Study&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2610-2621. doi: 10.1111/all.16593. Epub 2025 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40372110</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444858</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16593</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>611</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">611</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, W.</style></author><author><style face="normal" font="default" size="100%">Dhondalay, G. K.</style></author><author><style face="normal" font="default" size="100%">Liu, T. A.</style></author><author><style face="normal" font="default" size="100%">Kaushik, A.</style></author><author><style face="normal" font="default" size="100%">Hoh, R.</style></author><author><style face="normal" font="default" size="100%">Kwok, S.</style></author><author><style face="normal" font="default" size="100%">Kambham, N.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Becker, N. Q.</style></author><author><style face="normal" font="default" size="100%">Andorf, S.</style></author><author><style face="normal" font="default" size="100%">Desai, M.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author><author><style face="normal" font="default" size="100%">Boyd, S. D.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Manohar, M.</style></author><author><style face="normal" font="default" size="100%">DeKruyff, R. H.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Divisions of Biomedical Informatics and Allergy &amp; Immunology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Department of Biomedical Data Science, Stanford University, Stanford, California, USA.&#xD;Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gastrointestinal gammadelta T cells reveal differentially expressed transcripts and enriched pathways during peanut oral immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1606-1610</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Antigen, T-Cell, gamma-delta</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35143054</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Wenming&#xD;Dhondalay, Gopal Krishna&#xD;Liu, Taryn Audrey&#xD;Kaushik, Abhinav&#xD;Hoh, Ramona&#xD;Kwok, Shirley&#xD;Kambham, Neeraja&#xD;Fernandez-Becker, Nielsen Q&#xD;Andorf, Sandra&#xD;Desai, Manisha&#xD;Galli, Stephen J&#xD;Boyd, Scott D&#xD;Nadeau, Kari C&#xD;Manohar, Monali&#xD;DeKruyff, Rosemarie H&#xD;Chinthrajah, R Sharon&#xD;eng&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1606-1610. doi: 10.1111/all.15250. Epub 2022 Feb 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35143054</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9581524</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15250</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>715</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">715</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Neely, J. L.</style></author><author><style face="normal" font="default" size="100%">Reimers, A.</style></author><author><style face="normal" font="default" size="100%">Taylor, S.</style></author><author><style face="normal" font="default" size="100%">Garg, S.</style></author><author><style face="normal" font="default" size="100%">Masuda, M. Y.</style></author><author><style face="normal" font="default" size="100%">Schroeder, S.</style></author><author><style face="normal" font="default" size="100%">Wright, B. L.</style></author><author><style face="normal" font="default" size="100%">Doyle, A. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Arizona College of Medicine -Phoenix, Phoenix, Arizona, USA.&#xD;Division of Allergy, Asthma, and Clinical Immunology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA.&#xD;Division of Laboratory Medicine and Pathology, Phoenix Children&apos;s Hospital, Phoenix, Arizona, USA.&#xD;Division of Gastroenterology, Phoenix Children&apos;s Hospital, Phoenix, Arizona, USA.&#xD;Section of Allergy and Immunology, Division of Pulmonology, Phoenix Children&apos;s Hospital, Phoenix, Arizona, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">GATA-3 and T-bet as diagnostic markers of non-esophageal eosinophilic gastrointestinal disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1042-1044</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Enteritis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilia/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastritis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Gata-3</style></keyword><keyword><style face="normal" font="default" size="100%">T-bet</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic enteritis</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic gastritis</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic gastrointestinal disease</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric subjects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34735725</style></accession-num><notes><style face="normal" font="default" size="100%">Neely, Joseph L&#xD;Reimers, Annika&#xD;Taylor, Steve&#xD;Garg, Shipra&#xD;Masuda, Mia Y&#xD;Schroeder, Shauna&#xD;Wright, Benjamin L&#xD;Doyle, Alfred D&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1042-1044. doi: 10.1111/all.15171. Epub 2021 Nov 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34735725</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15171</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>661</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">661</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Malvik, L. B.</style></author><author><style face="normal" font="default" size="100%">De Pater, G. H.</style></author><author><style face="normal" font="default" size="100%">Dahle, G. O.</style></author><author><style face="normal" font="default" size="100%">Guttormsen, A. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Haukeland University Hospital, Bergen, Norway.&#xD;Drammen Hospital, Drammen, Norway.&#xD;Department of Clinical Medicine, University of Bergen, Bergen, Norway.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gender-specific decline in perioperative allergic reactions in Norway after withdrawal of pholcodine</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1317-1319</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/12/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Codeine/analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Morpholines</style></keyword><keyword><style face="normal" font="default" size="100%">Norway/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34963030</style></accession-num><notes><style face="normal" font="default" size="100%">Malvik, Lars Berg&#xD;De Pater, Gerrit Hendrik&#xD;Dahle, Geir Olav&#xD;Guttormsen, Anne Berit&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1317-1319. doi: 10.1111/all.15201. Epub 2022 Jan 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34963030</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15201</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1087</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1087</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Camilleri, A. E.</style></author><author><style face="normal" font="default" size="100%">Nag, S.</style></author><author><style face="normal" font="default" size="100%">Russo, A. R.</style></author><author><style face="normal" font="default" size="100%">Stiles, K. M.</style></author><author><style face="normal" font="default" size="100%">Crystal, R. G.</style></author><author><style face="normal" font="default" size="100%">Pagovich, O. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Genetic Medicine, Weill Cornell Medical College, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gene therapy for a murine model of eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2740-2752</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/03/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33748982</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophils are specialized granulocytic effector cells that store and release highly active mediators used in immune defense. Eosinophils are also implicated in the pathogenesis of allergic disorders, including eosinophilic esophagitis (EoE), a chronic disorder characterized by infiltration of eosinophils into the esophagus and release of mediators that damage tissue, resulting in gastrointestinal morbidity, food impaction, and dysphagia. Treatment with elimination diets and/or topical corticosteroid therapy slow disease progression, but are complicated by adverse effects, limited compliance, and loss of response to therapy. We hypothesized that a single administration of an adeno-associated virus (AAV) coding for an anti-eosinophil monoclonal antibody that induces eosinophil clearance (anti-Siglec-F) would treat on a persistent basis a murine model of EoE. METHODS: A mouse model of peanut-induced EoE that mimics the human disease was established by sensitization and challenge with peanut extract. After challenge, these mice exhibited an EoE phenotype demonstrated by elevated levels of blood eosinophils, infiltration of eosinophils in the esophagus with associated esophageal remodeling and food impaction. RESULTS: The mice were treated with a single intravenous administration (10(11) genome copies) of AAVrh.10mAnti-Eos, a serotype rh.10 AAV vector coding for an anti-Siglec-F monoclonal antibody. Vector administration resulted in persistent, high levels of anti-Siglec-F antibody expression. Administration of AAVrh.10mAnti-Eos to the mouse model of EoE reduced blood (P &lt; 0.02) and esophageal eosinophil numbers (P &lt; 0.002) protected from esophageal tissue remodeling and minimized food impaction. CONCLUSION: These results suggest that a single treatment with AAVrh.10mAnti-Eos has the potential to provide persistent therapeutic benefit to patients with EoE.</style></abstract><notes><style face="normal" font="default" size="100%">Camilleri, Anna E&#xD;Nag, Saparja&#xD;Russo, Anthony R&#xD;Stiles, Katie M&#xD;Crystal, Ronald G&#xD;Pagovich, Odelya E&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2740-2752. doi: 10.1111/all.14822. Epub 2021 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33748982</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14822</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>52</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">52</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vogeley, C.</style></author><author><style face="normal" font="default" size="100%">Kress, S.</style></author><author><style face="normal" font="default" size="100%">Lang, D.</style></author><author><style face="normal" font="default" size="100%">Vogel, C. F. A.</style></author><author><style face="normal" font="default" size="100%">Hartung, F.</style></author><author><style face="normal" font="default" size="100%">Brenden, H.</style></author><author><style face="normal" font="default" size="100%">Nakamura, M.</style></author><author><style face="normal" font="default" size="100%">Grether-Beck, S.</style></author><author><style face="normal" font="default" size="100%">Rossi, A.</style></author><author><style face="normal" font="default" size="100%">Krutmann, J.</style></author><author><style face="normal" font="default" size="100%">Schikowski, T.</style></author><author><style face="normal" font="default" size="100%">Haarmann-Stemmann, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">IUF - Leibniz Research Institute for Environmental Medicine, Dusseldorf, Germany.&#xD;Bayer AG, Pharmaceuticals, Research Center, Wuppertal, Germany.&#xD;Center for Health and the Environment, University of California, Davis, California, USA.&#xD;Department of Environmental Toxicology, University of California, Davis, California, USA.&#xD;Department of Environmental and Geriatric Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.&#xD;Medical Faculty, Heinrich-Heine-University, Dusseldorf, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A gene variant of AKR1C3 contributes to interindividual susceptibilities to atopic dermatitis triggered by particulate air pollution</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1372-1375</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/12/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Aldo-Keto Reductase Family 1 Member C3</style></keyword><keyword><style face="normal" font="default" size="100%">air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">aldo-keto reductase</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">particulate matter</style></keyword><keyword><style face="normal" font="default" size="100%">polycyclic aromatic hydrocarbons</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36524327</style></accession-num><notes><style face="normal" font="default" size="100%">Vogeley, Christian&#xD;Kress, Sara&#xD;Lang, Dieter&#xD;Vogel, Christoph F A&#xD;Hartung, Frederick&#xD;Brenden, Heidi&#xD;Nakamura, Motoki&#xD;Grether-Beck, Susanne&#xD;Rossi, Andrea&#xD;Krutmann, Jean&#xD;Schikowski, Tamara&#xD;Haarmann-Stemmann, Thomas&#xD;eng&#xD;P30 ES023513/ES/NIEHS NIH HHS/&#xD;R01 ES029126/ES/NIEHS NIH HHS/&#xD;R01 ES032827/ES/NIEHS NIH HHS/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1372-1375. doi: 10.1111/all.15622. Epub 2022 Dec 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36524327</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10159942</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15622</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2900</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2900</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Standl, M.</style></author><author><style face="normal" font="default" size="100%">Budu-Aggrey, A.</style></author><author><style face="normal" font="default" size="100%">Johnston, L. J.</style></author><author><style face="normal" font="default" size="100%">Elias, M. S.</style></author><author><style face="normal" font="default" size="100%">Arshad, S. H.</style></author><author><style face="normal" font="default" size="100%">Bager, P.</style></author><author><style face="normal" font="default" size="100%">Bataille, V.</style></author><author><style face="normal" font="default" size="100%">Blakeway, H.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Boomsma, D.</style></author><author><style face="normal" font="default" size="100%">Brumpton, B. M.</style></author><author><style face="normal" font="default" size="100%">Bustamante Pineda, M.</style></author><author><style face="normal" font="default" size="100%">Campbell, A.</style></author><author><style face="normal" font="default" size="100%">Curtin, J. A.</style></author><author><style face="normal" font="default" size="100%">Eliasen, A.</style></author><author><style face="normal" font="default" size="100%">Fadista, J. P. S.</style></author><author><style face="normal" font="default" size="100%">Feenstra, B.</style></author><author><style face="normal" font="default" size="100%">Gerner, T.</style></author><author><style face="normal" font="default" size="100%">Medina-Gomez, C.</style></author><author><style face="normal" font="default" size="100%">Grosche, S.</style></author><author><style face="normal" font="default" size="100%">Gutzkow, K. B.</style></author><author><style face="normal" font="default" size="100%">Halling, A. S.</style></author><author><style face="normal" font="default" size="100%">Hayward, C.</style></author><author><style face="normal" font="default" size="100%">Henderson, J.</style></author><author><style face="normal" font="default" size="100%">Herrera-Luis, E.</style></author><author><style face="normal" font="default" size="100%">Holloway, J. W.</style></author><author><style face="normal" font="default" size="100%">Hottenga, J.</style></author><author><style face="normal" font="default" size="100%">O&apos;B Hourihane J</style></author><author><style face="normal" font="default" size="100%">Hu, C.</style></author><author><style face="normal" font="default" size="100%">Hveem, K.</style></author><author><style face="normal" font="default" size="100%">Irizar, A.</style></author><author><style face="normal" font="default" size="100%">Jacquemin, B.</style></author><author><style face="normal" font="default" size="100%">Jessen, L.</style></author><author><style face="normal" font="default" size="100%">Kress, S.</style></author><author><style face="normal" font="default" size="100%">Kurukulaaratchy, R. J.</style></author><author><style face="normal" font="default" size="100%">Lau, S.</style></author><author><style face="normal" font="default" size="100%">Llop, S.</style></author><author><style face="normal" font="default" size="100%">Loset, M.</style></author><author><style face="normal" font="default" size="100%">Marenholz, I.</style></author><author><style face="normal" font="default" size="100%">Mason, D.</style></author><author><style face="normal" font="default" size="100%">McCartney, D. L.</style></author><author><style face="normal" font="default" size="100%">Melbye, M.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Minica, C.</style></author><author><style face="normal" font="default" size="100%">Murray, C. S.</style></author><author><style face="normal" font="default" size="100%">Nijsten, T.</style></author><author><style face="normal" font="default" size="100%">Pardo, L. M.</style></author><author><style face="normal" font="default" size="100%">Pasmans, S.</style></author><author><style face="normal" font="default" size="100%">Pennell, C. E.</style></author><author><style face="normal" font="default" size="100%">Rinnov, M. R.</style></author><author><style face="normal" font="default" size="100%">Santorelli, G.</style></author><author><style face="normal" font="default" size="100%">Schikowski, T.</style></author><author><style face="normal" font="default" size="100%">Sheehan, D.</style></author><author><style face="normal" font="default" size="100%">Simpson, A.</style></author><author><style face="normal" font="default" size="100%">Soderhall, C.</style></author><author><style face="normal" font="default" size="100%">Thomas, L. F.</style></author><author><style face="normal" font="default" size="100%">Thyssen, J. P.</style></author><author><style face="normal" font="default" size="100%">Torrent, M.</style></author><author><style face="normal" font="default" size="100%">van Beijsterveldt, T.</style></author><author><style face="normal" font="default" size="100%">Visconti, A.</style></author><author><style face="normal" font="default" size="100%">Vonk, J. M.</style></author><author><style face="normal" font="default" size="100%">Wang, C. A.</style></author><author><style face="normal" font="default" size="100%">Xu, C. J.</style></author><author><style face="normal" font="default" size="100%">Ziyab, A. H.</style></author><author><style face="normal" font="default" size="100%">U. K. Translational Research Network in Dermatology</style></author><author><style face="normal" font="default" size="100%">Biomap Consortium</style></author><author><style face="normal" font="default" size="100%">Custovic, A.</style></author><author><style face="normal" font="default" size="100%">Di Meglio, P.</style></author><author><style face="normal" font="default" size="100%">Duijts, L.</style></author><author><style face="normal" font="default" size="100%">Flohr, C.</style></author><author><style face="normal" font="default" size="100%">Irvine, A. D.</style></author><author><style face="normal" font="default" size="100%">Koppelman, G. H.</style></author><author><style face="normal" font="default" size="100%">Lee, Y. A.</style></author><author><style face="normal" font="default" size="100%">Reynolds, N. J.</style></author><author><style face="normal" font="default" size="100%">Smith, C.</style></author><author><style face="normal" font="default" size="100%">Langan, S. M.</style></author><author><style face="normal" font="default" size="100%">Paternoster, L.</style></author><author><style face="normal" font="default" size="100%">Brown, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Epidemiology, Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg, Germany.&#xD;German Center for Child and Adolescent Health (DZKJ), partner site Munich, Munich, Germany.&#xD;MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK.&#xD;Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.&#xD;Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;NIHR Southampton Biomedical Research Centre, University Hospitals Southampton NHS Foundation Trust, Southampton, UK.&#xD;Asthma and Allergy Research Centre, Isle of Wight, UK.&#xD;Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark.&#xD;Department of Twin Research and Genetic Epidemiology, King&apos;s College London, London, UK.&#xD;COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Biological Psychology, Faculty of Behavioral and Movement Sciences, Vrije Universiteit, Amsterdam, the Netherlands.&#xD;Department of Public Health and Nursing, HUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim, Norway.&#xD;ISGlobal, Institute for Global Health, Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.&#xD;Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester Academic Health Science Centre, and Manchester University NHS Foundation Trust, Manchester, UK.&#xD;Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.&#xD;Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.&#xD;Max-Delbruck-Center (MDC) for Molecular Medicine, Berlin, Germany.&#xD;Division of Climate and Environmental Health, Department of Air Quality and Noise, Norwegian Institute of Public Health (NIPH), Oslo, Norway.&#xD;Department of Dermatology and Venereology, Bispebjerg Hospital, University of Copenhagen, Copenhagen N, Denmark.&#xD;Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.&#xD;Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Royal College of Surgeons in Ireland, Dublin, Ireland.&#xD;Children&apos;s Health Ireland, Dublin, Ireland.&#xD;INFANT Centre, University College Cork, Cork, Ireland.&#xD;The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.&#xD;Department of Dermatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.&#xD;Department for Research, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.&#xD;Department of Preventive Medicine and Public Health, UPV/EHU, Leioa, Spain.&#xD;Biogipuzkoa HRI, Donostia, Spain.&#xD;Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en sante, environnement et travail) - UMR_S 1085, Rennes, France.&#xD;IUF-Leibniz Research Institute for Environmental Medicine, Dusseldorf, Germany.&#xD;Department of Pediatric Respiratory Medicine, Immunology, and Intensive Care Medicine, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de Valencia, Valencia, Spain.&#xD;Department of Dermatology, Clinic of Orthopedy, Rheumatology and Dermatology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.&#xD;Clinic for Pediatric Allergy, Experimental and Clinical Research Center, Charite University Medical Center, Berlin, Germany.&#xD;Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.&#xD;Danish Cancer Institute, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;School of Medicine and Public Health, The University of Newcastle, Newcastle, New South Wales, Australia.&#xD;Mothers and Babies Research Program, Hunter Medical Research Institute, Newcastle, New South Wales, Australia.&#xD;Department of Neonatology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.&#xD;University College Cork, Cork, Ireland.&#xD;Cork University Hospital, Cork, Ireland.&#xD;Department of Women&apos;s and Children&apos;s Health, Karolinska Institutet, Stockholm, Sweden.&#xD;Astrid Lindgren&apos;s Children&apos;s Hospital, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.&#xD;BioCore - Bioinformatics Core Facility, Norwegian University of Science and Technology, Trondheim, Norway.&#xD;Area de Salut de Menorca, ib-salut, Balearic Islands, Spain.&#xD;Department of Clinical and Biological Sciences, Center for Biostatistics, Epidemiology and Public Health, University of Turin, Turin, Italy.&#xD;Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.&#xD;University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands.&#xD;Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School (MHH), Hannover, Germany.&#xD;TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.&#xD;Department of Community Medicine and Behavioral Sciences, College of Medicine, Kuwait University, Kuwait City, Kuwait.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;St John&apos;s Institute of Dermatology and the School of Basic and Medical Sciences, King&apos;s College London, London, UK.&#xD;Division of Respiratory Medicine and Allergology, and Neonatology, Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.&#xD;Division of Neonatology, Department of Neonatal and Intensive Care, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.&#xD;Department of Paediatric Dermatology, St John&apos;s Institute of Dermatology, Guy&apos;s and St Thomas&apos; NHS Foundation Trust and King&apos;s College London, London, UK.&#xD;Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland.&#xD;Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children&apos;s Hospital, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.&#xD;Faculty of Medical Sciences, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.&#xD;Department of Dermatology and NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.&#xD;Faculty of Epidemiology and Population Health, London School of Hygiene &amp; Tropical Medicine, London, UK.&#xD;St John&apos;s Institute of Dermatology, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK.&#xD;NIHR Bristol Biomedical Research Centre, University Hospital Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.&#xD;Department of Dermatology, NHS Lothian, Edinburgh, Scotland, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gene-Environment Interaction Affects Risk of Atopic Eczema: Population and In Vitro Studies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2201-2212</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/06/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/etiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Gene-Environment Interaction</style></keyword><keyword><style face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">*Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">atopic eczema</style></keyword><keyword><style face="normal" font="default" size="100%">dog</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">gene</style></keyword><keyword><style face="normal" font="default" size="100%">interaction</style></keyword><keyword><style face="normal" font="default" size="100%">the Wellcome Trust (220875/Z/20/Z), UKRI, Medical Research Council, Rosetrees</style></keyword><keyword><style face="normal" font="default" size="100%">Trust, Stoneygates Trust, British Skin Foundation, Charles Wolfson Charitable</style></keyword><keyword><style face="normal" font="default" size="100%">Trust, anonymous donations from people with eczema, Unilever, Pfizer, Abbvie,</style></keyword><keyword><style face="normal" font="default" size="100%">Sosei-Heptares, Janssen, and European Lead Factory (which includes multiple</style></keyword><keyword><style face="normal" font="default" size="100%">industry partners). S.J.B., A.B.-A., K.B., A.D.I., G.H.K., C.S., S.M.L., and L.P.</style></keyword><keyword><style face="normal" font="default" size="100%">have received funding from the BIOMAP-IMI consortium (EU H2020 project ref. no.</style></keyword><keyword><style face="normal" font="default" size="100%">821511) which receives support from several pharmaceutical industry partners.</style></keyword><keyword><style face="normal" font="default" size="100%">L.P. has received an honorarium payment for a scientific talk on eczema genetics</style></keyword><keyword><style face="normal" font="default" size="100%">from LEO Pharma. G.H.K. reports grants from the Netherlands Lung Foundation,</style></keyword><keyword><style face="normal" font="default" size="100%">ZON-MW, Ubbo Emmius Foundation, TEVA the Netherlands, GSK, Vertex, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work (money to institution). His institution received compensation for</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy or lectures from Astra Zeneca, Boehringer Ingelheim, and Sanofi.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40462597</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Multiple environmental and genetic factors play a role in the pathogenesis of atopic eczema (AE). We aimed to investigate gene-environment interactions (G x E) to improve understanding of the pathophysiology. METHODS: We analysed data from 16 European studies to test for interaction between the 24 most significant AE-associated loci identified from genome-wide association studies and 18 early-life environmental factors. We tested for replication using a further 10 studies and in vitro modeling to independently assess findings. RESULTS: The discovery analysis (including 25,339 individuals) showed suggestive evidence for interaction (p &lt; 0.05) between seven environmental factors (antibiotic use, cat ownership, dog ownership, breastfeeding, elder sibling, smoking and washing practices) and at least one established variant for AE, 14 interactions in total. In the replication analysis (254,532 individuals) dog exposure x rs10214237 (on chromosome 5p13.2 near IL7R) was nominally significant (OR(interaction) = 0.91 [0.83-0.99] p = 0.025), with a risk effect of the T allele observed only in those not exposed to dogs. A similar interaction with rs10214237 was observed for siblings in the discovery analysis (OR(interaction) = 0.84 [0.75-0.94] p = 0.003), but replication analysis was under-powered (OR(interaction) = 1.09 [0.82-1.46]). rs10214237 homozygous risk genotype is associated with lower IL-7R expression in human keratinocytes, and dog exposure modelled in vitro showed a differential response according to rs10214237 genotype. CONCLUSION: Interaction analysis and functional assessment provide preliminary evidence that early-life dog exposure may modify the genetic effect of rs10214237 on AE via IL7R, supporting observational epidemiology showing a protective effect for dog ownership. The lack of evidence for other G x E studied here implies only weak effects are likely to occur.</style></abstract><notes><style face="normal" font="default" size="100%">Standl, Marie&#xD;Budu-Aggrey, Ashley&#xD;Johnston, Luke J&#xD;Elias, Martina S&#xD;Arshad, S Hasan&#xD;Bager, Peter&#xD;Bataille, Veronique&#xD;Blakeway, Helena&#xD;Bonnelykke, Klaus&#xD;Boomsma, Dorret&#xD;Brumpton, Ben M&#xD;Bustamante Pineda, Mariona&#xD;Campbell, Archie&#xD;Curtin, John A&#xD;Eliasen, Anders&#xD;Fadista, Joao P S&#xD;Feenstra, Bjarke&#xD;Gerner, Trine&#xD;Medina-Gomez, Carolina&#xD;Grosche, Sarah&#xD;Gutzkow, Kristine B&#xD;Halling, Anne-Sofie&#xD;Hayward, Caroline&#xD;Henderson, John&#xD;Herrera-Luis, Esther&#xD;Holloway, John W&#xD;Hottenga, Joukejan&#xD;O&apos;B Hourihane, Jonathan&#xD;Hu, Chen&#xD;Hveem, Kristian&#xD;Irizar, Amaia&#xD;Jacquemin, Benedicte&#xD;Jessen, Leon&#xD;Kress, Sara&#xD;Kurukulaaratchy, Ramesh J&#xD;Lau, Susanne&#xD;Llop, Sabrina&#xD;Loset, Mari&#xD;Marenholz, Ingo&#xD;Mason, Dan&#xD;McCartney, Daniel L&#xD;Melbye, Mads&#xD;Melen, Erik&#xD;Minica, Camelia&#xD;Murray, Clare S&#xD;Nijsten, Tamar&#xD;Pardo, Luba M&#xD;Pasmans, Suzanne&#xD;Pennell, Craig E&#xD;Rinnov, Maria R&#xD;Santorelli, Gillian&#xD;Schikowski, Tamara&#xD;Sheehan, Darina&#xD;Simpson, Angela&#xD;Soderhall, Cilla&#xD;Thomas, Laurent F&#xD;Thyssen, Jacob P&#xD;Torrent, Maties&#xD;van Beijsterveldt, Toos&#xD;Visconti, Alessia&#xD;Vonk, Judith M&#xD;Wang, Carol A&#xD;Xu, Cheng-Jian&#xD;Ziyab, Ali H&#xD;Custovic, Adnan&#xD;Di Meglio, Paola&#xD;Duijts, Liesbeth&#xD;Flohr, Carsten&#xD;Irvine, Alan D&#xD;Koppelman, Gerard H&#xD;Lee, Young-Ae&#xD;Reynolds, Nick J&#xD;Smith, Catherine&#xD;Langan, Sinead M&#xD;Paternoster, Lavinia&#xD;Brown, Sara J&#xD;eng&#xD;MRC_/Medical Research Council/United Kingdom&#xD;Netherlands Organization for Scientific Research/&#xD;Netherlands Organization for Health Research and Development/&#xD;ERC_/European Research Council/International&#xD;Netherlands Ministry of Health, Welfare, and Sport/&#xD;Lung Foundation Netherlands/&#xD;Netherlands Ministry of Spatial Planning, Housing, and the Environment/&#xD;Innovative Medicines Initiative/&#xD;Asthma and Lung UK/&#xD;European Science Foundation/&#xD;The North West Lung Centre Charity/&#xD;German Federal Ministry of Education and Research/&#xD;Ministerio de Ciencia e Innovacion/&#xD;National Institute for Health and Care Research/&#xD;WT_/Wellcome Trust/United Kingdom&#xD;BMA James Trust/&#xD;The JP Moulton Charitable Foundation/&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2201-2212. doi: 10.1111/all.16605. Epub 2025 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40462597</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368900</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16605</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2445</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2445</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gharailoo, Z.</style></author><author><style face="normal" font="default" size="100%">Plattner, K.</style></author><author><style face="normal" font="default" size="100%">Augusto, G.</style></author><author><style face="normal" font="default" size="100%">Engeroff, P.</style></author><author><style face="normal" font="default" size="100%">Vogel, M.</style></author><author><style face="normal" font="default" size="100%">Bachmann, M. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, University Clinic for Rheumatology and Immunology, University of Bern, Bern, Switzerland.&#xD;Department of Biomedical Research Bern (DBMR), University of Bern, Bern, Switzerland.&#xD;Graduate School for Cellular and Biomedical Sciences (GCB), Bern, Switzerland.&#xD;Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Generation of a virus-like particles based vaccine against IgE</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2207-2221</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/03/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines, Virus-Like Particle/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Anti-Idiotypic/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">VLPs</style></keyword><keyword><style face="normal" font="default" size="100%">allergens</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38445568</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Anti-IgE immunotherapy with monoclonal antibodies represents a breakthrough in treatment of severe allergic diseases. However, drawbacks such as short half-life and high price are not negligible. Our objective is to develop an anti-IgE vaccine based on virus-like particles (VLPs) which can induce long-lasting neutralizing IgG anti-IgE antibodies reducing allergic responses without causing intrinsic mast cell activation due to IgE cross-linking. METHODS: The vaccines were made by chemically coupling three synthetic mouse IgE-Fc fragments to plant-derived immunologically optimized CuMV(TT) VLPs. The immunogenicity of the vaccines was tested by immunizing naive or allergic mice either with the coupled vaccines or the VLP control followed by systemic or local allergen challenge. RESULTS: Mice immunized with the vaccines exhibited high titers of anti-IgE antibodies in the sera and high levels of anti-IgE secreting plasma cells in lymphoid organs. Moreover, free IgE in serum were reduced by the induced anti-IgE antibodies; therefore, less IgE was bound to FcepsilonRI on the surface of basophils. In line with these reduced IgE levels on effector cells after vaccination, immunized mice were protected from challenge with allergens. Importantly, despite presence of anti-IgE antibodies, no signs of acute or chronic allergic response were seen in immunized allergic mice. CONCLUSION: The generated vaccines can effectively induce anti-IgE antibodies that did not cause allergic responses in sensitized mice but were able to decrease the level of free and cell bound IgE and protected sensitized animals from allergic responses upon allergen challenge.</style></abstract><notes><style face="normal" font="default" size="100%">Gharailoo, Zahra&#xD;Plattner, Kevin&#xD;Augusto, Gilles&#xD;Engeroff, Paul&#xD;Vogel, Monique&#xD;Bachmann, Martin F&#xD;eng&#xD;310030_185114/SNF Martin Bachmann/&#xD;310030_179165/SNF Monique Vogel/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2207-2221. doi: 10.1111/all.16090. Epub 2024 Mar 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38445568</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16090</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1572</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1572</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boccabella, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario &quot;A Gemelli&quot; - IRCCS, University of the Sacred Heart, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Generation of functional lungs with pluripotent stem cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3297-3298</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2020/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">*Induced Pluripotent Stem Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">*Pluripotent Stem Cells</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">genetics</style></keyword><keyword><style face="normal" font="default" size="100%">pneumology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32623729</style></accession-num><notes><style face="normal" font="default" size="100%">Boccabella, Cristina&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2020 Dec;75(12):3297-3298. doi: 10.1111/all.14485. Epub 2020 Jul 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32623729</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14485</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1207</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1207</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Larsson, S. C.</style></author><author><style face="normal" font="default" size="100%">Gill, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.&#xD;Department of Epidemiology and Biostatistics, School of Public Health, St Mary&apos;s Hospital, Imperial College London, London, UK.&#xD;Clinical Pharmacology and Therapeutics Section, Institute of Medical and Biomedical Education and Institute for Infection and Immunity, St George&apos;s, University of London, London, UK.&#xD;Clinical Pharmacology Group, Pharmacy and Medicines Directorate, St George&apos;s University Hospitals NHS Foundation Trust, London, UK.&#xD;Novo Nordisk Research Centre Oxford, Oxford, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genetic predisposition to allergic diseases is inversely associated with risk of COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1911-1913</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/01/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33382452</style></accession-num><notes><style face="normal" font="default" size="100%">Larsson, Susanna C&#xD;Gill, Dipender&#xD;eng&#xD;20190247/Swedish Heart-Lung Foundation/&#xD;2019-00977/Swedish Research Council/&#xD;2018-00123/Swedish Research Council for Health, Working Life and Welfare/&#xD;RE/18/4/34215/British Heart Foundation Research Centre of Excellence/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1911-1913. doi: 10.1111/all.14728. Epub 2021 Jan 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33382452</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8327281 Larsson has nothing to disclose.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14728</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>962</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">962</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Losol, P.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Ahn, S.</style></author><author><style face="normal" font="default" size="100%">Lee, S.</style></author><author><style face="normal" font="default" size="100%">Choi, J. P.</style></author><author><style face="normal" font="default" size="100%">Kim, Y. H.</style></author><author><style face="normal" font="default" size="100%">Hong, S. J.</style></author><author><style face="normal" font="default" size="100%">Kim, B. S.</style></author><author><style face="normal" font="default" size="100%">Chang, Y. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.&#xD;Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.&#xD;Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Council, Seoul, Korea.&#xD;Division of Statistics, Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam, Korea.&#xD;Precision Medicine Center, Seoul National University Bundang Hospital, Seongnam, Korea.&#xD;Department of Pediatrics, Childhood Asthma Atopy Center, Humidifier Disinfectant Health Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Department of Life Science, Multidisciplinary Genome Institute, Hallym University, Chuncheon, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genetic variants in the TLR-related pathway and smoking exposure alter the upper airway microbiota in adult asthmatic patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3217-3220</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/06/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Smoking/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">genetics</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">smoking</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34061362</style></accession-num><notes><style face="normal" font="default" size="100%">Losol, Purevsuren&#xD;Kim, Sae-Hoon&#xD;Ahn, Soyeon&#xD;Lee, Sejoon&#xD;Choi, Jun-Pyo&#xD;Kim, Yong-Hyun&#xD;Hong, Soo-Jong&#xD;Kim, Bong-Soo&#xD;Chang, Yoon-Seok&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3217-3220. doi: 10.1111/all.14970. Epub 2021 Jun 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34061362</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14970</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2901</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2901</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hernandez-Pacheco, N.</style></author><author><style face="normal" font="default" size="100%">Bjorkander, S.</style></author><author><style face="normal" font="default" size="100%">Merid, S. K.</style></author><author><style face="normal" font="default" size="100%">Kere, M.</style></author><author><style face="normal" font="default" size="100%">Kumar, A.</style></author><author><style face="normal" font="default" size="100%">Klevebro, S.</style></author><author><style face="normal" font="default" size="100%">Mogensen, I.</style></author><author><style face="normal" font="default" size="100%">Ekstrom, S.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Palmberg, L.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Malarstig, A.</style></author><author><style face="normal" font="default" size="100%">Merritt, A. S.</style></author><author><style face="normal" font="default" size="100%">Pershagen, G.</style></author><author><style face="normal" font="default" size="100%">Bergstrom, A.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Schwenk, J. M.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Centre for Occupational and Environmental Medicine, Region Stockholm, Stockholm, Sweden.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.&#xD;Division of Immunology and Respiratory Medicine, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.&#xD;Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.&#xD;Pfizer Research and Development, Stockholm, Sweden.&#xD;Science for Life Laboratory, Department of Protein Science, KTH Royal Institute of Technology, Solna, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genetically Determined Inflammation-Related Proteins in Asthma and Type-2 Signatures</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1702-1714</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/06/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics/diagnosis/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Quantitative Trait Loci</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Blood Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Sweden</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">genetics</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">proteins</style></keyword><keyword><style face="normal" font="default" size="100%">type-2 signatures</style></keyword><keyword><style face="normal" font="default" size="100%">Immunology (EAACI) and the European Respiratory Society (ERS). S.K. reports</style></keyword><keyword><style face="normal" font="default" size="100%">funding from the Region Stockholm and the Swedish Heart-Lung Foundation, lecture</style></keyword><keyword><style face="normal" font="default" size="100%">payments from AstraZeneca, and participation on the Advisory Board at Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">Sweden, Stallergenes Greer Denmark, and ALK Sweden outside the submitted work.</style></keyword><keyword><style face="normal" font="default" size="100%">E.M. declares Advisory Board fees from ALK and AstraZeneca and lecture payments</style></keyword><keyword><style face="normal" font="default" size="100%">from Chiesi and Sanofi outside the submitted work. M.H. has received lecture fees</style></keyword><keyword><style face="normal" font="default" size="100%">from AstraZeneca and Thermo Fisher Scientific outside the submitted work. The</style></keyword><keyword><style face="normal" font="default" size="100%">remaining authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40464643</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Protein quantitative trait loci (pQTLs) remain underexplored in asthma but might provide valuable insights into the underlying molecular mechanisms. This study aimed to investigate associations between genetic variation and inflammation-related plasma proteins and to assess differences in the levels of genetically determined proteins in subjects with signatures of type-2 inflammation and/or asthma. METHODS: A pQTL mapping of 92 inflammation-related plasma proteins was conducted in young adults from the Swedish BAMSE cohort (n = 1538). Replication of sentinel pQTLs was attempted, and the overlap and colocalization of pQTLs with expression quantitative trait loci (eQTLs) were investigated using publicly available data. Proteins with significant pQTLs were tested for association with type-2 signatures defined as high levels of fractional exhaled nitric oxide, blood eosinophils, and/or sensitization to airborne allergens in subjects with or without asthma in BAMSE. RESULTS: Forty-five sentinel pQTLs (33 cis, 12 trans) for 39 inflammation-related proteins were identified (p &lt;/= 7.14 x 10(-11)), and a high proportion of these were validated in independent populations. A high likelihood for colocalization of cis-pQTLs and cis-eQTLs was observed for 19 proteins in different tissues. Six of the 39 circulating proteins with significant pQTLs were associated with type-2 signatures and/or asthma, and matrix metalloproteinase-10 (MMP-10) showed the most significant associations. CONCLUSIONS: These findings underscore the existence of a genetic component influencing the plasma levels of proteins involved in inflammatory processes, including MMP-10, which is suggested to have a role in high type-2 inflammation in asthma subjects.</style></abstract><notes><style face="normal" font="default" size="100%">Hernandez-Pacheco, Natalia&#xD;Bjorkander, Sophia&#xD;Merid, Simon Kebede&#xD;Kere, Maura&#xD;Kumar, Ashish&#xD;Klevebro, Susanna&#xD;Mogensen, Ida&#xD;Ekstrom, Sandra&#xD;Janson, Christer&#xD;Palmberg, Lena&#xD;van Hage, Marianne&#xD;Malarstig, Anders&#xD;Merritt, Anne-Sophie&#xD;Pershagen, Goran&#xD;Bergstrom, Anna&#xD;Kull, Inger&#xD;Schwenk, Jochen M&#xD;Melen, Erik&#xD;eng&#xD;2016-03086/Vetenskapsradet/&#xD;2018-02524/Vetenskapsradet/&#xD;2019-01060/Vetenskapsradet/&#xD;2020-02170/Vetenskapsradet/&#xD;2017-00526/Forskningsradet for halsa, Arbetsliv och valfard/&#xD;2016-01646/Formas/&#xD;Hjart-Lungfonden/&#xD;the European Academy of Allergy and Clinical Immunology (EAACI)/&#xD;LTRF202101-00861/Long-Term Research Fellowship by the European Respiratory Society (ERS)/&#xD;TRIBAL/European Union, European Research Council/&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1702-1714. doi: 10.1111/all.16608. Epub 2025 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40464643</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186602</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16608</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3138</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3138</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Han, J. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, J. Y.</style></author><author><style face="normal" font="default" size="100%">Jung, C. G.</style></author><author><style face="normal" font="default" size="100%">Lockey, R. F.</style></author><author><style face="normal" font="default" size="100%">Kumar, R.</style></author><author><style face="normal" font="default" size="100%">Yon, D. K.</style></author><author><style face="normal" font="default" size="100%">Kolliputi, N.</style></author><author><style face="normal" font="default" size="100%">Cho, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Department of Internal Medicine, USF Morsani College of Medicine, Tampa, Florida, USA.&#xD;Division of Allergy and Clinical Immunology, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Pediatrics, Kyung Hee University College of Medicine, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genistein Reduced Eosinophilic Inflammation and Remodeling by Downregulating PAI-1 and TSLP</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">remodeling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41074673</style></accession-num><notes><style face="normal" font="default" size="100%">Han, Jung Yeon&#xD;Lee, Jea-Young&#xD;Jung, Chang-Gyu&#xD;Lockey, Richard F&#xD;Kumar, Rajesh&#xD;Yon, Dong Keon&#xD;Kolliputi, Narasaiah&#xD;Cho, Seong H&#xD;eng&#xD;the Joy McCann Culverhouse endowment/&#xD;61231302/National Institute of Allergy and Infectious Diseases/&#xD;Denmark&#xD;Allergy. 2025 Oct 11. doi: 10.1111/all.70098.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41074673</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70098</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>277</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">277</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Xiong, Q.</style></author><author><style face="normal" font="default" size="100%">Saelim, N.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Nong, W.</style></author><author><style face="normal" font="default" size="100%">Wan, A. T.</style></author><author><style face="normal" font="default" size="100%">Shi, M.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Cao, Q.</style></author><author><style face="normal" font="default" size="100%">Hui, J. H. L.</style></author><author><style face="normal" font="default" size="100%">Sookrung, N.</style></author><author><style face="normal" font="default" size="100%">Leung, T. F.</style></author><author><style face="normal" font="default" size="100%">Tungtrongchitr, A.</style></author><author><style face="normal" font="default" size="100%">Tsui, S. K. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong City, Hong Kong.&#xD;Hong Kong Bioinformatics Centre, The Chinese University of Hong Kong, Hong Kong City, Hong Kong.&#xD;Department of Parasitology, Faculty of Medicine Siriraj Hospital, Biodesign Innovation Center, Mahidol University, Bangkok, Thailand.&#xD;Simon F.S. Li Marine Science Laboratory, State Key Laboratory of Agrobiotechnology, School of Life Sciences, The Chinese University of Hong Kong, Hong Kong City, Hong Kong.&#xD;Shenzhen Key Laboratory of Allergy and Immunology, School of Medicine, Shenzhen University, Shenzhen, China.&#xD;Biomedical Research Incubator Unit, Department of Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Pediatrics, The Chinese University of Hong Kong, Hong Kong City, Hong Kong.&#xD;Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong City, Hong Kong.&#xD;Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Centre for Microbial Genomics and Proteomics, The Chinese University of Hong Kong, Hong Kong City, Hong Kong.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genome assembly and annotation of Periplaneta americana reveal a comprehensive cockroach allergen profile</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1088-1103</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/09/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Periplaneta</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Cockroaches</style></keyword><keyword><style face="normal" font="default" size="100%">American cockroach genome</style></keyword><keyword><style face="normal" font="default" size="100%">allergy cross-reactivity</style></keyword><keyword><style face="normal" font="default" size="100%">cockroach allergy</style></keyword><keyword><style face="normal" font="default" size="100%">comparative analysis</style></keyword><keyword><style face="normal" font="default" size="100%">novel allergen</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36153808</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: One of the most common cockroach types in urban areas, the American cockroach (Periplaneta americana), has been reported to impose an increased risk of allergies and asthma. Limited groups of allergens (Per a 1-13) have been identified in this species due to the lack of genome-related information. METHODS: To expand the allergen profile of P. americana, genomic, transcriptomic, and proteomic approaches were applied. With the support of a high-quality genome assembled using nanopore, Illumina, and Hi-C sequencing techniques, potential allergens were identified based on protein homology. Then, using enzyme-linked immunosorbent assay, selected allergens were tested in Thai patients allergic to P. americana. RESULTS: A chromosomal-level genome of P. americana (3.06 Gb) has been assembled with 94.6% BUSCO completeness, and its contiguity has been significantly improved (N50 = 151 Mb). A comprehensive allergen profile has been characterized, with seven novel groups of allergens, including enolase (Per a 14), cytochrome C (Per a 15), cofilin (Per a 16), alpha-tubulin (Per a 17), cyclophilin (Per a 18), porin3 (Per a 19), and peroxiredoxin-6 (Per a 20), showing IgE sensitivity in enzyme-linked immunosorbent assay. A new isoallergen of tropomyosin (Per a 7.02) and multiple potential isoallergens of Per a 5 were revealed using bioinformatics and proteomic approaches. Additionally, comparative analysis of P. americana with the closely related Blattodea species revealed the possibility of cross-reaction. CONCLUSION: The high-quality genome and proteome of P. americana are beneficial in studying cockroach allergens at the molecular level. Seven novel allergen groups and one isoallergen in Per a 7 were identified.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Lingyi&#xD;Xiong, Qing&#xD;Saelim, Nawannaporn&#xD;Wang, Lin&#xD;Nong, Wenyan&#xD;Wan, Angel Tsz-Yau&#xD;Shi, Mai&#xD;Liu, Xiaoyu&#xD;Cao, Qin&#xD;Hui, Jerome Ho Lam&#xD;Sookrung, Nitat&#xD;Leung, Ting-Fan&#xD;Tungtrongchitr, Anchalee&#xD;Tsui, Stephen Kwok Wing&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):1088-1103. doi: 10.1111/all.15531. Epub 2022 Oct 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36153808</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15531</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>980</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">980</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, K. W.</style></author><author><style face="normal" font="default" size="100%">Kim, D. Y.</style></author><author><style face="normal" font="default" size="100%">Yoon, D.</style></author><author><style face="normal" font="default" size="100%">Kim, K. K.</style></author><author><style face="normal" font="default" size="100%">Jang, H.</style></author><author><style face="normal" font="default" size="100%">Schoettler, N.</style></author><author><style face="normal" font="default" size="100%">Kim, E. G.</style></author><author><style face="normal" font="default" size="100%">Kim, M. N.</style></author><author><style face="normal" font="default" size="100%">Hong, J. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, J. K.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Ober, C.</style></author><author><style face="normal" font="default" size="100%">Gee, H. Y.</style></author><author><style face="normal" font="default" size="100%">Sohn, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Severance Hospital, Institute of Allergy, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.&#xD;Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.&#xD;Department of Medicine, Physician-Scientist Program, Yonsei University Graduate School of Medicine, Seoul, Korea.&#xD;Division of Allergy and Respiratory Disease Research, Department of Chronic Disease Convergence Research, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Korea.&#xD;Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.&#xD;Department of Medicine, University of Chicago, Chicago, IL, USA.&#xD;Department of Human Genetics, University of Chicago, Chicago, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genome-wide association study identifies TNFSF15 associated with childhood asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">218-229</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/05/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">*Tumor Necrosis Factor Ligand Superfamily Member 15/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Tnfsf15</style></keyword><keyword><style face="normal" font="default" size="100%">allergic sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">genome-wide association study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34022066</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Genome-wide association studies (GWASs) of asthma have identified several risk alleles and loci, but most have been conducted in individuals with European-ancestry. Studies in Asians, especially children, are still lacking. We aimed to identify susceptibility loci by performing the first GWAS of asthma in Korean children with persistent asthma. METHODS: We used a discovery set of 741 children with persistent asthma as cases and 589 healthy children and 551 healthy adults as controls to perform a GWAS. We validated our GWAS findings using UK Biobank data. We then used the Genotype-Tissue Expression database to identify expression quantitative trait loci of candidate variants. Finally, we quantified proteins of genes associated with asthma. RESULTS: Variants at the 17q12-21 locus and SNPs in CYBRD1 and TNFSF15 genes were associated with persistent childhood asthma at genome-wide thresholds of significance. Four SNPs in the TNFSF15 gene were also associated with childhood-onset asthma in British white participants in the UK Biobank data. The asthma-associated rs7856856-C allele, the lead SNP, was associated with decreased TNFSF15 expression in whole blood and in arteries. Korean children with asthma had lower serum TNFSF15 levels than controls, and those with the asthma risk rs7856856-CC genotype exhibited the lowest serum TNFSF15 levels overall, especially asthmatic children. CONCLUSIONS: Our GWAS of persistent childhood asthma with allergic sensitization identified a new susceptibility gene, TNFSF15, and replicated associations at the 17q12-21 childhood-onset asthma locus. This novel association may be mediated by reduced expression of serum TNFSF15 and loss of suppression of angiogenesis.</style></abstract><notes><style face="normal" font="default" size="100%">Kim, Kyung Won&#xD;Kim, Dong Yun&#xD;Yoon, Dankyu&#xD;Kim, Ka-Kyung&#xD;Jang, Haerin&#xD;Schoettler, Nathan&#xD;Kim, Eun Gyul&#xD;Kim, Mi Na&#xD;Hong, Jung Yeon&#xD;Lee, Jeom-Kyu&#xD;Kim, Sangwoo&#xD;Ober, Carole&#xD;Gee, Heon Yung&#xD;Sohn, Myung Hyun&#xD;eng&#xD;K08 HL153955/HL/NHLBI NIH HHS/&#xD;R01 HL129735/HL/NHLBI NIH HHS/&#xD;UG3 OD023282/OD/NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):218-229. doi: 10.1111/all.14952. Epub 2021 Jun 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34022066</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8606614</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14952</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2745</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2745</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sun, Y.</style></author><author><style face="normal" font="default" size="100%">Vonk, J. M.</style></author><author><style face="normal" font="default" size="100%">Kersten, E. T. G.</style></author><author><style face="normal" font="default" size="100%">Qi, C.</style></author><author><style face="normal" font="default" size="100%">Sprikkelman, A. B.</style></author><author><style face="normal" font="default" size="100%">Koppelman, G. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Pulmonology and Pediatric Allergy, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;University Medical Center Groningen, GRIAC Research Institute, University of Groningen, Groningen, The Netherlands.&#xD;Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;Division of Laboratory Medicine, Microbiome Medicine Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genome-Wide Association Study Reveals a Causal Relationship Between Allergic Rhinitis and Hazelnut Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">309-318</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/12/14 20:04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">*Corylus/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/genetics/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Nut Hypersensitivity/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Gwas</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">genetics</style></keyword><keyword><style face="normal" font="default" size="100%">genomics</style></keyword><keyword><style face="normal" font="default" size="100%">the Netherlands Lung Foundation. G.H.K. reports grant support from the</style></keyword><keyword><style face="normal" font="default" size="100%">Netherlands Lung Foundation, ZON-MW (VICI grant), Health Holland, European Union,</style></keyword><keyword><style face="normal" font="default" size="100%">TEVA the Netherlands, GSK and Vertex outside the submitted work (Money to</style></keyword><keyword><style face="normal" font="default" size="100%">Institution). G.H.K. participated in advisory boards or gave lectures supported</style></keyword><keyword><style face="normal" font="default" size="100%">by AZ, PURE-IMS, Boehringer Ingelheim and Sanofi (money to Institution). A.B.S.</style></keyword><keyword><style face="normal" font="default" size="100%">reports research grants from Nestle Research, Lausanne and Aimmune, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. Her institution received compensation for her consultancy for</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi Netherlands and Nestle Research, Lausanne.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39673378</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Little is known about the genetics of food allergy (FA) to various allergens and the heterogeneity of FA in adults. OBJECTIVE: We aimed to investigate genetic susceptibility to FA in an adult population and to assess the association between secondary FA and allergic rhinitis (AR). METHODS: FA and allergen-specific FA were defined based on in-depth questionnaires and a previously published FA algorithm in the Lifelines. We performed a series of genome-wide association studies (GWAS) on FA and nine allergen-specific (e.g., hazelnut) FA in 21,353 adults in Lifelines. Single nucleotide polymorphisms (SNPs) (p &lt; 1E-5) were replicated in a second independent set of 15,518 adults participating in the Lifelines followed by meta-analysis of the results of the two datasets. We subsequently investigated the causal relationship of AR to FA using Mendelian randomization (MR) analysis. RESULTS: We observed co-occurrence of tree nuts and apple FA, with over 80% of this group also reporting AR. After meta-analysis, we identified one genome-wide significant locus near HLA-DPA1 associated with self-reported hazelnut allergy (hazelnutFA), of which the top SNP is rs5025825 (p = 2.51E-9, OR = 1.43). Two-sample MR indicated that AR is a significant causal risk factor for hazelnutFA (p(-IVW) = 5.27E-10, beta = 5.90, p(-pleiotropy) = 0.46). CONCLUSION: Our questionnaire enabled a large GWAS on self-reported FA in Dutch adults. We report one novel locus in the human leukocyte antigens (HLA) region associated with hazelnutFA, implying an association with antigen recognition. Our findings genetically link secondary FA to AR in adults.</style></abstract><notes><style face="normal" font="default" size="100%">Sun, Yidan&#xD;Vonk, Judith M&#xD;Kersten, Elin T G&#xD;Qi, Cancan&#xD;Sprikkelman, Aline B&#xD;Koppelman, Gerard H&#xD;eng&#xD;Meta-Analysis&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):309-318. doi: 10.1111/all.16411. Epub 2024 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39673378</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724235</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16411</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3141</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3141</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lahnsteiner, A.</style></author><author><style face="normal" font="default" size="100%">Ellmer, V.</style></author><author><style face="normal" font="default" size="100%">Hao, M.</style></author><author><style face="normal" font="default" size="100%">Tannert, L. K.</style></author><author><style face="normal" font="default" size="100%">Versteeg, S. A.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Risch, A.</style></author><author><style face="normal" font="default" size="100%">Aglas, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.&#xD;Center for Tumor Biology and Immunology (CTBI), Paris Lodron University of Salzburg, Salzburg, Austria.&#xD;Odense Research Center for Anaphylaxis, Odense University Hospital, Odense, Denmark.&#xD;Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.&#xD;Department of Dermatology and Allergy Center, Odense University Hospital, Odense, Denmark.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.&#xD;Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genome-Wide Blood DNA Methylation Profiling in Birch Pollen Allergic Patients Undergoing Allergen-Specific Immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3412-3423</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">*Betula/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/therapy/immunology/genetics/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">CD8+ T cells</style></keyword><keyword><style face="normal" font="default" size="100%">DNA methylation</style></keyword><keyword><style face="normal" font="default" size="100%">Hla</style></keyword><keyword><style face="normal" font="default" size="100%">NK cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">birch pollen allergy</style></keyword><keyword><style face="normal" font="default" size="100%">epigenome-wide DNA methylation study</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy BV, Citeq BV, ThermoFisher Scientific, ALK Abello, Reacta Healthcare</style></keyword><keyword><style face="normal" font="default" size="100%">Ltd., Mission MightyMe, and The Protein Brewery and has stock options from Angany</style></keyword><keyword><style face="normal" font="default" size="100%">Inc. The remaining authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41065049</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Until now, no study has investigated the impact of allergen immunotherapy (AIT) on genome-wide DNA methylation in a longitudinal set-up. Herein, we investigated whether differences in DNA methylation occur in birch pollen allergic patients undergoing 6 months of birch pollen AIT, assessed alterations in methylation-based blood cell type composition, and correlated DNA methylation to serological AIT biomarkers. METHODS: We performed genome-wide DNA-methylation analysis on bisulfite-converted DNA derived from whole blood samples of 16 birch pollen-allergic patients (pre-/post-birch pollen AIT) and 15 placebo (pre-/post-placebo treatment). RESULTS: Our analysis identified cg22187251, located within a regulatory region upstream of the glucosaminyl (N-acetyl) transferase 2 (GCNT2) gene and cg22336863 upstream of the transcription start site of actin binding rho activating protein (ABRA), as hypermethylated. Functional assays revealed that these regions exhibit methylation-dependent promoter and enhancer activities. We identified differentially methylated positions within the HLA gene complex, and an AIT-specific increase of CD8+ T cell populations accompanied by a decrease in natural killer (NK) cell proportion. Strong to moderate correlations with clinical biomarkers (such as specific IgG(4)) were observed for 42% of the top 100 differentially methylated positions. CONCLUSION: GCNT2 and ABRA are implicated in Rho-signaling, a pathway involved in Th2 differentiation. GCNT2 modulates the SMAD-dependent TGF-beta pathway, indicating a role in mediating AIT-induced immunotolerance. This is the first longitudinal study investigating DNA methylation changes induced by birch pollen AIT.</style></abstract><notes><style face="normal" font="default" size="100%">Lahnsteiner, Angelika&#xD;Ellmer, Victoria&#xD;Hao, Mengzhen&#xD;Tannert, Line Kring&#xD;Versteeg, Serge A&#xD;Bindslev-Jensen, Carsten&#xD;van Ree, Ronald&#xD;Risch, Angela&#xD;Aglas, Lorenz&#xD;eng&#xD;Early Career Grant of the University of Salzburg/&#xD;China Scholarship Council/&#xD;Austrian Science Fund/&#xD;University of Salzburg Priority Program &quot;Center for Tumor Biology and Immunology (CTBI)&quot;/&#xD;European Union&apos;s Seventh Framework Program FP7/&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3412-3423. doi: 10.1111/all.70094. Epub 2025 Oct 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41065049</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666740</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70094</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2588</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2588</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nunez, R.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Diez-Echave, P.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Fernandez, T. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;Departamento de Medicina, Universidad de Malaga-UMA, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-ARADyAL, Malaga, Spain.&#xD;Departamento de Biologia Celular, Genetica y Fisiologia, Universidad de Malaga-UMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genomic variants association with selective hypersensitivity reactions to amoxicillin and clavulanic acid</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">578-581</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/07/05</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38966952</style></accession-num><notes><style face="normal" font="default" size="100%">Nunez, Rafael&#xD;Fernandez-Santamaria, Ruben&#xD;Salas, Maria&#xD;Bogas, Gador&#xD;Diez-Echave, Patricia&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;Fernandez, Tahia Diana&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):578-581. doi: 10.1111/all.16229. Epub 2024 Jul 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38966952</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804304</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16229</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2769</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2769</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Slob, E. M. A.</style></author><author><style face="normal" font="default" size="100%">Vijverberg, S. J. H.</style></author><author><style face="normal" font="default" size="100%">Ruffles, T.</style></author><author><style face="normal" font="default" size="100%">Noij, L. C. E.</style></author><author><style face="normal" font="default" size="100%">Biermann, J.</style></author><author><style face="normal" font="default" size="100%">Brouwer, A. F. J.</style></author><author><style face="normal" font="default" size="100%">van den Brink, K.</style></author><author><style face="normal" font="default" size="100%">de Bruin-Kok, A.</style></author><author><style face="normal" font="default" size="100%">Van Ewijk, B. E.</style></author><author><style face="normal" font="default" size="100%">Haarman, E.</style></author><author><style face="normal" font="default" size="100%">Hammer, S. C.</style></author><author><style face="normal" font="default" size="100%">Hashimoto, S.</style></author><author><style face="normal" font="default" size="100%">Hogarth, F.</style></author><author><style face="normal" font="default" size="100%">Jones, C. J.</style></author><author><style face="normal" font="default" size="100%">Kamps, A. W. A.</style></author><author><style face="normal" font="default" size="100%">Kersten, E. T. G.</style></author><author><style face="normal" font="default" size="100%">de Kleer, I.</style></author><author><style face="normal" font="default" size="100%">Lipworth, B. J.</style></author><author><style face="normal" font="default" size="100%">Littleford, R.</style></author><author><style face="normal" font="default" size="100%">Merelle, M.</style></author><author><style face="normal" font="default" size="100%">Moeller, A.</style></author><author><style face="normal" font="default" size="100%">Palmer, C. N. A.</style></author><author><style face="normal" font="default" size="100%">Pilvinyte, K.</style></author><author><style face="normal" font="default" size="100%">Rutjes, N. W.</style></author><author><style face="normal" font="default" size="100%">van Schaik, R. H. N.</style></author><author><style face="normal" font="default" size="100%">Smith, H. E.</style></author><author><style face="normal" font="default" size="100%">Tavendale, R.</style></author><author><style face="normal" font="default" size="100%">Terheggen-Lagro, S. W. J.</style></author><author><style face="normal" font="default" size="100%">Turner, S.</style></author><author><style face="normal" font="default" size="100%">Twisk, J. W. R.</style></author><author><style face="normal" font="default" size="100%">Vaessen-Verberne, A.</style></author><author><style face="normal" font="default" size="100%">Verwaal, M.</style></author><author><style face="normal" font="default" size="100%">de Vries, T.</style></author><author><style face="normal" font="default" size="100%">Wesseling, J.</style></author><author><style face="normal" font="default" size="100%">Pijnenburg, M. W.</style></author><author><style face="normal" font="default" size="100%">Koppelman, G. H.</style></author><author><style face="normal" font="default" size="100%">Mukhopadhyay, S.</style></author><author><style face="normal" font="default" size="100%">Maitland-van der Zee, A. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary Medicine, AmsterdamUMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Clinical Pharmacy, Haaglanden Medical Center, The Hague, The Netherlands.&#xD;Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.&#xD;Academic Department of Paediatrics, Royal Alexandra Children&apos;s Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.&#xD;Brighton and Sussex Medical School, Brighton, UK.&#xD;Department of Pediatric Pulmonology &amp; Allergy, AmsterdamUMC, Emma Children&apos;s Hospital, Amsterdam, The Netherlands.&#xD;Department of Paediatrics, Martini Hospital, Groningen, The Netherlands.&#xD;Department of Paediatrics, Nij Smellinghe Hospital, Drachten, The Netherlands.&#xD;Department of Pediatrics, Spaarne Hospital, Hoofddorp, The Netherlands.&#xD;Deptartment of Paediatrics, Tergooi MC, Hilversum, The Netherlands.&#xD;Deptartment of Paediatrics, Amphia Hospital, Breda, The Netherlands.&#xD;Tayside Clinical Trials Unit, University of Dundee, Dundee, UK.&#xD;School of Psychology, Faculty of Health &amp; Medical Sciences, University of Surrey, Guildford, UK.&#xD;Department of Pediatric Pulmonology &amp; Allergology, Beatrix Children&apos;s Hospital, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Groningen Research Institute on Asthma and COPD, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Department of Paediatrics, Franciscus Gasthuis &amp; Vlietland, Rotterdam, The Netherlands.&#xD;Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.&#xD;Clinical Trial Centre, The University of Queensland, Brisbane, Australia.&#xD;Department of Respiratory Medicine, University Children Hospital and University of Zurich, Zurich, Switzerland.&#xD;Pat McPherson Centre for Pharmacogenetics and Pharmacogenomics, Division of Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.&#xD;Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.&#xD;School of Medicine, Keele University, Keele, Staffordshire, UK.&#xD;Women and Children&apos;s Division, NHS Grampian, Aberdeen, UK.&#xD;Department of Epidemiology and Data Science, AmsterdamUMC, Amsterdam, The Netherlands.&#xD;Department of Paediatrics, Maasstad Hospital, Rotterdam, The Netherlands.&#xD;Department of Paediatrics, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.&#xD;Department of Paediatrics, Rijnstate Hospital, Arnhem, The Netherlands.&#xD;Department of Pediatrics, Pediatric Pulmonology &amp; Allergology, Erasmus Medical Center, Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genotype-Guided Asthma Treatment Reduces Exacerbations in Children: Meta-Analysis of Two Randomized Control Trials</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1006-1014</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/genetics/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Adrenergic, beta-2/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenergic beta-2 Receptor Agonists/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style face="normal" font="default" size="100%">Adrb2</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">long-acting beta2-agonist</style></keyword><keyword><style face="normal" font="default" size="100%">paediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacogenetics</style></keyword><keyword><style face="normal" font="default" size="100%">for More Oxygen)) sponsored by Health Holland involving many private partners</style></keyword><keyword><style face="normal" font="default" size="100%">that contribute in cash and/or in kind (AbbVie, Boehringer Ingelheim, Breathomix,</style></keyword><keyword><style face="normal" font="default" size="100%">Clear, Fluidda, Ortec Logiqcare, Olive, Philips, Quantib-U, Smartfish, Clear,</style></keyword><keyword><style face="normal" font="default" size="100%">SODAQ, Thirona, Roche, TopMD, Novartis and RespiQ). A.H.M.v.d.Z. also reports</style></keyword><keyword><style face="normal" font="default" size="100%">funding from GSK, Boehringer Ingelheim, Vertex and Astra Zeneca. G.H.K. reports</style></keyword><keyword><style face="normal" font="default" size="100%">funding from the Lung Foundation Netherlands, ZON-MW, Health Holland, European</style></keyword><keyword><style face="normal" font="default" size="100%">Union, TEVA the Netherlands, GSK, Vertex and participated in advisory boards of</style></keyword><keyword><style face="normal" font="default" size="100%">Astra Zeneca and Pure-IMS (money to institution)</style></keyword><keyword><style face="normal" font="default" size="100%">his institution received</style></keyword><keyword><style face="normal" font="default" size="100%">compensation for invited lectures from Boehringer Ingelheim and Sanofi. S.</style></keyword><keyword><style face="normal" font="default" size="100%">Mukhopadhyay reports funding from the National Health Service, UK, National</style></keyword><keyword><style face="normal" font="default" size="100%">Institute of Health Research, UK, Action Medical Research charity, UK and</style></keyword><keyword><style face="normal" font="default" size="100%">Rockinghorse Children&apos;s Charity, UK. M.W.P. reports funding from Lung Foundation</style></keyword><keyword><style face="normal" font="default" size="100%">Netherlands, Zon-MW, Sanofi, Novartis and Astra Zeneca. B.L. reports personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Sandoz, AstraZeneca, Chiesi, Lupin and Cipla, E.M.A.S., E.T.G.K. and</style></keyword><keyword><style face="normal" font="default" size="100%">S.J.H.V. report funding from Lung Foundation Netherlands. M.V. participated in</style></keyword><keyword><style face="normal" font="default" size="100%">the revision of the Dutch asthma guideline in children (Dutch Association of</style></keyword><keyword><style face="normal" font="default" size="100%">Paediatrics) and is chairman of the foundation for nurse practitioners in</style></keyword><keyword><style face="normal" font="default" size="100%">paediatric lung diseases. C.J. reports research funding from the National</style></keyword><keyword><style face="normal" font="default" size="100%">Institute for Health Research, the Food Standards Agency Coeliac UK and honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">from the National Institute for Health Research, Nutricia, Reckitt Benckiser, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies and Allergy UK. T.R., L.N., R.H.N.v.S., A.F.J.B., A.A.P.H.V.,</style></keyword><keyword><style face="normal" font="default" size="100%">S.C.H., E.G.H., B.v.E., H.E.S., K.P., F.H., S.W.J.T.-L., R.L., J.W., T.d.V.,</style></keyword><keyword><style face="normal" font="default" size="100%">J.B., I.d.K., C.N.A.P., R.T., A.d.B. and J.W.R.T. declare no conflicts of</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39723595</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Long-acting beta2-agonists (LABA) in combination with inhaled corticosteroids (ICS) are commonly used to treat asthma, however, some children lack response to the addition of LABA. This might be partially due to the presence of the Arg16Gly polymorphism, encoded by rs1042713 G&gt;A in the ADRB2 gene. Carrying the A allele (Arg16) at this variant has been associated with an increased risk of exacerbations despite LABA treatment. We investigated whether genotype-guided treatment improved asthma-related outcomes. METHODS: We conducted an individual participant data meta-analysis of two randomised controlled trials: PUFFIN (Dutch and Swiss 6-18 year-olds) and PACT (English and Scottish 12-18 year-olds). Children with uncontrolled asthma despite ICS who required a step-up in treatment were included. Participants were randomised to genotype-guided treatment or the control group with a follow-up of at least 6 months. Genotype-guided treatment consisted of adding LABA for children with ADRB2 Gly16/Gly16, whilst children with ADRB2 Arg16/Arg16 or Arg16/Gly16 were treated with double dose ICS (PUFFIN) or add-on montelukast (PACT). The primary outcome was a change in asthma control; secondary outcomes included exacerbation rate and time to exacerbation. Repeated measures mixed models and Cox regression were used. RESULTS: Fifty-nine out of 102 (PUFFIN) and 59 out of 91 (PACT) children had at least one Arg (A allele). Amongst all 193 children, no difference was observed in asthma control between the study groups. However, genotype-guided treatment resulted in lower asthma exacerbation rates (-0.08 (95%CI -0.16 to -0.00, p = 0.04)) compared to the control group. CONCLUSION: Genotype-guided step-up treatment for children with uncontrolled asthma on ICS may lower asthma exacerbation rates and may be useful for personalising asthma care.</style></abstract><notes><style face="normal" font="default" size="100%">Slob, Elise M A&#xD;Vijverberg, Susanne J H&#xD;Ruffles, Tom&#xD;Noij, Lieke C E&#xD;Biermann, Jacqueline&#xD;Brouwer, Alwin F J&#xD;van den Brink, Kristel&#xD;de Bruin-Kok, Annette&#xD;Van Ewijk, Bart E&#xD;Haarman, Eric&#xD;Hammer, Sanne C&#xD;Hashimoto, Simone&#xD;Hogarth, Fiona&#xD;Jones, Christina J&#xD;Kamps, Arvid W A&#xD;Kersten, Elin T G&#xD;de Kleer, Isme&#xD;Lipworth, Brian J&#xD;Littleford, Roberta&#xD;Merelle, Marieke&#xD;Moeller, Alexander&#xD;Palmer, Colin N A&#xD;Pilvinyte, Kristina&#xD;Rutjes, Niels W&#xD;van Schaik, Ron H N&#xD;Smith, Helen E&#xD;Tavendale, Roger&#xD;Terheggen-Lagro, Suzanne W J&#xD;Turner, Steve&#xD;Twisk, Jos W R&#xD;Vaessen-Verberne, Anja&#xD;Verwaal, Mariel&#xD;de Vries, Tjalling&#xD;Wesseling, Judit&#xD;Pijnenburg, Marielle W&#xD;Koppelman, Gerard H&#xD;Mukhopadhyay, Somnath&#xD;Maitland-van der Zee, Anke H&#xD;eng&#xD;Henry Smith Charity/&#xD;Lung Foundation Netherlands/&#xD;Meta-Analysis&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1006-1014. doi: 10.1111/all.16438. Epub 2024 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39723595</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969299</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16438</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3154</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3154</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">De Vriese, S.</style></author><author><style face="normal" font="default" size="100%">Belasri, H.</style></author><author><style face="normal" font="default" size="100%">Badloe, F. M. S.</style></author><author><style face="normal" font="default" size="100%">De Bauw, L. D. I.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author><author><style face="normal" font="default" size="100%">Kortekaas Krohn, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Vrije Universiteit Brussel (VUB), Skin Immunology &amp; Immune Tolerance (SKIN) Research Group, Brussels, Belgium.&#xD;Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Dermatology, Brussels, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Geographic Differences in Dupilumab Treatment Outcomes for Atopic Dermatitis: A Systematic Review and Meta-Regression Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">geographic region</style></keyword><keyword><style face="normal" font="default" size="100%">treatment response</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41251331</style></accession-num><abstract><style face="normal" font="default" size="100%">Dupilumab, a monoclonal antibody targeting interleukins (IL)-4/IL-13 signaling, demonstrated efficacy in clinical trials for atopic dermatitis. However, real-world variability remains underexplored. A systematic review with meta-regression was conducted to primarily assess geographic influences on dupilumab efficacy measured by percentage eczema area severity index (EASI) reduction and secondly, the presence of adverse events (AEs). Searches were conducted in PubMed, Web of Science, Embase, and Cochrane CENTRAL (PROSPERO:CRD42024579722). Risk of bias was assessed using the Cochrane risk-of-bias tool for nonrandomized studies of interventions (ROBINS-1). Prior to model fitting, articles were subdivided by geographic region. Subsequently, meta-regression analysis was adjusted for geographic region, baseline EASI score, and proportion of female participants. To identify geographic differences, post hoc analysis was performed. Twenty-eight articles were included, covering 509 East Asians, 1604 Northern/Central Europeans, and 4429 Southern Europeans. Baseline EASI scores were highest in East Asians. However, meta-regression revealed that Southern Europeans experienced a 15.33% greater EASI reduction compared with East Asians (95% CI: 6.8%-23.9%, p = 0.0012) and a 10.2% higher reduction compared with Northern/Central Europeans (95% CI: 0.6%-19.8%, p = 0.0434). Additionally, AEs were most frequent in Northern/Central Europeans (95% CI: 0.610-7.633) compared to East Asians (95% CI: 0.145-1.267) and Southern Europeans (95% CI: 0.113-0.484), with geographic variation in AE types. Geographic factors appear to influence dupilumab&apos;s clinical outcomes, though the underlying mechanism remains unknown. Trial Registration: PROSPERO: CRD42024579722.</style></abstract><notes><style face="normal" font="default" size="100%">De Vriese, Shauni&#xD;Belasri, Hafsa&#xD;Badloe, Fariza Mishaal Saiema&#xD;De Bauw, Lize Dimitri Inge&#xD;Gutermuth, Jan&#xD;Kortekaas Krohn, Inge&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Nov 18. doi: 10.1111/all.70144.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41251331</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70144</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2537</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2537</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bal, C.</style></author><author><style face="normal" font="default" size="100%">Stoshikj, S.</style></author><author><style face="normal" font="default" size="100%">Milger, K.</style></author><author><style face="normal" font="default" size="100%">Skowasch, D.</style></author><author><style face="normal" font="default" size="100%">Gappa, M.</style></author><author><style face="normal" font="default" size="100%">Koerner-Rettberg, C.</style></author><author><style face="normal" font="default" size="100%">Jandl, M.</style></author><author><style face="normal" font="default" size="100%">Schmidt, O.</style></author><author><style face="normal" font="default" size="100%">Ehmann, R.</style></author><author><style face="normal" font="default" size="100%">Taube, C.</style></author><author><style face="normal" font="default" size="100%">Hamelmann, E.</style></author><author><style face="normal" font="default" size="100%">Buhl, R.</style></author><author><style face="normal" font="default" size="100%">Korn, S.</style></author><author><style face="normal" font="default" size="100%">Idzko, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pneumology, University Hospital Vienna AKH, Medical University of Vienna, Vienna, Austria.&#xD;Department of Medicine V, Ludwig-Maximilians-University (LMU) of Munich, Comprehensive Pneumology Center (CPC-M) German Center for Lung Research (DZL), Munich, Germany.&#xD;Department of Internal Medicine II - Pneumology, University Hospital Bonn, Bonn, Germany.&#xD;Evangelisches Krankenhaus Dusseldorf, Children&apos;s Hospital, Dusseldorf, Germany.&#xD;Department of Pediatrics, Research Institute, Marien-Hospital Wesel, Wesel, Germany.&#xD;Hamburger Institut fur Therapieforschung GmbH, Hamburg, Germany.&#xD;Pneumologische Gemeinschaftspraxis und Studienzentrum KPPK, Koblenz, Germany.&#xD;Ambulante Pneumologie mit Allergiezentrum, Stuttgart, Germany.&#xD;Department of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, Essen, Germany.&#xD;Kinderzentrum Bethel, Evangelisches Klinikum Bethel, University Bielefeld, Bielefeld, Germany.&#xD;Mainz University Hospital, Pulmonary Department, Mainz, Germany.&#xD;Thoraxklinik Heidelberg und IKF Pneumologie Mainz, Mainz, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">German asthma net: Nasal polyposis in patients in the severe asthma registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3133-3138</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/06/12</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38864229</style></accession-num><notes><style face="normal" font="default" size="100%">Bal, Christina&#xD;Stoshikj, Slagjana&#xD;Milger, Katrin&#xD;Skowasch, Dirk&#xD;Gappa, Monika&#xD;Koerner-Rettberg, Cordula&#xD;Jandl, Margret&#xD;Schmidt, Olaf&#xD;Ehmann, Rainer&#xD;Taube, Christian&#xD;Hamelmann, Eckard&#xD;Buhl, Roland&#xD;Korn, Stephanie&#xD;Idzko, Marco&#xD;eng&#xD;No specific funding was received for this study. The GAN Severe Asthma Registry is supported by the German Asthma Net e.V., a German nonprofit society, and is funded by the German Ministry for Education and Research in the CHAMP consortium (BMBF, 01GL1742D); the GAN is also receiving funding by AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, and Sanofi./&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3133-3138. doi: 10.1111/all.16186. Epub 2024 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38864229</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16186</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2718</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2718</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rousseaux, A.</style></author><author><style face="normal" font="default" size="100%">Misme-Aucouturier, B.</style></author><author><style face="normal" font="default" size="100%">Le Romancer, M.</style></author><author><style face="normal" font="default" size="100%">Villette, R.</style></author><author><style face="normal" font="default" size="100%">Larsen, M.</style></author><author><style face="normal" font="default" size="100%">De Carvalho, M.</style></author><author><style face="normal" font="default" size="100%">Bouchaud, G.</style></author><author><style face="normal" font="default" size="100%">Perrin, E.</style></author><author><style face="normal" font="default" size="100%">Barbarot, S.</style></author><author><style face="normal" font="default" size="100%">Brosseau, C.</style></author><author><style face="normal" font="default" size="100%">Bodinier, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">UR1268 Bia, INRAE Pays de la Loire, Nantes, France.&#xD;INSERM U1135, Centre d&apos;Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universite, Paris, France.&#xD;Department of Dermatology, CHU Nantes, Nantes, France.&#xD;UMR1080 PhAN, INRAE Pays de la Loire, Nantes, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Gestational Supplementation With 2&apos;-Fucosyllactose Is an Effective Strategy to Prevent Food Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">886-889</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/11/13</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39526795</style></accession-num><notes><style face="normal" font="default" size="100%">Rousseaux, A&#xD;Misme-Aucouturier, B&#xD;Le Romancer, M&#xD;Villette, R&#xD;Larsen, M&#xD;De Carvalho, M&#xD;Bouchaud, G&#xD;Perrin, E&#xD;Barbarot, S&#xD;Brosseau, C&#xD;Bodinier, M&#xD;eng&#xD;Region Pays de la Loire/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):886-889. doi: 10.1111/all.16396. Epub 2024 Nov 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39526795</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16396</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1093</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1093</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Iizuka, T.</style></author><author><style face="normal" font="default" size="100%">Takei, M.</style></author><author><style face="normal" font="default" size="100%">Saito, Y.</style></author><author><style face="normal" font="default" size="100%">Rumi, F.</style></author><author><style face="normal" font="default" size="100%">Zheng, J.</style></author><author><style face="normal" font="default" size="100%">Lu, X.</style></author><author><style face="normal" font="default" size="100%">Chafey, P.</style></author><author><style face="normal" font="default" size="100%">Broussard, C.</style></author><author><style face="normal" font="default" size="100%">Guilloux-Assalet, L.</style></author><author><style face="normal" font="default" size="100%">Charpin, D.</style></author><author><style face="normal" font="default" size="100%">Ebisawa, M.</style></author><author><style face="normal" font="default" size="100%">Senechal, H.</style></author><author><style face="normal" font="default" size="100%">Aizawa, T.</style></author><author><style face="normal" font="default" size="100%">Poncet, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Protein Science Laboratory, Hokkaido University, Sapporo, Japan.&#xD;Department of Allergy, National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan.&#xD;3P5 Proteomics Platform, Universite de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104, Paris, France.&#xD;Eurofins Biomnis, Lyon, France.&#xD;APPA, Aix-Marseille University, Marseille, France.&#xD;Allergy &amp; Environment, Armand Trousseau Children Hospital, Paris, France.&#xD;Immunology Department, Institut Pasteur, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gibberellin-regulated protein sensitization in Japanese cedar (Cryptomeria japonica) pollen allergic Japanese cohorts</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2297-2302</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/03/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">*Cryptomeria</style></keyword><keyword><style face="normal" font="default" size="100%">Gibberellins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Cry j 7</style></keyword><keyword><style face="normal" font="default" size="100%">Japanese cedar pollen</style></keyword><keyword><style face="normal" font="default" size="100%">fruits</style></keyword><keyword><style face="normal" font="default" size="100%">gibberellin-regulated protein</style></keyword><keyword><style face="normal" font="default" size="100%">pollen-food allergy syndrome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33725383</style></accession-num><notes><style face="normal" font="default" size="100%">Iizuka, Tomona&#xD;Takei, Mari&#xD;Saito, Yukiko&#xD;Rumi, Farhana&#xD;Zheng, Jingkang&#xD;Lu, Xiaoshuang&#xD;Chafey, Philippe&#xD;Broussard, Cedric&#xD;Guilloux-Assalet, Laurence&#xD;Charpin, Denis&#xD;Ebisawa, Motohiro&#xD;Senechal, Helene&#xD;Aizawa, Tomoyasu&#xD;Poncet, Pascal&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2297-2302. doi: 10.1111/all.14816. Epub 2021 Mar 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33725383</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14816</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2338</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2338</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chaki, S.</style></author><author><style face="normal" font="default" size="100%">Amponnawarat, A.</style></author><author><style face="normal" font="default" size="100%">Levenstein, B.</style></author><author><style face="normal" font="default" size="100%">Hui, Y.</style></author><author><style face="normal" font="default" size="100%">Oskeritzian, C.</style></author><author><style face="normal" font="default" size="100%">Ali, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Basic and Translational Sciences, University of Pennsylvania School of Dental Medicine, Philadelphia, Pennsylvania, USA.&#xD;Department of Family and Community Dentistry, Faculty of Dentistry, Chiang Mai University, Chiang Mai, Thailand.&#xD;Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, South California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Glatiramer acetate induces mast cell degranulation via MRGPRX2, implications for local and systemic adverse reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">758-761</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/12/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Glatiramer Acetate</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Degranulation</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, G-Protein-Coupled</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Neuropeptide</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38095027</style></accession-num><notes><style face="normal" font="default" size="100%">Chaki, Shaswati&#xD;Amponnawarat, Aetas&#xD;Levenstein, Brett&#xD;Hui, Yvonne&#xD;Oskeritzian, Carole&#xD;Ali, Hydar&#xD;eng&#xD;R01 AI143185/AI/NIAID NIH HHS/&#xD;P20 GM103641/GM/NIGMS NIH HHS/&#xD;R01 AI124182/AI/NIAID NIH HHS/&#xD;R01-AI124182/NH/NIH HHS/&#xD;P20GM103641/GM/NIGMS NIH HHS/&#xD;R01 AI149487/AI/NIAID NIH HHS/&#xD;R01-AI149487/NH/NIH HHS/&#xD;R01-AI143185/NH/NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):758-761. doi: 10.1111/all.15978. Epub 2023 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38095027</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10922971</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15978</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2404</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2404</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ni, D.</style></author><author><style face="normal" font="default" size="100%">Senior, A. M.</style></author><author><style face="normal" font="default" size="100%">Raubenheimer, D.</style></author><author><style face="normal" font="default" size="100%">Simpson, S. J.</style></author><author><style face="normal" font="default" size="100%">Macia, L.</style></author><author><style face="normal" font="default" size="100%">Nanan, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sydney Medical School Nepean, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Nepean Hospital, Nepean Blue Mountains Local Health District, Sydney, New South Wales, Australia.&#xD;Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.&#xD;School of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Sydney Precision Data Science Centre, The University of Sydney, Sydney, New South Wales, Australia.&#xD;School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Sydney Cytometry Core Research Facility, Charles Perkins Centre, The University of Sydney and Centenary Institute, Sydney, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Global associations of macronutrient supply and asthma disease burden</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1989-1991</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/02/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nutrients</style></keyword><keyword><style face="normal" font="default" size="100%">Cost of Illness</style></keyword><keyword><style face="normal" font="default" size="100%">Global Health</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38372164</style></accession-num><notes><style face="normal" font="default" size="100%">Ni, Duan&#xD;Senior, Alistair M&#xD;Raubenheimer, David&#xD;Simpson, Stephen J&#xD;Macia, Laurence&#xD;Nanan, Ralph&#xD;eng&#xD;Norman Ernest Bequest Fund/&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1989-1991. doi: 10.1111/all.16067. Epub 2024 Feb 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38372164</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16067</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2529</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2529</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Knibb, R. C.</style></author><author><style face="normal" font="default" size="100%">Herbert, L. J.</style></author><author><style face="normal" font="default" size="100%">Jones, C. J.</style></author><author><style face="normal" font="default" size="100%">Protudjer, J. L. P.</style></author><author><style face="normal" font="default" size="100%">Screti, C.</style></author><author><style face="normal" font="default" size="100%">Roleston, C.</style></author><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Warren, C.</style></author><author><style face="normal" font="default" size="100%">Lombard, L.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Gupta, R.</style></author><author><style face="normal" font="default" size="100%">Vickery, B. P.</style></author><author><style face="normal" font="default" size="100%">Marchisotto, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Aston Institute for Health and Neurodevelopment, Aston University, Birmingham, UK.&#xD;Children&apos;s National Health System, Washington, DC, USA.&#xD;George Washington University School of Medicine, Washington, DC, USA.&#xD;School of Psychology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.&#xD;Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.&#xD;Children&apos;s Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.&#xD;Children&apos;s Allergy Service, Evelina Children&apos;s Hospital, Guy&apos;s and St. Thomas&apos;s NHS Foundation Trust, London, UK.&#xD;Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Center for Food Allergy and Asthma Research, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Private Practice, Chicago, Illinois, USA.&#xD;Ann &amp; Robert H. Lurie Children&apos;s Hospital of Chicago, Chicago, Illinois, USA.&#xD;Institute for Public Health and Medicine, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Emory University School of Medicine, Atlanta, Georgia, USA.&#xD;Children&apos;s Healthcare of Atlanta, Atlanta, Georgia, USA.&#xD;MJM Advisory, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Global availability and uptake of psychological services for adults, caregivers and children with food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2787-2797</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/07/20 20:46</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/psychology/therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Caregivers/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Health Services Accessibility</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Psychological/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Health Services</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Psychological Distress</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">caregiver</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">mental health</style></keyword><keyword><style face="normal" font="default" size="100%">psychological</style></keyword><keyword><style face="normal" font="default" size="100%">support</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39031702</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food allergy (FA) is associated with poor health-related quality of life and high levels of psychological distress. Psychological support is extremely important but not always available. As part of the Global Access to Psychological Services for Food Allergy (GAPS) study, we aimed to assess psychological distress and service use among adults, caregivers and children with FA in a global survey. METHODS: Participants (n = 1329 adults with FA; n = 1907 caregivers of children with FA) from &gt;20 countries were recruited through patient organisations, social media advertisements and online survey panels to complete an online survey. Surveys were available in six languages. RESULTS: A total of 67.7% of adults and 77.2% of caregivers reported direct experience, and 51.6% of caregivers said their child had experienced FA-related psychological distress. The most commonly reported issue was anxiety about having an allergic reaction. Less than 20% had been assessed for FA-related psychological distress. There were significant differences across countries for levels of distress, screening for distress, seeing a mental health professional and being diagnosed with a FA-related mental health disorder (all p &lt; .001). The United Kingdom, Australia and Brazil had the highest number of participants reporting distress. The most commonly reported barrier to seeing a mental health professional was cost. CONCLUSIONS: FA-related distress is common across countries, but with substantial country-to-country variability. Allergy providers are encouraged to routinely assess families for psychological distress and provide access to appropriate mental health resources. Development and implementation of evidence-based, patient-informed accessible, affordable FA interventions in multiple languages is urgently needed.</style></abstract><notes><style face="normal" font="default" size="100%">Knibb, R C&#xD;Herbert, L J&#xD;Jones, C J&#xD;Protudjer, J L P&#xD;Screti, C&#xD;Roleston, C&#xD;Brough, H A&#xD;Warren, C&#xD;Lombard, L&#xD;Santos, A F&#xD;Gupta, R&#xD;Vickery, B P&#xD;Marchisotto, M J&#xD;eng&#xD;Novartis/&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Aimmune Therapeutics/&#xD;National Peanut Board/&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2787-2797. doi: 10.1111/all.16204. Epub 2024 Jun 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39031702</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16204</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2782</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2782</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Luo, H.</style></author><author><style face="normal" font="default" size="100%">Wen, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory and Critical Care Medicine, West China Hospital, West China School of Medicine, and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Global Burden of Asthma and Atopic Dermatitis in 2021: A Systemic Analysis of the Global Burden of Disease Study 2021</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1460-1463</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/12/20</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39704398</style></accession-num><notes><style face="normal" font="default" size="100%">Luo, Hong&#xD;Wen, Fuqiang&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1460-1463. doi: 10.1111/all.16449. Epub 2024 Dec 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39704398</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16449</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1262</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1262</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lieberman, J. A.</style></author><author><style face="normal" font="default" size="100%">Gupta, R. S.</style></author><author><style face="normal" font="default" size="100%">Knibb, R. C.</style></author><author><style face="normal" font="default" size="100%">Haselkorn, T.</style></author><author><style face="normal" font="default" size="100%">Tilles, S.</style></author><author><style face="normal" font="default" size="100%">Mack, D. P.</style></author><author><style face="normal" font="default" size="100%">Pouessel, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Tennessee Health Science Center/Le Bonheur Children&apos;s Hospital, Memphis, TN, USA.&#xD;Institute for Public Health and Medicine, Ann &amp; Robert H. Lurie Children&apos;s Hospital of Chicago, Northwestern School of Medicine, Chicago, IL, USA.&#xD;School of Psychology, Aston University, Birmingham, UK.&#xD;EpiMetrix, Inc., Los Altos, CA, USA.&#xD;Aimmune Therapeutics, Brisbane, CA, USA.&#xD;Department of Pediatrics, McMaster University, Hamilton, ON, Canada.&#xD;Pneumology and Allergology Unit, Children&apos;s Hospital, Lille University Hospital, Jeanne de Flandre, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The global burden of illness of peanut allergy: A comprehensive literature review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1367-1384</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cost of Illness</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">accidental exposure</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">burden</style></keyword><keyword><style face="normal" font="default" size="100%">health-related quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics and serving as an advisor to DBV Technologies and Covis Pharma. RG</style></keyword><keyword><style face="normal" font="default" size="100%">reports receiving grants from the National Institutes of Health (NIH), Stanford</style></keyword><keyword><style face="normal" font="default" size="100%">University, and Aimmune Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">serving as a medical consultant/advisor for</style></keyword><keyword><style face="normal" font="default" size="100%">DBV technologies, Aimmune, Before Brands, Pfizer, Mylan and Kaleo, Inc,</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">receiving grants from the NIH, Allergy and Asthma Network, Food Allergy Research</style></keyword><keyword><style face="normal" font="default" size="100%">&amp; Education, Rho Inc, Northwestern University Clinical and Translational Sciences</style></keyword><keyword><style face="normal" font="default" size="100%">Institute, Thermo Fisher, United Health Group, Mylan and the National</style></keyword><keyword><style face="normal" font="default" size="100%">Confectioners Association. RK is a consultant for Aimmune Therapeutics. TH is a</style></keyword><keyword><style face="normal" font="default" size="100%">former consultant for Aimmune Therapeutics. ST is an employee of Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics. DPM is a member of the Board of Directors for the Canadian Society</style></keyword><keyword><style face="normal" font="default" size="100%">of Allergy and Clinical Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">serves on the Editorial Board of the Journal</style></keyword><keyword><style face="normal" font="default" size="100%">of Food Allergy. He has provided consultation and speaker services for Pfizer,</style></keyword><keyword><style face="normal" font="default" size="100%">ALK, Aimmune, Merck, Covis and Pediapharm and has been part of an advisory board</style></keyword><keyword><style face="normal" font="default" size="100%">for ALK, Pfizer and Bausch Health. GP has provided consultation and speaker</style></keyword><keyword><style face="normal" font="default" size="100%">services for Aimmune Therapeutics, Bausch and Lomb, Stallergenes, ALK-Abello</style></keyword><keyword><style face="normal" font="default" size="100%">serves as a medical consultant/advisor for Bausch and Lomb.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33216994</style></accession-num><abstract><style face="normal" font="default" size="100%">Peanut allergy (PA) currently affects approximately 2% of the general population of Western nations and may be increasing in prevalence. Patients with PA and their families/caregivers bear a considerable burden of self-management to avoid accidental peanut exposure and to administer emergency medication (adrenaline) if needed. Compared with other food allergies, PA is associated with higher rates of accidental exposure, severe reactions and potentially fatal anaphylaxis. Approximately 7%-14% of patients with PA experience accidental peanut exposure annually, and one-third to one-half may experience anaphylaxis, although fatalities are rare. These risks impose considerably high healthcare utilization and economic costs for patients with PA and restrictions on daily activities. Measures to accommodate patients with PA are often inadequate, with inconsistent standards for food labelling and inadequate safety policies in public establishments such as restaurants and schools. Children with PA are often bullied, resulting in sadness, humiliation and anxiety. These factors cumulatively contribute to significantly reduced health-related quality of life for patients with PA and families/caregivers. Such factors also provide essential context for risk/benefit assessments of new PA therapies. This narrative review comprehensively assessed the various factors comprising the burden of PA.</style></abstract><notes><style face="normal" font="default" size="100%">Lieberman, Jay A&#xD;Gupta, Ruchi S&#xD;Knibb, Rebecca C&#xD;Haselkorn, Tmirah&#xD;Tilles, Stephen&#xD;Mack, Douglas P&#xD;Pouessel, Guillaume&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1367-1384. doi: 10.1111/all.14666. Epub 2021 Jan 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33216994</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8247890</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14666</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2348</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2348</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, K.</style></author><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Kwon, R.</style></author><author><style face="normal" font="default" size="100%">Shin, Y. H.</style></author><author><style face="normal" font="default" size="100%">Yeo, S. G.</style></author><author><style face="normal" font="default" size="100%">Lee, Y. J.</style></author><author><style face="normal" font="default" size="100%">Kim, M. S.</style></author><author><style face="normal" font="default" size="100%">Choi, Y. S.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Rahmati, M.</style></author><author><style face="normal" font="default" size="100%">Jung, J.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author><author><style face="normal" font="default" size="100%">Yon, D. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Chung-Ang University Hospital, Seoul, South Korea.&#xD;Department of Biomedical Engineering, Kyung Hee University College of Electronics and Information, Yongin, South Korea.&#xD;Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Otolaryngology - Head &amp; Neck Surgery, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Obstetrics and Gynecology, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.&#xD;Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Allergy Department, 2nd Paediatric Clinic, National Kapodistrian University of Athens, Athens, Greece.&#xD;Lydia Becker Institute of Immunology &amp; Inflammation, University of Manchester, Manchester, UK.&#xD;Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran.&#xD;Department of Physical Education and Sport Sciences, Faculty of Literature and Humanities, Vali-E-Asr University of Rafsanjan, Rafsanjan, Iran.&#xD;Department of Anatomy and Neurobiology, Kyung Hee University College of Medicine, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Global burden of vaccine-associated anaphylaxis and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">690-701</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/12/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adverse Drug Reaction Reporting Systems</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/etiology/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacovigilance</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">World Health Organization</style></keyword><keyword><style face="normal" font="default" size="100%">global</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine-associated anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38071735</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Vaccine-associated anaphylaxis is a rare but life-threatening reaction that occurs within minutes to hours of exposure to allergens. As studies utilizing large-scale data to investigate this topic are limited, further research is needed to assess its burden, long-term trends, and associated risk factors so as to gain a comprehensive understanding of vaccine-associated anaphylaxis globally. Therefore, this study aimed to investigate the global burden of vaccine-associated anaphylaxis and related vaccines. METHOD: This study utilized the World Health Organization International Pharmacovigilance Database, in which reports of vaccine-associated anaphylaxis between 1967 and 2023 were obtained (total reports = 131,255,418). We estimated the global reporting counts, reported odds ratio (ROR), and information component (IC) to identify the relationship between 19 vaccines and associated anaphylaxis in 156 countries and territories. RESULTS: We identified 31,676 reports of vaccine-associated anaphylaxis among 363,290 reports of all-cause anaphylaxis. The cumulative number of reports on vaccine-associated anaphylaxis has gradually increased over time, with a dramatic increase after 2020, owing to reports of COVID-19 mRNA vaccine-associated anaphylaxis. The typhoid vaccines were associated with the most anaphylactic reports (ROR: 4.35; IC(0.25) : 1.86), followed by encephalitis (3.27; 1.45), hepatitis B (2.69; 1.30), cholera (2.65; 0.54), hepatitis A (2.44; 1.12), influenza (2.36; 1.16), inactivated whole-virus COVID-19 (2.21; 1.02), and COVID-19 mRNA vaccines (1.89; 0.79). In terms of age- and sex-specific risks, vaccine-associated anaphylaxis reports develop more frequently in females and at young ages. The Ad5-vectored COVID-19 vaccine anaphylaxis reports were associated with the highest fatality rate (15.0%). CONCLUSIONS: Although multiple vaccines are associated with various spectra and risks of anaphylaxis, clinicians should recognize the possibility of anaphylaxis occurring with all vaccines, particularly the COVID-19 mRNA and inactivated whole-virus COVID-19 vaccines, and consider the risk factors associated with vaccine anaphylaxis reports. Further studies are warranted to identify better ways of preventing vaccine-associated anaphylaxis.</style></abstract><notes><style face="normal" font="default" size="100%">Lee, Kyeonghun&#xD;Lee, Hayeon&#xD;Kwon, Rosie&#xD;Shin, Youn Ho&#xD;Yeo, Seung Geun&#xD;Lee, Young Joo&#xD;Kim, Min Seo&#xD;Choi, Yong Sung&#xD;Papadopoulos, Nikolaos G&#xD;Rahmati, Masoud&#xD;Jung, Junyang&#xD;Lee, Jinseok&#xD;Yon, Dong Keon&#xD;eng&#xD;HV22C0233; Health Fellowship Foundation of South Korea (2022)/Korea Health Industry Development Institute (KHIDI)/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):690-701. doi: 10.1111/all.15968. Epub 2023 Dec 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38071735</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15968</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2661</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2661</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jeong, Y. D.</style></author><author><style face="normal" font="default" size="100%">Lee, K.</style></author><author><style face="normal" font="default" size="100%">Park, J.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author><author><style face="normal" font="default" size="100%">Kang, J.</style></author><author><style face="normal" font="default" size="100%">Yeo, S. G.</style></author><author><style face="normal" font="default" size="100%">Smith, L.</style></author><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Yon, D. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.&#xD;Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea.&#xD;Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Department of Otolaryngology-Head &amp; Neck Surgery, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.&#xD;Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Global burden of vaccine-associated angioedema and their related vaccines, 1967-2023: Findings from the global pharmacovigilance database</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">590-594</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/08/31</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39212223</style></accession-num><notes><style face="normal" font="default" size="100%">Jeong, Yi Deun&#xD;Lee, Kyeongmin&#xD;Park, Jaeyu&#xD;Lee, Jinseok&#xD;Kang, Jiseung&#xD;Yeo, Seung Geun&#xD;Smith, Lee&#xD;Lee, Hayeon&#xD;Yon, Dong Keon&#xD;eng&#xD;Ministry of Science and ICT, South Korea/&#xD;National Research Foundation of Korea/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):590-594. doi: 10.1111/all.16304. Epub 2024 Aug 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39212223</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16304</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">6</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thurmann, L.</style></author><author><style face="normal" font="default" size="100%">Klos, M.</style></author><author><style face="normal" font="default" size="100%">Mackowiak, S. D.</style></author><author><style face="normal" font="default" size="100%">Bieg, M.</style></author><author><style face="normal" font="default" size="100%">Bauer, T.</style></author><author><style face="normal" font="default" size="100%">Ishaque, N.</style></author><author><style face="normal" font="default" size="100%">Messingschlager, M.</style></author><author><style face="normal" font="default" size="100%">Herrmann, C.</style></author><author><style face="normal" font="default" size="100%">Roder, S.</style></author><author><style face="normal" font="default" size="100%">Bauer, M.</style></author><author><style face="normal" font="default" size="100%">Schauble, S.</style></author><author><style face="normal" font="default" size="100%">Faessler, E.</style></author><author><style face="normal" font="default" size="100%">Hahn, U.</style></author><author><style face="normal" font="default" size="100%">Weichenhan, D.</style></author><author><style face="normal" font="default" size="100%">Mucke, O.</style></author><author><style face="normal" font="default" size="100%">Plass, C.</style></author><author><style face="normal" font="default" size="100%">Borte, M.</style></author><author><style face="normal" font="default" size="100%">von Mutius, E.</style></author><author><style face="normal" font="default" size="100%">Stangl, G. I.</style></author><author><style face="normal" font="default" size="100%">Lauener, R.</style></author><author><style face="normal" font="default" size="100%">Karvonen, A. M.</style></author><author><style face="normal" font="default" size="100%">Divaret-Chauveau, A.</style></author><author><style face="normal" font="default" size="100%">Riedler, J.</style></author><author><style face="normal" font="default" size="100%">Heinrich, J.</style></author><author><style face="normal" font="default" size="100%">Standl, M.</style></author><author><style face="normal" font="default" size="100%">von Berg, A.</style></author><author><style face="normal" font="default" size="100%">Schaaf, B.</style></author><author><style face="normal" font="default" size="100%">Herberth, G.</style></author><author><style face="normal" font="default" size="100%">Kabesch, M.</style></author><author><style face="normal" font="default" size="100%">Eils, R.</style></author><author><style face="normal" font="default" size="100%">Trump, S.</style></author><author><style face="normal" font="default" size="100%">Lehmann, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Associated Member of the German Center for Lung Research, Unit for Molecular Epidemiology, Berlin Institute of Health at Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Associated Member of the German Center for Lung Research, Center for Digital Health, Berlin Institute of Health at Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;German Cancer Research Center (DKFZ), Division of Theoretical Bioinformatics and Heidelberg Center for Personalized Oncology (DKFZ-HIPO), Heidelberg, Germany.&#xD;Health Data Science Unit, Heidelberg University Hospital, Heidelberg, Germany.&#xD;Department of Environmental Immunology, Helmholtz Centre for Environmental Research (UFZ), Leipzig, Germany.&#xD;Friedrich-Schiller-University Jena, Jena University Language &amp; Information Engineering (JULIE) Lab, Jena, Germany.&#xD;Leibniz Institute for Natural Product Research and Infection Biology-Hans Knoll Institute, Systems Biology and Bioinformatics Unit, Jena, Germany.&#xD;Division of Cancer Epigenetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.&#xD;German Center for Lung Research (DZL), Heidelberg, Munich, Germany.&#xD;Children&apos;s Hospital, Municipal Hospital &quot;St. Georg&quot;, Leipzig, Germany.&#xD;Dr. von Hauner Children&apos;s Hospital, Ludwig Maximilian University Munich, Munich, Germany.&#xD;Helmholtz Zentrum Munchen-German Research Center for Environmental Health, Institute for Asthma and Allergy Prevention, Neuherberg, Germany.&#xD;Martin Luther University Halle-Wittenberg, Institute of Agricultural and Nutritional Sciences, Halle (Saale), Germany.&#xD;Children&apos;s Hospital of Eastern Switzerland, St. Gallen, Switzerland.&#xD;Department of Health Security, Finnish Institute for Health and Welfare, Kuopio, Finland.&#xD;Pediatric Allergy Department, Children&apos;s Hospital, University Hospital of Nancy, Vandoeuvre les Nancy, France.&#xD;UMR 6249 Chrono-Environment, Centre National de la Recherche Scientifique and University of Franche-Comte, Besancon, France.&#xD;EA3450 Development, Adaptation and Handicap, University of Lorraine, Nancy, France.&#xD;Children&apos;s Hospital, Schwarzach, Austria.&#xD;Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU, Munich, Germany.&#xD;Institute of Epidemiology, Helmholtz Zentrum Munchen-German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Department of Pediatrics, Research Institute, Marien-Hospital Wesel, Wesel, Germany.&#xD;Pediatric Outpatient Department, Bad Honnef, Germany.&#xD;Department of Pediatric Pneumology and Allergy, University Children&apos;s Hospital Regensburg (KUNO), Regensburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Global hypomethylation in childhood asthma identified by genome-wide DNA-methylation sequencing preferentially affects enhancer regions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1489-1506</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">DNA</style></keyword><keyword><style face="normal" font="default" size="100%">DNA-methylation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">cord blood</style></keyword><keyword><style face="normal" font="default" size="100%">prenatal exposure</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36704932</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Childhood asthma is a result of a complex interaction of genetic and environmental components causing epigenetic and immune dysregulation, airway inflammation and impaired lung function. Although different microarray based EWAS studies have been conducted, the impact of epigenetic regulation in asthma development is still widely unknown. We have therefore applied unbiased whole genome bisulfite sequencing (WGBS) to characterize global DNA-methylation profiles of asthmatic children compared to healthy controls. METHODS: Peripheral blood samples of 40 asthmatic and 42 control children aged 5-15 years from three birth cohorts were sequenced together with paired cord blood samples. Identified differentially methylated regions (DMRs) were categorized in genotype-associated, cell-type-dependent, or prenatally primed. Network analysis and subsequent natural language processing of DMR-associated genes was complemented by targeted analysis of functional translation of epigenetic regulation on the transcriptional and protein level. RESULTS: In total, 158 DMRs were identified in asthmatic children compared to controls of which 37% were related to the eosinophil content. A global hypomethylation was identified affecting predominantly enhancer regions and regulating key immune genes such as IL4, IL5RA, and EPX. These DMRs were confirmed in n = 267 samples and could be linked to aberrant gene expression. Out of the 158 DMRs identified in the established phenotype, 56 were perturbed already at birth and linked, at least in part, to prenatal influences such as tobacco smoke exposure or phthalate exposure. CONCLUSION: This is the first epigenetic study based on whole genome sequencing to identify marked dysregulation of enhancer regions as a hallmark of childhood asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Thurmann, Loreen&#xD;Klos, Matthias&#xD;Mackowiak, Sebastian D&#xD;Bieg, Matthias&#xD;Bauer, Tobias&#xD;Ishaque, Naveed&#xD;Messingschlager, Marey&#xD;Herrmann, Carl&#xD;Roder, Stefan&#xD;Bauer, Mario&#xD;Schauble, Sascha&#xD;Faessler, Erik&#xD;Hahn, Udo&#xD;Weichenhan, Dieter&#xD;Mucke, Oliver&#xD;Plass, Christoph&#xD;Borte, Michael&#xD;von Mutius, Erika&#xD;Stangl, Gabriele I&#xD;Lauener, Roger&#xD;Karvonen, Anne M&#xD;Divaret-Chauveau, Amandine&#xD;Riedler, Josef&#xD;Heinrich, Joachim&#xD;Standl, Marie&#xD;von Berg, Andrea&#xD;Schaaf, Beate&#xD;Herberth, Gunda&#xD;Kabesch, Michael&#xD;Eils, Roland&#xD;Trump, Saskia&#xD;Lehmann, Irina&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1489-1506. doi: 10.1111/all.15658. Epub 2023 Feb 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36704932</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15658</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1981</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1981</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Reddel, H. K.</style></author><author><style face="normal" font="default" size="100%">Gina Board of Directors</style></author><author><style face="normal" font="default" size="100%">Gina Science Committee</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonology, Celal Bayar University, Manisa, Turkey.&#xD;GINA Science Committee, Woolcock Institute of Medical Research, Sydney, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Global initiative for asthma: 30 years of promoting evidence-based asthma care</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1737-1739</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/03/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Global Health</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36934290</style></accession-num><notes><style face="normal" font="default" size="100%">Yorgancioglu, Arzu&#xD;Reddel, Helen K&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1737-1739. doi: 10.1111/all.15714.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36934290</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15714</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2200</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2200</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shin, Y. H.</style></author><author><style face="normal" font="default" size="100%">Hwang, J.</style></author><author><style face="normal" font="default" size="100%">Kwon, R.</style></author><author><style face="normal" font="default" size="100%">Lee, S. W.</style></author><author><style face="normal" font="default" size="100%">Kim, M. S.</style></author><author><style face="normal" font="default" size="100%">G. B. D. Allergic Disorders Collaborators</style></author><author><style face="normal" font="default" size="100%">Shin, J. I.</style></author><author><style face="normal" font="default" size="100%">Yon, D. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, The Catholic University of Korea, Yeouido St. Mary&apos;s Hospital, Seoul, South Korea.&#xD;Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.&#xD;Department of Pediatrics, Yonsei University, Seoul, South Korea.&#xD;Center for Digital Health, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Precision Medicine, Sungkyunkwan University, Suwon, South Korea.&#xD;Department of Digital Health, Samsung Advanced Institute for Health Sciences &amp; Technology (SAIHST), Seoul, South Korea.&#xD;Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.&#xD;Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea.&#xD;Department of Pediatrics, Kyung Hee University College of Medicine, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2232-2254</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/07/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Global Burden of Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Quality-Adjusted Life Years</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Global Health</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">disability-adjusted life years</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">global burden</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">board, society, committee or advocacy group, unpaid, as President of the Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Section, Canadian Pediatric Society, and as Chair of the Food Allergy/Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Section, Canadian Society of Allergy and Clinical Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">other financial or</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial interests in the Public Health Agency of Canada (PHAC) as their</style></keyword><keyword><style face="normal" font="default" size="100%">employee. The views expressed in this manuscript are not necessarily</style></keyword><keyword><style face="normal" font="default" size="100%">representative of PHAC</style></keyword><keyword><style face="normal" font="default" size="100%">all outside the submitted work. A Agrawal reports</style></keyword><keyword><style face="normal" font="default" size="100%">leadership or fiduciary role in other board, society, committee or advocacy</style></keyword><keyword><style face="normal" font="default" size="100%">group, paid or unpaid, with the International Clinical Epidemiology Network as a</style></keyword><keyword><style face="normal" font="default" size="100%">board member, outside the submitted work. N Bayileyegn reports a planned patent</style></keyword><keyword><style face="normal" font="default" size="100%">for surgical instruments to be used in low resources settings (Jan 2024)</style></keyword><keyword><style face="normal" font="default" size="100%">participation on a Data Safety Monitoring Board or Advisory Board as hospital</style></keyword><keyword><style face="normal" font="default" size="100%">lead for HIPPO and supervision of surgical data quality</style></keyword><keyword><style face="normal" font="default" size="100%">leadership or fiduciary</style></keyword><keyword><style face="normal" font="default" size="100%">role in other board, society, committee or advocacy group, paid or unpaid, as</style></keyword><keyword><style face="normal" font="default" size="100%">surgical unit head at the hospital department of surgery Jimma University</style></keyword><keyword><style face="normal" font="default" size="100%">all</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. A Bikov reports grants or contracts form the</style></keyword><keyword><style face="normal" font="default" size="100%">Northwest Lung Charity and Manchester NIHR Biomedical Research Centre outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. A Carungo reports consulting fees from AbbVie as personal</style></keyword><keyword><style face="normal" font="default" size="100%">payments</style></keyword><keyword><style face="normal" font="default" size="100%">payment or honoraria for educational events from Janssen-Cilag,</style></keyword><keyword><style face="normal" font="default" size="100%">Almirall, Novartis, Eli Lilly, Leo Pharma, and Amgen, all as personal payments</style></keyword><keyword><style face="normal" font="default" size="100%">all outside the submitted work. J S K Chan reports grants or contracts from the</style></keyword><keyword><style face="normal" font="default" size="100%">Observational and Pragmatic Research Institute as their employee, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. X Dai reports support for the present work from UW and IHME as</style></keyword><keyword><style face="normal" font="default" size="100%">salary payments. T Fukumoto reports payment or honoraria for lectures,</style></keyword><keyword><style face="normal" font="default" size="100%">presentations, speakers bureaus, manuscript writing or educational events from</style></keyword><keyword><style face="normal" font="default" size="100%">AbbVie, Eli Lilly, Sanofi, Pfizer, and Maruho, all outside the submitted work. R</style></keyword><keyword><style face="normal" font="default" size="100%">F Gillum reports other financial or non-financial interest in Annals of</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiology as the Associate Editor, and in the Journal of the National Medical</style></keyword><keyword><style face="normal" font="default" size="100%">Association as a member of the editorial board, all outside the submitted work. V</style></keyword><keyword><style face="normal" font="default" size="100%">K Gupta reports grants or contracts from National Health and Medical Research</style></keyword><keyword><style face="normal" font="default" size="100%">Council (NHMRC), Australia outside the submitted work. N E Ismail reports</style></keyword><keyword><style face="normal" font="default" size="100%">leadership or fiduciary role in other board, society, committee or advocacy</style></keyword><keyword><style face="normal" font="default" size="100%">group, unpaid, as Bursar for the Malaysian Academy of Pharmacy, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. B Kaambwa reports leadership or fiduciary role in other board,</style></keyword><keyword><style face="normal" font="default" size="100%">society, committee or advocacy group, paid or unpaid, with PloS One,</style></keyword><keyword><style face="normal" font="default" size="100%">PharmacoEconomics Open, and International Journal of Environmental Research and</style></keyword><keyword><style face="normal" font="default" size="100%">Public Health as a member of their editorial boards, all outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. I M Karaye reports support for attending meetings and/or travel from</style></keyword><keyword><style face="normal" font="default" size="100%">Hofstra University, Hempstead, New York, for the American Public Health</style></keyword><keyword><style face="normal" font="default" size="100%">Association Meeting 2022, and the American College of Epidemiology Meeting 2022,</style></keyword><keyword><style face="normal" font="default" size="100%">all outside the submitted work. P Kolkhir reports consulting fees from</style></keyword><keyword><style face="normal" font="default" size="100%">ValenzaBio</style></keyword><keyword><style face="normal" font="default" size="100%">payment or honoraria for lectures, presentations, speakers bureaus,</style></keyword><keyword><style face="normal" font="default" size="100%">manuscript writing or educational events from Novartis and Roche</style></keyword><keyword><style face="normal" font="default" size="100%">leadership or</style></keyword><keyword><style face="normal" font="default" size="100%">fiduciary role in other board, society, committee or advocacy group, paid or</style></keyword><keyword><style face="normal" font="default" size="100%">unpaid, with EAACI Dermatology Section as a board member</style></keyword><keyword><style face="normal" font="default" size="100%">all outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. K Krishan reports non-financial support from UGC Centre of</style></keyword><keyword><style face="normal" font="default" size="100%">Advanced Study, CAS II, Department of Anthropology, Panjab University,</style></keyword><keyword><style face="normal" font="default" size="100%">Chandigarh, India, outside the submitted work. M-C Li reports support for the</style></keyword><keyword><style face="normal" font="default" size="100%">present manuscript from National Science and Technology Council, Taiwan through</style></keyword><keyword><style face="normal" font="default" size="100%">research funding (NSTC 111-2410-H-003-100-SSS). G L L Lopes reports grants or</style></keyword><keyword><style face="normal" font="default" size="100%">contracts from Fundacao para a Ciencia e Tecnologia (FCT), under the Scientific</style></keyword><keyword><style face="normal" font="default" size="100%">Employment Stimulus-Individual Call (CEECIND/01768/2021), outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. J R Medina reports support for attending meetings and/or travel from SPARK</style></keyword><keyword><style face="normal" font="default" size="100%">Consortium to attend the Introduction to Mathematical Modeling for Infectious</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases in Bali, Indonesia, March 6 - 12, 2023, outside the submitted work. A-F</style></keyword><keyword><style face="normal" font="default" size="100%">Mentis reports grants or contracts from &apos;MilkSafe: A novel pipeline to enrich</style></keyword><keyword><style face="normal" font="default" size="100%">formula milk using omics technologies&apos;, a research co financed by the European</style></keyword><keyword><style face="normal" font="default" size="100%">Regional Development Fund of the European Union and Greek national funds through</style></keyword><keyword><style face="normal" font="default" size="100%">the Operational Program Competitiveness, Entrepreneurship and Innovation, under</style></keyword><keyword><style face="normal" font="default" size="100%">the call RESEARCH - CREATE - INNOVATE (project code: T2EDK-02222), as well as</style></keyword><keyword><style face="normal" font="default" size="100%">from ELIDEK (Hellenic Foundation for Research and Innovation, MIMS-860)</style></keyword><keyword><style face="normal" font="default" size="100%">payment</style></keyword><keyword><style face="normal" font="default" size="100%">for expert testimony as a peer-reviewer for Fondazione Cariplo, Italy</style></keyword><keyword><style face="normal" font="default" size="100%">leadership</style></keyword><keyword><style face="normal" font="default" size="100%">or fiduciary role in other board, society, committee or advocacy group, paid or</style></keyword><keyword><style face="normal" font="default" size="100%">unpaid, by serving as Editorial Board Member for &quot;Systematic Reviews&quot; journal,</style></keyword><keyword><style face="normal" font="default" size="100%">for &quot;Annals of Epidemiology&quot; journal, and as Associate Editor for &quot;Translational</style></keyword><keyword><style face="normal" font="default" size="100%">Psychiatry&quot;</style></keyword><keyword><style face="normal" font="default" size="100%">stocks in a family winery</style></keyword><keyword><style face="normal" font="default" size="100%">and other financial or non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">interests as a scientific officer with the BGI Group</style></keyword><keyword><style face="normal" font="default" size="100%">all outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. S Mohammed reports support for the present manuscript from the Bill and</style></keyword><keyword><style face="normal" font="default" size="100%">Melinda Gates Foundation. L Monasta reports support for the present manuscript</style></keyword><keyword><style face="normal" font="default" size="100%">from Italian Ministry of Health through a contribution given to the Institute for</style></keyword><keyword><style face="normal" font="default" size="100%">Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy (RC 34/2017). D</style></keyword><keyword><style face="normal" font="default" size="100%">Munblit reports grants or contracts from the European Cooperation in Science and</style></keyword><keyword><style face="normal" font="default" size="100%">Technology (COST) as payments made to their institution for the Core Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Measures for Food Allergy (COMFA) consortium</style></keyword><keyword><style face="normal" font="default" size="100%">support for attending meetings</style></keyword><keyword><style face="normal" font="default" size="100%">and/or travel from European Cooperation in Science and Technology (COST) as</style></keyword><keyword><style face="normal" font="default" size="100%">personal payments</style></keyword><keyword><style face="normal" font="default" size="100%">all outside the submitted work. T P Ng reports support from</style></keyword><keyword><style face="normal" font="default" size="100%">the present manuscript from Agency for Science, Technology and Research and</style></keyword><keyword><style face="normal" font="default" size="100%">National Medical Research Council as grant funding</style></keyword><keyword><style face="normal" font="default" size="100%">payment or honoraria for</style></keyword><keyword><style face="normal" font="default" size="100%">lectures, presentations, speakers bureaus, manuscript writing or educational</style></keyword><keyword><style face="normal" font="default" size="100%">events from Singapore Institute of Technology, Singapore Nanyang Technological</style></keyword><keyword><style face="normal" font="default" size="100%">University, Singapore</style></keyword><keyword><style face="normal" font="default" size="100%">all outside the submitted work. A Sheikh reports grants or</style></keyword><keyword><style face="normal" font="default" size="100%">contracts from HDRUK through a research infrastructure grant, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. C Simpson reports research grants to their institution from MBIE</style></keyword><keyword><style face="normal" font="default" size="100%">(NZ), HRC (NZ), Ministry of Health (NZ), MRC (UK), HDRUK, and CSO (UK), all</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. J A Singh reports consulting fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs Inc., Adept Field Solutions,</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus</style></keyword><keyword><style face="normal" font="default" size="100%">Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio</style></keyword><keyword><style face="normal" font="default" size="100%">Health, Medscape, WebMD, and Practice Point Communications, the National</style></keyword><keyword><style face="normal" font="default" size="100%">Institutes of Health, and the American College of Rheumatology</style></keyword><keyword><style face="normal" font="default" size="100%">payment or</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria for speakers&apos; bureaus from Simply Speaking</style></keyword><keyword><style face="normal" font="default" size="100%">support for attending</style></keyword><keyword><style face="normal" font="default" size="100%">meetings or travel from the steering committee of OMERACT</style></keyword><keyword><style face="normal" font="default" size="100%">participation on a</style></keyword><keyword><style face="normal" font="default" size="100%">Data Safety Monitoring Board or Advisory Board with the US Food and Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Administration Arthritis Advisory Committee</style></keyword><keyword><style face="normal" font="default" size="100%">leadership or fiduciary role in</style></keyword><keyword><style face="normal" font="default" size="100%">board, society, committee or advocacy group, paid or unpaid, with OMERACT as a</style></keyword><keyword><style face="normal" font="default" size="100%">steering committee member, with the Veterans Affairs Rheumatology Field Advisory</style></keyword><keyword><style face="normal" font="default" size="100%">Committee as Chair (unpaid), and with the UAB Cochrane Musculoskeletal Group</style></keyword><keyword><style face="normal" font="default" size="100%">Satellite Center on Network Meta-analysis and editor and director (unpaid)</style></keyword><keyword><style face="normal" font="default" size="100%">stock</style></keyword><keyword><style face="normal" font="default" size="100%">or stock options in TPT Global Tech, Vaxart Pharmaceuticals, Aytu BioPharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Seres</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Tonix Pharmaceuticals and Charlotte&apos;s Web Holdings, and previously</style></keyword><keyword><style face="normal" font="default" size="100%">owned stock options in Amarin, Viking, and Moderna Pharmaceuticals</style></keyword><keyword><style face="normal" font="default" size="100%">all outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work. E Upadhyay reports patents planned, issued or pending for a</style></keyword><keyword><style face="normal" font="default" size="100%">system and method of reusable filters for anti-pollution mask (published), a</style></keyword><keyword><style face="normal" font="default" size="100%">system and method for electricity generation through crop stubble by using</style></keyword><keyword><style face="normal" font="default" size="100%">microbial fuel cells (published), a system for disposed personal protection</style></keyword><keyword><style face="normal" font="default" size="100%">equipment (PPE) into biofuel through pyrolysis and method (published), and a</style></keyword><keyword><style face="normal" font="default" size="100%">novel herbal pharmaceutical aid for formulation of gel and method thereof</style></keyword><keyword><style face="normal" font="default" size="100%">(filed)</style></keyword><keyword><style face="normal" font="default" size="100%">leadership or fiduciary role in other board, society, committee or</style></keyword><keyword><style face="normal" font="default" size="100%">advocacy group, paid or unpaid, Indian Meteorological Society, Jaipur Chapter, as</style></keyword><keyword><style face="normal" font="default" size="100%">joint secretary</style></keyword><keyword><style face="normal" font="default" size="100%">all outside the submitted work. J F M van Boven reports grants</style></keyword><keyword><style face="normal" font="default" size="100%">or contracts from Aardex, AstraZeneca, Chiesi, European Commission COST Action</style></keyword><keyword><style face="normal" font="default" size="100%">19132 &quot;ENABLE&quot;, Novartis, Pill Connect, Pfizer, and Trudell Medical, all as</style></keyword><keyword><style face="normal" font="default" size="100%">payments made to their institution</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from AstraZeneca, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, Novartis, Teva, and Vertex as payments made to their institution</style></keyword><keyword><style face="normal" font="default" size="100%">all</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37431853</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma and atopic dermatitis (AD) are chronic allergic conditions, along with allergic rhinitis and food allergy and cause high morbidity and mortality both in children and adults. This study aims to evaluate the global, regional, national, and temporal trends of the burden of asthma and AD from 1990 to 2019 and analyze their associations with geographic, demographic, social, and clinical factors. METHODS: Using data from the Global Burden of Diseases (GBD), Injuries, and Risk Factors Study 2019, we assessed the age-standardized prevalence, incidence, mortality, and disability-adjusted life years (DALYs) of both asthma and AD from 1990 to 2019, stratified by geographic region, age, sex, and socio-demographic index (SDI). DALYs were calculated as the sum of years lived with disability and years of life lost to premature mortality. Additionally, the disease burden of asthma attributable to high body mass index, occupational asthmagens, and smoking was described. RESULTS: In 2019, there were a total of 262 million [95% uncertainty interval (UI): 224-309 million] cases of asthma and 171 million [95% UI: 165-178 million] total cases of AD globally; age-standardized prevalence rates were 3416 [95% UI: 2899-4066] and 2277 [95% UI: 2192-2369] per 100,000 population for asthma and AD, respectively, a 24.1% [95% UI: -27.2 to -20.8] decrease for asthma and a 4.3% [95% UI: 3.8-4.8] decrease for AD compared to baseline in 1990. Both asthma and AD had similar trends according to age, with age-specific prevalence rates peaking at age 5-9 years and rising again in adulthood. The prevalence and incidence of asthma and AD were both higher for individuals with higher SDI; however, mortality and DALYs rates of individuals with asthma had a reverse trend, with higher mortality and DALYs rates in those in the lower SDI quintiles. Of the three risk factors, high body mass index contributed to the highest DALYs and deaths due to asthma, accounting for a total of 3.65 million [95% UI: 2.14-5.60 million] asthma DALYs and 75,377 [95% UI: 40,615-122,841] asthma deaths. CONCLUSIONS: Asthma and AD continue to cause significant morbidity worldwide, having increased in total prevalence and incidence cases worldwide, but having decreased in age-standardized prevalence rates from 1990 to 2019. Although both are more frequent at younger ages and more prevalent in high-SDI countries, each condition has distinct temporal and regional characteristics. Understanding the temporospatial trends in the disease burden of asthma and AD could guide future policies and interventions to better manage these diseases worldwide and achieve equity in prevention, diagnosis, and treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Shin, Youn Ho&#xD;Hwang, Jimin&#xD;Kwon, Rosie&#xD;Lee, Seung Won&#xD;Kim, Min Seo&#xD;Shin, Jae Il&#xD;Yon, Dong Keon&#xD;eng&#xD;P01 AG017625/AG/NIA NIH HHS/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2232-2254. doi: 10.1111/all.15807. Epub 2023 Jul 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37431853</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10529296</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15807</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1013</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1013</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Toki, S.</style></author><author><style face="normal" font="default" size="100%">Newcomb, D. C.</style></author><author><style face="normal" font="default" size="100%">Printz, R. L.</style></author><author><style face="normal" font="default" size="100%">Cahill, K. N.</style></author><author><style face="normal" font="default" size="100%">Boyd, K. L.</style></author><author><style face="normal" font="default" size="100%">Niswender, K. D.</style></author><author><style face="normal" font="default" size="100%">Peebles, R. S., Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.&#xD;Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.&#xD;Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University School of Medicine, Nashville, TN, USA.&#xD;Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, USA.&#xD;United States Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3433-3445</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/05/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alternaria</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Glucagon-Like Peptide-1 Receptor</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Obese</style></keyword><keyword><style face="normal" font="default" size="100%">glucagon-like peptide-1 receptor (GLP-1R)</style></keyword><keyword><style face="normal" font="default" size="100%">group 2 innate lymphoid cells (ILC2)</style></keyword><keyword><style face="normal" font="default" size="100%">liraglutide</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophilia</style></keyword><keyword><style face="normal" font="default" size="100%">obese asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33955007</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Obesity is a risk factor for the development of asthma. However, pharmacologic therapeutic strategies that specifically target obese asthmatics have not been identified. We hypothesize that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment inhibits aeroallergen-induced early innate airway inflammation in a mouse model of asthma in the setting of obesity. METHODS: SWR (lean) and TALLYHO (obese) mice were challenged intranasally with Alternaria alternata extract (Alt-Ext) or PBS for 4 consecutive days concurrent with GLP-1RA or vehicle treatment. RESULTS: TALLYHO mice had greater Alt-Ext-induced airway neutrophilia and lung protein expression of IL-5, IL-13, CCL11, CXCL1, and CXCL5, in addition to ICAM-1 expression on lung epithelial cells compared with SWR mice, and all endpoints were reduced by GLP-1RA treatment. Alt-Ext significantly increased BALF IL-33 in both TALLYHO and SWR mice compared to PBS challenge, but there was no difference in the BALF IL-33 levels between these two strains. However, TALLYHO, but not SWR, mice had significantly higher airway TSLP in BALF following Alt-Ext challenge compared to PBS, and BALF TSLP was significantly greater in TALLYHO mice compared to SWR mice following airway Alt-Ext challenge. GLP-1RA treatment significantly decreased the Alt-Ext-induced TSLP and IL-33 release in TALLYHO mice. While TSLP or ST2 inhibition with a neutralizing antibody decreased airway eosinophils, they did not reduce airway neutrophils in TALLYHO mice. CONCLUSIONS: These results suggest that GLP-1RA treatment may be a novel pharmacologic therapeutic strategy for obese persons with asthma by inhibiting aeroallergen-induced neutrophilia, a feature not seen with either TSLP or ST2 inhibition.</style></abstract><notes><style face="normal" font="default" size="100%">Toki, Shinji&#xD;Newcomb, Dawn C&#xD;Printz, Richard L&#xD;Cahill, Katherine N&#xD;Boyd, Kelli L&#xD;Niswender, Kevin D&#xD;Peebles, R Stokes Jr&#xD;eng&#xD;R01 HL090664/HL/NHLBI NIH HHS/&#xD;R21 AI145397/AI/NIAID NIH HHS/&#xD;R01 HL122554/HL/NHLBI NIH HHS/&#xD;R01 AI111820/AI/NIAID NIH HHS/&#xD;R01 AI145265/AI/NIAID NIH HHS/&#xD;R01 AI124456/AI/NIAID NIH HHS/&#xD;I01 BX000624/BX/BLRD VA/&#xD;R01 HL136664/HL/NHLBI NIH HHS/&#xD;U19 AI095227/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3433-3445. doi: 10.1111/all.14879. Epub 2021 May 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33955007</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8597133</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14879</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2133</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2133</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Merk, V. M.</style></author><author><style face="normal" font="default" size="100%">Renzulli, P.</style></author><author><style face="normal" font="default" size="100%">Vrugt, B.</style></author><author><style face="normal" font="default" size="100%">Fleischmann, A.</style></author><author><style face="normal" font="default" size="100%">Brunner, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Biochemical Pharmacology, Department of Biology, University of Konstanz, Konstanz, Germany.&#xD;Department of Surgery, Cantonal Hospital Munsterlingen, Munsterlingen, Switzerland.&#xD;Institute of Pathology, Cantonal Hospital Munsterlingen, Munsterlingen, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Glucocorticoids are differentially synthesized along the murine and human respiratory tree</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2428-2440</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/05/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Glucocorticoids/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Trees</style></keyword><keyword><style face="normal" font="default" size="100%">Steroid 11-beta-Hydroxylase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lipopolysaccharides</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cyp11b1</style></keyword><keyword><style face="normal" font="default" size="100%">Hsd11b1</style></keyword><keyword><style face="normal" font="default" size="100%">extra-adrenal</style></keyword><keyword><style face="normal" font="default" size="100%">glucocorticoids</style></keyword><keyword><style face="normal" font="default" size="100%">lung</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37171450</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Synthetic glucocorticoids (GC) are effective in the treatment of inflammatory diseases of the lung. However, long-term use leads to severe side effects. Endogenous GC can be synthesized locally, either de novo from cholesterol in a 11beta-hydroxylase (Cyp11b1)-dependent manner, or by reactivation from 11-dehydrocorticosterone/cortisone by 11beta-hydroxysteroid dehydrogenase 1 (Hsd11b1). We aimed to define the molecular pathways of endogenous GC synthesis along the respiratory tree to provide a basis for understanding how local GC synthesis contributes to tissue homeostasis. METHODS: Expression of steroidogenic enzymes in murine lung epithelium was analyzed by macroscopic and laser capture microdissection, followed by RT-qPCR. Flow cytometry analysis was performed to identify the cellular source of steroidogenic enzymes. Additionally, the induction of steroidogenic enzyme expression in the lung was analyzed after lipopolysaccharide (LPS) injection. mRNA and protein expression of steroidogenic enzymes was confirmed in human lung tissue by RT-qPCR and immunohistochemistry. Furthermore, GC synthesis was examined in ex vivo cultures of fresh tissue from mice and human lobectomy patients. RESULTS: We observed that the murine and human lung tissue differentially expresses synthesis pathway-determining enzymes along the respiratory tree. We detected Hsd11b1 expression in bronchial, alveolar, club and basal epithelial cells, whereas Cyp11b1 expression was detectable only in tracheal epithelial cells of mice. Accordingly, de novo synthesis of bioactive GC occurred in the large conducting airways, whereas reactivation occurred everywhere along the respiratory tree. Strikingly, Cyp11b1 but not Hsd11b1 expression was enhanced in the trachea upon LPS injection in mice. CONCLUSION: We report here the differential synthesis of bioactive GC along the murine and human respiratory tree. Thus, extra-adrenal de novo GC synthesis and reactivation may differentially contribute to the regulation of immunological and inflammatory processes in the lung.</style></abstract><notes><style face="normal" font="default" size="100%">Merk, Verena M&#xD;Renzulli, Pietro&#xD;Vrugt, Bart&#xD;Fleischmann, Achim&#xD;Brunner, Thomas&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2428-2440. doi: 10.1111/all.15765. Epub 2023 May 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37171450</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15765</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>759</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">759</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, J. M.</style></author><author><style face="normal" font="default" size="100%">Im, Y. N.</style></author><author><style face="normal" font="default" size="100%">Chung, Y. J.</style></author><author><style face="normal" font="default" size="100%">Youm, J. H.</style></author><author><style face="normal" font="default" size="100%">Im, S. Y.</style></author><author><style face="normal" font="default" size="100%">Han, M. K.</style></author><author><style face="normal" font="default" size="100%">Lee, H. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Institute for Medical Science, Jeonbuk National University Medical School, Jeonju, South Korea.&#xD;Center for University-wide Research Facilities, Jeonbuk National University Medical School, Jeonju, South Korea.&#xD;Department of Preventive Medicine, Jeonbuk National University Medical School, Jeonju, South Korea.&#xD;Department of Biological Sciences, College of Natural Sciences, Chonnam National University, Gwangju, South Korea.&#xD;Department of Microbiology and Institute for Medical Science, Jeonbuk National University Medical School, Jeonju, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Glutamine deficiency shifts the asthmatic state toward neutrophilic airway inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1180-1191</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/10/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Dual Specificity Phosphatase 1/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Glutamate-Ammonia Ligase</style></keyword><keyword><style face="normal" font="default" size="100%">*Glutamine/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Ovalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">p38 Mitogen-Activated Protein Kinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">MAPK phosphatase-1</style></keyword><keyword><style face="normal" font="default" size="100%">cPLA2</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous glutamine</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophilic airway inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">p38 MAPK</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34601745</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The administration of L-glutamine (Gln) suppresses allergic airway inflammation via the rapid upregulation of MAPK phosphatase (MKP)-1, which functions as a negative regulator of inflammation by deactivating p38 and JNK mitogen-activated protein kinases (MAPKs). However, the role of endogenous Gln remains to be elucidated. Therefore, we investigated the mechanism by which endogenous Gln regulates MKP-1 induction and allergic airway inflammation in an ovalbumin-based murine asthma model. METHODS: We depleted endogenous Gln levels using L-gamma-glutamyl-p-nitroanilide (GPNA), an inhibitor of the Gln transporter ASCT2 and glutamine synthetase small interfering siRNA. Lentivirus expressing MKP-1 was injected to achieve overexpression of MKP-1. Asthmatic phenotypes were assessed using our previously developed ovalbumin-based murine model, which is suitable for examining sequential asthmatic events, including neutrophil infiltration. Gln levels were analyzed using a Gln assay kit. RESULTS: GPNA or glutamine synthetase siRNA successfully depleted endogenous Gln levels. Importantly, homeostatic MKP-1 induction did not occur at all, which resulted in prolonged p38 MAPK and cytosolic phospholipase A(2) (cPLA(2) ) phosphorylation in Gln-deficient mice. Gln deficiency augmented all examined asthmatic reactions, but it exhibited a strong bias toward increasing the neutrophil count, which was not observed in MKP-1-overexpressing lungs. This neutrophilia was inhibited by a cPLA(2) inhibitor and a leukotriene B4 inhibitor but not by dexamethasone. CONCLUSION: Gln deficiency leads to the impairment of MKP-1 induction and activation of p38 MAPK and cPLA(2) , resulting in the augmentation of neutrophilic, more so than eosinophilic, airway inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Kim, June-Mo&#xD;Im, Yoo Na&#xD;Chung, Yun-Jo&#xD;Youm, Jung-Ho&#xD;Im, Suhn Young&#xD;Han, Myung Kwan&#xD;Lee, Hern Ku&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1180-1191. doi: 10.1111/all.15121. Epub 2021 Oct 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34601745</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9293426</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15121</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1062</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1062</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fauquert, J. L.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CHU Montpied, Consultation d&apos;Ophtalmo-allergologie, University Hospital, Clermont-Ferrand, France.&#xD;Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Glycomics in tears: seeking for new biomarkers for ocular allergy diagnosis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2335-2336</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/04/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Glycomics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Tears</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33825208</style></accession-num><notes><style face="normal" font="default" size="100%">Fauquert, Jean-Luc&#xD;Kowalski, Marek L&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2335-2336. doi: 10.1111/all.14846. Epub 2021 May 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33825208</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14846</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>335</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">335</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Swoboda, I.</style></author><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular Biotechnology Section, FH Campus Wien, University of Applied Sciences, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Glycotopes as players in the allergic immune response</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">14-16</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/08/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36036874</style></accession-num><notes><style face="normal" font="default" size="100%">Swoboda, Ines&#xD;Breiteneder, Heimo&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):14-16. doi: 10.1111/all.15500. Epub 2022 Dec 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36036874</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15500</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1061</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1061</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pan, L. L.</style></author><author><style face="normal" font="default" size="100%">Ren, Z.</style></author><author><style face="normal" font="default" size="100%">Tu, X.</style></author><author><style face="normal" font="default" size="100%">Liu, H.</style></author><author><style face="normal" font="default" size="100%">Tay, H. L.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Pan, X.</style></author><author><style face="normal" font="default" size="100%">Dong, X.</style></author><author><style face="normal" font="default" size="100%">Foster, P. S.</style></author><author><style face="normal" font="default" size="100%">Sun, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Wuxi School of Medicine, Jiangnan University, Wuxi, China.&#xD;State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China.&#xD;School of Food Science and Technology, Jiangnan University, Wuxi, China.&#xD;Department of Microbiology and Immunology, Faculty of Health and Medicine, Priority Research Centre for Healthy Lungs, School of Biomedical Sciences and Pharmacy, Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">GPR109A deficiency promotes IL-33 overproduction and type 2 immune response in food allergy in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2613-2616</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/04/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33/genetics/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Transport</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, G-Protein-Coupled/*genetics/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33829517</style></accession-num><notes><style face="normal" font="default" size="100%">Pan, Li-Long&#xD;Ren, Zhengnan&#xD;Tu, Xing&#xD;Liu, He&#xD;Tay, Hock L&#xD;Li, Jiahong&#xD;Pan, Xiaohua&#xD;Dong, Xiaoliang&#xD;Foster, Paul S&#xD;Sun, Jia&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2613-2616. doi: 10.1111/all.14849. Epub 2021 Apr 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33829517</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14849</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2563</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2563</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pascal, M.</style></author><author><style face="normal" font="default" size="100%">Bax, H. J.</style></author><author><style face="normal" font="default" size="100%">Bergmann, C.</style></author><author><style face="normal" font="default" size="100%">Bianchini, R.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author><author><style face="normal" font="default" size="100%">Chauhan, J.</style></author><author><style face="normal" font="default" size="100%">De Las Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Hartmann, K.</style></author><author><style face="normal" font="default" size="100%">Alvarez, E. I.</style></author><author><style face="normal" font="default" size="100%">Jappe, U.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Rodriguez, T. W.</style></author><author><style face="normal" font="default" size="100%">Knol, E.</style></author><author><style face="normal" font="default" size="100%">Levi-Schaffer, F.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Poli, A.</style></author><author><style face="normal" font="default" size="100%">Redegeld, F.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Karagiannis, S. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunology Department, CDB, Hospital Clinic de Barcelona; Institut d&apos;Investigacio Biomedica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.&#xD;Department of Medicine, Universitat de Barcelona, Barcelona, Spain.&#xD;RETICS Asma, reacciones adversas y alergicas (ARADYAL) and RICORS Red De Enfermedades Inflamatorias (REI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.&#xD;St. John&apos;s Institute of Dermatology, School of Basic &amp; Medical Biosciences &amp; KHP Centre for Translational Medicine, King&apos;s College London, London, UK.&#xD;Department of Otorhinolaryngology, RKM740 Interdisciplinary Clinics, Dusseldorf, Germany.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, Vienna, Austria.&#xD;The interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna, Vienna, Austria.&#xD;Division of Allergy and Clinical Immunology, Drug Hypersensitivity and Desensitization Center, Mastocytosis Center, Brigham and Women&apos;s Hospital; Harvard Medical School, Boston, USA.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.&#xD;Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Department of Basic Medical Sciences, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Urbanizacion Monteprincipe, Institute of Applied Molecular Medicine Instituto de Medicina Molecular Aplicada Nemesio Diez (IMMA), Madrid, Spain.&#xD;Division of Clinical and Molecular Allergology, Priority Research Area Chronic Lung Diseases, Research Center Borstel, Leibniz Lung Center, German Center for Lung Research (DZL), Airway Research Center North (ARCN), Borstel, Germany.&#xD;Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University of Luebeck, Luebeck, Germany.&#xD;Allergy Section, Dr. Balmis General University Hospital; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.&#xD;Departments Center of Translational Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Pharmacology and Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine. The Hebrew University of Jerusalem, Ein Kerem Campus, Jerusalem, Israel.&#xD;Allergy Unit and Research Laboratory, Hospital Regional Universitario de Malaga-HRUM, Instituto de investigacion Biomedica de Malaga -IBIMA-Plataforma BIONAND, Malaga, Spain.&#xD;Neuro-Immunology Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.&#xD;Division of Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.&#xD;Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Breast Cancer Now Research Unit, School of Cancer &amp; Pharmaceutical Sciences, King&apos;s College London, Guy&apos;s Cancer Centre, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Granulocytes and mast cells in AllergoOncology-Bridging allergy to cancer: An EAACI position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2319-2345</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/07/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Neoplasms/immunology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology/therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Granulocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Microenvironment/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">AllergoOncology</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">cancer</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">granulocytes</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophils</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39036854</style></accession-num><abstract><style face="normal" font="default" size="100%">Derived from the myeloid lineage, granulocytes, including basophils, eosinophils, and neutrophils, along with mast cells, play important, often disparate, roles across the allergic disease spectrum. While these cells and their mediators are commonly associated with allergic inflammation, they also exhibit several functions either promoting or restricting tumor growth. In this Position Paper we discuss common granulocyte and mast cell features relating to immunomodulatory functions in allergy and in cancer. We highlight key mechanisms which may inform cancer treatment and propose pertinent areas for future research. We suggest areas where understanding the communication between granulocytes, mast cells, and the tumor microenvironment, will be crucial for identifying immune mechanisms that may be harnessed to counteract tumor development. For example, a comprehensive understanding of allergic and immune factors driving distinct neutrophil states and those mechanisms that link mast cells with immunotherapy resistance, might enable targeted manipulation of specific subpopulations, leading to precision immunotherapy in cancer. We recommend specific areas of investigation in AllergoOncology and knowledge exchange across disease contexts to uncover pertinent reciprocal functions in allergy and cancer and allow therapeutic manipulation of these powerful cell populations. These will help address the unmet needs in stratifying and managing patients with allergic diseases and cancer.</style></abstract><notes><style face="normal" font="default" size="100%">Pascal, Mariona&#xD;Bax, Heather J&#xD;Bergmann, Christoph&#xD;Bianchini, Rodolfo&#xD;Castells, Mariana&#xD;Chauhan, Jitesh&#xD;De Las Vecillas, Leticia&#xD;Hartmann, Karin&#xD;Alvarez, Elena Izquierdo&#xD;Jappe, Uta&#xD;Jimenez-Rodriguez, Teodorikez-Wilfox&#xD;Knol, Edward&#xD;Levi-Schaffer, Francesca&#xD;Mayorga, Cristobalina&#xD;Poli, Aurelie&#xD;Redegeld, Frank&#xD;Santos, Alexandra F&#xD;Jensen-Jarolim, Erika&#xD;Karagiannis, Sophia N&#xD;eng&#xD;MR/L023091/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/V049445/1/MRC_/Medical Research Council/United Kingdom&#xD;Consensus Development Conference&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2319-2345. doi: 10.1111/all.16246. Epub 2024 Jul 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39036854</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16246</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2289</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2289</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blom, L. H.</style></author><author><style face="normal" font="default" size="100%">Schmidt, L. B.</style></author><author><style face="normal" font="default" size="100%">Johnsen, C. R.</style></author><author><style face="normal" font="default" size="100%">Elberling, J.</style></author><author><style face="normal" font="default" size="100%">Poulsen, L. K.</style></author><author><style face="normal" font="default" size="100%">Garvey, L. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Allergy Clinic, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Granzyme B production by Th2 helper and NK cells improves the LTT test in patients with non-immediate drug hypersensitivity reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">520-523</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/10/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Granzymes</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Killer Cells, Natural</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Activation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37888939</style></accession-num><notes><style face="normal" font="default" size="100%">Blom, Lars H&#xD;Schmidt, Lasse B&#xD;Johnsen, Claus R&#xD;Elberling, Jesper&#xD;Poulsen, Lars K&#xD;Garvey, Lene H&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):520-523. doi: 10.1111/all.15936. Epub 2023 Oct 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37888939</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15936</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>839</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">839</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhan, C.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Li, B.</style></author><author><style face="normal" font="default" size="100%">Xu, R.</style></author><author><style face="normal" font="default" size="100%">Liang, W.</style></author><author><style face="normal" font="default" size="100%">Zhang, S.</style></author><author><style face="normal" font="default" size="100%">Fang, L.</style></author><author><style face="normal" font="default" size="100%">Zhong, S.</style></author><author><style face="normal" font="default" size="100%">Shaniya Helen de Silva, S. D.</style></author><author><style face="normal" font="default" size="100%">Sivapalan, D.</style></author><author><style face="normal" font="default" size="100%">Luo, W.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Lai, K.</style></author><author><style face="normal" font="default" size="100%">Zhong, N.</style></author><author><style face="normal" font="default" size="100%">Sehmi, R.</style></author><author><style face="normal" font="default" size="100%">O&apos;Byrne, P. M.</style></author><author><style face="normal" font="default" size="100%">Chen, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.&#xD;International College of Education, Guangzhou Medical University, Guangzhou, China.&#xD;Department of Medicine, Firestone Institute for Respiratory Health, St. Joseph&apos;s Healthcare and McMaster University, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Group 2 innate lymphoid cells in patients with nonasthmatic eosinophilic bronchitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">649-652</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/08/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Bronchitis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cells</style></keyword><keyword><style face="normal" font="default" size="100%">non-asthmatic eosinophilic bronchitis</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34455599</style></accession-num><notes><style face="normal" font="default" size="100%">Zhan, Chen&#xD;Liu, Jiaxing&#xD;Li, Bizhou&#xD;Xu, Rong&#xD;Liang, Wanqin&#xD;Zhang, Shengfang&#xD;Fang, Liman&#xD;Zhong, Shuxin&#xD;Shaniya Helen de Silva, S Dushinka&#xD;Sivapalan, Dhinesan&#xD;Luo, Wei&#xD;Wang, Hongyu&#xD;Li, Jing&#xD;Lai, Kefang&#xD;Zhong, Nanshan&#xD;Sehmi, Roma&#xD;O&apos;Byrne, Paul M&#xD;Chen, Ruchong&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):649-652. doi: 10.1111/all.15068. Epub 2021 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34455599</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15068</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2926</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2926</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hofer, V.</style></author><author><style face="normal" font="default" size="100%">Dolle-Bierke, S.</style></author><author><style face="normal" font="default" size="100%">Sabouraud-Leclerc, D.</style></author><author><style face="normal" font="default" size="100%">Divaret-Chauveau, A.</style></author><author><style face="normal" font="default" size="100%">Kohli, A.</style></author><author><style face="normal" font="default" size="100%">Breiding, M.</style></author><author><style face="normal" font="default" size="100%">Hartmann, K.</style></author><author><style face="normal" font="default" size="100%">Lange, L.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N.</style></author><author><style face="normal" font="default" size="100%">Ott, H.</style></author><author><style face="normal" font="default" size="100%">Hompes, S.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Garcia, B. E.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat Zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;Presidency on Behalf of Allergy Vigilance Network, Vandoeuvre les Nancy, France.&#xD;Pediatric Unit, University Hospital Reims, Reims, France.&#xD;UR 3450 DevAH - Department of Physiology, Health Faculty, University of Lorraine, Vandoeuvre-les-Nancy, France.&#xD;Pediatric Allergy Department, Children&apos;s Hospital, University Hospital of Nancy, Vandoeuvre-les-Nancy, France.&#xD;Division of Paediatric Allergology, Department of Pediatrics, Children&apos;s Hospital Lucerne, Lucerne, Switzerland.&#xD;Department of Pediatrics, Hospital Baden, Baden, Switzerland.&#xD;Division of Allergy, University Children&apos;s Hospital and Children&apos;s Research Center, University of Zurich (UZH), Zurich, Switzerland.&#xD;Divison of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Department of Paediatrics, St. Marien-Hospital, Bonn, Germany.&#xD;Department of Allergy, 2nd Paediatric Clinic, University of Athens, Athens, Greece.&#xD;Division of Pediatric Dermatology and Allergology, Children&apos;s Hospital Auf der Bult, Hannover, Germany.&#xD;Department of Paediatrics, Altona Children&apos;s Hospital, Hamburg, Germany.&#xD;Department of Clinical and Molecular Sciences, Universita, Politecnica Delle Marche, Ancona, Italy.&#xD;Department of Internal Medicine/Allergy Unit, University Hospital Ospedali Riuniti, Ancona, Italy.&#xD;Allergology Service, Hospital Universitario de Navarra, Pamplona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Growing Concern for Cashew and an Unexpected Risk From Almonds: Data From the Anaphylaxis Registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2837-2848</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/06/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Anacardium/adverse effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Nut Hypersensitivity/epidemiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Prunus dulcis/adverse effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">European Anaphylaxis Registry</style></keyword><keyword><style face="normal" font="default" size="100%">almond allergy</style></keyword><keyword><style face="normal" font="default" size="100%">cashew allergy</style></keyword><keyword><style face="normal" font="default" size="100%">hazelnut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">tree nut anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">paper. D.S.-L. has no COI in relation to this paper. A.D.-C. outside of the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work, reports grants from Don du Souffle, Novartis, ARAIRLOR,</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Sanofi, Stallergens, ALK, Aimmune Therapeutics, payment for</style></keyword><keyword><style face="normal" font="default" size="100%">presentations for Aimmune Therapeutics, Novartis, ALK, support for attending</style></keyword><keyword><style face="normal" font="default" size="100%">meetings from Mead Johnson, Nutricia, Aimmune Therapeutics, Novartis, ALK, stocks</style></keyword><keyword><style face="normal" font="default" size="100%">from Essilor Luxottica. A.K. has no COI in relation to this paper. M.B. has no</style></keyword><keyword><style face="normal" font="default" size="100%">COI in relation to this paper. K.H. received research funding from the Swiss</style></keyword><keyword><style face="normal" font="default" size="100%">National Science Foundation (SNSF</style></keyword><keyword><style face="normal" font="default" size="100%">grant 310030_207705), the Swiss Cancer</style></keyword><keyword><style face="normal" font="default" size="100%">Research Foundation (grant KFS-5979-08-2023) and the EU-H2020-MSCA-COFUND EURIdoc</style></keyword><keyword><style face="normal" font="default" size="100%">programme (No. 101034170). K.H. is or recently was a speaker/advisor for ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, Almirall, BioCryst, Blueprint, Cogent, Galderma, KalVista, Leo,</style></keyword><keyword><style face="normal" font="default" size="100%">Menarini, Novartis, Pfizer, Sanofi, Takeda and ThermoFisher. L.L. has received</style></keyword><keyword><style face="normal" font="default" size="100%">speaker fees from DBV, Nutricia, Nestle, and Thermofisher Scientific. N.P. has</style></keyword><keyword><style face="normal" font="default" size="100%">received speaker/advisor fees from Abbott, Abbvie, ALK, Asit Biotech,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Biomay, Boehringer Ingelheim, GSK, HAL, Faes Farma, Medscape,</style></keyword><keyword><style face="normal" font="default" size="100%">Menarini, MSD, Novartis, Nutricia, OM Pharma, Regeneron, Sanofi, Takeda, and</style></keyword><keyword><style face="normal" font="default" size="100%">Viatris. H.O. has no COI in relation to this paper. S.H. has no COI in relation</style></keyword><keyword><style face="normal" font="default" size="100%">to this paper. M.B.B. has no COI in relation to this paper. B.E.G. has no COI in</style></keyword><keyword><style face="normal" font="default" size="100%">relation to this paper. M.W. declares the receipt of honoraria or consultation</style></keyword><keyword><style face="normal" font="default" size="100%">fees by the following companies: Abbvie, Aimmune, ALK-Abello, Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Almirall, Amgen, AstraZeneca, Bayer, Bencard, Bioprojet Pharma, Bristol-Myers</style></keyword><keyword><style face="normal" font="default" size="100%">Squibb, Boehringer Ingelheim, Galderma, Glaxosmithkline, Infectopharm, Leo</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Eli Lilly, Mylan/Viatris, Novartis, Octapharma, Pfizer and Sanofi.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40511587</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food allergies are a major health concern with rising prevalence. Dietary habits are changing, and information about cashew-induced anaphylaxis is limited. METHODS: Cases of tree nut-induced anaphylaxis (TIA) registered from 2007 until April 2024 were extracted from the European Anaphylaxis Registry and analyzed. RESULTS: 1389 cases of TIA out of 5945 registered food-induced reactions (23%) were identified. 1,083 cases with confirmed elicitor status, including 845 children (median age 4 years, 61% male) and 238 adults (38 years, 40% male), were selected for further analysis. The most frequent elicitors among children were cashew (n = 334), hazelnut (n = 211) and walnut (n = 146). The proportion of cashew-induced anaphylaxis increased from 2007 to 2024, and reactions were frequently caused by small amounts (&lt; 1 teaspoon). Adults reacted frequently to hazelnut (n = 105), walnut (n = 47) but also almond (n = 35) and to higher amounts. Potential cofactors were present in 50% of the adult patients and 17% of children. The reaction severity was age-independent, and only a minority of patients was previously aware of their allergy (children 23%, adults 21%). The use of adrenaline was low in lay treatment (children 13%, adults 3%) and reached approximately 40% upon professional treatment. CONCLUSION: Cashew is an increasing, relevant allergen leading to anaphylaxis and is now the most frequent cause of TIA among children. These findings highlight the need for effective prevention and treatment measures. Almond was a frequent elicitor among adults and should be further monitored. The acute management requires improvement to comply with current guidelines.</style></abstract><notes><style face="normal" font="default" size="100%">Hofer, Veronika&#xD;Dolle-Bierke, Sabine&#xD;Sabouraud-Leclerc, Dominique&#xD;Divaret-Chauveau, Amandine&#xD;Kohli, Alice&#xD;Breiding, Maria&#xD;Hartmann, Karin&#xD;Lange, Lars&#xD;Papadopoulos, Nikolaos&#xD;Ott, Hagen&#xD;Hompes, Stephanie&#xD;Bilo, Maria Beatrice&#xD;Garcia, Blanca E&#xD;Worm, Margitta&#xD;eng&#xD;NORA e.V/&#xD;409525714/Deutsche Forschungsgemeinschaft/&#xD;01EA2107B/Bundesministerium fur Bildung und Forschung/&#xD;310030_207705/Swiss National Science Foundation (SNSF)/&#xD;KFS-5979-08-2023/The Swiss Cancer Research Foundation/&#xD;101034170/EU-H2020-MSCA-COFUND EURIdoc programme/&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2837-2848. doi: 10.1111/all.16619. Epub 2025 Jun 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40511587</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486339</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16619</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3158</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3158</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Miyake, K.</style></author><author><style face="normal" font="default" size="100%">Watanabe, D.</style></author><author><style face="normal" font="default" size="100%">Otawa, S.</style></author><author><style face="normal" font="default" size="100%">Kushima, M.</style></author><author><style face="normal" font="default" size="100%">Yui, H.</style></author><author><style face="normal" font="default" size="100%">Shinohara, R.</style></author><author><style face="normal" font="default" size="100%">Sakurai, D.</style></author><author><style face="normal" font="default" size="100%">Yamagata, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology and Environmental Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, Graduate Faculty of Interdisciplinary Research, University of Yamanashi, Yamanashi, Japan.&#xD;Center for Birth Cohort Studies, University of Yamanashi, Yamanashi, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gut Microbiome Alterations by Allergen Sensitisation and Symptom Severity in Paediatric Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">paediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41246908</style></accession-num><notes><style face="normal" font="default" size="100%">Miyake, Kunio&#xD;Watanabe, Daisuke&#xD;Otawa, Sanae&#xD;Kushima, Megumi&#xD;Yui, Hideki&#xD;Shinohara, Ryoji&#xD;Sakurai, Daiju&#xD;Yamagata, Zentaro&#xD;eng&#xD;20H03928/Scientific Research conferred by the Japanese Ministry of Education, Culture, Sports, Science, and Technology/&#xD;24K13437/Scientific Research conferred by the Japanese Ministry of Education, Culture, Sports, Science, and Technology/&#xD;23-iii5024/TERUMO LIFE SCIENCE FOUNDATION/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov 17. doi: 10.1111/all.70163.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41246908</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70163</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2154</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2154</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Svabova, T.</style></author><author><style face="normal" font="default" size="100%">Jelinkova, A.</style></author><author><style face="normal" font="default" size="100%">Gautam, U. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Gnotobiology, Institute of Microbiology of the Czech Academy of Sciences, Novy Hradek, Czech Republic.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gut microbiota and Lactobacillus species maintain the small intestine stem cell niche and ameliorate the severity of necrotizing enterocolitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3038-3040</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/08/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Lacticaseibacillus rhamnosus</style></keyword><keyword><style face="normal" font="default" size="100%">Paneth cells</style></keyword><keyword><style face="normal" font="default" size="100%">intestinal stem cells</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">necrotizing enterocolitis (NEC)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37610035</style></accession-num><notes><style face="normal" font="default" size="100%">Svabova, Tereza&#xD;Jelinkova, Anna&#xD;Gautam, Umesh Kumar&#xD;eng&#xD;Agentura Pro Zdravotnicky Vyzkum Ceske Republiky/&#xD;Grantova Agentura Ceske Republiky/&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):3038-3040. doi: 10.1111/all.15856. Epub 2023 Aug 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37610035</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15856</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1649</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1649</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bannier, Mage</style></author><author><style face="normal" font="default" size="100%">van Best, N.</style></author><author><style face="normal" font="default" size="100%">Bervoets, L.</style></author><author><style face="normal" font="default" size="100%">Savelkoul, P. H. M.</style></author><author><style face="normal" font="default" size="100%">Hornef, M. W.</style></author><author><style face="normal" font="default" size="100%">van de Kant, K. D. G.</style></author><author><style face="normal" font="default" size="100%">Jobsis, Q.</style></author><author><style face="normal" font="default" size="100%">Dompeling, E.</style></author><author><style face="normal" font="default" size="100%">Penders, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatric Respiratory Medicine, School for Public Health and Primary Care (CAPHRI), Maastricht University Medical Centre+, Maastricht, The Netherlands.&#xD;Department of Medical Microbiology, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University Medical Centre+, Maastricht, The Netherlands.&#xD;Institute of Medical Microbiology, RWTH Aachen University Hospital, RWTH Aachen University, Aachen, Germany.&#xD;Department of Medical Microbiology, School for Public Health and Primary Care (CAPHRI), Maastricht University Medical Centre+, Maastricht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gut microbiota in wheezing preschool children and the association with childhood asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1473-1476</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2019/12/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Sounds/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31838753</style></accession-num><notes><style face="normal" font="default" size="100%">Bannier, Michiel A G E&#xD;van Best, Niels&#xD;Bervoets, Liene&#xD;Savelkoul, Paul H M&#xD;Hornef, Mathias W&#xD;van de Kant, Kim D G&#xD;Jobsis, Quirijn&#xD;Dompeling, Edward&#xD;Penders, John&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Jun;75(6):1473-1476. doi: 10.1111/all.14156. Epub 2020 Jan 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31838753</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7317729</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14156</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3068</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3068</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Lin, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Plastic and Aesthetic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.&#xD;Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gut Microbiota-Derived Secondary Bile Acids Regulate Allergic Diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">gut microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">secondary bile acids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40990098</style></accession-num><notes><style face="normal" font="default" size="100%">Yang, Lan&#xD;Lin, Zhen&#xD;Wang, Gaofeng&#xD;eng&#xD;National Natural Science Foundation of China/&#xD;China Postdoctoral Science Foundation/&#xD;Denmark&#xD;Allergy. 2025 Sep 24. doi: 10.1111/all.70076.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40990098</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70076</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2723</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2723</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, D. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, A. S.</style></author><author><style face="normal" font="default" size="100%">Park, S. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">An, J.</style></author><author><style face="normal" font="default" size="100%">Kwon, J. W.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Kim, B. K.</style></author><author><style face="normal" font="default" size="100%">Nam, Y. H.</style></author><author><style face="normal" font="default" size="100%">Yang, M. S.</style></author><author><style face="normal" font="default" size="100%">Park, H. K.</style></author><author><style face="normal" font="default" size="100%">Lee, H. Y.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author><author><style face="normal" font="default" size="100%">Lee, S. E.</style></author><author><style face="normal" font="default" size="100%">Lee, T.</style></author><author><style face="normal" font="default" size="100%">Kim, M. H.</style></author><author><style face="normal" font="default" size="100%">Park, C. S.</style></author><author><style face="normal" font="default" size="100%">Sim, D. W.</style></author><author><style face="normal" font="default" size="100%">Song, W. J.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Park, H. K.</style></author><author><style face="normal" font="default" size="100%">Ko, S. A. R. investigators</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea.&#xD;BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Daegu, South Korea.&#xD;Department of Family Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Deagu, South Korea.&#xD;Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, South Korea.&#xD;Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea.&#xD;Department of Pulmonary, Allergy and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, South Korea.&#xD;Department of Allergy and Clinical Immunology, Kangwon National University School of Medicine, Chuncheon, South Korea.&#xD;Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.&#xD;Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.&#xD;Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea.&#xD;Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea.&#xD;Department of Internal Medicine, Pusan National University School of Medicine, Busan, South Korea.&#xD;Division of Allergy, Department of Internal Medicine, Seoul St Mary&apos;s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.&#xD;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea.&#xD;Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea.&#xD;Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.&#xD;Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, South Korea.&#xD;Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, South Korea.&#xD;Department of Allergy and Clinical Immunology, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, South Korea.&#xD;Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.&#xD;Department of Internal Medicine, Hanyang University College of Medicine, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gut permeability and its correlation with patient&apos;s traits and blood inflammatory markers in severe asthma: Real-world assessment from the Korean severe asthma registry-2 (KoSAR-2)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3512-3516</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/11/13</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39513670</style></accession-num><notes><style face="normal" font="default" size="100%">Choi, Doo Young&#xD;Kim, A-Sol&#xD;Park, So-Young&#xD;Kim, Joo-Hee&#xD;An, Jin&#xD;Kwon, Jae-Woo&#xD;Kim, Sujeong&#xD;Kim, Byung Keun&#xD;Nam, Young-Hee&#xD;Yang, Min-Suk&#xD;Park, Hye-Kyung&#xD;Lee, Hwa Young&#xD;Park, Hae-Sim&#xD;Lee, Seung-Eun&#xD;Lee, Taehoon&#xD;Kim, Min-Hye&#xD;Park, Chan Sun&#xD;Sim, Da Woon&#xD;Song, Woo-Jung&#xD;Kim, Sang-Heon&#xD;Park, Han-Ki&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3512-3516. doi: 10.1111/all.16392. Epub 2024 Nov 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39513670</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16392</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2792</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2792</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, D. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, S.</style></author><author><style face="normal" font="default" size="100%">Jung, J. H.</style></author><author><style face="normal" font="default" size="100%">Sub, Y.</style></author><author><style face="normal" font="default" size="100%">Lee, S.</style></author><author><style face="normal" font="default" size="100%">Kim, E. G.</style></author><author><style face="normal" font="default" size="100%">Kim, M. N.</style></author><author><style face="normal" font="default" size="100%">Kim, S. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, Y. H.</style></author><author><style face="normal" font="default" size="100%">Sohn, M. H.</style></author><author><style face="normal" font="default" size="100%">Gee, H. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, K. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.&#xD;Department of Pediatrics, Severance Hospital, Institute of Allergy, Institute for Innovation in Digital Healthcare, Yonsei University College of Medicine, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">GWAS Identifies CACNA2D3 Associated With Asthma and Atopic Dermatitis Multimorbidity in Children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1776-1781</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/01/27</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39868909</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Dong Yun&#xD;Lee, Soyeon&#xD;Jung, Jae Hwa&#xD;Sub, Yujin&#xD;Lee, Sumin&#xD;Kim, Eun Gyul&#xD;Kim, Mi Na&#xD;Kim, Soo Yeon&#xD;Kim, Yoon Hee&#xD;Sohn, Myung Hyun&#xD;Gee, Heon Yung&#xD;Kim, Kyung Won&#xD;eng&#xD;2022R1A2C1010462/National Research Foundation of Korea/&#xD;2018R1A5A2025079/National Research Foundation of Korea/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1776-1781. doi: 10.1111/all.16483. Epub 2025 Jan 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39868909</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186590</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16483</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1320</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1320</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schaper-Gerhardt, K.</style></author><author><style face="normal" font="default" size="100%">Kother, B.</style></author><author><style face="normal" font="default" size="100%">Wolff, L.</style></author><author><style face="normal" font="default" size="100%">Kabatas, A.</style></author><author><style face="normal" font="default" size="100%">Gehring, M.</style></author><author><style face="normal" font="default" size="100%">Nikolouli, E.</style></author><author><style face="normal" font="default" size="100%">Mommert, S.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Gutzmer, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The H(4) R is highly expressed on eosinophils from AD patients and IL-4 upregulates expression and function via the JAK/STAT pathway</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1261-1264</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/09/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-4/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, G-Protein-Coupled</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Histamine</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Histamine H4</style></keyword><keyword><style face="normal" font="default" size="100%">H4r</style></keyword><keyword><style face="normal" font="default" size="100%">Il-31</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">histamine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32975872</style></accession-num><notes><style face="normal" font="default" size="100%">Schaper-Gerhardt, Katrin&#xD;Kother, Brigitta&#xD;Wolff, Luca&#xD;Kabatas, Aylin&#xD;Gehring, Manuela&#xD;Nikolouli, Eirini&#xD;Mommert, Susanne&#xD;Werfel, Thomas&#xD;Gutzmer, Ralf&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1261-1264. doi: 10.1111/all.14599. Epub 2020 Oct 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32975872</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14599</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2146</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2146</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Versi, A.</style></author><author><style face="normal" font="default" size="100%">Ivan, F. X.</style></author><author><style face="normal" font="default" size="100%">Abdel-Aziz, M. I.</style></author><author><style face="normal" font="default" size="100%">Bates, S.</style></author><author><style face="normal" font="default" size="100%">Riley, J.</style></author><author><style face="normal" font="default" size="100%">Baribaud, F.</style></author><author><style face="normal" font="default" size="100%">Kermani, N. Z.</style></author><author><style face="normal" font="default" size="100%">Montuschi, P.</style></author><author><style face="normal" font="default" size="100%">Dahlen, S. E.</style></author><author><style face="normal" font="default" size="100%">Djukanovic, R.</style></author><author><style face="normal" font="default" size="100%">Sterk, P.</style></author><author><style face="normal" font="default" size="100%">Maitland-Van Der Zee, A. H.</style></author><author><style face="normal" font="default" size="100%">Chotirmall, S. H.</style></author><author><style face="normal" font="default" size="100%">Howarth, P.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">U. Biopred consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart &amp; Lung Institute &amp; Data Science Institute, Imperial College London, London, UK.&#xD;Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore City, Singapore.&#xD;Department of Pulmonary Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Respiratory Therapeutic Unit, GSK, Brentford, UK.&#xD;Janssen Research and Development, High Wycombe, UK.&#xD;Department of Pharmacology, Catholic University of the Sacred Heart, Rome, Italy.&#xD;Centre for Allergy Research, Karolinska Institute, Stockholm, Sweden.&#xD;Faculty of Medicine, Southampton University, Southampton, UK.&#xD;NIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK.&#xD;Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore City, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Haemophilus influenzae and Moraxella catarrhalis in sputum of severe asthma with inflammasome and neutrophil activation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2906-2920</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/06/08</style></edition><section><style face="normal" font="default" size="100%">2906</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Haemophilus influenzae</style></keyword><keyword><style face="normal" font="default" size="100%">Moraxella catarrhalis</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammasomes</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophil Activation</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria</style></keyword><keyword><style face="normal" font="default" size="100%">Haemophilus influenzae</style></keyword><keyword><style face="normal" font="default" size="100%">Tropheryma whipplei</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-diversity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37287344</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Because of altered airway microbiome in asthma, we analysed the bacterial species in sputum of patients with severe asthma. METHODS: Whole genome sequencing was performed on induced sputum from non-smoking (SAn) and current or ex-smoker (SAs/ex) severe asthma patients, mild/moderate asthma (MMA) and healthy controls (HC). Data were analysed by asthma severity, inflammatory status and transcriptome-associated clusters (TACs). RESULTS: alpha-diversity at the species level was lower in SAn and SAs/ex, with an increase in Haemophilus influenzae and Moraxella catarrhalis, and Haemophilus influenzae and Tropheryma whipplei, respectively, compared to HC. In neutrophilic asthma, there was greater abundance of Haemophilus influenzae and Moraxella catarrhalis and in eosinophilic asthma, Tropheryma whipplei was increased. There was a reduction in alpha-diversity in TAC1 and TAC2 that expressed high levels of Haemophilus influenzae and Tropheryma whipplei, and Haemophilus influenzae and Moraxella catarrhalis, respectively, compared to HC. Sputum neutrophils correlated positively with Moraxella catarrhalis and negatively with Prevotella, Neisseria and Veillonella species and Haemophilus parainfluenzae. Sputum eosinophils correlated positively with Tropheryma whipplei which correlated with pack-years of smoking. alpha- and beta-diversities were stable at one year. CONCLUSIONS: Haemophilus influenzae and Moraxella catarrhalis were more abundant in severe neutrophilic asthma and TAC2 linked to inflammasome and neutrophil activation, while Haemophilus influenzae and Tropheryma whipplei were highest in SAs/ex and in TAC1 associated with highest expression of IL-13 type 2 and ILC2 signatures with the abundance of Tropheryma whipplei correlating positively with sputum eosinophils. Whether these bacterial species drive the inflammatory response in asthma needs evaluation.</style></abstract><notes><style face="normal" font="default" size="100%">Versi, Ali&#xD;Ivan, Fransiskus Xaverius&#xD;Abdel-Aziz, Mahmoud I&#xD;Bates, Stewart&#xD;Riley, John&#xD;Baribaud, Frederic&#xD;Kermani, Nazanin Zounemat&#xD;Montuschi, Paolo&#xD;Dahlen, Sven-Erik&#xD;Djukanovic, Ratko&#xD;Sterk, Peter&#xD;Maitland-Van Der Zee, Anke H&#xD;Chotirmall, Sanjay H&#xD;Howarth, Peter&#xD;Adcock, Ian M&#xD;Chung, Kian Fan&#xD;eng&#xD;115010/Innovative Medicines Initiative/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2906-2920. doi: 10.1111/all.15776. Epub 2023 Jun 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37287344</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15776</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2635</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2635</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Zemelka-Wiacek, M.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Immunology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Harnessing mass spectrometric methods for exquisite allergen product characterization</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3189-3191</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/09/26</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39324360</style></accession-num><notes><style face="normal" font="default" size="100%">Jutel, Marek&#xD;Zemelka-Wiacek, Magdalena&#xD;Pfaar, Oliver&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3189-3191. doi: 10.1111/all.16340. Epub 2024 Sep 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39324360</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16340</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>582</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">582</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Maesano, C. N.</style></author><author><style face="normal" font="default" size="100%">Dessimond, B.</style></author><author><style face="normal" font="default" size="100%">Prud&apos;homme, J.</style></author><author><style face="normal" font="default" size="100%">Colette, A.</style></author><author><style face="normal" font="default" size="100%">Banerjee, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute Desbrest of Epidemiology and Public Health (IDESP), Montpellier University and INSERM, Montpellier, France.&#xD;INERIS, National Institute on Industrial Environment and Risks, Verneuil en Halatte, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Has the Spring 2020 lockdown modified the relationship between air pollution and COVID-19 mortality in Europe?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1620-1622</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cities</style></keyword><keyword><style face="normal" font="default" size="100%">Communicable Disease Control</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Particulate Matter/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35212015</style></accession-num><notes><style face="normal" font="default" size="100%">Annesi-Maesano, Isabella&#xD;Maesano, Cara Nichole&#xD;Dessimond, Boris&#xD;Prud&apos;homme, Julie&#xD;Colette, Augustin&#xD;Banerjee, Soutrik&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1620-1622. doi: 10.1111/all.15267. Epub 2022 Mar 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35212015</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9111378 work.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15267</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1220</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1220</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tsunoda, Y.</style></author><author><style face="normal" font="default" size="100%">Sherpa, M. T.</style></author><author><style face="normal" font="default" size="100%">Kiwamoto, T.</style></author><author><style face="normal" font="default" size="100%">Matsuyama, M.</style></author><author><style face="normal" font="default" size="100%">Osawa, H.</style></author><author><style face="normal" font="default" size="100%">Sakurai, H.</style></author><author><style face="normal" font="default" size="100%">Hayashi, S.</style></author><author><style face="normal" font="default" size="100%">Matsuno, Y.</style></author><author><style face="normal" font="default" size="100%">Morishima, Y.</style></author><author><style face="normal" font="default" size="100%">Ishii, Y.</style></author><author><style face="normal" font="default" size="100%">Hizawa, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Has2 deficiency enhances OVA-induced airway inflammation and hyperresponsiveness in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2214-2218</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/12/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Bronchial Hyperreactivity/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Ovalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">Cd44</style></keyword><keyword><style face="normal" font="default" size="100%">Has2</style></keyword><keyword><style face="normal" font="default" size="100%">TGF-beta</style></keyword><keyword><style face="normal" font="default" size="100%">airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic airway inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33340420</style></accession-num><notes><style face="normal" font="default" size="100%">Tsunoda, Yoshiya&#xD;Sherpa, Mingma Thsering&#xD;Kiwamoto, Takumi&#xD;Matsuyama, Masashi&#xD;Osawa, Hajime&#xD;Sakurai, Hirofumi&#xD;Hayashi, Shigen&#xD;Matsuno, Yosuke&#xD;Morishima, Yuko&#xD;Ishii, Yukio&#xD;Hizawa, Nobuyuki&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2214-2218. doi: 10.1111/all.14715. Epub 2021 Jan 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33340420</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14715</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2852</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2852</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lipworth, B. J.</style></author><author><style face="normal" font="default" size="100%">Greig, R.</style></author><author><style face="normal" font="default" size="100%">Chan, R.</style></author><author><style face="normal" font="default" size="100%">Kuo, C. R.</style></author><author><style face="normal" font="default" size="100%">Jackson, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, Department of Respiratory Medicine, University of Dundee, Dundee, Scotland, UK.&#xD;Department of Respiratory Medicine, Aberdeen Royal Infirmary, Aberdeen, Scotland, UK.&#xD;Department of Medicine and Health Sciences, University of Lancashire, Preston, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Head-To-Head Comparison of Biologic Efficacy in Asthma: What Have We Learned?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1226-1241</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/03/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">benralizumab</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">tezepelumab</style></keyword><keyword><style face="normal" font="default" size="100%">board), other support (attending meetings) from AstraZeneca</style></keyword><keyword><style face="normal" font="default" size="100%">grants, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees (talks) and other support (attending meetings) from Sanofi and Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees (talks and consulting) from Niox</style></keyword><keyword><style face="normal" font="default" size="100%">grants, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">(consulting, talks, advisory board), other support (attending meetings) from</style></keyword><keyword><style face="normal" font="default" size="100%">Teva</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees (talks and consulting), grants and other support (attending</style></keyword><keyword><style face="normal" font="default" size="100%">meetings) from Chiesi</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees (consulting and talks) from Lupin, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees (consulting and talks) from Glenmark</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees (consulting) from Sandoz</style></keyword><keyword><style face="normal" font="default" size="100%">and Cipla</style></keyword><keyword><style face="normal" font="default" size="100%">grants, personal fees (consulting, talks, advisory board), other</style></keyword><keyword><style face="normal" font="default" size="100%">support (attending meetings) from Boehringer Ingelheim</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">(consulting) from Bambusa and Upstream Bio), the son of BJL is presently an</style></keyword><keyword><style face="normal" font="default" size="100%">employee of AstraZeneca. Dr. Greig reports personal fees (talks) from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca. Dr. Chan reports institutional grants from Chiesi and AstraZeneca</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees (talks and advisory boards) from AstraZeneca, Chiesi, Thorasys and</style></keyword><keyword><style face="normal" font="default" size="100%">Vitalograph</style></keyword><keyword><style face="normal" font="default" size="100%">support for attending meetings from AstraZeneca, Chiesi, NIOX and</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron. Dr. Kuo reports personal fees from AstraZeneca, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi and non-financial support from GSK outside the submitted work. Prof</style></keyword><keyword><style face="normal" font="default" size="100%">Jackson has shares as part of a managed portfolio in Verona Pharma, Canvatech</style></keyword><keyword><style face="normal" font="default" size="100%">PLC, Haleon PLC, GSK, Smith and Nephew, AstraZeneca, Hikma Pharmaceuticals, has a</style></keyword><keyword><style face="normal" font="default" size="100%">son currently working for AstraZeneca and is in receipt of an institutional grant</style></keyword><keyword><style face="normal" font="default" size="100%">from Chiesi.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40156481</style></accession-num><abstract><style face="normal" font="default" size="100%">We performed an in-depth appraisal of indirect head-to-head comparisons of biologics approved for asthma, including anti-IL5/5Ralpha (mepolizumab, benralizumab), anti-IL4Ralpha (dupilumab), anti-TSLP (tezepelumab) and anti-IgE (omalizumab), which was neither a systematic review nor a meta-analysis. A crude evaluation of 95% CI&apos;s for rate ratios which excluded unity revealed greater overall reductions in annualised exacerbations with dupilumab versus either mepolizumab or benralizumab and also with tezepelumab versus benralizumab. Furthermore in patients with eosinophils &gt;/= 300/muL exacerbation rates were lower for tezepelumab, dupilumab and mepolizumab versus benralizumab; and with eosinophils&lt; 150/muL for tezepelumab versus dupilumab. For lung function, no overall differences in FEV1 response were observed between drugs where there was considerable heterogeneity of overlapping 95% CI&apos;s. Dupilumab was superior to benralizumab for oscillometry-derived peripheral lung resistance and compliance, as well as for attenuation of mannitol airway hyperresponsiveness. There were no differences in asthma control or quality of life scores where the effect sizes were small, along with wide overlaps in 95% CI&apos;s. There is an unmet need for prospective pragmatic randomised controlled trials to directly compare biologics, especially to assess clinical remission in both type 2 high and low asthma patients. Real-life studies might also evaluate complete remission with different biologics to include outcomes such as inhaled corticosteroid sparing, small airways dysfunction using oscillometry, abolition of airway hyperresponsiveness and to assess mucus plugging and remodelling as wall thickening with imaging.</style></abstract><notes><style face="normal" font="default" size="100%">Lipworth, Brian J&#xD;Greig, Robert&#xD;Chan, Rory&#xD;Kuo, Chris RuiWen&#xD;Jackson, Catherine&#xD;eng&#xD;Comparative Study&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1226-1241. doi: 10.1111/all.16537. Epub 2025 Mar 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40156481</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105071</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16537</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>890</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">890</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Couto, M.</style></author><author><style face="normal" font="default" size="100%">Bernard, A.</style></author><author><style face="normal" font="default" size="100%">Delgado, L.</style></author><author><style face="normal" font="default" size="100%">Drobnic, F.</style></author><author><style face="normal" font="default" size="100%">Kurowski, M.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Rodrigues-Alves, R.</style></author><author><style face="normal" font="default" size="100%">Rukhadze, M.</style></author><author><style face="normal" font="default" size="100%">Seys, S.</style></author><author><style face="normal" font="default" size="100%">Wiszniewska, M.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centro de Alergia, Hospital CUF Descobertas, Lisboa, Portugal.&#xD;Louvain Centre for Toxicology and Applied Pharmacology, Institute of Experimental and Clinical Research (IREC), Catholic University of Louvain, Brussels, Belgium.&#xD;Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Servico de Imunoalergologia, Centro Hospitalar de Sao Joao E.P.E., Porto, Portugal.&#xD;Center for Health Technology and Services Research (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Head of Medical Services - Shenhua Greenland FC, Shanghai, China.&#xD;Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland.&#xD;Epidemiology Research Unit- Instituto de Saude Publica, Universidade do Porto, Porto, Portugal.&#xD;Unidade de Imunoalergologia, Hospital do Divino Espirito Santo, Ponta Delgada, Portugal.&#xD;Center of Allergy &amp; Immunology, Teaching University Geomedi LLC, Tbilisi, Georgia.&#xD;Laboratory of Clinical Immunology, Department of Clinical Immunology, KU Leuven, Leuven, Belgium.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, and Universidad Autonoma de Madrid, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Health effects of exposure to chlorination by-products in swimming pools</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3257-3275</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/07/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Chlorine/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Disinfectants/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">Halogenation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Swimming Pools</style></keyword><keyword><style face="normal" font="default" size="100%">chlorination by-products</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection by-products</style></keyword><keyword><style face="normal" font="default" size="100%">occupational exposure</style></keyword><keyword><style face="normal" font="default" size="100%">recreational exposure</style></keyword><keyword><style face="normal" font="default" size="100%">sports</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34289125</style></accession-num><abstract><style face="normal" font="default" size="100%">Concerns have been raised regarding the potential negative effects on human health of water disinfectants used in swimming pools. Among the disinfection options, the approaches using chlorine-based products have been typically preferred. Chlorine readily reacts with natural organic matter that are introduced in the water mainly through the bathers, leading to the formation of potentially harmful chlorination by-products (CBPs). The formation of CBPs is of particular concern since some have been epidemiologically associated with the development of various clinical manifestations. The higher the concentration of volatile CBPs in the water, the higher their concentration in the air above the pool, and different routes of exposure to chemicals in swimming pools (water ingestion, skin absorption, and inhalation) contribute to the individual exposome. Some CBPs may affect the respiratory and skin health of those who stay indoor for long periods, such as swimming instructors, pool staff, and competitive swimmers. Whether those who use chlorinated pools as customers, particularly children, may also be affected has been a matter of debate. In this article, we discuss the current evidence regarding the health effects of both acute and chronic exposures in different populations (work-related exposures, intensive sports, and recreational attendance) and identify the main recommendations and unmet needs for research in this area.</style></abstract><notes><style face="normal" font="default" size="100%">Couto, Mariana&#xD;Bernard, Alfred&#xD;Delgado, Luis&#xD;Drobnic, Franchek&#xD;Kurowski, Marcin&#xD;Moreira, Andre&#xD;Rodrigues-Alves, Rodrigo&#xD;Rukhadze, Maia&#xD;Seys, Sven&#xD;Wiszniewska, Marta&#xD;Quirce, Santiago&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3257-3275. doi: 10.1111/all.15014. Epub 2021 Jul 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34289125</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15014</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3099</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3099</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Watanabe, S.</style></author><author><style face="normal" font="default" size="100%">Sato, A.</style></author><author><style face="normal" font="default" size="100%">Seki, H.</style></author><author><style face="normal" font="default" size="100%">Kawauchi, Y.</style></author><author><style face="normal" font="default" size="100%">Yauchi, T.</style></author><author><style face="normal" font="default" size="100%">Yamamoto-Hanada, K.</style></author><author><style face="normal" font="default" size="100%">Fukuie, T.</style></author><author><style face="normal" font="default" size="100%">Ohya, Y.</style></author><author><style face="normal" font="default" size="100%">Nomura, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gastroenterology, Soka Municipal Hospital, Saitama, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.&#xD;Department of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.&#xD;Department of Environmental and Occupational Health, Nagoya City University Graduate School of Medicine, Aichi, Japan.&#xD;Division of General Allergy, Bantane Hospital, Fujita Health University, Aichi, Japan.&#xD;Division of Eosinophilic Gastrointestinal Disorders, National Research Institute for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Health-Related Quality of Life in Adults With Food Protein-Induced Enterocolitis Syndrome: Generic Versus Allergy-Specific Tools</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2938-2941</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/09/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Faim</style></keyword><keyword><style face="normal" font="default" size="100%">Faqlq-af</style></keyword><keyword><style face="normal" font="default" size="100%">Fpies</style></keyword><keyword><style face="normal" font="default" size="100%">Hrqol</style></keyword><keyword><style face="normal" font="default" size="100%">Sf-36</style></keyword><keyword><style face="normal" font="default" size="100%">food protein-induced enterocolitis syndrome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40904169</style></accession-num><notes><style face="normal" font="default" size="100%">Watanabe, Sho&#xD;Sato, Ayako&#xD;Seki, Hiroto&#xD;Kawauchi, Yukari&#xD;Yauchi, Tsunehito&#xD;Yamamoto-Hanada, Kiwako&#xD;Fukuie, Tatsuki&#xD;Ohya, Yukihiro&#xD;Nomura, Ichiro&#xD;eng&#xD;JSA WAO 2020 Memorial Research Grant Program/&#xD;scientific research grants from the Japanese Ministry of Education, Culture, Science and Technology (KAKENHI grant number 25K19282)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2938-2941. doi: 10.1111/all.70041. Epub 2025 Sep 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40904169</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70041</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1380</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1380</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kauppila, T. K.</style></author><author><style face="normal" font="default" size="100%">Pelkonen, A. S.</style></author><author><style face="normal" font="default" size="100%">Roine, R. P.</style></author><author><style face="normal" font="default" size="100%">Paassilta, M.</style></author><author><style face="normal" font="default" size="100%">Kukkonen, K.</style></author><author><style face="normal" font="default" size="100%">Sintonen, H.</style></author><author><style face="normal" font="default" size="100%">Makela, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Helsinki, Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.&#xD;Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.&#xD;Department of Health and Social Management, University of Eastern Finland, Kuopio, Finland.&#xD;Allergy Center, Tampere University Hospital, Tampere, Finland.&#xD;Department of Public Health, University of Helsinki, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Health-related quality of life in patients who had partaken in milk oral immunotherapy and comparison to the general population</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">387-390</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Milk</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32738148</style></accession-num><notes><style face="normal" font="default" size="100%">Kauppila, Tiina Kaisa&#xD;Pelkonen, Anna S&#xD;Roine, Risto P&#xD;Paassilta, Marita&#xD;Kukkonen, Kaarina&#xD;Sintonen, Harri&#xD;Makela, Mika&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):387-390. doi: 10.1111/all.14525. Epub 2020 Aug 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32738148</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14525</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3201</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3201</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vassilopoulou, E.</style></author><author><style face="normal" font="default" size="100%">Tsabouri, S.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Comotti, A.</style></author><author><style face="normal" font="default" size="100%">Milani, G. P.</style></author><author><style face="normal" font="default" size="100%">Ryczaj, K.</style></author><author><style face="normal" font="default" size="100%">Agostoni, C.</style></author><author><style face="normal" font="default" size="100%">Pagkalos, I.</style></author><author><style face="normal" font="default" size="100%">Vlieg-Boerstra, B.</style></author><author><style face="normal" font="default" size="100%">Caballero-Lopez, C. G.</style></author><author><style face="normal" font="default" size="100%">Feketea, G.</style></author><author><style face="normal" font="default" size="100%">Nowak-Wegrzyn, A.</style></author><author><style face="normal" font="default" size="100%">Halken, S.</style></author><author><style face="normal" font="default" size="100%">Beken, B.</style></author><author><style face="normal" font="default" size="100%">Alvaro-Lozano, M.</style></author><author><style face="normal" font="default" size="100%">Padua, I.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Perea, A.</style></author><author><style face="normal" font="default" size="100%">Canani, R. B.</style></author><author><style face="normal" font="default" size="100%">Peroni, D.</style></author><author><style face="normal" font="default" size="100%">Perez-Gordo, M.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Berghea, E. C.</style></author><author><style face="normal" font="default" size="100%">Roth-Walter, F.</style></author><author><style face="normal" font="default" size="100%">Ozdemir, C.</style></author><author><style face="normal" font="default" size="100%">Smith, P.</style></author><author><style face="normal" font="default" size="100%">Mahony, L. O.</style></author><author><style face="normal" font="default" size="100%">Meyer, R. W.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nutritional Sciences and Dietetics, School of Health Sciences, International Hellenic University, Thessaloniki, Greece.&#xD;Pediatric Area, Fondazione IRCCS Ca&apos; Granda-Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Department of Clinical Sciences and Community Health, Universita degli Studi di Milano, Milan, Italy.&#xD;Department of Life Sciences, School of Life and Health Sciences, Universiy of Nicosia, Nicosia, Cyprus.&#xD;Department of Paediatrics, Child Health Department, School of Medicine, University of Ioannina, Ioannina, Greece.&#xD;Pediatric Allergology Unit, Bambino Gesu Children&apos;s Hospital (IRCCS), Rome, Italy.&#xD;Occupational Medicine Unit, Fondazione IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Pediatric Teaching Hospital of the Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Paediatrics, OLVG Hospital, Amsterdam, the Netherlands.&#xD;Rijnstate Allergy Center, Rijnstate Hospital, Arnhem, the Netherlands.&#xD;Allergology and Clinical Immunology Department, Hospital Universitario de Puebla-Faculty of Medicine, Benemerita, Universidad Autonoma de Puebla, Puebla, Mexico.&#xD;Pediatric Allergy Outpatient Clinic, Department of Pediatrics, &quot;Karamandaneio&quot; Children&apos;s Hospital of Patra, Patras, Greece.&#xD;Atena Medical Center, Bucharest, Romania.&#xD;Department of Pediatrics, Division of Allergy and Immunology, NYU Grossman School of Medicine, New York, New York, USA.&#xD;Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.&#xD;Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Odense, Denmark.&#xD;Department of Pediatric Allergy and Immunology, Acibadem University, Istanbul, Turkiye.&#xD;Allergology and Clinical Immunology Department, Hospital Sant Joan de Deu, Barcelona, Spain.&#xD;Institut de Recerca Sant Joan de Deu, Universitat de Barcelona, Barcelona, Spain.&#xD;Department of Sciences, University Institute of Health Sciences, Gandra, Portugal.&#xD;i4HB/UCIBIO Translational Toxicology Research Laboratory, Gandra, Portugal.&#xD;CUF Porto Trindade Hospital, Porto, Portugal.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Guy&apos;s and St. Thomas&apos; 25 National Health Service Foundation Trust and Kings College, London, UK.&#xD;Allergy Service, Hospital General Universitario Gregorio Maranon, Madrid, Spain.&#xD;Gregorio Maranon Health Research Institute, Madrid, Spain.&#xD;Department of Translational Medical Science, ImmunoNutritionLab at CEINGE Biotechnologies, Naples, Italy.&#xD;Research Center and Task Force for Microbiome Studies, University of Naples Federico II, Naples, Italy.&#xD;Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Departamento de Ciencias Medicas Basicas, Facultad de Medicina, Instituto de Medicina Molecular Aplicada (IMMA) Nemesio Diez, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Franklin-Kay Alleergy Center, Imperial College London, London, UK.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Transylvania University, Brasov, Romania.&#xD;Marie S. Curie Emergency Children&apos;s Clinical Hospital, Bucharest, Romania.&#xD;Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.&#xD;Department of Biological Sciences and Pathobiology, University of Veterinary Medicine Vienna, Wien, Austria.&#xD;Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkiye.&#xD;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkiye.&#xD;Clinical School of Medicine, Griffith University, Southport, Queensland, Australia.&#xD;Department of Medicine, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;School of Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Department of Medicine, KU Leuven, Leuven, Belgium.&#xD;Section of Pediatric Allergy and Immunology, Children&apos;s Hospital Colorado, University of Colorado, Boulder, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Healthcare Professional Survey on Complementary Feeding and Allergy Prevention in High- Versus Low-Risk Infants: An EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy prevention</style></keyword><keyword><style face="normal" font="default" size="100%">complementary feeding</style></keyword><keyword><style face="normal" font="default" size="100%">dietary guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">early life nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">regional feeding practices</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41388872</style></accession-num><abstract><style face="normal" font="default" size="100%">Complementary feeding (CF) influences infants&apos; long-term dietary preferences, growth, and food allergy (FA) risk. However, guidance given to families and the implementation of FA prevention guidelines by healthcare professionals (HCPs) remain unclear. This study explored HCPs&apos; perspectives and practices regarding CF strategies in the context of FA prevention across different regions and professional backgrounds. An online survey conducted by an EAACI task force between December 2023 and May 2024 assessed CF timing, allergenic food introduction, nutrient supplementation, and FA preventive measures. 550 HCPs (pediatricians, allergists, dietitians), 68% from Europe, participated. HCPs recommended CF initiation at a median of six months for breastfed infants and five months for formula-fed and FA high-risk infants. Atopic dermatitis (94%) and family history of allergies (87%) were the most recognized FA risk factors. Vitamin D (49%), probiotics (28%), and omega-3 fatty acids (18%) were commonly recommended supplements. Regional, professional, and educational influences differences emerged, with Northern European HCPs favoring earlier CF and allergen introduction, often without structured guidance. Southern European HCPs preferred a structured sequence and later CF initiation. A flexible, evidence-based framework is needed to guide FA prevention while accommodating cultural and geographical differences.</style></abstract><notes><style face="normal" font="default" size="100%">Vassilopoulou, Emilia&#xD;Tsabouri, Sophia&#xD;Arasi, Stefania&#xD;Comotti, Anna&#xD;Milani, Gregorio Paolo&#xD;Ryczaj, Klaudia&#xD;Agostoni, Carlo&#xD;Pagkalos, Ioannis&#xD;Vlieg-Boerstra, Berber&#xD;Caballero-Lopez, Chrystopherson Gengyny&#xD;Feketea, Gavriela&#xD;Nowak-Wegrzyn, Anna&#xD;Halken, Susanne&#xD;Beken, Burcin&#xD;Alvaro-Lozano, Montserrat&#xD;Padua, Ines&#xD;Giovannini, Mattia&#xD;Du Toit, George&#xD;Alvarez-Perea, Alberto&#xD;Canani, Roberto Berni&#xD;Peroni, Diego&#xD;Perez-Gordo, Marina&#xD;Shamji, Mohamed H&#xD;Klimek, Ludger&#xD;Agache, Ioana&#xD;Berghea, Elena Camelia&#xD;Roth-Walter, Franziska&#xD;Ozdemir, Cevdet&#xD;Smith, Peter&#xD;Mahony, Liam O&apos;&#xD;Meyer, Rosan W&#xD;Venter, Carina&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Denmark&#xD;Allergy. 2025 Dec 13. doi: 10.1111/all.70188.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41388872</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70188</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2837</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2837</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bourdin, A.</style></author><author><style face="normal" font="default" size="100%">Nogue, E.</style></author><author><style face="normal" font="default" size="100%">Suehs, C. M.</style></author><author><style face="normal" font="default" size="100%">Malafaye, N.</style></author><author><style face="normal" font="default" size="100%">Pissarra, J.</style></author><author><style face="normal" font="default" size="100%">Vachier, I.</style></author><author><style face="normal" font="default" size="100%">Ahmed, E.</style></author><author><style face="normal" font="default" size="100%">Molinari, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Diseases; Univ Montpellier, CHU Montpellier, Montpellier, France.&#xD;PhyMedExp, Univ Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France.&#xD;Clinical Research and Epidemiology Unit, CHU Montpellier, Univ Montpellier, Montpellier, France.&#xD;Laboratory of Immunoregulation and Mucosal Immunology, VIB-UGent Center for Inflammation Research, Ghent, Belgium.&#xD;IDESP, INSERM, Univ Montpellier, CHU Montpellier, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Healthcare Resource Utilisation and Costs of Mepolizumab Initiation: A 5-Year National Cohort Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1169-1172</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/02/12</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39936563</style></accession-num><notes><style face="normal" font="default" size="100%">Bourdin, Arnaud&#xD;Nogue, Erika&#xD;Suehs, Carey M&#xD;Malafaye, Nicolas&#xD;Pissarra, Joana&#xD;Vachier, Isabelle&#xD;Ahmed, Engi&#xD;Molinari, Nicolas&#xD;eng&#xD;GlaxoSmithKline/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1169-1172. doi: 10.1111/all.16501. Epub 2025 Feb 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39936563</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969291 lectures, presentations, meetings, and travel from Boeringher Ingelheim, Novartis, Astra Zeneca, Sanofi, Regeneron, GSK, Chiesi, AB science, Celltrion, Cipla, and Areteia. C.M.S. declares receiving institutional grants or contracts from Astra Zeneca and GSK, and personal fees for lectures, presentations or manuscript writing from Astra Zeneca. Remaining authors declare no conflicts of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16501</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3150</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3150</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Maesano, I. A.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Han, J.</style></author><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, C.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunoallergology, University of Porto, Porto, Portugal.&#xD;French NIH (INSERM), Paris, France.&#xD;Nofer Institute of Medicine, Lodz, Poland.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Swiss Institute of Allergy and Asthma Research, Davos, Switzerland.&#xD;Inflammatory Immune Diseases Group, University San Pablo CEU, Madrid, Spain.&#xD;Allergy Department of Malaga Regional University Hospital, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Healthy Planet, Healthier People: EAACI&apos;s Integrated Planetary Health Strategy for Asthma, Allergies and Immune Diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7-10</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/11/21</style></edition><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41268612</style></accession-num><notes><style face="normal" font="default" size="100%">Moreira, Andre&#xD;Maesano, Isabella Annesi&#xD;Walusiak-Skorupa, Jolanta&#xD;Han, Jooeun&#xD;Layhadi, Janice A&#xD;Akdis, Cezmi&#xD;Escribese, Maria M&#xD;Shamji, Mohamed H&#xD;Torres, Maria J&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):7-10. doi: 10.1111/all.70164. Epub 2025 Nov 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41268612</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70164</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3215</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3215</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karaguzel, D.</style></author><author><style face="normal" font="default" size="100%">Walewska, A.</style></author><author><style face="normal" font="default" size="100%">Sarac, B. E.</style></author><author><style face="normal" font="default" size="100%">Tynecka, M.</style></author><author><style face="normal" font="default" size="100%">Bondarczuk, K.</style></author><author><style face="normal" font="default" size="100%">Tarasik, A.</style></author><author><style face="normal" font="default" size="100%">Kisiel, D.</style></author><author><style face="normal" font="default" size="100%">Partyk, K.</style></author><author><style face="normal" font="default" size="100%">Pogodzinski, D.</style></author><author><style face="normal" font="default" size="100%">Hanczaruk, B.</style></author><author><style face="normal" font="default" size="100%">Toczydlowska, A.</style></author><author><style face="normal" font="default" size="100%">Bicakci, C.</style></author><author><style face="normal" font="default" size="100%">Oztabak, D.</style></author><author><style face="normal" font="default" size="100%">Niemira, M.</style></author><author><style face="normal" font="default" size="100%">Kretowski, A.</style></author><author><style face="normal" font="default" size="100%">Dubatowka, M.</style></author><author><style face="normal" font="default" size="100%">Ogrodnik, N.</style></author><author><style face="normal" font="default" size="100%">Chlabicz, M.</style></author><author><style face="normal" font="default" size="100%">Sowa, P.</style></author><author><style face="normal" font="default" size="100%">Kaminski, K.</style></author><author><style face="normal" font="default" size="100%">Moniuszko, M.</style></author><author><style face="normal" font="default" size="100%">Eljaszewicz, A.</style></author><author><style face="normal" font="default" size="100%">Karaaslan, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre of Regenerative Medicine, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Biology, Molecular Biology Section, Faculty of Science, Hacettepe University, Ankara, Turkiye.&#xD;Centre for Bioinformatics and Data Analyis, Medical University of Bialystok, Bialystok, Poland.&#xD;Biobank, Medical University of Bialystok, Bialystok, Poland.&#xD;Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.&#xD;Population Research Centre, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.&#xD;Tissue and Cell Bank, Medical University of Bialystok Clinical Hospital, Bialystok, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Heat-Not-Burn Tobacco Aerosols Induce Immune Dysregulation and Barrier Disruption Comparable to Conventional Cigarettes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">conventional cigarette smoke</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">heat-not-burn tobacco products</style></keyword><keyword><style face="normal" font="default" size="100%">lung inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">tobacco product-mediated inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41324155</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Heat-not-burn (HnB) tobacco products are marketed as a safer alternative to conventional cigarettes (CC), yet their health effects remain controversial, largely based on industry-funded studies. We aimed to assess lung function in HnB and CC users and examine the mechanistic effects of HnB exposure using animal and in vitro models. METHODS: Spirometry data from 650 non-smokers (NS), 293 CC smokers, and 49 HnB users enrolled in the Bialystok-PLUS cohort were analyzed. To investigate underlying mechanisms, a whole-body mouse exposure model was performed with HnB aerosol or 3R4F cigarette smoke, assessing lung transcriptomic profiles (by means of RNA sequencing), lung inflammation (by flow cytometry and histochemical staining), and barrier integrity (by using immunofluorescent staining). Moreover, an in vitro ALI-culture model of human airway epithelial cells was used to validate the mouse experiments. The effect of HnB and CC was assessed through cytotoxic effect (MTT and LDH), inflammatory responses (cytokine release by ELISA), and tight junction proteins (immunofluorescence staining). RESULT: Spirometric analysis (FEV1, FVC, VC) revealed no significant overall differences in lung function among HnB users, CC smokers, and non-smokers (NS) in the unadjusted comparison. However, subgroup analyses showed that younger (&lt; 45 years) HnB users and those with shorter smoking histories (&lt; 20 years) already exhibited significantly lower FEV1, FVC, and VC compared to NS and CC smokers. After adjustment for age and smoking-related covariates, HnB users displayed modest but significant reductions in static FEV1 and FVC relative to NS, while no adjusted differences were detected between HnB and CC groups, indicating comparable baseline ventilatory function. Both exposures in mice increased eosinophils and B cell counts by ~2-fold, while decreasing ST2(+) CD4(+) T cells over 80%, and induced epithelial apoptosis. HnB aerosol selectively reduced basophils by almost 50%. Both HnB and CC exposure in mice caused significant epithelial damage and impaired airway barrier function, evidenced by a ~60% reduction in ZO-1. Transcriptomic analysis revealed that CC smoke triggered a robust inflammatory gene response, whereas HnB aerosol predominantly altered metabolic pathways. In vitro, barrier function was impaired under both conditions, but cytokine secretion increased only after CC smoke exposure. CONCLUSION: Despite different molecular impacts, HnB aerosol exposure induces a level of airway epithelial injury and immune cell infiltration comparable to CC smoke. Our findings challenged the narrative of HnB products being a harmless alternative and highlight their potential to cause significant lung pathology.</style></abstract><notes><style face="normal" font="default" size="100%">Karaguzel, Dilara&#xD;Walewska, Alicja&#xD;Sarac, Basak Ezgi&#xD;Tynecka, Marlena&#xD;Bondarczuk, Kinga&#xD;Tarasik, Agnieszka&#xD;Kisiel, Dariusz&#xD;Partyk, Karolina&#xD;Pogodzinski, Damian&#xD;Hanczaruk, Bartosz&#xD;Toczydlowska, Alicja&#xD;Bicakci, Cagla&#xD;Oztabak, Doga&#xD;Niemira, Magdalena&#xD;Kretowski, Adam&#xD;Dubatowka, Marlena&#xD;Ogrodnik, Natalia&#xD;Chlabicz, Malgorzata&#xD;Sowa, Pawel&#xD;Kaminski, Karol&#xD;Moniuszko, Marcin&#xD;Eljaszewicz, Andrzej&#xD;Karaaslan, Cagatay&#xD;eng&#xD;Narodowa Agencja Wymiany Akademickiej/&#xD;Fundacja na rzecz Nauki Polskiej/&#xD;Narodowe Centrum Badan i Rozwoju/&#xD;Medical University of Bialystok&apos;s/&#xD;Turkiye Bilimsel ve Teknolojik Arastirma Kurumu/&#xD;FUK-2021-19791/Hacettepe Universitesi/&#xD;Denmark&#xD;Allergy. 2025 Dec 1. doi: 10.1111/all.70174.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41324155</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70174</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3125</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3125</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Han, J.</style></author><author><style face="normal" font="default" size="100%">Cha, H. W.</style></author><author><style face="normal" font="default" size="100%">Eom, Y.</style></author><author><style face="normal" font="default" size="100%">Kim, S. J.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, College of Veterinary Medicine, Chonnam National University, Gwangju, South Korea.&#xD;BK 21 Project Team, College of Veterinary Medicine, Chonnam National University, Gwangju, South Korea.&#xD;YS Institute of Environmental Technology Co., Ltd., Seoul, South Korea.&#xD;Department of Dermatology, Chonnam National University Hospital, Gwangju, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Heavy Metals as Key Environmental Aggravators in Atopic Dermatitis in Companion Dogs: A One Health Perspective</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">environment and hygiene hypothesis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 20</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41116593</style></accession-num><notes><style face="normal" font="default" size="100%">Han, Jungwoo&#xD;Cha, Hee-Woo&#xD;Eom, Yujin&#xD;Kim, Seong Jin&#xD;Kim, Ha-Jung&#xD;eng&#xD;National Research Foundation of Korea/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct 20. doi: 10.1111/all.70117.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41116593</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70117</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2521</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2521</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Burgess, M. O.</style></author><author><style face="normal" font="default" size="100%">Janas, P.</style></author><author><style face="normal" font="default" size="100%">Berry, K.</style></author><author><style face="normal" font="default" size="100%">Mayr, H.</style></author><author><style face="normal" font="default" size="100%">Mack, M.</style></author><author><style face="normal" font="default" size="100%">Jenkins, S. J.</style></author><author><style face="normal" font="default" size="100%">Bain, C. C.</style></author><author><style face="normal" font="default" size="100%">McSorley, H. J.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.&#xD;Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria.&#xD;Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.&#xD;Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK.&#xD;Child Life and Health, Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Helminth induced monocytosis conveys protection from respiratory syncytial virus infection in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2157-2172</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Syncytial Virus Infections/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Monocytes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Viral Load</style></keyword><keyword><style face="normal" font="default" size="100%">Nematospiroides dubius/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/immunology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Strongylida Infections/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Syncytial Viruses/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon Type I/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rsv</style></keyword><keyword><style face="normal" font="default" size="100%">helminth</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">mononuclear phagocyte</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38924546</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Respiratory syncytial virus (RSV) infection in infants is a major cause of viral bronchiolitis and hospitalisation. We have previously shown in a murine model that ongoing infection with the gut helminth Heligmosomoides polygyrus protects against RSV infection through type I interferon (IFN-I) dependent reduction of viral load. Yet, the cellular basis for this protection has remained elusive. Given that recruitment of mononuclear phagocytes to the lung is critical for early RSV infection control, we assessed their role in this coinfection model. METHODS: Mice were infected by oral gavage with H. polygyrus. Myeloid immune cell populations were assessed by flow cytometry in lung, blood and bone marrow throughout infection and after secondary infection with RSV. Monocyte numbers were depleted by anti-CCR2 antibody or increased by intravenous transfer of enriched monocytes. RESULTS: H. polygyrus infection induces bone marrow monopoiesis, increasing circulatory monocytes and lung mononuclear phagocytes in a IFN-I signalling dependent manner. This expansion causes enhanced lung mononuclear phagocyte counts early in RSV infection that may contribute to the reduction of RSV load. Depletion or supplementation of circulatory monocytes prior to RSV infection confirms that these are both necessary and sufficient for helminth induced antiviral protection. CONCLUSIONS: H. polygyrus infection induces systemic monocytosis contributing to elevated mononuclear phagocyte numbers in the lung. These cells are central to an anti-viral effect that reduces the peak viral load in RSV infection. Treatments to promote or modulate these cells may provide novel paths to control RSV infection in high risk individuals.</style></abstract><notes><style face="normal" font="default" size="100%">Burgess, Matthew O&#xD;Janas, Piotr&#xD;Berry, Karla&#xD;Mayr, Hannah&#xD;Mack, Matthias&#xD;Jenkins, Stephen J&#xD;Bain, Calum C&#xD;McSorley, Henry J&#xD;Schwarze, Jurgen&#xD;eng&#xD;MR/T029668/1/MRC_/Medical Research Council/United Kingdom&#xD;WT_/Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2157-2172. doi: 10.1111/all.16206. Epub 2024 Jun 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38924546</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16206</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2595</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2595</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Burgess, M. O.</style></author><author><style face="normal" font="default" size="100%">Janas, P.</style></author><author><style face="normal" font="default" size="100%">Berry, K.</style></author><author><style face="normal" font="default" size="100%">Mayr, H.</style></author><author><style face="normal" font="default" size="100%">Mack, M.</style></author><author><style face="normal" font="default" size="100%">Jenkins, S. J.</style></author><author><style face="normal" font="default" size="100%">Bain, C. C.</style></author><author><style face="normal" font="default" size="100%">McSorley, H. J.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.&#xD;Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria.&#xD;Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.&#xD;Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK.&#xD;Child Life and Health, Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Helminth induced monocytosis conveys protection from respiratory syncytial virus infection in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2157-2172</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Syncytial Virus Infections/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Monocytes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Viral Load</style></keyword><keyword><style face="normal" font="default" size="100%">Nematospiroides dubius/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/immunology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Strongylida Infections/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Syncytial Viruses/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon Type I/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rsv</style></keyword><keyword><style face="normal" font="default" size="100%">helminth</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">mononuclear phagocyte</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38924546</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Respiratory syncytial virus (RSV) infection in infants is a major cause of viral bronchiolitis and hospitalisation. We have previously shown in a murine model that ongoing infection with the gut helminth Heligmosomoides polygyrus protects against RSV infection through type I interferon (IFN-I) dependent reduction of viral load. Yet, the cellular basis for this protection has remained elusive. Given that recruitment of mononuclear phagocytes to the lung is critical for early RSV infection control, we assessed their role in this coinfection model. METHODS: Mice were infected by oral gavage with H. polygyrus. Myeloid immune cell populations were assessed by flow cytometry in lung, blood and bone marrow throughout infection and after secondary infection with RSV. Monocyte numbers were depleted by anti-CCR2 antibody or increased by intravenous transfer of enriched monocytes. RESULTS: H. polygyrus infection induces bone marrow monopoiesis, increasing circulatory monocytes and lung mononuclear phagocytes in a IFN-I signalling dependent manner. This expansion causes enhanced lung mononuclear phagocyte counts early in RSV infection that may contribute to the reduction of RSV load. Depletion or supplementation of circulatory monocytes prior to RSV infection confirms that these are both necessary and sufficient for helminth induced antiviral protection. CONCLUSIONS: H. polygyrus infection induces systemic monocytosis contributing to elevated mononuclear phagocyte numbers in the lung. These cells are central to an anti-viral effect that reduces the peak viral load in RSV infection. Treatments to promote or modulate these cells may provide novel paths to control RSV infection in high risk individuals.</style></abstract><notes><style face="normal" font="default" size="100%">Burgess, Matthew O&#xD;Janas, Piotr&#xD;Berry, Karla&#xD;Mayr, Hannah&#xD;Mack, Matthias&#xD;Jenkins, Stephen J&#xD;Bain, Calum C&#xD;McSorley, Henry J&#xD;Schwarze, Jurgen&#xD;eng&#xD;MR/T029668/1/MRC_/Medical Research Council/United Kingdom&#xD;WT_/Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2157-2172. doi: 10.1111/all.16206. Epub 2024 Jun 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38924546</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16206</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2194</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2194</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mules, T. C.</style></author><author><style face="normal" font="default" size="100%">Inns, S.</style></author><author><style face="normal" font="default" size="100%">Le Gros, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Malaghan Institute of Medical Research, Wellington, New Zealand.&#xD;University of Otago, Wellington, New Zealand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Helminths&apos; therapeutic potential to treat intestinal barrier dysfunction</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2892-2905</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Intestines</style></keyword><keyword><style face="normal" font="default" size="100%">*Intestinal Diseases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens</style></keyword><keyword><style face="normal" font="default" size="100%">*Helminths</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">helminths</style></keyword><keyword><style face="normal" font="default" size="100%">intestinal barrier function</style></keyword><keyword><style face="normal" font="default" size="100%">microbial translocation</style></keyword><keyword><style face="normal" font="default" size="100%">mucus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37449458</style></accession-num><abstract><style face="normal" font="default" size="100%">The intestinal barrier is a dynamic multi-layered structure which can adapt to environmental changes within the intestinal lumen. It has the complex task of allowing nutrient absorption while limiting entry of harmful microbes and microbial antigens present in the intestinal lumen. Excessive entry of microbial antigens via microbial translocation due to &apos;intestinal barrier dysfunction&apos; is hypothesised to contribute to the increasing incidence of allergic, autoimmune and metabolic diseases, a concept referred to as the &apos;epithelial barrier theory&apos;. Helminths reside in the intestinal tract are in intimate contact with the mucosal surfaces and induce a range of local immunological changes which affect the layers of the intestinal barrier. Helminths are proposed to prevent, or even treat, many of the diseases implicated in the epithelial barrier theory. This review will focus on the effect of helminths on intestinal barrier function and explore whether this could explain the proposed health benefits delivered by helminths.</style></abstract><notes><style face="normal" font="default" size="100%">Mules, Thomas C&#xD;Inns, Stephen&#xD;Le Gros, Graham&#xD;eng&#xD;Health Research Council of New Zealand/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2892-2905. doi: 10.1111/all.15812. Epub 2023 Jul 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37449458</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15812</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1447</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1447</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mjosberg, J.</style></author><author><style face="normal" font="default" size="100%">Roncarolo, M. G.</style></author><author><style face="normal" font="default" size="100%">Blom, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.&#xD;Center for Definitive and Curative Medicine (CDCM) Stanford University School of Medicine, Stanford, CA, USA.&#xD;Institute for Stem Cell Biology and Regenerative Medicine Stanford University School of Medicine, Stanford, CA, USA.&#xD;Department of Experimental Immunology, Amsterdam Institute for Infection and Immunity (AII), Cancer Center Amsterdam, Amsterdam UMC, location AMC, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hergen Spits-A legend at the top of his career</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1925-1928</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/03/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33751599</style></accession-num><notes><style face="normal" font="default" size="100%">Mjosberg, Jenny&#xD;Roncarolo, Maria Grazia&#xD;Blom, Bianca&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1925-1928. doi: 10.1111/all.14788. Epub 2021 Mar 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33751599</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14788</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1184</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lipp, T.</style></author><author><style face="normal" font="default" size="100%">Acar Sahin, A.</style></author><author><style face="normal" font="default" size="100%">Aggelidis, X.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Barbalace, A.</style></author><author><style face="normal" font="default" size="100%">Bourgoin, A.</style></author><author><style face="normal" font="default" size="100%">Bregu, B.</style></author><author><style face="normal" font="default" size="100%">Brighetti, M. A.</style></author><author><style face="normal" font="default" size="100%">Caeiro, E.</style></author><author><style face="normal" font="default" size="100%">Caglayan Sozmen, S.</style></author><author><style face="normal" font="default" size="100%">Caminiti, L.</style></author><author><style face="normal" font="default" size="100%">Charpin, D.</style></author><author><style face="normal" font="default" size="100%">Couto, M.</style></author><author><style face="normal" font="default" size="100%">Delgado, L.</style></author><author><style face="normal" font="default" size="100%">Di Rienzo Businco, A.</style></author><author><style face="normal" font="default" size="100%">Dimier, C.</style></author><author><style face="normal" font="default" size="100%">Dimou, M. V.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Goksel, O.</style></author><author><style face="normal" font="default" size="100%">Guvensen, A.</style></author><author><style face="normal" font="default" size="100%">Hernandez, D.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, T. M.</style></author><author><style face="normal" font="default" size="100%">Jang, D. T.</style></author><author><style face="normal" font="default" size="100%">Kalpaklioglu, F.</style></author><author><style face="normal" font="default" size="100%">Lame, B.</style></author><author><style face="normal" font="default" size="100%">Llusar, R.</style></author><author><style face="normal" font="default" size="100%">Makris, M. P.</style></author><author><style face="normal" font="default" size="100%">Mazon, A.</style></author><author><style face="normal" font="default" size="100%">Mesonjesi, E.</style></author><author><style face="normal" font="default" size="100%">Nieto, A.</style></author><author><style face="normal" font="default" size="100%">Ozturk, A.</style></author><author><style face="normal" font="default" size="100%">Pahus, L.</style></author><author><style face="normal" font="default" size="100%">Pajno, G. B.</style></author><author><style face="normal" font="default" size="100%">Panasiti, I.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Pellegrini, E.</style></author><author><style face="normal" font="default" size="100%">Pelosi, S.</style></author><author><style face="normal" font="default" size="100%">Pereira, A. M.</style></author><author><style face="normal" font="default" size="100%">Pereira, M.</style></author><author><style face="normal" font="default" size="100%">Pinar, M.</style></author><author><style face="normal" font="default" size="100%">Potapova, E.</style></author><author><style face="normal" font="default" size="100%">Priftanji, A.</style></author><author><style face="normal" font="default" size="100%">Psarros, F.</style></author><author><style face="normal" font="default" size="100%">Sackesen, C.</style></author><author><style face="normal" font="default" size="100%">Sfika, I.</style></author><author><style face="normal" font="default" size="100%">Suarez, J.</style></author><author><style face="normal" font="default" size="100%">Thibaudon, M.</style></author><author><style face="normal" font="default" size="100%">Travaglini, A.</style></author><author><style face="normal" font="default" size="100%">Tripodi, S.</style></author><author><style face="normal" font="default" size="100%">Verdier, V.</style></author><author><style face="normal" font="default" size="100%">Villella, V.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P. M.</style></author><author><style face="normal" font="default" size="100%">Dramburg, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Biology, Faculty of Science, Ankara University, Ankara, Turkey.&#xD;Allergy Unit, 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University Hospital &quot;Attikon&quot;, Athens, Greece.&#xD;Pediatric Allergology Unit, Department of Pediatric Medicine, Bambino Gesu Children&apos;s Research Hospital (IRCCS), Rome, Italy.&#xD;Department of Pediatrics-Allergy Unit, University of Messina, Messina, Italy.&#xD;Department of Pneumonology and Allergy, La Timone Hospital, APHM, Aix-Marseille University, Marseille, France.&#xD;Department of Allergology and Clinical Immunology, UHC Mother Teresa, Medical University Tirana, Tirana, Albania.&#xD;Department of Biology, Tor Vergata University, Rome, Italy.&#xD;MED-Mediterranean Institute for Agriculture, Environment and Development, Institute for Advanced Studies and Research, University of Evora, Evora, Portugal.&#xD;Portuguese Society of Allergology and Clinical Immunology, Lisbon, Portugal.&#xD;Department of Pediatric Allergy and Immunology, Okan University Faculty of Medicine, Istanbul, Turkey.&#xD;Department of Immunoallergology, CUF Decobertas Hospital, Jose de Mello Saude, Porto, Portugal.&#xD;Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS, Center for Health Technology and Services Research, Porto, Portugal.&#xD;Allergy Unit, Instituto &amp; Hospital CUF Porto, Porto, Portugal.&#xD;Pediatric Allergy Unit, Sandro Pertini Hospital, Rome, Italy.&#xD;Allergy Department, 2nd Pediatric Clinic, Athens General Children&apos;s Hospital &quot;P&amp;A Kyriakou&quot;, University of Athens, Athens, Greece.&#xD;MEDCIDS-Department of Community Medicine, Information, and Health Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Department of Pulmonary Medicine, Division of Immunology, Allergy and Asthma, Faculty of Medicine, Ege University, Izmir, Turkey.&#xD;Department of Biology, Faculty of Science, Ege University, Izmir, Turkey.&#xD;Department of Allergy, Health Research Institute Hospital La Fe, Valencia, Spain.&#xD;Pediatric Allergy and Pneumology Unit, Children&apos;s Hospital La Fe, Health Research Institute La Fe, Valencia, Spain.&#xD;Department of Immunology and Allergic Diseases, Kirikkale University School of Medicine, Ankara, Turkey.&#xD;Department of Pulmonary Medicine, Division of Allergy and Immunology, Koc University, School of Medicine, Istanbul, Turkey.&#xD;Department of Pneumonology and Allergy, North Hospital, APHM, Aix-Marseille University, Marseille, France.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, Royal Manchester Children&apos;s Hospital, University of Manchester, Manchester, UK.&#xD;Department of Reggio Calabria, ARPA-Regional Agency for Environmental Protection, Calabria, Italy.&#xD;TPS Production srl, Rome, Italy.&#xD;Allergy Department, Athens Naval Hospital, Athens, Greece.&#xD;Division of Pediatric Allergy, Koc University School of Medicine, Istanbul, Turkey.&#xD;Department of Biology of Organisms and Systems, Area of Botany, University of Oviedo, Oviedo, Spain.&#xD;Reseau National de Surveillance Aerobiologique, Brussieu, France.&#xD;Italian Aerobiology Monitoring Network-Italian Aerobiology Association, Rome, Italy.&#xD;Allergolology Service, Policlinico Casilino, Rome, Italy.&#xD;Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Cellular and Molecular Medicine, KUTTAM, Graduate School of Health Sciences, Koc University, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3041-3052</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/01/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Southern Europe</style></keyword><keyword><style face="normal" font="default" size="100%">oral allergy syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">panallergen</style></keyword><keyword><style face="normal" font="default" size="100%">pollen food allergy syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">seasonal allergic rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33492738</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Pollen food allergy syndrome (PFAS) is a frequently underdiagnosed disease due to diverse triggers, clinical presentations, and test results. This is especially relevant in geographic areas with a broad spectrum of pollen sensitization, such as Southern Europe. OBJECTIVES: To elucidate similarities and differences of PFAS in nine Southern European centers and identify associated characteristics and unique markers of PFAS. METHODS: As part of the @IT.2020 Multicenter Study, 815 patients with seasonal allergic rhinitis (SAR), aged 10-60 years, were recruited in seven countries. They completed questionnaires regarding SAR, comorbidities, family history, and PFAS, and underwent skin prick testing (SPT) and serum IgE testing. RESULTS: Of the 815 patients, 167 (20.5%) reported PFAS reactions. Most commonly, eliciting foods were kiwi (58, 34.7%), peach (43, 25.7%), and melon (26, 15.6%). Reported reactions were mostly local (216/319, 67.7%), occurring within 5 min of contact with elicitors (209/319, 65.5%). Associated characteristics included positive IgE to at least one panallergen (profilin, PR-10, or nsLTP) (p = 0.007), maternal PFAS (OR: 3.716, p = 0.026), and asthma (OR: 1.752, p = 0.073). Between centers, heterogeneity in prevalence (Marseille: 7.5% vs. Rome: 41.4%, p &lt; 0.001) and of clinical characteristics was apparent. Cypress played a limited role, with only 1/22 SPT mono-sensitized patients reporting a food reaction (p &lt; 0.073). CONCLUSIONS: PFAS is a frequent comorbidity in Southern European SAR patients. Significant heterogeneity of clinical characteristics in PFAS patients among the centers was observed and may be related to the different pollen sensitization patterns in each geographic area. IgE to panallergen(s), maternal PFAS, and asthma could be PFAS-associated characteristics.</style></abstract><notes><style face="normal" font="default" size="100%">Lipp, Theresa&#xD;Acar Sahin, Aydan&#xD;Aggelidis, Xenophon&#xD;Arasi, Stefania&#xD;Barbalace, Andrea&#xD;Bourgoin, Anne&#xD;Bregu, Blerina&#xD;Brighetti, Maria Antonia&#xD;Caeiro, Elsa&#xD;Caglayan Sozmen, Sule&#xD;Caminiti, Lucia&#xD;Charpin, Denis&#xD;Couto, Mariana&#xD;Delgado, Luis&#xD;Di Rienzo Businco, Andrea&#xD;Dimier, Claire&#xD;Dimou, Maria V&#xD;Fonseca, Joao A&#xD;Goksel, Ozlem&#xD;Guvensen, Aykut&#xD;Hernandez, Dolores&#xD;Hoffmann, Tara Maria&#xD;Jang, Dah Tay&#xD;Kalpaklioglu, Fusun&#xD;Lame, Blerta&#xD;Llusar, Ruth&#xD;Makris, Michael P&#xD;Mazon, Angel&#xD;Mesonjesi, Eris&#xD;Nieto, Antonio&#xD;Ozturk, Ayse&#xD;Pahus, Laurie&#xD;Pajno, Giovanni Battista&#xD;Panasiti, Ilenia&#xD;Papadopoulos, Nikolaos G&#xD;Pellegrini, Elisabetta&#xD;Pelosi, Simone&#xD;Pereira, Ana M&#xD;Pereira, Mariana&#xD;Pinar, Munevver&#xD;Potapova, Ekaterina&#xD;Priftanji, Alfred&#xD;Psarros, Fotis&#xD;Sackesen, Cansin&#xD;Sfika, Ifigenia&#xD;Suarez, Javier&#xD;Thibaudon, Michel&#xD;Travaglini, Alessandro&#xD;Tripodi, Salvatore&#xD;Verdier, Valentine&#xD;Villella, Valeria&#xD;Xepapadaki, Paraskevi&#xD;Yazici, Duygu&#xD;Matricardi, Paolo M&#xD;Dramburg, Stephanie&#xD;eng&#xD;Multicenter Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3041-3052. doi: 10.1111/all.14742. Epub 2021 Jul 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33492738</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14742</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2416</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2416</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dramburg, S.</style></author><author><style face="normal" font="default" size="100%">Grittner, U.</style></author><author><style face="normal" font="default" size="100%">Potapova, E.</style></author><author><style face="normal" font="default" size="100%">Travaglini, A.</style></author><author><style face="normal" font="default" size="100%">Tripodi, S.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Pelosi, S.</style></author><author><style face="normal" font="default" size="100%">Acar Sahin, A.</style></author><author><style face="normal" font="default" size="100%">Aggelidis, X.</style></author><author><style face="normal" font="default" size="100%">Barbalace, A.</style></author><author><style face="normal" font="default" size="100%">Bourgoin, A.</style></author><author><style face="normal" font="default" size="100%">Bregu, B.</style></author><author><style face="normal" font="default" size="100%">Brighetti, M. A.</style></author><author><style face="normal" font="default" size="100%">Caeiro, E.</style></author><author><style face="normal" font="default" size="100%">Caglayan Sozmen, S.</style></author><author><style face="normal" font="default" size="100%">Caminiti, L.</style></author><author><style face="normal" font="default" size="100%">Charpin, D.</style></author><author><style face="normal" font="default" size="100%">Couto, M.</style></author><author><style face="normal" font="default" size="100%">Delgado, L.</style></author><author><style face="normal" font="default" size="100%">Di Rienzo Businco, A.</style></author><author><style face="normal" font="default" size="100%">Dimier, C.</style></author><author><style face="normal" font="default" size="100%">Dimou, M. V.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Goksel, O.</style></author><author><style face="normal" font="default" size="100%">Hernandez, D.</style></author><author><style face="normal" font="default" size="100%">Hernandez Toro, C. J.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, T. M.</style></author><author><style face="normal" font="default" size="100%">Jang, D. T.</style></author><author><style face="normal" font="default" size="100%">Kalpaklioglu, F.</style></author><author><style face="normal" font="default" size="100%">Lame, B.</style></author><author><style face="normal" font="default" size="100%">Llusar, R.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Mazon, A.</style></author><author><style face="normal" font="default" size="100%">Mesonjesi, E.</style></author><author><style face="normal" font="default" size="100%">Nieto, A.</style></author><author><style face="normal" font="default" size="100%">Ozturk, A. B.</style></author><author><style face="normal" font="default" size="100%">Pahus, L.</style></author><author><style face="normal" font="default" size="100%">Pajno, G.</style></author><author><style face="normal" font="default" size="100%">Panasiti, I.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Pellegrini, E.</style></author><author><style face="normal" font="default" size="100%">Pereira, A. M.</style></author><author><style face="normal" font="default" size="100%">Pereira, M.</style></author><author><style face="normal" font="default" size="100%">Pinar, N. M.</style></author><author><style face="normal" font="default" size="100%">Priftanji, A.</style></author><author><style face="normal" font="default" size="100%">Psarros, F.</style></author><author><style face="normal" font="default" size="100%">Sackesen, C.</style></author><author><style face="normal" font="default" size="100%">Sfika, I.</style></author><author><style face="normal" font="default" size="100%">Suarez, J.</style></author><author><style face="normal" font="default" size="100%">Thibaudon, M.</style></author><author><style face="normal" font="default" size="100%">Uguz, U.</style></author><author><style face="normal" font="default" size="100%">Verdier, V.</style></author><author><style face="normal" font="default" size="100%">Villella, V.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Respiratory Care, Immunology and Intensive Care Medicine, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Institute of Biometry and Clinical Epidemiology, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Biology, Tor Vergata University, Rome, Italy.&#xD;Italian Aerobiology Monitoring Network - Italian Aerobiology Association, Rome, Italy.&#xD;Pediatric Allergy Unit, Sandro Pertini Hospital, Rome, Italy.&#xD;Allergolology Service, Policlinico Casilino, Rome, Italy.&#xD;Pediatric Allergology Unit, Department of Pediatric Medicine, Bambino Gesu Children&apos;s Research Hospital (IRCCS), Rome, Italy.&#xD;TPS Production srl, Rome, Italy.&#xD;Department of Biology, Faculty of Science, Ankara University, Ankara, Turkey.&#xD;Allergy Unit, 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University Hospital &quot;Attikon&quot;, Athens, Greece.&#xD;Allergy Unit, Department of Pediatrics, University of Messina, Messina, Italy.&#xD;Department of Pneumonology and Allergy, La Timone Hospital, APHM, Aix-Marseille University, Marseille, France.&#xD;Department of Allergology and Clinical Immunology, UHC Mother Teresa, Medical University Tirana, Tirana, Albania.&#xD;MED- Mediterranean Institute for Agriculture, Environment and Development, Institute for Advanced Studies and Research, University of Evora, Evora, Portugal.&#xD;Portuguese Society of Allergology and Clinical Immunology, Lisbon, Portugal.&#xD;Medicana International Izmir Hospital, Izmir, Turkey.&#xD;Immunoallergology, Hospital CUF Trindade, Porto, Portugal.&#xD;Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE, MEDCIDS, Faculty of Medicine of the University of Porto, Porto, Portugal.&#xD;Allergy Unit, Instituto &amp; Hospital CUF Porto, Porto, Portugal.&#xD;Allergy Department, 2nd Pediatric Clinic, Athens General Children&apos;s Hospital &quot;P&amp;A Kyriakou&quot;, University of Athens, Athens, Greece.&#xD;MEDCIDS-Department of Community Medicine, Information, and Health Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Department of Pulmonary Medicine, Division of Immunology, Allergy and Asthma. Faculty of Medicine, Ege University, Izmir, Turkey.&#xD;Department of Allergy, Health Research Institute Hospital La Fe, Valencia, Spain.&#xD;Pediatric Allergy and Pneumology Unit, Children&apos;s Hospital La Fe; Health Research Institute La Fe, Valencia, Spain.&#xD;Department of Immunology and Allergic Diseases, Kirikkale University School of Medicine, Kirikkale, Turkey.&#xD;Division of Allergy and Immunology, Department of Pulmonary Medicine, Arel University, School of Medicine, Istanbul, Turkey.&#xD;Aix Marseille Univ, APHM, INSERM CIC 1409, INSERM U1263, INRA 1260 (C2VN), Marseille, France.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, Royal Manchester Children&apos;s Hospital, University of Manchester, Manchester, UK.&#xD;Department of Reggio Calabria, ARPA - Regional Agency for Environmental Protection, Calabria, Italy.&#xD;Allergy Department, Athens Naval Hospital, Athens, Greece.&#xD;Division of Pediatric Allergy, Koc University School of Medicine, Istanbul, Turkey.&#xD;Department of Biology of Organisms and Systems, Area of Botany, University of Oviedo, Oviedo, Spain.&#xD;Reseau National de Surveillance Aerobiologique, Brussieu, France.&#xD;Department of Biology, Faculty of Science, Ege University, Izmir, Turkey.&#xD;Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Cellular and Molecular Medicine, KUTTAM, Graduate School of Health Sciences, Koc University, Istanbul, Turkey.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Heterogeneity of sensitization profiles and clinical phenotypes among patients with seasonal allergic rhinitis in Southern European countries-The @IT.2020 multicenter study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">908-923</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/02/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">component-resolved diagnostics</style></keyword><keyword><style face="normal" font="default" size="100%">phenotypes</style></keyword><keyword><style face="normal" font="default" size="100%">pollen allergy</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38311961</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Pollen allergy poses a significant health and economic burden in Europe. Disease patterns are relatively homogeneous within Central and Northern European countries. However, no study broadly assessed the features of seasonal allergic rhinitis (SAR) across different Southern European countries with a standardized approach. OBJECTIVE: To describe sensitization profiles and clinical phenotypes of pollen allergic patients in nine Southern European cities with a uniform methodological approach. METHODS: Within the @IT.2020 multicenter observational study, pediatric and adult patients suffering from SAR were recruited in nine urban study centers located in seven countries. Clinical questionnaires, skin prick tests (SPT) and specific IgE (sIgE) tests with a customized multiplex assay (Euroimmun Labordiagnostika, Lubeck, Germany) were performed. RESULTS: Three hundred forty-eight children (mean age 13.1 years, SD: 2.4 years) and 467 adults (mean age 35.7 years SD: 10.0 years) with a predominantly moderate to severe, persistent phenotype of SAR were recruited. Grass pollen major allergenic molecules (Phl p 1 and/or Phl p 5) ranged among the top three sensitizers in all study centers. Sensitization profiles were very heterogeneous, considering that patients in Rome were highly poly-sensitized (sIgE to 3.8 major allergenic molecules per patient), while mono-sensitization was prominent and heterogeneous in other cities, such as Marseille (sIgE to Cup a 1: n = 55/80, 68.8%) and Messina (sIgE to Par j 2: n = 47/82, 57.3%). Co-sensitization to perennial allergens, as well as allergic comorbidities also broadly varied between study centers. CONCLUSIONS: In Southern European countries, pollen allergy is heterogeneous in terms of sensitization profiles and clinical manifestations. Despite the complexity, a unique molecular, multiplex, and customized in-vitro IgE test detected relevant sensitization in all study centers. Nevertheless, this geographical diversity in pollen allergic patients imposes localized clinical guidelines and study protocols for clinical trials of SAR in this climatically complex region.</style></abstract><notes><style face="normal" font="default" size="100%">Dramburg, S&#xD;Grittner, U&#xD;Potapova, E&#xD;Travaglini, A&#xD;Tripodi, S&#xD;Arasi, S&#xD;Pelosi, S&#xD;Acar Sahin, A&#xD;Aggelidis, X&#xD;Barbalace, A&#xD;Bourgoin, A&#xD;Bregu, B&#xD;Brighetti, M A&#xD;Caeiro, E&#xD;Caglayan Sozmen, S&#xD;Caminiti, L&#xD;Charpin, D&#xD;Couto, M&#xD;Delgado, L&#xD;Di Rienzo Businco, A&#xD;Dimier, C&#xD;Dimou, M V&#xD;Fonseca, J A&#xD;Goksel, O&#xD;Hernandez, D&#xD;Hernandez Toro, C J&#xD;Hoffmann, T M&#xD;Jang, D T&#xD;Kalpaklioglu, F&#xD;Lame, B&#xD;Llusar, R&#xD;Makris, M&#xD;Mazon, A&#xD;Mesonjesi, E&#xD;Nieto, A&#xD;Ozturk, A B&#xD;Pahus, L&#xD;Pajno, G&#xD;Panasiti, I&#xD;Papadopoulos, N G&#xD;Pellegrini, E&#xD;Pereira, A M&#xD;Pereira, M&#xD;Pinar, N M&#xD;Priftanji, A&#xD;Psarros, F&#xD;Sackesen, C&#xD;Sfika, I&#xD;Suarez, J&#xD;Thibaudon, M&#xD;Uguz, U&#xD;Verdier, V&#xD;Villella, V&#xD;Xepapadaki, P&#xD;Yazici, D&#xD;Matricardi, P M&#xD;eng&#xD;Euroimmun/&#xD;Multicenter Study&#xD;Observational Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):908-923. doi: 10.1111/all.16029. Epub 2024 Feb 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38311961</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16029</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>711</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">711</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Luo, L.</style></author><author><style face="normal" font="default" size="100%">Luo, Y.</style></author><author><style face="normal" font="default" size="100%">Xu, J.</style></author><author><style face="normal" font="default" size="100%">Zhu, R.</style></author><author><style face="normal" font="default" size="100%">Wu, J.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Yao, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.&#xD;University of Chinese Academy of Sciences, Beijing, China.&#xD;Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.&#xD;Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.&#xD;Department of Allergy, Huashan Hospital, Fudan University, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Heterogeneous origin of IgE in atopic dermatitis and psoriasis revealed by B cell receptor repertoire analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">559-568</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/11/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear</style></keyword><keyword><style face="normal" font="default" size="100%">*Psoriasis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Antigen, B-Cell</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">immune repertoire</style></keyword><keyword><style face="normal" font="default" size="100%">natural antibody</style></keyword><keyword><style face="normal" font="default" size="100%">psoriasis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34738638</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Epicutaneous sensitization is an important route for the production of IgE, and skin inflammation-induced IgE has recently been reported having features of natural antibody. Atopic dermatitis (AD) and psoriasis have differentially increased level of serum IgE; however, the production mechanism of IgE in these inflammatory skin diseases remains unknown. OBJECTIVE: To explore the origin of IgE in AD and psoriasis by analyzing the B cell receptor repertoire. METHODS: mRNA was prepared from peripheral blood mononuclear cells of AD and psoriasis patients that had elevated serum levels of IgE, and immunoglobulin heavy chain (IGH) repertoires were sequenced after reverse transcription. Clonal lineages of B cells containing members expressing IgE were identified, and somatic hypermutations in IGH inherited from common ancestors within the clonal lineage were used to infer the relationships between B cells. RESULTS: The proportions of IGHE from AD and psoriasis were higher than that of normal control, which were positively correlated with the levels of serum total IgE. The somatic hypermutation value of IGHE variable region was lower than that of IGHG and IGHA, but higher than IGHM and IGHD, indicating a mixed natural and adaptive origins of IgE; and psoriasis demonstrated lower level of hypermutation than AD. The Shannon indexes of CDR3 in IGHE of AD and psoriasis were higher than that of normal control, also supporting the natural origin. The VH usage of IgE was weakly biased in AD and psoriasis patients with high level of house dust mite-specific IgE. Comparison of the number of shared mutations in multi-isotype lineages containing IgE showed that isotype-switching from IgG-expressing B cells might be the major source of IgE in AD and psoriasis. CONCLUSION: IgE has heterogeneous origin in AD and psoriasis, and skin inflammation may contribute to the increased production of natural IgE.</style></abstract><notes><style face="normal" font="default" size="100%">Luo, Lihua&#xD;Luo, Yang&#xD;Xu, Jing&#xD;Zhu, Ronghui&#xD;Wu, Jinghua&#xD;Liu, Xiao&#xD;Li, Wei&#xD;Yao, Xu&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):559-568. doi: 10.1111/all.15173. Epub 2021 Nov 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34738638</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15173</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2439</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Korosec, P.</style></author><author><style face="normal" font="default" size="100%">Sturm, G. J.</style></author><author><style face="normal" font="default" size="100%">Lyons, J. J.</style></author><author><style face="normal" font="default" size="100%">Marolt, T. P.</style></author><author><style face="normal" font="default" size="100%">Svetina, M.</style></author><author><style face="normal" font="default" size="100%">Kosnik, M.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author><author><style face="normal" font="default" size="100%">Kacar, M.</style></author><author><style face="normal" font="default" size="100%">Frelih, N.</style></author><author><style face="normal" font="default" size="100%">Lalek, N.</style></author><author><style face="normal" font="default" size="100%">Luzar, A. D.</style></author><author><style face="normal" font="default" size="100%">Zver, S.</style></author><author><style face="normal" font="default" size="100%">Skerget, M.</style></author><author><style face="normal" font="default" size="100%">Czarnobilska, E.</style></author><author><style face="normal" font="default" size="100%">Dyga, W.</style></author><author><style face="normal" font="default" size="100%">Grle, S. P.</style></author><author><style face="normal" font="default" size="100%">Samarzija, M.</style></author><author><style face="normal" font="default" size="100%">Arzt-Gradwohl, L.</style></author><author><style face="normal" font="default" size="100%">Cerpes, U.</style></author><author><style face="normal" font="default" size="100%">Porebski, G.</style></author><author><style face="normal" font="default" size="100%">Pevec, B.</style></author><author><style face="normal" font="default" size="100%">Schadelbauer, E.</style></author><author><style face="normal" font="default" size="100%">Kopac, P.</style></author><author><style face="normal" font="default" size="100%">Selb, J.</style></author><author><style face="normal" font="default" size="100%">Rijavec, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.&#xD;Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.&#xD;Faculty of Medicine, University of Maribor, Maribor, Slovenia.&#xD;Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.&#xD;Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.&#xD;Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia.&#xD;Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.&#xD;The Department of Hematology, University Medical Center Ljubljana, Ljubljana, Slovenia.&#xD;Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Krakow, Poland.&#xD;Clinic for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High burden of clonal mast cell disorders and hereditary alpha-tryptasemia in patients who need Hymenoptera venom immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2458-2469</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/03/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthropod Venoms/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Tryptases/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Hymenoptera/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mastocytosis/therapy/genetics/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-kit/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Insect Bites and Stings/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary alpha-tryptasemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">mastocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">venom</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, Stallergens-Greer and Allergopharma. Other authors declare that they</style></keyword><keyword><style face="normal" font="default" size="100%">have no relevant conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38477502</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In patients who require venom immunotherapy (VIT), there is a need to identify underlying mast cell (MC) disorders since these may affect the risk and severity of future sting reactions and the long-term effectiveness of VIT. METHODS: 1319 individuals with Hymenoptera venom allergy (HVA) who needed VIT from referral centers in Slovenia, Austria, Croatia, and Poland underwent examination for KIT p.D816V in peripheral blood leukocytes (PBL) using a highly sensitive PCR test and tryptase genotyping by digital droplet PCR. We also included 183 control individuals with large local reactions (LLRs) to Hymenoptera stings and with asymptomatic sensitization to Hymenoptera venoms. RESULTS: 285 of 1319 individuals recommended for VIT (21.6%) were positive for KIT p.D816V in PBL, preferably those who present with severe reaction (33.9% [n = 207 of 610] with Ring-Messmer grade 3-4 vs. 11% [n = 78 of 709] with Grade 1-2; p &lt; .0001), whereas only 1.3% (n = 2 of 152) of controls with LLR and none with asymptomatic sensitization (n = 31) had KIT p.D816V. KIT p.D816V allelic burden was higher in those with severe reaction (median 0.018% [n = 207] in Grade 3-4 vs. 0.001% [n = 78] in Grade 1-2; p &lt; .0001), and the majority had normal baseline serum tryptase levels (69% [n = 196 of 285]). All KIT p.D816V-positive individuals (n = 41) who underwent bone marrow (BM) biopsy were found to have underlying clonal diseases, principally BM mastocytosis. HalphaT was also associated with severe HVA and symptoms (p &lt; .01), and remarkably, 31.0% (n = 31 of 100) were found to have concomitant KIT p.D816V. Concomitant HalphaT and KIT p.D816V showed an additive effect, and having both was associated with the highest risk for severe HVA, even higher than having either HalphaT or KIT p.D816V alone (OR = 3.8; p &lt; .01). CONCLUSIONS: By employing prospective universal tryptase genotyping and examination for KIT p.D816V in PBL in large HVA populations, we have demonstrated a high burden of clonal MC disorders and HalphaT in patients who require VIT.</style></abstract><notes><style face="normal" font="default" size="100%">Korosec, Peter&#xD;Sturm, Gunter J&#xD;Lyons, Jonathan J&#xD;Marolt, Tinkara Pirc&#xD;Svetina, Manca&#xD;Kosnik, Mitja&#xD;Zidarn, Mihaela&#xD;Kacar, Mark&#xD;Frelih, Nina&#xD;Lalek, Nika&#xD;Luzar, Ajda Demsar&#xD;Zver, Samo&#xD;Skerget, Matevz&#xD;Czarnobilska, Ewa&#xD;Dyga, Wojciech&#xD;Grle, Sanja Popovic&#xD;Samarzija, Miroslav&#xD;Arzt-Gradwohl, Lisa&#xD;Cerpes, Urban&#xD;Porebski, Grzegorz&#xD;Pevec, Branko&#xD;Schadelbauer, Eva&#xD;Kopac, Peter&#xD;Selb, Julij&#xD;Rijavec, Matija&#xD;eng&#xD;Javna Agencija za Raziskovalno Dejavnost RS/&#xD;Division of Intramural Research, National Institute of Allergy and Infectious Diseases/&#xD;Austrian Science Fund/&#xD;SI2 AI138586/AI/NIAID NIH HHS/&#xD;R00 AI138586/AI/NIAID NIH HHS/&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2458-2469. doi: 10.1111/all.16084. Epub 2024 Mar 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38477502</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11939115</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16084</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1408</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1408</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Endo, Y.</style></author><author><style face="normal" font="default" size="100%">Shirai, T.</style></author><author><style face="normal" font="default" size="100%">Hirai, K.</style></author><author><style face="normal" font="default" size="100%">Akamatsu, T.</style></author><author><style face="normal" font="default" size="100%">Kato, E.</style></author><author><style face="normal" font="default" size="100%">Furui, H.</style></author><author><style face="normal" font="default" size="100%">Hiramatsu, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.&#xD;Department of Clinical Pharmacology and Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.&#xD;Laboratory of Clinical Pharmacogenomics, Shizuoka General Hospital, Shizuoka, Japan.&#xD;Hanasaki Clinic, Kiyosu, Japan.&#xD;Furui Clinic, Tarui, Japan.&#xD;Hiramatsu Clinic, Komaki, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High fractional exhaled nitric oxide levels may predict short-term worsening of respiratory oscillometry in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">363-366</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Breath Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Exhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nitric Oxide</style></keyword><keyword><style face="normal" font="default" size="100%">Oscillometry</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default" size="100%">reactance</style></keyword><keyword><style face="normal" font="default" size="100%">resistance</style></keyword><keyword><style face="normal" font="default" size="100%">short-term</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32623752</style></accession-num><notes><style face="normal" font="default" size="100%">Endo, Yoshinari&#xD;Shirai, Toshihiro&#xD;Hirai, Keita&#xD;Akamatsu, Taisuke&#xD;Kato, Eishi&#xD;Furui, Hidehiko&#xD;Hiramatsu, Tetsuo&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):363-366. doi: 10.1111/all.14484. Epub 2020 Jul 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32623752</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14484</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2762</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2762</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Niwa, Y.</style></author><author><style face="normal" font="default" size="100%">Hayama, K.</style></author><author><style face="normal" font="default" size="100%">Toyoshima, S.</style></author><author><style face="normal" font="default" size="100%">Shimizu, K.</style></author><author><style face="normal" font="default" size="100%">Tagui, M.</style></author><author><style face="normal" font="default" size="100%">Ito, M.</style></author><author><style face="normal" font="default" size="100%">Sakamoto, T.</style></author><author><style face="normal" font="default" size="100%">Terui, T.</style></author><author><style face="normal" font="default" size="100%">Fujita, H.</style></author><author><style face="normal" font="default" size="100%">Okayama, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan.&#xD;Center for Allergy, Nihon University School of Medicine, Tokyo, Japan.&#xD;Department of Biochemistry &amp; Molecular Biology, Nippon Medical School, Tokyo, Japan.&#xD;Department of Allergy, Internal Medicine, Misato Kenwa Hospital, Saitama, Japan.&#xD;Division of Respiratory Medicine, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.&#xD;Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.&#xD;Advanced Medical Science Research Center, Graduate School of Health Sciences, Gunma Paz University, Takasaki, Gunma, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High IgG Anti-IgE Autoantibodies Prevent Early Omalizumab Response in Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1115-1118</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/06</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39641592</style></accession-num><notes><style face="normal" font="default" size="100%">Niwa, Yusuke&#xD;Hayama, Koremasa&#xD;Toyoshima, Shota&#xD;Shimizu, Keisuke&#xD;Tagui, Maho&#xD;Ito, Mana&#xD;Sakamoto, Tomomi&#xD;Terui, Tadashi&#xD;Fujita, Hideki&#xD;Okayama, Yoshimichi&#xD;eng&#xD;So21-1203/Grants-in-Aid for Scientific Research from the Nihon University Multidisciplinary Research/&#xD;09670463/MEXT-Supported Program for the Strategic Research Foundation at Private Universities/&#xD;22K08393/Ministry of Education, Culture, Sports, Science, and Technology of the Japanese Government/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1115-1118. doi: 10.1111/all.16419. Epub 2024 Dec 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39641592</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16419</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2541</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2541</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Madrange, M.</style></author><author><style face="normal" font="default" size="100%">Rossignol, J.</style></author><author><style face="normal" font="default" size="100%">Devin, C.</style></author><author><style face="normal" font="default" size="100%">Bekel, L.</style></author><author><style face="normal" font="default" size="100%">Bellon, N.</style></author><author><style face="normal" font="default" size="100%">Welfringer-Morin, A.</style></author><author><style face="normal" font="default" size="100%">Meni, C.</style></author><author><style face="normal" font="default" size="100%">Bonigen, J.</style></author><author><style face="normal" font="default" size="100%">Bataille, P.</style></author><author><style face="normal" font="default" size="100%">Burdet, C.</style></author><author><style face="normal" font="default" size="100%">Agopian, J.</style></author><author><style face="normal" font="default" size="100%">Dubreuil, P.</style></author><author><style face="normal" font="default" size="100%">Hermine, O.</style></author><author><style face="normal" font="default" size="100%">Bodemer, C.</style></author><author><style face="normal" font="default" size="100%">Polivka, L.</style></author><author><style face="normal" font="default" size="100%">Ceremast network</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CEREMAST, Imagine Institute, INSERM U1163, AP-HP, Necker-Children&apos;s Hospital, Paris Centre University, Paris, France.&#xD;Department of Hematology, Necker-Children&apos;s Hospital, AP-HP, Paris Centre University, Paris, France.&#xD;Department of Dermatology, Reference Center for Rare Skin disorders in Children, AP-HP, Necker-Children&apos;s Hospital, Paris Centre University, Paris, France.&#xD;Centre d&apos;Investigation Clinique, Inserm CIC 1425, AP-HP, Bichat Hospital, Paris Centre University, Paris, France.&#xD;Centre de Recherche en Cancerologie de Marseille, INSERM U1068, Marseille, France.&#xD;Association Francaise pour les Initiatives de Recherche sur le Mastocyte et les Mastocytoses (AFIRMM), Marseille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A high prevalence of hereditary alpha-tryptasemia in pediatric mastocytoma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3129-3132</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/06/08</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38850228</style></accession-num><notes><style face="normal" font="default" size="100%">Madrange, M&#xD;Rossignol, J&#xD;Devin, C&#xD;Bekel, L&#xD;Bellon, N&#xD;Welfringer-Morin, A&#xD;Meni, C&#xD;Bonigen, J&#xD;Bataille, P&#xD;Burdet, C&#xD;Agopian, J&#xD;Dubreuil, P&#xD;Hermine, O&#xD;Bodemer, C&#xD;Polivka, L&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3129-3132. doi: 10.1111/all.16185. Epub 2024 Jun 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38850228</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16185</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2542</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2542</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Madrange, M.</style></author><author><style face="normal" font="default" size="100%">Rossignol, J.</style></author><author><style face="normal" font="default" size="100%">Devin, C.</style></author><author><style face="normal" font="default" size="100%">Bekel, L.</style></author><author><style face="normal" font="default" size="100%">Bellon, N.</style></author><author><style face="normal" font="default" size="100%">Welfringer-Morin, A.</style></author><author><style face="normal" font="default" size="100%">Meni, C.</style></author><author><style face="normal" font="default" size="100%">Bonigen, J.</style></author><author><style face="normal" font="default" size="100%">Bataille, P.</style></author><author><style face="normal" font="default" size="100%">Burdet, C.</style></author><author><style face="normal" font="default" size="100%">Agopian, J.</style></author><author><style face="normal" font="default" size="100%">Dubreuil, P.</style></author><author><style face="normal" font="default" size="100%">Hermine, O.</style></author><author><style face="normal" font="default" size="100%">Bodemer, C.</style></author><author><style face="normal" font="default" size="100%">Polivka, L.</style></author><author><style face="normal" font="default" size="100%">Ceremast network</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CEREMAST, Imagine Institute, INSERM U1163, AP-HP, Necker-Children&apos;s Hospital, Paris Centre University, Paris, France.&#xD;Department of Hematology, Necker-Children&apos;s Hospital, AP-HP, Paris Centre University, Paris, France.&#xD;Department of Dermatology, Reference Center for Rare Skin disorders in Children, AP-HP, Necker-Children&apos;s Hospital, Paris Centre University, Paris, France.&#xD;Centre d&apos;Investigation Clinique, Inserm CIC 1425, AP-HP, Bichat Hospital, Paris Centre University, Paris, France.&#xD;Centre de Recherche en Cancerologie de Marseille, INSERM U1068, Marseille, France.&#xD;Association Francaise pour les Initiatives de Recherche sur le Mastocyte et les Mastocytoses (AFIRMM), Marseille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A high prevalence of hereditary alpha-tryptasemia in pediatric mastocytoma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3129-3132</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/06/08</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38850228</style></accession-num><notes><style face="normal" font="default" size="100%">Madrange, M&#xD;Rossignol, J&#xD;Devin, C&#xD;Bekel, L&#xD;Bellon, N&#xD;Welfringer-Morin, A&#xD;Meni, C&#xD;Bonigen, J&#xD;Bataille, P&#xD;Burdet, C&#xD;Agopian, J&#xD;Dubreuil, P&#xD;Hermine, O&#xD;Bodemer, C&#xD;Polivka, L&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3129-3132. doi: 10.1111/all.16185. Epub 2024 Jun 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38850228</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16185</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3199</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3199</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zeyneloglu, C.</style></author><author><style face="normal" font="default" size="100%">Bicer, C.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos Wolfgang, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High Serum Thymic Stromal Lymphopoietin (TSLP) Levels Link Epithelial Barrier Dysfunction With Local and Systemic Inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">alarmins</style></keyword><keyword><style face="normal" font="default" size="100%">chronic inflammatory diseases</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier theory</style></keyword><keyword><style face="normal" font="default" size="100%">systemic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">thymic stromal lymphopoietin (TSLP)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 16</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41403141</style></accession-num><notes><style face="normal" font="default" size="100%">Zeyneloglu, Can&#xD;Bicer, Ceren&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Dec 16. doi: 10.1111/all.70198.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41403141</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70198</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3119</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3119</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suzukawa, M.</style></author><author><style face="normal" font="default" size="100%">Ohta, K.</style></author><author><style face="normal" font="default" size="100%">Tashimo, H.</style></author><author><style face="normal" font="default" size="100%">Narumoto, O.</style></author><author><style face="normal" font="default" size="100%">Hashimoto, H.</style></author><author><style face="normal" font="default" size="100%">Kita, T.</style></author><author><style face="normal" font="default" size="100%">Takato, H.</style></author><author><style face="normal" font="default" size="100%">Nagase, H.</style></author><author><style face="normal" font="default" size="100%">Kobayashi, K.</style></author><author><style face="normal" font="default" size="100%">Yamaguchi, M.</style></author><author><style face="normal" font="default" size="100%">Abe, M.</style></author><author><style face="normal" font="default" size="100%">Ito, R.</style></author><author><style face="normal" font="default" size="100%">Endo, T.</style></author><author><style face="normal" font="default" size="100%">Yanai, H.</style></author><author><style face="normal" font="default" size="100%">Chibana, K.</style></author><author><style face="normal" font="default" size="100%">Hizawa, N.</style></author><author><style face="normal" font="default" size="100%">Tanimoto, Y.</style></author><author><style face="normal" font="default" size="100%">Takagi, K.</style></author><author><style face="normal" font="default" size="100%">Oguma, T.</style></author><author><style face="normal" font="default" size="100%">Harada, N.</style></author><author><style face="normal" font="default" size="100%">Sagara, H.</style></author><author><style face="normal" font="default" size="100%">Kato, A.</style></author><author><style face="normal" font="default" size="100%">Takata, S.</style></author><author><style face="normal" font="default" size="100%">Komase, Y.</style></author><author><style face="normal" font="default" size="100%">Hyodo, K.</style></author><author><style face="normal" font="default" size="100%">Matsunaga, K.</style></author><author><style face="normal" font="default" size="100%">Tsujino, K.</style></author><author><style face="normal" font="default" size="100%">Niimi, A.</style></author><author><style face="normal" font="default" size="100%">Wakamatsu, K.</style></author><author><style face="normal" font="default" size="100%">Sugiura, H.</style></author><author><style face="normal" font="default" size="100%">Sakakibara, Y.</style></author><author><style face="normal" font="default" size="100%">Kamimura, M.</style></author><author><style face="normal" font="default" size="100%">Shibata, Y.</style></author><author><style face="normal" font="default" size="100%">Tanaka, G.</style></author><author><style face="normal" font="default" size="100%">Nakamoto, K.</style></author><author><style face="normal" font="default" size="100%">Tamaki, S.</style></author><author><style face="normal" font="default" size="100%">Minakata, Y.</style></author><author><style face="normal" font="default" size="100%">Numata, T.</style></author><author><style face="normal" font="default" size="100%">Saito, A. M.</style></author><author><style face="normal" font="default" size="100%">Kobayashi, N.</style></author><author><style face="normal" font="default" size="100%">Taniguchi, M.</style></author><author><style face="normal" font="default" size="100%">T. NH-Azma Research Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.&#xD;Japan Anti-Tuberculosis Association, JATA Fukujuji Hospital, Tokyo, Japan.&#xD;Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan.&#xD;Core Laboratory, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.&#xD;National Hospital Organization Kanazawa Medical Center, Ishikawa, Japan.&#xD;Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.&#xD;National Hospital Organization Ehime Medical Center, Ehime, Japan.&#xD;National Hospital Organization Mito Medical Center, Ibaraki, Japan.&#xD;National Hospital Organization Okinawa National Hospital, Okinawa, Japan.&#xD;Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.&#xD;National Hospital Organization Minami-Okayama Medical Center, Okayama, Japan.&#xD;Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.&#xD;Division of Pulmonary Medicine, Department of Medicine, Tokai University Hospital, Kanagawa, Japan.&#xD;Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.&#xD;Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University, School of Medicine, Tokyo, Japan.&#xD;Misato Kenwa Hospital, Saitama, Japan.&#xD;Terada Hospital, Tokyo, Japan.&#xD;National Hospital Organization Fukuokahigashi Medical Center, Fukuoka, Japan.&#xD;Department of Respiratory Internal Medicine, St. Marianna University Yokohama Seibu Hospital, Kanagawa, Japan.&#xD;Department of Respiratory Medicine, Ibarakihigashi National Hospital, Ibaraki, Japan.&#xD;Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University Hospital, Yamaguchi, Japan.&#xD;National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.&#xD;Department of Respiratory Medicine, Allergy, and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya City University Hospital, Aichi, Japan.&#xD;National Hospital Organization Omuta National Hospital, Fukuoka, Japan.&#xD;Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Miyagi, Japan.&#xD;Department of Respiratory Medicine, Hiratsuka Kyosai Hospital, Kanagawa, Japan.&#xD;National Hospital Organization Disaster Medical Center, Tokyo, Japan.&#xD;Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.&#xD;The Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo, Japan.&#xD;Department of Respiratory Medicine, Kyorin University School of Medicine, Tokyo, Japan.&#xD;National Hospital Organization Nara Medical Center, Nara, Japan.&#xD;National Hospital Organization Wakayama Hospital, Wakayama, Japan.&#xD;Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.&#xD;Fureai Machida Hospital, Tokyo, Japan.&#xD;Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High Serum TSLP Is Characteristic of Late-Onset, Long-Duration, Eosinophilic Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">thymic stromal lymphopoietin (TSLP)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41117145</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Thymic stromal lymphopoietin (TSLP) is a master regulator of type 2 immune responses; however, the associations between serum TSLP and the characteristics of adult asthma have not been fully clarified. The aim of this study was to determine the characteristics of adult asthma with high serum TSLP and explore TSLP&apos;s association with the late-onset eosinophilic asthma phenotype. METHODS: Baseline data of the TNH-Azma study (a real-world observational cohort study conducted in Japan on 1344 patients with asthma from 30 hospitals) was used and serum cytokines were measured. Patients were stratified into quartile groups based on the baseline serum TSLP levels, and their clinical characteristics were compared. Multivariable regression analyses were used to determine clinical variables associated with serum TSLP and cytokines associated with the late-onset eosinophilic asthma phenotype. RESULTS: Patients with TSLP-high asthma were older, late-onset, eosinophilic, and less atopic; had a higher BMI; more smoking history; and more asthma-COPD overlap, sleep apnea syndrome (SAS), hypertension, and heart disease. They also exhibited lower lung function with worse asthma symptoms and were more frequently on oral corticosteroids. Multivariable regression analyses adjusted for age and sex demonstrated that a high TSLP level was positively associated with later asthma onset, longer asthma duration, hypertension, higher blood eosinophils, BMI, smoking history, use of biologics, SAS, and high Fres, and was negatively associated with pollinosis. Among the serum cytokines, TSLP exhibited the strongest association with late-onset, eosinophilic asthma. CONCLUSION: High serum TSLP is a distinctive feature of late-onset, long-duration, eosinophilic asthma. Patients with asthma with this feature may be a unique target population for specific asthma therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Suzukawa, Maho&#xD;Ohta, Ken&#xD;Tashimo, Hiroyuki&#xD;Narumoto, Osamu&#xD;Hashimoto, Hiroya&#xD;Kita, Toshiyuki&#xD;Takato, Hazuki&#xD;Nagase, Hiroyuki&#xD;Kobayashi, Konomi&#xD;Yamaguchi, Masao&#xD;Abe, Masahiro&#xD;Ito, Ryoji&#xD;Endo, Takeo&#xD;Yanai, Hidetoshi&#xD;Chibana, Kenji&#xD;Hizawa, Nobuyuki&#xD;Tanimoto, Yasushi&#xD;Takagi, Koichi&#xD;Oguma, Tsuyoshi&#xD;Harada, Norihiro&#xD;Sagara, Hironori&#xD;Kato, Aika&#xD;Takata, Shohei&#xD;Komase, Yuko&#xD;Hyodo, Kentaro&#xD;Matsunaga, Kazuto&#xD;Tsujino, Kazuyuki&#xD;Niimi, Akio&#xD;Wakamatsu, Kentaro&#xD;Sugiura, Hisatoshi&#xD;Sakakibara, Yumi&#xD;Kamimura, Mitsuhiro&#xD;Shibata, Yoko&#xD;Tanaka, Goh&#xD;Nakamoto, Keitaro&#xD;Tamaki, Shinji&#xD;Minakata, Yoshiaki&#xD;Numata, Takanori&#xD;Saito, Akiko M&#xD;Kobayashi, Nobuyuki&#xD;Taniguchi, Masami&#xD;(TARG)&#xD;eng&#xD;AstraZeneca KK/&#xD;Denmark&#xD;Allergy. 2025 Oct 21. doi: 10.1111/all.70109.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41117145</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70109</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1158</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1158</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huber, S.</style></author><author><style face="normal" font="default" size="100%">Lang, R.</style></author><author><style face="normal" font="default" size="100%">Asam, C.</style></author><author><style face="normal" font="default" size="100%">Ferreira, F.</style></author><author><style face="normal" font="default" size="100%">Hawranek, T.</style></author><author><style face="normal" font="default" size="100%">Gadermaier, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biosciences, University of Salzburg, Salzburg, Austria.&#xD;Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High-affinity Bet v 1-specific secretory IgA antibodies in nasal fluids protect against birch pollen allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2267-2270</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Betula</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin A, Secretory</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">immunologic tests</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">pollen</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, non-financial support from Thermo Fisher Scientific, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Ferreira reports personal fees from HAL Allergy, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Swiss Institute of Allergy and Asthma Research (SIAF), personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from AllergenOnline, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Hawranek reports personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from ALK, personal fees from Novartis, personal fees from Takeda, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Bencard, personal fees from Lofarma, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Gadermaier reports personal fees from Bencard, personal fees from Compare,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. The rest of the authors declares no conflict of</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33594667</style></accession-num><notes><style face="normal" font="default" size="100%">Huber, Sara&#xD;Lang, Roland&#xD;Asam, Claudia&#xD;Ferreira, Fatima&#xD;Hawranek, Thomas&#xD;Gadermaier, Gabriele&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2267-2270. doi: 10.1111/all.14782. Epub 2021 Mar 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33594667</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8359210</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14782</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1063</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1063</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Czarnowicki, T.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author><author><style face="normal" font="default" size="100%">Villani, A. P.</style></author><author><style face="normal" font="default" size="100%">Glickman, J.</style></author><author><style face="normal" font="default" size="100%">Duca, E. D.</style></author><author><style face="normal" font="default" size="100%">Han, J.</style></author><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Lee, B. H.</style></author><author><style face="normal" font="default" size="100%">Rahman, A. H.</style></author><author><style face="normal" font="default" size="100%">Merad, M.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.&#xD;Human Immune Monitoring Center, Icahn School of Medicine at Mt. Sinai, New York, NY, USA.&#xD;Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Icahn School of Medicine at Mount Sinai, The Precision Immunology Institute, New York, NY, USA.&#xD;Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High-dimensional analysis defines multicytokine T-cell subsets and supports a role for IL-21 in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3080-3093</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/04/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukins/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocyte Subsets/cytology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-21</style></keyword><keyword><style face="normal" font="default" size="100%">CyTOF</style></keyword><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">Il-21</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">mass cytometry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33818809</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Flow cytometry is a well-accepted approach for immune profiling; however, its value is restricted by the limited number of markers that can be analyzed simultaneously. Mass cytometry/CyTOF offers broad-scale immune characterization integrating large number of parameters. While partial blood phenotyping was reported in atopic dermatitis (AD), patients&apos; comprehensive profiling, critical for leveraging new targeted treatments, is not available. IL-21 may be involved in inflammatory skin diseases but its role in AD is not well established. METHODS: We studied T-cell polarization in the blood of 20 moderate-to-severe AD and 15 controls. Using CyTOF and an unsupervised analysis, we measured the frequencies and mean metal intensities of activated polar CD4(+) /CD8(+) T-cell subsets. Immunohistochemistry, immunofluorescence, and qRT-PCR were used to analyze skin samples. RESULTS: Examining 24 surface, intracellular markers, and transcription factors, we identified six CD4(+) and five CD8(+) T-cell metaclusters. A CD4(+) skin-homing IL-13(+) monocytokine and a novel IL-13(+) IL-21(+) multicytokine metaclusters were increased in AD vs. controls (p &lt; .01). While IL-13 signature characterized both clusters, levels were significantly higher in the IL-21(+) group. Both clusters correlated with AD severity (r = 0.49, p = .029). Manual gating corroborated these results and identified additional multicytokine subsets in AD. Immunohistochemistry and immunofluorescence, validated by mRNA expression, displayed significantly increasedIL-21 counts and colocalization with IL-13/IL-4R in AD skin. CONCLUSION: A multicytokine signature characterizes moderate-to-severe AD, possibly explaining partial therapeutic responses to one cytokine targeting, particularly in severe patients. Prominent IL-21 signature in blood and skin hints for a potential pathogenic role of IL-21 in AD.</style></abstract><notes><style face="normal" font="default" size="100%">Czarnowicki, Tali&#xD;Kim, Hyun Je&#xD;Villani, Axel P&#xD;Glickman, Jacob&#xD;Duca, Ester Del&#xD;Han, Joseph&#xD;Pavel, Ana B&#xD;Lee, Brian H&#xD;Rahman, Adeeb H&#xD;Merad, Miriam&#xD;Krueger, James G&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3080-3093. doi: 10.1111/all.14845. Epub 2021 Apr 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33818809</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14845</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2950</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2950</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wirth, L.</style></author><author><style face="normal" font="default" size="100%">Weigel, W.</style></author><author><style face="normal" font="default" size="100%">Stamper, C. T.</style></author><author><style face="normal" font="default" size="100%">Kolmert, J.</style></author><author><style face="normal" font="default" size="100%">de Souza Ferreira, S.</style></author><author><style face="normal" font="default" size="100%">Hammer, Q.</style></author><author><style face="normal" font="default" size="100%">Sparreman Mikus, M.</style></author><author><style face="normal" font="default" size="100%">Theorell, J.</style></author><author><style face="normal" font="default" size="100%">Andersson, L. st</style></author><author><style face="normal" font="default" size="100%">Lantz, A. S.</style></author><author><style face="normal" font="default" size="100%">Wallen-Nielsen, E.</style></author><author><style face="normal" font="default" size="100%">Petren, A.</style></author><author><style face="normal" font="default" size="100%">Wheelock, C. E.</style></author><author><style face="normal" font="default" size="100%">Bossios, A.</style></author><author><style face="normal" font="default" size="100%">Lazarinis, N.</style></author><author><style face="normal" font="default" size="100%">Malinovschi, A.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Dahlen, B.</style></author><author><style face="normal" font="default" size="100%">Hochdorfer, T.</style></author><author><style face="normal" font="default" size="100%">Tibbitt, C. A.</style></author><author><style face="normal" font="default" size="100%">Dahlen, S. E.</style></author><author><style face="normal" font="default" size="100%">Yasinska, V.</style></author><author><style face="normal" font="default" size="100%">Mjosberg, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.&#xD;Mechanistic Biology and Profiling, Discovery Sciences, R&amp;D, AstraZeneca, Gothenburg, Sweden.&#xD;Department of Medicine Huddinge, Clinical Lung- and Allergy Research Unit (CLARU), Karolinska Institutet, Stockholm, Sweden.&#xD;Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Respiratory Medicine and Allergy, Karolinska University Hospital Huddinge, Stockholm, Sweden.&#xD;Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.&#xD;Karolinska Severe Asthma Center, Karolinska University Hospital Huddinge, Stockholm, Sweden.&#xD;Division of Lung and Airway Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Medical Sciences, Clinical Physiology, Uppsala University, Uppsala, Sweden.&#xD;Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High-Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab or Dupilumab Treatment in Severe Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2541-2556</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/immunology/diagnosis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells/immunology/metabolism/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphocytes/immunology/metabolism/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Immunophenotyping</style></keyword><keyword><style face="normal" font="default" size="100%">Ilc2</style></keyword><keyword><style face="normal" font="default" size="100%">Tc2</style></keyword><keyword><style face="normal" font="default" size="100%">Th2</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">employee. Jenny Mjosberg is an AstraZeneca grant holder for the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and has received honoraria for lectures from AstraZeneca, Chiesi, Novartis and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi outside the submitted work. Apostolos Bossios reports institutional fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Chiesi, GSK, and AstraZeneca and institutional grants from AstraZeneca</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. Nikolaos Lazarinis reports personal honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Chiesi, Sanofi, GSK outside the submitted work. Craig Wheelock</style></keyword><keyword><style face="normal" font="default" size="100%">reports institutional grants from AstraZeneca and Cayman Chemicals outside the</style></keyword><keyword><style face="normal" font="default" size="100%">scope of the current work. Christer Janson has received honoraria for educational</style></keyword><keyword><style face="normal" font="default" size="100%">activities and lectures from AstraZeneca, Boehringer Ingelheim, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Orion, Novartis and Sanofi outside the submitted work. Sven-Erik</style></keyword><keyword><style face="normal" font="default" size="100%">Dahlen reports institutional grants from AstraZeneca, Cayman Chemicals, GSK and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi and personal honoraria for lectures or advisory boards from Affibody,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GSK, Sanofi, and Teva. Valentyna Yasinska reports institutional fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Sanofi, GSK and AstraZeneca and institutional grants from AstraZeneca</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. All other authors have nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40566935</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Although the type 2 biologics mepolizumab and dupilumab show clinical efficacy in severe asthma, their influence on circulating lymphocytes is largely unknown. Here, we studied their impact on type 2 lymphocytes in severe asthma. METHODS: We performed high-parameter flow cytometry analysis of peripheral blood mononuclear cells from 40 patients with severe asthma before, and after 4 and 12 months of mepolizumab (n = 33) or dupilumab (n = 7) treatment, focusing on type 2 lymphocytes. Additionally, we performed single-cell RNA sequencing (scRNA-seq) (n = 3) and stimulation experiments of type 2 lymphocytes (n = 3) to explore transcriptional and functional changes associated with mepolizumab treatment. RESULTS: Mepolizumab treatment increased circulating type 2 innate lymphoid cell (ILC2), type 2 T helper (Th2) and type 2 cytotoxic (Tc2) cell frequencies, skewing ILC2 towards a CD117(low) signature with high CD62L expression, and Th2/Tc2 cells towards a CD45RA(-)CD62L(+) central memory phenotype. Dupilumab-treated patients also showed increased frequencies of total ILC2 and CD117(low) ILC2. Mepolizumab treatment reduced the expression of tissue homing receptors CXCR4 in ILC2, and GPR183 in ILC2, Th2, and Tc2 cells while enhancing their type 2 cytokine producing capability in response to alarmins. CONCLUSION: Mepolizumab increases the frequencies of circulating ILC2, Th2, and Tc2 cells, with reduced tissue homing receptor expression but increased type 2 cytokine production potential. This reveals a potentially new mechanism for how mepolizumab reduces airway inflammation by re-directing trafficking of inflammatory type 2 lymphocytes away from airway-homing, with implications for the possibility of achieving biologics-free remission in asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Wirth, Lorenz&#xD;Weigel, Whitney&#xD;Stamper, Christopher T&#xD;Kolmert, Johan&#xD;de Souza Ferreira, Sabrina&#xD;Hammer, Quirin&#xD;Sparreman Mikus, Maria&#xD;Theorell, Jakob&#xD;Andersson, Lars 1st&#xD;Lantz, Ann-Sofie&#xD;Wallen-Nielsen, Eva&#xD;Petren, Anne&#xD;Wheelock, Craig E&#xD;Bossios, Apostolos&#xD;Lazarinis, Nikolaos&#xD;Malinovschi, Andrei&#xD;Janson, Christer&#xD;Dahlen, Barbro&#xD;Hochdorfer, Thomas&#xD;Tibbitt, Christopher Andrew&#xD;Dahlen, Sven-Erik&#xD;Yasinska, Valentyna&#xD;Mjosberg, Jenny&#xD;eng&#xD;This project has received funding from the European UnionCloseCurlyQuote;s Horizon 2020 research and innovation programme under the Marie Sklstrok;odowska-Curie grant agreement No 813343. The study was further supported by funds from the Swedish Heart-Lung Foundation (to JM, BD, AB (2020-0619 and 2022-0478), CEW and SED), the Center for Innovative Medicine (CIMED, to JM and BD), the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (to JM, BD and SED), Torst/&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2541-2556. doi: 10.1111/all.16633. Epub 2025 Jun 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40566935</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444942</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16633</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>435</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">435</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klueber, J.</style></author><author><style face="normal" font="default" size="100%">Czolk, R.</style></author><author><style face="normal" font="default" size="100%">Codreanu-Morel, F.</style></author><author><style face="normal" font="default" size="100%">Montamat, G.</style></author><author><style face="normal" font="default" size="100%">Revets, D.</style></author><author><style face="normal" font="default" size="100%">Konstantinou, M.</style></author><author><style face="normal" font="default" size="100%">Cosma, A.</style></author><author><style face="normal" font="default" size="100%">Hunewald, O.</style></author><author><style face="normal" font="default" size="100%">Skov, P. S.</style></author><author><style face="normal" font="default" size="100%">Ammerlaan, W.</style></author><author><style face="normal" font="default" size="100%">Hilger, C.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Kuehn, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, University of Southern Denmark, Odense C, Denmark.&#xD;Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.&#xD;Department of Allergology and Immunology, Centre Hospitalier de Luxembourg-Kanner Klinik, Luxembourg, Luxembourg.&#xD;National Cytometry Platform, Luxembourg Institute of Health, Strassen, Luxembourg.&#xD;RefLab ApS, Copenhagen, Denmark.&#xD;Institute of Immunology, National University of Copenhagen, Copenhagen, Denmark.&#xD;Integrated BioBank of Luxembourg, Luxembourg Institute of Health, Dudelange, Luxembourg.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High-dimensional immune profiles correlate with phenotypes of peanut allergy during food-allergic reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1020-1035</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/06/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">immune cell phenotyping</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">oral food challenge</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35700055</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food challenges carry a burden of safety, effort and resources. Clinical reactivity and presentation, such as thresholds and symptoms, are considered challenging to predict ex vivo. AIMS: To identify changes of peripheral immune signatures during oral food challenges (OFC) that correlate with the clinical outcome in patients with peanut allergy (PA). METHODS: Children with a positive (OFC(+) , n = 16) or a negative (OFC(-) , n = 10) OFC-outcome were included (controls, n = 7). Single-cell mass cytometry/unsupervised analysis allowed unbiased immunophenotyping during OFC. RESULTS: Peripheral immune profiles correlated with OFC outcome. OFC(+) -profiles revealed mainly decreased Th2 cells, memory Treg and activated NK cells, which had an increased homing marker expression signifying immune cell migration into effector tissues along with symptom onset. OFC(-) -profiles had also signs of ongoing inflammation, but with a signature of a controlled response, lacking homing marker expression and featuring a concomitant increase of Th2-shifted CD4(+) T cells and Treg cells. Low versus high threshold reactivity-groups had differential frequencies of intermediate monocytes and myeloid dendritic cells at baseline. Low threshold was associated with increased CD8(+) T cells and reduced memory cells (central memory [CM] CD4(+) [Th2] T cells, CM CD8(+) T cells, Treg). Immune signatures also discriminated patients with preferential skin versus gastrointestinal symptoms, whereby skin signs correlated with increased expression of CCR4, a molecule enabling skin trafficking, on various immune cell types. CONCLUSION: We showed that peripheral immune signatures reflected dynamics of clinical outcome during OFC with peanut. Those immune alterations hold promise as a basis for predictive OFC biomarker discovery to monitor disease outcome and therapy of PA.</style></abstract><notes><style face="normal" font="default" size="100%">Klueber, Julia&#xD;Czolk, Rebecca&#xD;Codreanu-Morel, Francoise&#xD;Montamat, Guillem&#xD;Revets, Dominique&#xD;Konstantinou, Maria&#xD;Cosma, Antonio&#xD;Hunewald, Oliver&#xD;Skov, Per Stahl&#xD;Ammerlaan, Wim&#xD;Hilger, Christiane&#xD;Bindslev-Jensen, Carsten&#xD;Ollert, Markus&#xD;Kuehn, Annette&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):1020-1035. doi: 10.1111/all.15408. Epub 2022 Jun 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35700055</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15408</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>862</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">862</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hellkvist, L.</style></author><author><style face="normal" font="default" size="100%">Hjalmarsson, E.</style></author><author><style face="normal" font="default" size="100%">Weinfeld, D.</style></author><author><style face="normal" font="default" size="100%">Dahl, A.</style></author><author><style face="normal" font="default" size="100%">Karlsson, A.</style></author><author><style face="normal" font="default" size="100%">Westman, M.</style></author><author><style face="normal" font="default" size="100%">Lundkvist, K.</style></author><author><style face="normal" font="default" size="100%">Winqvist, O.</style></author><author><style face="normal" font="default" size="100%">Georen, S. K.</style></author><author><style face="normal" font="default" size="100%">Westin, U.</style></author><author><style face="normal" font="default" size="100%">Cardell, L. O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden.&#xD;Asthma and Allergy Clinic Outpatient Unit (adults), Department of Internal Medicine, South Alvsborgs Central Hospital, Boras, Sweden.&#xD;Departments of Biological and Environmental Sciences, Gothenburg University, Gothenburg, Sweden.&#xD;Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.&#xD;ABC Labs, Biomedicum, Stockholm, Sweden.&#xD;Laboratory of Clinical and Experimental Allergy Research, Department of Otorhinolaryngology Malmo, Lund University, Skane University Hospital, Malmo, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">High-dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">883-896</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/08/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Poaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34379802</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The same dosing schedule, 1000 SQ-U times three, with one-month intervals, have been evaluated in most trials of intralymphatic immunotherapy (ILIT) for the treatment of allergic rhinitis (AR). The present studies evaluated if a dose escalation in ILIT can enhance the clinical and immunological effects, without compromising safety. METHODS: Two randomized double-blind placebo-controlled trials of ILIT for grass pollen-induced AR were performed. The first included 29 patients that had recently ended 3 years of SCIT and the second contained 39 not previously vaccinated patients. An up-dosage of 1000-3000-10,000 (5000 + 5000 with 30 minutes apart) SQ-U with 1 month in between was evaluated. RESULTS: Doses up to 10,000 SQ-U were safe after recent SCIT. The combined symptom-medication scores (CSMS) were reduced by 31% and the grass-specific IgG4 levels in blood were doubled. In ILIT de novo, the two first patients that received active treatment developed serious adverse reactions at 5000 SQ-U. A modified up-dosing schedule; 1000-3000-3000 SQ-U appeared to be safe but failed to improve the CSMS. Flow cytometry analyses showed increased activation of lymph node-derived dendritic but not T cells. Quality of life and nasal provocation response did not improve in any study. CONCLUSION: Intralymphatic immunotherapy in high doses after SCIT appears to further reduce grass pollen-induced seasonal symptoms and may be considered as an add-on treatment for patients that do not reach full symptom control after SCIT. Up-dosing schedules de novo with three monthly injections that exceeds 3000 SQ-U should be avoided.</style></abstract><notes><style face="normal" font="default" size="100%">Hellkvist, Laila&#xD;Hjalmarsson, Eric&#xD;Weinfeld, Dan&#xD;Dahl, Aslog&#xD;Karlsson, Agneta&#xD;Westman, Marit&#xD;Lundkvist, Karin&#xD;Winqvist, Ola&#xD;Georen, Susanna Kumlien&#xD;Westin, Ulla&#xD;Cardell, Lars Olaf&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):883-896. doi: 10.1111/all.15042. Epub 2021 Aug 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34379802</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15042</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1256</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1256</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, S.</style></author><author><style face="normal" font="default" size="100%">He, Y.</style></author><author><style face="normal" font="default" size="100%">Liang, H.</style></author><author><style face="normal" font="default" size="100%">Gao, J.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Xie, X.</style></author><author><style face="normal" font="default" size="100%">Sun, M.</style></author><author><style face="normal" font="default" size="100%">Yuan, C.</style></author><author><style face="normal" font="default" size="100%">Ma, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biostatistics and Epidemiology, School of Public Health, China Medical University, Shenyang, China.&#xD;Department of Big Data and Health Science, School of Public Health, Zhejiang University School of Medicine, Hangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Higher environmental composite quality index score and risk of asthma and allergy in Northeast China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1875-1879</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">environmental composite quality index score</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33247966</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Shen&#xD;He, Yu&#xD;Liang, Hong&#xD;Gao, Jie&#xD;Li, Yinbang&#xD;Li, Yahong&#xD;Wang, Lining&#xD;Xie, Xili&#xD;Sun, Ming&#xD;Yuan, Changzheng&#xD;Ma, Yanan&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1875-1879. doi: 10.1111/all.14672. Epub 2020 Dec 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33247966</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14672</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>644</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">644</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lunjani, N.</style></author><author><style face="normal" font="default" size="100%">Albrich, W. C.</style></author><author><style face="normal" font="default" size="100%">Suh, N.</style></author><author><style face="normal" font="default" size="100%">Barda, B.</style></author><author><style face="normal" font="default" size="100%">Finnegan, L. A.</style></author><author><style face="normal" font="default" size="100%">Dam, S. A.</style></author><author><style face="normal" font="default" size="100%">Walter, J.</style></author><author><style face="normal" font="default" size="100%">Sadlier, C.</style></author><author><style face="normal" font="default" size="100%">Horgan, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Toole, P. W.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">APC Microbiome Ireland, University College Cork, National University of Ireland, Cork, Ireland.&#xD;Division of Infectious Diseases &amp; Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.&#xD;Division of Intensive Care, Geneva University Hospitals and the University of Geneva Faculty of Medicine, Geneva, Switzerland.&#xD;Fondazione Epatocentro Ticino and Clinica Luganese, Lugano, Switzerland.&#xD;Seqbiome, Cork, Ireland.&#xD;Department of Medicine, University College Cork, National University of Ireland, Cork, Ireland.&#xD;Department of Infectious Diseases, Cork University Hospital, Cork, Ireland.&#xD;School of Microbiology, University College Cork, National University of Ireland, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Higher levels of bacterial DNA in serum associate with severe and fatal COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1312-1314</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/01/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">DNA, Bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperplasia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35020222</style></accession-num><notes><style face="normal" font="default" size="100%">Lunjani, Nonhlanhla&#xD;Albrich, Werner C&#xD;Suh, Noemie&#xD;Barda, Beatrice&#xD;Finnegan, Laura A&#xD;Dam, Sarita A&#xD;Walter, Jens&#xD;Sadlier, Corinna&#xD;Horgan, Mary&#xD;O&apos;Toole, Paul W&#xD;O&apos;Mahony, Liam&#xD;eng&#xD;SFI_/Science Foundation Ireland/Ireland&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1312-1314. doi: 10.1111/all.15218. Epub 2022 Jan 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35020222</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9303653 GSK and Chiesi. LOM has participated in speaker&apos;s bureau for Nestle, Nutricia, Reckitt, and Abbott. WCA has participated in advisory boards for Pfizer, MSD, and Sanofi, with reimbursements paid to his institution. LAF and SAD are employees of Seqbiome. None of the other authors report any conflict of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15218</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2611</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2611</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chantran, Y.</style></author><author><style face="normal" font="default" size="100%">Choi, S.</style></author><author><style face="normal" font="default" size="100%">Roda, C.</style></author><author><style face="normal" font="default" size="100%">Nicaise-Roland, P.</style></author><author><style face="normal" font="default" size="100%">de Chaisemartin, L.</style></author><author><style face="normal" font="default" size="100%">Chollet-Martin, S.</style></author><author><style face="normal" font="default" size="100%">Arock, M.</style></author><author><style face="normal" font="default" size="100%">Ranciere, F.</style></author><author><style face="normal" font="default" size="100%">Momas, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environmental Risk Assessment (HERA) Team, CRESS, Universite Paris Cite, Inserm, INRAE, Paris, France.&#xD;Molecular Platform for the Analysis of cKIT Mutations and Other Gene Defects, ECNM Reference Center, Saint-Antoine Hospital, DMU BioGeMH, AP-HP.Sorbonne University, Centre National de Reference des Mastocytoses, CEREMAST, Filiere MaRIH, Paris, France.&#xD;Department of Biological Immunology, Saint-Antoine Hospital, DMU BioGeMH, AP-HP, Sorbonne University, Paris, France.&#xD;Department of Immunology, UF Autoimmunity and Hypersensitivity, Bichat Hospital, DMU BioGeM, AP-HP Nord, Paris, France.&#xD;Department of Biological Hematology, Groupe Hospitalier Pitie-Salpetriere-C. Foix, DMU BioGeMH, AP-HP, Sorbonne University, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Higher levels of basal serum tryptase are associated with sensitization, FeNO, allergic morbidity, and lower control of allergic asthma in teenagers from the PARIS birth cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">584-587</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/08/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Tryptase</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">birth cohort</style></keyword><keyword><style face="normal" font="default" size="100%">drug reactions</style></keyword><keyword><style face="normal" font="default" size="100%">eczema/dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">teenagers</style></keyword><keyword><style face="normal" font="default" size="100%">received honoraria from ThermoFisher Scientific, and research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Blueprint Medicines and ThermoFisher Scientific. M. Arock receives research grant</style></keyword><keyword><style face="normal" font="default" size="100%">from Blueprint Medicines, and serves on advisory boeard and receives honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">from AB Science, Blueprint Medicines, Novartis and ThermoFisher Scientific. The</style></keyword><keyword><style face="normal" font="default" size="100%">rest of the authors declare that they have no relevant conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39155860</style></accession-num><notes><style face="normal" font="default" size="100%">Chantran, Yannick&#xD;Choi, Simone&#xD;Roda, Celine&#xD;Nicaise-Roland, Pascale&#xD;de Chaisemartin, Luc&#xD;Chollet-Martin, Sylvie&#xD;Arock, Michel&#xD;Ranciere, Fanny&#xD;Momas, Isabelle&#xD;eng&#xD;261357/Mechanisms of the Development of Allergy (MeDALL)/&#xD;Universite Paris Descartes/&#xD;DASES/&#xD;Thermo Fisher Scientific/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):584-587. doi: 10.1111/all.16284. Epub 2024 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39155860</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804298</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16284</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1076</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1076</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kamphorst, K.</style></author><author><style face="normal" font="default" size="100%">Vlieger, A. M.</style></author><author><style face="normal" font="default" size="100%">Oosterloo, B. C.</style></author><author><style face="normal" font="default" size="100%">Waarlo, S.</style></author><author><style face="normal" font="default" size="100%">van Elburg, R. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Amsterdam Gastroenterology, Metabolism &amp; Nutrition, Amsterdam Reproduction &amp; Development Amsterdam, Emma Children&apos;s Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Pediatrics, St. Antonius Hospital, Nieuwegein, The Netherlands.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.&#xD;Division of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Higher risk of allergies at 4-6 years of age after systemic antibiotics in the first week of life</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2599-2602</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Bacterial Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33772817</style></accession-num><notes><style face="normal" font="default" size="100%">Kamphorst, Kim&#xD;Vlieger, Arine M&#xD;Oosterloo, Berthe C&#xD;Waarlo, Susan&#xD;van Elburg, Ruurd M&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2599-2602. doi: 10.1111/all.14829. Epub 2021 May 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33772817</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14829</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1941</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1941</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoehener, C.</style></author><author><style face="normal" font="default" size="100%">Engeroff, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Cell Biology, University of Bern, Bern, Switzerland.&#xD;Department of BioMedical Research, University of Bern, Bern, Switzerland.&#xD;Department of Immunology, University Clinic of Rheumatology and Immunology, Inselspital, University of Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hinge region modification for the engineering of antibody function</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1717-1718</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/02/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">*Protein Engineering</style></keyword><keyword><style face="normal" font="default" size="100%">ChiLob7/4</style></keyword><keyword><style face="normal" font="default" size="100%">IgG2</style></keyword><keyword><style face="normal" font="default" size="100%">agonistic antibody</style></keyword><keyword><style face="normal" font="default" size="100%">anti-CD40</style></keyword><keyword><style face="normal" font="default" size="100%">disulfide bonds</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36805570</style></accession-num><notes><style face="normal" font="default" size="100%">Hoehener, Cristina&#xD;Engeroff, Paul&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1717-1718. doi: 10.1111/all.15684. Epub 2023 Mar 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36805570</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15684</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1335</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1335</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mommert, S.</style></author><author><style face="normal" font="default" size="100%">Schaper, J. T.</style></author><author><style face="normal" font="default" size="100%">Schaper-Gerhardt, K.</style></author><author><style face="normal" font="default" size="100%">Gutzmer, R.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Histamine down-regulates the FCERI alpha-chain expression in human IL-4-activated M2 macrophages</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1250-1254</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/09/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Histamine</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine Release</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-4/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgE</style></keyword><keyword><style face="normal" font="default" size="100%">high-affinity Fc receptor for IgE</style></keyword><keyword><style face="normal" font="default" size="100%">histamine</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32882088</style></accession-num><notes><style face="normal" font="default" size="100%">Mommert, Susanne&#xD;Schaper, Judith Tabea&#xD;Schaper-Gerhardt, Katrin&#xD;Gutzmer, Ralf&#xD;Werfel, Thomas&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1250-1254. doi: 10.1111/all.14576. Epub 2020 Sep 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32882088</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14576</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3096</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3096</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Goh, S. J. R.</style></author><author><style face="normal" font="default" size="100%">Lu, H. H. W.</style></author><author><style face="normal" font="default" size="100%">Scull, K. E.</style></author><author><style face="normal" font="default" size="100%">Pandey, K.</style></author><author><style face="normal" font="default" size="100%">Dorvash, M.</style></author><author><style face="normal" font="default" size="100%">Deckert, K.</style></author><author><style face="normal" font="default" size="100%">Puy, R.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">Purcell, A. W.</style></author><author><style face="normal" font="default" size="100%">Mifsud, N. A.</style></author><author><style face="normal" font="default" size="100%">Illing, P. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.&#xD;Allergy, Asthma and Clinical Immunology Service, Alfred Health, Melbourne, Victoria, Australia.&#xD;Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">HLA-A*02:01 Presents Penicillin-Modified Cysteinylated Peptides for T Cell Recognition</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3165-3177</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/09/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Peptides/immunology/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">*HLA-A2 Antigen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Antigen, T-Cell/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Penicillins/immunology/chemistry/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Haptens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Cysteine/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigen Presentation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Ligands</style></keyword><keyword><style face="normal" font="default" size="100%">Hla</style></keyword><keyword><style face="normal" font="default" size="100%">T cell-mediated hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin</style></keyword><keyword><style face="normal" font="default" size="100%">beta-lactam antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Grey Wolf Therapeutics (United Kingdom), a shareholder and scientific advisor for</style></keyword><keyword><style face="normal" font="default" size="100%">Evaxion Biotech (Denmark), and a co-founder of Resseptor Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">(Australia). S.J.R.G. is currently an employee of Resseptor Therapeutics. These</style></keyword><keyword><style face="normal" font="default" size="100%">organisations had no role in the design of the study</style></keyword><keyword><style face="normal" font="default" size="100%">in the collection, analyses</style></keyword><keyword><style face="normal" font="default" size="100%">or interpretation of data</style></keyword><keyword><style face="normal" font="default" size="100%">in the writing of the manuscript</style></keyword><keyword><style face="normal" font="default" size="100%">or in the decision</style></keyword><keyword><style face="normal" font="default" size="100%">to publish the results.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40906332</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A subset of patients experience immune-mediated hypersensitivity reactions towards beta-lactam antibiotics, with drug-specific T cells implicated as one of the causative factors. The principal mechanism is thought to involve chemical haptenation of self-peptides, resulting in novel peptide drug-adducts that may trigger T cell recognition. Understanding the interactions between the beta-lactam drug, the T cell receptor (TCR) and the peptide/human leukocyte antigen (pHLA) complex is critical to gain further mechanistic insights into these hypersensitivity reactions. This study aimed to 1) explore the array of haptenated ligands presented by HLA-A*02:01, 2) evaluate the repertoire of T cells involved in penicillin-induced reactions in a hypersensitive patient and 3) determine if a dominant penicillin-specific TCR clonotype recognises haptenated HLA peptides. METHOD: An immunopeptidomics approach was applied to identify benzylpenicillin (BP)-modified peptide ligands within the HLA-A*02:01 ligandome. The drug-reactive TCR repertoire was analysed by single-cell sequencing of CD8(+) T cells expanded in the presence of BP, and the dominant TCR assayed for reactivity in a reporter cell line. RESULT: We report that BP modifies cysteine in preference to lysine residues within the HLA-A*02:01 immunopeptidome. This modification occurs via cysteine-drug conjugate formation, in conjunction with disulphide-mediated peptide modification, which has not previously been considered in the context of drug hypersensitivities. Furthermore, we demonstrate that a BP-specific TCR expanded from a patient reacts towards a reduction-sensitive epitope, consistent with a BP-cysteine adduct disulphide linked to a cysteine residue within the T cell epitope. CONCLUSION: Our study provides evidence that cysteine-penicillin adducts can be accommodated by HLA ligands with the potential to induce T cell-mediated allergic reactions.</style></abstract><notes><style face="normal" font="default" size="100%">Goh, Shawn J R&#xD;Lu, Hovey H W&#xD;Scull, Katherine E&#xD;Pandey, Kirti&#xD;Dorvash, Mohammadreza&#xD;Deckert, Kirsten&#xD;Puy, Robert&#xD;O&apos;Hehir, Robyn E&#xD;Purcell, Anthony W&#xD;Mifsud, Nicole A&#xD;Illing, Patricia T&#xD;eng&#xD;National Health and Medical Research Council/&#xD;Faculty of Medicine, Nursing and Health Sciences, Monash University/&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3165-3177. doi: 10.1111/all.70025. Epub 2025 Sep 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40906332</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590334</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70025</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>608</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">608</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kidoguchi, M.</style></author><author><style face="normal" font="default" size="100%">Morii, W.</style></author><author><style face="normal" font="default" size="100%">Noguchi, E.</style></author><author><style face="normal" font="default" size="100%">Yuta, A.</style></author><author><style face="normal" font="default" size="100%">Ogawa, Y.</style></author><author><style face="normal" font="default" size="100%">Nakamura, T.</style></author><author><style face="normal" font="default" size="100%">Kikuoka, H.</style></author><author><style face="normal" font="default" size="100%">Kouzaki, H.</style></author><author><style face="normal" font="default" size="100%">Arai, H.</style></author><author><style face="normal" font="default" size="100%">Ii, R.</style></author><author><style face="normal" font="default" size="100%">Adachi, N.</style></author><author><style face="normal" font="default" size="100%">Koyama, K.</style></author><author><style face="normal" font="default" size="100%">Ninomiya, T.</style></author><author><style face="normal" font="default" size="100%">Imoto, Y.</style></author><author><style face="normal" font="default" size="100%">Sakashita, M.</style></author><author><style face="normal" font="default" size="100%">Fujieda, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Genetics, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.&#xD;Division of Otorhinolaryngology and Head &amp; Neck Surgery, Department of Sensory and Locomotor Medicine, Faculty of Medical Science, University of Fukui, Fukui, Japan.&#xD;Yuta Clinic, Mie, Japan.&#xD;Department of Otorhinolaryngology and Head &amp; Neck Surgery, Shiga University of Medical Science, Shiga, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">HLA-DPB1*05:01 genotype is associated with poor response to sublingual immunotherapy for Japanese cedar pollinosis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1633-1635</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/13</style></edition><section><style face="normal" font="default" size="100%">1633</style></section><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Cryptomeria</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">HLA-DP beta-Chains</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Japan</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/complications/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hla-dpb1</style></keyword><keyword><style face="normal" font="default" size="100%">Japanese cedar pollinosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacogenetics</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35150450</style></accession-num><notes><style face="normal" font="default" size="100%">Kidoguchi, Masanori&#xD;Morii, Wataru&#xD;Noguchi, Emiko&#xD;Yuta, Atsushi&#xD;Ogawa, Yukiko&#xD;Nakamura, Takako&#xD;Kikuoka, Hirotaka&#xD;Kouzaki, Hideaki&#xD;Arai, Hiroyuki&#xD;Ii, Rieko&#xD;Adachi, Naoto&#xD;Koyama, Keisuke&#xD;Ninomiya, Takahiro&#xD;Imoto, Yoshimasa&#xD;Sakashita, Masafumi&#xD;Fujieda, Shigeharu&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1633-1635. doi: 10.1111/all.15254. Epub 2022 Feb 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35150450</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15254</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2643</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2643</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhou, X.</style></author><author><style face="normal" font="default" size="100%">Dunham, D.</style></author><author><style face="normal" font="default" size="100%">Sindher, S. B.</style></author><author><style face="normal" font="default" size="100%">Long, A.</style></author><author><style face="normal" font="default" size="100%">Fernandes, A.</style></author><author><style face="normal" font="default" size="100%">Chang, I.</style></author><author><style face="normal" font="default" size="100%">Assa&apos;ad, A.</style></author><author><style face="normal" font="default" size="100%">Pongracic, J.</style></author><author><style face="normal" font="default" size="100%">Spergel, J. M.</style></author><author><style face="normal" font="default" size="100%">Tam, J.</style></author><author><style face="normal" font="default" size="100%">Tilles, S.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Boyd, S. D.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.&#xD;Division of Allergy and Immunology, Cincinnati Children&apos;s Medical Center, Cincinnati, Ohio, USA.&#xD;Division of Allergy and Immunology, The Ann and Robert H. Lurie Children&apos;s Hospital of Chicago, Chicago, Illinois, USA.&#xD;Division of Allergy and Immunology, Department of Pediatrics, The Children&apos;s Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;Division of Clinical Immunology and Allergy, Children&apos;s Hospital Los Angeles, Los Angeles, California, USA.&#xD;Seattle Allergy and Asthma Research Institute, Seattle, Washington, USA.&#xD;University of Washington, Seattle, Washington, USA.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Human Immune Monitoring Center, Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">HLA-DR(+) regulatory T cells and IL-10 are associated with success or failure of desensitization outcomes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">762-774</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/09/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-10/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*HLA-DR Antigens/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">of Allergy and Infectious Diseases (NIAID), National Heart, Lung, and Blood</style></keyword><keyword><style face="normal" font="default" size="100%">Institute (NHLBI), National Institute of Environmental Health Sciences (NIEHS),</style></keyword><keyword><style face="normal" font="default" size="100%">and Food Allergy Research &amp; Education (FARE)</style></keyword><keyword><style face="normal" font="default" size="100%">Stock options from IgGenix, Seed</style></keyword><keyword><style face="normal" font="default" size="100%">Health, ClostraBio, Cour, Alladapt</style></keyword><keyword><style face="normal" font="default" size="100%">Advisor at Cour Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">Consultant for</style></keyword><keyword><style face="normal" font="default" size="100%">Excellergy, Red tree ventures, Before Brands, Alladapt, Cour, Latitude,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">Co-founder of Before Brands, Alladapt, Latitude, and</style></keyword><keyword><style face="normal" font="default" size="100%">IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">National Scientific Committee member at Immune Tolerance Network (ITN),</style></keyword><keyword><style face="normal" font="default" size="100%">and National Institutes of Health (NIH) clinical research centers</style></keyword><keyword><style face="normal" font="default" size="100%">patents</style></keyword><keyword><style face="normal" font="default" size="100%">include, &quot;Mixed allergen com-position and methods for using the same,&quot;</style></keyword><keyword><style face="normal" font="default" size="100%">&quot;Granulocyte-based methods for detecting and monitoring immune system disorders,&quot;</style></keyword><keyword><style face="normal" font="default" size="100%">and &quot;Methods and Assays for Detecting and Quantifying Pure Subpopulations of</style></keyword><keyword><style face="normal" font="default" size="100%">White Blood Cells in Immune System Disorders&quot;. Dr. Tilles reports Consultant for</style></keyword><keyword><style face="normal" font="default" size="100%">FARE, Stallergenes Greer, and Nestle Health Science. Dr. Long reports consulting</style></keyword><keyword><style face="normal" font="default" size="100%">fees from COUR Pharmaceuticals Development Company Inc. and study support from</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals Inc. in the form of study drug. Dr. Wang reports</style></keyword><keyword><style face="normal" font="default" size="100%">research grants to the institution from NIAID, Aimmune, DBV, and Siolta</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy fees from ALK Abello, DBV, and Novartis.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39291303</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Omalizumab (XOLAIR(R))-assisted multi-food oral immunotherapy (mOIT) has been shown to safely, effectively, and rapidly desensitize patients with multiple food allergies. In our clinical trial (NCT02626611) on omalizumab-assisted mOIT, different desensitization outcomes (success or failure of desensitization) were observed following a period of either continued or discontinued mOIT. However, the association between the immunological changes induced by omalizumab-assisted mOIT and desensitization outcomes has not yet been fully elucidated. In this study, due to the key roles of regulatory T (Treg) cells and the type 2 helper T cell (Th2) pathway in immune tolerance to food allergens, we aimed to characterize their association with the desensitization outcomes of omalizumab-assisted mOIT. METHODS: Mass cytometry and multiplex cytokine assays were performed on blood samples obtained from participants with allergies to peanut, cashew, or milk in our phase 2 clinical study (NCT02626611). Comprehensive statistical and bioinformatic analyses were conducted on high-dimensional cytometry-based single-cell data and high-throughput multiplex cytokine data. RESULTS: Our results demonstrated that the frequency of HLA-DR(+) Treg cells, and the production of Th2 cytokines (IL-4, IL-5, IL-13, and IL-9) as well as the immunoregulatory cytokine IL-10 by peripheral blood mononuclear cells (PBMCs) was significantly increased in cultures with allergen compared to cultures with media alone at baseline (Week 0). We also observed increased frequency of allergen responsive HLA-DR(+) Treg cells and enhanced production of IL-10 by PBMCs in participants who achieved successful desensitization compared to those with failure of desensitization. However, the production of Th2 cytokines by PBMCs did not show significant differences between participants with different desensitization outcomes (success vs. failure of desensitization), despite omalizumab-assisted mOIT inducing a significant reduction in the production of Th2 cytokines. CONCLUSIONS: We demonstrated that the frequency of HLA-DR(+) Treg cells and IL-10 cytokine production by PBMCs are associated with desensitization outcomes of omalizumab-assisted mOIT. These findings suggest potential immunological parameters that could be targeted to enhance desensitization success rates.</style></abstract><notes><style face="normal" font="default" size="100%">Zhou, Xiaoying&#xD;Dunham, Diane&#xD;Sindher, Sayantani B&#xD;Long, Andrew&#xD;Fernandes, Andrea&#xD;Chang, Iris&#xD;Assa&apos;ad, Amal&#xD;Pongracic, Jacqueline&#xD;Spergel, Jonathan M&#xD;Tam, Jonathan&#xD;Tilles, Stephen&#xD;Wang, Julie&#xD;Boyd, Scott D&#xD;Chinthrajah, R Sharon&#xD;Nadeau, Kari C&#xD;eng&#xD;the Sean N. Parker Center for Allergy and Asthma Research at Stanford University/&#xD;Bezos Foundation/&#xD;NH/NIH HHS/&#xD;Sunshine foundation/&#xD;R01 AI140134/AI/NIAID NIH HHS/&#xD;Hartman Family Foundation/&#xD;Clinical Trial, Phase II&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):762-774. doi: 10.1111/all.16311. Epub 2024 Sep 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39291303</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11893263</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16311</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2304</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2304</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zemelka-Wiacek, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Casale, T. B.</style></author><author><style face="normal" font="default" size="100%">Dramburg, S.</style></author><author><style face="normal" font="default" size="100%">Jahnz-Rozyk, K.</style></author><author><style face="normal" font="default" size="100%">Kosowska, A.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P. M.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Departments of Medicine and Pediatrics and Division of Allergy and Immunology, Joy McCann Culverhouse Clinical Research Center, University of South Florida, Tampa, Florida, USA.&#xD;Department of Pediatric Respiratory Care, Immunology and Critical Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Internal Diseases, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine-National Research Institute, Warsaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hot topics in allergen immunotherapy, 2023: Current status and future perspective</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">823-842</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Artificial Intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy (AIT)</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy endpoint</style></keyword><keyword><style face="normal" font="default" size="100%">novel vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">trial design</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37984449</style></accession-num><abstract><style face="normal" font="default" size="100%">The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality-of-life improvements and cost-effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen-specific T- and B-cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen-specific IgE and increased IgG(1) and IgG(4), decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non-omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as well as real-world evidence, allow more flexibility and cost reduction. The analyses of AIT cost-effectiveness show a clear long-term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects.</style></abstract><notes><style face="normal" font="default" size="100%">Zemelka-Wiacek, Magdalena&#xD;Agache, Ioana&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Casale, Thomas B&#xD;Dramburg, Stephanie&#xD;Jahnz-Rozyk, Karina&#xD;Kosowska, Anna&#xD;Matricardi, Paolo M&#xD;Pfaar, Oliver&#xD;Shamji, Mohamed H&#xD;Jutel, Marek&#xD;eng&#xD;SUBZ.A020.22.060/Ministry of Health/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):823-842. doi: 10.1111/all.15945. Epub 2023 Nov 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37984449</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15945</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2462</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2462</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Richter, H.</style></author><author><style face="normal" font="default" size="100%">Bruggenjurgen, B.</style></author><author><style face="normal" font="default" size="100%">Vogelberg, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Epidemiology, IQVIA, Frankfurt am Main, Germany.&#xD;Institute for Health Services Research and Technical Orthopedics, Orthopedic Clinic of Hannover Medical School, Hannover, Germany.&#xD;Department of Pneumology and Allergology, Carl Gustav Carus University Clinic, Dresden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1042-1051</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/03/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite</style></keyword><keyword><style face="normal" font="default" size="100%">long-term effect</style></keyword><keyword><style face="normal" font="default" size="100%">real-world evidence</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38429981</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The German Therapy Allergen Ordinance (TAO) triggered an ongoing upheaval in the market for house dust mite (HDM) allergen immunotherapy (AIT) products. Three HDM subcutaneous AIT (SCIT) products hold approval in Germany and therefore will be available after the scheduled completion of the TAO procedure in 2026. In general, data from clinical trials on the long-term effectiveness of HDM AIT are rare. We evaluated real-world data (RWD) in a retrospective, observational cohort study based on a longitudinal claims database including 60% of all German statutory healthcare prescriptions to show the long-term effectiveness of one of these products in daily life. Aim of this analysis was to provide a per product analysis on effectiveness of mite AIT as it is demanded by international guidelines on AIT. METHODS: Subjects between 5 and 70 years receiving their first (index) prescription of SCIT with a native HDM product (SCIT group) between 2009 and 2013 were included. The exactly 3:1 matched control group received prescriptions for only symptomatic AR medication (non-AIT group); the evaluation period for up to 6 years of follow-up ended in February 2017. Study endpoints were the progression of allergic rhinitis (AR) and asthma, asthma occurrence and time to the onset of asthma after at least 2 treatment years. RESULTS: In total, 892 subjects (608 adults and 284 children/adolescents) were included in the SCIT group and 2676 subjects (1824 adults and 852 children/adolescents) in the non-AIT group. During the follow-up period after at least 2 years of SCIT, the number of prescriptions in the SCIT group was reduced by 62.8% (p &lt; .0001) for AR medication and by 42.4% for asthma medication (p = .0003). New-onset asthma risk was significantly reduced in the SCIT vs non-AIT group by 27.0% (p = .0212). The asthma-preventive effect of SCIT occurred 15 months after start of the treatment. In the SCIT group, the time to onset of asthma was prolonged compared to the non-AIT group (p = .0010). CONCLUSION: In this first product based RWD analysis on SCIT with a native HDM product, patients aged 5 to 70 years benefited from AIT in the long term in terms of reduced progression of AR and asthma after at least 2 years of treatment. The effects seemed to last for up to 6 years after treatment termination. A significantly reduced risk of asthma onset was observed, starting after 15 months of treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Jutel, Marek&#xD;Klimek, Ludger&#xD;Richter, Hartmut&#xD;Bruggenjurgen, Bernd&#xD;Vogelberg, Christian&#xD;eng&#xD;Allergopharma/&#xD;Observational Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):1042-1051. doi: 10.1111/all.16052. Epub 2024 Mar 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38429981</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16052</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>618</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">618</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cerps, S.</style></author><author><style face="normal" font="default" size="100%">Sverrild, A.</style></author><author><style face="normal" font="default" size="100%">Ramu, S.</style></author><author><style face="normal" font="default" size="100%">Nieto-Fontarigo, J. J.</style></author><author><style face="normal" font="default" size="100%">Akbarshahi, H.</style></author><author><style face="normal" font="default" size="100%">Menzel, M.</style></author><author><style face="normal" font="default" size="100%">Andersson, C.</style></author><author><style face="normal" font="default" size="100%">Tillgren, S.</style></author><author><style face="normal" font="default" size="100%">Hvidtfeldt, M.</style></author><author><style face="normal" font="default" size="100%">Porsbjerg, C.</style></author><author><style face="normal" font="default" size="100%">Uller, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental Medical Science, BMC D12, Lund University, Lund, Sweden.&#xD;Department of Respiratory Medicine, University Hospital Bispebjerg, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">House dust mite sensitization and exposure affects bronchial epithelial anti-microbial response to viral stimuli in patients with asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2498-2508</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/02/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-8</style></keyword><keyword><style face="normal" font="default" size="100%">Poly I-C/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Virus Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*beta-Defensins</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchial epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi and ALK-ABELLO outside the present work. J.J.N.F had grant from GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">ISCIII and SEPAR outside the present work. All the other authors had nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35114024</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Allergen exposure worsens viral-triggered asthma exacerbations and could predispose the host to secondary bacterial infections. We have previously demonstrated that exposure to house dust mite (HDM) reduced TLR-3-induced IFN-beta in human bronchial epithelial cells (HBECs) from healthy donors. We hypothesize that HDM sensitization in different ways may be involved in both viral and bacterial resistance of HBECs in asthma. In this study, the role of HDM sensitization and effects of HDM exposure on viral stimulus-challenged HBECs from asthmatic donors have been explored with regard to expression and release of molecules involved in anti-viral and anti-bacterial responses, respectively. METHODS: HBECs from HDM-sensitized (HDM+) and unsensitized (HDM-) patients with asthma were used. HBECs were exposed to HDM or heat inactivated (hi)-HDM (20 mug/ml) for 24 h prior to stimulation with the viral infection mimic, Poly(I:C), for 3 or 24 h. Samples were analyzed with ELISA and RT-qPCR for beta-defensin-2, IFN-beta, TSLP, and neutrophil-recruiting mediators: IL-8 and TNF-⍺. NFkappaB signaling proteins p105, p65, and IkappaB-⍺ were analyzed by Western blot. RESULTS: Poly(I:C)-induced IFN-beta expression was reduced in HBECs from HDM + compared to HDM- patients (p = 0.05). In vitro exposure of HBECs to HDM furthermore reduced anti-microbial responses to Poly(I:C) including beta-defensin-2, IL-8, and TNF-⍺, along with reduced NFkappaB activity. This was observed in HBECs from asthma patients sensitized to HDM, as well as in non-sensitized patients. By contrast, Poly (I:C)-induced release of TSLP, a driver of T2 inflammation, was not reduced with exposure to HDM. CONCLUSION: Using HBECs challenged with viral infection mimic, Poly(I:C), we demonstrated that allergic sensitization to HDM was associated with impaired anti-viral immunity and that HDM exposure reduced anti-viral and anti-bacterial defense molecules, but not TSLP, across non-allergic as well as allergic asthma. These data suggest a role of HDM in the pathogenesis of asthma exacerbations evoked by viral infections including sequential viral-bacterial and viral-viral infections.</style></abstract><notes><style face="normal" font="default" size="100%">Cerps, Samuel&#xD;Sverrild, Asger&#xD;Ramu, Sangeetha&#xD;Nieto-Fontarigo, Juan Jose&#xD;Akbarshahi, Hamid&#xD;Menzel, Mandy&#xD;Andersson, Cecilia&#xD;Tillgren, Sofia&#xD;Hvidtfeldt, Morten&#xD;Porsbjerg, Celeste&#xD;Uller, Lena&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2498-2508. doi: 10.1111/all.15243. Epub 2022 Feb 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35114024</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9546181</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15243</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1581</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1581</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cerps, S.</style></author><author><style face="normal" font="default" size="100%">Sverrild, A.</style></author><author><style face="normal" font="default" size="100%">Ramu, S.</style></author><author><style face="normal" font="default" size="100%">Nieto-Fontarigo, J. J.</style></author><author><style face="normal" font="default" size="100%">Akbarshahi, H.</style></author><author><style face="normal" font="default" size="100%">Menzel, M.</style></author><author><style face="normal" font="default" size="100%">Andersson, C.</style></author><author><style face="normal" font="default" size="100%">Tillgren, S.</style></author><author><style face="normal" font="default" size="100%">Hvidtfeldt, M.</style></author><author><style face="normal" font="default" size="100%">Porsbjerg, C.</style></author><author><style face="normal" font="default" size="100%">Uller, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental Medical Science, BMC D12, Lund University, Lund, Sweden.&#xD;Department of Respiratory Medicine, University Hospital Bispebjerg, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">House dust mite sensitization and exposure affects bronchial epithelial anti-microbial response to viral stimuli in patients with asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2498-2508</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/02/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-8</style></keyword><keyword><style face="normal" font="default" size="100%">Poly I-C/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Virus Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*beta-Defensins</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchial epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi and ALK-ABELLO outside the present work. J.J.N.F had grant from GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">ISCIII and SEPAR outside the present work. All the other authors had nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35114024</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Allergen exposure worsens viral-triggered asthma exacerbations and could predispose the host to secondary bacterial infections. We have previously demonstrated that exposure to house dust mite (HDM) reduced TLR-3-induced IFN-beta in human bronchial epithelial cells (HBECs) from healthy donors. We hypothesize that HDM sensitization in different ways may be involved in both viral and bacterial resistance of HBECs in asthma. In this study, the role of HDM sensitization and effects of HDM exposure on viral stimulus-challenged HBECs from asthmatic donors have been explored with regard to expression and release of molecules involved in anti-viral and anti-bacterial responses, respectively. METHODS: HBECs from HDM-sensitized (HDM+) and unsensitized (HDM-) patients with asthma were used. HBECs were exposed to HDM or heat inactivated (hi)-HDM (20 mug/ml) for 24 h prior to stimulation with the viral infection mimic, Poly(I:C), for 3 or 24 h. Samples were analyzed with ELISA and RT-qPCR for beta-defensin-2, IFN-beta, TSLP, and neutrophil-recruiting mediators: IL-8 and TNF-⍺. NFkappaB signaling proteins p105, p65, and IkappaB-⍺ were analyzed by Western blot. RESULTS: Poly(I:C)-induced IFN-beta expression was reduced in HBECs from HDM + compared to HDM- patients (p = 0.05). In vitro exposure of HBECs to HDM furthermore reduced anti-microbial responses to Poly(I:C) including beta-defensin-2, IL-8, and TNF-⍺, along with reduced NFkappaB activity. This was observed in HBECs from asthma patients sensitized to HDM, as well as in non-sensitized patients. By contrast, Poly (I:C)-induced release of TSLP, a driver of T2 inflammation, was not reduced with exposure to HDM. CONCLUSION: Using HBECs challenged with viral infection mimic, Poly(I:C), we demonstrated that allergic sensitization to HDM was associated with impaired anti-viral immunity and that HDM exposure reduced anti-viral and anti-bacterial defense molecules, but not TSLP, across non-allergic as well as allergic asthma. These data suggest a role of HDM in the pathogenesis of asthma exacerbations evoked by viral infections including sequential viral-bacterial and viral-viral infections.</style></abstract><notes><style face="normal" font="default" size="100%">Cerps, Samuel&#xD;Sverrild, Asger&#xD;Ramu, Sangeetha&#xD;Nieto-Fontarigo, Juan Jose&#xD;Akbarshahi, Hamid&#xD;Menzel, Mandy&#xD;Andersson, Cecilia&#xD;Tillgren, Sofia&#xD;Hvidtfeldt, Morten&#xD;Porsbjerg, Celeste&#xD;Uller, Lena&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2498-2508. doi: 10.1111/all.15243. Epub 2022 Feb 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35114024</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9546181</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15243</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>820</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">820</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Molinska, K.</style></author><author><style face="normal" font="default" size="100%">Latek, M.</style></author><author><style face="normal" font="default" size="100%">Rychlik, B.</style></author><author><style face="normal" font="default" size="100%">Lach, J.</style></author><author><style face="normal" font="default" size="100%">Strapagiel, D.</style></author><author><style face="normal" font="default" size="100%">Majak, J.</style></author><author><style face="normal" font="default" size="100%">Blazowski, L.</style></author><author><style face="normal" font="default" size="100%">Jerzynska, J.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Majak, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland.&#xD;Department of Molecular Biophysics, University of Lodz, Lodz, Poland.&#xD;Biobank Lab, Department of Molecular Biophysics, University of Lodz, Lodz, Poland.&#xD;Audiology and Phoniatrics Clinic, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;Department of Allergology and Pulmonology, National Research Institute of Tuberculosis and Lung Diseases, Rabka-Zdroj Branch, Poland.&#xD;Department of Pathophysiology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland.&#xD;Department of Pediatrics and Allergy, Medical University of Lodz, Lodz, Poland.&#xD;Department of Pediatric Pulmonology, Medical University of Lodz, Lodz, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">House dust mite sensitization and frequent antibiotic courses may suppress remission of rhinosinusitis and asthma symptoms in young children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">301-304</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/09/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mites</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">HDM sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">remission</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34510485</style></accession-num><notes><style face="normal" font="default" size="100%">Molinska, Katarzyna&#xD;Latek, Marta&#xD;Rychlik, Blazej&#xD;Lach, Jakub&#xD;Strapagiel, Dominik&#xD;Majak, Joanna&#xD;Blazowski, Lukasz&#xD;Jerzynska, Joanna&#xD;Kuna, Piotr&#xD;Majak, Pawel&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):301-304. doi: 10.1111/all.15085. Epub 2021 Sep 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34510485</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15085</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2259</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2259</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rinaldi, A. O.</style></author><author><style face="normal" font="default" size="100%">Li, M.</style></author><author><style face="normal" font="default" size="100%">Barletta, E.</style></author><author><style face="normal" font="default" size="100%">D&apos;Avino, P.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Ward, S.</style></author><author><style face="normal" font="default" size="100%">Burla, D.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Askary, N.</style></author><author><style face="normal" font="default" size="100%">Larsson, R.</style></author><author><style face="normal" font="default" size="100%">Bost, J.</style></author><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">Dhir, R.</style></author><author><style face="normal" font="default" size="100%">Gaudenzio, N.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;SciBase AB, Sundbyberg, Sweden.&#xD;SEED, Inc, Co, Los Angeles, California, USA.&#xD;Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France.&#xD;Genoskin SAS, Toulouse, France.&#xD;Department of Environmental Studies, Harvard T.H. Chan School of Public Health, Cambridge, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Household laundry detergents disrupt barrier integrity and induce inflammation in mouse and human skin</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">128-141</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/09/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Detergents/adverse effects/chemistry/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Epidermis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">electrical impedance spectroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">ex vivo human skin</style></keyword><keyword><style face="normal" font="default" size="100%">laundry detergents</style></keyword><keyword><style face="normal" font="default" size="100%">skin inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">transepidermal water loss</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37766519</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Epithelial barrier impairment is associated with many skin and mucosal inflammatory disorders. Laundry detergents have been demonstrated to affect epithelial barrier function in vitro using air-liquid interface cultures of human epithelial cells. METHODS: Back skin of C57BL/6 mice was treated with two household laundry detergents at several dilutions. Barrier function was assessed by electric impedance spectroscopy (EIS) and transepidermal water loss (TEWL) measurements after the 4 h of treatments with detergents. RNA sequencing (RNA-seq) and targeted multiplex proteomics analyses in skin biopsy samples were performed. The 6-h treatment effect of laundry detergent and sodium dodecyl sulfate (SDS) was investigated on ex vivo human skin. RESULTS: Detergent-treated skin showed a significant EIS reduction and TEWL increase compared to untreated skin, with a relatively higher sensitivity and dose-response in EIS. The RNA-seq showed the reduction of the expression of several genes essential for skin barrier integrity, such as tight junctions and adherens junction proteins. In contrast, keratinization, lipid metabolic processes, and epidermal cell differentiation were upregulated. Proteomics analysis showed that the detergents treatment generally downregulated cell adhesion-related proteins, such as epithelial cell adhesion molecule and contactin-1, and upregulated proinflammatory proteins, such as interleukin 6 and interleukin 1 beta. Both detergent and SDS led to a significant decrease in EIS values in the ex vivo human skin model. CONCLUSION: The present study demonstrated that laundry detergents and its main component, SDS impaired the epidermal barrier in vivo and ex vivo human skin. Daily detergent exposure may cause skin barrier disruption and may contribute to the development of atopic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Rinaldi, Arturo O&#xD;Li, Manru&#xD;Barletta, Elena&#xD;D&apos;Avino, Paolo&#xD;Yazici, Duygu&#xD;Pat, Yagiz&#xD;Ward, Siobhan&#xD;Burla, Daniel&#xD;Tan, Ge&#xD;Askary, Nima&#xD;Larsson, Rasmus&#xD;Bost, Jeremy&#xD;Babayev, Huseyn&#xD;Dhir, Raja&#xD;Gaudenzio, Nicolas&#xD;Akdis, Mubeccel&#xD;Nadeau, Kari&#xD;Akdis, Cezmi A&#xD;Mitamura, Yasutaka&#xD;eng&#xD;Genoskin SAS/&#xD;SciBase AB/&#xD;the Swiss National Foundation/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):128-141. doi: 10.1111/all.15891. Epub 2023 Sep 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37766519</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15891</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2175</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2175</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Fritzsching, B.</style></author><author><style face="normal" font="default" size="100%">Wolf, H.</style></author><author><style face="normal" font="default" size="100%">Woehlk, C.</style></author><author><style face="normal" font="default" size="100%">Wustenberg, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Paediatric Pulmonology and Allergy, Children&apos;s Doctor Service, Heidelberg, Germany.&#xD;Medical Department, Clinical Development, ALK-Abello Arzneimittel GmbH, Hamburg, Germany.&#xD;ALK A/S, Research and Development, Translational Research, Immunology, Horsholm, Denmark.&#xD;Faculty of Medicine (and University Hospital) Carl Gustav Carus, Department of Otorhinolaryngology Head and Neck Surgery, Technische Universitat Dresden, Dresden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">How does allergen immunotherapy-induced tolerance improve the airway epithelial barrier function: A mechanistical-driven hypothesis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2577-2580</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37545142</style></accession-num><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Fritzsching, Benedikt&#xD;Wolf, Hendrik&#xD;Woehlk, Christian&#xD;Wustenberg, Eike&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2577-2580. doi: 10.1111/all.15835. Epub 2023 Aug 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37545142</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15835</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>29</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">29</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Olesiejuk, K.</style></author><author><style face="normal" font="default" size="100%">Chalubinski, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Allergy, Chair of Pulmonology, Rheumatology and Clinical Immunology, Medical University of Lodz, Lodz, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">How does particulate air pollution affect barrier functions and inflammatory activity of lung vascular endothelium?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">629-638</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/01/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Particulate Matter/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution, Indoor</style></keyword><keyword><style face="normal" font="default" size="100%">aerobiology</style></keyword><keyword><style face="normal" font="default" size="100%">blood-air barrier</style></keyword><keyword><style face="normal" font="default" size="100%">environment and hygiene hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">indoor air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">microvascular permeability</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36588285</style></accession-num><abstract><style face="normal" font="default" size="100%">Both particulate matter and gaseous components of air pollution have already been shown to increase cardiovascular mortality in numerous studies. It is, however, important to note that on their way to the bloodstream the polluting agents pass the lung barrier. Inside the alveoli, particles of approximately 0.4-1 mum are most efficiently deposited and commonly undergo phagocytosis by lung macrophages. Not only the soluble agents, but also particles fine enough to leave the alveoli enter the bloodstream in this finite part of the endothelium, reaching thus higher concentrations in close proximity of the alveoli and endothelium. Additionally, deposits of particulate matter linger in direct proximity of the endothelial cells and may induce inflammation, immune responses, and influence endothelial barrier dysfunction thus increasing PM bioavailability in positive feedback. The presented discussion provides an overview of possible components of indoor PM and how endothelium is thus influenced, with emphasis on lung vascular endothelium and clinical perspectives.</style></abstract><notes><style face="normal" font="default" size="100%">Olesiejuk, Krzysztof&#xD;Chalubinski, Maciej&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):629-638. doi: 10.1111/all.15630. Epub 2023 Jan 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36588285</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15630</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2785</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2785</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Michils, A.</style></author><author><style face="normal" font="default" size="100%">Hackx, M.</style></author><author><style face="normal" font="default" size="100%">Mlynarski, L.</style></author><author><style face="normal" font="default" size="100%">Haccuria, A.</style></author><author><style face="normal" font="default" size="100%">Perez-Bogerd, S.</style></author><author><style face="normal" font="default" size="100%">Malinovschi, A.</style></author><author><style face="normal" font="default" size="100%">Van Muylem, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Chest Department, Erasme University Hospital, Universite libre de Bruxelles, Brussels, Belgium.&#xD;Radiology Department, Erasme University Hospital, Universite libre de Bruxelles, Brussels, Belgium.&#xD;Department of Medical Sciences, Clinical Physiology, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">How FEV(1) Improvement Induced by Anti-IL-5 in Severe Type-2 Asthma Is Linked to Mucus Plugs Clearance</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1143-1145</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/19</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39698780</style></accession-num><notes><style face="normal" font="default" size="100%">Michils, Alain&#xD;Hackx, Maxime&#xD;Mlynarski, Lucas&#xD;Haccuria, Amaryllis&#xD;Perez-Bogerd, Silvia&#xD;Malinovschi, Andrei&#xD;Van Muylem, Alain&#xD;eng&#xD;Chiesi Farmaceutici/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1143-1145. doi: 10.1111/all.16441. Epub 2024 Dec 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39698780</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16441</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2512</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2512</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Flory, S.</style></author><author><style face="normal" font="default" size="100%">Hviid-Vyff, B.</style></author><author><style face="normal" font="default" size="100%">Sosic, L.</style></author><author><style face="normal" font="default" size="100%">Schmid, J. M.</style></author><author><style face="normal" font="default" size="100%">Ahlbeck, L.</style></author><author><style face="normal" font="default" size="100%">Widmer, E. C. J.</style></author><author><style face="normal" font="default" size="100%">Lang, C. C. V.</style></author><author><style face="normal" font="default" size="100%">Ikenberg, K.</style></author><author><style face="normal" font="default" size="100%">Kundig, T. M.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, H. J.</style></author><author><style face="normal" font="default" size="100%">Johansen, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, University of Zurich, Zurich, Switzerland.&#xD;Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.&#xD;Department of Respiratory Diseases and Allergy, Aarhus University, Aarhus, Denmark.&#xD;Allergy Center, University Hospital Linkoping, Linkoping, Sweden.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">How to hit the allergy target: A critical appraisal of intralymphatic immunotherapy with practical recommendations on ultrasound-guided injections</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2222-2234</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/05/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Intralymphatic</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/administration &amp; dosage/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Lymph Nodes/immunology/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Ultrasonography, Interventional/methods</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">intralymphatic immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">ultrasound</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38712754</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Intralymphatic immunotherapy (ILIT) represents a promising novel approach treating allergic diseases. However, no standardized procedures or recommendations have been established or reported, despite the recognized fact that treatment efficacy relies on the ability to inject the allergen intranodally. OBJECTIVE: We aim to provide a critical appraisal of ILIT as a method of allergen immunotherapy and to deliver practical recommendations for accurate ILIT. METHODS: One hundred and seventy-three ILIT injections were performed in 28 (47%) women and 32 (53%) men with median age of 29 years (21-59). The injections were ultrasound-guided and recorded for retrospective analysis with respect to injection location, needle visibility, medication release, and patient characteristics. RESULTS: The results show that the correct positioning of the needle within the lymph node (LN) was most critical. If the whole length of the needle bevel was not inserted into the LN, substance backflush into the interstitium was observed. Selecting a more superficial LN and inserting the needle at a smaller angle towards the LN significantly improved needle visibility in the ultrasound. Longitudinal results showed that continuous practice significantly correlated with improved needle visibility and more accurate ILIT injections. CONCLUSION: Based on our results and practical experience, we propose several recommendations for LN selection and the correct handling of ultrasound probe and needle. We are confident that ILIT standardization and training will be important as to meet the goals of good safety and efficacy of ILIT.</style></abstract><notes><style face="normal" font="default" size="100%">Flory, Stephan&#xD;Hviid-Vyff, Bjarke&#xD;Sosic, Lara&#xD;Schmid, Johannes M&#xD;Ahlbeck, Lars&#xD;Widmer, Emma C J&#xD;Lang, Claudia C V&#xD;Ikenberg, Kristian&#xD;Kundig, Thomas M&#xD;Hoffmann, Hans Jurgen&#xD;Johansen, Pal&#xD;eng&#xD;Universitat Zurich/&#xD;Innovationsfonden/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2222-2234. doi: 10.1111/all.16138. Epub 2024 May 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38712754</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16138</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2634</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2634</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ronchese, F.</style></author><author><style face="normal" font="default" size="100%">Webb, G. R.</style></author><author><style face="normal" font="default" size="100%">Ochiai, S.</style></author><author><style face="normal" font="default" size="100%">Lamiable, O.</style></author><author><style face="normal" font="default" size="100%">Brewerton, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Malaghan Institute of Medical Research, Wellington, New Zealand.&#xD;Department of Clinical Immunology and Allergy, Auckland City Hospital, Auckland, New Zealand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">How type-2 dendritic cells induce Th2 differentiation: Instruction, repression, or fostering T cell-T cell communication?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">395-407</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/09/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dendritic Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells/immunology/metabolism/cytology</style></keyword><keyword><style face="normal" font="default" size="100%">*Cell Differentiation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Cell Communication/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Activation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ilc2</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">alarmins</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">dendritic cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39324367</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic disease is caused by the activation of allergen-specific CD4+ type-2 T follicular helper cells (Tfh2) and T helper 2 (Th2) effector cells that secrete the cytokines IL-4, IL-5, IL-9, and IL-13 upon allergen encounter, thereby inducing IgE production by B cells and tissue inflammation. While it is accepted that the priming and differentiation of naive CD4+ T cells into Th2 requires allergen presentation by type 2 dendritic cells (DC2s), the underlying signals remain unidentified. In this review we focus on the interaction between allergen-presenting DC2s and naive CD4+ T cells in lymph node (LN), and the potential mechanisms by which DC2s might instruct Th2 differentiation. We outline recent advances in characterizing DC2 development and heterogeneity. We review mechanisms of allergen sensing and current proposed mechanisms of Th2 differentiation, with specific consideration of the role of DC2s and how they might contribute to each mechanism. Finally, we assess recent publications reporting a detailed analysis of DC-T cell interactions in LNs and how they support Th2 differentiation. Together, these studies are starting to shape our understanding of this key initial step of the allergic immune response.</style></abstract><notes><style face="normal" font="default" size="100%">Ronchese, Franca&#xD;Webb, Greta R&#xD;Ochiai, Sotaro&#xD;Lamiable, Olivier&#xD;Brewerton, Maia&#xD;eng&#xD;Health Research Council of New Zealand/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):395-407. doi: 10.1111/all.16337. Epub 2024 Sep 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39324367</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804308</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16337</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1648</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1648</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barretto, K. T.</style></author><author><style face="normal" font="default" size="100%">Brockman-Schneider, R. A.</style></author><author><style face="normal" font="default" size="100%">Kuipers, I.</style></author><author><style face="normal" font="default" size="100%">Basnet, S.</style></author><author><style face="normal" font="default" size="100%">Bochkov, Y. A.</style></author><author><style face="normal" font="default" size="100%">Altman, M. C.</style></author><author><style face="normal" font="default" size="100%">Jarjour, N. N.</style></author><author><style face="normal" font="default" size="100%">Gern, J. E.</style></author><author><style face="normal" font="default" size="100%">Esnault, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics and Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.&#xD;Department of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.&#xD;Systems Immunology Program, Benaroya Research Institute, Seattle, WA, USA.&#xD;Division of Allergy, Department of Medicine, Pulmonary and Critical Care Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human airway epithelial cells express a functional IL-5 receptor</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2127-2130</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/04/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bronchi/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">*Epithelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Interleukin-5</style></keyword><keyword><style face="normal" font="default" size="100%">IL-5 receptor</style></keyword><keyword><style face="normal" font="default" size="100%">RNA-sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">airway epithelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">intracellular signaling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32246831</style></accession-num><abstract><style face="normal" font="default" size="100%">We found that HBEC expressed the IL-5 receptor, which triggered intracellular signaling and changed gene expression. This data indicate that in addition to targeting eosinophils, IL-5 and anti-IL-5 biologics may have a direct role on AEC.</style></abstract><notes><style face="normal" font="default" size="100%">Barretto, Karina T&#xD;Brockman-Schneider, Rebecca A&#xD;Kuipers, Ine&#xD;Basnet, Sarmila&#xD;Bochkov, Yury A&#xD;Altman, Matthew C&#xD;Jarjour, Nizar N&#xD;Gern, James E&#xD;Esnault, Stephane&#xD;eng&#xD;UM1 AI114271/AI/NIAID NIH HHS/&#xD;P01 HL088594/HL/NHLBI NIH HHS/&#xD;U19 AI104317/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2020 Aug;75(8):2127-2130. doi: 10.1111/all.14297. Epub 2020 Apr 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32246831</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7387204</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14297</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1647</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1647</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bartel, S.</style></author><author><style face="normal" font="default" size="100%">La Grutta, S.</style></author><author><style face="normal" font="default" size="100%">Cilluffo, G.</style></author><author><style face="normal" font="default" size="100%">Perconti, G.</style></author><author><style face="normal" font="default" size="100%">Bongiovanni, A.</style></author><author><style face="normal" font="default" size="100%">Giallongo, A.</style></author><author><style face="normal" font="default" size="100%">Behrends, J.</style></author><author><style face="normal" font="default" size="100%">Kruppa, J.</style></author><author><style face="normal" font="default" size="100%">Hermann, S.</style></author><author><style face="normal" font="default" size="100%">Chiang, D.</style></author><author><style face="normal" font="default" size="100%">Pfaffl, M. W.</style></author><author><style face="normal" font="default" size="100%">Krauss-Etschmann, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Early Life Origins of Chronic Lung Disease, Research Center Borstel, Leibniz Lung Center, Member of the German Center for Lung Research (DZL) and the Airway Research Center North (ARCN), Borstel, Germany.&#xD;Department of Pathology and Medical Biology, GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Institute for Research and Biomedical Innovation (IRIB), National Research Council, Palermo, Italy.&#xD;Core Facility Fluorescence Cytometry, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.&#xD;Institute of Biometry and Clinical Epidemiology, Charite - Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health, Berlin, Germany.&#xD;Berlin Institute of Health (BIH), Berlin, Germany.&#xD;Division of Animal Physiology and Immunology, School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany.&#xD;Institute for Experimental Medicine, Christian-Albrechts-Universitat zu Kiel, Kiel, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human airway epithelial extracellular vesicle miRNA signature is altered upon asthma development</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">346-356</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2019/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/chemically induced/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Polarity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Extracellular Vesicles/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs/genetics/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Lavage</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Mucosa/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 polarization</style></keyword><keyword><style face="normal" font="default" size="100%">airway epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">extracellular vesicles</style></keyword><keyword><style face="normal" font="default" size="100%">miRNA</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31386204</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: miRNAs are master regulators of signaling pathways critically involved in asthma and are transferred between cells in extracellular vesicles (EV). We aimed to investigate whether the miRNA content of EV secreted by primary normal human bronchial epithelial cells (NHBE) is altered upon asthma development. METHODS: NHBE cells were cultured at air-liquid interface and treated with interleukin (IL)-13 to induce an asthma-like phenotype. EV isolations by precipitation from basal culture medium or apical surface wash were characterized by nanoparticle tracking analysis, transmission electron microscopy, and Western blot, and EV-associated miRNAs were identified by a RT-qPCR-based profiling. Significant candidates were confirmed in EVs isolated by size-exclusion chromatography from nasal lavages of children with mild-to-moderate (n = 8) or severe asthma (n = 9), and healthy controls (n = 9). RESULTS: NHBE cells secrete EVs to the apical and basal side. 47 miRNAs were expressed in EVs and 16 thereof were significantly altered in basal EV upon IL-13 treatment. Expression of miRNAs could be confirmed in EVs from human nasal lavages. Of note, levels of miR-92b, miR-210, and miR-34a significantly correlated with lung function parameters in children (FEV(1) FVC(%pred) and FEF(25-75%pred) ), thus lower sEV-miRNA levels in nasal lavages associated with airway obstruction. Subsequent ingenuity pathway analysis predicted the miRNAs to regulate Th2 polarization and dendritic cell maturation. CONCLUSION: Our data indicate that secretion of miRNAs in EVs from the airway epithelium, in particular miR-34a, miR-92b, and miR-210, might be involved in the early development of a Th2 response in the airways and asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Bartel, Sabine&#xD;La Grutta, Stefania&#xD;Cilluffo, Giovanna&#xD;Perconti, Giovanni&#xD;Bongiovanni, Antonella&#xD;Giallongo, Agata&#xD;Behrends, Jochen&#xD;Kruppa, Jochen&#xD;Hermann, Stefanie&#xD;Chiang, Dapi&#xD;Pfaffl, Michael W&#xD;Krauss-Etschmann, Susanne&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Feb;75(2):346-356. doi: 10.1111/all.14008. Epub 2019 Oct 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31386204</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14008</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3118</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3118</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kwon, H. S.</style></author><author><style face="normal" font="default" size="100%">Lee, S. E.</style></author><author><style face="normal" font="default" size="100%">Sharma, A.</style></author><author><style face="normal" font="default" size="100%">Youn, M.</style></author><author><style face="normal" font="default" size="100%">Chang, C. A.</style></author><author><style face="normal" font="default" size="100%">Wells, A.</style></author><author><style face="normal" font="default" size="100%">Romo, A. R.</style></author><author><style face="normal" font="default" size="100%">Ji, A.</style></author><author><style face="normal" font="default" size="100%">Ratia, S.</style></author><author><style face="normal" font="default" size="100%">Kattel, S.</style></author><author><style face="normal" font="default" size="100%">Nerkar, R.</style></author><author><style face="normal" font="default" size="100%">Meneses, K.</style></author><author><style face="normal" font="default" size="100%">Kwan, C.</style></author><author><style face="normal" font="default" size="100%">Yu, M.</style></author><author><style face="normal" font="default" size="100%">Pang, W. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Jasper Therapeutics, Redwood City, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human KIT Antibody Briquilimab Diminishes Anaphylactic Responses in Mice Expressing Chimeric Human-Mouse KIT</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Kit</style></keyword><keyword><style face="normal" font="default" size="100%">briquilimab</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">monoclonal antibody</style></keyword><keyword><style face="normal" font="default" size="100%">stem cell factor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41117424</style></accession-num><notes><style face="normal" font="default" size="100%">Kwon, Hye-Sook&#xD;Lee, Song Eun&#xD;Sharma, Ajay&#xD;Youn, Minyoung&#xD;Chang, Charles A&#xD;Wells, Andrew&#xD;Romo, Andrea R&#xD;Ji, Allison&#xD;Ratia, Sara&#xD;Kattel, Sambidhan&#xD;Nerkar, Revati&#xD;Meneses, Karl&#xD;Kwan, Cheryl&#xD;Yu, Mang&#xD;Pang, Wendy W&#xD;eng&#xD;Jasper Therapeutics Inc/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct 21. doi: 10.1111/all.70105.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41117424</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70105</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2713</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2713</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">Palmer, D. J.</style></author><author><style face="normal" font="default" size="100%">Geddes, D.</style></author><author><style face="normal" font="default" size="100%">Lai, C. T.</style></author><author><style face="normal" font="default" size="100%">Prescott, S. L.</style></author><author><style face="normal" font="default" size="100%">D&apos;Vaz, N.</style></author><author><style face="normal" font="default" size="100%">Vlaskovsky, P.</style></author><author><style face="normal" font="default" size="100%">Stinson, L. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Molecular Sciences, The University of Western Australia, Crawley, Western Australia, Australia.&#xD;ABREAST Network, Perth, Western Australia, Australia.&#xD;UWA Centre for Human Lactation Research and Translation, Perth, Western Australia, Australia.&#xD;Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia.&#xD;School of Medicine, The University of Western Australia, Perth, Western Australia, Australia.&#xD;Nova Institute for Health, Baltimore, Maryland, USA.&#xD;Department of Family and Community Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.&#xD;School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.&#xD;School of Mathematics and Statistics, The University of Western Australia, Perth, Western Australia, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human Milk Microbiome Is Associated With Allergic Diseases in Early Childhood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3509-3511</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/11/15</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39545381</style></accession-num><notes><style face="normal" font="default" size="100%">Ma, Jie&#xD;Palmer, Debra J&#xD;Geddes, Donna&#xD;Lai, Ching Tat&#xD;Prescott, Susan L&#xD;D&apos;Vaz, Nina&#xD;Vlaskovsky, Philip&#xD;Stinson, Lisa F&#xD;eng&#xD;Telethon Kids Institute Ascend Fellowship/&#xD;Medela/&#xD;GNT353555/National Health and Medical Research Council/&#xD;University of Western Australia/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3509-3511. doi: 10.1111/all.16399. Epub 2024 Nov 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39545381</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16399</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2585</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2585</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sohail, A.</style></author><author><style face="normal" font="default" size="100%">Cho, L.</style></author><author><style face="normal" font="default" size="100%">Hacker, J.</style></author><author><style face="normal" font="default" size="100%">Bergmark, R. W.</style></author><author><style face="normal" font="default" size="100%">Lee, S. E.</style></author><author><style face="normal" font="default" size="100%">Maxfield, A.</style></author><author><style face="normal" font="default" size="100%">Roditi, R. E.</style></author><author><style face="normal" font="default" size="100%">Dwyer, D. F.</style></author><author><style face="normal" font="default" size="100%">Buchheit, K. M.</style></author><author><style face="normal" font="default" size="100%">Laidlaw, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Allergy and Clinical Immunology, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Department of Surgery, Division of Otolaryngology-Head &amp; Neck Surgery, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human nasal epithelial cells express IL-5Ralpha but not the co-receptor CSF2RB and do not signal to IL-5</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3146-3150</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/07/07</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38972002</style></accession-num><notes><style face="normal" font="default" size="100%">Sohail, Aaqib&#xD;Cho, Laura&#xD;Hacker, Jonathan&#xD;Bergmark, Regan W&#xD;Lee, Stella E&#xD;Maxfield, Alice&#xD;Roditi, Rachel E&#xD;Dwyer, Daniel F&#xD;Buchheit, Kathleen M&#xD;Laidlaw, Tanya M&#xD;eng&#xD;K23 AI139352/AI/NIAID NIH HHS/&#xD;K24 AI180296/AI/NIAID NIH HHS/&#xD;U19 AI095219/AI/NIAID NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3146-3150. doi: 10.1111/all.16218. Epub 2024 Jul 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38972002</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12487116</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16218</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>370</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">370</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Polak, D.</style></author><author><style face="normal" font="default" size="100%">Elbe-Burger, A.</style></author><author><style face="normal" font="default" size="100%">Kitzmuller, C.</style></author><author><style face="normal" font="default" size="100%">Zlabinger, G. J.</style></author><author><style face="normal" font="default" size="100%">Bohle, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Dermatology, Medical University of Vienna, Vienna, Austria.&#xD;Institute of Immunology, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human neutrophils require short exposure to cytokines and allergen to become functional antigen-presenting cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">291-293</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35912416</style></accession-num><notes><style face="normal" font="default" size="100%">Polak, Dominika&#xD;Elbe-Burger, Adelheid&#xD;Kitzmuller, Claudia&#xD;Zlabinger, Gerhard J&#xD;Bohle, Barbara&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):291-293. doi: 10.1111/all.15460. Epub 2022 Aug 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35912416</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087710</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15460</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2288</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2288</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tacquard, C.</style></author><author><style face="normal" font="default" size="100%">Tupin, F.</style></author><author><style face="normal" font="default" size="100%">Magnenat, S.</style></author><author><style face="normal" font="default" size="100%">Brouard, N.</style></author><author><style face="normal" font="default" size="100%">Eckly, A.</style></author><author><style face="normal" font="default" size="100%">Proamer, F.</style></author><author><style face="normal" font="default" size="100%">Metz-Favre, C.</style></author><author><style face="normal" font="default" size="100%">Stenger, R.</style></author><author><style face="normal" font="default" size="100%">Piotin, A.</style></author><author><style face="normal" font="default" size="100%">De Blay, F.</style></author><author><style face="normal" font="default" size="100%">Ebo, D.</style></author><author><style face="normal" font="default" size="100%">Elst, J.</style></author><author><style face="normal" font="default" size="100%">Mertes, P. M.</style></author><author><style face="normal" font="default" size="100%">Hechler, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite de Strasbourg, INSERM, Etablissement Francais du Sang (EFS) Grand Est, BPPS UMR_S1255, Federation de Medecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.&#xD;Department of Anesthesia and Intensive Care, Strasbourg University Hospital, Strasbourg, France.&#xD;Department of Pneumology and Allergology, Strasbourg University Hospital, Strasbourg, France.&#xD;Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp and Antwerp University Hospital, Antwerpen, Belgium.&#xD;Department of Immunology and Allergology, AZ Jan Palfijn Gent, Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human platelets do not possess the FcepsilonRI and FcepsilonRII receptors for IgE</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3278-3281</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/10/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, IgE</style></keyword><keyword><style face="normal" font="default" size="100%">*Blood Platelets</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37897054</style></accession-num><notes><style face="normal" font="default" size="100%">Tacquard, Charles&#xD;Tupin, Florian&#xD;Magnenat, Stephanie&#xD;Brouard, Nathalie&#xD;Eckly, Anita&#xD;Proamer, Fabienne&#xD;Metz-Favre, Carine&#xD;Stenger, Rodolphe&#xD;Piotin, Anays&#xD;De Blay, Frederic&#xD;Ebo, Didier&#xD;Elst, Jessy&#xD;Mertes, Paul Michel&#xD;Hechler, Beatrice&#xD;eng&#xD;Association de Recherche et Developpement en Medecine et Sante Publique (ARMESA)/&#xD;Etablissement Francais du Sang/&#xD;Institut National de la Sante et de la Recherche Medicale/&#xD;Region Grand-Est/&#xD;Strasbourg University Hospital/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3278-3281. doi: 10.1111/all.15935. Epub 2023 Oct 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37897054</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15935</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2734</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2734</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mann-Nuttel, R.</style></author><author><style face="normal" font="default" size="100%">Mandal, S.</style></author><author><style face="normal" font="default" size="100%">Armbruster, M.</style></author><author><style face="normal" font="default" size="100%">Puttagunta, L.</style></author><author><style face="normal" font="default" size="100%">Forsythe, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary Medicine, Department of Medicine, Faculty of Medicine &amp; Dentistry, and Alberta Respiratory Centre, University of Alberta, Edmonton, Alberta, Canada.&#xD;Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human Pulmonary Neuroendocrine Cells Respond to House Dust Mite Extract With PAR-1 Dependent Release of CGRP</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">976-985</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/11/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroglyphidae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Calcitonin Gene-Related Peptide/metabolism/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Neuroendocrine Cells/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Lung/immunology/cytology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Induced Pluripotent Stem Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cgrp</style></keyword><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite</style></keyword><keyword><style face="normal" font="default" size="100%">neurotransmitters</style></keyword><keyword><style face="normal" font="default" size="100%">pulmonary neuroendocrine cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39601620</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Pulmonary neuroendocrine cells (PNEC) are rare airway epithelial cells that have recently gained attention as potential amplifiers of allergic asthma. However, studying PNEC function in humans has been challenging due to a lack of cell isolation methods, and little is known about human PNEC function in response to asthma-relevant stimuli. Here we developed and characterized an in vitro human PNEC model and investigated the neuroendocrine response to extracts of the common aeroallergen house dust mite (HDM). METHODS: PNEC-enriched cultures were generated from human induced pluripotent stem cells (iPNEC) and primary bronchial epithelial cells (ePNEC). Characterized PNEC cultures were exposed to HDM extract, a volatile chemical odorant (Bergamot oil), or the bacterial membrane component, lipopolysaccharide (LPS), and neuroendocrine gene expression and neuropeptide release determined. RESULTS: Both iPNEC and ePNEC models demonstrated similar baseline neuroendocrine characteristics and a stimuli-specific modulation of gene expression. Most notably, exposure to HDM but not Bergamot oil or LPS, leads to dose-dependent induction of the CGRP encoding gene, CALCB, and corresponding release of the neuropeptide. HDM-induced CALCB expression and CGRP release could be inhibited by a protease-activated receptor 1 (PAR1) antagonist or protease inhibitors and was mimicked by a PAR1 agonist. CONCLUSIONS: We have characterized a novel model of PNEC-enriched human airway epithelium and utilized this model to demonstrate a previously unrecognized role for human PNEC in mediating a direct neuroendocrine response to aeroallergen exposure.</style></abstract><notes><style face="normal" font="default" size="100%">Mann-Nuttel, Ritu&#xD;Mandal, Shivani&#xD;Armbruster, Marie&#xD;Puttagunta, Lakshmi&#xD;Forsythe, Paul&#xD;eng&#xD;AstraZeneca Canada/&#xD;CAPMC/CIHR/Canada&#xD;Canadian Allergy, Asthma and Immunology Foundation/&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):976-985. doi: 10.1111/all.16416. Epub 2024 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39601620</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969319</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16416</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1258</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1258</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gawrysiak, M.</style></author><author><style face="normal" font="default" size="100%">Gajewski, A.</style></author><author><style face="normal" font="default" size="100%">Szewczyk, R.</style></author><author><style face="normal" font="default" size="100%">Likonska, A.</style></author><author><style face="normal" font="default" size="100%">Michlewska, S.</style></author><author><style face="normal" font="default" size="100%">Chmiela, M.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author><author><style face="normal" font="default" size="100%">Chalubinski, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland.&#xD;Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.&#xD;Laboratory of Microscopic Imaging and Specialized Biological Techniques, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human rhinovirus HRV16 impairs barrier functions and regeneration of human lung vascular endothelium</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1872-1875</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Endothelium, Vascular</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneration</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinovirus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33247950</style></accession-num><notes><style face="normal" font="default" size="100%">Gawrysiak, Mateusz&#xD;Gajewski, Adrian&#xD;Szewczyk, Robert&#xD;Likonska, Aleksandra&#xD;Michlewska, Sylwia&#xD;Chmiela, Magdalena&#xD;Kowalski, Marek L&#xD;Chalubinski, Maciej&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1872-1875. doi: 10.1111/all.14671. Epub 2020 Dec 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33247950</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14671</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2347</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2347</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shu, L.</style></author><author><style face="normal" font="default" size="100%">He, Q.</style></author><author><style face="normal" font="default" size="100%">Yan, B.</style></author><author><style face="normal" font="default" size="100%">Wu, D.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of Nasal Diseases, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China.&#xD;Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.&#xD;College of Control Science and Engineering, Zhejiang University, Hangzhou, PR China.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human-in-the-loop: Human involvement in enhancing medical inquiry performance in large language models</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1348-1351</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Language</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38078613</style></accession-num><notes><style face="normal" font="default" size="100%">Shu, Linping&#xD;He, Qunshan&#xD;Yan, Bing&#xD;Wu, Di&#xD;Wang, Menglin&#xD;Wang, Chengshuo&#xD;Zhang, Luo&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1348-1351. doi: 10.1111/all.15976. Epub 2023 Dec 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38078613</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15976</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2373</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2373</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, D.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Xu, C.</style></author><author><style face="normal" font="default" size="100%">Qi, Q.</style></author><author><style face="normal" font="default" size="100%">Zeng, R.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Pan, Y.</style></author><author><style face="normal" font="default" size="100%">Xu, J.</style></author><author><style face="normal" font="default" size="100%">Dong, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory and Critical Care Medicine, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China.&#xD;Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A humanized mouse model to study asthmatic airway remodeling and Muc-5ac secretion via the human IL-33</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1364-1367</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/01/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Airway Remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-33/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Mucin 5AC/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38226717</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Dong&#xD;Zhang, Jintao&#xD;Xu, Changjuan&#xD;Qi, Qian&#xD;Zeng, Rong&#xD;Liu, Xiaofei&#xD;Pan, Yun&#xD;Xu, Jiawei&#xD;Dong, Liang&#xD;eng&#xD;National Natural Science Foundation of China/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1364-1367. doi: 10.1111/all.16030. Epub 2024 Jan 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38226717</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16030</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>888</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">888</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barnes, H.</style></author><author><style face="normal" font="default" size="100%">Troy, L.</style></author><author><style face="normal" font="default" size="100%">Lee, C. T.</style></author><author><style face="normal" font="default" size="100%">Sperling, A.</style></author><author><style face="normal" font="default" size="100%">Strek, M.</style></author><author><style face="normal" font="default" size="100%">Glaspole, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Central Clinical School, Monash University, Melbourne, VIC, Australia.&#xD;Alfred Hospital, Melbourne, VIC, Australia.&#xD;Royal Prince Alfred Hospital, Sydney, NSW, Australia.&#xD;University of Sydney, Sydney, NSW, Australia.&#xD;Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">442-453</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/07/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Alveolitis, Extrinsic Allergic/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Lung Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">extrinsic allergic alveolitis</style></keyword><keyword><style face="normal" font="default" size="100%">interstitial pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">occupational lung disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34293188</style></accession-num><abstract><style face="normal" font="default" size="100%">Hypersensitivity pneumonitis is an immune-mediated interstitial lung disease caused by an aberrant response to an inhaled exposure, which results in mostly T cell-mediated inflammation, granuloma formation, and fibrosis in some cases. HP is diagnosed by exposure identification, HRCT findings of ground-glass opacities, centrilobular nodules, and mosaic attenuation, with traction bronchiectasis and honeycombing in fibrotic cases. Additional testing including serum IgG testing for the presence of antigen exposure, bronchoalveolar lavage lymphocytosis, and lung biopsy demonstrating granulomas, inflammation, and fibrosis, increases the diagnostic confidence. Treatment for HP includes avoidance of the implicated exposure, immunosuppression, and anti-fibrotic therapy in select cases. This narrative review presents the recent literature in the understanding of the immunopathological mechanisms, diagnosis, and treatment of HP.</style></abstract><notes><style face="normal" font="default" size="100%">Barnes, Hayley&#xD;Troy, Lauren&#xD;Lee, Cathryn T&#xD;Sperling, Anne&#xD;Strek, Mary&#xD;Glaspole, Ian&#xD;eng&#xD;Research Support, N.I.H., Extramural&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):442-453. doi: 10.1111/all.15017. Epub 2021 Jul 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34293188</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15017</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>932</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">932</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bavbek, S.</style></author><author><style face="normal" font="default" size="100%">Pagani, M.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Cuesta, E.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author><author><style face="normal" font="default" size="100%">Dursun, A. B.</style></author><author><style face="normal" font="default" size="100%">Hamadi, S.</style></author><author><style face="normal" font="default" size="100%">Madrigal-Burgaleta, R.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Sanchez, S.</style></author><author><style face="normal" font="default" size="100%">Vultaggio, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergy, Department of Chest Diseases, School of Medicine, Ankara University, Ankara, Turkey.&#xD;Medical Department, Medicine Ward ASST di Mantova, Mantova, Italy.&#xD;Allergy Division, Former Head, Ramon y Cajal University Hospital, Madrid, Spain.&#xD;Division of Allergy and Immunology, Department of Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Immunology and Allergic Diseases, Recep Tayyip Erdogan University, Rize, Turkey.&#xD;Allergy &amp; Severe Asthma Service, St Bartholomew&apos;s Hospital, Barts Health NHS Trust, London, UK.&#xD;Drug Desensitisation Centre, Catalan Institute of Oncology, Barcelona, Spain.&#xD;Allergy Department, Complexo Hospitalario Universitario A Coruna (CHUAC), A Coruna, Spain.&#xD;Department of Biomedicine, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypersensitivity reactions to biologicals: An EAACI position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">39-54</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/06/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Antineoplastic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Precision Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">biologicals</style></keyword><keyword><style face="normal" font="default" size="100%">desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default" size="100%">monoclonal Abs</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34157134</style></accession-num><abstract><style face="normal" font="default" size="100%">Biologicals are crucial targeted therapeutic agents in oncological, immunological, and inflammatory diseases, and their use in clinical practice is broadening. In recent years, the spread of Personalized Precision Medicine has facilitated a proliferation of new treatment options, especially biologicals. Consequently, biologicals are now among the drugs that most frequently cause hypersensitivity reactions (HSRs). Patients can develop HSRs to these agents during the first-lifetime exposure or after repeated exposure, and these HSRs can be potentially life-threatening or limit therapeutic options. Despite the relatively high prevalence, the underlying mechanisms of these HSRs remain obscure, and the optimal management pathways are still a matter of discussion. In this Position Paper, the authors will provide evidence-based recommendations for diagnosing and managing HSRs to biologicals. Additionally, the document defines unmet needs as an opportunity to shape future research.</style></abstract><notes><style face="normal" font="default" size="100%">Bavbek, Sevim&#xD;Pagani, Mauro&#xD;Alvarez-Cuesta, Emilio&#xD;Castells, Mariana&#xD;Dursun, Adile Berna&#xD;Hamadi, Sahar&#xD;Madrigal-Burgaleta, Ricardo&#xD;Sanchez-Sanchez, Soledad&#xD;Vultaggio, Alessandra&#xD;eng&#xD;Consensus Development Conference&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):39-54. doi: 10.1111/all.14984. Epub 2021 Jul 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34157134</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14984</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>801</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">801</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pagani, M.</style></author><author><style face="normal" font="default" size="100%">Bavbek, S.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Cuesta, E.</style></author><author><style face="normal" font="default" size="100%">Berna Dursun, A.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author><author><style face="normal" font="default" size="100%">Cernadas, J.</style></author><author><style face="normal" font="default" size="100%">Chiriac, A.</style></author><author><style face="normal" font="default" size="100%">Sahar, H.</style></author><author><style face="normal" font="default" size="100%">Madrigal-Burgaleta, R.</style></author><author><style face="normal" font="default" size="100%">Sanchez Sanchez, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Medicine Ward C. Poma Mantova Hospital, ASST Mantova, Mantova, Italy.&#xD;Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey.&#xD;Allergy Division, Former Head, Ramon y Cajal University Hospital, Madrid, Spain.&#xD;Department of Immunology and Allergic Diseases, Recep Tayyip Erdogan University, Rize, Turkey.&#xD;Allergy Unit, Azienda Ospedaliera di Verona, Verona, Italy.&#xD;Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Allergy and Clinical Immunology, Medical University, H. S. Joao, Porto, Portugal.&#xD;Division of Allergy, Department of Pulmonology, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France.&#xD;The Department of Medicine, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Allergy &amp; Severe Asthma Service, St Bartholomew&apos;s Hospital&apos;s, Barts Health NHS Trust, London, UK.&#xD;Drug Desensitisation Centre, Catalan Institute of Oncology (ICO) Bellvitge University Hospital, Barcelona, Spain.&#xD;Division of Allergy &amp; Clinical Immunology, Department of Medicine, University Hospital Complex of A Coruna, A Coruna, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypersensitivity reactions to chemotherapy: an EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">388-403</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/09/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Antineoplastic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Neoplasms/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">drug provocation test</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity reactions</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34587281</style></accession-num><abstract><style face="normal" font="default" size="100%">Chemotherapeutic drugs have been widely used in the treatment of cancer disease for about 70 years. The development of new treatments has not hindered their use, and oncologists still prescribe them routinely, alone or in combination with other antineoplastic agents. However, all chemotherapeutic agents can induce hypersensitivity reactions (HSRs), with different incidences depending on the culprit drug. These reactions are the third leading cause of fatal drug-induced anaphylaxis in the United States. In Europe, deaths related to chemotherapy have also been reported. In particular, most reactions are caused by platinum compounds, taxanes, epipodophyllotoxins and asparaginase. Despite their prevalence and relevance, the ideal pathways for diagnosis, treatment and prevention of these reactions are still unclear, and practice remains considerably heterogeneous with vast differences from center to center. Thus, the European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology organized a task force to provide data and recommendations regarding the allergological work-up in this field of drug hypersensitivity reactions. This position paper aims to provide consensus on the investigation of HSRs to chemotherapeutic drugs and give practical recommendations for clinicians that treat these patients, such as oncologists, allergologists and internists. Key sections cover risk factors, pathogenesis, symptoms, the role of skin tests, in vitro tests, indications and contraindications of drug provocation tests and desensitization of neoplastic patients with allergic reactions to chemotherapeutic drugs. Statements, recommendations and unmet needs were discussed and proposed at the end of each section.</style></abstract><notes><style face="normal" font="default" size="100%">Pagani, Mauro&#xD;Bavbek, Sevim&#xD;Alvarez-Cuesta, Emilio&#xD;Berna Dursun, Adile&#xD;Bonadonna, Patrizia&#xD;Castells, Mariana&#xD;Cernadas, Josefina&#xD;Chiriac, Anca&#xD;Sahar, Hamadi&#xD;Madrigal-Burgaleta, Ricardo&#xD;Sanchez Sanchez, Soledad&#xD;eng&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):388-403. doi: 10.1111/all.15113. Epub 2021 Oct 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34587281</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15113</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2337</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2337</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Basu, M. N.</style></author><author><style face="normal" font="default" size="100%">Melchiors, B. B.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Garvey, L. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.&#xD;Allergy Clinic, Department of Dermatology and Allergy, Danish Anaesthesia Allergy Centre, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.&#xD;University of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypersensitivity reactions to human albumin-A case series and diagnostic algorithm</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">752-754</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/12/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Serum Albumin, Human</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Delayed</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38102983</style></accession-num><notes><style face="normal" font="default" size="100%">Basu, Millie Nguyen&#xD;Melchiors, Birgitte Bech&#xD;Mortz, Charlotte G&#xD;Garvey, Lene H&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):752-754. doi: 10.1111/all.15971. Epub 2023 Dec 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38102983</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15971</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1137</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1137</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gauthier, A.</style></author><author><style face="normal" font="default" size="100%">Mankouri, F.</style></author><author><style face="normal" font="default" size="100%">Demoly, P.</style></author><author><style face="normal" font="default" size="100%">Sgarbura, O.</style></author><author><style face="normal" font="default" size="100%">Chiriac, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Department of Pulmonology, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Univ Montpellier, Montpellier, France.&#xD;Department of Allergy and Immunology, Laval University Hospital Center, Laval University, Quebec City, QC, Canada.&#xD;UMR-S 1136, INSERM-Sorbonne Universite, Equipe EPAR-IPLESP, Paris, France.&#xD;Department of Surgical Oncology, Cancer Institute of Montpellier, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypersensitivity reactions to platinum-based compounds in the context of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Description and management</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1882-1885</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/02/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aerosols</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Organoplatinum Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Oxaliplatin</style></keyword><keyword><style face="normal" font="default" size="100%">*Platinum Compounds</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33616981</style></accession-num><notes><style face="normal" font="default" size="100%">Gauthier, Amelie&#xD;Mankouri, Farid&#xD;Demoly, Pascal&#xD;Sgarbura, Olivia&#xD;Chiriac, Anca Mirela&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1882-1885. doi: 10.1111/all.14679. Epub 2020 Dec 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33616981</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14679</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2300</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2300</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bavbek, S.</style></author><author><style face="normal" font="default" size="100%">Kepil Ozdemir, S.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Atanaskovic-Markovic, M.</style></author><author><style face="normal" font="default" size="100%">Barbaud, A.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Laguna Martinez, J.</style></author><author><style face="normal" font="default" size="100%">Nakonechna, A.</style></author><author><style face="normal" font="default" size="100%">Pagani, M.</style></author><author><style face="normal" font="default" size="100%">Arcolaci, A.</style></author><author><style face="normal" font="default" size="100%">Lombardo, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergy, Department of Chest Diseases, School of Medicine, Ankara University, Ankara, Turkey.&#xD;Department of Chest Diseases, Allergy and Immunology Unit, Izmir Faculty of Medicine, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, University of Health Sciences, Izmir, Turkey.&#xD;Allergy Unit, Borgo Roma University Hospital, Verona, Italy.&#xD;Department of Allergology and Pulmonology, Faculty of Medicine, University of Belgrade, University Children&apos;s Hospital, Belgrade, Serbia.&#xD;Departement de dermatologie et allergologie, Sorbonne Universite, INSERM, Institut Pierre Louis d&apos;Epidemiologie et de Sante Publique, AP-HP, Sorbonne Universite, Hopital Tenon, Paris, France.&#xD;Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich, Germany.&#xD;Allergy Unit, Allergo-Anaesthesia Unit, Faculty of Medicine, Hospital Central de la Cruz Roja, Alfonso X El Sabio University, Madrid, Spain.&#xD;Allergy and Clinical Immunology Department, University of Liverpool, Royal Preston Hospital, Lancashire Teaching Hospitals, NHS Foundation Trust, Liverpool, UK.&#xD;Medicine Department, Medicine Ward Mantova Hospital, ASST di Mantova, Mantova, Italy.&#xD;Immunology Unit, Borgo Roma University Hospital, Verona, Italy.&#xD;Division of Dermatology and Allergy, APSS - Trento Hospital, Trento, Italy.&#xD;Allergy Unit, Regional University Hospital of Malaga, IBIMA-UMA-ARADyAL, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">552-564</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/11/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Proton Pump Inhibitors/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default" size="100%">proton pump inhibitors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38013608</style></accession-num><abstract><style face="normal" font="default" size="100%">Proton pump inhibitors (PPIs) are invaluable therapeutic options in a variety of dyspeptic diseases. In addition to their well-known risk profile, PPI consumption is related to food and environmental allergies, dysbiosis, osteoporosis, as well as immediate and delayed hypersensitivity reactions (HSRs). The latter, although a rare event, around 1%-3%, due to the extraordinarily high rate of prescription and consumption of PPIs are related to a substantial risk. In this Position Paper, we provide clinicians with practical evidence-based recommendations for the diagnosis and management of HSRs to PPIs. Furthermore, the unmet needs proposed in the document aim to stimulate more in-depth investigations in the topic.</style></abstract><notes><style face="normal" font="default" size="100%">Bavbek, Sevim&#xD;Kepil Ozdemir, Secil&#xD;Bonadonna, Patrizia&#xD;Atanaskovic-Markovic, Marina&#xD;Barbaud, Annick&#xD;Brockow, Knut&#xD;Laguna Martinez, Jose&#xD;Nakonechna, Alla&#xD;Pagani, Mauro&#xD;Arcolaci, Alessandra&#xD;Lombardo, Carla&#xD;Torres, Maria J&#xD;eng&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):552-564. doi: 10.1111/all.15961. Epub 2023 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38013608</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15961</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2238</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2238</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chanasit, S.</style></author><author><style face="normal" font="default" size="100%">Johnston, E.</style></author><author><style face="normal" font="default" size="100%">Thanasarnthungcharoen, C.</style></author><author><style face="normal" font="default" size="100%">Kamath, S. D.</style></author><author><style face="normal" font="default" size="100%">Bohle, B.</style></author><author><style face="normal" font="default" size="100%">Lopata, A. L.</style></author><author><style face="normal" font="default" size="100%">Jacquet, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.&#xD;Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia.&#xD;Medical Microbiology, Graduate School, Chulalongkorn University, Bangkok, Thailand.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Tropical Futures Institute, James Cook University, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypoallergenic chimeric virus-like particles for the development of shrimp tropomyosin allergen Pen m 1-specific blocking antibodies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1052-1055</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/09/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Tropomyosin</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Blocking</style></keyword><keyword><style face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">*Penaeidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37753807</style></accession-num><notes><style face="normal" font="default" size="100%">Chanasit, Supapich&#xD;Johnston, Elecia&#xD;Thanasarnthungcharoen, Chanatip&#xD;Kamath, Sandip D&#xD;Bohle, Barbara&#xD;Lopata, Andreas L&#xD;Jacquet, Alain&#xD;eng&#xD;M 3295/Austrian Science Fund (FWF)/&#xD;Faculty of Medicine, Chulalongkorn University/&#xD;GNT1124143/National Health and Medical Research Council/&#xD;CU_FRB640001_01_30_2/Thailand Science Research and Innovation (TSRI)/&#xD;CUFRB65_hea(32)_039_30_20/Thailand Science Research and Innovation (TSRI)/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):1052-1055. doi: 10.1111/all.15892. Epub 2023 Sep 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37753807</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15892</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2260</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2260</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chanasit, S.</style></author><author><style face="normal" font="default" size="100%">Johnston, E.</style></author><author><style face="normal" font="default" size="100%">Thanasarnthungcharoen, C.</style></author><author><style face="normal" font="default" size="100%">Kamath, S. D.</style></author><author><style face="normal" font="default" size="100%">Bohle, B.</style></author><author><style face="normal" font="default" size="100%">Lopata, A. L.</style></author><author><style face="normal" font="default" size="100%">Jacquet, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.&#xD;Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia.&#xD;Medical Microbiology, Graduate School, Chulalongkorn University, Bangkok, Thailand.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Tropical Futures Institute, James Cook University, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypoallergenic chimeric virus-like particles for the development of shrimp tropomyosin allergen Pen m 1-specific blocking antibodies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1052-1055</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/09/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Tropomyosin</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Blocking</style></keyword><keyword><style face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">*Penaeidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37753807</style></accession-num><notes><style face="normal" font="default" size="100%">Chanasit, Supapich&#xD;Johnston, Elecia&#xD;Thanasarnthungcharoen, Chanatip&#xD;Kamath, Sandip D&#xD;Bohle, Barbara&#xD;Lopata, Andreas L&#xD;Jacquet, Alain&#xD;eng&#xD;M 3295/Austrian Science Fund (FWF)/&#xD;Faculty of Medicine, Chulalongkorn University/&#xD;GNT1124143/National Health and Medical Research Council/&#xD;CU_FRB640001_01_30_2/Thailand Science Research and Innovation (TSRI)/&#xD;CUFRB65_hea(32)_039_30_20/Thailand Science Research and Innovation (TSRI)/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):1052-1055. doi: 10.1111/all.15892. Epub 2023 Sep 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37753807</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15892</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1342</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1342</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhong, B.</style></author><author><style face="normal" font="default" size="100%">Du, J.</style></author><author><style face="normal" font="default" size="100%">Liu, F.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, S.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Lin, P.</style></author><author><style face="normal" font="default" size="100%">Zhou, J.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Ong, H. H.</style></author><author><style face="normal" font="default" size="100%">Tan, K. S.</style></author><author><style face="normal" font="default" size="100%">Wang, D.</style></author><author><style face="normal" font="default" size="100%">Ba, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Upper Airway Research Laboratory, Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, China.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore.&#xD;State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.&#xD;Department of Otolaryngology, People&apos;s Hospital of Tibet Autonomous Region, Lhasa, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypoxia-induced factor-1alpha induces NLRP3 expression by M1 macrophages in noneosinophilic chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">582-586</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/08/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">NLR Family, Pyrin Domain-Containing 3 Protein/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">NOD-like receptor family</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">hypoxia-induced factor-1alpha</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">macrophage</style></keyword><keyword><style face="normal" font="default" size="100%">pyrin domain containing 3</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32854144</style></accession-num><notes><style face="normal" font="default" size="100%">Zhong, Bing&#xD;Du, Jintao&#xD;Liu, Feng&#xD;Liu, Yafeng&#xD;Liu, Shixi&#xD;Zhang, Jie&#xD;Lin, Ping&#xD;Zhou, Jiao&#xD;Liu, Jing&#xD;Ong, Hsiao Hui&#xD;Tan, Kai Sen&#xD;Wang, Deyun&#xD;Ba, Luo&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):582-586. doi: 10.1111/all.14571. Epub 2020 Sep 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32854144</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14571</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2715</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2715</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhong, B.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Ong, H. H.</style></author><author><style face="normal" font="default" size="100%">Du, J.</style></author><author><style face="normal" font="default" size="100%">Liu, F.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Ba, L.</style></author><author><style face="normal" font="default" size="100%">Sun, S.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, China.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Infectious Diseases Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Department of Otolaryngology, People&apos;s Hospital of Tibet Autonomous Region, Lhasa, China.&#xD;State Key Laboratory of Oral Diseases &amp; National Center for Stomatology &amp; National Clinical Research Center for Oral Diseases &amp; Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypoxia-reduced YAP phosphorylation enhances expression of Mucin5AC in nasal epithelial cells of chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1271-1285</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/11/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mucin 5AC/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/metabolism/complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/metabolism/complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/metabolism/complications/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">YAP-Signaling Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Mucosa/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Epithelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia-Inducible Factor 1, alpha Subunit/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypoxia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Adaptor Proteins, Signal Transducing/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Transcription Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">Mucin5AC</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">hypoxia-inducible factor-1alpha</style></keyword><keyword><style face="normal" font="default" size="100%">yes-associated protein</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39535516</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an upper respiratory disease characterized by persistent inflammation of the nasal mucosa. However, the mechanism of abnormal Mucin5AC expression by CRSwNP epithelial cells is not fully understood. OBJECTIVE: We investigated the potential role of yes-associated protein (YAP) underlying the mechanism of excessive epithelial Mucin5AC expression in CRSwNP in a hypoxic model. METHODS: Tissue biopsies of CRSwNP (n = 60), chronic rhinosinusitis without nasal polyps (CRSsNP) (n = 9) and healthy controls (n = 30) were investigated together with a well-established hypoxic model of primary human nasal epithelial cells (hNECs). The expression levels of hypoxia inducible factor (HIF)-1alpha and YAP, and the effect of the signaling axis on mucus secretion in hNECs were analyzed. RESULTS: We observed a significant elevated expression levels of YAP in patients with CRSwNP and CRSsNP compared to controls. In addition, HIF-1alpha expression of CRSwNP was higher than that of control group. Under hypoxic conditions, HIF-1alpha was found to regulate the upregulation of YAP in hNECs. Further investigations revealed that HIF-1alpha facilitated the activation and nuclear localization of active-YAP by reducing the phosphorylation of YAP. This mechanism appeared to be linked to HIF-1alpha-mediated inhibition of LATS 1 phosphorylation and subsequent YAP degradation. HIF-1alpha was shown to promote the expression of P63 and the levels of Mucin5AC in hNECs by enhancing YAP activation. CONCLUSION: Our findings indicated that hypoxia enhances YAP activation by decreasing p-LATS 1 and YAP phosphorylation. This has the potential to impact on the proliferation of basal cells and the differentiation of goblet cells in CRSwNP, ultimately leading to a pathological condition characterized by excessive Mucin5AC expression.</style></abstract><notes><style face="normal" font="default" size="100%">Zhong, Bing&#xD;Liu, Jing&#xD;Ong, Hsiao Hui&#xD;Du, Jintao&#xD;Liu, Feng&#xD;Liu, Yafeng&#xD;Ba, Luo&#xD;Sun, Silu&#xD;Wang, De Yun&#xD;eng&#xD;China Postdoctoral Science Foundation/&#xD;Special support from China Postdoctoral Science Foundation/&#xD;Full time postdoctoral research and development fund of West China Hospital of Sichuan University/&#xD;Natural Science Foundation of Sichuan Province/&#xD;Postdoctoral Fellowship Program of CPSF/&#xD;National Natural Science Foundation of China/&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1271-1285. doi: 10.1111/all.16394. Epub 2024 Nov 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39535516</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16394</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>752</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">752</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Papi, A.</style></author><author><style face="normal" font="default" size="100%">Jesenak, M.</style></author><author><style face="normal" font="default" size="100%">Alfano, F.</style></author><author><style face="normal" font="default" size="100%">G. Peroni D</style></author><author><style face="normal" font="default" size="100%">Baraldi, F.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medicine, Respiratory Medicine, University of Ferrara and Emergency Department, University Hospital, Ferrara, Italy.&#xD;Department of Paediatrics, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.&#xD;Department of Clinical Immunology and Allergology, University Teaching Hospital in Martin, Martin, Slovakia.&#xD;Department of Clinical and Experimental Medicine, Pediatric Clinic, AOUP, University of Pisa, University Hospital, Pisa, Italy.&#xD;Department of Microbiology Immunology &amp; Transplantation, KU Leuven, Catholic University of Leuven, Leuven, Belgium.&#xD;Department of Respiratory Medicine &amp; Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.&#xD;Department Clin Pharm &amp; Pharmacol, University Groningen, University Medical Center Groningen, Groningen, Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The ICQ asthma algorithm: Inhaled corticosteroid Containing resCUE (ICQ) treatment for present and future asthma management</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1325-1327</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/10/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34614223</style></accession-num><notes><style face="normal" font="default" size="100%">Papi, Alberto&#xD;Jesenak, Milos&#xD;Alfano, Franco&#xD;G Peroni, Diego&#xD;Baraldi, Federico&#xD;Diamant, Zuzana&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1325-1327. doi: 10.1111/all.15131. Epub 2021 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34614223</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15131</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1847</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1847</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Papi, A.</style></author><author><style face="normal" font="default" size="100%">Jesenak, M.</style></author><author><style face="normal" font="default" size="100%">Alfano, F.</style></author><author><style face="normal" font="default" size="100%">G. Peroni D</style></author><author><style face="normal" font="default" size="100%">Baraldi, F.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medicine, Respiratory Medicine, University of Ferrara and Emergency Department, University Hospital, Ferrara, Italy.&#xD;Department of Paediatrics, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.&#xD;Department of Clinical Immunology and Allergology, University Teaching Hospital in Martin, Martin, Slovakia.&#xD;Department of Clinical and Experimental Medicine, Pediatric Clinic, AOUP, University of Pisa, University Hospital, Pisa, Italy.&#xD;Department of Microbiology Immunology &amp; Transplantation, KU Leuven, Catholic University of Leuven, Leuven, Belgium.&#xD;Department of Respiratory Medicine &amp; Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.&#xD;Department Clin Pharm &amp; Pharmacol, University Groningen, University Medical Center Groningen, Groningen, Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The ICQ asthma algorithm: Inhaled corticosteroid Containing resCUE (ICQ) treatment for present and future asthma management</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1325-1327</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/10/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34614223</style></accession-num><abstract><style face="normal" font="default" size="100%">Anti-inflammatory treatment is the pharmacological cornerstone of asthma management. However, for a long time, short-acting beta-agonists (SABAs) have been proposed as rescue medications in all treatment steps and as monotherapy for milder asthma. This was based on the unproven assumption that symptom relief requires only bronchodilation. Herein, we describe the evolution of the Inhaled corticosteroid (ICS) Containing resCUE (IC-CUE; ICQ) algorithm by tracing its origins and projecting it into the future.</style></abstract><notes><style face="normal" font="default" size="100%">Papi, Alberto&#xD;Jesenak, Milos&#xD;Alfano, Franco&#xD;G Peroni, Diego&#xD;Baraldi, Federico&#xD;Diamant, Zuzana&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1325-1327. doi: 10.1111/all.15131. Epub 2021 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34614223</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15131</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>677</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">677</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wangorsch, A.</style></author><author><style face="normal" font="default" size="100%">Lidholm, J.</style></author><author><style face="normal" font="default" size="100%">Mattsson, L. A.</style></author><author><style face="normal" font="default" size="100%">Larsson, H.</style></author><author><style face="normal" font="default" size="100%">Reuter, A.</style></author><author><style face="normal" font="default" size="100%">Gubesch, M.</style></author><author><style face="normal" font="default" size="100%">Gadermaier, G.</style></author><author><style face="normal" font="default" size="100%">Bures, P.</style></author><author><style face="normal" font="default" size="100%">Scheurer, S.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular Allergology, Paul-Ehrlich-Institut, Langen, Germany.&#xD;Thermo Fisher Scientific, Uppsala, Sweden.&#xD;Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany.&#xD;Department of Biosciences, Paris Lodron University Salzburg, Salzburg, Austria.&#xD;Allergie+haut2, Uster, Switzerland.&#xD;Department of Dermatology, Allergy Unit, University Hospital, Zurich, Switzerland.&#xD;Clinic for Dermatology and Allergology, Kantonsspital St., Gallen, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of a defensin as novel allergen in celery root: Api g 7 as a missing link in the diagnosis of celery allergy?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1294-1296</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/12/16</style></edition><section><style face="normal" font="default" size="100%">1294</style></section><keywords><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Plant/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Apium/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">*Defensins/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34908171</style></accession-num><notes><style face="normal" font="default" size="100%">Wangorsch, Andrea&#xD;Lidholm, Jonas&#xD;Mattsson, Lars A&#xD;Larsson, Hakan&#xD;Reuter, Andreas&#xD;Gubesch, Michaela&#xD;Gadermaier, Gabriele&#xD;Bures, Peter&#xD;Scheurer, Stephan&#xD;Ballmer-Weber, Barbara&#xD;Vieths, Stefan&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1294-1296. doi: 10.1111/all.15196. Epub 2021 Dec 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34908171</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15196</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>391</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">391</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kunimura, K.</style></author><author><style face="normal" font="default" size="100%">Yamamura, K.</style></author><author><style face="normal" font="default" size="100%">Nakahara, T.</style></author><author><style face="normal" font="default" size="100%">Kido-Nakahara, M.</style></author><author><style face="normal" font="default" size="100%">Uruno, T.</style></author><author><style face="normal" font="default" size="100%">Fukui, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.&#xD;Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of a functional DOCK8 gene polymorphism associated with atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3670-3672</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/07/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Guanine Nucleotide Exchange Factors/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35841182</style></accession-num><notes><style face="normal" font="default" size="100%">Kunimura, Kazufumi&#xD;Yamamura, Kazuhiko&#xD;Nakahara, Takeshi&#xD;Kido-Nakahara, Makiko&#xD;Uruno, Takehito&#xD;Fukui, Yoshinori&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3670-3672. doi: 10.1111/all.15429. Epub 2022 Jul 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35841182</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10083996</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15429</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2413</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2413</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rick, E. M.</style></author><author><style face="normal" font="default" size="100%">Woolnough, K.</style></author><author><style face="normal" font="default" size="100%">Richardson, M.</style></author><author><style face="normal" font="default" size="100%">Monteiro, W.</style></author><author><style face="normal" font="default" size="100%">Craner, M.</style></author><author><style face="normal" font="default" size="100%">Bourne, M.</style></author><author><style face="normal" font="default" size="100%">Cousins, D. J.</style></author><author><style face="normal" font="default" size="100%">Swoboda, I.</style></author><author><style face="normal" font="default" size="100%">Wardlaw, A. J.</style></author><author><style face="normal" font="default" size="100%">Pashley, C. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Sciences, Aerobiology and Mycology Group, Institute for Lung Health, Leicester Biomedical Research Centre - Respiratory, University of Leicester, Leicester, UK.&#xD;Division of Clinical and Molecular Allergology, Airway Research Center North (ARCN), Member of the German Center for Lung Research, Borstel Sulfeld, Germany.&#xD;Department of Allergy and Respiratory Medicine, Leicester Biomedical Research Centre - Respiratory, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK.&#xD;Competence Center for Molecular Biotechnology, Molecular Biotechnology Section, FH Campus Wien, University of Applied Sciences, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of allergens from Aspergillus fumigatus-Potential association with lung damage in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1208-1218</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/02/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Aspergillus fumigatus/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Fungal/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoprecipitation</style></keyword><keyword><style face="normal" font="default" size="100%">Fungal Proteins/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="default" size="100%">allergens</style></keyword><keyword><style face="normal" font="default" size="100%">allergic fungal airway disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38334146</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Component-resolved diagnosis allows detection of IgE sensitization having the advantage of reproducibility and standardization compared to crude extracts. The main disadvantage of the traditional allergen identification methods, 1- or 2-dimensional western blotting and screening of expression cDNA libraries with patients&apos; IgEs, is that the native structure of the protein is not necessarily maintained. METHODS: We used a novel immunoprecipitation technique in combination with mass spectrometry to identify new allergens of Aspergillus fumigatus. Magnetic Dynabeads coupled with anti-human IgE antibodies were used to purify human serum IgE and subsequently allergens from A. fumigatus protein extract. RESULTS: Of the 184 proteins detected by subsequent mass peptide fingerprinting, a subset of 13 were recombinantly expressed and purified. In a panel of 52 A. fumigatus-sensitized people with asthma, 23 non-fungal-sensitized asthmatics and 18 healthy individuals, only the former showed an IgE reaction by immunoblotting and/or ELISA. We discovered 11 proteins not yet described as A. fumigatus allergens, with fructose-bisphosphate aldolase class II (FBA2) (33%), NAD-dependent malate dehydrogenase (31%) and Cu/Zn superoxide dismutase (27%) being the most prevalent. With respect to these three allergens, native versus denatured protein assays indicated a better recognition of the native proteins. Seven of 11 allergens fulfilled the WHO/IUIS criteria and were accepted as new A. fumigatus allergens. CONCLUSION: In conclusion, we introduce a straightforward method of allergen identification from complex allergenic sources such as A. fumigatus by immunoprecipitation combined with mass spectrometry, which has the advantage over traditional methods of identifying allergens by maintaining the structure of the proteins.</style></abstract><notes><style face="normal" font="default" size="100%">Rick, Eva-Maria&#xD;Woolnough, Kerry&#xD;Richardson, Matthew&#xD;Monteiro, William&#xD;Craner, Michelle&#xD;Bourne, Michelle&#xD;Cousins, David John&#xD;Swoboda, Ines&#xD;Wardlaw, Andrew John&#xD;Pashley, Catherine Helen&#xD;eng&#xD;NIHR Leicester Biomedical Research Centre/&#xD;Midlands Asthma and Allergy Research Association/&#xD;Asthma UK/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1208-1218. doi: 10.1111/all.16032. Epub 2024 Feb 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38334146</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16032</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>757</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">757</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turk, M.</style></author><author><style face="normal" font="default" size="100%">Ertas, R.</style></author><author><style face="normal" font="default" size="100%">Zeydan, E.</style></author><author><style face="normal" font="default" size="100%">Turk, Y.</style></author><author><style face="normal" font="default" size="100%">Atasoy, M.</style></author><author><style face="normal" font="default" size="100%">Gutsche, A.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinic of Immunologic and Allergic Diseases, Kayseri City Education and Research Hospital, Kayseri, Turkey.&#xD;Department of Dermatology, Kayseri City Education and Research Hospital, Kayseri, Turkey.&#xD;Communication Networks Division, Centre Tecnologic de Telecomunicacions de Catalunya (CTTC), Barcelona, Spain.&#xD;Aselsan Inc, Ankara, Turkey.&#xD;Dermatological Allergology, Department of Dermatology and Allergy, Berlin Institute of Health, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of chronic urticaria subtypes using machine learning algorithms</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">323-326</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/10/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Machine Learning</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">chronic urticarial</style></keyword><keyword><style face="normal" font="default" size="100%">cluster analysis</style></keyword><keyword><style face="normal" font="default" size="100%">endotype</style></keyword><keyword><style face="normal" font="default" size="100%">phenotype</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34606643</style></accession-num><notes><style face="normal" font="default" size="100%">Turk, Murat&#xD;Ertas, Ragip&#xD;Zeydan, Engin&#xD;Turk, Yekta&#xD;Atasoy, Mustafa&#xD;Gutsche, Annika&#xD;Maurer, Marcus&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):323-326. doi: 10.1111/all.15119. Epub 2021 Oct 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34606643</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15119</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2187</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2187</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alhamdan, F.</style></author><author><style face="normal" font="default" size="100%">Greulich, T.</style></author><author><style face="normal" font="default" size="100%">Daviaud, C.</style></author><author><style face="normal" font="default" size="100%">Marsh, L. M.</style></author><author><style face="normal" font="default" size="100%">Pedersen, F.</style></author><author><style face="normal" font="default" size="100%">Tholken, C.</style></author><author><style face="normal" font="default" size="100%">Pfefferle, P. I.</style></author><author><style face="normal" font="default" size="100%">Bahmer, T.</style></author><author><style face="normal" font="default" size="100%">Potaczek, D. P.</style></author><author><style face="normal" font="default" size="100%">Tost, J.</style></author><author><style face="normal" font="default" size="100%">Garn, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Translational Inflammation Research Division &amp; Core Facility for Single Cell Multiomics, Member of the German Center for Lung Research (DZL) and the Universities of Giessen and Marburg Lung Center (UGMLC), Medical Faculty, Philipps University of Marburg, Marburg, Germany.&#xD;Department of Medicine, Pulmonary and Critical Care Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Medicine, Pulmonary and Critical Care Medicine, German Center for Lung Research (DZL), University Medical Center Giessen and Marburg, Marburg, Germany.&#xD;Laboratory for Epigenetics &amp; Environment, Centre National de Recherche en Genomique Humaine, CEA-Institut de Biologie Francois Jacob, Universite Paris-Saclay, France.&#xD;Division of Physiology and Pathophysiology, Ludwig Boltzmann Institute for Lung Vascular Research and Otto Loewi Research Center, Medical University of Graz, Graz, Austria.&#xD;Lungen Clinic Grosshansdorf GmbH, Member of the German Center for Lung Research (DZL), Airway Research Center North (ARCN), Grosshansdorf, Germany.&#xD;Institute of Medical Bioinformatics and Biostatistics, Medical Faculty, Philipps University of Marburg, Marburg, Germany.&#xD;Comprehensive Biobank Marburg (CBBMR), Member of the German Biobank Alliance (GBA) and the German Center for Lung Research (DZL), Medical Faculty, Philipps University of Marburg, Marburg, Germany.&#xD;Department for Internal Medicine I, Campus Kiel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), University Hospital Schleswig-Holstein, Kiel, Germany.&#xD;Center for Infection and Genomics of the Lung (CIGL), Member of the German Center for Lung Research (DZL) and Universities of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University of Giessen, Giessen, Germany.&#xD;Bioscientia MVZ Labor Mittelhessen GmbH, Giessen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of extracellular vesicle microRNA signatures specifically linked to inflammatory and metabolic mechanisms in obesity-associated low type-2 asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2944-2958</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/07/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-6/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Extracellular Vesicles/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity/complications/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">asthma endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">asthma phenotypes</style></keyword><keyword><style face="normal" font="default" size="100%">extracellular vesicles</style></keyword><keyword><style face="normal" font="default" size="100%">microRNA clusters</style></keyword><keyword><style face="normal" font="default" size="100%">obesity-associated asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37486026</style></accession-num><abstract><style face="normal" font="default" size="100%">RATIONALE AND OBJECTIVE: Plasma extracellular vesicles (EVs) represent a vital source of molecular information about health and disease states. Due to their heterogenous cellular sources, EVs and their cargo may predict specific pathomechanisms behind disease phenotypes. Here we aimed to utilize EV microRNA (miRNA) signatures to gain new insights into underlying molecular mechanisms of obesity-associated low type-2 asthma. METHODS: Obese low type-2 asthma (OA) and non-obese low type-2 asthma (NOA) patients were selected from an asthma cohort conjointly with healthy controls. Plasma EVs were isolated and characterised by nanoparticle tracking analysis. EV-associated small RNAs were extracted, sequenced and bioinformatically analysed. RESULTS: Based on EV miRNA expression profiles, a clear distinction between the three study groups could be established using a principal component analysis. Integrative pathway analysis of potential target genes of the differentially expressed miRNAs revealed inflammatory cytokines (e.g., interleukin-6, transforming growth factor-beta, interferons) and metabolic factors (e.g., insulin, leptin) signalling pathways to be specifically associated with OA. The miR-17-92 and miR-106a-363 clusters were significantly enriched only in OA. These miRNA clusters exhibited discrete bivariate correlations with several key laboratory (e.g., C-reactive protein) and lung function parameters. Plasma EV miRNA signatures mirrored blood-derived CD4(+) T-cell transcriptome data, but achieved an even higher sensitivity in identifying specifically affected biological pathways. CONCLUSION: The identified plasma EV miRNA signatures and particularly the miR-17-92 and -106a-363 clusters were capable to disentangle specific mechanisms of the obesity-associated low type-2 asthma phenotype, which may serve as basis for stratified treatment development.</style></abstract><notes><style face="normal" font="default" size="100%">Alhamdan, Fahd&#xD;Greulich, Timm&#xD;Daviaud, Christian&#xD;Marsh, Leigh M&#xD;Pedersen, Frauke&#xD;Tholken, Clemens&#xD;Pfefferle, Petra Ina&#xD;Bahmer, Thomas&#xD;Potaczek, Daniel P&#xD;Tost, Jorg&#xD;Garn, Holger&#xD;eng&#xD;German Academic Exchange Service (DAAD)/&#xD;German Center for Lung Research (DZL)/&#xD;Hessen State Ministry for Higher Education, Research, Science and and the Arts/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2944-2958. doi: 10.1111/all.15824. Epub 2023 Jul 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37486026</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15824</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2399</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2399</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Song, L. B.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Zhu, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, Y. S.</style></author><author><style face="normal" font="default" size="100%">Xu, Z. Q.</style></author><author><style face="normal" font="default" size="100%">Sun, J. L.</style></author><author><style face="normal" font="default" size="100%">Wei, J. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacy, Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.&#xD;Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.&#xD;Division of Respiratory and Critical Care Medicine, Respiratory Infection and Intervention Laboratory of Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, China.&#xD;Department of Blood Transfusion, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.&#xD;Department of Allergy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.&#xD;Department of Pharmacy, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of fructose-bisphosphate aldolase as new pollen allergens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1368-1372</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Fructose-Bisphosphate Aldolase/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinitis, Allergic, Seasonal/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38375932</style></accession-num><notes><style face="normal" font="default" size="100%">Song, Le-Bin&#xD;Zhang, Li&#xD;Zhu, Ying&#xD;Yang, Yong-Shi&#xD;Xu, Zhi-Qiang&#xD;Sun, Jin-Lyu&#xD;Wei, Ji-Fu&#xD;eng&#xD;National Natural Science Foundation of China/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1368-1372. doi: 10.1111/all.16058. Epub 2024 Feb 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38375932</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16058</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2774</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2774</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lemoine, A.</style></author><author><style face="normal" font="default" size="100%">Kapel, N.</style></author><author><style face="normal" font="default" size="100%">Nicolis, I.</style></author><author><style face="normal" font="default" size="100%">Tounian, P.</style></author><author><style face="normal" font="default" size="100%">Bruneau, A.</style></author><author><style face="normal" font="default" size="100%">Kapandji, N.</style></author><author><style face="normal" font="default" size="100%">Adel-Patient, K.</style></author><author><style face="normal" font="default" size="100%">Thomas, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculte de Sante, Sorbonne Universite, Paris, France.&#xD;INRAE, Micalis Institute, UMR1319, AgroParisTech, Paris Saclay University, Jouy-en-Josas, France.&#xD;Pediatric Nutrition and Gastroenterology Department, APHP-Trousseau Hospital, Paris, France.&#xD;FHU-PaCeMM (Paris Center for Microbiome Medicine), Paris, France.&#xD;Functional Coprology Laboratory, APHP-Pitie-Salpetriere Hospital, Paris, France.&#xD;INSERM S1139, Universite Paris Cite, Paris, France.&#xD;UR 7537 BioSTM, Universite Paris Cite, Paris, France.&#xD;CEA, INRAE, DMTS, LIAA, Paris-Saclay University, Gif-sur-Yvette, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of Gut Biomarkers of FPIES in a Longitudinal Comparative Pediatric Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1389-1399</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/12/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte L1 Antigen Complex/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Feces/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">*Enterocolitis/diagnosis/immunology/metabolism/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophil-Derived Neurotoxin/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Dietary Proteins/adverse effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Edn</style></keyword><keyword><style face="normal" font="default" size="100%">Fpies</style></keyword><keyword><style face="normal" font="default" size="100%">IgA</style></keyword><keyword><style face="normal" font="default" size="100%">calprotectin</style></keyword><keyword><style face="normal" font="default" size="100%">zonulin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39723604</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated allergy without known biomarkers. We aimed to compare fecal biomarkers related to gut inflammation and immunity in children with FPIES, with resolved FPIES (tolerant), and in matched controls. METHODS: Stools were collected from FPIES children on elimination diet, before and after an oral food challenge (OFC) performed to assess their natural tolerance, at the end of a follow-up in tolerant FPIES children, and in matched controls (1:1 ratio). Concentrations of calprotectin, EDN (eosinophilic derived neurotoxin), and secretory IgA (sIgA) underwent comparative paired analysis. RESULTS: Thirty-eight patients were included (age: 1.3 years old, interquartile range: IQR [0.9-2.0]), of which 22 became tolerant during follow-up. Upon inclusion, allergic patients and controls had similar concentrations of calprotectin (38 mug/g [8-85] vs. 27 mug/g [11-46], p = 0.15) and EDN (504 ng/g [275-1252] vs. 516 ng/g [215-844], p = 0.86). However, concentrations of these inflammatory biomarkers increased transiently after a failed OFC (p &lt; 0.001 and p = 0.01 respectively), without correlating with the severity of an allergic reaction. sIgA were higher in allergic than in tolerant patients: 2224 mug/g [878-3529] vs. 794 mug/g [699-1767] (p &lt; 0.01). Calprotectin, EDN, and sIgA were comparable in tolerant patients and controls. sIgA less than 2637 mug/g had a negative predictive value of 75.3% for the differentiation allergic patients from tolerant patients and controls (area under curve: 0.63, 95% CI: 0.52-0.74). CONCLUSION: A few days after an acute allergic reaction, there was no detectable chronic gut inflammation in FPIES. sIgA may be a useful tool for clinicians in timing OFC.</style></abstract><notes><style face="normal" font="default" size="100%">Lemoine, A&#xD;Kapel, N&#xD;Nicolis, I&#xD;Tounian, P&#xD;Bruneau, A&#xD;Kapandji, N&#xD;Adel-Patient, K&#xD;Thomas, M&#xD;eng&#xD;Societe Francaise d&apos;Allergologie/&#xD;Soredab/&#xD;Sodilac/&#xD;Societe Francophone Nutrition Clinique et Metabolisme/&#xD;Societe Nationale Francaise de Gastro-Enterologie/&#xD;Societe Francaise de Pediatrie/&#xD;Comparative Study&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1389-1399. doi: 10.1111/all.16457. Epub 2024 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39723604</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105057</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16457</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3247</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3247</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liang, Shixiu</style></author><author><style face="normal" font="default" size="100%">Dong, Meihua</style></author><author><style face="normal" font="default" size="100%">Zhu, Xiaodi</style></author><author><style face="normal" font="default" size="100%">Wang, Siqi</style></author><author><style face="normal" font="default" size="100%">Lin, Sitong</style></author><author><style face="normal" font="default" size="100%">Li, Yanwen</style></author><author><style face="normal" font="default" size="100%">Yi, Shiting</style></author><author><style face="normal" font="default" size="100%">Wu, Di</style></author><author><style face="normal" font="default" size="100%">Yang, Zhaowei</style></author><author><style face="normal" font="default" size="100%">Chen, Yingjun</style></author><author><style face="normal" font="default" size="100%">Li, Jing</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Identification of Key Genes Associated With Epithelial Barrier Dysfunction by Comprehensive Analysis and Experimental Validation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Epithelial barrier dysfunction is a pivotal feature of asthma, and it also commonly occurs in other inflammatory conditions such as atopic dermatitis (AD) and ulcerative colitis (UC). However, the core regulatory mechanisms underlying epithelial barrier dysfunction—especially whether shared mechanisms exist across these diseases—remain unclear. Methods Gene expression profiles of patients with asthma, AD, and UC were retrieved from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified using the limma package. Common DEGs among the three diseases were identified via a Venn diagram, followed by correlation analysis with junction molecules to screen for key genes. Interaction networks (protein–protein, transcription factor–gene, miRNA–gene, chemical–gene) of the key genes were constructed, and their correlations with asthma clinical features [Asthma Control Questionnaire (ACQ) score, Inhaled Corticosteroid (ICS) dose, lung function parameters] were analyzed. The effects of the key genes on epithelial barrier function were assessed in airway, epidermal, and intestinal epithelial cells. Results A total of eight common DEGs exhibited consistent upregulation in the epithelial tissues of patients with asthma, AD, and UC. Four key genes—CDC7, PXDN, TCN1, and TIMP1—were identified; they were upregulated in the epithelium of all three diseases, significantly elevated in IL-13-stimulated airway epithelial cells, and negatively correlated with junction molecules that were downregulated in the three diseases. Furthermore, the expression of these key genes was associated with the severity of asthma. Correlation analysis between key gene expression and asthma clinical features revealed that PXDN expression was significantly negatively correlated with the lung function parameter FEV1 (forced expiratory volume in 1 s), while TCN1 expression showed a significant negative correlation with FEV1/FVC (forced expiratory volume in 1 s/forced vital capacity). Chemical-gene interaction analysis revealed that benzo[a]pyrene could induce the expression of these four key genes. Subsequent experiments confirmed that stimulation of airway epithelial cells with benzo[a]pyrene significantly upregulated the expression of these key genes. Finally, targeting these key molecules was found to alleviate the IL-13-induced reduction in CLDN1 expression in airway epithelial cells. In in vitro collagen-coated transwell assays, knocking down either CDC7 or TCN1 significantly attenuated IL-13-induced epithelial barrier disruption in airway, epidermal, and intestinal epithelia. Conclusion Our findings confirm that targeting CDC7 and TCN1 facilitates the improvement of barrier function in airway epithelial cells, epidermal keratinocytes, and intestinal epithelial cells in vitro, thereby providing promising therapeutic targets for diseases characterized by epithelial barrier dysfunction.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70275</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70275</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3331</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3331</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liang, Shixiu</style></author><author><style face="normal" font="default" size="100%">Dong, Meihua</style></author><author><style face="normal" font="default" size="100%">Zhu, Xiaodi</style></author><author><style face="normal" font="default" size="100%">Wang, Siqi</style></author><author><style face="normal" font="default" size="100%">Lin, Sitong</style></author><author><style face="normal" font="default" size="100%">Li, Yanwen</style></author><author><style face="normal" font="default" size="100%">Yi, Shiting</style></author><author><style face="normal" font="default" size="100%">Wu, Di</style></author><author><style face="normal" font="default" size="100%">Yang, Zhaowei</style></author><author><style face="normal" font="default" size="100%">Chen, Yingjun</style></author><author><style face="normal" font="default" size="100%">Li, Jing</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Identification of Key Genes Associated With Epithelial Barrier Dysfunction by Comprehensive Analysis and Experimental Validation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Epithelial barrier dysfunction is a pivotal feature of asthma, and it also commonly occurs in other inflammatory conditions such as atopic dermatitis (AD) and ulcerative colitis (UC). However, the core regulatory mechanisms underlying epithelial barrier dysfunction—especially whether shared mechanisms exist across these diseases—remain unclear. Methods Gene expression profiles of patients with asthma, AD, and UC were retrieved from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified using the limma package. Common DEGs among the three diseases were identified via a Venn diagram, followed by correlation analysis with junction molecules to screen for key genes. Interaction networks (protein–protein, transcription factor–gene, miRNA–gene, chemical–gene) of the key genes were constructed, and their correlations with asthma clinical features [Asthma Control Questionnaire (ACQ) score, Inhaled Corticosteroid (ICS) dose, lung function parameters] were analyzed. The effects of the key genes on epithelial barrier function were assessed in airway, epidermal, and intestinal epithelial cells. Results A total of eight common DEGs exhibited consistent upregulation in the epithelial tissues of patients with asthma, AD, and UC. Four key genes—CDC7, PXDN, TCN1, and TIMP1—were identified; they were upregulated in the epithelium of all three diseases, significantly elevated in IL-13-stimulated airway epithelial cells, and negatively correlated with junction molecules that were downregulated in the three diseases. Furthermore, the expression of these key genes was associated with the severity of asthma. Correlation analysis between key gene expression and asthma clinical features revealed that PXDN expression was significantly negatively correlated with the lung function parameter FEV1 (forced expiratory volume in 1 s), while TCN1 expression showed a significant negative correlation with FEV1/FVC (forced expiratory volume in 1 s/forced vital capacity). Chemical-gene interaction analysis revealed that benzo[a]pyrene could induce the expression of these four key genes. Subsequent experiments confirmed that stimulation of airway epithelial cells with benzo[a]pyrene significantly upregulated the expression of these key genes. Finally, targeting these key molecules was found to alleviate the IL-13-induced reduction in CLDN1 expression in airway epithelial cells. In in vitro collagen-coated transwell assays, knocking down either CDC7 or TCN1 significantly attenuated IL-13-induced epithelial barrier disruption in airway, epidermal, and intestinal epithelia. Conclusion Our findings confirm that targeting CDC7 and TCN1 facilitates the improvement of barrier function in airway epithelial cells, epidermal keratinocytes, and intestinal epithelial cells in vitro, thereby providing promising therapeutic targets for diseases characterized by epithelial barrier dysfunction.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70275</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70275</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>332</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">332</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Murphy, R. C.</style></author><author><style face="normal" font="default" size="100%">Chow, Y. H.</style></author><author><style face="normal" font="default" size="100%">Lai, Y.</style></author><author><style face="normal" font="default" size="100%">Al-Shaikhly, T.</style></author><author><style face="normal" font="default" size="100%">Petroni, D. H.</style></author><author><style face="normal" font="default" size="100%">Black, M.</style></author><author><style face="normal" font="default" size="100%">Hamerman, J. A.</style></author><author><style face="normal" font="default" size="100%">Lacy-Hulbert, A.</style></author><author><style face="normal" font="default" size="100%">Piliponsky, A. M.</style></author><author><style face="normal" font="default" size="100%">Hallstrand, T. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, Washington, USA.&#xD;Center for Lung Biology, Department of Medicine, University of Washington, Seattle, Washington, USA.&#xD;Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington, USA.&#xD;Seattle Allergy and Asthma Research Institute, Seattle, Washington, USA.&#xD;Department of Immunology, University of Washington, Seattle, Washington, USA.&#xD;Immunology Program, Benaroya Research Institute, Seattle, Washington, USA.&#xD;Seattle Children&apos;s Research Institute, Seattle, Washington, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of mast cell progenitor cells in the airways of individuals with allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">547-549</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/08/30</style></edition><section><style face="normal" font="default" size="100%">547</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">induced sputum</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">progenitor</style></keyword><keyword><style face="normal" font="default" size="100%">to disclose. RCM, JAM, ALH, AMP, and TSH report grant funding from the National</style></keyword><keyword><style face="normal" font="default" size="100%">Institutes of Health. TA-S has patents pending for MicroRNAs as Predictors of</style></keyword><keyword><style face="normal" font="default" size="100%">Response to Anti-IgE Therapies in Chronic Spontaneous Urticaria as well as for</style></keyword><keyword><style face="normal" font="default" size="100%">MicroRNAs in Methods of Treatment using Omalizumab and Ligelizumab. JAM reports</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from aTyr Pharma. ALH reports grant funding from the Department</style></keyword><keyword><style face="normal" font="default" size="100%">of Defense. AMP has patents for Composition and Methods for Detecting Sepsis and</style></keyword><keyword><style face="normal" font="default" size="100%">Inhibiting Mast Cell Activation by Binding Sialic Acid-binding</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin-like Lection-9 (SIGLEC-9).</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36038252</style></accession-num><notes><style face="normal" font="default" size="100%">Murphy, Ryan C&#xD;Chow, Yu-Hua&#xD;Lai, Ying&#xD;Al-Shaikhly, Taha&#xD;Petroni, Daniel H&#xD;Black, Michele&#xD;Hamerman, Jessica A&#xD;Lacy-Hulbert, Adam&#xD;Piliponsky, Adrian M&#xD;Hallstrand, Teal S&#xD;eng&#xD;K24 AI130263/AI/NIAID NIH HHS/&#xD;R01 HL153979/HL/NHLBI NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):547-549. doi: 10.1111/all.15498. Epub 2022 Sep 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36038252</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9892201</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15498</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>893</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">893</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bindke, G.</style></author><author><style face="normal" font="default" size="100%">Gehring, M.</style></author><author><style face="normal" font="default" size="100%">Wieczorek, D.</style></author><author><style face="normal" font="default" size="100%">Kapp, A.</style></author><author><style face="normal" font="default" size="100%">Buhl, T.</style></author><author><style face="normal" font="default" size="100%">Wedi, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Hannover Medical School, Comprehensive Allergy Center, Hereditary Angioedema center for rare diseases, Hannover, Germany.&#xD;Department of Dermatology, Venerology and Allergology, University Medical Centre Gottingen, Gottingen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of novel biomarkers to distinguish bradykinin-mediated angioedema from mast cell-/histamine-mediated angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">946-955</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/07/22</style></edition><section><style face="normal" font="default" size="100%">946</style></section><keywords><keyword><style face="normal" font="default" size="100%">*Angioedema/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Bradykinin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Selectins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Tie-2</style></keyword><keyword><style face="normal" font="default" size="100%">angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">bradykinin</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34287950</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The pathophysiology of the underlying paroxysmal permeability disturbances in angioedema (AE) is not well understood. METHODS: To identify clinical and laboratory parameters specific for a certain AE subtype, 40 AE patients were prospectively enrolled: 15 hereditary (HAE), 13 ACE-inhibitor induced (ACE-AE), and 12 mast cell-mediated without wheals in chronic spontaneous urticaria (CSU-AE). Ten healthy subjects served as controls. Serum levels of markers indicating activation of the ficolin-lectin pathway, of endothelial cells, or those indicating impairment of vascular integrity or inflammation were assessed by enzyme-linked immunosorbent assay. RESULTS: New routine clinical diagnostic criteria could not be identified, not even for distinguishing bradykinin-mediated (BK-) AE (ie, HAE and ACE-AE) from mast cell-/histamine-mediated CSU-AE. However, FAP-alpha and tPA were significantly increased in all AE compared to controls. In HAE, FAP- alpha, tPA, uPAR, pentraxin-3, Tie-2, sE-selectin, and VE-cadherin were significantly increased compared to controls. In HAE compared to CSU-AE and ACE-AE, sE-Selectin, Tie-2, and VE-Cadherin were significantly increased, whereas for Ang-2 the difference was significant compared to CSU-AE only. Tie-2 correlated strongly negatively with C4, C1-INH activity, and C1-INH function. CONCLUSIONS: This study is the first to compare HAE, ACE-AE, and CSU-AE. Although significance is limited by small sample size, Tie-2 was identified as a new promising biomarker candidate for HAE. FAP- alpha and tPA might serve as a marker for AE in general, whereas sE-selectin and Ang-2 were increased in BK-AE only. Our results add information to the role of endothelial dysfunction and serine proteases in different AE subtypes.</style></abstract><notes><style face="normal" font="default" size="100%">Bindke, Gesa&#xD;Gehring, Manuela&#xD;Wieczorek, Dorothea&#xD;Kapp, Alexander&#xD;Buhl, Timo&#xD;Wedi, Bettina&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):946-955. doi: 10.1111/all.15013. Epub 2021 Jul 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34287950</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15013</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1336</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1336</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Werner, P.</style></author><author><style face="normal" font="default" size="100%">Wisgrill, L.</style></author><author><style face="normal" font="default" size="100%">Riskumaki, M.</style></author><author><style face="normal" font="default" size="100%">Jalonen, E.</style></author><author><style face="normal" font="default" size="100%">Vendelin, J.</style></author><author><style face="normal" font="default" size="100%">Suomela, S.</style></author><author><style face="normal" font="default" size="100%">Lauerma, A.</style></author><author><style face="normal" font="default" size="100%">Alenius, H.</style></author><author><style face="normal" font="default" size="100%">Fyhrquist, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.&#xD;Finnish Institute of Occupational Health, Helsinki, Finland.&#xD;Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of novel miRNA-mRNA regulatory networks in contact dermatitis by integrated microarray analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1257-1261</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/09/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Microarray Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Patch Tests</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">irritant contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">miRNA</style></keyword><keyword><style face="normal" font="default" size="100%">miRNA-mRNA integration</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32882078</style></accession-num><notes><style face="normal" font="default" size="100%">Werner, Paulina&#xD;Wisgrill, Lukas&#xD;Riskumaki, Matilda&#xD;Jalonen, Erja&#xD;Vendelin, Johanna&#xD;Suomela, Sari&#xD;Lauerma, Antti&#xD;Alenius, Harri&#xD;Fyhrquist, Nanna&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1257-1261. doi: 10.1111/all.14578. Epub 2020 Sep 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32882078</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246963</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14578</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1309</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1309</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kabasser, S.</style></author><author><style face="normal" font="default" size="100%">Hafner, C.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, S.</style></author><author><style face="normal" font="default" size="100%">Sindher, S. B.</style></author><author><style face="normal" font="default" size="100%">Kumar, D.</style></author><author><style face="normal" font="default" size="100%">Kost, L. E.</style></author><author><style face="normal" font="default" size="100%">Long, A. J.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author><author><style face="normal" font="default" size="100%">Bublin, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Department of Dermatology, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, St. Poelten, Austria.&#xD;Karl Landsteiner Institute for Dermatological Research, St. Poelten, Austria.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA, USA.&#xD;Department of Pediatrics, Stanford University, Stanford, CA, USA.&#xD;Department of Medicine, Stanford University, Stanford, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of Pru du 6 as a potential marker allergen for almond allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1463-1472</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/07</style></edition><section><style face="normal" font="default" size="100%">1463</style></section><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Food Hypersensitivity/*diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Prunus dulcis</style></keyword><keyword><style face="normal" font="default" size="100%">almond allergens</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostic specificity</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">molecular allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">tree nut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Astellas, Regeneron, an Advisory member for Alladapt, Genentech, Novartis, and</style></keyword><keyword><style face="normal" font="default" size="100%">receives personal fees from Before Brands outside the submitted work. Dr. Nadeau</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from National Institute of Allergy and Infectious Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">(NIAID), grants from National Heart, Lung, and Blood Institute (NHLBI), grants</style></keyword><keyword><style face="normal" font="default" size="100%">from National Institute of Environmental Health Sciences (NIEHS), grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Food Allergy Research &amp; Education (FARE), other from World Allergy Organization</style></keyword><keyword><style face="normal" font="default" size="100%">(WAO), other from Cour Pharma, other from Before Brands, other from Alladapt,</style></keyword><keyword><style face="normal" font="default" size="100%">other from Latitude, other from IgGenix, other from Immune Tolerance Network</style></keyword><keyword><style face="normal" font="default" size="100%">(ITN), other from National Institutes of Health (NIH) clinical research centers,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">In addition, Dr. Nadeau has a patent Inhibition of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergic Reaction to Peanut Allergen using an IL-33 Inhibitor pending, a patent</style></keyword><keyword><style face="normal" font="default" size="100%">Special Oral Formula for Decreasing Food Allergy Risk and Treatment for Food</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy pending, a patent Basophil Activation Based Diagnostic Allergy Test</style></keyword><keyword><style face="normal" font="default" size="100%">pending, a patent Granulocyte-based methods for detecting and monitoring immune</style></keyword><keyword><style face="normal" font="default" size="100%">system disorders pending, a patent Methods and Assays for Detecting and</style></keyword><keyword><style face="normal" font="default" size="100%">Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">pending, a patent Mixed Allergen Compositions and Methods for Using the Same</style></keyword><keyword><style face="normal" font="default" size="100%">pending, and a patent Microfluidic Device and Diagnostic Methods for Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Testing Based on Detection of Basophil Activation pending. The rest of the</style></keyword><keyword><style face="normal" font="default" size="100%">authors declare that they have no relevant conflict of interest related to this</style></keyword><keyword><style face="normal" font="default" size="100%">study.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33020913</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Oral food challenges have demonstrated that diagnosis of almond allergy based on extract-sIgE tests displays low specificity. Molecular allergy diagnosis is expected to improve accuracy, but its value in diagnosing almond allergy remains unknown. The aim of this study was to identify relevant almond allergens and examine their ability to improve almond allergy diagnosis. METHODS: IgE-reactive proteins were purified from almond kernels. IgE binding to almond extract and the allergens was analyzed by quantitative ELISA using sera from 18 subjects with a proven almond allergy. The control group consisted of sera from 18 subjects allergic to peanut and/or tree nuts but tolerant to almond. RESULTS: Three IgE-binding proteins were identified: legumin (Pru du 6), alpha-hairpinin (Pru du 8), and mandelonitrile lyase (Pru du 10). Positive IgE (&gt;/=0.35 kU/L) to almond extract showed 94% sensitivity but only 33% specificity. IgE to Pru du 6 maintained high sensitivity (83%) and provided superior specificity (78%). Sera from almond-allergic subjects had significantly higher IgE levels to almond extract (P &lt; .0001) and Pru du 6 (P &lt; .0001) than sera from tolerant donors. Sensitization to Pru du 6 was highly specific for almond allergy, while frequencies of sensitization to legumins from peanut, walnut, hazelnut, and cashew were similar in both groups. IgE to Pru du 8 and Pru du 10 was less sensitive (41% and 67%), but showed specificities of 100% and 61%. CONCLUSION: The use of almond allergens markedly increases the diagnostic specificity compared to the extract. Pru du 6 is a potential new molecular marker for almond allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Kabasser, Stefan&#xD;Hafner, Christine&#xD;Chinthrajah, Sharon&#xD;Sindher, Sayantani B&#xD;Kumar, Divya&#xD;Kost, Laurie E&#xD;Long, Andrew J&#xD;Nadeau, Kari C&#xD;Breiteneder, Heimo&#xD;Bublin, Merima&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1463-1472. doi: 10.1111/all.14613. Epub 2020 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33020913</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8247360</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14613</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>77</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">77</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bitting, K.</style></author><author><style face="normal" font="default" size="100%">Hedgespeth, B.</style></author><author><style face="normal" font="default" size="100%">Ehrhardt-Humbert, L. C.</style></author><author><style face="normal" font="default" size="100%">Arthur, G. K.</style></author><author><style face="normal" font="default" size="100%">Schubert, A. G.</style></author><author><style face="normal" font="default" size="100%">Bradding, P.</style></author><author><style face="normal" font="default" size="100%">Tilley, S. L.</style></author><author><style face="normal" font="default" size="100%">Cruse, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Biomedical Sciences, College of Veterinary Medicine, NC State University, Raleigh, North Carolina, USA.&#xD;Department of Respiratory Sciences, University of Leicester, Glenfield Hospital, Leicester, UK.&#xD;Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of redundancy between human FcepsilonRIbeta and MS4A6A proteins points toward additional complex mechanisms for FcepsilonRI trafficking and signaling</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1204-1217</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/11/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Degranulation</style></keyword><keyword><style face="normal" font="default" size="100%">Exons</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, IgE/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">the research reported in this study. An exclusive licensing agreement has been</style></keyword><keyword><style face="normal" font="default" size="100%">granted to Hoth Therapeutics for this technology. G.C. has research support from</style></keyword><keyword><style face="normal" font="default" size="100%">Hoth Therapeutics for a project related to the research reported in this</style></keyword><keyword><style face="normal" font="default" size="100%">publication and also serves on their Scientific Advisory Board. The terms of this</style></keyword><keyword><style face="normal" font="default" size="100%">arrangement have been reviewed and approved by NC State University in accordance</style></keyword><keyword><style face="normal" font="default" size="100%">with its policy on objectivity in research. The remaining authors declare no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36424895</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic diseases are triggered by signaling through the high-affinity IgE receptor, FcepsilonRI. In both mast cells (MCs) and basophils, FcepsilonRI is a tetrameric receptor complex comprising a ligand-binding alpha subunit (FcepsilonRIalpha), a tetraspan beta subunit (FcepsilonRIbeta, MS4A2) responsible for trafficking and signal amplification, and a signal transducing dimer of single transmembrane gamma subunits (FcepsilonRIgamma). However, FcepsilonRI also exists as presumed trimeric complexes that lack FcepsilonRIbeta and are expressed on several cell types outside the MC and basophil lineages. Despite known differences between humans and mice in the presence of the trimeric FcepsilonRI complex, questions remain as to how it traffics and whether it signals in the absence of FcepsilonRIbeta. We have previously reported that targeting FcepsilonRIbeta with exon-skipping oligonucleotides eliminates IgE-mediated degranulation in mouse MCs, but equivalent targeting in human MCs was not effective at reducing degranulation. RESULTS: Here, we report that the FcepsilonRIbeta-like protein MS4A6A exists in human MCs and compensates for FcepsilonRIbeta in FcepsilonRI trafficking and signaling. Human MS4A6A promotes surface expression of FcepsilonRI complexes and facilitates degranulation. MS4A6A and FcepsilonRIbeta are encoded by highly related genes within the MS4A gene family that cluster within the human gene loci 11q12-q13, a region linked to allergy and asthma susceptibility. CONCLUSIONS: Our data suggest the presence of either FcepsilonRIbeta or MS4A6A is sufficient for degranulation, indicating that MS4A6A could be an elusive FcepsilonRIbeta-like protein in human MCs that performs compensatory functions in allergic disease.</style></abstract><notes><style face="normal" font="default" size="100%">Bitting, Katie&#xD;Hedgespeth, Barry&#xD;Ehrhardt-Humbert, Lauren C&#xD;Arthur, Greer K&#xD;Schubert, Alicia G&#xD;Bradding, Peter&#xD;Tilley, Stephen L&#xD;Cruse, Glenn&#xD;eng&#xD;R01 AI143985/AI/NIAID NIH HHS/&#xD;T32 OD011130/OD/NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1204-1217. doi: 10.1111/all.15595. Epub 2022 Dec 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36424895</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10159887</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15595</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>916</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">916</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfeiffer, S.</style></author><author><style face="normal" font="default" size="100%">Sandler, P.</style></author><author><style face="normal" font="default" size="100%">Raith, M.</style></author><author><style face="normal" font="default" size="100%">Pascal, M.</style></author><author><style face="normal" font="default" size="100%">Munoz-Cano, R. M.</style></author><author><style face="normal" font="default" size="100%">San Bartolome, C.</style></author><author><style face="normal" font="default" size="100%">Nobauer, K.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Razzazi-Fazeli, E.</style></author><author><style face="normal" font="default" size="100%">Focke-Tejkl, M.</style></author><author><style face="normal" font="default" size="100%">Sterflinger, K.</style></author><author><style face="normal" font="default" size="100%">Swoboda, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Molecular Biotechnology Section, FH Campus Wien, Campus Vienna Biocenter, University of Applied Sciences, Vienna, Austria.&#xD;Immunology Department, CDB, Hospital Clinic de Barcelona; IDIBAPS, University of Barcelona, Barcelona, Spain.&#xD;Spanish Network for Allergy - RETIC de Asma, Reacciones adversas y Alergicas (ARADYAL, Madrid, Spain.&#xD;Hospital Clinic de Barcelona, Allergy Unit, IDIBAPS, University of Barcelona, ARADyAL, Barcelona, Spain.&#xD;VetCORE Facility for Research, University of Veterinary Medicine, Vienna, Austria.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, Universidad Autonoma de Madrid, Madrid, Spain.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Institute of Natural Sciences and Technology in the Arts, Academy of Fine Arts Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of Ulocladium chartarum as an important indoor allergen source</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3202-3206</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/07/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Air Pollution, Indoor/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Alternaria</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">indoor allergens</style></keyword><keyword><style face="normal" font="default" size="100%">mold allergy</style></keyword><keyword><style face="normal" font="default" size="100%">recombinant allergens</style></keyword><keyword><style face="normal" font="default" size="100%">ulocladium chartarum</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees and non-financial support from GSK, personal fees and</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from AstraZeneca, personal fees and non-financial support</style></keyword><keyword><style face="normal" font="default" size="100%">from Sanofi, personal fees and non-financial support from Novartis, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">and non-financial support from Mundipharma, personal fees and non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support from Teva, and personal fees and non-financial support from Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, outside the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34216490</style></accession-num><notes><style face="normal" font="default" size="100%">Pfeiffer, Sandra&#xD;Sandler, Peter&#xD;Raith, Marianne&#xD;Pascal, Mariona&#xD;Munoz-Cano, Rosa Maria&#xD;San Bartolome, Clara&#xD;Nobauer, Katharina&#xD;Quirce, Santiago&#xD;Razzazi-Fazeli, Ebrahim&#xD;Focke-Tejkl, Margarete&#xD;Sterflinger, Katja&#xD;Swoboda, Ines&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3202-3206. doi: 10.1111/all.14999. Epub 2021 Jul 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34216490</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9290848</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14999</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>535</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">535</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buttgereit, T.</style></author><author><style face="normal" font="default" size="100%">Gu, S.</style></author><author><style face="normal" font="default" size="100%">Carneiro-Leao, L.</style></author><author><style face="normal" font="default" size="100%">Gutsche, A.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Siebenhaar, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Allergy and Clinical Immunology Department, Centro Hospitalar Universitario de Sao Joao, E.P.E., Oporto, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Idiopathic mast cell activation syndrome is more often suspected than diagnosed-A prospective real-life study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2794-2802</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/04/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cell Activation Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptases</style></keyword><keyword><style face="normal" font="default" size="100%">Mcas</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell activation syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">real-life</style></keyword><keyword><style face="normal" font="default" size="100%">targeted treatment</style></keyword><keyword><style face="normal" font="default" size="100%">tryptase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35364617</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Idiopathic mast cell activation syndrome (MCAS) is characterized by three diagnostic criteria: (1) episodic mast cell (MC)-driven signs/symptoms of at least two organ systems in the absence of clonal MC expansion and definite triggers, (2) episodic increase in tryptase, and (3) response to MC-targeted treatment. Many patients believe they have MCAS, but how often this is the case remains unknown. METHODS: We prospectively investigated patients with suspected MCAS (n = 100) for the diagnostic criteria including baseline tryptase, KIT D816V mutation, and patient-reported outcome measures (PROMs) over the course of 12 weeks. Comorbid depression and anxiety were explored with the Hospital Anxiety and Depression Scale (HADS). RESULTS: In 53% of our patients (80% females), suspicion of MCAS was based on self-evaluation. In total, patients reported 87 different symptoms, mostly fatigue (n = 57), musculoskeletal pain/weakness (n = 49), and abdominal pain (n = 43), with overall high disease activity and impact. Two of 79 patients had increased tryptase (by &gt;20% +2 ng/ml) following an episode. Only 5%, with any of the PROMs used, showed complete response to MC-targeted treatment. Depression and anxiety disorders were frequent comorbidities (n = 23 each), and 65 patients had pathological HADS values, which were linked to high disease impact and poor symptom control. CONCLUSION: Mast cell activation syndrome was confirmed in only 2% of patients, which implies that it is not MC activation that drives signs and symptoms in most patients with suspected MCAS. There is a high need for comprehensive research efforts aimed at the identification of the true underlying pathomechanism(s) in patients with suspected MCAS.</style></abstract><notes><style face="normal" font="default" size="100%">Buttgereit, Thomas&#xD;Gu, Sophie&#xD;Carneiro-Leao, Leonor&#xD;Gutsche, Annika&#xD;Maurer, Marcus&#xD;Siebenhaar, Frank&#xD;eng&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2794-2802. doi: 10.1111/all.15304. Epub 2022 Apr 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35364617</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15304</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2358</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2358</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kubota, N.</style></author><author><style face="normal" font="default" size="100%">Suzuki, S.</style></author><author><style face="normal" font="default" size="100%">Kuwano, Y.</style></author><author><style face="normal" font="default" size="100%">Kakiyama, S.</style></author><author><style face="normal" font="default" size="100%">Harima-Mizusawa, N.</style></author><author><style face="normal" font="default" size="100%">Nishida, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Yakult Central Institute, Tokyo, Japan.&#xD;Department of Clinical Research, NHO Shimoshizu National Hospital, Chiba, Japan.&#xD;Department of Pathophysiology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IDO1 and FOXP3: Possible immune-regulating genes alleviating cedar pollinosis via L. plantarum YIT 0132</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1966-1969</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/01/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Forkhead Transcription Factors/metabolism/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cryptomeria/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38279616</style></accession-num><notes><style face="normal" font="default" size="100%">Kubota, Norihiro&#xD;Suzuki, Shuichi&#xD;Kuwano, Yuki&#xD;Kakiyama, Sayaka&#xD;Harima-Mizusawa, Naomi&#xD;Nishida, Kensei&#xD;eng&#xD;Yakult Honsha Co., Ltd/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1966-1969. doi: 10.1111/all.16039. Epub 2024 Jan 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38279616</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16039</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2909</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2909</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Clement, R. L.</style></author><author><style face="normal" font="default" size="100%">Dilollo, J.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Lopez, E. M.</style></author><author><style face="normal" font="default" size="100%">Guerrier, C. M.</style></author><author><style face="normal" font="default" size="100%">Hill, D. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;Division of Allergy and Immunology, Children&apos;s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.&#xD;Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IFNgamma Signaling Impairs Regulatory B Cell Function Resulting in Worse Control of Esophageal Food Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2824-2836</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/05/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Interferon-gamma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/immunology/metabolism/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*B-Lymphocytes, Regulatory/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Signal Transduction/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-10/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Esophagus/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">interferon-gamma</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-10</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory B cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40387177</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophilic Esophagitis (EoE) is a chronic food allergy that causes esophageal inflammation and fibrosis and manifests with symptoms of reflux, chest pain, swallowing difficulty, and food impactions. Though the prevalence of EoE is increasing by ~15% each year, our understanding of EoE immunopathology is limited. A noted feature of EoE is the presence of food-specific IgG4 antibodies in the circulation and esophageal tissue. Production of IgG4 is confined to IL-10(+) B cells (Bregs) in other allergic diseases, suggesting Bregs may be present in EoE. METHODS: We examined circulating Bregs in patients with EoE milk allergy. In parallel, we performed mechanistic investigations of the role of Bregs in a murine model of food-antigen-dependent EoE. Flow cytometry and histologic analyses were used to assess esophageal and draining lymph node immune cells, and in vitro assays were used to evaluate Breg functional capacity. RESULTS: Breg frequency was reduced in both EoE milk allergic subjects and an EoE disease model. Murine Breg suppressive capacity was impaired during EoE-like inflammation. Inducible deletion of Breg-derived IL-10 worsened EoE-like inflammation, while adoptive transfer of IL-10 sufficient Bregs suppressed DC activation and improved esophageal eosinophilia. IFNgamma was sufficient to suppress Breg expansion and IL-10 production in vitro and contributed to Breg dysfunction and esophageal inflammation in vivo. CONCLUSION: Bregs play an immunoregulatory role during EoE by controlling esophageal eosinophilia but are functionally impaired due to IFNgamma-mediated signaling. These findings have important implications for understanding EoE&apos;s etiology and implementing future therapies that target IFNgamma.</style></abstract><notes><style face="normal" font="default" size="100%">Clement, Rachel L&#xD;Dilollo, Julie&#xD;Rodriguez-Lopez, Eric M&#xD;Guerrier, Cleandre M&#xD;Hill, David A&#xD;eng&#xD;Hartwell Foundation/&#xD;Children&apos;s Hospital of Philadelphia/&#xD;American Partnership for Eosinophilic Disorders/&#xD;Food Allergy Fund/&#xD;American Academy of Allergy, Asthma and Immunology Foundation/&#xD;T32 AI055428/AI/NIAID NIH HHS/&#xD;5T32AI055428-19/NH/NIH HHS/&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2824-2836. doi: 10.1111/all.16594. Epub 2025 May 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40387177</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12354031</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16594</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1050</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1050</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Starkl, P.</style></author><author><style face="normal" font="default" size="100%">Gaudenzio, N.</style></author><author><style face="normal" font="default" size="100%">Marichal, T.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author><author><style face="normal" font="default" size="100%">Sibilano, R.</style></author><author><style face="normal" font="default" size="100%">Watzenboeck, M. L.</style></author><author><style face="normal" font="default" size="100%">Fontaine, F.</style></author><author><style face="normal" font="default" size="100%">Mueller, A. C.</style></author><author><style face="normal" font="default" size="100%">Tsai, M.</style></author><author><style face="normal" font="default" size="100%">Knapp, S.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Infection Biology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.&#xD;CeMM - Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.&#xD;Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR1291, CNRS, UMR5051, University of Toulouse III, Toulouse, France.&#xD;GIGA-Research and Faculty of Veterinary Medicine, University of Liege, Liege, Belgium.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA, USA.&#xD;Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.&#xD;Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IgE antibodies increase honeybee venom responsiveness and detoxification efficiency of mast cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">499-512</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/04/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Bee Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Degranulation</style></keyword><keyword><style face="normal" font="default" size="100%">Heparin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Peptide Hydrolases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">honeybee venom</style></keyword><keyword><style face="normal" font="default" size="100%">host defense</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">toxin hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">S.K., and S.J.G. have nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33840121</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In contrast to their clearly defined roles in allergic diseases, the physiologic functions of Immunoglobulin E antibodies (IgEs) and mast cells (MCs) remain enigmatic. Recent research supports the toxin hypothesis, showing that MCs and IgE-related type 2 immune responses can enhance host defense against certain noxious substances, including honeybee venom (BV). However, the mechanisms by which MCs can interfere with BV toxicity are unknown. In this study, we assessed the role of IgE and certain MC products in MC-mediated BV detoxification. METHODS: We applied in vitro and in vivo fluorescence microscopyimaging, and flow cytometry, fibroblast-based toxicity assays and mass spectrometry to investigate IgE-mediated detoxification of BV cytotoxicity by mouse and human MCs in vitro. Pharmacologic strategies to interfere with MC-derived heparin and proteases helped to define the importance of specific detoxification mechanisms. RESULTS: Venom-specific IgE increased the degranulation and cytokine responses of MCs to BV in vitro. Passive serum sensitization enhanced MC degranulation in vivo. IgE-activated mouse or human MCs exhibited enhanced potential for detoxifying BV by both proteolytic degradation and heparin-related interference with toxicity. Mediators released by IgE-activated human MCs efficiently degraded multiple BV toxins. CONCLUSIONS: Our results both reveal that IgE sensitization enhances the MC&apos;s ability to detoxify BV and also assign efficient toxin-neutralizing activity to MC-derived heparin and proteases. Our study thus highlights the potential importance of IgE, MCs, and particular MC products in defense against BV.</style></abstract><notes><style face="normal" font="default" size="100%">Starkl, Philipp&#xD;Gaudenzio, Nicolas&#xD;Marichal, Thomas&#xD;Reber, Laurent L&#xD;Sibilano, Riccardo&#xD;Watzenboeck, Martin L&#xD;Fontaine, Frederic&#xD;Mueller, Andre C&#xD;Tsai, Mindy&#xD;Knapp, Sylvia&#xD;Galli, Stephen J&#xD;eng&#xD;R01 AI132494/AI/NIAID NIH HHS/&#xD;R01 AI023990/AI/NIAID NIH HHS/&#xD;J 3399/FWF_/Austrian Science Fund FWF/Austria&#xD;R01 AR067145/AR/NIAMS NIH HHS/&#xD;P 31113/FWF_/Austrian Science Fund FWF/Austria&#xD;R01 AI070813/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):499-512. doi: 10.1111/all.14852. Epub 2021 May 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33840121</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8502784</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14852</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2624</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2624</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McCraw, A. J.</style></author><author><style face="normal" font="default" size="100%">Palhares, Lcgf</style></author><author><style face="normal" font="default" size="100%">Hendel, J. L.</style></author><author><style face="normal" font="default" size="100%">Gardner, R. A.</style></author><author><style face="normal" font="default" size="100%">Santaolalla, A.</style></author><author><style face="normal" font="default" size="100%">Crescioli, S.</style></author><author><style face="normal" font="default" size="100%">McDonnell, J.</style></author><author><style face="normal" font="default" size="100%">Van Hemelrijck, M.</style></author><author><style face="normal" font="default" size="100%">Chenoweth, A.</style></author><author><style face="normal" font="default" size="100%">Spencer, D. I. R.</style></author><author><style face="normal" font="default" size="100%">Wagner, G. K.</style></author><author><style face="normal" font="default" size="100%">Karagiannis, S. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">St. John&apos;s Institute of Dermatology, School of Basic &amp; Medical Biosciences &amp; KHP Centre for Translational Medicine, Guy&apos;s Hospital, King&apos;s College London, London, UK.&#xD;Department of Chemistry, Trent University, Peterborough, Ontario, Canada.&#xD;Ludger, Ltd., Abingdon, Oxfordshire, UK.&#xD;Translational Oncology &amp; Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King&apos;s College, London, UK.&#xD;Randall Centre for Cell and Molecular Biophysics, School of Basic &amp; Medical Biosciences, King&apos;s College London, London, UK.&#xD;Breast Cancer Now Research Unit, School of Cancer &amp; Pharmaceutical Sciences, Guy&apos;s Cancer Centre, King&apos;s College London, London, UK.&#xD;School of Pharmacy, Medical Biology Centre, Queen&apos;s University Belfast, Belfast, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IgE glycosylation and impact on structure and function: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2625-2661</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/08/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Glycosylation</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Polysaccharides/metabolism/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">cancer</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39099223</style></accession-num><abstract><style face="normal" font="default" size="100%">The impact of human IgE glycosylation on structure, function and disease mechanisms is not fully elucidated, and heterogeneity in different studies renders drawing conclusions challenging. Previous reviews discussed IgE glycosylation focusing on specific topics such as health versus disease, FcepsilonR binding or impact on function. We present the first systematic review of human IgE glycosylation conducted utilizing the PRISMA guidelines. We sought to define the current consensus concerning the roles of glycosylation on structure, biology and disease. Despite diverse analytical methodologies, source, expression systems and the sparsity of data on IgE antibodies from non-allergic individuals, collectively evidence suggests differential glycosylation profiles, particularly in allergic diseases compared with healthy states, and indicates functional impact, and contributions to IgE-mediated hypersensitivities and atopic diseases. Beyond allergic diseases, dysregulated terminal glycan structures, including sialic acid, may regulate IgE metabolism. Glycan sites such as N394 may contribute to stabilizing IgE structure, with alterations in these glycans likely influencing both structure and IgE-FcepsilonR interactions. This systematic review therefore highlights critical IgE glycosylation attributes in health and disease that may be exploitable for therapeutic intervention, and the need for novel analytics to explore pertinent research avenues.</style></abstract><notes><style face="normal" font="default" size="100%">McCraw, Alexandra J&#xD;Palhares, Lais C G F&#xD;Hendel, Jenifer L&#xD;Gardner, Richard A&#xD;Santaolalla, Aida&#xD;Crescioli, Silvia&#xD;McDonnell, James&#xD;Van Hemelrijck, Mieke&#xD;Chenoweth, Alicia&#xD;Spencer, Daniel I R&#xD;Wagner, Gerd K&#xD;Karagiannis, Sophia N&#xD;eng&#xD;C30122/A15774/CRUK_/Cancer Research UK/United Kingdom&#xD;24-0087/AICR_/Worldwide Cancer Research/United Kingdom&#xD;006/R/22/British Skin Foundation/&#xD;MR/L023091/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/R015643/1/UK Medical Research Council/&#xD;C604/A25135/Cancer Research UK King&apos;s Health Partners Centre at King&apos;s College London/&#xD;KCL-BCN-Q3/BBC_/Breast Cancer Now/United Kingdom&#xD;C30122/A11527/CRUK_/Cancer Research UK/United Kingdom&#xD;King&apos;s Health Partners Centre for Translational Medicine/&#xD;SPF573/Guy&apos;s Cancer Charity Melanoma Special Fund/&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2625-2661. doi: 10.1111/all.16259. Epub 2024 Aug 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39099223</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16259</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2113</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2113</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Plattner, K.</style></author><author><style face="normal" font="default" size="100%">Augusto, G.</style></author><author><style face="normal" font="default" size="100%">Muerner, L.</style></author><author><style face="normal" font="default" size="100%">von Gunten, S.</style></author><author><style face="normal" font="default" size="100%">Jorg, L.</style></author><author><style face="normal" font="default" size="100%">Engeroff, P.</style></author><author><style face="normal" font="default" size="100%">Bachmann, M. F.</style></author><author><style face="normal" font="default" size="100%">Vogel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, University Clinic for Rheumatology and Immunology, University of Bern, Bern, Switzerland.&#xD;Department of Biomedical Research Bern (DBMR), University of Bern, Bern, Switzerland.&#xD;Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, UK.&#xD;Institute of Pharmacology, University of Bern, Bern, Switzerland.&#xD;Division of Allergology and Clinical Immunology, Department of Pneumology, Inselspital, Bern University Hospital, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IgE glycosylation is essential for the function of omalizumab</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2546-2549</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/04/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Glycosylation</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">IgE regulation</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">glycans</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37073887</style></accession-num><notes><style face="normal" font="default" size="100%">Plattner, Kevin&#xD;Augusto, Gilles&#xD;Muerner, Lukas&#xD;von Gunten, Stephan&#xD;Jorg, Lukas&#xD;Engeroff, Paul&#xD;Bachmann, Martin F&#xD;Vogel, Monique&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2546-2549. doi: 10.1111/all.15748. Epub 2023 Apr 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37073887</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15748</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1278</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1278</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moya, B.</style></author><author><style face="normal" font="default" size="100%">Tontini, C.</style></author><author><style face="normal" font="default" size="100%">Santos, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Service, Hospital Universitario 12 de Octubre, Madrid, Spain.&#xD;Faculty of Biology, Medicine and Health, Lydia Becker Institute for Immunology and Inflammation, University of Manchester, Manchester, UK.&#xD;Department of Women and Children&apos;s Health (Paediatric Allergy), Faculty of Life Sciences and Medicine, School of Life Course Sciences, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Asthma UK Centre of Allergic Mechanisms of Asthma, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IgE sialylation: Unravelling a key anaphylactic mediator</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1598-1600</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33147354</style></accession-num><notes><style face="normal" font="default" size="100%">Moya, Beatriz&#xD;Tontini, Chiara&#xD;Santos, Alexandra&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1598-1600. doi: 10.1111/all.14649. Epub 2020 Nov 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33147354</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14649</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1094</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1094</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grilo, J. R.</style></author><author><style face="normal" font="default" size="100%">Kitzmuller, C.</style></author><author><style face="normal" font="default" size="100%">Aglas, L.</style></author><author><style face="normal" font="default" size="100%">Sanchez Acosta, G.</style></author><author><style face="normal" font="default" size="100%">Vollmann, U.</style></author><author><style face="normal" font="default" size="100%">Ebner, C.</style></author><author><style face="normal" font="default" size="100%">Horak, F.</style></author><author><style face="normal" font="default" size="100%">Kinaciyan, T.</style></author><author><style face="normal" font="default" size="100%">Radauer, C.</style></author><author><style face="normal" font="default" size="100%">Ferreira, F.</style></author><author><style face="normal" font="default" size="100%">Jahn-Schmid, B.</style></author><author><style face="normal" font="default" size="100%">Bohle, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Biosciences, University of Salzburg, Salzburg, Austria.&#xD;Allergy Clinic Reumannplatz, Vienna, Austria.&#xD;Allergiezentrum Wien West, Vienna, Austria.&#xD;Department of Dermatology, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IgE-cross-blocking antibodies to Fagales following sublingual immunotherapy with recombinant Bet v 1</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2555-2564</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Blocking</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant/*immunology/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Fagales</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Bet v 1</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-blocking IgG antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">birch pollen-related allergy</style></keyword><keyword><style face="normal" font="default" size="100%">cross-blocking antibodies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33724487</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Evidence has accumulated that birch pollen immunotherapy reduces rhinoconjunctivitis to pollen of birch homologous trees. Therapeutic efficacy has been associated with IgE-blocking IgG antibodies. We have recently shown that sera collected after 16 weeks of sublingual immunotherapy with recombinant Bet v 1 (rBet v 1-SLIT) display strong IgE-blocking bioactivity for Bet v 1. Here, we assessed whether rBet v 1-SLIT-induced IgG antibodies display cross-blocking activity to related allergens in Fagales pollen. METHODS: IgE, IgG1 and IgG4 reactivity to recombinant Bet v 1, Aln g 1, Car b 1, Ost c 1, Cor a 1, Fag s 1, Cas s 1 and Que a 1 were assessed in pre- and post-SLIT samples of 17 individuals by ELISA. A basophil inhibition assay using stripped basophils re-sensitized with a serum pool containing high Bet v 1-specific IgE levels was established and used to assess CD63 expression in response to allergens after incubation with pre-SLIT or post-SLIT samples. IgG1 and IgG4 were depleted from post-SLIT samples to assess its contribution to IgE-cross-blocking. RESULTS: Sublingual immunotherapy with recombinant Bet v 1 boosted cross-reactive IgE antibodies and induced IgG1 and IgG4 antibodies with inter- and intra-individually differing reactivity to the homologs. Highly variable cross-blocking activities of post-SLIT samples to the different allergens were found. IgG1 and IgG4 antibodies displayed cross-blocking activity with individual variance. CONCLUSIONS: Our mechanistic approach suggested that immunotherapy with the reference allergen Bet v 1 induces individual repertoires of cross-reactive IgG1 and IgG4 antibodies. The cross-blocking bioactivity of these antibodies was also highly variable and neither predictable from protein homology nor IgE-cross-reactivity.</style></abstract><notes><style face="normal" font="default" size="100%">Grilo, Joao Rodrigues&#xD;Kitzmuller, Claudia&#xD;Aglas, Lorenz&#xD;Sanchez Acosta, Gabriela&#xD;Vollmann, Ute&#xD;Ebner, Christof&#xD;Horak, Fritz&#xD;Kinaciyan, Tamar&#xD;Radauer, Christian&#xD;Ferreira, Fatima&#xD;Jahn-Schmid, Beatrice&#xD;Bohle, Barbara&#xD;eng&#xD;P 30936/FWF_/Austrian Science Fund FWF/Austria&#xD;P 32953/FWF_/Austrian Science Fund FWF/Austria&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2555-2564. doi: 10.1111/all.14817. Epub 2021 May 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33724487</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14817</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2431</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2431</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bozek, A.</style></author><author><style face="normal" font="default" size="100%">Krupka-Olek, M.</style></author><author><style face="normal" font="default" size="100%">Krupka, A. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Department of Internal Diseases, Dermatology and Allergology Medical University of Silesia, Zabrze, Poland.&#xD;Department of Internal Medicine, Angiology, and Physical Medicine, Center for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IgE-mediated allergic diseases are associated with Alzheimer&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2006-2008</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/03/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38553995</style></accession-num><notes><style face="normal" font="default" size="100%">Bozek, Andrzej&#xD;Krupka-Olek, Magdalena&#xD;Krupka, Aleksandra Kawczyk&#xD;eng&#xD;Medical University of Silesia/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):2006-2008. doi: 10.1111/all.16114. Epub 2024 Mar 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38553995</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16114</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>678</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">678</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author><author><style face="normal" font="default" size="100%">Duca, B.</style></author><author><style face="normal" font="default" size="100%">Chastell, S. A.</style></author><author><style face="normal" font="default" size="100%">Alvarez, O.</style></author><author><style face="normal" font="default" size="100%">Bazire, R.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Ortiz, M.</style></author><author><style face="normal" font="default" size="100%">Rodriguez Del Rio, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Complexo Hospitalario Universitario de Ferrol, A Coruna, Spain.&#xD;Department of Allergy, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.&#xD;Health Research Institute Princesa, Madrid, Spain.&#xD;ARADyAL Research Network, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IgE-sensitization predicts threshold but not anaphylaxis during oral food challenges to cow&apos;s milk</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1291-1293</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/12/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Milk/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Milk Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">cow&apos;s milk</style></keyword><keyword><style face="normal" font="default" size="100%">eliciting dose</style></keyword><keyword><style face="normal" font="default" size="100%">food challenge</style></keyword><keyword><style face="normal" font="default" size="100%">lowest observed adverse effect level</style></keyword><keyword><style face="normal" font="default" size="100%">thresholds</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34874567</style></accession-num><notes><style face="normal" font="default" size="100%">Turner, Paul J&#xD;Duca, Bettina&#xD;Chastell, Sophia A&#xD;Alvarez, Olaya&#xD;Bazire, Raphaelle&#xD;Vazquez-Ortiz, Marta&#xD;Rodriguez Del Rio, Pablo&#xD;eng&#xD;MR/K010468/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/S036954/1/MRC_/Medical Research Council/United Kingdom&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1291-1293. doi: 10.1111/all.15195. Epub 2021 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34874567</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15195</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>68</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">68</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aranda, C. J.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Kozlova, E.</style></author><author><style face="normal" font="default" size="100%">Saunders, S. P.</style></author><author><style face="normal" font="default" size="100%">Fernandes-Braga, W.</style></author><author><style face="normal" font="default" size="100%">Ota, M.</style></author><author><style face="normal" font="default" size="100%">Narayanan, S.</style></author><author><style face="normal" font="default" size="100%">He, J. S.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Swaroop, B.</style></author><author><style face="normal" font="default" size="100%">Gnjatic, S.</style></author><author><style face="normal" font="default" size="100%">Shattner, G.</style></author><author><style face="normal" font="default" size="100%">Reibman, J.</style></author><author><style face="normal" font="default" size="100%">Soter, N. A.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Curotto de Lafaille, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Department of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, USA.&#xD;Precision Immunology Institute (PrIISM), ISMMS, New York, New York, USA.&#xD;Department of Oncological Sciences, ISMMS, New York, New York, USA.&#xD;Division of Pulmonary, Critical Care, and Sleep Medicine, New York University School of Medicine (NYUSM), New York, New York, USA.&#xD;Agency for Science, Technology, and Research (A*STAR), Singapore, Singapore.&#xD;Department of Dermatology, ISMMS, New York, New York, USA.&#xD;Tisch Cancer Institute, ISMMS, New York, New York, USA.&#xD;Department of Dermatology, NYUSM, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">752-766</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/11/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Memory B Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, IgE/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4 Receptor alpha Subunit</style></keyword><keyword><style face="normal" font="default" size="100%">Lectins, C-Type</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">atopic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">high-dimensional flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">memory IgG</style></keyword><keyword><style face="normal" font="default" size="100%">single-cell sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">Genentech, Boehringer-Ingelheim, EMD Serono, Takeda, and Regeneron. E.G.Y. has</style></keyword><keyword><style face="normal" font="default" size="100%">served as a consultant for AbbVie, Amgen, Allergan, Asana Bioscience, Celgene,</style></keyword><keyword><style face="normal" font="default" size="100%">Concert, Dermira, DS Bio- pharma, Escalier, Galderma, Glenmark, Kyowa Kirin, LEO</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Lilly, Mit- subishi Tanabe, Novartis, Pfizer, Regeneron, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">and Union Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">a member of advisory boards of Allergan, Asana</style></keyword><keyword><style face="normal" font="default" size="100%">Bioscience, Celgene, DBV, Dermavant, Dermira, Escalier, Galderma, Glenmark, Kyowa</style></keyword><keyword><style face="normal" font="default" size="100%">Kirin, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and a</style></keyword><keyword><style face="normal" font="default" size="100%">recipient of research grants from AbbVie, AnaptysBio, AntibioTx, Asana</style></keyword><keyword><style face="normal" font="default" size="100%">Bioscience, Boehringer-Ingelheim, Celgene, DBV, Dermavant, DS Biopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Galderma, Glenmark, Innovaderm, Janssen Biotech, Kiniska Pharma, LEO</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Lilly, Medimmune, Sienna Biopharmaceuticals, Novan, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Ralexar, Regeneron, Pfizer, UCB, and Union Therapeutics. M.A.C.L. received</style></keyword><keyword><style face="normal" font="default" size="100%">advisory fees from Genentech. J.R. received consultancy fees from AstraZeneca.</style></keyword><keyword><style face="normal" font="default" size="100%">Work in this manuscript was funded by NIH grants to M.A.C.L. and was solely</style></keyword><keyword><style face="normal" font="default" size="100%">carried out at academic institutions (NYU and ISMMS).</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36445014</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic diseases are characterized by IgE antibody responses that are dependent on cognate CD4 T cell help and T cell-produced IL-4 and IL-13. Current models of IgE cell differentiation point to the role of IgG memory B cells as precursors of pathogenic IgE plasma cells. The goal of this work was to identify intrinsic features of memory B cells that are associated with IgE production in atopic diseases. METHODS: Peripheral blood B lymphocytes were collected from individuals with physician diagnosed asthma or atopic dermatitis (AD) and from non-atopic individuals. These samples were analyzed by spectral flow cytometry, single cell RNA sequencing (scRNAseq), and in vitro activation assays. RESULTS: We identified a novel population of IgG memory B cells characterized by the expression of IL-4/IL-13 regulated genes FCER2/CD23, IL4R, IL13RA1, and IGHE, denoting a history of differentiation during type 2 immune responses. CD23(+) IL4R(+) IgG(+) memory B cells had increased occurrence in individuals with atopic disease. Importantly, the frequency of CD23(+) IL4R(+) IgG(+) memory B cells correlated with levels of circulating IgE. Consistently, in vitro stimulated B cells from atopic individuals generated more IgE(+) cells than B cells from non-atopic subjects. CONCLUSIONS: These findings suggest that CD23(+) IL4R(+) IgG(+) memory B cells transcribing IGHE are potential precursors of IgE plasma cells and are linked to pathogenic IgE production.</style></abstract><notes><style face="normal" font="default" size="100%">Aranda, Carlos J&#xD;Gonzalez-Kozlova, Edgar&#xD;Saunders, Sean P&#xD;Fernandes-Braga, Weslley&#xD;Ota, Miyo&#xD;Narayanan, Sriram&#xD;He, Jin-Shu&#xD;Del Duca, Ester&#xD;Swaroop, Bose&#xD;Gnjatic, Sacha&#xD;Shattner, Gail&#xD;Reibman, Joan&#xD;Soter, Nicholas A&#xD;Guttman-Yassky, Emma&#xD;Curotto de Lafaille, Maria A&#xD;eng&#xD;R01 AI130343/AI/NIAID NIH HHS/&#xD;U01 DK124165/DK/NIDDK NIH HHS/&#xD;R01 AI153708/AI/NIAID NIH HHS/&#xD;S10 OD026880/OD/NIH HHS/&#xD;UL1 TR004419/TR/NCATS NIH HHS/&#xD;P30 CA196521/CA/NCI NIH HHS/&#xD;R01 AI151707/AI/NIAID NIH HHS/&#xD;U24 CA224319/CA/NCI NIH HHS/&#xD;S10 OD030463/OD/NIH HHS/&#xD;R21 AI133076/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):752-766. doi: 10.1111/all.15601. Epub 2022 Dec 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36445014</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9991991</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15601</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2913</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2913</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cespedes, J. A.</style></author><author><style face="normal" font="default" size="100%">Perez-Moreno, A. M.</style></author><author><style face="normal" font="default" size="100%">Jurado-Escobar, R.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Ariza, A.</style></author><author><style face="normal" font="default" size="100%">Munoz-Cano, R.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Paris, J. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">IBIMA-Plataforma BIONAND, Malaga, Spain.&#xD;Universidad de Malaga, Malaga, Spain.&#xD;Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;RICORS &quot;Enfermedades Inflamatorias&quot;, Spain.&#xD;Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.&#xD;Clinical and Experimental Respiratory Immunoallergy, Institut Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IgG Removal Enhances the Sensitivity of Amoxicillin-Specific IgE Detection in ImmunoCAP and Radioallergosorbent Test</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3190-3194</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/05/16</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40377358</style></accession-num><notes><style face="normal" font="default" size="100%">Cespedes, Jose A&#xD;Perez-Moreno, Ana M&#xD;Jurado-Escobar, Raquel&#xD;Bogas, Gador&#xD;Salas, Maria&#xD;Ariza, Adriana&#xD;Munoz-Cano, Rosa&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;Paris, Juan L&#xD;eng&#xD;Universidad de Malaga/&#xD;Instituto de Salud Carlos III/&#xD;Ministerio de Economia y Competitividad/&#xD;PIN-0113-2020/Andalusian Regional Ministry of Health/&#xD;RC-0004-2021/Andalusian Regional Ministry of Health/&#xD;RD21/0002/0008/European Regional Development Fund, RICORS REI/&#xD;RD21/0002/0058/European Regional Development Fund, RICORS REI/&#xD;PI18/00095/European Regional Development Fund, RICORS REI/&#xD;PI21/00329/European Regional Development Fund, RICORS REI/&#xD;RYC2021-034536-I/MCIN/AEI/&#xD;PREP2022-000567/MCIN/AEI/&#xD;European Union NextGenerationEU/PRTR/&#xD;ESF+/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3190-3194. doi: 10.1111/all.16595. Epub 2025 May 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40377358</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590310 patent application (patent application number: [WO2024023382A1]) related to the methods described in this manuscript. The rest of the authors declare that they have no conflicts of interest related to the content of this manuscript.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16595</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1379</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1379</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sereme, Y.</style></author><author><style face="normal" font="default" size="100%">Casanovas, N.</style></author><author><style face="normal" font="default" size="100%">Michel, M.</style></author><author><style face="normal" font="default" size="100%">Martin-Blondel, A.</style></author><author><style face="normal" font="default" size="100%">Mankouri, F.</style></author><author><style face="normal" font="default" size="100%">Pinchemel, S.</style></author><author><style face="normal" font="default" size="100%">Chartier, C.</style></author><author><style face="normal" font="default" size="100%">Mezouar, S.</style></author><author><style face="normal" font="default" size="100%">Buffat, C.</style></author><author><style face="normal" font="default" size="100%">Chamayou, G.</style></author><author><style face="normal" font="default" size="100%">Blancher, A.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Vitte, J.</style></author><author><style face="normal" font="default" size="100%">Apoil, P. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Aix-Marseille Univ, APHM, IRD, MEPHI, Marseille, France.&#xD;IHU Mediterranee Infection, Marseille, France.&#xD;Pneumologie &amp; Allergologie, Hopital des Enfants, CHU de Toulouse, Toulouse, France.&#xD;Aix-Marseille Univ, APHM, Hopital de la Conception, Laboratoire de Biochimie et de Biologie Moleculaire, Marseille, France.&#xD;Institut Federatif de Biologie, CHU de Toulouse, Toulouse, France.&#xD;MACVIA-France, Montpellier, France.&#xD;Comprehensive Allergy Center, Department of Dermatology and Allergy, Charite, Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;UMR 1056 INSERM, Hopital Purpan, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IgG removal significantly enhances detection of microarray allergen-specific IgE reactivity in patients&apos; serum</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">395-398</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32738813</style></accession-num><notes><style face="normal" font="default" size="100%">Sereme, Youssouf&#xD;Casanovas, Natacha&#xD;Michel, Moise&#xD;Martin-Blondel, Audrey&#xD;Mankouri, Farid&#xD;Pinchemel, Simon&#xD;Chartier, Celine&#xD;Mezouar, Soraya&#xD;Buffat, Christophe&#xD;Chamayou, Ghislaine&#xD;Blancher, Antoine&#xD;Bousquet, Jean&#xD;Vitte, Joana&#xD;Apoil, Pol Andre&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):395-398. doi: 10.1111/all.14536. Epub 2020 Oct 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32738813</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14536</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2977</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2977</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martini, M.</style></author><author><style face="normal" font="default" size="100%">Cinti, B.</style></author><author><style face="normal" font="default" size="100%">Claudi, I.</style></author><author><style face="normal" font="default" size="100%">Braschi, M. C.</style></author><author><style face="normal" font="default" size="100%">Aboud, Y.</style></author><author><style face="normal" font="default" size="100%">Buti, E.</style></author><author><style face="normal" font="default" size="100%">Palmeri, D.</style></author><author><style face="normal" font="default" size="100%">Danieli, M. G.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Department of Internal Medicine, University Hospital AOU Delle Marche, Ancona, Italy.&#xD;Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.&#xD;Laboratory Medicine, University Hospital AOU Delle Marche, Ancona, Italy.&#xD;Post-Graduate School of Allergy and Clinical Immunology, Marche Polytechnic University, Ancona, Italy.&#xD;Marche Polytechnic University, Ancona, Italy.&#xD;Department of Internal Medicine, Immunology of Rare Diseases and Transplants Unit, University Hospital AOU Delle Marche, Ancona, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IgG4 Kinetics in Ultra-Rush Vespula Venom Immunotherapy: How Early Is the Response?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2902-2903</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/07/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgG4</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunoglobulins</style></keyword><keyword><style face="normal" font="default" size="100%">hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">kinetics</style></keyword><keyword><style face="normal" font="default" size="100%">systemic reactions</style></keyword><keyword><style face="normal" font="default" size="100%">ultra-rush protocol</style></keyword><keyword><style face="normal" font="default" size="100%">venom immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40673409</style></accession-num><notes><style face="normal" font="default" size="100%">Martini, Matteo&#xD;Cinti, Barbara&#xD;Claudi, Ilaria&#xD;Braschi, Maria Chiara&#xD;Aboud, Yara&#xD;Buti, Elena&#xD;Palmeri, Davide&#xD;Danieli, Maria Giovanna&#xD;Bilo, Maria Beatrice&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2902-2903. doi: 10.1111/all.16648. Epub 2025 Jul 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40673409</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486365</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16648</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3040</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3040</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tedesco, L.</style></author><author><style face="normal" font="default" size="100%">Ali, S. B.</style></author><author><style face="normal" font="default" size="100%">Erman, B.</style></author><author><style face="normal" font="default" size="100%">Baris, S.</style></author><author><style face="normal" font="default" size="100%">Pant, H.</style></author><author><style face="normal" font="default" size="100%">Hissaria, P.</style></author><author><style face="normal" font="default" size="100%">Bilginer, Y.</style></author><author><style face="normal" font="default" size="100%">Tumes, D. J.</style></author><author><style face="normal" font="default" size="100%">Cildir, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.&#xD;Department of Clinical Immunology and Allergy, Flinders Medical Centre, Bedford Park, South Australia, Australia.&#xD;School of Medicine and Biomedical Sciences, Flinders University, Bedford Park, South Australia, Australia.&#xD;Can Sucak Research Laboratory for Translational Immunology, Hacettepe University, Ankara, Turkiye.&#xD;Institute of Child Health, Hacettepe University, Ankara, Turkiye.&#xD;Faculty of Medicine, Division of Pediatric Allergy and Immunology, Marmara University, Istanbul, Turkiye.&#xD;Isil Berat Barlan Center for Translational Medicine, Istanbul Jeffrey Modell Foundation Diagnostic Center for Primary Immune Deficiencies, Istanbul, Turkiye.&#xD;Discipline of Medicine, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.&#xD;Adelaide Centre for Epigenetics, School of Biomedicine, University of Adelaide, Adelaide, South Australia, Australia.&#xD;Adelaide Medical School, University of Adelaide, Adelaide, Australia; Division of Human Immunology, SA Pathology, Adelaide, Australia; Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, Australia.&#xD;Department of Pediatric Rheumatology, Faculty of Medicine, Hacettepe University, Ankara, Turkiye.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IgG4-Related Disease: Emerging Roles of Novel Genetic Variants, Immune Cell Subsets and Therapeutic Targets</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2738-2754</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/08/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin G4-Related Disease/genetics/therapy/immunology/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin G/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Genetic Variation</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Targeted Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4-related disease</style></keyword><keyword><style face="normal" font="default" size="100%">fibrosis</style></keyword><keyword><style face="normal" font="default" size="100%">immune dysregulation</style></keyword><keyword><style face="normal" font="default" size="100%">inebilizumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40785550</style></accession-num><abstract><style face="normal" font="default" size="100%">IgG4, the least abundant IgG subclass in humans, is increasingly recognised for its involvement in allergic and autoimmune pathologies. Its unique properties, such as the tendency to form half-molecules (one heavy chain and one light chain) and its generally non-inflammatory nature, distinguish it from other IgG subclasses. Its role in immune dysregulation is further underscored by a distinct disease entity called IgG4-related disease (IgG4-RD), a systemic fibroinflammatory disorder characterised by IgG4(+) plasma cell tissue infiltration, storiform fibrosis and obliterative phlebitis, reflecting a dysregulated immune response affecting multiple organs. This review examines the current understanding of IgG4, its emerging roles in immune dysregulation and IgG4-RD, including clinical manifestations and treatment options. We also discuss the recent advances in understanding the genetic underpinnings of IgG4-RD, highlighting the significance of germline gene variants and implicated immune cell types. Finally, we explore future research directions, emphasising the need for deeper insights into pathogenesis, specific biomarkers and optimised treatment strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Tedesco, Louisa&#xD;Ali, Syed B&#xD;Erman, Baran&#xD;Baris, Safa&#xD;Pant, Harshita&#xD;Hissaria, Pravin&#xD;Bilginer, Yelda&#xD;Tumes, Damon J&#xD;Cildir, Gokhan&#xD;eng&#xD;2027602/National Health and Medical Research Council (NHMRC)/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2738-2754. doi: 10.1111/all.16686. Epub 2025 Aug 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40785550</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486373</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16686</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1175</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1175</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Iype, J.</style></author><author><style face="normal" font="default" size="100%">Odermatt, A.</style></author><author><style face="normal" font="default" size="100%">Bachmann, S.</style></author><author><style face="normal" font="default" size="100%">Coeudevez, M.</style></author><author><style face="normal" font="default" size="100%">Fux, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Cytomics Facility, University Institute of Clinical Chemistry, University Hospital Bern, Inselspital, Bern, Switzerland.&#xD;University Institute of Immunology, University Hospital Bern, Inselspital, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-1beta promotes immunoregulatory responses in human blood basophils</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2017-2029</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-1beta/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-3</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgE</style></keyword><keyword><style face="normal" font="default" size="100%">Il-1ri</style></keyword><keyword><style face="normal" font="default" size="100%">IL-1beta</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">p38 MAPK signaling pathway</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33544413</style></accession-num><abstract><style face="normal" font="default" size="100%">Human basophils are essential effector cells of chronic allergic inflammation. IL-1 family cytokines such as interleukin (IL)-33 and IL-1beta are elevated in serum and bronchoalveolar lavage fluid of allergic asthmatics. IL-33 is known to be a critical regulator of basophil&apos;s T2 immune responses. However, the effect of IL-1beta on the function of basophils has not been well investigated. Here, we elucidate whether IL-1beta regulates the function of human basophils and compared the effects of IL-1beta and IL-33 on basophils of healthy and allergic subjects. We found that IL-1beta activates the p38 MAPK signaling pathway and promotes IL-8 release in basophils of healthy donors, while FcepsilonRI-mediated LCT(4) and histamine secretion is not affected. Strikingly, in the presence of IL-3, IL-1beta shows more potency than IL-33, as evidenced by the enhanced p38 phosphorylation and NF-kappaB activation, as well as the release of both IL-13 and IL-8. We found that the enhanced basophil responsiveness is achieved through IL-3-induced IL-1RI surface expression. Importantly, basophils of allergic donors release significantly higher amounts of IL-8 compared to those from healthy donors upon IL-33 and IL-1beta stimulation. Consistently, we detected increased IL-1RI and decreased IL-3 receptor alpha-chain (CD123) and CCR3 expression on basophils of allergic subjects compared to healthy controls, suggesting an in vivo IL-3 priming in allergic donors. In summary, our results suggest enhanced sensitivity of basophils toward IL-33 and IL-1beta in allergic subjects compared to those from healthy controls.</style></abstract><notes><style face="normal" font="default" size="100%">Iype, Joseena&#xD;Odermatt, Andrea&#xD;Bachmann, Sofia&#xD;Coeudevez, Mazarine&#xD;Fux, Michaela&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2017-2029. doi: 10.1111/all.14760. Epub 2021 Mar 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33544413</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14760</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2787</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2787</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Engeroff, P.</style></author><author><style face="normal" font="default" size="100%">Belbezier, A.</style></author><author><style face="normal" font="default" size="100%">Vaineau, R.</style></author><author><style face="normal" font="default" size="100%">Fourcade, G.</style></author><author><style face="normal" font="default" size="100%">Lujan, H. D.</style></author><author><style face="normal" font="default" size="100%">Bellier, B.</style></author><author><style face="normal" font="default" size="100%">Graff-Dubois, S.</style></author><author><style face="normal" font="default" size="100%">Klatzmann, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sorbonne Universite, INSERM, UMRS 959, Immunology-Immunopathology-Immunotherapy, i3, Paris, France.&#xD;Department of Rheumatology and Immunology, University Hospital of Bern, Department for BioMedical Research, University of Bern, Bern, Switzerland.&#xD;Centro de Investigacion y Desarrollo en Immunologia y Enfermedades Infecciosas (CIDIE), Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)/Universidad Catolica de Cordoba (UCC), Cordoba, Argentina.&#xD;AP-HP, Hopital Pitie-Salpetriere, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-1R2 Expression in Tfr Cells Controls Allergic Anaphylaxis by Regulating IgG Versus IgE Responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2636-2639</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/12/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">B cells</style></keyword><keyword><style face="normal" font="default" size="100%">Il-1</style></keyword><keyword><style face="normal" font="default" size="100%">Il-1r1</style></keyword><keyword><style face="normal" font="default" size="100%">Tfh cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">germinal center</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">type I hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39692165</style></accession-num><notes><style face="normal" font="default" size="100%">Engeroff, Paul&#xD;Belbezier, Aude&#xD;Vaineau, Romain&#xD;Fourcade, Gwladys&#xD;Lujan, Hugo D&#xD;Bellier, Bertrand&#xD;Graff-Dubois, Stephanie&#xD;Klatzmann, David&#xD;eng&#xD;Novartis Stiftung fur Medizinisch-Biologische Forschung/&#xD;Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;Agence Nationale de la Recherche/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2636-2639. doi: 10.1111/all.16437. Epub 2024 Dec 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39692165</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444838</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16437</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>517</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">517</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hansen, P. M.</style></author><author><style face="normal" font="default" size="100%">Tollenaere, M. A. X.</style></author><author><style face="normal" font="default" size="100%">Hedengran, A.</style></author><author><style face="normal" font="default" size="100%">Heegaard, S.</style></author><author><style face="normal" font="default" size="100%">Amoudruz, P.</style></author><author><style face="normal" font="default" size="100%">Ropke, M.</style></author><author><style face="normal" font="default" size="100%">Thyssen, J. P.</style></author><author><style face="normal" font="default" size="100%">Kolko, M.</style></author><author><style face="normal" font="default" size="100%">Norsgaard, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Ophthalmology, Rigshospitalet-Glostrup, University Hospital of Copenhagen, Copenhagen, Denmark.&#xD;Department of In Vitro Biology, Molecular Biomedicine, Research and Early Development, LEO Pharma A/S, Ballerup, Denmark.&#xD;Department of Pathology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.&#xD;Department of Dermatology, Frederiksberg and Bispebjerg Hospital, Frederiksberg, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2555-2558</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/04/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Conjunctiva</style></keyword><keyword><style face="normal" font="default" size="100%">*Goblet Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35474220</style></accession-num><notes><style face="normal" font="default" size="100%">Hansen, Pernille M&#xD;Tollenaere, Maxim A X&#xD;Hedengran, Anne&#xD;Heegaard, Steffen&#xD;Amoudruz, Petra&#xD;Ropke, Mads&#xD;Thyssen, Jacob P&#xD;Kolko, Miriam&#xD;Norsgaard, Hanne&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2555-2558. doi: 10.1111/all.15326. Epub 2022 May 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35474220</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9542340 P.H. has received funding from LEO Pharma A/S. A.H. has received funding and acted as speaker for Laboratories Thea. S.H. has attended advisory boards for Sanofi-Genzyme and received speaker honoraria from LEO Pharma, Sanofi-Genzyme, Santen and Thea Pharmaceuticals. J.T. is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly &amp; Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, a speaker for AbbVie, Almirall, Eli Lilly &amp; Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, and received research grants from Pfizer, Regeneron, and Sanofi-Genzyme. M.K. is an advisor for AbbVie, Thea Pharmaceuticals and Santen, and received research grants from Thea Pharmaceuticals.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15326</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1956</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1956</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cho, H. J.</style></author><author><style face="normal" font="default" size="100%">Chung, Y. W.</style></author><author><style face="normal" font="default" size="100%">Moon, S.</style></author><author><style face="normal" font="default" size="100%">Seo, J. H.</style></author><author><style face="normal" font="default" size="100%">Kang, M.</style></author><author><style face="normal" font="default" size="100%">Nam, J. S.</style></author><author><style face="normal" font="default" size="100%">Lee, S. N.</style></author><author><style face="normal" font="default" size="100%">Kim, C. H.</style></author><author><style face="normal" font="default" size="100%">Choi, A. M. K.</style></author><author><style face="normal" font="default" size="100%">Yoon, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, South Korea.&#xD;The Airway Mucus Institute, Yonsei University College of Medicine, Seoul, South Korea.&#xD;Global Research Laboratory for Allergic Airway Disease, Yonsei University College of Medicine, Seoul, South Korea.&#xD;Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-4 drastically decreases deuterosomal and multiciliated cells via alteration in progenitor cell differentiation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1866-1877</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">*Epithelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-4/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Serine-Threonine Kinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Il-4</style></keyword><keyword><style face="normal" font="default" size="100%">deuterosomal cells</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">multiciliated cells</style></keyword><keyword><style face="normal" font="default" size="100%">single-cell RNA sequencing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36883528</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic inflammation affects the epithelial cell populations resulting in goblet cell hyperplasia and decreased ciliated cells. Recent advances in single-cell RNA sequencing (scRNAseq) have enabled the identification of new cell subtypes and genomic features of single cells. In this study, we aimed to investigate the effect of allergic inflammation in nasal epithelial cell transcriptomes at the single-cell level. METHODS: We performed scRNAseq in cultured primary human nasal epithelial (HNE) cells and in vivo nasal epithelium. The transcriptomic features and epithelial cell subtypes were determined under IL-4 stimulation, and cell-specific marker genes and proteins were identified. RESULTS: We confirmed that cultured HNE cells were similar to in vivo epithelial cells through scRNAseq. Cell-specific marker genes were utilized to cluster the cell subtypes, and FOXJ1(+) -ciliated cells were sub-classified into multiciliated and deuterosomal cells. PLK4 and CDC20B were specific for deuterosomal cells, and SNTN, CPASL, and GSTA2 were specific for multiciliated cells. IL-4 altered the proportions of cell subtypes, resulting in a decrease in multiciliated cells and loss of deuterosomal cells. The trajectory analysis revealed deuterosomal cells as precursor cells of multiciliated cells and deuterosomal cells function as a bridge between club and multiciliated cells. A decrease in deuterosomal cell marker genes was observed in nasal tissue samples with type 2 inflammation. CONCLUSION: The effects of IL-4 appear to be mediated through the loss of the deuterosomal population, resulting in the reduction in multiciliated cells. This study also newly suggests cell-specific markers that might be pivotal for investigating respiratory inflammatory diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Cho, Hyung-Ju&#xD;Chung, Youn Wook&#xD;Moon, Sungmin&#xD;Seo, Ju Hee&#xD;Kang, Miran&#xD;Nam, Jae Sung&#xD;Lee, Sang-Nam&#xD;Kim, Chang-Hoon&#xD;Choi, Augustine M K&#xD;Yoon, Joo-Heon&#xD;eng&#xD;&quot;Team Science Award&quot; of Yonsei University College of Medicine/&#xD;Global Research Laboratory Program of the National Research Foundation of Korea (NRF)/&#xD;National Research Foundation of Korea (NRF)/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1866-1877. doi: 10.1111/all.15705. Epub 2023 Mar 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36883528</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15705</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2681</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2681</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hara, Y.</style></author><author><style face="normal" font="default" size="100%">Jha, M. K.</style></author><author><style face="normal" font="default" size="100%">Huang, J. Y.</style></author><author><style face="normal" font="default" size="100%">Han, Y.</style></author><author><style face="normal" font="default" size="100%">Langohr, I. M.</style></author><author><style face="normal" font="default" size="100%">Gaglia, G.</style></author><author><style face="normal" font="default" size="100%">Zhu, C.</style></author><author><style face="normal" font="default" size="100%">Piepenhagen, P.</style></author><author><style face="normal" font="default" size="100%">Gayvert, K.</style></author><author><style face="normal" font="default" size="100%">Lim, W. K.</style></author><author><style face="normal" font="default" size="100%">Asrat, S.</style></author><author><style face="normal" font="default" size="100%">Nash, S.</style></author><author><style face="normal" font="default" size="100%">Jacob-Nara, J. A.</style></author><author><style face="normal" font="default" size="100%">Orengo, J. M.</style></author><author><style face="normal" font="default" size="100%">Bangari, D. S.</style></author><author><style face="normal" font="default" size="100%">de Rinaldis, E.</style></author><author><style face="normal" font="default" size="100%">Mattoo, H.</style></author><author><style face="normal" font="default" size="100%">Hicks, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Type 2 Inflammation, Immunology and Inflammation, Sanofi, Cambridge, Massachusetts, USA.&#xD;Precision Medicine and Computational Biology, Sanofi, Cambridge, Massachusetts, USA.&#xD;Global Discovery Pathology, Sanofi, Cambridge, Massachusetts, USA.&#xD;Molecular Profiling and Data Science, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.&#xD;Immunology and Inflammation, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.&#xD;Medical Affairs, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.&#xD;Global Medical Affairs, Sanofi, Bridgewater, New Jersey, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The IL-4-IL-4Ralpha axis modulates olfactory neuroimmune signaling to induce loss of smell</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">440-461</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/10/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-4/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">*Smell/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Neuroimmunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-4 Receptor alpha Subunit/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Olfaction Disorders/metabolism/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39418114</style></accession-num><abstract><style face="normal" font="default" size="100%">IL-4 and IL-13 have non-redundant effects in olfaction, with loss of smell in mice evoked only by intranasal administration of IL-4, but not IL-13. IL-4-evoked pathophysiological effects on olfaction is independent of compromised structural integrity of the olfactory neuroepithelium. IL-4-IL-4Ralpha signaling modulates neuronal crosstalk with immune cells, suggesting a functional link between olfactory impairment and neuroinflammation. Abbreviations: IL, interleukin; KO, knock-out; wk, week; WT, wild-type.</style></abstract><notes><style face="normal" font="default" size="100%">Hara, Yannis&#xD;Jha, Mithilesh Kumar&#xD;Huang, Jeremy Y&#xD;Han, Yingnan&#xD;Langohr, Ingeborg M&#xD;Gaglia, Giorgio&#xD;Zhu, Cheng&#xD;Piepenhagen, Peter&#xD;Gayvert, Kaitlyn&#xD;Lim, Wei Keat&#xD;Asrat, Seblewongel&#xD;Nash, Scott&#xD;Jacob-Nara, Juby A&#xD;Orengo, Jamie M&#xD;Bangari, Dinesh S&#xD;de Rinaldis, Emanuele&#xD;Mattoo, Hamid&#xD;Hicks, Alexandra&#xD;eng&#xD;Regeneron Pharmaceuticals/&#xD;Sanofi/&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):440-461. doi: 10.1111/all.16338. Epub 2024 Oct 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39418114</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804309 and may hold stock and/or stock options in their respective company.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16338</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>35</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">35</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bajbouj, K.</style></author><author><style face="normal" font="default" size="100%">AbuJabal, R.</style></author><author><style face="normal" font="default" size="100%">Sahnoon, L.</style></author><author><style face="normal" font="default" size="100%">Olivenstein, R.</style></author><author><style face="normal" font="default" size="100%">Mahboub, B.</style></author><author><style face="normal" font="default" size="100%">Hamid, Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.&#xD;Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.&#xD;Meakins-Christie Laboratories, McGill University, Montreal, Quebec, Canada.&#xD;Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-5 receptor expression in lung fibroblasts: Potential role in airway remodeling in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">882-885</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/12/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Airway Remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Fibroblasts/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">IL-5 receptor</style></keyword><keyword><style face="normal" font="default" size="100%">airway fibroblasts</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">fibrosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36575907</style></accession-num><notes><style face="normal" font="default" size="100%">Bajbouj, Khuloud&#xD;AbuJabal, Rola&#xD;Sahnoon, Lina&#xD;Olivenstein, Ronald&#xD;Mahboub, Bassam&#xD;Hamid, Qutayba&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):882-885. doi: 10.1111/all.15627. Epub 2023 Jan 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36575907</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15627</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>875</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">875</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cevhertas, L.</style></author><author><style face="normal" font="default" size="100%">Ma, S.</style></author><author><style face="normal" font="default" size="100%">Stanic, B.</style></author><author><style face="normal" font="default" size="100%">Ochsner, U.</style></author><author><style face="normal" font="default" size="100%">Jansen, K.</style></author><author><style face="normal" font="default" size="100%">Ferstl, R.</style></author><author><style face="normal" font="default" size="100%">Frei, R.</style></author><author><style face="normal" font="default" size="100%">Chijioke, O.</style></author><author><style face="normal" font="default" size="100%">Munz, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Medical Immunology, Institute of Health Sciences, Bursa Uludag University, Bursa, Turkey.&#xD;Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Christine Kuhne Center for Allergy Research and Education (CK-CARE, Davos, Switzerland.&#xD;Cellular Immunotherapy, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.&#xD;Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.&#xD;Department of Otolaryngology Head and Neck surgery and department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-10 induces IgG4 production in NOD-scid Il2rgamma(null) mice humanized by engraftment of peripheral blood mononuclear cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3525-3529</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-10</style></keyword><keyword><style face="normal" font="default" size="100%">*Leukocytes, Mononuclear</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred NOD</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, SCID</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34324719</style></accession-num><notes><style face="normal" font="default" size="100%">Cevhertas, Lacin&#xD;Ma, Siyuan&#xD;Stanic, Barbara&#xD;Ochsner, Urs&#xD;Jansen, Kirstin&#xD;Ferstl, Ruth&#xD;Frei, Remo&#xD;Chijioke, Obinna&#xD;Munz, Christian&#xD;Zhang, Luo&#xD;O&apos;Mahony, Liam&#xD;Akdis, Mubeccel&#xD;van de Veen, Willem&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3525-3529. doi: 10.1111/all.15031. Epub 2021 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34324719</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9291614</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15031</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2551</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2551</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heinl, P. V.</style></author><author><style face="normal" font="default" size="100%">Graulich, E.</style></author><author><style face="normal" font="default" size="100%">Weigmann, B.</style></author><author><style face="normal" font="default" size="100%">Wangorsch, A.</style></author><author><style face="normal" font="default" size="100%">Ose, R.</style></author><author><style face="normal" font="default" size="100%">Bellinghausen, I.</style></author><author><style face="normal" font="default" size="100%">Khatri, R.</style></author><author><style face="normal" font="default" size="100%">Raker, V. K.</style></author><author><style face="normal" font="default" size="100%">Scheurer, S.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author><author><style face="normal" font="default" size="100%">Saloga, J.</style></author><author><style face="normal" font="default" size="100%">Steinbrink, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Division for Experimental and Translational Research, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.&#xD;Department of Internal Medicine, University Hospital Erlangen, University Erlangen-Nurnberg, Erlangen, Germany.&#xD;Molecular Allergology, Paul-Ehrlich-Institute, Langen, Germany.&#xD;Department of Dermatology, University Medical Center of the Johannes, Gutenberg-University, Mainz, Germany.&#xD;Department of Dermatology, University Hospital Munster, University of Munster, Munster, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-10-modulated dendritic cells from birch pollen- and hazelnut-allergic patients facilitate Treg-mediated allergen-specific and cross-reactive tolerance</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2826-2839</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/07/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dendritic Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-10/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Cross Reactions/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Corylus/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Betula/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Nut Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinitis, Allergic, Seasonal/immunology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">bet v 1.01</style></keyword><keyword><style face="normal" font="default" size="100%">cross-reactive tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cells</style></keyword><keyword><style face="normal" font="default" size="100%">tolerogenic IL-10 DC</style></keyword><keyword><style face="normal" font="default" size="100%">type I allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39073174</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Approximately 70% of individuals allergic to birch pollen (Bet v 1.01 [Bet]) develop a secondary food allergy (e.g., hazelnut: Cor a 1.04 [Cor]), due to allergen cross-reactivity. However, standard immunotherapy for type I allergies often does not improve the food allergy sufficiently. We analyzed the allergen-specific and cross-reactive suppressive capacity of primary human regulatory T cells (Treg) induced by autologous IL-10-modulated dendritic cells (IL-10 DC) in vitro and in vivo. METHODS: CD4(+) T cells of patients with birch pollen and associated hazelnut allergies were differentiated into Bet-specific or non-specific induced Treg (iTreg). After Bet- or Cor-specific restimulation the phenotype, proliferation, and suppressive capacity of iTreg subsets were analyzed. iTreg function was further investigated in humanized mouse models of airway and intestinal allergy, generated by engraftment of peripheral blood mononuclear cells from allergic donors into immunodeficient animals. RESULTS: After IL-10 DC priming and allergen-specific restimulation (Bet or Cor), non-specific control iTreg remained anergic, whereas Bet-specific iTreg proliferated extensively and exhibited a regulatory phenotype (enhanced expression of CTLA-4, PD-1, TNFR2, IL-10). Accordingly, activated Bet-specific iTreg displayed a high capacity to suppress Bet- and Cor-induced responder Th2 cell responses in vitro, indicating induction of both allergen-specific (birch) and cross-reactive tolerance (hazelnut). In vivo, the beneficial effect of Bet-specific iTreg was verified in humanized mouse models of allergic airway and intestinal inflammation, resulting in reduced allergen-induced clinical symptoms, and immune responses. CONCLUSION: Human IL-10 DC-induced iTreg facilitate allergen-specific and cross-reactive tolerance. Therefore, they are potential candidates for regulatory cell therapy in allergic and autoimmune diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Heinl, Patricia Vanessa&#xD;Graulich, Edith&#xD;Weigmann, Benno&#xD;Wangorsch, Andrea&#xD;Ose, Robert&#xD;Bellinghausen, Iris&#xD;Khatri, Rahul&#xD;Raker, Verena K&#xD;Scheurer, Stephan&#xD;Vieths, Stefan&#xD;Saloga, Joachim&#xD;Steinbrink, Kerstin&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2826-2839. doi: 10.1111/all.16255. Epub 2024 Jul 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39073174</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16255</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>945</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">945</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tynecka, M.</style></author><author><style face="normal" font="default" size="100%">Radzikowska, U.</style></author><author><style face="normal" font="default" size="100%">Eljaszewicz, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-10-producing innate lymphoid cells: Did we find a missing piece of the puzzle?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3849-3851</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/06/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-10</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphocytes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Il-10</style></keyword><keyword><style face="normal" font="default" size="100%">Ilc</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">immunotolerance</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34133765</style></accession-num><notes><style face="normal" font="default" size="100%">Tynecka, Marlena&#xD;Radzikowska, Urszula&#xD;Eljaszewicz, Andrzej&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3849-3851. doi: 10.1111/all.14980. Epub 2021 Jun 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34133765</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9292492</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14980</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1901</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1901</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tynecka, M.</style></author><author><style face="normal" font="default" size="100%">Radzikowska, U.</style></author><author><style face="normal" font="default" size="100%">Eljaszewicz, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-10-producing innate lymphoid cells: Did we find a missing piece of the puzzle?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3849-3851</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/06/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-10</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphocytes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Il-10</style></keyword><keyword><style face="normal" font="default" size="100%">Ilc</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">immunotolerance</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34133765</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Innate lymphoid cells (ILCs) represent the most recently described family of cells belonging to the innate immune responses. Different subpopulations of ILCs orchestrate distinct immunomodulatory functions and play an essential role in homeostasis maintenance and disease development, including allergic inflammation. Recently, a subpopulation of IL-10-producing ILC2s was characterized. Here, we highlight a recent groundbreaking discovery of Golebski et al. (2021), demonstrating broad characterization of IL-10+ ILC2s in allergic patients in the course of allergen-specific immunotherapy (AIT). Additionally, we discuss on ILCs in the context of cellular plasticity and trained tolerance.</style></abstract><notes><style face="normal" font="default" size="100%">Tynecka, Marlena&#xD;Radzikowska, Urszula&#xD;Eljaszewicz, Andrzej&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3849-3851. doi: 10.1111/all.14980. Epub 2021 Jun 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34133765</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9292492</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14980</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1161</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1161</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, McMaster University &amp; Firestone Institute for Respiratory Health, St. Joseph&apos;s Healthcare, Hamilton, ON, Canada.&#xD;Allergy &amp; Clinical Immunology, Transylvania University, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-13 signature in severe adult asthmatics with airway neutrophilia: A new endotype to treat!</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1964-1966</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">T2 inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">airway microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33583056</style></accession-num><notes><style face="normal" font="default" size="100%">Mukherjee, Manali&#xD;Agache, Ioana&#xD;eng&#xD;G0900453/MRC_/Medical Research Council/United Kingdom&#xD;Comment&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):1964-1966. doi: 10.1111/all.14772.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33583056</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14772</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1608</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1608</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, McMaster University &amp; Firestone Institute for Respiratory Health, St. Joseph&apos;s Healthcare, Hamilton, ON, Canada.&#xD;Allergy &amp; Clinical Immunology, Transylvania University, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-13 signature in severe adult asthmatics with airway neutrophilia: A new endotype to treat!</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1964-1966</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">T2 inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">airway microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33583056</style></accession-num><notes><style face="normal" font="default" size="100%">Mukherjee, Manali&#xD;Agache, Ioana&#xD;eng&#xD;G0900453/MRC_/Medical Research Council/United Kingdom&#xD;Comment&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):1964-1966. doi: 10.1111/all.14772.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33583056</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14772</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maintz, L.</style></author><author><style face="normal" font="default" size="100%">Welchowski, T.</style></author><author><style face="normal" font="default" size="100%">Herrmann, N.</style></author><author><style face="normal" font="default" size="100%">Brauer, J.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Havenith, R.</style></author><author><style face="normal" font="default" size="100%">Muller, S.</style></author><author><style face="normal" font="default" size="100%">Rhyner, C.</style></author><author><style face="normal" font="default" size="100%">Dreher, A.</style></author><author><style face="normal" font="default" size="100%">Schmid, M.</style></author><author><style face="normal" font="default" size="100%">Bieber, T.</style></author><author><style face="normal" font="default" size="100%">Ck-Care study group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, University Hospital Bonn, Venusberg-Campus 1, Bonn, Germany.&#xD;Christine Kuhne Center for Allergy Research and Education Davos (CK-CARE), Herman-Burchard-Str. 1, 7265, Davos, Switzerland.&#xD;Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Venusberg-Campus 1, Bonn, Germany.&#xD;Environmental Medicine, Faculty of Medicine, University of Augsburg, Stenglinstrasse 2, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, Augsburg, Germany.&#xD;Davos Biosciences, Herman-Burchard-Str. 1, 7265, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype-phenotype associations in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><edition><style face="normal" font="default" size="100%">2023/01/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">endotype</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">tralokinumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36647778</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The heterogeneous (endo)phenotypes of atopic dermatitis (AD) require precision medicine. Currently, systemic therapy is recommended to patients with an Eczema Area and Severity Index (EASI)&gt;/=16. Previous studies have demonstrated an improved treatment response to the anti-interleukin (IL)-13 antibody tralokinumab in AD subgroups with elevated levels of the IL-13-related biomarkers dipeptidyl-peptidase (DPP)-4 and periostin. METHODS: Herein, 373 AD patients aged&gt;/=12 years were stratified by IL-13(high) , periostin(high) and DPP-4(high) endotypes using cross-sectional data from the ProRaD cohort Bonn. &quot;High&quot; was defined as &gt;80(th) quantile of 47 non-atopic controls. We analyzed endotype-phenotype associations using machine-learning gradient boosting compared to logistic regression. RESULTS: AD severity and eosinophils correlated with IL-13 and periostin levels. Correlations of IL-13 with EASI were stronger in patients with increased (rs=0.482) than with normal (rs=0.342) periostin levels. We identified eosinophilia&gt;6% and an EASI range of 5.5-17 dependent on the biomarker combination to be associated with increasing probabilities of biomarker(high) endotypes. Also patients with mild-to-low-moderate severity (EASI&lt;16) featured increased biomarkers (IL-13(high) : 41%, periostin(high) : 48.4%, DPP-4(high) : 22.3%). Herthoge sign (adjusted Odds Ratio (aOR)=1.89, 95% Confidence Interval (CI) [1.14-3.14]) and maternal allergic rhinitis (aOR=2.79-4.47) increased the probability of an IL-13(high) -endotype, &quot;dirty neck&quot; (aOR=2.83 [1.32-6.07]), orbital darkening (aOR=2.43 [1.08-5.50]), keratosis pilaris (aOR=2.21 [1.1-4.42]) and perleche (aOR=3.44 [1.72-6.86]) of a DPP-4(high) -endotype. CONCLUSIONS: A substantial proportion of patients with EASI&lt;16 featured high biomarker levels suggesting systemic impact of skin inflammation already below the current cut-off for systemic therapy. Our findings facilitate the identification of patients with distinct endotypes potentially linked to response to IL-13-targeted therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Maintz, Laura&#xD;Welchowski, Thomas&#xD;Herrmann, Nadine&#xD;Brauer, Juliette&#xD;Traidl-Hoffmann, Claudia&#xD;Havenith, Regina&#xD;Muller, Svenja&#xD;Rhyner, Claudio&#xD;Dreher, Anita&#xD;Schmid, Matthias&#xD;Bieber, Thomas&#xD;eng&#xD;Denmark&#xD;Allergy. 2023 Jan 17. doi: 10.1111/all.15647.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36647778</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15647</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1541</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1541</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Canas, J. A.</style></author><author><style face="normal" font="default" size="100%">Aranda, C. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA), Malaga, Spain.&#xD;Andalusian Centre for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-13: An essential cDC2s partner to maintain skin homeostasis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2869-2871</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/06/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin</style></keyword><keyword><style face="normal" font="default" size="100%">CD11b</style></keyword><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">conventional dendritic cells</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35691002</style></accession-num><notes><style face="normal" font="default" size="100%">Fernandez-Santamaria, Ruben&#xD;Canas, Jose Antonio&#xD;Aranda, Carlos J&#xD;eng&#xD;Comment&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2869-2871. doi: 10.1111/all.15407. Epub 2022 Jun 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35691002</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15407</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1959</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1959</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Waldetario, Mcgm</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Icahn School of Medicine at Mount Sinai, Jaffe Food Allergy Institute, New York, New York, USA.&#xD;Icahn School of Medicine at Mount Sinai, Precision Immunology Institute, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-21 boosts germinal center response through independent actions on T and B cells in a concentration-dependent manner</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1719-1721</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/03/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Germinal Center</style></keyword><keyword><style face="normal" font="default" size="100%">*B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukins</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Helper-Inducer</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-21</style></keyword><keyword><style face="normal" font="default" size="100%">B cells</style></keyword><keyword><style face="normal" font="default" size="100%">Il-21</style></keyword><keyword><style face="normal" font="default" size="100%">T follicular helper cells</style></keyword><keyword><style face="normal" font="default" size="100%">germinal center</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36872451</style></accession-num><notes><style face="normal" font="default" size="100%">Waldetario, Mariana C G Miranda&#xD;eng&#xD;R01AI130343/GF/NIH HHS/&#xD;R01AI153708/GF/NIH HHS/&#xD;News&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1719-1721. doi: 10.1111/all.15697. Epub 2023 Mar 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36872451</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15697</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2781</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2781</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zaleska, A.</style></author><author><style face="normal" font="default" size="100%">Gajewski, A.</style></author><author><style face="normal" font="default" size="100%">Dor-Wojnarowska, A.</style></author><author><style face="normal" font="default" size="100%">Radlinska, A.</style></author><author><style face="normal" font="default" size="100%">Rorat, M.</style></author><author><style face="normal" font="default" size="100%">Chalubinski, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Pneumonology and Allergology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland.&#xD;Department of Social Sciences and Infectious Diseases, Wroclaw University of Science and Technology, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-25 and Periostin Serum Concentrations May Be Associated With COVID-19 Severity and Recovery</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1150-1153</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/20</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39704394</style></accession-num><notes><style face="normal" font="default" size="100%">Zaleska, Anna&#xD;Gajewski, Adrian&#xD;Dor-Wojnarowska, Anna&#xD;Radlinska, Anna&#xD;Rorat, Marta&#xD;Chalubinski, Maciej&#xD;eng&#xD;STM.A200.21.060/Ministry of Health/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1150-1153. doi: 10.1111/all.16431. Epub 2024 Dec 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39704394</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16431</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2799</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2799</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abdu, S.</style></author><author><style face="normal" font="default" size="100%">Xia, J.</style></author><author><style face="normal" font="default" size="100%">Yuan, H.</style></author><author><style face="normal" font="default" size="100%">Tan, T. J.</style></author><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">McKenzie, A. N. J.</style></author><author><style face="normal" font="default" size="100%">Haloob, N.</style></author><author><style face="normal" font="default" size="100%">Hopkins, C.</style></author><author><style face="normal" font="default" size="100%">Woszczek, G.</style></author><author><style face="normal" font="default" size="100%">Till, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;King&apos;s Centre for Lung Health, King&apos;s College London, London, UK.&#xD;ENT Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China.&#xD;Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.&#xD;Department of ENT Surgery, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-25 Enhances B Cell Responses in Type 2 Inflammation Through IL-17RB Receptor</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">965-975</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/01/20 22:54</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*B-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Interleukin-17/metabolism/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-17/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Activation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Polyps/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">B cells</style></keyword><keyword><style face="normal" font="default" size="100%">Il-17rb</style></keyword><keyword><style face="normal" font="default" size="100%">Il-25</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">and GSK. All other authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39829150</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Alarmin cytokine IL-25 promotes type 2 inflammatory responses in disorders such as asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and known targets include ILC2 and Th2 cells. However, other cellular targets for IL-25 remain poorly defined. OBJECTIVE: To investigate induction and expression of IL-25 receptor (IL-17RB) by B cells and evaluate responsiveness of IL-17RB-expressing B cells to IL-25 in vitro. METHODS: IL-17RB expression, regulation and function on B cells were evaluated in peripheral blood-derived B cells by flow cytometry and RT-PCR, including in response to IgE-inducing stimuli (anti-CD40 mAb and IL-4). Single-cell RNA sequencing was used to compare IL-17RB+ and IL-17RB-activated peripheral blood-derived B cells. To evaluate B cell IL-17RB expression within type 2 inflamed tissue, B cells were compared from nasal polyps, control turbinate tissue and matched peripheral blood. RESULTS: Activation of B cells with anti-CD40 and IL-4 increased IL-17RB expression at both protein and mRNA level, which was further upregulated by IL-25. B cells induced to express IL-17RB responded to IL-25 with enhanced antibody production. Single-cell RNA-sequencing showed that IL17RB+ activated B cells expressed higher levels of IGHE, CCL17 and CCL22 compared to IL17RB- B cells. B cells from nasal polyp tissue expressed higher levels of surface IL-17RB compared with control tissue, correlating with patient-reported CRSwNP severity (SNOT-22). CONCLUSION: Peripheral blood B cells activated under IgE-inducing conditions express surface IL-17RB, and tissue IL-17RB+ B cells are increased in type 2 inflammation. IL-17RB+ cells have a distinct transcriptional profile and respond to IL-25 with enhanced antibody production, highlighting the IL-25/IL-17RB pathway as a potential therapeutic target for CRSwNP and other type 2 inflammatory disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Abdu, Semah&#xD;Xia, Jiao&#xD;Yuan, Huihui&#xD;Tan, Tiak Ju&#xD;Layhadi, Janice A&#xD;Shamji, Mohamed H&#xD;McKenzie, Andrew N J&#xD;Haloob, Nora&#xD;Hopkins, Claire&#xD;Woszczek, Grzegorz&#xD;Till, Stephen J&#xD;eng&#xD;Asthma UK Centre Grant/&#xD;NIHR BRC Guy&apos;s &amp; St Thomas&apos; NHS Foundation Trust in Partnership With King&apos;s College London and King&apos;s College Hospital NHS Foundation Trust/&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):965-975. doi: 10.1111/all.16472. Epub 2025 Jan 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39829150</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969324</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16472</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1114</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1114</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gajewski, A.</style></author><author><style face="normal" font="default" size="100%">Gawrysiak, M.</style></author><author><style face="normal" font="default" size="100%">Szewczyk, R.</style></author><author><style face="normal" font="default" size="100%">Gulbas, I.</style></author><author><style face="normal" font="default" size="100%">Likonska, A.</style></author><author><style face="normal" font="default" size="100%">Michlewska, S.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author><author><style face="normal" font="default" size="100%">Chalubinski, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland.&#xD;Laboratory of Microscopic Imaging and Specialized Biological Techniques, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-33 augments the effect of rhinovirus HRV16 on inflammatory activity of human lung vascular endothelium-possible implications for rhinoviral asthma exacerbations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2282-2285</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinovirus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33683708</style></accession-num><notes><style face="normal" font="default" size="100%">Gajewski, Adrian&#xD;Gawrysiak, Mateusz&#xD;Szewczyk, Robert&#xD;Gulbas, Izabela&#xD;Likonska, Aleksandra&#xD;Michlewska, Sylwia&#xD;Kowalski, Marek L&#xD;Chalubinski, Maciej&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2282-2285. doi: 10.1111/all.14806. Epub 2021 Mar 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33683708</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14806</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3294</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3294</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Matsuyama, Emiko</style></author><author><style face="normal" font="default" size="100%">Miyata, Jun</style></author><author><style face="normal" font="default" size="100%">Mochimaru, Takao</style></author><author><style face="normal" font="default" size="100%">Onozato, Ryuta</style></author><author><style face="normal" font="default" size="100%">Otsu, Yo</style></author><author><style face="normal" font="default" size="100%">Sasaki, Hisashi</style></author><author><style face="normal" font="default" size="100%">Sunata, Keeya</style></author><author><style face="normal" font="default" size="100%">Okuzumi, Shinichi</style></author><author><style face="normal" font="default" size="100%">Masaki, Katsunori</style></author><author><style face="normal" font="default" size="100%">Kabata, Hiroki</style></author><author><style face="normal" font="default" size="100%">Hizuka, Keinosuke</style></author><author><style face="normal" font="default" size="100%">Hasegawa, Yoshinori</style></author><author><style face="normal" font="default" size="100%">Konno, Ryo</style></author><author><style face="normal" font="default" size="100%">Kawashima, Yusuke</style></author><author><style face="normal" font="default" size="100%">Arita, Makoto</style></author><author><style face="normal" font="default" size="100%">Ueki, Shigeharu</style></author><author><style face="normal" font="default" size="100%">Fukunaga, Koichi</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">IL-33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background IL-33 levels are elevated in the airways of patients with eosinophilic diseases, and IL-33 receptor expression on eosinophils is upregulated in type 2-high environments. However, the role of IL-33 in the regulation of human eosinophils remains unclear. Objective To elucidate the inflammatory effects of IL-33 on the cellular function of human eosinophils. Methods Blood eosinophils were stimulated with IL-33, TNF-α, oxidised low-density lipoprotein (oxLDL) and complement fragments (C3a and C5a). Multi-omics analyses, including transcriptomics and proteomics, were performed. Extracellular trap formation (ETosis) was assessed by SYTOX nucleic acid staining and was visualised by immunofluorescence and transmission electron microscopy. Results Multi-omics analyses revealed an IL-33- and TNF-α-induced inflammatory gene signature characterised by the upregulation of cell surface markers (oxLDL receptor 1, CD22, CD4 and ICAM-1) and inflammatory mediators (C3, CCL3/4 and IL1A/B). CD22 upregulation was specific to IL-33 stimulation. Eosinophils derived from nasal polyps exhibited a gene expression profile similar to that of IL-33-stimulated eosinophils. Functional assays demonstrated that oxLDL and complement fragments differentially prolonged eosinophil survival and altered the expression of adhesion molecules. OxLDL- and complement fragment-induced gene signatures were partly detected in eosinophils derived from nasal polyps. Furthermore, IL-33 triggered ETosis via NADPH oxidase, mitogen-activated protein kinase and phosphoinositide 3-kinase pathways. Conclusions IL-33, in conjunction with oxLDL and the complement cascade, induces inflammatory changes in eosinophils, promoting an ETosis-prone phenotype. These pathways represent potential therapeutic targets in refractory eosinophilic diseases.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70313</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70313</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>612</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">612</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gulbas, I.</style></author><author><style face="normal" font="default" size="100%">Gajewski, A.</style></author><author><style face="normal" font="default" size="100%">Gawrysiak, M.</style></author><author><style face="normal" font="default" size="100%">Szewczyk, R.</style></author><author><style face="normal" font="default" size="100%">Likonska, A.</style></author><author><style face="normal" font="default" size="100%">Michlewska, S.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author><author><style face="normal" font="default" size="100%">Chalubinski, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland.&#xD;Laboratory of Microscopic Imaging and Specialized Biological Techniques, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-33 prevents the enhancement of AP-N, DPP4, and ACE2 expression induced by rhinovirus HRV16 in the human lung endothelium-potential implications for coronaviral airway infections</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1610-1613</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2</style></keyword><keyword><style face="normal" font="default" size="100%">Dipeptidyl Peptidase 4/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-33/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinovirus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35143044</style></accession-num><notes><style face="normal" font="default" size="100%">Gulbas, Izabela&#xD;Gajewski, Adrian&#xD;Gawrysiak, Mateusz&#xD;Szewczyk, Robert&#xD;Likonska, Aleksandra&#xD;Michlewska, Sylwia&#xD;Kowalski, Marek L&#xD;Chalubinski, Maciej&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1610-1613. doi: 10.1111/all.15251. Epub 2022 Feb 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35143044</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9111265</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15251</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2712</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2712</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kobayashi, Y.</style></author><author><style face="normal" font="default" size="100%">Sakai, K.</style></author><author><style face="normal" font="default" size="100%">Tran, N. Q. V.</style></author><author><style face="normal" font="default" size="100%">Ishimaru, K.</style></author><author><style face="normal" font="default" size="100%">Sato, T.</style></author><author><style face="normal" font="default" size="100%">Nakamura, Y.</style></author><author><style face="normal" font="default" size="100%">Nakagomi, D.</style></author><author><style face="normal" font="default" size="100%">Tanaka, S.</style></author><author><style face="normal" font="default" size="100%">Koizumi, S.</style></author><author><style face="normal" font="default" size="100%">Nakao, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.&#xD;Department of Rheumatology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.&#xD;Yamanashi GLIA Center, University of Yamanashi, Yamanashi, Japan.&#xD;Department of Dermatology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.&#xD;Laboratory of Pharmacology, Division of Pathological Sciences, Kyoto Pharmaceutical University, Kyoto, Japan.&#xD;Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Kofu, Japan.&#xD;Atopy Research Center, Juntendo University School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-33 Sensitizes Mast Cells to PIEZO1 Stimulation Leading to Degranulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3517-3520</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/11/15</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39545515</style></accession-num><notes><style face="normal" font="default" size="100%">Kobayashi, Yoshiaki&#xD;Sakai, Kent&#xD;Tran, Nguyen Quoc Vuong&#xD;Ishimaru, Kayoko&#xD;Sato, Takuya&#xD;Nakamura, Yuki&#xD;Nakagomi, Daiki&#xD;Tanaka, Satoshi&#xD;Koizumi, Schuichi&#xD;Nakao, Atsuhito&#xD;eng&#xD;22K19427/the Ministry of Education, Culture, Sports, Science and Technology of Japan/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3517-3520. doi: 10.1111/all.16397. Epub 2024 Nov 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39545515</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657013</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16397</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>834</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">834</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schroder, A.</style></author><author><style face="normal" font="default" size="100%">Lunding, L. P.</style></author><author><style face="normal" font="default" size="100%">Zissler, U. M.</style></author><author><style face="normal" font="default" size="100%">Vock, C.</style></author><author><style face="normal" font="default" size="100%">Webering, S.</style></author><author><style face="normal" font="default" size="100%">Ehlers, J. C.</style></author><author><style face="normal" font="default" size="100%">Orinska, Z.</style></author><author><style face="normal" font="default" size="100%">Chaker, A.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Lang, N. J.</style></author><author><style face="normal" font="default" size="100%">Schiller, H. B.</style></author><author><style face="normal" font="default" size="100%">Mall, M. A.</style></author><author><style face="normal" font="default" size="100%">Fehrenbach, H.</style></author><author><style face="normal" font="default" size="100%">Dinarello, C. A.</style></author><author><style face="normal" font="default" size="100%">Wegmann, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Asthma Exacerbation &amp;-Regulation, Priority Area Asthma &amp; Allergy, Research Center Borstel-Leibniz Lung Center, Borstel, Germany.&#xD;Airway Research Center North, Member of the German Center for Lung Research (DZL), Munich, Germany.&#xD;Center of Allergy and Environment (ZAUM), Technische Universitat and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.&#xD;Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.&#xD;Division of Experimental Pneumology, Priority Area Asthma &amp; Allergy, Research Center Borstel- Leibniz Lung Center, Borstel, Germany.&#xD;Department of Otorhinolaryngology and Head and Neck Surgery, Medical School, Technical, University of Munich, Munich, Germany.&#xD;Institute of Lung Biology and Disease, Helmholtz Zentrum Munchen, Munich, Germany.&#xD;Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Berlin Institute of Health (BIH), Berlin, Germany.&#xD;German Center for Lung Research (DZL), associated partner site, Berlin, Germany.&#xD;Department of Medicine, University of Colorado Denver, Denver, CO, USA.&#xD;Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL-37 regulates allergic inflammation by counterbalancing pro-inflammatory IL-1 and IL-33</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">856-869</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/08/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-33</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34460953</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Children with asthma have impaired production of interleukin (IL) 37; in mice, IL-37 reduces hallmarks of experimental allergic asthma (EAA). However, it remains unclear how IL-37 exerts its inhibitory properties in asthma. This study aimed to identify the mechanism(s) by which IL-37 controls allergic inflammation. METHODS: IL-37 target cells were identified by single-cell RNA-seq of IL-1R5 and IL-1R8. Airway tissues were isolated by laser-capture microdissection and examined by microarray-based gene expression analysis. Mononuclear cells (MNC) and airway epithelial cells (AECs) were isolated and stimulated with allergen, IL-1beta, or IL-33 together with recombinant human (rh) IL-37. Wild-type, IL-1R1- and IL-33-deficient mice with EAA were treated with rhIL-37. IL-1beta, IL-33, and IL-37 levels were determined in sputum and nasal secretions from adult asthma patients without glucocorticoid therapy. RESULTS: IL-37 target cells included AECs, T cells, and dendritic cells. In mice with EAA, rhIL-37 led to differential expression of &gt;90 genes induced by IL-1beta and IL-33. rhIL-37 reduced production of Th2 cytokines in allergen-activated MNCs from wild-type but not from IL-1R1-deficient mice and inhibited IL-33-induced Th2 cytokine release. Furthermore, rhIL-37 attenuated IL-1beta- and IL-33-induced pro-inflammatory mediator expression in murine AEC cultures. In contrast to wild-type mice, hIL-37 had no effect on EAA in IL-1R1- or IL-33-deficient mice. We also observed that expression/production ratios of both IL-1beta and IL-33 to IL-37 were dramatically increased in asthma patients compared to healthy controls. CONCLUSION: IL-37 downregulates allergic airway inflammation by counterbalancing the disease-amplifying effects of IL-1beta and IL-33.</style></abstract><notes><style face="normal" font="default" size="100%">Schroder, Alexandra&#xD;Lunding, Lars P&#xD;Zissler, Ulrich M&#xD;Vock, Christina&#xD;Webering, Sina&#xD;Ehlers, Johanna C&#xD;Orinska, Zane&#xD;Chaker, Adam&#xD;Schmidt-Weber, Carsten B&#xD;Lang, Niklas J&#xD;Schiller, Herbert B&#xD;Mall, Marcus A&#xD;Fehrenbach, Heinz&#xD;Dinarello, Charles A&#xD;Wegmann, Michael&#xD;eng&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):856-869. doi: 10.1111/all.15072. Epub 2021 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34460953</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15072</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>343</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">343</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Badi, Y. E.</style></author><author><style face="normal" font="default" size="100%">Salcman, B.</style></author><author><style face="normal" font="default" size="100%">Taylor, A.</style></author><author><style face="normal" font="default" size="100%">Rana, B.</style></author><author><style face="normal" font="default" size="100%">Kermani, N. Z.</style></author><author><style face="normal" font="default" size="100%">Riley, J. H.</style></author><author><style face="normal" font="default" size="100%">Worsley, S.</style></author><author><style face="normal" font="default" size="100%">Mumby, S.</style></author><author><style face="normal" font="default" size="100%">Dahlen, S. E.</style></author><author><style face="normal" font="default" size="100%">Cousins, D.</style></author><author><style face="normal" font="default" size="100%">Bulfone-Paus, S.</style></author><author><style face="normal" font="default" size="100%">Affleck, K.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Bates, S.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Data Science Institute, Imperial College London, London, UK.&#xD;BenevolentAI, London, UK.&#xD;School of Biological Sciences, University of Manchester, Manchester, UK.&#xD;GSK Respiratory Therapeutic Area Unit, Stevenage, UK.&#xD;Orchard Therapeutics, London, UK.&#xD;GSK Value Evidence and Outcomes, GSK House, Brentford, UK.&#xD;Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.&#xD;Department of Respiratory Sciences, University of Leicester, Leicester, UK.&#xD;GSK Adaptive Immunity Research Unit, Stevenage, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IL1RAP expression and the enrichment of IL-33 activation signatures in severe neutrophilic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">156-167</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/08/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-1 Receptor Accessory Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">gene set variation analysis</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">worked or are currently working for GSK. Batika Rana is currently working for</style></keyword><keyword><style face="normal" font="default" size="100%">Orchard Therapeutics and Yusef Eamon Badi is currently working at BenevolentAI.</style></keyword><keyword><style face="normal" font="default" size="100%">MN, Silvia Bulfone-Paus, Kian Fan Chung, DJC and IMA have received</style></keyword><keyword><style face="normal" font="default" size="100%">investigator-led research grants from GSK. YB and Barbora Salcman are supported</style></keyword><keyword><style face="normal" font="default" size="100%">by BBSRC CASE awards. DJC has received investigator-led research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca and Genentech. There are no other conflicts of interest regarding</style></keyword><keyword><style face="normal" font="default" size="100%">this manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35986608</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Interleukin (IL)-33 is an upstream regulator of type 2 (T2) eosinophilic inflammation and has been proposed as a key driver of some asthma phenotypes. OBJECTIVE: To derive gene signatures from in vitro studies of IL-33-stimulated cells and use these to determine IL-33-associated enrichment patterns in asthma. METHODS: Signatures downstream of IL-33 stimulation were derived from our in vitro study of human mast cells and from public datasets of in vitro stimulated human basophils, type 2 innate lymphoid cells (ILC2), regulatory T cells (Treg) and endothelial cells. Gene Set Variation Analysis (GSVA) was used to probe U-BIOPRED and ADEPT sputum transcriptomics to determine enrichment scores (ES) for each signature according to asthma severity, sputum granulocyte status and previously defined molecular phenotypes. RESULTS: IL-33-activated gene signatures were cell-specific with little gene overlap. Individual signatures, however, were associated with similar signalling pathways (TNF, NF-kappaB, IL-17 and JAK/STAT signalling) and immune cell differentiation pathways (Th17, Th1 and Th2 differentiation). ES for IL-33-activated gene signatures were significantly enriched in asthmatic sputum, particularly in patients with neutrophilic and mixed granulocytic phenotypes. IL-33 mRNA expression was not elevated in asthma whereas the expression of mRNA for IL1RL1, the IL-33 receptor, was up-regulated in the sputum of severe eosinophilic asthma. The mRNA expression for IL1RAP, the IL1RL1 co-receptor, was greatest in severe neutrophilic and mixed granulocytic asthma. CONCLUSIONS: IL-33-activated gene signatures are elevated in neutrophilic and mixed granulocytic asthma corresponding with IL1RAP co-receptor expression. This suggests incorporating T2-low asthma in anti-IL-33 trials.</style></abstract><notes><style face="normal" font="default" size="100%">Badi, Yusef Eamon&#xD;Salcman, Barbora&#xD;Taylor, Adam&#xD;Rana, Batika&#xD;Kermani, Nazanin Zounemat&#xD;Riley, John H&#xD;Worsley, Sally&#xD;Mumby, Sharon&#xD;Dahlen, Sven-Eric&#xD;Cousins, David&#xD;Bulfone-Paus, Silvia&#xD;Affleck, Karen&#xD;Chung, Kian Fan&#xD;Bates, Stewart&#xD;Adcock, Ian M&#xD;eng&#xD;MR/T010371/1/MRC_/Medical Research Council/United Kingdom&#xD;G1000758/MRC_/Medical Research Council/United Kingdom&#xD;DH_/Department of Health/United Kingdom&#xD;MR/M016579/1/MRC_/Medical Research Council/United Kingdom&#xD;208340/Z/17/Z/WT_/Wellcome Trust/United Kingdom&#xD;WT_/Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):156-167. doi: 10.1111/all.15487. Epub 2022 Aug 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35986608</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10086999</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15487</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>89</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">89</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Franceschini, L.</style></author><author><style face="normal" font="default" size="100%">Farsi, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergology and Clinical Immunology Unit, Santo Stefano Hospital, Prato, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immediate hypersensitivity reactions to anti-SARS-CoV-2 neutralizing monoclonal antibodies: A real-life experience</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1119-1120</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/11/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Neutralizing</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36383041</style></accession-num><notes><style face="normal" font="default" size="100%">Franceschini, Laura&#xD;Farsi, Alessandro&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):1119-1120. doi: 10.1111/all.15583. Epub 2022 Nov 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36383041</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15583</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1075</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1075</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Manohar, M.</style></author><author><style face="normal" font="default" size="100%">Dunham, D.</style></author><author><style face="normal" font="default" size="100%">Gupta, S.</style></author><author><style face="normal" font="default" size="100%">Yan, Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, W.</style></author><author><style face="normal" font="default" size="100%">Minnicozzi, S.</style></author><author><style face="normal" font="default" size="100%">Kirkey, M.</style></author><author><style face="normal" font="default" size="100%">Bunning, B.</style></author><author><style face="normal" font="default" size="100%">Roy Chowdhury, R.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author><author><style face="normal" font="default" size="100%">Boyd, S. D.</style></author><author><style face="normal" font="default" size="100%">Kost, L. E.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author><author><style face="normal" font="default" size="100%">Desai, M.</style></author><author><style face="normal" font="default" size="100%">Oettgen, H. C.</style></author><author><style face="normal" font="default" size="100%">Maecker, H. T.</style></author><author><style face="normal" font="default" size="100%">Yu, W.</style></author><author><style face="normal" font="default" size="100%">DeKruyff, R. H.</style></author><author><style face="normal" font="default" size="100%">Andorf, S.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy and Asthma Research, Stanford, CA, USA.&#xD;Human Immune Monitoring Center, Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Division of Immunology, Department of Pediatrics, Boston Children&apos;s Hospital, Boston, MA, USA.&#xD;Department of Pediatrics, Harvard Medical School, Boston, MA, USA.&#xD;Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Department of Biomedical and Data Science, Stanford University, Stanford, CA, USA.&#xD;Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.&#xD;Divisions of Biomedical Informatics and Allergy &amp; Immunology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2809-2826</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/03/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocytes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33782956</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Multifood oral immunotherapy (mOIT) with adjunctive anti-IgE (omalizumab, XOLAIR((R)) ) treatment affords safe, effective, and rapid desensitization to multiple foods, although the specific immune mechanisms mediating this desensitization remain to be fully elucidated. METHODS: Participants in our phase 2 mOIT trial (NCT02643862) received omalizumab from baseline to week 16 and mOIT from week 8 to week 36. We compared the immune profile of PBMCs and plasma taken at baseline, week 8, and week 36 using high-dimensional mass cytometry, component-resolved diagnostics, the indirect basophil activation test, and Luminex. RESULTS: We found (i) decreased frequency of IL-4(+) peanut-reactive CD4(+) T cells and a marked downregulation of GPR15 expression and CXCR3 frequency among gammadelta and CD8(+) T-cell subsets at week 8 during the initial, omalizumab-alone induction phase; (ii) significant upregulation of the skin-homing receptor CCR4 in peanut-reactive CD4(+) T and Th2 effector memory (EM) cells and of cutaneous lymphocyte-associated antigen (CLA) in peanut-reactive CD8(+) T and CD8(+) EM cells; (iii) downregulation of CD86 expression among antigen-presenting cell subsets; and (iv) reduction in pro-inflammatory cytokines, notably IL-17, at week 36 post-OIT. We also observed significant attenuation of the Th2 phenotype post-OIT, defined by downregulation of IL-4 peanut-reactive T cells and OX40 in Th2EM cells, increased allergen component-specific IgG4/IgE ratio, and decreased allergen-driven activation of indirectly sensitized basophils. CONCLUSIONS: This exploratory study provides novel comprehensive insight into the immune underpinnings of desensitization through omalizumab-facilitated mOIT. Moreover, this study provides encouraging results to support the complex immune changes that can be induced by OIT.</style></abstract><notes><style face="normal" font="default" size="100%">Manohar, Monali&#xD;Dunham, Diane&#xD;Gupta, Sheena&#xD;Yan, Zheng&#xD;Zhang, Wenming&#xD;Minnicozzi, Samantha&#xD;Kirkey, Matthew&#xD;Bunning, Bryan&#xD;Roy Chowdhury, Roshni&#xD;Galli, Stephen J&#xD;Boyd, Scott D&#xD;Kost, Laurie Elizabeth&#xD;Chinthrajah, R Sharon&#xD;Desai, Manisha&#xD;Oettgen, Hans C&#xD;Maecker, Holden T&#xD;Yu, Wong&#xD;DeKruyff, Rosemarie H&#xD;Andorf, Sandra&#xD;Nadeau, Kari C&#xD;eng&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;R01AI140134-02/NH/NIH HHS/&#xD;5UM2AI130836-04/NH/NIH HHS/&#xD;5T32AI007512/NH/NIH HHS/&#xD;T32 AI007512/AI/NIAID NIH HHS/&#xD;R01AI119918/NH/NIH HHS/&#xD;U01 AI140498/AI/NIAID NIH HHS/&#xD;U19AI104209/NH/NIH HHS/&#xD;U01 AI140498-03/NH/NIH HHS/&#xD;UM2 AI130836/AI/NIAID NIH HHS/&#xD;U01 AI147462/AI/NIAID NIH HHS/&#xD;R01 AI119918/AI/NIAID NIH HHS/&#xD;R01 AI140134/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2809-2826. doi: 10.1111/all.14833. Epub 2021 May 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33782956</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8609920</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14833</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1067</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1067</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Goretzki, A.</style></author><author><style face="normal" font="default" size="100%">Lin, Y. J.</style></author><author><style face="normal" font="default" size="100%">Schulke, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular Allergology, Paul-Ehrlich-Institut, Langen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immune metabolism in allergies, does it matter?-A review of immune metabolic basics and adaptations associated with the activation of innate immune cells in allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3314-3331</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/04/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergies</style></keyword><keyword><style face="normal" font="default" size="100%">glycolysis</style></keyword><keyword><style face="normal" font="default" size="100%">immune metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative phosphorylation</style></keyword><keyword><style face="normal" font="default" size="100%">warburg effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33811351</style></accession-num><abstract><style face="normal" font="default" size="100%">Type I allergies are pathological, type 2 inflammatory immune responses against otherwise harmless environmental allergens that arise from complex interactions between different types of immune cells. Activated immune cells undergo extensive changes in phenotype and function to fulfill their effector functions. Hereby, activation, differentiation, proliferation, migration, and mounting of effector responses require metabolic reprogramming. While the metabolic changes associated with activation of dendritic cells, macrophages, and T cells are extensively studied, data about the metabolic phenotypes of the other cell types critically involved in allergic responses (epithelial cells, eosinophils, basophils, mast cells, and ILC2s) are rather limited. This review briefly covers the basics of cellular energy metabolism and its connection to immune cell function. In addition, it summarizes the current state of knowledge in terms of dendritic cell and macrophage metabolism and subsequently focuses on the metabolic changes associated with activation of epithelial cells, eosinophils, basophils, mast cells, as well as ILC2s in allergy. Interestingly, the innate key cell types in allergic inflammation were reported to change their metabolic phenotype during activation, shifting to either glycolysis (epithelial cells, M1 macrophages, DCs, eosinophils, basophils, acutely activated mast cells), oxidative phosphorylation (M2 macrophages, longer term activated mast cells), or fatty acid oxidation (ILC2s). Therefore, immune metabolism is of relevance in allergic diseases and its connection to immune cell effector function needs to be considered to better understand induction and maintenance of allergic responses. Further progress in this field will likely improve both our understanding of disease pathology and enable new treatment targets/strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Goretzki, Alexandra&#xD;Lin, Yen-Ju&#xD;Schulke, Stefan&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3314-3331. doi: 10.1111/all.14843. Epub 2021 May 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33811351</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14843</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1412</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1412</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roth-Walter, F.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Benito-Villalvilla, C.</style></author><author><style face="normal" font="default" size="100%">Bianchini, R.</style></author><author><style face="normal" font="default" size="100%">Bjermer, L.</style></author><author><style face="normal" font="default" size="100%">Boyman, O.</style></author><author><style face="normal" font="default" size="100%">Caramori, G.</style></author><author><style face="normal" font="default" size="100%">Cari, L.</style></author><author><style face="normal" font="default" size="100%">Fan Chung, K.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Knol, E. F.</style></author><author><style face="normal" font="default" size="100%">Kolios, A.</style></author><author><style face="normal" font="default" size="100%">Levi-Schaffer, F.</style></author><author><style face="normal" font="default" size="100%">Nocentini, G.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Redegeld, F.</style></author><author><style face="normal" font="default" size="100%">Van Esch, B.</style></author><author><style face="normal" font="default" size="100%">Stellato, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria.&#xD;Molecular Cell Biology Group, National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Respiratory Medicine and Allergology, Lung and Allergy research, Allergy, Asthma and COPD Competence Center, Lund University, Lund, Sweden.&#xD;Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Department of Biomedical Sciences, Dentistry and Morphological and Functional Imaging (BIOMORF), Respiratory Medicine Unit, University of Messina, Messina, Italy.&#xD;Department of Medicine, Section of Pharmacology, University of Perugia, Perugia, Italy.&#xD;Experimental Studies Medicine at National Heart &amp; Lung Institute, Imperial College London &amp; Royal Brompton &amp; Harefield NHS Trust, London, UK.&#xD;Department of Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Hospital, Lund, Sweden.&#xD;Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.&#xD;Department of Clinical Pharmacy &amp; Pharmacology, University Groningen, University Medical Center Groningen and QPS-NL, Groningen, Netherlands.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-Instituto de Investigacion Biomedica de Malaga (IBIMA)-ARADyAL, Malaga, Spain.&#xD;Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Pharmacology Unit, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Israel.&#xD;Faculty of Science, Division of Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.&#xD;Department of Medicine, Surgery and Dentistry &quot;Scuola Medica Salernitana&quot;, University of Salerno, Salerno, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases-An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">90-113</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/06/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">*Autoimmune Diseases/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">CAR-Treg cells</style></keyword><keyword><style face="normal" font="default" size="100%">adoptive cell therapies</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunoregulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32593226</style></accession-num><abstract><style face="normal" font="default" size="100%">Therapeutic advances using targeted biologicals and small-molecule drugs have achieved significant success in the treatment of chronic allergic, autoimmune, and inflammatory diseases particularly for some patients with severe, treatment-resistant forms. This has been aided by improved identification of disease phenotypes. Despite these achievements, not all severe forms of chronic inflammatory and autoimmune diseases are successfully targeted, and current treatment options, besides allergen immunotherapy for selected allergic diseases, fail to change the disease course. T cell-based therapies aim to cure diseases through the selective induction of appropriate immune responses following the delivery of engineered, specific cytotoxic, or regulatory T cells (Tregs). Adoptive cell therapies (ACT) with genetically engineered T cells have revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while therapies exploiting the suppressive functions of Tregs have been developed in nononcological settings, such as in transplantation and autoimmune diseases. ACT with Tregs are also being considered in nononcological settings such as cardiovascular disease, obesity, and chronic inflammatory disorders. After describing the general features of T cell-based approaches and current applications in autoimmune diseases, this position paper reviews the experimental models testing or supporting T cell-based approaches, especially Treg-based approaches, in severe IgE-mediated responses and chronic respiratory airway diseases, such as severe asthma and COPD. Along with an assessment of challenges and unmet needs facing the application of ACT in these settings, this article underscores the potential of ACT to offer curative options for patients with severe or treatment-resistant forms of these immune-driven disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Roth-Walter, Franziska&#xD;Adcock, Ian M&#xD;Benito-Villalvilla, Cristina&#xD;Bianchini, Rodolfo&#xD;Bjermer, Leif&#xD;Boyman, Onur&#xD;Caramori, Gaetano&#xD;Cari, Luigi&#xD;Fan Chung, Kian&#xD;Diamant, Zuzana&#xD;Eguiluz-Gracia, Ibon&#xD;Knol, Edward F&#xD;Kolios, Antonios&#xD;Levi-Schaffer, Francesca&#xD;Nocentini, Giuseppe&#xD;Palomares, Oscar&#xD;Redegeld, Frank&#xD;Van Esch, Betty&#xD;Stellato, Cristiana&#xD;eng&#xD;MR/T010371/1/MRC_/Medical Research Council/United Kingdom&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):90-113. doi: 10.1111/all.14478.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32593226</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14478</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1972</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1972</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bastin, M.</style></author><author><style face="normal" font="default" size="100%">Carr, W. W.</style></author><author><style face="normal" font="default" size="100%">Davis, C. M.</style></author><author><style face="normal" font="default" size="100%">Fleischer, D. M.</style></author><author><style face="normal" font="default" size="100%">Lieberman, J. A.</style></author><author><style face="normal" font="default" size="100%">Mustafa, S. S.</style></author><author><style face="normal" font="default" size="100%">Helleputte, T.</style></author><author><style face="normal" font="default" size="100%">Bois, T.</style></author><author><style face="normal" font="default" size="100%">Campbell, D. E.</style></author><author><style face="normal" font="default" size="100%">Green, T. D.</style></author><author><style face="normal" font="default" size="100%">Greenhawt, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">DNAlytics, Ottignies-Louvain-la-Neuve, Belgium.&#xD;Allergy and Asthma Associates of Southern California, Southern California Research, California, Mission Viejo, USA.&#xD;Department of Pediatrics, Immunology, Allergy, and Retrovirology Division, Baylor College of Medicine, Houston, Texas, USA.&#xD;Children&apos;s Hospital Colorado, University of Colorado Denver School of Medicine, Aurora, Colorado, USA.&#xD;The University of Tennessee Health Science Center, Le Bonheur Children&apos;s Hospital, Memphis, Tennessee, USA.&#xD;Rochester Regional Health, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.&#xD;DBV Technologies SA, Montrouge, France.&#xD;UPMC Children&apos;s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immune response evolution in peanut epicutaneous immunotherapy for peanut-allergic children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2467-2476</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/03/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4</style></keyword><keyword><style face="normal" font="default" size="100%">Viaskin Peanut</style></keyword><keyword><style face="normal" font="default" size="100%">epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36916639</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Epicutaneous immunotherapy with investigational Viaskin Peanut 250 mug (DBV712) has demonstrated statistically superior desensitization versus placebo in peanut-allergic children in clinical trials. It is unclear whether serologic biomarkers predict response. METHODS: Serum-specific IgG4 and IgE (whole peanut and components) from subjects enrolled in the phase 3 Efficacy and Safety of Viaskin Peanut in Children With IgE-Mediated Peanut Allergy study were examined by exploratory univariate and multivariate analyses to determine trajectories and predictors of treatment response, based upon peanut protein eliciting dose (ED) at Month (M) 12 double-blind placebo-controlled food challenge. RESULTS: Among Viaskin Peanut-treated subjects, peanut sIgG4 significantly increased from baseline through M12 and peanut sIgE peaked at M3 and fell below baseline by M12, with sIgG4 and sIgE peanut components mirroring these trajectories. Placebo subjects had no significant changes. By univariate analysis, M12 peanut sIgG4/sIgE was higher in treatment responders (p &lt; 0.001) and had highest area under the curve (AUC) for predicting ED &gt;/=300 mg and &gt;/=1000 mg (AUC 69.5% and 69.9%, respectively). M12 peanut sIgG4/sIgE &gt;20.1 predicted M12 ED &gt;/=300 mg (80% positive predictive value). The best performing component was Ara h 1 sIgE &lt;15.7 kU(A) /L (AUC 66.5%). A multivariate model combining Ara h 1 and peanut sIgG4/sIgE had an AUC of 68.2% (ED &gt;/=300 mg) and 67.8% (ED &gt;/=1000 mg). CONCLUSIONS: Peanut sIgG4 rise most clearly differentiated Viaskin Peanut versus placebo subjects. sIgG4/sIgE ratios &gt;20.1 and the combination of Ara h 1 and peanut sIgG4/sIgE had moderate ability to predict treatment response and could potentially be useful for clinical monitoring. Additional data are needed to confirm these relationships.</style></abstract><notes><style face="normal" font="default" size="100%">Bastin, Marie&#xD;Carr, Warner W&#xD;Davis, Carla M&#xD;Fleischer, David M&#xD;Lieberman, Jay A&#xD;Mustafa, S Shahzad&#xD;Helleputte, Thibault&#xD;Bois, Timothee&#xD;Campbell, Dianne E&#xD;Green, Todd D&#xD;Greenhawt, Matthew&#xD;eng&#xD;R34 AI157948/AI/NIAID NIH HHS/&#xD;Randomized Controlled Trial&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2467-2476. doi: 10.1111/all.15709. Epub 2023 May 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36916639</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15709</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1173</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1173</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adel-Patient, K.</style></author><author><style face="normal" font="default" size="100%">Grauso, M.</style></author><author><style face="normal" font="default" size="100%">Abou-Taam, R.</style></author><author><style face="normal" font="default" size="100%">Guillon, B.</style></author><author><style face="normal" font="default" size="100%">Dietrich, C.</style></author><author><style face="normal" font="default" size="100%">Machavoine, F.</style></author><author><style face="normal" font="default" size="100%">Garcelon, N.</style></author><author><style face="normal" font="default" size="100%">Briard, M.</style></author><author><style face="normal" font="default" size="100%">Faour, H.</style></author><author><style face="normal" font="default" size="100%">Neuraz, A.</style></author><author><style face="normal" font="default" size="100%">Delacourt, C.</style></author><author><style face="normal" font="default" size="100%">Molina, T. J.</style></author><author><style face="normal" font="default" size="100%">Leite-de-Moraes, M.</style></author><author><style face="normal" font="default" size="100%">Lezmi, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite Paris-Saclay, CEA, INRAE, Departement Medicaments et Technologies pour la Sante (DMTS), SPI, Laboratoire d&apos;Immuno-Allergie Alimentaire, Gif-sur-Yvette, France.&#xD;AP-HP, Hopital Necker-Enfants Malades, Service de Pneumologie et Allergologie Pediatriques, Paris, France.&#xD;Universite de Paris, Institut Necker Enfants Malades, Equipe Immunoregulation et Immunopathologie, Inserm UMR1151, CNRS UMR8253, Paris, France.&#xD;Universite de Paris, UMRS 1138, INSERM, Sorbonne Paris-Cite, Paris, France.&#xD;AP-HP, Hopital Necker-Enfants Malades, Service Informatique Medicale, Paris, France.&#xD;AP-HP, Centre-Universite de Paris, Hopital Necker-Enfant-Malades, Service d&apos;Anatomie et Cytologie Pathologiques, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immune signatures distinguish frequent from non-frequent exacerbators among children with severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2261-2264</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33544926</style></accession-num><notes><style face="normal" font="default" size="100%">Adel-Patient, Karine&#xD;Grauso, Marta&#xD;Abou-Taam, Rola&#xD;Guillon, Blanche&#xD;Dietrich, Celine&#xD;Machavoine, Francois&#xD;Garcelon, Nicolas&#xD;Briard, Melanie&#xD;Faour, Hassan&#xD;Neuraz, Antoine&#xD;Delacourt, Christophe&#xD;Molina, Thierry J&#xD;Leite-de-Moraes, Maria&#xD;Lezmi, Guillaume&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2261-2264. doi: 10.1111/all.14759. Epub 2021 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33544926</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14759</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2460</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2460</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, N.</style></author><author><style face="normal" font="default" size="100%">Song, J.</style></author><author><style face="normal" font="default" size="100%">Sun, S. R.</style></author><author><style face="normal" font="default" size="100%">Zhu, K. Z.</style></author><author><style face="normal" font="default" size="100%">Li, J. X.</style></author><author><style face="normal" font="default" size="100%">Wang, Z. C.</style></author><author><style face="normal" font="default" size="100%">Guo, C. L.</style></author><author><style face="normal" font="default" size="100%">Xiang, W. X.</style></author><author><style face="normal" font="default" size="100%">Tong, Y. L.</style></author><author><style face="normal" font="default" size="100%">Zeng, M.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Xu, X. Y.</style></author><author><style face="normal" font="default" size="100%">Yao, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Hubei Clinical Research Center for Nasal Inflammatory Diseases, Wuhan, China.&#xD;Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, China Resources &amp; Wisco General Hospital, Wuhan, China.&#xD;Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1230-1241</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/02/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroglyphidae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Subcutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">immune signature</style></keyword><keyword><style face="normal" font="default" size="100%">prediction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38403941</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Identifying predictive biomarkers for allergen immunotherapy response is crucial for enhancing clinical efficacy. This study aims to identify such biomarkers in patients with allergic rhinitis (AR) undergoing subcutaneous immunotherapy (SCIT) for house dust mite allergy. METHODS: The Tongji (discovery) cohort comprised 72 AR patients who completed 1-year SCIT follow-up. Circulating T and B cell subsets were characterized using multiplexed flow cytometry before SCIT. Serum immunoglobulin levels and combined symptom and medication score (CSMS) were assessed before and after 12-month SCIT. Responders, exhibiting &gt;/=30% CSMS improvement, were identified. The random forest algorithm and logistic regression analysis were used to select biomarkers and establish predictive models for SCIT efficacy in the Tongji cohort, which was validated in another Wisco cohort with 43 AR patients. RESULTS: Positive SCIT response correlated with higher baseline CSMS, allergen-specific IgE (sIgE)/total IgE (tIgE) ratio, and frequencies of Type 2 helper T cells, Type 2 follicular helper T (T(FH)2) cells, and CD23(+) nonswitched memory B (B(NSM)) and switched memory B (B(SM)) cells, as well as lower follicular regulatory T (T(FR)) cell frequency and T(FR)/T(FH)2 cell ratio. The random forest algorithm identified sIgE/tIgE ratio, T(FR)/T(FH)2 cell ratio, and B(NSM) frequency as the key biomarkers discriminating responders from nonresponders in the Tongji cohort. Logistic regression analysis confirmed the predictive value of a combination model, including sIgE/tIgE ratio, T(FR)/T(FH)2 cell ratio, and CD23(+) B(SM) frequency (AUC = 0.899 in Tongji; validated AUC = 0.893 in Wisco). CONCLUSIONS: A T- and B-cell signature combination efficiently identified SCIT responders before treatment, enabling personalized approaches for AR patients.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Nan&#xD;Song, Jia&#xD;Sun, Shi-Ran&#xD;Zhu, Ke-Zhang&#xD;Li, Jing-Xian&#xD;Wang, Zhi-Chao&#xD;Guo, Cui-Lian&#xD;Xiang, Wen-Xuan&#xD;Tong, Yun-Long&#xD;Zeng, Ming&#xD;Wang, Heng&#xD;Xu, Xiao-Yan&#xD;Yao, Yin&#xD;Liu, Zheng&#xD;eng&#xD;National Natural Science Foundation of China/&#xD;Fundamental Research Funds for the Central Universities/&#xD;National Key Research and Development Program of China/&#xD;Knowledge Innovation Program of Wuhan-Shuguang Project/&#xD;Key Research and Development Program of Hubei Province/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1230-1241. doi: 10.1111/all.16068. Epub 2024 Feb 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38403941</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16068</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3127</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3127</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lunding, L. P.</style></author><author><style face="normal" font="default" size="100%">Weckmann, M.</style></author><author><style face="normal" font="default" size="100%">Zissler, U. M.</style></author><author><style face="normal" font="default" size="100%">Jakwerth, C.</style></author><author><style face="normal" font="default" size="100%">Bodenstein-Sgro, R.</style></author><author><style face="normal" font="default" size="100%">Webering, S.</style></author><author><style face="normal" font="default" size="100%">Vock, C.</style></author><author><style face="normal" font="default" size="100%">Ehlers, J. C.</style></author><author><style face="normal" font="default" size="100%">Fernandez Ceballos, R. A. M.</style></author><author><style face="normal" font="default" size="100%">Nemani, S. S. P.</style></author><author><style face="normal" font="default" size="100%">Reddy, K. D.</style></author><author><style face="normal" font="default" size="100%">Oliver, B. G. G.</style></author><author><style face="normal" font="default" size="100%">Vermeulen, C. J.</style></author><author><style face="normal" font="default" size="100%">van de Berge, M.</style></author><author><style face="normal" font="default" size="100%">Ober, C.</style></author><author><style face="normal" font="default" size="100%">Kunstner, A.</style></author><author><style face="normal" font="default" size="100%">Busch, H.</style></author><author><style face="normal" font="default" size="100%">Konig, I.</style></author><author><style face="normal" font="default" size="100%">Garbers, C.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Nold, M. F.</style></author><author><style face="normal" font="default" size="100%">Yildirim, A. O.</style></author><author><style face="normal" font="default" size="100%">Nold-Petry, C. A.</style></author><author><style face="normal" font="default" size="100%">Orinska, Z.</style></author><author><style face="normal" font="default" size="100%">Bahmer, T.</style></author><author><style face="normal" font="default" size="100%">Heyckendorf, J.</style></author><author><style face="normal" font="default" size="100%">Hansen, G.</style></author><author><style face="normal" font="default" size="100%">von Mutius, E.</style></author><author><style face="normal" font="default" size="100%">Rabe, K. F.</style></author><author><style face="normal" font="default" size="100%">Dittrich, A. M.</style></author><author><style face="normal" font="default" size="100%">Schaub, B.</style></author><author><style face="normal" font="default" size="100%">Brinkmann, F.</style></author><author><style face="normal" font="default" size="100%">Kopp, M. V.</style></author><author><style face="normal" font="default" size="100%">Wegmann, M.</style></author><author><style face="normal" font="default" size="100%">Alliance Study Group as part of the German Centre for Lung Research</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Lung Immunology, Priority Area Chronic Lung Diseases, Research Centre Borstel - Leibniz Lung Centre, Borstel, Germany.&#xD;Airway Research Centre North, Member of the German Centre for Lung Research (DZL), Germany.&#xD;Department of Paediatric Pneumology &amp; Allergology, University Clinics Schleswig-Holstein (UKSH), Lubeck, Germany.&#xD;Division of Epigenetics of Chronic Lung Diseases, Priority Area Chronic Lung Diseases, Research Centre Borstel - Leibniz Lung Centre, Borstel, Germany.&#xD;Centre of Allergy and Environment (ZAUM), Technische Universitat and Helmholtz Centre Munich, Munich, Germany.&#xD;Technology Transfer Center for Building Biology and Indoor Health, Rosenheim Technical University of Applied Sciences, Freilassing, Germany.&#xD;Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, German Center for Lung Research (DZL), Universities of Giessen and Marburg Lung Center (UGMLC), Marburg, Germany.&#xD;Comprehensive Pneumology Centre Munich (CPC-M), Member of the German Centre for Lung Research (DZL), Germany.&#xD;Division of Experimental Pneumology, Priority Area Chronic Lung Diseases, Research Centre Borstel- Leibniz Lung Centre, Borstel, Germany.&#xD;School of Medical and Molecular Biosciences, University of Technology Sydney, Australia.&#xD;Woolcock Institute of Medical Research, The University of Sydney, Australia.&#xD;University Medical Centre Groningen, Department of Pulmonary Diseases, GRIAC, the Netherlands.&#xD;Department of Human Genetics, University of Chicago, Chicago, Illinois, USA.&#xD;Luebeck Institute of Experimental Dermatology and Institute for Cardiogenetics, University of Luebeck, Luebeck, Germany.&#xD;Luebeck Institute of Experimental Dermatology, Institute for Cardiogenetics and Centre for Research of Inflammatory Skin Disease (CRIS), University of Luebeck, Luebeck, Germany.&#xD;Institute for Medical Biometry and Statistics, University of Luebeck, Luebeck, Germany.&#xD;Instititute for Clinical Biochemistry, Hannover Medical School, Hannover, Germany.&#xD;Department of Paediatrics, Monash University, Melbourne, Victoria, Australia.&#xD;Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Victoria, Australia.&#xD;Monash Newborn, Monash Children&apos;s Hospital, Melbourne, Victoria, Australia.&#xD;Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Munich, Germany.&#xD;Institute of Experimental Pneumology, LMU University Hospital, German Ludwig-Maximilian&apos;s University, Munich, Germany.&#xD;Division of Immunology and Cell Biology, Priority Area Chronic Lung Diseases, Research Centre Borstel - Leibniz Lung Centre, Borstel, Germany.&#xD;University Hospital Schleswig-Holstein Campus Kiel, Department for Internal Medicine I, Kiel, Germany.&#xD;Translational Paediatric Pneumology, Department of Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.&#xD;Biomedical Research in End Stage and Obstructive Lung Disease Hannover (BREATH), Member of the German Centre of Lung Research (DZL), Germany.&#xD;Institute for Asthma and Allergy Prevention, Helmholtz Centre Munich, German Research Centre for Environmental Health, Neuherberg, Germany.&#xD;Dr. von Hauner University Children&apos;s Hospital of Ludwig Maximilian&apos;s University, Munich, Germany.&#xD;Department of Pneumology, LungenClinic Grosshansdorf, Grosshansdorf, Germany.&#xD;Department of Paediatric Respiratory Medicine, Inselspital, University Children&apos;s Hospital of Bern, University of Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immune Training of the Interleukin 6 Gene in Airway Epithelial Cells is Central to Asthma Exacerbations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">157-169</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/10/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/immunology/etiology/metabolism/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-6/genetics/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Epithelial Cells/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Mucosa/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">Il-6</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbations</style></keyword><keyword><style face="normal" font="default" size="100%">immune training</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory viruses</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41099307</style></accession-num><abstract><style face="normal" font="default" size="100%">QUESTION: Epidemiological studies suggest that respiratory viral infections are major triggers of asthma exacerbations, and clinical studies have suggested the involvement of an increased interleukin-6 (IL-6) release. What is the pathophysiological role of IL-6 in asthma exacerbation, and which mechanisms lead to enhanced IL-6 release? MATERIALS AND METHODS: Exacerbations of ovalbumin-induced experimental allergic asthma were elicited in wild-type and IL-6-deficient mice by intranasal (i.n.) application of poly(I:C). Airway inflammation, cytokine expression and release, mucus production and airway hyperresponsiveness were measured. IL-6 was neutralised by i.n. anti-IL-6 antibody application. The human bronchial epithelial cell line, BEAS-2B, was stimulated with poly(I:C) and infected with human rhinovirus-16 in vitro, followed by quantification of IL6 gene expression and DNA methylation. Genome-wide DNA methylation was assessed in bronchial epithelial cells from adults with asthma (cohort I, n = 54) and in nasal epithelial cells from children and adults in the All-Age-Asthma cohort (ALLIANCE, n = 53 and n = 108 respectively). RESULTS: Poly(I:C)-induced experimental exacerbations in mice were preceded and paralleled by exaggerated IL-6 release in the airway epithelium, with IL-6 neutralisation completely preventing experimental exacerbations. Repetitive infection/stimulation with RV16 or poly(I:C) resulted in training of the IL-6 release in human respiratory epithelial cells. In patients, hypomethylation at the IL6 gene methylation was associated with high IL6 expression and future exacerbations. ANSWER: An exaggerated IL-6 release is required for exacerbation of experimental asthma, potentially the result of viral PAMP-induced immune training of airway epithelial cells. Additionally, patients with asthma carrying the epigenetic signature of a trained IL-6 response exacerbate more frequently. These findings open new avenues to identify and treat exacerbation-prone patients.</style></abstract><notes><style face="normal" font="default" size="100%">Lunding, Lars P&#xD;Weckmann, Markus&#xD;Zissler, Ulrich M&#xD;Jakwerth, Constanze&#xD;Bodenstein-Sgro, Rebecca&#xD;Webering, Sina&#xD;Vock, Christina&#xD;Ehlers, Johanna C&#xD;Fernandez Ceballos, Romina A M&#xD;Nemani, Sai Sneha Priya&#xD;Reddy, Karosham Diren&#xD;Oliver, Brian George G&#xD;Vermeulen, Cornelis J&#xD;van de Berge, Maarten&#xD;Ober, Carole&#xD;Kunstner, Axel&#xD;Busch, Hauke&#xD;Konig, Inke&#xD;Garbers, Christoph&#xD;Schmidt-Weber, Carsten B&#xD;Nold, Marcel F&#xD;Yildirim, Ali Onder&#xD;Nold-Petry, Claudia A&#xD;Orinska, Zane&#xD;Bahmer, Thomas&#xD;Heyckendorf, Jan&#xD;Hansen, Gesine&#xD;von Mutius, Erika&#xD;Rabe, Klaus F&#xD;Dittrich, Anna-Maria&#xD;Schaub, Bianca&#xD;Brinkmann, Folke&#xD;Kopp, Matthias V&#xD;Wegmann, Michael&#xD;(DZL)&#xD;eng&#xD;75N92020D00005/HL/NHLBI NIH HHS/&#xD;LGL;K1-2497-GLB-20-V4/Bavarian State Office for Health and Food Safety/&#xD;75N93022D00005/AI/NIAID NIH HHS/&#xD;75N93023D00005/AI/NIAID NIH HHS/&#xD;Deutsches Zentrum fur Lungenforschung/&#xD;75N95020D00005/DA/NIDA NIH HHS/&#xD;75N99020D00005/OF/ORFDO NIH HHS/&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):157-169. doi: 10.1111/all.70070. Epub 2025 Oct 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41099307</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773691</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70070</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1551</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1551</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Avino, G.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Allergy, Immunology and Rheumatology Division, Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.&#xD;Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immune-epithelial barrier interactions mediate intestinal adaptation to diverse diets</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1636-1637</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/11/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adaptation, Physiological</style></keyword><keyword><style face="normal" font="default" size="100%">*Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Intestines</style></keyword><keyword><style face="normal" font="default" size="100%">diet</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">gamma-delta T cells</style></keyword><keyword><style face="normal" font="default" size="100%">immune cells</style></keyword><keyword><style face="normal" font="default" size="100%">nutrient uptake</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34773279</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract The gastrointestinal tract is a complex ecosystem responsible for dietary nutrient absorption but also involved in defense against pathogens and toxins. Such functions are thought to result from the crosstalk between the intestinal epithelial barrier, the resident microbiota, and the gut-associated lymphoid tissue, that dynamically adapt to dietary changes and external threats to ensure efficient nutrient uptake and intestinal immune-barrier homeostasis1.</style></abstract><notes><style face="normal" font="default" size="100%">Avino, Gabriele&#xD;Riggioni, Carmen&#xD;Comberiati, Pasquale&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1636-1637. doi: 10.1111/all.15177. Epub 2021 Nov 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34773279</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15177</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>449</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">449</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maurer, D. J.</style></author><author><style face="normal" font="default" size="100%">Barletta, E.</style></author><author><style face="normal" font="default" size="100%">Heider, A.</style></author><author><style face="normal" font="default" size="100%">Stocker, N.</style></author><author><style face="normal" font="default" size="100%">Wallimann, A.</style></author><author><style face="normal" font="default" size="100%">Villiger, M.</style></author><author><style face="normal" font="default" size="100%">Villiger, B.</style></author><author><style face="normal" font="default" size="100%">Barenfaller, K.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Kistler, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Research Institute for Sports Medicine (SRISM), Davos, Switzerland.&#xD;Division of Sports and Exercise Medicine, Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.&#xD;Department of Sports Medicine, Hospital Davos, Davos, Switzerland.&#xD;Medical Center Bad Ragaz, Bad Ragaz, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immune-inflammatory proteome of elite ice hockey players before and after SARS-CoV-2 infection</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3144-3147</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/06/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Athletes</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">*Hockey</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Proteome</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">proteomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35690999</style></accession-num><notes><style face="normal" font="default" size="100%">Maurer, Debbie J&#xD;Barletta, Elena&#xD;Heider, Anja&#xD;Stocker, Nino&#xD;Wallimann, Alexandra&#xD;Villiger, Michael&#xD;Villiger, Beat&#xD;Barenfaller, Katja&#xD;Akdis, Cezmi A&#xD;Kistler, Walter&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3144-3147. doi: 10.1111/all.15405. Epub 2022 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35690999</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9347679</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15405</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1969</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1969</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vlieg-Boerstra, B.</style></author><author><style face="normal" font="default" size="100%">Groetch, M.</style></author><author><style face="normal" font="default" size="100%">Vassilopoulou, E.</style></author><author><style face="normal" font="default" size="100%">Meyer, R.</style></author><author><style face="normal" font="default" size="100%">Laitinen, K.</style></author><author><style face="normal" font="default" size="100%">Swain, A.</style></author><author><style face="normal" font="default" size="100%">Durban, R.</style></author><author><style face="normal" font="default" size="100%">Benjamin, O.</style></author><author><style face="normal" font="default" size="100%">Bottse, R.</style></author><author><style face="normal" font="default" size="100%">Grimshaw, K.</style></author><author><style face="normal" font="default" size="100%">Netting, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">de Jong, N.</style></author><author><style face="normal" font="default" size="100%">Skypala, I. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, OLVG Hospital, Amsterdam, The Netherlands.&#xD;Rijnstate Allergy Centre, Rijnstate Hospital, Arnhem, The Netherlands.&#xD;Vlieg Dieticians, Private Practice for Dietary Management of Food Allergy, Arnhem, Amsterdam, The Netherlands.&#xD;Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece.&#xD;Department Paediatrics, Imperial College, London, UK.&#xD;Department Dietetics, Winchester University, Winchester, UK.&#xD;Institute of Biomedicine and Functional Foods Forum, University of Turku, Turku, Finland.&#xD;Allergy Unit, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.&#xD;Carolina Asthma and Allergy Center, Charlotte, North Carolina, USA.&#xD;Department of Paediatrics, Hospital Group Noord West, Location Alkmaar, Alkmaar, The Netherlands.&#xD;Salford Royal NHS Foundation Trust, Salford, UK.&#xD;Women and Kids Theme, South Australian Health and Medical Research Institute (SAHMRI), North Adelaide, South Australia, Australia.&#xD;Discipline of Paediatrics, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia.&#xD;Department of Nutrition, Women&apos;s and Children&apos;s Hospital, North Adelaide, South Australia, Australia.&#xD;APC Microbiome Ireland, National University of Ireland, Cork, Ireland.&#xD;Department of Medicine, National University of Ireland, Cork, Ireland.&#xD;School of Microbiology, National University of Ireland, Cork, Ireland.&#xD;Internal Medicine, Allergology and Clinical Immunology, Paediatric Allergology, University Medical Centre Rotterdam, Rotterdam, The Netherlands.&#xD;Sophia Children Hospital Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.&#xD;Royal Brompton and Harefield Hospitals, Part of Guys and St Thomas&apos; NHS Foundation Trust, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The immune-supportive diet in allergy management: A narrative review and proposal</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1441-1458</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/02/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Diet</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Meat</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Eggs</style></keyword><keyword><style face="normal" font="default" size="100%">allergic disease</style></keyword><keyword><style face="normal" font="default" size="100%">diet</style></keyword><keyword><style face="normal" font="default" size="100%">immune health</style></keyword><keyword><style face="normal" font="default" size="100%">immune-supportive diet</style></keyword><keyword><style face="normal" font="default" size="100%">immunomodulatory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36802268</style></accession-num><abstract><style face="normal" font="default" size="100%">The role of nutrition is increasingly recognized in the management of chronic immune diseases. However, the role of an immune-supportive diet as adjuvant therapy in the management of allergic disease has not been similarly explored. This review assesses the existing evidence for a relationship between nutrition, immune function, and allergic disease from a clinical perspective. In addition, the authors propose an immune-supportive diet to enhance dietary interventions and complementing other therapeutic options for allergic disease from early life to adulthood. A narrative review of the literature was conducted, to determine the evidence of the relationship between nutrition and immune function, overall health, epithelial barrier function, and gut microbiome, particularly in relation to allergy. Studies on food supplements were excluded. The evidence was assessed and utilized to develop a sustainable immune-supportive diet to complement other therapies in allergic disease. The proposed diet consists of a highly diverse range of fresh, whole, and minimally processed plant-based and fermented foods supplemented with moderate amounts of nuts, omega-3-rich foods and animal-based products in proportional amounts of the EAT-Lancet diet, such as (fatty) fish, (fermented) milk products which may be full-fat and eggs, lean meat or poultry, which may be free-range or organic.</style></abstract><notes><style face="normal" font="default" size="100%">Vlieg-Boerstra, Berber&#xD;Groetch, Marion&#xD;Vassilopoulou, Emilia&#xD;Meyer, Rosan&#xD;Laitinen, Kirsi&#xD;Swain, Anne&#xD;Durban, Raquel&#xD;Benjamin, Olga&#xD;Bottse, Rachelle&#xD;Grimshaw, Kate&#xD;Netting, Merryn&#xD;O&apos;Mahony, Liam&#xD;de Jong, Nicolette&#xD;Skypala, Isabel J&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1441-1458. doi: 10.1111/all.15687. Epub 2023 Apr 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36802268</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15687</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2186</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2186</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kortekaas Krohn, I.</style></author><author><style face="normal" font="default" size="100%">Badloe, F. M. S.</style></author><author><style face="normal" font="default" size="100%">Herrmann, N.</style></author><author><style face="normal" font="default" size="100%">Maintz, L.</style></author><author><style face="normal" font="default" size="100%">De Vriese, S.</style></author><author><style face="normal" font="default" size="100%">Ring, J.</style></author><author><style face="normal" font="default" size="100%">Ck-Care Study Group</style></author><author><style face="normal" font="default" size="100%">Bieber, T.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Skin Immunology &amp; Immune Tolerance (SKIN) Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium.&#xD;Department of Dermatology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.&#xD;Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department Dermatology and Allergy Biederstein, Technical University Munich, Munich, Germany.&#xD;Davos Biosciences, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunoglobulin E autoantibodies in atopic dermatitis associate with Type-2 comorbidities and the atopic march</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3178-3192</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/07/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Autoantibodies</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Keratinocytes</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-mediated autoreactivity</style></keyword><keyword><style face="normal" font="default" size="100%">Type-2 diseases</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">autoreactive IgE</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37489049</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Autoreactive immunoglobulin E (IgE) antibodies to self-peptides within the epidermis have been identified in patients with atopic dermatitis (AD). Prevalence, concomitant diseases, patient characteristics, and risk factors of IgE autoantibody development remain elusive. We aimed to determine IgE autoantibodies in serum samples (n = 672) from well-characterized patients with AD and controls (1.2-88.9 years). METHODS: Atopic dermatitis patients were sub-grouped in AD with comorbid Type-2 diseases (&quot;AD + Type 2&quot;; asthma, allergic rhinitis, food allergy, n = 431) or &quot;solely AD&quot; (n = 115). Also, subjects without AD but with Type-2 diseases (&quot;atopic controls,&quot; n = 52) and non-atopic &quot;healthy controls&quot; (n = 74) were included. Total proteins from primary human keratinocytes were used for the immunoassay to detect IgE autoantibodies. Values were compared to already known positive and negative serum samples. RESULTS: Immunoglobulin E autoantibodies were found in 15.0% (82/546) of all analyzed AD-patients. &quot;AD + Type 2&quot; showed a higher prevalence (16.4%) than &quot;solely AD&quot; (9.6%). &quot;Atopic controls&quot; (9.6%) were comparable with &quot;solely AD&quot; patients, while 2.7% of healthy controls showed IgE autoantibodies. Of those with high levels of IgE autoantibodies, 15 out of 16 were patients with &quot;AD + Type 2&quot;. AD patients with IgE autoantibodies were younger than those without. Patients with IgE autoreactivity also displayed higher total serum IgE levels. Factors that affected IgE autoantibody development were as follows: birth between January and June, cesarean-section and diversity of domestic pets. CONCLUSIONS: Immunoglobulin E autoantibodies in AD seem to associate with the presence of atopic comorbidities and environmental factors. The potential value of IgE autoantibodies as a predictive biomarker for the course of AD, including the atopic march, needs further exploration.</style></abstract><notes><style face="normal" font="default" size="100%">Kortekaas Krohn, Inge&#xD;Badloe, Fariza Mishaal Saiema&#xD;Herrmann, Nadine&#xD;Maintz, Laura&#xD;De Vriese, Shauni&#xD;Ring, Johannes&#xD;Bieber, Thomas&#xD;Gutermuth, Jan&#xD;eng&#xD;12W2219N/Fonds Wetenschappelijk Onderzoek/&#xD;0000000122/Sanofi Genzyme/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3178-3192. doi: 10.1111/all.15822. Epub 2023 Jul 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37489049</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15822</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>633</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">633</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Colas, L.</style></author><author><style face="normal" font="default" size="100%">Magnan, A.</style></author><author><style face="normal" font="default" size="100%">Brouard, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Plateforme Transversale d&apos;Allergologie et d&apos;immunologie Clinique, PFTA, Clinique dermatologique, CHU de Nantes, Nantes, France.&#xD;Nantes Universite, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, Nantes, France.&#xD;Hopital Foch, Suresnes; Universite de Versailles Saint-Quentin Paris-Saclay; INRAe, Paris, France.&#xD;Labex IGO, Nantes, France.&#xD;Centre d&apos;Investigation Clinique en Biotherapie, Centre de ressources biologiques (CRB), Nantes, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunoglobulin E response in health and disease beyond allergic disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1700-1718</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/01/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, IgE</style></keyword><keyword><style face="normal" font="default" size="100%">Cd23</style></keyword><keyword><style face="normal" font="default" size="100%">FcepsilonRI</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">facilitated antigen presentation</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35073421</style></accession-num><abstract><style face="normal" font="default" size="100%">Immunoglobulin E is the latest discovered of immunoglobulin family and has been long associated with anaphylaxis and worm expulsion. Immunoglobulin E, along with mast cells, basophils, and eosinophils, is also a hallmark of type 2 immunity which is dysregulated in numerous diseases such as asthma, rhinitis, atopic dermatitis, and eosinophilic esophagitis in addition to anaphylaxis as aforementioned. However, recent advances have shed light on IgE regulation and memory explaining the low level of free IgE, the scarcity of IgE plasma cells that are mainly short live and the absence of IgE memory B cells in homeostatic conditions. Furthermore, IgE was implicated in inflammatory conditions beyond allergic disorders where IgE-mediated facilitated antigen presentation can enhance cellular and humoral response against autoantigens in systemic lupus or chronic urticaria leading to more severe disease and even against neoantigen facilitating tumor cell lysis. At last, IgE was unexpectedly associated with allograft rejection or atheromatous cardiovascular diseases where precise mechanisms remain to be deciphered. The purpose of this review is to summarize these recent advances in IgE regulation, biology, and physiopathology beyond allergic diseases opening whole new fields of IgE biology to explore.</style></abstract><notes><style face="normal" font="default" size="100%">Colas, Luc&#xD;Magnan, Antoine&#xD;Brouard, Sophie&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1700-1718. doi: 10.1111/all.15230. Epub 2022 Feb 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35073421</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15230</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2456</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2456</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caruso, C.</style></author><author><style face="normal" font="default" size="100%">Ciasca, G.</style></author><author><style face="normal" font="default" size="100%">Baglivo, I.</style></author><author><style face="normal" font="default" size="100%">Di Santo, R.</style></author><author><style face="normal" font="default" size="100%">Gasbarrini, A.</style></author><author><style face="normal" font="default" size="100%">Firinu, D.</style></author><author><style face="normal" font="default" size="100%">Bagnasco, D.</style></author><author><style face="normal" font="default" size="100%">Passalacqua, G.</style></author><author><style face="normal" font="default" size="100%">Schiappoli, M.</style></author><author><style face="normal" font="default" size="100%">Caminati, M.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Crimi, C.</style></author><author><style face="normal" font="default" size="100%">Intravaia, R.</style></author><author><style face="normal" font="default" size="100%">Basile, V.</style></author><author><style face="normal" font="default" size="100%">Marino, M.</style></author><author><style face="normal" font="default" size="100%">Colantuono, S.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">UOSD DH Internal Medicine and Gastroenterology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario &quot;A. Gemelli&quot; IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;Dipartimento di Neuroscienze, Sezione di Fisica, Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario &quot;A. Gemelli&quot; IRCCS, Rome, Italy.&#xD;CEMAD Digestive Diseases Center, Fondazione Policlinico Universitario &quot;A. Gemelli&quot; IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, Genoa, Italy.&#xD;Allergy and Asthma Unit, Verona University Hospital, Verona, Italy.&#xD;Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy.&#xD;Personalized Medicine, Asthma and Allergy-IRCCS Humanitas Research Hospital, Rozzano, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Respiratory Medicine Unit, Policlinico &quot;G. Rodolico-San Marco&quot; University Hospital, Catania, Italy.&#xD;Unit of Cardiology, University Hospital Paolo Giaccone, University of Palermo, Palermo.&#xD;Clinical Pathology Unit and Cancer Biobank, Department of research and Advanced Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.&#xD;Sezione di Patologia Generale, Dipartimento di Medicina e Chirurgia Traslazionale, Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario &quot;A. Gemelli&quot; IRCCS, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunoglobulin free light chains in severe asthma patient: Could they be a new biomarker?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2414-2422</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin Light Chains/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin lambda-Chains/blood</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">free light chains</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38425088</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Increasing evidence is available about the presence of increased serum concentration of immunoglobulin (Ig) free light chains (FLCs) in both atopic and non-atopic inflammatory diseases, including severe asthma, providing a possible new biomarker of disease. METHODS: We analyzed clinical and laboratory data, including FLCs, obtained from a cohort of 79 asthmatic subjects, clinically classified into different GINA steps. A control group of 40 age-matched healthy donors (HD) was considered. Particularly, HD have been selected according to the absence of monoclonal components (in order to exclude paraproteinemias), were tested for total IgE (that were in the normal ranges) and were negative for aeroallergens specific IgE. Moreover, no abnormality of common inflammatory markers (i.e., erythrocyte sedimentation rate and C-reactive protein) was detectable. RESULTS: FLC-k levels were significantly increased in the asthmatic population, compared to the control group. Despite the absence of statistically significant differences in FLC-lambda levels, the FLC-k/FLC-lambda ratio displayed remarkable differences between the two groups. A positive correlation between FLC-kappa and FLC-lambda levels was found. FLC- lambda level displayed a significant negative correlation with the FEV1 value. Moreover, the FLC-kappa /FLC- lambda ratio was negatively correlated with the SNOT-22 score and a positive correlation was observed between FLCs and Staphylococcus Aureus IgE enterotoxins sensitization. CONCLUSIONS: Our findings confirmed the role of FLCs in asthma as a potential biomarker in an inflammatory disease characterized by different endotypes and phenotypes. In particular, FLC-kappa and FLC-k/FLC-lambda ratio could be a qualitative indicator for asthma, while FLC-lambda levels could be a quantitative indicator for clinical severity parameters.</style></abstract><notes><style face="normal" font="default" size="100%">Caruso, C&#xD;Ciasca, G&#xD;Baglivo, I&#xD;Di Santo, R&#xD;Gasbarrini, A&#xD;Firinu, D&#xD;Bagnasco, D&#xD;Passalacqua, G&#xD;Schiappoli, M&#xD;Caminati, M&#xD;Canonica, G W&#xD;Heffler, E&#xD;Crimi, C&#xD;Intravaia, R&#xD;Basile, V&#xD;Marino, M&#xD;Colantuono, S&#xD;Del Giacco, S&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2414-2422. doi: 10.1111/all.16082. Epub 2024 Feb 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38425088</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16082</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2181</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Medernach, J. G.</style></author><author><style face="normal" font="default" size="100%">Li, R. C.</style></author><author><style face="normal" font="default" size="100%">Zhao, X. Y.</style></author><author><style face="normal" font="default" size="100%">Yin, B.</style></author><author><style face="normal" font="default" size="100%">Noonan, E. A.</style></author><author><style face="normal" font="default" size="100%">Etter, E. F.</style></author><author><style face="normal" font="default" size="100%">Raghavan, S. S.</style></author><author><style face="normal" font="default" size="100%">Borish, L. C.</style></author><author><style face="normal" font="default" size="100%">Wilson, J. M.</style></author><author><style face="normal" font="default" size="100%">Barnes, B. H.</style></author><author><style face="normal" font="default" size="100%">Platts-Mills, T. A. E.</style></author><author><style face="normal" font="default" size="100%">Ewald, S. E.</style></author><author><style face="normal" font="default" size="100%">Sauer, B. G.</style></author><author><style face="normal" font="default" size="100%">McGowan, E. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Gastroenterology and Hepatology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.&#xD;Division of Allergy and Immunology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.&#xD;Department of Microbiology, Immunology and Cancer Biology and The Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, Virginia, USA.&#xD;Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.&#xD;Division of Gastroenterology and Hepatology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.&#xD;Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunoglobulin G4 in eosinophilic esophagitis: Immune complex formation and correlation with disease activity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3193-3203</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/07/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Antigen-Antibody Complex</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Milk Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin G4</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37497566</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Recent studies have shown deposition of immunoglobulin G4 (IgG4) and food proteins in the esophageal mucosa of eosinophilic esophagitis (EoE) patients. Our aims were to assess whether co-localization of IgG4 and major cow&apos;s milk proteins (CMPs) was associated with EoE disease activity and to investigate the proteins enriched in proximity to IgG4 deposits. METHODS: This study included adult subjects with EoE (n = 13) and non-EoE controls (n = 5). Esophageal biopsies were immunofluorescence stained for IgG4 and CMPs. Co-localization in paired samples from active disease and remission was assessed and compared to controls. The proteome surrounding IgG4 deposits was evaluated by the novel technique, AutoSTOMP. IgG4-food protein interactions were confirmed with co-immunoprecipitation and mass spectrometry. RESULTS: IgG4-CMP co-localization was higher in the active EoE group compared to paired remission samples (Bos d 4, p = .02; Bos d 5, p = .002; Bos d 8, p = .002). Co-localization was also significantly higher in the active EoE group compared to non-EoE controls (Bos d 4, p = .0013; Bos d 5, p = .0007; Bos d 8, p = .0013). AutoSTOMP identified eosinophil-derived proteins (PRG 2 and 3, EPX, RNASE3) and calpain-14 in IgG4-enriched areas. Co-immunoprecipitation and mass spectrometry confirmed IgG4 binding to multiple food allergens. CONCLUSION: These findings further contribute to the understanding of the interaction of IgG4 with food antigens as it relates to EoE disease activity. These data strongly suggest the immune complex formation of IgG4 and major cow&apos;s milk proteins. These immune complexes may have a potential role in the pathophysiology of EoE by contributing to eosinophil activation and disease progression.</style></abstract><notes><style face="normal" font="default" size="100%">Medernach, Jonathan G&#xD;Li, Rung-Chi&#xD;Zhao, Xiao-Yu&#xD;Yin, Bocheng&#xD;Noonan, Emily A&#xD;Etter, Elaine F&#xD;Raghavan, Shyam S&#xD;Borish, Larry C&#xD;Wilson, Jeffrey M&#xD;Barnes, Barrett H&#xD;Platts-Mills, Thomas A E&#xD;Ewald, Sarah E&#xD;Sauer, Bryan G&#xD;McGowan, Emily C&#xD;eng&#xD;R21 AI151497/AI/NIAID NIH HHS/&#xD;UO1AI123337/NH/NIH HHS/&#xD;U01 AI123337/AI/NIAID NIH HHS/&#xD;R21 EB028971/EB/NIBIB NIH HHS/&#xD;R56AI158519/NH/NIH HHS/&#xD;UL1 TR003015/TR/NCATS NIH HHS/&#xD;UL1TR003015/NH/NIH HHS/&#xD;R21AI151497/NH/NIH HHS/&#xD;R35GM138381/NH/NIH HHS/&#xD;R35 GM138381/GM/NIGMS NIH HHS/&#xD;R56 AI158519/AI/NIAID NIH HHS/&#xD;R21 AI156153/AI/NIAID NIH HHS/&#xD;K23 AI123596/AI/NIAID NIH HHS/&#xD;R21EB028971/EB/NIBIB NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3193-3203. doi: 10.1111/all.15826. Epub 2023 Jul 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37497566</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11976675</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15826</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3287</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3287</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thormann, Kathrin</style></author><author><style face="normal" font="default" size="100%">Arms, Charlotte</style></author><author><style face="normal" font="default" size="100%">Cazzaniga, Simone</style></author><author><style face="normal" font="default" size="100%">Martignoni, Zora</style></author><author><style face="normal" font="default" size="100%">Lehmann, Mathias</style></author><author><style face="normal" font="default" size="100%">Simon, Hans-Uwe</style></author><author><style face="normal" font="default" size="100%">Schlapbach, Christoph</style></author><author><style face="normal" font="default" size="100%">Radonjic-Hoesli, Susanne</style></author><author><style face="normal" font="default" size="100%">Simon, Dagmar</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">An Immunologic Perspective on Adverse Reactions Observed Upon Systemic Therapies of Atopic Dermatitis: A Retrospective Study of 145 Cases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70321</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70321</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1225</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1225</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, Y. W.</style></author><author><style face="normal" font="default" size="100%">Tonti, E.</style></author><author><style face="normal" font="default" size="100%">Hickey, P.</style></author><author><style face="normal" font="default" size="100%">Ellis, A. K.</style></author><author><style face="normal" font="default" size="100%">Neighbour, H.</style></author><author><style face="normal" font="default" size="100%">Larche, M.</style></author><author><style face="normal" font="default" size="100%">Tebbutt, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Experimental Medicine, University of British Columbia, Vancouver, BC, Canada.&#xD;Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada.&#xD;Centre for Heart Lung Innovation, St. Paul&apos;s Hospital, Vancouver, BC, Canada.&#xD;Department of Medicine, McMaster University, Hamilton, ON, Canada.&#xD;Adiga Life Sciences, Hamilton, ON, Canada.&#xD;Departments of Medicine and Biomedical &amp; Molecular Science, Queen&apos;s University, Kingston, ON, Canada.&#xD;Allergy Research Unit, Kingston General Hospital, Kingston, ON, Canada.&#xD;Firestone Institute for Respiratory Health, St. Joseph&apos;s Healthcare, Hamilton, ON, Canada.&#xD;Department of Medicine (Respiratory Division), University of British Columbia, Vancouver, BC, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunological changes in peripheral blood following nasal allergen challenge in subjects with allergic rhinitis pre- and post-peptide immunotherapy: An open-label clinical study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1907-1911</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33320968</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Young Woong&#xD;Tonti, Elena&#xD;Hickey, Pascal&#xD;Ellis, Anne K&#xD;Neighbour, Helen&#xD;Larche, Mark&#xD;Tebbutt, Scott J&#xD;eng&#xD;Letter&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1907-1911. doi: 10.1111/all.14710. Epub 2020 Dec 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33320968</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14710</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>891</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">891</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heldner, A.</style></author><author><style face="normal" font="default" size="100%">Alessandrini, F.</style></author><author><style face="normal" font="default" size="100%">Russkamp, D.</style></author><author><style face="normal" font="default" size="100%">Heine, S.</style></author><author><style face="normal" font="default" size="100%">Schnautz, B.</style></author><author><style face="normal" font="default" size="100%">Chaker, A.</style></author><author><style face="normal" font="default" size="100%">Mwange, J.</style></author><author><style face="normal" font="default" size="100%">Carreno Velazquez, T. L.</style></author><author><style face="normal" font="default" size="100%">Heath, M. D.</style></author><author><style face="normal" font="default" size="100%">Skinner, M. A.</style></author><author><style face="normal" font="default" size="100%">Kramer, M. F.</style></author><author><style face="normal" font="default" size="100%">Zissler, U. M.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Blank, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Allergy and Environment (ZAUM), Technical University of Munich, Faculty of Medicine and Helmholtz Center Munich, German Research Center for Environmental Health, Member of the German Center of Lung Research (DZL), Member of the Immunology and Inflammation Initiative of the Helmholtz Association, Munich, Germany.&#xD;Department of Otolaryngology, Klinikum rechts der Isar, Faculty of Medicine, Technical University of Munich, Munich, Germany.&#xD;Allergy Therapeutic PLC., Worthing, UK.&#xD;Bencard Allergie GmbH, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunological effects of adjuvanted low-dose allergoid allergen-specific immunotherapy in experimental murine house dust mite allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">907-919</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/07/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adjuvants, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Allergoids</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">adjuvant</style></keyword><keyword><style face="normal" font="default" size="100%">allergen extract</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergoid</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34287971</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Native allergen extracts or chemically modified allergoids are routinely used to induce allergen tolerance in allergen-specific immunotherapy (AIT), although mechanistic side-by-side studies are rare. It is paramount to balance optimal dose and allergenicity to achieve efficacy warranting safety. AIT safety and efficacy could be addressed by allergen dose reduction and/or use of allergoids and immunostimulatory adjuvants, respectively. In this study, immunological effects of experimental house dust mite (HDM) AIT were investigated applying high-dose HDM extract and low-dose HDM allergoids with and without the adjuvants microcrystalline tyrosine (MCT) and monophosphoryl lipid A (MPL) in a murine model of HDM allergy. METHODS: Cellular, humoral, and clinical effects of the different AIT strategies were assessed applying a new experimental AIT model of murine allergic asthma based on physiological, adjuvant-free intranasal sensitization followed by subcutaneous AIT. RESULTS: While low-dose allergoid and high-dose extract AIT demonstrated comparable potency to suppress allergic airway inflammation and Th2-type cytokine secretion of lung-resident lymphocytes and draining lymph node cells, low-dose allergoid AIT was less effective in inducing a potentially protective IgG1 response. Combining low-dose allergoid AIT with MCT or MCT and dose-adjusted MPL promoted Th1-inducing mechanisms and robust B-cell activation counterbalancing the allergic Th2 immune response. CONCLUSION: Low allergen doses induce cellular and humoral mechanisms counteracting Th2-driven inflammation by using allergoids and dose-adjusted adjuvants. In light of safety and efficacy improvement, future therapeutic approaches may use low-dose allergoid strategies to drive cellular tolerance and adjuvants to modulate humoral responses.</style></abstract><notes><style face="normal" font="default" size="100%">Heldner, Alexander&#xD;Alessandrini, Francesca&#xD;Russkamp, Dennis&#xD;Heine, Sonja&#xD;Schnautz, Benjamin&#xD;Chaker, Adam&#xD;Mwange, Juliet&#xD;Carreno Velazquez, Thalia L&#xD;Heath, Matthew D&#xD;Skinner, Murray A&#xD;Kramer, Matthias F&#xD;Zissler, Ulrich M&#xD;Schmidt-Weber, Carsten B&#xD;Blank, Simon&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):907-919. doi: 10.1111/all.15012. Epub 2021 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34287971</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15012</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2848</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2848</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schlunder, S.</style></author><author><style face="normal" font="default" size="100%">Echternach, J.</style></author><author><style face="normal" font="default" size="100%">Bartel, D.</style></author><author><style face="normal" font="default" size="100%">Mahler, V.</style></author><author><style face="normal" font="default" size="100%">Muhlebach, M. D.</style></author><author><style face="normal" font="default" size="100%">Fuhrer, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Veterinary Medicine Division, Paul-Ehrlich-Institut, Langen, Germany.&#xD;Allergology Division, Paul-Ehrlich-Institut, Langen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunological In Vitro Assay for Quantification of Adjuvanted Allergoids</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2008-2017</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/03/31 21:16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergoids/immunology/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Adjuvants, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Aluminum Hydroxide/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Poaceae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adjuvanted immunotherapy products</style></keyword><keyword><style face="normal" font="default" size="100%">Allergoid content assay</style></keyword><keyword><style face="normal" font="default" size="100%">batch quality control</style></keyword><keyword><style face="normal" font="default" size="100%">grass pollen allergen immunotherapy (AIT)</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory framework</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40162575</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Many IgE-mediated allergic disorders can be treated with allergen immunotherapy (AIT). In order to improve safety and efficacy, some AIT products contain allergen extracts which are chemically cross-linked to generate allergoids and are adsorbed to aluminum hydroxide adjuvant. The modification and adsorption impair accessibility of the protein and quantification of the allergoid content. METHODS: An ELISA-like assay to quantify the allergoid content in adjuvanted grass pollen allergoid AIT products (from here on called: AIT drug products; AIT-DPs) was developed using a fluorescence detection system. The high density of the aluminum hydroxide particles enabled pelleting the antigen complexes by centrifugation. Rabbit anti-grass pollen allergoid sera or a mouse anti-Phl p 5 monoclonal antibody (mAb) was used as the primary antibody. Protein content of the samples was quantified by nitrogen analysis. RESULTS: High specificity of the primary antibodies was confirmed by isoelectric focusing, gel-electrophoresis, and immunoblotting. Performance of the allergoid content assay was demonstrated in grass pollen AIT-DPs with high specificity and low/absent cross-reactivity with tree pollen or mite AIT-DPs. It was used to confirm batch-to-batch consistency and allergoid content of distinct grass pollen AIT-DPs. Overall, in relation to their total protein content, the allergoid content ranged between 0.8 and 2.1 relative to an in-house reference for all grass pollen AIT-DPs, whereas use of mAb revealed product-specific differences in the Phl p 5 amount. Additionally, the assay detects product alteration by heat stress. CONCLUSION: The described assay is suitable to quantify the allergoid content and quality of allergoids in complex with aluminum hydroxide. It is suitable for animal-free final product testing in vitro, for example, for batch release to ensure the quality of AIT-DPs.</style></abstract><notes><style face="normal" font="default" size="100%">Schlunder, S&#xD;Echternach, J&#xD;Bartel, D&#xD;Mahler, V&#xD;Muhlebach, M D&#xD;Fuhrer, F&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2008-2017. doi: 10.1111/all.16543. Epub 2025 Mar 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40162575</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261872</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16543</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1011</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1011</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Alenius, H.</style></author><author><style face="normal" font="default" size="100%">Lehtimaki, J.</style></author><author><style face="normal" font="default" size="100%">Sinkkonen, A.</style></author><author><style face="normal" font="default" size="100%">Fyhrquist, N.</style></author><author><style face="normal" font="default" size="100%">Hyoty, H.</style></author><author><style face="normal" font="default" size="100%">Ruokolainen, L.</style></author><author><style face="normal" font="default" size="100%">Makela, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland.&#xD;Finnish Environment Institute, Helsinki, Finland.&#xD;Natural Resources Institute Finland, Horticulture Technologies, Turku, Finland.&#xD;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.&#xD;Fimlab Laboratories, Pirkanmaa Hospital District, Tampere, Finland.&#xD;Lasse Ruokolainen, Department of Biosciences, University of Helsinki, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunological resilience and biodiversity for prevention of allergic diseases and asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3613-3626</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/complications/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Biodiversity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Prebiotics</style></keyword><keyword><style face="normal" font="default" size="100%">allergy prevention</style></keyword><keyword><style face="normal" font="default" size="100%">allergy program</style></keyword><keyword><style face="normal" font="default" size="100%">immunological resilience</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33959980</style></accession-num><abstract><style face="normal" font="default" size="100%">Increase of allergic conditions has occurred at the same pace with the Great Acceleration, which stands for the rapid growth rate of human activities upon earth from 1950s. Changes of environment and lifestyle along with escalating urbanization are acknowledged as the main underlying causes. Secondary (tertiary) prevention for better disease control has advanced considerably with innovations for oral immunotherapy and effective treatment of inflammation with corticosteroids, calcineurin inhibitors, and biological medications. Patients are less disabled than before. However, primary prevention has remained a dilemma. Factors predicting allergy and asthma risk have proven complex: Risk factors increase the risk, while protective factors counteract them. Interaction of human body with environmental biodiversity with micro-organisms and biogenic compounds as well as the central role of epigenetic adaptation in immune homeostasis have given new insight. Allergic diseases are good indicators of the twisted relation to environment. In various non-communicable diseases, the protective mode of the immune system indicates low-grade inflammation without apparent cause. Giving microbes, pro- and prebiotics, has shown some promise in prevention and treatment. The real-world public health programme in Finland (2008-2018) emphasized nature relatedness and protective factors for immunological resilience, instead of avoidance. The nationwide action mitigated the allergy burden, but in the lack of controls, primary preventive effect remains to be proven. The first results of controlled biodiversity interventions are promising. In the fast urbanizing world, new approaches are called for allergy prevention, which also has a major cost saving potential.</style></abstract><notes><style face="normal" font="default" size="100%">Haahtela, Tari&#xD;Alenius, Harri&#xD;Lehtimaki, Jenni&#xD;Sinkkonen, Aki&#xD;Fyhrquist, Nanna&#xD;Hyoty, Heikki&#xD;Ruokolainen, Lasse&#xD;Makela, Mika J&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3613-3626. doi: 10.1111/all.14895. Epub 2021 May 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33959980</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14895</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1621</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1621</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Alenius, H.</style></author><author><style face="normal" font="default" size="100%">Lehtimaki, J.</style></author><author><style face="normal" font="default" size="100%">Sinkkonen, A.</style></author><author><style face="normal" font="default" size="100%">Fyhrquist, N.</style></author><author><style face="normal" font="default" size="100%">Hyoty, H.</style></author><author><style face="normal" font="default" size="100%">Ruokolainen, L.</style></author><author><style face="normal" font="default" size="100%">Makela, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland.&#xD;Finnish Environment Institute, Helsinki, Finland.&#xD;Natural Resources Institute Finland, Horticulture Technologies, Turku, Finland.&#xD;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.&#xD;Fimlab Laboratories, Pirkanmaa Hospital District, Tampere, Finland.&#xD;Lasse Ruokolainen, Department of Biosciences, University of Helsinki, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunological resilience and biodiversity for prevention of allergic diseases and asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3613-3626</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/complications/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Biodiversity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Prebiotics</style></keyword><keyword><style face="normal" font="default" size="100%">allergy prevention</style></keyword><keyword><style face="normal" font="default" size="100%">allergy program</style></keyword><keyword><style face="normal" font="default" size="100%">immunological resilience</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33959980</style></accession-num><abstract><style face="normal" font="default" size="100%">Increase of allergic conditions has occurred at the same pace with the Great Acceleration, which stands for the rapid growth rate of human activities upon earth from 1950s. Changes of environment and lifestyle along with escalating urbanization are acknowledged as the main underlying causes. Secondary (tertiary) prevention for better disease control has advanced considerably with innovations for oral immunotherapy and effective treatment of inflammation with corticosteroids, calcineurin inhibitors, and biological medications. Patients are less disabled than before. However, primary prevention has remained a dilemma. Factors predicting allergy and asthma risk have proven complex: Risk factors increase the risk, while protective factors counteract them. Interaction of human body with environmental biodiversity with micro-organisms and biogenic compounds as well as the central role of epigenetic adaptation in immune homeostasis have given new insight. Allergic diseases are good indicators of the twisted relation to environment. In various non-communicable diseases, the protective mode of the immune system indicates low-grade inflammation without apparent cause. Giving microbes, pro- and prebiotics, has shown some promise in prevention and treatment. The real-world public health programme in Finland (2008-2018) emphasized nature relatedness and protective factors for immunological resilience, instead of avoidance. The nationwide action mitigated the allergy burden, but in the lack of controls, primary preventive effect remains to be proven. The first results of controlled biodiversity interventions are promising. In the fast urbanizing world, new approaches are called for allergy prevention, which also has a major cost saving potential.</style></abstract><notes><style face="normal" font="default" size="100%">Haahtela, Tari&#xD;Alenius, Harri&#xD;Lehtimaki, Jenni&#xD;Sinkkonen, Aki&#xD;Fyhrquist, Nanna&#xD;Hyoty, Heikki&#xD;Ruokolainen, Lasse&#xD;Makela, Mika J&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3613-3626. doi: 10.1111/all.14895. Epub 2021 May 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33959980</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14895</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>376</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">376</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Forde, B.</style></author><author><style face="normal" font="default" size="100%">Yao, L.</style></author><author><style face="normal" font="default" size="100%">Shaha, R.</style></author><author><style face="normal" font="default" size="100%">Murphy, S.</style></author><author><style face="normal" font="default" size="100%">Lunjani, N.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">APC Microbiome Ireland, UCC, Cork, Ireland.&#xD;School of Microbiology, UCC, Cork, Ireland.&#xD;University of Cape Town, Cape Town, South Africa.&#xD;Department of Medicine, UCC, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunomodulation by foods and microbes: Unravelling the molecular tango</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3513-3526</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">AhR</style></keyword><keyword><style face="normal" font="default" size="100%">GPCRs</style></keyword><keyword><style face="normal" font="default" size="100%">metabolites</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">nuclear receptors</style></keyword><keyword><style face="normal" font="default" size="100%">GSK and Chiesi. LOM has participated in speaker&apos;s bureau for Nestle, Nutricia,</style></keyword><keyword><style face="normal" font="default" size="100%">Reckitt and Abbott. None of the other authors report any conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35892227</style></accession-num><abstract><style face="normal" font="default" size="100%">Metabolic health and immune function are intimately connected via diet and the microbiota. Nearly 90% of all immune cells in the body are associated with the gastrointestinal tract and these immune cells are continuously exposed to a wide range of microbes and microbial-derived compounds, with important systemic ramifications. Microbial dysbiosis has consistently been observed in patients with atopic dermatitis, food allergy and asthma and the molecular mechanisms linking changes in microbial populations with disease risk and disease endotypes are being intensively investigated. The discovery of novel bacterial metabolites that impact immune function is at the forefront of host-microbe research. Co-evolution of microbial communities within their hosts has resulted in intertwined metabolic pathways that affect physiological and pathological processes. However, recent dietary and lifestyle changes are thought to negatively influence interactions between microbes and their host. This review provides an overview of some of the critical metabolite-receptor interactions that have been recently described, which may underpin the immunomodulatory effects of the microbiota, and are of relevance for allergy, asthma and infectious diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Forde, Brian&#xD;Yao, Lu&#xD;Shaha, Rupin&#xD;Murphy, Sally&#xD;Lunjani, Nonhlanhla&#xD;O&apos;Mahony, Liam&#xD;eng&#xD;SFI_/Science Foundation Ireland/Ireland&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3513-3526. doi: 10.1111/all.15455. Epub 2022 Aug 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35892227</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087875</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15455</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1370</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1370</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heine, G.</style></author><author><style face="normal" font="default" size="100%">Francuzik, W.</style></author><author><style face="normal" font="default" size="100%">Doelle-Bierke, S.</style></author><author><style face="normal" font="default" size="100%">Drozdenko, G.</style></author><author><style face="normal" font="default" size="100%">Frischbutter, S.</style></author><author><style face="normal" font="default" size="100%">Schumacher, N.</style></author><author><style face="normal" font="default" size="100%">Radbruch, A.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergy, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.&#xD;A Leibniz Institute, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunomodulation of high-dose vitamin D supplementation during allergen-specific immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">930-933</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Vitamin D</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32750735</style></accession-num><notes><style face="normal" font="default" size="100%">Heine, Guido&#xD;Francuzik, Wojciech&#xD;Doelle-Bierke, Sabine&#xD;Drozdenko, Gennadiy&#xD;Frischbutter, Stefan&#xD;Schumacher, Nora&#xD;Radbruch, Andreas&#xD;Worm, Margitta&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):930-933. doi: 10.1111/all.14541. Epub 2020 Sep 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32750735</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14541</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1994</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1994</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Zhao, N.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Jin, Z. B.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, 100730, China.&#xD;Beijing Key Laboratory of Nasal Diseases, Beijing Laboratory of Allergic Diseases, Beijing Institute of Otolaryngology, Beijing, 100005, China.&#xD;Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, 100730, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunomodulatory properties of mesenchymal stem cells: A potential therapeutic strategy for allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1425-1440</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/03/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Mesenchymal Stem Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Immunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">extracellular vesicles</style></keyword><keyword><style face="normal" font="default" size="100%">mesenchymal stem cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36975714</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic rhinitis is a highly prevalent chronic inflammatory disorder of the nasal mucosa that poses a significant burden on patients&apos; health and quality of life. Current therapies for allergic rhinitis are unable to reinstate immune homeostasis or are restricted by specific allergens. Potential therapeutic strategies for allergic rhinitis are urgently needed. Mesenchymal stem cells (MSCs) are immune-privileged, have strong immunomodulatory effects, and can be easily isolated from various sources. Thus, MSC-based therapies demonstrate potential for treating inflammatory diseases. Recently, numerous studies have investigated the therapeutic effects of MSCs in animal models of allergic rhinitis. Here, we review the immunomodulatory effects and mechanisms of MSCs on allergic airway inflammation, especially allergic rhinitis, highlight the recent research regarding MSCs in the modulation of immune cells, and discuss the clinical potential of MSC-based therapy for allergic rhinitis.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Ming&#xD;Zhao, Ning&#xD;Wang, Chengshuo&#xD;Jin, Zi-Bing&#xD;Zhang, Luo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1425-1440. doi: 10.1111/all.15729. Epub 2023 Apr 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36975714</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15729</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1157</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1157</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Allergy and Immunology, University of Colorado School of Medicine, Colorado, USA.&#xD;Children&apos;s Hospital Colorado, Colorado, USA.&#xD;APC Microbiome Ireland, National University of Ireland, Cork, Ireland.&#xD;Department of Medicine, National University of Ireland, Cork, Ireland.&#xD;School of Microbiology, National University of Ireland, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunonutrition: The importance of a new European Academy of Allergy and Clinical Immunology working group addressing a significant burden and unmet need</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2303-2305</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Academies and Institutes</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33594668</style></accession-num><notes><style face="normal" font="default" size="100%">Venter, Carina&#xD;O&apos;Mahony, Liam&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2303-2305. doi: 10.1111/all.14781. Epub 2021 Mar 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33594668</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14781</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1592</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1592</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Allergy and Immunology, University of Colorado School of Medicine, Colorado, USA.&#xD;Children&apos;s Hospital Colorado, Colorado, USA.&#xD;APC Microbiome Ireland, National University of Ireland, Cork, Ireland.&#xD;Department of Medicine, National University of Ireland, Cork, Ireland.&#xD;School of Microbiology, National University of Ireland, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunonutrition: The importance of a new European Academy of Allergy and Clinical Immunology working group addressing a significant burden and unmet need</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2303-2305</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Academies and Institutes</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33594668</style></accession-num><notes><style face="normal" font="default" size="100%">Venter, Carina&#xD;O&apos;Mahony, Liam&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2303-2305. doi: 10.1111/all.14781. Epub 2021 Mar 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33594668</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14781</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2814</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2814</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bilotta, M. T.</style></author><author><style face="normal" font="default" size="100%">Vacca, P.</style></author><author><style face="normal" font="default" size="100%">Esposito, M.</style></author><author><style face="normal" font="default" size="100%">Buzzonetti, L.</style></author><author><style face="normal" font="default" size="100%">Bianco, G.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A. G.</style></author><author><style face="normal" font="default" size="100%">Moretta, L.</style></author><author><style face="normal" font="default" size="100%">Raponi, M.</style></author><author><style face="normal" font="default" size="100%">Artesani, M. C.</style></author><author><style face="normal" font="default" size="100%">Tumino, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Innate Lymphoid Cells Unit, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;Ophthalmology Unit, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;Unit of Hospital Pharmacy, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;Allergy Unit, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;Tumor Immunology Unit, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;Medical Direction, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunophenotyping in Vernal Keratoconjunctivitis: Schirmer Test for Therapy Response Prediction</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2050-2054</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/03/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Schirmer test</style></keyword><keyword><style face="normal" font="default" size="100%">immune cells</style></keyword><keyword><style face="normal" font="default" size="100%">immunosuppressive therapy</style></keyword><keyword><style face="normal" font="default" size="100%">ocular allergy</style></keyword><keyword><style face="normal" font="default" size="100%">vernal keratoconjunctivitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40071439</style></accession-num><notes><style face="normal" font="default" size="100%">Bilotta, Maria Teresa&#xD;Vacca, Paola&#xD;Esposito, Mariacristina&#xD;Buzzonetti, Luca&#xD;Bianco, Giuseppe&#xD;Fiocchi, Alessandro Giovanni&#xD;Moretta, Lorenzo&#xD;Raponi, Massimiliano&#xD;Artesani, Maria Cristina&#xD;Tumino, Nicola&#xD;eng&#xD;Ministero della Salute/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2050-2054. doi: 10.1111/all.16525. Epub 2025 Mar 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40071439</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261867</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16525</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2415</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2415</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thanasarnthungcharoen, C.</style></author><author><style face="normal" font="default" size="100%">Chanasit, S.</style></author><author><style face="normal" font="default" size="100%">Fievez, L.</style></author><author><style face="normal" font="default" size="100%">Kaewamatawong, T.</style></author><author><style face="normal" font="default" size="100%">Patniboon, P.</style></author><author><style face="normal" font="default" size="100%">Lin, P. J. C.</style></author><author><style face="normal" font="default" size="100%">Bureau, F.</style></author><author><style face="normal" font="default" size="100%">Jacquet, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical Microbiology, Interdisciplinary Program, Graduate School, Chulalongkorn University, Bangkok, Thailand.&#xD;Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.&#xD;Laboratory of Cellular and Molecular Immunology, GIGA-Research, University of Liege, Liege, Belgium.&#xD;Veterinary Pathology Unit, Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand.&#xD;Acuitas Therapeutics, Vancouver, British Columbia, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunotherapeutic effects of specific and nonspecific mRNA-lipid nanoparticles in a mouse model of HDM-induced airway inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1974-1978</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/02/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Nanoparticles</style></keyword><keyword><style face="normal" font="default" size="100%">*RNA, Messenger/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Lipids</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Liposomes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38328982</style></accession-num><notes><style face="normal" font="default" size="100%">Thanasarnthungcharoen, Chanatip&#xD;Chanasit, Supapich&#xD;Fievez, Laurence&#xD;Kaewamatawong, Theerayuth&#xD;Patniboon, Piyachat&#xD;Lin, Paulo J C&#xD;Bureau, Fabrice&#xD;Jacquet, Alain&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1974-1978. doi: 10.1111/all.16049. Epub 2024 Feb 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38328982</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16049</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2502</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2502</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Oton, T.</style></author><author><style face="normal" font="default" size="100%">Carmona, L.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Skypala, I.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Khoo Teck Puat-National University Children&apos;s Medical Institute, National University Hospital, National University Health System, Singapore, Singapore.&#xD;Instituto de Salud Musculoesqueletica, Madrid, Spain.&#xD;Children&apos;s Allergy Service, Evelina London, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Department of Women and Children&apos;s Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Department of Allergy and Clinical Immunology, Royal Brompton and Harefield NHS Foundation Trust, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunotherapy and biologics in the management of IgE-mediated food allergy: Systematic review and meta-analyses of efficacy and safety</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2097-2127</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/therapy/drug therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">egg</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">milk</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">peanut</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38747333</style></accession-num><abstract><style face="normal" font="default" size="100%">Food allergy (FA) is a potentially life-threatening chronic condition that is becoming an increasing public health problem worldwide. This systematic review (SR) was carried out to inform the development of clinical recommendations on the treatment of IgE-mediated FA with biologics and/or IT for the update of the EAACI guidelines. A SR of randomized-controlled trials or quasi-controlled trials was carried out. Studies were identified via comprehensive search strategies in Medline, Embase, and Cochrane Library, up to April 2022. POPULATION: Human adults, children, and adolescents with IgE-mediated FA. INTERVENTION: IT and/or biologics. COMPARATOR: Placebo or standard-of-care (allergen avoidance). OUTCOME: Efficacy (desensitization, sustained unresponsiveness (SU), remission), quality of life, and safety (systemic and local adverse reactions (AR)). The Cochrane RoB tool was used to assess the risk of bias. It was reported according to PRISMA and registered in PROSPERO CRD4202229828. After screening, 121 studies were included (111 for IT and 10 for biologics). Most studies had a high risk of bias and showed high heterogeneity in design and results. Metanalysis showed a positive effect of biologics and IT in terms of relative risk (RR) for achieving tolerance to the culprit food compared to avoidance or placebo. Omalizumab for any FA showed a RR of 2.17 [95% confidence interval: 1.22, 3.85]. For peanut allergy, oral IT (OIT) had a RR of 11.94 [1.76, 80.84] versus avoidance or placebo, sublingual IT (SLIT) had a RR of 3.00 [1.04, 8.66], and epicutaneous IT (EPIT) of 2.16 [1.56, 3.00]. OIT had a RR of 5.88 [2.27, 15.18] for cow&apos;s milk allergy, and of 3.43 [2.24, 5.27] for egg allergy. There was insufficient data on SLIT or EPIT for the treatment of egg and milk allergies. Most ARs reported were mild. For OIT the most common AR involved the gastrointestinal system and for EPIT, AR&apos;s most commonly affected the skin. There was limited data on severe or life-threatening ARs. There was limited evidence for long term efficacy and quality of life. In conclusion, biologics and IT, alone or in combination, are effective in achieving desensitization while on active treatment but more evidence is needed on long-term tolerance as current evidence is not of high quality. Adverse events while on therapy are generally mild to moderate but a long-term comprehensive safety profile is missing. There is a critical need to optimize and standardize desensitization protocols and outcome measures to facilitate our understanding of the efficacy and safety as well as to allow for comparison between interventions.</style></abstract><notes><style face="normal" font="default" size="100%">Riggioni, Carmen&#xD;Oton, Teresa&#xD;Carmona, Loreto&#xD;Du Toit, George&#xD;Skypala, Isabel&#xD;Santos, Alexandra F&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2097-2127. doi: 10.1111/all.16129. Epub 2024 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38747333</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16129</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2622</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2622</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lucas, M.</style></author><author><style face="normal" font="default" size="100%">Mak, H. W. F.</style></author><author><style face="normal" font="default" size="100%">Lee, J. T. Y.</style></author><author><style face="normal" font="default" size="100%">Kulkarni, R.</style></author><author><style face="normal" font="default" size="100%">Chan, S. S. C.</style></author><author><style face="normal" font="default" size="100%">Li, P. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunology Department, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.&#xD;Medical School, University of Western Australia, Perth, Western Australia, Australia.&#xD;Immunology Department, Perth Children&apos;s Hospital, Perth, Western Australia, Australia.&#xD;Immunology Department, PathWest Laboratory Medicine, Perth, Western Australia, Australia.&#xD;Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.&#xD;School of Nursing, The University of Hong Kong, Pokfulam, Hong Kong.&#xD;Department of Medicine, University of Hong Kong-Shenzhen Hospital, Guangdong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of a drug allergy education course for non-specialists: Findings from ADAPT-A randomized crossover trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">525-533</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Health Knowledge, Attitudes, Practice</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Physicians</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword><keyword><style face="normal" font="default" size="100%">multidisciplinary</style></keyword><keyword><style face="normal" font="default" size="100%">non-allergist</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39109415</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The consequences of drug allergy remain a global health concern. Drug allergy is often a neglected topic and many non-specialists lack sufficient knowledge or confidence in evaluating or managing this common condition. Evidence-based interventions to better equip non-specialists to tackle drug allergy are needed. The aim of the study is to evaluate the effectiveness of an intensive educational course on drug allergy knowledge and practice of non-specialists. METHODS: A randomized crossover trial (NCT06399601) was conducted among practicing physicians and nurses participating in an intensive drug allergy course-Advances in Drug Allergy &amp; Penicillin Testing (ADAPT). Participants&apos; baseline knowledge and self-reported practices were assessed with standardized questionnaires (scored from 0 to 100, with &quot;satisfactory&quot; defined as &gt;/=60/100). Participants were randomized into two cohorts and attended ADAPT at different time points. Serial responses before and after the course were compared within and between cohorts. RESULTS: Seventy participants (25 physicians, 45 nurses) randomized into two groups completed the course. Baseline drug allergy knowledge (58.0 +/- 19.9) and self-reported practice (36.9 +/- 24.3) were unsatisfactory among non-specialists, with significantly lower scores from nurses than physicians in both domains (knowledge: 49.0 +/- 17.4 vs. 74.0 +/- 12.7; practice: 32.1 +/- 21.3 vs. 53.3 +/- 23.1; all p &lt; 0.001). Following completion of ADAPT, participants demonstrated significant improvements in knowledge (58.0 +/- 19.9 vs. 77.7 +/- 15.9, p &lt; 0.001) and self-reported practice (36.9 +/- 24.3 vs. 71.0 +/- 20.2, p &lt; 0.001). All participants (100%) and 99% of participants agreed that the course improved their clinical knowledge and practice, respectively. CONCLUSIONS: ADAPT, an intensive drug allergy educational course was effective in improving drug allergy knowledge and practice for non-specialists. Further longitudinal studies are required to evaluate long-term impact.</style></abstract><notes><style face="normal" font="default" size="100%">Lucas, Michaela&#xD;Mak, Hugo W F&#xD;Lee, Jasmine T Y&#xD;Kulkarni, Rishabh&#xD;Chan, Sophia S C&#xD;Li, Philip H&#xD;eng&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):525-533. doi: 10.1111/all.16270. Epub 2024 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39109415</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804302</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16270</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2461</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2461</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Na, S.</style></author><author><style face="normal" font="default" size="100%">Yanan, H.</style></author><author><style face="normal" font="default" size="100%">Lufang, T.</style></author><author><style face="normal" font="default" size="100%">Zhenfeng, S.</style></author><author><style face="normal" font="default" size="100%">Wei, T.</style></author><author><style face="normal" font="default" size="100%">Yu, H.</style></author><author><style face="normal" font="default" size="100%">Jingrong, G.</style></author><author><style face="normal" font="default" size="100%">Wei, H.</style></author><author><style face="normal" font="default" size="100%">Kangning, A.</style></author><author><style face="normal" font="default" size="100%">Haidong, K.</style></author><author><style face="normal" font="default" size="100%">Yusen, D.</style></author><author><style face="normal" font="default" size="100%">Shaoqing, Y.</style></author><author><style face="normal" font="default" size="100%">Ruxin, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Huadong Hospital, Fudan University, Shanghai, China.&#xD;Department of Otolaryngology, Shanghai Seventh People&apos;s Hospital, Shanghai Traditional Chinese Medicine, Shanghai, China.&#xD;Department of Otolaryngology, Shanghai Fifth People&apos;s Hospital, Fudan University, Shanghai, China.&#xD;Department of Otolaryngology, Shanghai General Hospital, Jiaotong University School of Medicine, Shanghai, China.&#xD;Department of Otolaryngology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.&#xD;School of Mathematics and Statistics, Northwestern Polytechnical University, Xi&apos;an, China.&#xD;School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and Key Lab of Health Technology Assessment of the Ministry of Health, Fudan University, Shanghai, China.&#xD;Shanghai Technology Center for Reduction of Pollution and Carbon Emissions, Shanghai, China.&#xD;Department of Allergy, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of air pollutants and meteorological factors on allergic rhinitis outpatient visits in Shanghai, China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1372-1376</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/02/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Meteorological Concepts</style></keyword><keyword><style face="normal" font="default" size="100%">Outpatients</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38403960</style></accession-num><notes><style face="normal" font="default" size="100%">Na, Sun&#xD;Yanan, Hao&#xD;Lufang, Tian&#xD;Zhenfeng, Sun&#xD;Wei, Tang&#xD;Yu, Huang&#xD;Jingrong, Gong&#xD;Wei, Huang&#xD;Kangning, An&#xD;Haidong, Kan&#xD;Yusen, Duan&#xD;Shaoqing, Yu&#xD;Ruxin, Zhang&#xD;eng&#xD;81974140/National Natural Science Foundation of China/&#xD;81670906/National Natural Science Foundation of China/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1372-1376. doi: 10.1111/all.16070. Epub 2024 Feb 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38403960</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16070</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>362</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">362</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Luo, X.</style></author><author><style face="normal" font="default" size="100%">Hong, H.</style></author><author><style face="normal" font="default" size="100%">Lu, Y.</style></author><author><style face="normal" font="default" size="100%">Deng, S.</style></author><author><style face="normal" font="default" size="100%">Wu, N.</style></author><author><style face="normal" font="default" size="100%">Zhou, Q.</style></author><author><style face="normal" font="default" size="100%">Chen, Z.</style></author><author><style face="normal" font="default" size="100%">Feng, P.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Tao, J.</style></author><author><style face="normal" font="default" size="100%">Dai, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, K.</style></author><author><style face="normal" font="default" size="100%">Zhang, P.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Xiong, G.</style></author><author><style face="normal" font="default" size="100%">Cheng, Y.</style></author><author><style face="normal" font="default" size="100%">Su, J.</style></author><author><style face="normal" font="default" size="100%">Li, T.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Chao, M.</style></author><author><style face="normal" font="default" size="100%">Liang, G.</style></author><author><style face="normal" font="default" size="100%">Wu, Q.</style></author><author><style face="normal" font="default" size="100%">Zhou, M.</style></author><author><style face="normal" font="default" size="100%">Zheng, R.</style></author><author><style face="normal" font="default" size="100%">Wu, S.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Huang, X.</style></author><author><style face="normal" font="default" size="100%">Yin, L.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Lu, H.</style></author><author><style face="normal" font="default" size="100%">Yang, Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.&#xD;Department of Allergy, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.&#xD;Department of Otolaryngology, Allergy Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.&#xD;Department of Ear Nose Throat (ENT), Second People&apos;s Hospital of Shenzhen, First Affiliated Hospital of Shenzhen University, Shenzhen, China.&#xD;Department of Clinical Data Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.&#xD;Guangdong Ecological Meteorology Center, Guangzhou, China.&#xD;Department of Pediatrics, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.&#xD;Department of Dermatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.&#xD;Department of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.&#xD;Department of Gastroenterol, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.&#xD;Department of Traditional Chinese Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.&#xD;Department of Information, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of air pollution and meteorological factors on incidence of allergic rhinitis: A low-latitude multi-city study in China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1656-1659</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/08/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Meteorological Concepts</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Particulate Matter/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">air pollutants</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">distributed non-linear lag model</style></keyword><keyword><style face="normal" font="default" size="100%">generalized additive model</style></keyword><keyword><style face="normal" font="default" size="100%">meteorological factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35924735</style></accession-num><notes><style face="normal" font="default" size="100%">Luo, Xin&#xD;Hong, Haiyu&#xD;Lu, Yongtian&#xD;Deng, Shumin&#xD;Wu, Naigeng&#xD;Zhou, Qilin&#xD;Chen, Zhuanggui&#xD;Feng, Peiying&#xD;Zhou, Yuqi&#xD;Tao, Jin&#xD;Dai, Min&#xD;Zhang, Kun&#xD;Zhang, Pingping&#xD;Li, Yating&#xD;Xiong, Guowei&#xD;Cheng, Yun&#xD;Su, Jing&#xD;Li, Tingyuan&#xD;Chen, Jingyang&#xD;Chao, Manhou&#xD;Liang, Guixian&#xD;Wu, Qingwu&#xD;Zhou, Min&#xD;Zheng, Rui&#xD;Wu, Shuo&#xD;Zhang, Yana&#xD;Huang, Xuekun&#xD;Yin, Lin&#xD;Liu, Zifeng&#xD;Lu, Huanping&#xD;Yang, Qintai&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1656-1659. doi: 10.1111/all.15469. Epub 2022 Aug 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35924735</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15469</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1129</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1129</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eyice Karabacak, D.</style></author><author><style face="normal" font="default" size="100%">Demir, S.</style></author><author><style face="normal" font="default" size="100%">Yegit, O. O.</style></author><author><style face="normal" font="default" size="100%">Can, A.</style></author><author><style face="normal" font="default" size="100%">Terzioglu, K.</style></author><author><style face="normal" font="default" size="100%">Unal, D.</style></author><author><style face="normal" font="default" size="100%">Olgac, M.</style></author><author><style face="normal" font="default" size="100%">Coskun, R.</style></author><author><style face="normal" font="default" size="100%">Colakoglu, B.</style></author><author><style face="normal" font="default" size="100%">Buyukozturk, S.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Kartal Lutfi Kirdar Education and Research Hospital, Adult Immunology and Allergy Clinic, Istanbul, Turkey.&#xD;Sisli Hamidiye Etfal Education and Research Hospital, Adult Immunology and Allergy Clinic, Istanbul, Turkey.&#xD;Prof Dr Cemil Tascioglu City Hospital, Adult Immunology and Allergy Clinic, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of anxiety, stress and depression related to COVID-19 pandemic on the course of hereditary angioedema with C1-inhibitor deficiency</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2535-2543</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Anxiety/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein</style></keyword><keyword><style face="normal" font="default" size="100%">Depression/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">pandemic</style></keyword><keyword><style face="normal" font="default" size="100%">psychological effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33650198</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hereditary angioedema (HAE) attacks can be provoked with psychological factors. The aim of this study was to assess the effects of anxiety, depression and stress related to COVID-19 pandemic on disease activity of HAE patients during the quarantine period (QP) and the return to normal period (RTNP). METHODS: This study was conducted between March 2020 and September 2020 in four allergy centres. Demographic, clinical features and mental health status were evaluated in QP (from March to the beginning of June) and RTNP (from June to the beginning of September) applied by the government. The 10-point visual analogue scale (VAS10) was used to define the severity of HAE attacks. Depression, Anxiety and Stress Scales-21 (DASS-21) and Fear of COVID-19 (FC-19) scale were performed to assess mental health status. RESULTS: 139 HAE patients were included in the study. In QP, median attack numbers and median VAS10 scores were 5 (min-max: 0-45) and 6 (min-max: 0-10), respectively. HAE attack numbers, DASS-21 stress, anxiety, depression and total DASS-21 scores, and FC-19 scores were higher in QP than RTNP (p = 0.001, p &lt; 0.001, p = 0.001, p &lt; 0.001, p &lt; 0.001, p &lt; 0.001, respectively). However, there was no difference in attack severity scores between the two periods (p &gt; 0.05). CONCLUSIONS: This study revealed that the restriction measures during COVID-19 outbreak cause an increase in the number of HAE attacks in relation to anxiety, depression, stress and fear of COVID-19 pandemic. Therefore, it is important to provide psychological support to HAE patients during the pandemic.</style></abstract><notes><style face="normal" font="default" size="100%">Eyice Karabacak, Deniz&#xD;Demir, Semra&#xD;Yegit, Osman Ozan&#xD;Can, Ali&#xD;Terzioglu, Kadriye&#xD;Unal, Derya&#xD;Olgac, Muge&#xD;Coskun, Raif&#xD;Colakoglu, Bahauddin&#xD;Buyukozturk, Suna&#xD;Gelincik, Asli&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2535-2543. doi: 10.1111/all.14796. Epub 2021 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33650198</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8014132</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14796</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2251</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2251</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">De Marchi, S.</style></author><author><style face="normal" font="default" size="100%">Cecchin, E.</style></author><author><style face="normal" font="default" size="100%">De Marchi, S. U.</style></author><author><style face="normal" font="default" size="100%">Sechi, L. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University of Udine, School of Medicine, Udine, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of atopic respiratory disease on contact dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">242-245</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/09/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Contact/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37705339</style></accession-num><notes><style face="normal" font="default" size="100%">De Marchi, Sergio&#xD;Cecchin, Emanuela&#xD;De Marchi, Sergio Umberto&#xD;Sechi, Leonardo Alberto&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):242-245. doi: 10.1111/all.15890. Epub 2023 Sep 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37705339</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15890</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2362</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2362</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, S. P.</style></author><author><style face="normal" font="default" size="100%">Stefanovic, N.</style></author><author><style face="normal" font="default" size="100%">Orfali, R. L.</style></author><author><style face="normal" font="default" size="100%">Aoki, V.</style></author><author><style face="normal" font="default" size="100%">Brown, S. J.</style></author><author><style face="normal" font="default" size="100%">Dhar, S.</style></author><author><style face="normal" font="default" size="100%">Eichenfield, L. F.</style></author><author><style face="normal" font="default" size="100%">Flohr, C.</style></author><author><style face="normal" font="default" size="100%">Ha, A.</style></author><author><style face="normal" font="default" size="100%">Mora, C.</style></author><author><style face="normal" font="default" size="100%">Murase, J. E.</style></author><author><style face="normal" font="default" size="100%">Rosenbach, M.</style></author><author><style face="normal" font="default" size="100%">Srinivas, S. M.</style></author><author><style face="normal" font="default" size="100%">Thyssen, J. P.</style></author><author><style face="normal" font="default" size="100%">Wei, M. L.</style></author><author><style face="normal" font="default" size="100%">Irvine, A. D.</style></author><author><style face="normal" font="default" size="100%">Abuabara, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, University of California San Francisco, San Francisco, California, USA.&#xD;Clinical Medicine, Trinity College Dublin, Dublin, Ireland.&#xD;Department of Dermatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.&#xD;Centre for Genomic &amp; Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.&#xD;Department of Pediatric Dermatology, Institute of Child Health, Kolkata, India.&#xD;Departments of Dermatology and Pediatrics, University of California San Diego, San Diego, California, USA.&#xD;Unit for Population-Based Dermatology Research, St John&apos;s Institute of Dermatology, Guy&apos;s &amp; St Thomas&apos; NHS Foundation Trust and King&apos;s College London, London, UK.&#xD;Department of Geography and Environment, University of Hawai&apos;i at Manoa, Honolulu, Hawai&apos;i, USA.&#xD;Department of Dermatology, Palo Alto Foundation Medical Group, Mountain View, California, USA.&#xD;Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;Department of Dermatology, Indira Gandhi Institute of Child Health, Bengaluru, India.&#xD;Department of Dermatology and Venereology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Dermatology Service, San Francisco VA Health Care System, San Francisco, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of climate change on atopic dermatitis: A review by the International Eczema Council</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1455-1469</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Climate Change</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Air Pollution/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">climate change</style></keyword><keyword><style face="normal" font="default" size="100%">climatic hazards</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38265114</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopic dermatitis (AD), the most burdensome skin condition worldwide, is influenced by climatic factors and air pollution; however, the impact of increasing climatic hazards on AD remains poorly characterized. Leveraging an existing framework for 10 climatic hazards related to greenhouse gas emissions, we identified 18 studies with evidence for an impact on AD through a systematic search. Most climatic hazards had evidence for aggravation of AD the impact ranged from direct effects like particulate matter-induced AD exacerbations from wildfires to the potential for indirect effects like drought-induced food insecurity and migration. We then created maps comparing the past, present, and future projected burden of climatic hazards to global AD prevalence data. Data are lacking, especially from those regions most likely to experience more climatic hazards. We highlight gaps important for future research: understanding the synergistic impacts of climatic hazards on AD, long-term disease activity, the differential impact on vulnerable populations, and how basic mechanisms explain population-level trends.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Sheng-Pei&#xD;Stefanovic, Nicholas&#xD;Orfali, Raquel L&#xD;Aoki, Valeria&#xD;Brown, Sara J&#xD;Dhar, Sandipan&#xD;Eichenfield, Lawrence F&#xD;Flohr, Carsten&#xD;Ha, Alex&#xD;Mora, Camilo&#xD;Murase, Jenny E&#xD;Rosenbach, Misha&#xD;Srinivas, Sahana M&#xD;Thyssen, Jacob P&#xD;Wei, Maria L&#xD;Irvine, Alan D&#xD;Abuabara, Katrina&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1455-1469. doi: 10.1111/all.16007. Epub 2024 Jan 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38265114</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16007</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2385</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2385</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez de Llano, L.</style></author><author><style face="normal" font="default" size="100%">Urrutia, I.</style></author><author><style face="normal" font="default" size="100%">G. Cosio B</style></author><author><style face="normal" font="default" size="100%">Gullon-Blanco, J. A.</style></author><author><style face="normal" font="default" size="100%">Habernau Mena, A.</style></author><author><style face="normal" font="default" size="100%">Cisneros, C.</style></author><author><style face="normal" font="default" size="100%">Martinez-Moragon, E.</style></author><author><style face="normal" font="default" size="100%">Marina Malanda, N.</style></author><author><style face="normal" font="default" size="100%">Munoz Esquerre, M.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Dacal Rivas, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pneumology Service, Lucus Augusti University Hospital, Lugo, Spain.&#xD;Pneumology Service, Galdakao-Usansolo University Hospital, Galdakao, Spain.&#xD;Pneumology Service, Son Espases University Hospital, IdISBa-Ciberes, Palma de Mallorca, Spain.&#xD;Pneumology Service, San Agustin University Hospital, Aviles, Spain.&#xD;Allergy Section, Internal Medicine Service, Complejo Hospitalario de Merida, Badajoz, Spain.&#xD;Pneumology Service, La Princesa University Hospital, Madrid, Spain.&#xD;Pneumology Service, Doctor Peset University Hospital, Valencia, Spain.&#xD;Pneumology Service, Cruces University Hospital, Barakaldo, Spain.&#xD;Pneumology Service, Bellvitge University Hospital, IBIDELL, Barcelona University, Barcelona, Spain.&#xD;Department of Allergy, La Paz University Hospital, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of comorbidities on the achievement of specific therapeutic goals in biologic-treated asthma patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2235-2240</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/01/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38180244</style></accession-num><notes><style face="normal" font="default" size="100%">Perez de Llano, Luis&#xD;Urrutia, Isabel&#xD;G Cosio, Borja&#xD;Gullon-Blanco, Jose Antonio&#xD;Habernau Mena, Alicia&#xD;Cisneros, Carolina&#xD;Martinez-Moragon, Eva&#xD;Marina Malanda, Nuria&#xD;Munoz Esquerre, Mariana&#xD;Quirce, Santiago&#xD;Dacal Rivas, David&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2235-2240. doi: 10.1111/all.15999. Epub 2024 Jan 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38180244</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15999</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2311</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2311</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Akasaki, Y.</style></author><author><style face="normal" font="default" size="100%">Iwagami, M.</style></author><author><style face="normal" font="default" size="100%">Sung, J.</style></author><author><style face="normal" font="default" size="100%">Nagino, K.</style></author><author><style face="normal" font="default" size="100%">Adachi, T.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author><author><style face="normal" font="default" size="100%">Tamari, M.</style></author><author><style face="normal" font="default" size="100%">Kainuma, K.</style></author><author><style face="normal" font="default" size="100%">Kan, O. K.</style></author><author><style face="normal" font="default" size="100%">Ogata, H.</style></author><author><style face="normal" font="default" size="100%">Sakashita, M.</style></author><author><style face="normal" font="default" size="100%">Futamura, M.</style></author><author><style face="normal" font="default" size="100%">Kurashima, Y.</style></author><author><style face="normal" font="default" size="100%">Nakajima, S.</style></author><author><style face="normal" font="default" size="100%">Masaki, K.</style></author><author><style face="normal" font="default" size="100%">Ogawa, Y.</style></author><author><style face="normal" font="default" size="100%">Sato, S.</style></author><author><style face="normal" font="default" size="100%">Miyagawa, A.</style></author><author><style face="normal" font="default" size="100%">Midorikawa-Inomata, A.</style></author><author><style face="normal" font="default" size="100%">Fujimoto, K.</style></author><author><style face="normal" font="default" size="100%">Okumura, Y.</style></author><author><style face="normal" font="default" size="100%">Fujio, K.</style></author><author><style face="normal" font="default" size="100%">Huang, T.</style></author><author><style face="normal" font="default" size="100%">Hirosawa, K.</style></author><author><style face="normal" font="default" size="100%">Morooka, Y.</style></author><author><style face="normal" font="default" size="100%">Nakao, S.</style></author><author><style face="normal" font="default" size="100%">Murakami, A.</style></author><author><style face="normal" font="default" size="100%">Kobayashi, H.</style></author><author><style face="normal" font="default" size="100%">Inomata, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Department of Digital Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;ENGAGE-Task Force, Tokyo, Japan.&#xD;Department of Health Services Research, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.&#xD;Department of Hospital Administration, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Department of Telemedicine and Mobile Health, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.&#xD;Department of Medical Regulatory Science, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.&#xD;Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.&#xD;Division of Molecular Genetics, Research Center for Medical Science, The Jikei University School of Medicine, Tokyo, Japan.&#xD;Institute for Clinical Research, National Hospital Organization, Mie National Hospital, Mie, Japan.&#xD;Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.&#xD;Department of Respiratory Medicine, NHO Fukuoka National Hospital, Fukuoka, Japan.&#xD;Division of Otorhinolaryngology Head and Neck Surgery, Department of Sensory and Locomotor Medicine, University of Fukui, Fukui, Japan.&#xD;Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Aichi, Japan.&#xD;Department of Innovative Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.&#xD;Institute for Advanced Academic Research, Chiba University, Chiba, Japan.&#xD;International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.&#xD;Department of Pathology/Medicine, Allergy and Vaccines, CU-UCSD Center for Mucosal Immunology, University of California, San Diego, California, USA.&#xD;Mucosal Immunology and Allergy Therapeutics, Institute for Global Prominent Research, Graduate School of Medicine, Chiba University, Chiba, Japan.&#xD;Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.&#xD;Department of Advanced Medicine, Nagoya University Hospital, Aichi, Japan.&#xD;Department of Allergy, Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Kanagawa, Japan.&#xD;AI Incubation Farm, Juntendo University Graduate School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of COVID-19 on care-seeking patterns for hay fever in Japan: A retrospective claims database cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1056-1060</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/11/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Japan/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37966466</style></accession-num><notes><style face="normal" font="default" size="100%">Akasaki, Yasutsugu&#xD;Iwagami, Masao&#xD;Sung, Jaemyoung&#xD;Nagino, Ken&#xD;Adachi, Takeya&#xD;Morita, Hideaki&#xD;Tamari, Mayumi&#xD;Kainuma, Keigo&#xD;Kan-O, Keiko&#xD;Ogata, Hiroaki&#xD;Sakashita, Masafumi&#xD;Futamura, Masaki&#xD;Kurashima, Yosuke&#xD;Nakajima, Saeko&#xD;Masaki, Katsunori&#xD;Ogawa, Yasushi&#xD;Sato, Sakura&#xD;Miyagawa, Akihiro&#xD;Midorikawa-Inomata, Akie&#xD;Fujimoto, Keiichi&#xD;Okumura, Yuichi&#xD;Fujio, Kenta&#xD;Huang, Tianxiang&#xD;Hirosawa, Kunihiko&#xD;Morooka, Yuki&#xD;Nakao, Shintaro&#xD;Murakami, Akira&#xD;Kobayashi, Hiroyuki&#xD;Inomata, Takenori&#xD;eng&#xD;Japan Agency for Medical Research and Development/&#xD;The Institute for Environmental &amp;amp; Gender-specific Medicine, Juntendo University/&#xD;The OTC Self-Medication Promotion Foundation/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):1056-1060. doi: 10.1111/all.15947. Epub 2023 Nov 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37966466</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15947</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1365</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1365</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alemao, C. A.</style></author><author><style face="normal" font="default" size="100%">Budden, K. F.</style></author><author><style face="normal" font="default" size="100%">Gomez, H. M.</style></author><author><style face="normal" font="default" size="100%">Rehman, S. F.</style></author><author><style face="normal" font="default" size="100%">Marshall, J. E.</style></author><author><style face="normal" font="default" size="100%">Shukla, S. D.</style></author><author><style face="normal" font="default" size="100%">Donovan, C.</style></author><author><style face="normal" font="default" size="100%">Forster, S. C.</style></author><author><style face="normal" font="default" size="100%">Yang, I. A.</style></author><author><style face="normal" font="default" size="100%">Keely, S.</style></author><author><style face="normal" font="default" size="100%">Mann, E. R.</style></author><author><style face="normal" font="default" size="100%">El Omar, E. M.</style></author><author><style face="normal" font="default" size="100%">Belz, G. T.</style></author><author><style face="normal" font="default" size="100%">Hansbro, P. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton, Newcastle, NSW, Australia.&#xD;The University of Newcastle, Newcastle, NSW, Australia.&#xD;Faculty of Science, Centre for Inflammation, Centenary Institute, University of Technology Sydney, Sydney, NSW, Australia.&#xD;Department of Molecular and Translational Sciences, Hudson Institute of Medical Research, Centre for Innate Immunity and Infectious Diseases, Monash University, Clayton, VIC, Australia.&#xD;Thoracic Program, The Prince Charles Hospital, Metro North Hospital and Health Service, Brisbane, QLD, Australia.&#xD;Faculty of Medicine, UQ Thoracic Research Centre, The University of Queensland, Brisbane, QLD, Australia.&#xD;Hunter Medical Research Institute, Priority Research Centre for Digestive Health and Neurogastroenterology, University of Newcastle, New Lambton Heights, NSW, Australia.&#xD;Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.&#xD;Faculty of Biology Medicine and Health, Manchester Collaborative Centre for Inflammation Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.&#xD;St George &amp; Sutherland Clinical School, Microbiome Research Centre, University of New South Wales, Sydney, NSW, Australia.&#xD;Diamantina Institute, University of Queensland, Woolloongabba, QLD, Australia.&#xD;Department of Medical Biology, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Parkville, VIC, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of diet and the bacterial microbiome on the mucous barrier and immune disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">714-734</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immune System Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default" size="100%">disease</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">induction</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">mucus</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32762040</style></accession-num><abstract><style face="normal" font="default" size="100%">The prevalence of chronic immune and metabolic disorders is increasing rapidly. In particular, inflammatory bowel diseases, obesity, diabetes, asthma and chronic obstructive pulmonary disease have become major healthcare and economic burdens worldwide. Recent advances in microbiome research have led to significant discoveries of associative links between alterations in the microbiome and health, as well as these chronic supposedly noncommunicable, immune/metabolic disorders. Importantly, the interplay between diet, microbiome and the mucous barrier in these diseases has gained significant attention. Diet modulates the mucous barrier via alterations in gut microbiota, resulting in either disease onset/exacerbation due to a &quot;poor&quot; diet or protection against disease with a &quot;healthy&quot; diet. In addition, many mucosa-associated disorders possess a specific gut microbiome fingerprint associated with the composition of the mucous barrier, which is further influenced by host-microbiome and inter-microbial interactions, dietary choices, microbe immigration and antimicrobials. Our review focuses on the interactions of diet (macronutrients and micronutrients), gut microbiota and mucous barriers (gastrointestinal and respiratory tract) and their importance in the onset and/or progression of major immune/metabolic disorders. We also highlight the key mechanisms that could be targeted therapeutically to prevent and/or treat these disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Alemao, Charlotte A&#xD;Budden, Kurtis F&#xD;Gomez, Henry M&#xD;Rehman, Saima F&#xD;Marshall, Jacqueline E&#xD;Shukla, Shakti D&#xD;Donovan, Chantal&#xD;Forster, Samuel C&#xD;Yang, Ian A&#xD;Keely, Simon&#xD;Mann, Elizabeth R&#xD;El Omar, Emad M&#xD;Belz, Gabrielle T&#xD;Hansbro, Philip M&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):714-734. doi: 10.1111/all.14548. Epub 2020 Aug 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32762040</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14548</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3297</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3297</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Handoko, Claireta</style></author><author><style face="normal" font="default" size="100%">Singh, Ankur</style></author><author><style face="normal" font="default" size="100%">Dharmage, Shyamali C.</style></author><author><style face="normal" font="default" size="100%">Hu, Yanhong J.</style></author><author><style face="normal" font="default" size="100%">Dashper, Stuart G.</style></author><author><style face="normal" font="default" size="100%">Bertelsen, Randi J.</style></author><author><style face="normal" font="default" size="100%">Lowe, Adrian J.</style></author><author><style face="normal" font="default" size="100%">Lopez, Diego J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Impact of Early Childhood Caries on Asthma Trajectories During the First 15 Years of Life</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70307</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70307</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1088</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1088</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cooper, P. J.</style></author><author><style face="normal" font="default" size="100%">Chis Ster, I.</style></author><author><style face="normal" font="default" size="100%">Chico, M. E.</style></author><author><style face="normal" font="default" size="100%">Vaca, M.</style></author><author><style face="normal" font="default" size="100%">Oviedo, Y.</style></author><author><style face="normal" font="default" size="100%">Maldonado, A.</style></author><author><style face="normal" font="default" size="100%">Barreto, M. L.</style></author><author><style face="normal" font="default" size="100%">Platts-Mills, T. A. E.</style></author><author><style face="normal" font="default" size="100%">Strachan, D. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Infection and Immunity, St George&apos;s University of London, London, UK.&#xD;School of Medicine, Universidad Internacional del Ecuador, Quito, Ecuador.&#xD;Fundacion Ecuatoriana Para La Investigacion en Salud, Quito, Ecuador.&#xD;Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Quito, Ecuador.&#xD;CIDACS-FIOCRUZ, Salvador, Brazil.&#xD;Division of Allergy and Clinical Immunology, University of Virginia, Charlottesville, VA, USA.&#xD;Population Health Research Institute, St George&apos;s University of London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of early life geohelminths on wheeze, asthma and atopy in Ecuadorian children at 8 years</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2765-2775</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/03/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Ecuador/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Sounds/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Ecuador</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">geohelminths</style></keyword><keyword><style face="normal" font="default" size="100%">wheeze</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33745189</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Early-life exposures to geohelminths may protect against development of wheeze/asthma and atopy. OBJECTIVE: To study the effect of maternal geohelminths and infections in children during the first 5 years on atopy, wheeze/asthma and airways reactivity/inflammation at 8 years. METHODS: Birth cohort of 2404 neonates followed to 8 years in rural Ecuador. Data on wheeze/asthma were collected by questionnaire and atopy by skin prick test (SPT) reactivity to 9 allergens. We measured airways reactivity to bronchodilator, fractional exhaled nitric oxide (FeNO) and nasal eosinophilia. Stool samples were examined for geohelminths by microscopy. RESULTS: 1933 (80.4%) children were evaluated at 8 years. Geohelminths were detected in 45.8% of mothers and 45.5% of children to 5 years. Frequencies of outcomes at 8 years were as follows: wheeze (6.6%), asthma between 5 and 8 years (7.9%), SPT (14.7%), airways reactivity (10%) and elevated FeNO (10.3%) and nasal eosinophilia (9.2%). Any maternal geohelminth was associated with reduced SPT prevalence (OR 0.72). Childhood Trichuris trichiura infections during the first 5 years were associated with reduced wheeze (OR 0.57) but greater parasite burdens with Ascaris lumbricoides at 5 years were associated with increased wheeze (OR 2.83) and asthma (OR 2.60). Associations between maternal geohelminths and wheeze/asthma were modified by atopy. Parasite-specific effects on wheeze/asthma and airways reactivity and inflammation were observed in non-atopic children. CONCLUSIONS: Our data provide novel evidence for persistent effects of in utero geohelminth exposures on childhood atopy but highlight the complex nature of the relationship between geohelminths and the airways. Registered as an observational study (ISRCTN41239086).</style></abstract><notes><style face="normal" font="default" size="100%">Cooper, Philip J&#xD;Chis Ster, Irina&#xD;Chico, Martha E&#xD;Vaca, Maritza&#xD;Oviedo, Yisela&#xD;Maldonado, Augusto&#xD;Barreto, Mauricio L&#xD;Platts-Mills, Thomas A E&#xD;Strachan, David P&#xD;eng&#xD;WT_/Wellcome Trust/United Kingdom&#xD;R37 AI020565/AI/NIAID NIH HHS/&#xD;088862/Z/09/Z/WT_/Wellcome Trust/United Kingdom&#xD;Observational Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2765-2775. doi: 10.1111/all.14821. Epub 2021 Apr 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33745189</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8496980</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14821</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2500</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2500</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Ricci-Cabello, I.</style></author><author><style face="normal" font="default" size="100%">Canelo-Aybar, C.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Biagioni, B.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">De Las Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Dominguez-Ortega, J.</style></author><author><style face="normal" font="default" size="100%">Galan, C.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Holgate, S.</style></author><author><style face="normal" font="default" size="100%">Jeebhay, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Salazar, J.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Colom, M.</style></author><author><style face="normal" font="default" size="100%">Fiol-deRoque, M. A.</style></author><author><style face="normal" font="default" size="100%">Gorreto Lopez, L.</style></author><author><style face="normal" font="default" size="100%">Malih, N.</style></author><author><style face="normal" font="default" size="100%">Moro, L.</style></author><author><style face="normal" font="default" size="100%">Pardo, M. G.</style></author><author><style face="normal" font="default" size="100%">Pazo, P. G.</style></author><author><style face="normal" font="default" size="100%">Campos, R. Z.</style></author><author><style face="normal" font="default" size="100%">Saletti-Cuesta, L.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Alonso-Coello, P.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Research Group in Primary Care and Promotion - Balearic Islands Community (GRAPP-caIB), Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain.&#xD;Primary Care Research Unit of Mallorca, Balearic Islands Health Services, Palma, Spain.&#xD;CIBER Biomedical Research Center in Epidemiology and Public Health (CIBERESP), Health Institute Carlos III (ISCIII), Madrid, Spain.&#xD;Iberoamerican Cochrane Centre, Barcelona, Spain.&#xD;Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain.&#xD;Institute Desbrest of Epidemiology and Public Health, INSERM, University Hospital, University of Montpellier, Montpellier, France.&#xD;SOSD Allergy and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Allergy and Clinical Immunology Unit San Giovanni di Dio Hospital, Florence, Italy.&#xD;Imperial College, London, UK.&#xD;Respiratory Disease Department, Hospital Cardarelli, Naples, Italy.&#xD;Medical School of Respiratory Allergy, University of Naples Federico II, Naples, Italy.&#xD;Terrestrial Ecology and Climate Change, Department of Ecology, School of Biology, Faculty of Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.&#xD;Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.&#xD;Inter-University Institute for Earth System Research (IISTA), International Campus of Excellence on Agrifood (ceiA3), University of Cordoba, Cordoba, Spain.&#xD;Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Occupational Medicine Division and Centre for Environmental &amp; Occupational Health Research, University of Cape Town, Cape Town, South Africa.&#xD;John Rock Professor of Climate and Population Studies Chair, Department of Environmental Health, Interim Director, Center for Climate, Health, and the Global Environment, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Allergy and Clinical Immunology Unit, Second Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK.&#xD;Allergy Service, Fundacion Jimenez Diaz, Faculty of Medicine Universidad Autonoma de Madrid and CIBERES, Instituto Carlos III, Ministry of Science and Innovation, Madrid, Spain.&#xD;Institute of Environmental Medicine, Helmholtz Munich - German Research Center for Environmental Health, Augsburg, Germany.&#xD;Christine-Kuhne Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Prevention and Health Promotion Research Network (redIAPP)/Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Barcelona, Spain.&#xD;Gabinete tecnico de atencion primaria de Mallorca, Balearic Islands Health Services, Palma, Spain.&#xD;Servicio de urgencias de atencion primaria de Inca, Balearic Islands Health Services, Palma, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Department of Clinical Immunology, Wroclaw Medical University, ALL-MED Medical Research Institute, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The impact of exposure to tobacco smoke and e-cigarettes on asthma-related outcomes: Systematic review informing the EAACI guidelines on environmental science for allergic diseases and asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2346-2365</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/05/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Tobacco Smoke Pollution/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Electronic Nicotine Delivery Systems</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Grade</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">guideline</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">tobacco smoke</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38783343</style></accession-num><abstract><style face="normal" font="default" size="100%">To inform the clinical practice guidelines&apos; recommendations developed by the European Academy of Allergy and Clinical Immunology systematic reviews (SR) assessed using GRADE on the impact of environmental tobacco smoke (ETS) and active smoking on the risk of new-onset asthma/recurrent wheezing (RW)/low lung function (LF), and on asthma-related outcomes. Only longitudinal studies were included, almost all on combustion cigarettes, only one assessing e-cigarettes and LF. According to the first SR (67 studies), prenatal ETS increases the risk of RW (moderate certainty evidence) and may increase the risk of new-onset asthma and of low LF (low certainty evidence). Postnatal ETS increases the risk of new-onset asthma and of RW (moderate certainty evidence) and may impact LF (low certainty evidence). Combined in utero and postnatal ETS may increase the risk of new-onset asthma (low certainty evidence) and increases the risk of RW (moderate certainty evidence). According to the second SR (24 studies), ETS increases the risk of severe asthma exacerbations and impairs asthma control and LF (moderate certainty evidence). According to the third SR (25 studies), active smoking increases the risk of severe asthma exacerbations and of suboptimal asthma control (moderate certainty evidence) and may impact asthma-related quality-of-life and LF (low certainty evidence).</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Ricci-Cabello, Ignacio&#xD;Canelo-Aybar, Carlos&#xD;Annesi-Maesano, Isabella&#xD;Cecchi, Lorenzo&#xD;Biagioni, Benedetta&#xD;Chung, Kian Fan&#xD;D&apos;Amato, Gennaro&#xD;Damialis, Athanasios&#xD;Del Giacco, Stefano&#xD;De Las Vecillas, Leticia&#xD;Dominguez-Ortega, Javier&#xD;Galan, Carmen&#xD;Gilles, Stefanie&#xD;Giovannini, Mattia&#xD;Holgate, Stephen&#xD;Jeebhay, Mohamed&#xD;Nadeau, Kari&#xD;Papadopoulos, Nikolaos&#xD;Quirce, Santiago&#xD;Sastre, Joaquin&#xD;Traidl-Hoffmann, Claudia&#xD;Walusiak-Skorupa, Jolanta&#xD;Salazar, Josefina&#xD;Sousa-Pinto, Bernardo&#xD;Colom, Miquel&#xD;Fiol-deRoque, Maria A&#xD;Gorreto Lopez, Lucia&#xD;Malih, Narges&#xD;Moro, Laura&#xD;Pardo, Marina Garcia&#xD;Pazo, Patricia Garcia&#xD;Campos, Rocio Zamanillo&#xD;Saletti-Cuesta, L&#xD;Akdis, Mubeccel&#xD;Alonso-Coello, Pablo&#xD;Jutel, Marek&#xD;Akdis, Cezmi A&#xD;eng&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2346-2365. doi: 10.1111/all.16151. Epub 2024 May 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38783343</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16151</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2526</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2526</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zubeldia-Varela, E.</style></author><author><style face="normal" font="default" size="100%">Blanco-Perez, F.</style></author><author><style face="normal" font="default" size="100%">Barker-Tejeda, T. C.</style></author><author><style face="normal" font="default" size="100%">Rojo, D.</style></author><author><style face="normal" font="default" size="100%">Villasenor, A.</style></author><author><style face="normal" font="default" size="100%">Islam, J.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Menendez, I.</style></author><author><style face="normal" font="default" size="100%">Laino, J.</style></author><author><style face="normal" font="default" size="100%">Krause, M.</style></author><author><style face="normal" font="default" size="100%">Steigerwald, H.</style></author><author><style face="normal" font="default" size="100%">Martella, M.</style></author><author><style face="normal" font="default" size="100%">Quintanilla-Martinez, L.</style></author><author><style face="normal" font="default" size="100%">Yu, P.</style></author><author><style face="normal" font="default" size="100%">Barbas, C.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author><author><style face="normal" font="default" size="100%">Nochi, T.</style></author><author><style face="normal" font="default" size="100%">Barber, D.</style></author><author><style face="normal" font="default" size="100%">Toda, M.</style></author><author><style face="normal" font="default" size="100%">Perez-Gordo, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Applied Molecular Medicine (IMMA), Department of Basic Medical Sciences, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Centre for Metabolomics and Bioanalysis (CEMBIO), Department of Chemistry and Biochemistry, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Molecular Allergology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.&#xD;Laboratory of Animal Functional Morphology, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan.&#xD;Cluster of Excellence iFIT (EXC 2180) &apos;Image Guided and Functionally Instructed Tumor Therapies&apos;, Tubingen, Germany.&#xD;Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tuebingen, Eberhard Karls University, Tubingen, Germany.&#xD;Institute for Immunology, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Laboratory of Food and Biomolecular Science, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The impact of high-IgE levels on metabolome and microbiome in experimental allergic enteritis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3430-3447</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Metabolome</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Enteritis/metabolism/etiology/microbiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Food Hypersensitivity/metabolism/immunology/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">murine model</style></keyword><keyword><style face="normal" font="default" size="100%">J. Allergy Clin Immunol, non-financial support from European Academy of Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">and Clinical Immunology.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38932655</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The pathological mechanism of the gastrointestinal forms of food allergies is less understood in comparison to other clinical phenotypes, such as asthma and anaphylaxis Importantly, high-IgE levels are a poor prognostic factor in gastrointestinal allergies. METHODS: This study investigated how high-IgE levels influence the development of intestinal inflammation and the metabolome in allergic enteritis (AE), using IgE knock-in (IgEki) mice expressing high levels of IgE. In addition, correlation of the altered metabolome with gut microbiome was analysed. RESULTS: Ovalbumin-sensitized and egg-white diet-fed (OVA/EW) BALB/c WT mice developed moderate AE, whereas OVA/EW IgEki mice induced more aggravated intestinal inflammation with enhanced eosinophil accumulation. Untargeted metabolomics detected the increased levels of N-tau-methylhistamine and 2,3-butanediol, and reduced levels of butyric acid in faeces and/or sera of OVA/EW IgEki mice, which was accompanied with reduced Clostridium and increased Lactobacillus at the genus level. Non-sensitized and egg-white diet-fed (NC/EW) WT mice did not exhibit any signs of AE, whereas NC/EW IgEki mice developed marginal degrees of AE. Compared to NC/EW WT mice, enhanced levels of lysophospholipids, sphinganine and sphingosine were detected in serum and faecal samples of NC/EW IgEki mice. In addition, several associations of altered metabolome with gut microbiome-for example Akkermansia with lysophosphatidylserine-were detected. CONCLUSIONS: Our results suggest that high-IgE levels alter intestinal and systemic levels of endogenous and microbiota-associated metabolites in experimental AE. This study contributes to deepening the knowledge of molecular mechanisms for the development of AE and provides clues to advance diagnostic and therapeutic strategies of allergic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Zubeldia-Varela, Elisa&#xD;Blanco-Perez, Frank&#xD;Barker-Tejeda, Tomas Clive&#xD;Rojo, David&#xD;Villasenor, Alma&#xD;Islam, Jahidul&#xD;Gonzalez-Menendez, Irene&#xD;Laino, Jonathan&#xD;Krause, Maren&#xD;Steigerwald, Hanna&#xD;Martella, Manuela&#xD;Quintanilla-Martinez, Leticia&#xD;Yu, Philipp&#xD;Barbas, Coral&#xD;Vieths, Stefan&#xD;Nochi, Tomonori&#xD;Barber, Domingo&#xD;Toda, Masako&#xD;Perez-Gordo, Marina&#xD;eng&#xD;Deutscher Akademischer Austausch Dienst (DAAD)/&#xD;(RD21/0002/0008)/FEDER &apos;Investing in your future&apos; for the thematic network and co-operative research centres RICORS &apos;Red de Enfermedades Inflamatorias (REI)&apos;/&#xD;Japan Society for the Promotion of Science (JSPS)/&#xD;PI19/00044/Instituto de Salud Carlos III/&#xD;PI17/01087/Instituto de Salud Carlos III/&#xD;PI20/01366/Instituto de Salud Carlos III/&#xD;PID2021-122490NB-I00/European Regional Development Fund/&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3430-3447. doi: 10.1111/all.16202. Epub 2024 Jun 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38932655</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657046</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16202</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2496</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2496</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Musiol, S.</style></author><author><style face="normal" font="default" size="100%">Harris, C. P.</style></author><author><style face="normal" font="default" size="100%">Gschwendtner, S.</style></author><author><style face="normal" font="default" size="100%">Burrell, A.</style></author><author><style face="normal" font="default" size="100%">Amar, Y.</style></author><author><style face="normal" font="default" size="100%">Schnautz, B.</style></author><author><style face="normal" font="default" size="100%">Renisch, D.</style></author><author><style face="normal" font="default" size="100%">Braun, S. C.</style></author><author><style face="normal" font="default" size="100%">Haak, S.</style></author><author><style face="normal" font="default" size="100%">Schloter, M.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Zielinski, C. E.</style></author><author><style face="normal" font="default" size="100%">Alessandrini, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Allergy &amp; Environment (ZAUM), Technical University of Munich (TUM) and Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Member of the German Center of Lung Research (DZL), Munich, Germany.&#xD;Institute of Epidemiology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Dr. von Hauner Children&apos;s Hospital, University Hospital, LMU of Munich, Munich, Germany.&#xD;Research Unit for Comparative Microbiome Analysis, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Department of Infection Immunology, Leibniz Institute for Natural Product Research &amp; Infection Biology, Hans-Knoll-Institute, Jena, Germany.&#xD;Institute of Microbiology, Faculty of Biological Sciences, Friedrich Schiller University, Jena, Germany.&#xD;Department of Dermatology and Allergy, School of Medicine, Technical University of Munich (TUM), Munich, Germany.&#xD;Department of Chemistry - TRIGA site, Johannes Gutenberg University Mainz, Mainz, Germany.&#xD;Chair of Epidemiology, Faculty of Medicine, LMU of Munich, Munich, Germany.&#xD;Center for Translational Cancer Research &amp; Institute of Virology, Technical University of Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The impact of high-salt diet on asthma in humans and mice: Effect on specific T-cell signatures and microbiome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1844-1857</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/05/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Sodium Chloride, Dietary/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">allergic airway inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">dietary salt</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38798015</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The rise in asthma has been linked to different environmental and lifestyle factors including dietary habits. Whether dietary salt contributes to asthma incidence, remains controversial. We aimed to investigate the impact of higher salt intake on asthma incidence in humans and to evaluate underlying mechanisms using mouse models. METHODS: Epidemiological research was conducted using the UK Biobank Resource. Data were obtained from 42,976 participants with a history of allergies. 24-h sodium excretion was estimated from spot urine, and its association with asthma incidence was assessed by Cox regression, adjusting for relevant covariates. For mechanistic studies, a mouse model of mite-induced allergic airway inflammation (AAI) fed with high-salt diet (HSD) or normal-salt chow was used to characterize disease development. The microbiome of lung and feces (as proxy for gut) was analyzed via 16S rRNA gene based metabarcoding approach. RESULTS: In humans, urinary sodium excretion was directly associated with asthma incidence among females but not among males. HSD-fed female mice displayed an aggravated AAI characterized by increased levels of total IgE, a T(H)2-T(H)17-biased inflammatory cell infiltration accompanied by upregulation of osmosensitive stress genes. HSD induced distinct changes in serum short chain fatty acids and in both gut and lung microbiome, with a lower Bacteroidetes to Firmicutes ratio and decreased Lactobacillus relative abundance in the gut, and enriched members of Gammaproteobacteria in the lung. CONCLUSIONS: High dietary salt consumption correlates with asthma incidence in female adults with a history of allergies. Female mice revealed HSD-induced T-cell lung profiles accompanied by alterations of gut and lung microbiome.</style></abstract><notes><style face="normal" font="default" size="100%">Musiol, Stephanie&#xD;Harris, Carla P&#xD;Gschwendtner, Silvia&#xD;Burrell, Amy&#xD;Amar, Yacine&#xD;Schnautz, Benjamin&#xD;Renisch, Dennis&#xD;Braun, Sonja C&#xD;Haak, Stefan&#xD;Schloter, Michael&#xD;Schmidt-Weber, Carsten B&#xD;Zielinski, Christina E&#xD;Alessandrini, Francesca&#xD;eng&#xD;Welsh Government/&#xD;NIHR/&#xD;Helmholtz Munich: intramural funding (FA)/&#xD;SFB1054, FungiNet TR124, Excellence Cluster Balance of the Microverse (CEZ)/&#xD;BHF_/British Heart Foundation/United Kingdom&#xD;CRUK_/Cancer Research UK/United Kingdom&#xD;DUK_/Diabetes UK/United Kingdom&#xD;WT_/Wellcome Trust/United Kingdom&#xD;MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1844-1857. doi: 10.1111/all.16148. Epub 2024 May 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38798015</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16148</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2406</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2406</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Canelo-Aybar, C.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Biagioni, B.</style></author><author><style face="normal" font="default" size="100%">Chung, F.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">De Las Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Dominguez-Ortega, J.</style></author><author><style face="normal" font="default" size="100%">Galan, C.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Holgate, S.</style></author><author><style face="normal" font="default" size="100%">Jeebhay, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Salazar, J.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Tanta, L. Y.</style></author><author><style face="normal" font="default" size="100%">Cantero, Y.</style></author><author><style face="normal" font="default" size="100%">Montesinos-Guevara, C.</style></author><author><style face="normal" font="default" size="100%">Song, Y.</style></author><author><style face="normal" font="default" size="100%">Alvarado-Gamarra, G.</style></author><author><style face="normal" font="default" size="100%">Sola, I.</style></author><author><style face="normal" font="default" size="100%">Alonso-Coello, P.</style></author><author><style face="normal" font="default" size="100%">Nieto-Gutierrez, W.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain.&#xD;Centro Cochrane Iberoamericano, Sant Antoni Maria Claret, Barcelona, Spain.&#xD;Institute Desbrest of Epidemiology and Public Health, University of Montpellier and INSERM, Montpellier, France.&#xD;Centre of Bioclimatology, University of Florence, Florence, Italy.&#xD;Allergy and Clinical Immunology Unit, San Giovanni di Dio Hospital, Florence, Italy.&#xD;Imperial College, London, UK.&#xD;Respiratory Disease Department, Hospital Cardarelli, Naples, Italy.&#xD;Medical School of Respiratory Allergy, University of Naples Federico II, Naples, Italy.&#xD;Department of Ecology, School of Biology, Faculty of Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.&#xD;Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.&#xD;Department of Botany, Ecology and Plant Physiology, International Campus of Excellence on Agrifood (ceiA3), University of Cordoba, Cordoba, Spain.&#xD;Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Occupational Medicine Division and Centre for Environmental &amp; Occupational Health Research, University of Cape Town, Cape Town, South Africa.&#xD;Department of Environmental Health, Center for Climate, Health, and the Global Environment, Climate and Population Studies, Harvard T.H. Chan School of Public Health, Boston, USA.&#xD;Allergy and Clinical Immunology Unit, Second Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;University of Manchester, Manchester, UK.&#xD;Allergy Service, Fundacion Jimenez Diaz, Faculty of Medicine Universidad Autonoma de Madrid and CIBERES, Instituto Carlos III, Ministry of Science and Innovation, Madrid, Spain.&#xD;Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Center Munich -German Research Center for Environmental Health, Augsburg, Germany.&#xD;Christine Kuhne Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Centro de Investigacion en Salud Publica y Epidemiologia Clinica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador.&#xD;Centro de Investigacion Biomedica en Red de Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.&#xD;Department of Clinical Immunology, Wroclaw Medical University, and ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The impact of indoor pollution on asthma-related outcomes: A systematic review for the EAACI guidelines on environmental science for allergic diseases and asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1761-1788</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/02/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution, Indoor/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Volatile Organic Compounds/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/etiology/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Pesticides/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Grade</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">guideline</style></keyword><keyword><style face="normal" font="default" size="100%">indoor pollution</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38366695</style></accession-num><abstract><style face="normal" font="default" size="100%">Systematic review using GRADE of the impact of exposure to volatile organic compounds (VOCs), cleaning agents, mould/damp, pesticides on the risk of (i) new-onset asthma (incidence) and (ii) adverse asthma-related outcomes (impact). MEDLINE, EMBASE and Web of Science were searched for indoor pollutant exposure studies reporting on new-onset asthma and critical and important asthma-related outcomes. Ninety four studies were included: 11 for VOCs (7 for incidenceand 4 for impact), 25 for cleaning agents (7 for incidenceand 8 for impact), 48 for damp/mould (26 for incidence and 22 for impact) and 10 for pesticides (8 for incidence and 2 for impact). Exposure to damp/mould increases the risk of new-onset wheeze (moderate certainty evidence). Exposure to cleaning agents may be associated with a higher risk of new-onset asthma and with asthma severity (low level of certainty). Exposure to pesticides and VOCs may increase the risk of new-onset asthma (very low certainty evidence). The impact on asthma-related outcomes of all major indoor pollutants is uncertain. As the level of certainty is low or very low for most of the available evidence on the impact of indoor pollutants on asthma-related outcomes more rigorous research in the field is warranted.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Canelo-Aybar, Carlos&#xD;Annesi-Maesano, Isabella&#xD;Cecchi, Lorenzo&#xD;Biagioni, Benedetta&#xD;Chung, Fan&#xD;D&apos;Amato, Gennaro&#xD;Damialis, Athanasios&#xD;Del Giacco, Stefano&#xD;De Las Vecillas, Leticia&#xD;Dominguez-Ortega, Javier&#xD;Galan, Carmen&#xD;Gilles, Stefanie&#xD;Giovannini, Mattia&#xD;Holgate, Stephen&#xD;Jeebhay, Mohamed&#xD;Nadeau, Kari&#xD;Papadopoulos, Nikolaos&#xD;Quirce, Santiago&#xD;Sastre, Joaquin&#xD;Traidl-Hoffmann, Claudia&#xD;Walusiak-Skorupa, Jolanta&#xD;Sousa-Pinto, Bernardo&#xD;Salazar, Josefina&#xD;Rodriguez-Tanta, L Yesenia&#xD;Cantero, Yahveth&#xD;Montesinos-Guevara, Camila&#xD;Song, Yang&#xD;Alvarado-Gamarra, Giancarlo&#xD;Sola, Ivan&#xD;Alonso-Coello, Pablo&#xD;Nieto-Gutierrez, Wendy&#xD;Jutel, Marek&#xD;Akdis, Cezmi A&#xD;eng&#xD;MR/T010371/1/MRC_/Medical Research Council/United Kingdom&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1761-1788. doi: 10.1111/all.16051. Epub 2024 Feb 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38366695</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16051</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1252</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1252</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lumry, W. R.</style></author><author><style face="normal" font="default" size="100%">Weller, K.</style></author><author><style face="normal" font="default" size="100%">Magerl, M.</style></author><author><style face="normal" font="default" size="100%">Banerji, A.</style></author><author><style face="normal" font="default" size="100%">Longhurst, H. J.</style></author><author><style face="normal" font="default" size="100%">Riedl, M. A.</style></author><author><style face="normal" font="default" size="100%">Lewis, H. B.</style></author><author><style face="normal" font="default" size="100%">Lu, P.</style></author><author><style face="normal" font="default" size="100%">Devercelli, G.</style></author><author><style face="normal" font="default" size="100%">Jain, G.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Help Study Investigators</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Asthma Research Associates Research Center, Dallas, TX, USA.&#xD;Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.&#xD;Addenbrooke&apos;s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, and University College London Hospitals, London, UK.&#xD;Division of Rheumatology, Allergy &amp; Immunology, University of California San Diego, La Jolla, CA, USA.&#xD;ICON plc, London, UK.&#xD;Takeda Pharmaceutical Company Limited, Lexington, MA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1188-1198</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/12/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">AE-QoL</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">lanadelumab</style></keyword><keyword><style face="normal" font="default" size="100%">long-term prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">has received research grants from BioCryst, CSL Behring, Ionis, and Takeda,</style></keyword><keyword><style face="normal" font="default" size="100%">consultant fees from BioCryst, CSL Behring, Fresenius Kabi, Pharming, and Takeda,</style></keyword><keyword><style face="normal" font="default" size="100%">and payments for lectures from CSL Behring, Pharming, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and is a</style></keyword><keyword><style face="normal" font="default" size="100%">medical advisory board member of the US Hereditary Angioedema Association. K.</style></keyword><keyword><style face="normal" font="default" size="100%">Weller has received research grant support and/or honoraria for educational</style></keyword><keyword><style face="normal" font="default" size="100%">lectures and/or consultant fees from BioCryst, CSL Behring, Moxie, and Takeda. M.</style></keyword><keyword><style face="normal" font="default" size="100%">Magerl has received research grant support and/or speaker/consultancy fees from</style></keyword><keyword><style face="normal" font="default" size="100%">BioCryst, CSL Behring, KalVista, Octapharma, Pharming, and Takeda. A. Banerji has</style></keyword><keyword><style face="normal" font="default" size="100%">received institutional research/study support from BioCryst and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and/or</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria for consulting from Alnylam, BioCryst, CSL Behring, KalVista, Pharming,</style></keyword><keyword><style face="normal" font="default" size="100%">Pharvaris, and Takeda, and is a medical advisory board member of the US</style></keyword><keyword><style face="normal" font="default" size="100%">Hereditary Angioedema Association. H. J. Longhurst has received research grant</style></keyword><keyword><style face="normal" font="default" size="100%">support and/or speaker/consultancy fees from Adverum, BioCryst, CSL Behring,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Octapharma, Pharming, Pharvaris, and Takeda. M. A. Riedl has</style></keyword><keyword><style face="normal" font="default" size="100%">received research grants from BioCryst, CSL Behring, Ionis, Pharming, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Adverum, Attune, BioCryst, CSL Behring, Ionis, KalVista,</style></keyword><keyword><style face="normal" font="default" size="100%">Pharming, Pharvaris, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and speaker honoraria from CSL Behring,</style></keyword><keyword><style face="normal" font="default" size="100%">Pharming, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and is a medical advisory board member of the US Hereditary</style></keyword><keyword><style face="normal" font="default" size="100%">Angioedema Association. H. B. Lewis is a full-time employee of ICON plc. P. Lu</style></keyword><keyword><style face="normal" font="default" size="100%">was a full-time employee of Takeda at the time of the study and holds stock/stock</style></keyword><keyword><style face="normal" font="default" size="100%">options in Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">her current affiliation is Pharvaris B.V. G. Devercelli and G.</style></keyword><keyword><style face="normal" font="default" size="100%">Jain are full-time employees of and hold stock/stock options in Takeda. M. Maurer</style></keyword><keyword><style face="normal" font="default" size="100%">is or recently was a speaker and/or advisor for BioCryst, CSL Behring, KalVista,</style></keyword><keyword><style face="normal" font="default" size="100%">Moxie, Pharming, Pharvaris, and Takeda, and has received research funding from</style></keyword><keyword><style face="normal" font="default" size="100%">BioCryst, CSL Behring, Moxie, Pharming, and Takeda.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33258114</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: An objective of the phase 3 HELP Study was to investigate the effect of lanadelumab on health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE). METHODS: Patients with HAE-1/2 received either lanadelumab 150 mg every 4 weeks (q4wks; n = 28), 300 mg q4wks (n = 29), 300 mg every 2 weeks (q2wks; n = 27), or placebo (n = 41) for 26 weeks (days 0-182). The Angioedema Quality of Life Questionnaire (AE-QoL) was administered monthly, consisting of four domain (functioning, fatigue/mood, fears/shame, nutrition) and total scores. The generic EQ-5D-5L questionnaire was administered on days 0, 98, and 182. Comparisons were made between placebo and (a) all lanadelumab-treated patients and (b) individual lanadelumab groups for changes in scores (day 0-182) and proportions achieving the minimal clinically important difference (MCID, -6) in AE-QoL total score. RESULTS: Compared with the placebo group, the lanadelumab total group demonstrated significantly greater improvements in AE-QoL total and domain scores (mean change, -13.0 to -29.3; p &lt; 0.05 for all); the largest improvement was in functioning. A significantly greater proportion of the lanadelumab total group achieved the MCID (70% vs 37%; p = 0.001). The lanadelumab 300 mg q2wks group had the highest proportion (81%; p = 0.001) and was 7.2 times more likely to achieve the MCID than the placebo group. Mean EQ-5D-5L scores at day 0 were high in all groups, indicating low impairment, with no significant changes at day 182. CONCLUSION: Patients with HAE-1/2 experienced significant and clinically meaningful improvements in HRQoL measured by AE-QoL following lanadelumab treatment in the HELP Study.</style></abstract><notes><style face="normal" font="default" size="100%">Lumry, William R&#xD;Weller, Karsten&#xD;Magerl, Markus&#xD;Banerji, Aleena&#xD;Longhurst, Hilary J&#xD;Riedl, Marc A&#xD;Lewis, Hannah B&#xD;Lu, Peng&#xD;Devercelli, Giovanna&#xD;Jain, Gagan&#xD;Maurer, Marcus&#xD;eng&#xD;Clinical Trial, Phase III&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1188-1198. doi: 10.1111/all.14680. Epub 2020 Dec 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33258114</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8247292</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14680</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>363</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">363</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kothari, A.</style></author><author><style face="normal" font="default" size="100%">Hirschmugl, B.</style></author><author><style face="normal" font="default" size="100%">Lee, J. S.</style></author><author><style face="normal" font="default" size="100%">Pfaller, B.</style></author><author><style face="normal" font="default" size="100%">Schmidthaler, K.</style></author><author><style face="normal" font="default" size="100%">Szepfalusi, Z.</style></author><author><style face="normal" font="default" size="100%">Wadsack, C.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria.&#xD;BioTechMed-Graz, Graz, Austria.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Department of Internal Medicine 1, Karl Landsteiner Institute for Nephrology St. Polten, University Hospital St. Polten, St. Polten, Austria.&#xD;Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatric and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St Polten, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The impact of maternal-fetal omalizumab transfer on peanut-specific responses in an ex vivo placental perfusion model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3684-3686</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/08/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Placenta</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Perfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Maternal-Fetal Exchange</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35924691</style></accession-num><notes><style face="normal" font="default" size="100%">Kothari, Akash&#xD;Hirschmugl, Birgit&#xD;Lee, Jean-Soo&#xD;Pfaller, Birgit&#xD;Schmidthaler, Klara&#xD;Szepfalusi, Zsolt&#xD;Wadsack, Christian&#xD;Eiwegger, Thomas&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3684-3686. doi: 10.1111/all.15468. Epub 2022 Aug 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35924691</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087130 roles for Nutricia/Danone, Aimmune, and Sanofi. TE reports to act as local PI for company-sponsored trials by DBV and sub-investigator for Regeneron, holds grants from Innovation Fund Denmark, CIHR outside the submitted work. He is Co-Investigator or scientific lead in three investigator-initiated oral immunotherapy trials supported by the Food Allergy and Anaphylaxis Program SickKids and serves as an associate editor for Allergy. He/his laboratory received unconditional/in-kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK. He holds advisory board roles for ALK, Nutricia/Danone, and Aimmune.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15468</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2418</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2418</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Canelo-Aybar, C.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Rigau, D.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Tanta, L. Y.</style></author><author><style face="normal" font="default" size="100%">Nieto-Gutierrez, W.</style></author><author><style face="normal" font="default" size="100%">Song, Y.</style></author><author><style face="normal" font="default" size="100%">Cantero-Fortiz, Y.</style></author><author><style face="normal" font="default" size="100%">Roque, M.</style></author><author><style face="normal" font="default" size="100%">Vasquez, J. C.</style></author><author><style face="normal" font="default" size="100%">Sola, I.</style></author><author><style face="normal" font="default" size="100%">Biagioni, B.</style></author><author><style face="normal" font="default" size="100%">Chung, F.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Vecillas, L. L.</style></author><author><style face="normal" font="default" size="100%">Dominguez-Ortega, J.</style></author><author><style face="normal" font="default" size="100%">Galan, C.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Holgate, S.</style></author><author><style face="normal" font="default" size="100%">Jeebhay, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Alonso-Coello, P.</style></author><author><style face="normal" font="default" size="100%">Salazar, J.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.&#xD;Institute Desbrest of Epidemiology and Public Health, University of Montpellier and INSERM, Montpellier, France.&#xD;Centre of Bioclimatology, University of Florence, Florence, Italy.&#xD;Centro de Investigacion Biomedica en Red de Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.&#xD;Allergy and Clinical Immunology Unit San Giovanni di Dio Hospital, Florence, Italy.&#xD;Imperial College, London, UK.&#xD;Medical School of Respiratory Diseases, University of Naples Federico II, Naples, Italy.&#xD;Department of Ecology, School of Biology, Faculty of Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.&#xD;Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.&#xD;Department of Botany, Ecology and Plant Physiology, International Campus of Excellence on Agrifood (ceiA3), University of Cordoba, Cordoba, Spain.&#xD;Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Occupational Medicine Division and Centre for Environmental &amp; Occupational Health Research, University of Cape Town, Rondebosch, South Africa.&#xD;John Rock Professor of Climate and Population Studies; Chair, Department of Environmental Health, Interim Director, Center for Climate, Health, and The Global Environment, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Allergy and Clinical Immunology Unit, Second Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK.&#xD;Instituto Carlos III, Ministry of Science and Innovation, Allergy Service, Fundacion Jimenez Diaz, Faculty of Medicine Universidad Autonoma de Madrid and CIBERES, Madrid, Spain.&#xD;Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Center Munich-German Research Center for Environmental Health, Augsburg, Germany.&#xD;Christine Kuhne Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Department of Clinical Immunology, ALL-MED Medical Research Institute, Wroclaw Medical University, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The impact of outdoor pollution and extreme temperatures on asthma-related outcomes: A systematic review for the EAACI guidelines on environmental science for allergic diseases and asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1725-1760</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/02/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/prevention &amp; control/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Air Pollutants/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/etiology/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Grade</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">extreme temperatures</style></keyword><keyword><style face="normal" font="default" size="100%">outdoor pollution</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38311978</style></accession-num><abstract><style face="normal" font="default" size="100%">Air pollution is one of the biggest environmental threats for asthma. Its impact is augmented by climate change. To inform the recommendations of the EAACI Guidelines on the environmental science for allergic diseases and asthma, a systematic review (SR) evaluated the impact on asthma-related outcomes of short-term exposure to outdoor air pollutants (PM2.5, PM10, NO(2), SO(2), O(3), and CO), heavy traffic, outdoor pesticides, and extreme temperatures. Additionally, the SR evaluated the impact of the efficacy of interventions reducing outdoor pollutants. The risk of bias was assessed using ROBINS-E tools and the certainty of the evidence by using GRADE. Short-term exposure to PM2.5, PM10, and NO(2) probably increases the risk of asthma-related hospital admissions (HA) and emergency department (ED) visits (moderate certainty evidence). Exposure to heavy traffic may increase HA and deteriorate asthma control (low certainty evidence). Interventions reducing outdoor pollutants may reduce asthma exacerbations (low to very low certainty evidence). Exposure to fumigants may increase the risk of new-onset asthma in agricultural workers, while exposure to 1,3-dichloropropene may increase the risk of asthma-related ED visits (low certainty evidence). Heatwaves and cold spells may increase the risk of asthma-related ED visits and HA and asthma mortality (low certainty evidence).</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Canelo-Aybar, Carlos&#xD;Annesi-Maesano, Isabella&#xD;Cecchi, Lorenzo&#xD;Rigau, David&#xD;Rodriguez-Tanta, L Yesenia&#xD;Nieto-Gutierrez, Wendy&#xD;Song, Yang&#xD;Cantero-Fortiz, Yahveth&#xD;Roque, Marta&#xD;Vasquez, Juan Carlos&#xD;Sola, Ivan&#xD;Biagioni, Benedetta&#xD;Chung, Fan&#xD;D&apos;Amato, Gennaro&#xD;Damialis, Athanasios&#xD;Del Giacco, Stefano&#xD;Vecillas, Leticia de Las&#xD;Dominguez-Ortega, Javier&#xD;Galan, Carmen&#xD;Gilles, Stefanie&#xD;Giovannini, Mattia&#xD;Holgate, Stephen&#xD;Jeebhay, Mohamed&#xD;Nadeau, Kari&#xD;Papadopoulos, Nikolaos&#xD;Quirce, Santiago&#xD;Sastre, Joaquin&#xD;Traidl-Hoffmann, Claudia&#xD;Walusiak-Skorupa, Jolanta&#xD;Sousa-Pinto, Bernardo&#xD;Alonso-Coello, Pablo&#xD;Salazar, Josefina&#xD;Jutel, Marek&#xD;Akdis, Cezmi A&#xD;eng&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1725-1760. doi: 10.1111/all.16041. Epub 2024 Feb 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38311978</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16041</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2992</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2992</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Balbin-Ramon, G. J.</style></author><author><style face="normal" font="default" size="100%">Saenz, F. K. F.</style></author><author><style face="normal" font="default" size="100%">Sola-Arnau, I.</style></author><author><style face="normal" font="default" size="100%">Alonso-Coello, P.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Lauerma, A.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Renz, H.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Vercelli, D.</style></author><author><style face="normal" font="default" size="100%">Canelo-Aybar, C.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Iberoamerican Cochrane Centre, Barcelona, Spain.&#xD;Jose Casimiro Ulloa Emergency Hospital, Lima, Peru.&#xD;Institut de Recerca Sant Pau (IIB Sant Pau), Barcelona, Spain.&#xD;CIBER de Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland.&#xD;Terrestrial Ecology and Climate Change, Department of Ecology, School of Biology, Faculty of Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;John Rock Professor of Climate and Population Studies, Department of Environmental Health, Center for Climate, Health, and the Global Environment, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;The Interuniversity Messerli Research Institute, University of Veterinary Medicine and Medical University Vienna, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.&#xD;Institute of Laboratory Medicine, German Center for Lung Research (DZL) and the Lung Centre of the Universities of Giessen and Marburg (UGMLC), Philipps University Marburg, Marburg, Germany.&#xD;Kilimanjaro Christian Medical University College (KCMUCo), Moshi, Tanzania.&#xD;Tongji Medical School, Shanghai, China.&#xD;Child Life and Health, Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.&#xD;Department of Cellular and Molecular Medicine, University of Arizona, Tucson, Arizona, USA.&#xD;Asthma and Airway Disease Research Center, University of Arizona, Tucson, Arizona, USA.&#xD;BIO5 Institute, University of Arizona, Tucson, Arizona, USA.&#xD;Arizona Center for the Biology of Complex Diseases, University of Arizona, Tucson, Arizona, USA.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of Residential Greeness Exposure on the Development of Allergic Diseases and Asthma and on Asthma Control-A Systematic Review for the EAACI Guidelines of Environmental Science for Allergic Diseases and Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3027-3042</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/etiology/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Residence Characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Grade</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">guideline</style></keyword><keyword><style face="normal" font="default" size="100%">residential greeness exposure</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40632014</style></accession-num><abstract><style face="normal" font="default" size="100%">The role of residential greenness exposure (RGE) in prevention and control of allergic diseases remains controversial. This systematic review evaluated the association between RGE and the risk of developing asthma, allergic rhinitis (AR), food allergy, atopic dermatitis (AD), and asthma control. MEDLINE and EMBASE searches retrieved 17 cohort and case-control longitudinal studies (12 for asthma, 6 AR, 1 food allergy, 1 ad). Risk of bias was assessed with ROBINS-E, and certainty of evidence with GRADE. Data were meta-analyzed using adjusted odds ratios (aORs) with random-effects models. For &quot;ever asthma&quot; and &quot;ever AR&quot; a non-significant protective trend of RGE was observed (aOR 0.92, 95% CI 0.72-1.18; aOR 0.61; 95% CI 0.24-1.55). For &quot;current asthma&quot; RGE was associated with increased risk (aOR 1.17, 95% CI 1.04-1.33), with no clear association for &quot;current AR&quot; (aOR 1.03; 95% CI 0.80-1.32). Prenatal RGE reduced the risk of &quot;ever asthma&quot; (aOR 0.94, 95% CI 0.93-0.950) and AD (aOR 0.996, 95% CI 0.993-0.999). RGE increased the risk for peanut (aOR 1.78, 95% CI 1.13-2.82) and egg allergy (aOR 1.38, 95% CI [1.05-1.82]). Reduced RGE decreased asthma control (OR: 2.662, 95% CI [1.043-6.799]). Potential benefits or potential harms of RGE should be judged in a context-specific manner.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Balbin-Ramon, Graciela J&#xD;Saenz, Fiorella Karina Fernandez&#xD;Sola-Arnau, Ivan&#xD;Alonso-Coello, Pablo&#xD;Haahtela, Tari&#xD;Traidl-Hoffmann, Claudia&#xD;O&apos;Mahony, Liam&#xD;Damialis, Athanasios&#xD;Lauerma, Antti&#xD;Nadeau, Kari C&#xD;Pali-Scholl, Isabella&#xD;Palomares, Oscar&#xD;Renz, Harald&#xD;Schwarze, Jurgen&#xD;Vercelli, Donata&#xD;Canelo-Aybar, Carlos&#xD;Jutel, Marek&#xD;Akdis, Cezmi A&#xD;eng&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3027-3042. doi: 10.1111/all.16653. Epub 2025 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40632014</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16653</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2898</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2898</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Salazar, J.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Tanta, Y.</style></author><author><style face="normal" font="default" size="100%">Saenz, F. K. F.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Renz, H.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Sousa Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Urrutia-Pereira, M.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Vercelli, D.</style></author><author><style face="normal" font="default" size="100%">Winders, T.</style></author><author><style face="normal" font="default" size="100%">Sola-Arnau, I.</style></author><author><style face="normal" font="default" size="100%">Alonso-Coello, P.</style></author><author><style face="normal" font="default" size="100%">Canelo-Aybar, C.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Iberoamerican Cochrane Centre, Barcelona, Spain.&#xD;Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Faculty of Medicine, Institute of Environmental Medicine and Integrative Health, University of Augsburg, Augsburg, Germany.&#xD;Terrestrial Ecology and Climate Change, Department of Ecology, Faculty of Sciences, School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Department of Environmental Health, John Rock Professor of Climate and Population Studies, Boston, USA.&#xD;Center for Climate, Health, and the Global Environment, Harvard T.H. Chan School of Public Health, Boston, USA.&#xD;The Interuniversity Messerli Research Institute, University of Veterinary Medicine and Medical University Vienna, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.&#xD;Institute of Laboratory Medicine, member of the German Center for Lung Research (DZL) and the Lung Centre of the Universities of Giessen and Marburg (UGMLC), Philipps University Marburg, Marburg, Germany.&#xD;Kilimanjaro Christian Medical University College (KCMUCo), Moshi, Tanzania.&#xD;Child Life and Health, Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.&#xD;MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE - Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Brazilian Association of Allergy and Immunology, Sao Paulo, Brazil.&#xD;Federal University of Pampa, Uruguaiana, Brazil.&#xD;Section of Allergy and Clinical Immunology, Children&apos;s Hospital Colorado, University of Colorado, Aurora, Colorado, USA.&#xD;Department of Cellular and Molecular Medicine, University of Arizona, Tucson, Arizona, USA.&#xD;Asthma and Airway Disease Research Center, University of Arizona, Tucson, Arizona, USA.&#xD;BIO5 Institute, University of Arizona, Tucson, Arizona, USA.&#xD;Arizona Center for the Biology of Complex Diseases, University of Arizona, Tucson, Arizona, USA.&#xD;Global Allergy and Airways Patient Platform, Vienna, Austria.&#xD;CIBER de Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.&#xD;Department of Clinical Immunology, Wroclaw Medical University, and ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Impact of Rhinovirus, Syncytial Respiratory Virus and Helminth Infection on the Risk of New-Onset Asthma and Other Allergic Conditions-A Systematic Review for the EAACI Guidelines on Environmental Science for Allergic Diseases and Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1878-1898</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/06/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Helminthiasis/complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Syncytial Virus Infections/complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/etiology/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Picornaviridae Infections/complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Grade</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">guideline</style></keyword><keyword><style face="normal" font="default" size="100%">helminths</style></keyword><keyword><style face="normal" font="default" size="100%">syncytial respiratory virus</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40495394</style></accession-num><abstract><style face="normal" font="default" size="100%">This systematic review evaluated the association between lower respiratory tract infections (LRTI) in infancy with respiratory syncytial virus (RSV), rhinovirus (RV) or infestation with helminths and the risk of developing asthma and allergic diseases. The risk of bias was assessed with ROBINS-E, and the certainty of evidence (CoE) with GRADE. Meta-analysis applied a random-effects model. RSV LRTI is likely associated with an increased risk of developing asthma by age 7 (OR 3.02, 95% CI 2.23-4.09; I(2) = 98%; moderate CoE). The impact on wheezing, atopic dermatitis (AD), and allergic rhinitis is uncertain. RV LRTI may be associated with increased risk of developing asthma (OR 8.40, 95% CI 2.56-27.55; I(2) = 43%; low CoE). The impact on wheezing and AD is uncertain. Trichuris trichiura infestation might be associated with reduced risk of new-onset wheezing (OR 0.57, 95% CI 0.35-0.94; very low CoE) or AD (HR: 0.35, 95% CI 0.18-0.67; very low CoE). The association between Ascaris lumbricoides and hookworm infestation and the risk of developing asthma or AD is uncertain. Infestation with any helminths might be associated with reduced risk of new-onset asthma by age 5 (OR: 0.60, 95% CI 0.38-0.95; very low CoE) and wheezing (OR 0.70, 95% CI 0.51-0.95; very low CoE). More high-quality studies are needed to confirm these findings.</style></abstract><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Salazar, Josefina&#xD;Rodriguez-Tanta, Yesenia&#xD;Saenz, Fiorella Karina Fernandez&#xD;Haahtela, Tari&#xD;Traidl-Hoffmann, Claudia&#xD;Damialis, Athanasios&#xD;Vecillas, Letizia&#xD;Giovannini, Mattia&#xD;Nadeau, Kari C&#xD;Pali-Scholl, Isabella&#xD;Palomares, Oscar&#xD;Renz, Harald&#xD;Schwarze, Jurgen&#xD;Sousa Pinto, Bernardo&#xD;Urrutia-Pereira, Marilyn&#xD;Venter, Carina&#xD;Vercelli, Donata&#xD;Winders, Tonia&#xD;Sola-Arnau, Ivan&#xD;Alonso-Coello, Pablo&#xD;Canelo-Aybar, Carlos&#xD;Jutel, Marek&#xD;Akdis, Cezmi A&#xD;eng&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1878-1898. doi: 10.1111/all.16611. Epub 2025 Jun 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40495394</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16611</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>452</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">452</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Owora, A. H.</style></author><author><style face="normal" font="default" size="100%">Li, R.</style></author><author><style face="normal" font="default" size="100%">Tepper, R. S.</style></author><author><style face="normal" font="default" size="100%">Ramsey, C. D.</style></author><author><style face="normal" font="default" size="100%">Chan-Yeung, M.</style></author><author><style face="normal" font="default" size="100%">Watson, W. T. A.</style></author><author><style face="normal" font="default" size="100%">Becker, A. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology and Biostatistics, School of Public Health, Indiana University Bloomington, Bloomington, Indiana, USA.&#xD;Children&apos;s Hospital Research Institute of Manitoba, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada.&#xD;Indiana University School of Medicine, Indianapolis, Indiana, USA.&#xD;Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.&#xD;Department of Medicine, University of British Columbia, Vancouver, BC, Canada.&#xD;Department of Pediatrics, Dalhousie University, Halifax, NS, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of time-varying confounders on the association between early-life allergy sensitization and the risk of current asthma: A post hoc analysis of a birth cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3141-3144</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/06/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Birth Cohort</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">allergy sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">childhood asthma</style></keyword><keyword><style face="normal" font="default" size="100%">marginal structural models</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35686384</style></accession-num><notes><style face="normal" font="default" size="100%">Owora, Arthur H&#xD;Li, Rui&#xD;Tepper, Robert S&#xD;Ramsey, Clare D&#xD;Chan-Yeung, Moira&#xD;Watson, Wade T A&#xD;Becker, Allan B&#xD;eng&#xD;K12HS026390/NH/NIH HHS/&#xD;R03 HS029088/HS/AHRQ HHS/&#xD;CIHR/Canada&#xD;K01 HL166436/HL/NHLBI NIH HHS/&#xD;K12 HS026390/HS/AHRQ HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3141-3144. doi: 10.1111/all.15403. Epub 2022 Jun 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35686384</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9796543</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15403</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>414</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">414</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Gallego, N.</style></author><author><style face="normal" font="default" size="100%">Castillo-Gonzalez, R.</style></author><author><style face="normal" font="default" size="100%">Mendez-Barbero, N.</style></author><author><style face="normal" font="default" size="100%">Lopez-Sanz, C.</style></author><author><style face="normal" font="default" size="100%">Obeso, D.</style></author><author><style face="normal" font="default" size="100%">Villasenor, A.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author><author><style face="normal" font="default" size="100%">Lopez-Melgar, B.</style></author><author><style face="normal" font="default" size="100%">Salamanca, J.</style></author><author><style face="normal" font="default" size="100%">Benedicto-Buendia, A.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Borreguero, L. J.</style></author><author><style face="normal" font="default" size="100%">Ibanez, B.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Belver, M. T.</style></author><author><style face="normal" font="default" size="100%">Vega, F.</style></author><author><style face="normal" font="default" size="100%">Blanco, C.</style></author><author><style face="normal" font="default" size="100%">Barber, D.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Madrid, F.</style></author><author><style face="normal" font="default" size="100%">de la Fuente, H.</style></author><author><style face="normal" font="default" size="100%">Martin, P.</style></author><author><style face="normal" font="default" size="100%">Esteban, V.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Vascular Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.&#xD;Department of Immunology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Universidad Autonoma de Madrid (UAM), Madrid, Spain.&#xD;Department of Pathology, Hospital 12 de Octubre, Madrid, Spain.&#xD;Vascular Research Laboratory, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD), Madrid, Spain.&#xD;CIBER de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.&#xD;Department of Basic Medical Sciences, Faculty of Medicine, Institute of Applied Molecular Medicine Nemesio Diez (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Department of Chemistry and Biochemistry, Faculty of Pharmacy, Centre for Metabolomics and Bioanalysis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Department of Cardiology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Madrid, Spain.&#xD;Myocardial Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.&#xD;Department of Cardiology, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD), Madrid, Spain.&#xD;Department of Allergy and Immunology, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma de Madrid (UAM), Madrid, Spain.&#xD;CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.&#xD;Department of Allergy, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Madrid, Spain.&#xD;Faculty of Medicine and Biomedicine, Universidad Alfonso X El Sabio, Madrid, Spain.&#xD;Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain.&#xD;Department of Medicine, McMaster Immunology Research Centre (MIRC), McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The impact of type 2 immunity and allergic diseases in atherosclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3249-3266</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Atherosclerosis/etiology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">allergic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">atherogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">atherosclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35781885</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic diseases are allergen-induced immunological disorders characterized by the development of type 2 immunity and IgE responses. The prevalence of allergic diseases has been on the rise alike cardiovascular disease (CVD), which affects arteries of different organs such as the heart, the kidney and the brain. The underlying cause of CVD is often atherosclerosis, a disease distinguished by endothelial dysfunction, fibrofatty material accumulation in the intima of the artery wall, smooth muscle cell proliferation, and Th1 inflammation. The opposed T-cell identity of allergy and atherosclerosis implies an atheroprotective role for Th2 cells by counteracting Th1 responses. Yet, the clinical association between allergic disease and CVD argues against it. Within, we review different phases of allergic pathology, basic immunological mechanisms of atherosclerosis and the clinical association between allergic diseases (particularly asthma, atopic dermatitis, allergic rhinitis and food allergy) and CVD. Then, we discuss putative atherogenic mechanisms of type 2 immunity and allergic inflammation including acute allergic reactions (IgE, IgG1, mast cells, macrophages and allergic mediators such as vasoactive components, growth factors and those derived from the complement, contact and coagulation systems) and late phase inflammation (Th2 cells, eosinophils, type 2 innate-like lymphoid cells, alarmins, IL-4, IL-5, IL-9, IL-13 and IL-17).</style></abstract><notes><style face="normal" font="default" size="100%">Fernandez-Gallego, Nieves&#xD;Castillo-Gonzalez, Raquel&#xD;Mendez-Barbero, Nerea&#xD;Lopez-Sanz, Celia&#xD;Obeso, David&#xD;Villasenor, Alma&#xD;Escribese, Maria M&#xD;Lopez-Melgar, Beatriz&#xD;Salamanca, Jorge&#xD;Benedicto-Buendia, Amparo&#xD;Jimenez-Borreguero, Luis Jesus&#xD;Ibanez, Borja&#xD;Sastre, Joaquin&#xD;Belver, Maria Teresa&#xD;Vega, Francisco&#xD;Blanco, Carlos&#xD;Barber, Domingo&#xD;Sanchez-Madrid, Francisco&#xD;de la Fuente, Hortensia&#xD;Martin, Pilar&#xD;Esteban, Vanesa&#xD;Jimenez-Saiz, Rodrigo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3249-3266. doi: 10.1111/all.15426. Epub 2022 Jul 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35781885</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15426</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3098</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3098</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cavaleiro Rufo, J.</style></author><author><style face="normal" font="default" size="100%">Paciencia, I.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Suojalehto, H.</style></author><author><style face="normal" font="default" size="100%">Zemelka-Wiacek, M.</style></author><author><style face="normal" font="default" size="100%">Trikamjee, T.</style></author><author><style face="normal" font="default" size="100%">Demir, S.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Carvalho, D.</style></author><author><style face="normal" font="default" size="100%">Backland, A.</style></author><author><style face="normal" font="default" size="100%">Lawson, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">EPIUnit-Institute of Public Health, University of Porto, Porto, Portugal.&#xD;Centre for Translational Health and Medical Biotechnology, School of Health, Polytechnic of Porto, Porto, Portugal.&#xD;Laboratory for Integrative and Translational Research in Population Health, University of Porto, Porto, Portugal.&#xD;Center for Environmental and Respiratory Health Research (CERH), Population Health, University of Oulu, Oulu, Finland.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Servico de Imunologia Basica e Clinica, Departamento de Patologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.&#xD;Desbrest Institute of Epidemiology and Public Health, Univ Montpellier, INSERM, Montpellier, France.&#xD;Division of Respiratory Medicine, Allergology, and Thoracic Oncology, University Hospital of Montpellier, Montpellier, France.&#xD;Occupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland.&#xD;Department of Clinical Immunology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.&#xD;Allergy Immunology Unit, University of Cape Town, Lung Institute, University of Cape Town, Cape Town, South Africa.&#xD;Adult Immunology and Allergy Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkiye.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, IBIMA-Plataforma BIONAND, RICORS Inflammatory Diseases, Malaga, Spain.&#xD;Public Health Research Center, NOVA University of Lisbon, Lisboa, Portugal.&#xD;Centre for Rural and Agricultural Health, University of Saskatchewan, Saskatoon, Canada.&#xD;Department of Medicine, College of Medicine, University of Saskatchewan, Saskatoon, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Impact of War on Asthma, a Systematic Review and Meta-Analysis: An EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">69-83</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/09/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Stress Disorders, Post-Traumatic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Warfare</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">exposure</style></keyword><keyword><style face="normal" font="default" size="100%">kinetic warfare</style></keyword><keyword><style face="normal" font="default" size="100%">pollution</style></keyword><keyword><style face="normal" font="default" size="100%">post-traumatic stress disorder</style></keyword><keyword><style face="normal" font="default" size="100%">trauma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40906435</style></accession-num><abstract><style face="normal" font="default" size="100%">Wartime events have been followed by an increase in asthma prevalence, which is believed to result from a combination of environmental hazards and psychological trauma. This systematic review and meta-analysis aimed to investigate this relationship by pooling available data on various wartime exposures, such as occupational, environmental, and psychological factors. MEDLINE, Scopus, and Cochrane databases were searched for articles that measure the effect of war-related exposures on asthma. Risk of bias was assessed using the Effective Public Health Practice Project tool. The retrieved effects were then used to fit meta-analytical models. A total of 48 studies, corresponding to 90 effect measures, were included. War-related post-traumatic stress disorder showed the strongest association with asthma outcomes (OR [95% CI] = 2.25 [1.04, 4.89]), followed by experiencing at least one life-threatening event (1.96 [1.18, 3.26]) and depression (1.56 [1.02, 2.37]). Although environmental exposures were also associated with an increased asthma risk in subgroup analysis (1.64 [1.32, 2.04]), this effect was mitigated when psychological variables were included in the models. The study&apos;s results show that wartime events and conflicts may increase asthma prevalence and outcomes associated with asthma. The management of asthma symptoms, lung function, and mental health seems fundamental in individuals who have experienced psychological trauma in war zones. Trial Registration: PROSPERO registration number: CRD42023444101.</style></abstract><notes><style face="normal" font="default" size="100%">Cavaleiro Rufo, Joao&#xD;Paciencia, Ines&#xD;Jutel, Marek&#xD;Moreira, Andre&#xD;Annesi-Maesano, Isabella&#xD;Suojalehto, Hille&#xD;Zemelka-Wiacek, Magdalena&#xD;Trikamjee, Thulja&#xD;Demir, Semra&#xD;Eguiluz-Gracia, Ibon&#xD;Carvalho, Daniela&#xD;Backland, Anais&#xD;Lawson, Josh&#xD;eng&#xD;EAACI 41011/European Academy of Allergy and Clinical Immunology/&#xD;2020.01350.CEECIND/Fundacao para a Ciencia e a Tecnologia/&#xD;B-0007-2023/Health Ministry of the Andalusian Regional Government/&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):69-83. doi: 10.1111/all.70038. Epub 2025 Sep 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40906435</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773692</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70038</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1650</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1650</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andersson, C. K.</style></author><author><style face="normal" font="default" size="100%">Iwasaki, J.</style></author><author><style face="normal" font="default" size="100%">Cook, J.</style></author><author><style face="normal" font="default" size="100%">Robinson, P.</style></author><author><style face="normal" font="default" size="100%">Nagakumar, P.</style></author><author><style face="normal" font="default" size="100%">Mogren, S.</style></author><author><style face="normal" font="default" size="100%">Fleming, L.</style></author><author><style face="normal" font="default" size="100%">Bush, A.</style></author><author><style face="normal" font="default" size="100%">Saglani, S.</style></author><author><style face="normal" font="default" size="100%">Lloyd, C. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College, London.&#xD;Respiratory Cell Biology, Lund University, Lund, Sweden.&#xD;Respiratory Paediatrics, the Royal Brompton and Harefield NHS Trust, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impaired airway epithelial cell wound-healing capacity is associated with airway remodelling following RSV infection in severe preschool wheeze</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3195-3207</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2020/06/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Airway Remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Sounds</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Syncytial Virus Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Rsv</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">paediatric asthma</style></keyword><keyword><style face="normal" font="default" size="100%">severe therapy-resistant asthma</style></keyword><keyword><style face="normal" font="default" size="100%">wheeze</style></keyword><keyword><style face="normal" font="default" size="100%">of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32578219</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Respiratory syncytial virus (RSV) causes exacerbations of asthma and preschool wheeze (PSW). However, the anti-viral and repair responses of the bronchial epithelium in children with severe therapy-resistant asthma (STRA) and PSW are poorly understood. METHODS: Children with STRA (age 12 [6-16] years), PSW (age 2 [1-5] years) and non-asthmatic controls (age 7 [2-14] years) underwent bronchoscopy with endobronchial brushings and biopsies. Anti-viral, wound injury responses were quantified in biopsies and primary bronchial epithelial cells (PBECs) in response to RSV, poly(I:C), house dust mite (HDM) or IL-33 using RT-qPCR, Luminex and live cell imaging. Collagen deposition and tissue expression of epithelial growth factor receptor (EGFR), IL-33 and receptor ST2 were investigated in bronchial biopsies. RESULTS: PBECs from STRA and PSW had increased TLR3 gene expression and increased secretion of anti-viral and pro-inflammatory cytokines (IFN-gamma, IL-6 and IL-13) in response to RSV compared to controls. Exposure of PBECs to concomitant TLR3 agonist poly(I:C) and HDM resulted in a significant reduction in epithelial cell proliferation in PSW compared to controls. Wound-healing was also impaired in PSW compared to controls at baseline and following IL-33 stimulation. In addition, tissue EGFR expression was significantly reduced in PSW and correlated with collagen deposition in endobronchial biopsies. CONCLUSIONS: Despite increased anti-viral responses, preschool children with severe wheeze had impaired airway epithelial proliferative responses following damage. This might be connected to the low expression of EGFR in PSW which may affect epithelial function and contribute to asthma pathogenesis.</style></abstract><notes><style face="normal" font="default" size="100%">Andersson, Cecilia K&#xD;Iwasaki, Jua&#xD;Cook, James&#xD;Robinson, Polly&#xD;Nagakumar, Prasad&#xD;Mogren, Sofia&#xD;Fleming, Louise&#xD;Bush, Andrew&#xD;Saglani, Sejal&#xD;Lloyd, Clare M&#xD;eng&#xD;107059/WT_/Wellcome Trust/United Kingdom&#xD;107059/15/Z/WT_/Wellcome Trust/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Dec;75(12):3195-3207. doi: 10.1111/all.14466. Epub 2020 Jul 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32578219</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7613656</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14466</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2653</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2653</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lai, C. L.</style></author><author><style face="normal" font="default" size="100%">Santner-Nanan, B.</style></author><author><style face="normal" font="default" size="100%">Maltese, P. J.</style></author><author><style face="normal" font="default" size="100%">Ong, C. K. S.</style></author><author><style face="normal" font="default" size="100%">Palmer, D. J.</style></author><author><style face="normal" font="default" size="100%">Campbell, D. E.</style></author><author><style face="normal" font="default" size="100%">Makrides, M.</style></author><author><style face="normal" font="default" size="100%">Gold, M.</style></author><author><style face="normal" font="default" size="100%">Nanan, R.</style></author><author><style face="normal" font="default" size="100%">Prescott, S. L.</style></author><author><style face="normal" font="default" size="100%">Hsu, P. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Immunology, The Children&apos;s Hospital at Westmead, Westmead, New South Wales, Australia.&#xD;Kids Research, The Children&apos;s Hospital at Westmead, Westmead, New South Wales, Australia.&#xD;Discipline of Child and Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Centre for Food Allergy Research (CFAR), Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;Sydney Medical School Nepean and Charles Perkins Centre Nepean, The University of Sydney, Kingswood, New South Wales, Australia.&#xD;Telethon Kids Institute, The University of Western Australia, Nedlands, Western Australia, Australia.&#xD;School of Medicine, The University of Western Australia, Crawley, Western Australia, Australia.&#xD;South Australian Health and Medical Research Institute, SAHMRI Women and Kids, Adelaide, South Australia, Australia.&#xD;School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.&#xD;Discipline of Paediatrics, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.&#xD;The ORIGINS Project, Telethon Kids Institute, The University of Western Australia, Perth Children&apos;s Hospital, Nedlands, Western Australia, Australia.&#xD;Nova Institute for Health, Baltimore, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impaired calcium influx underlies skewed T helper cell differentiation in children with IgE-mediated food allergies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">513-524</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/09/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Cell Differentiation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Calcium/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Activation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Helper-Inducer/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Tacrolimus/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocyte Subsets/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">helper T cells</style></keyword><keyword><style face="normal" font="default" size="100%">naive CD4 T cells</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cell</style></keyword><keyword><style face="normal" font="default" size="100%">store operated calcium entry (SOCE)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39250135</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Reasons for Th2 skewing in IgE-mediated food allergies remains unclear. Clinical observations suggest impaired T cell activation may drive Th2 responses evidenced by increased atopic manifestations in liver transplant patients on tacrolimus (a calcineurin inhibitor). We aimed to assess differentiation potential, T cell activation and calcium influx of naive CD4(+) T cells in children with IgE-mediated food allergies. METHODS: Peripheral blood mononuclear cells from infants in the Starting Time for Egg Protein (STEP) Trial were analyzed by flow cytometry to assess Th1/Th2/Treg development. Naive CD4(+) T cells from children with and without food allergies were stimulated for 7 days to assess Th1/Th2/Treg transcriptional factors and cytokines. Store operated calcium entry (SOCE) was measured in children with and without food allergies. The effect of tacrolimus on CD4(+) T cell differentiation was assessed by treating stimulated naive CD4(+) T cells from healthy volunteers with tacrolimus for 7 days. RESULTS: Egg allergic infants had impaired development of IFNgamma(+) Th1 cells and FoxP3(+) transitional CD4(+) T cells compared with non-allergic infants. This parallels reduced T-bet, IFNgamma and FoxP3 expression in naive CD4(+) T cells from food allergic children after in vitro culture. SOCE of naive CD4(+) T cells was impaired in food allergic children. Naive CD4(+) T cells treated with tacrolimus had reduced IFNgamma, T-bet, and FoxP3, but preserved IL-4 expression. CONCLUSIONS: In children with IgE-mediated food allergies, dysregulation of T helper cell development is associated with impaired SOCE, which underlies an intrinsic impairment in Th1 and Treg differentiation. Along with tacrolimus-induced Th2 skewing, this highlights an important role of SOCE/calcineurin pathway in T helper cell differentiation.</style></abstract><notes><style face="normal" font="default" size="100%">Lai, C L&#xD;Santner-Nanan, B&#xD;Maltese, P J&#xD;Ong, C K S&#xD;Palmer, D J&#xD;Campbell, D E&#xD;Makrides, M&#xD;Gold, M&#xD;Nanan, R&#xD;Prescott, S L&#xD;Hsu, P S&#xD;eng&#xD;National Health and Medical Research Council/&#xD;Allergy and Immunology Foundation of Australasia/&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):513-524. doi: 10.1111/all.16310. Epub 2024 Sep 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39250135</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16310</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>712</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">712</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Warnberg Gerdin, S.</style></author><author><style face="normal" font="default" size="100%">Lie, A.</style></author><author><style face="normal" font="default" size="100%">Asarnoj, A.</style></author><author><style face="normal" font="default" size="100%">Borres, M. P.</style></author><author><style face="normal" font="default" size="100%">Lodrup Carlsen, K. C.</style></author><author><style face="normal" font="default" size="100%">Fardig, M.</style></author><author><style face="normal" font="default" size="100%">Konradsen, J. R.</style></author><author><style face="normal" font="default" size="100%">Monceyron Jonassen, C.</style></author><author><style face="normal" font="default" size="100%">Olsson Magi, C. A.</style></author><author><style face="normal" font="default" size="100%">Rehbinder, E. M.</style></author><author><style face="normal" font="default" size="100%">Rudi, K.</style></author><author><style face="normal" font="default" size="100%">Skjerven, H. O.</style></author><author><style face="normal" font="default" size="100%">Staff, A. C.</style></author><author><style face="normal" font="default" size="100%">Soderhall, C.</style></author><author><style face="normal" font="default" size="100%">Tedner, S. G.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Vettukattil, R.</style></author><author><style face="normal" font="default" size="100%">Nordlund, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Astrid Lindgren Children&apos;s Hospital, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Women&apos;s and Children&apos;s Health, Karolinska Institutet, Stockholm, Sweden.&#xD;Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.&#xD;Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.&#xD;Department of Women&apos;s and Children&apos;s Health, Uppsala University, Uppsala, Sweden.&#xD;Genetic Unit, Centre for Laboratory Medicine, Ostfold Hospital Trust, Kalnes, Norway.&#xD;Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, As, Norway.&#xD;Department of Dermatology, Oslo University Hospital, Oslo, Norway.&#xD;Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway.&#xD;Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impaired skin barrier and allergic sensitization in early infancy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1464-1476</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/11/06</style></edition><section><style face="normal" font="default" size="100%">1464</style></section><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">PreventADALL</style></keyword><keyword><style face="normal" font="default" size="100%">allergic sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">infancy</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34738238</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Factors predicting allergic sensitization in the first 6 months of life are poorly understood. We aimed to determine whether eczema, dry skin, and high transepidermal water loss (TEWL) at 3 months were associated with allergic sensitization at 6 months of age and, secondarily, to establish whether these characteristics predicted sensitization from 3 to 6 months of age. METHODS: At 3 months of age, 1,994 infants from the population-based PreventADALL birth cohort in Norway and Sweden were assessed for eczema and dry skin on the cheeks and/or extensors; impaired skin barrier function, defined as TEWL in the upper quartile (&gt;9.4 g/m(2) /h), and allergen-specific IgE levels &lt;0.1 kU(A) /L, available in 830. At 6 months, we assessed allergic sensitization to any food (egg, cow&apos;s milk, peanut, wheat, soy) or inhalant (birch, timothy grass, dog, and cat) allergen by a skin prick test wheal diameter &gt;/=2 mm larger than negative control. RESULTS: Any sensitization was found in 198 of the 1,994 infants (9.9%), the majority to food allergens (n = 177, 8.9%). Eczema, dry skin, and high TEWL at 3 months increased the risk of sensitization at 6 months; adjusted odds ratios 4.20 (95% CI 2.93-6.04), 2.09 (95% CI 1.51-2.90) and 3.67 (95% CI 2.58-5.22), respectively. Eczema predicted sensitization with 55.6% sensitivity and 68.1% specificity; dry skin with 65.3% sensitivity and 57.3% specificity; and high TEWL with 61.7% sensitivity and 78.1% specificity. CONCLUSION: Eczema, dry skin, and high TEWL at 3 months predicted allergic sensitization at 6 months of age.</style></abstract><notes><style face="normal" font="default" size="100%">Warnberg Gerdin, Sabina&#xD;Lie, Anine&#xD;Asarnoj, Anna&#xD;Borres, Magnus P&#xD;Lodrup Carlsen, Karin C&#xD;Fardig, Martin&#xD;Konradsen, Jon R&#xD;Monceyron Jonassen, Christine&#xD;Olsson Magi, Caroline-Aleksi&#xD;Rehbinder, Eva Maria&#xD;Rudi, Knut&#xD;Skjerven, Havard Ove&#xD;Staff, Anne Cathrine&#xD;Soderhall, Cilla&#xD;Tedner, Sandra G&#xD;van Hage, Marianne&#xD;Vettukattil, Riyas&#xD;Nordlund, Bjorn&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1464-1476. doi: 10.1111/all.15170. Epub 2021 Nov 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34738238</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15170</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>283</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">283</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kwasniewski, M.</style></author><author><style face="normal" font="default" size="100%">Korotko, U.</style></author><author><style face="normal" font="default" size="100%">Chwialkowska, K.</style></author><author><style face="normal" font="default" size="100%">Niemira, M.</style></author><author><style face="normal" font="default" size="100%">Jaroszewicz, J.</style></author><author><style face="normal" font="default" size="100%">Sobala-Szczygiel, B.</style></author><author><style face="normal" font="default" size="100%">Puzanowska, B.</style></author><author><style face="normal" font="default" size="100%">Moniuszko-Malinowska, A.</style></author><author><style face="normal" font="default" size="100%">Pancewicz, S.</style></author><author><style face="normal" font="default" size="100%">Parfieniuk-Kowerda, A.</style></author><author><style face="normal" font="default" size="100%">Martonik, D.</style></author><author><style face="normal" font="default" size="100%">Zarebska-Michaluk, D.</style></author><author><style face="normal" font="default" size="100%">Simon, K.</style></author><author><style face="normal" font="default" size="100%">Pazgan-Simon, M.</style></author><author><style face="normal" font="default" size="100%">Mozer-Lisewska, I.</style></author><author><style face="normal" font="default" size="100%">Bura, M.</style></author><author><style face="normal" font="default" size="100%">Adamek, A.</style></author><author><style face="normal" font="default" size="100%">Tomasiewicz, K.</style></author><author><style face="normal" font="default" size="100%">Pawlowska, M.</style></author><author><style face="normal" font="default" size="100%">Piekarska, A.</style></author><author><style face="normal" font="default" size="100%">Berkan-Kawinska, A.</style></author><author><style face="normal" font="default" size="100%">Horban, A.</style></author><author><style face="normal" font="default" size="100%">Kowalska, J.</style></author><author><style face="normal" font="default" size="100%">Podlasin, R.</style></author><author><style face="normal" font="default" size="100%">Wasilewski, P.</style></author><author><style face="normal" font="default" size="100%">Azzadin, A.</style></author><author><style face="normal" font="default" size="100%">Czuczwar, M.</style></author><author><style face="normal" font="default" size="100%">Borys, M.</style></author><author><style face="normal" font="default" size="100%">Piwowarczyk, P.</style></author><author><style face="normal" font="default" size="100%">Czaban, S.</style></author><author><style face="normal" font="default" size="100%">Bogocz, J.</style></author><author><style face="normal" font="default" size="100%">Ochab, M.</style></author><author><style face="normal" font="default" size="100%">Kruk, A.</style></author><author><style face="normal" font="default" size="100%">Uszok, S.</style></author><author><style face="normal" font="default" size="100%">Bielska, A.</style></author><author><style face="normal" font="default" size="100%">Szalkowska, A.</style></author><author><style face="normal" font="default" size="100%">Raczkowska, J.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, G.</style></author><author><style face="normal" font="default" size="100%">Chorostowska-Wynimko, J.</style></author><author><style face="normal" font="default" size="100%">Jezela-Stanek, A.</style></author><author><style face="normal" font="default" size="100%">Rozy, A.</style></author><author><style face="normal" font="default" size="100%">Lechowicz, U.</style></author><author><style face="normal" font="default" size="100%">Polowianiuk, U.</style></author><author><style face="normal" font="default" size="100%">Tycinska, A.</style></author><author><style face="normal" font="default" size="100%">Grubczak, K.</style></author><author><style face="normal" font="default" size="100%">Starosz, A.</style></author><author><style face="normal" font="default" size="100%">Izdebska, W.</style></author><author><style face="normal" font="default" size="100%">Krzeminski, T. F.</style></author><author><style face="normal" font="default" size="100%">Bousqet, J.</style></author><author><style face="normal" font="default" size="100%">Franchini, G.</style></author><author><style face="normal" font="default" size="100%">Hadlock, J.</style></author><author><style face="normal" font="default" size="100%">Kretowski, A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Eljaszewicz, A.</style></author><author><style face="normal" font="default" size="100%">Flisiak, R.</style></author><author><style face="normal" font="default" size="100%">Moniuszko, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Bioinformatics and Data Analysis, Medical University of Bialystok, Bialystok, Poland.&#xD;Imagene.me SA, Bialystok, Poland.&#xD;Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Infectious Diseases in Bytom, Medical University of Silesia, Bytom, Poland.&#xD;Department of Infectious Diseases, Megrez Hospital in Tychy, Tychy, Poland.&#xD;Department of Infectious Diseases and Neuroinfection, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Infectious Diseases, Jan Kochanowski University, Krakow, Poland.&#xD;Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Department of Infectious Diseases, Hepatology and Acquired Immunodeficiencies, Poznan University of Medical Sciences, Poznan, Poland.&#xD;Department of Infectious Diseases, Medical University of Lublin, Lublin, Poland.&#xD;Department of Infectious Diseases and Hepatology, Nicolaus Copernicus University, Bydgoszcz, Poland.&#xD;Department of Infectious Diseases and Hepatology, Medical University of Lodz, Lodz, Poland.&#xD;Department of Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Adults&apos; Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.&#xD;IV-th Department, Hospital for Infectious Diseases, Warsaw, Poland.&#xD;District Hospital in Bielsk Podlaski, Bielsk Podlask, Poland.&#xD;Department of Anesthesiology and Intensive Therapy, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Anesthesiology and Intensive Care, Medical University of Lublin, Lublin, Poland.&#xD;Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases in Warsaw, Warsaw, Poland.&#xD;District Sanitary Inspectorate in Bialystok, Bialystok, Poland.&#xD;Department of Cardiology, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Pharmacology, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland.&#xD;Universitatsmedizin Berlin, Berlin, Germany.&#xD;Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, USA.&#xD;Institute for Systems Biology, Seattle, Washington, USA.&#xD;Swiss Institute of Allergy and Asthma Research, University of Zurich, Zurich, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Implementation of the web-based calculator estimating odds ratio of severe COVID-19 for unvaccinated individuals in a country with high coronavirus-related death toll</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">311-314</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/09/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Internet</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36129377</style></accession-num><notes><style face="normal" font="default" size="100%">Kwasniewski, Miroslaw&#xD;Korotko, Urszula&#xD;Chwialkowska, Karolina&#xD;Niemira, Magdalena&#xD;Jaroszewicz, Jerzy&#xD;Sobala-Szczygiel, Barbara&#xD;Puzanowska, Beata&#xD;Moniuszko-Malinowska, Anna&#xD;Pancewicz, Slawomir&#xD;Parfieniuk-Kowerda, Anna&#xD;Martonik, Diana&#xD;Zarebska-Michaluk, Dorota&#xD;Simon, Krzysztof&#xD;Pazgan-Simon, Monika&#xD;Mozer-Lisewska, Iwona&#xD;Bura, Maciej&#xD;Adamek, Agnieszka&#xD;Tomasiewicz, Krzysztof&#xD;Pawlowska, Malgorzata&#xD;Piekarska, Anna&#xD;Berkan-Kawinska, Aleksandra&#xD;Horban, Andrzej&#xD;Kowalska, Justyna&#xD;Podlasin, Regina&#xD;Wasilewski, Piotr&#xD;Azzadin, Arsalin&#xD;Czuczwar, Miroslaw&#xD;Borys, Michal&#xD;Piwowarczyk, Pawel&#xD;Czaban, Slawomir&#xD;Bogocz, Jacek&#xD;Ochab, Magdalena&#xD;Kruk, Anna&#xD;Uszok, Sandra&#xD;Bielska, Agnieszka&#xD;Szalkowska, Anna&#xD;Raczkowska, Justyna&#xD;Sokolowska, Gabriela&#xD;Chorostowska-Wynimko, Joanna&#xD;Jezela-Stanek, Aleksandra&#xD;Rozy, Adriana&#xD;Lechowicz, Urszula&#xD;Polowianiuk, Urszula&#xD;Tycinska, Agnieszka&#xD;Grubczak, Kamil&#xD;Starosz, Aleksandra&#xD;Izdebska, Wiktoria&#xD;Krzeminski, Tadeusz F&#xD;Bousqet, Jean&#xD;Franchini, Genoveffa&#xD;Hadlock, Jennifer&#xD;Kretowski, Adam&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;Sokolowska, Milena&#xD;Eljaszewicz, Andrzej&#xD;Flisiak, Robert&#xD;Moniuszko, Marcin&#xD;eng&#xD;Comment&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):311-314. doi: 10.1111/all.15524. Epub 2022 Sep 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36129377</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9537959 during the conduct of the study (No 2020/ABM/COVID19/0001); JBog and AKru report personal fees from IMAGENE.ME SA outside the submitted work; AJ-S reports personal fees from IMAGENE.ME SA outside the submitted work; JB reports personal fees and other support from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, and Uriach and other support from KYomed INNOV outside the submitted work; AE and MM received grants from the National Science Centre and the National Research and Development Centre; TFK and MM are the members of the Council of the Medical Research Agency with no right to decide on grant applications and they received no remuneration for the work done in this study; MS received research grant from the Swiss National Science Foundation and from the GSK outside the submitted work; GF is the employee of the National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services; MM reports support from European Commission Horizon 2020 Programme and lecture fees from Berlin-Chemie/Menarini, Astra Zeneca, Novartis, Chiesi, GlaxoSmithKline, Takeda, Teva, Lek-AM outside the submitted work. Other authors declared no conflict of interest within the scope of this work.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15524</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>34</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">34</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lunjani, N.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;University of Cape Town, Cape Town, South Africa.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Medicine, University College Cork, Cork, Ireland.&#xD;School of Microbiology, University College Cork, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Importance of examining atopic dermatitis disease mechanisms in African populations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">329-330</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/12/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Black People</style></keyword><keyword><style face="normal" font="default" size="100%">African People</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36576006</style></accession-num><notes><style face="normal" font="default" size="100%">Lunjani, Nonhlanhla&#xD;Akdis, Cezmi A&#xD;O&apos;Mahony, Liam&#xD;eng&#xD;Comment&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):329-330. doi: 10.1111/all.15559.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36576006</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15559</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2511</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2511</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Unger, Z.</style></author><author><style face="normal" font="default" size="100%">Kuklinski, A.</style></author><author><style face="normal" font="default" size="100%">Gomez-Casado, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, University Hospital Dusseldorf, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Importance of SREBP signaling in controlling lipid metabolism and homeostasis in B cells for future vaccine design</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2885-2887</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/05/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Lipid Metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">*Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">*B-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Sterol Regulatory Element Binding Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccine Development</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38715449</style></accession-num><notes><style face="normal" font="default" size="100%">Unger, Zsofia&#xD;Kuklinski, Alina&#xD;Gomez-Casado, Cristina&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2885-2887. doi: 10.1111/all.16134. Epub 2024 May 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38715449</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16134</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>470</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">470</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Graham, F.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Adult Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier de l&apos;Universite de Montreal (CHUM), Montreal, QC, Canada.&#xD;Department of Pediatric Allergy and Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada.&#xD;Translational Research in Pediatric Specialities Area, Division of Allergy, Bambino Gesu Children&apos;s Hospital (IRCCS), Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The importance of threshold dose-distribution data for priority allergens and the need for future studies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2886-2887</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/05/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Food Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">eliciting dose</style></keyword><keyword><style face="normal" font="default" size="100%">food challenge</style></keyword><keyword><style face="normal" font="default" size="100%">lowest observed adverse effect level</style></keyword><keyword><style face="normal" font="default" size="100%">population threshold</style></keyword><keyword><style face="normal" font="default" size="100%">precautionary allergen labeling</style></keyword><keyword><style face="normal" font="default" size="100%">thresholds</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35608990</style></accession-num><notes><style face="normal" font="default" size="100%">Graham, Francois&#xD;Fiocchi, Alessandro&#xD;eng&#xD;Comment&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):2886-2887. doi: 10.1111/all.15387.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35608990</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15387</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>972</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">972</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pichler, W. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ADR-AC, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The important role of non-covalent drug-protein interactions in drug hypersensitivity reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">404-415</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/05/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">HLA Antigens</style></keyword><keyword><style face="normal" font="default" size="100%">Haptens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Antigen, T-Cell</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Immunologic/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">allo-immunity</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">fake antigen</style></keyword><keyword><style face="normal" font="default" size="100%">heterologous immunity</style></keyword><keyword><style face="normal" font="default" size="100%">virus reactivation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34037262</style></accession-num><abstract><style face="normal" font="default" size="100%">Drug hypersensitivity reactions (DHR) are heterogeneous and unusual immune reactions with rather unique clinical presentations. Accumulating evidence indicates that certain non-covalent drug-protein interactions are able to elicit exclusively effector functions of antibody reactions or complete T-cell reactions which contribute substantially to DHR. Here, we discuss three key interactions; (a) mimicry: whereby soluble, non-covalent drug-protein complexes (&quot;fake antigens&quot;) mimic covalent drug-protein adducts; (b) increased antibody affinity: for example, in quinine-type immune thrombocytopenia where the drug gets trapped between antibody and membrane-bound glycoprotein; and (c) p-i-stimulation: where naive and memory T cells are activated by direct binding of drugs to the human leukocyte antigen and/or T-cell receptors. This transient drug-immune receptor interaction initiates a polyclonal T-cell response with mild-to-severe DHR symptoms. Notable complications arising from p-i DHR can include viral reactivations, autoimmunity, and multiple drug hypersensitivity. In conclusion, DHR is characterized by abnormal immune stimulation driven by non-covalent drug-protein interactions. This contrasts DHR from &quot;normal&quot; immunity, which relies on antigen-formation by covalent hapten-protein adducts and predominantly results in asymptomatic immunity.</style></abstract><notes><style face="normal" font="default" size="100%">Pichler, Werner J&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):404-415. doi: 10.1111/all.14962. Epub 2021 Jun 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34037262</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9291849</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14962</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2191</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, T.</style></author><author><style face="normal" font="default" size="100%">Shi, S.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Zhou, L.</style></author><author><style face="normal" font="default" size="100%">Yu, Y.</style></author><author><style face="normal" font="default" size="100%">Cai, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Kan, H.</style></author><author><style face="normal" font="default" size="100%">Xu, Y.</style></author><author><style face="normal" font="default" size="100%">Huang, C.</style></author><author><style face="normal" font="default" size="100%">Tan, Y.</style></author><author><style face="normal" font="default" size="100%">Meng, X.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Environmental Health, School of Public Health, the Key Laboratory of Public Health Safety of the Ministry of Education, and NHC Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China.&#xD;Department of Biostatistics, School of Public Health, and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China.&#xD;Department of General Management and Statistics, Shanghai Environment Monitoring Center, Shanghai, China.&#xD;Pudong New Area Center for Disease Control and Prevention, Shanghai, China.&#xD;Typhoon Institute/CMA, Shanghai Key Laboratory of Meteorology and Health IRDR International Center of Excellence on Risk Interconnectivity and Governance on Weather/Climate Extremes Impact and Public Health WMO/IGAC MAP-AQ Asian Office Shanghai, Fudan University, Shanghai, China.&#xD;School of Environment and Architecture, University of Shanghai for Science and Technology, Shanghai, China.&#xD;Department of Pediatrics, Chongming Hospital Affiliated to Shanghai University of Medicine &amp; Health Sciences, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Improved ambient air quality is associated with decreased prevalence of childhood asthma and infancy shortly after weaning is a sensitive exposure window</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1166-1179</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/07/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Particulate Matter/analysis/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Weaning</style></keyword><keyword><style face="normal" font="default" size="100%">Air Pollutants/analysis/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Sounds/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">early life exposure</style></keyword><keyword><style face="normal" font="default" size="100%">infancy</style></keyword><keyword><style face="normal" font="default" size="100%">particulate matter</style></keyword><keyword><style face="normal" font="default" size="100%">uterus</style></keyword><keyword><style face="normal" font="default" size="100%">wheezing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37458141</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The urban ambient air quality has been largely improved in the past decade. It is unknown whether childhood asthma prevalence is still increasing in ever top-ranking city of Shanghai, whether the improved air quality is beneficial for children&apos;s asthma and what time window of exposure plays critical roles. METHODS: Using a repeat cross-sectional design, we analyzed the association between early life exposure to particles and wheezing/asthma in each individual and combined surveys in 2011 and 2019, respectively, in 11,825 preschool children in Shanghai. RESULTS: A significantly lower prevalence of doctor-diagnosed asthma (DDA) (6.6% vs. 10.5%, p &lt; 0.001) and wheezing (10.5% vs. 23.2%, p &lt; 0.001) was observed in 2019 compared to 2011. Exposure to fine particulate matter (PM(2.5)), coarse particles (PM(2.5-10)) and inhalable particles (PM(10)) was decreased in 2019 by 6.3%, 35.4%, and 44.7% in uterus and 24.3%, 20.2%, and 31.8% in infancy, respectively. Multilevel log-binomial regression analysis showed exposure in infancy had independent association with wheezing/DDA adjusting for exposure in uterus. For each interquartile range (IQR) increase of infancy PM(2.5), PM(2.5-10) and PM(10) exposure, the odds ratios were 1.39 (95% confidence interval (CI): 1.24-1.56), 1.51 (95% CI:1.15-1.98) and 1.53 (95% CI:1.27-1.85) for DDA, respectively. The distributed lag non-linear model showed the sensitive exposure window (SEW) was 5.5-11 months after birth. Stratified analysis showed the SEWs were at or shortly after weaning, but only in those with &lt;6 months of exclusive breastfeeding. CONCLUSIONS: Improved ambient PM benefits in decreasing childhood asthma prevalence. We firstly reported the finding of SEW to PM at or closely after weaning on childhood asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Tianyi&#xD;Shi, Su&#xD;Li, Xinyue&#xD;Zhou, Lu&#xD;Yu, Yongfu&#xD;Cai, Yunfei&#xD;Wang, Jing&#xD;Kan, Haidong&#xD;Xu, Yanyi&#xD;Huang, Chen&#xD;Tan, Yongqiang&#xD;Meng, Xia&#xD;Zhao, Zhuohui&#xD;eng&#xD;81861138005/National Natural Science Foundation of China/&#xD;GWV-10.1-XK11/Shanghai 3-year Public Health Action Plan/&#xD;22230750300/Shanghai B&amp;amp;R Joint Laboratory Project/&#xD;Shanghai Pudong New Area 3-year Public Health Action Plan (2020-2022)/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1166-1179. doi: 10.1111/all.15815. Epub 2023 Jul 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37458141</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15815</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2675</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2675</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Augustin, S.</style></author><author><style face="normal" font="default" size="100%">Eichhorn, T.</style></author><author><style face="normal" font="default" size="100%">Wald, M.</style></author><author><style face="normal" font="default" size="100%">Fischer, F.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Willers, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergopharma GmbH &amp; Co, Reinbek, Germany.&#xD;Merck KGaA, Darmstadt, Germany.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Improved quality control of allergen products: Assessing the molecular allergen composition by mass spectrometry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3489-3500</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/10/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens/analysis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality Control</style></keyword><keyword><style face="normal" font="default" size="100%">*Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Chromatography, Liquid</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests/methods/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Spectrometry/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">allergen composition</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergen products</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mites</style></keyword><keyword><style face="normal" font="default" size="100%">mass spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH &amp; Co. KG, Reinbek, Germany. Thomas Eichhorn &amp; Frank Fischer are employees of</style></keyword><keyword><style face="normal" font="default" size="100%">Merck KGaA. Darmstadt, Germany. Marek Jutel reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, ALK-Abello, Stallergenes, Anergis, Allergy Therapeutics, Eli</style></keyword><keyword><style face="normal" font="default" size="100%">Lilly, Inmunotek, Leti, HAL, GSK, Novartis, Teva, Takeda, Chiesi, Pfizer,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Sanofi, Astra-Zeneka, Lallemand, Shire, Celltrion Inc., Genentech,</style></keyword><keyword><style face="normal" font="default" size="100%">Roche, Upstream Bio, Verona, Lek Pharmaceuticals, Arcutis Biotherapeutics, FAES</style></keyword><keyword><style face="normal" font="default" size="100%">FARMA. Outside of submitted work, Marek Jutel is deputy editor in chief at</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and associate editor at CTA. Oliver Pfaar reports grants and/or personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees and/or travel support from ALK-Abello, Allergopharma, Stallergenes Greer,</style></keyword><keyword><style face="normal" font="default" size="100%">HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Laboratorios LETI/LETI Pharma, GlaxoSmithKline, ROXALL Medizin,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Sanofi-Aventis and Sanofi-Genzyme, Med Update Europe GmbH, streamedup!</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, Pohl-Boskamp, John Wiley and Sons/AS, Paul-Martini-Stiftung (PMS),</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals Inc., RG Aerztefortbildung, Institut fur Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Management, Springer GmbH, AstraZeneca, IQVIA Commercial, Inmunotek S.L., Ingress</style></keyword><keyword><style face="normal" font="default" size="100%">Health, Wort&amp;Bild Verlag, Verlag ME, Procter&amp;Gamble, ALTAMIRA, Meinhardt Congress</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, Deutsche Forschungsgemeinschaft, Thieme, Deutsche AllergieLiga e.V., AeDA,</style></keyword><keyword><style face="normal" font="default" size="100%">Alfried-Krupp Krankenhaus, Red Maple Trials Inc., Koniglich Danisches</style></keyword><keyword><style face="normal" font="default" size="100%">Generalkonsulat, Medizinische Hochschule Hannover, ECM Expro&amp;Conference</style></keyword><keyword><style face="normal" font="default" size="100%">Management, Technical University Dresden, Lilly, Japanese Society of Allergy,</style></keyword><keyword><style face="normal" font="default" size="100%">Forum fur Medizinische Fortbildung, Dustri-Verlag, Pneumolive, ASIT Biotech,</style></keyword><keyword><style face="normal" font="default" size="100%">LOFARMA, Almirall, Paul-Ehrlich-Institut, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and he is</style></keyword><keyword><style face="normal" font="default" size="100%">Vice President of the EAACI and member of EAACI Excom, member of ext. board of</style></keyword><keyword><style face="normal" font="default" size="100%">directors DGAKI</style></keyword><keyword><style face="normal" font="default" size="100%">coordinator, main- or co-author of different position papers and</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines in rhinology, allergology and allergen-immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">he is associate</style></keyword><keyword><style face="normal" font="default" size="100%">editor (AE) of Allergy and Clinical Translational Allergy.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39445581</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Natural allergen sources contain a variety of allergens, against which allergic subjects have developed individual sensitization profiles. Ideal allergen products for skin prick testing (SPT) and allergen immunotherapy (AIT) should contain the complete set of allergens of the respective allergen sources to cover all sensitization profiles. However, commercially available allergen products were shown to vary regarding their allergen composition. METHODS: The qualitative allergen composition of different SPT and AIT products produced from pollen of grasses, birch, mugwort and from house dust mites was assessed by a consistent high-resolution liquid chromatography-coupled tandem mass spectrometry method (LC-MS/MS). RESULTS: All major, mid-tier and most minor allergens were detected in each of the investigated three batches of SPT and AIT products, demonstrating the completeness of the allergen composition and a high degree of batch-to-batch consistency. CONCLUSION: This is the first study using a single consistent high-resolution LC-MS/MS method to provide solid data on the qualitative allergen composition of SPT and AIT products manufactured from various common allergen sources. The applied method showed high reliability in qualitative batch-to-batch consistency testing and can be performed fast and with high throughput. High-resolution LC-MS/MS is applicable for process development and quality control to ensure market availability of allergen products corresponding to the composition of the respective natural allergen sources.</style></abstract><notes><style face="normal" font="default" size="100%">Augustin, Steffen&#xD;Eichhorn, Thomas&#xD;Wald, Martin&#xD;Fischer, Frank&#xD;Jutel, Marek&#xD;Pfaar, Oliver&#xD;Willers, Christoph&#xD;eng&#xD;Allergopharma GmbH &amp; Co. KG/&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3489-3500. doi: 10.1111/all.16339. Epub 2024 Oct 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39445581</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657028</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16339</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2958</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2958</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Atzert, N.</style></author><author><style face="normal" font="default" size="100%">Gore, C.</style></author><author><style face="normal" font="default" size="100%">Knibb, R. C.</style></author><author><style face="normal" font="default" size="100%">Alviani, C.</style></author><author><style face="normal" font="default" size="100%">Angier, E.</style></author><author><style face="normal" font="default" size="100%">Blumchen, K.</style></author><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author><author><style face="normal" font="default" size="100%">Duca, B.</style></author><author><style face="normal" font="default" size="100%">DunnGalvin, A.</style></author><author><style face="normal" font="default" size="100%">Garriga-Baraut, T.</style></author><author><style face="normal" font="default" size="100%">Gowland, M. H.</style></author><author><style face="normal" font="default" size="100%">Egmose, B.</style></author><author><style face="normal" font="default" size="100%">Khaleva, E.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Pite, H.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Podesta, M.</style></author><author><style face="normal" font="default" size="100%">Sanchez Garcia, S.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Vazquez Ortiz, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Kinderspital Zurich, Zurich, Switzerland.&#xD;Department of Paediatric Allergy, Imperial College Healthcare NHS Trust, London, UK.&#xD;Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Institute of Health and Neurodevelopment, Aston University, Birmingham, UK.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;Primary Care and Population Sciences, University of Southampton, Southampton, UK.&#xD;Department of Pediatrics, Division of Pneumology, Allergology, Infectious Diseases and Gastroenterology, Goethe University, Frankfurt am Main, Germany.&#xD;Department of Clinical and Experimental Medicine, Section of Paediatrics, University of Pisa, Pisa, Italy.&#xD;Department of Child and Adolescent Health, Mater Dei Hospital, Msida, Malta.&#xD;Applied Psychology and Paediatrics and Child Health, University College Cork, Cork, Ireland.&#xD;Paediatrics and Child Infectious Diseases, First Moscow State Medical University, Moscow, Russia.&#xD;Unitat d&apos;Al.lergologia Pediatrica, Hospital Universitari Vall d&apos;Hebron, Barcelona, Spain.&#xD;Grup d&apos;Investigacio &quot;Creixement i Desenvolupament&quot;, Barcelona, Spain.&#xD;Allergy Action, St Albans, UK.&#xD;Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark, Odense, Denmark.&#xD;Immuno-Allergy Department, CUF Tejo Hospital, Lisbon, Portugal.&#xD;NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Food Allergy Italia APS, Padova, Italy.&#xD;European Federation of Allergy and Airways Diseases Patients&apos; Associations (EFA), Brussels, Belgium.&#xD;EAACI Patient Organisation Committee (POC), Zurich, Switzerland.&#xD;Allergy Department, Hospital Infantil Universitario del Nino Jesus, Madrid, Spain.&#xD;Department of Women and Children&apos;s Health (Paediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;David Hide Asthma and Allergy Centre, Isle of Wight NHS Trust, Newport, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Improved Transition Management of Adolescents and Young Adults With Allergy and/or Asthma: An EAACI Task Force Report on a Follow-Up European Survey</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1592-1612</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/06/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Transition to Adult Care/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Health Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Committees</style></keyword><keyword><style face="normal" font="default" size="100%">adolescents</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">teenager</style></keyword><keyword><style face="normal" font="default" size="100%">transfer</style></keyword><keyword><style face="normal" font="default" size="100%">transition</style></keyword><keyword><style face="normal" font="default" size="100%">young adults</style></keyword><keyword><style face="normal" font="default" size="100%">young people</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40525966</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Adolescents and young adults (AYA) with asthma and allergies have unexpectedly high mortality and morbidity. A survey in 2019 amongst healthcare professionals (HCPs) in Europe highlighted significant gaps in transition care, which negatively impacts patients&apos; outcomes. Since then, an evidence-based guideline and practical toolbox for effective transition of AYA with asthma and allergies have been published. AIMS: To assess HCPs&apos; perspectives, practice and challenges on transition care for AYA with asthma and allergies, including the impact of the recent guideline, potential differences across countries and changes since 2019. METHODS: Cross-sectional online survey-based study. European HCP managing AYA with allergies and/or asthma were invited to participate in May-June 2023. RESULTS: 511 responses were collected. Amongst respondents, 60%-70% were familiar with the guideline and toolbox, and found them helpful. At least for selected patients, 50%-85% of respondents adhered to some guideline recommendations and initiatives/resources for transition care such as simplifying medication regimes, seeing AYA on their own or producing transition reports. We observed improvements compared to 2019 in areas such as prioritising transition, training, assessment of psychosocial issues and transition readiness, access to other HCP, transfer and post-transfer feedback systems. However, 20% of respondents had no transition process and around 50% had no transition-specific elements. Sixty percent found transition care &apos;very&apos; or &apos;moderately challenging&apos;, with transition not being prioritised, time constraints and limited expertise on psychosocial issues as leading problems. Significant differences were observed in transition practice across countries. CONCLUSION: Despite improvement in training and approach towards transition care, challenges and limitations persist in effectively implementing evidence-based guidelines. Raising greater awareness about the need for, and the positive impact of high-quality transition care amongst policy-makers, HCP, and patients/families remains a key priority to unlock resources for training and effective implementation at a national/international level.</style></abstract><notes><style face="normal" font="default" size="100%">Atzert, N&#xD;Gore, C&#xD;Knibb, R C&#xD;Alviani, C&#xD;Angier, E&#xD;Blumchen, K&#xD;Comberiati, P&#xD;Duca, B&#xD;DunnGalvin, A&#xD;Garriga-Baraut, T&#xD;Gowland, M H&#xD;Egmose, B&#xD;Khaleva, E&#xD;Mortz, C G&#xD;Pite, H&#xD;Pfaar, O&#xD;Podesta, M&#xD;Sanchez Garcia, S&#xD;Santos, A F&#xD;Roberts, G&#xD;Vazquez Ortiz, M&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1592-1612. doi: 10.1111/all.16603. Epub 2025 Jun 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40525966</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186585</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16603</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2374</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2374</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.&#xD;Translational Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Improving &quot;may contain&quot; labels: A call to team up and share data</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1409-1412</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/01/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Information Dissemination/methods</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">eliciting dose</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">precautionary allergen labelling</style></keyword><keyword><style face="normal" font="default" size="100%">reference dose, thresholds</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38214128</style></accession-num><notes><style face="normal" font="default" size="100%">Turner, Paul J&#xD;Eiwegger, Thomas&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1409-1412. doi: 10.1111/all.16012. Epub 2024 Jan 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38214128</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16012</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3174</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3174</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chong, M. Y.</style></author><author><style face="normal" font="default" size="100%">Shi, W.</style></author><author><style face="normal" font="default" size="100%">Bulatovic-Calasan, M.</style></author><author><style face="normal" font="default" size="100%">Pleijhuis, R. G.</style></author><author><style face="normal" font="default" size="100%">Terreehorst, I.</style></author><author><style face="normal" font="default" size="100%">Li, P. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology &amp; Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, China.&#xD;Division of Rheumatology &amp; Clinical Immunology, Department of Medicine, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.&#xD;Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.&#xD;Department of Laboratory Medicine, Laboratory Specialized Diagnostics &amp; Research, Amsterdam UMC, Amsterdam, the Netherlands.&#xD;Department of Internal Medicine and Allergology, University Medical Centre Groningen, Groningen, the Netherlands.&#xD;Evidencio, Haaksbergen, the Netherlands.&#xD;ENT Department, Amsterdam University Medical Centre, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Improving Beta-Lactam Allergy Risk Stratification Through Digital Decision Support: A Randomized Crossover Study of BLAST-A</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Apaaaci</style></keyword><keyword><style face="normal" font="default" size="100%">Blast-a</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">beta-lactam</style></keyword><keyword><style face="normal" font="default" size="100%">delabeling</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 4</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41189044</style></accession-num><notes><style face="normal" font="default" size="100%">Chong, Man Yui&#xD;Shi, Weihong&#xD;Bulatovic-Calasan, Maja&#xD;Pleijhuis, Rick Gert-Jan&#xD;Terreehorst, Ingrid&#xD;Li, Philip H&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov 4. doi: 10.1111/all.70147.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41189044</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70147</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>114</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">114</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suprun, M.</style></author><author><style face="normal" font="default" size="100%">Bahnson, H. T.</style></author><author><style face="normal" font="default" size="100%">du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Suarez-Farinas, M.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Benaroya Research Institute, Seattle, Washington, USA.&#xD;St. Thomas Hospital &amp; King&apos;s College, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In children with eczema, expansion of epitope-specific IgE is associated with peanut allergy at 5 years of age</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">586-589</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/11/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36321870</style></accession-num><notes><style face="normal" font="default" size="100%">Suprun, Maria&#xD;Bahnson, Henry T&#xD;du Toit, George&#xD;Lack, Gideon&#xD;Suarez-Farinas, Mayte&#xD;Sampson, Hugh A&#xD;eng&#xD;UM1 AI109565/AI/NIAID NIH HHS/&#xD;UM2 AI117870/AI/NIAID NIH HHS/&#xD;Department of Health/United Kingdom&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):586-589. doi: 10.1111/all.15572. Epub 2022 Nov 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36321870</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15572</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2567</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2567</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ji, J.</style></author><author><style face="normal" font="default" size="100%">Tang, M.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, C.</style></author><author><style face="normal" font="default" size="100%">Shen, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, B.</style></author><author><style face="normal" font="default" size="100%">Liu, C.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Jiao, Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, The First Affiliated Hospital of Soochow University, Suzhou, China.&#xD;Department of Dermatology, The Second Affiliated Hospital of Soochow University, Su Zhou, China.&#xD;Department of Dermatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China.&#xD;Suzhou Kowloon hospital, Shanghai Jiaotong University School of Medicine, Suzhou, China.&#xD;Jiangsu Institute of Clinical Immunology &amp; Jiangsu Key Laboratory of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.&#xD;Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In chronic spontaneous urticaria, increased Galectin-9 expression on basophils and eosinophils is linked to high disease activity, endotype-specific markers, and response to omalizumab treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2435-2447</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/07/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Galectins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatitis A Virus Cellular Receptor 2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Galectin-9 (Gal-9)</style></keyword><keyword><style face="normal" font="default" size="100%">T cell immunoglobulin- and mucin-domain-containing molecules-3 (TIM-3)</style></keyword><keyword><style face="normal" font="default" size="100%">TH1 cells</style></keyword><keyword><style face="normal" font="default" size="100%">TH17 cells</style></keyword><keyword><style face="normal" font="default" size="100%">TNF-alpha</style></keyword><keyword><style face="normal" font="default" size="100%">angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">p38 MAPK</style></keyword><keyword><style face="normal" font="default" size="100%">wheals</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39021347</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Galectin-9 (Gal-9) has been implicated in allergic and autoimmune diseases, but its role and relevance in chronic spontaneous urticaria (CSU) are unclear. OBJECTIVES: To characterize the role and relevance of Gal-9 in the pathogenesis of CSU. METHODS: We assessed 60 CSU patients for their expression of Gal-9 on circulating eosinophils and basophils as well as T cell expression of the Gal-9 receptor TIM-3, compared them with 26 healthy controls (HCs), and explored possible links with disease features including disease activity (urticaria activity score, UAS), total IgE, basophil activation test (BAT), and response to omalizumab treatment. We also investigated potential drivers of Gal-9 expression by eosinophils and basophils. RESULTS: Our CSU patients had markedly increased rates of circulating Gal-9(+) eosinophils and basophils and high numbers of lesional Gal-9(+) cells. High rates of blood Gal-9(+) eosinophils/basophils were linked to high disease activity, IgE levels, and BAT negativity. Serum levels of TNF-alpha were positively correlated with circulating Gal-9(+) eosinophils/basophils, and TNF-alpha markedly upregulated Gal-9 on eosinophils. CSU patients who responded to omalizumab treatment had more Gal-9(+) eosinophils/basophils than non-responders, and omalizumab reduced blood levels of Gal-9(+) eosinophils/basophils in responders. Gal-9(+) eosinophils/basophils were negatively correlated with TIM-3(+)T(H)17 cells. CONCLUSION: Our findings demonstrate a previously unrecognized involvement of the Gal-9/TIM-3 pathway in the pathogenesis CSU and call for studies that explore its relevance.</style></abstract><notes><style face="normal" font="default" size="100%">Ji, Jiang&#xD;Tang, Minhui&#xD;Zhao, Yue&#xD;Zhang, Chuqiao&#xD;Shen, Yu&#xD;Zhou, Bin&#xD;Liu, Cuiping&#xD;Maurer, Marcus&#xD;Jiao, Qingqing&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2435-2447. doi: 10.1111/all.16239. Epub 2024 Jul 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39021347</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16239</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>874</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">874</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Decuyper,, II</style></author><author><style face="normal" font="default" size="100%">Rihs, H. P.</style></author><author><style face="normal" font="default" size="100%">Mertens, C. H.</style></author><author><style face="normal" font="default" size="100%">Van Gasse, A. L.</style></author><author><style face="normal" font="default" size="100%">Elst, J.</style></author><author><style face="normal" font="default" size="100%">Faber, M. A.</style></author><author><style face="normal" font="default" size="100%">Hagendorens, M. M.</style></author><author><style face="normal" font="default" size="100%">Sabato, V.</style></author><author><style face="normal" font="default" size="100%">Ebo, D. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine and Health Sciences, Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, and Immunology, Allergology, Rheumatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.&#xD;Faculty of Medicine and Health Sciences, Department of Paediatrics and the Infla-Med Centre of Excellence, and Paediatrics, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.&#xD;Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-University Bochum, Bochum, Germany.&#xD;Department of Immunology and Allergology, AZ Jan Palfijn Gent, Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In search of the golden ratio for cannabis allergy: Utility of specific allergen-to-total IgE ratios</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3522-3525</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Cannabis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">cannabis allergy</style></keyword><keyword><style face="normal" font="default" size="100%">sIgE</style></keyword><keyword><style face="normal" font="default" size="100%">sIgE-to-total IgE ratio</style></keyword><keyword><style face="normal" font="default" size="100%">total IgE</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34324720</style></accession-num><notes><style face="normal" font="default" size="100%">Decuyper, Ine I&#xD;Rihs, Hans-Peter&#xD;Mertens, Christel H&#xD;Van Gasse, Athina Ludovica&#xD;Elst, Jessy&#xD;Faber, Margaretha A&#xD;Hagendorens, Margo M&#xD;Sabato, Vito&#xD;Ebo, Didier G&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3522-3525. doi: 10.1111/all.15028. Epub 2021 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34324720</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15028</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>840</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">840</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Augusto, G.</style></author><author><style face="normal" font="default" size="100%">Mohsen, M. O.</style></author><author><style face="normal" font="default" size="100%">Zinkhan, S.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Vogel, M.</style></author><author><style face="normal" font="default" size="100%">Bachmann, M. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, University clinic of Rheumatology and Immunology, Inselspital, Bern, Switzerland.&#xD;Department of BioMedical Research, University of Bern, Bern, Switzerland.&#xD;The Jenner Institute, University of Oxford, Oxford, UK.&#xD;International Immunology Centre, Anhui Agricultural University, Hefei, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">111-117</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Evasion</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Binding</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Spike Glycoprotein, Coronavirus/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines, Synthetic</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Rbd</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">affinity</style></keyword><keyword><style face="normal" font="default" size="100%">neutralization</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">RBD-CuMV, a vaccine against COVID-19. All other authors declare no conflict of</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34453338</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Emerged mutations can be attributed to increased transmissibility of the B.1.617 and B.1.36 Indian delta variants of SARS-CoV-2, most notably substitutions L452R/E484Q and N440K, respectively, which occur in the receptor-binding domain (RBD) of the Spike (S) fusion glycoprotein. OBJECTIVE: We aimed to assess the effects of mutations L452R/E484Q and N440K (as well as the previously studied mutation E484K present in variants B.1.351 and P.1) on the affinity of RBD for ACE2, SARS-CoV-2 main receptor. We also aimed to assess the ability of antibodies induced by natural infection or by immunization with BNT162b2 mRNA vaccine to recognize the mutated versions of the RBD, as well as blocking the interaction RBD-ACE2, an important surrogate readout for virus neutralization. METHODS: To this end, we produced recombinant wild-type RBD, as well as RBD containing each of the mutations L452R/E484Q, N440K, or E484K (the latest present in variants of concern B.1.351 and P.1), as well as the ectodomain of ACE2. Using Biolayer Interferometry (BLI), we measured the binding affinity of RBD for ACE2 and the ability of sera from COVID-19 convalescent donors or subjects immunized with BNT162b2 mRNA vaccine to block this interaction. Finally, we correlated these results with total anti-RBD IgG titers measured from the same sera by direct ELISA. RESULTS: The binding assays showed L452R/E484Q double-mutant RBD to interact with ACE2 with higher affinity (K(D) = 4.6 nM) than wild-type (K(D) = 21.3 nM) or single mutants N440K (K(D) = 9.9 nM) and E484K (K(D) = 19.7 nM) RBDs. Meanwhile, the anti-RBD IgG titration resulted in lower recognition of mutants E484K and L452R/E484Q by infection-induced antibodies, whereas only mutant E484K was recognized less by antibodies induced by vaccination. More interestingly, sera from convalescent as well as immunized subjects showed reduced ability to block the interaction between ACE2 and RBD mutants E484K and L452R/E484Q, as shown by the inhibition assays. CONCLUSION: Our data suggest that the newly emerged SARS-CoV-2 variant B.1.617, as well as the better-studied variants B.1.351 and P.1 (all containing a mutation at position E484) display increased transmissibility both due to their higher affinity for the cell receptor ACE2 and their ability to partially bypass immunity generated against the wild-type virus. For variant B.1.36 (with a point mutation at position N440), only increased affinity seems to play a role.</style></abstract><notes><style face="normal" font="default" size="100%">Augusto, Gilles&#xD;Mohsen, Mona O&#xD;Zinkhan, Simon&#xD;Liu, Xuelan&#xD;Vogel, Monique&#xD;Bachmann, Martin F&#xD;eng&#xD;Saiba AG/&#xD;31003A 149925/SNSF_/Swiss National Science Foundation/Switzerland&#xD;310030-179459/SNSF_/Swiss National Science Foundation/Switzerland&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):111-117. doi: 10.1111/all.15065. Epub 2021 Sep 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34453338</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8652796</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15065</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>552</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">552</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Javadiyan, S.</style></author><author><style face="normal" font="default" size="100%">Germein, K. C.</style></author><author><style face="normal" font="default" size="100%">Cooksley, C. M.</style></author><author><style face="normal" font="default" size="100%">Ramezanpour, M.</style></author><author><style face="normal" font="default" size="100%">Singh, N.</style></author><author><style face="normal" font="default" size="100%">Wormald, P. J.</style></author><author><style face="normal" font="default" size="100%">Vreugde, S.</style></author><author><style face="normal" font="default" size="100%">Psaltis, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, University of Adelaide, Adelaide, SA, Australia.&#xD;Basil Hetzel Institute for Translational Health Research, Central Adelaide Local Health Network, Adelaide, SA, Australia.&#xD;Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.&#xD;Department of Otolaryngology, Head &amp; Neck Surgery, Westmead Hospital, Sydney, NSW, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vitro safety and anti-bacterial efficacy assessment of acriflavine</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1917-1920</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/03/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Acriflavine</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Bacterial Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35322438</style></accession-num><notes><style face="normal" font="default" size="100%">Javadiyan, Shari&#xD;Germein, Kitty C&#xD;Cooksley, Clare M&#xD;Ramezanpour, Mahnaz&#xD;Singh, Narinder&#xD;Wormald, Peter-John&#xD;Vreugde, Sarah&#xD;Psaltis, Alkis J&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1917-1920. doi: 10.1111/all.15289. Epub 2022 Mar 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35322438</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9311691 Fusetec, Tissium, Speakers of bureauSequiris and Shareholder of Chitogel. Professor Peter-John Wormald receives Royalties from Medtronic,Integra; Consultant for Stryker, Neurent, Neilmed and Stockholder of Chitogel and Fusetec. A/Prof NarinderSingh is a consultant for ResMed, Optinose, Nasus, GSK and ENT Technologies and receives grant fundingfrom Microsoft.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15289</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2107</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2107</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cespedes, J. A.</style></author><author><style face="normal" font="default" size="100%">Lebron-Martin, C.</style></author><author><style face="normal" font="default" size="100%">Garcia-Oton, R.</style></author><author><style face="normal" font="default" size="100%">Delgado, M. J.</style></author><author><style face="normal" font="default" size="100%">Martin-Astorga, M. D. C.</style></author><author><style face="normal" font="default" size="100%">Perez-Sanchez, N.</style></author><author><style face="normal" font="default" size="100%">Gomez, F.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Canas, J. A.</style></author><author><style face="normal" font="default" size="100%">Aranda, C. J.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universidad de Malaga (UMA), Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-Plataforma BIONAND (IBIMA-BIONAND), Malaga, Spain.&#xD;Allergy Clinical Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vitro supporting diagnostic tools in plant-food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2540-2543</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/04/08</style></edition><section><style face="normal" font="default" size="100%">2540</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Food</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37026176</style></accession-num><notes><style face="normal" font="default" size="100%">Cespedes, Jose Antonio&#xD;Lebron-Martin, Clara&#xD;Garcia-Oton, Reyes&#xD;Delgado, Maria Jesus&#xD;Martin-Astorga, Maria Del Carmen&#xD;Perez-Sanchez, Natalia&#xD;Gomez, Francisca&#xD;Torres, Maria Jose&#xD;Canas, Jose Antonio&#xD;Aranda, Carlos Jose&#xD;Mayorga, Cristobalina&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2540-2543. doi: 10.1111/all.15737. Epub 2023 Apr 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37026176</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15737</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>329</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">329</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ko, H. L.</style></author><author><style face="normal" font="default" size="100%">Zhuo, N.</style></author><author><style face="normal" font="default" size="100%">Chang, Z. W.</style></author><author><style face="normal" font="default" size="100%">Santosa, A.</style></author><author><style face="normal" font="default" size="100%">Kalimuddin, S.</style></author><author><style face="normal" font="default" size="100%">Lim, X. R.</style></author><author><style face="normal" font="default" size="100%">Tan, S. Y.</style></author><author><style face="normal" font="default" size="100%">Lye, D. C.</style></author><author><style face="normal" font="default" size="100%">Toh, D.</style></author><author><style face="normal" font="default" size="100%">Young, B. E.</style></author><author><style face="normal" font="default" size="100%">Renia, L.</style></author><author><style face="normal" font="default" size="100%">Lee, H. Y.</style></author><author><style face="normal" font="default" size="100%">Ren, E. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Singapore Immunology Network, A*STAR, Singapore, Singapore.&#xD;A*STAR Infectious Diseases Labs, A*STAR, Singapore, Singapore.&#xD;Changi General Hospital, Singapore, Singapore.&#xD;Duke-NUS Medical School, Singapore, Singapore.&#xD;Singapore General Hospital, Singapore, Singapore.&#xD;Tan Tock Seng Hospital, Singapore, Singapore.&#xD;National Centre for Infectious Diseases, Singapore, Singapore.&#xD;Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.&#xD;Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Health Sciences Authority, Singapore, Singapore.&#xD;School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.&#xD;Department of Microbiology &amp; Immunology, National University of Singapore, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vitro vaccine challenge of PBMCs from BNT162b2 anaphylaxis patients reveals HSP90alpha-NOD2-NLRP3 nexus</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">304-307</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/09/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*NLR Family, Pyrin Domain-Containing 3 Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammasomes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nod2 Signaling Adaptor Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 mRNA vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">HSP90alpha</style></keyword><keyword><style face="normal" font="default" size="100%">NLRP3 inflammasome</style></keyword><keyword><style face="normal" font="default" size="100%">Nod2</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36056775</style></accession-num><notes><style face="normal" font="default" size="100%">Ko, Hui Ling&#xD;Zhuo, Nicole&#xD;Chang, Zi Wei&#xD;Santosa, Anindita&#xD;Kalimuddin, Shirin&#xD;Lim, Xin Rong&#xD;Tan, Seow Yen&#xD;Lye, David Chien&#xD;Toh, Dorothy&#xD;Young, Barnaby Edward&#xD;Renia, Laurent&#xD;Lee, Haur Yueh&#xD;Ren, Ee Chee&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):304-307. doi: 10.1111/all.15503. Epub 2022 Sep 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36056775</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15503</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1962</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1962</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Haasnoot, M. L.</style></author><author><style face="normal" font="default" size="100%">Kleuskens, M. T. A.</style></author><author><style face="normal" font="default" size="100%">Lopez-Rincon, A.</style></author><author><style face="normal" font="default" size="100%">Diks, M. A. P.</style></author><author><style face="normal" font="default" size="100%">Terreehorst, I.</style></author><author><style face="normal" font="default" size="100%">Akkerdaas, J. H.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">van Ampting, M. T. J.</style></author><author><style face="normal" font="default" size="100%">Garssen, J.</style></author><author><style face="normal" font="default" size="100%">Redegeld, F. A.</style></author><author><style face="normal" font="default" size="100%">van Esch, Bcam</style></author><author><style face="normal" font="default" size="100%">Bredenoord, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands.&#xD;Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.&#xD;Department of Data Science, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Department of Ear Nose Throat, Amsterdam UMC, Amsterdam, The Netherlands.&#xD;Department of Experimental Immunology, Amsterdam UMC, Amsterdam, The Netherlands.&#xD;Danone Nutricia Research, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vivo and ex vivo inflammatory responses of the esophageal mucosa to food challenge in adults with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2044-2047</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/03/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Enteritis</style></keyword><keyword><style face="normal" font="default" size="100%">Food/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Gastritis</style></keyword><keyword><style face="normal" font="default" size="100%">Esophageal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophilia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36869622</style></accession-num><notes><style face="normal" font="default" size="100%">Haasnoot, Maria L&#xD;Kleuskens, Mirelle T A&#xD;Lopez-Rincon, Alejandro&#xD;Diks, Mara A P&#xD;Terreehorst, Ingrid&#xD;Akkerdaas, Jaap H&#xD;van Ree, Ronald&#xD;van Ampting, Marleen T J&#xD;Garssen, Johan&#xD;Redegeld, Frank A&#xD;van Esch, Betty C A M&#xD;Bredenoord, Albert J&#xD;eng&#xD;Danone Nutricia Research/&#xD;NWO domain Applied and Engineered Sciences/&#xD;Topsector Agri and Food/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2044-2047. doi: 10.1111/all.15694. Epub 2023 Mar 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36869622</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15694</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2579</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2579</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Smith, L. R.</style></author><author><style face="normal" font="default" size="100%">Shah, R. J.</style></author><author><style face="normal" font="default" size="100%">King, A. J.</style></author><author><style face="normal" font="default" size="100%">Shenoy, E. S.</style></author><author><style face="normal" font="default" size="100%">Landman, A. B.</style></author><author><style face="normal" font="default" size="100%">Hashimoto, D. M.</style></author><author><style face="normal" font="default" size="100%">Blumenthal, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Infection Control Unit, Mass General Brigham, Boston, Massachusetts, USA.&#xD;Department of Emergency Medicine, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Occupational Health Services, Mass General Brigham, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Incidence and risk factors of cutaneous reactions to the first COVID-19 booster vaccine</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">575-578</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">hives</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38979795</style></accession-num><notes><style face="normal" font="default" size="100%">Smith, Liam R&#xD;Shah, Ruchi J&#xD;King, Andrew J&#xD;Shenoy, Erica S&#xD;Landman, Adam B&#xD;Hashimoto, Dean M&#xD;Blumenthal, Kimberly&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):575-578. doi: 10.1111/all.16223. Epub 2024 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38979795</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16223</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>244</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">244</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Akenroye, A.</style></author><author><style face="normal" font="default" size="100%">Zhou, G.</style></author><author><style face="normal" font="default" size="100%">Jackson, J. W.</style></author><author><style face="normal" font="default" size="100%">Segal, J.</style></author><author><style face="normal" font="default" size="100%">Alexander, G. C.</style></author><author><style face="normal" font="default" size="100%">Singh, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Channing Division of Network Medicine, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.&#xD;Department of Medicine, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.&#xD;Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.&#xD;Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.&#xD;Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland, USA.&#xD;Department of Family Medicine and Community Health, Medicine and Quantitative Health Sciences, University of Massachusetts, Worcester, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Incidence of adverse events prompting switching between biologics among adults with asthma: A retrospective cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1116-1119</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/10/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/epidemiology/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36286487</style></accession-num><notes><style face="normal" font="default" size="100%">Akenroye, Ayobami&#xD;Zhou, Guohai&#xD;Jackson, John W&#xD;Segal, Jodi&#xD;Alexander, G Caleb&#xD;Singh, Sonal&#xD;eng&#xD;R00 MD015767/MD/NIMHD NIH HHS/&#xD;K99 MD015767/MD/NIMHD NIH HHS/&#xD;K01 HL145320/HL/NHLBI NIH HHS/&#xD;T32 HL139426/HL/NHLBI NIH HHS/&#xD;K24 AG049036/AG/NIA NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):1116-1119. doi: 10.1111/all.15564. Epub 2022 Nov 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36286487</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10066822</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15564</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2329</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2329</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, E.</style></author><author><style face="normal" font="default" size="100%">Rhee, E. H.</style></author><author><style face="normal" font="default" size="100%">Yu, J.</style></author><author><style face="normal" font="default" size="100%">Kim, K.</style></author><author><style face="normal" font="default" size="100%">Kim, H. S.</style></author><author><style face="normal" font="default" size="100%">Im, C. H.</style></author><author><style face="normal" font="default" size="100%">Seo, G.</style></author><author><style face="normal" font="default" size="100%">Kim, W. K.</style></author><author><style face="normal" font="default" size="100%">Song, D. J.</style></author><author><style face="normal" font="default" size="100%">Park, J. S.</style></author><author><style face="normal" font="default" size="100%">Yoo, Y.</style></author><author><style face="normal" font="default" size="100%">Suh, D. I.</style></author><author><style face="normal" font="default" size="100%">Jung, S.</style></author><author><style face="normal" font="default" size="100%">Yoon, J.</style></author><author><style face="normal" font="default" size="100%">Lim, D. H.</style></author><author><style face="normal" font="default" size="100%">Baek, H. S.</style></author><author><style face="normal" font="default" size="100%">Shin, M.</style></author><author><style face="normal" font="default" size="100%">Kwon, J. W.</style></author><author><style face="normal" font="default" size="100%">Jang, G. C.</style></author><author><style face="normal" font="default" size="100%">Seo, J. H.</style></author><author><style face="normal" font="default" size="100%">Woo, S. I.</style></author><author><style face="normal" font="default" size="100%">Shin, Y. H.</style></author><author><style face="normal" font="default" size="100%">Lee, J. S.</style></author><author><style face="normal" font="default" size="100%">Lee, S. W.</style></author><author><style face="normal" font="default" size="100%">Yang, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.&#xD;Department of Pediatrics, Pediatric Allergy and Respiratory Center, Soonchunhyang University College of Medicine, Seoul, Korea.&#xD;Department of Pediatrics, Childhood Asthma Atopy Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.&#xD;Department of Pediatrics, Bucheon St. Mary&apos;s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.&#xD;Department of Pediatrics, Inje University Seoul Paik Hospital, Seoul, Korea.&#xD;Department of Pediatrics, Korea University Guro Hospital, Seoul, Korea.&#xD;Department of Pediatrics, Korea University Anam Hospital, Seoul, Korea.&#xD;Department of Pediatrics, Pusan National University Yangsan Hospital, Yangsan, Korea.&#xD;Department of Pediatrics, Chung-Ang University Gwang-Myeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea.&#xD;Department of Pediatrics, College of Medicine, Inha University, Incheon, Korea.&#xD;Department of Pediatrics, Hallym University Kangdong Sacred Heart Hospital, Seoul, Korea.&#xD;Department of Pediatrics, Soonchunhyang University School of Medicine, Bucheon, Korea.&#xD;Department of Pediatrics, National Health Insurance Service Ilsan Hospital, Ilsan, Korea.&#xD;Department of Pediatrics, Dankook University Hospital, Cheonan, Korea.&#xD;Department of Pediatrics, College of Medicine, Chungbuk National University, Cheongju, Korea.&#xD;Department of Pediatrics, Yeouido St. Mary&apos;s Hospital, The Catholic University of Korea, Seoul, Korea.&#xD;Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.&#xD;Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Incidence of healthcare utilization for allergic and respiratory infectious diseases in children with asthma before and during the COVID-19 pandemic</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1064-1067</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/12/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/epidemiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Communicable Diseases/complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Acceptance of Health Care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38140807</style></accession-num><notes><style face="normal" font="default" size="100%">Lee, Eun&#xD;Rhee, Eun Hee&#xD;Yu, Jinho&#xD;Kim, Kyunghoon&#xD;Kim, Hwan Soo&#xD;Im, Chae Hyun&#xD;Seo, Gitae&#xD;Kim, Woo Kyung&#xD;Song, Dae Jin&#xD;Park, Ji Soo&#xD;Yoo, Young&#xD;Suh, Dong In&#xD;Jung, Sungsu&#xD;Yoon, Jisun&#xD;Lim, Dae Hyun&#xD;Baek, Hey Sung&#xD;Shin, Meeyong&#xD;Kwon, Ji Won&#xD;Jang, Gwang Cheon&#xD;Seo, Ju Hee&#xD;Woo, Sung Il&#xD;Shin, Youn Ho&#xD;Lee, Ju Suk&#xD;Lee, Seung Won&#xD;Yang, Hyeon-Jong&#xD;eng&#xD;2016-ER6703/Korea National Institute of Health/&#xD;2019-ER6701/Korea National Institute of Health/&#xD;2022-ER1201-00/Korea National Institute of Health/&#xD;2022-01/Soonchunhyang University/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):1064-1067. doi: 10.1111/all.15992. Epub 2023 Dec 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38140807</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15992</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1054</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1054</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bjorbak Alnaes, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Clinical Allergy, Department of Occupational Diseases, Haukeland University Hospital, Bergen, Norway.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Include desensitization to radiocontrast media in the diagnostic algorithm of radio contrast media hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1302-1303</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/04/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Contrast Media/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33840115</style></accession-num><notes><style face="normal" font="default" size="100%">Bjorbak Alnaes, Marie&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1302-1303. doi: 10.1111/all.14637.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33840115</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14637</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3109</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3109</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Curman, P.</style></author><author><style face="normal" font="default" size="100%">Thaci, D.</style></author><author><style face="normal" font="default" size="100%">Ludwig, R. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Lubeck Institute of Experimental Dermatology, University of Lubeck, Lubeck, Germany.&#xD;Dermato-Venereology Clinic, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.&#xD;Dermatology and Venereology Division, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden.&#xD;Institute and Comprehensive Center for Inflammation Medicine, University of Lubeck, Lubeck, Germany.&#xD;Department of Dermatology, University-Hospital Schleswig-Holstein (UKSH), Lubeck, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increased Cardiovascular Risk in Chronic Spontaneous Urticaria: A Large Real-World Cohort Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/25</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 25</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41137491</style></accession-num><notes><style face="normal" font="default" size="100%">Curman, Philip&#xD;Thaci, Diamant&#xD;Ludwig, Ralf J&#xD;eng&#xD;Novartis/&#xD;Deutsche Forschungsgemeinschaft/&#xD;Stockholms Lans Landsting/&#xD;HudFonden/&#xD;Stiftung Schleswig-Holsteinische Landschaft/&#xD;Karolinska Institutet/&#xD;Tore Nilsons Stiftelse for Medicinsk Forskning/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct 25. doi: 10.1111/all.70128.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41137491</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70128</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>737</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">737</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chantveerawong, T.</style></author><author><style face="normal" font="default" size="100%">Sangkangjanavanich, S.</style></author><author><style face="normal" font="default" size="100%">Chiewchalermsri, C.</style></author><author><style face="normal" font="default" size="100%">Pradubpongsa, P.</style></author><author><style face="normal" font="default" size="100%">Mitthamsiri, W.</style></author><author><style face="normal" font="default" size="100%">Jindarat, S.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Sangasapaviliya, A.</style></author><author><style face="normal" font="default" size="100%">Boonpiyathad, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand.&#xD;Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Medicine, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, Thailand.&#xD;Department of Pharmacology, Phramongkutklao College of Medicine, Bangkok, Thailand.&#xD;Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, and the Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, and the Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increased circulating CRTH2(+) Tregs are associated with asthma control and exacerbation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">681-685</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandin D2</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Prostaglandin</style></keyword><keyword><style face="normal" font="default" size="100%">ALI culture</style></keyword><keyword><style face="normal" font="default" size="100%">Crth2</style></keyword><keyword><style face="normal" font="default" size="100%">Pgd2</style></keyword><keyword><style face="normal" font="default" size="100%">Treg cells</style></keyword><keyword><style face="normal" font="default" size="100%">Tregs dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">allergic</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma control test score</style></keyword><keyword><style face="normal" font="default" size="100%">asthma exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial tight junction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34676900</style></accession-num><notes><style face="normal" font="default" size="100%">Chantveerawong, Teerapol&#xD;Sangkangjanavanich, Sasipa&#xD;Chiewchalermsri, Chirawat&#xD;Pradubpongsa, Panitan&#xD;Mitthamsiri, Wat&#xD;Jindarat, Sarawut&#xD;Wang, Ming&#xD;Akdis, Mubeccel&#xD;Sokolowska, Milena&#xD;Akdis, Cezmi A&#xD;Sangasapaviliya, Atik&#xD;Boonpiyathad, Tadech&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):681-685. doi: 10.1111/all.15145. Epub 2021 Oct 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34676900</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15145</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1580</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1580</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chantveerawong, T.</style></author><author><style face="normal" font="default" size="100%">Sangkangjanavanich, S.</style></author><author><style face="normal" font="default" size="100%">Chiewchalermsri, C.</style></author><author><style face="normal" font="default" size="100%">Pradubpongsa, P.</style></author><author><style face="normal" font="default" size="100%">Mitthamsiri, W.</style></author><author><style face="normal" font="default" size="100%">Jindarat, S.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Sangasapaviliya, A.</style></author><author><style face="normal" font="default" size="100%">Boonpiyathad, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand.&#xD;Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Medicine, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, Thailand.&#xD;Department of Pharmacology, Phramongkutklao College of Medicine, Bangkok, Thailand.&#xD;Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, and the Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, and the Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increased circulating CRTH2(+) Tregs are associated with asthma control and exacerbation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">681-685</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandin D2</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Prostaglandin</style></keyword><keyword><style face="normal" font="default" size="100%">ALI culture</style></keyword><keyword><style face="normal" font="default" size="100%">Crth2</style></keyword><keyword><style face="normal" font="default" size="100%">Pgd2</style></keyword><keyword><style face="normal" font="default" size="100%">Treg cells</style></keyword><keyword><style face="normal" font="default" size="100%">Tregs dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">allergic</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma control test score</style></keyword><keyword><style face="normal" font="default" size="100%">asthma exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial tight junction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34676900</style></accession-num><notes><style face="normal" font="default" size="100%">Chantveerawong, Teerapol&#xD;Sangkangjanavanich, Sasipa&#xD;Chiewchalermsri, Chirawat&#xD;Pradubpongsa, Panitan&#xD;Mitthamsiri, Wat&#xD;Jindarat, Sarawut&#xD;Wang, Ming&#xD;Akdis, Mubeccel&#xD;Sokolowska, Milena&#xD;Akdis, Cezmi A&#xD;Sangasapaviliya, Atik&#xD;Boonpiyathad, Tadech&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):681-685. doi: 10.1111/all.15145. Epub 2021 Oct 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34676900</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15145</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1098</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1098</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lammers, A.</style></author><author><style face="normal" font="default" size="100%">Brinkman, P.</style></author><author><style face="normal" font="default" size="100%">Te Nijenhuis, L. H.</style></author><author><style face="normal" font="default" size="100%">de Vries, R.</style></author><author><style face="normal" font="default" size="100%">Dagelet, Y. W. F.</style></author><author><style face="normal" font="default" size="100%">Duijvelaar, E.</style></author><author><style face="normal" font="default" size="100%">Xu, B.</style></author><author><style face="normal" font="default" size="100%">Abdel-Aziz, M. I.</style></author><author><style face="normal" font="default" size="100%">Vijverberg, S. J.</style></author><author><style face="normal" font="default" size="100%">Neerincx, A. H.</style></author><author><style face="normal" font="default" size="100%">Frey, U.</style></author><author><style face="normal" font="default" size="100%">Lutter, R.</style></author><author><style face="normal" font="default" size="100%">Maitland-van der Zee, A. H.</style></author><author><style face="normal" font="default" size="100%">Sterk, P. J.</style></author><author><style face="normal" font="default" size="100%">Sinha, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Breathomix BV, Leiden, The Netherlands.&#xD;EuroMov Digital Health in Motion, Univ Montpellier, IMT Mines Ales, Ales, France.&#xD;University Children&apos;s Hospital Basel UKBB, University of Basel, Basel, Switzerland.&#xD;Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection &amp; Immunity Institute, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increased day-to-day fluctuations in exhaled breath profiles after a rhinovirus challenge in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2488-2499</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Breath Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Electronic Nose</style></keyword><keyword><style face="normal" font="default" size="100%">Exhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">omics and systems biology</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword><keyword><style face="normal" font="default" size="100%">Louwrina H. te Nijenhuis has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Rianne de Vries reports</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees and other from Breathomix BV, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Yennece</style></keyword><keyword><style face="normal" font="default" size="100%">W.F. Dagelet has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Erik Duijvelaar has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Binbin Xu has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Mahmoud I. Abdel-Aziz has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Susanne J. Vijverberg has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Anne H. Neerincx has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Urs Frey has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Rene Lutter reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">European Respiratory Society/Marie Curie (EU), during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">Anke H. Maitland - van der Zee reports grants from GSK, grants from Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, grants from Chiesi, personal fees from Astra Zeneca, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Boehringer Ingelheim, grants from Vertex, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Peter</style></keyword><keyword><style face="normal" font="default" size="100%">J. Sterk reports other from being Scientific Advisor and having an officially</style></keyword><keyword><style face="normal" font="default" size="100%">non-substantial interest in the start-up company Breathomix BV that produces</style></keyword><keyword><style face="normal" font="default" size="100%">eNoses and accompanying cloud algorithms, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">Anirban Sinha has nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33704785</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Early detection/prediction of flare-ups in asthma, commonly triggered by viruses, would enable timely treatment. Previous studies on exhaled breath analysis by electronic nose (eNose) technology could discriminate between stable and unstable episodes of asthma, using single/few time-points. To investigate its monitoring properties during these episodes, we examined day-to-day fluctuations in exhaled breath profiles, before and after a rhinovirus-16 (RV16) challenge, in healthy and asthmatic adults. METHODS: In this proof-of-concept study, 12 atopic asthmatic and 12 non-atopic healthy adults were prospectively followed thrice weekly, 60 days before, and 30 days after a RV16 challenge. Exhaled breath profiles were detected using an eNose, consisting of 7 different sensors. Per sensor, individual means were calculated using pre-challenge visits. Absolute deviations (|%|) from this baseline were derived for all visits. Within-group comparisons were tested with Mann-Whitney U tests and receiver operating characteristic (ROC) analysis. Finally, Spearman&apos;s correlations between the total change in eNose deviations and fractional exhaled nitric oxide (FeNO), cold-like symptoms, and pro-inflammatory cytokines were examined. RESULTS: Both groups had significantly increased eNose fluctuations post-challenge, which in asthma started 1 day post-challenge, before the onset of symptoms. Discrimination between pre- and post-challenge reached an area under the ROC curve of 0.82 (95% CI = 0.65-0.99) in healthy and 0.97 (95% CI = 0.91-1.00) in asthmatic adults. The total change in eNose deviations moderately correlated with IL-8 and TNFalpha (rho approximately .50-0.60) in asthmatics. CONCLUSION: Electronic nose fluctuations rapidly increase after a RV16 challenge, with distinct differences between healthy and asthmatic adults, suggesting that this technology could be useful in monitoring virus-driven unstable episodes in asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Lammers, Ariana&#xD;Brinkman, Paul&#xD;Te Nijenhuis, Louwrina H&#xD;de Vries, Rianne&#xD;Dagelet, Yennece W F&#xD;Duijvelaar, Erik&#xD;Xu, Binbin&#xD;Abdel-Aziz, Mahmoud I&#xD;Vijverberg, Susanne J&#xD;Neerincx, Anne H&#xD;Frey, Urs&#xD;Lutter, Rene&#xD;Maitland-van der Zee, Anke H&#xD;Sterk, Peter J&#xD;Sinha, Anirban&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2488-2499. doi: 10.1111/all.14811. Epub 2021 Mar 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33704785</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8360186</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14811</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1371</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1371</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, Z.</style></author><author><style face="normal" font="default" size="100%">Vadali, V. G.</style></author><author><style face="normal" font="default" size="100%">Szabady, R. L.</style></author><author><style face="normal" font="default" size="100%">Zhang, W.</style></author><author><style face="normal" font="default" size="100%">Norman, J. M.</style></author><author><style face="normal" font="default" size="100%">Roberts, B.</style></author><author><style face="normal" font="default" size="100%">Tibshirani, R.</style></author><author><style face="normal" font="default" size="100%">Desai, M.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author><author><style face="normal" font="default" size="100%">Andorf, S.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Vedanta Biosciences, Cambridge, MA, USA.&#xD;Department of Statistics, Stanford University, Stanford, CA, USA.&#xD;Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Departments of Pathology and of Microbiology and Immunology, Stanford University, Stanford, CA, USA.&#xD;Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.&#xD;Divisions of Biomedical Informatics and Allergy &amp; Immunology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increased diversity of gut microbiota during active oral immunotherapy in peanut-allergic adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">927-930</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Oit</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32750160</style></accession-num><notes><style face="normal" font="default" size="100%">He, Ziyuan&#xD;Vadali, Vl Gouri&#xD;Szabady, Rose L&#xD;Zhang, Wenming&#xD;Norman, Jason M&#xD;Roberts, Bruce&#xD;Tibshirani, Robert&#xD;Desai, Manisha&#xD;Chinthrajah, R Sharon&#xD;Galli, Stephen J&#xD;Andorf, Sandra&#xD;Nadeau, Kari C&#xD;eng&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):927-930. doi: 10.1111/all.14540. Epub 2020 Aug 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32750160</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7858691</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14540</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1620</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1620</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, Z.</style></author><author><style face="normal" font="default" size="100%">Vadali, V. G.</style></author><author><style face="normal" font="default" size="100%">Szabady, R. L.</style></author><author><style face="normal" font="default" size="100%">Zhang, W.</style></author><author><style face="normal" font="default" size="100%">Norman, J. M.</style></author><author><style face="normal" font="default" size="100%">Roberts, B.</style></author><author><style face="normal" font="default" size="100%">Tibshirani, R.</style></author><author><style face="normal" font="default" size="100%">Desai, M.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author><author><style face="normal" font="default" size="100%">Andorf, S.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Vedanta Biosciences, Cambridge, MA, USA.&#xD;Department of Statistics, Stanford University, Stanford, CA, USA.&#xD;Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Departments of Pathology and of Microbiology and Immunology, Stanford University, Stanford, CA, USA.&#xD;Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.&#xD;Divisions of Biomedical Informatics and Allergy &amp; Immunology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increased diversity of gut microbiota during active oral immunotherapy in peanut-allergic adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">927-930</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Oit</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32750160</style></accession-num><notes><style face="normal" font="default" size="100%">He, Ziyuan&#xD;Vadali, Vl Gouri&#xD;Szabady, Rose L&#xD;Zhang, Wenming&#xD;Norman, Jason M&#xD;Roberts, Bruce&#xD;Tibshirani, Robert&#xD;Desai, Manisha&#xD;Chinthrajah, R Sharon&#xD;Galli, Stephen J&#xD;Andorf, Sandra&#xD;Nadeau, Kari C&#xD;eng&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):927-930. doi: 10.1111/all.14540. Epub 2020 Aug 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32750160</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7858691</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14540</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3299</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3299</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Gongqi</style></author><author><style face="normal" font="default" size="100%">Jie, Huiru</style></author><author><style face="normal" font="default" size="100%">Huang, Chunli</style></author><author><style face="normal" font="default" size="100%">Wang, Zhen</style></author><author><style face="normal" font="default" size="100%">Gu, Wei</style></author><author><style face="normal" font="default" size="100%">Xiong, Tiantian</style></author><author><style face="normal" font="default" size="100%">Liu, Yanxin</style></author><author><style face="normal" font="default" size="100%">Feng, Yuchen</style></author><author><style face="normal" font="default" size="100%">Yi, Lingling</style></author><author><style face="normal" font="default" size="100%">Xue, Zheng</style></author><author><style face="normal" font="default" size="100%">Zhen, Guohua</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increased Primary Cilia Contribute to Airway Epithelium Remodeling in Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70309</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70309</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3278</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3278</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chamy, Léa</style></author><author><style face="normal" font="default" size="100%">Maire, Kilian</style></author><author><style face="normal" font="default" size="100%">Hateb, Charlotte</style></author><author><style face="normal" font="default" size="100%">Subramaniam, Arun</style></author><author><style face="normal" font="default" size="100%">Deddouche-Grass, Safia</style></author><author><style face="normal" font="default" size="100%">Reber, Laurent L.</style></author><author><style face="normal" font="default" size="100%">Lutz, Pierre G.</style></author><author><style face="normal" font="default" size="100%">Lamsoul, Isabelle</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increasing Filamins A and B in Th2 Lymphocytes as a Therapeutic Opportunity to Attenuate Airway Inflammation in Mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70247</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70247</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2677</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2677</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leth-Moller, K. B.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Apostolovic, D.</style></author><author><style face="normal" font="default" size="100%">Sorensen, J. A.</style></author><author><style face="normal" font="default" size="100%">Vestergaard, C.</style></author><author><style face="normal" font="default" size="100%">Madsen, F.</style></author><author><style face="normal" font="default" size="100%">Kjaer, L. J.</style></author><author><style face="normal" font="default" size="100%">Hansen, T.</style></author><author><style face="normal" font="default" size="100%">Jonsson, A.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author><author><style face="normal" font="default" size="100%">Linneberg, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Clinical Research and Prevention, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.&#xD;Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.&#xD;Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Dermatology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.&#xD;Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.&#xD;Section for Animal Welfare and Disease Control, Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark.&#xD;Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increasing prevalence of galactose-alpha-1,3-galactose sensitization in the Danish general adult population</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">297-308</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/10/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Tick Bites</style></keyword><keyword><style face="normal" font="default" size="100%">*Galactose/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Disaccharides</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-gal syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">blood group a</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="default" size="100%">red meat allergy</style></keyword><keyword><style face="normal" font="default" size="100%">tick bites</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific. Marianne van Hage has received lecture fees from Thermo Fisher</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific and Astra Zeneca outside the submitted work. Christian Vestergaard has</style></keyword><keyword><style face="normal" font="default" size="100%">received speaker honorarium/participated in Add Borads/been investigator for</style></keyword><keyword><style face="normal" font="default" size="100%">Abbvie, Pfizer, Sanofi, Leo Pharma, OM pharma, Pierre Fabre, Almirall, Astra</style></keyword><keyword><style face="normal" font="default" size="100%">Zeneca, Eli Lilly, Novartis. Flemming Madsen has received a travel grant from</style></keyword><keyword><style face="normal" font="default" size="100%">Orion Pharma. With no relation to the present manuscript, Simon Francis Thomsen</style></keyword><keyword><style face="normal" font="default" size="100%">has received research support from Janssen, LEO Pharma, Novartis, Sanofi and UCB,</style></keyword><keyword><style face="normal" font="default" size="100%">and has been a speaker/consultant for Abbvie, Almirall, Eli Lilly, Janssen, LEO</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Novartis, Pfizer, Sanofi, Symphogen, UCB, and Union therapeutics.</style></keyword><keyword><style face="normal" font="default" size="100%">Danijela Apostolovic, Jennifer Astrup Sorensen, Lene Jung Kjaer, Torben Hansen,</style></keyword><keyword><style face="normal" font="default" size="100%">Anna Jonsson, and Allan Linneberg and have no conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39441524</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Alpha-gal syndrome is a novel food allergy to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) present in mammalian meat. Tick bites are considered an important route of sensitization to alpha-gal. Data on alpha-gal sensitization in the general population is scant. We utilized a unique data source of repeated population-based health examination studies to assess prevalence, time trends, risk factors, and characteristics of alpha-gal sensitization. METHODS: Alpha-gal sensitization was assessed in &gt;11.000 adults from four health examination studies of randomly invited residents in the Copenhagen region conducted in 1990-1991, 2011-2012, 2012-2015, and 2016-2017. Alpha-gal sensitization was defined as serum specific IgE (sIgE) to alpha-gal &gt;/=0.1 kU(A)/L; &gt;/=0.35 kU(A)/L; &gt;/=0.7 kU(A)/L; &gt;/=3.5 kU(A)/L. The population was characterized according to genetically determined ABO blood group, aeroallergen sensitization, and pets at home. RESULTS: The prevalence of sIgE to alpha-gal &gt;/=0.1 kUA/L was 1.3% in 1990-1991, 3.7% in 2012-2015 and 3.2% in 2016-2017. Of those sensitized to alpha-gal &gt;97% reported to consume red meat at least once a week, even for sIgE to alpha-gal &gt;/=3.5 kU(A)/L. Male sex, older age, aeroallergen sensitization, cat at home, and blood group A were associated with increased odds of alpha-gal sensitization. The known protective effect of blood group B was confirmed. CONCLUSION: In this general adult population, the prevalence of alpha-gal sensitization had doubled from 1990-1991 to 2016-2017. This could potentially be due to increased tick exposure and an increased atopic predisposition.</style></abstract><notes><style face="normal" font="default" size="100%">Leth-Moller, Katja Biering&#xD;van Hage, Marianne&#xD;Apostolovic, Danijela&#xD;Sorensen, Jennifer Astrup&#xD;Vestergaard, Christian&#xD;Madsen, Flemming&#xD;Kjaer, Lene Jung&#xD;Hansen, Torben&#xD;Jonsson, Anna&#xD;Thomsen, Simon Francis&#xD;Linneberg, Allan&#xD;eng&#xD;Astma- och Allergiforbundet/&#xD;Insamlingsstiftelsen Cancer- och Allergifonden/&#xD;Hjart-Lungfonden/&#xD;FoUI-986234/The Region Stockholm/&#xD;Konsul Th C Berghs Stiftelse/&#xD;Magnus Bergvalls Stiftelse/&#xD;Stiftelsen Konung Gustaf V:s 80-arsfond/&#xD;Ellen, Walter and Lennart Hesselman Foundation for Scientific Research/&#xD;Lundbeck Foundation/&#xD;Helsefonden/&#xD;Danmarks Frie Forskningsfond/&#xD;TrygFonden/&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):297-308. doi: 10.1111/all.16360. Epub 2024 Oct 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39441524</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724227</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16360</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1135</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1135</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hou, A.</style></author><author><style face="normal" font="default" size="100%">Silverberg, J. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.&#xD;Department of Dermatology, George Washington University School of Medicine, Washington, District of Columbia, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increasing rates of influenza vaccination were associated with lower asthma prevalence in United States children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2273-2275</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Influenza Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">*Influenza, Human/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">health</style></keyword><keyword><style face="normal" font="default" size="100%">influenza vaccination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33624361</style></accession-num><notes><style face="normal" font="default" size="100%">Hou, Alexander&#xD;Silverberg, Jonathan I&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2273-2275. doi: 10.1111/all.14790. Epub 2021 Mar 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33624361</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14790</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>807</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">807</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schoos, A. M.</style></author><author><style face="normal" font="default" size="100%">Chawes, B. L.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, M. A.</style></author><author><style face="normal" font="default" size="100%">Bisgaard, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Pediatrics, Slagelse Sygehus, Slagelse, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increasing severity of early-onset atopic dermatitis, but not late-onset, associates with development of aeroallergen sensitization and allergic rhinitis in childhood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1254-1262</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/09/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">early-onset</style></keyword><keyword><style face="normal" font="default" size="100%">late-onset</style></keyword><keyword><style face="normal" font="default" size="100%">specific IgE</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34558075</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Early exposure to allergens through a defect skin barrier has been proposed as a mechanism for inducing sensitization and development of allergic diseases. We hypothesized that early-onset, severe atopic dermatitis (AD) is associated with development of aeroallergen sensitization and allergic rhinitis. METHODS: We included 368 children from the Copenhagen Prospective Studies on Asthma in Childhood(2000) (COPSAC(2000) ) at-risk mother-child cohort. AD was diagnosed prospectively based on Hanifin&amp;Rajka&apos;s criteria and severity assessed using the Scoring Atopic Dermatitis (SCORAD) index. Early-onset AD was defined as debut &lt;/=1 year, late-onset as debut from 1-6 years. Aeroallergen sensitization and allergic rhinitis were diagnosed at ages 6-7 and 12 years. Associations between early-onset and late-onset AD and allergy endpoints were calculated using general estimating equations (GEE) models to compute the overall odds ratios (OR) for both time points. RESULTS: Early-onset AD (yes/no) and severity (SCORAD) were associated with development of aeroallergen sensitization during childhood; GEE OR = 1.68 [1.08; 2.62], p = .02 and 1.08 [1.03; 1.12], p &lt; .001, whereas late-onset AD showed a borderline significant association and late-onset severity showed no association; GEE OR = 1.65 [0.92; 2.94], p = .08 and 1.01 [0.97; 1.06], p = .55. The same trend was seen for allergic rhinitis with significant association between early-onset AD and allergic rhinitis; GEE OR = 1.56 [1.01; 2.41], p = .04 and severity; GEE OR = 1.09 [1.05; 1.13], p &lt; .001, whereas late-onset AD showed no association. The effects on sensitization and rhinitis of early-onset versus late-onset AD severity were significantly different: p-interaction(sensitization) = .03 and p-interaction(rhinitis) &lt; .01. CONCLUSION: Increasing severity of early-onset AD, but not late-onset AD, associates with aeroallergen sensitization and allergic rhinitis later in childhood.</style></abstract><notes><style face="normal" font="default" size="100%">Schoos, Ann-Marie Malby&#xD;Chawes, Bo Lund&#xD;Bonnelykke, Klaus&#xD;Stokholm, Jakob&#xD;Rasmussen, Morten Arendt&#xD;Bisgaard, Hans&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1254-1262. doi: 10.1111/all.15108. Epub 2021 Oct 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34558075</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15108</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2615</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2615</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chan, R.</style></author><author><style face="normal" font="default" size="100%">Stewart, K.</style></author><author><style face="normal" font="default" size="100%">Kuo, C. R.</style></author><author><style face="normal" font="default" size="100%">Lipworth, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Indirect case-matched comparison of anti-IL4Ralpha versus anti-IL5Ralpha on airway hyperresponsiveness</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2873-2875</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/08/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-4 Receptor alpha Subunit/antagonists &amp; inhibitors/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-5 Receptor alpha Subunit/antagonists &amp; inhibitors/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Hypersensitivity/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchial Hyperreactivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">benralizumab</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">mannitol</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39152564</style></accession-num><notes><style face="normal" font="default" size="100%">Chan, Rory&#xD;Stewart, Kirsten&#xD;Kuo, Chris RuiWen&#xD;Lipworth, Brian&#xD;eng&#xD;Sanofi/&#xD;AstraZeneca/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2873-2875. doi: 10.1111/all.16283. Epub 2024 Aug 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39152564</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16283</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2527</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2527</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Department of Clinical Immunology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-Med Medical Research Institute, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Indoor and outdoor pollutants-No safe amount of air to breathe in</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1649-1652</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution, Indoor/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38922700</style></accession-num><notes><style face="normal" font="default" size="100%">Agache, Ioana&#xD;Jutel, Marek&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1649-1652. doi: 10.1111/all.16209. Epub 2024 Jun 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38922700</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16209</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2758</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2758</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Oh, S.</style></author><author><style face="normal" font="default" size="100%">Han, J.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, College of Veterinary Medicine, Chonnam National University, Gwangju, South Korea.&#xD;BK 21 Project Team, College of Veterinary Medicine, Chonnam National University, Gwangju, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Indoor Mycotoxin Exposure on Atopic Dermatitis in Companion Dogs</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1124-1126</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/08</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39644196</style></accession-num><notes><style face="normal" font="default" size="100%">Oh, Songju&#xD;Han, Jungwoo&#xD;Kim, Ha-Jung&#xD;eng&#xD;NRF-2023R1A2C1005348/National Research Foundation of Korea/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1124-1126. doi: 10.1111/all.16407. Epub 2024 Dec 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39644196</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969294</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16407</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>280</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">280</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Orsi, L.</style></author><author><style face="normal" font="default" size="100%">Savoure, M.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Jacquemin, B.</style></author><author><style face="normal" font="default" size="100%">Siroux, V.</style></author><author><style face="normal" font="default" size="100%">Jaakkola, M. S.</style></author><author><style face="normal" font="default" size="100%">Jaakkola, J. J. K.</style></author><author><style face="normal" font="default" size="100%">Leynaert, B.</style></author><author><style face="normal" font="default" size="100%">Nadif, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Equipe d&apos;Epidemiologie respiratoire integrative, CESP, Villejuif, France.&#xD;French Environment and Energy Management Agency, Angers Cedex 01, France.&#xD;Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en sante, environnement et travail) - UMR_S 1085, Rennes, France.&#xD;Team of Environmental Epidemiology Applied to the Development and Respiratory Health, Institute for Advanced Biosciences (IAB), Inserm U1209, CNRS UMR 5309, Universite Grenoble Alpes, Grenoble, France.&#xD;Center for Environmental and Respiratory Health Research (CERH); Medical Research Center Oulu (MRC Oulu), Biocenter Oulu, University of Oulu, Oulu, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Indoor visible moulds and rhinitis in adults: The EGEA study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">864-867</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/09/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Fungi</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution, Indoor/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36136293</style></accession-num><notes><style face="normal" font="default" size="100%">Orsi, Laurent&#xD;Savoure, Marine&#xD;Bousquet, Jean&#xD;Jacquemin, Benedicte&#xD;Siroux, Valerie&#xD;Jaakkola, Maritta S&#xD;Jaakkola, Jouni J K&#xD;Leynaert, Benedicte&#xD;Nadif, Rachel&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):864-867. doi: 10.1111/all.15525. Epub 2022 Sep 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36136293</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15525</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1967</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1967</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Doyen, V.</style></author><author><style face="normal" font="default" size="100%">Poirot, A.</style></author><author><style face="normal" font="default" size="100%">Maumy-Bertrand, M.</style></author><author><style face="normal" font="default" size="100%">Bertrand, F.</style></author><author><style face="normal" font="default" size="100%">Khayath, N.</style></author><author><style face="normal" font="default" size="100%">Domis, N.</style></author><author><style face="normal" font="default" size="100%">de Blay, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chest Medicine, CHU UCL Namur, Universite Catholique de Louvain, Yvoir, Belgium.&#xD;Chest diseases Department, Strasbourg University Hospital, Strasbourg, France.&#xD;LIST3N, Universite de Technologie de Troyes, Troyes, France.&#xD;IRMA, CNRS UMR 7501, Labex IRMIA, Universite de Strasbourg, Strasbourg, France.&#xD;EA 3070 Federation of Translational Medicine, FHU Homicare, University of Strasbourg, Strasbourg, France.&#xD;CRISALIS / F-CRIN INSERM Network, Toulouse, France.&#xD;ALYATEC, Environmental Exposure Chamber, Strasbourg, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Induction of immunosuppressive CD39 but not the trafficking C-C chemokine receptor 4 on Treg during LAR in mite allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2031-2033</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Chemokines, CC</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">*Mites</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Chemokine</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36811418</style></accession-num><notes><style face="normal" font="default" size="100%">Doyen, Virginie&#xD;Poirot, Anh&#xD;Maumy-Bertrand, Myriam&#xD;Bertrand, Frederic&#xD;Khayath, Naji&#xD;Domis, Nathalie&#xD;de Blay, Frederic&#xD;eng&#xD;adiral/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2031-2033. doi: 10.1111/all.15681. Epub 2023 Mar 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36811418</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15681</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1028</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1028</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Seppo, A. E.</style></author><author><style face="normal" font="default" size="100%">Bu, K.</style></author><author><style face="normal" font="default" size="100%">Jumabaeva, M.</style></author><author><style face="normal" font="default" size="100%">Thakar, J.</style></author><author><style face="normal" font="default" size="100%">Choudhury, R. A.</style></author><author><style face="normal" font="default" size="100%">Yonemitsu, C.</style></author><author><style face="normal" font="default" size="100%">Bode, L.</style></author><author><style face="normal" font="default" size="100%">Martina, C. A.</style></author><author><style face="normal" font="default" size="100%">Allen, M.</style></author><author><style face="normal" font="default" size="100%">Tamburini, S.</style></author><author><style face="normal" font="default" size="100%">Piras, E.</style></author><author><style face="normal" font="default" size="100%">Wallach, D. S.</style></author><author><style face="normal" font="default" size="100%">Looney, R. J.</style></author><author><style face="normal" font="default" size="100%">Clemente, J. C.</style></author><author><style face="normal" font="default" size="100%">Jarvinen, K. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Center for Food Allergy, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Golisano Children&apos;s Hospital, Rochester, New York, USA.&#xD;Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.&#xD;Department of Microbiology and Immunology and Department of Biostatistics, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.&#xD;Division of Neonatology and Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of California San Diego, La Jolla, California, USA.&#xD;Mother-Milk-Infant Center of Research Excellence (MOMI CORE), University of California, San Diego, La Jolla, California, USA.&#xD;Department of Public Health &amp; Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.&#xD;Division of Allergy, Immunology, and Rheumatology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.&#xD;Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Infant gut microbiome is enriched with Bifidobacterium longum ssp. infantis in Old Order Mennonites with traditional farming lifestyle</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3489-3503</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/04/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Bifidobacterium longum subspecies infantis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Farms</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Life Style</style></keyword><keyword><style face="normal" font="default" size="100%">Milk, Human</style></keyword><keyword><style face="normal" font="default" size="100%">Oligosaccharides</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Bifidobacterium</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">farming lifestyle</style></keyword><keyword><style face="normal" font="default" size="100%">human milk</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33905556</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Growing up on traditional, single-family farms is associated with protection against asthma in school age, but the mechanisms against early manifestations of atopic disease are largely unknown. We sought determine the gut microbiome and metabolome composition in rural Old Order Mennonite (OOM) infants at low risk and Rochester, NY urban/suburban infants at high risk for atopic diseases. METHODS: In a cohort of 65 OOM and 39 Rochester mother-infant pairs, 101 infant stool and 61 human milk samples were assessed by 16S rRNA gene sequencing for microbiome composition and qPCR to quantify Bifidobacterium spp. and B. longum ssp. infantis (B. infantis), a consumer of human milk oligosaccharides (HMOs). Fatty acids (FAs) were analyzed in 34 stool and human 24 milk samples. Diagnoses and symptoms of atopic diseases by 3 years of age were assessed by telephone. RESULTS: At a median age of 2 months, stool was enriched with Bifidobacteriaceae, Clostridiaceae, and Aerococcaceae in the OOM compared with Rochester infants. B. infantis was more abundant (p &lt; .001) and prevalent, detected in 70% of OOM compared with 21% of Rochester infants (p &lt; .001). Stool colonized with B. infantis had higher levels of lactate and several medium- to long/odd-chain FAs. In contrast, paired human milk was enriched with a distinct set of FAs including butyrate. Atopic diseases were reported in 6.5% of OOM and 35% of Rochester children (p &lt; .001). CONCLUSION: A high rate of B. infantis colonization, similar to that seen in developing countries, is found in the OOM at low risk for atopic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Seppo, Antti E&#xD;Bu, Kevin&#xD;Jumabaeva, Madina&#xD;Thakar, Juilee&#xD;Choudhury, Rakin A&#xD;Yonemitsu, Chloe&#xD;Bode, Lars&#xD;Martina, Camille A&#xD;Allen, Maria&#xD;Tamburini, Sabrina&#xD;Piras, Enrica&#xD;Wallach, David S&#xD;Looney, R John&#xD;Clemente, Jose C&#xD;Jarvinen, Kirsi M&#xD;eng&#xD;R21 TR002516/TR/NCATS NIH HHS/&#xD;U01 AI131344/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3489-3503. doi: 10.1111/all.14877. Epub 2021 May 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33905556</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9230048</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14877</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1598</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1598</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Seppo, A. E.</style></author><author><style face="normal" font="default" size="100%">Bu, K.</style></author><author><style face="normal" font="default" size="100%">Jumabaeva, M.</style></author><author><style face="normal" font="default" size="100%">Thakar, J.</style></author><author><style face="normal" font="default" size="100%">Choudhury, R. A.</style></author><author><style face="normal" font="default" size="100%">Yonemitsu, C.</style></author><author><style face="normal" font="default" size="100%">Bode, L.</style></author><author><style face="normal" font="default" size="100%">Martina, C. A.</style></author><author><style face="normal" font="default" size="100%">Allen, M.</style></author><author><style face="normal" font="default" size="100%">Tamburini, S.</style></author><author><style face="normal" font="default" size="100%">Piras, E.</style></author><author><style face="normal" font="default" size="100%">Wallach, D. S.</style></author><author><style face="normal" font="default" size="100%">Looney, R. J.</style></author><author><style face="normal" font="default" size="100%">Clemente, J. C.</style></author><author><style face="normal" font="default" size="100%">Jarvinen, K. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Center for Food Allergy, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Golisano Children&apos;s Hospital, Rochester, New York, USA.&#xD;Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.&#xD;Department of Microbiology and Immunology and Department of Biostatistics, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.&#xD;Division of Neonatology and Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of California San Diego, La Jolla, California, USA.&#xD;Mother-Milk-Infant Center of Research Excellence (MOMI CORE), University of California, San Diego, La Jolla, California, USA.&#xD;Department of Public Health &amp; Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.&#xD;Division of Allergy, Immunology, and Rheumatology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.&#xD;Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Infant gut microbiome is enriched with Bifidobacterium longum ssp. infantis in Old Order Mennonites with traditional farming lifestyle</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3489-3503</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/04/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Bifidobacterium longum subspecies infantis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Farms</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Life Style</style></keyword><keyword><style face="normal" font="default" size="100%">Milk, Human</style></keyword><keyword><style face="normal" font="default" size="100%">Oligosaccharides</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Bifidobacterium</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">farming lifestyle</style></keyword><keyword><style face="normal" font="default" size="100%">human milk</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33905556</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Growing up on traditional, single-family farms is associated with protection against asthma in school age, but the mechanisms against early manifestations of atopic disease are largely unknown. We sought determine the gut microbiome and metabolome composition in rural Old Order Mennonite (OOM) infants at low risk and Rochester, NY urban/suburban infants at high risk for atopic diseases. METHODS: In a cohort of 65 OOM and 39 Rochester mother-infant pairs, 101 infant stool and 61 human milk samples were assessed by 16S rRNA gene sequencing for microbiome composition and qPCR to quantify Bifidobacterium spp. and B. longum ssp. infantis (B. infantis), a consumer of human milk oligosaccharides (HMOs). Fatty acids (FAs) were analyzed in 34 stool and human 24 milk samples. Diagnoses and symptoms of atopic diseases by 3 years of age were assessed by telephone. RESULTS: At a median age of 2 months, stool was enriched with Bifidobacteriaceae, Clostridiaceae, and Aerococcaceae in the OOM compared with Rochester infants. B. infantis was more abundant (p &lt; .001) and prevalent, detected in 70% of OOM compared with 21% of Rochester infants (p &lt; .001). Stool colonized with B. infantis had higher levels of lactate and several medium- to long/odd-chain FAs. In contrast, paired human milk was enriched with a distinct set of FAs including butyrate. Atopic diseases were reported in 6.5% of OOM and 35% of Rochester children (p &lt; .001). CONCLUSION: A high rate of B. infantis colonization, similar to that seen in developing countries, is found in the OOM at low risk for atopic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Seppo, Antti E&#xD;Bu, Kevin&#xD;Jumabaeva, Madina&#xD;Thakar, Juilee&#xD;Choudhury, Rakin A&#xD;Yonemitsu, Chloe&#xD;Bode, Lars&#xD;Martina, Camille A&#xD;Allen, Maria&#xD;Tamburini, Sabrina&#xD;Piras, Enrica&#xD;Wallach, David S&#xD;Looney, R John&#xD;Clemente, Jose C&#xD;Jarvinen, Kirsi M&#xD;eng&#xD;R21 TR002516/TR/NCATS NIH HHS/&#xD;U01 AI131344/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3489-3503. doi: 10.1111/all.14877. Epub 2021 May 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33905556</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9230048</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14877</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2369</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2369</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fardig, M.</style></author><author><style face="normal" font="default" size="100%">Hoyer, A.</style></author><author><style face="normal" font="default" size="100%">Almqvist, C.</style></author><author><style face="normal" font="default" size="100%">Bains, K. E. S.</style></author><author><style face="normal" font="default" size="100%">Carlsen, K. C. L.</style></author><author><style face="normal" font="default" size="100%">Gudmundsdottir, H. K.</style></author><author><style face="normal" font="default" size="100%">Granum, B.</style></author><author><style face="normal" font="default" size="100%">Haugen, G. N.</style></author><author><style face="normal" font="default" size="100%">Hedlin, G.</style></author><author><style face="normal" font="default" size="100%">Jonassen, C. M.</style></author><author><style face="normal" font="default" size="100%">Konradsen, J. R.</style></author><author><style face="normal" font="default" size="100%">Lie, A.</style></author><author><style face="normal" font="default" size="100%">Rehbinder, E. M.</style></author><author><style face="normal" font="default" size="100%">Skjerven, H. O.</style></author><author><style face="normal" font="default" size="100%">Staff, A. C.</style></author><author><style face="normal" font="default" size="100%">Vettukattil, R.</style></author><author><style face="normal" font="default" size="100%">Soderhall, C.</style></author><author><style face="normal" font="default" size="100%">Nordlund, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women&apos;s and Children&apos;s Health, Karolinska Institutet, Stockholm, Sweden.&#xD;Astrid Lindgren Children&apos;s Hospital, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.&#xD;Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.&#xD;Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.&#xD;Department of Chemical Toxicology, Norwegian Institute of Public Health, Oslo, Norway.&#xD;Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway.&#xD;Department of Virology, Norwegian Institute of Public Health, Oslo, Norway.&#xD;Genetic Unit, Centre for Laboratory Medicine, Ostfold Hospital Trust, Kalnes, Norway.&#xD;Department of Dermatology and Vaenerology, Oslo University Hospital, Oslo, Norway.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Infant lung function and early skin barrier impairment in the development of asthma at age 3 years</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">667-678</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/01/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema/epidemiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/genetics/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Intermediate Filament Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">PreventADALL</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">infants</style></keyword><keyword><style face="normal" font="default" size="100%">lung function</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier function</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38239099</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Largely unexplored, we investigated if lower lung function, impaired skin barrier function by transepidermal water loss (TEWL), eczema, and filaggrin (FLG) mutations in infancy were associated with asthma in early childhood. METHODS: From the factorially designed randomized controlled intervention study PreventADALL, we evaluated 1337/2394 children from all randomization groups with information on asthma at age 3 years, and at age 3 months either lung function, TEWL, eczema, and/or FLG mutations. Lower lung function was defined as the time to peak tidal expiratory flow to expiratory time (t(PTEF) /t(E) ) &lt;0.25, and skin barrier impairment as a high TEWL &gt;9.50 g/m(2) /h. Eczema was clinically observed, and DNA genotyped for FLG mutations. Asthma was defined as asthma-like symptoms (&gt;/=3 episodes of bronchial obstruction) between age 2-3 years as well as a history of doctor-diagnosed asthma and/or asthma medication use. Associations were analyzed in logistic regression models, presented with adjusted ORs (aOR) and 95% confidence intervals (CI). RESULTS: Lower lung function and skin barrier impairment were associated with asthma in general; aOR (95% CI) 5.4 (2.1, 13.7) and 1.6 (1.1, 2.5), while eczema and FLG mutations were associated with asthma in children with atopic dermatitis or allergic sensitization only. Stratifying for sex, the risk of asthma was only increased in boys with lower lung function; aOR (95% CI) 7.7 (2.5, 23.6), and in girls with FLG mutations; aOR (95% CI) 3.5 (1.5, 8.2). CONCLUSION: Lower lung function and impaired skin barrier function in infancy may increase the risk of asthma at age 3 years.</style></abstract><notes><style face="normal" font="default" size="100%">Fardig, Martin&#xD;Hoyer, Angela&#xD;Almqvist, Catarina&#xD;Bains, Karen Eline S&#xD;Carlsen, Karin C Lodrup&#xD;Gudmundsdottir, Hrefna Katrin&#xD;Granum, Berit&#xD;Haugen, Guttorm Nils&#xD;Hedlin, Gunilla&#xD;Jonassen, Christine Monceyron&#xD;Konradsen, Jon R&#xD;Lie, Anine&#xD;Rehbinder, Eva Maria&#xD;Skjerven, Havard O&#xD;Staff, Anne Cathrine&#xD;Vettukattil, Riyas&#xD;Soderhall, Cilla&#xD;Nordlund, Bjorn&#xD;eng&#xD;The Norwegian Research Council/&#xD;South-Eastern Norway Regional Health Authority/&#xD;The University of Oslo/&#xD;Oslo University Hospital/&#xD;The Foundation for Healthcare and Allergy Research in Sweden -Vardalstiftelsen/&#xD;Health and Rehabilitation Norway/&#xD;Furst Medical Laboratory, Oslo, Norway/&#xD;Thermo Fisher Scientific, Uppsala, Sweden/&#xD;Arne Ingel&apos;s legat/&#xD;Norwegian Society of Dermatology and Venerology/&#xD;Forskningsradet om Halsa, Arbetsliv och Valfard/&#xD;Region Stockholm/&#xD;The Sven Jerring Foundation/&#xD;Swedish Order of Freemasons Foundation Barnhuset/&#xD;The Swedish Research Council - the Initiative for Clinical Therapy Research/&#xD;SFO-V Karolinska Institutet/&#xD;The Swedish Heart-Lung Foundation/&#xD;Sykehuset Ostfold/&#xD;The Kloster foundation/&#xD;The Norwegian Association of Asthma and Allergy/&#xD;Barnestiftelsen at Oslo University Hospital/&#xD;The Samaritan Foundation for Pediatric Research/&#xD;The Frithjof Nansen Institute/&#xD;Roche/&#xD;The Magnus Bergwall foundation/&#xD;The Hesselman Foundation/&#xD;The Swedish Society of Medicine/&#xD;The Konsul Th C Bergh&apos;s Foundation/&#xD;KI grants/&#xD;The King Gustaf V 80th Birthday Foundation/&#xD;The Pediatric Research Foundation at Astrid Lindgren Children&apos;s Hospital/&#xD;The Cancer- and Allergy Foundation/&#xD;The Swedish Asthma and Allergy Association&apos;s Research Foundation/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):667-678. doi: 10.1111/all.16024. Epub 2024 Jan 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38239099</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16024</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2608</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2608</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Thorsen, J.</style></author><author><style face="normal" font="default" size="100%">Schoos, A. M.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, M. A.</style></author><author><style face="normal" font="default" size="100%">Brandt, S.</style></author><author><style face="normal" font="default" size="100%">Sorensen, S. J.</style></author><author><style face="normal" font="default" size="100%">Vahman, N.</style></author><author><style face="normal" font="default" size="100%">Chawes, B.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Food Science, University of Copenhagen, Frederiksberg, Denmark.&#xD;Department of Pediatrics, Slagelse Hospital, Slagelse, Denmark.&#xD;Department of Biology, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Infantile colic is associated with development of later constipation and atopic disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3360-3372</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/08/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Constipation/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Colic/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatitis, Atopic/epidemiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/epidemiology/diagnosis/microbiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity, Immediate/epidemiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">colic</style></keyword><keyword><style face="normal" font="default" size="100%">metagenomics</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota, RNA, ribosomal, 16S</style></keyword><keyword><style face="normal" font="default" size="100%">board for ALK and has received a speaking fee from Thermo Fisher Scientific. The</style></keyword><keyword><style face="normal" font="default" size="100%">authors declare no other potential, perceived, or real conflict of interest</style></keyword><keyword><style face="normal" font="default" size="100%">regarding the content of this manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39161223</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Infantile colic is a common condition with limited knowledge about later clinical manifestations. We evaluated the role of the early life gut microbiome in infantile colic and later development of atopic and gastrointestinal disorders. METHODS: Copenhagen Prospective Studies on Asthma in Childhood(2010) cohort was followed with 6 years of extensive clinical phenotyping. The 1-month gut microbiome was analyzed by 16S rRNA sequencing. Infantile colic was evaluated at age 3 months by interviews. Clinical endpoints included constipation to age 3 years and prospectively diagnosed asthma and atopic dermatitis in the first 6 years of life, and allergic sensitization from skin prick tests, specific Immunoglobulin E, and component analyses. RESULTS: Of 695 children, 55 children (7.9%) had infantile colic. Several factors were associated with colic including race, breastfeeding, and pets. The 1-month gut microbiome composition and taxa abundances were not associated with colic, however a sparse Partial Least Squares model including combined abundances of nine species was moderately predictive of colic: median, cross-validated AUC = 0.627, p = .003. Children with infantile colic had an increased risk of developing constipation (aOR, 2.88 [1.51-5.35], p = .001) later in life, but also asthma (aHR, 1.69 [1.02-2.79], p = .040), atopic dermatitis (aHR, 1.84 [1.20-2.81], p = .005) and had a higher number of positive allergic components (adjusted difference, 116% [14%-280%], p = .012) in the first 6 years. These associations were not mediated by gut microbiome differences. CONCLUSIONS: We link infantile colic with risk of developing constipation and atopic disorders in the first 6 years of life, which was not mediated through an altered gut microbiome at age 1-month. These results suggest infantile colic to involve gastrointestinal and/or atopic mechanisms.</style></abstract><notes><style face="normal" font="default" size="100%">Stokholm, Jakob&#xD;Thorsen, Jonathan&#xD;Schoos, Ann-Marie Malby&#xD;Rasmussen, Morten Arendt&#xD;Brandt, Sarah&#xD;Sorensen, Soren Johannes&#xD;Vahman, Nilo&#xD;Chawes, Bo&#xD;Bonnelykke, Klaus&#xD;eng&#xD;Region Hovedstaden/&#xD;Strategiske Forskningsrad/&#xD;Lundbeck Foundation/&#xD;Sundhed og Sygdom, Det Frie Forskningsrad/&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3360-3372. doi: 10.1111/all.16274. Epub 2024 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39161223</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657018</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16274</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1053</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1053</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gonzalez-Perez, R.</style></author><author><style face="normal" font="default" size="100%">Poza-Guedes, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, Hospital Universitario de Canarias, Tenerife, Spain.&#xD;Severe Asthma Unit, Hospital Universitario de Canarias, Tenerife, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inferring clinical relevance of Der p 23 from the restricted effect on treatment outcomes after tablet allergy immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1298-1299</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/04/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33840116</style></accession-num><notes><style face="normal" font="default" size="100%">Gonzalez-Perez, Ruperto&#xD;Poza-Guedes, Paloma&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1298-1299. doi: 10.1111/all.14433.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33840116</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14433</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3043</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3043</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ugarte-Berzal, E.</style></author><author><style face="normal" font="default" size="100%">Martens, E.</style></author><author><style face="normal" font="default" size="100%">Pereira, R. V. S.</style></author><author><style face="normal" font="default" size="100%">Wets, D.</style></author><author><style face="normal" font="default" size="100%">Ganseman, E.</style></author><author><style face="normal" font="default" size="100%">Gouwy, M.</style></author><author><style face="normal" font="default" size="100%">Breynaert, C.</style></author><author><style face="normal" font="default" size="100%">Guntermann, C.</style></author><author><style face="normal" font="default" size="100%">Schrijvers, R.</style></author><author><style face="normal" font="default" size="100%">Proost, P.</style></author><author><style face="normal" font="default" size="100%">Opdenakker, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology, Immunology and Transplantation, Laboratory of Immunobiology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.&#xD;Department of Microbiology, Immunology and Transplantation, Laboratory of Molecular Immunology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.&#xD;Department of Microbiology, Immunology, and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.&#xD;Department General Internal Medicine-Allergy and Clinical Immunology, University Hospitals Leuven, Leuven, Belgium.&#xD;Immunology Disease Area, Novartis BioMedical Research, Basel, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An Inflammation-Associated Control Mechanism of Allergy by Proteolysis of IgE</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2781-2799</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/08/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/metabolism/immunology/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">*Proteolysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology/metabolism/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgE/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophils/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Peptide Hydrolases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Binding</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">acute inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">granulocytes</style></keyword><keyword><style face="normal" font="default" size="100%">matrix metalloproteinases</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">proteolysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40785316</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Adaptive IgE-mediated reactions are faster than immune responses that depend on IgM, IgA, and IgG. Normal serum IgE concentrations are highly variable among individuals and extremely low in comparison with those of IgM and IgG. Omalizumab is a clinically approved monoclonal antibody that selectively binds free IgE, preventing allergy-specific IgE from binding to FcepsilonRI expressed on mast cells and basophils, thereby inhibiting degranulation and mediator release. We aimed to evaluate proteolysis of IgE within the contexts of acute inflammations in vitro and in patient samples and the biological effects of resulting IgE proteoforms. METHODS: IgE was subjected in vitro to neutrophil proteases. Biochemical and biological IgE proteoform identification was performed and IgE receptor binding capacity and abundance in patient samples were evaluated. RESULTS: Whereas IgG, IgA, and IgM are neutrophil protease-resistant, the IgE heavy chain was cleaved in a bait region by these inflammation-associated proteases. The cleavages occurred on both free and CD23-bound IgE; however, not with FcepsilonRI-bound IgE. Proteolysis generated two proteoforms: a large IgE cleavage fragment (IgEcl) and a smaller IgE carboxyterminal truncation fragment Cepsilontr. Proteolysed IgE did not bind to its receptors. The Cepsilontr fragment shared with chemokines high affinity to glycosaminoglycans (GAGs) and synergistically attracted neutrophils. The discovered bait region in IgE corresponded with a shared epitope recognized by omalizumab, and omalizumab prevented IgE proteolysis. Both IgEcl and Cepsilontr were present in plasma samples from patients suffering from IgE-mediated allergies, chronic spontaneous urticaria, and more abundantly in atopic dermatitis (AD) patients. CONCLUSIONS: This work reveals new mechanistic insights into the immunobiology of IgE and the action of omalizumab with potential clinical impacts. Indeed, IgE-specific cleavage by inflammation-associated granulocyte proteinases may be an important feedback mechanism to control allergic responses.</style></abstract><notes><style face="normal" font="default" size="100%">Ugarte-Berzal, Estefania&#xD;Martens, Erik&#xD;Pereira, Rafaela Vaz Sousa&#xD;Wets, Dries&#xD;Ganseman, Eva&#xD;Gouwy, Mieke&#xD;Breynaert, Christine&#xD;Guntermann, Christine&#xD;Schrijvers, Rik&#xD;Proost, Paul&#xD;Opdenakker, Ghislain&#xD;eng&#xD;C14/23/143/Onderzoeksraad, KU Leuven/&#xD;C3/22/054/Onderzoeksraad, KU Leuven/&#xD;G036423N/Fonds Wetenschappelijk Onderzoek/&#xD;Novartis Pharma/&#xD;Rega Foundation/&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2781-2799. doi: 10.1111/all.16622. Epub 2025 Aug 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40785316</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16622</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2246</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2246</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Golebski, K.</style></author><author><style face="normal" font="default" size="100%">van der Lans, R. J. L.</style></author><author><style face="normal" font="default" size="100%">van Egmond, D.</style></author><author><style face="normal" font="default" size="100%">de Groot, E.</style></author><author><style face="normal" font="default" size="100%">Spits, H.</style></author><author><style face="normal" font="default" size="100%">der Zee, A. M.</style></author><author><style face="normal" font="default" size="100%">van Drunen, C. M.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Otorhinolaryngology &amp; Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inflammatory innate lymphoid cells predict response speed to dupilumab in chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3265-3268</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/09/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Reaction Time</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/complications/drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37705461</style></accession-num><notes><style face="normal" font="default" size="100%">Golebski, Korneliusz&#xD;van der Lans, Rik Johannes Leonardus&#xD;van Egmond, Danielle&#xD;de Groot, Esther&#xD;Spits, Hergen&#xD;der Zee, Anke-Hilse Maitland-van&#xD;van Drunen, Cornelis Maria&#xD;Fokkens, Wytske Johanna&#xD;Reitsma, Sietze&#xD;eng&#xD;Amsterdam University Medical Centers/&#xD;STIMAG/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3265-3268. doi: 10.1111/all.15877. Epub 2023 Sep 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37705461</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15877</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2272</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2272</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Krenger, P. S.</style></author><author><style face="normal" font="default" size="100%">Josi, R.</style></author><author><style face="normal" font="default" size="100%">Sobczak, J.</style></author><author><style face="normal" font="default" size="100%">Velazquez, T. L. C.</style></author><author><style face="normal" font="default" size="100%">Balke, I.</style></author><author><style face="normal" font="default" size="100%">Skinner, M. A.</style></author><author><style face="normal" font="default" size="100%">Kramer, M. F.</style></author><author><style face="normal" font="default" size="100%">Scott, C. J. W.</style></author><author><style face="normal" font="default" size="100%">Hewings, S.</style></author><author><style face="normal" font="default" size="100%">Heath, M. D.</style></author><author><style face="normal" font="default" size="100%">Zeltins, A.</style></author><author><style face="normal" font="default" size="100%">Bachmann, M. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Rheumatology and Immunology, University Hospital of Bern, Bern, Switzerland.&#xD;Department of BioMedical Research, University of Bern, Bern, Switzerland.&#xD;Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.&#xD;Allergy Therapeutics (UK) Ltd, Worthing, UK.&#xD;Latvian Biomedical Research and Study Centre, Riga, Latvia.&#xD;Bencard Allergie GmbH, Munich, Germany.&#xD;Saiba AG, Zurich, Switzerland.&#xD;Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), The Jenner Institute, University of Oxford, Oxford, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Influence of antigen density and TLR ligands on preclinical efficacy of a VLP-based vaccine against peanut allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">184-199</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/10/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines, Virus-Like Particle</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 7</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Rna</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy vaccines and mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37815010</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Virus-like particle (VLP) Peanut is a novel immunotherapeutic vaccine candidate for the treatment of peanut allergy. The active pharmaceutical ingredient represents cucumber mosaic VLPs (CuMV(TT) -VLPs) that are genetically fused with one of the major peanut allergens, Ara h 2 (CuMV(TT) -Ara h 2). We previously demonstrated the immunogenicity and the protective capacity of VLP Peanut-based immunization in a murine model for peanut allergy. Moreover, a Phase I clinical trial has been initiated using VLP Peanut material manufactured following a GMP-compliant manufacturing process. Key product characterization studies were undertaken here to understand the role and contribution of critical quality attributes that translate as predictive markers of immunogenicity and protective efficacy for clinical vaccine development. METHOD: The role of prokaryotic RNA encapsulated within VLP Peanut on vaccine immunogenicity was assessed by producing a VLP Peanut batch with a reduced RNA content (VLP Peanut low RNA). Immunogenicity and peanut allergen challenge studies were conducted with VLP Peanut low RNA, as well as with VLP Peanut in WT and TLR 7 KO mice. Furthermore, mass spectrometry and SDS-PAGE based methods were used to determine Ara h 2 antigen density on the surface of VLP Peanut particles. This methodology was subsequently applied to investigate the relationship between Ara h 2 antigen density and immunogenicity of VLP Peanut. RESULTS: A TLR 7 dependent formation of Ara h 2 specific high-avidity IgG antibodies, as well as a TLR 7 dependent change in the dominant IgG subclass, was observed following VLP Peanut vaccination, while total allergen-specific IgG remained relatively unaffected. Consistently, a missing TLR 7 signal caused only a weak decrease in allergen tolerability after vaccination. In contrast, a reduced RNA content for VLP Peanut resulted in diminished total Ara h 2 specific IgG responses, followed by a significant impairment in peanut allergen tolerability. The discrepant effect on allergen tolerance caused by an absent TLR 7 signal versus a reduced RNA content is explained by the observation that VLP Peanut-derived RNA not only stimulates TLR 7 but also TLR 3. Additionally, a strong correlation was observed between the number of Ara h 2 antigens displayed on the surface of VLP Peanut particles and the vaccine&apos;s immunogenicity and protective capacity. CONCLUSIONS: Our findings demonstrate that prokaryotic RNA encapsulated within VLP Peanut, including antigen density of Ara h 2 on viral particles, are key contributors to the immunogenicity and protective capacity of the vaccine. Thus, antigenicity and RNA content are two critical quality attributes that need to be determined at the stage of manufacturing, providing robust information regarding the immunogenicity and protective capacity of VLP Peanut in the mouse which has translational relevance to the human setting.</style></abstract><notes><style face="normal" font="default" size="100%">Krenger, Pascal S&#xD;Josi, Romano&#xD;Sobczak, Jan&#xD;Velazquez, Thalia L C&#xD;Balke, Ina&#xD;Skinner, Murray A&#xD;Kramer, Matthias F&#xD;Scott, Callum J W&#xD;Hewings, Simon&#xD;Heath, Matthew D&#xD;Zeltins, Andris&#xD;Bachmann, Martin F&#xD;eng&#xD;Allergy Therapeutics/&#xD;Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):184-199. doi: 10.1111/all.15897. Epub 2023 Oct 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37815010</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15897</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2733</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2733</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kortekaas Krohn, I.</style></author><author><style face="normal" font="default" size="100%">Callewaert, C.</style></author><author><style face="normal" font="default" size="100%">Belasri, H.</style></author><author><style face="normal" font="default" size="100%">De Pessemier, B.</style></author><author><style face="normal" font="default" size="100%">Diez Lopez, C.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Perez-Gordo, M.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Unger, Z.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Homey, B.</style></author><author><style face="normal" font="default" size="100%">Gomez-Casado, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Vrije Universiteit Brussel (VUB), Skin Immunology &amp; Immune Tolerance (SKIN) Research Group, Brussels, Belgium.&#xD;Vrije Universiteit Brussel (VUB), Department of Dermatology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.&#xD;Faculty of Bioscience Engineering, Ghent University, Centre for Microbial Ecology and Technology (CMET), Ghent, Belgium.&#xD;Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, Odense, Denmark.&#xD;APC Microbiome Ireland, School of Microbiology, and Department of medicine, University College Cork, Cork, Ireland.&#xD;Departamento de Ciencias Medicas Basicas, Instituto de Medicina Molecular Aplicada (IMMA) Nemesio Diez, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Dermatology, University Hospital, Heinrich-Heine University, Duesseldorf, Germany.&#xD;Institute of Pathophysiology and Allergy Research, Centre of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The influence of lifestyle and environmental factors on host resilience through a homeostatic skin microbiota: An EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3269-3284</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/microbiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">*Life Style</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Diseases/etiology/immunology/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Environment</style></keyword><keyword><style face="normal" font="default" size="100%">homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">lifestyle</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Stiftung vorm. Bundner Heilstatte Arosa and OM Pharma as well as</style></keyword><keyword><style face="normal" font="default" size="100%">speaker&apos;s fee from AstraZeneca. The other authors declare that they do not have</style></keyword><keyword><style face="normal" font="default" size="100%">any conflict of interest to disclose in relation to this manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39485000</style></accession-num><abstract><style face="normal" font="default" size="100%">Human skin is colonized with skin microbiota that includes commensal bacteria, fungi, arthropods, archaea and viruses. The composition of the microbiota varies at different anatomical locations according to changes in body temperature, pH, humidity/hydration or sebum content. A homeostatic skin microbiota is crucial to maintain epithelial barrier functions, to protect from invading pathogens and to interact with the immune system. Therefore, maintaining homeostasis holds promise to be an achievable goal for microbiome-directed treatment strategies as well as a prophylactic strategy to prevent the development of skin diseases, as dysbiosis or disruption of homeostatic skin microbiota is associated with skin inflammation. A healthy skin microbiome is likely modulated by genetic as well as environmental and lifestyle factors. In this review, we aim to provide a complete overview of the lifestyle and environmental factors that can contribute to maintaining the skin microbiome healthy. Awareness of these factors could be the basis for a prophylactic strategy to prevent the development of skin diseases or to be used as a therapeutic approach.</style></abstract><notes><style face="normal" font="default" size="100%">Kortekaas Krohn, Inge&#xD;Callewaert, Chris&#xD;Belasri, Hafsa&#xD;De Pessemier, Britta&#xD;Diez Lopez, Celia&#xD;Mortz, Charlotte G&#xD;O&apos;Mahony, Liam&#xD;Perez-Gordo, Marina&#xD;Sokolowska, Milena&#xD;Unger, Zsofia&#xD;Untersmayr, Eva&#xD;Homey, Bernhard&#xD;Gomez-Casado, Cristina&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3269-3284. doi: 10.1111/all.16378. Epub 2024 Nov 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39485000</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657040</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16378</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1012</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1012</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dahlin, J. S.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Metcalfe, D. D.</style></author><author><style face="normal" font="default" size="100%">Pejler, G.</style></author><author><style face="normal" font="default" size="100%">Sagi-Eisenberg, R.</style></author><author><style face="normal" font="default" size="100%">Nilsson, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergy, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Dermatology and Allergy, Dermatological Allergology, Allergie-Centrum-Charite, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health, Berlin, Germany.&#xD;Mast Cell Biology Section, Laboratory of Allergic Diseases, NIAID, NIH, Bethesda, MD, USA.&#xD;Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.&#xD;Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden.&#xD;Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.&#xD;Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The ingenious mast cell: Contemporary insights into mast cell behavior and function</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">83-99</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/05/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">mastocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33955017</style></accession-num><abstract><style face="normal" font="default" size="100%">Mast cells are (in)famous for their role in allergic diseases, but the physiological and pathophysiological roles of this ingenious cell are still not fully understood. Mast cells are important for homeostasis and surveillance of the human system, recognizing both endogenous and exogenous agents, which induce release of a variety of mediators acting on both immune and non-immune cells, including nerve cells, fibroblasts, endothelial cells, smooth muscle cells, and epithelial cells. During recent years, clinical and experimental studies on human mast cells, as well as experiments using animal models, have resulted in many discoveries that help decipher the function of mast cells in health and disease. In this review, we focus particularly on new insights into mast cell biology, with a focus on mast cell development, recruitment, heterogeneity, and reactivity. We also highlight the development in our understanding of mast cell-driven diseases and discuss the development of novel strategies to treat such conditions.</style></abstract><notes><style face="normal" font="default" size="100%">Dahlin, Joakim S&#xD;Maurer, Marcus&#xD;Metcalfe, Dean D&#xD;Pejler, Gunnar&#xD;Sagi-Eisenberg, Ronit&#xD;Nilsson, Gunnar&#xD;eng&#xD;Research Support, N.I.H., Intramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):83-99. doi: 10.1111/all.14881. Epub 2021 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33955017</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14881</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>864</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">864</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich - Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Clinical Immunology, ALL-MED Medical Research Institute, Medical University of Wroclaw, Wroclaw, Poland.&#xD;Clinic for Dermatology, Venereology and Allergology, Charite - University Medicine Berlin, Berlin, Germany.&#xD;Charite, Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Department of Dermatology and Allergy, Comprehensive Allergy Center, Berlin Institute of Health, Berlin, Germany.&#xD;Centre Hospitalier Universitaire, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhaled corticosteroids in early COVID-19-A tale of many facets</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3540-3542</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/08/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid 19</style></keyword><keyword><style face="normal" font="default" size="100%">inhalant steroids</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from MEDA/Mylan, personal fees from HAL Allergie, grants from ALK</style></keyword><keyword><style face="normal" font="default" size="100%">Abello, grants and personal fees from LETI Pharma, grants from Stallergenes,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Quintiles, grants and personal fees from Sanofi, grants from ASIT</style></keyword><keyword><style face="normal" font="default" size="100%">biotech, grants from Lofarma, personal fees from Allergy Therapeut., grants from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, grants from GSK, grants from Inmunotk, personal fees from Cassella</style></keyword><keyword><style face="normal" font="default" size="100%">med, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and Membership: AeDA, DGHNO, Deutsche Akademie</style></keyword><keyword><style face="normal" font="default" size="100%">fur Allergologie und klinische Immunologie, HNO-BV, GPA, EAACI. Dr. Akdis reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Allergopharma, grants from Idorsia, grants from Swiss National</style></keyword><keyword><style face="normal" font="default" size="100%">Science Foundation, grants from Christine Kuhne-Center for Allergy Research and</style></keyword><keyword><style face="normal" font="default" size="100%">Education, grants from European Commission&apos;s Horison&apos;s 2020 Framework Programme,</style></keyword><keyword><style face="normal" font="default" size="100%">Cure, grants from Novartis Research Institutes, grants from Astra Zeneca, grants</style></keyword><keyword><style face="normal" font="default" size="100%">from Scibase, other from Sanofi/Regeneron, grants from Glakso Smith-Kline, other</style></keyword><keyword><style face="normal" font="default" size="100%">from Scibase, outside the submitted work. Dr. Jutel reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Astra-Zeneka, personal fees from GSK, personal fees from Novartis, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Teva, personal fees from Chiesi, outside the submitted work. Dr. Zuberbier</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees from AstraZeneca, personal fees from AbbVie, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from ALK, personal fees from Almirall, personal fees from Astellas, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Bayer Health Care, personal fees from Bencard, personal fees from Berlin</style></keyword><keyword><style face="normal" font="default" size="100%">Chemie, personal fees from FAES, personal fees from HAL, personal fees from Leti,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Meda, personal fees from Menarini, personal fees from Merck,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from MSD, grants and personal fees from Novartis, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Pfizer, personal fees from Sanofi, personal fees from Stallergenes, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Takeda, personal fees from Teva, personal fees from UCB, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Henkel, personal fees from Kryolan, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">L Oreal, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and Organizational affiliations: Commitee</style></keyword><keyword><style face="normal" font="default" size="100%">member: WHO-Initiative &quot;Allergic Rhinitis and Its Impact on Asthma&quot; (ARIA)</style></keyword><keyword><style face="normal" font="default" size="100%">Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI)</style></keyword><keyword><style face="normal" font="default" size="100%">Board Chairman: European Centre for Allergy Research Foundation (ECARF)</style></keyword><keyword><style face="normal" font="default" size="100%">President: Global Allergy and Asthma European Network (GA2LEN)</style></keyword><keyword><style face="normal" font="default" size="100%">Member: Committee</style></keyword><keyword><style face="normal" font="default" size="100%">on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO).</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Bousquet has nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34374091</style></accession-num><notes><style face="normal" font="default" size="100%">Klimek, Ludger&#xD;Akdis, Cezmi A&#xD;Jutel, Marek&#xD;Zuberbier, Torsten&#xD;Bousquet, Jean&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3540-3542. doi: 10.1111/all.15041. Epub 2021 Aug 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34374091</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441805</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15041</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1265</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1265</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wawrzyniak, P.</style></author><author><style face="normal" font="default" size="100%">Krawczyk, K.</style></author><author><style face="normal" font="default" size="100%">Acharya, S.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Wawrzyniak, M.</style></author><author><style face="normal" font="default" size="100%">Karouzakis, E.</style></author><author><style face="normal" font="default" size="100%">Dreher, A.</style></author><author><style face="normal" font="default" size="100%">Jakiela, B.</style></author><author><style face="normal" font="default" size="100%">Altunbulakli, C.</style></author><author><style face="normal" font="default" size="100%">Sanak, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Cellular Immunology, Faculty of Biology and Environmental Protection, Lodz, Poland.&#xD;Departament of Medicine, Stanford University, Stanford, CA, USA.&#xD;Functional Genomics Center Zurich, ETH Zurich/University of Zurich, Zurich, Switzerland.&#xD;Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland.&#xD;Department of Medicine, Jagiellonian University Medical College, Krakow, Poland.&#xD;Department of Medicine and School of Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of CpG methylation improves the barrier integrity of bronchial epithelial cells in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1864-1868</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/11/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">CpG methylation</style></keyword><keyword><style face="normal" font="default" size="100%">DNA methyltransferases</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">tight junction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33210726</style></accession-num><notes><style face="normal" font="default" size="100%">Wawrzyniak, Paulina&#xD;Krawczyk, Krzysztof&#xD;Acharya, Swati&#xD;Tan, Ge&#xD;Wawrzyniak, Marcin&#xD;Karouzakis, Emmanuel&#xD;Dreher, Anita&#xD;Jakiela, Bogdan&#xD;Altunbulakli, Can&#xD;Sanak, Marek&#xD;O&apos;Mahony, Liam&#xD;Nadeau, Kari&#xD;Akdis, Cezmi A&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1864-1868. doi: 10.1111/all.14667. Epub 2020 Dec 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33210726</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14667</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1421</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1421</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kido-Nakahara, M.</style></author><author><style face="normal" font="default" size="100%">Wang, B.</style></author><author><style face="normal" font="default" size="100%">Ohno, F.</style></author><author><style face="normal" font="default" size="100%">Tsuji, G.</style></author><author><style face="normal" font="default" size="100%">Ulzii, D.</style></author><author><style face="normal" font="default" size="100%">Takemura, M.</style></author><author><style face="normal" font="default" size="100%">Furue, M.</style></author><author><style face="normal" font="default" size="100%">Nakahara, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.&#xD;Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, Fukuoka, Japan.&#xD;Department of Dermatology, National Dermatology Center of Mongolia, Ulaanbaatar, Mongolia.&#xD;Division of Skin Surface Sensing, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of mite-induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">291-301</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/06/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Bosentan</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelin Receptor Antagonists/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Mites</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">endothelin receptor</style></keyword><keyword><style face="normal" font="default" size="100%">endothelin-1</style></keyword><keyword><style face="normal" font="default" size="100%">nerve elongation</style></keyword><keyword><style face="normal" font="default" size="100%">pruritus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32535962</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Endothelin-1 (EDN1) can evoke histamine-independent pruritus in mammals and is upregulated in the lesional epidermis of atopic dermatitis (AD). EDN1 increases the production of interleukin 25 (IL-25) from keratinocytes to accelerate T helper type 2 immune deviation. Plasma EDN1 levels are positively correlated with the clinical severity and itch intensity of AD. Therefore, we hypothesized that the inhibition of EDN1 might be useful for treating atopic inflammation and itch and investigated the effects of the topical application of the EDN1 receptor antagonist bosentan on the skin inflammation and itch in a murine AD model. METHODS: We analyzed the mite-induced AD-like NC/Nga murine model, which was topically applied with bosentan or ethanol control every day for 3 weeks. We also subjected in vitro primary sensory neuron culture systems to nerve elongation and branching assays after EDN1 stimulation. RESULTS: Topical application of bosentan significantly attenuated the development of mite-induced AD-like skin inflammation, dermatitis scores, ear thickness, scratching bouts, and serum level of thymus and activation-regulated chemokine in NC/Nga mice. Bosentan application also significantly reduced the gene expression of Il13, Il17, and Ifng in the treated lesions. Histologically, the number of infiltrated dermal cells, the epidermal EDN1 expression, and the number of intraepidermal nerve fibers were significantly inhibited upon bosentan application. While EDN1 significantly elongated the neurites of dorsal root ganglion cells in a dose- and time-dependent manner, bosentan treatment attenuated this. CONCLUSIONS: EDN1 plays a significant role in mite-induced inflammation and itch. Topical bosentan is a potential protective candidate for AD.</style></abstract><notes><style face="normal" font="default" size="100%">Kido-Nakahara, Makiko&#xD;Wang, Bing&#xD;Ohno, Fumitaka&#xD;Tsuji, Gaku&#xD;Ulzii, Dugarmaa&#xD;Takemura, Masaki&#xD;Furue, Masutaka&#xD;Nakahara, Takeshi&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):291-301. doi: 10.1111/all.14451. Epub 2020 Jul 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32535962</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14451</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2476</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2476</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rademacher, F.</style></author><author><style face="normal" font="default" size="100%">Scheel, A.</style></author><author><style face="normal" font="default" size="100%">Glaser, R.</style></author><author><style face="normal" font="default" size="100%">Schroder, L.</style></author><author><style face="normal" font="default" size="100%">Heinemann, N.</style></author><author><style face="normal" font="default" size="100%">Bartels, J.</style></author><author><style face="normal" font="default" size="100%">Gerdes, S.</style></author><author><style face="normal" font="default" size="100%">Stolzl, D.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, E.</style></author><author><style face="normal" font="default" size="100%">Dohner, K.</style></author><author><style face="normal" font="default" size="100%">Weidinger, S.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Harder, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Quincke Research Center, Kiel University, Kiel, Germany.&#xD;Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Hannover Medical School, Cluster of Excellence RESIST (EXC 2155), Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of RNase 7 by RNase inhibitor promotes inflammation and Staphylococcus aureus growth: Implications for atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1573-1583</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/04/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/metabolism/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Keratinocytes/drug effects/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Ribonucleases/antagonists &amp; inhibitors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">RNase 7</style></keyword><keyword><style face="normal" font="default" size="100%">RNase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial protein</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">keratinocytes</style></keyword><keyword><style face="normal" font="default" size="100%">skin defense</style></keyword><keyword><style face="normal" font="default" size="100%">skin inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38641894</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The antimicrobial ribonuclease RNase 7 is abundantly expressed in the epidermis of lesional skin of atopic dermatitis (AD). Host RNase inhibitor (RI) binds to RNase 7 and blocks its ribonuclease activity. This study aimed to evaluate the impact of RNase 7-RI interactions on AD. METHODS: Cultured human primary keratinocytes, with siRNA-mediated downregulation of RNase 7 and RI, were stimulated with the synthetic RNA polyinosinic-polycytidylic acid (poly I:C). Induction of proinflammatory mediators was analyzed by real-time PCR and ELISA. RI expression in AD non-lesional and lesional skin biopsies and healthy controls was analyzed by real-time PCR and immunostaining. RI protein release in vivo on the AD skin surface was determined by western blot. Antimicrobial and ribonuclease assays were used to investigate the functional role of RI. RESULTS: RNase 7 inhibited the RNA-induced expression of proinflammatory mediators in keratinocytes. Accordingly, downregulation of RNase 7 in keratinocytes enhanced RNA-mediated induction of proinflammatory mediators, whereas downregulation of RI had the opposite effect. RI was released by damaged keratinocytes and epidermis. In vivo expression and release of RI on the skin surface were enhanced in lesional AD skin. Rinsing solution from the surface of lesional AD skin blocked the ribonuclease activity of RNase 7. The anti-Staphylococcus aureus activity of RNase 7 was abrogated by RI. CONCLUSIONS: Our data suggest a novel role of RI as a trigger factor of inflammation in AD by blocking the ribonuclease and antimicrobial activity of RNase 7, thereby enhancing RNA-mediated inflammation and S. aureus growth.</style></abstract><notes><style face="normal" font="default" size="100%">Rademacher, Franziska&#xD;Scheel, Annika&#xD;Glaser, Regine&#xD;Schroder, Lena&#xD;Heinemann, Nina&#xD;Bartels, Joachim&#xD;Gerdes, Sascha&#xD;Stolzl, Dora&#xD;Rodriguez, Elke&#xD;Dohner, Katinka&#xD;Weidinger, Stephan&#xD;Werfel, Thomas&#xD;Harder, Jurgen&#xD;eng&#xD;HA 3386/8-1/Deutsche Forschungsgemeinschaft/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1573-1583. doi: 10.1111/all.16125. Epub 2024 Apr 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38641894</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16125</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1006</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1006</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Smith, C. A.</style></author><author><style face="normal" font="default" size="100%">Payton, M.</style></author><author><style face="normal" font="default" size="100%">Jenkins, D.</style></author><author><style face="normal" font="default" size="100%">Janke, L. J.</style></author><author><style face="normal" font="default" size="100%">Relling, M. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmaceutical Sciences, St. Jude Children&apos;s Research Hospital, Memphis, Tennessee, USA.&#xD;Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA.&#xD;GMP, St. Jude Children&apos;s Research Hospital, Memphis, Tennessee, USA.&#xD;Department of Pathology, St. Jude Children&apos;s Research Hospital, Memphis, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An injectable excipient prevents anti-polyethylene glycol antibody-mediated hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2902-2904</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">*Excipients</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Polyethylene Glycols</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">hapten inhibition</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default" size="100%">polyethylene glycol</style></keyword><keyword><style face="normal" font="default" size="100%">from Servier and from NIH. Other authors have no conflict-of-interest to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33978966</style></accession-num><notes><style face="normal" font="default" size="100%">Liu, Yiwei&#xD;Smith, Colton A&#xD;Payton, Monique&#xD;Jenkins, David&#xD;Janke, Laura J&#xD;Relling, Mary V&#xD;eng&#xD;P30 CA021765/CA/NCI NIH HHS/&#xD;R01 CA142665/CA/NCI NIH HHS/&#xD;CA 21765/NH/NIH HHS/&#xD;CA 142665/NH/NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2902-2904. doi: 10.1111/all.14901. Epub 2021 May 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33978966</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8803213</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14901</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>478</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">478</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Celebi Sozener, Z.</style></author><author><style face="normal" font="default" size="100%">Cevhertas, L.</style></author><author><style face="normal" font="default" size="100%">Satitsuksanoa, P.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author><author><style face="normal" font="default" size="100%">Jansen, K.</style></author><author><style face="normal" font="default" size="100%">Secil, D.</style></author><author><style face="normal" font="default" size="100%">Sin, B. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Mungan, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ankara University School of Medicine Department of Chest Diseases Divission of Allergy and Immunology, Ankara, Turkey.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Department of Medical Immunology, Institute of Health Sciences, Bursa Uludag University, Bursa, Turkey.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Innate lymphoid cell subsets in obese asthma patients: Difference in activated cells in peripheral blood and their relationship to disease severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2835-2839</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/05/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35584279</style></accession-num><notes><style face="normal" font="default" size="100%">Celebi Sozener, Zeynep&#xD;Cevhertas, Lacin&#xD;Satitsuksanoa, Pattraporn&#xD;van de Veen, Willem&#xD;Jansen, Kirstin&#xD;Secil, Derya&#xD;Sin, Betul Ayse&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Mungan, Dilsad&#xD;eng&#xD;SNSF_/Swiss National Science Foundation/Switzerland&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2835-2839. doi: 10.1111/all.15378. Epub 2022 May 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35584279</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9545471</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15378</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2100</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2100</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bjorkander, S.</style></author><author><style face="normal" font="default" size="100%">Maier, P.</style></author><author><style face="normal" font="default" size="100%">Kere, M.</style></author><author><style face="normal" font="default" size="100%">Merid, S. K.</style></author><author><style face="normal" font="default" size="100%">Wirth, L.</style></author><author><style face="normal" font="default" size="100%">Wiegel, W.</style></author><author><style face="normal" font="default" size="100%">Ekstrom, S.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Bergstrom, A.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Mjosberg, J.</style></author><author><style face="normal" font="default" size="100%">Tibbitt, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.&#xD;Mechanistic &amp; Structural Biology, Discovery Sciences, R&amp;D, AstraZeneca, Gothenburg, Sweden.&#xD;Centre for Occupational and Environmental Medicine, Stockholm, Sweden.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Clinical Lung- and Allergy Research Unit, Medical unit for Lung and Allergy Diseases, Karolinska University Hospital Huddinge, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Innate lymphoid cells type 2 and CD8(+) T cells are perturbed in overweight and obese individuals with asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2533-2536</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/03/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*CD8-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Overweight</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity/complications</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36994759</style></accession-num><notes><style face="normal" font="default" size="100%">Bjorkander, Sophia&#xD;Maier, Paul&#xD;Kere, Maura&#xD;Merid, Simon Kebede&#xD;Wirth, Lorenz&#xD;Wiegel, Whitney&#xD;Ekstrom, Sandra&#xD;Kull, Inger&#xD;Bergstrom, Anna&#xD;Melen, Erik&#xD;Mjosberg, Jenny&#xD;Tibbitt, Christopher Andrew&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2533-2536. doi: 10.1111/all.15728. Epub 2023 Apr 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36994759</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15728</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1191</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palomares, F.</style></author><author><style face="normal" font="default" size="100%">Gomez, F.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Maggi, L.</style></author><author><style face="normal" font="default" size="100%">Cosmi, L.</style></author><author><style face="normal" font="default" size="100%">Annunziato, F.</style></author><author><style face="normal" font="default" size="100%">Nunez, R.</style></author><author><style face="normal" font="default" size="100%">Perez, N.</style></author><author><style face="normal" font="default" size="100%">Munoz-Cano, R.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Allergy Clinical Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.&#xD;Allergy Section, Pneumology Department, Institut Clinic Respiratori (ICR), Hospital Clinic de Barcelona, Barcelona, Spain.&#xD;Institut d&apos;Investigacions Biomediques August Pi iSunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.&#xD;Medicine Department, Universidad de Malaga-UMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Innate lymphoid cells type 2 in LTP-allergic patients and their modulation during sublingual immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2253-2256</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33476397</style></accession-num><notes><style face="normal" font="default" size="100%">Palomares, Francisca&#xD;Gomez, Francisca&#xD;Bogas, Gador&#xD;Maggi, Laura&#xD;Cosmi, Lorenzo&#xD;Annunziato, Francesco&#xD;Nunez, Rafael&#xD;Perez, Natalia&#xD;Munoz-Cano, Rosa&#xD;Torres, Maria Jose&#xD;Mayorga, Cristobalina&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2253-2256. doi: 10.1111/all.14745. Epub 2021 Feb 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33476397</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8359238</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14745</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1164</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1164</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sahiner, U. M.</style></author><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Golebski, K.</style></author><author><style face="normal" font="default" size="100%">Istvan Komlosi, Z.</style></author><author><style face="normal" font="default" size="100%">Peng, Y.</style></author><author><style face="normal" font="default" size="100%">Sekerel, B.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Brough, H.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Turner, P.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Spits, H.</style></author><author><style face="normal" font="default" size="100%">Akdis, C.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Imperial College London, London, UK.&#xD;School of Medicine Department of Pediatric Allergy, Hacettepe University, Ankara, Turkey.&#xD;Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Swiss Institute of Allergy and Asthma Research, Davos, Switzerland.&#xD;Children&apos;s Allergy Service, Evelina London, Guys and St Thomas, NHS Trust, London, UK.&#xD;Paediatric Allergy Group, Department of Women and Children&apos;s Heath, School of Life Course Sciences, London, UK.&#xD;Paediatric Allergy Group, School of Immunology &amp; Microbial Sciences, King&apos;s College London, London, UK.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Section of Inflammation, Repair and Development, National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Sean N. Parker Center for Allergy &amp; Asthma Research, Stanford University, Stanford, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Innate lymphoid cells: The missing part of a puzzle in food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2002-2016</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cell</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33583026</style></accession-num><abstract><style face="normal" font="default" size="100%">Food allergy is an increasingly prevalent disease driven by uncontrolled type 2 immune response. Currently, knowledge about the underlying mechanisms that initiate and promote the immune response to dietary allergens is limited. Patients with food allergy are commonly sensitized through the skin in their early life, later on developing allergy symptoms within the gastrointestinal tract. Food allergy results from a dysregulated type 2 response to food allergens, characterized by enhanced levels of IgE, IL-4, IL-5, and IL-13 with infiltration of mast cells, eosinophils, and basophils. Recent studies raised a possible role for the involvement of innate lymphoid cells (ILCs) in driving food allergy. Unlike lymphocytes, ILCs lack They represent a group of lymphocytes that lack specific antigen receptors. ILCs contribute to immune responses not only by releasing cytokines and other mediators but also by responding to cytokines produced by activated cells in their local microenvironment. Due to their localization at barrier surfaces of the airways, gut, and skin, ILCs form a link between the innate and adaptive immunity. This review summarizes recent evidence on how skin and gastrointestinal mucosal immune system contribute to both homeostasis and the development of food allergy, as well as the involvement of ILCs toward inflammatory processes and regulatory mechanisms.</style></abstract><notes><style face="normal" font="default" size="100%">Sahiner, Umit M&#xD;Layhadi, Janice A&#xD;Golebski, Korneliusz&#xD;Istvan Komlosi, Zsolt&#xD;Peng, Yaqi&#xD;Sekerel, Bulent&#xD;Durham, Stephen R&#xD;Brough, Helen&#xD;Morita, Hideaki&#xD;Akdis, Mubeccel&#xD;Turner, Paul&#xD;Nadeau, Kari&#xD;Spits, Hergen&#xD;Akdis, Cezmi&#xD;Shamji, Mohamed H&#xD;eng&#xD;MR/K010468/1/MRC_/Medical Research Council/United Kingdom&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2002-2016. doi: 10.1111/all.14776. Epub 2021 Mar 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33583026</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14776</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1007</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1007</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Behrends, J.</style></author><author><style face="normal" font="default" size="100%">Schwager, C.</style></author><author><style face="normal" font="default" size="100%">Hein, M.</style></author><author><style face="normal" font="default" size="100%">Scholzen, T.</style></author><author><style face="normal" font="default" size="100%">Kull, S.</style></author><author><style face="normal" font="default" size="100%">Jappe, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Core Facility Fluorescence Cytometry, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.&#xD;Division of Clinical and Molecular Allergology, Priority Area Asthma and Allergy, Airway Research Center North (ARCN), German Center for Lung Research (DZL, Borstel, Germany.&#xD;Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University of Lubeck, Lubeck, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Innovative robust basophil activation test using a novel gating strategy reliably diagnosing allergy with full automation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3776-3788</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Automation, Laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophil Degranulation Test/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Flow Cytometry/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnostic</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trials</style></keyword><keyword><style face="normal" font="default" size="100%">oleosins</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33973252</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergy is one of the most common chronic diseases in Europe. Therefore, an increased need for specific and sensitive diagnostic tests that truly detect allergy exists. This study aimed at establishing a highly specific high-throughput and automated basophil activation test (BAT) that proves the existence of an allergy with utmost probability. METHODS: BAT from 1104 samples was analyzed; a novel gating strategy with three antibodies (FcepsilonRIalpha, CD203c, CD63) was established and compared with our published protocol (12 antibodies). Based on the novel gating strategy, storage conditions, automated measurement, and analyses using R (1376 samples out of 1389) were optimized to set up a high-throughput BAT. RESULTS: No differences in sensitivity and specificity were found between the novel three antibody (FcepsilonRIalpha, CD203c, CD63) and the 12 antibody gating strategy or between automated and manually analyzed samples (saving up to 90% of labor time). The time frame for basophil activation measurement after blood donation has been extended considerably (whole blood storage &lt;/=7 days (RT) and 17 days (4 degrees C) prior to BAT preparation and measurement). Respective storage conditions were optimized for samples after stimulation, staining, and preparation (&lt;/=7 days (RT) and 28 days (4 degrees C)). These achievements were confirmed by a nationwide ring trial showing robustness and applicability of our BAT on a variety of flow cytometers. CONCLUSION: Our considerable optimizations overcame the hurdles that until now prevented the BAT from being used as high-throughput allergy diagnostic test in routine laboratories and shall allow for collaborative studies between clinics and research centers.</style></abstract><notes><style face="normal" font="default" size="100%">Behrends, Jochen&#xD;Schwager, Christian&#xD;Hein, Martina&#xD;Scholzen, Thomas&#xD;Kull, Skadi&#xD;Jappe, Uta&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3776-3788. doi: 10.1111/all.14900. Epub 2021 May 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33973252</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14900</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2394</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2394</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rossi, F.</style></author><author><style face="normal" font="default" size="100%">Votto, M.</style></author><author><style face="normal" font="default" size="100%">Castagnoli, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Unit, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.&#xD;Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Insights in intestinal immune tolerance: The role of the cleavage form of gasdermin D</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1631-1632</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/02/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Intracellular Signaling Peptides and Proteins/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphate-Binding Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Intestines/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Gasdermins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38403946</style></accession-num><notes><style face="normal" font="default" size="100%">Rossi, Federico&#xD;Votto, Martina&#xD;Castagnoli, Riccardo&#xD;eng&#xD;Letter&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1631-1632. doi: 10.1111/all.16076. Epub 2024 Feb 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38403946</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16076</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1253</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1253</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The inspirational journey of Chinese scholars in the field of allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">422-424</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/12/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">achievements</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">journal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33251625</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Luo&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):422-424. doi: 10.1111/all.14676.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33251625</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14676</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2592</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2592</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van der Valk, Jpmh</style></author><author><style face="normal" font="default" size="100%">den Besten, Laah</style></author><author><style face="normal" font="default" size="100%">Hylkema, T. H. T.</style></author><author><style face="normal" font="default" size="100%">van der Zee, J. S. J.</style></author><author><style face="normal" font="default" size="100%">Nijman, Sfms</style></author><author><style face="normal" font="default" size="100%">Van den Toorn, L. M. L.</style></author><author><style face="normal" font="default" size="100%">Braunstahl, G. J. G.</style></author><author><style face="normal" font="default" size="100%">In &apos;t Veen, Jccmj</style></author><author><style face="normal" font="default" size="100%">van Balen, P. P.</style></author><author><style face="normal" font="default" size="100%">Maas, J. J. J.</style></author><author><style face="normal" font="default" size="100%">Wennekes, Rhar</style></author><author><style face="normal" font="default" size="100%">de Groene, G. J. G.</style></author><author><style face="normal" font="default" size="100%">Kappen, J. H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary Diseases, Center of Excellence for Asthma, COPD and Respiratory Allergy, Franciscus Gasthuis and Vlietland, Rotterdam, Netherlands.&#xD;Department of Pulmonary Diseases, Erasmus Medical Centrum, Rotterdam, Netherlands.&#xD;Long Alliantie Nederland (LAN), Amersfoort, Netherlands.&#xD;Department of Pulmonary Diseases, Martini Hospital, Groningen, Netherlands.&#xD;Department of Pulmonary Diseases, Amsterdam University Medical Center, Amsterdam, Netherlands.&#xD;Cooperatie PreventPartner, Malden, Netherlands.&#xD;Polikliniek Mens en Arbeid, Amsterdam University Medical Center, Amsterdam, Netherlands.&#xD;General Practitioner, Maarssen, Netherlands.&#xD;National Heart and Lung Institute, Imperial College London; Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Integrated care pathway for occupational pulmonary diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3138-3141</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/06/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">blueprint</style></keyword><keyword><style face="normal" font="default" size="100%">integrated care pathway</style></keyword><keyword><style face="normal" font="default" size="100%">occupational</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">pulmonary diseases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38940064</style></accession-num><notes><style face="normal" font="default" size="100%">van der Valk, J P M Hanna&#xD;den Besten, L A A Heleen&#xD;Hylkema, T H Tjerk&#xD;van der Zee, J S Jaring&#xD;Nijman, S F M Suzan&#xD;Van den Toorn, L M Leon&#xD;Braunstahl, G J Gert-Jan&#xD;In &apos;t Veen, J C C M Johannes&#xD;van Balen, P Peter&#xD;Maas, J J Jaap&#xD;Wennekes, R H A Roel&#xD;de Groene, G J Gerda&#xD;Kappen, J H Jasper&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3138-3141. doi: 10.1111/all.16200. Epub 2024 Jun 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38940064</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16200</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3255</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3255</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gery, Perrine</style></author><author><style face="normal" font="default" size="100%">Ekren, Rüçhan</style></author><author><style face="normal" font="default" size="100%">Bérard, Emilie</style></author><author><style face="normal" font="default" size="100%">Du-Thanh, Aurélie</style></author><author><style face="normal" font="default" size="100%">Rimet, Hugo</style></author><author><style face="normal" font="default" size="100%">Jendoubi, Fatma</style></author><author><style face="normal" font="default" size="100%">Lenief, Vanina</style></author><author><style face="normal" font="default" size="100%">Raison-Peyron, Nadia</style></author><author><style face="normal" font="default" size="100%">Bouznad, Amel</style></author><author><style face="normal" font="default" size="100%">Konstantinou, Maria P.</style></author><author><style face="normal" font="default" size="100%">Rioual, Jonathan</style></author><author><style face="normal" font="default" size="100%">Basso, Lilian</style></author><author><style face="normal" font="default" size="100%">Mouiren, Juliette</style></author><author><style face="normal" font="default" size="100%">Boussier, Manon</style></author><author><style face="normal" font="default" size="100%">Milpied, Brigitte</style></author><author><style face="normal" font="default" size="100%">Bulai Livideanu, Cristina</style></author><author><style face="normal" font="default" size="100%">Jaulent, Louise</style></author><author><style face="normal" font="default" size="100%">Hacard, Florence</style></author><author><style face="normal" font="default" size="100%">Lefevre, Marine A.</style></author><author><style face="normal" font="default" size="100%">Nosbaum, Audrey</style></author><author><style face="normal" font="default" size="100%">Seneschal, Julien</style></author><author><style face="normal" font="default" size="100%">Vocanson, Marc</style></author><author><style face="normal" font="default" size="100%">Paul, Carle</style></author><author><style face="normal" font="default" size="100%">Gaudenzio, Nicolas</style></author><author><style face="normal" font="default" size="100%">Tauber, Marie</style></author><author><style face="normal" font="default" size="100%">the French Atopic Dermatitis Network from de GREAT Research group</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Chronic hand eczema (CHE) is a debilitating skin condition characterized by pain, itch, and chronic inflammation, with a complex multifactorial origin. Its diverse presentations, including overlapping traits of atopic dermatitis, contact dermatitis, and psoriasis, make diagnosis and treatment particularly challenging. The underlying immune mechanisms of CHE still need to be investigated. Methods Here we conducted a comprehensive molecular profiling of CHE patients, enrolled without prior selection on etiology and morphology, and performed a phase 2b randomized, multicenter, double-blind, placebo-controlled clinical trial comparing dupilumab to placebo over 16 weeks. Results We demonstrated that CHE patients may benefit from IL4Rα-blockade, regardless of etiological factors or clinical presentation. Skin transcriptomic and serum profiles of CHE patients closely resemble those seen in both atopic dermatitis and psoriasis, with dysregulated genes affecting keratinocyte differentiation, leucocyte-mediated immunity, cytokine signaling, and mixed type 1, 2, and 3 immunity. The clinical trial included 94 adults with moderate to severe CHE persisting for at least six months and resistant to potent topical corticosteroids. Compared to placebo control, 16-week dupilumab treatment significantly improved clinical severity and quality of life of all CHE patients while largely restoring appropriate transcriptomic and proteomic programs related to skin barrier and immune homeostasis. Conclusion These findings confirmed the involvement of not only type 2 but also type 1 and type 3 immunity across all CHE patients, and demonstrate that IL-4Rα blockade may offer effective therapeutic perspectives for this highly burdensome condition, independent of an atopic dermatitis background.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70263</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70263</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2824</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2824</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paller, A. S.</style></author><author><style face="normal" font="default" size="100%">Eichenfield, L. F.</style></author><author><style face="normal" font="default" size="100%">Irvine, A. D.</style></author><author><style face="normal" font="default" size="100%">Flohr, C.</style></author><author><style face="normal" font="default" size="100%">Wollenberg, A.</style></author><author><style face="normal" font="default" size="100%">Barbarot, S.</style></author><author><style face="normal" font="default" size="100%">Bangert, C.</style></author><author><style face="normal" font="default" size="100%">Spergel, J. M.</style></author><author><style face="normal" font="default" size="100%">Selfridge, A.</style></author><author><style face="normal" font="default" size="100%">Biswas, P.</style></author><author><style face="normal" font="default" size="100%">Fan, H.</style></author><author><style face="normal" font="default" size="100%">Alderfer, J.</style></author><author><style face="normal" font="default" size="100%">Watkins, M.</style></author><author><style face="normal" font="default" size="100%">Koppensteiner, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children&apos;s Hospital, Chicago, Illinois, USA.&#xD;University of California San Diego and Rady Children&apos;s Hospital-San Diego, San Diego, California, USA.&#xD;Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland.&#xD;St John&apos;s Institute of Dermatology, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, King&apos;s College London, London, UK.&#xD;University Hospital Augsburg, Augsburg, Germany.&#xD;Ludwig Maximilian University, Munich, Germany.&#xD;Comprehensive Center for Inflammation Medicine, University of Lubeck, Lubeck, Germany.&#xD;Department of Dermatology, CHU Nantes-Hotel Dieu, Nantes, France.&#xD;Department of Dermatology, Medical University of Vienna, Vienna, Austria.&#xD;Division of Allergy and Immunology, Children&apos;s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.&#xD;Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;Pfizer Inc., New York, New York, USA.&#xD;Pfizer Inc., Collegeville, Pennsylvania, USA.&#xD;Pfizer Corporation Austria GmbH, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2213-2224</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/03/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyrimidines/therapeutic use/adverse effects/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonamides</style></keyword><keyword><style face="normal" font="default" size="100%">adolescents</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Research, Dermavant, Eli Lilly and Company, Incyte, Janssen, Krystal Biotech,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals, Timber, and UCB</style></keyword><keyword><style face="normal" font="default" size="100%">has served as a consultant for</style></keyword><keyword><style face="normal" font="default" size="100%">AbbVie, Abeona Therapeutics, Apogee Therapeutics, Arcutis Biotherapeutics, ASLAN</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, BioCryst Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb,</style></keyword><keyword><style face="normal" font="default" size="100%">Dermavant, Incyte, Johnson &amp; Johnson, Krystal Biotech, LEO Pharma, Mitsubishi</style></keyword><keyword><style face="normal" font="default" size="100%">Tanabe, Nektar, Primus, Procter &amp; Gamble, Regeneron Pharmaceuticals, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">Genzyme, Seanergy, TWi Biotech, and UCB</style></keyword><keyword><style face="normal" font="default" size="100%">and has served on the Data Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Monitoring Board for AbbVie, Abeona Therapeutics, and Galderma. L. F. Eichenfield</style></keyword><keyword><style face="normal" font="default" size="100%">has served as a scientific adviser, consultant, and/or clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">investigator for Pfizer Inc., AbbVie, Almirall, Amgen, Arena, ASLAN</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Dermavant, Eli Lilly and Company, Forte, Galderma, Glenmark,</style></keyword><keyword><style face="normal" font="default" size="100%">Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Otsuka, Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, and Sanofi Genzyme. A. D. Irvine has served as a consultant for</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer Inc., AbbVie, Amgen, Arena, Benevolent AI, Eli Lilly and Company, LEO</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Novartis, Regeneron Pharmaceuticals, and Sanofi Genzyme</style></keyword><keyword><style face="normal" font="default" size="100%">and has received</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria for participation in the speakers&apos; bureau for Pfizer Inc., AbbVie, Eli</style></keyword><keyword><style face="normal" font="default" size="100%">Lilly and Company, LEO Pharma, Novartis, Regeneron Pharmaceuticals, and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">Genzyme. C. Flohr is chief investigator of the UK National Institute for Health</style></keyword><keyword><style face="normal" font="default" size="100%">Research-funded TREAT (ISRCTN15837754) and SOFTER (Clinicaltrials.gov:</style></keyword><keyword><style face="normal" font="default" size="100%">NCT03270566) trials as well as the UK-Irish Atopic Eczema Systemic Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Register (A-STAR</style></keyword><keyword><style face="normal" font="default" size="100%">ISRCTN11210918) and a principal investigator in the European</style></keyword><keyword><style face="normal" font="default" size="100%">Union (EU) Horizon 2020-funded BIOMAP Consortium (http://www.biomap-imi.eu/)</style></keyword><keyword><style face="normal" font="default" size="100%">leads the EU Trans-Foods consortium</style></keyword><keyword><style face="normal" font="default" size="100%">department has received funding from Pfizer</style></keyword><keyword><style face="normal" font="default" size="100%">Inc. and Sanofi Genzyme for skin microbiome work</style></keyword><keyword><style face="normal" font="default" size="100%">and has received compensation</style></keyword><keyword><style face="normal" font="default" size="100%">from the British Journal of Dermatology (reviewer and section editor) and</style></keyword><keyword><style face="normal" font="default" size="100%">EuroGuiDerm (guidelines lead) as well as from Almirall, Bioderma, and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">Genzyme for educational activities. A. Wollenberg has been an advisor, speaker,</style></keyword><keyword><style face="normal" font="default" size="100%">or investigator for Pfizer Inc., Aileens, Almirall, Beiersdorf, Bioderma, Bristol</style></keyword><keyword><style face="normal" font="default" size="100%">Myers Squibb, Chugai, Eli Lilly and Company, Galapagos, Galderma, GSK, Hans</style></keyword><keyword><style face="normal" font="default" size="100%">Karrer, Hexal, Janssen, LEO Pharma, L&apos;Oreal, Maruho, MedImmune, MSD, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Pierre Fabre, Regeneron, Santen, Sanofi-Genzyme, Serono, and UCB. S. Barbarot is</style></keyword><keyword><style face="normal" font="default" size="100%">an investigator or speaker for Pfizer Inc., AbbVie, Alexion, Almirall,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Eli Lilly and Company, Galderma, Janssen, LEO Pharma, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi Genzyme, and UCB. C. Bangert has been a clinical trial investigator for</style></keyword><keyword><style face="normal" font="default" size="100%">AbbVie, Eli Lilly and Company, Galderma, Merck, Novartis, and Sanofi Genzyme and</style></keyword><keyword><style face="normal" font="default" size="100%">an advisory board member, consultant, and/or invited lecturer for Pfizer Inc.,</style></keyword><keyword><style face="normal" font="default" size="100%">AbbVie, ALK, Almirall, Eli Lilly and Company, LEO Pharma, Mylan, Merck, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">and Sanofi Genzyme. J. Spergel has received grants from Novartis, Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, and Sanofi Genzyme and is a consultant/advisory board member for</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Readysetfood, Regeneron Pharmaceuticals, Sanofi Genzyme, and Takeda. A.</style></keyword><keyword><style face="normal" font="default" size="100%">Selfridge, H. Fan, J. Alderfer, M. Watkins, and H. Koppensteiner are employees</style></keyword><keyword><style face="normal" font="default" size="100%">and shareholders of Pfizer.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40028832</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Abrocitinib has demonstrated long-term efficacy (48 weeks) and safety (~4 years) in adults and adolescents with moderate-to-severe atopic dermatitis (AD). This analysis evaluated abrocitinib efficacy in adolescents through 112 weeks, and safety of up to 4.6 years of exposure. METHODS: Data were from adolescents in JADE MONO-1 (NCT03349060), MONO-2 (NCT03575871), TEEN (NCT03796676), REGIMEN (NCT03627767; safety analysis only), and the ongoing phase 3 extension trial, EXTEND (NCT03422822; data cutoff: September 5, 2022). Efficacy assessments included proportions of patients achieving an Investigator&apos;s Global Assessment score of 0 or 1 (IGA 0/1) and &gt;/= 75%/&gt;/= 90% improvement in Eczema Area and Severity Index (EASI-75/-90). Treatment-emergent adverse events (TEAEs) and AEs of special interest were reported as incidence rate/100 patient-years. A substudy of JADE TEEN assessed immune response to vaccination. RESULTS: Efficacy was assessed in 170 and 187 patients in the abrocitinib 200-mg and 100-mg arms, respectively; median exposure was 971.0 and 899.0 days. At Week 112, comparable proportions of patients treated with abrocitinib (200, 100 mg) achieved EASI-75 (85%, 83%), EASI-90 (62%, 60%), and IGA 0/1 (57%, 57%). Safety was assessed in 289 and 201 patients in the abrocitinib 200- and 100-mg arms, respectively; median exposure was 882.0 and 863.0 days. Incidence rates were numerically higher with abrocitinib 200 mg versus 100 mg, with overlapping confidence intervals for serious TEAEs (IR [95% CI]; 5.47 [3.69-7.80] vs. 3.45 [1.89-5.80]) and TEAEs leading to discontinuation (6.78 [4.80-9.31] vs. 5.39 [3.38-8.16]). CONCLUSIONS: Efficacy and safety results support long-term abrocitinib use in adolescent patients. TRAIL REGISTRATION: ClinicalTrials.gov Identifiers NCT03349060, NCT03575871, NCT03796676, NCT03627767, NCT03422822.</style></abstract><notes><style face="normal" font="default" size="100%">Paller, Amy S&#xD;Eichenfield, Lawrence F&#xD;Irvine, Alan D&#xD;Flohr, Carsten&#xD;Wollenberg, Andreas&#xD;Barbarot, Sebastien&#xD;Bangert, Christine&#xD;Spergel, Jonathan M&#xD;Selfridge, Andrew&#xD;Biswas, Pinaki&#xD;Fan, Haiyun&#xD;Alderfer, Justine&#xD;Watkins, Melissa&#xD;Koppensteiner, Herwig&#xD;eng&#xD;Pfizer/&#xD;Clinical Trial, Phase III&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2213-2224. doi: 10.1111/all.16512. Epub 2025 Mar 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40028832</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368748</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16512</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2380</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2380</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">De Paepe, E.</style></author><author><style face="normal" font="default" size="100%">Plekhova, V.</style></author><author><style face="normal" font="default" size="100%">Vangeenderhuysen, P.</style></author><author><style face="normal" font="default" size="100%">Baeck, N.</style></author><author><style face="normal" font="default" size="100%">Bullens, D.</style></author><author><style face="normal" font="default" size="100%">Claeys, T.</style></author><author><style face="normal" font="default" size="100%">De Graeve, M.</style></author><author><style face="normal" font="default" size="100%">Kamoen, K.</style></author><author><style face="normal" font="default" size="100%">Notebaert, A.</style></author><author><style face="normal" font="default" size="100%">Van de Wiele, T.</style></author><author><style face="normal" font="default" size="100%">Van Den Broeck, W.</style></author><author><style face="normal" font="default" size="100%">Vanlede, K.</style></author><author><style face="normal" font="default" size="100%">Van Winckel, M.</style></author><author><style face="normal" font="default" size="100%">Vereecke, L.</style></author><author><style face="normal" font="default" size="100%">Elliott, C.</style></author><author><style face="normal" font="default" size="100%">Cox, E.</style></author><author><style face="normal" font="default" size="100%">Vanhaecke, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Veterinary Medicine, Department of Translational Physiology, Infectiology and Public Health, Laboratory of Integrative Metabolomics (LIMET), Ghent University, Merelbeke, Belgium.&#xD;Department of Pediatrics, Pediatric Gastroenterology, AZ Jan Palfijn Ghent, Ghent, Belgium.&#xD;Department of Microbiology, Immunology and Transplantation, Allergy and Immunology Research Group, KU Leuven, Leuven, Belgium.&#xD;Clinical Division of Pediatrics, UZ Leuven, Leuven, Belgium.&#xD;Department of Pediatrics, Pediatric Gastroenterology and Nutrition &amp; General Pediatric Medicine, AZ Sint-Jan Bruges, Bruges, Belgium.&#xD;Department of Pediatrics, Maria Middelares Ghent, Ghent, Belgium.&#xD;Department of Pediatrics, Sint-Vincentius Hospital Deinze, Deinze, Belgium.&#xD;Faculty of Bioscience Engineering, Center for Microbial Ecology and Technology (CMET), Ghent University, Ghent, 9000, Belgium.&#xD;Faculty of Veterinary Medicine, Department of Morphology, Imaging, Orthopedics, Rehabilitation and Nutrition, Ghent University, Merelbeke, Belgium.&#xD;Department of General Pediatrics, VITAZ, Sint-Niklaas, Belgium.&#xD;Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.&#xD;VIB-UGent Center for Inflammation Research, Ghent, Belgium.&#xD;Ghent Gut Inflammation Group (GGIG), Ghent, Belgium.&#xD;School of Biological Sciences, Institute for Global Food Security, Queen&apos;s University Belfast, Belfast, United Kingdom.&#xD;Faculty of Veterinary Medicine, Department of Translational Physiology, Infectiology and Public Health, Laboratory of Immunology, Ghent University, Merelbeke, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Integrated gut metabolome and microbiome fingerprinting reveals that dysbiosis precedes allergic inflammation in IgE-mediated pediatric cow&apos;s milk allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">949-963</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/01/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Lactoglobulins</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolome</style></keyword><keyword><style face="normal" font="default" size="100%">16S rRNA sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">cow&apos;s milk allergy</style></keyword><keyword><style face="normal" font="default" size="100%">metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">multi-omics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38193259</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IgE-mediated cow&apos;s milk allergy (IgE-CMA) is one of the first allergies to arise in early childhood and may result from exposure to various milk allergens, of which beta-lactoglobulin (BLG) and casein are the most important. Understanding the underlying mechanisms behind IgE-CMA is imperative for the discovery of novel biomarkers and the design of innovative treatment and prevention strategies. METHODS: We report a longitudinal in vivo murine model, in which two mice strains (BALB/c and C57Bl/6) were sensitized to BLG using either cholera toxin or an oil emulsion (n = 6 per group). After sensitization, mice were challenged orally, their clinical signs monitored, antibody (IgE and IgG1) and cytokine levels (IL-4 and IFN-gamma) measured, and fecal samples subjected to metabolomics. The results of the murine models were further extrapolated to fecal microbiome-metabolome data from our population of IgE-CMA (n = 22) and healthy (n = 23) children (Trial: NCT04249973), on which polar metabolomics, lipidomics and 16S rRNA metasequencing were performed. In vitro gastrointestinal digestions and multi-omics corroborated the microbial origin of proposed metabolic changes. RESULTS: During mice sensitization, we observed multiple microbially derived metabolic alterations, most importantly bile acid, energy and tryptophan metabolites, that preceded allergic inflammation. We confirmed microbial dysbiosis, and its associated effect on metabolic alterations in our patient cohort, through in vitro digestions and multi-omics, which was accompanied by metabolic signatures of low-grade inflammation. CONCLUSION: Our results indicate that gut dysbiosis precedes allergic inflammation and nurtures a chronic low-grade inflammation in children on elimination diets, opening important new opportunities for future prevention and treatment strategies.</style></abstract><notes><style face="normal" font="default" size="100%">De Paepe, Ellen&#xD;Plekhova, Vera&#xD;Vangeenderhuysen, Pablo&#xD;Baeck, Nele&#xD;Bullens, Dominique&#xD;Claeys, Tania&#xD;De Graeve, Marilyn&#xD;Kamoen, Kristien&#xD;Notebaert, Anneleen&#xD;Van de Wiele, Tom&#xD;Van Den Broeck, Wim&#xD;Vanlede, Koen&#xD;Van Winckel, Myriam&#xD;Vereecke, Lars&#xD;Elliott, Chris&#xD;Cox, Eric&#xD;Vanhaecke, Lynn&#xD;eng&#xD;Fonds Wetenschappelijk Onderzoek/&#xD;Bijzonder Onderzoeksfonds UGent/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):949-963. doi: 10.1111/all.16005. Epub 2024 Jan 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38193259</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16005</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3258</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3258</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Skoog, Tiina</style></author><author><style face="normal" font="default" size="100%">Yang, Ying</style></author><author><style face="normal" font="default" size="100%">Olah, Peter</style></author><author><style face="normal" font="default" size="100%">Katayama, Shintaro</style></author><author><style face="normal" font="default" size="100%">Karisola, Piia</style></author><author><style face="normal" font="default" size="100%">Smith, Catherine</style></author><author><style face="normal" font="default" size="100%">Weidinger, Stephan</style></author><author><style face="normal" font="default" size="100%">Barker, Jonathan</style></author><author><style face="normal" font="default" size="100%">Lauerma, Antti</style></author><author><style face="normal" font="default" size="100%">Andersson, Björn</style></author><author><style face="normal" font="default" size="100%">Homey, Bernhard</style></author><author><style face="normal" font="default" size="100%">Fyhrquist, Nanna</style></author><author><style face="normal" font="default" size="100%">Kere, Juha</style></author><author><style face="normal" font="default" size="100%">Alenius, Harri</style></author><author><style face="normal" font="default" size="100%">MAARS Consortium</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Integrated Methylome–Transcriptome Analysis Reveals Epigenomic Remodeling and Rho GTPase–Linked Immune–Epithelial Crosstalk in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by immune dysregulation and epithelial barrier dysfunction. Although transcriptional changes in AD skin are increasingly well characterized, DNA methylation patterns remain less well understood. Methods Here, we present an integrated analysis of matched DNA methylomes, transcriptomes, and microbiomes from lesional (n = 40), adjacent non-lesional (n = 38), and healthy control (n = 40) skin, using complementary cell-type-adjusted models. Results We identified thousands of differentially methylated regions (DMRs) across all pairwise contrasts (lesional vs. healthy: n = 13,514; lesional vs. non-lesional: n = 4591; non-lesional vs. healthy: n = 1716), including both hyper- and hypo-methylated regions with balanced effect sizes. A core subset of DMRs persisted after methylation-based adjustment, whereas the extensive lesional vs. non-lesional set was largely composition-driven. Integration with transcriptomic co-expression networks linked DMRs to immune–epithelial modules, and 225 DMR–gene pairs showed significant anti-correlation (FDR &lt; 0.05). Lesional skin with dominant Staphylococcus aureus colonization differed at 92 DMRs compared with absent-colonized skin, of which 70 also overlapped with local severity. Pathway analyses consistently highlighted Rho GTPase and actin–junctional programs across analytic layers, suggesting that Rho GTPase signaling is a central integrator of immune, epithelial, and microbial interactions in AD. Conclusions Our study underscores the importance of epigenomic remodeling in AD and highlights potential avenues for precision intervention in chronic inflammatory skin disease.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70259</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70259</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1645</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1645</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Callejas-Diaz, B.</style></author><author><style face="normal" font="default" size="100%">Fernandez, G.</style></author><author><style face="normal" font="default" size="100%">Fuentes, M.</style></author><author><style face="normal" font="default" size="100%">Martinez-Anton, A.</style></author><author><style face="normal" font="default" size="100%">Alobid, I.</style></author><author><style face="normal" font="default" size="100%">Roca-Ferrer, J.</style></author><author><style face="normal" font="default" size="100%">Picado, C.</style></author><author><style face="normal" font="default" size="100%">Tubita, V.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">IRCE Laboratory, Institut d&apos;Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.&#xD;CIBER of Respiratory Diseases (CIBERES), Barcelona, Spain.&#xD;Bioinformatics Unit, Genetics and Molecular Medicine Service, Hospital Sant Joan de Deu, Barcelona, Spain.&#xD;Aix Marseille Universite, Marseille, France.&#xD;Rhinology Unit &amp; Smell Clinic, ENT Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.&#xD;Pneumology &amp; Respiratory Allergy Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Integrated mRNA and microRNA transcriptome profiling during differentiation of human nasal polyp epithelium reveals an altered ciliogenesis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2548-2561</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2020/04/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Phenomena</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Air-liquid Interface (ALI) 3D in vitro model</style></keyword><keyword><style face="normal" font="default" size="100%">Ciliogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">basal stem</style></keyword><keyword><style face="normal" font="default" size="100%">miR34 and miR449</style></keyword><keyword><style face="normal" font="default" size="100%">microRNA epigenetic regulation</style></keyword><keyword><style face="normal" font="default" size="100%">progenitor cells (BSCs)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32249954</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Human adult basal stem/progenitor cells (BSCs) obtained from chronic rhinosinusitis with nasal polyps (CRSwNP) when differentiated in an air-liquid interface (ALI) usually provide a pseudostratified airway epithelium with similar abnormalities than original in vivo phenotype. However, the intrinsic mechanisms regulating this complex process are not well defined and their understanding could offer potential new therapies for CRSwNP (incurable disease). METHODS: We performed a transcriptome-wide analysis during in vitro mucociliary differentiation of human adult BSCs from CRSwNP, compared to those isolated from control nasal mucosa (control-NM), in order to identify which key mRNA and microRNAs are regulating this complex process in pathological and healthy conditions. RESULTS: A number of genes, miRs, biological processes, and pathways were identified during mucociliary differentiation of both CRSwNP and control-NM epithelia, and notably, we have demonstrated for the first time that genetic transcriptional program responsible of ciliogenesis and cilia function is significantly impaired in CRSwNP epithelium, presumably produced by an altered expression of microRNAs, particularly of those miRs belonging to mir-34 and mi-449 families. CONCLUSIONS: This study provides for the first time a novel insight into the molecular basis of sinonasal mucociliary differentiation, demonstrating that transcriptome related to ciliogenesis and cilia function is significantly impaired during differentiation of CRSwNP epithelium due to an altered expression of microRNAs.</style></abstract><notes><style face="normal" font="default" size="100%">Callejas-Diaz, Borja&#xD;Fernandez, Guerau&#xD;Fuentes, Mireya&#xD;Martinez-Anton, Asuncion&#xD;Alobid, Isam&#xD;Roca-Ferrer, Jordi&#xD;Picado, Cesar&#xD;Tubita, Valeria&#xD;Mullol, Joaquim&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Oct;75(10):2548-2561. doi: 10.1111/all.14307. Epub 2020 Jul 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32249954</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14307</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1095</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1095</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Glickman, J. W.</style></author><author><style face="normal" font="default" size="100%">Dubin, C.</style></author><author><style face="normal" font="default" size="100%">Dahabreh, D.</style></author><author><style face="normal" font="default" size="100%">Han, J.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y. D.</style></author><author><style face="normal" font="default" size="100%">Zhang, N.</style></author><author><style face="normal" font="default" size="100%">Kimmel, G. W.</style></author><author><style face="normal" font="default" size="100%">Singer, G.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.&#xD;Department of Biomedical Engineering, The University of Mississippi, University, MS, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3053-3065</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/03/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Alopecia Areata/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Keratins, Hair-Specific</style></keyword><keyword><style face="normal" font="default" size="100%">Keratins, Type II</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Activation</style></keyword><keyword><style face="normal" font="default" size="100%">Scalp</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Olink</style></keyword><keyword><style face="normal" font="default" size="100%">RNAseq</style></keyword><keyword><style face="normal" font="default" size="100%">alopecia areata</style></keyword><keyword><style face="normal" font="default" size="100%">bioinformatics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33721346</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Alopecia areata (AA) is characterized by immune dysregulation in both scalp and blood, but a large-scale approach establishing biomarkers of AA incorporating both scalp tissue and serum compartments is lacking. We aimed to characterize the transcriptomic signature of AA lesional and nonlesional scalp compared to healthy scalp and determine its relationship with the blood proteome in the same individuals, with comparative correlations to clinical AA disease severity. METHODS: We evaluated lesional and nonlesional scalp tissues and serum from patients with moderate-to-severe AA (n = 18) and healthy individuals (n = 8). We assessed 33,118 genes in AA scalp tissue using RNAseq transcriptomic evaluation and 340 inflammatory proteins in serum using OLINK high-throughput proteomics. Univariate and multivariate approaches were used to correlate disease biomarkers with Severity of Alopecia Tool (SALT). RESULTS: A total of 608 inflammatory genes were differentially expressed in lesional AA scalp (fold change/FCH&gt;1.5, false discovery rate/FDR&lt;0.05) including Th1 (IFNG/IL12B/CXCL11), Th2 (IL13/CCL18), and T-cell activation-related (ICOS) products. Th1/Th2-related markers were significantly correlated with AA clinical severity in lesional/nonlesional tissue, while keratins (KRT35/KRT83/KRT81) were significantly downregulated in lesional compared to healthy scalp (p &lt; .05). Expression of cardiovascular/atherosclerosis-related markers (MMP9/CCL2/IL1RL1/IL33R/ST2/AGER) in lesional scalp correlated with their corresponding serum expression (p &lt; .05). AA scalp demonstrated significantly greater biomarker dysregulation compared to blood. An integrated multivariate approach combining scalp and serum biomarkers improved correlations with disease severity/SALT. CONCLUSION: This study contributes a unique understanding of the phenotype of moderate-to-severe AA with an integrated scalp and serum biomarker model suggesting the systemic nature of the disease, advocating for the need for immune-based systemic treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Glickman, Jacob W&#xD;Dubin, Celina&#xD;Dahabreh, Dante&#xD;Han, Joseph&#xD;Del Duca, Ester&#xD;Estrada, Yeriel D&#xD;Zhang, Ning&#xD;Kimmel, Grace W&#xD;Singer, Giselle&#xD;Krueger, James G&#xD;Pavel, Ana B&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3053-3065. doi: 10.1111/all.14814. Epub 2021 Jun 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33721346</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14814</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2492</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2492</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nakajima, S.</style></author><author><style face="normal" font="default" size="100%">Nakamizo, S.</style></author><author><style face="normal" font="default" size="100%">Nomura, T.</style></author><author><style face="normal" font="default" size="100%">Ishida, Y.</style></author><author><style face="normal" font="default" size="100%">Sawada, Y.</style></author><author><style face="normal" font="default" size="100%">Kabashima, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Alliance Laboratory for Advanced Medical Research, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Department of Drug Development for Intractable Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.&#xD;A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.&#xD;Skin Research Institute of Singapore (SRIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Integrating multi-omics approaches in deciphering atopic dermatitis pathogenesis and future therapeutic directions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2366-2379</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/therapy/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Genomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Epigenomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Lipidomics</style></keyword><keyword><style face="normal" font="default" size="100%">Precision Medicine/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Multiomics</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">epigenomics</style></keyword><keyword><style face="normal" font="default" size="100%">genomics</style></keyword><keyword><style face="normal" font="default" size="100%">multi-omics</style></keyword><keyword><style face="normal" font="default" size="100%">proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38837434</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopic dermatitis (AD), a complex and heterogeneous chronic inflammatory skin disorder, manifests in a spectrum of clinical subtypes. The application of genomics has elucidated the role of genetic variations in predisposing individuals to AD. Transcriptomics, analyzing gene expression alterations, sheds light on the molecular underpinnings of AD. Proteomics explores the involvement of proteins in AD pathophysiology, while epigenomics examines the impact of environmental factors on gene expression. Lipidomics, which investigates lipid profiles, enhances our understanding of skin barrier functionalities and their perturbations in AD. This review synthesizes insights from these omics approaches, highlighting their collective importance in unraveling the intricate pathogenesis of AD. The review culminates by projecting future trajectories in AD research, particularly the promise of multi-omics in forging personalized medicine and novel therapeutic interventions. Such an integrated multi-omics strategy is poised to transform AD comprehension and management, steering towards more precise and efficacious treatment modalities.</style></abstract><notes><style face="normal" font="default" size="100%">Nakajima, Saeko&#xD;Nakamizo, Satoshi&#xD;Nomura, Takashi&#xD;Ishida, Yoshihiro&#xD;Sawada, Yu&#xD;Kabashima, Kenji&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2366-2379. doi: 10.1111/all.16183. Epub 2024 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38837434</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16183</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2547</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2547</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nakajima, S.</style></author><author><style face="normal" font="default" size="100%">Nakamizo, S.</style></author><author><style face="normal" font="default" size="100%">Nomura, T.</style></author><author><style face="normal" font="default" size="100%">Ishida, Y.</style></author><author><style face="normal" font="default" size="100%">Sawada, Y.</style></author><author><style face="normal" font="default" size="100%">Kabashima, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Alliance Laboratory for Advanced Medical Research, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Department of Drug Development for Intractable Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.&#xD;A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.&#xD;Skin Research Institute of Singapore (SRIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Integrating multi-omics approaches in deciphering atopic dermatitis pathogenesis and future therapeutic directions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2366-2379</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/therapy/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Genomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Epigenomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Lipidomics</style></keyword><keyword><style face="normal" font="default" size="100%">Precision Medicine/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Multiomics</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">epigenomics</style></keyword><keyword><style face="normal" font="default" size="100%">genomics</style></keyword><keyword><style face="normal" font="default" size="100%">multi-omics</style></keyword><keyword><style face="normal" font="default" size="100%">proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38837434</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopic dermatitis (AD), a complex and heterogeneous chronic inflammatory skin disorder, manifests in a spectrum of clinical subtypes. The application of genomics has elucidated the role of genetic variations in predisposing individuals to AD. Transcriptomics, analyzing gene expression alterations, sheds light on the molecular underpinnings of AD. Proteomics explores the involvement of proteins in AD pathophysiology, while epigenomics examines the impact of environmental factors on gene expression. Lipidomics, which investigates lipid profiles, enhances our understanding of skin barrier functionalities and their perturbations in AD. This review synthesizes insights from these omics approaches, highlighting their collective importance in unraveling the intricate pathogenesis of AD. The review culminates by projecting future trajectories in AD research, particularly the promise of multi-omics in forging personalized medicine and novel therapeutic interventions. Such an integrated multi-omics strategy is poised to transform AD comprehension and management, steering towards more precise and efficacious treatment modalities.</style></abstract><notes><style face="normal" font="default" size="100%">Nakajima, Saeko&#xD;Nakamizo, Satoshi&#xD;Nomura, Takashi&#xD;Ishida, Yoshihiro&#xD;Sawada, Yu&#xD;Kabashima, Kenji&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2366-2379. doi: 10.1111/all.16183. Epub 2024 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38837434</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16183</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1644</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1644</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chiu, C. Y.</style></author><author><style face="normal" font="default" size="100%">Chou, H. C.</style></author><author><style face="normal" font="default" size="100%">Chang, L. C.</style></author><author><style face="normal" font="default" size="100%">Fan, W. L.</style></author><author><style face="normal" font="default" size="100%">Dinh, M. C. V.</style></author><author><style face="normal" font="default" size="100%">Kuo, Y. L.</style></author><author><style face="normal" font="default" size="100%">Chung, W. H.</style></author><author><style face="normal" font="default" size="100%">Lai, H. C.</style></author><author><style face="normal" font="default" size="100%">Hsieh, W. P.</style></author><author><style face="normal" font="default" size="100%">Su, S. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Pulmonology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.&#xD;Clinical Metabolomics Core Laboratory, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.&#xD;Institute of Statistics, National Tsing-Hua University, Hsinchu, Taiwan.&#xD;Department of Mathematical Sciences, Florida Atlantic University, Florida, USA.&#xD;Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan.&#xD;Department of Computer Science, Florida Atlantic University, Florida, USA.&#xD;Biotools, Co. Ltd, New Taipei City, Taiwan.&#xD;Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan.&#xD;Department of Medical Biotechnology and Laboratory Science, Microbiota Research Center, College of Medicine, Chang Gung University, Taoyuan, Taiwan.&#xD;Central Research Laboratory, XiaMen Chang Gung Hospital, XiaMen, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Integration of metagenomics-metabolomics reveals specific signatures and functions of airway microbiota in mite-sensitized childhood asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2846-2857</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2020/06/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">Metagenomics</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">*Mites</style></keyword><keyword><style face="normal" font="default" size="100%">Prevotella</style></keyword><keyword><style face="normal" font="default" size="100%">airway microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">circulating metabolites</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32506557</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Childhood asthma is a multifactorial inflammatory condition of the airways, associated with specific changes in respiratory microbiome and circulating metabolome. METHODS: To explore the functional capacity of asthmatic microbiome and its intricate connection with the host, we performed shotgun sequencing of airway microbiome and untargeted metabolomics profiling of serum samples in a cohort of children with mite-sensitized asthma and non-asthmatic controls. RESULTS: We observed higher gene counts and sample-to-sample dissimilarities in asthmatic microbiomes, indicating a more heterogeneous community structure and functionality among the cases than in controls. Moreover, we identified airway microbial species linked to changes in circulating metabolites and IgE responses of the host, including a positive correlation between Prevotella sp oral taxon 306 and dimethylglycine that were both decreased in patients. Several control-enriched species (Eubacterium sulci, Prevotella pallens, and Prevotella sp oral taxon 306) were inversely correlated with total and allergen-specific IgE levels. Genes related to microbial carbohydrate, amino acid, and lipid metabolism were differentially enriched, suggesting that changes in microbial metabolism may contribute to respiratory health in asthmatics. Pathway modules relevant to allergic responses were differentially abundant in asthmatic microbiome, such as enrichments for biofilm formation by Pseudomonas aeruginosa, membrane trafficking, histidine metabolism, and glycosaminoglycan degradation, and depletions for polycyclic aromatic hydrocarbon degradation. Further, we identified metagenomic and metabolomic markers (eg, Eubacterium sulci) to discriminate cases from the non-asthmatic controls. CONCLUSIONS: Our dual-omics data reveal the connections between respiratory microbes and circulating metabolites perturbed in mite-sensitized pediatric asthma, which may be of etiological and diagnostic implications.</style></abstract><notes><style face="normal" font="default" size="100%">Chiu, Chih-Yung&#xD;Chou, Hsin-Cheng&#xD;Chang, Lun-Ching&#xD;Fan, Wen-Lang&#xD;Dinh, Michael Cong Vinh&#xD;Kuo, Yu-Lun&#xD;Chung, Wen-Hung&#xD;Lai, Hsin-Chih&#xD;Hsieh, Wen-Ping&#xD;Su, Shih-Chi&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Nov;75(11):2846-2857. doi: 10.1111/all.14438. Epub 2020 Jul 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32506557</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14438</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1391</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1391</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wisgrill, L.</style></author><author><style face="normal" font="default" size="100%">Werner, P.</style></author><author><style face="normal" font="default" size="100%">Jalonen, E.</style></author><author><style face="normal" font="default" size="100%">Berger, A.</style></author><author><style face="normal" font="default" size="100%">Lauerma, A.</style></author><author><style face="normal" font="default" size="100%">Alenius, H.</style></author><author><style face="normal" font="default" size="100%">Fyhrquist, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.&#xD;Human Microbiome Program (HUMI), Medicum, University of Helsinki, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Integrative transcriptome analysis deciphers mechanisms of nickel contact dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">804-815</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/07/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nickel/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Patch Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">nickel</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword><keyword><style face="normal" font="default" size="100%">Fyhrquist have nothing to disclosure.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32706929</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Nickel-induced allergic contact dermatitis (nACD) remains a major occupational skin disorder, significantly impacting the quality of life of suffering patients. Complex cellular compositional changes and associated immunological pathways are partly resolved in humans; thus, the impact of nACD on human skin needs to be further elucidated. METHODS: To decipher involved immunological players and pathways, human skin biopsies were taken at 0, 2, 48, and 96 hours after nickel patch test in six nickel-allergic patients. Gene expression profiles were analyzed via microarray. RESULTS: Leukocyte deconvolution of nACD-affected skin identified major leukocyte compositional changes at 48 and 96 hours, including natural killer (NK) cells, macrophage polarization, and T-cell immunity. Gene set enrichment analysis mirrored cellular-linked functional pathways enriched over time. NK cell infiltration and cytotoxic pathways were uniquely found in nACD-affected skin compared to sodium lauryl sulfate-induced irritant skin reactions. CONCLUSION: These results highlight key immunological leukocyte subsets as well as associated pathways in nACD, providing insights into pathophysiology with the potential to unravel novel therapeutic targets.</style></abstract><notes><style face="normal" font="default" size="100%">Wisgrill, Lukas&#xD;Werner, Paulina&#xD;Jalonen, Erja&#xD;Berger, Angelika&#xD;Lauerma, Antti&#xD;Alenius, Harri&#xD;Fyhrquist, Nanna&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):804-815. doi: 10.1111/all.14519. Epub 2020 Aug 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32706929</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7984291</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14519</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3314</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3314</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Tianyi</style></author><author><style face="normal" font="default" size="100%">Fang, Xinyi</style></author><author><style face="normal" font="default" size="100%">Deng, Qihong</style></author><author><style face="normal" font="default" size="100%">Zhang, Xin</style></author><author><style face="normal" font="default" size="100%">Zhang, Ling</style></author><author><style face="normal" font="default" size="100%">Yu, Wei</style></author><author><style face="normal" font="default" size="100%">Zheng, Xiaohong</style></author><author><style face="normal" font="default" size="100%">Wang, Tingting</style></author><author><style face="normal" font="default" size="100%">Jiang, Hong</style></author><author><style face="normal" font="default" size="100%">Yu, Xiaodan</style></author><author><style face="normal" font="default" size="100%">Zhao, Zhuohui</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Interactive Effects of Ambient Fine Particulate Matter and Ozone on Childhood Allergic Rhinitis: China, Children, Homes, Health Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70285</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70285</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2170</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2170</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, Y. A.</style></author><author><style face="normal" font="default" size="100%">Kim, N.</style></author><author><style face="normal" font="default" size="100%">Jeong, N. H.</style></author><author><style face="normal" font="default" size="100%">Kwon, T. K.</style></author><author><style face="normal" font="default" size="100%">Bang, J. S.</style></author><author><style face="normal" font="default" size="100%">Jang, Y. H.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cell and Matrix Research Institute, Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.&#xD;Department of Immunology, School of Medicine, Keimyung University, Daegu, Republic of Korea.&#xD;Department of Dermatology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Interferon-gamma-inducible protein 10 augments atopic dermatitis via amplifying Th2 immune response</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">235-238</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon-gamma</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">Th1 Cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37548260</style></accession-num><notes><style face="normal" font="default" size="100%">Choi, Young-Ae&#xD;Kim, Namkyung&#xD;Jeong, Na-Hee&#xD;Kwon, Taeg Kyu&#xD;Bang, Jin Seon&#xD;Jang, Yong Hyun&#xD;Kim, Sang-Hyun&#xD;eng&#xD;National Research Foundation of Korea grant/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):235-238. doi: 10.1111/all.15833. Epub 2023 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37548260</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15833</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2156</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2156</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pantelyushin, S.</style></author><author><style face="normal" font="default" size="100%">Rhiner, T.</style></author><author><style face="normal" font="default" size="100%">Jebbawi, F.</style></author><author><style face="normal" font="default" size="100%">Sella, F.</style></author><author><style face="normal" font="default" size="100%">Waldern, N.</style></author><author><style face="normal" font="default" size="100%">Lam, J.</style></author><author><style face="normal" font="default" size="100%">Chemnitzer, A.</style></author><author><style face="normal" font="default" size="100%">Fricker, A.</style></author><author><style face="normal" font="default" size="100%">Schoster, A.</style></author><author><style face="normal" font="default" size="100%">Birkmann, K.</style></author><author><style face="normal" font="default" size="100%">Widmer, D.</style></author><author><style face="normal" font="default" size="100%">Canonica, F.</style></author><author><style face="normal" font="default" size="100%">Fettelschoss-Gabriel, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, University Hospital Zurich, Schlieren, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Evax AG, Guntershausen, Switzerland.&#xD;Equine Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Interleukin 5-dependent inflammatory eosinophil subtype involved in allergic insect bite hypersensitivity of horses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3020-3023</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/08/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IL-5 vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">allergic equine insect bite hypersensitivity (IBH)</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil subtypes</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">integrins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37605865</style></accession-num><notes><style face="normal" font="default" size="100%">Pantelyushin, Stanislav&#xD;Rhiner, Tanya&#xD;Jebbawi, Fadi&#xD;Sella, Federica&#xD;Waldern, Nina&#xD;Lam, Juwela&#xD;Chemnitzer, Alex&#xD;Fricker, Anna&#xD;Schoster, Angelika&#xD;Birkmann, Katharina&#xD;Widmer, Daniel&#xD;Canonica, Fabia&#xD;Fettelschoss-Gabriel, Antonia&#xD;eng&#xD;Evax AG/&#xD;40B2-0_194689/Swiss Bridge Foundation (SNF BRIDGE)/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):3020-3023. doi: 10.1111/all.15859. Epub 2023 Aug 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37605865</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15859</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2434</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2434</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Craig, N.</style></author><author><style face="normal" font="default" size="100%">Ahrens, K.</style></author><author><style face="normal" font="default" size="100%">Wilkes, R.</style></author><author><style face="normal" font="default" size="100%">Opriessnig, T.</style></author><author><style face="normal" font="default" size="100%">Hoyle, D. V.</style></author><author><style face="normal" font="default" size="100%">Bradford, B.</style></author><author><style face="normal" font="default" size="100%">Maxwell, S.</style></author><author><style face="normal" font="default" size="100%">Del Pozo, J.</style></author><author><style face="normal" font="default" size="100%">Parys, M.</style></author><author><style face="normal" font="default" size="100%">Kitamura, T.</style></author><author><style face="normal" font="default" size="100%">Marsella, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA.&#xD;The Roslin Institute, The University of Edinburgh, Easter Bush Campus, Midlothian, UK.&#xD;Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush Campus, Midlothian, UK.&#xD;MRC Centre for Reproductive Health, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Interleukin 31 transcription in a canine model of acute atopic dermatitis does not correlate with T-cell infiltration</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1622-1625</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/03/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukins/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription, Genetic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38532561</style></accession-num><notes><style face="normal" font="default" size="100%">Craig, Nicky&#xD;Ahrens, Kim&#xD;Wilkes, Rachel&#xD;Opriessnig, Tanja&#xD;Hoyle, Deborah V&#xD;Bradford, Barry&#xD;Maxwell, Scott&#xD;Del Pozo, Jorge&#xD;Parys, Maciej&#xD;Kitamura, Takanori&#xD;Marsella, Rosanna&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1622-1625. doi: 10.1111/all.16105. Epub 2024 Mar 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38532561</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16105</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2700</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2700</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buchheit, K. M.</style></author><author><style face="normal" font="default" size="100%">Shaw, D.</style></author><author><style face="normal" font="default" size="100%">Chupp, G.</style></author><author><style face="normal" font="default" size="100%">Lehtimaki, L.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Finney-Hayward, T.</style></author><author><style face="normal" font="default" size="100%">Zangrilli, J.</style></author><author><style face="normal" font="default" size="100%">Kwiatek, J.</style></author><author><style face="normal" font="default" size="100%">Siddiqui, S.</style></author><author><style face="normal" font="default" size="100%">Roufosse, F.</style></author><author><style face="normal" font="default" size="100%">Thamboo, A.</style></author><author><style face="normal" font="default" size="100%">West, N.</style></author><author><style face="normal" font="default" size="100%">Vichiendilokkul, A.</style></author><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author><author><style face="normal" font="default" size="100%">Peters, A.</style></author><author><style face="normal" font="default" size="100%">Howarth, P. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, AERD Center, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Respiratory Medicine and Thoracic Surgery, Institute for Lung Health, Glenfield Hospital, Leicester, UK.&#xD;Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.&#xD;Faculty of Medicine and Health Technology, Allergy Centre, Tampere University Hospital, Tampere University, Tampere, Finland.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Personalized Medicine, Asthma and Allergy Clinic, IRCCS Humanitas Research Hospital, Milan, Italy.&#xD;Global Medical Affairs, Respiratory Specialty Care, GSK, London, UK.&#xD;Clinical Science, GSK, Collegeville, Pennsylvania, USA.&#xD;US Medical Affairs, GSK, Collegeville, Pennsylvania, USA.&#xD;National Heart and Lung Institute, NIHR Imperial Biomedical Research Centre, Imperial College London, London, UK.&#xD;Department of Internal Medicine, Erasme Hospital, Universite Libre de Bruxelles, Brussels, Belgium.&#xD;Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.&#xD;School of Pharmacy and Medical Sciences, Griffith University, Southport, Queensland, Australia.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.&#xD;Upper Airways Disease Research Unit, University of Ghent, Ghent, Belgium.&#xD;Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2662-2679</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/10/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-5/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Il-5</style></keyword><keyword><style face="normal" font="default" size="100%">airway remodelling</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil-associated diseases</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39359069</style></accession-num><abstract><style face="normal" font="default" size="100%">Interleukin (IL)-5 is the key cytokine in the maturation, activation, proliferation, migration and survival of eosinophils, which are key effector cells in many upper and lower airway diseases. Through its effects on eosinophils, IL-5 indirectly contributes to various pathophysiological processes including tissue damage, repair and remodelling. Understanding the importance of IL-5 in eosinophil-associated diseases led to the development of anti-IL-5 therapies, which provide clinical benefits across a range of conditions. However, recent evidence suggests that eosinophil-depletion alone may not account for all of the therapeutic effects of anti-IL-5 therapy and that IL-5 may also contribute to disease independently of its effects on eosinophils. Indeed, evidence from ex vivo studies and targeted therapy in vivo demonstrates that IL-5 and its inhibition affects a much broader range of cells beyond eosinophils, including epithelial cells, plasma cells, mast cells, basophils, neutrophils, type 2 innate lymphoid cells, T regulatory cells and fibroblasts. This review will provide an update on the evidence supporting the breadth of IL-5 biology relevant to disease pathogenesis beyond eosinophil-associated inflammation, where there is a need for additional insight, and the clinical implications of a more central role of IL-5 in type 2 inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Buchheit, Kathleen M&#xD;Shaw, Dominick&#xD;Chupp, Geoffrey&#xD;Lehtimaki, Lauri&#xD;Heffler, Enrico&#xD;Finney-Hayward, Tricia&#xD;Zangrilli, James&#xD;Kwiatek, Justin&#xD;Siddiqui, Salman&#xD;Roufosse, Florence&#xD;Thamboo, Andrew&#xD;West, Nicholas&#xD;Vichiendilokkul, Anna&#xD;Hellings, Peter W&#xD;Peters, Anju&#xD;Howarth, Peter H&#xD;eng&#xD;GSK/&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2662-2679. doi: 10.1111/all.16303.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39359069</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16303</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1283</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1283</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jakubovic, B. D.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Sanchez, S.</style></author><author><style face="normal" font="default" size="100%">Hamadi, S.</style></author><author><style face="normal" font="default" size="100%">Lynch, D. M.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Harvard Medical School, Brigham and Women&apos;s Hospital, Boston, MA, USA.&#xD;Allergy Department, University Hospital Complex A Coruna (CHUAC), A Coruna, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Interleukin-6: A novel biomarker for monoclonal antibody and chemotherapy-associated hypersensitivity confirms a cytokine release syndrome phenotype-endotype association</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1571-1573</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokine Release Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-6/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Il-6</style></keyword><keyword><style face="normal" font="default" size="100%">Rapid Drug Desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33119137</style></accession-num><notes><style face="normal" font="default" size="100%">Jakubovic, Baruch D&#xD;Sanchez-Sanchez, Soledad&#xD;Hamadi, Sahar&#xD;Lynch, Donna-Marie&#xD;Castells, Mariana&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1571-1573. doi: 10.1111/all.14644. Epub 2020 Nov 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33119137</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14644</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3254</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3254</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fukushima-Nomura, Ayano</style></author><author><style face="normal" font="default" size="100%">Kawasaki, Hiroshi</style></author><author><style face="normal" font="default" size="100%">Hasegawa, Takehiro</style></author><author><style face="normal" font="default" size="100%">Yanagisawa, Erika</style></author><author><style face="normal" font="default" size="100%">Tanese, Keiji</style></author><author><style face="normal" font="default" size="100%">Yanagida, Nozomi</style></author><author><style face="normal" font="default" size="100%">Obata, Shoko</style></author><author><style face="normal" font="default" size="100%">Yashiro, Kiyoshi</style></author><author><style face="normal" font="default" size="100%">Ito, Yoshihiro</style></author><author><style face="normal" font="default" size="100%">Koseki, Haruhiko</style></author><author><style face="normal" font="default" size="100%">Amagai, Masayuki</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Interleukin-22 and Interleukin-18 as Potential Blood Biomarkers in Dupilumab-Treated Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70248</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70248</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1134</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1134</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Datsi, A.</style></author><author><style face="normal" font="default" size="100%">Steinhoff, M.</style></author><author><style face="normal" font="default" size="100%">Ahmad, F.</style></author><author><style face="normal" font="default" size="100%">Alam, M.</style></author><author><style face="normal" font="default" size="100%">Buddenkotte, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Transplantational Diagnostics and Cell Therapeutics, University Hospital Dusseldorf, Dusseldorf, Germany.&#xD;Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.&#xD;Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.&#xD;Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.&#xD;Department of Dermatology, Weill Cornell Medicine-Qatar, Doha, Qatar.&#xD;Qatar University, College of Medicine, Doha, Qatar.&#xD;Department of Dermatology, Weill Cornell Medicine, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Interleukin-31: The &quot;itchy&quot; cytokine in inflammation and therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2982-2997</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/02/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukins</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Interleukin</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-31</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-31 receptor A</style></keyword><keyword><style face="normal" font="default" size="100%">oncostatin M receptor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33629401</style></accession-num><abstract><style face="normal" font="default" size="100%">The cytokine interleukin-31 has been implicated in the pathophysiology of multiple atopic disorders such as atopic dermatitis (AD), allergic rhinitis, and airway hyper-reactivity. In AD, IL-31 has been identified as one of the main &quot;drivers&quot; of its cardinal symptom, pruritus. Here, we summarize the mechanisms by which IL-31 modulates inflammatory and allergic diseases. T(H) 2 cells play a central role in AD and release high levels of T(H) 2-associated cytokines including IL-31, thereby mediating inflammatory responses, initiating immunoregulatory circuits, stimulating itch, and neuronal outgrowth through activation of the heterodimeric receptor IL-31 receptor A (IL31RA)/Oncostatin M receptor (OSMRbeta). IL31RA expression is found on human and murine dorsal root ganglia neurons, epithelial cells including keratinocytes and various innate immune cells. IL-31 is a critical cytokine involved in neuroimmune communication, which opens new avenues for cytokine modulation in neuroinflammatory diseases including AD/pruritus, as validated by recent clinical trials using an anti-IL-31 antibody. Accordingly, inhibition of IL-31-downstream signaling may be a beneficial approach for various inflammatory diseases including prurigo. However, as to whether downstream JAK inhibitors directly block IL-31-mediated-signaling needs to be clarified. Targeting the IL-31/IL31RA/OSMRbeta axis appears to be a promising approach for inflammatory, neuroinflammatory, and pruritic disorders in the future.</style></abstract><notes><style face="normal" font="default" size="100%">Datsi, Angeliki&#xD;Steinhoff, Martin&#xD;Ahmad, Fareed&#xD;Alam, Majid&#xD;Buddenkotte, Joerg&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):2982-2997. doi: 10.1111/all.14791. Epub 2021 Mar 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33629401</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14791</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>814</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">814</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Abdul Latiff, A. H.</style></author><author><style face="normal" font="default" size="100%">Abuzakouk, M.</style></author><author><style face="normal" font="default" size="100%">Aquilina, S.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author><author><style face="normal" font="default" size="100%">Baker, D.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B.</style></author><author><style face="normal" font="default" size="100%">Bangert, C.</style></author><author><style face="normal" font="default" size="100%">Ben-Shoshan, M.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Brzoza, Z.</style></author><author><style face="normal" font="default" size="100%">Chong Neto, H. J.</style></author><author><style face="normal" font="default" size="100%">Church, M. K.</style></author><author><style face="normal" font="default" size="100%">Criado, P. R.</style></author><author><style face="normal" font="default" size="100%">Danilycheva, I. V.</style></author><author><style face="normal" font="default" size="100%">Dressler, C.</style></author><author><style face="normal" font="default" size="100%">Ensina, L. F.</style></author><author><style face="normal" font="default" size="100%">Fonacier, L.</style></author><author><style face="normal" font="default" size="100%">Gaskins, M.</style></author><author><style face="normal" font="default" size="100%">Gaspar, K.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A.</style></author><author><style face="normal" font="default" size="100%">Godse, K.</style></author><author><style face="normal" font="default" size="100%">Goncalo, M.</style></author><author><style face="normal" font="default" size="100%">Grattan, C.</style></author><author><style face="normal" font="default" size="100%">Grosber, M.</style></author><author><style face="normal" font="default" size="100%">Hamelmann, E.</style></author><author><style face="normal" font="default" size="100%">Hebert, J.</style></author><author><style face="normal" font="default" size="100%">Hide, M.</style></author><author><style face="normal" font="default" size="100%">Kaplan, A.</style></author><author><style face="normal" font="default" size="100%">Kapp, A.</style></author><author><style face="normal" font="default" size="100%">Kessel, A.</style></author><author><style face="normal" font="default" size="100%">Kocaturk, E.</style></author><author><style face="normal" font="default" size="100%">Kulthanan, K.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D.</style></author><author><style face="normal" font="default" size="100%">Lauerma, A.</style></author><author><style face="normal" font="default" size="100%">Leslie, T. A.</style></author><author><style face="normal" font="default" size="100%">Magerl, M.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Meshkova, R. Y.</style></author><author><style face="normal" font="default" size="100%">Metz, M.</style></author><author><style face="normal" font="default" size="100%">Micallef, D.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Nast, A.</style></author><author><style face="normal" font="default" size="100%">Oude-Elberink, H.</style></author><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Pigatto, P. D.</style></author><author><style face="normal" font="default" size="100%">Ratti Sisa, H.</style></author><author><style face="normal" font="default" size="100%">Rojo Gutierrez, M. I.</style></author><author><style face="normal" font="default" size="100%">Saini, S. S.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Sekerel, B. E.</style></author><author><style face="normal" font="default" size="100%">Siebenhaar, F.</style></author><author><style face="normal" font="default" size="100%">Siiskonen, H.</style></author><author><style face="normal" font="default" size="100%">Soria, A.</style></author><author><style face="normal" font="default" size="100%">Staubach-Renz, P.</style></author><author><style face="normal" font="default" size="100%">Stingeni, L.</style></author><author><style face="normal" font="default" size="100%">Sussman, G.</style></author><author><style face="normal" font="default" size="100%">Szegedi, A.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author><author><style face="normal" font="default" size="100%">Vadasz, Z.</style></author><author><style face="normal" font="default" size="100%">Vestergaard, C.</style></author><author><style face="normal" font="default" size="100%">Wedi, B.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Comprehensive Allergy Centre Charite, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;Allergy &amp; Immunology Centre, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.&#xD;Department of Allergy and Immunology, Respiratory Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.&#xD;Department of Dermatology, Mater Dei Hospital, Msida, Malta.&#xD;Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano (MI), Italy.&#xD;Baker Allergy, Asthma and Dermatology, Portland, Oregon, USA.&#xD;Clinic for Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, Medical University of Vienna, Vienna, Austria.&#xD;Division of Allergy, Immunology and Dermatology, Department of Pediatrics, Montreal Children&apos;s Hospital, McGill University, Montreal, Quebec, Canada.&#xD;University of Cincinnati Physicians Immunology Research Center, Cincinnati, OH, USA.&#xD;Department of Dermatology and Allergy Centre, Odense University Hospital and University of Southern Denmark, Odense, Denmark.&#xD;Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University Munich, Munich, Germany.&#xD;Department of Internal Diseases with Division of Allergology, University of Opole, Opole, Poland.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Federal University of Parana, Curitiba, Brazil.&#xD;University of Southampton, Southampton, UK.&#xD;Sociedade Brasileira de Dermatologia (SBD), Centro Universitario FMABC, Alergoskin (UCARE), Santo Andre, Brazil.&#xD;Department of Allergology and Immunotherapy, National Research Center-Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow, Russia.&#xD;Division of Evidence-Based Medicine, Department of Dermatology, Venereology and Allergy, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;New York University Long Island School of Medicine, New York, New York, USA.&#xD;Division of Dermatological Allergology, Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.&#xD;Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Department of Dermatology, Hospital del Mar, Institut Mar d&apos;Investigacions Mediques, Universitat Autonoma y Universitat Pompeu Fabra, Barcelona, Spain.&#xD;Department of Dermatology, D Y Patil University School of Medicine, Navi Mumbai, India.&#xD;Department of Dermatology, Coimbra University Hospital and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Guy&apos;s Hospital, St John&apos;s Institute of Dermatology, London, UK.&#xD;Department of Dermatology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.&#xD;Department of Pediatrics, Children&apos;s Center Bethel, University Hospital OWL, University Bielefeld, Bielefeld, Germany.&#xD;Service d&apos;allergie, Centre Hospitalier Universite Laval/Centre Hospitalier Universitaire de Quebec, Quebec, Quebec, Canada.&#xD;Department of Dermatology, Hiroshima University, Hiroshima, Japan.&#xD;Department of Dermatology, Hiroshima Citizens Hospital, Hiroshima, Japan.&#xD;Department of Medicine, Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.&#xD;Department of Dermatology &amp; Allergy, Hannover Medical School (MHH), Hannover, Germany.&#xD;Division of Allergy and Clinical Immunology, Bnai Zion Medical Center and the Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel.&#xD;Department of Dermatology, Koc University School of Medicine, Istanbul, Turkey.&#xD;Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Hospital Medica Sur, Mexico City, Mexico.&#xD;Department of Dermatology, Allergology and Venereology, Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.&#xD;Department of Dermatology, Royal Free Hospital, London, UK.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology, Berlin, Germany.&#xD;Allergy Unit, 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University General Hospital &quot;Attikon&quot;, Athens, Greece.&#xD;Department of Clinical Immunology and Allergology, Smolensk State Medical University, Smolensk, Russia.&#xD;Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital and University of Southern Denmark, Odense, Denmark.&#xD;University of Groningen, Groningen, The Netherlands.&#xD;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.&#xD;Primera Catedra de Clinica Medica, Hospital de Clinicas de la Facultad de Ciencias Medicas-Universidad Nacional de Asuncion, Asuncion, Paraguay.&#xD;Hospital Juarez de Mexico, Mexico City, Mexico.&#xD;Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, USA.&#xD;Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.&#xD;Division of Pediatric Allergy and Asthma, Hacettepe University Faculty of Medicine, Ankara, Turkey.&#xD;Department of Pathology, Diagnostic Imaging Centre, Kuopio University Hospital, Kuopio, Finland.&#xD;Department of Dermatology and Allergology, Tenon Hospital, APHP Sorbonne University and Cimi-Paris Inserm 1135, Paris, France.&#xD;Department of Dermatology, University Medical Center Mainz, Mainz, Germany.&#xD;Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy.&#xD;Division of Allergy and Clinical Immunology, St. Michael&apos;s Hospital and University of Toronto, Toronto, Canada.&#xD;Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Proteomic and Clinical Flow Cytometry Unit, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.&#xD;Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark.&#xD;Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover, Germany.&#xD;Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">734-766</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/09/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedema/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">consensus</style></keyword><keyword><style face="normal" font="default" size="100%">evidence-based</style></keyword><keyword><style face="normal" font="default" size="100%">hives</style></keyword><keyword><style face="normal" font="default" size="100%">itch</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">wheal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34536239</style></accession-num><abstract><style face="normal" font="default" size="100%">This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA(2)LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.</style></abstract><notes><style face="normal" font="default" size="100%">Zuberbier, Torsten&#xD;Abdul Latiff, Amir Hamzah&#xD;Abuzakouk, Mohamed&#xD;Aquilina, Susan&#xD;Asero, Riccardo&#xD;Baker, Diane&#xD;Ballmer-Weber, Barbara&#xD;Bangert, Christine&#xD;Ben-Shoshan, Moshe&#xD;Bernstein, Jonathan A&#xD;Bindslev-Jensen, Carsten&#xD;Brockow, Knut&#xD;Brzoza, Zenon&#xD;Chong Neto, Herberto Jose&#xD;Church, Martin K&#xD;Criado, Paulo R&#xD;Danilycheva, Inna V&#xD;Dressler, Corinna&#xD;Ensina, Luis Felipe&#xD;Fonacier, Luz&#xD;Gaskins, Matthew&#xD;Gaspar, Krisztian&#xD;Gelincik, Asli&#xD;Gimenez-Arnau, Ana&#xD;Godse, Kiran&#xD;Goncalo, Margarida&#xD;Grattan, Clive&#xD;Grosber, Martine&#xD;Hamelmann, Eckard&#xD;Hebert, Jacques&#xD;Hide, Michihiro&#xD;Kaplan, Allen&#xD;Kapp, Alexander&#xD;Kessel, Aharon&#xD;Kocaturk, Emek&#xD;Kulthanan, Kanokvalai&#xD;Larenas-Linnemann, Desiree&#xD;Lauerma, Antti&#xD;Leslie, Tabi A&#xD;Magerl, Markus&#xD;Makris, Michael&#xD;Meshkova, Raisa Y&#xD;Metz, Martin&#xD;Micallef, Daniel&#xD;Mortz, Charlotte G&#xD;Nast, Alexander&#xD;Oude-Elberink, Hanneke&#xD;Pawankar, Ruby&#xD;Pigatto, Paolo D&#xD;Ratti Sisa, Hector&#xD;Rojo Gutierrez, Maria Isabel&#xD;Saini, Sarbjit S&#xD;Schmid-Grendelmeier, Peter&#xD;Sekerel, Bulent E&#xD;Siebenhaar, Frank&#xD;Siiskonen, Hanna&#xD;Soria, Angele&#xD;Staubach-Renz, Petra&#xD;Stingeni, Luca&#xD;Sussman, Gordon&#xD;Szegedi, Andrea&#xD;Thomsen, Simon Francis&#xD;Vadasz, Zahava&#xD;Vestergaard, Christian&#xD;Wedi, Bettina&#xD;Zhao, Zuotao&#xD;Maurer, Marcus&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):734-766. doi: 10.1111/all.15090. Epub 2021 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34536239</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15090</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3085</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3085</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fu, Q. W.</style></author><author><style face="normal" font="default" size="100%">Liu, P.</style></author><author><style face="normal" font="default" size="100%">Ruan, Y.</style></author><author><style face="normal" font="default" size="100%">Li, X. R.</style></author><author><style face="normal" font="default" size="100%">Zhang, L. Z.</style></author><author><style face="normal" font="default" size="100%">Yang, S. S.</style></author><author><style face="normal" font="default" size="100%">Chai, F.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Chen, Q. Y.</style></author><author><style face="normal" font="default" size="100%">Chen, S. C.</style></author><author><style face="normal" font="default" size="100%">Chen, W. Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. N.</style></author><author><style face="normal" font="default" size="100%">Cheng, H. B.</style></author><author><style face="normal" font="default" size="100%">Cheng, L.</style></author><author><style face="normal" font="default" size="100%">Cui, L. J.</style></author><author><style face="normal" font="default" size="100%">Deng, K. B.</style></author><author><style face="normal" font="default" size="100%">Fang, C. S.</style></author><author><style face="normal" font="default" size="100%">Feng, R. C.</style></author><author><style face="normal" font="default" size="100%">Fu, L.</style></author><author><style face="normal" font="default" size="100%">Fu, W. Y.</style></author><author><style face="normal" font="default" size="100%">Gao, J. Y.</style></author><author><style face="normal" font="default" size="100%">Guo, H.</style></author><author><style face="normal" font="default" size="100%">He, M.</style></author><author><style face="normal" font="default" size="100%">Hu, K. H.</style></author><author><style face="normal" font="default" size="100%">Huang, C. J.</style></author><author><style face="normal" font="default" size="100%">Huang, H. Y.</style></author><author><style face="normal" font="default" size="100%">Jiang, L. Y.</style></author><author><style face="normal" font="default" size="100%">Qiao, F. Y.</style></author><author><style face="normal" font="default" size="100%">Leng, H.</style></author><author><style face="normal" font="default" size="100%">Li, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Liu, C. S.</style></author><author><style face="normal" font="default" size="100%">Liu, D. X.</style></author><author><style face="normal" font="default" size="100%">Liu, J. H.</style></author><author><style face="normal" font="default" size="100%">Liu, J. H.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Liu, M.</style></author><author><style face="normal" font="default" size="100%">Liu, W. T.</style></author><author><style face="normal" font="default" size="100%">Liu, Y. X.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Z. Q.</style></author><author><style face="normal" font="default" size="100%">Luo, Q. L.</style></author><author><style face="normal" font="default" size="100%">Ma, Y.</style></author><author><style face="normal" font="default" size="100%">Mao, D. H.</style></author><author><style face="normal" font="default" size="100%">Meng, J.</style></author><author><style face="normal" font="default" size="100%">Pang, K. Y.</style></author><author><style face="normal" font="default" size="100%">Peng, S. L.</style></author><author><style face="normal" font="default" size="100%">Tong, X. F.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Wang, J. X.</style></author><author><style face="normal" font="default" size="100%">Wang, J. G.</style></author><author><style face="normal" font="default" size="100%">Wang, R. Z.</style></author><author><style face="normal" font="default" size="100%">Wang, S. Z.</style></author><author><style face="normal" font="default" size="100%">Xia, J. Y.</style></author><author><style face="normal" font="default" size="100%">Xie, H.</style></author><author><style face="normal" font="default" size="100%">Xie, Q.</style></author><author><style face="normal" font="default" size="100%">Xie, Y.</style></author><author><style face="normal" font="default" size="100%">Xiong, D. J.</style></author><author><style face="normal" font="default" size="100%">Yan, Z. F.</style></author><author><style face="normal" font="default" size="100%">Yang, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, D. Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, F. B.</style></author><author><style face="normal" font="default" size="100%">Zhang, S. P.</style></author><author><style face="normal" font="default" size="100%">Zhang, Z. C.</style></author><author><style face="normal" font="default" size="100%">Zhao, J. P.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Zheng, Y.</style></author><author><style face="normal" font="default" size="100%">Zhong, D. Z.</style></author><author><style face="normal" font="default" size="100%">Zhou, L.</style></author><author><style face="normal" font="default" size="100%">Knyazev, V. M.</style></author><author><style face="normal" font="default" size="100%">Kostrova, I. V.</style></author><author><style face="normal" font="default" size="100%">Yeung, W. F.</style></author><author><style face="normal" font="default" size="100%">Wang, Q.</style></author><author><style face="normal" font="default" size="100%">Wang, D. Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Q. X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Chengdu University of Traditional Chinese Medicine, Chengdu, China.&#xD;Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.&#xD;Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada.&#xD;First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.&#xD;First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China.&#xD;Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.&#xD;Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.&#xD;School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China.&#xD;Sanmenxia Traditional Chinese Medicine Hospital, Sanmenxia, China.&#xD;The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.&#xD;Dongfang Hospital of Beijing University of Chinese Medicine, Beijing, China.&#xD;Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China.&#xD;Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Christian Family Service Center, Hong Kong, China.&#xD;Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.&#xD;Faculty of Health, Kwantlen Polytechnic University, Surrey, British Columbia, Canada.&#xD;Fourth Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.&#xD;Dazhou Central Hospital, Dazhou, China.&#xD;Keelung Hospital of Taiwan Health Department, Keelung, Taiwan.&#xD;The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming, China.&#xD;Sichuan Integrative Medicine Hospital, Chengdu, China.&#xD;First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.&#xD;Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China.&#xD;Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing, China.&#xD;Malaysia Nose King Chinese Medicine Clinic, Petaling Jaya, Malaysia.&#xD;Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.&#xD;Chengdu Women&apos;s and Children&apos;s Central Hospital, Chengdu, China.&#xD;School of Nursing and Midwifery, Edith Cowan University, Perth, Western Australia, Australia.&#xD;Institute of Ancient Book Compilation and Research of Sichuan University, Chengdu, China.&#xD;Yongchuan Hospital of Traditional Chinese Medicine of Chongqing Medical University, Chongqing, China.&#xD;West China Hospital of Sichuan University, Chengdu, China.&#xD;Shanxi Provincial People&apos;s Hospital, Taiyuan, China.&#xD;NPO Japan-China Health Association, Sagamihara, Japan.&#xD;Beijing University of Chinese Medicine, Beijing, China.&#xD;Beijing Hospital of Traditional Chinese Medicine of Capital Medical University, Beijing, China.&#xD;Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.&#xD;Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China.&#xD;The People&apos;s Hospital of Dujiangyan, Chengdu, China.&#xD;Leshan Traditional Chinese Medicine Hospital, Leshan, China.&#xD;First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.&#xD;UMMC-Health Medical Center, Yekaterinburg, Russia.&#xD;Ural State Medical University, Yekaterinburg, Russia.&#xD;Reproductive &amp; Women-Children Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, China.&#xD;World Health Organization Collaborating Centre (WHOCC), CHN-56, Sichuan Family Planning Research Institute, Chengdu, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">International Evidence-Based Guidelines for Traditional Chinese Medicine Management of Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Traditional Chinese Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">evidence-based</style></keyword><keyword><style face="normal" font="default" size="100%">guideline</style></keyword><keyword><style face="normal" font="default" size="100%">international practice</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40944470</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic rhinitis (AR) is a prevalent chronic condition that significantly impacts patients&apos; quality of life and poses challenges to effective management. Traditional Chinese medicine (TCM) offers a holistic approach, emphasizing syndrome differentiation, individualized care, and natural treatment strategies. OBJECTIVE: To develop comprehensive evidence-based guidelines for AR management using TCM interventions, incorporating rigorous evidence assessment and expert consensus. METHODS: The guidelines were developed using the GRADE-TCM framework, analyzing 351 randomized controlled trials (RCTs) involving 43,276 participants. Supplementary evidence from published textbooks, standardized documents, ancient literature, and TCM medical records was incorporated. Five rounds of expert consensus, involving 80 expert person-times and over 10,000 valid responses, refined the recommendations. RESULTS: The guidelines provide 32 recommendations covering four primary TCM syndromes (Deficiency-cold of Lung Qi, Spleen Qi Deficiency and Weakness, Kidney-yang Deficiency, and Latent Heat in Lung Meridian) which are mainly involved in AR. These recommendations include both internal interventions (such as herbal and patent medicines) and external therapies (such as acupuncture, moxibustion, and other acupoint-based treatment). Of these interventions, 10 received strong recommendations, while 22 were classified as weak recommendations. TCM treatments demonstrated significant efficacy in alleviating AR symptoms, reducing recurrence, and improving quality of life. Additionally, TCM can complement conventional AR treatments by reducing the need for pharmacological therapy while maintaining a favorable safety profile. CONCLUSION: The guidelines integrate classical TCM principles with modern evidence-based methodologies, offering a structured framework for AR management. They serve as clinical references for practitioners worldwide, supporting a promising approach to AR treatment. Future updates will incorporate emerging evidence and real-world clinical data to further optimize the role of TCM in AR management.</style></abstract><notes><style face="normal" font="default" size="100%">Fu, Qin-Wei&#xD;Liu, Peng&#xD;Ruan, Yan&#xD;Li, Xin-Rong&#xD;Zhang, Lan-Zhi&#xD;Yang, Sha-Sha&#xD;Chai, Feng&#xD;Chen, Ji&#xD;Chen, Qiao-Yan&#xD;Chen, Shu-Cheng&#xD;Chen, Wen-Yong&#xD;Chen, Yong-Na&#xD;Cheng, Hong-Bin&#xD;Cheng, Lei&#xD;Cui, Lu-Jia&#xD;Deng, Ke-Bin&#xD;Fang, Cai-Shan&#xD;Feng, Rong-Chang&#xD;Fu, Li&#xD;Fu, Wen-Yang&#xD;Gao, Jian-Ying&#xD;Guo, Hong&#xD;He, Miao&#xD;Hu, Ko-Hsin&#xD;Huang, Chun-Jiang&#xD;Huang, He-Yin&#xD;Jiang, Lu-Yun&#xD;Qiao, Feng-Ying&#xD;Leng, Hui&#xD;Li, Yun-Ying&#xD;Liu, Chun-Song&#xD;Liu, Da-Xin&#xD;Liu, Jian-Hua&#xD;Liu, Jin-Hui&#xD;Liu, Jing&#xD;Liu, Min&#xD;Liu, Wei-Ting&#xD;Liu, Yuan-Xian&#xD;Liu, Yang&#xD;Liu, Ying&#xD;Liu, Zhi-Qing&#xD;Luo, Qiu-Lan&#xD;Ma, Yu&#xD;Mao, De-Hong&#xD;Meng, Juan&#xD;Pang, Kai-Yun&#xD;Peng, Shun-Lin&#xD;Tong, Xuan-Fu&#xD;Wang, Ji&#xD;Wang, Jia-Xi&#xD;Wang, Jun-Ge&#xD;Wang, Ren-Zhong&#xD;Wang, Shi-Zhen&#xD;Xia, Ji-Yan&#xD;Xie, Hui&#xD;Xie, Qiang&#xD;Xie, Yan&#xD;Xiong, Da-Jing&#xD;Yan, Zhan-Feng&#xD;Yang, Hui&#xD;Zhang, Da-Zheng&#xD;Zhang, Fu-Bing&#xD;Zhang, Shi-Peng&#xD;Zhang, Zhi-Cheng&#xD;Zhao, Ji-Ping&#xD;Zhao, Yu&#xD;Zheng, Yun&#xD;Zhong, Dan-Zhu&#xD;Zhou, Li&#xD;Knyazev, Valentin Mikhailovich&#xD;Kostrova, Irina Viktorovna&#xD;Yeung, Wing-Fai&#xD;Wang, Qi&#xD;Wang, De-Yun&#xD;Zhang, Qin-Xiu&#xD;eng&#xD;World Federation of Chinese Medicine Societies (WFCMS) International Standard Development Project (SCM NP 2020-0097)/&#xD;National Natural Science Foundation of China (No. 82474587)/&#xD;Edith Cowan University and Industry Collaboration Program (No. G1004906)/&#xD;Xinglin Scholars Scientific Research Promotion Plan of Chengdu University of Traditional Chinese Medicine (No. XKTD2021003)/&#xD;Sichuan Natural Science Foundation Project (23NSFSC0668)/&#xD;Denmark&#xD;Allergy. 2025 Sep 13. doi: 10.1111/all.70057.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40944470</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70057</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3271</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3271</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Abdul Hameed Ansari, Z.</style></author><author><style face="normal" font="default" size="100%">Abdul Latiff, A. H.</style></author><author><style face="normal" font="default" size="100%">Abuzakouk, M. M.</style></author><author><style face="normal" font="default" size="100%">Agcaoili-De Jesus, M. S.</style></author><author><style face="normal" font="default" size="100%">Agondi, R. C.</style></author><author><style face="normal" font="default" size="100%">Al-Ahmad, M.</style></author><author><style face="normal" font="default" size="100%">Alangari, A. A.</style></author><author><style face="normal" font="default" size="100%">Alhameli, H.</style></author><author><style face="normal" font="default" size="100%">Alonso Bello, C. D.</style></author><author><style face="normal" font="default" size="100%">Alshareef, S.</style></author><author><style face="normal" font="default" size="100%">Al-Tamemi, S.</style></author><author><style face="normal" font="default" size="100%">Altrichter, S.</style></author><author><style face="normal" font="default" size="100%">Al Wahshi, H.</style></author><author><style face="normal" font="default" size="100%">Aquilina, S.</style></author><author><style face="normal" font="default" size="100%">Araújo, M.</style></author><author><style face="normal" font="default" size="100%">Arnaout, R.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B.</style></author><author><style face="normal" font="default" size="100%">Bangert, C.</style></author><author><style face="normal" font="default" size="100%">Bauer, A.</style></author><author><style face="normal" font="default" size="100%">Ben-Shoshan, M.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Bizjak, M.</style></author><author><style face="normal" font="default" size="100%">Boccon-Gibod, I.</style></author><author><style face="normal" font="default" size="100%">Bonnekoh, H.</style></author><author><style face="normal" font="default" size="100%">Bouillet, L.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Brzoza, Z.</style></author><author><style face="normal" font="default" size="100%">Bulatović Ćalasan, M.</style></author><author><style face="normal" font="default" size="100%">Bulkhi, A.</style></author><author><style face="normal" font="default" size="100%">Buttgereit, T.</style></author><author><style face="normal" font="default" size="100%">Bygum, A.</style></author><author><style face="normal" font="default" size="100%">Caballero, T.</style></author><author><style face="normal" font="default" size="100%">Calderon, O.</style></author><author><style face="normal" font="default" size="100%">Campos, R.</style></author><author><style face="normal" font="default" size="100%">Cancian, M.</style></author><author><style face="normal" font="default" size="100%">Carne, E.</style></author><author><style face="normal" font="default" size="100%">Castor, M. A.</style></author><author><style face="normal" font="default" size="100%">Cerecedo, I.</style></author><author><style face="normal" font="default" size="100%">Çetinarslan, T.</style></author><author><style face="normal" font="default" size="100%">Cherrez-Ojeda, I.</style></author><author><style face="normal" font="default" size="100%">Chkhikvadze, N.</style></author><author><style face="normal" font="default" size="100%">Chong-Neto, H. J.</style></author><author><style face="normal" font="default" size="100%">Choo, K.</style></author><author><style face="normal" font="default" size="100%">Christoff, G.</style></author><author><style face="normal" font="default" size="100%">Chu, C.-Y.</style></author><author><style face="normal" font="default" size="100%">Ciupka, K.</style></author><author><style face="normal" font="default" size="100%">Conlon, N.</style></author><author><style face="normal" font="default" size="100%">Costa, C.</style></author><author><style face="normal" font="default" size="100%">Craig, T.</style></author><author><style face="normal" font="default" size="100%">Criado, P.</style></author><author><style face="normal" font="default" size="100%">Danilycheva, I.</style></author><author><style face="normal" font="default" size="100%">Darlenski, R.</style></author><author><style face="normal" font="default" size="100%">De Arruda Chaves, E.</style></author><author><style face="normal" font="default" size="100%">de Montjoye, L.</style></author><author><style face="normal" font="default" size="100%">Doutre, M. S.</style></author><author><style face="normal" font="default" size="100%">Du-Thanh, A.</style></author><author><style face="normal" font="default" size="100%">Ebo, D.</style></author><author><style face="normal" font="default" size="100%">Elkhalifa, S.</style></author><author><style face="normal" font="default" size="100%">Elmariah, S.</style></author><author><style face="normal" font="default" size="100%">El-Shanawany, T.</style></author><author><style face="normal" font="default" size="100%">Ensina, L. F.</style></author><author><style face="normal" font="default" size="100%">Ertaş, R.</style></author><author><style face="normal" font="default" size="100%">Fachini Jardim Criado, R.</style></author><author><style face="normal" font="default" size="100%">Ferrer, M.</style></author><author><style face="normal" font="default" size="100%">Ferrucci, S.</style></author><author><style face="normal" font="default" size="100%">Fok, J. S.</style></author><author><style face="normal" font="default" size="100%">Fomina, D.</style></author><author><style face="normal" font="default" size="100%">Fonacier, L.</style></author><author><style face="normal" font="default" size="100%">Fouda, G.</style></author><author><style face="normal" font="default" size="100%">Francescantonio, I.</style></author><author><style face="normal" font="default" size="100%">Fukunaga, A.</style></author><author><style face="normal" font="default" size="100%">Galvan Calle, C. A.</style></author><author><style face="normal" font="default" size="100%">Garcia, E.</style></author><author><style face="normal" font="default" size="100%">Gáspár, K.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author><author><style face="normal" font="default" size="100%">Geng, S.</style></author><author><style face="normal" font="default" size="100%">Godse, K.</style></author><author><style face="normal" font="default" size="100%">Gonçalo, M.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Grattan, C.</style></author><author><style face="normal" font="default" size="100%">Grosber, M.</style></author><author><style face="normal" font="default" size="100%">Guidos Fogelbach, G.</style></author><author><style face="normal" font="default" size="100%">Guilarte, M.</style></author><author><style face="normal" font="default" size="100%">Guillod, R.</style></author><author><style face="normal" font="default" size="100%">Hamelmann, E.</style></author><author><style face="normal" font="default" size="100%">Hawkes, J.</style></author><author><style face="normal" font="default" size="100%">Hayama, K.</style></author><author><style face="normal" font="default" size="100%">Heuer, R.</style></author><author><style face="normal" font="default" size="100%">Hide, M.</style></author><author><style face="normal" font="default" size="100%">Hoetzenecker, W.</style></author><author><style face="normal" font="default" size="100%">Inomata, N.</style></author><author><style face="normal" font="default" size="100%">Kang, H.-R.</style></author><author><style face="normal" font="default" size="100%">Kaplan, A.</style></author><author><style face="normal" font="default" size="100%">Kapp, A.</style></author><author><style face="normal" font="default" size="100%">Karam, M.</style></author><author><style face="normal" font="default" size="100%">Kasperska-Zajac, A.</style></author><author><style face="normal" font="default" size="100%">Katelaris, C. H.</style></author><author><style face="normal" font="default" size="100%">Kessel, A.</style></author><author><style face="normal" font="default" size="100%">Khoshkhui, M.</style></author><author><style face="normal" font="default" size="100%">Kim, B.</style></author><author><style face="normal" font="default" size="100%">Kinaciyan, T.</style></author><author><style face="normal" font="default" size="100%">Kocatürk, E.</style></author><author><style face="normal" font="default" size="100%">Kolacinska-Flont, M.</style></author><author><style face="normal" font="default" size="100%">Kolkhir, P.</style></author><author><style face="normal" font="default" size="100%">Konstantinou, G. N.</style></author><author><style face="normal" font="default" size="100%">Kosnik, M.</style></author><author><style face="normal" font="default" size="100%">Krasowska, D.</style></author><author><style face="normal" font="default" size="100%">Kulthanan, K.</style></author><author><style face="normal" font="default" size="100%">Kumaran, M. S.</style></author><author><style face="normal" font="default" size="100%">Kuprys-Lipinska, I.</style></author><author><style face="normal" font="default" size="100%">Labrador, M.</style></author><author><style face="normal" font="default" size="100%">Larco, J. I.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D.</style></author><author><style face="normal" font="default" size="100%">Latysheva, E.</style></author><author><style face="normal" font="default" size="100%">Lazaridou, E.</style></author><author><style face="normal" font="default" size="100%">Li, P. H.</style></author><author><style face="normal" font="default" size="100%">Lima, H.</style></author><author><style face="normal" font="default" size="100%">Lippert, U.</style></author><author><style face="normal" font="default" size="100%">Magerl, M.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Alves Marcelino, J.</style></author><author><style face="normal" font="default" size="100%">Marzano, A. V.</style></author><author><style face="normal" font="default" size="100%">Medina, I.</style></author><author><style face="normal" font="default" size="100%">Meshkova, R.</style></author><author><style face="normal" font="default" size="100%">Micallef, D.</style></author><author><style face="normal" font="default" size="100%">Mohammed Ali, R.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Munoz, M.</style></author><author><style face="normal" font="default" size="100%">Oude Elberink, H. N. G.</style></author><author><style face="normal" font="default" size="100%">Nakonechna, A.</style></author><author><style face="normal" font="default" size="100%">Nasr, I.</style></author><author><style face="normal" font="default" size="100%">Nast, A.</style></author><author><style face="normal" font="default" size="100%">Netchiporouk, E.</style></author><author><style face="normal" font="default" size="100%">Nettis, E.</style></author><author><style face="normal" font="default" size="100%">Nieto, S.</style></author><author><style face="normal" font="default" size="100%">Ogueta Canales, I.</style></author><author><style face="normal" font="default" size="100%">Okas, T.-L.</style></author><author><style face="normal" font="default" size="100%">Orfali, R. L.</style></author><author><style face="normal" font="default" size="100%">Özkaya, E.</style></author><author><style face="normal" font="default" size="100%">Parisi, C.</style></author><author><style face="normal" font="default" size="100%">Pennitz, A.</style></author><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Pereira, M. P.</style></author><author><style face="normal" font="default" size="100%">Peter, J.</style></author><author><style face="normal" font="default" size="100%">Petkova, E.</style></author><author><style face="normal" font="default" size="100%">Pigatto, P. D.</style></author><author><style face="normal" font="default" size="100%">Podder, I.</style></author><author><style face="normal" font="default" size="100%">Popov, T.</style></author><author><style face="normal" font="default" size="100%">Porebski, G.</style></author><author><style face="normal" font="default" size="100%">Pyatilova, P.</style></author><author><style face="normal" font="default" size="100%">Ramon, G. D.</style></author><author><style face="normal" font="default" size="100%">Ratti Sisa, H. A.</style></author><author><style face="normal" font="default" size="100%">Recto, M.</style></author><author><style face="normal" font="default" size="100%">Ress, K.</style></author><author><style face="normal" font="default" size="100%">Ridge, K.</style></author><author><style face="normal" font="default" size="100%">Riedl, M.</style></author><author><style face="normal" font="default" size="100%">Ritchie, C.</style></author><author><style face="normal" font="default" size="100%">Rosario Filho, N.</style></author><author><style face="normal" font="default" size="100%">Rosmaninho, I.</style></author><author><style face="normal" font="default" size="100%">Rudenko, M.</style></author><author><style face="normal" font="default" size="100%">Rukhadze, M.</style></author><author><style face="normal" font="default" size="100%">Rutkowski, K.</style></author><author><style face="normal" font="default" size="100%">Sabato, V.</style></author><author><style face="normal" font="default" size="100%">Sahiner, U. M.</style></author><author><style face="normal" font="default" size="100%">Saini, S.</style></author><author><style face="normal" font="default" size="100%">Saleh Al Sabbagh, F.</style></author><author><style face="normal" font="default" size="100%">Salman, A.</style></author><author><style face="normal" font="default" size="100%">Salvo, F.</style></author><author><style face="normal" font="default" size="100%">Sanchez, J.</style></author><author><style face="normal" font="default" size="100%">Santucci, A.</style></author><author><style face="normal" font="default" size="100%">Schliemann, S.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Sekerel, B. E.</style></author><author><style face="normal" font="default" size="100%">Serpa, F.</style></author><author><style face="normal" font="default" size="100%">Sheikh, F.</style></author><author><style face="normal" font="default" size="100%">Sheikh, J.</style></author><author><style face="normal" font="default" size="100%">Shendi, H.</style></author><author><style face="normal" font="default" size="100%">Siebenhaar, F.</style></author><author><style face="normal" font="default" size="100%">Sonomjamts, M.</style></author><author><style face="normal" font="default" size="100%">Soria, A.</style></author><author><style face="normal" font="default" size="100%">Sousa Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Staevska, M.</style></author><author><style face="normal" font="default" size="100%">Staubach, P.</style></author><author><style face="normal" font="default" size="100%">Stephan, M.</style></author><author><style face="normal" font="default" size="100%">Stevanovic, K.</style></author><author><style face="normal" font="default" size="100%">Stingeni, L.</style></author><author><style face="normal" font="default" size="100%">Stobiecki, M.</style></author><author><style face="normal" font="default" size="100%">Su Küçük, Ö.</style></author><author><style face="normal" font="default" size="100%">Sussman, G.</style></author><author><style face="normal" font="default" size="100%">Szegedi, A.</style></author><author><style face="normal" font="default" size="100%">Takahagi, S.</style></author><author><style face="normal" font="default" size="100%">Tanaka, A.</style></author><author><style face="normal" font="default" size="100%">Teovska Mitrevska, N.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author><author><style face="normal" font="default" size="100%">Toubi, E.</style></author><author><style face="normal" font="default" size="100%">Tsatsou, F.</style></author><author><style face="normal" font="default" size="100%">Turk, M.</style></author><author><style face="normal" font="default" size="100%">Vadasz, Z.</style></author><author><style face="normal" font="default" size="100%">Valerieva, A.</style></author><author><style face="normal" font="default" size="100%">Valle, S.</style></author><author><style face="normal" font="default" size="100%">Doorn, M. v.</style></author><author><style face="normal" font="default" size="100%">Veleiro Perez, B.</style></author><author><style face="normal" font="default" size="100%">Vera Ayala, C. E.</style></author><author><style face="normal" font="default" size="100%">Vestergaard, C.</style></author><author><style face="normal" font="default" size="100%">Vieira, R. J.</style></author><author><style face="normal" font="default" size="100%">Maruta, C. W.</style></author><author><style face="normal" font="default" size="100%">Wedi, B.</style></author><author><style face="normal" font="default" size="100%">Werner, R. N.</style></author><author><style face="normal" font="default" size="100%">Yap, E. W. Y.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Xiang, Y.</style></author><author><style face="normal" font="default" size="100%">Ye, Y.-M.</style></author><author><style face="normal" font="default" size="100%">Yong, P.</style></author><author><style face="normal" font="default" size="100%">Yosipovitch, G.</style></author><author><style face="normal" font="default" size="100%">Zalewska-Janowska, A. Z. J.</style></author><author><style face="normal" font="default" size="100%">Zeyen, C.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z.</style></author><author><style face="normal" font="default" size="100%">Metz, M.</style></author><author><style face="normal" font="default" size="100%">Giménez-Arnau, A. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), with the participation of 210 delegates from 107 national and international societies, from 59 countries. The consensus conference was held on December 6th, 2024. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease, defined by a rapid appearance of wheals, angioedema, or both. The lifetime prevalence of acute urticaria is estimated to be approximately 20%. Chronic urticaria, categorized as either chronic spontaneous urticaria or chronic inducible urticaria, is disabling, impairs quality of life, and affects performance at work and school, however, novel therapies are available. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70210</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70210</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3285</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3285</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Farkas, Henriette</style></author><author><style face="normal" font="default" size="100%">Martinez-Saguer, Inmaculada</style></author><author><style face="normal" font="default" size="100%">Bork, Konrad</style></author><author><style face="normal" font="default" size="100%">Germenis, Anastasios E.</style></author><author><style face="normal" font="default" size="100%">Grumach, Anete S.</style></author><author><style face="normal" font="default" size="100%">Horváth, Hanga Réka</style></author><author><style face="normal" font="default" size="100%">Luczay, Andrea</style></author><author><style face="normal" font="default" size="100%">Zanichelli, Andrea</style></author><author><style face="normal" font="default" size="100%">Magerl, Markus</style></author><author><style face="normal" font="default" size="100%">Betschel, Stephen</style></author><author><style face="normal" font="default" size="100%">Aygören-Pürsün, Emel</style></author><author><style face="normal" font="default" size="100%">Bernstein, Jonathan A.</style></author><author><style face="normal" font="default" size="100%">Boccon-Gibod, Isabelle</style></author><author><style face="normal" font="default" size="100%">Caballero, Teresa</style></author><author><style face="normal" font="default" size="100%">Cancian, Mauro</style></author><author><style face="normal" font="default" size="100%">Christiansen, Sandra</style></author><author><style face="normal" font="default" size="100%">Cohn, Danny M.</style></author><author><style face="normal" font="default" size="100%">Contreras, Francisco</style></author><author><style face="normal" font="default" size="100%">Craig, Sansanee</style></author><author><style face="normal" font="default" size="100%">Isaic, Camelia</style></author><author><style face="normal" font="default" size="100%">Jindal, Ankur</style></author><author><style face="normal" font="default" size="100%">Katelaris, Constance H.</style></author><author><style face="normal" font="default" size="100%">Longhurst, Hilary J.</style></author><author><style face="normal" font="default" size="100%">MacGinnitie, Andrew</style></author><author><style face="normal" font="default" size="100%">Peter, Jonny</style></author><author><style face="normal" font="default" size="100%">Porebski, Grzegorz</style></author><author><style face="normal" font="default" size="100%">Reshef, Avner</style></author><author><style face="normal" font="default" size="100%">Van Nguyen, Dinh</style></author><author><style face="normal" font="default" size="100%">Zuraw, Bruce</style></author><author><style face="normal" font="default" size="100%">Castaldo, Anthony J.</style></author><author><style face="normal" font="default" size="100%">Boysen, Henrik Balle</style></author><author><style face="normal" font="default" size="100%">Craig, Timothy</style></author><author><style face="normal" font="default" size="100%">the Hereditary Angioedema Working Group</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Hereditary angioedema (HAE) with C1 inhibitor deficiency is a rare disease characterized by unpredictable episodes of tissue swelling (angioedema), which, in most cases, occur first under the age of 18 years, and entail a significant burden of disease not only for the patients but also for their families. Clinical symptoms of HAE are not specific, which may cause difficulties in differential diagnosis. Additionally, if not appropriately treated, HAE attacks can be life-threatening. The international HAE guidelines published so far have focused mainly on adults. A guideline that refers to the age-specific characteristics of pediatric patients, both in terms of diagnosis and management, was therefore needed. The International Steering Committee and Taskforce developed recommendations and provided evidence-based grading based on expert opinion and strength of evidence. Recommendations were presented to, discussed, and electronically voted by healthcare professionals during the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary, 2025. This international guideline will ensure early diagnosis, standardized and up-to-date treatment, and promote the availability of effective therapies for all pediatric patients affected with this rare disease. It also draws attention to the importance of establishing HAE centers and registries, which solicit specialist care and research of the disease.</style></abstract><notes><style face="normal" font="default" size="100%">(HAWK Group)</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70207</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70207</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1633</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1633</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paramasivan, S.</style></author><author><style face="normal" font="default" size="100%">Bassiouni, A.</style></author><author><style face="normal" font="default" size="100%">Shiffer, A.</style></author><author><style face="normal" font="default" size="100%">Dillon, M. R.</style></author><author><style face="normal" font="default" size="100%">Cope, E. K.</style></author><author><style face="normal" font="default" size="100%">Cooksley, C.</style></author><author><style face="normal" font="default" size="100%">Ramezanpour, M.</style></author><author><style face="normal" font="default" size="100%">Moraitis, S.</style></author><author><style face="normal" font="default" size="100%">Ali, M. J.</style></author><author><style face="normal" font="default" size="100%">Bleier, B.</style></author><author><style face="normal" font="default" size="100%">Callejas, C.</style></author><author><style face="normal" font="default" size="100%">Cornet, M. E.</style></author><author><style face="normal" font="default" size="100%">Douglas, R. G.</style></author><author><style face="normal" font="default" size="100%">Dutra, D.</style></author><author><style face="normal" font="default" size="100%">Georgalas, C.</style></author><author><style face="normal" font="default" size="100%">Harvey, R. J.</style></author><author><style face="normal" font="default" size="100%">Hwang, P. H.</style></author><author><style face="normal" font="default" size="100%">Luong, A. U.</style></author><author><style face="normal" font="default" size="100%">Schlosser, R. J.</style></author><author><style face="normal" font="default" size="100%">Tantilipikorn, P.</style></author><author><style face="normal" font="default" size="100%">Tewfik, M. A.</style></author><author><style face="normal" font="default" size="100%">Vreugde, S.</style></author><author><style face="normal" font="default" size="100%">Wormald, P. J.</style></author><author><style face="normal" font="default" size="100%">Caporaso, J. G.</style></author><author><style face="normal" font="default" size="100%">Psaltis, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, University of Adelaide, Adelaide, SA, Australia.&#xD;Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.&#xD;Dacryology Service, LV Prasad Institute, Hyderabad, India.&#xD;Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.&#xD;Department of Otolaryngology, Pontificia Universidad Catolica de Chile, Santiago, Chile.&#xD;Department of Otorhinolaryngology, Amsterdam UMC, Amsterdam, The Netherlands.&#xD;Department of Surgery, University of Auckland, Auckland, New Zealand.&#xD;Department of Otorhinolaryngology, University of Sao Paulo, Sao Paulo, Brazil.&#xD;Department of Otolaryngology, Rhinology and Skull base, University of New South Wales, Sydney, NSW, Australia.&#xD;Faculty of Medicine and Health sciences, Macquarie University, Sydney, NSW, Australia.&#xD;Department of Otolaryngology -Head and Neck Surgery, Stanford University, Stanford, CA, USA.&#xD;Department of Otolaryngology -Head and Neck Surgery, University of Texas, Austin, TX, USA.&#xD;Department of Otolaryngology, Medical University of South Carolina, Charleston, SC, USA.&#xD;Department of Otorhinolaryngology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Otolaryngology - Head and Neck Surgery, McGill University, Montreal, QC, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The international sinonasal microbiome study: A multicentre, multinational characterization of sinonasal bacterial ecology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2037-2049</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/03/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacteria/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">*Paranasal Sinuses</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">16S rRNA gene</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">next-generation sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">sinus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32167574</style></accession-num><abstract><style face="normal" font="default" size="100%">The sinonasal microbiome remains poorly defined, with our current knowledge based on a few cohort studies whose findings are inconsistent. Furthermore, the variability of the sinus microbiome across geographical divides remains unexplored. We characterize the sinonasal microbiome and its geographical variations in both health and disease using 16S rRNA gene sequencing of 410 individuals from across the world. Although the sinus microbial ecology is highly variable between individuals, we identify a core microbiome comprised of Corynebacterium, Staphylococcus, Streptococcus, Haemophilus and Moraxella species in both healthy and chronic rhinosinusitis (CRS) cohorts. Corynebacterium (mean relative abundance = 44.02%) and Staphylococcus (mean relative abundance = 27.34%) appear particularly dominant in the majority of patients sampled. Amongst patients suffering from CRS with nasal polyps, a statistically significant reduction in relative abundance of Corynebacterium (40.29% vs 50.43%; P = .02) was identified. Despite some measured differences in microbiome composition and diversity between some of the participating centres in our cohort, these differences would not alter the general pattern of core organisms described. Nevertheless, atypical or unusual organisms reported in short-read amplicon sequencing studies and that are not part of the core microbiome should be interpreted with caution. The delineation of the sinonasal microbiome and standardized methodology described within our study will enable further characterization and translational application of the sinus microbiota.</style></abstract><notes><style face="normal" font="default" size="100%">Paramasivan, Sathish&#xD;Bassiouni, Ahmed&#xD;Shiffer, Arron&#xD;Dillon, Matthew R&#xD;Cope, Emily K&#xD;Cooksley, Clare&#xD;Ramezanpour, Mahnaz&#xD;Moraitis, Sophia&#xD;Ali, Mohammad Javed&#xD;Bleier, Benjamin&#xD;Callejas, Claudio&#xD;Cornet, Marjolein E&#xD;Douglas, Richard G&#xD;Dutra, Daniel&#xD;Georgalas, Christos&#xD;Harvey, Richard J&#xD;Hwang, Peter H&#xD;Luong, Amber U&#xD;Schlosser, Rodney J&#xD;Tantilipikorn, Pongsakorn&#xD;Tewfik, Marc A&#xD;Vreugde, Sarah&#xD;Wormald, Peter-John&#xD;Caporaso, J Gregory&#xD;Psaltis, Alkis J&#xD;eng&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2020 Aug;75(8):2037-2049. doi: 10.1111/all.14276. Epub 2020 Mar 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32167574</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14276</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>646</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">646</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Magerl, M.</style></author><author><style face="normal" font="default" size="100%">Betschel, S.</style></author><author><style face="normal" font="default" size="100%">Aberer, W.</style></author><author><style face="normal" font="default" size="100%">Ansotegui, I. J.</style></author><author><style face="normal" font="default" size="100%">Aygoren-Pursun, E.</style></author><author><style face="normal" font="default" size="100%">Banerji, A.</style></author><author><style face="normal" font="default" size="100%">Bara, N. A.</style></author><author><style face="normal" font="default" size="100%">Boccon-Gibod, I.</style></author><author><style face="normal" font="default" size="100%">Bork, K.</style></author><author><style face="normal" font="default" size="100%">Bouillet, L.</style></author><author><style face="normal" font="default" size="100%">Boysen, H. B.</style></author><author><style face="normal" font="default" size="100%">Brodszki, N.</style></author><author><style face="normal" font="default" size="100%">Busse, P. J.</style></author><author><style face="normal" font="default" size="100%">Bygum, A.</style></author><author><style face="normal" font="default" size="100%">Caballero, T.</style></author><author><style face="normal" font="default" size="100%">Cancian, M.</style></author><author><style face="normal" font="default" size="100%">Castaldo, A.</style></author><author><style face="normal" font="default" size="100%">Cohn, D. M.</style></author><author><style face="normal" font="default" size="100%">Csuka, D.</style></author><author><style face="normal" font="default" size="100%">Farkas, H.</style></author><author><style face="normal" font="default" size="100%">Gompels, M.</style></author><author><style face="normal" font="default" size="100%">Gower, R.</style></author><author><style face="normal" font="default" size="100%">Grumach, A. S.</style></author><author><style face="normal" font="default" size="100%">Guidos-Fogelbach, G.</style></author><author><style face="normal" font="default" size="100%">Hide, M.</style></author><author><style face="normal" font="default" size="100%">Kang, H. R.</style></author><author><style face="normal" font="default" size="100%">Kaplan, A. P.</style></author><author><style face="normal" font="default" size="100%">Katelaris, C.</style></author><author><style face="normal" font="default" size="100%">Kiani-Alikhan, S.</style></author><author><style face="normal" font="default" size="100%">Lei, W. T.</style></author><author><style face="normal" font="default" size="100%">Lockey, R.</style></author><author><style face="normal" font="default" size="100%">Longhurst, H.</style></author><author><style face="normal" font="default" size="100%">Lumry, W. R.</style></author><author><style face="normal" font="default" size="100%">MacGinnitie, A.</style></author><author><style face="normal" font="default" size="100%">Malbran, A.</style></author><author><style face="normal" font="default" size="100%">Martinez Saguer, I.</style></author><author><style face="normal" font="default" size="100%">Matta, J. J.</style></author><author><style face="normal" font="default" size="100%">Nast, A.</style></author><author><style face="normal" font="default" size="100%">Nguyen, D.</style></author><author><style face="normal" font="default" size="100%">Nieto-Martinez, S. A.</style></author><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Peter, J.</style></author><author><style face="normal" font="default" size="100%">Porebski, G.</style></author><author><style face="normal" font="default" size="100%">Prior, N.</style></author><author><style face="normal" font="default" size="100%">Reshef, A.</style></author><author><style face="normal" font="default" size="100%">Riedl, M.</style></author><author><style face="normal" font="default" size="100%">Ritchie, B.</style></author><author><style face="normal" font="default" size="100%">Rafique Sheikh, F.</style></author><author><style face="normal" font="default" size="100%">Smith, W. B.</style></author><author><style face="normal" font="default" size="100%">Spaeth, P. J.</style></author><author><style face="normal" font="default" size="100%">Stobiecki, M.</style></author><author><style face="normal" font="default" size="100%">Toubi, E.</style></author><author><style face="normal" font="default" size="100%">Varga, L. A.</style></author><author><style face="normal" font="default" size="100%">Weller, K.</style></author><author><style face="normal" font="default" size="100%">Zanichelli, A.</style></author><author><style face="normal" font="default" size="100%">Zhi, Y.</style></author><author><style face="normal" font="default" size="100%">Zuraw, B.</style></author><author><style face="normal" font="default" size="100%">Craig, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;University of Toronto, Toronto, ON, Canada.&#xD;Department of Dermatology, Medical University of Graz, Graz, Austria.&#xD;Department of Allergy &amp; Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.&#xD;Center for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany.&#xD;Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Romanian Hereditary Angioedema Expertise Centre, Mediquest Clinical Research Center, Sangeorgiu de Mures, Romania.&#xD;National Reference Center for Angioedema (CREAK), Angioedema Center of Reference and Excellence (ACARE), Grenoble Alpes University Hospital, Grenoble, France.&#xD;Department of Dermatology, University Medical Center, Johannes Gutenberg University, Mainz, Germany.&#xD;HAE International (HAEi), Skanderborg, Denmark.&#xD;Department of Pediatric Immunology, Childrens Hospital, Skane University Hospital, Lund, Sweden.&#xD;Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Clinical Institute, University of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.&#xD;Allergy Department, Hospital Universitario La Paz, IdiPaz, CIBERER U754, Madrid, Spain.&#xD;Department of Systems Medicine, University Hospital of Padua, Padua, Italy.&#xD;Department of Vascular Medicine, Amsterdam UMC/University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Budapest, Hungary.&#xD;Clinical Immunology, North Bristol NHS Trust, Bristol, UK.&#xD;Marycliff Clinical Research, Principle Research Solutions, Spokane, Washington, USA.&#xD;Clinical Immunology, Centro Universitario FMABC, Sao Paulo, Brazil.&#xD;Instituto Politecnico Nacional SEPI-ENMH, Mexico City, Mexico.&#xD;Department of Dermatology, Hiroshima Citizens Hospital, Hiroshima, Japan.&#xD;Department of Dermatology, Hiroshima University, Hiroshima, Japan.&#xD;Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.&#xD;Division of Pulmonary, Critical Care, Allergy and Immunology, Medical university of South Carolina, Charleston, South Carolina, USA.&#xD;Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney, NSW, Australia.&#xD;Department of Immunology, Barts Health NHS Trust, London, UK.&#xD;Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Mackay Memorial Hospital, Hsinchu, Taiwan.&#xD;Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.&#xD;Department of Immunology, Auckland District Health Board and Department of Medicine, University of Auckland, Auckland, New Zealand.&#xD;Internal Medicine, Allergy Division, University of Texas Health Science Center, Dallas, Texas, USA.&#xD;Division of Immunology, Department of Pediatrics, Boston Children&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Unidad de Alergia, Asma e Inmunologia Clinica, Buenos Aires, Argentina.&#xD;Pediatrics, Haemophilia Centre Rhine Main (HZRM), Moerfelden-Walldorf, Germany.&#xD;H. Especialidades C.M.N.SXXI, I.M.S.S., Mexico City, Mexico.&#xD;Department of Dermatology, Venereology and Allergology, Division of Evidence-Based Medicine Charite - Universitatsmedizin Berlin, corporate member of Free University of Berlin, Humboldt University of Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;Respiratory, Allergy and Clinical Immunology Unit, Internal Medicine Department, Vinmec Healthcare System, College of Health Sciences, VinUniversity, Hanoi, Vietnam.&#xD;Genetic Unit of Nutrition, National Institute of Pediatrics, Mexico City, Mexico.&#xD;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Division of Allergy and Clinical Immunology, University of Cape Town, Cape Town, South Africa.&#xD;Allergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa.&#xD;Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Krakow, Poland.&#xD;Allergy, Hospital Universitario Severo Ochoa, Madrid, Spain.&#xD;Angioderma Center, Barzilai University Medical Center, Ashkelon, Israel.&#xD;Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA.&#xD;Departments of Medicine and Medical Oncology, University of Alberta, Edmonton, AB, Canada.&#xD;Section of Adult Allergy &amp; Immunology, Department of Medicine, King Faisal Specialist Hospital &amp; Research Centre, Riyadh, Saudi Arabia.&#xD;Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, SA, Australia.&#xD;Institute of Pharmacology, University of Bern, Bern, Switzerland.&#xD;Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.&#xD;Department of Internal Medicine, ASST Fatebenefratelli Sacco, Ospedale Luigi Sacco-University of Milan, Milan, Italy.&#xD;Department of Allergy and Clinical Immunology, Bejing Union Medical College Hospital &amp; Chinese Academy of Medical Sciences, Bejing, China.&#xD;University of California, San Diego, San Diego, California, USA.&#xD;Departments of Medicine and Pediatrics, Penn State University, Hershey, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1961-1990</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/01/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/prevention &amp; control/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/genetics/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Consensus</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">C1 inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">Delphi</style></keyword><keyword><style face="normal" font="default" size="100%">disease control</style></keyword><keyword><style face="normal" font="default" size="100%">guideline</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35006617</style></accession-num><abstract><style face="normal" font="default" size="100%">Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast-feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.</style></abstract><notes><style face="normal" font="default" size="100%">Maurer, Marcus&#xD;Magerl, Markus&#xD;Betschel, Stephen&#xD;Aberer, Werner&#xD;Ansotegui, Ignacio J&#xD;Aygoren-Pursun, Emel&#xD;Banerji, Aleena&#xD;Bara, Noemi-Anna&#xD;Boccon-Gibod, Isabelle&#xD;Bork, Konrad&#xD;Bouillet, Laurence&#xD;Boysen, Henrik Balle&#xD;Brodszki, Nicholas&#xD;Busse, Paula J&#xD;Bygum, Anette&#xD;Caballero, Teresa&#xD;Cancian, Mauro&#xD;Castaldo, Anthony&#xD;Cohn, Danny M&#xD;Csuka, Dorottya&#xD;Farkas, Henriette&#xD;Gompels, Mark&#xD;Gower, Richard&#xD;Grumach, Anete S&#xD;Guidos-Fogelbach, Guillermo&#xD;Hide, Michihiro&#xD;Kang, Hye-Ryun&#xD;Kaplan, Allen Phillip&#xD;Katelaris, Constance&#xD;Kiani-Alikhan, Sorena&#xD;Lei, Wei-Te&#xD;Lockey, Richard&#xD;Longhurst, Hilary&#xD;Lumry, William R&#xD;MacGinnitie, Andrew&#xD;Malbran, Alejandro&#xD;Martinez Saguer, Inmaculada&#xD;Matta, Juan Jose&#xD;Nast, Alexander&#xD;Nguyen, Dinh&#xD;Nieto-Martinez, Sandra A&#xD;Pawankar, Ruby&#xD;Peter, Jonathan&#xD;Porebski, Grzegorz&#xD;Prior, Nieves&#xD;Reshef, Avner&#xD;Riedl, Marc&#xD;Ritchie, Bruce&#xD;Rafique Sheikh, Farrukh&#xD;Smith, William B&#xD;Spaeth, Peter J&#xD;Stobiecki, Marcin&#xD;Toubi, Elias&#xD;Varga, Lilian Agnes&#xD;Weller, Karsten&#xD;Zanichelli, Andrea&#xD;Zhi, Yuxiang&#xD;Zuraw, Bruce&#xD;Craig, Timothy&#xD;eng&#xD;Practice Guideline&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):1961-1990. doi: 10.1111/all.15214. Epub 2022 Feb 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35006617</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15214</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1189</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1189</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Riskumaki, M.</style></author><author><style face="normal" font="default" size="100%">Tessas, I.</style></author><author><style face="normal" font="default" size="100%">Ottman, N.</style></author><author><style face="normal" font="default" size="100%">Suomalainen, A.</style></author><author><style face="normal" font="default" size="100%">Werner, P.</style></author><author><style face="normal" font="default" size="100%">Karisola, P.</style></author><author><style face="normal" font="default" size="100%">Lauerma, A.</style></author><author><style face="normal" font="default" size="100%">Ruokolainen, L.</style></author><author><style face="normal" font="default" size="100%">Karkman, A.</style></author><author><style face="normal" font="default" size="100%">Wisgrill, L.</style></author><author><style face="normal" font="default" size="100%">Sinkko, H.</style></author><author><style face="normal" font="default" size="100%">Lehtimaki, J.</style></author><author><style face="normal" font="default" size="100%">Alenius, H.</style></author><author><style face="normal" font="default" size="100%">Fyhrquist, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.&#xD;Department of Biosciences, University of Helsinki, Helsinki, Finland.&#xD;Department of Microbiology, University of Helsinki, Helsinki, Finland.&#xD;Helsinki Institute of Sustainability Science (HELSUS), University of Helsinki, Helsinki, Finland.&#xD;Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.&#xD;Finnish Environment Institute SYKE, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Interplay between skin microbiota and immunity in atopic individuals</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1280-1284</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/01/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">16S rRNA gene sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific IgE</style></keyword><keyword><style face="normal" font="default" size="100%">amplicon sequence variant (ASV)</style></keyword><keyword><style face="normal" font="default" size="100%">host-microbe interactions</style></keyword><keyword><style face="normal" font="default" size="100%">skin microbiota</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33480030</style></accession-num><notes><style face="normal" font="default" size="100%">Riskumaki, Matilda&#xD;Tessas, Ioannis&#xD;Ottman, Noora&#xD;Suomalainen, Alina&#xD;Werner, Paulina&#xD;Karisola, Piia&#xD;Lauerma, Antti&#xD;Ruokolainen, Lasse&#xD;Karkman, Antti&#xD;Wisgrill, Lukas&#xD;Sinkko, Hanna&#xD;Lehtimaki, Jenni&#xD;Alenius, Harri&#xD;Fyhrquist, Nanna&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1280-1284. doi: 10.1111/all.14744. Epub 2021 Feb 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33480030</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14744</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2412</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2412</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lucke, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Hannover Medical School (MHH), Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Interplay of a well-known medication and newly discovered transporters driving bacteria-induced inflammation in psoriasis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2019-2021</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/02/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Psoriasis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Transport Proteins/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38349022</style></accession-num><abstract><style face="normal" font="default" size="100%">SLC46A2 is crucial for the transportation of DAP-muropeptides into the cytosol, leading to NOD1 activation. Subsequent neutrophil recruitment through the release of IL-1alpha proves to be critical for the progression of psoriatic inflammation. The commonly prescribed anti-inflammatory drug methotrexate inhibits Slc46a2-mediated DAP-muropeptide transport in the mouse model, suggesting a therapeutic mechanism for suppressing psoriatic inflammation. C. accolens; Corynebacterium accolens; DAP, diaminopimelic acid; IMQ, imiquimod; MTX, methotrexate; Nod, nucleotide-binding and oligomerization domain; ns, not stimulated; SLC46, solute carrier family 46.</style></abstract><notes><style face="normal" font="default" size="100%">Lucke, Greta&#xD;eng&#xD;Letter&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):2019-2021. doi: 10.1111/all.16056. Epub 2024 Feb 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38349022</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16056</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2836</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2836</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paolucci, M.</style></author><author><style face="normal" font="default" size="100%">Nilsson, F. A. M.</style></author><author><style face="normal" font="default" size="100%">Duda, A.</style></author><author><style face="normal" font="default" size="100%">Tusup, M.</style></author><author><style face="normal" font="default" size="100%">Diken, M.</style></author><author><style face="normal" font="default" size="100%">Kundig, T. M.</style></author><author><style face="normal" font="default" size="100%">Johansen, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, University of Zurich, Schlieren, Switzerland.&#xD;TRON gGmbH - Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Mainz, Germany.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intralymphatic Administration of Naked mRNA Induces Allergen-Specific IgG, Promotes Th1 Responses and Reduces Anaphylactic Potential</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">901-903</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2025/02/13</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39945222</style></accession-num><notes><style face="normal" font="default" size="100%">Paolucci, Marta&#xD;Nilsson, Frida A M&#xD;Duda, Agathe&#xD;Tusup, Marina&#xD;Diken, Mustafa&#xD;Kundig, Thomas M&#xD;Johansen, Pal&#xD;eng&#xD;Universitatsspital Zurich/&#xD;Universitat Zurich/&#xD;407940_206399/1/SNSF_/Swiss National Science Foundation/Switzerland&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):901-903. doi: 10.1111/all.16504. Epub 2025 Feb 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39945222</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16504</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>63</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">63</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alashkar Alhamwe, B.</style></author><author><style face="normal" font="default" size="100%">Gao, Z.</style></author><author><style face="normal" font="default" size="100%">Alhamdan, F.</style></author><author><style face="normal" font="default" size="100%">Harb, H.</style></author><author><style face="normal" font="default" size="100%">Pichene, M.</style></author><author><style face="normal" font="default" size="100%">Garnier, A.</style></author><author><style face="normal" font="default" size="100%">El Andari, J.</style></author><author><style face="normal" font="default" size="100%">Kaufmann, A.</style></author><author><style face="normal" font="default" size="100%">Graumann, P. L.</style></author><author><style face="normal" font="default" size="100%">Kesper, D.</style></author><author><style face="normal" font="default" size="100%">Daviaud, C.</style></author><author><style face="normal" font="default" size="100%">Garn, H.</style></author><author><style face="normal" font="default" size="100%">Tost, J.</style></author><author><style face="normal" font="default" size="100%">Potaczek, D. P.</style></author><author><style face="normal" font="default" size="100%">Blaser, M. J.</style></author><author><style face="normal" font="default" size="100%">Renz, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Laboratory Medicine, member of the German Center for Lung Research (DZL) and the Universities of Giessen and Marburg Lung Center (UGMLC), Philipps-University Marburg, Marburg, Germany.&#xD;Institute for Tumor Immunology, Clinic for Hematology, Oncology and Immunology, Center for Tumor Biology, and Immunology (ZTI), Philipps University Marburg, Marburg, Germany.&#xD;College of Pharmacy, International University for Science and Technology (IUST), Daraa, Syria.&#xD;Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, New Jersey, USA.&#xD;Department of Medicine, Pulmonary and Critical Care Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Translational Inflammation Research Division &amp; Core Facility for Single Cell Multiomics, member of the German Center for Lung Research (DZL) and the Universities of Giessen and Marburg Lung Center (UGMLC), Philipps-University Marburg, Marburg, Germany.&#xD;Institute for Medical Microbiology and Virology, Technical University Dresden, Dresden, Germany.&#xD;Department of Psychosomatic Medicine and Psychotherapy, Psychoneuroimmunology Laboratory, Justus-Liebig University Giessen, Giessen, Germany.&#xD;The Laboratory for Epigenetics and Environment, Centre National de Recherche en Genomique Humaine, CEA-Institut de Biologie Francois Jacob, Universite Paris-Saclay, Evry, France.&#xD;SYNMIKRO, LOEWE Center for Synthetic Microbiology and Department of Chemistry, Philipps-University Marburg, Marburg, Germany.&#xD;Institute for Immunology, Philipps-University Marburg, Marburg, Germany.&#xD;Bioscientia MVZ Labor Mittelhessen GmbH, Giessen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intranasal administration of Acinetobacter lwoffii in a murine model of asthma induces IL-6-mediated protection associated with cecal microbiota changes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1245-1257</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/12/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Ovalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Intranasal</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-6</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-10</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">adaptive immunity</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epigenomics</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">exists.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36458896</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Early-life exposure to certain environmental bacteria including Acinetobacter lwoffii (AL) has been implicated in protection from chronic inflammatory diseases including asthma later in life. However, the underlying mechanisms at the immune-microbe interface remain largely unknown. METHODS: The effects of repeated intranasal AL exposure on local and systemic innate immune responses were investigated in wild-type and Il6(-/-) , Il10(-/-) , and Il17(-/-) mice exposed to ovalbumin-induced allergic airway inflammation. Those investigations were expanded by microbiome analyses. To assess for AL-associated changes in gene expression, the picture arising from animal data was supplemented by in vitro experiments of macrophage and T-cell responses, yielding expression and epigenetic data. RESULTS: The asthma preventive effect of AL was confirmed in the lung. Repeated intranasal AL administration triggered a proinflammatory immune response particularly characterized by elevated levels of IL-6, and consequently, IL-6 induced IL-10 production in CD4(+) T-cells. Both IL-6 and IL-10, but not IL-17, were required for asthma protection. AL had a profound impact on the gene regulatory landscape of CD4(+) T-cells which could be largely recapitulated by recombinant IL-6. AL administration also induced marked changes in the gastrointestinal microbiome but not in the lung microbiome. By comparing the effects on the microbiota according to mouse genotype and AL-treatment status, we have identified microbial taxa that were associated with either disease protection or activity. CONCLUSION: These experiments provide a novel mechanism of Acinetobacter lwoffii-induced asthma protection operating through IL-6-mediated epigenetic activation of IL-10 production and with associated effects on the intestinal microbiome.</style></abstract><notes><style face="normal" font="default" size="100%">Alashkar Alhamwe, Bilal&#xD;Gao, Zhan&#xD;Alhamdan, Fahd&#xD;Harb, Hani&#xD;Pichene, Matthieu&#xD;Garnier, Abel&#xD;El Andari, Jihad&#xD;Kaufmann, Andreas&#xD;Graumann, Peter L&#xD;Kesper, Dorthe&#xD;Daviaud, Christian&#xD;Garn, Holger&#xD;Tost, Jorg&#xD;Potaczek, Daniel P&#xD;Blaser, Martin J&#xD;Renz, Harald&#xD;eng&#xD;U01 AI122285/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1245-1257. doi: 10.1111/all.15606. Epub 2022 Dec 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36458896</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10160012</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15606</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>429</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">429</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, M.</style></author><author><style face="normal" font="default" size="100%">Ryu, G.</style></author><author><style face="normal" font="default" size="100%">Kang, S. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, M. A.</style></author><author><style face="normal" font="default" size="100%">Yang, S. I.</style></author><author><style face="normal" font="default" size="100%">Lee, I. H.</style></author><author><style face="normal" font="default" size="100%">Choi, G. S.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author><author><style face="normal" font="default" size="100%">Lee, S. M.</style></author><author><style face="normal" font="default" size="100%">Kim, D. K.</style></author><author><style face="normal" font="default" size="100%">Choi, J. H.</style></author><author><style face="normal" font="default" size="100%">Yang, H. J.</style></author><author><style face="normal" font="default" size="100%">Kim, S. W.</style></author><author><style face="normal" font="default" size="100%">Work Group for Rhinitis, the Korean Academy of Asthma Allergy</style></author><author><style face="normal" font="default" size="100%">Clinical, Immunology</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, South Korea.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.&#xD;Division of Pulmonology and Allergy, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea.&#xD;Department of Pulmonology, Allergy and Critical Care Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea.&#xD;Department of Pediatrics, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, South Korea.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, South Korea.&#xD;Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea.&#xD;Department of Preventive Medicine, College of Medicine, Korea University, Seoul, South Korea.&#xD;Department of Pulmonology and Allergy, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, South Korea.&#xD;Department of Pediatrics, Pediatric Allergy and Respiratory Center, Soonchunhyang University College of Medicine, Seoul, South Korea.&#xD;Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Seoul St. Mary&apos;s Hospital, The Catholic University of Korea, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intranasal antihistamine and corticosteroid to treat allergic rhinitis: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3436-3440</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/06/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Histamine Antagonists/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine H1 Antagonists/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Intranasal</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35716356</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Minji&#xD;Ryu, Gwanghui&#xD;Kang, Sung-Yoon&#xD;Kim, Mi-Ae&#xD;Yang, Song-I&#xD;Lee, Il Hwan&#xD;Choi, Gil-Soon&#xD;Kim, Hyun-Jung&#xD;Lee, Sang Min&#xD;Kim, Dong-Kyu&#xD;Choi, Jeong Hee&#xD;Yang, Hyeon-Jong&#xD;Kim, Soo Whan&#xD;eng&#xD;Letter&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3436-3440. doi: 10.1111/all.15415. Epub 2022 Jul 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35716356</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15415</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2163</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2163</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">He, H.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Pagan, A. D.</style></author><author><style face="normal" font="default" size="100%">David, E.</style></author><author><style face="normal" font="default" size="100%">Cheng, J.</style></author><author><style face="normal" font="default" size="100%">Carroll, B.</style></author><author><style face="normal" font="default" size="100%">Renert-Yuval, Y.</style></author><author><style face="normal" font="default" size="100%">Bar, J.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y. D.</style></author><author><style face="normal" font="default" size="100%">Maari, C.</style></author><author><style face="normal" font="default" size="100%">Proulx, E. S.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author><author><style face="normal" font="default" size="100%">Bissonnette, R.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.&#xD;Department of Dermatology, University of Magna Graecia, Catanzaro, Italy.&#xD;Laboratory for Investigative Dermatology, The Rockefeller University, New York City, New York, USA.&#xD;Innovaderm Research Inc., Montreal, Quebec, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape-strips and biopsies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">80-92</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/08/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Epidermis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biopsies</style></keyword><keyword><style face="normal" font="default" size="100%">immune</style></keyword><keyword><style face="normal" font="default" size="100%">pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">tape-strips</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37577841</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Our knowledge of etiopathogenesis of atopic dermatitis (AD) is largely derived from skin biopsies, which are associated with pain, scarring and infection. In contrast, tape-stripping is a minimally invasive, nonscarring technique to collect skin samples. METHODS: To construct a global AD skin transcriptomic profile comparing tape-strips to whole-skin biopsies, we performed RNA-seq on tape-strips and biopsies taken from the lesional skin of 20 moderate-to-severe AD patients and the skin of 20 controls. Differentially expressed genes (DEGs) were defined by fold-change (FCH) &gt;/=2.0 and false discovery rate &lt;0.05. RESULTS: We detected 4104 (2513 Up; 1591 Down) and 1273 (546 Up; 727 Down) DEGs in AD versus controls, in tape-strips and biopsies, respectively. Although both techniques captured dysregulation of key immune genes, tape-strips showed higher FCHs for innate immunity (IL-1B, IL-8), dendritic cell (ITGAX/CD11C, FCER1A), Th2 (IL-13, CCL17, TNFRSF4/OX40), and Th17 (CCL20, CXCL1) products, while biopsies showed higher upregulation of Th22 associated genes (IL-22, S100As) and dermal cytokines (IFN-gamma, CCL26). Itch-related genes (IL-31, TRPV3) were preferentially captured by tape-strips. Epidermal barrier abnormalities were detected in both techniques, with terminal differentiation defects (FLG2, PSORS1C2) better represented by tape-strips and epidermal hyperplasia changes (KRT16, MKI67) better detected by biopsies. CONCLUSIONS: Tape-strips and biopsies capture overlapping but distinct features of the AD molecular signature, suggesting their respective utility for monitoring specific AD-related immune, itch, and barrier abnormalities in clinical trials and longitudinal studies.</style></abstract><notes><style face="normal" font="default" size="100%">Del Duca, Ester&#xD;He, Helen&#xD;Liu, Ying&#xD;Pagan, Angel D&#xD;David, Eden&#xD;Cheng, Julia&#xD;Carroll, Britta&#xD;Renert-Yuval, Yael&#xD;Bar, Jonathan&#xD;Estrada, Yeriel D&#xD;Maari, Catherine&#xD;Proulx, Etienne Saint-Cyr&#xD;Krueger, James G&#xD;Bissonnette, Robert&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;T32 AR082315/AR/NIAMS NIH HHS/&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):80-92. doi: 10.1111/all.15845. Epub 2023 Aug 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37577841</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15845</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1032</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1032</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kohno, C.</style></author><author><style face="normal" font="default" size="100%">Kaneko, K.</style></author><author><style face="normal" font="default" size="100%">Takahashi, K.</style></author><author><style face="normal" font="default" size="100%">Ohya, Y.</style></author><author><style face="normal" font="default" size="100%">Nakajima, H.</style></author><author><style face="normal" font="default" size="100%">Murashima, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.&#xD;Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.&#xD;Department of Biostatistics, M&amp;D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.&#xD;Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development Tokyo, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intrauterine exposure to immunosuppressants influences the development of postnatal allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2890-2893</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/04/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">hygiene hypothesis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33905116</style></accession-num><notes><style face="normal" font="default" size="100%">Kohno, Chie&#xD;Kaneko, Kayoko&#xD;Takahashi, Kunihiko&#xD;Ohya, Yukihiro&#xD;Nakajima, Hiroshi&#xD;Murashima, Atsuko&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2890-2893. doi: 10.1111/all.14878. Epub 2021 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33905116</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14878</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>61</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">61</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmidt, V.</style></author><author><style face="normal" font="default" size="100%">Lalevee, S.</style></author><author><style face="normal" font="default" size="100%">Traidl, S.</style></author><author><style face="normal" font="default" size="100%">Ameri, M.</style></author><author><style face="normal" font="default" size="100%">Ziadlou, R.</style></author><author><style face="normal" font="default" size="100%">Ingen-Housz-Oro, S.</style></author><author><style face="normal" font="default" size="100%">Barau, C.</style></author><author><style face="normal" font="default" size="100%">de Prost, N.</style></author><author><style face="normal" font="default" size="100%">Nageli, M.</style></author><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Meier-Schiesser, B.</style></author><author><style face="normal" font="default" size="100%">Navarini, A. A.</style></author><author><style face="normal" font="default" size="100%">French, L. E.</style></author><author><style face="normal" font="default" size="100%">Contassot, E.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Dermatology, University Hospital Basel, Basel, Switzerland.&#xD;Department of Dermatology, AP-HP, Henri Mondor Hospital, Paris, France.&#xD;Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.&#xD;Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Faculty of Medicine, University Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;ToxiTEN Group, ERN-Skin.&#xD;Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Paris, France.&#xD;Universite Paris Est, EpiDermE, Paris, France.&#xD;Platform of Biological Resources, Henri Mondor Hospital, Paris, France.&#xD;Intensive Care Unit, AP-HP, Henri Mondor Hospital, Paris, France.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.&#xD;Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intravenous immunoglobulins, cyclosporine, and best supportive care in epidermal necrolysis: Diverse effects on systemic inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1280-1291</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulins, Intravenous/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Stevens-Johnson Syndrome/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclosporine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Stevens-Johnson syndrome (SJS)</style></keyword><keyword><style face="normal" font="default" size="100%">adjuvant treatments</style></keyword><keyword><style face="normal" font="default" size="100%">epidermal necrolysis</style></keyword><keyword><style face="normal" font="default" size="100%">immune signatures</style></keyword><keyword><style face="normal" font="default" size="100%">toxic epidermal necrolysis (TEN)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36463488</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but potentially life-threatening cutaneous adverse reactions. There is still no consensus on adjuvant treatments, and little is known about their effects on systemic inflammation in SJS/TEN. Our aim was to characterize the systemic and cutaneous immune profiles of SJS/TEN patients and to investigate whether/how intravenous immunoglobulins (IVIG), cyclosporine A (CSA), and best supportive care only (BSCO) affected the systemic immune signature and clinical outcome (6 week-mortality, complications, hospitalization stay). METHODS: We included 16 patients with SJS/TEN, treated with high-dose IVIG (n = 8), CSA (n = 4) or BSCO (n = 4). Serial serum samples were obtained prior-, 5-7 days, and 21 days after treatment onset. Serum levels of inflammation-/immune response-associated proteins were measured by high-throughput proteomics assay (OLINK) and cytotoxic molecules by ELISA. RNA extracted from skin biopsies collected prior treatment was analyzed by Nanostring. RESULTS: Serum inflammatory profiles in SJS/TEN patients were notably characterized by massive upregulation of type 1 immune response and proinflammatory markers. Surprisingly, there was limited overlap between cutaneous and serum immune profiles. Serial serological measurements of immune response markers showed very diverse dynamics between the different treatment groups. IVIG-treated patients showed completely different dynamics and most significant proteomic changes in an early phase (Day 5-7). In all treatment groups, type 1-/inflammatory response markers were dampened at day 21. Clinically, there were no outcome differences. CONCLUSION: Our study demonstrates that BSCO, CSA, and IVIG have very diverse biological effects on the systemic inflammatory response in SJS/TEN, which may not correlate with clinical outcome differences.</style></abstract><notes><style face="normal" font="default" size="100%">Schmidt, Veronika&#xD;Lalevee, Sophie&#xD;Traidl, Stephan&#xD;Ameri, Milad&#xD;Ziadlou, Reihane&#xD;Ingen-Housz-Oro, Saskia&#xD;Barau, Caroline&#xD;de Prost, Nicolas&#xD;Nageli, Mirjam&#xD;Mitamura, Yasutaka&#xD;Meier-Schiesser, Barbara&#xD;Navarini, Alexander A&#xD;French, Lars E&#xD;Contassot, Emmanuel&#xD;Bruggen, Marie-Charlotte&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1280-1291. doi: 10.1111/all.15608. Epub 2022 Dec 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36463488</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15608</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3126</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3126</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Santoro, D.</style></author><author><style face="normal" font="default" size="100%">Archer, L.</style></author><author><style face="normal" font="default" size="100%">Scotti, G.</style></author><author><style face="normal" font="default" size="100%">Ahrens, K.</style></author><author><style face="normal" font="default" size="100%">Riva, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Small Animal Clinical Sciences, College of Veterinary Medicine at University of Florida, Gainesville, Florida, USA.&#xD;National Facility for Data Handling and Analysis, Fondazione Human Technopole, Milano, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intrinsic Alterations of the Inflammatory Pathways in Primary Canine Atopic Keratinocytes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">genetics</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">keratinocytes</style></keyword><keyword><style face="normal" font="default" size="100%">signal transduction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41104852</style></accession-num><notes><style face="normal" font="default" size="100%">Santoro, Domenico&#xD;Archer, Linda&#xD;Scotti, Giulia&#xD;Ahrens, Kim&#xD;Riva, Alberto&#xD;eng&#xD;American College of Veterinary Dermatology/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct 17. doi: 10.1111/all.70118.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41104852</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70118</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1946</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1946</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Szepfalusi, Z.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Ped. Pulmonology, Allergy and Endocrinology, Department of Pediatrics and Adolescent Medicine, Comprehensive Center Pediatrics, Medical University of Vienna, Vienna, Austria.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Introducing peanut early in life - Ready for the general population?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1142-1144</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/02/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Arachis/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36794973</style></accession-num><notes><style face="normal" font="default" size="100%">Szepfalusi, Zsolt&#xD;Eiwegger, Thomas&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1142-1144. doi: 10.1111/all.15676. Epub 2023 Mar 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36794973</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15676</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>32</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">32</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zimmer, J.</style></author><author><style face="normal" font="default" size="100%">Bonertz, A.</style></author><author><style face="normal" font="default" size="100%">Kaul, S.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Paul-Ehrlich-Institut, Langen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Introduction of General Chapters on standard methods for allergen quantification in the European Pharmacopoeia</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">923-927</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/12/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay/methods</style></keyword><keyword><style face="normal" font="default" size="100%">European pharmacopoeia</style></keyword><keyword><style face="normal" font="default" size="100%">Phl p 5</style></keyword><keyword><style face="normal" font="default" size="100%">allergen quantification</style></keyword><keyword><style face="normal" font="default" size="100%">bet v 1</style></keyword><keyword><style face="normal" font="default" size="100%">standardization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36579359</style></accession-num><abstract><style face="normal" font="default" size="100%">The Biological Standardization Project BSP090 has been successfully concluded in 2021. As a result, two standard methods for quantification of the major allergens Bet v 1 and Phl p 5 will be implemented in the European Pharmacopoeia (Ph. Eur.). The General Chapter describing the protocol of the respective Bet v 1-specific ELISA has already been adopted by the Ph. Eur. Commission and will become an official part of the Ph. Eur. in the beginning of 2023. As this will be the first allergen-specific standard method in the EU, this paper intends to summarize the preceding process and outline the measures necessary to comply with the new regulatory requirement.</style></abstract><notes><style face="normal" font="default" size="100%">Zimmer, Julia&#xD;Bonertz, Andreas&#xD;Kaul, Susanne&#xD;Vieths, Stefan&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):923-927. doi: 10.1111/all.15631. Epub 2023 Jan 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36579359</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15631</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>824</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">824</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cho, S. I.</style></author><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Yang, M. S.</style></author><author><style face="normal" font="default" size="100%">Cho, S. J.</style></author><author><style face="normal" font="default" size="100%">Lee, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.&#xD;Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea.&#xD;Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inverse association between Helicobacter pylori infection and atopic, skin, and autoimmune diseases: A nationwide population-based study in South Korea</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3824-3826</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/09/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Autoimmune Diseases/complications/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Helicobacter Infections/complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Helicobacter pylori</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Republic of Korea/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34486760</style></accession-num><notes><style face="normal" font="default" size="100%">Cho, Soo Ick&#xD;Lee, Hanjae&#xD;Yang, Min-Suk&#xD;Cho, Soo-Jeong&#xD;Lee, Dong Hun&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3824-3826. doi: 10.1111/all.15081. Epub 2021 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34486760</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15081</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2726</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2726</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Testera-Montes, A.</style></author><author><style face="normal" font="default" size="100%">Ariza, A.</style></author><author><style face="normal" font="default" size="100%">Sola-Martinez, R. A.</style></author><author><style face="normal" font="default" size="100%">Aranda, C. J.</style></author><author><style face="normal" font="default" size="100%">Bentabol-Ramos, G.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Torralvo, D.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Group. IBIMA-Plataforma BIONAND, RICORS Inflammatory Diseases, Malaga, Spain.&#xD;Department of Biochemistry, Molecular Biology and Immunology (B), University of Murcia, Murcia, Spain.&#xD;Pulmonology Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Department of Medicine and Dermatology, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Investigation of the diagnostic accuracy of basophil activation test for allergic phenotypes of rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">738-749</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophil Degranulation Test/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">dual allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">local allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">nasal allergen challenge</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39498743</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Basophil activation test (BAT) might be an alternative to nasal allergen challenge (NAC) to identify the allergic etiology in rhinitis patients. Here, we investigate the diagnostic performance of BAT for allergic phenotypes of rhinitis. METHODS: Rhinitis patients and healthy controls were subjected to NAC with Dermatophagoides pteronyssinus (DP), Alternaria alternata (AA), grass (GP) and olive (OP) pollens. Rhinitis subjects also underwent skin prick test (SPT) with relevant allergens. Patients were classified into allergic rhinitis (AR, positive NAC and SPT), local allergic rhinitis (LAR, positive NAC and negative SPT), dual allergic rhinitis (DAR, defined as AR for &gt;/=1 allergen and LAR for &gt;/=1 allergen), and non-allergic rhinitis (NAR, negative NAC and SPT) phenotypes. BAT with DP, AA, GP and OP was conducted in study individuals and compared with NAC results. RESULTS: A total of 47 AR, 31 DAR, 26 LAR, 12 NAR and 21 control subjects were recruited. The best positivity cut-offs of BAT for DP-, AA-, GP- and OP-driven allergy (all phenotypes) were a %CD63 cells of 8.650, 14.250, 26.200, and 12.780, respectively (AUC 0.851, 0.701, 0.887, and 0.921, respectively). Sensitivity, specificity, negative and positive predictive values of BAT (all phenotypes) ranged 43.5%(AA)-83.3%(OP), 88.9%(GP)-100%(AA), 87%(GP)-100%(AA), and 61.1%(DP)-80.0%(pollens), respectively. BAT identified 79%-100% of SPT-positive allergies (AR and DAR), and 25%-75% of SPT-negative allergies (LAR and DAR), while &lt;/=10% of NAR/HC subjects tested positive. BAT positivity correlated with rhinitis severity in LAR patients (p = 0.018), and associated with conjunctivitis (p = 0.015) in allergic subjects. CONCLUSION: BAT can replace NAC for AR confirmation, and limit the number of NAC required for LAR and DAR diagnosis. BAT can demonstrate sIgE in SPT-negative allergies.</style></abstract><notes><style face="normal" font="default" size="100%">Testera-Montes, Almudena&#xD;Ariza, Adriana&#xD;Sola-Martinez, Rosa Alba&#xD;Aranda, Carlos Jose&#xD;Bentabol-Ramos, Guillermo&#xD;Sanchez-Torralvo, Dulce&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;Eguiluz-Gracia, Ibon&#xD;Rondon, Carmen&#xD;eng&#xD;Ministerio de Universidades. Gobierno de Espana/&#xD;European Commission/&#xD;Consejeria de Salud y Familias, Junta de Andalucia/&#xD;Instituto de Salud Carlos III/&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):738-749. doi: 10.1111/all.16390. Epub 2024 Nov 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39498743</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891400</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16390</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3304</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3304</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ahmad, Fareed</style></author><author><style face="normal" font="default" size="100%">Mateo, Jericha Miles P.</style></author><author><style face="normal" font="default" size="100%">Joy, Febu Elizabeth</style></author><author><style face="normal" font="default" size="100%">Anamangadan, Gazala</style></author><author><style face="normal" font="default" size="100%">Manjooran, Seena</style></author><author><style face="normal" font="default" size="100%">Jochebeth, Anh</style></author><author><style face="normal" font="default" size="100%">Al-Marri, Fahad</style></author><author><style face="normal" font="default" size="100%">Al-Khawaga, Sara</style></author><author><style face="normal" font="default" size="100%">Al-Obaidli, Amina</style></author><author><style face="normal" font="default" size="100%">AlHammadi, Ayda</style></author><author><style face="normal" font="default" size="100%">Alam, Majid Ali</style></author><author><style face="normal" font="default" size="100%">Buddenkotte, Jörg</style></author><author><style face="normal" font="default" size="100%">Steinhoff, Martin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Involvement of B Cell Subsets in Patients With Steven Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70269</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70269</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2927</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2927</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Osonoi, K.</style></author><author><style face="normal" font="default" size="100%">Sawada, A.</style></author><author><style face="normal" font="default" size="100%">Maekawa, Y.</style></author><author><style face="normal" font="default" size="100%">Yamaguchi, M.</style></author><author><style face="normal" font="default" size="100%">Yamada, S.</style></author><author><style face="normal" font="default" size="100%">Matsuyama, K.</style></author><author><style face="normal" font="default" size="100%">Rochman, M.</style></author><author><style face="normal" font="default" size="100%">Rothenberg, M. E.</style></author><author><style face="normal" font="default" size="100%">Han, X.</style></author><author><style face="normal" font="default" size="100%">Matsuda, N.</style></author><author><style face="normal" font="default" size="100%">Suzuki, I.</style></author><author><style face="normal" font="default" size="100%">Tanaka, F.</style></author><author><style face="normal" font="default" size="100%">Fujiwara, Y.</style></author><author><style face="normal" font="default" size="100%">Shoda, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Department of Gastroenterology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.&#xD;Department of Computer Science, University of Cincinnati, Cincinnati, Ohio, USA.&#xD;Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Department of Electronics, Graduate School of Engineering, Tohoku Institute of Technology, Sendai, Miyagi, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Involvement of IL-13-Induced Dysregulation of BDNF-NTRK2 Pathway in Symptoms of Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2894-2897</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/05/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">EoE diagnostic panel</style></keyword><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">asymptomatic esophageal eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">brain-derived neurotrophic factor</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">iPSC-derived sensory neurons</style></keyword><keyword><style face="normal" font="default" size="100%">neuropathic and inflammatory pain panel</style></keyword><keyword><style face="normal" font="default" size="100%">neurotrophic receptor tyrosine kinase 2</style></keyword><keyword><style face="normal" font="default" size="100%">writer funded by Cincinnati Children&apos;s Hospital Medical Center. T.S. is a</style></keyword><keyword><style face="normal" font="default" size="100%">co-inventor of patents owned by Cincinnati Children&apos;s Hospital Medical Center.</style></keyword><keyword><style face="normal" font="default" size="100%">M.E.R. is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm,</style></keyword><keyword><style face="normal" font="default" size="100%">Allakos, Celldex, Uniquity Bio, Santa Ana Bio, EnZen Therapeutics, Bristol Myers</style></keyword><keyword><style face="normal" font="default" size="100%">Squibb, Astra Zeneca, Pfizer, Glaxo Smith Kline, Regeneron/Sanofi, and Guidepoint</style></keyword><keyword><style face="normal" font="default" size="100%">and has an equity interest in the first nine listed and royalties from reslizumab</style></keyword><keyword><style face="normal" font="default" size="100%">(Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust), and UpToDate. M.E.R. is an</style></keyword><keyword><style face="normal" font="default" size="100%">inventor of patents owned by Cincinnati Children&apos;s Hospital Medical Center. All</style></keyword><keyword><style face="normal" font="default" size="100%">other authors declare that they have no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40358555</style></accession-num><notes><style face="normal" font="default" size="100%">Osonoi, Kasumi&#xD;Sawada, Akinari&#xD;Maekawa, Yuki&#xD;Yamaguchi, Mari&#xD;Yamada, Shingo&#xD;Matsuyama, Kazuhiro&#xD;Rochman, Mark&#xD;Rothenberg, Marc E&#xD;Han, Xiaobo&#xD;Matsuda, Naoki&#xD;Suzuki, Ikuro&#xD;Tanaka, Fumio&#xD;Fujiwara, Yasuhiro&#xD;Shoda, Tetsuo&#xD;eng&#xD;R00 AI158660/AI/NIAID NIH HHS/&#xD;NH/NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2894-2897. doi: 10.1111/all.16592. Epub 2025 May 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40358555</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12311799</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16592</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>882</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">882</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gendrisch, F.</style></author><author><style face="normal" font="default" size="100%">Volkel, L.</style></author><author><style face="normal" font="default" size="100%">Fluck, M.</style></author><author><style face="normal" font="default" size="100%">Apostolova, P.</style></author><author><style face="normal" font="default" size="100%">Zeiser, R.</style></author><author><style face="normal" font="default" size="100%">Jakob, T.</style></author><author><style face="normal" font="default" size="100%">Martin, S. F.</style></author><author><style face="normal" font="default" size="100%">Esser, P. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Department of Dermatology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.&#xD;Faculty of Biology, University of Freiburg, Freiburg, Germany.&#xD;Department of Dermatology, Research Center skinitial, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.&#xD;Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.&#xD;Experimental Dermatology and Allergy Research Group, Department of Dermatology and Allergology, University Medical Center Giessen (UKGM, Justus Liebig University, Giessen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IRE1 and PERK signaling regulates inflammatory responses in a murine model of contact hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">966-978</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Irritants</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">NF-kappa B</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Serine-Threonine Kinases</style></keyword><keyword><style face="normal" font="default" size="100%">allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">contact hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">unfolded protein response</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34314538</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Contact sensitizers may interfere with correct protein folding. Generation of un-/misfolded proteins can activate the IRE-1 or PERK signaling pathways initiating the unfolded protein response (UPR) and thereby determine inflammatory immune responses. We have analyzed the effect of sensitizers with different potencies on the induction of UPR activation/inhibition and the subsequent generation of a pro-inflammatory micromilieu in vitro as well as the effect of UPR modulation on the inflammatory response in the murine contact hypersensitivity (CHS) in vivo. METHODS: Semi-quantitative and quantitative PCR, fluorescence microscopy, ELISA, NF-kappaB activation and translocation assays, DC/keratinocyte co-culture assay, FACS, and in vivo CHS experiments were performed. RESULTS: Sensitizers and irritants activate IRE-1 and PERK in murine and human keratinocytes. Synergistic effects occur after combination of different weak sensitizers / addition of irritants. Moreover, tolerogenic dinitrothiocyanobenzene can be converted into a strong sensitizer by pre-activation of the UPR. Blocking UPR signaling results in decreased NF-kappaB activation and cytokine production in keratinocytes and in activation marker downregulation in a HaCaT/THP-1 co-culture. Interestingly, not only systemic but also topical application of UPR inhibitors abrogates CHS responses in vivo. CONCLUSION: These observations highlight an important role of the UPR in determination of the inflammatory response in vitro and in vivo further underlining the importance of tissue stress and damage responses in the development of ACD and provide mechanistically based concepts as a basis for the development of new therapeutic approaches to treat allergic contact dermatitis.</style></abstract><notes><style face="normal" font="default" size="100%">Gendrisch, Fabian&#xD;Volkel, Lukas&#xD;Fluck, Melanie&#xD;Apostolova, Petya&#xD;Zeiser, Robert&#xD;Jakob, Thilo&#xD;Martin, Stefan F&#xD;Esser, Philipp R&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):966-978. doi: 10.1111/all.15024. Epub 2021 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34314538</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15024</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>860</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">860</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cloots, E.</style></author><author><style face="normal" font="default" size="100%">Debeuf, N.</style></author><author><style face="normal" font="default" size="100%">Deswarte, K.</style></author><author><style face="normal" font="default" size="100%">Fayazpour, F.</style></author><author><style face="normal" font="default" size="100%">Vanheerswynghels, M.</style></author><author><style face="normal" font="default" size="100%">De Wolf, C.</style></author><author><style face="normal" font="default" size="100%">Van De Velde, E.</style></author><author><style face="normal" font="default" size="100%">Hammad, H.</style></author><author><style face="normal" font="default" size="100%">Lambrecht, B. N.</style></author><author><style face="normal" font="default" size="100%">Eyckerman, S.</style></author><author><style face="normal" font="default" size="100%">Janssens, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.&#xD;Laboratory of ER stress and Inflammation, VIB Center for Inflammation Research, Ghent, Belgium.&#xD;VIB Center for Medical Biotechnology, Ghent, Belgium.&#xD;Laboratory of Immunoregulation and Mucosal Immunology, VIB Center for Inflammation Research, Ghent, Belgium.&#xD;Department of Pulmonary Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.&#xD;Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">IRE1beta does not affect mucus secretion during allergic asthma development in a house dust mite murine model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3546-3549</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/08/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mucus</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroglyphidae</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34386990</style></accession-num><notes><style face="normal" font="default" size="100%">Cloots, Eva&#xD;Debeuf, Nincy&#xD;Deswarte, Kim&#xD;Fayazpour, Farzaneh&#xD;Vanheerswynghels, Manon&#xD;De Wolf, Caroline&#xD;Van De Velde, Evelien&#xD;Hammad, Hamida&#xD;Lambrecht, Bart N&#xD;Eyckerman, Sven&#xD;Janssens, Sophie&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3546-3549. doi: 10.1111/all.15045. Epub 2021 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34386990</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15045</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1427</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1427</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carli, G.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Stebbing, J.</style></author><author><style face="normal" font="default" size="100%">Parronchi, P.</style></author><author><style face="normal" font="default" size="100%">Farsi, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">SOS Allergy and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Department of Surgery and Cancer, Imperial College London, London, UK.&#xD;Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Is asthma protective against COVID-19?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">866-868</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/06/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Asthma/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*immunology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon Type I/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32479648</style></accession-num><notes><style face="normal" font="default" size="100%">Carli, Giulia&#xD;Cecchi, Lorenzo&#xD;Stebbing, Justin&#xD;Parronchi, Paola&#xD;Farsi, Alessandro&#xD;eng&#xD;NIHR-RP-011-053/DH_/Department of Health/United Kingdom&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):866-868. doi: 10.1111/all.14426. Epub 2020 Jun 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32479648</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7300712 Stebbing&apos;s conflicts of interest can be found at https://www.nature.com/onc/editors and none are relevant here.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14426</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1988</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1988</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Biagioni, B.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Clot, B.</style></author><author><style face="normal" font="default" size="100%">Collaud Coen, M.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">Damialis, A.</style></author><author><style face="normal" font="default" size="100%">Dominguez-Ortega, J.</style></author><author><style face="normal" font="default" size="100%">Galan, C.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Holgate, S.</style></author><author><style face="normal" font="default" size="100%">Jeebhay, M.</style></author><author><style face="normal" font="default" size="100%">Kazadzis, S.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Tummon, F.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Alonso-Coello, P.</style></author><author><style face="normal" font="default" size="100%">Canelo-Aybar, C.</style></author><author><style face="normal" font="default" size="100%">Cantero-Fortiz, Y.</style></author><author><style face="normal" font="default" size="100%">Rigau, D.</style></author><author><style face="normal" font="default" size="100%">Salazar, J.</style></author><author><style face="normal" font="default" size="100%">Verdugo-Paiva, F.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergic and Respiratory Diseases, Institute Desbrest of Epidemiology and Public Health, University of Montpellier and INSERM, Montpellier University Hospital, Montpellier, France.&#xD;Centre of Bioclimatology, University of Florence, Florence, Italy.&#xD;SOS Allergy and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Allergy and Clinical Immunology Unit, San Giovanni di Dio Hospital, Florence, Italy.&#xD;National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Federal Office of Meteorology and Climatology MeteoSwiss, Payerne, Switzerland.&#xD;Respiratory Disease Department, Hospital Cardarelli, Naples, Italy.&#xD;Terrestrial Ecology and Climate Change, Department of Ecology, School of Biology, Faculty of Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, and CIBER of Respiratory Diseases (CIBERES), Madrid, Spain.&#xD;International Campus of Excellence on Agrifood (ceiA3), University of Cordoba, Cordoba, Spain.&#xD;Andalusian Inter-University Institute for Earth System Research (IISTA), University of Cordoba, Cordoba, Spain.&#xD;Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Occupational Medicine Division and Centre for Environmental &amp; Occupational Health Research, School of Public Health, University of Cape Town, Cape Town, South Africa.&#xD;Physikalisch-Meteorologisches Observatorium Davos, World Radiation Center, Davos, Switzerland.&#xD;Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.&#xD;Allergy Service, Fundacion Jimenez Diaz, Faculty of Medicine Universidad Autonoma de Madrid, and CIBERES, Instituto Carlos III, Ministry of Science and Innovation, Madrid, Spain.&#xD;Institute of Environmental Medicine, Helmholtz Center Munich - German Research Center for Environmental Health, Augsburg, Germany.&#xD;Christine Kuhne Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;Iberoamerican Cochrane Centre, Department of Clinical Epidemiology and Public Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.&#xD;CIBER de Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.&#xD;Department of Clinical Immunology, Wroclaw Medical University, and ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Is exposure to pollen a risk factor for moderate and severe asthma exacerbations?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2121-2147</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/03/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">aerobiology</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36961370</style></accession-num><abstract><style face="normal" font="default" size="100%">Limited number of studies have focused on the impact of pollen exposure on asthma. As a part of the EAACI Guidelines on Environment Science, this first systematic review on the relationship of pollen exposure to asthma exacerbations aimed to bridge this knowledge gap in view of implementing recommendations of prevention. We searched electronic iPubMed, Embase, and Web of Science databases using a set of MeSH terms and related synonyms and identified 73 eligible studies that were included for systemic review. When possible, meta-analyses were conducted. Overall meta-analysis suggests that outdoor pollen exposure may have an effect on asthma exacerbation, but caution is needed due to the low number of studies and their heterogeneity. The strongest associations were found between asthma attacks, asthma-related ED admissions or hospitalizations, and an increase in grass pollen concentration in the previous 2-day overall in children aged less than 18 years of age. Tree pollen may increase asthma-related ED visits or admissions lagged up to 7-day overall in individuals younger than 18 years. Rare data show that among subjects under 18 years of age, an exposure to grass pollen lagged up to 3 days may lower lung function. Further research considering effect modifiers of pollen sensitization, hay fever, asthma, air pollution, green spaces, and pre-existing medications is urgently warranted to better evaluate the impacts of pollen on asthma exacerbation. Preventive measures in relation to pollen exposure should be integrated in asthma control as pollen increase continues due to climate change.</style></abstract><notes><style face="normal" font="default" size="100%">Annesi-Maesano, Isabella&#xD;Cecchi, Lorenzo&#xD;Biagioni, Benedetta&#xD;Chung, Kian Fan&#xD;Clot, Bernard&#xD;Collaud Coen, Martine&#xD;D&apos;Amato, Gennaro&#xD;Damialis, Athanasios&#xD;Dominguez-Ortega, Javier&#xD;Galan, Carmen&#xD;Gilles, Stefanie&#xD;Holgate, Stephen&#xD;Jeebhay, Mohamed&#xD;Kazadzis, Stelios&#xD;Papadopoulos, Nikolaos G&#xD;Quirce, Santiago&#xD;Sastre, Joaquin&#xD;Tummon, Fiona&#xD;Traidl-Hoffmann, Claudia&#xD;Walusiak-Skorupa, Jolanta&#xD;Alonso-Coello, Pablo&#xD;Canelo-Aybar, Carlos&#xD;Cantero-Fortiz, Yahveth&#xD;Rigau, David&#xD;Salazar, Josefina&#xD;Verdugo-Paiva, Francisca&#xD;Jutel, Marek&#xD;Akdis, Cezmi A&#xD;Agache, Ioana&#xD;eng&#xD;Meta-Analysis&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2121-2147. doi: 10.1111/all.15724. Epub 2023 Apr 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36961370</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15724</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>275</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">275</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yasuma, T.</style></author><author><style face="normal" font="default" size="100%">D&apos;Alessandro-Gabazza, C. N.</style></author><author><style face="normal" font="default" size="100%">Fujimoto, H.</style></author><author><style face="normal" font="default" size="100%">Kobayashi, T.</style></author><author><style face="normal" font="default" size="100%">Imoto, I.</style></author><author><style face="normal" font="default" size="100%">Gabazza, E. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.&#xD;Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Mie University Hospital, Tsu, Japan.&#xD;Digestive Endoscopy Center, Department of Internal Medicine, Doshinkai Tohyama Hospital, Tsu, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Is Helicobacter pylori infection inversely correlated with atopic, skin, and autoimmune diseases?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3165-3166</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/09/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Autoimmune Diseases/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Helicobacter Infections</style></keyword><keyword><style face="normal" font="default" size="100%">*Helicobacter pylori</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36169879</style></accession-num><notes><style face="normal" font="default" size="100%">Yasuma, Taro&#xD;D&apos;Alessandro-Gabazza, Corina N&#xD;Fujimoto, Hajime&#xD;Kobayashi, Tetsu&#xD;Imoto, Ichiro&#xD;Gabazza, Esteban C&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3165-3166. doi: 10.1111/all.15306.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36169879</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15306</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1347</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1347</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Idrose, N. S.</style></author><author><style face="normal" font="default" size="100%">Tham, R. C. A.</style></author><author><style face="normal" font="default" size="100%">Lodge, C. J.</style></author><author><style face="normal" font="default" size="100%">Lowe, A. J.</style></author><author><style face="normal" font="default" size="100%">Bui, D.</style></author><author><style face="normal" font="default" size="100%">Perret, J. L.</style></author><author><style face="normal" font="default" size="100%">Vicendese, D.</style></author><author><style face="normal" font="default" size="100%">Newbigin, E. J.</style></author><author><style face="normal" font="default" size="100%">Tang, M. L. K.</style></author><author><style face="normal" font="default" size="100%">Aldakheel, F. M.</style></author><author><style face="normal" font="default" size="100%">Waidyatillake, N. T.</style></author><author><style face="normal" font="default" size="100%">Douglass, J. A.</style></author><author><style face="normal" font="default" size="100%">Abramson, M. J.</style></author><author><style face="normal" font="default" size="100%">Walters, E. H.</style></author><author><style face="normal" font="default" size="100%">Erbas, B.</style></author><author><style face="normal" font="default" size="100%">Dharmage, S. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Carlton, Vic., Australia.&#xD;Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Vic., Australia.&#xD;Department of Mathematics and Statistics, La Trobe University, Bundoora, Vic., Australia.&#xD;School of BioSciences, The University of Melbourne, Parkville, Vic., Australia.&#xD;Allergy and Immunology, Murdoch Children&apos;s Research Institute, Royal Children&apos;s Hospital, Melbourne, Vic, Australia.&#xD;Department of Pediatrics, University of Melbourne, Melbourne, Vic., Australia.&#xD;Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.&#xD;Department of Clinical Immunology and Allergy, Royal Melbourne Hospital, Parkville, Vic., Australia.&#xD;Department of Medicine, University of Melbourne, Melbourne, Vic., Australia.&#xD;School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic., Australia.&#xD;School of Medicine, University of Tasmania, Hobart, Tas, Australia.&#xD;School of Psychology and Public Health, La Trobe University, Bundoora, Vic., Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Is short-term exposure to grass pollen adversely associated with lung function and airway inflammation in the community?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1136-1146</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/08/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Breath Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">*Nitric Oxide</style></keyword><keyword><style face="normal" font="default" size="100%">Poaceae</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">airway inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">environmental health</style></keyword><keyword><style face="normal" font="default" size="100%">grass</style></keyword><keyword><style face="normal" font="default" size="100%">lung function</style></keyword><keyword><style face="normal" font="default" size="100%">pollen</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32815173</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The association between grass pollen exposure and early markers of asthma exacerbations such as lung function changes and increase in airway inflammation is limited. We investigated the associations between short-term grass pollen exposure and lung function and airway inflammation in a community-based sample, and whether any such associations were modified by current asthma, current hay fever, pollen sensitization, age, and other environmental factors. METHODS: Cross-sectional and short-term analyses of data from the Melbourne Atopy Cohort Study (MACS) participants (n = 936). Lung function was assessed using spirometry. Airway inflammation was assessed by fractional exhaled nitric oxide (FeNO) and exhaled breath condensate pH and nitrogen oxides (NOx). Daily pollen counts were collected using a volumetric spore trap. The associations were examined by linear regression. RESULTS: Higher ambient levels of grass pollen 2 days before (lag 2) were associated with lower mid-forced expiratory flow (FEF(25%-75%) ) and FEV(1) /FVC ratio (Coef. [95% CI] = -119 [-226, -11] mL/s and -1.0 [-3.0, -0.03] %, respectively) and also 3 days before (lag 3). Increased levels of grass pollen a day before (lag 1) were associated with increased FeNO (4.35 [-0.1, 8.7] ppb) and also at lag 2. Adverse associations between pollen and multiple outcomes were greater in adults with current asthma, hay fever, and pollen sensitization. CONCLUSION: Grass pollen exposure was associated with eosinophilic airway inflammation 1-2 days after exposure and airway obstruction 2-3 days after exposure. Adults and individuals with asthma, hay fever, and pollen sensitization may be at higher risk.</style></abstract><notes><style face="normal" font="default" size="100%">Idrose, Nur Sabrina&#xD;Tham, Rachel C A&#xD;Lodge, Caroline J&#xD;Lowe, Adrian J&#xD;Bui, Dinh&#xD;Perret, Jennifer L&#xD;Vicendese, Don&#xD;Newbigin, Edward J&#xD;Tang, Mimi L K&#xD;Aldakheel, Fahad M&#xD;Waidyatillake, Nilakshi T&#xD;Douglass, Jo A&#xD;Abramson, Michael J&#xD;Walters, Eugene Haydn&#xD;Erbas, Bircan&#xD;Dharmage, Shyamali C&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1136-1146. doi: 10.1111/all.14566. Epub 2020 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32815173</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14566</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1579</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1579</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fiorito, S.</style></author><author><style face="normal" font="default" size="100%">Soligo, M.</style></author><author><style face="normal" font="default" size="100%">Gao, Y.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Bonini, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Translational Pharmacology, Italian National Research Council, Rome, Italy.&#xD;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Is the epithelial barrier hypothesis the key to understanding the higher incidence and excess mortality during COVID-19 pandemic? The case of Northern Italy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1408-1417</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Air Pollutants/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Italy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">Particulate Matter/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">and monoclonal antibodies. CA has received research grants from the Swiss</style></keyword><keyword><style face="normal" font="default" size="100%">National Science Foundation, European Union (EU CURE), Novartis Research</style></keyword><keyword><style face="normal" font="default" size="100%">Institutes (Basel, Switzerland), Stanford University (Redwood City, Calif) and</style></keyword><keyword><style face="normal" font="default" size="100%">SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">he is the Co-Chair for EAACI Guidelines on</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Science in Allergic diseases and Asthma, and serves on the Advisory</style></keyword><keyword><style face="normal" font="default" size="100%">Boards of Sanofi/Regeneron, Novartis, GlaxoSmithKline, and SciBase, and is the</style></keyword><keyword><style face="normal" font="default" size="100%">Editor-in-Chief of Allergy. SF, MS, YG and IO have no interests to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35102595</style></accession-num><abstract><style face="normal" font="default" size="100%">The high incidence and increased mortality of COVID-19 make Italy among the most impacted countries by SARS-CoV-2 outbreak. In the beginning of the pandemic, Northern regions accounted for 40% of cases and 45% of deaths from COVID-19 in Italy. Several factors have been suggested to explain the higher incidence and excess mortality from COVID-19 in these regions. It is noticed that Northern Italian regions, and particularly the cities in Po Valley, are the areas with the highest air pollution due to commercial vehicle traffic, industry and a stagnant meteorological condition, with one of the highest levels in Italy and Europe of fine particulate matter 2.5 micron or smaller in size (PM2.5). PM2.5, the major environmental pollutant deriving mainly by factory and automobile exhaust emissions and coal combustion, increases the expression of angiotensin-converting enzyme 2, the epithelial cell entry receptor for SARS-CoV-2, and thus increase the susceptibility to this virus. The epithelial barrier hypothesis proposes that many diverse diseases may rise from the disruption of epithelial barrier of skin, respiratory tract and gastrointestinal system, including allergic diseases, metabolic and autoimmune diseases, and chronic neuropsychiatric conditions. There is evidence of a close correlation between air pollution and airway epithelial barrier dysfunction. Air pollution, causing lung epithelial barrier dysfunction, may contribute to local chronic inflammation, microbiome dysbiosis and impaired antiviral immune response against SARS-CoV-2, all of which contribute to the high incidence and excess mortality from COVID-19. In addition, air pollution and epithelial barrier dysfunction contribute also to the higher prevalence of several comorbidities of COVID-19, such as diabetes, chronic obstructive pulmonary disease and obesity, which have been identified as risk factors for mortality of COVID-19. In this article, on the basis of epidemiological and environmental monitoring data in Northern Italy, it is suggested that epithelial barrier hypothesis may help to understand the excess burden and mortality from COVID-19.</style></abstract><notes><style face="normal" font="default" size="100%">Fiorito, Silvana&#xD;Soligo, Marzia&#xD;Gao, Yadong&#xD;Ogulur, Ismail&#xD;Akdis, Cezmi A&#xD;Bonini, Sergio&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1408-1417. doi: 10.1111/all.15239. Epub 2022 Feb 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35102595</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9304271</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15239</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1021</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1021</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lozano-Ojalvo, D.</style></author><author><style face="normal" font="default" size="100%">Tyler, S. R.</style></author><author><style face="normal" font="default" size="100%">Berin, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Is the plasticity of the Th17 subset a key source of allergenic Th2 responses?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3238-3240</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/05/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Th17 Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">CyTOF</style></keyword><keyword><style face="normal" font="default" size="100%">Il17</style></keyword><keyword><style face="normal" font="default" size="100%">Il4</style></keyword><keyword><style face="normal" font="default" size="100%">T helper cells</style></keyword><keyword><style face="normal" font="default" size="100%">Th17</style></keyword><keyword><style face="normal" font="default" size="100%">Th2</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bioinformatics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33930200</style></accession-num><notes><style face="normal" font="default" size="100%">Lozano-Ojalvo, Daniel&#xD;Tyler, Scott R&#xD;Berin, M Cecilia&#xD;eng&#xD;Comment&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3238-3240. doi: 10.1111/all.14888. Epub 2021 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33930200</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14888</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1905</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1905</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lozano-Ojalvo, D.</style></author><author><style face="normal" font="default" size="100%">Tyler, S. R.</style></author><author><style face="normal" font="default" size="100%">Berin, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Is the plasticity of the Th17 subset a key source of allergenic Th2 responses?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3238-3240</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/05/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Th17 Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">CyTOF</style></keyword><keyword><style face="normal" font="default" size="100%">Il17</style></keyword><keyword><style face="normal" font="default" size="100%">Il4</style></keyword><keyword><style face="normal" font="default" size="100%">T helper cells</style></keyword><keyword><style face="normal" font="default" size="100%">Th17</style></keyword><keyword><style face="normal" font="default" size="100%">Th2</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bioinformatics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33930200</style></accession-num><abstract><style face="normal" font="default" size="100%">This commentary summarizes and discusses a recent study from Tortola et al, which reports the vast plasticity of T helper (Th) 17 cells and suggests that this subset might be an important source of Th2 cells under certain inflammatory conditions.</style></abstract><notes><style face="normal" font="default" size="100%">Lozano-Ojalvo, Daniel&#xD;Tyler, Scott R&#xD;Berin, M Cecilia&#xD;eng&#xD;Comment&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3238-3240. doi: 10.1111/all.14888. Epub 2021 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33930200</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14888</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2411</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2411</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Is there a direct link between skin barrier dysfunction and asthma?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1416-1418</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/02/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/pathology/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38349007</style></accession-num><notes><style face="normal" font="default" size="100%">Santos, Alexandra F&#xD;eng&#xD;Food Allergy Research and Education/&#xD;MRC_/Medical Research Council/United Kingdom&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1416-1418. doi: 10.1111/all.16055. Epub 2024 Feb 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38349007</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16055</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>683</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">683</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zettl, I.</style></author><author><style face="normal" font="default" size="100%">Ivanova, T.</style></author><author><style face="normal" font="default" size="100%">Strobl, M. R.</style></author><author><style face="normal" font="default" size="100%">Weichwald, C.</style></author><author><style face="normal" font="default" size="100%">Goryainova, O.</style></author><author><style face="normal" font="default" size="100%">Khan, E.</style></author><author><style face="normal" font="default" size="100%">Rutovskaya, M. V.</style></author><author><style face="normal" font="default" size="100%">Focke-Tejkl, M.</style></author><author><style face="normal" font="default" size="100%">Drescher, A.</style></author><author><style face="normal" font="default" size="100%">Bohle, B.</style></author><author><style face="normal" font="default" size="100%">Flicker, S.</style></author><author><style face="normal" font="default" size="100%">Tillib, S. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunopathology, Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.&#xD;Division of Experimental Allergology, Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;A.N.Severtsov Institute of Ecology and Evolution, Russian Academy of Sciences, Moscow, Russia.&#xD;Cytiva Europe GmbH, Freiburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Isolation of nanobodies with potential to reduce patients&apos; IgE binding to Bet v 1</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1751-1760</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/11/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Single-Domain Antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">Bet v 1</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">Vhh</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">nanobody</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34837242</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Recent studies showed that a single injection of human monoclonal allergen-specific IgG antibodies significantly reduced allergic symptoms in birch pollen-allergic patients. Since the production of full monoclonal antibodies in sufficient amounts is laborious and expensive, we sought to investigate if smaller recombinant allergen-specific antibody fragments, that is, nanobodies, have similar protective potential. For this purpose, nanobodies specific for Bet v 1, the major birch pollen allergen, were generated to evaluate their efficacy to inhibit IgE-mediated responses. METHODS: A cDNA-VHH library was constructed from a camel immunized with Bet v 1 and screened for Bet v 1 binders encoding sequences by phage display. Selected nanobodies were expressed, purified, and analyzed in regards of epitope-specificity and affinity to Bet v 1. Furthermore, cross-reactivity to Bet v 1-homologues from alder, hazel and apple, and their usefulness to inhibit IgE binding and allergen-induced basophil activation were investigated. RESULTS: We isolated three nanobodies that recognize Bet v 1 with high affinity and cross-react with Aln g 1 (alder) and Cor a 1 (hazel). Their epitopes were mapped to the alpha-helix at the C-terminus of Bet v 1. All nanobodies inhibited allergic patients&apos; polyclonal IgE binding to Bet v 1, Aln g 1, and Cor a 1 and partially suppressed Bet v 1-induced basophil activation. CONCLUSION: We identified high-affinity Bet v 1-specific nanobodies that recognize an important IgE epitope and reduce allergen-induced basophil activation revealing the first proof that allergen-specific nanobodies are useful tools for future treatment of pollen allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Zettl, Ines&#xD;Ivanova, Tatiana&#xD;Strobl, Maria R&#xD;Weichwald, Christina&#xD;Goryainova, Oksana&#xD;Khan, Evgenia&#xD;Rutovskaya, Marina V&#xD;Focke-Tejkl, Margarete&#xD;Drescher, Anja&#xD;Bohle, Barbara&#xD;Flicker, Sabine&#xD;Tillib, Sergei V&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1751-1760. doi: 10.1111/all.15191. Epub 2021 Dec 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34837242</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15191</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3033</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3033</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Han, X.</style></author><author><style face="normal" font="default" size="100%">Wu, X.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, Q.</style></author><author><style face="normal" font="default" size="100%">Lin, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Wei, Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Kong, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Cognitive Science and Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China.&#xD;Department of Psychology, University of Chinese Academy of Sciences, Beijing, China.&#xD;Foshan Rehabilitation Hospital, Guangdong, China.&#xD;Department of Dermatology and Venereology, Xuanwu Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Itch Sensitivity Questionnaire: A Validated Tool for Assessing Sensitization in Chronic Pruritus</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/08/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">histamine</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">quality-of-life</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40823876</style></accession-num><notes><style face="normal" font="default" size="100%">Han, Xiuyi&#xD;Wu, Xiao&#xD;Chen, Ying&#xD;Zhou, Quanyu&#xD;Lin, Xiaomin&#xD;Zhang, Leiyao&#xD;Wei, Zhaoxing&#xD;Zhang, Ming&#xD;Zhang, Haiping&#xD;Kong, Yazhuo&#xD;eng&#xD;Beijing Natural Science Foundation/&#xD;National Natural Science Foundation of China/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug 18. doi: 10.1111/all.70015.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40823876</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70015</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>519</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">519</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peng, W.</style></author><author><style face="normal" font="default" size="100%">Benfadal, S.</style></author><author><style face="normal" font="default" size="100%">Yu, C.</style></author><author><style face="normal" font="default" size="100%">Wenzel, J.</style></author><author><style face="normal" font="default" size="100%">Oldenburg, J.</style></author><author><style face="normal" font="default" size="100%">Novak, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.&#xD;Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">JAK1/2 inhibitor but not IL-4 receptor alpha antibody suppresses allergen-mediated activation of human basophils in vitro</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2253-2256</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/04/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4 Receptor alpha Subunit</style></keyword><keyword><style face="normal" font="default" size="100%">Janus Kinase 1</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35460281</style></accession-num><notes><style face="normal" font="default" size="100%">Peng, Wenming&#xD;Benfadal, Said&#xD;Yu, Chunfeng&#xD;Wenzel, Jorg&#xD;Oldenburg, Johannes&#xD;Novak, Natalija&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2253-2256. doi: 10.1111/all.15322. Epub 2022 May 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35460281</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15322</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>534</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">534</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Simpson, E. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Oregon Health &amp; Science University, Portland, Oregon, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Jon M. Hanifin - A career of discovery, mentorship, advocacy, and scientific rigor</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2257-2259</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/04/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mentors</style></keyword><keyword><style face="normal" font="default" size="100%">Hanifin</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35364625</style></accession-num><notes><style face="normal" font="default" size="100%">Simpson, Eric L&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2257-2259. doi: 10.1111/all.15303. Epub 2022 Apr 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35364625</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15303</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1806</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1806</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Simpson, E. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Oregon Health &amp; Science University, Portland, Oregon, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Jon M. Hanifin - A career of discovery, mentorship, advocacy, and scientific rigor</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2257-2259</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/04/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mentors</style></keyword><keyword><style face="normal" font="default" size="100%">Hanifin</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35364625</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract -</style></abstract><notes><style face="normal" font="default" size="100%">Simpson, Eric L&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2257-2259. doi: 10.1111/all.15303. Epub 2022 Apr 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35364625</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15303</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2214</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2214</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayashi, K.</style></author><author><style face="normal" font="default" size="100%">Saeki, M.</style></author><author><style face="normal" font="default" size="100%">Miura, K.</style></author><author><style face="normal" font="default" size="100%">Yamasaki, N.</style></author><author><style face="normal" font="default" size="100%">Matsuda, M.</style></author><author><style face="normal" font="default" size="100%">Shimora, H.</style></author><author><style face="normal" font="default" size="100%">Nabe, T.</style></author><author><style face="normal" font="default" size="100%">Shimizu, Y.</style></author><author><style face="normal" font="default" size="100%">Fujita, T.</style></author><author><style face="normal" font="default" size="100%">Endou, H.</style></author><author><style face="normal" font="default" size="100%">Kaminuma, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Japan.&#xD;Cancer Immunology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.&#xD;Department of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.&#xD;Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan.&#xD;Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Shimotsuga, Japan.&#xD;J-Pharma Co., Ltd., Yokohama, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">JPH203, a LAT1 inhibitor, alleviates steroid-resistant murine airway inflammation mediated by Th17 cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2780-2783</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/06/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Th17 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Benzoxazoles/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Steroids</style></keyword><keyword><style face="normal" font="default" size="100%">Jph203</style></keyword><keyword><style face="normal" font="default" size="100%">L-type amino acid transporter 1 (LAT1)</style></keyword><keyword><style face="normal" font="default" size="100%">amino acid transporter</style></keyword><keyword><style face="normal" font="default" size="100%">immunosuppressant</style></keyword><keyword><style face="normal" font="default" size="100%">intractable asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37382229</style></accession-num><notes><style face="normal" font="default" size="100%">Hayashi, Keitaro&#xD;Saeki, Mayumi&#xD;Miura, Kento&#xD;Yamasaki, Norimasa&#xD;Matsuda, Masaya&#xD;Shimora, Hayato&#xD;Nabe, Takeshi&#xD;Shimizu, Yasuo&#xD;Fujita, Tomoe&#xD;Endou, Hitoshi&#xD;Kaminuma, Osamu&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2780-2783. doi: 10.1111/all.15798. Epub 2023 Jun 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37382229</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15798</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2754</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2754</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Takahashi, M.</style></author><author><style face="normal" font="default" size="100%">Nagata, K.</style></author><author><style face="normal" font="default" size="100%">Watanuki, Y.</style></author><author><style face="normal" font="default" size="100%">Yamaguchi, M.</style></author><author><style face="normal" font="default" size="100%">Ishii, K.</style></author><author><style face="normal" font="default" size="100%">Harada, T.</style></author><author><style face="normal" font="default" size="100%">Minamikawa, N.</style></author><author><style face="normal" font="default" size="100%">Katagiri, M.</style></author><author><style face="normal" font="default" size="100%">Zhao, W.</style></author><author><style face="normal" font="default" size="100%">Ito, N.</style></author><author><style face="normal" font="default" size="100%">Yashiro, T.</style></author><author><style face="normal" font="default" size="100%">Nishiyama, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biological Science and Technology, Faculty of Advanced Engineering, Tokyo University of Science, Katsushika-ku, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Kaempferol Exerts Anti-Inflammatory Effects by Accelerating Treg Development via Aryl Hydrocarbon Receptor-Mediated and PU.1/IRF4-Dependent Transactivation of the Aldh1a2/Raldh2 Gene in Dendritic Cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">896-900</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/12/11</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39660951</style></accession-num><notes><style face="normal" font="default" size="100%">Takahashi, Miki&#xD;Nagata, Kazuki&#xD;Watanuki, Yumi&#xD;Yamaguchi, Masaki&#xD;Ishii, Kenta&#xD;Harada, Tomohiro&#xD;Minamikawa, Natsuki&#xD;Katagiri, Mayuka&#xD;Zhao, Weiting&#xD;Ito, Naoto&#xD;Yashiro, Takuya&#xD;Nishiyama, Chiharu&#xD;eng&#xD;Scholarship for Doctoral Students in Immunology/&#xD;Japan Society for the Promotion of Science/&#xD;Mishima Kaiun Memorial Foundation/&#xD;Tojuro Iijima Foundation for Food Science and Technology/&#xD;Takeda Science Foundation/&#xD;23K26860/Grants-in-Aid for Scientific Research (B)/&#xD;23H02167/Grants-in-Aid for Scientific Research (B)/&#xD;20H02939/Grants-in-Aid for Scientific Research (B)/&#xD;24K17872/Grant-in-Aid for Early-Career Scientists/&#xD;21J12113/Grant-in-Aid for JSPS Fellows/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):896-900. doi: 10.1111/all.16410. Epub 2024 Dec 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39660951</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891405</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16410</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2899</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2899</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Phan, T. S.</style></author><author><style face="normal" font="default" size="100%">Lambrecht, R.</style></author><author><style face="normal" font="default" size="100%">Merk, V. M.</style></author><author><style face="normal" font="default" size="100%">Wiedmann, A.</style></author><author><style face="normal" font="default" size="100%">Zwicky, P.</style></author><author><style face="normal" font="default" size="100%">Becher, B.</style></author><author><style face="normal" font="default" size="100%">Brunner, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Biochemical Pharmacology, Department of Biology, University of Konstanz, Konstanz, Germany.&#xD;Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Keratinocyte-Derived Glucocorticoids Maintain Immune Balance During Transient Skin Barrier Perturbation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2384-2387</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">barrier</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">keratinocytes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40470757</style></accession-num><notes><style face="normal" font="default" size="100%">Phan, Truong San&#xD;Lambrecht, Rebekka&#xD;Merk, Verena M&#xD;Wiedmann, Alice&#xD;Zwicky, Pascale&#xD;Becher, Burkhard&#xD;Brunner, Thomas&#xD;eng&#xD;Deutsche Forschungsgemeinschaft/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2384-2387. doi: 10.1111/all.16613. Epub 2025 Jun 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40470757</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368758</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16613</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2627</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2627</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kubala, S. A.</style></author><author><style face="normal" font="default" size="100%">Young, F. D.</style></author><author><style face="normal" font="default" size="100%">Callier, V.</style></author><author><style face="normal" font="default" size="100%">Rasooly, M. M.</style></author><author><style face="normal" font="default" size="100%">Dempsey, C.</style></author><author><style face="normal" font="default" size="100%">Brittain, E.</style></author><author><style face="normal" font="default" size="100%">Frischmeyer-Guerrerio, P. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Food Allergy Research Section, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, Maryland, USA.&#xD;Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.&#xD;Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Key factors that influence quality of life in patients with IgE-mediated food allergy vary by age</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2812-2825</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/08/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Food Allergy Quality of Life Questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">psychosocial impact</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">reaction severity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39096008</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: While food allergy (FA) can be fatal, the greatest public health impact of FA arguably lies in its detrimental effect on quality of life (FAQOL). Understanding the factors that contribute to FAQOL at different ages is essential to develop personalized interventions that will improve FAQOL. OBJECTIVE: To determine the most influential factors that impact FAQOL across ages in well-phenotyped participants with confirmed FA. METHODS: One hundred and twenty-five individuals aged 2-28 years with IgE-mediated FA completed validated age-specific FAQOL questionnaires. The relationship between demographic/clinical variables and scores were analyzed to identify key predictors of FAQOL. RESULTS: Poor FAQOL was associated with increasing age, strict avoidance practices, reactions to trace exposures, and more severe reactions as assessed by epinephrine use, anaphylaxis, and/or treatment in the emergency department; FAQOL improved with time from the event. FAQOL was worse in subjects avoiding &gt;2 versus &lt;/=2 foods and in those avoiding milk, egg, soy, sesame, or wheat. Number of foods avoided had greatest impact on children ages 2-7 years, while total number of allergic reactions strongly impacted FAQOL in teens and adults; FAQOL of subjects ages 8-12 years appeared less affected by these variables compared to other age groups. A decision tree analysis identified key predictors of overall FAQOL (age, number of food avoidances, and time since epinephrine use) that can be used to guide intervention strategies to improve FAQOL. CONCLUSION: We directly compared FAQOL in extensively phenotyped children, teenagers, and adults with confirmed IgE-mediated FA. Age; timing, number, and severity of reactions; type and number of FA; and food avoidance practices influence FAQOL and should guide intervention strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Kubala, Stephanie A&#xD;Young, Fernanda D&#xD;Callier, Viviane&#xD;Rasooly, Marjohn M&#xD;Dempsey, Caeden&#xD;Brittain, Erica&#xD;Frischmeyer-Guerrerio, Pamela A&#xD;eng&#xD;HHSN261201500003C/CA/NCI NIH HHS/&#xD;HHSN261201500003I/CA/NCI NIH HHS/&#xD;ZIA AI001202/ImNIH/Intramural NIH HHS/&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2812-2825. doi: 10.1111/all.16253. Epub 2024 Aug 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39096008</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11449640</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16253</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2228</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2228</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Filuta, A. L.</style></author><author><style face="normal" font="default" size="100%">Amezcua, P.</style></author><author><style face="normal" font="default" size="100%">Ruff, B. P.</style></author><author><style face="normal" font="default" size="100%">Biagini, J. M.</style></author><author><style face="normal" font="default" size="100%">Kroner, J.</style></author><author><style face="normal" font="default" size="100%">He, H.</style></author><author><style face="normal" font="default" size="100%">Brandt, E. B.</style></author><author><style face="normal" font="default" size="100%">Martin, L. J.</style></author><author><style face="normal" font="default" size="100%">Palumbo, J. S.</style></author><author><style face="normal" font="default" size="100%">Khurana Hershey, G. K.</style></author><author><style face="normal" font="default" size="100%">Sherenian, M. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Asthma Research, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Division of Human Genetics, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Division of Hematology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The key roles of thrombin and fibrinogen in human infant and mice atopic dermatitis models</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">239-242</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/08/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Thrombin</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinogen</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">clotting</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37646328</style></accession-num><notes><style face="normal" font="default" size="100%">Filuta, Alyssa L&#xD;Amezcua, Peter&#xD;Ruff, Brandy P&#xD;Biagini, Jocelyn M&#xD;Kroner, John&#xD;He, Hua&#xD;Brandt, Eric B&#xD;Martin, Lisa J&#xD;Palumbo, Joseph S&#xD;Khurana Hershey, Gurjit K&#xD;Sherenian, Michael G&#xD;eng&#xD;K12 HD028827/HD/NICHD NIH HHS/&#xD;L40 AI154605/AI/NIAID NIH HHS/&#xD;U19 AI070235/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):239-242. doi: 10.1111/all.15868. Epub 2023 Aug 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37646328</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10840661</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15868</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>88</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">88</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Navarro-Navarro, P.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Twose, I.</style></author><author><style face="normal" font="default" size="100%">Perez-Pons, A.</style></author><author><style face="normal" font="default" size="100%">Henriques, A.</style></author><author><style face="normal" font="default" size="100%">Mayado, A.</style></author><author><style face="normal" font="default" size="100%">Garcia-Montero, A. C.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Munoz, L.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Lopez, O.</style></author><author><style face="normal" font="default" size="100%">Matito, A.</style></author><author><style face="normal" font="default" size="100%">Caldas, C.</style></author><author><style face="normal" font="default" size="100%">Jara-Acevedo, M.</style></author><author><style face="normal" font="default" size="100%">Orfao, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), Department of Medicine, Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain.&#xD;Red Espanola de Mastocitosis (REMA), Toledo and Salamanca, Spain.&#xD;Centro de Investigacion Biomedica en Red Cancer (CIBERONC; CB16/12/00400), Madrid, Spain.&#xD;Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Virgen del Valle Hospital, Toledo, Spain.&#xD;Sequencing Service (NUCLEUS), University of Salamanca and Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1347-1359</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/11/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis, Systemic/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cell Activation Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-kit/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Kitd816v</style></keyword><keyword><style face="normal" font="default" size="100%">MCAS (mast cell activation syndrome)</style></keyword><keyword><style face="normal" font="default" size="100%">Mastocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36385619</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Current diagnostic algorithms for systemic mastocytosis (SM) rely on the detection of KITD816V in blood to trigger subsequent bone marrow (BM) investigations. METHODS: Here, we correlated the KITD816V mutational status of paired blood and BM samples from 368 adults diagnosed with mast cell activation syndrome (MCAS) and mastocytosis and determined the potential utility of investigating KITD816V in genomic DNA from blood-purified myeloid cell populations to increase diagnostic sensitivity. In a subset of 69 patients, we further evaluated the kinetics of the KITD816V cell burden during follow-up and its association with disease outcome. RESULTS: Our results showed a high correlation (P &lt; .0001) between the KITD816V mutation burden in blood and BM (74% concordant samples), but with a lower mean of KITD816V-mutated cells in blood (P = .0004) and a high rate of discordant BM(+) /blood(-) samples particularly among clonal MCAS (73%) and BM mastocytosis (51%), but also in cutaneous mastocytosis (9%), indolent SM (15%), and well-differentiated variants of indolent SM (7%). Purification of different compartments of blood-derived myeloid cells was done in 28 patients who were BM mast cell (MC)(+) /blood(-) for KITD816V, revealing KITD816V-mutated eosinophils (56%), basophils (25%), neutrophils (29%), and/or monocytes (31%) in most (61%) patients. Prognostically, the presence of &gt;/=3.5% KITD816V-mutated cells (P &lt; .0001) and an unstable KITD816V mutation cell burden (P &lt; .0001) in blood and/or BM were both associated with a significantly shortened progression-free survival (PFS). CONCLUSIONS: These results confirm the high specificity but limited sensitivity of KITD816V analysis in whole blood for the diagnostic screening of SM and other primary MCAS, which might be overcome by assessing the mutation in blood-purified myeloid cell populations.</style></abstract><notes><style face="normal" font="default" size="100%">Navarro-Navarro, Paula&#xD;Alvarez-Twose, Ivan&#xD;Perez-Pons, Alba&#xD;Henriques, Ana&#xD;Mayado, Andrea&#xD;Garcia-Montero, Andres C&#xD;Sanchez-Munoz, Laura&#xD;Gonzalez-Lopez, Oscar&#xD;Matito, Almudena&#xD;Caldas, Carolina&#xD;Jara-Acevedo, Maria&#xD;Orfao, Alberto&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1347-1359. doi: 10.1111/all.15584. Epub 2022 Nov 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36385619</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15584</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>533</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">533</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lou, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Nasal Diseases and Beijing Laboratory of Allergic Diseases, Beijing Institute of Otorhinolaryngology, Beijing, China.&#xD;Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.&#xD;Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Knowledge gaps in using type 2 biologics for real-world treatment of chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1952-1954</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/04/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35377468</style></accession-num><notes><style face="normal" font="default" size="100%">Lou, Hongfei&#xD;Zhang, Luo&#xD;eng&#xD;Editorial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):1952-1954. doi: 10.1111/all.15307.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35377468</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15307</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>62</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">62</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palomares, F.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Leenhouts, K.</style></author><author><style face="normal" font="default" size="100%">Perez-Sanchez, N.</style></author><author><style face="normal" font="default" size="100%">Gomez, F.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Sorensen, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Laboratory and Allergy Service, IBIMA-Regional University Hospital of Malaga, UMA, Malaga, Spain.&#xD;Allero Therapeutics BV, Rotterdam, Netherlands.&#xD;Department of Biomedicine, Aarhus University, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lactococcus lactis-derived microparticles ad mixed with allergen shift immune responses towards a regulatory profile in tree-nut allergic patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">851-855</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Nuts</style></keyword><keyword><style face="normal" font="default" size="100%">*Lactococcus lactis</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36463436</style></accession-num><notes><style face="normal" font="default" size="100%">Palomares, Francisca&#xD;Mayorga, Cristobalina&#xD;Leenhouts, Kees&#xD;Perez-Sanchez, Natalia&#xD;Gomez, Francisca&#xD;Torres, Maria Jose&#xD;Sorensen, Poul&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):851-855. doi: 10.1111/all.15607. Epub 2022 Dec 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36463436</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15607</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>53</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">53</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dorr, A. D.</style></author><author><style face="normal" font="default" size="100%">Chopra, C.</style></author><author><style face="normal" font="default" size="100%">Coulter, T. I.</style></author><author><style face="normal" font="default" size="100%">Dempster, J.</style></author><author><style face="normal" font="default" size="100%">Dziadzio, M.</style></author><author><style face="normal" font="default" size="100%">El-Shanawany, T.</style></author><author><style face="normal" font="default" size="100%">Garcez, T.</style></author><author><style face="normal" font="default" size="100%">Gompels, M.</style></author><author><style face="normal" font="default" size="100%">Herriot, R.</style></author><author><style face="normal" font="default" size="100%">Jain, R.</style></author><author><style face="normal" font="default" size="100%">Levi, M.</style></author><author><style face="normal" font="default" size="100%">Lorenzo, L.</style></author><author><style face="normal" font="default" size="100%">Makki, I.</style></author><author><style face="normal" font="default" size="100%">Mapazire, E.</style></author><author><style face="normal" font="default" size="100%">Murng, S. H. K.</style></author><author><style face="normal" font="default" size="100%">Noorani, S.</style></author><author><style face="normal" font="default" size="100%">Savic, S.</style></author><author><style face="normal" font="default" size="100%">Steele, C. L.</style></author><author><style face="normal" font="default" size="100%">Symons, C.</style></author><author><style face="normal" font="default" size="100%">Tarzi, M.</style></author><author><style face="normal" font="default" size="100%">Yong, P. F. K.</style></author><author><style face="normal" font="default" size="100%">Kiani-Alikhan, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Barts Health NHS Trust, London, UK.&#xD;Royal Infirmary of Edinburgh, Edinburgh, UK.&#xD;Belfast Health and Social Care Trust, Belfast, UK.&#xD;University College London Hospitals NHS Foundation Trust, London, UK.&#xD;University Hospital of Wales, Cardiff, UK.&#xD;Manchester University NHS Foundation Trust, Manchester, UK.&#xD;North Bristol NHS Trust, Bristol, UK.&#xD;NHS Grampian, Aberdeen, UK.&#xD;Oxford University Hospitals NHS Foundation Trust, Oxford, UK.&#xD;Epsom and St Helier University Hospitals NHS Trust, Carshalton, UK.&#xD;Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.&#xD;St James&apos;s University Hospital, Leeds, UK.&#xD;NHS Tayside, Dundee, UK.&#xD;Plymouth Hospitals NHS Trust, Plymouth, UK.&#xD;Brighton and Sussex University Hospital NHS Trust, Brighton, UK.&#xD;Frimley Health NHS Foundation Trust, Frimley, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1369-1371</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/12/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Plasma Kallikrein</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36510404</style></accession-num><notes><style face="normal" font="default" size="100%">Dorr, Anthony D&#xD;Chopra, Charu&#xD;Coulter, Tanya I&#xD;Dempster, John&#xD;Dziadzio, Magdalena&#xD;El-Shanawany, Tariq&#xD;Garcez, Tomaz&#xD;Gompels, Mark&#xD;Herriot, Richard&#xD;Jain, Rashmi&#xD;Levi, Marcel&#xD;Lorenzo, Lorena&#xD;Makki, Inas&#xD;Mapazire, Elizabeth&#xD;Murng, Sai H K&#xD;Noorani, Sadia&#xD;Savic, Sinisa&#xD;Steele, Cathal L&#xD;Symons, Christine&#xD;Tarzi, Michael&#xD;Yong, Patrick F K&#xD;Kiani-Alikhan, Sorena&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1369-1371. doi: 10.1111/all.15620. Epub 2022 Dec 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36510404</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15620</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2986</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2986</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Deng, Y.</style></author><author><style face="normal" font="default" size="100%">Leib, N.</style></author><author><style face="normal" font="default" size="100%">Schnautz, S.</style></author><author><style face="normal" font="default" size="100%">Benfadal, S.</style></author><author><style face="normal" font="default" size="100%">Oldenburg, J.</style></author><author><style face="normal" font="default" size="100%">Bieber, T.</style></author><author><style face="normal" font="default" size="100%">Herrmann, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Skin Diseases, University Hospital Bonn, Bonn, Germany.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Bieber Dermatology Consulting, Bonn, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Langerhans Cell Modulation in Atopic Dermatitis Is TLR2/SOCS1-Dependent and JAK Inhibitor-Sensitive</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2586-2599</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Toll-Like Receptor 2/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/metabolism/immunology/etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Langerhans Cells/immunology/metabolism/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Suppressor of Cytokine Signaling 1 Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Janus Kinase Inhibitors/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Jak/stat</style></keyword><keyword><style face="normal" font="default" size="100%">Langerhans cells</style></keyword><keyword><style face="normal" font="default" size="100%">Tlr2</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under</style></keyword><keyword><style face="normal" font="default" size="100%">Germany&apos;s Excellence Strategy-EXC2151-390873048</style></keyword><keyword><style face="normal" font="default" size="100%">N.H. and N.L. were supported by</style></keyword><keyword><style face="normal" font="default" size="100%">CK-CARE. T.B. was speaker and/or consultant and/or Investigator for AbbVie,</style></keyword><keyword><style face="normal" font="default" size="100%">Affibody, Almirall, Amagma, AnaptysBio, AOBiom, Anergis, Apogee, Arena, Aristea,</style></keyword><keyword><style face="normal" font="default" size="100%">Artax, Asana Biosciences, ASLAN pharma, Astria, Attovia, BambusTx, Bayer Health,</style></keyword><keyword><style face="normal" font="default" size="100%">Belenos, BioVerSys, Bohringer-Ingelheim, Bristol-Myers Squibb, BYOME Labs,</style></keyword><keyword><style face="normal" font="default" size="100%">CellDex, Connect Pharma, Daichi-Sanyko, Dermavant, DICE Therapeutics, Domain</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, DS Pharma, EQRx, EMD Serono, Galderma, Galapagos, Glenmark, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Incyte, Innovaderm, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L&apos;Oreal, Mabylon,</style></keyword><keyword><style face="normal" font="default" size="100%">MSD, Medac, Micreos, Nektar, Nextech, Novartis, Numab, OM-Pharma, Ornavi,</style></keyword><keyword><style face="normal" font="default" size="100%">Overtone, Pfizer, Pierre Fabre, Protagonist Tx, Q32bio, RAPT, Samsung Bioepis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron, TIRmed, UCB, Union Therapeutics, UPStream Bio, and YUHAN. He is</style></keyword><keyword><style face="normal" font="default" size="100%">founder and chairman of the board of the non-profit biotech &quot;Davos Biosciences</style></keyword><keyword><style face="normal" font="default" size="100%">AG&quot; within the international Kuhne-Foundation and founder of the consulting firm</style></keyword><keyword><style face="normal" font="default" size="100%">&quot;Bieber Dermatology Consulting&quot;. J.O. has received research funding from Bayer,</style></keyword><keyword><style face="normal" font="default" size="100%">Biotest, CSL Behring, Octapharma, Pfizer, Swedish Orphan Biovitrum, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy, speakers bureau, honoraria, scientific advisory board, and travel</style></keyword><keyword><style face="normal" font="default" size="100%">expenses from Bayer, Biogen Idec, BioMarin, Biotest, Chugai, CSL Behring,</style></keyword><keyword><style face="normal" font="default" size="100%">Freeline, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Spark</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Swedish Orphan Biovitrum, and Takeda. All other authors have no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40631910</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Langerhans cells (LC) are epidermal dendritic cells building the skin&apos;s outermost immunological barrier and bridging innate and adaptive immune responses. Their sensing property of the microbiome via Toll-like receptors (TLR) is impaired in atopic dermatitis (AD). We hypothesize a desensitization of LC because of persistent Staphylococcus aureus exposure in AD and underlying mechanisms being TLR2-related. METHODS: Human LC generated from hematopoetic stem cells were desensitized via repetitive exposure to TLR2-ligands (priming) and compared to unprimed cells for their TLR-responsiveness. JAK inhibitors impact was evaluated. Maturation marker, migration marker and behavior, cytokine release, and downstream molecule regulation were addressed by flow cytometry, qPCR, and transwell and multiplex assays. RESULTS: Primed LC mimicked the LC behavior in AD skin, exhibiting desensitization toward TLR2-mediated activation monitored by impaired CD83/CD80/CD86 and MHCII expression as well as impaired regulation of chemokines CCR6 and CCR7, migration competence, and Th17-driving cytokines. IL-18 and IL-1beta were elevated under these conditions. Negative regulators of the TLR2 pathway, specifically SOCS1 and IRAKM, were significantly upregulated, whereas activating molecules were hardly affected. JAK inhibitors reduced SOCS1 expression in primed cells and restored activation markers CD83/80/86 and MHCII upon TLR2 engagement, but had no effect on IRAKM expression. CONCLUSION: Primed LC mimic the impaired LC-responsiveness toward TLR2 in AD skin. Our findings unravel a new direct contribution of LC to AD-associated IL-1beta and IL-18 under these conditions and shed light on the mechanistical role of SOCS1 and the mode of action of JAK inhibitors.</style></abstract><notes><style face="normal" font="default" size="100%">Deng, Yuxuan&#xD;Leib, Nicole&#xD;Schnautz, Sylvia&#xD;Benfadal, Said&#xD;Oldenburg, Johannes&#xD;Bieber, Thomas&#xD;Herrmann, Nadine&#xD;eng&#xD;Christine Kuhne - Center for Allergy Research and Education/&#xD;EXC2151-390873048/Deutsche Forschungsgemeinschaft/&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2586-2599. doi: 10.1111/all.16641. Epub 2025 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40631910</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444830</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16641</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2189</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2189</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmitt, J.</style></author><author><style face="normal" font="default" size="100%">Ehm, F.</style></author><author><style face="normal" font="default" size="100%">Vivirito, A.</style></author><author><style face="normal" font="default" size="100%">Wende, D.</style></author><author><style face="normal" font="default" size="100%">Batram, M.</style></author><author><style face="normal" font="default" size="100%">Loser, F.</style></author><author><style face="normal" font="default" size="100%">Menzer, S.</style></author><author><style face="normal" font="default" size="100%">Ludwig, M.</style></author><author><style face="normal" font="default" size="100%">Roessler, M.</style></author><author><style face="normal" font="default" size="100%">Seifert, M.</style></author><author><style face="normal" font="default" size="100%">Konig, C.</style></author><author><style face="normal" font="default" size="100%">Schulte, C.</style></author><author><style face="normal" font="default" size="100%">Buschmann, T.</style></author><author><style face="normal" font="default" size="100%">Hertle, D.</style></author><author><style face="normal" font="default" size="100%">Ballesteros, P.</style></author><author><style face="normal" font="default" size="100%">Bassler, S.</style></author><author><style face="normal" font="default" size="100%">Bertele, B.</style></author><author><style face="normal" font="default" size="100%">Bitterer, T.</style></author><author><style face="normal" font="default" size="100%">Riederer, C.</style></author><author><style face="normal" font="default" size="100%">Sobik, F.</style></author><author><style face="normal" font="default" size="100%">Kind, B.</style></author><author><style face="normal" font="default" size="100%">Abraham, S.</style></author><author><style face="normal" font="default" size="100%">Tesch, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine Carl Gustav Carus, Center for Evidence-Based Healthcare (ZEGV), TU Dresden, University Hospital, Dresden, Germany.&#xD;InGef-Institute for Applied Health Research GmbH Berlin, Berlin, Germany.&#xD;BARMER Institut fur Gesundheitssystemforschung (bifg), Berlin, Germany.&#xD;Vandage GmbH, Bielefeld, Germany.&#xD;Techniker Krankenkasse, Hamburg, Germany.&#xD;IKK classic, Dresden, Germany.&#xD;AOK PLUS, Dresden, Germany.&#xD;DAK-Gesundheit, Hamburg, Germany.&#xD;Department of Dermatology Faculty of Medicine Carl Gustav Carus, University Allergy Center, TU Dresden, Dresden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Large cohort study shows increased risk of developing atopic dermatitis after COVID-19 disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">232-234</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/07/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37469301</style></accession-num><notes><style face="normal" font="default" size="100%">Schmitt, Jochen&#xD;Ehm, Franz&#xD;Vivirito, Annika&#xD;Wende, Danny&#xD;Batram, Manuel&#xD;Loser, Friedrich&#xD;Menzer, Simone&#xD;Ludwig, Marion&#xD;Roessler, Martin&#xD;Seifert, Martin&#xD;Konig, Christina&#xD;Schulte, Claudia&#xD;Buschmann, Tilo&#xD;Hertle, Dagmar&#xD;Ballesteros, Pedro&#xD;Bassler, Stefan&#xD;Bertele, Barbara&#xD;Bitterer, Thomas&#xD;Riederer, Cordula&#xD;Sobik, Franziska&#xD;Kind, Barbara&#xD;Abraham, Susanne&#xD;Tesch, Falko&#xD;eng&#xD;Bundesministerium fur Gesundheit/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):232-234. doi: 10.1111/all.15827. Epub 2023 Jul 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37469301</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15827</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>886</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">886</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benamar, M.</style></author><author><style face="normal" font="default" size="100%">Charbonnier, L. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology, Boston Children&apos;s Hospital, Boston, MA, USA.&#xD;Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Large scale regulatory T cells screening</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">705-707</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/07/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*CRISPR-Cas Systems</style></keyword><keyword><style face="normal" font="default" size="100%">Forkhead Transcription Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">CRISPR-Cas9</style></keyword><keyword><style face="normal" font="default" size="100%">Foxp3</style></keyword><keyword><style face="normal" font="default" size="100%">Stability</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34293821</style></accession-num><notes><style face="normal" font="default" size="100%">Benamar, Mehdi&#xD;Charbonnier, Louis-Marie&#xD;eng&#xD;R01 AI153174/&#xD;News&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):705-707. doi: 10.1111/all.15019. Epub 2021 Jul 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34293821</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15019</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1548</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1548</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benamar, M.</style></author><author><style face="normal" font="default" size="100%">Charbonnier, L. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology, Boston Children&apos;s Hospital, Boston, MA, USA.&#xD;Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Large scale regulatory T cells screening</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">705-707</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/07/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*CRISPR-Cas Systems</style></keyword><keyword><style face="normal" font="default" size="100%">Forkhead Transcription Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">CRISPR-Cas9</style></keyword><keyword><style face="normal" font="default" size="100%">Foxp3</style></keyword><keyword><style face="normal" font="default" size="100%">Stability</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34293821</style></accession-num><notes><style face="normal" font="default" size="100%">Benamar, Mehdi&#xD;Charbonnier, Louis-Marie&#xD;eng&#xD;R01 AI153174/&#xD;News&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):705-707. doi: 10.1111/all.15019. Epub 2021 Jul 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34293821</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15019</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2961</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2961</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Frier Ruge, I.</style></author><author><style face="normal" font="default" size="100%">Rinnov, M. R.</style></author><author><style face="normal" font="default" size="100%">Liljendahl, M. S.</style></author><author><style face="normal" font="default" size="100%">Munk-Madsen, M. Z.</style></author><author><style face="normal" font="default" size="100%">Halling, A. S.</style></author><author><style face="normal" font="default" size="100%">Gerner, T.</style></author><author><style face="normal" font="default" size="100%">Ravn, N. H.</style></author><author><style face="normal" font="default" size="100%">Knudgaard, M. H.</style></author><author><style face="normal" font="default" size="100%">Trautner, S.</style></author><author><style face="normal" font="default" size="100%">Skov, L.</style></author><author><style face="normal" font="default" size="100%">Schlapbach, C.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author><author><style face="normal" font="default" size="100%">Egeberg, A.</style></author><author><style face="normal" font="default" size="100%">Jakasa, I.</style></author><author><style face="normal" font="default" size="100%">Kezic, S.</style></author><author><style face="normal" font="default" size="100%">Irvine, A.</style></author><author><style face="normal" font="default" size="100%">Ewertsen, C.</style></author><author><style face="normal" font="default" size="100%">Thyssen, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Venereology, Bispebjerg Hospital, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.&#xD;Department of Neonatology, Rigshospitalet, University of Copenhagen, Denmark.&#xD;Department of Radiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.&#xD;Laboratory for Analytical Chemistry, Department of Chemistry and Biochemistry, Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.&#xD;Coronel Institute of Occupational Health, Amsterdam Public Health Research Institute, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.&#xD;Clinical Medicine, Trinity, College Dublin, Dublin, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Large Thymus Size at 2 Months Is Associated With Increased Risk of Atopic Dermatitis at Age 2</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2600-2609</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/07/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/etiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Thymus Gland/diagnostic imaging/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Organ Size</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric</style></keyword><keyword><style face="normal" font="default" size="100%">predictor</style></keyword><keyword><style face="normal" font="default" size="100%">thymic</style></keyword><keyword><style face="normal" font="default" size="100%">thymus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40726247</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is driven by a complex interplay of skin barrier dysfunction and immune dysregulation, including a significant T-cell-mediated immune response. The thymus is the key organ of T cell receptor gene rearrangement and T-cell maturation in early life. This study investigated whether infant thymus size is associated with incident AD during the first 2 years of life. METHODS: Three hundred term newborns were followed clinically from birth until 2 years of age. Trans-sternal ultrasound scans of the thymus were performed at birth, 2 months, and 12 months. The thymic index was calculated and dichotomized at &gt;/= 90th percentile. Skin tape strips from the dorsal hand were analyzed for immune biomarkers. Hazard ratios (HR) with 95% confidence intervals (95% CI) were calculated for AD risk and early-onset AD. Multivariate analyses (aHR) were adjusted for sex, weight, height, breastfeeding, FLG mutation, and parental atopy. RESULTS: Of the 300 enrolled children, 290 (97%) were eligible for analyses. The 2-year cumulative prevalence of AD was 34.1% (95% CI: 28.7%-39.6%). A higher thymic index at 2 months was associated with increased AD risk during the first 2 years of life (HR: 3.51; 95% CI: [1.73-7.12]; p &lt; 0.001), (aHR: 6.32; 95% CI: [2.81-14.20]; p &lt; 0.001) and increased early-onset AD before 6 months (HR: 2.95; 95% CI: [1.29-6.76]; p = 0.01), (aHR: 5.35; 95% CI: [2.05-13.90]; p &lt; 0.001). A moderate correlation between thymic index and EASI (Eczema Area and Severity Index) was observed at 2 months of age (r = 0.39). CONCLUSION: Our findings indicate that increased thymic activity and T-cell development may be associated with a higher risk of AD onset, suggesting a potential role of early-life T-cell maturation in disease pathogenesis.</style></abstract><notes><style face="normal" font="default" size="100%">Frier Ruge, Iben&#xD;Rinnov, Maria Rasmussen&#xD;Liljendahl, Mie Sylow&#xD;Munk-Madsen, Maria Zurek&#xD;Halling, Anne-Sofie&#xD;Gerner, Trine&#xD;Ravn, Nina Haarup&#xD;Knudgaard, Mette Hjorslev&#xD;Trautner, Simon&#xD;Skov, Lone&#xD;Schlapbach, Christoph&#xD;Thomsen, Simon Francis&#xD;Egeberg, Alexander&#xD;Jakasa, Ivone&#xD;Kezic, Sanja&#xD;Irvine, Alan&#xD;Ewertsen, Caroline&#xD;Thyssen, Jacob P&#xD;eng&#xD;Novo Nordisk Fonden/&#xD;Kongelig Hofbuntmager Aage Bangs Fond/&#xD;LEO Fondet/&#xD;Lundbeck Foundation/&#xD;Herlev and Gentofte Hospital Research Foundation/&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2600-2609. doi: 10.1111/all.16673. Epub 2025 Jul 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40726247</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16673</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3156</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3156</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Glickman, J. W.</style></author><author><style face="normal" font="default" size="100%">David, E.</style></author><author><style face="normal" font="default" size="100%">Shokrian, N.</style></author><author><style face="normal" font="default" size="100%">Hawkins, K.</style></author><author><style face="normal" font="default" size="100%">Duca, E. D.</style></author><author><style face="normal" font="default" size="100%">Hu, B. D.</style></author><author><style face="normal" font="default" size="100%">Navrazhina, K.</style></author><author><style face="normal" font="default" size="100%">Carroll, B.</style></author><author><style face="normal" font="default" size="100%">Mishra, A.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y. D.</style></author><author><style face="normal" font="default" size="100%">Singer, G.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Large-Scale Blood Proteomic Analysis Across Different Inflammatory Skin Conditions Reveals Extensive Immune Dysregulation With Distinct Biomarker Profiles</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">bioinformatics</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">personalized medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41246813</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: While significant progress has been made in understanding the molecular characteristics of inflammatory skin diseases, their systemic impact warrants further investigation. A comprehensive large-scale study that examines systemic proteomic expression across the most common inflammatory skin diseases is currently lacking. METHODS: Serum from 38 alopecia areata/AA, 41 atopic dermatitis/AD, 21 psoriasis, 18 hidradenitis suppurativa/HS, and 25 vitiligo patients was analyzed using OLINK high-throughput multiplex assay explore panel and compared to 49 healthy-matched controls. Differentially expressed proteins/DEPs were defined using the criteria of fold change/|FCH| &gt; 1.2, FDR &lt; 0.1. Spearman analysis was also conducted to identify correlations between biomarkers and disease severity. Gene ontology of DEPs was performed using enrichr. RESULTS: Our results reveal both distinct and shared patterns of systemic dysregulation across the spectrum of inflammatory diseases. HS exhibited the highest level of dysregulation compared to healthy serum, followed by AA, AD, psoriasis, and vitiligo. The DEPs identified in HS showed the greatest overlap with those in psoriasis, while AA and AD also displayed significant similarity. HS and/or psoriasis primarily showed upregulation of markers belonging to T-cell activation/migration (interleukin/IL-2RA/CD40LG), innate immunity (IL-6/CXCL8/IL-8), Th1 (TNF/CXCL9/CXCL10), and Th17/22 (IL-17A/IL-20/CXCL1/LCN2) compared to normal. AA and/or AD were characterized by upregulation of markers of general inflammation (MMP12), T-cell activation/migration (IL-15/IL-16), T Helper 1/Th1 (IFNGR1/CXCL10), Th2 (IL-4R/CCL26/CCL27), Th17/22 (IL-19/IL-20/PI3) compared to controls. HS showed the largest dysregulation in cardiovascular/CV/atherosclerosis markers (PDGFA/SELP/MMP9) compared to controls (all FDR &lt; 0.05). Spearman analysis captured multiple positive correlations between key immune markers (IL-4R/OX40/TNFRSF4/IL-17A/TNF) and respective clinical severity scores (e.g., SALT, SCORAD, IHS4, PASI). CONCLUSIONS: Various inflammatory skin diseases show shared and distinct systemic protein immune activation. Overlap across conditions encourages the investigation of shared therapeutic approaches.</style></abstract><notes><style face="normal" font="default" size="100%">Glickman, Jacob W&#xD;David, Eden&#xD;Shokrian, Neda&#xD;Hawkins, Kelly&#xD;Duca, Ester Del&#xD;Hu, Benjamin D&#xD;Navrazhina, Kristina&#xD;Carroll, Britta&#xD;Mishra, Arnav&#xD;Estrada, Yeriel D&#xD;Singer, Giselle&#xD;Krueger, James G&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;Pfizer/&#xD;NH/NIH HHS/&#xD;Denmark&#xD;Allergy. 2025 Nov 17. doi: 10.1111/all.70157.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41246813</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70157</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>758</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">758</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Smith, A. M.</style></author><author><style face="normal" font="default" size="100%">Ramirez, R. M.</style></author><author><style face="normal" font="default" size="100%">Harper, N.</style></author><author><style face="normal" font="default" size="100%">Jimenez, F.</style></author><author><style face="normal" font="default" size="100%">Branum, A. P.</style></author><author><style face="normal" font="default" size="100%">Meunier, J. A.</style></author><author><style face="normal" font="default" size="100%">Pandranki, L.</style></author><author><style face="normal" font="default" size="100%">Carrillo, A.</style></author><author><style face="normal" font="default" size="100%">Winter, C.</style></author><author><style face="normal" font="default" size="100%">Winter, L.</style></author><author><style face="normal" font="default" size="100%">Rather, C. G.</style></author><author><style face="normal" font="default" size="100%">Ramirez, D. A.</style></author><author><style face="normal" font="default" size="100%">Andrews, C. P.</style></author><author><style face="normal" font="default" size="100%">Restrepo, M. I.</style></author><author><style face="normal" font="default" size="100%">Maselli, D. J.</style></author><author><style face="normal" font="default" size="100%">Pugh, J. A.</style></author><author><style face="normal" font="default" size="100%">Clark, R. A.</style></author><author><style face="normal" font="default" size="100%">Lee, G. C.</style></author><author><style face="normal" font="default" size="100%">Moreira, A. G.</style></author><author><style face="normal" font="default" size="100%">Manoharan, M. S.</style></author><author><style face="normal" font="default" size="100%">Okulicz, J. F.</style></author><author><style face="normal" font="default" size="100%">Jacobs, R. L.</style></author><author><style face="normal" font="default" size="100%">Ahuja, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Veterans Administration Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, Texas, USA.&#xD;Foundation for Advancing Veterans&apos; Health Research, South Texas Veterans Health Care System, San Antonio, Texas, USA.&#xD;Department of Microbiology, Immunology &amp; Molecular Genetics, UT Health San Antonio, San Antonio, Texas, USA.&#xD;Department of Medicine, UT Health San Antonio, San Antonio, Texas, USA.&#xD;Biogenics Research Chamber, San Antonio, Texas, USA.&#xD;Department of Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.&#xD;College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.&#xD;Pharmacotherapy Education and Research Center, School of Medicine, UT Health San Antonio, San Antonio, Texas, USA.&#xD;Division of Neonatology, Department of Pediatrics, UT Health San Antonio, San Antonio, Texas, USA.&#xD;Infectious Disease Service, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas, USA.&#xD;Department of Biochemistry and Structural Biology, UT Health San Antonio, San Antonio, Texas, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Large-scale provocation studies identify maladaptive responses to ubiquitous aeroallergens as a correlate of severe allergic rhinoconjunctivitis and asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1797-1814</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/10/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">T-cells</style></keyword><keyword><style face="normal" font="default" size="100%">aeroallergen challenge chamber</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">phenotypes</style></keyword><keyword><style face="normal" font="default" size="100%">declare that they have no relevant conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34606106</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic asthma (AA) and allergic rhinoconjunctivitis (ARC) are common comorbid environmentally triggered diseases. We hypothesized that severe AA/ARC reflects a maladaptive or unrestrained response to ubiquitous aeroallergens. METHODS: We performed provocation studies wherein six separate cohorts of persons (total n = 217) with ARC, with or without AA, were challenged once or more with fixed concentrations of seasonal or perennial aeroallergens in an aeroallergen challenge chamber (ACC). RESULTS: Aeroallergen challenges elicited fully or partially restrained vs. unrestrained evoked symptom responsiveness, corresponding to the resilient and adaptive vs. maladaptive AA/ARC phenotypes, respectively. The maladaptive phenotype was evoked more commonly during challenge with a non-endemic versus endemic seasonal aeroallergen. In an AA cohort, symptom responses evoked after house dust mite (HDM) challenges vs. recorded in the natural environment were more accurate and precise predictors of asthma severity and control, lung function (FEV1), and mechanistic correlates of maladaptation. Correlates included elevated levels of peripheral blood CD4+ and CD8+ T-cells, eosinophils, and T-cell activation, as well as gene expression proxies for ineffectual epithelial injury/repair responses. Evoked symptom severity after HDM challenge appeared to be more closely related to levels of CD4+ and CD8+ T-cells than eosinophils, neutrophils, or HDM-specific IgE. CONCLUSIONS: Provocation studies support the concept that resilience, adaptation, and maladaptation to environmental disease triggers calibrate AA/ARC severity. Despite the ubiquity of aeroallergens, in response to these disease triggers in controlled settings (ie, ACC), most atopic persons manifest the resilient or adaptive phenotype. Thus, ARC/AA disease progression may reflect the failure to preserve the resilient or adaptive phenotype. The triangulation of CD8+ T-cell activation, airway epithelial injury/repair processes and maladaptation in mediating AA disease severity needs more investigation.</style></abstract><notes><style face="normal" font="default" size="100%">Smith, Alisha M&#xD;Ramirez, Robert M&#xD;Harper, Nathan&#xD;Jimenez, Fabio&#xD;Branum, Anne P&#xD;Meunier, Justin A&#xD;Pandranki, Lavanya&#xD;Carrillo, Andrew&#xD;Winter, Caitlyn&#xD;Winter, Lauryn&#xD;Rather, Cynthia G&#xD;Ramirez, Daniel A&#xD;Andrews, Charles P&#xD;Restrepo, Marcos I&#xD;Maselli, Diego J&#xD;Pugh, Jacqueline A&#xD;Clark, Robert A&#xD;Lee, Grace C&#xD;Moreira, Alvaro G&#xD;Manoharan, Muthu Saravanan&#xD;Okulicz, Jason F&#xD;Jacobs, Robert L&#xD;Ahuja, Sunil K&#xD;eng&#xD;T32 DE014318/DE/NIDCR NIH HHS/&#xD;R37 AI046326/AI/NIAID NIH HHS/&#xD;UM1 TR004538/TR/NCATS NIH HHS/&#xD;K23 AG066933/AG/NIA NIH HHS/&#xD;IP1 CX000875/CX/CSRD VA/&#xD;UL1 TR002645/TR/NCATS NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1797-1814. doi: 10.1111/all.15124. Epub 2021 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34606106</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9298287</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15124</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1410</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1410</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Korotchenko, E.</style></author><author><style face="normal" font="default" size="100%">Schiessl, V.</style></author><author><style face="normal" font="default" size="100%">Scheiblhofer, S.</style></author><author><style face="normal" font="default" size="100%">Schubert, M.</style></author><author><style face="normal" font="default" size="100%">Dall, E.</style></author><author><style face="normal" font="default" size="100%">Joubert, I. A.</style></author><author><style face="normal" font="default" size="100%">Strandt, H.</style></author><author><style face="normal" font="default" size="100%">Neuper, T.</style></author><author><style face="normal" font="default" size="100%">Sarajlic, M.</style></author><author><style face="normal" font="default" size="100%">Bauer, R.</style></author><author><style face="normal" font="default" size="100%">Geppert, M.</style></author><author><style face="normal" font="default" size="100%">Joedicke, D.</style></author><author><style face="normal" font="default" size="100%">Wildner, S.</style></author><author><style face="normal" font="default" size="100%">Schaller, S.</style></author><author><style face="normal" font="default" size="100%">Winkler, S.</style></author><author><style face="normal" font="default" size="100%">Gadermaier, G.</style></author><author><style face="normal" font="default" size="100%">Horejs-Hoeck, J.</style></author><author><style face="normal" font="default" size="100%">Weiss, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biosciences, University of Salzburg, Salzburg, Austria.&#xD;Research and Development, University of Applied Biosciences Upper Austria, Hagenberg, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Laser-facilitated epicutaneous immunotherapy with hypoallergenic beta-glucan neoglycoconjugates suppresses lung inflammation and avoids local side effects in a mouse model of allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">210-222</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Lasers</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Ovalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">*Pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">*beta-Glucans</style></keyword><keyword><style face="normal" font="default" size="100%">dendritic cell targeting</style></keyword><keyword><style face="normal" font="default" size="100%">epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">glycoconjugates</style></keyword><keyword><style face="normal" font="default" size="100%">laser</style></keyword><keyword><style face="normal" font="default" size="100%">skin vaccination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32621318</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergen-specific immunotherapy via the skin targets a tissue rich in antigen-presenting cells, but can be associated with local and systemic side effects. Allergen-polysaccharide neoglycogonjugates increase immunization efficacy by targeting and activating dendritic cells via C-type lectin receptors and reduce side effects. OBJECTIVE: We investigated the immunogenicity, allergenicity, and therapeutic efficacy of laminarin-ovalbumin neoglycoconjugates (LamOVA). METHODS: The biological activity of LamOVA was characterized in vitro using bone marrow-derived dendritic cells. Immunogenicity and therapeutic efficacy were analyzed in BALB/c mice. Epicutaneous immunotherapy (EPIT) was performed using fractional infrared laser ablation to generate micropores in the skin, and the effects of LamOVA on blocking IgG, IgE, cellular composition of BAL, lung, and spleen, lung function, and T-cell polarization were assessed. RESULTS: Conjugation of laminarin to ovalbumin reduced its IgE binding capacity fivefold and increased its immunogenicity threefold in terms of IgG generation. EPIT with LamOVA induced significantly higher IgG levels than OVA, matching the levels induced by s.c. injection of OVA/alum (SCIT). EPIT was equally effective as SCIT in terms of blocking IgG induction and suppression of lung inflammation and airway hyperresponsiveness, but SCIT was associated with higher levels of therapy-induced IgE and TH2 cytokines. EPIT with LamOVA induced significantly lower local skin reactions during therapy compared to unconjugated OVA. CONCLUSION: Conjugation of ovalbumin to laminarin increased its immunogenicity while at the same time reducing local side effects. LamOVA EPIT via laser-generated micropores is safe and equally effective compared to SCIT with alum, without the need for adjuvant.</style></abstract><notes><style face="normal" font="default" size="100%">Korotchenko, Evgeniia&#xD;Schiessl, Viktoria&#xD;Scheiblhofer, Sandra&#xD;Schubert, Mario&#xD;Dall, Elfriede&#xD;Joubert, Isabella A&#xD;Strandt, Helen&#xD;Neuper, Theresa&#xD;Sarajlic, Muamera&#xD;Bauer, Renate&#xD;Geppert, Mark&#xD;Joedicke, David&#xD;Wildner, Sabrina&#xD;Schaller, Susanne&#xD;Winkler, Stephan&#xD;Gadermaier, Gabriele&#xD;Horejs-Hoeck, Jutta&#xD;Weiss, Richard&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):210-222. doi: 10.1111/all.14481. Epub 2020 Jul 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32621318</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7818228</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14481</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3089</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3089</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hashizume, H.</style></author><author><style face="normal" font="default" size="100%">Matsuura, A.</style></author><author><style face="normal" font="default" size="100%">Miyachi, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Future Wellness (endowed by Taica Co.), Shizuoka Graduate University of Public Health, Shizuoka, Japan.&#xD;Shizuoka Graduate University of Public Health, Shizuoka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Late-Onset Anaphylaxis and Tick Exposure: Epidemiological Insights From Shizuoka</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3209-3211</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/09/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40923631</style></accession-num><notes><style face="normal" font="default" size="100%">Hashizume, Hideo&#xD;Matsuura, Ammi&#xD;Miyachi, Yoshiki&#xD;eng&#xD;Japan Agency for Medical Research and Development (AMED)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3209-3211. doi: 10.1111/all.70049. Epub 2025 Sep 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40923631</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70049</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2968</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2968</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lisik, D.</style></author><author><style face="normal" font="default" size="100%">Backman, H.</style></author><author><style face="normal" font="default" size="100%">Basna, R.</style></author><author><style face="normal" font="default" size="100%">Hedman, L.</style></author><author><style face="normal" font="default" size="100%">Bashir, M. B. A.</style></author><author><style face="normal" font="default" size="100%">Ercan, S.</style></author><author><style face="normal" font="default" size="100%">Abohalaka, R.</style></author><author><style face="normal" font="default" size="100%">Ermis, S. S. O.</style></author><author><style face="normal" font="default" size="100%">Ekerljung, L.</style></author><author><style face="normal" font="default" size="100%">Stridsman, C.</style></author><author><style face="normal" font="default" size="100%">Winsa-Lindmark, S.</style></author><author><style face="normal" font="default" size="100%">Mincheva, R.</style></author><author><style face="normal" font="default" size="100%">Pullerits, T.</style></author><author><style face="normal" font="default" size="100%">Lotvall, J.</style></author><author><style face="normal" font="default" size="100%">Lindberg, A.</style></author><author><style face="normal" font="default" size="100%">Radinger, M.</style></author><author><style face="normal" font="default" size="100%">Ronmark, E.</style></author><author><style face="normal" font="default" size="100%">Kankaanranta, H.</style></author><author><style face="normal" font="default" size="100%">Nwaru, B. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.&#xD;Department of Public Health and Clinical Medicine, the OLIN and Sunderby Research Unit, Umea University, Umea, Sweden.&#xD;Division of Geriatric Medicine, Department of Clinical Sciences in Malmo, Lund University, Malmo, Sweden.&#xD;The Department of Clinical Neuroscience, Marianne Bernadotte Centrum, St: Erik&apos;s Eye Hospital, Karolinska Institutet, Stockholm, Sweden.&#xD;Respiratory Medicine and Allergy, Department of Internal Medicine &amp; Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.&#xD;Section of Allergology, Sahlgrenska University Hospital, Gothenburg, Sweden.&#xD;Tampere University Respiratory Research Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.&#xD;Department of Respiratory Medicine, Seinajoki Central Hospital, Seinajoki, Finland.&#xD;Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Late-Onset Asthma Phenotypes by Onset Age: A Cluster Analysis in Swedish Population-Based Cohorts</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3447-3451</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/07/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">personlized medicine</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work. Rani Basna reports consulting fees for this work from</style></keyword><keyword><style face="normal" font="default" size="100%">Krefting Research Center, University of Gothenburg. Reshed Abohalaka reports</style></keyword><keyword><style face="normal" font="default" size="100%">travel grants from the American Thoracic Society (ATS), the European Respiratory</style></keyword><keyword><style face="normal" font="default" size="100%">Society (ERS), the Swedish Heart and Lung Foundation (HLF), and the Adlerbertska</style></keyword><keyword><style face="normal" font="default" size="100%">foundations, outside the current work. Hannu Kankaanranta reports consulting fees</style></keyword><keyword><style face="normal" font="default" size="100%">unrelated to this work from AstraZeneca, Chiesi Pharma, COVIS Pharma, GSK, MSD,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Orion Pharma, Sanofi, as well as speakers&apos;/lecture/presentation fees</style></keyword><keyword><style face="normal" font="default" size="100%">unrelated to this work from AstraZeneca, Boehringer-Ingelheim, GSK, Orion Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">and Sanofi in the past 36 months. Caroline Stridsman has received personal and</style></keyword><keyword><style face="normal" font="default" size="100%">institutional fees from AstraZeneca, GSK, Chiesi, and TEVA outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. Anne Lindberg reports consulting fees from the Swedish Agency for Health</style></keyword><keyword><style face="normal" font="default" size="100%">Technology Assessment and Assessment of Social Services, for participation in an</style></keyword><keyword><style face="normal" font="default" size="100%">expert group for a systematic review on COPD, personal fees for lecturing from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, and personal fees for participation in advisory boards from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis, all outside the</style></keyword><keyword><style face="normal" font="default" size="100%">present work. The authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40704667</style></accession-num><notes><style face="normal" font="default" size="100%">Lisik, Daniil&#xD;Backman, Helena&#xD;Basna, Rani&#xD;Hedman, Linnea&#xD;Bashir, Muwada Bashir Awad&#xD;Ercan, Selin&#xD;Abohalaka, Reshed&#xD;Ermis, Saliha Selin Ozuygur&#xD;Ekerljung, Linda&#xD;Stridsman, Caroline&#xD;Winsa-Lindmark, Sofia&#xD;Mincheva, Roxana&#xD;Pullerits, Teet&#xD;Lotvall, Jan&#xD;Lindberg, Anne&#xD;Radinger, Madeleine&#xD;Ronmark, Eva&#xD;Kankaanranta, Hannu&#xD;Nwaru, Bright I&#xD;eng&#xD;VBG Group Herman Krefting Foundation for Allergy and Asthma Research/&#xD;ALFGBG-979095/Avtal om Lakarutbildning och Forskning, between the Swedish Government and the Vastra Gotaland County Council/&#xD;F2021-0041/Swedish Asthma &amp; Allergy Foundation/&#xD;20200832/Swedish Heart and Lung Foundation/&#xD;20220724/Swedish Heart and Lung Foundation/&#xD;2019-00247/Swedish Research Council/&#xD;2022-00381/FORTE/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3447-3451. doi: 10.1111/all.16680. Epub 2025 Jul 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40704667</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666743</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16680</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3274</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3274</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nagano, Naoko</style></author><author><style face="normal" font="default" size="100%">Tamari, Masato</style></author><author><style face="normal" font="default" size="100%">Yamamoto, Hiromichi</style></author><author><style face="normal" font="default" size="100%">Nakazaki, Hisataka</style></author><author><style face="normal" font="default" size="100%">Fujita, Satoshi</style></author><author><style face="normal" font="default" size="100%">Hayashi, Yuka</style></author><author><style face="normal" font="default" size="100%">Motomura, Kenichiro</style></author><author><style face="normal" font="default" size="100%">de Bruijn, Sanne Johanna Maria</style></author><author><style face="normal" font="default" size="100%">Arae, Ken</style></author><author><style face="normal" font="default" size="100%">Kubo, Terufumi</style></author><author><style face="normal" font="default" size="100%">Ikutani, Masashi</style></author><author><style face="normal" font="default" size="100%">Sudo, Katsuko</style></author><author><style face="normal" font="default" size="100%">Kage, Hidenori</style></author><author><style face="normal" font="default" size="100%">Saito, Hirohisa</style></author><author><style face="normal" font="default" size="100%">Nakae, Susumu</style></author><author><style face="normal" font="default" size="100%">Matsumoto, Kenji</style></author><author><style face="normal" font="default" size="100%">Akdis, Cezmi A.</style></author><author><style face="normal" font="default" size="100%">Morita, Hideaki</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Laundry Detergents Enhance Sensitization to Co-Inhaled Allergens and Exacerbate Airway Inflammation in Mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Our previous study demonstrated that laundry detergents induce group 2 innate lymphoid cell-driven eosinophilic airway inflammation by disrupting airway epithelial barriers and promoting IL-33 release, and that detergent residues are present in nearly all household dust. However, their impact on allergen-induced airway inflammation remains unclear. Methods C57BL/6 background mice were intranasally primed four times with ovalbumin (OVA) or house dust mite (HDM) allergens in the presence or absence of a commercial laundry detergent. Following priming, mice were challenged with the same antigen for 3 consecutive days and sacrificed the day after the final challenge. Bronchoalveolar lavage fluid (BALF) and sera were analyzed by ELISA. Lungs were evaluated histologically and analyzed by qPCR. Results Mice intranasally primed with antigen in the presence of detergent exhibited eosinophilic airway inflammation upon antigen challenge, accompanied by increased IL-5 and IL-13 levels in the BALF. Intranasal administration of detergent and antigen also stimulated antigen-specific IgE production. These detergent- and allergen-induced type 2 responses were significantly suppressed in Il33−/− and Il13−/− mice. Administration of an anti-IL-4 receptor α chain antibody during the challenge phase reduced eosinophil counts in the BALF and antigen-specific IgE levels in the serum. By contrast, anti-IL-33 antibody treatment during the challenge phase did not affect eosinophilic airway inflammation or antigen-specific IgE production. Conclusions Laundry detergents promote sensitization to co-inhaled allergens and exacerbate eosinophilic airway inflammation and antigen-specific IgE responses via IL-33 and IL-13. These findings suggest that detergents can act as adjuvants that facilitate airway sensitization.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70245</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70245</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1473</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1473</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Golden, D. B. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Johns Hopkins University, Baltimore, Maryland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends in allergy and immunology: Lawrence M. Lichtenstein</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2545-2546</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2019/05/11</style></edition><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31074498</style></accession-num><notes><style face="normal" font="default" size="100%">Golden, David B K&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Dec;74(12):2545-2546. doi: 10.1111/all.13859.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31074498</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13859</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1437</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1437</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Simon, H. U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pharmacology, University of Bern, Bern, Switzerland.&#xD;Institute of Biochemistry, Brandenburg Medical School, Neuruppin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergology and immunology: Alex Straumann</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">596-598</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/09/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36125318</style></accession-num><notes><style face="normal" font="default" size="100%">Simon, Hans-Uwe&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):596-598. doi: 10.1111/all.15520. Epub 2022 Sep 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36125318</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15520</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1450</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jahnsen, F. L.</style></author><author><style face="normal" font="default" size="100%">Johansen, F. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, University of Oslo and Oslo University Hospital, Oslo, Norway.&#xD;Department of Biosciences, University of Oslo, Oslo, Norway.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergology and immunology: Per Brandtzaeg - Pillar of mucosal immunology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2634-2635</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Mucous Membrane</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33752264</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract After graduating dental school,Per Brandtzaeg joined the Norwegian army for his mandatory national service. During his military service, he was able to workon gingivitis and his passionfor research was lit. In 1962,he obtained a Fulbright scholarship to joinFrederick W. Kraus’s laboratory at University of Alabama in Birmingham, where he became involved in the work on the immunological defense of human mucous membranes. His work was based on immunofluorescence for the localization of immunoglobulins and other proteins in human tissue sections.</style></abstract><notes><style face="normal" font="default" size="100%">Jahnsen, Frode L&#xD;Johansen, Finn-Eirik&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2634-2635. doi: 10.1111/all.14824. Epub 2021 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33752264</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14824</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3309</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3309</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Metz, M.</style></author><author><style face="normal" font="default" size="100%">Staubach, P.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Rhinology and Allergology Wiesbaden, Wiesbaden, Germany.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;Department of Dermatology and Allergology, Mainz University Medicine, Mainz, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergology/Immunology: Marcus Maurer (dagger)-Physician, Scientist, Allergist and Unbeatable Communicator</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/03/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41825956</style></accession-num><notes><style face="normal" font="default" size="100%">Klimek, Ludger&#xD;Metz, Martin&#xD;Staubach, Petra&#xD;Zuberbier, Torsten&#xD;eng&#xD;Denmark&#xD;Allergy. 2026 Mar 13. doi: 10.1111/all.70289.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41825956</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70289</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3288</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3288</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Berin, M. C.</style></author><author><style face="normal" font="default" size="100%">Jones, S. M.</style></author><author><style face="normal" font="default" size="100%">Kim, E. H.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children&apos;s Hospital, Little Rock, Arkansas, USA.&#xD;Department of Medicine and Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.&#xD;Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy &amp; Immunology: A. Wesley Burks, MD: Advocate for Children&apos;s Health Through Scientific Discovery</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/03/27</style></edition><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41891282</style></accession-num><notes><style face="normal" font="default" size="100%">Berin, M Cecilia&#xD;Jones, Stacie M&#xD;Kim, Edwin H&#xD;Sampson, Hugh A&#xD;eng&#xD;Denmark&#xD;Allergy. 2026 Mar 27. doi: 10.1111/all.70317.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41891282</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70317</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1470</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1470</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saito, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Research Institute for Child Health &amp; Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy &amp; Immunology: KImishige Ishizaka</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">12-13</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2018/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergy and Immunology/*history</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Japan</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30079562</style></accession-num><notes><style face="normal" font="default" size="100%">Saito, Hirohisa&#xD;eng&#xD;Biography&#xD;Historical Article&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Jan;74(1):12-13. doi: 10.1111/all.13589. Epub 2018 Aug 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30079562</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13589</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1996</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1996</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Akin, C.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Hartmann, K.</style></author><author><style face="normal" font="default" size="100%">Nilsson, G. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.&#xD;Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich, Germany.&#xD;Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Division of Allergy and Immunology, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy and Immunology-Dean D. Metcalfe</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1395-1396</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/01/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36704860</style></accession-num><notes><style face="normal" font="default" size="100%">Akin, Cem&#xD;Brockow, Knut&#xD;Hartmann, Karin&#xD;Nilsson, Gunnar P&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1395-1396. doi: 10.1111/all.15657. Epub 2023 Feb 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36704860</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15657</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1456</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1456</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ring, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.&#xD;Christine Kuhne Center for Allergy Research and Education (CK-Care), Hochgebirgsklinik, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Alain L. de Weck (1928-2013)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2409-2410</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2020/02/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32068888</style></accession-num><notes><style face="normal" font="default" size="100%">Ring, Johannes&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2020 Sep;75(9):2409-2410. doi: 10.1111/all.14237. Epub 2020 Mar 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32068888</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14237</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1442</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1442</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moretta, L.</style></author><author><style face="normal" font="default" size="100%">Sozzani, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Tumor Immunology, Bambino Gesu Children&apos;s Hospital, Rome, Italy.&#xD;Department Molecular Medicine, Sapienza University, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Alberto Mantovani, a visionary scientist unraveling the complexity of innate immunity in cancer and inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">886-888</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/11/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Neoplasms</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36373227</style></accession-num><notes><style face="normal" font="default" size="100%">Moretta, Lorenzo&#xD;Sozzani, Silvano&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):886-888. doi: 10.1111/all.15580. Epub 2022 Dec 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36373227</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15580</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1461</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1461</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Joseph, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Scientific Director, BioCryst Pharmaceuticals Inc, Durham, NC, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy and Immunology: Allen Kaplan</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3290-3292</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2020/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32496627</style></accession-num><notes><style face="normal" font="default" size="100%">Joseph, Kusumam&#xD;eng&#xD;Denmark&#xD;Allergy. 2020 Dec;75(12):3290-3292. doi: 10.1111/all.14431. Epub 2020 Jul 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32496627</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14431</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1279</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1279</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Gerth van Wijk, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Section of Allergology and Clinical Immunology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Anthony J. Frew-A true European advocate of allergology and clinical immunology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1285-1287</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">immune pathology</style></keyword><keyword><style face="normal" font="default" size="100%">occupational asthma</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33145774</style></accession-num><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Gerth van Wijk, Roy&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1285-1287. doi: 10.1111/all.14648. Epub 2020 Dec 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33145774</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14648</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1811</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1811</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Gerth van Wijk, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Section of Allergology and Clinical Immunology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Anthony J. Frew-A true European advocate of allergology and clinical immunology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1285-1287</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">immune pathology</style></keyword><keyword><style face="normal" font="default" size="100%">occupational asthma</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33145774</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Tony Frew (1955-2018) was a leading member of the British Society for Allergy and Clinical Immunology and was well-respected in the European and US scientific community. Prof. Frew’s outstanding aptitudes are evident from his academic achievements, teaching and research careers, and leadership and impact on the European Academy of Allergy and Clinical Immunology (EAACI).</style></abstract><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Gerth van Wijk, Roy&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1285-1287. doi: 10.1111/all.14648. Epub 2020 Dec 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33145774</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14648</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2813</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2813</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Gueant, J. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit and Research Group, Hospital Regional Universitario de Malaga, UMA-IBIMA-BIONAND, Malaga, Spain.&#xD;Allergy Unit, Verona University Hospital, Verona, Italy.&#xD;Inserm UMRS1256 NGERE and FHU ARRIMAGE, University of Lorraine and Regional University Hospital Center (CHRU) of Nancy, Nancy, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy and Immunology: Antonino Romano</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1180-1182</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/03/12</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40071440</style></accession-num><notes><style face="normal" font="default" size="100%">Torres, Maria J&#xD;Bonadonna, Patrizia&#xD;Gueant, Jean-Louis&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1180-1182. doi: 10.1111/all.16511. Epub 2025 Mar 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40071440</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16511</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1463</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1463</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author><author><style face="normal" font="default" size="100%">Hendler, P. N.</style></author><author><style face="normal" font="default" size="100%">Kraft, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Clemens von Pirquet</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1276-1277</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2019/11/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31733114</style></accession-num><notes><style face="normal" font="default" size="100%">Breiteneder, Heimo&#xD;Hendler, Petra-Natascha&#xD;Kraft, Dietrich&#xD;eng&#xD;Historical Article&#xD;News&#xD;Denmark&#xD;Allergy. 2020 May;75(5):1276-1277. doi: 10.1111/all.14115. Epub 2019 Dec 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31733114</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14115</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1454</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1454</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Szefler, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Breathing Institute, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Donald Y. M. Leung</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">724-726</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2019/08/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31465550</style></accession-num><abstract><style face="normal" font="default" size="100%">This issue is honoring Donald Leung, who is best known for his work in atopic dermatitis (AD), along with many other contributions in allergy and immunology. Donald was born October 1, 1949 in New York City. He received his PhD in biochemistry and MD at the University of Chicago. He subsequently went on to residency and fellowship at Children&apos;s Hospital Boston where he continued as a faculty member at Harvard Medical School until 1989. With Dr. Raif Geha, they studied the role of Th2 cells in allergic responses and he began work in Kawasaki&apos;s disease and AD. He made many relevant discoveries regarding Kawasaki Disease including its treatment with intravenous gamma globulin treatment for which he received a ten year NHLBI MERIT award.</style></abstract><notes><style face="normal" font="default" size="100%">Szefler, Stanley J&#xD;eng&#xD;U10 HL098075/HL/NHLBI NIH HHS/&#xD;UG1 HL139123/HL/NHLBI NIH HHS/&#xD;Denmark&#xD;Allergy. 2020 Mar;75(3):724-726. doi: 10.1111/all.14031. Epub 2019 Oct 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31465550</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7048641</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14031</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1475</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1475</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ferreira, F.</style></author><author><style face="normal" font="default" size="100%">Hubinger, G.</style></author><author><style face="normal" font="default" size="100%">Spangfort, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biosciences, University of Salzburg, Salzburg, Austria.&#xD;Pfizer Pharmaceuticals, Dubai, UAE.&#xD;Nobel Biosolutions Ltd, Hong Kong, Hong Kong.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy and Immunology: From a curious mind to a world class scientist-A brief biography of Professor T.P. King</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2014-2015</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2019/05/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/history</style></keyword><keyword><style face="normal" font="default" size="100%">*Famous Persons</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31125433</style></accession-num><notes><style face="normal" font="default" size="100%">Ferreira, Fatima&#xD;Hubinger, Gudrun&#xD;Spangfort, Michael D&#xD;eng&#xD;Biography&#xD;Historical Article&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Oct;74(10):2014-2015. doi: 10.1111/all.13917. Epub 2019 Jun 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31125433</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13917</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1457</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1457</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ring, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergology, Technical University Munich, Munich, Germany.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Hochgebirgsklinik, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Georg Rajka</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2709-2710</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2020/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">pruritus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32073670</style></accession-num><notes><style face="normal" font="default" size="100%">Ring, Johannes&#xD;eng&#xD;Denmark&#xD;Allergy. 2020 Oct;75(10):2709-2710. doi: 10.1111/all.14239. Epub 2020 Apr 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32073670</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14239</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1980</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1980</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Triggiani, M.</style></author><author><style face="normal" font="default" size="100%">Casolaro, V.</style></author><author><style face="normal" font="default" size="100%">Stellato, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Surgery and Dentistry &quot;Scuola Medica Salernitana&quot;, University of Salerno, Salerno, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy and Immunology: Gianni Marone</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1714-1716</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/03/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">histamine</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36934417</style></accession-num><notes><style face="normal" font="default" size="100%">Triggiani, Massimo&#xD;Casolaro, Vincenzo&#xD;Stellato, Cristiana&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1714-1716. doi: 10.1111/all.15718. Epub 2023 Mar 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36934417</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15718</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1443</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1443</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Passalacqua, G.</style></author><author><style face="normal" font="default" size="100%">Moretta, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, Genoa, Italy.&#xD;Immunology Area, Bambino Gesu Children&apos;s Hospital IRCCS, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Giorgio Walter Canonica-Physician, scientist, and visionary leader</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">695-697</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Physicians</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34610159</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Giorgio Walter (simply “Walter”) Canonica is one of the best-known Allergologists/Pulmunologists in the world. This since his major scientific contributions to the field, but also from his great capability of communicating science, together with his uncommon humanity and open mind. During the past 25 years, Walter has been a major influencer in Allergy not only as President of major International (and National) Societies, but also as the promoter of major advances in our understanding of Allergic Diseases, promoting major guidelines and establishing gold standards for therapeutic interventions.</style></abstract><notes><style face="normal" font="default" size="100%">Heffler, Enrico&#xD;Passalacqua, Giovanni&#xD;Moretta, Lorenzo&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):695-697. doi: 10.1111/all.15125. Epub 2021 Oct 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34610159</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15125</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1466</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1466</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wurtzen, P. A.</style></author><author><style face="normal" font="default" size="100%">Larsen, J. N.</style></author><author><style face="normal" font="default" size="100%">Ipsen, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ALK A/S, Horsholm, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Henning Lowenstein</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Allergy</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></alt-periodical><pages><style face="normal" font="default" size="100%">1203-1205</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2019/03/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens/*chemistry/*isolation &amp; purification/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Immunology/*history</style></keyword><keyword><style face="normal" font="default" size="100%">Alum Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*diagnosis/prevention &amp; control/*therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoelectrophoresis, Two-Dimensional/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines/chemistry/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30888698</style></accession-num><notes><style face="normal" font="default" size="100%">Wurtzen, Peter A&#xD;Larsen, Jorgen N&#xD;Ipsen, Henrik&#xD;eng&#xD;Historical Article&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Jun;74(6):1203-1205. doi: 10.1111/all.13781. Epub 2019 Apr 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30888698</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13781</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2409</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2409</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Morita, H.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Hirohisa Saito</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1629-1630</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/02/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/history</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38353283</style></accession-num><notes><style face="normal" font="default" size="100%">Morita, Hideaki&#xD;Matsumoto, Kenji&#xD;eng&#xD;Biography&#xD;Historical Article&#xD;News&#xD;Portrait&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1629-1630. doi: 10.1111/all.16057. Epub 2024 Feb 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38353283</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16057</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1459</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1459</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nowak-Wegrzyn, A.</style></author><author><style face="normal" font="default" size="100%">Berin, M. C.</style></author><author><style face="normal" font="default" size="100%">Sicherer, S. H.</style></author><author><style face="normal" font="default" size="100%">Burks, A. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy and Immunology, Department of Pediatrics, NYU Langone Health, Hassenfeld Children Hospital, New York, NY, USA.&#xD;Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.&#xD;Eliott and Roslyn Jaffe Food Allergy Institute, Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;University of North Carolina School of Medicine Health Care, Chapel Hill, NC, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Hugh A. Sampson</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1519-1521</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2019/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31659757</style></accession-num><notes><style face="normal" font="default" size="100%">Nowak-Wegrzyn, Anna&#xD;Berin, Maria Cecilia&#xD;Sicherer, Scott Howard&#xD;Burks, Arvil Wesley&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2020 Jun;75(6):1519-1521. doi: 10.1111/all.14094. Epub 2019 Dec 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31659757</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14094</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1081</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1081</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carballido, J. M.</style></author><author><style face="normal" font="default" size="100%">Spits, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Novartis Institutes for Biomedical Research, Translational Medicine, Preclinical Safety, Basel, Switzerland.&#xD;Department of Experimental Immunology, UMC, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Jan E. de Vries</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2924-2926</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/03/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword><keyword><style face="normal" font="default" size="100%">interleukins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33764534</style></accession-num><notes><style face="normal" font="default" size="100%">Carballido, Jose M&#xD;Spits, Hergen&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2924-2926. doi: 10.1111/all.14825. Epub 2021 Apr 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33764534</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14825</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1995</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1995</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carballido, J. M.</style></author><author><style face="normal" font="default" size="100%">Spits, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Novartis Institutes for Biomedical Research, Translational Medicine, Preclinical Safety, Basel, Switzerland.&#xD;Department of Experimental Immunology, UMC, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Jan E. de Vries</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2924-2926</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/03/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword><keyword><style face="normal" font="default" size="100%">interleukins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33764534</style></accession-num><notes><style face="normal" font="default" size="100%">Carballido, Jose M&#xD;Spits, Hergen&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2924-2926. doi: 10.1111/all.14825. Epub 2021 Apr 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33764534</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14825</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1430</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1430</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MACVIA-France, Montpellier, France.&#xD;Department of Dermatology and Allergy, Charite, Universitatsmedizin Berlin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Jean Julien Raoul Bousquet; a Chemist, a Pharmacist, a Biologist, a Physician and-above all-an innovative scientist</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">399-402</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/04/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacists</style></keyword><keyword><style face="normal" font="default" size="100%">*Physicians</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32294245</style></accession-num><notes><style face="normal" font="default" size="100%">Bedbrook, Anna&#xD;Zuberbier, Torsten&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):399-402. doi: 10.1111/all.14321. Epub 2020 Jun 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32294245</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14321</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1464</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1464</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boyce, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Brigham and Women&apos;s Hospital, Boston, MA, USA.&#xD;Department of Medicine, Harvard Medical School, Boston, MA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: K. Frank Austen</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1001-1002</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2019/09/29</style></edition><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31560800</style></accession-num><notes><style face="normal" font="default" size="100%">Boyce, Joshua A&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2020 Apr;75(4):1001-1002. doi: 10.1111/all.14066. Epub 2019 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31560800</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14066</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2444</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2444</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nunomura, S.</style></author><author><style face="normal" font="default" size="100%">Sugita, K.</style></author><author><style face="normal" font="default" size="100%">Arima, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Medical Biochemistry, Department of Biomolecular Sciences, Faculty of Medicine, Saga University, Saga, Japan.&#xD;Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.&#xD;Immunology Medical, Specialty Care Medical, Sanofi K.K., Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Kenji Izuhara</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2016-2018</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/03/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/history</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38456599</style></accession-num><notes><style face="normal" font="default" size="100%">Nunomura, Satoshi&#xD;Sugita, Kazunari&#xD;Arima, Kazuhiko&#xD;eng&#xD;Historical Article&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):2016-2018. doi: 10.1111/all.16097. Epub 2024 Mar 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38456599</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16097</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1805</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1805</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos-Wolfgang, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Kurt Blaser and major contributions to deciphering the role of T cells in allergic disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1393-1394</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/02/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">ENT (rhinitis, sinusitis, nasal polyps...)</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36718675</style></accession-num><notes><style face="normal" font="default" size="100%">Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1393-1394. doi: 10.1111/all.15648. Epub 2023 Jan 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36718675</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15648</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1445</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1445</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Fauci, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Personalized Medicine Asthma &amp; Allergy Unit, IRCCS Humanitas Research Hospital, Milan, Italy.&#xD;National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Lorenzo Moretta-Unfolding the mysteries of NK cells and much more</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3695-3696</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/09/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Killer Cells, Natural</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36125331</style></accession-num><notes><style face="normal" font="default" size="100%">Canonica, Giorgio Walter&#xD;Fauci, Anthony S&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3695-3696. doi: 10.1111/all.15519. Epub 2022 Sep 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36125331</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15519</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1460</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1460</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Legrand, Fanny</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Monique Capron</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">937-939</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><section><style face="normal" font="default" size="100%">937</style></section><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">0105-4538&#xD;1398-9995</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14501</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14501</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>867</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">867</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Niels Mygind</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3839-3840</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/history</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/history</style></keyword><keyword><style face="normal" font="default" size="100%">ENT (rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">common cold</style></keyword><keyword><style face="normal" font="default" size="100%">nasal corticosteroids</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps...)</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34363704</style></accession-num><notes><style face="normal" font="default" size="100%">Fokkens, Wytske J&#xD;eng&#xD;Biography&#xD;Historical Article&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3839-3840. doi: 10.1111/all.15040. Epub 2021 Aug 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34363704</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15040</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1816</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1816</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Niels Mygind</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3839-3840</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/history</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/history</style></keyword><keyword><style face="normal" font="default" size="100%">ENT (rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">common cold</style></keyword><keyword><style face="normal" font="default" size="100%">nasal corticosteroids</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps...)</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34363704</style></accession-num><notes><style face="normal" font="default" size="100%">Fokkens, Wytske J&#xD;eng&#xD;Biography&#xD;Historical Article&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3839-3840. doi: 10.1111/all.15040. Epub 2021 Aug 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34363704</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15040</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2591</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2591</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author><author><style face="normal" font="default" size="100%">Wiedermann, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Otto Scheiner</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2293-2294</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/07/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/history</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38953476</style></accession-num><notes><style face="normal" font="default" size="100%">Breiteneder, Heimo&#xD;Wiedermann, Ursula&#xD;eng&#xD;Historical Article&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2293-2294. doi: 10.1111/all.16217. Epub 2024 Jul 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38953476</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16217</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1462</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1462</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Creticos, P. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Johns Hopkins Division of Allergy and Clinical Immunology, Baltimore, MD, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Philip S. Norman</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1828-1829</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/01/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31950497</style></accession-num><notes><style face="normal" font="default" size="100%">Creticos, Peter S&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2020 Jul;75(7):1828-1829. doi: 10.1111/all.14183. Epub 2020 Feb 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31950497</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14183</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1444</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1444</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Caldas, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Scientific Director Inmunotek SL, Alcala de Henares, Spain.&#xD;Division of Allergy and Immunology, University of South Florida, Morsani College of Medicine, Tampa, Florida, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Richard F. Lockey</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2863-2865</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/06/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35661371</style></accession-num><notes><style face="normal" font="default" size="100%">Fernandez-Caldas, Enrique&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2863-2865. doi: 10.1111/all.15400. Epub 2022 Jun 22.</style></notes><work-type><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.15400</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35661371</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15400</style></electronic-resource-num><access-date><style face="normal" font="default" size="100%">2022/06/08</style></access-date></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1044</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1044</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kato, A.</style></author><author><style face="normal" font="default" size="100%">Stevens, W. W.</style></author><author><style face="normal" font="default" size="100%">Bochner, B. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.&#xD;Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Robert P. Schleimer</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3230-3232</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/04/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">ENT (rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergic disease</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps...)</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33864696</style></accession-num><notes><style face="normal" font="default" size="100%">Kato, Atsushi&#xD;Stevens, Whitney W&#xD;Bochner, Bruce S&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3230-3232. doi: 10.1111/all.14865. Epub 2021 May 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33864696</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14865</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1814</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1814</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kato, A.</style></author><author><style face="normal" font="default" size="100%">Stevens, W. W.</style></author><author><style face="normal" font="default" size="100%">Bochner, B. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.&#xD;Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Robert P. Schleimer</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3230-3232</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/04/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">ENT (rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergic disease</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps...)</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33864696</style></accession-num><notes><style face="normal" font="default" size="100%">Kato, Atsushi&#xD;Stevens, Whitney W&#xD;Bochner, Bruce S&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3230-3232. doi: 10.1111/all.14865. Epub 2021 May 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33864696</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14865</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1448</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1448</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maltese, G.</style></author><author><style face="normal" font="default" size="100%">Rasi, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Epsom and St Helier University Hospitals, Surrey, UK.&#xD;Unit for Metabolic Medicine, School of Cardiovascular Medicine &amp; Sciences, King&apos;s College London, London, UK.&#xD;Former Executive Director European Medicines Agency, University of Tor Vergata, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Sergio Bonini</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3227-3229</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/04/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33838049</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract In life, you are lucky if you meet people who can inspire and motivate. Sergio Bonini is one of those people. He can be regarded as a legend for his successful journey through the rapidly evolving discipline of Allergy and Clinical Immunology in the last 50 years.During his career Bonini has demonstrated to have an inquisitive mind that embraced new ideas. His work has provided insights into the understanding of allergic diseases and the role of IgE and his enthusiasm has been contagious among young scientists and physicians.</style></abstract><notes><style face="normal" font="default" size="100%">Maltese, Giuseppe&#xD;Rasi, Guido&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3227-3229. doi: 10.1111/all.14847. Epub 2021 May 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33838049</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14847</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1438</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1438</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maggi, E.</style></author><author><style face="normal" font="default" size="100%">Parronchi, P.</style></author><author><style face="normal" font="default" size="100%">Annunziato, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Sergio Romagnani</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">324-326</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/11/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36318520</style></accession-num><notes><style face="normal" font="default" size="100%">Maggi, Enrico&#xD;Parronchi, Paola&#xD;Annunziato, Francesco&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):324-326. doi: 10.1111/all.15570. Epub 2022 Nov 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36318520</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15570</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1439</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Corrigan, C. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Asthma, Allergy &amp; Lung Biology, MRC &amp; Asthma UK Centre in Allergic Mechanisms of Asthma, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy and immunology: Tak Lee</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">322-323</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/09/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36153793</style></accession-num><notes><style face="normal" font="default" size="100%">Corrigan, Chris J&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):322-323. doi: 10.1111/all.15530. Epub 2022 Sep 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36153793</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15530</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2910</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2910</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Joerg, L.</style></author><author><style face="normal" font="default" size="100%">Helbling, A.</style></author><author><style face="normal" font="default" size="100%">Hausmann, O.</style></author><author><style face="normal" font="default" size="100%">Yerly, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergology and Clinical Immunology, Department of Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Medbase Zentrum Bern, Bern, Switzerland.&#xD;Adverse Drug Reactions, Analysis and Consulting, ADR-AC GmbH, Bern, Switzerland.&#xD;Lowenpraxis Luzern, Lucerne, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy and Immunology: Werner Pichler</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2414-2416</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/05/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default" size="100%">p-i concept</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40387420</style></accession-num><notes><style face="normal" font="default" size="100%">Joerg, Lukas&#xD;Helbling, Arthur&#xD;Hausmann, Oliver&#xD;Yerly, Daniel&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2414-2416. doi: 10.1111/all.16597. Epub 2025 May 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40387420</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16597</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3329</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3329</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nilsson, G. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, and Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Solna, and Center for Molecular Medicine, Karolinska University Hospital, Solna, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy-Lawrence B. Schwartz</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/03/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 2</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41771804</style></accession-num><notes><style face="normal" font="default" size="100%">Nilsson, Gunnar P&#xD;eng&#xD;Denmark&#xD;Allergy. 2026 Mar 2. doi: 10.1111/all.70290.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41771804</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70290</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1453</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1453</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tsai, M.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, S.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, Stanford University School of Medicine, Stanford, California.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, California.&#xD;Division of Pulmonary and Critical Care Medicine and Division of Allergy, Immunology and Rheumatology, Stanford University, Stanford, California.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy: Stephen J. Galli</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">243-245</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2019/04/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergy and Immunology/*history</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*history</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30964544</style></accession-num><notes><style face="normal" font="default" size="100%">Tsai, Mindy&#xD;Chinthrajah, Sharon&#xD;Nadeau, Kari C&#xD;eng&#xD;Sean N. Parker Center for Allergy and Asthma Research at Stanford University/International&#xD;Biography&#xD;Historical Article&#xD;News&#xD;Portrait&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Jan;75(1):243-245. doi: 10.1111/all.13815. Epub 2019 Oct 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30964544</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13815</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1468</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1468</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scadding, G. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Royal National TNE Hospital, London.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy/ Immunology: Alfred William (Bill) Frankland</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Allergy</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></alt-periodical><pages><style face="normal" font="default" size="100%">380-381</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2018/09/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/history/trends</style></keyword><keyword><style face="normal" font="default" size="100%">England</style></keyword><keyword><style face="normal" font="default" size="100%">*Famous Persons</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30244495</style></accession-num><notes><style face="normal" font="default" size="100%">Scadding, Glenis K&#xD;eng&#xD;Biography&#xD;Historical Article&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Feb;74(2):380-381. doi: 10.1111/all.13612. Epub 2018 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30244495</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13612</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1472</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1472</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Larche, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Divisions of Clinical Immunology &amp; Allergy and Respirology, Department of Medicine, Firestone Institute for Respiratory Health, St. Joseph&apos;s Healthcare, McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy/immunology: A. Barry Kay</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Allergy</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></alt-periodical><pages><style face="normal" font="default" size="100%">1588-1590</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2019/03/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Famous Persons</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*etiology/history</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30924531</style></accession-num><notes><style face="normal" font="default" size="100%">Larche, Mark&#xD;eng&#xD;Biography&#xD;Historical Article&#xD;News&#xD;Portrait&#xD;Denmark&#xD;Allergy. 2019 Aug;74(8):1588-1590. doi: 10.1111/all.13799. Epub 2019 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30924531</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13799</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1469</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1469</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sanz, M. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergology and Clinical Immunology, University Clinic of Navarra, Pamplona, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy/Immunology: Albert K. Oehling</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">382-384</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2018/09/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/history/trends</style></keyword><keyword><style face="normal" font="default" size="100%">*Famous Persons</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Physicians</style></keyword><keyword><style face="normal" font="default" size="100%">Spain</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30204231</style></accession-num><notes><style face="normal" font="default" size="100%">Sanz, Maria L&#xD;eng&#xD;Biography&#xD;Historical Article&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Feb;74(2):382-384. doi: 10.1111/all.13601. Epub 2018 Oct 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30204231</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13601</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1474</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1474</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fieten, K. B.</style></author><author><style face="normal" font="default" size="100%">Knol, E. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.&#xD;Hochgebirgsklinik Davos, Davos, Switzerland.&#xD;Department of Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy/Immunology: Carla Bruijnzeel-Koomen</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">637-638</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2018/10/07</style></edition><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30291725</style></accession-num><notes><style face="normal" font="default" size="100%">Fieten, Karin B&#xD;Knol, Edward F&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Mar;74(3):637-638. doi: 10.1111/all.13627. Epub 2018 Nov 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30291725</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13627</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1477</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1477</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy/immunology: Dietrich Kraft</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1591-1593</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2019/04/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Austria</style></keyword><keyword><style face="normal" font="default" size="100%">*Famous Persons</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*etiology/history</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30964546</style></accession-num><notes><style face="normal" font="default" size="100%">Breiteneder, Heimo&#xD;eng&#xD;Biography&#xD;Historical Article&#xD;News&#xD;Portrait&#xD;Denmark&#xD;Allergy. 2019 Aug;74(8):1591-1593. doi: 10.1111/all.13816. Epub 2019 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30964546</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13816</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1478</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1478</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alkan, S. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Alkan Consulting, Basel, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy/immunology: Georges Kohler and the discovery of MONOCLONAL antibodies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1412-1414</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2019/03/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/history</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Famous Persons</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30920663</style></accession-num><notes><style face="normal" font="default" size="100%">Alkan, Sefik S&#xD;eng&#xD;Biography&#xD;Historical Article&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Jul;74(7):1412-1414. doi: 10.1111/all.13798. Epub 2019 Apr 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30920663</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13798</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1467</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1467</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Nilsson, G. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy/Immunology: Gunnar Johansson</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">635-636</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2018/09/24</style></edition><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30244486</style></accession-num><notes><style face="normal" font="default" size="100%">van Hage, Marianne&#xD;Nilsson, Gunnar P&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Mar;74(3):635-636. doi: 10.1111/all.13613. Epub 2018 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30244486</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13613</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1465</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1465</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bischoff, S. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy/immunology: John Bienenstock and mucosal immunity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">479-480</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2019/08/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Mucosal</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31376165</style></accession-num><notes><style face="normal" font="default" size="100%">Bischoff, Stephan C&#xD;eng&#xD;News&#xD;Portrait&#xD;Denmark&#xD;Allergy. 2020 Feb;75(2):479-480. doi: 10.1111/all.14006. Epub 2019 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31376165</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14006</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1458</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1458</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez-Diez, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">HIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy/immunology: Polly Matzinger</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2136-2138</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/01/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Famous Persons</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31960972</style></accession-num><notes><style face="normal" font="default" size="100%">Perez-Diez, Ainhoa&#xD;eng&#xD;Z99 AI999999/ImNIH/Intramural NIH HHS/&#xD;News&#xD;Research Support, N.I.H., Intramural&#xD;Denmark&#xD;Allergy. 2020 Aug;75(8):2136-2138. doi: 10.1111/all.14191. Epub 2020 Feb 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31960972</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7371501</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14191</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1471</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1471</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ludewig, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of allergy/immunology: Rolf Zinkernagel and the co-discovery of MHC restriction together with Peter Doherty</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1409-1411</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2019/03/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/history</style></keyword><keyword><style face="normal" font="default" size="100%">*Famous Persons</style></keyword><keyword><style face="normal" font="default" size="100%">*Histocompatibility Antigens/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">History, 20th Century</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30916402</style></accession-num><notes><style face="normal" font="default" size="100%">Ludewig, Burkhard&#xD;eng&#xD;Biography&#xD;Historical Article&#xD;Denmark&#xD;Allergy. 2019 Jul;74(7):1409-1411. doi: 10.1111/all.13796. Epub 2019 Apr 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30916402</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13796</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1476</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1476</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chapman, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Indoor Biotechnologies, Charlottesville, Virginia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legends of Allergy/Immunology: Thomas A.E. Platts-Mills</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">841-843</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2018/10/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">History, 21st Century</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30326142</style></accession-num><notes><style face="normal" font="default" size="100%">Chapman, Martin D&#xD;eng&#xD;Biography&#xD;Historical Article&#xD;News&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2019 Apr;74(4):841-843. doi: 10.1111/all.13633. Epub 2018 Nov 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30326142</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13633</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>118</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">118</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benito-Villalvilla, C.</style></author><author><style face="normal" font="default" size="100%">de la Rocha-Munoz, A.</style></author><author><style face="normal" font="default" size="100%">Lopez-Abente, J.</style></author><author><style face="normal" font="default" size="100%">Eggel, A.</style></author><author><style face="normal" font="default" size="100%">Bottoli, I.</style></author><author><style face="normal" font="default" size="100%">Severin, T.</style></author><author><style face="normal" font="default" size="100%">Woisetschlager, M.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.&#xD;Autonomous University of Madrid, Madrid, Spain.&#xD;Department of BioMedical Research, University of Bern, Bern, Switzerland.&#xD;Department of Rheumatology and Immunology, University Hospital of Bern, Bern, Switzerland.&#xD;Novartis Pharma AG, Basel, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-alpha production and FOXP3(+) Treg generation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1060-1072</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Forkhead Transcription Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgE/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 9/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon-alpha/biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36315052</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Ligelizumab is an anti-IgE monoclonal antibody binding IgE with higher affinity than omalizumab that is under clinical investigation for several IgE-mediated diseases. We previously showed that omalizumab removes IgE bound to FcepsilonRI on plasmacytoid dendritic cells (pDCs) and restores their ability to produce IFN-alpha and regulatory T cells (Tregs). The aim of this work is to investigate the capacity of ligelizumab to regulate functional properties of pDCs in comparison with omalizumab. METHODS: pDCs were isolated from atopic donors and IgE was detached from FcepsilonRI on pDCs with designed ankyrin repeat protein (DARPin) bi53-79. pDCs were resensitized with IgE alone or in the presence of ligelizumab or omalizumab prior to IgE-FcepsilonRI crosslinking and Toll-like receptor 9 (TLR9) stimulation. Flow cytometry, ELISA, coculture experiments and intranuclear staining were performed to determine cytokine production and Treg generation. An antigen-specific model of resensitization and IgE-crosslinking was also performed. RESULTS: The levels of serum total free IgE show a non-linear positive correlation with the frequency of IgE(+) pDCs displaying IgE bound to FcepsilonRI within the 43 individual donors included in the study. Ligelizumab displays stronger capacity than omalizumab to block the binding of free IgE to FcepsilonRI on human pDCs, resulting in a greater restoration of TLR9-L-induced IFN-alpha production. Ligelizumab also restores the ability of pDCs to generate FOXP3(+) Tregs as previously reported for omalizumab. CONCLUSIONS: The uncovered novel molecular mechanisms of ligelizumab to regulate functional properties of pDCs from atopic donors might have important clinical implications for anti-IgE treatments in different IgE-mediated diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Benito-Villalvilla, Cristina&#xD;de la Rocha-Munoz, Andres&#xD;Lopez-Abente, Jacobo&#xD;Eggel, Alexander&#xD;Bottoli, Ivan&#xD;Severin, Thomas&#xD;Woisetschlager, Maximilian&#xD;Palomares, Oscar&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):1060-1072. doi: 10.1111/all.15567. Epub 2022 Nov 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36315052</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15567</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1436</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1436</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stranzl, T.</style></author><author><style face="normal" font="default" size="100%">Ipsen, H.</style></author><author><style face="normal" font="default" size="100%">Christensen, L. H.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Johansen, N.</style></author><author><style face="normal" font="default" size="100%">Lund, K.</style></author><author><style face="normal" font="default" size="100%">Andersen, P. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ALK-Abello A/S, Horsholm, Denmark.&#xD;HICON, Hillerod, Denmark.&#xD;Division of Immunology and Allergy, Department of Pediatrics, Food allergy and Anaphylaxis Program, The Hospital for Sick Children, Toronto, Canada.&#xD;Research Institute, The Hospital for Sick Children, Translational Medicine program, Toronto, Canada.&#xD;Department of Immunology, University of Toronto, Toronto, Canada.&#xD;Papermill Medical, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Limited impact of Der p 23 IgE on treatment outcomes in tablet allergy immunotherapy phase III study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1235-1238</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/01/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Der p 23</style></keyword><keyword><style face="normal" font="default" size="100%">HDM SLIT-tablets</style></keyword><keyword><style face="normal" font="default" size="100%">cinical effect</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">employees of ALK A/S. KL is a consultant for ALK A/S.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31989625</style></accession-num><notes><style face="normal" font="default" size="100%">Stranzl, Thomas&#xD;Ipsen, Henrik&#xD;Christensen, Lars Harder&#xD;Eiwegger, Thomas&#xD;Johansen, Niels&#xD;Lund, Kaare&#xD;Andersen, Peter Sejer&#xD;eng&#xD;Clinical Trial, Phase III&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1235-1238. doi: 10.1111/all.14200. Epub 2020 Feb 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31989625</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246736</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14200</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2478</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2478</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ridge, K.</style></author><author><style face="normal" font="default" size="100%">Moran, B.</style></author><author><style face="normal" font="default" size="100%">Alvarado-Vazquez, P. A.</style></author><author><style face="normal" font="default" size="100%">Hallgren, J.</style></author><author><style face="normal" font="default" size="100%">Little, M. A.</style></author><author><style face="normal" font="default" size="100%">Irvine, A. D.</style></author><author><style face="normal" font="default" size="100%">O&apos;Farrelly, C.</style></author><author><style face="normal" font="default" size="100%">Dunne, J.</style></author><author><style face="normal" font="default" size="100%">Finlay, C. M.</style></author><author><style face="normal" font="default" size="100%">Conlon, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">UCARE Centre, Clinical and Diagnostic Immunology, St. James&apos;s Hospital, Dublin, Ireland.&#xD;Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland.&#xD;School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.&#xD;Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.&#xD;Trinity Kidney Centre, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, Dublin, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lin(-)CD117(+)CD34(+)FcepsilonRI(+) progenitor cells are increased in chronic spontaneous urticaria and predict clinical responsiveness to anti-IgE therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2423-2434</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/04/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, CD34/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, IgE/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Proto-Oncogene Proteins c-kit/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Allergic Agents/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Immunophenotyping</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Anti-Idiotypic/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">omics and systems biology</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38634175</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chronic spontaneous urticaria (CSU) is a common, debilitating skin disorder characterized by recurring episodes of raised, itchy and sometimes painful wheals lasting longer than 6 weeks. CSU is mediated by mast cells which are absent from peripheral blood. However, lineage(-)CD34(hi)CD117(int/hi)FcepsilonRI(+) cells in blood have previously been shown to represent a mast cell precursor. METHODS: We enumerated FcepsilonRI(-), FcepsilonRI(+) and FcepsilonRI(hi) lineage(-)CD34(+)CD117(+) cells using flow cytometry in blood of patients with CSU (n = 55), including 12 patients receiving omalizumab and 43 not receiving omalizumab (n = 43). Twenty-two control samples were studied. Disease control and patient response to omalizumab was evaluated using the urticaria control test. We performed single-cell RNA sequencing (scRNA-Seq) on lineage(-)CD34(hi)CD117(hi) blood cells from a subset of patients with CSU (n = 8) and healthy controls (n = 4). RESULTS: CSU patients had more lineage(-)CD34(+)CD117(+)FcepsilonRI(+) blood cells than controls. Lineage(-)CD34(+)CD117(+)FcepsilonRI(+) cells were significantly higher in patients with CSU who had an objective clinical response to omalizumab when compared to patients who had poor disease control 90 days after initiation of omalizumab. scRNA-Seq revealed that lineage(-)CD34(+)CD117(+)FcepsilonRI(+) cells contained both lymphoid and myeloid progenitor lineages, with omalizumab responsive patients having proportionally more myeloid progenitors. The myeloid progenitor lineage contained small numbers of true mast cell precursors along with more immature FcepsilonRI(-) and FcepsilonRI(+) myeloid progenitors. CONCLUSION: Increased blood CD34(+)CD117(+)FcepsilonRI(+) cells may reflect enhanced bone marrow egress in the setting of CSU. High expression of these cells strongly predicts better clinical responses to the anti-IgE therapy, omalizumab.</style></abstract><notes><style face="normal" font="default" size="100%">Ridge, Katie&#xD;Moran, Barry&#xD;Alvarado-Vazquez, P Abigail&#xD;Hallgren, Jenny&#xD;Little, Mark A&#xD;Irvine, Alan D&#xD;O&apos;Farrelly, Cliona&#xD;Dunne, Jean&#xD;Finlay, Conor M&#xD;Conlon, Niall&#xD;eng&#xD;Trinity College Dublin/&#xD;SFI_/Science Foundation Ireland/Ireland&#xD;HRBI_/Health Research Board/Ireland&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2423-2434. doi: 10.1111/all.16127. Epub 2024 Apr 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38634175</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16127</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2309</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2309</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tran, N. Q. V.</style></author><author><style face="normal" font="default" size="100%">Le, M. K.</style></author><author><style face="normal" font="default" size="100%">Nakamura, Y.</style></author><author><style face="normal" font="default" size="100%">Kondo, T.</style></author><author><style face="normal" font="default" size="100%">Nakao, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.&#xD;Department of Human Pathology, University of Yamanashi, Yamanashi, Japan.&#xD;Yamanashi GLIA Center, University of Yamanashi, Yamanashi, Japan.&#xD;Atopy Research Center, Juntendo University School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A link between KIT expression, mast cell abundance and activity, and Th2-high endotype in asthmatic airways</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1338-1342</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Proto-Oncogene Proteins c-kit/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells/immunology/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37984459</style></accession-num><notes><style face="normal" font="default" size="100%">Tran, Nguyen Quoc Vuong&#xD;Le, Minh-Khang&#xD;Nakamura, Yuki&#xD;Kondo, Tetsuo&#xD;Nakao, Atsuhito&#xD;eng&#xD;22K19427/The Ministry of Education, Culture, Sports, Science, and Technology, Japan/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1338-1342. doi: 10.1111/all.15954. Epub 2023 Nov 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37984459</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15954</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2895</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2895</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sanz-Rubio, D.</style></author><author><style face="normal" font="default" size="100%">Vera, E.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Sanz, J.</style></author><author><style face="normal" font="default" size="100%">Cubero, J.</style></author><author><style face="normal" font="default" size="100%">Langarita, R.</style></author><author><style face="normal" font="default" size="100%">Aguado, M.</style></author><author><style face="normal" font="default" size="100%">Pastor, L.</style></author><author><style face="normal" font="default" size="100%">Martin, L.</style></author><author><style face="normal" font="default" size="100%">Marin-Oto, M.</style></author><author><style face="normal" font="default" size="100%">Remacha, A. R.</style></author><author><style face="normal" font="default" size="100%">Ruiz, M.</style></author><author><style face="normal" font="default" size="100%">Gil, V.</style></author><author><style face="normal" font="default" size="100%">Domingo, J. A.</style></author><author><style face="normal" font="default" size="100%">Carretero, J. A.</style></author><author><style face="normal" font="default" size="100%">Marin, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Precision Medicine in Respiratory Diseases Group, IIS Aragon, HU Miguel Servet, Zaragoza, Spain.&#xD;Respiratory Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain.&#xD;University of Zaragoza, Zaragoza, Spain.&#xD;Tissue Microenvironment (TME) Lab, Aragon Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain.&#xD;Respiratory Medicine, Hospital Universitario Royo Villanova, Zaragoza, Spain.&#xD;CIBERES, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Linking Exosomal MicroRNA Signatures in Sputum and Peripheral Blood to Inflammatory Endotypes in Severe Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2073-2076</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/05/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">exosome</style></keyword><keyword><style face="normal" font="default" size="100%">extracellular vesicle</style></keyword><keyword><style face="normal" font="default" size="100%">microRNA</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40391775</style></accession-num><notes><style face="normal" font="default" size="100%">Sanz-Rubio, D&#xD;Vera, E&#xD;Rodriguez-Sanz, J&#xD;Cubero, J&#xD;Langarita, R&#xD;Aguado, M&#xD;Pastor, L&#xD;Martin, L&#xD;Marin-Oto, M&#xD;Remacha, A R&#xD;Ruiz, M&#xD;Gil, V&#xD;Domingo, J A&#xD;Carretero, J A&#xD;Marin, J M&#xD;eng&#xD;Externally Sponsored Scientific Research (ESR) AstraZeneca (ESR-20-20947)/&#xD;Health Research Institute of Aragon (IIS Aragon): &quot;Action supporting post-FSE contracts: translational research assistance IIS Aragon 2023&quot;/&#xD;Instituto de Salud Carlos III, Spanish Ministry of Health, Spain and the European Regional Development Fund (FEDER) (CD22/00033)/&#xD;Department of Science and Universities, Government of Aragon, Spain (CUS/1638/2022; B22_23R)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2073-2076. doi: 10.1111/all.16578. Epub 2025 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40391775</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16578</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2979</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2979</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Braskett, M.</style></author><author><style face="normal" font="default" size="100%">Goleva, E.</style></author><author><style face="normal" font="default" size="100%">Bronova, I.</style></author><author><style face="normal" font="default" size="100%">Bronoff, A. S.</style></author><author><style face="normal" font="default" size="100%">Lyubchenko, K.</style></author><author><style face="normal" font="default" size="100%">Nagendra, G.</style></author><author><style face="normal" font="default" size="100%">Warren, M.</style></author><author><style face="normal" font="default" size="100%">Shillingford, N.</style></author><author><style face="normal" font="default" size="100%">Cynamon, H.</style></author><author><style face="normal" font="default" size="100%">Alam, L.</style></author><author><style face="normal" font="default" size="100%">Bhardwaj, V.</style></author><author><style face="normal" font="default" size="100%">Hall, C. F.</style></author><author><style face="normal" font="default" size="100%">Durazo-Arvizu, R.</style></author><author><style face="normal" font="default" size="100%">Ong, P. Y.</style></author><author><style face="normal" font="default" size="100%">Berdyshev, E.</style></author><author><style face="normal" font="default" size="100%">Leung, D. Y. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Children&apos;s Hospital Los Angeles, Keck School of Medicine at USC, Los Angeles, California, USA.&#xD;Department of Pediatrics, National Jewish Health, Denver, Colorado, USA.&#xD;Department of Medicine, National Jewish Health, Denver, Colorado, USA.&#xD;Department of Pediatrics, Loma Linda University, Loma Linda, California, USA.&#xD;Department of Pathology, Children&apos;s Hospital Los Angeles, Keck School of Medicine at USC, Los Angeles, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lipidomic Analysis of Esophageal Epithelia Reveals a Distinctive Sphingolipid Profile in Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2849-2860</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/07/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/metabolism/diagnosis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Lipidomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Sphingolipids/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">*Esophageal Mucosa/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Esophagus/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">dihydroceramide desaturases</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">non-hydroxy fatty acid ceramides</style></keyword><keyword><style face="normal" font="default" size="100%">phytoceramides</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40673394</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Lipids play an essential role in epithelial barrier integrity. Despite increasing evidence of epithelial barrier dysfunction in eosinophilic esophagitis (EoE), the lipid composition of the esophageal epithelium is not characterized and any disruptions in EoE are unknown. METHODS: Esophageal brushings and biopsies were collected from patients (ages 1-19 years) who underwent clinically indicated esophagogastroduodenoscopy. Participants were classified based on the number of eosinophils per high-power field (eos/HPF) in esophageal biopsies into: an EoE group (&gt; 15 eos/HPF) and a control group (0-1 eos/HPF). Brushing samples were analyzed by targeted lipidomics using liquid chromatography tandem-mass spectrometry. The expression of inflammatory mediators and lipid biosynthesis enzymes was quantified by RT-PCR in esophageal biopsies and in a primary human esophageal epithelial cell line treated with IL-4/IL-13. RESULTS: EoE group had a significant increase in non-hydroxy fatty acid sphingosine ceramides (NS-CER) (p &lt; 0.01), and a decrease in non-hydroxy fatty acid phytoceramides (NP-CER) with 18-carbon sphingoid bases, resulting in selectively increased NS-CER/NP-CER ratios as compared to controls in esophageal brushes (Mean +/- SD: 5.0 +/- 1.9 vs. 1.6 +/- 1.2 p &lt; 0.01). EoE biopsies had significantly decreased expression of DEGS1 (p &lt; 0.01) and DEGS2 (p &lt; 0.05) mRNA, enzymes responsible for the biosynthesis of NS-CER and NP-CER. A significant inverse correlation between NS-CER/NP-CER and DEGS2/DEGS1 mRNA ratios (p &lt; 0.01) was observed. Conversely, a positive correlation between the NS-CER/NP-CER ratio and CCL26, IL-5, and IL-13 mRNA expression (p &lt; 0.05) was noted. IL-4/IL-13 significantly dysregulated the expression of DEGS1 and DEGS2 mRNA in a primary esophageal epithelial cell line. CONCLUSION: Distinctive abnormalities in esophageal epithelium sphingolipid composition and production were revealed in EoE. Mechanistic ex vivo data demonstrate dysregulation of lipid biosynthesis enzymes by IL-4/IL-13. The characteristic lipid profile in EoE has significant implications for epithelial barrier dysfunction and may serve as a biomarker of disease activity.</style></abstract><notes><style face="normal" font="default" size="100%">Braskett, Melinda&#xD;Goleva, Elena&#xD;Bronova, Irina&#xD;Bronoff, Anna Sofia&#xD;Lyubchenko, Katherine&#xD;Nagendra, Gautam&#xD;Warren, Mika&#xD;Shillingford, Nick&#xD;Cynamon, Harry&#xD;Alam, Lamia&#xD;Bhardwaj, Vrinda&#xD;Hall, Clifton F&#xD;Durazo-Arvizu, Ramon&#xD;Ong, Peck Y&#xD;Berdyshev, Evgeny&#xD;Leung, Donald Y M&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2849-2860. doi: 10.1111/all.16660. Epub 2025 Jul 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40673394</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16660</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2467</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2467</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cespedes, J. A.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Veguillas, A. A.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Fernandez Duarte, T. D.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Frecha, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;Medicine Department, Universidad de Malaga, Malaga, Spain.&#xD;RICORS Red de Enfermedades Inflamatorias (REI), Madrid, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;RETICS Asma, Reacciones Adversas y Alergicas (ARADYAL), Madrid, Spain.&#xD;Departamento de Biologia Celular, Genetica y Fisiologia, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lipopolysaccharides in combination with amoxicillin increases basophil activation test sensitivity to amoxicillin IgE-mediated hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2537-2542</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/04/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Amoxicillin/adverse effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/immunology/metabolism/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Lipopolysaccharides/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophil Degranulation Test/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38676446</style></accession-num><notes><style face="normal" font="default" size="100%">Cespedes, Jose A&#xD;Fernandez-Santamaria, Ruben&#xD;Bogas, Gador&#xD;Veguillas, Adriana Ariza&#xD;Dona, Inmaculada&#xD;Salas, Maria&#xD;Labella, Marina&#xD;Fernandez Duarte, Tahia D&#xD;Mayorga, Cristobalina&#xD;Torres, Maria J&#xD;Frecha, Cecilia A&#xD;eng&#xD;Consejeria de Salud y Bienestar Social, Junta de Andalucia/&#xD;Ministerio de Ciencia e Innovacion/&#xD;Instituto de Salud Carlos III/&#xD;European Commission/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2537-2542. doi: 10.1111/all.16133. Epub 2024 Apr 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38676446</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16133</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3249</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3249</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, Kyeongmin</style></author><author><style face="normal" font="default" size="100%">Kim, Tae Hyeon</style></author><author><style face="normal" font="default" size="100%">Lee, Sooji</style></author><author><style face="normal" font="default" size="100%">Lee, Hayeon</style></author><author><style face="normal" font="default" size="100%">Yon, Dong Keon</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Live Zoster Vaccination and Reduced Risk of Atopic Dermatitis and Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70272</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70272</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3075</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3075</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, T. H.</style></author><author><style face="normal" font="default" size="100%">Lee, K.</style></author><author><style face="normal" font="default" size="100%">Cho, J.</style></author><author><style face="normal" font="default" size="100%">Oh, J.</style></author><author><style face="normal" font="default" size="100%">Lee, S.</style></author><author><style face="normal" font="default" size="100%">Smith, L.</style></author><author><style face="normal" font="default" size="100%">Branda, F.</style></author><author><style face="normal" font="default" size="100%">Jung, J.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Yon, D. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.&#xD;Department of Medicine, CHA University School of Medicine, Seongnam, South Korea.&#xD;Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.&#xD;Department of Public Health, Faculty of Medicine, Biruni University, Istanbul, Turkey.&#xD;Unit of Medical Statistics and Molecular Epidemiology, Universita Campus Bio-Medico di Roma, Rome, Italy.&#xD;Department of Anatomy and Neurobiology, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea.&#xD;Department of Electronics and Information Convergence Engineering, Kyung Hee University, Yongin, South Korea.&#xD;Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Live Zoster Vaccination and the Reduced Risk of Chronic Respiratory Diseases: An Emulated Target Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">209-219</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/09/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Herpes Zoster Vaccine/administration &amp; dosage/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Republic of Korea/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">*Herpes Zoster/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Disease, Chronic Obstructive/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default" size="100%">chronic respiratory disease</style></keyword><keyword><style face="normal" font="default" size="100%">herpes zoster</style></keyword><keyword><style face="normal" font="default" size="100%">interstitial lung disease</style></keyword><keyword><style face="normal" font="default" size="100%">live zoster vaccination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40965002</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Recent previous study suggests that live zoster vaccination may reduce the risk of diseases like dementia and cardiovascular diseases, through prevention of herpes zoster. Thus, this study aims to evaluate whether live zoster vaccination can reduce the risk of chronic respiratory disease including chronic obstructive pulmonary disease (COPD), asthma, and interstitial lung disease (ILD). METHODS: This target trial emulation study utilized a nationwide, population-based cohort of 2,519,582 individuals aged &gt;/= 50 years in South Korea. The cohort was constructed by integrating health insurance data from the Korea Health Insurance Review and Assessment Service, national health examination data from the Korean National Health Insurance Service, and vaccination records from the Korea Disease Control and Prevention Agency. The exposure was receipt of at least one dose of live zoster vaccination between January 1, 2012, and December 31, 2021. Outcomes included the incidence of newly diagnosed COPD, asthma, and ILD, as well as hospitalizations associated with these conditions. Following stabilized inverse probability of treatment weighting, we employed the Cox proportional hazards model to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) and calculated restricted mean survival time (RMST) for the risk of outcomes associated with live zoster vaccination. The observation period extends from the index date to January 31, 2024. MEASUREMENTS AND MAIN RESULTS: After stabilized inverse probability of treatment weighting, 745,644 individuals were assigned to the vaccinated group and 1,069,230 to the unvaccinated group, with a mean age of 62.12 years (SD, 3.45) and 49.18% were male. Live zoster vaccination significantly reduced the risk of COPD (aHR, 0.70 [95% CI, 0.69-0.71]; RMST difference, 23.22 days [95% CI, 21.72-24.71]), asthma (0.68 [0.67-0.69]; 25.96 days [24.52-27.40]) and ILD (0.78 [0.73-0.82]; 2.39 days [2.05-2.74]). Additionally, the vaccination significantly reduced the risk of hospital admissions due to these conditions: COPD (0.59 [0.53-0.65]), asthma (0.54 [0.49-0.59]), and ILD (0.68 [0.58-0.79]). The observed protective benefit was more pronounced in non-smokers compared to current smokers. The time-attenuated effect was strongest during 1 to 2 years following live zoster vaccination and remained evident for up to 6 years. CONCLUSIONS: Live zoster vaccination significantly reduced the incidence of chronic respiratory disease and related hospitalizations. These findings suggest that live zoster vaccination may provide public health benefits beyond preventing herpes zoster in adults aged &gt;/= 50 years.</style></abstract><notes><style face="normal" font="default" size="100%">Kim, Tae Hyeon&#xD;Lee, Kyeongmin&#xD;Cho, Jaehyeong&#xD;Oh, Jiyeon&#xD;Lee, Sooji&#xD;Smith, Lee&#xD;Branda, Francesco&#xD;Jung, Junyang&#xD;Lee, Jinseok&#xD;Lee, Hayeon&#xD;Yon, Dong Keon&#xD;eng&#xD;IITP-2024-RS-2024-00438239/Ministry of Science and ICT, South Korea/&#xD;RS-2024-00509257/Ministry of Science and ICT, South Korea/&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):209-219. doi: 10.1111/all.70056. Epub 2025 Sep 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40965002</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773683</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70056</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>879</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">879</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lopez-Sanz, C.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author><author><style face="normal" font="default" size="100%">Ehlers, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-IP), Madrid, Spain.&#xD;Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain.&#xD;Department of Medicine, McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada.&#xD;Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.&#xD;Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Local inflammation enables a basophil-neuronal circuITCH in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">708-710</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/07/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">leukotriene C</style></keyword><keyword><style face="normal" font="default" size="100%">neuroimmunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34318483</style></accession-num><notes><style face="normal" font="default" size="100%">Lopez-Sanz, Celia&#xD;Jimenez-Saiz, Rodrigo&#xD;Ehlers, Anna M&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):708-710. doi: 10.1111/all.15026. Epub 2021 Aug 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34318483</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15026</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1886</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1886</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lopez-Sanz, C.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author><author><style face="normal" font="default" size="100%">Ehlers, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-IP), Madrid, Spain.&#xD;Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain.&#xD;Department of Medicine, McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada.&#xD;Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.&#xD;Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Local inflammation enables a basophil-neuronal circuITCH in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">708-710</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/07/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">leukotriene C</style></keyword><keyword><style face="normal" font="default" size="100%">neuroimmunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34318483</style></accession-num><notes><style face="normal" font="default" size="100%">Lopez-Sanz, Celia&#xD;Jimenez-Saiz, Rodrigo&#xD;Ehlers, Anna M&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):708-710. doi: 10.1111/all.15026. Epub 2021 Aug 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34318483</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15026</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>430</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">430</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Haruna, S.</style></author><author><style face="normal" font="default" size="100%">Takeda, K.</style></author><author><style face="normal" font="default" size="100%">El-Hussien, M. A.</style></author><author><style face="normal" font="default" size="100%">Maeda, Y.</style></author><author><style face="normal" font="default" size="100%">Hayama, M.</style></author><author><style face="normal" font="default" size="100%">Shikina, T.</style></author><author><style face="normal" font="default" size="100%">Doi, K.</style></author><author><style face="normal" font="default" size="100%">Inohara, H.</style></author><author><style face="normal" font="default" size="100%">Kikutani, H.</style></author><author><style face="normal" font="default" size="100%">Sakakibara, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Immune Regulation, Immunology Frontier Research Center, Osaka University, Osaka, Japan.&#xD;Department of Otolaryngology, Faculty of Medicine, Kindai University, Osaka, Japan.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.&#xD;Senri Nose Clinic, Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Local production of broadly cross-reactive IgE against multiple fungal cell wall polysaccharides in patients with allergic fungal rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3147-3151</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/06/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cell Wall</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Fungal Polysaccharides</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35716354</style></accession-num><notes><style face="normal" font="default" size="100%">Haruna, Soichiro&#xD;Takeda, Kazuya&#xD;El-Hussien, Marwa Ali&#xD;Maeda, Yohei&#xD;Hayama, Masaki&#xD;Shikina, Takashi&#xD;Doi, Katsumi&#xD;Inohara, Hidenori&#xD;Kikutani, Hitoshi&#xD;Sakakibara, Shuhei&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3147-3151. doi: 10.1111/all.15413. Epub 2022 Jun 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35716354</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15413</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1071</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1071</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Matsuyama, T.</style></author><author><style face="normal" font="default" size="100%">Machida, K.</style></author><author><style face="normal" font="default" size="100%">Motomura, Y.</style></author><author><style face="normal" font="default" size="100%">Takagi, K.</style></author><author><style face="normal" font="default" size="100%">Doutake, Y.</style></author><author><style face="normal" font="default" size="100%">Tanoue-Hamu, A.</style></author><author><style face="normal" font="default" size="100%">Kondo, K.</style></author><author><style face="normal" font="default" size="100%">Mizuno, K.</style></author><author><style face="normal" font="default" size="100%">Moro, K.</style></author><author><style face="normal" font="default" size="100%">Inoue, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.&#xD;Laboratory for Immune Cell Systems, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.&#xD;Laboratory for Innate Immune Systems, Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.&#xD;Laboratory for Innate Immune Systems, Immunology Frontier Research Center (iFReC), Osaka University, Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-acting muscarinic antagonist regulates group 2 innate lymphoid cell-dependent airway eosinophilic inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2785-2796</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/04/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Muscarinic Antagonists</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33792078</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tiotropium bromide, a long-acting muscarinic antagonist, reduces the frequency of exacerbation in patients with moderate to severe asthma, but its underlying mechanism is not clear. Asthma exacerbations are associated with exposure to external stimuli, and group 2 innate lymphoid cells (ILC2s) are considered to be involved in the pathophysiology of asthma exacerbation. We investigated whether tiotropium modulates airway inflammation through ILC2 functions. METHODS: Mice were administered papain intranasally to induce innate-type airway inflammation with or without tiotropium pretreatment, and bronchoalveolar lavage fluids (BALF) and lung tissues were collected. Lung-derived ILC2s and bone marrow-derived basophils were stimulated in vitro with IL-33 in the presence or absence of tiotropium. Muscarinic M3 receptor (M3R) expression on immune cells was assessed by RNA sequence. RESULTS: Papain induced airway eosinophilic inflammation, and tiotropium reduced the numbers of eosinophils in BALF. The concentrations of IL-4, IL-5, and IL-13, and the numbers of ILC2s in BALF were also reduced by tiotropium treatment. However, tiotropium did not affect IL-33-induced IL-5 and IL-13 production from ILC2s, suggesting that tiotropium regulates ILC2s indirectly. Gene-expression analysis showed that basophils predominantly expressed M3R mRNA among murine immune cells. Tiotropium reduced IL-4 production from basophils derived from mouse bone marrow and human basophils after stimulation with IL-33. CONCLUSIONS: These findings suggest that tiotropium attenuates ILC2-dependent airway inflammation by suppressing IL-4 production from basophils and, subsequently, regulating ILC2 activation. The inhibitory effects of long-acting muscarinic antagonists on the innate response may contribute to reducing asthma exacerbation.</style></abstract><notes><style face="normal" font="default" size="100%">Matsuyama, Takahiro&#xD;Machida, Kentaro&#xD;Motomura, Yasutaka&#xD;Takagi, Koichi&#xD;Doutake, Yoichi&#xD;Tanoue-Hamu, Asako&#xD;Kondo, Kiyotaka&#xD;Mizuno, Keiko&#xD;Moro, Kazuyo&#xD;Inoue, Hiromasa&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2785-2796. doi: 10.1111/all.14836. Epub 2021 Apr 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33792078</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14836</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1171</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1171</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cazzola, M.</style></author><author><style face="normal" font="default" size="100%">Calzetta, L.</style></author><author><style face="normal" font="default" size="100%">Matera, M. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental Medicine, University of Rome &quot;Tor Vergata&quot;, Rome, Italy.&#xD;Respiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.&#xD;Department of Experimental Medicine, University of Campania &quot;Luigi Vanvitelli&quot;, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-acting muscarinic antagonists and small airways in asthma: Which link?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1990-2001</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">*Muscarinic Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Muscarinic</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">long-acting mAChR antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">parasympathetic innervation</style></keyword><keyword><style face="normal" font="default" size="100%">small airways</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33559139</style></accession-num><abstract><style face="normal" font="default" size="100%">Involvement of small airways, those of &lt;2 mm in internal diameter, is present in all stages of asthma and contributes substantially to its pathophysiologic expression. Therefore, small airways are a potential target to achieve optimal asthma control. Airway tone, which is increased in asthma, is mainly controlled by the vagus nerve that releases acetylcholine (ACh) and activates muscarinic ACh receptors (mAChRs) post-synaptically on airway smooth muscle (ASM). In small airways, M(3) mAChRs are expressed, but there is no vagal innervation. Non-neuronal ACh released from the epithelial cells that may express choline acetyltransferase in response to inflammatory stimuli, as well as from other structural cells in the airways, including fibroblasts and mast cells, can activate mAChRs. By antagonizing M(3) mAChR, the contraction of the ASM is prevented and, potentially, local inflammation can be reduced and the progression of remodeling may be averted. In fact, ACh also contributes to inflammation and remodeling of the airways and regulates the growth of ASM. Several experimental studies have demonstrated the potential benefit derived from the use of mAChR antagonists, mainly long-acting mAChR antagonists (LAMAs), on small airways in asthma. However, there are several confounding factors that may cause a wrong estimation of the relationship between LAMAs and small airways in asthma. Further studies are needed to differentiate broncholytic and anti-inflammatory effects of LAMAs and to better understand the interaction between LAMAs and corticosteroids, also in the context of a triple therapy that includes a beta(2) -AR agonist, at different levels of the bronchial tree.</style></abstract><notes><style face="normal" font="default" size="100%">Cazzola, Mario&#xD;Calzetta, Luigino&#xD;Matera, Maria Gabriella&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):1990-2001. doi: 10.1111/all.14766. Epub 2021 Feb 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33559139</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14766</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2243</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2243</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kohanski, M. A.</style></author><author><style face="normal" font="default" size="100%">Qatanani, A.</style></author><author><style face="normal" font="default" size="100%">Lin, C.</style></author><author><style face="normal" font="default" size="100%">Tan, L. H.</style></author><author><style face="normal" font="default" size="100%">Chang, J.</style></author><author><style face="normal" font="default" size="100%">Corr, A.</style></author><author><style face="normal" font="default" size="100%">Herzberg, S.</style></author><author><style face="normal" font="default" size="100%">Adappa, N. D.</style></author><author><style face="normal" font="default" size="100%">Palmer, J. N.</style></author><author><style face="normal" font="default" size="100%">Reed, D. R.</style></author><author><style face="normal" font="default" size="100%">Bosso, J. V.</style></author><author><style face="normal" font="default" size="100%">Cohen, N. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology-Head and Neck Surgery, Division of Rhinology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.&#xD;Drexel School of Medicine, Philadelphia, Pennsylvania, USA.&#xD;Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA.&#xD;Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term aspirin desensitization has mucosal cytokine features of immune tolerance</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">507-509</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/09/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Aspirin/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37727998</style></accession-num><notes><style face="normal" font="default" size="100%">Kohanski, Michael A&#xD;Qatanani, Anas&#xD;Lin, Cailu&#xD;Tan, Li Hui&#xD;Chang, Jeremy&#xD;Corr, Andrew&#xD;Herzberg, Sabrina&#xD;Adappa, Nithin D&#xD;Palmer, James N&#xD;Reed, Danielle R&#xD;Bosso, John V&#xD;Cohen, Noam A&#xD;eng&#xD;American Rhinologic Society/&#xD;University of Pennsylvania/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):507-509. doi: 10.1111/all.15894. Epub 2023 Sep 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37727998</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15894</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3161</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3161</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Kong, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">He, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, W.</style></author><author><style face="normal" font="default" size="100%">Lu, Y.</style></author><author><style face="normal" font="default" size="100%">Meng, J.</style></author><author><style face="normal" font="default" size="100%">Yuan, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology-Head &amp; Neck Surgery, West China Hospital, Sichuan University, Chengdu, China.&#xD;Institute of Rare Diseases, West China Hospital, Sichuan University, Chengdu, China.&#xD;Allergy Center, West China Hospital, Sichuan University, Chengdu, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-Term Attenuation of Vascular Hyperpermeability in a Hereditary Angioedema Mouse Model by Adenine Base Editing</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Klkb1</style></keyword><keyword><style face="normal" font="default" size="100%">Serping1</style></keyword><keyword><style face="normal" font="default" size="100%">adenine base editing</style></keyword><keyword><style face="normal" font="default" size="100%">attenuation of vascular hyperpermeability</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 14</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41236489</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hereditary angioedema (HAE) is a rare and potentially life-threatening disorder caused by dysregulated kallikrein-kinin signaling and bradykinin-induced vascular hyperpermeability. Current therapies targeting this pathway are effective but require lifelong administration, underscoring the need for durable and potentially curative interventions. Adenine base editors (ABEs), engineered from CRISPR/Cas systems, enable precise single-nucleotide modifications with minimal genomic disruption, offering a promising strategy for long-term gene silencing. METHODS: NG-ABE8e was delivered via AAV8 or lipid nanoparticles (LNP) to disrupt the exon 2 splice donor site of Klkb1 in Serping1(+/-) mice. Editing outcomes were quantified by high-throughput sequencing; serum kallikrein levels were measured by ELISA; and vascular permeability was evaluated using Evans blue dye extravasation, fluorescent tracer leakage, and VE-cadherin immunostaining. Safety evaluations included off-target analysis, histopathology, serum biochemistry, activated partial thromboplastin time (aPTT), and systemic hemodynamic stability. RESULTS: AAV8-NG-ABE8e induced &gt; 60% A*T-to-G*C conversion at the target site, promoting exon 2 skipping and reducing Klkb1 mRNA and serum kallikrein levels by &gt; 85%, an effect sustained for at least 1 year. AAV8-NG-ABE8e also reversed bradykinin-driven vascular hyperpermeability and attenuated inflammatory gene signatures. Prolongation of aPTT was observed only when circulating kallikrein levels declined below 2 mug/mL. Similarly, LNP-mediated delivery of NG-ABE8e mRNA resulted in &gt; 90% reductions in Klkb1 expression and serum kallikrein levels. No evidence of significant long-term toxicity was detected. CONCLUSION: These findings demonstrate that, in a murine model, NG-ABE8e-mediated disruption of Klkb1 enables durable suppression of serum kallikrein and vascular stabilization, suggesting its potential as a promising single-intervention strategy for the treatment of HAE.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Yang&#xD;Kong, Yuxuan&#xD;Zhang, Yingjie&#xD;He, Yunjie&#xD;Wang, Wei&#xD;Lu, Yuanbin&#xD;Meng, Juan&#xD;Yuan, Huijun&#xD;eng&#xD;the National Natural Science Foundation of China/&#xD;West China Hospital, Sichuan University/&#xD;Denmark&#xD;Allergy. 2025 Nov 14. doi: 10.1111/all.70152.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41236489</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70152</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">351</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kauppila, T. K.</style></author><author><style face="normal" font="default" size="100%">Hinkkanen, V.</style></author><author><style face="normal" font="default" size="100%">Savinko, T.</style></author><author><style face="normal" font="default" size="100%">Karisola, P.</style></author><author><style face="normal" font="default" size="100%">Kukkonen, A. K.</style></author><author><style face="normal" font="default" size="100%">Paassilta, M.</style></author><author><style face="normal" font="default" size="100%">Pelkonen, A. S.</style></author><author><style face="normal" font="default" size="100%">Makela, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Helsinki, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.&#xD;University of Helsinki, Helsinki, Finland.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.&#xD;New Children&apos;s Hospital, Helsinki, Finland.&#xD;Allergy Center, Tampere University Hospital, Tampere, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term changes in milk component immunoglobulins reflect milk oral immunotherapy outcomes in Finnish children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">454-463</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/08/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Caseins</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Finland</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity/therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin A, Secretory</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">cow&apos;s milk allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulins</style></keyword><keyword><style face="normal" font="default" size="100%">long-term follow-up</style></keyword><keyword><style face="normal" font="default" size="100%">milk components</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Finland, and PK reports personal grant from the Finnish Cultural Foundation</style></keyword><keyword><style face="normal" font="default" size="100%">(00210499). All other authors have no conflict of interest within the scope of</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35969113</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Milk oral immunotherapy (OIT) may increase the amount of milk protein that can be ingested without triggering an allergic reaction. It is important to understand why some patients benefit from the treatment while others do not. OBJECTIVE: The aim was to define the differences in the milk allergen component-specific (casein, alpha-lactalbumin, ss-lactoglobulin) immunoglobulin (sIg [sIgE, sIgG4, and sIgA]) levels relative to the long-term outcomes of milk OIT. METHODS: In this long-term, open-label follow-up study, 286 children started milk OIT between 2005 and 2015. Follow-up data were collected at two points: the post-buildup phase and long term (range 1-11 years, median 6 years). Comparisons of sIg levels were made among three outcome groups of self-reported long-term milk consumption (high-milk dose, low-milk dose, and avoidance). RESULTS: A total of 168 (59%) of the 286 patients on OIT participated. Most patients (57%) were in the high-dose group; here, 80% of these patients had a baseline casein sIgE value less than 28 kUA/L, they had the lowest casein sIgE levels at all time (p &lt; .001), their casein sIgG4/IgE levels increased, and long-term casein sIgA was highest compared with the low-dose and avoidance groups (p = .02). Low-milk dose group had the highest casein sIgG4/IgE levels in long term (p = .002). CONCLUSION: The baseline Ig profiles and responses to milk OIT differed depending on long-term milk consumption. Lower casein sIgE levels were associated with better outcome. Milk casein sIgA differed in the long term among high-milk consumers.</style></abstract><notes><style face="normal" font="default" size="100%">Kauppila, Tiina Kaisa&#xD;Hinkkanen, Victoria&#xD;Savinko, Terhi&#xD;Karisola, Piia&#xD;Kukkonen, Anna Kaarina&#xD;Paassilta, Marita&#xD;Pelkonen, Anna S&#xD;Makela, Mika J&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):454-463. doi: 10.1111/all.15479. Epub 2022 Aug 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35969113</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087274</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15479</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>978</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">978</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ahearn-Ford, S.</style></author><author><style face="normal" font="default" size="100%">Lunjani, N.</style></author><author><style face="normal" font="default" size="100%">McSharry, B.</style></author><author><style face="normal" font="default" size="100%">MacSharry, J.</style></author><author><style face="normal" font="default" size="100%">Fanning, L.</style></author><author><style face="normal" font="default" size="100%">Murphy, G.</style></author><author><style face="normal" font="default" size="100%">Everard, C.</style></author><author><style face="normal" font="default" size="100%">Barry, A.</style></author><author><style face="normal" font="default" size="100%">McGreal, A.</style></author><author><style face="normal" font="default" size="100%">Al Lawati, S. M.</style></author><author><style face="normal" font="default" size="100%">Lapthorne, S.</style></author><author><style face="normal" font="default" size="100%">Sherlock, C.</style></author><author><style face="normal" font="default" size="100%">McKeogh, A.</style></author><author><style face="normal" font="default" size="100%">Jackson, A.</style></author><author><style face="normal" font="default" size="100%">Faller, E.</style></author><author><style face="normal" font="default" size="100%">Horgan, M.</style></author><author><style face="normal" font="default" size="100%">Sadlier, C.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;School of Microbiology, University College Cork, Cork, Ireland.&#xD;Department of Medicine, University College Cork, Cork, Ireland.&#xD;Department of Infectious Diseases, Cork University Hospital, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term disruption of cytokine signalling networks is evident in patients who required hospitalization for SARS-CoV-2 infection</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2910-2913</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">interleukins</style></keyword><keyword><style face="normal" font="default" size="100%">of the study</style></keyword><keyword><style face="normal" font="default" size="100%">grants from GSK</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from PrecisionBiotics, outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work. None of the other authors report any conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34028045</style></accession-num><notes><style face="normal" font="default" size="100%">Ahearn-Ford, Sinead&#xD;Lunjani, Nonhlanhla&#xD;McSharry, Brian&#xD;MacSharry, John&#xD;Fanning, Liam&#xD;Murphy, Gerard&#xD;Everard, Cormac&#xD;Barry, Aoife&#xD;McGreal, Aimee&#xD;Al Lawati, Sultan Mohamed&#xD;Lapthorne, Susan&#xD;Sherlock, Colin&#xD;McKeogh, Anna&#xD;Jackson, Arthur&#xD;Faller, Eamonn&#xD;Horgan, Mary&#xD;Sadlier, Corinna&#xD;O&apos;Mahony, Liam&#xD;eng&#xD;12/RC/2273-P2/SFI_/Science Foundation Ireland/Ireland&#xD;20/COV/0158/SFI_/Science Foundation Ireland/Ireland&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2910-2913. doi: 10.1111/all.14953. Epub 2021 Jun 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34028045</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8222932</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14953</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3152</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3152</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Testera-Montes, A.</style></author><author><style face="normal" font="default" size="100%">Zubiaga-Fernandez, L.</style></author><author><style face="normal" font="default" size="100%">Aranda, C. J.</style></author><author><style face="normal" font="default" size="100%">Garcia-Esteban, I.</style></author><author><style face="normal" font="default" size="100%">Gaitan-Nievas, T. I.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Torralvo, D.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Group, IBIMA-Plataforma BIONAND, RICORS Inflammatory Diseases, Malaga, Spain.&#xD;Department of Medicine and Dermatology, University of Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-Term Effect of Allergen Immunotherapy in Responder Local Allergic Rhinitis Patients: Symptom Control, and Prevention of Asthma and Allergic Sensitizations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">local allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">long-term effect</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 19</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41258979</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Clinical trials (CTs) have shown that allergen immunotherapy (AIT) is effective for local allergic rhinitis (LAR) while treatment is ongoing. However, its long-term effects remain unknown. This study investigates the long-term clinical and preventive effect of AIT in responder LAR patients. METHODS: LAR patients obtaining a clinical benefit from 1-year CT of subcutaneous AIT were enrolled in this 10-year follow-up study (AIT cohort). All completed a full 3-year AIT course and were followed for additional 7 years. A matched group of LAR patients who did not receive AIT (non-AIT cohort) was followed over the same period. Primary outcomes included nasal-ocular symptom scores (visual analogue scale, VAS), reliever medication use and medication-free days (MFD). Secondary outcomes were asthma incidence, asthma control (asthma control test, ACT), lung function (FEV(1)), quality of life (QoL), emergency visits, new sensitizations detected by nasal allergen challenge (NAC), and the analysis of the minimal clinically important difference (MCID). Assessments were conducted at baseline and at years 1, 3, 5, 7, and 10. RESULTS: Sixty-six patients were included (AIT n = 32; non-AIT n = 34). The AIT cohort showed a sustained reduction in nasal-ocular symptoms from year 1 (p &lt; 0.001) and significantly more MFD from year 3 (p &lt; 0.001). Asthma developed in 40.7% of non-AIT vs. 8.0% of AIT patients (p = 0.021). New sensitizations occurred in 38.2% of non-AIT and 6.3% of AIT patients (p = 0.002). FEV(1) improved in the AIT cohort and declined in non-AIT (p &lt; 0.001). QoL and emergency visits also favored AIT. CONCLUSION: AIT induces a sustained clinical improvement and prevents the onset of asthma and local sensitizations in responder LAR patients.</style></abstract><notes><style face="normal" font="default" size="100%">Testera-Montes, Almudena&#xD;Zubiaga-Fernandez, Laura&#xD;Aranda, Carlos J&#xD;Garcia-Esteban, Irene&#xD;Gaitan-Nievas, Trinidad Ilda&#xD;Sanchez-Torralvo, Dulce&#xD;Mayorga, Cristobalina&#xD;Torres, Maria J&#xD;Eguiluz-Gracia, Ibon&#xD;Rondon, Carmen&#xD;eng&#xD;European Commission/&#xD;Instituto de Salud Carlos III/&#xD;Consejeria de Salud y Familias, Junta de Andalucia/&#xD;Universidad de Malaga/CBUA/&#xD;Denmark&#xD;Allergy. 2025 Nov 19. doi: 10.1111/all.70153.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41258979</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70153</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>499</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">499</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hollstein, M. M.</style></author><author><style face="normal" font="default" size="100%">Munsterkotter, L.</style></author><author><style face="normal" font="default" size="100%">Schon, M. P.</style></author><author><style face="normal" font="default" size="100%">Bergmann, A.</style></author><author><style face="normal" font="default" size="100%">Husar, T. M.</style></author><author><style face="normal" font="default" size="100%">Abratis, A.</style></author><author><style face="normal" font="default" size="100%">Eidizadeh, A.</style></author><author><style face="normal" font="default" size="100%">Dierks, S.</style></author><author><style face="normal" font="default" size="100%">Schaffrinski, M.</style></author><author><style face="normal" font="default" size="100%">Zachmann, K.</style></author><author><style face="normal" font="default" size="100%">Schmitz, A.</style></author><author><style face="normal" font="default" size="100%">Holsapple, J. S.</style></author><author><style face="normal" font="default" size="100%">Stanisz-Bogeski, H.</style></author><author><style face="normal" font="default" size="100%">Schanz, J.</style></author><author><style face="normal" font="default" size="100%">Fischer, A.</style></author><author><style face="normal" font="default" size="100%">Gross, U.</style></author><author><style face="normal" font="default" size="100%">Leha, A.</style></author><author><style face="normal" font="default" size="100%">Zautner, A. E.</style></author><author><style face="normal" font="default" size="100%">Schnelle, M.</style></author><author><style face="normal" font="default" size="100%">Erpenbeck, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Venereology and Allergology, University Medical Center Gottingen, Gottingen, Germany.&#xD;Institute of Medical Microbiology and Virology, University Medical Center Gottingen, Gottingen, Germany.&#xD;Lower Saxony Institute of Occupational Dermatology, University Medical Center Gottingen, Gottingen, Germany.&#xD;Institute for Clinical Chemistry, University Medical Center Gottingen, Gottingen, Germany.&#xD;Department of Dermatology, University of Munster, Munster, Germany.&#xD;Department of Hematology and Medical Oncology, University Medical Center Gottingen, Gottingen, Germany.&#xD;Division Vascular Signaling and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.&#xD;Department of Medical Statistics, University Medical Center Gottingen, Gottingen, Germany.&#xD;Institute of Medical Microbiology and Hospital Hygiene, Medical Faculty, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term effects of homologous and heterologous SARS-CoV-2 vaccination on humoral and cellular immune responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2560-2564</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Cellular</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Humoral</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35567394</style></accession-num><notes><style face="normal" font="default" size="100%">Hollstein, Moritz M&#xD;Munsterkotter, Lennart&#xD;Schon, Michael P&#xD;Bergmann, Armin&#xD;Husar, Thea M&#xD;Abratis, Anna&#xD;Eidizadeh, Abass&#xD;Dierks, Sascha&#xD;Schaffrinski, Meike&#xD;Zachmann, Karolin&#xD;Schmitz, Anne&#xD;Holsapple, Jason S&#xD;Stanisz-Bogeski, Hedwig&#xD;Schanz, Julie&#xD;Fischer, Andreas&#xD;Gross, Uwe&#xD;Leha, Andreas&#xD;Zautner, Andreas E&#xD;Schnelle, Moritz&#xD;Erpenbeck, Luise&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2560-2564. doi: 10.1111/all.15373. Epub 2022 May 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35567394</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9348463</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15373</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1226</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1226</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gappa, M.</style></author><author><style face="normal" font="default" size="100%">Filipiak-Pittroff, B.</style></author><author><style face="normal" font="default" size="100%">Libuda, L.</style></author><author><style face="normal" font="default" size="100%">von Berg, A.</style></author><author><style face="normal" font="default" size="100%">Koletzko, S.</style></author><author><style face="normal" font="default" size="100%">Bauer, C. P.</style></author><author><style face="normal" font="default" size="100%">Heinrich, J.</style></author><author><style face="normal" font="default" size="100%">Schikowski, T.</style></author><author><style face="normal" font="default" size="100%">Berdel, D.</style></author><author><style face="normal" font="default" size="100%">Standl, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Research Institute, Marien-Hospital Wesel, Wesel, Germany.&#xD;Evangelisches Krankenhaus Dusseldorf, Children&apos;s Hospital, Dusseldorf, Germany.&#xD;Department of Child and Adolescent Psychiatry, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.&#xD;Department of Pediatrics, Dr. von Hauner Children&apos;s Hospital, LMU Klinikum, University of Munich, Munich, Germany.&#xD;Department of Pediatrics, Gastroenterology and Nutrition, School of Medicine Collegium, Medicum University of Warmia and Mazury, Olsztyn, Poland.&#xD;Department of Pediatrics, Technical University of Munich, Munich, Germany.&#xD;Institute of Epidemiology, Helmholtz Zentrum Munchen-German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany.&#xD;Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Vic, Australia.&#xD;IUF-Leibniz Research Institute for Environmental Medicine, Dusseldorf, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term effects of hydrolyzed formulae on atopic diseases in the GINI study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1903-1907</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immune System Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Infant Formula</style></keyword><keyword><style face="normal" font="default" size="100%">Milk Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Time</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33320352</style></accession-num><notes><style face="normal" font="default" size="100%">Gappa, Monika&#xD;Filipiak-Pittroff, Birgit&#xD;Libuda, Lars&#xD;von Berg, Andrea&#xD;Koletzko, Sibylle&#xD;Bauer, Carl-Peter&#xD;Heinrich, Joachim&#xD;Schikowski, Tamara&#xD;Berdel, Dietrich&#xD;Standl, Marie&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1903-1907. doi: 10.1111/all.14709. Epub 2020 Dec 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33320352</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14709</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3206</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3206</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A. M.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Reich, A.</style></author><author><style face="normal" font="default" size="100%">Chu, C. Y.</style></author><author><style face="normal" font="default" size="100%">Deleanu, D.</style></author><author><style face="normal" font="default" size="100%">Sussman, G.</style></author><author><style face="normal" font="default" size="100%">Sanchez, J.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Hayama, K.</style></author><author><style face="normal" font="default" size="100%">Hide, M.</style></author><author><style face="normal" font="default" size="100%">Denguezli, M.</style></author><author><style face="normal" font="default" size="100%">Meshkova, R.</style></author><author><style face="normal" font="default" size="100%">Criado, R. F. J.</style></author><author><style face="normal" font="default" size="100%">Saini, S.</style></author><author><style face="normal" font="default" size="100%">Valle, S.</style></author><author><style face="normal" font="default" size="100%">Hua, E.</style></author><author><style face="normal" font="default" size="100%">Wang, P.</style></author><author><style face="normal" font="default" size="100%">Burciu, A.</style></author><author><style face="normal" font="default" size="100%">Indermuehle, I.</style></author><author><style face="normal" font="default" size="100%">Varanasi, V.</style></author><author><style face="normal" font="default" size="100%">Joubert, Y.</style></author><author><style face="normal" font="default" size="100%">Severin, T.</style></author><author><style face="normal" font="default" size="100%">Patekar, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain.&#xD;Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt‑Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Immunology and Allergology, Berlin, Germany.&#xD;Department of Dermatology, University of Rzeszow, Rzeszow, Poland.&#xD;Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.&#xD;University Medicine and Pharmacy Iuliu Hatieganu, IRGH, Allergy, Cluj-Napoca, Romania.&#xD;Division of Clinical Immunology and Allergy, Department of Medicine, St. Michael&apos;s Hospital, University of Toronto, Toronto, Ontario, Canada.&#xD;Group of Clinical and Experimental Allergy, Hospital &quot;Alma Mater de antioquia,&quot; University of Antioquia (Medellin, Colombia), Medellin, Colombia.&#xD;Department of Dermatology and Allergy Biederstein, School of Medicine and Health, Technical University of Munich, Munich, Germany.&#xD;Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan.&#xD;Department of Dermatology, Hiroshima University Hospital, Hiroshima, Japan.&#xD;Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.&#xD;Farhat Hached Hospital, Dermatology Department, Sousse, Tunisia.&#xD;Smolensk State Medical University, Department of Clinical Immunology and Allergology, Smolensk, Russia.&#xD;Department of Dermatology, Centro Universitario ABC, Santo Andre, Brazil.&#xD;John Hopkins Asthma and Allergy Center, Baltimore, Maryland, USA.&#xD;Department of Clinical Medicine, Hospital Universitario Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.&#xD;China Novartis Institutes for Biomedical Research Co., Ltd, Shanghai, China.&#xD;Novartis Pharma AG, Basel, Switzerland.&#xD;Novartis Healthcare Pvt. Ltd., Hyderabad, India.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">Phase 3b</style></keyword><keyword><style face="normal" font="default" size="100%">anti-IgE</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">ligelizumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 8</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41358486</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chronic spontaneous urticaria (CSU) is a debilitating skin condition affecting approximately 1% of the global population, characterized by recurrent wheals, angioedema, or both for over 6 weeks without identifiable external triggers. METHODS: This Phase 3b multicentre, double-blinded followed by open-label extension study evaluated the long-term efficacy and safety of ligelizumab re-treatment in patients with CSU who rolled over from previous studies. Patients from the PEARL-1 or PEARL-2 Phase 3 trials (re-treatment subpopulation) received blinded re-treatment with ligelizumab 72 mg or 120 mg every 4 weeks for 12 weeks, followed by open-label ligelizumab 120 mg up to Week 104. Patients from a Phase 3 open-label Japanese study or a Phase 2 pediatric study received open-label ligelizumab 120 mg throughout. Primary and key secondary efficacy endpoints were assessed at Week 12 in the re-treatment subpopulation; safety was evaluated throughout. RESULTS: In the overall ligelizumab re-treatment subpopulation, 53.5% and 57.5% of patients treated with ligelizumab 72 mg and 120 mg, respectively, achieved weekly urticaria activity score (UAS7) of &lt;/= 6 at Week 12. Re-treatment efficacy was demonstrated in both treatment arms, across all secondary endpoints, maintained up to Week 52. Re-treatment efficacy in the overall trial population showed similar trends to those in the re-treatment subpopulation. The safety profile of ligelizumab showed no new or unexpected safety signals compared with the known safety profile of ligelizumab. CONCLUSION: Long-term and re-treatment with ligelizumab was well tolerated and efficacious in patients with CSU, aligning with the short-term outcomes observed in the Phase 3 PEARL studies.</style></abstract><notes><style face="normal" font="default" size="100%">Gimenez-Arnau, Ana M&#xD;Maurer, Marcus&#xD;Reich, Adam&#xD;Chu, Chia-Yu&#xD;Deleanu, Diana&#xD;Sussman, Gordon&#xD;Sanchez, Jorge&#xD;Brockow, Knut&#xD;Hayama, Koremasa&#xD;Hide, Michihiro&#xD;Denguezli, Mohamed&#xD;Meshkova, Raisa&#xD;Criado, Roberta F J&#xD;Saini, Sarbjit&#xD;Valle, Solange&#xD;Hua, Eva&#xD;Wang, Pengpeng&#xD;Burciu, Alis&#xD;Indermuehle, Isabelle&#xD;Varanasi, Vineeth&#xD;Joubert, Yolandi&#xD;Severin, Thomas&#xD;Patekar, Manmath&#xD;eng&#xD;Novartis Pharma AG/&#xD;Denmark&#xD;Allergy. 2025 Dec 8. doi: 10.1111/all.70181.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41358486</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70181</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2673</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2673</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Wu, L.</style></author><author><style face="normal" font="default" size="100%">Yang, B.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Diao, Q.</style></author><author><style face="normal" font="default" size="100%">Sun, Q.</style></author><author><style face="normal" font="default" size="100%">Zhu, X.</style></author><author><style face="normal" font="default" size="100%">Man, X.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Feng, Y.</style></author><author><style face="normal" font="default" size="100%">Zeng, H.</style></author><author><style face="normal" font="default" size="100%">Cai, T.</style></author><author><style face="normal" font="default" size="100%">Ren, H.</style></author><author><style face="normal" font="default" size="100%">Lu, J.</style></author><author><style face="normal" font="default" size="100%">Lu, Q.</style></author><author><style face="normal" font="default" size="100%">Tao, X.</style></author><author><style face="normal" font="default" size="100%">Xiao, R.</style></author><author><style face="normal" font="default" size="100%">Ji, C.</style></author><author><style face="normal" font="default" size="100%">Li, F.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Peking University People&apos;s Hospital, Beijing, China.&#xD;Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.&#xD;Department of Dermatology, Affiliated Hangzhou First People&apos;s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.&#xD;Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.&#xD;Department of Dermatology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.&#xD;Department of Dermatology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.&#xD;Department of Dermatovenereology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.&#xD;Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.&#xD;Department of Dermatology, Qilu Hospital of Shandong University, Jinan, Shandong, China.&#xD;Department of Dermatology, Wuxi No.2 People&apos;s Hospital (Jiangnan University Medical Center), Wuxi, Jiangsu, China.&#xD;Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.&#xD;Department of Dermatology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.&#xD;Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.&#xD;Department of Dermatology, Chengdu Second People&apos;s Hospital, Chengdu, Sichuan, China.&#xD;Department of Dermatology, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.&#xD;Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.&#xD;Department of Dermatology, The First People&apos;s Hospital of Lianyungang, Lianyungang, Jiangsu, China.&#xD;Department of Dermatology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.&#xD;Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China.&#xD;Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.&#xD;Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, Jiangsu, China.&#xD;Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.&#xD;Department of Dermatology, Zhejiang Provincial People&apos;s Hospital, Hangzhou, Zhejiang, China.&#xD;Department of Dermatology and Venereology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.&#xD;Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.&#xD;Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1348-1357</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects/administration</style></keyword><keyword><style face="normal" font="default" size="100%">&amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">adults</style></keyword><keyword><style face="normal" font="default" size="100%">long-term efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">moderate-to-severe atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">stapokibart</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39450683</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Management of moderate-to-severe atopic dermatitis (AD) needs long-term therapy. Stapokibart is a humanized monoclonal antibody targeting interleukin-4 receptor alpha subunit (IL-4Ralpha), a shared receptor for IL-4 and IL-13 which are key pathogenic drivers of AD. In a pivotal phase 3 trial (NCT05265923), significant higher proportions of adult AD patients receiving stapokibart than placebo achieved &gt;/=75% improvement from baseline in Eczema Area and Severity Index (EASI-75; 66.9% vs. 25.8%) and Investigator&apos;s Global Assessment (IGA) score of 0/1 with &gt;/=2-point reduction (44.2% vs. 16.1%) at Week 16. Herein, we report long-term (52 weeks) efficacy and safety of stapokibart from this trial. METHODS: After 16-week double-blind treatment completed, patients in both stapokibart and placebo groups entered a 36-week maintenance treatment period and received stapokibart 300 mg every 2 weeks. Concomitant use of topical medications for AD was permitted throughout the maintenance period. RESULTS: Of 476 patients entering maintenance period, 430 completed the treatment. At Week 52, EASI-75 was achieved in 92.5% of patients continuing stapokibart and 88.7% of those switching from placebo to stapokibart, respectively; an IGA score of 0 or 1 with a &gt;/=2-point reduction was achieved in 67.3% and 64.2% of patients, respectively; a &gt;/=4-point reduction in weekly average of daily Peak Pruritus Numerical Rating Scale (PP-NRS) was achieved in 67.3% and 60.5% of patients, respectively. Over the 52-week treatment period, 88.1% of patients reported treatment-emergent adverse events, most were mild or moderate. CONCLUSION: Long-term treatment with stapokibart demonstrated a sustained efficacy and favorable safety profile in adults with moderate-to-severe AD.</style></abstract><notes><style face="normal" font="default" size="100%">Zhao, Yan&#xD;Zhang, Litao&#xD;Wu, Liming&#xD;Yang, Bin&#xD;Wang, Jinyan&#xD;Li, Yumei&#xD;Li, Jingyi&#xD;Diao, Qingchun&#xD;Sun, Qing&#xD;Zhu, Xiaohong&#xD;Man, Xiaoyong&#xD;Wang, Lihua&#xD;Li, Linfeng&#xD;Feng, Yanyan&#xD;Zeng, Huiming&#xD;Cai, Tao&#xD;Ren, Hong&#xD;Lu, Jianyun&#xD;Lu, Qianjin&#xD;Tao, Xiaohua&#xD;Xiao, Rong&#xD;Ji, Chao&#xD;Li, Fuqiu&#xD;Zhang, Jianzhong&#xD;eng&#xD;Keymed Biosciences (Chengdu) Co., Ltd/&#xD;Clinical Trial, Phase III&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1348-1357. doi: 10.1111/all.16368. Epub 2024 Oct 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39450683</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16368</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2299</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2299</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Issa, M.</style></author><author><style face="normal" font="default" size="100%">Michaudel, C.</style></author><author><style face="normal" font="default" size="100%">Guinot, M.</style></author><author><style face="normal" font="default" size="100%">Grauso-Culetto, M.</style></author><author><style face="normal" font="default" size="100%">Guillon, B.</style></author><author><style face="normal" font="default" size="100%">Lecardonnel, J.</style></author><author><style face="normal" font="default" size="100%">Jouneau, L.</style></author><author><style face="normal" font="default" size="100%">Chapuis, C.</style></author><author><style face="normal" font="default" size="100%">Bernard, H.</style></author><author><style face="normal" font="default" size="100%">Hazebrouck, S.</style></author><author><style face="normal" font="default" size="100%">Castelli, F.</style></author><author><style face="normal" font="default" size="100%">Fenaille, F.</style></author><author><style face="normal" font="default" size="100%">Gaultier, E.</style></author><author><style face="normal" font="default" size="100%">Riviere, G.</style></author><author><style face="normal" font="default" size="100%">Houdeau, E.</style></author><author><style face="normal" font="default" size="100%">Adel-Patient, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite Paris-Saclay, CEA, INRAE, Departement Medicaments et Technologies pour la Sante (DMTS), SPI/Laboratoire d&apos;Immuno-Allergie Alimentaire, Gif-sur-Yvette, France.&#xD;Universite Paris-Saclay, INRAE, AgroParisTech, GABI, Jouy-en-Josas, France.&#xD;Universite Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France.&#xD;Universite Paris-Saclay, CEA, INRAE - UMR Medicaments et Technologies pour la Sante (DMTS), Laboratoire d&apos;Innovation en Spectrometrie de Masse, Saclay, France.&#xD;Toxalim UMR1331 (Research Centre in Food Toxicology), Toulouse University, INRAE, ENVT, INP-Purpan, UPS, Toulouse, France.&#xD;Agence nationale de securite sanitaire de l&apos;alimentation, de l&apos;environnement et du travail (ANSES), Direction de l&apos;Evaluation des Risques, Maisons-Alfort, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term exposure from perinatal life to food-grade TiO(2) alters intestinal homeostasis and predisposes to food allergy in young mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">471-484</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/11/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/etiology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Caseins</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food-grade TiO2</style></keyword><keyword><style face="normal" font="default" size="100%">intestinal homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">perinatal exposure</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38010857</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food allergy (FA) is an inappropriate immunological response to food proteins resulting from an impaired induction of oral tolerance. Various early environmental factors can affect the establishment of intestinal homeostasis, predisposing to FA in early life. In this context, we aimed to assess the effect of chronic perinatal exposure to food-grade titanium dioxide (fg-TiO(2) ), a common food additive. METHODS: Dams were fed a control versus fg-TiO(2) -enriched diet from preconception to weaning, and their progeny received the same diet at weaning. A comprehensive analysis of baseline intestinal and systemic homeostasis was performed in offspring 1 week after weaning by assessing gut barrier maturation and microbiota composition, and local and systemic immune system and metabolome. The effect of fg-TiO(2) on the susceptibility of progeny to develop oral tolerance versus FA to cow&apos;s milk proteins (CMP) was performed starting at the same baseline time-point, using established models. Sensitization to CMP was investigated by measuring beta-lactoglobulin and casein-specific IgG1 and IgE antibodies, and elicitation of the allergic reaction by measuring mouse mast cell protease (mMCP1) in plasma collected after an oral food challenge. RESULTS: Perinatal exposure to fg-TiO(2) at realistic human doses led to an increased propensity to develop FA and an impaired induction of oral tolerance only in young males, which could be related to global baseline alterations in intestinal barrier, gut microbiota composition, local and systemic immunity, and metabolism. CONCLUSIONS: Long-term perinatal exposure to fg-TiO(2) alters intestinal homeostasis establishment and predisposes to food allergy, with a clear gender effect.</style></abstract><notes><style face="normal" font="default" size="100%">Issa, Mohammad&#xD;Michaudel, Chloe&#xD;Guinot, Marine&#xD;Grauso-Culetto, Marta&#xD;Guillon, Blanche&#xD;Lecardonnel, Jerome&#xD;Jouneau, Luc&#xD;Chapuis, Celine&#xD;Bernard, Herve&#xD;Hazebrouck, Stephane&#xD;Castelli, Florence&#xD;Fenaille, Francois&#xD;Gaultier, Eric&#xD;Riviere, Gilles&#xD;Houdeau, Eric&#xD;Adel-Patient, Karine&#xD;eng&#xD;Departement Alimentation Humaine, Institut National de la Recherche Agronomique/&#xD;Institut National de Recherche pour l&apos;Agriculture, l&apos;Alimentation et l&apos;Environnement/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):471-484. doi: 10.1111/all.15960. Epub 2023 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38010857</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15960</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2480</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2480</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Valentin, S.</style></author><author><style face="normal" font="default" size="100%">Regnault, V.</style></author><author><style face="normal" font="default" size="100%">Gueant, J. L.</style></author><author><style face="normal" font="default" size="100%">Ribeiro Baptista, B.</style></author><author><style face="normal" font="default" size="100%">Abel, T.</style></author><author><style face="normal" font="default" size="100%">Lacolley, P.</style></author><author><style face="normal" font="default" size="100%">Schlemmer, F.</style></author><author><style face="normal" font="default" size="100%">Chaouat, A.</style></author><author><style face="normal" font="default" size="100%">Chabot, F.</style></author><author><style face="normal" font="default" size="100%">Gueant-Rodriguez, R. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departement de Pneumologie, Vandoeuvre-les-Nancy, Universite de Lorraine, CHRU de Nancy, France.&#xD;Inserm U1254 IADI Imagerie Adaptative Diagnostique et Interventionnelle, Universite de Lorraine, Nancy, France.&#xD;Inserm U1116 DCAC Defaillance Cardiovasculaire Aigue et Chronique, Universite de Lorraine, Nancy, France.&#xD;Inserm U1256 NGERE Nutrition-Genetique et Exposition aux Risques Environnementaux, Universite de Lorraine, Nancy, France.&#xD;Inserm U955, Universite Paris Est Creteil, Creteil, France.&#xD;Assistance Publique Hopitaux de Paris, Hopitaux Universitaires Henri-Mondor, Unite de Pneumologie, Creteil, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term follow-up of neutrophil activation after severe-to-critical SARS-CoV-2 infection: A longitudinal study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2270-2273</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/04/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Neutrophil Activation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Neutrophils/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38610102</style></accession-num><notes><style face="normal" font="default" size="100%">Valentin, Simon&#xD;Regnault, Veronique&#xD;Gueant, Jean-Louis&#xD;Ribeiro Baptista, Bruno&#xD;Abel, Thery&#xD;Lacolley, Patrick&#xD;Schlemmer, Frederic&#xD;Chaouat, Ari&#xD;Chabot, Francois&#xD;Gueant-Rodriguez, Rosa-Maria&#xD;eng&#xD;Association Regionale d&apos;Aide aux Insuffisants Respiratoires de Lorraine/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2270-2273. doi: 10.1111/all.16123. Epub 2024 Apr 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38610102</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16123</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2230</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2230</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lorente-Sorolla, C.</style></author><author><style face="normal" font="default" size="100%">Bernaola, J.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Mellado, D.</style></author><author><style face="normal" font="default" size="100%">Gil-Martinez, M.</style></author><author><style face="normal" font="default" size="100%">Naharro-Gonzalez, S.</style></author><author><style face="normal" font="default" size="100%">Betancor, D.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Nieto, M.</style></author><author><style face="normal" font="default" size="100%">Pinillos-Robles, E. J.</style></author><author><style face="normal" font="default" size="100%">Santillan Coello, J. M.</style></author><author><style face="normal" font="default" size="100%">Villacampa-Auba, J. M.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Nieto, M. J.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Valverde-Monge, M.</style></author><author><style face="normal" font="default" size="100%">Rodrigo-Munoz, J. M.</style></author><author><style face="normal" font="default" size="100%">Del Pozo, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunoallergy Laboratory, Department of Immunology, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD, UAM), Madrid, Spain.&#xD;Allergy Unit, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.&#xD;Pulmonology Unit, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.&#xD;CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.&#xD;Department of ENT and Cervicofacial Surgery, Fundacion Jimenez Diaz University Hospital, Madrid, Spain.&#xD;Universidad Autonoma de Madrid, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term immune response accompanies clinical outcomes in severe asthmatics treated with anti-IL-5/IL-5R biologics</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3027-3031</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/08/29</style></edition><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37643083</style></accession-num><notes><style face="normal" font="default" size="100%">Lorente-Sorolla, C&#xD;Bernaola, J&#xD;Sanchez-Mellado, D&#xD;Gil-Martinez, M&#xD;Naharro-Gonzalez, S&#xD;Betancor, D&#xD;Fernandez-Nieto, M&#xD;Pinillos-Robles, E J&#xD;Santillan Coello, J M&#xD;Villacampa-Auba, J M&#xD;Rodriguez-Nieto, M J&#xD;Sastre, J&#xD;Valverde-Monge, M&#xD;Rodrigo-Munoz, J M&#xD;Del Pozo, V&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):3027-3031. doi: 10.1111/all.15872. Epub 2023 Aug 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37643083</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15872</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>894</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">894</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Banerji, A.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Johnston, D. T.</style></author><author><style face="normal" font="default" size="100%">Lumry, W. R.</style></author><author><style face="normal" font="default" size="100%">Magerl, M.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Martinez-Saguer, I.</style></author><author><style face="normal" font="default" size="100%">Zanichelli, A.</style></author><author><style face="normal" font="default" size="100%">Hao, J.</style></author><author><style face="normal" font="default" size="100%">Inhaber, N.</style></author><author><style face="normal" font="default" size="100%">Yu, M.</style></author><author><style face="normal" font="default" size="100%">Riedl, M. A.</style></author><author><style face="normal" font="default" size="100%">Help Ole Investigators</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Immunology/Allergy Section, Department of Internal Medicine, University of Cincinnati, and Bernstein Clinical Research Center, Cincinnati, Ohio, USA.&#xD;Asthma &amp; Allergy Specialists, Charlotte, North Carolina, USA.&#xD;Allergy and Asthma Research Associates, Dallas, Texas, USA.&#xD;Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Haemophilia Centre Rhine Main, Morfelden-Walldorf, Germany.&#xD;Department of Internal Medicine, ASST Fatebenefratelli Sacco, Ospedale Luigi Sacco-University of Milan, Milan, Italy.&#xD;Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.&#xD;Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">979-990</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/07/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Hae</style></keyword><keyword><style face="normal" font="default" size="100%">HAE attacks</style></keyword><keyword><style face="normal" font="default" size="100%">Help ole</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">lanadelumab</style></keyword><keyword><style face="normal" font="default" size="100%">long-term prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Takeda and/or honoraria for consulting from BioCryst, CSL Behring, KalVista,</style></keyword><keyword><style face="normal" font="default" size="100%">Pharming, Pharvaris, and Takeda. J.A. Bernstein has been or is currently a</style></keyword><keyword><style face="normal" font="default" size="100%">clinical investigator for BioCryst, CSL Behring, Ionis, KalVista, Pharming, and</style></keyword><keyword><style face="normal" font="default" size="100%">Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">a speaker for CSL Behring, Pharming, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">a consultant for</style></keyword><keyword><style face="normal" font="default" size="100%">BioCryst, CSL Behring, Fresenius Kabi, Ionis, KalVista, Pharming, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">a member of the hereditary angioedema medical advisory board. D.T. Johnston has</style></keyword><keyword><style face="normal" font="default" size="100%">received consulting/speaker fees from CSL Behring, Pharming, and Takeda, and</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from BioCryst and REGENXBIO. W.R. Lumry is a member of advisory</style></keyword><keyword><style face="normal" font="default" size="100%">boards for BioCryst, CSL Behring, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">has received research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">BioCryst, CSL Behring, Ionis, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">has received consulting fees from</style></keyword><keyword><style face="normal" font="default" size="100%">BioCryst, CSL Behring, Fresenius Kabi, Pharming, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">payments for</style></keyword><keyword><style face="normal" font="default" size="100%">lectures from CSL Behring, Pharming, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and is an advisory board member</style></keyword><keyword><style face="normal" font="default" size="100%">of the US Hereditary Angioedema Association. M. Magerl has received research</style></keyword><keyword><style face="normal" font="default" size="100%">grant support and/or speaker/consultancy fees from BioCryst, CSL Behring,</style></keyword><keyword><style face="normal" font="default" size="100%">KalVista, Pharming, and Takeda. M. Maurer has received research grant support</style></keyword><keyword><style face="normal" font="default" size="100%">and/or speaker/consultancy fees from Adverum, BioCryst, CSL Behring, KalVista,</style></keyword><keyword><style face="normal" font="default" size="100%">Pharming, Pharvaris, and Takeda. I. Martinez-Saguer has received research grant</style></keyword><keyword><style face="normal" font="default" size="100%">support and/or speaker/consultancy fees from BioCryst, CSL Behring, KalVista,</style></keyword><keyword><style face="normal" font="default" size="100%">Pharming, and Takeda. A. Zanichelli has received speaker/consultancy fees from</style></keyword><keyword><style face="normal" font="default" size="100%">BioCryst, CSL Behring, Pharming, and Takeda. J. Hao, N. Inhaber, and M. Yu are</style></keyword><keyword><style face="normal" font="default" size="100%">full-time employees of and hold stock/stock options in Takeda. M.A. Riedl has</style></keyword><keyword><style face="normal" font="default" size="100%">received research grants from BioCryst, CSL Behring, Pharming, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">has</style></keyword><keyword><style face="normal" font="default" size="100%">received consulting fees from Adverum, Attune, BioCryst, CSL Behring, Ionis,</style></keyword><keyword><style face="normal" font="default" size="100%">KalVista, Pharming, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">payments for lectures from CSL Behring, Pharming,</style></keyword><keyword><style face="normal" font="default" size="100%">and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and is an advisory board member of the US Hereditary Angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">Association.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34287942</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The aim was to evaluate long-term effectiveness and safety of lanadelumab in patients &gt;/=12 y old with hereditary angioedema (HAE) 1/2 (NCT02741596). METHODS: Rollover patients completing the HELP Study and continuing into HELP OLE received one lanadelumab 300 mg dose until first attack (dose-and-wait period), then 300 mg q2wks (regular dosing stage). Nonrollovers (newly enrolled) received lanadelumab 300 mg q2wks from day 0. Baseline attack rate for rollovers: &gt;/=1 attack/4 weeks (based on run-in period attack rate during HELP Study); for nonrollovers: historical attack rate &gt;/=1 attack/12 weeks. The planned treatment period was 33 months. RESULTS: 212 patients participated (109 rollovers, 103 nonrollovers); 81.6% completed &gt;/=30 months on study (mean [SD], 29.6 [8.2] months). Lanadelumab markedly reduced mean HAE attack rate (reduction vs baseline: 87.4% overall). Patients were attack free for a mean of 97.7% of days during treatment; 81.8% and 68.9% of patients were attack free for &gt;/=6 and &gt;/=12 months, respectively. Angioedema Quality-of-Life total and domain scores improved from day 0 to end of study. Treatment-emergent adverse events (TEAEs) (excluding HAE attacks) were reported by 97.2% of patients; most commonly injection site pain (47.2%) and viral upper respiratory tract infection (42.0%). Treatment-related TEAEs were reported by 54.7% of patients. Most injection site reactions resolved within 1 hour (70.2%) or 1 day (92.6%). Six (2.8%) patients discontinued due to TEAEs. No treatment-related serious TEAEs or deaths were reported. Eleven treatment-related TEAEs of special interest were reported by seven (3.3%) patients. CONCLUSION: Lanadelumab demonstrated sustained efficacy and acceptable tolerability with long-term use in HAE patients.</style></abstract><notes><style face="normal" font="default" size="100%">Banerji, Aleena&#xD;Bernstein, Jonathan A&#xD;Johnston, Douglas T&#xD;Lumry, William R&#xD;Magerl, Markus&#xD;Maurer, Marcus&#xD;Martinez-Saguer, Inmaculada&#xD;Zanichelli, Andrea&#xD;Hao, James&#xD;Inhaber, Neil&#xD;Yu, Ming&#xD;Riedl, Marc A&#xD;eng&#xD;Clinical Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):979-990. doi: 10.1111/all.15011. Epub 2021 Aug 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34287942</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9292251</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15011</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2694</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2694</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reshef, A.</style></author><author><style face="normal" font="default" size="100%">Hsu, C.</style></author><author><style face="normal" font="default" size="100%">Katelaris, C. H.</style></author><author><style face="normal" font="default" size="100%">Li, P. H.</style></author><author><style face="normal" font="default" size="100%">Magerl, M.</style></author><author><style face="normal" font="default" size="100%">Yamagami, K.</style></author><author><style face="normal" font="default" size="100%">Guilarte, M.</style></author><author><style face="normal" font="default" size="100%">Keith, P. K.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Lawo, J. P.</style></author><author><style face="normal" font="default" size="100%">Shetty, H.</style></author><author><style face="normal" font="default" size="100%">Pollen, M.</style></author><author><style face="normal" font="default" size="100%">Wieman, L.</style></author><author><style face="normal" font="default" size="100%">Craig, T. J.</style></author><author><style face="normal" font="default" size="100%">Vanguard Study Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy, Immunology and Angioedema Center, Barzilai University Hospital, Ashkelon, Israel.&#xD;Research Solutions of Arizona, Litchfield Park, Arizona, USA.&#xD;Allergy and Immunology Unit, Campbelltown Hospital and Western Sydney University, Sydney, New South Wales, Australia.&#xD;Division of Rheumatology and Clinical Immunology, Department of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.&#xD;Institute of Allergology, Charite - University Medicine Berlin (joint medical faculty of Free University of Berlin and Humboldt University of Berlin), Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;Department of Internal Medicine, Osaka City General Hospital, Osaka, Japan.&#xD;Allergology Department, Vall d&apos;Hebron University Hospital, Barcelona, Spain.&#xD;McMaster University Medical Centre, Hamilton, Ontario, Canada.&#xD;Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.&#xD;Bernstein Clinical Research Center, Cincinnati, Ohio, USA.&#xD;CSL Innovation GmbH, Marburg, Germany.&#xD;CSL Behring, King of Prussia, Pennsylvania, USA.&#xD;Allergy, Asthma and Immunology, Department of Medicine and Pediatrics, Penn State University, Hershey, Pennsylvania, USA.&#xD;Vinmec Times City International Hospital, Hanoi, Vietnam.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">545-556</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/10/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/prevention &amp; control/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects/administration</style></keyword><keyword><style face="normal" font="default" size="100%">&amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">factor XIIa</style></keyword><keyword><style face="normal" font="default" size="100%">garadacimab</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">long-term prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">monoclonal antibody</style></keyword><keyword><style face="normal" font="default" size="100%">advisor for BioCryst, CSL Behring, Ionis, Pharming, Pharvaris, Shulov Innovative</style></keyword><keyword><style face="normal" font="default" size="100%">Science, and Takeda/Shire. C. Hsu is a CSL Behring advisory board member and has</style></keyword><keyword><style face="normal" font="default" size="100%">received honoraria. C.H. Katelaris has conducted research with and has acted as</style></keyword><keyword><style face="normal" font="default" size="100%">an advisory board member for BioCryst, CSL Behring, Genzyme, KalVista</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Sanofi, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and served on the scientific committee for</style></keyword><keyword><style face="normal" font="default" size="100%">HAE International educational meetings and the Budapest C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">workshop. P.H. Li has received financial support from CSL Behring for acting as a</style></keyword><keyword><style face="normal" font="default" size="100%">study center investigator during the conduct of the study. He has acted as an</style></keyword><keyword><style face="normal" font="default" size="100%">advisory board member for CSL Behring, KalVista Pharmaceuticals, Pharvaris, and</style></keyword><keyword><style face="normal" font="default" size="100%">Takeda. M. Magerl has received financial support from CSL Behring for acting as a</style></keyword><keyword><style face="normal" font="default" size="100%">study center investigator during the conduct of the study and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">BioCryst, CSL Behring, Intellia, Ionis, KalVista Pharmaceuticals, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Octapharma, Pharming Technologies, Pharvaris, and Takeda/Shire outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. K. Yamagami has received financial support from CSL Behring for</style></keyword><keyword><style face="normal" font="default" size="100%">acting as a study center investigator during the conduct of the study and</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria for educational purposes from CSL Behring, Mitsubishi Tanabe, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">and Takeda. M. Guilarte has received honoraria for educational purposes from</style></keyword><keyword><style face="normal" font="default" size="100%">BioCryst, CSL Behring, Novartis, Pharming, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">participated in advisory</style></keyword><keyword><style face="normal" font="default" size="100%">boards organized by BioCryst, CSL Behring, KalVista Pharmaceuticals, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Pharvaris, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and has received funding to attend conferences and</style></keyword><keyword><style face="normal" font="default" size="100%">educational events from CSL Behring, Novartis, Pharming, and Takeda. She is a</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial/registry investigator for BioCryst, CSL Behring, KalVista</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Novartis, Pharming, Pharvaris, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and is a researcher</style></keyword><keyword><style face="normal" font="default" size="100%">at the Vall d&apos;Hebron Research Institute program for promoting research</style></keyword><keyword><style face="normal" font="default" size="100%">activities. P.K. Keith has been a speaker, advisory board member, or consultant</style></keyword><keyword><style face="normal" font="default" size="100%">for and has received honoraria from ALK, AstraZeneca, Bausch, BioCryst, Canadian</style></keyword><keyword><style face="normal" font="default" size="100%">Agency for Drugs and Technologies in Health, Canadian Pharmacists Association,</style></keyword><keyword><style face="normal" font="default" size="100%">CSL Behring, GSK, Medexus, Merck, Novartis, Sanofi Genzyme, Takeda/Shire, and</style></keyword><keyword><style face="normal" font="default" size="100%">Valeo</style></keyword><keyword><style face="normal" font="default" size="100%">has received research grants from CSL Behring and Takeda/Shire</style></keyword><keyword><style face="normal" font="default" size="100%">serves as</style></keyword><keyword><style face="normal" font="default" size="100%">a medical advisor (volunteer) for Hereditary Angioedema Canada, a patient</style></keyword><keyword><style face="normal" font="default" size="100%">organization</style></keyword><keyword><style face="normal" font="default" size="100%">serves as a board member (volunteer) for the Canadian Hereditary</style></keyword><keyword><style face="normal" font="default" size="100%">Angioedema Network, a physician organization</style></keyword><keyword><style face="normal" font="default" size="100%">and is an employee of McMaster</style></keyword><keyword><style face="normal" font="default" size="100%">University. J.A. Bernstein is a consultant and principal investigator for</style></keyword><keyword><style face="normal" font="default" size="100%">BioCryst, BioMarin, CSL Behring, Intellia, Ionis, KalVista Pharmaceuticals,</style></keyword><keyword><style face="normal" font="default" size="100%">Pharming, and Takeda/Shire</style></keyword><keyword><style face="normal" font="default" size="100%">and is a consultant for Astria, Cycle</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, and ONO Pharmaceutical. J-P. Lawo is a full-time employee of CSL</style></keyword><keyword><style face="normal" font="default" size="100%">Behring Innovation GmbH and shareholder of CSL Limited. H. Shetty is a full-time</style></keyword><keyword><style face="normal" font="default" size="100%">employee of CSL Behring LLC and shareholder of CSL Limited. M. Pollen is a</style></keyword><keyword><style face="normal" font="default" size="100%">full-time employee of CSL Behring LLC and shareholder of CSL Limited. L. Wieman</style></keyword><keyword><style face="normal" font="default" size="100%">is a full-time employee of CSL Behring LLC and shareholder of CSL Limited. T.J.</style></keyword><keyword><style face="normal" font="default" size="100%">Craig is a speaker for CSL Behring, Grifols, KalVista Pharmaceuticals, and</style></keyword><keyword><style face="normal" font="default" size="100%">Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">has received research and consultancy grants from BioCryst, BioMarin, CSL</style></keyword><keyword><style face="normal" font="default" size="100%">Behring, Grifols, Ionis, KalVista Pharmaceuticals, Pharvaris, Astria, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and is on the Medical Advisory Board for the US Hereditary Angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">Association, Director of ACARE Angioedema Center at Penn State University,</style></keyword><keyword><style face="normal" font="default" size="100%">Hershey, PA, USA.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39370961</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hereditary angioedema (HAE) is a chronic, unpredictable disease. Long-term prophylactic treatments that offer durable efficacy, safety, and convenience are required to assist patients in achieving complete disease control, per international guidelines. We report an interim analysis of an ongoing phase 3 (VANGUARD) open-label extension (OLE) study evaluating the long-term safety and efficacy of garadacimab for HAE prophylaxis. METHODS: Adults and adolescents aged &gt;/=12 years with HAE previously participating in phase 2 and pivotal phase 3 (VANGUARD) studies were rolled over to an OLE, alongside newly enrolled patients. Patients received garadacimab 200 mg subcutaneously, once monthly for &gt;/=12 months. The primary endpoint was treatment-emergent adverse events (TEAEs) in patients with C1 inhibitor deficiency/dysfunction. RESULTS: At data cut-off (February 13, 2023; N = 161), median (interquartile range) exposure was 13.8 months (11.9-16.3). For the primary endpoint, 133/159 patients experienced &gt;/=1 TEAE (524 events), equivalent to 0.23 events/administration and 2.84 events/patient-year. Garadacimab-related TEAEs (13% of patients, 52 events) were most commonly injection-site reactions (ISRs). No deaths occurred. One patient discontinued treatment due to garadacimab-related moderate ISR. Most TEAEs were mild/moderate; three events were serious (COVID-19, two events; abdominal HAE attack, one event) and not garadacimab related. No abnormal bleeding, thromboembolic, severe hypersensitivity, or anaphylactic events were observed. Mean HAE attack rate decreased by 95% from the run-in period; 60% of patients were attack-free. Almost all patients (93%) rated their response to garadacimab as &quot;good&quot; or &quot;excellent.&quot; CONCLUSION: Garadacimab has a favorable safety profile suitable for long-term use and provides durable protection against HAE attacks.</style></abstract><notes><style face="normal" font="default" size="100%">Reshef, Avner&#xD;Hsu, Connie&#xD;Katelaris, Constance H&#xD;Li, Philip H&#xD;Magerl, Markus&#xD;Yamagami, Keiko&#xD;Guilarte, Mar&#xD;Keith, Paul K&#xD;Bernstein, Jonathan A&#xD;Lawo, John-Philip&#xD;Shetty, Harsha&#xD;Pollen, Maressa&#xD;Wieman, Lolis&#xD;Craig, Tim J&#xD;eng&#xD;CSL Behring/&#xD;Clinical Trial, Phase III&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):545-556. doi: 10.1111/all.16351. Epub 2024 Oct 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39370961</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804312</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16351</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3145</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3145</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Woehlk, C.</style></author><author><style face="normal" font="default" size="100%">Stranzl, T.</style></author><author><style face="normal" font="default" size="100%">Contoli, M.</style></author><author><style face="normal" font="default" size="100%">Freemantle, N.</style></author><author><style face="normal" font="default" size="100%">Slaettanes, A. K.</style></author><author><style face="normal" font="default" size="100%">Larsen, J. R.</style></author><author><style face="normal" font="default" size="100%">Porsbjerg, C.</style></author><author><style face="normal" font="default" size="100%">Fritzsching, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Respiratory Research Unit, Department of Respiratory Medicine and Infectious Medicine, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.&#xD;ALK-Abello, Horsholm, Denmark.&#xD;Respiratory Section, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.&#xD;Institute of Clinical Trials and Methodology, University College London, London, UK.&#xD;Paediatric Pulmonology and Allergy, Children&apos;s Doctor Service, Heidelberg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-Term, Real-World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3331-3341</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy/immunology/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy/immunology/epidemiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">real-world evidence</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello. T.S. and A.K.S. are employees of ALK-Abello. M.C. reports personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from ALK-Abello during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">grants, personal fees, and</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from Chiesi and GlaxoSmithKline, personal fees, and</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from AstraZeneca, Boehringer Ingelheim, Novartis, and</style></keyword><keyword><style face="normal" font="default" size="100%">Zambon, and grants from the University of Ferrara (Italy), outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. N.F. reports personal fees from Aimmune, Allergan, AstraZeneca, Grifols,</style></keyword><keyword><style face="normal" font="default" size="100%">Ipsen, MSD, Novartis, Sanofi Aventis, and Vertex, outside of the submitted work.</style></keyword><keyword><style face="normal" font="default" size="100%">J.R.L. is an employee of Novo Nordisk and a former employee of ALK-Abello (at the</style></keyword><keyword><style face="normal" font="default" size="100%">time the work was conducted). C.P. reports grants from ALK-Abello during the</style></keyword><keyword><style face="normal" font="default" size="100%">conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from Astra Zeneca, Chiesi, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Sanofi, and TEVA outside of the submitted work. B.F. reports personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from ALK-Abello during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">speaker honorarium from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis and Merck Sharp &amp; Dohme outside of the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41031547</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Respiratory allergies often begin in childhood and can progress over time, leading to increased disease burden. Allergen immunotherapy (AIT) is the only causal treatment for allergic respiratory diseases with disease-modifying potential. While randomised trials support its efficacy in controlling allergic rhinitis (AR) and asthma symptoms, long-term real-world data in children remain limited. METHODS: This paediatric study (n = 11,036) was conducted within the pre-defined framework of the REACT study, based on protocol-specified objectives. Children (&lt; 18 years) with physician-diagnosed AR, with or without pre-existing asthma, were included. AIT-treated patients were matched 1:1 to non-AIT controls. Effectiveness was assessed over 9 years by comparing AR and asthma medication prescriptions, using a public database covering all reimbursable AIT products. Relative differences were calculated across the full observation period. RESULTS: AIT-treated children (mean age 11.4 years; 62.1% male) exhibited greater reductions in AR medication use than controls (additional 9% reduction beyond 61% in controls). In children with asthma, AIT was associated with additional reductions in asthma medication use (-21% beyond -48% in controls), severe exacerbations (-21% beyond -36%), and new oral corticosteroid prescriptions (-33% beyond -41%). Age stratification revealed more pronounced AR medication reductions in younger children (0-11 years) than in adolescents (12-17 years). CONCLUSION: This large-scale, real-world study supports the long-term effectiveness of AIT in children with AR, with or without asthma. The findings reflect improved disease control and suggest a disease-modifying effect of AIT. Early intervention, particularly in younger children, may help mitigate the progression of allergic disease.</style></abstract><notes><style face="normal" font="default" size="100%">Woehlk, Christian&#xD;Stranzl, Thomas&#xD;Contoli, Marco&#xD;Freemantle, Nick&#xD;Slaettanes, Andreas Kallsoy&#xD;Larsen, Julie Rask&#xD;Porsbjerg, Celeste&#xD;Fritzsching, Benedikt&#xD;eng&#xD;ALK Abello/&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3331-3341. doi: 10.1111/all.70085. Epub 2025 Oct 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41031547</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666749</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70085</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>625</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">625</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Olin, A.</style></author><author><style face="normal" font="default" size="100%">Acevedo, N.</style></author><author><style face="normal" font="default" size="100%">Lakshmikanth, T.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Johansson, C.</style></author><author><style face="normal" font="default" size="100%">Alm, J.</style></author><author><style face="normal" font="default" size="100%">Scheynius, A.</style></author><author><style face="normal" font="default" size="100%">Brodin, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Science for Life Laboratory, Department of Women&apos;s and Children&apos;s Health, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden.&#xD;Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Institute for Immunological Research, University of Cartagena, Cartagena, Colombia.&#xD;Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Newborn Medicine, Karolinska University Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Longitudinal analyses of development of the immune system during the first five years of life in relation to lifestyle</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1583-1595</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/01/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Fetal Blood</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon-gamma</style></keyword><keyword><style face="normal" font="default" size="100%">Killer Cells, Natural</style></keyword><keyword><style face="normal" font="default" size="100%">*Leukocytes, Mononuclear</style></keyword><keyword><style face="normal" font="default" size="100%">Life Style</style></keyword><keyword><style face="normal" font="default" size="100%">IgE sensitization to allergens</style></keyword><keyword><style face="normal" font="default" size="100%">anthroposophic lifestyle</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine production</style></keyword><keyword><style face="normal" font="default" size="100%">mass cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">peripheral blood mononuclear cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35094423</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Changes in immune cell composition during the immunological window within the first years after birth are not fully understood, especially the effect that different lifestyles might have on immune cell functionality. METHODS: Peripheral blood mononuclear cells from mothers and their children at birth and at two anvd five years were analyzed by mass cytometry. Immune cell composition and functionality was analyzed according to family lifestyle (anthroposophic and non-anthroposophic). RESULTS: We found no significant differences in the proportions of major immune lineages between anthroposophic and non-anthroposophic children at each time point, but there were clear changes over time in the proportions of mononuclear leukocytes, especially in B-cells and T lymphocytes. Phenotypic distances between cord blood and maternal blood were high at birth but decreased sharply the first two years, indicating strong phenotypic convergence with maternal cells. We found that children exhibited similar stimulation responses at birth, but subsequently segregated into two discrete functional trajectories. Trajectory 1 was associated with a decrease in tumor necrosis factor alpha (TNFa) production by CD4(+) T- and NK-cells, while Trajectory 2 depicted an increase in the production of IL-2 and interferon gamma (INFg) by T-cells. In both trajectories, there was an increase in IL-17A production by T-cells resulting in prominent differences at five years of age. CONCLUSIONS: This exploratory study suggests that leukocyte frequencies and cell phenotypes change with age in the same way across all children, while functional development follows one of two discrete trajectories that largely segregate by family lifestyle, supporting the hypothesis that early environmental exposures imprint immune cell function which may contribute to IgE sensitization. Our results also support that the first two years are critical for the environmental exposures to imprint the immune cells. Further studies with larger sample sizes are required to validate our findings.</style></abstract><notes><style face="normal" font="default" size="100%">Olin, Axel&#xD;Acevedo, Nathalie&#xD;Lakshmikanth, Tadepally&#xD;Chen, Yang&#xD;Johansson, Catharina&#xD;Alm, Johan&#xD;Scheynius, Annika&#xD;Brodin, Petter&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1583-1595. doi: 10.1111/all.15232. Epub 2022 Feb 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35094423</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15232</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2294</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2294</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pham, D. D.</style></author><author><style face="normal" font="default" size="100%">Hong, C.</style></author><author><style face="normal" font="default" size="100%">Lee, J. H.</style></author><author><style face="normal" font="default" size="100%">Kwon, H. S.</style></author><author><style face="normal" font="default" size="100%">Song, W. J.</style></author><author><style face="normal" font="default" size="100%">Cho, Y. S.</style></author><author><style face="normal" font="default" size="100%">Oh, J. S.</style></author><author><style face="normal" font="default" size="100%">Kim, T. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Longitudinal asthma phenotypes by multi-trajectory analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1342-1345</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/11/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38031506</style></accession-num><notes><style face="normal" font="default" size="100%">Pham, Duong Duc&#xD;Hong, Chaelin&#xD;Lee, Ji-Hyang&#xD;Kwon, Hyouk-Soo&#xD;Song, Woo-Jung&#xD;Cho, You Sook&#xD;Oh, Ji Seon&#xD;Kim, Tae-Bum&#xD;eng&#xD;HI19C0481/Ministry of Health &amp;amp; Welfare, Republic of Korea/&#xD;HC20C0076/Ministry of Health &amp;amp; Welfare, Republic of Korea/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1342-1345. doi: 10.1111/all.15958. Epub 2023 Nov 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38031506</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15958</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1299</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1299</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lai, C. L.</style></author><author><style face="normal" font="default" size="100%">Campbell, D. E.</style></author><author><style face="normal" font="default" size="100%">Palmer, D. J.</style></author><author><style face="normal" font="default" size="100%">Makrides, M.</style></author><author><style face="normal" font="default" size="100%">Santner-Nanan, B.</style></author><author><style face="normal" font="default" size="100%">Gold, M.</style></author><author><style face="normal" font="default" size="100%">Tan, J. W.</style></author><author><style face="normal" font="default" size="100%">Valerio, C.</style></author><author><style face="normal" font="default" size="100%">Nanan, R.</style></author><author><style face="normal" font="default" size="100%">Prescott, S. L.</style></author><author><style face="normal" font="default" size="100%">Hsu, P. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Immunology, The Children&apos;s Hospital at Westmead, Westmead, NSW, Australia.&#xD;Kids Research Institute, The Children&apos;s Hospital at Westmead, Westmead, NSW, Australia.&#xD;Discipline of Paediatrics and Child Health, The University of Sydney, Sydney, NSW, Australia.&#xD;Murdoch Children&apos;s Research Institute, Centre for Food Allergy Research (CFAR), Parkville, Vic, Australia.&#xD;Telethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.&#xD;School of Medicine, The University of Western Australia, Crawley, WA, Australia.&#xD;South Australian Health and Medical Research Institute, SAHMRI Women and Kids, Adelaide, SA, Australia.&#xD;School of Medicine, University of Adelaide, Adelaide, SA, Australia.&#xD;Sydney Medical School Nepean and Charles Perkins Centre Nepean, The University of Sydney, Kingswood, NSW, Australia.&#xD;Discipline of Paediatrics, School of Medicine, University of Adelaide, Adelaide, SA, Australia.&#xD;The ORIGINS Project, Telethon Kids Institute, University of Western Australia, Perth Children&apos;s Hospital, Nedlands, WA, Australia.&#xD;InVIVO Planetary Health of the Worldwide Universities Network (WUN), West New York, NJ, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Longitudinal egg-specific regulatory T- and B-cell development: Insights from primary prevention clinical trials examining the timing of egg introduction</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1385-1397</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Egg Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Leukocytes, Mononuclear</style></keyword><keyword><style face="normal" font="default" size="100%">Ovalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">egg allergy</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory B cell</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cell</style></keyword><keyword><style face="normal" font="default" size="100%">tolerance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33040362</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Egg allergy affects almost 1 in 10 Australian infants. Early egg introduction has been associated with a reduced risk in developing egg allergy; however, the immune mechanisms underlying this protection remain unclear. OBJECTIVE: To examine the role of regulatory immune cells in tolerance induction during early egg introduction. METHODS: Cryopreserved peripheral blood mononuclear cells (PBMC) were obtained from infants from 2 randomized controlled trials of early introduction of egg for the primary prevention of egg allergy; BEAT (at 12 months, n = 42) and STEP (at 5 months n = 82; 12 months n = 82) study cohorts. In vitro ovalbumin-stimulated PBMC were analyzed by flow cytometry for presence of ovalbumin-specific regulatory T cells, using activation markers, FoxP3, and IL-10 expression. Ovalbumin-specific regulatory B cells were identified by co-expression of fluorescence-conjugated ovalbumin and IL-10. RESULTS: Specific, age-dependent expansion of ovalbumin-specific regulatory T cells was only observed in infants who (a) had early egg introduction and (b) did not have egg allergy at 12 months. This expansion was blunted or impaired in children who did not undergo early egg introduction and in those with clinical egg allergy at 12 months. Infants with egg allergy at 12 months of age also had reduced frequency of ovalbumin-specific regulatory B cells compared to egg-tolerant infants. CONCLUSION: Early egg introduction and clinical tolerance to egg were associated with expansion of ovalbumin-specific T and B regulatory cells, which may be an important developmental process for tolerance acquisition to food allergens.</style></abstract><notes><style face="normal" font="default" size="100%">Lai, Catherine L&#xD;Campbell, Dianne E&#xD;Palmer, Debra J&#xD;Makrides, Maria&#xD;Santner-Nanan, Brigitte&#xD;Gold, Michael&#xD;Tan, John Wei-Liang&#xD;Valerio, Carol&#xD;Nanan, Ralph&#xD;Prescott, Susan L&#xD;Hsu, Peter S&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1385-1397. doi: 10.1111/all.14621. Epub 2020 Oct 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33040362</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14621</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2510</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2510</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parker, K. M.</style></author><author><style face="normal" font="default" size="100%">Dang, T. D.</style></author><author><style face="normal" font="default" size="100%">Wijesuriya, R.</style></author><author><style face="normal" font="default" size="100%">Soriano, V. X.</style></author><author><style face="normal" font="default" size="100%">Lowe, A. J.</style></author><author><style face="normal" font="default" size="100%">Dharmage, S. C.</style></author><author><style face="normal" font="default" size="100%">Loke, P.</style></author><author><style face="normal" font="default" size="100%">Tang, M. L. K.</style></author><author><style face="normal" font="default" size="100%">Allen, K. J.</style></author><author><style face="normal" font="default" size="100%">Koplin, J. J.</style></author><author><style face="normal" font="default" size="100%">Perrett, K. P.</style></author><author><style face="normal" font="default" size="100%">Peters, R. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia.&#xD;Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia.&#xD;Monash Children&apos;s Hospital, Monash Health, Clayton, Victoria, Australia.&#xD;Department of Allergy and Immunology, Royal Children&apos;s Hospital, Parkville, Victoria, Australia.&#xD;Child Health Research Centre, University of Queensland, Brisbane, Queensland, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Longitudinal peanut and Ara h 2 specific-IgE, -IgG(4), and -IgG(4)/-IgE ratios are associated with the natural resolution of peanut allergy in childhood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1868-1880</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/05/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/immunology/diagnosis/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Plant/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*2S Albumins, Plant/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Arachis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin G/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Glycoproteins/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Ara h 2</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4</style></keyword><keyword><style face="normal" font="default" size="100%">peanut</style></keyword><keyword><style face="normal" font="default" size="100%">resolution</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38720169</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: There are no studies of longitudinal immunoglobulin measurements in a population-based cohort alongside challenge-confirmed peanut allergy outcomes. Little is known about biomarkers for identifying naturally resolving peanut allergy during childhood. OBJECTIVES: To measure longitudinal trends in whole peanut and component Ara h 2 sIgE and sIgG(4) in the first 10 years of life, in a population cohort of children with challenge-confirmed peanut allergy, and to determine whether peanut-specific immunoglobulin levels or trends are associated with peanut allergy persistence or resolution by 10 years of age. METHODS: One-year-old infants with challenge-confirmed peanut allergy (n = 156) from the HealthNuts study (n = 5276) were prospectively followed at ages 4, 6, and 10 years with questionnaires, skin prick tests, oral food challenges, and plasma total-IgE, sIgE and sIgG(4) to peanut and Ara h 2. RESULTS: Peanut allergy resolved in 33.9% (95% CI = 25.3%, 43.3%) of children by 10 years old with most resolving (97.4%, 95% CI = 86.5%, 99.9%) by 6 years old. Decreasing Ara h 2 sIgE (p = .01) and increasing peanut sIgG(4) (p &lt; .001), Ara h 2 sIgG(4) (p = .01), peanut sIgG(4)/sIgE (p &lt; .001) and Ara h 2 sIgG(4)/sIgE (p &lt; .001) from 1 to 10 years of age were associated with peanut allergy resolution. Peanut sIgE measured at 1 year old had the greatest prognostic value (AUC = 0.75 [95% CI = 0.66, 0.82]); however, no single threshold produced both high sensitivity and specificity. CONCLUSION: One third of infant peanut allergy resolved by 10 years of age. Decreasing sIgE and sIgG(4) to peanut and Ara h 2 over time were associated with natural resolution of peanut allergy. However, biomarker levels at diagnosis were not strongly associated with the natural history of peanut allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Parker, Kayla M&#xD;Dang, Thanh D&#xD;Wijesuriya, Rushani&#xD;Soriano, Victoria X&#xD;Lowe, Adrian J&#xD;Dharmage, Shyamali C&#xD;Loke, Paxton&#xD;Tang, Mimi L K&#xD;Allen, Katie J&#xD;Koplin, Jennifer J&#xD;Perrett, Kirsten P&#xD;Peters, Rachel L&#xD;eng&#xD;Elizabeth &amp;amp; Vernon Puzey Foundation/&#xD;Australian Government Research Training Program/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1868-1880. doi: 10.1111/all.16111. Epub 2024 May 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38720169</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16111</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2735</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2735</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thorsen, J.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, M. A.</style></author><author><style face="normal" font="default" size="100%">Chawes, B.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Schoos, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Food Microbiology, Gut Health and Fermentation, Department of Food Science, University of Copenhagen, Frederiksberg C, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Denmark.&#xD;Department of Pediatrics, Slagelse Hospital, Slagelse, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Longitudinal Sensitization Patterns in Childhood and Adolescence</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">893-895</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/11/27</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39601622</style></accession-num><notes><style face="normal" font="default" size="100%">Thorsen, Jonathan&#xD;Rasmussen, Morten A&#xD;Chawes, Bo&#xD;Stokholm, Jakob&#xD;Bonnelykke, Klaus&#xD;Schoos, Ann-Marie M&#xD;eng&#xD;The Capital Region Research Foundation/&#xD;0603-00280B/Danish Council for Strategic Research/&#xD;903516/The Ministry of Health/&#xD;R16-A1694/The Lundbeck Foundation/&#xD;NNF21OC0068517/novo nordisk foundation/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):893-895. doi: 10.1111/all.16408. Epub 2024 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39601622</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16408</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>64</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">64</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, F. M.</style></author><author><style face="normal" font="default" size="100%">Hu, M. C.</style></author><author><style face="normal" font="default" size="100%">Weng, C. M.</style></author><author><style face="normal" font="default" size="100%">Chuang, H. C.</style></author><author><style face="normal" font="default" size="100%">Lan, Y. T.</style></author><author><style face="normal" font="default" size="100%">Su, B. H.</style></author><author><style face="normal" font="default" size="100%">Heo, K. S.</style></author><author><style face="normal" font="default" size="100%">Kuo, H. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Graduate Institute of Physiology, National Taiwan University College of Medicine, Taipei, Taiwan.&#xD;Department of Thoracic Medicine, Taipei Medical University Hospital, Taipei, Taiwan.&#xD;College of Pharmacy, Chungnam National University, Daejeon, South Korea.&#xD;Pulmonary Medicine Research Center, Taipei Medical University, Taipei, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Loss of PP4 contributes to diesel exhaust particles-induced epithelial barrier integrity disruption and alarmins release</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1670-1673</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/12/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Vehicle Emissions/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">*Alarmins</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36458827</style></accession-num><notes><style face="normal" font="default" size="100%">Yang, Feng-Ming&#xD;Hu, Meng-Chun&#xD;Weng, Chih-Ming&#xD;Chuang, Hsiao-Chi&#xD;Lan, Yu-Ting&#xD;Su, Bing-Hua&#xD;Heo, Kyung-Sun&#xD;Kuo, Han-Pin&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1670-1673. doi: 10.1111/all.15604. Epub 2022 Dec 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36458827</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15604</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2640</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2640</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kaplan, B.</style></author><author><style face="normal" font="default" size="100%">Kimura, N.</style></author><author><style face="normal" font="default" size="100%">Fishbein, J. S.</style></author><author><style face="normal" font="default" size="100%">Varghese, P.</style></author><author><style face="normal" font="default" size="100%">Bruni, M.</style></author><author><style face="normal" font="default" size="100%">Fastenberg, J.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Asthma and Immunology, Cohen Children&apos;s Medical Center, Northwell, New Hyde Park, New York, USA.&#xD;Department of Medicine and Pediatrics, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.&#xD;Office of Academic Affairs, Northwell Health, New Hyde Park, New York, USA.&#xD;Department of Otolaryngology-Head and Neck Surgery, Northwell, New Hyde Park, New York, USA.&#xD;Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.&#xD;Division of Pulmonary, Department of Medicine, Critical Care and Sleep Medicine, Northwell, New Hyde Park, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Low mannose-binding lectin levels is associated with aspirin unresponsiveness in aspirin-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">608-610</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/09/22</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39306727</style></accession-num><notes><style face="normal" font="default" size="100%">Kaplan, Blanka&#xD;Kimura, Nikki&#xD;Fishbein, Joanna S&#xD;Varghese, Pinky&#xD;Bruni, Margherita&#xD;Fastenberg, Judd&#xD;Wang, Janice&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):608-610. doi: 10.1111/all.16329. Epub 2024 Sep 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39306727</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16329</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>884</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">884</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hochgerner, M.</style></author><author><style face="normal" font="default" size="100%">Sturm, E. M.</style></author><author><style face="normal" font="default" size="100%">Schnoegl, D.</style></author><author><style face="normal" font="default" size="100%">Kwapiszewska, G.</style></author><author><style face="normal" font="default" size="100%">Olschewski, H.</style></author><author><style face="normal" font="default" size="100%">Marsh, L. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.&#xD;Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria.&#xD;Division of Physiology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria.&#xD;Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Low oxygen levels decrease adaptive immune responses and ameliorate experimental asthma in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">870-882</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/07/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Humoral</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Oxygen/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mhc-ii</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">dendritic cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34309864</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: High-altitude therapy has been used as add-on treatment for allergic asthma with considerable success. However, the underlying mechanisms remain unclear. In order to investigate the possible therapeutic effects of high-altitude therapy on allergic asthma, we utilized a new in vivo mouse model. METHODS: Mice were treated with house dust mite (HDM) extract over 4 weeks and co-exposed to 10% oxygen (Hyp) or room air for the final 2 weeks. Experimental asthma was assessed by airway hyper-responsiveness, mucus hypersecretion and inflammatory cell recruitment. Isolated immune cells from mouse and allergic patients were stimulated in vitro with HDM under Hyp and normoxia in different co-culture systems to analyse the adaptive immune response. RESULTS: Compared to HDM-treated mice in room air, HDM-treated Hyp-mice displayed ameliorated mucosal hypersecretion and airway hyper-responsiveness. The attenuated asthma phenotype was associated with strongly reduced activation of antigen-presenting cells (APCs), effector cell infiltration and cytokine secretion. In vitro, hypoxia almost completely suppressed the HDM-induced adaptive immune response in both mouse and human immune cells. While hypoxia did not affect effector T-cell responses per-se, it interfered with antigen-presenting cell (APC) differentiation and APC/effector cell crosstalk. CONCLUSIONS: Hypoxia-induced reduction in the Th2-response to HDM ameliorates allergic asthma in vivo. Hypoxia interferes with APC/T-cell crosstalk and confers an unresponsive phenotype to APCs.</style></abstract><notes><style face="normal" font="default" size="100%">Hochgerner, Mathias&#xD;Sturm, Eva M&#xD;Schnoegl, Diana&#xD;Kwapiszewska, Grazyna&#xD;Olschewski, Horst&#xD;Marsh, Leigh M&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):870-882. doi: 10.1111/all.15020. Epub 2021 Aug 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34309864</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9290649</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15020</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1042</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1042</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chang, X.</style></author><author><style face="normal" font="default" size="100%">Zha, L.</style></author><author><style face="normal" font="default" size="100%">Wallimann, A.</style></author><author><style face="normal" font="default" size="100%">Mohsen, M. O.</style></author><author><style face="normal" font="default" size="100%">Krenger, P.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Vogel, M.</style></author><author><style face="normal" font="default" size="100%">Bachmann, M. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">International Immunology Center, Anhui Agricultural University, Anhui, China.&#xD;Immunology, RIA, Inselspital, University of Bern, Bern, Switzerland.&#xD;Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), The Jenner Institute, University of Oxford, Oxford, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Low-affinity but high-avidity interactions may offer an explanation for IgE-mediated allergen cross-reactivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2565-2574</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/04/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cats</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">IgE antibody</style></keyword><keyword><style face="normal" font="default" size="100%">affinity</style></keyword><keyword><style face="normal" font="default" size="100%">allergen cross-reactivity</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">avidity</style></keyword><keyword><style face="normal" font="default" size="100%">specificity</style></keyword><keyword><style face="normal" font="default" size="100%">for allergic diseases. The other authors declare no further conflict of</style></keyword><keyword><style face="normal" font="default" size="100%">interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33866583</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergy is a global disease with overall frequencies of &gt;20%. Symptoms vary from irritating local itching to life-threatening systemic anaphylaxis. Even though allergies are allergen-specific, there is a wide range of cross-reactivities (eg apple and latex) that remain largely unexplained. Given the abilities of low-affinity IgG antibodies to inhibit mast cells activation, here we elucidate the minimal affinity of IgE antibodies to induce type I hypersensitivity. METHODS: Three mature (high-affinity) IgE antibodies recognizing three distinct epitopes on Fel d 1, the major cat allergen, were back-mutated to germline conformation, resulting in binding to Fel d 1 with low affinity. The ability of these IgE antibodies to activate mast cells in vitro and in vivo was tested. RESULTS: We demonstrate that affinities as low as 10(-7) M are sufficient to activate mast cells in vitro and drive allergic reactions in vivo. Low-affinity IgE antibodies are able to do so, since they bind allergens bivalently on the surface of mast cells, leading to high-avidity interactions. CONCLUSIONS: These results suggest that the underlying mechanism of allergen cross-reactivity may be low-affinity but high-avidity binding between IgE antibodies and cross-reactive allergen.</style></abstract><notes><style face="normal" font="default" size="100%">Chang, Xinyue&#xD;Zha, Lisha&#xD;Wallimann, Alexandra&#xD;Mohsen, Mona O&#xD;Krenger, Pascal&#xD;Liu, Xuelan&#xD;Vogel, Monique&#xD;Bachmann, Martin F&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2565-2574. doi: 10.1111/all.14864. Epub 2021 May 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33866583</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8361967</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14864</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3168</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3168</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hviid-Vyff, B.</style></author><author><style face="normal" font="default" size="100%">Skaarup, S. H.</style></author><author><style face="normal" font="default" size="100%">Duin, A.</style></author><author><style face="normal" font="default" size="100%">Schmid, J. M.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Aarhus University, Aarhus, Denmark.&#xD;Aarhus University Hospital, Aarhus, Denmark.&#xD;Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.&#xD;AITSU, Operations ApS, Hojbjerg, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Low-Dose Intralymphatic Immunotherapy for Grass Pollen Allergy is Both Safe and Effective</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 9</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41208122</style></accession-num><notes><style face="normal" font="default" size="100%">Hviid-Vyff, Bjarke&#xD;Skaarup, Soren Helbo&#xD;Duin, Amber&#xD;Schmid, Johannes Martin&#xD;Hoffmann, Hans Jurgen&#xD;eng&#xD;909000065B/Innovation Fund of Denmark/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov 9. doi: 10.1111/all.70148.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41208122</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70148</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2740</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2740</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leveque, E.</style></author><author><style face="normal" font="default" size="100%">Pecalvel, C.</style></author><author><style face="normal" font="default" size="100%">Casanovas, N.</style></author><author><style face="normal" font="default" size="100%">Goyard, S.</style></author><author><style face="normal" font="default" size="100%">Janin, Y. L.</style></author><author><style face="normal" font="default" size="100%">Rose, T.</style></author><author><style face="normal" font="default" size="100%">Trouche-Estival, B.</style></author><author><style face="normal" font="default" size="100%">Apoil, P. A.</style></author><author><style face="normal" font="default" size="100%">Michelet, M.</style></author><author><style face="normal" font="default" size="100%">Guilleminault, L.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), UMR 1291, INSERM, CNRS, University of Toulouse, Toulouse, France.&#xD;Pediatric Pneumo-Allergology Department, Children&apos;s Hospital, University Hospital Centre of Toulouse, Toulouse, France.&#xD;Institut Pasteur, Universite de Paris Cite, Diagnostic Test Innovation and Development Core Facility, Paris, France.&#xD;Structure et Instabilite Des Genomes (StrInG), Museum National d&apos;Histoire Naturelle, INSERM, CNRS, Alliance Sorbonne Universite, Paris, France.&#xD;Institut Federatif de Biologie, University Hospital Centre of Toulouse, Toulouse, France.&#xD;Department of Respiratory Medicine, University Hospital Centre of Toulouse, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">LuLIPLEX: A Fast, Highly Sensitive, and Multiplexed Method for the Detection of IgE Against Major Allergens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">849-860</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/11/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Luminescent Measurements/methods</style></keyword><keyword><style face="normal" font="default" size="100%">V hh</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">bioluminescence</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">luciferase</style></keyword><keyword><style face="normal" font="default" size="100%">research funding from Argenx, Novartis, Ceva, and Neovacs and is an inventor on</style></keyword><keyword><style face="normal" font="default" size="100%">patents issued or pending related to IgE detection and anti-IgE therapies:</style></keyword><keyword><style face="normal" font="default" size="100%">EP2021/060829, EP20315224.4, and WO2019197607 (A1)</style></keyword><keyword><style face="normal" font="default" size="100%">L.G. has been an investigator</style></keyword><keyword><style face="normal" font="default" size="100%">in clinical trials for AstraZeneca, Bayer, GlaxoSmithKline, MSD, and Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants or fees for consulting from AstraZeneca, GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, and Sanofi-Regeneron and fees for consulting from ALK, Bayer, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">MSD, not related to the submitted work. P.A.P. has received funding from Hycor.</style></keyword><keyword><style face="normal" font="default" size="100%">S.G., Y.L.J., and T.R. are inventors on the patent issued related to IgE</style></keyword><keyword><style face="normal" font="default" size="100%">detection (EP20315224.4) and luciferase substrates (EP3395803/2017</style></keyword><keyword><style face="normal" font="default" size="100%">WO2018197727/2018). The rest of the authors declare no competing interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39601619</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Diagnosis of allergies is mostly based on the patient&apos;s clinical history and allergen provocation tests. Determination of specific IgE (sIgE) profiles can be performed to support allergy diagnosis. This is commonly done in vivo by the skin prick test or in vitro with automated systems. Several platforms exist to quantify sIgE levels, but all these methods require access to specific instruments, often delaying the test&apos;s results. The IgE luciferase-linked immunosorbent assay (LuLISA) allows bioluminescent quantification of IgE against peanut in microliter samples, but this method awaits extension to other allergens. This study aimed to validate a new method, named LuLIPLEX, for multiplexed bioluminescent detection of sIgE against 20 major molecular allergens. METHODS: Quantification of sIgE against 12 recombinant or purified food allergens and eight aeroallergens was performed by LuLIPLEX versus standard IgE detection methods (ImmunoCAP, ISAC, ALEX, or NOVEOS). Multiplexed detection of IgE against these 20 allergens was performed within 45 min using 50 muL of serum, plasma, or whole blood samples. RESULTS: A head-to-head comparison between LuLIPLEX and standard IgE detection methods showed a high correlation among all allergens tested. sIgE profiles in polysensitized subjects could be determined within 45 min in serum and plasma samples, as well as using a single drop of capillary blood. CONCLUSIONS: LuLIPLEX is a rapid and sensitive method to quantify sIgE levels against multiple allergens. Given that the test is very fast and can be performed on small and inexpensive luminometers, the IgE LuLIPLEX could allow point-of-care testing of sIgE profiles in allergic subjects.</style></abstract><notes><style face="normal" font="default" size="100%">Leveque, Edouard&#xD;Pecalvel, Cyprien&#xD;Casanovas, Natacha&#xD;Goyard, Sophie&#xD;Janin, Yves L&#xD;Rose, Thierry&#xD;Trouche-Estival, Benjamin&#xD;Apoil, Pol Andre&#xD;Michelet, Marine&#xD;Guilleminault, Laurent&#xD;Reber, Laurent L&#xD;eng&#xD;Institut National de la Sante et de la Recherche Medicale (INSERM)/&#xD;FRM EQU202103012566/the French Medical Research Foundation/&#xD;ANR-20-CE15-0026/the French National Research Agency/&#xD;the French Allergology Society (SFA)/&#xD;ERC-2021-CoG 101043749/ERC_/European Research Council/International&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):849-860. doi: 10.1111/all.16403. Epub 2024 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39601619</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891426</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16403</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2390</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2390</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nopsopon, T.</style></author><author><style face="normal" font="default" size="100%">Barrett, N. A.</style></author><author><style face="normal" font="default" size="100%">Phipatanakul, W.</style></author><author><style face="normal" font="default" size="100%">Laidlaw, T. M.</style></author><author><style face="normal" font="default" size="100%">Weiss, S. T.</style></author><author><style face="normal" font="default" size="100%">Akenroye, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Division of Immunology, Boston Children&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Channing Division of Network Medicine, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1195-1207</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/01/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Function Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/physiopathology/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">lung function</style></keyword><keyword><style face="normal" font="default" size="100%">monoclonal antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">trajectory</style></keyword><keyword><style face="normal" font="default" size="100%">Phipatanakul has received consultancy fees from GSK, Novartis, Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">Genentech, Sanofi, Teva and grant support from GSK, Novartis, Genentech,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, and Merck on asthma therapeutics. Dr. T. M. Laidlaw has served on</style></keyword><keyword><style face="normal" font="default" size="100%">scientific advisory boards for GlaxoSmithKline, Sanofi-Genzyme, Regeneron, Eli</style></keyword><keyword><style face="normal" font="default" size="100%">Lilly, and AstraZeneca</style></keyword><keyword><style face="normal" font="default" size="100%">and has received research grant support from</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline and Regeneron. Dr. Weiss receives royalties from UpToDate and is</style></keyword><keyword><style face="normal" font="default" size="100%">on the board of Histolix. Dr. Barrett receives royalties from UpToDate.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38164813</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Lung function is an independent predictor of mortality. We evaluated the lung function trajectories of a cohort of patients with asthma receiving biologic therapy. METHODS: We identified 229 monoclonal antibody-naive adult patients with moderate-to-severe asthma who initiated omalizumab, mepolizumab, or dupilumab between 2010 and 2022 in a large healthcare system in Boston, MA. Generalized additive mixed models were used to estimate the lung function trajectories during the 156 weeks following biologic initiation. Response was defined as an improvement in FEV(1) or a decrease of &lt;/=0.5% per year. The Kaplan-Meier estimator was used to assess time to no additional improvement in FEV(1) in responders. All models were adjusted for age, sex, body mass index, smoking status, baseline exacerbation rate, and baseline blood eosinophil count. RESULTS: Eighty-eight patients initiated mepolizumab, 76 omalizumab, and 65 dupilumab. Baseline eosinophil count was highest in the mepolizumab group (405 cells/mcL) and lowest for omalizumab (250 cells/mcL). Both FEV(1) and FVC improved in the mepolizumab group (FEV(1) + 20 mL/year; FVC +43 mL/year). For omalizumab, there was an initial improvement in the first year followed by decline with an overall FEV(1) loss of -44 mL/year and FVC -32 mL/year. For dupilumab, both FEV(1) (+61 mL/year) and FVC (+74 mL/year) improved over time. Fifty percent of the mepolizumab group, 58% omalizumab, and 72% of dupilumab were responders. The median time to no additional FEV(1) improvement in responders was 24 weeks for omalizumab, 48 weeks for mepolizumab, and 57 weeks for dupilumab. CONCLUSION: In this clinical cohort, mepolizumab, omalizumab, and dupilumab had beneficial effects on FEV(1) and FVC with distinct post-initiation trajectories.</style></abstract><notes><style face="normal" font="default" size="100%">Nopsopon, Tanawin&#xD;Barrett, Nora A&#xD;Phipatanakul, Wanda&#xD;Laidlaw, Tanya M&#xD;Weiss, Scott T&#xD;Akenroye, Ayobami&#xD;eng&#xD;R01 AI134989/AI/NIAID NIH HHS/&#xD;R00 MD015767/MD/NIMHD NIH HHS/&#xD;U19 AI095219/AI/NIAID NIH HHS/&#xD;R01 HL161362/HL/NHLBI NIH HHS/&#xD;L30 HL165481/HL/NHLBI NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1195-1207. doi: 10.1111/all.16002. Epub 2024 Jan 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38164813</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11062846</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16002</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2437</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2437</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pouessel, G.</style></author><author><style face="normal" font="default" size="100%">Sabouraud-Leclerc, D.</style></author><author><style face="normal" font="default" size="100%">Beaumont, P.</style></author><author><style face="normal" font="default" size="100%">Divaret-Chauveau, A.</style></author><author><style face="normal" font="default" size="100%">Bradatan, E.</style></author><author><style face="normal" font="default" size="100%">Dumond, P.</style></author><author><style face="normal" font="default" size="100%">Karaca, Y.</style></author><author><style face="normal" font="default" size="100%">Renaudin, J. M.</style></author><author><style face="normal" font="default" size="100%">Metz-Favre, C.</style></author><author><style face="normal" font="default" size="100%">Delalande, D.</style></author><author><style face="normal" font="default" size="100%">Correard, A. K.</style></author><author><style face="normal" font="default" size="100%">Tscheiller, S.</style></author><author><style face="normal" font="default" size="100%">Van der Brempt, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CH Roubaix, Department of Pediatrics, Children&apos;s Hospital, Roubaix, France.&#xD;CHU Lille, Pediatric Pulmonology and Allergy Department, Pole Enfant, Hopital Jeanne de Flandre, Lille, France.&#xD;Univ Lille, ULR 2694: METRICS, Lille, France.&#xD;Allergy-Vigilance Network(R), Vandoeuvre-les-Nancy, France.&#xD;Medical Office, Saint Maur des Fosses, France.&#xD;Paediatric Allergology, Children&apos;s Medicine, CHRU, Nancy, France.&#xD;Department of Paediatrics, CHRU, Namur, Belgium.&#xD;Allergology Department, CH Durkheim, Epinal, France.&#xD;Department of Pneumology and Allergology, Strasbourg University Hospital, Strasbourg, France.&#xD;Departement of Pediatrics, Centre Hospitalier Intercommunal de Creteil, Creteil, France.&#xD;Pediatric Pulmonology and Allergology Department, Pediatric Cystic Fibrosis Center, Hopital Femme Mere Enfant, Hospices Civils de Lyon, Bron, France.&#xD;Allergopole, Clinique Saint-Luc, Namur, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lupin, a potential &quot;hidden&quot; food anaphylaxis allergen: An alert from the Allergy-Vigilance Network(R)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2267-2270</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/03/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/etiology/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Lupinus/adverse effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">adrenaline</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">food</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">lupin</style></keyword><keyword><style face="normal" font="default" size="100%">peanut</style></keyword><keyword><style face="normal" font="default" size="100%">prepacked foods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38516981</style></accession-num><notes><style face="normal" font="default" size="100%">Pouessel, Guillaume&#xD;Sabouraud-Leclerc, Dominique&#xD;Beaumont, Pascale&#xD;Divaret-Chauveau, Amandine&#xD;Bradatan, Elena&#xD;Dumond, Pascale&#xD;Karaca, Yasemin&#xD;Renaudin, Jean-Marie&#xD;Metz-Favre, Carine&#xD;Delalande, Delphine&#xD;Correard, Anne-Karine&#xD;Tscheiller, Selina&#xD;Van der Brempt, Xavier&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2267-2270. doi: 10.1111/all.16107. Epub 2024 Mar 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38516981</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16107</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2168</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2168</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Landau, T.</style></author><author><style face="normal" font="default" size="100%">Gamrasni, K.</style></author><author><style face="normal" font="default" size="100%">Barlev, Y.</style></author><author><style face="normal" font="default" size="100%">Elizur, A.</style></author><author><style face="normal" font="default" size="100%">Benor, S.</style></author><author><style face="normal" font="default" size="100%">Mimouni, F.</style></author><author><style face="normal" font="default" size="100%">Brandwein, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MYOR Diagnostics Ltd., Zichron Yaakov, Israel.&#xD;Department of Statistics, University of Haifa, Haifa, Israel.&#xD;Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.&#xD;Institute of Allergy, Immunology and Pediatric Pulmonology, Shamir Medical Center, Tel Aviv, Israel.&#xD;Allergy and Clinical Immunology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.&#xD;Leumit Health Services, Leumit Research Institute, Tel Aviv, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A machine learning approach for stratifying risk for food allergies utilizing electronic medical record data</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">499-502</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/08/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Electronic Health Records</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Machine Learning</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37555336</style></accession-num><notes><style face="normal" font="default" size="100%">Landau, Tamar&#xD;Gamrasni, Keren&#xD;Barlev, Yotam&#xD;Elizur, Arnon&#xD;Benor, Shira&#xD;Mimouni, Francis&#xD;Brandwein, Michael&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):499-502. doi: 10.1111/all.15839. Epub 2023 Aug 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37555336</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15839</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2226</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2226</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guilleminault, L.</style></author><author><style face="normal" font="default" size="100%">Villeneuve, T.</style></author><author><style face="normal" font="default" size="100%">Didier, A.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author><author><style face="normal" font="default" size="100%">Sigfried, A.</style></author><author><style face="normal" font="default" size="100%">Serrano, E.</style></author><author><style face="normal" font="default" size="100%">de Bonnecaze, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory and Allergic Diseases, Toulouse University Hospital Center, Toulouse, France.&#xD;Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5051, Toulouse, France.&#xD;CRISALIS F-CRIN/INSERM, Toulouse, France.&#xD;Service d&apos;Anatomopathologie, CHU Toulouse, Toulouse, France.&#xD;Department of ENT and Head and Neck Surgery, Toulouse University Hospital, Larrey Hospital, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Maintained effect of endoscopic sinus surgery in asthma responders to drugs targeting the IL5 pathway with persistent nasal polyposis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3031-3034</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/08/31</style></edition><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37650422</style></accession-num><notes><style face="normal" font="default" size="100%">Guilleminault, Laurent&#xD;Villeneuve, Thomas&#xD;Didier, Alain&#xD;Reber, Laurent L&#xD;Sigfried, Aurore&#xD;Serrano, Elie&#xD;de Bonnecaze, Guillaume&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):3031-3034. doi: 10.1111/all.15874. Epub 2023 Aug 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37650422</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15874</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3146</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3146</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Todorovic, N.</style></author><author><style face="normal" font="default" size="100%">Trifonova, D.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Curin, M.</style></author><author><style face="normal" font="default" size="100%">Schooltink, L.</style></author><author><style face="normal" font="default" size="100%">Sagmeister, T.</style></author><author><style face="normal" font="default" size="100%">Grininger, C.</style></author><author><style face="normal" font="default" size="100%">Kiss, R.</style></author><author><style face="normal" font="default" size="100%">Gottstein, N.</style></author><author><style face="normal" font="default" size="100%">Gesslbauer, B.</style></author><author><style face="normal" font="default" size="100%">Winkler, A.</style></author><author><style face="normal" font="default" size="100%">Pavkov-Keller, T.</style></author><author><style face="normal" font="default" size="100%">Karaulov, A.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Keller, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Molecular Biosciences, University of Graz, Graz, Austria.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Laboratory for Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Life Improvement by Future Technologies (LIFT) Center, Skolkovo, Moscow, Russia.&#xD;Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria.&#xD;Institute of Biochemistry, Graz University of Technology, Graz, Austria.&#xD;Biotechmed-Graz, University of Graz, Graz, Austria.&#xD;Field of Excellence Biohealth, University of Graz, Graz, Austria.&#xD;Center for Molecular Allergology, Karl Landsteiner University of Health Sciences, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Major Cat Allergen Fel d 4: Structure and Identification of a Cross-Reactive IgE-Epitope-Containing Area</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Fel d 4</style></keyword><keyword><style face="normal" font="default" size="100%">cat allergy</style></keyword><keyword><style face="normal" font="default" size="100%">cross-reactivity</style></keyword><keyword><style face="normal" font="default" size="100%">crystal structure</style></keyword><keyword><style face="normal" font="default" size="100%">epitope</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41286560</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic sensitization to cats and other furry animals is a major cause of asthma and allergic rhinitis in more than 200 million people worldwide. According to the frequency of IgE recognition, allergen-specific IgE levels, and allergenic activity, Fel d 4 is a major allergen in the cat (Felis domesticus). The lipocalin allergen Fel d 4 is highly homologous to dog (Can f 6) and major horse (Equ c 1) allergens. Accordingly, IgE cross-reactivity to these allergens contributes to polysensitization and allergic responses upon exposure to different animals. METHODS: Fel d 4 was recombinantly produced in two systems, E. coli and Expi293F mammalian cells. Recombinant forms were characterized by circular dichroism and mass spectrometry. The Fel d 4 3D structure was determined using X-ray crystallography. Immunoreactivity, epitope analyses, and cross-reactive properties were assessed by ELISA and basophil release assays using allergic patients&apos; sera. RESULTS: We reveal the rFel d 4 crystal structures and demonstrate that mammalian cells produce an N-glycosylated recombinant Fel d 4 allergen. The C-terminal regions of Fel d 4, Can f 6, and Equ c 1 constitute conformational IgE-epitope-containing areas responsible for cross-reactivity. CONCLUSION: Uncovering the IgE-binding sites of Fel d 4 and cross-reactive allergens contributes to future rational design of active and passive allergen-specific treatment forms.</style></abstract><notes><style face="normal" font="default" size="100%">Todorovic, Nikolina&#xD;Trifonova, Daria&#xD;Liu, Zicheng&#xD;Curin, Mirela&#xD;Schooltink, Laszlo&#xD;Sagmeister, Theo&#xD;Grininger, Christoph&#xD;Kiss, Renata&#xD;Gottstein, Nina&#xD;Gesslbauer, Bernd&#xD;Winkler, Andreas&#xD;Pavkov-Keller, Tea&#xD;Karaulov, Alexander&#xD;Valenta, Rudolf&#xD;Keller, Walter&#xD;eng&#xD;Austrian Science Fund/&#xD;Russian Science Foundation/&#xD;Danube Allergy Research Cluster of the Country of Lower Austria/&#xD;Denmark&#xD;Allergy. 2025 Nov 24. doi: 10.1111/all.70146.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41286560</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70146</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3182</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3182</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Todorovic, N.</style></author><author><style face="normal" font="default" size="100%">Trifonova, D.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Curin, M.</style></author><author><style face="normal" font="default" size="100%">Schooltink, L.</style></author><author><style face="normal" font="default" size="100%">Sagmeister, T.</style></author><author><style face="normal" font="default" size="100%">Grininger, C.</style></author><author><style face="normal" font="default" size="100%">Kiss, R.</style></author><author><style face="normal" font="default" size="100%">Gottstein, N.</style></author><author><style face="normal" font="default" size="100%">Gesslbauer, B.</style></author><author><style face="normal" font="default" size="100%">Winkler, A.</style></author><author><style face="normal" font="default" size="100%">Pavkov-Keller, T.</style></author><author><style face="normal" font="default" size="100%">Karaulov, A.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Keller, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Molecular Biosciences, University of Graz, Graz, Austria.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Laboratory for Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Life Improvement by Future Technologies (LIFT) Center, Skolkovo, Moscow, Russia.&#xD;Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria.&#xD;Institute of Biochemistry, Graz University of Technology, Graz, Austria.&#xD;Biotechmed-Graz, University of Graz, Graz, Austria.&#xD;Field of Excellence Biohealth, University of Graz, Graz, Austria.&#xD;Center for Molecular Allergology, Karl Landsteiner University of Health Sciences, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Major Cat Allergen Fel d 4: Structure and Identification of a Cross-Reactive IgE-Epitope-Containing Area</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Fel d 4</style></keyword><keyword><style face="normal" font="default" size="100%">cat allergy</style></keyword><keyword><style face="normal" font="default" size="100%">cross-reactivity</style></keyword><keyword><style face="normal" font="default" size="100%">crystal structure</style></keyword><keyword><style face="normal" font="default" size="100%">epitope</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41286560</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic sensitization to cats and other furry animals is a major cause of asthma and allergic rhinitis in more than 200 million people worldwide. According to the frequency of IgE recognition, allergen-specific IgE levels, and allergenic activity, Fel d 4 is a major allergen in the cat (Felis domesticus). The lipocalin allergen Fel d 4 is highly homologous to dog (Can f 6) and major horse (Equ c 1) allergens. Accordingly, IgE cross-reactivity to these allergens contributes to polysensitization and allergic responses upon exposure to different animals. METHODS: Fel d 4 was recombinantly produced in two systems, E. coli and Expi293F mammalian cells. Recombinant forms were characterized by circular dichroism and mass spectrometry. The Fel d 4 3D structure was determined using X-ray crystallography. Immunoreactivity, epitope analyses, and cross-reactive properties were assessed by ELISA and basophil release assays using allergic patients&apos; sera. RESULTS: We reveal the rFel d 4 crystal structures and demonstrate that mammalian cells produce an N-glycosylated recombinant Fel d 4 allergen. The C-terminal regions of Fel d 4, Can f 6, and Equ c 1 constitute conformational IgE-epitope-containing areas responsible for cross-reactivity. CONCLUSION: Uncovering the IgE-binding sites of Fel d 4 and cross-reactive allergens contributes to future rational design of active and passive allergen-specific treatment forms.</style></abstract><notes><style face="normal" font="default" size="100%">Todorovic, Nikolina&#xD;Trifonova, Daria&#xD;Liu, Zicheng&#xD;Curin, Mirela&#xD;Schooltink, Laszlo&#xD;Sagmeister, Theo&#xD;Grininger, Christoph&#xD;Kiss, Renata&#xD;Gottstein, Nina&#xD;Gesslbauer, Bernd&#xD;Winkler, Andreas&#xD;Pavkov-Keller, Tea&#xD;Karaulov, Alexander&#xD;Valenta, Rudolf&#xD;Keller, Walter&#xD;eng&#xD;Austrian Science Fund/&#xD;Russian Science Foundation/&#xD;Danube Allergy Research Cluster of the Country of Lower Austria/&#xD;Denmark&#xD;Allergy. 2025 Nov 24. doi: 10.1111/all.70146.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41286560</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70146</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3324</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3324</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stodulski, Damian</style></author><author><style face="normal" font="default" size="100%">Garcia-Medina, Guadalupe</style></author><author><style face="normal" font="default" size="100%">Cabanillas, Beatriz</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Making Peanuts Safer: Autoclaving as a Heat and Pressure Strategy to Increase Peanut Tolerability</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70298</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70298</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3292</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3292</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suhrkamp, I.</style></author><author><style face="normal" font="default" size="100%">Heidland, T.</style></author><author><style face="normal" font="default" size="100%">Saft, C.</style></author><author><style face="normal" font="default" size="100%">Kamps, A. K.</style></author><author><style face="normal" font="default" size="100%">Edenhart, S.</style></author><author><style face="normal" font="default" size="100%">Kniemeyer, O.</style></author><author><style face="normal" font="default" size="100%">Francuzik, W.</style></author><author><style face="normal" font="default" size="100%">Weidinger, S.</style></author><author><style face="normal" font="default" size="100%">Bacher, P.</style></author><author><style face="normal" font="default" size="100%">Bang, C.</style></author><author><style face="normal" font="default" size="100%">Heine, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Malassezia-Induced Type 2 Immunity in Head Neck Shoulder Type Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70302</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70302</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>845</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">845</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaller, B.</style></author><author><style face="normal" font="default" size="100%">Bendien, S.</style></author><author><style face="normal" font="default" size="100%">Ditisheim, A.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Department of Internal Medicine 1, University Hospital St. Polten, Karl Landsteiner Institute for Nephrology St. Polten, St. Polten, Austria.&#xD;Department of Respiratory Medicine, Haga Teaching Hospital, The Hague, The Netherlands.&#xD;Center for Maternal-Fetal Medicine, La Tour Hospital, Meyrin, Switzerland.&#xD;Faculty of Medicine, University of Geneva, Geneva, Switzerland.&#xD;Translational Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Canada.&#xD;Department of Immunology, University of Toronto, Toronto, ON, Canada.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of allergic diseases in pregnancy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">798-811</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/08/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34427919</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic diseases like asthma, allergic rhinitis, food allergy, hymenoptera allergy, or atopic dermatitis are highly prevalent in women of childbearing age and may affect up to 30% of this age group. This review focuses on the management of allergic diseases during pregnancy. Furthermore, we discuss the challenges of counseling women with allergic diseases in the reproductive age, including considerations relevant to the ongoing SARS-CoV-2 pandemic. To create the optimal milieu for the unborn child, a multitude of immunological changes occur during pregnancy which may favor type 2 responses and aggravate disease phenotypes. In co-occurrence with suboptimal preconception disease control, this elevated Th2 responses may aggravate allergic disease manifestations during pregnancy and pose a risk for mother and child. Due to limitations in conducting clinical trials in pregnant women, safety data on anti-allergic drugs during pregnancy are limited. The lack of information and concerns among pregnant patients demands counseling on the benefits of anti-allergic drugs and the potential and known risks. This includes information on the risk for mother and child of disease aggravation in the absence of treatment. By doing so, informed decisions and shared decision-making can take place.</style></abstract><notes><style face="normal" font="default" size="100%">Pfaller, Birgit&#xD;Bendien, Sarah&#xD;Ditisheim, Agnes&#xD;Eiwegger, Thomas&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):798-811. doi: 10.1111/all.15063. Epub 2021 Sep 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34427919</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15063</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1066</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1066</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Blain, H.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Benetos, A.</style></author><author><style face="normal" font="default" size="100%">Bilo, B. M.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Abdul Latiff, A. H.</style></author><author><style face="normal" font="default" size="100%">Al-Ahmad, M.</style></author><author><style face="normal" font="default" size="100%">Angier, E.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Atanaskovic-Markovic, M.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Barbaud, A.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Bennoor, K. S.</style></author><author><style face="normal" font="default" size="100%">Berghea, E. C.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Bonini, S.</style></author><author><style face="normal" font="default" size="100%">Bosnic-Anticevich, S.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Camargos, P.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">Carreiro-Martins, P.</style></author><author><style face="normal" font="default" size="100%">Carriazo, A.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Caubet, J. C.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Cherubini, A.</style></author><author><style face="normal" font="default" size="100%">Christoff, G.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Dokic, D.</style></author><author><style face="normal" font="default" size="100%">El-Gamal, Y.</style></author><author><style face="normal" font="default" size="100%">Ebisawa, M.</style></author><author><style face="normal" font="default" size="100%">Eberlein, B.</style></author><author><style face="normal" font="default" size="100%">Farrell, J.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Gao, Y.</style></author><author><style face="normal" font="default" size="100%">Gavazzi, G.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Guerin, O.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, H. J.</style></author><author><style face="normal" font="default" size="100%">Hofmann, M.</style></author><author><style face="normal" font="default" size="100%">Hrubisko, M.</style></author><author><style face="normal" font="default" size="100%">Illario, M.</style></author><author><style face="normal" font="default" size="100%">Irani, C.</style></author><author><style face="normal" font="default" size="100%">Ispayeva, Z.</style></author><author><style face="normal" font="default" size="100%">Ivancevich, J. C.</style></author><author><style face="normal" font="default" size="100%">Julge, K.</style></author><author><style face="normal" font="default" size="100%">Kaidashev, I.</style></author><author><style face="normal" font="default" size="100%">Khaitov, M.</style></author><author><style face="normal" font="default" size="100%">Knol, E.</style></author><author><style face="normal" font="default" size="100%">Kraxner, H.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Lauerma, A.</style></author><author><style face="normal" font="default" size="100%">Le, L. T. T.</style></author><author><style face="normal" font="default" size="100%">Le Moing, V.</style></author><author><style face="normal" font="default" size="100%">Levin, M.</style></author><author><style face="normal" font="default" size="100%">Louis, R.</style></author><author><style face="normal" font="default" size="100%">Lourenco, O.</style></author><author><style face="normal" font="default" size="100%">Mahler, V.</style></author><author><style face="normal" font="default" size="100%">Martin, F. C.</style></author><author><style face="normal" font="default" size="100%">Matucci, A.</style></author><author><style face="normal" font="default" size="100%">Milenkovic, B.</style></author><author><style face="normal" font="default" size="100%">Miot, S.</style></author><author><style face="normal" font="default" size="100%">Montella, E.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Namazova-Baranova, L.</style></author><author><style face="normal" font="default" size="100%">Neffen, H.</style></author><author><style face="normal" font="default" size="100%">Nekam, K.</style></author><author><style face="normal" font="default" size="100%">Niedoszytko, M.</style></author><author><style face="normal" font="default" size="100%">Odemyr, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Panzner, P.</style></author><author><style face="normal" font="default" size="100%">Passalacqua, G.</style></author><author><style face="normal" font="default" size="100%">Patella, V.</style></author><author><style face="normal" font="default" size="100%">Petrovic, M.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, N.</style></author><author><style face="normal" font="default" size="100%">Plavec, D.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Recto, M. T.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Reynes, J.</style></author><author><style face="normal" font="default" size="100%">Roller-Winsberger, R. E.</style></author><author><style face="normal" font="default" size="100%">Rolland, Y.</style></author><author><style face="normal" font="default" size="100%">Romano, A.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author><author><style face="normal" font="default" size="100%">Rottem, M.</style></author><author><style face="normal" font="default" size="100%">Rouadi, P. W.</style></author><author><style face="normal" font="default" size="100%">Salles, N.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">S. Sarquis F</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">M. G. A. Schols J</style></author><author><style face="normal" font="default" size="100%">Scichilone, N.</style></author><author><style face="normal" font="default" size="100%">Sediva, A.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Skypala, I.</style></author><author><style face="normal" font="default" size="100%">Smolinska, S.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Sova, M.</style></author><author><style face="normal" font="default" size="100%">Stelmach, R.</style></author><author><style face="normal" font="default" size="100%">Sturm, G.</style></author><author><style face="normal" font="default" size="100%">Suppli Ulrik, C.</style></author><author><style face="normal" font="default" size="100%">Todo-Bom, A. M.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Tsiligianni, I.</style></author><author><style face="normal" font="default" size="100%">Torres, M.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Urrutia Pereira, M.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Vitte, J.</style></author><author><style face="normal" font="default" size="100%">Vultaggio, A.</style></author><author><style face="normal" font="default" size="100%">Wallace, D.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Wang, D. Y.</style></author><author><style face="normal" font="default" size="100%">Waserman, S.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Yusuf, O. M.</style></author><author><style face="normal" font="default" size="100%">Zernotti, M.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Comprehensive Allergy Center, Charite Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health, Berlin, Germany.&#xD;University Hospital Montpellier, France.&#xD;MACVIA-France, Montpellier, France.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Department of Geriatrics, Montpellier University Hospital, Montpellier, France.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy.&#xD;Department of Medical Sciences and Public Health, Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, University of Cagliari, Cagliari, Italy.&#xD;Department of Geriatrics, CHRU de Nancy and Inserm DCAC, Universite de Lorraine, Nancy, France.&#xD;Allergy Unit, Department of Clinical and Molecular Sciences, Universita Politecnica delle Marche, Ancona, Italy.&#xD;Department of Internal Medicine, University Hospital, Ospedali Riuniti di Ancona, Ancona, Italy.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;Department of Pediatrics, Allergy &amp; Immunology Centre, Pantai Hospital, Universiti Putra Malaysia Teaching Hospital, Kuala Lumpur, Malaysia.&#xD;Microbiology Department, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.&#xD;Department of Allergy, Al-Rashed Allergy Center, Kuwait City, Kuwait.&#xD;Primary Care and Population Sciences, University of Southampton, Southampton, UK.&#xD;Institut Desbrest d&apos;Epidemiologie et Sante Publique (IDESP), INSERM et Universite de Montpellier, Montpellier, France.&#xD;Faculty of Medicine, University Children&apos;s Hospital, University of Belgrade, Belgrade, Serbia.&#xD;Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium.&#xD;International Airway Research Center, Sun Yat-sen University, First Affiliated Hospital Guangzou, China.&#xD;Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden.&#xD;Division of Service de Dermatologie et Allergologie, Hopital Tenon, Paris, France.&#xD;Division of Equipe PEPITES, Sorbonne Universite, Institut Pierre Louis d&apos;Epidemiologie et de Sante Publique, Paris, France.&#xD;Department of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.&#xD;Allergology and Clinical Immunology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.&#xD;Clinical Emergency Hospital for Children MS Curie, Bucharest, Romania.&#xD;Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.&#xD;Institute of Translational Pharmacology, Italian National Research Council, Rome, Italy.&#xD;Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia.&#xD;Woolcock Emphysema Centre, Sydney Local Health District, Glebe, NSW, Australia.&#xD;Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino &amp; Mauriziano Hospital, Torino, Italy.&#xD;Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;IRCCS Humanitas Research Hospital, Personalized Medicine, Asthma and Allergy, Milan, Italy.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall d&apos;Hebron, Barcelona, Spain.&#xD;ARADyAL Research Network, Barcelona, Spain.&#xD;Servico de Imunoalergologia, Hospital de Dona Estefania, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.&#xD;Faculdade de Ciencias Medicas (FCM), CEDOC, Universidade Nova de Lisboa, Lisbon, Portugal.&#xD;Regional Ministry of Health of Andalusia, Seville, Spain.&#xD;Division of Allergy/Immunology, University of South Florida, Tampa, FL, USA.&#xD;Pediatric Allergy Unit, Department of Child and Adolescent, Geneva University Hospital, Geneva, Switzerland.&#xD;SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Geriatria, Accettazione Geriatrica e Centro di Ricerca per l&apos;invecchiamento, IRCCS INRCA, Ancona, Italy.&#xD;Faculty of Public Health, Medical University, Sofia, Bulgaria.&#xD;Department of Medicine and Health Research Methods, Evidence &amp; Impact, McMaster University, Hamilton, ON, Canada.&#xD;Fundacao ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, BA, Brazil.&#xD;Medical Faculty, University Clinic of Pulmology and Allergy, Skopje, Republic of Macedonia.&#xD;Pediatric Allergy and Immunology Unit, Children&apos;s Hospital, Ain Shams University, Cairo, Egypt.&#xD;Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.&#xD;LANUA International Healthcare Consultancy, Down, UK.&#xD;Allergy Department Hospital Clinico San Carlos, UCM, IdISSC, Madrid, Spain.&#xD;Department of Otorhinolaryngology, Academic Medical Centers, AMC, Amsterdam, The Netherland.&#xD;EUFOREA, Brussels, Belgium.&#xD;Faculdade de Medicina, CINTESIS, Center for Health Technology and Services Research, Universidade do Porto, Porto, Portugal.&#xD;Allergy Unit, CUF Porto, Porto, Portugal.&#xD;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Service Geriatrie Clinique, Centre Hospitalo-Universitaire Grenoble-Alpes, GREPI (TIMC-IMAG, CNRS 5525, Universite Grenoble-Alpes, Grenoble, France.&#xD;Department of Internal Medicine, Allergy and Clin Immunology, Silesian University of Medicine, Katowice, Poland.&#xD;Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.&#xD;Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia.&#xD;Service de Geriatrie, CHRU, Nice, France.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki University, Helsinki, Finland.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.&#xD;Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.&#xD;Department of Clinical Immunology and Allergy, Oncology Institute of St Elisabeth, Bratislava, Slovakia.&#xD;Department of Public Health and Research and Development Unit, Federico II University &amp; Hospital, Naples, Italy.&#xD;Department of Internal Medicine and Infectious Diseases, St Joseph University, Hotel Dieu de France Hospital, Beirut, Lebanon.&#xD;President of Kazakhstan Association of Allergology and Clinical Immunology, Department of Allergology and Clinical Immunology, Kazakh National Medical University, Almaty, Kazakhstan.&#xD;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;Tartu University Institute of Clinical Medicine, Children&apos;s Clinic, Tartu, Estonia.&#xD;Ukrainina Medical Stomatological Academy, Poltava, Ukraine.&#xD;National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular Immunology, Moscow, Russia.&#xD;Departments of Immunology and Dermatology/Allergology, University Medical Center, Utrecht, The Netherlands.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Department of Dermatology and Allergology, University of Helsinki and Helsinki University, Helsinki, Finland.&#xD;University of Medicine and Pharmacy, Hochiminh City, Vietnam.&#xD;Department of Infectiology, Montpellier University Hospital, Montpellier, France.&#xD;Division Paediatric Allergology, University of Cape Town, Cape Town, South Africa.&#xD;Department of Pulmonary Medicine, CHU Sart-Tilman, GIGA I3 Research Group, Liege, Belgium.&#xD;Faculty of Health Sciences, CICS - UBI, Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Paul-Ehrlich-Institut, Langen, Germany.&#xD;Emeritus Geriatrician and Professor of Medical Gerontology Population Health Sciences I, King&apos;s College London, London, UK.&#xD;Immunoallergology Unit, Careggi University Hospital, Florence, Italy.&#xD;Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;Rhinology Unit &amp; Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain.&#xD;Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.&#xD;Pediatrics and Child Health Research Institute, Central Clinical Hospital of the Russian Academy of Sciences, Russian National Research Medical University, Moscow, Russia.&#xD;Director of Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina.&#xD;Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.&#xD;Department of Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;EFA European Federation of Allergy and Airways Diseases Patients&apos; Associations, Brussels, Belgium.&#xD;Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University, Alfred Health, Melbourne, Vic., Australia.&#xD;Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, Odense University Hospital, University of Southern Denmark, Odense, Denmark.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.&#xD;Allergy Department, 2nd Pediatric Clinic, Athens General Children&apos;s Hospital &quot;P&amp;A Kyriakou&quot;, University of Athens, Athens, Greece.&#xD;Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic.&#xD;Allergy and Respiratory Diseases, Ospedale Policlino San Martino -University of Genoa, Genoa, Italy.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, &quot;Santa Maria della Speranza&quot; Hospital, Salerno, Italy.&#xD;Department of Internal Medicine and Paediatrics, Section of Geriatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Ecole polytechnique Palaiseau, IRBA (Institut de Recherche bio-Medicale des Armees), Bretigny, France.&#xD;Children&apos;s Hospital Srebrnjak, Zagreb, Croatia.&#xD;School of Medicine, University J.J. Strossmayer, Osijek, Croatia.&#xD;University Hospital, Sv Ivan Rilski&apos;, Sofia, Bulgaria.&#xD;Asian Hospital and Medical Center, Manilla, Philippines.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.&#xD;Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Faculty of Medicine, ICBR - Coimbra Institute for Clinical and Biomedical Research, CIBB, University of Coimbra, Coimbra, Portugal.&#xD;Medical University of Graz, Graz, Austria.&#xD;Gerontopole de Toulouse, INSERM 1027, Toulouse, France.&#xD;Oasi Research Institute-IRCCS, Troina, Italy.&#xD;Fondazione Mediterranea GB Morgagni, Catania, Italy.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA and ARADyAL, Malaga, Spain.&#xD;Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel.&#xD;Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.&#xD;Department of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon.&#xD;Societe Francaise de Geriatrie et Gerontologie, Paris, France.&#xD;Department of Prevention of Environmental Hazards, Allergology &amp; Immunology, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Women and Children&apos;s Health (Paediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital Guy&apos;sand St Thomas, Hospital, London, UK.&#xD;Asthma UK Centre for Allergic Mechanisms in Asthma, London, UK.&#xD;Asthma Reference Center, School of Medicine of Santa Casa de Misericordia of Vitoria, Espirito Santo, Brazil.&#xD;Faculty of Medicine, Fundacion Jimenez Diaz, CIBERES, Autonoma University of Madrid, Madrid, Spain.&#xD;Department of Health Services Research, Department of Family Medicine Caphri - Care and Public Health Research Institute, Maastricht University, Maastrich, NL, USA.&#xD;PROMISE Department, University of Palermo, Palermo, Italy.&#xD;Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.&#xD;Immunomodulation and Tolerance Group, Imperial College London, London, UK.&#xD;Allergy and Clinical Immunology, Imperial College London, London, UK.&#xD;Usher Institute, The University of Edinburgh, Edinburgh, UK.&#xD;Royal Brompton and Harefield NHS Foundation Trust, London, UK.&#xD;ALL-MED&quot; Medical Research Institute, Wroclaw, Poland.&#xD;Christine Kuhne - Center for Allergy Research and Education, CK-CARE, Davos, Switzerland.&#xD;MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic.&#xD;Pulmonary Division, Heart Institute (InCor, Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.&#xD;Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria.&#xD;Austria Outpatient Allergy Clinic Reumannplatz, Vienna, Austria.&#xD;Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Imunoalergologia, Centro Hospitalar Universitario de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece.&#xD;International Primary Care Respiratory Group IPCRG, Aberdeen, UK.&#xD;Allergy Unit, Malaga Regional University Hospital-IBIMA, Malaga, Spain.&#xD;Federal University of Pampa, Uruguaiana, Brazil.&#xD;Faculty of Medicine, Vilnius University, Institute of Clinical Medicine &amp; Institute of Health Sciences, Vilnius, Lithuania.&#xD;European Academy of Paediatrics (EAP/UEMS-SP, Brussels, Belgium.&#xD;Aix-Marseille University, IRD, APHM, MEPHI, Marseille, France.&#xD;IHU Mediterranee Infection, Marseille and IDESP, INSERM, University of Montpellier, Montpellier, France.&#xD;Nova Southeastern University, Fort Lauderdale, FL, USA.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.&#xD;The Allergy and Asthma Institute, Islamabad, Pakistan.&#xD;Universidad Catolica de Cordoba, Universidad Nacional de Villa Maria, Villa Maria, Argentina.&#xD;University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of anaphylaxis due to COVID-19 vaccines in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2952-2964</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/04/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">adrenaline</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">older (adults/people)</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis,</style></keyword><keyword><style face="normal" font="default" size="100%">Takeda, Teva, Uriach, other from KYomed-Innov, personal fees from Purina. VC</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees from ALK, Allergy Therapeutics, LETI, Thermo Fisher, Merck,</style></keyword><keyword><style face="normal" font="default" size="100%">Astrazeneca, GSK. AC reports personal fees from BMS, MSD. ME reports personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from DBV Technologies, Mylan. MFR reports grants from ISCII (Spanish</style></keyword><keyword><style face="normal" font="default" size="100%">Government), Aimmune, Diater, personal fees from Aimmune, DBV, Novartis, SPRIM,</style></keyword><keyword><style face="normal" font="default" size="100%">ALK, Allergy Therapeutics, Diater, GSK, Thermo Fisher. BG reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Astrazeneca, Novartis, MSD, Deva, Abdi Ibrahim, GSK. TH reports personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from GSK, Mundipharma, OrionPharma, Sanofi. LK reports grants and personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Allergopharma, LETI Pharma, MEDA/Mylan, Sanofi, personal fees from HAL</style></keyword><keyword><style face="normal" font="default" size="100%">Allergie, Allergy Therapeut., Cassella med, grants from ALK Abello, Stallergenes,</style></keyword><keyword><style face="normal" font="default" size="100%">Quintiles ASIT biotech, Lofarma, AstraZeneca, GSK, Inmunotk, and Membership:</style></keyword><keyword><style face="normal" font="default" size="100%">AeDA, DGHNO, Deutsche Akademie furAllergologie und klinischeImmunologie, HNO-BV,</style></keyword><keyword><style face="normal" font="default" size="100%">GPA, EAACI. PK reports personal fees from Adamed, AstraZeneca, Berlin Chemie,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Hal Allergy, Lekam, Mylan, GSK, Novartis, Polpharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, from Teva. VK reports non-financial support from AstraZeneca, DIMUNA,</style></keyword><keyword><style face="normal" font="default" size="100%">BerlinCHemieMenarini Baltic. RL reports grants from Astra Zeneca, Chiesi, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">other from Astra Zeneca, Novartis, GSK, Sanofi. JM reports personal fees and</style></keyword><keyword><style face="normal" font="default" size="100%">other from SANOFI GENZYME &amp; REGENERON, NOVARTIS, ALLAKOS, grants and personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from MYLAN Pharma, URIACH Group, personal fees from Mitsubishi-Tanabe,</style></keyword><keyword><style face="normal" font="default" size="100%">Menarini, UCB, AstraZeneca, GSK, MSD. MO reports grants from Astra Zeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, GSK, DBV Technologies, Aimmune, Novartis, Pfizer, Regeneron, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim</style></keyword><keyword><style face="normal" font="default" size="100%">and volunteer President of the European Federation of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Airways Diseases Patients&apos; Associations EFA who receives unrestricted</style></keyword><keyword><style face="normal" font="default" size="100%">grants from pharmaceutical companies. Second Vice President of the Swedish Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">and Allergy Association, who receives no income from companies. Takes part in</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis Asthma Patient Advisory Committee, GSK Global Respiratory Patient</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Group and have participated/presented in AstraZeneca events. Whenever</style></keyword><keyword><style face="normal" font="default" size="100%">there was a honorarium, this went to EFA. OP reports research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Inmunotek S.L., Novartis, and MINECO. fees for giving scientific lectures or</style></keyword><keyword><style face="normal" font="default" size="100%">participation in Advisory Boards from Allergy Therapeutics, Amgen, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Diater, GlaxoSmithKline, S.A, Inmunotek S.L, Novartis, Sanofi Genzyme and</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes. NP reports personal fees from Novartis, Nutricia, HAL,</style></keyword><keyword><style face="normal" font="default" size="100%">MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT</style></keyword><keyword><style face="normal" font="default" size="100%">BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA,</style></keyword><keyword><style face="normal" font="default" size="100%">Capricare. OP reports grants and personal fees from ALK-Abello, Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, BencardAllergie</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., rom Laboratorios</style></keyword><keyword><style face="normal" font="default" size="100%">LETI/LETI Pharma, Anergis S.A., Glaxo Smith Kline, personal fees from Astellas</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma Global, MEDA Pharma/MYLAN, EUFOREA, ROXALL Medizin, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Aventis, and Sanofi Genzyme, Med Update Europe GmbH, streamedup! GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">John Wiley and Sons, AS, Paul-Martini-Stiftung (PMS), Mobile Chamber Experts (a</style></keyword><keyword><style face="normal" font="default" size="100%">GA2LEN Partner), Indoor Biotechnologies grants from Pohl-Boskamp, Inmunotek S.L.,</style></keyword><keyword><style face="normal" font="default" size="100%">Biomay, Circassia. DP reports grants and personal fees from GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees and non-financial support from Boehringer Ingelheim, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Belupo, AbbVie, MSD, Chiesi, Menarini, Pliva, Revenio, non-financial support</style></keyword><keyword><style face="normal" font="default" size="100%">from Philips. YR reports grants from BIOPHYTIS, NOVARTIS. BS reports personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Allergopharma, Viatris, TEVA, ADAMED, patient ombudsman, Polish</style></keyword><keyword><style face="normal" font="default" size="100%">Allergology Society grants from AstraZeneca, National Health Programm, grant and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Polpharma, AstraZeneca. AS reports grants and personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Medical Research Council, Thermo Fisher, Buhlmann, Infomed, Nutricia and</style></keyword><keyword><style face="normal" font="default" size="100%">Nestle, Allergy Therapeutics, Novartis and Stallergenes, grants from Food Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Research and Education, Asthma UK, NIAID / Immune Tolerance Network,</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from National Institute for Health Research, Thermo Fisher</style></keyword><keyword><style face="normal" font="default" size="100%">and Buhlmann. Dr. Serpa reports personal fees from Takeda, personal fees and</style></keyword><keyword><style face="normal" font="default" size="100%">other from Novartis, personal fees from Sanofi, personal fees from GSK, other</style></keyword><keyword><style face="normal" font="default" size="100%">from Astra Zeneca. JS reports grants and personal fees from SANOFI, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from GSK, NOVARTIS, ASTRA ZENECA, MUNDIPHARMA, FAES FARMA. AS reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">HDRUK. MS reports grants from Swiss National Science Foundation (SNF),</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline (GSK). RS reports grants from Sao Paulo Research Foundation, MSD,</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from Novartis, grants, personal fees and non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support from AstraZeneca, grants, personal fees and non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, personal fees and non-financial support from Boehringer Ingelheim. GS</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants and personal fees from ALK-Abello, personal fees from Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard, Stallergens, HAL, Allergopharma, Mylan. AMTB reports grants and personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Teva, AstraZeneca, GSK (GlaxoSmithKline), Sanofi, Mundipharma, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Bial, grants from Leti, Novartis. STS reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, ERT, Novartis, Sanofi Pharma, Roche Products, grants from GSK. MT</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from European Commission, SEAIC, ISCIII, personal fees from Diater</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory, Leti laboratory, Aimmune Therapeutics. IT reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Honoraria for educational activities, speaking engagements, advisory boards from</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Astra Zeneca, GSK, Novartis and grants from GSK Hellas and</style></keyword><keyword><style face="normal" font="default" size="100%">Elpen. CSU reports personal fees from Astra Zeneca, personal fees from Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from Novartis, Boehringer Ingelheim, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, TEVA, Orion Pharma, grants Sanofi Genzyme, personal fees and</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from GSK. IV reports personal fees from Novartis, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees and non-financial support from Thermo Fisher, non-financial support</style></keyword><keyword><style face="normal" font="default" size="100%">from Beckman Coulter. DW reports other from Kaleo, Mylan, and on the AAAAI/ACAAI</style></keyword><keyword><style face="normal" font="default" size="100%">Joint Task Force on Practice Parameters updating the Anaphylaxis practice</style></keyword><keyword><style face="normal" font="default" size="100%">parameter. SW reports other from Pfizer, Kaleo, Bausch Lomb. MW reports other</style></keyword><keyword><style face="normal" font="default" size="100%">from Regeneron Pharmaceuticals, DBV Technologies S.A, Stallergenes GmbH, HAL</style></keyword><keyword><style face="normal" font="default" size="100%">Allergie GmbH, BencardAllergie GmbH, Allergopharma GmbH &amp; Co. KG,</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-AbelloArzneimittel GmbH, Mylan Germany GmbH, Leo Pharma GmbH, Sanofi-Aventis</style></keyword><keyword><style face="normal" font="default" size="100%">Deutschland GmbH, Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals</style></keyword><keyword><style face="normal" font="default" size="100%">Deutschland GmbH, Novartis AG, Biotest AG, AbbVie Deutschland GmbH &amp; Co. KG,</style></keyword><keyword><style face="normal" font="default" size="100%">Lilly Deutschland GmbH. TZ reports and Organizational affiliations: Committee</style></keyword><keyword><style face="normal" font="default" size="100%">member: WHO-Initiative &quot;Allergic Rhinitis and Its Impact on Asthma&quot; (ARIA),</style></keyword><keyword><style face="normal" font="default" size="100%">Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI),</style></keyword><keyword><style face="normal" font="default" size="100%">Board Chairman: European Centre for Allergy Research Foundation (ECARF).</style></keyword><keyword><style face="normal" font="default" size="100%">President: Global Allergy and Asthma European Network (GA(2)LEN), Member:</style></keyword><keyword><style face="normal" font="default" size="100%">Committee on Allergy Diagnosis and Molecular Allergology, World Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Organization (WAO).</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33811358</style></accession-num><abstract><style face="normal" font="default" size="100%">Older adults, especially men and/or those with diabetes, hypertension, and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritized to receive COVID-19 vaccines due to high risk of death. In very rare instances, the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society) Working Group has proposed some recommendations for older adults receiving the COVID-19 vaccines. Anaphylaxis to COVID-19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients.</style></abstract><notes><style face="normal" font="default" size="100%">Bousquet, Jean&#xD;Agache, Ioana&#xD;Blain, Hubert&#xD;Jutel, Marek&#xD;Ventura, Maria Teresa&#xD;Worm, Margitta&#xD;Del Giacco, Stefano&#xD;Benetos, Athanasios&#xD;Bilo, Beatrice Maria&#xD;Czarlewski, Wienczyslawa&#xD;Abdul Latiff, Amir Hamzah&#xD;Al-Ahmad, Mona&#xD;Angier, Elizabeth&#xD;Annesi-Maesano, Isabella&#xD;Atanaskovic-Markovic, Marina&#xD;Bachert, Claus&#xD;Barbaud, Annick&#xD;Bedbrook, Anna&#xD;Bennoor, Kazi S&#xD;Berghea, Elena Camelia&#xD;Bindslev-Jensen, Carsten&#xD;Bonini, Sergio&#xD;Bosnic-Anticevich, Sinthia&#xD;Brockow, Knut&#xD;Brussino, Luisa&#xD;Camargos, Paulo&#xD;Canonica, G Walter&#xD;Cardona, Victoria&#xD;Carreiro-Martins, Pedro&#xD;Carriazo, Ana&#xD;Casale, Thomas&#xD;Caubet, Jean-Christoph&#xD;Cecchi, Lorenzo&#xD;Cherubini, Antonio&#xD;Christoff, George&#xD;Chu, Derek K&#xD;Cruz, Alvaro A&#xD;Dokic, Dejan&#xD;El-Gamal, Yehia&#xD;Ebisawa, Motohiro&#xD;Eberlein, Bernadette&#xD;Farrell, John&#xD;Fernandez-Rivas, Montserrat&#xD;Fokkens, Wytske J&#xD;Fonseca, Joao A&#xD;Gao, Yadong&#xD;Gavazzi, Gaetan&#xD;Gawlik, Radoslaw&#xD;Gelincik, Asli&#xD;Gemicioglu, Bilun&#xD;Gotua, Maia&#xD;Guerin, Olivier&#xD;Haahtela, Tari&#xD;Hoffmann-Sommergruber, Karin&#xD;Hoffmann, Hans Jurgen&#xD;Hofmann, Maja&#xD;Hrubisko, Martin&#xD;Illario, Maddalena&#xD;Irani, Carla&#xD;Ispayeva, Zhanat&#xD;Ivancevich, Juan Carlos&#xD;Julge, Kaja&#xD;Kaidashev, Igor&#xD;Khaitov, Musa&#xD;Knol, Edward&#xD;Kraxner, Helga&#xD;Kuna, Piotr&#xD;Kvedariene, Violeta&#xD;Lauerma, Antti&#xD;Le, Lan T T&#xD;Le Moing, Vincent&#xD;Levin, Michael&#xD;Louis, Renaud&#xD;Lourenco, Olga&#xD;Mahler, Vera&#xD;Martin, Finbarr C&#xD;Matucci, Andrea&#xD;Milenkovic, Branislava&#xD;Miot, Stephanie&#xD;Montella, Emma&#xD;Morais-Almeida, Mario&#xD;Mortz, Charlotte G&#xD;Mullol, Joaquim&#xD;Namazova-Baranova, Leyla&#xD;Neffen, Hugo&#xD;Nekam, Kristof&#xD;Niedoszytko, Marek&#xD;Odemyr, Mikaela&#xD;O&apos;Hehir, Robyn E&#xD;Okamoto, Yoshitaka&#xD;Ollert, Markus&#xD;Palomares, Oscar&#xD;Papadopoulos, Nikolaos G&#xD;Panzner, Petr&#xD;Passalacqua, Giovanni&#xD;Patella, Vincenzo&#xD;Petrovic, Mirko&#xD;Pfaar, Oliver&#xD;Pham-Thi, Nhan&#xD;Plavec, Davor&#xD;Popov, Todor A&#xD;Recto, Marysia T&#xD;Regateiro, Frederico S&#xD;Reynes, Jacques&#xD;Roller-Winsberger, Regina E&#xD;Rolland, Yves&#xD;Romano, Antonino&#xD;Rondon, Carmen&#xD;Rottem, Menachem&#xD;Rouadi, Philip W&#xD;Salles, Nathalie&#xD;Samolinski, Boleslaw&#xD;Santos, Alexandra F&#xD;S Sarquis, Faradiba&#xD;Sastre, Joaquin&#xD;M G A Schols, Jos&#xD;Scichilone, Nicola&#xD;Sediva, Anna&#xD;Shamji, Mohamed H&#xD;Sheikh, Aziz&#xD;Skypala, Isabel&#xD;Smolinska, Sylwia&#xD;Sokolowska, Milena&#xD;Sousa-Pinto, Bernardo&#xD;Sova, Milan&#xD;Stelmach, Rafael&#xD;Sturm, Gunter&#xD;Suppli Ulrik, Charlotte&#xD;Todo-Bom, Ana Maria&#xD;Toppila-Salmi, Sanna&#xD;Tsiligianni, Ioanna&#xD;Torres, Maria&#xD;Untersmayr, Eva&#xD;Urrutia Pereira, Marilyn&#xD;Valiulis, Arunas&#xD;Vitte, Joana&#xD;Vultaggio, Alessandra&#xD;Wallace, Dana&#xD;Walusiak-Skorupa, Jolanta&#xD;Wang, De-Yun&#xD;Waserman, Susan&#xD;Yorgancioglu, Arzu&#xD;Yusuf, Osman M&#xD;Zernotti, Mario&#xD;Zidarn, Mihaela&#xD;Chivato, Tomas&#xD;Akdis, Cezmi A&#xD;Zuberbier, Torsten&#xD;Klimek, Ludger&#xD;eng&#xD;N/A/ARIA/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):2952-2964. doi: 10.1111/all.14838.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33811358</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8251336</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14838</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1389</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1389</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caubet, J. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Allergy, University Hospital of Geneva, Geneva, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of children with a suspicion of immediate drug hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">940-941</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32715493</style></accession-num><notes><style face="normal" font="default" size="100%">Caubet, Jean-Christoph&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):940-941. doi: 10.1111/all.14521. Epub 2020 Aug 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32715493</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14521</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1859</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1859</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caubet, J. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Allergy, University Hospital of Geneva, Geneva, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of children with a suspicion of immediate drug hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">940-941</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32715493</style></accession-num><notes><style face="normal" font="default" size="100%">Caubet, Jean-Christoph&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):940-941. doi: 10.1111/all.14521. Epub 2020 Aug 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32715493</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14521</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jimenez-Rodriguez, T. W.</style></author><author><style face="normal" font="default" size="100%">Berges-Gimeno, M. P.</style></author><author><style face="normal" font="default" size="100%">Barranco, R.</style></author><author><style face="normal" font="default" size="100%">Bartra, J.</style></author><author><style face="normal" font="default" size="100%">Dieguez, M. D. C.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Gandolfo-Cano, M. D. M.</style></author><author><style face="normal" font="default" size="100%">Gastaminza-Lasarte, G.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Mancebo, E.</style></author><author><style face="normal" font="default" size="100%">de la Hoz Caballer, B.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Morillas, L.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Vega, A.</style></author><author><style face="normal" font="default" size="100%">Munoz-Cano, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Section, Alicante General University Hospital-ISABIAL, Alicante, Spain.&#xD;ARADyAL Spanish Network (RD16/0006), Instituto de Salud Carlos III (ISCIII), Fundacion Espanola para la Ciencia y la Tecnologia (FECyT, Madrid, Spain.&#xD;Allergy Division, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain.&#xD;Allergy Department, Hospital Universitario 12 de Octubre, i+12. PIELenRed Consortium, Madrid, Spain.&#xD;Allergy Section, Pneumology Department, Hospital Clinic, IRCE- Institutd&apos;InvestigacionsBiomediques August Pi iSunyer (IDIBAPS, Universitat de Barcelona, Barcelona, Spain.&#xD;Allergy Research Group, Hospital Civil, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Allergy Unit, Hospital Civil, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Servicio de Alergia, Hospital Clinico San Carlos, IdISSC, UCM, Madrid, Spain.&#xD;Allergy Department, Hospital Universitario de Fuenlabrada, IdiPAZ, Madrid, Spain.&#xD;Allergy Department, Clinica Universidad de Navarra, Pamplona, Espana.&#xD;Universidad de Alcala, Madrid, Spain.&#xD;Allergy Service, Hospital Universitario de Guadalajara, Guadalajara, Spain.&#xD;Facultad de Medicina, Universidad Internacional de Cataluna, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of hypersensitivity reactions to chemotherapy and biologic agents: A survey of ARADyAL (Asthma, Adverse Drug Reactions and Allergy Network) Spanish allergy services</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2249-2253</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug-Related Side Effects and Adverse Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33476405</style></accession-num><notes><style face="normal" font="default" size="100%">Jimenez-Rodriguez, Teodorikez-Wilfox&#xD;Berges-Gimeno, Maria Pilar&#xD;Barranco, Ruth&#xD;Bartra, Joan&#xD;Dieguez, Maria Del Carmen&#xD;Dona, Inmaculada&#xD;Fernandez-Rivas, Montserrat&#xD;Gandolfo-Cano, Maria Del Mar&#xD;Gastaminza-Lasarte, Gabriel&#xD;Gonzalez-Mancebo, Eloina&#xD;de la Hoz Caballer, Belen&#xD;Sanchez-Morillas, Leticia&#xD;Torres, Maria Jose&#xD;Vega, Arantza&#xD;Munoz-Cano, Rosa&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2249-2253. doi: 10.1111/all.14743. Epub 2021 Feb 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33476405</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14743</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2871</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2871</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lan, F.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of New Medicine and Diagnostic Technology Research for Nasal Disease, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of Patients With Allergic Diseases in the Era of Biologics</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1203-1205</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/04/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergies</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">immunology</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40186441</style></accession-num><notes><style face="normal" font="default" size="100%">Lan, Feng&#xD;Akdis, Cezmi A&#xD;Zhang, Luo&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1203-1205. doi: 10.1111/all.16552. Epub 2025 Apr 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40186441</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16552</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>933</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">933</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chiricozzi, A.</style></author><author><style face="normal" font="default" size="100%">Talamonti, M.</style></author><author><style face="normal" font="default" size="100%">De Simone, C.</style></author><author><style face="normal" font="default" size="100%">Galluzzo, M.</style></author><author><style face="normal" font="default" size="100%">Gori, N.</style></author><author><style face="normal" font="default" size="100%">Fabbrocini, G.</style></author><author><style face="normal" font="default" size="100%">Marzano, A. V.</style></author><author><style face="normal" font="default" size="100%">Girolomoni, G.</style></author><author><style face="normal" font="default" size="100%">Offidani, A.</style></author><author><style face="normal" font="default" size="100%">Rossi, M. T.</style></author><author><style face="normal" font="default" size="100%">Bianchi, L.</style></author><author><style face="normal" font="default" size="100%">Cristaudo, A.</style></author><author><style face="normal" font="default" size="100%">Fierro, M. T.</style></author><author><style face="normal" font="default" size="100%">Stingeni, L.</style></author><author><style face="normal" font="default" size="100%">Pellacani, G.</style></author><author><style face="normal" font="default" size="100%">Argenziano, G.</style></author><author><style face="normal" font="default" size="100%">Patrizi, A.</style></author><author><style face="normal" font="default" size="100%">Pigatto, P.</style></author><author><style face="normal" font="default" size="100%">Romanelli, M.</style></author><author><style face="normal" font="default" size="100%">Savoia, P.</style></author><author><style face="normal" font="default" size="100%">Rubegni, P.</style></author><author><style face="normal" font="default" size="100%">Foti, C.</style></author><author><style face="normal" font="default" size="100%">Milanesi, N.</style></author><author><style face="normal" font="default" size="100%">Belloni Fortina, A.</style></author><author><style face="normal" font="default" size="100%">Bongiorno, M. R.</style></author><author><style face="normal" font="default" size="100%">Grieco, T.</style></author><author><style face="normal" font="default" size="100%">Di Nuzzo, S.</style></author><author><style face="normal" font="default" size="100%">Fargnoli, M. C.</style></author><author><style face="normal" font="default" size="100%">Carugno, A.</style></author><author><style face="normal" font="default" size="100%">Motolese, A.</style></author><author><style face="normal" font="default" size="100%">Rongioletti, F.</style></author><author><style face="normal" font="default" size="100%">Amerio, P.</style></author><author><style face="normal" font="default" size="100%">Balestri, R.</style></author><author><style face="normal" font="default" size="100%">Potenza, C.</style></author><author><style face="normal" font="default" size="100%">Micali, G.</style></author><author><style face="normal" font="default" size="100%">Patruno, C.</style></author><author><style face="normal" font="default" size="100%">Zalaudek, I.</style></author><author><style face="normal" font="default" size="100%">Lombardo, M.</style></author><author><style face="normal" font="default" size="100%">Feliciani, C.</style></author><author><style face="normal" font="default" size="100%">Di Nardo, L.</style></author><author><style face="normal" font="default" size="100%">Guarneri, F.</style></author><author><style face="normal" font="default" size="100%">Peris, K.</style></author><author><style face="normal" font="default" size="100%">Da-Covid- study group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.&#xD;Dermatologia, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;Dermatology Unit, Policlinico Tor Vergata, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy.&#xD;Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.&#xD;Dermatology Unit, Fondazione IRCCS Ca, Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Department of Pathophysiology and Transplantation, UniversitadegliStudi di Milano, Milan, Italy.&#xD;Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.&#xD;Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy.&#xD;Department of Dermatology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.&#xD;Clinical Dermatology, San Gallicano Dermatological Institute, Rome, Italy.&#xD;Medical Sciences Department, Dermatologic Clinic, University of Turin, Turin, Italy.&#xD;Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy.&#xD;Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.&#xD;Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy.&#xD;Dermatology UOC, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.&#xD;Department of Biomedical, Surgical and Dental Sciences, Clinical Dermatology, IRCCS Galeazzi Orthopaedic Institute, University of Milan, Milan, Italy.&#xD;Department of Dermatology, University of Pisa, Pisa, Italy.&#xD;Department of Health Sciences, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.&#xD;Dermatology Unit, Department of Medical, Surgical and Neurosciences, University of Siena, Siena, Italy.&#xD;Department of Biomedical Science and Human Oncology, Unit of Dermatology, University of Bari, Bari, Italy.&#xD;Dermatology Clinic, Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Dermatology Unit - Department of Medicine DIMED, University of Padova, Padova, Italy.&#xD;Section of Dermatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.&#xD;Unit of Dermatology, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.&#xD;Department of Medicine and Surgery, Section of Dermatology, University of Parma, Parma, Italy.&#xD;Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L&apos;Aquila, L&apos;Aquila, Italy.&#xD;Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.&#xD;Dermatology Unit, Department of MedicalSpecialties, Arcispedale Santa Maria Nuova-IRCCS di Reggio Emilia, Reggio Emilia, Italy.&#xD;Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy.&#xD;Department of Medicine and Aging Science, Dermatologic Clinic, G. D&apos;Annunzio University, Chieti, Italy.&#xD;Division of Dermatology, Santa Chiara Hospital, Trento, Italy.&#xD;Department of Medico-Surgical Sciences and Biotechnologies, Dermatology Unit, Daniele Innocenzi, Sapienza, University of Rome - Polo Pontino, Rome, Italy.&#xD;Dermatology Clinic, University of Catania, Catania, Italy.&#xD;Dermatology Unit, Department of Health Sciences, Universita Magna Graecia, Catanzaro, Italy.&#xD;Department of Dermatology, University of Trieste, Trieste, Italy.&#xD;Unit of DermatologicalDiseases, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy.&#xD;Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1813-1824</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/06/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Communicable Disease Control</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Italy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">fees and speaker&apos;s honoraria or has participated in clinical trials for AbbVie,</style></keyword><keyword><style face="normal" font="default" size="100%">Almirall, Biogen, Fresenius Kabi, Leo Pharma, Lilly, Janssen, Novartis, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">Genzyme, and UCB Pharma. G. Fabbrocini acted as speaker and consultant for AbbVie</style></keyword><keyword><style face="normal" font="default" size="100%">and Leo Pharma. G. Girolomoni has been principal investigator in clinical trials</style></keyword><keyword><style face="normal" font="default" size="100%">sponsored by and/or and has received personal fees from AbbVie, Abiogen,</style></keyword><keyword><style face="normal" font="default" size="100%">Almirall, Amgen, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Celgene,</style></keyword><keyword><style face="normal" font="default" size="100%">Celltrion, Eli-Lilly, Genzyme, Leo Pharma, Menlo therapeutics, Novartis, OM</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Pfizer, Regeneron, Samsung, Sandoz, and UCB Pharma. A. Offidani has been</style></keyword><keyword><style face="normal" font="default" size="100%">a scientific consultant/speaker/clinical study investigator for AbbVie, Celgene,</style></keyword><keyword><style face="normal" font="default" size="100%">Janssen, LEO Pharma, Eli-Lilly, MSD, Novartis, Pfizer, Sanofi, Alfasigma, and</style></keyword><keyword><style face="normal" font="default" size="100%">Almirall. M.T. Rossi has received personal fee for advisory board meeting from</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, Abbvie, Novartis, and Cantabria. L. Bianchi reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">speaker and as consultant for AbbVie, Novartis, Janssen-Cilag, Pfizer, UCB, and</style></keyword><keyword><style face="normal" font="default" size="100%">Leo Pharma, outside the submitted work. L. Stingeni has been principal</style></keyword><keyword><style face="normal" font="default" size="100%">investigator in clinical trials sponsored by and/or received personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AbbVie, Almirall, Celgene, Eli-Lilly, Janssen, Novartis, and Sanofi-Genzyme. G.</style></keyword><keyword><style face="normal" font="default" size="100%">Pellacani has been principal investigator in clinical trials sponsored by and/or</style></keyword><keyword><style face="normal" font="default" size="100%">received personal fees from AbbVie, Almirall, Eli-Lilly, Leo Pharma, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">and Sanofi. A. Patrizi has served as a speaker and received honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genzyme for lectures, research grants and as an advisory board member. C.</style></keyword><keyword><style face="normal" font="default" size="100%">Foti has been speaker for Sanofi and Abbvie. M.C. Fargnoli has served on advisory</style></keyword><keyword><style face="normal" font="default" size="100%">boards, received honoraria for lectures and research grants from Almirall,</style></keyword><keyword><style face="normal" font="default" size="100%">AbbVie, Galderma, Leo Pharma, Mylan, Medac Pharma, Celgene, Pierre Fabre, UCB,</style></keyword><keyword><style face="normal" font="default" size="100%">Eli-Lilly, Pfizer, Janssen, Novartis, Sanofi Genzyme, Roche, Sun Pharma, and MSD.</style></keyword><keyword><style face="normal" font="default" size="100%">F. Rongioletti has served on advisory board, received honoraria for lectures and</style></keyword><keyword><style face="normal" font="default" size="100%">research grants from Novartis, AbbVie, Janssen-Cilag, Eli-Lilly, Leo Pharma, and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genzyme. P. Amerio has received speaker honoraria from Sanofi, AbbVie,</style></keyword><keyword><style face="normal" font="default" size="100%">Janssen, Celgene, Novartis, and Sandoz. G. Micali has been a scientific</style></keyword><keyword><style face="normal" font="default" size="100%">consultant/clinical study investigator for Abbvie, Eli-Lilly, Janssen- Cilag, LEO</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, and Novartis. C. Patruno has been a consultant and held sponsored</style></keyword><keyword><style face="normal" font="default" size="100%">conferences for AbbVie, Novartis, Pfizer, and Sanofi. I. Zalaudek has been a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant and/or speaker for Novartis, Celgene, and Amgen. K. Peris reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees for advisory board meeting from Almirall, AbbVie,</style></keyword><keyword><style face="normal" font="default" size="100%">Biogen, Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Sandoz, Sun Pharma, and Janssen. The other authors reported no conflicts of</style></keyword><keyword><style face="normal" font="default" size="100%">interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34152613</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. METHODS: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. RESULTS: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. CONCLUSIONS: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.</style></abstract><notes><style face="normal" font="default" size="100%">Chiricozzi, Andrea&#xD;Talamonti, Marina&#xD;De Simone, Clara&#xD;Galluzzo, Marco&#xD;Gori, Niccolo&#xD;Fabbrocini, Gabriella&#xD;Marzano, Angelo Valerio&#xD;Girolomoni, Giampiero&#xD;Offidani, Annamaria&#xD;Rossi, Maria Teresa&#xD;Bianchi, Luca&#xD;Cristaudo, Antonio&#xD;Fierro, Maria Teresa&#xD;Stingeni, Luca&#xD;Pellacani, Giovanni&#xD;Argenziano, Giuseppe&#xD;Patrizi, Annalisa&#xD;Pigatto, Paolo&#xD;Romanelli, Marco&#xD;Savoia, Paola&#xD;Rubegni, Pietro&#xD;Foti, Caterina&#xD;Milanesi, Nicola&#xD;Belloni Fortina, Anna&#xD;Bongiorno, Maria Rita&#xD;Grieco, Teresa&#xD;Di Nuzzo, Sergio&#xD;Fargnoli, Maria Concetta&#xD;Carugno, Andrea&#xD;Motolese, Alberico&#xD;Rongioletti, Franco&#xD;Amerio, Paolo&#xD;Balestri, Riccardo&#xD;Potenza, Concetta&#xD;Micali, Giuseppe&#xD;Patruno, Cataldo&#xD;Zalaudek, Iris&#xD;Lombardo, Maurizio&#xD;Feliciani, Claudio&#xD;Di Nardo, Lucia&#xD;Guarneri, Fabrizio&#xD;Peris, Ketty&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1813-1824. doi: 10.1111/all.14767. Epub 2021 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34152613</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8014537</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14767</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>428</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">428</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Alexiou, A.</style></author><author><style face="normal" font="default" size="100%">Bauer, A.</style></author><author><style face="normal" font="default" size="100%">Treudler, R.</style></author><author><style face="normal" font="default" size="100%">Wurpts, G.</style></author><author><style face="normal" font="default" size="100%">Dickel, H.</style></author><author><style face="normal" font="default" size="100%">Buhl, T.</style></author><author><style face="normal" font="default" size="100%">Muller, S.</style></author><author><style face="normal" font="default" size="100%">Jung, A.</style></author><author><style face="normal" font="default" size="100%">Brehler, R.</style></author><author><style face="normal" font="default" size="100%">Fluhr, J.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Mulleneisen, N.</style></author><author><style face="normal" font="default" size="100%">Pfutzner, W.</style></author><author><style face="normal" font="default" size="100%">Raap, U.</style></author><author><style face="normal" font="default" size="100%">Roeseler, S.</style></author><author><style face="normal" font="default" size="100%">Schuh, S.</style></author><author><style face="normal" font="default" size="100%">Timmermann, H.</style></author><author><style face="normal" font="default" size="100%">Heine, G.</style></author><author><style face="normal" font="default" size="100%">Wedi, B.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergologie und Immunologie, Klinik fur Dermatologie, Venerologie und Allergologie, Campus Charite Mitte, Universitatsmedizin Berlin, Berlin, Germany.&#xD;Klinik und Poliklinik fur Dermatologie, Comprehensive Allergy Center (CAC), Universitatsklinikum Carl Gustav Carus an der Technischen Universitat Dresden, Dresden, Germany.&#xD;Klinik fur Dermatologie, Venerologie und Allergologie, Leipziger Interdisziplinares Centrum fur Allergologie (CAC), Universitatsmedizin Leipzig, Leipzig, Germany.&#xD;Klinik fur Dermatologie und Allergologie, Aachener Comprehensive Allergy Center (ACAC), Universitatsklinik der RWTH Aachen, Aachen, Germany.&#xD;Abteilung fur Allergologie, Berufs- und Umweltdermatologie, Klinik fur Dermatologie, Venerologie und Allergologie, St. Josef-Hospital, Ruhr-Universitat Bochum, Bochum, Germany.&#xD;Klinik fur Dermatologie Venerologie und Allergologie, Universitatsmedizin Gottingen Georg-August-Universitat, Gottingen, Germany.&#xD;Klinik fur Dermatologie, Universitatsklinikum Freiburg, Medizinische Fakultat, Albert-Ludwigs-Universitat Freiburg, Freiburg, Germany.&#xD;Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Giessen, Giessen, Germany.&#xD;Ambulanz fur Allergologie, Berufsdermatologie und Umweltmedizin, Universitatsklinikum Munster, Munster, Germany.&#xD;Comprehensive Allergy Centre Charite CACC, Campus Benjamin Franklin, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Allergiezentrum Wiesbaden/Rhein-Main, Zentrum fur Rhinologie und Allergologie, Wiesbaden, Germany.&#xD;Asthma- und Allergiezentrum Leverkusen, Leverkusen, Germany.&#xD;Allergiezentrum Hessen, Klinik fur Dermatologie und Allergologie, Universitatsklinikum Marburg, Marburg, Germany.&#xD;Comprehensive Allergy Center (CAC), Universitatsklinik fur Dermatologie und Allergologie Klinikum Oldenburg AoR, Allergiezentrum Oldenburg, Oldenburg, Germany.&#xD;Klinik fur Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Krankenhaus der Augustinerinnen, Koln, Germany.&#xD;Kooperationspartner Aachener Comprehensive Allergy Center (ACAC), Koln, Germany.&#xD;Klinik fur Dermatologie und Allergologie, Universitatsklinikum Augsburg - am Standort Medizincampus Sud, Augsburg, Germany.&#xD;Schwerpunktpraxis Colonaden, Hamburg, Germany.&#xD;Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.&#xD;Klinik fur Dermatologie, Allergologie und Venerologie, Comprehensive Allergy Center (CAC), Medizinische Hochschule Hannover, Hannover, Germany.&#xD;Klinik und Poliklinik fur Dermatologie und Allergologie am Biederstein, Technische Universitat Munchen, Munchen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3426-3434</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/06/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">polyethylene glycol</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35722723</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Systemic allergic reactions to vaccines are very rare. In this study we assessed the management and outcome of suspected SARS-CoV-2 vaccine hypersensitivity. METHODS: Totally, 334 individuals underwent an allergy work up regarding SARS-CoV-2 vaccination (group A: 115 individuals suspected to be at increased risk for vaccine-related reactions before vaccination and group B: 219 patients with reactions after COVID vaccination). The large majority of the SPT/IDT with the vaccines were negative; however, we identified in 14.1% (n = 47) a possible sensitization to the SARS-CoV-2 vaccine and/or its ingredients defined as one positive skin test. Of the 219 individuals (group B) who experienced symptoms suspicious for a hypersensitivity reaction after vaccination, 214 were reported after the first vaccination with a mRNA vaccine (157 mRNA (Comirnaty(R), 38 Spikevax(R)) and 18 with a vector vaccine (Vaxzevria(R)), 5 cases were after the second vaccination. RESULTS: The symptom profile in group B was as follows: skin symptoms occurred in 115 cases (n = 59 angioedema, n = 50 generalized urticaria and n = 23 erythema/flush. Seventy individuals had cardiovascular, 53 respiratory and 17 gastrointestinal symptoms. Of the overall 334 individuals, 78 patients tolerated (re)-vaccination (out of skin test positive/negative 7/19 from group A and 17/35 from group B). CONCLUSION: Proven IgE-mediated hypersensitivity to SARS-CoV-2 vaccines is extremely rare and not increased in comparison with reported hypersensitivity to other vaccines. The value of skin tests is unclear and nonspecific reactions, in particular when intradermal testing is applied, should be considered.</style></abstract><notes><style face="normal" font="default" size="100%">Worm, Margitta&#xD;Alexiou, Aikaterina&#xD;Bauer, Andrea&#xD;Treudler, Regina&#xD;Wurpts, Gerda&#xD;Dickel, Heinrich&#xD;Buhl, Timo&#xD;Muller, Sabine&#xD;Jung, Andreas&#xD;Brehler, Randolf&#xD;Fluhr, Joachim&#xD;Klimek, Ludger&#xD;Mulleneisen, Norbert&#xD;Pfutzner, Wolfgang&#xD;Raap, Ulrike&#xD;Roeseler, Stefani&#xD;Schuh, Sandra&#xD;Timmermann, Hartmut&#xD;Heine, Guido&#xD;Wedi, Bettina&#xD;Brockow, Knut&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3426-3434. doi: 10.1111/all.15414. Epub 2022 Jul 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35722723</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9350006</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15414</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>583</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">583</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Jantunen, J.</style></author><author><style face="normal" font="default" size="100%">Saarinen, K.</style></author><author><style face="normal" font="default" size="100%">Tommila, E.</style></author><author><style face="normal" font="default" size="100%">Valovirta, E.</style></author><author><style face="normal" font="default" size="100%">Vasankari, T.</style></author><author><style face="normal" font="default" size="100%">Makela, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Allergy, Skin and Asthma Federation, Helsinki, Finland.&#xD;Finnish Lung Health Association (FILHA), Helsinki, Finland.&#xD;Department of Lung Diseases and Clinical Allergology, University of Turku, and Allergy Clinic, Terveystalo, Turku, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Managing the allergy and asthma epidemic in 2020s-Lessons from the Finnish experience</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2367-2380</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/02/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cost of Illness</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">Finland/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">allergy campaign</style></keyword><keyword><style face="normal" font="default" size="100%">allergy epidemic</style></keyword><keyword><style face="normal" font="default" size="100%">allergy prevention</style></keyword><keyword><style face="normal" font="default" size="100%">allergy programme</style></keyword><keyword><style face="normal" font="default" size="100%">biodiversity</style></keyword><keyword><style face="normal" font="default" size="100%">public health</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Sanofi, Erkka Valovirta from ALK-Abello, AstraZeneca, Mylan, Nestle,</style></keyword><keyword><style face="normal" font="default" size="100%">Nigaard, Orion Pharma, Stallergenes Greer, ThermoFisher, TEVA, Tuula Vasankari</style></keyword><keyword><style face="normal" font="default" size="100%">from AstraZeneca, MSD, Boehringer Ingelheim, and Mika J. Makela from GSK and</style></keyword><keyword><style face="normal" font="default" size="100%">Orion Pharma, outside the submitted work. The other authors have nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35202479</style></accession-num><abstract><style face="normal" font="default" size="100%">In Finland, a systematic public health programme was implemented from 2008 to 2018 to mitigate the burden of allergic disorders by revisiting the prevention strategy. Allergy health and contacts with natural environment were emphasized to promote immunological and psychological resilience instead of poorly justified avoidance. Allergy management practices were improved and low-valued recommendations for care, for example for food allergy, were revised. Patients and families were empowered to use guided self-management to proactively stop symptom exacerbations. A professional non-governmental organization implemented the nationwide education for healthcare and patient NGOs for patients, families and lay public. In healthcare, the work supporting allergic patients and families was organized towards common goals and integrated into everyday work without extra costs. Reaching the predefined goals was followed by employing the national healthcare registers and questionnaire surveys. Governmental bodies contributed with kick-off funding, which was supplemented by private funding. International collaboration, for example with the European patient organization (EFA), increased awareness of the Finnish action and predisposed it for peer review. The 10-year results are favourable, patients are less disabled, practices and attitudes in healthcare have changed, and major cost savings have been obtained. Views of the lay public and patients are slow to move, however. Local multidisciplinary allergy teams were set up to continue the activities also after the Programme. Changes in environment and lifestyle in the last 50 years are the main reasons for the allergy rise. The Finnish experience may help to manage allergic diseases, improve nature relatedness in the fast-urbanizing world, combat nature loss and reduce the disease burden.</style></abstract><notes><style face="normal" font="default" size="100%">Haahtela, Tari&#xD;Jantunen, Juha&#xD;Saarinen, Kimmo&#xD;Tommila, Erja&#xD;Valovirta, Erkka&#xD;Vasankari, Tuula&#xD;Makela, Mika J&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2367-2380. doi: 10.1111/all.15266. Epub 2022 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35202479</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9546028</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15266</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3066</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3066</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shi, W.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Chen, S.</style></author><author><style face="normal" font="default" size="100%">Li, P. H.</style></author><author><style face="normal" font="default" size="100%">Luo, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, SAR, China.&#xD;Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.&#xD;Department of Allergy and Immunology, Huashan Hospital Affiliated to Fudan University, Shanghai, China.&#xD;Department of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, China.&#xD;Research Center of Allergy and Disease, Fudan University, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mandatory Preemptive Skin Testing and Its Impact on Penicillin Allergy Labeling Across Different Healthcare Settings in Mainland China and Hong Kong</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/24</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40990102</style></accession-num><notes><style face="normal" font="default" size="100%">Shi, Weihong&#xD;Wang, Lanting&#xD;Chen, Shengan&#xD;Li, Philip Hei&#xD;Luo, Xiaoqun&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep 24. doi: 10.1111/all.70065.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40990102</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70065</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>684</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">684</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Watts, Y.</style></author><author><style face="normal" font="default" size="100%">Dufresne, E.</style></author><author><style face="normal" font="default" size="100%">Samaan, K.</style></author><author><style face="normal" font="default" size="100%">Graham, F.</style></author><author><style face="normal" font="default" size="100%">Labrosse, R.</style></author><author><style face="normal" font="default" size="100%">Paradis, L.</style></author><author><style face="normal" font="default" size="100%">Des Roches, A.</style></author><author><style face="normal" font="default" size="100%">Poder, T. G.</style></author><author><style face="normal" font="default" size="100%">Begin, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Mathematics and Statistics, Universite de Montreal, Montreal, QC, Canada.&#xD;Department of Medicine, Universite de Montreal, Montreal, QC, Canada.&#xD;Departement of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada.&#xD;Department of Management, Evaluation and Health Policy, School of Public Health, Universite de Montreal, Montreal, QC, Canada.&#xD;Research Center of the Institut Universitaire de Sante Mentale de Montreal, Montreal, QC, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mapping the Food Allergy Quality of Life Questionnaire Parent Form onto the Short-Form Six-Dimensions version 2</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1815-1826</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/11/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Parents</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Faqlq-pf</style></keyword><keyword><style face="normal" font="default" size="100%">Qaly</style></keyword><keyword><style face="normal" font="default" size="100%">SF-6Dv2</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">utility</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34822184</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The Food Allergy Quality of Life Questionnaire Parent Form (FAQLQ-PF) is the most widely used quality of life questionnaire in food allergy. The objective of this study was to develop a mapping algorithm to convert FAQLQ-PF scores into health state utilities. METHODS: The Short-Form Six-Dimensions version 2 (SF-6Dv2) and FAQLQ-PF questionnaires were collected from an academic center oral immunotherapy referral cohort. Utility estimates were derived from the SF-6Dv2 using the food allergy preference set. Candidate mapping algorithm models were developed using seven regression methods starting from either the total average score, the average scores of each of the three domains or the individual item scores of FAQLQ-PF. The process was repeated twice, including only section A, common to all age groups, or including all age-applicable sections of the FAQLQ-PF. The mean absolute error (MAE) and root mean squared error (RMSE) were used to select the best fitting model. An independent cohort from a previous national online survey was used for external validation. RESULTS: In the index cohort, 1000 of 1257 respondents had completed both questionnaires. The lowest MAE (0.0791) and RMSE (0.1020) were recorded when entering individual item scores in a categorical regression model. The model including only FAQLQ-PF section A was found to be most consistent when tested in the external validation cohort (n = 248) (MAE of 0.0898). CONCLUSION: The FAQLQ-PF was mapped onto SF-6Dv2 utilities with good predictive accuracy in two independent cohorts. This will enable calculation of health utility for cost-effectiveness analyses in food allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Watts, Yan&#xD;Dufresne, Elise&#xD;Samaan, Kathryn&#xD;Graham, Francois&#xD;Labrosse, Roxane&#xD;Paradis, Louis&#xD;Des Roches, Anne&#xD;Poder, Thomas G&#xD;Begin, Philippe&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1815-1826. doi: 10.1111/all.15190. Epub 2021 Dec 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34822184</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15190</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2493</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2493</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jin, S. P.</style></author><author><style face="normal" font="default" size="100%">Lee, K.</style></author><author><style face="normal" font="default" size="100%">Bang, Y. J.</style></author><author><style face="normal" font="default" size="100%">Jeon, Y. H.</style></author><author><style face="normal" font="default" size="100%">Jung, S.</style></author><author><style face="normal" font="default" size="100%">Choi, S. J.</style></author><author><style face="normal" font="default" size="100%">Lee, J. S.</style></author><author><style face="normal" font="default" size="100%">Kim, J.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Park, C. G.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author><author><style face="normal" font="default" size="100%">Hong, S.</style></author><author><style face="normal" font="default" size="100%">Lee, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Seoul National University Hospital, Seoul, Korea.&#xD;Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea.&#xD;Institute of Human-Environmental Interface Biology, Medical Research Center, Seoul National University, Seoul, Korea.&#xD;Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea.&#xD;Brain Korea 21 (BK21) FOUR Program, Yonsei Education &amp; Research Center for Biosystems, Yonsei University, Seoul, Korea.&#xD;Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea.&#xD;Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA.&#xD;Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea.&#xD;Seoul National University Hospital, Seoul, Korea.&#xD;Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mapping the immune cell landscape of severe atopic dermatitis by single-cell RNA-seq</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1584-1597</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/05/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Single-Cell Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">*RNA-Seq</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Killer Cells, Natural/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Single-Cell Gene Expression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">chronic inflammatory disease</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">severe atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">single-cell RNA-Seq</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38817208</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Efforts to profile atopic dermatitis (AD) tissues have intensified, yet comprehensive analysis of systemic immune landscapes in severe AD remains crucial. METHODS: Employing single-cell RNA sequencing, we analyzed over 300,000 peripheral blood mononuclear cells from 12 severe AD patients (Eczema area and severity index (EASI) &gt; 21) and six healthy controls. RESULTS: Results revealed significant immune cell shifts in AD patients, including increased Th2 cell abundance, reduced NK cell clusters with compromised cytotoxicity, and correlated Type 2 innate lymphoid cell proportions with disease severity. Moreover, unique monocyte clusters reflecting activated innate immunity emerged in very severe AD (EASI &gt; 30). While overall dendritic cells (DCs) counts decreased, a distinct Th2-priming subset termed &quot;Th2_DC&quot; correlated strongly with disease severity, validated across skin tissue data, and flow cytometry with additional independent severe AD samples. Beyond the recognized role of Th2 adaptive immunity, our findings highlight significant innate immune cell alterations in severe AD, implicating their roles in disease pathogenesis and therapeutic potentials. CONCLUSION: Apart from the widely recognized role of Th2 adaptive immunity in AD pathogenesis, alterations in innate immune cells and impaired cytotoxic cells have also been observed in severe AD. The impact of these alterations on disease pathogenesis and the effectiveness of potential therapeutic targets requires further investigation.</style></abstract><notes><style face="normal" font="default" size="100%">Jin, Seon-Pil&#xD;Lee, Kyungchun&#xD;Bang, Yoon Ji&#xD;Jeon, Yun-Hui&#xD;Jung, Sunyoung&#xD;Choi, So-Jung&#xD;Lee, Ji Su&#xD;Kim, Junhan&#xD;Guttman-Yassky, Emma&#xD;Park, Chung-Gyu&#xD;Kim, Hyun Je&#xD;Hong, Seunghee&#xD;Lee, Dong Hun&#xD;eng&#xD;2022M3A9D3016848/National Research Foundation of Korea/&#xD;2020R1F1A1073692/National Research Foundation of Korea/&#xD;2022R1F1A1075235/National Research Foundation of Korea/&#xD;2022R1A2C10066566/National Research Foundation of Korea/&#xD;2022-22-0296/Younsei University Research Fund/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1584-1597. doi: 10.1111/all.16121.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38817208</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16121</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2117</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2117</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lopez-Sanz, C.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author><author><style face="normal" font="default" size="100%">Nunez-Borque, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Universidad Autonoma de Madrid (UAM), Madrid, Spain.&#xD;Department of Medicine, McMaster Immunology Research Centre (MIRC), Schroeder Allergy and Immunology Research Institute (SAIRI), McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain.&#xD;Department of Allergy and Immunology, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma de Madrid (UAM), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mapping the way to strengthening epithelial barriers: Neuronal circuits in mucus regulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2799-2801</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/05/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mucus</style></keyword><keyword><style face="normal" font="default" size="100%">*Goblet Cells/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barriers</style></keyword><keyword><style face="normal" font="default" size="100%">goblet cells</style></keyword><keyword><style face="normal" font="default" size="100%">mucus layer</style></keyword><keyword><style face="normal" font="default" size="100%">neuroimmunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37151124</style></accession-num><notes><style face="normal" font="default" size="100%">Lopez-Sanz, Celia&#xD;Jimenez-Saiz, Rodrigo&#xD;Nunez-Borque, Emilio&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2799-2801. doi: 10.1111/all.15760. Epub 2023 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37151124</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15760</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1079</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1079</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mostmans, Y.</style></author><author><style face="normal" font="default" size="100%">De Smedt, K.</style></author><author><style face="normal" font="default" size="100%">Richert, B.</style></author><author><style face="normal" font="default" size="100%">Elieh Ali Komi, D.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Michel, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology-Allergology, CHU Brugmann, Universite Libre de Bruxelles, Bruxelles, Belgium.&#xD;Department of Dermatology, CHU Brugmann, Universite Libre de Bruxelles, Bruxelles, Belgium.&#xD;Vrije Universiteit Brussel (VUB), Brussel, Belgium.&#xD;Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran.&#xD;Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite-Universitatsmedizin Berlin, Corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2998-3016</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/03/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Coagulation</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">chronic urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">coagulation and fibrinolysis</style></keyword><keyword><style face="normal" font="default" size="100%">endothelial cell</style></keyword><keyword><style face="normal" font="default" size="100%">vascular involvement</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33768540</style></accession-num><abstract><style face="normal" font="default" size="100%">Chronic urticaria (CU) is a chronic inflammatory mast cell-driven disorder. Endothelial cells (ECs) contribute importantly to key features of CU. Several markers of EC (dys)function in CU have been reported, but have not yet been systematically reviewed. In this study, we systematically reviewed and categorized all published markers of EC functions in CU through a comprehensive search in Pubmed, The Cochrane Library, Web of Science, and SCOPUS using the following Mesh terms: CU AND pathogenesis AND (vasculopathy OR microangiopathy OR ECs OR marker). In total, 79 articles were selected and the identified biomarkers were categorized according to EC (dys)function in CU. The most frequent and consistently reported upregulated biomarkers in CU skin were adhesion molecules, TF, and P-selectin. The most frequently reported upregulated and reliable biomarkers in sera of CU patients were F1+2 for coagulation cascade involvement, D-dimers for fibrinolysis, and MMP-9 for vascular permeability. Emerging biomarkers described in the selected articles were endostatin, heat shock proteins, cleaved high molecular weight kininogen, and adipokines. This systematic review contributes to the pool of growing evidence for vascular involvement in CU where EC dysfunction is present in different aspects of cell survival, maintenance of vascular structure, and coagulation/fibrinolysis balance.</style></abstract><notes><style face="normal" font="default" size="100%">Mostmans, Yora&#xD;De Smedt, Katleen&#xD;Richert, Bertrand&#xD;Elieh Ali Komi, Daniel&#xD;Maurer, Marcus&#xD;Michel, Olivier&#xD;eng&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):2998-3016. doi: 10.1111/all.14828. Epub 2021 Apr 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33768540</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14828</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3080</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3080</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Da Silva Sena, C. R.</style></author><author><style face="normal" font="default" size="100%">Martins Costa Gomes, G.</style></author><author><style face="normal" font="default" size="100%">Kunstle, N.</style></author><author><style face="normal" font="default" size="100%">Gorlanova, O.</style></author><author><style face="normal" font="default" size="100%">Marten, A.</style></author><author><style face="normal" font="default" size="100%">Schulzke, S.</style></author><author><style face="normal" font="default" size="100%">Wyler, F.</style></author><author><style face="normal" font="default" size="100%">Murphy, V. E.</style></author><author><style face="normal" font="default" size="100%">Robinson, P. D.</style></author><author><style face="normal" font="default" size="100%">Sly, P. D.</style></author><author><style face="normal" font="default" size="100%">Usemann, J.</style></author><author><style face="normal" font="default" size="100%">Stoecklin, B.</style></author><author><style face="normal" font="default" size="100%">Steinberg, R.</style></author><author><style face="normal" font="default" size="100%">Yammine, S.</style></author><author><style face="normal" font="default" size="100%">Muller, L.</style></author><author><style face="normal" font="default" size="100%">Latzin, P.</style></author><author><style face="normal" font="default" size="100%">Sinues, P.</style></author><author><style face="normal" font="default" size="100%">Gibson, P. G.</style></author><author><style face="normal" font="default" size="100%">Mattes, J.</style></author><author><style face="normal" font="default" size="100%">Collison, A.</style></author><author><style face="normal" font="default" size="100%">Frey, U.</style></author><author><style face="normal" font="default" size="100%">Bild,</style></author><author><style face="normal" font="default" size="100%">B. L. T. Study Groups</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Children&apos;s Hospital Basel UKBB, University of Basel, Basel, Switzerland.&#xD;Asthma &amp; Breathing Research Program, Hunter Medical Research Institute, Newcastle, New South Wales, Australia.&#xD;University of Newcastle, Newcastle, New South Wales, Australia.&#xD;Division of Pediatric Respiratory Medicine and Allergology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Department of Respiratory Medicine, Queensland Children&apos;s Hospital, Brisbane, Queensland, Australia.&#xD;Children&apos;s Health and Environment Program, Child Health Research Centre, The University of Queensland, Brisbane, Queensland, Australia.&#xD;Lung Precision Medicine (LPM), Department for Biomedical Research (DBMR), University of Bern, Bern, Switzerland.&#xD;Department of Biomedical Engineering, University of Basel, Allschwil, Switzerland.&#xD;Respiratory &amp; Sleep Medicine Department, John Hunter Hospital, Newcastle, New South Wales, Australia.&#xD;School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia.&#xD;Paediatric Respiratory &amp; Sleep Medicine Department, John Hunter Children&apos;s Hospital, Newcastle, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Markers in Infants of Mothers With Asthma and Associations With Respiratory Outcomes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">145-156</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/09/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/blood/epidemiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mothers</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Function Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchiolitis</style></keyword><keyword><style face="normal" font="default" size="100%">Fetal Blood/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Prenatal Exposure Delayed Effects</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma during pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">infant lung function</style></keyword><keyword><style face="normal" font="default" size="100%">proteins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40952045</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In utero mechanisms related to oxidative stress response, inflammation, and extracellular matrix turnover may influence fetal lung development in the offspring of asthmatic mothers. Therefore, we aimed to determine whether levels of cord blood proteins differ between the offspring of asthmatic and nonasthmatic mothers. In addition, we aimed to examine if these proteins are associated with infant lung function, bronchiolitis hospitalization in infancy, and asthma at six years. METHODS: We compared protein levels of infants (n = 715) from the Swiss Basel-Bern Infant Lung Development and the Australian Breathing for Life Trial birth cohorts using Tobit regression and network analyses. Using adjusted linear and logistic regression, we determined their association with postnatal infant lung function, bronchiolitis hospitalization in infancy, and asthma at six years. RESULTS: Infants born to asthmatic mothers had lower levels of matrix metalloproteinase-9 (MMP-9, beta-coefficient [beta] -0.67, 95% confidence interval [-1.07; -0.27] p(adj) = 0.009) and Interferon gamma (IFN-gamma, beta -0.77 [-1.21; -0.32], p(adj) = 0.009), and higher levels of p62 (beta 1.15 [0.30; 2.00], p(adj) = 0.030). p62 levels were inversely associated with minute ventilation (beta -16.18 [-28.44; -3.91], p(adj) = 0.032). Functional residual capacity values were inversely associated with both IFN-gamma (beta -1.26, [-2.41; -0.11], p(adj) = 0.063) and MMP-9 levels (beta -1.27, [-2.53; -0.01], p(adj) = 0.063). MMP-9 levels were inversely associated with both the risk of bronchiolitis hospitalization (odds ratio 0.47, [0.29; 0.77], p(adj) = 0.004) and the risk of asthma (aOR 0.53, 95% CI, 0.32-0.86, p(adj) = 0.033). CONCLUSIONS: Protein levels differed between offspring of asthmatic and non-asthmatic mothers. These markers were associated with postnatal lung function, bronchiolitis hospitalization, and asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Da Silva Sena, Carla Rebeca&#xD;Martins Costa Gomes, Gabriela&#xD;Kunstle, Noemi&#xD;Gorlanova, Olga&#xD;Marten, Andrea&#xD;Schulzke, Sven&#xD;Wyler, Florian&#xD;Murphy, Vanessa E&#xD;Robinson, Paul D&#xD;Sly, Peter D&#xD;Usemann, Jakob&#xD;Stoecklin, Benjamin&#xD;Steinberg, Ruth&#xD;Yammine, Sophie&#xD;Muller, Loretta&#xD;Latzin, Philipp&#xD;Sinues, Pablo&#xD;Gibson, Peter G&#xD;Mattes, Joerg&#xD;Collison, Adam&#xD;Frey, Urs&#xD;eng&#xD;European Union H2020/&#xD;European Respiratory Society/&#xD;Hunter Children&apos;s Research Foundation/&#xD;Priority Research Centre GrowUpWell/&#xD;320030_204717/Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;847462/Marie Sklodowska-Curie Grant/&#xD;Rebecca L. Cooper Medical Research Foundation/&#xD;1060983/National Health and Medical Research Council Australia/&#xD;1081667/National Health and Medical Research Council Australia/&#xD;2004514/National Health and Medical Research Council Australia/&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):145-156. doi: 10.1111/all.70044. Epub 2025 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40952045</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773685</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70044</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2166</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2166</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Pereira, A. M.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Taborda-Barata, L.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Vieira, R. J.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Aria Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;MASK-air, Montpellier, France.&#xD;MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE- Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.&#xD;Center for Innovative Biomedicine and Biotechnology (CIBB), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Department of Medical Sciences, University of Torino, Torino, Italy.&#xD;Allergy and Clinical Immunology Unit, Mauriziano Hospital, Torino, Italy.&#xD;Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Department of Pathology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;Department of Immunoallergology, Cova da Beira University Hospital Centre, Covilha, Portugal.&#xD;UBIAir - Clinical &amp; Experimental Lung Centre and CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Allergy and Clinical Immunology, University of Bari Medical School, Bari, Italy.&#xD;Institute of Sciences of Food Production, National Research Council (ISPA-CNR), Bari, Italy.&#xD;ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">MASK-air(R) direct patient data support the ARIA-MeDALL hypothesis on allergic phenotypes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2790-2794</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/08/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37564010</style></accession-num><notes><style face="normal" font="default" size="100%">Bousquet, Jean&#xD;Sousa-Pinto, Bernardo&#xD;Regateiro, Frederico S&#xD;Pereira, Ana Margarida&#xD;Brussino, Luisa&#xD;Kvedariene, Violeta&#xD;Larenas-Linnemann, Desiree E&#xD;Taborda-Barata, Luis&#xD;Ventura, Maria Teresa&#xD;Vieira, Rafael Jose&#xD;Fonseca, Joao A&#xD;Zuberbier, Torsten&#xD;Anto, Josep M&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2790-2794. doi: 10.1111/all.15842. Epub 2023 Aug 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37564010</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15842</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1213</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1213</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bartemes, K. R.</style></author><author><style face="normal" font="default" size="100%">Choby, G.</style></author><author><style face="normal" font="default" size="100%">O&apos;Brien, E. K.</style></author><author><style face="normal" font="default" size="100%">Stokken, J. K.</style></author><author><style face="normal" font="default" size="100%">Pavelko, K. D.</style></author><author><style face="normal" font="default" size="100%">Kita, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergic Diseases and Department of Medicine, Mayo Clinic, Rochester, MN, USA.&#xD;Department of Otolaryngology, Mayo Clinic, Rochester, MN, USA.&#xD;Department of Immunology, Mayo Clinic, Rochester, MN, USA.&#xD;Division of Allergy, Asthma, and Immunology and Department of Medicine, Mayo Clinic, Scottsdale, AZ, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mass cytometry reveals unique subsets of T cells and lymphoid cells in nasal polyps from patients with chronic rhinosinusitis (CRS)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2222-2226</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/12/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33370459</style></accession-num><notes><style face="normal" font="default" size="100%">Bartemes, Kathleen R&#xD;Choby, Garret&#xD;O&apos;Brien, Erin K&#xD;Stokken, Janalee K&#xD;Pavelko, Kevin D&#xD;Kita, Hirohito&#xD;eng&#xD;R01 HL117823/HL/NHLBI NIH HHS/&#xD;R37 AI071106/AI/NIAID NIH HHS/&#xD;R37 AI71106/National Institute of Allergy and Infectious Diseases/&#xD;HL117823/HL/NHLBI NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2222-2226. doi: 10.1111/all.14720. Epub 2021 Jan 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33370459</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8555365</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14720</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>804</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">804</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Raifer, H.</style></author><author><style face="normal" font="default" size="100%">Schulz, A. R.</style></author><author><style face="normal" font="default" size="100%">Theodorou, J.</style></author><author><style face="normal" font="default" size="100%">Romero-Olmedo, A. J.</style></author><author><style face="normal" font="default" size="100%">Bock, A.</style></author><author><style face="normal" font="default" size="100%">Bertrams, W.</style></author><author><style face="normal" font="default" size="100%">Schmeck, B. T.</style></author><author><style face="normal" font="default" size="100%">Chung, H. R.</style></author><author><style face="normal" font="default" size="100%">Lohoff, M.</style></author><author><style face="normal" font="default" size="100%">Chang, H. D.</style></author><author><style face="normal" font="default" size="100%">Schaub, B.</style></author><author><style face="normal" font="default" size="100%">Mei, H. E.</style></author><author><style face="normal" font="default" size="100%">Huber, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Medical Microbiology and Hospital Hygiene, Philipps-University Marburg, Marburg, Germany.&#xD;Core Facility Flow Cytometry, Philipps- University Marburg, Marburg, Germany.&#xD;German Rheumatism Research Center (DRFZ), An Institute of the Leibniz Association, Berlin, Germany.&#xD;Pediatric Allergology, Department of Pediatrics, Dr. von Hauner Children&apos;s Hospital, University Hospital, LMU Munich, Munich, Germany.&#xD;German Center of Lung Research, (DZL), Marburg, Germany.&#xD;Institute for Lung Research and Department of Pulmonary and Critical Care Medicine, Universities of Giessen and Marburg Lung Center, Philipps-University Marburg, German Center for Lung Research (DZL) and the German Center for Infection Research (DZIF), Marburg, Germany.&#xD;Institute for Medical Bioinformatics and Biostatistics, Philipps-University Marburg, Marburg, Germany.&#xD;Institute of Biotechnology, Chair of Cytometry, Technische Universitat Berlin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mass cytometry-based identification of a unique T-cell signature in childhood allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">313-316</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/09/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">CyTOF</style></keyword><keyword><style face="normal" font="default" size="100%">T-cell subpopulations</style></keyword><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">clinical disease parameters</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34564874</style></accession-num><notes><style face="normal" font="default" size="100%">Raifer, Hartmann&#xD;Schulz, Axel R&#xD;Theodorou, Johanna&#xD;Romero-Olmedo, Addi J&#xD;Bock, Andreas&#xD;Bertrams, Wilhelm&#xD;Schmeck, Bernd T&#xD;Chung, Ho-Ryun&#xD;Lohoff, Michael&#xD;Chang, Hyun-Dong&#xD;Schaub, Bianca&#xD;Mei, Henrik E&#xD;Huber, Magdalena&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):313-316. doi: 10.1111/all.15110. Epub 2021 Oct 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34564874</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15110</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2435</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2435</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giannetti, M. P.</style></author><author><style face="normal" font="default" size="100%">Godwin, G.</style></author><author><style face="normal" font="default" size="100%">Middlesworth, J.</style></author><author><style face="normal" font="default" size="100%">Espeland, A.</style></author><author><style face="normal" font="default" size="100%">Nicoloro-SantaBarbara, J.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Psychiatry, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mast cell activation identified through urine mediators</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2531-2533</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/03/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Degranulation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/urine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38532556</style></accession-num><notes><style face="normal" font="default" size="100%">Giannetti, Matthew P&#xD;Godwin, Grace&#xD;Middlesworth, Julia&#xD;Espeland, Andrew&#xD;Nicoloro-SantaBarbara, Jennifer&#xD;Castells, Mariana&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2531-2533. doi: 10.1111/all.16109. Epub 2024 Mar 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38532556</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16109</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>686</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">686</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wechsler, J. B.</style></author><author><style face="normal" font="default" size="100%">Butuci, M.</style></author><author><style face="normal" font="default" size="100%">Wong, A.</style></author><author><style face="normal" font="default" size="100%">Kamboj, A. P.</style></author><author><style face="normal" font="default" size="100%">Youngblood, B. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Allakos, Inc., Redwood City, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mast cell activation is associated with post-acute COVID-19 syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1288-1291</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/11/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*COVID-19/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Post-Acute COVID-19 Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">long covid</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">of lirentelimab with eosinophilic gastrointestinal diseases. J.B.W. is not</style></keyword><keyword><style face="normal" font="default" size="100%">employed by Allakos, Inc. and does not hold stock or stock options, and did not</style></keyword><keyword><style face="normal" font="default" size="100%">receive consulting fees from Allakos, Inc. for this manuscript</style></keyword><keyword><style face="normal" font="default" size="100%">M.B., A.W.,</style></keyword><keyword><style face="normal" font="default" size="100%">A.P.K., and B.A.Y. are employees of and hold stock or stock options in Allakos,</style></keyword><keyword><style face="normal" font="default" size="100%">Inc.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34820848</style></accession-num><notes><style face="normal" font="default" size="100%">Wechsler, Joshua B&#xD;Butuci, Melina&#xD;Wong, Alan&#xD;Kamboj, Amol P&#xD;Youngblood, Bradford A&#xD;eng&#xD;Allakos, Inc/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1288-1291. doi: 10.1111/all.15188. Epub 2021 Dec 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34820848</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9299596</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15188</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2391</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2391</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, X. O.</style></author><author><style face="normal" font="default" size="100%">Melo, F. R.</style></author><author><style face="normal" font="default" size="100%">Sommerhoff, C. P.</style></author><author><style face="normal" font="default" size="100%">Paivandy, A.</style></author><author><style face="normal" font="default" size="100%">Pejler, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.&#xD;Institute of Medical Education and Institute of Laboratory Medicine, LMU University Hospital, Munich, Germany.&#xD;Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mast cell chymase suppresses functional parameters in primary human airway smooth muscle cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2524-2527</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/02/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Chymases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Myocytes, Smooth Muscle/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38409848</style></accession-num><notes><style face="normal" font="default" size="100%">Zhao, Xinran O&#xD;Melo, Fabio Rabelo&#xD;Sommerhoff, Christian P&#xD;Paivandy, Aida&#xD;Pejler, Gunnar&#xD;eng&#xD;Familjen Erling-Perssons Stiftelse/&#xD;Cancerfonden/&#xD;Knut och Alice Wallenbergs Stiftelse/&#xD;Vetenskapsradet/&#xD;Hjart-Lungfonden/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2524-2527. doi: 10.1111/all.16085. Epub 2024 Feb 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38409848</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16085</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2459</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2459</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, X. O.</style></author><author><style face="normal" font="default" size="100%">Melo, F. R.</style></author><author><style face="normal" font="default" size="100%">Sommerhoff, C. P.</style></author><author><style face="normal" font="default" size="100%">Paivandy, A.</style></author><author><style face="normal" font="default" size="100%">Pejler, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.&#xD;Institute of Medical Education and Institute of Laboratory Medicine, LMU University Hospital, Munich, Germany.&#xD;Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mast cell chymase suppresses functional parameters in primary human airway smooth muscle cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2524-2527</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/02/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Chymases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Myocytes, Smooth Muscle/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38409848</style></accession-num><notes><style face="normal" font="default" size="100%">Zhao, Xinran O&#xD;Melo, Fabio Rabelo&#xD;Sommerhoff, Christian P&#xD;Paivandy, Aida&#xD;Pejler, Gunnar&#xD;eng&#xD;Familjen Erling-Perssons Stiftelse/&#xD;Cancerfonden/&#xD;Knut och Alice Wallenbergs Stiftelse/&#xD;Vetenskapsradet/&#xD;Hjart-Lungfonden/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2524-2527. doi: 10.1111/all.16085. Epub 2024 Feb 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38409848</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16085</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2561</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2561</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ranjitkar, S.</style></author><author><style face="normal" font="default" size="100%">Krajewski, D.</style></author><author><style face="normal" font="default" size="100%">Tedeschi, C.</style></author><author><style face="normal" font="default" size="100%">Perez, N. M.</style></author><author><style face="normal" font="default" size="100%">Jordan, N.</style></author><author><style face="normal" font="default" size="100%">Gregory, K.</style></author><author><style face="normal" font="default" size="100%">Schneider, S. S.</style></author><author><style face="normal" font="default" size="100%">Mathias, C. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nutritional Sciences, University of Connecticut, Storrs, Connecticut, USA.&#xD;Department of Immunology, University of Connecticut, Farmington, Connecticut, USA.&#xD;Pioneer Valley Life Sciences Institute, Baystate Medical Center, Springfield, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mast cell responses in a mouse model of food allergy are regulated via a ST2/IL-4 axis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2561-2564</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/07/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-4/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-1 Receptor-Like 1 Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39049569</style></accession-num><notes><style face="normal" font="default" size="100%">Ranjitkar, Saurav&#xD;Krajewski, Dylan&#xD;Tedeschi, Caitlin&#xD;Perez, Nicole Maldonado&#xD;Jordan, Nathan&#xD;Gregory, Kelly&#xD;Schneider, Sallie S&#xD;Mathias, Clinton B&#xD;eng&#xD;R01 AI167884/AI/NIAID NIH HHS/&#xD;R15 AI107668/AI/NIAID NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2561-2564. doi: 10.1111/all.16257. Epub 2024 Jul 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39049569</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11368605</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16257</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2155</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2155</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Metz, M.</style></author><author><style face="normal" font="default" size="100%">Kolkhir, P.</style></author><author><style face="normal" font="default" size="100%">Altrichter, S.</style></author><author><style face="normal" font="default" size="100%">Siebenhaar, F.</style></author><author><style face="normal" font="default" size="100%">Levi-Schaffer, F.</style></author><author><style face="normal" font="default" size="100%">Youngblood, B. A.</style></author><author><style face="normal" font="default" size="100%">Church, M. K.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite-Universitatsmedizin Berlin (corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin), Berlin, Germany.&#xD;Berlin Institute of Health, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology IA, Berlin, Germany.&#xD;Department of Dermatology and Venerology, Kepler University Hospital, Linz, Austria.&#xD;Pharmacology and Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.&#xD;Allakos Inc., San Carlos, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">37-51</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/08/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Antineoplastic Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Sialic Acid Binding Immunoglobulin-like Lectins/metabolism/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">allergic</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37605867</style></accession-num><abstract><style face="normal" font="default" size="100%">Chronic urticaria (CU) is a mast cell (MC)-dependent disease with limited therapeutic options. Current management strategies are directed at inhibiting IgE-mediated activation of MCs and antagonizing effects of released mediators. Due to the complexity and heterogeneity of CU and other MC diseases and mechanisms of MC activation-including multiple activating receptors and ligands, diverse signaling pathways, and a menagerie of mediators-strategies of MC depletion or MC silencing (i.e., inhibition of MC activation via binding of inhibitory receptors) have been developed to overcome limitations of singularly targeted agents. MC silencers, such as agonist monoclonal antibodies that engage inhibitory receptors (e.g., sialic acid-binding immunoglobulin-like lectin8 -[Siglec-8] [lirentelimab/AK002], Siglec-6 [AK006], and CD200R [LY3454738]), have reached preclinical and clinical stages of development. In this review, we (1) describe the role of MCs in the pathogenesis of CU, highlighting similarities with other MC diseases in disease mechanisms and response to treatment; (2) explore current therapeutic strategies, categorized by nonspecific immunosuppression, targeted inhibition of MC activation or mediators, and targeted modulation of MC activity; and (3) introduce the concept of MC silencing as an emerging strategy that could selectively block activation of MCs without eliciting or exacerbating on- or off-target, immunosuppressive adverse effects.</style></abstract><notes><style face="normal" font="default" size="100%">Metz, Martin&#xD;Kolkhir, Pavel&#xD;Altrichter, Sabine&#xD;Siebenhaar, Frank&#xD;Levi-Schaffer, Francesca&#xD;Youngblood, Bradford A&#xD;Church, Martin K&#xD;Maurer, Marcus&#xD;eng&#xD;Allakos, Inc./&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):37-51. doi: 10.1111/all.15850. Epub 2023 Aug 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37605867</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15850</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1185</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1185</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mendez-Enriquez, E.</style></author><author><style face="normal" font="default" size="100%">Alvarado-Vazquez, P. A.</style></author><author><style face="normal" font="default" size="100%">Abma, W.</style></author><author><style face="normal" font="default" size="100%">Simonson, O. E.</style></author><author><style face="normal" font="default" size="100%">Rodin, S.</style></author><author><style face="normal" font="default" size="100%">Feyerabend, T. B.</style></author><author><style face="normal" font="default" size="100%">Rodewald, H. R.</style></author><author><style face="normal" font="default" size="100%">Malinovschi, A.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Adner, M.</style></author><author><style face="normal" font="default" size="100%">Hallgren, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.&#xD;Unit of Experimental Asthma and Allergy Research, Institute of Environmental Medicine (IMM), Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Cardiothoracic Surgery and Anaesthesiology, Uppsala University Hospital, Uppsala, Sweden.&#xD;Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.&#xD;Division for Cellular Immunology, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.&#xD;Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mast cell-derived serotonin enhances methacholine-induced airway hyperresponsiveness in house dust mite-induced experimental asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2057-2069</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Methacholine Chloride/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Serotonin</style></keyword><keyword><style face="normal" font="default" size="100%">airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">mouse model</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33486786</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Airway hyperresponsiveness (AHR) is a feature of asthma in which airways are hyperreactive to stimuli causing extensive airway narrowing. Methacholine provocations assess AHR in asthma patients mainly by direct stimulation of smooth muscle cells. Using in vivo mouse models, mast cells have been implicated in AHR, but the mechanism behind has remained unknown. METHODS: Cpa3(Cre)(/+) mice, which lack mast cells, were used to assess the role of mast cells in house dust mite (HDM)-induced experimental asthma. Effects of methacholine in presence or absence of ketanserin were assessed on lung function and in lung mast cells in vitro. Airway inflammation, mast cell accumulation and activation, smooth muscle proliferation, and HDM-induced bronchoconstriction were evaluated. RESULTS: Repeated intranasal HDM sensitization induced allergic airway inflammation associated with accumulation and activation of lung mast cells. Lack of mast cells, absence of activating Fc-receptors, or antagonizing serotonin (5-HT)(2A) receptors abolished HDM-induced trachea contractions. HDM-sensitized mice lacking mast cells had diminished lung-associated 5-HT levels, reduced AHR and methacholine-induced airway contraction, while blocking 5-HT(2A) receptors in wild types eliminated AHR, implying that mast cells contribute to AHR by releasing 5-HT. Primary mouse and human lung mast cells express muscarinic M3 receptors. Mouse lung mast cells store 5-HT intracellularly, and methacholine induces release of 5-HT from lung-derived mouse mast cells and Ca(2+) flux in human LAD-2 mast cells. CONCLUSIONS: Methacholine activates mast cells to release 5-HT, which by acting on 5-HT(2A) receptors enhances bronchoconstriction and AHR. Thus, M3-directed asthma treatments like tiotropium may also act by targeting mast cells.</style></abstract><notes><style face="normal" font="default" size="100%">Mendez-Enriquez, Erika&#xD;Alvarado-Vazquez, Perla Abigail&#xD;Abma, Willem&#xD;Simonson, Oscar E&#xD;Rodin, Sergey&#xD;Feyerabend, Thorsten B&#xD;Rodewald, Hans-Reimer&#xD;Malinovschi, Andrei&#xD;Janson, Christer&#xD;Adner, Mikael&#xD;Hallgren, Jenny&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2057-2069. doi: 10.1111/all.14748. Epub 2021 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33486786</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14748</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>587</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">587</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, S.</style></author><author><style face="normal" font="default" size="100%">Shoda, T.</style></author><author><style face="normal" font="default" size="100%">Aceves, S. S.</style></author><author><style face="normal" font="default" size="100%">Arva, N. C.</style></author><author><style face="normal" font="default" size="100%">Chehade, M.</style></author><author><style face="normal" font="default" size="100%">Collins, M. H.</style></author><author><style face="normal" font="default" size="100%">Dellon, E. S.</style></author><author><style face="normal" font="default" size="100%">Falk, G. W.</style></author><author><style face="normal" font="default" size="100%">Gonsalves, N.</style></author><author><style face="normal" font="default" size="100%">Gupta, S. K.</style></author><author><style face="normal" font="default" size="100%">Hirano, I.</style></author><author><style face="normal" font="default" size="100%">Khoury, P.</style></author><author><style face="normal" font="default" size="100%">Leung, J.</style></author><author><style face="normal" font="default" size="100%">Spergel, A. K. R.</style></author><author><style face="normal" font="default" size="100%">Spergel, J. M.</style></author><author><style face="normal" font="default" size="100%">Wechsler, J. B.</style></author><author><style face="normal" font="default" size="100%">Yang, G. Y.</style></author><author><style face="normal" font="default" size="100%">Furuta, G. T.</style></author><author><style face="normal" font="default" size="100%">Rothenberg, M. E.</style></author><author><style face="normal" font="default" size="100%">Consortium of Eosinophilic Gastrointestinal Disease Researchers Investigators, Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, University of Cincinnati College of Medicine and Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Division of Allergy Immunology, Departments of Pediatrics and Medicine, University of California, San Diego, California, USA.&#xD;Rady Children&apos;s Hospital, San Diego, California, USA.&#xD;Department of Pathology, Feinberg School of Medicine, Ann &amp; Robert H. Lurie Children&apos;s Hospital of Chicago, Northwestern University, Chicago, Illinois, USA.&#xD;Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Division of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine and Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.&#xD;Division of Gastroenterology, Hospital of the University of Pennsylvania, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;Division of Gastroenterology &amp; Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Division of Pediatric Gastroenterology, Hepatology and Nutrition, Riley Hospital for Children/Indiana University School of Medicine, and Community Health Network, Indianapolis, Indiana, USA.&#xD;National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.&#xD;Division of Gastroenterology, Tufts Medical Center, Boston, Massachusetts, USA.&#xD;Division of Allergy and Immunology, University of Pennsylvania Perelman School of Medicine/Children&apos;s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.&#xD;Division of Gastroenterology, Hepatology &amp; Nutrition, Ann &amp; Robert H. Lurie Children&apos;s Hospital of Chicago, Chicago, Illinois, USA.&#xD;Department of Pathology, Northwestern University, Chicago, Illinois, USA.&#xD;Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mast cell-pain connection in eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1895-1899</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Enteritis</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Gastritis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Pain</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35175645</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Simin&#xD;Shoda, Tetsuo&#xD;Aceves, Seema S&#xD;Arva, Nicoleta C&#xD;Chehade, Mirna&#xD;Collins, Margaret H&#xD;Dellon, Evan S&#xD;Falk, Gary W&#xD;Gonsalves, Nirmala&#xD;Gupta, Sandeep K&#xD;Hirano, Ikuo&#xD;Khoury, Paneez&#xD;Leung, John&#xD;Spergel, Amanda K Rudman&#xD;Spergel, Jonathan M&#xD;Wechsler, Joshua B&#xD;Yang, Guang-Yu&#xD;Furuta, Glenn T&#xD;Rothenberg, Marc E&#xD;(CEGIR)&#xD;eng&#xD;U2C TR002818/TR/NCATS NIH HHS/&#xD;P30 DK078392/DK/NIDDK NIH HHS/&#xD;K99 AI158660/AI/NIAID NIH HHS/&#xD;U54 AI117804/AI/NIAID NIH HHS/&#xD;R00 AI158660/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1895-1899. doi: 10.1111/all.15260. Epub 2022 Mar 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35175645</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9167217</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15260</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2983</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2983</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Samanas, N. B.</style></author><author><style face="normal" font="default" size="100%">Miralda, I.</style></author><author><style face="normal" font="default" size="100%">Camp, N.</style></author><author><style face="normal" font="default" size="100%">Sachen, J.</style></author><author><style face="normal" font="default" size="100%">Puryear, V.</style></author><author><style face="normal" font="default" size="100%">Shah, L.</style></author><author><style face="normal" font="default" size="100%">Seo, A. J.</style></author><author><style face="normal" font="default" size="100%">Foronda, J. S.</style></author><author><style face="normal" font="default" size="100%">Shapiro, M.</style></author><author><style face="normal" font="default" size="100%">Baris, S.</style></author><author><style face="normal" font="default" size="100%">Unal, E.</style></author><author><style face="normal" font="default" size="100%">Eken, A.</style></author><author><style face="normal" font="default" size="100%">Morrison, S. D.</style></author><author><style face="normal" font="default" size="100%">Allenspach, E. J.</style></author><author><style face="normal" font="default" size="100%">Deutsch, G. H.</style></author><author><style face="normal" font="default" size="100%">James, R. G.</style></author><author><style face="normal" font="default" size="100%">Piliponsky, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Immunity and Immunotherapies, Seattle Children&apos;s Research Institute, Seattle, Washington, USA.&#xD;Division of Pediatric Allergy and Immunology, Marmara University School of Medicine, Istanbul, Turkey.&#xD;Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey.&#xD;The Isil Barlan Center for Translational Medicine, Istanbul, Turkey.&#xD;Pediatric Hematology and Oncology Clinic, Medical Point Hospital, Gaziantep, Turkey.&#xD;School of Health Sciences, Hasan Kalyoncu University, Gaziantep, Turkey.&#xD;Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.&#xD;Department of Medical Biology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.&#xD;Genome and Stem Cell Center (GENKOK), Erciyes University, Kayseri, Turkey.&#xD;Division of Plastic Surgery, Department of Surgery, Seattle Children&apos;s Hospital, Seattle, Washington, USA.&#xD;Departments of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.&#xD;Department of Laboratories, Seattle Children&apos;s Research Institute, Seattle, Washington, USA.&#xD;Department of Pharmacology, University of Washington, Seattle, Washington, USA.&#xD;Department of Pathology, University of Washington, Seattle, Washington, USA.&#xD;Department of Global Health, University of Washington School of Medicine, Seattle, Washington, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mast Cells Are Intrinsically Primed for Degranulation in DOCK8 Deficiency</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2650-2653</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">immune deficiencies</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40654159</style></accession-num><notes><style face="normal" font="default" size="100%">Samanas, Nyssa B&#xD;Miralda, Irina&#xD;Camp, Nate&#xD;Sachen, Josie&#xD;Puryear, Victoria&#xD;Shah, Liyana&#xD;Seo, Albert J&#xD;Foronda, Jake S&#xD;Shapiro, Madelyn&#xD;Baris, Safa&#xD;Unal, Ekrem&#xD;Eken, Ahmet&#xD;Morrison, Shane D&#xD;Allenspach, Eric J&#xD;Deutsch, Gail H&#xD;James, Richard G&#xD;Piliponsky, Adrian M&#xD;eng&#xD;NH/NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2650-2653. doi: 10.1111/all.16651. Epub 2025 Jul 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40654159</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16651</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>572</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">572</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lyberg, K.</style></author><author><style face="normal" font="default" size="100%">Ekoff, M.</style></author><author><style face="normal" font="default" size="100%">Westerberg, C. M.</style></author><author><style face="normal" font="default" size="100%">Engblom, C.</style></author><author><style face="normal" font="default" size="100%">Dahlen, B.</style></author><author><style face="normal" font="default" size="100%">Gulen, T.</style></author><author><style face="normal" font="default" size="100%">Nilsson, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.&#xD;Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mast cells derived from systemic mastocytosis exhibit an increased responsiveness to hyperosmolarity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1909-1911</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis, Systemic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptases</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">histamine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35258114</style></accession-num><notes><style face="normal" font="default" size="100%">Lyberg, Katarina&#xD;Ekoff, Maria&#xD;Westerberg, Christine Moller&#xD;Engblom, Camilla&#xD;Dahlen, Barbro&#xD;Gulen, Theo&#xD;Nilsson, Gunnar&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1909-1911. doi: 10.1111/all.15277. Epub 2022 Mar 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35258114</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9314727</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15277</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>547</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">547</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schaller, T.</style></author><author><style face="normal" font="default" size="100%">Markl, B.</style></author><author><style face="normal" font="default" size="100%">Claus, R.</style></author><author><style face="normal" font="default" size="100%">Sholl, L.</style></author><author><style face="normal" font="default" size="100%">Hornick, J. L.</style></author><author><style face="normal" font="default" size="100%">Giannetti, M. P.</style></author><author><style face="normal" font="default" size="100%">Schweizer, L.</style></author><author><style face="normal" font="default" size="100%">Mann, M.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departement of General Pathology and Molecular Diagnostics, Medical Faculty, University Augsburg, Augsburg, Germany.&#xD;Hematology and Oncology, Medical Faculty, University Augsburg, Augsburg, Germany.&#xD;Department of Pathology, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Allergy and Immunology Division, Brigham and Women&apos;s Hospital Mastocytosis Center, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.&#xD;Proteomics Program and Protein Signaling Program, NNF Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mast cells in lung damage of COVID-19 autopsies: A descriptive study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2237-2239</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/03/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Autopsy</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35340030</style></accession-num><notes><style face="normal" font="default" size="100%">Schaller, Tina&#xD;Markl, Bruno&#xD;Claus, Rainer&#xD;Sholl, Lynette&#xD;Hornick, Jason L&#xD;Giannetti, Matthew P&#xD;Schweizer, Lisa&#xD;Mann, Matthias&#xD;Castells, Mariana&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2237-2239. doi: 10.1111/all.15293. Epub 2022 Apr 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35340030</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9111237</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15293</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>690</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">690</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blanco-Perez, F.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Menendez, I.</style></author><author><style face="normal" font="default" size="100%">Stassen, M.</style></author><author><style face="normal" font="default" size="100%">Kato, Y.</style></author><author><style face="normal" font="default" size="100%">Laino, J.</style></author><author><style face="normal" font="default" size="100%">Kirberg, J.</style></author><author><style face="normal" font="default" size="100%">Krause, M.</style></author><author><style face="normal" font="default" size="100%">Martella, M.</style></author><author><style face="normal" font="default" size="100%">Shibata, N.</style></author><author><style face="normal" font="default" size="100%">Quintanilla-Martinez, L.</style></author><author><style face="normal" font="default" size="100%">Feyerabend, T. B.</style></author><author><style face="normal" font="default" size="100%">Rodewald, H. R.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author><author><style face="normal" font="default" size="100%">Scheurer, S.</style></author><author><style face="normal" font="default" size="100%">Toda, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Vice President Research Group &quot;Molecular Allergology&quot;, Paul-Ehrlich-Institut, Langen, Germany.&#xD;Institute of Pathology and Neuropathology, Comprehensive Cancer Center, University Hospital Tubingen, Eberhard Karls University of Tubingen, Tubingen, Germany.&#xD;Institute for Immunology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg University, Mainz, Germany.&#xD;Department of Pathology, Tokyo Women&apos;s Medical University, Tokyo, Japan.&#xD;Division of Immunology, Paul-Ehrlich-Institut, Langen, Germany.&#xD;Division of Cellular Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.&#xD;Department of Pathology, The Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.&#xD;Laboratory of Food and Biomolecular Science, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mast cells partly contribute to allergic enteritis development: Findings in two different mast cell-deficient mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1051-1054</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/11/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Enteritis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34807472</style></accession-num><notes><style face="normal" font="default" size="100%">Blanco-Perez, Frank&#xD;Gonzalez-Menendez, Irene&#xD;Stassen, Michael&#xD;Kato, Yoichiro&#xD;Laino, Jonathan&#xD;Kirberg, Jorg&#xD;Krause, Maren&#xD;Martella, Manuela&#xD;Shibata, Noriyuki&#xD;Quintanilla-Martinez, Leticia&#xD;Feyerabend, Thorsten B&#xD;Rodewald, Hans-Reimer&#xD;Galli, Stephen J&#xD;Vieths, Stefan&#xD;Scheurer, Stephan&#xD;Toda, Masako&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1051-1054. doi: 10.1111/all.15182. Epub 2021 Dec 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34807472</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15182</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2770</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2770</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">Palmer, D. J.</style></author><author><style face="normal" font="default" size="100%">Geddes, D.</style></author><author><style face="normal" font="default" size="100%">Lai, C. T.</style></author><author><style face="normal" font="default" size="100%">Rea, A.</style></author><author><style face="normal" font="default" size="100%">Prescott, S. L.</style></author><author><style face="normal" font="default" size="100%">D&apos;Vaz, N.</style></author><author><style face="normal" font="default" size="100%">Stinson, L. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Molecular Sciences, The University of Western Australia, Crawley, WA, Australia.&#xD;ABREAST Network, Perth, WA, Australia.&#xD;UWA Centre for Human Lactation Research and Translation, Perth, WA, Australia.&#xD;Telethon Kids Institute, The University of Western Australia, Perth, WA, Australia.&#xD;School of Medicine, The University of Western Australia, Perth, WA, Australia.&#xD;Mathematics and Statistics, Harry Butler Institute, Murdoch University, Murdoch, WA, Australia.&#xD;Nova Institute for Health, Baltimore, Maryland, USA.&#xD;Department of Family and Community Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.&#xD;School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Maternal Allergic Disease Phenotype and Infant Birth Season Influence the Human Milk Microbiome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1967-1981</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/12/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk, Human/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Seasons</style></keyword><keyword><style face="normal" font="default" size="100%">allergic disease</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">birth season</style></keyword><keyword><style face="normal" font="default" size="100%">human milk microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">infant feeding</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39723602</style></accession-num><abstract><style face="normal" font="default" size="100%">Early infancy is a critical period for immune development. In addition to being the primary food source during early infancy, human milk also provides multiple bioactive components that shape the infant gut microbiome and immune system and provides a constant source of exposure to maternal microbiota. Given the potential interplay between allergic diseases and the human microbiome, this study aimed to characterise the milk microbiome of allergic mothers. Full-length 16S rRNA gene sequencing was performed on milk samples collected at 3 and 6 months postpartum from 196 women with allergic disease. Multivariate linear mixed models were constructed to identify the maternal, infant, and environmental determinants of the milk microbiome. Human milk microbiome composition and beta diversity varied over time (PERMANOVA R(2) = 0.011, p = 0.011). The season of infant birth emerged as the strongest determinant of the microbiome community structure (PERMANOVA R(2) = 0.014, p = 0.011) with impacts on five of the most abundant taxa. The milk microbiome also varied according to the type of maternal allergic disease (allergic rhinitis, asthma, atopic dermatitis, and food allergy). Additionally, infant formula exposure reduced the relative abundance of several typical oral taxa in milk. In conclusion, the milk microbiome of allergic mothers was strongly shaped by the season of infant birth, maternal allergic disease phenotype, and infant feeding mode. Maternal allergic disease history and infant season of birth should therefore be considered in future studies of infant and maternal microbiota. Trial Registration: ClinicalTrials.gov identifier: ACTRN12606000281594.</style></abstract><notes><style face="normal" font="default" size="100%">Ma, Jie&#xD;Palmer, Debra J&#xD;Geddes, Donna&#xD;Lai, Ching Tat&#xD;Rea, Alethea&#xD;Prescott, Susan L&#xD;D&apos;Vaz, Nina&#xD;Stinson, Lisa F&#xD;eng&#xD;Medela/&#xD;National Health and Medical Research Council/&#xD;University of Western Australia/&#xD;Telethon Kids Institute Ascend Fellowship/&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1967-1981. doi: 10.1111/all.16442. Epub 2024 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39723602</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16442</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2598</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2598</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Pickett-Nairne, K.</style></author><author><style face="normal" font="default" size="100%">Leung, D.</style></author><author><style face="normal" font="default" size="100%">Fleischer, D.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Glueck, D. H.</style></author><author><style face="normal" font="default" size="100%">Dabelea, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Allergy and Immunology, Department of Pediatrics, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Children&apos;s Hospital Colorado, Aurora, Colorado, USA.&#xD;Department of Pediatrics, University of Colorado School of Medicine, University of Colorado Denver, Aurora, Colorado, USA.&#xD;Department of Pediatrics, National Jewish Health, Denver, Colorado, USA.&#xD;Department of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Lifecourse Epidemiology of Adiposity and Diabetes Center, University of Colorado Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado, USA.&#xD;Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Maternal allergy-preventive diet index, offspring infant diet diversity, and childhood allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3475-3488</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/08/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/etiology/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Prenatal Exposure Delayed Effects</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Maternal Nutritional Physiological Phenomena</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39192779</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Studies of childhood diet diversity and allergic disease have not examined additional associations with an offspring allergy-linked maternal diet index during pregnancy. We studied both associations in a pre-birth cohort. METHODS: Offspring allergic disease diagnoses were obtained from electronic medical records. Maternal and infant diet were self-reported. Adjusted parametric Weibull time-to-event models assessed associations between maternal diet index, infant diet diversity and time to development of allergic rhinitis, atopic dermatitis, asthma, wheeze, IgE-mediated food allergy, and a combined outcome of any allergic disease except for wheeze. RESULTS: Infant diet diversity at 1 year was associated with the risk of the combined outcome between 1 and 4 years of age (p = .002). While both maternal diet index and infant diet diversity at 1 year were associated with the risk of the combined outcome between 1 and 4 years of age (both p &lt; .05), infant diet diversity at 1 year did not modify the association between maternal diet index and the risk of the combined outcome between 1 and 4 years of age (p = .5). The group with the lowest risk of the combined allergy outcome had higher maternal diet index and higher infant diet diversity. CONCLUSIONS: The novel finding that both maternal diet index during pregnancy and infant diet diversity at 12 months are associated with the risk of a combined allergic disease outcome points to two targets for preventive interventions: maternal diet index scores during pregnancy and offspring diet diversity during infancy.</style></abstract><notes><style face="normal" font="default" size="100%">Venter, Carina&#xD;Pickett-Nairne, Kaci&#xD;Leung, Donald&#xD;Fleischer, David&#xD;O&apos;Mahony, Liam&#xD;Glueck, Deborah H&#xD;Dabelea, Dana&#xD;eng&#xD;P30 DK056350/DK/NIDDK NIH HHS/&#xD;NH/NIH HHS/&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3475-3488. doi: 10.1111/all.16292. Epub 2024 Aug 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39192779</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16292</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2101</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2101</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Inoue, Y.</style></author><author><style face="normal" font="default" size="100%">Yamamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Suzuki, S.</style></author><author><style face="normal" font="default" size="100%">Ochiai, S.</style></author><author><style face="normal" font="default" size="100%">Eguchi, A.</style></author><author><style face="normal" font="default" size="100%">Nakano, T.</style></author><author><style face="normal" font="default" size="100%">Yamaide, F.</style></author><author><style face="normal" font="default" size="100%">Hasegawa, S.</style></author><author><style face="normal" font="default" size="100%">Kojima, H.</style></author><author><style face="normal" font="default" size="100%">Mori, C.</style></author><author><style face="normal" font="default" size="100%">Kohno, Y.</style></author><author><style face="normal" font="default" size="100%">Suganuma, H.</style></author><author><style face="normal" font="default" size="100%">Shimojo, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.&#xD;Department of General Medical Science, Graduate School of Medicine, Chiba University, Chiba, Japan.&#xD;Nature and Wellness Research Department, Innovation Division, KAGOME CO., LTD., Tochigi, Japan.&#xD;Department of Bioenvironmental Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.&#xD;Center for Preventive Medical Sciences, Chiba University, Chiba, Japan.&#xD;Department of Pediatrics, International University of Health and Welfare Narita Hospital, Chiba, Japan.&#xD;Higashi Koiwa Wanpaku Clinic, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Maternal and infant serum carotenoids are associated with infantile atopic dermatitis development</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2323-2326</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/03/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Prenatal Exposure Delayed Effects</style></keyword><keyword><style face="normal" font="default" size="100%">Family</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36997306</style></accession-num><notes><style face="normal" font="default" size="100%">Inoue, Yuzaburo&#xD;Yamamoto, Yu&#xD;Suzuki, Shigenori&#xD;Ochiai, Shingo&#xD;Eguchi, Akifumi&#xD;Nakano, Taiji&#xD;Yamaide, Fumiya&#xD;Hasegawa, Satomi&#xD;Kojima, Hiroyuki&#xD;Mori, Chisato&#xD;Kohno, Yoichi&#xD;Suganuma, Hiroyuki&#xD;Shimojo, Naoki&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2323-2326. doi: 10.1111/all.15730. Epub 2023 Apr 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36997306</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15730</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2207</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2207</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mubanga, M.</style></author><author><style face="normal" font="default" size="100%">Brew, B. H.</style></author><author><style face="normal" font="default" size="100%">Karim, H.</style></author><author><style face="normal" font="default" size="100%">Curman, P.</style></author><author><style face="normal" font="default" size="100%">Hedman, A.</style></author><author><style face="normal" font="default" size="100%">Lundholm, C.</style></author><author><style face="normal" font="default" size="100%">Almqvist, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.&#xD;National Perinatal Epidemiology and Statistics Unit, Centre for Big Data Research in Health and School of Clinical Medicine, University of New South Wales, Kensington, New South Wales, Australia.&#xD;Dermato-Venereology Clinic, Karolinska University Hospital, Stockholm, Sweden.&#xD;Pediatric Allergy and Pulmonology Unit at Astrid Lindgren Children&apos;s Hospital, Karolinska University Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Maternal body mass index in pregnancy and offspring asthma and food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2556-2558</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/07/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Family</style></keyword><keyword><style face="normal" font="default" size="100%">*Prenatal Exposure Delayed Effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37403799</style></accession-num><notes><style face="normal" font="default" size="100%">Mubanga, Mwenya&#xD;Brew, Bronwyn H&#xD;Karim, Hanna&#xD;Curman, Philip&#xD;Hedman, Anna&#xD;Lundholm, Cecilia&#xD;Almqvist, Catarina&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2556-2558. doi: 10.1111/all.15803. Epub 2023 Jul 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37403799</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15803</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>983</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">983</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Palumbo, M. P.</style></author><author><style face="normal" font="default" size="100%">Glueck, D. H.</style></author><author><style face="normal" font="default" size="100%">Sauder, K. A.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Fleischer, D. M.</style></author><author><style face="normal" font="default" size="100%">Ben-Abdallah, M.</style></author><author><style face="normal" font="default" size="100%">Ringham, B. M.</style></author><author><style face="normal" font="default" size="100%">Dabelea, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Allergy &amp; Immunology, Department of Pediatrics, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Children&apos;s Hospital Colorado, Aurora, CO, USA.&#xD;Lifecourse Epidemiology of Adiposity and Diabetes Center, University of Colorado Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado, USA.&#xD;Department of Pediatrics, University of Colorado School of Medicine, University of Colorado Denver, Aurora, Colorado, USA.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The maternal diet index in pregnancy is associated with offspring allergic diseases: the Healthy Start study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">162-172</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/05/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Sounds</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">maternal diet index in pregnancy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34018205</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A systematic review showed limited associations between pregnancy diet and offspring allergy. We developed a maternal diet index during pregnancy that was associated with offspring allergy outcomes. METHODS: Data came from Healthy Start, a Colorado pre-birth cohort of mother/offspring dyads. Food propensity questionnaires were completed during pregnancy. Offspring allergic rhinitis, atopic dermatitis, asthma, wheeze, and food allergy diagnosis up to age four were verified from electronic medical records. Data were randomized into test and replication sets. The index included the weighted combination of variables that best predicted a combined outcome of any allergy in the test set. Index utility was verified in the replication set. Separate adjusted and unadjusted logistic models estimated associations between the index and each offspring allergy diagnosis in the full sample. RESULTS: The index included weighted measures of intake of vegetables, yogurt, fried potatoes, rice/grains, red meats, pure fruit juice, and cold cereals. Vegetables and yogurt were associated with the prevention of any allergy, while other components were associated with increased disease. In adjusted models, a one-unit increase in the index was significantly associated with reduced odds of offspring allergic rhinitis (odds ratio (CI) 0.82 [0.72-0.94]), atopic dermatitis (0.77 [0.69-0.86]), asthma (0.84 [0.74-0.96]), and wheeze (0.80 [0.71-0.90]), but not food allergy (0.84 [0.66-1.08]). CONCLUSIONS: This is the first study that has shown associations between an index of maternal dietary intake during pregnancy and multiple offspring allergic diseases. The results give hope for prevention of allergic diseases in utero.</style></abstract><notes><style face="normal" font="default" size="100%">Venter, Carina&#xD;Palumbo, Michaela P&#xD;Glueck, Deborah H&#xD;Sauder, Katherine A&#xD;O&apos;Mahony, Liam&#xD;Fleischer, David M&#xD;Ben-Abdallah, Miriam&#xD;Ringham, Brandy M&#xD;Dabelea, Dana&#xD;eng&#xD;R01 DK076648/DK/NIDDK NIH HHS/&#xD;R01 DK076648/DK/NIDDK NIH HHS/ /DK/NIDDK NIH HHS/&#xD;UH3 OD023248/OD/NIH HHS/&#xD;R25 GM111901/GM/NIGMS NIH HHS/&#xD;P30 DK056350/DK/NIDDK NIH HHS/&#xD;UG3 OD023248/OD/NIH HHS/ /DK/NIDDK NIH HHS/&#xD;UH3 OD023248/OD/NIH HHS/ /OD/NIH/&#xD;R25GM111901/GF/NIH HHS/&#xD;R01 GM121081/GM/NIGMS NIH HHS/&#xD;UG3 OD023248/OD/NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):162-172. doi: 10.1111/all.14949. Epub 2021 Jun 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34018205</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9292464</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14949</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>273</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">273</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zaitsu, M.</style></author><author><style face="normal" font="default" size="100%">Kono, K.</style></author><author><style face="normal" font="default" size="100%">Hosokawa, Y.</style></author><author><style face="normal" font="default" size="100%">Miyamoto, M.</style></author><author><style face="normal" font="default" size="100%">Nanishi, K.</style></author><author><style face="normal" font="default" size="100%">Okawa, S.</style></author><author><style face="normal" font="default" size="100%">Niki, S.</style></author><author><style face="normal" font="default" size="100%">Takahashi, K.</style></author><author><style face="normal" font="default" size="100%">Yoshihara, S.</style></author><author><style face="normal" font="default" size="100%">Kobashi, G.</style></author><author><style face="normal" font="default" size="100%">Tabuchi, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Research of the Aging Workforce, University of Occupational and Environmental Health, Fukuoka, Japan.&#xD;Department of Public Health, Dokkyo Medical University School of Medicine, Tochigi, Japan.&#xD;Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.&#xD;Department of Pediatrics, Dokkyo Medical University School of Medicine, Tochigi, Japan.&#xD;Office of International Academic Affairs, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan.&#xD;Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.&#xD;Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Maternal heated tobacco product use during pregnancy and allergy in offspring</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1104-1112</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Tobacco Products</style></keyword><keyword><style face="normal" font="default" size="100%">Smokers</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">heated tobacco products</style></keyword><keyword><style face="normal" font="default" size="100%">infant allergy</style></keyword><keyword><style face="normal" font="default" size="100%">maternal exposure</style></keyword><keyword><style face="normal" font="default" size="100%">smoking</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36176042</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Little is known about the association between maternal use of heated tobacco products (HTPs) during pregnancy and the onset of allergy among offspring. This study aimed to determine whether maternal HTP smoking is associated with allergy in their offspring and to evaluate the potential dose-response association. METHODS: In this web-based, cross-sectional survey conducted in July and August 2021 in Japan, we investigated 5688 pairs of postpartum women and infants (&lt;3 years). Clinical diagnoses of infant asthma, rhinitis, conjunctivitis, or atopic dermatitis were reported. Using multilevel Poisson regression, we estimated the prevalence ratios (PRs) and 95% confidence intervals (CIs) of allergy in infants with HTP smoking categories cross-classified by pregnancy periods, and adjusted for potential covariates including maternal cigarette smoking and partner&apos;s smoking status. Non-smokers served as the reference group. RESULTS: In total, 2.4% women smoked HTPs during pregnancy. Allergy occurred in 7.8% of the infants. The prevalence of allergy increased among the offspring of current HTP smokers during pregnancy at 15.2% (PR = 1.98, 95% CI 1.28-3.05); this association was the most pronounced during the first trimester but attenuated before pregnancy and postpartum. Dose-response associations were observed, for example a one-unit increase in daily maternal HTP use during pregnancy was associated with a 5% increase in allergy onset. Sub-group analyses excluding cigarette smokers during pregnancy and sensitivity analyses using the International Study of Asthma and Allergies in Childhood questionnaire showed a similar pattern. CONCLUSIONS: Maternal HTP smoking during pregnancy is associated with allergy in the offspring.</style></abstract><notes><style face="normal" font="default" size="100%">Zaitsu, Masayoshi&#xD;Kono, Kenta&#xD;Hosokawa, Yoshihiko&#xD;Miyamoto, Manabu&#xD;Nanishi, Keiko&#xD;Okawa, Sumiyo&#xD;Niki, Shinji&#xD;Takahashi, Kyo&#xD;Yoshihara, Shigemi&#xD;Kobashi, Gen&#xD;Tabuchi, Takahiro&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):1104-1112. doi: 10.1111/all.15536. Epub 2022 Oct 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36176042</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15536</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3226</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3226</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author><author><style face="normal" font="default" size="100%">Yim, Y.</style></author><author><style face="normal" font="default" size="100%">Nehs, C. J.</style></author><author><style face="normal" font="default" size="100%">Park, J.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Kang, J.</style></author><author><style face="normal" font="default" size="100%">Yon, D. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Mass General Brigham Department of Anesthesiology, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Department of Family Medicine, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Lydia Becker Institute, University of Manchester, Manchester, UK.&#xD;School of Health and Environmental Science, College of Health Science, Korea University, Seoul, South Korea.&#xD;Department of Health and Safety Convergence Science, Graduate School, Korea University, Seoul, South Korea.&#xD;Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Maternal Opioid Use and Subsequent Risk of Allergic Diseases in Children: Emulation of Target Trials Using the Korean Nationwide Birth Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41568403</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Hyeon Jin&#xD;Yim, Yesol&#xD;Nehs, Christa J&#xD;Park, Jaeyu&#xD;Kim, Sunyoung&#xD;Papadopoulos, Nikolaos G&#xD;Kang, Jiseung&#xD;Yon, Dong Keon&#xD;eng&#xD;Ministry of Education, South Korea/&#xD;Ministry of Science and ICT, South Korea/&#xD;Ministry of Health &amp; Welfare, South Korea/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan 22. doi: 10.1111/all.70231.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41568403</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70231</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>289</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">289</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee-Sarwar, K. A.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. C.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Kozyrskyj, A. L.</style></author><author><style face="normal" font="default" size="100%">Mandhane, P. J.</style></author><author><style face="normal" font="default" size="100%">Turvey, S. E.</style></author><author><style face="normal" font="default" size="100%">Subbarao, P.</style></author><author><style face="normal" font="default" size="100%">Bisgaard, H.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Chawes, B.</style></author><author><style face="normal" font="default" size="100%">Sorensen, S. J.</style></author><author><style face="normal" font="default" size="100%">Kelly, R. S.</style></author><author><style face="normal" font="default" size="100%">Lasky-Su, J.</style></author><author><style face="normal" font="default" size="100%">Zeiger, R. S.</style></author><author><style face="normal" font="default" size="100%">O&apos;Connor, G. T.</style></author><author><style face="normal" font="default" size="100%">Sandel, M. T.</style></author><author><style face="normal" font="default" size="100%">Bacharier, L. B.</style></author><author><style face="normal" font="default" size="100%">Beigelman, A.</style></author><author><style face="normal" font="default" size="100%">Carey, V. J.</style></author><author><style face="normal" font="default" size="100%">Harshfield, B. J.</style></author><author><style face="normal" font="default" size="100%">Laranjo, N.</style></author><author><style face="normal" font="default" size="100%">Gold, D. R.</style></author><author><style face="normal" font="default" size="100%">Weiss, S. T.</style></author><author><style face="normal" font="default" size="100%">Litonjua, A. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Channing Division of Network Medicine, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Allergy and Clinical Immunology, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.&#xD;Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.&#xD;Department of Pediatrics &amp; Physiology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.&#xD;COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark.&#xD;Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.&#xD;Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.&#xD;Department of Pediatrics, Boston Medical Center, Boston, Massachusetts, USA.&#xD;Division of Pediatric Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Monroe Carell Jr Children&apos;s Hospital at Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Division of Pediatric Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, MO and St Louis Children&apos;s Hospital, St Louis, Missouri, USA.&#xD;The Kipper Institute of Allergy and Immunology, Schneider Children&apos;s Medical Center of Israel, Tel Aviv University, Israel.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Division of Pediatric Pulmonary Medicine, Golisano Children&apos;s Hospital at Strong, University of Rochester Medical Center, Rochester, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The maternal prenatal and offspring early-life gut microbiome of childhood asthma phenotypes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">418-428</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/09/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Cesarean Section</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteroides</style></keyword><keyword><style face="normal" font="default" size="100%">metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">sphingolipids</style></keyword><keyword><style face="normal" font="default" size="100%">wheeze</style></keyword><keyword><style face="normal" font="default" size="100%">Inc. STW has received royalties from UpToDate, Inc. LBB reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">NIH/NIAID and NHLBI, personal fees from GlaxoSmithKline Genentech/Novartis, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Vectura, Circassia, Kinaset, Vertex, OM Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">and royalties from</style></keyword><keyword><style face="normal" font="default" size="100%">Elsevier outside the submitted work. AB holds stock from DBV Technologies, is a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant for AstraZeneca and Raffa, and received speaking honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZenica, Novartis and Sanofi. RSZ is a consultant for AstraZeneca, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Genentech, Inc., GlaxoSmithKline, Merck &amp; Co., Novartis, Quest</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostics, Regeneron/Sanofi, TEVA Pharmaceuticals, and has received research</style></keyword><keyword><style face="normal" font="default" size="100%">support from ALK Pharmaceuticals, AstraZeneca, Genentech, Inc., GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">NHLBI, MedImmune, Merck, and Teva Pharmaceuticals. GTO has been compensated for</style></keyword><keyword><style face="normal" font="default" size="100%">speaking at a conference supported by Menarini, Inc. and for serving on a Data</style></keyword><keyword><style face="normal" font="default" size="100%">and Safety Monitoring Committee for Dicerna, Inc. VJC has received research</style></keyword><keyword><style face="normal" font="default" size="100%">support from Bayer and has a financial interest in Gilead Sciences. KL-S, YSC,</style></keyword><keyword><style face="normal" font="default" size="100%">YYC, ALK, PJM, SET, PS, HS, JS, BC, SJS, RSK, JL-S, MS, BJH, NL and DRG have</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36107703</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The infant fecal microbiome is known to impact subsequent asthma risk, but the environmental exposures impacting this association, the role of the maternal microbiome, and how the microbiome impacts different childhood asthma phenotypes are unknown. METHODS: Our objective was to identify associations between features of the prenatal and early-life fecal microbiomes and child asthma phenotypes. We analyzed fecal 16 s rRNA microbiome profiling and fecal metabolomic profiling from stool samples collected from mothers during the third trimester of pregnancy (n = 120) and offspring at ages 3-6 months (n = 265), 1 (n = 436) and 3 years (n = 506) in a total of 657 mother-child pairs participating in the Vitamin D Antenatal Asthma Reduction Trial. We used clinical data from birth to age 6 years to characterize subjects with asthma as having early, transient or active asthma phenotypes. In addition to identifying specific genera that were robustly associated with asthma phenotypes in multiple covariate-adjusted models, we clustered subjects by their longitudinal microbiome composition and sought associations between fecal metabolites and relevant microbiome and clinical features. RESULTS: Seven maternal and two infant fecal microbial taxa were robustly associated with at least one asthma phenotype, and a longitudinal gut microenvironment profile was associated with early asthma (Fisher exact test p = .03). Though mode of delivery was not directly associated with asthma, we found substantial evidence for a pathway whereby cesarean section reduces fecal Bacteroides and microbial sphingolipids, increasing susceptibility to early asthma. CONCLUSION: Overall, our results suggest that the early-life, including prenatal, fecal microbiome modifies risk of asthma, especially asthma with onset by age 3 years.</style></abstract><notes><style face="normal" font="default" size="100%">Lee-Sarwar, Kathleen A&#xD;Chen, Yih-Chieh&#xD;Chen, Yuan Yao&#xD;Kozyrskyj, Anita L&#xD;Mandhane, Piush J&#xD;Turvey, Stuart E&#xD;Subbarao, Padmaja&#xD;Bisgaard, Hans&#xD;Stokholm, Jakob&#xD;Chawes, Bo&#xD;Sorensen, Soren J&#xD;Kelly, Rachel S&#xD;Lasky-Su, Jessica&#xD;Zeiger, Robert S&#xD;O&apos;Connor, George T&#xD;Sandel, Megan T&#xD;Bacharier, Leonard B&#xD;Beigelman, Avraham&#xD;Carey, Vincent J&#xD;Harshfield, Benjamin J&#xD;Laranjo, Nancy&#xD;Gold, Diane R&#xD;Weiss, Scott T&#xD;Litonjua, Augusto A&#xD;eng&#xD;U01 HL091528/HL/NHLBI NIH HHS/&#xD;R01 HL123915/HL/NHLBI NIH HHS/&#xD;R01 HL141826/HL/NHLBI NIH HHS/&#xD;R01 HL108818/HL/NHLBI NIH HHS/&#xD;P30 ES001247/ES/NIEHS NIH HHS/&#xD;U19 AI168643/AI/NIAID NIH HHS/&#xD;K08 HL148178/HL/NHLBI NIH HHS/&#xD;UG3 OD023268/OD/NIH HHS/&#xD;T32 HL007427/HL/NHLBI NIH HHS/&#xD;UH3 OD023268/OD/NIH HHS/&#xD;K01 HL146980/HL/NHLBI NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):418-428. doi: 10.1111/all.15516. Epub 2022 Sep 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36107703</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9892205</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15516</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>390</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">390</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">DeVries, A.</style></author><author><style face="normal" font="default" size="100%">McCauley, K.</style></author><author><style face="normal" font="default" size="100%">Fadrosh, D.</style></author><author><style face="normal" font="default" size="100%">Fujimura, K. E.</style></author><author><style face="normal" font="default" size="100%">Stern, D. A.</style></author><author><style face="normal" font="default" size="100%">Lynch, S. V.</style></author><author><style face="normal" font="default" size="100%">Vercelli, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Arizona, USA.&#xD;The BIO5 Institute, The University of Arizona, Tucson, Arizona, USA.&#xD;Department of Medicine, University of California San Francisco, San Francisco, California, USA.&#xD;Benioff Center for Microbiome Medicine, University of California San Francisco, San Francisco, California, USA.&#xD;Genetic Disease Lab, California Department of Public Health, Richmond, California, USA.&#xD;Department of Cellular and Molecular Medicine, The University of Arizona, Tucson, Arizona, USA.&#xD;Arizona Center for the Biology of Complex Diseases, The University of Arizona, Tucson, Arizona, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Maternal prenatal immunity, neonatal trained immunity, and early airway microbiota shape childhood asthma development</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3617-3628</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/07/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">DNA methylation</style></keyword><keyword><style face="normal" font="default" size="100%">childhood asthma</style></keyword><keyword><style face="normal" font="default" size="100%">maternal prenatal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">nasal microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">trained innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">co-founder, board member and consultant of Siolta Therapeutics Inc., and holds</style></keyword><keyword><style face="normal" font="default" size="100%">stock in this company, she also consults for Solarea Bio.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35841380</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The path to childhood asthma is thought to initiate in utero and be further promoted by postnatal exposures. However, the underlying mechanisms remain underexplored. We hypothesized that prenatal maternal immune dysfunction associated with increased childhood asthma risk (revealed by low IFN-gamma:IL-13 secretion during the third trimester of pregnancy) alters neonatal immune training through epigenetic mechanisms and promotes early-life airway colonization by asthmagenic microbiota. METHODS: We examined epigenetic, immunologic, and microbial features potentially related to maternal prenatal immunity (IFN-gamma:IL-13 ratio) and childhood asthma in a birth cohort of mother-child dyads sampled pre-, peri-, and postnatally (N = 155). Epigenome-wide DNA methylation and cytokine production were assessed in cord blood mononuclear cells (CBMC) by array profiling and ELISA, respectively. Nasopharyngeal microbiome composition was characterized at age 2-36 months by 16S rRNA sequencing. RESULTS: Maternal prenatal immune status related to methylome profiles in neonates born to non-asthmatic mothers. A module of differentially methylated CpG sites enriched for microbe-responsive elements was associated with childhood asthma. In vitro responsiveness to microbial products was impaired in CBMCs from neonates born to mothers with the lowest IFN-gamma:IL-13 ratio, suggesting defective neonatal innate immunity in those who developed asthma during childhood. These infants exhibited a distinct pattern of upper airway microbiota development characterized by early-life colonization by Haemophilus that transitioned to a Moraxella-dominated microbiota by age 36 months. CONCLUSIONS: Maternal prenatal immune status shapes asthma development in her child by altering the epigenome and trained innate immunity at birth, and is associated with pathologic upper airway microbial colonization in early life.</style></abstract><notes><style face="normal" font="default" size="100%">DeVries, Avery&#xD;McCauley, Kathryn&#xD;Fadrosh, Douglas&#xD;Fujimura, Kei E&#xD;Stern, Debra A&#xD;Lynch, Susan V&#xD;Vercelli, Donata&#xD;eng&#xD;U19 AI125357/AI/NIAID NIH HHS/&#xD;ES/NIEHS NIH HHS/&#xD;R21AI133765/NH/NIH HHS/&#xD;T32 ES007091/NH/NIH HHS/&#xD;P01AI148104/NH/NIH HHS/&#xD;P01 AI148104/AI/NIAID NIH HHS/&#xD;R21AI144722/NH/NIH HHS/&#xD;R21 AI144722/AI/NIAID NIH HHS/&#xD;R21 AI133765/AI/NIAID NIH HHS/&#xD;R01AI042268/NH/NIH HHS/&#xD;U19AI125357/NH/NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3617-3628. doi: 10.1111/all.15442. Epub 2022 Jul 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35841380</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9712226</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15442</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1036</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1036</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Miyano, T.</style></author><author><style face="normal" font="default" size="100%">Irvine, A. D.</style></author><author><style face="normal" font="default" size="100%">Tanaka, R. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Bioengineering, Imperial College London, London, UK.&#xD;Pediatric Dermatology, Children&apos;s Health Ireland at Crumlin, Dublin, Ireland.&#xD;Clinical Medicine, Trinity College Dublin, Dublin, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">582-594</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/04/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Theoretical</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">model-based meta-analysis</style></keyword><keyword><style face="normal" font="default" size="100%">poor responders</style></keyword><keyword><style face="normal" font="default" size="100%">quantitative systems pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33894014</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Several biologics for atopic dermatitis (AD) have demonstrated good efficacy in clinical trials, but with a substantial proportion of patients being identified as poor responders. This study aims to understand the pathophysiological backgrounds of patient variability in drug response, especially for dupilumab, and to identify promising drug targets in dupilumab poor responders. METHODS: We conducted model-based meta-analysis of recent clinical trials of AD biologics and developed a mathematical model that reproduces reported clinical efficacies for nine biological drugs (dupilumab, lebrikizumab, tralokinumab, secukinumab, fezakinumab, nemolizumab, tezepelumab, GBR 830, and recombinant interferon-gamma) by describing system-level AD pathogenesis. Using this model, we simulated the clinical efficacy of hypothetical therapies on virtual patients. RESULTS: Our model reproduced reported time courses of %improved EASI and EASI-75 of the nine drugs. The global sensitivity analysis and model simulation indicated the baseline level of IL-13 could stratify dupilumab good responders. Model simulation on the efficacies of hypothetical therapies revealed that simultaneous inhibition of IL-13 and IL-22 was effective, whereas application of the nine biologic drugs was ineffective, for dupilumab poor responders (EASI-75 at 24 weeks: 21.6% vs. max. 1.9%). CONCLUSION: Our model identified IL-13 as a potential predictive biomarker to stratify dupilumab good responders, and simultaneous inhibition of IL-13 and IL-22 as a promising drug therapy for dupilumab poor responders. This model will serve as a computational platform for model-informed drug development for precision medicine, as it allows evaluation of the effects of new potential drug targets and the mechanisms behind patient variability in drug response.</style></abstract><notes><style face="normal" font="default" size="100%">Miyano, Takuya&#xD;Irvine, Alan D&#xD;Tanaka, Reiko J&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):582-594. doi: 10.1111/all.14870. Epub 2021 May 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33894014</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14870</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2664</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2664</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cho, M. J.</style></author><author><style face="normal" font="default" size="100%">Nguyen, V.</style></author><author><style face="normal" font="default" size="100%">Suami, H.</style></author><author><style face="normal" font="default" size="100%">Kraft, C. T.</style></author><author><style face="normal" font="default" size="100%">Kraft, M. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Plastic and Reconstructive Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.&#xD;Division of Allergy and Immunology, The Ohio State University and Nationwide Children&apos;s Hospital, Columbus, Ohio, USA.&#xD;Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.&#xD;Columbus Cosmetic, Columbus, Ohio, USA.&#xD;Department of Otolaryngology, Division of Allergy and Immunology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Maximizing safety of ultrasound-guided intralymphatic allergen administration in the superficial inguinal lymph node</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">876-878</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/10/30</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39475404</style></accession-num><notes><style face="normal" font="default" size="100%">Cho, Min-Jeong&#xD;Nguyen, Victoria&#xD;Suami, Hiroo&#xD;Kraft, Casey T&#xD;Kraft, Monica T&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):876-878. doi: 10.1111/all.16379. Epub 2024 Oct 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39475404</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891398</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16379</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>716</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">716</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lyons, S. A.</style></author><author><style face="normal" font="default" size="100%">Welsing, P. M. J.</style></author><author><style face="normal" font="default" size="100%">Hakobyan, M.</style></author><author><style face="normal" font="default" size="100%">Kansen, H. M.</style></author><author><style face="normal" font="default" size="100%">Knol, E. F.</style></author><author><style face="normal" font="default" size="100%">Otten, H. G.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Knulst, A. C.</style></author><author><style face="normal" font="default" size="100%">Le, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.&#xD;Division of internal medicine and dermatology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.&#xD;Department of Pediatric Pulmonology and Allergology, Wilhelmina Children&apos;s Hospital, University Medical Center, Utrecht University, Utrecht, the Netherlands.&#xD;Center of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.&#xD;Department of experimental immunology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.&#xD;Department of otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Measurement of IgE to hazelnut allergen components cannot replace hazelnut challenge in Dutch adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1559-1569</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/11/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">*Corylus/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Nut Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">adults</style></keyword><keyword><style face="normal" font="default" size="100%">component-resolved diagnostics</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostic value</style></keyword><keyword><style face="normal" font="default" size="100%">hazelnut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">no further conflicts of interest in relation to this study. Outside submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work, Dr. Knol reports personal fees from Thermo Fisher Scientific, and Dr. Van</style></keyword><keyword><style face="normal" font="default" size="100%">Ree reports personal fees from HAL Allergy BV, Citeq BV, Angany Inc., Thermo</style></keyword><keyword><style face="normal" font="default" size="100%">Fisher Scientific</style></keyword><keyword><style face="normal" font="default" size="100%">and grants from the Dutch Science Foundation, European</style></keyword><keyword><style face="normal" font="default" size="100%">Commission, and Health Holland.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34731517</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Component-resolved diagnostics (CRD) help predict hazelnut allergy (HA) in children, but are of unknown diagnostic value in adults. This study aimed to evaluate the diagnostic accuracy of IgE to hazelnut extract and components in adults. METHODS: A Dutch population of consecutively presenting adults suspected of HA, who underwent a double-blind placebo-controlled food challenge, were included. Serum IgE to hazelnut extract and Cor a 1, 8, 9, and 14 was measured on ImmunoCAP. Diagnostic accuracy was assessed by area under the curve (AUC) analysis. RESULTS: Of 89 patients undergoing challenge, 46 had challenge-confirmed HA: 17 based on objective and 29 based on subjective symptoms. At commonly applied cutoffs 0.1 and 0.35 kU(A) /L, high sensitivity was observed for IgE to hazelnut extract and Cor a 1 (range 85-91%), and high specificity for IgE to Cor a 8, 9 and 14 (range 77-95%). However, the AUCs for hazelnut extract and components were too low for accurate prediction of HA (range 0.50-0.56). Combining hazelnut extract and component IgE measurements did not significantly improve accuracy. Higher IgE levels to Cor a 9 and 14 were tentatively associated with HA with objective symptoms, but the corresponding AUCs still only reached 0.68 and 0.63, respectively. CONCLUSIONS: Although hazelnut allergic adults are generally sensitized to hazelnut extract and Cor a 1, and hazelnut tolerant adults are usually not sensitized to Cor a 8, 9, or 14, challenge testing is still needed to accurately discriminate between presence and absence of HA in adults from a birch-endemic country.</style></abstract><notes><style face="normal" font="default" size="100%">Lyons, Sarah A&#xD;Welsing, Paco M J&#xD;Hakobyan, Mariam&#xD;Kansen, Hannah M&#xD;Knol, Edward F&#xD;Otten, Henny G&#xD;van Ree, Ronald&#xD;Knulst, Andre C&#xD;Le, Thuy-My&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1559-1569. doi: 10.1111/all.15166. Epub 2021 Nov 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34731517</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9298907</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15166</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2179</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2179</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Bingol, E. N.</style></author><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">Ardicli, S.</style></author><author><style face="normal" font="default" size="100%">Heider, A.</style></author><author><style face="normal" font="default" size="100%">Ruckert, B.</style></author><author><style face="normal" font="default" size="100%">Sampath, V.</style></author><author><style face="normal" font="default" size="100%">Dhir, R.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Bioengineering, Institute of Pure and Applied Sciences, Marmara University, Istanbul, Turkey.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.&#xD;SEED Inc. Co., Los Angeles, California, USA.&#xD;Department of Environmental Health, T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mechanisms of gut epithelial barrier impairment caused by food emulsifiers polysorbate 20 and polysorbate 80</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2441-2455</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Polysorbates/adverse effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Phosphatidylinositol 3-Kinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA-seq</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">food emulsifiers</style></keyword><keyword><style face="normal" font="default" size="100%">polysorbate-20</style></keyword><keyword><style face="normal" font="default" size="100%">polysorbate-80</style></keyword><keyword><style face="normal" font="default" size="100%">targeted proteomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37530764</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The rising prevalence of many chronic diseases related to gut barrier dysfunction coincides with the increased global usage of dietary emulsifiers in recent decades. We therefore investigated the effect of the frequently used food emulsifiers on cytotoxicity, barrier function, transcriptome alterations, and protein expression in gastrointestinal epithelial cells. METHODS: Human intestinal organoids originating from induced pluripotent stem cells, colon organoid organ-on-a-chip, and liquid-liquid interface cells were cultured in the presence of two common emulsifiers: polysorbate 20 (P20) and polysorbate 80 (P80). The cytotoxicity, transepithelial electrical resistance (TEER), and paracellular-flux were measured. Immunofluorescence staining of epithelial tight-junctions (TJ), RNA-seq transcriptome, and targeted proteomics were performed. RESULTS: Cells showed lysis in response to P20 and P80 exposure starting at a 0.1% (v/v) concentration across all models. Epithelial barrier disruption correlated with decreased TEER, increased paracellular-flux and irregular TJ immunostaining. RNA-seq and targeted proteomics analyses demonstrated upregulation of cell development, signaling, proliferation, apoptosis, inflammatory response, and response to stress at 0.05%, a concentration lower than direct cell toxicity. A proinflammatory response was characterized by the secretion of several cytokines and chemokines, interaction with their receptors, and PI3K-Akt and MAPK signaling pathways. CXCL5, CXCL10, and VEGFA were upregulated in response to P20 and CXCL1, CXCL8 (IL-8), CXCL10, LIF in response to P80. CONCLUSIONS: The present study provides direct evidence on the detrimental effects of food emulsifiers P20 and P80 on intestinal epithelial integrity. The underlying mechanism of epithelial barrier disruption was cell death at concentrations between 1% and 0.1%. Even at concentrations lower than 0.1%, these polysorbates induced a proinflammatory response suggesting a detrimental effect on gastrointestinal health.</style></abstract><notes><style face="normal" font="default" size="100%">Ogulur, Ismail&#xD;Yazici, Duygu&#xD;Pat, Yagiz&#xD;Bingol, Elif Naz&#xD;Babayev, Huseyn&#xD;Ardicli, Sena&#xD;Heider, Anja&#xD;Ruckert, Beate&#xD;Sampath, Vanitha&#xD;Dhir, Raja&#xD;Akdis, Mubeccel&#xD;Nadeau, Kari&#xD;Akdis, Cezmi A&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2441-2455. doi: 10.1111/all.15825. Epub 2023 Aug 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37530764</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15825</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>326</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">326</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ozcan, A.</style></author><author><style face="normal" font="default" size="100%">Boyman, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Faculty of Science, University of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mechanisms regulating neutrophil responses in immunity, allergy, and autoimmunity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3567-3583</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/09/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">Autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">*Autoimmune Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Infective Agents</style></keyword><keyword><style face="normal" font="default" size="100%">autoinflammation</style></keyword><keyword><style face="normal" font="default" size="100%">immunodeficiency</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36067034</style></accession-num><abstract><style face="normal" font="default" size="100%">Neutrophil granulocytes, or neutrophils, are the most abundant circulating leukocytes in humans and indispensable for antimicrobial immunity, as exemplified in patients with inborn and acquired defects of neutrophils. Neutrophils were long regarded as the foot soldiers of the immune system, solely destined to execute a set of effector functions against invading pathogens before undergoing apoptosis, the latter of which was ascribed to their short life span. This simplistic understanding of neutrophils has now been revised on the basis of insights gained from the use of mouse models and single-cell high-throughput techniques, revealing tissue- and context-specific roles of neutrophils in guiding immune responses. These studies also demonstrated that neutrophil responses were controlled by sophisticated feedback mechanisms, including directed chemotaxis of neutrophils to tissue-draining lymph nodes resulting in modulation of antimicrobial immunity and inflammation. Moreover, findings in mice and humans showed that neutrophil responses adapted to different deterministic cytokine signals, which controlled their migration and effector function as well as, notably, their biologic clock by affecting the kinetics of their aging. These mechanistic insights have important implications for health and disease in humans, particularly, in allergic diseases, such as atopic dermatitis and allergic asthma bronchiale, as well as in autoinflammatory and autoimmune diseases. Hence, our improved understanding of neutrophils sheds light on novel therapeutic avenues, focusing on molecularly defined biologic agents.</style></abstract><notes><style face="normal" font="default" size="100%">Ozcan, Alaz&#xD;Boyman, Onur&#xD;eng&#xD;P500PB-206852/SNSF_/Swiss National Science Foundation/Switzerland&#xD;310030-200669/SNSF_/Swiss National Science Foundation/Switzerland&#xD;CRSII5-189950/SNSF_/Swiss National Science Foundation/Switzerland&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3567-3583. doi: 10.1111/all.15505. Epub 2022 Sep 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36067034</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087481</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15505</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3207</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3207</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Natarajan, R.</style></author><author><style face="normal" font="default" size="100%">Szczesny, B.</style></author><author><style face="normal" font="default" size="100%">Kanchan, K.</style></author><author><style face="normal" font="default" size="100%">Esquinca, E.</style></author><author><style face="normal" font="default" size="100%">Boorgula, M. P.</style></author><author><style face="normal" font="default" size="100%">Chavan, S.</style></author><author><style face="normal" font="default" size="100%">Campbell, M.</style></author><author><style face="normal" font="default" size="100%">Lorizio, W.</style></author><author><style face="normal" font="default" size="100%">Doumatey, A. P.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Watson, H.</style></author><author><style face="normal" font="default" size="100%">Naureckas, E. T.</style></author><author><style face="normal" font="default" size="100%">Giles, B. L.</style></author><author><style face="normal" font="default" size="100%">Arinola, G.</style></author><author><style face="normal" font="default" size="100%">Sogaolu, O.</style></author><author><style face="normal" font="default" size="100%">Falade, A. G.</style></author><author><style face="normal" font="default" size="100%">Hansel, N. N.</style></author><author><style face="normal" font="default" size="100%">Olopade, C. O.</style></author><author><style face="normal" font="default" size="100%">Rotimi, C. N.</style></author><author><style face="normal" font="default" size="100%">Landis, R. C.</style></author><author><style face="normal" font="default" size="100%">Figueiredo, C. A.</style></author><author><style face="normal" font="default" size="100%">Kenny, E. E.</style></author><author><style face="normal" font="default" size="100%">Ruczinski, I.</style></author><author><style face="normal" font="default" size="100%">Liu, A. H.</style></author><author><style face="normal" font="default" size="100%">Ober, C.</style></author><author><style face="normal" font="default" size="100%">Taub, M. A.</style></author><author><style face="normal" font="default" size="100%">Johnson, R. K.</style></author><author><style face="normal" font="default" size="100%">Barnes, K. C.</style></author><author><style face="normal" font="default" size="100%">Wojcik, G. L.</style></author><author><style face="normal" font="default" size="100%">Mathias, R. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Genomics and Precision Health Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.&#xD;Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.&#xD;Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, USA.&#xD;Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.&#xD;Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.&#xD;Fundacao ProAR and Federal University of Bahia, Salvador, Bahia, Brazil.&#xD;Faculty of Medical Sciences, The University of the West Indies, Queen Elizabeth Hospital, St. Michael, Bridgetown, Barbados.&#xD;Department of Medicine, University of Chicago, Chicago, Illinois, USA.&#xD;Department of Pediatrics, University of Chicago, Chicago, Illinois, USA.&#xD;Department of Immunology, College of Medicine, University of Ibadan, Ibadan, Nigeria.&#xD;Department of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria.&#xD;Department of Pediatrics, University of Ibadan, Ibadan, Nigeria.&#xD;University College Hospital, Ibadan, Nigeria.&#xD;Edmund Cohen Laboratory for Vascular Research, George Alleyne Chronic Disease Research Centre, Caribbean Institute for Health Research, The University of the West Indies, Cave Hill Campus, Wanstead, Barbados.&#xD;Instituto de Ciencias de Saude, Universidade Federal da Bahia, Salvador, Brazil.&#xD;Program for Control of Asthma in Bahia (ProAR), Salvador, Brazil.&#xD;Center for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.&#xD;Department of Pediatrics, Childrens Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, USA.&#xD;Department of Human Genetics, University of Chicago, Chicago, Illinois, USA.&#xD;Department of Epidemiology, Colorado School of Public Health, Aurora, Colorado, USA.&#xD;Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mediation of Polygenic Asthma Risk Through Gene Expression</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">African ancestries</style></keyword><keyword><style face="normal" font="default" size="100%">Gwas</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">T2 inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">medication response</style></keyword><keyword><style face="normal" font="default" size="100%">polygenic risk scores</style></keyword><keyword><style face="normal" font="default" size="100%">wound healing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41351491</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Existing asthma polygenic risk scores (PRSs) have minimal validation in African-ancestry populations, leaving gaps in our understanding of the wide applicability of PRSs. To widen our understanding of the applicability of asthma PRSs, we apply published PRSs in African-ancestry individuals and quantify the extent to which the PRS-asthma relationship is mediated by clinical biomarkers and gene-expression signatures of asthma. METHODS: We applied 22 PRSs from the PGS Catalog in 673 individuals from the Consortium on Asthma among African-Ancestry Populations in the Americas (CAAPA) and calculated the percent of the PRS-asthma relationship that is statistically mediated by clinical and nasal epithelium transcriptomic biomarkers of asthma. Asthma case/control status was defined as ever/never having a doctor&apos;s diagnosis of disease. For gene expression mediation analysis, we limited the cases to those with current disease. RESULTS: The PRS (PGS001782) created by the Global Biobank Meta-analysis Initiative (N = 32,658 individuals of African ancestry) performed the best (DeltaAUC = 0.104, AUC = 0.657) adjusted for age, sex, study site, and the first two genetic principal components (PC1-2). The PRS&apos;s effect on asthma was mediated by total IgE (tIgE) (38.8%, p.adj &lt; 0.0002), multi-allergen ImmunoCAP phadiatop specific IgE (sIgE) (38.7%, p.adj &lt; 0.0002), and eosinophils (7.3%, p.adj = 0.004). Mediation was observed for gene expression modules related to T2 inflammation (21.9%, p.adj &lt; 0.0024), wound healing (11.9%, p.adj = 0.008), and medication response (6.8%, p.adj = 0.049). CONCLUSION: We found the best PRS to be the one derived using the largest sample size and including African-ancestry individuals. Mediation supports the well-documented biology of T2 inflammation in asthma as well as pathophysiological components of asthma like wound healing and medication response.</style></abstract><notes><style face="normal" font="default" size="100%">Natarajan, Rakesh&#xD;Szczesny, Brooke&#xD;Kanchan, Kanika&#xD;Esquinca, Erika&#xD;Boorgula, Meher Preethi&#xD;Chavan, Sameer&#xD;Campbell, Monica&#xD;Lorizio, Wendy&#xD;Doumatey, Ayo P&#xD;Cruz, Alvaro A&#xD;Watson, Harold&#xD;Naureckas, Edward T&#xD;Giles, B Louise&#xD;Arinola, Ganiyu&#xD;Sogaolu, Olumide&#xD;Falade, Adegoke G&#xD;Hansel, Nadia N&#xD;Olopade, Christopher O&#xD;Rotimi, Charles N&#xD;Landis, R Clive&#xD;Figueiredo, Camila A&#xD;Kenny, Eimear E&#xD;Ruczinski, Ingo&#xD;Liu, Andrew H&#xD;Ober, Carole&#xD;Taub, Margaret A&#xD;Johnson, Randi K&#xD;Barnes, Kathleen C&#xD;Wojcik, Genevieve L&#xD;Mathias, Rasika A&#xD;eng&#xD;R01HL104608/National Institutes of Health (NIH)/&#xD;National Institute of Allergy and Infectious Diseases/&#xD;HL/NHLBI NIH HHS/&#xD;Denmark&#xD;Allergy. 2025 Dec 6. doi: 10.1111/all.70101.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41351491</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70101</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1270</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1270</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Serrier, J.</style></author><author><style face="normal" font="default" size="100%">Khoy, K.</style></author><author><style face="normal" font="default" size="100%">Petit, G.</style></author><author><style face="normal" font="default" size="100%">Parienti, J. J.</style></author><author><style face="normal" font="default" size="100%">Laroche, D.</style></author><author><style face="normal" font="default" size="100%">Mariotte, D.</style></author><author><style face="normal" font="default" size="100%">Le Mauff, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratoire d&apos;Immunologie et Immunopathologie, Centre Hospitalier Universitaire de Caen, Caen, France.&#xD;Unite de Biostatistique et de Recherche Clinique, Direction Recherche et Enseignement, Centre Hospitalier Universitaire de Caen, Caen, France.&#xD;Universite de Caen Normandie, Caen, France.&#xD;Laboratoire d&apos;Hormonologie, Centre Hospitalier Universitaire de Caen, Caen, France.&#xD;INSERM U1237, Physiopathology and Imaging of Neurological Disorders, Caen, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mediators of anaphylactic reactions: Tryptase and histamine stability in whole blood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1579-1583</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/11/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Chymases</style></keyword><keyword><style face="normal" font="default" size="100%">*Histamine</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine Release</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptases</style></keyword><keyword><style face="normal" font="default" size="100%">histamine</style></keyword><keyword><style face="normal" font="default" size="100%">pre-analytic</style></keyword><keyword><style face="normal" font="default" size="100%">tryptase</style></keyword><keyword><style face="normal" font="default" size="100%">whole blood</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33202058</style></accession-num><notes><style face="normal" font="default" size="100%">Serrier, Julien&#xD;Khoy, Kathy&#xD;Petit, Gautier&#xD;Parienti, Jean-Jacques&#xD;Laroche, Dominique&#xD;Mariotte, Delphine&#xD;Le Mauff, Brigitte&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1579-1583. doi: 10.1111/all.14663. Epub 2020 Dec 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33202058</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14663</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>911</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">911</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lukaszewicz, R.</style></author><author><style face="normal" font="default" size="100%">Mahay, G.</style></author><author><style face="normal" font="default" size="100%">Boyer, O.</style></author><author><style face="normal" font="default" size="100%">Martinet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary, Thoracic Oncology and Respiratory Intensive Care, CHU Rouen, Rouen, France.&#xD;Department of Immunology and Biotherapy, Normandie Univ, UNIROUEN, Inserm U1234, CHU Rouen, Rouen, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Aspergillus fumigatus components in the diagnosis of allergic bronchopulmonary aspergillosis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">327-330</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/07/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Aspergillosis, Allergic Bronchopulmonary/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Abpa</style></keyword><keyword><style face="normal" font="default" size="100%">Copd</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34252208</style></accession-num><notes><style face="normal" font="default" size="100%">Lukaszewicz, Raphael&#xD;Mahay, Guillaume&#xD;Boyer, Olivier&#xD;Martinet, Jeremie&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):327-330. doi: 10.1111/all.15001. Epub 2021 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34252208</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15001</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1848</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1848</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lukaszewicz, R.</style></author><author><style face="normal" font="default" size="100%">Mahay, G.</style></author><author><style face="normal" font="default" size="100%">Boyer, O.</style></author><author><style face="normal" font="default" size="100%">Martinet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary, Thoracic Oncology and Respiratory Intensive Care, CHU Rouen, Rouen, France.&#xD;Department of Immunology and Biotherapy, Normandie Univ, UNIROUEN, Inserm U1234, CHU Rouen, Rouen, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Aspergillus fumigatus components in the diagnosis of allergic bronchopulmonary aspergillosis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">327-330</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/07/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Aspergillosis, Allergic Bronchopulmonary/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Abpa</style></keyword><keyword><style face="normal" font="default" size="100%">Copd</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34252208</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Allergic bronchopulmonary aspergillosis (ABPA) is a lung disease involving hypersensitivity to Aspergillus fumigatus (Af) antigens caused by repeated inhalation of spores in susceptible hosts. Its identification is sometimes difficult, and delayed diagnosis, or lack of treatment, leads to worsening lung function and major complications like pulmonary fibrosis or bronchiectasis.</style></abstract><notes><style face="normal" font="default" size="100%">Lukaszewicz, Raphael&#xD;Mahay, Guillaume&#xD;Boyer, Olivier&#xD;Martinet, Jeremie&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):327-330. doi: 10.1111/all.15001. Epub 2021 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34252208</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15001</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2464</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2464</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gonzalez-Delgado, P.</style></author><author><style face="normal" font="default" size="100%">Anvari, S.</style></author><author><style face="normal" font="default" size="100%">Entrala, A.</style></author><author><style face="normal" font="default" size="100%">Infante, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Service, Hospital General Universitario de Alicante, Instituto de Investigacion Sanitaria y Biomedica de Alicante (ISABIAL), Alicante, Spain.&#xD;Departamento de Medicina Clinica, Universidad Miguel Hernandez, Alicante, Spain.&#xD;Division of Immunology, Allergy and Retrovirology, Department of Pediatrics, Baylor College of Medicine, Texas Children&apos;s Hospital, Houston, Texas, USA.&#xD;Texas Children&apos;s Hospital, William T. Shearer Center for Human Immunobiology, Houston, Texas, USA.&#xD;Allergy Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain.&#xD;Gregorio Maranon Health Research Institute (IiSGM), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and management of adult food protein-induced enterocolitis syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2881-2884</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/04/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Enterocolitis/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Proteins/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">adult FPIES</style></keyword><keyword><style face="normal" font="default" size="100%">adult food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">non-IgE mediated food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38686652</style></accession-num><notes><style face="normal" font="default" size="100%">Gonzalez-Delgado, Purificacion&#xD;Anvari, Sara&#xD;Entrala, Ana&#xD;Infante, Sonsoles&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2881-2884. doi: 10.1111/all.16142. Epub 2024 Apr 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38686652</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16142</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>971</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">971</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sediva, A.</style></author><author><style face="normal" font="default" size="100%">Milota, T.</style></author><author><style face="normal" font="default" size="100%">Litzman, J.</style></author><author><style face="normal" font="default" size="100%">Quinti, I.</style></author><author><style face="normal" font="default" size="100%">Meyts, I.</style></author><author><style face="normal" font="default" size="100%">Burns, S.</style></author><author><style face="normal" font="default" size="100%">Jolles, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, 2nd Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czech Republic.&#xD;EAACI Primary Immunodeficiency Working Group.&#xD;Faculty of Medicine, Masaryk University, Brno, Czech Republic.&#xD;Department of Clinical Immunology and Allergology, St Anne s University Hospital, Brno, Czech Republic.&#xD;Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.&#xD;Department of Pediatrics, Leuven University Hospitals, Leuven, Belgium.&#xD;ESID Clinical Working Party.&#xD;Institute of Immunity and Transplantation, University College London, London, UK.&#xD;Department of Immunology, Royal Free London NHS Foundation Trust, London, UK.&#xD;Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and management of antibody immunodeficiencies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3841-3844</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunologic Deficiency Syndromes/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">b cells</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">immune deficiencies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34037990</style></accession-num><notes><style face="normal" font="default" size="100%">Sediva, Anna&#xD;Milota, Tomas&#xD;Litzman, Jiri&#xD;Quinti, Isabella&#xD;Meyts, Isabelle&#xD;Burns, Siobhan&#xD;Jolles, Stephen&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3841-3844. doi: 10.1111/all.14961. Epub 2021 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34037990</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14961</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1850</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1850</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sediva, A.</style></author><author><style face="normal" font="default" size="100%">Milota, T.</style></author><author><style face="normal" font="default" size="100%">Litzman, J.</style></author><author><style face="normal" font="default" size="100%">Quinti, I.</style></author><author><style face="normal" font="default" size="100%">Meyts, I.</style></author><author><style face="normal" font="default" size="100%">Burns, S.</style></author><author><style face="normal" font="default" size="100%">Jolles, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, 2nd Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czech Republic.&#xD;EAACI Primary Immunodeficiency Working Group.&#xD;Faculty of Medicine, Masaryk University, Brno, Czech Republic.&#xD;Department of Clinical Immunology and Allergology, St Anne s University Hospital, Brno, Czech Republic.&#xD;Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.&#xD;Department of Pediatrics, Leuven University Hospitals, Leuven, Belgium.&#xD;ESID Clinical Working Party.&#xD;Institute of Immunity and Transplantation, University College London, London, UK.&#xD;Department of Immunology, Royal Free London NHS Foundation Trust, London, UK.&#xD;Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and management of antibody immunodeficiencies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3841-3844</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/27</style></edition><section><style face="normal" font="default" size="100%">3841</style></section><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunologic Deficiency Syndromes/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">b cells</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">immune deficiencies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34037990</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Primary antibodydeficiencies (PAD) constitute the majority of all primary immunodeficiency diseases (PID) also termed in born errors of immunity (IEI). This category (PAD) representsaround 52% of all IEI and the proportion overall is still greater given that antibody deficiency is a component of other groups including combined and severe combined immunodeficiencies (SCID), autoinflammatory disorders, diseases of immune dysregulation and other well defined PIDs(1,2). Secondary antibody deficiencies (SAD) represent a larger and expanding number of individuals resulting from the use of a wide range of immunosuppressive therapies, in particular those targeting B cells, and may also result from renal orgastrointestinal immunoglobulin losses, infections, for example HIVormalaria,malnutritionorothers(3).</style></abstract><notes><style face="normal" font="default" size="100%">Sediva, Anna&#xD;Milota, Tomas&#xD;Litzman, Jiri&#xD;Quinti, Isabella&#xD;Meyts, Isabelle&#xD;Burns, Siobhan&#xD;Jolles, Stephen&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3841-3844. doi: 10.1111/all.14961. Epub 2021 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34037990</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14961</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>58</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">58</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ferrer, M.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Garijo, N.</style></author><author><style face="normal" font="default" size="100%">Sabate-Bresco, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain.&#xD;Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain.&#xD;RETIC de Asma, Reacciones Adversas y Alergicas (ARADYAL), Madrid, Spain.&#xD;Department of Dermatology, Clinica Universidad de Navarra, Pamplona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and management of histaminergic angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">599-602</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/12/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedema/diagnosis/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Bradykinin</style></keyword><keyword><style face="normal" font="default" size="100%">bradykinin-mediated angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">histaminergic angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell-mediated angioedema</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36478245</style></accession-num><notes><style face="normal" font="default" size="100%">Ferrer, Marta&#xD;Rodriguez-Garijo, Nuria&#xD;Sabate-Bresco, Marina&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):599-602. doi: 10.1111/all.15618. Epub 2022 Dec 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36478245</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15618</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1845</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1845</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ferrer, M.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Garijo, N.</style></author><author><style face="normal" font="default" size="100%">Sabate-Bresco, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain.&#xD;Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain.&#xD;RETIC de Asma, Reacciones Adversas y Alergicas (ARADYAL), Madrid, Spain.&#xD;Department of Dermatology, Clinica Universidad de Navarra, Pamplona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and management of histaminergic angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">599-602</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/12/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedema/diagnosis/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Bradykinin</style></keyword><keyword><style face="normal" font="default" size="100%">bradykinin-mediated angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">histaminergic angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell-mediated angioedema</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36478245</style></accession-num><notes><style face="normal" font="default" size="100%">Ferrer, Marta&#xD;Rodriguez-Garijo, Nuria&#xD;Sabate-Bresco, Marina&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):599-602. doi: 10.1111/all.15618. Epub 2022 Dec 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36478245</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15618</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1506</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1506</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Ghent University Hospital, Upper Airway Research Laboratory, Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">240-242</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2019/04/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Decision-Making/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/diagnosis/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30993703</style></accession-num><notes><style face="normal" font="default" size="100%">Bachert, Claus&#xD;Zhang, Nan&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2020 Jan;75(1):240-242. doi: 10.1111/all.13823. Epub 2019 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30993703</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13823</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1496</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1496</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, B. C.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, MA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of drug hypersensitivity reactions to biologicals</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3293-3296</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2020/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32496608</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Monoclonal antibodies have become an essential treatment modality for many inflammatory diseases and malignancies. Hypersensitivity reactions to monoclonal antibodies need not prevent their use as first-line therapy. Through the use of rapid desensitization, the patient may be safely re-exposed to the agent. In this article, we review the algorithm for rapid desensitization of monoclonal antibodies.</style></abstract><notes><style face="normal" font="default" size="100%">Yang, Barbara Carolyn&#xD;Castells, Mariana&#xD;eng&#xD;Denmark&#xD;Allergy. 2020 Dec;75(12):3293-3296. doi: 10.1111/all.14432. Epub 2020 Jun 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32496608</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14432</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2688</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2688</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, B. C.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of drug hypersensitivity reactions to biologicals, 2024 update</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1534-1539</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/10/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">personalized medicine</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39400368</style></accession-num><notes><style face="normal" font="default" size="100%">Yang, Barbara Carolyn&#xD;Castells, Mariana&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1534-1539. doi: 10.1111/all.16353. Epub 2024 Oct 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39400368</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16353</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2483</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2483</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">Traidl, S.</style></author><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Walsh, S.</style></author><author><style face="normal" font="default" size="100%">French, L. E.</style></author><author><style face="normal" font="default" size="100%">Gulati, N.</style></author><author><style face="normal" font="default" size="100%">Phillips, E.</style></author><author><style face="normal" font="default" size="100%">Maverakis, E.</style></author><author><style face="normal" font="default" size="100%">Ingen-Housz-Oro, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, University Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;ToxiTEN group of the ERN-skin.&#xD;Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF) Davos, Davos, Switzerland.&#xD;Department of Dermatology, King&apos;s College Hospital NHS Foundation Trust, London, UK.&#xD;Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.&#xD;Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida, USA.&#xD;The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Department of Dermatology, University of California, Davis, California, USA.&#xD;Department of Dermatology, Henri Mondor Hospital, Univ Paris Est Creteil EpidermE, Creteil, Paris, France.&#xD;Reference center for severe drug reactions TOXIBUL, Creteil, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of drug reaction with eosinophilia and systemic symptoms in adult patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2876-2880</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/04/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity Syndrome/diagnosis/etiology/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophilia/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">DRESS (Drug reaction with eosinophilia and systemic symptoms)</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38587051</style></accession-num><notes><style face="normal" font="default" size="100%">Bruggen, Marie-Charlotte&#xD;Traidl, Stephan&#xD;Mitamura, Yasutaka&#xD;Walsh, Sarah&#xD;French, Lars E&#xD;Gulati, Nicholas&#xD;Phillips, Elizabeth&#xD;Maverakis, Emanual&#xD;Ingen-Housz-Oro, Saskia&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2876-2880. doi: 10.1111/all.16122. Epub 2024 Apr 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38587051</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16122</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1501</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1501</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Greuter, T.</style></author><author><style face="normal" font="default" size="100%">Straumann, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss EoE Clinic, Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of eosinophilic esophagitis in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">727-730</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2019/11/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis, Differential</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31714997</style></accession-num><notes><style face="normal" font="default" size="100%">Greuter, Thomas&#xD;Straumann, Alex&#xD;eng&#xD;U54 AI117804/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Mar;75(3):727-730. doi: 10.1111/all.14112. Epub 2019 Dec 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31714997</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7067637</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14112</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1497</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1497</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spergel, J. M.</style></author><author><style face="normal" font="default" size="100%">Brown-Whitehorn, T. A.</style></author><author><style face="normal" font="default" size="100%">Muir, A.</style></author><author><style face="normal" font="default" size="100%">Liacouras, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, The Children&apos;s Hospital of Philadelphia, Philadelphia, PA, USA.&#xD;Department of Pediatrics, The Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, USA.&#xD;Division of Gastroenterology, Hepatology, and Nutrition, The Children&apos;s Hospital of Philadelphia, Philadelphia, PA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of eosinophilic esophagitis in children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Allergy</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></alt-periodical><pages><style face="normal" font="default" size="100%">1522-1524</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/01/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis, Differential</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31953959</style></accession-num><notes><style face="normal" font="default" size="100%">Spergel, Jonathan M&#xD;Brown-Whitehorn, Terri A&#xD;Muir, Amanda&#xD;Liacouras, Chris A&#xD;eng&#xD;R03 DK118310/DK/NIDDK NIH HHS/&#xD;U54 AI117804/AI/NIAID NIH HHS/&#xD;K08 DK106444/DK/NIDDK NIH HHS/&#xD;F32 DK100088/DK/NIDDK NIH HHS/&#xD;R01 DK124266/DK/NIDDK NIH HHS/&#xD;R21 TR003039/TR/NCATS NIH HHS/&#xD;News&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Jun;75(6):1522-1524. doi: 10.1111/all.14188. Epub 2020 Jan 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31953959</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8040021</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14188</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schulze, J.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Trischler, J.</style></author><author><style face="normal" font="default" size="100%">Zielen, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department for Children and Adolescents, Division of Allergology, Pulmonology and Cystic Fibrosis, Goethe-University Hospital, Frankfurt am Main, Germany.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Instituto de Investigacion Biomedica de Malaga (IBIMA), and RICORS &quot;Inflammatory diseases&quot;, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of house dust mite-driven allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1397-1399</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/01/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36691365</style></accession-num><notes><style face="normal" font="default" size="100%">Schulze, Johannes&#xD;Agache, Ioana&#xD;Eguiluz-Gracia, Ibon&#xD;Trischler, Jordis&#xD;Zielen, Stefan&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1397-1399. doi: 10.1111/all.15654. Epub 2023 Feb 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36691365</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15654</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1479</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1479</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schulze, J.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Trischler, J.</style></author><author><style face="normal" font="default" size="100%">Zielen, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department for Children and Adolescents, Division of Allergology, Pulmonology and Cystic Fibrosis, Goethe-University Hospital, Frankfurt am Main, Germany.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Instituto de Investigacion Biomedica de Malaga (IBIMA), and RICORS &quot;Inflammatory diseases&quot;, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of house dust mite-driven allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1397-1399</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/01/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36691365</style></accession-num><notes><style face="normal" font="default" size="100%">Schulze, Johannes&#xD;Agache, Ioana&#xD;Eguiluz-Gracia, Ibon&#xD;Trischler, Jordis&#xD;Zielen, Stefan&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1397-1399. doi: 10.1111/all.15654. Epub 2023 Feb 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36691365</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15654</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1498</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1498</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schuster, B.</style></author><author><style face="normal" font="default" size="100%">Zink, A.</style></author><author><style face="normal" font="default" size="100%">Eyerich, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Department of Medicine, Division of Dermatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of hypereosinophilic syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3003-3006</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2020/05/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypereosinophilic Syndrome/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">hypereosinophilic syndrome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32416612</style></accession-num><notes><style face="normal" font="default" size="100%">Schuster, Barbara&#xD;Zink, Alexander&#xD;Eyerich, Kilian&#xD;eng&#xD;Denmark&#xD;Allergy. 2020 Nov;75(11):3003-3006. doi: 10.1111/all.14368. Epub 2020 Jun 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32416612</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14368</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1112</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1112</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Madrigal-Burgaleta, R.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Revuelta, P.</style></author><author><style face="normal" font="default" size="100%">Marti-Garrido, J.</style></author><author><style face="normal" font="default" size="100%">Lleonart-Bellfill, R.</style></author><author><style face="normal" font="default" size="100%">Ali, F. R.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Cuesta, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy &amp; Severe Asthma Service, St Bartholomew&apos;s Hospital, Barts Health NHS Trust, London, UK.&#xD;Drug Desensitisation Centre, Catalan Institute of Oncology, Barcelona, Spain.&#xD;Allergy Service, Internal Medicine Department, Bellvitge University Hospital, Barcelona, Spain.&#xD;Allergy Division, Former Head, Ramon y Cajal University Hospital, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of hypersensitivity reactions to cancer chemotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2636-2640</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Neoplasms/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">de-labelling</style></keyword><keyword><style face="normal" font="default" size="100%">drug desensitisation</style></keyword><keyword><style face="normal" font="default" size="100%">personalised medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33683735</style></accession-num><notes><style face="normal" font="default" size="100%">Madrigal-Burgaleta, Ricardo&#xD;Vazquez-Revuelta, Paula&#xD;Marti-Garrido, Jaume&#xD;Lleonart-Bellfill, Ramon&#xD;Ali, Fawzia Runa&#xD;Alvarez-Cuesta, Emilio&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2636-2640. doi: 10.1111/all.14810. Epub 2021 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33683735</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14810</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1854</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1854</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Madrigal-Burgaleta, R.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Revuelta, P.</style></author><author><style face="normal" font="default" size="100%">Marti-Garrido, J.</style></author><author><style face="normal" font="default" size="100%">Lleonart-Bellfill, R.</style></author><author><style face="normal" font="default" size="100%">Ali, F. R.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Cuesta, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy &amp; Severe Asthma Service, St Bartholomew&apos;s Hospital, Barts Health NHS Trust, London, UK.&#xD;Drug Desensitisation Centre, Catalan Institute of Oncology, Barcelona, Spain.&#xD;Allergy Service, Internal Medicine Department, Bellvitge University Hospital, Barcelona, Spain.&#xD;Allergy Division, Former Head, Ramon y Cajal University Hospital, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of hypersensitivity reactions to cancer chemotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2636-2640</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Neoplasms/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">de-labelling</style></keyword><keyword><style face="normal" font="default" size="100%">drug desensitisation</style></keyword><keyword><style face="normal" font="default" size="100%">personalised medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33683735</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract All antineoplastic drugs could potentially trigger a drug hypersensitivity reaction (DHR), however, as described in different populations, DHRs are especially frequent with platinum drugs, taxanes, and biologics1–7. Other drugs that canusually trigger DHRs, with varying incidence depending on the population, are namely, anthracyclines, irinotecan, cyclophosphamide, gemcitabine or even concomitant agents such as leucovorin1,5,6. The diagnosis and treatment of DHRs tobiologics were addressed in a recent article from this series of medical algorithms8, and so this manuscript will focus on other antineoplastic agents.</style></abstract><notes><style face="normal" font="default" size="100%">Madrigal-Burgaleta, Ricardo&#xD;Vazquez-Revuelta, Paula&#xD;Marti-Garrido, Jaume&#xD;Lleonart-Bellfill, Ramon&#xD;Ali, Fawzia Runa&#xD;Alvarez-Cuesta, Emilio&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2636-2640. doi: 10.1111/all.14810. Epub 2021 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33683735</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14810</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1064</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1064</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Testera-Montes, A.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA) and ARADyAL, Malaga, Spain.&#xD;Department of Medicine and Dermatology, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of local allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2927-2930</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/04/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">dual allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">local allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">nasal allergen challenge</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33818807</style></accession-num><notes><style face="normal" font="default" size="100%">Eguiluz-Gracia, Ibon&#xD;Testera-Montes, Almudena&#xD;Rondon, Carmen&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2927-2930. doi: 10.1111/all.14848. Epub 2021 Apr 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33818807</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14848</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1858</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1858</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Testera-Montes, A.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA) and ARADyAL, Malaga, Spain.&#xD;Department of Medicine and Dermatology, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of local allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Allergy</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></alt-periodical><pages><style face="normal" font="default" size="100%">2927-2930</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/04/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">dual allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">local allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">nasal allergen challenge</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33818807</style></accession-num><notes><style face="normal" font="default" size="100%">Eguiluz-Gracia, Ibon&#xD;Testera-Montes, Almudena&#xD;Rondon, Carmen&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2927-2930. doi: 10.1111/all.14848. Epub 2021 Apr 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33818807</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14848</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1503</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1503</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Perez-Sanchez, N.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Moreno, E.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Departamento de Medicina, Facultad de Medicina, Universidad de Malaga, Malaga, Spain.&#xD;Allergy Service, Hospital Universitario de Salamanca, Salamanca, Spain.&#xD;Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.&#xD;Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of nonsteroidal antiinflammatory drugs hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1003-1005</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2019/11/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pharmaceutical Preparations</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31742729</style></accession-num><notes><style face="normal" font="default" size="100%">Dona, Inmaculada&#xD;Perez-Sanchez, Natalia&#xD;Bogas, Gador&#xD;Moreno, Esther&#xD;Salas, Maria&#xD;Torres, Maria Jose&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Apr;75(4):1003-1005. doi: 10.1111/all.14119. Epub 2019 Dec 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31742729</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14119</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1504</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1504</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bush, A.</style></author><author><style face="normal" font="default" size="100%">Saglani, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Paediatric Respiratory Medicine, NHLI, Imperial College London, London, UK.&#xD;Department of Respiratory Paediatrics, Royal Brompton &amp; Harefield NHS Foundation Trust, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of preschool asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2711-2712</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2020/01/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31898808</style></accession-num><notes><style face="normal" font="default" size="100%">Bush, Andrew&#xD;Saglani, Sejal&#xD;eng&#xD;CDF-2014-07-019/DH_/Department of Health/United Kingdom&#xD;Letter&#xD;Denmark&#xD;Allergy. 2020 Oct;75(10):2711-2712. doi: 10.1111/all.14172. Epub 2020 Jan 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31898808</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14172</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1505</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1505</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brockow, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis and treatment of radiocontrast media hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Allergy</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></alt-periodical><pages><style face="normal" font="default" size="100%">1278-1280</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2019/12/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Contrast Media/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31823375</style></accession-num><notes><style face="normal" font="default" size="100%">Brockow, Knut&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2020 May;75(5):1278-1280. doi: 10.1111/all.14147. Epub 2020 Jan 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31823375</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14147</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1289</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1289</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Janmohamed, S. R.</style></author><author><style face="normal" font="default" size="100%">Grosber, M.</style></author><author><style face="normal" font="default" size="100%">Eichenfield, L. F.</style></author><author><style face="normal" font="default" size="100%">Ring, J.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.&#xD;Departments of Dermatology and Pediatrics, San Diego School of Medicine and Rady Children&apos;s Hospital, University of California, San Diego, CA, USA.&#xD;Department of Dermatology and Allergology Biederstein, Technical University Munich, Munchen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis of atopic dermatitis in early childhood (part I)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">403-406</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/10/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">algorithm</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">atopic</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">childhood</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">immune system</style></keyword><keyword><style face="normal" font="default" size="100%">medical algorithm</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33089496</style></accession-num><notes><style face="normal" font="default" size="100%">Janmohamed, Sherief R&#xD;Grosber, Martine&#xD;Eichenfield, Lawrence F&#xD;Ring, Johannes&#xD;Gutermuth, Jan&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):403-406. doi: 10.1111/all.14638. Epub 2020 Nov 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33089496</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14638</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1856</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1856</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Janmohamed, S. R.</style></author><author><style face="normal" font="default" size="100%">Grosber, M.</style></author><author><style face="normal" font="default" size="100%">Eichenfield, L. F.</style></author><author><style face="normal" font="default" size="100%">Ring, J.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.&#xD;Departments of Dermatology and Pediatrics, San Diego School of Medicine and Rady Children&apos;s Hospital, University of California, San Diego, CA, USA.&#xD;Department of Dermatology and Allergology Biederstein, Technical University Munich, Munchen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis of atopic dermatitis in early childhood (part I)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">403-406</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/10/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">algorithm</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">atopic</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">childhood</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">immune system</style></keyword><keyword><style face="normal" font="default" size="100%">medical algorithm</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33089496</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Atopic dermatitis (AD, atopic eczema) is a chronic, relapsing, pruritic, non-communicable inflammatory skin disease that affects children and adults1. It almost always has its debut in early life2,3, therefore this medical algorithm focuses on diagnosis (part I) and therapy (part II4) of AD in early childhood, which is defined by UNESCO as ‘the period from birth to eight years old’.</style></abstract><notes><style face="normal" font="default" size="100%">Janmohamed, Sherief R&#xD;Grosber, Martine&#xD;Eichenfield, Lawrence F&#xD;Ring, Johannes&#xD;Gutermuth, Jan&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):403-406. doi: 10.1111/all.14638. Epub 2020 Nov 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33089496</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14638</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>869</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">869</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vera-Berrios, R. N.</style></author><author><style face="normal" font="default" size="100%">Freundt-Serpa, N. P.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">IdISSC, Allergy Department, Hospital Clinico San Carlos, Madrid, Spain.&#xD;IdISSC, ARADyAL, Allergy Department, Hospital Clinico San Carlos, Madrid, Spain.&#xD;IdISSC, ARADyAL, Allergy Department, Universidad Complutense, Hospital Clinico San Carlos, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis of plant food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">698-704</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34355404</style></accession-num><notes><style face="normal" font="default" size="100%">Vera-Berrios, Rosialzira N&#xD;Freundt-Serpa, Natalia P&#xD;Fernandez-Rivas, Montserrat&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):698-704. doi: 10.1111/all.15037. Epub 2021 Aug 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34355404</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15037</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1846</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1846</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vera-Berrios, R. N.</style></author><author><style face="normal" font="default" size="100%">Freundt-Serpa, N. P.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">IdISSC, Allergy Department, Hospital Clinico San Carlos, Madrid, Spain.&#xD;IdISSC, ARADyAL, Allergy Department, Hospital Clinico San Carlos, Madrid, Spain.&#xD;IdISSC, ARADyAL, Allergy Department, Universidad Complutense, Hospital Clinico San Carlos, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Diagnosis of plant food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">698-704</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34355404</style></accession-num><notes><style face="normal" font="default" size="100%">Vera-Berrios, Rosialzira N&#xD;Freundt-Serpa, Natalia P&#xD;Fernandez-Rivas, Montserrat&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):698-704. doi: 10.1111/all.15037. Epub 2021 Aug 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34355404</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15037</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1218</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1218</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fisher, H. R.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Bahnson, H. T.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Heath, Paediatric Allergy Group, School of Life Course Sciences, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, Paediatric Allergy Group, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina Children&apos;s Hospital, Guy&apos;s and St. Thomas&apos; NHS Foundation Trust, London, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Newport, UK.&#xD;NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Faculty of Medicine, Clinical and Experimental Sciences, Human Development in Health Academic Units, University of Southampton, Southampton, UK.&#xD;Immune Tolerance Network, Benaroya Research Institute, Seattle, WA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Early introduction of food allergens in high-risk populations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1592-1594</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/12/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">challenge tests</style></keyword><keyword><style face="normal" font="default" size="100%">complementary feeding</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">weaning</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33346913</style></accession-num><notes><style face="normal" font="default" size="100%">Fisher, Helen R&#xD;Lack, Gideon&#xD;Roberts, Graham&#xD;Bahnson, Henry T&#xD;Du Toit, George&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1592-1594. doi: 10.1111/all.14717. Epub 2021 Jan 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33346913</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14717</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1857</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1857</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fisher, H. R.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Bahnson, H. T.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Heath, Paediatric Allergy Group, School of Life Course Sciences, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, Paediatric Allergy Group, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina Children&apos;s Hospital, Guy&apos;s and St. Thomas&apos; NHS Foundation Trust, London, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Newport, UK.&#xD;NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Faculty of Medicine, Clinical and Experimental Sciences, Human Development in Health Academic Units, University of Southampton, Southampton, UK.&#xD;Immune Tolerance Network, Benaroya Research Institute, Seattle, WA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Early introduction of food allergens in high-risk populations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1592-1594</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/12/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">challenge tests</style></keyword><keyword><style face="normal" font="default" size="100%">complementary feeding</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">weaning</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33346913</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Oral Tolerance Induction (OTI) is the only RCT-proven effective intervention for preventing childhood food allergy.(1, 2) OTI to peanut is highly effective in a high-risk population with an 81% relative risk ration (RRR) to peanut allergy .(3) OTI also reduced egg allergy in the general population in a per protocol analysis.(1) These published RCT findings have changed practice and many governmental and allergy societies now recommend introducing peanut in infancy; some suggest that other foods, such as well-cooked egg, are also introduced. Only National Institute of Allergy and Infectious Diseases (NIAID) stratify their recommendations according to food allergy (FA) risk level.</style></abstract><notes><style face="normal" font="default" size="100%">Fisher, Helen R&#xD;Lack, Gideon&#xD;Roberts, Graham&#xD;Bahnson, Henry T&#xD;Du Toit, George&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1592-1594. doi: 10.1111/all.14717. Epub 2021 Jan 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33346913</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14717</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>800</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">800</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caballero, T.</style></author><author><style face="normal" font="default" size="100%">Cabanas, R.</style></author><author><style face="normal" font="default" size="100%">Pedrosa, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, Hospital Universitario La Paz, Madrid, Spain.&#xD;Hospital La Paz Institute for Health Research (IdiPaz), Madrid, Spain.&#xD;Center for Biomedical Research Network on Rare Diseases (CIBERER U754), Madrid, Spain.&#xD;Grupo Espanol de estudio del Angioedema mediado por Bradicinina (GEAB), Madrid, Spain.&#xD;PIELenRed Consortium, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Management of C1 inhibitor hereditary angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1060-1063</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/09/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inactivator Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/genetics/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34587298</style></accession-num><notes><style face="normal" font="default" size="100%">Caballero, Teresa&#xD;Cabanas, Rosario&#xD;Pedrosa, Maria&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1060-1063. doi: 10.1111/all.15115. Epub 2021 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34587298</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15115</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1849</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1849</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caballero, T.</style></author><author><style face="normal" font="default" size="100%">Cabanas, R.</style></author><author><style face="normal" font="default" size="100%">Pedrosa, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, Hospital Universitario La Paz, Madrid, Spain.&#xD;Hospital La Paz Institute for Health Research (IdiPaz), Madrid, Spain.&#xD;Center for Biomedical Research Network on Rare Diseases (CIBERER U754), Madrid, Spain.&#xD;Grupo Espanol de estudio del Angioedema mediado por Bradicinina (GEAB), Madrid, Spain.&#xD;PIELenRed Consortium, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Management of C1 inhibitor hereditary angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1060-1063</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/09/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inactivator Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/genetics/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34587298</style></accession-num><abstract><style face="normal" font="default" size="100%">C1-inhibitor (C1INH) inhibits several proteins from the complement, coagulation, kallikrein-kinin and fibrinolysis systems [1,2]. The decrease in functional C1INH (fC1INH) produces an excess of bradykinin and local increase in vascular permeability, resulting in angioedema (AE) [2,3]. The genetic deficiency of C1INH is responsible for two types of hereditary angioedema (HAE): HAE due to a deficiency in C1INH levels (HAE-C1INH-1) and HAE due to a dysfunctional C1INH with normal or elevated C1INH levels (HAE-C1INH-2) [4,5,6].</style></abstract><notes><style face="normal" font="default" size="100%">Caballero, Teresa&#xD;Cabanas, Rosario&#xD;Pedrosa, Maria&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1060-1063. doi: 10.1111/all.15115. Epub 2021 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34587298</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15115</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1495</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1495</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bocca-Tjeertes, I. F. A.</style></author><author><style face="normal" font="default" size="100%">van de Ven, Aajm</style></author><author><style face="normal" font="default" size="100%">Koppelman, G. H.</style></author><author><style face="normal" font="default" size="100%">Sprikkelman, A. B.</style></author><author><style face="normal" font="default" size="100%">Oude Elberink, Hjng</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Pulmonology and Allergology, Beatrix Children&apos;s Hospital, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Division of Allergology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Peri-operative management of mastocytosis patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3233-3235</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/05/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis/diagnosis/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33948959</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Mastocytosis is a clonal disorder characterized by the proliferation and accumulation of mast cells (MCs) in various tissue types, preferentially skinand bone marrow (BM). Mastocytosis consists of cutaneous and systemic forms in both pediatric and adult patients. Both the excess and increased propensity of MCs to release mediators leads to a higher frequency and severity ofimmediate hypersensitivity reactions.1-4</style></abstract><notes><style face="normal" font="default" size="100%">Bocca-Tjeertes, Inger Femke Astra&#xD;van de Ven, Annick A J M&#xD;Koppelman, Gerard H&#xD;Sprikkelman, Aline B&#xD;Oude Elberink, Hanneke J N G&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3233-3235. doi: 10.1111/all.14891. Epub 2021 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33948959</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8518526</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14891</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3227</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3227</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yorgun Altunbas, M.</style></author><author><style face="normal" font="default" size="100%">Ozdemir, C.</style></author><author><style face="normal" font="default" size="100%">Karakoc-Aydiner, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Department of Pediatrics, Division of Allergy and Immunology, Marmara University, Istanbul, Turkiye.&#xD;Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkiye.&#xD;The Isil Berat Barlan Center for Translational Medicine, Immune Deficiency Research and Application Center, Istanbul, Turkiye.&#xD;European Academy of Allergy and Clinical Immunology, Marmara University Hospital Center of Excellence, Istanbul, Turkiye.&#xD;Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkiye.&#xD;Istanbul Faculty of Medicine, Department of Pediatrics, Division of Pediatric Allergy and Immunology, Istanbul University, Istanbul, Turkiye.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical Algorithm: Personalized Immunoglobulin Replacement Therapy for Inborn Errors of Immunity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin replacement therapy</style></keyword><keyword><style face="normal" font="default" size="100%">inborn errors of immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41562154</style></accession-num><notes><style face="normal" font="default" size="100%">Yorgun Altunbas, Melek&#xD;Ozdemir, Cevdet&#xD;Karakoc-Aydiner, Elif&#xD;eng&#xD;Denmark&#xD;Allergy. 2026 Jan 21. doi: 10.1111/all.70223.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41562154</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70223</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1295</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1295</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Janmohamed, S. R.</style></author><author><style face="normal" font="default" size="100%">Ring, J.</style></author><author><style face="normal" font="default" size="100%">Eichenfield, L. F.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Jette, Belgium.&#xD;Department of Dermatology and Allergology Biederstein, Technical University Munich, Munchen, Germany.&#xD;Departments of Dermatology and Pediatrics, University of California, San Diego School of Medicine and Rady Children&apos;s Hospital, San Diego, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Treatment of atopic dermatitis in early childhood (part II)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">407-410</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/10/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">algorithm</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33064851</style></accession-num><notes><style face="normal" font="default" size="100%">Janmohamed, Sherief R&#xD;Ring, Johannes&#xD;Eichenfield, Lawrence F&#xD;Gutermuth, Jan&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):407-410. doi: 10.1111/all.14512. Epub 2020 Oct 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33064851</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14512</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1855</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1855</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Janmohamed, S. R.</style></author><author><style face="normal" font="default" size="100%">Ring, J.</style></author><author><style face="normal" font="default" size="100%">Eichenfield, L. F.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Jette, Belgium.&#xD;Department of Dermatology and Allergology Biederstein, Technical University Munich, Munchen, Germany.&#xD;Departments of Dermatology and Pediatrics, University of California, San Diego School of Medicine and Rady Children&apos;s Hospital, San Diego, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithm: Treatment of atopic dermatitis in early childhood (part II)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">407-410</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/10/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">algorithm</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33064851</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract The diagnostic work-up of atopic dermatitis (AD, atopic eczema) was discussed in part I. This part of the medical algorithm focuses on the therapy of AD in early childhood and is based on recent literature and international guidelines. The management of AD is mainly based on disease severity, which has already been discussed in part I. Basic therapy of the disturbed skin barrier is always necessary, i.e. also for children that do not suffer from active lesions. Normally, topical treatment is the first choice.</style></abstract><notes><style face="normal" font="default" size="100%">Janmohamed, Sherief R&#xD;Ring, Johannes&#xD;Eichenfield, Lawrence F&#xD;Gutermuth, Jan&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):407-410. doi: 10.1111/all.14512. Epub 2020 Oct 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33064851</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14512</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>957</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">957</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nair, P.</style></author><author><style face="normal" font="default" size="100%">O&apos;Byrne, P. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Firestone Institute for Respiratory Health, St Joseph&apos;s Healthcare &amp; Department of Medicine, McMaster University, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithms: Approach to adult asthma exacerbations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3556-3559</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34086360</style></accession-num><notes><style face="normal" font="default" size="100%">Nair, Parameswaran&#xD;O&apos;Byrne, Paul M&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3556-3559. doi: 10.1111/all.14976. Epub 2021 Jun 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34086360</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14976</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1852</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1852</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nair, P.</style></author><author><style face="normal" font="default" size="100%">O&apos;Byrne, P. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Firestone Institute for Respiratory Health, St Joseph&apos;s Healthcare &amp; Department of Medicine, McMaster University, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithms: Approach to adult asthma exacerbations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3556-3559</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34086360</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract An “operational” definition of an exacerbation of asthma is a (sub) acute worsening of asthma symptoms that requires a change in treatment.To standardize definitions for the purpose of clinical research and to categorize the severity, ERS and ATS jointly (1) proposed that severe exacerbations are those that require treatment with systemic corticosteroids for at least 3 days or a hospitalization or emergency room visit for asthma that requires systemic corticosteroids.</style></abstract><notes><style face="normal" font="default" size="100%">Nair, Parameswaran&#xD;O&apos;Byrne, Paul M&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3556-3559. doi: 10.1111/all.14976. Epub 2021 Jun 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34086360</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14976</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1502</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1502</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garvey, L. H.</style></author><author><style face="normal" font="default" size="100%">Melchiors, B. B.</style></author><author><style face="normal" font="default" size="100%">Ebo, D. G.</style></author><author><style face="normal" font="default" size="100%">Mertes, P. M.</style></author><author><style face="normal" font="default" size="100%">Kroigaard, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and allergy, Danish Anaesthesia Allergy Centre, Allergy Clinic, Gentofte Hospital, Hellerup, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Hellerup, Denmark.&#xD;Department of Immunology, Allergology and Rheumatology and Infla-Med Centre of Excellence, Antwerp University Hospital, University of Antwerp, Antwerpen, Belgium.&#xD;Department of Anesthesia and Intensive Care, Nouvel Hopital Civil, Hopitaux Universitaires de Strasbourg, Strasbourg, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithms: Diagnosis and investigation of perioperative immediate hypersensitivity reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Allergy</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></alt-periodical><pages><style face="normal" font="default" size="100%">2139-2142</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/02/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Delayed</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32053736</style></accession-num><notes><style face="normal" font="default" size="100%">Garvey, Lene H&#xD;Melchiors, Birgitte Bech&#xD;Ebo, Didier G&#xD;Mertes, Paul-Michel&#xD;Kroigaard, Mogens&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2020 Aug;75(8):2139-2142. doi: 10.1111/all.14226. Epub 2020 Mar 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32053736</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14226</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1507</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1507</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sturm, G. J.</style></author><author><style face="normal" font="default" size="100%">Arzt-Gradwohl, L.</style></author><author><style face="normal" font="default" size="100%">Varga, E. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.&#xD;Mozartpraxis, Paediatric Respiratory and Allergy Outpatient Practice, Graz, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical Algorithms: Diagnosis and treatment of Hymenoptera venom allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2016-2018</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2019/04/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arthropod Venoms/adverse effects/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Decision-Making</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Hymenoptera/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*diagnosis/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Insect Bites and Stings/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="default" size="100%">insect venom allergy</style></keyword><keyword><style face="normal" font="default" size="100%">venom immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30972798</style></accession-num><abstract><style face="normal" font="default" size="100%">Diagnosis of Hymenoptera venom allergy (HVA) is straightforward in the majority of patients, but can be challenging in double positive and test negative patients. Test results sometimes can be confusing as patients with high skin test reactivity and high specific IgE (sIgE) levels are not at risk for severe systemic sting reactions (SSR), and conversely, patients with weakly positive or even negative tests can experience severe SSR. Venom immunotherapy (VIT) is safe, highly effective, and recommended in patients with moderate to severe SSR and in patients with SSR confined to generalized skin symptoms if quality of life is impaired.</style></abstract><notes><style face="normal" font="default" size="100%">Sturm, Gunter J&#xD;Arzt-Gradwohl, Lisa&#xD;Varga, Eva-M&#xD;eng&#xD;Letter&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2019 Oct;74(10):2016-2018. doi: 10.1111/all.13817. Epub 2019 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30972798</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13817</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1510</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1510</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolarynogology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical algorithms: Management of chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1415-1416</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2019/03/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinitis/*diagnosis/*therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Sinusitis/*diagnosis/*therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30916791</style></accession-num><notes><style face="normal" font="default" size="100%">Fokkens, Wytske J&#xD;Reitsma, Sietze&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Jul;74(7):1415-1416. doi: 10.1111/all.13797. Epub 2019 May 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30916791</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13797</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3253</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3253</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Yang, Q.</style></author><author><style face="normal" font="default" size="100%">Soyka, M.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Wang, D. Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People&apos;s Republic of China.&#xD;Department of Otolaryngology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People&apos;s Republic of China.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic Barcelona, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Zhongnan Hospital, Wuhan University, Wuhan, People&apos;s Republic of China.&#xD;Taikang Center for Life and Medical Science, Wuhan University, Wuhan, People&apos;s Republic of China.&#xD;Hubei Key Laboratory of Immunology and Metabolism Research in Otolaryngology Diseases, Wuhan, People&apos;s Republic of China.&#xD;Institute of Allergy, Wuhan University, Wuhan, People&apos;s Republic of China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical Algorithms: Management of Chronic Rhinosinusitis Without Nasal Polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/02/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 19</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41711645</style></accession-num><notes><style face="normal" font="default" size="100%">Wang, Heng&#xD;Yang, Qingtai&#xD;Soyka, Micheal&#xD;Mullol, Joaquim&#xD;Wang, De-Yun&#xD;Liu, Zheng&#xD;eng&#xD;National Key Research and Development Program of China/&#xD;Denmark&#xD;Allergy. 2026 Feb 19. doi: 10.1111/all.70271.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41711645</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70271</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1511</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1511</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Feuille, E.</style></author><author><style face="normal" font="default" size="100%">Nowak-Wegrzyn, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Weill Cornell Medicine, New York, New York.&#xD;Icahn School of Medicine at Mount Sinai, Jaffe Food Allergy Institute, New York, New York.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical Algorithms: Recognizing and treating food protein-induced enterocolitis syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2019-2022</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2019/05/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Decision-Making</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Proteins/adverse effects/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Enterocolitis/*diagnosis/etiology/*therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Food Hypersensitivity/*diagnosis/*therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Fpies</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food challenge</style></keyword><keyword><style face="normal" font="default" size="100%">food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31070799</style></accession-num><notes><style face="normal" font="default" size="100%">Feuille, Elizabeth&#xD;Nowak-Wegrzyn, Anna&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Oct;74(10):2019-2022. doi: 10.1111/all.13857. Epub 2019 May 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31070799</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13857</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2174</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2174</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruiz de Azcarate, P. H.</style></author><author><style face="normal" font="default" size="100%">Lopez-Sanz, C.</style></author><author><style face="normal" font="default" size="100%">Lopez-Raigada, A.</style></author><author><style face="normal" font="default" size="100%">Vega, F.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author><author><style face="normal" font="default" size="100%">Blanco, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Universidad Autonoma de Madrid (UAM), Madrid, Spain.&#xD;Department of Allergy, Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Universidad Autonoma de Madrid (UAM), Madrid, Spain.&#xD;Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain.&#xD;Department of Medicine, McMaster Immunology Research Centre (MIRC), Schroeder Allergy and Immunology Research Institute (SAIRI), McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Meglumine gadoterate induces immunoglobulin-independent human mast cell activation via MRGPRX2</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3255-3258</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Meglumine</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Organometallic Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulins</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, G-Protein-Coupled</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Degranulation</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Tissue Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Neuropeptide</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37548384</style></accession-num><notes><style face="normal" font="default" size="100%">Ruiz de Azcarate, Paula H&#xD;Lopez-Sanz, Celia&#xD;Lopez-Raigada, Azahara&#xD;Vega, Francisco&#xD;Jimenez-Saiz, Rodrigo&#xD;Blanco, Carlos&#xD;eng&#xD;BECA20A9/Fundacion de la Sociedad Espanola de Alergologia e Inmunologia Clinica (SEAIC)/&#xD;CP20/00042;PI22/00236/Instituto de Salud Carlos III/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3255-3258. doi: 10.1111/all.15847. Epub 2023 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37548384</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15847</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2147</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2147</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van Dam, J. B.</style></author><author><style face="normal" font="default" size="100%">Ehlers, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemical Biology and Drug Discovery, Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Memory B cells with extraordinary longevity upon smallpox vaccination: Implications for type 1 hypersensitivities</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2805-2807</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/06/08</style></edition><section><style face="normal" font="default" size="100%">2805</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Memory B Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Smallpox/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Cellular Senescence</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">longevity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37287401</style></accession-num><notes><style face="normal" font="default" size="100%">van Dam, Jonas B&#xD;Ehlers, Anna M&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2805-2807. doi: 10.1111/all.15777. Epub 2023 Jun 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37287401</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15777</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2244</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2244</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Beken, B.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Carvalho, D.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author><author><style face="normal" font="default" size="100%">De Las Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Eyice Karabacak, D.</style></author><author><style face="normal" font="default" size="100%">Kolkhir, P.</style></author><author><style face="normal" font="default" size="100%">Moya, B.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Neil, S.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Skevaki, C.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Tsilochristou, O.</style></author><author><style face="normal" font="default" size="100%">van Wijk, R. G.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Department of Pediatric Allergy &amp; Immunology, Acibadem University School of Medicine, Istanbul, Turkey.&#xD;Transylvania University, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.&#xD;NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal.&#xD;CTI Clinical Trial and Consulting Services, Inc., Lisbon, Portugal.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Department of Allergy, La Paz University Hospital, Madrid, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital, Milan, Italy.&#xD;Department of Biomedical Sciences - Humanitas University, Milan, Italy.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute PL-53-201, Wroclaw, Poland.&#xD;Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany.&#xD;Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain.&#xD;Instituto de Investigacion Sanitaria, Hospital 12 de Octubre, Madrid, Spain.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), University of Southern Denmark, Odense, Denmark.&#xD;Krefting Research Centre, Department of Internal Medicine, Universityof Gothenburg, Gothenburg, Sweden.&#xD;Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Child Life and Health, Centre for Inflammation Research, The University of Edinburgh, Edinburgh, UK.&#xD;Institute of Laboratory Medicine, Philipps University Marburg, Marburg, Germany.&#xD;Universities of Giessen and Marburg Lung Center, German Center for Lung Research (DZL), Marburg, Germany.&#xD;Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Allergy, Guy&apos;s and St Thomas&apos; Foundation Trust, London, UK.&#xD;Section of Allergology and Clinical Immunology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Allergy, Immunology and Rheumatology Division, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mentoring as the cornerstone of continued education in Allergy and Clinical Immunology: 10th anniversary of the EAACI mentorship program</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7-11</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/09/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mentoring</style></keyword><keyword><style face="normal" font="default" size="100%">Mentors</style></keyword><keyword><style face="normal" font="default" size="100%">Anniversaries and Special Events</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37723898</style></accession-num><notes><style face="normal" font="default" size="100%">Giovannini, Mattia&#xD;Beken, Burcin&#xD;Agache, Ioana&#xD;Akdis, Cezmi A&#xD;Carvalho, Daniela&#xD;Chivato, Tomas&#xD;Comberiati, Pasquale&#xD;De Las Vecillas, Leticia&#xD;Eguiluz-Gracia, Ibon&#xD;Heffler, Enrico&#xD;Jutel, Marek&#xD;Eyice Karabacak, Deniz&#xD;Kolkhir, Pavel&#xD;Moya, Beatriz&#xD;Ollert, Markus&#xD;O&apos;Neil, Serena&#xD;Santos, Alexandra F&#xD;Schwarze, Jurgen&#xD;Skevaki, Chrysanthi&#xD;Sokolowska, Milena&#xD;Tsilochristou, Olympia&#xD;van Wijk, Roy Gerth&#xD;Del Giacco, Stefano&#xD;Riggioni, Carmen&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):7-11. doi: 10.1111/all.15878. Epub 2023 Sep 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37723898</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15878</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2618</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2618</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fricker, M.</style></author><author><style face="normal" font="default" size="100%">Harrington, J.</style></author><author><style face="normal" font="default" size="100%">Hiles, S. A.</style></author><author><style face="normal" font="default" size="100%">Gibson, P. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.&#xD;Asthma and Breathing Research Program, Hunter Medical Research Institute, Newcastle, New South Wales, Australia.&#xD;Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia.&#xD;School of Psychological Sciences, University of Newcastle, Newcastle, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3118-3128</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/metabolism/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">benralizumab</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">subset</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39115364</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophils are key therapeutic targets in severe asthma that are suppressed by IL5 (mepolizumab) and IL5 receptor (benralizumab) blockade. The effect of IL5 pathway biologics on recently described homeostatic (hEOs) and inflammatory (iEOs) eosinophil subsets is unknown. We aimed to determine the relative impact of mepolizumab and benralizumab treatment on eosinophil subset and phenotype, and explore clinical associations of eosinophil subsets with severe asthma characteristics and treatment response. METHODS: We performed a cross-sectional observational study of severe asthma (eosinophilic n = 32, non-eosinophilic n = 23, mepolizumab-treated n = 25), with longitudinal follow-up of 30 eosinophilic participants at two timepoints (4-24 weeks, &gt;24 weeks) post-commencement of mepolizumab (n = 20) or benralizumab (n = 10). Blood hEOs and iEOs were measured by flow cytometry assessment of surface CD62L protein. RESULTS: iEO proportion was significantly lower in mepolizumab-treated participants in both the cross-sectional and longitudinal study. Mepolizumab and benralizumab depleted iEOs to a similar extent, however a significantly greater number of hEOs remained in mepolizumab participants at follow-up. Greater iEO proportion correlated with poorer asthma control in eosinophilic but not non-eosinophilic asthma. Higher residual iEO proportion correlated with poorer asthma control in mepolizumab-treated individuals. Reduced blood eosinophil viability was observed in around half of mepolizumab-treated participants, which was associated with significantly better asthma control and spirometry. CONCLUSIONS: Mepolizumab depletes iEOs and reduces circulating eosinophil viability in severe asthma but preserves a residual population of circulatory hEOs. In contrast benralizumab depleted both iEOs and hEOs. Higher iEO abundance and eosinophil viability are associated with poorer clinical outcomes following mepolizumab-treatment. Monitoring circulating eosinophil phenotype and viability may be useful to predict biologic treatment response in severe asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Fricker, Michael&#xD;Harrington, John&#xD;Hiles, Sarah A&#xD;Gibson, Peter G&#xD;eng&#xD;GlaxoSmithKline/&#xD;Observational Study&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3118-3128. doi: 10.1111/all.16267. Epub 2024 Aug 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39115364</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16267</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2998</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2998</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schleich, F.</style></author><author><style face="normal" font="default" size="100%">Loukides, S.</style></author><author><style face="normal" font="default" size="100%">Chaudhuri, R.</style></author><author><style face="normal" font="default" size="100%">Leuppi, J. D.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Domingo, C.</style></author><author><style face="normal" font="default" size="100%">Micheletto, C.</style></author><author><style face="normal" font="default" size="100%">Paulsson, T.</style></author><author><style face="normal" font="default" size="100%">Gaw, N.</style></author><author><style face="normal" font="default" size="100%">Kallinikou, K.</style></author><author><style face="normal" font="default" size="100%">Vossen, C.</style></author><author><style face="normal" font="default" size="100%">Guelfucci, F.</style></author><author><style face="normal" font="default" size="100%">Menon, J.</style></author><author><style face="normal" font="default" size="100%">Ngami, A.</style></author><author><style face="normal" font="default" size="100%">Palomares, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">GIGA I3, Respiratory Medicine, Exercise Physiology Laboratory, University of Liege, Liege, Belgium.&#xD;2nd Respiratory Medicine Department Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.&#xD;University of Glasgow, Glasgow, Scotland, UK.&#xD;Cantonal Hospital Baselland, Liestal and Medical Faculty, University of Basel, Basel, Switzerland.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.&#xD;Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.&#xD;Department of Pulmonary Medicine, Parc Tauli Hospital Universitari, Institut d&apos;Investigacio i Innovacio Parc Tauli (I3PT-CERCA), Universitat Autonoma de Barcelona, Sabadell, Spain.&#xD;Respiratory Unit, Integrated University Hospital of Verona, Verona, Italy.&#xD;GSK, London, UK.&#xD;GSK, Athens, Greece.&#xD;Syneos Health, Amsterdam, the Netherlands.&#xD;Syneos Health, Paris, France.&#xD;Syneos Health, Aarhus, Denmark.&#xD;GSK, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real-World Pooled Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2557-2571</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/07/01 21:15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/drug therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">Palomares I, Loukides S, Schleich F, et al. Eur Resp J 2024</style></keyword><keyword><style face="normal" font="default" size="100%">64 (suppl 68):</style></keyword><keyword><style face="normal" font="default" size="100%">PA3929: doi.org/10.1183/13993003.congress-2024.PA3929. F. Schleich reports</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from AstraZeneca, Chiesi, GSK and TEVA</style></keyword><keyword><style face="normal" font="default" size="100%">and payment or honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">from AstraZeneca, Chiesi and GSK</style></keyword><keyword><style face="normal" font="default" size="100%">and support for attending meetings/travel from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca and Chiesi. S. Loukides reports consulting fees from GSK</style></keyword><keyword><style face="normal" font="default" size="100%">payment or</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria from AstraZeneca and GSK</style></keyword><keyword><style face="normal" font="default" size="100%">participation on a Drug Safety Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Board or Advisory Board for GSK</style></keyword><keyword><style face="normal" font="default" size="100%">and holding of an unpaid position as President</style></keyword><keyword><style face="normal" font="default" size="100%">of the Hellenic Thoracic Society. R. Chaudhuri reports receiving grants or</style></keyword><keyword><style face="normal" font="default" size="100%">contracts from AstraZeneca for an investigator-led study</style></keyword><keyword><style face="normal" font="default" size="100%">payment or honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">from AstraZeneca, Chiesi, GSK, Sanofi and TEVA</style></keyword><keyword><style face="normal" font="default" size="100%">support for attending</style></keyword><keyword><style face="normal" font="default" size="100%">meetings/travel from Chiesei, GSK and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and participation on a Drug Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Monitoring Board or Advisory Board for AstraZeneca, Celltrion Healthcare and GSK.</style></keyword><keyword><style face="normal" font="default" size="100%">J. D. Leuppi reports unrestricted grants from AstraZeneca, GSK, OM Pharma and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and payment or honoraria for lectures from AstraZeneca, GSK, OM Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">and Sanofi. E. Heffler reports a research grant from Chiesi</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Almirall, Apogee Therapeutics, AstraZeneca, Bosch, Celltrion Healthcare, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, Lofarma, Novartis, Regeneron and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and support for attending meetings</style></keyword><keyword><style face="normal" font="default" size="100%">or travel from AstraZeneca, GSK and Sanofi. C. Domingo reports consulting fees,</style></keyword><keyword><style face="normal" font="default" size="100%">payment or honoraria, payment for expert testimony, and support for attending</style></keyword><keyword><style face="normal" font="default" size="100%">meetings or travel from ALK, GSK, Novartis, Sanofi, not on the original submitted</style></keyword><keyword><style face="normal" font="default" size="100%">file AstraZeneca, Asac Pharmaceutical Immunology, Immunotek and MSD. C.</style></keyword><keyword><style face="normal" font="default" size="100%">Micheletto has received payment or honoraria from AstraZeneca, Berlin Chemie,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Chiesi, GSK, Guidotti, Lusofarmaco, Menarini, Roche, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and Zambon</style></keyword><keyword><style face="normal" font="default" size="100%">support for attending meetings or travel from AstraZeneca, Menarini</style></keyword><keyword><style face="normal" font="default" size="100%">and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and is President of the Italian Thoracic Society and member of the</style></keyword><keyword><style face="normal" font="default" size="100%">Regional Drug Commission. T. Paulsson, N. Gaw, K. Kallinikou and I. Palomares are</style></keyword><keyword><style face="normal" font="default" size="100%">employees of GSK and hold financial equities in GSK. C. Vossen, F. Guelfucci, J.</style></keyword><keyword><style face="normal" font="default" size="100%">Menon and A. Ngami are employees of Syneos Health, which received funding from</style></keyword><keyword><style face="normal" font="default" size="100%">GSK to conduct this study.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40590259</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Severe asthma with an eosinophilic phenotype (SAEP) and chronic rhinosinusitis with nasal polyps (CRSwNP) are predominantly type 2-driven diseases, characterised by eosinophilic inflammation and substantial disease burden. Mepolizumab, a humanised monoclonal antibody that targets interleukin-5, a key cytokine in type 2 inflammation, is an effective, approved treatment both in SAEP and CRSwNP. We aimed to analyse real-world evidence of mepolizumab effectiveness in patients with comorbid SAEP and CRSwNP. METHODS: This study pooled five existing, predominantly European cohorts to describe the impact of mepolizumab on the rate of clinically significant exacerbations (CSEs) and other outcomes in adults with SAEP without and with comorbid CRSwNP (SAEP[-]CRSwNP and SAEP[+]CRSwNP, respectively). RESULTS: Overall, 1037 patients were included. Baseline characteristics were similar in both cohorts. Mepolizumab was associated with a reduction from baseline in the annual rate of CSEs at 12-months post-initiation (SAEP[-]CRSwNP: 72.7%; SAEP[+]CRSwNP: 79.7%), irrespective of baseline blood eosinophil count (BEC). When patients with SAEP[+]CRSwNP were compared with patients with SAEP[-]CRSwNP, a 30.0% incremental benefit in the reduction of CSEs was observed. At 12-months post-initiation, mepolizumab was also associated with a reduction in oral corticosteroid use and BEC, and an improvement in lung function and Asthma Control Test (ACT) scores in both cohorts. Post-mepolizumab initiation, &gt;/= 3 clinical remission criteria were fulfilled by 47.2% and 52.3% of patients with SAEP[-]CRSwNP and SAEP[+]CRSwNP, respectively. CONCLUSIONS: The results provide a greater understanding of mepolizumab&apos;s effectiveness, demonstrating a substantial improvement in asthma outcomes, irrespective of baseline BEC and the presence of comorbid CRSwNP.</style></abstract><notes><style face="normal" font="default" size="100%">Schleich, Florence&#xD;Loukides, Stelios&#xD;Chaudhuri, Rekha&#xD;Leuppi, Joerg D&#xD;Heffler, Enrico&#xD;Domingo, Cristian&#xD;Micheletto, Claudio&#xD;Paulsson, Thomas&#xD;Gaw, Nina&#xD;Kallinikou, Konstantina&#xD;Vossen, Carla&#xD;Guelfucci, Florent&#xD;Menon, Jyothi&#xD;Ngami, Armel&#xD;Palomares, Ines&#xD;eng&#xD;GSK-sponsored study 219821/&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2557-2571. doi: 10.1111/all.16618. Epub 2025 Jul 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40590259</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444867</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16618</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>406</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">406</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Kennedy, D.</style></author><author><style face="normal" font="default" size="100%">Philpott, C.</style></author><author><style face="normal" font="default" size="100%">Seccia, V.</style></author><author><style face="normal" font="default" size="100%">Kern, R. C.</style></author><author><style face="normal" font="default" size="100%">Coste, A.</style></author><author><style face="normal" font="default" size="100%">Sousa, A. R.</style></author><author><style face="normal" font="default" size="100%">Howarth, P. H.</style></author><author><style face="normal" font="default" size="100%">Benson, V. S.</style></author><author><style face="normal" font="default" size="100%">Mayer, B.</style></author><author><style face="normal" font="default" size="100%">Yancey, S. W.</style></author><author><style face="normal" font="default" size="100%">Chan, R.</style></author><author><style face="normal" font="default" size="100%">Gane, S. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, University of Amsterdam, Amsterdam, Netherlands.&#xD;Department of Otorhinolaryngology, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.&#xD;Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;Norwich Medical School, University of East Anglia, Norwich, UK.&#xD;Norfolk and Waveney Ear Nose and Throat Service, James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, UK.&#xD;ENT Unit, Department of Neuroscience, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.&#xD;Department of Medicine and Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Service d&apos;ORL et de Chirurgie Cervico-faciale Centre, Hospitalier Intercommunal de Creteil, et APHP, Groupe Hospitalier Henri Mondor-Albert Chenevier, Universite Paris-Est Creteil, Creteil, France.&#xD;Clinical Sciences, Respiratory, GSK, GSK House, Brentford, Middlesex, UK.&#xD;Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton and NIHR Respiratory Biomedical Research Unit, Southampton General Hospital, Southampton, UK.&#xD;Global Respiratory Franchise, GSK House, Brentford, Middlesex, UK.&#xD;Epidemiology, Value Evidence and Outcomes, GSK House, Brentford, Middlesex, UK.&#xD;Clinical Statistics, GSK House, Brentford, Middlesex, UK.&#xD;Respiratory Medical Franchise, GSK, Research Triangle Park, North Carolina, USA.&#xD;Department of Rhinology, Royal National ENT Hospital, University College London Hospitals NHS Foundation Trust, London, UK.&#xD;UCL Ear Institute, University College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">812-821</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications/drug therapy/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/complications/drug therapy/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/complications/drug therapy/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">refractory</style></keyword><keyword><style face="normal" font="default" size="100%">sinonasal surgery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35822924</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) often require repeat sinus surgery. Mepolizumab reduced the need for sinus surgery in the SYNAPSE trial; this analysis sought to provide a more in-depth assessment of surgery endpoints in SYNAPSE. METHODS: SYNAPSE was a double-blind Phase III trial (NCT03085797) in adults with recurrent, refractory, severe, CRSwNP eligible for repeat sinus surgery despite standard of care treatments and previous surgery. Patients were randomized (1:1) to mepolizumab 100 mg subcutaneously or placebo, plus standard of care, every 4 weeks for 52 weeks. Time to first inclusion on a waiting list for sinus surgery and time to first actual sinus surgery (both up to week 52) were assessed; the latter endpoint was also analyzed post hoc according to time since last sinus surgery before study screening and baseline blood eosinophil count. RESULTS: Among 407 patients (mepolizumab: 206; placebo: 201), mepolizumab versus placebo reduced the risk of being included on a waiting list for sinus surgery (week 52 Kaplan-Meier probability estimate [95% confidence interval]: 13.9% [9.8%, 19.5%] vs. 28.5% [22.7%, 35.4%]). Mepolizumab versus placebo reduced the risk of sinus surgery irrespective of time (&lt;3 vs &gt;/=3 years) since patients&apos; last sinus surgery prior to study screening (hazard ratios [95% confidence intervals] 0.28 [0.09, 0.84] and 0.50 [0.26, 0.98], respectively) and baseline blood eosinophil count. CONCLUSIONS: Mepolizumab reduced the risk of further sinus surgery in patients with recurrent, refractory, severe CRSwNP, irrespective of the patient baseline characteristics assessed.</style></abstract><notes><style face="normal" font="default" size="100%">Fokkens, Wytske J&#xD;Mullol, Joaquim&#xD;Kennedy, David&#xD;Philpott, Carl&#xD;Seccia, Veronica&#xD;Kern, Robert C&#xD;Coste, Andre&#xD;Sousa, Ana R&#xD;Howarth, Peter H&#xD;Benson, Victoria S&#xD;Mayer, Bhabita&#xD;Yancey, Steve W&#xD;Chan, Robert&#xD;Gane, Simon B&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):812-821. doi: 10.1111/all.15434. Epub 2022 Jul 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35822924</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15434</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2566</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2566</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tynecka, M.</style></author><author><style face="normal" font="default" size="100%">Janucik, A.</style></author><author><style face="normal" font="default" size="100%">Tarasik, A.</style></author><author><style face="normal" font="default" size="100%">Zbikowski, A.</style></author><author><style face="normal" font="default" size="100%">Niemira, M.</style></author><author><style face="normal" font="default" size="100%">Kulczynska-Przybik, A.</style></author><author><style face="normal" font="default" size="100%">Zeller, A.</style></author><author><style face="normal" font="default" size="100%">Stocker, N.</style></author><author><style face="normal" font="default" size="100%">Reszec-Gielazyn, J.</style></author><author><style face="normal" font="default" size="100%">Mroczko, B.</style></author><author><style face="normal" font="default" size="100%">Kretowski, A.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Moniuszko, M.</style></author><author><style face="normal" font="default" size="100%">Eljaszewicz, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre of Regenerative Medicine, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland.&#xD;Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland.&#xD;Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.&#xD;Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.&#xD;Tissue and Cell Bank, Medical University of Bialystok Clinical Hospital, Bialystok, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mesenchymal stromal cells effectively limit house dust mite extract-induced mixed granulocytic lung inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3157-3161</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/07/20 20:44</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39031017</style></accession-num><notes><style face="normal" font="default" size="100%">Tynecka, Marlena&#xD;Janucik, Adrian&#xD;Tarasik, Agnieszka&#xD;Zbikowski, Arkadiusz&#xD;Niemira, Magdalena&#xD;Kulczynska-Przybik, Agnieszka&#xD;Zeller, Anna&#xD;Stocker, Nino&#xD;Reszec-Gielazyn, Joanna&#xD;Mroczko, Barbara&#xD;Kretowski, Adam&#xD;Akdis, Cezmi A&#xD;Sokolowska, Milena&#xD;Moniuszko, Marcin&#xD;Eljaszewicz, Andrzej&#xD;eng&#xD;POWR.03.02.00-00-I050/16/European Union Funds, PO WER 2014-2020/&#xD;the Medical University of Bialystok/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3157-3161. doi: 10.1111/all.16245. Epub 2024 Jul 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39031017</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16245</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2457</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2457</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ordak, M.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Paoletti, G.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Carvalho, D.</style></author><author><style face="normal" font="default" size="100%">Di Bona, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milan, Italy.&#xD;SCDU Immunologia e Allergologia, AO Ordine Mauriziano di Torino, Torino, Italy.&#xD;Dipartimento di Scienze Mediche, Universita degli Studi di Torino, Torino, Italy.&#xD;NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal.&#xD;Department of Medical and Surgical Sciences, School of Allergology and Clinical Immu-nology, University of Foggia, Foggia, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Meta-analysis in allergy-Statistical recommendations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1616-1618</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Meta-Analysis as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">meta-analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38425079</style></accession-num><notes><style face="normal" font="default" size="100%">Ordak, Michal&#xD;Canonica, Giorgio Walter&#xD;Paoletti, Giovanni&#xD;Brussino, Liusa&#xD;Carvalho, Daniela&#xD;Di Bona, Danilo&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1616-1618. doi: 10.1111/all.16091. Epub 2024 Feb 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38425079</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16091</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2847</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2847</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zielen, S.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">DuBuske, L.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Becker, S.</style></author><author><style face="normal" font="default" size="100%">Sellwood, F.</style></author><author><style face="normal" font="default" size="100%">Kramer, M. F.</style></author><author><style face="normal" font="default" size="100%">Skinner, M.</style></author><author><style face="normal" font="default" size="100%">de Kam, P. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, University Hospital, Goethe University, Frankfurt, Germany.&#xD;Respiratory Research Center Medaimun GmbH, Frankfurt, Germany.&#xD;Department of Internal Medicine, Division of Rheumatology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Allergy and Immunology and Bernstein Clinical Research Center, Cincinnati, Ohio, USA.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;George Washington University Hospital, Washington, DC, USA.&#xD;IMSB, Medical Faculty University at Cologne, Cologne, Germany.&#xD;ClinCompetence Cologne GmbH, Cologne, Germany.&#xD;Department for Otorhinolaryngology, Head and Neck Surgery, University of Tuebingen, Tubingen, Germany.&#xD;Allergy Therapeutics (UK) Plc, Worthing, UK.&#xD;Bencard Allergie GmbH, Munchen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Meta-Analysis of PQ Grass 27600 SU Efficacy and Quality of Life From Phase III Trials</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2055-2058</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/03/31 21:16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">grass pollen allergy</style></keyword><keyword><style face="normal" font="default" size="100%">meta-analysis</style></keyword><keyword><style face="normal" font="default" size="100%">short-course treatment</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, Allergy Therapeutics, AstraZeneca, SanofiAventis, EryDel SpA, and</style></keyword><keyword><style face="normal" font="default" size="100%">Lofarma during the last 3 years. J.A.B. is acting as a consultant and PI</style></keyword><keyword><style face="normal" font="default" size="100%">forAllergy Therapeutics, Stallergens, ALK, Eli Lilly, Novartis, Genentech, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, A.Z., G.S.K., and Amgen. O.P. reports grants for his institution as a</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial unit for RESONATE from Allergy Therapeutics PLC, UK</style></keyword><keyword><style face="normal" font="default" size="100%">and he</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants and/or personal fees and/or travel support from AEDA, Alfried</style></keyword><keyword><style face="normal" font="default" size="100%">Krupp Krankenhaus, ALK-Abello, Allergopharma, Almirall, Altamira Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">ASIT Biotech, AstraZeneca, Bencard Allergie GmbH/Allergy Therapeutics, Blueprint,</style></keyword><keyword><style face="normal" font="default" size="100%">Cliantha, Deutsche AllergieLiga e.V., Deutsche Forschungsgemeinschaft,</style></keyword><keyword><style face="normal" font="default" size="100%">Dustri-Verlag, ECM Expro&amp;Conference Management GmBH, Forum fur Medizinische</style></keyword><keyword><style face="normal" font="default" size="100%">Fortbildung, Georg-Thieme-Verlag, GSK, HAL Allergy Holding B.V./HAL Allergie</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, Immunotek, Ingress Health, Institut fur Disease Management (Essen,</style></keyword><keyword><style face="normal" font="default" size="100%">Germany), IQVIA Commercial, Japanese Society of Allergology, Koniglich Danisches</style></keyword><keyword><style face="normal" font="default" size="100%">Generalkonsulat, Laboratorios LETI/LETI Pharma, Lilly, Lofarma, Medizinische</style></keyword><keyword><style face="normal" font="default" size="100%">Hochschule Hannover, med update europe GmbH, Meinhardt Congress GmbH, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Paul-Ehrlich-Institut, Paul-Martini-Stiftung, PneumoLive, Pohl-Boskamp, Procter &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Gamble, Red Maple Trials Inc., R.G. Aerztefortbildung, ROXALL Medizin, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">Aventis, Sanofi Genzyme, Springer Publisher, Stallergenes Greer, streamedup!</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, Technical University Dresden, Wiley Publishers, Wort &amp; Bild Verlag, Verlag</style></keyword><keyword><style face="normal" font="default" size="100%">ME, all outside the submitted work. O.P. is Vice President of the European</style></keyword><keyword><style face="normal" font="default" size="100%">Academy of Allergy and Clinical Immunology (EAACI), a member of EAACI Excom, as</style></keyword><keyword><style face="normal" font="default" size="100%">well as a member of the external board of directors of the German Society of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Clinical Immunology (DGAKI)</style></keyword><keyword><style face="normal" font="default" size="100%">coordinator, main- or co-author of</style></keyword><keyword><style face="normal" font="default" size="100%">different position papers and guidelines in rhinology, allergology, and</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">and he is Editor-in-Chief of Clinical Translational</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy and Associate Editor of Allergy. LDB acts as a consultant for Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics and a Consultant and/or Speakers Bureau for GSK, Sanofi, Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">Astra Zeneca, ALK-Abello, Amgen, Bryn Pharm, and Areteia. JALreports grants via</style></keyword><keyword><style face="normal" font="default" size="100%">Biomedical Research Funding (Imperial College BRC), all outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. R.M. reports grants and personal fees from Allergy Therapeutics Ltd. during</style></keyword><keyword><style face="normal" font="default" size="100%">the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from ALK, grants from ASIT biotech,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Allergopharma, grants and personal fees from Bencard, grants</style></keyword><keyword><style face="normal" font="default" size="100%">from Leti, grants, personal fees, and non-financial support from Lofarma,</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from Roxall, grants and personal fees from Stallergenes,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Optima, personal fees from Friulchem, personal fees from Hexal,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Servier, personal fees from Klosterfrau, non-financial support</style></keyword><keyword><style face="normal" font="default" size="100%">from Atmos, personal fees from Bayer, non-financial support from Bionorica,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from FAES, personal fees from GSK, personal fees from MSD, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Johnson&amp;Johnson, personal fees from Meda, personal fees and</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from Novartis, non-financial support from Otonomy, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Stada, personal fees from UCB, non-financial support from Ferrero,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Hulka, personal fees from Nuvo, grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Ursapharm, personal fees from Menarini, personal fees from Mundipharma, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Pohl-Boskamp, grants from Inmunotek, grants from Cassella-med GmbH &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Co. KG, personal fees from Laboratoire de la Mer, personal fees from Sidroga,</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from HAL BV, personal fees from Lek, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">PRO-AdWise, personal fees from Angelini Pharma, grants and non-financial support</style></keyword><keyword><style face="normal" font="default" size="100%">from JGL, grants and personal fees from bitop, grants from Sanofi, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Probelte Pharma, grants from Diater, personal fees from Worg</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, outside the submitted work. S.B. reports about grants and/or</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees as an advisor and for lectures from Bencard Allergie, Brain, Karl</style></keyword><keyword><style face="normal" font="default" size="100%">Storz, Altamira, Allergy Therapeutics, HAL Allergy, Allergopharma, ALK Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, Novartis, GSK, Astra Zeneca, MSD, Viatris, Ambu, Stryker, and the Federal</style></keyword><keyword><style face="normal" font="default" size="100%">Ministry of Education and Research. F.S., M.F.K., M.S., and P.J.d.K. are</style></keyword><keyword><style face="normal" font="default" size="100%">employees of Allergy Therapeutics (UK) Plc., and P.J.d.K., M.F.K., M.S. are named</style></keyword><keyword><style face="normal" font="default" size="100%">inventors on patents related to PQ Grass.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40162598</style></accession-num><notes><style face="normal" font="default" size="100%">Zielen, Stefan&#xD;Bernstein, Jonathan A&#xD;Pfaar, Oliver&#xD;DuBuske, Lawrence&#xD;Mosges, Ralph&#xD;Becker, Sven&#xD;Sellwood, Fiona&#xD;Kramer, Matthias F&#xD;Skinner, Murray&#xD;de Kam, Pieter-Jan&#xD;eng&#xD;Allergy Therapeutics/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2055-2058. doi: 10.1111/all.16535. Epub 2025 Mar 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40162598</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261871</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16535</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2335</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2335</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roth-Walter, F.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Benito-Villalvilla, C.</style></author><author><style face="normal" font="default" size="100%">Bianchini, R.</style></author><author><style face="normal" font="default" size="100%">Bjermer, L.</style></author><author><style face="normal" font="default" size="100%">Caramori, G.</style></author><author><style face="normal" font="default" size="100%">Cari, L.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Knol, E. F.</style></author><author><style face="normal" font="default" size="100%">Jesenak, M.</style></author><author><style face="normal" font="default" size="100%">Levi-Schaffer, F.</style></author><author><style face="normal" font="default" size="100%">Nocentini, G.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Redegeld, F.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Van Esch, Bcam</style></author><author><style face="normal" font="default" size="100%">Stellato, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Molecular Cell Biology Group, National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Respiratory Medicine and Allergology, Lung and Allergy research, Allergy, Asthma and COPD Competence Center, Lund University, Lund, Sweden.&#xD;Department of Medicine and Surgery, University of Parma, Pneumologia, Italy.&#xD;Department of Medicine, Section of Pharmacology, University of Perugia, Perugia, Italy.&#xD;Experimental Studies Medicine at National Heart &amp; Lung Institute, Imperial College London &amp; Royal Brompton &amp; Harefield Hospital, London, UK.&#xD;Department of Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Hospital, Lund, Sweden.&#xD;Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.&#xD;Department of Clinical Pharmacy &amp; Pharmacology, University Groningen, University Medical Center Groningen and QPS-NL, Groningen, The Netherlands.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-Instituto de Investigacion Biomedica de Malaga (IBIMA)-ARADyAL, Malaga, Spain.&#xD;Departments of Center of Translational Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Department of Paediatrics, Department of Pulmonology and Phthisiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, University Teaching Hospital, Martin, Slovakia.&#xD;Institute for Drug Research, Pharmacology Unit, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.&#xD;APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Department of Medicine, University College Cork, Cork, Ireland.&#xD;School of Microbiology, University College Cork, Cork, Ireland.&#xD;Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Medicine, Surgery and Dentistry &quot;Scuola Medica Salernitana&quot;, University of Salerno, Salerno, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1089-1122</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/12/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Cellular Senescence/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Metabolic Networks and Pathways</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Lung Diseases/etiology/drug therapy/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Disease, Chronic Obstructive/metabolism/drug therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Aging/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">cell metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">immune senescence</style></keyword><keyword><style face="normal" font="default" size="100%">immunometabolism</style></keyword><keyword><style face="normal" font="default" size="100%">inflammaging</style></keyword><keyword><style face="normal" font="default" size="100%">senolytic drugs</style></keyword><keyword><style face="normal" font="default" size="100%">senomorphic drugs</style></keyword><keyword><style face="normal" font="default" size="100%">interest regarding the subject of this manuscript. GC has received unrestricted</style></keyword><keyword><style face="normal" font="default" size="100%">educational and/or research grants and/or Lecture fees and/or grants for travel</style></keyword><keyword><style face="normal" font="default" size="100%">and accommodation to participate to scientific meetings from Astra Zeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Biofutura, Boehringer Ingelheim, Chiesi, Enfarma, GSK, and Menarini Group. ZD has</style></keyword><keyword><style face="normal" font="default" size="100%">received honoraria or consultancy fees from the following pharmaceutical</style></keyword><keyword><style face="normal" font="default" size="100%">companies: Antabio, Boehringer Ingelheim, Foresee Pharmaceuticals,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, QPS-Netherlands, Sanofi-Genzyme-Regeneron, all outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. IEG received advisory fees from ALK and Novartis, lectures fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Astra-Zeneca, Novartis, Chiesi and Diater</style></keyword><keyword><style face="normal" font="default" size="100%">FRW is lead inventor of EP2894478</style></keyword><keyword><style face="normal" font="default" size="100%">(applicant Biomedical International R + D, Austria), has served as an</style></keyword><keyword><style face="normal" font="default" size="100%">investigator, speaker, and/or advisor for Biomedical Int R&amp;D, Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics and Bencard and is founder of Vialym</style></keyword><keyword><style face="normal" font="default" size="100%">OP received lecture fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GSK, Inmunotek, Novartis, Pfizer, Sanofi-Genzyme, and Regeneron and</style></keyword><keyword><style face="normal" font="default" size="100%">participated in advisory boards from AstraZeneca, GSK, Novartis, Pfizer,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genzyme, and Regeneron. CBV received the FPU fellowship from MINECO. KFC</style></keyword><keyword><style face="normal" font="default" size="100%">has received honoraria for participating in Advisory Board meetings of the</style></keyword><keyword><style face="normal" font="default" size="100%">pharmaceutical industry regarding treatments for asthma and chronic obstructive</style></keyword><keyword><style face="normal" font="default" size="100%">pulmonary disease and has also been renumerated for speaking engagements. BvE is</style></keyword><keyword><style face="normal" font="default" size="100%">partly employed by Nutricia Research. MS has received speaker&apos;s fee from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38108546</style></accession-num><abstract><style face="normal" font="default" size="100%">The accumulation of senescent cells drives inflammaging and increases morbidity of chronic inflammatory lung diseases. Immune responses are built upon dynamic changes in cell metabolism that supply energy and substrates for cell proliferation, differentiation, and activation. Metabolic changes imposed by environmental stress and inflammation on immune cells and tissue microenvironment are thus chiefly involved in the pathophysiology of allergic and other immune-driven diseases. Altered cell metabolism is also a hallmark of cell senescence, a condition characterized by loss of proliferative activity in cells that remain metabolically active. Accelerated senescence can be triggered by acute or chronic stress and inflammatory responses. In contrast, replicative senescence occurs as part of the physiological aging process and has protective roles in cancer surveillance and wound healing. Importantly, cell senescence can also change or hamper response to diverse therapeutic treatments. Understanding the metabolic pathways of senescence in immune and structural cells is therefore critical to detect, prevent, or revert detrimental aspects of senescence-related immunopathology, by developing specific diagnostics and targeted therapies. In this paper, we review the main changes and metabolic alterations occurring in senescent immune cells (macrophages, B cells, T cells). Subsequently, we present the metabolic footprints described in translational studies in patients with chronic asthma and chronic obstructive pulmonary disease (COPD), and review the ongoing preclinical studies and clinical trials of therapeutic approaches aiming at targeting metabolic pathways to antagonize pathological senescence. Because this is a recently emerging field in allergy and clinical immunology, a better understanding of the metabolic profile of the complex landscape of cell senescence is needed. The progress achieved so far is already providing opportunities for new therapies, as well as for strategies aimed at disease prevention and supporting healthy aging.</style></abstract><notes><style face="normal" font="default" size="100%">Roth-Walter, F&#xD;Adcock, I M&#xD;Benito-Villalvilla, C&#xD;Bianchini, R&#xD;Bjermer, L&#xD;Caramori, G&#xD;Cari, L&#xD;Chung, K F&#xD;Diamant, Z&#xD;Eguiluz-Gracia, I&#xD;Knol, E F&#xD;Jesenak, M&#xD;Levi-Schaffer, F&#xD;Nocentini, G&#xD;O&apos;Mahony, L&#xD;Palomares, O&#xD;Redegeld, F&#xD;Sokolowska, M&#xD;Van Esch, B C A M&#xD;Stellato, C&#xD;eng&#xD;Aimwell Charitable Trust/&#xD;Austrian Science Fund FWF project SFB F4606-B28/&#xD;Danube Allergy Research Cluster-DARC #08/&#xD;Emalie Gutterman Memorial Endowed Fund/&#xD;EPSRC (EP/T003189/1)/&#xD;European Academy for Allergy and Clinical Immunology/&#xD;Instituto de Salud Carlos III of the Spanish Ministry of Economy and Competitiveness/&#xD;Israel Science Foundation/&#xD;MICIIN (PID2020-114396RB-I00)/&#xD;Ministero dell&apos;Istruzione, dell&apos;Universita e della Ricerca/&#xD;MRC (MR/T010371/1)/&#xD;Novartis/&#xD;Stiftung vorm. Bundner Heilstatte Arosa/&#xD;Swiss National Science Foundation (SNSF nr 310030_189334/1)/&#xD;University of Messina, Sicilia Region/&#xD;University of Salerno and Campania Region/&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1089-1122. doi: 10.1111/all.15977. Epub 2023 Dec 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38108546</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11497319</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15977</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>267</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">267</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Robb, C. T.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Felton, J. M.</style></author><author><style face="normal" font="default" size="100%">Zhang, B.</style></author><author><style face="normal" font="default" size="100%">Goepp, M.</style></author><author><style face="normal" font="default" size="100%">Jheeta, P.</style></author><author><style face="normal" font="default" size="100%">Smyth, D. J.</style></author><author><style face="normal" font="default" size="100%">Duffin, R.</style></author><author><style face="normal" font="default" size="100%">Vermeren, S.</style></author><author><style face="normal" font="default" size="100%">Breyer, R. M.</style></author><author><style face="normal" font="default" size="100%">Narumiya, S.</style></author><author><style face="normal" font="default" size="100%">McSorley, H. J.</style></author><author><style face="normal" font="default" size="100%">Maizels, R. M.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J. K. J.</style></author><author><style face="normal" font="default" size="100%">Rossi, A. G.</style></author><author><style face="normal" font="default" size="100%">Yao, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Inflammation Research, Queen&apos;s Medical Research Institute, The University of Edinburgh, Edinburgh, UK.&#xD;Systems Immunity University Research Institute and Division of Infection and Immunity, Cardiff University, Cardiff, UK.&#xD;Division of Cell Signaling and Immunology, School of Life Sciences, Wellcome Trust Building, University of Dundee, Dundee, UK.&#xD;Department of Veterans Affairs, Tennessee Valley Health Authority, Nashville, Tennessee, USA.&#xD;Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Alliance Laboratory for Advanced Medical Research and Department of Drug Discovery Medicine, Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Wellcome Centre for Molecular Parasitology, Institute for Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Metabolic regulation by prostaglandin E(2) impairs lung group 2 innate lymphoid cell responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">714-730</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/10/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Prostaglandin E, EP4 Subtype/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Prostaglandin E, EP2 Subtype/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Dinoprostone/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">NSAID-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default" size="100%">cellular metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">group 2 innate lymphoid cell (ILC2)</style></keyword><keyword><style face="normal" font="default" size="100%">lung allergy</style></keyword><keyword><style face="normal" font="default" size="100%">prostaglandin E2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36181709</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Group 2 innate lymphoid cells (ILC2s) play a critical role in asthma pathogenesis. Non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NERD) is associated with reduced signaling via EP2, a receptor for prostaglandin E(2) (PGE(2) ). However, the respective roles for the PGE(2) receptors EP2 and EP4 (both share same downstream signaling) in the regulation of lung ILC2 responses has yet been deciphered. METHODS: The roles of PGE(2) receptors EP2 and EP4 on ILC2-mediated lung inflammation were investigated using genetically modified mouse lines and pharmacological approaches in IL-33-induced lung allergy model. The effects of PGE(2) receptors and downstream signals on ILC2 metabolic activation and effector function were examined using in vitro cell cultures. RESULTS: Deficiency of EP2 rather than EP4 augments IL-33-induced mouse lung ILC2 responses and eosinophilic inflammation in vivo. In contrast, exogenous agonism of EP4 and EP2 or inhibition of phosphodiesterase markedly restricts IL-33-induced lung ILC2 responses. Mechanistically, PGE(2) directly suppresses IL-33-dependent ILC2 activation through the EP2/EP4-cAMP pathway, which downregulates STAT5 and MYC pathway gene expression and ILC2 energy metabolism. Blocking glycolysis diminishes IL-33-dependent ILC2 responses in mice where endogenous PG synthesis or EP2 signaling is blocked but not in mice with intact PGE(2) -EP2 signaling. CONCLUSION: We have defined a mechanism for optimal suppression of mouse lung ILC2 responses by endogenous PGE(2) -EP2 signaling which underpins the clinical findings of defective EP2 signaling in patients with NERD. Our findings also indicate that exogenously targeting the PGE(2) -EP4-cAMP and energy metabolic pathways may provide novel opportunities for treating the ILC2-initiated lung inflammation in asthma and NERD.</style></abstract><notes><style face="normal" font="default" size="100%">Robb, Calum T&#xD;Zhou, You&#xD;Felton, Jennifer M&#xD;Zhang, Birong&#xD;Goepp, Marie&#xD;Jheeta, Privjyot&#xD;Smyth, Danielle J&#xD;Duffin, Rodger&#xD;Vermeren, Sonja&#xD;Breyer, Richard M&#xD;Narumiya, Shuh&#xD;McSorley, Henry J&#xD;Maizels, Rick M&#xD;Schwarze, Jurgen K J&#xD;Rossi, Adriano G&#xD;Yao, Chengcan&#xD;eng&#xD;MR/K013386/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/R008167/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T029668/1/MRC_/Medical Research Council/United Kingdom&#xD;C63480/A25246/CRUK_/Cancer Research UK/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):714-730. doi: 10.1111/all.15541. Epub 2022 Oct 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36181709</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10952163</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15541</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>607</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">607</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sadlier, C.</style></author><author><style face="normal" font="default" size="100%">Albrich, W. C.</style></author><author><style face="normal" font="default" size="100%">Neogi, U.</style></author><author><style face="normal" font="default" size="100%">Lunjani, N.</style></author><author><style face="normal" font="default" size="100%">Horgan, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Toole, P. W.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University College Cork, National University of Ireland, Cork, Ireland.&#xD;Department of Infectious Diseases, Cork University Hospital, Cork, Ireland.&#xD;Division of Infectious Diseases &amp; Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.&#xD;The Systems Virology Lab, Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, ANA Futura, Campus Flemingsberg, Stockholm, Sweden.&#xD;APC Microbiome Ireland, University College Cork, National University of Ireland, Cork, Ireland.&#xD;School of Microbiology, University College Cork, National University of Ireland, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Metabolic rewiring and serotonin depletion in patients with postacute sequelae of COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1623-1625</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Serotonin</style></keyword><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">lung diseases other than asthma and COPD</style></keyword><keyword><style face="normal" font="default" size="100%">GSK and Chiesi. LOM has participated in speaker&apos;s bureau for Nestle, Nutricia,</style></keyword><keyword><style face="normal" font="default" size="100%">Reckitt, and Abbott. WCA has participated in advisory boards for Pfizer, MSD, and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, with reimbursements paid to his institution. None of the other authors</style></keyword><keyword><style face="normal" font="default" size="100%">report any conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35150456</style></accession-num><notes><style face="normal" font="default" size="100%">Sadlier, Corinna&#xD;Albrich, Werner C&#xD;Neogi, Ujjwal&#xD;Lunjani, Nonhlanhla&#xD;Horgan, Mary&#xD;O&apos;Toole, Paul W&#xD;O&apos;Mahony, Liam&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1623-1625. doi: 10.1111/all.15253. Epub 2022 Feb 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35150456</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9111264</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15253</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>693</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">693</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ma, Y.</style></author><author><style face="normal" font="default" size="100%">Wei, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Dang, H.</style></author><author><style face="normal" font="default" size="100%">Zou, H.</style></author><author><style face="normal" font="default" size="100%">Tian, P.</style></author><author><style face="normal" font="default" size="100%">Zhong, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.&#xD;Department of Otorhinolaryngology, First Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Metabolomics analysis of metabolic patterns in chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">653-656</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/11/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34783368</style></accession-num><notes><style face="normal" font="default" size="100%">Ma, Yun&#xD;Wei, Yi&#xD;Liu, Xiang&#xD;Dang, Hua&#xD;Zou, Hua&#xD;Tian, Peng&#xD;Zhong, Hua&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):653-656. doi: 10.1111/all.15179. Epub 2021 Nov 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34783368</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15179</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>473</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">473</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carraro, S.</style></author><author><style face="normal" font="default" size="100%">di Palmo, E.</style></author><author><style face="normal" font="default" size="100%">Licari, A.</style></author><author><style face="normal" font="default" size="100%">Barni, S.</style></author><author><style face="normal" font="default" size="100%">Caldarelli, V.</style></author><author><style face="normal" font="default" size="100%">De Castro, G.</style></author><author><style face="normal" font="default" size="100%">Di Marco, A.</style></author><author><style face="normal" font="default" size="100%">Fenu, G.</style></author><author><style face="normal" font="default" size="100%">Giordano, G.</style></author><author><style face="normal" font="default" size="100%">Lombardi, E.</style></author><author><style face="normal" font="default" size="100%">Pirillo, P.</style></author><author><style face="normal" font="default" size="100%">Stocchero, M.</style></author><author><style face="normal" font="default" size="100%">Volpini, A.</style></author><author><style face="normal" font="default" size="100%">Zanconato, S.</style></author><author><style face="normal" font="default" size="100%">Rusconi, F.</style></author><author><style face="normal" font="default" size="100%">Italian Paediatric Severe Asthma, Network</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit of Pediatric Allergy and Respiratory Medicine, Women&apos;s and Children&apos;s Health Department, University of Padova.&#xD;Pediatric Unit - IRCCS Azienda Ospedaliero-Universitaria di Bologna.&#xD;Pediatric Clinic, Fondazione IRCSS Policlinico San Matteo, University of Pavia, Pavia.&#xD;Allergy Unit, Meyer Paediatric University Hospital, Florence.&#xD;Pediatric Unit, Department of Obstetrics, Gynecology and Pediatrics, Azienda USL - IRCCS, Reggio Emilia.&#xD;Pediatric Allergology Unit, Maternal and Child Department and Urological Science, Umberto I Hospital, Sapienza University, Rome.&#xD;Pediatric Pulmonology &amp; Respiratory Intermediate Care Unit, Sleep and long term Ventilation Unit, Academic Department of Pediatrics (DPUO), Bambino Gesu Children&apos;s Hospital, IRCCS, Rome.&#xD;Pulmonary Unit, Meyer Paediatric University Hospital, Florence.&#xD;Mass Spectrometry and Metabolomic Laboratory, Women&apos;s and Children&apos;s Health Department, University of Padova, Padova.&#xD;Fondazione Istituto di Ricerca Pediatrica (IRP), Padova.&#xD;Pediatric Unit, Department of Mother and Child Health, Salesi Children&apos;s Hospital, Ancona.&#xD;Department of Mother and Child Health, Azienda USL, Toscana, Pisa, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Metabolomics to identify omalizumab responders among children with severe asthma: a prospective study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2852-6</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/05/24</style></edition><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35603478</style></accession-num><notes><style face="normal" font="default" size="100%">Carraro, Silvia&#xD;di Palmo, Emanuela&#xD;Licari, Amelia&#xD;Barni, Simona&#xD;Caldarelli, Valeria&#xD;De Castro, Giovanna&#xD;Di Marco, Antonio&#xD;Fenu, Grazia&#xD;Giordano, Giuseppe&#xD;Lombardi, Enrico&#xD;Pirillo, Paola&#xD;Stocchero, Matteo&#xD;Volpini, Alessandro&#xD;Zanconato, Stefania&#xD;Rusconi, Franca&#xD;(IPSAN)&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 May 23;77(9):2852-6. doi: 10.1111/all.15385.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35603478</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9541025 Boehringer Ingelheim, GSK, Novartis, Sanofi, outside this work: AV reports financial or non-financial support from Chiesi, Fidia Sooft, Momento Medico, Lusofarmaco, outside this work; EL reports financial and non-financial support from AbbVie, Angelini, Boehringer, Chiesi, GlaxoSmithKline, Lusofarmaco, Novartis, Restech, Sanofi, Vertex, outside this work; SZ reports financial support from Sanofi, outside this work; AdM reports financial support from GlaxoSmithKline and Sanofi, outside this work. SC, EdP, FR, SB, PP, GDC, VC, AL, GG, MS, report no conflict of interest for this manuscript.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15385</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>968</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">968</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leonardi, A.</style></author><author><style face="normal" font="default" size="100%">Modugno, R. L.</style></author><author><style face="normal" font="default" size="100%">Cavarzeran, F.</style></author><author><style face="normal" font="default" size="100%">Rosani, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroscience, Ophthalmology Unit, University of Padova, Padova, Italy.&#xD;Department of Biology, University of Padova, Padova, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Metagenomic analysis of the conjunctival bacterial and fungal microbiome in vernal keratoconjunctivitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3215-3217</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacteria/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Metagenome</style></keyword><keyword><style face="normal" font="default" size="100%">Metagenomics</style></keyword><keyword><style face="normal" font="default" size="100%">*Mycobiome</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S</style></keyword><keyword><style face="normal" font="default" size="100%">16S rRNA gene amplicon sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">ITS2 rRNA gene amplicon sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">core microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">ocular surface microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">vernal keratoconjunctivitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34047368</style></accession-num><notes><style face="normal" font="default" size="100%">Leonardi, Andrea&#xD;Modugno, Rocco Luigi&#xD;Cavarzeran, Fabiano&#xD;Rosani, Umberto&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3215-3217. doi: 10.1111/all.14963. Epub 2021 Jun 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34047368</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14963</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1614</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1614</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leonardi, A.</style></author><author><style face="normal" font="default" size="100%">Modugno, R. L.</style></author><author><style face="normal" font="default" size="100%">Cavarzeran, F.</style></author><author><style face="normal" font="default" size="100%">Rosani, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroscience, Ophthalmology Unit, University of Padova, Padova, Italy.&#xD;Department of Biology, University of Padova, Padova, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Metagenomic analysis of the conjunctival bacterial and fungal microbiome in vernal keratoconjunctivitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3215-3217</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacteria/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Metagenome</style></keyword><keyword><style face="normal" font="default" size="100%">Metagenomics</style></keyword><keyword><style face="normal" font="default" size="100%">*Mycobiome</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S</style></keyword><keyword><style face="normal" font="default" size="100%">16S rRNA gene amplicon sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">ITS2 rRNA gene amplicon sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">core microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">ocular surface microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">vernal keratoconjunctivitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34047368</style></accession-num><notes><style face="normal" font="default" size="100%">Leonardi, Andrea&#xD;Modugno, Rocco Luigi&#xD;Cavarzeran, Fabiano&#xD;Rosani, Umberto&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3215-3217. doi: 10.1111/all.14963. Epub 2021 Jun 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34047368</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14963</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2508</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2508</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, D.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Gao, X.</style></author><author><style face="normal" font="default" size="100%">Choi, C. K.</style></author><author><style face="normal" font="default" size="100%">Giglio, G.</style></author><author><style face="normal" font="default" size="100%">Farah, L.</style></author><author><style face="normal" font="default" size="100%">Leung, T. F.</style></author><author><style face="normal" font="default" size="100%">Wong, K. C.</style></author><author><style face="normal" font="default" size="100%">Kan, L. L.</style></author><author><style face="normal" font="default" size="100%">Chong, J. W.</style></author><author><style face="normal" font="default" size="100%">Meng, Q. J.</style></author><author><style face="normal" font="default" size="100%">Liao, J.</style></author><author><style face="normal" font="default" size="100%">Cheung, P. F.</style></author><author><style face="normal" font="default" size="100%">Wong, C. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, China.&#xD;Department of Dermatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.&#xD;Center of Clinical Laboratory Medicine, Zhongda Hospital, Southeast University, Nanjing, China.&#xD;Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.&#xD;Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, partner site Essen) and German Cancer Research Center, DKFZ, Heidelberg, Germany.&#xD;Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong, China.&#xD;Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China.&#xD;Welcome Centre for Cell Matrix Research, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.&#xD;Centre for Biological Timing, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.&#xD;Spatiotemporal tumor heterogeneity, German Cancer Consortium (DKTK), A Partnership Between German Cancer Research Center (DKFZ) and University Hospital, Essen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Meteorin-like protein/METRNL/Interleukin-41 ameliorates atopic dermatitis-like inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">474-488</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/05/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/metabolism/etiology/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukins/metabolism/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Meteorin-like protein (METRNL)</style></keyword><keyword><style face="normal" font="default" size="100%">WNT signaling pathways</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">skin inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Wong, Dr. Kan, Mr. Chong, Dr. Meng, Dr. Liao, Dr. Cheung and Dr. Wong have</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38727640</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Meteorin-like protein (METRNL)/Interleukin-41 (IL-41) is a novel immune-secreted cytokine/myokine involved in several inflammatory diseases. However, how METRNL exerts its regulatory properties on skin inflammation remains elusive. This study aims to elucidate the functionality and regulatory mechanism of METRNL in atopic dermatitis (AD). METHODS: METRNL levels were determined in skin and serum samples from patients with AD and subsequently verified in the vitamin D3 analogue MC903-induced AD-like mice model. The cellular target of METRNL activity was identified by multiplex immunostaining, single-cell RNA-seq and RNA-seq. RESULTS: METRNL was significantly upregulated in lesions and serum of patients with dermatitis compared to healthy controls (p &lt;.05). Following repeated MC903 exposure, AD model mice displayed elevated levels of METRNL in both ears and serum. Administration of recombinant murine METRNL protein (rmMETRNL) ameliorated allergic skin inflammation and hallmarks of AD in mice, whereas blocking of METRNL signaling led to the opposite. METRNL enhanced beta-Catenin activation, limited the expression of Th2-related molecules that attract the accumulation of Arginase-1 (Arg1)(hi) macrophages, dendritic cells, and activated mast cells. CONCLUSIONS: METRNL can bind to KIT receptor and subsequently alleviate the allergic inflammation of AD by inhibiting the expansion of immune cells, and downregulating inflammatory gene expression by regulating the level of active WNT pathway molecule beta-Catenin.</style></abstract><notes><style face="normal" font="default" size="100%">Huang, Danqi&#xD;Liu, Xiuting&#xD;Gao, Xun&#xD;Choi, Chun Kit&#xD;Giglio, Giovanni&#xD;Farah, Luay&#xD;Leung, Ting-Fan&#xD;Wong, Katie Ching-Yau&#xD;Kan, Lea Ling-Yu&#xD;Chong, Jeffrey Wing-Heung&#xD;Meng, Qing-Jun&#xD;Liao, Jinyue&#xD;Cheung, Phyllis Fung-Yi&#xD;Wong, Chun-Kwok&#xD;eng&#xD;Jiangsu Province Basic Research Special Fund (Natural Science Foundation), Jiangsu Provincial Department of Science and Technology, China/&#xD;Innovation and Technology Commission/&#xD;National Natural Science Foundation of China/&#xD;Chinese University of Hong Kong/&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):474-488. doi: 10.1111/all.16150. Epub 2024 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38727640</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804313</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16150</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3148</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3148</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Vieira, R. J.</style></author><author><style face="normal" font="default" size="100%">Schunemann, H. J.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Bognanni, A.</style></author><author><style face="normal" font="default" size="100%">Togias, A.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Williams, S.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Vecillas, L. L.</style></author><author><style face="normal" font="default" size="100%">Dykewicz, M. S.</style></author><author><style face="normal" font="default" size="100%">Jacomelli, C.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Leemann, L.</style></author><author><style face="normal" font="default" size="100%">Lourenco, O.</style></author><author><style face="normal" font="default" size="100%">Palamarchuk, Y.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Pereira, A. M.</style></author><author><style face="normal" font="default" size="100%">Savoure, M.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S. K.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Yepes-Nunez, J. J.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Ciprandi, G.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Gradauskiene, B.</style></author><author><style face="normal" font="default" size="100%">Jartti, T.</style></author><author><style face="normal" font="default" size="100%">Jesenak, M.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Latiff, A. H. A.</style></author><author><style face="normal" font="default" size="100%">Mohammad, Y.</style></author><author><style face="normal" font="default" size="100%">Ohta, K.</style></author><author><style face="normal" font="default" size="100%">Mahesh, P. A.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Roche, N.</style></author><author><style face="normal" font="default" size="100%">Sofiev, M.</style></author><author><style face="normal" font="default" size="100%">Taborda-Barata, L.</style></author><author><style face="normal" font="default" size="100%">Ulrik, C. S.</style></author><author><style face="normal" font="default" size="100%">Rostan, M. V.</style></author><author><style face="normal" font="default" size="100%">Viegi, G.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Cherrez-Ojeda, I.</style></author><author><style face="normal" font="default" size="100%">Ivancevich, J. C.</style></author><author><style face="normal" font="default" size="100%">Khaltaev, N.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Abdullah, B.</style></author><author><style face="normal" font="default" size="100%">Al-Ahmad, M.</style></author><author><style face="normal" font="default" size="100%">Al-Nesf, M. A.</style></author><author><style face="normal" font="default" size="100%">Amaral, R.</style></author><author><style face="normal" font="default" size="100%">Asllani, J.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Blaiss, M. S.</style></author><author><style face="normal" font="default" size="100%">Braido, F.</style></author><author><style face="normal" font="default" size="100%">Camargos, P.</style></author><author><style face="normal" font="default" size="100%">Carreiro-Martins, P.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A. G.</style></author><author><style face="normal" font="default" size="100%">Giuliano, A. F. M.</style></author><author><style face="normal" font="default" size="100%">Christoff, G.</style></author><author><style face="normal" font="default" size="100%">Cirule, I.</style></author><author><style face="normal" font="default" size="100%">Correia-de-Sousa, J.</style></author><author><style face="normal" font="default" size="100%">Costa, E. M.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Dokic, D.</style></author><author><style face="normal" font="default" size="100%">Hossny, E.</style></author><author><style face="normal" font="default" size="100%">Iinuma, T.</style></author><author><style face="normal" font="default" size="100%">Irani, C.</style></author><author><style face="normal" font="default" size="100%">Ispayeva, Z.</style></author><author><style face="normal" font="default" size="100%">Julge, K.</style></author><author><style face="normal" font="default" size="100%">Kaidashev, I.</style></author><author><style face="normal" font="default" size="100%">Bennoor, K. S.</style></author><author><style face="normal" font="default" size="100%">Kraxner, H.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Kulus, M.</style></author><author><style face="normal" font="default" size="100%">Kupczyk, M.</style></author><author><style face="normal" font="default" size="100%">Kurchenko, A.</style></author><author><style face="normal" font="default" size="100%">La Grutta, S.</style></author><author><style face="normal" font="default" size="100%">Miculinic, N.</style></author><author><style face="normal" font="default" size="100%">Tuyet, L. L. T.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Milenkovic, B.</style></author><author><style face="normal" font="default" size="100%">Lee, S. M.</style></author><author><style face="normal" font="default" size="100%">Montefort, S.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Nadif, R.</style></author><author><style face="normal" font="default" size="100%">Nakonechna, A.</style></author><author><style face="normal" font="default" size="100%">Neffen, H. E.</style></author><author><style face="normal" font="default" size="100%">Niedoszytko, M.</style></author><author><style face="normal" font="default" size="100%">Nyembue, D.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Olze, H.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Panzner, P.</style></author><author><style face="normal" font="default" size="100%">Patella, V.</style></author><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Pitsios, C.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Puggioni, F.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Ramonaite, A.</style></author><author><style face="normal" font="default" size="100%">Recto, M.</style></author><author><style face="normal" font="default" size="100%">Repka-Ramirez, M. S.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Robles-Velasco, K.</style></author><author><style face="normal" font="default" size="100%">Rottem, M.</style></author><author><style face="normal" font="default" size="100%">Salapatas, M.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Scichilone, N.</style></author><author><style face="normal" font="default" size="100%">Sisul, J. C.</style></author><author><style face="normal" font="default" size="100%">Sole, D.</style></author><author><style face="normal" font="default" size="100%">Soto-Martinez, M. E.</style></author><author><style face="normal" font="default" size="100%">Sova, M.</style></author><author><style face="normal" font="default" size="100%">Tantilipikorn, P.</style></author><author><style face="normal" font="default" size="100%">Todo-Bom, A.</style></author><author><style face="normal" font="default" size="100%">Tsaryk, V.</style></author><author><style face="normal" font="default" size="100%">Tsiligianni, I.</style></author><author><style face="normal" font="default" size="100%">Urrutia-Pereira, M.</style></author><author><style face="normal" font="default" size="100%">Valovirta, E.</style></author><author><style face="normal" font="default" size="100%">Van Ganse, E.</style></author><author><style face="normal" font="default" size="100%">Vasankari, T.</style></author><author><style face="normal" font="default" size="100%">Wallace, D.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Yusuf, O. M.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author><author><style face="normal" font="default" size="100%">Gil-Mata, S.</style></author><author><style face="normal" font="default" size="100%">Marques-Cruz, M.</style></author><author><style face="normal" font="default" size="100%">Mahboub, B.</style></author><author><style face="normal" font="default" size="100%">Ansotegui, I. J.</style></author><author><style face="normal" font="default" size="100%">Romano, A.</style></author><author><style face="normal" font="default" size="100%">Artesani, M. C.</style></author><author><style face="normal" font="default" size="100%">Barreto, B.</style></author><author><style face="normal" font="default" size="100%">Becker, S.</style></author><author><style face="normal" font="default" size="100%">Beghe, B.</style></author><author><style face="normal" font="default" size="100%">Bouchard, J.</style></author><author><style face="normal" font="default" size="100%">Bourgoin-Heck, M.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Buhl, R.</style></author><author><style face="normal" font="default" size="100%">Calvo-Gil, M.</style></author><author><style face="normal" font="default" size="100%">Dahl, V. C.</style></author><author><style face="normal" font="default" size="100%">Vizuete, J. A. C.</style></author><author><style face="normal" font="default" size="100%">Charpin, D.</style></author><author><style face="normal" font="default" size="100%">Chavannes, N. H.</style></author><author><style face="normal" font="default" size="100%">Chelminska, M.</style></author><author><style face="normal" font="default" size="100%">Cheng, L.</style></author><author><style face="normal" font="default" size="100%">Chkhartishvili, E.</style></author><author><style face="normal" font="default" size="100%">Chong-Neto, H. J.</style></author><author><style face="normal" font="default" size="100%">Choudhury, D.</style></author><author><style face="normal" font="default" size="100%">Chu, D.</style></author><author><style face="normal" font="default" size="100%">Cingi, C.</style></author><author><style face="normal" font="default" size="100%">Compalati, E.</style></author><author><style face="normal" font="default" size="100%">Cvetkovski, B.</style></author><author><style face="normal" font="default" size="100%">Da Silva, J.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">Davies, J.</style></author><author><style face="normal" font="default" size="100%">Di Bona, D.</style></author><author><style face="normal" font="default" size="100%">Dimou, M. V.</style></author><author><style face="normal" font="default" size="100%">Teixeira, M. D. C.</style></author><author><style face="normal" font="default" size="100%">Doulaptsi, M.</style></author><author><style face="normal" font="default" size="100%">Perez, J. M. F.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Goksel, O.</style></author><author><style face="normal" font="default" size="100%">Gomez, M. R.</style></author><author><style face="normal" font="default" size="100%">Gonzalez Diaz, S. N.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Grigoreas, C.</style></author><author><style face="normal" font="default" size="100%">Grisle, I.</style></author><author><style face="normal" font="default" size="100%">Guzman, M. A.</style></author><author><style face="normal" font="default" size="100%">Tan, R. H.</style></author><author><style face="normal" font="default" size="100%">Hyland, M.</style></author><author><style face="normal" font="default" size="100%">Ierodiakonou, D.</style></author><author><style face="normal" font="default" size="100%">Karavelia, A.</style></author><author><style face="normal" font="default" size="100%">Kisiel, M.</style></author><author><style face="normal" font="default" size="100%">Kosnik, M.</style></author><author><style face="normal" font="default" size="100%">Kritikos, V.</style></author><author><style face="normal" font="default" size="100%">Lombardi, C.</style></author><author><style face="normal" font="default" size="100%">Martini, M.</style></author><author><style face="normal" font="default" size="100%">Meco, C.</style></author><author><style face="normal" font="default" size="100%">Mesonjesi, E.</style></author><author><style face="normal" font="default" size="100%">Mihaltan, F.</style></author><author><style face="normal" font="default" size="100%">Moniuszko, M.</style></author><author><style face="normal" font="default" size="100%">Naclerio, R.</style></author><author><style face="normal" font="default" size="100%">Neisinger, S.</style></author><author><style face="normal" font="default" size="100%">Ordak, M.</style></author><author><style face="normal" font="default" size="100%">Paoletti, G.</style></author><author><style face="normal" font="default" size="100%">Perdomo-Flores, E. A.</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, N.</style></author><author><style face="normal" font="default" size="100%">Prokopakis, E.</style></author><author><style face="normal" font="default" size="100%">Yeverino, D. R.</style></author><author><style face="normal" font="default" size="100%">Rolla, G.</style></author><author><style face="normal" font="default" size="100%">Romantowski, J.</style></author><author><style face="normal" font="default" size="100%">Rouadi, P. W.</style></author><author><style face="normal" font="default" size="100%">Rukhadze, M.</style></author><author><style face="normal" font="default" size="100%">Sakurai, D.</style></author><author><style face="normal" font="default" size="100%">Salameh, L.</style></author><author><style face="normal" font="default" size="100%">Sarquis, F. S.</style></author><author><style face="normal" font="default" size="100%">Kosak, T. S.</style></author><author><style face="normal" font="default" size="100%">Soyka, M.</style></author><author><style face="normal" font="default" size="100%">Sozinova, O.</style></author><author><style face="normal" font="default" size="100%">Specjalski, K.</style></author><author><style face="normal" font="default" size="100%">Tomic-Spiric, V.</style></author><author><style face="normal" font="default" size="100%">Vachova, M.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Koyuncu, I. V.</style></author><author><style face="normal" font="default" size="100%">Vichyanond, P.</style></author><author><style face="normal" font="default" size="100%">Wagenmann, M.</style></author><author><style face="normal" font="default" size="100%">Ko, F. W. S.</style></author><author><style face="normal" font="default" size="100%">Werminghaus, P.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, V. P.</style></author><author><style face="normal" font="default" size="100%">Xiang, Y. K.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;ARIA (Allergic Rhinitis and Its Impact on Asthma), Montpellier, France.&#xD;MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE-Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Department of Health Research Methods, Evidence, and Impact &amp; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, Italy.&#xD;Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, Maryland, USA.&#xD;Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland.&#xD;Institute of Clinical Medicine and Institute of Health Sciences, Medical Faculty of Vilnius University, Vilnius, Lithuania.&#xD;Clinic of Asthma, Allergy, and Chronic Lung Diseases, Asthma &amp; Allergy Department, Vilnius, Lithuania.&#xD;International Primary Care Respiratory Group IPCRG, Edinburgh, UK.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;Allergy Unit, Malaga Regional University Hospital of Malaga, Malaga University, ARADyAL, Malaga, Spain.&#xD;National Heart and Lung Institute (NHLI), Imperial College, and NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;Asthma &amp; Allergy Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.&#xD;Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.&#xD;Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.&#xD;&quot;Respiriamo Insieme&quot; Association, Asthma &amp; Allergy Center, Padova, Italy.&#xD;Department of Otolaryngology, Head &amp; Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Allergology &amp; Rhinology Department, Wiesbaden, Germany.&#xD;Department of Political Science, University of Zurich, Zurich, Switzerland.&#xD;RISE-Health, Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal.&#xD;Finnish Meteorological Institute (FMI), Helsinki, Finland.&#xD;Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;PaCeIT-Patient Centered Innovation and Technologies, Center for Health Technology and Services Research (CINTESIS), Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Allergy Unit, Instituto and Hospital CUF, Porto, Portugal.&#xD;Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Department of Allergy, Skin and Allergy Hospital, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Otorhinolaryngology, University of Eastern Finland and the North Savo Wellbeing Services County, Kuopio, Finland.&#xD;Allergy and Clinical Immunology, University of Bari Medical School, Bari, Italy.&#xD;Institute of Sciences of Food Production, National Research Council (ISPA-CNR), Bari, Italy.&#xD;School of Medicine, Universidad de los Andes, Bogota, DC, Colombia.&#xD;Pulmonology Service, Internal Medicine Section, Fundacion Santa Fe de Bogota, University Hospital, Bogota, DC, Colombia.&#xD;Fundacao ProAR and (Faculdade de Medicina da), Universidade Federal da Bahia, Salvador, Bahia, Brazil.&#xD;Casa di Cura Villa Montallegro, Allergology Department, Genova, Italy.&#xD;Department of Pulmonary Diseases and Institute of Pulmonology and Tuberculosis, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Immunology and Allergology, Lithuanian University of Health Sciences, Kaunas, Lithuania.&#xD;Department of Pediatrics and Adolescent Medicine, University of Turku, and Turku University Hospital, Turku, Finland.&#xD;Institute of Clinical Immunology and Medical Genetics, Department of Paediatrics and Adolescent Medicine, Department of Pulmonology and Phthisiology, Jessenius Faculty of Medicine, Martin, Slovakia.&#xD;Comenius University, Bratislava, Slovakia.&#xD;University Teaching Hospital Martin, Martin, Slovakia.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;Allergy &amp; Immunology Centre, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.&#xD;National Center for Research in Chronic Respiratory Diseases, Collaborating With WHO-EMRO Tishreen University School of Medicine, Latakia, Syria.&#xD;Al-Sham Private University, Damascus, Syria.&#xD;Japan Antituberculosis Association (JATA), Fukujuji Hospital, Tokyo, Japan.&#xD;Department of Respiratory Medicine, JSS Medical College, JSSAHER, Mysore, Karnataka, India.&#xD;Departement of Biological Sciences and Pathophysiology, University of Veterinary Medicine, Vienna, Austria.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Allergy and Clinical Immunology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saude de Coimbra, Coimbra, Portugal.&#xD;Center for Innovative Biomedicine and Biotechnology (CIBB), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;UBIAir-Clinical &amp; Experimental Lung Centre and CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Pneumologie, AP-HP Centre Universite de Paris Cite, Hopital Cochin, Paris, France.&#xD;UMR 1016, Institut Cochin, Paris, France.&#xD;Inserm, Equipe d&apos;Epidemiologie Respiratoire Integrative, CESP, Villejuif, France.&#xD;Department of Immunoallergology, Cova da Beira University Hospital Centre, Covilha, Portugal.&#xD;UBIAir-Clinical &amp; Experimental Lung Centre, University of Beira Interior, Covilha, Portugal.&#xD;Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Copenhagen, Denmark.&#xD;Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Pediatrics, Allergy &amp; Immunology, Latin American Society of Allergy, Asthma &amp; Immunology (SLAAi), Montevideo, Uruguay.&#xD;Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy.&#xD;Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital and Beijing Institute of Otolaryngology, Beijing, China.&#xD;ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.&#xD;Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Universidad Espiritu Santo, Samborondon, Ecuador.&#xD;Respiralab Research Group, Guayaquil, Guayas, Ecuador.&#xD;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;Global NCD Platform, Geneva, Switzerland.&#xD;Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.&#xD;Microbiology Department, College of Medicine, Kuwait University, Kuwait City, Kuwait.&#xD;Adult Allergy and Immunology Division-Hamad Medical Corporation, Doha, Qatar.&#xD;Department of Cardiovascular and Respiratory Sciences, Porto Health School, Polytechnic Institute of Porto, Porto, Portugal.&#xD;Department of Women&apos;s and Children&apos;s Health, Paediatric Research, Uppsala University, Uppsala, Sweden.&#xD;Department of Internal Medicine, University of Medicine, Tirana, Albania.&#xD;Division of Immunology, Allergy and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.&#xD;Department of Internal Medicine (DIMI), University of Genoa, Genoa, Italy.&#xD;Respiratory and Allergy Clinic, IRCCS - Policlinico San Martino, Genoa, Italy.&#xD;Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil.&#xD;CHRC, LA-REAL, NOVA Medical School, NMS, Universidade NOVA de Lisboa, Lisboa, Portugal.&#xD;Servico de Imunoalergologia, Hospital de Dona Estefania, Lisbon, Portugal.&#xD;Division of Allergy/Immunology, University of South Florida, Tampa, Florida, USA.&#xD;SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Allergy, Bambino Gesu Children&apos;s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.&#xD;Department of Internal Medicine &apos;A. Murri&apos; and Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.&#xD;Faculty of Public Health, Sofia Medical University, Sofia, Bulgaria.&#xD;Latvian Association of Allergists, University Children Hospital, Riga, Latvia.&#xD;Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.&#xD;CINTESIS@RISE, Biochemistry Lab, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing, University of Porto, Porto, Portugal.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, University of Cagliari, Cagliari, Italy.&#xD;VIM Suresnes, UMR 0892, Pole des Maladies des Voies Respiratoires, Hopital Foch, Universite Paris-Saclay, Suresnes, France.&#xD;Medical Faculty Skopje, University Clinic of Pulmonology and Allergy, Skopje, Republic of Macedonia.&#xD;Pediatric Allergy, Immunology and Rheumatology Unit, Children&apos;s Hospital, Ain Shams University, Cairo, Egypt.&#xD;Department of Otorhinolaryngology, Chiba University, Chiba, Japan.&#xD;Department of Internal Medicine and Infectious Diseases, St Joseph University, Hotel Dieu de France Hospital, Beirut, Lebanon.&#xD;Department of Allergology and Clinical Immunology, Kazakhstan Association of Allergology and Clinical Immunology, Kazakh National Medical University, Almaty, Kazakhstan.&#xD;Institute of Clinical Medicine, Children&apos;s Clinic, Tartu University, Tartu, Estonia.&#xD;Poltava State Medical University, Immunology &amp; Allergology Department, Poltava, Ukraine.&#xD;Department of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary.&#xD;Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Sach&apos;s Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Department of Pediatric Respiratory Diseases and Allergology, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Clinical and Laboratory Immunology, Allergology and Medical Genetics, Bogomolets National Medical University, Kyiv, Ukraine.&#xD;Institute of Translational Pharmacology (IFT)-National Research Council (CNR), Palermo, Italy.&#xD;Croatian Pulmonary Society, Clinical Center for Pulmonary Diseases, Zagreb, Croatia.&#xD;Asthma, COPD Outpatient Care Unit, University Medical Center, Ho-Chi-Minh, Vietnam.&#xD;Allergy Unit &quot;D Kalogeromitros&quot;, 2nd Department of Dermatology and Venereology, National &amp; Kapodistrian University of Athens, &quot;Attikon&quot; University Hospital, Athens, Greece.&#xD;Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia.&#xD;Division of Respiratory Disease and Allergy, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea.&#xD;Department of Medicine, Faculty of Medicine and Surgery, University of Malta, MSD, Msida, Malta.&#xD;EPIUnit-Institute of Public Health, University of Porto, and Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal.&#xD;Servico de Imunoalergologia, Centro Hospitalar Universitario Sao Joao, Porto, Portugal.&#xD;Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Rhinology Unit &amp; Smell Clinic, Department of Otorhinolaryngology, Hospital Clinic Barcelona, Universitat de Barcelona; FRCB-IDIBAPS; CIBERES, Barcelona, Spain.&#xD;Universite Paris-Saclay, UVSQ, Univ. Paris-Sud, Villejuif, France.&#xD;Inserm, Equipe d&apos;Epidemiologie Respiratoire Integrative, Villejuif, France.&#xD;Imperial College Healthcare NHS Trust, London, UK.&#xD;University of Liverpool, Liverpool, UK.&#xD;Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina.&#xD;Department of Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;ENT Department, University Hospital of Kinshasa, Kinshasa, Democratic Republic of Congo.&#xD;Allergy, Asthma and Clinical Immunology, Alfred Health, Department of Immunology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Chiba Rosai Hospital, ENT Department, Chiba, Japan.&#xD;Chiba University Hospital, Department of Otolaryngology, Head and Neck Surgery, Chiba, Japan.&#xD;Department of Otorhinolaryngology, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, &quot;Santa Maria della Speranza&quot; Hospital, Battipaglia, Salerno, Italy.&#xD;Agency of Health ASL, Division of Allergy and Clinical Immunology, Department of Medicine, Salerno, Italy.&#xD;Postgraduate Programme in Allergy and Clinical Immunology, University of Naples Federico II, Naples, Italy.&#xD;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Medical School, University of Cyprus, Nicosia, Cyprus.&#xD;Clinic of Occupational Diseases, University Hospital Sveti Ivan Rilski, Sofia, Bulgaria.&#xD;IRCCS Humanitas Research Center, Personalized Medicine Asthma &amp; Allergy, Rozzano, Milan, Italy.&#xD;Department of Pulmonology and Allergology, Klaipeda National Hospital, Klaipeda, Lithuania.&#xD;Vilnius University Medical Faculty, Department of Political Behaviour and Institutions, Vilnius, Lithuania.&#xD;Division of Adult and Pediatric Allergy and Immunology, University of the Philippines - Philippines General Hospital, Manila, Philippines.&#xD;Department of Allergy, Clinics Hospital, National University, San Lorenzo, Paraguay.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;The David Hide Asthma and Allergy Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;LEADER Research Inc, Hamilton, Ontario, Canada.&#xD;Division of Allergy, Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel.&#xD;Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.&#xD;ARIA, Asthma, Rhinitis, Immunology &amp; Allergy Department, Athens, Greece.&#xD;Allergy Service, Fundacion Jimenez Diaz, Autonoma University of Madrid, CIBERES-ISCIII, Madrid, Spain.&#xD;PROMISE Department, University of Palermo, Palermo, Italy.&#xD;Allergy &amp; Asthma, Medical Director, CLINICA SISUL, FACAAI, SPAAI, Asuncion, Paraguay.&#xD;Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;Division of Respiratory Medicine, Department of Pediatrics, Hospital Nacional de Ninos, Universidad de Costa Rica, San Jose, Costa Rica.&#xD;Department of Respiratory Medicine and Tuberculosis, University Hospital, Brno, Czech Republic.&#xD;Department of Otolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Imunoalergologia, Centro Hospitalar Universitario de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;International Primary Care Respiratory Group IPCRG, Aberdeen, UK.&#xD;Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece.&#xD;Department of Medicine, Federal University of Pampa, Uruguaiana, Brazil.&#xD;Department of Lung Diseases and Clinical Immunology, University of Turku, Turku, Finland.&#xD;Research on Healthcare Performance (RESHAPE), INSERM U1290, Pneumologie et Medicine Respiratoire, Groupement Hospitalier Nord, Hopital de la Croix Rousse, Lyon, France.&#xD;FiLHA, Finnish Lung Health Association, Helsinki, Finland.&#xD;Department of Clinical Medicine, Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland.&#xD;Nova Southeastern University, College of Allopathic Medicine, Fort Lauderdale, Florida, USA.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore.&#xD;Division of Allergy and Immunology, Department of Dermatology, Allergy and Venerology, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;The Allergy and Asthma Institute, Allergy &amp; Asthma Department, Islamabad, Pakistan.&#xD;University Clinic of Respiratory and Allergic Diseases, Pulmonary &amp; Allergy Department, Golnik, Slovenia.&#xD;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.&#xD;Pulmonary Department, Rashid Hospital, DUBAI Health, Dubai, UAE.&#xD;Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, UAE.&#xD;Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.&#xD;Oasi Research Institute-IRCCS, Troina, Italy.&#xD;BIOS S.p.A. Societa Benefit, Rome, Italy.&#xD;Department of Allergy and Immunology, Para State University Center - CESUPA, Belem, Brazil.&#xD;Department for Otorhinolaryngology, Head and Neck Surgery, University of Tubingen, Tubingen, Germany.&#xD;Respiratory Medicine, University of Modena &amp; Reggio Emilia, Azienda Ospedaliera-Universitaria di Modena, Modena, Italy.&#xD;Laval University, Quebec City, Quebec, Canada.&#xD;Department of Pediatric Allergology, Armand Trousseau University Hospital, Sorbonne University, AP-HP, Paris, France.&#xD;French National Reference Center for Angioedema (CREAK), Saint-Antoine University Hospital, Paris, France.&#xD;CRESS, Inserm, INRAE, HERA Team, Paris Cite University, Paris, France.&#xD;Department of Medical Sciences, University of Turin, Turin, Italy.&#xD;Allergy and Clinical Immunology Unit, Mauriziano Hospital, Torino, Italy.&#xD;Department of Pulmonary Medicine, Mainz University Hospital, Mainz, Germany.&#xD;Pediatrics Department, Faculty of Medicine, Universidad Austral de Chile, Valdivia, Chile.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall D&apos;hebron, Barcelona, Spain.&#xD;ARADyAL Research Network, Barcelona, Spain.&#xD;Pneumology Department, Hospital Universitari Dexeus, Barcelona, Spain.&#xD;CIBER of Respiratory Diseases, Group of Rhinitis, Rhinosinusitis and Nasal Polyps, Area of Asthma, Barcelona, Spain.&#xD;Clinique des Bronches, Allergie et Sommeil, Hopital Nord, Marseille, France.&#xD;National eHealth Living Lab, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands.&#xD;Department of Allergology and Department of Otorhinolaryngology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.&#xD;Allergist, David Tvildiani Medical University, Tbilisi, Georgia.&#xD;Associate Professor of Pediatrics, Division of Allergy and Immunology, Federal University of Parana, Curitiba, Brazil.&#xD;Paediatric Allergy Clinic, Department of Dermatology, Amersham Hospital - NHS Hospital Trust, Amersham, UK.&#xD;Department of Health Research Methods, Evidence &amp; Impact, McMaster University, Hamilton, Ontario, Canada.&#xD;Evidence in Allergy Group, McMaster University and the Research Institute of St. Joe&apos;s Hamilton, Hamilton, Ontario, Canada.&#xD;Medical Faculty, ENT Department, Eskisehir Osmangazi University, Eskisehir, Turkey.&#xD;Scientific &amp; Medical Department, Lofarma S.p.A, Milan, Italy.&#xD;Woolcock Institute of Medical Research, Sydney, Australia.&#xD;Allergy Service, University Hospital Professor Polydoro Ernani de Sao Thiago (HU-UFSC/EBSERH), Florianopolis, Brazil.&#xD;Department of Internal Medicine, Federal University of Santa Catarina (UFSC), Florianopolis, Brazil.&#xD;Division of Respiratory and Allergic Diseases, High Specialty Hospital &apos;a Cardarelli&apos;, and Respiratory Allergy School of Specialization in Respiratory Diseases, Federico II University of Naples, Naples, Italy.&#xD;Centre for Immunology and Infection Control, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia.&#xD;Office of Research, Metro North Hospital and Health Service, Brisbane, Australia.&#xD;Department of Medical and Surgical Sciences, School of Allergology and Clinical Immunology, University of Foggia, Foggia, Italy.&#xD;Dr Agostinho Neto University Hospital, Epidemiology Department, Praia, Cabo Verde.&#xD;Immunology, Cabo Verde University, Faculty of Medicine, Praia, Cape Verde.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University of Crete, School of Medicine, Heraklion, Crete, Greece.&#xD;Allergist, Private Practice, Mexico City, Mexico.&#xD;Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia in Katowice, Katowice, Poland.&#xD;Department of Pulmonary Medicine, Division of Immunology, Allergy and Asthma, Laboratory of Occupational and Environmental Respiratory Diseases, Faculty of Medicine, Ege University, EgeSAM (Ege University Translational Pulmonary Research, Center), Bornova, Turkiye.&#xD;Faculty of Health Sciences, Catholic University of Salta, Salta, Argentina.&#xD;Allergy and Clinical Immunology Centro Regional, Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico.&#xD;Center of Allergy and Immunology, and Georgian Academy of Allergy, Asthma, and Clinical Immunology, Tbilisi, Georgia.&#xD;Department of Allergy and Clinical Immunology, Air Force General Hospital, Athens, Greece.&#xD;Riga East University Hospital, Riga, Latvia.&#xD;Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile.&#xD;Quality Use of Research Medicines Group, Woolcock Institute of Medical Research, Macquarie Park NSW, Australia.&#xD;Macquarie University, Macquarie Park, NSW, Australia.&#xD;Faculty of Health, University of Plymouth, Plymouth, UK.&#xD;Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.&#xD;Otolaryngology Department, General Hospital of Kalamata, Kalamata, Greece.&#xD;Department of Medical Sciences, Occupational and Environmental Medicine, Uppsala University, Uppsala, Sweden.&#xD;Clinical Management Group, Woolcock Institute of Medical Research, Sydney, Australia.&#xD;Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.&#xD;Departmental Unit of Allergology, Clinical Immunology &amp; Pneumology, Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy.&#xD;Allergy Unit, Department of Internal Medicine, University Hospital AOU delle Marche, Ancona, Italy.&#xD;Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Ankara University Medical School, Ankara, Turkey.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Salzburg Paracelsus Medical University, Salzburg, Austria.&#xD;Department of Otolaryngology, Head and Neck Surgery, Weill Cornell Medical College, Cornell University, New York, NY, USA.&#xD;Allergy and Clinical Immunology Department, University Hospital Center &quot;Mother Teresa&quot;, Tirana, Albania.&#xD;UMF-University of Medicine and Pharmacy &apos;Carol Davila&apos;, Pneumology Department, National Institute of Pneumology &apos;Marius Nasta&apos;, Bucharest, Romania.&#xD;Department of Allergology and Internal Medicine, Medical University of Bialystok, Byalistok, Poland.&#xD;Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland, USA.&#xD;Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.&#xD;Otorhinolaryngology and Neck Surgery Unit, San Juan de Dios National Hospital, San Miguel, El Salvador.&#xD;Ecole Polytechnique de Palaiseau, Palaiseau, France.&#xD;IRBA (Institut de Recherche Bio-Medicale Des Armees), Bretigny sur Orge, France.&#xD;Universite Paris Cite, Paris, France.&#xD;Servicio de Alergia e Inmunologia clinica, Hospital Universitario de Puebla, Puebla, Mexico.&#xD;Department of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Dar Al Shifa Hospital, Salmiya, Kuwait.&#xD;Center Allergy &amp; Immunology and Geomedi Teaching University, Faculty of Medicine, Tbilisi, Georgia.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.&#xD;Mohammed Bin Rashid University (MBRU), Dubai Health, Dubai, UAE.&#xD;Asthma Reference Center-School of Medicine of Santa Casa de Misericordia of Vitoria, Espirito Santo, Brazil.&#xD;ORL SOKLIC KOSAK, Ljubljana, Slovenia.&#xD;Otolaryngology-HNS, University of Zurich, University Hospital of Zurich, Zurich, Switzerland.&#xD;Head of Laboratory of Atmospheric Processes and Aerobiology, University of Latvia, Riga, Latvia.&#xD;Clinic of Allergology and Immunology, University Clinical Center of Serbia, Belgrade, Serbia.&#xD;Faculty of Medicine, University of Belgrade, Belgrade, Serbia.&#xD;Department of Immunology and Allergology, University Hospital and Faculty of Medicine in Pilsen, Czech Republic.&#xD;Charles University, Prague, Czech Republic.&#xD;Department of Medicine Solna, Division of Immunology and Respiratory Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.&#xD;Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Chest Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Siriraj Hospital, Mahidol University Faculty of Medicine, Bangkok, Thailand.&#xD;Samitivej Allergy Institute, Bangkok, Thailand.&#xD;Department of Otorhinolaryngology, Heinrich Heine University Dusseldorf, Medical Faculty and University Hospital Dusseldorf, Dusseldorf, Germany.&#xD;Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.&#xD;ENT and Allergology, Dusseldorf, Germany.&#xD;Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024-2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">ENT (rhinitis, sinusitis, nasal polyps...)</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41268627</style></accession-num><abstract><style face="normal" font="default" size="100%">The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines produced their first edition in 1999, with subsequent revisions in 2008, 2010, 2016 and 2019. A new iteration of ARIA-ARIA 2024-2025-in collaboration with EAACI is currently being developed, focusing on the management of allergic rhinitis. ARIA 2024-2025 follows the GRADE framework and is endorsed by the European Academy of Allergy and Clinical Immunology (EAACI). A set of approaches has been used to develop guideline questions, including surveying key opinion leaders and using artificial intelligence (AI)-based tools to analyse web searches on allergic rhinitis and to generate questions. Each prioritised guideline question is assessed through an Evidence-to-Decision (EtD) framework. EtDs support the systematic and transparent formulation of recommendations, comprising 12 criteria for which the best available evidence should be sought. In the context of ARIA-EAACI 2024-2025, such evidence is derived not only from randomised controlled trials but also-among others-from patient-generated data sources that better reflect the affected individuals&apos; perspectives. Moreover, ARIA-EAACI 2024-2025 incorporates evidence on planetary health. Developed guideline recommendations will support the creation of digitalised decision algorithms and care pathways. This paper describes the methodology used to develop the person-centred, digitally enabled and AI-assisted ARIA-EAACI 2024-2025. Among others, it describes (i) the development and prioritisation of guideline questions, (ii) sources of evidence for EtDs and (iii) the development of digitalised decision algorithms and care pathways.</style></abstract><notes><style face="normal" font="default" size="100%">Bousquet, Jean&#xD;Sousa-Pinto, Bernardo&#xD;Vieira, Rafael Jose&#xD;Schunemann, Holger J&#xD;Zuberbier, Torsten&#xD;Bognanni, Antonio&#xD;Togias, Alkis&#xD;Samolinski, Boleslaw&#xD;Valiulis, Arunas&#xD;Williams, Sian&#xD;Bedbrook, Anna&#xD;Czarlewski, Wienczyslawa&#xD;Torres, Maria Jose&#xD;Shamji, Mohamed H&#xD;Morais-Almeida, Mario&#xD;Canonica, G Walter&#xD;Vecillas, Leticia de Las&#xD;Dykewicz, Mark S&#xD;Jacomelli, Cristina&#xD;Klimek, Ludger&#xD;Leemann, Lucas&#xD;Lourenco, Olga&#xD;Palamarchuk, Yuliia&#xD;Papadopoulos, Nikolaos G&#xD;Pereira, Ana Margarida&#xD;Savoure, Marine&#xD;Toppila-Salmi, Sanna K&#xD;Ventura, Maria Teresa&#xD;Yepes-Nunez, Juan Jose&#xD;Cruz, Alvaro A&#xD;Ciprandi, Giorgio&#xD;Gemicioglu, Bilun&#xD;Giovannini, Mattia&#xD;Gradauskiene, Brigita&#xD;Jartti, Tuomas&#xD;Jesenak, Milos&#xD;Kuna, Piotr&#xD;Kvedariene, Violeta&#xD;Larenas-Linnemann, Desiree E&#xD;Latiff, Amir H A&#xD;Mohammad, Yousser&#xD;Ohta, Ken&#xD;Mahesh, Padukudru A&#xD;Pali-Scholl, Isabella&#xD;Pfaar, Oliver&#xD;Regateiro, Frederico S&#xD;Roche, Nicolas&#xD;Sofiev, Mikhail&#xD;Taborda-Barata, Luis&#xD;Ulrik, Charlotte Suppli&#xD;Rostan, Marylin Valentin&#xD;Viegi, Giovanni&#xD;Zhang, Luo&#xD;Anto, Josep M&#xD;Haahtela, Tari&#xD;Cherrez-Ojeda, Ivan&#xD;Ivancevich, Juan Carlos&#xD;Khaltaev, Nikolai&#xD;Yorgancioglu, Arzu&#xD;Abdullah, Baharudin&#xD;Al-Ahmad, Mona&#xD;Al-Nesf, Maryam Ali&#xD;Amaral, Rita&#xD;Asllani, Julijana&#xD;Bergmann, Karl-C&#xD;Bernstein, Jonathan A&#xD;Blaiss, Michael S&#xD;Braido, Fulvio&#xD;Camargos, Paulo&#xD;Carreiro-Martins, Pedro&#xD;Casale, Thomas&#xD;Cecchi, Lorenzo&#xD;Fiocchi, Alessandro G&#xD;Giuliano, Antonio F M&#xD;Christoff, George&#xD;Cirule, Ieva&#xD;Correia-de-Sousa, Jaime&#xD;Costa, Elisio M&#xD;Del Giacco, Stefano&#xD;Devillier, Philippe&#xD;Dokic, Dejan&#xD;Hossny, Elham&#xD;Iinuma, Tomohisa&#xD;Irani, Carla&#xD;Ispayeva, Zhanat&#xD;Julge, Kaja&#xD;Kaidashev, Igor&#xD;Bennoor, Kazi S&#xD;Kraxner, Helga&#xD;Kull, Inger&#xD;Kulus, Marek&#xD;Kupczyk, Maciej&#xD;Kurchenko, Andriy&#xD;La Grutta, Stefania&#xD;Miculinic, Neven&#xD;Tuyet, Lan Le Thi&#xD;Makris, Michael&#xD;Milenkovic, Branislava&#xD;Lee, Sang Min&#xD;Montefort, Stephen&#xD;Moreira, Andre&#xD;Mullol, Joaquim&#xD;Nadif, Rachel&#xD;Nakonechna, Alla&#xD;Neffen, Hugo E&#xD;Niedoszytko, Marek&#xD;Nyembue, Dieudonne&#xD;O&apos;Hehir, Robyn&#xD;Ogulur, Ismail&#xD;Okamoto, Yoshitaka&#xD;Olze, Heidi&#xD;Palomares, Oscar&#xD;Panzner, Petr&#xD;Patella, Vincenzo&#xD;Pawankar, Ruby&#xD;Pitsios, Constantinos&#xD;Popov, Todor A&#xD;Puggioni, Francesca&#xD;Quirce, Santiago&#xD;Ramonaite, Agne&#xD;Recto, Marysia&#xD;Repka-Ramirez, Maria Susana&#xD;Roberts, Graham&#xD;Robles-Velasco, Karla&#xD;Rottem, Menachem&#xD;Salapatas, Marianella&#xD;Sastre, Joaquin&#xD;Scichilone, Nicola&#xD;Sisul, Juan Carlos&#xD;Sole, Dirceu&#xD;Soto-Martinez, Manuel E&#xD;Sova, Milan&#xD;Tantilipikorn, Pongsakorn&#xD;Todo-Bom, Ana&#xD;Tsaryk, Vladyslav&#xD;Tsiligianni, Ioanna&#xD;Urrutia-Pereira, Marilyn&#xD;Valovirta, Erkka&#xD;Van Ganse, Eric&#xD;Vasankari, Tuula&#xD;Wallace, Dana&#xD;Wang, De Yun&#xD;Worm, Margitta&#xD;Yusuf, Osman M&#xD;Zidarn, Mihaela&#xD;Gil-Mata, Sara&#xD;Marques-Cruz, Manuel&#xD;Mahboub, Bassam&#xD;Ansotegui, Ignacio J&#xD;Romano, Antonino&#xD;Artesani, Maria Cristina&#xD;Barreto, Bruno&#xD;Becker, Sven&#xD;Beghe, Bianca&#xD;Bouchard, Jacques&#xD;Bourgoin-Heck, Melisande&#xD;Brussino, Luisa&#xD;Buhl, Roland&#xD;Calvo-Gil, Mario&#xD;Dahl, Victoria Cardona&#xD;Vizuete, Jose Antonio Castillo&#xD;Charpin, Denis&#xD;Chavannes, Niels H&#xD;Chelminska, Marta&#xD;Cheng, Lei&#xD;Chkhartishvili, Ekaterine&#xD;Chong-Neto, Herberto Jose&#xD;Choudhury, Deepa&#xD;Chu, Derek&#xD;Cingi, Cemal&#xD;Compalati, Enrico&#xD;Cvetkovski, Biljana&#xD;Da Silva, Jane&#xD;D&apos;Amato, Gennaro&#xD;Davies, Janet&#xD;Di Bona, Danilo&#xD;Dimou, Maria V&#xD;Teixeira, Maria Do Ceu&#xD;Doulaptsi, Maria&#xD;Perez, Jose Miguel Fuentes&#xD;Gawlik, Radoslaw&#xD;Goksel, Ozlem&#xD;Gomez, Maximiliano R&#xD;Gonzalez Diaz, Sandra N&#xD;Gotua, Maia&#xD;Grigoreas, Christos&#xD;Grisle, Ineta&#xD;Guzman, Maria Antonieta&#xD;Tan, Rachel House&#xD;Hyland, Michael&#xD;Ierodiakonou, Despo&#xD;Karavelia, Aspasia&#xD;Kisiel, Marta&#xD;Kosnik, Mitja&#xD;Kritikos, Vicky&#xD;Lombardi, Carlo&#xD;Martini, Matteo&#xD;Meco, Cem&#xD;Mesonjesi, Eris&#xD;Mihaltan, Florin&#xD;Moniuszko, Marcin&#xD;Naclerio, Robert&#xD;Neisinger, Sophia&#xD;Ordak, Michal&#xD;Paoletti, Giovanni&#xD;Perdomo-Flores, Edgar Arturo&#xD;Pham-Thi, Nhan&#xD;Prokopakis, Emmanuel&#xD;Yeverino, Daniela Rivero&#xD;Rolla, Giovanni&#xD;Romantowski, Jan&#xD;Rouadi, Philip W&#xD;Rukhadze, Maia&#xD;Sakurai, Daiju&#xD;Salameh, Laila&#xD;Sarquis, Faradiba Serpa&#xD;Kosak, Tanja Soklic&#xD;Soyka, Michael&#xD;Sozinova, Olga&#xD;Specjalski, Krzysztof&#xD;Tomic-Spiric, Vesna&#xD;Vachova, Martina&#xD;van Hage, Marianne&#xD;Koyuncu, Ilgim Vardaloglu&#xD;Vichyanond, Pakit&#xD;Wagenmann, Martin&#xD;Ko, Fanny Wai San&#xD;Werminghaus, Pascal&#xD;Xepapadaki, Vicky Paraskevi&#xD;Xiang, Yi-Kui&#xD;Fonseca, Joao A&#xD;eng&#xD;001/WHO_/World Health Organization/International&#xD;CINTESIS@RISE, Porto, Portugal/&#xD;ARIA (Allergic Rhinitis and its Impact on Asthma), Montpellier, France/&#xD;Fraunhofer-Institut fur Translationale Medizin und Pharmakologie/&#xD;Denmark&#xD;Allergy. 2025 Nov 21. doi: 10.1111/all.70100.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41268627</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70100</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>526</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">526</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kilanowski, A.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Everson, T.</style></author><author><style face="normal" font="default" size="100%">Thiering, E.</style></author><author><style face="normal" font="default" size="100%">Wilson, R.</style></author><author><style face="normal" font="default" size="100%">Gladish, N.</style></author><author><style face="normal" font="default" size="100%">Waldenberger, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Celedon, J. C.</style></author><author><style face="normal" font="default" size="100%">Burchard, E. G.</style></author><author><style face="normal" font="default" size="100%">Peters, A.</style></author><author><style face="normal" font="default" size="100%">Standl, M.</style></author><author><style face="normal" font="default" size="100%">Huls, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.&#xD;Institute for Medical Information Processing, Biometry, and Epidemiology; Pettenkofer School of Public Health, LMU Munich, Munich, Germany.&#xD;Institute of Epidemiology, Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children&apos;s Hospital, University of Munich Medical Center, Munich, Germany.&#xD;Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.&#xD;Research Unit Molecular Epidemiology, Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg, Germany.&#xD;Centre for Molecular Medicine and Therapeutics, British Columbia Children&apos;s Hospital, Vancouver, BC, Canada.&#xD;Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.&#xD;Division of Epidemiology, Biostatistics, and Environmental Health Sciences, School of Public Health, University of Memphis, Memphis, Tennessee, USA.&#xD;Division of Pediatric Pulmonary Medicine, UPMC Children&apos;s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.&#xD;UCSF Asthma Collaboratory, University of California, San Francisco, California, USA.&#xD;Chair of Epidemiology, Ludwig-Maximilians University, Munich, Germany.&#xD;German Center for Lung Research (DZL), Giessen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Methylation risk scores for childhood aeroallergen sensitization: Results from the LISA birth cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2803-2817</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/04/20</style></edition><section><style face="normal" font="default" size="100%">2803</style></section><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Birth Cohort</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">methylation risk scores</style></keyword><keyword><style face="normal" font="default" size="100%">polygenic risk scores</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmavite, GSK, and Merck in order to provide medications free of cost to</style></keyword><keyword><style face="normal" font="default" size="100%">participants in NIH-funded studies, unrelated to the current work. All other</style></keyword><keyword><style face="normal" font="default" size="100%">authors have no further conflicts of interest to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35437756</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Epigenomic (e.g., DNA methylation [DNAm]) changes have been hypothesized as intermediate step linking environmental exposures with allergic disease. Associations between individual DNAm at CpGs and allergic diseases have been reported, but their joint predictive capability is unknown. METHODS: Data were obtained from 240 children of the German LISA cohort. DNAm was measured in blood clots at 6 (N = 234) and 10 years (N = 227) using the Illumina EPIC chip. Presence of aeroallergen sensitization was measured in blood at 6, 10, and 15 years. We calculated six methylation risk scores (MRS) for allergy-related phenotypes, like total and specific IgE, asthma, or any allergies, based on available publications and assessed their performances both cross-sectionally (biomarker) and prospectively (predictor of the disease). Dose-response associations between aeroallergen sensitization and MRS were evaluated. RESULTS: All six allergy-related MRS were highly correlated (r &gt; .86), and seven CpGs were included in more than one MRS. Cross-sectionally, we observed an 81% increased risk for aeroallergen sensitization at 6 years with an increased MRS by one standard deviation (best-performing MRS, 95% confidence interval = [43%; 227%]). Significant associations were also seen cross-sectionally at 10 years and prospectively, though the effect of the latter was attenuated when restricted to participants not sensitized at baseline. A clear dose-response relationship with levels of aeroallergen sensitization could be established cross-sectionally, but not prospectively. CONCLUSION: We found good classification and prediction capabilities of calculated allergy-related MRS cross-sectionally, underlining the relevance of altered gene-regulation in allergic diseases and providing insights into potential DNAm biomarkers of aeroallergen sensitization.</style></abstract><notes><style face="normal" font="default" size="100%">Kilanowski, Anna&#xD;Chen, Junyu&#xD;Everson, Todd&#xD;Thiering, Elisabeth&#xD;Wilson, Rory&#xD;Gladish, Nicole&#xD;Waldenberger, Melanie&#xD;Zhang, Hongmei&#xD;Celedon, Juan C&#xD;Burchard, Esteban G&#xD;Peters, Annette&#xD;Standl, Marie&#xD;Huls, Anke&#xD;eng&#xD;AI/NIAID NIH HHS/&#xD;ES/NIEHS NIH HHS/&#xD;ERC_/European Research Council/International&#xD;R01 AI121226/AI/NIAID NIH HHS/&#xD;P30 ES019776/ES/NIEHS NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2803-2817. doi: 10.1111/all.15315. Epub 2022 May 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35437756</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9437118</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15315</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2791</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2791</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Oishi, K.</style></author><author><style face="normal" font="default" size="100%">Nakano, N.</style></author><author><style face="normal" font="default" size="100%">Ota, M.</style></author><author><style face="normal" font="default" size="100%">Inage, E.</style></author><author><style face="normal" font="default" size="100%">Izawa, K.</style></author><author><style face="normal" font="default" size="100%">Kaitani, A.</style></author><author><style face="normal" font="default" size="100%">Ando, T.</style></author><author><style face="normal" font="default" size="100%">Hara, M.</style></author><author><style face="normal" font="default" size="100%">Ohtsuka, Y.</style></author><author><style face="normal" font="default" size="100%">Nishiyama, C.</style></author><author><style face="normal" font="default" size="100%">Ogawa, H.</style></author><author><style face="normal" font="default" size="100%">Kitaura, J.</style></author><author><style face="normal" font="default" size="100%">Okumura, K.</style></author><author><style face="normal" font="default" size="100%">Shimizu, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Department of Biological Science and Technology, Faculty of Advanced Engineering, Tokyo University of Science, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">MHC Class II-Expressing Mucosal Mast Cells Promote Intestinal Mast Cell Hyperplasia in a Mouse Model of Food Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2297-2309</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/01/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology/pathology/metabolism/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperplasia</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Intestinal Mucosa/pathology/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Histocompatibility Antigens Class II/metabolism/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">CD4-Positive T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Il-9</style></keyword><keyword><style face="normal" font="default" size="100%">MHC class II</style></keyword><keyword><style face="normal" font="default" size="100%">antigen presentation</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal mast cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39868907</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IgE-mediated food allergy is accompanied by mucosal mast cell (MMC) hyperplasia in the intestinal mucosa. Intestinal MMC numbers correlate with the severity of food allergy symptoms. However, the mechanisms by which MMCs proliferate excessively are poorly understood. Here, we clarify the role of newly identified MHC class II (MHCII)-expressing MMCs in the effector phase of IgE-mediated food allergy. METHODS: Mice reconstituted with MHCII-deficient or wild-type MMCs were used to generate a mouse mode of IgE-mediated food allergy. We assessed the extent of intestinal MMC hyperplasia and the severity of hypothermia in these mice. In addition, we performed in vitro antigen presentation assay using induced MHCII-expressing MMCs generated from bone marrow cells to evaluate the effect of CD4(+) T cell activation on MMC proliferation. RESULTS: In food-allergic mice, we identified the appearance of MHCII-expressing MMCs in the intestinal mucosa and showed that MMC hyperplasia was suppressed in mice with MHCII-deficient MMCs compared to mice with wild-type MMCs. In vitro assays demonstrated that MHCII-expressing MMCs incorporate food antigens directly and through the high-affinity IgE receptor FcepsilonRI-mediated endocytosis and activate antigen-specific CD4(+) T cells from food-allergic mice by antigen presentation. Activated CD4(+) T cells secrete IL-4 and large amounts of IL-5, which enhance production of the mast cell growth factor IL-9 by IL-33-activated MMCs. Excess IL-9 causes excessive MMC proliferation, leading to the development of MMC hyperplasia. CONCLUSION: Antigen presentation to CD4(+) T cells by MHCII-expressing MMCs triggers intestinal MMC hyperplasia and exacerbates IgE-mediated food allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Oishi, Kenji&#xD;Nakano, Nobuhiro&#xD;Ota, Masamu&#xD;Inage, Eisuke&#xD;Izawa, Kumi&#xD;Kaitani, Ayako&#xD;Ando, Tomoaki&#xD;Hara, Mutsuko&#xD;Ohtsuka, Yoshikazu&#xD;Nishiyama, Chiharu&#xD;Ogawa, Hideoki&#xD;Kitaura, Jiro&#xD;Okumura, Ko&#xD;Shimizu, Toshiaki&#xD;eng&#xD;JP22K08550/Japan Society for the Promotion of Science/&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2297-2309. doi: 10.1111/all.16477. Epub 2025 Jan 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39868907</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16477</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2730</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2730</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scala, E.</style></author><author><style face="normal" font="default" size="100%">Madonna, S.</style></author><author><style face="normal" font="default" size="100%">Abeni, D.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Cocuroccia, B.</style></author><author><style face="normal" font="default" size="100%">Dattolo, A.</style></author><author><style face="normal" font="default" size="100%">Moretta, G.</style></author><author><style face="normal" font="default" size="100%">Provini, A.</style></author><author><style face="normal" font="default" size="100%">Russo, F.</style></author><author><style face="normal" font="default" size="100%">Sordi, D.</style></author><author><style face="normal" font="default" size="100%">Pallotta, S.</style></author><author><style face="normal" font="default" size="100%">Galluzzo, M.</style></author><author><style face="normal" font="default" size="100%">Talamonti, M.</style></author><author><style face="normal" font="default" size="100%">Villella, V.</style></author><author><style face="normal" font="default" size="100%">Giani, M.</style></author><author><style face="normal" font="default" size="100%">Caprini, E.</style></author><author><style face="normal" font="default" size="100%">Albanesi, C.</style></author><author><style face="normal" font="default" size="100%">Villalta, D.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fondazione Luigi Maria Monti, IDI-IRCCS, Rome, Italy.&#xD;SOSD Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Asl roma2, Ospedale Sandro Pertini, Rome, Italy.&#xD;Dermatology Unit, Fondazione Policlinico &quot;Tor Vergata&quot;, Rome, Italy.&#xD;Department of Systems Medicine, University of Rome &quot;Tor Vergata&quot;, Rome, Italy.&#xD;S.C. di Immunologia e Allergologia di Laboratorio, PO S. Maria degli Angeli, Pordenone, Italy.&#xD;Ambulatorio di Allergologia, Clinica San Carlo, Milan, Italy.&#xD;Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite-Universitatsmedizin Berlin, a corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Institute of Allergology, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3415-3429</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/11/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/immunology/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Molecular Mimicry</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">autoreactivity</style></keyword><keyword><style face="normal" font="default" size="100%">macroarray</style></keyword><keyword><style face="normal" font="default" size="100%">molecular mimicry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39495073</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The role of autoimmune IgE responses in atopic dermatitis (AD) is highly debated. While IgE targeting self-proteins has been extensively studied, IgE responses induced by human-homologous exogenous molecular allergens (HEMAs) remains less understood. AIM: To investigate whether IgE antibody responses to HEMAs are associated with AD, its severity, and response to dupilumab. METHODS: We enrolled 3325 participants with a history of allergic diseases, including 577 (17.3%) diagnosed with AD. Serum IgE antibodies against 183 exogenous allergenic molecules were measured using the IgE microarray (Allergy Explorer-ALEX-2(R), MADX, Vienna). Based on international classification criteria, participants were stratified by AD severity and clinical phenotypes. For each patient, we developed an &apos;IgE molecular-mimicry index&apos; (IgE-MMI), calculated from IgE reactivity to a panel of five HEMA protein families: arginine kinase, enolase (ENO), cyclophilin (CYP), lipocalin, and MnSOD. Logistic regression was employed to assess the association between IgE to HEMAs or IgE-MMI and AD, its severity, and response to dupilumab. RESULTS: IgE sensitization to most HEMAs (32/48, 67%), but only to a small fraction of non-HEMAs (3/135, 2.2%), was significantly more common in patients with severe AD compared to other patient groups. The IgE-MMI was positive in 295/2748 (10.7%) of allergic patients without AD, and in 58/283 (20%), 52/134 (39%), and 86/160 (54%) of patients with remitting, moderate, or severe AD, respectively. It was strongly associated with specific phenotypes, such as flexural dermatitis (OR 8.4, 95% CI: 6.3-11.2), head and neck dermatitis (OR: 16.5, 95% CI: 7.4-37.2), and generalized eczema (OR: 8.6, 95% CI: 4.9-15.6). Poor response to dupilumab was associated with IgE antibodies to ENO (OR: 22.7, 95% CI: 1.7-302.9), but inversely associated with IgE antibodies to MnSOD (OR: 0.1, 95% CI: 0.02-0.8) and NPC-2 from dust mites (OR: 0.1, 95% CI: 0.01-0.9). CONCLUSION: IgE microarrays are useful for broadly assessing IgE to HEMAs in allergic patients. IgE reactivity to HEMAs and a positive IgE-MMI may serve as valuable biomarkers for severe AD, its clinical phenotypes, and the response to dupilumab.</style></abstract><notes><style face="normal" font="default" size="100%">Scala, Enrico&#xD;Madonna, Stefania&#xD;Abeni, Damiano&#xD;Cecchi, Lorenzo&#xD;Cocuroccia, Barbara&#xD;Dattolo, Anna&#xD;Moretta, Gaia&#xD;Provini, Alessia&#xD;Russo, Filomena&#xD;Sordi, Donatella&#xD;Pallotta, Sabatino&#xD;Galluzzo, Marco&#xD;Talamonti, Marina&#xD;Villella, Valeria&#xD;Giani, Mauro&#xD;Caprini, Elisabetta&#xD;Albanesi, Cristina&#xD;Villalta, Danilo&#xD;Asero, Riccardo&#xD;Matricardi, Paolo Maria&#xD;eng&#xD;Italian Ministry of Health/&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3415-3429. doi: 10.1111/all.16377. Epub 2024 Nov 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39495073</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16377</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3276</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3276</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dsouza, Nishelle</style></author><author><style face="normal" font="default" size="100%">Phanthong, Siratcha</style></author><author><style face="normal" font="default" size="100%">Huang, Huey-Jy</style></author><author><style face="normal" font="default" size="100%">Weber, Milena</style></author><author><style face="normal" font="default" size="100%">Sarzsinszky, Eszter</style></author><author><style face="normal" font="default" size="100%">Zieglmayer, Petra</style></author><author><style face="normal" font="default" size="100%">Pauli, Gabrielle</style></author><author><style face="normal" font="default" size="100%">Focke-Tejkl, Margarete</style></author><author><style face="normal" font="default" size="100%">Tulaev, Mikhail</style></author><author><style face="normal" font="default" size="100%">Todorovic, Nikolina</style></author><author><style face="normal" font="default" size="100%">Keller, Walter</style></author><author><style face="normal" font="default" size="100%">Schlederer, Thomas</style></author><author><style face="normal" font="default" size="100%">Caraballo, Luis</style></author><author><style face="normal" font="default" size="100%">Tungtrongchitr, Anchalee</style></author><author><style face="normal" font="default" size="100%">Valenta, Rudolf</style></author><author><style face="normal" font="default" size="100%">Tantilipikorn, Pongsakorn</style></author><author><style face="normal" font="default" size="100%">Vrtala, Susanne</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Microarrayed Allergen Molecules Distinguish IgE Sensitisation to Blomia tropicalis and Dermatophagoides pteronyssinus</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background House dust mites (HDMs) are the most important respiratory allergen sources. In temperate regions, the genus Dermatophagoides predominates, whereas in sub-tropical and tropical regions, the genus Blomia is also of high importance. There is only limited IgE cross-reactivity between Dermatophagoides and Blomia. Objective To produce a chip containing purified microarrayed Blomia tropicalis (Blo t) and Dermatophagoides pteronyssinus allergens (Der p) capable of identifying patients with a genuine Blo t or Der p IgE sensitisation, co-sensitisation and/or cross-sensitisation. Methods Chips containing seven purified Blo t and thirteen Der p allergens were generated by microarray technology and tested for IgE and IgG reactivity in HDM-sensitised patients from Blo t-endemic (group 1: n = 115) and Blo t-non-endemic (group 2: n = 33) regions. IgE cross-reactivity was analysed by IgE inhibition studies. Results IgE levels to Blo t 2, Blo t 5, Blo t 10, Blo t 12 and Blo t 21 were significantly higher in HDM-sensitised patients from Blo t-endemic as compared to patients from Blo t-non-endemic regions, whereas the opposite was observed for IgE to Der p 2 and Der p 21 in patients from Blo t-non-endemic regions. An algorithm based on IgE reactivity profiles and allergen-specific IgE levels capable of discriminating genuine sensitisation to Blo t and Der p or co-sensitisation was established. In HDM-sensitised patients from Blo t-endemic regions, each of the aforementioned sensitisation profiles was observed, whereas in HDM-sensitised patients from Blo t-non-endemic regions, only genuine sensitisations to Der p and co-sensitisations to Blo t and Der p were observed. Conclusion The algorithm based on microarrayed Blo t and Der p allergens for discrimination of Blo t and Der p sensitisation may support prescription of allergen-specific immunotherapy. At minimum, it will be helpful in understanding disease aetiology and for fine resolution mapping of allergic reactivities in HDM sensitisation.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70232</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70232</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1984</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1984</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bulanda, E.</style></author><author><style face="normal" font="default" size="100%">Wypych, T. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Host-Microbiota Interactions, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Microbes, antibodies, and breastfeeding as the trans-generational axis of microbiota maturation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2318-2320</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/03/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Breast Feeding</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">breastfeeding</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">secretory immunoglobulin A</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36928862</style></accession-num><notes><style face="normal" font="default" size="100%">Bulanda, Edyta&#xD;Wypych, Tomasz P&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2318-2320. doi: 10.1111/all.15713. Epub 2023 Mar 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36928862</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15713</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1314</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1314</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ottman, N.</style></author><author><style face="normal" font="default" size="100%">Barrientos-Somarribas, M.</style></author><author><style face="normal" font="default" size="100%">Fyhrquist, N.</style></author><author><style face="normal" font="default" size="100%">Alexander, H.</style></author><author><style face="normal" font="default" size="100%">Wisgrill, L.</style></author><author><style face="normal" font="default" size="100%">Olah, P.</style></author><author><style face="normal" font="default" size="100%">Tsoka, S.</style></author><author><style face="normal" font="default" size="100%">Greco, D.</style></author><author><style face="normal" font="default" size="100%">Levi-Schaffer, F.</style></author><author><style face="normal" font="default" size="100%">Soumelis, V.</style></author><author><style face="normal" font="default" size="100%">Schroder, J. M.</style></author><author><style face="normal" font="default" size="100%">Kere, J.</style></author><author><style face="normal" font="default" size="100%">Nestle, F. O.</style></author><author><style face="normal" font="default" size="100%">Barker, J.</style></author><author><style face="normal" font="default" size="100%">Ranki, A.</style></author><author><style face="normal" font="default" size="100%">Lauerma, A.</style></author><author><style face="normal" font="default" size="100%">Homey, B.</style></author><author><style face="normal" font="default" size="100%">Andersson, B.</style></author><author><style face="normal" font="default" size="100%">Alenius, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.&#xD;Human Microbiome Research Program, University of Helsinki, Helsinki, Finland.&#xD;St John&apos;s Institute of Dermatology, Guy&apos;s and St Thomas&apos; NHS Foundation Trust and King&apos;s College London, London, UK.&#xD;Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Medical University of Vienna, Vienna, Austria.&#xD;Department of Dermatology, University Hospital Duesseldorf, Duesseldorf, Germany.&#xD;Department of Dermatology, Venereology and Oncodermatology, University of Pecs, Pecs, Hungary.&#xD;Department of Informatics, Faculty of Natural and Mathematical Sciences, King&apos;s College London, London, UK.&#xD;Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.&#xD;Institute of Biomedical Technology, University of Tampere, Tampere, Finland.&#xD;Institute of Biotechnology, University of Helsinki, Helsinki, Finland.&#xD;Pharmacology Unit, School of Pharmacy, Faculty of Medicine, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel.&#xD;Institut Curie, Paris, France.&#xD;INSERM, Paris, France.&#xD;Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.&#xD;Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.&#xD;School of Basic and Medical Biosciences, King&apos;s College London, London, UK.&#xD;Cutaneous Medicine Unit, St. John&apos;s Institute of Dermatology and Biomedical Research Centre, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;St John&apos;s Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, Kings College London, London, UK.&#xD;Department of Dermatology, Allergology and Venereology, Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Microbial and transcriptional differences elucidate atopic dermatitis heterogeneity across skin sites</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1173-1187</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/10/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">study</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Barrientos-Somarribas has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Fyhrquist has nothing</style></keyword><keyword><style face="normal" font="default" size="100%">to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Alexander has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Wisgrill has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Olah has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Tsoka has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr</style></keyword><keyword><style face="normal" font="default" size="100%">Greco has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Levi-Schaffer has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr</style></keyword><keyword><style face="normal" font="default" size="100%">Soumelis has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Schroder has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Kere</style></keyword><keyword><style face="normal" font="default" size="100%">has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Nestle reports other from Sanofi, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Barker has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Ranki reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">EU FP7/2007-2013, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Lauerma reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Orion Corporation, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Homey reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">EU-MAARS, grants from EU-BIOMAP, grants from DFG-FOR2690-HO 2092/7-1, during the</style></keyword><keyword><style face="normal" font="default" size="100%">conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from Galderma, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AbbVie, personal fees from Janssen, personal fees from Sanofi/Regeneron, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Leo Pharmaceuticals, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr Andersson has</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">and Dr Alenius reports grants from BIOMAP IMI2 821511,</style></keyword><keyword><style face="normal" font="default" size="100%">during the conduct of the study.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33001460</style></accession-num><abstract><style face="normal" font="default" size="100%">It is well established that different sites in healthy human skin are colonized by distinct microbial communities due to different physiological conditions. However, few studies have explored microbial heterogeneity between skin sites in diseased skin, such as atopic dermatitis (AD) lesions. To address this issue, we carried out deep analysis of the microbiome and transcriptome in the skin of a large cohort of AD patients and healthy volunteers, comparing two physiologically different sites: upper back and posterior thigh. Microbiome samples and biopsies were obtained from both lesional and nonlesional skin to identify changes related to the disease process. Transcriptome analysis revealed distinct disease-related gene expression profiles depending on anatomical location, with keratinization dominating the transcriptomic signatures in posterior thigh, and lipid metabolism in the upper back. Moreover, we show that relative abundance of Staphylococcus aureus is associated with disease severity in the posterior thigh, but not in the upper back. Our results suggest that AD may select for similar microbes in different anatomical locations-an &quot;AD-like microbiome,&quot; but distinct microbial dynamics can still be observed when comparing posterior thigh to upper back. This study highlights the importance of considering the variability across skin sites when studying the development of skin inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Ottman, Noora&#xD;Barrientos-Somarribas, Mauricio&#xD;Fyhrquist, Nanna&#xD;Alexander, Helen&#xD;Wisgrill, Lukas&#xD;Olah, Peter&#xD;Tsoka, Sophia&#xD;Greco, Dario&#xD;Levi-Schaffer, Francesca&#xD;Soumelis, Vassili&#xD;Schroder, Jens M&#xD;Kere, Juha&#xD;Nestle, Frank O&#xD;Barker, Jonathan&#xD;Ranki, Annamari&#xD;Lauerma, Antti&#xD;Homey, Bernhard&#xD;Andersson, Bjorn&#xD;Alenius, Harri&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1173-1187. doi: 10.1111/all.14606. Epub 2020 Oct 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33001460</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246754</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14606</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3019</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3019</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Devotta, H.</style></author><author><style face="normal" font="default" size="100%">Lavelle, A.</style></author><author><style face="normal" font="default" size="100%">Korpela, K.</style></author><author><style face="normal" font="default" size="100%">Hurley, S.</style></author><author><style face="normal" font="default" size="100%">Shannon, E.</style></author><author><style face="normal" font="default" size="100%">Lunjani, N.</style></author><author><style face="normal" font="default" size="100%">Ambikan, A.</style></author><author><style face="normal" font="default" size="100%">Neogi, U.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Walter, J.</style></author><author><style face="normal" font="default" size="100%">Hourihane, J.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;School of Microbiology, University College Cork, Cork, Ireland.&#xD;Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland.&#xD;Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.&#xD;Department of Paediatrics, Cork University Hospital, University College Cork, Cork, Ireland.&#xD;University Hospital Limerick, Limerick, Ireland.&#xD;The Systems Virology Lab, Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, ANA Futura, Campus Flemingsberg, Stockholm, Sweden.&#xD;Section of Allergy &amp; Immunology, Department of Pediatrics, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Department of Medicine, University College Cork, Cork, Ireland.&#xD;Paediatrics and Child Health, Royal College of Surgeons in Ireland, Dublin, Ireland.&#xD;Children&apos;s Health Ireland, Dublin, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Microbial Sharing Between Siblings Supports Metabolic Functions Protective Against Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2934-2937</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">hygiene hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">and contributed to the speakers&apos; bureau for Reckitt, Nestle Nutrition Institute,</style></keyword><keyword><style face="normal" font="default" size="100%">Danone, and Abbott Nutrition. Liam O&apos;Mahony reports grants from Chiesi, Reckitt,</style></keyword><keyword><style face="normal" font="default" size="100%">and Fonterra, and participation in the speaker bureau for Nestle, Yakult,</style></keyword><keyword><style face="normal" font="default" size="100%">Reckitt, and Abbott. Jonathan Hourihane is a board member of the Clemens Von</style></keyword><keyword><style face="normal" font="default" size="100%">Pirquet Foundation and receives research funding and speaker fees from DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, as well as research funding from the City of Dublin Skin and Cancer</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital Charity and Kenvue. Ujjwal Neogi received travel support from Olink Ab,</style></keyword><keyword><style face="normal" font="default" size="100%">Sweden. The other authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40879391</style></accession-num><notes><style face="normal" font="default" size="100%">Devotta, Hannah&#xD;Lavelle, Aonghus&#xD;Korpela, Katri&#xD;Hurley, Sadhbh&#xD;Shannon, Emer&#xD;Lunjani, Nonhlanhla&#xD;Ambikan, Anoop&#xD;Neogi, Ujjwal&#xD;Venter, Carina&#xD;Walter, Jens&#xD;Hourihane, Jonathan&#xD;O&apos;Mahony, Liam&#xD;eng&#xD;Royal College of Surgeons in Ireland/&#xD;Temple Street Hospital Foundation/&#xD;Clemens Von Pirquet Foundation/&#xD;12/RC/2273_P2/Research Ireland/&#xD;21/FFP-A/10000/Research Ireland Frontiers for the Future Awards/&#xD;23/FFP-A/12076/Research Ireland Frontiers for the Future Awards/&#xD;SFI_/Science Foundation Ireland/Ireland&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2934-2937. doi: 10.1111/all.70033. Epub 2025 Aug 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40879391</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486347</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70033</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3088</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3088</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tontini, C.</style></author><author><style face="normal" font="default" size="100%">Bahri, R.</style></author><author><style face="normal" font="default" size="100%">Higham, A.</style></author><author><style face="normal" font="default" size="100%">Singh, D.</style></author><author><style face="normal" font="default" size="100%">Simpson, A.</style></author><author><style face="normal" font="default" size="100%">Bulfone-Paus, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester, UK.&#xD;Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.&#xD;Manchester University NHS Foundation Trust, Manchester, UK.&#xD;Medicines Evaluation Unit, Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Microenvironment-Driven Mast Cell Plasticity: Insights From Cytokine-Activated Gene Signatures in Skin and Respiratory Diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3077-3094</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/09/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Cell Plasticity/genetics/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">*Cellular Microenvironment/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Tract Diseases/immunology/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Ifn</style></keyword><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">Il-4</style></keyword><keyword><style face="normal" font="default" size="100%">TGFbeta</style></keyword><keyword><style face="normal" font="default" size="100%">artificial intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">machine learning</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">omics</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword><keyword><style face="normal" font="default" size="100%">meetings, honoraria for lecturing or attending advisory boards from the following</style></keyword><keyword><style face="normal" font="default" size="100%">companies: Adovate, Aerogen, Almirall, Apogee, Arrowhead, AstraZeneca, Bial,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Chiesi, Cipla, CONNECT Biopharm, Covis, CSL Behring, DevPro</style></keyword><keyword><style face="normal" font="default" size="100%">Biopharma LCC, Elpen, Empirico, EpiEndo, Genentech, Generate Biomedicines,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Glenmark, Kamada, Kinaset Therapeutics, Kymera, Menarini,</style></keyword><keyword><style face="normal" font="default" size="100%">MicroA, OM Pharma, Orion, Pieris Pharmaceuticals, Pulmatrix, Revolo, Roivant</style></keyword><keyword><style face="normal" font="default" size="100%">Sciences, Sanofi, Synairgen, Tetherex, Teva, Theravance Biopharma, Upstream, and</style></keyword><keyword><style face="normal" font="default" size="100%">Verona Pharma. All other authors have no conflicts of interest to disclose for</style></keyword><keyword><style face="normal" font="default" size="100%">the present manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40926620</style></accession-num><abstract><style face="normal" font="default" size="100%">Mast cells (MCs) rapidly adapt to the microenvironment due to the plethora of cytokine receptors expressed. Understanding microenvironment-primed immune responses is essential to elucidate the phenotypic/functional changes MCs undergo, and thus understand their contribution to diseases and predict the most effective therapeutic strategies. We exposed primary human MCs to cytokines mimicking a T1/pro-inflammatory (IFNgamma), T2/allergic (IL-4 + IL-13), alarmin-rich (IL-33) and pro-fibrotic/pro-tolerogenic (TGFbeta) microenvironment. We investigated MC surface receptor expression, activation, cytokine, histamine, and prostaglandin D2 release, and performed transcriptomics to define shared and unique genetic features. Using machine learning, we extracted minimal cytokine-activated signatures and performed gene set variation analysis (GSVA), single-cell clustering, and pseudotime analyses on tissue MCs from skin and respiratory diseases. MCs exposed in vitro to IFNgamma acquire an antigen-presenting phenotype (HLA-DR+), increase IgE-mediated responses and histamine release, while TGFbeta inhibits activation and boosts integrin alphavbeta3 expression. IL-33 primarily drives cytokine (GM-CSF, IL-5, IL-10, IL-13) and chemokine production (IL-8, MCP-1, MIP-1alpha) and facilitates mixed IgG-IgE responses. Among uniquely expressed genes, 245 were highly informative to discriminate cytokine-primed MCs. GSVA revealed MC IL-4 + IL-13 signatures enriched in atopic dermatitis and psoriasis, IFNgamma in COVID-19 infection and cystic fibrosis, IL-33 in COVID-19 and chronic obstructive pulmonary disease (COPD) and TGFbeta in pulmonary fibrosis (PF) and chronic rhinosinusitis. Furthermore, we detected positive IL-33/TGFbeta priming in eosinophil-high COPD. Minimal cytokine-activated signatures identified disease-cytokine-specific MC clusters and pseudotime trajectories, suggesting involvement of MCs in fibrosis (COPD/PF), T1/alarmin-driven inflammation (COVID-19) and mixed T1/T2 inflammatory responses (AD/psoriasis). In conclusion, in cytokine-driven settings, MCs are phenotypically and functionally diverse. Thus, unique MC signatures will help to identify cytokine-primed MCs and predict the efficacy of anti-cytokine treatment in MC-driven diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Tontini, Chiara&#xD;Bahri, Rajia&#xD;Higham, Andrew&#xD;Singh, Dave&#xD;Simpson, Angela&#xD;Bulfone-Paus, Silvia&#xD;eng&#xD;Medical Research Centre/&#xD;North West Lung Centre Charity/&#xD;UK Research and Innovation/&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3077-3094. doi: 10.1111/all.70052. Epub 2025 Sep 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40926620</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590347</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70052</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1957</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1957</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Zeng, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, D.</style></author><author><style face="normal" font="default" size="100%">Wen, Y.</style></author><author><style face="normal" font="default" size="100%">Fan, L.</style></author><author><style face="normal" font="default" size="100%">He, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Sun, W.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Tao, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Second Affiliated Hospital, The State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Allergy &amp; Clinical Immunology, Guangzhou Medical University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Microglia-neuron interactions promote chronic itch via the NLRP3-IL-1beta-GRPR axis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1570-1584</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/03/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammasomes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*NLR Family, Pyrin Domain-Containing 3 Protein/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Bombesin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-1beta/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Caspases</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">IL-1beta</style></keyword><keyword><style face="normal" font="default" size="100%">NLRP3 inflammasome</style></keyword><keyword><style face="normal" font="default" size="100%">chronic itch</style></keyword><keyword><style face="normal" font="default" size="100%">gastrin-releasing peptide receptor</style></keyword><keyword><style face="normal" font="default" size="100%">microglia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36876522</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Spinal astrocytes contribute to chronic itch via sensitization of itch-specific neurons expressing gastrin-releasing peptide receptor (GRPR). However, whether microglia-neuron interactions contribute to itch remains unclear. In this study, we aimed to explore how microglia interact with GRPR(+) neurons and promote chronic itch. METHODS: RNA sequencing, quantitative real-time PCR, western blot, immunohistochemistry, RNAscope ISH, pharmacologic and genetic approaches were performed to examine the roles of spinal NLRP3 (The NOD-like receptor family, pyrin-containing domain 3) inflammasome activation and IL-1beta-IL1R1 signaling in chronic itch. Grpr-eGFP and Grpr KO mice were used to investigate microglia-GRPR(+) neuron interactions. RESULTS: We observed NLRP3 inflammasome activation and IL-1beta production in spinal microglia under chronic itch conditions. Blockade of microglial activation and the NLRP3/caspase-1/IL-1beta axis attenuated chronic itch and neuronal activation. Type 1 IL-1 receptor (IL-1R1) was expressed in GRPR(+) neurons, which are essential for the development of chronic itch. Our studies also find that IL-1beta(+) microglia are localized in close proximity to GRPR(+) neurons. Consistently, intrathecal injection of IL1R1 antagonist or exogenous IL-1beta indicate that the IL-1beta-IL-1R1 signaling pathway enhanced the activation of GRPR(+) neurons. Furthermore, our results demonstrate that the microglial NLRP3/caspase-1/IL-1beta axis contributes to several different chronic itches triggered by small molecules and protein allergens from the environment and drugs. CONCLUSION: Our findings reveal a previously unknown mechanism in which microglia enhances the activation of GRPR(+) neurons through the NLRP3/caspase-1/IL-1beta/IL1R1 axis. These results will provide new insights into the pathophysiology of pruritus and novel therapeutic strategies for patients with chronic itch.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Xueting&#xD;Wang, Yanmei&#xD;Zeng, Yueling&#xD;Wang, De&#xD;Wen, Yuhuan&#xD;Fan, Limin&#xD;He, Ying&#xD;Zhang, Junyan&#xD;Sun, Weimin&#xD;Liu, Yongping&#xD;Tao, Ailin&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1570-1584. doi: 10.1111/all.15699. Epub 2023 Mar 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36876522</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15699</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1160</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1160</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Igarashi, A.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, K.</style></author><author><style face="normal" font="default" size="100%">Matsuda, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Department of Genome Medicine, National Research Institute for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">MicroRNA-29s suppressed both soluble ST2 release and IFNAR1 expression in human bronchial epithelial cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2264-2267</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Epithelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-1 Receptor-Like 1 Protein/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Interferon alpha-beta</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Ifnar1</style></keyword><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">bronchial epithelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">miR-29</style></keyword><keyword><style face="normal" font="default" size="100%">soluble ST2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33583067</style></accession-num><notes><style face="normal" font="default" size="100%">Igarashi, Arisa&#xD;Matsumoto, Kenji&#xD;Matsuda, Akio&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2264-2267. doi: 10.1111/all.14777. Epub 2021 Mar 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33583067</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14777</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1618</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1618</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Igarashi, A.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, K.</style></author><author><style face="normal" font="default" size="100%">Matsuda, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Department of Genome Medicine, National Research Institute for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">MicroRNA-29s suppressed both soluble ST2 release and IFNAR1 expression in human bronchial epithelial cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2264-2267</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Epithelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-1 Receptor-Like 1 Protein/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Interferon alpha-beta</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Ifnar1</style></keyword><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">bronchial epithelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">miR-29</style></keyword><keyword><style face="normal" font="default" size="100%">soluble ST2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33583067</style></accession-num><notes><style face="normal" font="default" size="100%">Igarashi, Arisa&#xD;Matsumoto, Kenji&#xD;Matsuda, Akio&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2264-2267. doi: 10.1111/all.14777. Epub 2021 Mar 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33583067</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14777</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>413</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">413</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Amoah, A. S.</style></author><author><style face="normal" font="default" size="100%">Prins, M.</style></author><author><style face="normal" font="default" size="100%">Bel, E. H. D.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Zwinderman, A. H.</style></author><author><style face="normal" font="default" size="100%">Yazdanbakhsh, M.</style></author><author><style face="normal" font="default" size="100%">Maitland-van der Zee, A. H.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Parasitology, Leiden University Medical Center, Leiden, the Netherlands.&#xD;Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.&#xD;Malawi Epidemiology and Intervention Research Unit, Chilumba, Malawi.&#xD;Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.&#xD;Department of Internal Medicine, Division of Infectious Diseases, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands.&#xD;Department of Respiratory Medicine, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands.&#xD;Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands.&#xD;Department of Experimental Immunology, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Migration and allergic diseases: Findings from a population-based study in adults in Amsterdam, the Netherlands</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3667-3670</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/07/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Netherlands/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immune System Diseases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35791844</style></accession-num><notes><style face="normal" font="default" size="100%">Amoah, Abena S&#xD;Prins, Maria&#xD;Bel, Elisabeth H D&#xD;Fokkens, Wytske J&#xD;Zwinderman, Aeilko H&#xD;Yazdanbakhsh, Maria&#xD;Maitland-van der Zee, Anke H&#xD;van Ree, Ronald&#xD;eng&#xD;200500003/ZONMW_/ZonMw/Netherlands&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3667-3670. doi: 10.1111/all.15427. Epub 2022 Jul 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35791844</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10084123 GlaxoSmithKline and Teva, and personal fees for consulting from GlaxoSmithKline, AstraZeneca, Sanofi, Roche and Teva. Professor Wytske J. Fokkens received consultation and/or speaker fees from Bioinspire, GSK, Novartis and Sanofi-Aventis/Regeneron. The department of Otorhinolaryngology of Amsterdam University Medical Centre (location AMC) received grants for research in Rhinology from ALK, Allergy Therapeutics, Chordate, Novartis, EU, GSK, MYLAN, Sanofi-Aventis and Zon-MW. Professor Anke H. Maitland-van der Zee is the principal investigator of a P4O2 (Precision Medicine for more Oxygen) public-private partnership sponsored by Health Holland involving many private partners that contribute in cash and/or in kind (Boehringer Ingelheim, Breathomix, Fluidda, Ortec Logiqcare, Philips, Quantib-U, Smartfish, SODAQ, Thirona, TopMD and Novartis). Furthermore, Professor Maitland-van der Zee has received unrestricted research grants from GSK, Boehringer Ingelheim and Vertex, and has had received consulting fees paid to her institution from Boehringer Ingelheim and AstraZeneca. She has also received honoraria for lectures paid to her institution from GlaxoSmithKline; outside the submitted work. Professor Ronald van Ree has consultancies with HAL Allergy BV, Citeq BV, Angany Inc., Reacta Healthcare Ltd., Mission MightyMe and AB Enzymes and has received speaker&apos;s fees from HAL Allergy BV, ThermoFisher Scientific, ALK, as well as stock options with Angany Inc.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15427</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2190</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cameron, S.</style></author><author><style face="normal" font="default" size="100%">Donnelly, A.</style></author><author><style face="normal" font="default" size="100%">Broderick, C.</style></author><author><style face="normal" font="default" size="100%">Arichi, T.</style></author><author><style face="normal" font="default" size="100%">Bartsch, U.</style></author><author><style face="normal" font="default" size="100%">Dazzan, P.</style></author><author><style face="normal" font="default" size="100%">Elberling, J.</style></author><author><style face="normal" font="default" size="100%">Godfrey, E.</style></author><author><style face="normal" font="default" size="100%">Gringras, P.</style></author><author><style face="normal" font="default" size="100%">Heathcote, L. C.</style></author><author><style face="normal" font="default" size="100%">Joseph, D.</style></author><author><style face="normal" font="default" size="100%">Wood, T. C.</style></author><author><style face="normal" font="default" size="100%">Pariante, C.</style></author><author><style face="normal" font="default" size="100%">Rubia, K.</style></author><author><style face="normal" font="default" size="100%">Flohr, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">St John&apos;s Institute of Dermatology, King&apos;s College London and Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK.&#xD;Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King&apos;s College London and Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK.&#xD;Surrey Sleep Research Centre, Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.&#xD;UK Dementia Research Institute, Care Research &amp; Technology Centre, Imperial College London and University of Surrey, Guildford, UK.&#xD;Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King&apos;s College London, London, UK.&#xD;Depart of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, Denmark.&#xD;Health Psychology Section, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King&apos;s College London, London, UK.&#xD;Paediatric Sleep Department, Evelina Children&apos;s Hospital, King&apos;s College London and Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK.&#xD;Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mind and skin: Exploring the links between inflammation, sleep disturbance and neurocognitive function in patients with atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">26-36</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/07/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Sleep Wake Disorders/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Sleep</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">quality-of-life</style></keyword><keyword><style face="normal" font="default" size="100%">sleep disruption</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37469218</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopic dermatitis (AD) is a chronic, pruritic and inflammatory, dry skin condition with many known comorbidities. These include airway disease, food allergies, atopic eye disease and autoimmune conditions. Furthermore, there is often significant sleep disturbance as well as increased psychological distress and mental health problems. Severe AD therefore often has a significant impact on the quality of life of both patients and their families. In this review we discuss recent findings on the putative links between AD, its association with itch, sleep disturbance and neuropsychiatric morbidity, including the role of inflammation in these conditions. Itch was thought to predominantly drive sleep disruption in AD. We now understand changes in sleep influence immune cell distribution and the associated inflammatory cytokines, which suggests a bidirectional relationship between AD and sleep. We also increasingly recognize inflammation as a key driver in psychological symptoms and disorders. The link between cutaneous, systemic and possible brain inflammation could at least in part be driven by the sleep deprivation and itch-driven neuronal proliferation seen in AD.</style></abstract><notes><style face="normal" font="default" size="100%">Cameron, Shona&#xD;Donnelly, Ali&#xD;Broderick, Conor&#xD;Arichi, Tomoki&#xD;Bartsch, Ullrich&#xD;Dazzan, Paola&#xD;Elberling, Jesper&#xD;Godfrey, Emma&#xD;Gringras, Paul&#xD;Heathcote, Lauren C&#xD;Joseph, Desaline&#xD;Wood, Tobias C&#xD;Pariante, Carmine&#xD;Rubia, Katya&#xD;Flohr, Carsten&#xD;eng&#xD;MR/X003078/1/MRC_/Medical Research Council/United Kingdom&#xD;MRF-176-0002-RG-FLOH-C0929/MRF_/MRF_/United Kingdom&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):26-36. doi: 10.1111/all.15818. Epub 2023 Jul 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37469218</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15818</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2973</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2973</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Blaiss, M. S.</style></author><author><style face="normal" font="default" size="100%">Becker, S.</style></author><author><style face="normal" font="default" size="100%">DuBuske, L.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Berger, U. E.</style></author><author><style face="normal" font="default" size="100%">Berger, M.</style></author><author><style face="normal" font="default" size="100%">Dramburg, S.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Graessel, A.</style></author><author><style face="normal" font="default" size="100%">Starchenka, S.</style></author><author><style face="normal" font="default" size="100%">Birkholz, K.</style></author><author><style face="normal" font="default" size="100%">Armfield, O.</style></author><author><style face="normal" font="default" size="100%">Sellwood, F.</style></author><author><style face="normal" font="default" size="100%">Kramer, M. F.</style></author><author><style face="normal" font="default" size="100%">Skinner, M. A.</style></author><author><style face="normal" font="default" size="100%">de Kam, P. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;IMSB, Medical Faculty University at Cologne, Cologne, Germany.&#xD;ClinCompetence Cologne GmbH, Cologne, Germany.&#xD;Division of Allergy and Immunology, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center of Eberhard-Karls University Tuebingen, Tuebingen, Germany.&#xD;George Washington University Hospital, Washington, District of Columbia, USA.&#xD;Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Allergy and Immunology and Bernstein Clinical Research Center, Cincinnati, Ohio, USA.&#xD;Department of Botany, University of Innsbruck, Innsbruck, Austria.&#xD;Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Klinik Landstrasse, Wiener Gesundheitsverbund, Vienna, Austria.&#xD;Allergy Centre Vienna West, Vienna, Austria.&#xD;Sigmund Freud Private University Vienna, Vienna, Austria.&#xD;Department of Pediatric Respiratory Care, Immunology and Intensive Care Medicine, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Bencard Allergie GmbH, Munich, Germany.&#xD;Allergy Therapeutics, Worthing, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence-Based Approach</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3369-3376</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/07/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Minimal Clinically Important Difference</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Poaceae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Eaaci csms0-6</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">grass pollen allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pivotal phase III clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">institution from Allergy Therapeutics, UK</style></keyword><keyword><style face="normal" font="default" size="100%">and he reports grants and/or personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees and/or travel support from AEDA, Alfried Krupp Krankenhaus, ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, Almirall, Altamira Therapeutics, ASIT Biotech, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard Allergie GmbH/Allergy Therapeutics, Blueprint, Cliantha, Deutsche</style></keyword><keyword><style face="normal" font="default" size="100%">AllergieLiga e.V., Deutsche Forschungsgemeinschaft, Dustri-Verlag, ECM</style></keyword><keyword><style face="normal" font="default" size="100%">Expro&amp;Conference Management GmBH, Forum fur Medizinische Fortbildung,</style></keyword><keyword><style face="normal" font="default" size="100%">Georg-Thieme-Verlag, GSK, HAL Allergy Holding B.V./HAL Allergie GmbH, Inmunotek,</style></keyword><keyword><style face="normal" font="default" size="100%">Ingress Health, Institut fur Disease Management, IQVIA Commercial, Japanese</style></keyword><keyword><style face="normal" font="default" size="100%">Society of Allergology, Koniglich Danisches Generalkonsulat, Laboratorios</style></keyword><keyword><style face="normal" font="default" size="100%">LETI/LETI Pharma, Lilly, Lofarma, Medizinische Hochschule Hannover, med update</style></keyword><keyword><style face="normal" font="default" size="100%">europe GmbH, Meinhardt Congress GmbH, Novartis, Paul-Ehrlich-Institut,</style></keyword><keyword><style face="normal" font="default" size="100%">Paul-Martini-Stiftung, PneumoLive, Pohl-Boskamp, Procter &amp; Gamble, Red Maple</style></keyword><keyword><style face="normal" font="default" size="100%">Trials Inc., RG Aerztefortbildung, ROXALL Medizin, Sanofi Aventis, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">Genzyme, Springer Publisher, Stallergenes Greer, streamedup! GmbH, Technical</style></keyword><keyword><style face="normal" font="default" size="100%">University Dresden, Wiley Publishers, Wort &amp; Bild Verlag, Verlag ME</style></keyword><keyword><style face="normal" font="default" size="100%">outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work, Oliver Pfaar is Vice President of the European Academy of Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">and Clinical Immunology (EAACI), a member of EAACI Excom as well as a member of</style></keyword><keyword><style face="normal" font="default" size="100%">the external board of directors of the German Society of Allergy and Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Immunology (DGAKI)</style></keyword><keyword><style face="normal" font="default" size="100%">coordinator, main- or co-author of different position papers</style></keyword><keyword><style face="normal" font="default" size="100%">and guidelines in rhinology, allergology and allergen-immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">and he is</style></keyword><keyword><style face="normal" font="default" size="100%">Editor-in-Chief of Clinical Translational Allergy and Associate Editor of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy. R.M. reports grants and personal fees from Allergy Therapeutics Ltd.,</style></keyword><keyword><style face="normal" font="default" size="100%">during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from ALK, grants from ASIT</style></keyword><keyword><style face="normal" font="default" size="100%">Biotech, personal fees from Allergopharma, grants and personal fees from Bencard,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Leti, grants, personal fees and nonfinancial support from Lofarma,</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from Roxall, grants and personal fees from Stallergenes,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Optima, personal fees from Friulchem, personal fees from Hexal,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Servier, personal fees from Klosterfrau, non-financial support</style></keyword><keyword><style face="normal" font="default" size="100%">from Atmos, personal fees from Bayer, non-financial support from Bionorica,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from FAES, personal fees from GSK, personal fees from MSD, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Johnson &amp; Johnson, personal fees from Meda, personal fees and</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from Novartis, non-financial support from Otonomy, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Stada, personal fees from UCB, non-financial support from Ferrero,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Hulka, personal fees from Nuvo, grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Ursapharm, personal fees from Menarini, personal fees from Mundipharma, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Pohl-Boskamp, grants from Inmunotek, grants from Cassella-med GmbH &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Co. KG, personal fees from Laboratoire de la Mer, personal fees from Sidroga,</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from HAL BV, personal fees from Lek, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">PRO-AdWise, personal fees from Angelini Pharma, grants and non-financial support</style></keyword><keyword><style face="normal" font="default" size="100%">from JGL, grants and personal fees from Bitop, grants from Sanofi, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Probelte Pharma, grants from Diater, personal fees from Worg</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, outside the submitted work. M. S. Blaiss reports personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Sanofi, personal fees from Regeneron, personal fees from ALK, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Merck, personal fees from AstraZeneca, personal fees from GSK, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Prollergy, personal fees from Lanier Biotherapeutics, and nonfinancial</style></keyword><keyword><style face="normal" font="default" size="100%">support from Bryn Pharma, outside the submitted work. S.B. reports about grants</style></keyword><keyword><style face="normal" font="default" size="100%">and/or personal fees as an advisor and for lectures from Bencard Allergie, Brain,</style></keyword><keyword><style face="normal" font="default" size="100%">Karl Storz, Altamira, Allergy Therapeutics, HAL Allergy, Allergopharma, ALK</style></keyword><keyword><style face="normal" font="default" size="100%">Abello, Sanofi, Novartis, GSK, Astra Zeneca, MSD, Viatris, Ambu, Stryker, and the</style></keyword><keyword><style face="normal" font="default" size="100%">Federal Ministry of Education and Research. L.D. acts as a consultant for Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics and a consultant and/or Speakers Bureau for GSK, Sanofi, Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">Astra Zeneca, ALK-Abello, Amgen, Bryn Pharma, and Areteia. J.A.B. is acting as a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant and PI for Allergy Therapeutics, Stallergens, ALK, Eli Lilly,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Genentech, Sanofi Regeneron, A.Z., G.S.K., and Amgen. U.E.B. and M.B.</style></keyword><keyword><style face="normal" font="default" size="100%">report grants and/or personal fees and/or travel support from AZ Pollen Research</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, outside the submitted work. SD received consultancy fees from Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics and OMRON Healthcare Technologies</style></keyword><keyword><style face="normal" font="default" size="100%">received honoraria for Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Allergopharma, OMRON Healthcare Technologies, DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, Stallergenes and Siemens Healthineers</style></keyword><keyword><style face="normal" font="default" size="100%">is part of a DSMB of a study</style></keyword><keyword><style face="normal" font="default" size="100%">funded by Allergy Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">is Secretary of the EAACI Interest Group Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis and Advisory Board Member of AeDA</style></keyword><keyword><style face="normal" font="default" size="100%">received equipment by Thermo Fisher</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. M.H.S. reports research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance Network, Medical Research Council, Allergy Therapeutics, LETI</style></keyword><keyword><style face="normal" font="default" size="100%">Laboratorios, Rovolo Biotherapeutics and lecture fees from Allergy Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">and Leti Laboratorios, all outside the submitted work. AG, SS, K.B., O.A., F.S.,</style></keyword><keyword><style face="normal" font="default" size="100%">M.F.K., M.A.S., and P-J.d.K. are employees of Allergy Therapeutics (UK)</style></keyword><keyword><style face="normal" font="default" size="100%">Plc./Bencard Allergie, and P-J.dK., M.F.K., and M.S. are named inventors on</style></keyword><keyword><style face="normal" font="default" size="100%">patents related to PQ Grass.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40678893</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Regulatory authorities recommend a combination of symptom and medication scores during the grass pollen season as a primary endpoint for Phase III allergen immunotherapy (AIT) trials targeting allergic rhinoconjunctivitis. However, many composite primary endpoint scales exist; none are validated, nor do they have a well-justified minimal clinically important difference (MCID). METHODS: Direct patient feedback from 1071 grass-allergic patients was obtained to determine the minimally relevant improvement in allergic symptoms and translated into an MCID for the EAACI recommended CSMS(0-6). Additionally, a clinically relevant threshold for the validated Rhinitis Quality of Life Questionnaire (RQLQ(S)) was determined from studies of registered SLIT products and subsequently used as an anchor to derive the MCID for CSMS(0-6) using the data of a Phase III clinical trial with PQ Grass 27,600 SU (RESONATE). RESULTS: 69% of grass-allergic patients were satisfied with a 1-point-improvement (e.g., from &quot;severe&quot; to &quot;moderate&quot;) in their most severe symptom. This translated into an MCID range for CSMS(0-6) of -0.23 to -0.21 points or -17% to -16%. Furthermore, a -0.34 point difference in RQLQ(S) compared to placebo was justified as clinically meaningful based on Phase III data from 2 registered SLIT grass tablets. Using this RQLQ(S) threshold as an anchor, an MCID of CSMS(0-6) of -0.21 points (-16%) was derived using RESONATE. CONCLUSIONS: Both patient feedback and RESONATE results support an average MCID of -0.22 points on the CSMS(0-6) scale and -16% on a composite primary endpoint scale, providing minimal thresholds to be achieved after AIT compared to placebo to conclude a positive Phase III trial outcome.</style></abstract><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Mosges, Ralph&#xD;Blaiss, Michael S&#xD;Becker, Sven&#xD;DuBuske, Lawrence&#xD;Bernstein, Jonathan A&#xD;Berger, Uwe E&#xD;Berger, Markus&#xD;Dramburg, Stephanie&#xD;Shamji, Mohamed H&#xD;Graessel, Anke&#xD;Starchenka, Sviatlana&#xD;Birkholz, Katrin&#xD;Armfield, Oliver&#xD;Sellwood, Fiona&#xD;Kramer, Matthias F&#xD;Skinner, Murray A&#xD;de Kam, Pieter-Jan&#xD;eng&#xD;Allergy Therapeutics Plc./&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3369-3376. doi: 10.1111/all.16654. Epub 2025 Jul 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40678893</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666754</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16654</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3301</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3301</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hartenstein, Diana</style></author><author><style face="normal" font="default" size="100%">Schmidt, Sandra</style></author><author><style face="normal" font="default" size="100%">Mahler, Vera</style></author><author><style face="normal" font="default" size="100%">Kaul, Susanne</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Minimal Clinically Important Difference in Allergen Immunotherapy: The Rocky Road Toward an Evidence-Based Value</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70310</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70310</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1646</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1646</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boutin, R. C. T.</style></author><author><style face="normal" font="default" size="100%">Sbihi, H.</style></author><author><style face="normal" font="default" size="100%">Dsouza, M.</style></author><author><style face="normal" font="default" size="100%">Malhotra, R.</style></author><author><style face="normal" font="default" size="100%">Petersen, C.</style></author><author><style face="normal" font="default" size="100%">Dai, D.</style></author><author><style face="normal" font="default" size="100%">Sears, M. R.</style></author><author><style face="normal" font="default" size="100%">Moraes, T. J.</style></author><author><style face="normal" font="default" size="100%">Becker, A. B.</style></author><author><style face="normal" font="default" size="100%">Azad, M. B.</style></author><author><style face="normal" font="default" size="100%">Mandhane, P. J.</style></author><author><style face="normal" font="default" size="100%">Subbarao, P.</style></author><author><style face="normal" font="default" size="100%">Finlay, B. B.</style></author><author><style face="normal" font="default" size="100%">Turvey, S. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of British Columbia, Vancouver, BC, Canada.&#xD;Michael Smith Laboratories, Vancouver, BC, Canada.&#xD;British Columbia Children&apos;s Hospital, Vancouver, BC, Canada.&#xD;Commense Inc. Current affiliation Vedanta Biosciences Inc., Boston, MA, USA.&#xD;Commense Inc. Current affiliation GNS Healthcare Inc., Boston, MA, USA.&#xD;McMaster University, Hamilton, ON, Canada.&#xD;Hospital for Sick Children, Toronto, ON, Canada.&#xD;University of Manitoba, Winnipeg, MB, Canada.&#xD;University of Alberta, Edmonton, AB, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mining the infant gut microbiota for therapeutic targets against atopic disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2065-2068</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/02/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">food sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">live biotherapeutic product</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32086944</style></accession-num><notes><style face="normal" font="default" size="100%">Boutin, Rozlyn C T&#xD;Sbihi, Hind&#xD;Dsouza, Melissa&#xD;Malhotra, Raunaq&#xD;Petersen, Charisse&#xD;Dai, Darlene&#xD;Sears, Malcolm R&#xD;Moraes, Theo J&#xD;Becker, Allan B&#xD;Azad, Meghan B&#xD;Mandhane, Piush J&#xD;Subbarao, Padmaja&#xD;Finlay, B Brett&#xD;Turvey, Stuart E&#xD;eng&#xD;AEC-85761/CIHR/Canada&#xD;PJT-148484/CIHR/Canada&#xD;EC1-144621/CIHR/Canada&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Aug;75(8):2065-2068. doi: 10.1111/all.14244. Epub 2020 Mar 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32086944</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14244</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2596</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2596</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Zhao, X.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Lu, C.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Mou, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Li, B.</style></author><author><style face="normal" font="default" size="100%">Song, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.&#xD;Department of Clinical Medicine, Binzhou Medical University, Yantai, China.&#xD;Department of Genetics and Cell Biology, Basic medical school, Qingdao University, Qingdao, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">MiR-10b-5p alleviates Th2 inflammatory response by targeting SHP2 phosphatase in allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1517-1521</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/08/31</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39206511</style></accession-num><notes><style face="normal" font="default" size="100%">Li, Yumei&#xD;Zhao, Xiangkun&#xD;Liu, Zhen&#xD;Lu, Congxian&#xD;Wang, Yaqi&#xD;Liu, Jiahui&#xD;Mou, Yakui&#xD;Zhang, Yu&#xD;Li, Bing&#xD;Song, Xicheng&#xD;eng&#xD;2022YFC2504104/Key R&amp;D Project of Shandong Province/&#xD;82071021/National Natural Science Foundation of China/&#xD;82301281/National Natural Science Foundation of China/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1517-1521. doi: 10.1111/all.16293. Epub 2024 Aug 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39206511</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16293</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>719</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">719</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Guo, J.</style></author><author><style face="normal" font="default" size="100%">Cui, L.</style></author><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Mou, Y.</style></author><author><style face="normal" font="default" size="100%">Jia, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Song, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.&#xD;Department of Otolaryngology, Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">miR-146a enhances regulatory T-cell differentiation and function in allergic rhinitis by targeting STAT5b</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">550-558</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cell Differentiation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Forkhead Transcription Factors/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-10/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">STAT5 Transcription Factor/genetics/metabolism/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Transforming Growth Factor beta/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">STAT5b</style></keyword><keyword><style face="normal" font="default" size="100%">Treg cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">miR-146a</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34716993</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: MicroRNA (miR)-146a, as an important immune regulatory factor with an anti-inflammatory effect, plays a crucial role in regulatory T-cell (Tregs) differentiation and function in allergic rhinitis (AR). The present study aimed to investigate the regulatory mechanism employed by miR-146a to control Treg differentiation and function in AR. METHODS: Expression of miR-146a and STAT5b in peripheral blood mononuclear cells (PBMCs) and nasal mucosa from patients with AR was detected by qPCR and Western blotting. Tregs were quantified by flow cytometry in miR-146a knockdown or STAT5b knockdown PBMCs. FOXP3, IL-10, and TGF-beta levels were detected by Western blotting or ELISA in miR-146a knockdown or STAT5b overexpressing PBMCs, as well as in STAT5b knockdown PBMCs overexpressing miR-146a. The effect of miR-146a on STAT5b was observed by luciferase assay and knockdown experiments. RESULTS: Levels of miR146a and STAT5b in the nasal mucosa or PBMCs were significantly lower in the AR group than in the control group. There were significantly fewer Tregs in miR-146a knockdown or STAT5b knockdown PBMCs compared to control PBMCs. Expression of FOXP3, IL-10, and TGF-beta was decreased in the miR-146a knockdown group but increased in the STAT5b overexpression group. In contrast, miR-146a overexpression increased the levels of these factors, but knockdown of STAT5b significantly inhibited this effect. Luciferase assay and knockdown experiments showed that miR-146a bound directly to STAT5b. CONCLUSIONS: miR-146a enhances Treg differentiation and function in AR by positively targeting STAT5b.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Yu&#xD;Yang, Yujuan&#xD;Guo, Jing&#xD;Cui, Limei&#xD;Yang, Liping&#xD;Li, Yumei&#xD;Mou, Yakui&#xD;Jia, Chuanliang&#xD;Zhang, Luo&#xD;Song, Xicheng&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):550-558. doi: 10.1111/all.15163. Epub 2021 Nov 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34716993</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15163</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2590</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2590</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bartko, E. A.</style></author><author><style face="normal" font="default" size="100%">Mellergaard, M.</style></author><author><style face="normal" font="default" size="100%">Groen, S. S.</style></author><author><style face="normal" font="default" size="100%">Nielsen, S. H.</style></author><author><style face="normal" font="default" size="100%">Elberling, J.</style></author><author><style face="normal" font="default" size="100%">Handberg, A.</style></author><author><style face="normal" font="default" size="100%">Poulsen, L. K.</style></author><author><style face="normal" font="default" size="100%">Blom, L. H.</style></author><author><style face="normal" font="default" size="100%">Jensen, B. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Clinic, Department of Dermatology and Allergy, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark.&#xD;Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.&#xD;Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.&#xD;ImmunoScience, Nordic Bioscience, Herlev, Denmark.&#xD;Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2558-2561</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/07/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Matrix Metalloproteinase 9/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chemokines, CC/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38953463</style></accession-num><notes><style face="normal" font="default" size="100%">Bartko, Ewa A&#xD;Mellergaard, Maiken&#xD;Groen, Solveig S&#xD;Nielsen, Signe Holm&#xD;Elberling, Jesper&#xD;Handberg, Aase&#xD;Poulsen, Lars K&#xD;Blom, Lars H&#xD;Jensen, Bettina M&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2558-2561. doi: 10.1111/all.16212. Epub 2024 Jul 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38953463</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16212</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1377</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1377</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoang, J. A.</style></author><author><style face="normal" font="default" size="100%">Celik, A.</style></author><author><style face="normal" font="default" size="100%">Lupinek, C.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Duan, L.</style></author><author><style face="normal" font="default" size="100%">Dai, R.</style></author><author><style face="normal" font="default" size="100%">Brydges, M. G.</style></author><author><style face="normal" font="default" size="100%">Dubeau, A.</style></author><author><style face="normal" font="default" size="100%">Lepine, C.</style></author><author><style face="normal" font="default" size="100%">Wong, S.</style></author><author><style face="normal" font="default" size="100%">Alexanian-Farr, M.</style></author><author><style face="normal" font="default" size="100%">Magder, A.</style></author><author><style face="normal" font="default" size="100%">Subbarao, P.</style></author><author><style face="normal" font="default" size="100%">Upton, J. E. M.</style></author><author><style face="normal" font="default" size="100%">Schmidthaler, K.</style></author><author><style face="normal" font="default" size="100%">Szepfalusi, Z.</style></author><author><style face="normal" font="default" size="100%">Ramani, A.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Centre for Computational Medicine, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;NRC Institute of Immunology FMBA of Russia, Moscow, Russia.&#xD;Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.&#xD;Division of Respiratory Medicine and Translational Medicine, Departments of Pediatrics and Physiology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada.&#xD;Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatric and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.&#xD;Departments of Pediatrics and Immunology, University of Toronto, Toronto, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Modeling the conversion between specific IgE test platforms for nut allergens in children and adolescents</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">831-841</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Austria</style></keyword><keyword><style face="normal" font="default" size="100%">Canada</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Nuts</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">conversion</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">molecular allergology</style></keyword><keyword><style face="normal" font="default" size="100%">specific IgE</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32738829</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Multiplex tests allow for measurement of allergen-specific IgE responses to multiple extracts and molecular allergens and have several advantages for large cohort studies. Due to significant methodological differences, test systems are difficult to integrate in meta-analyses/systematic reviews since there is a lack of datasets with direct comparison. We aimed to create models for statistical integration of allergen-specific IgE to peanut/tree nut allergens from three IgE test platforms. METHODS: Plasma from Canadian and Austrian children/adolescents with peanut/tree nut sensitization and a cohort of sensitized, high-risk, pre-school asthmatics (total n = 166) were measured with three R&amp;D multiplex IgE test platforms: Allergy Explorer version 1 (ALEX) (Macro Array Dx), MeDALL-chip (Mechanisms of Development of Allergy) (Thermo Fisher), and EUROLINE (EUROIMMUN). Skin prick test (n = 51) and ImmunoCAP (Thermo Fisher) (n = 62) results for extracts were available in a subset. Regression models (Multivariate Adaptive Regression Splines, local polynomial regression) were applied if &gt;30% of samples were positive to the allergen. Intra-test correlations between PR-10 and nsLTP allergens were assessed. RESULTS: Using two regression methods, we demonstrated the ability to model allergen-specific relationships with acceptable measures of fit (r(2) = 94%-56%) for peanut and tree nut sIgE testing at the extract and molecular-level, in order from highest to lowest: Ara h 2, Ara h 6, Jug r 1, Ana o 3, Ara h 1, Jug r 2, and Cor a 9. CONCLUSION: Our models support the notion that quantitative conversion is possible between sIgE multiplex platforms for extracts and molecular allergens and may provide options to aggregate data for future meta-analysis.</style></abstract><notes><style face="normal" font="default" size="100%">Hoang, Jennifer A&#xD;Celik, Alper&#xD;Lupinek, Christian&#xD;Valenta, Rudolf&#xD;Duan, Lucy&#xD;Dai, Ruixue&#xD;Brydges, May G&#xD;Dubeau, Aimee&#xD;Lepine, Claire&#xD;Wong, Samantha&#xD;Alexanian-Farr, Mara&#xD;Magder, Ahuva&#xD;Subbarao, Padmaja&#xD;Upton, Julia E M&#xD;Schmidthaler, Klara&#xD;Szepfalusi, Zsolt&#xD;Ramani, Arun&#xD;Eiwegger, Thomas&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):831-841. doi: 10.1111/all.14529. Epub 2020 Aug 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32738829</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14529</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Song, X.</style></author><author><style face="normal" font="default" size="100%">Liu, B.</style></author><author><style face="normal" font="default" size="100%">Luan, T.</style></author><author><style face="normal" font="default" size="100%">Liao, S.</style></author><author><style face="normal" font="default" size="100%">Tan, Y.</style></author><author><style face="normal" font="default" size="100%">Peng, C.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.&#xD;Beijing Key Laboratory of molecular Diagnosis on Dermatoses, Beijing, China.&#xD;National Clinical Research Center for Skin and Immune Diseases, Beijing, China.&#xD;NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China.&#xD;Peking University School of Nursing, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Moderate-to-severe atopic dermatitis in different age groups treated with dupilumab in China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1696-1699</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36708064</style></accession-num><notes><style face="normal" font="default" size="100%">Song, Xiaoting&#xD;Liu, Bo&#xD;Luan, Tingting&#xD;Liao, Shuanglu&#xD;Tan, Yen&#xD;Peng, Chengyue&#xD;Zhao, Zuotao&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1696-1699. doi: 10.1111/all.15660. Epub 2023 Feb 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36708064</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15660</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2994</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2994</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Starchenka, S.</style></author><author><style face="normal" font="default" size="100%">De Kam, P. J.</style></author><author><style face="normal" font="default" size="100%">Palmer, E.</style></author><author><style face="normal" font="default" size="100%">Wu, L. Y. D.</style></author><author><style face="normal" font="default" size="100%">Keane, S. T.</style></author><author><style face="normal" font="default" size="100%">Fulton, W. T.</style></author><author><style face="normal" font="default" size="100%">Hikmawati, P.</style></author><author><style face="normal" font="default" size="100%">Meng, X.</style></author><author><style face="normal" font="default" size="100%">Filipaviciute, P.</style></author><author><style face="normal" font="default" size="100%">Cutrina Pons, A.</style></author><author><style face="normal" font="default" size="100%">Oluwayi, K.</style></author><author><style face="normal" font="default" size="100%">Lis, K.</style></author><author><style face="normal" font="default" size="100%">Armfield, O.</style></author><author><style face="normal" font="default" size="100%">Skinner, M. A.</style></author><author><style face="normal" font="default" size="100%">Heath, M. D.</style></author><author><style face="normal" font="default" size="100%">Hewings, S. J.</style></author><author><style face="normal" font="default" size="100%">Kramer, M. F.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Allergy Therapeutics PLC, Worthing, UK.&#xD;Bencard Allergie GmbH, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">232-247</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/07/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/immunology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Poaceae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Humoral/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Cellular/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy vaccines and mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest. J.A.L. reports grants via Biomedical Research Funding</style></keyword><keyword><style face="normal" font="default" size="100%">(Imperial College BRC), all outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">M.H.S. reports research</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Immune Tolerance Network, Medical Research Council, Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, LETI Laboratorios, Rovolo Biotherapeutics and lecture fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics and Leti Laboratorios, all outside the submitted work. S.S.,</style></keyword><keyword><style face="normal" font="default" size="100%">P.-J.D.K., K.O., K.L., O.A., M.A.S., M.D.H., S.J.H., and M.F.K. are former or</style></keyword><keyword><style face="normal" font="default" size="100%">current employees of Allergy Therapeutics PLC. K.L. and M.F.K. are also current</style></keyword><keyword><style face="normal" font="default" size="100%">employees of Bencard Allergie GmbH.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40626378</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A short-course pre-seasonal subcutaneous injection of PQ Grass is clinically effective for the treatment of allergic rhinitis, though its mechanism remains unclear. The aim of the study was to interrogate immunological mechanisms induced by PQ Grass conventional and extended regimens. METHODS: A RDBPC exploratory field study involving participants that either received injections of PQ Grass with a cumulative dose of 27,600 SU conventional (six once weekly injections) or extended regimen (three once weekly injections followed by three once monthly injections) or placebo containing microcrystalline tyrosine (MCT) (placebo + MCT) or saline (placebo) was performed. Humoral, cellular, and molecular responses were assessed at baseline (V1), end of treatment, prior to grass pollen season (V12) and end of pollen season (V15). Immunoglobulin analyses and cellular/gene microarray analyses were performed in the sub-study cohort consisting of PQ Grass Conventional (n = 25 and n = 10, respectively), PQ Grass Extended (n = 26 and n = 10, respectively), Placebo with MCT (n = 13 and n = 5, respectively), and Placebo (saline; n = 12 and n = 5, respectively). RESULTS: Both PQ Grass regimens, conventional and extended, were associated with improvement in total combined scores (TCS) with a relative difference of -35.0% (p = 0.03) and -40.8% (p = 0.01) against placebo with MCT, respectively. Both PQ Grass treatment regimens were associated with increases in the sIgG(4)/sIgE ratio (all, p &lt; 0.05) and induction of IgA(1) (all, p &lt; 0.05) and IgA(2) (all, p &lt; 0.01) compared to placebo groups. Nasal fluid (p &lt; 0.01) and serum (p &lt; 0.05) blocking antibodies are functional and have the capacity to inhibit allergen-IgE complex formation and binding to B cells in the PQ Grass groups. In vitro cellular and microarray gene analyses demonstrated that the extended PQ Grass regimen was more proficient in modulating the immune response towards a tolerogenic milieu by dampening pro-inflammatory type 2 immune response and the associated cytokines (p &lt; 0.05), immune deviation towards a Th1 response (p &lt; 0.05), and induction of FOXP3(+) Treg cells (p &lt; 0.05). CONCLUSIONS: For the first time, we highlight differential mechanisms of tolerance induction by PQ Grass, with the extended regimen being superior in modulating T cell compartments. TRAIL REGISTRATION: Trial number: PQGrass309, EudraCT number: 2020-000408-13, Clinicaltrials.gov identifier: NCT04687059, and NCT05540717.</style></abstract><notes><style face="normal" font="default" size="100%">Layhadi, Janice A&#xD;Starchenka, Sviatlana&#xD;De Kam, Pieter-Jan&#xD;Palmer, Elizabeth&#xD;Wu, Lily Y D&#xD;Keane, Sean T&#xD;Fulton, William T&#xD;Hikmawati, Prista&#xD;Meng, Xun&#xD;Filipaviciute, Paulina&#xD;Cutrina Pons, Anna&#xD;Oluwayi, Kemi&#xD;Lis, Katarzyna&#xD;Armfield, Oliver&#xD;Skinner, Murray A&#xD;Heath, Matthew D&#xD;Hewings, Simon J&#xD;Kramer, Matthias F&#xD;Shamji, Mohamed H&#xD;eng&#xD;Allergy Therapeutics/&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):232-247. doi: 10.1111/all.16640. Epub 2025 Jul 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40626378</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773655</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16640</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3245</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3245</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, Lan</style></author><author><style face="normal" font="default" size="100%">Ma, Tingting</style></author><author><style face="normal" font="default" size="100%">Guo, Yirong</style></author><author><style face="normal" font="default" size="100%">Fu, Wanyi</style></author><author><style face="normal" font="default" size="100%">Wang, Qingqing</style></author><author><style face="normal" font="default" size="100%">Yang, Meirong</style></author><author><style face="normal" font="default" size="100%">Li, Shulin</style></author><author><style face="normal" font="default" size="100%">Gao, Biyuan</style></author><author><style face="normal" font="default" size="100%">Sun, Yi</style></author><author><style face="normal" font="default" size="100%">Zhu, Mingzhi</style></author><author><style face="normal" font="default" size="100%">Jin, Jing</style></author><author><style face="normal" font="default" size="100%">Wang, Siqin</style></author><author><style face="normal" font="default" size="100%">Fu, Linglin</style></author><author><style face="normal" font="default" size="100%">Versteeg, Serge A.</style></author><author><style face="normal" font="default" size="100%">Valenta, Rudolf</style></author><author><style face="normal" font="default" size="100%">van Ree, Ronald</style></author><author><style face="normal" font="default" size="100%">Gao, Yadong</style></author><author><style face="normal" font="default" size="100%">Wang, Xueyan</style></author><author><style face="normal" font="default" size="100%">Gao, Zhongshan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Molecular Allergen Diagnosis Reveals That Asthma Risk Is Linked to Desert Mugwort Pollen Exposure</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Artemisia desertorum (desert mugwort) is widely planted in the Mu Us Desert of northwestern China for windbreak and sand fixation, but extensive cultivation has unexpectedly increased pollen-induced allergies. This study aims to perform allergen molecular diagnosis and evaluate its utility in characterizing immunoglobulin E (IgE) sensitization profiles linked to allergic phenotypes. Methods One hundred and thirty-five Artemisia-allergic patients from three regions differing in the Artemisia pollen exposure were examined. Eleven allergens were either purified naturally or recombinantly for IgE quantification using the ImmunoCAP assay. Results At least one allergen response was detected in 134 patients. Major allergens included Art d 1 (85.2%), Art d 2 (62.2%), Art d 3 (88.9%), Art d 7 (82.2%), and Art d 9 (54.1%). Patients from the high desert mugwort exposure region exhibited elevated serum-specific immunoglobulin E (sIgE) levels, increased sensitization to mugwort extract and allergen molecules, broader polysensitization, and higher asthma prevalence. Number of sensitized allergens and sIgE levels to mugwort extract and Art d 3 were independently associated with asthma in multivariable analysis. A predictive model was developed for asthma prediction with an AUC of 0.832. Conclusions High environmental exposure to A. desertorum pollen increases pollen allergy prevalence and asthma risk in Mu Us Desert residents. Molecular allergy diagnostics with a comprehensive A. desertorum allergen panel enhanced diagnostic precision, supported disease severity prediction, and provided critical insights for improved clinical management.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70253</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70253</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3266</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3266</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, Lan</style></author><author><style face="normal" font="default" size="100%">Ma, Tingting</style></author><author><style face="normal" font="default" size="100%">Guo, Yirong</style></author><author><style face="normal" font="default" size="100%">Fu, Wanyi</style></author><author><style face="normal" font="default" size="100%">Wang, Qingqing</style></author><author><style face="normal" font="default" size="100%">Yang, Meirong</style></author><author><style face="normal" font="default" size="100%">Li, Shulin</style></author><author><style face="normal" font="default" size="100%">Gao, Biyuan</style></author><author><style face="normal" font="default" size="100%">Sun, Yi</style></author><author><style face="normal" font="default" size="100%">Zhu, Mingzhi</style></author><author><style face="normal" font="default" size="100%">Jin, Jing</style></author><author><style face="normal" font="default" size="100%">Wang, Siqin</style></author><author><style face="normal" font="default" size="100%">Fu, Linglin</style></author><author><style face="normal" font="default" size="100%">Versteeg, Serge A.</style></author><author><style face="normal" font="default" size="100%">Valenta, Rudolf</style></author><author><style face="normal" font="default" size="100%">van Ree, Ronald</style></author><author><style face="normal" font="default" size="100%">Gao, Yadong</style></author><author><style face="normal" font="default" size="100%">Wang, Xueyan</style></author><author><style face="normal" font="default" size="100%">Gao, Zhongshan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Molecular Allergen Diagnosis Reveals That Asthma Risk Is Linked to Desert Mugwort Pollen Exposure</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Artemisia desertorum (desert mugwort) is widely planted in the Mu Us Desert of northwestern China for windbreak and sand fixation, but extensive cultivation has unexpectedly increased pollen-induced allergies. This study aims to perform allergen molecular diagnosis and evaluate its utility in characterizing immunoglobulin E (IgE) sensitization profiles linked to allergic phenotypes. Methods One hundred and thirty-five Artemisia-allergic patients from three regions differing in the Artemisia pollen exposure were examined. Eleven allergens were either purified naturally or recombinantly for IgE quantification using the ImmunoCAP assay. Results At least one allergen response was detected in 134 patients. Major allergens included Art d 1 (85.2%), Art d 2 (62.2%), Art d 3 (88.9%), Art d 7 (82.2%), and Art d 9 (54.1%). Patients from the high desert mugwort exposure region exhibited elevated serum-specific immunoglobulin E (sIgE) levels, increased sensitization to mugwort extract and allergen molecules, broader polysensitization, and higher asthma prevalence. Number of sensitized allergens and sIgE levels to mugwort extract and Art d 3 were independently associated with asthma in multivariable analysis. A predictive model was developed for asthma prediction with an AUC of 0.832. Conclusions High environmental exposure to A. desertorum pollen increases pollen allergy prevalence and asthma risk in Mu Us Desert residents. Molecular allergy diagnostics with a comprehensive A. desertorum allergen panel enhanced diagnostic precision, supported disease severity prediction, and provided critical insights for improved clinical management.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70253</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70253</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>963</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">963</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barber, D.</style></author><author><style face="normal" font="default" size="100%">Diaz-Perales, A.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author><author><style face="normal" font="default" size="100%">Kleine-Tebbe, J.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P. M.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de Ciencias Medicas Basicas, Facultad de Medicina, IMMA, Universidad San Pablo CEU, CEU Universities, Madrid, Spain.&#xD;ARADyAL-RD16/0006/0015 RD16/0006/0003, Thematic Network and Cooperative Research Centers, ISCIII, Madrid, Spain.&#xD;Center for Plant Biotechnology and Genomic, Universidad Politecnica de Madrid, Pozuelo de Alarcon, Spain.&#xD;Allergy and Asthma Center Westend, Berlin, Germany.&#xD;Department of Pediatric Pneumology and Immunology, Charite Medical University of Berlin, Berlin, Germany.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.&#xD;Department of Women and Children&apos;s Health (Pediatric Allergy, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Children&apos;s Allergy Service, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Fundacion Jimenez Diaz, AllergyDepartment, Universidad Autonomade Madrid, CIBERES, Instituto de Salud Carlos III, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Molecular allergology and its impact in specific allergy diagnosis and therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3642-3658</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/06/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">component-resolved diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">major allergen</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34057744</style></accession-num><abstract><style face="normal" font="default" size="100%">Progressive knowledge of allergenic structures resulted in a broad availability of allergenic molecules for diagnosis. Component-resolved diagnosis allowed a better understanding of patient sensitization patterns, facilitating allergen immunotherapy decisions. In parallel to the discovery of allergenic molecules, there was a progressive development of a regulation framework that affected both in vitro diagnostics and Allergen Immunotherapy products. With a progressive understanding of underlying mechanisms associated to Allergen immunotherapy and an increasing experience of application of molecular diagnosis in daily life, we focus in analyzing the evidences of the value provided by molecular allergology in daily clinical practice, with a focus on Allergen Immunotherapy decisions.</style></abstract><notes><style face="normal" font="default" size="100%">Barber, Domingo&#xD;Diaz-Perales, Araceli&#xD;Escribese, Maria M&#xD;Kleine-Tebbe, Jorg&#xD;Matricardi, Paolo M&#xD;Ollert, Markus&#xD;Santos, Alexandra F&#xD;Sastre, Joaquin&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3642-3658. doi: 10.1111/all.14969. Epub 2021 Jun 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34057744</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14969</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>19</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">19</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, London, UK.&#xD;Children&apos;s Allergy Service, Guy&apos;s and St Thomas&apos; Hospital, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Molecular Allergology User&apos;s Guide version 2.0 is freely available!</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1139-1141</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/01/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36633102</style></accession-num><notes><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, Karin&#xD;Santos, Alexandra F&#xD;Breiteneder, Heimo&#xD;eng&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;Editorial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1139-1141. doi: 10.1111/all.15643. Epub 2023 Mar 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36633102</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15643</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1658</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1658</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, L.</style></author><author><style face="normal" font="default" size="100%">Xie, H.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Liu, M.</style></author><author><style face="normal" font="default" size="100%">Ma, T.</style></author><author><style face="normal" font="default" size="100%">Fu, W.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, D.</style></author><author><style face="normal" font="default" size="100%">Feng, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, S.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Luo, F.</style></author><author><style face="normal" font="default" size="100%">Guo, B.</style></author><author><style face="normal" font="default" size="100%">Wu, H.</style></author><author><style face="normal" font="default" size="100%">Yu, Y.</style></author><author><style face="normal" font="default" size="100%">Fu, L.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Vrtala, S.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Gao, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Center, School of Medicine, Zhejiang University, Hangzhou, China.&#xD;College of Agriculture and Biotechnology, Zhejiang University, Hangzhou, China.&#xD;Department of Allergy, the Third People&apos;s Hospital of Datong, Datong, China.&#xD;Department of Allergy, Xinhe Hospital of Datong, Datong, China.&#xD;Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.&#xD;State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.&#xD;Department of Otorhinolaryngology, the First Affiliated Hospital, Shanxi Medical University, Taiyuan, China.&#xD;Hangzhou Zheda Dixun Biological Gene Engineering Co. Ltd, Hangzhou, China.&#xD;Department of Allergy, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.&#xD;Department of Otorhinolaryngology, Qvjing Chinese Traditional Medicine Hospital, Yunnan, China.&#xD;Key Laboratory of Tropical Fruit Biology, Ministry of Agriculture, South Subtropical Crops Research Institute, Chinese Academy of Tropical Agricultural Sciences, Zhanjiang, China.&#xD;Department of Otorhinolaryngology, the First Affiliated Hospital, Kunming Medical University, Kunming, China.&#xD;School of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou, China.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;National Research Center - Institute of Immunology FMBA of Russia, Moscow, Russian Federation.&#xD;Karl Landsteiner University for Health Sciences, Krems, Austria.&#xD;Departments of Experimental Immunology and of Otorhinolaryngology, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Molecular characterization of allergens and component-resolved diagnosis of IgE-mediated mango fruit allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1699-1703</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/02/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Mangifera</style></keyword><keyword><style face="normal" font="default" size="100%">Fruit</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36724175</style></accession-num><notes><style face="normal" font="default" size="100%">Zhao, Lan&#xD;Xie, Hanbing&#xD;Wang, Xuefeng&#xD;Liu, Meiling&#xD;Ma, Tingting&#xD;Fu, Wanyi&#xD;Wang, Yuqi&#xD;Wu, Dongya&#xD;Feng, Yan&#xD;Liu, Yi&#xD;Wu, Shandong&#xD;Zhang, Xianqi&#xD;Wang, Huiying&#xD;Luo, Fangmei&#xD;Guo, Baohua&#xD;Wu, Hongxia&#xD;Yu, Yongmei&#xD;Fu, Linglin&#xD;Valenta, Rudolf&#xD;Vrtala, Susanne&#xD;van Ree, Ronald&#xD;Wang, Xueyan&#xD;Gao, Zhongshan&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1699-1703. doi: 10.1111/all.15664. Epub 2023 Feb 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36724175</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15664</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>914</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">914</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vogel, M.</style></author><author><style face="normal" font="default" size="100%">Augusto, G.</style></author><author><style face="normal" font="default" size="100%">Chang, X.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Speiser, D.</style></author><author><style face="normal" font="default" size="100%">Mohsen, M. O.</style></author><author><style face="normal" font="default" size="100%">Bachmann, M. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Inselspital, University clinic of Rheumatology and Immunology, Bern, Switzerland.&#xD;Department of BioMedical Research, University of Bern, Bern, Switzerland.&#xD;The Jenner Institute, Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), University of Oxford, Oxford, UK.&#xD;Dermatology, International Immunology Centre, Anhui Agricultural University, Hefei, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor-binding domain mutations: Receptor affinity versus neutralization of receptor interaction</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">143-149</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/07/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization, Passive</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Binding</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Virus</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Spike Glycoprotein, Coronavirus/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Serotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Ace2</style></keyword><keyword><style face="normal" font="default" size="100%">Rbd</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">affinity</style></keyword><keyword><style face="normal" font="default" size="100%">neutralization</style></keyword><keyword><style face="normal" font="default" size="100%">RBD-CuMV, a vaccine against COVID-19. All other authors declare no conflict of</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34240429</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Several new variants of SARS-CoV-2 have emerged since fall 2020 which have multiple mutations in the receptor-binding domain (RBD) of the spike protein. It is unclear which mutations affect receptor affinity versus immune recognition. METHODS: We produced wild type RBD, RBD with single mutations (E484K, K417N, or N501Y) or with all three mutations combined and tested their binding to ACE2 by biolayer interferometry (BLI). The ability of convalescent sera to recognize RBDs and block their interaction with ACE2 was tested as well. RESULTS: We demonstrated that single mutation N501Y increased binding affinity to ACE2 but did not strongly affect its recognition by convalescent sera. In contrast, single mutation E484K had almost no impact on the binding kinetics, but essentially abolished recognition of RBD by convalescent sera. Interestingly, combining mutations E484K, K417N, and N501Y resulted in a RBD with both features: enhanced receptor binding and abolished immune recognition. CONCLUSIONS: Our data demonstrate that single mutations either affect receptor affinity or immune recognition while triple mutant RBDs combine both features.</style></abstract><notes><style face="normal" font="default" size="100%">Vogel, Monique&#xD;Augusto, Gilles&#xD;Chang, Xinyue&#xD;Liu, Xuelan&#xD;Speiser, Daniel&#xD;Mohsen, Mona O&#xD;Bachmann, Martin F&#xD;eng&#xD;International Immunology Center, Anhui Agricultural University, Hefei, China/&#xD;Saiba AG/&#xD;31003A_185114/Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):143-149. doi: 10.1111/all.15002. Epub 2021 Jul 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34240429</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441680</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15002</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3162</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3162</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kazancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Huang, H. J.</style></author><author><style face="normal" font="default" size="100%">Aksakal, S.</style></author><author><style face="normal" font="default" size="100%">Bulut, I.</style></author><author><style face="normal" font="default" size="100%">Buzan, M. R.</style></author><author><style face="normal" font="default" size="100%">Chen, K. W.</style></author><author><style face="normal" font="default" size="100%">Cotarca, M. D.</style></author><author><style face="normal" font="default" size="100%">Dubovets, A.</style></author><author><style face="normal" font="default" size="100%">Gattinger, P.</style></author><author><style face="normal" font="default" size="100%">Gulbahar, O.</style></author><author><style face="normal" font="default" size="100%">Kalyoncu, A. F.</style></author><author><style face="normal" font="default" size="100%">Karaulov, A.</style></author><author><style face="normal" font="default" size="100%">Kozlov, E.</style></author><author><style face="normal" font="default" size="100%">Panaitescu, C.</style></author><author><style face="normal" font="default" size="100%">Schlederer, T.</style></author><author><style face="normal" font="default" size="100%">Trifonova, D.</style></author><author><style face="normal" font="default" size="100%">Tulaev, M.</style></author><author><style face="normal" font="default" size="100%">Turk, M.</style></author><author><style face="normal" font="default" size="100%">Vrtala, S.</style></author><author><style face="normal" font="default" size="100%">Weber, M.</style></author><author><style face="normal" font="default" size="100%">Zbircea, L. E.</style></author><author><style face="normal" font="default" size="100%">Sekerel, B. E.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Turkiye.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Center for Molecular Allergology, Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Department of Immunology and Allergy, Samsun Training and Research Hospital, Samsun, Turkiye.&#xD;Department of Allergy and Immunology, Sureyyapasa Training and Research Hospital, University of Health Sciences, Istanbul, Turkiye.&#xD;OncoGen Center, Pius Brinzeu County Clinical Emergency Hospital, Timisoara, Romania.&#xD;Center of Immuno-Physiology and Biotechnologies, Department of Functional Sciences, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.&#xD;Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Life Improvement by Future Technologies (LIFT) Center, Moscow, Russia.&#xD;Division of Allergy and Clinical Immunology, Department of Internal Medicine, Ege University School of Medicine, Izmir, Turkiye.&#xD;Division of Allergy and Clinical Immunology, Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkiye.&#xD;Clinic of Immunologic and Allergic Diseases, Kayseri City Education and Research Hospital, Kayseri, Turkiye.&#xD;Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkiye.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Molecular IgE Reactivity Profiling With Micro-Arrayed Allergens Reveals Distinct Interregional Patterns of Sensitization and a Hypoallergenic Region in Turkiye</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Turkey</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">allergen micro-array</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">population study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41229350</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Molecular immunoglobulin E (IgE) reactivity profiling with multiple micro-arrayed allergens is a valuable tool in allergy diagnosis and has provided fundamental insights into the evolution of allergic sensitization in longitudinal birth cohort studies. However, there is a need for systematic cross-sectional population-based studies. METHODS: A prospective, systematic and cross-sectional population study was performed involving 1000 adult subjects from five centers (Istanbul, Ankara, Izmir, Kayseri, Samsun) representing different climatic areas of Turkiye (Turkey). In each center adult subjects with (n = 100) and without (n = 100) allergic symptoms who were born and grew up in the region were recruited. Subjects underwent skin prick testing with a panel of common aeroallergen extracts and were tested for IgE reactivity to 108 micro-arrayed allergen molecules. RESULTS: IgE reactivity profiles of respiratory allergens differed in the five centers according to the regional allergen exposome and climate. Interestingly, Kayseri with a high-altitude, continental climate was identified as hypoallergenic region with low frequency of allergic symptoms and strongly reduced molecular sensitization rates. Between 31%-55% of subjects without allergic symptoms showed IgE sensitization to at least one of the allergens tested but allergen-specific IgE levels, numbers of recognized allergens and rates of poly-sensitization were more frequent in symptomatic individuals. CONCLUSIONS: This is the first comprehensive, systematic, prospective and cross-sectional study investigating molecular IgE sensitization profiles in a region at the crossroads of Europe, Asia, and Africa with different climatic conditions. It reveals clinically relevant differences in regional molecular IgE sensitization profiles depending on the allergen exposome and identifies a hypoallergenic region with distinct climatic features.</style></abstract><notes><style face="normal" font="default" size="100%">Kazancioglu, Alp&#xD;Huang, Huey-Jy&#xD;Aksakal, Sengul&#xD;Bulut, Ismet&#xD;Buzan, Maria-Roxana&#xD;Chen, Kuan-Wei&#xD;Cotarca, Monica Daniela&#xD;Dubovets, Alexandra&#xD;Gattinger, Pia&#xD;Gulbahar, Okan&#xD;Kalyoncu, Ali Fuat&#xD;Karaulov, Alexander&#xD;Kozlov, Evgenii&#xD;Panaitescu, Carmen&#xD;Schlederer, Thomas&#xD;Trifonova, Daria&#xD;Tulaev, Mikhail&#xD;Turk, Murat&#xD;Vrtala, Susanne&#xD;Weber, Milena&#xD;Zbircea, Lauriana-Eunice&#xD;Sekerel, Bulent Enis&#xD;Valenta, Rudolf&#xD;eng&#xD;The Danube Allergy Research Cluster program of the Country of Lower Austria/&#xD;The INSPIRED (Inovative Strategies for Prevention, diagnosis and therapy of ragweed pollen Induced REspiratoryDiseases) project/&#xD;23-75-30016/The Russian Science Foundation in its part related to allergen characterization/&#xD;COP 2014-2020 92/09.09.2016/The European Regional Development Fund (ERDF)/&#xD;P_37_747/The Romanian National Budget/&#xD;Denmark&#xD;Allergy. 2025 Nov 13. doi: 10.1111/all.70145.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41229350</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70145</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3102</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3102</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, H. J.</style></author><author><style face="normal" font="default" size="100%">Breyer-Kohansal, R.</style></author><author><style face="normal" font="default" size="100%">Niespodziana, K.</style></author><author><style face="normal" font="default" size="100%">Lim, C. J. M.</style></author><author><style face="normal" font="default" size="100%">Breyer, M. K.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Hartl, S.</style></author><author><style face="normal" font="default" size="100%">Allergochip Working, Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Center for Molecular Allergology, Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Ludwig Boltzmann Institute for Lung Health, Vienna, Austria.&#xD;Department of Respiratory and Pulmonary Diseases, Clinic Hietzing, Vienna Healthcare Group, Vienna, Austria.&#xD;Sigmund Freud Private University, Faculty of Medicine, Vienna, Austria.&#xD;Department of Respiratory and Pulmonary Diseases, Site Penzing of Clinic Ottakring, Vienna Healthcare Group, Vienna, Austria.&#xD;Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Life Improvement by Future Technologies (LIFT) Center, Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Molecular IgE Sensitization Profiling With Micro-Arrayed Allergen Molecules in Adult Patients With Asthma From the LEAD Cohort: A Precision Medicine Approach</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">130-144</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/08/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/immunology/diagnosis/therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Precision Medicine/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Austria</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">allergen micro-array</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">skin testing</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Hangzhou, China</style></keyword><keyword><style face="normal" font="default" size="100%">HVD Biotech, Vienna, Austria</style></keyword><keyword><style face="normal" font="default" size="100%">and Viravaxx,</style></keyword><keyword><style face="normal" font="default" size="100%">Vienna, Austria. R.V. serves as a consultant for HVD. The other authors declare</style></keyword><keyword><style face="normal" font="default" size="100%">no conflicts of interest. The funders had no role in the design of the study</style></keyword><keyword><style face="normal" font="default" size="100%">in</style></keyword><keyword><style face="normal" font="default" size="100%">the collection, analyses, or interpretation of data</style></keyword><keyword><style face="normal" font="default" size="100%">in the writing of the</style></keyword><keyword><style face="normal" font="default" size="100%">manuscript</style></keyword><keyword><style face="normal" font="default" size="100%">or in the decision to publish the results. The authors with a Russian</style></keyword><keyword><style face="normal" font="default" size="100%">affiliation declare that they have prepared the article in their &quot;personal</style></keyword><keyword><style face="normal" font="default" size="100%">capacity&quot; and/or that they are employed at an academic/research institution where</style></keyword><keyword><style face="normal" font="default" size="100%">research or education is the primary function of the entity.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40884204</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma is a chronic respiratory disease comprising different pheno- and endotypes. Diagnostic tools for the identification of allergic versus non-allergic asthma are needed for new precision medicine-based treatments. OBJECTIVE: To determine IgE sensitization profiles to multiple micro-arrayed allergen molecules in adult patients with asthma in the Austrian LEAD (Lung, hEart, sociAl, boDy) cohort; to compare IgE- and non-IgE sensitized patients with asthma; and to define possible allergen-specific immunotherapy concepts for sensitized patients. METHODS: Out of 893 patients with a history of asthma, patients with current asthma (n = 436) were analyzed for IgE sensitizations to 110 micro-arrayed molecules from airborne and food allergen sources and by skin prick testing (SPT) with 10 allergen extracts (English plantain, mugwort, ragweed, timothy grass, ash tree, mites, dog, cat, Alternaria alternata, and Fagales mix). Clinical asthma-related parameters were compared between patients with IgE sensitization to asthma allergen molecules and non-IgE sensitized patients with asthma. RESULTS: IgE sensitization was detected in 73.2% of patients with asthma using 63 micro-arrayed respiratory allergens. The most recognized respiratory outdoor allergen molecules were Bet v 1 (32.8%) and Ole e 1 (23.2%) followed by grass pollen, ragweed, and mugwort allergens. Fel d 1 was the most frequently recognized respiratory indoor allergen molecule (42.7%) followed by house dust mite and dog allergen molecules. Micro-arrayed allergens allowed the identification of IgE reactivity profiles indicative of genuine sensitizations to different allergen sources. IgE-sensitized patients were significantly younger than non-IgE-sensitized patients with asthma (median age 44 versus 58 years). Patients sensitized to respiratory allergens showed significantly better lung function (FEV1, FVC and FEV/FVC) and less dyspnea but more allergic bronchitis than non-IgE-sensitized patients with asthma. More IgE-sensitized patients used antihistamines but fewer inhaled corticosteroids than non-IgE-sensitized patients with asthma. Interestingly, eosinophil counts were lower both in ICS-treated as well as untreated sensitized patients than in non-sensitized patients with asthma. CONCLUSION: Molecular allergy diagnosis allowed the detection of genuine IgE sensitizations in adult patients with asthma; enabling stratification for precision medicine-based forms of personalized treatments such as allergen-based immunotherapy (AIT) and/or administration of biological treatments in asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Huang, Huey-Jy&#xD;Breyer-Kohansal, Robab&#xD;Niespodziana, Katarzyna&#xD;Lim, Charmaine J M&#xD;Breyer, Marie-Kathrin&#xD;Valenta, Rudolf&#xD;Hartl, Sylvia&#xD;eng&#xD;The Danube Allergy Research Cluster program of the Country of Lower Austria/&#xD;A GSK unrestricted grant of the LEAD study/&#xD;European Regional Development Fund (ERDF) and the Romanian National Budget/&#xD;23-75-30016/Russian Science Foundation/&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):130-144. doi: 10.1111/all.70017. Epub 2025 Aug 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40884204</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773682</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70017</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1193</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1193</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fricker, M.</style></author><author><style face="normal" font="default" size="100%">McDonald, V. M.</style></author><author><style face="normal" font="default" size="100%">Winter, N. A.</style></author><author><style face="normal" font="default" size="100%">Baines, K. J.</style></author><author><style face="normal" font="default" size="100%">Wark, P. A. B.</style></author><author><style face="normal" font="default" size="100%">Simpson, J. L.</style></author><author><style face="normal" font="default" size="100%">Gibson, P. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medicine and Public Health, Faculty of Health and Medicine and Priority Research Centre for Healthy Lungs, The University of Newcastle, Callaghan, NSW, Australia.&#xD;National Health and Medical Research Council Centre for Excellence in Severe Asthma, Newcastle, NSW, Australia.&#xD;Hunter Medical Research Institute, Newcastle, NSW, Australia.&#xD;School of Nursing and Midwifery, Faculty of Health and Medicine and Priority Research Centre for Healthy Lungs, The University of Newcastle, Callaghan, NSW, Australia.&#xD;Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Molecular markers of type 2 airway inflammation are similar between eosinophilic severe asthma and eosinophilic chronic obstructive pulmonary disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2079-2089</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Eosinophilia/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">obstructive airways disease</style></keyword><keyword><style face="normal" font="default" size="100%">prostaglandin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33470427</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Airway and systemic eosinophilia are important treatable traits in both severe asthma and COPD. The molecular basis of eosinophilia in COPD is poorly understood but could involve type 2 cytokines (IL5, IL13) and prostaglandin D(2) (PGD(2) ). METHODS: This study included non-obstructive airways disease (OAD) controls (n = 19), a COPD cohort (n = 96) and a severe asthma cohort (n = 84). Demographics, exacerbation history, disease impact (SGRQ) and spirometry were assessed. Participants were categorized as eosinophilic using either sputum eosinophil proportion (&gt;/=3%) or blood eosinophil count (&gt;/=300/muL). Sputum type 2 inflammatory measures included PGD(2) by ELISA and gene expression (qPCR) of IL5, IL13 and the haematopoietic PGD(2) synthase (HPGDS). RESULTS: Type 2 markers did not differ across groups except HPGDS mRNA which was highest in non-OAD controls and lowest in COPD. IL5 and IL13 mRNA and PGD(2) levels were significantly increased in eosinophilic vs non-eosinophilic severe asthma but did not differ between eosinophilic COPD and eosinophilic severe asthma or non-eosinophilic COPD. HPGDS expression was higher in eosinophilic severe asthma compared with eosinophilic COPD. Results were similar using sputum or blood eosinophil cut-offs. Sputum IL5 and IL13 were highly intercorrelated in severe asthma (r = 0.907, p &lt; 0.001) and COPD (r = 0.824, p &lt; 0.001), were moderately correlated with sputum eosinophils in severe asthma (IL5 r = 0.440, p &lt; 0.001; IL13 r = 0.428, p &lt; 0.001) and were weakly correlated in COPD (IL5 r = 0.245, p &lt; 0.05; IL13 r = 0.317, p &lt; 0.05). CONCLUSIONS: Molecular markers of type 2 airway inflammation do not differ between eosinophilic asthma and eosinophilic COPD; however, the relationship between eosinophilia and type 2 airway markers appears weaker in COPD than in severe asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Fricker, Michael&#xD;McDonald, Vanessa M&#xD;Winter, Natasha A&#xD;Baines, Katherine J&#xD;Wark, Peter A B&#xD;Simpson, Jodie L&#xD;Gibson, Peter G&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2079-2089. doi: 10.1111/all.14741. Epub 2021 Mar 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33470427</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14741</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>340</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">340</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schedel, M.</style></author><author><style face="normal" font="default" size="100%">Leach, S. M.</style></author><author><style face="normal" font="default" size="100%">Strand, M. J.</style></author><author><style face="normal" font="default" size="100%">Danhorn, T.</style></author><author><style face="normal" font="default" size="100%">MacBeth, M.</style></author><author><style face="normal" font="default" size="100%">Faino, A. V.</style></author><author><style face="normal" font="default" size="100%">Lynch, A. M.</style></author><author><style face="normal" font="default" size="100%">Winn, V. D.</style></author><author><style face="normal" font="default" size="100%">Munoz, L. L.</style></author><author><style face="normal" font="default" size="100%">Forsberg, S. M.</style></author><author><style face="normal" font="default" size="100%">Schwartz, D. A.</style></author><author><style face="normal" font="default" size="100%">Gelfand, E. W.</style></author><author><style face="normal" font="default" size="100%">Hauk, P. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Divisions of Allergy and Immunology and Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colorado, USA.&#xD;Department of Pulmonary Medicine, University Medicine Essen-Ruhrlandklinik, Essen, Germany.&#xD;Department of Pulmonary Medicine, University Medicine Essen, University Hospital, Essen, Germany.&#xD;Department of Biomedical Research, National Jewish Health, Denver, Colorado, USA.&#xD;Center for Genes, Environment &amp; Health, National Jewish Health, Denver, Colorado, USA.&#xD;Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, Colorado, USA.&#xD;Department of Pharmacology, School of Medicine, University of Colorado, Aurora, Colorado, USA.&#xD;Department of Medical Oncology, School of Medicine, University of Colorado, Aurora, Colorado, USA.&#xD;Biostatistics, Epidemiology and Research Core, Seattle Children&apos;s Research Institute, Seattle, Washington, USA.&#xD;Department of Ophthalmology, School of Medicine, University of Colorado, Aurora, Colorado, USA.&#xD;Department of Obstetrics and Gynecology, School of Medicine, University of Colorado, Aurora, Colorado, USA.&#xD;Department of Obstetrics and Gynecology, Stanford University, Stanford, California, USA.&#xD;Department of Thoracic Oncology, University of Colorado Cancer Center, University of Colorado, Aurora, Colorado, USA.&#xD;Department of Medicine, School of Medicine, University of Colorado, Aurora, Colorado, USA.&#xD;Section Allergy/Immunology, Children&apos;s Hospital Colorado, University of Colorado, Aurora, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Molecular networks in atopic mothers impact the risk of infant atopy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">244-257</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/08/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Family</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">cord blood</style></keyword><keyword><style face="normal" font="default" size="100%">differentially expressed gene</style></keyword><keyword><style face="normal" font="default" size="100%">differentially methylated region</style></keyword><keyword><style face="normal" font="default" size="100%">maternal atopy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35993851</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The prevalence of atopic diseases has increased with atopic dermatitis (AD) as the earliest manifestation. We assessed if molecular risk factors in atopic mothers influence their infants&apos; susceptibility to an atopic disease. METHODS: Pregnant women and their infants with (n = 174, high-risk) or without (n = 126, low-risk) parental atopy were enrolled in a prospective birth cohort. Global differentially methylated regions (DMRs) were determined in atopic (n = 92) and non-atopic (n = 82) mothers. Principal component analysis was used to predict atopy risk in children dependent on maternal atopy. Genome-wide transcriptomic analyses were performed in paired atopic (n = 20) and non-atopic (n = 15) mothers and cord blood. Integrative genomic analyses were conducted to define methylation-gene expression relationships. RESULTS: Atopic dermatitis was more prevalent in high-risk compared to low-risk children by age 2. Differential methylation analyses identified 165 DMRs distinguishing atopic from non-atopic mothers. Inclusion of DMRs in addition to maternal atopy significantly increased the odds ratio to develop AD in children from 2.56 to 4.26. In atopic compared to non-atopic mothers, 139 differentially expressed genes (DEGs) were identified significantly enriched of genes within the interferon signaling pathway. Expression quantitative trait methylation analyses dependent on maternal atopy identified 29 DEGs controlled by 136 trans-acting methylation marks, some located near transcription factors. Differential expression for the same nine genes, including MX1 and IFI6 within the interferon pathway, was identified in atopic and non-atopic mothers and high-risk and low-risk children. CONCLUSION: These data suggest that in utero epigenetic and transcriptomic mechanisms predominantly involving the interferon pathway may impact and predict the development of infant atopy.</style></abstract><notes><style face="normal" font="default" size="100%">Schedel, Michaela&#xD;Leach, Sonia M&#xD;Strand, Matthew J&#xD;Danhorn, Thomas&#xD;MacBeth, Morgan&#xD;Faino, Anna V&#xD;Lynch, Anne M&#xD;Winn, Virginia D&#xD;Munoz, Lindsay L&#xD;Forsberg, Shannon M&#xD;Schwartz, David A&#xD;Gelfand, Erwin W&#xD;Hauk, Pia J&#xD;eng&#xD;RC1 HD063508/HD/NICHD NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):244-257. doi: 10.1111/all.15490. Epub 2022 Sep 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35993851</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15490</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>516</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">516</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Potapova, E.</style></author><author><style face="normal" font="default" size="100%">Bordas-Le Floch, V.</style></author><author><style face="normal" font="default" size="100%">Schlederer, T.</style></author><author><style face="normal" font="default" size="100%">Vrtala, S.</style></author><author><style face="normal" font="default" size="100%">Huang, H. J.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P. M.</style></author><author><style face="normal" font="default" size="100%">Mascarell, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Pulmonology, Immunology and Critical Care Medicine, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Innovation &amp; Science Department, Stallergenes SAS, Antony, France.&#xD;Department of Pathophysiology and Allergy Research, Division of Immunopathology, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna and Krems, Austria.&#xD;Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Milan, Italy.&#xD;NRC Institute of Immunology, Federal Biomedical Agency of Russia, Moscow, Russia.&#xD;Department of Clinical Immunology and Allergy, Sechenov First State Medical University, Moscow, Russia.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3084-3095</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/04/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Pyridinolcarbamate</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">SLIT tablet</style></keyword><keyword><style face="normal" font="default" size="100%">allergen microarray</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite allergy</style></keyword><keyword><style face="normal" font="default" size="100%">molecular reactivity profile</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35474582</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Molecular antibody reactivity profiles have not yet been studied in depth in patients treated by sublingual house dust mite (HDM) tablet immunotherapy. Humoral immune responses to a large panel of HDM mite allergens were studied using allergen microarray technology in a subset of clinically defined high and low responder patients from a double-blind placebo-controlled allergen-specific immunotherapy (AIT) trial using sublingual 300 IR HDM tablets. METHODS: Serum levels of IgE, IgG and IgG(4) to 13 Dermatophagoides pteronyssinus molecules were measured at baseline and after 1-year AIT, using allergen microarrays in 100 subjects exhibiting high or low clinical benefit. RESULTS: Der p 1, Der p 2 and Der p 23 were the most frequently recognized allergens in the study population. Patients with HDM-related asthma had significantly higher allergen-specific IgE levels to Der p 1 and Der p 23. No significant difference in the distribution of allergen sensitization pattern was observed between high and low responders. An increase in serum allergen-specific IgG and IgG(4) occurred upon AIT, in particular to allergens Der p 1, Der p 2 and Der p 23 (p &lt; 0.0001). CONCLUSIONS: We confirm for our study population that Der p 1- and Der p 23-specific IgE levels are associated with asthma. IgE reactivity profiles were not predicitive of sublingual AIT outcomes, with 300 IR tablets as efficacious in pauci- and multi-sensitized subjects. Our study is the first to demonstrate the induction of IgG and IgG(4) specific for the HDM allergens Der p 1, Der p 2 and Der p 23 by sublingual AIT.</style></abstract><notes><style face="normal" font="default" size="100%">Potapova, Ekaterina&#xD;Bordas-Le Floch, Veronique&#xD;Schlederer, Thomas&#xD;Vrtala, Susanne&#xD;Huang, Huey-Jy&#xD;Canonica, Giorgio W&#xD;Valenta, Rudolf&#xD;Matricardi, Paolo M&#xD;Mascarell, Laurent&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3084-3095. doi: 10.1111/all.15327. Epub 2022 May 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35474582</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15327</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1964</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1964</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kiewiet, M. B. G.</style></author><author><style face="normal" font="default" size="100%">Lupinek, C.</style></author><author><style face="normal" font="default" size="100%">Vrtala, S.</style></author><author><style face="normal" font="default" size="100%">Wieser, S.</style></author><author><style face="normal" font="default" size="100%">Baar, A.</style></author><author><style face="normal" font="default" size="100%">Kiss, R.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Wickman, M.</style></author><author><style face="normal" font="default" size="100%">Porta, D.</style></author><author><style face="normal" font="default" size="100%">Gori, D.</style></author><author><style face="normal" font="default" size="100%">Gehring, U.</style></author><author><style face="normal" font="default" size="100%">Aalberse, R.</style></author><author><style face="normal" font="default" size="100%">Sunyer, J.</style></author><author><style face="normal" font="default" size="100%">Standl, M.</style></author><author><style face="normal" font="default" size="100%">Heinrich, J.</style></author><author><style face="normal" font="default" size="100%">Waiblinger, D.</style></author><author><style face="normal" font="default" size="100%">Wright, J.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Department of Clinical Science and Education Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Sachs&apos; Children&apos;s Hospital, Stockholm, Sweden.&#xD;Department of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Epidemiology, Lazio Regional Health Service, ASL Roma 1, Rome, Italy.&#xD;Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.&#xD;Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.&#xD;Division of Research, Department of Immunopathology, Sanquin Blood Supply, Amsterdam, The Netherlands.&#xD;Insituto de Salud Global Barcelona, Barcelona, Spain.&#xD;Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Germany.&#xD;Comprehensive Pneumology Center Munich, German Center for Lung Research, Munich, Germany.&#xD;Bradford Institute for Health Research, Bradford, UK.&#xD;Departament de Ciencies Experimentals i de la Salut, Centre for Research in Environmental Epidemiology (CREAL), Hospital del Mar Research Institute (IMIM), CIBER Epidemiologia y Salud Publica (CIBERESP), Universitat Pompeu Fabra, Barcelona, Spain.&#xD;ARIA, Montpellier, France.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Allergology and Immunology, Berlin, Germany.&#xD;Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Institute of Allergology, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;National Research Center - Institute of Immunology FMBA of Russia, Moscow, Russian Federation.&#xD;Karl Landsteiner University for Healthcare Sciences, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A molecular sensitization map of European children reveals exposome- and climate-dependent sensitization profiles</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2007-2018</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Exposome</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">IgE reactivity</style></keyword><keyword><style face="normal" font="default" size="100%">MeDALL chip</style></keyword><keyword><style face="normal" font="default" size="100%">allergen molecules</style></keyword><keyword><style face="normal" font="default" size="100%">exposome</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization profile</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36815272</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Understanding differences in sensitization profiles at the molecular allergen level is important for diagnosis, personalized treatment and prevention strategies in allergy. METHODS: Immunoglobulin E (IgE) sensitization profiles were determined in more than 2800 sera from children in nine population-based cohorts in different geographical regions of Europe; north [BAMSE (Sweden), ECA (Norway)], west/central [PIAMA (the Netherlands), BiB (the United Kingdom), GINIplus (Germany)], and south [INMA Sabadell and Gipuzkoa (Spain) and ROBBIC Rome and Bologna (Italy)] using the MeDALL-allergen chip. RESULTS: Sensitization to grass pollen allergen, Phl p 1, and to major cat allergen, Fel d 1, dominated in most European regions whereas sensitization to house dust mite allergens Der p 1, 2 and 23 varied considerably between regions and were lowest in the north. Less than half of children from Sabadell which has a hot and dry climate were sensitized to respiratory allergens, in particular house dust mite allergens as compared to Gipuzkoa nearby with a more humid climate. Peanut allergen Ara h 1 was the most frequently recognized class 1 food allergen in Northern/Western Europe, while the fruit allergens Pru p 3, Act d 1 and 2 were prominent in Southern and Western/Central Europe. Ves v 5-sensitization dominated in North and West/Central Europe. CONCLUSION: We show regional, exposome- and climate-dependent differences in molecular IgE-reactivity profiles in Northern, Western/Central and Southern Europe which may form a molecular basis for precision medicine-based approaches for treatment and prevention of allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Kiewiet, M B Gea&#xD;Lupinek, Christian&#xD;Vrtala, Susanne&#xD;Wieser, Sandra&#xD;Baar, Alexandra&#xD;Kiss, Renata&#xD;Kull, Inger&#xD;Melen, Erik&#xD;Wickman, Magnus&#xD;Porta, Daniela&#xD;Gori, Davide&#xD;Gehring, Ulrike&#xD;Aalberse, Rob&#xD;Sunyer, Jordi&#xD;Standl, Marie&#xD;Heinrich, Joachim&#xD;Waiblinger, Dagmar&#xD;Wright, John&#xD;Anto, Josep M&#xD;Bousquet, Jean&#xD;van Hage, Marianne&#xD;Valenta, Rudolf&#xD;eng&#xD;European Commission/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2007-2018. doi: 10.1111/all.15689. Epub 2023 Mar 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36815272</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15689</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1026</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1026</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hemmer, W.</style></author><author><style face="normal" font="default" size="100%">Sestak-Greinecker, G.</style></author><author><style face="normal" font="default" size="100%">Braunsteiner, T.</style></author><author><style face="normal" font="default" size="100%">Wantke, F.</style></author><author><style face="normal" font="default" size="100%">Wohrl, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Floridsdorf Allergy Center (FAZ), Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Molecular sensitization patterns in animal allergy: Relationship with clinical relevance and pet ownership</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3687-3696</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/04/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cats</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">Horses</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Ownership</style></keyword><keyword><style face="normal" font="default" size="100%">*Pets/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">animal allergens</style></keyword><keyword><style face="normal" font="default" size="100%">furry animals</style></keyword><keyword><style face="normal" font="default" size="100%">indoor allergens</style></keyword><keyword><style face="normal" font="default" size="100%">molecular allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">pet allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33914361</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In vitro diagnosis using single molecules is increasingly complementing conventional extract-based diagnosis. We explored in routine patients with animal allergy to what extent molecules can explain polysensitization and identify primary sensitizers and how individual IgE patterns correlate with previous pet ownership and clinical relevance. METHODS: Serum samples from 294 children and adults with suspect allergic rhino-conjunctivitis or asthma and a positive skin prick test to cat, dog and/or horse were tested by ImmunoCAP for IgE antibodies against eleven different allergens from cat (Fel d 1,2,4,7), dog (Can f 1,2,3,4,5,6) and horse (Equ c 1). RESULTS: Patients monosensitized to cat (40.8%) or dog (6.1%) showed simple IgE patterns dominated by Fel d 1 (93%) and Can f 5 (67%), respectively. Double-sensitization to cat+dog (25.9%), cat+horse (5.4%) and polysensitization (20.7%) was associated with an increasing prevalence of the cross-reactive lipocalins Fel d 4/Can f 6/Equ c 1 and Fel d 7/Can f 1. While these lipocalins were not reliable markers for genuine sensitization per se, comparison of sIgE levels may give a clue on the primary sensitizer. Sensitizations to dog appeared to result from cross-reactivity with cat in 48%, with half of these sensitizations lacking clinical relevance. Individual sensitization patterns strongly mirrored current or previous pet ownership with the exception of Fel d 1 which regularly caused sensitization also in non-owners. CONCLUSIONS: Allergen components can reasonably illuminate the molecular basis of animal (poly)sensitization in the majority of patients and are helpful in distinguishing between primary sensitization and sometimes less relevant cross-reactivity.</style></abstract><notes><style face="normal" font="default" size="100%">Hemmer, Wolfgang&#xD;Sestak-Greinecker, Gabriele&#xD;Braunsteiner, Tobias&#xD;Wantke, Felix&#xD;Wohrl, Stefan&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3687-3696. doi: 10.1111/all.14885. Epub 2021 May 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33914361</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14885</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3013</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3013</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bianchini, R.</style></author><author><style face="normal" font="default" size="100%">Escolar-Pena, A.</style></author><author><style face="normal" font="default" size="100%">Pick, V.</style></author><author><style face="normal" font="default" size="100%">Poli, A.</style></author><author><style face="normal" font="default" size="100%">Adams, R.</style></author><author><style face="normal" font="default" size="100%">Basilio, J.</style></author><author><style face="normal" font="default" size="100%">Cari, L.</style></author><author><style face="normal" font="default" size="100%">Chauhan, J.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Vecillas, L. L.</style></author><author><style face="normal" font="default" size="100%">Delgado-Dolset, M. I.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author><author><style face="normal" font="default" size="100%">Grandits, M.</style></author><author><style face="normal" font="default" size="100%">Bax, H. J.</style></author><author><style face="normal" font="default" size="100%">Martin-Antoniano, I. A.</style></author><author><style face="normal" font="default" size="100%">Martin-Cruz, L.</style></author><author><style face="normal" font="default" size="100%">Mayerhofer, H.</style></author><author><style face="normal" font="default" size="100%">Michelucci, A.</style></author><author><style face="normal" font="default" size="100%">Nocentini, G.</style></author><author><style face="normal" font="default" size="100%">Osborn, G.</style></author><author><style face="normal" font="default" size="100%">Pablo-Torres, C.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Pascal, M.</style></author><author><style face="normal" font="default" size="100%">Radzikowska, U.</style></author><author><style face="normal" font="default" size="100%">Rohr-Udilova, N.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Bergmann, C.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Karagiannis, S. N.</style></author><author><style face="normal" font="default" size="100%">Rebollido-Rios, R.</style></author><author><style face="normal" font="default" size="100%">Izquierdo, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biological Sciences and Pathobiology, University of Veterinary Medicine of Vienna, Vienna, Austria.&#xD;Department of Basic Medical Sciences, Facultad de Medicina, Institute of Applied Molecular Medicine Instituto de Medicina Molecular Aplicada Nemesio Diez (IMMA-ND), Universidad San Pablo-CEU, CEU Universities, Urbanizacion Monteprincipe, Madrid, Spain.&#xD;Department I of Internal Medicine, Center for Integrated Oncology Aachen, Bonn, Cologne, Dusseldorf, Faculty of Medicine and Cologne University Hospital, University of Cologne, Cologne, Germany.&#xD;CECAD Cologne Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases, Center for Molecular Medicine Cologne, Cologne, Germany.&#xD;Neuro-Immunology Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.&#xD;School of Basic &amp; Medical Biosciences &amp; KHP Centre for Translational Medicine, St. John&apos;s Institute of Dermatology, King&apos;s College London, Guy&apos;s Hospital, London, UK.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;INESC-ID, Instituto Superior Tecnico, Universidade de Lisboa, Lisboa, Portugal.&#xD;Section of Pharmacology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.&#xD;Department of Allergy, La Paz University Hospital - IdiPAZ, Madrid, Spain.&#xD;Centro de Metabolomica y Bioanalisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain.&#xD;Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.&#xD;Instituto de Estudios de las Adicciones IEA-CEU, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.&#xD;Department of Biochemistry and Molecular Biology, School of Pharmacy, Complutense University, Madrid, Spain.&#xD;The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna, and University of Vienna, Vienna, Austria.&#xD;Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Immunology Department, Centre de Diagnostic Biomedic, Hospital Clinic de Barcelona, Barcelona, Spain.&#xD;Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.&#xD;Department of Medicine, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Division of Gastroenterology and Hepatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria.&#xD;Department of Otorhinolaryngology, RKM740 Interdisciplinary Clinics, Dusseldorf, Germany.&#xD;Breast Cancer Now Research Unit, School of Cancer &amp; Pharmaceutical Sciences, King&apos;s College London, Guy&apos;s Cancer Centre, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Molecular Signatures and Functional Pathways of Human Monocytes and Macrophages in Allergy: An EAACI AllergoOncology Scoping Review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2710-2725</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Macrophages/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/metabolism/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Monocytes/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">AllergoOncology</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">data-driven bioinformatics</style></keyword><keyword><style face="normal" font="default" size="100%">macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">monocytes</style></keyword><keyword><style face="normal" font="default" size="100%">interest related to the manuscript are listed here: S.N.K. is the founder and</style></keyword><keyword><style face="normal" font="default" size="100%">shareholder of Epsilogen Ltd. (formerly IGEM Therapeutics Ltd.) and has received</style></keyword><keyword><style face="normal" font="default" size="100%">funds from IGEM Therapeutics Ltd/Epsilogen Ltd. H.J.B., and M.G. are employed</style></keyword><keyword><style face="normal" font="default" size="100%">through a fund provided by Epsilogen Ltd. J.C. has been employed through a fund</style></keyword><keyword><style face="normal" font="default" size="100%">provided by Epsilogen Ltd. S.N.K. and H.J.B. are inventors of patents on antibody</style></keyword><keyword><style face="normal" font="default" size="100%">technologies. S.N.K. reports grants from Worldwide Cancer Research (24-0087)</style></keyword><keyword><style face="normal" font="default" size="100%">Guy&apos;s and St Thomas&apos;s Foundation Trust Charity Melanoma Special Fund (573)</style></keyword><keyword><style face="normal" font="default" size="100%">the</style></keyword><keyword><style face="normal" font="default" size="100%">British Skin Foundation (006/R/22)</style></keyword><keyword><style face="normal" font="default" size="100%">the Biotechnology and Biological Sciences</style></keyword><keyword><style face="normal" font="default" size="100%">Research Council (BB/T008709/1)</style></keyword><keyword><style face="normal" font="default" size="100%">Cancer Research UK (C30122/A11527</style></keyword><keyword><style face="normal" font="default" size="100%">C30122/A15774)</style></keyword><keyword><style face="normal" font="default" size="100%">the Cancer Research UK King&apos;s Health Partners Centre at King&apos;s</style></keyword><keyword><style face="normal" font="default" size="100%">College London (C604/A25135)</style></keyword><keyword><style face="normal" font="default" size="100%">the CRUK City of London Centre Award</style></keyword><keyword><style face="normal" font="default" size="100%">(C7893/A29290)</style></keyword><keyword><style face="normal" font="default" size="100%">Breast Cancer Now (147</style></keyword><keyword><style face="normal" font="default" size="100%">KCL-BCN-Q3)</style></keyword><keyword><style face="normal" font="default" size="100%">the Medical Research Council</style></keyword><keyword><style face="normal" font="default" size="100%">(MR/L023091/1</style></keyword><keyword><style face="normal" font="default" size="100%">MR/R015643/1</style></keyword><keyword><style face="normal" font="default" size="100%">MR/V049445/1)</style></keyword><keyword><style face="normal" font="default" size="100%">Innovate UK (51746)</style></keyword><keyword><style face="normal" font="default" size="100%">S.N.K. has</style></keyword><keyword><style face="normal" font="default" size="100%">projects supported by the King&apos;s Health Partners Centre for Translational</style></keyword><keyword><style face="normal" font="default" size="100%">Medicine. The views expressed are those of the author(s) and not necessarily</style></keyword><keyword><style face="normal" font="default" size="100%">those of King&apos;s Health Partners. O.P. received research grants from MINECO,</style></keyword><keyword><style face="normal" font="default" size="100%">Ministerio de Ciencia e Innovacion, CAM, Inmunotek S.L., Novartis, and</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca and fees for giving scientific lectures or participation in Advisory</style></keyword><keyword><style face="normal" font="default" size="100%">Boards from: AstraZeneca, Pfizer, GlaxoSmithKline, Inmunotek S.L., Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Genzyme and Regeneron. E.J.J. is inventor in EP2894478</style></keyword><keyword><style face="normal" font="default" size="100%">&quot;LCN2 as a tool</style></keyword><keyword><style face="normal" font="default" size="100%">for allergy diagnostic therapy&quot;, EP 14150965.3, Year: 01/2014</style></keyword><keyword><style face="normal" font="default" size="100%">US 14/204,570,</style></keyword><keyword><style face="normal" font="default" size="100%">immunoBON, owned by Biomedical International R+D GmbH, Vienna, Austria, of which</style></keyword><keyword><style face="normal" font="default" size="100%">E.J.J. is shareholder.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40878618</style></accession-num><abstract><style face="normal" font="default" size="100%">AllergoOncology explores the intersection of allergic diseases and cancer, focusing on shared immune mechanisms. While monocytes and macrophages are extensively studied in cancer, their roles in allergic diseases remain underexplored. To address this gap, we conducted a scoping review to systematically characterize the molecular landscape and related pathways of human monocytes and macrophages in allergy. An automated search of PubMed and Web of Science databases retrieved 4668 unique articles, which were manually curated based on predefined inclusion and exclusion criteria, yielding 138 eligible studies. From these, we identified 451 molecules associated with monocyte and macrophage responses across allergic disorders. Data analyses revealed a research bias towards blood-derived monocytes, underrepresentation of tissue-resident macrophages, and limited inclusion of miRNAs. Semantic similarity and pathway enrichment analyses highlighted a common molecular signature across major allergic disorders, with consistent enrichment in interleukin signaling and immune activation pathways. To enhance reproducibility and translational utility for researchers and clinicians, we developed ALO*HA, a web application for interactive data exploration. This overview of monocyte and macrophage molecular responses in human allergy underscores the need for integrative, human-focused approaches to better define their roles, and to guide future therapeutic strategies in allergic diseases and at the interface with oncology.</style></abstract><notes><style face="normal" font="default" size="100%">Bianchini, Rodolfo&#xD;Escolar-Pena, Andrea&#xD;Pick, Vanda&#xD;Poli, Aurelie&#xD;Adams, Rebecca&#xD;Basilio, Jose&#xD;Cari, Luigi&#xD;Chauhan, Jitesh&#xD;Chivato, Tomas&#xD;Vecillas, Leticia de Las&#xD;Delgado-Dolset, Maria Isabel&#xD;Escribese, Maria M&#xD;Grandits, Melanie&#xD;Bax, Heather J&#xD;Martin-Antoniano, Isabel Adoracion&#xD;Martin-Cruz, Leticia&#xD;Mayerhofer, Hanna&#xD;Michelucci, Alessandro&#xD;Nocentini, Giuseppe&#xD;Osborn, Gabriel&#xD;Pablo-Torres, Carmela&#xD;Palomares, Oscar&#xD;Pascal, Mariona&#xD;Radzikowska, Urszula&#xD;Rohr-Udilova, Nataliya&#xD;Sokolowska, Milena&#xD;Bergmann, Christoph&#xD;Jensen-Jarolim, Erika&#xD;Karagiannis, Sophia N&#xD;Rebollido-Rios, Rocio&#xD;Izquierdo, Elena&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Scoping Review&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2710-2725. doi: 10.1111/all.16672. Epub 2025 Aug 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40878618</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486325</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16672</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>480</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">480</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kamath, S. D.</style></author><author><style face="normal" font="default" size="100%">Liu, T.</style></author><author><style face="normal" font="default" size="100%">Giacomin, P.</style></author><author><style face="normal" font="default" size="100%">Loukas, A.</style></author><author><style face="normal" font="default" size="100%">Navarro, S.</style></author><author><style face="normal" font="default" size="100%">Lopata, A. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, QLD, Australia.&#xD;Molecular Allergy Research Laboratory, College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, QLD, Australia.&#xD;Centre for Molecular Therapeutics, James Cook University, Cairns, QLD, Australia.&#xD;National University of Singapore (Suzhou) Research Institute, Suzhou, China.&#xD;QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.&#xD;Woolworths Centre for Childhood Nutrition Research, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia.&#xD;Tropical Futures Institute, James Cook University, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mollusk allergy: Not simply cross-reactivity with crustacean allergens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3127-3130</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/05/17</style></edition><section><style face="normal" font="default" size="100%">3127</style></section><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mollusca</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">crustacean</style></keyword><keyword><style face="normal" font="default" size="100%">mollusk</style></keyword><keyword><style face="normal" font="default" size="100%">shellfish</style></keyword><keyword><style face="normal" font="default" size="100%">tropomyosin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35575977</style></accession-num><notes><style face="normal" font="default" size="100%">Kamath, Sandip D&#xD;Liu, Tiange&#xD;Giacomin, Paul&#xD;Loukas, Alex&#xD;Navarro, Severine&#xD;Lopata, Andreas L&#xD;eng&#xD;M 3295/FWF_/Austrian Science Fund FWF/Austria&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3127-3130. doi: 10.1111/all.15377. Epub 2022 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35575977</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9796110</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15377</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>726</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">726</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maccarana, M.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Lampinen, M.</style></author><author><style face="normal" font="default" size="100%">Rollman, O.</style></author><author><style face="normal" font="default" size="100%">Adner, M.</style></author><author><style face="normal" font="default" size="100%">Pejler, G.</style></author><author><style face="normal" font="default" size="100%">Paivandy, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.&#xD;Karolinska Institutet, The Institute of Environmental Medicine - IMM, Solna, Sweden.&#xD;Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Monensin induces selective mast cell apoptosis through a secretory granule-mediated pathway</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1025-1028</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/10/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Monensin/metabolism/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Secretory Vesicles/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34706101</style></accession-num><notes><style face="normal" font="default" size="100%">Maccarana, Marco&#xD;Liu, Jielu&#xD;Lampinen, Maria&#xD;Rollman, Ola&#xD;Adner, Mikael&#xD;Pejler, Gunnar&#xD;Paivandy, Aida&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1025-1028. doi: 10.1111/all.15157. Epub 2021 Nov 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34706101</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15157</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1236</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1236</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koenderman, L.</style></author><author><style face="normal" font="default" size="100%">Hassani, M.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine and Laboratory of Translational Immunology, University of Utrecht, Utrecht, The Netherlands.&#xD;Department of Medicine, Division of Respirology, McMaster University and St Joseph&apos;s Healthcare, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1294-1297</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33301608</style></accession-num><notes><style face="normal" font="default" size="100%">Koenderman, Leo&#xD;Hassani, Marwan&#xD;Mukherjee, Manali&#xD;Nair, Parameswaran&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1294-1297. doi: 10.1111/all.14700. Epub 2020 Dec 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33301608</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246958 Coulter. MH declares no conflicts of interests. MM reports grants from Methapharm Specialty Pharmaceuticals, Canadian Institute of Health Research, Canadian Asthma Allergy and Immunology Foundation and personal fees from AstraZeneca. PN reports grants and/or personal fees from AZ, Novartis, Teva, Sanofi, Roche, Novartis, Merck and Equillium.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14700</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1656</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1656</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koenderman, L.</style></author><author><style face="normal" font="default" size="100%">Hassani, M.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine and Laboratory of Translational Immunology, University of Utrecht, Utrecht, The Netherlands.&#xD;Department of Medicine, Division of Respirology, McMaster University and St Joseph&apos;s Healthcare, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1294-1297</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33301608</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Eosinophils, since their initial description by Thomas Wharton Jones in 1846, and staining characteristics by Paul Ehrlich in 1879, have been associated with asthma1. They are produced in the bone marrow, from pluripotential stem cells, whichfirst differentiate, largely regulated by a transcription factor GATA-1, into a hybrid precursor for both basophils and eosinophils, and then into a separate eosinophil lineage. The eosinophilopoietins IL-3, GM-CSF and notably IL-5 regulatetheir further expansion and migration out of the bonemarrow into the circulation.Circulating eosinophils subsequently interactwith the endothelium by processes involving rolling, adhesion, and diapedesis. Depending on the targetorgan, eosinophils cross the endothelium into tissues by a regulated process involving the coordinatedinteraction between networks involving cytokines such as IL-13, the chemokine eotaxin-1, eosinophil adhesion molecules (α4β1, α4β7, αmβ2, αLβ2), and adhesion receptors on the endothelium (MAdCAM-1, VCAM-1, and ICAM-1). Under homeostatic conditions, eosinophils traffic into the thymus, mammary gland, uterus, and most prominently into the gastrointestinal tract.</style></abstract><notes><style face="normal" font="default" size="100%">Koenderman, Leo&#xD;Hassani, Marwan&#xD;Mukherjee, Manali&#xD;Nair, Parameswaran&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1294-1297. doi: 10.1111/all.14700. Epub 2020 Dec 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33301608</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246958 Coulter. MH declares no conflicts of interests. MM reports grants from Methapharm Specialty Pharmaceuticals, Canadian Institute of Health Research, Canadian Asthma Allergy and Immunology Foundation and personal fees from AstraZeneca. PN reports grants and/or personal fees from AZ, Novartis, Teva, Sanofi, Roche, Novartis, Merck and Equillium.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14700</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2729</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2729</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author><author><style face="normal" font="default" size="100%">Murdaca, G.</style></author><author><style face="normal" font="default" size="100%">Guemari, A.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Azkur, A. K.</style></author><author><style face="normal" font="default" size="100%">Aksoy, E.</style></author><author><style face="normal" font="default" size="100%">Vitte, J.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Karavelia, A.</style></author><author><style face="normal" font="default" size="100%">Castagnoli, R.</style></author><author><style face="normal" font="default" size="100%">Valdelvira, R.</style></author><author><style face="normal" font="default" size="100%">Orsi, A.</style></author><author><style face="normal" font="default" size="100%">Ogliastro, M.</style></author><author><style face="normal" font="default" size="100%">Massaro, E.</style></author><author><style face="normal" font="default" size="100%">Yucel, E. O.</style></author><author><style face="normal" font="default" size="100%">Novak, N.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Department of Internal Medicine, University of Genova, Genova, Italy.&#xD;Allergology and Clinical Immunology Unit, San Bartolomeo Hospital, Sarzana, Italy.&#xD;IDESP and PREMEDICAL, University of Montpellier-INSERM, INRIA, Montpellier, France.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Allergy Research Group, Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, ARADyAL, Malaga University, Malaga, Spain.&#xD;Department of Virology, Faculty of Veterinary Medicine, Kirikkale University, Kirikkale, Turkey.&#xD;University of Reims Champagne-Ardenne, INSERM UMR 1250 and Immunology Laboratory, University Hospital of Reims, Reims, France.&#xD;Immunology Department, IIS-Fundacion Jimenez Diaz, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.&#xD;Department of Ear-Nose-Throat Surgery, General Hospital of Nafplio, Nafplio, Greece.&#xD;Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.&#xD;Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.&#xD;Department of Health Sciences (DISSAL), University of Genova, Genova, Italy.&#xD;Hygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genova, Italy.&#xD;Division of Pediatrics, Department of Pediatric Allergy and Immunology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.&#xD;Department of Dermatology and Allergy, Venusberg Campus 1, Bonn, Germany.&#xD;Transylvania University, Brasov, Romania.&#xD;Theramed Medical Center, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Monkeypox 2024 outbreak: Fifty essential questions and answers</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3285-3309</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/11/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Disease Outbreaks</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mpox, Monkeypox/epidemiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Monkeypox virus/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Global Health</style></keyword><keyword><style face="normal" font="default" size="100%">monkeypox</style></keyword><keyword><style face="normal" font="default" size="100%">outbreak</style></keyword><keyword><style face="normal" font="default" size="100%">poxvirus</style></keyword><keyword><style face="normal" font="default" size="100%">upsurge</style></keyword><keyword><style face="normal" font="default" size="100%">viral zoonosis</style></keyword><keyword><style face="normal" font="default" size="100%">zoonotic infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39495103</style></accession-num><abstract><style face="normal" font="default" size="100%">As the world still vividly recalls the previous monkeypox (mpox) outbreak that impacted over 120 countries worldwide with more than 99,000 cases in 2022, we are now facing a second wave of infections from the monkeypox virus (MPXV), characterized by an exponential increase in cases. The current 2024 outbreak has already recorded more than 20,000 cases in Africa, marking a dramatic escalation compared to previous outbreaks. The predominance of the newly identified clade Ib variant, first detected in the Democratic Republic of the Congo (DRC) and now identified across multiple African nations and beyond, underscores its enhanced transmissibility and potential for international spread, evidenced by cases in Sweden and Thailand. The World Health Organization (WHO) declared on August 14, 2024, the current mpox outbreak a Public Health Emergency of International Concern (PHEIC), calling for heightened global public health measures. The ongoing pattern of unusual, frequent, and extensive outbreaks of mpox with potential global implications poses significant questions. This review addresses, in the format of 50 questions and answers, the 2024 mpox outbreak, detailing its characteristics, epidemiological data, and impact compared to previous outbreaks. It comprehensively explores critical questions related to MPXV virological characteristics, immunological response, clinical manifestations, epidemiology, diagnostics, and available treatments. The review also documents the significant and evolving challenges posed by the current mpox outbreak, highlighting its scale, spread, and public health response.</style></abstract><notes><style face="normal" font="default" size="100%">Cabanillas, Beatriz&#xD;Murdaca, Giuseppe&#xD;Guemari, Amir&#xD;Torres, Maria Jose&#xD;Azkur, Ahmet Kursat&#xD;Aksoy, Emel&#xD;Vitte, Joana&#xD;Fernandez-Santamaria, Ruben&#xD;Karavelia, Aspasia&#xD;Castagnoli, Riccardo&#xD;Valdelvira, Rafael&#xD;Orsi, Andrea&#xD;Ogliastro, Matilde&#xD;Massaro, Elvira&#xD;Yucel, Esra Ozek&#xD;Novak, Natalija&#xD;Agache, Ioana&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;eng&#xD;Instituto de Salud Carlos III (ISCIII) through project PI20/00351, co-funded by the European Union./&#xD;Community of Madrid Talento Investigador program (Regional Ministry of Science, Universities, and Innovation, Madrid, Spain), under the projects 2023-5A/BIO-28929 and 2019-T1/BIO-12690/&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3285-3309. doi: 10.1111/all.16374. Epub 2024 Nov 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39495103</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16374</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>461</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">461</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author><author><style face="normal" font="default" size="100%">Valdelvira, R.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Allergy, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Monkeypox outbreak in Europe, UK, North America, and Australia: A changing trend of a zoonotic disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2284-2286</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/06/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Outbreaks</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mpox, Monkeypox/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">North America/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom</style></keyword><keyword><style face="normal" font="default" size="100%">Zoonoses/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35645141</style></accession-num><notes><style face="normal" font="default" size="100%">Cabanillas, Beatriz&#xD;Valdelvira, Rafael&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2284-2286. doi: 10.1111/all.15393.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35645141</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15393</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3202</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3202</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shrestha Palikhe, N.</style></author><author><style face="normal" font="default" size="100%">Wu, Y.</style></author><author><style face="normal" font="default" size="100%">Howie, K. J.</style></author><author><style face="normal" font="default" size="100%">Stevens, C.</style></author><author><style face="normal" font="default" size="100%">Mitchell, J.</style></author><author><style face="normal" font="default" size="100%">Wiltshire, L.</style></author><author><style face="normal" font="default" size="100%">Gauvreau, G. M.</style></author><author><style face="normal" font="default" size="100%">Vliagoftis, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine and Alberta Respiratory Centre, University of Alberta, Edmonton, Canada.&#xD;Department of Medicine, McMaster University, Hamilton, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Monocyte Chemotactic Factors in the Airways of Patients With Mild Asthma Before and After an Allergen Challenge</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/13</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 12</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41388638</style></accession-num><notes><style face="normal" font="default" size="100%">Shrestha Palikhe, Nami&#xD;Wu, Yingqi&#xD;Howie, Karen J&#xD;Stevens, Caitlin&#xD;Mitchell, Jennifer&#xD;Wiltshire, Lesley&#xD;Gauvreau, Gail M&#xD;Vliagoftis, Harissios&#xD;eng&#xD;143901/GlaxoSmithKline foundation/&#xD;133475/CAPMC/CIHR/Canada&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec 12. doi: 10.1111/all.70192.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41388638</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70192</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3029</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3029</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, B.</style></author><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">Zeyneloglu, C.</style></author><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Ardicli, S.</style></author><author><style face="normal" font="default" size="100%">Garcia-Sanchez, A.</style></author><author><style face="normal" font="default" size="100%">Viscardi, O. G.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Genetics, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey.&#xD;Department of Biomedical and Diagnostic Science, School of Medicine, University of Salamanca, Salamanca, Spain.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Monosodium Glutamate Induces Cellular Stress, Endoplasmic Reticulum Stress, Mitochondrial Dysfunction, and Cell Death in Intestinal Epithelial Cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2916-2920</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/08/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Bern</style></keyword><keyword><style face="normal" font="default" size="100%">research grant from Stanford University</style></keyword><keyword><style face="normal" font="default" size="100%">Leading House for the Latin</style></keyword><keyword><style face="normal" font="default" size="100%">American Region, Seed Money Grant. She is the Scientific Advisory Board member of</style></keyword><keyword><style face="normal" font="default" size="100%">Stanford University Sean Parker Asthma Allergy Center, CA</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Board member</style></keyword><keyword><style face="normal" font="default" size="100%">of LEO Foundation Skin Immunology Research Center, Copenhagen</style></keyword><keyword><style face="normal" font="default" size="100%">and Scientific</style></keyword><keyword><style face="normal" font="default" size="100%">Co-Chair of World Allergy Congress (WAC) Istanbul, 2022, Scientific Program</style></keyword><keyword><style face="normal" font="default" size="100%">Committee Chair, EAACI. K.C.N. currently reports grants from National Institute</style></keyword><keyword><style face="normal" font="default" size="100%">of Allergy and Infectious Diseases (NIAID), National Heart, Lung, and Blood</style></keyword><keyword><style face="normal" font="default" size="100%">Institute (NHLBI), National Institute of Environmental Health Sciences (NIEHS)</style></keyword><keyword><style face="normal" font="default" size="100%">Stock options from IgGenix, Seed Health, ClostraBio, Cour, Alladapt</style></keyword><keyword><style face="normal" font="default" size="100%">Consultant</style></keyword><keyword><style face="normal" font="default" size="100%">for Excellergy, Red tree ventures, Regeneron, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">Co-founder of</style></keyword><keyword><style face="normal" font="default" size="100%">Alladapt, Latitude, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">National Scientific Committee member at Immune</style></keyword><keyword><style face="normal" font="default" size="100%">Tolerance Network (ITN), and National Institutes of Health (NIH) clinical</style></keyword><keyword><style face="normal" font="default" size="100%">research centers</style></keyword><keyword><style face="normal" font="default" size="100%">patents include, &quot;Mixed allergen composition and methods for</style></keyword><keyword><style face="normal" font="default" size="100%">using the same,&quot; &quot;Granulocyte-based methods for detecting and monitoring immune</style></keyword><keyword><style face="normal" font="default" size="100%">system disorders,&quot; and &quot;Methods and Assays for Detecting and Quantifying Pure</style></keyword><keyword><style face="normal" font="default" size="100%">Subpopulations of White Blood Cells in Immune System Disorders.&quot; C.A.A. has</style></keyword><keyword><style face="normal" font="default" size="100%">received research grants from the Swiss National Science Foundation, European</style></keyword><keyword><style face="normal" font="default" size="100%">Union (EU CURE, EU Syn-Air-G), Novartis Research Institutes (Basel, Switzerland),</style></keyword><keyword><style face="normal" font="default" size="100%">Stanford University (Redwood City, Calif), Seed Health (Boston, USA) and SciBase</style></keyword><keyword><style face="normal" font="default" size="100%">(Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">is the Co-Chair for EAACI Guidelines on Environmental</style></keyword><keyword><style face="normal" font="default" size="100%">Science in Allergic diseases and Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">is on the Advisory Boards of</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron (Bern, Switzerland, New York, USA), Stanford University Sean</style></keyword><keyword><style face="normal" font="default" size="100%">Parker Asthma Allergy Center (CA, USA), Novartis (Basel, Switzerland), Glaxo</style></keyword><keyword><style face="normal" font="default" size="100%">Smith Kline (Zurich, Switzerland), Bristol-Myers Squibb (New York, USA), Seed</style></keyword><keyword><style face="normal" font="default" size="100%">Health (Boston, USA), and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">and is the Editor-in-Chief</style></keyword><keyword><style face="normal" font="default" size="100%">of Allergy. I.O. is chair of the EAACI Epithelial Cell Biology Working Group.</style></keyword><keyword><style face="normal" font="default" size="100%">B.Z., H.B., C.Z., Y.P., D.Y., and S.A. declare no relevant conflicts of interest.</style></keyword><keyword><style face="normal" font="default" size="100%">B.Z. reports grant from the CSC scholarship program of China (No. 2023).</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40838342</style></accession-num><notes><style face="normal" font="default" size="100%">Zhao, Bingjie&#xD;Babayev, Huseyn&#xD;Zeyneloglu, Can&#xD;Pat, Yagiz&#xD;Yazici, Duygu&#xD;Ardicli, Sena&#xD;Garcia-Sanchez, Asuncion&#xD;Viscardi, Oliva Giannelli&#xD;Akdis, Mubeccel&#xD;Nadeau, Kari C&#xD;Akdis, Cezmi A&#xD;Ogulur, Ismail&#xD;eng&#xD;Stanford University/&#xD;SciBase/&#xD;CURE-Eubiosis Reinstatement Therapy/&#xD;Novartis Research Institutes/&#xD;SNSF_/Swiss National Science Foundation/Switzerland&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2916-2920. doi: 10.1111/all.70007. Epub 2025 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40838342</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486344</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70007</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2665</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2665</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Otten, J. J.</style></author><author><style face="normal" font="default" size="100%">van der Lans, R. J. L.</style></author><author><style face="normal" font="default" size="100%">Elzinga, H. B. E.</style></author><author><style face="normal" font="default" size="100%">Adriaensen, Gfjpm</style></author><author><style face="normal" font="default" size="100%">Benoist, L. B. L.</style></author><author><style face="normal" font="default" size="100%">Hoven, R. D.</style></author><author><style face="normal" font="default" size="100%">Seys, S.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology &amp; Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Galenus Health, Hasselt, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">More than half of chronic rhinosinusitis with nasal polyps (CRSwNP) patients treated with dupilumab experience early and fast olfactory improvement within 28 days</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3166-3168</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/10/29</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39470615</style></accession-num><notes><style face="normal" font="default" size="100%">Otten, Josje Janna&#xD;van der Lans, Rik Johannes Leonardus&#xD;Elzinga, Hester Beatrice Emilie&#xD;Adriaensen, Gwijde Flavius Jacobus Petrus Maria&#xD;Benoist, Linda Berendina Laurentia&#xD;Hoven, Rienk D&#xD;Seys, Sven&#xD;Fokkens, Wytske Johanna&#xD;Reitsma, Sietze&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3166-3168. doi: 10.1111/all.16357. Epub 2024 Oct 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39470615</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16357</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2494</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2494</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fakhimahmadi, A.</style></author><author><style face="normal" font="default" size="100%">Roth-Walter, F.</style></author><author><style face="normal" font="default" size="100%">Hofstetter, G.</style></author><author><style face="normal" font="default" size="100%">Wiederstein, M.</style></author><author><style face="normal" font="default" size="100%">Jensen, S. A.</style></author><author><style face="normal" font="default" size="100%">Berger, M.</style></author><author><style face="normal" font="default" size="100%">Szepannek, N.</style></author><author><style face="normal" font="default" size="100%">Bianchini, R.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Hufnagl, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Messerli Research Institute, Department of Interdisciplinary Life Sciences, University of Veterinary Medicine, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria.&#xD;AllergyCare Allergy Diagnosis Center, Private Clinic Dobling, Vienna, Austria.&#xD;Biomedical International R+D GmbH, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mould allergen Alt a 1 spiked with the micronutrient retinoic acid reduces Th2 response and ameliorates Alternaria allergy in BALB/c mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2144-2156</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/05/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Alternaria/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Tretinoin/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Fungal/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Fungal Proteins/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Alternaria alternata</style></keyword><keyword><style face="normal" font="default" size="100%">fungal allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">retinoic acid</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin A</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38818808</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: We investigated the biological function of the mould allergen Alt a 1 as a carrier of micronutrients, such as the vitamin A metabolite retinoic acid (RA) and the influence of RA binding on its allergenicity in vitro and in vivo. METHODS: Alt a 1-RA complex formation was analyzed in silico and in vitro. PBMCs from Alternaria-allergic donors were stimulated with Alt a 1 complexed with RA (holo-Alt a 1) or empty apo-Alt a 1 and analyzed for cytokine production and CD marker expression. Serum IgE-binding and crosslinking assays to apo- and holo-protein were correlated to B-cell epitope analysis. Female BALB/c mice already sensitized to Alt a 1 were intranasally treated with apo-Alt a 1, holo-Alt a 1 or RA alone before measuring anaphylactic response, serum antibody levels, splenic cytokines and CD marker expression. RESULTS: In silico docking calculations and in vitro assays showed that the extent of RA binding depended on the higher quaternary state of Alt a 1. Holo-Alt a 1 loaded with RA reduced IL-13 released from PBMCs and CD3+CD4+CRTh2 cells. Complexing Alt a 1 to RA masked its IgE B-cell epitopes and reduced its IgE-binding capacity. In a therapeutic mouse model of Alternaria allergy nasal application of holo-Alt a 1, but not of apo-Alt a 1, significantly impeded the anaphylactic response, impaired splenic antigen-presenting cells and induced IL-10 production. CONCLUSION: Holo-Alt a 1 binding to RA was able to alleviate Th2 immunity in vitro, modulate an ongoing Th2 response and prevent anaphylactic symptoms in vivo, presenting a novel option for improving allergen-specific immunotherapy in Alternaria allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Fakhimahmadi, Aila&#xD;Roth-Walter, Franziska&#xD;Hofstetter, Gerlinde&#xD;Wiederstein, Markus&#xD;Jensen, Sebastian A&#xD;Berger, Markus&#xD;Szepannek, Nathalie&#xD;Bianchini, Rodolfo&#xD;Pali-Scholl, Isabella&#xD;Jensen-Jarolim, Erika&#xD;Hufnagl, Karin&#xD;eng&#xD;Danube Allergy Research Cluster DARC #8 of the Karl Landsteiner University Krems, Austria/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2144-2156. doi: 10.1111/all.16181. Epub 2024 May 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38818808</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16181</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2395</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2395</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nguyen, L. M.</style></author><author><style face="normal" font="default" size="100%">Kanda, A.</style></author><author><style face="normal" font="default" size="100%">Kamioka, Y.</style></author><author><style face="normal" font="default" size="100%">Tokuhiro, K.</style></author><author><style face="normal" font="default" size="100%">Kobayashi, Y.</style></author><author><style face="normal" font="default" size="100%">Yun, Y.</style></author><author><style face="normal" font="default" size="100%">Bui, D. V.</style></author><author><style face="normal" font="default" size="100%">Chu, H. H.</style></author><author><style face="normal" font="default" size="100%">Le, N. K. T.</style></author><author><style face="normal" font="default" size="100%">Suzuki, K.</style></author><author><style face="normal" font="default" size="100%">Mitani, A.</style></author><author><style face="normal" font="default" size="100%">Shimamura, A.</style></author><author><style face="normal" font="default" size="100%">Fukui, K.</style></author><author><style face="normal" font="default" size="100%">Dombrowicz, D.</style></author><author><style face="normal" font="default" size="100%">Iwai, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka, Japan.&#xD;Laboratory Medicine Center, Kansai Medical University Hospital, Osaka, Japan.&#xD;Allergy Center, Kansai Medical University Hospital, Osaka, Japan.&#xD;Department of Molecular Genetics, Institute of Biomedical Science, Kansai Medical University, Osaka, Japan.&#xD;Department of Genome Editing, Institute of Biomedical Science, Kansai Medical University, Osaka, Japan.&#xD;Allergy, Immunology and Dermatology Department, E Hospital, Hanoi, Vietnam.&#xD;Allergy and Clinical Immunology Department, Hanoi Medical University, Hanoi, Vietnam.&#xD;Allergy, Immunology and Rheumatology Department, National Children Hospital, Hanoi, Vietnam.&#xD;University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mouse eosinophil-associated ribonuclease-2 exacerbates the allergic response</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2251-2255</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/02/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophil Cationic Protein/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38391260</style></accession-num><notes><style face="normal" font="default" size="100%">Nguyen, Linh Manh&#xD;Kanda, Akira&#xD;Kamioka, Yuji&#xD;Tokuhiro, Keizo&#xD;Kobayashi, Yoshiki&#xD;Yun, Yasutaka&#xD;Bui, Dan Van&#xD;Chu, Hanh Hong&#xD;Le, Nhi Kieu Thi&#xD;Suzuki, Kensuke&#xD;Mitani, Akitoshi&#xD;Shimamura, Akihiro&#xD;Fukui, Kenta&#xD;Dombrowicz, David&#xD;Iwai, Hiroshi&#xD;eng&#xD;Grants-in-Aid for Scientific Research (C) from MEXT/&#xD;Ministry of Education, Culture, Sports, Science, and Technology (MEXT)-Supported Program for the Strategic Research Foundation at Private Universities/&#xD;European Union/&#xD;Agence Nationale de la Recherche/&#xD;Fondation pour la Recherche Medicale/&#xD;Academic Society for Research in Otolaryngology, Kansai Medical University/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2251-2255. doi: 10.1111/all.16061. Epub 2024 Feb 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38391260</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16061</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2514</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2514</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sypka, M.</style></author><author><style face="normal" font="default" size="100%">Zwicker, M.</style></author><author><style face="normal" font="default" size="100%">Lagache, S. B.</style></author><author><style face="normal" font="default" size="100%">Uldry, A. C.</style></author><author><style face="normal" font="default" size="100%">Vogel, M.</style></author><author><style face="normal" font="default" size="100%">Engeroff, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland.&#xD;University of Bern, Bern, Switzerland.&#xD;Proteomics and Mass Spectrometry Core Facility, Department for BioMedical Research, University of Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mouse IgE clone SPE-7 can contain functional mouse IgG</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2544-2547</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/05/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin G/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38706436</style></accession-num><notes><style face="normal" font="default" size="100%">Sypka, Michalina&#xD;Zwicker, Marianne&#xD;Lagache, Sophie Braga&#xD;Uldry, Anne-Christine&#xD;Vogel, Monique&#xD;Engeroff, Paul&#xD;eng&#xD;Holcim Stiftung zur Forderung der Wissenschaftlichen Fortbildung/&#xD;Novartis Stiftung fur Medizinisch-Biologische Forschung/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2544-2547. doi: 10.1111/all.16141. Epub 2024 May 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38706436</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16141</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1376</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1376</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fukuda, K.</style></author><author><style face="normal" font="default" size="100%">Matsuzaki, H.</style></author><author><style face="normal" font="default" size="100%">Mikami, Y.</style></author><author><style face="normal" font="default" size="100%">Makita, K.</style></author><author><style face="normal" font="default" size="100%">Miyakawa, K.</style></author><author><style face="normal" font="default" size="100%">Miyashita, N.</style></author><author><style face="normal" font="default" size="100%">Hosoki, K.</style></author><author><style face="normal" font="default" size="100%">Ishii, T.</style></author><author><style face="normal" font="default" size="100%">Noguchi, S.</style></author><author><style face="normal" font="default" size="100%">Urushiyama, H.</style></author><author><style face="normal" font="default" size="100%">Horie, M.</style></author><author><style face="normal" font="default" size="100%">Mitani, A.</style></author><author><style face="normal" font="default" size="100%">Yamauchi, Y.</style></author><author><style face="normal" font="default" size="100%">Shimura, E.</style></author><author><style face="normal" font="default" size="100%">Nakae, S.</style></author><author><style face="normal" font="default" size="100%">Saito, A.</style></author><author><style face="normal" font="default" size="100%">Nagase, T.</style></author><author><style face="normal" font="default" size="100%">Hiraishi, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.&#xD;Centre for Epidemiology and Preventive Medicine, The University of Tokyo Hospital, Tokyo, Japan.&#xD;Marsico Lung Institute/UNC Cystic Fibrosis Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.&#xD;Meakins-Christie Laboratories, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.&#xD;Division for Health Service Promotion, The University of Tokyo, Tokyo, Japan.&#xD;Department of Cancer Genome Informatics, Graduate School of Medicine, Osaka University, Osaka, Japan.&#xD;Health Care Centre, Tokyo University of Foreign Studies, Tokyo, Japan.&#xD;Department of Chemistry, Juntendo University School of Medicine, Chiba, Japan.&#xD;The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.&#xD;Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A mouse model of asthma-chronic obstructive pulmonary disease overlap induced by intratracheal papain</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">390-394</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/08/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/chemically induced/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Papain</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Copd</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32740929</style></accession-num><notes><style face="normal" font="default" size="100%">Fukuda, Kensuke&#xD;Matsuzaki, Hirotaka&#xD;Mikami, Yu&#xD;Makita, Kosuke&#xD;Miyakawa, Kazuko&#xD;Miyashita, Naoya&#xD;Hosoki, Keisuke&#xD;Ishii, Takashi&#xD;Noguchi, Satoshi&#xD;Urushiyama, Hirokazu&#xD;Horie, Masafumi&#xD;Mitani, Akihisa&#xD;Yamauchi, Yasuhiro&#xD;Shimura, Eri&#xD;Nakae, Susumu&#xD;Saito, Akira&#xD;Nagase, Takahide&#xD;Hiraishi, Yoshihisa&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):390-394. doi: 10.1111/all.14528. Epub 2020 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32740929</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14528</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>509</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">509</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dolitzky, A.</style></author><author><style face="normal" font="default" size="100%">Grisaru-Tal, S.</style></author><author><style face="normal" font="default" size="100%">Avlas, S.</style></author><author><style face="normal" font="default" size="100%">Hazut, I.</style></author><author><style face="normal" font="default" size="100%">Gordon, Y.</style></author><author><style face="normal" font="default" size="100%">Itan, M.</style></author><author><style face="normal" font="default" size="100%">Munitz, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mouse resident lung eosinophils are dependent on IL-5</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2822-2825</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/05/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Differentiation, Myelomonocytic</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-5</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Siglec-F</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Sanofi and GlaxoSmithKline. The other authors declare no relevant</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35524429</style></accession-num><notes><style face="normal" font="default" size="100%">Dolitzky, Avishay&#xD;Grisaru-Tal, Sharon&#xD;Avlas, Shmuel&#xD;Hazut, Inbal&#xD;Gordon, Yaara&#xD;Itan, Michal&#xD;Munitz, Ariel&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2822-2825. doi: 10.1111/all.15362. Epub 2022 May 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35524429</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9542632</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15362</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>921</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">921</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Naidoo, K.</style></author><author><style face="normal" font="default" size="100%">Woods, K.</style></author><author><style face="normal" font="default" size="100%">Pellefigues, C.</style></author><author><style face="normal" font="default" size="100%">Cait, A.</style></author><author><style face="normal" font="default" size="100%">O&apos;Sullivan, D.</style></author><author><style face="normal" font="default" size="100%">Gell, K.</style></author><author><style face="normal" font="default" size="100%">Marshall, A. J.</style></author><author><style face="normal" font="default" size="100%">Anderson, R. J.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Schmidt, A.</style></author><author><style face="normal" font="default" size="100%">Prasit, K.</style></author><author><style face="normal" font="default" size="100%">Mayer, J. U.</style></author><author><style face="normal" font="default" size="100%">Gestin, A.</style></author><author><style face="normal" font="default" size="100%">Hermans, I. F.</style></author><author><style face="normal" font="default" size="100%">Painter, G.</style></author><author><style face="normal" font="default" size="100%">Jacobsen, E. A.</style></author><author><style face="normal" font="default" size="100%">Gasser, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Malaghan Institute of Medical Research, Wellington, New Zealand.&#xD;High-Value Nutrition National Science Challenge, Auckland, New Zealand.&#xD;Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand.&#xD;Division of Allergy, Asthma and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, AZ, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">MR1-dependent immune surveillance of the skin contributes to pathogenesis and is a photobiological target of UV light therapy in a mouse model of atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3155-3170</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/06/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Histocompatibility Antigens Class I</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Minor Histocompatibility Antigens</style></keyword><keyword><style face="normal" font="default" size="100%">*Mucosal-Associated Invariant T Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Ultraviolet Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">MAIT cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mr1</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">phototherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34185885</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Mucosal-associated invariant T (MAIT) cells are unconventional T cells which recognize microbial metabolites presented by the major histocompatibility complex class I-related molecule MR1. Although MAIT cells have been shown to reside in human and murine skin, their contribution to atopic dermatitis (AD), an inflammatory skin disease associated with barrier dysfunction and microbial translocation, has not yet been determined. METHODS: Genetic deletion of MR1 and topical treatment with inhibitory MR1 ligands, which result in the absence and functional inhibition of MAIT cells, respectively, were used to investigate the role of MR1-dependent immune surveillance in a MC903-driven murine model of AD. RESULTS: The absence or inhibition of MR1 arrested AD disease progression through the blockade of both eosinophil activation and recruitment of IL-4- and IL-13-producing cells. In addition, the therapeutic efficacy of phototherapy against MC903-driven AD could be increased with prior application of folate, which photodegrades into the inhibitory MR1 ligand 6-formylpterin. CONCLUSION: We identified MAIT cells as sentinels and mediators of cutaneous type 2 immunity. Their pathogenic activity can be inhibited by topical application or endogenous generation, via phototherapy, of inhibitory MR1 ligands.</style></abstract><notes><style face="normal" font="default" size="100%">Naidoo, Karmella&#xD;Woods, Katherine&#xD;Pellefigues, Christophe&#xD;Cait, Alissa&#xD;O&apos;Sullivan, David&#xD;Gell, Katie&#xD;Marshall, Andrew J&#xD;Anderson, Regan J&#xD;Li, Yanyan&#xD;Schmidt, Alfonso&#xD;Prasit, Kef&#xD;Mayer, Johannes U&#xD;Gestin, Aurelie&#xD;Hermans, Ian F&#xD;Painter, Gavin&#xD;Jacobsen, Elizabeth A&#xD;Gasser, Olivier&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3155-3170. doi: 10.1111/all.14994. Epub 2021 Jul 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34185885</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14994</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>627</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">627</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, C.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Liao, W.</style></author><author><style face="normal" font="default" size="100%">Liang, T.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author><author><style face="normal" font="default" size="100%">Xie, J.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Yang, P.</style></author><author><style face="normal" font="default" size="100%">Lu, W.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Respiratory Disease, Department of Otolaryngology, Head &amp; Neck Surgery, Laboratory of ENT-HNS Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.&#xD;Innovation and transformation platform of upper airway disease in Guangdong province, Guangzhou, China.&#xD;Department of Allergy and Clinical Immunology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.&#xD;State Key Laboratory of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.&#xD;Research Center of Allergy &amp; Immunology, Shenzhen University School of Medicine, Shenzhen, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">MUC1 deficiency induces the nasal epithelial barrier dysfunction via RBFOX3 shortage augment ubiquitin-proteasomal degradation in allergic rhinitis pathogenesis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1596-1599</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/01/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mucin-1</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitin</style></keyword><keyword><style face="normal" font="default" size="100%">ENT (rhinitis, sinusitis, nasal polyps...)</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35094408</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Chunyi&#xD;Wang, Yiyan&#xD;Liao, Wenjing&#xD;Liang, Tianhao&#xD;Liu, Weixing&#xD;Xie, Junyang&#xD;Wang, Xiaofen&#xD;Yang, Pingchang&#xD;Lu, Wenju&#xD;Zhang, Xiaowen&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1596-1599. doi: 10.1111/all.15235. Epub 2022 Feb 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35094408</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15235</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3034</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3034</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martin-Gonzalez, E.</style></author><author><style face="normal" font="default" size="100%">Perez-Garcia, J.</style></author><author><style face="normal" font="default" size="100%">Martin-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Witonsky, J.</style></author><author><style face="normal" font="default" size="100%">Eng, C.</style></author><author><style face="normal" font="default" size="100%">Huntsman, S.</style></author><author><style face="normal" font="default" size="100%">Hu, D.</style></author><author><style face="normal" font="default" size="100%">Lorenzo-Diaz, F.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Perez, R.</style></author><author><style face="normal" font="default" size="100%">Hernandez-Perez, J. M.</style></author><author><style face="normal" font="default" size="100%">Poza-Guedes, P.</style></author><author><style face="normal" font="default" size="100%">Sardon-Prado, O.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Machin, I.</style></author><author><style face="normal" font="default" size="100%">Mederos-Luis, E.</style></author><author><style face="normal" font="default" size="100%">Corcuera-Elosegui, P.</style></author><author><style face="normal" font="default" size="100%">Villar, J.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Santana, J.</style></author><author><style face="normal" font="default" size="100%">Ziv, E.</style></author><author><style face="normal" font="default" size="100%">Burchard, E. G.</style></author><author><style face="normal" font="default" size="100%">Pino-Yanes, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From Genomics and Health Group, Department of Biochemistry, Microbiology, Cell Biology, and Genetics, Universidad de La Laguna (ULL), La Laguna, Spain.&#xD;Instituto de Tecnologias Biomedicas (ITB), Universidad de La Laguna (ULL), San Cristobal de La Laguna, La Laguna, Spain.&#xD;Department of Epidemiology and Population Health, Stanford University, Stanford, USA.&#xD;Department of Medicine, University of California, San Francisco, California, USA.&#xD;Instituto Universitario de Enfermedades Tropicales y Salud Publica de Canarias, Universidad de La Laguna (ULL), La Laguna, Spain.&#xD;Allergy Department, Hospital Universitario de Canarias, La Laguna, Spain.&#xD;Severe Asthma Unit, Allergy Department, Hospital Universitario de Canarias, La Laguna, Spain.&#xD;Department of Respiratory Medicine, Hospital Universitario de N.S de Candelaria, Santa Cruz de Tenerife, Spain.&#xD;Respiratory Medicine, Hospital Universitario de La Palma, Santa Cruz de Tenerife, Spain.&#xD;Division of Pediatric Respiratory Medicine, Hospital Universitario Donostia, San Sebastian, Spain.&#xD;Department of Pediatrics, University of the Basque Country (UPV/EHU), San Sebastian, Spain.&#xD;CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.&#xD;Research Unit at Hospital Universitario Dr. Negrin, Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias, Las Palmas, Spain.&#xD;Faculty of Health Sciences, Universidad del Atlantico Medio, Las Palmas, Spain.&#xD;Li Ka Shing Knowledge Institute at St Michael&apos;s Hospital, Toronto, Canada.&#xD;Centro de Neumologia Pediatrica, San Juan, Puerto Rico, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multi-Ancestry Epigenome-Wide Association Study of Asthma Exacerbations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">263-266</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/08/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bioinformatics</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetics</style></keyword><keyword><style face="normal" font="default" size="100%">and the Information Society of the Counseling of Universities, Science and</style></keyword><keyword><style face="normal" font="default" size="100%">Innovation and Culture. J.P.-G. reports a fellowship from the MICIU. M.M.-A.</style></keyword><keyword><style face="normal" font="default" size="100%">reports a fellowship from the Spanish Ministry of Science, Innovation and</style></keyword><keyword><style face="normal" font="default" size="100%">Universities. M.P.-Y. reports grants from the Instituto de Salud Carlos III,</style></keyword><keyword><style face="normal" font="default" size="100%">Madrid, Spain. M.P.-Y. reports grants from the Spanish Ministry of Science,</style></keyword><keyword><style face="normal" font="default" size="100%">Innovation, and Universities (MICIU/AEI/10.13039/501100011033) and also received</style></keyword><keyword><style face="normal" font="default" size="100%">grant support from CSL Behring for a project outside of this work. The rest of</style></keyword><keyword><style face="normal" font="default" size="100%">the authors declare no conflicts of interest or other interests that might be</style></keyword><keyword><style face="normal" font="default" size="100%">perceived to influence the interpretation of the article. No supporting</style></keyword><keyword><style face="normal" font="default" size="100%">institution may gain or lose financially through this publication.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40823785</style></accession-num><notes><style face="normal" font="default" size="100%">Martin-Gonzalez, Elena&#xD;Perez-Garcia, Javier&#xD;Martin-Almeida, Mario&#xD;Witonsky, Jonathan&#xD;Eng, Celeste&#xD;Huntsman, Scott&#xD;Hu, Donglei&#xD;Lorenzo-Diaz, Fabian&#xD;Gonzalez-Perez, Ruperto&#xD;Hernandez-Perez, Jose M&#xD;Poza-Guedes, Paloma&#xD;Sardon-Prado, Olaia&#xD;Sanchez-Machin, Inmaculada&#xD;Mederos-Luis, Elena&#xD;Corcuera-Elosegui, Paula&#xD;Villar, Jesus&#xD;Rodriguez-Santana, Jose&#xD;Ziv, Elad&#xD;Burchard, Esteban G&#xD;Pino-Yanes, Maria&#xD;eng&#xD;Robert Wood Johnson Foundation/&#xD;American Asthma Foundation/&#xD;MD/NIMHD NIH HHS/&#xD;National Institute of Health and Environmental Health Sciences/&#xD;NHLBI of the National Institutes of Health/&#xD;Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II/&#xD;Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias (FIISC)/&#xD;Spanish Ministry of Science, Innovation, and Universities/&#xD;Tobacco-Related Disease Research Program/&#xD;Sandler Foundation/&#xD;New York Genome Center/&#xD;HL/NHLBI NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):263-266. doi: 10.1111/all.70016. Epub 2025 Aug 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40823785</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773656</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70016</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3090</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3090</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ao, K. F.</style></author><author><style face="normal" font="default" size="100%">Ng, J. K. W.</style></author><author><style face="normal" font="default" size="100%">Law, C. T.</style></author><author><style face="normal" font="default" size="100%">Mu, W.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Wai, C. Y. Y.</style></author><author><style face="normal" font="default" size="100%">Tang, M. F.</style></author><author><style face="normal" font="default" size="100%">Au, S. W. N.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Leung, T. F.</style></author><author><style face="normal" font="default" size="100%">Xiong, Q.</style></author><author><style face="normal" font="default" size="100%">Tsui, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.&#xD;Hong Kong Bioinformatics Centre, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.&#xD;School of Life Sciences, Faculty of Science, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.&#xD;Department of Paediatrics, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.&#xD;Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.&#xD;Shenzhen Key Laboratory of Allergy and Immunology, School of Medicine, Shenzhen University, Shenzhen, China.&#xD;Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR, China.&#xD;Centre for Microbial Genomics and Proteomics, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multi-Omic Analysis of Scylla serrata Reveals the Allergen Landscape of Mud Crabs and Decapoda Species</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">bioinformatics</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">&quot;omics&quot; and &quot;systems biology&quot;</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 9</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40926563</style></accession-num><notes><style face="normal" font="default" size="100%">Ao, Kelvin Fu-Kiu&#xD;Ng, Judy Kin Wing&#xD;Law, Cherie Tsz-Yiu&#xD;Mu, Weixue&#xD;Li, Shanshan&#xD;Wai, Christine Yee Yan&#xD;Tang, Man Fung&#xD;Au, Shannon Wing Ngor&#xD;Liu, Xiaoyu&#xD;Leung, Ting Fan&#xD;Xiong, Qing&#xD;Tsui, Stephen Kwok-Wing&#xD;eng&#xD;T11-709/21-N/Theme-based Research Scheme, Hong Kong Research Grants Council/&#xD;T12-716/22-R/Theme-based Research Scheme, Hong Kong Research Grants Council/&#xD;T11-702/24-N/Theme-based Research Scheme, Hong Kong Research Grants Council/&#xD;SGDX20201103095609027/Shenzhen Science and Technology Program/&#xD;JCYJ20200109143435556/Shenzhen Science and Technology Program/&#xD;82073950/The National Natural Science Foundation/&#xD;82003464/The National Natural Science Foundation/&#xD;14119420/General Research Fund, Hong Kong Research Grants Council/&#xD;14121222/General Research Fund, Hong Kong Research Grants Council/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep 9. doi: 10.1111/all.70053.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40926563</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70053</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2497</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2497</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Irizar, H.</style></author><author><style face="normal" font="default" size="100%">Chun, Y.</style></author><author><style face="normal" font="default" size="100%">Hsu, H. L.</style></author><author><style face="normal" font="default" size="100%">Li, Y. C.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Arditi, Z.</style></author><author><style face="normal" font="default" size="100%">Grishina, G.</style></author><author><style face="normal" font="default" size="100%">Grishin, A.</style></author><author><style face="normal" font="default" size="100%">Vicencio, A.</style></author><author><style face="normal" font="default" size="100%">Pandey, G.</style></author><author><style face="normal" font="default" size="100%">Bunyavanich, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Institute for Exposomic Research, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multi-omic integration reveals alterations in nasal mucosal biology that mediate air pollutant effects on allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3047-3061</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/05/26 20:47</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Mucosa/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/etiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Genomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Multiomics</style></keyword><keyword><style face="normal" font="default" size="100%">DNA methylation</style></keyword><keyword><style face="normal" font="default" size="100%">air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">causal mediation</style></keyword><keyword><style face="normal" font="default" size="100%">epigenome</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">multi-omic</style></keyword><keyword><style face="normal" font="default" size="100%">nasal</style></keyword><keyword><style face="normal" font="default" size="100%">systems biology</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">exists.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38796780</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic rhinitis is a common inflammatory condition of the nasal mucosa that imposes a considerable health burden. Air pollution has been observed to increase the risk of developing allergic rhinitis. We addressed the hypotheses that early life exposure to air toxics is associated with developing allergic rhinitis, and that these effects are mediated by DNA methylation and gene expression in the nasal mucosa. METHODS: In a case-control cohort of 505 participants, we geocoded participants&apos; early life exposure to air toxics using data from the US Environmental Protection Agency, assessed physician diagnosis of allergic rhinitis by questionnaire, and collected nasal brushings for whole-genome DNA methylation and transcriptome profiling. We then performed a series of analyses including differential expression, Mendelian randomization, and causal mediation analyses to characterize relationships between early life air toxics, nasal DNA methylation, nasal gene expression, and allergic rhinitis. RESULTS: Among the 505 participants, 275 had allergic rhinitis. The mean age of the participants was 16.4 years (standard deviation = 9.5 years). Early life exposure to air toxics such as acrylic acid, phosphine, antimony compounds, and benzyl chloride was associated with developing allergic rhinitis. These air toxics exerted their effects by altering the nasal DNA methylation and nasal gene expression levels of genes involved in respiratory ciliary function, mast cell activation, pro-inflammatory TGF-beta1 signaling, and the regulation of myeloid immune cell function. CONCLUSIONS: Our results expand the range of air pollutants implicated in allergic rhinitis and shed light on their underlying biological mechanisms in nasal mucosa.</style></abstract><notes><style face="normal" font="default" size="100%">Irizar, Haritz&#xD;Chun, Yoojin&#xD;Hsu, Hsiao-Hsien Leon&#xD;Li, Yan-Chak&#xD;Zhang, Lingdi&#xD;Arditi, Zoe&#xD;Grishina, Galina&#xD;Grishin, Alexander&#xD;Vicencio, Alfin&#xD;Pandey, Gaurav&#xD;Bunyavanich, Supinda&#xD;eng&#xD;R01 AI118833/AI/NIAID NIH HHS/&#xD;UL1TR004419/TR/NCATS NIH HHS/&#xD;S10 OD026880/OD/NIH HHS/&#xD;UL1 TR004419/TR/NCATS NIH HHS/&#xD;S10 OD030463/OD/NIH HHS/&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3047-3061. doi: 10.1111/all.16174. Epub 2024 May 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38796780</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11560721</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16174</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1072</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1072</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Park, J.</style></author><author><style face="normal" font="default" size="100%">Lutz, S. M.</style></author><author><style face="normal" font="default" size="100%">Choi, S.</style></author><author><style face="normal" font="default" size="100%">Lee, S.</style></author><author><style face="normal" font="default" size="100%">Park, S. C.</style></author><author><style face="normal" font="default" size="100%">Kim, K.</style></author><author><style face="normal" font="default" size="100%">Choi, H.</style></author><author><style face="normal" font="default" size="100%">Park, H.</style></author><author><style face="normal" font="default" size="100%">Lee, S. Y.</style></author><author><style face="normal" font="default" size="100%">Weiss, S. T.</style></author><author><style face="normal" font="default" size="100%">Hong, S. J.</style></author><author><style face="normal" font="default" size="100%">Kim, B. S.</style></author><author><style face="normal" font="default" size="100%">Won, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Interdisciplinary Program in Bioinformatics, College of Natural Sciences, Seoul National University, Seoul, Korea.&#xD;Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.&#xD;Department of Statistics, College of Natural Sciences, Seoul National University, Seoul, Korea.&#xD;Department of Medical Consilience, Graduate School, Dankook University, Yongin-Si, Korea.&#xD;Seoul National University Institute of Health and Environment, Seoul, Korea.&#xD;Department of Public Health Science, Graduate School of Public Health, Seoul National University, Seoul, Korea.&#xD;Graduate School, Department of Urban Big Data Convergence, University of Seoul, Seoul, Korea.&#xD;Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.&#xD;Genome &amp; Company, Seoungnam-si, Korea.&#xD;Department of Pediatrics, Childhood Asthma Atopy Center, Environmental Health Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.&#xD;Channing Division of Network Medicine, Department of Medicine, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, MA, USA.&#xD;Department of Life Science, Multidisciplinary Genome Institute, Hallym University, Chuncheon, Korea.&#xD;RexSoft Corps, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multi-omics analyses implicate EARS2 in the pathogenesis of atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2602-2604</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/04/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Ears2</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">multi-omics analysis</style></keyword><keyword><style face="normal" font="default" size="100%">prediction model</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33792063</style></accession-num><notes><style face="normal" font="default" size="100%">Park, Jaehyun&#xD;Lutz, Sharon M&#xD;Choi, Seungil&#xD;Lee, Sanghun&#xD;Park, Sang-Cheol&#xD;Kim, Kangjin&#xD;Choi, Hosik&#xD;Park, Hansoo&#xD;Lee, So Yeon&#xD;Weiss, Scott T&#xD;Hong, Soo-Jong&#xD;Kim, Bong-Soo&#xD;Won, Sungho&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2602-2604. doi: 10.1111/all.14837. Epub 2021 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33792063</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14837</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3232</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3232</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Oh, H. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, E.</style></author><author><style face="normal" font="default" size="100%">Yeom, J.</style></author><author><style face="normal" font="default" size="100%">Yoo, H. J.</style></author><author><style face="normal" font="default" size="100%">Lee, S. H.</style></author><author><style face="normal" font="default" size="100%">Lee, S. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, H. B.</style></author><author><style face="normal" font="default" size="100%">Yang, S. I.</style></author><author><style face="normal" font="default" size="100%">Lee, D. K.</style></author><author><style face="normal" font="default" size="100%">Yoon, J.</style></author><author><style face="normal" font="default" size="100%">Choi, E. J.</style></author><author><style face="normal" font="default" size="100%">Shin, Y. H.</style></author><author><style face="normal" font="default" size="100%">Ahn, K.</style></author><author><style face="normal" font="default" size="100%">Kim, J.</style></author><author><style face="normal" font="default" size="100%">Suh, D. I.</style></author><author><style face="normal" font="default" size="100%">Park, J. S.</style></author><author><style face="normal" font="default" size="100%">Kim, K. W.</style></author><author><style face="normal" font="default" size="100%">Hong, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Chonnam National University Hospital, Gwangju, Republic of Korea.&#xD;Prometabio Research Institute, Prometabio Co., Ltd., Hanam-si, Republic of Korea.&#xD;Department of Convergence Medicine, Department of Digital Medicine, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.&#xD;Institute for Innovation in Digital Healthcare, Yonsei University Medical Center, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Inha University Hospital, Inha University School of Medicine, Incheon, Republic of Korea.&#xD;Department of Pediatrics, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea.&#xD;Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.&#xD;Department of Pediatrics, CHA Gangnam Medical Center, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Kyung Hee University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Severance Children&apos;s Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Pediatrics, Humidifier Disinfectant Health Center, National Medical Center, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multi-Omics-Based Biological Mechanisms for Childhood Allergen Sensitization Trajectories: COCOA Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/20</style></edition><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 19</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41555723</style></accession-num><notes><style face="normal" font="default" size="100%">Oh, Hea Young&#xD;Lee, Eun&#xD;Yeom, Jeonghun&#xD;Yoo, Hyun Ju&#xD;Lee, Seung Hwa&#xD;Lee, So-Yeon&#xD;Kim, Hyo-Bin&#xD;Yang, Song-I&#xD;Lee, Da Kyeong&#xD;Yoon, Jisun&#xD;Choi, Eom Ji&#xD;Shin, Youn Ho&#xD;Ahn, Kangmo&#xD;Kim, Jihyun&#xD;Suh, Dong In&#xD;Park, Ji Soo&#xD;Kim, Kyung Won&#xD;Hong, Soo-Jong&#xD;eng&#xD;2008-E33030-00/Korea National Institute of Health/&#xD;2009-E33033-00/Korea National Institute of Health/&#xD;2011-E33021-00/Korea National Institute of Health/&#xD;2012-E33012-00/Korea National Institute of Health/&#xD;2013-E51003-00/Korea National Institute of Health/&#xD;2014-E51004-00/Korea National Institute of Health/&#xD;2014-E51004-01/Korea National Institute of Health/&#xD;2014-E51004-02/Korea National Institute of Health/&#xD;2017-E67002-00/Korea National Institute of Health/&#xD;2017-E67002-01/Korea National Institute of Health/&#xD;2017-E67002-02/Korea National Institute of Health/&#xD;2020E670200/Korea National Institute of Health/&#xD;2020E670201/Korea National Institute of Health/&#xD;2020E670202/Korea National Institute of Health/&#xD;2023E120300/Korea National Institute of Health/&#xD;RS-2022-KE002048/Korea Environment Industry &amp; Technology Institute/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan 19. doi: 10.1111/all.70230.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41555723</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70230</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2125</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2125</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Sima, Y.</style></author><author><style face="normal" font="default" size="100%">Zhao, J.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.&#xD;Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A multicenter time series study on pollen exposure and COVID-19 infection in five cities in China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1711-1713</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cities/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37185872</style></accession-num><notes><style face="normal" font="default" size="100%">Yang, Xiaozhe&#xD;Zhang, Jing&#xD;Sima, Yutong&#xD;Zhao, Jinming&#xD;Wang, Xiangdong&#xD;Zhang, Luo&#xD;eng&#xD;Letter&#xD;Multicenter Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1711-1713. doi: 10.1111/all.15752. Epub 2023 May 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37185872</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15752</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1231</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1231</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Crespo-Lessmann, A.</style></author><author><style face="normal" font="default" size="100%">Plaza, V.</style></author><author><style face="normal" font="default" size="100%">Consensus, Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multidisciplinary consensus on sputum induction biosafety during the COVID-19 pandemic</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2407-2419</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/12/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Containment of Biohazards</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biosafety</style></keyword><keyword><style face="normal" font="default" size="100%">sputum induction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33314245</style></accession-num><abstract><style face="normal" font="default" size="100%">Sputum induction (SI) is the gold standard approach to the non-invasive study of airway inflammation. The differential count of inflammatory cells for SI allows patients with asthma to be classified according to inflammatory phenotypes and predicted therapeutic responses. Since SI involves the generation of aerosols, there is a need to establish a protocol to ensure biosafety in clinical practice during the current COVID-19 pandemic. The multidisciplinary consensus on SI described in this article was developed by 22 experts in SI from different Spanish hospitals who drew on available scientific evidence in achieving consensuated opinions, compiled by means of an electronic survey. We hope that these unified criteria and recommendations will guide health professionals in implementing SI sampling and processing procedures as safely as possible during the COVID-19 pandemic.</style></abstract><notes><style face="normal" font="default" size="100%">Crespo-Lessmann, Astrid&#xD;Plaza, Vicente&#xD;eng&#xD;Consensus Statement&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2407-2419. doi: 10.1111/all.14697. Epub 2021 Jan 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33314245</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14697</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2607</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2607</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scholaert, M.</style></author><author><style face="normal" font="default" size="100%">Peries, M.</style></author><author><style face="normal" font="default" size="100%">Braun, E.</style></author><author><style face="normal" font="default" size="100%">Martin, J.</style></author><author><style face="normal" font="default" size="100%">Serhan, N.</style></author><author><style face="normal" font="default" size="100%">Loste, A.</style></author><author><style face="normal" font="default" size="100%">Bruner, A.</style></author><author><style face="normal" font="default" size="100%">Basso, L.</style></author><author><style face="normal" font="default" size="100%">Chaput, B.</style></author><author><style face="normal" font="default" size="100%">Merle, E.</style></author><author><style face="normal" font="default" size="100%">Descargues, P.</style></author><author><style face="normal" font="default" size="100%">Pages, E.</style></author><author><style face="normal" font="default" size="100%">Gaudenzio, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291-CNRS UMR5051, University Toulouse III, Toulouse, France.&#xD;Genoskin SAS, Toulouse, France.&#xD;Department of Plastic, Reconstructive and Aesthetic Surgery, Rangueil Hospital, CHU Toulouse, Toulouse, France.&#xD;Genoskin Inc, Salem, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multimodal profiling of biostabilized human skin modules reveals a coordinated ecosystem response to injected mRNA-1273 COVID-19 vaccine</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3341-3359</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/08/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*2019-nCoV Vaccine mRNA-1273/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">human skin modules</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA vaccine tracking</style></keyword><keyword><style face="normal" font="default" size="100%">multiplexed imaging</style></keyword><keyword><style face="normal" font="default" size="100%">single-cell RNA-Seq</style></keyword><keyword><style face="normal" font="default" size="100%">subject matter of this publication. N.G. acts as chief scientific officer, E.M is</style></keyword><keyword><style face="normal" font="default" size="100%">chief innovation officer and P.D is founder and chief executive officer at</style></keyword><keyword><style face="normal" font="default" size="100%">Genoskin. N.G., E.M., and P.D. are shareholders at Genoskin. M.S, E.M, E.B, M.P,</style></keyword><keyword><style face="normal" font="default" size="100%">and E.P are employees at Genoskin.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39157907</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The field of drug development is witnessing a remarkable surge in the development of innovative strategies. There is a need to develop technological platforms capable of generating human data prior to progressing to clinical trials. METHODS: Here we introduce a new flexible solution designed for the comprehensive monitoring of the natural human skin ecosystem&apos;s response to immunogenic drugs over time. Based on unique bioengineering to preserve surgical resections in a long survival state, it allows for the first time a comprehensive analysis of resident immune cells response at both organ and single-cell levels. RESULTS: Upon injection of the mRNA-1273 COVID-19 vaccine, we characterized precise sequential molecular events triggered upon detection of the exogenous substance. The vaccine consistently targets DC/macrophages and mast cells, regardless of the administration route, while promoting specific cell-cell communications in surrounding immune cell subsets. CONCLUSION: Given its direct translational relevance, this approach provides a multiscale vision of genuine human tissue immunity that could pave the way toward the development of new vaccination and drug development strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Scholaert, Manon&#xD;Peries, Mathias&#xD;Braun, Emilie&#xD;Martin, Jeremy&#xD;Serhan, Nadine&#xD;Loste, Alexia&#xD;Bruner, Audrey&#xD;Basso, Lilian&#xD;Chaput, Benoit&#xD;Merle, Eric&#xD;Descargues, Pascal&#xD;Pages, Emeline&#xD;Gaudenzio, Nicolas&#xD;eng&#xD;Agence Nationale de la Recherche/&#xD;Genoskin/&#xD;ERC_/European Research Council/International&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3341-3359. doi: 10.1111/all.16273. Epub 2024 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39157907</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657073</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16273</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2786</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2786</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Contreras, N.</style></author><author><style face="normal" font="default" size="100%">Escolar-Pena, A.</style></author><author><style face="normal" font="default" size="100%">Delgado-Dolset, M. I.</style></author><author><style face="normal" font="default" size="100%">Fernandez, P.</style></author><author><style face="normal" font="default" size="100%">Obeso, D.</style></author><author><style face="normal" font="default" size="100%">Izquierdo, E.</style></author><author><style face="normal" font="default" size="100%">Cuervo, H. G.</style></author><author><style face="normal" font="default" size="100%">Cumplido, J. A.</style></author><author><style face="normal" font="default" size="100%">Mugica, V.</style></author><author><style face="normal" font="default" size="100%">Cisneros, C.</style></author><author><style face="normal" font="default" size="100%">Angulo-Diaz-Parreno, S.</style></author><author><style face="normal" font="default" size="100%">Barbas, C.</style></author><author><style face="normal" font="default" size="100%">Blanco, C.</style></author><author><style face="normal" font="default" size="100%">Carrillo, T.</style></author><author><style face="normal" font="default" size="100%">Barber, D.</style></author><author><style face="normal" font="default" size="100%">Villasenor, A.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de Ciencias Medicas Basicas, Facultad de Medicina, Instituto de Medicina Molecular Aplicada - Nemesio Diez (IMMA-ND), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Centro de Metabolomica y Bioanalisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain.&#xD;Servicio de Alergia, Hospital Universitario de Gran Canaria Doctor Negrin, Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.&#xD;Servicio de Alergia, Hospital Universitario de La Princesa, Instituto De Investigacion Sanitaria Princesa (IIS-Princesa), Madrid, Spain.&#xD;Servicio de Neumologia, Hospital Universitario de La Princesa, Instituto De Investigacion Sanitaria Princesa (IIS-Princesa), Madrid, Spain.&#xD;Departamento de Matematicas y Ciencia de Datos, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1899-1911</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/12/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/diagnosis/metabolism/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biologicals</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees and/or honoraria from Astra, GSK, Sanofi, Gebro, Menarini, and</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi and has served Data Safety Monitoring Board and/or Advisory Board at</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, GSK, and Astra. T.C. reports personal fees and/or honoraria from GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, and AstraZeneca. The other authors declare no conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39692160</style></accession-num><abstract><style face="normal" font="default" size="100%">RATIONALE: Biologics are becoming increasingly important in the management of severe asthma. However, little is known about the systemic immunometabolic consequences of Th2 response blockage. OBJECTIVES: To provide a better immunometabolic understanding of the effects of mepolizumab and omalizumab treatments by identifying potential biomarkers for monitoring. METHODS: In this exploratory longitudinal study severe asthmatic patients were followed for 18 months after initiating mepolizumab (n = 36) or Omalizumab (n = 20) treatment. Serum samples were collected before, 6, and 18 months after treatment. Targeted omic approaches were performed to analyze inflammatory metabolites (n = 35) and proteins (n = 45). Multiomic integration was performed individually for each treatment applying supervised analysis Data Integration Analysis for Biomarker discovery using Latent cOmponents (DIABLO) framework. Then, potential biomarkers were confirmed using multivariate ROC analyses and correlated with clinical variables along treatment. MEASUREMENTS AND MAIN RESULTS: Mepolizumab and omalizumab were both effective (improved clinical variables) and showed different and specific metabolic and protein profiles in severe asthmatic patients during treatment. Multiomic integration and multivariate ROC analyses identified specific biomarkers, such as arachidonic acid, palmitoleic acid, oleic acid, propionylcarnitine, bilirubin, CCL11, and TNFSF10, which can explain the differences observed with Mepolizumab treatment over 18 months and significantly correlate with clinical improvement. However, no significant biomolecules and no discriminative multivariate ROC curves were found for Omalizumab treatment. CONCLUSIONS: Our results provide a comprehensive insight into the differential effects of mepolizumab and omalizumab on the immunometabolic kinetics of the inflammatory response in severe asthma. We identified a set of biomolecules with potential for monitoring mepolizumab treatment which could be useful for personalized medicine.</style></abstract><notes><style face="normal" font="default" size="100%">Contreras, Nuria&#xD;Escolar-Pena, Andrea&#xD;Delgado-Dolset, Maria I&#xD;Fernandez, Paloma&#xD;Obeso, David&#xD;Izquierdo, Elena&#xD;Cuervo, Heleia Gonzalez&#xD;Cumplido, Jose Angel&#xD;Mugica, Victoria&#xD;Cisneros, Carolina&#xD;Angulo-Diaz-Parreno, Santiago&#xD;Barbas, Coral&#xD;Blanco, Carlos&#xD;Carrillo, Teresa&#xD;Barber, Domingo&#xD;Villasenor, Alma&#xD;Escribese, Maria M&#xD;eng&#xD;PI19/00044/ISCIII/&#xD;RD16/0006/0015/FEDER &quot;Investing in your future&quot; for the thematic network and cooperative research centers ARADyAL/&#xD;RD21/0002/0008/RICORS &quot;Red de Enfermedades Inflamatorias (REI)&quot;/&#xD;RD24/0007/0018/RICORS &quot;Red de Enfermedades Inflamatorias (REI)&quot;/&#xD;AP177712021/Fundacion Mutua Madrilena/&#xD;PEJ-2023-AI/SAL-GL-27622/San Pablo CEU University Foundation/&#xD;FPI-CEU predoctoral fellowship/&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1899-1911. doi: 10.1111/all.16434. Epub 2024 Dec 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39692160</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261874</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16434</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2984</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2984</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xi, L.</style></author><author><style face="normal" font="default" size="100%">Peeva, E.</style></author><author><style face="normal" font="default" size="100%">Yamaguchi, Y.</style></author><author><style face="normal" font="default" size="100%">Ye, Z.</style></author><author><style face="normal" font="default" size="100%">Lejeune, A.</style></author><author><style face="normal" font="default" size="100%">Hyde, C.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pfizer Inc, Cambridge, Massachusetts, USA.&#xD;Pfizer Inc, Collegeville, Pennsylvania, USA.&#xD;Pfizer Inc, Paris, France.&#xD;Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2348-2360</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Alopecia Areata/drug therapy/genetics/diagnosis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">*Protein Kinase Inhibitors/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Multiomics</style></keyword><keyword><style face="normal" font="default" size="100%">alopecia areata</style></keyword><keyword><style face="normal" font="default" size="100%">microarray</style></keyword><keyword><style face="normal" font="default" size="100%">ritlecitinib</style></keyword><keyword><style face="normal" font="default" size="100%">are employees of Pfizer and may hold stock and/or stock options for Pfizer. Emma</style></keyword><keyword><style face="normal" font="default" size="100%">Guttman-Yassky declares being an employee of Mount Sinai receiving research funds</style></keyword><keyword><style face="normal" font="default" size="100%">(grants paid to the institution) from AbbVie, Almirall, Amgen, AnaptysBio, Asana</style></keyword><keyword><style face="normal" font="default" size="100%">Biosciences, AstraZeneca, Boehringer Ingelheim, Celgene, Dermavant, DS Biopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Eli Lilly, Galderma, Glenmark/Ichnos Sciences, Innovaderm Research, Janssen,</style></keyword><keyword><style face="normal" font="default" size="100%">Kiniksa, Kyowa Kirin, LEO Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Sienna Biopharma, UCB, and Union Therapeutics/AntibioTx and is a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant for AbbVie, Aditum Bio, Almirall, Alpine, Amgen, Arena, Asana</style></keyword><keyword><style face="normal" font="default" size="100%">Biosciences, AstraZeneca, Bluefin Biomedicine, Boehringer Ingelheim, Boston</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Botanix, Bristol Myers Squibb, Cara Therapeutics, Celgene,</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Outcome Solutions, DBV, Dermavant Sciences, Dermira, Douglas</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceutical, DS Biopharma, Eli Lilly, EMD Serono, Evelo Bioscience, Evidera,</style></keyword><keyword><style face="normal" font="default" size="100%">FIDE, Galderma, GlaxoSmithKline, Haus Bioceuticals, Ichnos Sciences, Incyte,</style></keyword><keyword><style face="normal" font="default" size="100%">Kyowa Kirin, Larrk Bio, LEO Pharma, Medicxi, Medscape, Neuralstem, Noble</style></keyword><keyword><style face="normal" font="default" size="100%">Insights, Novan, Novartis, Okava Pharmaceuticals, Pandion Therapeutics, Pfizer,</style></keyword><keyword><style face="normal" font="default" size="100%">Principia Biopharma, RAPT Therapeutics, Realm, Regeneron Pharmaceuticals, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">SATO Pharmaceutical, Sienna Biopharma, Seanergy Dermatology, Seelos Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">Serpin Pharma, Siolta Therapeutics, Sonoma Biotherapeutics, Sun Pharma, Target</style></keyword><keyword><style face="normal" font="default" size="100%">PharmaSolutions, Union Therapeutics, Vanda Pharmaceuticals, Ventyx Biosciences,</style></keyword><keyword><style face="normal" font="default" size="100%">and Vimalan.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40654284</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Alopecia areata (AA) is an autoimmune disease characterized by hair loss. This study examined changes in molecular signatures in lesional scalp of patients with AA subtypes (patchy-type AA [AAP] or alopecia totalis/alopecia universalis [AT/AU]) in response to treatment with JAK3/TEC family kinase inhibitor ritlecitinib and evaluated correlations between potential biomarker levels/changes and scalp hair regrowth. METHODS: This was a post hoc analysis of a biopsy substudy from a phase 2a trial of ritlecitinib in patients with AA and &gt;/= 50% scalp hair loss. Transcriptomic expression profiles from scalp samples of patients with AAP or AT/AU were analyzed using microarray. Changes from baseline in transcriptional and serum protein expression were evaluated, as were correlations between both these changes and the baseline profile with clinical response (scalp hair regrowth). RESULTS: Following 12 and 24 weeks of treatment, ritlecitinib downregulated key Type I (CCL5, CD8A, and GZMB) and Type II immunity-related genes (CCL13, CCL18, and IL13RA1), downregulated genes related to ritlecitinib&apos;s mechanism of action (ITK, JAK3, and BTK), and upregulated hair keratin genes in AAP and AT/AU lesions, with a lesser extent in AT/AU than AAP lesions. Baseline expression levels and changes from baseline to Weeks 12 and/or 24 in levels of genes and serum proteins related to Type I and II immunity, hair structure/function, and ritlecitinib&apos;s mechanism of action significantly correlated with clinical response at Weeks 12 and/or 24. CONCLUSION: These results provide support that treatment with ritlecitinib improves the gene expression profile in AA lesional scalp and is correlated with subsequent hair regrowth response. TRIAL REGISTRATION: NCT02974868.</style></abstract><notes><style face="normal" font="default" size="100%">Xi, Li&#xD;Peeva, Elena&#xD;Yamaguchi, Yuji&#xD;Ye, Zhan&#xD;Lejeune, Alexandre&#xD;Hyde, Craig&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;Pfizer/&#xD;Clinical Trial, Phase II&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2348-2360. doi: 10.1111/all.16659. Epub 2025 Jul 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40654284</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368755</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16659</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1951</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1951</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ordak, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Str., 02-097, Warsaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multiple comparisons and effect size: Statistical recommendations for authors planning to submit an article to Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1145-1147</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36883352</style></accession-num><notes><style face="normal" font="default" size="100%">Ordak, Michal&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1145-1147. doi: 10.1111/all.15700.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36883352</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15700</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2451</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2451</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Okunishi, K.</style></author><author><style face="normal" font="default" size="100%">Kochi, Y.</style></author><author><style face="normal" font="default" size="100%">Zhao, M.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Nakagome, K.</style></author><author><style face="normal" font="default" size="100%">Izumi, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Molecular Endocrinology and Metabolism, Department of Molecular Medicine, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.&#xD;Laboratory of Endocrine and Metabolic System Regulation, Department of Molecular Medicine, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.&#xD;Genomic Function and Diversity, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.&#xD;Department of Respiratory Medicine, Saitama Medical University, Saitama, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Munc13-4 regulates asthma and obesity in mice by controlling functions of CD11c(+) antigen-presenting cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1992-1995</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/immunology/etiology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Obesity/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*CD11c Antigen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigen-Presenting Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38426389</style></accession-num><notes><style face="normal" font="default" size="100%">Okunishi, Katsuhide&#xD;Kochi, Yuta&#xD;Zhao, Min&#xD;Wang, Hao&#xD;Nakagome, Kazuyuki&#xD;Izumi, Tetsuro&#xD;eng&#xD;Astellas Foundation for Research on Metabolic Disorders/&#xD;Medical Research Center Initiative for High Depth Omics/&#xD;Ono Medical Research Foundation/&#xD;SENSHIN Medical Research Foundation/&#xD;Naito Foundation/&#xD;Japan Society for the Promotion of Science/&#xD;Takeda Science Foundation/&#xD;Gunma University/&#xD;Sanofi and Mitsubishi Tanabe Pharma Scholarship Donations/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1992-1995. doi: 10.1111/all.16087. Epub 2024 Mar 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38426389</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16087</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>358</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">358</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Du, L.</style></author><author><style face="normal" font="default" size="100%">Yi, S.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Lin, Y.</style></author><author><style face="normal" font="default" size="100%">Bi, Y.</style></author><author><style face="normal" font="default" size="100%">Zhu, G.</style></author><author><style face="normal" font="default" size="100%">Jing, X.</style></author><author><style face="normal" font="default" size="100%">Song, W.</style></author><author><style face="normal" font="default" size="100%">Tang, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Rheumatology and Autoimmunology, Shandong Provincial Key Laboratory for Rheumatic Disease and Translational Medicine, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, Jinan, China.&#xD;School of Basic Medical Sciences, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Jinan, China.&#xD;Institute of Infection and Immunity, Medical Science and Technology Innovation Center, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Jinan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Murine lung cDC1s inhibit memory Th2 cell generation by reducing CD62L(+) memory precursors via IL-12</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3467-3470</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-12</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Memory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35933716</style></accession-num><notes><style face="normal" font="default" size="100%">Liu, Jianguo&#xD;Du, Linqing&#xD;Yi, Shuying&#xD;Li, Lina&#xD;Lin, Yan&#xD;Bi, Yanan&#xD;Zhu, Guangming&#xD;Jing, Xiuli&#xD;Song, Wengang&#xD;Tang, Hua&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3467-3470. doi: 10.1111/all.15470. Epub 2022 Aug 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35933716</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15470</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3238</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3238</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, Y.</style></author><author><style face="normal" font="default" size="100%">Ye, D.</style></author><author><style face="normal" font="default" size="100%">Guo, J.</style></author><author><style face="normal" font="default" size="100%">Zeng, W.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, The Second Affiliated Hospital of Xi&apos;an Jiaotong University, Xi&apos;an, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Murine Model of Chronic Spontaneous Urticaria-Like Skin</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">mouse model</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 9</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41510628</style></accession-num><notes><style face="normal" font="default" size="100%">He, Yanan&#xD;Ye, Dan&#xD;Guo, Jiahua&#xD;Zeng, Weihui&#xD;Wang, Zhao&#xD;eng&#xD;Natural Science Basic Research Program of Shaanxi Province/&#xD;National Natural Science Foundation of China/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan 9. doi: 10.1111/all.70211.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41510628</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70211</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1296</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1296</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kagoya, R.</style></author><author><style face="normal" font="default" size="100%">Kondo, K.</style></author><author><style face="normal" font="default" size="100%">Kishimoto-Urata, M.</style></author><author><style face="normal" font="default" size="100%">Shimizu, Y.</style></author><author><style face="normal" font="default" size="100%">Kikuta, S.</style></author><author><style face="normal" font="default" size="100%">Yamasoba, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.&#xD;Department of Otolaryngology, Teikyo University, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A murine model of eosinophilic chronic rhinosinusitis using the topical application of a vitamin D3 analog</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1432-1442</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cholecalciferol</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilia/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">olfactory epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">thymic stromal lymphopoietin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33058214</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophilic chronic rhinosinusitis (ECRS) is a chronic inflammatory disease, characterized by eosinophilic infiltration, T-helper type 2 (Th2-type) response, and olfactory dysfunction. A master regulator of Th2-type inflammation, thymic stromal lymphopoietin (TSLP), is important for basophil activation. TSLP-elicited basophils are a key factor in the pathogenesis of ECRS. METHODS: In order to elucidate the mechanisms of ECRS in humans, we aimed to establish a murine model of ECRS based on TSLP production in response to the topical application of MC903 (a vitamin D3 analog) and the subsequent TSLP-induced basophil activation. Histological analyses were performed to assess immune cell infiltration into the nasal mucosa and to explore the impact of eosinophilic inflammation on the olfactory epithelium. The status of Th2-type inflammation was evaluated by quantitative real-time PCR and enzyme-linked immunosorbent assay (ELISA). RESULTS: Eosinophils, basophils, and M2 macrophages increased significantly in the nasal mucosa of the mice treated with MC903 and ovalbumin (OVA), compared to those treated with OVA alone or the controls. Quantitative real-time PCR and ELISA revealed elevated expression of interleukin (IL)-4, IL-5, IL-13, TSLP, the chemokine CCL11, and CCL24 in the nasal mucosa of the ECRS mice. In parallel, thinned olfactory epithelium and decreased mature olfactory sensory neurons were observed in the ECRS mice. CONCLUSIONS: Our model of ECRS displayed Th2-type inflammation in the sinonasal region, including both eosinophil infiltration and basophil infiltration. Additionally, olfactory epithelium turned out to be affected by eosinophilic inflammation. These features are consistent with the characteristics of the human ECRS.</style></abstract><notes><style face="normal" font="default" size="100%">Kagoya, Ryoji&#xD;Kondo, Kenji&#xD;Kishimoto-Urata, Megumi&#xD;Shimizu, Yuya&#xD;Kikuta, Shu&#xD;Yamasoba, Tatsuya&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1432-1442. doi: 10.1111/all.14627. Epub 2020 Oct 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33058214</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14627</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1617</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1617</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kagoya, R.</style></author><author><style face="normal" font="default" size="100%">Kondo, K.</style></author><author><style face="normal" font="default" size="100%">Kishimoto-Urata, M.</style></author><author><style face="normal" font="default" size="100%">Shimizu, Y.</style></author><author><style face="normal" font="default" size="100%">Kikuta, S.</style></author><author><style face="normal" font="default" size="100%">Yamasoba, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.&#xD;Department of Otolaryngology, Teikyo University, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A murine model of eosinophilic chronic rhinosinusitis using the topical application of a vitamin D3 analog</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1432-1442</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cholecalciferol</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilia/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">olfactory epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">thymic stromal lymphopoietin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33058214</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophilic chronic rhinosinusitis (ECRS) is a chronic inflammatory disease, characterized by eosinophilic infiltration, T-helper type 2 (Th2-type) response, and olfactory dysfunction. A master regulator of Th2-type inflammation, thymic stromal lymphopoietin (TSLP), is important for basophil activation. TSLP-elicited basophils are a key factor in the pathogenesis of ECRS. METHODS: In order to elucidate the mechanisms of ECRS in humans, we aimed to establish a murine model of ECRS based on TSLP production in response to the topical application of MC903 (a vitamin D3 analog) and the subsequent TSLP-induced basophil activation. Histological analyses were performed to assess immune cell infiltration into the nasal mucosa and to explore the impact of eosinophilic inflammation on the olfactory epithelium. The status of Th2-type inflammation was evaluated by quantitative real-time PCR and enzyme-linked immunosorbent assay (ELISA). RESULTS: Eosinophils, basophils, and M2 macrophages increased significantly in the nasal mucosa of the mice treated with MC903 and ovalbumin (OVA), compared to those treated with OVA alone or the controls. Quantitative real-time PCR and ELISA revealed elevated expression of interleukin (IL)-4, IL-5, IL-13, TSLP, the chemokine CCL11, and CCL24 in the nasal mucosa of the ECRS mice. In parallel, thinned olfactory epithelium and decreased mature olfactory sensory neurons were observed in the ECRS mice. CONCLUSIONS: Our model of ECRS displayed Th2-type inflammation in the sinonasal region, including both eosinophil infiltration and basophil infiltration. Additionally, olfactory epithelium turned out to be affected by eosinophilic inflammation. These features are consistent with the characteristics of the human ECRS.</style></abstract><notes><style face="normal" font="default" size="100%">Kagoya, Ryoji&#xD;Kondo, Kenji&#xD;Kishimoto-Urata, Megumi&#xD;Shimizu, Yuya&#xD;Kikuta, Shu&#xD;Yamasoba, Tatsuya&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1432-1442. doi: 10.1111/all.14627. Epub 2020 Oct 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33058214</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14627</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3014</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3014</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Park, S. O.</style></author><author><style face="normal" font="default" size="100%">Uyangaa, E.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author><author><style face="normal" font="default" size="100%">Byeon, H. W.</style></author><author><style face="normal" font="default" size="100%">Choi, J. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, K.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author><author><style face="normal" font="default" size="100%">Bertin, S.</style></author><author><style face="normal" font="default" size="100%">Raz, E.</style></author><author><style face="normal" font="default" size="100%">Eo, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">College of Veterinary Medicine, Biosafety Research Institute and Core Facility Center for Zoonosis Research, Jeonbuk National University, Iksan, Republic of Korea.&#xD;Department of Pharmacology, School of Medicine, Pusan National University, Busan, Republic of Korea.&#xD;Division of Rheumatology, Allergy &amp; Immunology, Department of Medicine, University of California, San Diego, La Jolla, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Myeloid cAMP Reduction Shifts Rhinovirus-Induced Airway Inflammation From Neutrophilic to Eosinophilic by Suppressing M1-Interstitial Macrophages</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3055-3076</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinovirus/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Neutrophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Macrophages/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Cyclic AMP/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Picornaviridae Infections/immunology/complications/metabolism/virology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism/etiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Myeloid Cells/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">asthma exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">cAMP</style></keyword><keyword><style face="normal" font="default" size="100%">human rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">inflammasome</style></keyword><keyword><style face="normal" font="default" size="100%">macrophage polarization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40878403</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma exacerbations caused by human rhinovirus (hRV) infection are characterized by airway neutrophilia and reduced corticosteroid response, leading to significant healthcare costs and lung function impairment. The Galphas subunit of the trimeric G protein regulates immunopathological conditions by modulating cAMP levels. We aimed to investigate the impact of myeloid cAMP levels on neutrophil-dominated asthma exacerbation caused by hRV infection. METHODS: We generated mice with myeloid cell-specific deletion of the Galphas subunit by targeting the LysM gene, leading to a specific reduction of cAMP in myeloid cells. Neutrophilic asthma exacerbation was induced by hRV infection during allergen challenge, and cytokine production in BALF and lung tissue was assessed, along with histological examinations. RESULTS: Myeloid Galphas ablation was found to shift airway inflammation from a neutrophilic to an eosinophilic phenotype during hRV-induced asthma exacerbation. This change led to mucus hypersecretion and Th2-type inflammation, and enhanced CD4(+) Th2 effector cell expansion. In chronic asthma with repeated allergen and hRV exposure, myeloid Galphas ablation caused mixed Th2- and Th17-biased inflammation with increased neutrophil and eosinophil infiltration and collagen deposition. Myeloid Galphas deficiency hindered NLRP3 inflammasome activation, thereby suppressing M1 polarization of interstitial macrophages during eosinophilic inflammation. cAMP levels in macrophages were likely associated with M1 polarization, as cAMP analogs regulated NLRP3 inflammasome activation via PKA and EPAC pathways. Finally, adoptive transfer of cAMP analog-treated macrophages reversed eosinophilic to neutrophilic inflammation in myeloid Galphas-ablated mice following hRV infection. CONCLUSIONS: These results highlight the essential role of macrophage cAMP in steroid-resistant, neutrophil-dominant airway inflammation during hRV-induced asthma exacerbation.</style></abstract><notes><style face="normal" font="default" size="100%">Park, Seong Ok&#xD;Uyangaa, Erdenebileg&#xD;Kim, Hyo Jin&#xD;Byeon, Hee Won&#xD;Choi, Jin Young&#xD;Kim, Koanhoi&#xD;Lee, Jihyung&#xD;Bertin, Samuel&#xD;Raz, Eyal&#xD;Eo, Seong Kug&#xD;eng&#xD;National Research Foundation of Korea RS-2025-00513722/&#xD;National Research Foundation of Korea 2019R1A6A1A03033084/&#xD;Korea Basic Science Institute 2021R1A6C101C369/&#xD;Korea Health Industry Development Institute HI22C0591/&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3055-3076. doi: 10.1111/all.70018. Epub 2025 Aug 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40878403</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590349</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70018</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>863</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">863</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Y. H.</style></author><author><style face="normal" font="default" size="100%">Huang, S. Y.</style></author><author><style face="normal" font="default" size="100%">Kuo, H. P.</style></author><author><style face="normal" font="default" size="100%">Fan, H. Y.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Papamichael, M. M.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;School of Nutrition and Health Sciences, Taipei Medical University, Taipei, Taiwan.&#xD;Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Family Medicine, Taipei Medical University Hospital, Taipei, Taiwan.&#xD;Department of Immunology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;EPIUnit, Instituto de Saude Publica da Universidade do Porto, Porto, Portugal.&#xD;Department of Dietetics, Nutrition &amp; Sport, School of Allied Health, La Trobe University, Melbourne, Australia.&#xD;Department of Family Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">N-3 fatty acid supplementation in asthma management: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3042-3046</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/08/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">*Fatty Acids, Omega-3</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34378219</style></accession-num><notes><style face="normal" font="default" size="100%">Wang, Yu-Hsin&#xD;Huang, Shih-Yi&#xD;Kuo, Han-Pin&#xD;Fan, Hsien-Yu&#xD;Moreira, Andre&#xD;Papamichael, Maria Michelle&#xD;Chen, Yang-Ching&#xD;eng&#xD;Letter&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3042-3046. doi: 10.1111/all.15043. Epub 2021 Aug 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34378219</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15043</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1074</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1074</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tesfaye, A.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Nogales, A.</style></author><author><style face="normal" font="default" size="100%">Benede, S.</style></author><author><style face="normal" font="default" size="100%">Fernandez, T. D.</style></author><author><style face="normal" font="default" size="100%">Paris, J. L.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, M. J.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Sanchez, I. M.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Montanez, M. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Andalusian Centre for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Instituto de Investigacion en Ciencias de la Alimentacion (CIAL, CSIC-UAM), Madrid, Spain.&#xD;Departamento de Biologia Celular Genetica y Fisiologia, Facultad de Ciencias, Universidad de Malaga, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Departamento de Medicina, Facultad de Medicina, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3183-3193</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/03/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amoxicillin</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillins</style></keyword><keyword><style face="normal" font="default" size="100%">IgE cross-linking</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunocomplex</style></keyword><keyword><style face="normal" font="default" size="100%">nanostructure</style></keyword><keyword><style face="normal" font="default" size="100%">personal relationships that could appear to influence the work reported in this</style></keyword><keyword><style face="normal" font="default" size="100%">paper.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33784407</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Amoxicillin (AX) is nowadays the beta-lactam that more frequently induces immediate allergic reactions. Nevertheless, diagnosis of AX allergy is occasionally challenging due to risky in vivo tests and non-optimal sensitivity of in vitro tests. AX requires protein haptenation to form multivalent conjugates with increased size to be immunogenic. Knowing adduct structural features for promoting effector cell activation would help to improve in vitro tests. We aimed to identify the optimal structural requirement in specific cellular degranulation to AX using well-precised nanoarchitectures of different lengths. METHOD: We constructed eight Bidendron Antigens (BiAns) based on polyethylene glycol (PEG) linkers of different lengths (600-12,000 Da), end-coupled with polyamidoamine dendrons that were terminally multi-functionalized with amoxicilloyl (AXO). In vitro IgE recognition was studied by competitive radioallergosorbent test (RAST) and antibody-nanoarchitecture complexes by transmission electron microscopy (TEM). Their allergenic activity was evaluated using bone marrow-derived mast cells (MCs) passively sensitized with mouse monoclonal IgE against AX and humanized RBL-2H3 cells sensitized with polyclonal antibodies from sera of AX-allergic patients. RESULTS: All BiAns were recognized by AX-sIgE. Dose-dependent activation responses were observed in both cellular assays, only with longer structures, containing spacers in the range of PEG 6000-12,000 Da. Consistently, greater proportion of immunocomplexes and number of antibodies per complex for longer BiAns were visualized by TEM. CONCLUSIONS: BiAns are valuable platforms to study the mechanism of effector cell activation. These nanomolecular tools have demonstrated the importance of the adduct size to promote effector cell activation in AX allergy, which will impact for improving in vitro diagnostics.</style></abstract><notes><style face="normal" font="default" size="100%">Tesfaye, Amene&#xD;Rodriguez-Nogales, Alba&#xD;Benede, Sara&#xD;Fernandez, Tahia D&#xD;Paris, Juan L&#xD;Rodriguez, Maria J&#xD;Jimenez-Sanchez, Isabel M&#xD;Bogas, Gador&#xD;Mayorga, Cristobalina&#xD;Torres, Maria J&#xD;Montanez, Maria I&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3183-3193. doi: 10.1111/all.14834. Epub 2021 May 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33784407</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8518075</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14834</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>464</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">464</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aagaard, J. B.</style></author><author><style face="normal" font="default" size="100%">Sivelle, C.</style></author><author><style face="normal" font="default" size="100%">Fischer, M.</style></author><author><style face="normal" font="default" size="100%">Byskov, K.</style></author><author><style face="normal" font="default" size="100%">Laursen, N. S.</style></author><author><style face="normal" font="default" size="100%">Pfutzner, W.</style></author><author><style face="normal" font="default" size="100%">Jakob, T.</style></author><author><style face="normal" font="default" size="100%">Mobs, C.</style></author><author><style face="normal" font="default" size="100%">Miehe, M.</style></author><author><style face="normal" font="default" size="100%">Spillner, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunological Biotechnology, Department of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.&#xD;Department of Biomedicine, Aarhus University, Aarhus, Denmark.&#xD;Clinical &amp; Experimental Allergology, Department of Dermatology and Allergology, Philipps Universitat Marburg, Marburg, Germany.&#xD;Department of Dermatology and Allergy, University Medical Center Giessen, Justus Liebig University, Giessen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nanobody-based human antibody formats act as IgE surrogate in hymenoptera venom allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2859-2862</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/06/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthropod Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">*Bee Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hymenoptera</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Insect Bites and Stings</style></keyword><keyword><style face="normal" font="default" size="100%">Wasp Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">insect venom</style></keyword><keyword><style face="normal" font="default" size="100%">nanobodies</style></keyword><keyword><style face="normal" font="default" size="100%">MM, and ES. The other authors have no financial conflict of interest and nothing</style></keyword><keyword><style face="normal" font="default" size="100%">to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35643911</style></accession-num><notes><style face="normal" font="default" size="100%">Aagaard, Josephine Baunvig&#xD;Sivelle, Coline&#xD;Fischer, Michaela&#xD;Byskov, Kristina&#xD;Laursen, Nick S&#xD;Pfutzner, Wolfgang&#xD;Jakob, Thilo&#xD;Mobs, Christian&#xD;Miehe, Michaela&#xD;Spillner, Edzard&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2859-2862. doi: 10.1111/all.15391. Epub 2022 Jun 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35643911</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9541452</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15391</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3028</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3028</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lu, C. H.</style></author><author><style face="normal" font="default" size="100%">Tsai, C. H.</style></author><author><style face="normal" font="default" size="100%">Phillip, I. O.</style></author><author><style face="normal" font="default" size="100%">Chiang, P. C.</style></author><author><style face="normal" font="default" size="100%">Chang, S. H.</style></author><author><style face="normal" font="default" size="100%">Chen, H. Y.</style></author><author><style face="normal" font="default" size="100%">Weng, H. J.</style></author><author><style face="normal" font="default" size="100%">Liang, P. H.</style></author><author><style face="normal" font="default" size="100%">Chen, S. Y.</style></author><author><style face="normal" font="default" size="100%">Liu, F. T.</style></author><author><style face="normal" font="default" size="100%">Tsai, T. F.</style></author><author><style face="normal" font="default" size="100%">Lee, Y. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.&#xD;Department of Dermatology, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.&#xD;Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.&#xD;Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.&#xD;Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.&#xD;College of Public Health, China Medical University, Taichung, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Narrowband Ultraviolet B Induces Peripheral Regulatory T Cells to Exert Antigen-Specific Immune Suppression</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/08/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">antigen-specific regulatory T cell induction</style></keyword><keyword><style face="normal" font="default" size="100%">narrowband ultraviolet B</style></keyword><keyword><style face="normal" font="default" size="100%">skin inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40847567</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Commonly used to treat inflammatory skin diseases, narrowband ultraviolet B (UVB) has been shown to induce antigen-specific immune suppression when combined with alloantigen immunization, but the underlying mechanism remains elusive. METHODS: We used cytometry by time-of-flight (CyTOF) to analyze the peripheral blood mononuclear cells (PBMCs) from 19 psoriasis patients enrolled in UVB trial. Mouse models of ovalbumin (OVA)-induced skin inflammation and allogeneic skin transplantation were used to investigate the effects of UVB on antigen-specific regulatory T cell (Treg) induction. We applied bulk RNA sequencing (RNA-seq) and single-cell RNA sequencing (scRNA-seq) methods to the analyses of mouse skin Tregs and PBMCs, respectively. RESULTS: CyTOF analysis revealed patients&apos; therapeutic response to be determined by a cluster of CD4(+) T cells expressing T cell receptor (TCR)-activated and Treg-associated molecules. In clinical trial and mouse models of skin inflammation and allogeneic skin transplantation, UVB led to immunosuppressive phenotypes through antigen-specific Treg induction. RNA-seq from mouse skin Tregs showed that UVB enhanced gene expression associated with cell stability, cellular location, and cell proliferation. When compiling with human peripheral Tregs analyzed by scRNA-seq, we found similar gene expression patterns involved in Treg differentiation, maintenance, and function. Furthermore, scRNA-seq analysis also demonstrated that UVB inhibited negative regulators of Treg development, thereby promoting CD4(+) T differentiation into Tregs, clonal expansion of which was also noted. CONCLUSIONS: Our findings suggest UVB can induce antigen-specific Tregs in a clinical setting, highlighting its potential for broader immunosuppressive applications.</style></abstract><notes><style face="normal" font="default" size="100%">Lu, Chun-Hao&#xD;Tsai, Ching-Hui&#xD;Phillip, Iquo O&#xD;Chiang, Pei-Chuan&#xD;Chang, Shao-Han&#xD;Chen, Huan-Yuan&#xD;Weng, Hao-Jui&#xD;Liang, Pi-Hui&#xD;Chen, Shih-Yu&#xD;Liu, Fu-Tong&#xD;Tsai, Tsen-Fang&#xD;Lee, Yungling Leo&#xD;eng&#xD;UN112-0020/National Taiwan University Hospital/&#xD;UN111-0056/National Taiwan University Hospital/&#xD;IBMS-CRC112-P02/Academia Sinica/&#xD;Denmark&#xD;Allergy. 2025 Aug 22. doi: 10.1111/all.70019.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40847567</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70019</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3313</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3313</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wen, Hui</style></author><author><style face="normal" font="default" size="100%">Kole, Tessa</style></author><author><style face="normal" font="default" size="100%">Carpaij, Orestes A.</style></author><author><style face="normal" font="default" size="100%">Karp, Tatiana</style></author><author><style face="normal" font="default" size="100%">Guryev, Victor</style></author><author><style face="normal" font="default" size="100%">Faiz, Alen</style></author><author><style face="normal" font="default" size="100%">Chung, Kian Fan</style></author><author><style face="normal" font="default" size="100%">Bhavsar, Pankaj</style></author><author><style face="normal" font="default" size="100%">Adcock, Ian M.</style></author><author><style face="normal" font="default" size="100%">Siddiqui, Salman</style></author><author><style face="normal" font="default" size="100%">Lan, Andy</style></author><author><style face="normal" font="default" size="100%">Raby, Katie L.</style></author><author><style face="normal" font="default" size="100%">Zounemat-Kermani, Nazanin</style></author><author><style face="normal" font="default" size="100%">Brightling, Chris</style></author><author><style face="normal" font="default" size="100%">Singh, Dave</style></author><author><style face="normal" font="default" size="100%">Kocks, Janwillem</style></author><author><style face="normal" font="default" size="100%">Kraft, Monica</style></author><author><style face="normal" font="default" size="100%">Beghé, Bianca</style></author><author><style face="normal" font="default" size="100%">Rabe, Klaus F.</style></author><author><style face="normal" font="default" size="100%">Papi, Alberto</style></author><author><style face="normal" font="default" size="100%">Hylkema, Machteld N.</style></author><author><style face="normal" font="default" size="100%">Nawijn, Martijn C.</style></author><author><style face="normal" font="default" size="100%">van den Berge, Maarten</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nasal Airway Transcriptome Reflects Selected Asthma-Associated Gene Signatures in the Lower Airways</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Transcriptomic analysis of bronchial brushes reveals asthma-associated gene signatures but is limited by the invasiveness of bronchoscopy. Based on the “united airways” hypothesis, we evaluated whether and to what extent nasal brushes reflect asthma-associated transcriptomic changes in the lower airways. Methods In the ARMS study, we included 26 asthma patients and 28 healthy controls, all fully clinically characterized. Nasal and bronchial brushes were collected for RNA sequencing. We used edgeR and WGCNA to identify asthma-associated genes and modules in bronchial brushes. We assessed their expression patterns in ARMS nasal brushes and validated the findings in the independent ATLANTIS study (n = 427). Results We identified 51 asthma-associated genes in the lower airways, of which 40 were up-regulated and 11 were down-regulated in asthma compared to healthy controls. Seven of the 40 up-regulated genes were also up-regulated in ARMS nasal brushes and validated in ATLANTIS: CLCA1, FETUB, CST1, NTRK2, CDH26, TPSAB1, and DHX35. WGCNA revealed two modules that were consistently elevated in asthma across bronchial and nasal brushes in ARMS and confirmed in ATLANTIS. One module represents IL-13 related inflammation, whereas the other represents mast cell activity. Conclusion The asthma-associated gene signatures of the lower and upper airways show a limited but biologically coherent overlap, with seven genes and two gene modules consistently elevated in asthma. The shared gene signatures reflect two separate components of type 2 inflammation: IL-13 related inflammation and mast cell activity. Selected nasal gene signatures offer a non-invasive tool to identify asthma endotypes with distinct molecular mechanisms driving underlying disease biology.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70283</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70283</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2438</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2438</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Parkin, R. V.</style></author><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Palmer, E.</style></author><author><style face="normal" font="default" size="100%">Meng, X.</style></author><author><style face="normal" font="default" size="100%">Zhu, R.</style></author><author><style face="normal" font="default" size="100%">Sahiner, U.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, IBIMA-Hospital Regional Universitario de Malaga-ARADyAL, UMA, Malaga, Spain.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;The MRC &amp; Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nasal allergen-neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2197-2206</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/03/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Poaceae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/immunology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Neutralizing/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Intranasal</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinitis, Allergic, Seasonal/immunology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Subcutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">IgA1</style></keyword><keyword><style face="normal" font="default" size="100%">IgA2</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-FAB</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4</style></keyword><keyword><style face="normal" font="default" size="100%">blocking antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">local allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38483174</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Local allergic rhinitis (LAR) is defined by chronic nasal symptoms, absence of atopy, positive nasal allergen challenge (NAC) and a good response to subcutaneous allergen immunotherapy (SCIT). We sought to investigate SCIT capacity to induce local and systemic blocking antibodies in LAR patients. METHODS: A RDBPC study of grass SCIT was performed, with participants receiving either SCIT (Group A; n = 10) or placebo (Group B; n = 14) in the first 6 months. Both groups subsequently received SCIT for 12 months at Year 2. Nasal and serum antibodies (IgG(4), IgA(1) and IgA(2)) and their inhibitory capacity were measured at multiple timepoints. RESULTS: The allergen concentration tolerated increased significantly at 6 months (Group A; p = .047) and 24 months (Group B; p = .049) compared with baseline and persisted until the end of the study. Induction of serum sIgA(1) to Phl p was seen in Groups A and B, albeit the former being induced earlier (1.71-fold, p = .027). A significant induction in sIgG(4) to Phl p 1 and 5 was observed in serum of Group A (p = .047 and p = .0039) and sIgA(2) to Phl p in Group B (p = .032 and p = .0098) at 18 and 24 months, respectively. Both local and systemic blocking antibodies can inhibit allergen-IgE complexes binding to CD23 on B cells, and this correlated with level of allergen tolerated intra-nasally in Group A (serum; ? = -.47, p = .0006, nasal; ? = -.38, p = .0294). CONCLUSIONS: Grass pollen SCIT induced functional systemic blocking antibodies that correlate with the concentration of allergen tolerated following NAC, highlighting their potential as a biomarker of SCIT in LAR.</style></abstract><notes><style face="normal" font="default" size="100%">Eguiluz-Gracia, Ibon&#xD;Parkin, Rebecca V&#xD;Layhadi, Janice A&#xD;Palmer, Elizabeth&#xD;Meng, Xun&#xD;Zhu, Rongfei&#xD;Sahiner, Umit&#xD;Durham, Stephen R&#xD;Torres, Maria Jose&#xD;Mayorga, Cristobalina&#xD;Rondon, Carmen&#xD;Shamji, Mohamed H&#xD;eng&#xD;NIHR Imperial Biomedical Research Centre/&#xD;PI20/01715/Instituto de Salud Carlos III (ISCIII) of the Spanish Ministry of Science and Competitiveness/&#xD;JR19/00029/Instituto de Salud Carlos III (ISCIII) of the Spanish Ministry of Science and Competitiveness/&#xD;RD16/0006/0001/Instituto de Salud Carlos III (ISCIII) of the Spanish Ministry of Science and Competitiveness/&#xD;RD21/0002/0008/Instituto de Salud Carlos III (ISCIII) of the Spanish Ministry of Science and Competitiveness/&#xD;P20_00405/Regional Ministry of Education of Andalucia/&#xD;RC-0004-2021/Regional Ministry of Education of Andalucia/&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2197-2206. doi: 10.1111/all.16083. Epub 2024 Mar 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38483174</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16083</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1273</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1273</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhu, T.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Chen, X.</style></author><author><style face="normal" font="default" size="100%">Brown, A. P.</style></author><author><style face="normal" font="default" size="100%">Weirauch, M. T.</style></author><author><style face="normal" font="default" size="100%">Guilbert, T. W.</style></author><author><style face="normal" font="default" size="100%">Khurana Hershey, G. K.</style></author><author><style face="normal" font="default" size="100%">Biagini, J. M.</style></author><author><style face="normal" font="default" size="100%">Ji, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">California National Primate Research Center, Davis, CA, USA.&#xD;Division of Human Genetics, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH, USA.&#xD;Center for Autoimmune Genomics and Etiology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH, USA.&#xD;Divisions of Biomedical Informatics and Developmental Biology, Cincinnati, OH, USA.&#xD;Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.&#xD;Division of Pulmonary Medicine, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH, USA.&#xD;Divison of Asthma Research, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH, USA.&#xD;Department of Anatomy, Physiology and Cell biology, School of Veterinary Medicine, University of California, Davis, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nasal DNA methylation differentiates severe from non-severe asthma in African-American children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1836-1845</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/11/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Black or African American/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure</style></keyword><keyword><style face="normal" font="default" size="100%">Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">DNA methylation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma severity</style></keyword><keyword><style face="normal" font="default" size="100%">environmental exposures</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33175399</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma is highly heterogeneous, and severity evaluation is key to asthma management. DNA methylation (DNAm) contributes to asthma pathogenesis. This study aimed to identify nasal epithelial DNAm differences between severe and nonsevere asthmatic children and evaluate the impact of environmental exposures. METHODS: Thirty-three nonsevere and 22 severe asthmatic African American children were included in an epigenome-wide association study. Genome-wide nasal epithelial DNAm and gene expression were measured. CpG sites associated with asthma severity and environmental exposures and predictive of severe asthma were identified. DNAm was correlated with gene expression. Enrichment for transcription factor (TF) binding sites or histone modifications surrounding DNAm differences were determined. RESULTS: We identified 816 differentially methylated CpG positions (DMPs) and 10 differentially methylated regions (DMRs) associated with asthma severity. Three DMPs exhibited discriminatory ability for severe asthma. Intriguingly, six DMPs were simultaneously associated with asthma, allergic asthma, total IgE, environmental IgE, and FeNO in an independent cohort of children. Twenty-seven DMPs were associated with traffic-related air pollution or secondhand smoke. DNAm at 22 DMPs was altered by diesel particles or allergen in human bronchial epithelial cells. DNAm levels at 39 DMPs were correlated with mRNA expression. Proximal to 816 DMPs, three histone marks and several TFs involved in asthma pathogenesis were enriched. CONCLUSIONS: Significant differences in nasal epithelial DNAm were observed between nonsevere and severe asthma in African American children, a subset of which may be useful to predict disease severity. These CpG sites are subjected to the influences of environmental exposures and may regulate gene expression.</style></abstract><notes><style face="normal" font="default" size="100%">Zhu, Tao&#xD;Zhang, Xue&#xD;Chen, Xiaoting&#xD;Brown, Anthony P&#xD;Weirauch, Matthew T&#xD;Guilbert, Theresa W&#xD;Khurana Hershey, Gurjit K&#xD;Biagini, Jocelyn M&#xD;Ji, Hong&#xD;eng&#xD;R01 AR073228/AR/NIAMS NIH HHS/&#xD;R01 NS099068/NS/NINDS NIH HHS/&#xD;R01 AI141569/AI/NIAID NIH HHS/&#xD;P51 OD011107/OD/NIH HHS/&#xD;R01 HG010730/HG/NHGRI NIH HHS/&#xD;U19 AI070235/AI/NIAID NIH HHS/&#xD;R21 AI119236/AI/NIAID NIH HHS/&#xD;P30 ES023513/ES/NIEHS NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1836-1845. doi: 10.1111/all.14655. Epub 2020 Nov 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33175399</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8110596</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14655</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>813</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">813</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nwanaji-Enwerem, J. C.</style></author><author><style face="normal" font="default" size="100%">Osborne, A.</style></author><author><style face="normal" font="default" size="100%">Cardenas, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Gangarosa Department of Environmental Health, Emory Rollins School of Public Health, Atlanta, Georgia, USA.&#xD;Department of Emergency Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.&#xD;Division of Environmental Health Sciences, School of Public Health and Center for Computational Biology, University of California, Berkeley, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nasal epigenetic age and systemic steroid response in pediatric emergency department asthma patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">307-309</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/09/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Emergency Service, Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Steroids/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">DNA methylation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">steroids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34542184</style></accession-num><notes><style face="normal" font="default" size="100%">Nwanaji-Enwerem, Jamaji C&#xD;Osborne, Anwar&#xD;Cardenas, Andres&#xD;eng&#xD;R01 ES031259/ES/NIEHS NIH HHS/&#xD;R03 AG067064/AG/NIA NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):307-309. doi: 10.1111/all.15102. Epub 2021 Sep 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34542184</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8716423</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15102</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1635</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1635</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kortekaas Krohn, I.</style></author><author><style face="normal" font="default" size="100%">Seys, S. F.</style></author><author><style face="normal" font="default" size="100%">Lund, G.</style></author><author><style face="normal" font="default" size="100%">Jonckheere, A. C.</style></author><author><style face="normal" font="default" size="100%">Dierckx de Casterle, I.</style></author><author><style face="normal" font="default" size="100%">Ceuppens, J. L.</style></author><author><style face="normal" font="default" size="100%">Steelant, B.</style></author><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research group, KU Leuven, Leuven, Belgium.&#xD;European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium.&#xD;ALK-Abello, Horsholm, Denmark.&#xD;Clinical Division of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.&#xD;Clinical Division of Otorhinolaryngology, Head and Neck Surgery, Academic Medical Center, Amsterdam, The Netherlands.&#xD;Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nasal epithelial barrier dysfunction increases sensitization and mast cell degranulation in the absence of allergic inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1155-1164</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2019/11/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Degranulation</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Ovalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergic sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">fluticasone propionate</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell degranulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31769882</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Increased epithelial permeability has been reported in allergic rhinitis, with histamine and type-2 inflammation being responsible for tight junction dysfunction. The impact of an epithelial barrier defect on allergic sensitization and mast cell (MC) degranulation remains speculative. METHODS: Transepithelial passage of allergens was evaluated on primary human nasal epithelial cell cultures. Active sensitization was attempted by repeated intranasal ovalbumin (OVA) applications in Naive mice. In a passive sensitization model, mice were injected with IgE to Dermatophagoides pteronyssinus (rDer p)2 and then exposed intranasally to the allergen. Chitosan was used to disrupt nasal epithelial integrity in vitro and in vivo. RESULTS: Chitosan strongly reduced transepithelial electrical resistance and facilitated transepithelial allergen passage in cultured primary nasal epithelial cells. In vivo, intranasal chitosan affected occludin expression and facilitated allergen passage. After epithelial barrier disruption, intranasal OVA application induced higher OVA-specific IgG1 and total IgE in serum, and increased eosinophilia and interleukin-5 in bronchoalveolar lavage (BAL) compared to sham-OVA mice. Chitosan exposure, prior to rDer p2 allergen challenge in passively sensitized mice, resulted in increased beta-hexosaminidase levels in serum and BAL compared to sham-rDer p2 mice. Intranasal treatment with the synthetic glucocorticoid fluticasone propionate prevented chitosan-induced barrier dysfunction, allergic sensitization, and MC degranulation. CONCLUSION: Epithelial barrier dysfunction facilitates transepithelial allergen passage, allergic sensitization, and allergen-induced MC degranulation even in the absence of inflammatory environment. These results emphasize the crucial role of an intact epithelial barrier in prevention of allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Kortekaas Krohn, Inge&#xD;Seys, Sven F&#xD;Lund, Gitte&#xD;Jonckheere, Anne-Charlotte&#xD;Dierckx de Casterle, Isabelle&#xD;Ceuppens, Jan L&#xD;Steelant, Brecht&#xD;Hellings, Peter W&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 May;75(5):1155-1164. doi: 10.1111/all.14132. Epub 2019 Dec 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31769882</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14132</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3135</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3135</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez-Garcia, J.</style></author><author><style face="normal" font="default" size="100%">Bozack, A. K.</style></author><author><style face="normal" font="default" size="100%">Rifas-Shiman, S. L.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Sordillo, J.</style></author><author><style face="normal" font="default" size="100%">Coull, B.</style></author><author><style face="normal" font="default" size="100%">Luttmann-Gibson, H.</style></author><author><style face="normal" font="default" size="100%">Schwartz, J.</style></author><author><style face="normal" font="default" size="100%">Hivert, M. F.</style></author><author><style face="normal" font="default" size="100%">Oken, E.</style></author><author><style face="normal" font="default" size="100%">Gold, D. R.</style></author><author><style face="normal" font="default" size="100%">Cardenas, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford University, Stanford, California, USA.&#xD;Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School, and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.&#xD;Department of Medicine, UConn School of Medicine, Farmington, Connecticut, USA.&#xD;Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.&#xD;Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Department of Medicine, Diabetes Center, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Channing Division of Network Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Nasal Microbiome and Associations With Environmental Exposures and Respiratory Health</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">air pollutants</style></keyword><keyword><style face="normal" font="default" size="100%">allergy and immunology</style></keyword><keyword><style face="normal" font="default" size="100%">environmental health</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41074693</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The nasal microbiome is directly in contact with the external environment and may play a role in respiratory health. This study aimed to evaluate the association of the nasal microbiome with air pollutants, meteorological conditions, and respiratory health in adolescents. METHODS: We analyzed the nasal microbiome in 416 adolescents from the Project Viva cohort (mean age 13 years and 52% female). We tested for the association of alpha diversity, nasotypes, and bacterial genera abundance with environmental exposures from the past 2 days to the past year (PM(2.5), NO(2), O(3), temperature, humidity, residential greenness) and respiratory outcomes (asthma, hay fever, wheezing, IgE, aeroallergen sensitization, FeNO, lung function) through regression models adjusted for confounders and corrected using a false discovery rate (FDR) &lt; 5%. RESULTS: Bacterial diversity was positively associated with hay fever and short-term exposure to NO(2), while it was negatively correlated with temperature (FDR &lt; 0.05). Adolescents whose nasal microbiome was dominated by Moraxella were exposed in the past week to lower O(3) levels (ORs: 0.73-0.76) and higher temperature and humidity (ORs: 1.19-1.26). Staphylococcus dominance was positively associated with aeroallergen sensitization compared to Propionibacterium dominance (OR: 4.48, FDR = 0.03). Thirteen and eight bacterial genera abundance were associated with short-to-medium-term exposures (PM(2.5), NO(2), temperature) and respiratory outcomes (hay fever, wheezing, IgE, FeNO, lung function) (FDR &lt; 0.05). Staphylococcus, Corynebacterium, Pelomonas, Lactococcus, Lachnospiraceae (unclassified), and Faecalibacterium abundance were associated with both environmental exposures and respiratory traits. CONCLUSIONS: Nasal microbiome diversity was associated with hay fever, NO(2), and temperature exposure. Multiple short-to-medium-term environmental exposures and respiratory outcomes were associated with nasotypes and bacterial genera abundance in adolescents.</style></abstract><notes><style face="normal" font="default" size="100%">Perez-Garcia, Javier&#xD;Bozack, Anne K&#xD;Rifas-Shiman, Sheryl L&#xD;Zhou, Yanjiao&#xD;Sordillo, Joanne&#xD;Coull, Brent&#xD;Luttmann-Gibson, Heike&#xD;Schwartz, Joel&#xD;Hivert, Marie-France&#xD;Oken, Emily&#xD;Gold, Diane R&#xD;Cardenas, Andres&#xD;eng&#xD;ES/NIEHS NIH HHS/&#xD;NH/NIH HHS/&#xD;R01ES031259/ National Institutes of Health (NIH)/&#xD;R01HD034568/ National Institutes of Health (NIH)/&#xD;R24ES030894/ National Institutes of Health (NIH)/&#xD;P30-ES000002/ National Institutes of Health (NIH)/&#xD;Denmark&#xD;Allergy. 2025 Oct 11. doi: 10.1111/all.70089.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41074693</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70089</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>392</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">392</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, J. G.</style></author><author><style face="normal" font="default" size="100%">Zhang, A.</style></author><author><style face="normal" font="default" size="100%">Rauseo, A. M.</style></author><author><style face="normal" font="default" size="100%">Goss, C. W.</style></author><author><style face="normal" font="default" size="100%">Mudd, P. A.</style></author><author><style face="normal" font="default" size="100%">O&apos;Halloran, J. A.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.&#xD;Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.&#xD;Division of Biostatistics, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.&#xD;Department of Emergency Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The nasopharyngeal and salivary microbiomes in COVID-19 patients with and without asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3676-3679</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/07/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Nasopharynx</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Saliva</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35837881</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Josh G&#xD;Zhang, Ai&#xD;Rauseo, Adriana M&#xD;Goss, Charles W&#xD;Mudd, Philip A&#xD;O&apos;Halloran, Jane A&#xD;Wang, Leyao&#xD;eng&#xD;P30 CA091842/CA/NCI NIH HHS/&#xD;R21 AI139649/AI/NIAID NIH HHS/&#xD;UL1 TR002345/TR/NCATS NIH HHS/&#xD;NH/NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3676-3679. doi: 10.1111/all.15438. Epub 2022 Jul 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35837881</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9350136</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15438</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3134</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3134</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shibata, R.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Yaskolka Meir, A.</style></author><author><style face="normal" font="default" size="100%">Cregeen, S. J.</style></author><author><style face="normal" font="default" size="100%">Ross, M. C.</style></author><author><style face="normal" font="default" size="100%">Espinola, J. A.</style></author><author><style face="normal" font="default" size="100%">Sullivan, A. F.</style></author><author><style face="normal" font="default" size="100%">Liang, L.</style></author><author><style face="normal" font="default" size="100%">Hasegawa, K.</style></author><author><style face="normal" font="default" size="100%">Camargo, C. A.</style></author><author><style face="normal" font="default" size="100%">Zhu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Alkek Center for Metagenomics &amp; Microbiome Research, Baylor College of Medicine, Houston, Texas, USA.&#xD;Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nasopharyngeal Microbiome-Epigenome-Wide Association Analysis in Infants With Severe Bronchiolitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Airway microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">DNA methylation</style></keyword><keyword><style face="normal" font="default" size="100%">DNA methylation age</style></keyword><keyword><style face="normal" font="default" size="100%">Ewas</style></keyword><keyword><style face="normal" font="default" size="100%">bronchiolitis</style></keyword><keyword><style face="normal" font="default" size="100%">Cregeen reports grants from the National Institutes of Health during the conduct</style></keyword><keyword><style face="normal" font="default" size="100%">of the study. Dr. Ross reports grants from the National Institutes of Health</style></keyword><keyword><style face="normal" font="default" size="100%">during the conduct of the study. Dr. Hasegawa is employed by Sanofi Pasteur at</style></keyword><keyword><style face="normal" font="default" size="100%">the time of submission. Dr. Liang reports grants from the National Institutes of</style></keyword><keyword><style face="normal" font="default" size="100%">Health during the conduct of the study. Dr. Camargo reports grants from the</style></keyword><keyword><style face="normal" font="default" size="100%">National Institutes of Health during the conduct of the study. Dr. Zhu reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from the National Institutes of Health during the conduct of the study.</style></keyword><keyword><style face="normal" font="default" size="100%">All other authors have indicated that they have no financial relationships</style></keyword><keyword><style face="normal" font="default" size="100%">relevant to this article to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41078079</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Bronchiolitis exposes infants to both acute burdens (e.g., hospitalization in cases of severe bronchiolitis) and increased risks for chronic respiratory sequelae (e.g., asthma). In severe bronchiolitis, recent evidence suggests distinct pathobiological roles of microbiota (e.g., viruses, bacteria) and host responses influenced by genetic and epigenetic factors. However, the relationship of airway microbiota with host DNA methylation (DNAm) in infants with severe bronchiolitis remains unknown. METHODS: In a multi-center prospective cohort of 504 multi-ethnic infants with severe bronchiolitis (age &lt; 1 year), using nasopharyngeal microbiome (exposure) and blood DNAm (outcome, Infinium MethylationEPIC BeadChip, Illumina) data within 24 h of the hospitalization, we conducted microbiome-epigenome-wide association studies (mbEWAS). We examined microbiota-associated differentially methylated CpGs (mbDMCs, false discovery rate [FDR] &lt; 0.05), regions (mbDMRs, FDR &lt; 0.05), and DNAm age acceleration. We also determined the associations of DNAm age acceleration with asthma development by age 6 years. Furthermore, we focused on asthma-related pathogenic bacteria-Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae-for functional analyses by examining serum mbDMR-related proteins (Proseek Multiplex, Olink) and their enriched pathways (FDR &lt; 0.10). RESULTS: Across 23 common taxa-observed at least in 25% of the infants, we identified 1 mbDMC (S. pneumoniae, cg16594639, chr20: 39528675) and 96 mbDMRs (e.g., S. pneumoniae, chr5:27038497-27038802, CDH9; chr6:48068669-48068940, PTCHD4). A higher H. influenzae abundance was associated with DNAm age deceleration, and the deceleration was associated with a higher risk of developing asthma. In 29 mbDMRs of the asthma-related pathogenic bacteria, we identified 156 mbDMR-related proteins (e.g., MMP9, XCL1). These proteins were enriched in immune response-related pathways (e.g., regulation of ERBB signaling and eosinophil chemotaxis and migration pathways). CONCLUSIONS: In this multi-center prospective cohort study of severe bronchiolitis, our mbEWAS suggested the microbiota-host associations that regulate immune responses.</style></abstract><notes><style face="normal" font="default" size="100%">Shibata, Ryohei&#xD;Li, Yijun&#xD;Yaskolka Meir, Anat&#xD;Cregeen, Sara Javornik&#xD;Ross, Matthew Clayton&#xD;Espinola, Janice A&#xD;Sullivan, Ashley F&#xD;Liang, Liming&#xD;Hasegawa, Kohei&#xD;Camargo, Carlos A&#xD;Zhu, Zhaozhong&#xD;eng&#xD;the Harvard University William F. Milton Fund/&#xD;R01 AI127507/AI/NIAID NIH HHS/&#xD;R01 ES036966/ES/NIEHS NIH HHS/&#xD;R01 AI148338/AI/NIAID NIH HHS/&#xD;R01 AI137091/AI/NIAID NIH HHS/&#xD;American Lung Association Innovation Award/&#xD;K01 AI153558/AI/NIAID NIH HHS/&#xD;UG3 OD023253/OD/NIH HHS/&#xD;Massachusetts General Hospital/&#xD;R01 AI134940/AI/NIAID NIH HHS/&#xD;U01 AI087881/AI/NIAID NIH HHS/&#xD;Environmental influences on Child Health Outcomes (ECHO) Program Opportunities and Innovation Fund (OIF)/&#xD;R01 AI114552/AI/NIAID NIH HHS/&#xD;UH3 OD023253/OD/NIH HHS/&#xD;Denmark&#xD;Allergy. 2025 Oct 13:10.1111/all.70102. doi: 10.1111/all.70102.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41078079</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12709516</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70102</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3131</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3131</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elbashir, H.</style></author><author><style face="normal" font="default" size="100%">Dorr, A.</style></author><author><style face="normal" font="default" size="100%">Ahuja, M.</style></author><author><style face="normal" font="default" size="100%">Lorenzo, L.</style></author><author><style face="normal" font="default" size="100%">Al-Rashid, A.</style></author><author><style face="normal" font="default" size="100%">Yellon, R. L.</style></author><author><style face="normal" font="default" size="100%">Manson, A.</style></author><author><style face="normal" font="default" size="100%">Soo, X. Y.</style></author><author><style face="normal" font="default" size="100%">Ghanta, H.</style></author><author><style face="normal" font="default" size="100%">Eren, E.</style></author><author><style face="normal" font="default" size="100%">Herwadkar, A.</style></author><author><style face="normal" font="default" size="100%">Moustafa, M.</style></author><author><style face="normal" font="default" size="100%">Murng, S.</style></author><author><style face="normal" font="default" size="100%">Hall, B.</style></author><author><style face="normal" font="default" size="100%">Stroud, C.</style></author><author><style face="normal" font="default" size="100%">Jani, R.</style></author><author><style face="normal" font="default" size="100%">Leeman, L.</style></author><author><style face="normal" font="default" size="100%">Symons, C.</style></author><author><style face="normal" font="default" size="100%">Elamin, S.</style></author><author><style face="normal" font="default" size="100%">Garcez, T.</style></author><author><style face="normal" font="default" size="100%">Roa-Bautista, A.</style></author><author><style face="normal" font="default" size="100%">El-Shanawany, T.</style></author><author><style face="normal" font="default" size="100%">Abdelhakam, I.</style></author><author><style face="normal" font="default" size="100%">Mahabir, S.</style></author><author><style face="normal" font="default" size="100%">Lever, C.</style></author><author><style face="normal" font="default" size="100%">Alachkar, H.</style></author><author><style face="normal" font="default" size="100%">Morsi, H.</style></author><author><style face="normal" font="default" size="100%">Bower, C.</style></author><author><style face="normal" font="default" size="100%">Makki, I.</style></author><author><style face="normal" font="default" size="100%">Coulter, T.</style></author><author><style face="normal" font="default" size="100%">Ekbote, A.</style></author><author><style face="normal" font="default" size="100%">Sooriyakumar, K.</style></author><author><style face="normal" font="default" size="100%">Ghurye, R.</style></author><author><style face="normal" font="default" size="100%">Grammatikos, A.</style></author><author><style face="normal" font="default" size="100%">Anantharachagan, A.</style></author><author><style face="normal" font="default" size="100%">Vijayadurai, P.</style></author><author><style face="normal" font="default" size="100%">Yong, P.</style></author><author><style face="normal" font="default" size="100%">Kiani-Alikhan, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.&#xD;Department of Immunology, Barts Health NHS Trust, London, UK.&#xD;Regional Department of Immunology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.&#xD;Department of Clinical Immunology, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.&#xD;Immunology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Clinical Immunology Department, Salford Care Organisation, Northern Care Alliance, Salford, UK.&#xD;Clinical Immunology Department, Oxford University Hospital NHS Foundation Trust, Oxford, UK.&#xD;The Department of Clinical Immunology, University Hospitals Plymouth NHS Trust, Plymouth, UK.&#xD;Immunology Department, Manchester University NHS Foundation Trust, Manchester, UK.&#xD;Immunodeficiency Centre for Wales, Department of Immunology, University Hospital of Wales, Cardiff, UK.&#xD;Department of Immunology, University Hospitals of Leicester NHS Trust, Leicester, UK.&#xD;Immunology Department, Royal Free London NHS Foundation Trust, London, UK.&#xD;Allergy and Clinical Immunology Department, NHS University Hospitals of Liverpool Group, Liverpool, UK.&#xD;Regional Immunology Service, Royal Hospitals Belfast, Belfast, UK.&#xD;Department of Immunology and Allergy, University Hospitals Birmingham, NHS Foundation Trust, Birmingham, UK.&#xD;Allergy and Immunology, King&apos;s College Hospital NHS Foundation Trust, London, UK.&#xD;Clinical Immunology and Allergy, North Bristol NHS Trust, Bristol, UK.&#xD;Clinical Immunology and Allergy, Frimley Park Hospital and Royal Surrey County Hospital, Frimley, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">National Audit of Long-Term Real-World Outcomes of Berotralstat Use in UK Patients With Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/14</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 14</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41085099</style></accession-num><notes><style face="normal" font="default" size="100%">Elbashir, Haggar&#xD;Dorr, Anthony&#xD;Ahuja, Manisha&#xD;Lorenzo, Lorena&#xD;Al-Rashid, Ahmad&#xD;Yellon, Robert L&#xD;Manson, Ania&#xD;Soo, Xi Ying&#xD;Ghanta, Harichandana&#xD;Eren, Efrem&#xD;Herwadkar, Archana&#xD;Moustafa, Mahetab&#xD;Murng, Sai&#xD;Hall, Benjamin&#xD;Stroud, Catherine&#xD;Jani, Rashmi&#xD;Leeman, Lucy&#xD;Symons, Christine&#xD;Elamin, Shaza&#xD;Garcez, Tomaz&#xD;Roa-Bautista, Adriel&#xD;El-Shanawany, Tariq&#xD;Abdelhakam, Intisar&#xD;Mahabir, Shanti&#xD;Lever, Charley&#xD;Alachkar, Hana&#xD;Morsi, Hadeil&#xD;Bower, Clare&#xD;Makki, Inas&#xD;Coulter, Tanya&#xD;Ekbote, Anjali&#xD;Sooriyakumar, Kavitha&#xD;Ghurye, Rohit&#xD;Grammatikos, Alexandros&#xD;Anantharachagan, Ariharan&#xD;Vijayadurai, Pavaladurai&#xD;Yong, Patrick&#xD;Kiani-Alikhan, Sorena&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Oct 14. doi: 10.1111/all.70086.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41085099</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70086</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>73</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">73</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koo, M. J.</style></author><author><style face="normal" font="default" size="100%">Kwon, R.</style></author><author><style face="normal" font="default" size="100%">Lee, S. W.</style></author><author><style face="normal" font="default" size="100%">Choi, Y. S.</style></author><author><style face="normal" font="default" size="100%">Shin, Y. H.</style></author><author><style face="normal" font="default" size="100%">Rhee, S. Y.</style></author><author><style face="normal" font="default" size="100%">Min, C.</style></author><author><style face="normal" font="default" size="100%">Cho, S. H.</style></author><author><style face="normal" font="default" size="100%">Turner, S.</style></author><author><style face="normal" font="default" size="100%">Kim, S. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author><author><style face="normal" font="default" size="100%">Yeo, S. G.</style></author><author><style face="normal" font="default" size="100%">Abuabara, K.</style></author><author><style face="normal" font="default" size="100%">Lee, Y. J.</style></author><author><style face="normal" font="default" size="100%">Shin, J. I.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Shin, J. U.</style></author><author><style face="normal" font="default" size="100%">Yon, D. K.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Human Biology, University of Toronto, Toronto, Ontario, Canada.&#xD;Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA.&#xD;Department of Precision Medicine, Sungkyunkwan University School of medicine, Suwon, South Korea.&#xD;Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Pediatrics, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, South Korea.&#xD;Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, South Korea.&#xD;Division of Allergy-Immunology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.&#xD;Maternity and Child Health Division, NHS Grampian Aberdeen, Aberdeen, UK.&#xD;Department of Otorhinolaryngology-Head &amp; Neck Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.&#xD;Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea.&#xD;Department of Otolaryngology - Head &amp; Neck Surgery, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Dermatology, University of California San Francisco, San Francisco, California, USA.&#xD;Department of Obstetrics and Gynecology, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.&#xD;Department of Allergy and Clinical Immunology, Korean Armed Forces Capital Hospital, Seongnam, South Korea.&#xD;Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.&#xD;Allergy Department, 2nd Paediatric Clinic, National Kapodistrian University of Athens, Athens, Greece.&#xD;Lydia Becker Institute of Immunology &amp; Inflammation, University of Manchester, Manchester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">National trends in the prevalence of allergic diseases among Korean adolescents before and during COVID-19, 2009-2021: A serial analysis of the national representative study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1665-1670</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Republic of Korea/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36440490</style></accession-num><notes><style face="normal" font="default" size="100%">Koo, Min Ji&#xD;Kwon, Rosie&#xD;Lee, Seung Won&#xD;Choi, Yong Sung&#xD;Shin, Youn Ho&#xD;Rhee, Sang Youl&#xD;Min, Chanyang&#xD;Cho, Seong Ho&#xD;Turner, Stephen&#xD;Kim, So Young&#xD;Lee, Jinseok&#xD;Yeo, Seung-Geun&#xD;Abuabara, Katrina&#xD;Lee, Young Joo&#xD;Shin, Jae Il&#xD;Kim, Jung-Hyun&#xD;Shin, Jung U&#xD;Yon, Dong Keon&#xD;Papadopoulos, Nikolaos G&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1665-1670. doi: 10.1111/all.15600. Epub 2022 Dec 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36440490</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15600</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2975</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2975</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rontynen, P.</style></author><author><style face="normal" font="default" size="100%">Kukkonen, A. K.</style></author><author><style face="normal" font="default" size="100%">Savinko, T.</style></author><author><style face="normal" font="default" size="100%">Makela, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Helsinki and Helsinki University Hospital, Skin and Allergy Hospital, Helsinki, Finland.&#xD;University of Helsinki and Helsinki University Hospital, Children&apos;s Hospital, and Pediatric Research Center, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Natural Course and Predictors of Clinical Resolution in Pediatric Cashew Nut Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2914-2915</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/07/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40678938</style></accession-num><notes><style face="normal" font="default" size="100%">Rontynen, Petteri&#xD;Kukkonen, Anna Kaarina&#xD;Savinko, Terhi&#xD;Makela, Mika J&#xD;eng&#xD;Helsinki University Hospital Research Funds, Sigrid Juselius Foundation, Pediatric Research Foundation, Finnish Allergy Research Foundation, and Finnish Society of Allergology and Immunology/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2914-2915. doi: 10.1111/all.16664. Epub 2025 Jul 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40678938</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486358</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16664</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2316</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2316</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lindqvist, M.</style></author><author><style face="normal" font="default" size="100%">Leth-Moller, K. B.</style></author><author><style face="normal" font="default" size="100%">Linneberg, A.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Bergstrom, A.</style></author><author><style face="normal" font="default" size="100%">Georgellis, A.</style></author><author><style face="normal" font="default" size="100%">Borres, M. P.</style></author><author><style face="normal" font="default" size="100%">Ekebom, A.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Westman, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.&#xD;Center for Clinical Research and Prevention, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Frederiksberg, Denmark.&#xD;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Clinical Science and Education Sodersjukhuset, Karolinska Institutet, Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Centre for Occupational and Environmental Medicine, Region Stockholm, Stockholm, Sweden.&#xD;Department of Women&apos;s and Children&apos;s Health, Uppsala University, Uppsala, Sweden.&#xD;Department of Environmental Research and Monitoring, Palynological Laboratory, Swedish Museum of Natural History, Stockholm, Sweden.&#xD;Asthma- and Allergy Clinic S:t Goran, Praktikertjanst, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Natural course of pollen-induced allergic rhinitis from childhood to adulthood: A 20-year follow up</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">884-893</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/11/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Bamse</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">pollen allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37916606</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic rhinitis (AR) is one of the most common chronic diseases worldwide. There are limited prospective long-term data regarding persistency and remission of AR. The objective of this study was to investigate the natural course of pollen-induced AR (pollen-AR) over 20 years, from childhood into early adulthood. METHODS: Data from 1137 subjects in the Barn/Children Allergi/Allergy Milieu Stockholm Epidemiologic birth cohort (BAMSE) with a completed questionnaire regarding symptoms, asthma, treatment with allergen immunotherapy (AIT) and results of allergen-specific IgE for inhalant allergens at 4, 8, 16 and 24 years were analyzed. Pollen-AR was defined as sneezing, runny, itchy or blocked nose; and itchy or watery eyes when exposed to birch and/or grass pollen in combination with allergen-specific IgE &gt;/=0.35kU(A)/L to birch and/or grass. RESULTS: Approximately 75% of children with pollen-AR at 4 or 8 years had persistent disease up to 24 years, and 30% developed asthma. The probability of persistency was high already at low levels of pollen-specific IgE. The highest rate of remission from pollen-AR was seen between 16 and 24 years (21.5%); however, the majority remained sensitized. This period was also when pollen-specific IgE-levels stopped increasing and the average estimated annual incidence of pollen-AR decreased from 1.5% to 0.8% per year. CONCLUSION: Children with pollen-AR are at high risk of persistent disease for at least 20 years. Childhood up to adolescence seems to be the most dynamic period of AR progression. Our findings underline the close cross-sectional and longitudinal relationship between sensitization, AR and asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Lindqvist, Magnus&#xD;Leth-Moller, Katja Biering&#xD;Linneberg, Allan&#xD;Kull, Inger&#xD;Bergstrom, Anna&#xD;Georgellis, Antonios&#xD;Borres, Magnus P&#xD;Ekebom, Agneta&#xD;van Hage, Marianne&#xD;Melen, Erik&#xD;Westman, Marit&#xD;eng&#xD;ALK Nordic A/S/&#xD;asthma and allergy foundation sweden/&#xD;Ellen, Walter and Lennart Hesselman Foundation for Scientific Research/&#xD;European Commission/&#xD;Forskningsradet om Halsa, Arbetsliv och Valfard/&#xD;Hjart-Lungfonden/&#xD;Insamlingsstiftelsen Cancer- och Allergifonden/&#xD;Konsul Th C Berghs Stiftelse/&#xD;Magnus Bergvalls Stiftelse/&#xD;Stiftelsen Acta Oto-Laryngologica/&#xD;Stiftelsen Konung Gustaf V:s 80-arsfond/&#xD;Vetenskapsradet/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):884-893. doi: 10.1111/all.15927. Epub 2023 Nov 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37916606</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15927</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3027</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3027</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carra, S.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Kurukulaaratchy, R. J.</style></author><author><style face="normal" font="default" size="100%">Arshad, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Division of Epidemiology, Biostatistics, and Environmental Health Sciences, School of Public Health, University of Memphis, Memphis, Tennessee, USA.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Newport, UK.&#xD;Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Natural History of Airway Hyperresponsiveness and Its Association With Asthma Traits</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">121-129</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/08/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Hypersensitivity/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Methacholine Chloride</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchial Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchial challenge test</style></keyword><keyword><style face="normal" font="default" size="100%">methacholine</style></keyword><keyword><style face="normal" font="default" size="100%">wheeze</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40842367</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The natural history of airway hyperresponsiveness (AHR) from childhood to adulthood and its association with asthma status are poorly understood. We aim to define the natural history of AHR in relation to asthma characteristics such as symptoms, atopy and lung function to improve our understanding of the changes in AHR with asthma pathophysiology during adolescence. METHODS: Methacholine bronchial challenge test (BCT) was undertaken in the Isle of Wight whole population birth cohort at 10 years (n = 783), 18 years (n = 585) and 26 years (n = 86). Data on wheeze, lung function, and atopy were collected at each time point. Definite AHR was defined as methacholine concentration provoking a 20% decrease in Forced Expiratory Volume in 1 s (PC(20)) at &lt; 4 mg/mL. RESULTS: AHR prevalence was 21.6% (169/783) at 10 years and 5% (29/585) at 18 years of age (p &lt; 0.01). In 406 participants, where methacholine BCT was performed at both 10 and 18 years, 80.9% of those with AHR at age 10 became negative at 18 years. At a population level, AHR trajectory was in the opposite direction to that of asthma (14.7% at age 10 to 17.6% at age 18; p = 0.004), atopy (26.9% at age 10 to 41.5% at age 18; p &lt; 0.001) and airway obstruction (FEV(1)/FVC ratio of 0.88 at age 10 to 0.87 at age 18; p &lt; 0.001). AHR prevalence remained stable between the ages of 18 and 26 years. CONCLUSION: The natural history of AHR is characterised by a marked decrease in prevalence during adolescence, in contrast to asthma and other asthma characteristics. Age should be considered when interpreting AHR as an asthma defining trait.</style></abstract><notes><style face="normal" font="default" size="100%">Carra, Sophie&#xD;Zhang, Hongmei&#xD;Kurukulaaratchy, Ramesh J&#xD;Arshad, Syed Hasan&#xD;eng&#xD;R01 HL082925/HL/NHLBI NIH HHS/&#xD;National Institute of Heart Lung Blood/&#xD;Asthma and Lung UK/&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):121-129. doi: 10.1111/all.70006. Epub 2025 Aug 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40842367</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773667</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70006</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2247</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2247</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brazhnikov, G.</style></author><author><style face="normal" font="default" size="100%">Smolnikov, E.</style></author><author><style face="normal" font="default" size="100%">Litovkina, A.</style></author><author><style face="normal" font="default" size="100%">Jiang, T.</style></author><author><style face="normal" font="default" size="100%">Shatilov, A.</style></author><author><style face="normal" font="default" size="100%">Tulaeva, I.</style></author><author><style face="normal" font="default" size="100%">Tulaev, M.</style></author><author><style face="normal" font="default" size="100%">Karaulov, A.</style></author><author><style face="normal" font="default" size="100%">Poroshina, A.</style></author><author><style face="normal" font="default" size="100%">Zhernov, Y.</style></author><author><style face="normal" font="default" size="100%">Focke-Tejkl, M.</style></author><author><style face="normal" font="default" size="100%">Weber, M.</style></author><author><style face="normal" font="default" size="100%">Akinfenwa, O.</style></author><author><style face="normal" font="default" size="100%">Elisyutina, O.</style></author><author><style face="normal" font="default" size="100%">Andreev, S.</style></author><author><style face="normal" font="default" size="100%">Shilovskiy, I.</style></author><author><style face="normal" font="default" size="100%">Shershakova, N.</style></author><author><style face="normal" font="default" size="100%">Smirnov, V.</style></author><author><style face="normal" font="default" size="100%">Fedenko, E.</style></author><author><style face="normal" font="default" size="100%">Lepeshkova, T. S.</style></author><author><style face="normal" font="default" size="100%">Beltyukov, E. C.</style></author><author><style face="normal" font="default" size="100%">Naumova, V. V.</style></author><author><style face="normal" font="default" size="100%">Kundi, M.</style></author><author><style face="normal" font="default" size="100%">Khaitov, M.</style></author><author><style face="normal" font="default" size="100%">Wiedermann, U.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Campana, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Institute for Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;National Research Center Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow, Russia.&#xD;Department of Immunology, Institute of Medicine, RUDN University, Moscow, Russia.&#xD;Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.&#xD;F. Erismann Institute of Public Health, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Department of Polyclinic Pediatrics, Ural State Medical University, Yekaterinburg, Russia.&#xD;Department of Faculty Therapy, Endocrinology, Allergology and Immunology, Ural State Medical University, Yekaterinburg, Russia.&#xD;Institute for Hygiene and Applied Immunology, Center for Public Health, Medical University of Vienna, Vienna, Austria.&#xD;Pirogov Russian National Research Medical University, Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Natural human Bet v 1-specific IgG antibodies recognize non-conformational epitopes whereas IgE reacts with conformational epitopes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3136-3153</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/09/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Bet v 1</style></keyword><keyword><style face="normal" font="default" size="100%">IgG</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">birch pollen allergy</style></keyword><keyword><style face="normal" font="default" size="100%">epitope</style></keyword><keyword><style face="normal" font="default" size="100%">HVD Biotech, Vienna, Austria and Worg Pharmaceuticals, Hangzhou, China. He serves</style></keyword><keyword><style face="normal" font="default" size="100%">as a consultant for Viravaxx and Worg. The other authors have not conflicts of</style></keyword><keyword><style face="normal" font="default" size="100%">interest to declare. The authors with Russian affiliation declare that they have</style></keyword><keyword><style face="normal" font="default" size="100%">prepared the article in their &apos;personal capacity&apos; and/or that they are employed</style></keyword><keyword><style face="normal" font="default" size="100%">at an academic/research institution where research or education is the primary</style></keyword><keyword><style face="normal" font="default" size="100%">function of the entity.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37701941</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The nature of epitopes on Bet v 1 recognized by natural IgG antibodies of birch pollen allergic patients and birch pollen-exposed but non-sensitized subjects has not been studied in detail. OBJECTIVE: To investigate IgE and IgG recognition of Bet v 1 and to study the effects of natural Bet v 1-specific IgG antibodies on IgE recognition of Bet v 1 and Bet v 1-induced basophil activation. METHODS: Sera from birch pollen allergic patients (BPA, n = 76), allergic patients without birch pollen allergy (NBPA, n = 40) and non-allergic individuals (NA, n = 48) were tested for IgE, IgG as well as IgG(1) and IgG(4) reactivity to folded recombinant Bet v 1, two unfolded recombinant Bet v 1 fragments comprising the N-terminal (F1) and C-terminal half of Bet v 1 (F2) and unfolded peptides spanning the corresponding sequences of Bet v 1 and the apple allergen Mal d 1 by ELISA or micro-array analysis. The ability of Bet v 1-specific serum antibodies from non-allergic subjects to inhibit allergic patients IgE or IgG binding to rBet v 1 or to unfolded Bet v 1-derivatives was assessed by competition ELISAs. Furthermore, the ability of serum antibodies from allergic and non-allergic subjects to modulate Bet v 1-induced basophil activation was investigated using rat basophilic leukaemia cells expressing the human FcepsilonRI which had been loaded with IgE from BPA patients. RESULTS: IgE antibodies from BPA patients react almost exclusively with conformational epitopes whereas IgG, IgG(1) and IgG(4) antibodies from BPA, NBPA and NA subjects recognize mainly unfolded and sequential epitopes. IgG competition studies show that IgG specific for unfolded/sequential Bet v 1 epitopes is not inhibited by folded Bet v 1 and hence the latter seem to represent cryptic epitopes. IgG reactivity to Bet v 1 peptides did not correlate with IgG reactivity to the corresponding Mal d 1 peptides and therefore does not seem to be a result of primary sensitization to PR10 allergen-containing food. Natural Bet v 1-specific IgG antibodies inhibited IgE binding to Bet v 1 only poorly and could even enhance Bet v 1-specific basophil activation. CONCLUSION: IgE and IgG antibodies from BPA patients and birch pollen-exposed non-sensitized subjects recognize different epitopes. These findings explain why natural allergen-specific IgG do not protect against allergic symptoms and suggest that allergen-specific IgE and IgG have different clonal origin.</style></abstract><notes><style face="normal" font="default" size="100%">Brazhnikov, Georgii&#xD;Smolnikov, Evgenii&#xD;Litovkina, Alla&#xD;Jiang, Tianchi&#xD;Shatilov, Artem&#xD;Tulaeva, Inna&#xD;Tulaev, Mikhail&#xD;Karaulov, Alexander&#xD;Poroshina, Alina&#xD;Zhernov, Yury&#xD;Focke-Tejkl, Margarete&#xD;Weber, Milena&#xD;Akinfenwa, Oluwatoyin&#xD;Elisyutina, Olga&#xD;Andreev, Sergey&#xD;Shilovskiy, Igor&#xD;Shershakova, Nadezhda&#xD;Smirnov, Valeriy&#xD;Fedenko, Elena&#xD;Lepeshkova, Tatiana Sergeevna&#xD;Beltyukov, Evgeny Cronidovich&#xD;Naumova, Veronika Victorovna&#xD;Kundi, Michael&#xD;Khaitov, Musa&#xD;Wiedermann, Ursula&#xD;Valenta, Rudolf&#xD;Campana, Raffaela&#xD;eng&#xD;075-15-2021-632/Megagrant/&#xD;P34472-B/Austrian Science Fund/&#xD;Danube ARC grant of the country of Lower Austria/&#xD;23-75-30016/Russian Science Foundation/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3136-3153. doi: 10.1111/all.15865. Epub 2023 Sep 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37701941</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10952721</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15865</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2419</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2419</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;CK CARE, Christine Kuhne Center for Allergy Research and Education, Davos, Switzerland.&#xD;Institute of Environmental Medicine, Helmholtz Center Munich, Augsburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nature&apos;s pharmacy at risk: Unveiling the hidden molecular secrets of phytotherapy in the age of globalization</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1413-1415</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/02/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Internationality</style></keyword><keyword><style face="normal" font="default" size="100%">*Phytotherapy/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38308486</style></accession-num><notes><style face="normal" font="default" size="100%">Traidl-Hoffmann, Claudia&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1413-1415. doi: 10.1111/all.16037. Epub 2024 Feb 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38308486</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16037</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3296</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3296</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, Edwin H.</style></author><author><style face="normal" font="default" size="100%">Bird, J. Andrew</style></author><author><style face="normal" font="default" size="100%">Brough, Helen A.</style></author><author><style face="normal" font="default" size="100%">Fleischer, David M.</style></author><author><style face="normal" font="default" size="100%">Jones, Stacie M.</style></author><author><style face="normal" font="default" size="100%">Kun, Ildiko</style></author><author><style face="normal" font="default" size="100%">Shreffler, Wayne</style></author><author><style face="normal" font="default" size="100%">Van Eenwyk, Claire</style></author><author><style face="normal" font="default" size="100%">Vickery, Brian P.</style></author><author><style face="normal" font="default" size="100%">Wang, Julie</style></author><author><style face="normal" font="default" size="100%">Santos, Alexandra F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Navigating Oral Food Challenges in Clinical Trials to Keep the Science Moving Forward</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT The oral food challenge (OFC) has long been the reference standard for food allergy diagnosis, as well as to confirm natural development of oral tolerance. The utilization of OFCs has significantly broadened from its role in defining disease to defining participant eligibility, individual allergen reactivity thresholds and treatment outcomes metrics in clinical trials. Adopting OFCs as the sole primary metric to gauge the efficacy of an investigational drug can pose some limitations, such as: creating a barrier to recruitment of representative populations; excluding a vast number of allergic individuals through arbitrary reaction criteria; increasing cost and burden for participants, investigators, institutions, and sponsors; and, most importantly, adding additional risks and/or unpleasant experiences to study participants. A panel of expert allergists was convened by Parexel to discuss the current and future landscape for conducting clinical trials, the role of the OFC and immunologic biomarkers in the context of food allergy clinical trials, and potential innovations for advancing therapeutic development.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70304</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70304</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2623</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2623</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Afghani, J.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Aydin, H.</style></author><author><style face="normal" font="default" size="100%">Barenfaller, K.</style></author><author><style face="normal" font="default" size="100%">Behrendt, H.</style></author><author><style face="normal" font="default" size="100%">Bieber, T.</style></author><author><style face="normal" font="default" size="100%">Bigliardi, P.</style></author><author><style face="normal" font="default" size="100%">Bigliardi-Qi, M.</style></author><author><style face="normal" font="default" size="100%">Bonefeld, C. M.</style></author><author><style face="normal" font="default" size="100%">Bosch, S.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">Diemert, S.</style></author><author><style face="normal" font="default" size="100%">Duchna, H. W.</style></author><author><style face="normal" font="default" size="100%">Fahndrich, M.</style></author><author><style face="normal" font="default" size="100%">Fehr, D.</style></author><author><style face="normal" font="default" size="100%">Fellmann, M.</style></author><author><style face="normal" font="default" size="100%">Frei, R.</style></author><author><style face="normal" font="default" size="100%">Garvey, L. H.</style></author><author><style face="normal" font="default" size="100%">Gharbo, R.</style></author><author><style face="normal" font="default" size="100%">Gokkaya, M.</style></author><author><style face="normal" font="default" size="100%">Grando, K.</style></author><author><style face="normal" font="default" size="100%">Guillet, C.</style></author><author><style face="normal" font="default" size="100%">Guler, E.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author><author><style face="normal" font="default" size="100%">Herrmann, N.</style></author><author><style face="normal" font="default" size="100%">Hijnen, D. J.</style></author><author><style face="normal" font="default" size="100%">Hulpusch, C.</style></author><author><style face="normal" font="default" size="100%">Irvine, A. D.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Kong, H. H.</style></author><author><style face="normal" font="default" size="100%">Koren, H.</style></author><author><style face="normal" font="default" size="100%">Lang, C. C. V.</style></author><author><style face="normal" font="default" size="100%">Lauener, R.</style></author><author><style face="normal" font="default" size="100%">Maintz, L.</style></author><author><style face="normal" font="default" size="100%">Mantel, P. Y.</style></author><author><style face="normal" font="default" size="100%">Maverakis, E.</style></author><author><style face="normal" font="default" size="100%">Mohrenschlager, M.</style></author><author><style face="normal" font="default" size="100%">Muller, S.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Neumann, A. U.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Rabenja, F. R.</style></author><author><style face="normal" font="default" size="100%">Renz, H.</style></author><author><style face="normal" font="default" size="100%">Rhyner, C.</style></author><author><style face="normal" font="default" size="100%">Rietschel, E.</style></author><author><style face="normal" font="default" size="100%">Ring, J.</style></author><author><style face="normal" font="default" size="100%">Roduit, C.</style></author><author><style face="normal" font="default" size="100%">Sasaki, M.</style></author><author><style face="normal" font="default" size="100%">Schenk, M.</style></author><author><style face="normal" font="default" size="100%">Schroder, J.</style></author><author><style face="normal" font="default" size="100%">Simon, D.</style></author><author><style face="normal" font="default" size="100%">Simon, H. U.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Stander, S.</style></author><author><style face="normal" font="default" size="100%">Steinhoff, M.</style></author><author><style face="normal" font="default" size="100%">Piccirillo, D. S.</style></author><author><style face="normal" font="default" size="100%">Taieb, A.</style></author><author><style face="normal" font="default" size="100%">Takaoka, R.</style></author><author><style face="normal" font="default" size="100%">Tapparo, M.</style></author><author><style face="normal" font="default" size="100%">Teixeira, H.</style></author><author><style face="normal" font="default" size="100%">Thyssen, J. P.</style></author><author><style face="normal" font="default" size="100%">Traidl, S.</style></author><author><style face="normal" font="default" size="100%">Uhlmann, M.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Virchow, C.</style></author><author><style face="normal" font="default" size="100%">Wollenberg, A.</style></author><author><style face="normal" font="default" size="100%">Yasutaka, M.</style></author><author><style face="normal" font="default" size="100%">Zink, A.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Zentrum Munchen, Augsburg, Germany.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland.&#xD;AbbVie Inc., North Chicago, Illinois, USA.&#xD;Center for Allergy and Environment (ZAUM), Technische Universitat Munchen, Germany.&#xD;Davos Biosciences, Davos, Switzerland.&#xD;University of Minnesota, Minneapolis, Minnesota, USA.&#xD;Department of Immunology and Microbiology, The LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Dermatology, Allergy Unit, University Hospital of Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Almirall Hermal GmbH, Reinbek, Germany.&#xD;Hochgebirgsklinik Davos, Davos, Switzerland.&#xD;LEO Pharmaceutical Products Sarath Ltd, Zurich, Switzerland.&#xD;Pfizer Switzerland AG, Zurich, Switzerland.&#xD;Department of Pediatrics, Division of Respiratory Medicine and Allergology, Bern University Hospital, Bern, Switzerland.&#xD;Department of BioMedical Research (DBMR), University of Bern, Bern, Switzerland.&#xD;Department of Dermatology and Allergy, Allergy Clinic, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Psychosomatic Department, Hochgebirgsklinik, Davos, Switzerland.&#xD;Pfizer, Istanbul, Turkey.&#xD;Universitair Ziekenhuis, Brussel, Belgium.&#xD;Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.&#xD;Diakonessenhuis Utrecht Zeist Doorn Locatie Utrecht, Erasmus MC, University Medical Center Utrecht, Utrecht, Netherlands.&#xD;Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland.&#xD;Center of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;The interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria.&#xD;Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.&#xD;Environmental Health, LLC, Durham, North Carolina, USA.&#xD;Ostschweizer Kinderspital St. Gallen, St.Gallen, Switzerland.&#xD;Department of Dermatology, University of California Davis, Sacramento, California, USA.&#xD;Stanford University School of Medicine, Stanford, California, USA.&#xD;APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Department of Medicine and School of Microbiology, University College Cork, Cork, Ireland.&#xD;Faculty of Medicine, Antananarivo, Madagascar.&#xD;Institute of Laboratory Medicine, Philipps University, Marburg, Germany.&#xD;Klinik und Poliklinik fur Dermatologie und Allergologie am Biederstein, Technische Universitat Munchen, Munich, Germany.&#xD;Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.&#xD;Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Schleswig-Holstein (UK-SH), Kiel, Germany.&#xD;Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Institute of Pharmacology, University of Bern, Bern, Switzerland.&#xD;Institute of Biochemistry, Brandenburg Medical School, Neuruppin, Germany.&#xD;Center for Chronic Pruritus and Department of Dermatology, University Hospital Munster, Munster, Germany.&#xD;Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.&#xD;Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.&#xD;Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.&#xD;School of Medicine, Weill Cornell Medicine-Qatar, Ar-Rayyan, Qatar.&#xD;College of Medicine, Qatar University, Doha, Qatar.&#xD;College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.&#xD;Department of Dermatology, Weill Cornell Medicine, New York, New York, USA.&#xD;INSERM 1312, University of Bordeaux, Bordeaux, France.&#xD;Department of Dermatology, Faculdade de Medicina, Hospital das Clinicas, Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil.&#xD;Bencard Allergie GmbH Munchen, Munich, Germany.&#xD;Department of Dermatology and Venerology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.&#xD;Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institute and Karolinska University Hospital Stockholm, Solna, Sweden.&#xD;Department of Pneumology, Intensive Care Medicine, Center for Internal Medicine, Universitatsmedizin Rostock, Rostock, Germany.&#xD;Department of Dermatology and Allergy, Ludwig-Maximilian-University, Munich, Germany.&#xD;Department of Dermatology and Allergy, University Hospital Augsburg, Augsburg, Germany.&#xD;Comprehensive Center of Inflammation Medicine, University Hospital Schleswig Holstein Campus Luebeck, Lubeck, Germany.&#xD;Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Department of Medicine Solna, Division of Dermatology and Venereology, Karolinska Institutet, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2605-2624</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/08/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">barrier</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">hygiene hypothesis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39099205</style></accession-num><abstract><style face="normal" font="default" size="100%">The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient-centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to collaborate to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world.</style></abstract><notes><style face="normal" font="default" size="100%">Traidl-Hoffmann, Claudia&#xD;Afghani, Jamie&#xD;Akdis, Cezmi A&#xD;Akdis, Mubecel&#xD;Aydin, Handan&#xD;Barenfaller, Katja&#xD;Behrendt, Heidrun&#xD;Bieber, Thomas&#xD;Bigliardi, Paul&#xD;Bigliardi-Qi, Mei&#xD;Bonefeld, Charlotte Menne&#xD;Bosch, Stefanie&#xD;Bruggen, Marie Charlotte&#xD;Diemert, Sebastian&#xD;Duchna, Hans-Werner&#xD;Fahndrich, Martina&#xD;Fehr, Danielle&#xD;Fellmann, Marc&#xD;Frei, Remo&#xD;Garvey, Lena H&#xD;Gharbo, Raschid&#xD;Gokkaya, Mehmet&#xD;Grando, Karin&#xD;Guillet, Carole&#xD;Guler, Erman&#xD;Gutermuth, Jan&#xD;Herrmann, Nadine&#xD;Hijnen, Dirk Jan&#xD;Hulpusch, Claudia&#xD;Irvine, Alan D&#xD;Jensen-Jarolim, Erika&#xD;Kong, Heidi H&#xD;Koren, Hillel&#xD;Lang, Claudia C V&#xD;Lauener, Roger&#xD;Maintz, Laura&#xD;Mantel, Pierre-Yves&#xD;Maverakis, Emanuel&#xD;Mohrenschlager, Matthias&#xD;Muller, Svenja&#xD;Nadeau, Kari&#xD;Neumann, Avidan U&#xD;O&apos;Mahony, Liam&#xD;Rabenja, Fahafahantsoa Rapelanoro&#xD;Renz, Harald&#xD;Rhyner, Claudio&#xD;Rietschel, Ernst&#xD;Ring, Johannes&#xD;Roduit, Caroline&#xD;Sasaki, Mari&#xD;Schenk, Mirjam&#xD;Schroder, Jens&#xD;Simon, Dagmar&#xD;Simon, Hans-Uwe&#xD;Sokolowska, Milena&#xD;Stander, Sonja&#xD;Steinhoff, Martin&#xD;Piccirillo, Doris Straub&#xD;Taieb, Alain&#xD;Takaoka, Roberto&#xD;Tapparo, Martin&#xD;Teixeira, Henrique&#xD;Thyssen, Jacob Pontoppidan&#xD;Traidl, Stephan&#xD;Uhlmann, Miriam&#xD;van de Veen, Willem&#xD;van Hage, Marianne&#xD;Virchow, Christian&#xD;Wollenberg, Andreas&#xD;Yasutaka, Mitamura&#xD;Zink, Alexander&#xD;Schmid-Grendelmeier, Peter&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2605-2624. doi: 10.1111/all.16247. Epub 2024 Aug 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39099205</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16247</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>741</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">741</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, M. F.</style></author><author><style face="normal" font="default" size="100%">Wu, C. S.</style></author><author><style face="normal" font="default" size="100%">Lin, S. J.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, Taiwan.&#xD;School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Needle-free epicutaneous For t 2 DNA vaccine is effective for preventing and treating biting midge Forcipomyia taiwana allergy in a murine model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">678-681</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Ceratopogonidae/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Insect Bites and Stings/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines, DNA</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34653268</style></accession-num><notes><style face="normal" font="default" size="100%">Lee, Mey-Fann&#xD;Wu, Chi-Sheng&#xD;Lin, Shyh-Jye&#xD;Chen, Yi-Hsing&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):678-681. doi: 10.1111/all.15141. Epub 2021 Oct 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34653268</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15141</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1402</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1402</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cavaleiro Rufo, J.</style></author><author><style face="normal" font="default" size="100%">Paciencia, I.</style></author><author><style face="normal" font="default" size="100%">Hoffimann, E.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Barros, H.</style></author><author><style face="normal" font="default" size="100%">Ribeiro, A. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">EPIUnit, Instituto de Saude Publica da Universidade do Porto, Porto, Portugal.&#xD;Faculdade de Medicina da Universidade do Porto, Porto, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The neighbourhood natural environment is associated with asthma in children: A birth cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">348-358</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Environment</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Portugal/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">biodiversity</style></keyword><keyword><style face="normal" font="default" size="100%">birth cohort</style></keyword><keyword><style face="normal" font="default" size="100%">greenness</style></keyword><keyword><style face="normal" font="default" size="100%">neighbourhood</style></keyword><keyword><style face="normal" font="default" size="100%">species richness</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32654186</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A lower exposure to the natural environment has been hypothesized to adversely affect the human microbiome and its immunomodulatory capacity. However, the underlying effects of this hypothesis are still not understood. We aimed to evaluate the effect of early-life exposure to greenness and species richness on the development of allergic diseases and asthma in children. METHODS: A longitudinal study was conducted comprising 1050 children from a population-based birth cohort recruited in Portugal. Residential normalized difference vegetation index (NDVI) and species richness index (SRI) were assessed at baseline to estimate their association with allergic diseases and asthma at the ages of 4 and 7. RESULTS: Significant predisposing associations were observed between the exposure to species richness at baseline and the onset of asthma and wheezing at the age of 7. Children living in neighbourhoods surrounded by high levels of SRI were at a significantly higher risk developing allergic sensitization(OR [95% CI] = 2.00 [1.04:3.86] at age 4; 2.35 [1.20:4.63] at age 7). Living surrounded by greener environments was significantly associated with a lower prevalence of asthma and rhinitis at the age of 7(0.41 [0.18:0.97] and 0.37 [0.15:0.93], respectively). CONCLUSIONS: Living in close proximity to a greener environment at birth has a protective effect on the development of allergic diseases and asthma at the age of 7. Conversely, living in neighbourhoods with a high number of fauna species appears to be associated with a higher risk for allergy, asthma and wheezing.</style></abstract><notes><style face="normal" font="default" size="100%">Cavaleiro Rufo, Joao&#xD;Paciencia, Ines&#xD;Hoffimann, Elaine&#xD;Moreira, Andre&#xD;Barros, Henrique&#xD;Ribeiro, Ana Isabel&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):348-358. doi: 10.1111/all.14493. Epub 2020 Aug 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32654186</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14493</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1047</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1047</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chawes, B. L.</style></author><author><style face="normal" font="default" size="100%">Wolsk, H. M.</style></author><author><style face="normal" font="default" size="100%">Carlsson, C. J.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, M. A.</style></author><author><style face="normal" font="default" size="100%">Folsgaard, N.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Brix, S.</style></author><author><style face="normal" font="default" size="100%">Schoos, A. M.</style></author><author><style face="normal" font="default" size="100%">Bisgaard, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Food Science, University of Copenhagen, Frederiksberg C, Denmark.&#xD;Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neonatal airway immune profiles and asthma and allergy endpoints in childhood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3713-3722</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/04/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">chemokines</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33864271</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The immune system plays a key role in the pathogenesis of asthma and allergy, but the role of the airway cytokine and chemokine composition in vivo in early life prior to symptom development has not been described previously. Here, we aimed to examine whether the neonatal airway immune composition associates with development of allergy and asthma in childhood. METHODS: We measured unstimulated levels of 20 immune mediators related to the Type 1, Type 2, Type 17, or regulatory immune pathways in the airway mucosal lining fluid of 620 one-month-old healthy neonates from the COPSAC(2010) birth cohort. Allergy and asthma were diagnosed at our research clinic by predefined algorithms and objective assessments at age 6 years. Principal component analyses were used to describe the airway cytokine and chemokine composition. RESULTS: A neonatal airway immune profile particularly characterized by enhanced IL-1beta and reduced CCL26 was significantly associated with later development of elevated specific IgE to inhaled allergens, a positive skin prick test, and allergic rhinitis, but not with food sensitization. Conversely, reduced Type 17 immune-associated markers, including IL-1beta and CXCL8, showed trend of association with development of early asthma endpoints. CONCLUSIONS: Development of early asthma endpoints and inhalant allergy during the first 6 years of life seems associated with distinctly perturbed airway immune profiles in neonatal life, which is suggestive of an early origin and different pathogenesis of childhood asthma and allergy. These exploratory findings suggest pre- and perinatal life as an important window of opportunity for prevention of asthma and inhalant allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Chawes, Bo L&#xD;Wolsk, Helene M&#xD;Carlsson, Christian J&#xD;Rasmussen, Morten A&#xD;Folsgaard, Nilofar&#xD;Stokholm, Jakob&#xD;Bonnelykke, Klaus&#xD;Brix, Susanne&#xD;Schoos, Ann-Marie M&#xD;Bisgaard, Hans&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3713-3722. doi: 10.1111/all.14862. Epub 2021 May 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33864271</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14862</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3050</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3050</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pittet, L. F.</style></author><author><style face="normal" font="default" size="100%">Messina, N. L.</style></author><author><style face="normal" font="default" size="100%">Francis, K. L.</style></author><author><style face="normal" font="default" size="100%">Donath, S.</style></author><author><style face="normal" font="default" size="100%">Flanagan, K. L.</style></author><author><style face="normal" font="default" size="100%">Forbes, E. K.</style></author><author><style face="normal" font="default" size="100%">Gardiner, K.</style></author><author><style face="normal" font="default" size="100%">Phillips, R. J.</style></author><author><style face="normal" font="default" size="100%">Ponsonby, A. L.</style></author><author><style face="normal" font="default" size="100%">Robins-Browne, R.</style></author><author><style face="normal" font="default" size="100%">Shann, F.</style></author><author><style face="normal" font="default" size="100%">South, M.</style></author><author><style face="normal" font="default" size="100%">Vuillermin, P.</style></author><author><style face="normal" font="default" size="100%">Casalaz, D.</style></author><author><style face="normal" font="default" size="100%">Curtis, N.</style></author><author><style face="normal" font="default" size="100%">On the behalf of the Melbourne Infant Study, B. C. G. for Allergy</style></author><author><style face="normal" font="default" size="100%">Infection Reduction, Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infectious Diseases Group, Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Immunology, Vaccinology, Rheumatology and Infectious Diseases Unit, Faculty of Medicine, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.&#xD;Clinical Epidemiology and Biostatistics Unit, Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;School of Health Sciences, University of Tasmania, Hobart, Tasmania, Australia.&#xD;School of Health and Biomedical Science, RMIT University, Melbourne, Victoria, Australia.&#xD;Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia.&#xD;Department of Research Operations, The Royal Children&apos;s Hospital Melbourne, Parkville, Victoria, Australia.&#xD;Dermatology Unit, The Royal Children&apos;s Hospital Melbourne, Parkville, Victoria, Australia.&#xD;Population Allergy, Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.&#xD;Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.&#xD;Department of General Medicine, The Royal Children&apos;s Hospital Melbourne, Parkville, Victoria, Australia.&#xD;School of Medicine, Deakin University, Geelong, Victoria, Australia.&#xD;Child Health Research Unit, Barwon Health, Geelong, Victoria, Australia.&#xD;Neonatal Intensive Care Unit, Mercy Hospital for Women, Heidelberg, Victoria, Australia.&#xD;Infectious Diseases, The Royal Children&apos;s Hospital Melbourne, Parkville, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neonatal Bacillus Calmette-Guerin Vaccination Decreases Eczema Incidence at 5 years: The MIS BAIR Randomised Controlled Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3444-3446</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/07/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40742161</style></accession-num><notes><style face="normal" font="default" size="100%">Pittet, Laure F&#xD;Messina, Nicole L&#xD;Francis, Kate L&#xD;Donath, Susan&#xD;Flanagan, Katie L&#xD;Forbes, Emily K&#xD;Gardiner, Kaya&#xD;Phillips, Roderic J&#xD;Ponsonby, Anne-Louise&#xD;Robins-Browne, Roy&#xD;Shann, Frank&#xD;South, Mike&#xD;Vuillermin, Peter&#xD;Casalaz, Dan&#xD;Curtis, Nigel&#xD;(MIS BAIR)&#xD;eng&#xD;Murdoch Children&apos;s Research Institute/&#xD;Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;P2GEP3_178155/Early Postdoc Mobility Grantnumber/&#xD;PZ00P3-209050/Ambizione Grantnumber/&#xD;University of Melbourne/&#xD;Royal Children&apos;s Hospital Foundation/&#xD;GNT1051228/National Health and Medical Research Council/&#xD;GNT1099676/National Health and Medical Research Council/&#xD;GNT1197117/National Health and Medical Research Council/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3444-3446. doi: 10.1111/all.16677. Epub 2025 Jul 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40742161</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666751</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16677</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2443</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2443</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aoyama, R.</style></author><author><style face="normal" font="default" size="100%">Nakagawa, S.</style></author><author><style face="normal" font="default" size="100%">Ichikawa, Y.</style></author><author><style face="normal" font="default" size="100%">Inohara, N.</style></author><author><style face="normal" font="default" size="100%">Yamazaki, Y.</style></author><author><style face="normal" font="default" size="100%">Ito, T.</style></author><author><style face="normal" font="default" size="100%">Sugihira, T.</style></author><author><style face="normal" font="default" size="100%">Kono, M.</style></author><author><style face="normal" font="default" size="100%">Akiyama, M.</style></author><author><style face="normal" font="default" size="100%">Takahashi, H.</style></author><author><style face="normal" font="default" size="100%">Takaya, A.</style></author><author><style face="normal" font="default" size="100%">Ichikawa, F.</style></author><author><style face="normal" font="default" size="100%">Nakano, T.</style></author><author><style face="normal" font="default" size="100%">Tanaka, S.</style></author><author><style face="normal" font="default" size="100%">Koyano, Y.</style></author><author><style face="normal" font="default" size="100%">Fujimoto, M.</style></author><author><style face="normal" font="default" size="100%">Nunez, G.</style></author><author><style face="normal" font="default" size="100%">Shimojo, N.</style></author><author><style face="normal" font="default" size="100%">Nakamura, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.&#xD;Department of Cutaneous Immunology and Microbiology, Graduate School of Medicine, Osaka University, Osaka, Japan.&#xD;Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.&#xD;Department of Pediatrics, Ichikawa Clinic, Fukushima, Japan.&#xD;Cutaneous Allergy and Host Defense, Immunology Frontier Research Center, Osaka University, Osaka, Japan.&#xD;Department of Dermatology and Plastic Surgery, Akita University Graduate School of Medicine, Akita, Japan.&#xD;Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.&#xD;Medical Mycology Research Center, Chiba University, Chiba, Japan.&#xD;Plant Molecular Science Center, Chiba University, Chiba, Japan.&#xD;Department of Infection Control Science, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.&#xD;Department of Obstetrics and Gynecology, Ichikawa Clinic, Fukushima, Japan.&#xD;Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.&#xD;Natural Science Co., Ltd., Tokyo, Japan.&#xD;Center for Preventive Medical Sciences, Chiba University, Chiba, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neonatal skin dysbiosis to infantile atopic dermatitis: Mitigating effects of skin care</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1618-1622</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">*Dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin Care/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38459797</style></accession-num><notes><style face="normal" font="default" size="100%">Aoyama, Reika&#xD;Nakagawa, Seitaro&#xD;Ichikawa, Yoko&#xD;Inohara, Naohiro&#xD;Yamazaki, Yuriko&#xD;Ito, Tomoka&#xD;Sugihira, Takashi&#xD;Kono, Michihiro&#xD;Akiyama, Masashi&#xD;Takahashi, Hiroki&#xD;Takaya, Akiko&#xD;Ichikawa, Fumitaka&#xD;Nakano, Taiji&#xD;Tanaka, Seiko&#xD;Koyano, Yutaka&#xD;Fujimoto, Manabu&#xD;Nunez, Gabriel&#xD;Shimojo, Naoki&#xD;Nakamura, Yuumi&#xD;eng&#xD;Japan Science and Technology Agency/&#xD;Japan Society for the Promotion of Science/&#xD;Japan Agency for Medical Research and Development/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1618-1622. doi: 10.1111/all.16095. Epub 2024 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38459797</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16095</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2287</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2287</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liao, G.</style></author><author><style face="normal" font="default" size="100%">Wang, R.</style></author><author><style face="normal" font="default" size="100%">Wu, Y.</style></author><author><style face="normal" font="default" size="100%">Maheshwari, N. K.</style></author><author><style face="normal" font="default" size="100%">Penn, R. B.</style></author><author><style face="normal" font="default" size="100%">Tang, D. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular and Cellular Physiology, Albany Medical College, Albany, New York, USA.&#xD;Department of Medicine, Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nestin drives allergen-induced airway smooth muscle hyperplasia and airway remodeling</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">744-746</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/10/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperplasia/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Airway Remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Nestin</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Ovalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">Airway smooth muscle</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">cytoskeletal protein</style></keyword><keyword><style face="normal" font="default" size="100%">intermediate filament protein</style></keyword><keyword><style face="normal" font="default" size="100%">signal transduction</style></keyword><keyword><style face="normal" font="default" size="100%">exists.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37897062</style></accession-num><notes><style face="normal" font="default" size="100%">Liao, Guoning&#xD;Wang, Ruping&#xD;Wu, Yidi&#xD;Maheshwari, Neelam Kumari&#xD;Penn, Raymond B&#xD;Tang, Dale D&#xD;eng&#xD;R01 HL110951/HL/NHLBI NIH HHS/&#xD;R01 HL130304/HL/NHLBI NIH HHS/&#xD;R01 HL145392/HL/NHLBI NIH HHS/&#xD;NH/NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):744-746. doi: 10.1111/all.15932. Epub 2023 Oct 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37897062</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10922266</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15932</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2531</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2531</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wisgrill, L.</style></author><author><style face="normal" font="default" size="100%">Martens, A.</style></author><author><style face="normal" font="default" size="100%">Kasbauer, R.</style></author><author><style face="normal" font="default" size="100%">Eigenschink, M.</style></author><author><style face="normal" font="default" size="100%">Pummer, L.</style></author><author><style face="normal" font="default" size="100%">Redlberger-Fritz, M.</style></author><author><style face="normal" font="default" size="100%">Vegvari, A.</style></author><author><style face="normal" font="default" size="100%">Warth, B.</style></author><author><style face="normal" font="default" size="100%">Berger, A.</style></author><author><style face="normal" font="default" size="100%">Fyhrquist, N.</style></author><author><style face="normal" font="default" size="100%">Alenius, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.&#xD;Exposome Austria, Research Infrastructure and National EIRENE Hub, Vienna, Austria.&#xD;Center for Virology, Medical University of Vienna, Vienna, Austria.&#xD;Proteomics Biomedicum, Division of Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.&#xD;Division of Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.&#xD;Faculty of Chemistry, Department of Food Chemistry and Toxicology, University of Vienna, Vienna, Austria.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Human microbiome research program (HUMI), Medicum, University of Helsinki, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Network analysis reveals age- and virus-specific circuits in nasal epithelial cells of extremely premature infants</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3062-3081</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/06/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Mucosa/virology/immunology/cytology</style></keyword><keyword><style face="normal" font="default" size="100%">*Infant, Extremely Premature/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">*Epithelial Cells/immunology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza A virus/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Syncytial Virus Infections/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">antiviral immunity</style></keyword><keyword><style face="normal" font="default" size="100%">nasal epithelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">premature infants</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory infections</style></keyword><keyword><style face="normal" font="default" size="100%">systems biology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38898695</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND OBJECTIVES: Viral respiratory infections significantly affect young children, particularly extremely premature infants, resulting in high hospitalization rates and increased health-care burdens. Nasal epithelial cells, the primary defense against respiratory infections, are vital for understanding nasal immune responses and serve as a promising target for uncovering underlying molecular and cellular mechanisms. METHODS: Using a trans-well pseudostratified nasal epithelial cell system, we examined age-dependent developmental differences and antiviral responses to influenza A and respiratory syncytial virus through systems biology approaches. RESULTS: Our studies revealed differences in innate-receptor repertoires, distinct developmental pathways, and differentially connected antiviral network circuits between neonatal and adult nasal epithelial cells. Consensus network analysis identified unique and shared cellular-viral networks, emphasizing highly relevant virus-specific pathways, independent of viral replication kinetics. CONCLUSION: This research highlights the importance of nasal epithelial cells in innate antiviral immune responses and offers crucial insights that allow for a deeper understanding of age-related differences in nasal epithelial cell immunity following respiratory virus infections.</style></abstract><notes><style face="normal" font="default" size="100%">Wisgrill, Lukas&#xD;Martens, Anke&#xD;Kasbauer, Rajmund&#xD;Eigenschink, Michael&#xD;Pummer, Linda&#xD;Redlberger-Fritz, Monika&#xD;Vegvari, Akos&#xD;Warth, Benedikt&#xD;Berger, Angelika&#xD;Fyhrquist, Nanna&#xD;Alenius, Harri&#xD;eng&#xD;[10.47379/LS20025]/Vienna Science and Technology Fund/&#xD;2020-02090/Vetenskapsradet/&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3062-3081. doi: 10.1111/all.16196. Epub 2024 Jun 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38898695</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16196</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3160</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3160</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leo, R.</style></author><author><style face="normal" font="default" size="100%">Jochebeth, A.</style></author><author><style face="normal" font="default" size="100%">Abdulrahman, N.</style></author><author><style face="normal" font="default" size="100%">Agha, M. V.</style></author><author><style face="normal" font="default" size="100%">Joy, F. E.</style></author><author><style face="normal" font="default" size="100%">AlHammadi, A.</style></author><author><style face="normal" font="default" size="100%">Younis, S. M.</style></author><author><style face="normal" font="default" size="100%">Al-Harami, S.</style></author><author><style face="normal" font="default" size="100%">Al-Qahtani, A.</style></author><author><style face="normal" font="default" size="100%">Ahmad, F.</style></author><author><style face="normal" font="default" size="100%">Datsi, A.</style></author><author><style face="normal" font="default" size="100%">Meng, J.</style></author><author><style face="normal" font="default" size="100%">Steinhoff, M.</style></author><author><style face="normal" font="default" size="100%">Alam, M.</style></author><author><style face="normal" font="default" size="100%">Buddenkotte, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.&#xD;Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.&#xD;Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.&#xD;Center of Surgery, Hamad Medical Corporation, Doha, Qatar.&#xD;Institute for Transplantational Diagnostics and Cell Therapeutics, University Hospital Dusseldorf, Dusseldorf, Germany.&#xD;School of Biotechnology, Faculty of Science and Health, Dublin City University, Dublin, Ireland.&#xD;Department of Dermatology, Weill Cornell Medicine-Qatar, Doha, Qatar.&#xD;Qatar University, College of Medicine, Doha, Qatar.&#xD;Department of Dermatology, Weill Cornell Medicine, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Neurogenic Inflammation Mediator Endothelin-1 Causes Human Skin Barrier Disruption in Atopic Dermatitis via an ETAR/TRPA1-Axis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine</style></keyword><keyword><style face="normal" font="default" size="100%">neurogenic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">neuropeptide</style></keyword><keyword><style face="normal" font="default" size="100%">skin organ culture</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 14</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41236705</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is a common, relapsing inflammatory skin disease driven by an immune imbalance, microbial dysbiosis, and skin barrier impairment, culminating in (neurogenic) inflammation and itch. We hypothesized that the neuropeptide and pruritogen endothelin-1 (ET-1) contributes to AD pathology by impeding skin barrier formation via its cognate receptor ETAR and TRPA1, a cation channel involved in neurogenic inflammation, pain, and itch. METHODS: We utilized differentiated human keratinocytes and ex vivo human skin organ cultures in vitro to evaluate the impact of ET-1 on human skin barrier function. ET-1 effects were assessed at the RNA level by RT-qPCR and at the protein level by quantitative immunofluorescence microscopy. Barrier integrity was monitored using real-time cell analysis and transwell permeability assays. RESULTS: ET-1 markedly reduced cell resistance in differentiated keratinocytes, an effect abrogated by the ETAR antagonist bosentan. ET-1 significantly decreased expression of skin differentiation markers filaggrin and loricrin, and tight junction proteins occludin, claudin-1, and claudin-4, at mRNA and protein levels. ETAR-specific siRNA in combination with ET-1, rescued ET-1-mediated downregulation of filaggrin. Furthermore, TRPA1 antagonist HC-030031 abrogated the impairing effect of ET-1 on the skin barrier. We observed increased inflammatory responses of ET-1-stimulated keratinocytes, suggesting that the ET-1-initiated barrier disruption could be mediated by IL-6 and IL-1beta and induced by TNF-alpha. CONCLUSION: Our findings suggest that a neurogenic inflammation axis ET-1/ETAR/TRPA1 contributes to skin barrier impairment in AD by repressing differentiation markers and tight junction proteins. Additionally, we demonstrate ETAR-blockage as a rational therapeutic modality for patients with AD.</style></abstract><notes><style face="normal" font="default" size="100%">Leo, Rari&#xD;Jochebeth, Anh&#xD;Abdulrahman, Nabeel&#xD;Agha, Maha Victor&#xD;Joy, Febu Elizabeth&#xD;AlHammadi, Ayda&#xD;Younis, Shahad M&#xD;Al-Harami, Sara&#xD;Al-Qahtani, Ahmed&#xD;Ahmad, Fareed&#xD;Datsi, Angeliki&#xD;Meng, Jianghui&#xD;Steinhoff, Martin&#xD;Alam, Majid&#xD;Buddenkotte, Joerg&#xD;eng&#xD;MRC-01-21-696/Academic Health System, Hamad Medical Corporation, Doha, Qatar/&#xD;MRC-01-22-280/Academic Health System, Hamad Medical Corporation, Doha, Qatar/&#xD;Denmark&#xD;Allergy. 2025 Nov 14. doi: 10.1111/all.70149.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41236705</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70149</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1570</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1570</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">De Palma, G.</style></author><author><style face="normal" font="default" size="100%">Caminero, A.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.&#xD;Department of Immunology &amp; Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;Department of Pathology &amp; Molecular Medicine, McMaster Immunology Research Centre (MIRC), McMaster University, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The neuroimmunological toll of nutrient absorption</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2415-2417</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2020/06/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Neuroimmunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">*Nutrients</style></keyword><keyword><style face="normal" font="default" size="100%">Il22</style></keyword><keyword><style face="normal" font="default" size="100%">Ilc3</style></keyword><keyword><style face="normal" font="default" size="100%">Vip</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">intestine</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">neuroimmunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32544256</style></accession-num><notes><style face="normal" font="default" size="100%">De Palma, Giada&#xD;Caminero, Alberto&#xD;Jimenez-Saiz, Rodrigo&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Sep;75(9):2415-2417. doi: 10.1111/all.14458. Epub 2020 Jul 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32544256</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14458</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>763</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">763</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soler Palacios, B.</style></author><author><style face="normal" font="default" size="100%">Gutierrez-Gonzalez, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neuron-macrophage interaction in the healing process of the skin</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1064-1066</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/10/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin</style></keyword><keyword><style face="normal" font="default" size="100%">*Wound Healing</style></keyword><keyword><style face="normal" font="default" size="100%">Il-10</style></keyword><keyword><style face="normal" font="default" size="100%">Tafa4</style></keyword><keyword><style face="normal" font="default" size="100%">radiation</style></keyword><keyword><style face="normal" font="default" size="100%">resident macrophages</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34599601</style></accession-num><notes><style face="normal" font="default" size="100%">Soler Palacios, Blanca&#xD;Gutierrez-Gonzalez, Alejandra&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1064-1066. doi: 10.1111/all.15122. Epub 2021 Oct 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34599601</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15122</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1532</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1532</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soler Palacios, B.</style></author><author><style face="normal" font="default" size="100%">Gutierrez-Gonzalez, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neuron-macrophage interaction in the healing process of the skin</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1064-1066</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/10/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin</style></keyword><keyword><style face="normal" font="default" size="100%">*Wound Healing</style></keyword><keyword><style face="normal" font="default" size="100%">Il-10</style></keyword><keyword><style face="normal" font="default" size="100%">Tafa4</style></keyword><keyword><style face="normal" font="default" size="100%">radiation</style></keyword><keyword><style face="normal" font="default" size="100%">resident macrophages</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34599601</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract The skin is the largest organ of the human body. It controls body temperature and hydroelectrochemical balance, protects the organism and maintains its integrated structures. Immunologically, the skin is endowed with a complex network of immune-functioning cells consisting of macrophages, Langerhans cells and dendritic cells, as well as sensory neurons that detect damage.</style></abstract><notes><style face="normal" font="default" size="100%">Soler Palacios, Blanca&#xD;Gutierrez-Gonzalez, Alejandra&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1064-1066. doi: 10.1111/all.15122. Epub 2021 Oct 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34599601</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15122</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2732</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2732</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dragunas, G.</style></author><author><style face="normal" font="default" size="100%">Koster, C. S.</style></author><author><style face="normal" font="default" size="100%">de Souza Xavier Costa, N.</style></author><author><style face="normal" font="default" size="100%">Melgert, B. N.</style></author><author><style face="normal" font="default" size="100%">Munhoz, C. D.</style></author><author><style face="normal" font="default" size="100%">Gosens, R.</style></author><author><style face="normal" font="default" size="100%">Mauad, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de Farmacologia, Universidade de Sao Paulo Instituto de Ciencias Biomedicas, Sao Paulo, Brazil.&#xD;Department of Molecular Pharmacology, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.&#xD;Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands.&#xD;Departamento de Patologia, LIM-05, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neuroplasticity and neuroimmune interactions in fatal asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">462-473</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/mortality/immunology/metabolism/pathology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Neuronal Plasticity</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Neuroimmunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Sensory Receptor Cells/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Coculture Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Calcitonin Gene-Related Peptide/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquitin Thiolesterase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">fatal asthma</style></keyword><keyword><style face="normal" font="default" size="100%">innervation</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">neuroimmune</style></keyword><keyword><style face="normal" font="default" size="100%">neuroplasticity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39484998</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Alteration of airway neuronal function and density and bidirectional interaction between immune cells and sensory peripheral nerves have been proposed to trigger and perpetuate inflammation that contribute to asthma severity. To date, few studies analysed neuroplasticity and neuroinflammation in tissue of asthmatic individuals. We hypothesized that the presence of these phenomena would be a pathological feature in fatal asthma. METHODS: We have quantified the expression of the pan-neuronal marker PGP9.5 and the neuronal sensory-derived neuropeptide calcitonin gene-related peptide (CGRP) in the large airways of 12 individuals deceased due to an asthma attack and compared to 10 control lung samples. The proximity between nerve bundles to eosinophils, mast cells and CADM1(+) cells was also quantified. We have additionally developed a hPSC-derived sensory neuron/mast cell co-culture model, from where mast cells were purified and differences in gene expression profile assessed. RESULTS: Fatal asthma patients presented a higher PGP9.5 and CGRP positive area in the airways, indicating sensory neuroplasticity. Eosinophils, mast cells and CADM1(+) cells were observed in close contact or touching the airway nerve bundles, and this was found to be statistically higher in fatal asthma samples. In vitro co-culture model showed that human mast cells adhere to sensory neurons and develop a distinct gene expression profile characterized by upregulated expression of genes related to heterophilic adhesion, activation and differentiation markers, such as CADM4, PTGS2, C-KIT, GATA2, HDC, CPA3, ATXN1 and VCAM1. CONCLUSIONS: Our results support a significant role for neuroplasticity and neuroimmune interactions in fatal asthma, that could be implicated in the severity of the fatal attack. Accordingly, the presence of physical neuron and mast cell interaction leads to differential gene expression profile in the later cell type.</style></abstract><notes><style face="normal" font="default" size="100%">Dragunas, Guilherme&#xD;Koster, Carli S&#xD;de Souza Xavier Costa, Natalia&#xD;Melgert, Barbro N&#xD;Munhoz, Carolina D&#xD;Gosens, Reinoud&#xD;Mauad, Thais&#xD;eng&#xD;Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/&#xD;Fundacao de Amparo a Pesquisa do Estado de Sao Paulo/&#xD;Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/&#xD;Nederlandse Organisatie voor Wetenschappelijk Onderzoek/&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):462-473. doi: 10.1111/all.16373. Epub 2024 Nov 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39484998</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16373</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2466</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2466</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koduri, M. A.</style></author><author><style face="normal" font="default" size="100%">Pingali, T.</style></author><author><style face="normal" font="default" size="100%">Prasad, D.</style></author><author><style face="normal" font="default" size="100%">Singh, V.</style></author><author><style face="normal" font="default" size="100%">Singh, S.</style></author><author><style face="normal" font="default" size="100%">Shanbhag, S. S.</style></author><author><style face="normal" font="default" size="100%">Basu, S.</style></author><author><style face="normal" font="default" size="100%">Singh, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Ocular Regeneration (CORE), Prof. Brien Holden Eye Research Centre (BHERC), L V Prasad Eye Institute, Hyderabad, Telangana, India.&#xD;Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India.&#xD;The Shantilal Shanghvi Cornea Institute, L V Prasad Eye Institute, Hyderabad, Telangana, India.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neutrophil-driven and interleukin-36gamma-associated ocular surface inflammation in chronic Stevens-Johnson syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2128-2143</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/04/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Neutrophils/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-1/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Stevens-Johnson Syndrome/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Tears/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">IL-36gamma</style></keyword><keyword><style face="normal" font="default" size="100%">Il-8</style></keyword><keyword><style face="normal" font="default" size="100%">Sjs/ten</style></keyword><keyword><style face="normal" font="default" size="100%">Stevens-Johnson syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">cornea</style></keyword><keyword><style face="normal" font="default" size="100%">eyelid margin</style></keyword><keyword><style face="normal" font="default" size="100%">keratinization</style></keyword><keyword><style face="normal" font="default" size="100%">ocular surface</style></keyword><keyword><style face="normal" font="default" size="100%">tear</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38682250</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: This study aims to elucidate the tear proteome and understand the underlying molecular mechanisms involved in the ocular complications following Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). METHODS: Mass spectrometry (MS) was performed to quantify the tear fluid proteins from chronic SJS/TEN patients (n = 22 eyes) and age- and gender-matched controls (n = 22 eyes). The candidate proteins were validated using ELISA (n = 80 eyes) in tear samples and immunohistochemistry (IHC; n = 12) in eyelid margin specimens. These proteins were compared for significant differences based on age, gender, disease duration, and ocular severity. RESULTS: A total of 1692 tear fluid proteins were identified, of which 470 were significantly differentially regulated in chronic SJS/TEN. The top 10 significantly upregulated proteins were neutrophil secretions including neutrophil elastase (p &lt; .0001), defensin (p &lt; .0001), and matrix metalloproteinase 8 (p &lt; .0001). The presence of neutrophils was confirmed by the upregulation of IL-8 (p &lt; .001) in tears, a key cytokine known for recruiting neutrophils. Additionally, positive expression of myeloperoxidase was observed in the keratinized eyelid margins of SJS/TEN to validate the presence of neutrophils. Among 41 unique proteins identified by MS, IL-36gamma (p &lt; .01) was expressed in three SJS/TEN patients and was confirmed in SJS/TEN tears and eyelid margins by ELISA and IHC, respectively. IL-36gamma was specifically expressed in the superficial layers of eyelid margin keratinized conjunctiva. The majority of the significantly downregulated proteins were lacrimal gland secretions such as lacritin (p &lt; .0001) and opiorphin (p &lt; .002). Neutrophil elastase (p &lt; .02) was significantly elevated in patients with severe eyelid margin keratinization. CONCLUSION: Our observations indicate a clear correlation between eyelid margin keratinization and the expression of IL-36gamma, potentially mediated by neutrophils recruited via IL-8. Future experimental studies are needed to test the role of therapies targeting IL-8 and/or IL-36gamma in reducing eyelid margin keratinization and its associated ocular complications in SJS/TEN.</style></abstract><notes><style face="normal" font="default" size="100%">Koduri, Madhuri Amulya&#xD;Pingali, Tejaswini&#xD;Prasad, Deeksha&#xD;Singh, Vijay&#xD;Singh, Swati&#xD;Shanbhag, Swapna S&#xD;Basu, Sayan&#xD;Singh, Vivek&#xD;eng&#xD;Hyderabad Eye Research Foundation (HERF)/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2128-2143. doi: 10.1111/all.16126. Epub 2024 Apr 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38682250</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16126</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>663</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">663</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andiappan, A. K.</style></author><author><style face="normal" font="default" size="100%">Asad, M.</style></author><author><style face="normal" font="default" size="100%">Chua, C.</style></author><author><style face="normal" font="default" size="100%">Sehanobish, E.</style></author><author><style face="normal" font="default" size="100%">Ren, Z.</style></author><author><style face="normal" font="default" size="100%">Chan, X. Y.</style></author><author><style face="normal" font="default" size="100%">Lum, J.</style></author><author><style face="normal" font="default" size="100%">Ang, N.</style></author><author><style face="normal" font="default" size="100%">Duan, K.</style></author><author><style face="normal" font="default" size="100%">Gersten, A.</style></author><author><style face="normal" font="default" size="100%">Abuzeid, W. M.</style></author><author><style face="normal" font="default" size="100%">Akbar, N.</style></author><author><style face="normal" font="default" size="100%">Gibber, M.</style></author><author><style face="normal" font="default" size="100%">Howland, S.</style></author><author><style face="normal" font="default" size="100%">Lee, B.</style></author><author><style face="normal" font="default" size="100%">Rotzschke, O.</style></author><author><style face="normal" font="default" size="100%">Porcelli, S. A.</style></author><author><style face="normal" font="default" size="100%">Jerschow, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Singapore Immunology Network, Agency for Science, Technology and Research, Singapore City, Singapore.&#xD;Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA.&#xD;Department of Biological Science, National University of Singapore, Singapore City, Singapore.&#xD;Division of Allergy and Immunology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.&#xD;Rhinology and Endoscopic Skull Base Surgery, Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neutrophilic inflammation and epithelial barrier disruption in nasal polyps characterize non-steroidal anti-inflammatory drug exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1297-1299</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/12/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34921681</style></accession-num><notes><style face="normal" font="default" size="100%">Andiappan, Anand Kumar&#xD;Asad, Mohammad&#xD;Chua, Celine&#xD;Sehanobish, Esha&#xD;Ren, Zhen&#xD;Chan, Xue Ying&#xD;Lum, Josephine&#xD;Ang, Nicholas&#xD;Duan, Kaibo&#xD;Gersten, Adam&#xD;Abuzeid, Waleed M&#xD;Akbar, Nadeem&#xD;Gibber, Marc&#xD;Howland, Shanshan&#xD;Lee, Bernett&#xD;Rotzschke, Olaf&#xD;Porcelli, Steven A&#xD;Jerschow, Elina&#xD;eng&#xD;KL2 TR001071/TR/NCATS NIH HHS/&#xD;R21 AI146804/AI/NIAID NIH HHS/&#xD;UL1 TR002556/TR/NCATS NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1297-1299. doi: 10.1111/all.15198. Epub 2021 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34921681</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8960346</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15198</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3177</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3177</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Radauer, C.</style></author><author><style face="normal" font="default" size="100%">Gadermaier, G.</style></author><author><style face="normal" font="default" size="100%">Goodman, R. E.</style></author><author><style face="normal" font="default" size="100%">Jacquet, A.</style></author><author><style face="normal" font="default" size="100%">Jappe, U.</style></author><author><style face="normal" font="default" size="100%">Lopata, A. L.</style></author><author><style face="normal" font="default" size="100%">Pomes, A.</style></author><author><style face="normal" font="default" size="100%">Raulf, M.</style></author><author><style face="normal" font="default" size="100%">Santos, K. S.</style></author><author><style face="normal" font="default" size="100%">Zakzuk, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Vitte, J.</style></author><author><style face="normal" font="default" size="100%">Who Iuis Allergen Nomenclature Sub-Committee</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;WHO/IUIS Allergen Nomenclature Sub-Committee and EAACI Task Force on Allergen Nomenclature.&#xD;Department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria.&#xD;Food Allergy Research &amp; Resource Program, University of Nebraska-Lincoln, Lincoln, Nebraska, USA.&#xD;Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.&#xD;Division of Clinical &amp; Molecular Allergology, Research Center Borstel, Leibniz Lung Center, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany.&#xD;Department of Pneumology, Interdisciplinary Allergy Outpatient Clinic, UKSH Campus Lubeck, University of Lubeck, Lubeck, Germany.&#xD;College of Science and Engineering, Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia.&#xD;Tropical Futures Institute, James Cook University Singapore, Singapore, Singapore.&#xD;InBio, Charlottesville, Virginia, USA.&#xD;Department of Allergology/Immunology, Institute of Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-University Bochum, Bochum, Germany.&#xD;Departamento de Clinica Medica, Disciplina de Alergia e Imunologia Clinica, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.&#xD;Institute for Immunological Research, University of Cartagena, Cartagena de Indias, Colombia.&#xD;US Department of Agriculture, Agricultural Research Service, Pacific West Area, Western Regional Research Center, Albany, California, USA.&#xD;Immunology Laboratory, Faculty of Medicine, INSERM UMR-S 1250 P3CELL, University Hospital of Reims, University of Reims Champagne-Ardenne, Reims, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">New Allergens Approved by the WHO/IUIS Allergen Nomenclature Sub-Committee in 2021-2024 and Their Significance for Future Diagnostics, Regulation, and Research. An EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergen nomenclature</style></keyword><keyword><style face="normal" font="default" size="100%">allergens</style></keyword><keyword><style face="normal" font="default" size="100%">climate change</style></keyword><keyword><style face="normal" font="default" size="100%">genomics</style></keyword><keyword><style face="normal" font="default" size="100%">globalization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41319011</style></accession-num><abstract><style face="normal" font="default" size="100%">The WHO/IUIS Allergen Nomenclature Sub-Committee is an international body of experts that maintains the systematic nomenclature of allergenic proteins by assigning official names to newly identified allergens submitted by researchers. Here, we summarize the data on new allergens approved between 2021 and 2024. The sub-committee assigned names to 112 new allergens with 124 isoallergens/variants as well as 26 new isoallergens/variants of previously named allergens. Most new allergens were respiratory allergens from animals (35 allergens) and plants (25) as well as food allergens from animals (22) and plants (17). Many newly identified allergens reflect globalized allergen exposure and growing research activities outside of Western countries. This is illustrated by allergens from the tropical mite Blomia tropicalis, pollen allergens from tree and weed species native to Asia, and food allergens from regionally important foods such as mango, seafood, silkworm pupae, and natto. The allergen profiles of most relevant sources are well established, but gaps in our knowledge remain, particularly regarding allergens important for populations outside of Europe and North America. The still growing number of known allergens highlights the importance of a consistent, unambiguous allergen nomenclature that evolves with clinical demands and scientific discovery and supports efforts to close existing knowledge gaps.</style></abstract><notes><style face="normal" font="default" size="100%">Radauer, Christian&#xD;Gadermaier, Gabriele&#xD;Goodman, Richard E&#xD;Jacquet, Alain&#xD;Jappe, Uta&#xD;Lopata, Andreas L&#xD;Pomes, Anna&#xD;Raulf, Monika&#xD;Santos, Keity S&#xD;Zakzuk, Josefina&#xD;Zhang, Yuzhu&#xD;Vitte, Joana&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;International Union of Immunological Societies/&#xD;Austrian Science Fund/&#xD;Agricultural Research Service/&#xD;National Institute of Allergy and Infectious Diseases/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Nov 29. doi: 10.1111/all.70166.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41319011</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70166</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>848</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">848</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hulpusch, C.</style></author><author><style face="normal" font="default" size="100%">Weins, A. B.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Reiger, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Zentrum Munchen, Augsburg, Germany.&#xD;CK CARE - Christine Kuhne Center for Allergy research and Education, Davos, Switzerland.&#xD;Department of Dermatology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;ZIEL, Technical University of Munich, Freising, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A new era of atopic eczema research: Advances and highlights</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3408-3421</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/08/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Cutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">personalized medicine</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34407212</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopic eczema (AE) is an inflammatory skin disease with involvement of genetic, immunological and environmental factors. One hallmark of AE is a skin barrier disruption on multiple, highly interconnected levels: filaggrin mutations, increased skin pH and a microbiome dysbiosis towards Staphylococcus aureus overgrowth are observed in addition to an abnormal type 2 immune response. Extrinsic factors seem to play a major role in the development of AE. As AE is a first step in the atopic march, its prevention and appropriate treatment are essential. Although standard therapy remains topical treatment, powerful systemic treatment options emerged in the last years. However, thorough endotyping of the individual patients is still required for ideal precision medicine approaches in future. Therefore, novel microbial and immunological biomarkers were described recently for the prediction of disease development and treatment response. This review summarizes the current state of the art in AE research.</style></abstract><notes><style face="normal" font="default" size="100%">Hulpusch, Claudia&#xD;Weins, Andreas B&#xD;Traidl-Hoffmann, Claudia&#xD;Reiger, Matthias&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3408-3421. doi: 10.1111/all.15058. Epub 2021 Sep 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34407212</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15058</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1131</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1131</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy ResearchGroup, Instituto de Investigacion Biomedica de Malaga-IBIMA-ARADyAL, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-ARADyAL, Malaga, Spain.&#xD;Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.&#xD;Departamento de Medicina, Facultad de Medicina, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1619-1620</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/diagnosis/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Plasma Kallikrein</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33641193</style></accession-num><notes><style face="normal" font="default" size="100%">Dona, Inmaculada&#xD;Torres, Maria Jose&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1619-1620. doi: 10.1111/all.14798.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33641193</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14798</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2256</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2256</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Schunemann, H. J.</style></author><author><style face="normal" font="default" size="100%">Roche, N.</style></author><author><style face="normal" font="default" size="100%">Price, D.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Guidelines International Network, Hamilton, Ontario, Canada.&#xD;McMaster University, Hamilton, Ontario, Canada.&#xD;GRADE Working Group, Hamilton, Ontario, Canada.&#xD;Departement Medico-Universitaire THOROS (Thorax ORL Sommeil), AP-HP.Centre, Paris, France.&#xD;Universite Paris Cite, UMR 1016, Institut Cochin, Paris, France.&#xD;Optimum Patient Care Global, Cambridge, UK.&#xD;Observational and Pragmatic Research Institute, Singapore, Singapore.&#xD;Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, University of Cagliari, Cagliari, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Next generation health guidelines: The role of real-life data in evidence-based medicine</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">12-14</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37680074</style></accession-num><notes><style face="normal" font="default" size="100%">Canonica, G Walter&#xD;Agache, Ioana&#xD;Schunemann, Holger J&#xD;Roche, Nicolas&#xD;Price, David&#xD;Del Giacco, Stefano&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):12-14. doi: 10.1111/all.15887. Epub 2023 Sep 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37680074</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15887</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1955</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1955</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sobczak, J. M.</style></author><author><style face="normal" font="default" size="100%">Krenger, P. S.</style></author><author><style face="normal" font="default" size="100%">Storni, F.</style></author><author><style face="normal" font="default" size="100%">Mohsen, M. O.</style></author><author><style face="normal" font="default" size="100%">Balke, I.</style></author><author><style face="normal" font="default" size="100%">Resevica, G.</style></author><author><style face="normal" font="default" size="100%">Heath, M. D.</style></author><author><style face="normal" font="default" size="100%">Carreno Velazquez, T. L.</style></author><author><style face="normal" font="default" size="100%">Kramer, M. F.</style></author><author><style face="normal" font="default" size="100%">Scott, C. J. W.</style></author><author><style face="normal" font="default" size="100%">Skinner, M. A.</style></author><author><style face="normal" font="default" size="100%">Zeltins, A.</style></author><author><style face="normal" font="default" size="100%">Kundig, T. M.</style></author><author><style face="normal" font="default" size="100%">Vogel, M.</style></author><author><style face="normal" font="default" size="100%">Bachmann, M. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, University Clinic of Rheumatology and Immunology, Inselspital, Bern, Switzerland.&#xD;Department of BioMedical Research, University of Bern, Bern, Switzerland.&#xD;Department of Visceral Surgery and Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.&#xD;Latvian Biomedical Research and Study Centre, Riga, Latvia.&#xD;Allergy Therapeutics (UK) Ltd., Worthing, UK.&#xD;Bencard Allergie GmbH, Munich, Germany.&#xD;Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The next generation virus-like particle platform for the treatment of peanut allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1980-1996</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">novel therapy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">virus-like particles</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36883475</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergy to peanut is one of the leading causes of anaphylactic reactions among food allergic patients. Immunization against peanut allergy with a safe and protective vaccine holds a promise to induce durable protection against anaphylaxis caused by exposure to peanut. A novel vaccine candidate (VLP Peanut), based on virus-like particles (VLPs), is described here for the treatment of peanut allergy. METHODS AND RESULTS: VLP Peanut consists of two proteins: a capsid subunit derived from Cucumber mosaic virus engineered with a universal T-cell epitope (CuMV(TT) ) and a CuMV(TT) subunit fused with peanut allergen Ara h 2 (CuMV(TT) -Ara h 2), forming mosaic VLPs. Immunizations with VLP Peanut in both naive and peanut-sensitized mice resulted in a significant anti-Ara h 2 IgG response. Local and systemic protection induced by VLP Peanut were established in mouse models for peanut allergy following prophylactic, therapeutic, and passive immunizations. Inhibition of FcgammaRIIb function resulted in a loss of protection, confirming the crucial role of the receptor in conferring cross protection against peanut allergens other than Ara h 2. CONCLUSION: VLP Peanut can be delivered to peanut-sensitized mice without triggering allergic reactions, while remaining highly immunogenic and offering protection against all peanut allergens. In addition, vaccination ablates allergic symptoms upon allergen challenge. Moreover, the prophylactic immunization setting conferred the protection against subsequent peanut-induced anaphylaxis, showing the potential for preventive vaccination. This highlights the effectiveness of VLP Peanut as a prospective break-through immunotherapy vaccine candidate toward peanut allergy. VLP Peanut has now entered clinical development with the study PROTECT.</style></abstract><notes><style face="normal" font="default" size="100%">Sobczak, Jan M&#xD;Krenger, Pascal S&#xD;Storni, Federico&#xD;Mohsen, Mona O&#xD;Balke, Ina&#xD;Resevica, Gunta&#xD;Heath, Matthew D&#xD;Carreno Velazquez, Thalia L&#xD;Kramer, Matthias F&#xD;Scott, Callum J W&#xD;Skinner, Murray A&#xD;Zeltins, Andris&#xD;Kundig, Thomas M&#xD;Vogel, Monique&#xD;Bachmann, Martin F&#xD;eng&#xD;310030_185114/SNSF_/Swiss National Science Foundation/Switzerland&#xD;IZRPZO_194968/SNSF_/Swiss National Science Foundation/Switzerland&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1980-1996. doi: 10.1111/all.15704. Epub 2023 Mar 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36883475</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15704</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>735</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">735</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Romano, A.</style></author><author><style face="normal" font="default" size="100%">Oussalah, A.</style></author><author><style face="normal" font="default" size="100%">Chery, C.</style></author><author><style face="normal" font="default" size="100%">Gueant-Rodriguez, R. M.</style></author><author><style face="normal" font="default" size="100%">Gaeta, F.</style></author><author><style face="normal" font="default" size="100%">Cornejo-Garcia, J. A.</style></author><author><style face="normal" font="default" size="100%">Rouyer, P.</style></author><author><style face="normal" font="default" size="100%">Josse, T.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Gueant, J. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, University of Lorraine, Nancy, France.&#xD;Oasi Research Institute-IRCCS, Troina, Italy.&#xD;Department of Molecular Medicine, Division of Biochemistry, Molecular Biology, and Nutrition, University Hospital of Nancy, Nancy, France.&#xD;Allergy Unit, Columbus Hospital, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-UMA-ARADyAL, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Next-generation sequencing and genotype association studies reveal the association of HLA-DRB3*02:02 with delayed hypersensitivity to penicillins</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1827-1834</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/10/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">HLA-DRB3 Chains/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Delayed/chemically induced/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillins/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Hla-drb3</style></keyword><keyword><style face="normal" font="default" size="100%">amoxicillin</style></keyword><keyword><style face="normal" font="default" size="100%">beta-lactams</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">genome-wide association</style></keyword><keyword><style face="normal" font="default" size="100%">nonimmediate reactions</style></keyword><keyword><style face="normal" font="default" size="100%">penicillins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34687232</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Nonimmediate (delayed)-allergic reactions to penicillins are common and some of them can be life-threatening. The genetic factors influencing these reactions are unknown/poorly known/poorly understood. We assessed the genetic predictors of a delayed penicillin allergy that cover the HLA loci. METHODS: Using next-generation sequencing (NGS), we genotyped the MHC region in 24 patients with delayed hypersensitivity compared with 20 patients with documented immediate hypersensitivity to penicillins recruited in Italy. Subsequently, we analyzed in silico Illumina Immunochip genotyping data that covered the HLA loci in 98 Spanish patients with delayed hypersensitivity and 315 with immediate hypersensitivity compared to 1,308 controls. RESULTS: The two alleles DRB3*02:02:01:02 and DRB3*02:02:01:01 were reported in twenty cases with delayed reactions (83%) and ten cases with immediate reactions (50%), but not in the Allele Frequency Net Database. Bearing at least one of the two alleles increased the risk of delayed reactions compared to immediate reactions, with an OR of 8.88 (95% CI, 3.37-23.32; p &lt; .0001). The haplotype (ACAA) from rs9268835, rs6923504, rs6903608, and rs9268838 genetic variants of the HLA-DRB3 genomic region was significantly associated with an increased risk of delayed hypersensitivity to penicillins (OR, 1.7; 95% CI: 1.06-1.92; p = .001), but not immediate hypersensitivity. CONCLUSION: We showed that the HLA-DRB3 locus is strongly associated with an increased risk of delayed penicillin hypersensitivity, at least in Southwestern Europe. The determination of HLA-DRB3*02:02 alleles in the risk management of severe delayed hypersensitivity to penicillins should be evaluated further in larger population samples of different origins.</style></abstract><notes><style face="normal" font="default" size="100%">Romano, Antonino&#xD;Oussalah, Abderrahim&#xD;Chery, Celine&#xD;Gueant-Rodriguez, Rosa-Maria&#xD;Gaeta, Francesco&#xD;Cornejo-Garcia, Jose-Antonio&#xD;Rouyer, Pierre&#xD;Josse, Thomas&#xD;Mayorga, Cristobalina&#xD;Torres, Maria-Jose&#xD;Gueant, Jean-Louis&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1827-1834. doi: 10.1111/all.15147. Epub 2021 Nov 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34687232</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15147</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>812</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">812</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Poirot, A.</style></author><author><style face="normal" font="default" size="100%">Wacht, G.</style></author><author><style face="normal" font="default" size="100%">Lehalle, C.</style></author><author><style face="normal" font="default" size="100%">Saas, P.</style></author><author><style face="normal" font="default" size="100%">Frossard, N.</style></author><author><style face="normal" font="default" size="100%">Geny, B.</style></author><author><style face="normal" font="default" size="100%">de Blay, F.</style></author><author><style face="normal" font="default" size="100%">Barnig, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chest Disease, University Hospital of Strasbourg, Strasbourg, France.&#xD;EA 3072, University of Strasbourg, Strasbourg, France.&#xD;Laboratoire d&apos;Innovation Therapeutique and LabEx MEDALIS, Faculte de Pharmacie, UMR 7200 CNRS / Universite de Strasbourg, Strasbourg, France.&#xD;INSERM, EFS BFC, LabEx LipSTIC, UMR1098, Interactions Hote-Greffon-Tumeur/Ingenierie Cellulaire et Genique, Univ. Bourgogne Franche-Comte, Besancon, France.&#xD;Department of Chest Disease, University Hospital of Besancon, Besancon, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">NK cells and lipoxin A(4) promote resolution of eosinophilic inflammation after nasal allergen challenge</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">309-313</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/09/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Killer Cells, Natural</style></keyword><keyword><style face="normal" font="default" size="100%">*Lipoxins</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">challenge tests</style></keyword><keyword><style face="normal" font="default" size="100%">innate lymphoid cells and NK cells</style></keyword><keyword><style face="normal" font="default" size="100%">lipoxin</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34543440</style></accession-num><notes><style face="normal" font="default" size="100%">Poirot, Anh&#xD;Wacht, Guillaume&#xD;Lehalle, Christine&#xD;Saas, Philippe&#xD;Frossard, Nelly&#xD;Geny, Bernard&#xD;de Blay, Frederic&#xD;Barnig, Cindy&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):309-313. doi: 10.1111/all.15103. Epub 2021 Sep 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34543440</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15103</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2875</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2875</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pak, S. W.</style></author><author><style face="normal" font="default" size="100%">Kim, W. I.</style></author><author><style face="normal" font="default" size="100%">Lee, S. J.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author><author><style face="normal" font="default" size="100%">Park, M. J.</style></author><author><style face="normal" font="default" size="100%">Park, J. H.</style></author><author><style face="normal" font="default" size="100%">Kim, J. C.</style></author><author><style face="normal" font="default" size="100%">Kim, T.</style></author><author><style face="normal" font="default" size="100%">Kim, J. S.</style></author><author><style face="normal" font="default" size="100%">Kim, Y. H.</style></author><author><style face="normal" font="default" size="100%">Shin, I. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">College of Veterinary Medicine and BK21 FOUR Program, Chonnam National University, Gwangju, Republic of Korea.&#xD;KM Convergence Research Division, Korea Institute of Oriental Medicine (KIOM), Daejeon, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">NLRC4 Regulates Th2 Differentiation in Mice With Allergic Airway Inflammation Induced by House Dust Mite</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1790-1793</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/04/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40171954</style></accession-num><notes><style face="normal" font="default" size="100%">Pak, So-Won&#xD;Kim, Woong-Il&#xD;Lee, Se-Jin&#xD;Lee, Junhyeong&#xD;Park, Min-Jung&#xD;Park, Jong-Hwan&#xD;Kim, Jong-Choon&#xD;Kim, Taesoo&#xD;Kim, Joong-Sun&#xD;Kim, Yun Hee&#xD;Shin, In-Sik&#xD;eng&#xD;RS-2022-NR069617/National Research Foundation of Korea/&#xD;RS-2023-00219517/National Research Foundation of Korea/&#xD;2021RIS-002/Ministry of Education/&#xD;KSN1927330/Korea Institute of Oriental Medicine/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1790-1793. doi: 10.1111/all.16550. Epub 2025 Apr 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40171954</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186580</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16550</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>717</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">717</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lunding, L. P.</style></author><author><style face="normal" font="default" size="100%">Skouras, D. B.</style></author><author><style face="normal" font="default" size="100%">Vock, C.</style></author><author><style face="normal" font="default" size="100%">Dinarello, C. A.</style></author><author><style face="normal" font="default" size="100%">Wegmann, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Asthma Exacerbation &amp; Regulation, Priority Area Asthma &amp; Allergy, Research Center Borstel- Leibniz Lung Center, Borstel, Germany.&#xD;Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Marburg, Germany.&#xD;Olatec Therapeutics LLC, New York, New York, USA.&#xD;Division of Experimental Pneumology, Priority Area Asthma &amp; Allergy, Research Center Borstel- Leibniz Lung Center, Borstel, Germany.&#xD;Department of Medicine, University of Colorado, Denver, Colorado, USA.&#xD;Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The NLRP3 inflammasome inhibitor, OLT1177((R)) , ameliorates experimental allergic asthma in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1035-1038</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/10/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammasomes</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">NLR Family, Pyrin Domain-Containing 3 Protein</style></keyword><keyword><style face="normal" font="default" size="100%">Nitriles/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34716997</style></accession-num><notes><style face="normal" font="default" size="100%">Lunding, Lars P&#xD;Skouras, Damaris B&#xD;Vock, Christina&#xD;Dinarello, Charles A&#xD;Wegmann, Michael&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1035-1038. doi: 10.1111/all.15164. Epub 2021 Nov 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34716997</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15164</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>468</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">468</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chenuet, P.</style></author><author><style face="normal" font="default" size="100%">Marquant, Q.</style></author><author><style face="normal" font="default" size="100%">Fauconnier, L.</style></author><author><style face="normal" font="default" size="100%">Youness, A.</style></author><author><style face="normal" font="default" size="100%">Mellier, M.</style></author><author><style face="normal" font="default" size="100%">Marchiol, T.</style></author><author><style face="normal" font="default" size="100%">Rouxel, N.</style></author><author><style face="normal" font="default" size="100%">Messaoud-Nacer, Y.</style></author><author><style face="normal" font="default" size="100%">Maillet, I.</style></author><author><style face="normal" font="default" size="100%">Ledru, A.</style></author><author><style face="normal" font="default" size="100%">Quesniaux, V. F. J.</style></author><author><style face="normal" font="default" size="100%">Ryffel, B.</style></author><author><style face="normal" font="default" size="100%">Horsnell, W.</style></author><author><style face="normal" font="default" size="100%">Vegran, F.</style></author><author><style face="normal" font="default" size="100%">Apetoh, L.</style></author><author><style face="normal" font="default" size="100%">Togbe, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Artimmune SAS, Orleans, France.&#xD;Laboratory of Experimental and Molecular Immunology and Neurogenetics (INEM), UMR 7355 CNRS-University of Orleans, Orleans-Cedex 2, France.&#xD;Institute of Infectious Disease and Molecular Medicine and Division of Immunology, University of Cape Town 7925, South Africa &amp; South African Medical Research Council, Cape Town, South Africa.&#xD;Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK.&#xD;INSERM, U1231, Dijon, France.&#xD;INSERM, U1100, Tours, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">NLRP6 negatively regulates type 2 immune responses in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3320-3336</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/05/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammasomes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-18/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Nippostrongylus</style></keyword><keyword><style face="normal" font="default" size="100%">*Pneumonia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Nippostrongylus brasiliensis</style></keyword><keyword><style face="normal" font="default" size="100%">CD4+ T cells</style></keyword><keyword><style face="normal" font="default" size="100%">Gata3</style></keyword><keyword><style face="normal" font="default" size="100%">Il-18</style></keyword><keyword><style face="normal" font="default" size="100%">Ilc2</style></keyword><keyword><style face="normal" font="default" size="100%">Nlrp6</style></keyword><keyword><style face="normal" font="default" size="100%">Th17</style></keyword><keyword><style face="normal" font="default" size="100%">Th2</style></keyword><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">birch pollen</style></keyword><keyword><style face="normal" font="default" size="100%">inflammasome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35615773</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Inflammasomes are large protein complexes that assemble in the cytosol in response to danger such as tissue damage or infection. Following activation, inflammasomes trigger cell death and the release of biologically active forms of pro-inflammatory cytokines interleukin (IL)-1beta and IL-18. NOD-like receptor family pyrin domain containing 6 (NLRP6) inflammasome is required for IL-18 secretion by intestinal epithelial cells, macrophages, and T cells, contributing to homeostasis and self-defense against pathogenic microbes. However, the involvement of NLRP6 in type 2 lung inflammation remains elusive. METHODS: Wild-type (WT) and Nlrp6(-/-) mice were used. Birch pollen extract (BPE)-induced allergic lung inflammation, eosinophil recruitment, Th2-related cytokine and chemokine production, airway hyperresponsiveness, and lung histopathology, Th2 cell differentiation, GATA3, and Th2 cytokines expression, were determined. Nippostrongylus brasiliensis (Nb) infection, worm count in intestine, type 2 innate lymphoid cell (ILC2), and Th2 cells in lungs were evaluated. RESULTS: We demonstrate in Nlrp6(-/-) mice that a mixed Th2/Th17 immune responses prevailed following birch pollen challenge with increased eosinophils, ILC2, Th2, and Th17 cell induction and reduced IL-18 production. Nippostrongylus brasiliensis infected Nlrp6(-/-) mice featured enhanced early expulsion of the parasite due to enhanced type 2 immune responses compared to WT hosts. In vitro, NLRP6 repressed Th2 polarization, as shown by increased Th2 cytokines and higher expression of the transcription factor GATA3 in the absence of NLRP6. Exogenous IL-18 administration partially reduced the enhanced airways inflammation in Nlrp6(-/-) mice. CONCLUSIONS: In summary, our data identify NLRP6 as a negative regulator of type 2 immune responses.</style></abstract><notes><style face="normal" font="default" size="100%">Chenuet, Pauline&#xD;Marquant, Quentin&#xD;Fauconnier, Louis&#xD;Youness, Ali&#xD;Mellier, Manon&#xD;Marchiol, Tiffany&#xD;Rouxel, Nathalie&#xD;Messaoud-Nacer, Yasmine&#xD;Maillet, Isabelle&#xD;Ledru, Aurelie&#xD;Quesniaux, Valerie F J&#xD;Ryffel, Bernhard&#xD;Horsnell, William&#xD;Vegran, Frederique&#xD;Apetoh, Lionel&#xD;Togbe, Dieudonnee&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3320-3336. doi: 10.1111/all.15388. Epub 2022 Jun 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35615773</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15388</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>751</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">751</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alvarez Garcia, O.</style></author><author><style face="normal" font="default" size="100%">Bartra, J.</style></author><author><style face="normal" font="default" size="100%">Ruiz-Garcia, M.</style></author><author><style face="normal" font="default" size="100%">Skypala, I. J.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Boyle, R. J.</style></author><author><style face="normal" font="default" size="100%">Mills, E. N. C.</style></author><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Complexo Hospitalario Universitario de Ferrol, A Coruna, Spain.&#xD;Hospital Clinic de Barcelona, Barcelona, Spain.&#xD;Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, Manchester Institute of Biotechnology, University of Mancheste, Manchester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">No apparent impact of incremental dosing on eliciting dose at double-blind, placebo-controlled peanut challenge</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">667-670</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Arachis/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">eliciting dose</style></keyword><keyword><style face="normal" font="default" size="100%">food challenge</style></keyword><keyword><style face="normal" font="default" size="100%">lowest observed adverse effect level</style></keyword><keyword><style face="normal" font="default" size="100%">peanut</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34614236</style></accession-num><notes><style face="normal" font="default" size="100%">Alvarez Garcia, Olaya&#xD;Bartra, Joan&#xD;Ruiz-Garcia, Monica&#xD;Skypala, Isabel J&#xD;Durham, Stephen R&#xD;Boyle, Robert J&#xD;Mills, E N Clare&#xD;Turner, Paul J&#xD;eng&#xD;MR/K010468/1/MRC_/Medical Research Council/United Kingdom&#xD;DH_/Department of Health/United Kingdom&#xD;Letter&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):667-670. doi: 10.1111/all.15130. Epub 2021 Oct 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34614236</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15130</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2271</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2271</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Zemelka-Wiacek, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Gajdanowicz, P.</style></author><author><style face="normal" font="default" size="100%">Gracia, I. E.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Lauerma, A.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Skypala, I.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author><author><style face="normal" font="default" size="100%">Gomez, R. M.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Holgate, S. T.</style></author><author><style face="normal" font="default" size="100%">Izuhara, K.</style></author><author><style face="normal" font="default" size="100%">Kabashima, K.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">von Mutius, E.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Platts-Mills, T. A. E.</style></author><author><style face="normal" font="default" size="100%">Sicherer, S. H.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author><author><style face="normal" font="default" size="100%">Wong, G.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, Monserrato, Italy.&#xD;Allergy Unit, UMA-Regional University Hospital of Malaga, IBIMA-BIONAND, Malaga, Spain.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Department of Dermatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland.&#xD;Child Life and Health, Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Department of Inflammation and Repair, Imperial College London, London, UK.&#xD;Royal Brompton and Harefield Hospitals, Part of Guys and St Thomas&apos; NHS Foundation Trust, London, UK.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Fundacao ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Bahia, Brazil.&#xD;Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Pathology and Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.&#xD;Faculty of Health Sciences, Catholic University of Salta, Salta, Argentina.&#xD;Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Academic Unit of Clinical and Experimental Sciences, University of Southampton, Southampton, UK.&#xD;Department of Biomolecular Sciences, Division of Medical Biochemistry, Saga Medical School, Saga, Japan.&#xD;Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;Department of Pediatrics, Dr. von Hauner Children&apos;s Hospital, LMU University Hospital, Munich, Germany.&#xD;Institute of Asthma and Allergy Prevention, Helmholtz Centre Munich, Munich, Germany.&#xD;German Center for Lung Research (DZL), Giesen, Germany.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Department of Medicine, Division of Allergy and Clinical Immunology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.&#xD;Division of Pediatric Allergy and Immunology, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea.&#xD;Paul-Ehrlich-Institut, Langen, Germany.&#xD;Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China.&#xD;Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona and Allergy Unit, Department of Internal Medicine, University Hospital of Marche, Ancona, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2851-2874</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/10/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">EAACI position paper</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">nomenclature</style></keyword><keyword><style face="normal" font="default" size="100%">pathophysiology and mechanism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37814905</style></accession-num><abstract><style face="normal" font="default" size="100%">The exponential growth of precision diagnostic tools, including omic technologies, molecular diagnostics, sophisticated genetic and epigenetic editing, imaging and nano-technologies and patient access to extensive health care, has resulted in vast amounts of unbiased data enabling in-depth disease characterization. New disease endotypes have been identified for various allergic diseases and triggered the gradual transition from a disease description focused on symptoms to identifying biomarkers and intricate pathogenetic and metabolic pathways. Consequently, the current disease taxonomy has to be revised for better categorization. This European Academy of Allergy and Clinical Immunology Position Paper responds to this challenge and provides a modern nomenclature for allergic diseases, which respects the earlier classifications back to the early 20th century. Hypersensitivity reactions originally described by Gell and Coombs have been extended into nine different types comprising antibody- (I-III), cell-mediated (IVa-c), tissue-driven mechanisms (V-VI) and direct response to chemicals (VII). Types I-III are linked to classical and newly described clinical conditions. Type IVa-c are specified and detailed according to the current understanding of T1, T2 and T3 responses. Types V-VI involve epithelial barrier defects and metabolic-induced immune dysregulation, while direct cellular and inflammatory responses to chemicals are covered in type VII. It is notable that several combinations of mixed types may appear in the clinical setting. The clinical relevance of the current approach for allergy practice will be conferred in another article that will follow this year, aiming at showing the relevance in clinical practice where various endotypes can overlap and evolve over the lifetime.</style></abstract><notes><style face="normal" font="default" size="100%">Jutel, Marek&#xD;Agache, Ioana&#xD;Zemelka-Wiacek, Magdalena&#xD;Akdis, Mubeccel&#xD;Chivato, Tomas&#xD;Del Giacco, Stefano&#xD;Gajdanowicz, Pawel&#xD;Gracia, Ibon Eguiluz&#xD;Klimek, Ludger&#xD;Lauerma, Antti&#xD;Ollert, Markus&#xD;O&apos;Mahony, Liam&#xD;Schwarze, Jurgen&#xD;Shamji, Mohamed H&#xD;Skypala, Isabel&#xD;Palomares, Oscar&#xD;Pfaar, Oliver&#xD;Torres, Maria Jose&#xD;Bernstein, Jonathan A&#xD;Cruz, Alvaro A&#xD;Durham, Stephen R&#xD;Galli, Stephen J&#xD;Gomez, R Maximiliano&#xD;Guttman-Yassky, Emma&#xD;Haahtela, Tari&#xD;Holgate, Stephen T&#xD;Izuhara, Kenji&#xD;Kabashima, Kenji&#xD;Larenas-Linnemann, Desiree E&#xD;von Mutius, Erica&#xD;Nadeau, Kari C&#xD;Pawankar, Ruby&#xD;Platts-Mills, Tomas A E&#xD;Sicherer, Scott H&#xD;Park, Hae-Sim&#xD;Vieths, Stefan&#xD;Wong, Gary&#xD;Zhang, Luo&#xD;Bilo, M Beatrice&#xD;Akdis, Cezmi A&#xD;eng&#xD;Consensus Development Conference&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2851-2874. doi: 10.1111/all.15889. Epub 2023 Oct 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37814905</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15889</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2820</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2820</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stavraka, C.</style></author><author><style face="normal" font="default" size="100%">Chauhan, J.</style></author><author><style face="normal" font="default" size="100%">Crescioli, S.</style></author><author><style face="normal" font="default" size="100%">McSweeney, S. M.</style></author><author><style face="normal" font="default" size="100%">Pope, A.</style></author><author><style face="normal" font="default" size="100%">Gillett, C.</style></author><author><style face="normal" font="default" size="100%">Di Meo, A.</style></author><author><style face="normal" font="default" size="100%">Prassas, I.</style></author><author><style face="normal" font="default" size="100%">Laddach, R.</style></author><author><style face="normal" font="default" size="100%">Stoker, K.</style></author><author><style face="normal" font="default" size="100%">McCraw, A. J.</style></author><author><style face="normal" font="default" size="100%">Adams, R.</style></author><author><style face="normal" font="default" size="100%">Tull, T. J.</style></author><author><style face="normal" font="default" size="100%">Naban, N.</style></author><author><style face="normal" font="default" size="100%">Willsmore, Z.</style></author><author><style face="normal" font="default" size="100%">Semkova, K. V.</style></author><author><style face="normal" font="default" size="100%">Grattan, C. E. H.</style></author><author><style face="normal" font="default" size="100%">McGrath, J.</style></author><author><style face="normal" font="default" size="100%">Till, S. J.</style></author><author><style face="normal" font="default" size="100%">Corrigan, C. J.</style></author><author><style face="normal" font="default" size="100%">Kristeleit, R.</style></author><author><style face="normal" font="default" size="100%">Tsoka, S.</style></author><author><style face="normal" font="default" size="100%">Diamandis, E. P.</style></author><author><style face="normal" font="default" size="100%">Lacy, K. E.</style></author><author><style face="normal" font="default" size="100%">Pinder, S.</style></author><author><style face="normal" font="default" size="100%">Josephs, D. H.</style></author><author><style face="normal" font="default" size="100%">Spicer, J.</style></author><author><style face="normal" font="default" size="100%">Bax, H. J.</style></author><author><style face="normal" font="default" size="100%">Karagiannis, S. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">St. John&apos;s Institute of Dermatology, School of Basic &amp; Medical Biosciences &amp; KHP Centre for Translational Medicine, King&apos;s College London, London, UK.&#xD;School of Cancer &amp; Pharmaceutical Sciences, King&apos;s College London, Guy&apos;s Hospital, London, UK.&#xD;King&apos;s Health Partners Cancer Biobank, School of Cancer &amp; Pharmaceutical Sciences, King&apos;s College London, Guy&apos;s Hospital, London, UK.&#xD;Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.&#xD;Division of Clinical Biochemistry, Laboratory Medicine Program, Toronto General Hospital, Toronto, Canada.&#xD;Mount Sinai Hospital, Toronto, Canada.&#xD;Laboratory Medicine Program, University Health Network, Toronto, Canada.&#xD;Department of Informatics, Faculty of Natural, Mathematical and Engineering Sciences, King&apos;s College London, London, UK.&#xD;St. John&apos;s Institute of Dermatology, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK.&#xD;Cancer Centre at Guy&apos;s, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK.&#xD;King&apos;s Centre for Lung Health, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.&#xD;Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.&#xD;Breast Cancer Now Research Unit, School of Cancer &amp; Pharmaceutical Sciences, King&apos;s College London, Guy&apos;s Cancer Centre, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2225-2239</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/03/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Folate Receptor 1/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/immunology/pathology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/immunology/etiology/diagnosis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">AllergoOncology</style></keyword><keyword><style face="normal" font="default" size="100%">IgE antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">folate receptor alpha</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomic analysis</style></keyword><keyword><style face="normal" font="default" size="100%">urticarial skin reactions</style></keyword><keyword><style face="normal" font="default" size="100%">employed through a fund provided by Epsilogen Ltd. J.C. has been employed through</style></keyword><keyword><style face="normal" font="default" size="100%">a fund provided by Epsilogen Ltd. S.N.K., J.S., D.H.J. and H.J.B. declare patents</style></keyword><keyword><style face="normal" font="default" size="100%">on antibodies for cancer. R.K. is the Lead Investigator for the Phase IB/II MOv18</style></keyword><keyword><style face="normal" font="default" size="100%">trial and has received travel support from Epsilogen Ltd. All other authors</style></keyword><keyword><style face="normal" font="default" size="100%">declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40045925</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IgE antibodies directed against cancer antigens have demonstrated potent anti-tumour effects in pre-clinical studies. MOv18 IgE, the first-in-class IgE recognising the cancer antigen folate receptor alpha (FRalpha), showed preliminary signs of efficacy in a Phase I trial. Treatment was well tolerated, with the most common adverse event being transient urticarial skin reactions. We investigated immunological and allergic response parameters associated with urticarial skin reactions in MOv18 IgE-treated patients. METHODS: Expression of target antigen, FRalpha, and MOv18 IgE reactivity with FRalpha or any component in human skin was studied by immunohistochemistry, immunofluorescence and immuno-mass spectrometry. We conducted transcriptomic analyses in paired lesional and non-lesional skin biopsies from a patient who developed an urticarial skin reaction. Systemic immunological markers including cytokines, beta-tryptase and basophil activation states were interrogated throughout the trial and contemporaneously with the skin reaction. RESULTS: Of the 24 IgE-treated patients, 62.5% developed transient urticarial skin reactions, with onset during the first infusion, diminishing with consecutive infusions and no beta-tryptase elevation nor clinical features indicating allergic aetiology. No FRalpha expression or MOv18 IgE binding to human skin was identified. Lesional skin biopsies from a patient given the highest antibody dose revealed scattered eosinophils, neutrophils and mast cell degranulation, but no increased immune cell infiltration. Transcriptomic analysis indicated pro-inflammatory, but not allergic, pathway activation. No systemic allergic or hypersensitivity mediators or basophil activation were detected. CONCLUSIONS: Urticarial skin reactions following MOv18 IgE treatment were unlikely to result from allergic mechanisms or skin antigen recognition. The clinical presentation is consistent with infusion-related reactions commonly observed with monoclonal antibody treatments. TRIAL REGISTRATION: EudraCT number: 2014-000070-19; ClinicalTrials.gov identifier: NCT02546921, registered 11/Sept/2015.</style></abstract><notes><style face="normal" font="default" size="100%">Stavraka, Chara&#xD;Chauhan, Jitesh&#xD;Crescioli, Silvia&#xD;McSweeney, Sheila M&#xD;Pope, Amy&#xD;Gillett, Cheryl&#xD;Di Meo, Ashley&#xD;Prassas, Ioannis&#xD;Laddach, Roman&#xD;Stoker, Katie&#xD;McCraw, Alexandra J&#xD;Adams, Rebecca&#xD;Tull, Thomas J&#xD;Naban, Nabeel&#xD;Willsmore, Zena&#xD;Semkova, Kristina V&#xD;Grattan, Clive E H&#xD;McGrath, John&#xD;Till, Stephen J&#xD;Corrigan, Christopher J&#xD;Kristeleit, Rebecca&#xD;Tsoka, Sophia&#xD;Diamandis, Eleftherios P&#xD;Lacy, Katie E&#xD;Pinder, Sarah&#xD;Josephs, Debra H&#xD;Spicer, James&#xD;Bax, Heather J&#xD;Karagiannis, Sophia N&#xD;eng&#xD;573/CU/CSP VA/&#xD;006/R/22/British Skin Foundation/&#xD;C10355/A15587/CRUK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre/&#xD;C7893/A29290/The Cancer Research UK City of London Centre/&#xD;C604/A25135/Cancer Research UK King&apos;s Health Partners Centre at King&apos;s College London/&#xD;C30122/A11527;C30122/A15774/CRUK_/Cancer Research UK/United Kingdom&#xD;24-0087/AICR_/Worldwide Cancer Research/United Kingdom&#xD;MR/L023091/1;MR/V049445/1;MR/R015643/1/MRC_/Medical Research Council/United Kingdom&#xD;147;KCL-BCN-Q3/BBC_/Breast Cancer Now/United Kingdom&#xD;Clinical Trial, Phase I&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2225-2239. doi: 10.1111/all.16514. Epub 2025 Mar 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40045925</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368751</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16514</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>408</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">408</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gamboa, P.</style></author><author><style face="normal" font="default" size="100%">Sanchez de Vicente, J.</style></author><author><style face="normal" font="default" size="100%">Galan, C.</style></author><author><style face="normal" font="default" size="100%">Jauregui, I.</style></author><author><style face="normal" font="default" size="100%">Segurola, A.</style></author><author><style face="normal" font="default" size="100%">Garcia-Lirio, E.</style></author><author><style face="normal" font="default" size="100%">Seras, Y.</style></author><author><style face="normal" font="default" size="100%">Martinez-Anton, M. D.</style></author><author><style face="normal" font="default" size="100%">Arrien de Lecea, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Alergia, Hospital Universitario Cruces, Barakaldo, Spain.&#xD;Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Non-immediate hypersensitivity reactions to iomeprol: Diagnostic value of skin tests and cross-reactivity with other iodinated contrast media</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3641-3647</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/07/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Iopamidol/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Contrast Media/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Iodine Compounds/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">iodinated contrast media</style></keyword><keyword><style face="normal" font="default" size="100%">iomeprol</style></keyword><keyword><style face="normal" font="default" size="100%">iopamidol</style></keyword><keyword><style face="normal" font="default" size="100%">non-immediate hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35815908</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Iodinated contrast media produce non-immediate hypersensitivity reactions (NIHR). The goal of this prospective study was to determine the utility of skin tests and the subsequent tolerance to negative skin-tested iodinated contrasts in patients with NIHR caused by iomeprol. METHODS: Prick and intradermal tests with iomeprol, iopamidol, iopromide, and iobitridol were performed in all patients. IV challenge with the causative contrast (iomeprol in 90%) was made if skin tests were negative. In case of a positive skin test with the causal contrast, or a positive challenge test with it, IV challenge test with an alternative, negative skin-tested contrast was performed in all patients. RESULTS: Skin tests were positive in 47.6% (20/42) of patients with NIHR induced by iomeprol. Of the 66 challenge tests performed with negative skin-tested iodinated contrasts, tolerance was confirmed in 35 (53%): 32 iomeron, 2 iobitridol, 1 iopamidol. Cross-reactivity between iomeprol and iopamidol was 22% (4/20 in patients with positive skin tests and 5/21 in patients with negative skin tests). CONCLUSIONS: Sensitivity of the skin tests was less than 50% NIHRs due to iomeprol, while the negative predictive value of skin tests in patients who tolerated challenges with alternative contrasts (mainly iopamidol) was 53% (35 tolerated out of 66 performed). The cross-reactivity between iomeprol and iopamidol is high.</style></abstract><notes><style face="normal" font="default" size="100%">Gamboa, Pedro&#xD;Sanchez de Vicente, Javier&#xD;Galan, Cristina&#xD;Jauregui, Ignacio&#xD;Segurola, Aritza&#xD;Garcia-Lirio, Eduardo&#xD;Seras, Yolanda&#xD;Martinez-Anton, M feminine Dolores&#xD;Arrien de Lecea, Angel&#xD;eng&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3641-3647. doi: 10.1111/all.15433. Epub 2022 Jul 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35815908</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15433</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>378</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">378</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Van De Sijpe, G.</style></author><author><style face="normal" font="default" size="100%">Gilissen, L.</style></author><author><style face="normal" font="default" size="100%">Vandebotermet, M.</style></author><author><style face="normal" font="default" size="100%">Peetermans, W. E.</style></author><author><style face="normal" font="default" size="100%">Spriet, I.</style></author><author><style face="normal" font="default" size="100%">Schrijvers, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.&#xD;Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.&#xD;Department of Public Health and Primary Care, Centre for Environment and Health, KU Leuven, Leuven, Belgium.&#xD;Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.&#xD;Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Non-invasive delabeling and refining of beta-lactam allergy labels in inpatients to optimize antimicrobial stewardship</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3157-3159</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/07/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Antimicrobial Stewardship</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inpatients</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillins</style></keyword><keyword><style face="normal" font="default" size="100%">beta-Lactams/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35876226</style></accession-num><notes><style face="normal" font="default" size="100%">Van De Sijpe, Greet&#xD;Gilissen, Liesbeth&#xD;Vandebotermet, Martijn&#xD;Peetermans, Willy E&#xD;Spriet, Isabel&#xD;Schrijvers, Rik&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3157-3159. doi: 10.1111/all.15453. Epub 2022 Jul 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35876226</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15453</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3310</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3310</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mochón-Jiménez, Carmen</style></author><author><style face="normal" font="default" size="100%">Gay-Mimbrera, Jesús</style></author><author><style face="normal" font="default" size="100%">Dávila-Flores, Viviana</style></author><author><style face="normal" font="default" size="100%">He, Helen</style></author><author><style face="normal" font="default" size="100%">Zhou, Jerry</style></author><author><style face="normal" font="default" size="100%">Rivera-Ruiz, Irene</style></author><author><style face="normal" font="default" size="100%">Gómez-Arias, Pedro J.</style></author><author><style face="normal" font="default" size="100%">Luque-Fernández, Juan de</style></author><author><style face="normal" font="default" size="100%">Ungar, Benjamin</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, Emma</style></author><author><style face="normal" font="default" size="100%">Ruano, Juan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Non-Invasive Scalp Tape-Strip RNA Sequencing Captures Disease Activity and Treatment-Response Signatures in Alopecia Areata</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Tape-strip RNA sequencing enables non-invasive molecular profiling of inflammatory skin diseases. However, its ability to capture immune activity, disease severity, and treatment response in alopecia areata (AA)—a follicle-centered autoimmune disorder—has not been systematically evaluated in relation to follicular immune activity and treatment response. Objectives To determine whether scalp tape-strip RNA sequencing captures immune pathways associated with disease severity and treatment response in AA, and to assess its concordance with matched scalp biopsies. Methods We analyzed 61 RNA-seq profiles, including 46 scalp tape-strip samples (19 healthy controls, 17 active AA, and 10 post-baricitinib samples—five responders and five non-responders) and 15 lesional scalp biopsies. Nine tape-strip–biopsy pairs were obtained from the same scalp region. Batch-corrected expression data were analyzed using covariate-adjusted linear models and gene set–based enrichment analyses interrogating immune, cytotoxic, and follicular epithelial programs. Results Tape-strip RNA sequencing robustly recapitulated established AA-associated immune signatures, including activation of interferon/JAK–STAT signaling and cytotoxic T/NK cell pathways, together with suppression of follicular epithelial programs. Increasing disease severity was associated with progressive immune activation and epithelial loss. Baricitinib responders showed partial normalization of inflammatory signatures, whereas non-responders retained persistent immune activation, consistent with molecular non-response. Covariate-adjusted models identified treatment response–specific transcriptional changes. Tape-strip and biopsy transcriptomes demonstrated high concordance. Conclusions Scalp tape-strip RNA sequencing captures clinically relevant immune and treatment-responsive molecular signatures in alopecia areata and represents a promising platform for longitudinal immune monitoring and biomarker-driven stratification of treatment response in follicle-centered autoimmune disease.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70293</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70293</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3333</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3333</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ebo, Didier G.</style></author><author><style face="normal" font="default" size="100%">Bahri, Rajia</style></author><author><style face="normal" font="default" size="100%">Eggel, Alexander</style></author><author><style face="normal" font="default" size="100%">Hagendorens, Margo H.</style></author><author><style face="normal" font="default" size="100%">Knol, Edward</style></author><author><style face="normal" font="default" size="100%">Mertens, Christel</style></author><author><style face="normal" font="default" size="100%">Sabato, Vito</style></author><author><style face="normal" font="default" size="100%">Tontini, Chiara</style></author><author><style face="normal" font="default" size="100%">van Houdt, Michel</style></author><author><style face="normal" font="default" size="100%">Elst, Jessy</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Non-Releasers in the Basophil Activation Test: A Roadmap for the Correct Reporting and Interpretation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Flow cytometric analysis of activated basophils, known as the basophil activation test (BAT), is a tool available for the diagnosis of IgE-mediated allergic reactions. Despite its reported clinical utility, around 10%–20% of tested subjects fall into the category of basophil non-releasers, meaning that their basophils fail to degranulate upon IgE-mediated stimulation in vitro. Several factors causing this non-releaser status have been identified, but we currently lack a unified nomenclature to define such inconclusive BAT results and the practical steps to minimize such outcomes. In accordance with the STAndards for the Reporting of Diagnostic accuracy studies (STARD) statement, non-releasers must be reported and considered in the calculation of clinical BAT performance metrics, as failure to do so significantly limits the broader implementation of BAT in routine practice. This review provides an overview of intrinsic and extrinsic factors responsible for the basophil non-releaser phenotype in BAT. Furthermore, it proposes a standardized nomenclature for consistently reporting and integrating inconclusive BAT results in the diagnostic performance metrics and suggests diagnostic algorithms to facilitate their interpretation in clinical practice.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70326</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70326</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1280</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1280</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baumann, R.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Zissler, U. M.</style></author><author><style face="normal" font="default" size="100%">Eyerich, S.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Biedermann, T.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Chaker, A. M.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Garn, H.</style></author><author><style face="normal" font="default" size="100%">Thwaites, R. S.</style></author><author><style face="normal" font="default" size="100%">Togias, A.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author><author><style face="normal" font="default" size="100%">Hansel, T. T.</style></author><author><style face="normal" font="default" size="100%">Jakwerth, C. A.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical Faculty, Institute for Molecular Medicine, Medical School Hamburg (MSH) - Medical University, Hamburg, Germany.&#xD;RWTH Aachen University Hospital, Institute for Occupational, Social and Environmental Medicine, Aachen, Germany.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Center of Allergy and Environment (ZAUM), Technical University and Helmholtz Zentrum Munchen, Munchen, Germany.&#xD;Member of the German Center of Lung Research (DZL) and the Helmholtz I&amp;I Initiative, Munich, Germany.&#xD;National Heart and Lung Institute, Imperial College London, and Royal Brompton and Harefield NHS Trust, London, UK.&#xD;Department of Dermatology and Allergy Biederstein, School of Medicine, Technische Universitat Munchen, Munich, Germany.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Center, Odense Research Centre for Anaphylaxis (ORCA), University of Southern Denmark, Odense, Denmark.&#xD;Department of Otolaryngology, Allergy Section, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Biochemical Pharmacological Center (BPC) - Molecular Diagnostics, Translational Inflammation Research Division &amp; Core Facility for Single Cell Multiomics, Philipps University of Marburg - Medical Faculty, Member of the German Center for Lung Research (DZL), Universities of Giessen and Marburg Lung Center (UGMLC), Marburg, Germany.&#xD;Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.&#xD;Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Noninvasive and minimally invasive techniques for the diagnosis and management of allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1010-1023</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">noninvasive diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33128851</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic diseases of the (upper and lower) airways, the skin and the gastrointestinal tract, are on the rise, resulting in impaired quality of life, decreased productivity, and increased healthcare costs. As allergic diseases are mostly tissue-specific, local sampling methods for respective biomarkers offer the potential for increased sensitivity and specificity. Additionally, local sampling using noninvasive or minimally invasive methods can be cost-effective and well tolerated, which may even be suitable for primary or home care sampling. Non- or minimally invasive local sampling and diagnostics may enable a more thorough endotyping, may help to avoid under- or overdiagnosis, and may provide the possibility to approach precision prevention, due to early diagnosis of these local diseases even before they get systemically manifested and detectable. At the same time, dried blood samples may help to facilitate minimal-invasive primary or home care sampling for classical systemic diagnostic approaches. This EAACI position paper contains a thorough review of the various technologies in allergy diagnosis available on the market, which analytes or biomarkers are employed, and which samples or matrices can be used. Based on this assessment, EAACI position is to drive these developments to efficiently identify allergy and possibly later also viral epidemics and take advantage of comprehensive knowledge to initiate preventions and treatments.</style></abstract><notes><style face="normal" font="default" size="100%">Baumann, Ralf&#xD;Untersmayr, Eva&#xD;Zissler, Ulrich M&#xD;Eyerich, Stefanie&#xD;Adcock, Ian M&#xD;Brockow, Knut&#xD;Biedermann, Tilo&#xD;Ollert, Markus&#xD;Chaker, Adam M&#xD;Pfaar, Oliver&#xD;Garn, Holger&#xD;Thwaites, Ryan S&#xD;Togias, Alkis&#xD;Kowalski, Marek L&#xD;Hansel, Trevor T&#xD;Jakwerth, Constanze A&#xD;Schmidt-Weber, Carsten B&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1010-1023. doi: 10.1111/all.14645.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33128851</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14645</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1027</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1027</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wechsler, J. B.</style></author><author><style face="normal" font="default" size="100%">Ackerman, S. J.</style></author><author><style face="normal" font="default" size="100%">Chehade, M.</style></author><author><style face="normal" font="default" size="100%">Amsden, K.</style></author><author><style face="normal" font="default" size="100%">Riffle, M. E.</style></author><author><style face="normal" font="default" size="100%">Wang, M. Y.</style></author><author><style face="normal" font="default" size="100%">Du, J.</style></author><author><style face="normal" font="default" size="100%">Kleinjan, M. L.</style></author><author><style face="normal" font="default" size="100%">Alumkal, P.</style></author><author><style face="normal" font="default" size="100%">Gray, E.</style></author><author><style face="normal" font="default" size="100%">Kim, K. A.</style></author><author><style face="normal" font="default" size="100%">Wershil, B. K.</style></author><author><style face="normal" font="default" size="100%">Kagalwalla, A. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Northwestern University Feinberg School of Medicine, Chicago, IL, USA.&#xD;Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Eosinophilic Gastrointestinal Diseases Program, Ann &amp; Robert H. Lurie Children&apos;s Hospital of Chicago, Chicago, IL, USA.&#xD;Department of Biochemistry and Molecular Genetics, University of Illinois-Chicago, Chicago, IL, USA.&#xD;Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Preventive Medicine, Feinberg School of Medicine, Chicago, IL, USA.&#xD;John H. Stroger Hospital of Cook County, Chicago, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Noninvasive biomarkers identify eosinophilic esophagitis: A prospective longitudinal study in children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3755-3765</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/04/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophil-Derived Neurotoxin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">noninvasive</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33905577</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Esophageal histology is critical for diagnosis and surveillance of disease activity in eosinophilic esophagitis (EoE). A validated noninvasive biomarker has not been identified. We aimed to determine the utility of blood and urine eosinophil-associated proteins to diagnose EoE and predict esophageal eosinophilia. METHODS: Blood and urine were collected from children undergoing endoscopy with biopsy. Absolute eosinophil count (AEC), plasma eosinophil-derived neurotoxin (EDN), eosinophil cationic protein (ECP), major basic protein-1 (MBP-1), galectin-10 (CLC/GAL-10), Eotaxin-2 and Eotaxin-3, and urine osteopontin (OPN) and matrix metalloproteinase-9 (MMP-9) were determined. Differences were assessed between EoE and control, and with treatment response. The capacity to predict EoE diagnosis and esophageal eosinophil counts was assessed. RESULTS: Of 183 specimens were collected from 56 EoE patients and 15 non-EoE controls with symptoms of esophageal dysfunction; 33 EoE patients had paired pre- and post-treatment specimens. Plasma (CLC/GAL-10, ECP, EDN, Eotaxin-3, MBP-1) and urine (OPN) biomarkers were increased in EoE compared to control. A panel comprising CLC/GAL-10, Eotaxin-3, ECP, EDN, MBP-1, and AEC was superior to AEC alone in distinguishing EoE from control. AEC, CLC/GAL-10, ECP, and MBP-1 were significantly decreased in patients with esophageal eosinophil counts &lt;15/hpf in response to treatment. AEC, CLC/GAL-10, ECP, EDN, OPN, and MBP-1 each predicted esophageal eosinophil counts utilizing mixed models controlled for age, gender, treatment, and atopy; AEC combined with MBP-1 best predicted the counts. CONCLUSIONS: We identified novel panels of eosinophil-associated proteins that along with AEC are superior to AEC alone in distinguishing EoE from controls and predicting esophageal eosinophil counts.</style></abstract><notes><style face="normal" font="default" size="100%">Wechsler, Joshua B&#xD;Ackerman, Steven J&#xD;Chehade, Mirna&#xD;Amsden, Katie&#xD;Riffle, Mary E&#xD;Wang, Ming-Yu&#xD;Du, Jian&#xD;Kleinjan, Matt L&#xD;Alumkal, Preeth&#xD;Gray, Elizabeth&#xD;Kim, Kwang-Youn A&#xD;Wershil, Barry K&#xD;Kagalwalla, Amir F&#xD;eng&#xD;U54 AI117804/AI/NIAID NIH HHS/&#xD;K08 DK097721/DK/NIDDK NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3755-3765. doi: 10.1111/all.14874. Epub 2021 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33905577</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9017580</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14874</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>482</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">482</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ackland, J.</style></author><author><style face="normal" font="default" size="100%">Barber, C.</style></author><author><style face="normal" font="default" size="100%">Heinson, A.</style></author><author><style face="normal" font="default" size="100%">Azim, A.</style></author><author><style face="normal" font="default" size="100%">Cleary, D. W.</style></author><author><style face="normal" font="default" size="100%">Christodoulides, M.</style></author><author><style face="normal" font="default" size="100%">Kurukulaaratchy, R. J.</style></author><author><style face="normal" font="default" size="100%">Howarth, P.</style></author><author><style face="normal" font="default" size="100%">Wilkinson, T. M. A.</style></author><author><style face="normal" font="default" size="100%">Staples, K. J.</style></author><author><style face="normal" font="default" size="100%">Watch study investigators</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton, UK.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Wessex Investigational Sciences Hub, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nontypeable Haemophilus influenzae infection of pulmonary macrophages drives neutrophilic inflammation in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2961-2973</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/05/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">*Haemophilus Infections/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Haemophilus influenzae</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-8</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages, Alveolar</style></keyword><keyword><style face="normal" font="default" size="100%">NTHi</style></keyword><keyword><style face="normal" font="default" size="100%">T17 responses</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">macrophage</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophil</style></keyword><keyword><style face="normal" font="default" size="100%">GSK between April 2014 and October 2017. RJK received a nonpromotional grant</style></keyword><keyword><style face="normal" font="default" size="100%">( pound35,000) from Novartis to assist in funding initial database support for the</style></keyword><keyword><style face="normal" font="default" size="100%">WATCH study. PH reports that he is an employee of GSK. TW reports grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from AstraZeneca, personal fees and others from MMH, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from GSK, personal fees from BI, and grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Synairgen, outside the submitted work. KS reports grants from AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. The remaining authors declare that the research was</style></keyword><keyword><style face="normal" font="default" size="100%">conducted in the absence of any commercial or financial relationships that could</style></keyword><keyword><style face="normal" font="default" size="100%">be construed as a potential conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35570583</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Nontypeable Haemophilus influenzae (NTHi) is a respiratory tract pathobiont that chronically colonizes the airways of asthma patients and is associated with severe, neutrophilic disease phenotypes. The mechanism of NTHi airway persistence is not well understood, but accumulating evidence suggests NTHi can persist within host airway immune cells such as macrophages. We hypothesized that NTHi infection of pulmonary macrophages drives neutrophilic inflammation in severe asthma. METHODS: Bronchoalveolar lavage (BAL) samples from 25 severe asthma patients were assessed by fluorescence in situ hybridisation to quantify NTHi presence. Weighted gene correlation network analysis (WGCNA) was performed on RNASeq data from NTHi-infected monocyte-derived macrophages to identify transcriptomic networks associated with NTHi infection. RESULTS: NTHi was detected in 56% of BAL samples (NTHi+) and was associated with longer asthma duration (34 vs 22.5 years, p = .0436) and higher sputum neutrophil proportion (67% vs 25%, p = .0462). WGCNA identified a transcriptomic network of immune-related macrophage genes significantly associated with NTHi infection, including upregulation of T17 inflammatory mediators and neutrophil chemoattractants IL1B, IL8, IL23 and CCL20 (all p &lt; .05). Macrophage network genes SGPP2 (p = .0221), IL1B (p = .0014) and GBP1 (p = .0477) were more highly expressed in NTHi+ BAL and moderately correlated with asthma duration (IL1B; rho = 0.41, p = .041) and lower prebronchodilator FEV1/FVC% (GBP1; rho = -0.43, p = .046 and IL1B; rho = -0.42, p = .055). CONCLUSIONS: NTHi persistence with pulmonary macrophages may contribute to chronic airway inflammation and T17 responses in severe asthma, which can lead to decreased lung function and reduced steroid responsiveness. Identifying therapeutic strategies to reduce the burden of NTHi in asthma could improve patient outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Ackland, Jodie&#xD;Barber, Clair&#xD;Heinson, Ashley&#xD;Azim, Adnan&#xD;Cleary, David W&#xD;Christodoulides, Myron&#xD;Kurukulaaratchy, Ramesh J&#xD;Howarth, Peter&#xD;Wilkinson, Tom M A&#xD;Staples, Karl J&#xD;eng&#xD;DH_/Department of Health/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):2961-2973. doi: 10.1111/all.15375. Epub 2022 May 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35570583</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9796932</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15375</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3117</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3117</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Harama, D.</style></author><author><style face="normal" font="default" size="100%">Saito-Abe, M.</style></author><author><style face="normal" font="default" size="100%">Pak, K.</style></author><author><style face="normal" font="default" size="100%">Iwamoto, S.</style></author><author><style face="normal" font="default" size="100%">Sato, M.</style></author><author><style face="normal" font="default" size="100%">Miyaji, Y.</style></author><author><style face="normal" font="default" size="100%">Sakamoto, K.</style></author><author><style face="normal" font="default" size="100%">Mezawa, H.</style></author><author><style face="normal" font="default" size="100%">Nishizato, M.</style></author><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Kumasaka, N.</style></author><author><style face="normal" font="default" size="100%">Ohya, Y.</style></author><author><style face="normal" font="default" size="100%">Fukami, M.</style></author><author><style face="normal" font="default" size="100%">Yamamoto-Hanada, K.</style></author><author><style face="normal" font="default" size="100%">Japan, Environment</style></author><author><style face="normal" font="default" size="100%">Children&apos;s Study, Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Center, National Center for Child Health and Development, Tokyo, Japan.&#xD;Medical Support Center for the Japan Environment and Children&apos;s Study, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Division of Biostatistics, Department of Data Management, Center for Clinical Research, National Center for Child Health and Development, Tokyo, Japan.&#xD;Department of Occupational and Environmental Health, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Aichi, Japan.&#xD;Division of General Allergy, Bantane Hospital, Fujita Health University, Toyoake, Aichi, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Not All Rhinitis Follows the Atopic March: Early-Life Risk Factors and Implications of Infectious Disease Across Three Phenotypes in JECS Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergic march</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41121575</style></accession-num><notes><style face="normal" font="default" size="100%">Harama, Daisuke&#xD;Saito-Abe, Mayako&#xD;Pak, Kyongsun&#xD;Iwamoto, Shintaro&#xD;Sato, Miori&#xD;Miyaji, Yumiko&#xD;Sakamoto, Kei&#xD;Mezawa, Hidetoshi&#xD;Nishizato, Minaho&#xD;Yang, Limin&#xD;Kumasaka, Natsuhiko&#xD;Ohya, Yukihiro&#xD;Fukami, Maki&#xD;Yamamoto-Hanada, Kiwako&#xD;(JECS)&#xD;eng&#xD;Ministry of the Environment, Government of Japan/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct 21. doi: 10.1111/all.70103.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41121575</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70103</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2699</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2699</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benamar, M.</style></author><author><style face="normal" font="default" size="100%">Lai, P. S.</style></author><author><style face="normal" font="default" size="100%">Huang, C. Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Q.</style></author><author><style face="normal" font="default" size="100%">Oktelik, F. B.</style></author><author><style face="normal" font="default" size="100%">Contini, P.</style></author><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Okin, D.</style></author><author><style face="normal" font="default" size="100%">Crestani, E.</style></author><author><style face="normal" font="default" size="100%">Fong, J.</style></author><author><style face="normal" font="default" size="100%">Fion, T. M. C.</style></author><author><style face="normal" font="default" size="100%">Gokbak, M. N.</style></author><author><style face="normal" font="default" size="100%">Harb, H.</style></author><author><style face="normal" font="default" size="100%">Phipatanakul, W.</style></author><author><style face="normal" font="default" size="100%">Marri, L.</style></author><author><style face="normal" font="default" size="100%">Vassallo, C.</style></author><author><style face="normal" font="default" size="100%">Guastalla, A.</style></author><author><style face="normal" font="default" size="100%">Kim, M.</style></author><author><style face="normal" font="default" size="100%">Sui, H. Y.</style></author><author><style face="normal" font="default" size="100%">Berra, L.</style></author><author><style face="normal" font="default" size="100%">Goldberg, M. B.</style></author><author><style face="normal" font="default" size="100%">Angelini, C.</style></author><author><style face="normal" font="default" size="100%">De Palma, R.</style></author><author><style face="normal" font="default" size="100%">Chatila, T. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology, Boston Children&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Internal Medicine, Unit of Clinical Immunology and Translational Medicine, University of Genova, Genova, Italy.&#xD;Clinical Immunology Division, IRCCS-San Martino Hospital, Genoa, Italy.&#xD;Institute for Medical Microbiology and Virology, Technical University Dresden, Dresden, Germany.&#xD;Department of Anaesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Infectious Diseases Division, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Department of Microbiology, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Istituto per le Applicazioni del Calcolo &quot;M. Picone&quot;, Consiglio Nazionale delle Ricerche, Naples, Italy.&#xD;CNR-Institute of Biomolecular Chemistry (IBC), Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Notch4 regulatory T cells and SARS-CoV-2 viremia shape COVID19 survival outcome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">557-569</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/10/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/immunology/mortality/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Viremia/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptor, Notch4/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroptosis/drug effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza A Virus, H1N1 Subtype</style></keyword><keyword><style face="normal" font="default" size="100%">Covid19</style></keyword><keyword><style face="normal" font="default" size="100%">Notch4</style></keyword><keyword><style face="normal" font="default" size="100%">pyroptosis</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cells</style></keyword><keyword><style face="normal" font="default" size="100%">survival</style></keyword><keyword><style face="normal" font="default" size="100%">viremia</style></keyword><keyword><style face="normal" font="default" size="100%">inventors on provisional patent application US 63/038,186 titled &quot;Methods and</style></keyword><keyword><style face="normal" font="default" size="100%">Compositions for treating coronavirus infectious disease&quot;. H.H. and T.A.C. are</style></keyword><keyword><style face="normal" font="default" size="100%">co-founders of and hold equity in Alcea Therapeutics.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39361431</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Immune dysregulation and SARS-CoV-2 plasma viremia have been implicated in fatal COVID-19 disease. However, how these two factors interact to shape disease outcomes is unclear. METHODS: We carried out viral and immunological phenotyping on a prospective cohort of 280 patients with COVID-19 presenting to acute care hospitals in Boston, Massachusetts and Genoa, Italy between June 1, 2020 and February 8, 2022. Disease severity, mortality, plasma viremia, and immune dysregulation were assessed. A mouse model of lethal H1N1 influenza infection was used to analyze the therapeutic potential of Notch4 and pyroptosis inhibition in disease outcome. RESULTS: Stratifying patients based on %Notch4(+) Treg cells and/or the presence of plasma viremia identified four subgroups with different clinical trajectories and immune phenotypes. Patients with both high %Notch4(+) Treg cells and viremia suffered the most disease severity and 90-day mortality compared to the other groups even after adjusting for baseline comorbidities. Increased Notch4 and plasma viremia impacted different arms of the immune response in SARS-CoV-2 infection. Increased Notch4 was associated with decreased Treg cell amphiregulin expression and suppressive function whereas plasma viremia was associated with increased monocyte cell pyroptosis. Combinatorial therapies using Notch4 blockade and pyroptosis inhibition induced stepwise protection against mortality in a mouse model of lethal H1N1 influenza infection. CONCLUSIONS: The clinical trajectory and survival outcome in hospitalized patients with COVID-19 is predicated on two cardinal factors in disease pathogenesis: viremia and Notch4(+) Treg cells. Intervention strategies aimed at resetting the immune dysregulation in COVID-19 by antagonizing Notch4 and pyroptosis may be effective in severe cases of viral lung infection.</style></abstract><notes><style face="normal" font="default" size="100%">Benamar, Mehdi&#xD;Lai, Peggy S&#xD;Huang, Ching-Ying&#xD;Chen, Qian&#xD;Oktelik, Fatma Betul&#xD;Contini, Paola&#xD;Wang, Muyun&#xD;Okin, Daniel&#xD;Crestani, Elena&#xD;Fong, Jason&#xD;Fion, Tsz Man Chan&#xD;Gokbak, Merve Nida&#xD;Harb, Hani&#xD;Phipatanakul, Wanda&#xD;Marri, Luca&#xD;Vassallo, Chiara&#xD;Guastalla, Andrea&#xD;Kim, Minsik&#xD;Sui, Hui-Yu&#xD;Berra, Lorenzo&#xD;Goldberg, Marcia B&#xD;Angelini, Claudia&#xD;De Palma, Raffaele&#xD;Chatila, Talal A&#xD;eng&#xD;UL1 TR002541/TR/NCATS NIH HHS/&#xD;Deutsche Gesellschaft fur Suchtforschung und Suchttherapie/&#xD;R01 AI115699/AI/NIAID NIH HHS/&#xD;R01 AI065617/AI/NIAID NIH HHS/&#xD;Boston Children&apos;s Hospital/&#xD;NH/NIH HHS/&#xD;R01 AI144119/AI/NIAID NIH HHS/&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):557-569. doi: 10.1111/all.16333. Epub 2024 Oct 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39361431</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11805648</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16333</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>964</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">964</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moya, B.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain.&#xD;Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Division of Respirology, Department of Medicine, McMaster University, Hamilton &amp; Firestone Institute for Respiratory Health, St Joseph&apos;s Healthcare, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Notch4, uncovering an immunomodulator in allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3852-3854</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch4</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Notch4 receptor</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 cell</style></keyword><keyword><style face="normal" font="default" size="100%">Treg cell</style></keyword><keyword><style face="normal" font="default" size="100%">airway inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34050948</style></accession-num><notes><style face="normal" font="default" size="100%">Moya, Beatriz&#xD;Mukherjee, Manali&#xD;Nair, Parameswaran&#xD;eng&#xD;CIHR/Canada&#xD;Comment&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3852-3854. doi: 10.1111/all.14968. Epub 2021 Jun 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34050948</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14968</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1904</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1904</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moya, B.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain.&#xD;Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Division of Respirology, Department of Medicine, McMaster University, Hamilton &amp; Firestone Institute for Respiratory Health, St Joseph&apos;s Healthcare, Hamilton, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Notch4, uncovering an immunomodulator in allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3852-3854</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Notch4</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Notch4 receptor</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 cell</style></keyword><keyword><style face="normal" font="default" size="100%">Treg cell</style></keyword><keyword><style face="normal" font="default" size="100%">airway inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34050948</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Asthma is a chronic inflammatorydisease of the airwaysthat causesbronchial hyperreactivity, mucus overproduction, airwayremodelling and narrowing. Allergic asthmatic patients generally present a predisposition toward Thelper (Th) 2 inflammation that is maintained by allergen-driven innate factors and downstream activation of Th2 cells. In this regard, Notch signalling activates the key Th2 transcription factor Gata-3.In fact, Notch is considered as a master regulator of Th cells to terminally differentiate into Th1, Th2, Th17 lineages by directly inducing the respective transcription factors and cytokines.1 The latest findings by Harb et al., further report how Notch signalling enables an inflammatory response in the allergic airways by altering T-regulatory (Treg) cells into effector Th2 and Th17 cells.2</style></abstract><notes><style face="normal" font="default" size="100%">Moya, Beatriz&#xD;Mukherjee, Manali&#xD;Nair, Parameswaran&#xD;eng&#xD;CIHR/Canada&#xD;Comment&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3852-3854. doi: 10.1111/all.14968. Epub 2021 Jun 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34050948</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14968</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>632</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">632</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bonini, S.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Translational Pharmacology, Italian National Research Council, Rome, Italy.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Philipps-Universitat, Marburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Novel adaptive design for allergen immunotherapy clinical trials</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1950-1951</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/01/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">adaptive design</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">clinical development programs</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory aspects</style></keyword><keyword><style face="normal" font="default" size="100%">trial-design</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35088408</style></accession-num><notes><style face="normal" font="default" size="100%">Bonini, Sergio&#xD;Pfaar, Oliver&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):1950-1951. doi: 10.1111/all.15231.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35088408</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15231</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3268</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3268</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fang, Ruyu</style></author><author><style face="normal" font="default" size="100%">Yang, Jing</style></author><author><style face="normal" font="default" size="100%">Liang, Yifan</style></author><author><style face="normal" font="default" size="100%">Pang, Jiarui</style></author><author><style face="normal" font="default" size="100%">Zhao, Yupeng</style></author><author><style face="normal" font="default" size="100%">Han, Xiangpeng</style></author><author><style face="normal" font="default" size="100%">Wang, Yu</style></author><author><style face="normal" font="default" size="100%">Xu, Zhenlin</style></author><author><style face="normal" font="default" size="100%">Wang, Hong</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A Novel Alpaca-Derived Polyclonal Antibody Enables Highly Sensitive Detection of Gliadin in Food</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70255</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70255</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1182</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1182</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agyemang, A.</style></author><author><style face="normal" font="default" size="100%">Suprun, M.</style></author><author><style face="normal" font="default" size="100%">Suarez-Farinas, M.</style></author><author><style face="normal" font="default" size="100%">Boina, F.</style></author><author><style face="normal" font="default" size="100%">Arif-Lusson, R.</style></author><author><style face="normal" font="default" size="100%">Grishin, A.</style></author><author><style face="normal" font="default" size="100%">Busnel, J. M.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Beckman Coulter Life Sciences Research, Marseille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A novel approach to the basophil activation test for characterizing peanut allergic patients in the clinical setting</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2257-2259</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Basophil Degranulation Test</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33506502</style></accession-num><notes><style face="normal" font="default" size="100%">Agyemang, Amanda&#xD;Suprun, Maria&#xD;Suarez-Farinas, Mayte&#xD;Boina, Faouria&#xD;Arif-Lusson, Rihane&#xD;Grishin, Alexander&#xD;Busnel, Jean-Marc&#xD;Sampson, Hugh A&#xD;eng&#xD;T32GM062754/NIH/NIGMS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2257-2259. doi: 10.1111/all.14752. Epub 2021 Feb 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33506502</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14752</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3171</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3171</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bunyavanich, S.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Berin, M. C.</style></author><author><style face="normal" font="default" size="100%">Eggel, A.</style></author><author><style face="normal" font="default" size="100%">Patil, S. U.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Lopez, J. F.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy/Immunology, Department of Pediatrics, Department of Genetics &amp; Genomic Sciences, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Department for BioMedical Research, University of Bern, Bern, Switzerland.&#xD;Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland.&#xD;Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Frankland and Kay Allergy Centre, UK NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Division of Pediatric Allergy/Immunology; Icahn School of Medicine at Mount Sinai, Jaffe Food Allergy Institute, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Novel Biomarkers and Diagnostic Tools in Food Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">epitope profiling</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy diagnostics</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell activation test</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 5</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41194345</style></accession-num><abstract><style face="normal" font="default" size="100%">The double-blind placebo-controlled oral food challenge (DBPCFC) has been the &quot;gold standard&quot; for diagnosing IgE-mediated food allergy for the past 50 years. Despite tremendous strides in our understanding of basic mechanisms and clinical features of food allergy, we remain dependent on refinements of old technologies, i.e., skin tests and serum IgE measurements, to complement clinical history in making an accurate diagnosis of food allergies. However, recent technical advances in two effector cell assays, i.e., the basophil and mast cell activation tests, may soon bring these diagnostic biomarkers to the clinic. In addition, new advances in antibody assays, T-cell assays, transcriptomics, and metabolomics in conjunction with machine learning and artificial intelligence may soon enable us to diagnose food allergy and accurately monitor immunotherapeutic outcomes without the need for an oral food challenge.</style></abstract><notes><style face="normal" font="default" size="100%">Bunyavanich, Supinda&#xD;Akdis, Mubeccel&#xD;Berin, M Cecilia&#xD;Eggel, Alexander&#xD;Patil, Sarita U&#xD;Shamji, Mohamed H&#xD;Lopez, Juan-Felipe&#xD;Sampson, Hugh A&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Nov 5. doi: 10.1111/all.70133.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41194345</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70133</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3280</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3280</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Möller, Constantin</style></author><author><style face="normal" font="default" size="100%">Hambach, Julia</style></author><author><style face="normal" font="default" size="100%">Schaffrath, Alessa Zoe</style></author><author><style face="normal" font="default" size="100%">Eden, Thomas</style></author><author><style face="normal" font="default" size="100%">Cichutek, Sophia</style></author><author><style face="normal" font="default" size="100%">Gebhardt, Anna Josephine</style></author><author><style face="normal" font="default" size="100%">Tode, Natalie</style></author><author><style face="normal" font="default" size="100%">Maitschke-Rajasekharan, Ronald</style></author><author><style face="normal" font="default" size="100%">Lewe, Philipp</style></author><author><style face="normal" font="default" size="100%">Qi, Sharon</style></author><author><style face="normal" font="default" size="100%">Witt, Susanne</style></author><author><style face="normal" font="default" size="100%">Eggers, Marie</style></author><author><style face="normal" font="default" size="100%">Tomas, Nicola M.</style></author><author><style face="normal" font="default" size="100%">Haag, Friedrich</style></author><author><style face="normal" font="default" size="100%">Koch-Nolte, Friedrich</style></author><author><style face="normal" font="default" size="100%">Fehse, Boris</style></author><author><style face="normal" font="default" size="100%">Riecken, Kristoffer</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Novel Bispecific Engagers Targeting the CεmX Domain of mIgE-Expressing Cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background IgE-associated allergic diseases, affecting approximately 30% of the global population, are a major health burden. Standard treatments, including pharmacotherapy and allergen immunotherapy (AIT), have limitations such as adverse effects, insufficient symptom relief and long treatment durations. Methods In this study, we developed and evaluated a bispecific T-cell engager (TCE) and a half-life extended (HLE) bispecific natural killer (NK) cell engager (NKCE) targeting IgE-producing cells, to offer novel, potentially curative therapeutic options. The TCE and HLE-NKCE constructs were designed to target the CεmX domain of membrane-bound IgE (mIgE) and engage T cells and NK cells, respectively. Their efficacy was assessed through in vitro luciferase-based cytotoxicity assays using Ramos and U266 B-cell lines expressing mIgE as target cells, and primary human immune effector cells and the NK-cell line NK-92 as effector cells. Additional characterisation of the constructs was performed using flow cytometry. Results Both TCE and HLE-NKCE specifically mediated killing of CεmX-expressing cells in a dose- and effector-to-target (E:T) ratio-dependent manner. The TCE demonstrated robust activity even at low antigen densities and concentrations as low as 1 ng/mL (18 pM). The HLE-NKCE effectively mediated killing in the presence of human serum albumin, suggesting functionality in physiological conditions. T- and NK-cell activation was observed only in the presence of target cells and TCE. Conclusion Our novel anti-CεmX TCE and HLE-NKCE effectively target and eliminate mIgE-expressing cells in vitro. Although further investigation is needed, our bispecific engagers are promising off-the-shelf therapeutics for the treatment of IgE-associated allergic diseases.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70236</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70236</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3024</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3024</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yamada, S.</style></author><author><style face="normal" font="default" size="100%">Maruoka, S.</style></author><author><style face="normal" font="default" size="100%">Toyoshima, S.</style></author><author><style face="normal" font="default" size="100%">Kurosawa, Y.</style></author><author><style face="normal" font="default" size="100%">Ozoe, R.</style></author><author><style face="normal" font="default" size="100%">Kozu, Y.</style></author><author><style face="normal" font="default" size="100%">Mizumura, K.</style></author><author><style face="normal" font="default" size="100%">Okayama, Y.</style></author><author><style face="normal" font="default" size="100%">Ito, R.</style></author><author><style face="normal" font="default" size="100%">Gon, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.&#xD;Center for Allergy, Nihon University Itabashi Hospital, Tokyo, Japan.&#xD;Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo, Japan.&#xD;Department of Allergy, Internal Medicine, Misato Kenwa Hospital, Saitama, Japan.&#xD;Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.&#xD;Advanced Medical Science Research Center, Gunma Paz University, Graduate School of Health Sciences, Takasaki, Gunma, Japan.&#xD;Central Institute for Experimental Medicine and Life Science (CIEM), Kawasaki, Kanagawa, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Novel Humanized Mouse Model for Steroid-Resistant Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">256-259</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/08/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacology and pharmacogenomics</style></keyword><keyword><style face="normal" font="default" size="100%">Y recently was a speaker and/or adviser for and/or has received research funding</style></keyword><keyword><style face="normal" font="default" size="100%">from AbbVie, Animal Allergy Clinical Laboratories Inc., AstraZeneca, Kyorin,</style></keyword><keyword><style face="normal" font="default" size="100%">Nissan Chemical Co., Novartis, Ono Pharma, Sanofi, Seikagaku Co., Thermo Fisher</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific K.K., and Torii Pharmaceutical Co. Ltd. Gon Y has received research</style></keyword><keyword><style face="normal" font="default" size="100%">funding from AstraZeneca K.K.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40847683</style></accession-num><notes><style face="normal" font="default" size="100%">Yamada, Shiho&#xD;Maruoka, Shuichiro&#xD;Toyoshima, Shota&#xD;Kurosawa, Yusuke&#xD;Ozoe, Ryosuke&#xD;Kozu, Yutaka&#xD;Mizumura, Kenji&#xD;Okayama, Yoshimichi&#xD;Ito, Ryoji&#xD;Gon, Yasuhiro&#xD;eng&#xD;JP24K10563/Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):256-259. doi: 10.1111/all.70012. Epub 2025 Aug 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40847683</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773663</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70012</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2276</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2276</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nunomura, S.</style></author><author><style face="normal" font="default" size="100%">Ito, R.</style></author><author><style face="normal" font="default" size="100%">Nanri, Y.</style></author><author><style face="normal" font="default" size="100%">Ohno, Y.</style></author><author><style face="normal" font="default" size="100%">Honda, Y.</style></author><author><style face="normal" font="default" size="100%">Takedomi, H.</style></author><author><style face="normal" font="default" size="100%">Izuhara, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.&#xD;Central Institute for Experimental Animals, Kawasaki, Kanagawa, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Novel mechanisms by which benralizumab suppresses IgE expression in human B cells in humanized mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3271-3273</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/10/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37814937</style></accession-num><notes><style face="normal" font="default" size="100%">Nunomura, Satoshi&#xD;Ito, Ryoji&#xD;Nanri, Yasuhiro&#xD;Ohno, Yusuke&#xD;Honda, Yuko&#xD;Takedomi, Hironobu&#xD;Izuhara, Kenji&#xD;eng&#xD;AstraZeneca/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3271-3273. doi: 10.1111/all.15914. Epub 2023 Oct 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37814937</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15914</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1388</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1388</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cao, M.</style></author><author><style face="normal" font="default" size="100%">Han, X.</style></author><author><style face="normal" font="default" size="100%">Lu, C.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Xu, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Zhou, B.</style></author><author><style face="normal" font="default" size="100%">Zhang, C.</style></author><author><style face="normal" font="default" size="100%">Yu, C.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Wei, J. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Division of Clinical Pharmacology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.&#xD;Institute of Advanced Materials (IAM), Key Laboratory of Flexible Electronics (KLOFE), Nanjing Tech University (NanjingTech), Nanjing, China.&#xD;Precision Medicine Center, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A novel method for precise detection of allergen-specific IgE via immobilizing His-tagged allergens to paper-based device</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">567-571</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32716075</style></accession-num><notes><style face="normal" font="default" size="100%">Cao, Mengda&#xD;Han, Xisi&#xD;Lu, Chen&#xD;Wang, Yujie&#xD;Xu, Zhiqiang&#xD;Wang, Shuangxi&#xD;Zhou, Bicong&#xD;Zhang, Chengwu&#xD;Yu, Changmin&#xD;Li, Lin&#xD;Wei, Ji-Fu&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):567-571. doi: 10.1111/all.14500. Epub 2020 Aug 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32716075</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14500</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2971</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2971</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jeebhay, M. F.</style></author><author><style face="normal" font="default" size="100%">Suojalehto, H.</style></author><author><style face="normal" font="default" size="100%">Tarlo, S. M.</style></author><author><style face="normal" font="default" size="100%">Suarthana, E.</style></author><author><style face="normal" font="default" size="100%">Cullinan, P.</style></author><author><style face="normal" font="default" size="100%">Lindstrom, I.</style></author><author><style face="normal" font="default" size="100%">Mason, P.</style></author><author><style face="normal" font="default" size="100%">Munoz, X.</style></author><author><style face="normal" font="default" size="100%">Raulf, M.</style></author><author><style face="normal" font="default" size="100%">Valverde, M.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Henneberger, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Occupational Medicine Division and Centre for Environmental &amp; Occupational Health Research, University of Cape Town, Cape Town, South Africa.&#xD;Occupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland.&#xD;University of Toronto, Department of Medicine and Department of Public Health Sciences, University Health Network, Toronto Western Hospital, Toronto, Canada.&#xD;Research Institute of the McGill University Health Center, Montreal, Canada.&#xD;London, UK.&#xD;Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.&#xD;Pulmonology Service Hospital Vall D&apos;hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.&#xD;Department of Allergology/Immunology, Institute of Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-University Bochum, Germany.&#xD;Allergy Department, Fundacion Jimenez Diaz and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Poland.&#xD;Respiratory Health Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, West, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Novel Questionnaire and Algorithm for Work-Related Asthma Screening and Surveillance: An EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3260-3273</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/07/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma, Occupational/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Mass Screening/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Occupational Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Population Surveillance</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">algorithm</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">surveillance</style></keyword><keyword><style face="normal" font="default" size="100%">work-related</style></keyword><keyword><style face="normal" font="default" size="100%">the Ontario Workplace Safety and Insurance Board (WSIB) and the WSIB appeals</style></keyword><keyword><style face="normal" font="default" size="100%">tribunal. She has also received research funding from WSIB. The remaining authors</style></keyword><keyword><style face="normal" font="default" size="100%">declare no conflicts of interest in relation to this work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40682334</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Work-related exposures contribute to one in six new-onset adult asthma cases and exacerbation of one in five existing cases, which together are termed &apos;work-related asthma&apos; (WRA). A valid and standardized WRA questionnaire is needed for workplace surveillance and epidemiological studies. This project aimed to review evidence on WRA questionnaires and algorithms to propose a standardized instrument. METHODS: A scoping review was conducted using PubMed, Embase, and Cochrane databases up to March 2021. Search terms focused on asthma, occupational diseases, questionnaires, surveys, and algorithms. High-quality studies were identified and data extracted on instrument construction, validation, and performance. Common questions were used to develop a questionnaire and algorithm for detecting suspected WRA. RESULTS: Six studies were included. The final WRA questionnaire consists of eight questions on general asthma symptoms, diagnosis, and medication; four on WRA symptoms; and two on work-related ocular-nasal symptoms. The algorithm calculates a WRA total score (WRATS) based on the general asthma and work-related symptoms. A score of &gt;/= 1 triggers a referral for further evaluation. CONCLUSION: This is the first WRA questionnaire based on validated questionnaires. Evaluation of its performance and validation in diverse geographic and occupational settings are needed for further refinement and translation for broader applications.</style></abstract><notes><style face="normal" font="default" size="100%">Jeebhay, Mohamed F&#xD;Suojalehto, Hille&#xD;Tarlo, Susan M&#xD;Suarthana, Eva&#xD;Cullinan, Paul&#xD;Lindstrom, Irmeli&#xD;Mason, Paola&#xD;Munoz, Xavier&#xD;Raulf, Monika&#xD;Valverde, Marcela&#xD;Walusiak-Skorupa, Jolanta&#xD;Henneberger, Paul&#xD;eng&#xD;EAACI/&#xD;Scoping Review&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3260-3273. doi: 10.1111/all.16647. Epub 2025 Jul 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40682334</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666758</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16647</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2606</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2606</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khalmuratova, R.</style></author><author><style face="normal" font="default" size="100%">Ryu, J. S.</style></author><author><style face="normal" font="default" size="100%">Hwang, J. H.</style></author><author><style face="normal" font="default" size="100%">Kim, Y. S.</style></author><author><style face="normal" font="default" size="100%">Lim, S.</style></author><author><style face="normal" font="default" size="100%">Mo, J. H.</style></author><author><style face="normal" font="default" size="100%">Kim, J. Y.</style></author><author><style face="normal" font="default" size="100%">Shin, H. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Obstructive Upper airway Research (OUaR) Laboratory, Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea.&#xD;Ischemic Hypoxia Disease Institute, Seoul National University Medical Research Center, Seoul, Korea.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea.&#xD;Department of Biomedical Informatics, College of Medicine, Konyang University, Daejeon, Korea.&#xD;Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea.&#xD;Sensory Organ Research Institute, Seoul National University Medical Research Center, Seoul, Korea.&#xD;Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Dankook University College of Medicine, Cheonan, Korea.&#xD;Beckman Laser Institute Korea, Dankook University College of Medicine, Cheonan, Korea.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">NRP1 antagonism as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3095-3107</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/08/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Neuropilin-1/metabolism/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">neuropilin-1</style></keyword><keyword><style face="normal" font="default" size="100%">upper airway inflammatory diseases</style></keyword><keyword><style face="normal" font="default" size="100%">vascular endothelial growth factor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39166395</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Neuropilin-1 (NRP1) is expressed on the surface epithelium of respiratory tract and immune cells, demonstrating its possible function in regulating the immune response in airway disease. However, its role in patient with chronic rhinosinusitis (CRS) remains unknown. This study aimed to elucidate the role of NRP1 in CRS with nasal polyps (CRSwNP). METHODS: Sinonasal biopsy specimens were immunohistochemically stained to investigate NRP1 expression. Double immunofluorescence, immunoblotting, and real-time polymerase chain reaction were performed to evaluate NRP1 in primary human nasal epithelial cells (hNECs). An NRP1 inhibitor was administered to a murine nasal polyp (NP) model. RESULTS: NRP1 was highly expressed in the epithelium in patients with CRSwNP compared to nasal tissue from controls and CRS without NP patients. NRP1 and vascular endothelial growth factor were upregulated in hNECs under hypoxia. Treatment with NRP1 inhibitor (EG00229) reduced the secretion of interleukin (IL)-1beta, IL-6, IL-8, and IL-33 cytokines, as well as inducible nitric oxide synthase, cyclooxygenase-2, and prostaglandin E2 in hNECs. We found that NRP1 was highly expressed in the airway epithelium in the murine NP model. The group treated with the NRP1 inhibitor had significantly fewer nasal polypoid lesions and reduced accumulations of immune cells. CONCLUSIONS: These findings reveal that NRP1 is upregulated in CRS and NP epithelium, and the inhibition of NRP1 may lead to a reduction in NP growth and immune cell infiltration. Our results suggest that NRP1 inhibition could be a novel possibility for treating nasal polyposis.</style></abstract><notes><style face="normal" font="default" size="100%">Khalmuratova, Roza&#xD;Ryu, Jae-Sung&#xD;Hwang, Ji Hyeon&#xD;Kim, Yi Sook&#xD;Lim, Suha&#xD;Mo, Ji-Hun&#xD;Kim, Jong-Yeup&#xD;Shin, Hyun-Woo&#xD;eng&#xD;National Research Foundation of Korea/&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3095-3107. doi: 10.1111/all.16285. Epub 2024 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39166395</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16285</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2349</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2349</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bai, D.</style></author><author><style face="normal" font="default" size="100%">Ziadlou, R.</style></author><author><style face="normal" font="default" size="100%">Vaijayanthi, T.</style></author><author><style face="normal" font="default" size="100%">Karthikeyan, S.</style></author><author><style face="normal" font="default" size="100%">Chinnathambi, S.</style></author><author><style face="normal" font="default" size="100%">Parthasarathy, A.</style></author><author><style face="normal" font="default" size="100%">Cai, L.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">Sugiyama, H.</style></author><author><style face="normal" font="default" size="100%">Pandian, G. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Matsumoto, Japan.&#xD;Research &amp; Development Institute of Northwestern Polytechnical University in Shenzhen, Xi&apos;an Key Laboratory of Special Medicine and Health Engineering, Xi&apos;an, China.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Chief Executive Officer, Regugene Co. Ltd., Kyoto, Japan.&#xD;Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Kyoto, Japan.&#xD;Centre for Healthcare Advancement, Innovation and Research, Vellore Institute of Technology, Chennai, Tamil Nadu, India.&#xD;School of Chemistry and Biosciences, University of Bradford, Bradford, UK.&#xD;Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nucleic acid-based small molecules as targeted transcription therapeutics for immunoregulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">843-860</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/12/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nucleic Acids</style></keyword><keyword><style face="normal" font="default" size="100%">DNA</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">immunoregulation</style></keyword><keyword><style face="normal" font="default" size="100%">nucleic acid-based small molecules</style></keyword><keyword><style face="normal" font="default" size="100%">personalized medicine</style></keyword><keyword><style face="normal" font="default" size="100%">pyrrole-imidazole polyamides</style></keyword><keyword><style face="normal" font="default" size="100%">targeted transcription therapeutics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38055191</style></accession-num><abstract><style face="normal" font="default" size="100%">Transcription therapy is an emerging approach that centers on identifying the factors associated with the malfunctioning gene transcription machinery that causes diseases and controlling them with designer agents. Until now, the primary research focus in therapeutic gene modulation has been on small-molecule drugs that target epigenetic enzymes and critical signaling pathways. However, nucleic acid-based small molecules have gained popularity in recent years for their amenability to be pre-designed and realize operative control over the dynamic transcription machinery that governs how the immune system responds to diseases. Pyrrole-imidazole polyamides (PIPs) are well-established DNA-based small-molecule gene regulators that overcome the limitations of their conventional counterparts owing to their sequence-targeted specificity, versatile regulatory efficiency, and biocompatibility. Here, we emphasize the rational design of PIPs, their functional mechanisms, and their potential as targeted transcription therapeutics for disease treatment by regulating the immune response. Furthermore, we also discuss the challenges and foresight of this approach in personalized immunotherapy in precision medicine.</style></abstract><notes><style face="normal" font="default" size="100%">Bai, Dan&#xD;Ziadlou, Reihane&#xD;Vaijayanthi, Thangavel&#xD;Karthikeyan, Subramani&#xD;Chinnathambi, Shanmugavel&#xD;Parthasarathy, Anutthaman&#xD;Cai, Li&#xD;Bruggen, Marie-Charlotte&#xD;Sugiyama, Hiroshi&#xD;Pandian, Ganesh N&#xD;eng&#xD;NH/NIH HHS/&#xD;R01 CA236350/CA/NCI NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):843-860. doi: 10.1111/all.15959. Epub 2023 Dec 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38055191</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15959</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>281</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">281</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jitthamstaporn, S.</style></author><author><style face="normal" font="default" size="100%">Inthong, R.</style></author><author><style face="normal" font="default" size="100%">Audomsun, D.</style></author><author><style face="normal" font="default" size="100%">Chanasit, S.</style></author><author><style face="normal" font="default" size="100%">Thanasarnthungcharoen, C.</style></author><author><style face="normal" font="default" size="100%">Lin, P. J. C.</style></author><author><style face="normal" font="default" size="100%">Weissman, D.</style></author><author><style face="normal" font="default" size="100%">Pardi, N.</style></author><author><style face="normal" font="default" size="100%">Jacquet, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.&#xD;Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.&#xD;Chulalongkorn University Systems Biology Center (CUSB), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.&#xD;Acuitas Therapeutics, Vancouver, British Columbia, Canada.&#xD;Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nucleoside-modified mRNA vaccines yield robust blocking antibody responses against major house dust mite allergens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">315-318</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/09/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Nucleosides</style></keyword><keyword><style face="normal" font="default" size="100%">Antibody Formation</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36136090</style></accession-num><notes><style face="normal" font="default" size="100%">Jitthamstaporn, Sirikarn&#xD;Inthong, Rueangsit&#xD;Audomsun, Dittaya&#xD;Chanasit, Supapich&#xD;Thanasarnthungcharoen, Chanatip&#xD;Lin, Paulo J C&#xD;Weissman, Drew&#xD;Pardi, Norbert&#xD;Jacquet, Alain&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):315-318. doi: 10.1111/all.15527. Epub 2022 Sep 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36136090</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9538380 nucleoside-modified mRNA in lipid nanoparticles as a vaccine platform (WO 2016/176330 A1). P.J.C.L is employee at Acuitas Therapeutics. The remaining authors declare that they have no conflicts of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15527</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1284</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1284</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Skaarup, S. H.</style></author><author><style face="normal" font="default" size="100%">Graumann, O.</style></author><author><style face="normal" font="default" size="100%">Schmid, J.</style></author><author><style face="normal" font="default" size="100%">Bjerrum, A. S.</style></author><author><style face="normal" font="default" size="100%">Skjold, T.</style></author><author><style face="normal" font="default" size="100%">Hoffmann, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.&#xD;Department of Radiology, Odense University Hospital, Odense, Denmark.&#xD;Research and Innovation Unit of Radiology, University of Southern Denmark, Odense, Denmark.&#xD;Department of Respiratory Diseases and Allergy, Aarhus University Hospital and Institute for Clinical Medicine, Aarhus University, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The number of successful injections associates with improved clinical effect in intralymphatic immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1859-1861</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/10/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword><keyword><style face="normal" font="default" size="100%">intralymphatic immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33099797</style></accession-num><notes><style face="normal" font="default" size="100%">Skaarup, Soren Helbo&#xD;Graumann, Ole&#xD;Schmid, Johannes&#xD;Bjerrum, Anne-Sofie&#xD;Skjold, Tina&#xD;Hoffmann, Hans Jurgen&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1859-1861. doi: 10.1111/all.14642. Epub 2020 Nov 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33099797</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14642</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>747</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">747</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vlieg-Boerstra, B.</style></author><author><style face="normal" font="default" size="100%">de Jong, N.</style></author><author><style face="normal" font="default" size="100%">Meyer, R.</style></author><author><style face="normal" font="default" size="100%">Agostoni, C.</style></author><author><style face="normal" font="default" size="100%">De Cosmi, V.</style></author><author><style face="normal" font="default" size="100%">Grimshaw, K.</style></author><author><style face="normal" font="default" size="100%">Milani, G. P.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Oude Elberink, H.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Roduit, C.</style></author><author><style face="normal" font="default" size="100%">Sasaki, M.</style></author><author><style face="normal" font="default" size="100%">Skypala, I.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">van Splunter, M.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Nwaru, B. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, OLVG Hospital, Amsterdam, The Netherlands.&#xD;Internal Medicine, Allergology &amp; Clinical Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.&#xD;Paediatric Allergology, Sophia Children Hospital, ErasmusMC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.&#xD;National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Pediatric Unit, Fondazione IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Department of Clinical Sciences and Community Health, Universita degli Studi di Milano, Milan, Italy.&#xD;University Child Health, University of Southampton, Southampton General Hospital, Southampton, UK.&#xD;Food Allergy Referral Centre, Department of Woman and Child Health, Padua University Hospital, Padua, Italy.&#xD;Department of Internal Medicine, Allergology, University Medical Centre Groningen, Groningen, The Netherlands.&#xD;Interuniversity Messerli Research Institute, Comparative Medicine, University of Veterinary Medicine and Medical University Vienna, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;University Children&apos;s Hospital Zurich, Zurich, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Children&apos;s Hospital of Eastern Switzerland, St Gallen, Switzerland.&#xD;Department of Immunology and Allergy, University Children&apos;s Hospital Zurich, Zurich, Switzerland.&#xD;Department of Allergy &amp; Clinical Immunology, Royal Brompton &amp; Harefield NHS Foundation Trust, London, UK.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Section of Allergy and Immunology, Children&apos;s Hospital Colorado, University of Colorado, Denver, Colorado, USA.&#xD;Department of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland.&#xD;Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nutrient supplementation for prevention of viral respiratory tract infections in healthy subjects: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1373-1388</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/10/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Healthy Volunteers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Nutrients</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Tract Infections/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">acute respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">supplementation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34626488</style></accession-num><abstract><style face="normal" font="default" size="100%">It remains uncertain as to whether nutrient supplementation for the general population considered healthy could be useful in the prevention of RTIs, such as COVID-19. In this systematic review and meta-analysis, the evidence was evaluated for primary prevention of any viral respiratory tract infection (RTI) such as SARS-CoV-2, through supplementation of nutrients with a recognized role in immune function: multiple micronutrients, vitamin A, folic acid, vitamin B12, C, D, E, beta-carotene, zinc, iron and long-chain polyunsaturated fatty acids. The search produced 15,163 records of which 93 papers (based on 115 studies) met the inclusion criteria, resulting in 199,055 subjects (191,636 children and 7,419 adults) from 37 countries. Sixty-three studies were included in the meta-analyses, which was performed for children and adults separately. By stratifying the meta-analysis by world regions, only studies performed in Asia showed a significant but heterogeneous protective effect of zinc supplementation on RTIs (RR 0.86, 95% CI 0.7-0.96, I(2) = 79.1%, p = .000). Vitamin D supplementation in adults significantly decreased the incidence of RTI (RR 0.89, 95% CI 0.79-0.99, p = .272), particularly in North America (RR 0.82 95% CI 0.68-0.97), but not in Europe or Oceania. Supplementation of nutrients in the general population has either no or at most a very limited effect on prevention of RTIs. Zinc supplementation appears protective for children in Asia, whilst vitamin D may protect adults in the USA and Canada. In 10/115 (8.7%) studies post-hoc analyses based on stratification for nutritional status was performed. In only one study zinc supplementation was found to be more effective in children with low zinc serum as compared to children with normal zinc serum levels.</style></abstract><notes><style face="normal" font="default" size="100%">Vlieg-Boerstra, Berber&#xD;de Jong, Nicolette&#xD;Meyer, Rosan&#xD;Agostoni, Carlo&#xD;De Cosmi, Valentina&#xD;Grimshaw, Kate&#xD;Milani, Gregorio Paolo&#xD;Muraro, Antonella&#xD;Oude Elberink, Hanneke&#xD;Pali-Scholl, Isabella&#xD;Roduit, Caroline&#xD;Sasaki, Mari&#xD;Skypala, Isabel&#xD;Sokolowska, Milena&#xD;van Splunter, Marloes&#xD;Untersmayr, Eva&#xD;Venter, Carina&#xD;O&apos;Mahony, Liam&#xD;Nwaru, Bright I&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1373-1388. doi: 10.1111/all.15136. Epub 2021 Oct 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34626488</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15136</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2343</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2343</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roth-Walter, F.</style></author><author><style face="normal" font="default" size="100%">Berni Canani, R.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Peroni, D.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Vassilopoulou, E.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Translational Medical Science and ImmunoNutritionLab at CEINGE-Advanced Biotechnologies, University of Naples &quot;Federico II&quot;, Naples, Italy.&#xD;Department of Medicine, School of Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;Section of Paediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Pediatric Area, Fondazione IRCCS Ca&apos; Granda-Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Department of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece.&#xD;Children&apos;s Hospital Colorado, University of Colorado, Aurora, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nutrition in chronic inflammatory conditions: Bypassing the mucosal block for micronutrients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">353-383</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/12/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Micronutrients/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Vitamins/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidants/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin A</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Mucous Membrane/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidants</style></keyword><keyword><style face="normal" font="default" size="100%">chronic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">lipids</style></keyword><keyword><style face="normal" font="default" size="100%">lymph</style></keyword><keyword><style face="normal" font="default" size="100%">micronutrients</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal block</style></keyword><keyword><style face="normal" font="default" size="100%">polyphenols</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin B</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin C</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38084827</style></accession-num><abstract><style face="normal" font="default" size="100%">Nutritional Immunity is one of the most ancient innate immune responses, during which the body can restrict nutrients availability to pathogens and restricts their uptake by the gut mucosa (mucosal block). Though this can be a beneficial strategy during infection, it also is associated with non-communicable diseases-where the pathogen is missing; leading to increased morbidity and mortality as micronutritional uptake and distribution in the body is hindered. Here, we discuss the acute immune response in respect to nutrients, the opposing nutritional demands of regulatory and inflammatory cells and particularly focus on some nutrients linked with inflammation such as iron, vitamins A, Bs, C, and other antioxidants. We propose that while the absorption of certain micronutrients is hindered during inflammation, the dietary lymph path remains available. As such, several clinical trials investigated the role of the lymphatic system during protein absorption, following a ketogenic diet and an increased intake of antioxidants, vitamins, and minerals, in reducing inflammation and ameliorating disease.</style></abstract><notes><style face="normal" font="default" size="100%">Roth-Walter, Franziska&#xD;Berni Canani, Roberto&#xD;O&apos;Mahony, Liam&#xD;Peroni, Diego&#xD;Sokolowska, Milena&#xD;Vassilopoulou, Emilia&#xD;Venter, Carina&#xD;eng&#xD;Danube Allergy Research Cluster-DARC #8 of the Karl Landsteiner University/&#xD;Italian Ministry of Health - Health Operational Plan Trajectory 5/&#xD;National Recovery and Resilience Plan, European Union-Next Generation EU/&#xD;189334/1/Swiss National Science Foundation (SNSF)/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):353-383. doi: 10.1111/all.15972. Epub 2023 Dec 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38084827</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15972</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2610</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2610</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Angelina, A.</style></author><author><style face="normal" font="default" size="100%">Perez-Diego, M.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nutritional and environmental exposures in athletes: Implications on the epithelial barrier function</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2909-2911</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/08/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">athletes</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier theory</style></keyword><keyword><style face="normal" font="default" size="100%">exercise</style></keyword><keyword><style face="normal" font="default" size="100%">exposome</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39161221</style></accession-num><notes><style face="normal" font="default" size="100%">Angelina, Alba&#xD;Perez-Diego, Mario&#xD;Palomares, Oscar&#xD;eng&#xD;PID2020-114396RB-I00/MICINN, Spain/&#xD;SAF-20217-84978-R/Ministerio de Economia y Competitividad/&#xD;UCM-CT18/22/Ministerio de Universidades, the &quot;Plan de Recuperacion, Transformacion y Resilencia&quot; and the Complutense University of Madrid/&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):2909-2911. doi: 10.1111/all.16280. Epub 2024 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39161221</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16280</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>83</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">83</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Frei, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Allergy and Immunology, Children&apos;s Hospital Colorado, University of Colorado, Aurora, Colorado, USA.&#xD;Division of Pediatric Respiratory Medicine and Allergology, Department of Pediatrics, Bern University Hospital, Bern, Switzerland.&#xD;Department of BioMedical Research (DBMR), University of Bern, Bern, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nutritional metabolites as biomarker for food intake to improve dietary-based randomized control trials</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">349-350</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/11/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Diet</style></keyword><keyword><style face="normal" font="default" size="100%">*Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Eating</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36415079</style></accession-num><notes><style face="normal" font="default" size="100%">Venter, Carina&#xD;Frei, Remo&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):349-350. doi: 10.1111/all.15590.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36415079</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15590</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>342</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">342</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cook, E. C. L.</style></author><author><style face="normal" font="default" size="100%">Redondo-Urzainqui, A.</style></author><author><style face="normal" font="default" size="100%">Iborra, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Ophthalmology and ENT, School of Medicine, 2 de Octubre Health Research Institute (imas12), Universidad Complutense de Madrid, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Obesity can turn a therapy into an antitherapy in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3473-3475</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/08/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity/complications</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35989563</style></accession-num><notes><style face="normal" font="default" size="100%">Cook, Emma C L&#xD;Redondo-Urzainqui, Ana&#xD;Iborra, Salvador&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3473-3475. doi: 10.1111/all.15482. Epub 2022 Aug 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35989563</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15482</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1892</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1892</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cook, E. C. L.</style></author><author><style face="normal" font="default" size="100%">Redondo-Urzainqui, A.</style></author><author><style face="normal" font="default" size="100%">Iborra, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Ophthalmology and ENT, School of Medicine, 2 de Octubre Health Research Institute (imas12), Universidad Complutense de Madrid, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Obesity can turn a therapy into an antitherapy in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3473-3475</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/08/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity/complications</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35989563</style></accession-num><notes><style face="normal" font="default" size="100%">Cook, Emma C L&#xD;Redondo-Urzainqui, Ana&#xD;Iborra, Salvador&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3473-3475. doi: 10.1111/all.15482. Epub 2022 Aug 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35989563</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15482</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3070</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3070</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martinek, A.</style></author><author><style face="normal" font="default" size="100%">Deinzer, A.</style></author><author><style face="normal" font="default" size="100%">Gerlach, R. G.</style></author><author><style face="normal" font="default" size="100%">Petzold, J.</style></author><author><style face="normal" font="default" size="100%">Semmler, L.</style></author><author><style face="normal" font="default" size="100%">Vorsatz, C.</style></author><author><style face="normal" font="default" size="100%">Fallon, P. G.</style></author><author><style face="normal" font="default" size="100%">Schwartz, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Mikrobiologisches Institut-Klinische Mikrobiologie, Immunologie und Hygiene, Universitatsklinikum Erlangen and Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Erlangen, Germany.&#xD;FAU Immunomedicine (FAU I-MED), Erlangen, Germany.&#xD;Trinity Biomedical Sciences Institute, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Obesity Impairs Skin Barrier Function and Facilitates Allergic Sensitization in Mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">obesity</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40985565</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopic dermatitis is a chronic inflammatory skin condition marked by intense itching and a weakened skin barrier. The compromised skin barrier often leads to exaggerated immune responses and greater sensitivity to allergens. Previous studies have already implicated a link between obesity and atopic dermatitis; however, the mechanisms linking obesity to atopy are not yet well understood. We propose that obesity impairs skin barrier function, facilitating allergen penetration in the skin and triggering systemic and local allergic sensitization. We used a diet-induced obesity mouse model to examine skin barrier integrity and immune responses in both steady-state and inflammatory conditions. In order to induce dermatitis or food allergy, we epicutaneously applied MC903 or ovalbumin, respectively. We observed that obesity significantly alters skin barrier physiology, as indicated by increased transepidermal water loss in obese animals. Over time, we observed a decrease in key skin barrier proteins-preceding overt cutaneous inflammation, further indicating a loss of barrier integrity during obesity. Interestingly, skin barrier breakdown was independent of changes to the microbiome. On a cellular level, immune profiling revealed a shift towards a type 17 helper T-cell response bias, although this shift did not coincide with an increase in cytokine production under steady-state conditions. Topical application of MC903 in obese animals led to increased ear swelling and a pronounced Th17-biased inflammatory response compared to lean counterparts. Our findings show that obesity weakens the skin barrier, facilitating increased allergen penetration and allergic sensitization. The Th17-skewed immune environment in obese animals may also amplify inflammatory responses to allergens and act as a feed-forward loop to further disintegrate the skin barrier. This study highlights how obesity-induced skin barrier dysfunction contributes to allergic conditions like atopic dermatitis and may be therapeutically targeted by barrier restoration.</style></abstract><notes><style face="normal" font="default" size="100%">Martinek, Alicia&#xD;Deinzer, Andrea&#xD;Gerlach, Roman G&#xD;Petzold, Jana&#xD;Semmler, Lea&#xD;Vorsatz, Christof&#xD;Fallon, Padraic G&#xD;Schwartz, Christian&#xD;eng&#xD;Bundesministerium fur Bildung und Forschung/&#xD;National Children&apos;s Research Centre/&#xD;GRK 2740/447268119/Deutsche Forschungsgemeinschaft/&#xD;Manfred-Roth-Stiftung/&#xD;10/IN.1/B3004/SFI_/Science Foundation Ireland/Ireland&#xD;Forschungsstiftung Medizin am Universitatsklinikum Erlangen/&#xD;Denmark&#xD;Allergy. 2025 Sep 23. doi: 10.1111/all.70067.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40985565</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70067</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>323</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">323</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bourdin, A.</style></author><author><style face="normal" font="default" size="100%">Bommart, S.</style></author><author><style face="normal" font="default" size="100%">Marin, G.</style></author><author><style face="normal" font="default" size="100%">Vachier, I.</style></author><author><style face="normal" font="default" size="100%">Gamez, A. S.</style></author><author><style face="normal" font="default" size="100%">Ahmed, E.</style></author><author><style face="normal" font="default" size="100%">Suehs, C. M.</style></author><author><style face="normal" font="default" size="100%">Molinari, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Diseases, Univ Montpellier, CHU Montpellier, Montpellier, France.&#xD;PhyMedExp, Univ Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France.&#xD;Department of Medical Imaging, Univ Montpellier, CHU Montpellier, Montpellier, France.&#xD;Department of Medical Information, Univ Montpellier, CHU Montpellier, Montpellier, France.&#xD;IDESP, INSERM, Univ Montpellier, CHU Montpellier, Montpellier, France.&#xD;Department of Respiratory Diseases and Addictology, Medicine Biology Mediterranee, Arnaud de Villeneuve Hospital, CHRU Montpellier, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Obesity in women with asthma: Baseline disadvantage plus greater small-airway responsiveness</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">780-790</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Methacholine Chloride/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoconstriction</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchial Provocation Tests/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default" size="100%">air-trapping</style></keyword><keyword><style face="normal" font="default" size="100%">body mass index</style></keyword><keyword><style face="normal" font="default" size="100%">computed tomography</style></keyword><keyword><style face="normal" font="default" size="100%">mean lung density</style></keyword><keyword><style face="normal" font="default" size="100%">methacholine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36070075</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Obesity is known to diminish lung volumes and worsen asthma. However, mechanistic understanding is lacking, especially as concerns small-airway responsiveness. The objective of this study was therefore to compare small-airway responsiveness, as represented by the change in expiratory:inspiratory mean lung density ratios (MLD(e/i) , as determined by computed tomography [CT]) throughout methacholine testing in obese versus non-obese women with asthma. METHODS: Thoracic CT was performed during methacholine bronchoconstriction challenges to produce standardized response curves (SRC: response parameter versus ln[1 + % PD20], where PD20 is the cumulative methacholine dose) for 31 asthma patients (n = 18 non-obese and n = 13 obese patients). Mixed models evaluated obesity effects and interactions on SRCs while adjusting for age and bronchial morphology. Small airway responsiveness as represented by SRC slope was calculated for each third of the MLD(e/i) response and compared between groups. RESULTS: Obesity-associated effects observed during experimental bronchoconstriction included: (i) a significant baseline effect for forced expiratory volume in 1 second with lower values for the obese (73.11 +/- 13.44) versus non-obese (82.19 +/- 8.78; p = 0.002) groups prior to methacholine testing and (ii) significantly higher responsiveness in small airways as estimated via differences in MLD(e/i) slopes (groupxln(1 + % PD20 interaction; p = 0.023). The latter were pinpointed to higher slopes in the obese group at the beginning 2/3 of SRCs (p = 0.004 and p = 0.021). Significant obesity effects (p = 0.035 and p = 0.008) indicating lower forced vital capacity and greater % change in MLD(e/I) (respectively) throughout methacholine testing, were also observed. CONCLUSION: In addition to baseline differences, small-airway responsiveness (as represented by the change in MLD(e/i) ) during methacholine challenge is greater in obese women with asthma as compared to the non-obese.</style></abstract><notes><style face="normal" font="default" size="100%">Bourdin, Arnaud&#xD;Bommart, Sebastien&#xD;Marin, Gregory&#xD;Vachier, Isabelle&#xD;Gamez, Anne Sophie&#xD;Ahmed, Engi&#xD;Suehs, Carey M&#xD;Molinari, Nicolas&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):780-790. doi: 10.1111/all.15509. Epub 2022 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36070075</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15509</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2326</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2326</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Geissler, N.</style></author><author><style face="normal" font="default" size="100%">Orola, M.</style></author><author><style face="normal" font="default" size="100%">Alinaghi, M.</style></author><author><style face="normal" font="default" size="100%">Nardo, A.</style></author><author><style face="normal" font="default" size="100%">Stulnig, T. M.</style></author><author><style face="normal" font="default" size="100%">Seneca, J.</style></author><author><style face="normal" font="default" size="100%">Schmid, A.</style></author><author><style face="normal" font="default" size="100%">Korb, E.</style></author><author><style face="normal" font="default" size="100%">Svoboda, T.</style></author><author><style face="normal" font="default" size="100%">Garner-Spitzer, E.</style></author><author><style face="normal" font="default" size="100%">Kundi, M.</style></author><author><style face="normal" font="default" size="100%">Ehling-Schulz, M.</style></author><author><style face="normal" font="default" size="100%">Schabussova, I.</style></author><author><style face="normal" font="default" size="100%">Inic-Kanada, A.</style></author><author><style face="normal" font="default" size="100%">Wiedermann, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Functional Microbiology, Institute of Microbiology, Department of Pathobiology, University of Veterinary Medicine, Vienna, Austria.&#xD;Clinical Division of Endocrinology &amp; Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria.&#xD;Department of Medicine III and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Clinic Hietzing, Vienna, Austria.&#xD;Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria.&#xD;Department of Microbiology and Ecosystem Science, Centre for Microbiology and Environmental Systems Science, University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Obesity increases allergic airway inflammation that can be successfully treated by oral tolerance</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">529-533</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/12/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38149746</style></accession-num><notes><style face="normal" font="default" size="100%">Geissler, Nora&#xD;Orola, Maria&#xD;Alinaghi, Masoumeh&#xD;Nardo, Alexander&#xD;Stulnig, Thomas M&#xD;Seneca, Joana&#xD;Schmid, Anna&#xD;Korb, Elke&#xD;Svoboda, Tatjana&#xD;Garner-Spitzer, Erika&#xD;Kundi, Michael&#xD;Ehling-Schulz, Monika&#xD;Schabussova, Irma&#xD;Inic-Kanada, Aleksandra&#xD;Wiedermann, Ursula&#xD;eng&#xD;DK W1248-B30/The Austrian Science Fund (FWF)/&#xD;Government of Lower Austria (Land Niederosterreich)/&#xD;Danube-Allergy Research Cluster/&#xD;PhD Program Molecular, Cellular and Clinical Allergology (MCCA)/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):529-533. doi: 10.1111/all.15989. Epub 2023 Dec 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38149746</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11497298</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15989</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2340</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2340</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Hofer, V.</style></author><author><style face="normal" font="default" size="100%">Dolle-Bierke, S.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Hartmann, K.</style></author><author><style face="normal" font="default" size="100%">Sabouraud-Leclerc, D.</style></author><author><style face="normal" font="default" size="100%">Treudler, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Department of Clinical and Molecular Sciences, Universita Politecnica delle Marche, Ancona, Italy.&#xD;Allergy Unit, Department of Internal Medicine, University Hospital Ospedali Riuniti di Ancona, Torrette, Italy.&#xD;Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Praticien Hospitalier, Pediatre Allergologue, Service Pediatrie A, Pole Femme/Parents/Enfant, AMH 2, Reims, France.&#xD;Department of Dermatology, Venereology and Allergology, Universitatsklinikum Leipzig, Leipzig, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Occupational anaphylaxis-Data from the anaphylaxis registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">702-710</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/12/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Bees</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/etiology/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Latex</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthropod Venoms/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Insecta</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">drugs</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">occupational anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">venom</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38093663</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Epidemiologic data on occupational anaphylaxis is scarce, and there is a need of more knowledge about work-related anaphylactic episodes. METHODS: Based on the data of the Anaphylaxis Registry, we identified cases related to occupational exposure and analyzed the elicitors, demographics, severity of clinical reaction and management. RESULTS: Since 2017, 5851 cases with an information about the occupational relation of the anaphylactic episode were registered whereby 225 (3.8%) were assigned to be caused by an occupational allergen. The vast majority of these occupational anaphylaxis cases were caused by insects (n = 186, 82.7%) followed by food (n = 27, 12.0%) and drugs (n = 8, 3.6%). Latex elicited occupational anaphylaxis in only two cases. Beekeepers, gardeners, farmers, and individuals working in professions associated with food handling, for example, employees in restaurants, bakery, pastry, and cooks were most frequently affected. The comparison of the occupational insect venom-induced anaphylaxis to a group of non-occupational insect anaphylaxis in adults (n = 1842) revealed a significant younger age in occupational anaphylaxis (46 vs. 53 years), a predominance of bee-induced cases (38% vs. 17%), and a higher rate of venom immunotherapy in a primary care setting (3.3% vs. 1.3%, p = .044). In the occupational- versus non-occupational adults with food-induced anaphylaxis atopic dermatitis as concomitant atopic disease was observed more frequently (n = 486; 20% vs. 10%), although this was not significant. CONCLUSION: Our data demonstrate the impact of venom allergy in work-related anaphylaxis. Foods and drugs are less frequently elicitors, and latex-induced occupational anaphylaxis was rare. More data are needed to determine risk factors associated with occupational anaphylaxis.</style></abstract><notes><style face="normal" font="default" size="100%">Worm, Margitta&#xD;Hofer, Veronika&#xD;Dolle-Bierke, Sabine&#xD;Bilo, Maria Beatrice&#xD;Hartmann, Karin&#xD;Sabouraud-Leclerc, Dominique&#xD;Treudler, Regina&#xD;eng&#xD;NETWORK FOR ONLINE-REGISTRATION OF ANAPHYLAXIS - NORA e. V/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):702-710. doi: 10.1111/all.15974. Epub 2023 Dec 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38093663</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15974</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3036</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3036</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suojalehto, H.</style></author><author><style face="normal" font="default" size="100%">Jeebhay, M. F.</style></author><author><style face="normal" font="default" size="100%">Sander, I.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Vrtala, S.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Lopata, A. L.</style></author><author><style face="normal" font="default" size="100%">Vidal, C.</style></author><author><style face="normal" font="default" size="100%">Raulf, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Occupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland.&#xD;Occupational Medicine Division and Centre for Environmental &amp; Occupational Health Research, University of Cape Town, Cape Town, South Africa.&#xD;Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-University Bochum (IPA), Bochum, Germany.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, CIBER of Respiratory Diseases (CIBERES), Madrid, Spain.&#xD;Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Nofer Institute of Occupational Medicine, Department of Occupational Diseases and Environmental Health, Lodz, Poland.&#xD;Molecular Allergy Research Laboratory, College of Science and Engineering, Tropical Futures Institute-Singapore, James Cook University, Townsville, Australia.&#xD;Allergy Department, Faculty of Medicine USC, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Occupational Mite Allergy and Asthma: An EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2484-2500</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/08/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Occupational Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Mites/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Occupational Diseases/immunology/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/immunology/diagnosis/etiology/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma, Occupational/immunology/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">mites</style></keyword><keyword><style face="normal" font="default" size="100%">occupational</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40799117</style></accession-num><abstract><style face="normal" font="default" size="100%">Mite sensitization is notable in several occupational settings. Elevated house dust mite concentrations are primarily detected in workplaces where people congregate and are active. Allergy to storage mites and spider mites has commonly been reported in agricultural and various food processing occupations. Rapid expansion of biological pest control has resulted in increased exposure to predatory mites causing sensitization of greenhouse workers. Globally, mite populations in workplaces are likely to change due to climate change. Occupational relevant mites produce a variety of allergens and adjuvants that trigger both innate and adaptive immune responses. Cross-reactivity between allergens occurs due to shared IgE-binding epitopes to different allergens. Occupational allergy to mites typically causes rhinitis and asthma. Challenges of distinguishing the role of occupational exposure to allergens, also present in non-occupational environments, complicate the diagnosis of occupational mite allergy and asthma. Nevertheless, preventive measures to reduce exposure to mite allergens in workplaces are essential in mitigating occupational hazards. Further research is needed to better understand the incidence of occupational mite allergy and asthma. It is essential to identify the risk factors in different occupational settings, assess the impact of climate change on exposure, and determine the relevant allergens and their potential cross-reactivity.</style></abstract><notes><style face="normal" font="default" size="100%">Suojalehto, Hille&#xD;Jeebhay, Mohamed F&#xD;Sander, Ingrid&#xD;Quirce, Santiago&#xD;Vrtala, Susanne&#xD;Walusiak-Skorupa, Jolanta&#xD;Lopata, Andreas L&#xD;Vidal, Carmen&#xD;Raulf, Monika&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2484-2500. doi: 10.1111/all.16666. Epub 2025 Aug 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40799117</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444871</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16666</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3128</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3128</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leonardi, A.</style></author><author><style face="normal" font="default" size="100%">Frizzo, R.</style></author><author><style face="normal" font="default" size="100%">Cavarzeran, F.</style></author><author><style face="normal" font="default" size="100%">Ozkan, J.</style></author><author><style face="normal" font="default" size="100%">Rosani, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuroscience, Ophthalmology Unit, University of Padova, Padova, Italy.&#xD;Department of Biology, University of Padova, Padova, Italy.&#xD;School of Optometry and Vision Science, Faculty of Medicine and Health, School of Biological, Earth and Environmental Sciences, Faculty of Science, University of New South Wales, Sydney, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ocular Microbiome in Dupilumab-Induced Ocular Surface Disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">ocular allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 16</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41099294</style></accession-num><notes><style face="normal" font="default" size="100%">Leonardi, Andrea&#xD;Frizzo, Riccardo&#xD;Cavarzeran, Fabiano&#xD;Ozkan, Jerome&#xD;Rosani, Umberto&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct 16. doi: 10.1111/all.70104.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41099294</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70104</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3225</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3225</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jackson, C. M.</style></author><author><style face="normal" font="default" size="100%">Collado, M. C.</style></author><author><style face="normal" font="default" size="100%">Dallas, D. C.</style></author><author><style face="normal" font="default" size="100%">Insel, R. A.</style></author><author><style face="normal" font="default" size="100%">Macpherson, A. J.</style></author><author><style face="normal" font="default" size="100%">Palmer, D. J.</style></author><author><style face="normal" font="default" size="100%">Seppo, A. E.</style></author><author><style face="normal" font="default" size="100%">Verhasselt, V.</style></author><author><style face="normal" font="default" size="100%">Jarvinen, K. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Allergy and Immunology &amp; Center for Food Allergy, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.&#xD;Institute of Agrochemistry, Food Technology-National Research Council (IATA-CSIC), Paterna, Valencia, Spain.&#xD;Nutrition Program, School of Nutrition and Public Health, College of Health, Oregon State University, Corvallis, Oregon, USA.&#xD;Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Maurice Muller Laboratories, Department for Biomedical Research, University of Bern, Bern, Switzerland.&#xD;Bern Center for Precision Medicine (BCPM), University of Bern, Bern, Switzerland.&#xD;The Kids Research Institute Australia, The University of Western Australia, Nedlands, Western Australia, Australia.&#xD;School of Medicine, The University of Western Australia, Crawley, Western Australia, Australia.&#xD;Larsson-Rosenquist Foundation Centre for Immunology and Breastfeeding, Medical School, University of Western Australia, Perth, Western Australia, Australia.&#xD;Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An Old Story Back: Human Milk Antibodies&apos; Protective Roles Against Allergy Development</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">human milk</style></keyword><keyword><style face="normal" font="default" size="100%">immune complex</style></keyword><keyword><style face="normal" font="default" size="100%">infant microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41567085</style></accession-num><abstract><style face="normal" font="default" size="100%">Human milk is a rich source of immunomodulatory factors that influence the development of the infant immune system, including susceptibility to allergic diseases. Among these components, milk antibodies have been extensively studied for their role in protecting against infections; however, their potential contribution to allergy prevention may be equally important. The mechanisms of protection include allergen exclusion, enhanced and targeted antigen presentation, immune modulation via shaping of the infant gut microbiome, and direct regulation of gut immune responses. This review summarizes current evidence on the secretion of human milk antibodies, highlights what is known and what remains unclear about their role in allergy prevention and outlines the need for further research to develop antibody-based strategies for early allergy prevention.</style></abstract><notes><style face="normal" font="default" size="100%">Jackson, Courtney M&#xD;Collado, Maria Carmen&#xD;Dallas, David C&#xD;Insel, Richard A&#xD;Macpherson, Andrew J&#xD;Palmer, Debra J&#xD;Seppo, Antti E&#xD;Verhasselt, Valerie&#xD;Jarvinen, Kirsi M&#xD;eng&#xD;639226/H2020-ERC/&#xD;Horizon Europe Program/&#xD;European Joint Programming Initiative &quot;A Healthy Diet for a Healthy Life&quot; (JPI-HDHL)/&#xD;PCI2021-122059-2A/Programacion Conjunta Internacional/&#xD;PID2022-139475OB-I00/Spanish Ministry of Science and Innovation/&#xD;R01HD109193/GF/NIH HHS/&#xD;R01HD097367/GF/NIH HHS/&#xD;R01HD106140/GF/NIH HHS/&#xD;Family Larsson Rosenquist Foundation/&#xD;Stan Perron Charitable Foundation Fellowship/&#xD;U19AI175113/National Institute of Allergy and Infectious Diseases of the National Institutes of Health/&#xD;U01AI173032/National Institute of Allergy and Infectious Diseases of the National Institutes of Health/&#xD;Review&#xD;Denmark&#xD;Allergy. 2026 Jan 22. doi: 10.1111/all.70218.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41567085</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70218</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3231</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3231</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Bitetti, C.</style></author><author><style face="normal" font="default" size="100%">Lo Scalzo, L.</style></author><author><style face="normal" font="default" size="100%">Spagnoli, A.</style></author><author><style face="normal" font="default" size="100%">Fabrizi, E.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author><author><style face="normal" font="default" size="100%">Cafarotti, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Division, Pediatric Hospital Bambino Gesu IRCCS, Rome, Italy.&#xD;Department of Paediatrics, San Carlo Hospital, Potenza, Italy.&#xD;Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.&#xD;Department of Political Science, University of Teramo, Teramo, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Omalizumab Dose-Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anti-IgE</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab dosage</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 19</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41555682</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: We recently published on the clinical efficacy of a 1-year-long evaluation of 65 asthmatics with severe IgE-mediated food allergy (FA) under Omalizumab: Omalizumab is safe and able to increase reactivity threshold, allows safe food introduction, and improves quality of life (OSAFA-study, ClinicalTrials.gov, NCT06316414). Herein, we assess Omalizumab dose-related efficacy during the first year Omalizumab treatment in achieving food desensitization in patients with severe FA. METHODS: Children (6-18 years) with severe asthma and severe allergy to &gt;/= 1 food allergen were screened. Oral food challenges (OFCs), skin prick test (SPT), complete blood count, chemistry, total and specific IgE were measured at baseline and at 12 months of Omalizumab. RESULTS: Seventy-six patients (previously published cohort plus 11 newly-enrolled patients) were included (OSAFA [Omalizumab in Severe Asthmatics with Food Allergy] study). 69.7% were male; mean age (SD) 12.2 [4.19] years. 77.6% were allergic to 2+ foods. Total IgE median was 644 kU/L. After adjusting for confounders, such as age, sex, and co-existing allergies, a significant association was observed between the achievement of desensitization and the dosage (mg/month) of Omalizumab (OR: 1.151, 95% CI: 1.066-1.258), while no significant effect was observed for total IgE levels at the baseline (OR: 0.999, 95% CI: 0.998-1.001). CONCLUSIONS: The findings of this study indicate that the efficacy of Omalizumab is independent, all else being equal, from total IgE levels, suggesting that body weight is the most appropriate parameter for calculating its dosage in the treatment of patients with severe FA.</style></abstract><notes><style face="normal" font="default" size="100%">Arasi, Stefania&#xD;Bitetti, Carol&#xD;Lo Scalzo, Lucia&#xD;Spagnoli, Alessandra&#xD;Fabrizi, Elena&#xD;Fiocchi, Alessandro&#xD;Cafarotti, Arianna&#xD;eng&#xD;Allegria ONLUS, Milano, Italy/&#xD;Denmark&#xD;Allergy. 2026 Jan 19. doi: 10.1111/all.70228.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41555682</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70228</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1247</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1247</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Song, X. T.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. D.</style></author><author><style face="normal" font="default" size="100%">Yu, M.</style></author><author><style face="normal" font="default" size="100%">Liu, B.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z. T.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.&#xD;Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.&#xD;National Clinical Research Center for Skin and Immune Diseases, Beijing, China.&#xD;Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.&#xD;Peking University School of Nursing, Beijing, China.&#xD;Department of Dermatology and Allergy, Charite - Universitatsmedizin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Omalizumab in children and adolescents with chronic urticaria: A 16-week real-world study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1271-1273</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">quality-of-life</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33275779</style></accession-num><notes><style face="normal" font="default" size="100%">Song, Xiao-Ting&#xD;Chen, Yu-Di&#xD;Yu, Miao&#xD;Liu, Bo&#xD;Zhao, Zuo-Tao&#xD;Maurer, Marcus&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1271-1273. doi: 10.1111/all.14686. Epub 2020 Dec 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33275779</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14686</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2692</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2692</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soegiharto, R.</style></author><author><style face="normal" font="default" size="100%">Alizadeh Aghdam, M.</style></author><author><style face="normal" font="default" size="100%">Sorensen, J. A.</style></author><author><style face="normal" font="default" size="100%">van Lindonk, E.</style></author><author><style face="normal" font="default" size="100%">Bulut Demir, F.</style></author><author><style face="normal" font="default" size="100%">Mohammad Porras, N.</style></author><author><style face="normal" font="default" size="100%">Matsuo, Y.</style></author><author><style face="normal" font="default" size="100%">Kiefer, L.</style></author><author><style face="normal" font="default" size="100%">Knulst, A. C.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Ritchie, C.</style></author><author><style face="normal" font="default" size="100%">Rudenko, M.</style></author><author><style face="normal" font="default" size="100%">Kocaturk, E.</style></author><author><style face="normal" font="default" size="100%">Criado, R. F. J.</style></author><author><style face="normal" font="default" size="100%">Gregoriou, S.</style></author><author><style face="normal" font="default" size="100%">Bobylev, T.</style></author><author><style face="normal" font="default" size="100%">Kleinheinz, A.</style></author><author><style face="normal" font="default" size="100%">Takahagi, S.</style></author><author><style face="normal" font="default" size="100%">Hide, M.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A. M.</style></author><author><style face="normal" font="default" size="100%">Salman, A.</style></author><author><style face="normal" font="default" size="100%">Kara, R. O.</style></author><author><style face="normal" font="default" size="100%">Dikicier, B. S.</style></author><author><style face="normal" font="default" size="100%">van Doorn, M. B. A.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author><author><style face="normal" font="default" size="100%">van den Reek, Jmpa</style></author><author><style face="normal" font="default" size="100%">Rockmann, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology/Allergology, University Medical Centre Utrecht, Utrecht, Netherlands.&#xD;Department of Dermato-Venereology and Wound Healing Centre, University of Copenhagen, Bispebjerg Hospital, Copenhagen, Denmark.&#xD;Department of Dermatology, Erasmus MC, Rotterdam, Netherlands.&#xD;Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.&#xD;Department of Dermatology, Hospital del Mar Research Institute. Universitat Pompeu Fabra de Barcelona, Barcelona, Spain.&#xD;Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.&#xD;Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;Secciones Alergia Adultos y Pediatrica, Hospital Italiano de Buenos Aires Peron, Ciudad Autonoma de Buenos Aires, Argentina.&#xD;London Allergy and Immunology Centre, London, UK.&#xD;Department of Dermatology, Koc University School of Medicine, Topkapi Istanbul, Turkey.&#xD;Department of Dermatology, faculdade de medicina do ABC, Santo Andre, Brazil.&#xD;First Department of Dermatology and Veneorology, National and Kapodistrian University of Athens A Syggros Hospital, Athens, Greece.&#xD;Clinic for Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany.&#xD;Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.&#xD;Department of Dermatology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey.&#xD;Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey.&#xD;Centre for Human Drug Research, Leiden, Netherlands.&#xD;Department of Dermatology, Radboud University Medical Centre, Nijmegen, Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">489-499</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/10/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Inducible Urticaria/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">chronic inducible urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">drug survival</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">predictor</style></keyword><keyword><style face="normal" font="default" size="100%">research or consultancy from: ALK, Thermofisher, Nutricia/Danone, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">technologies, Novartis, EUROIMMUN, Stallergenes Greer. AGA is or recently was a</style></keyword><keyword><style face="normal" font="default" size="100%">speaker and/or advisor for and/or has received research funding from Almirall,</style></keyword><keyword><style face="normal" font="default" size="100%">Amgen, AstraZeneca, Avene, Blue -Print, Celldex, Escient Pharmaceutials,</style></keyword><keyword><style face="normal" font="default" size="100%">Genentech, GSK, Harmonic Bio, Instituto Carlos III- FEDER, Jaspers, Leo Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Menarini, Mitsubishi Tanabe Pharma, Noucor, Novartis, Sanofi-Regeneron ,</style></keyword><keyword><style face="normal" font="default" size="100%">Septerna, Servier, Thermo Fisher Scientific, Uriach Pharma. AK: No conflicts of</style></keyword><keyword><style face="normal" font="default" size="100%">interest. AS: None, in relation to this work. Outside of it, AS was speaker</style></keyword><keyword><style face="normal" font="default" size="100%">and/or advisor for Abbvie, Bayer, Menarini, Novartis, Pfizer, and Sanofi. BSD: No</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest. CR: No conflicts of interest. EK: Speaker and advisor for</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Menarini, LaRoche Posey, Sanofi, Bayer. EvL: No conflicts of interest.</style></keyword><keyword><style face="normal" font="default" size="100%">FBD: No conflicts of interest. HR has received research funding from Novartis to</style></keyword><keyword><style face="normal" font="default" size="100%">support this work. She received institutional sponsoring for Research,</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy or speakers fee outside the submitted work from Pharming and Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Sanofi, Third Harmonic Bio, Abbvie, Leo Pharma. JAS: No conflicts of</style></keyword><keyword><style face="normal" font="default" size="100%">interest. JvdR: J M.P.A. van den Reek carried out clinical trials for AbbVie,</style></keyword><keyword><style face="normal" font="default" size="100%">Celgene, Almirall, and Janssen and has received speaking fees/attended advisory</style></keyword><keyword><style face="normal" font="default" size="100%">boards from AbbVie, Janssen, BMS, Almirall, LEO Pharma, Novartis, UCB and Eli</style></keyword><keyword><style face="normal" font="default" size="100%">Lilly and reimbursement for attending or chairing a symposium from Janssen,</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, Celgene and AbbVie. All funding is not personal but goes to the</style></keyword><keyword><style face="normal" font="default" size="100%">independent research fund of the department of dermatology of Radboudumc</style></keyword><keyword><style face="normal" font="default" size="100%">Nijmegen, the Netherlands. LK: No conflicts of interest. MAA: No conflicts of</style></keyword><keyword><style face="normal" font="default" size="100%">interest. MM: None, in relation to this work. Outside of it, MM is or recently</style></keyword><keyword><style face="normal" font="default" size="100%">was a speaker and/or advisor for and/or has received research funding from</style></keyword><keyword><style face="normal" font="default" size="100%">Allakos, Alexion, Alvotech, Almirall, Amgen, Aquestive, argenX, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Celldex, Celltrion, Clinuvel, Escient, Evommune, Excellergy, GSK, Incyte, Jasper,</style></keyword><keyword><style face="normal" font="default" size="100%">Kashiv, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Moxie, Noucor, Novartis, Orion Biotechnology, Resoncance Medicine,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron, Santa Ana Bio, Septerna, Servier, Third HarmonicBio,</style></keyword><keyword><style face="normal" font="default" size="100%">ValenzaBio, Vitalli Bio, Yuhan Corporation, and Zurabio. MH: None, in relation to</style></keyword><keyword><style face="normal" font="default" size="100%">this work. Outside of it, MH is or recently was a speaker and/or advisor for</style></keyword><keyword><style face="normal" font="default" size="100%">and/or has received research funding from Amgen, Centogene, CSL Behring, Eisai,</style></keyword><keyword><style face="normal" font="default" size="100%">GI-Innovation, GSK, Kaken, Kyorin, Kyowa Kirin, Mitsubishi-Tanabe, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron, Taiho, Teikoku, UCB, and Uriach. MR: No conflicts of interest.</style></keyword><keyword><style face="normal" font="default" size="100%">MvD: has received grants from governmental research institutes NWO and ZonMW and</style></keyword><keyword><style face="normal" font="default" size="100%">has received consulting fees or honorarium from Novartis, Abbvie, Pfizer,</style></keyword><keyword><style face="normal" font="default" size="100%">Leopharma, Sanofi, Lilly, Janssen, BMS, Almiral and Celgene, has received a grant</style></keyword><keyword><style face="normal" font="default" size="100%">and payment for lectures including service on speakers bureaus from Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi and Janssen outside the submitted work. NMP: No conflicts of interest.</style></keyword><keyword><style face="normal" font="default" size="100%">RFJC: None in relation with this work. Outside of it, RFJC was a speaker and/or</style></keyword><keyword><style face="normal" font="default" size="100%">advisor for and/or has received research funding from, Abbvie, Amgen, Lilly,</style></keyword><keyword><style face="normal" font="default" size="100%">Mantecorp, Novartis, Pfizer, Sanofi/Regeneron, Takeda. ROK: None, in relation to</style></keyword><keyword><style face="normal" font="default" size="100%">this work. Outside of it, AS was speaker and/or advisor for Abbvie, Novartis. RS:</style></keyword><keyword><style face="normal" font="default" size="100%">No conflicts of interest. SFT: Outside the submitted work SFT has been a speaker</style></keyword><keyword><style face="normal" font="default" size="100%">or has served on advisory boards for Sanofi, AbbVie, LEO Pharma, Pfizer, Eli</style></keyword><keyword><style face="normal" font="default" size="100%">Lilly, Novartis, UCB Pharma, Union Therapeutics, Almirall, Galderma, Symphogen,</style></keyword><keyword><style face="normal" font="default" size="100%">and Janssen Pharmaceuticals, and has received research support from Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">AbbVie, LEO Pharma, Novartis, UCB Pharma, and Janssen Pharmaceuticals. ST: None,</style></keyword><keyword><style face="normal" font="default" size="100%">in relation to this work. Outside of it, ST has received research grant from</style></keyword><keyword><style face="normal" font="default" size="100%">Takeda, Mitsubishi-Tanabe, Maruho, Lilly, Sanofi and Taiho Pharma, and honorarium</style></keyword><keyword><style face="normal" font="default" size="100%">from Mitsubishi-Tanabe, CSL Behring, Kaken, Maruho, Takeda and Abbvie. SG:</style></keyword><keyword><style face="normal" font="default" size="100%">Outside the submitted work SG has been a speaker or has served on advisory boards</style></keyword><keyword><style face="normal" font="default" size="100%">for Sanofi, AbbVie, LEO Pharma, Pfizer, Eli Lilly, Novartis, UCB Pharma and</style></keyword><keyword><style face="normal" font="default" size="100%">Amgen. TB: No conflicts of interest. YM: No conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39377745</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Long-term data on the effectiveness and safety of omalizumab for chronic inducible urticaria (CIndU) in large populations are lacking. OBJECTIVE: To evaluate the effectiveness, safety, estimated omalizumab treatment duration and its predictors, as well as differences between CIndU subtypes, in a large long-term CIndU cohort. METHODS: A multinational multicenter study was conducted at 14 specialized urticaria centres (UCAREs), including all CIndU patients ever treated with omalizumab from 2009 until July 2022. Kaplan-Meier survival and regression analyses were performed. RESULTS: Across 234 CIndU patients (55% female; mean age 37 years), 76% (n = 178) had standalone CIndU and 24% (n = 56) had predominant CIndU plus minor CSU, with an observation period up to 13 years. Most CIndU patients (73%, n = 145/200 with available data on response) had complete/good response to omalizumab treatment, without significant differences between CIndU subtypes. Sixty-two (26%) patients discontinued omalizumab; due to well-controlled disease (47%, n = 29), ineffectiveness (34%, n = 21), side effects (3%, n = 2), combination of ineffectiveness and side effects (3%, n = 2) and other reasons (13%, n = 8). The median estimated omalizumab treatment duration exceeded 5 years (54% drug survival at 5 years) and was mostly determined by well-controlled disease. Higher age predicted a lower chance to discontinue omalizumab due to well-controlled disease (HR 0.969, 95%CI 0.945-0.995). CIndU subtype and presence of minor CSU were not related to response and time until omalizumab discontinuation for any reason. CONCLUSION: Omalizumab is highly effective and safe in CIndU patients, with long estimated treatment duration mainly reflecting long disease duration. Our data show omalizumab&apos;s high potential as treatment in any subtype of CIndU and support its clinical use for these patients.</style></abstract><notes><style face="normal" font="default" size="100%">Soegiharto, R&#xD;Alizadeh Aghdam, M&#xD;Sorensen, J A&#xD;van Lindonk, E&#xD;Bulut Demir, F&#xD;Mohammad Porras, N&#xD;Matsuo, Y&#xD;Kiefer, L&#xD;Knulst, A C&#xD;Maurer, M&#xD;Ritchie, C&#xD;Rudenko, M&#xD;Kocaturk, E&#xD;Criado, R F J&#xD;Gregoriou, S&#xD;Bobylev, T&#xD;Kleinheinz, A&#xD;Takahagi, S&#xD;Hide, M&#xD;Gimenez-Arnau, A M&#xD;Salman, A&#xD;Kara, R Oztas&#xD;Dikicier, B S&#xD;van Doorn, M B A&#xD;Thomsen, S F&#xD;van den Reek, J M P A&#xD;Rockmann, H&#xD;eng&#xD;Novartis Pharma/&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):489-499. doi: 10.1111/all.16334. Epub 2024 Oct 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39377745</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804303</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16334</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2646</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2646</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Cafarotti, A.</style></author><author><style face="normal" font="default" size="100%">Galletta, F.</style></author><author><style face="normal" font="default" size="100%">Panetta, V.</style></author><author><style face="normal" font="default" size="100%">Riccardi, C.</style></author><author><style face="normal" font="default" size="100%">Calandrelli, V.</style></author><author><style face="normal" font="default" size="100%">Fierro, V.</style></author><author><style face="normal" font="default" size="100%">Dahdah, L.</style></author><author><style face="normal" font="default" size="100%">Artesani, M. C.</style></author><author><style face="normal" font="default" size="100%">Valluzzi, R. L.</style></author><author><style face="normal" font="default" size="100%">Pecora, V.</style></author><author><style face="normal" font="default" size="100%">Tallarico, V.</style></author><author><style face="normal" font="default" size="100%">Dinardo, G.</style></author><author><style face="normal" font="default" size="100%">Lo Scalzo, L.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Division, Pediatric Hospital Bambino Gesu IRCCS, Rome, Italy.&#xD;Department of Human Pathology of Adult and Childhood Gaetano Barresi, Pediatric Unit, University of Messina, Messina, Italy.&#xD;L&apos;altrastatistica S.r.l., for GB Pharma Services &amp; Consulting S.r.l, Rome, Italy.&#xD;Department of Medical and Surgical Sciences, Pediatric Unit, University &quot;Magna Graecia&quot; of Catanzaro, Catanzaro, Italy.&#xD;Department of Woman, Child and of General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy.&#xD;Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties &quot;G. D&apos;Alessandro&quot; University of Palermo, Palermo, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Omalizumab reduces anaphylactic reactions and allows food introduction in food-allergic in children with severe asthma: An observational study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1074-1085</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/09/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/complications/drug therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/complications/drug therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/prevention &amp; control/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Food/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">anti IgE</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">food</style></keyword><keyword><style face="normal" font="default" size="100%">immunologic desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">speaker for Aimmune, D.B.V.-, Novartis, Ferrero and Ulrich outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. AF has participated as an advisory board member, and/or consultant, and/or</style></keyword><keyword><style face="normal" font="default" size="100%">speaker for Danone, Abbott, Aimmune, Ferrero, Novartis, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. Other Authors declare no conflict of interest related to this work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39282750</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In Europe, Omalizumab (anti-IgE) is indicated for the treatment of moderate to severe asthma, but not for IgE-mediated food allergy (FA). OBJECTIVE: We assessed the impact of Omalizumab on efficacy, safety, and quality of life (FA-QoL) in patients with moderate to severe asthma and who have a history of anaphylaxis to peanut, tree nuts, fish, egg, milk, and/or wheat. METHODS: Food-allergic children (6-18 years) with moderate to severe asthma underwent oral food challenges (OFCs) to establish the threshold of reaction to the culprit food(s) at baseline (T0) and at 4-month intervals (T1, T2, and T3) during their first year of treatment with Omalizumab. We recorded the number and severity of food-allergic reactions, Asthma Control Test (ACT) scores, FA-QoL, and total IgE levels. RESULTS: In 65 patients allergic to 107 foods, the No Observed Adverse Events Level (NOAEL) at T1 increased: 243- and 488-fold for fresh and baked milk, respectively; 172- and 134-fold for raw and baked egg; 245-fold for hazelnut; 55-fold for peanut; 31-fold for wheat; and 10-fold for fish. Full tolerance was achieved in 66.4% of OFCs at T1, 58.3% at T2, and 75% at T3. Ninety-five foods were liberalized in the diet of 55 patients; the remaining 12 were introduced by 10 patients at least in traces. Throughout the study, 40 out of 65 were able to get a free diet. ACT increased from 17 (Q1-Q3: 15-17) to 23.6 (Q1-Q3: 23-25). The FA-QoL score in children &lt;/=12 years decreased from 4.63 +/- 0.74 to 2.02 +/- 1.13, and in adolescents from 4.68 +/- 0.92 to 1.90 +/- 1.50. CONCLUSIONS: During Omalizumab therapy, a safe reintroduction of allergenic foods is feasible. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, NCT06316414.</style></abstract><notes><style face="normal" font="default" size="100%">Arasi, Stefania&#xD;Cafarotti, Arianna&#xD;Galletta, Francesca&#xD;Panetta, Valentina&#xD;Riccardi, Carla&#xD;Calandrelli, Veronica&#xD;Fierro, Vincenzo&#xD;Dahdah, Lamia&#xD;Artesani, Maria Cristina&#xD;Valluzzi, Rocco Luigi&#xD;Pecora, Valentina&#xD;Tallarico, Valeria&#xD;Dinardo, Giulio&#xD;Lo Scalzo, Lucia&#xD;Fiocchi, Alessandro&#xD;eng&#xD;Allegriallergia ONLUS - Milano -Italy/&#xD;Observational Study&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1074-1085. doi: 10.1111/all.16314. Epub 2024 Sep 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39282750</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969307</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16314</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1569</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1569</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, ARADyAL, IBIMA-Hospital Regional Universitario de Malaga-UMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Omega-3 fatty acids and the regulation of adipogenesis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1281-1282</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/01/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Adipogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Fats</style></keyword><keyword><style face="normal" font="default" size="100%">*Fatty Acids, Omega-3</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">adipogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">insulin resistance</style></keyword><keyword><style face="normal" font="default" size="100%">omega-3 fatty acids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31997361</style></accession-num><notes><style face="normal" font="default" size="100%">Eguiluz-Gracia, Ibon&#xD;Bogas, Gador&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 May;75(5):1281-1282. doi: 10.1111/all.14208. Epub 2020 Feb 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31997361</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14208</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3097</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3097</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">iAkushev, A.</style></author><author><style face="normal" font="default" size="100%">Szatkowski, P.</style></author><author><style face="normal" font="default" size="100%">Vorobeva, M.</style></author><author><style face="normal" font="default" size="100%">Chen, C. C.</style></author><author><style face="normal" font="default" size="100%">Jerschow, E.</style></author><author><style face="normal" font="default" size="100%">Mastalerz, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.&#xD;2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Omics in Nonsteroidal Anti-Inflammatory Drugs-Exacerbated Respiratory Disease: Current Evidence From the Upper and Lower Airways</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">56-68</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/09/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Inflammatory Agents, Non-Steroidal/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Tract Diseases/metabolism/etiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Epigenomics</style></keyword><keyword><style face="normal" font="default" size="100%">NSAID-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default" size="100%">N-erd</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">omics</style></keyword><keyword><style face="normal" font="default" size="100%">and served on the GSK Advisory Board, outside of the submitted work. All other</style></keyword><keyword><style face="normal" font="default" size="100%">authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40908647</style></accession-num><abstract><style face="normal" font="default" size="100%">Nonsteroidal anti-inflammatory drugs (NSAID)-exacerbated respiratory disease (N-ERD) is a mainly type 2 inflammatory condition that combines asthma, nasal polyps, and hypersensitivity to NSAIDs. Its pathogenesis involves both upper and lower airways, yet most studies to date have examined these compartments separately. It remains unclear whether the molecular mechanisms in the nose, sinuses, and lungs are distinct or overlapping-an important gap, given that clinical manifestations of N-ERD involve both sites. In this review, we summarize available omics studies-transcriptomics, proteomics, metabolomics, and epigenomics-performed on upper and lower airways in patients with N-ERD. While omics approaches have revealed new molecular insights, comparisons across studies are limited by heterogeneity in design, controls, and methodology. We emphasize the need for integrated multi-omics analyses and standardized frameworks to better characterize the disease across airways. Such efforts are essential for identifying robust biomarkers and therapeutic targets and for moving toward a systems-level understanding of N-ERD.</style></abstract><notes><style face="normal" font="default" size="100%">iAkushev, Aleksandr&#xD;Szatkowski, Piotr&#xD;Vorobeva, Maria&#xD;Chen, Chien-Chang&#xD;Jerschow, Elina&#xD;Mastalerz, Lucyna&#xD;eng&#xD;R21 AI146804/AI/NIAID NIH HHS/&#xD;R21 AI171306/AI/NIAID NIH HHS/&#xD;Narodowe Centrum Nauki/&#xD;National Institute of Allergy and Infectious Diseases/&#xD;Review&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):56-68. doi: 10.1111/all.70034. Epub 2025 Sep 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40908647</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12463314</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70034</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2811</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2811</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baalbaki, N.</style></author><author><style face="normal" font="default" size="100%">Slob, E. M. A.</style></author><author><style face="normal" font="default" size="100%">Kazer, S. W.</style></author><author><style face="normal" font="default" size="100%">I. Abdel-Aziz M</style></author><author><style face="normal" font="default" size="100%">Bogaard, H. J.</style></author><author><style face="normal" font="default" size="100%">Golebski, K.</style></author><author><style face="normal" font="default" size="100%">Maitland-van der Zee, A. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, the Netherlands.&#xD;Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.&#xD;Amsterdam Public Health, Amsterdam, the Netherlands.&#xD;Department of Clinical Pharmacy, Haaglanden Medical Centre, The Hague, the Netherlands.&#xD;Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.&#xD;Division of Gastroenterology, Hepatology, and Nutrition, Boston Children&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.&#xD;Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.&#xD;Department of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, Egypt.&#xD;Amsterdam Cardiovascular Sciences Research Institute, Amsterdam UMC, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Omics Landscape of Long COVID-A Comprehensive Systematic Review to Advance Biomarker, Target and Drug Discovery</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">932-948</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/03/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/metabolism/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Discovery</style></keyword><keyword><style face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Post-Acute COVID-19 Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">long COVID</style></keyword><keyword><style face="normal" font="default" size="100%">multi-omics</style></keyword><keyword><style face="normal" font="default" size="100%">phenotypes</style></keyword><keyword><style face="normal" font="default" size="100%">post-acute sequelae of COVID-19</style></keyword><keyword><style face="normal" font="default" size="100%">post-viral condition</style></keyword><keyword><style face="normal" font="default" size="100%">for More Oxygen)) sponsored by Health Holland involving many private partners</style></keyword><keyword><style face="normal" font="default" size="100%">that contribute in cash and/or in kind (AbbVie. Boehringer Ingelheim, Breathomix,</style></keyword><keyword><style face="normal" font="default" size="100%">Clear, Fluidda, Ortec Logiqcare, Olive, Philips, Quantib-U, Smartfish, Clear,</style></keyword><keyword><style face="normal" font="default" size="100%">SODAQ, Thirona, Roche, TopMD, Novartis, RespiQ). Received unrestricted research</style></keyword><keyword><style face="normal" font="default" size="100%">grant from GSK and Boehringer Ingelheim. Received Vertex Innovation Award Grant.</style></keyword><keyword><style face="normal" font="default" size="100%">Honoraria paid to the Institution from Boehringer Ingelheim, Astra Zeneca, and</style></keyword><keyword><style face="normal" font="default" size="100%">GSK. She is Chair of the DSMB of a study on BPD in neonates. K.G.: received</style></keyword><keyword><style face="normal" font="default" size="100%">funding from STIMAG, GSK ISS, ZonMw. Payments made to the institution by GSK and</style></keyword><keyword><style face="normal" font="default" size="100%">ALK. S.W.K.: received salary from the Cancer Research Institute, Postdoctoral</style></keyword><keyword><style face="normal" font="default" size="100%">Fellowship Grant. N.B., E.M.A.S., M.I.A.-A., H.J.B.: nothing to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40084919</style></accession-num><abstract><style face="normal" font="default" size="100%">An estimated 10% of coronavirus disease (COVID-19) survivors suffer from persisting symptoms referred to as long COVID (LC), a condition for which approved treatment options are still lacking. This systematic review (PROSPERO: CRD42024499281) aimed to explore the pathophysiological mechanisms underlying LC and potential treatable traits across symptom-based phenotypes. We included studies with primary data, written in English, focusing on omics analyses of human samples from LC patients with persistent symptoms of at least 3 months. Our search in PubMed and Embase, conducted on January 8, 2024, identified 642 studies, of which 29 met the inclusion criteria after full-text assessment. The risk of bias was evaluated using the Joanna Briggs Institute appraisal tool. The synthesis of omics data, including genomics, transcriptomics, proteomics, metabolomics, and metagenomics, revealed common findings associated with fatigue, cardiovascular, pulmonary, neurological, and gastrointestinal phenotypes. Key findings included mitochondrial dysfunction, dysregulated microRNAs associated with pulmonary dysfunction, tissue impairment, blood-brain barrier disruption, coagulopathy, vascular dysfunction, microbiome disturbances, microbial-derived metabolite production and persistent inflammation. Limitations include cross-study heterogeneity and variability in sampling methods. Our review emphasizes the complexity of LC and the need for further longitudinal omics-integrated studies to advance the development of biomarkers and targeted treatments.</style></abstract><notes><style face="normal" font="default" size="100%">Baalbaki, Nadia&#xD;Slob, Elise M A&#xD;Kazer, Samuel W&#xD;I Abdel-Aziz, Mahmoud&#xD;Bogaard, Harm Jan&#xD;Golebski, Korneliusz&#xD;Maitland-van der Zee, Anke H&#xD;eng&#xD;Health~Holland/&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):932-948. doi: 10.1111/all.16526. Epub 2025 Mar 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40084919</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969314</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16526</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>432</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">432</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Radzikowska, U.</style></author><author><style face="normal" font="default" size="100%">Baerenfaller, K.</style></author><author><style face="normal" font="default" size="100%">Cornejo-Garcia, J. A.</style></author><author><style face="normal" font="default" size="100%">Karaaslan, C.</style></author><author><style face="normal" font="default" size="100%">Barletta, E.</style></author><author><style face="normal" font="default" size="100%">Sarac, B. E.</style></author><author><style face="normal" font="default" size="100%">Zhakparov, D.</style></author><author><style face="normal" font="default" size="100%">Villasenor, A.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Barbas, C.</style></author><author><style face="normal" font="default" size="100%">Barber, D.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine-Kuhne Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Swiss Institute of Bioinformatics (SIB), Davos, Switzerland.&#xD;Research Laboratory, IBIMA, ARADyAL Instituto de Salud Carlos III, Regional University Hospital of Malaga, UMA, Malaga, Spain.&#xD;Department of Biology, Molecular Biology Section, Faculty of Science, Hacettepe University, Ankara, Turkey.&#xD;Centre for Metabolomics and Bioanalysis (CEMBIO), Department of Chemistry and Biochemistry, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Institute of Applied Molecular Medicine Nemesio Diaz (IMMAND), Department of Basic Medical Sciences, Facultad de Medicina, Universidad San Pablo CEU, CEU Universities, Madrid, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Andalusian Centre for Nanomedicine and Biotechnology - BIONAND, Malaga, Spain.&#xD;Department of Infection and Immunity, Luxembourg Institute of Healthy, Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, Odense University Hospital, University of Southern Denmark, Odense, Denmark.&#xD;Department of Clinic Medical Sciences, Facultad de Medicina, Universidad San Pablo CEU, CEU Universities, Madrid, Spain.&#xD;Transylvania University, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Omics technologies in allergy and asthma research: An EAACI position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2888-2908</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/06/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Genomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/genetics/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">omic</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword><keyword><style face="normal" font="default" size="100%">systems biology</style></keyword><keyword><style face="normal" font="default" size="100%">a member of the EAACI working group Genomics and Proteomics. IA is an Associate</style></keyword><keyword><style face="normal" font="default" size="100%">Editor of Allergy and CTA. KB reports: The Center for Precision Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">providing partial salary funding is funded through the Swiss canton of Grisons.</style></keyword><keyword><style face="normal" font="default" size="100%">Salary payments are made through the institution and are part of the regular</style></keyword><keyword><style face="normal" font="default" size="100%">salary. KB has been funded by the Earth Vision nonprofit corporation for chairing</style></keyword><keyword><style face="normal" font="default" size="100%">an event, performing a study and manuscript writing. The funding has been made to</style></keyword><keyword><style face="normal" font="default" size="100%">SIAF</style></keyword><keyword><style face="normal" font="default" size="100%">the resulting manuscript has been published</style></keyword><keyword><style face="normal" font="default" size="100%">https://doi.org/10.3390/microorganisms8040498</style></keyword><keyword><style face="normal" font="default" size="100%">the topic has no overlap with the</style></keyword><keyword><style face="normal" font="default" size="100%">study presented here. KB is a member of the board of directors of the Swiss</style></keyword><keyword><style face="normal" font="default" size="100%">Institute of Bioinformatics, member of the EAACI working group Genomics and</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics and president of the bioinformatics intersection of LS2 and member of</style></keyword><keyword><style face="normal" font="default" size="100%">LS2. MME is a Chair of EAACI WG on Genomics and Proteomics and report lecture</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Diater and Stallergenes. MS reports grants from SNSF, GSK, Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">payments from AstraZeneca, and position of European Academy of Allergy and</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Immunology (EAACI) Basic and Clinical Immunology Board Secretary. MO</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal consulting honoraria received from Hycor Biomedical</style></keyword><keyword><style face="normal" font="default" size="100%">Member-at-Large 2019-2022, Executive Committee, European Academy of Allergy and</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Immunology (EAACI). UR is a Secretary of the EAACI WG on Genomics and</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics. All other authors report no conflict of interest regarding this</style></keyword><keyword><style face="normal" font="default" size="100%">manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35713644</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic diseases and asthma are heterogenous chronic inflammatory conditions with several distinct complex endotypes. Both environmental and genetic factors can influence the development and progression of allergy. Complex pathogenetic pathways observed in allergic disorders present a challenge in patient management and successful targeted treatment strategies. The increasing availability of high-throughput omics technologies, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics allows studying biochemical systems and pathophysiological processes underlying allergic responses. Additionally, omics techniques present clinical applicability by functional identification and validation of biomarkers. Therefore, finding molecules or patterns characteristic for distinct immune-inflammatory endotypes, can subsequently influence its development, progression, and treatment. There is a great potential to further increase the effectiveness of single omics approaches by integrating them with other omics, and nonomics data. Systems biology aims to simultaneously and longitudinally understand multiple layers of a complex and multifactorial disease, such as allergy, or asthma by integrating several, separated data sets and generating a complete molecular profile of the condition. With the use of sophisticated biostatistics and machine learning techniques, these approaches provide in-depth insight into individual biological systems and will allow efficient and customized healthcare approaches, called precision medicine. In this EAACI Position Paper, the Task Force &quot;Omics technologies in allergic research&quot; broadly reviewed current advances and applicability of omics techniques in allergic diseases and asthma research, with a focus on methodology and data analysis, aiming to provide researchers (basic and clinical) with a desk reference in the field. The potential of omics strategies in understanding disease pathophysiology and key tools to reach unmet needs in allergy precision medicine, such as successful patients&apos; stratification, accurate disease prognosis, and prediction of treatment efficacy and successful prevention measures are highlighted.</style></abstract><notes><style face="normal" font="default" size="100%">Radzikowska, Urszula&#xD;Baerenfaller, Katja&#xD;Cornejo-Garcia, Jose Antonio&#xD;Karaaslan, Cagatay&#xD;Barletta, Elena&#xD;Sarac, Basak Ezgi&#xD;Zhakparov, Damir&#xD;Villasenor, Alma&#xD;Eguiluz-Gracia, Ibon&#xD;Mayorga, Cristobalina&#xD;Sokolowska, Milena&#xD;Barbas, Coral&#xD;Barber, Domingo&#xD;Ollert, Markus&#xD;Chivato, Tomas&#xD;Agache, Ioana&#xD;Escribese, Maria M&#xD;eng&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):2888-2908. doi: 10.1111/all.15412. Epub 2022 Jun 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35713644</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9796060</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15412</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2938</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2938</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosges, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">IMSB, Medical Faculty, University of Cologne, Cologne, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">On a Rainy Day, Placebo Is the Ideal Treatment for Your Hay Fever</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1206-1207</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/05/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40314131</style></accession-num><notes><style face="normal" font="default" size="100%">Mosges, Ralph&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1206-1207. doi: 10.1111/all.16565. Epub 2025 May 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40314131</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16565</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3112</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3112</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alvarado, D.</style></author><author><style face="normal" font="default" size="100%">Maurer, D. M.</style></author><author><style face="normal" font="default" size="100%">Golden, P.</style></author><author><style face="normal" font="default" size="100%">Hawthorne, T.</style></author><author><style face="normal" font="default" size="100%">Thomas, L. J.</style></author><author><style face="normal" font="default" size="100%">Heath-Chiozzi, M.</style></author><author><style face="normal" font="default" size="100%">Keler, T.</style></author><author><style face="normal" font="default" size="100%">Crowley, E.</style></author><author><style face="normal" font="default" size="100%">Young, D.</style></author><author><style face="normal" font="default" size="100%">Terhorst-Molawi, D.</style></author><author><style face="normal" font="default" size="100%">Munoz, M.</style></author><author><style face="normal" font="default" size="100%">Metz, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Celldex Therapeutics, Hampton, New Jersey, USA.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt Universitat Zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">On the Kinetics of Human Skin Mast Cell Depletion and Repopulation Following KIT Inhibition</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41133917</style></accession-num><notes><style face="normal" font="default" size="100%">Alvarado, Diego&#xD;Maurer, Deena M&#xD;Golden, Philip&#xD;Hawthorne, Thomas&#xD;Thomas, Lawrence J&#xD;Heath-Chiozzi, Margo&#xD;Keler, Tibor&#xD;Crowley, Elizabeth&#xD;Young, Diane&#xD;Terhorst-Molawi, Dorothea&#xD;Munoz, Melba&#xD;Metz, Martin&#xD;eng&#xD;Celldex Therapeutics/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct 24. doi: 10.1111/all.70129.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41133917</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70129</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2599</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2599</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bachmann, M. F.</style></author><author><style face="normal" font="default" size="100%">Krenger, P. S.</style></author><author><style face="normal" font="default" size="100%">Mohsen, M. O.</style></author><author><style face="normal" font="default" size="100%">Kramer, M. F.</style></author><author><style face="normal" font="default" size="100%">Starchenka, S.</style></author><author><style face="normal" font="default" size="100%">Whitehead, P.</style></author><author><style face="normal" font="default" size="100%">Vogel, M.</style></author><author><style face="normal" font="default" size="100%">Heath, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Rheumatology and Immunology, University Hospital of Bern, Bern, Switzerland.&#xD;Department for Biomedical Research Bern (DBMR), University of Bern, Bern, Switzerland.&#xD;Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, UK.&#xD;Allergy Therapeutics, Worthing, UK.&#xD;Bencard Allergie GmbH, Munich, Germany.&#xD;SeromYx Systems, Cambridge, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">On the role of antibody affinity and avidity in the IgE-mediated allergic response</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">37-46</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/08/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibody Affinity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, IgE/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgG/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">affinity</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">antibody</style></keyword><keyword><style face="normal" font="default" size="100%">avidity</style></keyword><keyword><style face="normal" font="default" size="100%">in the development of allergen-specific immunotherapies within Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutic LTD and Saiba AG.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39189064</style></accession-num><abstract><style face="normal" font="default" size="100%">Type I hypersensitivity, also known as classical allergy, is mediated via allergen-specific IgE antibodies bound to type I FcR (FcepsilonRI) on the surface of mast cells and basophils upon cross-linking by allergens. This IgE-mediated cellular activation may be blocked by allergen-specific IgG through multiple mechanisms, including direct neutralization of the allergen or engagement of the inhibitory receptor FcgammaRIIb which blocks IgE signal transduction. In addition, co-engagement of FcepsilonRI and FcgammaRIIb by IgE-IgG-allergen immune complexes causes down regulation of receptor-bound IgE, resulting in desensitization of the cells. Both, activation of FcepsilonRI by allergen-specific IgE and engagement of FcgammaRIIb by allergen-specific IgG are driven by allergen-binding. Here we delineate the distinct roles of antibody affinity versus avidity in driving these processes and discuss the role of IgG subclasses in inhibiting basophil and mast cell activation.</style></abstract><notes><style face="normal" font="default" size="100%">Bachmann, Martin F&#xD;Krenger, Pascal S&#xD;Mohsen, Mona O&#xD;Kramer, Matthias F&#xD;Starchenka, Sviatlana&#xD;Whitehead, Piers&#xD;Vogel, Monique&#xD;Heath, Matthew D&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):37-46. doi: 10.1111/all.16248. Epub 2024 Aug 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39189064</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724228</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16248</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2780</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2780</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Esnault, S.</style></author><author><style face="normal" font="default" size="100%">Bernau, K.</style></author><author><style face="normal" font="default" size="100%">Floerke, H. L.</style></author><author><style face="normal" font="default" size="100%">Dendooven, A.</style></author><author><style face="normal" font="default" size="100%">Delaunay, E.</style></author><author><style face="normal" font="default" size="100%">Dill-McFarland, K. A.</style></author><author><style face="normal" font="default" size="100%">Altman, M. C.</style></author><author><style face="normal" font="default" size="100%">Busse, W. W.</style></author><author><style face="normal" font="default" size="100%">Rosenkranz, M. A.</style></author><author><style face="normal" font="default" size="100%">Tattersall, M. C.</style></author><author><style face="normal" font="default" size="100%">Johansson, M. W.</style></author><author><style face="normal" font="default" size="100%">Labreuche, J.</style></author><author><style face="normal" font="default" size="100%">Beury, D.</style></author><author><style face="normal" font="default" size="100%">Sebda, S.</style></author><author><style face="normal" font="default" size="100%">Dezoteux, F.</style></author><author><style face="normal" font="default" size="100%">Segard, B.</style></author><author><style face="normal" font="default" size="100%">Mortuaire, G.</style></author><author><style face="normal" font="default" size="100%">Staumont-Salle, D.</style></author><author><style face="normal" font="default" size="100%">Stoup, T.</style></author><author><style face="normal" font="default" size="100%">Chenivesse, C.</style></author><author><style face="normal" font="default" size="100%">Sandbo, N.</style></author><author><style face="normal" font="default" size="100%">Jarjour, N. N.</style></author><author><style face="normal" font="default" size="100%">Lefevre, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Univ. Lille, INSERM, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, France.&#xD;Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.&#xD;Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.&#xD;Systems Immunology Division, Benaroya Research Institute, Seattle, Washington, USA.&#xD;Center for Healthy Minds, University of Wisconsin-Madison, Madison, Wisconsin, USA.&#xD;Department of Psychiatry, University of Wisconsin-Madison, Madison, Wisconsin, USA.&#xD;Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.&#xD;Health Statistics, SEED: Statistique, evaluation, economique, Data-Management Maison Regionale de la Recherche Clinique University Hospital of Lille, Lille, France.&#xD;Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur Lille, US 41-UAR 2014-PLBS, Lille, France.&#xD;Departement de Dermatologie, CHU Lille, Lille, France.&#xD;CEREO, National Reference Center for Hypereosinophilic Syndromes, Suresnes, France.&#xD;Departement d&apos;oto-Rhino-Laryngologie, CHU Lille, Lille, France.&#xD;Univ. Lille, CHU Lille, CNRS, Inserm, Institut Pasteur Lille, U1019-UMR9017-CIIL-Centre d&apos;Infection et d&apos;Immunite de Lille, Lille, France.&#xD;CRISALIS (Clinical Research Initiative in Severe Asthma: A Lever for Innovation &amp; Science), Toulouse, France.&#xD;CHU Lille, Institut d&apos;Immunologie, Medecine Interne et Immunologie Clinique, Lille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oncostatin-M Is Produced by Human Eosinophils and Expression Is Increased in Uncontrolled Severe Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1154-1157</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">Oncostatin M</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchoalveolar lavage</style></keyword><keyword><style face="normal" font="default" size="100%">cytolysis</style></keyword><keyword><style face="normal" font="default" size="100%">degranulation</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">independent grant from Boehringer Ingelheim Pharmaceuticals Inc. who provided the</style></keyword><keyword><style face="normal" font="default" size="100%">financial support outside of the submitted work. W. W. Busse reports consulting</style></keyword><keyword><style face="normal" font="default" size="100%">fees/honoraria from GlaxoSmithKline, Regeneron, Sanofi, and Genentech, and</style></keyword><keyword><style face="normal" font="default" size="100%">royalties from Elsevier. N. N. Jarjour received research funding from AstraZeneca</style></keyword><keyword><style face="normal" font="default" size="100%">for extension of the National Institutes of Health-funded severe asthma research</style></keyword><keyword><style face="normal" font="default" size="100%">program</style></keyword><keyword><style face="normal" font="default" size="100%">and received consulting fees over the past 3 years from GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiese, and AstraZeneca related to asthma treatment. K. A. Dill-McFarland reports</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Seattle BioSoftware and EuropaDX related to computational</style></keyword><keyword><style face="normal" font="default" size="100%">tool development. F. Dezoteux was investigator for clinical trials sponsored by</style></keyword><keyword><style face="normal" font="default" size="100%">Abbvie, Almirall, Amgen, AstraZeneca, Eli Lilly, Galderma, Leo Pharma, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, and Sanofi-Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">received consulting fees by AbbVie, Almirall, Eli</style></keyword><keyword><style face="normal" font="default" size="100%">Lilly, Galderma, Leo Pharma, Novartis, Pfizer, Sanofi-Regeneron, and UCB. D.</style></keyword><keyword><style face="normal" font="default" size="100%">Staumont-Salle received funding from AstraZeneca for a research study in DRESS</style></keyword><keyword><style face="normal" font="default" size="100%">syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">was investigator for clinical trials sponsored by Abbvie, Almirall,</style></keyword><keyword><style face="normal" font="default" size="100%">Amgen, AstraZeneca, Eli Lilly, Galderma, Leo Pharma, Novartis, Pfizer, and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">received consulting fees by AbbVie, Almirall, AstraZeneca, Eli</style></keyword><keyword><style face="normal" font="default" size="100%">Lilly, Galderma, GSK, Leo Pharma, Novartis, Pfizer, Sanofi-Regeneron, and UCB. C.</style></keyword><keyword><style face="normal" font="default" size="100%">Chenivesse declares research grants from AstraZeneca, GlaxoSmithKlein, Santelys,</style></keyword><keyword><style face="normal" font="default" size="100%">and Novartis, personal fees from ALK-Abello, AstraZeneca, Boehringer Ingelheim,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, Sanofi, and GlaxoSmithKlein and congress support from AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Chiesi, and Novartis. G. Lefevre received consulting fees,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees for advisory boards or meetings, and research fundings from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca and GSK. These relationships with pharmaceutical companies are not</style></keyword><keyword><style face="normal" font="default" size="100%">relevant to the current study. M. W. Johansson received funding from Hoffmann-La</style></keyword><keyword><style face="normal" font="default" size="100%">Roche, outside of the submitted work. The rest of the authors declare that they</style></keyword><keyword><style face="normal" font="default" size="100%">have no relevant conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39707874</style></accession-num><notes><style face="normal" font="default" size="100%">Esnault, Stephane&#xD;Bernau, Ksenija&#xD;Floerke, Heather L&#xD;Dendooven, Arnaud&#xD;Delaunay, Emeline&#xD;Dill-McFarland, Kimberly A&#xD;Altman, Matthew C&#xD;Busse, William W&#xD;Rosenkranz, Melissa A&#xD;Tattersall, Matthew C&#xD;Johansson, Mats W&#xD;Labreuche, Julien&#xD;Beury, Delphine&#xD;Sebda, Sheherazade&#xD;Dezoteux, Frederic&#xD;Segard, Baptiste&#xD;Mortuaire, Geoffrey&#xD;Staumont-Salle, Delphine&#xD;Stoup, Thomas&#xD;Chenivesse, Cecile&#xD;Sandbo, Nathan&#xD;Jarjour, Nizar N&#xD;Lefevre, Guillaume&#xD;eng&#xD;U.S. Department of Defense/&#xD;R01 HL146402/HL/NHLBI NIH HHS/&#xD;University of Wisconsin-Madison/&#xD;Centre hospitalier regional universitaire de Lille/&#xD;UL1 RR025011/RR/NCRR NIH HHS/&#xD;Pulmonary Fibrosis Foundation/&#xD;P01 HL088594/HL/NHLBI NIH HHS/&#xD;K01 AT006202/AT/NCCIH NIH HHS/&#xD;Institut National de la Sante et de la Recherche Medicale/&#xD;R01 HL123284/HL/NHLBI NIH HHS/&#xD;NH/NIH HHS/&#xD;UL1 TR002373/TR/NCATS NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1154-1157. doi: 10.1111/all.16453. Epub 2024 Dec 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39707874</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969300</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16453</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2121</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2121</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Mosnaim, G. S.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Khan, D. A.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Zemelka-Wiacek, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Division of Allergy and Immunology, Department of Medicine, Northshore University Health System, Evanston, Illinois, USA.&#xD;Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.&#xD;Division of Allergy and Immunology, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna and Medical University Vienna, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Medical University Vienna, Vienna, Austria.&#xD;Allergy Unit, Regional University Hospital of Malaga, IBIMA-UMA-ARADyAL, Malaga, Spain.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The One Health approach for allergic diseases and asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1777-1793</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/04/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*One Health</style></keyword><keyword><style face="normal" font="default" size="100%">Irritants</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biodiversity</style></keyword><keyword><style face="normal" font="default" size="100%">climate change</style></keyword><keyword><style face="normal" font="default" size="100%">exposome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37119496</style></accession-num><abstract><style face="normal" font="default" size="100%">The One Health approach is a collaborative and interdisciplinary strategy with focal point on human, animal, and environmental health interconnections. One Health can support the advanced management of allergic diseases and asthma, as complex, multifactorial diseases driven by interactions between the resilience response to the exposome. According to the One Health concept allergic diseases and asthma arising from exposures to a wide range of allergens, infectious agents and irritants (such as pollutants) occurring indoors and outdoors can be heavily influenced by environmental health (air, water, and soil quality) intermingled with animal health. These are currently heavily impacted by climate change, land use, urbanization, migration, overpopulation, and many more. Thus, a coordinated response to address the underlying factors that contribute to the development of allergic diseases and asthma needs to focus on the environment, human, and animal health altogether. Collaborative efforts across multiple sectors, including public health, veterinary medicine, environmental science, and community engagement are thus needed. A wide range of activities, including monitoring and surveillance of environmental and health data, targeted interventions to reduce exposures to allergens and irritants, and research on the underlying mechanisms that drive the development of allergic diseases and asthma are needed to move the field forward. In this consensus document elaborated by the European Academy of Allergy and Clinical Immunology (EAACI) and American Academy of Allergy, Asthma, and Immunology (AAAAI) under the practical allergy (PRACTALL) series, we provide insights into the One Heath approach aiming to provide a framework for addressing the complex and multifactorial nature of allergic diseases and asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Jutel, Marek&#xD;Mosnaim, Giselle S&#xD;Bernstein, Jonathan A&#xD;Del Giacco, Stefano&#xD;Khan, David A&#xD;Nadeau, Kari C&#xD;Pali-Scholl, Isabella&#xD;Torres, Maria J&#xD;Zemelka-Wiacek, Magdalena&#xD;Agache, Ioana&#xD;eng&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1777-1793. doi: 10.1111/all.15755. Epub 2023 May 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37119496</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15755</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1122</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1122</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Roth-Walter, F.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Comparative Medicine, Interuniversity Messerli Research Institute, University of Veterinary Medicine, Vienna, Austria.&#xD;Center of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">One Health in allergology: A concept that connects humans, animals, plants, and the environment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2630-2633</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*One Health</style></keyword><keyword><style face="normal" font="default" size="100%">climate</style></keyword><keyword><style face="normal" font="default" size="100%">global</style></keyword><keyword><style face="normal" font="default" size="100%">planet</style></keyword><keyword><style face="normal" font="default" size="100%">public health</style></keyword><keyword><style face="normal" font="default" size="100%">tool for allergy diagnostic and therapy,&quot; EP 14150965.3, Year: 01/2014</style></keyword><keyword><style face="normal" font="default" size="100%">US</style></keyword><keyword><style face="normal" font="default" size="100%">14/204,570, owned by Biomedical International R + D GmbH, Vienna, Austria. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Jensen-Jarolim is shareholder in this company. Dr. Pali-Scholl has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33665860</style></accession-num><notes><style face="normal" font="default" size="100%">Pali-Scholl, Isabella&#xD;Roth-Walter, Franziska&#xD;Jensen-Jarolim, Erika&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2630-2633. doi: 10.1111/all.14804. Epub 2021 Mar 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33665860</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8359833</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14804</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>923</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">923</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Korath, A. D. J.</style></author><author><style face="normal" font="default" size="100%">Janda, J.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Feleszko, W.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Adel Seida, A.</style></author><author><style face="normal" font="default" size="100%">Hartmann, K.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Comparative Medicine, Interuniversity Messerli Research Institute, University of Veterinary Medicine and Medical University Vienna, Vienna, Austria.&#xD;Faculty of Science, Charles University, Prague, Czech Republic.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF),, University of Zurich, Zurich, Switzerland.&#xD;Department of Paediatric Allergy and Pulmonology, The Medical University of Warsaw, Warsaw, Poland.&#xD;Transylvania University, Brasov, Romania.&#xD;Department of Microbiology and Immunology, Faculty of Veterinary Medicine, Cairo University, Cairo, Egypt.&#xD;Medizinische Kleintierklinik, Zentrum fur Klinische Tiermedizin, LMU, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">One Health: EAACI Position Paper on coronaviruses at the human-animal interface, with a specific focus on comparative and zoonotic aspects of SARS-CoV-2</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">55-71</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/06/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*One Health</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">(reverse) zoonosis</style></keyword><keyword><style face="normal" font="default" size="100%">One Health</style></keyword><keyword><style face="normal" font="default" size="100%">companion animals and pets</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus</style></keyword><keyword><style face="normal" font="default" size="100%">disease transmission</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34180546</style></accession-num><abstract><style face="normal" font="default" size="100%">The latest outbreak of a coronavirus disease in 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), evolved into a worldwide pandemic with massive effects on health, quality of life, and economy. Given the short period of time since the outbreak, there are several knowledge gaps on the comparative and zoonotic aspects of this new virus. Within the One Health concept, the current EAACI position paper dwells into the current knowledge on SARS-CoV-2&apos;s receptors, symptoms, transmission routes for human and animals living in close vicinity to each other, usefulness of animal models to study this disease and management options to avoid intra- and interspecies transmission. Similar pandemics might appear unexpectedly and more frequently in the near future due to climate change, consumption of exotic foods and drinks, globe-trotter travel possibilities, the growing world population, the decreasing production space, declining room for wildlife and free-ranging animals, and the changed lifestyle including living very close to animals. Therefore, both the society and the health authorities need to be aware and well prepared for similar future situations, and research needs to focus on prevention and fast development of treatment options (medications, vaccines).</style></abstract><notes><style face="normal" font="default" size="100%">Korath, Anna D J&#xD;Janda, Jozef&#xD;Untersmayr, Eva&#xD;Sokolowska, Milena&#xD;Feleszko, Wojciech&#xD;Agache, Ioana&#xD;Adel Seida, Ahmed&#xD;Hartmann, Katrin&#xD;Jensen-Jarolim, Erika&#xD;Pali-Scholl, Isabella&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology (EAACI)/&#xD;Consensus Development Conference&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):55-71. doi: 10.1111/all.14991. Epub 2021 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34180546</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441637</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14991</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>880</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">880</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Kleine-Tebbe, J.</style></author><author><style face="normal" font="default" size="100%">Larche, M.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Gerth van Wijk, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Dermatology and Allergy, Charite, Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany.&#xD;University Hospital Montpellier, Montpellier, France.&#xD;Allergy and Clinical Immunology, Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College NIHR Biomedical Research Centre, National Heart and Lung Institute, London, UK.&#xD;Allergy &amp; Asthma Center Westend, Outpatient and Clinical Research Center, Berlin, Germany.&#xD;Department of Medicine, McMaster University, Hamilton, ON, Canada.&#xD;Firestone Institute for Respiratory Health, St. Joseph&apos;s Healthcare, Hamilton, ON, Canada.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Section of Allergology and Clinical Immunology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">454-468</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">evidence</style></keyword><keyword><style face="normal" font="default" size="100%">innovations</style></keyword><keyword><style face="normal" font="default" size="100%">mechanisms</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34315190</style></accession-num><abstract><style face="normal" font="default" size="100%">One hundred and ten years after Noon&apos;s first clinical report of the subcutaneous application of allergen extracts, allergen immunotherapy (AIT) has evolved as the most important pillar of the treatment of allergic patients. It is the only disease-modifying treatment option available and the evidence for its clinical efficacy and safety is broad and undisputed. Throughout recent decades, more insights into the underlying mechanisms, in particular the modulation of innate and adaptive immune responses, have been described. AIT is acknowledged by worldwide regulatory authorities, and following the regulatory guidelines for product development, AIT products are subject to a rigorous evaluation before obtaining market authorization. Knowledge and practice are anchored in international guidelines, such as the recently published series of the European Academy of Allergy and Clinical Immunology (EAACI). Innovative approaches continue to be further developed with the focus on clinical improvement by, for example, the usage of adjuvants, peptides, recombinants, modification of allergens, new routes of administration, and the concomitant use of biologicals. In addition, real-life data provide complementary and valuable information on the effectiveness and tolerability of this treatment option in the clinical routine. New mobile health technologies and big-data approaches will improve daily treatment convenience, adherence, and efficacy of AIT. However, the current coronavirus disease 2019 (COVID-19) pandemic has also had some implications for the feasibility and practicability of AIT. Taken together, AIT as the only disease-modifying therapy in allergic diseases has been broadly investigated over the past 110 years laying the path for innovations and further improvement.</style></abstract><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Bousquet, Jean&#xD;Durham, Stephen R&#xD;Kleine-Tebbe, Jorg&#xD;Larche, Mark&#xD;Roberts, Graham&#xD;Shamji, Mohamed H&#xD;Gerth van Wijk, Roy&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):454-468. doi: 10.1111/all.15023. Epub 2021 Sep 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34315190</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15023</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2109</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2109</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Su, H.</style></author><author><style face="normal" font="default" size="100%">Kolkhir, P.</style></author><author><style face="normal" font="default" size="100%">Scheffel, J.</style></author><author><style face="normal" font="default" size="100%">Xiang, Y. K.</style></author><author><style face="normal" font="default" size="100%">Yao, X.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Altrichter, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Department of Dermatology, Fujian Medical University Union Hospital, Fuzhou, China.&#xD;Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.&#xD;Department of Dermatology and Venerology, Kepler University Hospital, Linz, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">One in five patients with chronic spontaneous urticaria has IgE to tissue transglutaminase 2</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2537-2539</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/04/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Glutamine gamma Glutamyltransferase 2</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37017141</style></accession-num><notes><style face="normal" font="default" size="100%">Su, Huichun&#xD;Kolkhir, Pavel&#xD;Scheffel, Jorg&#xD;Xiang, Yi-Kui&#xD;Yao, Xu&#xD;Maurer, Marcus&#xD;Altrichter, Sabine&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2537-2539. doi: 10.1111/all.15734. Epub 2023 Apr 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37017141</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15734</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2714</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2714</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Vogelberg, C.</style></author><author><style face="normal" font="default" size="100%">Duwensee, K.</style></author><author><style face="normal" font="default" size="100%">Troyke, D.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">All-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Clinical Immunology, Faculty of Medicine of Wroclaw Medical University, Wroclaw, Poland.&#xD;Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.&#xD;Allergopharma GmbH &amp; Co. KG, Reinbek, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">One-strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">807-816</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/11/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroglyphidae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Subcutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Dermatophagoides/administration &amp; dosage/immunology/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/immunology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/administration &amp; dosage/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinitis, Allergic/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mites</style></keyword><keyword><style face="normal" font="default" size="100%">one-strength dose escalation scheme</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics, Leti, HAL, GSK, Novartis, Teva, Takeda, Chiesi, Pfizer,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Astra Zeneka, Lallemand, Shire, CELLTRION Inc. Genetech, Roche,</style></keyword><keyword><style face="normal" font="default" size="100%">Verona, Lek Pharmaceuticals, Arcutis Biotherapeutics, FAES FARMA outside of</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work and is the Allergy Journal Deputy Editor and EAACI Board of</style></keyword><keyword><style face="normal" font="default" size="100%">Officers Member-Past President. C.V. has received personal fees for lectures or</style></keyword><keyword><style face="normal" font="default" size="100%">consultancy from Aimmune Therapeutics, Allergopharma, ALK-Abello, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard Allergie, DBV Technology, LETI Pharma, Novartis Pharma, Orion Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi Aventis, and Stallergenes outside of submitted work. He is the President</style></keyword><keyword><style face="normal" font="default" size="100%">of the Society of Paediatric Allergology and Environmental Medicine and member of</style></keyword><keyword><style face="normal" font="default" size="100%">AeDA, DGAKI, EAACI, ERS. K.D. and D.T. are employees of Allergopharma GmbH &amp; Co.</style></keyword><keyword><style face="normal" font="default" size="100%">KG, Reinbek, Germany. L.K. reports grants and personal fees from Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from Viatris, personal fees from HAL Allergie, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from ALK Abello, grants and personal fees from LETI Pharma, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Stallergenes, grants from Quintiles, grants and personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Sanofi, grants from ASIT bio-tech, grants from Lofarma, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics, grants from AstraZeneca, grants and personal fees from GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Inmunotek, personal fees from Cassella med, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, personal fees from Regeneron Pharmaceuticals, personal fees from ROXALL</style></keyword><keyword><style face="normal" font="default" size="100%">Medizin GmbH, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and Membership: AeDA</style></keyword><keyword><style face="normal" font="default" size="100%">DGHNO</style></keyword><keyword><style face="normal" font="default" size="100%">Deutsche</style></keyword><keyword><style face="normal" font="default" size="100%">Akademie furAllergologie und klinische Immunologie</style></keyword><keyword><style face="normal" font="default" size="100%">HNO-BV</style></keyword><keyword><style face="normal" font="default" size="100%">GPA</style></keyword><keyword><style face="normal" font="default" size="100%">EAACI.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39540587</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergen immunotherapy (AIT) aims at modulating the immune response by administration of allergen preparations at regular intervals over several years (1). For subcutaneous AIT (SCIT), the treatment is initiated with a dose escalation phase followed by a maintenance dose administration. Over the last decade, there has been a trend towards shortening dose escalation regimens to increase patient adherence. This open-label, phase II trial aimed to investigate the safety and tolerability of a house dust mites (HDMs) SCIT product when used in a newly designed one-strength dose escalation scheme. METHOD: Patients, aged 12-65, suffering from HDM-allergic rhinitis/rhinoconjunctivitis +/- asthma were included. Patients were randomized to the one-strength (6 injections from the highest strength 3) or the Standard dose escalation regimen (14 injections from strengths 1 to 3) using the HDMs-SCIT product. All adverse events were reported. Tolerability was assessed on the Likert scale. RESULTS: One hundred and forty-three patients were randomized, 79 adults and 64 adolescents. In total, the one-strength regimen caused more adverse drug reactions (ADRs) than the Standard regimen (p = .0457). With both regimens most ADRs were local reactions which occurred more often in the one-strength group (p = .0393). But there was no significant difference in the number of patients affected by systemic or serious ADRs between both regimens. No relevant differences occurred between the two age groups and no other risks were observed for adolescents compared to adults. CONCLUSION: The safety and tolerability of both regimens can be considered comparable, as most ADRs were local reactions, primarily rated as mild in intensity. Nevertheless, the one-strength regimen caused more ADRs. Reducing the number of injections from 14 to 6 while using only one strength offers the potential to improve patient adherence which further might increase clinical efficacy. Future trials could confirm this hypothesis.</style></abstract><notes><style face="normal" font="default" size="100%">Jutel, M&#xD;Vogelberg, C&#xD;Duwensee, K&#xD;Troyke, D&#xD;Klimek, L&#xD;eng&#xD;Allergopharma GmbH &amp; Co. KG/&#xD;Clinical Trial, Phase II&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):807-816. doi: 10.1111/all.16370. Epub 2024 Nov 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39540587</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891436</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16370</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3250</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3250</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jutel, Marek</style></author><author><style face="normal" font="default" size="100%">Klimek, Ludger</style></author><author><style face="normal" font="default" size="100%">Gerstlauer, Michael</style></author><author><style face="normal" font="default" size="100%">Troyke, Dana</style></author><author><style face="normal" font="default" size="100%">Duwensee, Kristina</style></author><author><style face="normal" font="default" size="100%">Vogelberg, Christian</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A One-Strength Dose Escalation Regimen for Birch Pollen SCIT Is Safe and Tolerable in Children, Adolescents, and Adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Allergen immunotherapy is the only disease-modifying treatment for IgE-mediated diseases for patients 5 years and over. The question is often asked why children receive the same doses as adults. There is not a single dose-finding study including children and/or adolescents. Moreover, randomized controlled trials that include all age groups but report effects separately are rare. Method This randomized trial investigated the safety and tolerability of an accelerated dose escalation schedule (One-Strength group) compared to the standard regimen (Standard group) when using a birch pollen SCIT allergoid in patients aged 5–65 years. Results Overall, 201 patients were randomized to the two regimens: 87 adults, 52 adolescents, 62 children. Three hundred eighty-two treatment-related adverse drug reactions (ADRs) occurred in 81 patients (40.5%). A higher proportion of patients in the One-Strength group (48.5%) experienced at least one ADR compared to those in the Standard group (32.0%). The majority of ADRs were local (93.3%), and the majority were of mild intensity (95.8%). 3 patients in the One-Strength and 1 patient in the Standard group developed a total of 9 systemic ADRs, which all were classified as WAO grade 1 or 2 and most of mild intensity. No event of WAO grade 3 or higher was reported. No serious ADR occurred. Overall, tolerability was assessed as “very good” or “good” by more than 96% of investigators and patients. Safety and tolerability were comparable in the three age groups. Conclusion Birch pollen SCIT was safe and well-tolerated when administered using a One-Strength dose-escalation regimen in patients aged 5–65 years.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70265</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70265</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>878</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">878</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Vereda, A.</style></author><author><style face="normal" font="default" size="100%">Vickery, B. P.</style></author><author><style face="normal" font="default" size="100%">Sharma, V.</style></author><author><style face="normal" font="default" size="100%">Nilsson, C.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Hourihane, J. O.</style></author><author><style face="normal" font="default" size="100%">DunnGalvin, A.</style></author><author><style face="normal" font="default" size="100%">du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Blumchen, K.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Smith, A.</style></author><author><style face="normal" font="default" size="100%">Ryan, R.</style></author><author><style face="normal" font="default" size="100%">Adelman, D. C.</style></author><author><style face="normal" font="default" size="100%">Jones, S. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.&#xD;Aimmune Therapeutics, London, UK.&#xD;Emory University School of Medicine, Atlanta, Georgia, USA.&#xD;Department of Paediatric Allergy and Immunology, Royal Manchester Children&apos;s Hospital, Manchester, UK.&#xD;Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Sachs&apos; Children and Youth Hospital, Stockholm, Sweden.&#xD;Food Allergy Referral Centre Veneto Region, Department of Woman and Child Health, Padua University Hospital, Padua, Italy.&#xD;Paediatrics and Child Health, Royal College of Surgeons in Ireland, Dublin, Ireland.&#xD;Infant Centre and Pediatrics and Child Health, University College Cork, and HRB Clinical Research Facility-Cork, Cork, Ireland.&#xD;Department of Pediatrics and Pediatric Infectious Diseases, Sechenov University, Moscow, Russia.&#xD;Guy&apos;s and St. Thomas&apos; NHS Foundation Trust, London, UK.&#xD;Division of Allergology, Pneumology and Cystic Fibrosis, Department of Children and Adolescent Medicine, Goethe University Frankfurt, Frankfurt, Germany.&#xD;Division of Pulmonology, Immunology and Critical Care Medicine, Department of Pediatrics, Charite Universtatsmedizin Berlin, Berlin, Germany.&#xD;Aimmune Therapeutics, Brisbane, California, USA.&#xD;Department of Medicine, University of California San Francisco, San Francisco, California, USA.&#xD;University of Arkansas for Medical Sciences and Arkansas Children&apos;s Hospital, Little Rock, Arkansas, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">991-1003</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/07/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/adverse effects/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, SPRIM</style></keyword><keyword><style face="normal" font="default" size="100%">research funding from European Commission, MINECO and ISCIII of</style></keyword><keyword><style face="normal" font="default" size="100%">Spanish government</style></keyword><keyword><style face="normal" font="default" size="100%">speakers bureau for ALK, Allergy Therapeutics, Diater,</style></keyword><keyword><style face="normal" font="default" size="100%">Fundacion SEAIC, GSK, HAL Allergy, Thermo Fisher Scientific. Andrea Vereda is an</style></keyword><keyword><style face="normal" font="default" size="100%">employee and stockholder of Aimmune Therapeutics. Brian P Vickery reports</style></keyword><keyword><style face="normal" font="default" size="100%">advisory board/consultant: Aimmune Therapeutics, AllerGenis, FARE, Reacta</style></keyword><keyword><style face="normal" font="default" size="100%">site</style></keyword><keyword><style face="normal" font="default" size="100%">investigator: Aimmune Therapeutics, DBV, Genentech, Regeneron</style></keyword><keyword><style face="normal" font="default" size="100%">research grants:</style></keyword><keyword><style face="normal" font="default" size="100%">FARE, NIAID. Vibha Sharma reports speaker fees from Aimmune Therapeutics outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work. Caroline Nilsson reports grants to institution and advisory</style></keyword><keyword><style face="normal" font="default" size="100%">board fees from Aimmune Therapeutics and Novartis and speakers fees from MEDA,</style></keyword><keyword><style face="normal" font="default" size="100%">ALK, Thermo Fisher, GSK. Antonella Muraro reports personal fees from DVB</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Aimmune, Nestle-Purina, Nestle Health Institute, Mylan, and</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia outside the submitted work. Jonathan O&apos;B. Hourihane reports advisory</style></keyword><keyword><style face="normal" font="default" size="100%">board fees, Aimmune Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">speakers bureau, Aimmune Therapeutics, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Nutricia, Mead Johnson</style></keyword><keyword><style face="normal" font="default" size="100%">grants to institution/research funding, and</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trials within past 2 years, Aimmune Therapeutics, DBV Technologies.</style></keyword><keyword><style face="normal" font="default" size="100%">Audrey DunnGalvin reports personal fees from Aimmune Therapeutics and DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies outside the submitted work. George du Toit reports research grants</style></keyword><keyword><style face="normal" font="default" size="100%">to institution and advisory board fees from Aimmune Therapeutics. Katharina</style></keyword><keyword><style face="normal" font="default" size="100%">Blumchen reports consulting for Aimmune Therapeutics, DBV Technologies, Bencard</style></keyword><keyword><style face="normal" font="default" size="100%">Allergie, HAL Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">speakers bureau for Aimmune Therapeutics, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, HAL Allergy, Nutricia, Thermo Fisher Scientific, ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, Nestle</style></keyword><keyword><style face="normal" font="default" size="100%">and conducting clinical trials for Aimmune Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">DBV Technologies, and Hipp. Kirsten Beyer reports advisory board/consulting fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Aimmune Therapeutics, ALK, Bausch &amp; Lomb, Bencard, Danone, DBV, Hycor,</style></keyword><keyword><style face="normal" font="default" size="100%">Infectopharm, Mabylon, Meda Pharma, Mylan, Nestle</style></keyword><keyword><style face="normal" font="default" size="100%">speakers bureau for Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Allergopharma, Bencard, Danone, Di-Text, Hammer und Rall Media,</style></keyword><keyword><style face="normal" font="default" size="100%">Infectopharm, Meda Pharma, Med Update, Nestle, Nutricia</style></keyword><keyword><style face="normal" font="default" size="100%">and research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune, ALK, Danone, DBV, Good Mills, Hipp, Hycor, Infectopharm, Nutricia,</style></keyword><keyword><style face="normal" font="default" size="100%">ThermoFisher, VDI. Alex Smith is an employee and stockholder of Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics. Robert Ryan an employee and stockholder of Aimmune Therapeutics.</style></keyword><keyword><style face="normal" font="default" size="100%">Daniel C. Adelman was an employee and stockholder of Aimmune Therapeutics at the</style></keyword><keyword><style face="normal" font="default" size="100%">time of the development of this work. He has patents pending for the following:</style></keyword><keyword><style face="normal" font="default" size="100%">US 16/542,198</style></keyword><keyword><style face="normal" font="default" size="100%">PCT/US2019/046706</style></keyword><keyword><style face="normal" font="default" size="100%">US 16/721,805</style></keyword><keyword><style face="normal" font="default" size="100%">PCT/US2019/067634. Stacie M.</style></keyword><keyword><style face="normal" font="default" size="100%">Jones reports advisory board fees, Aimmune Therapeutics, FARE</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trials grants, Aimmune Therapeutics, DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">Astellas, Sanofi, Regeneron, FARE, Genentech, and NIH-NIAID.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34320250</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The benefit of daily administration of Peanut (Arachis hypogaea) Allergen Powder-dnfp (PTAH)-formerly AR101-has been established in clinical trials, but limited data past the first year of treatment are available. This longitudinal analysis aimed to explore the impact of continued PTAH therapeutic maintenance dosing (300 mg/day) on efficacy, safety/tolerability, and food allergy-related quality of life. METHODS: We present a subset analysis of PALISADE-ARC004 participants (aged 4-17 years) who received 300 mg PTAH daily for a total of ~1.5 (Group A, n = 110) or ~2 years (Group B, n = 32). Safety assessments included monitoring the incidence of adverse events (AEs), accidental exposures to food allergens, and adrenaline use. Efficacy was assessed by double-blind, placebo-controlled food challenge (DBPCFC); skin prick testing; peanut-specific antibody assays; and Food Allergy Quality of Life Questionnaire (FAQLQ) and Food Allergy Independent Measure (FAIM) scores. RESULTS: Continued maintenance with PTAH increased participants&apos; ability to tolerate peanut protein: 48.1% of completers in Group A (n = 50/104) and 80.8% in Group B (n = 21/26) tolerated 2000 mg peanut protein at exit DBPCFC without dose-limiting symptoms. Immune biomarkers showed a pattern consistent with treatment-induced desensitization. Among PTAH-continuing participants, the overall and treatment-related exposure-adjusted AE rate decreased throughout the intervention period in both groups. Clinically meaningful improvements in FAQLQ and FAIM scores over time suggest a potential link between increased desensitization as determined by the DBPCFC and improved quality of life. CONCLUSIONS: These results demonstrate that daily PTAH treatment for peanut allergy beyond 1 year leads to an improved safety/tolerability profile and continued clinical and immunological response.</style></abstract><notes><style face="normal" font="default" size="100%">Fernandez-Rivas, Montserrat&#xD;Vereda, Andrea&#xD;Vickery, Brian P&#xD;Sharma, Vibha&#xD;Nilsson, Caroline&#xD;Muraro, Antonella&#xD;Hourihane, Jonathan O&apos;B&#xD;DunnGalvin, Audrey&#xD;du Toit, George&#xD;Blumchen, Katharina&#xD;Beyer, Kirsten&#xD;Smith, Alex&#xD;Ryan, Robert&#xD;Adelman, Daniel C&#xD;Jones, Stacie M&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):991-1003. doi: 10.1111/all.15027. Epub 2021 Sep 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34320250</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9293305</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15027</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1945</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1945</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patel, N.</style></author><author><style face="normal" font="default" size="100%">Isaacs, E.</style></author><author><style face="normal" font="default" size="100%">Duca, B.</style></author><author><style face="normal" font="default" size="100%">Nagaratnam, N.</style></author><author><style face="normal" font="default" size="100%">Donovan, J.</style></author><author><style face="normal" font="default" size="100%">Fontanella, S.</style></author><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Department of Clinical Biochemistry, Royal Brompton and Harefield NHS Trust, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Optimal dose of adrenaline auto-injector for children and young people at risk of anaphylaxis: A phase IV randomized controlled crossover study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1997-2006</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Epinephrine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Single-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Self Administration</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Intramuscular</style></keyword><keyword><style face="normal" font="default" size="100%">adrenaline</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">auto-injector</style></keyword><keyword><style face="normal" font="default" size="100%">epinephrine</style></keyword><keyword><style face="normal" font="default" size="100%">stroke volume</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36794963</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Guidelines recommend intramuscular injection of 500 mug adrenaline (epinephrine) for anaphylaxis in teenagers and adults; however, most autoinjectors deliver a maximum 300 mug dose. We evaluated plasma adrenaline levels and cardiovascular parameters (including cardiac output) following self-injection with 300 mug or 500 mug adrenaline in teenagers at risk of anaphylaxis. METHODS: Subjects were recruited to a randomized, single-blind two period crossover trial. Participants received all 3 injections (Emerade(R) 500 mug, Emerade(R) 300 mug, Epipen(R) 0.3 mg) on 2 separate visits (allocated in a randomized block design), at least 28 days apart. Intramuscular injection was confirmed by ultrasound, and heart rate/stroke volume assessed using continuous monitoring. The trial was registered at Clinicaltrials.gov (NCT03366298). RESULTS: Twelve participants (58% male, median 15.4 years) participated; all completed the study. 500 mug injection resulted in a higher and more prolonged peak concentration (p = 0.01) and greater Area-Under-Curve for plasma adrenaline (p &lt; 0.05) compared to 300 mug, with no difference in adverse events. Adrenaline caused a significant increase in heart rate irrespective of dose and device. Unexpectedly, 300 mug adrenaline resulted in a significant increase in stroke volume when delivered with Emerade(R), but a negative inotropic effect with Epipen(R) (p &lt; 0.05). CONCLUSIONS: These data support a 500 mug dose of adrenaline to treat anaphylaxis in individuals &gt;40 kg in the community. The contrasting effects on stroke volume between Epipen(R) and Emerade(R), despite similar peak plasma adrenaline levels, are unexpected. There is an urgent need to better understand differences in pharmacodynamics following adrenaline administration by autoinjector. In the meantime, we recommend adrenaline injection by needle/syringe in the healthcare setting in individuals with anaphylaxis refractory to initial treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Patel, Nandinee&#xD;Isaacs, Emily&#xD;Duca, Bettina&#xD;Nagaratnam, Nanthagopan&#xD;Donovan, Jackie&#xD;Fontanella, Sara&#xD;Turner, Paul J&#xD;eng&#xD;MR/K010468/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/W018616/1/MRC_/Medical Research Council/United Kingdom&#xD;Clinical Trial, Phase IV&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1997-2006. doi: 10.1111/all.15675. Epub 2023 Feb 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36794963</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15675</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1183</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1183</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van der Valk, J. P. M.</style></author><author><style face="normal" font="default" size="100%">Kappen, J. H.</style></author><author><style face="normal" font="default" size="100%">Ruikes-Mertens, S.</style></author><author><style face="normal" font="default" size="100%">van Maaren, M. S.</style></author><author><style face="normal" font="default" size="100%">Bindels, P. J. E.</style></author><author><style face="normal" font="default" size="100%">van Wijk, R. G.</style></author><author><style face="normal" font="default" size="100%">Braunstahl, G. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonary Medicine, Franciscus Gasthuis &amp; Vlietland, Rotterdam, The Netherlands.&#xD;Allergy and Clinical Immunology, Immunomodulation and Tolerance Group, Imperial College London, London, UK.&#xD;Department of Internal Medicine, Allergology, Maasstad Hospital, Rotterdam, The Netherlands.&#xD;Department of Internal Medicine, Allergology, Erasmus Medical Center, Rotterdam, The Netherlands.&#xD;Department of General Practice, Erasmus Medical Center, Rotterdam, The Netherlands.&#xD;Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Optimization of a transmural care pathway for allergen immunotherapy to primary care by an integrated personal eHealth environment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2259-2261</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">*Telemedicine</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">eHealth</style></keyword><keyword><style face="normal" font="default" size="100%">feasibility</style></keyword><keyword><style face="normal" font="default" size="100%">primary care</style></keyword><keyword><style face="normal" font="default" size="100%">secondary care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33502783</style></accession-num><notes><style face="normal" font="default" size="100%">van der Valk, Johanna P M&#xD;Kappen, Jasper H&#xD;Ruikes-Mertens, Sanne&#xD;van Maaren, Maurits S&#xD;Bindels, Patrick J E&#xD;van Wijk, Roy Gerth&#xD;Braunstahl, G J&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2259-2261. doi: 10.1111/all.14753. Epub 2021 Feb 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33502783</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14753</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1525</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1525</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roth-Walter, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Comparative Medicine, The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna and University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oral allergen immunotherapy by targeting Peyer&apos;s patches</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1594-1597</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2019/04/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/administration &amp; dosage/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*immunology/*therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Peyer&apos;s Patches/*immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31006121</style></accession-num><notes><style face="normal" font="default" size="100%">Roth-Walter, Franziska&#xD;eng&#xD;Letter&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Aug;74(8):1594-1597. doi: 10.1111/all.13828. Epub 2019 May 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31006121</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13828</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2846</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2846</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Chun, Y.</style></author><author><style face="normal" font="default" size="100%">Grishina, G.</style></author><author><style face="normal" font="default" size="100%">Lo, T.</style></author><author><style face="normal" font="default" size="100%">Reed, K.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Sicherer, S.</style></author><author><style face="normal" font="default" size="100%">Berin, M. C.</style></author><author><style face="normal" font="default" size="100%">Bunyavanich, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Division of Allergy and Immunology, Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oral and Gut Microbial Hubs Associated With Reaction Threshold Interact With Circulating Immune Factors in Peanut Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2800-2809</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/01/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/immunology/microbiology/blood/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Saliva/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Mouth/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">threshold</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">from NIH, Aimmune, DBV Technologies, and Siolta outside of submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from DBV Technologies and Novartis outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and royalties from UpToDate. S.H. reports royalty payments from UpToDate and from</style></keyword><keyword><style face="normal" font="default" size="100%">Johns Hopkins University Press</style></keyword><keyword><style face="normal" font="default" size="100%">grants to his institution from the NIH, from Food</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Research and Education, and from Pfizer</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from the</style></keyword><keyword><style face="normal" font="default" size="100%">American Academy of Allergy, Asthma and Immunology as Deputy Editor of the</style></keyword><keyword><style face="normal" font="default" size="100%">Journal of Allergy and Clinical Immunology: In Practice, outside of the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. The remaining authors declare no conflicts of interest relevant to this</style></keyword><keyword><style face="normal" font="default" size="100%">manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39887792</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Among peanut-allergic individuals, there is high variability in the amount of peanut that triggers reactions (i.e., reaction threshold) that is not predictable or well-understood. We conducted this study to characterize relationships between the oral and gut microbiomes and systemic processes associated with reaction threshold in peanut allergy (PA). METHODS: In a cohort of 120 children with suspected PA who underwent double-blind, placebo-controlled food challenges, we generated and analyzed parallel profiles of the oral microbiome, gut microbiome, peripheral blood transcriptome, peripheral blood cytometry, and serum antibody levels to identify threshold-associated markers and their inter-relationships. RESULTS: The 120 participants included 23 children with no PA, 74 with high-threshold PA (reacting to &gt;/= 443 mg cumulative peanut protein), and 23 with low-threshold PA (reacting to &lt; 443 mg cumulative peanut protein). Ten hub microbes were each identified in saliva and stool microbiome networks that were constructed, including the hub microbes Rothia aeria in saliva and Bacteroides sp. in stool that were associated with reaction threshold. These hub microbes were also associated with peripheral blood transcript levels for threshold-associated key drivers of FcgammaR-mediated phagocytosis and TLR signaling. Correlation network construction with additional data on threshold-associated peripheral blood neutrophil abundance and peanut-specific serum IgE and Ara h 2 antibody levels revealed central roles for saliva Rothia aeria and stool Bacteroides sp. in local-systemic networks for IgE- and IgG-mediated peanut allergy. CONCLUSIONS: This integrated study of oral and stool microbiomes, blood transcriptome, cellular profiles, and peanut-specific serum antibodies revealed new relationships between local microbiota and systemic measures associated with reaction threshold in peanut allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Lingdi&#xD;Chun, Yoojin&#xD;Grishina, Galina&#xD;Lo, Tracy&#xD;Reed, Kyle&#xD;Wang, Julie&#xD;Sicherer, Scott&#xD;Berin, M Cecilia&#xD;Bunyavanich, Supinda&#xD;eng&#xD;R01 AI147028/AI/NIAID NIH HHS/&#xD;U19 AI136053/AI/NIAID NIH HHS/&#xD;U19 AI136053/NH/NIH HHS/&#xD;R01 AI147028/NH/NIH HHS/&#xD;S10 OD030463/OD/NIH HHS/&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2800-2809. doi: 10.1111/all.16481. Epub 2025 Jan 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39887792</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12310987</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16481</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1257</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1257</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ohsawa, I.</style></author><author><style face="normal" font="default" size="100%">Honda, D.</style></author><author><style face="normal" font="default" size="100%">Suzuki, Y.</style></author><author><style face="normal" font="default" size="100%">Fukuda, T.</style></author><author><style face="normal" font="default" size="100%">Kohga, K.</style></author><author><style face="normal" font="default" size="100%">Morita, E.</style></author><author><style face="normal" font="default" size="100%">Moriwaki, S.</style></author><author><style face="normal" font="default" size="100%">Ishikawa, O.</style></author><author><style face="normal" font="default" size="100%">Sasaki, Y.</style></author><author><style face="normal" font="default" size="100%">Tago, M.</style></author><author><style face="normal" font="default" size="100%">Chittick, G.</style></author><author><style face="normal" font="default" size="100%">Cornpropst, M.</style></author><author><style face="normal" font="default" size="100%">Murray, S. C.</style></author><author><style face="normal" font="default" size="100%">Dobo, S. M.</style></author><author><style face="normal" font="default" size="100%">Nagy, E.</style></author><author><style face="normal" font="default" size="100%">Van Dyke, S.</style></author><author><style face="normal" font="default" size="100%">Reese, L.</style></author><author><style face="normal" font="default" size="100%">Best, J. M.</style></author><author><style face="normal" font="default" size="100%">Iocca, H.</style></author><author><style face="normal" font="default" size="100%">Collis, P.</style></author><author><style face="normal" font="default" size="100%">Sheridan, W. P.</style></author><author><style face="normal" font="default" size="100%">Hide, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Internal Medicine, Saiyu Soka Hospital, Saitama, Japan.&#xD;Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.&#xD;Juntendo University Urayasu Hospital, Chiba, Japan.&#xD;Saitama Medical Center, Saitama, Japan.&#xD;Community Hospital Kohga Hospital, Shizuoka, Japan.&#xD;Shimane University Hospital, Shimane, Japan.&#xD;Osaka Medical College Hospital, Osaka, Japan.&#xD;Gunma University Hospital, Gunma, Japan.&#xD;National Hospital Organization Disaster Medical Center, Tokyo, Japan.&#xD;Division of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine, Tokyo, Japan.&#xD;Department of General Medicine, Saga University Hospital, Saga, Japan.&#xD;BioCryst Pharmaceuticals, Inc, Durham, NC, USA.&#xD;Hiroshima University, Hiroshima, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1789-1799</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/diagnosis/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Japan/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Japan</style></keyword><keyword><style face="normal" font="default" size="100%">berotralstat</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">kallikrein inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. GC, MC, SCM, SMD, EN, SVD, LR, JB, HI, PC, and WPS</style></keyword><keyword><style face="normal" font="default" size="100%">are employees of BioCryst Pharmaceuticals. GC, EN, LR, and WPS hold stock options</style></keyword><keyword><style face="normal" font="default" size="100%">in BioCryst Pharmaceuticals. MH reports personal fees from BioCryst</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Shire/Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and grants and personal fees from CSL Behring, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and a</style></keyword><keyword><style face="normal" font="default" size="100%">grant of the Ministry of Health, Labour and Welfare of Japan. IO, YSuzuki, TF,</style></keyword><keyword><style face="normal" font="default" size="100%">KK, EM, SM, OI, YSasaki, and MT have nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33247955</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: With no approved treatments in Japan for the prevention of hereditary angioedema (HAE) attacks, there is a significant unmet need for long-term prophylactic therapies for Japanese patients with HAE. Berotralstat (BCX7353) is an oral, once-daily, highly selective inhibitor of plasma kallikrein in development for prophylaxis of angioedema attacks in HAE patients. METHODS: APeX-J is a phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-part trial conducted in Japan (University Hospital Medical Information Network identifier, UMIN000034869; ClinicalTrials.gov identifier, NCT03873116). Patients with a clinical diagnosis of type 1 or 2 HAE underwent a prospective run-in period of 56 days to determine eligibility, allowing enrollment of those with &gt;/=2 expert-confirmed angioedema attacks. Patients were randomly assigned (1:1:1) and stratified by baseline attack rate (&gt;/=2 vs. &lt;2 expert-confirmed attacks/month between screening and randomization) to receive once-daily berotralstat 110 mg, berotralstat 150 mg, or placebo. The primary endpoint was the rate of expert-confirmed angioedema attacks during dosing in the 24-week treatment period. RESULTS: Nineteen patients were randomized to receive once-daily berotralstat 110 mg (n = 6), berotralstat 150 mg (n = 7), or placebo (n = 6). Treatment with berotralstat 150 mg significantly reduced HAE attacks relative to placebo (1.11 vs. 2.18 attacks/month, p = .003). The most frequently reported treatment-emergent adverse events (TEAEs) in berotralstat-treated patients (n = 13) were nasopharyngitis (n = 4, 31%), abdominal pain, cough, diarrhea, and pyrexia (n = 2 each, 15%). CONCLUSIONS: Orally administered, once-daily berotralstat 150 mg significantly reduced the frequency of HAE attacks and was safe and well tolerated, supporting its use as a prophylactic therapy in patients with type 1 or 2 HAE in Japan.</style></abstract><notes><style face="normal" font="default" size="100%">Ohsawa, Isao&#xD;Honda, Daisuke&#xD;Suzuki, Yusuke&#xD;Fukuda, Tomoo&#xD;Kohga, Keisuke&#xD;Morita, Eishin&#xD;Moriwaki, Shinichi&#xD;Ishikawa, Osamu&#xD;Sasaki, Yoshihiro&#xD;Tago, Masaki&#xD;Chittick, Greg&#xD;Cornpropst, Melanie&#xD;Murray, Sharon C&#xD;Dobo, Sylvia M&#xD;Nagy, Eniko&#xD;Van Dyke, Sharon&#xD;Reese, Lacy&#xD;Best, Jessica M&#xD;Iocca, Heather&#xD;Collis, Phil&#xD;Sheridan, William P&#xD;Hide, Michihiro&#xD;eng&#xD;Clinical Trial, Phase III&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1789-1799. doi: 10.1111/all.14670. Epub 2020 Dec 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33247955</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8247297</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14670</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>571</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">571</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bajzik, V.</style></author><author><style face="normal" font="default" size="100%">DeBerg, H. A.</style></author><author><style face="normal" font="default" size="100%">Garabatos, N.</style></author><author><style face="normal" font="default" size="100%">Rust, B. J.</style></author><author><style face="normal" font="default" size="100%">Obrien, K. K.</style></author><author><style face="normal" font="default" size="100%">Nguyen, Q. A.</style></author><author><style face="normal" font="default" size="100%">O&apos;Rourke, C.</style></author><author><style face="normal" font="default" size="100%">Smith, A.</style></author><author><style face="normal" font="default" size="100%">Walker, A. H.</style></author><author><style face="normal" font="default" size="100%">Quinn, C.</style></author><author><style face="normal" font="default" size="100%">Gersuk, V. H.</style></author><author><style face="normal" font="default" size="100%">Farrington, M.</style></author><author><style face="normal" font="default" size="100%">Jeong, D.</style></author><author><style face="normal" font="default" size="100%">Vickery, B. P.</style></author><author><style face="normal" font="default" size="100%">Adelman, D. C.</style></author><author><style face="normal" font="default" size="100%">Wambre, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA.&#xD;Aimmune Therapeutics, Brisbane, California, USA.&#xD;Virginia Mason Medical Center, Seattle, Washington, USA.&#xD;Emory University School of Medicine, Atlanta, Georgia, USA.&#xD;University of California, San Francisco, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2534-2548</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/03/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">CD4+ T cells</style></keyword><keyword><style face="normal" font="default" size="100%">Th2A cells</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Research and Education (FARE), Immune Tolerance Network (ITN), research</style></keyword><keyword><style face="normal" font="default" size="100%">sponsorship from Regeneron Pharmaceuticals, Astellas, COUR Pharma and Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics. DCA is a former employee of Aimmune Therapeutics and currently</style></keyword><keyword><style face="normal" font="default" size="100%">chairs the company&apos;s scientific advisory board. AS is an active employee of</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune Therapeutics. BPV receives grant support from NIH-NIAID, Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Network and Food Allergy Research and Education (FARE), research sponsorship from</style></keyword><keyword><style face="normal" font="default" size="100%">Genentech. BPV is also an advisory board member for Aimmune Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">AllerGenis, LLC, FARE and Reacta Biosciences.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35266148</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The PALISADE study, an international, phase 3 trial of peanut oral immunotherapy (POIT) with AR101, resulted in desensitization in children and adolescents who were highly allergic to peanut. An improved understanding of the immune mechanism induced in response to food allergen immunotherapy would enable more informed and effective therapeutic strategies. Our main purpose was to examine the immunological changes in blood samples from a subset of peanut-allergic individuals undergoing oral desensitization immunotherapy with AR101. METHODS: Blood samples obtained as part of enrollment screening and at multiple time points during PALISADE study were used to assess basophil and CD4+ T-cell reactivity to peanut. RESULTS: The absence of clinical reactivity to the entry double-blinded placebo-controlled peanut challenge (DBPCFC) was accompanied by a significantly lower basophil sensitivity and T-cell reactivity to peanut compared with DBPCFC reactors. At baseline, peanut-reactive TH2A cells were observed in many but not all peanut-allergic patients and their level in peripheral blood correlates with T-cell reactivity to peanut and with serum peanut-specific IgE and IgG4 levels. POIT reshaped circulating peanut-reactive T-cell responses in a subset-dependent manner. Changes in basophil and T-cell responses to peanut closely paralleled clinical benefits to AR101 therapy and resemble responses in those with lower clinical sensitivity to peanut. However, no difference in peanut-reactive Treg cell frequency was observed between groups. CONCLUSION: Oral desensitization therapy with AR101 leads to decreased basophil sensitivity to peanut and reshapes peanut-reactive T effector cell responses supporting its potential as an immunomodulatory therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Bajzik, Veronique&#xD;DeBerg, Hannah A&#xD;Garabatos, Nahir&#xD;Rust, Blake J&#xD;Obrien, Kimberly K&#xD;Nguyen, Quynh-Anh&#xD;O&apos;Rourke, Colin&#xD;Smith, Alex&#xD;Walker, Alex H&#xD;Quinn, Charlie&#xD;Gersuk, Vivian H&#xD;Farrington, Mary&#xD;Jeong, David&#xD;Vickery, Brian P&#xD;Adelman, Daniel C&#xD;Wambre, Erik&#xD;eng&#xD;R01 AI108839/AI/NIAID NIH HHS/&#xD;U19 AI135817/AI/NIAID NIH HHS/&#xD;Clinical Trial, Phase III&#xD;Randomized Controlled Trial&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2534-2548. doi: 10.1111/all.15276. Epub 2022 Mar 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35266148</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9356972</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15276</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>50</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">50</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Upton, J. E. M.</style></author><author><style face="normal" font="default" size="100%">Correa, N.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Division of Immunology and Allergy, Department of Pediatrics, SickKids Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Division of Clinical Immunology and Allergy, Department of Medicine, St. Michael&apos;s Hospital, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Translational Medicine Program, Research Institute, SickKids Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oral immunotherapy for food allergy: What&apos;s age got to do with it?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">626-628</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/12/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36541027</style></accession-num><notes><style face="normal" font="default" size="100%">Upton, Julia E M&#xD;Correa, Natasha&#xD;Eiwegger, Thomas&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):626-628. doi: 10.1111/all.15623.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36541027</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15623</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2171</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2171</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Unal, D.</style></author><author><style face="normal" font="default" size="100%">Eyice-Karabacak, D.</style></author><author><style face="normal" font="default" size="100%">Kutlu, A.</style></author><author><style face="normal" font="default" size="100%">Demir, S.</style></author><author><style face="normal" font="default" size="100%">Tuzer, C.</style></author><author><style face="normal" font="default" size="100%">Arslan, A. F.</style></author><author><style face="normal" font="default" size="100%">Isik, S. R.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergy Diseases, Internal Medicine Department, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Medical Park Hospital Ordu, Ordu, Turkey.&#xD;Division of Immunology and Allergy Diseases, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oral immunotherapy in alpha-gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3241-3251</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Sheep</style></keyword><keyword><style face="normal" font="default" size="100%">Galactose</style></keyword><keyword><style face="normal" font="default" size="100%">*Tick Bites/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Red Meat/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Meat/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-gal allergy</style></keyword><keyword><style face="normal" font="default" size="100%">delayed-onset</style></keyword><keyword><style face="normal" font="default" size="100%">early-onset</style></keyword><keyword><style face="normal" font="default" size="100%">long-term efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37545316</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Oral immunotherapy (OIT) is a promising treatment for food allergies. Our aim was to establish the long-term safety and efficacy of a novel red meat (RM) OIT in galactose-alpha-1,3-galactose (alpha-gal) allergy in adults. METHODS: Out of 20 patients with confirmed RM allergy, five (41.66%) underwent an early OIT, seven (58.33%) underwent a delayed protocol and eight patients who were not desensitized formed the patient control group. 15 and 27 day RM OIT for early-onset and delayed-onset alpha-gal allergy were administered, respectively. Desensitized patients were recommended to continue eating at least 100 g RM every day for 6 months and every other day in the following 6 months. After a year, the consumption was recommended 2/3 times in a week. Patients were followed up with skin tests with commercial beef and lamb extracts, fresh raw/cooked beef and lamb and cetuximab and also with serum alpha-gal specific Immunoglobulin-E (sIgE) in the first and fifth years. RESULTS: All patients who underwent OIT became tolerant to RM. During the 5 year follow-up, the median alpha-gal sIgE concentration gradually decreased in nine patients who consumed RM uneventfully while remained unchanged in the control group (p = .016). In two patients, rare tick bites acted as inducers of hypersensitivity reactions with concomitant elevation of alpha-gal sIgE concentrations whereas one patient with low follow-up alpha-gal sIgE concentrations consumed RM uneventfully after frequent tick bites. CONCLUSIONS: Our study showed the long-term safety and efficacy of alpha-gal OIT. Additionally, alpha-gal sIgE seems to be a potential biomarker to monitor OIT.</style></abstract><notes><style face="normal" font="default" size="100%">Unal, D&#xD;Eyice-Karabacak, D&#xD;Kutlu, A&#xD;Demir, S&#xD;Tuzer, C&#xD;Arslan, A F&#xD;Isik, S R&#xD;Gelincik, A&#xD;eng&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3241-3251. doi: 10.1111/all.15840. Epub 2023 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37545316</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15840</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2859</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2859</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hunter, H.</style></author><author><style face="normal" font="default" size="100%">Ue, K. L.</style></author><author><style face="normal" font="default" size="100%">Cornelius, V.</style></author><author><style face="normal" font="default" size="100%">Yung, C. C.</style></author><author><style face="normal" font="default" size="100%">Thomas, I.</style></author><author><style face="normal" font="default" size="100%">Tsilochristou, O.</style></author><author><style face="normal" font="default" size="100%">Layhadi, J.</style></author><author><style face="normal" font="default" size="100%">Siew, L. Q. C.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Till, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK.&#xD;Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Section of Allergy and Immunology, University of Colorado, Denver, USA.&#xD;School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;King&apos;s Centre for Lung Health, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oral Immunotherapy in Peanut-Allergic Adults Using Real-World Materials</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2310-2318</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/04/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">desensitisation</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">peanut</style></keyword><keyword><style face="normal" font="default" size="100%">quality-of-life</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40268292</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Peanut oral immunotherapy (OIT) has shown effectiveness in achieving desensitization of children; however, evidence in adults is lacking. METHODS: This phase II trial evaluated peanut OIT in peanut-allergic adults using real-world peanut products. A Simon&apos;s minimax two-stage design, incorporating a stop:go for futility, was employed. A separate untreated control group was also recruited for comparison of mechanistic parameters. Participants underwent baseline double-blind placebo-control food challenges (DBPCFC) with peanut protein doses of 0.3 to 300 mg. Reacting participants were initiated on daily OIT with 2-weekly updosing until reaching a maintenance dose of 1000 mg (four large peanuts). The primary outcome was the proportion of OIT participants who tolerated a cumulative dose of 1.4 g peanut protein during exit DBPCFC (doses provided 0.3-3000 mg). RESULTS: Twenty-one adults (8 female; mean age 24.2 years [SD 4.9]) were enrolled in the OIT group, with 67% achieving the daily maintenance dose and meeting the primary endpoint. Three withdrew due to adverse reactions, and a further three did not complete the trial for reasons unrelated to OIT. The median tolerated dose increased from 30 mg (equivalent to approximately 1/8th of a peanut) to 3000 mg (12 peanuts) at the exit challenge, representing a 100-fold increase (p &lt; 0.0001). OIT was associated with an improvement in QoL measures. Suppression of peanut skin prick test sizes and induction of peanut-specific IgG were observed in OIT but not in control participants. CONCLUSIONS: Peanut OIT appears to be an efficacious treatment for adults with peanut allergy. Further studies are needed for confirmation and to characterize safety profiles in different adult subgroups. TRIAL REGISTRATION: Grown Up Peanut Immunotherapy (GUPI) study; ClinicalTrials.gov identifier: NCT03648320.</style></abstract><notes><style face="normal" font="default" size="100%">Hunter, Hannah&#xD;Ue, Kok Loong&#xD;Cornelius, Victoria&#xD;Yung, Ching Ching&#xD;Thomas, Iason&#xD;Tsilochristou, Olympia&#xD;Layhadi, Janice&#xD;Siew, Leonard Q C&#xD;Venter, Carina&#xD;Shamji, Mohamed H&#xD;Till, Stephen J&#xD;eng&#xD;PB-PG-1215-20006/NIHR Research for Patient Benefit program/&#xD;Clinical Trial, Phase II&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2310-2318. doi: 10.1111/all.16493. Epub 2025 Apr 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40268292</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368739</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16493</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3179</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3179</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liong, O.</style></author><author><style face="normal" font="default" size="100%">Palosuo, K.</style></author><author><style face="normal" font="default" size="100%">Hinkkanen, V.</style></author><author><style face="normal" font="default" size="100%">Fortino, V.</style></author><author><style face="normal" font="default" size="100%">Makela, M. J.</style></author><author><style face="normal" font="default" size="100%">Karisola, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Human Microbiome (HUMI) Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland.&#xD;Department of Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.&#xD;School of Medicine, Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oral Immunotherapy Induces Shift in lncRNA Expression Modulating Allergen-Specific Immune Responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">hen&apos;s egg allergy</style></keyword><keyword><style face="normal" font="default" size="100%">lncRNA</style></keyword><keyword><style face="normal" font="default" size="100%">network analyses</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 28</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41316695</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Previously, we reported the success of egg oral immunotherapy (OIT) in liberating most participants from dietary restrictions. The diminishing symptoms and declining inflammation were accompanied by differential expression of genes in peripheral blood mononuclear cells (PBMCs) of 50 egg-allergic children following 8 months of OIT. METHODS: Here, we explore the impact of OIT on long non-coding RNA (lncRNA) expression and its downstream effects on allergen-specific immune response with the help of PBMC transcriptome, co-expression gene module identification, pathway enrichment analyses and in vitro stimulation in both PBMC and THP1 cells. RESULTS: We observed 17 lncRNAs which correlated positively with genes involved in IL-13, IL-4, and IL-10 signaling pathways. The same set of lncRNAs correlated negatively with genes playing a role in neutrophil degranulation, phagosome formation, and pyroptosis signaling. The expression of one of the most important lncRNAs, LOC644727, was found to align with CXCL8 expression in egg extract-stimulated PBMCs and LPS-stimulated THP1-derived macrophages. CONCLUSIONS: Our results highlight the involvement of lncRNA in the regulation of gene expression during OIT. LOC644727 may serve as a potential marker for inflammatory responses and it may offer a therapeutic target for future desensitization protocols.</style></abstract><notes><style face="normal" font="default" size="100%">Liong, Olivia&#xD;Palosuo, Kati&#xD;Hinkkanen, Victoria&#xD;Fortino, Vittorio&#xD;Makela, Mika J&#xD;Karisola, Piia&#xD;eng&#xD;190150/Pediatric Research Foundation/&#xD;Finnish Society of Allergology and Immunology/&#xD;TYH2019313/Helsinki University Hospital Research Fund/&#xD;TYH2020322/Helsinki University Hospital Research Fund/&#xD;Allergy Research Foundation/&#xD;Helsingin Yliopisto/&#xD;338325/Academy of Finland/&#xD;Finnish Cultural Foundation/&#xD;Magnus Ehrnrooth Foundation/&#xD;Sigrid Juselius Foundation/&#xD;Denmark&#xD;Allergy. 2025 Nov 28. doi: 10.1111/all.70173.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41316695</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70173</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3047</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3047</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuehn, A.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oral Immunotherapy of Peanut Allergy: A Critical Role for Gut-Associated Immunity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2705-2709</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/08/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal tissue</style></keyword><keyword><style face="normal" font="default" size="100%">immune mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40747962</style></accession-num><notes><style face="normal" font="default" size="100%">Kuehn, A&#xD;Eiwegger, T&#xD;eng&#xD;C23/BM/18096599/IFAM/Fonds National de la Recherche Luxembourg/&#xD;10.55776/I6897/Austrian Science Fund/&#xD;Lower Austrian Research Fund supported Danube Allergy Research Cluster/&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2705-2709. doi: 10.1111/all.16657. Epub 2025 Aug 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40747962</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16657</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2099</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2099</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fauquert, J. L.</style></author><author><style face="normal" font="default" size="100%">Alba-Linero, C.</style></author><author><style face="normal" font="default" size="100%">Gherasim, A.</style></author><author><style face="normal" font="default" size="100%">Testera-Montes, A.</style></author><author><style face="normal" font="default" size="100%">Bentabol-Ramos, G.</style></author><author><style face="normal" font="default" size="100%">Saenz de Santa Maria-Garcia, R.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Hospital, Clermont-Ferrand, France.&#xD;Ophthalmology Unit, Hospital Clinico Virgen de la Victoria, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA)-Plataforma BIONAND, RICORS &quot;Inflammatory Diseases&quot;, Malaga, Spain.&#xD;Universidad de Malaga, Malaga, Spain.&#xD;ALYATEC Environmental Exposure Chamber, Strasbourg, France.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Pulmonology Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Organ-specific allergen challenges in airway allergy: Current utilities and future directions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1794-1809</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/04/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">bronchial allergen challenge</style></keyword><keyword><style face="normal" font="default" size="100%">conjunctival allergen challenge</style></keyword><keyword><style face="normal" font="default" size="100%">nasal allergen challenge</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37002709</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopy has been long used as the screening method for airway allergy. Nevertheless, aeroallergens can trigger respiratory symptoms not only in atopic patients (atopic respiratory allergy, ARA), but also in non-atopic subjects (local respiratory allergy, LRA). Moreover, ARA and LRA can coexist in the same patient, and this clinical scenario has been called dual respiratory allergy (DRA). When the clinical history cannot determine the relevance of sensitizations in ARA patients, nasal, conjunctival or bronchial allergen challenges (NAC, CAC, and BAC, respectively) should be conducted. Moreover, these tests are required to identify patients with LRA and DRA. The clarification of the allergic triggers of airway diseases has a profound impact on the management strategies the patients can be offered. Importantly, allergen immunotherapy (AIT) remains as the only disease-modifying intervention for ARA. Recent data indicate that AIT might have a similar effect on LRA patients. Nevertheless, AIT success relies largely on the correct phenotyping of allergic individuals, and NAC, CAC, and BAC are very helpful tools in this regard. In this review, we will summarize the main indications and methodology of CAC, NAC, and BAC. Importantly, the clinical implementation of these tests might translate into precision medicine approaches and better health outcomes for patients with airway allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Fauquert, J L&#xD;Alba-Linero, C&#xD;Gherasim, A&#xD;Testera-Montes, A&#xD;Bentabol-Ramos, G&#xD;Saenz de Santa Maria-Garcia, R&#xD;Torres, M J&#xD;Eguiluz-Gracia, I&#xD;Rondon, C&#xD;eng&#xD;P20_00405/Consejeria de Salud, Junta de Andalucia/&#xD;PI20/01715/Instituto de Salud Carlos III/&#xD;RD21/0002/0008/Instituto de Salud Carlos III/&#xD;CM21/00262/Instituto de Salud Carlos III/&#xD;CM20/00160/Instituto de Salud Carlos III/&#xD;JR22/00048/Instituto de Salud Carlos III/&#xD;JR19/00029/Instituto de Salud Carlos III/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1794-1809. doi: 10.1111/all.15731. Epub 2023 Apr 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37002709</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15731</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2764</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2764</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pernin-Schneider, M.</style></author><author><style face="normal" font="default" size="100%">Amazouz, H.</style></author><author><style face="normal" font="default" size="100%">Lezmi, G.</style></author><author><style face="normal" font="default" size="100%">Bourgoin-Heck, M.</style></author><author><style face="normal" font="default" size="100%">Just, J.</style></author><author><style face="normal" font="default" size="100%">Momas, I.</style></author><author><style face="normal" font="default" size="100%">Ranciere, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite Paris Cite, Inserm U1153 CRESS, INRAE, HERA Team, Paris, France.&#xD;Service de Pneumologie et d&apos;Allergologie Pediatriques, AP-HP, Hopital Necker-Enfants Malades, Paris, France.&#xD;Service d&apos;Allergologie Pediatrique, AP-HP, Hopital d&apos;Enfants Armand-Trousseau, Paris, France.&#xD;Unite d&apos;Allergologie, Hopital Americain de Paris, Neuilly-sur-Seine, France.&#xD;Faculte de Pharmacie de Paris, Universite Paris Cite, Paris, France.&#xD;Cellule Cohorte, Direction de l&apos;Action Sociale de l&apos;Enfance et de la Sante, Mairie de Paris, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Organic Food Consumption Might Protect Against Sensitisation to Inhalant Allergens at School Age: The PARIS Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">258-270</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/01/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Paris/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">birth cohort</style></keyword><keyword><style face="normal" font="default" size="100%">cluster analysis</style></keyword><keyword><style face="normal" font="default" size="100%">organic food</style></keyword><keyword><style face="normal" font="default" size="100%">school-aged children</style></keyword><keyword><style face="normal" font="default" size="100%">sensitisation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39749568</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Interest has grown recently in childhood diet&apos;s role in allergy development. However, the studies focusing on organic food consumption are scarce. We address the relationships between such consumption and respiratory/allergic morbidity at school age in the PARIS (Pollution and asthma risk: An infant study) cohort. METHODS: Diet was assessed using a food frequency questionnaire completed by the parents at 8 years. Dietary patterns were identified by cluster analysis based on the consumption frequency of 30 foods (either organic or conventional) and 19 organic foods. Associations between dietary patterns and respiratory/allergic morbidity (asthma, rhinitis, eczema and sensitisation) were studied using multivariable logistic regression models adjusted for potential confounders, including family socioeconomic status and adherence to the Mediterranean diet as a proxy for dietary balance. RESULTS: Among 1258 children, three dietary patterns were identified, which differed significantly in terms of organic food consumption frequency: low frequency in G0 (51% of children), moderate in G1 (28%) and high in G2 (21%). No association was found between dietary patterns and asthma, eczema, rhinitis or sensitisation to food allergens. Children in G2 had lower likelihood of sensitisation to any allergen than those in G0 (adjusted odds ratio [aOR] = 0.60; 95% confidence interval [CI]: 0.40-0.91), particularly to inhalant allergens (aOR = 0.64; 95% CI: 0.42-0.99). CONCLUSIONS: Our findings suggest that frequent organic food consumption may be protective against allergic sensitisation at school age, based on the assumption that organic food consumption at the age of eight reflects consumption at earlier ages. Further research is warranted to explore the underlying mechanisms for this association, including nutritional and environmental exposures.</style></abstract><notes><style face="normal" font="default" size="100%">Pernin-Schneider, Maelys&#xD;Amazouz, Helene&#xD;Lezmi, Guillaume&#xD;Bourgoin-Heck, Melisande&#xD;Just, Jocelyne&#xD;Momas, Isabelle&#xD;Ranciere, Fanny&#xD;eng&#xD;FP7-261357/European Collaborative Program MeDALL/&#xD;Paris Municipal Department of Social Action, Childhood, and Health (DASES)/&#xD;Universite Paris Cite/&#xD;French Nestle Foundation/&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):258-270. doi: 10.1111/all.16433. Epub 2025 Jan 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39749568</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724254</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16433</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2204</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2204</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ding, Z.</style></author><author><style face="normal" font="default" size="100%">Mulder, J.</style></author><author><style face="normal" font="default" size="100%">Robinson, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Monash University, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The origins and longevity of IgE responses as indicated by serological and cellular studies in mice and humans</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3103-3117</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/07/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Plasma Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">longevity</style></keyword><keyword><style face="normal" font="default" size="100%">plasma cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37417548</style></accession-num><abstract><style face="normal" font="default" size="100%">The existence of long-lived IgE antibody-secreting cells (ASC) is contentious, with the maintenance of sensitization by the continuous differentiation of short-lived IgE(+) ASC a possibility. Here, we review the epidemiological profile of IgE production, and give an overview of recent discoveries made on the mechanisms regulating IgE production from mouse models. Together, these data suggest that for most individuals, in most IgE-associated diseases, IgE(+) ASC are largely short-lived cells. A subpopulation of IgE(+) ASC in humans is likely to survive for tens of months, although due to autonomous IgE B cell receptor (BCR) signaling and antigen-driven IgE(+) ASC apoptosis, in general IgE(+) ASC probably do not persist for the decades that other ASC are inferred to do. We also report on recently identified memory B cell transcriptional subtypes that are the likely source of IgE in ongoing responses, highlighting the probable importance of IL-4Ralpha in their regulation. We suggest the field should look at dupilumab and other drugs that prohibit IgE(+) ASC production as being effective treatments for IgE-mediated aspects of disease in most individuals.</style></abstract><notes><style face="normal" font="default" size="100%">Ding, Zhoujie&#xD;Mulder, Jesse&#xD;Robinson, Marcus J&#xD;eng&#xD;Monash University/&#xD;National Health and Medical Research Council/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3103-3117. doi: 10.1111/all.15799. Epub 2023 Jul 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37417548</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10952832</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15799</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1637</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1637</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hur, G. Y.</style></author><author><style face="normal" font="default" size="100%">Pham, A.</style></author><author><style face="normal" font="default" size="100%">Miller, M.</style></author><author><style face="normal" font="default" size="100%">Weng, N.</style></author><author><style face="normal" font="default" size="100%">Hu, J.</style></author><author><style face="normal" font="default" size="100%">Kurten, R. C.</style></author><author><style face="normal" font="default" size="100%">Broide, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University of California San Diego, La Jolla, CA, USA.&#xD;Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.&#xD;Department of Physiology and Biophysics, Arkansas Children&apos;s Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">ORMDL3 but not neighboring 17q21 gene LRRC3C is expressed in human lungs and lung cells of asthmatics</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2061-2065</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/02/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Chromosomes, Human, Pair 17</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">Lrrc3c</style></keyword><keyword><style face="normal" font="default" size="100%">Ormdl3</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">chromosome 17q21</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">related to this research. These include consultant arrangements, speakers&apos; bureau</style></keyword><keyword><style face="normal" font="default" size="100%">participation, stock or other equity ownership, patent licensing arrangements,</style></keyword><keyword><style face="normal" font="default" size="100%">employment, or expert witness testimony. Dr. Hur reports grants from NIAID,</style></keyword><keyword><style face="normal" font="default" size="100%">during the conduct of the study. Dr. Pham reports grants from NIAID, during the</style></keyword><keyword><style face="normal" font="default" size="100%">conduct of the study. Dr. Miller reports grants from NIAID, during the conduct of</style></keyword><keyword><style face="normal" font="default" size="100%">the study. Dr. Weng reports grants from NIAID, during the conduct of the study.</style></keyword><keyword><style face="normal" font="default" size="100%">Jingwen Hu reports grants from NIAID, during the conduct of the study. Dr. Kurten</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from NIAID, during the conduct of the study. Dr. Broide reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from NIAID, during the conduct of the study.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32086831</style></accession-num><notes><style face="normal" font="default" size="100%">Hur, Gyu Young&#xD;Pham, Alexa&#xD;Miller, Marina&#xD;Weng, Ning&#xD;Hu, Jingwen&#xD;Kurten, Richard C&#xD;Broide, David H&#xD;eng&#xD;U19 AI070535/AI/NIAID NIH HHS/&#xD;R01 AI107779/AI/NIAID NIH HHS/&#xD;T32 AI007469/AI/NIAID NIH HHS/&#xD;R01 AI124236/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2020 Aug;75(8):2061-2065. doi: 10.1111/all.14243. Epub 2020 Mar 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32086831</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7387186</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14243</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1132</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1132</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Galdiero, M. R.</style></author><author><style face="normal" font="default" size="100%">Maio, F.</style></author><author><style face="normal" font="default" size="100%">Arcoleo, F.</style></author><author><style face="normal" font="default" size="100%">Boni, E.</style></author><author><style face="normal" font="default" size="100%">Bonzano, L.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Cancian, M.</style></author><author><style face="normal" font="default" size="100%">Cremonte, L.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S. R.</style></author><author><style face="normal" font="default" size="100%">De Paulis, A.</style></author><author><style face="normal" font="default" size="100%">Detoraki, A.</style></author><author><style face="normal" font="default" size="100%">Firinu, D.</style></author><author><style face="normal" font="default" size="100%">Lamacchia, D.</style></author><author><style face="normal" font="default" size="100%">Loffredo, S.</style></author><author><style face="normal" font="default" size="100%">Nettis, E.</style></author><author><style face="normal" font="default" size="100%">Parente, R.</style></author><author><style face="normal" font="default" size="100%">Parronchi, P.</style></author><author><style face="normal" font="default" size="100%">Pellacani, G.</style></author><author><style face="normal" font="default" size="100%">Petraroli, A.</style></author><author><style face="normal" font="default" size="100%">Rolla, G.</style></author><author><style face="normal" font="default" size="100%">Senter, R.</style></author><author><style face="normal" font="default" size="100%">Triggiani, M.</style></author><author><style face="normal" font="default" size="100%">Vitiello, G.</style></author><author><style face="normal" font="default" size="100%">Spadaro, G.</style></author><author><style face="normal" font="default" size="100%">Bova, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medical Sciences, Allergy and Clinical Immunology, Center for Basic and Clinical Immunology Research (CISI), WAO Center of Excellence, University of Naples Federico II, Naples, Italy.&#xD;Ospedali Riuniti Villa Sofia-Cervello, Unita Operativa Complessa di Patologia Clinica, Palermo, Italy.&#xD;Laboratorio Unico Metropolitano, Maggiore Hospital AUSL, Bologna, Italy.&#xD;Dermatology and Allergy Unit, Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.&#xD;Department of Medical Sciences, Allergy and Clinical Immunology, University of Turin &amp; AO Mauriziano &quot;UmbertoI&quot;, Turin, Italy.&#xD;Department of Medicine, University of Padova, Padova, Italy.&#xD;Allergy Unit, San Giacomo Hospital, Novi Ligure, Alessandria, Italy.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.&#xD;IRCCS Humanitas Research Hospital, Milan, Italy.&#xD;Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Bari, Italy.&#xD;Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.&#xD;Experimental and Clinical Medicine Department, University of Florence, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Orofacial granulomatosis: Clinical and therapeutic features in an Italian cohort and review of the literature</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2189-2200</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Delayed Diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Granulomatosis, Orofacial/diagnosis/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Italy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Melkersson-Rosenthal Syndrome/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Italian registries</style></keyword><keyword><style face="normal" font="default" size="100%">Melkersson-Rosenthal syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">granulomatous cheilitis</style></keyword><keyword><style face="normal" font="default" size="100%">orofacial granulomatosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33641182</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Orofacial granulomatosis (OFG) is characterized by granulomatous inflammation of the soft tissues of maxillofacial region. We explored OFG patients from 10 different Italian centers and summarized the most recent literature data. METHODS: A review of patients with OFG was carried out. An extensive online literature search was performed to identify studies reporting diagnosis and management of OFG. RESULTS: Thirty-nine patients were recruited between January 2018 and February 2020. Most of them (97.4%) displayed involvement of the lips, and 28.2% suffered from Melkersson-Rosenthal syndrome. Two patients received diagnosis of CD and one patient of sarcoidosis, suggesting secondary OFG. Oral aphthosis and cervical lymphadenopathy were also described. The mean diagnostic delay was 3.4 years. Histological evaluation was performed in 34/39 patients (87.2%); non-caseating granulomas were found in 73.5% of them. Neurological symptoms (28.2%), gastrointestinal symptoms in absence of overt inflammatory bowel disease (IBD) (20.5%), and atopy (35.9%) were also identified. Therapeutic approaches varied among the centers. Steroids (51.3%) were used with good or partial results. Anti-TNF-alpha and anti-IgE monoclonal antibodies were used in 6 (15.4%) and 1 (2.6%) patients, respectively, with variable results. Surgery was the choice for 2 patients with good response. CONCLUSIONS: OFG is a rare and neglected disease showing multiple clinical phenotypes. While early diagnosis is crucial, management is difficult and highly dependent on the expertise of clinicians due to the lack of international guidelines. There is a need to establish registry databases and address challenges of long-term management.</style></abstract><notes><style face="normal" font="default" size="100%">Galdiero, Maria R&#xD;Maio, Filomena&#xD;Arcoleo, Francesco&#xD;Boni, Elisa&#xD;Bonzano, Laura&#xD;Brussino, Luisa&#xD;Cancian, Mauro&#xD;Cremonte, Luigi&#xD;Del Giacco, Stefano R&#xD;De Paulis, Amato&#xD;Detoraki, Aikaterini&#xD;Firinu, Davide&#xD;Lamacchia, Donatella&#xD;Loffredo, Stefania&#xD;Nettis, Eustachio&#xD;Parente, Roberta&#xD;Parronchi, Paola&#xD;Pellacani, Giovanni&#xD;Petraroli, Angelica&#xD;Rolla, Giovanni&#xD;Senter, Riccardo&#xD;Triggiani, Massimo&#xD;Vitiello, Gianfranco&#xD;Spadaro, Giuseppe&#xD;Bova, Maria&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2189-2200. doi: 10.1111/all.14799. Epub 2021 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33641182</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14799</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>955</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">955</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Borgsteede, S. D.</style></author><author><style face="normal" font="default" size="100%">Geersing, T. H.</style></author><author><style face="normal" font="default" size="100%">Tempels-Pavlica, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Decision Support, Health Base Foundation, Houten, The Netherlands.&#xD;Department of Clinical Pharmacy, OLVG, Amsterdam, The Netherlands.&#xD;Department of Allergology, Diakonessenhuis, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1941-1942</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/06/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Excipients/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34128559</style></accession-num><notes><style face="normal" font="default" size="100%">Borgsteede, Sander D&#xD;Geersing, Tjerk H&#xD;Tempels-Pavlica, Zana&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1941-1942. doi: 10.1111/all.14774.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34128559</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441744</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14774</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2866</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2866</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Bergmann, C.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Hox, V.</style></author><author><style face="normal" font="default" size="100%">Gevaert, P.</style></author><author><style face="normal" font="default" size="100%">Tomazic, P. V.</style></author><author><style face="normal" font="default" size="100%">Rondon Segovia, C.</style></author><author><style face="normal" font="default" size="100%">Cingi, C.</style></author><author><style face="normal" font="default" size="100%">Cuevas, M.</style></author><author><style face="normal" font="default" size="100%">Groger, M.</style></author><author><style face="normal" font="default" size="100%">Huber, P.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Rudenko, M.</style></author><author><style face="normal" font="default" size="100%">Maza-Solano, J.</style></author><author><style face="normal" font="default" size="100%">Gane, S.</style></author><author><style face="normal" font="default" size="100%">Karavelia, A.</style></author><author><style face="normal" font="default" size="100%">van Gerven, L.</style></author><author><style face="normal" font="default" size="100%">Schiappoli, M.</style></author><author><style face="normal" font="default" size="100%">Bozkurt, B.</style></author><author><style face="normal" font="default" size="100%">Becker, S.</style></author><author><style face="normal" font="default" size="100%">Chaker, A.</style></author><author><style face="normal" font="default" size="100%">Wollenberg, B.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Huppertz, T.</style></author><author><style face="normal" font="default" size="100%">Hagemann, J.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Barhold, F.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">de Las Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Alvaro Lozano, M.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Feleszko, W.</style></author><author><style face="normal" font="default" size="100%">Cianferoni, A.</style></author><author><style face="normal" font="default" size="100%">Sahiner, U. M.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author><author><style face="normal" font="default" size="100%">Torres Jaen, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Allergy and Rhinology, Wiesbaden, Germany.&#xD;Children&apos;s Allergy Service, Evelina Children&apos;s Hospital, Guy&apos;s and St. Thomas&apos; Hospital, London, UK.&#xD;Department of Women and Children&apos;s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Translational Research in Pediatric Specialties Area, Division of Allergy, Bambino Gesu Children&apos;s Hospital, Rome, Italy.&#xD;Department of Otorhinolaryngology, University of Eastern Finland, Joensuu and Kuopio, Finland and Wellbeing Services County of Pohjois-Savo, Kuopio, Finland.&#xD;Department of Allergology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Otorhinolaryngology, RKM740 Interdisciplinary Clinics, Dusseldorf, Germany.&#xD;Department of Clinical Immunology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Dermatology and Allergy, Charite, Universitatsmedizin Berlin, Humboldt-Universitat Zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany.&#xD;University Hospital Montpellier, France and MACVIA-France, Montpellier, France.&#xD;Department of Otorhinolaryngology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.&#xD;Department of Otorhinolaryngology, Upper Airways Research Laboratory, Ghent University, Ghent, Belgium.&#xD;Department of General Otorhinolaryngology, H&amp;N Surgery, Medical University of Graz, Graz, Austria.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Group, Biomedical Research Institute of Malaga (IBIMA)-BIONAND Platform, RICORS Inflammatory Diseases, Malaga, Spain.&#xD;Department of Otorhinolaryngology, Eskisehir Osmangazi University, Eskisehir, Turkey.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Technische Universitat Dresden, Faculty of Medicine (And University Hospital) Carl Gustav Carus, Dresden, Germany.&#xD;Department of Otorhinolaryngology, Grosshadern Medical Center of the University of Munich, Munich, Germany.&#xD;Otolaryngology-HNS, University of Amsterdam, Amsterdam, the Netherlands.&#xD;The London Allergy and Immunology Centre, London, UK.&#xD;Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen Macarena University Hospital, Sevilla, Spain.&#xD;The Centre for Olfactory Research and Applications, Institute of Philosophy, School of Advanced Studies, University of London, London, UK.&#xD;Royal National Throat Nose and Ear Hospital, UCLH, London, UK.&#xD;ENT Department, General Hopsital of Nafplio, Nafplio, Greece.&#xD;Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.&#xD;Department of Neurosciences, Experimental Otorhinolaryngology, KU Leuven, Leuven, Belgium.&#xD;Allergy Unit and Asthma Center, Integrated University Hospital of Verona, Verona, Italy.&#xD;Department of Ophthalmology, Selcuk University Faculty of Medicine, Konya, Turkey.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center, Tubingen, Germany.&#xD;Technical University of Munich, TUM School of Medicine and Health, TUM University Hospital, Munich, Germany.&#xD;IMSB, Medical Faculty, University Cologne, Cologne, Germany.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center, Mainz, Germany.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.&#xD;EPIUnit-Instituto de Saude Publica, Universidade do Porto, and Laboratorio de Investigacao Integrativa e Translacional Em Saude Populacional (ITR), Porto, Portugal.&#xD;Immunoallergology Service, Centro Hospitalar Universitario Sao Joao, Porto, Portugal.&#xD;Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, Universidade do Porto, Porto, Portugal.&#xD;Faculty of Medicine, Transylvania University of Brasov, Brasov, Romania.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.&#xD;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.&#xD;Department of Allergy, La Paz University Hospital, Madrid, Spain.&#xD;IdiPAZ, Madrid, Spain.&#xD;Pediatric Allergology and Clinical Immunology Department, Hospital Sant Joan de Deu, Barcelona, Spain.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Pediatric Allergy and Pneumonology, Medical University of Warsaw, Warsaw, Poland.&#xD;The Children&apos;s Hospital of Philadelphia, University of Pennsylvania, Pediatrics Allergy and Immunology Division, Philadelphia, USA.&#xD;Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Turkey.&#xD;National Heart and Lung Institute, Imperial College London, London, United Kingdom, NIHR Imperial Biomedical Research Centre, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity-An EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2429-2441</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/04/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eustachian Tube/physiopathology/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Otitis Media with Effusion/etiology/immunology/epidemiology/therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">IgE allergy</style></keyword><keyword><style face="normal" font="default" size="100%">eustachian</style></keyword><keyword><style face="normal" font="default" size="100%">eustachian tube</style></keyword><keyword><style face="normal" font="default" size="100%">middle ear</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric allergy</style></keyword><keyword><style face="normal" font="default" size="100%">tube dysfunction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40242889</style></accession-num><abstract><style face="normal" font="default" size="100%">IgE-mediated allergies play a significant role in respiratory diseases. Given the similar mucosal epithelium of the upper and lower respiratory tracts and their shared (patho)physiological immune responses, the &quot;unified airways&quot; concept views these tracts as a single system. Recently, this model has been extended to include the middle ear, with studies confirming that the Eustachian tube and middle ear are both anatomically and functionally part of the upper airways. However, the relationship between allergies and middle ear disorders remains controversial, with conflicting findings regarding pathogenesis and treatment. The increasing prevalence of allergies highlights the importance of further research. In Germany, the current sensitization rate to aeroallergens is 33.6%, with similar trends across Europe, where rates commonly range up to 30%. This widespread increase underscores the urgent need for a deeper understanding of the correlation between allergies and middle ear disorders across diverse European populations. Ineffective pharmacotherapy or possibly harmful medication for acute and chronic OME, such as systemic steroids, is most likely used globally in an uninformed way, due to a lack of evidence on the connection between allergic inflammation and eustachian tube dysfunction. Further research is essential to clarify the mechanisms linking IgE-mediated allergies to middle ear pathologies and to develop effective treatment strategies. Addressing these knowledge gaps is critical for improving patient outcomes and managing the rising burden of allergic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Klimek, L&#xD;Brough, H A&#xD;Arasi, S&#xD;Toppila-Salmi, S&#xD;Bergmann, C&#xD;Jutel, M&#xD;Bousquet, J&#xD;Hox, V&#xD;Gevaert, P&#xD;Tomazic, P V&#xD;Rondon Segovia, C&#xD;Cingi, C&#xD;Cuevas, M&#xD;Groger, M&#xD;Huber, P&#xD;Reitsma, S&#xD;Rudenko, M&#xD;Maza-Solano, J&#xD;Gane, S&#xD;Karavelia, A&#xD;van Gerven, L&#xD;Schiappoli, M&#xD;Bozkurt, B&#xD;Becker, S&#xD;Chaker, A&#xD;Wollenberg, B&#xD;Mosges, R&#xD;Huppertz, T&#xD;Hagemann, J&#xD;Palomares, O&#xD;Barhold, F&#xD;Pfaar, O&#xD;Del Giacco, S&#xD;Bonadonna, P&#xD;Moreira, A&#xD;Agache, I&#xD;Akdis, C A&#xD;Fokkens, W&#xD;Walusiak-Skorupa, J&#xD;de Las Vecillas, L&#xD;Alvaro Lozano, M&#xD;Giovannini, M&#xD;Untersmayr, E&#xD;Feleszko, W&#xD;Cianferoni, A&#xD;Sahiner, U M&#xD;Eguiluz-Gracia, I&#xD;Shamji, M&#xD;Torres Jaen, M J&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Consensus Development Conference&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2429-2441. doi: 10.1111/all.16554. Epub 2025 Apr 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40242889</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16554</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>615</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">615</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fijen, L. M.</style></author><author><style face="normal" font="default" size="100%">Petersen, R. S.</style></author><author><style face="normal" font="default" size="100%">Cohn, D. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Outcome measures in randomized controlled studies of acute therapy for hereditary angioedema: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2222-2224</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/02/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Bradykinin</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment, Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">outcomes</style></keyword><keyword><style face="normal" font="default" size="100%">swelling</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword><keyword><style face="normal" font="default" size="100%">fees from BioCryst, CSL Behring, Intellia, Ionis Pharmaceuticals inc., KalVista,</style></keyword><keyword><style face="normal" font="default" size="100%">Pharming, Pharvaris, and Shire/Takeda.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35122275</style></accession-num><notes><style face="normal" font="default" size="100%">Fijen, Laure M&#xD;Petersen, Remy S&#xD;Cohn, Danny M&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2222-2224. doi: 10.1111/all.15244. Epub 2022 Feb 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35122275</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9305446</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15244</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giannetti, M. P.</style></author><author><style face="normal" font="default" size="100%">Olivieri, F.</style></author><author><style face="normal" font="default" size="100%">Godwin, G.</style></author><author><style face="normal" font="default" size="100%">Weller, E.</style></author><author><style face="normal" font="default" size="100%">Nicoloro-SantaBarbara, J.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Zanotti, R.</style></author><author><style face="normal" font="default" size="100%">Zanoni, G.</style></author><author><style face="normal" font="default" size="100%">Hartmann, K.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Harvard Medical School, Boston, Massachusetts, USA.&#xD;Allergy Unit, Verona University Hospital, Verona, Italy.&#xD;Department of Psychiatry, Brigham and Women&apos;s, Boston, Massachusetts, USA.&#xD;Department of Medicine, Section of Hematology, Verona, Italy.&#xD;Immunology Unit, Verona University Hospital, Verona, Italy.&#xD;Division of Allergy, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Outcomes of COVID-19 vaccination in 323 patients with clonal and non-clonal mast cell activation disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">301-304</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/08/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cell Activation Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35962620</style></accession-num><notes><style face="normal" font="default" size="100%">Giannetti, Matthew P&#xD;Olivieri, Francesco&#xD;Godwin, Grace&#xD;Weller, Emma&#xD;Nicoloro-SantaBarbara, Jennifer&#xD;Bonadonna, Patrizia&#xD;Zanotti, Roberta&#xD;Zanoni, Giovanna&#xD;Hartmann, Karin&#xD;Castells, Mariana&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):301-304. doi: 10.1111/all.15476. Epub 2022 Aug 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35962620</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9538600 Biosciences. Karin Hartmann receives funding from Thermo Fisher. Mariana Castells receives funding from Blueprint Medicines and Cogent Biosciences.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15476</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>24</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">24</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Ryu, J.</style></author><author><style face="normal" font="default" size="100%">Chung, S. J.</style></author><author><style face="normal" font="default" size="100%">Park, D. W.</style></author><author><style face="normal" font="default" size="100%">Park, T. S.</style></author><author><style face="normal" font="default" size="100%">Moon, J. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, T. H.</style></author><author><style face="normal" font="default" size="100%">Sohn, J. W.</style></author><author><style face="normal" font="default" size="100%">Yoon, H. J.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Overall and respiratory mortality reduction with physical activity in subjects with and without asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1677-1680</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36602280</style></accession-num><notes><style face="normal" font="default" size="100%">Lee, Hyun&#xD;Ryu, Jiin&#xD;Chung, Sung Jun&#xD;Park, Dong Won&#xD;Park, Tai Sun&#xD;Moon, Ji-Yong&#xD;Kim, Tae-Hyung&#xD;Sohn, Jang Won&#xD;Yoon, Ho Joo&#xD;Kim, Sang-Heon&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1677-1680. doi: 10.1111/all.15638. Epub 2023 Jan 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36602280</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15638</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1022</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1022</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, S.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Hayes, A.</style></author><author><style face="normal" font="default" size="100%">Hon, K.</style></author><author><style face="normal" font="default" size="100%">Zhang, G.</style></author><author><style face="normal" font="default" size="100%">Bennett, C.</style></author><author><style face="normal" font="default" size="100%">Hu, H.</style></author><author><style face="normal" font="default" size="100%">Finnie, J.</style></author><author><style face="normal" font="default" size="100%">Morales, S.</style></author><author><style face="normal" font="default" size="100%">Shearwin, L.</style></author><author><style face="normal" font="default" size="100%">Psaltis, A. J.</style></author><author><style face="normal" font="default" size="100%">Shearwin, K.</style></author><author><style face="normal" font="default" size="100%">Wormald, P. J.</style></author><author><style face="normal" font="default" size="100%">Vreugde, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Surgery-Otolaryngology Head and Neck Surgery, Basil Hetzel Institute for Translational Health Research, Central Adelaide Local Health Network, Woodville South, SA, Australia.&#xD;Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.&#xD;Department of Otolaryngology, Head and Neck Surgery, The Second Hospital of Jilin University, Changchun, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, Tianjin First Center Hospital, Tianjin, China.&#xD;Department of Otolaryngology, Head and Neck Surgery, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.&#xD;Discipline of Anatomy and Pathology, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.&#xD;AmpliPhi Australia, Brookvale, NSW, Australia.&#xD;Department of Molecular and Biomedical Science, Adelaide University, Adelaide, SA, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Overcoming bacteriophage insensitivity in Staphylococcus aureus using clindamycin and azithromycinat subinhibitory concentrations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3446-3458</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/05/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Bacteriophages</style></keyword><keyword><style face="normal" font="default" size="100%">Clindamycin/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Methicillin-Resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style face="normal" font="default" size="100%">*Staphylococcal Infections/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">S. aureus</style></keyword><keyword><style face="normal" font="default" size="100%">bacteriophage therapy</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">clindamycin</style></keyword><keyword><style face="normal" font="default" size="100%">subinhibitory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33930199</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Staphylococcus aureus is a pathogen of major concern in both acute infections and chronic conditions such as chronic rhinosinusitis (CRS). Bacteriophage (phage) therapy has recently regained interest for its potential to treat infections caused by antibiotic resistant strains including Methicillin Resistant Staphylococcus aureus (MRSA). However, bacteria can adapt and become resistant to phages. The aim of this study is to determine the potential for antibiotics to overcome phage resistance. METHODS: The susceptibility of S. aureus clinical isolates (CIs) to phages J-Sa36, Sa83 and Sa87 alone or in combination with protein synthesis inhibitor (PSI) antibiotics clindamycin, azithromycin and erythromycin was assessed using plaque spot assays, minimum inhibitory concentration (MIC) assays, double layer spot assays and resazurin assays. The safety and efficacy of subinhibitory PSI antibiotics in combination with phage was tested in a Sprague Dawley rat model of sinusitis infected with a phage resistant S. aureus CI. RESULTS: All three antibiotics at subinhibitory concentrations showed synergy when combined with all 3 phages against S. aureus CIs in planktonic and biofilm form and could sensitize phage-resistant S. aureus to promote phage infection. The combination of topical subinhibitory clindamycin or azithromycin and phage was safe and could eradicate S. aureus sinonasal biofilms in vivo. CONCLUSION: Subinhibitory concentrations of PSI antibiotics could sensitize phage-resistant S. aureus and MRSA strains to phages in vitro and in vivo. This data supports the potential use of phage-PSI antibiotic combination therapies, in particular for difficult-to-treat infections with phage-resistant S. aureus and MRSA strains.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Sha&#xD;Zhao, Yin&#xD;Hayes, Andrew&#xD;Hon, Karen&#xD;Zhang, Guimin&#xD;Bennett, Catherine&#xD;Hu, Hua&#xD;Finnie, John&#xD;Morales, Sandra&#xD;Shearwin, Linda&#xD;Psaltis, Alkis J&#xD;Shearwin, Keith&#xD;Wormald, Peter-John&#xD;Vreugde, Sarah&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3446-3458. doi: 10.1111/all.14883. Epub 2021 May 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33930199</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14883</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1177</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1177</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Krawiec, M.</style></author><author><style face="normal" font="default" size="100%">Fisher, H. R.</style></author><author><style face="normal" font="default" size="100%">Du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Bahnson, H. T.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Women and Children&apos;s Health (Paediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Benaroya Research Institute and the Immune Tolerance Network, Seattle, USA.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Overview of oral tolerance induction for prevention of food allergy-Where are we now?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2684-2698</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/02/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Weaning</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33539570</style></accession-num><abstract><style face="normal" font="default" size="100%">Oral tolerance induction through early introduction of allergenic food has proven effective in randomized controlled trials. This new approach to weaning has been incorporated into many national and international infants&apos; feeding guidelines. However, there are questions that require further discussion, such as, which foods should be introduced early, should the intervention be targeted to infants at high-risk or to the general population, and what is the ideal timing for early food introduction. This review examines the extent to which recent trials address these critical questions and highlights areas where further research is required.</style></abstract><notes><style face="normal" font="default" size="100%">Krawiec, Marta&#xD;Fisher, Helen R&#xD;Du Toit, George&#xD;Bahnson, Henry T&#xD;Lack, Gideon&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2684-2698. doi: 10.1111/all.14758. Epub 2021 Mar 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33539570</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14758</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1069</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1069</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Itoh, N.</style></author><author><style face="normal" font="default" size="100%">Yasutomi, M.</style></author><author><style face="normal" font="default" size="100%">Kawasaki, A.</style></author><author><style face="normal" font="default" size="100%">Murai, H.</style></author><author><style face="normal" font="default" size="100%">Nomura, E.</style></author><author><style face="normal" font="default" size="100%">Hagihara, Y.</style></author><author><style face="normal" font="default" size="100%">Ogura, K.</style></author><author><style face="normal" font="default" size="100%">Ohshima, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.&#xD;Department of Pediatrics, Fukui Red Cross Hospital, Fukui, Japan.&#xD;Department of Pediatrics, Municipal Tsuruga Hospital, Fukui, Japan.&#xD;Department of Pediatrics, Ohtaki Hospital, Fukui, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ovomucoid-specific IgD increases in children who naturally outgrow egg allergy in a cross-sectional study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2607-2609</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/04/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Egg Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Egg White</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin D</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Ovomucin</style></keyword><keyword><style face="normal" font="default" size="100%">IgD</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">ovomucoid</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33811337</style></accession-num><notes><style face="normal" font="default" size="100%">Itoh, Naohiro&#xD;Yasutomi, Motoko&#xD;Kawasaki, Akiko&#xD;Murai, Hiroki&#xD;Nomura, Eishi&#xD;Hagihara, Yuuki&#xD;Ogura, Kazumasa&#xD;Ohshima, Yusei&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2607-2609. doi: 10.1111/all.14841. Epub 2021 Apr 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33811337</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14841</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2945</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2945</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bar, J.</style></author><author><style face="normal" font="default" size="100%">David, E.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Guenin, S.</style></author><author><style face="normal" font="default" size="100%">Tam, C.</style></author><author><style face="normal" font="default" size="100%">Wasserburg, J. R.</style></author><author><style face="normal" font="default" size="100%">Patel, D.</style></author><author><style face="normal" font="default" size="100%">Rothenberg-Lausell, C.</style></author><author><style face="normal" font="default" size="100%">Facheris, P.</style></author><author><style face="normal" font="default" size="100%">Taub, P.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Dermatology, University of Magna Graecia, Catanzaro, Italy.&#xD;Division of Plastic and Maxillofacial Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Dermatology Unit, Humanitas Research Hospital, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">OX40 and Regulatory Marker Alterations in Lesional and Non-Lesional Keloid Tissues</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2240-2257</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Keloid/metabolism/pathology/genetics/etiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Pcr</style></keyword><keyword><style face="normal" font="default" size="100%">RNA sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">fibrosis</style></keyword><keyword><style face="normal" font="default" size="100%">immune</style></keyword><keyword><style face="normal" font="default" size="100%">immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">keloids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40577225</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Keloids are pathologic scars that result from abnormal wound healing processes following skin trauma, with a higher prevalence in the Black population. The pathogenesis of keloids is not fully understood, hindering effective treatment options for this highly disfiguring and distressing condition. METHODS: Biopsies from lesional and non-lesional skin from keloid patients and healthy skin from age/gender/race-matched controls were collected and analyzed using RNA-sequencing, RT-qPCR, and immunohistochemistry. Spearman analysis was used to evaluate the correlations between biomarker expressions and clinical severity measurements. RESULTS: Both keloidal lesions and non-lesional skin showed a distinct transcriptomic profile compared to healthy skin. Keloids demonstrated significant upregulation of fibrosis-related markers (e.g., COL10A1, COL11A1, and BMP1). Lesional and/or non-lesional samples showed significant upregulation of key immune biomarkers belonging to T-cells (e.g., CD2, CD3D, and CD3E), T-cell/NK-cell activation/migration (e.g., CCL19, CCR7, GZMA, GZMB, and GZMK), Th1 (e.g., OASL, MX1, CCL4), Th2 (e.g., IL4R, OX40/TNFRSF4, and OX40L/TNFSF4), and Th17/22 (e.g., S100A7, S100A8, S100A9, and CCL20). Multiple immune biomarkers expression (e.g., CCL2, CXCL1, and S100A7) in lesional and/or non-lesional skin significantly and positively correlated with keloid severity parameters (e.g., keloid size, distensibility, and number). CONCLUSION: Both lesional and non-lesional keloid skin show distinct upregulation of immune axes, underscoring the role of inflammation in keloid pathogenesis and pointing to potential novel therapeutic targets.</style></abstract><notes><style face="normal" font="default" size="100%">Bar, Jonathan&#xD;David, Eden&#xD;Del Duca, Ester&#xD;Guenin, Sophie&#xD;Tam, Curtis&#xD;Wasserburg, J Roscoe&#xD;Patel, Dev&#xD;Rothenberg-Lausell, Camille&#xD;Facheris, Paola&#xD;Taub, Peter&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2240-2257. doi: 10.1111/all.16628. Epub 2025 Jun 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40577225</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16628</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3320</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3320</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yamamura, Kazuhiko</style></author><author><style face="normal" font="default" size="100%">Dahabreh, Dante</style></author><author><style face="normal" font="default" size="100%">Del Duca, Ester</style></author><author><style face="normal" font="default" size="100%">Lozano-Ojalvo, Daniel</style></author><author><style face="normal" font="default" size="100%">Kim, Madeline</style></author><author><style face="normal" font="default" size="100%">Murai-Yamamura, Mika</style></author><author><style face="normal" font="default" size="100%">Garcet, Sandra</style></author><author><style face="normal" font="default" size="100%">Gonzalez, Juana</style></author><author><style face="normal" font="default" size="100%">Miura, Shunsuke</style></author><author><style face="normal" font="default" size="100%">Williams, Samuel C.</style></author><author><style face="normal" font="default" size="100%">Hur, Hong Beom</style></author><author><style face="normal" font="default" size="100%">Li, Xuan</style></author><author><style face="normal" font="default" size="100%">Liu, Ying</style></author><author><style face="normal" font="default" size="100%">Lin, Xinyi E.</style></author><author><style face="normal" font="default" size="100%">Metukuru, Ragasruti</style></author><author><style face="normal" font="default" size="100%">Zhou, Jerry</style></author><author><style face="normal" font="default" size="100%">Estrada, Yeriel D.</style></author><author><style face="normal" font="default" size="100%">Krueger, James G.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, Emma</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The OX40/OX40L Axis Promotes Th2 Activity and Impairs Regulatory T Cell Function in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Clinical trials using monoclonal antibodies targeting the OX40/OX40L axis (AMG451, GBR830, KHK4083, and KY1005) have shown promise in long-term disease modification of atopic dermatitis (AD). OX40/OX40L enhances survival of effector T cells and inhibits regulatory T cells (Tregs) function in other inflammatory diseases, but its mechanism of action in AD is unelucidated. We aimed to evaluate OX40- and OX40L-expressing cells in the skin and blood of AD patients to understand how the axis promotes T cell activity and inflammation. Methods Skin samples from AD and healthy controls (HCs) were evaluated using immunohistochemistry (IHC) and immunofluorescence (IF). Flow cytometry was used to analyze peripheral blood mononuclear cells (PBMCs), and RT-qPCR and ELISA were performed on purified effector CD4+ T cells and from AD patients and HCs. RNA-seq analysis was conducted on effector CD4+ T cells and Tregs stimulated with anti-CD3/28, with and without OX40L, in both AD patients and HCs. Results IHC showed increased OX40+ and OX40L+ cell expression in AD skin lesions. Circulating CLA+CD4+ T cells and CLA+ Tregs upregulate OX40 expression in AD patients compared to HCs. OX40+CLA+CD4+ Tregs correlated with SCORAD. RNA-seq, RT-qPCR, and ELISA revealed that the OX40/OX40L axis maintained the Th2 phenotype of effector CD4+ T cells and decreased IL-10 produced by Tregs. Conclusion AD patients exhibit significant upregulation of OX40 expression in effector and regulatory CD4+ T cells. Both subsets interact with OX40L-expressing cells in the skin, leading to the promotion of skin inflammation by downregulation of function and anti-inflammatory capacity of Tregs.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70252</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70252</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2605</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2605</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saarimaki, L.</style></author><author><style face="normal" font="default" size="100%">Ekstrom, S.</style></author><author><style face="normal" font="default" size="100%">Protudjer, J. L. P.</style></author><author><style face="normal" font="default" size="100%">Huhtala, H.</style></author><author><style face="normal" font="default" size="100%">Karjalainen, J.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Kivisto, J. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Tampere University Hospital, Tampere, Finland.&#xD;Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Center for Occupational and Environmental Medicine, Region Stockholm, Stockholm, Sweden.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Pediatrics and Child Health, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.&#xD;Children&apos;s Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada.&#xD;Department of Food and Human Nutritional Sciences, Faculty of Agricultural and Food Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.&#xD;George and Fay Yee Centre for Healthcare Innovation, Winnipeg, Manitoba, Canada.&#xD;Faculty of Social Sciences, Tampere University, Tampere, Finland.&#xD;Allergy Centre, Tampere University Hospital, Tampere, Finland.&#xD;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.&#xD;Sachs&apos; Children&apos;s and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Tampere Center for Child Health Research, University of Tampere, Tampere, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Paediatric hospitalizations due to allergic reactions increasing in Finland and decreasing in Sweden</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3542-3545</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/08/22</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39169594</style></accession-num><notes><style face="normal" font="default" size="100%">Saarimaki, Lasse&#xD;Ekstrom, Sandra&#xD;Protudjer, Jennifer L P&#xD;Huhtala, Heini&#xD;Karjalainen, Jussi&#xD;Kull, Inger&#xD;Kivisto, Juho E&#xD;eng&#xD;Konsul Th C Bergh Foundation/&#xD;Hesselmans Foundation/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3542-3545. doi: 10.1111/all.16282. Epub 2024 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39169594</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657030 Canadian Society of Allergy and Clinical Immunology and is on the steering committee for Canada&apos;s National Food Allergy Action Plan. She reports consulting for Ajonomoto Cambrooke, Novartis, Nutricia and ALK Abello. Other authors have no conflicts of interest relevant to this article to disclose.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16282</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2359</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2359</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yamamoto-Hanada, K.</style></author><author><style face="normal" font="default" size="100%">Pak, K.</style></author><author><style face="normal" font="default" size="100%">Iwamoto, S.</style></author><author><style face="normal" font="default" size="100%">Konishi, M.</style></author><author><style face="normal" font="default" size="100%">Saito-Abe, M.</style></author><author><style face="normal" font="default" size="100%">Sato, M.</style></author><author><style face="normal" font="default" size="100%">Miyaji, Y.</style></author><author><style face="normal" font="default" size="100%">Mezawa, H.</style></author><author><style face="normal" font="default" size="100%">Nishizato, M.</style></author><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Kumasaka, N.</style></author><author><style face="normal" font="default" size="100%">Ohya, Y.</style></author><author><style face="normal" font="default" size="100%">Japan, Environment</style></author><author><style face="normal" font="default" size="100%">Children&apos;s Study, Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Center, National Center for Child Health and Development, Tokyo, Japan.&#xD;Medical Support Center for the Japan Environment and Children&apos;s Study, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Division of Biostatistics, Department of Data Management, Center for Clinical Research, National Center for Child Health and Development, Tokyo, Japan.&#xD;Faculty of Applied Psychology, Tokyo Seitoku University, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Parental stress and food allergy phenotypes in young children: A National Birth Cohort (JECS)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1881-1892</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/01/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology/psychology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Parents/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">*Stress, Psychological/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Birth Cohort</style></keyword><keyword><style face="normal" font="default" size="100%">Japan/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">cohort</style></keyword><keyword><style face="normal" font="default" size="100%">distress</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">stress</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38269609</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food allergy children and their families tend to have emotional distress and anxiety. There have been few reports of differences in parenting stress and a child&apos;s food allergy phenotypes. METHODS: We examined the associations between food allergy phenotypes in children and parenting stress assessed by the Parenting Stress Index-Short Form (PSI-SF) from a national birth cohort (Japan Environment and Children&apos;s Study). RESULTS: We included 65,805 children for statistical analysis. Of them, 7.2% of children had a food allergy diagnosis at 2 years old. The means of the total PSI-SF (39.9 +/- 10.3, 39.1 +/- 9.9), CD-SF (19.5 +/- 5.4, 19.1 +/- 5.2), and PD-SF (20.5 +/- 6.3, 20.0 +/- 6.1) scores are similar for caregivers in the with and without food allergy groups. Food allergy diagnosis resulted in significantly higher total PSI scores (coefficient .47, 95% CI 0.19-0.75, p = .001), CD-SF (coefficient .22, 95% CI 0.07-0.38, p = .004), and PD-SF (coefficient .24, 95% CI 0.08-0.41, p = .004). A similar trend was observed for allergy reactions to hen&apos;s egg. However, there was no clear relationship between allergic reactions to milk, wheat, nuts, and PSI-SF. CONCLUSIONS: Parental stress was significantly related to a child&apos;s food allergy. Furthermore, hen&apos;s egg allergy increased parental stress. Multiple food avoidance might also increase parental stress. Healthcare providers need to be aware of parental stress in our daily clinic.</style></abstract><notes><style face="normal" font="default" size="100%">Yamamoto-Hanada, Kiwako&#xD;Pak, Kyongsun&#xD;Iwamoto, Shintaro&#xD;Konishi, Mizuho&#xD;Saito-Abe, Mayako&#xD;Sato, Miori&#xD;Miyaji, Yumiko&#xD;Mezawa, Hidetoshi&#xD;Nishizato, Minaho&#xD;Yang, Limin&#xD;Kumasaka, Natsuhiko&#xD;Ohya, Yukihiro&#xD;(JECS)&#xD;eng&#xD;Ministry of the Environment, Government of Japan/&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1881-1892. doi: 10.1111/all.16035. Epub 2024 Jan 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38269609</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16035</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2823</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2823</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, T. H.</style></author><author><style face="normal" font="default" size="100%">Chou, C. C. K.</style></author><author><style face="normal" font="default" size="100%">Chiang, B. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Graduate Institute of Clinical Medicine, National Taiwan University, Taipei, Taiwan.&#xD;Air Quality Research Center, Academia Sinica, Taipei, Taiwan.&#xD;Research Center for Environmental Changes, Academia Sinica, Taipei, Taiwan.&#xD;Genome and Systems Biology Degree Program, College of Life Science, National Taiwan University, Taipei, Taiwan.&#xD;Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Particulate Matter 2.5 Aggravates Airway Inflammation by Neutrophil-Mediated Inflammasome Activation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1176-1179</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/03/05</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40042067</style></accession-num><notes><style face="normal" font="default" size="100%">Chen, Tien-Hsuan&#xD;Chou, Charles C K&#xD;Chiang, Bor-Luen&#xD;eng&#xD;NSTC-112-2314-B-002-172/National Science and Technology Council/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1176-1179. doi: 10.1111/all.16521. Epub 2025 Mar 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40042067</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16521</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2386</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2386</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lubner, R. J.</style></author><author><style face="normal" font="default" size="100%">Rubel, K.</style></author><author><style face="normal" font="default" size="100%">Chandra, R. K.</style></author><author><style face="normal" font="default" size="100%">Turner, J. H.</style></author><author><style face="normal" font="default" size="100%">Chowdhury, N. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Particulate matter exposure is associated with increased inflammatory cytokines and eosinophils in chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1219-1229</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/01/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation Mediators/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Particulate Matter/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinosinusitis/etiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Pm2.5</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38180309</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chronic rhinosinusitis (CRS) is thought to result from complex interactions between the host immune system, microbiota, and environmental exposures. Currently, there is limited data regarding the impact of ambient particulate matter &lt;/=2.5 mum in diameter (PM(2.5)) in the pathogenesis of CRS, despite evidence linking PM(2.5) to other respiratory diseases. We hypothesized that PM(2.5) may result in differential cytokine patterns that could inform our mechanistic understanding of the effect of environmental factors on CRS. METHODS: We conducted an analysis of data prospectively collected from 308 CRS patients undergoing endoscopic sinus surgery. Cytokines were quantified in intraoperative mucus specimens using a multiplex flow cytometric bead assay. Clinical and demographic data including zip codes were extracted and used to obtain tract-level income and rurality measures. A spatiotemporal machine learning model was used to estimate daily PM(2.5) levels for the year prior to each patient&apos;s surgery date. Spearman correlations and regression analysis were performed to characterize the relationship between mucus cytokines and PM(2.5.) RESULTS: Several inflammatory cytokines including IL-2, IL-5/IL-13, IL-12, and 21 were significantly correlated with estimated average 6, 9, and 12-month preoperative PM(2.5) levels. These relationships were maintained for most cytokines after adjusting for age, income, body mass index, rurality, polyps, asthma, and allergic rhinitis (AR) (p &lt; .05). There were also higher odds of asthma (OR = 1.5, p = .01) and AR (OR = 1.48, p = .03) with increasing 12-month PM(2.5) exposure. Higher tissue eosinophil counts were associated with increasing PM(2.5) levels across multiple timeframes (p &lt; .05). CONCLUSIONS: Chronic PM(2.5) exposure may be an independent risk factor for development of a mixed, type-2 dominant CRS inflammatory response.</style></abstract><notes><style face="normal" font="default" size="100%">Lubner, Rory J&#xD;Rubel, Kolin&#xD;Chandra, Rakesh K&#xD;Turner, Justin H&#xD;Chowdhury, Naweed I&#xD;eng&#xD;K24 AI177947/AI/NIAID NIH HHS/&#xD;R01 AG065550/AG/NIA NIH HHS/&#xD;NH/NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1219-1229. doi: 10.1111/all.16006. Epub 2024 Jan 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38180309</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11062815</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16006</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1432</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1432</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dorofeeva, Y.</style></author><author><style face="normal" font="default" size="100%">Shilovskiy, I.</style></author><author><style face="normal" font="default" size="100%">Tulaeva, I.</style></author><author><style face="normal" font="default" size="100%">Focke-Tejkl, M.</style></author><author><style face="normal" font="default" size="100%">Flicker, S.</style></author><author><style face="normal" font="default" size="100%">Kudlay, D.</style></author><author><style face="normal" font="default" size="100%">Khaitov, M.</style></author><author><style face="normal" font="default" size="100%">Karsonova, A.</style></author><author><style face="normal" font="default" size="100%">Riabova, K.</style></author><author><style face="normal" font="default" size="100%">Karaulov, A.</style></author><author><style face="normal" font="default" size="100%">Khanferyan, R.</style></author><author><style face="normal" font="default" size="100%">Pickl, W. F.</style></author><author><style face="normal" font="default" size="100%">Wekerle, T.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;National Research Center, Institute of immunology, FMBA of Russia, Moscow, Russian Federation.&#xD;Department of Clinical Immunology and Allergy, Laboratory of Immunopathology, Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;Department of Immunology and Allergy, Russian People&apos;s Friendship University, Moscow, Russian Federation.&#xD;Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Section of Transplantation Immunology, Department of Surgery, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Past, present, and future of allergen immunotherapy vaccines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">131-149</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/04/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">molecular allergy vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer. Dr Wekerle reports personal fees from Astellas, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, personal fees from Therakos, grants from TEVA, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. Rudolf Valenta has received research grants from Viravaxx (Vienna, Austria)</style></keyword><keyword><style face="normal" font="default" size="100%">and serves as consultant for this company. The other authors declare that they</style></keyword><keyword><style face="normal" font="default" size="100%">have no competing interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32249442</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergen-specific immunotherapy (AIT) is an allergen-specific form of treatment for patients suffering from immunoglobulin E (IgE)-associated allergy; the most common and important immunologically mediated hypersensitivity disease. AIT is based on the administration of the disease-causing allergen with the goal to induce a protective immunity consisting of allergen-specific blocking IgG antibodies and alterations of the cellular immune response so that the patient can tolerate allergen contact. Major advantages of AIT over all other existing treatments for allergy are that AIT induces a long-lasting protection and prevents the progression of disease to severe manifestations. AIT is cost effective because it uses the patient s own immune system for protection and potentially can be used as a preventive treatment. However, broad application of AIT is limited by mainly technical issues such as the quality of allergen preparations and the risk of inducing side effects which results in extremely cumbersome treatment schedules reducing patient s compliance. In this article we review progress in AIT made from its beginning and provide an overview of the state of the art, the needs for further development, and possible technical solutions available through molecular allergology. Finally, we consider visions for AIT development towards prophylactic application.</style></abstract><notes><style face="normal" font="default" size="100%">Dorofeeva, Yulia&#xD;Shilovskiy, Igor&#xD;Tulaeva, Inna&#xD;Focke-Tejkl, Margarete&#xD;Flicker, Sabine&#xD;Kudlay, Dmitriy&#xD;Khaitov, Musa&#xD;Karsonova, Antonina&#xD;Riabova, Ksenja&#xD;Karaulov, Alexander&#xD;Khanferyan, Roman&#xD;Pickl, Winfried F&#xD;Wekerle, Thomas&#xD;Valenta, Rudolf&#xD;eng&#xD;P 29991/FWF_/Austrian Science Fund FWF/Austria&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):131-149. doi: 10.1111/all.14300. Epub 2020 Apr 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32249442</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7818275</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14300</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>651</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">651</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The past, present, and future of allergic diseases in China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">354-356</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34995371</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Luo&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):354-356. doi: 10.1111/all.15213.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34995371</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15213</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1526</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1526</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peters, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental Pneumology, Ruhr-University Bochum, Bochum, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A patent on the synthesis of arabino-oligosaccharides for regulation of immune responses in the lung</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2547-2549</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2019/05/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Oligosaccharides/biosynthesis/chemistry/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">environment and hygiene hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacology and pharmacogenomics</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31145814</style></accession-num><notes><style face="normal" font="default" size="100%">Peters, Marcus&#xD;eng&#xD;Letter&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2019 Dec;74(12):2547-2549. doi: 10.1111/all.13930. Epub 2019 Jun 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31145814</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13930</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>387</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">387</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maggi, E.</style></author><author><style face="normal" font="default" size="100%">Parronchi, P.</style></author><author><style face="normal" font="default" size="100%">Azzarone, B. G.</style></author><author><style face="normal" font="default" size="100%">Moretta, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A pathogenic integrated view explaining the different endotypes of asthma and allergic disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3267-3292</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">allergic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">cell plasticity</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">environmental signals</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35842745</style></accession-num><abstract><style face="normal" font="default" size="100%">The inflammation of allergic diseases is characterized by a complex interaction between type 2 and type 3 immune responses, explaining clinical symptoms and histopathological patterns. Airborne stimuli activate the mucosal epithelium to release a number of molecules impacting the activity of resident immune and environmental cells. Signals from the mucosal barrier, regulatory cells, and the inflamed tissue are crucial conditions able to modify innate and adaptive effector cells providing the selective homing of eosinophils or neutrophils. The high plasticity of resident T- and innate lymphoid cells responding to external signals is the prerequisite to explain the multiplicity of endotypes of allergic diseases. This notion paved the way for the huge use of specific biologic drugs interfering with pathogenic mechanisms of inflammation. Based on the response of the epithelial barrier, the activity of resident regulatory cells, and functions of structural non-lymphoid environmental cells, this review proposes some immunopathogenic scenarios characterizing the principal endotypes which can be associated with a precise phenotype of asthma. Recent literature indicates that similar concepts can also be applied to the inflammation of other non-respiratory allergic disorders. The next challenges will consist in defining specific biomarker(s) of each endotype allowing for a quick diagnosis and the most effective personalized therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Maggi, Enrico&#xD;Parronchi, Paola&#xD;Azzarone, Bruno Giuseppe&#xD;Moretta, Lorenzo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3267-3292. doi: 10.1111/all.15445. Epub 2022 Aug 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35842745</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15445</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2115</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2115</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Schunemann, H. J.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Amaral, R.</style></author><author><style face="normal" font="default" size="100%">Ansotegui, I. J.</style></author><author><style face="normal" font="default" size="100%">Bosnic-Anticevich, S.</style></author><author><style face="normal" font="default" size="100%">Braido, F.</style></author><author><style face="normal" font="default" size="100%">Chaves Loureiro, C.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Kulus, M.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Kupczyk, M.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P. M.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Sofiev, M.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Barbara, C.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Bewick, M.</style></author><author><style face="normal" font="default" size="100%">Blain, H.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Boulet, L. P.</style></author><author><style face="normal" font="default" size="100%">Bourret, R.</style></author><author><style face="normal" font="default" size="100%">Brusselle, G.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Buhl, R.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Charpin, D.</style></author><author><style face="normal" font="default" size="100%">Cherrez-Ojeda, I.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Cingi, C.</style></author><author><style face="normal" font="default" size="100%">Costa, E. M.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Dramburg, S.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Ispayeva, Z.</style></author><author><style face="normal" font="default" size="100%">Ivancevich, J. C.</style></author><author><style face="normal" font="default" size="100%">Joos, G.</style></author><author><style face="normal" font="default" size="100%">Kaidashev, I.</style></author><author><style face="normal" font="default" size="100%">Kraxner, H.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Laune, D.</style></author><author><style face="normal" font="default" size="100%">Lourenco, O.</style></author><author><style face="normal" font="default" size="100%">Louis, R.</style></author><author><style face="normal" font="default" size="100%">Makela, M.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Micheli, Y.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Niedoszytko, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Olze, H.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Papi, A.</style></author><author><style face="normal" font="default" size="100%">Patella, V.</style></author><author><style face="normal" font="default" size="100%">Petre, B.</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, N.</style></author><author><style face="normal" font="default" size="100%">Puggioni, F.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Roche, N.</style></author><author><style face="normal" font="default" size="100%">Rouadi, P. W.</style></author><author><style face="normal" font="default" size="100%">Sa-Sousa, A.</style></author><author><style face="normal" font="default" size="100%">Sagara, H.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Scichilone, N.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Sova, M.</style></author><author><style face="normal" font="default" size="100%">Suppli Ulrik, C.</style></author><author><style face="normal" font="default" size="100%">Taborda-Barata, L.</style></author><author><style face="normal" font="default" size="100%">Todo-Bom, A.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Tsiligianni, I.</style></author><author><style face="normal" font="default" size="100%">Usmani, O. S.</style></author><author><style face="normal" font="default" size="100%">Valovirta, E.</style></author><author><style face="normal" font="default" size="100%">Vasankari, T.</style></author><author><style face="normal" font="default" size="100%">Vieira, R. J.</style></author><author><style face="normal" font="default" size="100%">Wallace, D.</style></author><author><style face="normal" font="default" size="100%">Waserman, S.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite - Universitatsmedizin Berlin, Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;University Hospital Montpellier, Montpellier, France.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;National Heart and Lung Institute (NHLI), Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Department of Health Research Methods, Evidence, and Impact, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Personalized Medicine, Asthma &amp; Allergy, IRCCS Humanitas Research Center, Milan, Italy.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula,&quot; University of Cagliari, Cagliari, Italy.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE- Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;MASK-air, Montpellier, France.&#xD;ARIA, Montpellier, France.&#xD;Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.&#xD;Quality Use of Respiratory Medicines Group, Woolcock Institute of Medical Research, Sydney, New South Wales, Australia.&#xD;Sydney Local Health District, Sydney, New South Wales, Australia.&#xD;Sydney Pharmacy School, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Respiratory Clinic, Department of Internal Medicine, University of Genoa, Genoa, Italy.&#xD;IRCCS Ospedale Policlinico San Martino, Genoa, Italy.&#xD;Pneumology Unit, Hospitais da Universidade de Coimbra, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.&#xD;Department of Pulmonary Diseases, Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Department of Pediatric Respiratory Diseases and Allergology, Medical University of Warsaw, Warsaw, Poland.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.&#xD;Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (ICBR), University of Coimbra, Coimbra, Portugal.&#xD;Faculty of Medicine, Institute of Immunology, University of Coimbra, Coimbra, Portugal.&#xD;Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland.&#xD;Finnish Meteorological Institute (FMI), Helsinki, Finland.&#xD;Institute of Clinical Medicine and Institute of Health Sciences, Medical Faculty of Vilnius University, Vilnius, Lithuania.&#xD;Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.&#xD;Institute of Sciences of Food Production, National Research Council (Ispa-CNR), Bari, Italy.&#xD;Portuguese National Programme for Respiratory Diseases, Direcao -Geral da Saude, Faculdade de Medicina de Lisboa, Instituto de Saude Ambiental, Lisbon, Portugal.&#xD;University of Central Lancashire Medical School, Preston, UK.&#xD;Department of Geriatrics, Montpellier University Hospital, MUSE, Montpellier, France.&#xD;Department of Cardiovascular and Respiratory Sciences, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;Department of Neurological, ENT and Thoracic Sciences, Fondazione Policlinico Universitario A Gemelli - IRCCS, Rome, Italy.&#xD;Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.&#xD;University Hospital of Nice, Nice, France.&#xD;Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.&#xD;Department of Medical Sciences, University of Torino, Torino, Italy.&#xD;Allergy and Clinical Immunology Unit, Mauriziano Hospital, Torino, Italy.&#xD;Department of Pulmonary Medicine, Mainz University Hospital, Mainz, Germany.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall d&apos;Hebron, Barcelona, Spain.&#xD;ARADyAL Research Network, Barcelona, Spain.&#xD;Division of Allergy/Immunology, University of South Florida, Tampa, Florida, USA.&#xD;SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Clinique des Bronches, Allergie et Sommeil, Hopital Nord, Marseille, France.&#xD;Universidad Espiritu Santo, Samborondon, Ecuador.&#xD;Respiralab Research Group, Guayas, Ecuador.&#xD;ENT Department, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey.&#xD;UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing, University of Porto (Porto4Ageing), Porto, Portugal.&#xD;Fundacao ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Brazil.&#xD;VIM Suresnes, UMR 0892, Pole des Maladies des Voies Respiratoires, Hopital Foch, Universite Paris-Saclay, Suresnes, France.&#xD;Department of Pediatric Pneumology, Immunology and Intensive Care Medicine, Charite Medical University, Berlin, Germany.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.&#xD;Center of Allergy and Immunology, David Tvildiani Medical University, Tbilisi, Georgia.&#xD;Kazakhstan Association of Allergology and Clinical Immunology, Department of Allergology and Clinical Immunology of the Kazakh National Medical University, Almaty, Kazakhstan.&#xD;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;Poltava State Medical University, Poltava, Ukraine.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary.&#xD;Faculty of Medicine, Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Vilnius University, Vilnius, Lithuania.&#xD;Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;KYomed INNOV, Montpellier, France.&#xD;Faculty of Health Sciences and CICS - UBI, Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Department of Pulmonary Medicine, CHU Liege, Liege, Belgium.&#xD;GIGA I3 Research Group, University of Liege, Liege, Belgium.&#xD;Allergy Unit &quot;D Kalogeromitros,&quot; 2nd Department of Dermatology and Venereology, National &amp; Kapodistrian University of Athens, &quot;Attikon&quot; University Hospital, Athens, Greece.&#xD;Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Sach&apos;s Children and Youth Hospital, Stockholm, Sweden.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;Rhinology Unit &amp; Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain.&#xD;Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.&#xD;Department of Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;Allergy, Asthma and Clinical Immunology, Alfred Health and Department of Immunology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.&#xD;Chiba Rosai Hospital, Chiba, Japan.&#xD;Chiba University Hospital, Chiba, Japan.&#xD;Department of Otorhinolaryngology, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Berlin Institute of Health, Berlin, Germany.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Respiratory Medicine, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, &quot;Santa Maria della Speranza&quot; Hospital, Battipaglia, Salerno, Italy.&#xD;Agency of Health ASL, Salerno, Italy.&#xD;Postgraduate Programme in Allergy and Clinical Immunology, University of Naples Federico II, Naples, Italy.&#xD;Department of Public Health, University of Liege, Liege, Belgium.&#xD;Ecole Polytechnique de Palaiseau, Palaiseau, France.&#xD;IRBA (Institut de Recherche Bio-Medicale des Armees), Bretigny sur Orge, France.&#xD;Universite Paris Cite, Paris, France.&#xD;Personalized Medicine, Asthma &amp; Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy.&#xD;Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.&#xD;Pneumologie, AP-HP Centre Universite de Paris Cite, Hopital Cochin, et UMR 1016, Institut Cochin, Paris, France.&#xD;Department of Otolaryngology, Head and Neck Surgery, Eye and Ear, University Hospital, Beirut, Lebanon.&#xD;Department of Otolaryngology, Head and Neck Surgery, Dar Al Shifa Hospital - Salmiya, Hawally, Kuwait.&#xD;Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.&#xD;Allergy Service, Fundacion Jimenez Diaz, Autonoma University of Madrid, CIBERES-ISCIII, Madrid, Spain.&#xD;PROMISE Department, University of Palermo, Palermo, Italy.&#xD;Usher Institute, The University of Edinburgh, Edinburgh, UK.&#xD;Department of Respiratory Medicine and Tuberculosis, University Hospital Brno, Liskovec, Czech Republic.&#xD;Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Copenhagen, Denmark.&#xD;Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Immunoallergology, Cova da Beira University Hospital Centre, Covilha, Portugal.&#xD;UBIAir - Clinical &amp; Experimental Lung Centre and CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Imunoalergologia, Faculty of Medicine, Centro Hospitalar Universitario de Coimbra, University of Coimbra, Coimbra, Portugal.&#xD;Allergy Unit, Malaga Regional University Hospital-IBIMA, Malaga, Spain.&#xD;International Primary Care Respiratory Group (IPCRG), Aberdeen, UK.&#xD;Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece.&#xD;Royal Brompton Hospital, Airways Disease Section, London, UK.&#xD;Department of Lung Diseases and Clinical Immunology, University of Turku, Turku, Finland.&#xD;FIHLA, Finnish Lung Health Association, Helsinki, Finland.&#xD;Department of Clinical Medicine, Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland.&#xD;Nova Southeastern University, College of Allopathic Medicine, Fort Lauderdale, Florida, USA.&#xD;Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada.&#xD;University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.&#xD;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.&#xD;Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.&#xD;Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital and Beijing Institute of Otolaryngology, Beijing, China.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1758-1776</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/04/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiration Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Patient-Centered Care</style></keyword><keyword><style face="normal" font="default" size="100%">Aria</style></keyword><keyword><style face="normal" font="default" size="100%">Eaaci</style></keyword><keyword><style face="normal" font="default" size="100%">apps</style></keyword><keyword><style face="normal" font="default" size="100%">digital health</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37042071</style></accession-num><abstract><style face="normal" font="default" size="100%">Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed.</style></abstract><notes><style face="normal" font="default" size="100%">Bousquet, Jean&#xD;Shamji, Mohamed H&#xD;Anto, Josep M&#xD;Schunemann, Holger J&#xD;Canonica, G Walter&#xD;Jutel, Marek&#xD;Del Giacco, Stefano&#xD;Zuberbier, Torsten&#xD;Pfaar, Oliver&#xD;Fonseca, Joao A&#xD;Sousa-Pinto, Bernardo&#xD;Klimek, Ludger&#xD;Czarlewski, Wienczyslawa&#xD;Bedbrook, Anna&#xD;Amaral, Rita&#xD;Ansotegui, Ignacio J&#xD;Bosnic-Anticevich, Sinthia&#xD;Braido, Fulvio&#xD;Chaves Loureiro, Claudia&#xD;Gemicioglu, Bilun&#xD;Haahtela, Tari&#xD;Kulus, Marek&#xD;Kuna, Piotr&#xD;Kupczyk, Maciej&#xD;Matricardi, Paolo M&#xD;Regateiro, Frederico S&#xD;Samolinski, Boleslaw&#xD;Sofiev, Mikhail&#xD;Toppila-Salmi, Sanna&#xD;Valiulis, Arunas&#xD;Ventura, Maria Teresa&#xD;Barbara, Cristina&#xD;Bergmann, Karl C&#xD;Bewick, Michael&#xD;Blain, Hubert&#xD;Bonini, Matteo&#xD;Boulet, Louis-Philippe&#xD;Bourret, Rodolphe&#xD;Brusselle, Guy&#xD;Brussino, Luisa&#xD;Buhl, Roland&#xD;Cardona, Victoria&#xD;Casale, Thomas&#xD;Cecchi, Lorenzo&#xD;Charpin, Denis&#xD;Cherrez-Ojeda, Ivan&#xD;Chu, Derek K&#xD;Cingi, Cemal&#xD;Costa, Elisio M&#xD;Cruz, Alvaro A&#xD;Devillier, Philippe&#xD;Dramburg, Stephanie&#xD;Fokkens, Wytske J&#xD;Gotua, Maia&#xD;Heffler, Enrico&#xD;Ispayeva, Zhanat&#xD;Ivancevich, Juan Carlos&#xD;Joos, Guy&#xD;Kaidashev, Igor&#xD;Kraxner, Helga&#xD;Kvedariene, Violeta&#xD;Larenas-Linnemann, Desiree E&#xD;Laune, Daniel&#xD;Lourenco, Olga&#xD;Louis, Renaud&#xD;Makela, Mika&#xD;Makris, Michael&#xD;Maurer, Marcus&#xD;Melen, Erik&#xD;Micheli, Yann&#xD;Morais-Almeida, Mario&#xD;Mullol, Joaquim&#xD;Niedoszytko, Marek&#xD;O&apos;Hehir, Robyn&#xD;Okamoto, Yoshitaka&#xD;Olze, Heidi&#xD;Papadopoulos, Nikolaos G&#xD;Papi, Alberto&#xD;Patella, Vincenzo&#xD;Petre, Benoit&#xD;Pham-Thi, Nhan&#xD;Puggioni, Francesca&#xD;Quirce, Santiago&#xD;Roche, Nicolas&#xD;Rouadi, Philip W&#xD;Sa-Sousa, Ana&#xD;Sagara, Hironori&#xD;Sastre, Joaquin&#xD;Scichilone, Nicola&#xD;Sheikh, Aziz&#xD;Sova, Milan&#xD;Suppli Ulrik, Charlotte&#xD;Taborda-Barata, Luis&#xD;Todo-Bom, Ana&#xD;Torres, Maria J&#xD;Tsiligianni, Ioanna&#xD;Usmani, Omar S&#xD;Valovirta, Erkka&#xD;Vasankari, Tuula&#xD;Vieira, Rafael Jose&#xD;Wallace, Dana&#xD;Waserman, Susan&#xD;Zidarn, Mihaela&#xD;Yorgancioglu, Arzu&#xD;Zhang, Luo&#xD;Chivato, Tomas&#xD;Ollert, Markus&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1758-1776. doi: 10.1111/all.15740.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37042071</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15740</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>393</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">393</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spekhorst, L. S.</style></author><author><style face="normal" font="default" size="100%">Bakker, D.</style></author><author><style face="normal" font="default" size="100%">Drylewicz, J.</style></author><author><style face="normal" font="default" size="100%">Rispens, T.</style></author><author><style face="normal" font="default" size="100%">Loeff, F.</style></author><author><style face="normal" font="default" size="100%">Boesjes, C. M.</style></author><author><style face="normal" font="default" size="100%">Thijs, J.</style></author><author><style face="normal" font="default" size="100%">Romeijn, G. L. E.</style></author><author><style face="normal" font="default" size="100%">Loman, L.</style></author><author><style face="normal" font="default" size="100%">Schuttelaar, M. L.</style></author><author><style face="normal" font="default" size="100%">van Wijk, F.</style></author><author><style face="normal" font="default" size="100%">de Graaf, M.</style></author><author><style face="normal" font="default" size="100%">de Bruin-Weller, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Division Laboratories, Pharmacy and Biomedical Genetics, Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Sanquin Diagnostic Services, Sanquin, Amsterdam, The Netherlands.&#xD;Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3398-3407</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Tapering</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Patient-Centered Care</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">daily practice</style></keyword><keyword><style face="normal" font="default" size="100%">dose reduction</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">patient-centered dosing regimen</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35837880</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: At present, no real-world studies are available on different dupilumab dosing regimens in controlled atopic dermatitis (AD). The aim of this study was to clinically evaluate a patient-centered dupilumab dosing regimen in patients with controlled AD and to relate this to serum drug levels and serum biomarkers. METHODS: Ninety adult AD patients from the prospective BioDay registry were included based on their dupilumab administration interval according to a predefined patient-centered dosing regimen. Group A (n = 30) did not fulfill the criteria for interval prolongation and continued using the standard dupilumab dosage (300 mg/2 weeks), group B (n = 30) prolonged dupilumab interval with 50% (300 mg/4 weeks), and group C (n = 30) prolonged dupilumab interval with 66%-75% (300 mg/6-8 weeks). AD severity score, patient-reported outcomes, serum dupilumab levels, and serum biomarkers were analyzed over time. RESULTS: Disease severity scores did not significantly change over time during the tapering period in any of the groups. In groups B and C, the Numeric Rating Scale (NRS)-pruritus temporarily significantly increased after interval prolongation but remained low (median NRS-pruritus&lt;/=4). Median dupilumab levels remained stable in group A (standard dosage), but significantly decreased in groups B and C (24.1 mg/L (IQR = 17.1-45.6); 12.5 mg/L (IQR = 1.7-22.3)) compared with the levels during the standard dosage (88.2 mg/L [IQR = 67.1-123.0, p &lt; .001]). Disease severity biomarker levels (CCL17/CCL18) remained low in all study groups during the whole observation period. CONCLUSIONS: This study showed that dose reduction was successful in a subgroup of patients with controlled AD by using a patient-centered dosing regimen. These patients showed stable low disease activity and low severity biomarkers over time.</style></abstract><notes><style face="normal" font="default" size="100%">Spekhorst, Lotte S&#xD;Bakker, Daphne&#xD;Drylewicz, Julia&#xD;Rispens, Theo&#xD;Loeff, Floris&#xD;Boesjes, Celeste M&#xD;Thijs, Judith&#xD;Romeijn, Geertruida L E&#xD;Loman, Laura&#xD;Schuttelaar, Marie-Louise&#xD;van Wijk, Femke&#xD;de Graaf, Marlies&#xD;de Bruin-Weller, Marjolein S&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3398-3407. doi: 10.1111/all.15439. Epub 2022 Jul 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35837880</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15439</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2229</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2229</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Magerl, M.</style></author><author><style face="normal" font="default" size="100%">Schiffhorst, G.</style></author><author><style face="normal" font="default" size="100%">Fanter, L.</style></author><author><style face="normal" font="default" size="100%">Muller, G.</style></author><author><style face="normal" font="default" size="100%">Hirche, C.</style></author><author><style face="normal" font="default" size="100%">Berkemeier, F.</style></author><author><style face="normal" font="default" size="100%">Aygoren, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;IGES Institute GmbH, Berlin, Germany.&#xD;Takeda Pharma Vertrieb GmbH &amp; Co. KG, Berlin, Germany.&#xD;Universitatsklinikum Frankfurt, Frankfurt, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">215-224</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">C1-esterase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">indirect comparison</style></keyword><keyword><style face="normal" font="default" size="100%">lanadelumab</style></keyword><keyword><style face="normal" font="default" size="100%">laryngeal attacks</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37641968</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hereditary angioedema (HAE) is an autosomal dominant inherited disease in which patients suffer from local attacks primarily affecting skin and gastrointestinal tract, and sometimes even the upper respiratory tract leading to asphyxiation. Since head-to-head trials between authorized treatments are lacking, this study compares efficacy and safety of lanadelumab and intravenous plasma-derived C1-esterase inhibitor (pdC1-INH i.v.) in HAE patients on long-term prophylaxis by means of an indirect treatment comparison. METHODS: Efficacy and safety of lanadelumab against pdC1-INH i.v. were analyzed in a fully prespecified indirect comparison based on individual patient data (n = 231) from the HELP and CHANGE clinical trials. Primary and secondary efficacy endpoints were compared using a generalized linear model for count data. Confounding variables were identified a priori via systematic literature research and validated by clinical experts. Adjustment of confounders was implemented using a conditional regression model. RESULTS: Lanadelumab showed a statistically significant improvement in reduction of HAE attack rates compared to pdC1-INH i.v. across multiple endpoints: Monthly attack rate of patients treated with lanadelumab was less than half compared to pdC1-INH i.v. (Rate ratio: 0.486; 95% CI: 0.253, 0.932). Monthly rate of laryngeal attacks was found to be five times lower for lanadelumab (Rate ratio: 0.2; 95% CI: 0.044, 0.915) and monthly rate of acute treated HAE attacks among lanadelumab patients was about one third of the attack rate of pdC1-INH i.v. patients (Rate ratio: 0.366; 95% CI: 0.185, 0.727). CONCLUSION: This study contributes to current knowledge in the treatment of HAE by indicating a statistically significant reduction of HAE attacks under lanadelumab compared to pdC1-INH i.v.</style></abstract><notes><style face="normal" font="default" size="100%">Magerl, Markus&#xD;Schiffhorst, Guido&#xD;Fanter, Lena&#xD;Muller, Gerrit&#xD;Hirche, Christoph&#xD;Berkemeier, Fabian&#xD;Aygoren, Emel&#xD;eng&#xD;Takeda Pharmaceutical Company/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):215-224. doi: 10.1111/all.15861. Epub 2023 Aug 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37641968</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15861</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3317</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3317</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caimmi, Davide</style></author><author><style face="normal" font="default" size="100%">Abouelfath, Abdelilah</style></author><author><style face="normal" font="default" size="100%">Lassalle, Régis</style></author><author><style face="normal" font="default" size="100%">Lignot-Maleyran, Séverine</style></author><author><style face="normal" font="default" size="100%">Bignon, Emmanuelle</style></author><author><style face="normal" font="default" size="100%">Blin, Patrick</style></author><author><style face="normal" font="default" size="100%">Clark, Evangéline</style></author><author><style face="normal" font="default" size="100%">Cottet, Julien</style></author><author><style face="normal" font="default" size="100%">Carcaillon-Bentata, Laure</style></author><author><style face="normal" font="default" size="100%">Demoly, Pascal</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Patient-Perceived Benefits of Named-Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real-World Cohort Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Named-patient product sublingual immunotherapy (NPP-SLIT) is widely used in France, yet real-world evidence on patient-perceived benefit remains limited. Objective To assess treatment expectations and patient-perceived benefit over 12–15 months among recent NPP-SLIT initiators using the Patient Benefit Index (PBI) and validated patient-reported outcome measures (PROMs). Methods ERAPP is a prospective, multicenter, observational study in children and adults with IgE-mediated respiratory allergy. Initiators (≤ 6 months on NPP-SLIT at baseline) completed digital PROMs at baseline, Month 6, and Month 12–15. The primary endpoint was the proportion with PBI ≥ 1 at Months 12–15. Secondary endpoints were changes in PROMs; exploratory analyses examined higher PBI thresholds and item-level fulfillment. Results Of 9439 enrolled, 4794 were initiators (950 children; 3844 adolescents/adults). At Month 12–15, PBI ≥ 1 was achieved by 83.8% of children and 84.0% of adolescents/adults. Symptom burden (T5SS) and rhinitis severity (ARIA) improved beyond published MIDs. Asthma control (ACT) improved, whereas changes in rhinitis control (ARCT, ≥ 12 years) and daytime sleepiness (ESS, adults) were below their respective MIDs. Treatment satisfaction (ESPIA-Q11) increased, while adherence (GIRERD) decreased from baseline to follow-up. Nearly half reached PBI ≥ 2 and about one-fifth PBI ≥ 3. Item-level analyses showed highest fulfillment for nasal obstruction relief, improved sleep, and overall symptom relief; fatigue, mood, and social aspects were less frequently fulfilled. Children generally reported slightly higher fulfillment than adolescents/adults. Conclusion NPP-SLIT provides sustained, clinically meaningful benefit from the patient&apos;s perspective in both age groups. ERAPP supports the PBI as a complementary endpoint that links patient expectations to outcomes and informs patient-centered allergy care.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70270</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70270</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>613</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">613</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Scichilone, N.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Center for Health Technology and Services Research, University of Porto, Porto, Portugal.&#xD;Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitario de Coimbra, and Institute of Immunology, Faculty of Medicine, University of Coimbra, and ICBR - Coimbra Institute for Clinical and Biomedical Research, (iCBR), Facutly of Medicine, University of Combra, Coimbra, Portugal.&#xD;PROMISE Department, University of Palermo, Palermo, Italy.&#xD;Unit of Geriatric Immunoallergology, University of Bari, Bari, Italy.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patient-reported outcome measures (PROMs) using the MASK-air((R)) app in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1600-1602</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mobile Applications</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Reported Outcome Measures</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35137430</style></accession-num><notes><style face="normal" font="default" size="100%">Sousa-Pinto, Bernardo&#xD;Fonseca, Joao A&#xD;Gemicioglu, Bilun&#xD;Regateiro, Frederico S&#xD;Scichilone, Nicola&#xD;Ventura, Maria Teresa&#xD;Bousquet, Jean&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1600-1602. doi: 10.1111/all.15248. Epub 2022 Feb 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35137430</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15248</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>256</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">256</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bahbah, F.</style></author><author><style face="normal" font="default" size="100%">Gentil, C.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Stallergenes Greer Ltd, Antony, France.&#xD;Axiodis, Toulouse, France.&#xD;Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE - Health Research Network, University of Porto, Porto, Portugal.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.&#xD;VIM Suresnes, UMR_0892, Pole des Maladies des Voies Respiratoires, Hopital Foch, Universite Paris-Saclay, Suresnes, France.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Berlin, Germany.&#xD;Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany.&#xD;University Hospital Montpellier, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patient-reported outcome measures in birch pollen allergic patients treated with sublingual immunotherapy reflect real life</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1113-1116</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/10/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Betula</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/diagnosis/therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Reported Outcome Measures</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36226843</style></accession-num><notes><style face="normal" font="default" size="100%">Bahbah, Farah&#xD;Gentil, Catherine&#xD;Sousa-Pinto, Bernardo&#xD;Canonica, G Walter&#xD;Devillier, Philippe&#xD;Pfaar, Oliver&#xD;Bousquet, Jean&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):1113-1116. doi: 10.1111/all.15550. Epub 2022 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36226843</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15550</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2863</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2863</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Riedl, M. A.</style></author><author><style face="normal" font="default" size="100%">Yarlas, A.</style></author><author><style face="normal" font="default" size="100%">Bordone, L.</style></author><author><style face="normal" font="default" size="100%">Treadwell, S.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Newman, K. B.</style></author><author><style face="normal" font="default" size="100%">Cohn, D. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, University of California San Diego School of Medicine, La Jolla, California, USA.&#xD;Ionis, Carlsbad, California, USA.&#xD;Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patient-Reported Outcomes in the Phase III OASIS-HAE Study of Donidalorsen for Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2361-2368</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/04/19 22:11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient Reported Outcome Measures</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Oligonucleotides</style></keyword><keyword><style face="normal" font="default" size="100%">disease control</style></keyword><keyword><style face="normal" font="default" size="100%">donidalorsen</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">patient-reported outcomes</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">Behring, Ionis, Kalvista, Pharvaris, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">consulted for Astria, BioCryst,</style></keyword><keyword><style face="normal" font="default" size="100%">BioMarin Pharmaceutical, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia,</style></keyword><keyword><style face="normal" font="default" size="100%">Ionis, KalVista, Pfizer, Pharming, Pharvaris, Sanofi-Regeneron, and Takeda</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">provided speaker presentations for CSL Behring, Grifols, Pharming, and Takeda.</style></keyword><keyword><style face="normal" font="default" size="100%">A.Y., L.B., S.T., S.W., and K.B.N. are employees of Ionis and hold shares and/or</style></keyword><keyword><style face="normal" font="default" size="100%">options in Ionis. D.M.C. has received speaker or consultancy fees from Astria,</style></keyword><keyword><style face="normal" font="default" size="100%">BioCryst, CSL Behring, Intellia, Ionis, KalVista, Pharvaris, and Takeda.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40251904</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, frequently severe swelling that negatively impacts patients&apos; quality of life (QoL). In the phase III OASIS-HAE study (NCT05139810), donidalorsen reduced HAE attack rate, increased disease control, and improved QoL. Here, we report further analysis of donidalorsen&apos;s impact on QoL and other patient-reported outcomes (PROs). METHODS: This double-blind, placebo-controlled study randomized patients with HAE to donidalorsen 80 mg or placebo once every 4 (Q4W) or 8 weeks (Q8W) over 24 weeks. PROs included Angioedema (AE)-QoL Questionnaire, Angioedema Control Test (AECT), Patient Global Impression of Severity (PGIS), and Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions (WPAI+CIQ). RESULTS: Ninety patients received donidalorsen Q4W (n = 45), donidalorsen Q8W (n = 23), or placebo (n = 22). A larger percentage of the donidalorsen Q4W group (88%) achieved clinically meaningful improvement (&gt;/= 6-point reduction) in AE-QoL total score vs. placebo (45%). Both donidalorsen groups reported larger least-squares mean (LSM) changes from baseline to week 24 vs. placebo in AE-QoL functioning (difference: Q4W, -24.5; Q8W, -16.1), fears/shame (Q4W, -23.9; Q8W, -20.1), and nutrition (Q4W, -15.7; Q8W, -10.7) domains. Donidalorsen improved AECT scores vs. placebo (difference: Q4W, 6.0; Q8W, 4.1). A greater proportion of the donidalorsen Q4W group reported decreased disease severity vs. the placebo group (PGIS; 82% vs. 44%). Donidalorsen Q4W showed benefits vs. placebo in the presenteeism, overall work/school impairment, and activity impairment domains of the WPAI+CIQ. CONCLUSIONS: Donidalorsen significantly improved QoL and other PROs vs. placebo in patients with HAE.</style></abstract><notes><style face="normal" font="default" size="100%">Riedl, Marc A&#xD;Yarlas, Aaron&#xD;Bordone, Laura&#xD;Treadwell, Sabrina&#xD;Wang, Sophie&#xD;Newman, Kenneth B&#xD;Cohn, Danny M&#xD;eng&#xD;Ionis Pharmaceuticals/&#xD;Clinical Trial, Phase III&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2361-2368. doi: 10.1111/all.16563. Epub 2025 Apr 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40251904</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368753</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16563</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2931</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2931</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vogi, V.</style></author><author><style face="normal" font="default" size="100%">Jukic, E.</style></author><author><style face="normal" font="default" size="100%">Gruber, R.</style></author><author><style face="normal" font="default" size="100%">Fiona, A.</style></author><author><style face="normal" font="default" size="100%">Minzaghi, D.</style></author><author><style face="normal" font="default" size="100%">Zschocke, J.</style></author><author><style face="normal" font="default" size="100%">Dubrac, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.&#xD;Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patients With Atopic Dermatitis Show Increased Clonal Hematopoiesis and Risk of Hematological Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2646-2649</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/05/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">cancer</style></keyword><keyword><style face="normal" font="default" size="100%">clonal hematopoiesis of indeterminate potential</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40346994</style></accession-num><notes><style face="normal" font="default" size="100%">Vogi, Verena&#xD;Jukic, Emina&#xD;Gruber, Robert&#xD;Fiona, Andre&#xD;Minzaghi, Deborah&#xD;Zschocke, Johannes&#xD;Dubrac, Sandrine&#xD;eng&#xD;Austrian Science Fund/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2646-2649. doi: 10.1111/all.16587. Epub 2025 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40346994</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444847</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16587</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2180</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2180</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thomson, P.</style></author><author><style face="normal" font="default" size="100%">Fragkas, N.</style></author><author><style face="normal" font="default" size="100%">Kafu, L. M.</style></author><author><style face="normal" font="default" size="100%">Aithal, G. P.</style></author><author><style face="normal" font="default" size="100%">Lucena, M. I.</style></author><author><style face="normal" font="default" size="100%">Terracciano, L.</style></author><author><style face="normal" font="default" size="100%">Meng, X.</style></author><author><style face="normal" font="default" size="100%">Pirmohamed, M.</style></author><author><style face="normal" font="default" size="100%">Brees, D.</style></author><author><style face="normal" font="default" size="100%">Kullak-Ublick, G. A.</style></author><author><style face="normal" font="default" size="100%">Odermatt, A.</style></author><author><style face="normal" font="default" size="100%">Hammond, T.</style></author><author><style face="normal" font="default" size="100%">Kammuller, M.</style></author><author><style face="normal" font="default" size="100%">Naisbitt, D. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular&amp; Clinical Pharmacology, University of Liverpool, Liverpool, UK.&#xD;Novartis Institutes for BioMedical Research, Basel, Switzerland.&#xD;NIHR Nottingham Biomedical Research Centre and Nottingham Digestive Diseases Centre, Translational Medical Sciences, West Block, Queen&apos;s Medical Centre, University of Nottingham, Nottingham, UK.&#xD;Unidad de Gestion Clinica de Aparato Digestivo y Servicio de Farmacologia Clinica, Instituto de Investigacion Biomedica de Malaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Malaga, CIBERehd, Malaga, Spain.&#xD;Institute of Pathology, University Hospital Basel, Basel, Switzerland.&#xD;University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Novartis Global Drug Development, Basel, Switzerland.&#xD;Division of Molecular &amp; Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.&#xD;Oncology Safety, Clinical Pharmacology and Safety Sciences R&amp;D, Cambridge, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patients with naproxen-induced liver injury display T-cell memory responses toward an oxidative (S)-O-desmethyl naproxen metabolite but not the acyl glucuronide</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">200-214</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/07/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Naproxen/adverse effects/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Glucuronides/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Chemical and Drug Induced Liver Injury, Chronic</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal</style></keyword><keyword><style face="normal" font="default" size="100%">Ibuprofen</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Activation</style></keyword><keyword><style face="normal" font="default" size="100%">T lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">drug-induced liver injury</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune system</style></keyword><keyword><style face="normal" font="default" size="100%">is an employee and shareholder of AstraZeneca. MP has received partnership</style></keyword><keyword><style face="normal" font="default" size="100%">funding for the following: MRC Clinical Pharmacology Training Scheme (co-funded</style></keyword><keyword><style face="normal" font="default" size="100%">by MRC and Roche, UCB, Eli Lilly and Novartis). MP has developed an HLA</style></keyword><keyword><style face="normal" font="default" size="100%">genotyping panel with MC Diagnostics, but does not benefit financially from this.</style></keyword><keyword><style face="normal" font="default" size="100%">Both MP and DN are part of the IMI Consortium ARDAT (www.ardat.org).</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37515456</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (IBU) and naproxen (NAP) is associated with idiosyncratic drug-induced liver injury (DILI). Carboxylate bioactivation into reactive metabolites (e.g., acyl glucuronides, AG) and resulting T-cell activation is hypothesized as causal for this adverse event. However, conclusive evidence supporting this is lacking. METHODS: In this work, we identify CD4(+) and CD8(+) T-cell hepatic infiltration in a biopsy from an IBU DILI patient. Lymphocyte transformation test and IFN-gamma ELIspot, conducted on peripheral blood mononuclear cells (PBMCs) of patients with NAP-DILI, were used to explore drug-specific T-cell activation. T-cell clones (TCC) were generated and tested for drug specificity, phenotype/function, and pathways of T-cell activation. Cells were exposed to NAP, its oxidative metabolite 6-O-desmethyl NAP (DM-NAP), its AG or synthesized NAP-AG human-serum albumin adducts (NAP-AG adduct). RESULTS: CD4(+) and CD8(+) T-cells from patients expressing a range of different Vbeta receptors were stimulated to proliferate and secrete IFN-gamma and IL-22 when exposed to DM-NAP, but not NAP, NAP-AG or the NAP-AG adduct. Activation of the CD4(+) TCC was HLA-DQ-restricted and dependent on antigen presenting cells (APC); most TCC were activated with DM-NAP-pulsed APC, while fixation of APC blocked the T-cell response. Cross-reactivity was not observed with structurally-related drugs. CONCLUSION: Our results confirm hepatic T-cell infiltrations in NSAID-induced DILI, and show a T-cell memory response toward DM-NAP indicating an immune-mediated basis for the adverse event. Whilst bioactivation at the carboxylate group is widely hypothesized to be pathogenic for NSAID associated DILI, we found no evidence of this with NAP.</style></abstract><notes><style face="normal" font="default" size="100%">Thomson, Paul&#xD;Fragkas, Nik&#xD;Kafu, Laila M&#xD;Aithal, Guruprasad P&#xD;Lucena, M Isabel&#xD;Terracciano, Luigi&#xD;Meng, Xiaoli&#xD;Pirmohamed, Munir&#xD;Brees, Dominique&#xD;Kullak-Ublick, Gerd A&#xD;Odermatt, Alex&#xD;Hammond, Thomas&#xD;Kammuller, Michael&#xD;Naisbitt, Dean J&#xD;eng&#xD;G0700654/MRC_/Medical Research Council/United Kingdom&#xD;MR/R009635/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):200-214. doi: 10.1111/all.15830. Epub 2023 Jul 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37515456</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10952231</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15830</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>832</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">832</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Impellizzieri, D.</style></author><author><style face="normal" font="default" size="100%">Egholm, C.</style></author><author><style face="normal" font="default" size="100%">Valaperti, A.</style></author><author><style face="normal" font="default" size="100%">Distler, O.</style></author><author><style face="normal" font="default" size="100%">Boyman, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, University Hospital Zurich, Zurich, Switzerland.&#xD;Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patients with systemic sclerosis show phenotypic and functional defects in neutrophils</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1274-1284</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/09/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Extracellular Traps</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">Phagocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Scleroderma, Systemic/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">IL-4 receptor</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophil</style></keyword><keyword><style face="normal" font="default" size="100%">systemic sclerosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34467524</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Systemic sclerosis (SSc) is a multiorgan autoimmune disease characterized by inflammation, vascular modification, and progressive fibrosis of the skin and several visceral organs. Innate and adaptive immune cells, including myeloid, B and T cells, are believed to be central to the pathogenesis of SSc. However, the role and functional state of neutrophil granulocytes (neutrophils) are ill-defined in SSc. METHODS: We performed a prospective study of neutrophils freshly isolated from SSc patients and healthy donors (HD) by measuring in these neutrophils (i) functional cell surface markers, including CD16, CD62L, CD66b, CD66c, CXCR1, CXCR2, and CXCR4; (ii) cytokine-activated intracellular signal transducer and activator of transcription (STAT) pathways, such as phosphorylated STAT3 (pSTAT3), pSTAT5, and pSTAT6; (iii) production of neutrophil extracellular traps (NET) and intracellular myeloperoxidase (MPO); and (iv) phagocytosis of bacteria by the neutrophils. RESULTS: Neutrophils of SSc patients expressed lower CD16 and CD62L and higher pSTAT3 and pSTAT6 compared to HD. Moreover, neutrophils of SSc patients lacked CXCR1 and CXCR2, the receptors responding to the potent neutrophil chemoattractant CXCL8. Neutrophils of SSc patients were also deficient in MPO levels, NET formation, and phagocytosis of bacteria. CONCLUSIONS: Neutrophils of patients with SSc display several functional defects affecting cell migration, NET formation, and phagocytosis of bacteria.</style></abstract><notes><style face="normal" font="default" size="100%">Impellizzieri, Daniela&#xD;Egholm, Cecilie&#xD;Valaperti, Alan&#xD;Distler, Oliver&#xD;Boyman, Onur&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1274-1284. doi: 10.1111/all.15073. Epub 2021 Sep 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34467524</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9293168</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15073</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2432</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2432</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brozek, J.</style></author><author><style face="normal" font="default" size="100%">Borowiack, E.</style></author><author><style face="normal" font="default" size="100%">Sadowska, E.</style></author><author><style face="normal" font="default" size="100%">Nowak, A.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Vieira, R. J.</style></author><author><style face="normal" font="default" size="100%">Bognanni, A.</style></author><author><style face="normal" font="default" size="100%">Yepes Nunez, J. J.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Schunemann, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.&#xD;Michael G. DeGroote Cochrane Canada &amp; McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Medicine, McMaster University, Hamilton, Canada.&#xD;Evidence Prime, Hamilton, Ontario, Canada.&#xD;Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Centre for Health Technology and Services Research, Health Research Network (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Department of Medicine, Evidence in Allergy Group, McMaster University, Hamilton, Canada.&#xD;School of Medicine, Universidad de los Andes, Bogota, Colombia.&#xD;Fundacion Santa Fe de Bogota Hospital University, Bogota, Colombia.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Frankfurt/Main, Germany.&#xD;Clinical Epidemiology and Research Center (CERC), Humanitas University and Humanitas Research Hospital, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patients&apos; values and preferences for health states in allergic rhinitis-An artificial intelligence supported systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1812-1830</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/03/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Artificial Intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">Health Status</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient Preference</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">health states</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">utility</style></keyword><keyword><style face="normal" font="default" size="100%">values and preferences</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38551028</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic rhinitis (AR) impacts patients&apos; physical and emotional well-being. Assessing patients&apos; values and preferences (V&amp;P) related to AR is an essential part of patient-centered care and of the guideline development process. We aimed to systematically summarize the information about patients&apos; V&amp;P on AR and its symptoms and impact on daily life. METHODS: We conducted systematic review in a MEDLINE, Embase, PsychInfo, and CINAHL databases. We included studies which quantitatively assessed patients&apos; V&amp;P for specific outcomes in AR by assessing utilities, applying discrete choice approaches, or rating and ranking outcomes. We grouped outcomes as AR symptoms, functional status, and care-related patient experience. Study selection and data extraction were supported by the Laser AI tool. We rated the certainty of evidence (CoE) using the GRADE approach. RESULTS: Thirty-six studies (41 records) were included: nine utility studies, seven direct-choice studies and 21 studies of rating or ranking outcomes. Utilities were lower with increased AR severity and with the concomitant presence of asthma, but not with whether AR was seasonal or perennial (CoE = low-high). Patients rated AR symptom-related outcomes as more important than those related to care-related patient experience and functional status (CoE = very low-moderate). Nasal symptoms (mainly nasal congestion) followed by breathing disorders, general and ocular symptoms were rated as the symptoms with the highest impact. CONCLUSIONS: This systematic review provides a comprehensive overview of V&amp;P of patients with AR. Patients generally considered nasal symptoms as the most important. Future studies with standardized methods are needed to provide more information on V&amp;P in AR.</style></abstract><notes><style face="normal" font="default" size="100%">Brozek, Jan&#xD;Borowiack, Ewa&#xD;Sadowska, Ewelina&#xD;Nowak, Artur&#xD;Sousa-Pinto, Bernardo&#xD;Vieira, Rafael Jose&#xD;Bognanni, Antonio&#xD;Yepes Nunez, Juan Jose&#xD;Zhang, Yuan&#xD;Zuberbier, Torsten&#xD;Bousquet, Jean&#xD;Schunemann, Holger J&#xD;eng&#xD;2022.12787.BD/European Social Fund/&#xD;Programa Por_Norte/&#xD;Fundacao para a Ciencia e a Tecnologia (FCT-MCTES, Portugal)/&#xD;Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1812-1830. doi: 10.1111/all.16100. Epub 2024 Mar 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38551028</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16100</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2486</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2486</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Porras-Gutierrez-de-Velasco, R.</style></author><author><style face="normal" font="default" size="100%">Maruthukunnel-Mani, B.</style></author><author><style face="normal" font="default" size="100%">Vizuet-de-Rueda, J. C.</style></author><author><style face="normal" font="default" size="100%">Montero-Vargas, J. M.</style></author><author><style face="normal" font="default" size="100%">Teran, L. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunogenetics and Allergy, National Institute of Respiratory Diseases Ismael Cosio Villegas, Mexico City, Mexico.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patterns of allergen recognition in Ligustrum polysensitized patients: An immunoproteomics approach</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2000-2005</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/04/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Ligustrum</style></keyword><keyword><style face="normal" font="default" size="100%">Food Hypersensitivity/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38573058</style></accession-num><notes><style face="normal" font="default" size="100%">Porras-Gutierrez-de-Velasco, Raul&#xD;Maruthukunnel-Mani, Blessy&#xD;Vizuet-de-Rueda, Juan Carlos&#xD;Montero-Vargas, Josaphat Miguel&#xD;Teran, Luis M&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):2000-2005. doi: 10.1111/all.16110. Epub 2024 Apr 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38573058</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16110</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2877</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2877</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cucco, A.</style></author><author><style face="normal" font="default" size="100%">Simpson, A.</style></author><author><style face="normal" font="default" size="100%">Haider, S.</style></author><author><style face="normal" font="default" size="100%">Murray, C.</style></author><author><style face="normal" font="default" size="100%">Turner, S.</style></author><author><style face="normal" font="default" size="100%">Cullinan, P.</style></author><author><style face="normal" font="default" size="100%">Filippi, S.</style></author><author><style face="normal" font="default" size="100%">Fontanella, S.</style></author><author><style face="normal" font="default" size="100%">Custovic, A.</style></author><author><style face="normal" font="default" size="100%">Stelar Unicorn Investigators</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Socio-Economic, Managerial, and Statistical Studies, G. d&apos;Annunzio University Chieti-Pescara, Chieti, Italy.&#xD;Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.&#xD;Royal Aberdeen Children&apos;s Hospital, NHS Grampian, Aberdeen, UK.&#xD;Department of Mathematics, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patterns of Respiratory Symptoms and Asthma Diagnosis in School-Age Children: Three Birth Cohorts</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1923-1934</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Sounds</style></keyword><keyword><style face="normal" font="default" size="100%">Cluster Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Birth Cohort</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">RSV bronchiolitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">birth cohorts</style></keyword><keyword><style face="normal" font="default" size="100%">childhood</style></keyword><keyword><style face="normal" font="default" size="100%">clustering</style></keyword><keyword><style face="normal" font="default" size="100%">in the Imperial College repository, Spiral, under a CC BY-NC licence after a</style></keyword><keyword><style face="normal" font="default" size="100%">minimum 2-year embargo period (extendable). Dr. Custovic reports personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Sanofi and personal fees from Reacta Healthcare outside the submitted work.</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Simpson reports lecture fees from Chiesi. Dr. Murray reports personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Novartis, grants and personal fees from GSK, personal fees from Boerhinger</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim. Other authors have no competing interests to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40501205</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Many studies used information on wheeze presence/absence to determine asthma-related phenotypes. We investigated whether clinically intuitive asthma subtypes can be identified by applying data-driven semi-supervised techniques to information on frequency and triggers of different respiratory symptoms. METHODS: Partitioning Around Medoids clustering was applied to data on multiple symptoms and their triggers in school-age children from three birth cohorts: MAAS (n = 947, age 8 years), SEATON (n = 763, age 10) and ASHFORD (n = 584, age 8). &apos;Guided&apos; clustering, incorporating asthma diagnosis, was used to select the optimal number of clusters. RESULTS: Five-cluster solution was optimal. Based on their clinical characteristics, including frequency of asthma diagnosis, we interpreted one cluster as &apos;Healthy&apos;. Two clusters were characterised by high asthma prevalence (95.89% and 78.13%). We assigned children with asthma in these two clusters as &apos;persistent, multiple-trigger, more severe&apos; (PMTS) and &apos;persistent, triggered by infection, milder&apos; (PIM). Children with asthma in the remaining two clusters were assigned as &apos;mild-remitting wheeze&apos; (MRW) and &apos;post-bronchiolitis resolving asthma&apos; (PBRA). PBRA was associated with RSV bronchiolitis in infancy. In most children with asthma in this cluster wheezing resolved by age 5-6, and predominant symptoms were shortness of breath and chest tightness. Children in PBRA had the highest hospitalisation rates and wheeze exacerbations in infancy. From age 8 years (cluster derivation) to early adulthood (18-20 years), lung function was significantly lower, and FeNO and airway hyperreactivity significantly higher in PMTS compared to all other clusters. CONCLUSIONS: Patterns of coexisting symptoms identified by semi-supervised data-driven methods may reflect pathophysiological mechanisms of distinct subtypes of childhood wheezing disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Cucco, Alex&#xD;Simpson, Angela&#xD;Haider, Sadia&#xD;Murray, Clare&#xD;Turner, Stephen&#xD;Cullinan, Paul&#xD;Filippi, Sarah&#xD;Fontanella, Sara&#xD;Custovic, Adnan&#xD;eng&#xD;Meaningful Dragon PhD scholarship/&#xD;301/Asthma UK/&#xD;362/Asthma UK/&#xD;01/012/Asthma UK/&#xD;04/014/Asthma UK/&#xD;BMA James Trust/&#xD;JP Moulton Charitable Foundation/&#xD;North West Lung Centre Charity/&#xD;MR/S025340/1/MRC_/Medical Research Council/United Kingdom&#xD;G0601361/MRC_/Medical Research Council/United Kingdom&#xD;MR/K002449/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/L012693/1/MRC_/Medical Research Council/United Kingdom&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1923-1934. doi: 10.1111/all.16617. Epub 2025 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40501205</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261878</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16617</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3121</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3121</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Singh, N.</style></author><author><style face="normal" font="default" size="100%">Kesselring, J.</style></author><author><style face="normal" font="default" size="100%">Humphrey, J.</style></author><author><style face="normal" font="default" size="100%">Herlihy, L.</style></author><author><style face="normal" font="default" size="100%">Burks, A. W.</style></author><author><style face="normal" font="default" size="100%">Smeekens, J.</style></author><author><style face="normal" font="default" size="100%">Keet, C.</style></author><author><style face="normal" font="default" size="100%">Bird, J. A.</style></author><author><style face="normal" font="default" size="100%">Kim, E. H.</style></author><author><style face="normal" font="default" size="100%">Kulis, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.&#xD;Department of Nutrition, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.&#xD;Curriculum in Toxicology and Environmental Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.&#xD;Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Peanut Component-Specific IgE and IgG4 Are Modulated by Sublingual Immunotherapy and Are Associated With Remission in 1-4-Year-Old Children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Slit</style></keyword><keyword><style face="normal" font="default" size="100%">desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">remission</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41117056</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The safety and efficacy of 36-month peanut sublingual immunotherapy (SLIT) was recently demonstrated in peanut-allergic children (1-4 years old), with high remission rates three months post-treatment. METHODS: We performed a post hoc analysis of longitudinal changes in peanut component-specific IgE (PnC-sIgE) and IgG4 (PnC-sIgG4) levels in 1-4 year olds who underwent peanut SLIT to uncover immune mechanisms and potential biomarkers of remission. Plasma from 30 participants was analyzed at 0, 12, 24, 36, and 39 months using ImmunoCAP250 for PnC-sIgE and PnC-sIgG4 to Ara h 1, Ara h 2, Ara h 3, and Ara h 6 (Ah1-6). Mixed-effects models assessed longitudinal antibody changes, Wilcoxon tests compared antibody levels by remission status, and correlations evaluated age and baseline antibody levels. RESULTS: Peanut SLIT reduced IgE levels while increasing IgG4 levels specific to Pn and Ah1-6 over 36 months. No changes in sIgE were observed in the placebo group, whereas increases in Pn-, Ah1-, and Ah3-sIgG4 were noted. Participants achieving remission had lower IgE and IgG4 to Pn and Ah1-6 at baseline and throughout 36 months of SLIT. Ah2-sIgG4 showed no overlap between outcome groups at baseline, suggesting potential as a biomarker. Children under 3 had lower baseline Ah6-sIgE and Ah1-, Ah2-, and Ah6-sIgG4 levels and higher remission rates than those 3 and older, linking age, remission, and antibody profiles. CONCLUSION: Component-resolved analysis offers key insights into the immunological mechanisms in young children undergoing peanut SLIT, revealing lower baseline levels of Ah2-sIgG4 as a potential biomarker of remission.</style></abstract><notes><style face="normal" font="default" size="100%">Singh, Neel&#xD;Kesselring, Janelle&#xD;Humphrey, Jess&#xD;Herlihy, Lauren&#xD;Burks, A Wesley&#xD;Smeekens, Johanna&#xD;Keet, Corinne&#xD;Bird, J Andrew&#xD;Kim, Edwin H&#xD;Kulis, Michael&#xD;eng&#xD;NH/NIH HHS/&#xD;Food Allergy Research and Education/&#xD;AT/NCCIH NIH HHS/&#xD;University of North Carolina at Chapel Hill/&#xD;Meade Family Pediatric Allergy Research Fund/&#xD;TR/NCATS NIH HHS/&#xD;Denmark&#xD;Allergy. 2025 Oct 21. doi: 10.1111/all.70111.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41117056</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70111</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1250</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1250</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maris, I.</style></author><author><style face="normal" font="default" size="100%">Dolle-Bierke, S.</style></author><author><style face="normal" font="default" size="100%">Renaudin, J. M.</style></author><author><style face="normal" font="default" size="100%">Lange, L.</style></author><author><style face="normal" font="default" size="100%">Koehli, A.</style></author><author><style face="normal" font="default" size="100%">Spindler, T.</style></author><author><style face="normal" font="default" size="100%">Hourihane, J.</style></author><author><style face="normal" font="default" size="100%">Scherer, K.</style></author><author><style face="normal" font="default" size="100%">Nemat, K.</style></author><author><style face="normal" font="default" size="100%">Kemen, C.</style></author><author><style face="normal" font="default" size="100%">Neustadter, I.</style></author><author><style face="normal" font="default" size="100%">Vogelberg, C.</style></author><author><style face="normal" font="default" size="100%">Reese, T.</style></author><author><style face="normal" font="default" size="100%">Yildiz, I.</style></author><author><style face="normal" font="default" size="100%">Szepfalusi, Z.</style></author><author><style face="normal" font="default" size="100%">Ott, H.</style></author><author><style face="normal" font="default" size="100%">Straube, H.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Hammerling, S.</style></author><author><style face="normal" font="default" size="100%">Staden, U.</style></author><author><style face="normal" font="default" size="100%">Polz, M.</style></author><author><style face="normal" font="default" size="100%">Mustakov, T.</style></author><author><style face="normal" font="default" size="100%">Cichocka-Jarosz, E.</style></author><author><style face="normal" font="default" size="100%">Cocco, R.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A. G.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Network for Online Registration of, Anaphylaxis</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Bon Secours Hospital Cork/Paediatrics and Child Health, University College Cork, Cork, Ireland.&#xD;Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergology, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;Allergy Vigilance Network, Vandoeuvre les Nancy, France.&#xD;Department of Paediatrics, St. Marien-Hospital, Bonn, Germany.&#xD;Division of Allergology, University Children&apos;s Hospital Zurich, Zurich, Switzerland.&#xD;Department of Paediatrics, Medical Campus Hochgebirgsklinik Davos, Davos, Switzerland.&#xD;Paediatrics and Child Health, Royal College of Surgeons in Ireland, Dublin, Ireland.&#xD;Children&apos;s Health Ireland, Dublin, Ireland.&#xD;Medical Faculty, University of Basel, Basel, Switzerland.&#xD;Practice for paediatric pneumology and allergology, Kinderzentrum Dresden-Friedrichstadt, Dresden, Germany.&#xD;Department of Paediatrics, Children&apos;s Hospital WILHELMSTIFT, Hamburg, Germany.&#xD;Department of Paediatrics, Hallerwiese Cnopfsche Kinderklinik, Nuremberg, Germany.&#xD;Department of Paediatrics, Universitatsklinikum Carl Gustav Carus, Technical University, Dresden, Germany.&#xD;Department of Paediatrics, Mathias-Spital Rheine, Rheine, Germany.&#xD;Department of Paediatrics, Friedrich-Ebert-Krankenhaus, Neumuenster, Germany.&#xD;Division of Paediatric Pulmonology, Allergology and Endocrinology, Department of Paediatrics and Adolescent Medicine, Competence Center Paediatrics, Medical University of Vienna, Vienna, Austria.&#xD;Division of Paediatric Dermatology and Allergology, Epidermolysis bullosa-Centre Hannover, Children&apos;s Hospital AUF DER BULT, Hanover, Germany.&#xD;Division of Allergology, Darmstadter Kinderkliniken Prinzessin Margaret, Darmstadt, Germany.&#xD;Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Division of Infection, Immunity&amp; Respiratory Medicine, University of Manchester, Manchester, UK.&#xD;Division of Paediatric Pulmonology and Allergology, University Children;s Hospital Heidelberg, Heidelberg, Germany.&#xD;Paediatric Pneumology &amp; Allergology, Medical practice Klettke/Staden, Berlin, Germany.&#xD;Department of Paediatrics, GPR Klinikum, Russelsheim, Germany.&#xD;Chair of Allergy, University Hospital Alexandrovska, Sofia, Bulgaria.&#xD;Department of Paediatrics, Jagiellonian University Medical College, Krakow, Poland.&#xD;Division of Allergy, Clinical Immunology and Rheumatology, Department of Paediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;Paediatric Hospital Bambino Gesu IRCCS, Rome, Holy See.&#xD;Allergy Department, Hospital Clinico San Carlos, Universidad Complutense, IdISSC, ARADyAL, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Peanut-induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1517-1527</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">paediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33274436</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Peanut allergy has a rising prevalence in high-income countries, affecting 0.5%-1.4% of children. This study aimed to better understand peanut anaphylaxis in comparison to anaphylaxis to other food triggers in European children and adolescents. METHODS: Data was sourced from the European Anaphylaxis Registry via an online questionnaire, after in-depth review of food-induced anaphylaxis cases in a tertiary paediatric allergy centre. RESULTS: 3514 cases of food anaphylaxis were reported between July 2007 - March 2018, 56% in patients younger than 18 years. Peanut anaphylaxis was recorded in 459 children and adolescents (85% of all peanut anaphylaxis cases). Previous reactions (42% vs. 38%; p = .001), asthma comorbidity (47% vs. 35%; p &lt; .001), relevant cofactors (29% vs. 22%; p = .004) and biphasic reactions (10% vs. 4%; p = .001) were more commonly reported in peanut anaphylaxis. Most cases were labelled as severe anaphylaxis (Ring&amp;Messmer grade III 65% vs. 56% and grade IV 1.1% vs. 0.9%; p = .001). Self-administration of intramuscular adrenaline was low (17% vs. 15%), professional adrenaline administration was higher in non-peanut food anaphylaxis (34% vs. 26%; p = .003). Hospitalization was higher for peanut anaphylaxis (67% vs. 54%; p = .004). CONCLUSIONS: The European Anaphylaxis Registry data confirmed peanut as one of the major causes of severe, potentially life-threatening allergic reactions in European children, with some characteristic features e.g., presence of asthma comorbidity and increased rate of biphasic reactions. Usage of intramuscular adrenaline as first-line treatment is low and needs to be improved. The Registry, designed as the largest database on anaphylaxis, allows continuous assessment of this condition.</style></abstract><notes><style face="normal" font="default" size="100%">Maris, Ioana&#xD;Dolle-Bierke, Sabine&#xD;Renaudin, Jean-Marie&#xD;Lange, Lars&#xD;Koehli, Alice&#xD;Spindler, Thomas&#xD;Hourihane, Jonathan&#xD;Scherer, Kathrin&#xD;Nemat, Katja&#xD;Kemen, C&#xD;Neustadter, Irena&#xD;Vogelberg, Christian&#xD;Reese, Thomas&#xD;Yildiz, Ismail&#xD;Szepfalusi, Zsolt&#xD;Ott, Hagen&#xD;Straube, Helen&#xD;Papadopoulos, Nikolaos G&#xD;Hammerling, Susanne&#xD;Staden, Ute&#xD;Polz, Michael&#xD;Mustakov, Tihomir&#xD;Cichocka-Jarosz, Ewa&#xD;Cocco, Renata&#xD;Fiocchi, Alessandro Giovanni&#xD;Fernandez-Rivas, Montserrat&#xD;Worm, Margitta&#xD;(NORA)&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1517-1527. doi: 10.1111/all.14683. Epub 2021 Jan 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33274436</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14683</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>805</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">805</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khaleva, E.</style></author><author><style face="normal" font="default" size="100%">Knibb, R.</style></author><author><style face="normal" font="default" size="100%">DunnGalvin, A.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Ortiz, M.</style></author><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author><author><style face="normal" font="default" size="100%">Alviani, C.</style></author><author><style face="normal" font="default" size="100%">Garriga-Baraut, T.</style></author><author><style face="normal" font="default" size="100%">Gowland, M. H.</style></author><author><style face="normal" font="default" size="100%">Gore, C.</style></author><author><style face="normal" font="default" size="100%">Angier, E.</style></author><author><style face="normal" font="default" size="100%">Blumchen, K.</style></author><author><style face="normal" font="default" size="100%">Duca, B.</style></author><author><style face="normal" font="default" size="100%">Hox, V.</style></author><author><style face="normal" font="default" size="100%">Jensen, B.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Pite, H.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Garcia, S.</style></author><author><style face="normal" font="default" size="100%">Timmermans, F.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;School of Psychology, College of Health and Life Sciences, Aston University, Birmingham, UK.&#xD;Applied Psychology and Paediatrics and Child Health, University College Cork, Cork, Ireland.&#xD;Paediatrics and Child Infectious Diseases, First Moscow State Medical University, Moscow, Russia.&#xD;Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Section of Paediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.&#xD;Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;Unitat d&apos;Allergologia Pediatrica, Hospital Universitari Vall d&apos;Hebron, Barcelona, Spain.&#xD;Grup d&apos;Investigacio &quot;Creixement i Desenvolupament&quot;, Institut de Recerca de l&apos;Hospital Universitari Vall d&apos;Hebron (VHIR), Barcelona, Spain.&#xD;Allergy Action, St Albans, UK.&#xD;Department of Paediatrics, Imperial College Healthcare NHS Trust, London, UK.&#xD;Primary Care and Population Sciences, University of Southampton, Southampton, UK.&#xD;Department of Paediatric and Adolescent Medicine, Paediatric Pneumology, Allergology and Cystic Fibrosis, University Hospital Frankfurt, Frankfurt am Main, Germany.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Saint-Luc, Brussels, Belgium.&#xD;Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, Odense C, Denmark.&#xD;Allergy Center, CUF Descobertas Hospital and CUF Tejo Hospital, Lisbon, Portugal.&#xD;CEDOC, Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciencias Medicas, Universidade Nova de Lisboa, Lisbon, Portugal.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Women and Children&apos;s Health (Paediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Allergy Department, Hospital Infantil Universitario del Nino Jesus, Madrid, Spain.&#xD;Nederlands Anafylaxis Netwerk - European Anaphylaxis Taskforce, Dordrecht, The Netherlands.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Perceptions of adolescents and young adults with allergy and/or asthma and their parents on EAACI guideline recommendations about transitional care: A European survey</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1094-1104</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/09/27</style></edition><section><style face="normal" font="default" size="100%">1094</style></section><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Parents</style></keyword><keyword><style face="normal" font="default" size="100%">*Transitional Care</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">adolescents</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">survey</style></keyword><keyword><style face="normal" font="default" size="100%">transition</style></keyword><keyword><style face="normal" font="default" size="100%">young adults</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34564855</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The European Academy of Allergy and Clinical Immunology has developed a guideline to provide evidence-based recommendations for healthcare professionals to support the transitional care of adolescents and young adults (AYA) with allergy and/or asthma. The goal of this work was to ensure that the draft recommendations are also important for patients. METHODS: We surveyed patients aged 11-25 years with allergy and/or asthma and their parents across Europe between 17 February and 16 March 2020. The multilingual survey was distributed through national allergy and asthma patient organizations in Europe as well as through social media. RESULTS: A total of 1210 responses from 24 European countries were collected. There were 415 (34.3%) AYA and 795 (65.7%) parents. The majority of AYA (72.3%) and parents (81.9%) were female. Patients had a history of asthma (61.1%), allergic rhinoconjunctivitis (54.1%), food allergy (53.8%), atopic eczema (42.6%) and anaphylaxis (28.8%). All recommendations achieved the median score of either &apos;important&apos; or &apos;very important&apos;. The least supported recommendations were the use of joint clinics with both paediatric and adult physicians attending and the use of web-based or mobile technologies for communication with the AYA. The most supported recommendation was checking that the AYA is knowledgeable and compliant with their prescribed medication. Qualitative analysis revealed conditional approval for some recommendations. CONCLUSIONS: There was agreement from patients and parents on the importance of the draft recommendations on transitional care for AYA with allergy and/or asthma and their parents. The recommendations now need to be implemented into clinical practice across Europe.</style></abstract><notes><style face="normal" font="default" size="100%">Khaleva, Ekaterina&#xD;Knibb, Rebecca&#xD;DunnGalvin, Audrey&#xD;Vazquez-Ortiz, Marta&#xD;Comberiati, Pasquale&#xD;Alviani, Cherry&#xD;Garriga-Baraut, Teresa&#xD;Gowland, Mary Hazel&#xD;Gore, Claudia&#xD;Angier, Elizabeth&#xD;Blumchen, Katharina&#xD;Duca, Bettina&#xD;Hox, Valerie&#xD;Jensen, Britt&#xD;Mortz, Charlotte G&#xD;Pite, Helena&#xD;Pfaar, Oliver&#xD;Santos, Alexandra F&#xD;Sanchez-Garcia, Silvia&#xD;Timmermans, Frans&#xD;Roberts, Graham&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1094-1104. doi: 10.1111/all.15109. Epub 2021 Nov 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34564855</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15109</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2266</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2266</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Okubo, H.</style></author><author><style face="normal" font="default" size="100%">Nakayama, S. F.</style></author><author><style face="normal" font="default" size="100%">Ohya, Y.</style></author><author><style face="normal" font="default" size="100%">Japan, Environment</style></author><author><style face="normal" font="default" size="100%">Children&apos;s Study, Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Japan Environment and Children&apos;s Study Programme Office, National Institute for Environmental Studies, Ibaraki, Japan.&#xD;Japan Society for the Promotion of Science, Tokyo, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.&#xD;Medical Support Centre for the Japan Environment and Children&apos;s Study, National Center for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Periconceptional maternal diet quality and offspring wheeze trajectories: Japan Environment and Children&apos;s Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">393-403</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/10/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Bayes Theorem</style></keyword><keyword><style face="normal" font="default" size="100%">*Diet/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Japan/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Sounds</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Early childhood</style></keyword><keyword><style face="normal" font="default" size="100%">current wheeze</style></keyword><keyword><style face="normal" font="default" size="100%">maternal diet quality</style></keyword><keyword><style face="normal" font="default" size="100%">periconception</style></keyword><keyword><style face="normal" font="default" size="100%">trajectory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37850508</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The role of prenatal diet on childhood wheezing and subsequent risk of asthma is inconclusive, which may be partly due to the heterogeneity in wheezing phenotypes. We aimed to identify wheeze trajectories in early childhood and to examine their associations with periconceptional maternal diet quality. METHODS: Data from 70,530 mother-child pairs of liveborn singletons from the Japan Environment and Children&apos;s Study were analysed. Wheezing was reported by caregivers using a modified International Study of Asthma and Allergies in Childhood questionnaire yearly from 1 to 4 years of age, from which trajectories were derived using group-based trajectory modelling. Maternal diet in the year preceding the first trimester of pregnancy was assessed using a validated food frequency questionnaire; overall diet quality was determined using the balanced diet score based on the Japanese Food Guide Spinning Top. Bayesian inference of multinomial logistic regression models was performed to examine the association between maternal diet quality and wheeze trajectory in early childhood. RESULTS: We identified four wheeze trajectories: &apos;never/infrequent&apos; (69.1%; reference group), &apos;early-childhood onset&apos; (6.2%), &apos;transient early&apos; (16.5%) and &apos;persistent&apos; (8.2%). After adjustment for confounders, a higher quartile of maternal balanced diet score was associated with a lower risk of belonging to the &apos;transient early&apos; and &apos;persistent&apos; wheeze trajectories compared with the &apos;never/infrequent&apos; wheeze trajectory by 10% of both. Maternal balanced diet score was not associated with belonging to the &apos;early-childhood onset&apos; wheeze trajectory. CONCLUSION: Improving maternal diet quality prior to conception may reduce certain wheeze phenotypes in early childhood.</style></abstract><notes><style face="normal" font="default" size="100%">Okubo, Hitomi&#xD;Nakayama, Shoji F&#xD;Ohya, Yukihiro&#xD;eng&#xD;Ministry of the Environment, Government of Japan/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):393-403. doi: 10.1111/all.15916. Epub 2023 Oct 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37850508</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15916</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2831</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2831</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wallraff, J. P.</style></author><author><style face="normal" font="default" size="100%">Traub, A.</style></author><author><style face="normal" font="default" size="100%">Morfeld, P.</style></author><author><style face="normal" font="default" size="100%">Hellmich, M.</style></author><author><style face="normal" font="default" size="100%">Erren, T. C.</style></author><author><style face="normal" font="default" size="100%">Lewis, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute and Policlinic for Occupational Medicine, Environmental Medicine and Prevention Research, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.&#xD;Institute of Medical Statistics and Computational Biology, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Perinatal Photoperiod Associations With Allergic and Respiratory Disease in the UK Biobank Database</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2047-2049</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Pliccs</style></keyword><keyword><style face="normal" font="default" size="100%">circadian</style></keyword><keyword><style face="normal" font="default" size="100%">light</style></keyword><keyword><style face="normal" font="default" size="100%">perinatal</style></keyword><keyword><style face="normal" font="default" size="100%">photoperiod</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39976177</style></accession-num><notes><style face="normal" font="default" size="100%">Wallraff, Jonas P&#xD;Traub, Achim&#xD;Morfeld, Peter&#xD;Hellmich, Martin&#xD;Erren, Thomas C&#xD;Lewis, Philip&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2047-2049. doi: 10.1111/all.16508. Epub 2025 Feb 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39976177</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261865</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16508</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1204</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1204</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Azim, A.</style></author><author><style face="normal" font="default" size="100%">Green, B.</style></author><author><style face="normal" font="default" size="100%">Lau, L.</style></author><author><style face="normal" font="default" size="100%">Rupani, H.</style></author><author><style face="normal" font="default" size="100%">Jayasekera, N.</style></author><author><style face="normal" font="default" size="100%">Bruce, K.</style></author><author><style face="normal" font="default" size="100%">Howarth, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Academic Unit of Clinical and Experimental Sciences University of Southampton, Southampton, UK.&#xD;NIHR Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK.&#xD;Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, London, UK.&#xD;Newham University Hospital, Barts Health Trust, London, UK.&#xD;Molecular Microbiology Research Laboratory, Pharmaceutical Science Division, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Peripheral airways type 2 inflammation, neutrophilia and microbial dysbiosis in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2070-2078</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchi</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default" size="100%">*Dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">16srRNA</style></keyword><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">peripheral airways</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose. Dr. Rupani has nothing to disclose. Dr. Jayasekera has</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose. Dr. Bruce has nothing to disclose. Prof. Howarth reports</style></keyword><keyword><style face="normal" font="default" size="100%">employment by and has shares in GSK.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33411348</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IL-13 is considered an archetypal T2 cytokine central to the clinical disease expression of asthma. The IL-13 response genes, which are upregulated in central airway bronchial epithelial of asthma patients, can be normalized by high-dose inhaled steroid therapy in severe asthma. However, this is not the case within the peripheral airways. We have sought to further understand IL-13 in the peripheral airways in severe asthma through bronchoalveolar analysis. METHODS: Bronchoalveolar lavage samples were collected from 203 asthmatic and healthy volunteers, including 78 with severe asthma. Inflammatory mediators were measured using a multiple cytokine immunoassay platform. This analysis was replicated in a further 59 volunteers, in whom 16S rRNA analysis of BAL samples was undertaken by terminal restriction fragment length polymorphism. RESULTS: Severe asthma patients with high BAL IL-13, despite treatment with high-dose inhaled corticosteroids, had more severe lung function and significantly higher BAL neutrophil percentages, but not BAL eosinophils than those with normal BAL-13 concentrations. This finding was replicated in the second cohort, which further associated BAL IL-13 and neutrophilia with a greater abundance of potentially pathogenic bacteria in the peripheral airways. CONCLUSION: Our findings demonstrate a steroid unresponsive source of IL-13 that is associated with BAL neutrophilia and bacterial dysbiosis in severe asthma. Our findings highlight the biological complexity of severe asthma and the importance of a greater understanding of the innate and adaptive immune responses in the peripheral airways in this disease.</style></abstract><notes><style face="normal" font="default" size="100%">Azim, Adnan&#xD;Green, Ben&#xD;Lau, Laurie&#xD;Rupani, Hitasha&#xD;Jayasekera, Nivenka&#xD;Bruce, Kenneth&#xD;Howarth, Peter&#xD;eng&#xD;G0900453/Medical Research Council UK/&#xD;G0800649/Medical Research Council UK/&#xD;G0900453/MRC_/Medical Research Council/United Kingdom&#xD;G0800649/MRC_/Medical Research Council/United Kingdom&#xD;G0800766/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2070-2078. doi: 10.1111/all.14732. Epub 2021 Jan 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33411348</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8629111</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14732</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2144</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2144</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Trad, G.</style></author><author><style face="normal" font="default" size="100%">Sanak, M.</style></author><author><style face="normal" font="default" size="100%">Cmiel, A.</style></author><author><style face="normal" font="default" size="100%">Celejewska-Wojcik, N.</style></author><author><style face="normal" font="default" size="100%">Czekaj, M.</style></author><author><style face="normal" font="default" size="100%">Mastalerz, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.&#xD;Doctoral School of Medical and Health Sciences, Jagiellonian University, Krakow, Poland.&#xD;Department of Applied Mathematics, AGH University of Science and Technology, Krakow, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Peripheral biomarkers for predicting sputum eosinophilia in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3001-3003</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiration Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilia/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37306265</style></accession-num><notes><style face="normal" font="default" size="100%">Trad, Gabriela&#xD;Sanak, Marek&#xD;Cmiel, Adam&#xD;Celejewska-Wojcik, Natalia&#xD;Czekaj, Michal&#xD;Mastalerz, Lucyna&#xD;eng&#xD;Narodowe Centrum Nauki/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):3001-3003. doi: 10.1111/all.15780. Epub 2023 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37306265</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15780</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1243</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1243</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Petrarca, C.</style></author><author><style face="normal" font="default" size="100%">Lanuti, P.</style></author><author><style face="normal" font="default" size="100%">Petrosino, M. I.</style></author><author><style face="normal" font="default" size="100%">Di Pillo, S.</style></author><author><style face="normal" font="default" size="100%">Mistrello, G.</style></author><author><style face="normal" font="default" size="100%">Compalati, E.</style></author><author><style face="normal" font="default" size="100%">Otzuki, T.</style></author><author><style face="normal" font="default" size="100%">Marchisio, M.</style></author><author><style face="normal" font="default" size="100%">Pierdomenico, L.</style></author><author><style face="normal" font="default" size="100%">Paganelli, R.</style></author><author><style face="normal" font="default" size="100%">Di Gioacchino, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine and Science of Aging, G. d&apos;Annunzio University, Chieti, Italy.&#xD;Center for Advanced Science and Technology (CAST), G. d&apos;Annunzio University, Chieti, Italy.&#xD;Unit of Pediatrics, University Hospital, Chieti, Italy.&#xD;Lofarma Allergeni, SpA, Milan, Italy.&#xD;Department of Hygiene, Kawasaki Medical School, Okayama, Japan.&#xD;Foundation for Clinical Immunotherapy and Advanced Biological Treatments, Pescara, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Peripheral effector memory regulatory T cells are incremented and functionally enhanced in successful mite monomeric allergoid sublingual immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2208-2211</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/12/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Allergoids</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mites</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33284458</style></accession-num><notes><style face="normal" font="default" size="100%">Petrarca, Claudia&#xD;Lanuti, Paola&#xD;Petrosino, Marianna Immacolata&#xD;Di Pillo, Sabrina&#xD;Mistrello, Gianni&#xD;Compalati, Enrico&#xD;Otzuki, Takemi&#xD;Marchisio, Marco&#xD;Pierdomenico, Laura&#xD;Paganelli, Roberto&#xD;Di Gioacchino, Mario&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2208-2211. doi: 10.1111/all.14692. Epub 2020 Dec 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33284458</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8359259 has nothing to disclose. Dr. Petrosino has nothing to disclose. Dr. Di Pillo has nothing to disclose. Dr Mistrello has nothing to discloseDr. Compalati reports other from Lofarma, outside the submitted work. Dr. Marchisio has nothing to disclose. Dr. Pierdomenico has nothing to disclose. Dr. Otsuki has nothing to disclose. Dr. Paganelli has nothing to disclose. Dr. Di Gioacchino reports grants and personal fees from GSK, grants from Novartis, grants, personal fees and non-financial support from Lofarma, personal fees from Menarini, grants from Sanofi-Genzyme outside the submitted work.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14692</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1056</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1056</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dilollo, J.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Lopez, E. M.</style></author><author><style face="normal" font="default" size="100%">Wilkey, L.</style></author><author><style face="normal" font="default" size="100%">Martin, E. K.</style></author><author><style face="normal" font="default" size="100%">Spergel, J. M.</style></author><author><style face="normal" font="default" size="100%">Hill, D. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Center for Pediatric Eosinophilic Disorders, Children&apos;s Hospital of Philadelphia, Philadelphia, PA, USA.&#xD;Institute for Immunology and Department of Pediatrics, Perelman School of Medicine, Philadelphia, PA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Peripheral markers of allergen-specific immune activation predict clinical allergy in eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3470-3478</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/04/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Milk</style></keyword><keyword><style face="normal" font="default" size="100%">T cell</style></keyword><keyword><style face="normal" font="default" size="100%">assay</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33840099</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophilic esophagitis (EoE) is a T-cell-mediated disease that is caused by specific foods and results in esophageal dysfunction. Existing allergy testing modalities are not helpful when attempting to identify EoE-causal foods necessitating empiric food elimination and recurrent endoscopy. The goal of this study was to identify and compare allergen-specific immune features that can be assayed in a minimally invasive manner to predict clinical food allergy in EoE. METHODS: We obtained blood samples from control subjects (n = 17), subjects with clinical EoE milk allergy (n = 17), and subjects with immunoglobulin E-mediated milk allergy (n = 9). We measured total and milk-specific plasma immunoglobulin G (IgG)4 levels and peripheral memory CD4(+) T helper (T(H) ) cell proliferation and cytokine production after stimulation with endotoxin-depleted milk proteins. Sensitivity and specificity for predicting clinical EoE milk allergy were calculated and compared between approaches. RESULTS: Total and milk-specific IgG4 levels were not significantly different between control subjects and subjects with clinical EoE milk allergy. Stimulation with milk proteins caused T(H) lymphocytes from subjects with clinical EoE milk allergy to proliferate more (%P1 of 38.3 +/- 4.6 vs. 12.7 +/- 2.8, p &lt; 0.0001), and produce more type 2 cytokines (%IL-4(+) of 33.7 +/- 2.8 vs. 6.9 +/- 1.6, p &lt; 0.0001) than cells from control subjects. Milk-dependent memory T(H) -cell proliferation (sensitivity and specificity of 88% and 82%, respectively) and interleukin 4 (IL-4) production (sensitivity and specificity of 100%) most strongly predicted clinical EoE milk allergy. CONCLUSIONS: Peripheral markers of allergen-specific immune activation may be useful in identifying EoE-causal foods. Assaying milk-dependent IL-4 production by circulating memory T(H) lymphocytes most accurately predicts clinical EoE milk allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Dilollo, Julianna&#xD;Rodriguez-Lopez, Eric M&#xD;Wilkey, Leah&#xD;Martin, Elizabeth K&#xD;Spergel, Jonathan M&#xD;Hill, David A&#xD;eng&#xD;K08 DK116668/DK/NIDDK NIH HHS/&#xD;T32 AI055428/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3470-3478. doi: 10.1111/all.14854. Epub 2021 May 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33840099</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8502783</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14854</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2452</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2452</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salciccioli, I.</style></author><author><style face="normal" font="default" size="100%">Bhatt, P.</style></author><author><style face="normal" font="default" size="100%">Shalhoub, J.</style></author><author><style face="normal" font="default" size="100%">Marshall, D.</style></author><author><style face="normal" font="default" size="100%">Salciccioli, J.</style></author><author><style face="normal" font="default" size="100%">Blumenthal, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts, USA.&#xD;Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Surgery and Cancer, Imperial College London, London, UK.&#xD;Medical Data Research Collaborative, London, UK.&#xD;Department of Respiratory Medicine, Imperial College Healthcare NHS Trust, London, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Pulmonary and Critical Care Medicine, Brigham and Women&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Persistent sex and race disparities in United States anaphylaxis mortality from 1999 to 2020</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2255-2258</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/03/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/mortality/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Racial Groups</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Health Status Disparities</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38429934</style></accession-num><notes><style face="normal" font="default" size="100%">Salciccioli, Ingrid&#xD;Bhatt, Padmanabh&#xD;Shalhoub, Joseph&#xD;Marshall, Dominic&#xD;Salciccioli, Justin&#xD;Blumenthal, Kimberly&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2255-2258. doi: 10.1111/all.16088. Epub 2024 Mar 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38429934</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16088</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2582</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2582</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ng, C. L.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, National University Health System, Singapore, Singapore.&#xD;Department of Otolaryngology, Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Person-centred care in allergen immunotherapy in a digital era</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2034-2036</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Patient-Centered Care</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Telemedicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38979772</style></accession-num><notes><style face="normal" font="default" size="100%">Ng, Chew Lip&#xD;Wang, De Yun&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2034-2036. doi: 10.1111/all.16234. Epub 2024 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38979772</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16234</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>389</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">389</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nunez-Borque, E.</style></author><author><style face="normal" font="default" size="100%">Betancor, D.</style></author><author><style face="normal" font="default" size="100%">Pastor-Vargas, C.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Bravo, S.</style></author><author><style face="normal" font="default" size="100%">Martin-Blazquez, A.</style></author><author><style face="normal" font="default" size="100%">Casado-Navarro, N.</style></author><author><style face="normal" font="default" size="100%">Lopez-Dominguez, D.</style></author><author><style face="normal" font="default" size="100%">Gomez-Lopez, A.</style></author><author><style face="normal" font="default" size="100%">Rodriguez Del Rio, P.</style></author><author><style face="normal" font="default" size="100%">Tramon, P.</style></author><author><style face="normal" font="default" size="100%">Beitia, J. M.</style></author><author><style face="normal" font="default" size="100%">Moreno-Aguilar, C.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-de-Olano, D.</style></author><author><style face="normal" font="default" size="100%">Goikoetxea, M. J.</style></author><author><style face="normal" font="default" size="100%">Ibanez-Sandin, M. D.</style></author><author><style face="normal" font="default" size="100%">Laguna, J. J.</style></author><author><style face="normal" font="default" size="100%">Cuesta-Herranz, J.</style></author><author><style face="normal" font="default" size="100%">Esteban, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Immunology, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain.&#xD;Department of Allergy, Fundacion Jimenez Diaz University Hospital, UAM, Madrid, Spain.&#xD;Department of Biochemistry and Molecular Biology, UCM, Madrid, Spain.&#xD;Department of Clinical Analysis, Fundacion Jimenez Diaz University Hospital, UAM, Madrid, Spain.&#xD;Clinical Biostatistics Unit, IDIPHIM, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain.&#xD;Allergy Department, Hospital Infantil Universitario Nino Jesus, Fundacion HNJ, IIS-P, Madrid, Spain.&#xD;Allergy Service, Guadalajara Hospital, Guadalajara, Spain.&#xD;Allergy Service, Reina Sofia de Cordoba University Hospital-IMIBIC, Cordoba, Spain.&#xD;Allergy Service, Ramon y Cajal University Hospital, Madrid, Spain.&#xD;Allergy Department, Navarra University Clinic, Pamplona, Spain.&#xD;Allergy Unit, Allergo-Anaesthesia Unit, Hospital Central de la Cruz Roja, Madrid, Spain.&#xD;Faculty of Medicine and Biomedicine, Alfonso X El Sabio University, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Personalized diagnostic approach and indirect quantification of extravasation in human anaphylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">202-213</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/07/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptases</style></keyword><keyword><style face="normal" font="default" size="100%">Serum Albumin, Human</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">haemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">human serum albumin</style></keyword><keyword><style face="normal" font="default" size="100%">protein concentration</style></keyword><keyword><style face="normal" font="default" size="100%">tryptase</style></keyword><keyword><style face="normal" font="default" size="100%">Research Contract, from the Instituto Carlos III. All other authors have no</style></keyword><keyword><style face="normal" font="default" size="100%">conflict of interest within the scope of the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35841381</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Anaphylaxis is the most acute and life-threatening manifestation of allergic disorders. Currently, there is a need to improve its medical management and increase the understanding of its molecular mechanisms. This study aimed to quantify the extravasation underlying human anaphylactic reactions and propose new theragnostic approaches. METHODS: Molecular determinations were performed in paired serum samples obtained during the acute phase and at baseline from patients presenting with hypersensitivity reactions. These were classified according to their severity as Grades 1, 2 and 3, the two latter being considered anaphylaxis. Tryptase levels were measured by ImmunoCAP, and serum protein concentration was quantified by Bradford assay. Human serum albumin (HSA) and haemoglobin beta subunit (HBB) levels were determined by Western blot and polyacrylamide gel electrophoresis, respectively. RESULTS: A total of 150 patients were included in the study. Of them, 112 had experienced anaphylaxis (83 and 29 with Grade 2 and 3 reactions, respectively). Tryptase diagnostic efficiency substantially improved when considering patients&apos; baseline values (33%-54%) instead of the acute value threshold (21%). Serum protein concentration and HSA significantly decreased in anaphylaxis (p &lt; .0001). HSA levels dropped with the severity of the reaction (6% and 15% for Grade 2 and 3 reactions, respectively). Furthermore, HBB levels increased during the acute phase of all hypersensitivity reactions (p &lt; .0001). CONCLUSIONS: For the first time, the extravasation underlying human anaphylaxis has been evaluated based on the severity of the reaction using HSA and protein concentration measurements. Additionally, our findings propose new diagnostic and potential therapeutic approaches for this pathological event.</style></abstract><notes><style face="normal" font="default" size="100%">Nunez-Borque, Emilio&#xD;Betancor, Diana&#xD;Pastor-Vargas, Carlos&#xD;Fernandez-Bravo, Sergio&#xD;Martin-Blazquez, Ariadna&#xD;Casado-Navarro, Natalia&#xD;Lopez-Dominguez, David&#xD;Gomez-Lopez, Alicia&#xD;Rodriguez Del Rio, Pablo&#xD;Tramon, Paloma&#xD;Beitia, Juan Maria&#xD;Moreno-Aguilar, Carmen&#xD;Gonzalez-de-Olano, David&#xD;Goikoetxea, Maria Jose&#xD;Ibanez-Sandin, Maria Dolores&#xD;Laguna, Jose Julio&#xD;Cuesta-Herranz, Javier&#xD;Esteban, Vanesa&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):202-213. doi: 10.1111/all.15443. Epub 2022 Jul 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35841381</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087983</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15443</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1339</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1339</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Incorvaia, C.</style></author><author><style face="normal" font="default" size="100%">Al-Ahmad, M.</style></author><author><style face="normal" font="default" size="100%">Ansotegui, I. J.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Bos, C.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Bozek, A.</style></author><author><style face="normal" font="default" size="100%">Caimmi, D.</style></author><author><style face="normal" font="default" size="100%">Calderon, M. A.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Custovic, A.</style></author><author><style face="normal" font="default" size="100%">De Blay, F.</style></author><author><style face="normal" font="default" size="100%">Demoly, P.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Didier, A.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author><author><style face="normal" font="default" size="100%">Fox, A. T.</style></author><author><style face="normal" font="default" size="100%">Gevaert, P.</style></author><author><style face="normal" font="default" size="100%">Gomez, M.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Ilina, N.</style></author><author><style face="normal" font="default" size="100%">Irani, C.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Karagiannis, E.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R.</style></author><author><style face="normal" font="default" size="100%">Kurbacheva, O.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P. M.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Novak, N.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Panzner, P.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author><author><style face="normal" font="default" size="100%">Passalacqua, G.</style></author><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Scurati, S.</style></author><author><style face="normal" font="default" size="100%">Tortajada-Girbes, M.</style></author><author><style face="normal" font="default" size="100%">Vidal, C.</style></author><author><style face="normal" font="default" size="100%">Virchow, J. C.</style></author><author><style face="normal" font="default" size="100%">Wahn, U.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Zieglmayer, P.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, Milan, Italy.&#xD;Microbiology Department, Faculty of Medicine, Kuwait University, Kuwait.&#xD;Drug Allergy Unit, Department of Allergy, Al-Rashed Allergy Center, Kuwait.&#xD;Hospital Quironsalud Bizkaia, Bilbao, Spain.&#xD;Department of Allergy, Bambino Gesu&apos; Childrens&apos; Hospital IRCCS, Rome, Italy.&#xD;Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium.&#xD;Karolinska Institutet, Stockholm, Sweden.&#xD;Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden.&#xD;Stallergenes Greer Medical Affairs Department, Antony, France.&#xD;University Hospital Montpellier, France - MACVIA-France, Montpellier, France.&#xD;Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, Katowice, Poland.&#xD;Department of Pulmonology and Addictology, Arnaud de Villeneuve Hospital, Montpellier University, Montpellier, France.&#xD;Imperial College London - National Heart and Lung Institute, Royal Brompton Hospital NHS, London, UK.&#xD;Division of Allergy/Immunology, University of South Florida, Tampa, FL, USA.&#xD;Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester and University Hospital of South Manchester, Manchester, UK.&#xD;Allergy Division, Chest Diseases Department, Strasbourg University Hospital, Strasbourg, France.&#xD;Sorbonne Universite, UMR-S 1136 INSERM, IPLESP, EPAR Team, Paris, France.&#xD;Laboratoire de Recherche en Pharmacologie Respiratoire, Pole des Maladies des Voies Respiratoires, Hopital Foch, Universite Paris-Saclay, Suresnes, France.&#xD;Respiratory Disease Dept, Larrey Hospital, University Hospital of Toulouse, Paul Sabatier University, Toulouse, France.&#xD;Department of Paediatric Allergy, Guy&apos;s &amp; St Thomas&apos; Hospitals NHS Foundation Trust, London, UK.&#xD;Allergy &amp; Asthma Unit, Hospital San Bernardo Salta, Salta, Argentina.&#xD;Personalized Medicine, Asthma &amp; Allergy - Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.&#xD;Department of Biomedical Science, Humanitas University, Pieve Emanuele, Italy.&#xD;Federal Institute of Immunology of Russia, Moscow, Russia.&#xD;Department of Internal Medicine and Clinical Immunology, Faculty of Medicine, Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Alfred Hospital and Monash University, Melbourne, Australia.&#xD;National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow, Russia.&#xD;Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charite - University Medicine Berlin, Berlin, Germany.&#xD;Immunoallergy Department of CUF-Descobertas Hospital, Lisbon, Portugal.&#xD;CUF-Infante Santo Hospital, Lisbon, Portugal.&#xD;Faculty of Medicine, Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany.&#xD;CRI - Clinical Research International Ltd., Cologne, Germany.&#xD;Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.&#xD;Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.&#xD;Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, Royal Manchester Children&apos;s Hospital, University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Pediatric Clinic, Athens General Children&apos;s Hospital &quot;P&amp;A Kyriakou&quot;, University of Athens, Athens, Greece.&#xD;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea.&#xD;Allergy and Respiratory Diseases, Ospedale Policlino San Martino - University of Genoa, Genoa, Italy.&#xD;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.&#xD;Pediatric Pulmonology and Allergy Unit, Department of Pediatrics, Dr. Peset University Hospital, Valencia, Spain.&#xD;Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain.&#xD;IVI Foundation, Valencia, Spain.&#xD;Allergy Service, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.&#xD;Department of Pneumology/Intensive Care Medicine, University of Rostock, Rostock, Germany.&#xD;Vienna Challenge Chamber, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1041-1052</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/09/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Precision Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">molecular diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">omics</style></keyword><keyword><style face="normal" font="default" size="100%">personalized medicine</style></keyword><keyword><style face="normal" font="default" size="100%">treatable traits</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32869882</style></accession-num><abstract><style face="normal" font="default" size="100%">The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to detect specific IgE to single-allergen molecules and to distinguish the causative molecules from those merely cross-reactive, pursuit of patient&apos;s treatable traits addressing genetic, phenotypic, and psychosocial features, and omics, such as proteomics, epi-genomics, metabolomics, and breathomics, to forecast patient&apos;s responsiveness to therapies, to detect biomarker and mediators, and to verify the disease control. This new approach has already improved the precision of allergy diagnosis and is likely to significantly increase, through the higher performance achieved with the personalized treatment, the effectiveness of allergen immunotherapy by enhancing its already known and unique characteristics of treatment that acts on the causes.</style></abstract><notes><style face="normal" font="default" size="100%">Incorvaia, Cristoforo&#xD;Al-Ahmad, Mona&#xD;Ansotegui, Ignacio J&#xD;Arasi, Stefania&#xD;Bachert, Claus&#xD;Bos, Catherine&#xD;Bousquet, Jean&#xD;Bozek, Andrzej&#xD;Caimmi, Davide&#xD;Calderon, Moises A&#xD;Casale, Thomas&#xD;Custovic, Adnan&#xD;De Blay, Frederic&#xD;Demoly, Pascal&#xD;Devillier, Philippe&#xD;Didier, Alain&#xD;Fiocchi, Alessandro&#xD;Fox, Adam T&#xD;Gevaert, Philippe&#xD;Gomez, Maximiliano&#xD;Heffler, Enrico&#xD;Ilina, Natalia&#xD;Irani, Carla&#xD;Jutel, Marek&#xD;Karagiannis, Efstrathios&#xD;Klimek, Ludger&#xD;Kuna, Piotr&#xD;O&apos;Hehir, Robin&#xD;Kurbacheva, Oxana&#xD;Matricardi, Paolo M&#xD;Morais-Almeida, Mario&#xD;Mosges, Ralph&#xD;Novak, Natalija&#xD;Okamoto, Yoshitaka&#xD;Panzner, Petr&#xD;Papadopoulos, Nikolaos G&#xD;Park, Hae-Sim&#xD;Passalacqua, Giovanni&#xD;Pawankar, Ruby&#xD;Pfaar, Oliver&#xD;Schmid-Grendelmeier, Peter&#xD;Scurati, Silvia&#xD;Tortajada-Girbes, Miguel&#xD;Vidal, Carmen&#xD;Virchow, J Christian&#xD;Wahn, Ulrich&#xD;Worm, Margitta&#xD;Zieglmayer, Petra&#xD;Canonica, Giorgio W&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1041-1052. doi: 10.1111/all.14575. Epub 2020 Oct 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32869882</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14575</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>85</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">85</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liccardi, G.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Calzetta, L.</style></author><author><style face="normal" font="default" size="100%">Milanese, M.</style></author><author><style face="normal" font="default" size="100%">Martini, M.</style></author><author><style face="normal" font="default" size="100%">Bresciani, M.</style></author><author><style face="normal" font="default" size="100%">Cilia, M.</style></author><author><style face="normal" font="default" size="100%">Cucinelli, F.</style></author><author><style face="normal" font="default" size="100%">D&apos;Angelo, R.</style></author><author><style face="normal" font="default" size="100%">Feliziani, A.</style></author><author><style face="normal" font="default" size="100%">Filon, F. L.</style></author><author><style face="normal" font="default" size="100%">Longo, R.</style></author><author><style face="normal" font="default" size="100%">Losappio, L.</style></author><author><style face="normal" font="default" size="100%">Manzotti, G.</style></author><author><style face="normal" font="default" size="100%">Minale, P.</style></author><author><style face="normal" font="default" size="100%">Modica, S.</style></author><author><style face="normal" font="default" size="100%">Murzilli, F.</style></author><author><style face="normal" font="default" size="100%">Musarra, A.</style></author><author><style face="normal" font="default" size="100%">Pingitore, G.</style></author><author><style face="normal" font="default" size="100%">Polillo, B. R.</style></author><author><style face="normal" font="default" size="100%">Puggioni, F.</style></author><author><style face="normal" font="default" size="100%">Quercia, O.</style></author><author><style face="normal" font="default" size="100%">Rapone, C.</style></author><author><style face="normal" font="default" size="100%">Rogliani, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Postgraduate School of Respiratory Medicine. Department of Experimental Medicine, University of Rome &quot;Tor Vergata&quot;, Rome, Italy.&#xD;Allergy Unit, Department of Internal Medicine, University Hospital Ospedali Riuniti, Ancona, Italy.&#xD;Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.&#xD;Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.&#xD;Division of Pulmonology, S.Corona Hospital, Savona, Italy.&#xD;Allergy Unit, Ospedali Riuniti Marche Nord, Fano, Italy.&#xD;Asl Roma 4, S. Paolo Hospital, Civitavecchia, Italy.&#xD;Unit of Allergology, Casa della Salute di Scilla, ASP di Reggio Calabria, Italy.&#xD;Department of Internal Medicine, Unit of Allergology, S.S. Filippo e Nicola Hospital Avezzano, L&apos;Aquila, Italy.&#xD;Ecosystem S.R.L, Naples, Italy.&#xD;A.F. Allergy Center, Chieti, Italy.&#xD;Unit of Occupational Medicine, University of Trieste, Trieste, Italy.&#xD;Allergy Unit, ASP Tropea, Vibo Valentia, Italy.&#xD;Unit of Allergology, Niguarda Hospital, Milan, Italy.&#xD;Allergy Unit, Division of Internal Medicine, ASST Bergamo Ovest, Bergamo, Italy.&#xD;Montallegro Clinic, Genoa, Italy.&#xD;Unit of Reumatology, Allergology and Clinical Immunology, Policlinico Tor Vergata, Rome, Italy.&#xD;G.P. Allergy Center, Rome, Italy.&#xD;R.P. Allergy Center, Rome, Italy.&#xD;Personalized Medicine, Asthma &amp; Allergy - Humanitas Clinical and Research Center IRCCS, Milan, Italy.&#xD;O.Q. Allergy Center, Faenza, Italy.&#xD;Allergy Unit, ASL Atri, Teramo, Italy.&#xD;Department of Experimental Medicine, Unit of Respiratory Medicine, University of Rome. &quot;Tor Vergata&quot;, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pest sensitization to cockroach, mouse, and rat: An Italian multicenter study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1360-1363</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/11/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Cockroaches</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Italy/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36398484</style></accession-num><notes><style face="normal" font="default" size="100%">Liccardi, Gennaro&#xD;Bilo, Maria Beatrice&#xD;Calzetta, Luigino&#xD;Milanese, Manlio&#xD;Martini, Matteo&#xD;Bresciani, Megon&#xD;Cilia, Marcello&#xD;Cucinelli, Francesco&#xD;D&apos;Angelo, Romina&#xD;Feliziani, Annamaria&#xD;Filon, Francesca Larese&#xD;Longo, Rocco&#xD;Losappio, Laura&#xD;Manzotti, Giusy&#xD;Minale, Paola&#xD;Modica, Stella&#xD;Murzilli, Francesco&#xD;Musarra, Antonino&#xD;Pingitore, Giuseppe&#xD;Polillo, Battista Roberto&#xD;Puggioni, Francesca&#xD;Quercia, Oliviero&#xD;Rapone, Carla&#xD;Rogliani, Paola&#xD;eng&#xD;Letter&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1360-1363. doi: 10.1111/all.15586. Epub 2022 Nov 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36398484</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15586</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2668</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2668</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vitte, J.</style></author><author><style face="normal" font="default" size="100%">Bouazzi, L.</style></author><author><style face="normal" font="default" size="100%">Barbe, C.</style></author><author><style face="normal" font="default" size="100%">Pham, B. N.</style></author><author><style face="normal" font="default" size="100%">Sanchez, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Reims Champagne-Ardenne, INSERM UMR-S 1250, P3Cell, Reims, France.&#xD;Immunology Laboratory, Biology and Pathology Department, University Hospital of Reims, Reims, France.&#xD;University of Reims Champagne-Ardenne, University Committee of Resources for Research in Health (CURRS), Reims, France.&#xD;University of Reims Champagne-Ardenne, IRMAIC, Reims, France.&#xD;Department of public health and performance, Champagne Sud Hospital, Troyes, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pesticides as an overlooked exposomic association in allergic asthma exacerbations: A nationwide database study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3505-3508</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/10/29</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39470617</style></accession-num><notes><style face="normal" font="default" size="100%">Vitte, Joana&#xD;Bouazzi, Leila&#xD;Barbe, Coralie&#xD;Pham, Bach-Nga&#xD;Sanchez, Stephane&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3505-3508. doi: 10.1111/all.16380. Epub 2024 Oct 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39470617</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657063 HpVac, L&apos;Oreal, Novartis, Sanofi, Thermo Fisher Scientific, and travel support from Stallergenes-Greer, outside the submitted work. The other authors declare no competing interests in relation to this study.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16380</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1971</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1971</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">de Souza Ferreira, S.</style></author><author><style face="normal" font="default" size="100%">Bek, M. K.</style></author><author><style face="normal" font="default" size="100%">Tibbitt, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.&#xD;Clinical Lung and Allergy Research, Medical Unit for Lung and Allergy Diseases, Karolinska University Hospital Huddinge, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">pH sensing shapes immune cell function: The role of GPR65 and its implications for allergic disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2061-2063</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/03/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, G-Protein-Coupled</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrogen-Ion Concentration</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36916643</style></accession-num><notes><style face="normal" font="default" size="100%">de Souza Ferreira, Sabrina&#xD;Bek, Marie Kaarup&#xD;Tibbitt, Christopher Andrew&#xD;eng&#xD;Center for Innovative Medicine/&#xD;Jeanssons Stiftelser/&#xD;Vetenskapsradet/&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2061-2063. doi: 10.1111/all.15708. Epub 2023 Mar 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36916643</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15708</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2333</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2333</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Voskamp, A. L.</style></author><author><style face="normal" font="default" size="100%">Khosa, S.</style></author><author><style face="normal" font="default" size="100%">Phan, T.</style></author><author><style face="normal" font="default" size="100%">DeBerg, H. A.</style></author><author><style face="normal" font="default" size="100%">Bingham, J.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author><author><style face="normal" font="default" size="100%">Smith, W.</style></author><author><style face="normal" font="default" size="100%">Abramovitch, J.</style></author><author><style face="normal" font="default" size="100%">Rolland, J. M.</style></author><author><style face="normal" font="default" size="100%">Moyle, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Larche, M.</style></author><author><style face="normal" font="default" size="100%">Wambre, E.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">Hickey, P.</style></author><author><style face="normal" font="default" size="100%">Prickett, S. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Aravax Pty Ltd, Melbourne, Victoria, Australia.&#xD;Monash University, Melbourne, Victoria, Australia.&#xD;Alfred Health, Melbourne, Victoria, Australia.&#xD;WhiteFox Science Consulting, Nelson, New Zealand.&#xD;Benaroya Research Institute, Seattle, Washington, USA.&#xD;Easington Pty Ltd, Melbourne, Victoria, Australia.&#xD;AllergySA, Adelaide, South Australia, Australia.&#xD;Stanford University, San Francisco, California, USA.&#xD;Kings College, London, UK.&#xD;Schroeder Allergy &amp; Immunology Research Institute, Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">485-498</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/12/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">T cell</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">peptide immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">phase 1 clinical trial</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38112286</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food allergy is a leading cause of anaphylaxis worldwide. Allergen-specific immunotherapy is the only treatment shown to modify the natural history of allergic disease, but application to food allergy has been hindered by risk of severe allergic reactions and short-lived efficacy. Allergen-derived peptides could provide a solution. PVX108 comprises seven short peptides representing immunodominant T-cell epitopes of major peanut allergens for treatment of peanut allergy. METHODS: Pre-clinical safety of PVX108 was assessed using ex vivo basophil activation tests (n = 185). Clinical safety and tolerability of single and repeat PVX108 doses were evaluated in a first-in-human, randomized, double-blind, placebo-controlled trial in peanut-allergic adults (46 active, 21 placebo). The repeat-dose cohort received six doses over 16 weeks with safety monitored to 21 weeks. Exploratory immunological analyses were performed at pre-dose, Week 21 and Month 18 after treatment. RESULTS: PVX108 induced negligible activation of peanut-sensitised basophils. PVX108 was safe and well tolerated in peanut-allergic adults. There were no treatment-related hypersensitivity events or AEs of clinical concern. The only events occurring more frequently in active than placebo were mild injection site reactions. Exploratory immunological analyses revealed a decrease in the ratio of ST2(+) Th2A:CCR6(+) Th17-like cells within the peanut-reactive Th pool which strengthened following treatment. CONCLUSION: This study supports the concept that PVX108 could provide a safe alternative to whole peanut immunotherapies and provides evidence of durable peanut-specific T-cell modulation. Translation of these findings to clinical efficacy in ongoing Phase 2 trials would provide important proof-of-concept for using peptides to treat food allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Voskamp, Astrid L&#xD;Khosa, Sugandhika&#xD;Phan, Tracy&#xD;DeBerg, Hannah A&#xD;Bingham, Judy&#xD;Hew, Mark&#xD;Smith, William&#xD;Abramovitch, Jodie&#xD;Rolland, Jennifer M&#xD;Moyle, Matthew&#xD;Nadeau, Kari C&#xD;Lack, Gideon&#xD;Larche, Mark&#xD;Wambre, Erik&#xD;O&apos;Hehir, Robyn E&#xD;Hickey, Pascal&#xD;Prickett, Sara R&#xD;eng&#xD;U19 AI125378-01/NH/NIH HHS/&#xD;Clinical Trial, Phase I&#xD;Randomized Controlled Trial&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):485-498. doi: 10.1111/all.15966. Epub 2023 Dec 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38112286</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15966</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2298</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2298</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Petersen, R. S.</style></author><author><style face="normal" font="default" size="100%">Bordone, L.</style></author><author><style face="normal" font="default" size="100%">Riedl, M. A.</style></author><author><style face="normal" font="default" size="100%">Tachdjian, R.</style></author><author><style face="normal" font="default" size="100%">Craig, T. J.</style></author><author><style face="normal" font="default" size="100%">Lumry, W. R.</style></author><author><style face="normal" font="default" size="100%">Manning, M. E.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Raasch, J.</style></author><author><style face="normal" font="default" size="100%">Zuraw, B. L.</style></author><author><style face="normal" font="default" size="100%">Deng, Y.</style></author><author><style face="normal" font="default" size="100%">Newman, K. B.</style></author><author><style face="normal" font="default" size="100%">Alexander, V. J.</style></author><author><style face="normal" font="default" size="100%">Lui, C.</style></author><author><style face="normal" font="default" size="100%">Schneider, E.</style></author><author><style face="normal" font="default" size="100%">Cohn, D. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.&#xD;Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.&#xD;University of California San Diego, La Jolla, California, USA.&#xD;Department of Pediatrics, University of California, Los Angeles, California, USA.&#xD;Providence Saint John&apos;s Health Center, Santa Monica, California, USA.&#xD;Department of Medicine, Pediatrics, and Biomedical Sciences, Pennsylvania State University, Hershey, Pennsylvania, USA.&#xD;Vinmec International Hospital, Times City, Hanoi, Vietnam.&#xD;Allergy and Asthma Research Associates Research Center, Dallas, Texas, USA.&#xD;Medical Research of Arizona, Scottsdale, Arizona, USA.&#xD;Department of Internal Medicine, University of Cincinnati College of Medicine, and Bernstein Clinical Research Center, Cincinnati, Ohio, USA.&#xD;Midwest Immunology Clinic, Plymouth, Minnesota, USA.&#xD;Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">724-734</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/11/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Prekallikrein</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Oligonucleotides</style></keyword><keyword><style face="normal" font="default" size="100%">AE-QoL</style></keyword><keyword><style face="normal" font="default" size="100%">HAE attack</style></keyword><keyword><style face="normal" font="default" size="100%">HAE safety</style></keyword><keyword><style face="normal" font="default" size="100%">HAE treatment</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">donidalorsen</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">ligand-conjugated antisense oligonucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">long-term prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">plasma kallikrein</style></keyword><keyword><style face="normal" font="default" size="100%">quality-of-life</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38009241</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hereditary angioedema (HAE) is a potentially fatal disease characterized by unpredictable, recurrent, often disabling swelling attacks. In a randomized phase 2 study, donidalorsen reduced HAE attack frequency and improved patient quality-of-life (ISIS721744-CS2, NCT04030598). We report the 2-year interim analysis of the phase 2 open-label extension (OLE) study (ISIS 721744-CS3, NCT04307381). METHODS: In the OLE, the on-treatment study period consisted of fixed (weeks 1-13, donidalorsen 80 mg subcutaneously every 4 weeks [Q4W]) and flexible (weeks 17-105, donidalorsen 80 mg Q4W, 80 mg every 8 weeks [Q8W], or 100 mg Q4W) dosing periods. The primary outcome was incidence and severity of treatment-emergent adverse events (TEAEs). The secondary outcomes included efficacy, pharmacodynamic, and quality-of-life assessments. RESULTS: Seventeen patients continued in the OLE study. No serious TEAEs or TEAEs leading to treatment discontinuation were reported. Mean monthly HAE attack rate was 96% lower than the study run-in baseline rate (mean, 0.06/month; 95% confidence interval [CI], 0.02-0.10; median, 0.04 on-treatment vs. mean, 2.70/month; 95% CI, 1.94-3.46; median, 2.29 at baseline). Mean monthly attack rate for Q8W dosing (n = 8) was 0.29 (range, 0.0-1.7; 95% CI, -0.21 to 0.79; median, 0.00). Mean plasma prekallikrein and D-dimer concentrations decreased, and Angioedema Quality of Life Questionnaire total score improved from baseline to week 105 with donidalorsen. CONCLUSION: The 2-year interim results of this phase 2 OLE study of donidalorsen in patients with HAE demonstrated no new safety signals; donidalorsen was well tolerated. There was durable efficacy with a 96% reduction in HAE attacks.</style></abstract><notes><style face="normal" font="default" size="100%">Petersen, Remy S&#xD;Bordone, Laura&#xD;Riedl, Marc A&#xD;Tachdjian, Raffi&#xD;Craig, Timothy J&#xD;Lumry, William R&#xD;Manning, Michael E&#xD;Bernstein, Jonathan A&#xD;Raasch, Jason&#xD;Zuraw, Bruce L&#xD;Deng, Yiwen&#xD;Newman, Kenneth B&#xD;Alexander, Veronica J&#xD;Lui, Cindy&#xD;Schneider, Eugene&#xD;Cohn, Danny M&#xD;eng&#xD;Ionis Pharmaceuticals/&#xD;Clinical Trial, Phase II&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):724-734. doi: 10.1111/all.15948. Epub 2023 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38009241</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15948</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2825</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2825</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khaitov, M.</style></author><author><style face="normal" font="default" size="100%">Nikonova, A.</style></author><author><style face="normal" font="default" size="100%">Smirnov, V.</style></author><author><style face="normal" font="default" size="100%">Shilovsky, I.</style></author><author><style face="normal" font="default" size="100%">Kofiadi, I.</style></author><author><style face="normal" font="default" size="100%">Ruzanova, E.</style></author><author><style face="normal" font="default" size="100%">Teplykh, V.</style></author><author><style face="normal" font="default" size="100%">Makarov, D.</style></author><author><style face="normal" font="default" size="100%">Vertichikh, A.</style></author><author><style face="normal" font="default" size="100%">Teplykh, S.</style></author><author><style face="normal" font="default" size="100%">Alpenidze, D.</style></author><author><style face="normal" font="default" size="100%">Muldagalieva, E.</style></author><author><style face="normal" font="default" size="100%">Simakina, E.</style></author><author><style face="normal" font="default" size="100%">Ivanushkina, T.</style></author><author><style face="normal" font="default" size="100%">Zakharov, K.</style></author><author><style face="normal" font="default" size="100%">Melnikova, L.</style></author><author><style face="normal" font="default" size="100%">Medvedev, D.</style></author><author><style face="normal" font="default" size="100%">Zuev, O.</style></author><author><style face="normal" font="default" size="100%">Kudlay, D.</style></author><author><style face="normal" font="default" size="100%">Kruchko, D.</style></author><author><style face="normal" font="default" size="100%">Berzin, I.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Skvortsova, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Research Center (NRC) Institute of Immunology Federal Medical-Biological Agency (FMBA) of Russia, Moscow, Russia.&#xD;Pirogov Russian National Research Medical University, Moscow, Russia.&#xD;I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.&#xD;Federal State Unitary Enterprise &quot;the Saint Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations&quot; of Federal Medical and Biologic Agency (FSUE SPbSRIVS FMBA of Russia), St. Petersburg, Russia.&#xD;Limited Liability Company &apos;Professorskaya Clinic&apos;, Perm, Russia.&#xD;St. Petersburg State Budgetary Healthcare Institution &quot;City Clinic No. 117&quot;, St. Petersburg, Russia.&#xD;State Autonomous Healthcare Institution &apos;Engels City Clinical Hospital No. 1&apos;, Engels, Russia.&#xD;Regional State Budgetary Healthcare Institution &quot;Clinical Hospital No. 1&quot;, Smolensk, Russia.&#xD;State Budgetary Healthcare Institution of the City of Moscow &apos;City Clinic No. 109 of the Moscow Health Department&apos;, Moscow, Russia.&#xD;Limited Liability Company &apos;Research Centre Eco-Safety&apos;, St. Petersburg, Russia.&#xD;Federal State Healthcare Institution &quot;Clinical Hospital No. 85 of the Federal Medical-Biological Agency&quot;, Moscow, Russia.&#xD;Joint Stock Company &apos;Northwestern Centre of Evidence-Based Medicine&apos;, St. Petersburg, Russia.&#xD;Federal State Budgetary Institution &apos;Federal Clinical Centre for High Medical Technologies of the Federal Medical-Biological Agency&apos;, Moscow Region, Russia.&#xD;Federal Medico-Biological Agency of Russia (FMBA Russia), Moscow, Russia.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Center for Molecular Allergology, Karl Landsteiner University for Healthcare Sciences, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phase 2-3 Trial: Prevention of the Progression to Moderate and Severe COVID-19 in SARS-CoV-2-Infected Non-Hospitalized Adults With Inhaled siRNA-Based MIR 19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2031-2042</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/03/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*RNA, Small Interfering/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">siRNA</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40028836</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: COVID-19 continues to be a major global health challenge. Inhaled siRNA-based MIR 19 has been shown to reduce the time to clinical improvement in patients hospitalized with moderate COVID-19. METHODS: We conducted an open-label, randomized, controlled multicenter phase 2b-3 trial (NCT05783206) evaluating the safety and efficacy of inhaled siR-7-EM/KK-46 (MIR 19) (5.55 mg/day) in comparison with standard care (control group) in outpatients with mild COVID-19 (N = 492 for each group). The primary endpoint was the proportion of patients who developed moderate or severe COVID-19 by the 28th day of randomization. RESULTS: Moderate or severe course of the disease was detected in 14 (2.85%) and 34 (6.91%) patients in the siR-7-EM/KK-46 (5.55 mg) and standard therapy groups, respectively (the difference in proportions was -4.107% [95% CI: -7.28% to -1.03%] (p = 0.002)). Adverse events (AE) were reported in 77 (15.65%) patients from the siR-7-EM/KK-46 (5.55 mg) group, while in the standard therapy group AEs were registered in 100 (20.33%) patients. No severe, treatment-related AEs were observed in the siR-7-EM/KK-46 group. CONCLUSIONS: siR-7-EM/KK-46, a SARS-CoV-2-specific RNAi-based drug, was well-tolerated and significantly decreased the progression to moderate/severe disease in outpatients with mild COVID-19.</style></abstract><notes><style face="normal" font="default" size="100%">Khaitov, M&#xD;Nikonova, A&#xD;Smirnov, V&#xD;Shilovsky, I&#xD;Kofiadi, I&#xD;Ruzanova, E&#xD;Teplykh, V&#xD;Makarov, D&#xD;Vertichikh, A&#xD;Teplykh, S&#xD;Alpenidze, D&#xD;Muldagalieva, E&#xD;Simakina, E&#xD;Ivanushkina, T&#xD;Zakharov, K&#xD;Melnikova, L&#xD;Medvedev, D&#xD;Zuev, O&#xD;Kudlay, D&#xD;Kruchko, D&#xD;Berzin, I&#xD;Valenta, R&#xD;Skvortsova, V&#xD;eng&#xD;Clinical Trial, Phase II&#xD;Clinical Trial, Phase III&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2031-2042. doi: 10.1111/all.16515. Epub 2025 Mar 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40028836</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16515</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>645</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">645</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sindher, S. B.</style></author><author><style face="normal" font="default" size="100%">Kumar, D.</style></author><author><style face="normal" font="default" size="100%">Cao, S.</style></author><author><style face="normal" font="default" size="100%">Purington, N.</style></author><author><style face="normal" font="default" size="100%">Long, A.</style></author><author><style face="normal" font="default" size="100%">Sampath, V.</style></author><author><style face="normal" font="default" size="100%">Zedeck, S. S.</style></author><author><style face="normal" font="default" size="100%">Woch, M. A.</style></author><author><style face="normal" font="default" size="100%">Garcia-Lloret, M.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.&#xD;Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA.&#xD;Quantitative Sciences Unit, Stanford University, Stanford, California, USA.&#xD;University of California, Los Angeles, California, USA.&#xD;Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Los Angeles, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phase 2, randomized multi oral immunotherapy with omalizumab &apos;real life&apos; study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1873-1884</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/01/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4</style></keyword><keyword><style face="normal" font="default" size="100%">maintenance dose</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35014049</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Oral immunotherapy (OIT) is frequently discontinued due to adverse events (AEs) and current data suggests that lowering OIT doses can minimize severity and frequency of AEs. However, the minimum daily dose that can enable desensitization and induce immune responses in multi-food OIT (mOIT) is unknown. METHODS: Participants aged 2-25 years with multi-food allergies were pretreated with fixed-dose omalizumab (150 mg, 3 doses, every 4 weeks), and randomized 1:1 to receive mOIT to a total maintenance dose of either 300 or 1200 mg total protein, (total dose includes at least two and up to a max of five allergens) and then transitioned to real-food protein equivalents after 18 weeks of treatment. The primary endpoint was the proportion of subjects with increases in IgG4/IgE ratio of at least 2 allergens by &gt;/=25% from baseline after 18 weeks of therapy. The primary efficacy and safety analyses were done in the intention-to-treat population. RESULTS: Sixty participants were enrolled across two sites. Seventy percent of participants in both arms showed changes in sIgG4/sIgE ratio in at least 2 allergens with no difference between the treatment groups (OR [95% CI] = 1.00 [0.29, 3.49]). Overall, there were no differences in AEs between the 300 and 1200 mg groups (19% vs. 17%, p = .69), respectively. CONCLUSIONS: Our data suggest that plasma marker changes are induced early, even at a total protein dose of 300 mg inclusive of multiple allergens when mOIT is combined with fixed-dose omalizumab. Identification of optimal mOIT dosing with adjunct omalizumab is needed for the long-term success of OIT. TRIAL REGISTRATION: ClinicalTrials.gov (NCT03181009).</style></abstract><notes><style face="normal" font="default" size="100%">Sindher, Sayantani B&#xD;Kumar, Divya&#xD;Cao, Shu&#xD;Purington, Natasha&#xD;Long, Andrew&#xD;Sampath, Vanitha&#xD;Zedeck, Stacey S&#xD;Woch, Margaret A&#xD;Garcia-Lloret, Maria&#xD;Chinthrajah, Rebecca Sharon&#xD;eng&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;R01 AI140134/AI/NIAID NIH HHS/&#xD;UM1 AI130839/AI/NIAID NIH HHS/&#xD;Clinical Trial, Phase II&#xD;Randomized Controlled Trial&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1873-1884. doi: 10.1111/all.15217. Epub 2022 Jan 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35014049</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15217</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>835</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">835</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Renert-Yuval, Y.</style></author><author><style face="normal" font="default" size="100%">Bares, J.</style></author><author><style face="normal" font="default" size="100%">Chima, M.</style></author><author><style face="normal" font="default" size="100%">Hawkes, J. E.</style></author><author><style face="normal" font="default" size="100%">Gilleaudeau, P.</style></author><author><style face="normal" font="default" size="100%">Sullivan-Whalen, M.</style></author><author><style face="normal" font="default" size="100%">Singer, G. K.</style></author><author><style face="normal" font="default" size="100%">Garcet, S.</style></author><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Lebwohl, M. G.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Laboratory for Investigative Dermatology, Rockefeller University, New York, NY, USA.&#xD;Department of Dermatology, UC Davis Medical Center, University of California Davis Health System, Sacramento, CA, USA.&#xD;Department of Biomedical Engineering, University of Mississippi, Oxford, MS, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phase 2a randomized clinical trial of dupilumab (anti-IL-4Ralpha) for alopecia areata patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">897-906</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/08/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Alopecia Areata/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">Th2</style></keyword><keyword><style face="normal" font="default" size="100%">alopecia areata</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34460948</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Treatments for alopecia areata (AA) patients with extensive scalp hair loss are limited, and recent evidence supports a role for type 2 T-cell (Th2)-immune response in AA. Dupilumab, a monoclonal antibody inhibiting Th2 signaling, approved for type 2 diseases including atopic dermatitis, was evaluated in AA patients. METHODS: Alopecia areata patients with and without concomitant atopic dermatitis were randomized 2:1 to receive weekly subcutaneous dupilumab (300 mg) or placebo for 24 weeks, followed by another 24-week dupilumab open-label phase. The primary outcome was change from baseline in the Severity of Alopecia Tool (SALT) score at week 24; secondary outcomes included a range of measures of hair regrowth. RESULTS: Forty and 20 patients were assigned to the dupilumab and placebo arms, respectively. At week 24, disease worsening was documented in the placebo arm, with a least-squares mean change in the SALT score of -6.5 (95% confidence-interval [CI], -10.4 to -2.6), versus a change of 2.2 (95% CI, -0.6 to 4.94) in the dupilumab arm (p &lt; .05). After 48 weeks of dupilumab treatment, 32.5%, 22.5% and 15% of patients achieved SALT(30) /SALT(50) /SALT(75) improvement, respectively, while in patients with baseline IgE &gt;/= 200 IU/ml response rates increased to 53.8%, 46.2%, and 38.5%, respectively. Moreover, baseline IgE predicts treatment response with 83% accuracy. No new safety signals were detected. CONCLUSIONS: This hypothesis-driven trial is the first to indicate the possible pathogenic role of the Th2 axis and Th2 targeting in AA patients. Patient selection based on baseline serum IgE levels may improve treatment results (Clinicaltrials.gov number, NCT03359356).</style></abstract><notes><style face="normal" font="default" size="100%">Guttman-Yassky, Emma&#xD;Renert-Yuval, Yael&#xD;Bares, Jennifer&#xD;Chima, Margot&#xD;Hawkes, Jason E&#xD;Gilleaudeau, Patricia&#xD;Sullivan-Whalen, Mary&#xD;Singer, Giselle K&#xD;Garcet, Sandra&#xD;Pavel, Ana B&#xD;Lebwohl, Mark G&#xD;Krueger, James G&#xD;eng&#xD;P30 AR079200/AR/NIAMS NIH HHS/&#xD;U01 AI152036/AI/NIAID NIH HHS/&#xD;UL1 TR001866/TR/NCATS NIH HHS/&#xD;Clinical Trial, Phase II&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):897-906. doi: 10.1111/all.15071. Epub 2021 Sep 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34460948</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9997752</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15071</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2844</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2844</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pizzarello, C. R.</style></author><author><style face="normal" font="default" size="100%">Jackson, C. M.</style></author><author><style face="normal" font="default" size="100%">Herman, K.</style></author><author><style face="normal" font="default" size="100%">Seppo, A. E.</style></author><author><style face="normal" font="default" size="100%">Rebhahn, J.</style></author><author><style face="normal" font="default" size="100%">Scherzi, T.</style></author><author><style face="normal" font="default" size="100%">Berin, M. C.</style></author><author><style face="normal" font="default" size="100%">Looney, R. J.</style></author><author><style face="normal" font="default" size="100%">Mosmann, T. R.</style></author><author><style face="normal" font="default" size="100%">Jarvinen, K. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Center for Food Allergy, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Golisano Children&apos;s Hospital, Rochester, New York, USA.&#xD;Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.&#xD;David H. Smith Center for Vaccine Biology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.&#xD;Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Division of Allergy, Immunology, and Rheumatology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Phenotypically Distinct Human Th2 Cell Subpopulation Is Associated With Development of Allergic Disorders in Infancy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">949-964</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/02/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunophenotyping</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocyte Subsets/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 cells</style></keyword><keyword><style face="normal" font="default" size="100%">Tregs</style></keyword><keyword><style face="normal" font="default" size="100%">development</style></keyword><keyword><style face="normal" font="default" size="100%">farming lifestyle</style></keyword><keyword><style face="normal" font="default" size="100%">infant immunity</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, DBV Technologies, consulting fees from Jovie, Harmony/Milk Care Co</style></keyword><keyword><style face="normal" font="default" size="100%">and royalties from UpToDate during conduct of the study. The rest of the authors</style></keyword><keyword><style face="normal" font="default" size="100%">report no potential conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39899007</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Little is known about the ontogeny of T cell immunity during infancy in farming and urban lifestyles due to the lack of immunophenotyping in such birth cohorts. METHODS: Two birth cohorts (farming and urban) at differing risks and rates of allergic diseases were compared. Blood mononuclear cells were collected from infants at birth, and 6 and 12 months of age. Full spectrum flow cytometry, followed by traditional gating and the Scalable Weighted Iterative Flow-clustering Technique (SWIFT) high-dimensional analysis, were used to identify cell populations that differed between farming and urban infants. Additionally, single-cell RNAseq and multiplex cytokine assays were used to assess the function of cell populations of interest. RESULTS: Several regulatory T cell (Treg) subpopulations were elevated in farming lifestyles and in non-atopic infants. A unique effector memory CD25(+)CD127(+)CD161(-)CD49d(+)CCR4(+)CRTH2(+) Th2 population was elevated at 6 months in urban infants and in those who developed atopic dermatitis and/or food allergy and allergic sensitization. Although this population shared Th2 and IL-9 skewing with Th2A cells, the population uniquely failed to express CD161, produced more IL-2 and TNF-alpha, and upregulated the differentially expressed genes (DEGs), FOXP3 and the cytokine inducible SH2-containing protein gene (CISH) relative to Th2A cells. This population has been termed Th2B cells. CONCLUSION: We describe a unique effector memory Th2 population elevated in urban high-risk infants, potentially implicated in the development of allergic disease.</style></abstract><notes><style face="normal" font="default" size="100%">Pizzarello, Catherine R&#xD;Jackson, Courtney M&#xD;Herman, Katherine&#xD;Seppo, Antti E&#xD;Rebhahn, Jonathan&#xD;Scherzi, Tyler&#xD;Berin, M Cecilia&#xD;Looney, R John&#xD;Mosmann, Tim R&#xD;Jarvinen, Kirsi M&#xD;eng&#xD;U01 AI131344/AI/NIAID NIH HHS/&#xD;U19 AI175113/AI/NIAID NIH HHS/&#xD;National Institute of Allergy and Infectious Diseases/&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):949-964. doi: 10.1111/all.16489. Epub 2025 Feb 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39899007</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11971024</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16489</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>809</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">809</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maurer, D. J.</style></author><author><style face="normal" font="default" size="100%">Liu, C.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Stanic, B.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Finotto, S.</style></author><author><style face="normal" font="default" size="100%">Gao, Y. D.</style></author><author><style face="normal" font="default" size="100%">Graser, A.</style></author><author><style face="normal" font="default" size="100%">Jartti, T.</style></author><author><style face="normal" font="default" size="100%">Kistler, W.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M.</style></author><author><style face="normal" font="default" size="100%">Lukkarinen, H.</style></author><author><style face="normal" font="default" size="100%">Pasioti, M.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Villiger, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Zhang, N.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Swiss Research Institute for Sports Medicine (SRISM), Davos, Switzerland.&#xD;Department of Sports Medicine, Davos Hospital, Davos, Switzerland.&#xD;Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Upper Airway Research Laboratory, Ghent University Hospital, Ghent, Belgium.&#xD;Department of Molecular Pneumology, Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Universitatsklinikum Erlangen, Erlangen, Germany.&#xD;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Department of Pediatrics and Adolescent Medicine, University of Turku and Turku University Hospital, Turku, Finland.&#xD;PEDEGO Research Unit, Medical Research Center, University of Oulu, Oulu, Finland.&#xD;Department of Pediatrics and Adolescent Medicine, Oulu University Hospital, Oulu, Finland.&#xD;Department of Immunology, Rheumatology and Allergy, Central University Hospital, Lodz, Poland.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, University of Manchester, Manchester, UK.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Physical activity in asthma control and its immune modulatory effect in asthmatic preschoolers</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1216-1230</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/09/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">*Leukocytes, Mononuclear/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">PreDicta</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">immune modulation</style></keyword><keyword><style face="normal" font="default" size="100%">physical activity</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. PX reports personal fees from Uriach, Novartis, Nestle, and Nutricia</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. MP reports grants from University of Athens during</style></keyword><keyword><style face="normal" font="default" size="100%">the conduct of the study and personal fees from Aimmune Therapeutics, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Hellenic Society of Allergy and Clinical Immunology outside the submitted work.</style></keyword><keyword><style face="normal" font="default" size="100%">NP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA,</style></keyword><keyword><style face="normal" font="default" size="100%">SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, grants from Gerolymatos International SA, Capricare outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. CA reports grants form Allergopharma, Idorsia, Swiss National</style></keyword><keyword><style face="normal" font="default" size="100%">Science Foundation, Christine Kuhne-Center for Allergy Research and Education,</style></keyword><keyword><style face="normal" font="default" size="100%">European Commission&apos;s Horison&apos;s 2020 Framework Programme, Cure, Novartis Research</style></keyword><keyword><style face="normal" font="default" size="100%">Institutes, Astra Zeneca, SciBase advisory role and is on the advisory board for</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron, GSK, Novartis. CB received honoraria from ALK, Astra-Zeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, Novartis, and Sanofi outside of this work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34547110</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The impact of physical activity on immune response is a hot topic in exercise immunology, but studies involving asthmatic children are scarce. Our aims were to examine whether there were any differences in the level of physical activity and daily TV attendance, to assess its role on asthma control and immune responses to various immune stimulants. METHODS: Weekly physical activity and daily television attendance were obtained from questionnaires at inclusion of the PreDicta study. PBMC cultures were stimulated with phytohemagglutinin (PHA), R848, poly I:C, and zymosan. A panel of cytokines was measured and quantified in cell culture supernatants using luminometric multiplex immunofluorescence beads-based assay. RESULTS: Asthmatic preschoolers showed significantly more TV attendance than their healthy peers (58.6% vs. 41.5% 1-3 h daily and only 25.7% vs. 47.2% &lt;/=1 h daily) and poor asthma control was associated with less frequent physical activity (PA) (75% no or occasional activity in uncontrolled vs. 20% in controlled asthma; 25% &gt;/=3 times weekly vs. 62%). Asthmatics with increased PA exhibited elevated cytokine levels in response to polyclonal stimulants, suggesting a readiness of circulating immune cells for type 1, 2, and 17 cytokine release compared to subjects with low PA and high TV attendance. This may also represent a proinflammatory state in high PA asthmatic children. Low physical activity and high TV attendance were associated with a decrease in proinflammatory cytokines. Proinflammatory cytokines were correlating with each other in in vitro immune responses of asthmatic children, but not healthy controls, this correlation was more pronounced in children with sedentary behavior. CONCLUSION: Asthmatic children show more sedentary behavior than healthy subjects, while poor asthma control is associated with a substantial decrease in physical activity. Our results suggest that asthmatic children may profit from regular exercise, as elevated cytokine levels in stimulated conditions indicate an immune system prepared for responding strongly in case of different types of infections. However, it has to be considered that a hyperinflammatory state in high PA may not be beneficial in asthmatic children.</style></abstract><notes><style face="normal" font="default" size="100%">Maurer, Debbie J&#xD;Liu, Chengyao&#xD;Xepapadaki, Paraskevi&#xD;Stanic, Barbara&#xD;Bachert, Claus&#xD;Finotto, Susetta&#xD;Gao, Ya-Dong&#xD;Graser, Anna&#xD;Jartti, Tuomas&#xD;Kistler, Walter&#xD;Kowalski, Marek&#xD;Lukkarinen, Heikki&#xD;Pasioti, Maria&#xD;Tan, Ge&#xD;Villiger, Michael&#xD;Zhang, Luo&#xD;Zhang, Nan&#xD;Akdis, Mubeccel&#xD;Papadopoulos, Nikolaos G&#xD;Akdis, Cezmi A&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1216-1230. doi: 10.1111/all.15105. Epub 2021 Oct 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34547110</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9291774</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15105</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>515</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">515</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kurowski, M.</style></author><author><style face="normal" font="default" size="100%">Seys, S.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Delgado, L.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Rukhadze, M.</style></author><author><style face="normal" font="default" size="100%">Couto, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland.&#xD;Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.&#xD;Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;National Heart and Lung Institute (NHLI), Imperial College London, London, UK.&#xD;Department of Medical Sciences and Public Health &quot;M. Aresu&quot;, University of Cagliari, Cagliari, Italy.&#xD;Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Servico de Imunoalergologia, Centro Hospitalar de Sao Joao E.P.E, Porto, Portugal.&#xD;Department of Respiratory Medicine &amp; Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.&#xD;Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.&#xD;Epidemiology Research Unit- Instituto de Saude Publica, University of Porto, Porto, Portugal.&#xD;Allergy &amp; Immunology Centre, Tbilisi, Georgia.&#xD;Teaching University Geomedi LLC, Tbilisi, Georgia.&#xD;Allergy Unit, Hospital CUF Descobertas, Lisbon, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Physical exercise, immune response, and susceptibility to infections-current knowledge and growing research areas</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2653-2664</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/04/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Cellular</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Tract Infections/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">infections</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">sports</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35485959</style></accession-num><abstract><style face="normal" font="default" size="100%">This review presents state-of-the-art knowledge and identifies knowledge gaps for future research in the area of exercise-associated modifications of infection susceptibility. Regular moderate-intensity exercise is believed to have beneficial effects on immune health through lowering inflammation intensity and reducing susceptibility to respiratory infections. However, strenuous exercise, as performed by professional athletes, may promote infection: in about half of athletes presenting respiratory symptoms, no causative pathogen can be identified. Acute bouts of exercise enhance the release of pro-inflammatory mediators, which may induce infection-like respiratory symptoms. Relatively few studies have assessed the influence of regularly repeated exercise on the immune response and systemic inflammation compared to the effects of acute exercise. Additionally, ambient and environmental conditions may modify the systemic inflammatory response and infection susceptibility, particularly in outdoor athletes. Both acute and chronic regular exercise influence humoral and cellular immune response mechanisms, resulting in decreased specific and non-specific response in competitive athletes. The most promising areas of further research in exercise immunology include detailed immunological characterization of infection-prone and infection-resistant athletes, examining the efficacy of nutritional and pharmaceutical interventions as countermeasures to infection symptoms, and determining the influence of various exercise loads on susceptibility to infections with respiratory viruses, including SARS-CoV-2. By establishing a uniform definition of an &quot;elite athlete,&quot; it will be possible to make a comparable and straightforward interpretation of data from different studies and settings.</style></abstract><notes><style face="normal" font="default" size="100%">Kurowski, Marcin&#xD;Seys, Sven&#xD;Bonini, Matteo&#xD;Del Giacco, Stefano&#xD;Delgado, Luis&#xD;Diamant, Zuzana&#xD;Kowalski, Marek L&#xD;Moreira, Andre&#xD;Rukhadze, Maia&#xD;Couto, Mariana&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2653-2664. doi: 10.1111/all.15328. Epub 2022 May 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35485959</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15328</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3015</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3015</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, C.</style></author><author><style face="normal" font="default" size="100%">Yi, W.</style></author><author><style face="normal" font="default" size="100%">Shao, Z.</style></author><author><style face="normal" font="default" size="100%">Yao, B.</style></author><author><style face="normal" font="default" size="100%">Tian, G.</style></author><author><style face="normal" font="default" size="100%">Li, F.</style></author><author><style face="normal" font="default" size="100%">Du, X.</style></author><author><style face="normal" font="default" size="100%">Hu, Y.</style></author><author><style face="normal" font="default" size="100%">Guo, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, T.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Chen, Z.</style></author><author><style face="normal" font="default" size="100%">Ju, Z.</style></author><author><style face="normal" font="default" size="100%">Ying, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.&#xD;Department of Anatomy, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.&#xD;Department of Pharmacy, Center for Regeneration and Aging Medicine, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, Zhejiang, China.&#xD;Key Laboratory of Regenerative Medicine of Ministry of Education, Institute of Aging and Regenerative Medicine, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China.&#xD;Zhejiang-Denmark Joint Laboratory of Regeneration and Aging Medicine, Yiwu, Zhejiang, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Physiological Level of Eosinophils Is Essential for the Regeneration and Homeostasis of Murine Hematopoietic Stem Cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">hematopoietic stem cell</style></keyword><keyword><style face="normal" font="default" size="100%">homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">reconstitution</style></keyword><keyword><style face="normal" font="default" size="100%">regeneration</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40879006</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophils play a crucial role in host defense and immunity, yet their regulatory functions within the hematopoietic homeostasis remain poorly understood. Our prior investigations revealed that pathologically elevated eosinophil levels in asthma not only disrupt bone marrow hematopoietic stem cell (HSC) quiescence but also establish a self-reinforcing cycle of eosinophil lineage commitment. Here, we further investigate the critical role of physiologically steady-state levels of eosinophils in maintaining HSC functions. METHODS: Using eosinophil lineage-specific null (Eos-null) mice, we established models of chemotherapy-induced HSC regeneration and competitive bone marrow transplantation (cBMT) assay to evaluate the impact of eosinophil depletion on HSC regeneration and function. In vitro colony forming assay assessed HSC reconstitute capability, while bone marrow chimeric mice were established with wild-type (WT) and eosinophil-related transgenic mice to further elucidate the role of physiological levels of eosinophils. RNA-seq and cytokine array analyses were utilized to investigate the potential protective mechanisms of eosinophils. RESULTS: Compared to WT controls, Eos-null mice exhibited significantly impaired HSC regeneration, characterized by a diminished response to 5-fluorouracil (5-FU) and carboplatin treatment. Both long-term HSCs (LT-HSCs) and lineage(-)Sca-1(+)c-Kit(+) (LSK) demonstrated compromised reconstitution capacity in vivo and in vitro. HSCs from Eos-null mice demonstrated elevated apoptosis under 5-FU treatment, potentially due to the absence of eosinophil-derived protective factors. Conversely, both chimeric mice and eosinophil incorporation within bone marrow transplantation systems significantly disrupted HSC homeostasis and function. CONCLUSION: Physiological eosinophil level is essential for maintaining HSC regeneration, reconstitution capacity, and homeostasis.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Chao&#xD;Yi, Weiwei&#xD;Shao, Zhehua&#xD;Yao, Bingpeng&#xD;Tian, Guoxiong&#xD;Li, Fei&#xD;Du, Xufei&#xD;Hu, Yangmingzi&#xD;Guo, Yanqi&#xD;Wu, Tao&#xD;Li, Wen&#xD;Chen, Zhihua&#xD;Ju, Zhenyu&#xD;Ying, Songmin&#xD;eng&#xD;82170020/National Natural Science Foundation of China/&#xD;82470022/National Natural Science Foundation of China/&#xD;82225001/National Natural Science Foundation of China/&#xD;82430002/National Natural Science Foundation of China/&#xD;82300026/National Natural Science Foundation of China/&#xD;GZNL2024A02002/Major Project of Guangzhou National Laboratory/&#xD;Denmark&#xD;Allergy. 2025 Aug 29. doi: 10.1111/all.70021.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40879006</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70021</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2988</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2988</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, P.</style></author><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Chen, L.</style></author><author><style face="normal" font="default" size="100%">Huang, X.</style></author><author><style face="normal" font="default" size="100%">Lin, Z.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Qi, C.</style></author><author><style face="normal" font="default" size="100%">Xu, T.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Qi, M.</style></author><author><style face="normal" font="default" size="100%">Cheng, B.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Hu, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Plastic and Aesthetic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China.&#xD;Department of Plastic Surgery of the Third People&apos;s Hospital of Henan Province, Zhengzhou Key Laboratory of Tissue Regeneration and Wound Repair, Zhengzhou, Henan Province, China.&#xD;Department of Dermatology, Shenzhen People&apos;s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong Province, China.&#xD;Department of Burns and Plastic Surgery, Shenzhen Hospital, Southern Medical University, Guangzhou, China.&#xD;Department of Burn and Plastic Surgery, General Hospital of Southern Theater Command, PLA, Guangzhou, China.&#xD;Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phytic Acid Improves the Skin Barrier Function in Murine Models of Atopic Dermatitis Through Skin Microbiota-Derived Indole-3-Propionic Acid</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2258-2270</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/metabolism/drug therapy/etiology/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/microbiology/metabolism/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Phytic Acid/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Indoles/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Propionates/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">aryl hydrocarbon receptor</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">phytic acid</style></keyword><keyword><style face="normal" font="default" size="100%">skin microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">tryptophan metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40631934</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Barrier dysfunction and dysbiosis of the skin microbiota are two of the key factors in the pathogenesis of atopic dermatitis (AD). Phytic acid (PA) is a common constituent of high-fiber foods, whereas its role in AD remains unelucidated. The aim of this study was to investigate the effects of PA-altered skin microbial metabolites on AD and to explore its specific mechanism. METHODS: MC903-induced AD mouse models were used to explore the role of PA on AD by TEWL, immunofluorescence, and qPCR analysis. Using cohouse experiments with feces removal to verify the role of skin microbiota. The specific mechanism of effect of PA was explored through 16S, RNA-seq, LC-MS/MS, luciferase assay, and in vivo experiments with siRNA. RESULTS: Diet-derived PA significantly improved the barrier function of MC903-induced AD, whether administered by gavage or topically. Topical application of PA reshaped the skin microbiota in AD mice and increased tryptophan-metabolizing bacteria, especially Staphylococcus epidermidis. Furthermore, PA upregulated skin microbiota-derived indole derivatives, especially indole-3-propionic acid (IPA), thus activating AHR to promote the transcription of KRT10, which further ameliorated AD. CONCLUSION: Our findings showed that diet-derived PA improved barrier function in AD via altering skin microbiota-derived metabolites, highlighting PA as a novel therapeutic strategy for the treatment of AD.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Piao&#xD;Yang, Lan&#xD;Chen, Lu&#xD;Huang, Xinyu&#xD;Lin, Zhen&#xD;Li, Yue&#xD;Qi, Caiyu&#xD;Xu, Tianren&#xD;Zhang, Jianglin&#xD;Qi, Min&#xD;Cheng, Biao&#xD;Wang, Junjie&#xD;Hu, Zhiqi&#xD;Wang, Gaofeng&#xD;eng&#xD;2023 M741582/China Postdoctoral Science Foundation/&#xD;GZC20231077/Postdoctoral Fellowship Program of China Postdoctoral Science Foundation/&#xD;National Natural Science Foundation of China/&#xD;231111312500/Henan 2023 Second Batch of Science and Technology Development Program Key Research and Development Projects/&#xD;2022 J003/Nanfang Hospital Distinguished Young Cultivation Program/&#xD;High Level Introduction of Talent Research Startup Fund Southern Medical University/&#xD;2023A1515012227/Natural Science Foundation of Guangdong Province/&#xD;Foundation of Guangzhou Municipal Science and Technology Bureau/&#xD;SL2022A04J02027/Basic Research Program-Basic and Applied Basic Research Project/&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2258-2270. doi: 10.1111/all.16644. Epub 2025 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40631934</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16644</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1317</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1317</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pranger, C. L.</style></author><author><style face="normal" font="default" size="100%">Fazekas-Singer, J.</style></author><author><style face="normal" font="default" size="100%">Kohler, V. K.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author><author><style face="normal" font="default" size="100%">Karagiannis, S. N.</style></author><author><style face="normal" font="default" size="100%">Zenarruzabeitia, O.</style></author><author><style face="normal" font="default" size="100%">Borrego, F.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Centre of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Institute of Science and Technology Austria, Klosterneuburg, Austria.&#xD;Allergy Division, Pediatric Hospital Bambino Gesu IRCCS, Roma, Italy.&#xD;St. John&apos;s Institute of Dermatology, School of Basic &amp; Medical Biosciences, King&apos;s College London, Guy&apos;s Hospital, London, UK.&#xD;Breast Cancer Now Research Unit, School of Cancer &amp; Pharmaceutical Sciences, King&apos;s College London, London, UK.&#xD;Immunopathology Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.&#xD;Ikerbasque, Basque Foundation for Science, Bilbao, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">PIPE-cloned human IgE and IgG4 antibodies: New tools for investigating cow&apos;s milk allergy and tolerance</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1553-1556</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/09/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Milk Proteins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32990982</style></accession-num><notes><style face="normal" font="default" size="100%">Pranger, Christina L&#xD;Fazekas-Singer, Judit&#xD;Kohler, Verena K&#xD;Pali-Scholl, Isabella&#xD;Fiocchi, Alessandro&#xD;Karagiannis, Sophia N&#xD;Zenarruzabeitia, Olatz&#xD;Borrego, Francisco&#xD;Jensen-Jarolim, Erika&#xD;eng&#xD;C604/A25135/Cancer Research UK King&apos;s Health Partners Centre at King&apos;s College London/&#xD;C10355/A15587/CRUK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre/&#xD;C30122/A11527/CRUK_/Cancer Research UK/United Kingdom&#xD;C30122/A15774/CRUK_/Cancer Research UK/United Kingdom&#xD;MR/L023091/1/MRC_/Medical Research Council/United Kingdom&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1553-1556. doi: 10.1111/all.14604. Epub 2020 Oct 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32990982</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8247298 business partner of Bencard Allergie GmbH, Germany as well as AllergyTherapeutics Ltd., UK, but has no COI in relation to the presented work. EJJ also holds patents in lipocalins including BLG for allergen immunotherapy. SNK is founder and shareholder of Epsilogen Ltd. and holds patents on IgE antibodies for cancer therapy. AF is conducting research supported by Danone SA and Hipp GmbH. He has been in the advisory boards of Abbott SA and Hipp GmbH over the last two years. The other authors have no potential conflicts of interest to disclose.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14604</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>57</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">57</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giang, N.</style></author><author><style face="normal" font="default" size="100%">Villeneuve, T.</style></author><author><style face="normal" font="default" size="100%">Maire, K.</style></author><author><style face="normal" font="default" size="100%">Mejia, J. E.</style></author><author><style face="normal" font="default" size="100%">Guery, J. C.</style></author><author><style face="normal" font="default" size="100%">Pelletier, L.</style></author><author><style face="normal" font="default" size="100%">Savignac, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 - Centre National de la Recherche Scientifique UMR5051, University Paul Sabatier Toulouse III, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">PKCalpha interacts with Ca(v) 1.3 calcium channels to promote the Ca(v) 1.2/Ca(v) 1.3 duo tuning Th2 functions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">879-882</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/12/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Calcium Channels</style></keyword><keyword><style face="normal" font="default" size="100%">*Protein Kinase C-alpha</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36478369</style></accession-num><notes><style face="normal" font="default" size="100%">Giang, Nicolas&#xD;Villeneuve, Thomas&#xD;Maire, Kilian&#xD;Mejia, Jose Enrique&#xD;Guery, Jean-Charles&#xD;Pelletier, Lucette&#xD;Savignac, Magali&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):879-882. doi: 10.1111/all.15611. Epub 2022 Dec 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36478369</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15611</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1429</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1429</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Creticos, P. S.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Hellings, P.</style></author><author><style face="normal" font="default" size="100%">Kaul, S.</style></author><author><style face="normal" font="default" size="100%">Kleine-Tebbe, J.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Jacobsen, L.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Rief, W.</style></author><author><style face="normal" font="default" size="100%">Scadding, G. K.</style></author><author><style face="normal" font="default" size="100%">Schedlowski, M.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Sturm, G.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Vidal, C.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author><author><style face="normal" font="default" size="100%">Wedi, B.</style></author><author><style face="normal" font="default" size="100%">Gerth van Wijk, R.</style></author><author><style face="normal" font="default" size="100%">Frew, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Transylvania University, Brasov, Romania.&#xD;Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Berlin Institute of Health, Allergy-Centre-Charite, Berlin, Germany.&#xD;Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.&#xD;MACVIA-France, Montpellier, France.&#xD;University Hospital Montpellier, Montpellier, France.&#xD;Division of Allergy &amp; Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.&#xD;Creticos Research Group, Crownsville, MD, USA.&#xD;Department of Airway Diseases, Exhalomics, Hopital Foch, Universite Paris-Saclay, Suresnes, France.&#xD;Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Otorhinolaryngology, University Hospitals of Leuven, Leuven, Belgium.&#xD;Department of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Neuroscience, University of Ghent, Ghent, Belgium.&#xD;Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.&#xD;Allergy &amp; Asthma Center Westend, Outpatient Clinic and Clinical Research Center, Berlin, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;ALC, Allergy Learning and Consulting, Copenhagen, Denmark.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;All-Med Medical Research Institute, Wroclaw, Poland.&#xD;Food Allergy Referral Centre, Padua University Hospital Padua, Padua, Italy.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Department of Clinical Psychology and Psychotherapy, Philipps-University of Marburg, Marburg, Germany.&#xD;RNTNE Hospital, University College London Hospitals, London, UK.&#xD;Institute of Medical Psychology and Behavioral Immunobiology, University Clinic Essen, Essen, Germany.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Biomedical Research Centre, Imperial College London, London, UK.&#xD;Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.&#xD;Departments of Experimental Immunology and of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.&#xD;Department of Allergy and Faculty of Medicine, University of Santiago de Compostela, Santiago, Spain.&#xD;Department of Dermatology and Allergy, Hannover Medical School, Comprehensive Allergy Center, Hannover, Germany.&#xD;Section of Allergology, Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands.&#xD;Department of Respiratory Medicine, Royal Sussex County Hospital, University of Sussex and University of Brighton, Brighton, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Placebo effects in allergen immunotherapy-An EAACI Task Force Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">629-647</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/04/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Advisory Committees</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Placebo Effect</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Position Paper</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trials</style></keyword><keyword><style face="normal" font="default" size="100%">methods</style></keyword><keyword><style face="normal" font="default" size="100%">placebo effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32324902</style></accession-num><abstract><style face="normal" font="default" size="100%">The placebo (Latin &quot;I will please&quot;) effect commonly occurs in clinical trials. The psychological and physiological factors associated with patients&apos; expectations about a treatment&apos;s positive and negative effects have yet to be well characterized, although a functional prefrontal cortex and intense bidirectional communication between the central nervous system and the immune system appear to be prerequisites for a placebo effect. The use of placebo raises certain ethical issues, especially if patients in a placebo group are denied an effective treatment for a long period of time. The placebo effect appears to be relatively large (up to 77%, relative to pretreatment scores) in controlled clinical trials of allergen immunotherapy (AIT), such as the pivotal, double-blind, placebo-controlled (DBPC) randomized clinical trials currently required by regulatory authorities worldwide. The European Academy of Allergy and Clinical Immunology (EAACI) therefore initiated a Task Force, in order to better understand the placebo effect in AIT and its specific role in comorbidities, blinding issues, adherence, measurement time points, variability and the natural course of the disease. In this Position Paper, the EAACI Task Force highlights several important topics regarding the placebo effect in AIT such as a) regulatory aspects, b) neuroimmunological and psychological mechanisms, c) placebo effect sizes in AIT trials, d) methodological limitations in AIT trial design and e) potential solutions in future AIT trial design. In conclusion, this Position Paper aims to examine the methodological problem of placebo in AIT from different aspects and also to highlight unmet needs and possible solutions for future trials.</style></abstract><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Agache, Ioana&#xD;Bergmann, Karl-Christian&#xD;Bindslev-Jensen, Carsten&#xD;Bousquet, Jean&#xD;Creticos, Peter S&#xD;Devillier, Philippe&#xD;Durham, Stephen R&#xD;Hellings, Peter&#xD;Kaul, Susanne&#xD;Kleine-Tebbe, Jorg&#xD;Klimek, Ludger&#xD;Jacobsen, Lars&#xD;Jutel, Marek&#xD;Muraro, Antonella&#xD;Papadopoulos, Nikolaos G&#xD;Rief, Winfried&#xD;Scadding, Glenis K&#xD;Schedlowski, Manfred&#xD;Shamji, Mohamed H&#xD;Sturm, Gunter&#xD;van Ree, Ronald&#xD;Vidal, Carmen&#xD;Vieths, Stefan&#xD;Wedi, Bettina&#xD;Gerth van Wijk, Roy&#xD;Frew, Anthony J&#xD;eng&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):629-647. doi: 10.1111/all.14331.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32324902</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14331</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2284</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2284</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tome-Amat, J.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Klein, Z.</style></author><author><style face="normal" font="default" size="100%">Pazos-Castro, D.</style></author><author><style face="normal" font="default" size="100%">Resuela-Gonzalez, J. L.</style></author><author><style face="normal" font="default" size="100%">Vilchez-Pinto, G.</style></author><author><style face="normal" font="default" size="100%">Berreiros-Hortala, H.</style></author><author><style face="normal" font="default" size="100%">Palacio-Garcia, L.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Bravo, S.</style></author><author><style face="normal" font="default" size="100%">Esteban, V.</style></author><author><style face="normal" font="default" size="100%">Diaz-Perales, A.</style></author><author><style face="normal" font="default" size="100%">Garrido-Arandia, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centro de Biotecnologia y Genomica de Plantas (CBGP), Universidad Politecnica de Madrid (UPM)- Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria (INIA/CSIC), Madrid, Spain.&#xD;Departamento de Biotecnologia-Biologia Vegetal, Escuela Tecnica Superior de Ingenieria Agronomica, Alimentaria y de Biosistemas, Universidad Politecnica de Madrid (UPM), Madrid, Spain.&#xD;Department of Allergy and Immunology, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Plant lipid transfer proteins&apos; ligand enhances allergic sensitization to non-related proteins in murine models</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">246-249</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/09/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Ligands</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Lipids</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37776066</style></accession-num><notes><style face="normal" font="default" size="100%">Tome-Amat, Jaime&#xD;Gonzalez-Klein, Zulema&#xD;Pazos-Castro, Diego&#xD;Resuela-Gonzalez, Jose Luis&#xD;Vilchez-Pinto, Gonzalo&#xD;Berreiros-Hortala, Helena&#xD;Palacio-Garcia, Lucia&#xD;Fernandez-Bravo, Sergio&#xD;Esteban, Vanesa&#xD;Diaz-Perales, Araceli&#xD;Garrido-Arandia, Maria&#xD;eng&#xD;Comunidad de Madrid/&#xD;European Social Fund/&#xD;Fundacion Banco Santander/&#xD;Instituto de Salud Carlos III/&#xD;Ministerio de Ciencia e Innovacion/&#xD;Universidad Politecnica de Madrid/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):246-249. doi: 10.1111/all.15898. Epub 2023 Sep 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37776066</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15898</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1395</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1395</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mao, M.</style></author><author><style face="normal" font="default" size="100%">Liu, H.</style></author><author><style face="normal" font="default" size="100%">Yan, S.</style></author><author><style face="normal" font="default" size="100%">Yuan, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, R.</style></author><author><style face="normal" font="default" size="100%">Wu, Y.</style></author><author><style face="normal" font="default" size="100%">Peng, C.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Chen, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.&#xD;Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China.&#xD;Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Plasma adenosine is linked to disease activity and response to treatment in patients with chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">571-573</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/07/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adenosine</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32687639</style></accession-num><notes><style face="normal" font="default" size="100%">Mao, Manyun&#xD;Liu, Hong&#xD;Yan, Siyu&#xD;Yuan, Yan&#xD;Liu, Runqiu&#xD;Wu, Yingfang&#xD;Peng, Cong&#xD;Li, Jie&#xD;Chen, Xiang&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):571-573. doi: 10.1111/all.14502. Epub 2020 Aug 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32687639</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14502</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2363</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2363</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Smilnak, G. J.</style></author><author><style face="normal" font="default" size="100%">Lee, Y.</style></author><author><style face="normal" font="default" size="100%">Chattopadhyay, A.</style></author><author><style face="normal" font="default" size="100%">Wyss, A. B.</style></author><author><style face="normal" font="default" size="100%">White, J. D.</style></author><author><style face="normal" font="default" size="100%">Sikdar, S.</style></author><author><style face="normal" font="default" size="100%">Jin, J.</style></author><author><style face="normal" font="default" size="100%">Grant, A. J.</style></author><author><style face="normal" font="default" size="100%">Motsinger-Reif, A. A.</style></author><author><style face="normal" font="default" size="100%">Li, J. L.</style></author><author><style face="normal" font="default" size="100%">Lee, M.</style></author><author><style face="normal" font="default" size="100%">Yu, B.</style></author><author><style face="normal" font="default" size="100%">London, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.&#xD;Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA.&#xD;GenOmics and Translational Research Center, Biostatistics and Epidemiology Division, RTI International, Research Triangle Park, North Carolina, USA.&#xD;Department of Mathematics and Statistics, Old Dominion University, Norfolk, Virginia, USA.&#xD;Westat, Inc., Durham, North Carolina, USA.&#xD;MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.&#xD;Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.&#xD;Integrative Bioinformatics Support Group, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Plasma protein signatures of adult asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">643-655</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">area under curve</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword><keyword><style face="normal" font="default" size="100%">proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">of the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38263798</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Adult asthma is complex and incompletely understood. Plasma proteomics is an evolving technique that can both generate biomarkers and provide insights into disease mechanisms. We aimed to identify plasma proteomic signatures of adult asthma. METHODS: Protein abundance in plasma was measured in individuals from the Agricultural Lung Health Study (ALHS) (761 asthma, 1095 non-case) and the Atherosclerosis Risk in Communities study (470 asthma, 10,669 non-case) using the SOMAScan 5K array. Associations with asthma were estimated using covariate adjusted logistic regression and meta-analyzed using inverse-variance weighting. Additionally, in ALHS, we examined phenotypes based on both asthma and seroatopy (asthma with atopy (n = 207), asthma without atopy (n = 554), atopy without asthma (n = 147), compared to neither (n = 948)). RESULTS: Meta-analysis of 4860 proteins identified 115 significantly (FDR&lt;0.05) associated with asthma. Multiple signaling pathways related to airway inflammation and pulmonary injury were enriched (FDR&lt;0.05) among these proteins. A proteomic score generated using machine learning provided predictive value for asthma (AUC = 0.77, 95% CI = 0.75-0.79 in training set; AUC = 0.72, 95% CI = 0.69-0.75 in validation set). Twenty proteins are targeted by approved or investigational drugs for asthma or other conditions, suggesting potential drug repurposing. The combined asthma-atopy phenotype showed significant associations with 20 proteins, including five not identified in the overall asthma analysis. CONCLUSION: This first large-scale proteomics study identified over 100 plasma proteins associated with current asthma in adults. In addition to validating previous associations, we identified many novel proteins that could inform development of diagnostic biomarkers and therapeutic targets in asthma management.</style></abstract><notes><style face="normal" font="default" size="100%">Smilnak, Gordon J&#xD;Lee, Yura&#xD;Chattopadhyay, Abhijnan&#xD;Wyss, Annah B&#xD;White, Julie D&#xD;Sikdar, Sinjini&#xD;Jin, Jianping&#xD;Grant, Andrew J&#xD;Motsinger-Reif, Alison A&#xD;Li, Jian-Liang&#xD;Lee, Mikyeong&#xD;Yu, Bing&#xD;London, Stephanie J&#xD;eng&#xD;75N92022D00002/HL/NHLBI NIH HHS/&#xD;Z01 ES049030/ImNIH/Intramural NIH HHS/&#xD;75N92022D00004/HL/NHLBI NIH HHS/&#xD;N01 ES055546/ES/NIEHS NIH HHS/&#xD;ZIA ES102385/ImNIH/Intramural NIH HHS/&#xD;CA/NCI NIH HHS/&#xD;75N92022D00003/HL/NHLBI NIH HHS/&#xD;R01 HL134320/HL/NHLBI NIH HHS/&#xD;75N92022D00001/HL/NHLBI NIH HHS/&#xD;Z01 CP010119/ImNIH/Intramural NIH HHS/&#xD;75N92022D00005/HL/NHLBI NIH HHS/&#xD;Meta-Analysis&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, N.I.H., Intramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):643-655. doi: 10.1111/all.16000. Epub 2024 Jan 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38263798</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10994188</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16000</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2498</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2498</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ghazanfar, M. N.</style></author><author><style face="normal" font="default" size="100%">Petrosius, V.</style></author><author><style face="normal" font="default" size="100%">Sorensen, J. A.</style></author><author><style face="normal" font="default" size="100%">Zhang, D. G.</style></author><author><style face="normal" font="default" size="100%">Ali, Z.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Kocaturk, E.</style></author><author><style face="normal" font="default" size="100%">Nielsen, V. W.</style></author><author><style face="normal" font="default" size="100%">Savickas, S.</style></author><author><style face="normal" font="default" size="100%">Keller, U. A. D.</style></author><author><style face="normal" font="default" size="100%">Schoof, E. M.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermato-Venereology &amp; Wound Healing Centre, Urticaria Center of Reference and Excellence (UCARE), Bispebjerg Hospital, Copenhagen, Denmark.&#xD;Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.&#xD;Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;Department of Dermatology, Koc University School of Medicine, Istanbul, Turkey.&#xD;Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Plasma proteomics analysis of patients with chronic spontaneous urticaria reveals significant associations with key disease characteristics but not with response to omalizumab treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2547-2550</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/05/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Proteome</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38798066</style></accession-num><notes><style face="normal" font="default" size="100%">Ghazanfar, Misbah Noshela&#xD;Petrosius, Valdemaras&#xD;Sorensen, Jennifer Astrup&#xD;Zhang, Ditte Georgina&#xD;Ali, Zarqa&#xD;Maurer, Marcus&#xD;Kocaturk, Emek&#xD;Nielsen, Valdemar Wendelboe&#xD;Savickas, Simonas&#xD;Keller, Ulrich Auf dem&#xD;Schoof, Erwin M&#xD;Thomsen, Simon Francis&#xD;eng&#xD;LF-OC-21-000832/LEO Foundation/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2547-2550. doi: 10.1111/all.16175. Epub 2024 May 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38798066</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16175</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>532</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">532</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Upton, J. E. M.</style></author><author><style face="normal" font="default" size="100%">Hoang, J. A.</style></author><author><style face="normal" font="default" size="100%">Leon-Ponte, M.</style></author><author><style face="normal" font="default" size="100%">Finkelstein, Y.</style></author><author><style face="normal" font="default" size="100%">Du, Y. J.</style></author><author><style face="normal" font="default" size="100%">Adeli, K.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Grunebaum, E.</style></author><author><style face="normal" font="default" size="100%">Vadas, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.&#xD;Department of Pediatrics, Division of Immunology and Allergy, The Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Medicine, Division of Clinical Immunology and Allergy, St. Michael&apos;s Hospital, University of Toronto, Toronto, Ontario, Canada.&#xD;Department of Immunology, University of Toronto, Toronto, Ontario, Canada.&#xD;Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Pediatrics, Division of Emergency Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.&#xD;Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;University of Health Sciences, University Hospital St. Poelten, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Platelet-activating factor acetylhydrolase is a biomarker of severe anaphylaxis in children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2665-2676</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/04/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*1-Alkyl-2-acetylglycerophosphocholine Esterase</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Activating Factor/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">mediator</style></keyword><keyword><style face="normal" font="default" size="100%">platelet-activating factor</style></keyword><keyword><style face="normal" font="default" size="100%">severity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35396721</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: There is limited ability to predict the severity of allergic reactions in children. Data derived predominantly from adults have implicated the platelet-activating factor pathway as a potential contributor to severe anaphylaxis. In this study, we sought to prospectively assess involvement of key components of the platelet-activating factor pathway in pediatric patients with anaphylaxis. METHODS: Forty-six pediatric patients (&lt;18 years) presenting with acute anaphylaxis were assessed. Anaphylaxis severity was graded and serum anaphylaxis markers were measured acutely and in 36 children who returned for follow-up &gt;4 weeks after their acute presentation. These markers were compared with pediatric laboratory reference sera. RESULTS: Severe anaphylaxis was experienced by 12/46 (26%) and mild-moderate anaphylaxis in 34/46 (74%) children. Platelet-activating factor acetylhydrolase (PAF-AH) activity was inversely associated with severe anaphylaxis: 9/12 children with severe anaphylaxis had reduced PAF-AH activity as compared with 14/34 with mild-moderate anaphylaxis (p &lt; .05). Furthermore, 3/3 children who required intensive care had markedly reduced mean PAF-AH (nmol/ml/min) (13.73, 95%CI: 7.42-20.03) versus 20/23 who required ward/emergency department care (17.81, 95%CI: 16.80-18.83; p &lt; .05). In children with anaphylaxis, PAF-AH during acute anaphylaxis was unchanged relative to the child&apos;s basal levels (mean, 17.26, 95%CI: 16.10-18.42 vs 17.50, 95%CI: 16.21-18.78, p = .63) and was lower than healthy pediatric controls (mean 19.21; 95%CI:18.21-20.21; p &lt; .05). CONCLUSION: Decreased serum PAF-AH activity is a biomarker of severe anaphylaxis. Levels of this enzyme do not change from basal levels during acute anaphylaxis. Our results show that PAF-AH is a biomarker of anaphylaxis severity in children. This key regulatory enzyme may modulate susceptibility to severe anaphylaxis.</style></abstract><notes><style face="normal" font="default" size="100%">Upton, Julia E M&#xD;Hoang, Jennifer A&#xD;Leon-Ponte, Matilde&#xD;Finkelstein, Yaron&#xD;Du, Yue Jennifer&#xD;Adeli, Khosrow&#xD;Eiwegger, Thomas&#xD;Grunebaum, Eyal&#xD;Vadas, Peter&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2665-2676. doi: 10.1111/all.15308. Epub 2022 Apr 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35396721</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15308</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>720</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">720</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Corsi, A.</style></author><author><style face="normal" font="default" size="100%">Martini, M.</style></author><author><style face="normal" font="default" size="100%">Danieli, M. G.</style></author><author><style face="normal" font="default" size="100%">Alia, S.</style></author><author><style face="normal" font="default" size="100%">Di Paolo, A.</style></author><author><style face="normal" font="default" size="100%">Moroncini, G.</style></author><author><style face="normal" font="default" size="100%">Vignini, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.&#xD;Allergy Unit, Department of Internal Medicine, Ospedali Riuniti Ancona University Hospital, Ancona, Italy.&#xD;Postgraduate School of Allergy and Clinical Immunology, Marche Polytechnic University, Ancona, Italy.&#xD;Allergy Unit, &quot;Santa Croce&quot; Hospital, Fano, Italy.&#xD;Department of Internal Medicine, Clinica Medica, Ospedali Riuniti Ancona University Hospital, Ancona, Italy.&#xD;Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Marche Polytechnic University, Ancona, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Platelet-activating factor acetylhydrolase: A biomarker in Hymenoptera venom allergy?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1032-1035</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/10/31</style></edition><section><style face="normal" font="default" size="100%">1032</style></section><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthropod Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hymenoptera</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Insect Bites and Stings/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">platelet-activating factor acetylhydrolase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34716604</style></accession-num><notes><style face="normal" font="default" size="100%">Bilo, Maria Beatrice&#xD;Corsi, Alice&#xD;Martini, Matteo&#xD;Danieli, Maria Giovanna&#xD;Alia, Sonila&#xD;Di Paolo, Alice&#xD;Moroncini, Gianluca&#xD;Vignini, Arianna&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1032-1035. doi: 10.1111/all.15161. Epub 2021 Nov 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34716604</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9299147</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15161</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1973</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1973</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jia, P.</style></author><author><style face="normal" font="default" size="100%">Feng, C.</style></author><author><style face="normal" font="default" size="100%">Ye, T.</style></author><author><style face="normal" font="default" size="100%">Shao, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Resource and Environmental Sciences, Wuhan University, Wuhan, China.&#xD;Hubei Luojia Laboratory, Wuhan, China.&#xD;School of Public Health, Wuhan University, Wuhan, China.&#xD;International Institute of Spatial Lifecourse Health (ISLE), Wuhan University, Wuhan, China.&#xD;West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.&#xD;Institute for Disaster Management and Reconstruction, Sichuan University-The Hong Kong Polytechnic University, Chengdu, China.&#xD;Yunnan Center for Disease Control and Prevention, Kunming, China.&#xD;Department of Health Management Center, Clinical Medical College &amp; Affiliated Hospital, Chengdu University, Chengdu, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">PM(2) (.5) chemical constituents and allergic rhinitis: Findings from a prospective cohort study in China</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1703-1706</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/03/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Particulate Matter</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36905295</style></accession-num><notes><style face="normal" font="default" size="100%">Jia, Peng&#xD;Feng, Chuanteng&#xD;Ye, Tingting&#xD;Shao, Ying&#xD;Yang, Shujuan&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1703-1706. doi: 10.1111/all.15706. Epub 2023 Mar 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36905295</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15706</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2829</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2829</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hillson, K.</style></author><author><style face="normal" font="default" size="100%">Fontanella, S.</style></author><author><style face="normal" font="default" size="100%">Almeida, H.</style></author><author><style face="normal" font="default" size="100%">Pavlou, B.</style></author><author><style face="normal" font="default" size="100%">Lajunen, K.</style></author><author><style face="normal" font="default" size="100%">Irving, S.</style></author><author><style face="normal" font="default" size="100%">Testa, I.</style></author><author><style face="normal" font="default" size="100%">Bingham, Y.</style></author><author><style face="normal" font="default" size="100%">Oritz, K. M.</style></author><author><style face="normal" font="default" size="100%">Lacbay, S.</style></author><author><style face="normal" font="default" size="100%">Hay, S.</style></author><author><style face="normal" font="default" size="100%">Gore, M.</style></author><author><style face="normal" font="default" size="100%">Scotney, E.</style></author><author><style face="normal" font="default" size="100%">Paraskakis, E.</style></author><author><style face="normal" font="default" size="100%">Sonnappa, S.</style></author><author><style face="normal" font="default" size="100%">Fleming, L.</style></author><author><style face="normal" font="default" size="100%">Bush, A.</style></author><author><style face="normal" font="default" size="100%">Saglani, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Department of Respiratory Paediatrics, Royal Brompton Hospital, London, UK.&#xD;Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Lighthouse Hospital, Turku, Finland.&#xD;Department of Paediatrics, Heraklion University Hospital, University of Crete Medical School, Crete, Greece.&#xD;Centre for Paediatrics &amp; Child Health, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Point-of-Care Blood Eosinophils to Predict Preschool Wheeze Attacks</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1038-1046</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Sounds/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">*Point-of-Care Systems</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">machine learning</style></keyword><keyword><style face="normal" font="default" size="100%">point-of-care test</style></keyword><keyword><style face="normal" font="default" size="100%">preschool wheeze</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">wheeze attacks</style></keyword><keyword><style face="normal" font="default" size="100%">Innovation to AstraZeneca, outside the submitted work. Other authors declare no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39976168</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Post hoc analysis of clinical trials shows blood eosinophil counts (BEC) predict future preschool wheeze attacks; however, prospective usefulness in a clinical setting is unreported. We assessed the feasibility of point-of-care (POC) eosinophil measurements in preschool wheezers and related BEC to symptoms, lung function, and utility in predicting attacks. METHODS: Children aged 1-5 years with recurrent wheeze underwent finger-prick sampling during the outpatient clinic for POC eosinophils, forced oscillation technique (FOT) and/or spirometry, and symptom score (TRACK questionnaire). The utility of BEC and/or the other tests in predicting wheeze attacks in the subsequent 3 months was analysed by comparing those with and without an attack and using a predictive decision tree (DT) model. RESULTS: Seventy-three children (median age 4.27 years) were recruited; BEC were higher in atopic children (median 0.5 x 10(9)/L vs. 0.3 x 10(9)/L non-atopic, p &lt; 0.01). BEC moderately correlated with FOT reactance bronchodilator reversibility z-score changes (r = 0.495, p = 0.005), but no other lung function measures or TRACK score. 68/73 (93%) children were followed up at 3 months. 29/68 (43%) children had &gt; 1 wheeze attack requiring unscheduled healthcare attendance. Absolute and %eosinophils at the baseline visit were higher in those who had an attack (median 0.5 x 10(9)/L vs. 0.3 x 10(9)/L, p = 0.03 and median 6% vs. 4%, p &lt; 0.01). The DT model showed children with BEC &gt;/= 4% and TRACK score &lt; 75 were more likely to have a future attack (probability 0.63). CONCLUSION: POC blood eosinophils were feasible in a clinical setting. Our preliminary data suggest elevated BEC with a low symptom score predicts a wheeze attack within 3 months.</style></abstract><notes><style face="normal" font="default" size="100%">Hillson, Kushalinii&#xD;Fontanella, Sara&#xD;Almeida, Hernani&#xD;Pavlou, Barbara&#xD;Lajunen, Katariina&#xD;Irving, Samantha&#xD;Testa, Ilaria&#xD;Bingham, Yvonne&#xD;Oritz, Karina Mayoral&#xD;Lacbay, Shane&#xD;Hay, Sophie&#xD;Gore, Mindy&#xD;Scotney, Elizabeth&#xD;Paraskakis, Emmanouil&#xD;Sonnappa, Samatha&#xD;Fleming, Louise&#xD;Bush, Andrew&#xD;Saglani, Sejal&#xD;eng&#xD;NIHR Imperial Biomedical Research Centre/&#xD;Action Medical Research/&#xD;Masonic Charitable Foundation/&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1038-1046. doi: 10.1111/all.16500. Epub 2025 Feb 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39976168</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969302</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16500</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>554</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">554</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gisler, A.</style></author><author><style face="normal" font="default" size="100%">Eeftens, M.</style></author><author><style face="normal" font="default" size="100%">de Hoogh, K.</style></author><author><style face="normal" font="default" size="100%">Vienneau, D.</style></author><author><style face="normal" font="default" size="100%">Salem, Y.</style></author><author><style face="normal" font="default" size="100%">Yammine, S.</style></author><author><style face="normal" font="default" size="100%">Jakob, J.</style></author><author><style face="normal" font="default" size="100%">Gorlanova, O.</style></author><author><style face="normal" font="default" size="100%">Decrue, F.</style></author><author><style face="normal" font="default" size="100%">Gehrig, R.</style></author><author><style face="normal" font="default" size="100%">Frey, U.</style></author><author><style face="normal" font="default" size="100%">Latzin, P.</style></author><author><style face="normal" font="default" size="100%">Fuchs, O.</style></author><author><style face="normal" font="default" size="100%">Usemann, J.</style></author><author><style face="normal" font="default" size="100%">Bild study group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Children&apos;s Hospital Basel (UKBB), Basel, Switzerland.&#xD;Division of Pediatric Respiratory Medicine and Allergology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Swiss Tropical and Public Health Institute Basel, Basel, Switzerland.&#xD;University of Basel, Basel, Switzerland.&#xD;Institute of Primary Health Care (BIHAM), Bern, Switzerland.&#xD;Federal Office of Meteorology and Climatology MeteoSwiss, Zurich, Switzerland.&#xD;Division of Respiratory Medicine, University Children&apos;s Hospital of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pollen exposure is associated with risk of respiratory symptoms during the first year of life</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3606-3616</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/03/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Particulate Matter</style></keyword><keyword><style face="normal" font="default" size="100%">aeroallergen</style></keyword><keyword><style face="normal" font="default" size="100%">cohort study</style></keyword><keyword><style face="normal" font="default" size="100%">infancy</style></keyword><keyword><style face="normal" font="default" size="100%">interaction</style></keyword><keyword><style face="normal" font="default" size="100%">longitudinal study</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. JU reports personal fees from Vertex outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. OF reports personal fees from OM Pharma, Menarini, ALK, Vertex,</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard, Medical Tribune, Milupa-Nutricia, Stallergenes Greer and aha! Allergie</style></keyword><keyword><style face="normal" font="default" size="100%">Zentrum outside the submitted work. The remaining authors declare no conflict of</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35302662</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Pollen exposure is associated with respiratory symptoms in children and adults. However, the association of pollen exposure with respiratory symptoms during infancy, a particularly vulnerable period, remains unclear. We examined whether pollen exposure is associated with respiratory symptoms in infants and whether maternal atopy, infant&apos;s sex or air pollution modifies this association. METHODS: We investigated 14,874 observations from 401 healthy infants of a prospective birth cohort. The association between pollen exposure and respiratory symptoms, assessed in weekly telephone interviews, was evaluated using generalized additive mixed models (GAMMs). Effect modification by maternal atopy, infant&apos;s sex, and air pollution (NO(2) , PM(2.5) ) was assessed with interaction terms. RESULTS: Per infant, 37 +/- 2 (mean +/- SD) respiratory symptom scores were assessed during the analysis period (January through September). Pollen exposure was associated with increased respiratory symptoms during the daytime (RR [95% CI] per 10% pollen/m(3) : combined 1.006 [1.002, 1.009]; tree 1.005 [1.002, 1.008]; grass 1.009 [1.000, 1.23]) and nighttime (combined 1.003 [0.999, 1.007]; tree 1.003 [0.999, 1.007]; grass 1.014 [1.004, 1.024]). While there was no effect modification by maternal atopy and infant&apos;s sex, a complex crossover interaction between combined pollen and PM(2.5) was found (p-value 0.003). CONCLUSION: Even as early as during the first year of life, pollen exposure was associated with an increased risk of respiratory symptoms, independent of maternal atopy and infant&apos;s sex. Because infancy is a particularly vulnerable period for lung development, the identified adverse effect of pollen exposure may be relevant for the evolvement of chronic childhood asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Gisler, Amanda&#xD;Eeftens, Marloes&#xD;de Hoogh, Kees&#xD;Vienneau, Danielle&#xD;Salem, Yasmin&#xD;Yammine, Sophie&#xD;Jakob, Julian&#xD;Gorlanova, Olga&#xD;Decrue, Fabienne&#xD;Gehrig, Regula&#xD;Frey, Urs&#xD;Latzin, Philipp&#xD;Fuchs, Oliver&#xD;Usemann, Jakob&#xD;eng&#xD;320300_204717/SNSF_/Swiss National Science Foundation/Switzerland&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3606-3616. doi: 10.1111/all.15284. Epub 2022 Mar 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35302662</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10078730</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15284</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1329</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1329</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Speidel, J. D.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Steer, B.</style></author><author><style face="normal" font="default" size="100%">Vafadari, B.</style></author><author><style face="normal" font="default" size="100%">Rauer, D.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Adler, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit Lung Repair and Regeneration, Comprehensive Pneumology Center, Helmholtz Zentrum Munchen - German Research Center for Environmental Health (GmbH); Member of the German Center of Lung Research (DZL), Munich, Germany.&#xD;Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum Munchen, Augsburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pollen induces reactivation of latent herpesvirus and differentially affects infected and uninfected murine macrophages</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1539-1542</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/09/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Herpesviridae</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Simplexvirus</style></keyword><keyword><style face="normal" font="default" size="100%">Virus Activation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32905616</style></accession-num><notes><style face="normal" font="default" size="100%">Speidel, Jan Dominik&#xD;Gilles, Stefanie&#xD;Steer, Beatrix&#xD;Vafadari, Behnam&#xD;Rauer, Denise&#xD;Traidl-Hoffmann, Claudia&#xD;Adler, Heiko&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1539-1542. doi: 10.1111/all.14587. Epub 2020 Sep 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32905616</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14587</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>336</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">336</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Center Munich - German Research Center for Environmental Health, Augsburg, Germany.&#xD;CK-CARE, Christine Kuhne-Center for Allergy Research and Education, Davos Wolfgang, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pollen on their way astray - First contact via cross-kingdom signaling leading to far-reaching consequences for the atopic march</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3496-3497</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/08/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36029177</style></accession-num><notes><style face="normal" font="default" size="100%">Traidl-Hoffmann, Claudia&#xD;eng&#xD;Comment&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3496-3497. doi: 10.1111/all.15496.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36029177</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15496</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3290</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3290</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ardicli, Sena</style></author><author><style face="normal" font="default" size="100%">Babayev, Huseyn</style></author><author><style face="normal" font="default" size="100%">Chang, Lihong</style></author><author><style face="normal" font="default" size="100%">Ardicli, Ozge</style></author><author><style face="normal" font="default" size="100%">Zeyneloglu, Can</style></author><author><style face="normal" font="default" size="100%">Pat, Yagiz</style></author><author><style face="normal" font="default" size="100%">Yazici, Duygu</style></author><author><style face="normal" font="default" size="100%">Liu, Xiaoqing</style></author><author><style face="normal" font="default" size="100%">Bektas, Ezgi Irem</style></author><author><style face="normal" font="default" size="100%">Beha, Carina</style></author><author><style face="normal" font="default" size="100%">Akyildiz, Halil I.</style></author><author><style face="normal" font="default" size="100%">B. Mammadova, Nazrin</style></author><author><style face="normal" font="default" size="100%">Sari, Muhammed Emin</style></author><author><style face="normal" font="default" size="100%">Rückert, Beate</style></author><author><style face="normal" font="default" size="100%">Dhir, Raja</style></author><author><style face="normal" font="default" size="100%">Ogulur, Ismail</style></author><author><style face="normal" font="default" size="100%">Nadeau, Kari C.</style></author><author><style face="normal" font="default" size="100%">Akdis, Mubeccel</style></author><author><style face="normal" font="default" size="100%">Akdis, Cezmi A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Polyethylene Terephthalate Micro and Nanoplastics Induce Oxidative and Endoplasmic Reticulum Stress, Compromising Intestinal Epithelial Integrity and Viability</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70291</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70291</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3216</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3216</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leighton, G. O.</style></author><author><style face="normal" font="default" size="100%">Cosey, T. M.</style></author><author><style face="normal" font="default" size="100%">De Diavoukana, E. R.</style></author><author><style face="normal" font="default" size="100%">Lytle, I. R.</style></author><author><style face="normal" font="default" size="100%">Foo, A. C. Y.</style></author><author><style face="normal" font="default" size="100%">Pedersen, L. C.</style></author><author><style face="normal" font="default" size="100%">Gabel, S. A.</style></author><author><style face="normal" font="default" size="100%">Petrovich, R. M.</style></author><author><style face="normal" font="default" size="100%">Shi, M.</style></author><author><style face="normal" font="default" size="100%">Aruva, V.</style></author><author><style face="normal" font="default" size="100%">Creeks, P.</style></author><author><style face="normal" font="default" size="100%">Wong, J. J. W.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Peebles, R. S., Jr.</style></author><author><style face="normal" font="default" size="100%">Croote, D.</style></author><author><style face="normal" font="default" size="100%">Smith, S. A.</style></author><author><style face="normal" font="default" size="100%">Mueller, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Institute of Environmental Health Sciences, NIH, Durham, North Carolina, USA.&#xD;IgGenix, Inc, South San Francisco, California, USA.&#xD;Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Polymeric alpha-Hairpinin Allergens Induce a Functional Response via a Single Antibody</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergens</style></keyword><keyword><style face="normal" font="default" size="100%">epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">stakeholders in, IgGenix.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 31</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41476027</style></accession-num><notes><style face="normal" font="default" size="100%">Leighton, Gage O&#xD;Cosey, Taylor M&#xD;De Diavoukana, Emmanuel R&#xD;Lytle, Isabelle R&#xD;Foo, Alexander C Y&#xD;Pedersen, Lars C&#xD;Gabel, Scott A&#xD;Petrovich, Robert M&#xD;Shi, Min&#xD;Aruva, Venu&#xD;Creeks, Paige&#xD;Wong, Joyce J W&#xD;Zhang, Jian&#xD;Peebles, R Stokes Jr&#xD;Croote, Derek&#xD;Smith, Scott A&#xD;Mueller, Geoffrey A&#xD;eng&#xD;ZIC ES102487/ImNIH/Intramural NIH HHS/&#xD;ZIC ES102645/ImNIH/Intramural NIH HHS/&#xD;ES/NIEHS NIH HHS/&#xD;ZIA ES102906/ImNIH/Intramural NIH HHS/&#xD;ZIC ES103362/ImNIH/Intramural NIH HHS/&#xD;Intramural Research Program/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec 31:10.1111/all.70201. doi: 10.1111/all.70201.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41476027</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12758636</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70201</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3241</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3241</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leighton, G. O.</style></author><author><style face="normal" font="default" size="100%">Cosey, T. M.</style></author><author><style face="normal" font="default" size="100%">De Diavoukana, E. R.</style></author><author><style face="normal" font="default" size="100%">Lytle, I. R.</style></author><author><style face="normal" font="default" size="100%">Foo, A. C. Y.</style></author><author><style face="normal" font="default" size="100%">Pedersen, L. C.</style></author><author><style face="normal" font="default" size="100%">Gabel, S. A.</style></author><author><style face="normal" font="default" size="100%">Petrovich, R. M.</style></author><author><style face="normal" font="default" size="100%">Shi, M.</style></author><author><style face="normal" font="default" size="100%">Aruva, V.</style></author><author><style face="normal" font="default" size="100%">Creeks, P.</style></author><author><style face="normal" font="default" size="100%">Wong, J. J. W.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Peebles, R. S., Jr.</style></author><author><style face="normal" font="default" size="100%">Croote, D.</style></author><author><style face="normal" font="default" size="100%">Smith, S. A.</style></author><author><style face="normal" font="default" size="100%">Mueller, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Institute of Environmental Health Sciences, NIH, Durham, North Carolina, USA.&#xD;IgGenix, Inc, South San Francisco, California, USA.&#xD;Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Polymeric alpha-Hairpinin Allergens Induce a Functional Response via a Single Antibody</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergens</style></keyword><keyword><style face="normal" font="default" size="100%">epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">stakeholders in, IgGenix.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 31</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41476027</style></accession-num><notes><style face="normal" font="default" size="100%">Leighton, Gage O&#xD;Cosey, Taylor M&#xD;De Diavoukana, Emmanuel R&#xD;Lytle, Isabelle R&#xD;Foo, Alexander C Y&#xD;Pedersen, Lars C&#xD;Gabel, Scott A&#xD;Petrovich, Robert M&#xD;Shi, Min&#xD;Aruva, Venu&#xD;Creeks, Paige&#xD;Wong, Joyce J W&#xD;Zhang, Jian&#xD;Peebles, R Stokes Jr&#xD;Croote, Derek&#xD;Smith, Scott A&#xD;Mueller, Geoffrey A&#xD;eng&#xD;ZIC ES102487/ImNIH/Intramural NIH HHS/&#xD;ZIC ES102645/ImNIH/Intramural NIH HHS/&#xD;ES/NIEHS NIH HHS/&#xD;ZIA ES102906/ImNIH/Intramural NIH HHS/&#xD;ZIC ES103362/ImNIH/Intramural NIH HHS/&#xD;Intramural Research Program/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec 31:10.1111/all.70201. doi: 10.1111/all.70201.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41476027</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12758636</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70201</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2855</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2855</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mohrenschlager, M.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Hochgebirgsklinik, Davos, Switzerland.&#xD;Christine Kuhne Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Dermatology, University of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Possible In-Cabin Exposure to Cat Allergen: A 2025 Airline Survey on Live Animal Transport and a Review of Literature</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2068-2069</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/04/30</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40304288</style></accession-num><notes><style face="normal" font="default" size="100%">Mohrenschlager, Matthias&#xD;Bruggen, Marie-Charlotte&#xD;Schmid-Grendelmeier, Peter&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2068-2069. doi: 10.1111/all.16568. Epub 2025 Apr 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40304288</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16568</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2940</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2940</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mohrenschlager, M.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Hochgebirgsklinik, Davos, Switzerland.&#xD;Christine Kuhne Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Dermatology, University of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Possible In-Cabin Exposure to Cat Allergen: A 2025 Airline Survey on Live Animal Transport and a Review of Literature</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2068-2069</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/04/30</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40304288</style></accession-num><notes><style face="normal" font="default" size="100%">Mohrenschlager, Matthias&#xD;Bruggen, Marie-Charlotte&#xD;Schmid-Grendelmeier, Peter&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2068-2069. doi: 10.1111/all.16568. Epub 2025 Apr 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40304288</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16568</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3223</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3223</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pat, Y.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">Ardicli, S.</style></author><author><style face="normal" font="default" size="100%">Bu, X.</style></author><author><style face="normal" font="default" size="100%">Simmons, S.</style></author><author><style face="normal" font="default" size="100%">Almada, A.</style></author><author><style face="normal" font="default" size="100%">Avena, C.</style></author><author><style face="normal" font="default" size="100%">Jensen, T.</style></author><author><style face="normal" font="default" size="100%">Dhir, R.</style></author><author><style face="normal" font="default" size="100%">Westermann, P.</style></author><author><style face="normal" font="default" size="100%">Garcia-Sanchez, A.</style></author><author><style face="normal" font="default" size="100%">Li, M.</style></author><author><style face="normal" font="default" size="100%">Ardicli, O.</style></author><author><style face="normal" font="default" size="100%">Zeyneloglu, C.</style></author><author><style face="normal" font="default" size="100%">Pane, M.</style></author><author><style face="normal" font="default" size="100%">Amoruso, A.</style></author><author><style face="normal" font="default" size="100%">Messner, C.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Genetics, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkiye.&#xD;SEED Inc. Co., Los Angeles, California, USA.&#xD;Precision Proteomics Center, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Biomedical and Diagnostic Sciences, University of Salamanca, Salamanca, Spain.&#xD;Division of Food Processing, Milk and Dairy Products Technology Program, Karacabey Vocational School, Bursa Uludag University, Bursa, Turkiye.&#xD;Probiotical Research S.r.l., Novara, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Postbiotics and Nicotinamide Utilize Distinct Mechanisms to Improve Skin Barrier Integrity, Inflammation, and Keratinocyte Differentiation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">ex vivo human skin</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">postbiotics</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41574683</style></accession-num><abstract><style face="normal" font="default" size="100%">The modulation of immune responses and tissue regeneration by postbiotics is a rapidly advancing area in skin care. Here, we show that whole-cell postbiotics derived from Bifidobacterium breve, Limosilactobacillus reuteri, and Ligilactobacillus salivarius, along with nicotinamide (NAM), enhance keratinocyte growth, differentiation, and skin epithelial barrier integrity in ex vivo human skin, as determined by electrical impedance spectroscopy (EIS), multiomics, and machine learning. B. breve promoted keratinocyte differentiation and suppressed inflammatory pathways, while L. reuteri and L. salivarius primarily reduced inflammatory pathways. Although NAM downregulated keratinocyte differentiation, it exerted anti-inflammatory effects. Machine learning analyses linked EIS changes to certain genes, highlighting strain-specific mechanisms. In addition, B. breve, L. reuteri, and NAM mitigated a common skin cleanser-induced skin epithelial damage, further supporting their therapeutic potential. In conclusion, integrating skin barrier measurements with omics and machine learning enabled the dissection of essential anti-inflammatory and keratinocyte differentiation mechanisms and genes of a strengthened skin barrier.</style></abstract><notes><style face="normal" font="default" size="100%">Pat, Yagiz&#xD;Yazici, Duygu&#xD;Babayev, Huseyn&#xD;Ardicli, Sena&#xD;Bu, Xiangting&#xD;Simmons, Sheri&#xD;Almada, Anthony&#xD;Avena, Christine&#xD;Jensen, Tye&#xD;Dhir, Raja&#xD;Westermann, Patrick&#xD;Garcia-Sanchez, Asuncion&#xD;Li, Manru&#xD;Ardicli, Ozge&#xD;Zeyneloglu, Can&#xD;Pane, Marco&#xD;Amoruso, Angela&#xD;Messner, Christoph&#xD;Ogulur, Ismail&#xD;Mitamura, Yasutaka&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;eng&#xD;Swiss National Science Foundation, Bern/&#xD;Stanford University/&#xD;Leading House for the Latin American Region/&#xD;European Union/&#xD;Novartis Research Institutes (Basel, Switzerland)/&#xD;Stanford University (Redwood City, Calif)/&#xD;Seed Health (Boston, USA)/&#xD;SciBase (Stockholm, Sweden)/&#xD;202008210164/CSC scholarship program of China/&#xD;Denmark&#xD;Allergy. 2026 Jan 23. doi: 10.1111/all.70225.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41574683</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70225</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2659</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2659</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ebo, D. G.</style></author><author><style face="normal" font="default" size="100%">Bahri, R.</style></author><author><style face="normal" font="default" size="100%">Tontini, C.</style></author><author><style face="normal" font="default" size="100%">Van Houdt, M.</style></author><author><style face="normal" font="default" size="100%">Beyens, M.</style></author><author><style face="normal" font="default" size="100%">Toscano, A.</style></author><author><style face="normal" font="default" size="100%">Hagendorens, M. M.</style></author><author><style face="normal" font="default" size="100%">Van Gasse, A. L.</style></author><author><style face="normal" font="default" size="100%">Mertens, C.</style></author><author><style face="normal" font="default" size="100%">Elst, J.</style></author><author><style face="normal" font="default" size="100%">Sabato, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunology-Allergology-Rheumatology, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp University Hospital and Infla-Med Centre of Excellence Antwerp University, Antwerpen, Belgium.&#xD;Immunology-Allergology, AZ Jan Palfijn Ghent, Ghent, Belgium.&#xD;Lydia Becker Institute of Immunology and Inflammation, Division of Musculo-skeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Core Technology Facility, University of Manchester, Manchester, UK.&#xD;Paediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp University Hospital and Infla-Med Centre of Excellence Antwerp University, Antwerpen, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Potential and limitations of the human mast cell activation test in amoxicillin hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">594-597</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/08/31</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39215537</style></accession-num><notes><style face="normal" font="default" size="100%">Ebo, Didier G&#xD;Bahri, Rajia&#xD;Tontini, Chiara&#xD;Van Houdt, Michel&#xD;Beyens, Michiel&#xD;Toscano, Alessandro&#xD;Hagendorens, Margo M&#xD;Van Gasse, Athina L&#xD;Mertens, Christel&#xD;Elst, Jessy&#xD;Sabato, Vito&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):594-597. doi: 10.1111/all.16305. Epub 2024 Aug 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39215537</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16305</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>512</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">512</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ardicli, O.</style></author><author><style face="normal" font="default" size="100%">Azkur, A. K.</style></author><author><style face="normal" font="default" size="100%">Azkur, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Food Processing, Milk and Dairy Products Technology Program, Karacabey Vocational School, University of Bursa Uludag, Bursa, Turkey.&#xD;Department of Virology, Faculty of Veterinary Medicine, University of Kirikkale, Kirikkale, Turkey.&#xD;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, University of Kirikkale, Kirikkale, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A potential immunological silver bullet for COVID-19: The trivalent chimpanzee adenoviral serotype-68 vector (Tri:ChAd)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2565-2567</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/05/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Chad</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Vectors/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pan troglodytes</style></keyword><keyword><style face="normal" font="default" size="100%">Serogroup</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">adenoviral vectors</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">next-generation vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">trained innate immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35491434</style></accession-num><notes><style face="normal" font="default" size="100%">Ardicli, Ozge&#xD;Azkur, Ahmet Kursat&#xD;Azkur, Dilek&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2565-2567. doi: 10.1111/all.15333. Epub 2022 May 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35491434</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9347580</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15333</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1900</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1900</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ardicli, O.</style></author><author><style face="normal" font="default" size="100%">Azkur, A. K.</style></author><author><style face="normal" font="default" size="100%">Azkur, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Food Processing, Milk and Dairy Products Technology Program, Karacabey Vocational School, University of Bursa Uludag, Bursa, Turkey.&#xD;Department of Virology, Faculty of Veterinary Medicine, University of Kirikkale, Kirikkale, Turkey.&#xD;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, University of Kirikkale, Kirikkale, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A potential immunological silver bullet for COVID-19: The trivalent chimpanzee adenoviral serotype-68 vector (Tri:ChAd)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2565-2567</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/05/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Chad</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Vectors/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pan troglodytes</style></keyword><keyword><style face="normal" font="default" size="100%">Serogroup</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">adenoviral vectors</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">next-generation vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">trained innate immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35491434</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract -</style></abstract><notes><style face="normal" font="default" size="100%">Ardicli, Ozge&#xD;Azkur, Ahmet Kursat&#xD;Azkur, Dilek&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2565-2567. doi: 10.1111/all.15333. Epub 2022 May 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35491434</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9347580</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15333</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>243</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">243</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xian, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Potential of biologics to alter the need for repeated surgery in patients with chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">623-625</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/10/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications/drug therapy/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36301187</style></accession-num><notes><style face="normal" font="default" size="100%">Xian, Mu&#xD;Zhang, Luo&#xD;eng&#xD;Editorial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):623-625. doi: 10.1111/all.15565. Epub 2022 Dec 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36301187</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15565</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>507</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">507</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xing, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, M. H.</style></author><author><style face="normal" font="default" size="100%">Leung, T. F.</style></author><author><style face="normal" font="default" size="100%">Wong, C. K.</style></author><author><style face="normal" font="default" size="100%">Roponen, M.</style></author><author><style face="normal" font="default" size="100%">Schaub, B.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Wong, G. W. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.&#xD;Jockey Club School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, China.&#xD;Department of Chemical Pathology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.&#xD;Department of Environmental and Biological Sciences, University of Eastern Finland, Kuopio, Finland.&#xD;Pediatric Allergology, Department of Pediatrics, Dr von Hauner Children&apos;s Hospital, University Hospital, LMU Munich, Munich, Germany.&#xD;Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Poultry exposure and environmental protection against asthma in rural children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2949-2960</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/05/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Conservation of Natural Resources</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Exposure/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Poultry</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Rural Population</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">environmental protection</style></keyword><keyword><style face="normal" font="default" size="100%">poultry exposure</style></keyword><keyword><style face="normal" font="default" size="100%">rural</style></keyword><keyword><style face="normal" font="default" size="100%">urban</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35531632</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma is one of the most common chronic diseases in childhood, and the prevalence has been increasing over the past few decades. One of the most consistent epidemiological findings is that children living in a farming or rural environment are protected from development of asthma and allergies, but the protective factors in rural China are not clear. METHODS: A community-based, cross-sectional epidemiological study was performed in a total of 17,587 children aged 5-8 years, 3435 from Hong Kong (urban) and 14,152 from Conghua (rural county in southern China). Asthma and allergic symptoms as well as environmental exposures were ascertained by using a standardized and validated questionnaire. RESULTS: The prevalence of current wheeze was significantly lower in rural Conghua than that of urban Hong Kong (1.7% vs. 7.7%, p &lt; 0.001). A lower rate of asthma ever was also reported in rural children compared with their urban counterparts (2.5% vs. 5.3%, p &lt; 0.001). After adjusting for confounding factors, exposure to agricultural farming (adjusted odds ratio 0.74, 95% confidence interval: 0.56-0.97) and poultry (0.75, 0.59-0.96) were the most important factors associated with the asthma-protective effect in the rural area. Further propensity score-adjusted analysis indicated that such protection conferred by living in the rural environment was mainly attributable to poultry exposure. CONCLUSIONS: We confirmed that the prevalence of asthma and atopic disorders was significantly lower in rural children when compared with their urban peers. Exposure to poultry and agricultural farming are the most important factors associated with asthma protection in the rural area.</style></abstract><notes><style face="normal" font="default" size="100%">Xing, Yuhan&#xD;Wang, Maggie H&#xD;Leung, Ting-Fan&#xD;Wong, Chun-Kwok&#xD;Roponen, Marjut&#xD;Schaub, Bianca&#xD;Li, Jing&#xD;Wong, Gary W K&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):2949-2960. doi: 10.1111/all.15365. Epub 2022 May 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35531632</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15365</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>272</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">272</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vazquez-Ortiz, M.</style></author><author><style face="normal" font="default" size="100%">Gore, C.</style></author><author><style face="normal" font="default" size="100%">Alviani, C.</style></author><author><style face="normal" font="default" size="100%">Angier, E.</style></author><author><style face="normal" font="default" size="100%">Blumchen, K.</style></author><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author><author><style face="normal" font="default" size="100%">Duca, B.</style></author><author><style face="normal" font="default" size="100%">DunnGalvin, A.</style></author><author><style face="normal" font="default" size="100%">Garriga-Baraut, T.</style></author><author><style face="normal" font="default" size="100%">Gowland, M. H.</style></author><author><style face="normal" font="default" size="100%">Egmose, B.</style></author><author><style face="normal" font="default" size="100%">Knibb, R.</style></author><author><style face="normal" font="default" size="100%">Khaleva, E.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Pite, H.</style></author><author><style face="normal" font="default" size="100%">Podesta, M.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Garcia, S.</style></author><author><style face="normal" font="default" size="100%">Timmermans, F.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Paediatrics, Imperial College Healthcare NHS Trust, London, UK.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;The David Hide Asthma and Allergy Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;Primary Care, Population Science and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Department of Paediatric and Adolescent Medicine, Paediatric Pneumology, Allergology and Cystic Fibrosis, University Hospital Frankfurt, Goethe-University, Frankfurt am Main, Germany.&#xD;Department of Clinical and Experimental Medicine, Section of Paediatrics, University of Pisa, Pisa, Italy.&#xD;Department of Child and Adolescent Health, Mater Dei Hospital, Malta.&#xD;Applied Psychology and Paediatrics and Child Health, University College Cork, Cork, Ireland.&#xD;Pediatric Allergy Unit. Vall d&apos;Hebron University Hospital, Barcelona, Spain.&#xD;&apos;Growth and Development&apos; Research Group. Vall d&apos;Hebron Institute of Research (VHIR), Barcelona, Spain.&#xD;Allergy Action, St Albans, UK.&#xD;Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.&#xD;School of Psychology, College of Health and Life Sciences, Aston University, Birmingham, UK.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Allergy Center, CUF Descobertas Hospital and CUF Tejo Hospital; CEDOC, Cardiovascular and Metabolic Pharmacology, iNOVA4Health, NOVA.&#xD;Food Allergy Italia, Italy.&#xD;Department of Women and Children&apos;s Health (Paediatric Allergy, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Allergy Department, Hospital Infantil Universitario del Nino Jesus, Madrid, Spain.&#xD;Nederlands Anafylaxis Netwerk-European Anaphylaxis Taskforce, Dordrecht, The Netherlands.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A practical toolbox for the effective transition of adolescents and young adults with asthma and allergies: An EAACI position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">20-46</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Health Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Caregivers</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">transition</style></keyword><keyword><style face="normal" font="default" size="100%">young adult</style></keyword><keyword><style face="normal" font="default" size="100%">Health Research into the challenges associated with asthma during adolescents. EA</style></keyword><keyword><style face="normal" font="default" size="100%">reports research funding from the Natasha Allergy research Foundation. KB reports</style></keyword><keyword><style face="normal" font="default" size="100%">consulting for Aimmune Therapeutics, DBV Technologies, Bencard Allergie,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">and research grants from Aimmune Therapeutics, DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis and Hipp, outside the submitted work. FT reports being a parent of a</style></keyword><keyword><style face="normal" font="default" size="100%">young adult with food allergy. None of the other authors have anything to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. RK reports research funding from Aimmune Therapeutics, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">National Peanut Board, consulting for Aimmune Therapeutics, speaker fees from DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies and Nutricia.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36176045</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Adolescence is a critical stage of rapid biological, emotional and social change and development. Adolescents and young adults (AYA) with asthma and allergies need to develop the knowledge and skills to self-manage their health independently. Healthcare professionals (HCP), parents and their wider network play an essential role in supporting AYA in this process. Previous work showed significant limitations in transition care across Europe. In 2020, the first evidence-based guideline on effective transition for AYA with asthma and allergies was published by EAACI. AIM: We herein summarize practical resources to support this guideline&apos;s implementation in clinical practice. METHODS: For this purpose, multi-stakeholder Task Force members searched for resources in peer review journals and grey literature. These resources were included if relevant and of good quality and were pragmatically rated for their evidence-basis and user friendliness. RESULTS: Resources identified covered a range of topics and targeted healthcare professionals, AYA, parents/carers, schools, workplace and wider community. Most resources were in English, web-based and had limited evidence-basis. CONCLUSIONS: This position paper provides a valuable selection of practical resources for all stakeholders to support effective transitional care for AYA with asthma and allergies. Future research should focus on developing validated, patient-centred tools to further assist evidence-based transition care.</style></abstract><notes><style face="normal" font="default" size="100%">Vazquez-Ortiz, Marta&#xD;Gore, Claudia&#xD;Alviani, Cherry&#xD;Angier, Elizabeth&#xD;Blumchen, Katharina&#xD;Comberiati, Pasquale&#xD;Duca, Bettina&#xD;DunnGalvin, Audrey&#xD;Garriga-Baraut, Teresa&#xD;Gowland, M Hazel&#xD;Egmose, Britt&#xD;Knibb, Rebecca&#xD;Khaleva, Ekaterina&#xD;Mortz, Charlotte G&#xD;Pfaar, Oliver&#xD;Pite, Helena&#xD;Podesta, Marcia&#xD;Santos, Alexandra F&#xD;Sanchez-Garcia, Silvia&#xD;Timmermans, Frans&#xD;Roberts, Graham&#xD;eng&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):20-46. doi: 10.1111/all.15533. Epub 2022 Oct 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36176045</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10091987</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15533</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1274</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1274</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Trautmann, A.</style></author><author><style face="normal" font="default" size="100%">Bohm, I.</style></author><author><style face="normal" font="default" size="100%">Scherer, K.</style></author><author><style face="normal" font="default" size="100%">Barbaud, A.</style></author><author><style face="normal" font="default" size="100%">Bavbek, S.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Cernadas, J. R.</style></author><author><style face="normal" font="default" size="100%">Chiriac, A. M.</style></author><author><style face="normal" font="default" size="100%">Gaeta, F.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A. M.</style></author><author><style face="normal" font="default" size="100%">Kang, H. R.</style></author><author><style face="normal" font="default" size="100%">Moreno, E.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA-ARADyAL, Malaga, Spain.&#xD;Department of Dermatology and Allergy, University Hospital Wurzburg, Wurzburg, Germany.&#xD;Department of Diagnostic, Interventional, and Pediatric Radiology, Inselspital, University of Bern, Bern, Switzerland.&#xD;Allergology, University Hospital Basel, Basel, Switzerland.&#xD;Service de Dermatologie et Allergologie, Sorbonne Universite, INSERM, Institut Pierre Louis d&apos;Epidemiologie et de Sante Publique, AP-HP, Sorbonne Universite, Hopital Tenon, Paris, France.&#xD;Department of Chest Disease, Division of Immunology and Allergy, School of Medicine, Ankara University, Ankara, Turkey.&#xD;Allergy Unit, Verona University Hospital, Verona, Italy.&#xD;Department of Allergy and Immunology, Centro Hospitalar Universitario de S Joao, Porto, Portugal.&#xD;Department of Pulmonology, Division of Allergy, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France.&#xD;Allergy Unit, Columbus Hospital, Agostino Gemelli IRCCS University Hospital, Rome, Italy.&#xD;Department of Dermatology, Hospital del Mar, IMIM, Universitat Autonoma Barcelona, Barcelona, Spain.&#xD;Department of Internal Medicine, Division of Allergy and Clinical Immunology, Seoul National University College of Medicine, Seoul, Korea.&#xD;Allergy Unit, University Hospital of Salamanca-IBSAL-UMA-ARADyAL, Salamanca, Spain.&#xD;Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1325-1339</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/11/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Contrast Media/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Delayed</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/chemically induced/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Iodine Compounds/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">Iodinated contrast media</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33170954</style></accession-num><abstract><style face="normal" font="default" size="100%">Immediate and nonimmediate hypersensitivity reactions to iodinated contrast media (ICM) have been reported to occur in a frequency of about 0.5%-3% of patients receiving nonionic ICM. The diagnosis and management of these patients vary among guidelines published by various national and international scientific societies, with recommendations ranging from avoidance or premedication to drug provocation test. This position paper aims to give recommendations for the management of patients with ICM hypersensitivity reactions and analyze controversies in this area. Skin tests are recommended as the initial step for diagnosing patients with immediate and nonimmediate hypersensitivity reactions; besides, they may also help guide on tolerability of alternatives. Re-exposition or drug provocation test should only be done with skin test-negative ICMs. The decision for performing either re-exposition or drug provocation test needs to be taken based on a risk-benefit analysis. The role of in vitro tests for diagnosis and pretreatment for preventing reactions remains controversial.</style></abstract><notes><style face="normal" font="default" size="100%">Torres, Maria Jose&#xD;Trautmann, Axel&#xD;Bohm, Ingrid&#xD;Scherer, Kathrin&#xD;Barbaud, Annick&#xD;Bavbek, Sevim&#xD;Bonadonna, Patrizia&#xD;Cernadas, Josefina Rodrigues&#xD;Chiriac, Anca Mirela&#xD;Gaeta, Francesco&#xD;Gimenez-Arnau, Ana M&#xD;Kang, Hye-Ryun&#xD;Moreno, Esther&#xD;Brockow, Knut&#xD;eng&#xD;Practice Guideline&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1325-1339. doi: 10.1111/all.14656.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33170954</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14656</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2947</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2947</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruinemans-Koerts, J.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Hieltjes, Y.</style></author><author><style face="normal" font="default" size="100%">de Waard, H.</style></author><author><style face="normal" font="default" size="100%">Ferwerda, G.</style></author><author><style face="normal" font="default" size="100%">Busch, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Chemistry and Haematology, Rijnstate Hospital, Arnhem, the Netherlands.&#xD;Department of Clinical Chemistry Dicoon BV, Rijnstate Hospital, Arnhem, the Netherlands.&#xD;Department of Internal Medicine, Rijnstate Allergy Center, Rijnstate Hospital, Arnhem, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pre-Analytical Stability of Diagnostic Biomarkers in Primary Blood Tubes for Supporting Remote Allergy Care</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3195-3197</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40577203</style></accession-num><notes><style face="normal" font="default" size="100%">Ruinemans-Koerts, Janneke&#xD;Schmidt-Hieltjes, Yvonne&#xD;de Waard, Harm&#xD;Ferwerda, Gerben&#xD;Busch, Matthias H&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3195-3197. doi: 10.1111/all.16639. Epub 2025 Jun 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40577203</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16639</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2407</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2407</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jee, M. H.</style></author><author><style face="normal" font="default" size="100%">Funch, A. B.</style></author><author><style face="normal" font="default" size="100%">Weber, J. F.</style></author><author><style face="normal" font="default" size="100%">Yeung, K.</style></author><author><style face="normal" font="default" size="100%">Mraz, V.</style></author><author><style face="normal" font="default" size="100%">Gadsboll, A. O.</style></author><author><style face="normal" font="default" size="100%">Song, T.</style></author><author><style face="normal" font="default" size="100%">Woetmann, A.</style></author><author><style face="normal" font="default" size="100%">Odum, N.</style></author><author><style face="normal" font="default" size="100%">Johansen, J. D.</style></author><author><style face="normal" font="default" size="100%">Geisler, C.</style></author><author><style face="normal" font="default" size="100%">Bonefeld, C. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Microbiology, LEO Foundation Skin Immunology Research Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Dermato-Allergology, National Allergy Research Centre, Copenhagen University Hospital Herlev-Gentofte, Hellerup, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pre-existing inflammation reduces the response to contact allergens in Tmem79-deficient mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1978-1981</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/02/17 21:43</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Proteins/genetics/deficiency/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38366993</style></accession-num><notes><style face="normal" font="default" size="100%">Jee, Mia Hamilton&#xD;Funch, Anders Boutrup&#xD;Weber, Julie Friis&#xD;Yeung, Kelvin&#xD;Mraz, Veronika&#xD;Gadsboll, Anne-Sofie Ostergaard&#xD;Song, Tinghuan&#xD;Woetmann, Anders&#xD;Odum, Niels&#xD;Johansen, Jeanne Duus&#xD;Geisler, Carsten&#xD;Bonefeld, Charlotte Menne&#xD;eng&#xD;The Danish Enviromental Protection Agency/&#xD;The Leo Foundation/&#xD;A.P. Moller og Hustru Chastine Mc-Kinney Mollers Fond til almene Formaal/&#xD;The Aase and Ejnar Danielsen Foundation/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1978-1981. doi: 10.1111/all.16053. Epub 2024 Feb 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38366993</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16053</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>91</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">91</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hung, L.</style></author><author><style face="normal" font="default" size="100%">Celik, A.</style></author><author><style face="normal" font="default" size="100%">Yin, X.</style></author><author><style face="normal" font="default" size="100%">Yu, K.</style></author><author><style face="normal" font="default" size="100%">Berenjy, A.</style></author><author><style face="normal" font="default" size="100%">Kothari, A.</style></author><author><style face="normal" font="default" size="100%">Obernolte, H.</style></author><author><style face="normal" font="default" size="100%">Upton, J. E. M.</style></author><author><style face="normal" font="default" size="100%">Lindholm Bogh, K.</style></author><author><style face="normal" font="default" size="100%">Somers, G. R.</style></author><author><style face="normal" font="default" size="100%">Siddiqui, I.</style></author><author><style face="normal" font="default" size="100%">Grealish, M.</style></author><author><style face="normal" font="default" size="100%">Quereshy, F. A.</style></author><author><style face="normal" font="default" size="100%">Sewald, K.</style></author><author><style face="normal" font="default" size="100%">Chiu, P. P. L.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Centre for Computational Medicine, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Division of Advanced Diagnostics, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.&#xD;Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Department of Preclinical Pharmacology and In-Vitro Toxicology, Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.&#xD;Division of Immunology and Allergy, SickKids Food Allergy and Anaphylaxis Program, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;National Food Institute, Technical University of Denmark, Kongens Lyngby, Denmark.&#xD;Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Surgical Pathology, University Health Network, Toronto, Ontario, Canada.&#xD;Surgical Oncology and Minimally Invasive Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.&#xD;Department of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Division of General and Thoracic Surgery, Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Precision cut intestinal slices, a novel model of acute food allergic reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">500-511</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/11/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Pcis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy model</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">intestine</style></keyword><keyword><style face="normal" font="default" size="100%">precision cut intestinal slices</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. JEMU reports grants/research support from DBV Technologies, Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">CIHR, ALK-Abello, SickKids Food Allergy and Anaphylaxis Program, Advisory board</style></keyword><keyword><style face="normal" font="default" size="100%">for Pfizer, Kaleo, Bausch Health, Food Allergy Canada</style></keyword><keyword><style face="normal" font="default" size="100%">in-kind drug donation from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, other for Astra-Zeneca, all outside the current work. TE reports to act</style></keyword><keyword><style face="normal" font="default" size="100%">as local PI for company sponsored trials by DBV Therapeutics, Greer Stallergens,</style></keyword><keyword><style face="normal" font="default" size="100%">and sub-investigator for Regeneron and ALK-Abello. He is Co-Investigator or</style></keyword><keyword><style face="normal" font="default" size="100%">scientific lead in three investigator-initiated oral immunotherapy trials</style></keyword><keyword><style face="normal" font="default" size="100%">supported by the SickKids Food Allergy and Anaphylaxis Program and serves as an</style></keyword><keyword><style face="normal" font="default" size="100%">associate editor for Allergy. He/his laboratory received unconditional/in-kind</style></keyword><keyword><style face="normal" font="default" size="100%">contributions from Macro Array Diagnostics and an unrestricted grant from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello. He holds advisory board roles for ALK-Abello, VAMED, Nutricia/Danone</style></keyword><keyword><style face="normal" font="default" size="100%">and Aimmune. TE reports lecture fees from Novartis, ThermoFisher,</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia/Danone, Aimmune, ALK-Abello.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36377289</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food allergy affects up to 10% of the pediatric population. Despite ongoing efforts, treatment options remain limited. Novel models of food allergy are needed to study response patterns downstream of IgE-crosslinking and evaluate drugs modifying acute events. Here, we report a novel human ex vivo model that displays acute, allergen-specific, IgE-mediated smooth muscle contractions using precision cut intestinal slices (PCIS). METHODS: PCIS were generated using gut tissue samples from children who underwent clinically indicated surgery. Viability and metabolic activity were assessed from 0 to 24 h. Distribution of relevant cell subsets was confirmed using single nucleus RNA sequencing. PCIS were passively sensitized using plasma from peanut allergic donors or peanut-sensitized non-allergic donors, and exposed to various stimuli including serotonin, histamine, FcvarepsilonRI-crosslinker, and food allergens. Smooth muscle contractions and mediator release functioned as readouts. A novel program designed to measure contractions was developed to quantify responses. The ability to demonstrate the impact of antihistamines and immunomodulation from peanut oral immunotherapy (OIT) was assessed. RESULTS: PCIS viability was maintained for 24 h. Cellular distribution confirmed the presence of key cell subsets including mast cells. The video analysis tool reliably quantified responses to different stimulatory conditions. Smooth muscle contractions were allergen-specific and reflected the clinical phenotype of the plasma donor. Tryptase measurement confirmed IgE-dependent mast cell-derived mediator release. Antihistamines suppressed histamine-induced contraction and plasma from successful peanut OIT suppressed peanut-specific PCIS contraction. CONCLUSION: PCIS represent a novel human tissue-based model to study acute, IgE-mediated food allergy and pharmaceutical impacts on allergic responses in the gut.</style></abstract><notes><style face="normal" font="default" size="100%">Hung, Lisa&#xD;Celik, Alper&#xD;Yin, Xiaojun&#xD;Yu, Kai&#xD;Berenjy, Alireza&#xD;Kothari, Akash&#xD;Obernolte, Helena&#xD;Upton, Julia E M&#xD;Lindholm Bogh, Katrine&#xD;Somers, Gino R&#xD;Siddiqui, Iram&#xD;Grealish, Martin&#xD;Quereshy, Fayez A&#xD;Sewald, Katherina&#xD;Chiu, Priscilla P L&#xD;Eiwegger, Thomas&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):500-511. doi: 10.1111/all.15579. Epub 2022 Nov 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36377289</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10098956</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15579</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2915</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2915</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Luo, S.</style></author><author><style face="normal" font="default" size="100%">Hao, X.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Hu, J.</style></author><author><style face="normal" font="default" size="100%">Yang, J.</style></author><author><style face="normal" font="default" size="100%">Qin, H.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Beijing Wisdomab Biotechnology Co. Ltd, Beijing, China.&#xD;State Key Laboratory of Chemo and Biosensing, Hunan Research Center of the Basic Discipline for Cell Signaling, College of Biology, Hunan University, Changsha, China.&#xD;Genrix (Shanghai) Biopharmaceutical Co. Ltd, Shanghai, China.&#xD;Chongqing Genrix Biopharmaceutical Co. Ltd., Chongqing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Preclinical Development of GR2002, a Novel Anti-TSLP Bispecific Antibody With Potent TSLP Inhibitory Effects</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2077-2080</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40372096</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Xueping&#xD;Luo, Suya&#xD;Hao, Xiaobo&#xD;Liu, Yulan&#xD;Hu, Junjie&#xD;Yang, Jiaqian&#xD;Qin, Hongtao&#xD;Liu, Zhigang&#xD;eng&#xD;CSTB2023TIAD-STX0005/Chongqing Municipal Technology Innovation and Application Development Special Program/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2077-2080. doi: 10.1111/all.16591. Epub 2025 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40372096</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16591</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2674</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2674</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patniboon, P.</style></author><author><style face="normal" font="default" size="100%">Thanasarnthungcharoen, C.</style></author><author><style face="normal" font="default" size="100%">Chanasit, S.</style></author><author><style face="normal" font="default" size="100%">Fievez, L.</style></author><author><style face="normal" font="default" size="100%">Kaewamatawong, T.</style></author><author><style face="normal" font="default" size="100%">Bureau, F.</style></author><author><style face="normal" font="default" size="100%">Jacquet, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.&#xD;Medical Microbiology, Graduate School, Chulalongkorn University, Bangkok, Thailand.&#xD;Laboratory of Cellular and Molecular Immunology, GIGA-Research, University of Liege, Liege, Belgium.&#xD;Veterinary Pathology Unit, Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Preclinical development of virus-like particle (VLP)-based immunotherapy against house dust mite allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">872-876</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/10/25</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39450698</style></accession-num><notes><style face="normal" font="default" size="100%">Patniboon, Piyachat&#xD;Thanasarnthungcharoen, Chanatip&#xD;Chanasit, Supapich&#xD;Fievez, Laurence&#xD;Kaewamatawong, Theerayuth&#xD;Bureau, Fabrice&#xD;Jacquet, Alain&#xD;eng&#xD;Thailand Science Research and Innovation (TSRI) Fund Chulalongkorn University/&#xD;90th Anniversary of Chulalongkorn University Ratchadaphiseksomphot Fund/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):872-876. doi: 10.1111/all.16375. Epub 2024 Oct 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39450698</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16375</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>961</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">961</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Remington, B. C.</style></author><author><style face="normal" font="default" size="100%">Koppelman, S. J.</style></author><author><style face="normal" font="default" size="100%">Green, T. D.</style></author><author><style face="normal" font="default" size="100%">Lack, G.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Campbell, D. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Food Allergy Research and Resource Program, University of Nebraska, Lincoln, NE, USA.&#xD;Remington Consulting Group BV, Utrecht, The Netherlands.&#xD;DBV Technologies, Montrouge, France.&#xD;UPMC Children&apos;s Hospital of Pittsburgh, Pittsburgh, PA, USA.&#xD;Paediatric Allergy Group, Department of Women and Children&apos;s Health, School of Life Course Sciences, King&apos;s College London, London, UK.&#xD;Peter Gorer Department of Immunobiology, School of Immunology &amp; Microbial Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Guy&apos;s and St. Thomas&apos; NHS Foundation Trust, London, UK.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Clinical and Experimental Sciences and Human Development in Health, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;Department of Allergy &amp; Immunology, Children&apos;s Hospital at Westmead, Sydney, NSW, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3223-3226</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/06/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34077581</style></accession-num><notes><style face="normal" font="default" size="100%">Remington, Benjamin C&#xD;Koppelman, Stef J&#xD;Green, Todd D&#xD;Lack, Gideon&#xD;Roberts, Graham&#xD;Campbell, Dianne E&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3223-3226. doi: 10.1111/all.14973. Epub 2021 Jun 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34077581</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9291584 Technologies, during the conduct of the study; non-financial support from ILSI Europe, outside the submitted work; and is an adjunct faculty member of the University of Nebraska. Dr. Koppelman reports grants, personal fees, and other from DBV Technologies and grants from University of Nebraska, during the conduct of the study; personal fees and other from DBV Technologies, outside the submitted work; and is an adjunct faculty member of the University of Nebraska. Dr. Green reports other from DBV Technologies, during the conduct of the study. Dr. Lack reports grants from National Institute of Allergy and Infectious Diseases (NIAID, NIH), other from Food Allergy &amp; Research Education (FARE), MRC &amp; Asthma UK Centre, UK Dept of Health through NIHR, National Peanut Board (NPB), and The Davis Foundation, and grants from UK Food Standards Agency (FSA), during the conduct of the study; and personal fees and other from DBV Technologies, other from Mighty Mission Me, personal fees from Novartis, Sanofi-Genzyme, Regeneron, and ALK-Abello, and personal fees and other from Lurie Children&apos;s Hospital, outside the submitted work. Dr. Roberts reports acting as a consultant to DBV during the conduct of the study. Dr. Campbell reports personal fees from DBV, during the conduct of the study; and grants from National Health and Medical Research Council of Australia, personal fees from AllerGenis, and other from Nestle Health Science and from Westmead Fertility Centre, outside the submitted work.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14973</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>276</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">276</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soyka, M. B.</style></author><author><style face="normal" font="default" size="100%">Ryser, F. S.</style></author><author><style face="normal" font="default" size="100%">Bruhlmann, C.</style></author><author><style face="normal" font="default" size="100%">Fehr, D.</style></author><author><style face="normal" font="default" size="100%">Dulgeroglu, J.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">Steiner, U. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Allergy Unit, Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1036-1046</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/09/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/drug therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">anti IL-4/13</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">predictor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36161658</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chronic rhinosinusitis with a type 2 inflammatory pattern (T2CRS) is believed to be restricted to the nose and sinuses and associated with polyps, without clear serologic markers. Dupilumab is a promising new therapy in difficult to treat T2CRS. No factors are known to predict dupilumab treatment outcome. METHODS: Patients undergoing dupilumab treatment were assessed clinically to report ultra-short- and short-term outcome up to 90 days. Serum samples were taken on day 0 and 30 days of treatment, and proteomic analyses were performed using Olink(R). The results were compared with healthy controls (HC). The aim was to identify clinical and serological markers associated with a treatment response to dupilumab. Confirmation of predictive parameters was evaluated in a prospective cohort of 20 T2CRS patients. RESULTS: Thirty patients were included, 80% of which were treatment responders. SinoNasalOutcomeTest-20 (SNOT-20) scores and the total nasal polyp score improved significantly (p &lt; .05) on Day 7. An improvement of 2.5 points at the first visit was associated with a favorable outcome with a sensitivity of 86%. Proteomic analyses revealed significant changes compared with HC. Furthermore, we could identify OPG in the serum of dupilumab-treated patients that may serve as a predictor of the clinical outcome of dupilumab treatment. The predictive value of OPG was confirmed in the second cohort. CONCLUSION: Clinical response after 1 week of treatment with dupilumab is highly associated with a favorable outcome. High sensitivity proteomic analyses can identify T2CRS-specific dysregulated proteins in serum. Serum OPG may serve as a predictor for dupilumab treatment outcome before the initiation of any therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Soyka, Michael B&#xD;Ryser, Fabio S&#xD;Bruhlmann, Catrin&#xD;Fehr, Danielle&#xD;Dulgeroglu, Jacqueline&#xD;Schmid-Grendelmeier, Peter&#xD;Bruggen, Marie-Charlotte&#xD;Steiner, Urs C&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):1036-1046. doi: 10.1111/all.15532. Epub 2022 Oct 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36161658</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15532</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1333</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1333</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lyons, S. A.</style></author><author><style face="normal" font="default" size="100%">Knulst, A. C.</style></author><author><style face="normal" font="default" size="100%">Burney, P. G. J.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B. K.</style></author><author><style face="normal" font="default" size="100%">Barreales, L.</style></author><author><style face="normal" font="default" size="100%">Bieli, C.</style></author><author><style face="normal" font="default" size="100%">Clausen, M.</style></author><author><style face="normal" font="default" size="100%">Dubakiene, R.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Perez, C.</style></author><author><style face="normal" font="default" size="100%">Jedrzejczak-Czechowicz, M.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author><author><style face="normal" font="default" size="100%">Kummeling, I.</style></author><author><style face="normal" font="default" size="100%">Kralimarkova, T.</style></author><author><style face="normal" font="default" size="100%">Mustakov, T. B.</style></author><author><style face="normal" font="default" size="100%">van Os-Medendorp, H.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Potts, J.</style></author><author><style face="normal" font="default" size="100%">Versteeg, S. A.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Welsing, P. M. J.</style></author><author><style face="normal" font="default" size="100%">Mills, C.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Le, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Allergy Department, Hospital Clinico San Carlos, IdISSC, ARADyAL, RD16/0006/0009, Madrid, Spain.&#xD;Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Clinic for Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland.&#xD;Clinical Epidemiology Unit, Preventive Medicine Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.&#xD;Department of Paediatric Pulmonology, University Children&apos;s Hospital, Zurich, Switzerland.&#xD;Children&apos;s Hospital, Landspitali University Hospital, Reykjavik, Iceland.&#xD;Medical Faculty, Vilnius University, Vilnius, Lithuania.&#xD;Department of Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.&#xD;Clinical Centre of Allergology of the Alexandrovska Hospital, Medical University of Sofia, Sofia, Bulgaria.&#xD;Saxion University of Applied Sciences, Deventer, The Netherlands.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.&#xD;University Hospital Sv. Ivan Rilski, Sofia, Bulgaria.&#xD;Department of Experimental Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands.&#xD;Division of Internal Medicine and Dermatology, University Medical Center Utrecht, Utrecht University, The Netherlands.&#xD;Division of Infection, Immunity and Respiratory Medicine, Manchester Institute of Biotechnology &amp; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Center, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Predicting food allergy: The value of patient history reinforced</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1454-1462</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">patient history</style></keyword><keyword><style face="normal" font="default" size="100%">prediction</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia, HAL Allergy, Menarine/Faes Farma, Sanofi, Mylan/Meda, Biomay,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GSK, MSD, ASIT Biotech, Boehringer Ingelheim</style></keyword><keyword><style face="normal" font="default" size="100%">and grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Gerolymatos International SA, and Capricare. Dr Fernandez-Rivas reports grants</style></keyword><keyword><style face="normal" font="default" size="100%">from Aimmune and Diater, and personal fees from Aimmune, Diater, ALK, DBV,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics, GSK, HAL Allergy, Thermo Fisher Scientific and SPRIM. Dr</style></keyword><keyword><style face="normal" font="default" size="100%">Ballmer-Weber reports personal fees from Thermo Fisher Scientific. Dr Xepapadaki</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees from Uriach, Novartis, Nestle, and Nutricia. Dr Mills</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from Reacta Biotech</style></keyword><keyword><style face="normal" font="default" size="100%">and is shareholder of Reacta Biotech Ltd. Dr</style></keyword><keyword><style face="normal" font="default" size="100%">Van Ree reports personal fees from HAL Allergy BV, Citeq BV, Angany Inc, and</style></keyword><keyword><style face="normal" font="default" size="100%">Thermo Fisher Scientific. The other authors declare that they have no relevant</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32894581</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: EAACI guidelines emphasize the importance of patient history in diagnosing food allergy (FA) and the need for studies investigating its value using standardized allergy-focused questionnaires. OBJECTIVE: To determine the contribution of reaction characteristics, allergic comorbidities and demographics to prediction of FA in individuals experiencing food-related adverse reactions. METHODS: Adult and school-age participants in the standardized EuroPrevall population surveys, with self-reported FA, were included. Penalized multivariable regression was used to assess the association of patient history determinants with &quot;probable&quot; FA, defined as a food-specific case history supported by relevant IgE sensitization. RESULTS: In adults (N = 844), reproducibility of reaction (OR 1.35 [95% CI 1.29-1.41]), oral allergy symptoms (OAS) (4.46 [4.19-4.75]), allergic rhinitis (AR) comorbidity (2.82 [2.68-2.95]), asthma comorbidity (1.38 [1.30-1.46]) and male sex (1.50 [1.41-1.59]) were positively associated with probable FA. Gastrointestinal symptoms (0.88 [0.85-0.91]) made probable FA less likely. The AUC of a model combining all selected predictors was 0.85 after cross-validation. In children (N = 670), OAS (2.26 [2.09-2.44]) and AR comorbidity (1.47 [CI 1.39-1.55]) contributed most to prediction of probable FA, with a combined cross-validation-based AUC of 0.73. When focusing on plant foods, the dominant source of FA in adults, the pediatric model also included gastrointestinal symptoms (inverse association), and the AUC increased to 0.81. CONCLUSIONS: In both adults and school-age children from the general population, reporting of OAS and of AR comorbidity appear to be the strongest predictors of probable FA. Patient history particularly allows for good discrimination between presence and absence of probable plant FA.</style></abstract><notes><style face="normal" font="default" size="100%">Lyons, Sarah A&#xD;Knulst, Andre C&#xD;Burney, Peter G J&#xD;Fernandez-Rivas, Montserrat&#xD;Ballmer-Weber, Barbara K&#xD;Barreales, Laura&#xD;Bieli, Christian&#xD;Clausen, Michael&#xD;Dubakiene, Ruta&#xD;Fernandez-Perez, Cristina&#xD;Jedrzejczak-Czechowicz, Monika&#xD;Kowalski, Marek L&#xD;Kummeling, Ischa&#xD;Kralimarkova, Tanya&#xD;Mustakov, Tihomir B&#xD;van Os-Medendorp, Harmieke&#xD;Papadopoulos, Nikolaos G&#xD;Popov, Todor A&#xD;Potts, James&#xD;Versteeg, Serge A&#xD;Xepapadaki, Paraskevi&#xD;Welsing, Paco M J&#xD;Mills, Clare&#xD;van Ree, Ronald&#xD;Le, Thuy-My&#xD;eng&#xD;BBS/E/F/00041800/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1454-1462. doi: 10.1111/all.14583. Epub 2020 Sep 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32894581</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246712</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14583</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1353</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1353</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lauffer, F.</style></author><author><style face="normal" font="default" size="100%">Baghin, V.</style></author><author><style face="normal" font="default" size="100%">Standl, M.</style></author><author><style face="normal" font="default" size="100%">Stark, S. P.</style></author><author><style face="normal" font="default" size="100%">Jargosch, M.</style></author><author><style face="normal" font="default" size="100%">Wehrle, J.</style></author><author><style face="normal" font="default" size="100%">Thomas, J.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Biedermann, T.</style></author><author><style face="normal" font="default" size="100%">Eyerich, S.</style></author><author><style face="normal" font="default" size="100%">Eyerich, K.</style></author><author><style face="normal" font="default" size="100%">Garzorz-Stark, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.&#xD;Institute of Epidemiology, Helmholtz Center Munich - German Research Center for Environmental Health, Neuherberg, Germany.&#xD;ZAUM - Center of Allergy and Environment, Technical University of Munich and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.&#xD;Department of Medicine I, Medical Center, University of Freiburg, Freiburg, Germany.&#xD;German Cancer Consortium (DKTK), Freiburg, Germany.&#xD;German Cancer Research Center (DKFZ), Heidelberg, Germany.&#xD;Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1158-1172</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/08/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic eczema</style></keyword><keyword><style face="normal" font="default" size="100%">endotype</style></keyword><keyword><style face="normal" font="default" size="100%">predictive biomarker</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32794228</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is the most common inflammatory skin disease in children, with 30% of all those diagnosed developing chronic or relapsing disease by adolescence. Such disease persistence cannot yet be predicted. The aim of the present study was to predict the natural course of AD using clinical parameters and serum proteins. METHODS: Sera of 144 children with AD (age 0-3 years) were analyzed for IgE and 33 cytokines, chemokines, and growth factors. Patient disease course until the age of 7 years was assessed retrospectively. Unsupervised k-means clustering was performed to define disease endotypes. Identified factors associated with AD persistence at the age of 7 years were validated in children with AD in an independent cohort (LISA Munich; n = 168). Logistic regression and XGBoosting methods followed by cross-validation were applied to predict individual disease outcomes. RESULTS: Three distinct endotypes were found in infancy, characterized by a unique inflammatory signature. Factors associated with disease persistence were disease score (SCORAD), involvement of the limbs, flexural lesion distribution at the age of 3 years, allergic comorbidities, and disease exacerbation by the trigger factors stress, pollen exposure, and change in weather. Persistence was predicted with a sensitivity of 81.8% and a specificity of 82.4%. Factors with a high impact on the prediction of persistence were SCORAD at the age of 3 years, trigger factors, and low VEGF serum levels. CONCLUSION: Atopic dermatitis in infancy comprises three immunological endotypes. Disease persistence can be predicted using serum cytokines and clinical variables.</style></abstract><notes><style face="normal" font="default" size="100%">Lauffer, Felix&#xD;Baghin, Veronika&#xD;Standl, Marie&#xD;Stark, Sebastian P&#xD;Jargosch, Manja&#xD;Wehrle, Julius&#xD;Thomas, Jenny&#xD;Schmidt-Weber, Carsten B&#xD;Biedermann, Tilo&#xD;Eyerich, Stefanie&#xD;Eyerich, Kilian&#xD;Garzorz-Stark, Natalie&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1158-1172. doi: 10.1111/all.14557. Epub 2020 Sep 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32794228</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14557</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>353</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">353</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suprun, M.</style></author><author><style face="normal" font="default" size="100%">Kearney, P.</style></author><author><style face="normal" font="default" size="100%">Hayward, C.</style></author><author><style face="normal" font="default" size="100%">Butler, H.</style></author><author><style face="normal" font="default" size="100%">Getts, R.</style></author><author><style face="normal" font="default" size="100%">Sicherer, S. H.</style></author><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author><author><style face="normal" font="default" size="100%">Campbell, D. E.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;AllerGenis LLC, Hatfield, Pennsylvania, USA.&#xD;National Heart &amp; Lung Institute, Imperial College London, England, UK.&#xD;The University of Sydney, Sydney, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Predicting probability of tolerating discrete amounts of peanut protein in allergic children using epitope-specific IgE antibody profiling</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3061-3069</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/08/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Arachis/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Probability</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Ctd</style></keyword><keyword><style face="normal" font="default" size="100%">Dbpcfc</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">Ofc</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">epitope</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Butler, and Robert Getts are employees of AllerGenis LLC. Dr. Getts has a patent</style></keyword><keyword><style face="normal" font="default" size="100%">PCT/US15/020715 (WO) pending. Scott H Sicherer reports royalty payments from</style></keyword><keyword><style face="normal" font="default" size="100%">UpToDate and from Johns Hopkins University Press</style></keyword><keyword><style face="normal" font="default" size="100%">grants to his institution from</style></keyword><keyword><style face="normal" font="default" size="100%">the National Institute of Allergy and Infectious Diseases, and from Food Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Research and Education</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from the American Academy of Allergy,</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma and Immunology as Deputy Editor of the Journal of Allergy and Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Immunology: In Practice, outside of the submitted work. Paul J. Turner reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from UK Medical Research Council, NIHR/Imperial Biomedical Research Centre</style></keyword><keyword><style face="normal" font="default" size="100%">and Jon Moulton Charity Trust</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from UK Food Standards Agency,</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune Therapeutics, Allergenis, Aquestive Therapeutics, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. Dianne E Campbell is a part-time employee of DBV Technologies and reports</style></keyword><keyword><style face="normal" font="default" size="100%">receiving grant support from National Health and Medical Research Council of</style></keyword><keyword><style face="normal" font="default" size="100%">Australia and personal fees from Allergenis (Advisory board) and Westmead</style></keyword><keyword><style face="normal" font="default" size="100%">Fertility Centre (Governance committee). Hugh A Sampson reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance Network, and NIH-NIAID, consulting fees from DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">N-Fold, LLC, and Siolta Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">Mount Sinai has licensed the technology for</style></keyword><keyword><style face="normal" font="default" size="100%">a bead-based epitope assay for food-allergen epitope analysis to AllerGenis LLC,</style></keyword><keyword><style face="normal" font="default" size="100%">where Dr. Sampson serves as an unpaid Board of Directors member and advisor.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35960650</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IgE-epitope profiling can accurately diagnose clinical peanut allergy. OBJECTIVE: We sought to determine whether sequential (linear) epitope-specific IgE (ses-IgE) profiling can provide probabilities of tolerating discrete doses of peanut protein in allergic subjects undergoing double-blind, placebo-controlled food challenges utilizing PRACTALL dosing. METHODS: Sixty four ses-IgE antibodies were quantified in blood samples using a bead-based epitope assay. A pair of ses-IgEs that predicts Cumulative Tolerated Dose (CTD) was determined using regression in 75 subjects from the discovery cohort. This epitope-based predictor was validated on 331 subjects from five independent cohorts (ages 4-25 years). Subjects were grouped based on their predicted values and probabilities of reactions at each CTD threshold were calculated. RESULTS: In discovery, an algorithm using two ses-IgE antibodies was correlated with CTDs (rho = 0.61, p &lt; .05); this correlation was 0.51 (p &lt; .05) in validation. Using the ses-IgE-based predictor, subjects were assigned into &quot;high,&quot; &quot;moderate,&quot; or &quot;low&quot; dose-reactivity groups. On average, subjects in the &quot;high&quot; group were four times more likely to tolerate a specific dose, compared with the &quot;low&quot; group. For example, predicted probabilities of tolerating 4, 14, 44, and 144 or 444 mg in the &quot;low&quot; group were 92%, 77%, 53%, 29%, and 10% compared with 98%, 95%, 94%, 88%, and 73% in the &quot;high&quot; group. CONCLUSIONS: Accurate predictions of food challenge thresholds are complex due to factors including limited responder sample sizes at each dose and variations in study-specific challenge protocols. Despite these limitations, an epitope-based predictor was able to accurately identify CTDs and may provide a useful surrogate for peanut challenges.</style></abstract><notes><style face="normal" font="default" size="100%">Suprun, Maria&#xD;Kearney, Paul&#xD;Hayward, Clive&#xD;Butler, Heather&#xD;Getts, Robert&#xD;Sicherer, Scott H&#xD;Turner, Paul J&#xD;Campbell, Dianne E&#xD;Sampson, Hugh A&#xD;eng&#xD;AI-066738/AI/NIAID NIH HHS/&#xD;MR/K010468/1/MRC_/Medical Research Council/United Kingdom&#xD;U19 AI136053/AI/NIAID NIH HHS/&#xD;U19AI066738/AI/NIAID NIH HHS/&#xD;U01AI066560/AI/NIAID NIH HHS/&#xD;U01 AI066560/AI/NIAID NIH HHS/&#xD;MRC_/Medical Research Council/United Kingdom&#xD;Randomized Controlled Trial&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3061-3069. doi: 10.1111/all.15477. Epub 2022 Aug 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35960650</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10286745</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15477</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2525</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2525</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kucharczyk, A.</style></author><author><style face="normal" font="default" size="100%">Marczyk, K.</style></author><author><style face="normal" font="default" size="100%">Kucharczyk, B.</style></author><author><style face="normal" font="default" size="100%">Plisko, R.</style></author><author><style face="normal" font="default" size="100%">Perkowska, J.</style></author><author><style face="normal" font="default" size="100%">Owczarek, W.</style></author><author><style face="normal" font="default" size="100%">Jahnz-Rozyk, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Diseases, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine - National Research Institute, Warszawa, Poland.&#xD;Medical Faculty I, Medical University of Warsaw, Warszawa, Poland.&#xD;HTA Consulting, Krakow, Poland.&#xD;Department of Infectious Diseases and Allergology, Military Institute of Medicine - National Research Institute, Warszawa, Poland.&#xD;Department of Dermatology, Military Institute of Medicine - National Research Institute, Warszawa, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Predicting relapse in chronic spontaneous urticaria: A retrospective cohort study evaluating omalizumab withdrawal regimens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2554-2557</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">risk factors</style></keyword><keyword><style face="normal" font="default" size="100%">withdrawal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38922945</style></accession-num><notes><style face="normal" font="default" size="100%">Kucharczyk, Aleksandra&#xD;Marczyk, Katarzyna&#xD;Kucharczyk, Barbara&#xD;Plisko, Robert&#xD;Perkowska, Jolanta&#xD;Owczarek, Witold&#xD;Jahnz-Rozyk, Karina&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2554-2557. doi: 10.1111/all.16194. Epub 2024 Jun 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38922945</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16194</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>714</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">714</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Hao, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, B.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Q.</style></author><author><style face="normal" font="default" size="100%">Zhao, J.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, P.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, P.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Nasal Diseases and Beijing Laboratory of Allergic Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, China.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, Fujian Provincial Hospital, Fuzhou, China.&#xD;Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, Beijing Children&apos;s Hospital, Capital Medical University, National Center for Children&apos;s Health, Beijing, China.&#xD;Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Predicting the recurrence of chronic rhinosinusitis with nasal polyps using nasal microbiota</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">540-549</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/diagnosis/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/diagnosis/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Lasso</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">nasal microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">prediction model</style></keyword><keyword><style face="normal" font="default" size="100%">recurrence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34735742</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Recent studies have revealed that the nasal microbiota in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is profoundly altered and is correlated with systemic inflammation. However, little is known regarding whether the microbiota can be utilized to predict nasal polyp recurrence. This study is aimed to determine whether altered nasal microbiota constituents could be used as biomarkers to predict CRSwNP recurrence. METHODS: Nasal microbiota constituents were quantified and characterized using bacterial 16S ribosomal RNA gene sequencing. Selected features for least absolute shrinkage and selection operator regression-based predictors were the nasal microbiota community composition and CRSwNP patient clinical characteristics. The primary outcome was recurrence, which was determined post-admission. RESULTS: By distinguishing recurrence-associated nasal microbiota taxa and exploiting the distinct nasal microbiota abundance between patients with recurrent and non-recurrent CRSwNP, we developed a predictive classifier for the diagnosis of nasal polyps&apos; recurrence with 91.4% accuracy. CONCLUSIONS: Key taxonomical features of the nasal microbiome could predict recurrence in CRSwNP patients. The nasal microbiome is an understudied source of clinical variation in CRSwNP and represents a novel therapeutic target for future prevention and treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Zhao, Yan&#xD;Chen, Junru&#xD;Hao, Yun&#xD;Wang, Boqian&#xD;Wang, Yue&#xD;Liu, Qinghua&#xD;Zhao, Jinming&#xD;Li, Ying&#xD;Wang, Ping&#xD;Wang, Xiangdong&#xD;Zhang, Peng&#xD;Zhang, Luo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):540-549. doi: 10.1111/all.15168. Epub 2021 Nov 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34735742</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15168</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2222</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2222</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Farhan, A. J.</style></author><author><style face="normal" font="default" size="100%">Kothalawala, D. M.</style></author><author><style face="normal" font="default" size="100%">Kurukulaaratchy, R. J.</style></author><author><style face="normal" font="default" size="100%">Granell, R.</style></author><author><style face="normal" font="default" size="100%">Simpson, A.</style></author><author><style face="normal" font="default" size="100%">Murray, C.</style></author><author><style face="normal" font="default" size="100%">Custovic, A.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Arshad, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The David Hide Asthma and Allergy Research Centre, St. Mary&apos;s Hospital, Isle of Wight, UK.&#xD;Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;NIHR Biomedical Research Centre, University Hospital Southampton, Southampton, UK.&#xD;Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.&#xD;Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester Academic Health Science Centre, and Manchester University NHS Foundation Trust, Manchester, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prediction of adult asthma risk in early childhood using novel adult asthma predictive risk scores</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2969-2979</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/09/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">Logistic Models</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Sounds</style></keyword><keyword><style face="normal" font="default" size="100%">allergic sensitisation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">prediction</style></keyword><keyword><style face="normal" font="default" size="100%">risk scores</style></keyword><keyword><style face="normal" font="default" size="100%">wheeze</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37661293</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Numerous risk scores have been developed to predict childhood asthma. However, they may not predict asthma beyond childhood. We aim to create childhood risk scores that predict development and persistence of asthma up to young adult life. METHODS: The Isle of Wight Birth Cohort (n = 1456) was prospectively assessed up to 26 years of age. Asthma predictive scores were developed based on factors during the first 4 years, using logistic regression and tested for sensitivity, specificity and area under the curve (AUC) for prediction of asthma at (i) 18 and (ii) 26 years, and persistent asthma (PA) (iii) at 10 and 18 years, and (iv) at 10, 18 and 26 years. Models were internally and externally validated. RESULTS: Four models were generated for prediction of each asthma outcome. ASthma PredIctive Risk scorE (ASPIRE)-1: a 2-factor model (recurrent wheeze [RW] and positive skin prick test [+SPT] at 4 years) for asthma at 18 years (sensitivity: 0.49, specificity: 0.80, AUC: 0.65). ASPIRE-2: a 3-factor model (RW, +SPT and maternal rhinitis) for asthma at 26 years (sensitivity: 0.60, specificity: 0.79, AUC: 0.73). ASPIRE-3: a 3-factor model (RW, +SPT and eczema at 4 years) for PA-18 (sensitivity: 0.63, specificity: 0.87, AUC: 0.77). ASPIRE-4: a 3-factor model (RW, +SPT at 4 years and recurrent chest infection at 2 years) for PA-26 (sensitivity: 0.68, specificity: 0.87, AUC: 0.80). ASPIRE-1 and ASPIRE-3 scores were replicated externally. Further assessments indicated that ASPIRE-1 can be used in place of ASPIRE-2-4 with same predictive accuracy. CONCLUSION: ASPIRE predicts persistent asthma up to young adult life.</style></abstract><notes><style face="normal" font="default" size="100%">Farhan, Abdal J&#xD;Kothalawala, Dilini M&#xD;Kurukulaaratchy, Ramesh J&#xD;Granell, Raquel&#xD;Simpson, Angela&#xD;Murray, Clare&#xD;Custovic, Adnan&#xD;Roberts, Graham&#xD;Zhang, Hongmei&#xD;Arshad, S Hasan&#xD;eng&#xD;G0601361/MRC_/Medical Research Council/United Kingdom&#xD;R01 AI121426/AI/NIAID NIH HHS/&#xD;R01 AI121226/AI/NIAID NIH HHS/&#xD;R01 HL082925/HL/NHLBI NIH HHS/&#xD;NH/NIH HHS/&#xD;WT_/Wellcome Trust/United Kingdom&#xD;MR/L012693/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2969-2979. doi: 10.1111/all.15876. Epub 2023 Sep 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37661293</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10840748</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15876</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3079</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3079</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rattu, A.</style></author><author><style face="normal" font="default" size="100%">Dixey, P.</style></author><author><style face="normal" font="default" size="100%">Charles, D.</style></author><author><style face="normal" font="default" size="100%">Brightling, C.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Bossios, A.</style></author><author><style face="normal" font="default" size="100%">Bourdin, A.</style></author><author><style face="normal" font="default" size="100%">Djukanovic, R.</style></author><author><style face="normal" font="default" size="100%">Dahlen, S. E.</style></author><author><style face="normal" font="default" size="100%">Fleming, L.</style></author><author><style face="normal" font="default" size="100%">Chaudhuri, R.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Deschildre, A.</style></author><author><style face="normal" font="default" size="100%">Pilette, C.</style></author><author><style face="normal" font="default" size="100%">Koppelman, G. H.</style></author><author><style face="normal" font="default" size="100%">Exley, A.</style></author><author><style face="normal" font="default" size="100%">Anckers, F.</style></author><author><style face="normal" font="default" size="100%">Miller, S.</style></author><author><style face="normal" font="default" size="100%">Nielsen, H.</style></author><author><style face="normal" font="default" size="100%">Williams, C.</style></author><author><style face="normal" font="default" size="100%">Khaleva, E.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">T. R. consortium Respiratory Work Package</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;National Heart Lung Institute, Imperial College, London, UK.&#xD;Royal Brompton Hospital, London, UK.&#xD;Academic Clinical Medicine, Southampton General Hospital, Southampton, UK.&#xD;Institute for Lung Health, Leicester NIHR BRC, University of Leicester, Leicester, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Karolinska Severe Asthma Center, Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.&#xD;Division of Lung and Airway Research, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.&#xD;Lung Laboratory, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.&#xD;PhyMedExp, University of Montpellier, Montpellier, France.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, UK.&#xD;Sir Henry Wellcome Laboratories, Southampton, UK.&#xD;Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Huddinge, Sweden.&#xD;Department of Medicine, Huddinge, Karolinska Institutet, and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Imperial College Healthcare Trust and National Heart and Lung Institute, Imperial College, London, UK.&#xD;School of Infection and Immunity, University of Glasgow, Glasgow, UK.&#xD;Department of Clinical Science and Education Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;CHU Lille, Unite de Pneumologie et Allergologie Pediatrique, Hopital Jeanne de Flandre, Lille, France.&#xD;Univ. Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, Lille, France.&#xD;Department of Pulmonology, Cliniques Universitaires Saint-Luc and Pole of Lung, Nose and Skin Research (LUNS), Institute of Experimental and Clinical Research (IREC), Brussels, Belgium.&#xD;Department of Pediatric Pulmonology and Pediatric Allergology, University of Groningen, University Medical Center Groningen, Beatrix Children&apos;s Hospital, Groningen, the Netherlands.&#xD;Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.&#xD;Adept Biologica Consulting Limited, London, UK.&#xD;Patient and Public Involvement Representative, Sweden.&#xD;Patient and Public Involvement Representative, UK.&#xD;Falu Lasarett, Region Dalarna, Falun, Sweden.&#xD;European Lung Foundation, Sheffield, UK.&#xD;Royal Hampshire County Hospital, Winchester, UK.&#xD;Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Paediatric Allergy and Respiratory Medicine, University Hospital Southampton NHS Foundation Trust, Southampton, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">24-55</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/09/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">predictive biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">response</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Initiative 2 Joint Undertaking (JU) under grant agreement No. 831434 (3TR) and</style></keyword><keyword><style face="normal" font="default" size="100%">National Institute for Health and Care Research (NIHR) Southampton Biomedical</style></keyword><keyword><style face="normal" font="default" size="100%">Research Centre (BRC). Chris Brightling declares grants and consulting fees from</style></keyword><keyword><style face="normal" font="default" size="100%">4D Pharma, Areteia, AstraZeneca (AZ), Chiesi, Genentech, GlaxoSmithKline (GSK),</style></keyword><keyword><style face="normal" font="default" size="100%">Mologic, Novartis, Regeneron Pharmaceuticals, Roche, and Sanofi paid to his</style></keyword><keyword><style face="normal" font="default" size="100%">institution</style></keyword><keyword><style face="normal" font="default" size="100%">and support from the 3TR EU IMI2 project and NIHR BRC. Kian Fan</style></keyword><keyword><style face="normal" font="default" size="100%">Chung has received grants from MRC, EPSRC, and GSK paid to his institution</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria for speaking engagements for GSK, Novartis, AZ</style></keyword><keyword><style face="normal" font="default" size="100%">remuneration for</style></keyword><keyword><style face="normal" font="default" size="100%">participation in Advisory Board meetings of GSK, AZ, Novartis, Roche, Merck,</style></keyword><keyword><style face="normal" font="default" size="100%">Trevi, Rickett-Beckinson, Nocion, Shionogi, and participation in the Scientific</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Board of the Clean Breathing Institute supported by Haleon. Apostolos</style></keyword><keyword><style face="normal" font="default" size="100%">Bossios has received honoraria for lectures from AZ, GSK, Chiesi, and an</style></keyword><keyword><style face="normal" font="default" size="100%">institutional grant from AZ outside of the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">is head of Assembly</style></keyword><keyword><style face="normal" font="default" size="100%">five for the European Respiratory Society (ERS), co-chair of the Nordic Severe</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma Network (NSAN), member of the steering committee of SHARP, ERS severe</style></keyword><keyword><style face="normal" font="default" size="100%">asthma Clinical Research Collaboration, and member of the Swedish National Airway</style></keyword><keyword><style face="normal" font="default" size="100%">Register steering committee. Arnaud Bourdin declares grants from Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, AZ, and GSK</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Boehringer Ingelheim, AZ, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Chiesi, Sanofi, Celltrion</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria from Sanofi, Regeneron, AZ, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Boehringer Ingelheim</style></keyword><keyword><style face="normal" font="default" size="100%">support for attending meetings from AZ and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">participates in the advisory board for A.B. science. Ratko Djukanovic</style></keyword><keyword><style face="normal" font="default" size="100%">declares consulting fees for Synairgen plc, GSK, ZenasBio, Celltrion, ALK Abello</style></keyword><keyword><style face="normal" font="default" size="100%">was past co-chair of the ERS Clinical collaboration on severe asthma (SHARP)</style></keyword><keyword><style face="normal" font="default" size="100%">shares in Synairgen plc outside of the submitted work. Sven-Erik Dahlen declares</style></keyword><keyword><style face="normal" font="default" size="100%">grants from AZ and GSK</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Affibody, AZ, Cayman Chemical, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, and Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria for lectures from AZ and Sanofi. Louise J</style></keyword><keyword><style face="normal" font="default" size="100%">Fleming has received a NIHR HTA grant outside of the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">consulting</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Sanofi, Regeneron, AZ, GSK</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria from AZ and Sanofi. All payments</style></keyword><keyword><style face="normal" font="default" size="100%">were made to the institution. Rekha Chaudhuri has received a grant from AZ for an</style></keyword><keyword><style face="normal" font="default" size="100%">investigator-led study</style></keyword><keyword><style face="normal" font="default" size="100%">lecture fees from GSK, AZ, TEVA, Chiesi, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">support</style></keyword><keyword><style face="normal" font="default" size="100%">for attending conferences from Chiesi, Sanofi, GSK</style></keyword><keyword><style face="normal" font="default" size="100%">participation in Advisory</style></keyword><keyword><style face="normal" font="default" size="100%">Board Meetings for GSK, AZ, and Celltrion. Erik Melen declares advisory board</style></keyword><keyword><style face="normal" font="default" size="100%">fees from ALK and AZ outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">lecture fees from ALK, AZ,</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, and Sanofi outside the submitted study. Antoine Deschildre has received</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from ALK, Stallergenes-Greer, GSK, Sanofi, Regeneron, Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Celltrion, and Viatris</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria from Novartis, ALK, GSK, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune Therapeutics, DBV Technologies, Viatris, and Stallergenes-Greer</style></keyword><keyword><style face="normal" font="default" size="100%">support</style></keyword><keyword><style face="normal" font="default" size="100%">for attending international congresses from Celltrion, ALK, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes-Greer, Novartis, AZ, and Aimmune Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">participation on the</style></keyword><keyword><style face="normal" font="default" size="100%">Data Safety Monitoring Board for the BOOM study (ClinicalTrials.gov ID:</style></keyword><keyword><style face="normal" font="default" size="100%">NCT04045301). Charles Pilette has received grants from AZ, Chiesi, GSK, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from AstraZeneca, Chiesi, GSK</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria from ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Chiesi, GSK, and Sanofi. All payments were made to his institution.</style></keyword><keyword><style face="normal" font="default" size="100%">Gerard H. Koppelman reports receiving research grants from the Netherlands Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, Ubbo Emmius Foundation, Zon MW, H2020, and Vertex paid to his</style></keyword><keyword><style face="normal" font="default" size="100%">institution</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from AZ paid to his institution</style></keyword><keyword><style face="normal" font="default" size="100%">institutional</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria from AZ, Sanofi, and Boehringer Ingelheim</style></keyword><keyword><style face="normal" font="default" size="100%">and is the chair and founder</style></keyword><keyword><style face="normal" font="default" size="100%">of the ExquAIro foundation. Andrew Exley declares being a minority shareholder in</style></keyword><keyword><style face="normal" font="default" size="100%">GSK. Ekaterina Khaleva has received grants from the Allergy and Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Research (AAIR) charity and NIHR paid to her institution. Graham Roberts declares</style></keyword><keyword><style face="normal" font="default" size="100%">3TR EU IMI2 funding and AZ fees paid to his institution. No other author has any</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40956008</style></accession-num><abstract><style face="normal" font="default" size="100%">Biologics are effective for severe asthma, but not all patients benefit equally. There is an urgent need to understand which biologic works best for which patient. We systematically searched for predictors of response to biologics (except omalizumab) for severe asthma in four bibliographic databases and two trial registries from 1990 to 2024. Two reviewers screened records, extracted data, and assessed risk of bias using a modified CASP checklist. Data were synthesized narratively, and certainty of evidence assessed using the modified GRADE framework. Comparable studies were meta-analyzed using a random-effects model. From 5853 records, 21 studies were identified investigating predictors of anti-IL5/5Ralpha, 4Ralpha, and anti-TSLP response. We found predominantly &apos;moderate&apos; to &apos;high&apos; quality evidence that raised blood eosinophil counts (&gt;/= 300 cells/muL), FeNO levels (&gt; 40 ppb), lack of or low OCS dose (&lt; 10 mg/day), and better asthma control predict biologic response. Evidence for the predictive value of other characteristics was limited and mostly &apos;low&apos; quality. Key reasons for downgrading the evidence were heterogeneous response definitions and imprecision. No data were identified for the pediatric population or biologics targeting the non-T2 pathway. Outside of traditional inflammatory and clinical variables, there is an unmet need for universally applicable predictors of biologic response for severe asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Rattu, Anna&#xD;Dixey, Piers&#xD;Charles, David&#xD;Brightling, Chris&#xD;Chung, Kian Fan&#xD;Bossios, Apostolos&#xD;Bourdin, Arnaud&#xD;Djukanovic, Ratko&#xD;Dahlen, Sven-Erik&#xD;Fleming, Louise&#xD;Chaudhuri, Rekha&#xD;Melen, Erik&#xD;Deschildre, Antoine&#xD;Pilette, Charles&#xD;Koppelman, Gerard H&#xD;Exley, Andrew&#xD;Anckers, Freja&#xD;Miller, Sarah&#xD;Nielsen, Hanna&#xD;Williams, Clare&#xD;Khaleva, Ekaterina&#xD;Roberts, Graham&#xD;eng&#xD;831434/Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU)/&#xD;University of Southampton/&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):24-55. doi: 10.1111/all.70031. Epub 2025 Sep 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40956008</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773690</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70031</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1176</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1176</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fok, J. S.</style></author><author><style face="normal" font="default" size="100%">Kolkhir, P.</style></author><author><style face="normal" font="default" size="100%">Church, M. K.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;Department of Respiratory Medicine, Box Hill Hospital, Melbourne, Vic, Australia.&#xD;Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic, Australia.&#xD;Division of Immune-mediated Skin Diseases, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Predictors of treatment response in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2965-2981</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/02/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Histamine Antagonists/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">antihistamines</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">cyclosporine</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">predictors</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33539587</style></accession-num><abstract><style face="normal" font="default" size="100%">The current therapeutic algorithm for chronic spontaneous urticaria (CSU), endorsed by the international guideline, entails treatment escalation from second-generation H(1) -antihistamines (sgAHs) to omalizumab and cyclosporine until complete response is achieved. Recently, several predictors of response to these treatment options have been described. Here, we discuss the most promising predictors of response and nonresponse to these treatments in CSU. A systematic search was performed by two independent researchers using the MEDLINE/PubMed database with specific keywords and 73 studies included in the review. Levels of evidence were categorized as strong (robust predictors), weak (emerging predictors) or no association, based on the outcome and number of studies available. High disease activity, high levels of C-reactive protein and D-dimer are robust predictors for a poor or no response to sgAHs. Poor or no response to omalizumab is robustly predicted by low serum levels of total IgE. A good response to cyclosporine is robustly predicted by a positive basophil histamine release assay, whereas low total IgE is an emerging predictor. The response to treatment with sgAHs, omalizumab and cyclosporine can be predicted by the use of markers that are readily available in routine clinical practice. Further studies are needed to confirm these predictors.</style></abstract><notes><style face="normal" font="default" size="100%">Fok, Jie Shen&#xD;Kolkhir, Pavel&#xD;Church, Martin K&#xD;Maurer, Marcus&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):2965-2981. doi: 10.1111/all.14757. Epub 2021 Feb 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33539587</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14757</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3091</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3091</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Steinberg, A.</style></author><author><style face="normal" font="default" size="100%">Goebel, S.</style></author><author><style face="normal" font="default" size="100%">Eckert, T.</style></author><author><style face="normal" font="default" size="100%">Sturmfels, M.</style></author><author><style face="normal" font="default" size="100%">Meixner, L.</style></author><author><style face="normal" font="default" size="100%">Schulke, S.</style></author><author><style face="normal" font="default" size="100%">Blumchen, K.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Ahrens, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Division of Pneumology, Allergology, Infectious Diseases and Gastroenterology, Goethe University Frankfurt, Frankfurt am Main, Germany.&#xD;Department of Paediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany.&#xD;Paul-Ehrlich-Institut, Allergology Division, Research Allergology, Langen, Germany.&#xD;German Center for Child and Adolescent Health (DZKJ), Partner Site Charite Universitat Berlin, Berlin, Germany.&#xD;Paul-Ehrlich-Institut, Allergology Division, Allergology Clinical Assessment Section, Langen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Premastication-Review of an Infant Feeding Practice and Its Potential Impact on Allergy and Microbiome Development</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2726-2737</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/prevention &amp; control/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">environment and hygiene hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">personal views and may not be understood or quoted as being made on behalf of or</style></keyword><keyword><style face="normal" font="default" size="100%">reflecting the position of the respective national competent authority, the</style></keyword><keyword><style face="normal" font="default" size="100%">European Medicines Agency, or one of its committees or working parties. B. Ahrens</style></keyword><keyword><style face="normal" font="default" size="100%">receives research funding from the Federal Ministry of Food and Agriculture</style></keyword><keyword><style face="normal" font="default" size="100%">(BMEL)</style></keyword><keyword><style face="normal" font="default" size="100%">she reports participation in RCTs dealing with (hydrolyzed) infant</style></keyword><keyword><style face="normal" font="default" size="100%">formulas for allergy prevention (HiPP), the latter outside the submitted work. K.</style></keyword><keyword><style face="normal" font="default" size="100%">Beyer reports advisory board/consulting fees or speaker&apos;s bureau from Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Bencard, Danone/Nutricia, DBV, Hycor, Infectopharm, Mabylon, Meda</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma/Mylan, Nestle, Novartis and ThermoFisher</style></keyword><keyword><style face="normal" font="default" size="100%">and research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune, ALK, Danone/Nutricia, DBV Technologies, Hipp, Infectopharm and Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. K. Blumchen reports advisory board/consulting fees or</style></keyword><keyword><style face="normal" font="default" size="100%">speaker&apos;s bureau from Aimmune Therapeutics, DBV Technologies, Novartis, Bencard</style></keyword><keyword><style face="normal" font="default" size="100%">Allergie, Stallergenes Greer, Thermofisher Scientific, Danone, Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Mylan, Sanofi, Engelhard, ALK, Siemens Healthineers</style></keyword><keyword><style face="normal" font="default" size="100%">and research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis Pharma GmbH, Aimmune Therapeutics, DBV Technologies and Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics outside the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40916851</style></accession-num><abstract><style face="normal" font="default" size="100%">Premastication, or pre-chewing, of food as a feeding practice for infants has been practiced across cultures as an ancient evolutionary method. Whilst literature on the topic remains slim, the majority of existing research has highlighted the potential risks, such as transmission of infections. Although the concerns are valid, potential beneficial aspects have, until now, received less attention. These benefits are hypothesised to include exposure to a healthy, balanced oral microbiome, in combination with the anti-inflammatory properties of saliva and the pre-digestion of food by salivary enzymes. The hypothesis is supported by various studies that have shown the importance of early exposure to microbes for the development of the child&apos;s immune system. Moreover, a more varied microbiome earlier on in life is assumed to reduce the development of atopic diseases. Provided that the person chewing and its receiver/the child are healthy, premastication could offer a simple, well-rehearsed method to shape the child&apos;s immune system with health-promoting effects particularly in regard to primary allergy prevention. The interactive benefits of transferring an immune-stimulating pre-digested soft food portion containing small amounts of (diverse) food proteins via the oral route could be a valuable contribution to oral tolerance development in the decisive period of microbial-driven immune system maturation. This review aims to evaluate the risks but especially the potential benefits of premastication, by focussing on its possible implications in (food) allergy prevention and oral tolerance development.</style></abstract><notes><style face="normal" font="default" size="100%">Steinberg, Anne&#xD;Goebel, Sophie&#xD;Eckert, Tara&#xD;Sturmfels, Meral&#xD;Meixner, Lara&#xD;Schulke, Stefan&#xD;Blumchen, Katharina&#xD;Beyer, Kirsten&#xD;Ahrens, Birgit&#xD;eng&#xD;SOLIDS-By-Kiss is part of the collaborative project Solids-by-Kiss. The project is supported by funds of the Federal Ministry of Food and Agriculture (BMEL) based on a decision of the Parliament of the Federal Republic of Germany via the Federal Office for Agriculture and Food (BLE) under the innovation support program. Project code: 281A305A18, 281A305B18/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2726-2737. doi: 10.1111/all.16676. Epub 2025 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40916851</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486369</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16676</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>451</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">451</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cait, A.</style></author><author><style face="normal" font="default" size="100%">Wedel, A.</style></author><author><style face="normal" font="default" size="100%">Arntz, J. L.</style></author><author><style face="normal" font="default" size="100%">Duinkerken, J.</style></author><author><style face="normal" font="default" size="100%">Datye, S.</style></author><author><style face="normal" font="default" size="100%">Cait, J.</style></author><author><style face="normal" font="default" size="100%">Alhasan, M. M.</style></author><author><style face="normal" font="default" size="100%">Conrad, M. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Malaghan Institute of Medical Research, Wellington, New Zealand.&#xD;Department of Impact and Evaluation, German Children and Youth Foundation, Berlin, Germany.&#xD;Institute of Microbiology, Infectious Diseases and Immunology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;Department of Integrative Biology, University of Guelph, Guelph, Canada.&#xD;Division of Psychosomatic Medicine, Department of Internal Medicine, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prenatal antibiotic exposure, asthma, and the atopic march: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3233-3248</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Sounds/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">atopic march</style></keyword><keyword><style face="normal" font="default" size="100%">childhood asthma</style></keyword><keyword><style face="normal" font="default" size="100%">meta-analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35689800</style></accession-num><abstract><style face="normal" font="default" size="100%">Antibiotic use during pregnancy may increase the risk for asthma in children. We performed a meta-analysis assessing prenatal antibiotic exposure and the risk for childhood wheeze or asthma, as well as for diseases associated with the atopic march. A systematic literature search protocol (PROSPERO-ID: CRD42020191940) was registered and searches were completed using Medline, Proquest, Embase, and the Cochrane central register of controlled trials. Screening for inclusion criteria: published in English, German, French, Dutch, or Arabic, intervention (use of any antibiotic at any time point during pregnancy), and disease (reporting atopic disease incidence in children with a primary outcome of asthma or wheeze), and exclusion criteria: reviews, preclinical data, and descriptive studies, yielded 27 studies. Study quality was assessed using the Newcastle-Ottawa Assessment Scale. Quality of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Our meta-analysis demonstrates that antibiotic use during pregnancy is associated with an increased relative risk (RR) of developing wheeze RR 1.51 (95% CI: 1.17-1.94) or asthma RR 1.28 (95% CI 1.22-1.34) during childhood. Assessment of the atopic march in association with asthma or wheeze revealed that antibiotic use during pregnancy also increases the risk for eczema/dermatitis RR 1.28 (95% CI: 1.06-1.53) and allergic rhinitis RR 1.13 (95% CI: 1.02-1.25). One study found an increase in food allergy RR 1.81 (95% CI: 1.11-2.95). Maternal antibiotic use during pregnancy is associated with an increased risk for wheeze or asthma development in children, as well as for diseases involved in the atopic march. There was high heterogeneity in the data, and the certainty of the evidence was determined to be low quality, highlighting the need for more high-quality studies on this topic. These results have importance for antibiotic stewardship throughout the prenatal period. This work was supported by the Deutsche Forschungsgemeinschaft and the Konrad Adenauer Foundation.</style></abstract><notes><style face="normal" font="default" size="100%">Cait, Alissa&#xD;Wedel, Alexander&#xD;Arntz, Jeanne L&#xD;Duinkerken, Jacyra&#xD;Datye, Swarali&#xD;Cait, Jessica&#xD;Alhasan, Moumen M&#xD;Conrad, Melanie L&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3233-3248. doi: 10.1111/all.15404. Epub 2022 Jun 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35689800</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15404</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>113</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">113</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ta, L. D. H.</style></author><author><style face="normal" font="default" size="100%">Chan, J. C. Y.</style></author><author><style face="normal" font="default" size="100%">Yap, G. C.</style></author><author><style face="normal" font="default" size="100%">Huang, C. H.</style></author><author><style face="normal" font="default" size="100%">Tham, E. H.</style></author><author><style face="normal" font="default" size="100%">Loo, E. X. L.</style></author><author><style face="normal" font="default" size="100%">Suaini, N. H. A.</style></author><author><style face="normal" font="default" size="100%">Shek, L. P.</style></author><author><style face="normal" font="default" size="100%">Karnani, N.</style></author><author><style face="normal" font="default" size="100%">Goh, A. E. N.</style></author><author><style face="normal" font="default" size="100%">Van Bever, H. P. S.</style></author><author><style face="normal" font="default" size="100%">Teoh, O. H.</style></author><author><style face="normal" font="default" size="100%">Chan, Y. H.</style></author><author><style face="normal" font="default" size="100%">Lay, C.</style></author><author><style face="normal" font="default" size="100%">Knol, J.</style></author><author><style face="normal" font="default" size="100%">Yap, F.</style></author><author><style face="normal" font="default" size="100%">Tan, K. H.</style></author><author><style face="normal" font="default" size="100%">Chong, Y. S.</style></author><author><style face="normal" font="default" size="100%">Chong, M. F.</style></author><author><style face="normal" font="default" size="100%">Chan, S. Y.</style></author><author><style face="normal" font="default" size="100%">Eriksson, J. G.</style></author><author><style face="normal" font="default" size="100%">Godfrey, K. M.</style></author><author><style face="normal" font="default" size="100%">Chan, E. C. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, B. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Singapore Institute of Food and Biotechnology Innovation, A*STAR, Singapore, Singapore.&#xD;A*STAR Skin Research Labs, A*STAR, Singapore, Singapore.&#xD;Khoo Teck Puat-National University Children&apos;s Medical Institute, National University Health System, Singapore, Singapore.&#xD;Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.&#xD;Department of Paediatrics, KK Women&apos;s and Children&apos;s Hospital, Singapore, Singapore.&#xD;Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Danone Nutricia Research, Singapore, Singapore.&#xD;Danone Nutricia Research, Utrecht, The Netherlands.&#xD;Wageningen University, Wageningen, The Netherlands.&#xD;Department of Obstetrics &amp; Gynaecology, National University of Singapore, Singapore.&#xD;Folkhalsan Research Center, Helsinki, Finland and Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland.&#xD;Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland.&#xD;MRC Lifecourse Epidemiology Centre and NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prenatal diet, plasma micronutrients/metabolome and inflammatory status influence the development of atopic eczema in early childhood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">867-871</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/11/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Micronutrients</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36321872</style></accession-num><notes><style face="normal" font="default" size="100%">Ta, Le Duc Huy&#xD;Chan, James Chun Yip&#xD;Yap, Gaik Chin&#xD;Huang, Chiung-Hui&#xD;Tham, Elizabeth Huiwen&#xD;Loo, Evelyn Xiu Ling&#xD;Suaini, Noor H A&#xD;Shek, Lynette P&#xD;Karnani, Neerja&#xD;Goh, Anne Eng Neo&#xD;Van Bever, Hugo P S&#xD;Teoh, Oon Hoe&#xD;Chan, Yiong Huak&#xD;Lay, Christophe&#xD;Knol, Jan&#xD;Yap, Fabian&#xD;Tan, Kok Hian&#xD;Chong, Yap-Seng&#xD;Chong, Mary Foong-Fong&#xD;Chan, Shiao Yng&#xD;Eriksson, Johan Gunnar&#xD;Godfrey, Keith M&#xD;Chan, Eric Chun Yong&#xD;Lee, Bee Wah&#xD;eng&#xD;MC_UU_12011/4/MRC_/Medical Research Council/United Kingdom&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):867-871. doi: 10.1111/all.15573. Epub 2022 Nov 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36321872</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15573</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1019</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1019</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thurmann, L.</style></author><author><style face="normal" font="default" size="100%">Herberth, G.</style></author><author><style face="normal" font="default" size="100%">Seiwert, B.</style></author><author><style face="normal" font="default" size="100%">Schlittenbauer, L.</style></author><author><style face="normal" font="default" size="100%">Rolle-Kampczyk, U.</style></author><author><style face="normal" font="default" size="100%">Roder, S.</style></author><author><style face="normal" font="default" size="100%">Sack, U.</style></author><author><style face="normal" font="default" size="100%">Borte, M.</style></author><author><style face="normal" font="default" size="100%">von Bergen, M.</style></author><author><style face="normal" font="default" size="100%">Trump, S.</style></author><author><style face="normal" font="default" size="100%">Reemtsma, T.</style></author><author><style face="normal" font="default" size="100%">Lehmann, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular Epidemiology Unit, Berlin Institute of Health at Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, associated partner of the German Center for Lung Research (DZL), Berlin, Germany.&#xD;Department of Environmental Immunology, Helmholtz Centre for Environmental Research-UFZ, Leipzig, Germany.&#xD;Department of Analytical Chemistry, Helmholtz Centre for Environmental Research - UFZ, Leipzig, Germany.&#xD;Department of Molecular Systems Biology, Helmholtz Centre for Environmental Research-UFZ, Leipzig, Germany.&#xD;Institute of Clinical Immunology, Medical Faculty, University Leipzig, Leipzig, Germany.&#xD;Children&apos;s Hospital, Municipal Hospital &quot;St.Georg&quot;, Academic Teaching Hospital of the University of Leipzig, Leipzig, Germany.&#xD;Department of Biochemistry, Faculty of Biosciences, Pharmacy and Psychology, University of Leipzig, Leipzig, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prenatal paraben exposure and atopic dermatitis-related outcomes among children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3122-3132</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/05/03</style></edition><section><style face="normal" font="default" size="100%">3122</style></section><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Parabens/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">paraben</style></keyword><keyword><style face="normal" font="default" size="100%">prenatal</style></keyword><keyword><style face="normal" font="default" size="100%">sex</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33934374</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Parabens, widely used as preservatives in cosmetics, foods, and other consumer products, are suspected of contributing to allergy susceptibility. The detection of parabens in the placenta or amniotic fluid raised concerns about potential health consequences for the child. Recently, an increased asthma risk following prenatal exposure has been reported. Here, we investigated whether prenatal paraben exposure can influence the risk for atopic dermatitis (AD). METHODS: 261 mother-child pairs of the German mother-child study LINA were included in this analysis. Eight paraben species were quantified in maternal urine obtained at gestational week 34. According to the parental report of physician-diagnosed AD from age 1 to 8 years, disease onset, and persistence, childhood AD was classified into four different phenotypes. RESULTS: 4.6% (n = 12) and 12.3% (n = 32) of the children were classified as having very early-onset AD (until age two) either with or without remission, 11.9% (n = 31) as early-onset (after age two), and 3.1% (n = 8) as childhood-onset AD (after age six). Exposure to ethylparaben and n-butylparaben was associated with an increased risk to develop very early-onset AD without remission (EtP: adj.OR/95% CI:1.44/1.04-2.00,nBuP:adj.OR/95% CI:1.95/1.22-3.12). The effects of both parabens were predominant in children without a history of maternal AD and independent of children&apos;s sex. CONCLUSION: Prenatal EtP or nBuP exposure may increase children&apos;s susceptibility for persistent AD with disease onset at very early age. This association was particularly pronounced in children without a history of maternal AD, indicating that children without a genetic predisposition are more susceptible to paraben exposure.</style></abstract><notes><style face="normal" font="default" size="100%">Thurmann, Loreen&#xD;Herberth, Gunda&#xD;Seiwert, Bettina&#xD;Schlittenbauer, Linda&#xD;Rolle-Kampczyk, Ulrike&#xD;Roder, Stefan&#xD;Sack, Ulrich&#xD;Borte, Michael&#xD;von Bergen, Martin&#xD;Trump, Saskia&#xD;Reemtsma, Thorsten&#xD;Lehmann, Irina&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3122-3132. doi: 10.1111/all.14890. Epub 2021 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33934374</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14890</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>76</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">76</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rosenquist, N. A.</style></author><author><style face="normal" font="default" size="100%">Richards, M.</style></author><author><style face="normal" font="default" size="100%">Ferber, J. R.</style></author><author><style face="normal" font="default" size="100%">Li, D. K.</style></author><author><style face="normal" font="default" size="100%">Ryu, S. Y.</style></author><author><style face="normal" font="default" size="100%">Burkin, H.</style></author><author><style face="normal" font="default" size="100%">Strickland, M. J.</style></author><author><style face="normal" font="default" size="100%">Darrow, L. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Public Health, University of Nevada, Reno, Nevada, USA.&#xD;Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.&#xD;School of Medicine, University of Nevada, Reno, Nevada, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prepregnancy body mass index and risk of childhood asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1234-1244</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/11/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Overweight/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">Thinness/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity/complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">gestational weight gain</style></keyword><keyword><style face="normal" font="default" size="100%">maternal obesity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36435989</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Growing evidence suggests that maternal obesity may affect the intrauterine environment and increase a child&apos;s risk of developing asthma. We aim to investigate the relationship between prepregnancy obesity and childhood asthma risk. METHODS: Cohorts of children enrolled in Kaiser Permanente Northern California integrated healthcare system were followed from birth (2005-2014) to age 4 (n = 104,467), 6 (n = 63,084), or 8 (n = 31,006) using electronic medical records. Child&apos;s asthma was defined using ICD codes and asthma-related prescription medication dispensing. Risk ratios (RR) and 95% confidence intervals (95% CIs) for child&apos;s asthma were estimated using Poisson regression with robust error variance for (1) prepregnancy BMI categories (underweight [&lt;18.5], normal [18.5-24.9], overweight [25-29.9], obese 1 [30-34.9], and obese 2/3 [&gt;/=35]) and (2) continuous prepregnancy BMI modeled using cubic splines with knots at BMI category boundaries. Models were adjusted for maternal age, education, race, asthma, allergies, smoking, gestational weight gain, child&apos;s birth year, parity, infant sex, gestational age, and child&apos;s BMI. RESULTS: Relative to normal BMI, RRs (95%CIs) for asthma at ages 4, 6, and 8 were 0.91 (0.75, 1.11), 0.95 (0.78, 1.16), and 0.97 (0.75, 1.27) for underweight, 1.06 (0.99, 1.14), 1.08 (1.01, 1.16), and 1.03 (0.94, 1.14) for overweight, 1.09 (1.00, 1.19), 1.12 (1.03, 1.23), 1.03 (0.91, 1.17) for obese 1, and 1.10 (0.99, 1.21), 1.13 (1.02, 1.25), 1.14 (0.99, 1.31) for obese 2/3. When continuous prepregnancy BMI was modeled with splines, child&apos;s asthma risk generally increased linearly with increasing prepregnancy BMI. CONCLUSIONS: Higher prepregnancy BMI is associated with modestly increased childhood asthma risk.</style></abstract><notes><style face="normal" font="default" size="100%">Rosenquist, Natalie A&#xD;Richards, Megan&#xD;Ferber, Jeannette R&#xD;Li, De-Kun&#xD;Ryu, So Young&#xD;Burkin, Heather&#xD;Strickland, Matthew J&#xD;Darrow, Lyndsey A&#xD;eng&#xD;R01 AI122266/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1234-1244. doi: 10.1111/all.15598. Epub 2022 Dec 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36435989</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15598</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1986</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1986</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">de Fine Licht, S.</style></author><author><style face="normal" font="default" size="100%">Telg, G.</style></author><author><style face="normal" font="default" size="100%">Maslova, E.</style></author><author><style face="normal" font="default" size="100%">Tran, T. N.</style></author><author><style face="normal" font="default" size="100%">Surmont, F.</style></author><author><style face="normal" font="default" size="100%">Wiklund, F.</style></author><author><style face="normal" font="default" size="100%">Olsson, U.</style></author><author><style face="normal" font="default" size="100%">Nwaru, B. I.</style></author><author><style face="normal" font="default" size="100%">Ekstrom, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.&#xD;Department of Clinical Science and Education, Karolinska Institutet, Sodersjukhuset, Stockholm, Sweden.&#xD;AstraZeneca Nordic, Sodertalje, Sweden.&#xD;AstraZeneca, Cambridge, UK.&#xD;AstraZeneca, Gaithersburg, Maryland, USA.&#xD;Statisticon AB, Uppsala, Sweden.&#xD;Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.&#xD;Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.&#xD;Department of Respiratory Medicine and Allergology, Lund University, Lund, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prescribing patterns of budesonide/formoterol maintenance and reliever therapy in patients with asthma in Sweden</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2311-2314</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/03/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Sweden/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/epidemiology/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Budesonide, Formoterol Fumarate Drug Combination/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Budesonide/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchodilator Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36919650</style></accession-num><notes><style face="normal" font="default" size="100%">Janson, Christer&#xD;Melen, Erik&#xD;de Fine Licht, Sofie&#xD;Telg, Gunilla&#xD;Maslova, Ekaterina&#xD;Tran, Trung N&#xD;Surmont, Filip&#xD;Wiklund, Fredrik&#xD;Olsson, Urban&#xD;Nwaru, Bright I&#xD;Ekstrom, Magnus&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2311-2314. doi: 10.1111/all.15710. Epub 2023 Apr 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36919650</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15710</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>426</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">426</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hagemann, J.</style></author><author><style face="normal" font="default" size="100%">Onorato, G.</style></author><author><style face="normal" font="default" size="100%">Seifen, C.</style></author><author><style face="normal" font="default" size="100%">Becker, S.</style></author><author><style face="normal" font="default" size="100%">Huppertz, T.</style></author><author><style face="normal" font="default" size="100%">Olze, H.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Toppila Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J.</style></author><author><style face="normal" font="default" size="100%">Rouadi, P.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Aria group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;University Hospital Montpellier, France.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Tubingen, Tubingen, Germany.&#xD;Department of Otolaryngology, Charite Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, Germany.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Department of Otolaryngology, University Hospital Bercelona, Spain.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.&#xD;Faculdade de Medicina da Universidade do Porto, Porto, Portugal.&#xD;Center for Research in Health Technologies and Information Systems, CINTESIS, Universidade do Porto, Porto, Portugal.&#xD;Allergy Unit, Instituto CUF Porto e Hospital CUF Porto, Porto, Portugal.&#xD;Health Information and Decision Sciences Department - CIDES, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.&#xD;Department of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon.&#xD;Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany.&#xD;MACVIA-France, Montpellier, France.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Presentation of airway and general symptoms in Covid-19 caused by dominant SARS-CoV-2 variants: a follow-up on ARIA consensus</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><edition><style face="normal" font="default" size="100%">2022/06/23</style></edition><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35730253</style></accession-num><notes><style face="normal" font="default" size="100%">Hagemann, Jan&#xD;Onorato, Gabrielle&#xD;Seifen, Christopher&#xD;Becker, Sven&#xD;Huppertz, Tilman&#xD;Olze, Heidi&#xD;Kuna, Piotr&#xD;Mullol, Joaquim&#xD;Toppila Salmi, Sanna&#xD;Fonseca, Joao&#xD;Rouadi, Philip&#xD;Zuberbier, Torsten&#xD;Bousquet, Jean&#xD;Klimek, Ludger&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Jun 22:10.1111/all.15416. doi: 10.1111/all.15416.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35730253</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9349691</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15416</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>825</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">825</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mitselou, N.</style></author><author><style face="normal" font="default" size="100%">Andersson, N.</style></author><author><style face="normal" font="default" size="100%">Bergstrom, A.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Georgelis, A.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Hedman, A. M.</style></author><author><style face="normal" font="default" size="100%">Almqvist, C.</style></author><author><style face="normal" font="default" size="100%">Ludvigsson, J. F.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Orebro University Hospital, Orebro, Sweden.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Centre for Occupational and Environmental Medicine, Region Stockholm, Stockholm, Sweden.&#xD;Department of Clinical Science and Education, Sodersjukhuset, Stockholm, Sweden.&#xD;Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.&#xD;Pediatric Allergy and Pulmonology Unit at Astrid Lindgren Children&apos;s Hospital, Karolinska University Hospital, Stockholm, Sweden.&#xD;Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK.&#xD;Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Preterm birth reduces the risk of IgE sensitization up to early adulthood: A population-based birth cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1570-1582</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/09/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Birth Cohort</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">*Premature Birth/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">paediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34486741</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Immunoglobulin E (IgE) sensitization is associated with asthma and allergic diseases. Gestational age influences early immune system development, thereby potentially affecting the process of tolerance induction to allergens. OBJECTIVE: To study IgE sensitization to common allergens by gestational age from childhood up to early adulthood. METHODS: Population-based birth cohort, data from the Swedish BAMSE study were used. Allergen-specific IgE antibodies to a mix of common food (fx5) and inhalant (Phadiatop) allergens were analysed at 4, 8, 16 and 24 years. Sensitization was defined as allergen-specific IgE &gt;/=0.35 kU(A) /L to fx5 and/or Phadiatop at each time point. Using logistic regression and generalized estimated equations, adjusted odds ratios (aORs) for sensitization in relation to gestational age were calculated. Replication was sought within the Swedish twin study STOPPA. RESULTS: In BAMSE, 3522 participants were screened for IgE antibodies during follow-up; of these, 197 (5.6%) were born preterm (&lt;37 gestational weeks) and 330 (9.4%) post-term (&gt;/=42 weeks). Preterm birth reduced the risk of sensitization to common food and/or inhalant allergens up to early adulthood by 29% (overall aOR = 0.71; 95% CI: 0.52-0.98), and to food allergens specifically by 40% (overall aOR = 0.60; 95% CI: 0.38-0.93). No relation was found between post-term birth and IgE sensitization at any time point. Replication analyses in STOPPA (N = 675) showed similar risk estimates for sensitization to food and/or inhalant allergens (aOR = 0.72; 95% CI: 0.42-1.21), which resulted in a combined meta-analysis aOR = 0.71 (95% CI: 0.54-0.94). CONCLUSIONS: Our study suggests an inverse association between preterm birth and long-term IgE sensitization.</style></abstract><notes><style face="normal" font="default" size="100%">Mitselou, Niki&#xD;Andersson, Niklas&#xD;Bergstrom, Anna&#xD;Kull, Inger&#xD;Georgelis, Antonios&#xD;van Hage, Marianne&#xD;Hedman, Anna M&#xD;Almqvist, Catarina&#xD;Ludvigsson, Jonas F&#xD;Melen, Erik&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1570-1582. doi: 10.1111/all.15077. Epub 2021 Sep 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34486741</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15077</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1020</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1020</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sigurdardottir, S. T.</style></author><author><style face="normal" font="default" size="100%">Jonasson, K.</style></author><author><style face="normal" font="default" size="100%">Clausen, M.</style></author><author><style face="normal" font="default" size="100%">Lilja Bjornsdottir, K.</style></author><author><style face="normal" font="default" size="100%">Sigurdardottir, S. E.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Grimshaw, K.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Fiandor, A.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Sprikkelman, A. B.</style></author><author><style face="normal" font="default" size="100%">Hulshof, L.</style></author><author><style face="normal" font="default" size="100%">Kowalski, M. L.</style></author><author><style face="normal" font="default" size="100%">Kurowski, M.</style></author><author><style face="normal" font="default" size="100%">Dubakiene, R.</style></author><author><style face="normal" font="default" size="100%">Rudzeviciene, O.</style></author><author><style face="normal" font="default" size="100%">Bellach, J.</style></author><author><style face="normal" font="default" size="100%">Yurek, S.</style></author><author><style face="normal" font="default" size="100%">Reich, A.</style></author><author><style face="normal" font="default" size="100%">Erhard, S. M.</style></author><author><style face="normal" font="default" size="100%">Couch, P.</style></author><author><style face="normal" font="default" size="100%">Rivas, M. F.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Mills, C.</style></author><author><style face="normal" font="default" size="100%">Grabenhenrich, L.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Keil, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Landspitali University Hospital, Reykjavik, Iceland.&#xD;Faculty of Medicine, University of Iceland, Reykjavik, Iceland.&#xD;Department of Computer Science, University of Iceland, Reykjavik, Iceland.&#xD;Children&apos;s Hospital Reykjavik, Reykjavik, Iceland.&#xD;Department of Allergy, Landspitali University Hospital, Reykjavik, Iceland.&#xD;Children&apos;s Hospital, Landspitali University Hospital, Reykjavik, Iceland.&#xD;Human Development and Health &amp; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;Dietetic Department, Salford Royal NHS Foundation Trust, UK.&#xD;Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK.&#xD;Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Manchester Institute of Biotechnology, University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, University of Manchester, Manchester, UK.&#xD;Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.&#xD;Department of Pediatric Pulmonology and Pediatric Allergology, University Medical Center Groningen, University of Groningen, The Netherlands.&#xD;Department of Pediatric Pulmonology and Pediatric Allergology, Emma Children&apos;s Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Immunology, Allergy and Rheumatology, Medical University of Lodz, Lodz, Poland.&#xD;Medical Faculty Clinic of Chest Diseases, Allergology and Immunology, Vilnius University, Vilnius, Lithuania.&#xD;Faculty of Medicine Clinic of Children&apos;s Diseases, Vilnius University, Vilnius, Lithuania.&#xD;Department of Paediatric Pneumology and Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.&#xD;Institute of Social Medicine, Epidemiology and Health Economics, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Centre for Health Informatics, School of Health Sciences, The University of Manchester, Manchester, UK.&#xD;Allergy Department, Hospital Clinico San Carlos, Universidad Complutense, IdISSC, ARADyAl, Madrid, Spain.&#xD;Departments of Experimental Immunology and of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.&#xD;Institute of Inflammation and Repair, University of Manchester, Manchester, UK.&#xD;Department for Infectious Disease Epidemiology, Robert Koch-Institut, Berlin, Germany.&#xD;Institute of Clinical Epidemiology and Biometry, University of Wurzburg, Wurzburg, Germany.&#xD;State Institute of Health, Bavarian Health and Food Safety Authority, Bad Kissingen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence and early-life risk factors of school-age allergic multimorbidity: The EuroPrevall-iFAAM birth cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2855-2865</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/05/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Multimorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Schools</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">allergic multimorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Grimshaw reports grants from Food Standards Agency</style></keyword><keyword><style face="normal" font="default" size="100%">UK, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Papadopoulos reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, personal fees from Nutricia, personal fees from HAL, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">MENARINI/FAES FARMA, personal fees from SANOFI, personal fees from MYLAN/MEDA,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from BIOMAY, personal fees from AstraZeneca, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, personal fees from MSD, personal fees from ASIT Biotech, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, grants from Gerolymatos International SA and grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Capricare, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Xepapadaki reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Uriach, personal fees from Novartis, personal fees from Nestle and personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Nutricia, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Fiandor reports personal fees and</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from AstraZeneca, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Quirce</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees and non-financial support from GSK, personal fees and</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from AstraZeneca, personal fees and non-financial support</style></keyword><keyword><style face="normal" font="default" size="100%">from Sanofi, personal fees and non-financial support from Novartis, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">and non-financial support from Mundipharma, personal fees and non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support from Teva, and personal fees and non-financial support from Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Sprikkelman reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia Advanced Medical Nutrition Netherlands, grants from AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Netherlands, grants from TEVA Netherlands and grants from GlaxoSmithKline</style></keyword><keyword><style face="normal" font="default" size="100%">Netherlands, during the conduct of the study, and grants from Aimmune, outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Couch reports grants from EU FP7-KBBE, during the conduct</style></keyword><keyword><style face="normal" font="default" size="100%">of the study</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Fernandez-Rivas reports grants from European Commission, during</style></keyword><keyword><style face="normal" font="default" size="100%">the conduct of the study, personal fees from Aimmune, DBV, Novartis and SPRIM,</style></keyword><keyword><style face="normal" font="default" size="100%">and grants from Aimmune, Diater, ALK, DIATER, GSK and HAL Allergy, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. van Ree reports personal fees from HAL Allergy BV, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Citeq BV, personal fees from Angany Inc, personal fees from Thermo</style></keyword><keyword><style face="normal" font="default" size="100%">Fisher Scientific, grants from European Commission and grants from Dutch Science</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">ENC Mills reports grants from Reacta</style></keyword><keyword><style face="normal" font="default" size="100%">Biotech Ltd, outside the submitted work, and Chief Scientific Adviser and</style></keyword><keyword><style face="normal" font="default" size="100%">shareholder of Reacta Biotech Ltd, a start-up developed to commercialise foods</style></keyword><keyword><style face="normal" font="default" size="100%">for use in oral food challenges</style></keyword><keyword><style face="normal" font="default" size="100%">and Dr. Beyer reports grants from European</style></keyword><keyword><style face="normal" font="default" size="100%">Commission, during the conduct of the study, grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune, personal fees from Bencard, grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Danone/Nutricia/Milupa, grants and personal fees from DBV, grants and personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Hipp, grants and personal fees from Hycor, grants and personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from InfectoPharm, personal fees from Jenapharm, personal fees from Mylan/Meda,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Nestle, personal fees from Novartis and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Thermo Fisher, outside the submitted work. All other authors have nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33934363</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Coexistence of childhood asthma, eczema and allergic rhinitis is higher than can be expected by chance, suggesting a common mechanism. Data on allergic multimorbidity from a pan-European, population-based birth cohort study have been lacking. This study compares the prevalence and early-life risk factors of these diseases in European primary school children. METHODS: In the prospective multicentre observational EuroPrevall-iFAAM birth cohort study, we used standardized questionnaires on sociodemographics, medical history, parental allergies and lifestyle, and environmental exposures at birth, 12 and 24 months. At primary school age, parents answered ISAAC-based questions on current asthma, rhinitis and eczema. Allergic multimorbidity was defined as the coexistence of at least two of these. RESULTS: From 10,563 children recruited at birth in 8 study centres, we included data from 5,572 children (mean age 8.2 years; 51.8% boys). Prevalence estimates were as follows: asthma, 8.1%; allergic rhinitis, 13.3%; and eczema, 12.0%. Allergic multimorbidity was seen in 7.0% of the whole cohort, ranging from 1.2% (Athens, Greece) to 10.9% (Madrid, Spain). Risk factors for allergic multimorbidity, identified with AICc, included family-allergy-score, odds ratio (OR) 1.50 (95% CI 1.32-1.70) per standard deviation; early-life allergy symptoms, OR 2.72 (2.34-3.16) for each symptom; and caesarean birth, OR 1.35 (1.04-1.76). Female gender, OR 0.72 (0.58-0.90); older siblings, OR 0.79 (0.63-0.99); and day care, OR 0.81 (0.63-1.06) were protective factors. CONCLUSION: Allergic multimorbidity should be regarded as an important chronic childhood disease in Europe. Some of the associated early-life factors are modifiable and may be considered for prevention strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Sigurdardottir, Sigurveig T&#xD;Jonasson, Kristjan&#xD;Clausen, Michael&#xD;Lilja Bjornsdottir, Kristin&#xD;Sigurdardottir, Sigridur Erla&#xD;Roberts, Graham&#xD;Grimshaw, Kate&#xD;Papadopoulos, Nikolaos G&#xD;Xepapadaki, Paraskevi&#xD;Fiandor, Ana&#xD;Quirce, Santiago&#xD;Sprikkelman, Aline B&#xD;Hulshof, Lies&#xD;Kowalski, Marek L&#xD;Kurowski, Marcin&#xD;Dubakiene, Ruta&#xD;Rudzeviciene, Odilija&#xD;Bellach, Johanna&#xD;Yurek, Songul&#xD;Reich, Andreas&#xD;Erhard, Sina Maria&#xD;Couch, Philip&#xD;Rivas, Montserrat Fernandez&#xD;van Ree, Ronald&#xD;Mills, Clare&#xD;Grabenhenrich, Linus&#xD;Beyer, Kirsten&#xD;Keil, Thomas&#xD;eng&#xD;WT_/Wellcome Trust/United Kingdom&#xD;Multicenter Study&#xD;Observational Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2855-2865. doi: 10.1111/all.14857. Epub 2021 Jun 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33934363</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8453757</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14857</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2530</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2530</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Allen, H. I.</style></author><author><style face="normal" font="default" size="100%">Wing, O.</style></author><author><style face="normal" font="default" size="100%">Milkova, D.</style></author><author><style face="normal" font="default" size="100%">Jackson, E.</style></author><author><style face="normal" font="default" size="100%">Li, K.</style></author><author><style face="normal" font="default" size="100%">Bradshaw, L. E.</style></author><author><style face="normal" font="default" size="100%">Wyatt, L.</style></author><author><style face="normal" font="default" size="100%">Haines, R.</style></author><author><style face="normal" font="default" size="100%">Santer, M.</style></author><author><style face="normal" font="default" size="100%">Murphy, A. W.</style></author><author><style face="normal" font="default" size="100%">Brown, S. J.</style></author><author><style face="normal" font="default" size="100%">Kelleher, M.</style></author><author><style face="normal" font="default" size="100%">Perkin, M. R.</style></author><author><style face="normal" font="default" size="100%">Jay, N.</style></author><author><style face="normal" font="default" size="100%">Smith, T. D. H.</style></author><author><style face="normal" font="default" size="100%">Moriarty, F.</style></author><author><style face="normal" font="default" size="100%">Montgomery, A. A.</style></author><author><style face="normal" font="default" size="100%">Williams, H. C.</style></author><author><style face="normal" font="default" size="100%">Boyle, R. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Centre of Evidence Based Dermatology, Lifespan and Population Health, University of Nottingham, Nottingham, UK.&#xD;Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.&#xD;Primary Care Research Centre, University of Southampton, Southampton, UK.&#xD;Department of General Practice &amp; HRB Clinical Trial Network Primary Care Ireland, University of Galway, Galway, Ireland.&#xD;Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK.&#xD;Children&apos;s Health Ireland, Crumlin Children&apos;s Hospital, Dublin, Ireland.&#xD;Population Health Research Institute, St George&apos;s University of London, London, UK.&#xD;Sheffield Children&apos;s NHS Foundation Trust, Sheffield, UK.&#xD;NIHR Clinical Research Network North West Coast Primary Care Team, Liverpool, UK.&#xD;School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence and risk factors for milk allergy overdiagnosis in the BEEP trial cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">148-160</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/06/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">*Medical Overuse/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">England/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">cow&apos;s milk allergy</style></keyword><keyword><style face="normal" font="default" size="100%">low-allergy formula</style></keyword><keyword><style face="normal" font="default" size="100%">overdiagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">primary care</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis and an infant formula health claim, and payment for editorial work</style></keyword><keyword><style face="normal" font="default" size="100%">from Cochrane, Wiley and the British Society for Allergy and Clinical Immunology.</style></keyword><keyword><style face="normal" font="default" size="100%">HCW directed the NIHR Health Technology Assessment Programme 2015 to 2020 which</style></keyword><keyword><style face="normal" font="default" size="100%">funded the BEEP study. He played no part in the decision to fund the study. All</style></keyword><keyword><style face="normal" font="default" size="100%">other authors declare no conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38899450</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cow&apos;s milk allergy (CMA) overdiagnosis in young children appears to be increasing and has not been well characterised. We used a clinical trial population to characterise CMA overdiagnosis and identify individual-level and primary care practice-level risk factors. METHODS: We analysed data from 1394 children born in England in 2014-2016 (BEEP trial, ISRCTN21528841). Participants underwent formal CMA diagnosis at &lt;/=2 years. CMA overdiagnosis was defined in three separate ways: parent-reported milk reaction; primary care record of milk hypersensitivity symptoms; and primary care record of low-allergy formula prescription. RESULTS: CMA was formally diagnosed in 19 (1.4%) participants. CMA overdiagnosis was common: 16.1% had parent-reported cow&apos;s milk hypersensitivity, 11.3% primary care recorded milk hypersensitivity and 8.7% had low-allergy formula prescription. Symptoms attributed to cow&apos;s milk hypersensitivity in participants without CMA were commonly gastrointestinal and reported from a median age of 49 days. Low-allergy formula prescriptions in participants without CMA lasted a median of 10 months (interquartile range 1, 16); the estimated volume consumed was a median of 272 litres (26, 448). Risk factors for CMA overdiagnosis were high practice-based low-allergy formula prescribing in the previous year and maternal report of antibiotic prescription during pregnancy. Exclusive formula feeding from birth was associated with increased low-allergy formula prescription. There was no evidence that practice prescribing of paediatric adrenaline auto-injectors or anti-reflux medications, or maternal features such as anxiety, age, parity and socioeconomic status were associated with CMA overdiagnosis. CONCLUSION: CMA overdiagnosis is common in early infancy. Risk factors include high primary care practice-based low-allergy formula prescribing and maternal report of antibiotic prescription during pregnancy.</style></abstract><notes><style face="normal" font="default" size="100%">Allen, Hilary I&#xD;Wing, Olivia&#xD;Milkova, Dara&#xD;Jackson, Emilia&#xD;Li, Karen&#xD;Bradshaw, Lucy E&#xD;Wyatt, Laura&#xD;Haines, Rachel&#xD;Santer, Miriam&#xD;Murphy, Andrew W&#xD;Brown, Sara J&#xD;Kelleher, Maeve&#xD;Perkin, Michael R&#xD;Jay, Nicola&#xD;Smith, Timothy D H&#xD;Moriarty, Frank&#xD;Montgomery, Alan A&#xD;Williams, Hywel C&#xD;Boyle, Robert J&#xD;eng&#xD;Children&apos;s Hospital Charity/&#xD;Goldman Sachs/&#xD;National Institute for Health and Care Research/&#xD;WT_/Wellcome Trust/United Kingdom&#xD;Irish College of General Practitioners/&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):148-160. doi: 10.1111/all.16203. Epub 2024 Jun 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38899450</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724250</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16203</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>549</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">549</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Song, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, M.</style></author><author><style face="normal" font="default" size="100%">Li, C.</style></author><author><style face="normal" font="default" size="100%">Huang, Z.</style></author><author><style face="normal" font="default" size="100%">Liu, B.</style></author><author><style face="normal" font="default" size="100%">Yu, M.</style></author><author><style face="normal" font="default" size="100%">Liao, S.</style></author><author><style face="normal" font="default" size="100%">Luan, T.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.&#xD;Department of Dermatology and Venerology, Peking University First Hospital; National Clinical Research Center for Skin and Immune Diseases; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses; NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China.&#xD;Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology, Venereology and Allergy, Charite - Universitatsmedizin Berlin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence and risk factors of chronic urticaria in China: A nationwide cross-sectional study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2233-2236</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/03/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/epidemiology/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35332543</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Xiao&#xD;Song, Xiaoting&#xD;Zhang, Mei&#xD;Li, Chun&#xD;Huang, Zhengjing&#xD;Liu, Bo&#xD;Yu, Miao&#xD;Liao, Shuanglu&#xD;Luan, Tingting&#xD;Zuberbier, Torsten&#xD;Maurer, Marcus&#xD;Zhao, Zuotao&#xD;Wang, Limin&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2233-2236. doi: 10.1111/all.15287. Epub 2022 Mar 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35332543</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15287</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2206</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2206</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spolidoro, G. C. I.</style></author><author><style face="normal" font="default" size="100%">Ali, M. M.</style></author><author><style face="normal" font="default" size="100%">Amera, Y. T.</style></author><author><style face="normal" font="default" size="100%">Nyassi, S.</style></author><author><style face="normal" font="default" size="100%">Lisik, D.</style></author><author><style face="normal" font="default" size="100%">Ioannidou, A.</style></author><author><style face="normal" font="default" size="100%">Rovner, G.</style></author><author><style face="normal" font="default" size="100%">Khaleva, E.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Vlieg-Boerstra, B.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Nwaru, B. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.&#xD;School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.&#xD;Krefting Research Centre, University of Gothenburg, Gothenburg, Sweden.&#xD;ACT Institutet Sweden, Gothenburg, Sweden.&#xD;Division of Physiotherapy, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Section of Allergy &amp; Immunology, School of Medicine, University of Colorado Denver, Children&apos;s Hospital Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.&#xD;Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.&#xD;Division of Allergy and Immunology, Department of Dermatology, Allergy and Venerology, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Pediatrics, OLVG Hospital, Amsterdam, The Netherlands.&#xD;Department of Pediatrics, Rijnstate Hospital, Arnhem, The Netherlands.&#xD;Usher Institute, University of Edinburgh, Edinburgh, UK.&#xD;Department of Mother and Child Health, The Referral Centre for Food Allergy Diagnosis and Treatment Veneto Region, University of Padua, Padua, Italy.&#xD;David Hide Asthma and Allergy Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence estimates of eight big food allergies in Europe: Updated systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2361-2417</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/07/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Protocols</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Studies as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37405695</style></accession-num><abstract><style face="normal" font="default" size="100%">In 2014, the European Academy of Allergy and Clinical Immunology published prevalence estimates for food allergy (FA) and food sensitization (FS) to the so-called eight big food allergens (i.e. cow&apos;s milk, egg, wheat, soy, peanut, tree nuts, fish and shellfish) in Europe for studies published between 2000 and 2012. The current work provides 10-year updated prevalence estimates for these food allergens. A protocol was registered on PROSPERO before starting the research (reference number CRD42021266657). Six databases were searched for studies published 2012-2021, added to studies published up to 2012, resulting in a total of 93 studies. Most studies were graded as at moderate risk of bias. The overall pooled estimates for all age groups of self-reported lifetime prevalence were as follows: cow&apos;s milk (5.7%, 95% confidence interval 4.4-6.9), egg (2.4%, 1.8-3.0), wheat (1.6%, 0.9-2.3), soy (0.5%, 0.3-0.7), peanut (1.5%, 1.0-2.1), tree nuts (0.9%, 0.6-1.2), fish (1.4%, 0.8-2.0) and shellfish (0.4%, 0.3-0.6). The point prevalence of food challenge-verified allergy were as follows: cow&apos;s milk (0.3%, 0.1-0.5), egg (0.8%, 0.5-1.2), wheat (0.1%, 0.01-0.2), soy (0.3%, 0.1-0.4), peanut (0.1%, 0.0-0.2), tree nuts (0.04%, 0.02-0.1), fish (0.02%, 0.0-0.1) and shellfish (0.1%, 0.0-0.2). With some exceptions, the prevalence of allergy to common foods did not substantially change during the last decade; variations by European regions were observed.</style></abstract><notes><style face="normal" font="default" size="100%">Spolidoro, Giulia C I&#xD;Ali, Mohamed Mustafa&#xD;Amera, Yohannes Tesfaye&#xD;Nyassi, Sungkutu&#xD;Lisik, Daniil&#xD;Ioannidou, Athina&#xD;Rovner, Graciela&#xD;Khaleva, Ekaterina&#xD;Venter, Carina&#xD;van Ree, Ronald&#xD;Worm, Margitta&#xD;Vlieg-Boerstra, Berber&#xD;Sheikh, Aziz&#xD;Muraro, Antonella&#xD;Roberts, Graham&#xD;Nwaru, Bright I&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2361-2417. doi: 10.1111/all.15801. Epub 2023 Jul 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37405695</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15801</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3237</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3237</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pu, X.</style></author><author><style face="normal" font="default" size="100%">Zheng, M.</style></author><author><style face="normal" font="default" size="100%">Ge, S.</style></author><author><style face="normal" font="default" size="100%">Sima, Y.</style></author><author><style face="normal" font="default" size="100%">Yu, X.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Key Laboratory of Otolaryngology-Head and Neck Surgery (Ministry of Education of China), Capital Medical University, Beijing, China.&#xD;Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission and Beijing Key Laboratory of New Medicine and Diagnostic Technology Research for Nasal Disease, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.&#xD;Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence of Allergic Rhinitis in China Continues to Increase Without Reaching a Plateau: An Analysis of Three Waves of National Surveys From 2005 to 2019</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">ENT (rhinitis, sinusitis, nasal polyps...)</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41527961</style></accession-num><notes><style face="normal" font="default" size="100%">Pu, Xiaoyu&#xD;Zheng, Ming&#xD;Ge, Siqi&#xD;Sima, Yutong&#xD;Yu, Xiaoru&#xD;Wang, Zhongyi&#xD;Wang, Xiangdong&#xD;Zhang, Luo&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan 13. doi: 10.1111/all.70216.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41527961</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70216</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2475</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2475</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Niedoszytko, M.</style></author><author><style face="normal" font="default" size="100%">Gorska, A.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Lange, M.</style></author><author><style face="normal" font="default" size="100%">Kluin-Nelemans, H.</style></author><author><style face="normal" font="default" size="100%">Oude-Elberink, H.</style></author><author><style face="normal" font="default" size="100%">Sabato, V.</style></author><author><style face="normal" font="default" size="100%">Shoumariyeh, K.</style></author><author><style face="normal" font="default" size="100%">von Bubnoff, D.</style></author><author><style face="normal" font="default" size="100%">Muller, S.</style></author><author><style face="normal" font="default" size="100%">Illerhaus, A.</style></author><author><style face="normal" font="default" size="100%">Doubek, M.</style></author><author><style face="normal" font="default" size="100%">Angelova-Fischer, I.</style></author><author><style face="normal" font="default" size="100%">Hermine, O.</style></author><author><style face="normal" font="default" size="100%">Arock, M.</style></author><author><style face="normal" font="default" size="100%">Elena, C.</style></author><author><style face="normal" font="default" size="100%">Malcovati, L.</style></author><author><style face="normal" font="default" size="100%">Yavuz, A. S.</style></author><author><style face="normal" font="default" size="100%">Schug, T. D.</style></author><author><style face="normal" font="default" size="100%">Fortina, A. B.</style></author><author><style face="normal" font="default" size="100%">Judit, V.</style></author><author><style face="normal" font="default" size="100%">Gotlib, J.</style></author><author><style face="normal" font="default" size="100%">Panse, J.</style></author><author><style face="normal" font="default" size="100%">Vucinic, V.</style></author><author><style face="normal" font="default" size="100%">Reiter, A.</style></author><author><style face="normal" font="default" size="100%">Schwaab, J.</style></author><author><style face="normal" font="default" size="100%">Triggiani, M.</style></author><author><style face="normal" font="default" size="100%">Mattsson, M.</style></author><author><style face="normal" font="default" size="100%">Breynaert, C.</style></author><author><style face="normal" font="default" size="100%">Romantowski, J.</style></author><author><style face="normal" font="default" size="100%">Zanotti, R.</style></author><author><style face="normal" font="default" size="100%">Olivieri, E.</style></author><author><style face="normal" font="default" size="100%">Zink, A.</style></author><author><style face="normal" font="default" size="100%">van de Ven, A.</style></author><author><style face="normal" font="default" size="100%">Stefan, A.</style></author><author><style face="normal" font="default" size="100%">Barete, S.</style></author><author><style face="normal" font="default" size="100%">Caroppo, F.</style></author><author><style face="normal" font="default" size="100%">Perkins, C.</style></author><author><style face="normal" font="default" size="100%">Kennedy, V.</style></author><author><style face="normal" font="default" size="100%">Christen, D.</style></author><author><style face="normal" font="default" size="100%">Jawhar, M.</style></author><author><style face="normal" font="default" size="100%">Luebke, J.</style></author><author><style face="normal" font="default" size="100%">Parente, R.</style></author><author><style face="normal" font="default" size="100%">Levedahl, K.</style></author><author><style face="normal" font="default" size="100%">Hadzijusufovic, E.</style></author><author><style face="normal" font="default" size="100%">Hartmann, K.</style></author><author><style face="normal" font="default" size="100%">Nedoszytko, B.</style></author><author><style face="normal" font="default" size="100%">Sperr, W. R.</style></author><author><style face="normal" font="default" size="100%">Valent, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;Department of Dermatology and Allergy Biederstein, Technical University of Munich, School of Medicine, Munich, Germany.&#xD;Allergy Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.&#xD;Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;Department of Allergology, University Medical Center, Groningen, The Netherlands.&#xD;Department of Immunology, Allergology Rheumatology University of Antwerp and Antwerp University Hospital, Edegem, Belgium.&#xD;Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany and German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), Heidelberg, Germany.&#xD;Dagmar von Bubnoff, Department of Dermatology, Allergy and Venerology, University of Schleswig Holstein, Lubeck, Germany.&#xD;Department of Dermatology, Medical Centre-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.&#xD;Dermatologie, Uniklinik Koln, Koln, Germany.&#xD;Brno University Hospital, Brno, Czech Republic.&#xD;Department of Dermatology, Kepler University Hospital, Linz, Austria.&#xD;Unit of Dermatology and CEREMAST, Pitie-Salpetriere Hospital, Sorbonne Universite, Paris, France.&#xD;Department of Hematological Biology and CEREMAST, Pitie-Salpetriere Hospital, Paris Sorbonne University, Paris, France.&#xD;Department of Hematology, Fondazione IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.&#xD;Department of Molecular Medicine, University of Pavia, Pavia, Italy.&#xD;Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkiye.&#xD;Medical University of Graz, Univ.Klinik fur Dermatologie, Graz, Austria.&#xD;Pediatric Dermatology, Internal Medicine, Azienda Ospedaliera, Universita di Padova, Padova, Italy.&#xD;Semmelweis University Budapest, Budapest, Hungary.&#xD;Stanford University, School of Medicine, Hematology Clinic, Stanford, USA.&#xD;Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Center for Integrated Oncology Aachen, Bonn Cologne, Duesseldorf (CIO ABCD), Aachen, Germany.&#xD;Universitatsklinikum Leipzig AoR, Leipzig, Germany.&#xD;Universitatsmedizin Mannheim, III.Medizinische Klinik, Mannhein, Germany.&#xD;University of Salerno, Salerno, Italy.&#xD;Uppsala University Hospital, Uppsala, Sweden.&#xD;KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology ResearchGroup and MASTeL, University Hospitals Leuven, Leuven, Belgium.&#xD;Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.&#xD;Clinic for Hematology and Oncology, Kepler University Hospital, Linz, Austria.&#xD;Department of Hematology and Oncology, Helios Pforzheim, Pforzheim, Germany.&#xD;Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.&#xD;Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.&#xD;Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.&#xD;Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.&#xD;Invicta Fertility and Reproductive Center, Molecular Laboratory, Sopot, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2470-2481</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Registries</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis/epidemiology/diagnosis/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/epidemiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">food hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">hymenoptera venoms</style></keyword><keyword><style face="normal" font="default" size="100%">immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">mastocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">tryptase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38651829</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hypersensitivity reactions (HR) are common in mastocytosis. However, little is known about triggers and risk factors. The registry of the European Competence Network on Mastocytosis (ECNM) enables reliable studies in a larger cohort of mastocytosis patients. We assessed prevalence, triggers and risk factors of HR in adults with mastocytosis in the ECNM registry. METHODS: Data were collected in 27 ECNM centers. We analyzed potential triggers (Hymenoptera venoms, food, drug, inhalant and others) and risk factors at diagnosis and during follow-up. The study group consisted of 2485 adults with mastocytosis, 1379 women (55.5%) and 1106 men (44.5%). Median age was 48.2 years (range 18-91 years). RESULTS: Nine hundred and forty eight patients (38.1%) reported one or more HR;. Most common triggers were Hymenoptera venoms in cutaneous mastocytosis (CM) and indolent systemic mastocytosis (ISM), whereas in advanced SM (advSM), most common elicitors were drugs, including nonsteroidal anti-inflammatory agents and penicillin. In multivariate analyses, tryptase level &lt; 90 ng/mL, &lt;15% infiltration by mast cells in bone marrow biopsy-sections, and diagnosis of ISM were identified as independent risk factors for HR. For drug-induced HR, prominent risk factors were advSM and high tryptase levels. New reactions were observed in 4.8% of all patients during 4 years follow-up. CONCLUSIONS: HR are mainly triggered by Hymenoptera venoms in patients with CM and ISM and by drugs in patients with advSM. Tryptase levels &lt;90 ng/mL, mast cell bone marrow infiltration &lt;15%, and WHO category ISM are predictors of HR. New HR occur in 4.8% of all patients within 4 years.</style></abstract><notes><style face="normal" font="default" size="100%">Niedoszytko, Marek&#xD;Gorska, Aleksandra&#xD;Brockow, Knut&#xD;Bonadonna, Patrizia&#xD;Lange, Magdalena&#xD;Kluin-Nelemans, Hanneke&#xD;Oude-Elberink, Hanneke&#xD;Sabato, Vito&#xD;Shoumariyeh, Khalid&#xD;von Bubnoff, Dagmar&#xD;Muller, Sabine&#xD;Illerhaus, Anja&#xD;Doubek, Michael&#xD;Angelova-Fischer, Irena&#xD;Hermine, Olivier&#xD;Arock, Michel&#xD;Elena, Chiara&#xD;Malcovati, Luca&#xD;Yavuz, Akif Selim&#xD;Schug, Tanja Daniela&#xD;Fortina, Anna Belloni&#xD;Judit, Varkonyi&#xD;Gotlib, Jason&#xD;Panse, Jens&#xD;Vucinic, Vladan&#xD;Reiter, Andreas&#xD;Schwaab, Juliana&#xD;Triggiani, Massimo&#xD;Mattsson, Mattias&#xD;Breynaert, Christine&#xD;Romantowski, Jan&#xD;Zanotti, Roberta&#xD;Olivieri, Elisa&#xD;Zink, Alexander&#xD;van de Ven, Annick&#xD;Stefan, Alex&#xD;Barete, Stephane&#xD;Caroppo, Francesca&#xD;Perkins, Cecelia&#xD;Kennedy, Vanessa&#xD;Christen, Deborah&#xD;Jawhar, Mohamad&#xD;Luebke, Johannes&#xD;Parente, Roberta&#xD;Levedahl, Kerstin&#xD;Hadzijusufovic, Emir&#xD;Hartmann, Karin&#xD;Nedoszytko, Boguslaw&#xD;Sperr, Wolfgang R&#xD;Valent, Peter&#xD;eng&#xD;Gdanski Uniwersytet Medyczny/&#xD;Fonds Wetenschappelijk Onderzoek/&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2470-2481. doi: 10.1111/all.16132. Epub 2024 Apr 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38651829</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16132</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2789</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2789</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rayner, D. G.</style></author><author><style face="normal" font="default" size="100%">Gou, D.</style></author><author><style face="normal" font="default" size="100%">Weiler, L.</style></author><author><style face="normal" font="default" size="100%">Irelewuyi, L.</style></author><author><style face="normal" font="default" size="100%">Xiong, G.</style></author><author><style face="normal" font="default" size="100%">Wang, E.</style></author><author><style face="normal" font="default" size="100%">Sivanesanathan, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.&#xD;Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.&#xD;Faculty of Engineering, McMaster University, Hamilton, Ontario, Canada.&#xD;Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;Faculty of Science, McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence of Mental Health Symptoms in Chronic Urticaria: A Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2392-2394</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/01/28</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39873233</style></accession-num><notes><style face="normal" font="default" size="100%">Rayner, Daniel G&#xD;Gou, David&#xD;Weiler, Laura&#xD;Irelewuyi, Lola&#xD;Xiong, Grace&#xD;Wang, Elaine&#xD;Sivanesanathan, Tresha&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2392-2394. doi: 10.1111/all.16482. Epub 2025 Jan 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39873233</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368746</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16482</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>640</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">640</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Avdeeva, K. S.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Segboer, C. L.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Amsterdam UMC, Location Academic Medical Centre, Amsterdam, The Netherlands.&#xD;Department of Otorhinolaryngology, Dijklander Ziekenhuis, Hoorn, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The prevalence of non-allergic rhinitis phenotypes in the general population: A cross-sectional study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2163-2174</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/01/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinorrhea</style></keyword><keyword><style face="normal" font="default" size="100%">endotype</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">non-allergic rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35038765</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Non-allergic rhinitis (NAR) can be subdivided into several phenotypes: rhinorrhea of the elderly, rhinitis medicamentosa, smokers&apos;, occupational, hormonal, drug-induced, gustatory, and idiopathic rhinitis. There are two pathophysiological endotypes of NAR: inflammatory and neurogenic. Phenotypes may serve as an indicator of an underlying endotype and, therefore, help to guide the treatment. The prevalence of each phenotype in the general population is currently unknown. METHODOLOGY/PRINCIPAL: Cross-sectional questionnaire-based study in the general population of the Netherlands. RESULTS: The prevalence of chronic rhinitis in the general population was 40% (N = 558, of those, 65% had NAR and 28% AR, in 7% allergy status is unknown). Individuals with NAR (N = 363) had significantly more complaints in October-February. Those with AR (N = 159) had significantly more complaints in April-August. The most common NAR phenotypes were idiopathic (39%) and rhinitis medicamentosa (14%), followed by occupational (8%), smokers&apos; (6%), hormonal (4%), gustatory (4%), and rhinorrhea of the elderly (4%). The least prevalent phenotype was drug induced (1%). Nineteen percent of the NAR group could not be classified into any of the phenotypes. CONCLUSIONS: This is the first study to describe the prevalences of NAR phenotypes in the general population. AR and NAR have a distinct seasonality pattern with NAR being more prevalent in autumn/winter and AR in spring/summer. Our data on the prevalence of phenotypes may help clinicians to anticipate the type of patients at their clinic and help guide a tailored treatment approach. The high prevalence of rhinitis medicamentosa is alarming, since this is a potentially preventable phenotype.</style></abstract><notes><style face="normal" font="default" size="100%">Avdeeva, Klementina S&#xD;Fokkens, Wytske J&#xD;Segboer, Christine L&#xD;Reitsma, Sietze&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2163-2174. doi: 10.1111/all.15223. Epub 2022 Jan 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35038765</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9306544</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15223</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3082</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3082</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kulthanan, K.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Rudenko, M.</style></author><author><style face="normal" font="default" size="100%">Salameh, P.</style></author><author><style face="normal" font="default" size="100%">Komoltri, C.</style></author><author><style face="normal" font="default" size="100%">Adisen, E.</style></author><author><style face="normal" font="default" size="100%">Al Abri, S.</style></author><author><style face="normal" font="default" size="100%">Al-Ahmad, M.</style></author><author><style face="normal" font="default" size="100%">Al-Ahmed, N.</style></author><author><style face="normal" font="default" size="100%">Al Hinai, B.</style></author><author><style face="normal" font="default" size="100%">Allenova, A.</style></author><author><style face="normal" font="default" size="100%">Alshareef, S.</style></author><author><style face="normal" font="default" size="100%">Angkoolpakdeekul, N.</style></author><author><style face="normal" font="default" size="100%">Arnaout, R.</style></author><author><style face="normal" font="default" size="100%">Bartosinska, J.</style></author><author><style face="normal" font="default" size="100%">Cherrez-Ojeda, I.</style></author><author><style face="normal" font="default" size="100%">Chularojanamontri, L.</style></author><author><style face="normal" font="default" size="100%">Criado, P. R.</style></author><author><style face="normal" font="default" size="100%">Ensina, L. F.</style></author><author><style face="normal" font="default" size="100%">Criado, R. F. J.</style></author><author><style face="normal" font="default" size="100%">Calle, C. A. G.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A. M.</style></author><author><style face="normal" font="default" size="100%">Godse, K.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Inomata, N.</style></author><author><style face="normal" font="default" size="100%">Jantanapornchai, N.</style></author><author><style face="normal" font="default" size="100%">Jung, C. G.</style></author><author><style face="normal" font="default" size="100%">Kasperska-Zajac, A.</style></author><author><style face="normal" font="default" size="100%">Khoshkhui, M.</style></author><author><style face="normal" font="default" size="100%">Kolkhir, P.</style></author><author><style face="normal" font="default" size="100%">Krasowska, D.</style></author><author><style face="normal" font="default" size="100%">Laomoleethorn, J.</style></author><author><style face="normal" font="default" size="100%">Maiorowa, A.</style></author><author><style face="normal" font="default" size="100%">Meshkova, R.</style></author><author><style face="normal" font="default" size="100%">Mijakoski, D.</style></author><author><style face="normal" font="default" size="100%">Munoz, M.</style></author><author><style face="normal" font="default" size="100%">Nanchaipruek, Y.</style></author><author><style face="normal" font="default" size="100%">Nasr, I.</style></author><author><style face="normal" font="default" size="100%">Kara, R. O.</style></author><author><style face="normal" font="default" size="100%">Panjapakkul, W.</style></author><author><style face="normal" font="default" size="100%">Paringkarn, T.</style></author><author><style face="normal" font="default" size="100%">Podder, I.</style></author><author><style face="normal" font="default" size="100%">Robles-Velasco, K.</style></author><author><style face="normal" font="default" size="100%">Rosmaninho, I.</style></author><author><style face="normal" font="default" size="100%">Presa, A. R.</style></author><author><style face="normal" font="default" size="100%">Rujitharanawong, C.</style></author><author><style face="normal" font="default" size="100%">Saengthong-Aram, P.</style></author><author><style face="normal" font="default" size="100%">Tafrishi, R.</style></author><author><style face="normal" font="default" size="100%">Mitrevska, N. T.</style></author><author><style face="normal" font="default" size="100%">Tuchinda, P.</style></author><author><style face="normal" font="default" size="100%">Wannawittayapa, T.</style></author><author><style face="normal" font="default" size="100%">Wilson, A.</style></author><author><style face="normal" font="default" size="100%">Ye, Y. M.</style></author><author><style face="normal" font="default" size="100%">Zalewska-Janowska, A.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Division of Rheumatology, Allergy and Immunology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;London Allergy and Immunology Centre, London, UK.&#xD;Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, Lebanon.&#xD;Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.&#xD;Faculty of Pharmacy, Lebanese University, Beirut, Lebanon.&#xD;Institut National de Sante Publique D&apos;epidemiologie Clinique et de Toxicologie-Liban (INSPECT-LB), Beirut, Lebanon.&#xD;Division of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Dermatology, Faculty of Medicine, Gazi University, Ankara, Turkey.&#xD;Clinical Immunology and Allergy Unit, Royal Hospital, Muscat, Oman.&#xD;College of Medicine, Kuwait University, Kuwait City, Kuwait.&#xD;Al-Rashed Allergy Center, Ministry of Health, Kuwait City, Kuwait.&#xD;Laboratory of Immune-Mediated Skin Diseases, Institute of Regenerative Medicine, Biomedical Science &amp; Technology Park, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.&#xD;King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.&#xD;Department of Cosmetology and Aesthetic Medicine, Medical University of Lublin, Lublin, Poland.&#xD;Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lubin, Poland.&#xD;Universidad Espiritu Santo, Samborondon, Ecuador.&#xD;Respiralab Research Group, Guayaquil, Ecuador.&#xD;Department of Dermatology, Centro Universitario Faculdade de Medicina do ABC, Santo Andre, Brazil.&#xD;Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;Emedic Salud, Lima, Peru.&#xD;Department of Dermatology, Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain.&#xD;Department of Dermatology, D. Y. Patil University and School of Medicine, Navi Mumbai, India.&#xD;Center of Allergy and Immunology, David Tvildiani Medical University, Tbilisi, Georgia.&#xD;Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.&#xD;Department of Allergy and Clinical Immunology, Keimyung University School of Medicine, Daegu, South Korea.&#xD;Department of Clinical Allergology and Urticaria, Medical University of Silesia, Katowice, Poland.&#xD;Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.&#xD;Smolensk State Medical University, Smolensk, Russia.&#xD;Institute of Occupational Health of R.N. Macedonia, WHO Collaborating Center, GA2LEN Collaborating Center, Skopje, Republic of North Macedonia.&#xD;Faculty of Medicine, Ss. Cyril and Methodius, University of Skopje, Skopje, Republic of North Macedonia.&#xD;Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey.&#xD;Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kolkata, India.&#xD;Unidade Local de Saude Gaia e Espinho, Vila Nova de Gaia, Portugal.&#xD;Tamega/Sousa Hospital Center, Penafiel, Portugal.&#xD;Dermatology Department, Remedika General Hospital, Skopje, Republic of North Macedonia.&#xD;Department of Dermatology, International Balkan University, Skopje, Republic of North Macedonia.&#xD;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea.&#xD;Psychodermatology Department, Medical University of Lodz, Lodz, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE-D Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">chronic inducible urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">dermographism</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">symptomatic dermographism</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40944435</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The prevalence of symptomatic dermographism (SD) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes-physiological red dermographism and simple urticarial dermographism-among adults worldwide. METHODS: The PREVALENCE-D (Prevalence Estimation of Dermographism) study was the largest international, cross-sectional, internet-based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert-designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD. Participants were recruited into three age groups (18-24, 25-60, and &gt; 60 years), with &gt;/= 1000 individuals per group per country. We calculated sex- and age-adjusted prevalence estimates internationally and by country, with 95% confidence intervals. RESULTS: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [CI] 2.68%-3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%-6.56%). The 25-60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%-10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%-34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%-1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%-5.79%). CONCLUSION: These findings provide comprehensive international estimates of dermographism, particularly SD, and emphasize the need for appropriate healthcare resource allocation and disease recognition.</style></abstract><notes><style face="normal" font="default" size="100%">Kulthanan, Kanokvalai&#xD;Bernstein, Jonathan A&#xD;Rudenko, Michael&#xD;Salameh, Pascale&#xD;Komoltri, Chulaluk&#xD;Adisen, Esra&#xD;Al Abri, Salma&#xD;Al-Ahmad, Mona&#xD;Al-Ahmed, Nasser&#xD;Al Hinai, Bushra&#xD;Allenova, Anastasiia&#xD;Alshareef, Saad&#xD;Angkoolpakdeekul, Nattha&#xD;Arnaout, Rand&#xD;Bartosinska, Joanna&#xD;Cherrez-Ojeda, Ivan&#xD;Chularojanamontri, Leena&#xD;Criado, Paulo Ricardo&#xD;Ensina, Luis Felipe&#xD;Criado, Roberta Fachini Jardim&#xD;Calle, Cesar Alberto Galvan&#xD;Gimenez-Arnau, Ana Maria&#xD;Godse, Kiran&#xD;Gotua, Maia&#xD;Inomata, Naoko&#xD;Jantanapornchai, Nuttagarn&#xD;Jung, Chang-Gyu&#xD;Kasperska-Zajac, Alicja&#xD;Khoshkhui, Maryam&#xD;Kolkhir, Pavel&#xD;Krasowska, Dorota&#xD;Laomoleethorn, Jomgriditip&#xD;Maiorowa, Antonina&#xD;Meshkova, Raisa&#xD;Mijakoski, Dragan&#xD;Munoz, Melba&#xD;Nanchaipruek, Yanisorn&#xD;Nasr, Iman&#xD;Kara, Rabia Oztas&#xD;Panjapakkul, Waratchaya&#xD;Paringkarn, Teerapat&#xD;Podder, Indrashis&#xD;Robles-Velasco, Karla&#xD;Rosmaninho, Isabel&#xD;Presa, Ana Rita&#xD;Rujitharanawong, Chuda&#xD;Saengthong-Aram, Phuwakorn&#xD;Tafrishi, Rana&#xD;Mitrevska, Natasa Teovska&#xD;Tuchinda, Papapit&#xD;Wannawittayapa, Teerapat&#xD;Wilson, Anushka&#xD;Ye, Young-Min&#xD;Zalewska-Janowska, Anna&#xD;Maurer, Marcus&#xD;Zuberbier, Torsten&#xD;eng&#xD;Global Allergy and Asthma Excellency and Asthma Excellence Network/&#xD;Denmark&#xD;Allergy. 2025 Sep 13. doi: 10.1111/all.70047.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40944435</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70047</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2281</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2281</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spolidoro, G. C. I.</style></author><author><style face="normal" font="default" size="100%">Lisik, D.</style></author><author><style face="normal" font="default" size="100%">Nyassi, S.</style></author><author><style face="normal" font="default" size="100%">Ioannidou, A.</style></author><author><style face="normal" font="default" size="100%">Ali, M. M.</style></author><author><style face="normal" font="default" size="100%">Amera, Y. T.</style></author><author><style face="normal" font="default" size="100%">Rovner, G.</style></author><author><style face="normal" font="default" size="100%">Khaleva, E.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Vlieg-Boerstra, B.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Nwaru, B. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.&#xD;Krefting Research Centre, University of Gothenburg, Gothenburg, Sweden.&#xD;School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.&#xD;ACT Institutet Sweden, Vejbystrand, Sweden.&#xD;Division of Physiotherapy, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.&#xD;Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Section of Allergy &amp; Immunology, School of Medicine, University of Colorado Denver, Children&apos;s Hospital Colorado, Aurora, Colorado, USA.&#xD;Department of Experimental Immunology and Department of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.&#xD;Division of Allergy and Immunology, Department of Dermatology, Allergy and Venerology, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Pediatrics, OLVG Hospital, Amsterdam, The Netherlands.&#xD;Department of Pediatrics, Rijnstate Hospital, Arnhem, The Netherlands.&#xD;Usher Institute, University of Edinburgh, Edinburgh, UK.&#xD;Department of Mother and Child Health, The Referral Centre for Food Allergy Diagnosis and Treatment Veneto Region, University of Padua, Padua, Italy.&#xD;David Hide Asthma and Allergy Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence of tree nut allergy in Europe: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">302-323</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/10/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nut Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Nuts</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Corylus/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Prunus dulcis</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37792850</style></accession-num><abstract><style face="normal" font="default" size="100%">In 2014, the European Academy of Allergy and Clinical Immunology (EAACI) published the first systematic review that summarized the prevalence of food allergy (FA) and food sensitization in Europe for studies published 2000-2012. However, only summary estimates for tree nut allergy (TNA) were feasible in that work. In the current update of that systematic review, we summarized the prevalence of tree nut allergy/sensitization to individual tree nuts. Six databases were searched for relevant papers published 2012-2021 and 17 eligible studies were added to the 15 studies already identified between 2000 and 2012, giving a total of 32 studies. Of the investigated tree nuts, meta-analysis was possible for hazelnut, walnut, almond, and in few cases, for cashew, and Brazil nut. The lifetime self-reported prevalence was 0.8% (95% CI 0.5-1.1) for hazelnut and 0.4% (0.2-0.9) for walnut. The point self-reported prevalence was 4.0% (2.9-5.2) for hazelnut, 3.4% (2.0-4.9) for Brazil nut, 2.0% (1.1-2.9) for almond, and 1.8% (1.1-2.5) for walnut. Point prevalence of food challenge-confirmed TNA was 0.04% (0.0-0.1) for hazelnut and 0.02% (0.01-0.1) for walnut. Due to paucity of data, we could not identify any meaningful and consistent differences across age groups and European regions.</style></abstract><notes><style face="normal" font="default" size="100%">Spolidoro, Giulia C I&#xD;Lisik, Daniil&#xD;Nyassi, Sungkutu&#xD;Ioannidou, Athina&#xD;Ali, Mohamed Mustafa&#xD;Amera, Yohannes Tesfaye&#xD;Rovner, Graciela&#xD;Khaleva, Ekaterina&#xD;Venter, Carina&#xD;van Ree, Ronald&#xD;Worm, Margitta&#xD;Vlieg-Boerstra, Berber&#xD;Sheikh, Aziz&#xD;Muraro, Antonella&#xD;Roberts, Graham&#xD;Nwaru, Bright I&#xD;eng&#xD;DBV Technologies SA/&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):302-323. doi: 10.1111/all.15905. Epub 2023 Oct 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37792850</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15905</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3291</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3291</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Melles, Mireille C.</style></author><author><style face="normal" font="default" size="100%">Veen, Johannes C. C. M. in &apos;t</style></author><author><style face="normal" font="default" size="100%">Slebos, Dirk-Jan</style></author><author><style face="normal" font="default" size="100%">Franssen, Frits M. E.</style></author><author><style face="normal" font="default" size="100%">van Dijk, Marlies</style></author><author><style face="normal" font="default" size="100%">Hekking, Pieter-Paul W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prevalence of Type 2 Inflammation in Chronic Obstructive Pulmonary Disease Patients With Frequent Exacerbations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70300</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70300</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1323</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1323</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Luo, W.</style></author><author><style face="normal" font="default" size="100%">Wang, D.</style></author><author><style face="normal" font="default" size="100%">Zhang, T.</style></author><author><style face="normal" font="default" size="100%">Zheng, P.</style></author><author><style face="normal" font="default" size="100%">Leng, D.</style></author><author><style face="normal" font="default" size="100%">Li, L.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Sun, B.</style></author><author><style face="normal" font="default" size="100%">Zhang, X. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.&#xD;Faculty of Health Sciences, University of Macau, Taipa, Macau, China.&#xD;Department of Immunology, Guangzhou Kingmed Diagnostics Group Co., Ltd., Guangzhou, Guangdong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence patterns of allergen sensitization by region, gender, age, and season among patients with allergic symptoms in mainland China: A four-year multicenter study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">589-593</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/09/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Seasons</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32965683</style></accession-num><notes><style face="normal" font="default" size="100%">Luo, Wenting&#xD;Wang, Dandan&#xD;Zhang, Teng&#xD;Zheng, Peiyan&#xD;Leng, Dongliang&#xD;Li, Ling&#xD;Liu, Yong&#xD;Sun, Baoqinq&#xD;Zhang, Xiaohua Douglas&#xD;eng&#xD;Letter&#xD;Multicenter Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):589-593. doi: 10.1111/all.14597. Epub 2020 Oct 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32965683</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7984441</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14597</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2709</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2709</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shimamura, A.</style></author><author><style face="normal" font="default" size="100%">Ishii, H.</style></author><author><style face="normal" font="default" size="100%">Matsuoka, T.</style></author><author><style face="normal" font="default" size="100%">Watanabe, D.</style></author><author><style face="normal" font="default" size="100%">Yonaga, T.</style></author><author><style face="normal" font="default" size="100%">Masuyama, K.</style></author><author><style face="normal" font="default" size="100%">Sakurai, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, University of Yamanashi, Chuo, Japan.&#xD;Department of Otolaryngology, Suwa Central Hospital, Nagano, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence Survey on Oral Allergy Syndrome in Patients With Seasonal Allergic Rhinitis in Yamanashi, Japan</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">890-892</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/11/18</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39555772</style></accession-num><notes><style face="normal" font="default" size="100%">Shimamura, Ayumi&#xD;Ishii, Hiroki&#xD;Matsuoka, Tomokazu&#xD;Watanabe, Daisuke&#xD;Yonaga, Takaaki&#xD;Masuyama, Keisuke&#xD;Sakurai, Daiju&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):890-892. doi: 10.1111/all.16398. Epub 2024 Nov 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39555772</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891411</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16398</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>548</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">548</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Piontek, K.</style></author><author><style face="normal" font="default" size="100%">Ittermann, T.</style></author><author><style face="normal" font="default" size="100%">Arnold, A.</style></author><author><style face="normal" font="default" size="100%">Volzke, H.</style></author><author><style face="normal" font="default" size="100%">Baumeister, S. E.</style></author><author><style face="normal" font="default" size="100%">Apfelbacher, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Social Medicine and Health Systems Research, Medical Faculty Magdeburg, Magdeburg, Germany.&#xD;Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.&#xD;Department of Dermatology, University Medicine Greifswald, Greifswald, Germany.&#xD;Institute of Health Services Research in Dentistry, University of Munster, Munster, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence, atopic and psychological comorbidity of physician-diagnosed atopic dermatitis in an adult general population sample: A cross-sectional study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1915-1917</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/03/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Physicians</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35332565</style></accession-num><notes><style face="normal" font="default" size="100%">Piontek, Katharina&#xD;Ittermann, Till&#xD;Arnold, Andreas&#xD;Volzke, Henry&#xD;Baumeister, Sebastian-Edgar&#xD;Apfelbacher, Christian&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1915-1917. doi: 10.1111/all.15288. Epub 2022 Mar 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35332565</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15288</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2587</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2587</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khatri, R.</style></author><author><style face="normal" font="default" size="100%">Weigmann, B.</style></author><author><style face="normal" font="default" size="100%">Shahneh, F.</style></author><author><style face="normal" font="default" size="100%">Sudowe, S.</style></author><author><style face="normal" font="default" size="100%">Schuppan, D.</style></author><author><style face="normal" font="default" size="100%">Saloga, J.</style></author><author><style face="normal" font="default" size="100%">Bellinghausen, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.&#xD;Institute of Translational Immunology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.&#xD;Department of Internal Medicine I, University Hospital Erlangen, University of Erlangen-Nurnberg, Erlangen, Germany.&#xD;Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.&#xD;Ganzimmun Diagnostics GmbH, Mainz, Germany.&#xD;Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of allergic airway and gut inflammation in humanized mice by lactobacilli, bifidobacteria, and butyrate</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3150-3154</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/07/07</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38972005</style></accession-num><notes><style face="normal" font="default" size="100%">Khatri, Rahul&#xD;Weigmann, Benno&#xD;Shahneh, Fatemeh&#xD;Sudowe, Stephan&#xD;Schuppan, Detlef&#xD;Saloga, Joachim&#xD;Bellinghausen, Iris&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3150-3154. doi: 10.1111/all.16230. Epub 2024 Jul 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38972005</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16230</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>885</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">885</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pittet, L. F.</style></author><author><style face="normal" font="default" size="100%">Messina, N. L.</style></author><author><style face="normal" font="default" size="100%">Gardiner, K.</style></author><author><style face="normal" font="default" size="100%">Freyne, B.</style></author><author><style face="normal" font="default" size="100%">Abruzzo, V.</style></author><author><style face="normal" font="default" size="100%">Francis, K. L.</style></author><author><style face="normal" font="default" size="100%">Morrison, C.</style></author><author><style face="normal" font="default" size="100%">Zufferey, C.</style></author><author><style face="normal" font="default" size="100%">Vuillermin, P.</style></author><author><style face="normal" font="default" size="100%">Allen, K. J.</style></author><author><style face="normal" font="default" size="100%">Ponsonby, A. L.</style></author><author><style face="normal" font="default" size="100%">Robins-Browne, R.</style></author><author><style face="normal" font="default" size="100%">Shann, F.</style></author><author><style face="normal" font="default" size="100%">Flanagan, K. L.</style></author><author><style face="normal" font="default" size="100%">Phillips, R.</style></author><author><style face="normal" font="default" size="100%">Donath, S.</style></author><author><style face="normal" font="default" size="100%">Casalaz, D.</style></author><author><style face="normal" font="default" size="100%">Curtis, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infectious Diseases Group, Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Infectious Diseases, The Royal Children&apos;s Hospital Melbourne, Parkville, Victoria, Australia.&#xD;Department of Research Operations, The Royal Children&apos;s Hospital Melbourne, Parkville, Victoria, Australia.&#xD;Department of Paediatrics, College of Medicine, University of Malawi, Queen Elizabeth Central Hospital, Blantyre, Malawi.&#xD;Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool and Malawi-Liverpool Wellcome Trust Research Programme, Blantyre, Malawi.&#xD;Clinical Epidemiology &amp; Biostatistics Unit, Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;School of Medicine, Deakin University, Geelong, Victoria, Australia.&#xD;Child Health Research Unit, Barwon Health, Geelong, Victoria, Australia.&#xD;Formerly Centre for Food and Allergy Research, Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;Population Allergy, Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;The Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia.&#xD;Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.&#xD;School of Health Sciences, University of Tasmania, Hobart, Tasmania, Australia.&#xD;School of Health and Biomedical Science, RMIT University, Melbourne, Victoria, Australia.&#xD;Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia.&#xD;Dermatology Unit, The Royal Children&apos;s Hospital Melbourne, Parkville, Victoria, Australia.&#xD;Neonatal Intensive Care Unit, Mercy Hospital for Women, Heidelberg, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of infant eczema by neonatal Bacillus Calmette-Guerin vaccination: The MIS BAIR randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">956-965</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/07/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">BCG Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Mycobacterium bovis</style></keyword><keyword><style face="normal" font="default" size="100%">Atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">SCORing Atopic Dermatitis scoring system</style></keyword><keyword><style face="normal" font="default" size="100%">William&apos;s UK diagnostic criteria</style></keyword><keyword><style face="normal" font="default" size="100%">patient-oriented eczema measure</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine non-specific effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34309859</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Bacille Calmette-Guerin (BCG) vaccine could play a role in counteracting the rising prevalence of atopic diseases, through its beneficial off-target effects. We aimed to determine whether neonatal BCG vaccination reduces the incidence of eczema in infants. METHODS: Randomized controlled trial with 1272 infants allocated to receive BCG-Denmark or no BCG at birth. The primary outcome was the 12-month incidence of eczema based on 3-monthly questionnaires. Eczema was also assessed at a 12-month clinic visit. ClinicalTrial.gov: NCT01906853. RESULTS: The 12-month eczema incidence was 32.2% in the BCG group compared with 36.6% in the control group (adjusted risk difference (aRD) -4.3%, 95% CI -9.9% to 1.3%, multiple imputation model). In addition, comparing infants in the BCG group with the control group, 15.7% vs. 19.2% had eczema lesions at the 12-month visit (aRD -3.5%, 95% CI -8.0% to 1.0%); 35.7% vs. 39.0% reported using topical steroids (aRD -3.3, 95% CI -9.2 to 2.7); and 7.3% vs. 10.2% had severe eczema scores (aRD -3.0%, 95% CI -8.8% to 2.7%). In 344 high-risk infants (two atopic parents), the 12-month eczema incidence was 35.3% in the BCG group compared with 46.8% in the control group (aRD -11.5%, 95% CI -21.9% to -1.2%; number needed to treat 8.7, 95% CI 4.6 to 83.3). CONCLUSION: There is insufficient evidence to recommend neonatal BCG vaccination in all infants for the prevention of eczema in the first year of life; however, a modest beneficial effect was observed among high-risk infants. A single dose of BCG-Denmark soon after birth could reduce the incidence of eczema in infants with two atopic parents.</style></abstract><notes><style face="normal" font="default" size="100%">Pittet, Laure F&#xD;Messina, Nicole L&#xD;Gardiner, Kaya&#xD;Freyne, Bridget&#xD;Abruzzo, Veronica&#xD;Francis, Kate L&#xD;Morrison, Clare&#xD;Zufferey, Christel&#xD;Vuillermin, Peter&#xD;Allen, Katrina J&#xD;Ponsonby, Anne-Louise&#xD;Robins-Browne, Roy&#xD;Shann, Frank&#xD;Flanagan, Katie L&#xD;Phillips, Rod&#xD;Donath, Susan&#xD;Casalaz, Dan&#xD;Curtis, Nigel&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):956-965. doi: 10.1111/all.15022. Epub 2021 Aug 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34309859</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15022</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2482</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2482</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dwivedi, V.</style></author><author><style face="normal" font="default" size="100%">Kopanja, S.</style></author><author><style face="normal" font="default" size="100%">Schmidthaler, K.</style></author><author><style face="normal" font="default" size="100%">Sieber, J.</style></author><author><style face="normal" font="default" size="100%">Bannert, C.</style></author><author><style face="normal" font="default" size="100%">Szepfalusi, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Paediatric Pulmonology, Allergy and Endocrinology, Department of Paediatrics and Adolescent Medicine, Comprehensive Centre of Paediatrics, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Preventive allergen immunotherapy with inhalant allergens in children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2065-2087</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/04/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/therapy/immunology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38588176</style></accession-num><abstract><style face="normal" font="default" size="100%">The efficacy and safety of preventive allergen immunotherapy (pAIT) in children are currently under investigation. Here, we provide an overview of pAIT with respiratory allergens concerning the prevention of new sensitizations, allergic disease onset and progression as well as further immunomodulatory effects. Three databases were searched for clinical pAIT studies in children. Selected publications were reviewed for preventive outcomes according to prevention level (primary, secondary, and tertiary), allergen type, administration route, dose, and treatment duration. The primary prevention approach appears safe but showed no allergen-specific effect on new sensitizations. Secondary prevention seems feasible and may induce regulatory T cell-mediated immunotolerance. The number of studies at these prevention levels is limited. Tertiary prevention with grass and/or tree pollen-based pAIT has shown efficacy in preventing disease progression from allergic rhinitis/conjunctivitis to asthma. Data on tertiary pAIT with house dust mites and other allergen types are inconclusive. Subcutaneous and sublingual routes appear similarly effective, but head-to-head comparative paediatric studies are scarce. Additionally, there are fewer placebo-controlled studies. Nevertheless, immunomodulatory outcomes of pAIT are encouraging. Currently, limited but favourably suggestive evidence is available for preventing respiratory allergic diseases in children by pAIT. Primary and secondary prevention have potential and warrant further investigation through well-designed studies.</style></abstract><notes><style face="normal" font="default" size="100%">Dwivedi, Varsha&#xD;Kopanja, Sonja&#xD;Schmidthaler, Klara&#xD;Sieber, Justyna&#xD;Bannert, Christina&#xD;Szepfalusi, Zsolt&#xD;eng&#xD;DK-W1248-B30/Austrian Science Fund/&#xD;F4615-B19/Austrian Science Fund/&#xD;COVID028/Medical Scientific Fund of the Mayor of the City of Vienna/&#xD;&quot;Danube Allergy Research Cluster - Towards Cure of Allergy&quot; of the Karl Landsteiner Private University/Country of Lower Austria/&#xD;Danube Allergy Research Cluster- Towards Cure of Allergy&apos; of the Karl Landsteiner Private University, by the Federal State of Lower Austria/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2065-2087. doi: 10.1111/all.16115. Epub 2024 Apr 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38588176</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16115</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3035</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3035</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Jang, J. G.</style></author><author><style face="normal" font="default" size="100%">Kang, M. G.</style></author><author><style face="normal" font="default" size="100%">Kim, Y.</style></author><author><style face="normal" font="default" size="100%">Moon, J. Y.</style></author><author><style face="normal" font="default" size="100%">Min, K. H.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Yoo, K. H.</style></author><author><style face="normal" font="default" size="100%">Yun, H. J.</style></author><author><style face="normal" font="default" size="100%">Kim, J. S.</style></author><author><style face="normal" font="default" size="100%">Lee, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.&#xD;Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea.&#xD;Department of Medical Informatics, Jeonbuk National University Medical School, Jeonju, Republic of Korea.&#xD;Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea.&#xD;Division of Pulmonary and Allergy, Department of Internal Medicine, Konkuk University Hospital, School of Medicine, Konkuk University, Seoul, Republic of Korea.&#xD;Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Jeonbuk National University Medical School, Jeonju, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Preventive Role of COVID-19 Vaccination on Future Severe Exacerbation of Asthma According to Severe COVID-19 Status: A Nationwide Population-Based Cohort Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2678-2681</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/08/14 22:50</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40810369</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Sang Hyuk&#xD;Jang, Jong Geol&#xD;Kang, Min Gu&#xD;Kim, Youlim&#xD;Moon, Ji-Yong&#xD;Min, Kyung Hoon&#xD;Kim, Sang-Heon&#xD;Yoo, Kwang-Ha&#xD;Yun, Ho Joo&#xD;Kim, Jong Seung&#xD;Lee, Hyun&#xD;eng&#xD;RS-2025-00557268/This work was supported by a National Research Foundation of Korea grant funded by the Korean government (MSIT)/&#xD;RS-2025-00514175/This work was supported by a National Research Foundation of Korea grant funded by the Korean government (MSIT)/&#xD;HY-202500000001668/This work was supported by the research fund of Hanyang University/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2678-2681. doi: 10.1111/all.70011. Epub 2025 Aug 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40810369</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444816</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70011</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2485</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2485</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, H. J.</style></author><author><style face="normal" font="default" size="100%">Kim, M. J.</style></author><author><style face="normal" font="default" size="100%">Kim, J. S.</style></author><author><style face="normal" font="default" size="100%">Lee, Y. C.</style></author><author><style face="normal" font="default" size="100%">Jeong, J. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Research Center for Pulmonary Disorders, Jeonbuk National University Hospital, Jeonju, Republic of Korea.&#xD;Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea.&#xD;Department of Medical Informatics, Jeonbuk National University Medical School, Jeonju, Republic of Korea.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Jeonbuk National University Hospital, Jeonju, Republic of Korea.&#xD;Respiratory Drug Development Research Institute, Jeonbuk National University Medical School, Jeonju, Republic of Korea.&#xD;Laboratory of Respiratory Immunology and Infectious Diseases, Korea Zoonosis Research Institute, Jeonbuk National University, Iksan, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prior respiratory syncytial viral infection contributes to severe COVID-19 illness: A nationwide cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2534-2537</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/04/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Syncytial Virus Infections/epidemiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38577792</style></accession-num><notes><style face="normal" font="default" size="100%">Lee, Hwan Jin&#xD;Kim, Min Ji&#xD;Kim, Jong Seung&#xD;Lee, Yong Chul&#xD;Jeong, Jae Seok&#xD;eng&#xD;The Bio &amp; Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. RS-2023-00236157; JSJ)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2534-2537. doi: 10.1111/all.16118. Epub 2024 Apr 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38577792</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16118</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2442</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2442</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yong, P. F. K.</style></author><author><style face="normal" font="default" size="100%">Guilarte, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Immunology and Allergy, Frimley Health NHS Foundation Trust, Frimley, UK.&#xD;Allergy Department, National Reference Hereditary Angioedema Center (CSUR), Hospital universitari Vall d&apos;Hebron, Barcelona, Spain.&#xD;Allergy Research Unit, Vall d&apos;Hebron Research Institute (VHIR), Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prodromal symptoms of hereditary angioedema (HAE) attacks: A patient survey in UK and Spain</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2258-2262</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/03/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Spain/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Prodromal Symptoms</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Hae</style></keyword><keyword><style face="normal" font="default" size="100%">early signs and symptoms</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">prodromes</style></keyword><keyword><style face="normal" font="default" size="100%">treating early</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38462815</style></accession-num><notes><style face="normal" font="default" size="100%">Yong, Patrick F K&#xD;Guilarte, Mar&#xD;eng&#xD;Pharming Technologies N.V./&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2258-2262. doi: 10.1111/all.16099. Epub 2024 Mar 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38462815</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16099</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>650</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">650</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leibovich-Nassi, I.</style></author><author><style face="normal" font="default" size="100%">Reshef, A.</style></author><author><style face="normal" font="default" size="100%">Somech, R.</style></author><author><style face="normal" font="default" size="100%">Golander, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Barzilai University Medical Center, Ashkelon, Israel.&#xD;Sackler school of Medicine, Tel Aviv University, Tel Aviv, Israel.&#xD;Safra Pediatric Medical Center, Ramat Gan, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prodromes as predictors of hereditary angioedema attacks</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1309-1312</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/01/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">attacks</style></keyword><keyword><style face="normal" font="default" size="100%">dimensions</style></keyword><keyword><style face="normal" font="default" size="100%">domains</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">prodromes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35000208</style></accession-num><notes><style face="normal" font="default" size="100%">Leibovich-Nassi, Iris&#xD;Reshef, Avner&#xD;Somech, Raz&#xD;Golander, Hava&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1309-1312. doi: 10.1111/all.15215. Epub 2022 Jan 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35000208</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15215</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>251</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">251</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leibovich-Nassi, I.</style></author><author><style face="normal" font="default" size="100%">Golander, H.</style></author><author><style face="normal" font="default" size="100%">Reshef, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Barzilai University Medical Center, Ashkelon, Israel.&#xD;Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prodromes predict attacks of hereditary angioedema: Results of a prospective study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">577-579</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/10/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">attacks</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">patient-reported outcomes</style></keyword><keyword><style face="normal" font="default" size="100%">prodromes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36259763</style></accession-num><notes><style face="normal" font="default" size="100%">Leibovich-Nassi, Iris&#xD;Golander, Hava&#xD;Reshef, Avner&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):577-579. doi: 10.1111/all.15556. Epub 2022 Oct 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36259763</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10092815</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15556</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1008</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1008</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Rosenwasser, L. J.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Department of Pediatrics, Division of Immunology Research, Children&apos;s Mercy Hospitals &amp; Clinics, Kansas City, MO, USA.&#xD;Personalized Medicine Asthma &amp; Allergy Clinic-Humanitas University &amp; Research Hospital, IRCCS-Milano, Milano, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prof. Mario Sanchez Borges: An enduring legacy and a life well-lived</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1948-1949</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/05/11</style></edition><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33969904</style></accession-num><notes><style face="normal" font="default" size="100%">Pawankar, Ruby&#xD;Rosenwasser, Lanny J&#xD;Canonica, Giorgio Walter&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1948-1949. doi: 10.1111/all.14869. Epub 2021 May 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33969904</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14869</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>740</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">740</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garib, V.</style></author><author><style face="normal" font="default" size="100%">Ben-Ali, M.</style></author><author><style face="normal" font="default" size="100%">Kundi, M.</style></author><author><style face="normal" font="default" size="100%">Curin, M.</style></author><author><style face="normal" font="default" size="100%">Yaakoubi, R.</style></author><author><style face="normal" font="default" size="100%">Ben-Mustapha, I.</style></author><author><style face="normal" font="default" size="100%">Mekki, N.</style></author><author><style face="normal" font="default" size="100%">Froeschl, R.</style></author><author><style face="normal" font="default" size="100%">Perkmann, T.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Barbouche, M. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Wien, Austria.&#xD;Ministry of Innovation Development, Tashkent, Uzbekistan.&#xD;Laboratory of Transmission, Control and Immunobiology of Infections (LR11IPT02), Department of Immunology, Institut Pasteur de Tunis and University Tunis El Manar, Tunis, Tunisia.&#xD;Department for Environmental Health, Center for Public Health, Medical University Vienna, Wien, Austria.&#xD;Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.&#xD;NRC Institute of Immunology FMBA of Russia, Moscow, Russia.&#xD;Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Medical School, University of Tunis El Manar, Tunis, Tunisia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Profound differences in IgE and IgG recognition of micro-arrayed allergens in hyper-IgE syndromes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1761-1771</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/10/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Job Syndrome/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">hyper-IgE syndrome (HIES)</style></keyword><keyword><style face="normal" font="default" size="100%">micro-array</style></keyword><keyword><style face="normal" font="default" size="100%">phosphoglucomutase-3 (PGM3) deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">signal transducer and activator of transcription (STAT3)</style></keyword><keyword><style face="normal" font="default" size="100%">HVD-Biotech, Vienna, Austria and WORG Pharmaceuticals, Hangzhou, China. He serves</style></keyword><keyword><style face="normal" font="default" size="100%">as a consultant for Viravaxx. The other authors have no conflicts of interest to</style></keyword><keyword><style face="normal" font="default" size="100%">declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34653276</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The specificities of IgE and IgG for allergen molecules in patients with inborn errors of immunity (IEI) have not been investigated in detail. OBJECTIVE: To study IgE and IgG antibody specificities in patients with defined hyper-IgE syndromes (HIES) using a comprehensive panel of allergen molecules. METHODS: We used chips containing micro-arrayed allergen molecules to analyze allergen-specific IgE and IgG levels in sera from two groups of HIES patients: Autosomal recessive mutations in phosphoglucomutase-3 (PGM3); Autosomal dominant negative mutations of STAT3 (STAT3); and age-matched subjects with allergic sensitizations. Assays with rat basophil leukemia cells transfected with human FcepsilonRI were performed to study the biological relevance of IgE sensitizations. RESULTS: Median total IgE levels were significantly lower in the sensitized control group (212.9 kU/L) as compared to PGM3 (5042 kU/L) and STAT3 patients (2561 kU/L). However, PGM3 patients had significantly higher allergen-specific IgE levels and were sensitized to a larger number of allergen molecules as compared to STAT3 patients. Biological relevance of IgE sensitization was confirmed for PGM3 patients by basophil activation testing. PGM3 patients showed significantly lower cumulative allergen-specific IgG responses in particular to milk and egg allergens as compared to STAT3 patients and sensitized controls whereas total IgG levels were comparable to STAT3 patients and significantly higher than in controls. CONCLUSION: The analysis with multiple micro-arrayed allergen molecules reveals profound differences of allergen-specific IgE and IgG recognition in PGM3 and STAT3 patients which may be useful for classification of IEI and clinical characterization of patients.</style></abstract><notes><style face="normal" font="default" size="100%">Garib, Victoria&#xD;Ben-Ali, Meriem&#xD;Kundi, Michael&#xD;Curin, Mirela&#xD;Yaakoubi, Roukaya&#xD;Ben-Mustapha, Imen&#xD;Mekki, Najla&#xD;Froeschl, Renate&#xD;Perkmann, Thomas&#xD;Valenta, Rudolf&#xD;Barbouche, Mohamed-Ridha&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1761-1771. doi: 10.1111/all.15143. Epub 2021 Nov 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34653276</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9298271</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15143</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1038</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1038</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adamo, S.</style></author><author><style face="normal" font="default" size="100%">Chevrier, S.</style></author><author><style face="normal" font="default" size="100%">Cervia, C.</style></author><author><style face="normal" font="default" size="100%">Zurbuchen, Y.</style></author><author><style face="normal" font="default" size="100%">Raeber, M. E.</style></author><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Sivapatham, S.</style></author><author><style face="normal" font="default" size="100%">Jacobs, A.</style></author><author><style face="normal" font="default" size="100%">Baechli, E.</style></author><author><style face="normal" font="default" size="100%">Rudiger, A.</style></author><author><style face="normal" font="default" size="100%">Stussi-Helbling, M.</style></author><author><style face="normal" font="default" size="100%">Huber, L. C.</style></author><author><style face="normal" font="default" size="100%">Schaer, D. J.</style></author><author><style face="normal" font="default" size="100%">Bodenmiller, B.</style></author><author><style face="normal" font="default" size="100%">Boyman, O.</style></author><author><style face="normal" font="default" size="100%">Nilsson, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.&#xD;Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.&#xD;Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.&#xD;Clinic for Internal Medicine, Uster Hospital, Uster, Switzerland.&#xD;Department of Medicine, Limmattal Hospital, Schlieren, Switzerland.&#xD;Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland.&#xD;Department of Internal Medicine, USZ, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2866-2881</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Activation</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">lymphopenia</style></keyword><keyword><style face="normal" font="default" size="100%">conduct of the study. Dr. Chevrier has nothing to disclose. Dr. Cervia reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Swiss Academy of Medical Sciences, during the conduct of the study.</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Zurbuchen reports grants from Swiss Academy of Medical Sciences, during the</style></keyword><keyword><style face="normal" font="default" size="100%">conduct of the study. Dr. Raeber reports grants from Young Talents in Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Research Fellowship by the Swiss Academy of Medical Sciences and Bangerter</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, during the conduct of the study. Dr. Yang has nothing to disclose.</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Sivapatham has nothing to disclose. Dr. Jacobs has nothing to disclose. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Baechli has nothing to disclose. Dr. Rudiger has nothing to disclose. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Stussi-Helbling has nothing to disclose. Dr. Huber has nothing to disclose. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Schaer has nothing to disclose. Dr. Bodenmiller reports grants from Swiss</style></keyword><keyword><style face="normal" font="default" size="100%">National Science Foundation, grants from Pandemic Fund of the University of</style></keyword><keyword><style face="normal" font="default" size="100%">Zurich, during the conduct of the study. Dr. Boyman reports grants from Swiss</style></keyword><keyword><style face="normal" font="default" size="100%">National Science Foundation, grants from Clinical Research Priority Program of</style></keyword><keyword><style face="normal" font="default" size="100%">the University of Zurich, from Innovation grant of University Hospital Zurich,</style></keyword><keyword><style face="normal" font="default" size="100%">during the conduct of the study. Dr. Nilsson reports grants from Swiss National</style></keyword><keyword><style face="normal" font="default" size="100%">Science Foundation, during the conduct of the study.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33884644</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and shows a broad clinical presentation ranging from asymptomatic infection to fatal disease. A very prominent feature associated with severe COVID-19 is T cell lymphopenia. However, homeostatic and functional properties of T cells are ill-defined in COVID-19. METHODS: We prospectively enrolled individuals with mild and severe COVID-19 into our multicenter cohort and performed a cross-sectional analysis of phenotypic and functional characteristics of T cells using 40-parameter mass cytometry, flow cytometry, targeted proteomics, and functional assays. RESULTS: Compared with mild disease, we observed strong perturbations of peripheral T cell homeostasis and function in severe COVID-19. Individuals with severe COVID-19 showed T cell lymphopenia and redistribution of T cell populations, including loss of naive T cells, skewing toward CD4(+) T follicular helper cells and cytotoxic CD4(+) T cells, and expansion of activated and exhausted T cells. Extensive T cell apoptosis was particularly evident with severe disease and T cell lymphopenia, which in turn was accompanied by impaired T cell responses to several common viral antigens. Patients with severe disease showed elevated interleukin-7 and increased T cell proliferation. Furthermore, patients sampled at late time points after symptom onset had higher T cell counts and improved antiviral T cell responses. CONCLUSION: Our study suggests that severe COVID-19 is characterized by extensive T cell dysfunction and T cell apoptosis, which is associated with signs of homeostatic T cell proliferation and T cell recovery.</style></abstract><notes><style face="normal" font="default" size="100%">Adamo, Sarah&#xD;Chevrier, Stephane&#xD;Cervia, Carlo&#xD;Zurbuchen, Yves&#xD;Raeber, Miro E&#xD;Yang, Liliane&#xD;Sivapatham, Sujana&#xD;Jacobs, Andrea&#xD;Baechli, Esther&#xD;Rudiger, Alain&#xD;Stussi-Helbling, Melina&#xD;Huber, Lars C&#xD;Schaer, Dominik J&#xD;Bodenmiller, Bernd&#xD;Boyman, Onur&#xD;Nilsson, Jakob&#xD;eng&#xD;Innovation grant of University Hospital Zurich/&#xD;323530-177975/Schweizerische Akademie der Medizinischen Wissenschaften/&#xD;323530-191220/Schweizerische Akademie der Medizinischen Wissenschaften/&#xD;323530-191230/Schweizerische Akademie der Medizinischen Wissenschaften/&#xD;Young Talents in Clinical Research Fellowship/Schweizerische Akademie der Medizinischen Wissenschaften/&#xD;310030-172978/Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;4078P0-198431/Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;R&apos;Equip grant/Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;Clinical Research Priority Program of the University of Zurich for CRPP CYTIMM-Z/&#xD;Multicenter Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2866-2881. doi: 10.1111/all.14866. Epub 2021 Jun 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33884644</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8251365</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14866</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2671</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2671</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, A. R.</style></author><author><style face="normal" font="default" size="100%">Jeong, M.</style></author><author><style face="normal" font="default" size="100%">Koo, K.</style></author><author><style face="normal" font="default" size="100%">Kim, S. J.</style></author><author><style face="normal" font="default" size="100%">Pyo, M. J.</style></author><author><style face="normal" font="default" size="100%">Hong, Y.</style></author><author><style face="normal" font="default" size="100%">Ha, Y.</style></author><author><style face="normal" font="default" size="100%">Moon, K. A.</style></author><author><style face="normal" font="default" size="100%">Shim, H. J.</style></author><author><style face="normal" font="default" size="100%">Lee, J. H.</style></author><author><style face="normal" font="default" size="100%">Kwon, H. S.</style></author><author><style face="normal" font="default" size="100%">Cho, Y. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Progranulin derivative attenuates lung neutrophilic infiltration from diesel exhaust particle exposure</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">703-714</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/10/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Vehicle Emissions/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">*Progranulins/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Neutrophil Infiltration/drug effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Particulate Matter/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Lung/pathology/immunology/metabolism/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Air Pollutants</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Ros</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">diesel exhaust particles</style></keyword><keyword><style face="normal" font="default" size="100%">lung inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">progranulin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39462225</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Air pollutants, such as diesel exhaust particles (DEPs), induce respiratory disease exacerbation with neutrophilic infiltration. Progranulin (PGRN), an epithelial cell and macrophage-derived secretory protein, is associated with neutrophilic inflammation. PGRN is digested into various derivatives at inflammatory sites and is involved in several inflammatory processes. PGRN and its derivatives likely regulate responses to DEP exposure in allergic airway inflammation. AIM: To investigate the role of PGRN and its derivatives in the regulation of responses to DEP exposure in allergic airway inflammation. METHODS: A murine model of allergic airway inflammation was generated in PGRN-deficient mice, and they were simultaneously exposed to DEP followed by intranasal administration of full-length recombinant PGRN (PGRN-FL) and a PGRN-derived fragment (FBAC). Inflammatory status was evaluated by bronchoalveolar lavage fluid and histopathologic analyses. Human bronchial epithelial cells were stimulated with DEPs and house dust mites (HDMs), and the effect of FBAC treatment was evaluated by assessing various intracellular signaling molecules, autophagy markers, inflammatory cytokines, and intracellular oxidative stress. RESULTS: DEP exposure exaggerated neutrophilic inflammation, enhanced IL-6 and CXCL15 secretions, and increased oxidative stress in the murine model; this effect was greater in PGRN-deficient mice than in wild-type mice. The DEP-exposed mice with PGRN-FL treatment revealed no change in neutrophil infiltration and higher oxidative stress status in the lungs. On the contrary, FBAC administration inhibited neutrophilic infiltration and reduced oxidative stress. In human bronchial epithelial cells, DEP and HDM exposure increased intracellular oxidative stress and IL-6 and IL-8 secretion. Decreased nuclear factor erythroid 2-related factor 2 (Nrf2) expression and increased phosphor-p62 and LC3B expression were also observed. FBAC treatment attenuated oxidative stress from DEP and HDM exposure. CONCLUSIONS: FBAC reduced neutrophilic inflammation exaggerated by DEP exposure in a mouse model of allergic airway inflammation by reducing oxidative stress. PGRN and PGRN-derived proteins may be novel therapeutic agents in attenuating asthma exacerbation induced by air pollutant exposure.</style></abstract><notes><style face="normal" font="default" size="100%">Lee, A Ryang&#xD;Jeong, Mini&#xD;Koo, Kyomoon&#xD;Kim, Sin-Jeong&#xD;Pyo, Min Ju&#xD;Hong, Yeeun&#xD;Ha, Yura&#xD;Moon, Keun-Ai&#xD;Shim, Hyun Jae&#xD;Lee, Ji-Hyang&#xD;Kwon, Hyouk-Soo&#xD;Cho, You Sook&#xD;eng&#xD;HR21C0198/Korea Health Industry Development Institute (KHIDI)/&#xD;NRF-2021R1A2B5B01002545/National Research Foundation of Korea (NRF)/&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):703-714. doi: 10.1111/all.16362. Epub 2024 Oct 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39462225</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891434</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16362</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1985</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1985</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Movassagh, H.</style></author><author><style face="normal" font="default" size="100%">Prunicki, M.</style></author><author><style face="normal" font="default" size="100%">Kaushik, A.</style></author><author><style face="normal" font="default" size="100%">Zhou, X.</style></author><author><style face="normal" font="default" size="100%">Dunham, D.</style></author><author><style face="normal" font="default" size="100%">Smith, E. M.</style></author><author><style face="normal" font="default" size="100%">He, Z.</style></author><author><style face="normal" font="default" size="100%">Aleman Muench, G. R.</style></author><author><style face="normal" font="default" size="100%">Shi, M.</style></author><author><style face="normal" font="default" size="100%">Weimer, A. K.</style></author><author><style face="normal" font="default" size="100%">Cao, S.</style></author><author><style face="normal" font="default" size="100%">Andorf, S.</style></author><author><style face="normal" font="default" size="100%">Feizi, A.</style></author><author><style face="normal" font="default" size="100%">Snyder, M. P.</style></author><author><style face="normal" font="default" size="100%">Soroosh, P.</style></author><author><style face="normal" font="default" size="100%">Mellins, E. D.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA.&#xD;Janssen Research &amp; Development, LLC, San Diego, California, USA.&#xD;Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.&#xD;Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Divisions of Biomedical Informatics and Allergy &amp; Immunology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;OMass Therapeutics, Oxford, UK.&#xD;Department of Pediatrics, Stanford Program in Immunology, Stanford University School of Medicine, Stanford, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Proinflammatory polarization of monocytes by particulate air pollutants is mediated by induction of trained immunity in pediatric asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1922-1933</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/03/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Particulate Matter/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Monocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Trained Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollutants/adverse effects/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36929161</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The impact of exposure to air pollutants, such as fine particulate matter (PM), on the immune system and its consequences on pediatric asthma, are not well understood. We investigated whether ambient levels of fine PM with aerodynamic diameter &lt;/=2.5 microns (PM(2.5) ) are associated with alterations in circulating monocytes in children with or without asthma. METHODS: Monocyte phenotyping was performed by cytometry time-of-flight (CyTOF). Cytokines were measured using cytometric bead array and Luminex assay. ChIP-Seq was utilized to address histone modifications in monocytes. RESULTS: Increased exposure to ambient PM(2.5) was linked to specific monocyte subtypes, particularly in children with asthma. Mechanistically, we hypothesized that innate trained immunity is evoked by a primary exposure to fine PM and accounts for an enhanced inflammatory response after secondary stimulation in vitro. We determined that the trained immunity was induced in circulating monocytes by fine particulate pollutants, and it was characterized by the upregulation of proinflammatory mediators, such as TNF, IL-6, and IL-8, upon stimulation with house dust mite or lipopolysaccharide. This phenotype was epigenetically controlled by enhanced H3K27ac marks in circulating monocytes. CONCLUSION: The specific alterations of monocytes after ambient pollution exposure suggest a possible prognostic immune signature for pediatric asthma, and pollution-induced trained immunity may provide a potential therapeutic target for asthmatic children living in areas with increased air pollution.</style></abstract><notes><style face="normal" font="default" size="100%">Movassagh, Hesam&#xD;Prunicki, Mary&#xD;Kaushik, Abhinav&#xD;Zhou, Xiaoying&#xD;Dunham, Diane&#xD;Smith, Eric M&#xD;He, Ziyuan&#xD;Aleman Muench, German R&#xD;Shi, Minyi&#xD;Weimer, Annika K&#xD;Cao, Shu&#xD;Andorf, Sandra&#xD;Feizi, Amir&#xD;Snyder, Michael P&#xD;Soroosh, Pejman&#xD;Mellins, Elizabeth D&#xD;Nadeau, Kari C&#xD;eng&#xD;P01 HL152953/HL/NHLBI NIH HHS/&#xD;R01 ES020926/ES/NIEHS NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1922-1933. doi: 10.1111/all.15692. Epub 2023 Mar 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36929161</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15692</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3124</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3124</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Teufelberger, A. R.</style></author><author><style face="normal" font="default" size="100%">Koltgen, C.</style></author><author><style face="normal" font="default" size="100%">Babina, M.</style></author><author><style face="normal" font="default" size="100%">Wolf, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Medical University of Graz, Graz, Austria.&#xD;Institute of Allergology, Charite-Universitatsmedizin Berlin, Freie Universitat Berlin and Humboldt Universitat Zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prolonged IL-33 Exposure Switches the Secreted Mast Cell Cytokine Profile From Pro-Inflammatory to Pro-Tolerant</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">St2</style></keyword><keyword><style face="normal" font="default" size="100%">c-kit (CD117)</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">tolerance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41117102</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: During desensitization, the immune response to an allergen switches from a type 2 inflammation towards immunological tolerance. Subcutaneous Hymenoptera venom and alum injections induce IL-33 release during venom immunotherapy (VIT). To elucidate whether mast cells (MCs) contribute to this switch in immune response, we investigated the effect of IL-33 and Hymenoptera venom on MC cytokine profiles under VIT-like conditions. METHODS: LAD2 cells or primary human skin MCs were stimulated with IL-33 and Hymenoptera venom or Compound 48/80, with or without IL-33 pre-exposure (priming) for up to four days. In addition, c-kit was stimulated or inhibited. Cell surface marker expression was monitored by flow cytometry. Secreted cytokines were measured in supernatants by a bead-based multiplex assay and ELISA. Phosphorylated c-kit was determined by Western blot. RESULTS: LAD2 cell stimulation led to the secretion of IL-2, IL-5, IL-6, IL-13, TNF-alpha, and TGF-beta1, phosphorylation of c-kit, and a reduced c-kit surface expression after 24 h. IL-33 primed LAD2 cells secreted mainly the tolerance-promoting cytokine TGF-beta1 but little pro-inflammatory/type 2 cytokines, showed less c-kit phosphorylation, and a higher c-kit surface expression following stimulation. Inhibition of c-kit before stimulation led to a similar secreted cytokine profile phenotype as IL-33 priming. IL-33 primed skin MCs showed a comparable cytokine switch and receptor expression pattern. CONCLUSION: Changes in the interaction of IL-33 receptor (ST2) and c-kit after prolonged IL-33 exposure skewed MCs towards tolerance-promoting cytokines during desensitization therapy. These findings suggest a trendsetting role of MCs for the type of response towards Hymenoptera venom.</style></abstract><notes><style face="normal" font="default" size="100%">Teufelberger, Andrea R&#xD;Koltgen, Carolin&#xD;Babina, Magda&#xD;Wolf, Peter&#xD;eng&#xD;Austrian Science Fund/&#xD;Deutsche Forschungsgemeinschaft/&#xD;Denmark&#xD;Allergy. 2025 Oct 21. doi: 10.1111/all.70122.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41117102</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70122</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>381</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">381</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Matsui, T.</style></author><author><style face="normal" font="default" size="100%">Yamashita, H.</style></author><author><style face="normal" font="default" size="100%">Kitamura, K.</style></author><author><style face="normal" font="default" size="100%">Makino, A.</style></author><author><style face="normal" font="default" size="100%">Takasato, Y.</style></author><author><style face="normal" font="default" size="100%">Sugiura, S.</style></author><author><style face="normal" font="default" size="100%">Ito, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Allergy and Immunology Center, Aichi Children&apos;s Health and Medical Center, Obu, Japan.&#xD;Department of Pharmacology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.&#xD;Department of Comprehensive Pediatric Medicine, Nagoya University Graduate School of Medicine, Obu, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prophylactic steroid use is ineffective in food allergy: A randomized-controlled clinical trial and a murine model</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">537-539</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/07/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">food hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">glucocorticoid</style></keyword><keyword><style face="normal" font="default" size="100%">prednisolone</style></keyword><keyword><style face="normal" font="default" size="100%">steroid</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35861126</style></accession-num><notes><style face="normal" font="default" size="100%">Matsui, Teruaki&#xD;Yamashita, Hirotaka&#xD;Kitamura, Katsumasa&#xD;Makino, Atsushi&#xD;Takasato, Yoshihiro&#xD;Sugiura, Shiro&#xD;Ito, Komei&#xD;eng&#xD;Letter&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):537-539. doi: 10.1111/all.15451. Epub 2022 Jul 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35861126</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15451</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2314</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2314</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shin, K.</style></author><author><style face="normal" font="default" size="100%">Lee, J. S.</style></author><author><style face="normal" font="default" size="100%">Jeon, H.</style></author><author><style face="normal" font="default" size="100%">Lee, G. W.</style></author><author><style face="normal" font="default" size="100%">Shin, J. O.</style></author><author><style face="normal" font="default" size="100%">Roh, D.</style></author><author><style face="normal" font="default" size="100%">Kim, Y.</style></author><author><style face="normal" font="default" size="100%">Won, S. H.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author><author><style face="normal" font="default" size="100%">Kim, H. S.</style></author><author><style face="normal" font="default" size="100%">Kim, B. S.</style></author><author><style face="normal" font="default" size="100%">Kim, M. B.</style></author><author><style face="normal" font="default" size="100%">Ko, H. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea.&#xD;Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.&#xD;Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.&#xD;Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.&#xD;Department of Ophthalmology, School of Medicine, Pusan National University, Busan, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prophylactic use of diquafosol eye drops for dupilumab-associated conjunctivitis in patients with severe atopic dermatitis: An open-label prospective study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">746-748</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/11/08</style></edition><section><style face="normal" font="default" size="100%">746</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">*Polyphosphates</style></keyword><keyword><style face="normal" font="default" size="100%">*Uracil Nucleotides</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37937411</style></accession-num><notes><style face="normal" font="default" size="100%">Shin, Kihyuk&#xD;Lee, Jin-Su&#xD;Jeon, Hyeshin&#xD;Lee, Gi-Wook&#xD;Shin, Jun-Oh&#xD;Roh, Dongyoung&#xD;Kim, Yeona&#xD;Won, Sang-Hyeon&#xD;Lee, Jungsoo&#xD;Kim, Hoon-Soo&#xD;Kim, Byung-Soo&#xD;Kim, Moon-Bum&#xD;Ko, Hyun-Chang&#xD;eng&#xD;KFRM000706782G0001278/Korean Fund for Regenerative Medicine (KFRM)/&#xD;2021R1I1A3044245/National Research Foundation of Korea/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):746-748. doi: 10.1111/all.15943. Epub 2023 Nov 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37937411</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15943</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2389</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2389</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, Y.</style></author><author><style face="normal" font="default" size="100%">Qiu, Z.</style></author><author><style face="normal" font="default" size="100%">Gu, C.</style></author><author><style face="normal" font="default" size="100%">Yu, S.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Li, C.</style></author><author><style face="normal" font="default" size="100%">Yao, X.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology, Shanghai, China.&#xD;Guangdong Institute of Intelligence Science and Technology, Zhuhai, China.&#xD;Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for skin diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Propionate alleviates itch in murine models of atopic dermatitis by modulating sensory TRP channels of dorsal root ganglion</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1271-1290</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/01/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Ganglia, Spinal/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/metabolism/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Pruritus/etiology/metabolism/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Propionates/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Transient Receptor Potential Channels/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Sensory Receptor Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">HEK293 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Calcitonin Gene-Related Peptide/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Docking Simulation</style></keyword><keyword><style face="normal" font="default" size="100%">TRP channels</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">calcitonin gene-related peptide</style></keyword><keyword><style face="normal" font="default" size="100%">dorsal root ganglion</style></keyword><keyword><style face="normal" font="default" size="100%">itch</style></keyword><keyword><style face="normal" font="default" size="100%">propionate</style></keyword><keyword><style face="normal" font="default" size="100%">skin microbiome metabolite</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38164798</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Itch is the most common symptom of atopic dermatitis (AD) and significantly decreases the quality of life. Skin microbiome is involved in AD pathogenesis, whereas its role in the regulation of itch remains elusive. In this study, we aimed to investigate the effects of skin microbial metabolite propionate on acute and chronic pruritus and to explore the mechanism. METHODS: Using various mouse models of itch, the roles of propionate were explored by behavioral tests and histopathology/immunofluorescent analysis. Primary-cultured dorsal root ganglion neurons and HEK293 cells expressing recombinant human TRP channels were utilized for in vitro calcium imaging/in vivo miniature two-photon imaging in combination with electrophysiology and molecular docking approaches for investigation of the mechanism. RESULTS: Propionate significantly alleviated itch and alloknesis in various mouse models of pruritus and AD and decreased the density of intraepidermal nerve fibers. Propionate reduced the responsiveness of dorsal root ganglion neurons to pruritogens in vitro, attenuated the hyper-excitability in sensory neurons in MC903-induced AD model, and inhibited capsaicin-evoked hTRPV1 currents (IC(50) = 20.08 +/- 1.11 muM) via interacting with the vanilloid binding site. Propionate also decreased the secretion of calcitonin gene-related peptide by nerves in MC903-induced AD mouse model, which further attenuated itch and skin inflammation. CONCLUSION: Our study revealed a protective effect of propionate against persistent itch through direct modulation of sensory TRP channels and neuropeptide production in neurons. Regulation of itch via the skin microbiome might be a novel strategy for the treatment of AD.</style></abstract><notes><style face="normal" font="default" size="100%">Xu, Yao&#xD;Qiu, Zhuoqiong&#xD;Gu, Chaoying&#xD;Yu, Su&#xD;Wang, Shangshang&#xD;Li, Changlin&#xD;Yao, Xu&#xD;Li, Wei&#xD;eng&#xD;Nanjing Incubation Program for National Clinical Research Centre/&#xD;2021-01-07-00-07-E00078/Key Project of the Innovation Program of Shanghai Municipal Education Commission/&#xD;Shanghai Municipal Commission of Health and Family Planning/&#xD;Key Project of Social Development in Jiangsu Province/&#xD;Milstein Medical Asian American Partnership Foundation/&#xD;shslczdzk01002/Shanghai Municipal Key Clinical Specialty/&#xD;82073446/National Natural Science Foundation of China/&#xD;81972939/National Natural Science Foundation of China/&#xD;82273531/National Natural Science Foundation of China/&#xD;82003349/National Natural Science Foundation of China/&#xD;82003357/National Natural Science Foundation of China/&#xD;82330098/National Natural Science Foundation of China/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1271-1290. doi: 10.1111/all.15998. Epub 2024 Jan 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38164798</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15998</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>710</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">710</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Dorr, T.</style></author><author><style face="normal" font="default" size="100%">Aberer, W.</style></author><author><style face="normal" font="default" size="100%">Alvaro, M.</style></author><author><style face="normal" font="default" size="100%">Angier, E.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Arshad, H.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B.</style></author><author><style face="normal" font="default" size="100%">Bartra, J.</style></author><author><style face="normal" font="default" size="100%">Beck, L.</style></author><author><style face="normal" font="default" size="100%">Begin, P.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Bislimovska, J.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Bush, A.</style></author><author><style face="normal" font="default" size="100%">Cianferoni, A.</style></author><author><style face="normal" font="default" size="100%">Cork, M. J.</style></author><author><style face="normal" font="default" size="100%">Custovic, A.</style></author><author><style face="normal" font="default" size="100%">Darsow, U.</style></author><author><style face="normal" font="default" size="100%">de Jong, N.</style></author><author><style face="normal" font="default" size="100%">Deleanu, D.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Deschildre, A.</style></author><author><style face="normal" font="default" size="100%">Dunn Galvin, A.</style></author><author><style face="normal" font="default" size="100%">Ebisawa, M.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Ferrer, M.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author><author><style face="normal" font="default" size="100%">Gerth van Wijk, R.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Grimshaw, K.</style></author><author><style face="normal" font="default" size="100%">Grunhagen, J.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Hide, M.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Incorvaia, C.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Malte John, S.</style></author><author><style face="normal" font="default" size="100%">Jones, C.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Katoh, N.</style></author><author><style face="normal" font="default" size="100%">Kendziora, B.</style></author><author><style face="normal" font="default" size="100%">Kinaciyan, T.</style></author><author><style face="normal" font="default" size="100%">Knol, E.</style></author><author><style face="normal" font="default" size="100%">Kurbacheva, O.</style></author><author><style face="normal" font="default" size="100%">Lau, S.</style></author><author><style face="normal" font="default" size="100%">Loh, R.</style></author><author><style face="normal" font="default" size="100%">Lombardi, C.</style></author><author><style face="normal" font="default" size="100%">Makela, M.</style></author><author><style face="normal" font="default" size="100%">Marchisotto, M. J.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Meyer, R.</style></author><author><style face="normal" font="default" size="100%">Mijakoski, D.</style></author><author><style face="normal" font="default" size="100%">Minov, J.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Nilsson, C.</style></author><author><style face="normal" font="default" size="100%">Nowak-Wegrzyn, A.</style></author><author><style face="normal" font="default" size="100%">Nwaru, B. I.</style></author><author><style face="normal" font="default" size="100%">Odemyr, M.</style></author><author><style face="normal" font="default" size="100%">Pajno, G. B.</style></author><author><style face="normal" font="default" size="100%">Paudel, S.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Renz, H.</style></author><author><style face="normal" font="default" size="100%">Ricci, G.</style></author><author><style face="normal" font="default" size="100%">Ring, J.</style></author><author><style face="normal" font="default" size="100%">Rogala, B.</style></author><author><style face="normal" font="default" size="100%">Sampson, H.</style></author><author><style face="normal" font="default" size="100%">Senna, G.</style></author><author><style face="normal" font="default" size="100%">Sitkauskiene, B.</style></author><author><style face="normal" font="default" size="100%">Smith, P. K.</style></author><author><style face="normal" font="default" size="100%">Stevanovic, K.</style></author><author><style face="normal" font="default" size="100%">Stoleski, S.</style></author><author><style face="normal" font="default" size="100%">Szajewska, H.</style></author><author><style face="normal" font="default" size="100%">Tanaka, A.</style></author><author><style face="normal" font="default" size="100%">Todo-Bom, A.</style></author><author><style face="normal" font="default" size="100%">Topal, F. A.</style></author><author><style face="normal" font="default" size="100%">Valovirta, E.</style></author><author><style face="normal" font="default" size="100%">Van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Wohrl, S.</style></author><author><style face="normal" font="default" size="100%">Wong, G. W. K.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Charite-Universitatsmedizin Berlin, Humboldt-Uniersitat zu Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Berlin, Germany.&#xD;Department of Dermatology, Medical University of Graz, Graz, Austria.&#xD;Servei Al-lergologia Immunologia Clinica, Hospital Sant Joan de Deu, Barcelona, Spain.&#xD;Primary Care, Population Science and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Pediatric Allergology Unit, Bambino Gesu Hospital (IRCCS), Rome, Italy.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Clinic for Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland.&#xD;Unitat d&apos;Al.lergia, Servei de Neumologia i Al.lergia Respiratoria, Hospital Clinic, Barcelona, Spain.&#xD;Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.&#xD;Department of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.&#xD;CHU Sainte-Justine, Montreal, Canada.&#xD;Department of Dermatology and Allergy Center, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital Denmark, Odense, Denmark.&#xD;Faculty of Medicine, Ss. Cyril and Methodius, University in Skopje, Institute of Occupational Health of RNM, WHO Collaborating Center, Skopje, Macedonia.&#xD;University Hospital Montpellier, Montpellier, France.&#xD;MACVIA-France, Montpellier, France.&#xD;Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Imperial College and Royal Brompton Hospital, London, UK.&#xD;Department of Pediatrics, University of Pennsylvania, The Children&apos;s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.&#xD;University of Sheffield, Sheffield, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Section of Allergology and Clinical Immunology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.&#xD;University Medicine and Pharmacy Iuliu Hatieganu, IRGH, Allergy, Cluj-Napoca, Romania.&#xD;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.&#xD;CHU Lille, Univ Lille, Lille, France.&#xD;Pediatric Pulmonology and Allergy Unit, Hopital Jeanne de Flandre, Lille, France.&#xD;University College Cork, Cork, Ireland.&#xD;Sechenov University Moscow, Moscow, Russia.&#xD;Anaphylaxis Ireland, Cork, Ireland.&#xD;Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.&#xD;Allergy Department, Facultad de Medicina, Hospital Clinico San Carlos, Universidad Complutense (UCM), IdISSC, Madrid, Spain.&#xD;Department of Allergy, Clinica Universidad de Navarra, Pamplona, Spain.&#xD;Center of Allergy and Immunology, Tbilisi, Georgia.&#xD;Dietetic Department, Salford Care Organisation, Salford Royal Foundation Trust, Salford, UK.&#xD;Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.&#xD;Department of Dermatology, Hiroshima Citizens Hospital, Hiroshima, Japan.&#xD;Department of Pathophysiology and Allergy Research, Medical University of Vienna, Austria.&#xD;Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, Milan, Italy.&#xD;Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.&#xD;Department of Dermatology, Environmental Medicine, Health Theory, University of Osnabrueck, Osnabrueck, Germany.&#xD;Institute for Interdisciplinary Dermatological Prevention and Rehabilitation (iDerm) at the University of Osnabrueck, Osnabrueck, Germany.&#xD;Allergy, Kent, UK.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Poland.&#xD;All-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Dermatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.&#xD;Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.&#xD;Department of Dermatology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;NRC Institute of Immunology FMBA, Moscow, Russia.&#xD;Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Immunology, Perth Children&apos;s Hospital, University of Western Australia, Perth, Western Australia, Australia.&#xD;Unita Dipartimentale di Allergologia-Immunologia Clinica &amp; Malattie Apparato Respiratorio, Ente Ospedaliero Fondazione Poliambulanza, Brescia, Italy.&#xD;Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;MJM Advisory, New York, New York, USA.&#xD;Mary H. Weiser Food Allergy Center, University of Michigan Medicine, Ann Arbor, Michigan, USA.&#xD;Allergy Unit, 2nd Dpt of Dermatology and Venereology, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.&#xD;Department of Paediatrics, Imperial College, London, UK.&#xD;Rhinology Unit &amp; Smell Clinic, ENT Department, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.&#xD;Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Department of Clinical Science and Education Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, Kravis Children&apos;s Hospital, New York, New York, USA.&#xD;Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.&#xD;Asthma and Allergy Association, Stockholm, Sweden.&#xD;Pediatric unit, Policlinico Hospitsl, University of Messina, Messina, Italy.&#xD;Civil Service Hospital, Kathmandu, Nepal.&#xD;Allergy Dpt, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg University Hospital Giessen and Marburg, Marburg, Germany.&#xD;Department of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov University, Moscow, Russia.&#xD;Pediatric Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.&#xD;Christine Kuhne Center for Allergy Research and Education (CK-Care), Davos, Switzerland.&#xD;Department of Internal Diseases, Allergology &amp; Clinical Immunology Medical, University of Silesia, Katowice, Poland.&#xD;Elliot and Roslyn Jaffe Food Allergy Institute, New York, New York, USA.&#xD;Division of Allergy and Immunology, Kravis Children&apos;s Hospital, New York, New York, USA.&#xD;Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Asthma Center and Allergy Unit, Verona University and General Hospital, Verona, Italy.&#xD;Department of Immunology and Allergology, Lithuanian University of Health Sciences, Kaunas, Lithuania.&#xD;Griffith University, Southport, Qld, Australia.&#xD;Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.&#xD;Department of Lung Diseases and Clinical Allergology, University of Turku, and Terveystalo Turku, Allergy Clinic, Turku, Finland.&#xD;Departments of Experimental Immunology and Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.&#xD;University of Colorado Denver School of Medicine and Children&apos;s Hospital Colorado, Aurora, Colorado, USA.&#xD;Floridsdorf Allergy Center (FAZ), Vienna, Austria.&#xD;Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong, Hong Kong.&#xD;Department of Dermatology, First Hospital, Peking University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA(2)LEN position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1736-1750</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/11/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Eggs</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Food Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34741557</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food anaphylaxis is commonly elicited by unintentional ingestion of foods containing the allergen above the tolerance threshold level of the individual. While labeling the 14 main allergens used as ingredients in food products is mandatory in the EU, there is no legal definition of declaring potential contaminants. Precautionary allergen labeling such as &quot;may contain traces of&quot; is often used. However, this is unsatisfactory for consumers as they get no information if the contamination is below their personal threshold. In discussions with the food industry and technologists, it was suggested to use a voluntary declaration indicating that all declared contaminants are below a threshold of 0.5 mg protein per 100 g of food. This concentration is known to be below the threshold of most patients, and it can be technically guaranteed in most food production. However, it was also important to assess that in case of accidental ingestion of contaminants below this threshold by highly allergic patients, no fatal anaphylactic reaction could occur. Therefore, we performed a systematic review to assess whether a fatal reaction to 5mg of protein or less has been reported, assuming that a maximum portion size of 1kg of a processed food exceeds any meal and thus gives a sufficient safety margin. METHODS: MEDLINE and EMBASE were searched until 24 January 2021 for provocation studies and case reports in which one of the 14 major food allergens was reported to elicit fatal or life-threatening anaphylactic reactions and assessed if these occurred below the ingestion of 5mg of protein. A Delphi process was performed to obtain an expert consensus on the results. RESULTS: In the 210 studies included, in our search, no reports of fatal anaphylactic reactions reported below 5 mg protein ingested were identified. However, in provocation studies and case reports, severe reactions below 5 mg were reported for the following allergens: eggs, fish, lupin, milk, nuts, peanuts, soy, and sesame seeds. CONCLUSION: Based on the literature studied for this review, it can be stated that cross-contamination of the 14 major food allergens below 0.5 mg/100 g is likely not to endanger most food allergic patients when a standard portion of food is consumed. We propose to use the statement &quot;this product contains the named allergens in the list of ingredients, it may contain traces of other contaminations (to be named, e.g. nut) at concentrations less than 0.5 mg per 100 g of this product&quot; for a voluntary declaration on processed food packages. This level of avoidance of cross-contaminations can be achieved technically for most processed foods, and the statement would be a clear and helpful message to the consumers. However, it is clearly acknowledged that a voluntary declaration is only a first step to a legally binding solution. For this, further research on threshold levels is encouraged.</style></abstract><notes><style face="normal" font="default" size="100%">Zuberbier, Torsten&#xD;Dorr, Tamara&#xD;Aberer, Werner&#xD;Alvaro, Montserrat&#xD;Angier, Elizabeth&#xD;Arasi, Stefania&#xD;Arshad, Hasan&#xD;Ballmer-Weber, Barbara&#xD;Bartra, Joan&#xD;Beck, Lisa&#xD;Begin, Philippe&#xD;Bindslev-Jensen, Carsten&#xD;Bislimovska, Jovanka&#xD;Bousquet, Jean&#xD;Brockow, Knut&#xD;Bush, Andrew&#xD;Cianferoni, Antonella&#xD;Cork, Michael J&#xD;Custovic, Adnan&#xD;Darsow, Ulf&#xD;de Jong, Nicolette&#xD;Deleanu, Diana&#xD;Del Giacco, Stefano&#xD;Deschildre, Antoine&#xD;Dunn Galvin, Audrey&#xD;Ebisawa, Motohiro&#xD;Fernandez-Rivas, Montserrat&#xD;Ferrer, Marta&#xD;Fiocchi, Alessandro&#xD;Gerth van Wijk, Roy&#xD;Gotua, Maia&#xD;Grimshaw, Kate&#xD;Grunhagen, Josefine&#xD;Heffler, Enrico&#xD;Hide, Michihiro&#xD;Hoffmann-Sommergruber, Karin&#xD;Incorvaia, Cristoforo&#xD;Janson, Christer&#xD;Malte John, Swen&#xD;Jones, Carla&#xD;Jutel, Marek&#xD;Katoh, Norito&#xD;Kendziora, Benjamin&#xD;Kinaciyan, Tamar&#xD;Knol, Edward&#xD;Kurbacheva, Oksana&#xD;Lau, Susanne&#xD;Loh, Richard&#xD;Lombardi, Carlo&#xD;Makela, Mika&#xD;Marchisotto, Mary Jane&#xD;Makris, Michael&#xD;Maurer, Marcus&#xD;Meyer, Rosan&#xD;Mijakoski, Dragan&#xD;Minov, Jordan&#xD;Mullol, Joaquim&#xD;Nilsson, Caroline&#xD;Nowak-Wegrzyn, Anna&#xD;Nwaru, Bright I&#xD;Odemyr, Mikela&#xD;Pajno, Giovanni Battista&#xD;Paudel, Sushil&#xD;Papadopoulos, Nikolaos G&#xD;Renz, Harald&#xD;Ricci, Giampaolo&#xD;Ring, Johannes&#xD;Rogala, Barbara&#xD;Sampson, Hugh&#xD;Senna, Gianenrico&#xD;Sitkauskiene, Brigita&#xD;Smith, Peter Kenneth&#xD;Stevanovic, Katarina&#xD;Stoleski, Sasho&#xD;Szajewska, Hania&#xD;Tanaka, Akio&#xD;Todo-Bom, Ana&#xD;Topal, Fatih Alexander&#xD;Valovirta, Erkka&#xD;Van Ree, Ronald&#xD;Venter, Carina&#xD;Wohrl, Stefan&#xD;Wong, Gary W K&#xD;Zhao, Zuotao&#xD;Worm, Margitta&#xD;eng&#xD;MR/S025340/1/MRC_/Medical Research Council/United Kingdom&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1736-1750. doi: 10.1111/all.15167. Epub 2021 Nov 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34741557</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15167</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>263</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">263</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Valent, P.</style></author><author><style face="normal" font="default" size="100%">Klion, A. D.</style></author><author><style face="normal" font="default" size="100%">Roufosse, F.</style></author><author><style face="normal" font="default" size="100%">Simon, D.</style></author><author><style face="normal" font="default" size="100%">Metzgeroth, G.</style></author><author><style face="normal" font="default" size="100%">Leiferman, K. M.</style></author><author><style face="normal" font="default" size="100%">Schwaab, J.</style></author><author><style face="normal" font="default" size="100%">Butterfield, J. H.</style></author><author><style face="normal" font="default" size="100%">Sperr, W. R.</style></author><author><style face="normal" font="default" size="100%">Sotlar, K.</style></author><author><style face="normal" font="default" size="100%">Vandenberghe, P.</style></author><author><style face="normal" font="default" size="100%">Hoermann, G.</style></author><author><style face="normal" font="default" size="100%">Haferlach, T.</style></author><author><style face="normal" font="default" size="100%">Moriggl, R.</style></author><author><style face="normal" font="default" size="100%">George, T. I.</style></author><author><style face="normal" font="default" size="100%">Akin, C.</style></author><author><style face="normal" font="default" size="100%">Bochner, B. S.</style></author><author><style face="normal" font="default" size="100%">Gotlib, J.</style></author><author><style face="normal" font="default" size="100%">Reiter, A.</style></author><author><style face="normal" font="default" size="100%">Horny, H. P.</style></author><author><style face="normal" font="default" size="100%">Arock, M.</style></author><author><style face="normal" font="default" size="100%">Simon, H. U.</style></author><author><style face="normal" font="default" size="100%">Gleich, G. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine I, Division of Hematology &amp; Hemostaseology, Medical University of Vienna, Vienna, Austria.&#xD;Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.&#xD;Human Eosinophil Section, Laboratory of Parasitic Diseases, NIH/NIAID, Bethesda, MD, USA.&#xD;Department of Internal Medicine, Erasme Hospital, Universite Libre de Bruxelles, Brussels, Belgium.&#xD;Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.&#xD;Department of Hematology and Oncology, University Hospital Mannheim - Heidelberg University, Mannheim, Germany.&#xD;Department of Dermatology, University of Utah Health, Salt Lake City, UT, USA.&#xD;Division of Allergic Diseases, Mayo Clinic, Rochester, MN, USA.&#xD;Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.&#xD;Division of Hematology, University Hospital Leuven and Department of Human Genetics, KU Leuven, Leuven, Belgium.&#xD;MLL Munich Leukemia Laboratory, Munich, Germany.&#xD;Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria.&#xD;Department of Pathology, University of Utah, Salt Lake City, UT, USA.&#xD;Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, MI, USA.&#xD;Northwestern University Feinberg School of Medicine, Division of Allergy and Immunology, Chicago, IL, USA.&#xD;Stanford Cancer Institute/Stanford University School of Medicine, Stanford, CA, USA.&#xD;Institute of Pathology, Ludwig Maximilian University Munich (LMU), Munich, Germany.&#xD;Department of Hematological Biology, Pitie-Salpetriere Hospital, Pierre et Marie Curie University (UPMC), Paris, France.&#xD;Institute of Pharmacology, University of Bern, Bern, Switzerland.&#xD;Institute of Biochemistry, Brandenburg Medical School, Neuruppin, Germany.&#xD;Departments of Dermatology and Medicine, University of Utah Health, Salt Lake City, UT, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">47-59</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/10/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilia/diagnosis/etiology/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypereosinophilic Syndrome/etiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">classification</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostic criteria</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic leukemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypereosinophilic syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">personalized medicine</style></keyword><keyword><style face="normal" font="default" size="100%">interest. The authors declare the following conflicts of interest outside of this</style></keyword><keyword><style face="normal" font="default" size="100%">project: P.Valent received research grants from Pfizer, BMS/Celgene and AOP</style></keyword><keyword><style face="normal" font="default" size="100%">Orphan, and consultancy honoraria from Novartis, Pfizer, BMS/Celgene, Blueprint,</style></keyword><keyword><style face="normal" font="default" size="100%">Accord, and AOP Health. F.R. has received consultancy fees from Astra Zeneca and</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline (GSK) and receives publication-related royalty payments from</style></keyword><keyword><style face="normal" font="default" size="100%">UpToDate contributions. D.S. has been an investigator and/or advisor of AbbVie,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Galderma, GSK, LEO Pharma, Elli Lilly, Novartis, Pfizer, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">Genzyme. K.M.L. receives publication-related royalty payments from UpToDate</style></keyword><keyword><style face="normal" font="default" size="100%">contributions, has a grant from Regeneron, receives royalties from Mayo</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, and holds patents for diagnosing, monitoring, and treating</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil-related diseases. J.S. received consultancy honoraria from Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, Astra Zeneca and Blueprint. W.R.S. received consultancy honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">AbbVie, BMS/Celgene, Jazz, Novartis, Pfizer, StemLine, and Thermo Fisher. K.S.</style></keyword><keyword><style face="normal" font="default" size="100%">received consultancy honoraria from Novartis and Blueprint. P.Vandenberghe has</style></keyword><keyword><style face="normal" font="default" size="100%">received research support from Janssen Biotech and Pfizer via KU Leuven</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria as speaker or advisory board member from Bristol-Myers-Squibb, Janssen</style></keyword><keyword><style face="normal" font="default" size="100%">Biotech, Miltenyi Biotec and Novartis Pharma. G.H. received honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis and Incyte. T.H. is part owner of the Munich Leukemia Laboratory (MLL).</style></keyword><keyword><style face="normal" font="default" size="100%">T.I.G has been a consultant for Incyte, Blueprint Medicines and Celgene/BMS. C.A.</style></keyword><keyword><style face="normal" font="default" size="100%">received consultancy honoraria from Novartis and Blueprint Medicines. B.S.B.</style></keyword><keyword><style face="normal" font="default" size="100%">receives publication-related royalty payments from Elsevier and UpToDate(R)/Wolters</style></keyword><keyword><style face="normal" font="default" size="100%">Kluwer. He receives remuneration for consulting services (Third Harmonic Bio,</style></keyword><keyword><style face="normal" font="default" size="100%">Acelyrin Inc. and Lupagen) and for serving on the scientific advisory board of</style></keyword><keyword><style face="normal" font="default" size="100%">Allakos Inc., which he co-founded, and owns stock in Allakos. He is a co-inventor</style></keyword><keyword><style face="normal" font="default" size="100%">on existing Siglec-8-related patents and thus receives royalty payments from</style></keyword><keyword><style face="normal" font="default" size="100%">Johns Hopkins University during development and potential sales of such products.</style></keyword><keyword><style face="normal" font="default" size="100%">The terms of this arrangement are being managed by Johns Hopkins University and</style></keyword><keyword><style face="normal" font="default" size="100%">Northwestern University in accordance with their conflict of interest policies.</style></keyword><keyword><style face="normal" font="default" size="100%">A.R. received research funding from Novartis and Blueprint and consultancy</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria, speaker fees, and travel reimbursement from Novartis, Incyte, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Blueprint, BMS/Celgene and Abbvie. J.G. received research funding from Incyte,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Kartos, Blueprint Medicines, Deciphera, Cogent Biosciences, Abbvie,</style></keyword><keyword><style face="normal" font="default" size="100%">Celgene, BMS, Protagonist Therapeutics, and advisory board/consulting honoraria</style></keyword><keyword><style face="normal" font="default" size="100%">from Incyte, Novartis, Kartos, Blueprint Medicines, Deciphera, Cogent</style></keyword><keyword><style face="normal" font="default" size="100%">Biosciences, Abbvie, Protagonist Therapeutics, and PharmaEssentia</style></keyword><keyword><style face="normal" font="default" size="100%">he is also a</style></keyword><keyword><style face="normal" font="default" size="100%">PI and receives research funding for the FIGHT-203 phase II study of pemigatinib</style></keyword><keyword><style face="normal" font="default" size="100%">in patients with FGFR1-rearranged neoplasms</style></keyword><keyword><style face="normal" font="default" size="100%">and is chair in the central review</style></keyword><keyword><style face="normal" font="default" size="100%">committee for the FIGHT-203 study. M.A. received a research grant from Blueprint</style></keyword><keyword><style face="normal" font="default" size="100%">and honoraria from AB Science, Blueprint, and Novartis. H.U.S. is a consultant</style></keyword><keyword><style face="normal" font="default" size="100%">for GSK. G.J.G. has or had grants from National Institutes of Health,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, and GSK, is a science officer with NexEosBio, has a royalty sharing</style></keyword><keyword><style face="normal" font="default" size="100%">agreement with Teva, has received remuneration for consulting with AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, Genentech, Knopp Biosciences, is on the Board of Directors for American</style></keyword><keyword><style face="normal" font="default" size="100%">Partnership for Eosinophilic Disorders (APFED), receives royalties from Mayo</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation and holds patents for diagnosing, monitoring, and treating</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil-related diseases. The authors declare no other conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36207764</style></accession-num><abstract><style face="normal" font="default" size="100%">Eosinophilia and eosinophil activation are recurrent features in various reactive states and certain hematologic malignancies. In patients with hypereosinophilia (HE), HE-induced organ damage is often encountered and may lead to the diagnosis of a hypereosinophilic syndrome (HES). A number of known mechanisms and etiologies contribute to the development of HE and HES. Based on these etiologies and the origin of eosinophils, HE and HES are divided into primary forms where eosinophils are clonal cells, reactive forms where an underlying reactive or neoplastic condition is detected and eosinophils are considered to be &quot;non-clonal&quot; cells, and idiopathic HE and HES in which neither a clonal nor a reactive underlying pathology is detected. Since 2012, this classification and the related criteria have been widely accepted and regarded as standard. However, during the past few years, new developments in the field and an increasing number of markers and targets have created a need to update these criteria and the classification of HE and HES. To address this challenge, a Working Conference on eosinophil disorders was organized in 2021. In this conference, a panel of experts representing the relevant fields, including allergy, dermatology, hematology, immunology, laboratory medicine, and pathology, met and discussed new markers and concepts as well as refinements in definitions, criteria and classifications of HE and HES. The outcomes of this conference are presented in this article and should assist in the diagnosis and management of patients with HE and HES in daily practice and in the preparation and conduct of clinical trials.</style></abstract><notes><style face="normal" font="default" size="100%">Valent, Peter&#xD;Klion, Amy D&#xD;Roufosse, Florence&#xD;Simon, Dagmar&#xD;Metzgeroth, Georgia&#xD;Leiferman, Kristin M&#xD;Schwaab, Juliana&#xD;Butterfield, Joseph H&#xD;Sperr, Wolfgang R&#xD;Sotlar, Karl&#xD;Vandenberghe, Peter&#xD;Hoermann, Gregor&#xD;Haferlach, Torsten&#xD;Moriggl, Richard&#xD;George, Tracy I&#xD;Akin, Cem&#xD;Bochner, Bruce S&#xD;Gotlib, Jason&#xD;Reiter, Andreas&#xD;Horny, Hans-Peter&#xD;Arock, Michel&#xD;Simon, Hans-Uwe&#xD;Gleich, Gerald J&#xD;eng&#xD;U19 AI136443/AI/NIAID NIH HHS/&#xD;ZIA AI001130/ImNIH/Intramural NIH HHS/&#xD;R21 AI159586/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, N.I.H., Intramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):47-59. doi: 10.1111/all.15544. Epub 2022 Oct 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36207764</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9797433</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15544</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1657</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1657</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">Maesano, C. N.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, M.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">INSERM and Montpellier University, Institute Desbrest of Epidemiology and Public Health, IDESP, Montpellier, France.&#xD;First Division of Pneumology, High Speciality Hospital V. Monaldi and University Federico II Medical School Naples, Napoli, Italy.&#xD;Division of Respiratory and Allergic Diseases, Department of Chest Diseases, High Specialty A. Cardarelli Hospital, Napoli, Italy.&#xD;Medical School of Specialization in Respiratory Diseases, University on Naples Federico II, Napoli, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pros and cons for the role of air pollution on COVID-19 development</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2647-2649</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Covid</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV</style></keyword><keyword><style face="normal" font="default" size="100%">aerobiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33733491</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract As SARS-CoV-2 has spread across the globe, it has been difficult to ignore patterns suggesting that regions with poor air quality are witnessing disproportionate impacts in terms of the frequency and severity of COVID-19 infection. Consequently, researchers have rightly recognized the importance of considering the role of air pollution inthe COVID-19 pandemic.Here, we discussthe pros and cons of air pollution as a contributing factorto COVID-19,according to existing research questions (Table 1).</style></abstract><notes><style face="normal" font="default" size="100%">Annesi-Maesano, Isabella&#xD;Maesano, Cara Nichole&#xD;D&apos;Amato, Maria&#xD;D&apos;Amato, Gennaro&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2647-2649. doi: 10.1111/all.14818. Epub 2021 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33733491</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8251006</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14818</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1188</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1188</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marrs, T.</style></author><author><style face="normal" font="default" size="100%">Walter, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Children&apos;s Allergies, Evelina London, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK.&#xD;Department of Paediatric Allergy, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;APC Microbiome, Ireland, School of Microbiology, and Department of Medicine, University College Cork, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pros and cons: Is faecal microbiota transplantation a safe and efficient treatment option for gut dysbiosis?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2312-2317</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Clostridium Infections/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Dysbiosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Fecal Microbiota Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Feces</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridioides difficile-infection</style></keyword><keyword><style face="normal" font="default" size="100%">allergic disease</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">faecal microbiota transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">immune-mediated disease</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33483999</style></accession-num><abstract><style face="normal" font="default" size="100%">Faecal Microbiota Transplantation (FMT) is well established as an effective treatment for Clostridioides difficile infection (CDI), restoring gut microbiome diversity and function. The utility of FMT is currently being explored in relation to other immune-mediated pathologies, such as allergic disease, inflammatory bowel diseases and autoimmune diseases. Clinical trials in these areas are ongoing, and the altered gut microbiota (dysbiosis) that is often observed in these pathologies provides a rationale for the application of FMT to restore the microbiome. However, there is controversy on the risk-benefit ratio as it relates to the use of FMTs in pathologies other than CDI. In this Pro and Con article, we present the arguments for and against the use of FMT in immune-mediated pathologies, such as allergic disease. We further identify research gaps and recommend how these may be addressed in future studies.</style></abstract><notes><style face="normal" font="default" size="100%">Marrs, Tom&#xD;Walter, Jens&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2312-2317. doi: 10.1111/all.14750. Epub 2021 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33483999</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14750</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1655</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1655</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marrs, T.</style></author><author><style face="normal" font="default" size="100%">Walter, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Children&apos;s Allergies, Evelina London, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK.&#xD;Department of Paediatric Allergy, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;APC Microbiome, Ireland, School of Microbiology, and Department of Medicine, University College Cork, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pros and cons: Is faecal microbiota transplantation a safe and efficient treatment option for gut dysbiosis?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Allergy</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></alt-periodical><pages><style face="normal" font="default" size="100%">2312-2317</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Clostridium Infections/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Dysbiosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Fecal Microbiota Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Feces</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridioides difficile-infection</style></keyword><keyword><style face="normal" font="default" size="100%">allergic disease</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">faecal microbiota transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">immune-mediated disease</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33483999</style></accession-num><abstract><style face="normal" font="default" size="100%">Faecal Microbiota Transplantation (FMT) is well established as an effective treatment for Clostridioides difficile infection (CDI), restoring gut microbiome diversity and function. The utility of FMT is currently being explored in relation to other immune-mediated pathologies, such as allergic disease, inflammatory bowel diseases and autoimmune diseases. Clinical trials in these areas are ongoing, and the altered gut microbiota (dysbiosis) that is often observed in these pathologies provides a rationale for the application of FMT to restore the microbiome. However, there is controversy on the risk-benefit ratio as it relates to the use of FMTs in pathologies other than CDI. In this Pro and Con article, we present the arguments for and against the use of FMT in immune-mediated pathologies, such as allergic disease. We further identify research gaps and recommend how these may be addressed in future studies.</style></abstract><notes><style face="normal" font="default" size="100%">Marrs, Tom&#xD;Walter, Jens&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2312-2317. doi: 10.1111/all.14750. Epub 2021 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33483999</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14750</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>756</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">756</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gerth van Wijk, R.</style></author><author><style face="normal" font="default" size="100%">Dahl, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Allergology and Clinical Immunology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.&#xD;Aarhus University, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pros and cons: Should allergen immunotherapy be considered in all patients with allergic asthma?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1070-1072</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/10/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Subcutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34608654</style></accession-num><notes><style face="normal" font="default" size="100%">Gerth van Wijk, Roy&#xD;Dahl, Ronald&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1070-1072. doi: 10.1111/all.15123. Epub 2021 Oct 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34608654</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15123</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1652</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1652</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gerth van Wijk, R.</style></author><author><style face="normal" font="default" size="100%">Dahl, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Allergology and Clinical Immunology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.&#xD;Aarhus University, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pros and cons: Should allergen immunotherapy be considered in all patients with allergic asthma?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1070-1072</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/10/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Subcutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34608654</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Allergen immunotherapy (AIT) has gained a permanent place in the therapeutic arsenal for the patient with allergic rhinitis. It is, however, a matter of debate whether AIT can be implemented for patients with asthma. Asthma is a heterogeneous disorder, with many pathophysiological mechanisms underlying the typical clinical presentation. The term “asthma” could be considered as an umbrella diagnosis. Several components are involved in the asthma disease process and “one size” does not fit to all individuals. Each patient should be evaluated for the clinically relevant factors involved, including atopic sensitisation.</style></abstract><notes><style face="normal" font="default" size="100%">Gerth van Wijk, Roy&#xD;Dahl, Ronald&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1070-1072. doi: 10.1111/all.15123. Epub 2021 Oct 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34608654</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15123</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>334</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">334</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dramburg, S.</style></author><author><style face="normal" font="default" size="100%">Perna, S.</style></author><author><style face="normal" font="default" size="100%">Di Fraia, M.</style></author><author><style face="normal" font="default" size="100%">Tripodi, S.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Castelli, S.</style></author><author><style face="normal" font="default" size="100%">Villalta, D.</style></author><author><style face="normal" font="default" size="100%">Buzzulini, F.</style></author><author><style face="normal" font="default" size="100%">Sfika, I.</style></author><author><style face="normal" font="default" size="100%">Villella, V.</style></author><author><style face="normal" font="default" size="100%">Potapova, E.</style></author><author><style face="normal" font="default" size="100%">Brighetti, M. A.</style></author><author><style face="normal" font="default" size="100%">Travaglini, A.</style></author><author><style face="normal" font="default" size="100%">Pelosi, S.</style></author><author><style face="normal" font="default" size="100%">Grittner, U.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Respiratory Care, Immunology and Critical Care Medicine, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Pediatric Allergology Unit, Sandro Pertini Hospital, Rome, Italy.&#xD;Allergology Service, Policlinico Casilino, Rome, Italy.&#xD;Translational Research in Pediatric Specialities Area, Division of Allergy, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;Pediatric Allergology Unit, Department of Pediatric Medicine, Bambino Gesu Children&apos;s Research Hospital (IRCCS), Rome, Italy.&#xD;Department of Immunology-Allergy, &quot;S. Maria degli Angeli&quot; Hospital, Pordenone, Italy.&#xD;Department of Biology, University of Rome &quot;Tor Vergata&quot;, Rome, Italy.&#xD;TPS Production, Rome, Italy.&#xD;Berlin Institute of Health (BIH), Berlin, Germany.&#xD;Institute of Biometry and Clinical Epidemiology, Charite - Universitatsmedizin Berlin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prospective (e-diary) vs retrospective (ARIA) measures of severity in allergic rhinoconjunctivitis: An observational compatibility study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">550-553</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/08/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36037276</style></accession-num><notes><style face="normal" font="default" size="100%">Dramburg, Stephanie&#xD;Perna, Serena&#xD;Di Fraia, Marco&#xD;Tripodi, Salvatore&#xD;Arasi, Stefania&#xD;Castelli, Sveva&#xD;Villalta, Danilo&#xD;Buzzulini, Francesca&#xD;Sfika, Ifigenia&#xD;Villella, Valeria&#xD;Potapova, Ekaterina&#xD;Brighetti, Maria Antonia&#xD;Travaglini, Alessandro&#xD;Pelosi, Simone&#xD;Grittner, Ulrike&#xD;Matricardi, Paolo Maria&#xD;eng&#xD;Letter&#xD;Observational Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):550-553. doi: 10.1111/all.15499. Epub 2022 Sep 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36037276</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15499</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>729</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">729</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sturm, G. J.</style></author><author><style face="normal" font="default" size="100%">Arzt-Gradwohl, L.</style></author><author><style face="normal" font="default" size="100%">Cerpes, U.</style></author><author><style face="normal" font="default" size="100%">Koch, L.</style></author><author><style face="normal" font="default" size="100%">Bokanovic, D.</style></author><author><style face="normal" font="default" size="100%">Laipold, K.</style></author><author><style face="normal" font="default" size="100%">Vollmann, J.</style></author><author><style face="normal" font="default" size="100%">Binder, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.&#xD;Institute of Zoology, University of Graz, Graz, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prospective studies are needed to elucidate the clinical impact of predominant Api m 10 sensitization</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">687-689</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Bee Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34695255</style></accession-num><notes><style face="normal" font="default" size="100%">Sturm, Gunter J&#xD;Arzt-Gradwohl, Lisa&#xD;Cerpes, Urban&#xD;Koch, Lukas&#xD;Bokanovic, Danijela&#xD;Laipold, Karin&#xD;Vollmann, Jutta&#xD;Binder, Barbara&#xD;eng&#xD;Comment&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):687-689. doi: 10.1111/all.15151. Epub 2021 Nov 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34695255</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15151</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1307</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1307</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Munoz-Cano, R. M.</style></author><author><style face="normal" font="default" size="100%">Casas, R.</style></author><author><style face="normal" font="default" size="100%">Araujo, G.</style></author><author><style face="normal" font="default" size="100%">de la Cruz, C.</style></author><author><style face="normal" font="default" size="100%">Martin, M.</style></author><author><style face="normal" font="default" size="100%">Roca-Ferrer, J.</style></author><author><style face="normal" font="default" size="100%">Perez, M.</style></author><author><style face="normal" font="default" size="100%">Torradeflot, M.</style></author><author><style face="normal" font="default" size="100%">San Bartolome, C.</style></author><author><style face="normal" font="default" size="100%">Picado, C.</style></author><author><style face="normal" font="default" size="100%">Bartra, J.</style></author><author><style face="normal" font="default" size="100%">Pascal, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pneumology Department, Allergy Section, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.&#xD;Clinical and Experimental Respiratory Immunoallergy (IRCE), Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.&#xD;ARADyAL, Instituto de Salud Carlos III, Madrid, Spain.&#xD;Faculty of Medicine, Biochemistry Unit, University of Barcelona, Barcelona, Spain.&#xD;Centro de Investigaciones Biomedicas en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.&#xD;Immunology Department, Centre de Diagnostic Biomedic (CDB), Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prostaglandin E2 decreases basophil activation in patients with food-induced anaphylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1556-1559</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">*Dinoprostone</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Pge2</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">eicosanoids</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33029821</style></accession-num><notes><style face="normal" font="default" size="100%">Munoz-Cano, Rosa M&#xD;Casas, Rocio&#xD;Araujo, Giovanna&#xD;de la Cruz, Cinthia&#xD;Martin, Margarita&#xD;Roca-Ferrer, Jordi&#xD;Perez, Maria&#xD;Torradeflot, Maria&#xD;San Bartolome, Clara&#xD;Picado, Cesar&#xD;Bartra, Joan&#xD;Pascal, Mariona&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1556-1559. doi: 10.1111/all.14615. Epub 2020 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33029821</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14615</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1938</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1938</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, Y. H.</style></author><author><style face="normal" font="default" size="100%">Lim, J. O.</style></author><author><style face="normal" font="default" size="100%">Kim, J. S.</style></author><author><style face="normal" font="default" size="100%">Kim, B. Y.</style></author><author><style face="normal" font="default" size="100%">Pyun, B. J.</style></author><author><style face="normal" font="default" size="100%">Lee, S. J.</style></author><author><style face="normal" font="default" size="100%">Kim, D. E.</style></author><author><style face="normal" font="default" size="100%">Lee, S. H.</style></author><author><style face="normal" font="default" size="100%">Shin, I. S.</style></author><author><style face="normal" font="default" size="100%">Kim, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">KM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.&#xD;College of Veterinary Medicine and BK21 FOUR Program, Chonnam National University, Gwangju, Republic of Korea.&#xD;Graduate School of Medical Science and Engineering, Biomedical Research Center, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Protease allergen-induced HMGB1 contributes to NLRC4 inflammasome-mediated inflammation in experimental asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1387-1392</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/02/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammasomes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Peptide Hydrolases</style></keyword><keyword><style face="normal" font="default" size="100%">*HMGB1 Protein</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium-Binding Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">CARD Signaling Adaptor Proteins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36748908</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Yun Hee&#xD;Lim, Je-Oh&#xD;Kim, Joong Sun&#xD;Kim, Bu-Yeo&#xD;Pyun, Bo-Jeong&#xD;Lee, Se-Jin&#xD;Kim, Dong Eon&#xD;Lee, Seung-Hyo&#xD;Shin, In-Sik&#xD;Kim, Taesoo&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1387-1392. doi: 10.1111/all.15668. Epub 2023 Mar 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36748908</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15668</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1948</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1948</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soh, W. T.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Hollenberg, M. D.</style></author><author><style face="normal" font="default" size="100%">Vliagoftis, H.</style></author><author><style face="normal" font="default" size="100%">Rothenberg, M. E.</style></author><author><style face="normal" font="default" size="100%">Sokol, C. L.</style></author><author><style face="normal" font="default" size="100%">Robinson, C.</style></author><author><style face="normal" font="default" size="100%">Jacquet, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Max-Planck-Institute for Multidisciplinary Sciences, Gottingen, Germany.&#xD;State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.&#xD;Department of Physiology &amp; Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.&#xD;Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.&#xD;Division of Pulmonary Medicine, Department of Medicine, Faculty of Medicine &amp; Dentistry, and Alberta Respiratory Centre, University of Alberta, Edmonton, Alberta, Canada.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children&apos;s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Division of Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Institute for Infection and Immunity, St George&apos;s University of London, London, UK.&#xD;Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Protease allergens as initiators-regulators of allergic inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1148-1168</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/02/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Peptide Hydrolases</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">protease allergen</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial cell</style></keyword><keyword><style face="normal" font="default" size="100%">protease-activated receptor</style></keyword><keyword><style face="normal" font="default" size="100%">sensory neuron</style></keyword><keyword><style face="normal" font="default" size="100%">are inventors on patents granted in multiple territories concerning allergens,</style></keyword><keyword><style face="normal" font="default" size="100%">protease inhibitor design and composition of matter, and medical uses thereof. St</style></keyword><keyword><style face="normal" font="default" size="100%">George&apos;s, University of London is beneficial owner of this patent estate. C.R. is</style></keyword><keyword><style face="normal" font="default" size="100%">co-founder and holds equity in Aldezon Ltd. M.E.R. is a consultant for Pulm One,</style></keyword><keyword><style face="normal" font="default" size="100%">Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, Nextstone One, Bristol</style></keyword><keyword><style face="normal" font="default" size="100%">Myers Squibb, Astra Zeneca, Ellodi Pharma, GlaxoSmith Kline, Regeneron/Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Revolo Biotherapeutics, and Guidepoint and has an equity interest in the first</style></keyword><keyword><style face="normal" font="default" size="100%">seven listed, and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi</style></keyword><keyword><style face="normal" font="default" size="100%">Research Trust) and UpToDate. M.E.R. is an inventor of patents owned by</style></keyword><keyword><style face="normal" font="default" size="100%">Cincinnati Children&apos;s Hospital. The remaining authors declare that they have no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36794967</style></accession-num><abstract><style face="normal" font="default" size="100%">Tremendous progress in the last few years has been made to explain how seemingly harmless environmental proteins from different origins can induce potent Th2-biased inflammatory responses. Convergent findings have shown the key roles of allergens displaying proteolytic activity in the initiation and progression of the allergic response. Through their propensity to activate IgE-independent inflammatory pathways, certain allergenic proteases are now considered as initiators for sensitization to themselves and to non-protease allergens. The protease allergens degrade junctional proteins of keratinocytes or airway epithelium to facilitate allergen delivery across the epithelial barrier and their subsequent uptake by antigen-presenting cells. Epithelial injuries mediated by these proteases together with their sensing by protease-activated receptors (PARs) elicit potent inflammatory responses resulting in the release of pro-Th2 cytokines (IL-6, IL-25, IL-1beta, TSLP) and danger-associated molecular patterns (DAMPs; IL-33, ATP, uric acid). Recently, protease allergens were shown to cleave the protease sensor domain of IL-33 to produce a super-active form of the alarmin. At the same time, proteolytic cleavage of fibrinogen can trigger TLR4 signaling, and cleavage of various cell surface receptors further shape the Th2 polarization. Remarkably, the sensing of protease allergens by nociceptive neurons can represent a primary step in the development of the allergic response. The goal of this review is to highlight the multiple innate immune mechanisms triggered by protease allergens that converge to initiate the allergic response.</style></abstract><notes><style face="normal" font="default" size="100%">Soh, Wai Tuck&#xD;Zhang, Jihui&#xD;Hollenberg, Morley D&#xD;Vliagoftis, Harissios&#xD;Rothenberg, Marc E&#xD;Sokol, Caroline L&#xD;Robinson, Clive&#xD;Jacquet, Alain&#xD;eng&#xD;R21 AG072204/AG/NIA NIH HHS/&#xD;087650/WT_/Wellcome Trust/United Kingdom&#xD;R01 AI151163/AI/NIAID NIH HHS/&#xD;R01 AI045898/AI/NIAID NIH HHS/&#xD;U19 AI070235/AI/NIAID NIH HHS/&#xD;WT_/Wellcome Trust/United Kingdom&#xD;R01 AI057803/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1148-1168. doi: 10.1111/all.15678. Epub 2023 Feb 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36794967</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10159943</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15678</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>372</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">372</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zeng, B.</style></author><author><style face="normal" font="default" size="100%">Jiang, T.</style></author><author><style face="normal" font="default" size="100%">Xiong, W.</style></author><author><style face="normal" font="default" size="100%">Che, H.</style></author><author><style face="normal" font="default" size="100%">Sun, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Food Science and Nutrition Engineering College, China Agricultural University, Beijing, China.&#xD;School of Food Science and Bioengineering, Yantai Institute of Technology, Shandong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Protective properties of polyphenols in food allergy: A review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1654-1656</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/08/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Polyphenols</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonoids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35908194</style></accession-num><notes><style face="normal" font="default" size="100%">Zeng, Binghui&#xD;Jiang, Tianyi&#xD;Xiong, Wenwen&#xD;Che, Huilian&#xD;Sun, Shengqian&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1654-1656. doi: 10.1111/all.15459. Epub 2022 Aug 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35908194</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15459</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3111</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3111</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Albers, G. J.</style></author><author><style face="normal" font="default" size="100%">Ogger, P. P.</style></author><author><style face="normal" font="default" size="100%">Michalaki, C.</style></author><author><style face="normal" font="default" size="100%">Stolting, H.</style></author><author><style face="normal" font="default" size="100%">Walker, S. A.</style></author><author><style face="normal" font="default" size="100%">Caldwell, A.</style></author><author><style face="normal" font="default" size="100%">Halket, J. M.</style></author><author><style face="normal" font="default" size="100%">Duvall, K.</style></author><author><style face="normal" font="default" size="100%">Batool, A.</style></author><author><style face="normal" font="default" size="100%">Joshi, L.</style></author><author><style face="normal" font="default" size="100%">O&apos;Brien, H.</style></author><author><style face="normal" font="default" size="100%">McCarthy, C.</style></author><author><style face="normal" font="default" size="100%">Hinks, T.</style></author><author><style face="normal" font="default" size="100%">Gauvreau, G. M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Byrne, P. M.</style></author><author><style face="normal" font="default" size="100%">Lloyd, C. M.</style></author><author><style face="normal" font="default" size="100%">Byrne, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Nutritional Sciences, School of Life Course &amp; Population Health Sciences, King&apos;s College London, London, UK.&#xD;Conway Institute and School of Medicine, University College Dublin, Dublin, Ireland.&#xD;Respiratory Medicine Unit, Nuffield Department of Medicine and National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.&#xD;Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories, and the NIHR Southampton Respiratory Biomedical Research Unit, Southampton University Hospital, Southampton, UK.&#xD;Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Protective Role for Itaconate During Inhaled Allergen Challenge</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">airway inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">allergen exposure</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">itaconate</style></keyword><keyword><style face="normal" font="default" size="100%">macrophage metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41137193</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma is a chronic, heterogeneous disease characterised by airway remodelling, inflammation, and mucus production. Airway macrophages&apos; functions are underpinned by changes in cellular metabolism. The TCA cycle-derived metabolite itaconic acid (whose synthesis is mediated by aconitate decarboxylase) is a master regulator of macrophage function; however, its role during inhaled allergen challenge is not clear. The objective of this study was to define the role of itaconate during inhaled allergen challenge. METHODS: Sputum metabolite levels were measured in participants with mild allergic asthma undergoing allergen inhalation challenge, and in a second cohort, baseline levels in mild, moderate, and severe asthmatics. Airway inflammation, lung function, and bronchoalveolar lavage metabolite levels were assessed in wild-type and aconitate decarboxylase-deficient mice, or in mice treated with inhaled itaconate. RESULTS: Allergen inhalation in mild asthmatics led to a significant reduction in sputum itaconate. We found no difference in baseline sputum itaconate levels when comparing healthy controls to mild, moderate, or severe asthmatics. Continuous exposure to aeroallergen in wild type and aconitate decarboxylase-deficient mice showed no change in disease phenotype after 48 h, 1, 3, or 5 weeks of allergen exposure. Treatment of house dust mite-exposed mice with inhaled itaconate reduced airway inflammation. CONCLUSION: Levels of itaconate are altered after allergen challenge in mild asthmatics and in murine models of disease. Itaconate deficiency did not alter house dust mite-induced pathology at any of the timepoints tested; however, inhaled itaconate ameliorated inflammatory responses to inhaled allergen.</style></abstract><notes><style face="normal" font="default" size="100%">Albers, Gesa J&#xD;Ogger, Patricia P&#xD;Michalaki, Christina&#xD;Stolting, Helen&#xD;Walker, Simone A&#xD;Caldwell, Anna&#xD;Halket, John M&#xD;Duvall, Kathryn&#xD;Batool, Atia&#xD;Joshi, Lisha&#xD;O&apos;Brien, Helen&#xD;McCarthy, Cormac&#xD;Hinks, Timothy&#xD;Gauvreau, Gail M&#xD;O&apos;Byrne, Paul M&#xD;Lloyd, Clare M&#xD;Byrne, Adam J&#xD;eng&#xD;225242/Z/22/Z/WT_/Wellcome Trust/United Kingdom&#xD;088365/z/09/z/WT_/Wellcome Trust/United Kingdom&#xD;211050/Z/18/Z/WT_/Wellcome Trust/United Kingdom&#xD;Asthma and Lung UK/&#xD;Denmark&#xD;Allergy. 2025 Oct 24. doi: 10.1111/all.70107.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41137193</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70107</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2219</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2219</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Whetstone, C. E.</style></author><author><style face="normal" font="default" size="100%">Ranjbar, M.</style></author><author><style face="normal" font="default" size="100%">Cusack, R. P.</style></author><author><style face="normal" font="default" size="100%">Al-Sajee, D.</style></author><author><style face="normal" font="default" size="100%">Omer, H.</style></author><author><style face="normal" font="default" size="100%">Alsaji, N.</style></author><author><style face="normal" font="default" size="100%">Ho, T.</style></author><author><style face="normal" font="default" size="100%">Duong, M.</style></author><author><style face="normal" font="default" size="100%">Mitchell, P.</style></author><author><style face="normal" font="default" size="100%">Satia, I.</style></author><author><style face="normal" font="default" size="100%">Keith, P.</style></author><author><style face="normal" font="default" size="100%">Xie, Y.</style></author><author><style face="normal" font="default" size="100%">MacLean, J.</style></author><author><style face="normal" font="default" size="100%">Sommer, D. D.</style></author><author><style face="normal" font="default" size="100%">O&apos;Byrne, P. M.</style></author><author><style face="normal" font="default" size="100%">Sehmi, R.</style></author><author><style face="normal" font="default" size="100%">Gauvreau, G. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Respirology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, Canada.&#xD;Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.&#xD;Otolaryngology, Head &amp; Neck Surgery Division, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Protein expression of SARS-CoV-2 receptors ACE2 and TMPRSS2 in allergic airways after allergen challenge</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3010-3013</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Serine Endopeptidases/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37357419</style></accession-num><notes><style face="normal" font="default" size="100%">Whetstone, Christiane E&#xD;Ranjbar, Maral&#xD;Cusack, Ruth P&#xD;Al-Sajee, Dhuha&#xD;Omer, Hafsa&#xD;Alsaji, Nadia&#xD;Ho, Terence&#xD;Duong, MyLinh&#xD;Mitchell, Patrick&#xD;Satia, Imran&#xD;Keith, Paul&#xD;Xie, Yanqing&#xD;MacLean, Jonathan&#xD;Sommer, Doron D&#xD;O&apos;Byrne, Paul M&#xD;Sehmi, Roma&#xD;Gauvreau, Gail M&#xD;eng&#xD;AstraZeneca Canada/&#xD;Mitacs/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):3010-3013. doi: 10.1111/all.15793. Epub 2023 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37357419</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15793</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3178</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3178</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, P.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Zeng, M.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China.&#xD;Hubei Clinical Research Center for Nasal Inflammatory Diseases, Wuhan, P.R. China.&#xD;Hubei Key Laboratory of Otorhinolaryngologic and Ophthalmic Diseases, Wuhan, P.R. China.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Zhongnan Hospital, Wuhan University, Wuhan, P.R. China.&#xD;Institute of Allergy, Wuhan University, Wuhan, P.R. China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Protein Glycosylation: An Emerging Regulator of Allergic Diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">glycosylation</style></keyword><keyword><style face="normal" font="default" size="100%">therapeutic target</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 28</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41316688</style></accession-num><abstract><style face="normal" font="default" size="100%">Type 2 (T2) inflammation is central to allergic disorders. Glycosylation, a post-translational modification, is emerging as a pivotal regulator in T2 inflammation and associated allergic diseases. This review synthesizes current knowledge on glycosylation patterns of key T2 inflammation players, including cytokines, immunoglobulins (e.g., IgE, IgG4) and their receptors, STAT6, mucins, and CTLA-4. We detail how site-specific glycosylation fine-tunes cytokine-receptor interactions, alters signaling pathways, and stabilizes proteins, thereby dictating their bioactivity. Moreover, we examine the enzymatic machinery orchestrating these glycosylation events and the regulatory factors modulating their activity in the context of T2 inflammation. By leveraging these mechanistic insights, we highlight how glycosylation aberrations contribute to food allergy, eosinophilic esophagitis, asthma, allergic rhinitis, and atopic dermatitis, while allergen immunotherapy exploits glycosylation reprogramming (e.g., sialylated IgG4 induction) to restore immune tolerance. Furthermore, we explore the diagnostic and prognostic potential of glycosylation patterns in predicting disease severity and allergen immunotherapy responsiveness, while underscoring the therapeutic promise of targeting glycosylation enzymes or glycan-immune receptor interactions to mitigate T2 inflammation-driven pathologies. A deeper understanding of glycosylation dynamics in T2 inflammation not only enhances our grasp of disease pathogenesis but also opens new avenues for innovative therapeutic interventions.</style></abstract><notes><style face="normal" font="default" size="100%">Li, Pan&#xD;Wang, Xianghong&#xD;Zeng, Ming&#xD;Liu, Zheng&#xD;eng&#xD;2023BCB008/Key Research and Development Program of Hubei Province/&#xD;82071025/National Natural Science Foundation of China/&#xD;2022YFE0131200/National Key Research and Development Program of China/&#xD;2023YFC2507900/National Key Research and Development Program of China/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Nov 28. doi: 10.1111/all.70171.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41316688</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70171</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2148</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2148</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Molina-Jimenez, F.</style></author><author><style face="normal" font="default" size="100%">Ugalde-Trivino, L.</style></author><author><style face="normal" font="default" size="100%">Arias-Gonzalez, L.</style></author><author><style face="normal" font="default" size="100%">Relano-Ruperez, C.</style></author><author><style face="normal" font="default" size="100%">Casabona, S.</style></author><author><style face="normal" font="default" size="100%">Perez-Fernandez, M. T.</style></author><author><style face="normal" font="default" size="100%">Martin-Dominguez, V.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Pacheco, J.</style></author><author><style face="normal" font="default" size="100%">Laserna-Mendieta, E. J.</style></author><author><style face="normal" font="default" size="100%">Munoz-Hernandez, P.</style></author><author><style face="normal" font="default" size="100%">Arias-Arias, A.</style></author><author><style face="normal" font="default" size="100%">Cano, A.</style></author><author><style face="normal" font="default" size="100%">Munoz, J.</style></author><author><style face="normal" font="default" size="100%">Lucendo, A. J.</style></author><author><style face="normal" font="default" size="100%">Santander, C.</style></author><author><style face="normal" font="default" size="100%">Majano, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular Biology Unit, Hospital Universitario de la Princesa, Madrid, Spain.&#xD;Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Madrid, Spain.&#xD;Department of Gastroenterology, Hospital General de Tomelloso, Ciudad Real, Spain.&#xD;Instituto de Investigacion Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain.&#xD;Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Madrid, Spain.&#xD;Department of Gastroenterology, Hospital Universitario de La Princesa, Madrid, Spain.&#xD;Clinical Laboratory, Hospital Universitario de La Princesa, Madrid, Spain.&#xD;Department of Pathology, Hospital Universitario de La Princesa, Madrid, Spain.&#xD;Research Unit, Hospital General La Mancha Centro, Alcazar de San Juan, Spain.&#xD;Food Research, AZTI, Basque Research and Technology Alliance (BRTA), Parque Tecnologico de Bizkaia, Derio, Spain.&#xD;Cell Signalling and Clinical Proteomics Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.&#xD;Ikerbasque, Basque Foundation for Science, Bilbao, Spain.&#xD;Department of Cellular Biology, Faculty of Biology, Universidad Complutense de Madrid, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Proteomic analysis of the esophageal epithelium reveals key features of eosinophilic esophagitis pathophysiology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2732-2744</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/06/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Esophageal Mucosa/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proteome</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">proteomic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37287363</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic non-IgE-mediated allergic disease of the esophagus. An unbiased proteomics approach was performed to investigate pathophysiological changes in esophageal epithelium. Additionally, an RNAseq-based transcriptomic analysis in paired samples was also carried out. METHODS: Total proteins were purified from esophageal endoscopic biopsies in a cohort of adult EoE patients (n = 25) and healthy esophagus controls (n = 10). Differentially accumulated (DA) proteins in EoE patients compared to control tissues were characterized to identify altered biological processes and signaling pathways. Results were also compared with a quantitative proteome dataset of the human esophageal mucosa. Next, results were contrasted with those obtained after RNAseq analysis in paired samples. Finally, we matched up protein expression with two EoE-specific mRNA panels (EDP and Eso-EoE panel). RESULTS: A total of 1667 proteins were identified, of which 363 were DA in EoE. RNA sequencing in paired samples identified 1993 differentially expressed (DE) genes. Total RNA and protein levels positively correlated, especially in DE mRNA-proteins pairs. Pathway analysis of these proteins in EoE showed alterations in immune and inflammatory responses for the upregulated proteins, and in epithelial differentiation, cornification and keratinization in those downregulated. Interestingly, a set of DA proteins, including eosinophil-related and secreted proteins, were not detected at the mRNA level. Protein expression positively correlated with EDP and Eso-EoE, and corresponded with the most abundant proteins of the human esophageal proteome. CONCLUSIONS: We unraveled for the first time key proteomic features involved in EoE pathogenesis. An integrative analysis of transcriptomic and proteomic datasets provides a deeper insight than transcriptomic alone into understanding complex disease mechanisms.</style></abstract><notes><style face="normal" font="default" size="100%">Molina-Jimenez, Francisca&#xD;Ugalde-Trivino, Lola&#xD;Arias-Gonzalez, Laura&#xD;Relano-Ruperez, Carlos&#xD;Casabona, Sergio&#xD;Perez-Fernandez, Maria Teresa&#xD;Martin-Dominguez, Veronica&#xD;Fernandez-Pacheco, Jennifer&#xD;Laserna-Mendieta, Emilio Jose&#xD;Munoz-Hernandez, Patricia&#xD;Arias-Arias, Angel&#xD;Cano, Ainara&#xD;Munoz, Javier&#xD;Lucendo, Alfredo J&#xD;Santander, Cecilio&#xD;Majano, Pedro&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2732-2744. doi: 10.1111/all.15779. Epub 2023 Jun 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37287363</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15779</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3205</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3205</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Antao, J.</style></author><author><style face="normal" font="default" size="100%">Rodrigues, G.</style></author><author><style face="normal" font="default" size="100%">Zounemat-Kermani, N.</style></author><author><style face="normal" font="default" size="100%">Montuschi, P.</style></author><author><style face="normal" font="default" size="100%">Deng, Q.</style></author><author><style face="normal" font="default" size="100%">Franssen, F. M. E.</style></author><author><style face="normal" font="default" size="100%">Andersson, L. I.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Dahlen, S. E.</style></author><author><style face="normal" font="default" size="100%">Wagers, S. S.</style></author><author><style face="normal" font="default" size="100%">Spruit, M. A.</style></author><author><style face="normal" font="default" size="100%">Marques, A.</style></author><author><style face="normal" font="default" size="100%">U. Biopred Study Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Lab3R - Respiratory Research and Rehabilitation Laboratory, School of Health Sciences (ESSUA) and Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal.&#xD;Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.&#xD;Department of Research and Development, Ciro, Horn, the Netherlands.&#xD;NUTRIM Institute of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.&#xD;National Heart and Lung Institute, Imperial College, London, UK.&#xD;Data Science Institute, Imperial College London, London, UK.&#xD;Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy.&#xD;Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands.&#xD;Department of Medicine Huddinge, and, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.&#xD;BioSci Consulting, Maasmechelen, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Proteomic and Transcriptomic Signatures of Poor Asthma Symptom Control in the U-BIOPRED Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">patient outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 8</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41358571</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Controlling asthma symptoms remains challenging. Understanding its molecular mechanisms may provide new insights into asthma pathophysiology. We explored the associations between the transcriptome and proteome in blood and sputum and asthma symptom control. METHODS: This cross-sectional study included asthmatic and healthy adults from the U-BIOPRED cohort. Uncontrolled symptoms were defined as a mean &gt;/= 1.5 points on the 5-item asthma control questionnaire. Stability selection using LASSO logistic regression identified genes/proteins associated with symptom control, followed by logistic regression. Analyses were adjusted for age, sex, age of asthma onset, smoking status, body mass index (BMI), FEV(1)% predicted, exacerbation history, anti-IgE therapy and urinary steroid levels. The selected variables were compared with healthy controls using linear regression, adjusted for age, sex, BMI, smoking status and urinary steroid levels. RESULTS: Four serum proteins were selected based on data from 415 asthmatics (median age 52 [41, 61] years; 59% female; 64% uncontrolled). Higher TWEAKR/TNFRSF12A [OR 2.25 (95% CI 1.15, 4.77)] and MBL/MBP-C [1.6 (1.07, 2.42)] levels increased the odds of uncontrolled symptoms, whereas higher MK08/MAPK8 [0.48 (0.29, 0.76)] and CD5L [0.59 (0.41, 0.82)] levels decreased the odds. CD5L levels were significantly lower in severe asthma than in healthy controls [estimate -0.23 (95% CI -0.41, -0.04)]. No associations were found between symptom control and the sputum proteome (N = 90) or the sputum (N = 96) and blood (N = 360) transcriptomes. CONCLUSION: Four serum proteins distinguished asthmatics with uncontrolled from controlled symptoms. CD5L levels were also lower in asthmatics with severe disease than in healthy controls, warranting further investigation into its potential therapeutic value.</style></abstract><notes><style face="normal" font="default" size="100%">Antao, Joana&#xD;Rodrigues, Guilherme&#xD;Zounemat-Kermani, Nazanin&#xD;Montuschi, Paolo&#xD;Deng, Qichen&#xD;Franssen, Frits M E&#xD;Andersson, Lars I&#xD;Adcock, Ian M&#xD;Dahlen, Sven-Erik&#xD;Wagers, Scott S&#xD;Spruit, Martijn A&#xD;Marques, Alda&#xD;eng&#xD;EU/EFPIA/&#xD;Teva Pharmaceutical Industries/&#xD;Chiesi/&#xD;BI/ESSUA/9878/2021/University of Aveiro/CIRO + B.V/&#xD;BI/ESSUA/9841/2023/University of Aveiro/CIRO + B.V/&#xD;UID 4501 - Instituto de Biomedicina - Aveiro/&#xD;AstraZeneca/&#xD;Denmark&#xD;Allergy. 2025 Dec 8. doi: 10.1111/all.70178.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41358571</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70178</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1133</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1133</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nunez-Borque, E.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Bravo, S.</style></author><author><style face="normal" font="default" size="100%">Pastor-Vargas, C.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Llamas, G.</style></author><author><style face="normal" font="default" size="100%">Gutierrez-Blazquez, M. D.</style></author><author><style face="normal" font="default" size="100%">Alwashali, E.</style></author><author><style face="normal" font="default" size="100%">Laguna, J. J.</style></author><author><style face="normal" font="default" size="100%">Dionicio, J.</style></author><author><style face="normal" font="default" size="100%">Betancor, D.</style></author><author><style face="normal" font="default" size="100%">Villalobos, V.</style></author><author><style face="normal" font="default" size="100%">Tome-Amat, J.</style></author><author><style face="normal" font="default" size="100%">Cuesta-Herranz, J.</style></author><author><style face="normal" font="default" size="100%">Benito-Martin, A.</style></author><author><style face="normal" font="default" size="100%">Esteban, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Immunology, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain.&#xD;Department of Biochemistry and Molecular Biology, Universidad Complutense de Madrid, Madrid, Spain.&#xD;Red de asma, reacciones adversas y alergicas (ARADyAL), Instituto de Salud Carlos III, Madrid, Spain.&#xD;Immunoallergy and Proteomics Laboratory, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain.&#xD;Red de Investigacion Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain.&#xD;CAI Genomics and Proteomics, Proteomic Unit, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain.&#xD;Allergy Unit, Allergo-Anaesthesia Unit, Hospital Central de la Cruz Roja, Madrid, Spain.&#xD;Faculty of Medicine and Biomedicine, Alfonso X El Sabio University, Madrid, Spain.&#xD;Centro de Biotecnologia y Genomica de Plantas (UPM-INIA), Universidad Politecnica de Madrid, Madrid, Spain.&#xD;Department of Medicine, Weill Cornell Medicine, New York, New York, USA.&#xD;Instituto Biomedico de Nutricion y Salud, IBIONS, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Proteomic profile of extracellular vesicles in anaphylaxis and their role in vascular permeability</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2276-2279</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Capillary Permeability</style></keyword><keyword><style face="normal" font="default" size="100%">*Extracellular Vesicles/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33629411</style></accession-num><notes><style face="normal" font="default" size="100%">Nunez-Borque, Emilio&#xD;Fernandez-Bravo, Sergio&#xD;Pastor-Vargas, Carlos&#xD;Alvarez-Llamas, Gloria&#xD;Gutierrez-Blazquez, Maria Dolores&#xD;Alwashali, Ebrahim&#xD;Laguna, Jose Julio&#xD;Dionicio, Javier&#xD;Betancor, Diana&#xD;Villalobos, Victoria&#xD;Tome-Amat, Jaime&#xD;Cuesta-Herranz, Javier&#xD;Benito-Martin, Alberto&#xD;Esteban, Vanesa&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2276-2279. doi: 10.1111/all.14792. Epub 2021 Mar 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33629411</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8360103</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14792</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2507</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2507</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Cui, L.</style></author><author><style face="normal" font="default" size="100%">Yu, P.</style></author><author><style face="normal" font="default" size="100%">Guo, J.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Song, Z.</style></author><author><style face="normal" font="default" size="100%">Zhai, Z.</style></author><author><style face="normal" font="default" size="100%">Li, T.</style></author><author><style face="normal" font="default" size="100%">Wang, G.</style></author><author><style face="normal" font="default" size="100%">Sun, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Song, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.&#xD;Department of Allergy, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Proteomics and metabolomics of sputum reveal the potential impact of allergic rhinitis on asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2277-2280</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/05/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/metabolism/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Sputum/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Metabolomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38733207</style></accession-num><notes><style face="normal" font="default" size="100%">Yang, Yujuan&#xD;Cui, Limei&#xD;Yu, Pengyi&#xD;Guo, Jing&#xD;Wang, Jianwei&#xD;Wang, Hanrui&#xD;Song, Zheying&#xD;Zhai, Zhaoxue&#xD;Li, Tong&#xD;Wang, Guangkuo&#xD;Sun, Yuemei&#xD;Zhang, Yu&#xD;Song, Xicheng&#xD;eng&#xD;National Natural Science Foundation of China/&#xD;Medical and Health Science and Technology Development Program of Shandong Province/&#xD;Major Scientific and Technological Innovation Project of Shandong Province/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2277-2280. doi: 10.1111/all.16153. Epub 2024 May 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38733207</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16153</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>466</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">466</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ooka, T.</style></author><author><style face="normal" font="default" size="100%">Raita, Y.</style></author><author><style face="normal" font="default" size="100%">Fujiogi, M.</style></author><author><style face="normal" font="default" size="100%">Freishtat, R. J.</style></author><author><style face="normal" font="default" size="100%">Gerszten, R. E.</style></author><author><style face="normal" font="default" size="100%">Mansbach, J. M.</style></author><author><style face="normal" font="default" size="100%">Zhu, Z.</style></author><author><style face="normal" font="default" size="100%">Camargo, C. A., Jr.</style></author><author><style face="normal" font="default" size="100%">Hasegawa, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Health Science, University of Yamanashi, Chuo, Japan.&#xD;Center for Genetic Medicine Research and Division of Emergency Medicine Children&apos;s National Hospital, Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.&#xD;Division of Cardiovascular Medicine and Cardiovascular Institute, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.&#xD;Department of Pediatrics, Boston Children&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Proteomics endotyping of infants with severe bronchiolitis and risk of childhood asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3350-3361</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/05/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Syncytial Virus Infections/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Proteome</style></keyword><keyword><style face="normal" font="default" size="100%">*Bronchiolitis/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Syncytial Virus, Human</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinovirus</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Viruses</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchiolitis</style></keyword><keyword><style face="normal" font="default" size="100%">endotyping</style></keyword><keyword><style face="normal" font="default" size="100%">infants</style></keyword><keyword><style face="normal" font="default" size="100%">proteome</style></keyword><keyword><style face="normal" font="default" size="100%">relevant to this article to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35620861</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Bronchiolitis is the leading cause of hospitalization in U.S. infants and a major risk factor for childhood asthma. Growing evidence supports clinical heterogeneity within bronchiolitis. We aimed to identify endotypes of infant bronchiolitis by integrating clinical, virus, and serum proteome data, and examine their relationships with asthma development. METHODS: This is a multicenter prospective cohort study of infants hospitalized for physician-diagnosis of bronchiolitis. We identified bronchiolitis endotypes by applying unsupervised machine learning (clustering) approaches to integrated clinical, virus (respiratory syncytial virus [RSV], rhinovirus [RV]), and serum proteome data measured at hospitalization. We then examined their longitudinal association with the risk for developing asthma by age 6 years. RESULTS: In 140 infants hospitalized with bronchiolitis, we identified three endotypes: (1) clinical(atopic) virus(RV) proteome(NFkappaB-dysregulated) , (2) clinical(non-atopic) virus(RSV/RV) proteome(TNF-dysregulated) , and (3) clinical(classic) virus(RSV) proteome(NFkappaB/TNF-regulated) endotypes. Endotype 1 infants were characterized by high proportion of IgE sensitization and RV infection. These endotype 1 infants also had dysregulated NFkappaB pathways (FDR &lt; 0.001) and significantly higher risks for developing asthma (53% vs. 22%; adjOR 4.04; 95% CI, 1.49-11.0; p = 0.006), compared with endotype 3 (clinically resembling &quot;classic&quot; bronchiolitis). Likewise, endotype 2 infants were characterized by low proportion of IgE sensitization and high proportion of RSV or RV infection. These endotype 2 infants had dysregulated tumor necrosis factor (TNF)-mediated signaling pathway (FDR &lt;0.001) and significantly higher risks for developing asthma (44% vs. 22%; adjOR 2.71; 95% CI, 1.03-7.11, p = 0.04). CONCLUSION: In this multicenter cohort, integrated clustering of clinical, virus, and proteome data identified biologically distinct endotypes of bronchiolitis that have differential risks of asthma development.</style></abstract><notes><style face="normal" font="default" size="100%">Ooka, Tadao&#xD;Raita, Yoshihiko&#xD;Fujiogi, Michimasa&#xD;Freishtat, Robert J&#xD;Gerszten, Robert E&#xD;Mansbach, Jonathan M&#xD;Zhu, Zhaozhong&#xD;Camargo, Carlos A Jr&#xD;Hasegawa, Kohei&#xD;eng&#xD;R01 AI127507/AI/NIAID NIH HHS/&#xD;R01 AI148338/AI/NIAID NIH HHS/&#xD;R01 AI134940/AI/NIAID NIH HHS/&#xD;UH3 OD023253/OD/NIH HHS/&#xD;R01 AI137091/AI/NIAID NIH HHS/&#xD;K01 AI153558/AI/NIAID NIH HHS/&#xD;UG3 OD023253/OD/NIH HHS/&#xD;NH/NIH HHS/&#xD;Multicenter Study&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3350-3361. doi: 10.1111/all.15390. Epub 2022 Jun 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35620861</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9617778</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15390</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2628</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2628</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Molina-Jimenez, F.</style></author><author><style face="normal" font="default" size="100%">Ugalde-Trivino, L.</style></author><author><style face="normal" font="default" size="100%">Arias-Gonzalez, L.</style></author><author><style face="normal" font="default" size="100%">Armenteros, E.</style></author><author><style face="normal" font="default" size="100%">Relano-Ruperez, C.</style></author><author><style face="normal" font="default" size="100%">Casabona, S.</style></author><author><style face="normal" font="default" size="100%">Moreno-Monteagudo, J. A.</style></author><author><style face="normal" font="default" size="100%">Perez-Fernandez, M. T.</style></author><author><style face="normal" font="default" size="100%">Martin-Dominguez, V.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Pacheco, J.</style></author><author><style face="normal" font="default" size="100%">Laserna-Mendieta, E. J.</style></author><author><style face="normal" font="default" size="100%">Munoz-Hernandez, P.</style></author><author><style face="normal" font="default" size="100%">Garcia-Martinez, J.</style></author><author><style face="normal" font="default" size="100%">Munoz, J.</style></author><author><style face="normal" font="default" size="100%">Lucendo, A. J.</style></author><author><style face="normal" font="default" size="100%">Santander, C.</style></author><author><style face="normal" font="default" size="100%">Majano, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular Biology Unit, Hospital Universitario de la Princesa, Madrid, Spain.&#xD;Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (IIS-IP), Madrid, Spain.&#xD;Department of Gastroenterology, Hospital General de Tomelloso, Ciudad Real, Spain.&#xD;Instituto de Investigacion Sanitaria de Castilla-La Mancha (IDISCAM), Spain.&#xD;Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Madrid, Spain.&#xD;Department of Gastroenterology, Hospital Universitario de La Princesa, Madrid, Spain.&#xD;Clinical Laboratory, Hospital Universitario de La Princesa, Madrid, Spain.&#xD;Department of Pathology, Hospital Universitario de La Princesa, Madrid, Spain.&#xD;Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.&#xD;Cell Signalling and Clinical Proteomics Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.&#xD;Ikerbasque, Basque Foundation for Science, Bilbao, Spain.&#xD;Department of Cellular Biology, Faculty of Biology, Universidad Complutense de Madrid, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Proton pump inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction, and evaluation of treatment response</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3448-3463</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Proton Pump Inhibitors/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Esophagus/pathology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Proteome</style></keyword><keyword><style face="normal" font="default" size="100%">Biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">prediction treatment response</style></keyword><keyword><style face="normal" font="default" size="100%">protein signature</style></keyword><keyword><style face="normal" font="default" size="100%">proton pump inhibitors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39092539</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Recently, we have identified a dysregulated protein signature in the esophageal epithelium of eosinophilic esophagitis (EoE) patients including proteins associated with inflammation and epithelial barrier function; however, the effect of proton pump inhibitor (PPI) treatment on this signature is unknown. Herein, we used a proteomic approach to investigate: (1) whether PPI treatment alters the esophageal epithelium protein profile observed in EoE patients and (2) whether the protein signature at baseline predicts PPI response. METHODS: We evaluated the protein signature of esophageal biopsies using a cohort of adult EoE (n = 25) patients and healthy controls (C) (n = 10). In EoE patients, esophageal biopsies were taken before (pre) and after (post) an 8-week PPI treatment, determining the histologic response. Eosinophil count PostPPI was used to classify the patients: &gt;/=15 eosinophils/hpf as non-responders (non-responder) and &lt; 15 eosinophils/hpf as responders (R). Protein signature was determined and differentially accumulated proteins were characterized to identify altered biological processes and signaling pathways. RESULTS: Comparative analysis of differentially accumulated proteins between groups revealed common signatures between three groups of patients with inflammation (responder-PrePPI, non-responder-PrePPI, and non-responder-PostPPI) and without inflammation (controls and responder-PostPPI). PPI therapy almost reversed the EoE specific esophageal protein signature, which is enriched in pathways associated with inflammation and epithelial barrier function, in responder-PostPPI. Furthermore, we identified a set of candidate proteins to differentiate responder-PrePPI and non-responder-PrePPI EoE patients before treatment. CONCLUSION: These findings provide evidence that PPI therapy reverses the alterations in esophageal inflammatory and epithelial proteins characterizing EoE, thereby providing new insights into the mechanism of PPI clinical response. Interestingly, our results also suggest that PPI response could be predicted at baseline in EoE.</style></abstract><notes><style face="normal" font="default" size="100%">Molina-Jimenez, Francisca&#xD;Ugalde-Trivino, Lola&#xD;Arias-Gonzalez, Laura&#xD;Armenteros, Elisa&#xD;Relano-Ruperez, Carlos&#xD;Casabona, Sergio&#xD;Moreno-Monteagudo, Jose Andres&#xD;Perez-Fernandez, Maria Teresa&#xD;Martin-Dominguez, Veronica&#xD;Fernandez-Pacheco, Jennifer&#xD;Laserna-Mendieta, Emilio Jose&#xD;Munoz-Hernandez, Patricia&#xD;Garcia-Martinez, Jorge&#xD;Munoz, Javier&#xD;Lucendo, Alfredo J&#xD;Santander, Cecilio&#xD;Majano, Pedro&#xD;eng&#xD;Ministerio de Asuntos Economicos y Transformacion Digital, Gobierno de Espana/&#xD;Instituto de Salud Carlos III/&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3448-3463. doi: 10.1111/all.16261. Epub 2024 Aug 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39092539</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657045</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16261</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>518</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">518</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lins de Holanda Coelho, G.</style></author><author><style face="normal" font="default" size="100%">DunnGalvin, A.</style></author><author><style face="normal" font="default" size="100%">Greenhawt, M.</style></author><author><style face="normal" font="default" size="100%">Hourihane, J. O.</style></author><author><style face="normal" font="default" size="100%">Fleischer, D. M.</style></author><author><style face="normal" font="default" size="100%">Chen, G.</style></author><author><style face="normal" font="default" size="100%">Shaker, M.</style></author><author><style face="normal" font="default" size="100%">Campbell, D. E.</style></author><author><style face="normal" font="default" size="100%">Green, T. D.</style></author><author><style face="normal" font="default" size="100%">Begin, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Applied Psychology, University College Cork, Cork, Ireland.&#xD;Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Department of Paediatrics, Royal College of Surgeons in Ireland and Children&apos;s Health Ireland, Temple St Hospital, Dublin, Ireland.&#xD;Centre for Health Economics, Monash Business School, Monash University, Caulfield East, Vic., Australia.&#xD;Section of Allergy and Immunology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.&#xD;Dartmouth Geisel School of Medicine, Hanover, New Hampshire, USA.&#xD;DBV Technologies SA, Montrouge, France.&#xD;The Children&apos;s Hospital at Westmead, Sydney, NSW, Australia.&#xD;UPMC Children&apos;s Hospital of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.&#xD;CHU Sainte-Justine, Montreal, QC, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Psychometric parameters of food allergy quality of life during an allergen immunotherapy trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2770-2777</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/04/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Psychometrics</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Faqlq</style></keyword><keyword><style face="normal" font="default" size="100%">Irt</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">item response theory</style></keyword><keyword><style face="normal" font="default" size="100%">psychometrics</style></keyword><keyword><style face="normal" font="default" size="100%">DunnGalvin has received research grants from Aimmune Therapeutics, National</style></keyword><keyword><style face="normal" font="default" size="100%">Children&apos;s Research Centre, DBV Technologies, and Food Allergy Research and</style></keyword><keyword><style face="normal" font="default" size="100%">Resource Program, and other research support from Safefood Ireland, and has</style></keyword><keyword><style face="normal" font="default" size="100%">served as a consultant and/or advisory board member for Aimmune Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">Atlantia Clinical Trials in Food Ireland, and Anaphylaxis Ireland. Matthew</style></keyword><keyword><style face="normal" font="default" size="100%">Greenhawt is a consultant for Aquestive, is a member of physician/medical</style></keyword><keyword><style face="normal" font="default" size="100%">advisory boards for DBV Technologies, Sanofi/Regeneron, Nutricia, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Aquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello, and Prota, with all</style></keyword><keyword><style face="normal" font="default" size="100%">activity unrelated to vaccines/vaccine development or COVID-19 treatment, is an</style></keyword><keyword><style face="normal" font="default" size="100%">unpaid member of the scientific advisory council for the National Peanut Board</style></keyword><keyword><style face="normal" font="default" size="100%">and medical advisory board of the International Food Protein-Induced</style></keyword><keyword><style face="normal" font="default" size="100%">Enterocolitis Syndrome Association, is a member of the Brighton Collaboration</style></keyword><keyword><style face="normal" font="default" size="100%">Criteria Vaccine Anaphylaxis 2.0 working group, is the senior associate editor</style></keyword><keyword><style face="normal" font="default" size="100%">for the Annals of Allergy, Asthma, and Immunology, and is member of the Joint</style></keyword><keyword><style face="normal" font="default" size="100%">Taskforce on Allergy Practice Parameters. He has received honorarium for lectures</style></keyword><keyword><style face="normal" font="default" size="100%">from ImSci, MedLearningGroup, RMEI Medical Education, and multiple state/local</style></keyword><keyword><style face="normal" font="default" size="100%">allergy societies. He received past research support ending in 2020 from the</style></keyword><keyword><style face="normal" font="default" size="100%">Agency for Healthcare Quality and Research (K08-HS024599). Jonathan O&apos;B Hourihane</style></keyword><keyword><style face="normal" font="default" size="100%">reports advisory board fees, Aimmune Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">speakers bureau, Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Nutricia, and Mead Johnson</style></keyword><keyword><style face="normal" font="default" size="100%">grants to institution/research funding</style></keyword><keyword><style face="normal" font="default" size="100%">and clinical trials within past 2 years, Aimmune Therapeutics, Johnson&amp; Johnson,</style></keyword><keyword><style face="normal" font="default" size="100%">National Childrens&apos; Research Centre Ireland, Dublin Skin and Cancer Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Charity, Temple St Foundation, and Clemens von Pirquet Foundation. David M.</style></keyword><keyword><style face="normal" font="default" size="100%">Fleischer has received research support to his institution from DBV Technologies</style></keyword><keyword><style face="normal" font="default" size="100%">and Aimmune Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">reports clinical medical advisory board membership with</style></keyword><keyword><style face="normal" font="default" size="100%">DBV Technologies</style></keyword><keyword><style face="normal" font="default" size="100%">has served as a consultant for DBV Technologies, Allergenis,</style></keyword><keyword><style face="normal" font="default" size="100%">Aquestive Therapeutics, Aravax, Genentech, Nasus Pharma, and Intrommune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">and has received honorarium for lectures from DBV Technologies and</style></keyword><keyword><style face="normal" font="default" size="100%">royalties from UpToDate. Marcus Shaker has participated in research funded by DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, is a member of the Joint Task Force on Practice Parameters, is an</style></keyword><keyword><style face="normal" font="default" size="100%">associate editor for Annals of Allergy, Asthma, and Immunology, and serves on the</style></keyword><keyword><style face="normal" font="default" size="100%">Editorial Boards for the Journal of Allergy and Clinical Immunology In Practice</style></keyword><keyword><style face="normal" font="default" size="100%">and the Journal of Food Allergy. Philippe Begin has received grants through his</style></keyword><keyword><style face="normal" font="default" size="100%">institution from DBV Technologies during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from ALK, Novartis, Sanofi, Bausch Health, Aralez, and Pfizer</style></keyword><keyword><style face="normal" font="default" size="100%">and grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Sanofi, Novartis and the Canadian Allergy, Asthma, and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation outside the submitted work. The following authors have no conflicts of</style></keyword><keyword><style face="normal" font="default" size="100%">interest to disclose: Gang Chen and Gabriel Lins de Holanda Coelho.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35466405</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The Food Allergy Quality of Life Questionnaire-Parent Form (FAQLQ-PF) is a commonly used patient-reported outcome measure in food allergy (FA) research. It was developed before FA treatment clinical trials were commonplace and is used as a secondary outcome measure in pivotal FA treatment trials. We examined the psychometric properties of the FAQLQ-PF and its relevance to children with peanut allergy engaged in an epicutaneous immunotherapy (EPIT) clinical trial. METHODS: Analysis was performed on 26 universally answered items of the FAQLQ-PF, from assessments undertaken during the phase 3 PEPITES study (baseline, Month 12), which examined the safety and efficacy of EPIT for children with peanut allergy aged 4-11 years. Item response theory (IRT) was used to assess psychometric parameters of the FAQLQ-PF (i.e., discrimination, difficulty, and information). Confirmatory factor analysis was also employed; reliability was assessed using McDonald&apos;s omega (omega) and Cronbach&apos;s alpha (alpha). RESULTS: A total of 23 of 26 items presented very high discrimination levels (&gt;1.7), and all 26 fell within the recommended difficulty threshold (between -1.5 and 1.5). The items contributed a reasonable information level for their respective factors/subdomains. The measure also presented a marginally acceptable model fit for the 3-factor structure (e.g., comparative fit index = 0.88, Tucker-Lewis index = 0.87) and good reliability levels across time points (omega and alpha &gt; 0.90). CONCLUSIONS: Herein, we present a novel reanalysis of the FAQLQ-PF items using IRT. The longitudinal performance of individual items and subscales was corroborated, and items with the highest discrimination were identified, showing that the tool is suitable for longitudinal measurements in FA treatment trials.</style></abstract><notes><style face="normal" font="default" size="100%">Lins de Holanda Coelho, Gabriel&#xD;DunnGalvin, Audrey&#xD;Greenhawt, Matthew&#xD;Hourihane, Jonathan O&apos;B&#xD;Fleischer, David M&#xD;Chen, Gang&#xD;Shaker, Marcus&#xD;Campbell, Dianne E&#xD;Green, Todd D&#xD;Begin, Philippe&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2770-2777. doi: 10.1111/all.15323. Epub 2022 May 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35466405</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9546060</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15323</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2572</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2572</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Panganiban, R. A.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Lu, Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Asthma Research, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Division of Human Genetics, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Division of Allergy and Inflammation, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pyroptosis, gasdermins and allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2380-2395</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroptosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphate-Binding Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gasdermins</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">barrier</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Vesigen Therapeutics and Evantigen Inc. All other coauthors declare no competing</style></keyword><keyword><style face="normal" font="default" size="100%">interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39003568</style></accession-num><abstract><style face="normal" font="default" size="100%">Pyroptosis is an inflammatory form of programmed cell death that is distinct from necrosis and apoptosis. Pyroptosis is primarily mediated by the gasdermin family of proteins (GSDMA-E and PVJK), which, when activated by proteolytic cleavage, form pores in the plasma membrane, leading to cell death. While much of the past research on pyroptosis has focused on its role in cancer, metabolic disorders, and infectious diseases, recent experimental and observational studies have begun to implicate pyroptosis in allergic diseases. These studies suggest that gasdermin-mediated pyroptosis contributes to the development of allergic conditions and could offer novel targets for therapy. Here, we review our current understanding of pyroptosis with an emphasis on the role of gasdermins as executioners of pyroptosis and potential mediators to allergic disease. We highlight new discoveries that establish a mechanistic link between the biochemical actions of gasdermins and the onset of allergic diseases. Additionally, we discuss how pyroptosis and gasdermins might contribute to the dysfunction of epithelial barrier, a key factor believed to initiate the progression of various allergic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Panganiban, Ronald Allan&#xD;Nadeau, Kari C&#xD;Lu, Quan&#xD;eng&#xD;R01 ES029097/ES/NIEHS NIH HHS/&#xD;P01HL152953/HB/NHLBI NIH HHS/&#xD;P01 HL152953/HL/NHLBI NIH HHS/&#xD;R01HL139496/NH/NIH HHS/&#xD;R01 HL139496/HL/NHLBI NIH HHS/&#xD;U19AI104209/AI/NIAID NIH HHS/&#xD;Harvard T.H. Chan School of Public Health/&#xD;P42 ES030990/ES/NIEHS NIH HHS/&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2380-2395. doi: 10.1111/all.16236. Epub 2024 Jul 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39003568</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11368650</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16236</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2573</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2573</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Panganiban, R. A.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Lu, Q.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Asthma Research, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Division of Human Genetics, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Division of Allergy and Inflammation, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pyroptosis, gasdermins and allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2380-2395</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroptosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphate-Binding Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gasdermins</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">barrier</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Vesigen Therapeutics and Evantigen Inc. All other coauthors declare no competing</style></keyword><keyword><style face="normal" font="default" size="100%">interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39003568</style></accession-num><abstract><style face="normal" font="default" size="100%">Pyroptosis is an inflammatory form of programmed cell death that is distinct from necrosis and apoptosis. Pyroptosis is primarily mediated by the gasdermin family of proteins (GSDMA-E and PVJK), which, when activated by proteolytic cleavage, form pores in the plasma membrane, leading to cell death. While much of the past research on pyroptosis has focused on its role in cancer, metabolic disorders, and infectious diseases, recent experimental and observational studies have begun to implicate pyroptosis in allergic diseases. These studies suggest that gasdermin-mediated pyroptosis contributes to the development of allergic conditions and could offer novel targets for therapy. Here, we review our current understanding of pyroptosis with an emphasis on the role of gasdermins as executioners of pyroptosis and potential mediators to allergic disease. We highlight new discoveries that establish a mechanistic link between the biochemical actions of gasdermins and the onset of allergic diseases. Additionally, we discuss how pyroptosis and gasdermins might contribute to the dysfunction of epithelial barrier, a key factor believed to initiate the progression of various allergic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Panganiban, Ronald Allan&#xD;Nadeau, Kari C&#xD;Lu, Quan&#xD;eng&#xD;R01 ES029097/ES/NIEHS NIH HHS/&#xD;P01HL152953/HB/NHLBI NIH HHS/&#xD;P01 HL152953/HL/NHLBI NIH HHS/&#xD;R01HL139496/NH/NIH HHS/&#xD;R01 HL139496/HL/NHLBI NIH HHS/&#xD;U19AI104209/AI/NIAID NIH HHS/&#xD;Harvard T.H. Chan School of Public Health/&#xD;P42 ES030990/ES/NIEHS NIH HHS/&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2380-2395. doi: 10.1111/all.16236. Epub 2024 Jul 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39003568</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11368650</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16236</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2455</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2455</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spiric, J.</style></author><author><style face="normal" font="default" size="100%">Schulenborg, T.</style></author><author><style face="normal" font="default" size="100%">Holzhauser, T.</style></author><author><style face="normal" font="default" size="100%">Schuler, F.</style></author><author><style face="normal" font="default" size="100%">Bonertz, A.</style></author><author><style face="normal" font="default" size="100%">Lauer, I.</style></author><author><style face="normal" font="default" size="100%">Bartel, D.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author><author><style face="normal" font="default" size="100%">Mahler, V.</style></author><author><style face="normal" font="default" size="100%">Reuter, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergology Division, Central Method Development Section, Paul-Ehrlich-Institut, Langen, Germany.&#xD;Allergology Division, Allergology Quality Assessment Section, Paul-Ehrlich-Institut, Langen, Germany.&#xD;Allergology Division, Allergens Product Testing Section, Paul-Ehrlich-Institut, Langen, Germany.&#xD;Paul-Ehrlich-Institut, Langen, Germany.&#xD;Allergology Division, Paul-Ehrlich-Institut, Langen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quality control of allergen products with mass spectrometry part I: Positioning within the EU regulatory framework</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2088-2096</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Mass Spectrometry/methods/standards</style></keyword><keyword><style face="normal" font="default" size="100%">*European Union</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality Control</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Standards</style></keyword><keyword><style face="normal" font="default" size="100%">allergen mass units</style></keyword><keyword><style face="normal" font="default" size="100%">allergen standardization</style></keyword><keyword><style face="normal" font="default" size="100%">batch testing</style></keyword><keyword><style face="normal" font="default" size="100%">consistence testing</style></keyword><keyword><style face="normal" font="default" size="100%">mass spectrometry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38425053</style></accession-num><abstract><style face="normal" font="default" size="100%">Mass spectrometry (MS) has advanced greatly and many of its applications are ready for utilization within regulatory procedures and could significantly contribute to overcome challenges in standardization of allergen products. It seems sensible to discuss MS within the regulatory framework, before addressing technical questions. While the application to purified proteins is well established from product development to manufacturer&apos;s release analytics, its application to complex products such as allergen products is still under development. It needs to be determined where it can complement or replace established methods or where MS offers limited improvement. Despite its technical appeal and versatility, currently MS is mentioned in regulatory guidelines only as one possible measurement method. For example, no specific MS method is given in the European Pharmacopoeia. We discuss applications of MS within the EU regulatory framework. This includes their advantages and disadvantages and their positioning between research, characterization, manufacturer&apos;s release analytics and official batch testing. We discuss the qualitative detection of single and multiple allergens as proof of identity, qualitative to semi-quantitative protein profiles for batch to batch consistency testing, and quantification of allergens to state mass units of allergens. MS may also facilitate standardization of allergen products, reference products and reference standards.</style></abstract><notes><style face="normal" font="default" size="100%">Spiric, Jelena&#xD;Schulenborg, Thomas&#xD;Holzhauser, Thomas&#xD;Schuler, Frank&#xD;Bonertz, Andreas&#xD;Lauer, Iris&#xD;Bartel, Detlef&#xD;Vieths, Stefan&#xD;Mahler, Vera&#xD;Reuter, Andreas&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2088-2096. doi: 10.1111/all.16080. Epub 2024 Feb 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38425053</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16080</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>412</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">412</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Miyabe, Y.</style></author><author><style face="normal" font="default" size="100%">Tomizawa, H.</style></author><author><style face="normal" font="default" size="100%">Saito, H.</style></author><author><style face="normal" font="default" size="100%">Yamada, T.</style></author><author><style face="normal" font="default" size="100%">Shiina, K.</style></author><author><style face="normal" font="default" size="100%">Koizumi, K.</style></author><author><style face="normal" font="default" size="100%">Kawasaki, Y.</style></author><author><style face="normal" font="default" size="100%">Suzuki, S.</style></author><author><style face="normal" font="default" size="100%">Fukuchi, M.</style></author><author><style face="normal" font="default" size="100%">Ueki, S.</style></author><author><style face="normal" font="default" size="100%">Ebihara, T.</style></author><author><style face="normal" font="default" size="100%">Yamada, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Akita University Graduate School of Medicine, Akita, Japan.&#xD;Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.&#xD;Department of Medical Biology, Akita University Graduate School of Medicine, Akita, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quantification of Aspergillus fumigatus antigen Asp f 1 in airway tissue and allergic inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3154-3156</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/07/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Fungal</style></keyword><keyword><style face="normal" font="default" size="100%">*Aspergillosis, Allergic Bronchopulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">*Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35793422</style></accession-num><notes><style face="normal" font="default" size="100%">Miyabe, Yui&#xD;Tomizawa, Hiroki&#xD;Saito, Hidekazu&#xD;Yamada, Toshiki&#xD;Shiina, Kazuhiro&#xD;Koizumi, Koh&#xD;Kawasaki, Yohei&#xD;Suzuki, Shinsuke&#xD;Fukuchi, Mineyo&#xD;Ueki, Shigeharu&#xD;Ebihara, Takashi&#xD;Yamada, Takechiyo&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3154-3156. doi: 10.1111/all.15428. Epub 2022 Jul 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35793422</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15428</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2731</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2731</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van Nunen, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Northern Clinical School, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Northern Beaches Clinical School, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.&#xD;Leadership Group &amp; Co-chair Insect Allergy Stream, National Allergy Centre of Excellence, Parkville, Victoria, Australia.&#xD;Department of Clinical Immunology and Allergy, Northern Beaches Hospital, Sydney, New South Wales, Australia.&#xD;Convenor, TiARA (Tick-induced Allergies Research &amp; Awareness), Sydney, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quantifying the allergenic potency of mammalian meat sources, an important step in providing a framework for improved management of mammalian meat allergy after tick bite (alpha-gal syndrome/AGS)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">9-11</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/11/04</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39495100</style></accession-num><notes><style face="normal" font="default" size="100%">van Nunen, Sheryl&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):9-11. doi: 10.1111/all.16381. Epub 2024 Nov 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39495100</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16381</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2327</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2327</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hamelmann, E.</style></author><author><style face="normal" font="default" size="100%">Hammerby, E.</style></author><author><style face="normal" font="default" size="100%">Scharling, K. S.</style></author><author><style face="normal" font="default" size="100%">Pedersen, M.</style></author><author><style face="normal" font="default" size="100%">Okkels, A.</style></author><author><style face="normal" font="default" size="100%">Schmitt, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Children&apos;s Center Bethel, Bielefeld University, Bielefeld, Germany.&#xD;ALK, Horsholm, Germany.&#xD;EY Godkendt Revisionspartnerselskab, Frederiksberg, Germany.&#xD;Center for Evidence-based Healthcare, TU Dresden, Dresden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1018-1027</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/12/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/prevention &amp; control/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">cost-effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38146654</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic rhinitis (AR) is a chronic inflammatory disease of the upper airway, which progresses into allergic asthma (AA) in up to 45% of children. This analysis aimed to investigate clinical and economic benefits of sublingual allergen immunotherapy (SLIT tablets) initiated early in childhood for the treatment of AR by quantifying the long-term reduction in new cases of AA. METHODS: A Markov model was developed to estimate the long-term effects of SLIT tablets on the risk of developing asthma. Key parameters were primarily based on data from the GRAZAX(R) Asthma Prevention trial and included the age- and treatment-dependent risk of developing AA as well as annual probabilities of progression/remission in AR severity. Healthcare costs were estimated using data from the REACT study. RESULTS: In a modelled cohort of children with moderate-to-severe seasonal AR initiated on SLIT tablets at ages 7 and 12, 24% and 29%, respectively, develop AA during a 20-year period. In comparison, when initiated at age 5, 19% develop AA. Additionally, initiation of SLIT tablets at age 5 is associated with a total healthcare cost of EUR 20,429 per patient, whereas initiation at ages 7 and 12 is associated with, respectively, EUR 21,050 and EUR 22,379 per patient 20 years after AR diagnosis. CONCLUSION: Initiation of SLIT tablets in early childhood is associated with a clinically meaningful and permanent reduction in new cases of AA and lower healthcare costs among children with AR. This finding supports the clinical relevance of initiating SLIT tablets early for children with AR to obtain long-term clinical benefits.</style></abstract><notes><style face="normal" font="default" size="100%">Hamelmann, Eckard&#xD;Hammerby, Eva&#xD;Scharling, Katrine Skaarup&#xD;Pedersen, Mikkel&#xD;Okkels, Anna&#xD;Schmitt, Jochen&#xD;eng&#xD;ALK, Boge Alle 1, 2970 Horsholm/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):1018-1027. doi: 10.1111/all.15985. Epub 2023 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38146654</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15985</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1974</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1974</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, A. S.</style></author><author><style face="normal" font="default" size="100%">Parsons, E. S.</style></author><author><style face="normal" font="default" size="100%">Chang, I.</style></author><author><style face="normal" font="default" size="100%">Dunham, D.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Environmental Studies, Harvard T.H. Chan School of Public Health, Cambridge, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quantitative analysis of urinary cytokines in food-allergic and healthy individuals</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2523-2526</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/03/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Food</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36905306</style></accession-num><notes><style face="normal" font="default" size="100%">Lee, Alexandra S&#xD;Parsons, Ella S&#xD;Chang, Iris&#xD;Dunham, Diane&#xD;Chinthrajah, R Sharon&#xD;Nadeau, Kari C&#xD;eng&#xD;R01 HL118612/HL/NHLBI NIH HHS/&#xD;R01 AI140134/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2523-2526. doi: 10.1111/all.15707. Epub 2023 Mar 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36905306</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15707</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2324</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2324</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Takada, K.</style></author><author><style face="normal" font="default" size="100%">Fukuie, T.</style></author><author><style face="normal" font="default" size="100%">Ogita, H.</style></author><author><style face="normal" font="default" size="100%">Hirai, S.</style></author><author><style face="normal" font="default" size="100%">Toyokuni, K.</style></author><author><style face="normal" font="default" size="100%">Yamamoto-Hanada, K.</style></author><author><style face="normal" font="default" size="100%">Ohya, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Center, National Center for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quantitative risk assessment of egg-white, milk and wheat in infants</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">533-536</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/12/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Triticum/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Milk/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Egg Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38152894</style></accession-num><notes><style face="normal" font="default" size="100%">Takada, Kazuma&#xD;Fukuie, Tatsuki&#xD;Ogita, Hiroya&#xD;Hirai, Seiko&#xD;Toyokuni, Kenji&#xD;Yamamoto-Hanada, Kiwako&#xD;Ohya, Yukihiro&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):533-536. doi: 10.1111/all.15991. Epub 2023 Dec 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38152894</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15991</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1097</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1097</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Savoure, M.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Burte, E.</style></author><author><style face="normal" font="default" size="100%">Just, J.</style></author><author><style face="normal" font="default" size="100%">Pin, I.</style></author><author><style face="normal" font="default" size="100%">Siroux, V.</style></author><author><style face="normal" font="default" size="100%">Orsi, L.</style></author><author><style face="normal" font="default" size="100%">Jacquemin, B.</style></author><author><style face="normal" font="default" size="100%">Nadif, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Equipe d&apos;Epidemiologie Respiratoire Integrative, CESP, Villejuif, France.&#xD;French Environment and Energy Management Agency, Angers, France.&#xD;Centre de l&apos;Asthme et des Allergies, APHP, Hopital Trousseau, UMPC, Paris 6, Paris, France.&#xD;Univ. Grenoble Alpes, Inserm, CNRS, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, IAB, Grenoble, France.&#xD;CHU de Grenoble-Alpes, Pediatrie, Grenoble, France.&#xD;Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en sante, environnement et travail) - UMR_S 1085, Rennes, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Questionnaire as an alternative of skin prick tests to differentiate allergic from non-allergic rhinitis in epidemiological studies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2291-2294</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/03/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiologic Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33711176</style></accession-num><notes><style face="normal" font="default" size="100%">Savoure, Marine&#xD;Bousquet, Jean&#xD;Burte, Emilie&#xD;Just, Jocelyne&#xD;Pin, Isabelle&#xD;Siroux, Valerie&#xD;Orsi, Laurent&#xD;Jacquemin, Benedicte&#xD;Nadif, Rachel&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2291-2294. doi: 10.1111/all.14812. Epub 2021 Mar 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33711176</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14812</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3212</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3212</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shimamura, A.</style></author><author><style face="normal" font="default" size="100%">Kojima, R.</style></author><author><style face="normal" font="default" size="100%">Ishii, H.</style></author><author><style face="normal" font="default" size="100%">Matsuoka, T.</style></author><author><style face="normal" font="default" size="100%">Ikeda, H.</style></author><author><style face="normal" font="default" size="100%">Sakurai, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, University of Yamanashi, Yamanashi, Japan.&#xD;Department of Epidemiology and Environmental Medicine, University of Yamanashi, Yamanashi, Japan.&#xD;Department of Pediatrics, Yamanashi Kosei Hospital, Yamanashi, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Questionnaire Survey on Loquat-Induced Oral Allergy Syndrome in School Children in Yamanashi, Japan</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pollen</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 3</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41340423</style></accession-num><notes><style face="normal" font="default" size="100%">Shimamura, Ayumi&#xD;Kojima, Reiji&#xD;Ishii, Hiroki&#xD;Matsuoka, Tomokazu&#xD;Ikeda, Hisatake&#xD;Sakurai, Daiju&#xD;eng&#xD;University of Yamanashi/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec 3. doi: 10.1111/all.70177.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41340423</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70177</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>90</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">90</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jeong, H.</style></author><author><style face="normal" font="default" size="100%">Lee, N.</style></author><author><style face="normal" font="default" size="100%">Uhm, C.</style></author><author><style face="normal" font="default" size="100%">Cho, K.</style></author><author><style face="normal" font="default" size="100%">Oh, H.</style></author><author><style face="normal" font="default" size="100%">Oh, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, K.</style></author><author><style face="normal" font="default" size="100%">Kim, H. L.</style></author><author><style face="normal" font="default" size="100%">Goldenring, J. R.</style></author><author><style face="normal" font="default" size="100%">Lim, K. M.</style></author><author><style face="normal" font="default" size="100%">Park, C. O.</style></author><author><style face="normal" font="default" size="100%">Nam, K. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Severance Biomedical Science Institute, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea.&#xD;Department of Dermatology, Cutaneous Biology Research Institute, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea.&#xD;Epithelial Biology Center, Nashville VA Medical Center, Department of Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.&#xD;College of Pharmacy, Ewha Womans University, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">RAB25 coordinates filaggrin-containing keratohyalin granule maturation and affects atopic dermatitis severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1007-1019</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/11/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Actins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Intermediate Filament Proteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">rab GTP-Binding Proteins/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin</style></keyword><keyword><style face="normal" font="default" size="100%">Keratohyalin granule</style></keyword><keyword><style face="normal" font="default" size="100%">Rab25</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36383036</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Keratohyalin granules (KHGs) supply the critical epidermal protein constituents such as filaggrin for maintaining skin barrier function during epidermal differentiation; however, their regulating mechanism remains largely unelucidated. METHODS: To investigate the role of Ras-related protein Rab-25 (RAB25) expression in skin disease, we utilized skin specimens of patients with moderate-to-severe atopic dermatitis (AD) and healthy controls. To investigate the susceptibility of Rab25 knockout mice to AD, we established an oxazolone-induced AD model. RESULTS: We investigated the role of RAB25 in KHG maturation and AD. RAB25-deficient mice showed a disrupted stratum corneum along with skin barrier dysfunction, decreased KHG production, and abnormal KHG processing. Consistently, in the human keratinocyte cell line HaCaT, RAB25 co-expressed with filaggrin-containing KHG and RAB25 silencing impaired KHG formation, which was attributable to abnormal actin dynamics. Most importantly, RAB25 expression was severely downregulated in the skin lesions of patients with AD, which was strongly correlated with disease severity scores. CONCLUSIONS: RAB25 coordinates KHG homeostasis by regulating actin dynamics and is critical for epidermal differentiation and the pathophysiology of AD.</style></abstract><notes><style face="normal" font="default" size="100%">Jeong, Haengdueng&#xD;Lee, Nakyum&#xD;Uhm, Chanyang&#xD;Cho, Kyungrae&#xD;Oh, Heeju&#xD;Oh, Yeseul&#xD;Zhang, KeLun&#xD;Kim, Hye Li&#xD;Goldenring, James R&#xD;Lim, Kyung-Min&#xD;Park, Chang Ook&#xD;Nam, Ki Taek&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):1007-1019. doi: 10.1111/all.15582. Epub 2022 Nov 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36383036</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15582</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1350</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1350</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Allam, Vsrr</style></author><author><style face="normal" font="default" size="100%">Faiz, A.</style></author><author><style face="normal" font="default" size="100%">Lam, M.</style></author><author><style face="normal" font="default" size="100%">Rathnayake, S. N. H.</style></author><author><style face="normal" font="default" size="100%">Ditz, B.</style></author><author><style face="normal" font="default" size="100%">Pouwels, S. D.</style></author><author><style face="normal" font="default" size="100%">Brandsma, C. A.</style></author><author><style face="normal" font="default" size="100%">Timens, W.</style></author><author><style face="normal" font="default" size="100%">Hiemstra, P. S.</style></author><author><style face="normal" font="default" size="100%">Tew, G. W.</style></author><author><style face="normal" font="default" size="100%">Neighbors, M.</style></author><author><style face="normal" font="default" size="100%">Grimbaldeston, M.</style></author><author><style face="normal" font="default" size="100%">van den Berge, M.</style></author><author><style face="normal" font="default" size="100%">Donnelly, S.</style></author><author><style face="normal" font="default" size="100%">Phipps, S.</style></author><author><style face="normal" font="default" size="100%">Bourke, J. E.</style></author><author><style face="normal" font="default" size="100%">Sukkar, M. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Graduate School of Health, Faculty of Health, The University of Technology Sydney, Ultimo, NSW, Australia.&#xD;School of Life Sciences, Faculty of Science, The University of Technology Sydney, Ultimo, NSW, Australia.&#xD;Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Biomedicine Discovery Institute and Department of Pharmacology, School of Biomedical Sciences, Monash University, Melbourne, Vic., Australia.&#xD;Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.&#xD;OMNI-Biomarker Development, Genentech Inc, South San Francisco, CA, USA.&#xD;QIMR Berghofer Medical Research Institute, Herston, Qld, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">RAGE and TLR4 differentially regulate airway hyperresponsiveness: Implications for COPD</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1123-1135</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/08/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mitogen-Activated Protein Kinases</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor for Advanced Glycation End Products/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Smoking</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 4/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default" size="100%">chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default" size="100%">cigarette smoke</style></keyword><keyword><style face="normal" font="default" size="100%">receptor for advanced glycation end products</style></keyword><keyword><style face="normal" font="default" size="100%">toll-like receptor 4</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32799375</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The receptor for advanced glycation end products (RAGE) and Toll-like receptor 4 (TLR4) is implicated in COPD. Although these receptors share common ligands and signalling pathways, it is not known whether they act in concert to drive pathological processes in COPD. We examined the impact of RAGE and/or TLR4 gene deficiency in a mouse model of COPD and also determined whether expression of these receptors correlates with airway neutrophilia and airway hyperresponsiveness (AHR) in COPD patients. METHODS: We measured airway inflammation and AHR in wild-type, RAGE(-/-) , TLR4(-/-) and TLR4(-/-) RAGE(-/-) mice following acute exposure to cigarette smoke (CS). We also examined the impact of smoking status on AGER (encodes RAGE) and TLR4 bronchial gene expression in patients with and without COPD. Finally, we determined whether expression of these receptors correlates with airway neutrophilia and AHR in COPD patients. RESULTS: RAGE(-/-) mice were protected against CS-induced neutrophilia and AHR. In contrast, TLR4(-/-) mice were not protected against CS-induced neutrophilia and had more severe CS-induced AHR. TLR4(-/-) RAGE(-/-) mice were not protected against CS-induced neutrophilia but were partially protected against CS-induced mediator release and AHR. Current smoking was associated with significantly lower AGER and TLR4 expression irrespective of COPD status, possibly reflecting negative feedback regulation. However, consistent with preclinical findings, AGER expression correlated with higher sputum neutrophil counts and more severe AHR in COPD patients. TLR4 expression did not correlate with neutrophilic inflammation or AHR. CONCLUSIONS: Inhibition of RAGE but not TLR4 signalling may protect against airway neutrophilia and AHR in COPD.</style></abstract><notes><style face="normal" font="default" size="100%">Allam, Venkata Sita Rama Raju&#xD;Faiz, Alen&#xD;Lam, Maggie&#xD;Rathnayake, Senani N H&#xD;Ditz, Benedikt&#xD;Pouwels, Simon D&#xD;Brandsma, Corry-Anke&#xD;Timens, Wim&#xD;Hiemstra, Pieter S&#xD;Tew, Gaik W&#xD;Neighbors, Margaret&#xD;Grimbaldeston, Michele&#xD;van den Berge, Maarten&#xD;Donnelly, Sheila&#xD;Phipps, Simon&#xD;Bourke, Jane E&#xD;Sukkar, Maria B&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1123-1135. doi: 10.1111/all.14563. Epub 2020 Oct 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32799375</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14563</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1301</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1301</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rauer, D.</style></author><author><style face="normal" font="default" size="100%">Gilles, S.</style></author><author><style face="normal" font="default" size="100%">Wimmer, M.</style></author><author><style face="normal" font="default" size="100%">Frank, U.</style></author><author><style face="normal" font="default" size="100%">Mueller, C.</style></author><author><style face="normal" font="default" size="100%">Musiol, S.</style></author><author><style face="normal" font="default" size="100%">Vafadari, B.</style></author><author><style face="normal" font="default" size="100%">Aglas, L.</style></author><author><style face="normal" font="default" size="100%">Ferreira, F.</style></author><author><style face="normal" font="default" size="100%">Schmitt-Kopplin, P.</style></author><author><style face="normal" font="default" size="100%">Durner, J.</style></author><author><style face="normal" font="default" size="100%">Winkler, J. B.</style></author><author><style face="normal" font="default" size="100%">Ernst, D.</style></author><author><style face="normal" font="default" size="100%">Behrendt, H.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Alessandrini, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum Munchen, Augsburg, Germany.&#xD;Center of Allergy &amp; Environment (ZAUM), Technical University of Munich (TUM) and Helmholtz Zentrum Munchen, Munich, Germany.&#xD;Members of the German Center of Lung Research (DZL), Munich, Germany.&#xD;Institute of Biochemical Plant Pathology (BIOP), Helmholtz Zentrum Munchen, Neuherberg, Germany.&#xD;BGC, Research Unit Analytical BioGeoChemistry, Helmholtz Zentrum Munchen, Neuherberg, Germany.&#xD;Department of Biosciences, University of Salzburg, Salzburg, Austria.&#xD;Research Unit Environmental Simulation, Institute of Biochemical Plant Pathology, Helmholtz Zentrum Munchen, Neuherberg, Germany.&#xD;Outpatient Clinic for Environmental Medicine, University Clinic Augsburg, Augsburg, Germany.&#xD;Christine-Kuhne Center for Allergy Research and Education (CK-Care), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ragweed plants grown under elevated CO(2) levels produce pollen which elicit stronger allergic lung inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1718-1730</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Ambrosia</style></keyword><keyword><style face="normal" font="default" size="100%">*Carbon Dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">allergic lung inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">carbon dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">climate change</style></keyword><keyword><style face="normal" font="default" size="100%">pollen metabolome</style></keyword><keyword><style face="normal" font="default" size="100%">ragweed</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33037672</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Common ragweed has been spreading as a neophyte in Europe. Elevated CO(2) levels, a hallmark of global climate change, have been shown to increase ragweed pollen production, but their effects on pollen allergenicity remain to be elucidated. METHODS: Ragweed was grown in climate-controlled chambers under normal (380 ppm, control) or elevated (700 ppm, based on RCP4.5 scenario) CO(2) levels. Aqueous pollen extracts (RWE) from control- or CO(2) -pollen were administered in vivo in a mouse model for allergic disease (daily for 3-11 days, n = 5) and employed in human in vitro systems of nasal epithelial cells (HNECs), monocyte-derived dendritic cells (DCs), and HNEC-DC co-cultures. Additionally, adjuvant factors and metabolites in control- and CO(2) -RWE were investigated using ELISA and untargeted metabolomics. RESULTS: In vivo, CO(2) -RWE induced stronger allergic lung inflammation compared to control-RWE, as indicated by lung inflammatory cell infiltrate and mediators, mucus hypersecretion, and serum total IgE. In vitro, HNECs stimulated with RWE increased indistinctively the production of pro-inflammatory cytokines (IL-8, IL-1beta, and IL-6). In contrast, supernatants from CO(2) -RWE-stimulated HNECs, compared to control-RWE-stimulated HNECS, significantly increased TNF and decreased IL-10 production in DCs. Comparable results were obtained by stimulating DCs directly with RWEs. The metabolome analysis revealed differential expression of secondary plant metabolites in control- vs CO(2) -RWE. Mixes of these metabolites elicited similar responses in DCs as compared to respective RWEs. CONCLUSION: Our results indicate that elevated ambient CO(2) levels elicit a stronger RWE-induced allergic response in vivo and in vitro and that RWE increased allergenicity depends on the interplay of multiple metabolites.</style></abstract><notes><style face="normal" font="default" size="100%">Rauer, Denise&#xD;Gilles, Stefanie&#xD;Wimmer, Maria&#xD;Frank, Ulrike&#xD;Mueller, Constanze&#xD;Musiol, Stephanie&#xD;Vafadari, Behnam&#xD;Aglas, Lorenz&#xD;Ferreira, Fatima&#xD;Schmitt-Kopplin, Philippe&#xD;Durner, Jorg&#xD;Winkler, Jana Barbro&#xD;Ernst, Dieter&#xD;Behrendt, Heidrun&#xD;Schmidt-Weber, Carsten B&#xD;Traidl-Hoffmann, Claudia&#xD;Alessandrini, Francesca&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1718-1730. doi: 10.1111/all.14618. Epub 2020 Nov 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33037672</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14618</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2405</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2405</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Parke, L.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, H. M.</style></author><author><style face="normal" font="default" size="100%">Kjaer, H. F.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomized, double-blind placebo-controlled study on the efficacy of Omalizumab on food allergy threshold in children with severe food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">964-976</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/02/17 21:42</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Food</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">threshold value</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38366983</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food allergy is common in childhood with some children having a low threshold and being difficult to protect from accidental ingestion of the offending food. Therapies for this potentially life-threatening condition are highly needed. The aim of this study was to evaluate the efficacy of Omalizumab in food-allergic children. METHODS: This is a single-center, double-blind, placebo-controlled study. Food allergic children with a cumulative threshold &lt;/=443 mg food protein at DBPCFC were randomized to Omalizumab (asthma dose) or placebo (3:1). After 3 months, a second DBPCFC was performed (steps 3, 10, 30, 100, 300, 1000, and 3000 mg food protein), followed by a separate open challenge up to 10,000 and 30,000 mg food protein if negative. Responders were defined as &gt;/=2-step increases in threshold. Non-responders received high-dose Omalizumab. A third DBPCFC was performed after 6 months. Skin testing, blood samples, and the severity of atopic co-morbidity were registered during the study and 3 months after treatment. RESULTS: In total, 20 children were evaluated at 3 months (14 Omalizumab, 6 placebo). All treated with Omalizumab increased their threshold at least two steps and with a significant difference between the Omalizumab and the placebo group (p = .003), although the intended number of included children was not reached. The threshold before Omalizumab treatment was 13-443 mg food protein while the threshold after 3 months of treatment increased up to 44,000 mg (1143-44,000). In the placebo group, two children improved threshold during the study. CONCLUSION: An increase in the threshold level during Omalizumab treatment significantly improve patient safety and protected all children against small amount of allergen.</style></abstract><notes><style face="normal" font="default" size="100%">Mortz, Charlotte G&#xD;Parke, Louise&#xD;Rasmussen, Helene M&#xD;Kjaer, Henrik Fomsgaard&#xD;Bindslev-Jensen, Carsten&#xD;eng&#xD;Novartis/&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):964-976. doi: 10.1111/all.16046. Epub 2024 Feb 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38366983</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16046</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2269</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2269</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Zeyen, C.</style></author><author><style face="normal" font="default" size="100%">Raskopf, E.</style></author><author><style face="normal" font="default" size="100%">Acikel, C.</style></author><author><style face="normal" font="default" size="100%">Sahin, H.</style></author><author><style face="normal" font="default" size="100%">Allekotte, S.</style></author><author><style face="normal" font="default" size="100%">Cuevas, M.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Subiza, J. L.</style></author><author><style face="normal" font="default" size="100%">Casanovas, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ClinCompetence Cologne GmbH, Cologne, Germany.&#xD;Faculty of Medicine, Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany.&#xD;Department of Dermatology, Venereology and Allergology, Division of Evidence-Based Medicine (dEBM), Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Carl Gustav Carus Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine (and University Hospital), Technische Universitat Dresden, Dresden, Germany.&#xD;Allergy and Clinical Immunology Section, Imperial College London, London, UK.&#xD;Inmunotek S.L., Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomized, double-blind, placebo-controlled trial with mannan-conjugated birch pollen allergoids</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">990-1000</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/10/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergoids</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Betula</style></keyword><keyword><style face="normal" font="default" size="100%">Mannans</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergoid</style></keyword><keyword><style face="normal" font="default" size="100%">birch pollen</style></keyword><keyword><style face="normal" font="default" size="100%">combined symptom and medication score</style></keyword><keyword><style face="normal" font="default" size="100%">mannan conjugate</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37822222</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: There is still great need to develop new strategies to improve the efficacy of allergen immunotherapies with optimal safety standards for patients. A new promising approach is to couple allergoids to mannan. The objective of this phase IIa/IIb study was to identify the optimal dose of mannan-conjugated birch pollen allergoids for the short-course treatment of birch pollen-induced allergic rhinoconjunctivitis. METHODS: For this prospective, randomized, double-blind, placebo-controlled, dose-finding study, 246 birch pollen-allergic adults received 0.5 mL placebo or 1000, 3000 or 10,000 mTU/mL of mannan-conjugated birch pollen allergoids at five pre-seasonal visits. Efficacy was assessed by comparing allergic rhinoconjunctivitis symptoms and use of anti-allergic medication during the peak of the birch pollen season 2020. Immunologic, tolerability and safety effects were also analysed. RESULTS: The highest dose of mannan-conjugated birch pollen allergoids reduced the combined symptom and medication score during the peak birch pollen season by a median of 24.7% compared to placebo. The production of Bet v 1 specific IgG4 significantly increased in a dose-dependent manner (3.6- and 4.5-fold) in the 3000 and 10,000 mTU/mL groups. The Bet v 1 specific IgE/IgG4 ratio was also strongly reduced (up to -70%). No fatalities nor serious adverse events were reported, and no adrenaline was used. In total, four systemic reactions occurred (two grade I and two grade II). CONCLUSION: All doses of mannan-conjugated birch pollen allergoids can be considered as safe. Since the application of 10,000 mTU/mL resulted in the highest efficacy, this dose qualifies for further investigation.</style></abstract><notes><style face="normal" font="default" size="100%">Mosges, Ralph&#xD;Zeyen, Christoph&#xD;Raskopf, Esther&#xD;Acikel, Cengizhan&#xD;Sahin, Hacer&#xD;Allekotte, Silke&#xD;Cuevas, Mandy&#xD;Shamji, Mohamed H&#xD;Subiza, Jose Luis&#xD;Casanovas, Miguel&#xD;eng&#xD;Inmunotek/&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):990-1000. doi: 10.1111/all.15910. Epub 2023 Oct 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37822222</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15910</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2580</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2580</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez-Sanchez, N.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author><author><style face="normal" font="default" size="100%">Canas, J. A.</style></author><author><style face="normal" font="default" size="100%">de Santa Maria-Garcia, R. S.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, J.</style></author><author><style face="normal" font="default" size="100%">Andugar-Moreno, M.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Gomez, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Clinical Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-Plataforma BIONAND (IBIMA-BIONAND), Malaga, Spain.&#xD;Medicine Department, Universidad de Malaga (UMA), Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reaction severity and peach threshold amount during oral challenge in nonspecific lipid transfer protein allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3534-3536</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/07/09</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38979766</style></accession-num><notes><style face="normal" font="default" size="100%">Perez-Sanchez, Natalia&#xD;Rondon, Carmen&#xD;Canas, Jose Antonio&#xD;de Santa Maria-Garcia, Rocio Saenz&#xD;Rodriguez, Julia&#xD;Andugar-Moreno, Marta&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;Gomez, Francisca&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3534-3536. doi: 10.1111/all.16228. Epub 2024 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38979766</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16228</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2504</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2504</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Winther, L.</style></author><author><style face="normal" font="default" size="100%">Curtz, A. C.</style></author><author><style face="normal" font="default" size="100%">Domokos, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Clinic, Department of Dermatology and Allergy, Copenhagen University Hospital-Gentofte, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real world study of grass pollen immunotherapy-Similar efficacy of SCIT and SLIT</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2280-2282</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Poaceae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38747116</style></accession-num><notes><style face="normal" font="default" size="100%">Winther, Lone&#xD;Curtz, Anne Caroline&#xD;Domokos, Zsuzsa&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2280-2282. doi: 10.1111/all.16159. Epub 2024 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38747116</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16159</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3058</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3058</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Horn, A.</style></author><author><style face="normal" font="default" size="100%">Knulst, A. C.</style></author><author><style face="normal" font="default" size="100%">Demoly, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.&#xD;ENT Practice Am Neckar Dres. Horn &amp; Choudry, Heidelberg, Germany.&#xD;Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.&#xD;Allergy Unit, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France.&#xD;IDESP and PREMEDICAL, University of Montpellier - Inserm - Inria, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-Life Clinical Experience With SQ Grass, Tree, Ragweed, and House Dust Mite Sublingual Immunotherapy Tablets: A Review of Evidence From Non-Interventional Studies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3290-3301</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/09/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Ambrosia/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Poaceae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Trees/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">non-interventional</style></keyword><keyword><style face="normal" font="default" size="100%">real-life effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy (SLIT)-tablet</style></keyword><keyword><style face="normal" font="default" size="100%">purposes from ALK-Abello A/S, AstraZeneca, Chiesi, Menarini, GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">Puressentiel, Stallergenes Greer, Thermo Fisher Scientific, Viatris, and Zambon.</style></keyword><keyword><style face="normal" font="default" size="100%">Christer Janson: has served on an advisory board and/or served as a speaker</style></keyword><keyword><style face="normal" font="default" size="100%">and/or participated in educational activities arranged by ALK-Abello A/S,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, Orion, Stallergenes Greer, and</style></keyword><keyword><style face="normal" font="default" size="100%">Thermo Fisher Scientific. Andreas Horn: has received grants for studies and/or</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from ALK-Abello A/S, Allergopharma, Almirall, ASIT Biotech,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, BerlinChemie, HAL Allergie GmbH, Immunotek, IQVIA, LETI Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Meinhardt Congress GmbH, Novartis, Sanofi Aventis, and Stallergenes Greer. Andre</style></keyword><keyword><style face="normal" font="default" size="100%">C. Knulst: has received institutional sponsoring for research or consultancy from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello A/S, Thermo Fisher Scientific, Nutricia/Danone, DBV technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, EUROIMMUN, Stallergenes Greer, TNO, FARRP, NVWA, and STW. Oliver Pfaar:</style></keyword><keyword><style face="normal" font="default" size="100%">has received grants, and/or personal fees, and/or travel support from AEDA,</style></keyword><keyword><style face="normal" font="default" size="100%">Alfried Krupp Krankenhaus, ALK-Abello A/S, Allergopharma, Almirall, Altamira</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, ASIT Biotech, AstraZeneca, Bencard Allergie GmbH/Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Blueprint, Breazy Health GmbH, Cliantha, Deutsche AllergieLiga</style></keyword><keyword><style face="normal" font="default" size="100%">e.V., Deutsche Forschungsgemeinschaft, Dustri-Verlag, ECM Expro&amp;Conference</style></keyword><keyword><style face="normal" font="default" size="100%">Management GmBH, Forum fur Medizinische Fortbildung, Georg-Thieme-Verlag, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">HAL Allergy Holding B.V./HAL Allergie GmbH, Immunotek, Ingress Health, Institut</style></keyword><keyword><style face="normal" font="default" size="100%">fur Disease Management (Essen, Germany), IQVIA Commercial, Japanese Society of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergology, Koniglich Danisches Generalkonsulat, Laboratorios LETI/LETI Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Lilly, Lofarma, Medizinische Hochschule Hannover, med update europe GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">Meinhardt Congress GmbH, Novartis, Paul-Ehrlich-Institut, Paul-Martini-Stiftung,</style></keyword><keyword><style face="normal" font="default" size="100%">PneumoLive, Pohl-Boskamp, Procter &amp; Gamble, Red Maple Trials Inc., Regeneron, RG</style></keyword><keyword><style face="normal" font="default" size="100%">Aerztefortbildung, ROXALL Medizin, Sanofi Aventis, Sanofi Genzyme, Springer</style></keyword><keyword><style face="normal" font="default" size="100%">Publisher, Stallergenes Greer, streamedup! GmbH, Technical University Dresden,</style></keyword><keyword><style face="normal" font="default" size="100%">Wiley Publishers, Wort &amp; Bild Verlag, Verlag ME</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work, O.P.</style></keyword><keyword><style face="normal" font="default" size="100%">is Vice President of the European Academy of Allergy and Clinical Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">(EAACI), a member of EAACI Excom as well as a member of the external board of</style></keyword><keyword><style face="normal" font="default" size="100%">directors of the German Society of Allergy and Clinical Immunology (DGAKI)</style></keyword><keyword><style face="normal" font="default" size="100%">coordinator, main- or co-author of different position papers and guidelines in</style></keyword><keyword><style face="normal" font="default" size="100%">rhinology, allergology and allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">and he is Editor-in-Chief of</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Translational Allergy and Associate Editor of Allergy.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41013980</style></accession-num><abstract><style face="normal" font="default" size="100%">This review evaluates data from &gt; 12,000 children, adolescents and adults (&gt;/= 4 years) in non-interventional studies to assess the real-life effectiveness and safety of SQ sublingual immunotherapy (SLIT)-tablets for allergic rhinitis (AR). Non-interventional studies of SQ grass, tree, ragweed, and house dust mite (HDM) SLIT tablets were identified from PubMed (1 January 2006 to 11 February 2025) and supplemented by manual searches. Effectiveness was captured as patient-reported change in AR symptoms; AR and/or asthma medication use, safety and treatment satisfaction were also evaluated. In total, 12,136 participants were enrolled across 22 SQ SLIT tablet studies (grass: n = 6744; HDM: n = 4323; tree: n = 1069; ragweed: n = 102). Across studies, a high proportion of participants reported improvements from baseline or the previous season across nasal (up to 87%), ocular (up to 81%), and bronchial symptoms (up to 78%) with SQ SLIT tablets. Compared to baseline, a lower proportion of patients reported use of symptom-relieving medication, consistent across key drug classes including oral antihistamine, intranasal corticosteroids, short-acting beta-agonist, and inhaled corticosteroids. Discontinuations due to adverse events were low (0%-14.5%). Among studies reporting treatment satisfaction, 73%-96% of participants were found to be &apos;satisfied&apos; or &apos;very satisfied&apos; with this treatment. SQ SLIT tablets showed consistent effectiveness for AR, were well-tolerated, and were associated with a high degree of patient satisfaction. These real-life data from clinical practice are a valuable and important source of complementary evidence to the well established efficacy and safety from randomised clinical trials.</style></abstract><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Janson, Christer&#xD;Horn, Andreas&#xD;Knulst, Andre C&#xD;Demoly, Pascal&#xD;eng&#xD;ALK-Abello/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3290-3301. doi: 10.1111/all.70039. Epub 2025 Sep 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41013980</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666741</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70039</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>514</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">514</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Diem, L.</style></author><author><style face="normal" font="default" size="100%">Neuherz, B.</style></author><author><style face="normal" font="default" size="100%">Rohrhofer, J.</style></author><author><style face="normal" font="default" size="100%">Koidl, L.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Diaz Perales, A.</style></author><author><style face="normal" font="default" size="100%">Faber, M.</style></author><author><style face="normal" font="default" size="100%">Gebhardt, J.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Jensen-Jarolim, E.</style></author><author><style face="normal" font="default" size="100%">Zehetmayer, S.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano (MI), Italy.&#xD;Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich, Germany.&#xD;Centro de Biotecnologia Y Genomica de Plantas (CBGP, UPM-INIA), Universidad Politecnica de Madrid (UPM) -Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria (INIA), Madrid, Spain.&#xD;Departamento de Biotecnologia-Biologia Vegetal, Escuela Tecnica Superior de Ingenieria Agronomica, Alimentaria y de Biosistemas. Universidad Politecnica de Madrid (UPM), Madrid, Spain.&#xD;Department of Dermatology AZ KLINA, Brasschaat, Belgium.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Universidad de Malaga-IBIMA-BIONAND, Malaga, Spain.&#xD;The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University of Vienna, and University of Vienna, Vienna, Austria.&#xD;AllergyCare, Allergy Diagnosis and Study Center, Vienna, Austria.&#xD;Center for Medical Statistics, Informatics and Intelligent Systems (Institute of Medical Statistics), Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-life evaluation of molecular multiplex IgE test methods in the diagnosis of pollen associated food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3028-3040</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/04/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Profilins</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests/methods</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">molecular diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">multiplex testing</style></keyword><keyword><style face="normal" font="default" size="100%">pollen food syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">ThermoFisher. The other authors have no other relevant affiliations or financial</style></keyword><keyword><style face="normal" font="default" size="100%">involvement with any organization or entity with a financial interest in or</style></keyword><keyword><style face="normal" font="default" size="100%">financial conflict with the subject matter or materials discussed in the</style></keyword><keyword><style face="normal" font="default" size="100%">manuscript apart from those disclosed.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35485989</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Diagnosis of food allergies is challenging, as combining information from specific IgE (sIgE)-sensitization pattern and skin prick tests (SPTs) with clinical history is necessary for a personalized management of allergic patients. The aim of this study was to compare two molecular tests, the ImmunoCAP ISAC (ISAC) and the Allergy Explorer, version 2 (ALEX(2) ) in the context of pollen food syndrome (PFS) diagnosis in a real-life scenario, to assess the benefit of multiplex testing in PFS patients. METHODS: Diagnosis of food allergy was performed in 53 patients. Allergen-sIgE concentrations were measured with ISAC and ALEX(2) . Results for sIgE were statistically compared with each other, with SPT results and with clinical presentation of the patients. RESULTS: Using ISAC as reference test for sIgE measurements, the average sensitivity of ALEX(2) for PR-10 allergens was 83.2% and the average specificity 88.0%. If only low sIgE concentrations were included, the sensitivity was 60.8% and the specificity 91.1%. Apple and hazelnut sensitizations were confirmed in most patients by concordance of sIgE and SPT results. Significant correlations were shown between clinical symptoms and Mal d 1- and Gly m 4-sIgE levels measured by both tests and for Cor a 1-sIgE levels measured by ALEX(2) . In eight patients, profilin related symptoms were supported by Hev b 8-sensitization. CONCLUSION: Multiplex testing is beneficial to understand patient-specific individual sensitization profiles and to providing personalized management recommendations. In the future, custom-designed test kits might enable reducing costs of multiplex testing for specific patient groups without compromising the diagnostic value.</style></abstract><notes><style face="normal" font="default" size="100%">Diem, Luisa&#xD;Neuherz, Bellinda&#xD;Rohrhofer, Johanna&#xD;Koidl, Larissa&#xD;Asero, Riccardo&#xD;Brockow, Knut&#xD;Diaz Perales, Araceli&#xD;Faber, Margaretha&#xD;Gebhardt, Julia&#xD;Torres, Maria Jose&#xD;Jensen-Jarolim, Erika&#xD;Zehetmayer, Sonja&#xD;Untersmayr, Eva&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3028-3040. doi: 10.1111/all.15329. Epub 2022 May 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35485989</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9790655</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15329</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2184</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Graham, F.</style></author><author><style face="normal" font="default" size="100%">Benhamou, A. H.</style></author><author><style face="normal" font="default" size="100%">Liu, Y. J.</style></author><author><style face="normal" font="default" size="100%">Caubet, J. C.</style></author><author><style face="normal" font="default" size="100%">Eigenmann, P. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Allergy Unit, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.&#xD;Department of Allergy and Immunology, Centre Hospitalier Universitaire Sainte-Justine and Centre Hospitalier de l&apos;Universite de Montreal, Montreal, Quebec, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-life evaluation of tolerance to foods with precautionary allergen labeling in children with IgE-mediated food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2558-2561</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/07/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Food</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Food Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">may contain traces</style></keyword><keyword><style face="normal" font="default" size="100%">oral food challenge</style></keyword><keyword><style face="normal" font="default" size="100%">precautionary allergen labeling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37493219</style></accession-num><notes><style face="normal" font="default" size="100%">Graham, Francois&#xD;Benhamou, Avigael H&#xD;Liu, Yan Jiao&#xD;Caubet, Jean-Christoph&#xD;Eigenmann, Philippe A&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2558-2561. doi: 10.1111/all.15821. Epub 2023 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37493219</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15821</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1077</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1077</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">van den Berge, M.</style></author><author><style face="normal" font="default" size="100%">Boccabella, C.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Caruso, C.</style></author><author><style face="normal" font="default" size="100%">Couto, M.</style></author><author><style face="normal" font="default" size="100%">Erkekol, F.</style></author><author><style face="normal" font="default" size="100%">Rukhadze, M.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Garcia, S.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Group, Instituto de InvestigacionBiomedica de Malaga (IBIMA) and ARADyAL, Malaga, Spain.&#xD;Groningen Research Institute for Asthma and COPD, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.&#xD;Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.&#xD;Department of Cardiovascular and Thoracic Sciences, Fondazione PoliclinicoUniversitario &quot;A Gemelli&quot; - IRCCS, University of the Sacred Heart, Rome, Italy.&#xD;National Heart and Lung Institute (NHLI, Imperial College, London, UK.&#xD;Allergy Unit, Fondazione Policlinico Universitario &quot;A. Gemelli&quot; - IRCCS, Rome, Italy.&#xD;Centro de Alergia, Hospital CUF Descobertas, Lisboa, Portugal.&#xD;Division of Allergy and Clinical Immunology, Faculty of Medicine, Ankara YildirimBeyazit University, Ankara, Turkey.&#xD;Center of Allergy &amp;Immunology, Tbilisi, Georgia.&#xD;Teaching University Geomedi LLC, Tbilisi, Georgia.&#xD;Allergy Department, Hospital Infantil Universitario del Nino Jesus, Madrid, Spain.&#xD;Allergy Group, Instituto de Investigacion del Hospital de la Princesa (IP) and ARADyAL, Madrid, Spain.&#xD;Allergy and Clinical Immunology Unit, Department of Medical Sciences and Public Health, University Hospital &quot;DuilioCasula&quot;, Monserrato (Cagliari), Italy.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Faculty of Medicine, Department of Allergy and Clinical Immunology, Transylvania University Brasov, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-life impact of COVID-19 pandemic lockdown on the management of pediatric and adult asthma: A survey by the EAACI Asthma Section</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2776-2784</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/03/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Communicable Disease Control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 lockdown</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbations</style></keyword><keyword><style face="normal" font="default" size="100%">lung function test</style></keyword><keyword><style face="normal" font="default" size="100%">peak expiratory flow</style></keyword><keyword><style face="normal" font="default" size="100%">SdG reports grants and personal fees from AstraZeneca, GSK and Novartis and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Sanofi-Regeneron, Menarini, Chiesi, and</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer-Ingelheimoutside the submitted work. The other authors have no</style></keyword><keyword><style face="normal" font="default" size="100%">conflict of interest to disclose in relation to this work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33772815</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The restrictions imposed by the COVID-19 pandemic impact heavily the management of chronic diseases like asthma. This study aimed to evaluate the management of adults and children with asthma during COVID-19-related lockdown. METHODS: A survey was launched by the European Academy of Allergy and Clinical Immunology (EAACI) via e-mail, website, and social media to EAACI members and members of peer societies. RESULTS: The survey was completed by 339 healthcare professionals from 52 countries. 79% of follow-up consultations were replaced by phone calls, whereas 49% of newly referred patients attended the clinic. 62%, 76%, 66%, 76%, and 87% of responders did not conduct spirometry, impulse oscillometry, bronchodilator test, FeNO, or methacholine provocation, respectively, for asthma diagnosis in adults. The numbers were similar for children. 73% of responders based the initial asthma diagnosis and the prescription of inhaled therapy on clinical parameters only. Lung function tests were used in 29% of cases to monitor asthma worsening, and only 56% of participants were recommended to their patients ambulatory peak expiratory flow (PEF) measurements. Using a 1 (not at all) to 5 (very much) scale, the responders considered that the quality of healthcare provided and the patients&apos; asthma status had deteriorated during the lockdown with 3.2 points and 2.8 points, respectively. CONCLUSION: Collectively, these results suggest that all necessary resources should be allocated to ensure the performance of lung function tests for initial diagnosis, whereas digital remote monitoring should be reinforced for the follow-up of children and adults with asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Eguiluz-Gracia, Ibon&#xD;van den Berge, Maarten&#xD;Boccabella, Cristina&#xD;Bonini, Matteo&#xD;Caruso, Cristiano&#xD;Couto, Mariana&#xD;Erkekol, FerdaOner&#xD;Rukhadze, Maia&#xD;Sanchez-Garcia, Silvia&#xD;Del Giacco, Stefano&#xD;Jutel, Marek&#xD;Agache, Ioana&#xD;eng&#xD;EAACI Position Paper/&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2776-2784. doi: 10.1111/all.14831. Epub 2021 Apr 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33772815</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8250685</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14831</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3031</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3031</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Greig, R.</style></author><author><style face="normal" font="default" size="100%">Chan, R.</style></author><author><style face="normal" font="default" size="100%">Lipworth, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Scottish Centre for Respiratory Research, University of Dundee, Dundee, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-Life Indirect Case Matched Comparison of Dupilumab and Tezepelumab on Airway Oscillometry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">260-262</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/08/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">airway oscillometry</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">case matched</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">small airways dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">tezepelumab</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees (talks) and support attending ERS from AstraZeneca, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">(consulting) from Vitalograph, and personal fees (talks) from Thorasys.Dr</style></keyword><keyword><style face="normal" font="default" size="100%">Lipworth reports non-financial support (equipment) from GSK</style></keyword><keyword><style face="normal" font="default" size="100%">grants, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees (consulting, talks and advisory board), other support (attending ATS and</style></keyword><keyword><style face="normal" font="default" size="100%">ERS) and from AstraZeneca</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees (talks and consulting) from Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees (consulting, talks and advisory board) from Circassia in relation</style></keyword><keyword><style face="normal" font="default" size="100%">to the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">grants, personal fees (consulting, talks, advisory board),</style></keyword><keyword><style face="normal" font="default" size="100%">other support (attending ERS) from Teva, personal fees (talks and consulting),</style></keyword><keyword><style face="normal" font="default" size="100%">grants and other support (attending ERS and BTS) from Chiesi, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">(consulting) from Lupin, personal fees (consulting) from Glenmark, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">(consulting) from Dr Reddy, personal fees (consulting) from Sandoz</style></keyword><keyword><style face="normal" font="default" size="100%">grants,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees (consulting, talks, advisory board), other support (attending BTS)</style></keyword><keyword><style face="normal" font="default" size="100%">from Boehringer Ingelheim, grants and personal fees (advisory board and talks)</style></keyword><keyword><style face="normal" font="default" size="100%">from Mylan outside of the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and the son of BJL is presently an</style></keyword><keyword><style face="normal" font="default" size="100%">employee of AstraZeneca.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40827412</style></accession-num><notes><style face="normal" font="default" size="100%">Greig, Robert&#xD;Chan, Rory&#xD;Lipworth, Brian&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):260-262. doi: 10.1111/all.70014. Epub 2025 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40827412</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773657</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70014</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>746</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">746</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van der Lans, R. J. L.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Adriaensen, Gfjpm</style></author><author><style face="normal" font="default" size="100%">Hoven, D. R.</style></author><author><style face="normal" font="default" size="100%">Drubbel, J. J.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology &amp; Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">670-674</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">biological therapy</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">observational study</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">consultant and guest speaker for Sanofi, Novartis, and GSK. SR has acted as a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant for Sanofi and Novartis. RL has acted as a consultant for GSK.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34626497</style></accession-num><notes><style face="normal" font="default" size="100%">van der Lans, Rik Johannes Leonardus&#xD;Fokkens, Wytske Johanna&#xD;Adriaensen, Gwijde Flavius Jacobus Petrus Maria&#xD;Hoven, Dinand Rienk&#xD;Drubbel, Joekio Jade&#xD;Reitsma, Sietze&#xD;eng&#xD;Letter&#xD;Observational Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):670-674. doi: 10.1111/all.15134. Epub 2021 Oct 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34626497</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9298295</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15134</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1261</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1261</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Campo, P.</style></author><author><style face="normal" font="default" size="100%">Soto Campos, G.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Padilla-Galo, A.</style></author><author><style face="normal" font="default" size="100%">Martinez-Moragon, E.</style></author><author><style face="normal" font="default" size="100%">Mardones, A.</style></author><author><style face="normal" font="default" size="100%">Davila, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, IBIMA-Regional University Hospital of Malaga, ARADyAL, Malaga, Spain.&#xD;Pneumology and Allergy Unit, University Hospital of Jerez, Cadiz, Spain.&#xD;Novartis Farmaceutica, Barcelona, Spain.&#xD;Department of Allergy, La Paz Hospital Institute for Health Research (IdiPAZ), Centro de investigacion en red de enfermedades respiratorias (CIBERES), Madrid, Spain.&#xD;Pneumology Unit, Costa del Sol Hospital, Marbella, Malaga, Spain.&#xD;Pneumology Service, University Hospital Doctor Peset, Valencia, Spain.&#xD;Pneumology Service, University Hospital Basurto, Bilbao, Spain.&#xD;Allergy Service, University Hospital of Salamanca and Institute for Biomedical Research of Salamanca (IBSAL), Biomedical and Diagnosis Science Department, Salamanca University School of Medicine, Salamanca, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-life study in non-atopic severe asthma patients achieving disease control by omalizumab treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1868-1872</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/11/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33220106</style></accession-num><notes><style face="normal" font="default" size="100%">Campo, Paloma&#xD;Soto Campos, Gregorio&#xD;Moreira, Ana&#xD;Quirce, Santiago&#xD;Padilla-Galo, Alicia&#xD;Martinez-Moragon, Eva&#xD;Mardones, Aizea&#xD;Davila, Ignacio&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1868-1872. doi: 10.1111/all.14668. Epub 2020 Dec 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33220106</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14668</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2528</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2528</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Denton, E.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author><author><style face="normal" font="default" size="100%">Peters, M. J.</style></author><author><style face="normal" font="default" size="100%">Upham, J. W.</style></author><author><style face="normal" font="default" size="100%">Bulathsinhala, L.</style></author><author><style face="normal" font="default" size="100%">Tran, T. N.</style></author><author><style face="normal" font="default" size="100%">Martin, N.</style></author><author><style face="normal" font="default" size="100%">Bergeron, C.</style></author><author><style face="normal" font="default" size="100%">Al-Ahmad, M.</style></author><author><style face="normal" font="default" size="100%">Altraja, A.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D.</style></author><author><style face="normal" font="default" size="100%">Murray, R.</style></author><author><style face="normal" font="default" size="100%">Celis-Preciado, C. A.</style></author><author><style face="normal" font="default" size="100%">Al-Lehebi, R.</style></author><author><style face="normal" font="default" size="100%">Belhassen, M.</style></author><author><style face="normal" font="default" size="100%">Bhutani, M.</style></author><author><style face="normal" font="default" size="100%">Bosnic-Anticevich, S. Z.</style></author><author><style face="normal" font="default" size="100%">Bourdin, A.</style></author><author><style face="normal" font="default" size="100%">Brusselle, G. G.</style></author><author><style face="normal" font="default" size="100%">Busby, J.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Chapman, K. R.</style></author><author><style face="normal" font="default" size="100%">Charriot, J.</style></author><author><style face="normal" font="default" size="100%">Christoff, G. C.</style></author><author><style face="normal" font="default" size="100%">Chung, L. P.</style></author><author><style face="normal" font="default" size="100%">Cosio, B. G.</style></author><author><style face="normal" font="default" size="100%">Cote, A.</style></author><author><style face="normal" font="default" size="100%">Costello, R. W.</style></author><author><style face="normal" font="default" size="100%">Cushen, B.</style></author><author><style face="normal" font="default" size="100%">Fingleton, J.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Gibson, P. G.</style></author><author><style face="normal" font="default" size="100%">Heaney, L. G.</style></author><author><style face="normal" font="default" size="100%">Huang, E. W.</style></author><author><style face="normal" font="default" size="100%">Iwanaga, T.</style></author><author><style face="normal" font="default" size="100%">Jackson, D. J.</style></author><author><style face="normal" font="default" size="100%">Koh, M. S.</style></author><author><style face="normal" font="default" size="100%">Lehtimaki, L.</style></author><author><style face="normal" font="default" size="100%">Maspero, J.</style></author><author><style face="normal" font="default" size="100%">Mahboub, B.</style></author><author><style face="normal" font="default" size="100%">Menzies-Gow, A. N.</style></author><author><style face="normal" font="default" size="100%">Mitchell, P. D.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Papaioannou, A. I.</style></author><author><style face="normal" font="default" size="100%">Perez-de-Llano, L.</style></author><author><style face="normal" font="default" size="100%">Perng, D. W.</style></author><author><style face="normal" font="default" size="100%">Pfeffer, P. E.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Porsbjerg, C. M.</style></author><author><style face="normal" font="default" size="100%">Rhee, C. K.</style></author><author><style face="normal" font="default" size="100%">Roche, N.</style></author><author><style face="normal" font="default" size="100%">Sadatsafavi, M.</style></author><author><style face="normal" font="default" size="100%">Salvi, S.</style></author><author><style face="normal" font="default" size="100%">Schmid, J. M.</style></author><author><style face="normal" font="default" size="100%">Sheu, C. C.</style></author><author><style face="normal" font="default" size="100%">Sirena, C.</style></author><author><style face="normal" font="default" size="100%">Torres-Duque, C. A.</style></author><author><style face="normal" font="default" size="100%">Salameh, L.</style></author><author><style face="normal" font="default" size="100%">Patel, P. H.</style></author><author><style face="normal" font="default" size="100%">Ulrik, C. S.</style></author><author><style face="normal" font="default" size="100%">Wang, E.</style></author><author><style face="normal" font="default" size="100%">Wechsler, M. E.</style></author><author><style face="normal" font="default" size="100%">Price, D. B.</style></author><author><style face="normal" font="default" size="100%">Isar Luminant Working Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy, Asthma &amp; Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia.&#xD;Department of Medicine, Central Clinical School, Monash University, Melbourne, Victoria, Australia.&#xD;Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.&#xD;Department of Thoracic Medicine, Concord Hospital, Sydney, New South Wales, Australia.&#xD;Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.&#xD;Frazer Institute &amp; PA-Southside Clinical Unit, The University of Queensland, Brisbane, Queensland, Australia.&#xD;Optimum Patient Care Global, Cambridge, UK.&#xD;Observational and Pragmatic Research Institute, Singapore, Singapore.&#xD;BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.&#xD;Department of Respiratory Medicine, University of Leicester, Leicester, UK.&#xD;Centre for Lung Health, Vancouver General Hospital, Vancouver, British Columbia, Canada.&#xD;University of British Columbia, Vancouver, British Columbia, Canada.&#xD;Microbiology Department, College of Medicine, Kuwait University, Kuwait City, Kuwait.&#xD;Al-Rashed Allergy Center, Ministry of Health, Kuwait City, Kuwait.&#xD;Department of Pulmonology, University of Tartu and Lung Clinic, Tartu University Hospital, Tartu, Estonia.&#xD;Centro de Excelencia en Asma y Alergia, Hospital Medica Sur, Mexico City, Mexico.&#xD;Pulmonary Unit, Hospital Universitario San Ignacio, Bogota, Colombia.&#xD;Faculty of Medicine, Pontificia Universidad Javeriana, Bogota, Colombia.&#xD;Department of Pulmonology, King Fahad Medical City, Riyadh, Saudi Arabia.&#xD;Alfaisal University, Riyadh, Saudi Arabia.&#xD;PELyon, Lyon, France.&#xD;Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Alberta, Canada.&#xD;Faculty of Medicine, Health and Human Sciences, Macquarie Medical School, Macquarie University, Sydney, New South Wales, Australia.&#xD;Woolcock Institute of Medical Research, Sydney, New South Wales, Australia.&#xD;PhyMedExp, University of Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France.&#xD;Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.&#xD;Department of Epidemiology and Respiratory Medicine, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands.&#xD;Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen&apos;s University Belfast, Belfast, UK.&#xD;Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;University of Toronto, Toronto, Ontario, Canada.&#xD;Faculty of Public Health, Medical University, Sofia, Bulgaria.&#xD;Fiona Stanley Hospital, Perth, Western Australia, Australia.&#xD;Son Espases University Hospital-IdISBa-Ciberes, Mallorca, Spain.&#xD;Department of Medicine, Laval University, Quebec City, Quebec, Canada.&#xD;Department of Respiratory Medicine, Clinical Research Centre, Smurfit Building Beaumont Hospital, RCSI, Dublin, Ireland.&#xD;Department of Respiratory Medicine, Beaumont Hospital, Dublin, Ireland.&#xD;Capital and Coast District Health Board, Wellington, New Zealand.&#xD;CINTESIS@RISE, MEDCIDS, Faculty of Medicine of the University of Porto, Porto, Portugal.&#xD;Australian Severe Asthma Network, Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, New South Wales, Australia.&#xD;Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.&#xD;Wellcome-Wolfson Institute for Experimental Medicine, Queen&apos;s University Belfast, Belfast, UK.&#xD;Department of Internal Medicine, Division of Pulmonary Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.&#xD;Kindai University Hospital, Osakasayama, Japan.&#xD;Guy&apos;s Severe Asthma Centre, Guy&apos;s Hospital, King&apos;s College London, London, UK.&#xD;Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore, Singapore.&#xD;Allergy Centre, Tampere University Hospital, Tampere, Finland.&#xD;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.&#xD;Clinical Research for Allergy and Respiratory Medicine, CIDEA Foundation, Buenos Aires, Argentina.&#xD;University Career of Specialists in Allergy and Clinical Immunology at the Buenos Aires University School of Medicine, Buenos Aires, Argentina.&#xD;Rashid hospital, Dubai Health Authority (DHA), Dubai, United Arab Emirates.&#xD;AstraZeneca, Cambridge, UK.&#xD;Lung Division, Royal Brompton &amp; Harefield Hospital, London, UK.&#xD;School of Medicine, Trinity College Dublin, Dublin, Ireland.&#xD;Division of Infection, Immunity &amp; Respiratory Medicine, University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;2nd Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece.&#xD;Pneumology Service, Lucus Augusti University Hospital, EOXI Lugo, Monforte, Cervo, Spain.&#xD;School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.&#xD;Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.&#xD;Department of Respiratory Medicine, Barts Health NHS Trust, London, UK.&#xD;Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.&#xD;University Hospital St. Ivan Rilski, Sofia, Bulgaria.&#xD;Department of Respiratory Medicine and Infectious Diseases, Research Unit, Bispebjerg Hospital, Copenhagen, Denmark.&#xD;Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Seoul St. Mary&apos;s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.&#xD;Department of Respiratory Medicine, APHP-Centre University Paris Cite, Cochin Hospital and Institute (UMR1016), Paris, France.&#xD;Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.&#xD;Pulmocare Research and Education Foundation, Pune, India.&#xD;University Hospital of Aarhus, Aarhus, Denmark.&#xD;Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Severe Asthma Network Italy (SANI), Milan, Italy.&#xD;CINEUMO, Respiratory Research Center, Fundacion Neumologica Colombiana, Bogota, Colombia.&#xD;Universidad de La Sabana, Chia, Colombia.&#xD;College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.&#xD;Respiratory Medicine, Royal Brompton Hospital, London, UK.&#xD;Department of Respiratory Medicine, Copenhagen University Hospital, Hvidovre, Denmark.&#xD;Department of Medicine, Division of Allergy and Clinical Immunology, National Jewish Health and University of Colorado School of Medicine, Denver, Colorado, USA.&#xD;Department of Medicine, NJH Cohen Family Asthma Institute, National Jewish Health, Denver, Colorado, USA.&#xD;Division of Applied Health Sciences, Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-world biologics response and super-response in the International Severe Asthma Registry cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2700-2716</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Registries</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">International Severe Asthma Registry (ISAR)</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">clinical response</style></keyword><keyword><style face="normal" font="default" size="100%">monoclonal antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">super-responders</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38923444</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Biologic asthma therapies reduce exacerbations and long-term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real-world population of adults with severe asthma. METHODS: Adults in the International Severe Asthma Registry (ISAR) with &gt;/=24 weeks of follow-up were grouped into those who did, or did not, initiate biologics (anti-IgE, anti-IL5/IL5R, anti-IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV(1)) increase by &gt;/=100 mL, improved asthma control, annualized exacerbation rate (AER) reduction &gt;/=50%, and any LTOCS dose reduction. Super-response criteria were: FEV(1) increase by &gt;/=500 mL, new well-controlled asthma, no exacerbations, and LTOCS cessation or tapering to &lt;/=5 mg/day. RESULTS: 5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non-initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV(1) increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super-responses. Responses/super-responses were more frequent in biologic initiators than in non-initiators; nevertheless, ~40-50% of initiators did not meet response criteria. CONCLUSIONS: Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non-initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super-responses in all outcome domains, 40-50% did not meet the response criteria.</style></abstract><notes><style face="normal" font="default" size="100%">Denton, Eve&#xD;Hew, Mark&#xD;Peters, Matthew J&#xD;Upham, John W&#xD;Bulathsinhala, Lakmini&#xD;Tran, Trung N&#xD;Martin, Neil&#xD;Bergeron, Celine&#xD;Al-Ahmad, Mona&#xD;Altraja, Alan&#xD;Larenas-Linnemann, Desiree&#xD;Murray, Ruth&#xD;Celis-Preciado, Carlos Andres&#xD;Al-Lehebi, Riyad&#xD;Belhassen, Manon&#xD;Bhutani, Mohit&#xD;Bosnic-Anticevich, Sinthia Z&#xD;Bourdin, Arnaud&#xD;Brusselle, Guy G&#xD;Busby, John&#xD;Canonica, Giorgio Walter&#xD;Heffler, Enrico&#xD;Chapman, Kenneth R&#xD;Charriot, Jeremy&#xD;Christoff, George C&#xD;Chung, Li Ping&#xD;Cosio, Borja G&#xD;Cote, Andreanne&#xD;Costello, Richard W&#xD;Cushen, Breda&#xD;Fingleton, James&#xD;Fonseca, Joao A&#xD;Gibson, Peter G&#xD;Heaney, Liam G&#xD;Huang, Erick Wan-Chun&#xD;Iwanaga, Takashi&#xD;Jackson, David J&#xD;Koh, Mariko Siyue&#xD;Lehtimaki, Lauri&#xD;Maspero, Jorge&#xD;Mahboub, Bassam&#xD;Menzies-Gow, Andrew N&#xD;Mitchell, Patrick D&#xD;Papadopoulos, Nikolaos G&#xD;Papaioannou, Andriana I&#xD;Perez-de-Llano, Luis&#xD;Perng, Diahn-Warng&#xD;Pfeffer, Paul E&#xD;Popov, Todor A&#xD;Porsbjerg, Celeste M&#xD;Rhee, Chin Kook&#xD;Roche, Nicolas&#xD;Sadatsafavi, Mohsen&#xD;Salvi, Sundeep&#xD;Schmid, Johannes Martin&#xD;Sheu, Chau-Chyun&#xD;Sirena, Concetta&#xD;Torres-Duque, Carlos A&#xD;Salameh, Laila&#xD;Patel, Pujan H&#xD;Ulrik, Charlotte Suppli&#xD;Wang, Eileen&#xD;Wechsler, Michael E&#xD;Price, David B&#xD;eng&#xD;AstraZeneca/&#xD;Optimum Patient Care/&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2700-2716. doi: 10.1111/all.16178. Epub 2024 Jun 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38923444</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16178</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2318</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2318</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Okubo, Y.</style></author><author><style face="normal" font="default" size="100%">Kuwabara, Y.</style></author><author><style face="normal" font="default" size="100%">Sato, S.</style></author><author><style face="normal" font="default" size="100%">Sakashita, M.</style></author><author><style face="normal" font="default" size="100%">Yuka, H.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Social Medicine, National Center for Child Health and Development, Tokyo, Japan.&#xD;Department of Pediatrics, Ehime University Graduate School of Medicine, Ehime, Japan.&#xD;Department of Allergy, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan.&#xD;Division of Otorhinolaryngology Head &amp; Neck Surgery, Department of Sensory and Locomotor Medicine, Faculty of Medical Science, University of Fukui, Fukui, Japan.&#xD;Department of Allergy and Clinical Immunology, National Center for Child Health and Development, Tokyo, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-world compliance and determinants for sublingual allergen immunotherapy in children and parents</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">523-525</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/11/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Parents</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37916610</style></accession-num><notes><style face="normal" font="default" size="100%">Okubo, Yusuke&#xD;Kuwabara, Yu&#xD;Sato, Sakura&#xD;Sakashita, Masafumi&#xD;Yuka, Hayashi&#xD;Morita, Hideaki&#xD;eng&#xD;Japan Science and Technology Agency/&#xD;Ministry of Health, Labour and Welfare in Japan/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):523-525. doi: 10.1111/all.15938. Epub 2023 Nov 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37916610</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15938</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2621</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2621</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huber, P.</style></author><author><style face="normal" font="default" size="100%">Forster-Ruhrmann, U.</style></author><author><style face="normal" font="default" size="100%">Olze, H.</style></author><author><style face="normal" font="default" size="100%">Becker, S.</style></author><author><style face="normal" font="default" size="100%">Barhold, F.</style></author><author><style face="normal" font="default" size="100%">Cuevas, M.</style></author><author><style face="normal" font="default" size="100%">Gunder, N.</style></author><author><style face="normal" font="default" size="100%">Hagemann, J.</style></author><author><style face="normal" font="default" size="100%">Matthias, C.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Groger, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Munich, Germany.&#xD;Department of Otorhinolaryngology, Charite-Universitatsmedizin, Berlin, Germany.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Tubingen, Tubingen, Germany.&#xD;Department of Otolaryngology, Head and Neck Surgery, University Hospital Carl Gustav Carus, Dresden, Germany.&#xD;Clinic and Polyclinic for Otolaryngology, University Medical Center Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3108-3117</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/drug therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">long-term impact</style></keyword><keyword><style face="normal" font="default" size="100%">multicentric study</style></keyword><keyword><style face="normal" font="default" size="100%">real-word data</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39109388</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent chronic inflammatory condition affecting the nose and paranasal sinuses, posing a significant socio-economic impact with substantial challenges in management. Biologics targeting type 2 inflammation such as dupilumab, have emerged as promising options. This study addresses a critical knowledge gap by comprehensively evaluating the 3-year impact of sustained dupilumab therapy in CRSwNP. METHODS: A multicentric, retrospective collection of real-world data from five tertiary referral centers in Germany was conducted, enrolling 150 adult patients. The study investigated patient-reported outcomes, disease-specific indices and clinical measures, focusing on therapeutic response persistence, adverse events, and factors influencing treatment continuity. RESULTS: Results indicate significant improvements in clinical parameters from baseline (n = 150) with sustained effectiveness after 36 months (n = 138) as indicated in mean score +/- standard deviation. Dupilumab treatment significantly improved overall disease-related impairment (VAS score: 7.5 +/- 2.5 to 1.6 +/- 1.3) and rhinosinusitis symptoms (SNOT-22: 59.4 +/- 19.4 to 18.0 +/- 15.0). Nasal Polyp Scores (NPS) decreased (5.3 +/- 1.8 to 0.7 +/- 1.1), and olfactory function improved (3.2 +/- 2.5 to 8.4 +/- 2.8), with three out of four patients achieving normosmia or hyposmia after 36 months. An &quot;Excellent&quot; treatment response according to EUFOREA23 criteria was observed in 76.5% of patients after 36 months. Sixteen patients discontinued Dupilumab, 12 permanently. Adverse events totaled 69 in 48 patients, commonly self-limiting. CONCLUSION: The study highlights the enduring effectiveness and lack of habituation to dupilumab after a sustained therapy of 3 years, providing valuable insights into its long-term therapeutic implications for CRSwNP patients.</style></abstract><notes><style face="normal" font="default" size="100%">Huber, Patrick&#xD;Forster-Ruhrmann, Ulrike&#xD;Olze, Heidi&#xD;Becker, Sven&#xD;Barhold, Friederike&#xD;Cuevas, Mandy&#xD;Gunder, Nadine&#xD;Hagemann, Jan&#xD;Matthias, Christoph&#xD;Klimek, Ludger&#xD;Groger, Moritz&#xD;eng&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3108-3117. doi: 10.1111/all.16263. Epub 2024 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39109388</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16263</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2990</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2990</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Okubo, Y.</style></author><author><style face="normal" font="default" size="100%">Kuwabara, Y.</style></author><author><style face="normal" font="default" size="100%">Sato, S.</style></author><author><style face="normal" font="default" size="100%">Sakashita, M.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Social Medicine, National Center for Child Health and Development, Tokyo, Japan.&#xD;Allergy Center, NHO Mie National Hospital, Tsu, Mie, Japan.&#xD;Department of Allergy, Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.&#xD;Division of Otorhinolaryngology Head &amp; Neck Surgery, Department of Sensory and Locomotor Medicine, Faculty of Medical Science, University of Fukui, Fukui, Japan.&#xD;Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-World Effectiveness for Sublingual Allergen Immunotherapy Among School-Aged Children and Adolescents</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3359-3368</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy/methods/economics</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Health Care Costs</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">JMDC claims database</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">causal inference</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40631972</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Sublingual allergen immunotherapy (SLIT) is a safe and effective treatment of allergic rhinitis, and its use has been increasing in recent years. Although several randomized and observational studies showed the effectiveness of SLIT among adults and children aged &gt; 12 years, its extent remains unclear in nationwide routine healthcare settings for school-aged children. METHODS: We conducted a propensity score (PS)-matched cohort study using a nationwide administrative database. Data from 13,449 individuals who received SLIT for house dust mites between 2015 and 2021 were extracted and matched with data from 1,732,961 individuals who did not. The PS-matching procedure created 10,985 pairs and followed them for three years, totaling 812,795 person-months. Then, we compared healthcare costs, resource use, and prescriptions between the SLIT and control groups over the three years. RESULTS: The introduction of SLIT was associated with an 8.9% reduction in antibiotic use (95% CI, 12.0% to 34.7%) and a 65.2% reduction in hospitalizations (95% CI, 52.8% to 74.4%), as well as a 44.1% increase in health resource utilization (95% CI, 40.7% to 47.6%), with minimal impact on overall healthcare costs (+8.9% [95% CI, -12.0% to +34.7%]) over the three-year follow-up period. Similar findings were observed in event-study design and intention-to-treat analyses, as well as in age-stratified analyses (ages 5-10 years and 11-19 years). CONCLUSIONS: The introduction of SLIT for house dust mites was associated with a reduction in antibiotic prescriptions and hospitalizations among children aged 5-19 years with minimal impact on healthcare costs, demonstrating sustained benefits over three years.</style></abstract><notes><style face="normal" font="default" size="100%">Okubo, Yusuke&#xD;Kuwabara, Yu&#xD;Sato, Sakura&#xD;Sakashita, Masafumi&#xD;Morita, Hideaki&#xD;eng&#xD;Japan Science and Technology Agency/&#xD;Cabinet Office, Government of Japan/&#xD;Ministry of Health, Labour and Welfare/&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3359-3368. doi: 10.1111/all.16646. Epub 2025 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40631972</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16646</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2838</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2838</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, Y.</style></author><author><style face="normal" font="default" size="100%">Yin, H.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Wu, H.</style></author><author><style face="normal" font="default" size="100%">Qin, H.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Yao, X.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Gu, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Shanghai Institute of Dermatology, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, P.R. China.&#xD;Department of Biostatistics, School of Public Health, and The Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China.&#xD;Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, P.R. China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-World Efficacy and Safety of Abrocitinib in Chinese Atopic Dermatitis Patients: A Single-Center Prospective Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1417-1427</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/02/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyrimidines/therapeutic use/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonamides</style></keyword><keyword><style face="normal" font="default" size="100%">Chinese</style></keyword><keyword><style face="normal" font="default" size="100%">abrocitinib</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">real-world</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39927851</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Phase 3 trials have demonstrated the efficacy and safety of abrocitinib for atopic dermatitis (AD), but real-world evidence remains limited. METHODS: This study prospectively enrolled 117 moderate-to-severe AD patients at Huashan Hospital, Shanghai, China. Physician- and patient-reported outcomes were evaluated at multiple time points. Blood eosinophil counts, serum IgE, and 24 cytokines/chemokines were measured. RESULTS: Abrocitinib treatment led to rapid and potent improvements in disease severity. At week 12, 74.3% and 50.5% of AD patients achieved at least 75% and 90% improvement in the eczema area and severity index (EASI), respectively. Compared to dupilumab, abrocitinib showed greater improvement in Itch-NRS at week 2 and a higher proportion of EASI-75 at week 4. Adverse events occurred in 42.7% of AD patients, with gastrointestinal symptoms being the most common (17.1%). No tuberculosis (TB) reactivation was observed in patients who screened positive for TB and received isoniazid prophylaxis during the study period. Lower body mass index (BMI &lt; 24; adjusted OR: 4.01, 95% CI: 1.36-11.73) and no prior dupilumab use (adjusted OR: 5.81, 95% CI: 1.8-18.7) were identified as predictors of a good response. By week 4, blood eosinophil counts and serum IgE significantly decreased. Reductions in Th2-, Th1-, and Treg-related cytokines/chemokines after 4 weeks of abrocitinib treatment, including IL-5, CCL17, CCL18, TNF-alpha, IL-6, IL-10, and CD25/IL-2Ralpha, were more pronounced in good responders. CONCLUSION: Abrocitinib demonstrated robust efficacy and a well-tolerated safety profile in Chinese patients with moderate-to-severe AD in routine clinical practice, accompanied by normalization of elevated blood biomarkers. TRIAL REGISTRATION: ChiCRT Identifier: ChiCTR2200063195.</style></abstract><notes><style face="normal" font="default" size="100%">Li, Zheng&#xD;Wang, Yu&#xD;Wu, Yuemeng&#xD;Yin, Huibin&#xD;Wang, Shangshang&#xD;Wu, Hao&#xD;Qin, Haihong&#xD;Wang, Ce&#xD;Yao, Xu&#xD;Li, Wei&#xD;Gu, Chaoying&#xD;eng&#xD;82273531/National Natural Science Foundation of China/&#xD;82330098/National Natural Science Foundation of China/&#xD;82304016/National Natural Science Foundation of China/&#xD;82473524/National Natural Science Foundation of China/&#xD;82404141/National Natural Science Foundation of China/&#xD;82404144/National Natural Science Foundation of China/&#xD;82073446/National Natural Science Foundation of China/&#xD;82373489/National Natural Science Foundation of China/&#xD;2021-01-07-00-07-E00078/the Key Project of the Innovation Program of Shanghai Municipal Education Commission/&#xD;SHDC22022302/the Clinical Research Plan of Shanghai Shenkang Hospital Development Center/&#xD;2023ZZ02018/the Shanghai Municipal Commission of Health and Family Planning/&#xD;shslczdzk01002/the Shanghai Municipal Key Clinical Specialty/&#xD;23Y31920300/Shanghai Municipal Commission of Science and Technology/&#xD;77570023/the Pfizer Research Grant/&#xD;the National Key Specialty/&#xD;23XD1400400/the Program of Shanghai Academic/Technology Research Leader/&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1417-1427. doi: 10.1111/all.16495. Epub 2025 Feb 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39927851</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16495</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>321</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">321</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vogelberg, C.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Bruggenjurgen, B.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Pneumology and Allergology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Institute for Healthcare Research and Technical Orthopedics, Medical University, Hannover, Germany.&#xD;All-MED Medical Research Institute, Wroclaw, Poland.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-world evidence for the long-term effect of allergen immunotherapy: Current status on database-derived European studies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3584-3592</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/09/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">long-term efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">real-world evidence</style></keyword><keyword><style face="normal" font="default" size="100%">lectures, presentations, or speakers bureaus from Allergy Therapeutics, Bencard</style></keyword><keyword><style face="normal" font="default" size="100%">Allergie, Allergopharma, HAL Allergy, Stallergenes Greer, Novartis Pharma, LETI</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, DBV Technology, Aimmune, Sanofi Aventis, ALK-Abello, Memberships: AeDA,</style></keyword><keyword><style face="normal" font="default" size="100%">GPA, APPA, DGAKI, EAACI. Ludger Klimek reports grants, institutional fees, and/or</style></keyword><keyword><style face="normal" font="default" size="100%">institutional payment for expert testimony from Allergopharma, Viatris,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes Greer, GSK, Sanofi, Leti Pharma, HAL Allergy, ALK-Abello, Quintiles,</style></keyword><keyword><style face="normal" font="default" size="100%">ASIT biotech, Lofarma, AstraZeneca, Inmunotek, Allergy Therapeutics, Cassella</style></keyword><keyword><style face="normal" font="default" size="100%">med, Novartis, Regeneron Pharmaceuticals, Roxall Medizin GmbH</style></keyword><keyword><style face="normal" font="default" size="100%">Memberships: AeDA,</style></keyword><keyword><style face="normal" font="default" size="100%">DGHNO, Deutsche Akademie fur Allergologie and klinische Immunologie, HNO-BV, GPA,</style></keyword><keyword><style face="normal" font="default" size="100%">EAACI. Bernd Bruggenjurgen reports payment or honoraria for lectures,</style></keyword><keyword><style face="normal" font="default" size="100%">presentations, speakers bureaus, manuscript writing, or educational events from</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma and IQVIA, outside the submitted work. Marek Jutel reports</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees and/or payment or honoraria for lectures, presentations, speakers</style></keyword><keyword><style face="normal" font="default" size="100%">bureaus, manuscript writing, or educational events from Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes Greer, ALK Abello, Chiesi, HAL Allergy, GSK</style></keyword><keyword><style face="normal" font="default" size="100%">Leadership or fiduciary</style></keyword><keyword><style face="normal" font="default" size="100%">role in other board, society, committee or advocacy group, paid or unpaid: EAACI,</style></keyword><keyword><style face="normal" font="default" size="100%">Fundacja Centrum Walki z Alergia.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36074052</style></accession-num><abstract><style face="normal" font="default" size="100%">Randomized controlled trials (RCTs) are the gold-standard for benefit-risk assessments during drug approval processes. Real-word data (RWD) and the resulting real-world evidence (RWE) are becoming increasingly important for assessing the effectiveness of drug products after marketing authorization showing how RCT results are transferred into real life care. The effectiveness of allergen immunotherapy (AIT) has been assessed in several RWE studies based on large prescription databases. We performed a literature search for retrospective cohort assessments of prescription databases in Europe to provide an overview on the methodology, long-term effectiveness outcomes, and adherence to AIT. Thirteen respective publications were selected. AIT was more effective in reducing the progression of allergic rhinitis (AR) compared to a non-AIT control group receiving only symptomatic treatment for AR for up to 6 years. The development and progression of asthma were hampered for most endpoints in patients treated with most preparations compared to the non-AIT group, receiving only anti-asthmatic medication. The results for &quot;time to onset&quot; of asthma were inconsistent. Adherence to AIT decreased during the recommended 3-year treatment period, however, in most studies higher adherence to subcutaneous than to sublingual AIT was shown. The analysis of long-term effectiveness outcomes of the RWE studies based on prescription databases confirms the long-term efficacy of AIT demonstrated in RCTs. Progression of rhinitis and asthma symptoms as well as delayed onset of asthma triggered by different allergens, real life adherence to the treatment shows differences in particular application routes.</style></abstract><notes><style face="normal" font="default" size="100%">Vogelberg, Christian&#xD;Klimek, Ludger&#xD;Bruggenjurgen, Bernd&#xD;Jutel, Marek&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3584-3592. doi: 10.1111/all.15506. Epub 2022 Sep 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36074052</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087412</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15506</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>836</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">836</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jantunen, J.</style></author><author><style face="normal" font="default" size="100%">Kauppi, P.</style></author><author><style face="normal" font="default" size="100%">Linna, M.</style></author><author><style face="normal" font="default" size="100%">Makela, M.</style></author><author><style face="normal" font="default" size="100%">Pelkonen, A.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy, Skin and Asthma Federation, Helsinki, Finland.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.&#xD;Healthcare Engineering, Management and Architecture Institute, Aalto University, Espoo, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-world evidence of reduced disability costs during the Finnish Allergy Programme 2008-2018</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3817-3819</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/08/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Finland/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34460940</style></accession-num><notes><style face="normal" font="default" size="100%">Jantunen, Juha&#xD;Kauppi, Paula&#xD;Linna, Miika&#xD;Makela, Mika&#xD;Pelkonen, Anna&#xD;Haahtela, Tari&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3817-3819. doi: 10.1111/all.15070. Epub 2021 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34460940</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15070</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>38</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">38</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mota, D.</style></author><author><style face="normal" font="default" size="100%">Rama, T. A.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servico de Imunoalergologia, Centro Hospitalar Universitario Sao Joao, Porto, Portugal.&#xD;Servico de Imunologia Basica e Clinica, Departamento de Patologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.&#xD;EPIUnit - Institute of Public Health, University of Porto, Porto, Portugal.&#xD;Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-world evidence on the risk of cancer with anti-IL-5 and anti-IL-4Ra biologicals</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1375-1377</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/12/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Neoplasms/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-5/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Interleukin-4/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36572508</style></accession-num><notes><style face="normal" font="default" size="100%">Mota, Diogo&#xD;Rama, Tiago Azenha&#xD;Moreira, Andre&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1375-1377. doi: 10.1111/all.15628. Epub 2023 Jan 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36572508</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15628</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2759</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2759</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Martini, M.</style></author><author><style face="normal" font="default" size="100%">Antonicelli, L.</style></author><author><style face="normal" font="default" size="100%">de Michele, F.</style></author><author><style face="normal" font="default" size="100%">Vaghi, A.</style></author><author><style face="normal" font="default" size="100%">Musarra, A.</style></author><author><style face="normal" font="default" size="100%">Micheletto, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Department of Internal Medicine, University Hospital AOU Delle Marche, Ancona, Italy.&#xD;Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.&#xD;Allergy and Asthma Outpatient Clinic, Ancona, Italy.&#xD;Pulmonology and Respiratory Pathophysiology Unit, A. Cardarelli Hospital, Naples, Italy.&#xD;Department of Medicine and Rehabilitation, Guido Salvini Hospital-ASST Rhodense, Garbagnate Milanese (MI), Italy.&#xD;Allergy Unit, Casa della Salute di Scilla, Scilla (RC), Italy.&#xD;Pulmonary Unit, Integrated University Hospital of Verona, Verona, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-World Finetuning of Biomarkers in Severe Asthma: Longitudinal Latent Class Analysis From the Italian Registry on Severe Asthma (IRSA)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1119-1123</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/06</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39641587</style></accession-num><notes><style face="normal" font="default" size="100%">Bilo, M Beatrice&#xD;Martini, Matteo&#xD;Antonicelli, Leonardo&#xD;de Michele, Fausto&#xD;Vaghi, Adriano&#xD;Musarra, Antonino&#xD;Micheletto, Claudio&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1119-1123. doi: 10.1111/all.16409. Epub 2024 Dec 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39641587</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969295</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16409</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>81</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">81</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, H. P.</style></author><author><style face="normal" font="default" size="100%">Sun, Y. L.</style></author><author><style face="normal" font="default" size="100%">Wang, Y. F.</style></author><author><style face="normal" font="default" size="100%">Yazici, D.</style></author><author><style face="normal" font="default" size="100%">Azkur, D.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Azkur, A. K.</style></author><author><style face="normal" font="default" size="100%">Yang, Z. W.</style></author><author><style face="normal" font="default" size="100%">Chen, X. X.</style></author><author><style face="normal" font="default" size="100%">Zhang, A. Z.</style></author><author><style face="normal" font="default" size="100%">Hu, J. Q.</style></author><author><style face="normal" font="default" size="100%">Liu, G. H.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Gao, Y. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergology, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.&#xD;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Department of Pediatrics, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, University of Kirikkale, Kirikkale, Turkey.&#xD;Department of Virology, Faculty of Veterinary Medicine, University of Kirikkale, Kirikkale, Turkey.&#xD;Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.&#xD;Intensive Care Unit, The Second Hospital of Shanxi Medical University, Taiyuan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recent developments in the immunopathology of COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">369-388</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/11/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Systemic Inflammatory Response Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Post-Acute COVID-19 Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">angiotensin-converting enzyme 2</style></keyword><keyword><style face="normal" font="default" size="100%">immunity</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, European Union (EU CURE, EU Syn-Air-G), European Union, Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">Research Institutes, (Basel, Switzerland), Stanford University (Redwood City,</style></keyword><keyword><style face="normal" font="default" size="100%">Calif), and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">is the Co-Chair for EAACI Guidelines on</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Science in Allergic diseases and Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">is on the Advisory Boards</style></keyword><keyword><style face="normal" font="default" size="100%">of Sanofi/Regeneron, Stanford University Sean Parker Asthma Allergy Center,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, GlaxoSmithKline, Bristol-Myers Squibb (London) and SciBase</style></keyword><keyword><style face="normal" font="default" size="100%">and is the</style></keyword><keyword><style face="normal" font="default" size="100%">Editor-in-Chief of Allergy. M. Akdis has received research grants from Swiss</style></keyword><keyword><style face="normal" font="default" size="100%">National science Foundation, Bern</style></keyword><keyword><style face="normal" font="default" size="100%">research grant from the Stanford University</style></keyword><keyword><style face="normal" font="default" size="100%">Leading House for the Latin American Region, Seed Money Grant. She is in the</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific Advisory Board member of Stanford University-Sean Parker Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Center, CA</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Board member of LEO Foundation Skin Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Research Center, Copenhagen</style></keyword><keyword><style face="normal" font="default" size="100%">and Scientific Co-Chair of World allergy Congress</style></keyword><keyword><style face="normal" font="default" size="100%">(WAC) Istanbul, 2022. The other authors have none to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36420736</style></accession-num><abstract><style face="normal" font="default" size="100%">There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 (COVID-19) patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID-19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID-19. The efficacy of the COVID-19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4, and BA.5 and the global administration of COVID-19 vaccines have changed the clinical scenario of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) may cause severe and heterogeneous disease but with a lower mortality rate. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long-term symptoms of COVID-19. There is conflicting evidence about whether atopic diseases, such as allergic asthma and rhinitis, are associated with a lower susceptibility and better outcomes of COVID-19. At the beginning of pandemic, the European Academy of Allergy and Clinical Immunology (EAACI) developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID-19 vaccines and emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID-19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID-19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID-19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS-CoV-2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high-risk groups, the development of MIS-C and long COVID-19.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Huan-Ping&#xD;Sun, Yuan-Li&#xD;Wang, Yan-Fen&#xD;Yazici, Duygu&#xD;Azkur, Dilek&#xD;Ogulur, Ismail&#xD;Azkur, Ahmet Kursat&#xD;Yang, Zhao-Wei&#xD;Chen, Xiao-Xue&#xD;Zhang, Ai-Zhi&#xD;Hu, Jia-Qian&#xD;Liu, Guang-Hui&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;Gao, Ya-Dong&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):369-388. doi: 10.1111/all.15593. Epub 2022 Dec 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36420736</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10108124</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15593</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2583</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2583</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van Zelm, M. C.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">McKenzie, C. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.&#xD;Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia.&#xD;Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A recent patent in allergy &amp; immunology: Biomarkers on allergen-specific memory B cells to predict allergen immunotherapy outcome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2295-2297</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Memory B Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/therapy/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Patents as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">B cell</style></keyword><keyword><style face="normal" font="default" size="100%">Cd29</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38979794</style></accession-num><notes><style face="normal" font="default" size="100%">van Zelm, Menno C&#xD;O&apos;Hehir, Robyn E&#xD;McKenzie, Craig I&#xD;eng&#xD;2000773/Central Clinical School Early Career Fellowship to CIM, NHMRC Ideas/&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2295-2297. doi: 10.1111/all.16238. Epub 2024 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38979794</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16238</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>525</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">525</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Harb, H.</style></author><author><style face="normal" font="default" size="100%">Chatila, T. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology, Department of Pediatrics, Harvard Medical School, Boston Children&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Institute of Microbiology and Virology, Technical University Dresden, Dresden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recent patents in allergy and immunology: Method for treating asthma or allergic disease via anti-Notch4 mAb</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2260-2261</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/04/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Ashma</style></keyword><keyword><style face="normal" font="default" size="100%">Notch4</style></keyword><keyword><style face="normal" font="default" size="100%">Patent</style></keyword><keyword><style face="normal" font="default" size="100%">Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">in Alcea Therapeutics. H.H. serves as an interim Chief Scientific Officer of</style></keyword><keyword><style face="normal" font="default" size="100%">Alcea Therapeutics.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35437758</style></accession-num><notes><style face="normal" font="default" size="100%">Harb, Hani&#xD;Chatila, Talal A&#xD;eng&#xD;R01 AI065617/AI/NIAID NIH HHS/&#xD;R01 AI115699/AI/NIAID NIH HHS/&#xD;R56 AI115699/AI/NIAID NIH HHS/&#xD;R01 AI115699/NH/NIH HHS/&#xD;News&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2260-2261. doi: 10.1111/all.15317. Epub 2022 Apr 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35437758</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11694330</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15317</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1922</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1922</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Harb, H.</style></author><author><style face="normal" font="default" size="100%">Chatila, T. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology, Department of Pediatrics, Harvard Medical School, Boston Children&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Institute of Microbiology and Virology, Technical University Dresden, Dresden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recent patents in allergy and immunology: Method for treating asthma or allergic disease via anti-Notch4 mAb</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2260-2261</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/04/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Ashma</style></keyword><keyword><style face="normal" font="default" size="100%">Notch4</style></keyword><keyword><style face="normal" font="default" size="100%">Patent</style></keyword><keyword><style face="normal" font="default" size="100%">Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">in Alcea Therapeutics. H.H. serves as an interim Chief Scientific Officer of</style></keyword><keyword><style face="normal" font="default" size="100%">Alcea Therapeutics.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35437758</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract -</style></abstract><notes><style face="normal" font="default" size="100%">Harb, Hani&#xD;Chatila, Talal A&#xD;eng&#xD;R01 AI065617/AI/NIAID NIH HHS/&#xD;R01 AI115699/AI/NIAID NIH HHS/&#xD;R56 AI115699/AI/NIAID NIH HHS/&#xD;R01 AI115699/NH/NIH HHS/&#xD;News&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2260-2261. doi: 10.1111/all.15317. Epub 2022 Apr 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35437758</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11694330</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15317</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1259</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1259</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martin-Serrano, A.</style></author><author><style face="normal" font="default" size="100%">Perez-Inestrosa, E.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Montanez, M. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.&#xD;Departamento de Quimica Organica, Universidad de Malaga-IBIMA, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Departamento de Medicina, Facultad de Medicina, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recent patents in allergy and immunology: New pyrazinones for the diagnosis of allergies to aminocephalosporins</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1288-1291</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33247441</style></accession-num><notes><style face="normal" font="default" size="100%">Martin-Serrano, Angela&#xD;Perez-Inestrosa, Ezequiel&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;Montanez, Maria Isabel&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1288-1291. doi: 10.1111/all.14673. Epub 2020 Dec 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33247441</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14673</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1520</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1520</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martin-Serrano, A.</style></author><author><style face="normal" font="default" size="100%">Perez-Inestrosa, E.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Montanez, M. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.&#xD;Departamento de Quimica Organica, Universidad de Malaga-IBIMA, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Departamento de Medicina, Facultad de Medicina, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recent patents in allergy and immunology: New pyrazinones for the diagnosis of allergies to aminocephalosporins</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1288-1291</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33247441</style></accession-num><notes><style face="normal" font="default" size="100%">Martin-Serrano, Angela&#xD;Perez-Inestrosa, Ezequiel&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;Montanez, Maria Isabel&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1288-1291. doi: 10.1111/all.14673. Epub 2020 Dec 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33247441</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14673</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2613</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2613</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fanton, C.</style></author><author><style face="normal" font="default" size="100%">Zalevsky, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Nektar Therapeutics, San Francisco, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recent patents in allergy and immunology: The interleukin-2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2565-2566</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2024/08/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Autoimmune Diseases/immunology/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Patents as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Interleukin-2</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39152563</style></accession-num><notes><style face="normal" font="default" size="100%">Fanton, Christie&#xD;Zalevsky, Jonathan&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Sep;79(9):2565-2566. doi: 10.1111/all.16271. Epub 2024 Aug 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39152563</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16271</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2377</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2377</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schuler, C. F. th</style></author><author><style face="normal" font="default" size="100%">Lukacs, N. W.</style></author><author><style face="normal" font="default" size="100%">Baker, J. R., Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Mary H. Weiser Food Allergy Center, University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan, USA.&#xD;Department of Internal Medicine, Division of Allergy and Clinical Immunology, University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan, USA.&#xD;Department of Pathology, University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan, USA.&#xD;Michigan Nanotechnology Institute for Medicine and the Biomedical Sciences, University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recent patents in allergy and immunology: Transepidermal water loss for anaphylaxis monitoring</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">765-766</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/01/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">transepidermal water loss</style></keyword><keyword><style face="normal" font="default" size="100%">present.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38205722</style></accession-num><notes><style face="normal" font="default" size="100%">Schuler, Charles F 4th&#xD;Lukacs, Nicholas W&#xD;Baker, James R Jr&#xD;eng&#xD;K23 AI162661/AI/NIAID NIH HHS/&#xD;L30 AI171988/AI/NIAID NIH HHS/&#xD;News&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):765-766. doi: 10.1111/all.16017. Epub 2024 Jan 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38205722</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10922900</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16017</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1527</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1527</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meurs, H.</style></author><author><style face="normal" font="default" size="100%">Zaagsma, J.</style></author><author><style face="normal" font="default" size="100%">Maarsingh, H.</style></author><author><style face="normal" font="default" size="100%">van Duin, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Pharmacology, Groningen Research Institute for Asthma and COPD, University of Groningen, Groningen, The Netherlands.&#xD;Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, Florida.&#xD;Ferring Pharmaceuticals, San Diego, California.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recent Patents in Allergy/Immunology: Use of arginase inhibitors in the treatment of asthma and allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1206-1208</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2019/03/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Arginase/*antagonists &amp; inhibitors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/*drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Discovery/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Guinea Pigs</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Inventions</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Targeted Therapy/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinitis, Allergic/*drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacology and pharmacogenomics</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">Organon, Oss, The Netherlands, grants from Schering-Plough Research Institute,</style></keyword><keyword><style face="normal" font="default" size="100%">Oss, The Netherlands, grants from Merck Sharpe and Dohme, Oss, The Netherlands,</style></keyword><keyword><style face="normal" font="default" size="100%">during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Netherlands Organisation for</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific Research (NWO), grants from Carmolex Inc., Pittsburgh, PA, USA,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">In addition, Dr. Meurs has a patent Use of arginase</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors in the treatment of asthma and allergic rhinitis licensed to Carmolex</style></keyword><keyword><style face="normal" font="default" size="100%">Inc., Pittsburgh, PA, USA. Dr. Zaagsma reports grants from Lung Foundation</style></keyword><keyword><style face="normal" font="default" size="100%">Netherlands, grants from N.V. Organon, Oss, The Netherlands, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Schering-Plough Research Institute, Oss, The Netherlands, grants from Merck</style></keyword><keyword><style face="normal" font="default" size="100%">Sharpe and Dohme, Oss, The Netherlands, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">In</style></keyword><keyword><style face="normal" font="default" size="100%">addition, Dr. Zaagsma has a patent Use of arginase inhibitors in the treatment of</style></keyword><keyword><style face="normal" font="default" size="100%">asthma and allergic rhinitis licensed to Carmolex Inc., Pittsburgh, PA, USA. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Maarsingh reports grants from N.V. Organon, Oss, The Netherlands, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Schering-Plough Research Institute, Oss, The Netherlands, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Schering-Plough, Kenilworth, NJ, USA, grants from Merck Sharpe and Dohme, Oss,</style></keyword><keyword><style face="normal" font="default" size="100%">The Netherlands, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">In addition, Dr. Maarsingh has</style></keyword><keyword><style face="normal" font="default" size="100%">a patent Use of arginase inhibitors in the treatment of asthma and allergic</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis licensed to Carmolex Inc., Pittsburgh, PA, USA. At the time of this work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. van Duin was an employee of Organon/Schering Plough/Merck MSD and involved in</style></keyword><keyword><style face="normal" font="default" size="100%">the scientific collaboration with the corresponding author, Dr. Meurs. In</style></keyword><keyword><style face="normal" font="default" size="100%">addition, Dr. van Duin has a patent Use of arginase inhibitors in the treatment</style></keyword><keyword><style face="normal" font="default" size="100%">of asthma and allergic rhinitis licensed to Carmolex Inc., Pittsburgh, PA, USA.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30865303</style></accession-num><notes><style face="normal" font="default" size="100%">Meurs, Herman&#xD;Zaagsma, Johan&#xD;Maarsingh, Harm&#xD;van Duin, Marcel&#xD;eng&#xD;N.V. Organon, Oss, The Netherlands/International&#xD;Merck Sharpe and Dohme, Oss, The Netherlands/International&#xD;Schering-Plough Research Institute, Oss, The Netherlands/International&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2019 Jun;74(6):1206-1208. doi: 10.1111/all.13770. Epub 2019 Apr 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30865303</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC6593796</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13770</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3095</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3095</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pasikhov, G. B.</style></author><author><style face="normal" font="default" size="100%">Shilovskiy, I. P.</style></author><author><style face="normal" font="default" size="100%">Nikolskii, A. A.</style></author><author><style face="normal" font="default" size="100%">Yumashev, K. V.</style></author><author><style face="normal" font="default" size="100%">Kaganova, M. M.</style></author><author><style face="normal" font="default" size="100%">Gurskii Dcapital A, Cyrillic</style></author><author><style face="normal" font="default" size="100%">Popova, M. V.</style></author><author><style face="normal" font="default" size="100%">Strueva, P. A.</style></author><author><style face="normal" font="default" size="100%">Shershakova, N. N.</style></author><author><style face="normal" font="default" size="100%">Kovaleva, E. V.</style></author><author><style face="normal" font="default" size="100%">Onatsky, N. M.</style></author><author><style face="normal" font="default" size="100%">Kudlay, D. A.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Khaitov, M. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation.&#xD;Research Center for Toxicology and Hygienic Regulation of Biopreparations - Branch of National Research Center - Institute of Immunology of the Federal Medical-Biological Agency, Serpukhov, Russian Federation.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Clinical Immunology and Allergy, Laboratory of Immunopathology, Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;Center for Molecular Allergology, Karl Landsteiner University, Krema, Austria.&#xD;Life Improvement by Future Technologies (LIFT) Center, Moscow, Russia.&#xD;N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recombinant Allergy Vaccine-Induced Transmission of Maternal Allergen-Specific Neutralizing IgG</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3461-3464</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/09/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bet v 1</style></keyword><keyword><style face="normal" font="default" size="100%">Mal d 1</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific IgG</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">transplacental transmission</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40913341</style></accession-num><notes><style face="normal" font="default" size="100%">Pasikhov, George B&#xD;Shilovskiy, Igor P&#xD;Nikolskii, Aleksandr A&#xD;Yumashev, Kirill V&#xD;Kaganova, Mariya M&#xD;Gurskii, Danila capital A, Cyrillic&#xD;Popova, Maya V&#xD;Strueva, Polina A&#xD;Shershakova, Nadezda N&#xD;Kovaleva, Elena V&#xD;Onatsky, Nikolay M&#xD;Kudlay, Dmitry A&#xD;Valenta, Rudolf&#xD;Khaitov, Musa R&#xD;eng&#xD;24-15-00206/Russian Science Foundation/&#xD;DANUBE Allergy Research Cluster of the Country of Lower Austria/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3461-3464. doi: 10.1111/all.70042. Epub 2025 Sep 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40913341</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70042</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>394</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">394</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alizadeh Aghdam, M.</style></author><author><style face="normal" font="default" size="100%">Hofman, Z. L. M.</style></author><author><style face="normal" font="default" size="100%">Meertens, M.</style></author><author><style face="normal" font="default" size="100%">Lebens, A.</style></author><author><style face="normal" font="default" size="100%">Hack, C. E.</style></author><author><style face="normal" font="default" size="100%">Knulst, A. C.</style></author><author><style face="normal" font="default" size="100%">Maas, C.</style></author><author><style face="normal" font="default" size="100%">Rockmann, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.&#xD;Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.&#xD;CDL Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recombinant human C1 esterase inhibitor as prophylactic treatment in idiopathic non-histaminergic angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3673-3676</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/07/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inhibitor Protein/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Esterases</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedema/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Bradykinin</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Complement C1 Inactivator Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedemas, Hereditary</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35837765</style></accession-num><notes><style face="normal" font="default" size="100%">Alizadeh Aghdam, Mehran&#xD;Hofman, Zonne L M&#xD;Meertens, Michelle&#xD;Lebens, Ans&#xD;Hack, C Erik&#xD;Knulst, Andre C&#xD;Maas, Coen&#xD;Rockmann, Heike&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3673-3676. doi: 10.1111/all.15437. Epub 2022 Jul 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35837765</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10084080 Hofman received contribution to publication cost thesis from Pharming Technologies. Andre Knulst is a member of advisory board, Novartis. Health care innovation grant from Novartis to institution. Coen Maas has been advisor to Shire/Takeda and Biomarin. Heike Rockmann is a member of national advisory board Novartis, Sanofi. Michelle Meertens: None. Erik Hack: None. Ans Lebens: None.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15437</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2872</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2872</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Trifonova, D.</style></author><author><style face="normal" font="default" size="100%">Curin, M.</style></author><author><style face="normal" font="default" size="100%">Focke-Tejkl, M.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Borochova, K.</style></author><author><style face="normal" font="default" size="100%">Gattinger, P.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Gronlund, H.</style></author><author><style face="normal" font="default" size="100%">Kiss, R.</style></author><author><style face="normal" font="default" size="100%">Huang, H. J.</style></author><author><style face="normal" font="default" size="100%">Keller, W.</style></author><author><style face="normal" font="default" size="100%">Riabova, K.</style></author><author><style face="normal" font="default" size="100%">Karsonova, A.</style></author><author><style face="normal" font="default" size="100%">Kundi, M.</style></author><author><style face="normal" font="default" size="100%">Tulaeva, I.</style></author><author><style face="normal" font="default" size="100%">Fomina, D.</style></author><author><style face="normal" font="default" size="100%">Karaulov, A.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;LIFE Improvement by Future Technologies (LIFT) Center, Skolkovo, Moscow, Russia.&#xD;Department of Medicine Solna, Division of Immunology and Respiratory Medicine and Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden.&#xD;Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.&#xD;Center for Molecular Allergology, Karl Landsteiner University for Healthcare Sciences, Krems, Austria.&#xD;Institute of Molecular Biosciences, BioTechMed Graz, University of Graz, Graz, Austria.&#xD;Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Department of Environmental Health, Center for Public Health, Medical University of Vienna, Vienna, Austria.&#xD;Moscow Clinical and Research Center of Allergy and Immunology, Clinical City Hospital #52, Moscow, Russia.&#xD;Department of Pulmonology, Astana Medical University, Astana, Kazakhstan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recombinant Hypoallergenic Cat Allergy Vaccines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2622-2635</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/04/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Vaccines, Synthetic/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Cats</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Fusion Proteins/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Epitope Mapping</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Glycoproteins</style></keyword><keyword><style face="normal" font="default" size="100%">Lipocalins</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy (AIT)</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">cat allergy</style></keyword><keyword><style face="normal" font="default" size="100%">molecular allergy vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">China) and HVD Life Biotech (Vienna, Austria). He serves as a consultant for HVD</style></keyword><keyword><style face="normal" font="default" size="100%">and WORG Pharmaceuticals. D.T., M.C., K.R., A.K. (Antonina Karsonova), M.v.H.,</style></keyword><keyword><style face="normal" font="default" size="100%">A.K. (Alexander Karaulov) and R.V. are authors of the patent application &quot;Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">for treating allergies&quot; application number: PCT/CN2022/130414, reference:</style></keyword><keyword><style face="normal" font="default" size="100%">P20222370. The authors with a Russian affiliation declare that they have prepared</style></keyword><keyword><style face="normal" font="default" size="100%">the article in their &quot;personal capacity&quot; and/or that they are employed at an</style></keyword><keyword><style face="normal" font="default" size="100%">academic/research institution where research or education is the primary function</style></keyword><keyword><style face="normal" font="default" size="100%">of the entity. M.v.H. has received lecture fees from Astra Zeneca and</style></keyword><keyword><style face="normal" font="default" size="100%">Thermofisher scientific outside the submitted work. The other authors declare no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest. The funders had no role in the design of the study</style></keyword><keyword><style face="normal" font="default" size="100%">in the</style></keyword><keyword><style face="normal" font="default" size="100%">collection, analyses, or interpretation of data</style></keyword><keyword><style face="normal" font="default" size="100%">in the writing of the</style></keyword><keyword><style face="normal" font="default" size="100%">manuscript</style></keyword><keyword><style face="normal" font="default" size="100%">or in the decision to publish the results.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40178413</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Molecular forms of allergen-specific immunotherapy (AIT) for cat allergy are needed. Fel d 1, Fel d 4, and Fel d 7 are the most important cat allergens. METHODS: IgE epitopes of Fel d 4 and Fel d 7 were mapped by blocking allergic patients&apos; IgE binding with allergen peptide-specific antisera. Five recombinant fusion proteins (PreS-Cat 1-PreS-Cat 5) each containing hepatitis B virus (HBV)-derived PreS as an immunological carrier and non-allergenic peptides from the IgE binding sites of Fel d 1, Fel d 4, and Fel d 7 were expressed in Escherichia coli, purified, and characterized by mass spectrometry, circular dichroism (CD), and size exclusion chromatography. ImmunoCAP and basophil activation experiments demonstrated the hypoallergenic activity of PreS-Cat 1-5. The ability of PreS-Cat 1-5 to induce IgE-blocking antibodies in rabbits was compared to three licensed allergen extract-based AIT vaccines. PreS-Cat 1-5-specific IgG antibodies were tested for inhibition of allergen-specific IgE binding and specific basophil activation. T cell activation and induction of specific cytokine secretion by PreS-Cat proteins were compared with cat allergens in PBMC cultures. RESULTS: Recombinant hypoallergenic, biochemically and structurally defined PreS-Cat 1-5 were obtained. Two subcutaneous immunizations of rabbits with PreS-Cat 1-5 induced equal (Fel d 1) or better (Fel d 4 and Fel d 7) antibodies (PreS-Cat 5 &gt; PreS-Cat 1 &gt; PreS-Cat 3) blocking allergic patients&apos; IgE binding to cat allergens than six to fifteen immunizations with allergen extract-based vaccines. PreS-Cat-specific antibodies strongly inhibited specific basophil activation. PreS-Cat 5 &gt; PreS-Cat 1 induced significantly more IL-10 in cultured PBMCs from cat allergic patients than cat allergens. CONCLUSIONS: PreS-Cat 5 and PreS-Cat 1 are highly promising molecular vaccine candidates for AIT of cat allergy, combining Fel d 1-, Fel d 4-, and Fel d 7-peptides in single PreS fusion proteins.</style></abstract><notes><style face="normal" font="default" size="100%">Trifonova, Daria&#xD;Curin, Mirela&#xD;Focke-Tejkl, Margarete&#xD;Liu, Zicheng&#xD;Borochova, Kristina&#xD;Gattinger, Pia&#xD;van Hage, Marianne&#xD;Gronlund, Hans&#xD;Kiss, Renata&#xD;Huang, Huey-Jy&#xD;Keller, Walter&#xD;Riabova, Ksenja&#xD;Karsonova, Antonina&#xD;Kundi, Michael&#xD;Tulaeva, Inna&#xD;Fomina, Daria&#xD;Karaulov, Alexander&#xD;Valenta, Rudolf&#xD;eng&#xD;Worg Pharmaceuticals/&#xD;Danube Allergy Research Cluster of the Country of Lower Austria/&#xD;Russian Science Foundation/&#xD;Region Stockholm (ALF Project)/&#xD;Swedish Asthma and Allergy Association&apos;s Research Foundation/&#xD;Swedish Heart-Lung Foundation/&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2622-2635. doi: 10.1111/all.16542. Epub 2025 Apr 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40178413</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444911</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16542</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2796</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2796</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kozlov, E.</style></author><author><style face="normal" font="default" size="100%">Trifonova, D.</style></author><author><style face="normal" font="default" size="100%">Dubovets, A.</style></author><author><style face="normal" font="default" size="100%">Usanova, A.</style></author><author><style face="normal" font="default" size="100%">Tulaeva, I.</style></author><author><style face="normal" font="default" size="100%">Gattinger, P.</style></author><author><style face="normal" font="default" size="100%">Fomina, D.</style></author><author><style face="normal" font="default" size="100%">Hemmer, W.</style></author><author><style face="normal" font="default" size="100%">Gorokhovets, N.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Karaulov, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, First Moscow State Medical University Sechenov, Moscow, Russia.&#xD;Life Improvement by Future Technologies (LIFT) Center, Moscow, Russia.&#xD;Department of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Moscow Clinical and Research Center of Allergy and Immunology, Clinical City Hospital, Moscow, Russia.&#xD;Department of Pulmonology, Astana Medical University, Kazakhstan.&#xD;FAZ-Floridsdorfer Allergiezentrum, Vienna, Austria.&#xD;Center of Synthetic Biotechnology of the Institute of Translational Medicine and Biotechnology, First Moscow State Medical University Sechenov, Moscow, Russia.&#xD;Center for Molecular Allergology, Karl Landsteiner University of Health Sciences, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recombinant IgE-Reactive Functional Can f 5 Devoid of Cross-Reactive Carbohydrate Determinants</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1785-1789</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/01/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">CCD-cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="default" size="100%">Can f 5</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation</style></keyword><keyword><style face="normal" font="default" size="100%">dog allergy</style></keyword><keyword><style face="normal" font="default" size="100%">expression</style></keyword><keyword><style face="normal" font="default" size="100%">Austria, and from WORG Pharmaceuticals, Hangzhou, China. He serves as a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant for HVD and WORG Pharmaceuticals. The authors with a Russian</style></keyword><keyword><style face="normal" font="default" size="100%">affiliation declare that they have prepared the article in their &quot;personal</style></keyword><keyword><style face="normal" font="default" size="100%">capacity&quot; and/or that they are employed at an academic/research institution where</style></keyword><keyword><style face="normal" font="default" size="100%">research or education is the primary function of the entity. The funders had no</style></keyword><keyword><style face="normal" font="default" size="100%">role in the design of the study</style></keyword><keyword><style face="normal" font="default" size="100%">in the collection, analyses, or interpretation</style></keyword><keyword><style face="normal" font="default" size="100%">of data</style></keyword><keyword><style face="normal" font="default" size="100%">in the writing of the manuscript</style></keyword><keyword><style face="normal" font="default" size="100%">or in the decision to publish the</style></keyword><keyword><style face="normal" font="default" size="100%">results. The other authors have no conflicts of interest to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39836011</style></accession-num><notes><style face="normal" font="default" size="100%">Kozlov, Evgenii&#xD;Trifonova, Daria&#xD;Dubovets, Alexandra&#xD;Usanova, Anastasia&#xD;Tulaeva, Inna&#xD;Gattinger, Pia&#xD;Fomina, Daria&#xD;Hemmer, Wolfgang&#xD;Gorokhovets, Neonila&#xD;Valenta, Rudolf&#xD;Karaulov, Alexander&#xD;eng&#xD;Russian Science Foundation/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1785-1789. doi: 10.1111/all.16465. Epub 2025 Jan 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39836011</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186582</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16465</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>456</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">456</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stark, J. M.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Tibbitt, C. A.</style></author><author><style face="normal" font="default" size="100%">Christian, M.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">Wintersand, A.</style></author><author><style face="normal" font="default" size="100%">Dunst, J.</style></author><author><style face="normal" font="default" size="100%">Kreslavsky, T.</style></author><author><style face="normal" font="default" size="100%">Murrell, B.</style></author><author><style face="normal" font="default" size="100%">Adner, M.</style></author><author><style face="normal" font="default" size="100%">Gronlund, H.</style></author><author><style face="normal" font="default" size="100%">Gafvelin, G.</style></author><author><style face="normal" font="default" size="100%">Coquet, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.&#xD;Institute of Environmental Medicine and Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Clinical Neuroscience, Karolinska Institutet, Centre for Molecular Medicine, Stockholm, Sweden.&#xD;Department of Medicine, Division of Immunology and Allergy, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.&#xD;Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recombinant multimeric dog allergen prevents airway hyperresponsiveness in a model of asthma marked by vigorous T(H) 2 and T(H) 17 cell responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2987-3001</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/06/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiration Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Hypersensitivity/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Th17</style></keyword><keyword><style face="normal" font="default" size="100%">Th2</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immune therapy</style></keyword><keyword><style face="normal" font="default" size="100%">dog allergy</style></keyword><keyword><style face="normal" font="default" size="100%">single cell RNA-Seq</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35657107</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergy to dogs affects around 10% of the population in developed countries. Immune therapy of allergic patients with dog allergen extracts has shown limited therapeutic benefit. METHODS: We established a mouse model of dog allergy by repeatedly administering dog dander and epithelium extracts via the intranasal route. We also assessed the efficacy of a recombinant multimeric protein containing Can f 1, f 2, f 4 and f 6 in preventing inflammatory responses to dog extracts. RESULTS: Repeated inhalation of dog extracts induced infiltration of the airways by T(H) 2 cells, eosinophils and goblet cells, reminiscent of the house dust mite (HDM) model of asthma. Dog extracts also induced robust airway hyperresponsiveness and promoted T(H) 17 cell responses, which was associated with a high neutrophilic infiltration of the airways. scRNA-Seq analysis of T helper cells in the airways pinpointed a unique gene signature for T(H) 17 cells. Analysis of T-cell receptors depicted a high frequency of clones that were shared between T(H) 17, T(H) 2 and suppressive Treg cells, indicative of a common differentiation trajectory for these subsets. Importantly, sublingual administration of multimeric Can f 1-2-4-6 protein prior to sensitization reduced airway hyperresponsiveness and type 2-mediated inflammation in this model. CONCLUSION: Dog allergen extracts induce robust T(H) 2 and T(H) 17 cell-mediated responses in mice. Recombinant Can f 1-2-4-6 can induce tolerance to complex dog allergen extracts.</style></abstract><notes><style face="normal" font="default" size="100%">Stark, Julian M&#xD;Liu, Jielu&#xD;Tibbitt, Christopher A&#xD;Christian, Murray&#xD;Ma, Junjie&#xD;Wintersand, Anna&#xD;Dunst, Josefine&#xD;Kreslavsky, Taras&#xD;Murrell, Ben&#xD;Adner, Mikael&#xD;Gronlund, Hans&#xD;Gafvelin, Guro&#xD;Coquet, Jonathan M&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):2987-3001. doi: 10.1111/all.15399. Epub 2022 Jun 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35657107</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9796107</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15399</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2265</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2265</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khaitov, M.</style></author><author><style face="normal" font="default" size="100%">Shilovskiy, I.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Weber, M.</style></author><author><style face="normal" font="default" size="100%">Korneev, A.</style></author><author><style face="normal" font="default" size="100%">Tulaeva, I.</style></author><author><style face="normal" font="default" size="100%">Gattinger, P.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Hofer, G.</style></author><author><style face="normal" font="default" size="100%">Konradsen, J. R.</style></author><author><style face="normal" font="default" size="100%">Keller, W.</style></author><author><style face="normal" font="default" size="100%">Akinfenwa, O.</style></author><author><style face="normal" font="default" size="100%">Poroshina, A.</style></author><author><style face="normal" font="default" size="100%">Ilina, N.</style></author><author><style face="normal" font="default" size="100%">Fedenko, E.</style></author><author><style face="normal" font="default" size="100%">Elisyutina, O.</style></author><author><style face="normal" font="default" size="100%">Litovkina, A.</style></author><author><style face="normal" font="default" size="100%">Smolnikov, E.</style></author><author><style face="normal" font="default" size="100%">Nikonova, A.</style></author><author><style face="normal" font="default" size="100%">Rybalkin, S.</style></author><author><style face="normal" font="default" size="100%">Aldobaev, V.</style></author><author><style face="normal" font="default" size="100%">Smirnov, V.</style></author><author><style face="normal" font="default" size="100%">Shershakova, N.</style></author><author><style face="normal" font="default" size="100%">Petukhova, O.</style></author><author><style face="normal" font="default" size="100%">Kudlay, D.</style></author><author><style face="normal" font="default" size="100%">Shatilov, A.</style></author><author><style face="normal" font="default" size="100%">Timofeeva, A.</style></author><author><style face="normal" font="default" size="100%">Campana, R.</style></author><author><style face="normal" font="default" size="100%">Udin, S.</style></author><author><style face="normal" font="default" size="100%">Skvortsova, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation.&#xD;Pirogov Russian National Research Medical University, Moscow, Russian Federation.&#xD;Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;Karl Landsteiner University for Healthcare Sciences, Krems, Austria.&#xD;Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Materials and Environmental Chemistry, University of Stockholm, Stockholm, Sweden.&#xD;Department of Women&apos;s and Children&apos;s Health, Astrid Lindgren Children&apos;s Hospital, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.&#xD;Institute of Molecular Biosciences, BioTechMed Graz, University of Graz, Graz, Austria.&#xD;Peoples&apos; Friendship University of Russia (RUDN University), Moscow, Russian Federation.&#xD;Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;Federal State Budgetary Institution &quot;Centre for Strategic Planning and Management of Biomedical Health Risks&quot; of the Federal Medical Biological Agency, Moscow, Russian Federation.&#xD;Federal Medical Biological Agency of Russia (FMBA Russia), Moscow, Russian Federation.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1001-1017</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/10/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style face="normal" font="default" size="100%">*Malus</style></keyword><keyword><style face="normal" font="default" size="100%">Betula</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Fusion Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines, Synthetic</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">birch pollen-associated food allergy syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">molecular allergy vaccine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37855043</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IgE cross-sensitization to major birch pollen allergen Bet v 1 and pathogenesis-related (PR10) plant food allergens is responsible for the pollen-food allergy syndrome. METHODS: We designed a recombinant protein, AB-PreS, consisting of non-allergenic peptides derived from the IgE-binding sites of Bet v 1 and the cross-reactive apple allergen, Mal d 1, fused to the PreS domain of HBV surface protein as immunological carrier. AB-PreS was expressed in E. coli and purified by chromatography. The allergenic and inflammatory activity of AB-PreS was tested using basophils and PBMCs from birch pollen allergic patients. The ability of antibodies induced by immunization of rabbits with AB-PreS and birch pollen extract-based vaccines to inhibit allergic patients IgE binding to Bet v 1 and Mal d 1 was assessed by ELISA. RESULTS: IgE-binding experiments and basophil activation test revealed the hypoallergenic nature of AB-PreS. AB-PreS induced lower T-cell activation and inflammatory cytokine production in cultured PBMCs from allergic patients. IgG antibodies induced by five injections with AB-PreS inhibited allergic patients&apos; IgE binding to Bet v 1 and Mal d 1 better than did IgG induced by up to 30 injections of six licensed birch pollen allergen extract-based vaccines. Additionally, immunization with AB-PreS induced HBV-specific antibodies potentially protecting from infection with HBV. CONCLUSION: The recombinant AB-PreS-based vaccine is hypoallergenic and superior over currently registered allergen extract-based vaccines regarding the induction of blocking antibodies to Bet v 1 and Mal d 1 in animals.</style></abstract><notes><style face="normal" font="default" size="100%">Khaitov, Musa&#xD;Shilovskiy, Igor&#xD;Valenta, Rudolf&#xD;Weber, Milena&#xD;Korneev, Artem&#xD;Tulaeva, Inna&#xD;Gattinger, Pia&#xD;van Hage, Marianne&#xD;Hofer, Gerhard&#xD;Konradsen, Jon R&#xD;Keller, Walter&#xD;Akinfenwa, Oluwatoyin&#xD;Poroshina, Alina&#xD;Ilina, Nataliya&#xD;Fedenko, Elena&#xD;Elisyutina, Olga&#xD;Litovkina, Alla&#xD;Smolnikov, Evgenii&#xD;Nikonova, Aleksandra&#xD;Rybalkin, Sergei&#xD;Aldobaev, Vladimir&#xD;Smirnov, Valeriy&#xD;Shershakova, Nadezhda&#xD;Petukhova, Olga&#xD;Kudlay, Dmitriy&#xD;Shatilov, Artem&#xD;Timofeeva, Anastasiya&#xD;Campana, Raffaela&#xD;Udin, Sergei&#xD;Skvortsova, Veronica&#xD;eng&#xD;Austrian Science Fund/&#xD;Megagrants/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):1001-1017. doi: 10.1111/all.15919. Epub 2023 Oct 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37855043</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15919</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>727</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">727</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tejedor-Alonso, M. A.</style></author><author><style face="normal" font="default" size="100%">Perez-Codesido, S.</style></author><author><style face="normal" font="default" size="100%">Nieto-Nieto, A.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Moreno, A.</style></author><author><style face="normal" font="default" size="100%">Rosado Ingelmo, A.</style></author><author><style face="normal" font="default" size="100%">Laiseca Garcia, J.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Bravo, L.</style></author><author><style face="normal" font="default" size="100%">Alberti-Masgrau, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Universitario Fundacion Alcorcon, Alcorcon (Madrid), Spain.&#xD;Facultad Ciencias de la Salud, Department of Medical Specialties and Public Health, Universidad Rey Juan Carlos, Alcorcon (Madrid), Spain.&#xD;International Doctoral School, Facultad Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcon (Madrid), Spain.&#xD;Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrence of anaphylaxis: A systematic review of observational studies</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1020-1025</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/10/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">rate</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34704265</style></accession-num><notes><style face="normal" font="default" size="100%">Tejedor-Alonso, Miguel A&#xD;Perez-Codesido, Sabela&#xD;Nieto-Nieto, Ana&#xD;Gonzalez-Moreno, Ana&#xD;Rosado Ingelmo, Ana&#xD;Laiseca Garcia, Jimena&#xD;Gonzalez-Bravo, Lucia&#xD;Alberti-Masgrau, Nuria&#xD;eng&#xD;Letter&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):1020-1025. doi: 10.1111/all.15156. Epub 2021 Nov 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34704265</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15156</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2680</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2680</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Puel, M.</style></author><author><style face="normal" font="default" size="100%">Rossignol, J.</style></author><author><style face="normal" font="default" size="100%">Devin, C.</style></author><author><style face="normal" font="default" size="100%">Madrange, M.</style></author><author><style face="normal" font="default" size="100%">Diep, A.</style></author><author><style face="normal" font="default" size="100%">Roland, P. N.</style></author><author><style face="normal" font="default" size="100%">Chollet-Martin, S.</style></author><author><style face="normal" font="default" size="100%">Husson, J.</style></author><author><style face="normal" font="default" size="100%">Hermine, O.</style></author><author><style face="normal" font="default" size="100%">Bodemer, C.</style></author><author><style face="normal" font="default" size="100%">Brouzes, C.</style></author><author><style face="normal" font="default" size="100%">De Chaisemartin, L.</style></author><author><style face="normal" font="default" size="100%">Polivka, L.</style></author><author><style face="normal" font="default" size="100%">Ceremast network</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">AP-HP, Immunology Laboratory, Bichat Hospital, Paris, France.&#xD;CEREMAST, Imagine Institute, INSERM U1163, AP-HP, Necker-Children&apos;s Hospital, Paris Centre University, Paris, France.&#xD;Department of Hematology, AP-HP, Necker-Children&apos;s Hospital, Paris, France.&#xD;Data Science Platform, Imagine Institute, INSERM U1163, Paris Centre University, Paris, France.&#xD;AP-HP, Necker-Children&apos;s Hospital, Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Paris Centre University, Paris, France.&#xD;AP-HP, Hematology Laboratory, Necker-Children&apos;s Hospital, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Redefining tryptase norms in the pediatric population reveals sex-based differences: Clinical implications</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">335-338</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/10/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">hereditary alpha-tryptasemia</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric allergy</style></keyword><keyword><style face="normal" font="default" size="100%">serum basal tryptase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39425617</style></accession-num><notes><style face="normal" font="default" size="100%">Puel, Mathilde&#xD;Rossignol, Julien&#xD;Devin, Clotilde&#xD;Madrange, Marine&#xD;Diep, Antoine&#xD;Roland, Pascale Nicaise&#xD;Chollet-Martin, Sylvie&#xD;Husson, Julien&#xD;Hermine, Olivier&#xD;Bodemer, Christine&#xD;Brouzes, Chantal&#xD;De Chaisemartin, Luc&#xD;Polivka, Laura&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):335-338. doi: 10.1111/all.16365. Epub 2024 Oct 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39425617</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724225</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16365</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>909</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">909</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Craig, N.</style></author><author><style face="normal" font="default" size="100%">Ahrens, K.</style></author><author><style face="normal" font="default" size="100%">Wilkes, R.</style></author><author><style face="normal" font="default" size="100%">Marsella, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reduced IL-31 receptor alpha splice variant mRNA following allergen challenge in a canine model of atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3206-3209</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34255350</style></accession-num><notes><style face="normal" font="default" size="100%">Craig, Nicky&#xD;Ahrens, Kim&#xD;Wilkes, Rachel&#xD;Marsella, Rosanna&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3206-3209. doi: 10.1111/all.15005. Epub 2021 Jul 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34255350</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15005</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>54</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">54</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gorris, S.</style></author><author><style face="normal" font="default" size="100%">Uyttebroek, S.</style></author><author><style face="normal" font="default" size="100%">Backaert, W.</style></author><author><style face="normal" font="default" size="100%">Jorissen, M.</style></author><author><style face="normal" font="default" size="100%">Schrijvers, R.</style></author><author><style face="normal" font="default" size="100%">Thompson, M. J.</style></author><author><style face="normal" font="default" size="100%">Loeckx, D.</style></author><author><style face="normal" font="default" size="100%">Seys, S. F.</style></author><author><style face="normal" font="default" size="100%">Van Gerven, L.</style></author><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hippo Dx, Aarschot, Belgium.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, UZ Leuven, Leuven, Belgium.&#xD;Laboratory of Experimental Otorhinolaryngology, Department of Neurosciences, KU Leuven, Leuven, Belgium.&#xD;Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology &amp; Transplantation, KU Leuven, Leuven, Belgium.&#xD;Department of General Internal Medicine, UZ Leuven, Leuven, Belgium.&#xD;Zurich University of Applied Sciences, Winterthur, Switzerland.&#xD;Department of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Otorhinolaryngology, University of Ghent, Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reduced intra-subject variability of an automated skin prick test device compared to a manual test</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1366-1368</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36495473</style></accession-num><notes><style face="normal" font="default" size="100%">Gorris, Senne&#xD;Uyttebroek, Saartje&#xD;Backaert, Wout&#xD;Jorissen, Mark&#xD;Schrijvers, Rik&#xD;Thompson, Mark J&#xD;Loeckx, Dirk&#xD;Seys, Sven F&#xD;Van Gerven, Laura&#xD;Hellings, Peter W&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1366-1368. doi: 10.1111/all.15619. Epub 2022 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36495473</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15619</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2218</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2218</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liao, T. L.</style></author><author><style face="normal" font="default" size="100%">Lin, C. C.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. H.</style></author><author><style face="normal" font="default" size="100%">Tang, K. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.&#xD;Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.&#xD;Institute of Biomedical Science, the iEGG and Animal Biotechnology Center, National Chung-Hsing University, Taichung, Taiwan.&#xD;Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.&#xD;Department of Pharmacology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.&#xD;Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.&#xD;Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.&#xD;Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reduced miR-223 increases blood neutrophil extracellular trap and promotes skin inflammation in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3252-3254</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">*Extracellular Traps</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37365911</style></accession-num><notes><style face="normal" font="default" size="100%">Liao, Tsai-Ling&#xD;Lin, Chi-Chien&#xD;Chen, Yi-Hsing&#xD;Tang, Kuo-Tung&#xD;eng&#xD;Taichung Veterans General Hospital/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3252-3254. doi: 10.1111/all.15794. Epub 2023 Jun 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37365911</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15794</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3039</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3039</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Coenen, I.</style></author><author><style face="normal" font="default" size="100%">Jones, A. C.</style></author><author><style face="normal" font="default" size="100%">White, A. A.</style></author><author><style face="normal" font="default" size="100%">Takashima, M.</style></author><author><style face="normal" font="default" size="100%">Lee, W. R.</style></author><author><style face="normal" font="default" size="100%">Wong, M. D.</style></author><author><style face="normal" font="default" size="100%">Vilcins, D.</style></author><author><style face="normal" font="default" size="100%">Kadolsky, U.</style></author><author><style face="normal" font="default" size="100%">Cheema, A. S.</style></author><author><style face="normal" font="default" size="100%">Saxena, A.</style></author><author><style face="normal" font="default" size="100%">Bosco, A.</style></author><author><style face="normal" font="default" size="100%">Grimwood, K.</style></author><author><style face="normal" font="default" size="100%">Sly, P. D.</style></author><author><style face="normal" font="default" size="100%">Strickland, D. H.</style></author><author><style face="normal" font="default" size="100%">Leffler, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Wal-Yan Respiratory Research Centre, The Kids Research Institute Australia, University of Western Australia, Perth, Western Australia, Australia.&#xD;INSiGENe Pty Ltd, Perth, Western Australia, Australia.&#xD;The Kids Research Institute Australia, University of Western Australia, Perth, Western Australia, Australia.&#xD;Child Health Research Centre, The University of Queensland, South Brisbane, Queensland, Australia.&#xD;Genomics WA, Perth, Western Australia, Australia.&#xD;Asthma and Airway Disease Research Center, University of Arizona, Tucson, Arizona, USA.&#xD;Department of Immunobiology, University of Arizona College of Medicine, Tucson, Arizona, USA.&#xD;School of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reduced Type-I Interferon by Plasmacytoid Dendritic Cells and Asthma in School-Aged Children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">109-120</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/08/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/immunology/metabolism/etiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Dendritic Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Interferon Type I/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">childhood asthma</style></keyword><keyword><style face="normal" font="default" size="100%">interferon response</style></keyword><keyword><style face="normal" font="default" size="100%">plasmacytoid dendritic cells</style></keyword><keyword><style face="normal" font="default" size="100%">Respiradigm Pty Ltd. that is related to this work. A.B. is the founder of</style></keyword><keyword><style face="normal" font="default" size="100%">INSiGENe Pty Ltd.</style></keyword><keyword><style face="normal" font="default" size="100%">the rest of the authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40799176</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic sensitization and reduced ability to respond to viral infections may contribute to virus-induced wheeze and asthma development in young children. Plasmacytoid dendritic cells (pDC) are rare immune cells that produce type I interferons (IFN-I) and play a key role in orchestrating immune responses against viruses. OBJECTIVE: To further evaluate the function of pDC in children with asthma. METHODS: This study was based on a subset of 71 children from the Early Life Lung Function (ELLF) cohort at the age of 7 years. As part of the ELLF study, participants were characterized for atopic sensitization, viral infection history, and lung function testing. pDC responses to a TLR7/8 agonist were assessed in the presence or absence of anti-IgE using an in vitro assay. Responses were evaluated utilizing flow cytometry, multiplexed cytokine assays, and transcriptional analysis of isolated pDC. RESULTS: pDC responses varied considerably across individuals, and those who responded with IFN-I following stimulation showed a lower proportion of asthma compared to those who responded with TNF-only. A TNF-only response was associated with increased atopy and reduced upregulation of IFN-associated genes. Anti-IgE stimulation reduced pDC activation, and the reduction was associated with baseline expression of the IgE receptor (FcepsilonR1). A reduction in a gene module centralized around genes such as TPM2, LILRA4, and CLEC4C was also observed. CONCLUSION: Together, these findings suggest that pDC responses are variable, associated with asthma, and appear influenced by environmental stimuli. This response thus appears to be an important aspect of asthma pathology in children.</style></abstract><notes><style face="normal" font="default" size="100%">Coenen, Isabelle&#xD;Jones, Anya C&#xD;White, Alice A&#xD;Takashima, Mari&#xD;Lee, Wen Ray&#xD;Wong, Matthew D&#xD;Vilcins, Dwan&#xD;Kadolsky, Ulrich&#xD;Cheema, Ali Sadiq&#xD;Saxena, Alka&#xD;Bosco, Anthony&#xD;Grimwood, Keith&#xD;Sly, Peter D&#xD;Strickland, Deborah H&#xD;Leffler, Jonatan&#xD;eng&#xD;Stan Perron Charitable Foundation/&#xD;Wal-yan Respiratory Research Centre/&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):109-120. doi: 10.1111/all.70005. Epub 2025 Aug 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40799176</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773650</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70005</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2158</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2158</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abbasi, Kamran</style></author><author><style face="normal" font="default" size="100%">Ali, Parveen</style></author><author><style face="normal" font="default" size="100%">Barbour, Virginia</style></author><author><style face="normal" font="default" size="100%">Bibbins-Domingo, Kirsten</style></author><author><style face="normal" font="default" size="100%">Gm Olde Rikkert, Marcel</style></author><author><style face="normal" font="default" size="100%">Gong, Peng</style></author><author><style face="normal" font="default" size="100%">Haines, Andy</style></author><author><style face="normal" font="default" size="100%">Helfand, Ira</style></author><author><style face="normal" font="default" size="100%">Horton, Richard</style></author><author><style face="normal" font="default" size="100%">Mash, Bob</style></author><author><style face="normal" font="default" size="100%">Mitra, Arun</style></author><author><style face="normal" font="default" size="100%">Monteiro, Carlos</style></author><author><style face="normal" font="default" size="100%">N. Naumova, Elena</style></author><author><style face="normal" font="default" size="100%">J. Rubin, Eric</style></author><author><style face="normal" font="default" size="100%">Ruff, Tilman</style></author><author><style face="normal" font="default" size="100%">Sahni, Peush</style></author><author><style face="normal" font="default" size="100%">Tumwine, James</style></author><author><style face="normal" font="default" size="100%">Yonga, Paul</style></author><author><style face="normal" font="default" size="100%">Zielinski, Chris</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Editor-in-Chief, British Medical Journal.&#xD;Editor-in-Chief, International Nursing Review.&#xD;Editor-in-Chief, Medical Journal of Australia.&#xD;Editor-in-Chief, Journal of the American Medical Association.&#xD;Editor-in-Chief, Dutch Journal of Medicine.&#xD;Editor-in-Chief, Chinese Science Bulletin.&#xD;London School of Hygiene and Tropical Medicine.&#xD;Past President, International Physicians for the Prevention of Nuclear War.&#xD;Editor-in-Chief, The Lancet.&#xD;Editor-in-Chief, African Journal of Primary Health Care &amp; Family Medicine.&#xD;Editor-in-Chief, Revista de Saude Publica.&#xD;Editor-in-Chief, Journal of Public Health Policy.&#xD;Editor-in-Chief, New England Journal of Medicine.&#xD;Editor-in-Chief, National Medical Journal of India.&#xD;Editor-in-Chief, African Health Sciences.&#xD;Editor-in-Chief, East African Medical Journal.&#xD;University of Winchester, World Association of Medical Editors.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reducing the risks of nuclear war—the role of health professionals</style></title><secondary-title><style face="normal" font="default" size="100%">Ghana Medical Journal</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">165-166</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/07/03</style></edition><section><style face="normal" font="default" size="100%">2826</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nuclear Warfare/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Professional Role</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0016-9560</style></isbn><accession-num><style face="normal" font="default" size="100%">38957676</style></accession-num><notes><style face="normal" font="default" size="100%">Abbasi, Kamran&#xD;Ali, Parveen&#xD;Barbour, Virginia&#xD;Bibbins-Domingo, Kirsten&#xD;Rikkert, Marcel Gm Olde&#xD;Gong, Peng&#xD;Haines, Andy&#xD;Helfand, Ira&#xD;Horton, Richard&#xD;Mash, Bob&#xD;Mitra, Arun&#xD;Monteiro, Carlos&#xD;Naumova, Elena N&#xD;Rubin, Eric J&#xD;Ruff, Tilman&#xD;Sahni, Peush&#xD;Tumwine, James&#xD;Yonga, Paul&#xD;Zielinski, Chris&#xD;eng&#xD;Editorial&#xD;Ghana&#xD;Ghana Med J. 2023 Sep;57(3):165-166. doi: 10.4314/gmj.v57i3.1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38957676</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11216728</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.4314/gmj.v57i3.1</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>823</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">823</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Begin, P.</style></author><author><style face="normal" font="default" size="100%">Bird, J. A.</style></author><author><style face="normal" font="default" size="100%">Spergel, J. M.</style></author><author><style face="normal" font="default" size="100%">Campbell, D. E.</style></author><author><style face="normal" font="default" size="100%">Green, T. D.</style></author><author><style face="normal" font="default" size="100%">Bee, K. J.</style></author><author><style face="normal" font="default" size="100%">Lambert, R.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author><author><style face="normal" font="default" size="100%">Fleischer, D. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CHU Sainte-Justine, Montreal, QC, Canada.&#xD;University of Texas Southwestern Medical Center, Dallas, TX, USA.&#xD;Children&apos;s Hospital of Philadelphia, Philadelphia, PA, USA.&#xD;DBV Technologies, Montrouge, France.&#xD;The Children&apos;s Hospital at Westmead, Sydney, NSW, Australia.&#xD;UPMC Children&apos;s Hospital of Pittsburgh, Pittsburgh, PA, USA.&#xD;Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Children&apos;s Hospital Colorado, University of Colorado, Aurora, CO, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3835-3838</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Arachis/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34492123</style></accession-num><notes><style face="normal" font="default" size="100%">Begin, Philippe&#xD;Bird, John Andrew&#xD;Spergel, Jonathan M&#xD;Campbell, Dianne E&#xD;Green, Todd D&#xD;Bee, Katharine J&#xD;Lambert, Romain&#xD;Sampson, Hugh A&#xD;Fleischer, David M&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3835-3838. doi: 10.1111/all.15083. Epub 2021 Sep 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34492123</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9545690 during the conduct of this study, personal fees from Novartis, Pfizer, Sanofi, DBV Technologies, ALK, and Aralez outside the submitted work and research support from Novartis, Regeneron, and Sanofi outside the submitted work. J. Andrew Bird reports research support from DBV Technologies during the conduct of this study, research support from NIH-NIAID, Genentech, Astellas, Aimmune Therapeutics, DBV Technologies, and Food Allergy Research and Education outside the submitted work and consulting fees from Food Allergy Research and Education, Pharm-Olam International LTD, Pfizer, Aimmune, Prota Therapeutics, Allergy Therapeutics, AllerGenis, Abbott Nutrition International, DBV Technologies, and Novartis. Dianne E. Campbell is a part-time employee of DBV Technologies and reported receiving grant support from the National Health and Medical Research Council of Australia and personal fees from AllerGenis, Westmead Fertility Centre, and Financial Markets Foundation for Children. David M. Fleischer received research support to his institution from Aimmune Therapeutics and DBV Technologies and is a member of the Medical Advisory Board for the Food Allergy &amp; Anaphylaxis Connection Team (FAACT), Medical Advisory Council for the National Peanut Board, the Adverse Reactions to Food Committee (former chair 2017-2019) for the AAAAI, and Food Allergy Committee for the ACAAI; has received royalties from UpToDate and is a consultant to AllerGenis, Aquestive, Aravax, Danone, DBV Technologies, Genentech, Intrommune, Nasus, and Nurture Inc (Happy Family Organics). Hugh A. Sampson receives consulting fees from DBV Technologies, Siolta Therapeutics, and N-Fold Therapeutics and received stock options from DBV Technologies and grants to his institution from the National Institutes of Health. Jonathan M. Spergel reports board membership from the American Partnership for Eosinophilic Disorders and the International Food Protein-Induced Enterocolitis Syndrome Association; consultancy fees from DBV Technologies, Sanofi/Regeneron, and Medscape; speaker fees from Abbott; and grants to his institution from the National Institutes of Health and End Allergies Together and Aimmune Therapeutics. Todd D. Green, Katharine J. Bee, and Romain Lambert are employees of DBV Technologies.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15083</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1156</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1156</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sargant, N.</style></author><author><style face="normal" font="default" size="100%">Dodd, A.</style></author><author><style face="normal" font="default" size="100%">Hughes, A.</style></author><author><style face="normal" font="default" size="100%">Whyte, A. F.</style></author><author><style face="normal" font="default" size="100%">Soar, J.</style></author><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Bristol Royal Hospital for Children, Bristol, UK.&#xD;Severn Deanery, Bristol, UK.&#xD;University Hospitals Plymouth NHS Trust, Plymouth, UK.&#xD;North Bristol NHS Trust, Bristol, UK.&#xD;National Heart &amp; Lung Institute, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Refractory anaphylaxis: Treatment algorithm</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1595-1597</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33594699</style></accession-num><notes><style face="normal" font="default" size="100%">Sargant, Nicholas&#xD;Dodd, Amy&#xD;Hughes, Anna&#xD;Whyte, Andrew F&#xD;Soar, Jasmeet&#xD;Turner, Paul J&#xD;eng&#xD;MR/K010468/1/MRC_/Medical Research Council/United Kingdom&#xD;News&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1595-1597. doi: 10.1111/all.14780. Epub 2021 Mar 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33594699</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14780</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1851</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1851</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sargant, N.</style></author><author><style face="normal" font="default" size="100%">Dodd, A.</style></author><author><style face="normal" font="default" size="100%">Hughes, A.</style></author><author><style face="normal" font="default" size="100%">Whyte, A. F.</style></author><author><style face="normal" font="default" size="100%">Soar, J.</style></author><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Bristol Royal Hospital for Children, Bristol, UK.&#xD;Severn Deanery, Bristol, UK.&#xD;University Hospitals Plymouth NHS Trust, Plymouth, UK.&#xD;North Bristol NHS Trust, Bristol, UK.&#xD;National Heart &amp; Lung Institute, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Refractory anaphylaxis: Treatment algorithm</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1595-1597</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33594699</style></accession-num><notes><style face="normal" font="default" size="100%">Sargant, Nicholas&#xD;Dodd, Amy&#xD;Hughes, Anna&#xD;Whyte, Andrew F&#xD;Soar, Jasmeet&#xD;Turner, Paul J&#xD;eng&#xD;MR/K010468/1/MRC_/Medical Research Council/United Kingdom&#xD;News&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1595-1597. doi: 10.1111/all.14780. Epub 2021 Mar 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33594699</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14780</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1303</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1303</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Song, J.</style></author><author><style face="normal" font="default" size="100%">Pan, L.</style></author><author><style face="normal" font="default" size="100%">Deng, Y. K.</style></author><author><style face="normal" font="default" size="100%">Yao, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, Z. C.</style></author><author><style face="normal" font="default" size="100%">Liao, B.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">Zeng, M.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Regional differences in ACE2 expression in the sinonasal mucosa of adult Chinese patients with chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1565-1568</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mucous Membrane</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">angiotensin-converting enzyme II</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus disease 2019</style></keyword><keyword><style face="normal" font="default" size="100%">inferior turbinate</style></keyword><keyword><style face="normal" font="default" size="100%">interferon</style></keyword><keyword><style face="normal" font="default" size="100%">sinus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33037637</style></accession-num><notes><style face="normal" font="default" size="100%">Wang, Hai&#xD;Song, Jia&#xD;Pan, Li&#xD;Deng, Yi-Ke&#xD;Yao, Yin&#xD;Wang, Zhi-Chao&#xD;Liao, Bo&#xD;Ma, Jin&#xD;Zeng, Ming&#xD;Liu, Zheng&#xD;eng&#xD;2018CFB602/Natural Science Foundation of Hubei Province of China/&#xD;81630024/National Natural Science Foundation of China/&#xD;81900925/National Natural Science Foundation of China/&#xD;81920108011/National Natural Science Foundation of China/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1565-1568. doi: 10.1111/all.14623. Epub 2020 Oct 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33037637</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7675498</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14623</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2365</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2365</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meisser, S. S.</style></author><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Altunbulakli, C.</style></author><author><style face="normal" font="default" size="100%">Bandier, J.</style></author><author><style face="normal" font="default" size="100%">Opstrup, M. S.</style></author><author><style face="normal" font="default" size="100%">Gadsboll, A. O.</style></author><author><style face="normal" font="default" size="100%">Li, M.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Geisler, C.</style></author><author><style face="normal" font="default" size="100%">Johansen, J. D.</style></author><author><style face="normal" font="default" size="100%">Bonefeld, C. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Allergy Research Centre, Department of Dermato-Allergology, Copenhagen University Hospital Gentofte, Hellerup, Denmark.&#xD;The LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland.&#xD;Christine Kuhne- Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Regulation of immune response genes in the skin of allergic and clinically tolerant individuals exposed to p-phenylenediamine</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1291-1305</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Phenylenediamines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact/immunology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/immunology/pathology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Regulation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Hair Dyes/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Patch Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Ppd</style></keyword><keyword><style face="normal" font="default" size="100%">RNA sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">confocal microscopy</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38263750</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: p-Phenylenediamine (PPD) is a potent contact allergen found in many hair colour products. However, not all individuals develop allergic contact dermatitis (ACD) although they are regularly exposed to PPD. It is unclear whether these asymptomatic individuals are true non-responders to PPD or whether they mount a response to PPD without showing any symptoms. METHODS: Skin biopsies were collected from 11 asymptomatic hairdressers regularly exposed to PPD and from 10 individuals with known ACD on day 4 after patch testing with 1% PPD in petrolatum and petrolatum exclusively as control. RNA sequencing and confocal microscopy were performed. RESULTS: T cell activation, inflammation and apoptosis pathways were up-regulated by PPD in both asymptomatic and allergic individuals. Compared to asymptomatic individuals with a negative patch test, individuals with a strong reaction to PPD strongly up-regulated both pro- and anti-inflammatory cytokines genes. Interestingly, PPD treatment induced significant up-regulation of several genes for chemokines, classical type 2 dendritic cell markers and regulatory T cell markers in both asymptomatic and allergic individuals. In addition, apoptosis signalling pathway was activated in both non-responders and allergic individuals. CONCLUSION: This study demonstrates that there are no true non-responders to PPD but that the immune response elicited by PPD differs between individuals and can lead to either tolerance, subclinical inflammation or allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Meisser, Sanne S&#xD;Mitamura, Yasutaka&#xD;Altunbulakli, Can&#xD;Bandier, Josefine&#xD;Opstrup, Morten S&#xD;Gadsboll, Anne-Sofie O&#xD;Li, Manru&#xD;Tan, Ge&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;Geisler, Carsten&#xD;Johansen, Jeanne D&#xD;Bonefeld, Charlotte M&#xD;eng&#xD;Danish Hairdressers and Beauticians&apos; Union/&#xD;Danish Hairdresser Association/&#xD;LEO foundation/&#xD;Swiss Institute for Asthma and Allergy Research/&#xD;Danish Working Environment Research Fund/&#xD;Aage Bangs Foundation/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1291-1305. doi: 10.1111/all.16031. Epub 2024 Jan 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38263750</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16031</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2383</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2383</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Korver, W.</style></author><author><style face="normal" font="default" size="100%">Benet, Z.</style></author><author><style face="normal" font="default" size="100%">Wong, A.</style></author><author><style face="normal" font="default" size="100%">Negri, G. L.</style></author><author><style face="normal" font="default" size="100%">Chang, K.</style></author><author><style face="normal" font="default" size="100%">Sanchez, R.</style></author><author><style face="normal" font="default" size="100%">Leung, J.</style></author><author><style face="normal" font="default" size="100%">De Freitas, N.</style></author><author><style face="normal" font="default" size="100%">Luu, T.</style></author><author><style face="normal" font="default" size="100%">Schanin, J.</style></author><author><style face="normal" font="default" size="100%">Youngblood, B. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allakos Inc., San Carlos, California, USA.&#xD;LM Biostat Consulting Inc., Victoria, British Columbia, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Regulation of mast cells by overlapping but distinct protein interactions of Siglec-6 and Siglec-8</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">629-642</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, CD/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Sialic Acid Binding Immunoglobulin-like Lectins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-kit/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Kit</style></keyword><keyword><style face="normal" font="default" size="100%">Siglec</style></keyword><keyword><style face="normal" font="default" size="100%">interactome</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38186079</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Sialic acid-binding immunoglobulin-like lectin (Siglec)-6 and Siglec-8 are closely related mast cell (MC) receptors with broad inhibitory activity, but whose functional differences are incompletely understood. METHODS: Proteomic profiling using quantitative mass spectrometry was performed on primary mouse MCs to identify proteins associated with Siglec-6 and Siglec-8. For functional characterization, each receptor was evaluated biochemically and in ex vivo and in vivo inhibition models of IgE and non-IgE-mediated MC activation in Siglec-6- or Siglec-8-expressing transgenic mice. RESULTS: Siglec-6 and Siglec-8 were found in MCs within large complexes, interacting with 66 and 86 proteins, respectively. Strikingly, Siglec-6 and Siglec-8 interacted with a large cluster of proteins involved in IgE and non-IgE-mediated MC activation, including the high affinity IgE receptor, stem cell factor (SCF) receptor KIT/CD117, IL-4 and IL-33 receptors, and intracellular kinases LYN and JAK1. Protein interaction networks revealed Siglec-6 and Siglec-8 had overlapping yet distinct MC functions, with a potentially broader regulatory role for Siglec-6. Indeed, Siglec-6 preferentially interacted with the mature form of KIT at the cell surface, and treatment with an anti-Siglec-6 antibody significantly inhibited SCF-mediated MC activation more in comparison to targeting Siglec-8. CONCLUSION: These data demonstrate a central role for Siglec-6 and Siglec-8 in controlling MC activation through interactions with multiple activating receptors and key signaling molecules. Our findings suggest that Siglec-6 has a role distinct from that of Siglec-8 in regulating MC function and represents a distinct potential therapeutic target in mast cell-driven diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Korver, Wouter&#xD;Benet, Zachary&#xD;Wong, Alan&#xD;Negri, Gian Luca&#xD;Chang, Katherine&#xD;Sanchez, Robert&#xD;Leung, John&#xD;De Freitas, Naomi&#xD;Luu, Thuy&#xD;Schanin, Julia&#xD;Youngblood, Bradford A&#xD;eng&#xD;Allakos, Inc./&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):629-642. doi: 10.1111/all.16004. Epub 2024 Jan 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38186079</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16004</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1174</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1174</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jansen, K.</style></author><author><style face="normal" font="default" size="100%">Cevhertas, L.</style></author><author><style face="normal" font="default" size="100%">Ma, S.</style></author><author><style face="normal" font="default" size="100%">Satitsuksanoa, P.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Medical Immunology, Institute of Health Sciences, Bursa Uludag University, Bursa, Turkey.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Otolaryngology Head and Neck Surgery+, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Regulatory B cells, A to Z</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2699-2715</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/02/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*B-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Breg cells</style></keyword><keyword><style face="normal" font="default" size="100%">Il-10</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">suppression</style></keyword><keyword><style face="normal" font="default" size="100%">tolerance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33544905</style></accession-num><abstract><style face="normal" font="default" size="100%">B cells play a central role in the immune system through the production of antibodies. During the past two decades, it has become increasingly clear that B cells also have the capacity to regulate immune responses through mechanisms that extend beyond antibody production. Several types of human and murine regulatory B cells have been reported that suppress inflammatory responses in autoimmune disease, allergy, infection, transplantation, and cancer. Key suppressive molecules associated with regulatory B-cell function include the cytokines IL-10, IL-35, and TGF-beta as well as cell membrane-bound molecules such as programmed death-ligand 1, CD39, CD73, and aryl hydrocarbon receptor. Regulatory B cells can be induced by a range of different stimuli, including microbial products such as TLR4 or TLR9 ligands, inflammatory cytokines such as IL-6, IL-1beta, and IFN-alpha, as well as CD40 ligation. This review provides an overview of our current knowledge on regulatory B cells. We discuss different types of regulatory B cells, the mechanisms through which they exert their regulatory functions, factors that lead to induction of regulatory B cells and their role in the alteration of inflammatory responses in different diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Jansen, Kirstin&#xD;Cevhertas, Lacin&#xD;Ma, Siyuan&#xD;Satitsuksanoa, Pattraporn&#xD;Akdis, Mubeccel&#xD;van de Veen, Willem&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2699-2715. doi: 10.1111/all.14763. Epub 2021 Mar 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33544905</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14763</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1037</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1037</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wagner, R.</style></author><author><style face="normal" font="default" size="100%">Meissner, J.</style></author><author><style face="normal" font="default" size="100%">Grabski, E.</style></author><author><style face="normal" font="default" size="100%">Sun, Y.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author><author><style face="normal" font="default" size="100%">Hildt, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section for Viral Vaccines, Department of Virology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.&#xD;Vice President, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.&#xD;Department of Virology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">72-82</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 pandemic</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">licensure</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory requirements</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr. Elena Grabski has nothing to disclose. Dr. Yuansheng Sun has</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose. Dr. Stefan Vieths reports personal fees from Schattauer</style></keyword><keyword><style face="normal" font="default" size="100%">Allergologie Handbuch, personal fees from Elsevier Nahrung smittel allergien und</style></keyword><keyword><style face="normal" font="default" size="100%">Intoleranzen, personal fees from Karger Food Allergy: Molecular Basis and</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Practice, non-financial support from German Research Foundation,</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from European Directorate for the Quality of Medicines and</style></keyword><keyword><style face="normal" font="default" size="100%">Health Care, non-financial support from European Academy of Allergy and Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Immunology, non-financial support from German Chemical Society (GDCh),</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from AKM Allergiekongress, non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">International Union of Immunological Societies, non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">Spanish Society for Allergy and Clinical Immunology (SEAIC), outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. Dr. Eberhard Hildt has nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33887070</style></accession-num><abstract><style face="normal" font="default" size="100%">The ongoing COVID-19 pandemic caused by the SARS-CoV-2 coronavirus has affected the health of tens of millions of people worldwide. In particular, in elderly and frail individuals the infection can lead to severe disease and even fatal outcomes. Although the pandemic is primarily a human health crisis its consequences are much broader with a tremendous impact on global economics and social systems. Vaccines are considered the most powerful measure to fight the pandemic and protect people from COVID-19. Based on the concerted activities of scientists, manufacturers and regulators, the urgent need for effective countermeasures has provoked the development and licensure of novel COVID-19 vaccines in an unprecedentedly fast and flexible manner within &lt;1 year. To ensure the safety and efficacy of these novel vaccines during the clinical development and the routine use in post-licensure vaccination campaigns existing regulatory requirements and procedures had to be wisely and carefully adapted to allow for an expedited evaluation without compromising the thoroughness of the regulatory and scientific assessment. In this review, we describe the regulatory procedures, concepts and requirements applied to guide and promote the highly accelerated development and licensure of safe and efficacious COVID-19 vaccines in Europe.</style></abstract><notes><style face="normal" font="default" size="100%">Wagner, Ralf&#xD;Meissner, Juliane&#xD;Grabski, Elena&#xD;Sun, Yuansheng&#xD;Vieths, Stefan&#xD;Hildt, Eberhard&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):72-82. doi: 10.1111/all.14868. Epub 2021 May 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33887070</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8251031</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14868</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>803</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">803</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Li, Q.</style></author><author><style face="normal" font="default" size="100%">Pan, R.</style></author><author><style face="normal" font="default" size="100%">Wang, Q.</style></author><author><style face="normal" font="default" size="100%">Zhu, X.</style></author><author><style face="normal" font="default" size="100%">Yuan, C.</style></author><author><style face="normal" font="default" size="100%">Cai, F.</style></author><author><style face="normal" font="default" size="100%">Gao, Y. D.</style></author><author><style face="normal" font="default" size="100%">Cui, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics Laboratory, The Affiliated Wuxi Children&apos;s Hospital of Nanjing Medical University, Wuxi, China.&#xD;Department of Clinical Laboratory, The Affiliated Wuxi People&apos;s Hospital of Nanjing Medical University, Wuxi, China.&#xD;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Regulatory roles of three miRNAs on allergen mRNA expression in Tyrophagus putrescentiae</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">469-482</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/09/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Acaridae</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Regulatory Networks</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Mites</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Tyrophagus putrescentiae</style></keyword><keyword><style face="normal" font="default" size="100%">double-fluorescent reporter gene system</style></keyword><keyword><style face="normal" font="default" size="100%">microRNA</style></keyword><keyword><style face="normal" font="default" size="100%">qRT-PCR</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34570913</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tyrophagus putresecentiae is an important mite species in rural and urban environments, causing sensitization and allergic disease. While evidence suggests that microRNAs (miRNAs) may regulate the expression of allergen-encoding genes, no study has directly investigated this possibility. Here, this gap was addressed by profiling miRNAs and elucidating their target allergen messenger RNAs (mRNAs) in this mite species. METHODS: Small RNA and transcriptome libraries were constructed for eggs, larvae, nymphs, and adults. After deep miRNA and whole-transcriptome sequencing were performed, the miRNA and allergen-encoding mRNA regulatory networks were explored. RESULTS: A total of 540 miRNAs were identified, including 155 with expression levels differing significantly across the four mite developmental stages (p &lt; .01), 59 of which were novel. The mRNA expression for allergens was higher for Tyr p 1 in adults than in other developmental stages; Tyr p 2-5, 7, 10, 13, 33, and 34 in immature stages; and Tyr p 28, 35, and 36 in eggs and adults. A combined miRNA and transcriptome bioinformatics analysis showed that allergen Tyr p 3 was regulated by miRNA PC-5p-5698441_1, Tyr p 4 was regulated by PC-5p-7050653_1, and Tyr p 34 was regulated by PC-5p-5534223_1 and PC-5p-5698441_1. These three allergen mRNA and three miRNAs were identified using qRT-PCR, and their regulatory roles were confirmed by double-fluorescent reporter gene system and site-directed mutagenesis technology. CONCLUSIONS: For the first time, allergen mRNA expression and miRNAs were profiled throughout the life cycle for an allergen-producing mite, and the results showed that miRNAs bind to target allergen mRNAs to regulate their expression.</style></abstract><notes><style face="normal" font="default" size="100%">Zhou, Ying&#xD;Li, Qingqing&#xD;Pan, Ruilin&#xD;Wang, Qiong&#xD;Zhu, Xuming&#xD;Yuan, Cunyin&#xD;Cai, Fangfang&#xD;Gao, Ya-Dong&#xD;Cui, Yubao&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):469-482. doi: 10.1111/all.15111. Epub 2021 Oct 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34570913</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15111</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>384</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">384</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Elewaut, D.</style></author><author><style face="normal" font="default" size="100%">Irving, P. M.</style></author><author><style face="normal" font="default" size="100%">Jaumont, X.</style></author><author><style face="normal" font="default" size="100%">Tassinari, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Complutense University of Madrid, Madrid, Spain.&#xD;Department of Rheumatology, VIB Center for Inflammation Research, Ghent University, Ghent University Hospital, Ghent, Belgium.&#xD;Guy&apos;s and St Thomas&apos; Hospital Foundation Trust, London, UK.&#xD;King&apos;s College London, London, UK.&#xD;Novartis Pharma AG, Basel, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Regulatory T cells and immunoglobulin E: A new therapeutic link for autoimmunity?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3293-3308</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Autoimmune Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">anti-IgE</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmune disease</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35852798</style></accession-num><abstract><style face="normal" font="default" size="100%">Autoimmune diseases have a prevalence of approximately 7 to 9% and are classified as either organ-specific diseases, including type I diabetes, multiple sclerosis, inflammatory bowel disease and myasthenia gravis, or systemic diseases, including systemic lupus erythematosus, rheumatoid arthritis and Sjogren&apos;s syndrome. While many advancements have been made in understanding of the mechanisms of autoimmune disease, including the nature of self-tolerance and its breakdown, there remain unmet needs in terms of effective and highly targeted treatments. T regulatory cells (Tregs) are key mediators of peripheral tolerance and are implicated in many autoimmune diseases, either as a result of reduced numbers or altered function. Tregs may be broadly divided into those generated in the thymus (tTregs) and those generated in the periphery (pTregs). Tregs target many different immune cell subsets and tissues to suppress excessive inflammation and to support tissue repair and homeostasis: there is a fine balance between Treg cell stability and the plasticity that is required to adjust Tregs&apos; regulatory purposes to particular immune responses. The central role of immunoglobulin E (IgE) in allergic disease is well recognized, and it is becoming increasingly apparent that this immunoglobulin also has a wider role encompassing other diseases including autoimmune disease. Anti-IgE treatment restores the capacity of plasmacytoid dendritic cells (pDCs) impaired by IgE- high-affinity IgE receptor (FcepsilonR1) cross-linking to induce Tregs in vitro in atopic patients. The finding that anti-IgE therapy restores Treg cell homeostasis, and that this mechanism is associated with clinical improvement in asthma and chronic spontaneous urticaria suggests that anti-IgE therapy may also have a potential role in the treatment of autoimmune diseases in which Tregs are involved.</style></abstract><notes><style face="normal" font="default" size="100%">Palomares, Oscar&#xD;Elewaut, Dirk&#xD;Irving, Peter M&#xD;Jaumont, Xavier&#xD;Tassinari, Paolo&#xD;eng&#xD;MR/T005564/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3293-3308. doi: 10.1111/all.15449. Epub 2022 Jul 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35852798</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15449</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2632</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2632</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Conrad, M. L.</style></author><author><style face="normal" font="default" size="100%">Barrientos, G.</style></author><author><style face="normal" font="default" size="100%">Cai, X.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, S.</style></author><author><style face="normal" font="default" size="100%">Das, M.</style></author><author><style face="normal" font="default" size="100%">Stephen-Victor, E.</style></author><author><style face="normal" font="default" size="100%">Harb, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Microbiology, Infectious Diseases and Immunology, Charite Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Institute of Medical Psychology, Charite Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Neonatology and Pediatric Intensive Care, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Laboratory of Experimental Medicine, Hospital Aleman, Buenos Aires, Argentina.&#xD;National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.&#xD;Institute of Medical Microbiology and Virology, Medical Faculty, TU Dresden, University Hospital Dresden, Dresden, Germany.&#xD;Division of Immunology, Boston Children&apos;s Hospital, Boston, Massachusetts, USA.&#xD;Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Pathology, Division of Microbiology and Immunology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Regulatory T cells and their role in allergic disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">77-93</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/06/11</style></edition><section><style face="normal" font="default" size="100%">77</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology/metabolism/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocyte Subsets/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">T regulatory cell</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40497455</style></accession-num><abstract><style face="normal" font="default" size="100%">The incidence of allergic diseases has been rising over the past decades, and this troubling trend coincides with environmental changes such as shifts in diet and increased antibiotic use, both of which can impact our immune system. Allergic reactions occur when the immune system overreacts to normally harmless substances, and it is known that regulatory T cells (Tregs) play a major role in immune system suppression and the generation of tolerance. However, new research suggests that Tregs can malfunction in environments that promote allergies. This review delves into Treg function, and how environmental factors can influence their ability to maintain immune homeostasis. Specifically, we explore the origins of Treg cells, as well as the mechanisms used for suppression of inflammation and tissue healing, with a concentration on food allergies, atopic dermatitis and asthma. Understanding Treg function in the context of a changing environment is crucial for developing new strategies to prevent and treat allergies.</style></abstract><notes><style face="normal" font="default" size="100%">Conrad, Melanie L&#xD;Barrientos, Gabriela&#xD;Cai, Xuejun&#xD;Mukherjee, Saikat&#xD;Das, Mrinmoy&#xD;Stephen-Victor, Emmanuel&#xD;Harb, Hani&#xD;eng&#xD;CO 1058/3-2 (Melanie L. Conrad)/Deutsche Forschungsgemeinschaft/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):77-93. doi: 10.1111/all.16326. Epub 2024 Sep 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40497455</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724253</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16326</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2772</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2772</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leung, A. S.</style></author><author><style face="normal" font="default" size="100%">Xing, Y.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Wong, G. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.&#xD;Hong Kong Hub of Paediatric Excellence (HOPE), The Chinese University of Hong Kong, Hong Kong, China.&#xD;School of Public Health (Shenzhen), Sun Yat-Sen University, Shenzhen, China.&#xD;Allergy Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Relationship Between Dietary Patterns and the Epidemiology of Food Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">690-702</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/12/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Diet/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Scfa</style></keyword><keyword><style face="normal" font="default" size="100%">emulsifier</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">fiber</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">modernization</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional transition</style></keyword><keyword><style face="normal" font="default" size="100%">ultra-processed foods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39723599</style></accession-num><abstract><style face="normal" font="default" size="100%">Food allergies are increasing globally, particularly in Asia; however, the etiologies of allergic diseases remain poorly understood despite comprehensive studies conducted across a variety of populations. Epidemiological research demonstrates that food allergy is more prevalent in Westernized or urbanized societies than in rural or developing ones. As such, comparing the distribution and patterns of food allergies as well as the environmental exposures between regions may provide insight into potential causal and protective factors of food allergy. Diet is an important exposome that has been shown to modulate the immune system both directly and indirectly via pathways involving the microbiota. Changes in dietary patterns, especially the shift to a Westernized diet with reduced dietary fiber and an abundance of processed foods, impact the gut and skin epithelial barrier and contribute to the development of chronic inflammatory diseases, such as food allergy. Although dietary intervention is believed to have tremendous potential as a strategy to promote immunological health, it is essential to recognize that diet is only one of many factors that have changed in urbanized societies. Other factors, such as pollution, microplastics, the use of medications like antibiotics, and exposure to biodiversity and animals, may also play significant roles, and further research is needed to determine which exposures are most critical for the development of food allergies.</style></abstract><notes><style face="normal" font="default" size="100%">Leung, Agnes Sze-Yin&#xD;Xing, Yuhan&#xD;Fernandez-Rivas, Montserrat&#xD;Wong, Gary Wing-Kin&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):690-702. doi: 10.1111/all.16455. Epub 2024 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39723599</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891427</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16455</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>415</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">415</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Diver, S.</style></author><author><style face="normal" font="default" size="100%">Haldar, K.</style></author><author><style face="normal" font="default" size="100%">McDowell, P. J.</style></author><author><style face="normal" font="default" size="100%">Busby, J.</style></author><author><style face="normal" font="default" size="100%">Mistry, V.</style></author><author><style face="normal" font="default" size="100%">Micieli, C.</style></author><author><style face="normal" font="default" size="100%">Brown, V.</style></author><author><style face="normal" font="default" size="100%">Cox, C.</style></author><author><style face="normal" font="default" size="100%">Yang, F.</style></author><author><style face="normal" font="default" size="100%">Borg, C.</style></author><author><style face="normal" font="default" size="100%">Shrimanker, R.</style></author><author><style face="normal" font="default" size="100%">Ramsheh, M. Y.</style></author><author><style face="normal" font="default" size="100%">Hardman, T.</style></author><author><style face="normal" font="default" size="100%">Arron, J.</style></author><author><style face="normal" font="default" size="100%">Bradding, P.</style></author><author><style face="normal" font="default" size="100%">Cowan, D.</style></author><author><style face="normal" font="default" size="100%">Mansur, A. H.</style></author><author><style face="normal" font="default" size="100%">Fowler, S. J.</style></author><author><style face="normal" font="default" size="100%">Lordan, J.</style></author><author><style face="normal" font="default" size="100%">Menzies-Gow, A.</style></author><author><style face="normal" font="default" size="100%">Robinson, D.</style></author><author><style face="normal" font="default" size="100%">Matthews, J.</style></author><author><style face="normal" font="default" size="100%">Pavord, I. D.</style></author><author><style face="normal" font="default" size="100%">Chaudhuri, R.</style></author><author><style face="normal" font="default" size="100%">Heaney, L. G.</style></author><author><style face="normal" font="default" size="100%">Barer, M. R.</style></author><author><style face="normal" font="default" size="100%">Brightling, C.</style></author><author><style face="normal" font="default" size="100%">Medical Research Council: Refractory Asthma Stratification, Programme</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Sciences, Leicester NIHR BRC, Institute for Lung Health, University of Leicester, Leicester, UK.&#xD;Wellcome-Wolfson Centre for Experimental Medicine, School of Medicine, Dentistry, and Biological Sciences, Belfast, UK.&#xD;Queen&apos;s University Belfast, Belfast, UK.&#xD;Regional Virus Laboratory, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, UK.&#xD;Division of Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK.&#xD;Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK.&#xD;Niche Science &amp; Technology Ltd., Unit 26, Falstaff House, Richmond, UK.&#xD;Genentech Inc., South San Francisco, California, USA.&#xD;NHS Greater Glasgow and Clyde, Stobhill Hospital, Glasgow, UK.&#xD;University of Birmingham and Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.&#xD;Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.&#xD;Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.&#xD;The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK.&#xD;Royal Brompton &amp; Harefield Hospitals, London, UK.&#xD;University College Hospitals NHS Foundation Trust, London, UK.&#xD;23andMe, Sunnyvale, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3362-3376</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35778780</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In T2-mediated severe asthma, biologic therapies, such as mepolizumab, are increasingly used to control disease. Current biomarkers can indicate adequate suppression of T2 inflammation, but it is unclear whether they provide information about airway microbial composition. We investigated the relationships between current T2 biomarkers and microbial profiles, characteristics associated with a Proteobacteria(HIGH) microbial profile and the effects of mepolizumab on airway ecology. METHODS: Microbiota sequencing was performed on sputum samples obtained at stable and exacerbation state from 140 subjects with severe asthma participating in two clinical trials. Inflammatory subgroups were compared on the basis of biomarkers, including FeNO and sputum and blood eosinophils. Proteobacteria(HIGH) subjects were identified by Proteobacteria to Firmicutes ratio &gt;/=0.485. Where paired sputum from stable visits was available, we compared microbial composition at baseline and following &gt;/=12 weeks of mepolizumab. RESULTS: Microbial composition was not related to inflammatory subgroup based on sputum or blood eosinophils. FeNO &gt;/=50 ppb when stable and at exacerbation indicated a group with less dispersed microbial profiles characterised by high alpha-diversity and low Proteobacteria. Proteobacteria(HIGH) subjects were neutrophilic and had a longer time from asthma diagnosis than Proteobacteria(LOW) subjects. In those studied, mepolizumab did not alter airway bacterial load or lead to increased Proteobacteria. CONCLUSION: High FeNO could indicate a subgroup of severe asthma less likely to benefit from antimicrobial strategies at exacerbation or in the context of poor control. Where FeNO is &lt;50 ppb, biomarkers of microbial composition are required to identify those likely to respond to microbiome-directed strategies. We found no evidence that mepolizumab alters airway microbial composition.</style></abstract><notes><style face="normal" font="default" size="100%">Diver, Sarah&#xD;Haldar, Koirobi&#xD;McDowell, Pamela Jane&#xD;Busby, John&#xD;Mistry, Vijay&#xD;Micieli, Claudia&#xD;Brown, Vanessa&#xD;Cox, Ciara&#xD;Yang, Freda&#xD;Borg, Catherine&#xD;Shrimanker, Rahul&#xD;Ramsheh, Mohammadali Yavari&#xD;Hardman, Tim&#xD;Arron, Joseph&#xD;Bradding, Peter&#xD;Cowan, Douglas&#xD;Mansur, Adel Hasan&#xD;Fowler, Stephen J&#xD;Lordan, Jim&#xD;Menzies-Gow, Andrew&#xD;Robinson, Douglas&#xD;Matthews, John&#xD;Pavord, Ian D&#xD;Chaudhuri, Rekha&#xD;Heaney, Liam G&#xD;Barer, Michael R&#xD;Brightling, Christopher&#xD;(RASP-UK Consortium)&#xD;eng&#xD;G0801980/MRC_/Medical Research Council/United Kingdom&#xD;MR/M016579/1/MRC_/Medical Research Council/United Kingdom&#xD;DH_/Department of Health/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3362-3376. doi: 10.1111/all.15425. Epub 2022 Jul 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35778780</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15425</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>355</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">355</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Morales-Palacios, M. P.</style></author><author><style face="normal" font="default" size="100%">Nunez-Cordoba, J. M.</style></author><author><style face="normal" font="default" size="100%">Tejero, E.</style></author><author><style face="normal" font="default" size="100%">Matellanes, O.</style></author><author><style face="normal" font="default" size="100%">Quan, P. L.</style></author><author><style face="normal" font="default" size="100%">Carvallo, A.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Fernandez, S.</style></author><author><style face="normal" font="default" size="100%">Urtasun, M.</style></author><author><style face="normal" font="default" size="100%">Larrea, C.</style></author><author><style face="normal" font="default" size="100%">Iniguez, M. T.</style></author><author><style face="normal" font="default" size="100%">Gimenez, R.</style></author><author><style face="normal" font="default" size="100%">Goikoetxea, M. J.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amelio, C. M.</style></author><author><style face="normal" font="default" size="100%">Ferrer, M.</style></author><author><style face="normal" font="default" size="100%">Gastaminza, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain.&#xD;Central Clinical Trials Unit, Research Support Service, Clinica Universidad de Navarra, Pamplona, Spain.&#xD;Nexkin Medical, Donostia-San Sebastian, Spain.&#xD;Spanish Research Network on Allergy RD 1600060031 (ARADyAL: Red Nacional de Alergia -Asma, Reacciones Adversas y Alergicas) of the Carlos III Health Institute, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reliability of a novel electro-medical device for wheal size measurement in allergy skin testing: An exploratory clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">299-301</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/08/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">automated measurement</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">prick test</style></keyword><keyword><style face="normal" font="default" size="100%">Measuring Wheals and Detecting Allergies. OM and ET are Nexkin Medical employees</style></keyword><keyword><style face="normal" font="default" size="100%">and shareholders. The remaining authors have no conflicts of interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35950712</style></accession-num><notes><style face="normal" font="default" size="100%">Morales-Palacios, Maria de la Paz&#xD;Nunez-Cordoba, Jorge M&#xD;Tejero, Eduardo&#xD;Matellanes, Oscar&#xD;Quan, Paola Leonor&#xD;Carvallo, Alvaro&#xD;Sanchez-Fernandez, Sergio&#xD;Urtasun, Maite&#xD;Larrea, Carla&#xD;Iniguez, Maria Teresa&#xD;Gimenez, Rosa&#xD;Goikoetxea, Maria Jose&#xD;D&apos;Amelio, Carmen M&#xD;Ferrer, Marta&#xD;Gastaminza, Gabriel&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):299-301. doi: 10.1111/all.15474. Epub 2022 Aug 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35950712</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087902</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15474</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>474</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">474</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kallieri, M.</style></author><author><style face="normal" font="default" size="100%">Zervas, E.</style></author><author><style face="normal" font="default" size="100%">Fouka, E.</style></author><author><style face="normal" font="default" size="100%">Porpodis, K.</style></author><author><style face="normal" font="default" size="100%">Mitrova, M. H.</style></author><author><style face="normal" font="default" size="100%">Tzortzaki, E.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Ntakoula, M.</style></author><author><style face="normal" font="default" size="100%">Papaioannou, A. I.</style></author><author><style face="normal" font="default" size="100%">Lyberopoulos, P.</style></author><author><style face="normal" font="default" size="100%">Dimakou, K.</style></author><author><style face="normal" font="default" size="100%">Koukidou, S.</style></author><author><style face="normal" font="default" size="100%">Ampelioti, S.</style></author><author><style face="normal" font="default" size="100%">Papaporfyriou, A.</style></author><author><style face="normal" font="default" size="100%">Katsoulis, K.</style></author><author><style face="normal" font="default" size="100%">Kipourou, M.</style></author><author><style face="normal" font="default" size="100%">Rovina, N.</style></author><author><style face="normal" font="default" size="100%">Antoniou, K.</style></author><author><style face="normal" font="default" size="100%">Vittorakis, S.</style></author><author><style face="normal" font="default" size="100%">Bakakos, P.</style></author><author><style face="normal" font="default" size="100%">Steiropoulos, P.</style></author><author><style face="normal" font="default" size="100%">Markopoulou, K.</style></author><author><style face="normal" font="default" size="100%">Avarlis, P.</style></author><author><style face="normal" font="default" size="100%">Papanikolaou Iota, C.</style></author><author><style face="normal" font="default" size="100%">Markatos, M.</style></author><author><style face="normal" font="default" size="100%">Gaki, E.</style></author><author><style face="normal" font="default" size="100%">Samitas, K.</style></author><author><style face="normal" font="default" size="100%">Glynos, K.</style></author><author><style face="normal" font="default" size="100%">Papiris, S. A.</style></author><author><style face="normal" font="default" size="100%">Papakosta, D.</style></author><author><style face="normal" font="default" size="100%">Tzanakis, N.</style></author><author><style face="normal" font="default" size="100%">Gaga, M.</style></author><author><style face="normal" font="default" size="100%">Kostikas, K.</style></author><author><style face="normal" font="default" size="100%">Loukides, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">2nd Respiratory Department, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.&#xD;7th Respiratory Clinic, &quot;Sotiria&quot; Chest Hospital, Athens, Greece.&#xD;Pulmonary Department, Aristotle University of Thessaloniki, G. Papanikolaou Hospital, Thessaloniki, Greece.&#xD;Outpatient Respiratory Clinic, Heraklion, Greece.&#xD;Allergy Unit, 2nd Department of Dermatology and Venereology, Attikon University General Hospital, Athens, Greece.&#xD;5th Respiratory Clinic, &quot;Sotiria&quot; Chest Hospital, Athens, Greece.&#xD;Pulmonary Department, 424 Army General Hospital, Thessaloniki, Greece.&#xD;1st Respiratory Department, National and Kapodistrian University of Athens Medical School, &quot;Sotiria&quot; Chest Hospital, Athens, Greece.&#xD;Respiratory Medicine School of Medicine, University of Crete, Heraklion, Greece.&#xD;Private Practice, Chania, Greece.&#xD;Department of Respiratory Medicine, Medical School, Democritus University of Thrace, University General Hospital Dragana, Alexandroupolis, Greece.&#xD;1st Pulmonary Department, Papanikolaou General Hospital Thessaloniki, Thessaloniki, Greece.&#xD;Private Practice, Kalamata, Greece.&#xD;Pulmonary Department, Corfu General Hospital, Corfu, Greece.&#xD;Private Practice, Trikala, Greece.&#xD;GSK Medical Department Greece, Athens, Greece.&#xD;Respiratory Medicine Department, University of Ioannina Medical School, Ioannina, Greece.</style></auth-address><titles><title><style face="normal" font="default" size="100%">RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2848-2852</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/05/21</style></edition><section><style face="normal" font="default" size="100%">2848</style></section><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Greece/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Eosinophilia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35595723</style></accession-num><notes><style face="normal" font="default" size="100%">Kallieri, Maria&#xD;Zervas, Eleftherios&#xD;Fouka, Evangelia&#xD;Porpodis, Konstantinos&#xD;Mitrova, Marija Hadji&#xD;Tzortzaki, Eleni&#xD;Makris, Michael&#xD;Ntakoula, Maria&#xD;Papaioannou, Andriana I&#xD;Lyberopoulos, Panagiotis&#xD;Dimakou, Katerina&#xD;Koukidou, Sofia&#xD;Ampelioti, Sevasti&#xD;Papaporfyriou, Anastasia&#xD;Katsoulis, Konstantinos&#xD;Kipourou, Maria&#xD;Rovina, Nikoletta&#xD;Antoniou, Katerina&#xD;Vittorakis, Stylianos&#xD;Bakakos, Petros&#xD;Steiropoulos, Paschalis&#xD;Markopoulou, Katerina&#xD;Avarlis, Panteleimon&#xD;Papanikolaou, Iotalias C&#xD;Markatos, Miltiadis&#xD;Gaki, Eleni&#xD;Samitas, Konstantinos&#xD;Glynos, Konstantinos&#xD;Papiris, Spyros A&#xD;Papakosta, Despoina&#xD;Tzanakis, Nikolaos&#xD;Gaga, Mina&#xD;Kostikas, Konstantinos&#xD;Loukides, Stelios&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2848-2852. doi: 10.1111/all.15382. Epub 2022 May 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35595723</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15382</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>467</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">467</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ashley, S. E.</style></author><author><style face="normal" font="default" size="100%">Jones, A. C.</style></author><author><style face="normal" font="default" size="100%">Anderson, D.</style></author><author><style face="normal" font="default" size="100%">Holt, P. G.</style></author><author><style face="normal" font="default" size="100%">Bosco, A.</style></author><author><style face="normal" font="default" size="100%">Tang, M. L. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Immunology, Murdoch Children&apos;s Research Institute, Melbourne, Victoria, Australia.&#xD;Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.&#xD;The Royal Children&apos;s Hospital, Melbourne, Victoria, Australia.&#xD;Telethon Kids Institute, Perth, Western Australia, Australia.&#xD;The University of Western Australia, Perth, Western Australia, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Remission of peanut allergy is associated with rewiring of allergen-driven T helper 2-related gene networks</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3015-3027</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/05/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Regulatory Networks</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interferons</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">CD4+ T cells</style></keyword><keyword><style face="normal" font="default" size="100%">food oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">network analysis</style></keyword><keyword><style face="normal" font="default" size="100%">remission of allergy</style></keyword><keyword><style face="normal" font="default" size="100%">sustained unresponsiveness</style></keyword><keyword><style face="normal" font="default" size="100%">PPOIT</style></keyword><keyword><style face="normal" font="default" size="100%">is an employee and scientific founder and holds share interest/options in</style></keyword><keyword><style face="normal" font="default" size="100%">Prota Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">is a member of the Medical Advisory Board of Anaphylaxis &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Anaphylaxis Australia and past member of the International Union of Immunological</style></keyword><keyword><style face="normal" font="default" size="100%">Societies (IUIS, ended 2019), the International Expert Panel on Guidelines for</style></keyword><keyword><style face="normal" font="default" size="100%">Food Allergy in Schools (ended 2021) and of the Board of Directors and an expert</style></keyword><keyword><style face="normal" font="default" size="100%">committee of the World Allergy Organisation (WAO, both ended 2019)</style></keyword><keyword><style face="normal" font="default" size="100%">is a member</style></keyword><keyword><style face="normal" font="default" size="100%">of expert committees of the American Academy of Allergy Asthma and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">(AAAAI), Asia Pacific Association of Allergy Asthma and Clinical Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">(APAAACI) and the Australasian Society of Clinical Immunology and Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">(ASCIA). All other authors declare no competing interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35615783</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The immunological changes underpinning acquisition of remission (also called sustained unresponsiveness) following food immunotherapy remain poorly defined. Limited access to effective therapies and biosamples from treatment responders has prevented progress. Probiotic peanut oral immunotherapy is highly effective at inducing remission, providing an opportunity to investigate immune changes. METHODS: Using a systems biology approach, we examined gene co-expression network patterns in peanut-specific CD4(+) T cell responses before and after probiotic and peanut oral immunotherapy in subjects enrolled in the PPOIT-001 randomized trial: Responders who attained remission (n = 16), placebo-treated who remained allergic (n = 16). RESULTS: Acquisition of remission was associated with rewiring of gene network patterns, which was characterized by integration of T helper 2 and interferon signalling modules, markedly reduced T helper 2 gene connectivity, and shutdown in co-expression activity between T helper 2 effectors and cell cycle regulators. CONCLUSION: The immunological changes underlying remission following peanut oral immunotherapy are mediated by reprogramming of T helper 2-associated gene networks in the CD4(+) T cell compartment. Findings provide insight into immune mechanisms driving the acquisition of remission following oral immunotherapy, paving the way for the development of improved approaches to induce remission/sustained unresponsiveness in patients with food allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Ashley, Sarah E&#xD;Jones, Anya C&#xD;Anderson, Denise&#xD;Holt, Patrick G&#xD;Bosco, Anthony&#xD;Tang, Mimi L K&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3015-3027. doi: 10.1111/all.15324. Epub 2022 May 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35615783</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9790273</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15324</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1000</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1000</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Morishima, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to &quot;Acute scrotum in a 8- year- old Italian child caused by extraintestinal anisakiasis in a seaside area&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1603</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/05/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Anisakiasis</style></keyword><keyword><style face="normal" font="default" size="100%">*Anisakis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Italy</style></keyword><keyword><style face="normal" font="default" size="100%">Japan</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Scrotum</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33983664</style></accession-num><notes><style face="normal" font="default" size="100%">Morishima, Ryo&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1603. doi: 10.1111/all.14572.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33983664</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14572</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1121</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1121</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ISGlobAL, Barcelona, Spain.&#xD;IMIM (Hospital del Mar Research Institute), Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Charite, Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;MACVIA-France and Centre Hospitalier Universitaire of Montpellier, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to &quot;Cabbage and COVID-19&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">968</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/03/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Brassica</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Tandem Mass Spectrometry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33675250</style></accession-num><notes><style face="normal" font="default" size="100%">Anto, Josep M&#xD;Bousquet, Jean&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):968. doi: 10.1111/all.14653.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33675250</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8251352</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14653</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2339</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2339</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schwartz, B. S.</style></author><author><style face="normal" font="default" size="100%">Hirsch, A. G.</style></author><author><style face="normal" font="default" size="100%">Bandeen-Roche, K.</style></author><author><style face="normal" font="default" size="100%">Kato, A.</style></author><author><style face="normal" font="default" size="100%">Schleimer, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Environmental Health and Engineering, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.&#xD;Department of Population Health Sciences, Geisinger, Danville, Pennsylvania, USA.&#xD;Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.&#xD;Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to &quot;correspondence to &apos;association between chronic rhinosinusitis and new onset asthma implications for prevention&apos;&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1394-1395</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/12/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinosinusitis/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38098347</style></accession-num><notes><style face="normal" font="default" size="100%">Schwartz, Brian S&#xD;Hirsch, Annemarie G&#xD;Bandeen-Roche, Karen&#xD;Kato, Atsushi&#xD;Schleimer, Robert&#xD;eng&#xD;P01 AI106683/AI/NIAID NIH HHS/&#xD;Comment&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1394-1395. doi: 10.1111/all.15984. Epub 2023 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38098347</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11062883</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15984</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1055</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1055</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stranzl, T.</style></author><author><style face="normal" font="default" size="100%">Ipsen, H.</style></author><author><style face="normal" font="default" size="100%">Christensen, L. H.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Johansen, N.</style></author><author><style face="normal" font="default" size="100%">Lund, K.</style></author><author><style face="normal" font="default" size="100%">Andersen, P. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ALK-Abello A/S, Horsholm, Denmark.&#xD;HICon, Capital Region, Denmark.&#xD;Division of Immunology and Allergy, Department of Pediatrics, Food allergy and Anaphylaxis Program, The Hospital for Sick Children, Toronto, ON, Canada.&#xD;Research Institute, The Hospital for Sick Children, Translational Medicine Program, Toronto, ON, Canada.&#xD;Department of Immunology, University of Toronto, Toronto, ON, Canada.&#xD;Papermill Medical, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to &quot;Inferring clinical relevance of der p 23 from the restricted effect on treatment outcomes after tablet allergy immunotherapy&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1300-1301</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/04/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33840114</style></accession-num><notes><style face="normal" font="default" size="100%">Stranzl, Thomas&#xD;Ipsen, Henrik&#xD;Christensen, Lars Harder&#xD;Eiwegger, Thomas&#xD;Johansen, Niels&#xD;Lund, Kaare&#xD;Andersen, Peter Sejr&#xD;eng&#xD;Comment&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1300-1301. doi: 10.1111/all.14636.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33840114</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14636</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2477</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2477</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Unal, D.</style></author><author><style face="normal" font="default" size="100%">Eyice-Karabacak, D.</style></author><author><style face="normal" font="default" size="100%">Kutlu, A.</style></author><author><style face="normal" font="default" size="100%">Demir, S.</style></author><author><style face="normal" font="default" size="100%">Tuzer, O. C.</style></author><author><style face="normal" font="default" size="100%">Arslan, F. A.</style></author><author><style face="normal" font="default" size="100%">Isik, S. R.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Division of Immunology and Allergy Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Medical Park Hospital Ordu, Ordu, Turkey.&#xD;Division of Immunology and Allergy Diseases, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to corresponcence: &quot;Oral immunotherapy in alpha-gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management?&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2893-2894</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/04/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology/therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Red Meat/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38641896</style></accession-num><notes><style face="normal" font="default" size="100%">Unal, D&#xD;Eyice-Karabacak, D&#xD;Kutlu, A&#xD;Demir, S&#xD;Tuzer, O C&#xD;Arslan, F A&#xD;Isik, S R&#xD;Gelincik, A&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2893-2894. doi: 10.1111/all.16137. Epub 2024 Apr 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38641896</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16137</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2182</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2182</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez, T. D.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;RICORS Red De Enfermedades Inflamatorias (REI), Spain.&#xD;RETICS Asma, Reacciones Adversas y Alergicas (ARADYAL), Spain.&#xD;Departamento de Biologia Celular, Genetica y Fisiologia, Universidad de Malaga, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-ARADyAL, Malaga, Spain.&#xD;Departamento de Medicina, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to correspondence to &apos;Diagnosis of immediate reactions to amoxicillin: Comparison of basophil activation markers CD63 and CD203c in a prospective study&apos;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2810-2812</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/07/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">*Amoxicillin/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Basophil Degranulation Test</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, CD</style></keyword><keyword><style face="normal" font="default" size="100%">Tetraspanin 30</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37497852</style></accession-num><notes><style face="normal" font="default" size="100%">Fernandez, Tahia Diana&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;eng&#xD;Comment&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2810-2812. doi: 10.1111/all.15829. Epub 2023 Jul 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37497852</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15829</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>361</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">361</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hagemann, J.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Walter Canonica, G.</style></author><author><style face="normal" font="default" size="100%">Blain, H.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.&#xD;IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.&#xD;University Hospital Montpellier, Montpellier, France.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to correspondence to &apos;Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus&apos;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2574-2575</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*COVID-19/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Common Cold/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Consensus</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Perennial/diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35932252</style></accession-num><notes><style face="normal" font="default" size="100%">Hagemann, Jan&#xD;Zuberbier, Torsten&#xD;Walter Canonica, Giorgio&#xD;Blain, Hubert&#xD;Bousquet, Jean&#xD;Klimek, Ludger&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2574-2575. doi: 10.1111/all.15330.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35932252</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9538534</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15330</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2957</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2957</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Contreras, N.</style></author><author><style face="normal" font="default" size="100%">Delgado-Dolset, M. I.</style></author><author><style face="normal" font="default" size="100%">Villasenor, A.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de Ciencias Medicas Basicas, Facultad de Medicina, Instituto de Medicina Molecular Aplicada-Nemesio Diez (IMMA-ND), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Centro de Metabolomica y Bioanalisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to Correspondence: &apos;Challenging the Frontier: Bridging Systemic Biomarkers and Small Airway Dynamics in Severe Asthma Management&apos;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2688-2690</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/06/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">lung function</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">systemic biomarkers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40539843</style></accession-num><notes><style face="normal" font="default" size="100%">Contreras, Nuria&#xD;Delgado-Dolset, Maria Isabel&#xD;Villasenor, Alma&#xD;Escribese, Maria M&#xD;eng&#xD;Instituto de Salud Carlos III/&#xD;AP177712021/Fundacion Mutua Madrilena/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2688-2690. doi: 10.1111/all.16614. Epub 2025 Jun 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40539843</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16614</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3147</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3147</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pouessel, G.</style></author><author><style face="normal" font="default" size="100%">Divaret-Chauveau, A.</style></author><author><style face="normal" font="default" size="100%">Herrero, S. I.</style></author><author><style face="normal" font="default" size="100%">Garriga-Baraut, T.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Sabouraud-Leclerc, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Children&apos;s Hospital, CH Roubaix, Roubaix, France.&#xD;Paediatric Pulmonology and Allergy Department, Pole Enfant, Hopital Jeanne de Flandre, CHU Lille, Lille, France.&#xD;ULR 2694: Metrics, University of Lille, Lille, France.&#xD;Allergy-Vigilance Network, Vandoeuvre-les-Nancy, France.&#xD;Paediatric Allergy Unit, Children&apos;s Hospital, University Hospital of Nancy, Vandoeuvre-les-Nancy, France.&#xD;UR 3450 DevAH, Health Faculty, Vandoeuvre-les-Nancy, France.&#xD;Pediatric Allergy Unit, Hospital General Universitario Gregorio Maranon, Madrid, Spain.&#xD;Gregorio Maranon Health Research Institute (IiSGM), Madrid, Spain.&#xD;Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid, Spain.&#xD;Department of Pediatrics, Pediatric Allergy Unit, Vall D&apos;hebron University Hospital, Barcelona, Spain.&#xD;Universitat Autonoma de Barcelona, Barcelona, Spain.&#xD;Research Group &apos;Growth and Development&apos;, Vall D&apos;hebron University Hospital Research Institute (VHIR), Barcelona, Spain.&#xD;Division of Allergy, Translational Research in Pediatric Specialities Area, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;General and Specialized Pediatrics Department, American Hospital, Reims University Hospital Center, Reims, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to Correspondence: &quot;Anaphylaxis Induced by Goat&apos;s and Sheep&apos;s Milk-A Rare Entity in Europe&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">314-315</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/11/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41277774</style></accession-num><notes><style face="normal" font="default" size="100%">Pouessel, Guillaume&#xD;Divaret-Chauveau, Amandine&#xD;Herrero, Sonsoles Infante&#xD;Garriga-Baraut, Teresa&#xD;Arasi, Stefania&#xD;Sabouraud-Leclerc, Dominique&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):314-315. doi: 10.1111/all.70158. Epub 2025 Nov 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41277774</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70158</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>274</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">274</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Cho, S. I.</style></author><author><style face="normal" font="default" size="100%">Yang, M. S.</style></author><author><style face="normal" font="default" size="100%">Cho, S. J.</style></author><author><style face="normal" font="default" size="100%">Lee, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.&#xD;Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, South Korea.&#xD;Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to correspondence: &quot;Is Helicobacter pylori infection inversely correlated with atopic, skin, and autoimmune diseases?&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3167-3168</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/09/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Autoimmune Diseases/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Helicobacter Infections/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Helicobacter pylori</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36169881</style></accession-num><notes><style face="normal" font="default" size="100%">Lee, Hanjae&#xD;Cho, Soo Ick&#xD;Yang, Min-Suk&#xD;Cho, Soo-Jeong&#xD;Lee, Dong Hun&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3167-3168. doi: 10.1111/all.15435.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36169881</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15435</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>423</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">423</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Cespedes, J. A.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Departamento de Medicina, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to correspondence: Basophil reactivity to BNT162b2 in COVID-19 convalescence</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2266-2267</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/07/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Convalescence</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35770813</style></accession-num><notes><style face="normal" font="default" size="100%">Labella, Marina&#xD;Cespedes, Jose Antonio&#xD;Dona, Inmaculada&#xD;Shamji, Mohamed H&#xD;Agache, Ioana&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;eng&#xD;Comment&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2266-2267. doi: 10.1111/all.15208.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35770813</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9350273</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15208</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>463</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">463</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhong, Y.</style></author><author><style face="normal" font="default" size="100%">Samuel, M.</style></author><author><style face="normal" font="default" size="100%">van Bever, H.</style></author><author><style face="normal" font="default" size="100%">Tham, E. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore.&#xD;Khoo Teck Puat-National University Children&apos;s Medical Institute, National University Health System (NUHS), Singapore, Singapore.&#xD;Research Support Unit, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore.&#xD;Human Potential Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to correspondence: Emollients in infancy to prevent atopic dermatitis: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1934-1935</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/06/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Emollients/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Systematic Reviews as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Meta-Analysis as Topic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35643981</style></accession-num><notes><style face="normal" font="default" size="100%">Zhong, Youjia&#xD;Samuel, Miny&#xD;van Bever, Hugo&#xD;Tham, Elizabeth Huiwen&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1934-1935. doi: 10.1111/all.15309.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35643981</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15309</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1334</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1334</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ozdemir, C.</style></author><author><style face="normal" font="default" size="100%">Kucuksezer, U. C.</style></author><author><style face="normal" font="default" size="100%">Tamay, Z. U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkey.&#xD;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to Dr. Vincenzo Patella et al. Could anti-tubercular vaccination protect against COVID-19 infection?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">946-948</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">infections</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32893365</style></accession-num><notes><style face="normal" font="default" size="100%">Ozdemir, Cevdet&#xD;Kucuksezer, Umut C&#xD;Tamay, Zeynep Ulker&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):946-948. doi: 10.1111/all.14559. Epub 2020 Sep 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32893365</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14559</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>419</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">419</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Navaratna, S.</style></author><author><style face="normal" font="default" size="100%">Burgess, J.</style></author><author><style face="normal" font="default" size="100%">Waidyatillake, N.</style></author><author><style face="normal" font="default" size="100%">Peters, R. L.</style></author><author><style face="normal" font="default" size="100%">Dharmage, S. C.</style></author><author><style face="normal" font="default" size="100%">Lodge, C. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Community Medicine, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka.&#xD;Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Vic., Australia.&#xD;Murdoch Children&apos;s Research Institute, Royal Children&apos;s Hospital, Parkville, Vic., Australia.&#xD;Department of Paediatrics, The University of Melbourne, Parkville, Vic., Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to the correspondence: Bacillus Calmette-Guerin vaccination to prevent childhood asthma-A revised analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2264-2265</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/07/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*BCG Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35770818</style></accession-num><notes><style face="normal" font="default" size="100%">Navaratna, Samidi&#xD;Burgess, John&#xD;Waidyatillake, Nilakshi&#xD;Peters, Rachel L&#xD;Dharmage, Shyamali C&#xD;Lodge, Caroline J&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2264-2265. doi: 10.1111/all.15282.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35770818</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15282</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>71</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">71</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fiorito, S.</style></author><author><style face="normal" font="default" size="100%">Soligo, M.</style></author><author><style face="normal" font="default" size="100%">Gao, Y.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Bonini, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Translational Pharmacology, Italian National Research Council, Rome, Italy.&#xD;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to: &quot;COVID-19 pandemic and environment: Not only air pollution.&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3702-3703</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">*Air Pollution/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36441592</style></accession-num><notes><style face="normal" font="default" size="100%">Fiorito, Silvana&#xD;Soligo, Marzia&#xD;Gao, Yadong&#xD;Ogulur, Ismail&#xD;Akdis, Cezmi A&#xD;Bonini, Sergio&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3702-3703. doi: 10.1111/all.15492.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36441592</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9878027 European Union (EU CURE), Novartis Research Institutes (Basel, Switzerland), Stanford University (Redwood City, Calif), and SciBase (Stockholm, Sweden); he is the Co-Chair for EAACI Guidelines on Environmental Science in Allergic diseases and Asthma and serves on the Advisory Boards of Sanofi/Regeneron, Novartis, GlaxoSmithKline, and SciBase, and is the Editor-in-Chief of Allergy. SB is consultant for Lallemand Pharma and DSMB member for some COVID-19 vaccines and monoclonal antibodies.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15492</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1118</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1118</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Detoraki, A.</style></author><author><style face="normal" font="default" size="100%">Contoli, M.</style></author><author><style face="normal" font="default" size="100%">Papi, A.</style></author><author><style face="normal" font="default" size="100%">Paoletti, G.</style></author><author><style face="normal" font="default" size="100%">Malipiero, G.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Crimi, C.</style></author><author><style face="normal" font="default" size="100%">Morrone, D.</style></author><author><style face="normal" font="default" size="100%">Padovani, M.</style></author><author><style face="normal" font="default" size="100%">Guida, G.</style></author><author><style face="normal" font="default" size="100%">Gerli, A. G.</style></author><author><style face="normal" font="default" size="100%">Centanni, S.</style></author><author><style face="normal" font="default" size="100%">Senna, G.</style></author><author><style face="normal" font="default" size="100%">Paggiaro, P.</style></author><author><style face="normal" font="default" size="100%">Blasi, F.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Sani Working Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Department of Internal Medicine, Clinical Immunology, Clinical Pathology and Infectious Disease, Azienda Ospedaliera Universitaria Federico II, Napoli, Italy.&#xD;Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.&#xD;Department of Medical Sciences, AO Ordine Mauriziano Umberto I, University of Torino, Torino, Italy.&#xD;Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.&#xD;Severe Asthma Network in Italy (SANI) infrastructure, Milano, Italy.&#xD;Allergy and Pneumology Unit, A.O. S. Croce e Carle, Cuneo, Italy.&#xD;Management Engineering Tourbillon Tech srl, Padova, Italy.&#xD;Respiratory Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, San Paolo Hospital, University of Milano, Milano, Italy.&#xD;Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy.&#xD;Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Pisa, Italy.&#xD;Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, Italy.&#xD;Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">961-962</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/03/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33675253</style></accession-num><notes><style face="normal" font="default" size="100%">Heffler, Enrico&#xD;Detoraki, Aikaterini&#xD;Contoli, Marco&#xD;Papi, Alberto&#xD;Paoletti, Giovanni&#xD;Malipiero, Giacomo&#xD;Brussino, Luisa&#xD;Crimi, Claudia&#xD;Morrone, Daniela&#xD;Padovani, Marianna&#xD;Guida, Giuseppe&#xD;Gerli, Alberto Giovanni&#xD;Centanni, Stefano&#xD;Senna, Gianenrico&#xD;Paggiaro, Pierluigi&#xD;Blasi, Francesco&#xD;Canonica, Giorgio Walter&#xD;eng&#xD;Glaxo Smith Kline/&#xD;AstraZeneca/&#xD;Sanofi Genzyme/&#xD;Novartis/&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):961-962. doi: 10.1111/all.14593.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33675253</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8251003 AstraZeneca, Sanofi, GSK, Novartis, Circassia, Nestle Purina, Boheringer Ingelheim and Valeas, outside the submitted work. Marco Contoli reports grants from Chiesi, and University of Ferrara-Italy, and personal fees from Chiesi, AstraZeneca, Boehringer Ingelheim, Alk-Abello, GlaxoSmithKline, Novartis and Zambon, outside the submitted work. Alberto Papi reports grants, grants, personal fees and non-financial support from AstraZeneca and Menarini; grants, personal fees, non-financial support and other from Boehringer Ingelheim, Chiesi Farmaceutici and TEVA; personal fees, non-financial support and other from GlaxoSmithKline, Mundipharma, Zambon, Novartis and Sanofi/Regeneron; personal fees from Roche and Edmond Pharma; and grants from Fondazione Maugeri and Fondazione Chiesi, outside the submitted work. Claudia Crimi reports personal fees from Menarini. Stefano Centanni reports personal fees from GlaxoSmithKline, Novartis, Menarini SpA, and Guidotti-Malesci, and grants and personal fees from Chiesi SpA, AstraZeneca, Valeas and Boehringer Ingelheim, outside the submitted work. Pierluigi Paggiaro reports grants and personal fees from AstraZeneca, Chiesi, Novartis and Sanofi, and personal fees from GlaxoSmithKline, Guidotti, and Mundipharma, outside the submitted work. Francesco Blasi reports grants and personal fees from AstraZeneca, Chiesi, GSK, Pfizer and Insmed; grants from Bayer; and personal fees from Guidotti, Grifols, Menarini, Mundipharma, Novartis and Zambon, outside the submitted work. Giorgio Walter Canonica reports grants as well as lecture or advisory board fees from: A. Menarini, Alk-Abello, Allergy Therapeutics, AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, GlaxoSmithKline, Hal Allergy, Mylan, Merck, Mundipharma, Novartis, Regeneron, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes Greer, UCB pharma, Uriach Pharma, Valeas and Vibro Pharma. Giovanni Paoletti, Aikaterini Detoraki, Giacomo Malipiero, Luisa Brussino, Daniela Morrone, Marianna Padovani, Giuseppe Guida, Alberto Giovanni Gerli and Gianenrico Senna do not have any conflict of interest to report.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14593</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>610</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">610</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adachi, T.</style></author><author><style face="normal" font="default" size="100%">Ogawa, Y.</style></author><author><style face="normal" font="default" size="100%">Fukushi, T.</style></author><author><style face="normal" font="default" size="100%">Ito, K.</style></author><author><style face="normal" font="default" size="100%">Koizumi, A.</style></author><author><style face="normal" font="default" size="100%">Shirabe, M.</style></author><author><style face="normal" font="default" size="100%">Toriya, M.</style></author><author><style face="normal" font="default" size="100%">Hirako, J.</style></author><author><style face="normal" font="default" size="100%">Inomata, T.</style></author><author><style face="normal" font="default" size="100%">Masaki, K.</style></author><author><style face="normal" font="default" size="100%">Sasano, R.</style></author><author><style face="normal" font="default" size="100%">Sato, S.</style></author><author><style face="normal" font="default" size="100%">Kainuma, K.</style></author><author><style face="normal" font="default" size="100%">Futamura, M.</style></author><author><style face="normal" font="default" size="100%">Kan, O. K.</style></author><author><style face="normal" font="default" size="100%">Kurashima, Y.</style></author><author><style face="normal" font="default" size="100%">Nakajima, S.</style></author><author><style face="normal" font="default" size="100%">Sakashita, M.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author><author><style face="normal" font="default" size="100%">Iwamoto, A.</style></author><author><style face="normal" font="default" size="100%">Nishima, S.</style></author><author><style face="normal" font="default" size="100%">Tamari, M.</style></author><author><style face="normal" font="default" size="100%">Iizuka, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ENGAGE-Task Force, Tokyo, Japan.&#xD;Keio Frontier Research &amp; Education Collaborative Square (K-FRECS) at Tonomachi, Keio University, Kanagawa, Japan.&#xD;Department of Medical Regulatory Science, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.&#xD;Department of Dermatology, Tachikawa Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Tokyo, Japan.&#xD;Department of Advanced Medicine, Nagoya University, Nagoya, Japan.&#xD;Department of Dermatology, Nagoya University, Nagoya, Japan.&#xD;Japan Agency for Medical Research and Development (AMED), Tokyo, Japan.&#xD;Accenture Inc., Tokyo, Japan.&#xD;National Institutes of Natural Science (NINS), Tokyo, Japan.&#xD;Tokyo Institute of Technology, Tokyo, Japan.&#xD;Global Research Institute, Keio University, Tokyo, Japan.&#xD;Graduate School of Informatics, Nagoya University, Nagoya, Japan.&#xD;Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Department of Digital Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.&#xD;Department of Allergy, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan.&#xD;Institute for Clinical Research, National Hospital Organization Mie National Hospital, Mie, Japan.&#xD;Division of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.&#xD;Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.&#xD;Department of Innovative Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.&#xD;Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, University of Fukui, Fukui, Japan.&#xD;Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.&#xD;National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan.&#xD;Division of Molecular Genetics, The Jikei University School of Medicine, Research Center for Medical Science, Tokyo, Japan.&#xD;Research Institute of Psoriasis, Housui General Medical Clinic, Sapporo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Research impact analysis of international funding agencies in the realm of allergy and immunology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1602-1606</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunology</style></keyword><keyword><style face="normal" font="default" size="100%">research impact analysis</style></keyword><keyword><style face="normal" font="default" size="100%">research strategy</style></keyword><keyword><style face="normal" font="default" size="100%">substantiality index</style></keyword><keyword><style face="normal" font="default" size="100%">MTa is the Program Officer, and HI is the Program Supervisor of the AMED-PPAI. TA</style></keyword><keyword><style face="normal" font="default" size="100%">(2015-2020) and YO (2018-2020) were employees of the AMED. SNi was the former</style></keyword><keyword><style face="normal" font="default" size="100%">Program Supervisor of the AMED-PPAI (2015-2018). The other details about</style></keyword><keyword><style face="normal" font="default" size="100%">competing interests are provided separately.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35143695</style></accession-num><notes><style face="normal" font="default" size="100%">Adachi, Takeya&#xD;Ogawa, Yasushi&#xD;Fukushi, Tamami&#xD;Ito, Kei&#xD;Koizumi, Amane&#xD;Shirabe, Masashi&#xD;Toriya, Masako&#xD;Hirako, Jun&#xD;Inomata, Takenori&#xD;Masaki, Katsunori&#xD;Sasano, Ryohei&#xD;Sato, Sakura&#xD;Kainuma, Keigo&#xD;Futamura, Masaki&#xD;Kan-O, Keiko&#xD;Kurashima, Yosuke&#xD;Nakajima, Saeko&#xD;Sakashita, Masafumi&#xD;Morita, Hideaki&#xD;Iwamoto, Aikichi&#xD;Nishima, Sankei&#xD;Tamari, Mayumi&#xD;Iizuka, Hajime&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1602-1606. doi: 10.1111/all.15249. Epub 2022 Feb 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35143695</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9306960</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15249</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>327</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">327</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Guidolin, L.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Olivieri, E.</style></author><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Schiappoli, M.</style></author><author><style face="normal" font="default" size="100%">Saenz de Santa Maria, R.</style></author><author><style face="normal" font="default" size="100%">Dama, A.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Senna, G.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Unit, Verona University Hospital, Verona, Italy.&#xD;Departamento de Medicina, Universidad de Malaga, Malaga, Spain.&#xD;Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Resensitization in suspected penicillin allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">214-224</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/09/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillins/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Tetradecyl Sulfate</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">drug provocation test</style></keyword><keyword><style face="normal" font="default" size="100%">penicillins</style></keyword><keyword><style face="normal" font="default" size="100%">resensitization</style></keyword><keyword><style face="normal" font="default" size="100%">skin test, specific IgE</style></keyword><keyword><style face="normal" font="default" size="100%">given final approval to the version to be published. Research is part of their</style></keyword><keyword><style face="normal" font="default" size="100%">daily activities. All the authors had full access to all the data and can take</style></keyword><keyword><style face="normal" font="default" size="100%">responsibility for the integrity of the data and the accuracy of the data</style></keyword><keyword><style face="normal" font="default" size="100%">analysis.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36067012</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The diagnosis of allergic reactions to penicillins (AR-PEN) is very complex as there is a loss of sensitization over time, which leads to negative skin tests (STs) and specific IgE in serum, and even to tolerance to the drug involved. However, STs may become positive after subsequent exposure to the culprit drug (resensitization), with the risk of inducing potentially severe reactions. The exact rate of resensitization to penicillins is unknown, ranging from 0% to 27.9% in published studies. OBJECTIVES: To analyze the rate of resensitization in patients with suggestive AR-PEN by repeating STs (retest) after an initial evaluation (IE). MATERIAL AND METHODS: Patients with suspected AR-PEN were prospectively evaluated between 2017 and 2020. They underwent STs, and a randomized group also underwent a drug provocation test (DPT) with the culprit. Only patients with negative STs and/or DPT were included. All included cases were retested by STs at 2-8 weeks. RESULTS: A total of 545 patients were included: 296 reporting immediate reactions (IRs) and 249 non-immediate reactions (NIRs). Eighty (14.7%) cases had positive results in retest (RT+): 63 (21.3%) IRs and 17 (6.8%) NIRs (p &lt; 0.0001). The rate of RT+ was higher in anaphylaxis compared with all other reactions (45.8% vs 9.1%, p &lt; 0.0001). The risk of RT+ was higher from the fifth week after IE (OR: 4.64, CI: 2.1-11.6; p &lt; 0.001) and increased with the patient&apos;s age (OR: 1.02; CI: 1.01-1.04; p = 0.009). CONCLUSIONS: Due to the high rate of resensitization, retest should be included in the diagnostic algorithm of IRs to penicillins after an initial negative study, especially in anaphylaxis, to avoid potentially severe reactions after subsequent prescriptions of these drugs.</style></abstract><notes><style face="normal" font="default" size="100%">Dona, Inmaculada&#xD;Guidolin, Lucia&#xD;Bogas, Gador&#xD;Olivieri, Elisa&#xD;Labella, Marina&#xD;Schiappoli, Michele&#xD;Saenz de Santa Maria, Rocio&#xD;Dama, Annarita&#xD;Salas, Maria&#xD;Senna, Gianenrico&#xD;Bonadonna, Patrizia&#xD;Torres, Maria Jose&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):214-224. doi: 10.1111/all.15508. Epub 2022 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36067012</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087608</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15508</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2286</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2286</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peh, H. Y.</style></author><author><style face="normal" font="default" size="100%">Bruggemann, T. R.</style></author><author><style face="normal" font="default" size="100%">Duvall, M. G.</style></author><author><style face="normal" font="default" size="100%">Nshimiyimana, R.</style></author><author><style face="normal" font="default" size="100%">Nijmeh, J.</style></author><author><style face="normal" font="default" size="100%">Cinelli, M. A.</style></author><author><style face="normal" font="default" size="100%">Israel, E.</style></author><author><style face="normal" font="default" size="100%">Serhan, C. N.</style></author><author><style face="normal" font="default" size="100%">Levy, B. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pulmonary and Critical Care Medicine Division, Department of Medicine, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Resolvin D2 regulates type 2 inflammatory responses and promotes resolution of mouse allergic inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">739-743</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/10/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Docosahexaenoic Acids/pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37888888</style></accession-num><notes><style face="normal" font="default" size="100%">Peh, Hong Yong&#xD;Bruggemann, Thayse R&#xD;Duvall, Melody G&#xD;Nshimiyimana, Robert&#xD;Nijmeh, Julie&#xD;Cinelli, Maria A&#xD;Israel, Elliot&#xD;Serhan, Charles N&#xD;Levy, Bruce D&#xD;eng&#xD;P01 GM095467/GM/NIGMS NIH HHS/&#xD;R01 HL122531/HL/NHLBI NIH HHS/&#xD;R35 GM139430/GM/NIGMS NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):739-743. doi: 10.1111/all.15920. Epub 2023 Oct 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37888888</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10922258</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15920</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1987</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1987</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Resolving the etiology and treatments of allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1419-1421</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/03/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/etiology/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36965003</style></accession-num><notes><style face="normal" font="default" size="100%">Zhang, Luo&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1419-1421. doi: 10.1111/all.15727.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36965003</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15727</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>28</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">28</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rovira Rubio, J.</style></author><author><style face="normal" font="default" size="100%">Megremis, S.</style></author><author><style face="normal" font="default" size="100%">Pasioti, M.</style></author><author><style face="normal" font="default" size="100%">Lakoumentas, J.</style></author><author><style face="normal" font="default" size="100%">Constantinides, B.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Finotto, S.</style></author><author><style face="normal" font="default" size="100%">Jartti, T.</style></author><author><style face="normal" font="default" size="100%">Andreakos, E.</style></author><author><style face="normal" font="default" size="100%">Stanic, B.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Infection, Immunity &amp; Respiratory Medicine, University of Manchester, Manchester, UK.&#xD;Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.&#xD;Upper Airway Research Laboratory, Ghent University Hospital, Ghent, Belgium.&#xD;Department of Molecular Pneumology, Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Universitatsklinikum Erlangen, Erlangen, Germany.&#xD;PEDEGO Research Unit, University of Oulu, Oulu, Finland.&#xD;Department of Pediatrics and Adolescent Medicine, University of Oulu, Oulu, Finland.&#xD;Department of Pediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.&#xD;Biomedical Research Foundation of the Academy of Athens, Athens, Greece.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Respiratory virome profiles reflect antiviral immune responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1258-1268</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/01/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Antiviral Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Virome</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Interferons</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bacteriophages</style></keyword><keyword><style face="normal" font="default" size="100%">interferon-lambda</style></keyword><keyword><style face="normal" font="default" size="100%">rhinoviruses</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36595290</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: From early life, respiratory viruses are implicated in the development, exacerbation and persistence of respiratory conditions such as asthma. Complex dynamics between microbial communities and host immune responses shape immune maturation and homeostasis, influencing health outcomes. We evaluated the hypothesis that the respiratory virome is linked to systemic immune responses, using peripheral blood and nasopharyngeal swab samples from preschool-age children in the PreDicta cohort. METHODS: Peripheral blood mononuclear cells from 51 children (32 asthmatics and 19 healthy controls) participating in the 2-year multinational PreDicta cohort were cultured with bacterial (Bacterial-DNA, LPS) or viral (R848, Poly:IC, RV) stimuli. Supernatants were analysed by Luminex for the presence of 22 relevant cytokines. Virome composition was obtained using untargeted high throughput sequencing of nasopharyngeal samples. The metagenomic data were used for the characterization of virome profiles and the presence of key viral families (Picornaviridae, Anelloviridae, Siphoviridae). These were correlated to cytokine secretion patterns, identified through hierarchical clustering and principal component analysis. RESULTS: High spontaneous cytokine release was associated with increased presence of Prokaryotic virome profiles and reduced presence of Eukaryotic and Anellovirus profiles. Antibacterial responses did not correlate with specific viral families or virome profile; however, low antiviral responders had more Prokaryotic and less Eukaryotic virome profiles. Anelloviruses and Anellovirus-dominated profiles were equally distributed among immune response clusters. The presence of Picornaviridae and Siphoviridae was associated with low interferon-lambda responses. Asthma or allergy did not modify these correlations. CONCLUSION: Antiviral cytokine responses at a systemic level reflect the upper airway virome composition. Individuals with low innate interferon responses have higher abundance of Picornaviruses (mostly Rhinoviruses) and bacteriophages. Bacteriophages, particularly Siphoviridae, appear to be sensitive sensors of host antimicrobial capacity, while Anelloviruses are not correlated with TLR-induced immune responses.</style></abstract><notes><style face="normal" font="default" size="100%">Rovira Rubio, Judit&#xD;Megremis, Spyridon&#xD;Pasioti, Maria&#xD;Lakoumentas, John&#xD;Constantinides, Bede&#xD;Xepapadaki, Paraskevi&#xD;Bachert, Claus&#xD;Finotto, Susetta&#xD;Jartti, Tuomas&#xD;Andreakos, Evangelos&#xD;Stanic, Barbara&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;Papadopoulos, Nikolaos G&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1258-1268. doi: 10.1111/all.15634. Epub 2023 Jan 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36595290</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15634</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2474</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2474</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nair, P.</style></author><author><style face="normal" font="default" size="100%">Radford, K.</style></author><author><style face="normal" font="default" size="100%">Nunomura, S.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Izuhara, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Respirology, McMaster University and St Joseph&apos;s Healthcare Hamilton, Ontario, Canada.&#xD;Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Response of sputum periostin to anti-T2 biologics treatment in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2842-2844</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Cell Adhesion Molecules/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Periostin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38651839</style></accession-num><notes><style face="normal" font="default" size="100%">Nair, Parameswaran&#xD;Radford, Katherine&#xD;Nunomura, Satoshi&#xD;Mukherjee, Manali&#xD;Izuhara, Kenji&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2842-2844. doi: 10.1111/all.16131. Epub 2024 Apr 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38651839</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16131</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2315</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2315</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gutsche, A.</style></author><author><style face="normal" font="default" size="100%">Salameh, P.</style></author><author><style face="normal" font="default" size="100%">Aulenbacher, F.</style></author><author><style face="normal" font="default" size="100%">Buttgereit, T.</style></author><author><style face="normal" font="default" size="100%">Weller, K.</style></author><author><style face="normal" font="default" size="100%">Siebenhaar, F.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;School of Medicine, Lebanese American University, Byblos, Lebanon.&#xD;Institut National de Sante Publique d&apos;Epidemiologie Clinique et de Toxicologie-Liban (INSPECT-LB), Beirut, Lebanon.&#xD;Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Response to &quot;Clinical applicability of the Urticaria control test in patients with chronic urticaria: Further evidence from 622 adult and pediatric patients with different disease subtypes&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">265-267</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/11/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37921400</style></accession-num><notes><style face="normal" font="default" size="100%">Gutsche, Annika&#xD;Salameh, Pascale&#xD;Aulenbacher, Felix&#xD;Buttgereit, Thomas&#xD;Weller, Karsten&#xD;Siebenhaar, Frank&#xD;Maurer, Marcus&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):265-267. doi: 10.1111/all.15941. Epub 2023 Nov 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37921400</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15941</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3060</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3060</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kayikci, H.</style></author><author><style face="normal" font="default" size="100%">Damadoglu, E.</style></author><author><style face="normal" font="default" size="100%">Cihanbeylerden, M.</style></author><author><style face="normal" font="default" size="100%">Tuccar, C.</style></author><author><style face="normal" font="default" size="100%">Ustaoglu, A. P.</style></author><author><style face="normal" font="default" size="100%">Karakaya, G.</style></author><author><style face="normal" font="default" size="100%">Kalyoncu, A. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Hacettepe University, Ankara, Turkiye.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">267-270</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/09/26</style></edition><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41001912</style></accession-num><notes><style face="normal" font="default" size="100%">Kayikci, Hazal&#xD;Damadoglu, Ebru&#xD;Cihanbeylerden, Melek&#xD;Tuccar, Cise&#xD;Ustaoglu, Aysegul Pehlivanlar&#xD;Karakaya, Gul&#xD;Kalyoncu, Ali Fuat&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):267-270. doi: 10.1111/all.70078. Epub 2025 Sep 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41001912</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70078</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2960</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2960</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Bian, J.</style></author><author><style face="normal" font="default" size="100%">Xiong, Q.</style></author><author><style face="normal" font="default" size="100%">Wong, B. S.</style></author><author><style face="normal" font="default" size="100%">Tsui, S. K.</style></author><author><style face="normal" font="default" size="100%">Kwan, K. M.</style></author><author><style face="normal" font="default" size="100%">Leung, N. Y.</style></author><author><style face="normal" font="default" size="100%">Leung, T. F.</style></author><author><style face="normal" font="default" size="100%">Leung, P. S. C.</style></author><author><style face="normal" font="default" size="100%">Chu, K. H.</style></author><author><style face="normal" font="default" size="100%">Xiao, X.</style></author><author><style face="normal" font="default" size="100%">Wai, C. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Life Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Institute of Allergy and Immunology of Shenzhen University School of Medicine, State Key Laboratory of Respiratory Disease Allergy Shenzhen University Division, Shenzhen, China.&#xD;Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China.&#xD;School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Hong Kong Bioinformatics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Department of Paediatrics, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, California, USA.&#xD;Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou), Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Revealing the Diverse Allergenic Protein Repertoire of Six Widely Consumed Crab Species: A Species-Specific Allergen in King Crab</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergen comparison</style></keyword><keyword><style face="normal" font="default" size="100%">crab allergen</style></keyword><keyword><style face="normal" font="default" size="100%">king crab</style></keyword><keyword><style face="normal" font="default" size="100%">novel allergen</style></keyword><keyword><style face="normal" font="default" size="100%">shellfish allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40736448</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Shellfish allergy poses a significant health risk affecting up to 2% of the global population. Comprehensive allergen profiling across species is crucial for improving diagnostics and therapies, given the challenges posed by cross-reactivity. This study aims to identify and compare the allergen profiles of six widely consumed edible crab species. METHODS: Muscle proteins were extracted from five brachyurans (true crabs) including Charybdis feriata, Portunus pelagicus, Scylla paramamosain, Chionoecetes opilio, and Eriocheir sinensis, as well as the king crab Paralithodes camtschaticus, and were analyzed for IgE reactivity with serum samples from 29 crab-allergic individuals and three nonallergic controls. IgE-binding proteins were identified by immunoblotting followed by mass spectrometry. Recombinant king crab allergen was purified and tested on ELISA against samples from 50 crab-allergic individuals, with its specific IgE reactivity evaluated by inhibition ELISA and immunoblot. Comparison of the gene expression of the identified allergens along with reported epitopes was revealed through comparative transcriptomics and multiple sequence alignments. RESULTS: IgE reactivity was detected only in serum samples from crab-allergic individuals. Immunoblotting distinguished eight putative crab allergens and three registered crab allergens. The protein and allergen profiles of the king crab were distinct from the brachyuran crab species based on dendrogram analysis; malate dehydrogenase (MDH) was distinctly reactive only in king crab with 41.4% sensitization on immunoblot, while recombinant MDH displayed a 14% sensitization rate, leading to its registration as Para c 11. MDH homologs from true crabs showed minimal inhibition to Para c 11 (&lt; 10%). Based on transcriptomic analysis, the identified crab allergens showed similar expression across species, while the sequence and epitope similarity exceeded 68%. CONCLUSION: The study provides molecular insights into crab allergen diversity and highlights the potential for species-specific crab allergies with Para c 11 as a potential king crab-specific allergen, paving the way for personalized and advanced component-resolved diagnostics.</style></abstract><notes><style face="normal" font="default" size="100%">Li, Shanshan&#xD;Bian, Jingyuan&#xD;Xiong, Qing&#xD;Wong, Brian Shing-Hei&#xD;Tsui, Stephen Kwok-Wing&#xD;Kwan, Kin-Ming&#xD;Leung, Nicki Yat-Hin&#xD;Leung, Ting-Fan&#xD;Leung, Patrick S C&#xD;Chu, Ka-Hou&#xD;Xiao, Xiaojun&#xD;Wai, Christine Yee-Yan&#xD;eng&#xD;Research Grants Council Research Impact Fund (R4035-19) of Hong Kong Special Administrative Region Government,/&#xD;Shenzhen Medical Research Fund (A2403062)/&#xD;Science and Technology Program of Shenzhen (JCYJ20220818102005011, JCYJ20200109143435556, JCYJ20220531102217038)/&#xD;Science and Technology Planning Project of Guangdong Province (2022B1515120055, 2023A1515012245, 2024A1515011412)/&#xD;The National Natural Science Foundation of China (82341060, 22106108)/&#xD;Idea Booster Fund (IDBF24MED11) of The Chinese University of Hong Kong/&#xD;Direct Grant for Research (2024.078), The Chinese University of Hong Kong/&#xD;Health and Medical Research Fund (06170856 &amp; 08191356) of the Health Bureau, Hong Kong Special Administrative Region Government/&#xD;Denmark&#xD;Allergy. 2025 Jul 30. doi: 10.1111/all.16674.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40736448</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16674</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3051</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3051</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Bian, J.</style></author><author><style face="normal" font="default" size="100%">Xiong, Q.</style></author><author><style face="normal" font="default" size="100%">Wong, B. S.</style></author><author><style face="normal" font="default" size="100%">Tsui, S. K.</style></author><author><style face="normal" font="default" size="100%">Kwan, K. M.</style></author><author><style face="normal" font="default" size="100%">Leung, N. Y.</style></author><author><style face="normal" font="default" size="100%">Leung, T. F.</style></author><author><style face="normal" font="default" size="100%">Leung, P. S. C.</style></author><author><style face="normal" font="default" size="100%">Chu, K. H.</style></author><author><style face="normal" font="default" size="100%">Xiao, X.</style></author><author><style face="normal" font="default" size="100%">Wai, C. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Life Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Institute of Allergy and Immunology of Shenzhen University School of Medicine, State Key Laboratory of Respiratory Disease Allergy Shenzhen University Division, Shenzhen, China.&#xD;Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China.&#xD;School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Hong Kong Bioinformatics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Department of Paediatrics, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong SAR, China.&#xD;Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, California, USA.&#xD;Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou), Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Revealing the Diverse Allergenic Protein Repertoire of Six Widely Consumed Crab Species: A Species-Specific Allergen in King Crab</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergen comparison</style></keyword><keyword><style face="normal" font="default" size="100%">crab allergen</style></keyword><keyword><style face="normal" font="default" size="100%">king crab</style></keyword><keyword><style face="normal" font="default" size="100%">novel allergen</style></keyword><keyword><style face="normal" font="default" size="100%">shellfish allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40736448</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Shellfish allergy poses a significant health risk affecting up to 2% of the global population. Comprehensive allergen profiling across species is crucial for improving diagnostics and therapies, given the challenges posed by cross-reactivity. This study aims to identify and compare the allergen profiles of six widely consumed edible crab species. METHODS: Muscle proteins were extracted from five brachyurans (true crabs) including Charybdis feriata, Portunus pelagicus, Scylla paramamosain, Chionoecetes opilio, and Eriocheir sinensis, as well as the king crab Paralithodes camtschaticus, and were analyzed for IgE reactivity with serum samples from 29 crab-allergic individuals and three nonallergic controls. IgE-binding proteins were identified by immunoblotting followed by mass spectrometry. Recombinant king crab allergen was purified and tested on ELISA against samples from 50 crab-allergic individuals, with its specific IgE reactivity evaluated by inhibition ELISA and immunoblot. Comparison of the gene expression of the identified allergens along with reported epitopes was revealed through comparative transcriptomics and multiple sequence alignments. RESULTS: IgE reactivity was detected only in serum samples from crab-allergic individuals. Immunoblotting distinguished eight putative crab allergens and three registered crab allergens. The protein and allergen profiles of the king crab were distinct from the brachyuran crab species based on dendrogram analysis; malate dehydrogenase (MDH) was distinctly reactive only in king crab with 41.4% sensitization on immunoblot, while recombinant MDH displayed a 14% sensitization rate, leading to its registration as Para c 11. MDH homologs from true crabs showed minimal inhibition to Para c 11 (&lt; 10%). Based on transcriptomic analysis, the identified crab allergens showed similar expression across species, while the sequence and epitope similarity exceeded 68%. CONCLUSION: The study provides molecular insights into crab allergen diversity and highlights the potential for species-specific crab allergies with Para c 11 as a potential king crab-specific allergen, paving the way for personalized and advanced component-resolved diagnostics.</style></abstract><notes><style face="normal" font="default" size="100%">Li, Shanshan&#xD;Bian, Jingyuan&#xD;Xiong, Qing&#xD;Wong, Brian Shing-Hei&#xD;Tsui, Stephen Kwok-Wing&#xD;Kwan, Kin-Ming&#xD;Leung, Nicki Yat-Hin&#xD;Leung, Ting-Fan&#xD;Leung, Patrick S C&#xD;Chu, Ka-Hou&#xD;Xiao, Xiaojun&#xD;Wai, Christine Yee-Yan&#xD;eng&#xD;Research Grants Council Research Impact Fund (R4035-19) of Hong Kong Special Administrative Region Government,/&#xD;Shenzhen Medical Research Fund (A2403062)/&#xD;Science and Technology Program of Shenzhen (JCYJ20220818102005011, JCYJ20200109143435556, JCYJ20220531102217038)/&#xD;Science and Technology Planning Project of Guangdong Province (2022B1515120055, 2023A1515012245, 2024A1515011412)/&#xD;The National Natural Science Foundation of China (82341060, 22106108)/&#xD;Idea Booster Fund (IDBF24MED11) of The Chinese University of Hong Kong/&#xD;Direct Grant for Research (2024.078), The Chinese University of Hong Kong/&#xD;Health and Medical Research Fund (06170856 &amp; 08191356) of the Health Bureau, Hong Kong Special Administrative Region Government/&#xD;Denmark&#xD;Allergy. 2025 Jul 30. doi: 10.1111/all.16674.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40736448</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16674</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1943</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1943</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Koppelman, G. H.</style></author><author><style face="normal" font="default" size="100%">Togias, A.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Rothenberg, M.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Wickman, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Aguilar, D.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Bosnic-Anticevich, S.</style></author><author><style face="normal" font="default" size="100%">Boulet, L. P.</style></author><author><style face="normal" font="default" size="100%">Brightling, C. E.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Burte, E.</style></author><author><style face="normal" font="default" size="100%">Bustamante, M.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Celedon, J. C.</style></author><author><style face="normal" font="default" size="100%">Chaves Loureiro, C.</style></author><author><style face="normal" font="default" size="100%">Costa, E.</style></author><author><style face="normal" font="default" size="100%">Cruz, A. A.</style></author><author><style face="normal" font="default" size="100%">Erhola, M.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Garcia-Aymerich, J.</style></author><author><style face="normal" font="default" size="100%">Guerra, S.</style></author><author><style face="normal" font="default" size="100%">Heinrich, J.</style></author><author><style face="normal" font="default" size="100%">Ivancevich, J. C.</style></author><author><style face="normal" font="default" size="100%">Keil, T.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Kuna, P.</style></author><author><style face="normal" font="default" size="100%">Kupczyk, M.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Lemonnier, N.</style></author><author><style face="normal" font="default" size="100%">Lodrup Carlsen, K. C.</style></author><author><style face="normal" font="default" size="100%">Louis, R.</style></author><author><style face="normal" font="default" size="100%">Makela, M.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Momas, I.</style></author><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Naclerio, R. N.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Nadif, R.</style></author><author><style face="normal" font="default" size="100%">Niedoszytko, M.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Passalacqua, G.</style></author><author><style face="normal" font="default" size="100%">Patella, V.</style></author><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Pham-Thi, N.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Regateiro, F. S.</style></author><author><style face="normal" font="default" size="100%">Ring, J.</style></author><author><style face="normal" font="default" size="100%">Rouadi, P. W.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Savoure, M.</style></author><author><style face="normal" font="default" size="100%">Scichilone, N.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Sheikh, A.</style></author><author><style face="normal" font="default" size="100%">Siroux, V.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Standl, M.</style></author><author><style face="normal" font="default" size="100%">Sunyer, J.</style></author><author><style face="normal" font="default" size="100%">Taborda-Barata, L.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Tsiligianni, I.</style></author><author><style face="normal" font="default" size="100%">Valovirta, E.</style></author><author><style face="normal" font="default" size="100%">Vandenplas, O.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Weiss, S.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Abdul Latiff, A. H.</style></author><author><style face="normal" font="default" size="100%">Aberer, W.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Al-Ahmad, M.</style></author><author><style face="normal" font="default" size="100%">Alobid, I.</style></author><author><style face="normal" font="default" size="100%">Ansotegui, I. J.</style></author><author><style face="normal" font="default" size="100%">Arshad, S. H.</style></author><author><style face="normal" font="default" size="100%">Asayag, E.</style></author><author><style face="normal" font="default" size="100%">Barbara, C.</style></author><author><style face="normal" font="default" size="100%">Baharudin, A.</style></author><author><style face="normal" font="default" size="100%">Battur, L.</style></author><author><style face="normal" font="default" size="100%">Bennoor, K. S.</style></author><author><style face="normal" font="default" size="100%">Berghea, E. C.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Bernstein, D.</style></author><author><style face="normal" font="default" size="100%">Bewick, M.</style></author><author><style face="normal" font="default" size="100%">Blain, H.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Braido, F.</style></author><author><style face="normal" font="default" size="100%">Buhl, R.</style></author><author><style face="normal" font="default" size="100%">Bumbacea, R. S.</style></author><author><style face="normal" font="default" size="100%">Bush, A.</style></author><author><style face="normal" font="default" size="100%">Calderon, M.</style></author><author><style face="normal" font="default" size="100%">Calvo-Gil, M.</style></author><author><style face="normal" font="default" size="100%">Camargos, P.</style></author><author><style face="normal" font="default" size="100%">Caraballo, L.</style></author><author><style face="normal" font="default" size="100%">Cardona, V.</style></author><author><style face="normal" font="default" size="100%">Carr, W.</style></author><author><style face="normal" font="default" size="100%">Carreiro-Martins, P.</style></author><author><style face="normal" font="default" size="100%">Casale, T.</style></author><author><style face="normal" font="default" size="100%">Cepeda Sarabia, A. M.</style></author><author><style face="normal" font="default" size="100%">Chandrasekharan, R.</style></author><author><style face="normal" font="default" size="100%">Charpin, D.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. Z.</style></author><author><style face="normal" font="default" size="100%">Cherrez-Ojeda, I.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author><author><style face="normal" font="default" size="100%">Chkhartishvili, E.</style></author><author><style face="normal" font="default" size="100%">Christoff, G.</style></author><author><style face="normal" font="default" size="100%">Chu, D. K.</style></author><author><style face="normal" font="default" size="100%">Cingi, C.</style></author><author><style face="normal" font="default" size="100%">Correia de Sousa, J.</style></author><author><style face="normal" font="default" size="100%">Corrigan, C.</style></author><author><style face="normal" font="default" size="100%">Custovic, A.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">De Blay, F.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Didier, A.</style></author><author><style face="normal" font="default" size="100%">do Ceu Teixeira, M.</style></author><author><style face="normal" font="default" size="100%">Dokic, D.</style></author><author><style face="normal" font="default" size="100%">Douagui, H.</style></author><author><style face="normal" font="default" size="100%">Doulaptsi, M.</style></author><author><style face="normal" font="default" size="100%">Durham, S.</style></author><author><style face="normal" font="default" size="100%">Dykewicz, M.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">El-Sayed, Z. A.</style></author><author><style face="normal" font="default" size="100%">Emuzyte, R.</style></author><author><style face="normal" font="default" size="100%">Fiocchi, A.</style></author><author><style face="normal" font="default" size="100%">Fyhrquist, N.</style></author><author><style face="normal" font="default" size="100%">Gomez, R. M.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Guzman, M. A.</style></author><author><style face="normal" font="default" size="100%">Hagemann, J.</style></author><author><style face="normal" font="default" size="100%">Hamamah, S.</style></author><author><style face="normal" font="default" size="100%">Halken, S.</style></author><author><style face="normal" font="default" size="100%">Halpin, D. M. G.</style></author><author><style face="normal" font="default" size="100%">Hofmann, M.</style></author><author><style face="normal" font="default" size="100%">Hossny, E.</style></author><author><style face="normal" font="default" size="100%">Hrubisko, M.</style></author><author><style face="normal" font="default" size="100%">Irani, C.</style></author><author><style face="normal" font="default" size="100%">Ispayeva, Z.</style></author><author><style face="normal" font="default" size="100%">Jares, E.</style></author><author><style face="normal" font="default" size="100%">Jartti, T.</style></author><author><style face="normal" font="default" size="100%">Jassem, E.</style></author><author><style face="normal" font="default" size="100%">Julge, K.</style></author><author><style face="normal" font="default" size="100%">Just, J.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Kaidashev, I.</style></author><author><style face="normal" font="default" size="100%">Kalayci, O.</style></author><author><style face="normal" font="default" size="100%">Kalyoncu, A. F.</style></author><author><style face="normal" font="default" size="100%">Kardas, P.</style></author><author><style face="normal" font="default" size="100%">Kirenga, B.</style></author><author><style face="normal" font="default" size="100%">Kraxner, H.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Kulus, M.</style></author><author><style face="normal" font="default" size="100%">La Grutta, S.</style></author><author><style face="normal" font="default" size="100%">Lau, S.</style></author><author><style face="normal" font="default" size="100%">Le Tuyet Thi, L.</style></author><author><style face="normal" font="default" size="100%">Levin, M.</style></author><author><style face="normal" font="default" size="100%">Lipworth, B.</style></author><author><style face="normal" font="default" size="100%">Lourenco, O.</style></author><author><style face="normal" font="default" size="100%">Mahboub, B.</style></author><author><style face="normal" font="default" size="100%">Martinez-Infante, E.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P.</style></author><author><style face="normal" font="default" size="100%">Miculinic, N.</style></author><author><style face="normal" font="default" size="100%">Migueres, N.</style></author><author><style face="normal" font="default" size="100%">Mihaltan, F.</style></author><author><style face="normal" font="default" size="100%">Mohammad, Y.</style></author><author><style face="normal" font="default" size="100%">Moniuszko, M.</style></author><author><style face="normal" font="default" size="100%">Montefort, S.</style></author><author><style face="normal" font="default" size="100%">Neffen, H.</style></author><author><style face="normal" font="default" size="100%">Nekam, K.</style></author><author><style face="normal" font="default" size="100%">Nunes, E.</style></author><author><style face="normal" font="default" size="100%">Nyembue Tshipukane, D.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Ohta, K.</style></author><author><style face="normal" font="default" size="100%">Okubo, K.</style></author><author><style face="normal" font="default" size="100%">Ouedraogo, S.</style></author><author><style face="normal" font="default" size="100%">Olze, H.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Palosuo, K.</style></author><author><style face="normal" font="default" size="100%">Panaitescu, C.</style></author><author><style face="normal" font="default" size="100%">Panzner, P.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author><author><style face="normal" font="default" size="100%">Pitsios, C.</style></author><author><style face="normal" font="default" size="100%">Plavec, D.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Puggioni, F.</style></author><author><style face="normal" font="default" size="100%">Quirce, S.</style></author><author><style face="normal" font="default" size="100%">Recto, M.</style></author><author><style face="normal" font="default" size="100%">Repka-Ramirez, M. S.</style></author><author><style face="normal" font="default" size="100%">Robalo Cordeiro, C.</style></author><author><style face="normal" font="default" size="100%">Roche, N.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Gonzalez, M.</style></author><author><style face="normal" font="default" size="100%">Romantowski, J.</style></author><author><style face="normal" font="default" size="100%">Rosario Filho, N.</style></author><author><style face="normal" font="default" size="100%">Rottem, M.</style></author><author><style face="normal" font="default" size="100%">Sagara, H.</style></author><author><style face="normal" font="default" size="100%">Serpa, F. S.</style></author><author><style face="normal" font="default" size="100%">Sayah, Z.</style></author><author><style face="normal" font="default" size="100%">Scheire, S.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Sisul, J. C.</style></author><author><style face="normal" font="default" size="100%">Sole, D.</style></author><author><style face="normal" font="default" size="100%">Soto-Martinez, M.</style></author><author><style face="normal" font="default" size="100%">Sova, M.</style></author><author><style face="normal" font="default" size="100%">Sperl, A.</style></author><author><style face="normal" font="default" size="100%">Spranger, O.</style></author><author><style face="normal" font="default" size="100%">Stelmach, R.</style></author><author><style face="normal" font="default" size="100%">Suppli Ulrik, C.</style></author><author><style face="normal" font="default" size="100%">Thomas, M.</style></author><author><style face="normal" font="default" size="100%">To, T.</style></author><author><style face="normal" font="default" size="100%">Todo-Bom, A.</style></author><author><style face="normal" font="default" size="100%">Tomazic, P. V.</style></author><author><style face="normal" font="default" size="100%">Urrutia-Pereira, M.</style></author><author><style face="normal" font="default" size="100%">Valentin-Rostan, M.</style></author><author><style face="normal" font="default" size="100%">Van Ganse, E.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Vasankari, T.</style></author><author><style face="normal" font="default" size="100%">Vichyanond, P.</style></author><author><style face="normal" font="default" size="100%">Viegi, G.</style></author><author><style face="normal" font="default" size="100%">Wallace, D.</style></author><author><style face="normal" font="default" size="100%">Wang, D. Y.</style></author><author><style face="normal" font="default" size="100%">Williams, S.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Yiallouros, P.</style></author><author><style face="normal" font="default" size="100%">Yusuf, O.</style></author><author><style face="normal" font="default" size="100%">Zaitoun, F.</style></author><author><style face="normal" font="default" size="100%">Zernotti, M.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, J.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany.&#xD;University Hospital Montpellier, Montpellier, France.&#xD;Inserm, Equipe d&apos;Epidemiologie Respiratoire Integrative, CESP, Villejuif, France.&#xD;Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Sach s Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.&#xD;Department of Pediatric Pulmonology and Pediatric Allergology, GRIAC Research Institute, University Medical Center Groningen, Beatrix Children&apos;s Hospital, University of Groningen, Groningen, the Netherlands.&#xD;Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;MASK-air, Montpellier, France.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Institute of Clinical Medicine and Institute of Health Sciences, Vilnius, Lithuania.&#xD;Medical Faculty of Vilnius University, Vilnius, Lithuania.&#xD;Institute of Environmental medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;6AM Data Mining, Barcelona, Spain.&#xD;ARIA, Montpellier, France.&#xD;Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.&#xD;Odense Research Center for Anaphylaxis &lt;&lt; ORCA &gt;&gt;, Odense, Denmark.&#xD;Quality Use of Respiratory Medicines Group, Woolcock Institute of Medical Research, Sydney, NSW, Australia.&#xD;Sydney Local Health District, Sydney, NSW, Australia.&#xD;Sydney Pharmacy School, The University of Sydney, Sydney, NSW, Australia.&#xD;Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.&#xD;Institute of Lung Health, NIHR Biomedical Research Centre, Department of Respiratory and Infection Sciences, University of Leicester, Leicester, UK.&#xD;Department of Medical Sciences, University of Torino, Torino, Italy.&#xD;Allergy and Clinical Immunology Unit, Mauriziano Hospital, Torino, Italy.&#xD;Universite Paris-Saclay, UVSQ, UnivParis-Sud, Villejuif, France.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.&#xD;Personalized medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.&#xD;SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.&#xD;Division of Pediatric Pulmonary Medicine, UPMC Children&apos;s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.&#xD;Pneumology Unit, Hospitais da Universidade de Coimbra, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.&#xD;UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), Porto, Portugal.&#xD;Fundacao ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Bahia, Brazil.&#xD;Pirkanmaa Welfare district, Tampere, Finland.&#xD;Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centres, Amsterdam, the Netherlands.&#xD;Asthma and Airway Disease Research Center, University of Arizona, Tucson, Arizona, USA.&#xD;Ludwig Maximilians University Munich, University Hospital Munich - Instituteand Outpatient Clinic for Occupational, Social and Environmental Medicine, Munich, Germany.&#xD;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.&#xD;Institute of Social Medicine, Epidemiology and Health Economics, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany.&#xD;State Institute of Health, Bavarian Health and Food Safety Authority, Erlangen, Germany.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Center of Excellence in Asthma and Allergy, Medica Sur Clinical Foundation and Hospital, Mexico City, Mexico.&#xD;Institute for Advanced Biosciences, UGA - INSERM U1209 - CNRS UMR5309, Site Sante, La Tronche, France.&#xD;Department of Paediatrics, Oslo University Hospital, Oslo, Norway.&#xD;Department of Pulmonary Medicine, CHU Liege, Liege, Belgium.&#xD;GIGA I3 Research Group, University of Liege, Liege, Belgium.&#xD;Allergy Unit &quot;D Kalogeromitros&quot;, 2nd Department of Dermatology and Venereology, National &amp; Kapodistrian University of Athens, &quot;Attikon&quot; University Hospital, Athens, Greece.&#xD;Department of Public Health and Health Products, Paris Descartes University-Sorbonne Paris Cite, EA 4064, Paris, France.&#xD;Paris Municipal Department of Social Action, Childhood, and Health, Paris, France.&#xD;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;ENT Department, Rhinology Unit &amp; Smell Clinic, Hospital Clinic, Barcelona, Spain.&#xD;Clinical &amp; Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.&#xD;Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.&#xD;Department of Allergology, Medical University of Gdansk, Gdansk, Poland.&#xD;Chiba Rosai Hospital, Chiba, Japan.&#xD;Chiba University Hospital, Chiba, Japan.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Allergy and Respiratory Diseases, IRCCS Policlinico San Martino - University of Genoa, Genoa, Italy.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, &quot;Santa Maria della Speranza&quot; Hospital, Battipaglia, Salerno, Italy.&#xD;Agency of Health ASL, Salerno, Italy.&#xD;Postgraduate Programme in Allergy and Clinical Immunology, University of Naples Federico II, Naples, Italy.&#xD;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Ecole Polytechnique de Palaiseau, Palaiseau, France.&#xD;IRBA (Institut de Recherche Bio-Medicale des Armees), Bretigny sur Orge, France.&#xD;Universite Paris Cite, Paris, France.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.&#xD;Coimbra Institute for Clinical and Biomedical Research (ICBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Christine Kuhne Center for Allergy Research and Education (CK-Care), Davos, Switzerland.&#xD;Department of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Dar Al Shifa Hospital, Salmiya, Kuwait.&#xD;Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland.&#xD;Allergy Service, Fundacion Jimenez Diaz, Autonoma University of Madrid, CIBERES-ISCIII, Madrid, Spain.&#xD;French Environment and Energy Management Agency, Angers, France.&#xD;PROMISE Department, University of Palermo, Palermo, Italy.&#xD;National Heart and Lung Institute, Imperial College, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Usher Institute, The University of Edinburgh, Edinburgh, UK.&#xD;INSERM, Universite Grenoble Alpes, IAB, U 1209, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Universite Joseph Fourier, Grenoble, France.&#xD;MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences; Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE- Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Institute of Epidemiology, Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg, Germany.&#xD;German Center of Lung Research (DZL), Munich, Germany.&#xD;IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.&#xD;Department of Immunoallergology, Cova da Beira University Hospital Centre, Covilha, Portugal.&#xD;UBIAir - Clinical &amp; Experimental Lung Centre and CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Allergy Unit, Malaga Regional University Hospital of Malaga, Malaga University, ARADyAL, Malaga, Spain.&#xD;International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland.&#xD;Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece.&#xD;Department of Lung Diseases and Clinical Allergology, University of Turku, Turku, Finland.&#xD;Department of Chest Medicine, Centre Hospitalier Universitaire UCL, Namur, Belgium.&#xD;Universite Catholique de Louvain, Yvoir, Belgium.&#xD;Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.&#xD;Institute of Sciences of Food Production, National Research Council (ISPA-CNR), Bari, Italy.&#xD;Harvard Medical School and Channing Division of Network Medicine, Boston, USA.&#xD;Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey.&#xD;Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital and Beijing Institute of Otolaryngology, Beijing, China.&#xD;Allergy &amp; Immunology Centre, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.&#xD;Department of Dermatology, Medical University of Graz, Graz, Austria.&#xD;Faculty of Medicine, Transylvania University of Brasov, Brasov, Romania.&#xD;Microbiology Department, College of Medicine, Kuwait University, Kuwait City, Kuwait.&#xD;Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.&#xD;Centro Medico Teknon, Barcelona, Spain.&#xD;Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.&#xD;Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;David Hide Asthma and Allergy Research Centre, Isle of Wight, UK.&#xD;Argentine Society of Allergy and Immunopathology, Buenos Aires, Argentina.&#xD;Portuguese National Programme for Respiratory Diseases, Direcao -Geral da Saude, Faculdade de Medicina de Lisboa, Instituto de Saude Ambiental, Lisbon, Portugal.&#xD;Department of Otorhinolaryngology, Head and Neck, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.&#xD;Mongolian Association of Hospital Managers, Ulaanbaatar, Mongolia.&#xD;Department of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.&#xD;Department of Pediatrics, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.&#xD;Division of Immunology, Allergy and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;University of Central Lancashire Medical School, Preston, UK.&#xD;Department of Geriatrics, Montpellier University Hospital, MUSE, Montpellier, France.&#xD;Department of Cardiovascular and Respiratory Sciences, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;Department of Neurological, ENT and Thoracic Sciences, Fondazione Policlinico Universitario A Gemelli - IRCCS, Rome, Italy.&#xD;National Heart and Lung Institute (NHLI), Imperial College London, London, UK.&#xD;Respiratory Clinic, Department of Internal Medicine, University of Genoa, Genoa, Italy.&#xD;IRCCS Ospedale Policlinico San Martino, Genoa, Italy.&#xD;Department of Pulmonary Medicine, Mainz University Hospital, Mainz, Germany.&#xD;Department of Allergy, &quot;Carol Davila&quot; University of Medicine and Pharmacy Bucharest, Bucharest, Romania.&#xD;Imperial College and Royal Brompton Hospital, London, UK.&#xD;Imperial College and National Heart and Lung Institute, London, UK.&#xD;Pediatrics Department, Universidad Austral de Chile, Valvidia, Chile.&#xD;Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil.&#xD;Institute for Immunological Research, University of Cartagena, Campus de Zaragocilla, Edificio Biblioteca Primer piso, Cartagena, Colombia.&#xD;Allergy Section, Department of Internal Medicine, Hospital Vall d&apos;Hebron, Barcelona, Spain.&#xD;ARADyAL Research Network, Barcelona, Spain.&#xD;Allergy &amp; Asthma Associates of Southern California, A Medical Group, Southern California Research, Mission Viejo, California, USA.&#xD;NOVA Medical School/Comprehensive Health Research Centre (CHRC), Lisbon, Portugal.&#xD;Servico de Imunoalergologia, Hospital de Dona Estefania, Centro Hospitalar Universitario de Lisboa Central, Lisbon, Portugal.&#xD;Division of Allergy/Immunology, University of South Florida, Tampa, Florida, USA.&#xD;Allergy and Immunology Laboratory, Metropolitan University, Simon Bolivar University, Barranquilla, Colombia.&#xD;SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia, Barranquilla, Columbia.&#xD;Department of ENT, Badr al Samaa Hospital, Salalah, Sultanate of Oman.&#xD;Clinique des Bronches, Allergie et Sommeil, Hopital Nord, Marseille, France.&#xD;The Capital Institute of Pediatrics, Chaoyang district, Beijing, China.&#xD;Universidad Espiritu Santo, Samborondon, Ecuador.&#xD;Respiralab Research Group, Guayaquil, Guayas, Ecuador.&#xD;School of Medicine, University CEU San Pablo, Madrid, Spain.&#xD;David Tatishvili Medical Center; David Tvildiani Medical University-AIETI Medical School, Tbilisi, Georgia.&#xD;Faculty of Public Health, Medical University - Sofia, Sofia, Bulgaria.&#xD;Department of Health Research Methods, Evidence, and Impact &amp; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;Medical Faculty, ENT Department, Eskisehir Osmangazi University, Eskisehir, Turkey.&#xD;School of Medicine, Life and Health Sciences Research Institute (ICVS), University of Minho, Braga, Portugal.&#xD;Division of Asthma, Allergy &amp; Lung Biology, MRC &amp; Asthma UK Centre in Allergic Mechanisms of Asthma, King&apos;s College London, London, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Division of Respiratory and Allergic Diseases, Hospital &apos;A Cardarelli&apos;, University of Naples Federico II, Naples, Italy.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &quot;Duilio Casula&quot;, University of Cagliari, Cagliari, Italy.&#xD;Allergy Division, Chest Disease Department, University Hospital of Strasbourg, Strasbourg, France.&#xD;Federation of Translational Medicine, University of Strasbourg, Strasbourg, France.&#xD;VIM Suresnes, UMR 0892, Pole des Maladies des Voies Respiratoires, Hopital Foch, Universite Paris-Saclay, Suresnes, France.&#xD;Department of Respiratory Diseases, Larrey Hospital, Toulouse University Hospital, Toulouse, France.&#xD;Dr Agostinho Neto University hospital, Praia, Cape Verde.&#xD;Immunology, Faculty of Medicine, Cabo Verde University, Praia, Cape Verde.&#xD;Medical Faculty Skopje, University Clinic of Pulmonology and Allergy, Skopje, Republic of Macedonia.&#xD;Service de Pneumo-Allergologie, Centre Hospitalo-Universitaire de Beni-Messous, Algiers, Algeria.&#xD;Department of Otorhinolaryngology Head and Neck Surgery, University Hospital of Crete, Heraklion, Crete, Greece.&#xD;Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.&#xD;The Hospital for Sick Children, Department of Paediatrics, Division of Clinical Immunology and Allergy, Food allergy and Anaphylaxis Program, The University of Toronto, Toronto, Ontario, Canada.&#xD;Pediatric Allergy, Immunology and Rheumatology Unit, Children&apos;s Hospital, Ain Shams University, Cairo, Egypt.&#xD;Clinic of Children&apos;s Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Allergy, Bambino Gesu Children&apos;s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.&#xD;School of Health Sciences, Catholic University of Salta, Salta, Argentina.&#xD;Center of Allergy and Immunology, David Tvildiani Medical University, Tbilisi, Georgia.&#xD;Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile.&#xD;Biology of Reproduction department, INSERM 1203, University hospital, Montpellier, France.&#xD;Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Odense, Denmark.&#xD;University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, Devon, UK.&#xD;Berlin Institute of Health, Berlin, Germany.&#xD;Department of Clinical Immunology and Allergy, Oncology Institute of St Elisabeth, Bratislava, Slovakia.&#xD;Department of Internal Medicine and Infectious Diseases, St Joseph University, Hotel Dieu de France Hospital, Beirut, Lebanon.&#xD;Kazakhstan Association of Allergology and Clinical Immunology, Department of Allergology and Clinical Immunology of the Kazakh National Medical University, Almaty, Kazakhstan.&#xD;Servicio de Alergia, Consultorios Medicos Privados, Buenos Aires, Argentina.&#xD;EDEGO Research Unit, University of Oulu, Oulu, Finland.&#xD;Department of Pneumology, Medical University of Gdansk, Gdansk, Poland.&#xD;Tartu University Institute of Clinical Medicine, Children&apos;s Clinic, Tartu, Estonia.&#xD;Sorbonne universite, Hopital americain de Paris, Neuilly, France.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Poltava State Medical University, Poltava, Ukraine.&#xD;Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey.&#xD;School of Medicine, Department of Chest Diseases, Immunology and Allergy Division, Hacettepe University, Ankara, Turkey.&#xD;Department of Family Medicine, Medical University of Lodz, Lodz, Poland.&#xD;Makerere University Lung Institute, Kampala, Uganda.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary.&#xD;Department of Pediatric Respiratory Diseases and Allergology, Medical University of Warsaw, Warsaw, Poland.&#xD;Institute of Translational Pharmacology, National Research Council, Palermo, Italy.&#xD;Department of Paediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite Universitatsmedizin, Berlin, Germany.&#xD;University of Medicine and Pharmacy, Hochiminh City, Vietnam.&#xD;Division Paediatric Allergology, University of Cape Town, Cape Town, South Africa.&#xD;Scottish Centre for Respiratory Research, Cardiovascular &amp; Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, Dundee, UK.&#xD;Faculty of Health Sciences and CICS - UBI, Health Sciences Research Centre, University of Beira Interior, Covilha, Portugal.&#xD;Department of Pulmonary Medicine, Rashid Hospital, Dubai, UAE.&#xD;Hospital San Luca, Oaxaca, Mexico.&#xD;Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Croatian Pulmonary Society, Zagreb, Croatia.&#xD;National Institute of Pneumology M Nasta, Bucharest, Romania.&#xD;National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, Syria.&#xD;Syrian Private University, Damascus, Syria.&#xD;Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystock, Poland.&#xD;Department of Medicine, Faculty of Medicine and Surgery, University of Malta, Msida, Malta.&#xD;Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina.&#xD;Hungarian Allergy Association, Budapest, Hungary.&#xD;Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.&#xD;ENT Department, University Hospital of Kinshasa, Kinshasa, Congo.&#xD;Allergy, Asthma and Clinical Immunology, Alfred Health and Department of Immunology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.&#xD;Japan Anti-Tuberculosis Association (JATA), Fukujuji Hospital, Tokyo, Japan.&#xD;Department of Otolaryngology, Nippon Medical School, Tokyo, Japan.&#xD;Centre Hospitalier Universitaire Pediatrique Charles de Gaulle, Ouagadougou, Burkina Faso.&#xD;Department of Otorhinolaryngology, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Comparative Medicine, Messerli Research Institute of the University of Veterinary Medicine, Medical University, and University of Vienna, Vienna, Austria.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.&#xD;Department of Dermatology, University of Helsinki and Hospital for Skin and Allergic Diseases, Helsinki, Finland.&#xD;OncoGen Center, County Clinical Emergency Hospital &quot;Pius Branzeu,&quot; and University of Medicine and Pharmacy V Babes, Timisoara, Romania.&#xD;Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic.&#xD;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea.&#xD;Medical School, University of Cyprus, Nicosia, Cyprus.&#xD;Srebrnjak Children&apos;s Hospital, Zagreb, Croatia.&#xD;Medical Faculty, University JJ Strossmayer of Osijek, Osijek, Croatia.&#xD;Clinic of Occupational Diseases, University Hospital Sveti Ivan Rilski, Sofia, Bulgaria.&#xD;Personalized medicine Asthma &amp; Allergy, Rozzano, IRCCS Humanitas Research Center, Milan, Italy.&#xD;Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.&#xD;Division of Adult and Pediatric Allergy and Immunology, University of the Philippines- Philippines General Hospital, Manila, Philippines.&#xD;Division of Allergy, Asthma and Immunology, Clinics Hospital, San Lorenzo, Paraguay.&#xD;Pneumologie, AP-HP Centre, Universite de Paris Cite, Hopital Cochin, Paris, France.&#xD;UMR 1016, Institut Cochin, Paris, France.&#xD;Pediatric Allergy and Clinical Immunology, Hospital Espanol de Mexico, Mexico City, Mexico.&#xD;Department of Pediatrics, Federal University of Parana, Curitiba, Brazil.&#xD;Division of Allergy, Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel.&#xD;Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.&#xD;Asthma Reference Center - School of Medicine of Santa Casa de Misericordia of Vitoria, Espirito Santo, Brazil.&#xD;SMAIC Societe Marocaine d&apos; Allergologie et Immunologie Clinique, Rabat, Morocco.&#xD;Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.&#xD;Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.&#xD;Allergy &amp; Asthma, Clinica SISUL, FACAAI, SPAAI, Asuncion, Paraguay.&#xD;Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;Division of Respiratory Medicine, Department of Pediatrics, Hospital Nacional de Ninos, Universidad de Costa Rica, San Jose, Costa Rica.&#xD;Department of Respiratory Medicine and Tuberculosis, University Hospital, Brno, Czech Republic.&#xD;Global Allergy and Airways Patient Platform GAAPP, Vienna, Austria.&#xD;Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.&#xD;Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Copenhagen, Denmark.&#xD;Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;University of Southampton, Southampton, UK.&#xD;The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.&#xD;Imunoalergologia, Centro Hospitalar Universitario de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Department of General ORL, H&amp;NS, Medical University of Graz, ENT-University Hospital Graz, Graz, Austria.&#xD;Universidade Federal dos Pampa, Uruguaiana, Brazil.&#xD;Allergist, Montevideo, Uruguay.&#xD;Research on Healthcare Performance (RESHAPE), INSERM U1290, Universite Claude Bernard Lyon1, Lyon, France.&#xD;Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.&#xD;Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.&#xD;FILHA, Finnish Lung Health Association, Helsinki, Finland.&#xD;Department of Clinical Medicine, Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland.&#xD;Division of Allergy and Immunology, Department of Pediatrics, Siriraj Hospital, Mahidol University Faculty of Medicine, Bangkok, Thailand.&#xD;Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy.&#xD;College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, Florida, USA.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;International Primary Care Respiratory Group IPCRG, Aberdeen, UK.&#xD;Division of Allergy and Immunology Department of Dermatology, Allergy and Venerology, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;The Allergy and Asthma Institute, Islamabad, Pakistan.&#xD;Lebanese-American University, Clemenceau Medical Center DHCC, Dubai, UAE.&#xD;Universidad Catolica de Cordoba, Universidad Nacional de Villa Maria, Villa Maria, Argentina.&#xD;University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.&#xD;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1169-1203</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/diagnosis/epidemiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Multimorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-like receptors</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36799120</style></accession-num><abstract><style face="normal" font="default" size="100%">Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of &quot;one-airway-one-disease,&quot; coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the &quot;Epithelial Barrier Hypothesis.&quot; This review determined that the &quot;one-airway-one-disease&quot; concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme &quot;allergic&quot; (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono- or pauci-sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Bousquet, J&#xD;Melen, E&#xD;Haahtela, T&#xD;Koppelman, G H&#xD;Togias, A&#xD;Valenta, R&#xD;Akdis, C A&#xD;Czarlewski, W&#xD;Rothenberg, M&#xD;Valiulis, A&#xD;Wickman, M&#xD;Akdis, M&#xD;Aguilar, D&#xD;Bedbrook, A&#xD;Bindslev-Jensen, C&#xD;Bosnic-Anticevich, S&#xD;Boulet, L P&#xD;Brightling, C E&#xD;Brussino, L&#xD;Burte, E&#xD;Bustamante, M&#xD;Canonica, G W&#xD;Cecchi, L&#xD;Celedon, J C&#xD;Chaves Loureiro, C&#xD;Costa, E&#xD;Cruz, A A&#xD;Erhola, M&#xD;Gemicioglu, B&#xD;Fokkens, W J&#xD;Garcia-Aymerich, J&#xD;Guerra, S&#xD;Heinrich, J&#xD;Ivancevich, J C&#xD;Keil, T&#xD;Klimek, L&#xD;Kuna, P&#xD;Kupczyk, M&#xD;Kvedariene, V&#xD;Larenas-Linnemann, D E&#xD;Lemonnier, N&#xD;Lodrup Carlsen, K C&#xD;Louis, R&#xD;Makela, M&#xD;Makris, M&#xD;Maurer, M&#xD;Momas, I&#xD;Morais-Almeida, M&#xD;Mullol, J&#xD;Naclerio, R N&#xD;Nadeau, K&#xD;Nadif, R&#xD;Niedoszytko, M&#xD;Okamoto, Y&#xD;Ollert, M&#xD;Papadopoulos, N G&#xD;Passalacqua, G&#xD;Patella, V&#xD;Pawankar, R&#xD;Pham-Thi, N&#xD;Pfaar, O&#xD;Regateiro, F S&#xD;Ring, J&#xD;Rouadi, P W&#xD;Samolinski, B&#xD;Sastre, J&#xD;Savoure, M&#xD;Scichilone, N&#xD;Shamji, M H&#xD;Sheikh, A&#xD;Siroux, V&#xD;Sousa-Pinto, B&#xD;Standl, M&#xD;Sunyer, J&#xD;Taborda-Barata, L&#xD;Toppila-Salmi, S&#xD;Torres, M J&#xD;Tsiligianni, I&#xD;Valovirta, E&#xD;Vandenplas, O&#xD;Ventura, M T&#xD;Weiss, S&#xD;Yorgancioglu, A&#xD;Zhang, L&#xD;Abdul Latiff, A H&#xD;Aberer, W&#xD;Agache, I&#xD;Al-Ahmad, M&#xD;Alobid, I&#xD;Ansotegui, I J&#xD;Arshad, S H&#xD;Asayag, E&#xD;Barbara, C&#xD;Baharudin, A&#xD;Battur, L&#xD;Bennoor, K S&#xD;Berghea, E C&#xD;Bergmann, K C&#xD;Bernstein, D&#xD;Bewick, M&#xD;Blain, H&#xD;Bonini, M&#xD;Braido, F&#xD;Buhl, R&#xD;Bumbacea, R S&#xD;Bush, A&#xD;Calderon, M&#xD;Calvo-Gil, M&#xD;Camargos, P&#xD;Caraballo, L&#xD;Cardona, V&#xD;Carr, W&#xD;Carreiro-Martins, P&#xD;Casale, T&#xD;Cepeda Sarabia, A M&#xD;Chandrasekharan, R&#xD;Charpin, D&#xD;Chen, Y Z&#xD;Cherrez-Ojeda, I&#xD;Chivato, T&#xD;Chkhartishvili, E&#xD;Christoff, G&#xD;Chu, D K&#xD;Cingi, C&#xD;Correia de Sousa, J&#xD;Corrigan, C&#xD;Custovic, A&#xD;D&apos;Amato, G&#xD;Del Giacco, S&#xD;De Blay, F&#xD;Devillier, P&#xD;Didier, A&#xD;do Ceu Teixeira, M&#xD;Dokic, D&#xD;Douagui, H&#xD;Doulaptsi, M&#xD;Durham, S&#xD;Dykewicz, M&#xD;Eiwegger, T&#xD;El-Sayed, Z A&#xD;Emuzyte, R&#xD;Fiocchi, A&#xD;Fyhrquist, N&#xD;Gomez, R M&#xD;Gotua, M&#xD;Guzman, M A&#xD;Hagemann, J&#xD;Hamamah, S&#xD;Halken, S&#xD;Halpin, D M G&#xD;Hofmann, M&#xD;Hossny, E&#xD;Hrubisko, M&#xD;Irani, C&#xD;Ispayeva, Z&#xD;Jares, E&#xD;Jartti, T&#xD;Jassem, E&#xD;Julge, K&#xD;Just, J&#xD;Jutel, M&#xD;Kaidashev, I&#xD;Kalayci, O&#xD;Kalyoncu, A F&#xD;Kardas, P&#xD;Kirenga, B&#xD;Kraxner, H&#xD;Kull, I&#xD;Kulus, M&#xD;La Grutta, S&#xD;Lau, S&#xD;Le Tuyet Thi, L&#xD;Levin, M&#xD;Lipworth, B&#xD;Lourenco, O&#xD;Mahboub, B&#xD;Martinez-Infante, E&#xD;Matricardi, P&#xD;Miculinic, N&#xD;Migueres, N&#xD;Mihaltan, F&#xD;Mohammad, Y&#xD;Moniuszko, M&#xD;Montefort, S&#xD;Neffen, H&#xD;Nekam, K&#xD;Nunes, E&#xD;Nyembue Tshipukane, D&#xD;O&apos;Hehir, R&#xD;Ogulur, I&#xD;Ohta, K&#xD;Okubo, K&#xD;Ouedraogo, S&#xD;Olze, H&#xD;Pali-Scholl, I&#xD;Palomares, O&#xD;Palosuo, K&#xD;Panaitescu, C&#xD;Panzner, P&#xD;Park, H S&#xD;Pitsios, C&#xD;Plavec, D&#xD;Popov, T A&#xD;Puggioni, F&#xD;Quirce, S&#xD;Recto, M&#xD;Repka-Ramirez, M S&#xD;Robalo Cordeiro, C&#xD;Roche, N&#xD;Rodriguez-Gonzalez, M&#xD;Romantowski, J&#xD;Rosario Filho, N&#xD;Rottem, M&#xD;Sagara, H&#xD;Serpa, F S&#xD;Sayah, Z&#xD;Scheire, S&#xD;Schmid-Grendelmeier, P&#xD;Sisul, J C&#xD;Sole, D&#xD;Soto-Martinez, M&#xD;Sova, M&#xD;Sperl, A&#xD;Spranger, O&#xD;Stelmach, R&#xD;Suppli Ulrik, C&#xD;Thomas, M&#xD;To, T&#xD;Todo-Bom, A&#xD;Tomazic, P V&#xD;Urrutia-Pereira, M&#xD;Valentin-Rostan, M&#xD;Van Ganse, E&#xD;van Hage, M&#xD;Vasankari, T&#xD;Vichyanond, P&#xD;Viegi, G&#xD;Wallace, D&#xD;Wang, D Y&#xD;Williams, S&#xD;Worm, M&#xD;Yiallouros, P&#xD;Yusuf, O&#xD;Zaitoun, F&#xD;Zernotti, M&#xD;Zidarn, M&#xD;Zuberbier, J&#xD;Fonseca, J A&#xD;Zuberbier, T&#xD;Anto, J M&#xD;eng&#xD;MR/S002359/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/S025340/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/K002449/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/K002449/2/MRC_/Medical Research Council/United Kingdom&#xD;MR/T031565/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/W028352/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1169-1203. doi: 10.1111/all.15679. Epub 2023 Apr 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36799120</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15679</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3289</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3289</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, Yang</style></author><author><style face="normal" font="default" size="100%">Li, Yanhua</style></author><author><style face="normal" font="default" size="100%">Zeyneloglu, Can</style></author><author><style face="normal" font="default" size="100%">Tian, Wenqu</style></author><author><style face="normal" font="default" size="100%">Babayev, Huseyn</style></author><author><style face="normal" font="default" size="100%">D&apos;Avino, Paolo</style></author><author><style face="normal" font="default" size="100%">He, Ying</style></author><author><style face="normal" font="default" size="100%">Ogulur, Ismail</style></author><author><style face="normal" font="default" size="100%">Bicer, Ceren</style></author><author><style face="normal" font="default" size="100%">Lu, Gan</style></author><author><style face="normal" font="default" size="100%">Li, Yachun</style></author><author><style face="normal" font="default" size="100%">Zhao, Bingjie</style></author><author><style face="normal" font="default" size="100%">Li, Shengjie</style></author><author><style face="normal" font="default" size="100%">Chang, Lihong</style></author><author><style face="normal" font="default" size="100%">Li, Manru</style></author><author><style face="normal" font="default" size="100%">Liu, Xiaoqing</style></author><author><style face="normal" font="default" size="100%">Huang, Xinyuan</style></author><author><style face="normal" font="default" size="100%">Cheng, Hang</style></author><author><style face="normal" font="default" size="100%">Göksel, Ozlem</style></author><author><style face="normal" font="default" size="100%">Göksel, Tuncay</style></author><author><style face="normal" font="default" size="100%">Agache, Ioana</style></author><author><style face="normal" font="default" size="100%">Khaitov, Musa</style></author><author><style face="normal" font="default" size="100%">Kudlay, Dimitry</style></author><author><style face="normal" font="default" size="100%">Nadeau, Kari</style></author><author><style face="normal" font="default" size="100%">Cheng, Lei</style></author><author><style face="normal" font="default" size="100%">Shamji, Mohamed</style></author><author><style face="normal" font="default" size="100%">Torres, Maria J.</style></author><author><style face="normal" font="default" size="100%">Zhang, Luo</style></author><author><style face="normal" font="default" size="100%">Akdis, Mübeccel</style></author><author><style face="normal" font="default" size="100%">Gao, Ya-dong</style></author><author><style face="normal" font="default" size="100%">Akdis, Cezmi A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Risk and Protective Factors for Infection, Severe Disease, and Mortality in Epidemic Respiratory Viruses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT The post-COVID pandemic era has witnessed a concerning resurgence of respiratory viruses, driving a global increase in acute respiratory infections. This trend may stem from relaxed non-pharmaceutical interventions, waning herd immunity, immunological imprinting limiting heterosubtypic protection, or viral antigenic evolution. This review aims to identify and characterize risk and protective factors associated with infection, hospitalization, severe illness, and mortality, while elucidating the drivers of the rising incidence of respiratory virus infections post-pandemic. Evidence on SARS-CoV-2 sublineages, influenza, respiratory syncytial virus, rhinovirus, adenovirus, human metapneumovirus, human parainfluenza virus, human coronaviruses, and cytomegalovirus has been collected and identified. Identified risk factors include demographic characteristics such as pediatrics and older age, male sex, race (Black, Hispanic, American Indian or Alaska native), preterm birth, and HLA-DQA1, IFNAR2, ST6GAL, and B3GALT5 genetic susceptibility. Behavioral, socioeconomic (low socioeconomic status, crowded living conditions), environmental influences (cold seasons, pollution), smoking, obesity and malnutrition could also exacerbate the risk of infection and adverse outcomes. Comorbidities, such as chronic conditions and immunocompromised states, significantly increase the risk of severe disease and hospitalization. Laboratory indices linked to severe disease outcomes include neutrophilia or neutropenia, lymphopenia, eosinopenia, and elevated C-reactive protein. Viral subtypes, viral load kinetics, vaccination status, and antiviral therapies further delineate risk profiles. Epithelial barrier impairment and underlying chronic airway diseases characterized by type 2 immunity also play a detrimental role in the development and severity of respiratory viral infections. Our findings highlight the need for stratified prevention strategies, which combine universal measures targeting shared determinants with virus-specific interventions addressing unique virological and transmission dynamics. It will provide a critical framework for optimizing precision public health strategies to counter repeated respiratory threats in the evolving post-COVID-19 pandemic landscape.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70314</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70314</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1271</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1271</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gao, Y. D.</style></author><author><style face="normal" font="default" size="100%">Ding, M.</style></author><author><style face="normal" font="default" size="100%">Dong, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, J. J.</style></author><author><style face="normal" font="default" size="100%">Kursat Azkur, A.</style></author><author><style face="normal" font="default" size="100%">Azkur, D.</style></author><author><style face="normal" font="default" size="100%">Gan, H.</style></author><author><style face="normal" font="default" size="100%">Sun, Y. L.</style></author><author><style face="normal" font="default" size="100%">Fu, W.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Liang, H. L.</style></author><author><style face="normal" font="default" size="100%">Cao, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Yan, Q.</style></author><author><style face="normal" font="default" size="100%">Cao, C.</style></author><author><style face="normal" font="default" size="100%">Gao, H. Y.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland.&#xD;Department of Virology, Faculty of Veterinary Medicine, University of Kirikkale, Kirikkale, Turkey.&#xD;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, University of Kirikkale, Kirikkale, Turkey.&#xD;Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, China.&#xD;Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Huazhong, China.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Hochgebirgsklinik Davos, Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk factors for severe and critically ill COVID-19 patients: A review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">428-455</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/11/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Critical Illness</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">severity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33185910</style></accession-num><abstract><style face="normal" font="default" size="100%">The pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused an unprecedented global social and economic impact, and high numbers of deaths. Many risk factors have been identified in the progression of COVID-19 into a severe and critical stage, including old age, male gender, underlying comorbidities such as hypertension, diabetes, obesity, chronic lung diseases, heart, liver and kidney diseases, tumors, clinically apparent immunodeficiencies, local immunodeficiencies, such as early type I interferon secretion capacity, and pregnancy. Possible complications include acute kidney injury, coagulation disorders, thoromboembolism. The development of lymphopenia and eosinopenia are laboratory indicators of COVID-19. Laboratory parameters to monitor disease progression include lactate dehydrogenase, procalcitonin, high-sensitivity C-reactive protein, proinflammatory cytokines such as interleukin (IL)-6, IL-1beta, Krebs von den Lungen-6 (KL-6), and ferritin. The development of a cytokine storm and extensive chest computed tomography imaging patterns are indicators of a severe disease. In addition, socioeconomic status, diet, lifestyle, geographical differences, ethnicity, exposed viral load, day of initiation of treatment, and quality of health care have been reported to influence individual outcomes. In this review, we highlight the scientific evidence on the risk factors of severity of COVID-19.</style></abstract><notes><style face="normal" font="default" size="100%">Gao, Ya-Dong&#xD;Ding, Mei&#xD;Dong, Xiang&#xD;Zhang, Jin-Jin&#xD;Kursat Azkur, Ahmet&#xD;Azkur, Dilek&#xD;Gan, Hui&#xD;Sun, Yuan-Li&#xD;Fu, Wei&#xD;Li, Wei&#xD;Liang, Hui-Ling&#xD;Cao, Yi-Yuan&#xD;Yan, Qi&#xD;Cao, Can&#xD;Gao, Hong-Yu&#xD;Bruggen, Marie-Charlotte&#xD;van de Veen, Willem&#xD;Sokolowska, Milena&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):428-455. doi: 10.1111/all.14657. Epub 2020 Dec 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33185910</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14657</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>523</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">523</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B.</style></author><author><style face="normal" font="default" size="100%">Baseggio Conrado, A.</style></author><author><style face="normal" font="default" size="100%">Deschildre, A.</style></author><author><style face="normal" font="default" size="100%">Gerdts, J.</style></author><author><style face="normal" font="default" size="100%">Halken, S.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Patel, N.</style></author><author><style face="normal" font="default" size="100%">Van Ree, R.</style></author><author><style face="normal" font="default" size="100%">de Silva, D.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Global Allergy, Asthma European Network Food Allergy Guideline Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Translational Research in Paediatric Specialities Area, Division of Allergy, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;Clinic for Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;CHU Lille, Univ. Lille, Pediatric Pulmonology and Allergy Department, Hopital Jeanne de Flandre, Lille, France.&#xD;Food Allergy Canada, Toronto, Ontario, Canada.&#xD;Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Odense, Denmark.&#xD;Food Allergy Centre, Padua General University Hospital, Padua, Italy.&#xD;Departments of Experimental Immunology and of Otorhinolaryngology, Amsterdam University Medical Centers, location AMC, Amsterdam, The Netherlands.&#xD;The Evidence Centre, London, UK.&#xD;Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charite, Universitatsmedizin Berlin, Berlin, Germany.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Isle of Wight, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk factors for severe reactions in food allergy: Rapid evidence review with meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2634-2652</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/04/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Food/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/complications/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">severity</style></keyword><keyword><style face="normal" font="default" size="100%">Allergenis, UK Food Standards Agency and ILSI Europe</style></keyword><keyword><style face="normal" font="default" size="100%">grants from National</style></keyword><keyword><style face="normal" font="default" size="100%">Institute for Health Research (NIHR)/Imperial Biomedical Research Centre, UK</style></keyword><keyword><style face="normal" font="default" size="100%">Medical Research Council, UK Food Standards Agency, End Allergies Together, Jon</style></keyword><keyword><style face="normal" font="default" size="100%">Moulton Charity Trust, outside the submitted work. Prof Halken reports</style></keyword><keyword><style face="normal" font="default" size="100%">speaker/chair fees from Nestle Purina and ABIGO Pharma A/S. Dr Muraro reports</style></keyword><keyword><style face="normal" font="default" size="100%">speaker fees from Aimmune Therapeutics, DBV, and Nestle Purina</style></keyword><keyword><style face="normal" font="default" size="100%">and is an</style></keyword><keyword><style face="normal" font="default" size="100%">advisory board member/fees from Regeneron IDMC. Dr Deschildre reports personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from ALK, Stallergenes-Greer, GSK, Novartis, Sanofi, Regeneron, Bohringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, Aimmune therapeutics, DBV technologies, Nestle Health Science,</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia, outside the submitted work. Dr Ballmer-Weber reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK, Allergopharma, ThermoFisher, Menarini, Sanofi, Novartis. Prof. van Ree</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees from HAL Allergy, ALK, Citeq, Angany, ThermoFisher, Reacta</style></keyword><keyword><style face="normal" font="default" size="100%">Healthcare, and Mission MightyMe</style></keyword><keyword><style face="normal" font="default" size="100%">grants from European Commission, Dutch Science</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, and Health Holland, outside the submitted work. Prof. Worm declares</style></keyword><keyword><style face="normal" font="default" size="100%">the receipt of honoraria or consultation fees by the following companies:</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello Arzneimittel GmbH, Mylan Germany GmbH, Leo Pharma GmbH, Sanofi-Aventis</style></keyword><keyword><style face="normal" font="default" size="100%">Deutschland GmbH, Regeneron Pharmaceuticals, DBV Technologies S.A, Stallergenes</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, HAL Allergie GmbH, Allergopharma GmbH &amp; Co.KG, Bencard Allergie GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis AG, Biotest AG., AbbVie Deutschland GmbH &amp; Co. KG and Lilly Deutschland</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, outside the submitted work. Prof Zuberbier reports personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Bayer, FAES, Novartis, Henkel, AstraZeneca, AbbVie, ALK, Almirall, Astellas,</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard, Berlin Chemie, HAL, Leti, Meda, Menarini, Merck, MSD, Pfizer, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes, Takeda, Teva, UCB, Henkel, Kryolan, L&apos;Oreal, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work. Prof Roberts reports grants from UK Food Standards Agency, DBV and the</style></keyword><keyword><style face="normal" font="default" size="100%">European Union. The other authors have no relevant conflicts of interest to</style></keyword><keyword><style face="normal" font="default" size="100%">declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35441718</style></accession-num><abstract><style face="normal" font="default" size="100%">This rapid review summarizes the most up to date evidence about the risk factors for severe food-induced allergic reactions. We searched three bibliographic databases for studies published between January 2010 and August 2021. We included 88 studies and synthesized the evidence narratively, undertaking meta-analysis where appropriate. Significant uncertainties remain with respect to the prediction of severe reactions, both anaphylaxis and/or severe anaphylaxis refractory to treatment. Prior anaphylaxis, an asthma diagnosis, IgE sensitization or basophil activation tests are not good predictors. Some molecular allergology markers may be helpful. Hospital presentations for anaphylaxis are highest in young children, yet this age group appears at lower risk of severe outcomes. Risk of severe outcomes is greatest in adolescence and young adulthood, but the contribution of risk taking behaviour in contributing to severe outcomes is unclear. Evidence for an impact of cofactors on severity is lacking, although food-dependent exercise-induced anaphylaxis may be an exception. Some medications such as beta-blockers or ACE inhibitors may increase severity, but appear less important than age as a factor in life-threatening reactions. The relationship between dose of exposure and severity is unclear. Delays in symptom recognition and anaphylaxis treatment have been associated with more severe outcomes. An absence of prior anaphylaxis does not exclude its future risk.</style></abstract><notes><style face="normal" font="default" size="100%">Turner, Paul J&#xD;Arasi, Stefania&#xD;Ballmer-Weber, Barbara&#xD;Baseggio Conrado, Alessia&#xD;Deschildre, Antoine&#xD;Gerdts, Jennifer&#xD;Halken, Susanne&#xD;Muraro, Antonella&#xD;Patel, Nandinee&#xD;Van Ree, Ronald&#xD;de Silva, Debra&#xD;Worm, Margitta&#xD;Zuberbier, Torsten&#xD;Roberts, Graham&#xD;(GA2LEN)&#xD;eng&#xD;DH_/Department of Health/United Kingdom&#xD;MR/K010468/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/W018616/1/MRC_/Medical Research Council/United Kingdom&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2634-2652. doi: 10.1111/all.15318. Epub 2022 Apr 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35441718</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9544052</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15318</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>680</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">680</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bizjak, M.</style></author><author><style face="normal" font="default" size="100%">Kosnik, M.</style></author><author><style face="normal" font="default" size="100%">Dinevski, D.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author><author><style face="normal" font="default" size="100%">Fomina, D.</style></author><author><style face="normal" font="default" size="100%">Borzova, E.</style></author><author><style face="normal" font="default" size="100%">Kulthanan, K.</style></author><author><style face="normal" font="default" size="100%">Meshkova, R.</style></author><author><style face="normal" font="default" size="100%">Ahsan, D. M.</style></author><author><style face="normal" font="default" size="100%">Al-Ahmad, M.</style></author><author><style face="normal" font="default" size="100%">Altrichter, S.</style></author><author><style face="normal" font="default" size="100%">Bauer, A.</style></author><author><style face="normal" font="default" size="100%">Brockstadt, M.</style></author><author><style face="normal" font="default" size="100%">Costa, C.</style></author><author><style face="normal" font="default" size="100%">Demir, S.</style></author><author><style face="normal" font="default" size="100%">Fachini Criado, R.</style></author><author><style face="normal" font="default" size="100%">Ensina, L. F.</style></author><author><style face="normal" font="default" size="100%">Gelincik, A.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A. M.</style></author><author><style face="normal" font="default" size="100%">Goncalo, M.</style></author><author><style face="normal" font="default" size="100%">Gotua, M.</style></author><author><style face="normal" font="default" size="100%">Holm, J. G.</style></author><author><style face="normal" font="default" size="100%">Inomata, N.</style></author><author><style face="normal" font="default" size="100%">Kasperska-Zajac, A.</style></author><author><style face="normal" font="default" size="100%">Khoshkhui, M.</style></author><author><style face="normal" font="default" size="100%">Klyucharova, A.</style></author><author><style face="normal" font="default" size="100%">Kocaturk, E.</style></author><author><style face="normal" font="default" size="100%">Lu, R.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Maltseva, N.</style></author><author><style face="normal" font="default" size="100%">Miljkovic, J.</style></author><author><style face="normal" font="default" size="100%">Pasali, M.</style></author><author><style face="normal" font="default" size="100%">Paulino, M.</style></author><author><style face="normal" font="default" size="100%">Pesque, D.</style></author><author><style face="normal" font="default" size="100%">Peter, J.</style></author><author><style face="normal" font="default" size="100%">Ramon, G. D.</style></author><author><style face="normal" font="default" size="100%">Ritchie, C.</style></author><author><style face="normal" font="default" size="100%">Rodrigues Valle, S. O.</style></author><author><style face="normal" font="default" size="100%">Rudenko, M.</style></author><author><style face="normal" font="default" size="100%">Sikora, A.</style></author><author><style face="normal" font="default" size="100%">de Souza Lima, E. M.</style></author><author><style face="normal" font="default" size="100%">Wagner, N.</style></author><author><style face="normal" font="default" size="100%">Xepapadaki, P.</style></author><author><style face="normal" font="default" size="100%">Xue, X.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z.</style></author><author><style face="normal" font="default" size="100%">Terhorst-Molawi, D.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy, Urticaria Center of Reference and Excellence (UCARE), University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.&#xD;Faculty of Medicine, University of Maribor, Maribor, Slovenia.&#xD;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Urticaria Center of Reference and Excellence (UCARE), Center of Allergy and Immunology, Clinical State Hospital 52, Moscow Ministry of Healthcare, Moscow, Russian Federation.&#xD;Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;Department of Clinical Genetics, Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University, Moscow, Russian Federation.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Clinical Immunology and Allergology, Urticaria Center of Reference and Excellence (UCARE), Smolensk State Medical University, Smolensk, Russian Federation.&#xD;Urticaria Center of Reference and Excellence (UCARE), Institute for Allergology, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;Microbiology Department, Faculty of Medicine, Urticaria Center of Reference and Excellence (UCARE), Kuwait University, Safat, Kuwait.&#xD;Department of Dermatology and Venerology, Urticaria Center of Reference and Excellence (UCARE), Comprehensive Allergy Center, Kepler University Hospital, Linz, Austria.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), University Allergy Center, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.&#xD;Immunoallergology Department, Urticaria Center of Reference and Excellence (UCARE), Hospital de Santa Maria, CHULN, Lisbon, Portugal.&#xD;Division of Allergy, Department of Internal Medicine, Istanbul Faculty of Medicine, Urticaria Center of Reference and Excellence (UCARE), Istanbul University, Istanbul, Turkey.&#xD;Faculdade de Medicina do ABC (FMABC), Urticaria Center of Reference and Excellence (UCARE), Santo Andre, Brazil.&#xD;Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Urticaria Center of Reference and Excellence (UCARE), Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), Hospital del Mar, IMIM, Universitat Autonoma, Barcelona, Spain.&#xD;Clinic of Dermatology, Urticaria Center of Reference and Excellence (UCARE), University Hospital and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.&#xD;Center of Allergy and Immunology, Urticaria Center of Reference and Excellence (UCARE), Tbilsi, Georgia.&#xD;Department of Environmental Immuno-Dermatology, Urticaria Center of Reference and Excellence (UCARE), Yokohama City University Graduate School of Medicine, Yokohama, Japan.&#xD;Clinical Department of Internal Diseases, European Center for Diagnosis and Treatment of Urticaria, Urticaria Center of Reference and Excellence (UCARE), Dermatology and Allergology of Medical University of Silesia, Zabrze, Poland.&#xD;Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.&#xD;Department of Clinical Immunology and Allergology, Republican Center of Clinical Immunology and Allergology, Urticaria Center of Reference and Excellence (UCARE), Republican Clinical Hospital, Kazan State Medical University, Kazan, Russian Federation.&#xD;Department of Fundamental Principles of Clinical Medicine, Institute of Fundamental Medicine and Biology (IFMB) of Kazan Federal University, Kazan, Russian Federation.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), Koc University School of Medicine, Istanbul, Turkey.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.&#xD;Allergy Unit, Second Department of Dermatology and Venereology, Urticaria Center of Reference and Excellence (UCARE), National and Kapodistrian University of Athens, University General Hospital &quot;Attikon&quot;, Athens, Greece.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, Urticaria Center of Reference and Excellence (UCARE), University of Cape Town, Cape Town, South Africa.&#xD;Allergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa.&#xD;Urticaria Center of Reference and Excellence (UCARE), Instituto de Alergia e Inmunologia del Sur, Buenos Aires, Argentina.&#xD;Adults and Pediatrics Allergy Unit, Urticaria Center of Reference and Excellence (UCARE), Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.&#xD;Department of Internal Medicine, Immunology Service, Urticaria Center of Reference and Excellence (UCARE), Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.&#xD;Urticaria Center of Reference and Excellence (UCARE), London Allergy and Immunology Centre, London, UK.&#xD;Faculdade de Ciencias, Medicas e da Saude de Juiz de Fora (SUPREMA), Urticaria Center of Reference and Excellence (UCARE), Hospital Maternidade Therezinha de Jesus, Minas Gerais, Brazil.&#xD;Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), University Hospital of Erlangen, University of Erlangen-Nuremberg (FAU), Germany.&#xD;Allergy Unit, 2nd Pediatric Clinic, Urticaria Center of Reference and Excellence (UCARE), National and Kapodistrian University of Athens, Greece.&#xD;Department of General Practice, Urticaria Center of Reference and Excellence (UCARE), Community Health Service Center, Guangzhou City, China.&#xD;Department of Dermatology and Venerology, Urticaria Center of Reference and Excellence (UCARE), Beijing Key Laboratory of Molecular Diagnosis on Dermatoses and National Clinical Research Center for Skin and Immune Diseases, Peking University First Hospital, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk factors for systemic reactions in typical cold urticaria: Results from the COLD-CE study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2185-2199</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/12/05</style></edition><section><style face="normal" font="default" size="100%">2185</style></section><keywords><keyword><style face="normal" font="default" size="100%">*Angioedema/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Cold Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hymenoptera</style></keyword><keyword><style face="normal" font="default" size="100%">*Insect Bites and Stings/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cold-ce</style></keyword><keyword><style face="normal" font="default" size="100%">adrenaline autoinjector</style></keyword><keyword><style face="normal" font="default" size="100%">cold urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">systemic reactions</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34862605</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cold urticaria (ColdU), that is, the occurrence of wheals or angioedema in response to cold exposure, is classified into typical and atypical forms. The diagnosis of typical ColdU relies on whealing in response to local cold stimulation testing (CST). It can also manifest with cold-induced anaphylaxis (ColdA). We aimed to determine risk factors for ColdA in typical ColdU. METHODS: An international, cross-sectional study COLD-CE was carried out at 32 urticaria centers of reference and excellence (UCAREs). Detailed history was taken and CST with an ice cube and/or TempTest((R)) performed. ColdA was defined as an acute cold-induced involvement of the skin and/or visible mucosal tissue and at least one of: cardiovascular manifestations, difficulty breathing, or gastrointestinal symptoms. RESULTS: Of 551 ColdU patients, 75% (n = 412) had a positive CST and ColdA occurred in 37% (n = 151) of the latter. Cold-induced generalized wheals, angioedema, acral swelling, oropharyngeal/laryngeal symptoms, and itch of earlobes were identified as signs/symptoms of severe disease. ColdA was most commonly provoked by complete cold water immersion and ColdA caused by cold air was more common in countries with a warmer climate. Ten percent (n = 40) of typical ColdU patients had a concomitant chronic spontaneous urticaria (CSU). They had a lower frequency of ColdA than those without CSU (4% vs. 39%, p = .003). We identified the following risk factors for cardiovascular manifestations: previous systemic reaction to a Hymenoptera sting, angioedema, oropharyngeal/laryngeal symptoms, and itchy earlobes. CONCLUSION: ColdA is common in typical ColdU. High-risk patients require education about their condition and how to use an adrenaline autoinjector.</style></abstract><notes><style face="normal" font="default" size="100%">Bizjak, Mojca&#xD;Kosnik, Mitja&#xD;Dinevski, Dejan&#xD;Thomsen, Simon Francis&#xD;Fomina, Daria&#xD;Borzova, Elena&#xD;Kulthanan, Kanokvalai&#xD;Meshkova, Raisa&#xD;Ahsan, Dalia Melina&#xD;Al-Ahmad, Mona&#xD;Altrichter, Sabine&#xD;Bauer, Andrea&#xD;Brockstadt, Maxi&#xD;Costa, Celia&#xD;Demir, Semra&#xD;Fachini Criado, Roberta&#xD;Ensina, Luis Felipe&#xD;Gelincik, Asli&#xD;Gimenez-Arnau, Ana Maria&#xD;Goncalo, Margarida&#xD;Gotua, Maia&#xD;Holm, Jesper Gronlund&#xD;Inomata, Naoko&#xD;Kasperska-Zajac, Alicja&#xD;Khoshkhui, Maryam&#xD;Klyucharova, Aliya&#xD;Kocaturk, Emek&#xD;Lu, Rongbiao&#xD;Makris, Michael&#xD;Maltseva, Natalya&#xD;Miljkovic, Jovan&#xD;Pasali, Maria&#xD;Paulino, Marisa&#xD;Pesque, David&#xD;Peter, Jonny&#xD;Ramon, German Dario&#xD;Ritchie, Carla&#xD;Rodrigues Valle, Solange Oliveira&#xD;Rudenko, Michael&#xD;Sikora, Agnieszka&#xD;de Souza Lima, Eduardo M&#xD;Wagner, Nicola&#xD;Xepapadaki, Paraskevi&#xD;Xue, Xiaoyang&#xD;Zhao, Zuotao&#xD;Terhorst-Molawi, Dorothea&#xD;Maurer, Marcus&#xD;eng&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2185-2199. doi: 10.1111/all.15194. Epub 2021 Dec 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34862605</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15194</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2344</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2344</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yoon, D.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Jeong, H. E.</style></author><author><style face="normal" font="default" size="100%">Ko, H. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, S. R.</style></author><author><style face="normal" font="default" size="100%">Shin, J. Y.</style></author><author><style face="normal" font="default" size="100%">CoVa, S. C. Investigators</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.&#xD;Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea.&#xD;Division of Pulmonology, Allergy and Critical Care Medicine, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, South Korea.&#xD;Department of Clinical Research Design &amp; Evaluation, Samsung Advanced Institute for Health Sciences &amp; Technology, Sungkyunkwan University, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk of anaphylaxis after COVID-19 vaccination in South Korea: A nationwide self-controlled case series analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">754-757</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/12/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/chemically induced/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Republic of Korea/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38084802</style></accession-num><notes><style face="normal" font="default" size="100%">Yoon, Dongwon&#xD;Kim, Ju Hwan&#xD;Jeong, Han Eol&#xD;Ko, Hwa Yeon&#xD;Kim, Sung-Ryeol&#xD;Shin, Ju-Young&#xD;eng&#xD;Korea Disease Control and Prevention Agency/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):754-757. doi: 10.1111/all.15975. Epub 2023 Dec 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38084802</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15975</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1992</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1992</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soria, A.</style></author><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Nicaise-Roland, P.</style></author><author><style face="normal" font="default" size="100%">Chollet-Martin, S.</style></author><author><style face="normal" font="default" size="100%">Autegarden, J. E.</style></author><author><style face="normal" font="default" size="100%">Castagna, J.</style></author><author><style face="normal" font="default" size="100%">Le Thai, C.</style></author><author><style face="normal" font="default" size="100%">de Chaisemartin, L.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Barbaud, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Service de dermatologie et allergologie, Hopital Tenon, Assistance Publique-Hopitaux de Paris (AP-HP), Medecine Sorbonne Universite, Paris, France.&#xD;Cimi-Paris, INSERM 1135, Paris, France.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Service d&apos;Immunologie &lt;&lt; Autoimmunite, Hypersensibilites et Biotherapies &gt;&gt;, Hopital Bichat, DMU BIOGeM, APHP, Paris, France.&#xD;Inserm, PHERE, Universite Paris Cite, Paris, France.&#xD;Inflammation Microbiome Immunosurveillance, Inserm, Universite Paris-Saclay, Orsay, France.&#xD;Departamento de Medicina, Universidad de Malaga, Malaga, Spain.&#xD;INSERM, Institut Pierre Louis d&apos;Epidemiologie et de Sante Publique, AP-HP Sorbonne Universite, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk stratification through extensive allergy work-up in COVID-19-mRNA vaccine allergic reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2320-2323</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/03/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19-mRNA vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36971457</style></accession-num><notes><style face="normal" font="default" size="100%">Soria, Angele&#xD;Labella, Marina&#xD;Dona, Inmaculada&#xD;Nicaise-Roland, Pascale&#xD;Chollet-Martin, Sylvie&#xD;Autegarden, Jean-Eric&#xD;Castagna, Julie&#xD;Le Thai, Claire&#xD;de Chaisemartin, Luc&#xD;Torres, Maria Jose&#xD;Barbaud, Annick&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2320-2323. doi: 10.1111/all.15715. Epub 2023 Mar 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36971457</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15715</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>279</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">279</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McKenzie, C. I.</style></author><author><style face="normal" font="default" size="100%">Varese, N.</style></author><author><style face="normal" font="default" size="100%">Aui, P. M.</style></author><author><style face="normal" font="default" size="100%">Reinwald, S.</style></author><author><style face="normal" font="default" size="100%">Wines, B. D.</style></author><author><style face="normal" font="default" size="100%">Hogarth, P. M.</style></author><author><style face="normal" font="default" size="100%">Thien, F.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author><author><style face="normal" font="default" size="100%">Rolland, J. M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">van Zelm, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.&#xD;Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University, Melbourne, Victoria, Australia.&#xD;Immune Therapies Group, Burnet Institute, Melbourne, Victoria, Australia.&#xD;Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Respiratory Medicine, Eastern Health, Box Hill and Monash University, Melbourne, Victoria, Australia.&#xD;School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.&#xD;Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">RNA sequencing of single allergen-specific memory B cells after grass pollen immunotherapy: Two unique cell fates and CD29 as a biomarker for treatment effect</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">822-835</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/09/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Memory B Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Lolium</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Sequence Analysis, RNA</style></keyword><keyword><style face="normal" font="default" size="100%">Poaceae</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">grass pollen allergy</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword><keyword><style face="normal" font="default" size="100%">All the other authors declare that they have no relevant conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36153670</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Sublingual immunotherapy (SLIT) for grass pollen allergy can modify the natural history of allergic rhinitis and is associated with increased allergen-specific IgG(4) . IgG(4) competitively inhibits functional IgE on the surface of effector cells, such as mast cells and basophils, from binding to allergens. To further understand the important role memory B-cell (Bmem) responses play in mediating the beneficial effects of SLIT, we assessed changes in allergen-specific Bmem subsets induced by SLIT for grass pollen allergy. METHODS: Blood samples were collected twice outside the pollen season from twenty-seven patients with sensitization to ryegrass pollen (RGP; Lolium perenne) and seasonal rhinoconjunctivitis. Thirteen received 4-month pre-seasonal SLIT for grass pollen allergy, and 14 received standard pharmacotherapy only. Single-cell RNA sequencing was performed on FACS-purified Lol p 1-specific Bmem before and after SLIT from four patients, and significant genes were validated by flow cytometry on the total cohort. RESULTS: Four months of SLIT increased RGP-specific IgE and IgG(4) in serum and induced two Lol p 1-specific Bmem subsets with unique transcriptional profiles. Both subsets had upregulated expression of beta 1 integrin ITGB1 (CD29), whereas IGHE (IgE), IGHG4 (IgG(4) ), FCER2 (CD23), and IL13RA1 were upregulated in one subset. There was an increase in the proportion of Lol p 1(+) Bmem expressing surface IgG(4) , CD23, and CD29 after SLIT. CONCLUSIONS: A clinically successful 4 months course of SLIT for grass pollen allergy induces two transcriptionally unique Bmem fates. Associated changes in surface-expressed proteins on these Bmem subsets can be used as early biomarkers for treatment effects.</style></abstract><notes><style face="normal" font="default" size="100%">McKenzie, Craig I&#xD;Varese, Nirupama&#xD;Aui, Pei Mun&#xD;Reinwald, Simone&#xD;Wines, Bruce D&#xD;Hogarth, P Mark&#xD;Thien, Francis&#xD;Hew, Mark&#xD;Rolland, Jennifer M&#xD;O&apos;Hehir, Robyn E&#xD;van Zelm, Menno C&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):822-835. doi: 10.1111/all.15529. Epub 2022 Oct 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36153670</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10952829</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15529</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1023</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1023</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vidal-Quist, J. C.</style></author><author><style face="normal" font="default" size="100%">Vidal, C.</style></author><author><style face="normal" font="default" size="100%">Escolar, F.</style></author><author><style face="normal" font="default" size="100%">Lambrecht, B. N.</style></author><author><style face="normal" font="default" size="100%">Rombauts, S.</style></author><author><style face="normal" font="default" size="100%">Hernandez-Crespo, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratorio de Interaccion Planta-Insecto, Departamento de Biotecnologia Microbiana y de Plantas, Centro de Investigaciones Biologicas Margarita Salas - CSIC, Madrid, Spain.&#xD;Servicio de Alergologia, Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain.&#xD;Servicio de Microscopia Electronica, Centro de Investigaciones Biologicas Margarita Salas - CSIC, Madrid, Spain.&#xD;Laboratory of Immunoregulation and Mucosal Immunology, VIB Center for Inflammation Research, Ghent, Belgium.&#xD;Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.&#xD;Center for Plant Systems Biology, VIB, Ghent, Belgium.&#xD;Department of Plant Biotechnology and Bioinformatics, Ghent University, Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">RNA viruses in the house dust mite Dermatophagoides pteronyssinus, detection in environmental samples and in commercial allergen extracts used for in vivo diagnosis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3743-3754</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/04/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus/immunology/*virology</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*RNA Viruses/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Entomopathogens</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">skin-prick test</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">viral infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33914957</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergy to house dust mites (HDM), the most important source of indoor allergens worldwide, is diagnosed and treated using natural extracts from cultures that can contain immunoactive components from the HDM microbiome, including mite-infecting viruses. This study aimed to contribute to the discovery and characterization of RNA viruses from Dermatophagoides pteronyssinus, followed by their detection in different mite-derived sources. METHODS: Viruses were assembled after in silico metatranscriptomic analysis of D. pteronyssinus RNA samples, visualized by electron microscopy, and RNA detected by direct RT-PCR or data mining. Mite culture performance was evaluated in vivo. RESULTS: Seven RNA viruses were identified in our laboratory stock colony. Picornavirus-like viral particles were detected in epithelial cells of the digestive system and in fecal pellets. Most of these viruses could be persistently transmitted to an inbred virus-free colony by inoculating fecal material from the stock colony. Upon viral infection, no significant effect could be seen on mite population growth. Transcriptomic screening confirmed the presence of homolog sequences to these viruses in independent laboratory stocks of D. pteronyssinus and in other Astigmata mites. Noteworthy, RNA from most of the viruses could be detected by RT-PCR on house dust samples, reference standards, and/or commercial diagnostic D. pteronyssinus extracts. CONCLUSIONS: Our results show that viral infections are common and widespread in D. pteronyssinus, both in natural and culture-based growth conditions. Potential effects on the mites themselves and consequences toward allergenicity in humans whether exposed naturally or after immunotherapy are discussed.</style></abstract><notes><style face="normal" font="default" size="100%">Vidal-Quist, Jose Cristian&#xD;Vidal, Carmen&#xD;Escolar, Fernando&#xD;Lambrecht, Bart N&#xD;Rombauts, Stephane&#xD;Hernandez-Crespo, Pedro&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3743-3754. doi: 10.1111/all.14884. Epub 2021 May 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33914957</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14884</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1407</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1407</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bahmer, T.</style></author><author><style face="normal" font="default" size="100%">Krauss-Etschmann, S.</style></author><author><style face="normal" font="default" size="100%">Buschmann, D.</style></author><author><style face="normal" font="default" size="100%">Behrends, J.</style></author><author><style face="normal" font="default" size="100%">Watz, H.</style></author><author><style face="normal" font="default" size="100%">Kirsten, A. M.</style></author><author><style face="normal" font="default" size="100%">Pedersen, F.</style></author><author><style face="normal" font="default" size="100%">Waschki, B.</style></author><author><style face="normal" font="default" size="100%">Fuchs, O.</style></author><author><style face="normal" font="default" size="100%">Pfaffl, M. W.</style></author><author><style face="normal" font="default" size="100%">von Mutius, E.</style></author><author><style face="normal" font="default" size="100%">Rabe, K. F.</style></author><author><style face="normal" font="default" size="100%">Hansen, G.</style></author><author><style face="normal" font="default" size="100%">Kopp, M. V.</style></author><author><style face="normal" font="default" size="100%">Konig, I. R.</style></author><author><style face="normal" font="default" size="100%">Bartel, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pneumology, LungenClinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Airway Research Center North (ARCN), Grosshansdorf, Germany.&#xD;University Hospital Schleswig-Holstein, Campus Kiel, Member of the German Center for Lung Research (DZL), Airway Research Center North (ARCN), Kiel, Germany.&#xD;Leibniz Lung Center, Research Center Borstel, Member of the German Center for Lung Research (DZL),Airway Research Center North (ARCN), Borstel, Germany.&#xD;Division of Animal Physiology and Immunology, School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany.&#xD;Flow Cytometry Core Unit, Leibniz Lung Center Borstel, Member of the German Center for Lung Research (DZL), Airway Research Center North (ARCN), Borstel, Germany.&#xD;Pulmonary Research Institute, LungenClinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Airway Research Center North (ARCN), Grosshansdorf, Germany.&#xD;Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany.&#xD;Inselspital Bern, University Children&apos;s Hospital, Bern, Switzerland.&#xD;Department of Pediatric Pulmonology and Allergology, Children&apos;s Hospital at the University of Luebeck, Member of the German Center for Lung Research (DZL), Airway Research Center North (ARCN), Luebeck, Germany.&#xD;Dr. von Hauner Children&apos;s Hospital, Helmholtz Center Munich, Comprehensive Pneumology Center - Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.&#xD;Department of Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Member of the German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), Hannover, Germany.&#xD;Institute of Medical Biometry and Statistics, University of Luebeck, Member of the German Center for Lung Research (DZL), Airway Research Center North (ARCN), Luebeck, Germany.&#xD;Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">RNA-seq-based profiling of extracellular vesicles in plasma reveals a potential role of miR-122-5p in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">366-371</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Extracellular Vesicles</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">RNA-Seq</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">microRNA</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard Allergie GmbH to SB, which did not influence the content of the</style></keyword><keyword><style face="normal" font="default" size="100%">manuscript or the conclusions drawn. The authors declare no further conflict of</style></keyword><keyword><style face="normal" font="default" size="100%">interest relating to this manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32627209</style></accession-num><notes><style face="normal" font="default" size="100%">Bahmer, Thomas&#xD;Krauss-Etschmann, Susanne&#xD;Buschmann, Dominik&#xD;Behrends, Jochen&#xD;Watz, Henrik&#xD;Kirsten, Anne-Marie&#xD;Pedersen, Frauke&#xD;Waschki, Benjamin&#xD;Fuchs, Oliver&#xD;Pfaffl, Michael W&#xD;von Mutius, Erika&#xD;Rabe, Klaus F&#xD;Hansen, Gesine&#xD;Kopp, Matthias V&#xD;Konig, Inke R&#xD;Bartel, Sabine&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):366-371. doi: 10.1111/all.14486. Epub 2020 Jul 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32627209</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7818394</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14486</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2440</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2440</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fritz, B.</style></author><author><style face="normal" font="default" size="100%">Halling, A. S.</style></author><author><style face="normal" font="default" size="100%">Cort, I. D.</style></author><author><style face="normal" font="default" size="100%">Christensen, M. O.</style></author><author><style face="normal" font="default" size="100%">Ronnstad, A. T. M.</style></author><author><style face="normal" font="default" size="100%">Olesen, C. M.</style></author><author><style face="normal" font="default" size="100%">Knudgaard, M. H.</style></author><author><style face="normal" font="default" size="100%">Zachariae, C.</style></author><author><style face="normal" font="default" size="100%">Heegaard, S.</style></author><author><style face="normal" font="default" size="100%">Thyssen, J. P.</style></author><author><style face="normal" font="default" size="100%">Bjarnsholt, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Microbiology, University of Copenhagen, Copenhagen N, Denmark.&#xD;Department of Dermatology, Bispebjerg Hospital, Copenhagen NV, Denmark.&#xD;Department of Allergy, Skin, and Venereology, Gentofte Hospital, Gentofte, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen N, Denmark.&#xD;Department of Clinical Microbiology, Rigshospitalet, Copenhagen N, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">RNA-sequencing of paired tape-strips and skin biopsies in atopic dermatitis reveals key differences</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1548-1559</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/03/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/pathology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Sequence Analysis, RNA</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Surgical Tape</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">RNA sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biopsies</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">tape-strips</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38477552</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Skin tape-strips and biopsies are widely used methods for investigating the skin in atopic dermatitis (AD). Biopsies are more commonly used but can cause scarring and pain, whereas tape-strips are noninvasive but sample less tissue. The study evaluated the performance of skin tape-strips and biopsies for studying AD. METHODS: Whole-transcriptome RNA-sequencing was performed on paired tape-strips and biopsies collected from lesional and non-lesional skin from AD patients (n = 7) and non-AD controls (n = 5). RNA yield, mapping efficiency, and differentially expressed genes (DEGs) for the two methods (tape-strip/biopsy) and presence of AD (AD/non-AD) were compared. RESULTS: Tape-strips demonstrated a lower RNA yield (22 vs. 4596 ng) and mapping efficiency to known genes (28% vs. 93%) than biopsies. Gene-expression profiles of paired tape-strips and biopsies demonstrated a medium correlation (R(2) = 0.431). Tape-strips and biopsies demonstrated systematic differences in measured expression levels of 6483 genes across both AD and non-AD samples. Tape-strips preferentially detected many itch (CCL3/CCL4/OSM) and immune-response (CXCL8/IL4/IL5/IL22) genes as well as markers of epidermal dendritic cells (CD1a/CD207), while certain cytokines (IL18/IL37), skin-barrier genes (KRT2/FLG2), and dermal fibroblasts markers (COL1A/COL3A) were preferentially detected by biopsies. Tape-strips identified more DEGs between AD and non-AD (3157 DEGs) then biopsies (44 DEGs). Tape-strips also detected higher levels of bacterial mRNA than biopsies. CONCLUSIONS: This study concludes that tape-strips and biopsies each demonstrate respective advantages for measuring gene-expression changes in AD. Thus, the specific skin layers and genes of interest should be considered before selecting either method.</style></abstract><notes><style face="normal" font="default" size="100%">Fritz, Blaine&#xD;Halling, Anne-Sofie&#xD;Cort, Isabel Diaz-Pines&#xD;Christensen, Maria Oberlander&#xD;Ronnstad, Amalie Thorsti Moller&#xD;Olesen, Caroline Meyer&#xD;Knudgaard, Mette Hjorslev&#xD;Zachariae, Claus&#xD;Heegaard, Steffen&#xD;Thyssen, Jacob P&#xD;Bjarnsholt, Thomas&#xD;eng&#xD;Kongelig Hofbuntmager Aage Bangs Fond/&#xD;Novo Nordisk Fonden/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1548-1559. doi: 10.1111/all.16086. Epub 2024 Mar 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38477552</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16086</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1305</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1305</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gerth van Wijk, R.</style></author><author><style face="normal" font="default" size="100%">Mulleneisen, N.</style></author><author><style face="normal" font="default" size="100%">Demoly, P.</style></author><author><style face="normal" font="default" size="100%">Olaguibel, J. M.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Tsilochristou, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Section of Allergology and Clinical Immunology, Erasmus MC, Rotterdam, The Netherlands.&#xD;Asthma-Allergiezentrum Leverkusen, Leverkusen, Germany.&#xD;Division of Allergy, Department of Pulmonology, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France.&#xD;Severe Asthma Unit Complejo Hospitalario de Navarra, Pamplona, Spain.&#xD;University Hospital Sv. Ivan Rilski, Sofia, Bulgaria.&#xD;Department of Dermatology, Allergy Unit, University Hospital of Zurich, Zurich, Switzerland.&#xD;Peter Gorer Department of Immunobiology, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The roadmap for allergology in Europe: The European training requirements for the specialty of allergology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1588-1591</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33032359</style></accession-num><notes><style face="normal" font="default" size="100%">Gerth van Wijk, Roy&#xD;Mulleneisen, Norbert&#xD;Demoly, Pascal&#xD;Olaguibel, Jose Maria&#xD;Popov, Todor A&#xD;Schmid-Grendelmeier, Peter&#xD;Tsilochristou, Olympia&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1588-1591. doi: 10.1111/all.14614. Epub 2020 Oct 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33032359</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8247307 AstraZeneca, grants from Bausch &amp; Lomb, grants from Thermo Fisher Scientific, personal fees from Sanofi-Regeneron. JMO reports personal fees from ASTRA ZENECA, personal fees from MUNDI-PHARMA, personal fees from ALK. PSG reports personal fees from Allergopharma, personal fees from ALK, personal fees from AbbVie, grants from Christine Kuhne Center for Allergy Research and Education CK-CARE, personal fees from EliLilly, personal fees from GSK, from LEO, personal fees from Novartis, personal fees from Galderma, personal fees from Biomed, personal fees from Stallergenes, personal fees from Thermo Fisher, personal fees from Sanofi, outside the submitted work; and Peter Schmid-Grendelmeier is outside of EAACI also member of the following societies: International society for atopic dermatitis ISAD (Board member)World Allergy Organization WAO Swiss Society for Allergy and Immunology SSAI (Board member) Swiss Society for Dermatology and Venerology SSDV European Academy for Dermatology and Venerology EADV European Dermatology Forum EDF. The other authors do not declare any conflict of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14614</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1561</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1561</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gerth van Wijk, R.</style></author><author><style face="normal" font="default" size="100%">Mulleneisen, N.</style></author><author><style face="normal" font="default" size="100%">Demoly, P.</style></author><author><style face="normal" font="default" size="100%">Olaguibel, J. M.</style></author><author><style face="normal" font="default" size="100%">Popov, T. A.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Tsilochristou, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Section of Allergology and Clinical Immunology, Erasmus MC, Rotterdam, The Netherlands.&#xD;Asthma-Allergiezentrum Leverkusen, Leverkusen, Germany.&#xD;Division of Allergy, Department of Pulmonology, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France.&#xD;Severe Asthma Unit Complejo Hospitalario de Navarra, Pamplona, Spain.&#xD;University Hospital Sv. Ivan Rilski, Sofia, Bulgaria.&#xD;Department of Dermatology, Allergy Unit, University Hospital of Zurich, Zurich, Switzerland.&#xD;Peter Gorer Department of Immunobiology, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The roadmap for allergology in Europe: The European training requirements for the specialty of allergology</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1588-1591</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33032359</style></accession-num><notes><style face="normal" font="default" size="100%">Gerth van Wijk, Roy&#xD;Mulleneisen, Norbert&#xD;Demoly, Pascal&#xD;Olaguibel, Jose Maria&#xD;Popov, Todor A&#xD;Schmid-Grendelmeier, Peter&#xD;Tsilochristou, Olympia&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1588-1591. doi: 10.1111/all.14614. Epub 2020 Oct 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33032359</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8247307 AstraZeneca, grants from Bausch &amp; Lomb, grants from Thermo Fisher Scientific, personal fees from Sanofi-Regeneron. JMO reports personal fees from ASTRA ZENECA, personal fees from MUNDI-PHARMA, personal fees from ALK. PSG reports personal fees from Allergopharma, personal fees from ALK, personal fees from AbbVie, grants from Christine Kuhne Center for Allergy Research and Education CK-CARE, personal fees from EliLilly, personal fees from GSK, from LEO, personal fees from Novartis, personal fees from Galderma, personal fees from Biomed, personal fees from Stallergenes, personal fees from Thermo Fisher, personal fees from Sanofi, outside the submitted work; and Peter Schmid-Grendelmeier is outside of EAACI also member of the following societies: International society for atopic dermatitis ISAD (Board member)World Allergy Organization WAO Swiss Society for Allergy and Immunology SSAI (Board member) Swiss Society for Dermatology and Venerology SSDV European Academy for Dermatology and Venerology EADV European Dermatology Forum EDF. The other authors do not declare any conflict of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14614</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2959</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2959</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dong, C.</style></author><author><style face="normal" font="default" size="100%">Lu, S.</style></author><author><style face="normal" font="default" size="100%">Deng, Z.</style></author><author><style face="normal" font="default" size="100%">Cai, X.</style></author><author><style face="normal" font="default" size="100%">Shen, H.</style></author><author><style face="normal" font="default" size="100%">Shi, G.</style></author><author><style face="normal" font="default" size="100%">Ou, C.</style></author><author><style face="normal" font="default" size="100%">Peng, Z.</style></author><author><style face="normal" font="default" size="100%">Jiang, W.</style></author><author><style face="normal" font="default" size="100%">Fu, X.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Jin, M.</style></author><author><style face="normal" font="default" size="100%">Qiu, Z.</style></author><author><style face="normal" font="default" size="100%">Wei, X.</style></author><author><style face="normal" font="default" size="100%">Gu, W.</style></author><author><style face="normal" font="default" size="100%">Huang, K.</style></author><author><style face="normal" font="default" size="100%">Li, Q.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Zhong, N.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Zhang, Q.</style></author><author><style face="normal" font="default" size="100%">C. Biopred Consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.&#xD;Sino-French Hoffmann Institute, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.&#xD;Department of Respiratory Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.&#xD;Department of Respiratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.&#xD;Alpha X(Beijing) Biotech CO., Beijing, China.&#xD;AstraZeneca, Shanghai Shi, China.&#xD;Department of Respiratory Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Huhhot, China.&#xD;Department of Respiratory Medicine, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.&#xD;Department of Respiratory Medicine, Zhongshan Hospital, Shanghai, China.&#xD;Department of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.&#xD;Department of Respiratory Medicine, The Eighth Medical Center of PLA General Hospital, Beijing, China.&#xD;Department of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.&#xD;Department of Respiratory Medicine, Beijing Chao-Yang Hospital, Beijing, China.&#xD;Department of Respiratory Medicine, Shanghai General Hospital, Shanghai, China.&#xD;Department of Respiratory Medicine, Guizhou Province People&apos;s Hospital, Guiyang, China.&#xD;National Heart and Lung Institute, Imperial College London, &amp; Royal Brompton &amp; Harefield Hospital, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role for Complement C5 in Eosinophilic Inflammation of Severe Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/06/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">C5aR1</style></keyword><keyword><style face="normal" font="default" size="100%">C5aR2</style></keyword><keyword><style face="normal" font="default" size="100%">complement C5</style></keyword><keyword><style face="normal" font="default" size="100%">complement C5 receptors</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">weighted correlation network analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 16</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40524528</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: We investigated the role of the complement system, particularly complement C5, in severe asthma defined from an analysis of sputum proteomics. Although there has been evidence of complement activation in asthma, its role in severe asthma remains unclear. METHOD: Sputum protein expression profiles were analyzed from healthy controls and severe asthma patients using data-dependent acquisition mass spectrometry. Weighted correlation network analysis (WGCNA) was used to define the unique modules that were highly correlated with clinical, physiologic, and inflammatory traits. Differential analysis was performed for the complement C5 pathway protein levels and eosinophilic protein expression as influenced by C5. Asthmatic mouse models were used to verify the effect of complement C5 administration and inhibition. RESULTS: The WGCNA &quot;brown&quot; module related to the complement system activation was positively correlated with eosinophilic inflammation. Specifically, C5 and downstream complement proteins were up-regulated in patients with high sputum eosinophil levels (&gt;/= 3%) compared to low sputum eosinophils (&lt; 3%). Patients with reduced C5 expression had less eosinophilic inflammation and better lung function. Using single-cell RNA sequencing and immunofluorescence staining led to identification of macrophages as the main source of C5. In vivo experiments confirmed that inhibiting C5 reduced inflammation in allergic mouse models, while direct stimulation with recombinant C5 in IL-5 transgenic mice increased eosinophilic inflammation. CONCLUSION: We demonstrate a direct role for complement C5 in exacerbating eosinophilic inflammation in severe asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Dong, Cong&#xD;Lu, Shaohua&#xD;Deng, Zhenan&#xD;Cai, Xuliang&#xD;Shen, Huahao&#xD;Shi, Guochao&#xD;Ou, Changxing&#xD;Peng, Zuofu&#xD;Jiang, Wei&#xD;Fu, Xiuhua&#xD;Wang, Changzheng&#xD;Jin, Meiling&#xD;Qiu, Zhongmin&#xD;Wei, Xiaoyang&#xD;Gu, Wei&#xD;Huang, Kewu&#xD;Li, Qiang&#xD;Zhang, Xiangyan&#xD;Zhong, Nanshan&#xD;Chung, Kian Fan&#xD;Zhang, Qingling&#xD;eng&#xD;ZNSA-2020013/Zhongnanshan Medical Foundation of Guangdong Province/&#xD;ZNSXS-20220083/Zhongnanshan Medical Foundation of Guangdong Province/&#xD;ZNSXS-20240005/Zhongnanshan Medical Foundation of Guangdong Province/&#xD;82070026/National Natural Science Foundation of China/&#xD;SKLRD-L-202404/Clinical and Epidemiological Research Project of State Key Laboratory of Respiratory Disease/&#xD;202102010355/Guangzhou Science and Technology Plan Project and Zhongnanshan Medical Foundation of Guangdong Province/&#xD;ZNSA-2020003/Guangzhou Science and Technology Plan Project and Zhongnanshan Medical Foundation of Guangdong Province/&#xD;GMUCR2024-01010/Major clinical research project of the Guangzhou Medical University Research Ability Enhancement Program/&#xD;Denmark&#xD;Allergy. 2025 Jun 16. doi: 10.1111/all.16616.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40524528</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16616</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>764</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">764</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yasuma, T.</style></author><author><style face="normal" font="default" size="100%">D&apos;Alessandro-Gabazza, C. N.</style></author><author><style face="normal" font="default" size="100%">Kobayashi, T.</style></author><author><style face="normal" font="default" size="100%">Morser, J.</style></author><author><style face="normal" font="default" size="100%">Gabazza, E. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Mie University Faculty and Graduate School of Medicine, and Mie University Hospital, Tsu, Japan.&#xD;Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, and Mie University Hospital, Tsu, Japan.&#xD;Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of activation of the coagulation system in the pathogenesis of urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3243-3244</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/10/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Blood Coagulation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34596273</style></accession-num><notes><style face="normal" font="default" size="100%">Yasuma, Taro&#xD;D&apos;Alessandro-Gabazza, Corina N&#xD;Kobayashi, Tetsu&#xD;Morser, John&#xD;Gabazza, Esteban C&#xD;eng&#xD;Comment&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3243-3244. doi: 10.1111/all.15015.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34596273</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15015</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>994</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">994</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Jardetzky, T.</style></author><author><style face="normal" font="default" size="100%">Verhasselt, V.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Wurtzen, P. A.</style></author><author><style face="normal" font="default" size="100%">van Neerven, R. J. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Imperial College London, National Heart &amp; Lung Institute, London, UK.&#xD;Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;NRC Institute of Immunology FMBA of Russia, Moscow, Russia.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Stanford University School of Medicine, Stanford, CA, USA.&#xD;School of Molecular Sciences, University of Western Australia, Perth, WA, Australia.&#xD;ALK, Horsholm, Denmark.&#xD;Wageningen University &amp; Research, Wageningen, The Netherlands.&#xD;FrieslandCampina, Amersfoort, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of allergen-specific IgE, IgG and IgA in allergic disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3627-3641</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin A</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgE</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms in allergy</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">tolerance induction</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines and mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">from Viravaxx, Vienna, Austria, grants from HVD Biotech, Vienna, Austria, grants</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from WORG Pharmaceuticals, Hangzhou, China, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Jardetzky reports other from Excellergy, Inc., outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">In addition, Dr. Jardetzky has a patent covering novel anti-IgE</style></keyword><keyword><style face="normal" font="default" size="100%">agents pending</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Verhasselt has nothing to disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Durham has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. Wurtzen is an employee of and owns stocks in ALK, a medical company</style></keyword><keyword><style face="normal" font="default" size="100%">producing allergy vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Dr van Neerven has nothing to disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33999439</style></accession-num><abstract><style face="normal" font="default" size="100%">Immunoglobulin E (IgE)-mediated allergy is the most common hypersensitivity disease affecting more than 30% of the population. Exposure to even minute quantities of allergens can lead to the production of IgE antibodies in atopic individuals. This is termed allergic sensitization, which occurs mainly in early childhood. Allergen-specific IgE then binds to the high (FcepsilonRI) and low-affinity receptors (FcepsilonRII, also called CD23) for IgE on effector cells and antigen-presenting cells. Subsequent and repeated allergen exposure increases allergen-specific IgE levels and, by receptor cross-linking, triggers immediate release of inflammatory mediators from mast cells and basophils whereas IgE-facilitated allergen presentation perpetuates T cell-mediated allergic inflammation. Due to engagement of receptors which are highly selective for IgE, even tiny amounts of allergens can induce massive inflammation. Naturally occurring allergen-specific IgG and IgA antibodies usually recognize different epitopes on allergens compared with IgE and do not efficiently interfere with allergen-induced inflammation. However, IgG and IgA antibodies to these important IgE epitopes can be induced by allergen-specific immunotherapy or by passive immunization. These will lead to competition with IgE for binding with the allergen and prevent allergic responses. Similarly, anti-IgE treatment does the same by preventing IgE from binding to its receptor on mast cells and basophils. Here, we review the complex interplay of allergen-specific IgE, IgG and IgA and the corresponding cell receptors in allergic diseases and its relevance for diagnosis, treatment and prevention of allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Shamji, Mohamed H&#xD;Valenta, Rudolf&#xD;Jardetzky, Theodore&#xD;Verhasselt, Valerie&#xD;Durham, Stephen R&#xD;Wurtzen, Peter A&#xD;van Neerven, R J Joost&#xD;eng&#xD;G0601303/MRC_/Medical Research Council/United Kingdom&#xD;R01 AI115469/AI/NIAID NIH HHS/&#xD;R01 HL141493/HL/NHLBI NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3627-3641. doi: 10.1111/all.14908. Epub 2021 Jun 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33999439</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8601105</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14908</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3189</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3189</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Poto, R.</style></author><author><style face="normal" font="default" size="100%">Chan, R.</style></author><author><style face="normal" font="default" size="100%">Pelaia, C.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Virchow, J. C.</style></author><author><style face="normal" font="default" size="100%">Varricchi, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.&#xD;Istituti Clinici Scientifici ICS Maugeri - S.P.A., Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Scientifico di Telese Terme, Telese, Italy.&#xD;School of Medicine, University of Dundee, Dundee, UK.&#xD;Pneumology, Department of Medical and Surgical Sciences, University of Catanzaro, Catanzaro, Italy.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;IRCCS Humanitas Research Hospital, Milan, Italy.&#xD;Klinik und Poliklinik fur Pneumologie, Allergologie und Internistische Intensivmedizin, Department fur Innere Medizin, Germany.&#xD;Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Role of Biologics in Reducing Mucous Plug Burden in Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">airway remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">benralizumab</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">mucous plugs</style></keyword><keyword><style face="normal" font="default" size="100%">tezepelumab</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41432089</style></accession-num><abstract><style face="normal" font="default" size="100%">Asthma is a chronic inflammatory respiratory disease, affecting hundreds of millions of individuals worldwide. Mucous hypersecretion, which leads to the formation of mucous plugs within the airways, is a key pathophysiological feature associated with severe asthma and airway remodeling. Persistent airflow obstruction due to mucous plugging has been recognized as a contributor to poor symptom control in patients with asthma. This phenomenon is driven by type 2 inflammation, mediated by elevated levels of IL-5 and IL-13, as well as eosinophilic infiltration, which collectively promote the formation and persistence of mucous plugs. The presence of mucous plugging has been linked to the frequency and severity of exacerbations, as well as airflow obstruction. Imaging modalities such as high-resolution computed tomography (HRCT), hyperpolarized (129)Xe MRI, and optical coherence tomography (OCT) have provided insights into the extent of mucous plugging and its association with airflow limitation. Over the past decade, biological therapies targeting specific pathways of type 2 inflammation have emerged as highly effective treatment options for patients with severe asthma. These therapies have conferred substantial improvements in lung function, reduction in exacerbation rates, and decreased oral glucocorticoid use. One of their mechanisms of action might be due to removal of persistent mucous plugs not achieved by conventional anti-asthmatic therapies such as inhaled corticosteroids (ICS) and oral corticosteroids (OCS). This comprehensive review summarizes the effects of biologics on mucous plugging in severe asthma, focusing on their mechanisms of action, clinical efficacy, and potential implications for optimizing treatment strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Poto, Remo&#xD;Chan, Rory&#xD;Pelaia, Corrado&#xD;Canonica, G Walter&#xD;Virchow, J Christian&#xD;Varricchi, Gilda&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Dec 23. doi: 10.1111/all.70197.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41432089</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70197</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1210</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1210</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Engeroff, P.</style></author><author><style face="normal" font="default" size="100%">Vogel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">INSERM, UMR_S 959, Immunology-Immunopathology-Immunotherapy (i3), Sorbonne Universite, Paris, France.&#xD;Center for Clinical Research, Region Vastmanland/Uppsala University, Vastmanland hospital, Vasteras, Sweden.&#xD;Department of BioMedical Research, University of Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of CD23 in the regulation of allergic responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1981-1989</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/12/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigen Presentation</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens</style></keyword><keyword><style face="normal" font="default" size="100%">B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgE</style></keyword><keyword><style face="normal" font="default" size="100%">B cells</style></keyword><keyword><style face="normal" font="default" size="100%">Cd23</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-immune complexes</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33378583</style></accession-num><abstract><style face="normal" font="default" size="100%">IgE, the key molecule in atopy has been shown to bind two receptors, FcepsilonRI, the high-affinity receptor, and FcepsilonRII (CD23), binding IgE with lower affinity. Whereas cross-linking of IgE on FcepsilonRI expressed by mast cells and basophils triggers the allergic reaction, binding of IgE to CD23 on B cells plays an important role in both IgE regulation and presentation. Furthermore, IgE-immune complexes (IgE-ICs) bound by B cells enhance antibody and T cell responses in mice and humans. However, the mechanisms that regulate the targeting of the two receptors and the respective function of the two pathways in inflammation or homeostasis are still a matter of debate. Here, we focus on CD23 and discuss several mechanisms related to IgE binding, as well as the impact of the IgE/antigen-binding on different immune cells expressing CD23. One recent paper has shown that free IgE preferentially binds to FcepsilonRI whereas IgE-ICs are preferentially captured by CD23. Binding of IgE-ICs to CD23 on B cells can, on one hand, regulate serum IgE and prevent effector cell activation and on the other hand facilitate antigen presentation by delivering the antigen to dendritic cells. These data argue for a multifunctional role of CD23 for modulating IgE serum levels and immune responses.</style></abstract><notes><style face="normal" font="default" size="100%">Engeroff, Paul&#xD;Vogel, Monique&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):1981-1989. doi: 10.1111/all.14724. Epub 2021 Jan 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33378583</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8359454</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14724</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1228</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1228</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Glickman, J. W.</style></author><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Miller, R. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Biomedical Engineering, The University of Mississippi, Oxford, MS, USA.&#xD;Division of Clinical Immunology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of circulating eosinophils on COVID-19 mortality varies by race/ethnicity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">925-927</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/12/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Asian People</style></keyword><keyword><style face="normal" font="default" size="100%">Black People</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/ethnology/*mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/*physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Health Status Disparities</style></keyword><keyword><style face="normal" font="default" size="100%">Hispanic or Latino</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Logistic Models</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">White People</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33319360</style></accession-num><notes><style face="normal" font="default" size="100%">Glickman, Jacob W&#xD;Pavel, Ana B&#xD;Guttman-Yassky, Emma&#xD;Miller, Rachel L&#xD;eng&#xD;R21 ES029607/ES/NIEHS NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):925-927. doi: 10.1111/all.14708. Epub 2020 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33319360</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8290320</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14708</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>411</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">411</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Meyer, R. W.</style></author><author><style face="normal" font="default" size="100%">Greenhawt, M.</style></author><author><style face="normal" font="default" size="100%">Pali-Scholl, I.</style></author><author><style face="normal" font="default" size="100%">Nwaru, B.</style></author><author><style face="normal" font="default" size="100%">Roduit, C.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author><author><style face="normal" font="default" size="100%">Adel-Patient, K.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Agostoni, C.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Feeney, M.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Lunjani, N.</style></author><author><style face="normal" font="default" size="100%">Grimshaw, K.</style></author><author><style face="normal" font="default" size="100%">Reese, I.</style></author><author><style face="normal" font="default" size="100%">Smith, P. K.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Vassilopoulou, E.</style></author><author><style face="normal" font="default" size="100%">Vlieg-Boerstra, B.</style></author><author><style face="normal" font="default" size="100%">Amara, S.</style></author><author><style face="normal" font="default" size="100%">Walter, J.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Allergy and Immunology, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Children&apos;s Hospital Colorado, Aurora, Colorado, USA.&#xD;Imperial College, London, UK.&#xD;Comparative Medicine, Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna, Vienna, Austria.&#xD;Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.&#xD;University Children&apos;s Hospital Zurich, Zurich, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Universite Paris-Saclay, CEA, INRAE, UMR MTS/SPI/Laboratoire d&apos;Immuno-Allergie Alimentaire (LIAA), INRA, CEA, Universite Paris Saclay, Gif sur Yvette Cedex, France.&#xD;Transylvania University, Brasov, Romania.&#xD;Pediatric Unit, De Marchi Clinic, Fondazione IRCCS Ca&apos; Granda - Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Dipartimento di Scienze Cliniche e di Comunita, Universita&apos; degli Studi, Milan, Italy.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Division of Asthma, Allergy and Lung Biology, Department of Paediatric Allergy, King&apos;s College London, London, UK.&#xD;Guy&apos;s &amp; St Thomas&apos; Hospital, London, UK.&#xD;APC Microbiome Ireland, National University of Ireland, Cork, Ireland.&#xD;University of Cape Town, Cape Town, South Africa.&#xD;Dietetic Department, Salford Royal NHS Foundation Trust, Salford, UK.&#xD;Private Practice for Dietary Advice and Nutrition Therapy, Munich, Germany.&#xD;School of Medicine, Griffith University, Southport, Australia.&#xD;Department of Nutritonal Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece.&#xD;OLVG, Department of Paediatrics, Amsterdam, the Netherlands.&#xD;Rijnstate Hospital, Department of Paediatrics, Arnhem, The Netherlands.&#xD;Undergraduate, University College Los Angeles, Los Angeles, California, USA.&#xD;Department of Medicine, National University of Ireland, Cork, Ireland.&#xD;School of Microbiology, National University of Ireland, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of dietary fiber in promoting immune health-An EAACI position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3185-3198</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Fiber</style></keyword><keyword><style face="normal" font="default" size="100%">Prebiotics</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">diet</style></keyword><keyword><style face="normal" font="default" size="100%">fiber</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35801383</style></accession-num><abstract><style face="normal" font="default" size="100%">Microbial metabolism of specific dietary components, such as fiber, contributes to the sophisticated inter-kingdom dialogue in the gut that maintains a stable environment with important beneficial physiological, metabolic, and immunological effects on the host. Historical changes in fiber intake may be contributing to the increase of allergic and hypersensitivity disorders as fiber-derived metabolites are evolutionarily hardwired into the molecular circuitry governing immune cell decision-making processes. In this review, we highlight the importance of fiber as a dietary ingredient, its effects on the microbiome, its effects on immune regulation, the importance of appropriate timing of intervention to target any potential window of opportunity, and potential mechanisms for dietary fibers in the prevention and management of allergic diseases. In addition, we review the human studies examining fiber or prebiotic interventions on asthma and respiratory outcomes, allergic rhinitis, atopic dermatitis, and overall risk of atopic disorders. While exposures, interventions, and outcomes were too heterogeneous for meta-analysis, there is significant potential for using fiber in targeted manipulations of the gut microbiome and its metabolic functions in promoting immune health.</style></abstract><notes><style face="normal" font="default" size="100%">Venter, Carina&#xD;Meyer, Rosan W&#xD;Greenhawt, Matthew&#xD;Pali-Scholl, Isabella&#xD;Nwaru, Bright&#xD;Roduit, Caroline&#xD;Untersmayr, Eva&#xD;Adel-Patient, Karine&#xD;Agache, Ioana&#xD;Agostoni, Carlo&#xD;Akdis, Cezmi A&#xD;Feeney, Mary&#xD;Hoffmann-Sommergruber, Karin&#xD;Lunjani, Nonhlanhla&#xD;Grimshaw, Kate&#xD;Reese, Imke&#xD;Smith, Peter K&#xD;Sokolowska, Milena&#xD;Vassilopoulou, Emilia&#xD;Vlieg-Boerstra, Berber&#xD;Amara, Shriya&#xD;Walter, Jens&#xD;O&apos;Mahony, Liam&#xD;eng&#xD;Consensus Statement&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3185-3198. doi: 10.1111/all.15430. Epub 2022 Jul 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35801383</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15430</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>472</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">472</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhong, B.</style></author><author><style face="normal" font="default" size="100%">Seah, J. J.</style></author><author><style face="normal" font="default" size="100%">Liu, F.</style></author><author><style face="normal" font="default" size="100%">Ba, L.</style></author><author><style face="normal" font="default" size="100%">Du, J.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Upper Airways Research Laboratory, Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, China.&#xD;Department of Otolaryngology, Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Department of Otolaryngology, People&apos;s Hospital of Tibet Autonomous Region, Lhasa, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of hypoxia in the pathophysiology of chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3217-3232</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/05/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/etiology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial-Mesenchymal Transition</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoxia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/etiology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35603933</style></accession-num><abstract><style face="normal" font="default" size="100%">Chronic rhinosinusitis (CRS) is a chronic inflammatory disease of the nasal cavity characterized by excessive nasal mucus secretion and nasal congestion. The development of CRS is related to pathological mechanisms induced by hypoxia. Under hypoxic conditions, the stable expression of both Hypoxia inducible factor-1 (HIF-1) alpha and HIF-2alpha are involved in the immune response and inflammatory pathways of CRS. The imbalance in the composition of nasal microbiota may affect the hypoxic state of CRS and perpetuate existing inflammation. Hypoxia affects the differentiation of nasal epithelial cells such as ciliated cells and goblet cells, induces fibroblast proliferation, and leads to epithelial-mesenchymal transition (EMT) and tissue remodeling. Hypoxia also affects the proliferation and differentiation of macrophages, eosinophils, basophils, and mast cells in sinonasal mucosa, and thus influences the inflammatory state of CRS by regulating T cells and B cells. Given the multifactorial nature in which HIF is linked to CRS, this study aims to elucidate the effect of hypoxia on the pathogenic mechanisms of CRS.</style></abstract><notes><style face="normal" font="default" size="100%">Zhong, Bing&#xD;Seah, Jun Jie&#xD;Liu, Feng&#xD;Ba, Luo&#xD;Du, Jintao&#xD;Wang, De Yun&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3217-3232. doi: 10.1111/all.15384. Epub 2022 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35603933</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15384</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2819</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2819</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">de la Rocha-Munoz, A.</style></author><author><style face="normal" font="default" size="100%">Benito-Villalvilla, C.</style></author><author><style face="normal" font="default" size="100%">Olivares, D.</style></author><author><style face="normal" font="default" size="100%">Sirvent, S.</style></author><author><style face="normal" font="default" size="100%">Garcia-Brenes, M. A.</style></author><author><style face="normal" font="default" size="100%">Angelina, A.</style></author><author><style face="normal" font="default" size="100%">Martin-Cruz, L.</style></author><author><style face="normal" font="default" size="100%">Cuesta, J.</style></author><author><style face="normal" font="default" size="100%">Tassinari, P.</style></author><author><style face="normal" font="default" size="100%">Jaumont, X.</style></author><author><style face="normal" font="default" size="100%">Taxonera, C.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.&#xD;Autonomous University of Madrid, Madrid, Spain.&#xD;Department of Biochemistry and Molecular Biology, School of Medicine, Complutense University, Madrid, Spain.&#xD;Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinico San Carlos and Instituto de Investigacion del Hospital Clinico San Carlos [IdISSC], Madrid, Spain.&#xD;National Center of Epidemiology, Carlos III Health Institute, Madrid, Spain.&#xD;Department of Biochemistry and Molecular Biology, School of Pharmacy, Complutense University, Madrid, Spain.&#xD;Allergy Department, Fundacion Jimenez Diaz, Madrid, Spain.&#xD;Novartis Pharma AG, Basel, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Role of IgE in Crohn&apos;s Disease by Impairing the Capacity of Plasmacytoid Dendritic Cells to Generate FOXP3(+) Tregs</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2319-2331</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/03/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dendritic Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Crohn Disease/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Forkhead Transcription Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgE/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Crohn&apos;s disease</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">plasmacytoid dendritic cells</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cells</style></keyword><keyword><style face="normal" font="default" size="100%">CAM, Inmunotek S.L., Novartis, and AstraZeneca, and fees for giving scientific</style></keyword><keyword><style face="normal" font="default" size="100%">lectures or participation in Advisory Boards fromAstraZeneca, Pfizer,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Inmunotek S.L., Novartis, Sanofi-Genzyme, and Regeneron. P.T.</style></keyword><keyword><style face="normal" font="default" size="100%">and X.J. are Novartis employees. C.T. has served as a speaker, consultant, and</style></keyword><keyword><style face="normal" font="default" size="100%">advisory board member for MSD, AbbVie, Pfizer, Takeda, Janssen, Galapagos, Lilly,</style></keyword><keyword><style face="normal" font="default" size="100%">Fresenius Kabi, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, and</style></keyword><keyword><style face="normal" font="default" size="100%">Tillots. The rest of the authors declare no competing financial interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40052502</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A causal relationship between Crohn&apos;s disease (CD) and asthma is reported, but the underlying mechanisms are not fully understood. We sought to investigate the role of IgE and IgE-mediated pathways in the pathophysiology of CD. METHODS: 20 CD patients, 10 allergic patients without inflammatory bowel disease, and 10 healthy donors (HD) were included in the study. Total serum IgE was quantified by ELISA. Circulating IgE(+) and FcepsilonRIalpha(+) immune cells, as well as specific CD4(+) T cell populations, were determined by flow cytometry. Gene set enrichment signatures from available single-cell (sc)RNAseq datasets of the intestine from CD patients were analyzed. Purified plasmacytoid dendritic cells (pDCs) from CD patients were cocultured with naive CD4(+) T cells to assess Tregs generation. RESULTS: CD patients, similar to allergic non-CD patients, displayed significantly higher numbers of circulating IgE(+) or FcepsilonRIalpha(+) immune cells than HD. The percentage of blood IgE(+) or FcepsilonRIalpha(+) pDCs was significantly higher in CD than HD and similar to allergic non-CD patients. CD patients showed significantly higher numbers of effector memory CD4(+) T cells and lower numbers of FOXP3(+) Tregs than HD. scRNAseq data from CD patients confirmed that Tregs imbalance and overactivation of IgE-mediated pathways take place also in gut tissues of children and adults, suggesting IgE could interfere in the pDC-Tregs axis. In vitro functional experiments demonstrated that IgE-crosslinking on pDCs from CD patients impairs Treg generation, which was restored by the anti-IgE mAb omalizumab. CONCLUSIONS: IgE might play an unprecedented role in CD by impairing the capacity of pDCs to generate Tregs, which could represent a novel mechanism contributing to CD to be exploited for alternative therapeutic interventions.</style></abstract><notes><style face="normal" font="default" size="100%">de la Rocha-Munoz, Andres&#xD;Benito-Villalvilla, Cristina&#xD;Olivares, David&#xD;Sirvent, Sofia&#xD;Garcia-Brenes, Miguel A&#xD;Angelina, Alba&#xD;Martin-Cruz, Leticia&#xD;Cuesta, Javier&#xD;Tassinari, Paolo&#xD;Jaumont, Xavier&#xD;Taxonera, Carlos&#xD;Palomares, Oscar&#xD;eng&#xD;Ministerio de Universidades/&#xD;Novartis Pharma/&#xD;Ministerio de Ciencia e Innovacion/&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2319-2331. doi: 10.1111/all.16517. Epub 2025 Mar 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40052502</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368764</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16517</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>692</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">692</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mishra, A.</style></author><author><style face="normal" font="default" size="100%">Majid, D.</style></author><author><style face="normal" font="default" size="100%">Kandikattu, H. K.</style></author><author><style face="normal" font="default" size="100%">Yadavalli, C. S.</style></author><author><style face="normal" font="default" size="100%">Upparahalli Venkateshaiah, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">John W. Deming Department of Medicine, Tulane Eosinophilic Disorders Center (TEDC), Section of Pulmonary Diseases, Tulane University School of Medicine, New Orleans, Louisina, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of IL-18-transformed CD274-expressing eosinophils in promoting airway obstruction in experimental asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1165-1179</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Airway Obstruction/etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">B7-H1 Antigen/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-18/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-5/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Aspergillus</style></keyword><keyword><style face="normal" font="default" size="100%">DeltadblGATA</style></keyword><keyword><style face="normal" font="default" size="100%">Cd274</style></keyword><keyword><style face="normal" font="default" size="100%">Il-18</style></keyword><keyword><style face="normal" font="default" size="100%">Il-5</style></keyword><keyword><style face="normal" font="default" size="100%">airway resistance (RI)</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34800294</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: IL-5-dependent residential and IL-18-transformed pathogenic eosinophils have been reported; however, the role of IL-18-transformed CD274-expressing pathogenic eosinophils compared to IL-5-generated eosinophils in promoting airway obstruction in asthma has not yet been examined. METHODS: Eosinophils are detected by tissue anti-MBP and anti-EPX immunostaining, CD274 expression by flow cytometry, and airway resistance using the Buxco FinePointe RC system. RESULTS: We show that A. fumigatus-challenged wild-type mice, and different gene-deficient mice including naive CC10-IL-18-transgenic mice, accumulate mostly peribronchial and perivascular CD274-expressing eosinophils except naive CD2-IL-5-transgenic mice. Additionally, we show that CD2-IL-5 transgenic mice following rIL-18 treatment accumulate high number of CD274-expressing perivascular and peribronchial eosinophils with induced collagen, goblet cell hyperplasia and airway resistance compared to saline-challenged CD2-IL5 transgenic mice. Furthermore, we also show that even A. fumigatus-challenged IL-5 (-/-) mice and rIL-18 given DeltadblGATA mice accumulate CD274-expressing eosinophil-associated asthma pathogenesis including airway obstruction. Most importantly, we provide evidence that neutralization of CD274 and IL-18 in A. fumigatus-challenged mice ameliorate experimental asthma. Taken together, the data presented are clinically significant in establishing that anti-IL-18 neutralization is a novel immunotherapy to restrict asthma pathogenesis. CONCLUSIONS: We demonstrate that IL-18 is critical for inducing asthma pathogenesis, and neutralization of CD274 is a potential immunotherapeutic strategy for asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Mishra, Anil&#xD;Majid, Dewan&#xD;Kandikattu, Hemanth Kumar&#xD;Yadavalli, Chandra Sekhar&#xD;Upparahalli Venkateshaiah, Sathisha&#xD;eng&#xD;R01 AI080581/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1165-1179. doi: 10.1111/all.15180. Epub 2021 Dec 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34800294</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8960341</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15180</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3107</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3107</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Bravo, S.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Immunology, IIS-Fundacion Jimenez Diaz, Universidad Autonoma de Madrid (UAM), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of Inflammasome in IgE-Mediated Anaphylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 25</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41137486</style></accession-num><notes><style face="normal" font="default" size="100%">Fernandez-Bravo, S&#xD;Fernandez-Santamaria, R&#xD;eng&#xD;Instituto de Salud Carlos III/&#xD;Denmark&#xD;Allergy. 2025 Oct 25. doi: 10.1111/all.70123.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41137486</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70123</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1233</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1233</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tubita, V.</style></author><author><style face="normal" font="default" size="100%">Callejas-Diaz, B.</style></author><author><style face="normal" font="default" size="100%">Roca-Ferrer, J.</style></author><author><style face="normal" font="default" size="100%">Marin, C.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">INGENIO, Immunoal.lergia Respiratoria Clinica i Experimental (IRCE), Institut d&apos;Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.&#xD;CIBER of Respiratory Diseases (CIBERES), Carlos III Institute, Barcelona, Spain.&#xD;Department of Otolaryngology, Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore.&#xD;ENT Department, Rhinology Unit &amp; Smell Clinic, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of microRNAs in inflammatory upper airway diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1967-1980</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/12/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhino sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">miRNAs</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">non-allergic rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33314198</style></accession-num><abstract><style face="normal" font="default" size="100%">MicroRNAs (miRNAs) are a conserved family of small endogenous noncoding RNA molecules that modulate post-transcriptional gene expression in physiological and pathological processes. miRNAs can silence target mRNAs through degradation or inhibition of translation, showing their pivotal role in the pathogenesis of many human diseases. miRNAs play a role in regulating immune functions and inflammation and are implicated in controlling the development and activation of T and B cells. Inflammatory chronic upper airway diseases, such as rhinitis and rhinosinusitis, are spread all over the world and characterized by an exaggerated inflammation involving a complex interaction between immune and resident cells. Until now and despite allergy, little is known about their etiology and the processes implicated in the immune response and tuning inflammation of these diseases. This review highlights the knowledge of the current literature about miRNAs in inflammatory chronic upper airways diseases and how this may be exploited in the development of new clinical and therapeutic strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Tubita, Valeria&#xD;Callejas-Diaz, Borja&#xD;Roca-Ferrer, Jordi&#xD;Marin, Concepcio&#xD;Liu, Zheng&#xD;Wang, De Yun&#xD;Mullol, Joaquim&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):1967-1980. doi: 10.1111/all.14706. Epub 2020 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33314198</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14706</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1169</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1169</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Perez-Inestrosa, E.</style></author><author><style face="normal" font="default" size="100%">Rojo, J.</style></author><author><style face="normal" font="default" size="100%">Ferrer, M.</style></author><author><style face="normal" font="default" size="100%">Montanez, M. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Andalusian Centre for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.&#xD;Departamento de Quimica Organica, and the Biomimetic Dendrimers and Photonic Laboratory, Instituto de Investigacion Biomedica de Malaga-IBIMA, Universidad de Malaga, Malaga, Spain.&#xD;Glycosystems Laboratory, Instituto de Investigaciones Quimicas (IIQ), CSIC-Universidad de Sevilla, Sevilla, Spain.&#xD;Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of nanostructures in allergy: Diagnostics, treatments and safety</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3292-3306</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/02/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Nanostructures</style></keyword><keyword><style face="normal" font="default" size="100%">Nanotechnology</style></keyword><keyword><style face="normal" font="default" size="100%">*Nanotubes, Carbon</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">dendrimers</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostic test</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">nanostructures</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33559903</style></accession-num><abstract><style face="normal" font="default" size="100%">Nanotechnology is science, engineering and technology conducted at the nanoscale, which is about 1-100 nm. It has led to the development of nanomaterials, which behave very differently from materials with larger scales and can have a wide range of applications in biomedicine. The physical and chemical properties of materials of such small compounds depend mainly on the size, shape, composition and functionalization of the system. Nanoparticles, carbon nanotubes, liposomes, polymers, dendrimers and nanogels, among others, can be nanoengineeried for controlling all parameters, including their functionalization with ligands, which provide the desired interaction with the immunological system, that is dendritic cell receptors to activate and/or modulate the response, as well as specific IgE, or effector cell receptors. However, undesired issues related to toxicity and hypersensitivity responses can also happen and would need evaluation. There are wide panels of accessible structures, and controlling their physico-chemical properties would permit obtaining safer and more efficient compounds for clinical applications goals, either in diagnosis or treatment. The application of dendrimeric antigens, nanoallergens and nanoparticles in allergy diagnosis is very promising since it can improve sensitivity by increasing specific IgE binding, mimicking carrier proteins or enhancing signal detection. Additionally, in the case of immunotherapy, glycodendrimers, liposomes, polymers and nanoparticles have shown interest, behaving as platforms of allergenic structures, adjuvants or protectors of allergen from degradation or having a depot capacity. Taken together, the application of nanotechnology to allergy shows promising facts facing important goals related to the improvement of diagnosis as well as specific immunotherapy.</style></abstract><notes><style face="normal" font="default" size="100%">Mayorga, Cristobalina&#xD;Perez-Inestrosa, Ezequiel&#xD;Rojo, Javier&#xD;Ferrer, Marta&#xD;Montanez, Maria Isabel&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3292-3306. doi: 10.1111/all.14764. Epub 2021 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33559903</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14764</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1419</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1419</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xie, G.</style></author><author><style face="normal" font="default" size="100%">Ding, F.</style></author><author><style face="normal" font="default" size="100%">Han, L.</style></author><author><style face="normal" font="default" size="100%">Yin, D.</style></author><author><style face="normal" font="default" size="100%">Lu, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory and Critical Care Medicine, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.&#xD;Department of Clinical Laboratory, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of peripheral blood eosinophil counts in COVID-19 patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">471-482</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/06/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*blood/*diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">peripheral blood eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32562554</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Coronavirus disease 2019 (COVID-19) emerged in Wuhan city and rapidly spread globally outside China. We aimed to investigate the role of peripheral blood eosinophil (EOS) as a marker in the course of the virus infection to improve the efficiency of diagnosis and evaluation of COVID-19 patients. METHODS: 227 pneumonia patients who visited the fever clinics in Shanghai General Hospital and 97 hospitalized COVID-19 patients admitted to Shanghai Public Health Clinical Center were involved in a retrospective research study. Clinical, laboratory, and radiologic data were collected. The trend of EOS level in COVID-19 patients and comparison among patients with different severity were summarized. RESULTS: The majority of COVID-19 patients (71.7%) had a decrease in circulating EOS counts, which was significantly more frequent than other types of pneumonia patients. EOS counts had good value for COVID-19 prediction, even higher when combined with neutrophil-to-lymphocyte ratio. Patients with low EOS counts at admission were more likely to have fever, fatigue, and shortness of breath, with more lesions in chest CT and radiographic aggravation, and longer length of hospital stay and course of disease than those with normal EOS counts. Circulating EOS level gradually increased over the time, and was synchronous with the improvement in chest CT (12 days vs 13 days, P = .07), later than that of body temperature (12 days vs 10 days, P = .014), but earlier than that of the negative conversion of nucleic acid assays (12 days vs 17 days, P = .001). CONCLUSION: Peripheral blood EOS counts may be an effective and efficient indicator in diagnosis, Evaluation, and prognosis monitoring of COVID-19 patients.</style></abstract><notes><style face="normal" font="default" size="100%">Xie, Guogang&#xD;Ding, Fengming&#xD;Han, Lei&#xD;Yin, Dongning&#xD;Lu, Hongzhou&#xD;Zhang, Min&#xD;eng&#xD;YG2020YQ22/Shanghai Jiaotong University medical and engineering scientific fund for COVID-19/&#xD;2020XGZX009/Zhejiang University special scientific research fund for COVID-19 prevention and control/&#xD;2020YJKY01/Shanghai Public Health Clinical Center special projects in scientific research for COVID-19 prevention/&#xD;NO IDF162005/The first class discipline construction project of Fudan University/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):471-482. doi: 10.1111/all.14465. Epub 2020 Jul 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32562554</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7323233</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14465</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1046</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1046</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Oka, A.</style></author><author><style face="normal" font="default" size="100%">Kidoguchi, M.</style></author><author><style face="normal" font="default" size="100%">Kariya, S.</style></author><author><style face="normal" font="default" size="100%">Fujiwara, T.</style></author><author><style face="normal" font="default" size="100%">Yuta, A.</style></author><author><style face="normal" font="default" size="100%">Miyashita, H.</style></author><author><style face="normal" font="default" size="100%">Higaki, T.</style></author><author><style face="normal" font="default" size="100%">Ogawa, Y.</style></author><author><style face="normal" font="default" size="100%">Kanai, K.</style></author><author><style face="normal" font="default" size="100%">Makihara, S. I.</style></author><author><style face="normal" font="default" size="100%">Haruna, T.</style></author><author><style face="normal" font="default" size="100%">Kunisawa, J.</style></author><author><style face="normal" font="default" size="100%">Adachi, N.</style></author><author><style face="normal" font="default" size="100%">Koyama, K.</style></author><author><style face="normal" font="default" size="100%">Ii, R.</style></author><author><style face="normal" font="default" size="100%">Noguchi, E.</style></author><author><style face="normal" font="default" size="100%">Fujieda, S.</style></author><author><style face="normal" font="default" size="100%">Nishizaki, K.</style></author><author><style face="normal" font="default" size="100%">Okano, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, International University of Health and Welfare Graduate School of Medicine, Narita, Japan.&#xD;Department of Otorhinolaryngology Head &amp; Neck Surgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.&#xD;Department of Medical Genetics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.&#xD;Departments of Otolaryngology-Head &amp; Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.&#xD;Yuta Clinic, Tsu, Japan.&#xD;Department Otorhinolaryngology-Head &amp; Neck Surgery, Kagawa Prefectural Central Hospital, Takamatsu, Japan.&#xD;Department Otorhinolaryngology-Head &amp; Neck Surgery, Kagawa Rosai Hospital, Marugame, Japan.&#xD;Department Otorhinolaryngology, Himeji St. Mary&apos;s Hospital, Himeji, Japan.&#xD;Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of salivary microbiome in IL-10 production and efficacy of sublingual immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2617-2620</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/04/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-10</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Saliva</style></keyword><keyword><style face="normal" font="default" size="100%">Sublingual immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33864682</style></accession-num><notes><style face="normal" font="default" size="100%">Oka, Aiko&#xD;Kidoguchi, Masanori&#xD;Kariya, Shin&#xD;Fujiwara, Tazuko&#xD;Yuta, Atsushi&#xD;Miyashita, Hiromi&#xD;Higaki, Takaya&#xD;Ogawa, Yukiko&#xD;Kanai, Kengo&#xD;Makihara, Sei-Ichiro&#xD;Haruna, Takenori&#xD;Kunisawa, Jun&#xD;Adachi, Naoto&#xD;Koyama, Keisuke&#xD;Ii, Rieko&#xD;Noguchi, Emiko&#xD;Fujieda, Shigeharu&#xD;Nishizaki, Kazunori&#xD;Okano, Mitsuhiro&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2617-2620. doi: 10.1111/all.14858. Epub 2021 May 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33864682</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14858</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>721</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">721</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Castagnoli, R.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.&#xD;Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.&#xD;Department of Molecular Medicine, University of Pavia, Pavia, Italy.&#xD;Allergy Unit, Department of Pediatrics, Meyer Children&apos;s University Hospital, Florence, Italy.&#xD;Allergy, Immunology and Rheumatology Division, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of the microbiota in the development of thymic-derived specific T-cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1328-1330</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Thymus Gland</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34713464</style></accession-num><notes><style face="normal" font="default" size="100%">Castagnoli, Riccardo&#xD;Giovannini, Mattia&#xD;Riggioni, Carmen&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1328-1330. doi: 10.1111/all.15159. Epub 2021 Nov 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34713464</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15159</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1894</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1894</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Castagnoli, R.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.&#xD;Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.&#xD;Department of Molecular Medicine, University of Pavia, Pavia, Italy.&#xD;Allergy Unit, Department of Pediatrics, Meyer Children&apos;s University Hospital, Florence, Italy.&#xD;Allergy, Immunology and Rheumatology Division, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of the microbiota in the development of thymic-derived specific T-cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1328-1330</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Thymus Gland</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34713464</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Microbes, including bacteria, viruses, and fungi, have evolved and continue to live on and within humans. The massive presence of foreign microorganisms, known as microbiota, is allowed by the development of a delicate equilibrium between the colonizing microbes and the host immunity.1 Through this symbiotic relationship, the microbiota provides, among others, nutritional benefits and protection from infections.</style></abstract><notes><style face="normal" font="default" size="100%">Castagnoli, Riccardo&#xD;Giovannini, Mattia&#xD;Riggioni, Carmen&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1328-1330. doi: 10.1111/all.15159. Epub 2021 Nov 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34713464</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15159</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2765</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2765</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Daud, T.</style></author><author><style face="normal" font="default" size="100%">Roberts, S.</style></author><author><style face="normal" font="default" size="100%">Zounemat Kermani, N.</style></author><author><style face="normal" font="default" size="100%">Richardson, M.</style></author><author><style face="normal" font="default" size="100%">Heaney, L. G.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Amrani, Y.</style></author><author><style face="normal" font="default" size="100%">Bradding, P.</style></author><author><style face="normal" font="default" size="100%">Siddiqui, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Sciences, College of Life Sciences, and NIHR Biomedical Research Centre (Respiratory Theme), Glenfield Hospital, Leicester, UK.&#xD;Data Science Institute, Imperial College, London, UK.&#xD;Imperial NIHR Biomedical Research Centre, National Heart and Lung Institute (NHLI), Imperial College London, London, UK.&#xD;Wellcome-Wolfson Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen&apos;s University, Belfast, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Role of WNT5a and TGF-beta1 in Airway Remodelling and Severe Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1025-1037</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/01/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Airway Remodeling/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism/pathology/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Mucosa/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">*Transforming Growth Factor beta1/metabolism/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Wnt-5a Protein/metabolism/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">TGF-beta1</style></keyword><keyword><style face="normal" font="default" size="100%">WNT5a</style></keyword><keyword><style face="normal" font="default" size="100%">airway remodelling</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39749571</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Airway remodelling is a feature of severe asthma with airway epithelial damage observed frequently. We evaluated the role of WNT5a and TGF-beta(1) in asthmatic airway biopsies and in sputum and bronchial brushings assessed their role in remodelling. METHODS: WNT5a and TGF-beta(1) protein expression were assessed in the lamina propria epithelium of people with asthma (GINA 1-3, n-8 and GINA 4-5, n-14) and healthy subjects (n-9), alongside relevant remodelling markers. The effects of WNT5a and TGF-beta(1) on BEAS-2B epithelial cell wound healing and differentiation were assessed in vitro. Replication was performed in the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) study in sputum (n = 120) and bronchial brushes (n = 147). RESULTS: WNT5a and TGF-beta(1) protein expression were significantly increased in the airway epithelium and lamina propria in asthma patients with concurrent airflow limitation or severe disease. Furthermore, WNT5a protein expression in the lamina propria correlated with tissue eosinophils and vascular remodelling. Airway epithelial WNT5a was co-localised predominantly to airway basal cells and correlated with Th17 gene expression (r = 0.40, p = 0.025) and both the % intact (r(s) = 0.54, p = 0.001) and % denuded epithelium (r(s) = -0.39, p = 0.003). Experiments in BEAS-2B cells confirmed that WNT5a at maximal physiological concentrations (1 mug/mL), promoted epithelial wound healing, independently of TGF-beta(1), as well as induction of EMT-like morphology. WNT5a mRNA was associated with severe asthma, airflow limitation, sputum eosinophilia and Th2, and Th17 and neutrophil activation transcriptomes in sputum in U-BIOPRED. CONCLUSION: WNT5a is associated with both airway remodelling and severe asthma. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01982162.</style></abstract><notes><style face="normal" font="default" size="100%">Daud, Tariq&#xD;Roberts, Sheree&#xD;Zounemat Kermani, Nazanin&#xD;Richardson, Matthew&#xD;Heaney, Liam G&#xD;Adcock, Ian M&#xD;Amrani, Yassine&#xD;Bradding, Peter&#xD;Siddiqui, Salman&#xD;eng&#xD;AUK-PG-2013-208/Asthma and Lung UK/&#xD;Genentech/&#xD;NIHR Imperial Biomedical Research Centre/&#xD;NIHR Leicester Biomedical Research Centre/&#xD;Observational Study&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1025-1037. doi: 10.1111/all.16445. Epub 2025 Jan 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39749571</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16445</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1235</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1235</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yuan, T.</style></author><author><style face="normal" font="default" size="100%">Zheng, R.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Tan, K. S.</style></author><author><style face="normal" font="default" size="100%">Huang, Z. Q.</style></author><author><style face="normal" font="default" size="100%">Zhou, X. M.</style></author><author><style face="normal" font="default" size="100%">Zi, X. X.</style></author><author><style face="normal" font="default" size="100%">Qiu, H. J.</style></author><author><style face="normal" font="default" size="100%">Wang, X. Y.</style></author><author><style face="normal" font="default" size="100%">Wang, W. H.</style></author><author><style face="normal" font="default" size="100%">Deng, H. Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. B.</style></author><author><style face="normal" font="default" size="100%">Kong, W. F.</style></author><author><style face="normal" font="default" size="100%">Wu, Q. W.</style></author><author><style face="normal" font="default" size="100%">Huang, Y.</style></author><author><style face="normal" font="default" size="100%">Ong, H. H.</style></author><author><style face="normal" font="default" size="100%">Huang, X. K.</style></author><author><style face="normal" font="default" size="100%">Chen, Z. G.</style></author><author><style face="normal" font="default" size="100%">Wang, D. Y.</style></author><author><style face="normal" font="default" size="100%">Yang, Q. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology-Head and Neck Surgery, Department of Allergy, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore.&#xD;Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nanchang University, Nanchang, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.&#xD;Department of Otolaryngology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.&#xD;Marketing Department, Cyagen Biosciences (Guangzhou) Inc, Guangzhou, China.&#xD;Department of Pediatrics, Department of Allergy, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of yes-associated protein in interleukin-13 induced nasal remodeling of chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">600-604</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Adaptor Proteins, Signal Transducing</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Nose</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Transcription Factors</style></keyword><keyword><style face="normal" font="default" size="100%">YAP-Signaling Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">Hippo</style></keyword><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">Yap</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial remodeling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33301614</style></accession-num><notes><style face="normal" font="default" size="100%">Yuan, Tian&#xD;Zheng, Rui&#xD;Liu, Jing&#xD;Tan, Kai Sen&#xD;Huang, Zhi-Qun&#xD;Zhou, Xiang-Min&#xD;Zi, Xiao-Xue&#xD;Qiu, Hui-Jun&#xD;Wang, Xin-Yue&#xD;Wang, Wei-Hao&#xD;Deng, Hui-Yi&#xD;Chen, Yu-Bin&#xD;Kong, Wei-Feng&#xD;Wu, Qing-Wu&#xD;Huang, Ying&#xD;Ong, Hsiao Hui&#xD;Huang, Xue-Kun&#xD;Chen, Zhuang-Gui&#xD;Wang, De-Yun&#xD;Yang, Qin-Tai&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):600-604. doi: 10.1111/all.14699. Epub 2021 Jan 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33301614</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14699</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1585</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1585</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yuan, T.</style></author><author><style face="normal" font="default" size="100%">Zheng, R.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Tan, K. S.</style></author><author><style face="normal" font="default" size="100%">Huang, Z. Q.</style></author><author><style face="normal" font="default" size="100%">Zhou, X. M.</style></author><author><style face="normal" font="default" size="100%">Zi, X. X.</style></author><author><style face="normal" font="default" size="100%">Qiu, H. J.</style></author><author><style face="normal" font="default" size="100%">Wang, X. Y.</style></author><author><style face="normal" font="default" size="100%">Wang, W. H.</style></author><author><style face="normal" font="default" size="100%">Deng, H. Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. B.</style></author><author><style face="normal" font="default" size="100%">Kong, W. F.</style></author><author><style face="normal" font="default" size="100%">Wu, Q. W.</style></author><author><style face="normal" font="default" size="100%">Huang, Y.</style></author><author><style face="normal" font="default" size="100%">Ong, H. H.</style></author><author><style face="normal" font="default" size="100%">Huang, X. K.</style></author><author><style face="normal" font="default" size="100%">Chen, Z. G.</style></author><author><style face="normal" font="default" size="100%">Wang, D. Y.</style></author><author><style face="normal" font="default" size="100%">Yang, Q. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology-Head and Neck Surgery, Department of Allergy, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.&#xD;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore.&#xD;Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nanchang University, Nanchang, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.&#xD;Department of Otolaryngology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.&#xD;Marketing Department, Cyagen Biosciences (Guangzhou) Inc, Guangzhou, China.&#xD;Department of Pediatrics, Department of Allergy, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of yes-associated protein in interleukin-13 induced nasal remodeling of chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">600-604</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Adaptor Proteins, Signal Transducing</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Nose</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Transcription Factors</style></keyword><keyword><style face="normal" font="default" size="100%">YAP-Signaling Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">Hippo</style></keyword><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">Yap</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial remodeling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33301614</style></accession-num><notes><style face="normal" font="default" size="100%">Yuan, Tian&#xD;Zheng, Rui&#xD;Liu, Jing&#xD;Tan, Kai Sen&#xD;Huang, Zhi-Qun&#xD;Zhou, Xiang-Min&#xD;Zi, Xiao-Xue&#xD;Qiu, Hui-Jun&#xD;Wang, Xin-Yue&#xD;Wang, Wei-Hao&#xD;Deng, Hui-Yi&#xD;Chen, Yu-Bin&#xD;Kong, Wei-Feng&#xD;Wu, Qing-Wu&#xD;Huang, Ying&#xD;Ong, Hsiao Hui&#xD;Huang, Xue-Kun&#xD;Chen, Zhuang-Gui&#xD;Wang, De-Yun&#xD;Yang, Qin-Tai&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):600-604. doi: 10.1111/all.14699. Epub 2021 Jan 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33301614</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14699</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1286</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1286</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yao, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, C. L.</style></author><author><style face="normal" font="default" size="100%">Yu, D.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, Qld, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">456-470</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Germinal Center</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Helper-Inducer</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">follicular helper T cell</style></keyword><keyword><style face="normal" font="default" size="100%">follicular regulatory T cell</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin E</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33098663</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic diseases are characterized by overactive type 2 immune responses to allergens and immunoglobulin E (IgE)-mediated hypersensitivity. Emerging evidence suggests that follicular helper T (T(FH) ) cells, rather than type 2 T-helper (T(H) 2) cells, play a crucial role in controlling IgE production. However, follicular regulatory T (T(FR) ) cells, a specialized subset of regulatory T (T(REG) ) cells resident in B-cell follicles, restricts T(FH) cell-mediated help in extrafollicular antibody production, germinal center (GC) formation, immunoglobulin affinity maturation, and long-lived, high-affinity plasma and memory B-cell differentiation. In mouse models of allergic asthma and food allergy, CXCR5(+) T(FH) cells, not CXCR5(-) conventional T(H) 2 cells, are needed to support IgE production, otherwise exacerbated by CXCR5(+) T(FR) cell deletion. Upregulation of T(FH) cell activities, including a skewing toward type 2 T(FH) (T(FH) 2) and IL-13 producing T(FH) (T(FH) 13) phenotypes, and defects in T(FR) cells have been identified in patients with allergic diseases. Allergen immunotherapy (AIT) reinstates the balance between T(FH) and T(FR) cells in patients with allergic diseases, resulting in clinical benefits. Collectively, further understanding of T(FH) and T(FR) cells and their role in the immunopathogenesis of allergic diseases creates opportunities to develop novel therapeutic approaches.</style></abstract><notes><style face="normal" font="default" size="100%">Yao, Yin&#xD;Chen, Cai-Ling&#xD;Yu, Di&#xD;Liu, Zheng&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):456-470. doi: 10.1111/all.14639. Epub 2020 Nov 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33098663</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14639</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2798</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2798</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bryant, M.</style></author><author><style face="normal" font="default" size="100%">Janas, P. P.</style></author><author><style face="normal" font="default" size="100%">Sanchez, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medicine, Medical Sciences and Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.&#xD;Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Roles of Interleukin-24 in Epithelial Repair: Bridging Injury and Regeneration</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1543-1545</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/01/21</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39835989</style></accession-num><notes><style face="normal" font="default" size="100%">Bryant, Morgan&#xD;Janas, Piotr P&#xD;Sanchez, Thibaut&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1543-1545. doi: 10.1111/all.16479. Epub 2025 Jan 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39835989</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105056</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16479</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2178</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2178</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lunjani, N.</style></author><author><style face="normal" font="default" size="100%">Ambikan, A. T.</style></author><author><style face="normal" font="default" size="100%">Hlela, C.</style></author><author><style face="normal" font="default" size="100%">Levin, M.</style></author><author><style face="normal" font="default" size="100%">Mankahla, A.</style></author><author><style face="normal" font="default" size="100%">Heldstab-Kast, J. I.</style></author><author><style face="normal" font="default" size="100%">Boonpiyathad, T.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Altunbulakli, C.</style></author><author><style face="normal" font="default" size="100%">Gray, C.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Neogi, U.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Dermatology, University of Cape Town, Cape Town, South Africa.&#xD;APC Microbiome Ireland, University College Cork, Cork, Ireland.&#xD;The Systems Virology Lab, Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, ANA Futura, Stockholm, Sweden.&#xD;Division of Paediatric Allergy, Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.&#xD;The Division of Dermatology, Department of Medicine and Pharmacology, Walter Sisulu University, Mthatha, Eastern Cape, South Africa.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Division of Immunology, University of Cape Town, Cape Town, South Africa.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.&#xD;Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Medicine, University College Cork, Cork, Ireland.&#xD;School of Microbiology, University College Cork, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Rural and urban exposures shape early life immune development in South African children with atopic dermatitis and nonallergic children</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">65-79</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/08/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">South Africa/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">immune development</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases (NIAID), National Heart, Lung, and Blood Institute (NHLBI), National</style></keyword><keyword><style face="normal" font="default" size="100%">Institute of Environmental Health Sciences (NIEHS), and Food Allergy Research &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Education (FARE)</style></keyword><keyword><style face="normal" font="default" size="100%">Stock options from IgGenix, Seed Health, ClostraBio, Cour,</style></keyword><keyword><style face="normal" font="default" size="100%">Alladapt</style></keyword><keyword><style face="normal" font="default" size="100%">Advisor at Cour Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">Consultant for Excellergy, Red tree ventures,</style></keyword><keyword><style face="normal" font="default" size="100%">Before Brands, Alladapt, Cour, Latitude, Regeneron, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">Co-founder of</style></keyword><keyword><style face="normal" font="default" size="100%">Before Brands, Alladapt, Latitude, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">National Scientific Committee</style></keyword><keyword><style face="normal" font="default" size="100%">member at Immune Tolerance Network (ITN), and National Institutes of Health (NIH)</style></keyword><keyword><style face="normal" font="default" size="100%">clinical research centers</style></keyword><keyword><style face="normal" font="default" size="100%">patents include, &quot;Mixed allergen composition and</style></keyword><keyword><style face="normal" font="default" size="100%">methods for using the same,&quot; &quot;Granulocyte-based methods for detecting and</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring immune system disorders,&quot; and &quot;Methods and Assays for Detecting and</style></keyword><keyword><style face="normal" font="default" size="100%">Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders.&quot;</style></keyword><keyword><style face="normal" font="default" size="100%">Dr. O&apos;Mahony reports grants from Science Foundation Ireland, during the conduct</style></keyword><keyword><style face="normal" font="default" size="100%">of the study</style></keyword><keyword><style face="normal" font="default" size="100%">grants from GSK, grants from Chiesi, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">PrecisionBiotics, personal fees from Nestle, personal fees from Reckitt, outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work. Dr. Akdis has received research grants from the Swiss</style></keyword><keyword><style face="normal" font="default" size="100%">National Science Foundation, European Union (EU CURE, EU Syn-Air-G), Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">Research Institutes, (Basel, Switzerland), Stanford University (Redwood City,</style></keyword><keyword><style face="normal" font="default" size="100%">Calif), Seed Health (Boston, USA) and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">is the</style></keyword><keyword><style face="normal" font="default" size="100%">Co-Chair for EAACI Guidelines on Environmental Science in Allergic diseases and</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Chair of the EAACI Epithelial Cell Biology Working Group</style></keyword><keyword><style face="normal" font="default" size="100%">is on the</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory Boards of Sanofi/Regeneron (Bern, Switzerland, New York, USA), Stanford</style></keyword><keyword><style face="normal" font="default" size="100%">University Sean Parker Asthma Allergy Center (CA, USA), Novartis (Basel,</style></keyword><keyword><style face="normal" font="default" size="100%">Switzerland), Glaxo Smith Kline (Zurich, Switzerland), Bristol-Myers Squibb (New</style></keyword><keyword><style face="normal" font="default" size="100%">York, USA), Seed Health (Boston, USA) and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">and is the</style></keyword><keyword><style face="normal" font="default" size="100%">Editor-in-Chief of Allergy. The remaining authors declare no competing interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37534631</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Immunological traits and functions have been consistently associated with environmental exposures and are thought to shape allergic disease susceptibility and protection. In particular, specific exposures in early life may have more significant effects on the developing immune system, with potentially long-term impacts. METHODS: We performed RNA-Seq on peripheral blood mononuclear cells (PBMCs) from 150 children with atopic dermatitis and healthy nonallergic children in rural and urban settings from the same ethnolinguistic AmaXhosa background in South Africa. We measured environmental exposures using questionnaires. RESULTS: A distinct PBMC gene expression pattern was observed in those children with atopic dermatitis (132 differentially expressed genes [DEGs]). However, the predominant influences on the immune cell transcriptome were related to early life exposures including animals, time outdoors, and types of cooking and heating fuels. Sample clustering revealed two rural groups (Rural_1 and Rural_2) that separated from the urban group (3413 and 2647 DEGs, respectively). The most significantly regulated pathways in Rural_1 children were related to innate activation of the immune system (e.g., TLR and cytokine signaling), changes in lymphocyte polarization (e.g., TH17 cells), and immune cell metabolism (i.e., oxidative phosphorylation). The Rural_2 group displayed evidence for ongoing lymphocyte activation (e.g., T cell receptor signaling), with changes in immune cell survival and proliferation (e.g., mTOR signaling, insulin signaling). CONCLUSIONS: This study highlights the importance of the exposome on immune development in early life and identifies potentially protective (e.g., animal) exposures and potentially detrimental (e.g., pollutant) exposures that impact key immunological pathways.</style></abstract><notes><style face="normal" font="default" size="100%">Lunjani, Nonhlanhla&#xD;Ambikan, Anoop T&#xD;Hlela, Carol&#xD;Levin, Michael&#xD;Mankahla, Avumile&#xD;Heldstab-Kast, Jeannette I&#xD;Boonpiyathad, Tadech&#xD;Tan, Ge&#xD;Altunbulakli, Can&#xD;Gray, Clive&#xD;Nadeau, Kari C&#xD;Neogi, Ujjwal&#xD;Akdis, Cezmi A&#xD;O&apos;Mahony, Liam&#xD;eng&#xD;12/RC/2273-P2/SFI_/Science Foundation Ireland/Ireland&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):65-79. doi: 10.1111/all.15832. Epub 2023 Aug 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37534631</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10952395</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15832</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1628</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1628</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Willis, A. L.</style></author><author><style face="normal" font="default" size="100%">Calton, J. B.</style></author><author><style face="normal" font="default" size="100%">Calton, J.</style></author><author><style face="normal" font="default" size="100%">Kim, A. S.</style></author><author><style face="normal" font="default" size="100%">Lee, R.</style></author><author><style face="normal" font="default" size="100%">Torabzadeh, E.</style></author><author><style face="normal" font="default" size="100%">Billheimer, D. D.</style></author><author><style face="normal" font="default" size="100%">Le, C. H.</style></author><author><style face="normal" font="default" size="100%">Martinez, F. D.</style></author><author><style face="normal" font="default" size="100%">Chang, E. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, University of Arizona, Tucson, AZ, USA.&#xD;The Arizona Statistical Consulting Laboratory, University of Arizona, Tucson, AZ, USA.&#xD;Asthma and Airway Disease Research Center, University of Arizona, Tucson, AZ, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">RV-C infections result in greater clinical symptoms and epithelial responses compared to RV-A infections in patients with CRS</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3264-3267</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2020/06/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinovirus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32510622</style></accession-num><notes><style face="normal" font="default" size="100%">Willis, Amanda L&#xD;Calton, Joshua B&#xD;Calton, Jaeden&#xD;Kim, Alexander S&#xD;Lee, Ray&#xD;Torabzadeh, Elmira&#xD;Billheimer, Dean D&#xD;Le, Christopher H&#xD;Martinez, Fernando D&#xD;Chang, Eugene H&#xD;eng&#xD;R01 AI146131/AI/NIAID NIH HHS/&#xD;R01 HL132523/HL/NHLBI NIH HHS/&#xD;R01 AI146131/GF/NIH HHS/&#xD;R01 HL132523/GF/NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2020 Dec;75(12):3264-3267. doi: 10.1111/all.14435. Epub 2020 Jun 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32510622</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9171905</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14435</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>865</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">865</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kessel, A.</style></author><author><style face="normal" font="default" size="100%">Bamberger, E.</style></author><author><style face="normal" font="default" size="100%">Nachshon, L.</style></author><author><style face="normal" font="default" size="100%">Rosman, Y.</style></author><author><style face="normal" font="default" size="100%">Confino-Cohen, R.</style></author><author><style face="normal" font="default" size="100%">Elizur, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy &amp; Clinical Immunology, Bnai Zion Medical Center, Haifa, Rappaport Faculty of Medicine, Technion, Haifa, Israel.&#xD;Institute of Allergy, Immunology and Pediatric Pulmonology, Yitzhak Shamir Medical Center, Zerifin, Israel.&#xD;Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel.&#xD;Allergy and Clinical Immunology Unit, Meir Medical Center, Kfar Saba, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Safe administration of the Pfizer-BioNtTech COVID-19 vaccine following an immediate reaction to the first dose</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3538-3540</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/08/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34370884</style></accession-num><notes><style face="normal" font="default" size="100%">Kessel, Aharon&#xD;Bamberger, Ellen&#xD;Nachshon, Liat&#xD;Rosman, Yossi&#xD;Confino-Cohen, Ronit&#xD;Elizur, Arnon&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3538-3540. doi: 10.1111/all.15038. Epub 2021 Aug 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34370884</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441877</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15038</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2810</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2810</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arzt-Gradwohl, L.</style></author><author><style face="normal" font="default" size="100%">Cerpes, U.</style></author><author><style face="normal" font="default" size="100%">Schadelbauer, E.</style></author><author><style face="normal" font="default" size="100%">Schoffl, C.</style></author><author><style face="normal" font="default" size="100%">Herzog, S. A.</style></author><author><style face="normal" font="default" size="100%">Schrautzer, C.</style></author><author><style face="normal" font="default" size="100%">Bokanovic, D.</style></author><author><style face="normal" font="default" size="100%">Koch, L.</style></author><author><style face="normal" font="default" size="100%">Laipold, K.</style></author><author><style face="normal" font="default" size="100%">Binder, B.</style></author><author><style face="normal" font="default" size="100%">Sturm, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.&#xD;Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Safe and Efficient 7-Week Immunotherapy Protocol With Aluminum Hydroxide Adsorbed Bee Venom</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3424-3426</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/03/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">accelerated up-dosing protocol</style></keyword><keyword><style face="normal" font="default" size="100%">depot bee venom immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="default" size="100%">sting challenge</style></keyword><keyword><style face="normal" font="default" size="100%">systemic reaction</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Allergopharma, personal fees from Novartis, and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes-Greer, outside the submitted work. All other authors have no</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest to declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40087913</style></accession-num><notes><style face="normal" font="default" size="100%">Arzt-Gradwohl, Lisa&#xD;Cerpes, Urban&#xD;Schadelbauer, Eva&#xD;Schoffl, Clemes&#xD;Herzog, Sereina Annik&#xD;Schrautzer, Christoph&#xD;Bokanovic, Danijela&#xD;Koch, Lukas&#xD;Laipold, Karin&#xD;Binder, Barbara&#xD;Sturm, Gunter&#xD;eng&#xD;ALK Abello/&#xD;Austrian Science Fund/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3424-3426. doi: 10.1111/all.16528. Epub 2025 Mar 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40087913</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666734</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16528</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2296</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2296</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ferslew, B. C.</style></author><author><style face="normal" font="default" size="100%">Smulders, R.</style></author><author><style face="normal" font="default" size="100%">Zhu, T.</style></author><author><style face="normal" font="default" size="100%">Blauwet, M. B.</style></author><author><style face="normal" font="default" size="100%">Kusawake, T.</style></author><author><style face="normal" font="default" size="100%">Spence, A.</style></author><author><style face="normal" font="default" size="100%">Aldridge, K.</style></author><author><style face="normal" font="default" size="100%">DeBerg, H. A.</style></author><author><style face="normal" font="default" size="100%">Khosa, S.</style></author><author><style face="normal" font="default" size="100%">Wambre, E.</style></author><author><style face="normal" font="default" size="100%">Chichili, G. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Astellas Pharma Global Development Inc., Northbrook, Illinois, USA.&#xD;Astellas Pharma Inc., Tokyo, Japan.&#xD;Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Safety and immunopharmacology of ASP0892 in adults or adolescents with peanut allergy: two randomized trials</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">456-470</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/11/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Asp0892</style></keyword><keyword><style face="normal" font="default" size="100%">DNA vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">lysosomal-associated membrane protein (LAMP)</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">phase 1</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38010254</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: New treatment options with improved safety and novel mechanisms of actions are needed for patients with peanut allergy. OBJECTIVES: To evaluate the safety, tolerability, and immunogenicity of ASP0892, a peanut DNA vaccine, after intradermal (id) or intramuscular (im) administration in adult or adolescent patients with peanut allergy in two phase 1 studies. METHODS: ASP0892 or placebo was administered every 2 weeks for a total of 4 doses. The doses were 1 mg or 4 mg id or 4 mg im for adults, and 1 mg or 4 mg id for adolescents. Immunologic parameters were assessed longitudinally. RESULTS: Thirty-one adults (mean age 24.3 years, 17 males) received ASP0892 (9, 8, 8 patients for 1 mg id, 4 mg id or 4 mg im, respectively) or placebo (2 patients/group). Twenty adolescents (mean age 14.2 years, 11 males) received ASP0892 (8 patients/group) or placebo (2 patients/group). In both studies, the most common treatment-emergent adverse event (TEAE) was injection site pruritus. No deaths or treatment withdrawal were related to TEAEs. No serious TEAEs related to treatment were observed in adult or adolescent patients. ASP0892 treatment led to modest increases in allergen-specific IgG and/or IgG4 in adults (1 mg id, 4 mg im) and adolescents (1 mg id, 4 mg id). No improvements in clinical outcomes, including double-blind placebo-controlled food challenge, were found after ASP0892 treatment. CONCLUSIONS: In two phase 1 studies, ASP0892 was well tolerated with modest but not clinically relevant changes in immune responses. GOV IDENTIFIERS: NCT02851277, NCT03755713.</style></abstract><notes><style face="normal" font="default" size="100%">Ferslew, Brian C&#xD;Smulders, Ronald&#xD;Zhu, Tong&#xD;Blauwet, Mary B&#xD;Kusawake, Tomohiro&#xD;Spence, Anna&#xD;Aldridge, Kelly&#xD;DeBerg, Hannah A&#xD;Khosa, Sugandhika&#xD;Wambre, Erik&#xD;Chichili, Gurunadh R&#xD;eng&#xD;Astellas Pharma/&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):456-470. doi: 10.1111/all.15931. Epub 2023 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38010254</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15931</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2805</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2805</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buonomo, A.</style></author><author><style face="normal" font="default" size="100%">Massaro, R.</style></author><author><style face="normal" font="default" size="100%">Longhino, D.</style></author><author><style face="normal" font="default" size="100%">Aruanno, A.</style></author><author><style face="normal" font="default" size="100%">Caruso, C.</style></author><author><style face="normal" font="default" size="100%">Nucera, E.</style></author><author><style face="normal" font="default" size="100%">Gasbarrini, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, Fondazione Policlinico Universitario &quot;Agostino Gemelli&quot; IRCCS, Rome, Italy.&#xD;Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario &quot;Agostino Gemelli IRCCS&quot;, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Safety and Tolerability of a 3-h Build-Up Phase With Hymenoptera Venom Depot Extracts: Preliminary Results</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3427-3429</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/03/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">build-up phase</style></keyword><keyword><style face="normal" font="default" size="100%">hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="default" size="100%">side effects</style></keyword><keyword><style face="normal" font="default" size="100%">ultrarush venom immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40129195</style></accession-num><notes><style face="normal" font="default" size="100%">Buonomo, Alessandro&#xD;Massaro, Roberta&#xD;Longhino, David&#xD;Aruanno, Arianna&#xD;Caruso, Cristiano&#xD;Nucera, Eleonora&#xD;Gasbarrini, Antonio&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3427-3429. doi: 10.1111/all.16532. Epub 2025 Mar 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40129195</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666726</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16532</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>477</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">477</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lommatzsch, M.</style></author><author><style face="normal" font="default" size="100%">Suhling, H.</style></author><author><style face="normal" font="default" size="100%">Korn, S.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Schreiber, J.</style></author><author><style face="normal" font="default" size="100%">Bahmer, T.</style></author><author><style face="normal" font="default" size="100%">Rabe, K. F.</style></author><author><style face="normal" font="default" size="100%">Buhl, R.</style></author><author><style face="normal" font="default" size="100%">Virchow, J. C.</style></author><author><style face="normal" font="default" size="100%">Milger, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.&#xD;Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.&#xD;IKF Pneumologie, Mainz, Germany and Department of Pneumology and Respiratory Care Medicine, University of Heidelberg, Heidelberg, Germany.&#xD;Institute of Allergology, Charite, Universitatsmedizin Berlin and Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology, Berlin, Germany.&#xD;Department of Pneumonology, University Hospital, Otto-Von-Guericke-University, Magdeburg, Germany.&#xD;University Hospital Schleswig-Holstein, Campus Kiel, Internal Medicine Department I, Kiel, Germany.&#xD;LungenClinic Grosshansdorf, Grosshansdorf, Germany and University Hospital Schleswig-Holstein-Campus Kiel, Department for Internal Medicine I, Kiel, Germany.&#xD;Pulmonary Department, Mainz University Hospital, Mainz, Germany.&#xD;Department of Medicine V, University Hospital, LMU Munich, and Helmholtz Center Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2839-2843</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/05/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35585763</style></accession-num><notes><style face="normal" font="default" size="100%">Lommatzsch, Marek&#xD;Suhling, Hendrik&#xD;Korn, Stephanie&#xD;Bergmann, Karl-Christian&#xD;Schreiber, Jens&#xD;Bahmer, Thomas&#xD;Rabe, Klaus F&#xD;Buhl, Roland&#xD;Virchow, Johann Christian&#xD;Milger, Katrin&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2839-2843. doi: 10.1111/all.15379. Epub 2022 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35585763</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15379</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>364</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">364</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">De Luca, J. F.</style></author><author><style face="normal" font="default" size="100%">Awad, A.</style></author><author><style face="normal" font="default" size="100%">Vogrin, S.</style></author><author><style face="normal" font="default" size="100%">Douglas, A. P.</style></author><author><style face="normal" font="default" size="100%">Lutjen, A.</style></author><author><style face="normal" font="default" size="100%">Gordon, S. F.</style></author><author><style face="normal" font="default" size="100%">Crawford, N. W.</style></author><author><style face="normal" font="default" size="100%">Barnes, S.</style></author><author><style face="normal" font="default" size="100%">Trubiano, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, Vic., Australia.&#xD;Department of Medicine, University of Melbourne, Melbourne, Vic., Australia.&#xD;Department of Medicine, St Vincent&apos;s Hospital, University of Melbourne, Fitzroy, Vic., Australia.&#xD;Department of Allergy, Monash Health, Clayton, Vic., Australia.&#xD;Vaccine Safety and Evaluation, COVID-19 Vaccination Program, Victorian Department of Health, Melbourne, Vic., Australia.&#xD;SAEFVIC, Victorian Vaccine Safety Service, MCRI, Parkville, Vic., Australia.&#xD;Department of Paediatrics, University of Melbourne, Melbourne, Vic., Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Safety of COVID-19 vaccine challenge in patients with immediate adverse reactions to prior doses: A multi-centre cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">293-296</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/08/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">challenge</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35924675</style></accession-num><notes><style face="normal" font="default" size="100%">De Luca, Joseph F&#xD;Awad, Andrew&#xD;Vogrin, Sara&#xD;Douglas, Abby P&#xD;Lutjen, Antje&#xD;Gordon, Sally F&#xD;Crawford, Nigel W&#xD;Barnes, Sara&#xD;Trubiano, Jason A&#xD;eng&#xD;Letter&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):293-296. doi: 10.1111/all.15467. Epub 2022 Aug 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35924675</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9539178</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15467</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3122</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3122</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nalin, F.</style></author><author><style face="normal" font="default" size="100%">Olivieri, B.</style></author><author><style face="normal" font="default" size="100%">Olivieri, F.</style></author><author><style face="normal" font="default" size="100%">Olivieri, E.</style></author><author><style face="normal" font="default" size="100%">Zanotti, R.</style></author><author><style face="normal" font="default" size="100%">Tanasi, I.</style></author><author><style face="normal" font="default" size="100%">Bernardelli, A.</style></author><author><style face="normal" font="default" size="100%">Bonifacio, M.</style></author><author><style face="normal" font="default" size="100%">Norelli, F.</style></author><author><style face="normal" font="default" size="100%">Marta, G.</style></author><author><style face="normal" font="default" size="100%">Gueli, V.</style></author><author><style face="normal" font="default" size="100%">Sfriso, G.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, University Hospital, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.&#xD;Department of Medicine, University of Verona, Verona, Italy.&#xD;Medical Genetics &amp; Genomics Unit, AULSS8 Berica, Vicenza, Italy.&#xD;Section of Hematology, Department of Medicine, Verona University Hospital, Verona, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Safety of Drug Provocation Tests in Adults With and Without Clonal Mast Cell Disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default" size="100%">drug provocations test</style></keyword><keyword><style face="normal" font="default" size="100%">mastocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">tryptase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41117115</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Mastocytosis is a clonal mast cell disorder (CMD) characterized by the proliferation and accumulation of mast cells (MC) in different tissues. Anaphylaxis, resulting from massive MC activation and mediators&apos; release, is reported in 22%-49% of mastocytosis cases, with drugs being potential triggers. Proper counseling on drug safety is crucial. We aim to demonstrate that, after a careful evaluation of clinical history and allergic work-up, drug provocation tests (DPT) are a safe and effective diagnostic tool in patients with CMD. METHODS: We enrolled 104 CMD patients with a suspicion of drug hypersensitivity reactions (DHR) or without known tolerated drugs and 100 control patients with DHR. The types of DHR and the results of DPT were compared between CMD and control groups. RESULTS: In both groups, previous DHR was mostly represented by skin reactions (46.4% in CMD and 82.9% in the control group); the most involved drugs were aminopenicillins and nonsteroidal anti-inflammatory drugs (NSAIDs). We performed 250 DPTs in the CMD group and 231 in the control group; challenges were well tolerated in both groups, except for 6 skin reactions: 1 in the CMD group (1.0%) and 5 in the control group (5%). CONCLUSION: Drug challenge is a safe and effective diagnostic tool in patients with CMD. Moreover, patients that have never had adverse reactions to NSAIDs or antibiotics before the diagnosis of CMD do not need to undergo challenge tests. In contrast, patients with a history of reactions should avoid the culprit drugs and undergo DPT to identify a safe alternative drug.</style></abstract><notes><style face="normal" font="default" size="100%">Nalin, Francesca&#xD;Olivieri, Bianca&#xD;Olivieri, Francesco&#xD;Olivieri, Elisa&#xD;Zanotti, Roberta&#xD;Tanasi, Ilaria&#xD;Bernardelli, Andrea&#xD;Bonifacio, Massimiliano&#xD;Norelli, Francesca&#xD;Marta, Giorgia&#xD;Gueli, Valentina&#xD;Sfriso, Giovanna&#xD;Bonadonna, Patrizia&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Oct 21. doi: 10.1111/all.70113.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41117115</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70113</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1031</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1031</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Biedermann, T.</style></author><author><style face="normal" font="default" size="100%">Couroux, P.</style></author><author><style face="normal" font="default" size="100%">Greve, T. M.</style></author><author><style face="normal" font="default" size="100%">Makela, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergology, Technical University of Munich, Munich, Germany.&#xD;Clinical Unit Allergology, Helmholtz Zentrum Munich, German Research Center for Environmental Health GmbH, Munich, Germany.&#xD;Inflamax Research Inc, Mississauga, ON, Canada.&#xD;Global Clinical Development, ALK, Horsholm, Denmark.&#xD;Inflammatory Diseases, Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Safety of the standardized quality tree sublingual immunotherapy tablet: Pooled safety analysis of clinical trials</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3733-3742</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/04/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials, Phase II as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials, Phase III as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treatment</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pollen</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33905129</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The standardized quality (SQ) tree sublingual immunotherapy (SLIT)-tablet has recently been approved for treatment of tree pollen allergy. Healthcare workers should be provided with detailed safety data for clinical use. OBJECTIVE: To assess the tolerability and safety of the SQ tree SLIT-tablet (12 SQ-Bet) in adults and adolescents. METHODS: Safety data were pooled from three double-blinded, randomized, placebo-controlled trials (2 phase-II/1 phase-III) including adults and adolescents 12-65 years with allergic rhinitis and/or conjunctivitis treated before and during one pollen season once-daily with 12 SQ-Bet (n = 471) or placebo (n = 458): EudraCT no: 2012-000031-59; NCT02481856; EudraCT 2015-004821-15. RESULTS: The most frequently reported investigational medicinal product (IMP)-related AEs with 12 SQ-Bet were oral pruritis (39% of subjects) and throat irritation (29%). IMP-related AEs were mainly mild or moderate in severity, and the majority resolved without treatment and did not lead to treatment interruption/discontinuation. With 12 SQ-Bet, oral pruritus was more frequent among subjects with pollen food syndrome (PFS) (45%) than without PFS (29%). The 12 SQ-Bet did not seem to induce an increased risk of asthma: 7 events were reported in 7 subjects with 12 SQ-Bet and 11 in 10 subjects with placebo. No differences were seen in the risk of moderate-to-severe IMP-related AEs regardless of age, PFS status and asthma medical history. CONCLUSIONS: The 12 SQ tree SLIT-tablet was well tolerated in tree pollen allergic subjects with no major safety concerns detected. This safety profile supports daily at-home sublingual administration once the first dose is tolerated when administered under medical supervision.</style></abstract><notes><style face="normal" font="default" size="100%">Biedermann, Tilo&#xD;Couroux, Peter&#xD;Greve, Tina Maria&#xD;Makela, Mika&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3733-3742. doi: 10.1111/all.14882. Epub 2021 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33905129</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14882</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2355</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2355</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hiremath, G.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Correa, H.</style></author><author><style face="normal" font="default" size="100%">Sheng, Q.</style></author><author><style face="normal" font="default" size="100%">Rajagopala, S. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Department of Medicine, Division of Infectious Disease, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Salivary immunoinflammatory proteins identify children with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1969-1971</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/01/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Salivary Proteins and Peptides/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Saliva/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38284246</style></accession-num><notes><style face="normal" font="default" size="100%">Hiremath, Girish&#xD;Wang, Yu&#xD;Correa, Hernan&#xD;Sheng, Quanhu&#xD;Rajagopala, Seesandra V&#xD;eng&#xD;K23 DK131341/DK/NIDDK NIH HHS/&#xD;R21 AI168832/AI/NIAID NIH HHS/&#xD;5R21AI168832/GF/NIH HHS/&#xD;1K23DK131341/GF/NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1969-1971. doi: 10.1111/all.16040. Epub 2024 Jan 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38284246</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12462636</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16040</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2779</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2779</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hiremath, G.</style></author><author><style face="normal" font="default" size="100%">Codreanu, S. G.</style></author><author><style face="normal" font="default" size="100%">Sherrod, S. D.</style></author><author><style face="normal" font="default" size="100%">Tyree, R.</style></author><author><style face="normal" font="default" size="100%">Correa, H.</style></author><author><style face="normal" font="default" size="100%">Choksi, Y.</style></author><author><style face="normal" font="default" size="100%">McLean, J. A.</style></author><author><style face="normal" font="default" size="100%">Locke, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Department of Chemistry and Center for Innovative Technology, Vanderbilt University, Nashville, Tennessee, USA.&#xD;Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Salivary Metabolomic Signatures in Pediatric Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">354-358</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/12/22</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39707873</style></accession-num><notes><style face="normal" font="default" size="100%">Hiremath, Girish&#xD;Codreanu, Simona G&#xD;Sherrod, Stacy D&#xD;Tyree, Regina&#xD;Correa, Hernan&#xD;Choksi, Yash&#xD;McLean, John A&#xD;Locke, Andrea&#xD;eng&#xD;IK2 BX004648/BX/BLRD VA/&#xD;P30 DK058404/DK/NIDDK NIH HHS/&#xD;U2C-DK119886/NH/NIH HHS/&#xD;OT2-OD030544/NH/NIH HHS/&#xD;K23DK13141/NH/NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):354-358. doi: 10.1111/all.16450. Epub 2024 Dec 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39707873</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724226 declare no conflicts of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16450</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>291</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">291</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gotoh, M.</style></author><author><style face="normal" font="default" size="100%">Kurokawa, T.</style></author><author><style face="normal" font="default" size="100%">Yonekura, S.</style></author><author><style face="normal" font="default" size="100%">Okano, M.</style></author><author><style face="normal" font="default" size="100%">Maekawa, Y.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Okubo, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.&#xD;Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.&#xD;Clinical Research Center, Chiba University Hospital, Chiba, Japan.&#xD;Department of Otorhinolaryngology, International University of Health and Welfare, Chiba, Japan.&#xD;Department of Medical Affairs, Torii Pharmaceutical Co., Ltd, Tokyo, Japan.&#xD;Chiba Rousai Hospital, Chiba, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Same dose of Japanese cedar pollen sublingual immunotherapy tablets is optimal for allergic rhinitis caused by either Japanese cedar or Japanese cypress pollen</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">563-568</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/09/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Cryptomeria</style></keyword><keyword><style face="normal" font="default" size="100%">*Cupressus</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Japanese cedar</style></keyword><keyword><style face="normal" font="default" size="100%">Japanese cypress</style></keyword><keyword><style face="normal" font="default" size="100%">cross-reactivity</style></keyword><keyword><style face="normal" font="default" size="100%">homologous</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hisamitsu, Meiji Seika Pharma, and Novartis. TK received consulting fees and</style></keyword><keyword><style face="normal" font="default" size="100%">honoraria from Torii. SY received grants from Thermo Fisher Diagnostic, Japan,</style></keyword><keyword><style face="normal" font="default" size="100%">and Kyowa Kirin, Japan</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Torii</style></keyword><keyword><style face="normal" font="default" size="100%">and honoraria from Torii,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis Pharma, Sanofi, Kyorin, Mitsubishi Tanabe, Hisamitsu, Taiho, and Meiji</style></keyword><keyword><style face="normal" font="default" size="100%">Seika Pharma. MO received consulting fees from Torii and honoraria from Torii,</style></keyword><keyword><style face="normal" font="default" size="100%">Mitsubishi Tanabe, Taiho, Sanofi, and Novartis. YO received consulting fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Torii and honoraria from Torii, Mitsubishi Tanabe, Taiho, Shionogi, Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Kirin, and Kyorin. KO received consulting fees and honoraria from Torii.</style></keyword><keyword><style face="normal" font="default" size="100%">YM is employed by Torii.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36106517</style></accession-num><notes><style face="normal" font="default" size="100%">Gotoh, Minoru&#xD;Kurokawa, Tomoya&#xD;Yonekura, Syuji&#xD;Okano, Mitsuhiro&#xD;Maekawa, Yuriko&#xD;Okamoto, Yoshitaka&#xD;Okubo, Kimihiro&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):563-568. doi: 10.1111/all.15514. Epub 2022 Sep 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36106517</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10086994</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15514</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>379</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">379</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jeong, J. S.</style></author><author><style face="normal" font="default" size="100%">Choi, J. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, J. S.</style></author><author><style face="normal" font="default" size="100%">Park, S. O.</style></author><author><style face="normal" font="default" size="100%">Kim, W.</style></author><author><style face="normal" font="default" size="100%">Yoon, Y. G.</style></author><author><style face="normal" font="default" size="100%">Park, H. J.</style></author><author><style face="normal" font="default" size="100%">Park, K. H.</style></author><author><style face="normal" font="default" size="100%">Kim, D. H.</style></author><author><style face="normal" font="default" size="100%">Kim, J. M.</style></author><author><style face="normal" font="default" size="100%">Koh, G. Y.</style></author><author><style face="normal" font="default" size="100%">Eo, S. K.</style></author><author><style face="normal" font="default" size="100%">Lee, Y. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Research Center for Pulmonary Disorders, Jeonbuk National University Medical School, Jeonju, South Korea.&#xD;Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, South Korea.&#xD;College of Veterinary Medicine and Zoonosis Research Institute, Jeonbuk National University, Iksan, South Korea.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, Jeonbuk National University Medical School, Jeonju, South Korea.&#xD;Department of Medical Informatics, Jeonbuk National University Medical School, Jeonju, South Korea.&#xD;Department of Life Sciences, Ewha Womans University, Seoul, South Korea.&#xD;Kaipharm, Seoul, South Korea.&#xD;National Health Insurance Service (NHIS), Wonju, South Korea.&#xD;Basgenbio Inc., Seoul, South Korea.&#xD;Center for Vascular Research, Institute for Basic Science (IBS), Daejeon, South Korea.&#xD;Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">SARS-CoV-2 infection in severe asthma is associated with worsening of COVID-19 through respiratory NLRP3 inflammasome activation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">287-290</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/07/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammasomes</style></keyword><keyword><style face="normal" font="default" size="100%">NLR Family, Pyrin Domain-Containing 3 Protein</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/complications/diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35871401</style></accession-num><notes><style face="normal" font="default" size="100%">Jeong, Jae Seok&#xD;Choi, Jin Young&#xD;Kim, Jong Seung&#xD;Park, Seong Ok&#xD;Kim, Wankyu&#xD;Yoon, Yeo-Gha&#xD;Park, Hae Jin&#xD;Park, Kyung Hwa&#xD;Kim, Doo Hwan&#xD;Kim, Jung Mo&#xD;Koh, Gou Young&#xD;Eo, Seong Kug&#xD;Lee, Yong Chul&#xD;eng&#xD;Comment&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):287-290. doi: 10.1111/all.15452. Epub 2022 Aug 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35871401</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9349818</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15452</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1384</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1384</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Wu, J.</style></author><author><style face="normal" font="default" size="100%">Renert-Yuval, Y.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Glickman, J. W.</style></author><author><style face="normal" font="default" size="100%">Miller, R. L.</style></author><author><style face="normal" font="default" size="100%">Paller, A. S.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Biomedical Engineering, University of Mississippi, Oxford, MS, USA.&#xD;State University of New York Downstate Medical Center, College of Medicine, Brooklyn, NY, USA.&#xD;Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.&#xD;Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.&#xD;Department of Medicine, Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">SARS-CoV-2 receptor ACE2 protein expression in serum is significantly associated with age</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">875-878</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/07/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cathepsin L/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatitis, Atopic/enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Coronavirus/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Ace2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Olink</style></keyword><keyword><style face="normal" font="default" size="100%">adults</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">Miller have nothing to disclose. Dr Paller reports grants from AbbVie,</style></keyword><keyword><style face="normal" font="default" size="100%">AnaptysBio, Celgene, Eli Lilly, Galderma, Incyte, Leo, Janssen, Novartis, and</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">and other from Almirall, Amgen,</style></keyword><keyword><style face="normal" font="default" size="100%">Asana, Boehringer Ingelheim, Castle Creek, Celgene, Dermavant, Dermira, Eli</style></keyword><keyword><style face="normal" font="default" size="100%">Lilly, Exicure, Forte, Galderma, Lenus, Leo, MEDACorp, Meiji Seika, Novan,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sol-Gel, and UCB, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. Dr Krueger reports grants and personal fees from Pfizer, Amgen,</style></keyword><keyword><style face="normal" font="default" size="100%">Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa,</style></keyword><keyword><style face="normal" font="default" size="100%">BMS, Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Parexel, Xenoport, and</style></keyword><keyword><style face="normal" font="default" size="100%">Kineta, during the conduct of the study. Dr Guttman-Yassky reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">AbbVie, Celgene, Eli Lilly, Janssen, MedImmune/Astra Zeneca, Novartis, Pfizer,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, and UCB, during</style></keyword><keyword><style face="normal" font="default" size="100%">the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">and other from Sanofi Aventis, Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira,</style></keyword><keyword><style face="normal" font="default" size="100%">Galderma, Glenmark, Novartis, Pfizer, Vitae, LEO Pharma, AbbVie, Eli Lilly,</style></keyword><keyword><style face="normal" font="default" size="100%">Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius, outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32726474</style></accession-num><notes><style face="normal" font="default" size="100%">Pavel, Ana B&#xD;Wu, Jianni&#xD;Renert-Yuval, Yael&#xD;Del Duca, Ester&#xD;Glickman, Jacob W&#xD;Miller, Rachel L&#xD;Paller, Amy S&#xD;Krueger, James G&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;R21 ES029607/ES/NIEHS NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):875-878. doi: 10.1111/all.14522. Epub 2020 Aug 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32726474</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8278339</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14522</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1400</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1400</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Novak, N.</style></author><author><style face="normal" font="default" size="100%">Peng, W.</style></author><author><style face="normal" font="default" size="100%">Naegeli, M. C.</style></author><author><style face="normal" font="default" size="100%">Galvan, C.</style></author><author><style face="normal" font="default" size="100%">Kolm-Djamei, I.</style></author><author><style face="normal" font="default" size="100%">Bruggen, C.</style></author><author><style face="normal" font="default" size="100%">Cabanillas, B.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Catala, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University Zurich, Zurich, Switzerland.&#xD;Department of Dermatology and Venereology, Mostoles Hospital, Madrid, Spain.&#xD;Hochgebirgsklinik Davos, Davos, Switzerland.&#xD;Department of Dermatology and Venereology, Plato Hospital, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">SARS-CoV-2, COVID-19, skin and immunology - What do we know so far?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">698-713</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*complications/immunology/pathology/transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Diseases/*etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32658359</style></accession-num><abstract><style face="normal" font="default" size="100%">The pandemic condition coronavirus disease (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can take asymptomatic, mild, moderate, and severe courses. COVID-19 affects primarily the respiratory airways leading to dry cough, fever, myalgia, headache, fatigue, and diarrhea and can end up in interstitial pneumonia and severe respiratory failure. Reports about the manifestation of various skin lesions and lesions of the vascular system in some subgroups of SARS-CoV-2-positive patients as such features outside the respiratory sphere, are rapidly emerging. Vesicular, urticarial, and maculopapular eruptions and livedo, necrosis, and other vasculitis forms have been reported most frequently in association with SARS-CoV-2 infection. In order to update information gained, we provide a systematic overview of the skin lesions described in COVID-19 patients, discuss potential causative factors, and describe differential diagnostic evaluations. Moreover, we summarize current knowledge about immunologic, clinical, and histologic features of virus- and drug-induced lesions of the skin and changes to the vascular system in order to transfer this knowledge to potential mechanisms induced by SARS-CoV-2.</style></abstract><notes><style face="normal" font="default" size="100%">Novak, Natalijia&#xD;Peng, Wenming&#xD;Naegeli, Mirjam C&#xD;Galvan, Christina&#xD;Kolm-Djamei, Isabel&#xD;Bruggen, Charlotte&#xD;Cabanillas, Beatriz&#xD;Schmid-Grendelmeier, Peter&#xD;Catala, Alba&#xD;eng&#xD;EXC2151/Deutsche Forschungsgemeinschaft/&#xD;390873048/Deutsche Forschungsgemeinschaft/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):698-713. doi: 10.1111/all.14498. Epub 2020 Aug 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32658359</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7404682</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14498</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>247</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">247</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Renert-Yuval, Y.</style></author><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Facheris, P.</style></author><author><style face="normal" font="default" size="100%">Pagan, A. D.</style></author><author><style face="normal" font="default" size="100%">Bose, S.</style></author><author><style face="normal" font="default" size="100%">Gomez-Arias, P. J.</style></author><author><style face="normal" font="default" size="100%">Angelov, M.</style></author><author><style face="normal" font="default" size="100%">Bares, J.</style></author><author><style face="normal" font="default" size="100%">Chima, M.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y. D.</style></author><author><style face="normal" font="default" size="100%">Garcet, S.</style></author><author><style face="normal" font="default" size="100%">Lebwohl, M. G.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Laboratory for Investigative Dermatology, Rockefeller University, New York, New York, USA.&#xD;Department of Dermatology, University of Magna Graecia, Catanzaro, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1047-1059</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2022/10/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Alopecia Areata/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Scalp/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Keratins, Hair-Specific/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Virulence</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">Asana Bioscience, Celgene, Concert, Dermira, DS Biopharma, Escalier, Galderma,</style></keyword><keyword><style face="normal" font="default" size="100%">Glenmark, Kyowa Kirin, LEO Pharmaceuticals, Lilly, Mitsubishi Tanabe, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, Regeneron, Sanofi, and Union Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">a member of advisory boards of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergan, Asana Bioscience, Celgene, DBV, Dermavant, Dermira, Escalier, Galderma,</style></keyword><keyword><style face="normal" font="default" size="100%">Glenmark, Kyowa Kirin, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, and</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">and a recipient of research grants from AbbVie, AnaptysBio, AntibioTx,</style></keyword><keyword><style face="normal" font="default" size="100%">Asana Bioscience, Boehringer-Ingelheim, Celgene, DBV, Dermavant, DS Biopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Galderma, Glenmark, Innovaderm, Janssen Biotech, Kiniska Pharma, LEO</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Lilly, Medimmune, Sienna Biopharmaceuticals, Novan, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Ralexar, Regeneron, Pfizer, UCB, and Union Therapeutics. MGL is an employee of</style></keyword><keyword><style face="normal" font="default" size="100%">Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Avotres,</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, Cara therapeutics, Dermavant Sciences, Eli Lilly, Incyte,</style></keyword><keyword><style face="normal" font="default" size="100%">Janssen Research &amp; Development, LLC, Ortho Dermatologics, Regeneron, and UCB,</style></keyword><keyword><style face="normal" font="default" size="100%">Inc., and is a consultant for Aditum Bio, Almirall, AltruBio Inc., AnaptysBio,</style></keyword><keyword><style face="normal" font="default" size="100%">Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">BiomX, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences,</style></keyword><keyword><style face="normal" font="default" size="100%">Evommune, Inc., Facilitatation of International Dermatology Education, Forte</style></keyword><keyword><style face="normal" font="default" size="100%">Biosciences, Foundation for Research and Education in Dermatology, Hexima Ltd.,</style></keyword><keyword><style face="normal" font="default" size="100%">LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, Trevi, and Verrica.</style></keyword><keyword><style face="normal" font="default" size="100%">JGK has received grants paid to The Rockefeller University from Amgen, Boehringer</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, Bristol Myers Squibb, Dermira, Innovaderm, Janssen, Kadmon, Kineta,</style></keyword><keyword><style face="normal" font="default" size="100%">Kyowa, LEO Pharma, Lilly, Novartis, Paraxel, Pfizer, Provectus, Regeneron, and</style></keyword><keyword><style face="normal" font="default" size="100%">Vitae and personal fees from AbbVie, Baxter, Biogen Idec, Boehringer Ingelheim,</style></keyword><keyword><style face="normal" font="default" size="100%">Bristol Myers Squibb, Delenex, Dermira, Janssen, Kadmon, Kineta, Lilly, Merck,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Pfizer, Sanofi, Serono, and XenoPort. All other authors declare no</style></keyword><keyword><style face="normal" font="default" size="100%">competing interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36271804</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The mechanisms driving alopecia areata (AA) are still unclear, hindering development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides a unique opportunity to dissect its pathogenesis and explore the role of Th2 pathway. METHODS: We evaluated changes in scalp biomarkers in AA patients (with and without concomitant atopy) randomized to weekly dupilumab or placebo for 24 weeks, followed by open-label dupilumab for 24 weeks. Changes in biomarker levels were measured at weeks 12, 24, and 48 and were also correlated with clinical hair regrowth. RESULTS: At week 24, preceding clinical hair regrowth outcomes, only dupilumab-treated patients presented significant suppression of cellular infiltrates, and multiple Th2-related, markers (CCL13/MCP-4, CCL18/PARC, CCL26/eotaxin-3, CCL24/Eotaxin-2), coupled with significant upregulation in the hair keratins. Th1-related suppression was evident later (week 48) when all patients received open-label dupilumab. Results were more pronounced in atopic AA patients, that showed 48% and 97% improvements in the lesional AA scalp profile at weeks 24 and 48, respectively, while 2% worsening was seen in the placebo arm at week 24. Moreover, placebo-treated patients presented 54% worsening in hair keratins when compared with baseline at week 24. At week 24, increases in hair keratins showed significant correlations only with decreases in Th2-related markers. CONCLUSIONS: Scalp biomarkers provide evidence of dupilumab efficacy in AA, detected even prior to clinical response, with exclusive correlations between early suppression of Th2 markers and increased hair keratins. These findings strengthen previous reports suggesting a possible role for Th2 cytokines as AA drivers.</style></abstract><notes><style face="normal" font="default" size="100%">Renert-Yuval, Yael&#xD;Pavel, Ana B&#xD;Del Duca, Ester&#xD;Facheris, Paola&#xD;Pagan, Angel D&#xD;Bose, Swaroop&#xD;Gomez-Arias, Pedro J&#xD;Angelov, Michael&#xD;Bares, Jennifer&#xD;Chima, Margo&#xD;Estrada, Yeriel D&#xD;Garcet, Sandra&#xD;Lebwohl, Mark G&#xD;Krueger, James G&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;UL1 TR001866/TR/NCATS NIH HHS/&#xD;Randomized Controlled Trial&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):1047-1059. doi: 10.1111/all.15561. Epub 2022 Nov 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36271804</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11344221</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15561</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>457</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">457</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Franke, K.</style></author><author><style face="normal" font="default" size="100%">Kirchner, M.</style></author><author><style face="normal" font="default" size="100%">Mertins, P.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Babina, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology IA, Berlin, Germany.&#xD;Core Unit Proteomics, Berlin Institute of Health at Charite- Universitatsmedizin Berlin and Max Delbruck Center for Molecular Medicine (MDC), Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The SCF/KIT axis in human mast cells: Capicua acts as potent KIT repressor and ERK predominates PI3K</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3337-3349</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/06/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Chromatography, Liquid</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mitogen-Activated Protein Kinase Kinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphatidylinositol 3-Kinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-kit/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Stem Cell Factor/pharmacology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">Extracellular Signal-Regulated MAP Kinases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Kit</style></keyword><keyword><style face="normal" font="default" size="100%">RTKs</style></keyword><keyword><style face="normal" font="default" size="100%">capicua</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">signal transduction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35652819</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The SCF/KIT axis regulates nearly all aspects of mast cell (MC) biology. A comprehensive view of SCF-triggered phosphorylation dynamics is lacking. The relationship between signaling modules and SCF-supported functions likewise remains ill-defined. METHODS: Mast cells were isolated from human skin; upon stimulation by SCF, global phosphoproteomic changes were analyzed by LC-MS/MS and selectively validated by immunoblotting. MC survival was inspected by YoPro; BrdU incorporation served to monitor proliferation. Gene expression was quantified by RT-qPCR and cytokines by ELISA. Pharmacological inhibitors were supplemented by ERK1 and/or ERK2 knockdown. CIC translocation and degradation were studied in nuclear and cytoplasmic fractions. CIC&apos;s impact on KIT signaling and function was assessed following RNA interference. RESULTS: approximately 5400 out of approximately 10,500 phosphosites experienced regulation by SCF. The MEK/ERK cascade was strongly induced surpassing STAT5 &gt; PI3K/Akt &gt; p38 &gt; JNK. Comparison between MEK/ERK&apos;s and PI3K&apos;s support of basic programs (apoptosis, proliferation) revealed equipotency between modules. In functional outputs (gene expression, cytokines), ERK was the most influential kinase. OSM and LIF production was identified in skin MCs. Strikingly, SCF triggered massive phosphorylation of a protein not associated with KIT previously: CIC. Phosphorylation was followed by CIC&apos;s cytoplasmic appearance and degradation, the latter sensitive to protease but not preoteasome inhibition. Both shuttling and degradation were ERK-dependent. Conversely, CIC-siRNA facilitated KIT signaling, functional outputs, and survival. CONCLUSION: The SCF/KIT axis shows notable strength in MCs, and MEK/ERK as most prominent module. An inhibitory circuit exists between KIT and CIC. CIC stabilization in MCs may turn out as a therapeutic option to interfere with allergic and MC-driven diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Franke, Kristin&#xD;Kirchner, Marieluise&#xD;Mertins, Philipp&#xD;Zuberbier, Torsten&#xD;Babina, Magda&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3337-3349. doi: 10.1111/all.15396. Epub 2022 Jun 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35652819</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15396</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>328</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">328</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koskinen, A.</style></author><author><style face="normal" font="default" size="100%">Lemmetyinen, R.</style></author><author><style face="normal" font="default" size="100%">Luukkainen, A.</style></author><author><style face="normal" font="default" size="100%">Kankaanranta, H.</style></author><author><style face="normal" font="default" size="100%">Ilmarinen, P.</style></author><author><style face="normal" font="default" size="100%">Karjalainen, J.</style></author><author><style face="normal" font="default" size="100%">Pekkanen, J.</style></author><author><style face="normal" font="default" size="100%">Huhtala, H.</style></author><author><style face="normal" font="default" size="100%">Haukka, J.</style></author><author><style face="normal" font="default" size="100%">But, A.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Inflammation Center, Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Public Health, University of Helsinki, Helsinki, Finland.&#xD;Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Respiratory Medicine, Seinajoki Central Hospital, Seinajoki, Finland.&#xD;Department of Internal Medicine and Clinical Nutrition, Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.&#xD;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.&#xD;Allergy Centre, Tampere University Hospital, Tampere, Finland.&#xD;Environmental Health, National Institute for Health and Welfare, Kuopio, Finland.&#xD;Faculty of Social Sciences, Tampere University, Tampere, Finland.&#xD;Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Haartman Institute, Medicum, University of Helsinki, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Season of birth affects the risk of adult-onset asthma in Finland</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">555-558</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/09/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Finland/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Seasons</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36067009</style></accession-num><notes><style face="normal" font="default" size="100%">Koskinen, Anni&#xD;Lemmetyinen, Riikka&#xD;Luukkainen, Annika&#xD;Kankaanranta, Hannu&#xD;Ilmarinen, Pinja&#xD;Karjalainen, Jussi&#xD;Pekkanen, Juha&#xD;Huhtala, Heini&#xD;Haukka, Jari&#xD;But, Anna&#xD;Toppila-Salmi, Sanna&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):555-558. doi: 10.1111/all.15504. Epub 2022 Sep 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36067009</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087432 and Roche Products outside the submitted work, as well as grant of GSK outside the current work. JK reports personal fees for consultancies or lectures from AstraZeneca, Boehringer-Ingelheim, Chiesi Pharma, GSK, MSD, Novartis, Orion Pharma, and SanofiGenzyme outside the current work. HK reports personal fees for consultancies or lectures from AstraZeneca, Boehringer-Ingelheim, Chiesi Pharma, GSK, MSD, Novartis, Orion Pharma, and SanofiGenzyme outside the current work. PI is an employee of GSK. All other authors report no conflicts of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15504</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>418</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">418</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sans-De San Nicolas, L.</style></author><author><style face="normal" font="default" size="100%">Figueras-Nart, I.</style></author><author><style face="normal" font="default" size="100%">Bonfill-Orti, M.</style></author><author><style face="normal" font="default" size="100%">De Jesus-Gil, C.</style></author><author><style face="normal" font="default" size="100%">Garcia-Jimenez, I.</style></author><author><style face="normal" font="default" size="100%">Guilabert, A.</style></author><author><style face="normal" font="default" size="100%">Curto-Barredo, L.</style></author><author><style face="normal" font="default" size="100%">Bertolin-Colilla, M.</style></author><author><style face="normal" font="default" size="100%">Ferran, M.</style></author><author><style face="normal" font="default" size="100%">Serra-Baldrich, E.</style></author><author><style face="normal" font="default" size="100%">Zalewska-Janowska, A.</style></author><author><style face="normal" font="default" size="100%">Wang, Y. H.</style></author><author><style face="normal" font="default" size="100%">Howell, M. D.</style></author><author><style face="normal" font="default" size="100%">Pujol, R. M.</style></author><author><style face="normal" font="default" size="100%">Santamaria-Babi, L. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Grup d&apos;Immunologia Translacional, Departament de Biologia Cel.lular, Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona (UB), Parc Cientific de Barcelona (PCB), Barcelona, Spain.&#xD;Departament de Dermatologia, Hospital de Bellvitge, Universitat de Barcelona (UB), L&apos;Hospitalet de Llobregat, Spain.&#xD;Departament de Dermatologia, Hospital General de Granollers, Granollers, Spain.&#xD;Departament de Dermatologia, Hospital del Mar, Institut Hospital del Mar d&apos;Investigacions Meditques (IMIM), Universitat Autonoma de Barcelona (UAB), Barcelona, Spain.&#xD;Departament de Dermatologia, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona (UAB), Barcelona, Spain.&#xD;Psychodermatology Department, Rheumatology and Clinical Immunology, Medical University of Lodz, Lodz, Poland.&#xD;Division of Allergy and Immunology, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Type 2 Inflammation and Fibrosis Cluster, Immunology and Inflammation Research, Sanofi, Cambridge, Massachusetts, USA.&#xD;DermTech, Inc, La Jolla, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3448-3451</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Memory T Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Enterotoxins/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Th1 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35773619</style></accession-num><notes><style face="normal" font="default" size="100%">Sans-De San Nicolas, Lidia&#xD;Figueras-Nart, Ignasi&#xD;Bonfill-Orti, Montserrat&#xD;De Jesus-Gil, Carmen&#xD;Garcia-Jimenez, Irene&#xD;Guilabert, Antonio&#xD;Curto-Barredo, Laia&#xD;Bertolin-Colilla, Marta&#xD;Ferran, Marta&#xD;Serra-Baldrich, Esther&#xD;Zalewska-Janowska, Anna&#xD;Wang, Yui-Hsi&#xD;Howell, Michael D&#xD;Pujol, Ramon M&#xD;Santamaria-Babi, Luis F&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3448-3451. doi: 10.1111/all.15424. Epub 2022 Jul 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35773619</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15424</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>49</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">49</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hartley, G. E.</style></author><author><style face="normal" font="default" size="100%">Edwards, E. S. J.</style></author><author><style face="normal" font="default" size="100%">Varese, N.</style></author><author><style face="normal" font="default" size="100%">Boo, I.</style></author><author><style face="normal" font="default" size="100%">Aui, P. M.</style></author><author><style face="normal" font="default" size="100%">Bornheimer, S. J.</style></author><author><style face="normal" font="default" size="100%">Hogarth, P. M.</style></author><author><style face="normal" font="default" size="100%">Drummer, H. E.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">van Zelm, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy and Clinical Immunology Laboratory, Department of Immunology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.&#xD;Viral Entry and Vaccines Group, Burnet Institute, Melbourne, Victoria, Australia.&#xD;BD Biosciences, San Jose, California, USA.&#xD;Immune Therapies Group, Burnet Institute, Melbourne, Victoria, Australia.&#xD;Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.&#xD;Department of Microbiology, Monash University, Clayton, Victoria, Australia.&#xD;Allergy, Asthma and Clinical Immunology Service, Alfred Hospital, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The second COVID-19 mRNA vaccine dose enhances the capacity of Spike-specific memory B cells to bind Omicron BA.2</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">855-858</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/12/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Memory B Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Neutralizing</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA Vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36541822</style></accession-num><notes><style face="normal" font="default" size="100%">Hartley, Gemma E&#xD;Edwards, Emily S J&#xD;Varese, Nirupama&#xD;Boo, Irene&#xD;Aui, Pei M&#xD;Bornheimer, Scott J&#xD;Hogarth, P Mark&#xD;Drummer, Heidi E&#xD;O&apos;Hehir, Robyn E&#xD;van Zelm, Menno C&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):855-858. doi: 10.1111/all.15624. Epub 2022 Dec 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36541822</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9877979 SJB is an employee of and owns stock in BD Biosciences. All the other authors declare no conflict of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15624</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3144</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3144</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Burris, A. D.</style></author><author><style face="normal" font="default" size="100%">Diaz, N.</style></author><author><style face="normal" font="default" size="100%">Meddings, J. B.</style></author><author><style face="normal" font="default" size="100%">Karmakar, B.</style></author><author><style face="normal" font="default" size="100%">Keswani, T.</style></author><author><style face="normal" font="default" size="100%">Patil, S. U.</style></author><author><style face="normal" font="default" size="100%">Seppo, A. E.</style></author><author><style face="normal" font="default" size="100%">Jarvinen, K. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Allergy and Immunology, Department of Pediatrics, University of Rochester Medical Center, Rochester, New York, USA.&#xD;Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.&#xD;Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Harvard Medical School, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Secretion of Peanut Protein With IgE Crosslinking Capacity in Human Milk</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Ara h 2</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">breast milk</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">human milk</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41035191</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Human milk provides an infant one of the first routes of exposure to dietary antigens. A better understanding of the levels and functional capacity of maternal dietary proteins in human milk (HM) and their impact on infant food allergy (FA) is needed. OBJECTIVE: To measure the quantity and biologic activity of maternal dietary proteins in HM and determine factors associated with their presence. METHODS: HM samples from mothers of infants with or without FA were collected before and serially after consumption of a meal with prespecified amounts of peanut, egg, and cow&apos;s milk protein. Ara h 2 from peanut, egg ovalbumin, and bovine beta-lactoglobulin in HM was detected using ELISA. IgE-crosslinking capacity of Ara h 2 was assessed by the basophil activation test (BAT). Maternal intestinal permeability was measured with the lactulose/mannitol test. RESULTS: Thirty-nine mothers were included and 69% had measurable Ara h 2 in HM. Secretion of food allergens was variable between different mothers and across allergens, but did not correlate with intestinal permeability. Atopic mothers&apos; milk had a higher peak Ara h 2 concentration (median 246 pg/mL, range 2.0-1634) than nonatopic mothers (median 0 pg/mL, range 0-135, p = 0.017). In samples with the most BAT reactivity, there was a significant correlation between BAT reactivity and Ara h 2 level (R = 0.72, p = 2 x 10(-8)). Multiple monoclonal antibodies directed at different epitopes detected Ara h 2 at similar levels. CONCLUSION: Ara h 2 is secreted in HM as intact protein or significant parts of it that are capable of IgE-crosslinking, found in higher levels in atopic mothers. HM levels of peanut lack correlation with other dietary proteins, which suggests antigen specificity of the secretion of dietary protein into HM.</style></abstract><notes><style face="normal" font="default" size="100%">Burris, Amy D&#xD;Diaz, Nichole&#xD;Meddings, Jon B&#xD;Karmakar, Bijoya&#xD;Keswani, Tarun&#xD;Patil, Sarita U&#xD;Seppo, Antti E&#xD;Jarvinen, Kirsi M&#xD;eng&#xD;U01AI131344/National Institute of Allergy and Infectious Diseases/&#xD;R01AI163571/National Institute of Allergy and Infectious Diseases/&#xD;1R01AI155630/National Institute of Allergy and Infectious Diseases/&#xD;R03 AI151965/AI/NIAID NIH HHS/&#xD;1R01AI182001/National Institute of Allergy and Infectious Diseases/&#xD;Food Allergy Science Initiative (FASI)/&#xD;Denmark&#xD;Allergy. 2025 Oct 1. doi: 10.1111/all.70066.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41035191</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70066</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>873</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">873</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mootz, M.</style></author><author><style face="normal" font="default" size="100%">Jakwerth, C. A.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Zissler, U. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Allergy &amp; Environment (ZAUM), Technical University of Munich (TUM) and Helmholtz Center Munich, German Research Center for Environmental Health (HMGU), Munich, Germany.&#xD;Member of the German Center of Lung Research (DZL), CPC-M, Munich, Germany.&#xD;Technical University of Munich (TUM), TUM School of Medicine, Klinikum Rechts der Isar, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Secretoglobins in the big picture of immunoregulation in airway diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">767-777</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/08/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">Secretoglobins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Scgb1a1</style></keyword><keyword><style face="normal" font="default" size="100%">Secretoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">Th1</style></keyword><keyword><style face="normal" font="default" size="100%">Th2</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34343347</style></accession-num><abstract><style face="normal" font="default" size="100%">The proteins of the secretoglobin (SCGB) family are expressed by secretory tissues of barrier organs. They are embedded in immunoregulatory and anti-inflammatory processes of airway diseases. This review particularly illustrates the immune regulation of SCGBs by cytokines and their implication in the pathophysiology of airway diseases. The biology of SCGBs is a complex topic of increasing importance, as they are highly abundant in the respiratory tract and can also be detected in malignant tissues and as elements of immune control. In addition, SCGBs react to cytokines, they are embedded in Th1 and Th2 immune responses, and they are expressed in a manner dependent on cell maturation. The big picture of the SCGB family identifies these factors as critical elements of innate immune control at the epithelial barriers and highlights their potential for diagnostic assessment of epithelial activity. Some members of the SCGB family have so far only been superficially examined, but have high potential for translational research.</style></abstract><notes><style face="normal" font="default" size="100%">Mootz, Martine&#xD;Jakwerth, Constanze A&#xD;Schmidt-Weber, Carsten B&#xD;Zissler, Ulrich M&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):767-777. doi: 10.1111/all.15033. Epub 2021 Aug 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34343347</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15033</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>453</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">453</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McGrath, J. J. C.</style></author><author><style face="normal" font="default" size="100%">Cass, S. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Drukier Institute for Children&apos;s Health, Weill Cornell Medicine, New York, New York, USA.&#xD;Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA.&#xD;Peter Gorer Department of Immunobiology, Faculty of Life Sciences &amp; Medicine, King&apos;s College London, London, UK.&#xD;School of Immunology &amp; Microbial Sciences, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Secretory RAS cells: A novel AT2 progenitor in the human transitional bronchioles</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2866-2868</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/06/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Bronchioles</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Alveoli</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35665940</style></accession-num><notes><style face="normal" font="default" size="100%">McGrath, Joshua J C&#xD;Cass, Steven P&#xD;eng&#xD;Comment&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2866-2868. doi: 10.1111/all.15402. Epub 2022 Jun 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35665940</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15402</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1536</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1536</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McGrath, J. J. C.</style></author><author><style face="normal" font="default" size="100%">Cass, S. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Drukier Institute for Children&apos;s Health, Weill Cornell Medicine, New York, New York, USA.&#xD;Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA.&#xD;Peter Gorer Department of Immunobiology, Faculty of Life Sciences &amp; Medicine, King&apos;s College London, London, UK.&#xD;School of Immunology &amp; Microbial Sciences, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Secretory RAS cells: A novel AT2 progenitor in the human transitional bronchioles</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2866-2868</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/06/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Bronchioles</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Alveoli</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35665940</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract -</style></abstract><notes><style face="normal" font="default" size="100%">McGrath, Joshua J C&#xD;Cass, Steven P&#xD;eng&#xD;Comment&#xD;News&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2866-2868. doi: 10.1111/all.15402. Epub 2022 Jun 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35665940</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15402</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>382</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">382</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, A.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Guan, J.</style></author><author><style face="normal" font="default" size="100%">Huang, Y.</style></author><author><style face="normal" font="default" size="100%">Xie, H.</style></author><author><style face="normal" font="default" size="100%">Chen, H.</style></author><author><style face="normal" font="default" size="100%">Wen, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Q.</style></author><author><style face="normal" font="default" size="100%">Xie, S.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Ou, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, Q.</style></author><author><style face="normal" font="default" size="100%">Tao, A.</style></author><author><style face="normal" font="default" size="100%">Yan, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Second Affiliated Hospital, The State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Allergy &amp; Clinical Immunology, Sino-French Hoffmann Institute, Guangzhou Medical University, Guangzhou, China.&#xD;Department of Plastic and Reconstructive Surgery, Center for Medical and Engineering Innovation, Central Laboratory, Ningbo First Hospital, Ningbo, China.&#xD;Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Selective eosinophil necroptosis contributes to airway inflammation and remodeling in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3456-3459</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Necroptosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Airway Remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35855664</style></accession-num><notes><style face="normal" font="default" size="100%">He, Andong&#xD;Chen, Jiaqian&#xD;Guan, Jieying&#xD;Huang, Yuye&#xD;Xie, Huancheng&#xD;Chen, Honglv&#xD;Wen, Yuhuan&#xD;Chen, Qile&#xD;Xie, Shiyun&#xD;Li, Haoyang&#xD;Ou, Changxing&#xD;Zhang, Qingling&#xD;Tao, Ailin&#xD;Yan, Jie&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3456-3459. doi: 10.1111/all.15448. Epub 2022 Jul 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35855664</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15448</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3263</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3263</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Williams, Thomas J.</style></author><author><style face="normal" font="default" size="100%">Griffiths, James S.</style></author><author><style face="normal" font="default" size="100%">Gonzales-Huerta, Luis E.</style></author><author><style face="normal" font="default" size="100%">Bell, David</style></author><author><style face="normal" font="default" size="100%">Reed, Anna K.</style></author><author><style face="normal" font="default" size="100%">Shah, Anand</style></author><author><style face="normal" font="default" size="100%">Naglik, Julian R.</style></author><author><style face="normal" font="default" size="100%">Armstrong-James, Darius</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Selective Targeting of IL-1RAP-Dependent Eosinophilic Inflammation in Allergic Fungal Airway Disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70256</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70256</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>521</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">521</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, X.</style></author><author><style face="normal" font="default" size="100%">Blokhuis, B. R. J.</style></author><author><style face="normal" font="default" size="100%">Redegeld, F. A.</style></author><author><style face="normal" font="default" size="100%">Chang, I.</style></author><author><style face="normal" font="default" size="100%">Dunham, D.</style></author><author><style face="normal" font="default" size="100%">Chen, H.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Garssen, J.</style></author><author><style face="normal" font="default" size="100%">Knippels, L. M. J.</style></author><author><style face="normal" font="default" size="100%">Hogenkamp, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Food Science and Technology, Nanchang University, Jiangxi, China.&#xD;Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.&#xD;School of Food Science Technology, Nanchang University, Nanchang, Jiangxi, China.&#xD;Sino-German Joint Research Institute, Nanchang University, Nanchang, China.&#xD;Global Centre of Excellence Immunology, Danone/Nutricia Research, Utrecht, The Netherlands.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Division of Pulmonary, Allergy, Critical Care Medicine, Stanford University, Stanford, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Selenomethionine attenuates allergic effector responses in human primary mast cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2552-2555</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Selenomethionine</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">primary human mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">soy allergy</style></keyword><keyword><style face="normal" font="default" size="100%">time employee of Danone Nutricia Research and Utrecht University. Dr. Nadeau</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from National Institute of Allergy and Infectious Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">(NIAID), National Heart, Lung, and Blood Institute (NHLBI), National Institute of</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Health Sciences (NIEHS), and Food Allergy Research &amp; Education</style></keyword><keyword><style face="normal" font="default" size="100%">(FARE)</style></keyword><keyword><style face="normal" font="default" size="100%">stock options from IgGenix, Seed Health, ClostraBio, and ImmuneID</style></keyword><keyword><style face="normal" font="default" size="100%">is</style></keyword><keyword><style face="normal" font="default" size="100%">Director of the World Allergy Organization Center of Excellence for Stanford,</style></keyword><keyword><style face="normal" font="default" size="100%">Advisor at Cour Pharma, Consultant for Excellergy, Red tree ventures, Eli Lilly,</style></keyword><keyword><style face="normal" font="default" size="100%">and Phylaxis, Co-founder of Before Brands, Alladapt, Latitude, and IgGenix</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">National Scientific Committee member at Immune Tolerance Network (ITN), and</style></keyword><keyword><style face="normal" font="default" size="100%">National Institutes of Health (NIH) clinical research centers, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">patents include, &quot;Mixed allergen composition and methods for</style></keyword><keyword><style face="normal" font="default" size="100%">using the same,&quot; &quot;Granulocyte-based methods for detecting and monitoring immune</style></keyword><keyword><style face="normal" font="default" size="100%">system disorders,&quot; and &quot;Methods and Assays for Detecting and Quantifying Pure</style></keyword><keyword><style face="normal" font="default" size="100%">Subpopulations of White Blood Cells in Immune System Disorders.&quot; All remaining</style></keyword><keyword><style face="normal" font="default" size="100%">authors declare no conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35451124</style></accession-num><notes><style face="normal" font="default" size="100%">Zhao, Xiaoli&#xD;Blokhuis, Bart R J&#xD;Redegeld, Frank A&#xD;Chang, Iris&#xD;Dunham, Diane&#xD;Chen, Hongbing&#xD;Nadeau, Kari&#xD;Garssen, Johan&#xD;Knippels, Leon M J&#xD;Hogenkamp, Astrid&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2552-2555. doi: 10.1111/all.15320. Epub 2022 May 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35451124</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9710852</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15320</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>799</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">799</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, Y. C.</style></author><author><style face="normal" font="default" size="100%">Choi, S.</style></author><author><style face="normal" font="default" size="100%">Sohn, K. H.</style></author><author><style face="normal" font="default" size="100%">Bang, J. Y.</style></author><author><style face="normal" font="default" size="100%">Kim, Y.</style></author><author><style face="normal" font="default" size="100%">Jung, J. W.</style></author><author><style face="normal" font="default" size="100%">Kim, H. Y.</style></author><author><style face="normal" font="default" size="100%">Park, J.</style></author><author><style face="normal" font="default" size="100%">Kim, K.</style></author><author><style face="normal" font="default" size="100%">Kang, M. G.</style></author><author><style face="normal" font="default" size="100%">Yang, M. S.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Choi, J. H.</style></author><author><style face="normal" font="default" size="100%">Park, H. J.</style></author><author><style face="normal" font="default" size="100%">Lee, S. M.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Park, J. W.</style></author><author><style face="normal" font="default" size="100%">Lee, J. M.</style></author><author><style face="normal" font="default" size="100%">Cho, S. H.</style></author><author><style face="normal" font="default" size="100%">Won, S.</style></author><author><style face="normal" font="default" size="100%">Yi, H.</style></author><author><style face="normal" font="default" size="100%">Kang, H. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.&#xD;Interdisciplinary Program in Precision Public Health, Korea University, Seoul, Korea.&#xD;Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea.&#xD;Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.&#xD;Laboratory of Mucosal Immunology in Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.&#xD;Interdisciplinary Program in Bioinformatics, College of Natural Sciences, Seoul National University, Seoul, Korea.&#xD;Institute of Health and Environment, Seoul National University, Seoul, Korea.&#xD;Department of Internal Medicine, Chungbuk National University College of Medicine, Chungbuk National University Hospital, Cheongju, Korea.&#xD;Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea.&#xD;Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.&#xD;Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.&#xD;Department of Pulmonology and Allergy, Allergy and Clinical Immunology Research Center, Hallym University College of Medicine, Chuncheon, Korea.&#xD;Department of Internal Medicine, Gangnam Severance Hospital, Seoul, Korea.&#xD;Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.&#xD;Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.&#xD;Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul, Korea.&#xD;School of Biosystems and Biomedical Sciences, Korea University, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Selenomonas: A marker of asthma severity with the potential therapeutic effect</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">317-320</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/09/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S</style></keyword><keyword><style face="normal" font="default" size="100%">*Selenomonas/genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34587325</style></accession-num><notes><style face="normal" font="default" size="100%">Kim, Young-Chan&#xD;Choi, Sungmi&#xD;Sohn, Kyoung-Hee&#xD;Bang, Ji-Young&#xD;Kim, Yuldam&#xD;Jung, Jae-Woo&#xD;Kim, Hye-Young&#xD;Park, Jaehyun&#xD;Kim, Kangjin&#xD;Kang, Min-Gyu&#xD;Yang, Min-Suk&#xD;Kim, Sujeong&#xD;Kim, Sae-Hoon&#xD;Choi, Jeong-Hee&#xD;Park, Hye Jung&#xD;Lee, Sang Min&#xD;Kim, Sang Heon&#xD;Park, Jung-Won&#xD;Lee, Jong Myung&#xD;Cho, Sang-Heon&#xD;Won, Sungho&#xD;Yi, Hana&#xD;Kang, Hye-Ryun&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):317-320. doi: 10.1111/all.15114. Epub 2021 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34587325</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15114</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>846</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">846</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Backaert, W.</style></author><author><style face="normal" font="default" size="100%">Steelant, B.</style></author><author><style face="normal" font="default" size="100%">Jorissen, M.</style></author><author><style face="normal" font="default" size="100%">Van Oudenhove, L.</style></author><author><style face="normal" font="default" size="100%">Talavera, K.</style></author><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author><author><style face="normal" font="default" size="100%">Van Gerven, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.&#xD;Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.&#xD;Department of Neurosciences, Experimental Otorhinolaryngology, Rhinology Research, KU Leuven, Leuven, Belgium.&#xD;Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), Laboratory for Brain-Gut Axis Studies (LaBGAS), KU Leuven, Leuven, Belgium.&#xD;Department of Psychological and Brain Sciences, Cognitive and Affective Neuroscience Laboratory (CANlab), Center for Cognitive Neuroscience, Dartmouth College, Hanover, New Hampshire, USA.&#xD;Department of Cellular and Molecular Medicine, Laboratory of Ion Channel Research, VIB-KU Leuven Center for Brain &amp; Disease Research, KU Leuven, Leuven, Belgium.&#xD;Department of Otorhinolaryngology, Laboratory of Upper Airways Research, U Ghent, Ghent, Belgium.&#xD;Department of Otorhinolaryngology, Academic Medical Center, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Self-reported nasal hyperreactivity is common in all chronic upper airway inflammatory phenotypes and not related to general well-being</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3806-3809</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/08/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Self Report</style></keyword><keyword><style face="normal" font="default" size="100%">ENT (rhinitis sinusitis nasal polyps...)</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">quality-of-life</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34418126</style></accession-num><notes><style face="normal" font="default" size="100%">Backaert, Wout&#xD;Steelant, Brecht&#xD;Jorissen, Mark&#xD;Van Oudenhove, Lukas&#xD;Talavera, Karel&#xD;Hellings, Peter W&#xD;Van Gerven, Laura&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3806-3809. doi: 10.1111/all.15060. Epub 2021 Sep 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34418126</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15060</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3260</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3260</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ni, Duan</style></author><author><style face="normal" font="default" size="100%">Nanan, Ralph</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Self-Reported Racial Group-Associated Immune Signaling Differences in Atopic Dermatitis and Dupilumab Treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70260</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70260</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1522</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1522</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Toubi, E.</style></author><author><style face="normal" font="default" size="100%">Vadasz, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Proteomic and Flow Cytometry Unit, Division of Allergy and Clinical Immunology, Faculty of Medicine, Bnai-Zion Medical Center, Technion, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Semaphorin3A is a promising therapeutic tool for bronchial asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">481-483</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2019/08/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/blood/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Physiologic/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophils/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins/blood/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Semaphorin-3A/*administration &amp; dosage/blood/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A/antagonists &amp; inhibitors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31444800</style></accession-num><notes><style face="normal" font="default" size="100%">Toubi, Elias&#xD;Vadasz, Zahava&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2020 Feb;75(2):481-483. doi: 10.1111/all.14026. Epub 2019 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31444800</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14026</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2145</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2145</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yin, W.</style></author><author><style face="normal" font="default" size="100%">Xiaoli, Z.</style></author><author><style face="normal" font="default" size="100%">Wenjin, D.</style></author><author><style face="normal" font="default" size="100%">Lin, Y.</style></author><author><style face="normal" font="default" size="100%">Xiaofei, Y.</style></author><author><style face="normal" font="default" size="100%">Qing, J.</style></author><author><style face="normal" font="default" size="100%">Nan, H.</style></author><author><style face="normal" font="default" size="100%">Wenjing, L.</style></author><author><style face="normal" font="default" size="100%">Yaqi, Y.</style></author><author><style face="normal" font="default" size="100%">Dongxia, M.</style></author><author><style face="normal" font="default" size="100%">Hao, C.</style></author><author><style face="normal" font="default" size="100%">Rongfei, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Allergy, Chongqing General Hospital, University of Chinese Academy of Sciences, Chongqing, China.&#xD;Department of Allergy, Henan Provincial People&apos;s Hospital, Zhengzhou, China.&#xD;Kindstar Global Precision Medicine Institute, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sensitization profiles of aeroallergens among allergic rhinitis patients in China: A 13-year multicenter retrospective study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1329-1332</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">China/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37305996</style></accession-num><notes><style face="normal" font="default" size="100%">Yin, Wang&#xD;Xiaoli, Zeng&#xD;Wenjin, Du&#xD;Lin, Yang&#xD;Xiaofei, Ye&#xD;Qing, Jiang&#xD;Nan, Huang&#xD;Wenjing, Li&#xD;Yaqi, Yang&#xD;Dongxia, Ma&#xD;Hao, Chen&#xD;Rongfei, Zhu&#xD;eng&#xD;Letter&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1329-1332. doi: 10.1111/all.15784. Epub 2023 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37305996</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15784</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3325</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3325</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Yufei</style></author><author><style face="normal" font="default" size="100%">Peng, Xueting</style></author><author><style face="normal" font="default" size="100%">Ren, Kaixuan</style></author><author><style face="normal" font="default" size="100%">Kang, Shiran</style></author><author><style face="normal" font="default" size="100%">Xue, Zihan</style></author><author><style face="normal" font="default" size="100%">Li, Yazhuo</style></author><author><style face="normal" font="default" size="100%">Yan, Zhu</style></author><author><style face="normal" font="default" size="100%">Feng, Rongfang</style></author><author><style face="normal" font="default" size="100%">Gao, Min</style></author><author><style face="normal" font="default" size="100%">Chen, Qin</style></author><author><style face="normal" font="default" size="100%">Ning, Xiaoying</style></author><author><style face="normal" font="default" size="100%">Bai, Fan</style></author><author><style face="normal" font="default" size="100%">Meng, Liesu</style></author><author><style face="normal" font="default" size="100%">Xia, Yumin</style></author><author><style face="normal" font="default" size="100%">Liu, Yale</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Sensitizer-Induced Basophils Accelerate Skin Re-Epithelialization via IL-4/IL-13-Mediated Macrophage Polarization</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Atopic dermatitis (AD) patients exhibit a paradox of impaired skin barrier with intense itching, yet often demonstrate rapid re-epithelialization after scratching. While basophils are key effector cells in allergic inflammation, their role in the subsequent tissue repair remains unexplored. Objective We investigated whether basophils, recruited during sensitized skin responses, contribute to wound healing. Methods Using single-cell RNA sequencing, flow cytometry, and immunofluorescence, we mapped basophil infiltration and activation in sensitizer (oxazolone)-induced skin injury models. We employed genetic (Mcpt8CT/+R26DTA/+) and antibody-mediated (anti-FcεRI) basophil depletion, as well as basophil-specific Il4/Il13 knockout mice (Il4/13fl/flMcpt8CT/+) to define their functional contribution. Macrophage polarization was assessed by flow cytometry, RT-qPCR, and immunohistochemistry. Results We identified a significant enrichment of basophils in wounded skin, peaking at day 3–6 post-injury. Sensitizer-challenge enhanced basophil recruitment and accelerated wound closure, angiogenesis, and re-epithelialization. Depletion of basophils severely impaired these repair processes. Mechanistically, basophils were the predominant source of IL-4 and IL-13 in the early wound microenvironment. These cytokines were essential for driving macrophage polarization toward a pro-repair M2 phenotype. Loss of IL4/IL13 specifically in basophils phenocopied the healing defects observed in basophil-deficient mice, and this could be rescued by local cytokine administration. Conclusion Our study uncovers a novel pro-repair function of basophils in sensitizer-exposed skin. Beyond their well-known role in provoking itch and inflammation, basophils are critical for initiating type 2 immune-mediated tissue regeneration via IL-4/IL-13-dependent macrophage reprogramming. This axis represents a promising therapeutic target for chronic wounds, particularly in the context of allergic skin disorders.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70279</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70279</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>922</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">922</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giang, N.</style></author><author><style face="normal" font="default" size="100%">Mars, M.</style></author><author><style face="normal" font="default" size="100%">Moreau, M.</style></author><author><style face="normal" font="default" size="100%">Mejia, J. E.</style></author><author><style face="normal" font="default" size="100%">Bouchaud, G.</style></author><author><style face="normal" font="default" size="100%">Magnan, A.</style></author><author><style face="normal" font="default" size="100%">Michelet, M.</style></author><author><style face="normal" font="default" size="100%">Ronsin, B.</style></author><author><style face="normal" font="default" size="100%">Murphy, G. G.</style></author><author><style face="normal" font="default" size="100%">Striessnig, J.</style></author><author><style face="normal" font="default" size="100%">Guery, J. C.</style></author><author><style face="normal" font="default" size="100%">Pelletier, L.</style></author><author><style face="normal" font="default" size="100%">Savignac, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291, CNRS UMR5051, Universite Paul Sabatier Toulouse III, Toulouse, France.&#xD;Centre de Biologie du Developpement, Centre de Biologie Integrative, Universite de Toulouse, CNRS, Universite Paul Sabatier III, Toulouse, France.&#xD;INRA, Nantes, France.&#xD;Institut du Thorax, INSERM CNRS, Universite de Nantes, Nantes, France.&#xD;Service de Pneumologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.&#xD;Pediatric Pneumology and Allergology Unit, Hopital des Enfants, Centre Hospitalier Universitaire Toulouse, Toulouse, France.&#xD;Unite de Recherche Clinique Pediatrique/module plurithematique pediatrique du CIC, Toulouse, France.&#xD;Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, USA.&#xD;Department of Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences, University of Innsbruck, Innsbruck, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Separation of the Ca(V) 1.2-Ca(V) 1.3 calcium channel duo prevents type 2 allergic airway inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">525-539</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/06/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Calcium Channels/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Antigen, T-Cell/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cav1</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">calcium channels</style></keyword><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">signaling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34181765</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Voltage-gated calcium (Ca(v) 1) channels contribute to T-lymphocyte activation. Ca(v) 1.2 and Ca(v) 1.3 channels are expressed in Th2 cells but their respective roles are unknown, which is investigated herein. METHODS: We generated mice deleted for Ca(v) 1.2 in T cells or Ca(v) 1.3 and analyzed TCR-driven signaling. In this line, we developed original fast calcium imaging to measure early elementary calcium events (ECE). We also tested the impact of Ca(v) 1.2 or Ca(v) 1.3 deletion in models of type 2 airway inflammation. Finally, we checked whether the expression of both Ca(v) 1.2 and Ca(v) 1.3 in T cells from asthmatic children correlates with Th2-cytokine expression. RESULTS: We demonstrated non-redundant and synergistic functions of Ca(v) 1.2 and Ca(v) 1.3 in Th2 cells. Indeed, the deficiency of only one channel in Th2 cells triggers TCR-driven hyporesponsiveness with weakened tyrosine phosphorylation profile, a strong decrease in initial ECE and subsequent reduction in the global calcium response. Moreover, Ca(v) 1.3 has a particular role in calcium homeostasis. In accordance with the singular roles of Ca(v) 1.2 and Ca(v) 1.3 in Th2 cells, deficiency in either one of these channels was sufficient to inhibit cardinal features of type 2 airway inflammation. Furthermore, Ca(v) 1.2 and Ca(v) 1.3 must be co-expressed within the same CD4(+) T cell to trigger allergic airway inflammation. Accordingly with the concerted roles of Ca(v) 1.2 and Ca(v) 1.3, the expression of both channels by activated CD4(+) T cells from asthmatic children was associated with increased Th2-cytokine transcription. CONCLUSIONS: Thus, Ca(v) 1.2 and Ca(v) 1.3 act as a duo, and targeting only one of these channels would be efficient in allergy treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Giang, Nicolas&#xD;Mars, Marion&#xD;Moreau, Marc&#xD;Mejia, Jose E&#xD;Bouchaud, Gregory&#xD;Magnan, Antoine&#xD;Michelet, Marine&#xD;Ronsin, Brice&#xD;Murphy, Geoffrey G&#xD;Striessnig, Joerg&#xD;Guery, Jean-Charles&#xD;Pelletier, Lucette&#xD;Savignac, Magali&#xD;eng&#xD;P 27809/FWF_/Austrian Science Fund FWF/Austria&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):525-539. doi: 10.1111/all.14993. Epub 2021 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34181765</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14993</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3186</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3186</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nagy, N. A.</style></author><author><style face="normal" font="default" size="100%">Schnoegl, D.</style></author><author><style face="normal" font="default" size="100%">Houghton, V.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Knol, E. F.</style></author><author><style face="normal" font="default" size="100%">Kuehn, A.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Department of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland.&#xD;Department of Women and Children&apos;s Health (Pediatric Allergy), Faculty of Life Sciences and Medicine, School of Life Course Sciences, King&apos;s College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Center of Translational Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.&#xD;Translational Medicine, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sequence of Immunological Events During IgE-Mediated Allergic Reactions to Food</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">T2 responses</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal tissue</style></keyword><keyword><style face="normal" font="default" size="100%">immune mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41437806</style></accession-num><abstract><style face="normal" font="default" size="100%">Food allergies (FA) represent a significant global health burden. Upon allergen re-exposure, allergic patients exhibit a sequence of symptoms that vary in terms of affected organ systems, severity, time of onset and allergen reactivity thresholds. This review focuses on the sequence of immediate immunological and clinical events that occur during allergen exposure in individuals with FA. It highlights both clinical and immunological baseline risk factors and discusses recent advances in understanding the acute allergic response. We explore the implications of immune mechanistic knowledge for predicting clinical reactivity and therapy of FA. The current diagnostic gold standard, the oral food challenge (OFC), may help identify early biomarkers for patient stratification and provide insights into the immune dynamics underlying acute allergic reactions in vivo.</style></abstract><notes><style face="normal" font="default" size="100%">Nagy, N A&#xD;Schnoegl, D&#xD;Houghton, V&#xD;O&apos;Mahony, L&#xD;Santos, A F&#xD;Knol, E F&#xD;Kuehn, A&#xD;Eiwegger, T&#xD;eng&#xD;Austrian Science Fund/&#xD;Fonds National de la Recherche Luxembourg/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Dec 24. doi: 10.1111/all.70194.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41437806</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70194</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>546</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">546</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Testera-Montes, A.</style></author><author><style face="normal" font="default" size="100%">Palomares, F.</style></author><author><style face="normal" font="default" size="100%">Jurado-Escobar, R.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Ariza, A.</style></author><author><style face="normal" font="default" size="100%">Verge, J.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Campo, P.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA), RICORS &quot;Enfermedades inflamatorias&quot;, Malaga, Spain.&#xD;ENT Unit, Hospital Clinico Virgen de la Victoria, Malaga, Spain.&#xD;Andalusian Center for Nanomedicine and Biotechnology (BIONAND), Malaga, Spain.&#xD;Universidad de Malaga (UMA), Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sequential class switch recombination to IgE and allergen-induced accumulation of IgE(+) plasmablasts occur in the nasal mucosa of local allergic rhinitis patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2712-2724</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/03/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">class switch recombination</style></keyword><keyword><style face="normal" font="default" size="100%">local allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">plasma cell</style></keyword><keyword><style face="normal" font="default" size="100%">plasmablast</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35340036</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The involvement of allergen-specific (s)IgE in local allergic rhinitis (LAR) has been debated. Here, we investigate the effect of nasal allergen challenge with Dermatophagoides pteronyssinus (NAC-DP) in mucosal and peripheral B-cell subpopulations in LAR patients. METHODS: Nine LAR, 5 allergic rhinitis (AR), and 5 non-atopic healthy control (HC) individuals were subjected to a 3-day NAC-DP protocol, and nasal biopsies and blood samples were collected before and after provocation. Nasal biopsies were used for immunohistochemistry and gene expression studies, whereas the frequency of lymphocyte subsets and basophil activation test (BAT) were analyzed in blood samples by flow cytometry. sIgG was measured in sera. RESULTS: NAC-DP induced an increase in IgE(+) CD38(+) plasmablasts in the nasal mucosa of LAR patients, but not in AR or HC individuals. Markers of sequential recombination to IgE (epsilonCSR) (from IgG) were observed in 33% of LAR, 20% of AR, and 0% of HC subjects. NAC-DP increased the proportion of peripheral CD19(+) CD20(+) CD38(+) plasmablasts in AR and LAR patients, but not in HC. Expression of the mucosal homing receptor CXCR3 in peripheral CD19(+) CD20(+) CD38(+) plasmablasts from LAR, AR, and HC individuals was 7%, 5%, and 0.5%, respectively. In vitro DP stimulation increased proliferating CD19(+) CD20(+) CD38(+) plasmablasts in LAR and AR patients, but not in HC. Serum DP-sIgG was higher in LAR and AR patients as compared to HC. BAT was positive in 33%, 100%, and 0% of LAR, AR, and HC subjects, respectively. CONCLUSION: These results suggest that allergen exposure induces the sequential epsilonCSR of IgG(+) CD19(+) CD20(+) CD38(+) plasmablasts in the nasal mucosa of LAR patients.</style></abstract><notes><style face="normal" font="default" size="100%">Testera-Montes, Almudena&#xD;Palomares, Francisca&#xD;Jurado-Escobar, Raquel&#xD;Fernandez-Santamaria, Ruben&#xD;Ariza, Adriana&#xD;Verge, Jesus&#xD;Salas, Maria&#xD;Campo, Paloma&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;Rondon, Carmen&#xD;Eguiluz-Gracia, Ibon&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2712-2724. doi: 10.1111/all.15292. Epub 2022 Apr 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35340036</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15292</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>350</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">350</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vazquez-Mera, S.</style></author><author><style face="normal" font="default" size="100%">Martelo-Vidal, L.</style></author><author><style face="normal" font="default" size="100%">Miguens-Suarez, P.</style></author><author><style face="normal" font="default" size="100%">Saavedra-Nieves, P.</style></author><author><style face="normal" font="default" size="100%">Arias, P.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Fernandez, C.</style></author><author><style face="normal" font="default" size="100%">Mosteiro-Anon, M.</style></author><author><style face="normal" font="default" size="100%">Corbacho-Abelaira, M. D.</style></author><author><style face="normal" font="default" size="100%">Blanco-Aparicio, M.</style></author><author><style face="normal" font="default" size="100%">Mendez-Brea, P.</style></author><author><style face="normal" font="default" size="100%">Salgado, F. J.</style></author><author><style face="normal" font="default" size="100%">Nieto-Fontarigo, J. J.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Barcala, F. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.&#xD;Translational Research In Airway Diseases Group (TRIAD), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.&#xD;Department of Statistics, Mathematical Analysis and Optimization, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.&#xD;Department of Respiratory Medicine, University Hospital of Ourense, Ourense, Spain.&#xD;Department of Respiratory Medicine, University Hospital Alvaro Cunqueiro, Vigo, Spain.&#xD;Department of Respiratory Medicine, Ribera Hospital POVISA of Vigo, Vigo, Spain.&#xD;Department of Respiratory Medicine, University Hospital of A Coruna, A Coruna, Spain.&#xD;Allergy Service, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.&#xD;Department of Medicine, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.&#xD;Department of Respiratory Medicine, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.&#xD;Spanish Biomedical Research Networking Centre in Respiratory Diseases (CIBERES), Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serum exosome inflamma-miRs are surrogate biomarkers for asthma phenotype and severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">141-155</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/08/17</style></edition><section><style face="normal" font="default" size="100%">141</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Exosomes</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers, Tumor</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">miRNAs</style></keyword><keyword><style face="normal" font="default" size="100%">phenotypes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35971848</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma is a heterogeneous disease with several phenotypes, endotypes and severity degrees, in which different T-cell subpopulations are involved. These cells express specific miRNAs (i.e. inflamma-miRs) that can be released to serum in exosomes after activation and be used as biomarkers of underlying inflammation. Thus, we aim to evaluate specific T-cell miRNA signatures in serum exosomes from different subgroups of asthmatic patients. METHODS: Samples from healthy donors (N = 30) and patients (N = 119) with different asthma endotypes (T2(high) -Atopic/T2(high) -Non-atopic/T2(low) ) and severity degrees (mild/MA and moderate-severe/MSA) were used. Demographic, clinical, haematological and biochemical characteristics were collected. Twelve miRNAs previously associated with different Th subsets were preselected and their levels in serum exosome samples were measured using RTqPCR. RESULTS: We detected five miRNAs with high confidence in serum exosomes: miR-16-5p, miR-21-5p, miR-126-3p, miR146a-5p and miR-215-5p. All of them, except miR-16-5p were upregulated in MSA patients compared to MA. A logistic regression model including each of these miRNAs was created to discriminate both conditions, rendering a ROC curve AUC of 0.896 (0.830-0.961). miR-21-5p and miR-126-3p, both involved in Th1/Th2 differentiation, were specifically augmented in T2(high) -Atopic patients. Of note, all these changes were found in samples collected in autumn. On the contrary, IL-6(high) patients with MSA, which were more obese, older, with higher neutrophil and basophil counts and TNF levels, displayed a decrease of miR-21-5p, miR-126-3p and miR-146a-5p. CONCLUSION: Immune-related miRNAs, including miR-21-5p, miR-126-3p, miR-146a-5p and miR-215-5p, can be used as clinically relevant non-invasive biomarkers of the phenotype/endotype and severity of asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Vazquez-Mera, Sara&#xD;Martelo-Vidal, Laura&#xD;Miguens-Suarez, Pablo&#xD;Saavedra-Nieves, Paula&#xD;Arias, Pilar&#xD;Gonzalez-Fernandez, Coral&#xD;Mosteiro-Anon, Mar&#xD;Corbacho-Abelaira, Maria Dolores&#xD;Blanco-Aparicio, Marina&#xD;Mendez-Brea, Paula&#xD;Salgado, Francisco Javier&#xD;Nieto-Fontarigo, Juan Jose&#xD;Gonzalez-Barcala, Francisco Javier&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):141-155. doi: 10.1111/all.15480. Epub 2022 Aug 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35971848</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15480</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>649</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">649</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nanishi, M.</style></author><author><style face="normal" font="default" size="100%">Fujiogi, M.</style></author><author><style face="normal" font="default" size="100%">Freishtat, R. J.</style></author><author><style face="normal" font="default" size="100%">Hoptay, C. E.</style></author><author><style face="normal" font="default" size="100%">Bauer, C. S.</style></author><author><style face="normal" font="default" size="100%">Stevenson, M. D.</style></author><author><style face="normal" font="default" size="100%">Camargo, C. A., Jr.</style></author><author><style face="normal" font="default" size="100%">Hasegawa, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Emergency Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Department of Genomics and Precision Medicine, George Washington University, Washington, District of Columbia, USA.&#xD;Division of Emergency Medicine, Children&apos;s National Hospital, Washington, District of Columbia, USA.&#xD;Children&apos;s Research Institute, Children&apos;s National Hospital, Washington, District of Columbia, USA.&#xD;Division of Allergy and Immunology, Phoenix Children&apos;s Hospital, Phoenix, Arizona, USA.&#xD;Department of Pediatrics, Emergency Medicine, Norton Children&apos;s Hospital, University of Louisville School of Medicine, Louisville, Kentucky, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serum periostin among infants with severe bronchiolitis and risk of developing asthma: A prospective multicenter cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2121-2130</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/01/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Bronchiolitis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">allergic predisposition</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchiolitis</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">periostin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35000210</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Infants hospitalized for bronchiolitis (severe bronchiolitis) are at high risk for developing childhood asthma. However, the pathobiological link between these conditions remains unclear. We examined the longitudinal relationship of periostin (an extracellular matrix protein upregulated in response to type 2 inflammation) during bronchiolitis with the subsequent development of asthma. METHODS: In a 17-center prospective cohort study of infants (aged &lt;1 year) with severe bronchiolitis, we measured the serum periostin level at hospitalization and grouped infants into 3 groups: low, intermediate, and high levels. We examined their association with asthma development by age 6 years and investigated effect modification by allergic predisposition (eg, infant&apos;s IgE sensitization). RESULTS: The analytic cohort consists of 847 infants with severe bronchiolitis (median age, 3 months). Overall, 28% developed asthma by age 6 years. In the multivariable model adjusting for nine patient-level factors, compared to the low periostin group, the asthma risk was significantly higher among infants in the intermediate group (23% vs. 32%, OR 1.68, 95%CI 1.12-2.51, p = .01) and non-significantly higher in the high-level group (28%, OR 1.29, 95%CI 0.86-1.95, p = .22). In the stratified analysis, infants with IgE sensitization had a significantly higher risk for developing asthma (intermediate group, OR 4.76, 95%CI 1.70-13.3, p = .002; high group, OR 3.19, 95%CI 1.08-9.36, p = .04). By contrast, infants without IgE sensitization did not have a significantly higher risk (p &gt; .15). CONCLUSIONS: In infants with severe bronchiolitis, serum periostin level at bronchiolitis hospitalization was associated with asthma risk by age 6 years, particularly among infants with an allergic predisposition.</style></abstract><notes><style face="normal" font="default" size="100%">Nanishi, Makiko&#xD;Fujiogi, Michimasa&#xD;Freishtat, Robert J&#xD;Hoptay, Claire E&#xD;Bauer, Cindy S&#xD;Stevenson, Michelle D&#xD;Camargo, Carlos A Jr&#xD;Hasegawa, Kohei&#xD;eng&#xD;R01 AI127507/AI/NIAID NIH HHS/&#xD;R01 AI148338/AI/NIAID NIH HHS/&#xD;R01 AI134940/AI/NIAID NIH HHS/&#xD;UH3 OD023253/OD/NIH HHS/&#xD;R01 AI137091/AI/NIAID NIH HHS/&#xD;UG3 OD023253/OD/NIH HHS/&#xD;Multicenter Study&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2121-2130. doi: 10.1111/all.15216. Epub 2022 Jan 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35000210</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9247040</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15216</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>960</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">960</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sakai, T.</style></author><author><style face="normal" font="default" size="100%">Herrmann, N.</style></author><author><style face="normal" font="default" size="100%">Maintz, L.</style></author><author><style face="normal" font="default" size="100%">Numm, T. J.</style></author><author><style face="normal" font="default" size="100%">Welchowski, T.</style></author><author><style face="normal" font="default" size="100%">Bieber, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Christine Kuhne-Center for Allergy Research and Education (CK-CARE), University Hospital Bonn, Bonn, Germany.&#xD;Department of Dermatology, Faculty of Medicine, Oita University, Oita, Japan.&#xD;Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serum receptor activator of nuclear factor kappa-Beta ligand/osteoprotegerin ratio correlates with severity and suggests fracture&apos;s risk in older women with atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3220-3223</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/06/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Ligands</style></keyword><keyword><style face="normal" font="default" size="100%">NF-kappa B</style></keyword><keyword><style face="normal" font="default" size="100%">Osteoprotegerin</style></keyword><keyword><style face="normal" font="default" size="100%">RANK Ligand</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34080196</style></accession-num><notes><style face="normal" font="default" size="100%">Sakai, Takashi&#xD;Herrmann, Nadine&#xD;Maintz, Laura&#xD;Numm, Tim Joachim&#xD;Welchowski, Thomas&#xD;Bieber, Thomas&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3220-3223. doi: 10.1111/all.14971. Epub 2021 Jun 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34080196</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14971</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1080</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1080</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sakai, T.</style></author><author><style face="normal" font="default" size="100%">Herrmann, N.</style></author><author><style face="normal" font="default" size="100%">Maintz, L.</style></author><author><style face="normal" font="default" size="100%">Numm, T. J.</style></author><author><style face="normal" font="default" size="100%">Welchowski, T.</style></author><author><style face="normal" font="default" size="100%">Claus, R. A.</style></author><author><style face="normal" font="default" size="100%">Graler, M. H.</style></author><author><style face="normal" font="default" size="100%">Bieber, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Christine Kuhne-Center for Allergy Research and Education (CK-CARE), University Hospital Bonn, Bonn, Germany.&#xD;Department of Dermatology, Faculty of Medicine, Oita University, Oita, Japan.&#xD;Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.&#xD;Department of Anesthesiology and Intensive Care Medicine, Center for Sepsis Control and Care (CSCC), and the Center for Molecular Biomedicine (CMB), Jena University Hospital, Jena, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serum sphingosine-1-phosphate is elevated in atopic dermatitis and associated with severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2592-2595</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lysophospholipids</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Sphingosine/analogs &amp; derivatives</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33764548</style></accession-num><notes><style face="normal" font="default" size="100%">Sakai, Takashi&#xD;Herrmann, Nadine&#xD;Maintz, Laura&#xD;Numm, Tim Joachim&#xD;Welchowski, Thomas&#xD;Claus, Ralf A&#xD;Graler, Markus H&#xD;Bieber, Thomas&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2592-2595. doi: 10.1111/all.14826. Epub 2021 Apr 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33764548</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14826</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2157</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2157</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nachshon, L.</style></author><author><style face="normal" font="default" size="100%">Westerhout, J.</style></author><author><style face="normal" font="default" size="100%">Blom, W. M.</style></author><author><style face="normal" font="default" size="100%">Remington, B.</style></author><author><style face="normal" font="default" size="100%">Levy, M. B.</style></author><author><style face="normal" font="default" size="100%">Goldberg, M. R.</style></author><author><style face="normal" font="default" size="100%">Epstein-Rigbi, N.</style></author><author><style face="normal" font="default" size="100%">Katz, Y.</style></author><author><style face="normal" font="default" size="100%">Elizur, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergy, Immunology and Pediatric Pulmonology, Yitzhak Shamir Medical Center, Be&apos;er Ya&apos;akov, Israel.&#xD;Department of Medicine, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.&#xD;The Netherlands Organization for Applied Scientific Research TNO, Utrecht, The Netherlands.&#xD;Food Allergy Research and Resource Program, Department of Food Science and Technology, University of Nebraska, Lincoln, Nebraska, USA.&#xD;Department of Pediatrics, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sesame eliciting and safe doses in a large sesame allergic population</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3212-3220</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/08/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sesamum/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Food</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">adverse reactions</style></keyword><keyword><style face="normal" font="default" size="100%">eliciting dose</style></keyword><keyword><style face="normal" font="default" size="100%">reaction threshold</style></keyword><keyword><style face="normal" font="default" size="100%">safe dose</style></keyword><keyword><style face="normal" font="default" size="100%">sesame allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37606275</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Sesame is a significant food allergen causing severe and even fatal reactions. Given its increasing prevalence in western diet, sesame is listed as an allergenic food requiring labeling in the United States and EU. However, data on the population reaction doses to sesame are limited. METHODS: All sesame oral food challenges (OFCs), performed either for diagnosis or for threshold identification before the beginning of sesame oral immunotherapy (OIT) between November 2011 and July 2021 in Shamir medical center were analyzed for reaction threshold distribution. Safe-dose challenges with 90-120 min intervals were also analyzed. RESULTS: Two hundred and fifty patients underwent 338 positive OFCs, and additional 158 safe-dose OFCs were performed. The discrete and cumulative protein amounts estimated to elicit an objective reaction in 1% (ED01) of the entire cohort (n = 250) were 0.8 mg (range 0.3-6.3) and 0.7 mg (range 0.1-7.1), respectively, and those for 5% of the population (ED05) were 3.4 mg (range 1.2-20.6) and 4.5 mg (range 1.2-28.8), respectively. Safe-dose OFCs showed similar values of ED01 (0.8, 0.4-7.5 mg) and ED05 (3.4, 1.2-22.9 mg). While doses of &lt;/=1 mg sesame protein elicited oral pruritus in 11.6% of the patients, no objective reaction was documented to this amount in any of the challenges, including safe-dose OFCs. CONCLUSIONS: This study provides data on sesame reaction threshold distribution in the largest population of allergic patients studied, with no right or left censored data, and with validation using a safe-dose OFC. It further supports the current methods for ED determination as appropriate for establishing safety precautions for the food industry.</style></abstract><notes><style face="normal" font="default" size="100%">Nachshon, Liat&#xD;Westerhout, Joost&#xD;Blom, W Marty&#xD;Remington, Benjamin&#xD;Levy, Michael B&#xD;Goldberg, Michael R&#xD;Epstein-Rigbi, Naama&#xD;Katz, Yitzhak&#xD;Elizur, Arnon&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3212-3220. doi: 10.1111/all.15863. Epub 2023 Aug 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37606275</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15863</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1983</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1983</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pouessel, G.</style></author><author><style face="normal" font="default" size="100%">Trochu, C.</style></author><author><style face="normal" font="default" size="100%">Chagnon, F.</style></author><author><style face="normal" font="default" size="100%">Diesnis, R.</style></author><author><style face="normal" font="default" size="100%">Leteurtre, S.</style></author><author><style face="normal" font="default" size="100%">Deschildre, A.</style></author><author><style face="normal" font="default" size="100%">French Group for Paediatric Intensive, Care</style></author><author><style face="normal" font="default" size="100%">Emergencies,</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Children&apos;s Hospital, Roubaix, France.&#xD;Paediatric Pulmonology and Allergy Department, Hopital Jeanne de Flandre, CHU Lille, Lille, France.&#xD;Department of Paediatrics, Children&apos;s Hospital, Valenciennes, France.&#xD;Clinical Research Unit, Department of Biostatistics, Roubaix Hospital, Roubaix, France.&#xD;Univ. Lille, CHU Lille, ULR 2694 - METRICS: Evaluation des technologies de sante et des, pratiques medicales, F-59000, Lille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Severe and refractory anaphylaxis in pediatric intensive care unit</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2315-2318</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/03/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine</style></keyword><keyword><style face="normal" font="default" size="100%">Intensive Care Units, Pediatric</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36929486</style></accession-num><notes><style face="normal" font="default" size="100%">Pouessel, Guillaume&#xD;Trochu, Capucine&#xD;Chagnon, Flore&#xD;Diesnis, Remy&#xD;Leteurtre, Stephane&#xD;Deschildre, Antoine&#xD;(FGPICE)&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2315-2318. doi: 10.1111/all.15712. Epub 2023 Mar 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36929486</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15712</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1509</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1509</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hamelmann, E.</style></author><author><style face="normal" font="default" size="100%">Szefler, S. J.</style></author><author><style face="normal" font="default" size="100%">Lau, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Children&apos;s Center Bethel, Protestant Hospital Bethel, University of Bielefeld, Bielefeld, Germany.&#xD;Section of Pediatric Pulmonary and Sleep Medicine, Department of Pediatrics, Breathing Institute, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado.&#xD;Department of Pediatric Pneumology and Immunology, University Medicine Charite Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Severe asthma in children and adolescents</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Allergy</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></alt-periodical><pages><style face="normal" font="default" size="100%">2280-2282</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2019/05/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma/*diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Function Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31074873</style></accession-num><notes><style face="normal" font="default" size="100%">Hamelmann, Eckard&#xD;Szefler, Stanley J&#xD;Lau, Susanne&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Nov;74(11):2280-2282. doi: 10.1111/all.13862. Epub 2019 Jul 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31074873</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13862</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1070</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1070</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bizjak, M.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Kosnik, M.</style></author><author><style face="normal" font="default" size="100%">Terhorst-Molawi, D.</style></author><author><style face="normal" font="default" size="100%">Zver, S.</style></author><author><style face="normal" font="default" size="100%">Burmeister, T.</style></author><author><style face="normal" font="default" size="100%">Siebenhaar, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.&#xD;Department of Dermatology and Allergy, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Dermatological Allergology, Allergie-Centrum Charite, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Hematology Department, University Medical Centre Ljubljana, Ljubljana, Slovenia.&#xD;Medical Department for Hematology, Oncology and Tumor Immunology, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Charite - Universitatsmedizin Berlin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Severe cold urticaria can point to an underlying clonal mast cell disorder</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2609-2613</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/04/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptases</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">basal serum tryptase</style></keyword><keyword><style face="normal" font="default" size="100%">clonal mast cell disorder</style></keyword><keyword><style face="normal" font="default" size="100%">cold urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">systemic mastocytosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33797762</style></accession-num><notes><style face="normal" font="default" size="100%">Bizjak, Mojca&#xD;Maurer, Marcus&#xD;Kosnik, Mitja&#xD;Terhorst-Molawi, Dorothea&#xD;Zver, Samo&#xD;Burmeister, Thomas&#xD;Siebenhaar, Frank&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2609-2613. doi: 10.1111/all.14844. Epub 2021 May 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33797762</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14844</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>20</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">20</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, P. C.</style></author><author><style face="normal" font="default" size="100%">Huang, I. H.</style></author><author><style face="normal" font="default" size="100%">Wang, C. W.</style></author><author><style face="normal" font="default" size="100%">Chung, W. H.</style></author><author><style face="normal" font="default" size="100%">Chen, C. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taipei, and Keelung branches, Taoyuan, Taiwan.&#xD;Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei, and Keelung branches, Taoyuan, Taiwan.&#xD;Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan.&#xD;Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan.&#xD;College of Medicine, Chang Gung University, Taoyuan, Taiwan.&#xD;Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China.&#xD;Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan.&#xD;Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan.&#xD;Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.&#xD;Department of Dermatology, Beijing Tsinghua Chang Gung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.&#xD;Department of Dermatology, Ruijin Hospital; School of Medicine, Shanghai Jiao Tong University, Shanghai, China.&#xD;Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.&#xD;School of Medicine, National Tsing Hua University, Hsinchu, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Severe cutaneous adverse reactions after COVID-19 vaccination: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1383-1386</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/01/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Cutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36627233</style></accession-num><notes><style face="normal" font="default" size="100%">Wu, Po-Chien&#xD;Huang, I-Hsin&#xD;Wang, Chuang-Wei&#xD;Chung, Wen-Hung&#xD;Chen, Chun-Bing&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1383-1386. doi: 10.1111/all.15642. Epub 2023 Jan 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36627233</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15642</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2739</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2739</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Piletta-Zanin, A.</style></author><author><style face="normal" font="default" size="100%">Scherl, A.</style></author><author><style face="normal" font="default" size="100%">Benhamou, A.</style></author><author><style face="normal" font="default" size="100%">Braendle, G.</style></author><author><style face="normal" font="default" size="100%">Caubet, J. C.</style></author><author><style face="normal" font="default" size="100%">Graham, F.</style></author><author><style face="normal" font="default" size="100%">Grosgurin, O.</style></author><author><style face="normal" font="default" size="100%">Harr, T.</style></author><author><style face="normal" font="default" size="100%">Manzano, S.</style></author><author><style face="normal" font="default" size="100%">Nigolian, H.</style></author><author><style face="normal" font="default" size="100%">Ortelli, D.</style></author><author><style face="normal" font="default" size="100%">Pahud, J. P.</style></author><author><style face="normal" font="default" size="100%">la Tour, A. T.</style></author><author><style face="normal" font="default" size="100%">Spechbach, H.</style></author><author><style face="normal" font="default" size="100%">Edder, P.</style></author><author><style face="normal" font="default" size="100%">Eigenmann, P. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Allergy Unit, Department of Woman, Child and Adolescent, University Hospitals of Geneva (HUG), Geneva, Switzerland.&#xD;Official Food Control Authority of the State of Geneva (SCAV), Health Department, Geneva, Switzerland.&#xD;Pediatric Admissions and Emergency Division, Department of Woman, Child and Adolescent, Hug, Geneva, Switzerland.&#xD;Pediatric Emergency Division, Hirslanden Clinique Des Grangettes, Chene-Bougerie, Switzerland.&#xD;Emergency Division, Department of Acute Medicine, Hug, Geneva, Switzerland.&#xD;Allergy and Immunology Service, Department of Medicine, Hug, Geneva, Switzerland.&#xD;Intercommunal Grouping for Extra-Curricular Activities, Association of Geneva Municipalities, Geneva, Switzerland.&#xD;Pediatric Emergency Division, Hopital de la Tour, Meyrin, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Severity of Allergic Reactions in a Real-World Environment Is Independent of the Eliciting Amounts of Foods</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">238-247</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/11/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Food/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39606880</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Patients with food allergies need personalized information on their risk of reaction in &quot;real-life&quot; situations. This multicentric study aimed to investigate the link during accidental reactions between the nature and amount of food allergens consumed in &quot;real-life situation&quot; and the severity of the symptoms. METHODS: Patients were prospectively recruited from December 1, 2020, to December 31, 2021, at the emergency departments in the Geneva University Hospitals and local pediatric emergency facilities, through an allergy outpatient clinic, at school and daycare facilities and trough their primary care physicians. Medical history of patients presenting reactions suggestive with immediate food allergy and suspected food samples were collected. Allergy diagnostic tests were retrospectively and prospectively collected. The samples were analyzed for their allergen content. RESULTS: We recruited 147 subjects with an accidental immediate-type allergic reaction to a food. We were able to collect 115 reaction-eliciting food samples allowing to quantify the allergen amount causing the reaction, as well as correlating this amount to the severity of the reaction. Children represented a large part of the reactors, and most reactions were to common food allergens such as tree nuts, cow&apos;s milk as well as peanuts and hen&apos;s egg. Reactions were mostly to prepackaged foods and seven reactions were to products with precautionary allergy labeling, or without labelling to the eliciting allergen. Reactions were of various degrees of severity, and independent to the amount of allergen ingested. DISCUSSION: The severity of reactions did not show a direct correlation with allergen quantity, emphasizing individual sensitivity. Some reactions occurred with allergen amounts significantly below the legal limit for mandatory labelling of 1 g/kg (1000 ppm) in Switzerland. The study also highlighted considerable variability in allergen concentrations in foods labeled with possible &quot;contaminations&quot; or &quot;traces&quot;. These findings raise questions about the accuracy of allergen labeling and regulations in Switzerland.</style></abstract><notes><style face="normal" font="default" size="100%">Piletta-Zanin, Alexandre&#xD;Scherl, Alexander&#xD;Benhamou, Avigael&#xD;Braendle, Gabriel&#xD;Caubet, Jean-Christoph&#xD;Graham, Francois&#xD;Grosgurin, Olivier&#xD;Harr, Thomas&#xD;Manzano, Sergio&#xD;Nigolian, Haig&#xD;Ortelli, Didier&#xD;Pahud, Jean-Pierre&#xD;la Tour, Aude Tonson&#xD;Spechbach, Herve&#xD;Edder, Patrick&#xD;Eigenmann, Philippe A&#xD;eng&#xD;Direction generale de la sante de Geneve/&#xD;Hopitaux Universitaires de Geneve/&#xD;Service De La Consommation Et Des Affaires Veterinaires/&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):238-247. doi: 10.1111/all.16413. Epub 2024 Nov 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39606880</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16413</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2942</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2942</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lindqvist, M.</style></author><author><style face="normal" font="default" size="100%">Westman, M.</style></author><author><style face="normal" font="default" size="100%">Linneberg, A.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Bergstrom, A.</style></author><author><style face="normal" font="default" size="100%">van Hage, M.</style></author><author><style face="normal" font="default" size="100%">Melen, E.</style></author><author><style face="normal" font="default" size="100%">Leth-Moller, K. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine Solna, Division of Immunology and Respiratory Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.&#xD;Center for Clinical Research and Prevention, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Frederiksberg, Denmark.&#xD;Department of Clinical Science and Education Sodersjukhuset, Karolinska Institutet, Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Centre for Occupational and Environmental Medicine, Region Stockholm, Stockholm, Sweden.&#xD;Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Severity of Pollen-Induced Allergic Rhinitis at 16 Years of Age: Data From the Population-Based BAMSE Birth Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2070-2072</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/04/29</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40298191</style></accession-num><notes><style face="normal" font="default" size="100%">Lindqvist, Magnus&#xD;Westman, Marit&#xD;Linneberg, Allan&#xD;Kull, Inger&#xD;Bergstrom, Anna&#xD;van Hage, Marianne&#xD;Melen, Erik&#xD;Leth-Moller, Katja Biering&#xD;eng&#xD;Astma- och Allergiforbundet/&#xD;Region Stockholm/&#xD;Swedish Resarch Council/&#xD;Swedish cancer and allergy foundation/&#xD;Stiftelsen Konung Gustaf V:s 80-arsfond/&#xD;Hesselman foundation/&#xD;The konsul Th C Bergh foundation/&#xD;Working life and welfare/&#xD;European Comission&apos;s seventh framework 29 program MeDall under grant agreement No. 261357/&#xD;ALK Nordic A/S/&#xD;Hjart-Lungfonden/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2070-2072. doi: 10.1111/all.16571. Epub 2025 Apr 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40298191</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261869 lecture and/or advisory board fees from Airsonett, ALK, AstraZeneca, Chiesi, Novartis, and Sanofi outside the submitted work. M.v.H. reports personal fees from Thermo Fisher Scientific and AstraZeneca, outside the submitted work. M.W. reports lecture fees from Sanofi and Orion Pharma, personal fees from Viatris, and research funding from ALK. Other authors declare no conflicts of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16571</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>259</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">259</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Radzikowska, U.</style></author><author><style face="normal" font="default" size="100%">Golebski, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos Wolfgang, Switzerland.&#xD;Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sex hormones and asthma: The role of estrogen in asthma development and severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">620-622</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Gonadal Steroid Hormones</style></keyword><keyword><style face="normal" font="default" size="100%">Estrogens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">estrogen</style></keyword><keyword><style face="normal" font="default" size="100%">immune mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">menopause</style></keyword><keyword><style face="normal" font="default" size="100%">testosterone</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36214616</style></accession-num><notes><style face="normal" font="default" size="100%">Radzikowska, Urszula&#xD;Golebski, Korneliusz&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):620-622. doi: 10.1111/all.15548. Epub 2022 Dec 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36214616</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15548</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>12</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">12</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brigger, D.</style></author><author><style face="normal" font="default" size="100%">Guntern, P.</style></author><author><style face="normal" font="default" size="100%">Jonsdottir, H. R.</style></author><author><style face="normal" font="default" size="100%">Pennington, L. F.</style></author><author><style face="normal" font="default" size="100%">Weber, B.</style></author><author><style face="normal" font="default" size="100%">Taddeo, A.</style></author><author><style face="normal" font="default" size="100%">Zimmer, G.</style></author><author><style face="normal" font="default" size="100%">Leborgne, N. G. F.</style></author><author><style face="normal" font="default" size="100%">Benarafa, C.</style></author><author><style face="normal" font="default" size="100%">Jardetzky, T. S.</style></author><author><style face="normal" font="default" size="100%">Eggel, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Rheumatology and Immunology, Inselspital, University Hospital, Bern, Switzerland.&#xD;Department of BioMedical Research, University of Bern, Bern, Switzerland.&#xD;Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerland.&#xD;Department of Structural Biology, Stanford University School of Medicine, Stanford, California, USA.&#xD;Institute of Virology and Immunology (IVI), Mittelhausern and Bern, Bern, Switzerland.&#xD;Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.&#xD;Multidisciplinary Center for Infectious Diseases (MCID), University of Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sex-specific differences in immune response to SARS-CoV-2 vaccination vanish with age</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1683-1686</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">age</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">sex</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36680391</style></accession-num><notes><style face="normal" font="default" size="100%">Brigger, Daniel&#xD;Guntern, Pascal&#xD;Jonsdottir, Hulda R&#xD;Pennington, Luke F&#xD;Weber, Benjamin&#xD;Taddeo, Adriano&#xD;Zimmer, Gert&#xD;Leborgne, Nathan G F&#xD;Benarafa, Charaf&#xD;Jardetzky, Theodore S&#xD;Eggel, Alexander&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1683-1686. doi: 10.1111/all.15652. Epub 2023 Jan 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36680391</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15652</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1422</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1422</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dufresne, E.</style></author><author><style face="normal" font="default" size="100%">Poder, T. G.</style></author><author><style face="normal" font="default" size="100%">Samaan, K.</style></author><author><style face="normal" font="default" size="100%">Lacombe-Barrios, J.</style></author><author><style face="normal" font="default" size="100%">Paradis, L.</style></author><author><style face="normal" font="default" size="100%">Des Roches, A.</style></author><author><style face="normal" font="default" size="100%">Begin, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Universite de Montreal, Montreal, QC, Canada.&#xD;Department of Management, Evaluation and Health Policy, School of Public Health, Universite de Montreal, Montreal, QC, Canada.&#xD;Research center of the Institut universitaire de sante mentale de Montreal, Montreal, QC, Canada.&#xD;Departement of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">SF-6Dv2 preference value set for health utility in food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">326-338</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/06/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Canada</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Health Status</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">health utilities</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">quality-adjusted life-year</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32533705</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The lack of a value set allowing the calculation of QALY is an important limitation when establishing the value of emerging therapies to treat food allergy. The aim of this study was to develop a Short-Form Six-Dimension version 2 (SF-6Dv2) preference value set for the calculation of health utility from the Canadian food-allergic population. METHODS: Two hundred ninety-five parents of patients aged 0-17 years old and 154 patients aged 12 years old and above with food allergy were recruited in clinic and online. Participants were asked to complete a self-administered online questionnaire including generic health-related quality of life questionnaires. Various health states described by the SF-6Dv2 were valued with time-trade-off and discrete choice experiments. Data from elicitation techniques were combined using the hybrid regression model. RESULTS: A total of 241 parents and 125 patients performed 3904 time-trade-off and 5112 discrete choice experiments. Utility decrements were estimated for each level of each SF-6Dv2 dimension. Utility values calculated based on the validated preference set were in average 0.15 lower (95%CI: 0.12-0.18) and were poorly correlated (R(2) = 0.46) with those derived from the EQ-5D-5L generic questionnaire in the same cohort. CONCLUSION: A representative preference value set for patients with food allergy was determined using the SF-6Dv2 generic questionnaire. This adapted preference set will contribute to improve the validity of future utility estimates in this population for the appraisal of upcoming potentially impactful but sometimes costly therapies.</style></abstract><notes><style face="normal" font="default" size="100%">Dufresne, Elise&#xD;Poder, Thomas G&#xD;Samaan, Kathryn&#xD;Lacombe-Barrios, Jonathan&#xD;Paradis, Louis&#xD;Des Roches, Anne&#xD;Begin, Philippe&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):326-338. doi: 10.1111/all.14444. Epub 2020 Jul 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32533705</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14444</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2721</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2721</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Raskopf, E.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Zielen, S.</style></author><author><style face="normal" font="default" size="100%">Xenofontos, E.</style></author><author><style face="normal" font="default" size="100%">Decker, L.</style></author><author><style face="normal" font="default" size="100%">Neuhof, C.</style></author><author><style face="normal" font="default" size="100%">Rybachuk, A.</style></author><author><style face="normal" font="default" size="100%">Acikel, C.</style></author><author><style face="normal" font="default" size="100%">Sahin, H.</style></author><author><style face="normal" font="default" size="100%">Allekotte, S.</style></author><author><style face="normal" font="default" size="100%">Del Pozo Collado, S.</style></author><author><style face="normal" font="default" size="100%">Subiza, J. L.</style></author><author><style face="normal" font="default" size="100%">Casanovas, M.</style></author><author><style face="normal" font="default" size="100%">Cuevas, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, Cologne, Germany.&#xD;Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University of Cologne, Cologne, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Pediatrics, University Hospital, Goethe University Frankfurt, Frankfurt, Germany.&#xD;Respiratory Research Institute, Medaimun GmbH, Frankfurt, Germany.&#xD;Inmunotek S.L., Calle Punto Mobi 5, Madrid, Spain.&#xD;Department of Otorhinolaryngology, Technische Universitat Dresden, Dresden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Short-course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">817-826</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/11/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Betula/immunology/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/immunology/therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Subcutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergoids/administration &amp; dosage/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Conjunctivitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">birch pollen</style></keyword><keyword><style face="normal" font="default" size="100%">combined symptom and medication score</style></keyword><keyword><style face="normal" font="default" size="100%">mannan conjugate</style></keyword><keyword><style face="normal" font="default" size="100%">polymerized allergoid</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Inmunotek during the conduct of the trial</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK, grants from ASIT biotech, personal fees from allergopharma, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Allergy Therapeutics, grants and personal fees from Bencard, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Leti, grants, personal fees and non-financial support from Lofarma, non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support from Roxall, grants and personal fees from Stallergenes, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Optima, personal fees from Friulchem, personal fees from Hexal, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Servier, personal fees from Klosterfrau, non-financial support from Atmos,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Bayer, non-financial support from Bionorica, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from FAES, personal fees from GSK, personal fees from MSD, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Johnson and Johnson, personal fees from Meda, personal fees and non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support from Novartis, non-financial support from Otonomy, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Stada, personal fees from UCB, non-financial support from Ferrero, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Hulka, personal fees from Nuvo, grants and personal fees from Ursapharm, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Menarini, personal fees from Mundipharma, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Pohl-Boskamp, grants from Cassella-med GmbH &amp; Co. KG, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Laboratoire de la Mer, personal fees from Sidroga, grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">HAL BV, personal fees from Lek, personal fees from PRO-AdWise, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Angelini Pharma, grants and non-financial support from JGL, grants and personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from bitop, grants from Sanofi, personal fees from Menarini, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">MC declares honoraria for presentations from ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, AstraZeneca, Bencard Allergie/ Allergy Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">GalaxoSmithKline, HAL Allergy, Leti Pharma, Novartis, Roxall, Sanofi-Aventis,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes outside the submitted work. Other non-financial interests: Member of</style></keyword><keyword><style face="normal" font="default" size="100%">German Society of Allergy (AeDA) and German Society of Oto-Rhino-Laryngology,</style></keyword><keyword><style face="normal" font="default" size="100%">Head and Neck Surgery DGHNO-KHC. Coordinating investigator of the present</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">LK reports grants and personal fees from Inmunotek during the</style></keyword><keyword><style face="normal" font="default" size="100%">conduct of the trial</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from Allergopharma, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Viatris, personal fees from HAL Allergie, personal fees form</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, grants and personal fees from LETI Pharma, grants and personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Stallergenes, grants from Quintiles, grants and personal fees from Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from ASIT biotech, grants bromoform, personal fees from Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeut., grants from Astra-Zeneca, grants and personal fees from GSK, grants</style></keyword><keyword><style face="normal" font="default" size="100%">from Inmunotek, personal fees from Cassella med, personal fees from Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Regeneron Pharmaceuticals, personal fees from ROXALL Medizin</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and Membership: AeDA, DGHNO, Deutsche Akademie</style></keyword><keyword><style face="normal" font="default" size="100%">fur Allergologie und klinische Immunologie, HNO-BV, GPA, EAACI. OP reports grants</style></keyword><keyword><style face="normal" font="default" size="100%">for his institution during the conduct of the trial from Inmunotek S.L., Spain,</style></keyword><keyword><style face="normal" font="default" size="100%">and he reports grants and/or personal fees and/or travel support from ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard Allergie GmbH/Allergy Therapeutics, Laboratorios LETI/LETI Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, ROXALL Medizin, Novartis, Sanofi-Aventis and Sanofi-Genzyme, Med</style></keyword><keyword><style face="normal" font="default" size="100%">Update Europe GmbH, streamedup! GmbH, Pohl-Boskamp, John Wiley and Sons/AS,</style></keyword><keyword><style face="normal" font="default" size="100%">Paul-Martini-Stiftung (PMS), Regeneron Pharmaceuticals Inc., RG</style></keyword><keyword><style face="normal" font="default" size="100%">Aerztefortbildung, Institut fur Disease Management, Springer GmbH, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">IQVIA Commercial, Ingress Health, Wort&amp;Bild Verlag, Verlag ME, Procter&amp;Gamble,</style></keyword><keyword><style face="normal" font="default" size="100%">ALTAMIRA, Meinhardt Congress GmbH, Deutsche Forschungsgemeinschaft, Thieme,</style></keyword><keyword><style face="normal" font="default" size="100%">Deutsche AllergieLiga e.V., AeDA, Alfried-Krupp Krankenhaus, Red Maple Trials</style></keyword><keyword><style face="normal" font="default" size="100%">Inc., Koniglich Danisches Generalkonsulat, Medizinische Hochschule Hannover, ECM</style></keyword><keyword><style face="normal" font="default" size="100%">Expro and Conference Management, Technical University Dresden, Lilly, Japanese</style></keyword><keyword><style face="normal" font="default" size="100%">Society of Allergy, Forum fur Medizinische Fortbildung, Dustri-Verlag,</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumolive, ASIT Biotech, LOFARMA, Almirall, Paul-Ehrlich-Institut, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and he is Vice President of the EAACI and member of EAACI Excom,</style></keyword><keyword><style face="normal" font="default" size="100%">member of ext. board of directors DGAKI</style></keyword><keyword><style face="normal" font="default" size="100%">coordinator, main- or co-author of</style></keyword><keyword><style face="normal" font="default" size="100%">different position papers and guidelines in rhinology, allergology and</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">he is associate editor (AE) of Allergy and Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Translational Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">SZ reports grants and personal fees from Inmunotek during</style></keyword><keyword><style face="normal" font="default" size="100%">the conduct of the trial</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Palas GmbH, grants and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics GmbH, grants and personal fees from Bohringer Ingelheim,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Novartis GmbH, personal fees from Lofarma GmbH, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from IMS HEALTH GmbH &amp; Co. OHG, personal fees from GSK, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes, personal fees from Engelhard Arzeneimittel, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Pasteur, personal fees from AstraZeneca, personal fees from Erydel,</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work. SPC is an employee of Inmunotek, JLS and MC are</style></keyword><keyword><style face="normal" font="default" size="100%">shareholders of Inmunotek. All authors had full access to all the data in this</style></keyword><keyword><style face="normal" font="default" size="100%">trial and take complete responsibility for the integrity of the data and accuracy</style></keyword><keyword><style face="normal" font="default" size="100%">of the data analysis.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39520181</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Subcutaneous immunotherapy has emerged as an effective option for treating allergic diseases. Here, we assessed the clinical impact of the mannan-conjugated birch pollen polymerized allergoid T502 in birch pollen-induced allergic rhinoconjunctivitis. METHODS: In this prospective, randomized, double-blind placebo-controlled phase III trial, 298 birch pollen-allergic adult patients were treated across 28 trial sites in Germany. Patients received either placebo or 23,000 mTU T502 subcutaneously over five pre-seasonal visits. Efficacy was assessed by comparing the combined symptom and medication score (CSMS) between placebo and T502 during the peak birch pollen season 2022. Safety, tolerability and immunologic effects were also analyzed. RESULTS: During the peak birch pollen season, the median CSMS of the T502 group was reduced by 33% (p = 0.002) compared to placebo. The median daily symptom score and daily medication score were reduced by 30.4% (p &lt; 0.001) and 56.3% (p = 0.045), respectively. Health related quality of life improved as reflected by reduction of RQLQ values by 31.5% (p &lt; 0.0001). Production of Bet v 1 sIgG4 and Bet v 1 sIgG increased up to 6.2-fold and 3-fold respectively in the T502 group (p &lt; 0.0001). The sIgE/sIgG4 ratio was strongly reduced in the T502 group at V7 (-62.9%, p &lt; 0.0001). No fatalities nor serious adverse events were reported. In total, 16 systemic allergic reactions occurred (Grade I/II). CONCLUSIONS: Treatment with T502 significantly reduced symptoms and medication need in rhinoconjunctivitis patients. The treatment is well tolerated and safe.</style></abstract><notes><style face="normal" font="default" size="100%">Mosges, Ralph&#xD;Raskopf, Esther&#xD;Klimek, Ludger&#xD;Pfaar, Oliver&#xD;Zielen, Stefan&#xD;Xenofontos, Elena&#xD;Decker, Lea&#xD;Neuhof, Christian&#xD;Rybachuk, Anna&#xD;Acikel, Cengizhan&#xD;Sahin, Hacer&#xD;Allekotte, Silke&#xD;Del Pozo Collado, Sandra&#xD;Subiza, Jose Luis&#xD;Casanovas, Miguel&#xD;Cuevas, Mandy&#xD;eng&#xD;Inmunotek S.L., Calle Punto Mobi 5, 28805 Alcala de Henares, Madrid, Spain/&#xD;Clinical Trial, Phase III&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):817-826. doi: 10.1111/all.16387. Epub 2024 Nov 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39520181</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891431</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16387</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2215</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2215</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">de Kam, P. J.</style></author><author><style face="normal" font="default" size="100%">Zielen, S.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Berger, U.</style></author><author><style face="normal" font="default" size="100%">Berger, M.</style></author><author><style face="normal" font="default" size="100%">Cuevas, M.</style></author><author><style face="normal" font="default" size="100%">Cypcar, D.</style></author><author><style face="normal" font="default" size="100%">Fuhr-Horst, A.</style></author><author><style face="normal" font="default" size="100%">Greisner, W. A.</style></author><author><style face="normal" font="default" size="100%">Jandl, M.</style></author><author><style face="normal" font="default" size="100%">Lassmann, S.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Matz, J.</style></author><author><style face="normal" font="default" size="100%">Sher, E.</style></author><author><style face="normal" font="default" size="100%">Smith, C.</style></author><author><style face="normal" font="default" size="100%">Steven, G. C.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">DuBuske, L.</style></author><author><style face="normal" font="default" size="100%">Borghese, F.</style></author><author><style face="normal" font="default" size="100%">Oluwayi, K.</style></author><author><style face="normal" font="default" size="100%">Zwingers, T.</style></author><author><style face="normal" font="default" size="100%">Seybold, M.</style></author><author><style face="normal" font="default" size="100%">Armfield, O.</style></author><author><style face="normal" font="default" size="100%">Heath, M. D.</style></author><author><style face="normal" font="default" size="100%">Hewings, S. J.</style></author><author><style face="normal" font="default" size="100%">Kramer, M. F.</style></author><author><style face="normal" font="default" size="100%">Skinner, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Therapeutics PLC, Worthing, UK.&#xD;Children and Adolescents Department, Allergology, Pulmonology &amp; Cystic Fibrosis, Goethe University, Frankfurt, Germany.&#xD;Bernstein Clinical Research Center, LLC, Cincinnati, Ohio, USA.&#xD;Aerobiology and Pollen Research Unit, Department of Oto-Rhino-Laryngology, Medical University Vienna, Vienna, Austria.&#xD;Department of Otorhinolaryngology, Wiener Gesundheitsverbund, Hospital Hietzing, Vienna, Austria.&#xD;Clinic and Polyclinic of Otorhinolaryngology, University Clinic Carl Gustav Carus, Dresden, Germany.&#xD;Allergy Partners of Western North Carolina, Asheville, North Carolina, USA.&#xD;ENT Research- Institut fur klinische Studien, Essen, Germany.&#xD;Bluegrass Allergy Research, Lexington, Kentucky, USA.&#xD;Hamburger Institut fur Therapieforschung GmbH, Hamburg, Germany.&#xD;Studienzentrum Dr. Sabine Lassmann, Saalfeld, Germany.&#xD;Department of Dermatology and Allergy-Charite Campus Mitte, Universitatsmedizin Berlin, Berlin, Germany.&#xD;Chesapeake Clinical Research, Inc, White Marsh, Maryland, USA.&#xD;Allergy Partners of New Jersey, Ocean Township, New Jersey, USA.&#xD;Certified Research Associates, Cortland, New York, USA.&#xD;Allergy Asthma &amp; Sinus Center, S.C., Greenfield, Wisconsin, USA.&#xD;IMSB (Institute of Computational Biology and Medical Statistics), University at Cologne, Cologne, Germany.&#xD;ClinCompetence, Cologne, Germany.&#xD;Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London, UK.&#xD;Division of Allergy and Immunology, Department of Internal Medicine, George Washington University Hospital, Washington, DC, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2756-2766</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Poaceae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/drug therapy/therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Subcutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/administration &amp; dosage/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">grass pollen allergy</style></keyword><keyword><style face="normal" font="default" size="100%">short-course treatment</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37366581</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A modified grass allergen subcutaneous immunotherapy (SCIT) product with MicroCrystalline Tyrosine and monophosphoryl lipid-A as an adjuvant system (Grass MATA MPL [PQ Grass]) is being developed as short-course treatment of grass-pollen allergic rhinitis (SAR) and/or rhinoconjunctivitis. We sought to evaluate the combined symptom and medication score (CSMS) of the optimized cumulative dose of 27,600 standardized units (SU) PQ Grass in a field setting prior to embarking on a pivotal Phase III trial. METHODS: In this exploratory, randomized, double-blind, placebo-controlled trial subjects were enrolled across 14 sites (Germany and the United States of America). Six pre-seasonal subcutaneous injections of PQ Grass (using conventional or extended regimens) or placebo were administered to 119 subjects (aged 18-65 years) with moderate-to-severe SAR with or without asthma that was well-controlled. The primary efficacy endpoint was CSMS during peak grass pollen season (GPS). Secondary endpoints included Rhinoconjunctivitis Quality of Life Questionnaire standardized (RQLQ-S) and allergen-specific IgG4 response. RESULTS: The mean CSMS compared to placebo was 33.1% (p = .0325) and 39.5% (p = .0112) for the conventional and extended regimens, respectively. An increase in IgG4 was shown for both regimens (p &lt; .01) as well as an improvement in total RQLQ-S for the extended regimen (mean change -0.72, p = .02). Both regimens were well-tolerated. CONCLUSIONS: This trial demonstrated a clinically relevant and statistically significant efficacy response to PQ Grass. Unprecedented effect sizes were reached for grass allergy of up to approximately 40% compared to placebo for CSMS after only six PQ Grass injections. Both PQ Grass regimens were considered equally safe and well-tolerated. Based on enhanced efficacy profile extended regime will be progressed to the pivotal Phase III trial.</style></abstract><notes><style face="normal" font="default" size="100%">de Kam, P J&#xD;Zielen, S&#xD;Bernstein, J A&#xD;Berger, U&#xD;Berger, M&#xD;Cuevas, M&#xD;Cypcar, D&#xD;Fuhr-Horst, A&#xD;Greisner, W A&#xD;Jandl, M&#xD;Lassmann, S&#xD;Worm, M&#xD;Matz, J&#xD;Sher, E&#xD;Smith, C&#xD;Steven, G C&#xD;Mosges, R&#xD;Shamji, M H&#xD;DuBuske, L&#xD;Borghese, F&#xD;Oluwayi, K&#xD;Zwingers, T&#xD;Seybold, M&#xD;Armfield, O&#xD;Heath, M D&#xD;Hewings, S J&#xD;Kramer, M F&#xD;Skinner, M A&#xD;eng&#xD;Allergy Therapeutics/&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2756-2766. doi: 10.1111/all.15788. Epub 2023 Jun 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37366581</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15788</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2202</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2202</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chaudhary, P. P.</style></author><author><style face="normal" font="default" size="100%">Myles, I. A.</style></author><author><style face="normal" font="default" size="100%">Zeldin, J.</style></author><author><style face="normal" font="default" size="100%">Dabdoub, S.</style></author><author><style face="normal" font="default" size="100%">Deopujari, V.</style></author><author><style face="normal" font="default" size="100%">Baveja, R.</style></author><author><style face="normal" font="default" size="100%">Baker, R.</style></author><author><style face="normal" font="default" size="100%">Bengtson, S.</style></author><author><style face="normal" font="default" size="100%">Sutton, A.</style></author><author><style face="normal" font="default" size="100%">Levy, S.</style></author><author><style face="normal" font="default" size="100%">Hourigan, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Epithelial Therapeutics Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.&#xD;Division of Biostatistics and Computational Biology, College of Dentistry, University of Iowa, Iowa City, Iowa, USA.&#xD;Inova Children&apos;s Hospital, Falls Church, Virginia, USA.&#xD;Fairfax Neonatal Associates, Fairfax, Virginia, USA.&#xD;College of William and Mary, Williamsburg, Virginia, USA.&#xD;Clinical Microbiome Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Shotgun metagenomic sequencing on skin microbiome indicates dysbiosis exists prior to the onset of atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2724-2731</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Dysbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Malassezia</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">declare.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37422700</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: While the microbiome is increasingly seen as a targetable contributor to atopic dermatitis (AD), questions remain as to whether the dysbiosis is secondary to diseased skin or if it predates symptom onset. Previous work has evaluated how the skin microbiome changes with age and established the influence of factors like delivery mode and breastfeeding on global microbiome diversity. However, these studies were unable to identify taxa which predict subsequent AD. METHODS: Skin swab samples were collected from the first week of life for 72 children in the neonatal intensive care unit (NICU) at a single site hospital. Participants were followed for 3 years to determine their health status. We applied shotgun metagenomic sequencing to assess the microbiome differences between 31 children who went on to develop AD and 41 controls. RESULTS: We identified that subsequent development of AD was associated with differential abundance of several bacterial and fungal taxa as well as several metabolic pathways, each of which have been previously associated with active AD. CONCLUSIONS: Our work provides evidence of reproducibility for the previously reported dysbiotic signatures predating AD onset while also expanding prior findings through the first use of metagenomic assessment prior to AD onset. While extrapolation of our findings beyond the pre-term, NICU cohort is limited, our findings add to the evidence that the dysbiosis associated with AD pre-dates disease onset rather than reflect a secondary consequence of skin inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Chaudhary, Prem Prashant&#xD;Myles, Ian A&#xD;Zeldin, Jordan&#xD;Dabdoub, Shareef&#xD;Deopujari, Varsha&#xD;Baveja, Rajiv&#xD;Baker, Robin&#xD;Bengtson, Sarah&#xD;Sutton, Ashleigh&#xD;Levy, Shira&#xD;Hourigan, Suchitra K&#xD;eng&#xD;ZIA AI001043/ImNIH/Intramural NIH HHS/&#xD;Research Support, N.I.H., Intramural&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2724-2731. doi: 10.1111/all.15806. Epub 2023 Jul 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37422700</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10543534</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15806</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2974</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2974</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karnaneedi, S.</style></author><author><style face="normal" font="default" size="100%">Anvari, S.</style></author><author><style face="normal" font="default" size="100%">Brunner, S.</style></author><author><style face="normal" font="default" size="100%">Tuano, K. S.</style></author><author><style face="normal" font="default" size="100%">Su, B. B.</style></author><author><style face="normal" font="default" size="100%">Hira, S.</style></author><author><style face="normal" font="default" size="100%">Heidari, S.</style></author><author><style face="normal" font="default" size="100%">Hira, D.</style></author><author><style face="normal" font="default" size="100%">Davis, C. M.</style></author><author><style face="normal" font="default" size="100%">Lopata, A. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular Allergy Research Laboratory, College of Science and Engineering, James Cook University, Townsville, QLD, Australia.&#xD;Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, QLD, Australia.&#xD;Centre for Food and Allergy Research, Murdoch Children&apos;s Research Institute, Melbourne, Victoria, Australia.&#xD;Baylor College of Medicine, Texas Children&apos;s Hospital, Department of Pediatrics, Division of Immunology, Allergy and Retrovirology, Houston, Texas, USA.&#xD;Texas Children&apos;s Hospital, William T. Shearer Center for Human Immunobiology, Houston, Texas, USA.&#xD;Allergy Medical Centre, Townsville, QLD, Australia.&#xD;Tropical Futures Institute, James Cook University Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Shrimp Allergy-Distinct Allergen Sensitization Profiles Between Intercontinental Cohorts</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2909-2913</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/07/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">hemocyanin</style></keyword><keyword><style face="normal" font="default" size="100%">igE antibody</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">shrimp allergy</style></keyword><keyword><style face="normal" font="default" size="100%">tropomyosin</style></keyword><keyword><style face="normal" font="default" size="100%">from NIH NIAID and DBV Technologies for contracted work outside of the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">project</style></keyword><keyword><style face="normal" font="default" size="100%">S.A. acknowledges consulting fees with DBV Technologies. C.M.D. receives</style></keyword><keyword><style face="normal" font="default" size="100%">research grant support from the NIH NIAID (U01 AI126614, U54 AI17804), DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Regeneron Pharmaceuticals, Takeda Pharmaceuticals, and Novartis.</style></keyword><keyword><style face="normal" font="default" size="100%">The other authors declare that they have no known competing financial interests</style></keyword><keyword><style face="normal" font="default" size="100%">or personal relationships that could have appeared to influence the work reported</style></keyword><keyword><style face="normal" font="default" size="100%">in this paper.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40678828</style></accession-num><notes><style face="normal" font="default" size="100%">Karnaneedi, Shaymaviswanathan&#xD;Anvari, Sara&#xD;Brunner, Shea&#xD;Tuano, Karen S&#xD;Su, Brenda Bin&#xD;Hira, Saachi&#xD;Heidari, Sahel&#xD;Hira, Diamond&#xD;Davis, Carla M&#xD;Lopata, Andreas L&#xD;eng&#xD;National Health and Medical Research Council/&#xD;Centre for Food and Allergy Research/&#xD;National Institute of Allergy and Infectious Diseases/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2909-2913. doi: 10.1111/all.16662. Epub 2025 Jul 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40678828</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486353</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16662</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2372</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2372</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Banerjee, S.</style></author><author><style face="normal" font="default" size="100%">Phelan, C. P.</style></author><author><style face="normal" font="default" size="100%">Reese, B. B.</style></author><author><style face="normal" font="default" size="100%">Conroy, M. E.</style></author><author><style face="normal" font="default" size="100%">Anthony, R. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sialylation of IgE does not impact its interaction with FcepsilonRI</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">761-764</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/01/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, IgE</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38226716</style></accession-num><notes><style face="normal" font="default" size="100%">Banerjee, Sayantan&#xD;Phelan, Colleen P&#xD;Reese, Brian B&#xD;Conroy, Michelle E&#xD;Anthony, Robert M&#xD;eng&#xD;R01 AI139669/AI/NIAID NIH HHS/&#xD;R01 AI167933/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):761-764. doi: 10.1111/all.16014. Epub 2024 Jan 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38226716</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11064860</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16014</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1659</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1659</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Duhring, L.</style></author><author><style face="normal" font="default" size="100%">Petry, J.</style></author><author><style face="normal" font="default" size="100%">Lilienthal, G. M.</style></author><author><style face="normal" font="default" size="100%">Bartsch, Y. C.</style></author><author><style face="normal" font="default" size="100%">Kubiak, M.</style></author><author><style face="normal" font="default" size="100%">Pfeufer, C.</style></author><author><style face="normal" font="default" size="100%">Lehrian, S.</style></author><author><style face="normal" font="default" size="100%">Buhre, J. S.</style></author><author><style face="normal" font="default" size="100%">Lunding, H. B.</style></author><author><style face="normal" font="default" size="100%">Kern, C.</style></author><author><style face="normal" font="default" size="100%">Behrends, J.</style></author><author><style face="normal" font="default" size="100%">Walsemann, T.</style></author><author><style face="normal" font="default" size="100%">Gadert, L.</style></author><author><style face="normal" font="default" size="100%">Sommer, C.</style></author><author><style face="normal" font="default" size="100%">Kruger, L.</style></author><author><style face="normal" font="default" size="100%">Blanchard, V.</style></author><author><style face="normal" font="default" size="100%">Dehmel, S.</style></author><author><style face="normal" font="default" size="100%">Jappe, U.</style></author><author><style face="normal" font="default" size="100%">Rahmoller, J.</style></author><author><style face="normal" font="default" size="100%">Ehlers, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratories of Immunology and Antibody Glycan Analysis, Institute of Nutritional Medicine, University of Lubeck and University Hospital Schleswig-Holstein, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Lubeck, Germany.&#xD;Core Facility Fluorescence Cytometry, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.&#xD;Division of Clinical and Molecular Allergology, Priority Area Chronic Lung Diseases, Research Center Borstel, Leibniz Lung Center, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany.&#xD;Fraunhofer Institute of Toxicology and Experimental Medicine, German Center for Lung Research (DZL), Hannover, Germany.&#xD;Department of Human Medicine, Medical School Berlin, Berlin, Germany.&#xD;Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charite-Universitatsmedizin Berlin, Corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University of Lubeck, Lubeck, Germany.&#xD;Department of Anesthesiology and Intensive Care, University of Lubeck and University Medical Center of Schleswig-Holstein, Lubeck, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sialylation of IgE reduces FcepsilonRIalpha interaction and mast cell and basophil activation in vitro and increases IgE half-life in vivo</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2301-2305</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/02/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Half-Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgE</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36724158</style></accession-num><notes><style face="normal" font="default" size="100%">Duhring, Lara&#xD;Petry, Janina&#xD;Lilienthal, Gina-Maria&#xD;Bartsch, Yannic C&#xD;Kubiak, Marie&#xD;Pfeufer, Clarissa&#xD;Lehrian, Selina&#xD;Buhre, Jana S&#xD;Lunding, Hanna B&#xD;Kern, Carsten&#xD;Behrends, Jochen&#xD;Walsemann, Theresa&#xD;Gadert, Leonie&#xD;Sommer, Charline&#xD;Kruger, Lynn&#xD;Blanchard, Veronique&#xD;Dehmel, Susann&#xD;Jappe, Uta&#xD;Rahmoller, Johann&#xD;Ehlers, Marc&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2301-2305. doi: 10.1111/all.15665. Epub 2023 Feb 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36724158</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15665</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>460</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">460</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Gao, Y.</style></author><author><style face="normal" font="default" size="100%">Jiao, J.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Nasal diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Signatures of positive selection are enriched in genome-wide associated allergy alleles</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3134-3137</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/06/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style face="normal" font="default" size="100%">*Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35652364</style></accession-num><notes><style face="normal" font="default" size="100%">Li, Jingyun&#xD;Zhang, Xu&#xD;Gao, Yunbo&#xD;Jiao, Jian&#xD;Wang, Chengshuo&#xD;Zhang, Yuan&#xD;Zhang, Luo&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3134-3137. doi: 10.1111/all.15398. Epub 2022 Jun 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35652364</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15398</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>765</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">765</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walters, E. H.</style></author><author><style face="normal" font="default" size="100%">Shukla, S. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medicine and Menzies Institute, University of Tasmania, Hobart, TAS, Australia.&#xD;Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Silicosis: Pathogenesis and utility of animal models of disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3241-3242</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/10/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Silicosis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">occupational allergies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34596272</style></accession-num><notes><style face="normal" font="default" size="100%">Walters, Eugene Haydn&#xD;Shukla, Shakti D&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3241-3242. doi: 10.1111/all.14880.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34596272</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14880</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2795</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2795</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Denton, E.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Asthma, Allergy and Clinical Immunology, Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia.&#xD;School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.&#xD;Public Health &amp; Preventive Medicine, Monash University, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Silver (Birch) Bullet for Children With Tree Pollen Allergy: Single Allergen Immunotherapy With Birch Extract Protects Across the Birch Homologous Group Pollen Season</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">647-650</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2025/01/23</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39846331</style></accession-num><notes><style face="normal" font="default" size="100%">Denton, Eve&#xD;Hew, Mark&#xD;O&apos;Hehir, Robyn E&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):647-650. doi: 10.1111/all.16480. Epub 2025 Jan 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39846331</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16480</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>508</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">508</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anvari, S.</style></author><author><style face="normal" font="default" size="100%">Brunner, S.</style></author><author><style face="normal" font="default" size="100%">Tuano, K. S.</style></author><author><style face="normal" font="default" size="100%">Su, B. B.</style></author><author><style face="normal" font="default" size="100%">Karnaneedi, S.</style></author><author><style face="normal" font="default" size="100%">Lopata, A. L.</style></author><author><style face="normal" font="default" size="100%">Davis, C. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Section of Immunology, Allergy and Retrovirology, Baylor College of Medicine, Texas Children&apos;s Hospital, Houston, Texas, USA.&#xD;Baylor College of Medicine, William T. Shearer Center for Human Immunobiology, Houston, Texas, USA.&#xD;James Cook University, Australian Institute of Tropical Health and Medicine, Centre for Molecular Therapeutics, Douglas, QLD, Australia.&#xD;Tropical Futures Institute, James Cook University, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Similar IgE binding patterns in Gulf of Mexico and Southeast Asian shrimp species in US shrimp allergic patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2825-2829</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/05/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Gulf of Mexico</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">shrimp allergy</style></keyword><keyword><style face="normal" font="default" size="100%">shrimp oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">tropomyosin</style></keyword><keyword><style face="normal" font="default" size="100%">DBV Technologies, Regeneron and Aimmune Therapeutics. Dr. Davis is a consultant</style></keyword><keyword><style face="normal" font="default" size="100%">for Moonlight Therapeutics and received grant funding from ThermoFisher</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific. Dr Lopata received research contract funding from Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics. The other authors declare that they have no known competing</style></keyword><keyword><style face="normal" font="default" size="100%">financial interests or personal relationships that could have appeared to</style></keyword><keyword><style face="normal" font="default" size="100%">influence the work reported in this paper.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35524542</style></accession-num><notes><style face="normal" font="default" size="100%">Anvari, Sara&#xD;Brunner, Shea&#xD;Tuano, Karen S&#xD;Su, Brenda Bin&#xD;Karnaneedi, Shaymaviswanathan&#xD;Lopata, Andreas L&#xD;Davis, Carla M&#xD;eng&#xD;R34 AI157948/AI/NIAID NIH HHS/&#xD;NH/NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2825-2829. doi: 10.1111/all.15363. Epub 2022 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35524542</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10585665</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15363</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3130</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3130</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmidt, M.</style></author><author><style face="normal" font="default" size="100%">Knorz, A.</style></author><author><style face="normal" font="default" size="100%">Meder, K.</style></author><author><style face="normal" font="default" size="100%">Goller, S.</style></author><author><style face="normal" font="default" size="100%">Imdahl, F.</style></author><author><style face="normal" font="default" size="100%">Rocca, Y.</style></author><author><style face="normal" font="default" size="100%">Goebeler, M.</style></author><author><style face="normal" font="default" size="100%">Khoueiry, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Venereology and Allergology, University Hospital Wurzburg, Wurzburg, Germany.&#xD;Single Cell Center Wurzburg, Helmholtz Institute for RNA-Based Infection Research (HIRI), Wurzburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single Cell Analysis Reveals Dynamic Changes of Distinct Cell Populations in Human Nickel Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">T cell response</style></keyword><keyword><style face="normal" font="default" size="100%">allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">innate immune activation</style></keyword><keyword><style face="normal" font="default" size="100%">nickel allergy</style></keyword><keyword><style face="normal" font="default" size="100%">single cell analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41090989</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Metal allergies are prime examples of delayed-type hypersensitivity divided into two phases: in the sensitization phase, initial contact with an allergen leads to activation of skin-resident cells and formation of metal-reactive T cells. during elicitation, these T cells mount an immune response resulting in clinically apparent eczema within 72 h after exposure. Two main mechanisms have been implicated in the initiation of metal hypersensitivity: direct or indirect activation of innate immune receptors such as Toll-like receptor 4, and conditional innate immune activation via the NLRP3 inflammasome. Yet, the responsible cell type(s) mediating these responses are unknown. Moreover, it is unclear whether the elicitation phase is mainly dominated by infiltration of circulating metal-responsive T cells or if tissue-resident T cells contribute. METHODS: Here, we analyzed the relevance of different cell types in human nickel hypersensitivity by single-cell RNA sequencing and immunofluorescence analysis of skin samples of nickel-sensitized donors epicutaneously exposed to diluent and nickel for 8 or 72 h. RESULTS AND CONCLUSION: Nickel specifically activated distinct populations of endothelial cells, suprabasal keratinocytes, fibroblasts, and CCR7(+) dendritic cells, co-expressing the TLR4-interacting proteogylcan DCN and CCR7 ligand CCL21 within 8 h. Skin-resident T cells were not involved in the early hypersensitivity response, as their gene expression remained unaltered 8 h after nickel exposure. However, substantial changes in the cutaneous T cell compartments occurred after 72 h, with massive infiltration of KLF2(+) central memory T cells being a recurrent feature of both nickel-sensitized patients and individuals allergic to the glucocorticoid contact allergen budesonide.</style></abstract><notes><style face="normal" font="default" size="100%">Schmidt, Marc&#xD;Knorz, Andrea&#xD;Meder, Katharina&#xD;Goller, Simon&#xD;Imdahl, Fabian&#xD;Rocca, Yamila&#xD;Goebeler, Matthias&#xD;Khoueiry, Pierre&#xD;eng&#xD;SG is supported by TWINSIGHT, a fellowship program of the University Hospital Wurzburg funded by the Else Kroner-Fresenius Stiftung./&#xD;This work was funded by the Bavarian State Ministry of Economic Affairs, Regional Development and Energy within the project: Single-cell analysis in personalized medicine at the Helmholtz-Institute for RNA-based Infection Research implemented in the Single-Cell Center Wurzburg./&#xD;Denmark&#xD;Allergy. 2025 Oct 15. doi: 10.1111/all.70108.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41090989</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70108</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>859</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">859</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brnjarchevska Blazhevska, T.</style></author><author><style face="normal" font="default" size="100%">Babacic, H.</style></author><author><style face="normal" font="default" size="100%">Sibinovska, O.</style></author><author><style face="normal" font="default" size="100%">Dobrevski, B.</style></author><author><style face="normal" font="default" size="100%">Kirijas, M.</style></author><author><style face="normal" font="default" size="100%">Milanovski, G.</style></author><author><style face="normal" font="default" size="100%">Arsov, T.</style></author><author><style face="normal" font="default" size="100%">Petlichkovski, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine-Skopje, Institute for Immunobiology and Human Genetics, Ss. Cyril and Methodius University, Skopje, North Macedonia.&#xD;Karolinska Institute, Stockholm, Sweden.&#xD;John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A single dose of BNT162b2 vaccine elicits strong humoral response in SARS-CoV-2 seropositive individuals</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">296-298</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/08/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Spike Glycoprotein, Coronavirus</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34386995</style></accession-num><notes><style face="normal" font="default" size="100%">Brnjarchevska Blazhevska, Teodora&#xD;Babacic, Haris&#xD;Sibinovska, Olgica&#xD;Dobrevski, Boban&#xD;Kirijas, Meri&#xD;Milanovski, Gorjan&#xD;Arsov, Todor&#xD;Petlichkovski, Aleksandar&#xD;eng&#xD;Faculty of Medicine, University Ss Cyril and Methodius, Skopje, North Macedonia/&#xD;National Health Insurance Fund and Ministry of Education and Science of North Macedonia/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):296-298. doi: 10.1111/all.15047. Epub 2021 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34386995</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441874</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15047</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>828</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">828</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agusti, A.</style></author><author><style face="normal" font="default" size="100%">Fabbri, L.</style></author><author><style face="normal" font="default" size="100%">Lahousse, L.</style></author><author><style face="normal" font="default" size="100%">Singh, D.</style></author><author><style face="normal" font="default" size="100%">Papi, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Respiratory Institute, IDIBAPS, CIBERES, Hospital Clinic, Univ. Barcelona, Barcelona, Spain.&#xD;Section of Respiratory Medicine, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.&#xD;Department of Bioanalysis, Ghent University, Ghent, Belgium.&#xD;Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.&#xD;Emergency Department, Respiratory Medicine, University of Ferrara, University Hospital S. Anna, Ferrara, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1105-1113</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/09/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenergic beta-2 Receptor Agonists</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/chemically induced/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchodilator Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Muscarinic Antagonists/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Nebulizers and Vaporizers</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">quality-of-life</style></keyword><keyword><style face="normal" font="default" size="100%">grants and personal fees from GSK, grants and personal fees from Menarini, grants</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from Chiesi, grants and personal fees from AZ, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Zambon, outside the submitted work. Dr. Fabbri reports personal fees and</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from AstraZeneca, personal fees and non-financial support</style></keyword><keyword><style face="normal" font="default" size="100%">from Chiesi, personal fees and non-financial support from GSK, personal fees and</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from Novartis, personal fees and non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, personal fees and non-financial support from Zambon,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Lusofarmaco, outside the submitted work. Dr. Lahousse has</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose. Dr. Singh reports personal fees from Chiesi, during the</style></keyword><keyword><style face="normal" font="default" size="100%">conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from AstraZeneca, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, personal fees from Chiesi, personal fees from Cipla,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Genentech, personal fees from GlaxoSmithKline, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Glenmark, personal fees from Gossamerbio, personal fees from Menarini,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Mundipharma, personal fees from Novartis, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Peptinnovate, personal fees from Pfizer, personal fees from Pulmatrix, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Theravance, personal fees from Verona, outside the submitted work. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Papi reports grants, personal fees, non-financial support and other from</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, grants, personal fees and non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, grants, personal fees, non-financial support and other from</style></keyword><keyword><style face="normal" font="default" size="100%">Boehringer Ingelheim, grants, personal fees, non-financial support and other from</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi Farmaceutici, grants, personal fees, non-financial support and other from</style></keyword><keyword><style face="normal" font="default" size="100%">TEVA, personal fees, non-financial support and other from Mundipharma, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees, non-financial support and other from Zambon, personal fees, non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support and other from Novartis, grants, personal fees and non-financial support</style></keyword><keyword><style face="normal" font="default" size="100%">from Menarini, personal fees, non-financial support and other from</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron, personal fees from Roche, grants from Fondazione Maugeri,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from Fondazione Chiesi, personal fees from Edmondpharma, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34478578</style></accession-num><abstract><style face="normal" font="default" size="100%">A significant number of patients with asthma remain uncontrolled despite treatment with inhaled corticosteroids (ICS) and long-acting beta2 adrenergic bronchodilators (LABA). The addition of long-acting antimuscarinic agents (LAMA) can improve the management of asthma in these patients. Recently, three novel triple therapy (ICS/LABA/LAMA) formulations in a single-inhaler device (SITT) have been investigated in patients with uncontrolled asthma despite ICS/LABA treatment. Here, we review systematically the evidence available to date in relation to SITT in patients with uncontrolled asthma despite ICS-LABA treatment and conclude that SITT is a safe and effective therapeutic alternative in these patients. We also discuss how to position this new therapeutic alternative in their practical clinical management as well as the opportunities and challenges that it may generate for patients, physicians, and payers.</style></abstract><notes><style face="normal" font="default" size="100%">Agusti, Alvar&#xD;Fabbri, Leonardo&#xD;Lahousse, Lies&#xD;Singh, Dave&#xD;Papi, Alberto&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1105-1113. doi: 10.1111/all.15076. Epub 2021 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34478578</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9290056</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15076</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>531</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">531</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">d&apos;Art, Y. M.</style></author><author><style face="normal" font="default" size="100%">Forristal, L.</style></author><author><style face="normal" font="default" size="100%">Byrne, A. M.</style></author><author><style face="normal" font="default" size="100%">Fitzsimons, J.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">DunnGalvin, A.</style></author><author><style face="normal" font="default" size="100%">Hourihane, J. O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Paediatrics and Child Health, University College Cork, Cork, Ireland.&#xD;INFANT Centre, University College Cork, Cork, Ireland.&#xD;Applied Psychology, University College Cork, Cork, Ireland.&#xD;Children&apos;s Health Ireland, Dublin, Ireland.&#xD;Trinity College Dublin, Dublin, Ireland.&#xD;Royal College of Surgeons in Ireland, Dublin, Ireland.&#xD;Amsterdam University Medical Centers, AMC, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single low-dose exposure to cow&apos;s milk at diagnosis accelerates cow&apos;s milk allergic infants&apos; progress on a milk ladder programme</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2760-2769</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/04/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Milk Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Cow&apos;s milk allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Nutricia, RvR declares consultancies for HAL Allergy BV, Citeq BV, Angany Inc.,</style></keyword><keyword><style face="normal" font="default" size="100%">speaker fees from HAL Allergy BV, ThermoFisher Scientific, ALK and stock options</style></keyword><keyword><style face="normal" font="default" size="100%">from Angany Inc. ADG receives research funding and speaker fees from Aimmune</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics and DBV Technologies, JO&apos;BH receives research funding, speaker fees</style></keyword><keyword><style face="normal" font="default" size="100%">and consultancy fees from Aimmune Therapeutics, research funding and speaker fees</style></keyword><keyword><style face="normal" font="default" size="100%">from DBV Technologies, research funding from Johnson&amp;Johnson, Clemens von Pirquet</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation and Temple St Hospital Research Foundation.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35403213</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cow&apos;s milk protein allergy (CMPA) is one of the most common food allergies in infancy. Most infants with CMPA tolerate baked milk from diagnosis and gradually acquire increased tolerance. Nevertheless, parents often display significant anxiety about this condition and a corresponding reluctance to progress with home introduction of dairy due to concerns about possible allergic reactions. OBJECTIVE: To evaluate the impact on gradual home introduction of foods containing cows&apos; milk after a supervised, single low-dose exposure to whole milk at time of diagnosis. METHODS: Infants less than 12 months old referred with suspected IgE-mediated cow&apos;s milk allergy were recruited to an open-label randomized, controlled trial of intervention-a single dose of fresh cow&apos;s milk, using the validated dose of milk that would elicit reactions in 5% of CMPA subjects-the ED(05) - vs routine care. Both groups implemented graded exposure to CM (using the 12 step MAP Milk Tolerance Induction Ladder), at home. Parents completed food allergy quality of life questionnaires and State and Trait Anxiety Inventories (STAI). Main outcome measures were milk ladder position at 6 months and 12 months post-randomization. RESULTS: Sixty patients were recruited, 57 (95%) were followed to 6 months. By 6 months, 27/37 (73%) intervention subjects had reached step 6 or above on the milk ladder compared to 10/20 (50%) control subjects (p = .048). By 6 months, 11/37 (30%) intervention subjects had reached step 12 (i.e. drinking unheated cow&apos;s milk) compared to 2/20 (10%) of the controls (p = .049). Twelve months post-randomization, 31/36(86%) of the intervention group and 15/19(79%) of the control group were on step 6 or above. However, 24/37 (65%) of the intervention group were at step 12 compared to 7/20 (35%) of the control group (p = .03). Maternal STAIs were significantly associated with their infants&apos; progress on the milk ladder and with changes in skin prick test and spIgE levels at 6 and 12 months. CONCLUSION: This study demonstrates the safety and effectiveness of introduction of baked milk implemented immediately after diagnosis of cows&apos; milk allergy in a very young cohort. A supervised single dose of milk at the ED(05) significantly accelerates this further, probably by giving parents the confidence to proceed. Maternal anxiety generally reflects infants&apos; progress towards completion of the milk ladder, but pre-existing high levels of maternal anxiety are associated with poorer progress.</style></abstract><notes><style face="normal" font="default" size="100%">d&apos;Art, Yvonne M&#xD;Forristal, Lisa&#xD;Byrne, Aideen M&#xD;Fitzsimons, John&#xD;van Ree, Ronald&#xD;DunnGalvin, Audrey&#xD;Hourihane, Jonathan O&apos;Brien&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2760-2769. doi: 10.1111/all.15312. Epub 2022 Apr 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35403213</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9543429</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15312</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2817</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2817</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hsin, L.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author><author><style face="normal" font="default" size="100%">Aui, P. M.</style></author><author><style face="normal" font="default" size="100%">Deckert, K.</style></author><author><style face="normal" font="default" size="100%">Hogarth, P. M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">van Zelm, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.&#xD;Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia.&#xD;Public Health &amp; Preventive Medicine, Monash University, Melbourne, Victoria, Australia.&#xD;Immune Therapies Group, Burnet Institute, Melbourne, Victoria, Australia.&#xD;Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Single Multiplex CytoBas Assay Incorporating Eight Major Components for Accurate Detection of Allergen Sensitization in Asthma and Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1047-1059</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/03/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Flow Cytometry/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis (AR)</style></keyword><keyword><style face="normal" font="default" size="100%">atopic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">component-resolved diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">grass pollen</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite</style></keyword><keyword><style face="normal" font="default" size="100%">pet allergy</style></keyword><keyword><style face="normal" font="default" size="100%">(PCT/AU2020/051116). All other authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40052465</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic rhinitis and asthma can be triggered by a variety of aeroallergens, including house dust mites (HDM), tree and grass pollen, and household pets. Identification of the relevant allergen is critical for lifestyle changes and treatments, including allergen immunotherapy. We here assessed the diagnostic performance and clinical utility of a single flow cytometry staining of basophils with major aeroallergen components (AeroDiff CytoBas). METHODS: In 156 atopic patients with allergic rhinitis/asthma and 21 non-atopic individuals, allergen-specific IgE levels were determined by ImmunoCAP, and component-specific IgE by ELISA. PBMCs were analyzed by flow cytometry with basophil markers and eight fluorochrome-conjugated allergen component tetramers. RESULTS: Patients were stratified for sensitization to each of the four allergens. Allergen-component staining in a single multiplex CytoBas assay and component-specific IgE serology performed similarly for Der p 2, Lol p 1, Fel d 1, and Can f 1 (ROC AUC: 0.76-0.97 vs. 0.73-0.93). CytoBas had greater diagnostic accuracy than component-specific IgE serology (p &lt; 0.001) for HDM sensitization using Der f 1 or Der p 1, and grass pollen using Lol p 5 or Phl p 1. Furthermore, the combined evaluation of Der p 1 and Der p 2 with CytoBas was 96.3% sensitive and 90.7% specific for HDM sensitization. The combined evaluation of Lol p 1 and Lol p 5 achieved 95.4% sensitivity and 96.4% specificity for ryegrass pollen sensitization. CONCLUSION: AeroDiff CytoBas has similar to superior diagnostic accuracy compared to singleplex IgE serology, with the additional advantage of a single assay to evaluate multiple allergens. This enables precise and efficient component-resolved diagnosis of aeroallergen sensitization to guide personalized treatment for patients with allergic rhinitis and/or asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Hsin, Lin&#xD;Hew, Mark&#xD;Aui, Pei Mun&#xD;Deckert, Kirsten&#xD;Hogarth, P Mark&#xD;O&apos;Hehir, Robyn E&#xD;van Zelm, Menno C&#xD;eng&#xD;National Health and Medical Research Council/&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1047-1059. doi: 10.1111/all.16513. Epub 2025 Mar 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40052465</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969309</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16513</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>816</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">816</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weng, N.</style></author><author><style face="normal" font="default" size="100%">Miller, M.</style></author><author><style face="normal" font="default" size="100%">Pham, A. K.</style></author><author><style face="normal" font="default" size="100%">Komor, A. C.</style></author><author><style face="normal" font="default" size="100%">Broide, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University of California San Diego, La Jolla, California, USA.&#xD;Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-base editing of rs12603332 on chromosome 17q21 with a cytosine base editor regulates ORMDL3 and ATF6alpha expression</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1139-1149</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/09/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Chromosomes</style></keyword><keyword><style face="normal" font="default" size="100%">*Chromosomes, Human, Pair 17</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytosine</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style face="normal" font="default" size="100%">Transcription Factors/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Crispr</style></keyword><keyword><style face="normal" font="default" size="100%">Cytosine Base Editor</style></keyword><keyword><style face="normal" font="default" size="100%">Ormdl3</style></keyword><keyword><style face="normal" font="default" size="100%">Snp</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34525218</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Genetic association studies have demonstrated that the SNP rs12603332 located on chromosome 17q21 is highly associated with the risk of the development of asthma. METHODS: To determine whether SNP rs1260332 is functional in regulating levels of ORMDL3 expression, we used a Cytosine Base Editor (CBE) plasmid DNA or a CBE mRNA to edit the rs12603332 C risk allele to the T non-risk allele in a human lymphocyte cell line (i.e., Jurkat cells) and in primary human CD4 T cells that carry the C risk alleles. RESULTS: Jurkat cells with the rs12603332 C risk allele expressed significantly higher levels of ORMDL3 mRNA, as well as the ORMDL3 regulated gene ATF6alpha as assessed by qPCR compared to Jurkat clones with the T non-risk allele. In primary human CD4 T cells, we edited 90 +/- 3% of the rs12603332-C risk allele to the T non-risk allele and observed a reduction in ORMDL3 and ATF6alpha expression. Bioinformatic analysis predicted that the non-risk allele rs12603332-T could be the central element of the E-box binding motif (CANNTG) recognized by the E47 transcription factor. An EMSA assay confirmed the bioinformatics prediction demonstrating that a rs12603332-T containing probe bound to the transcription factor E47 in vitro. CONCLUSIONS: SNP rs12603332 is functional in regulating the expression of ORMDL3 as well as ORMDL3 regulated gene ATF6alpha expression. In addition, we demonstrate the use of CBE technology in functionally interrogating asthma-associated SNPs using studies of primary human CD4 cells.</style></abstract><notes><style face="normal" font="default" size="100%">Weng, Ning&#xD;Miller, Marina&#xD;Pham, Alexa K&#xD;Komor, Alexis C&#xD;Broide, David H&#xD;eng&#xD;U19 AI070535/AI/NIAID NIH HHS/&#xD;R01 AI107779/AI/NIAID NIH HHS/&#xD;T32 AI007469/AI/NIAID NIH HHS/&#xD;R01 AI124236/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1139-1149. doi: 10.1111/all.15092. Epub 2021 Sep 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34525218</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8920947</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15092</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-cell analysis of allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">346-348</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/01/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Single-Cell Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36707981</style></accession-num><notes><style face="normal" font="default" size="100%">Mitamura, Yasutaka&#xD;Akdis, Cezmi A&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):346-348. doi: 10.1111/all.15581.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36707981</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15581</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1292</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1292</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hamey, F. K.</style></author><author><style face="normal" font="default" size="100%">Lau, W. W. Y.</style></author><author><style face="normal" font="default" size="100%">Kucinski, I.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Diamanti, E.</style></author><author><style face="normal" font="default" size="100%">Wilson, N. K.</style></author><author><style face="normal" font="default" size="100%">Gottgens, B.</style></author><author><style face="normal" font="default" size="100%">Dahlin, J. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Haematology, Wellcome-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.&#xD;Present address: JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.&#xD;Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-cell molecular profiling provides a high-resolution map of basophil and mast cell development</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1731-1742</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Bone Marrow Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Stem Cells</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">single-cell RNA sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33078414</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Basophils and mast cells contribute to the development of allergic reactions. Whereas these mature effector cells are extensively studied, the differentiation trajectories from hematopoietic progenitors to basophils and mast cells are largely uncharted at the single-cell level. METHODS: We performed multicolor flow cytometry, high-coverage single-cell RNA sequencing analyses, and cell fate assays to chart basophil and mast cell differentiation at single-cell resolution in mouse. RESULTS: Analysis of flow cytometry data reconstructed a detailed map of basophil and mast cell differentiation, including a bifurcation of progenitors into two specific trajectories. Molecular profiling and pseudotime ordering of the single cells revealed gene expression changes during differentiation. Cell fate assays showed that multicolor flow cytometry and transcriptional profiling successfully predict the bipotent phenotype of a previously uncharacterized population of peritoneal basophil-mast cell progenitors. CONCLUSIONS: A combination of molecular and functional profiling of bone marrow and peritoneal cells provided a detailed road map of basophil and mast cell development. An interactive web resource was created to enable the wider research community to explore the expression dynamics for any gene of interest.</style></abstract><notes><style face="normal" font="default" size="100%">Hamey, Fiona K&#xD;Lau, Winnie W Y&#xD;Kucinski, Iwo&#xD;Wang, Xiaonan&#xD;Diamanti, Evangelia&#xD;Wilson, Nicola K&#xD;Gottgens, Berthold&#xD;Dahlin, Joakim S&#xD;eng&#xD;206328/Z/17/Z/WT_/Wellcome Trust/United Kingdom&#xD;MR/S036113/1/MRC_/Medical Research Council/United Kingdom&#xD;21762/CRUK_/Cancer Research UK/United Kingdom&#xD;R24 DK106766/DK/NIDDK NIH HHS/&#xD;MC_PC_12009/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1731-1742. doi: 10.1111/all.14633. Epub 2020 Nov 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33078414</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246912</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14633</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3239</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3239</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Papavasileiou, S.</style></author><author><style face="normal" font="default" size="100%">Mo, J.</style></author><author><style face="normal" font="default" size="100%">Boey, D.</style></author><author><style face="normal" font="default" size="100%">Wu, C.</style></author><author><style face="normal" font="default" size="100%">Tronstad, M.</style></author><author><style face="normal" font="default" size="100%">Margerie, L.</style></author><author><style face="normal" font="default" size="100%">Olsen, R. A.</style></author><author><style face="normal" font="default" size="100%">Bachmann, J. A.</style></author><author><style face="normal" font="default" size="100%">Low, J. H.</style></author><author><style face="normal" font="default" size="100%">Ong, J.</style></author><author><style face="normal" font="default" size="100%">Blom, L. H.</style></author><author><style face="normal" font="default" size="100%">Andiappan, A. K.</style></author><author><style face="normal" font="default" size="100%">Nilsson, G.</style></author><author><style face="normal" font="default" size="100%">Dahlin, J. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, and Center for Molecular Medicine, and Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Biochemistry and Biophysics, Science for Life Laboratory, Stockholm University, Stockholm, Sweden.&#xD;Singapore Immunology Network (SIgN), agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.&#xD;Allergy Clinic, Department of Dermatology and Allergy, Herlev and Gentofte University Hospital, Denmark.&#xD;A*STAR Skin Research Labs (A*SRL), agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.&#xD;Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-Cell Omics Analysis of Human Basophils Reveals Two Transcriptionally Distinct Populations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">heterogeneity</style></keyword><keyword><style face="normal" font="default" size="100%">long-read sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">scRNA-seq</style></keyword><keyword><style face="normal" font="default" size="100%">single-cell omics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 7</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41498390</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Basophils are implicated in various diseases including allergies, but a comprehensive single-cell characterization of human basophils has yet to be performed. Here, we aimed to generate a single-cell omics-based reference resource of circulating human basophils, integrating transcriptomic and large-scale immunoprofiling data. We also sought to investigate basophil heterogeneity at the molecular level. METHODS: Circulating basophils were analyzed using cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq). Both short- and long-read single-cell RNA-sequencing platforms were used to capture the transcriptomic data. RESULTS: CITE-seq enabled accurate identification and profiling of side scatter(low) lineage(-) CCR3(+) FcepsilonRI(+) basophils. Short-read single-cell RNA-sequencing data revealed two previously unresolved basophil populations, defined by 66 differentially expressed genes and reproducibly identified across donors. Despite the transcriptional differences, the populations displayed similar immunophenotypes based on more than 100 investigated cell surface markers. Long-read single-cell RNA-sequencing analysis confirmed the existence of the two populations and provided further insights into their gene expression profiles. CONCLUSIONS: We present a multimodal single-cell resource that defines two novel transcriptionally distinct basophil populations. This resource, accessible through a user-friendly web interface, constitutes a cellular and molecular reference map for future studies of basophils in health and disease.</style></abstract><notes><style face="normal" font="default" size="100%">Papavasileiou, Sofia&#xD;Mo, Jiezhen&#xD;Boey, Daryl&#xD;Wu, Chenyan&#xD;Tronstad, Magnus&#xD;Margerie, Lucille&#xD;Olsen, Remi-Andre&#xD;Bachmann, Jorg A&#xD;Low, Jing Hui&#xD;Ong, Jocelyn&#xD;Blom, Lars Heede&#xD;Andiappan, Anand Kumar&#xD;Nilsson, Gunnar&#xD;Dahlin, Joakim S&#xD;eng&#xD;Vetenskapsradet/&#xD;Onassis Foundation/&#xD;Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR)/&#xD;Cancerfonden/&#xD;Karolinska Institutet/&#xD;Science for Life Laboratory/&#xD;Uppsala Multidisciplinary Center for Advanced Computational Science/&#xD;Denmark&#xD;Allergy. 2026 Jan 7. doi: 10.1111/all.70209.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41498390</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70209</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>344</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">344</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, B.</style></author><author><style face="normal" font="default" size="100%">Roesner, L. M.</style></author><author><style face="normal" font="default" size="100%">Traidl, S.</style></author><author><style face="normal" font="default" size="100%">Koeken, Vacm</style></author><author><style face="normal" font="default" size="100%">Xu, C. J.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Computational Biology for Individualised Medicine, Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz Centre for Infection Research (HZI), Hannover Medical School (MHH), Hannover, Germany.&#xD;TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and Hannover Medical School (MHH), Hannover, Germany.&#xD;Department of Dermatology and Allergy, Division of Immunodermatology and Allergy Research, Hannover Medical School, Hannover, Germany.&#xD;Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.&#xD;Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">439-453</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/08/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">*Psoriasis</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin Diseases/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">chronic inflammatory diseases</style></keyword><keyword><style face="normal" font="default" size="100%">single-cell immune profiling</style></keyword><keyword><style face="normal" font="default" size="100%">type-2 immunity</style></keyword><keyword><style face="normal" font="default" size="100%">type-3 immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35986602</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Understanding the complex orchestrated inflammation in atopic dermatitis (AD), one of the most common chronic inflammatory diseases worldwide, is essential for therapeutic approaches. However, a comparative analysis on the single-cell level of the inflammation signatures correlated with the severity is missing so far. METHODS: We applied single-cell RNA and T-cell receptor (TCR) sequencing on immune cells enriched from skin biopsies and matched blood samples of AD in comparison with psoriasis (PS) patients. RESULTS: Clonally propagated skin-derived T cells showed disease-specific TCR motifs shared between patients which was more pronounced in PS compared to AD. The disease-specific T-cell clusters were mostly of a Th2/Th22 sub-population in AD and Th17/Tc17 in PS, and their numbers were associated with severity scores in both diseases. Herein, we provide for the first time a list that associates cell type-specific gene expression with the severity of the two most common chronic inflammatory skin diseases. Investigating the cell signatures in the patients PBMCs and skin stromal cells, a systemic involvement of type-3 inflammation was clearly detectable in PS circulating cells, while in AD inflammatory signatures were most pronounced in fibroblasts, pericytes, and keratinocytes. Compositional and functional analyses of myeloid cells revealed the activation of antiviral responses in macrophages in association with disease severity in both diseases. CONCLUSION: Different disease-driving cell types and subtypes which contribute to the hallmarks of type-2 and type-3 inflammatory signatures and are associated with disease activities could be identified by single-cell RNA-seq and TCR-seq in AD and PS.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Bowen&#xD;Roesner, Lennart M&#xD;Traidl, Stephan&#xD;Koeken, Valerie A C M&#xD;Xu, Cheng-Jian&#xD;Werfel, Thomas&#xD;Li, Yang&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):439-453. doi: 10.1111/all.15486. Epub 2022 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35986602</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15486</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2505</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2505</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Lv, J.</style></author><author><style face="normal" font="default" size="100%">Chen, S.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">Yao, J.</style></author><author><style face="normal" font="default" size="100%">Yuan, Z.</style></author><author><style face="normal" font="default" size="100%">Yang, C.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Zhu, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Wu, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Immunology, Tsinghua-Peking Joint Center for Life Sciences, School of Basic Medical Sciences, Tsinghua University, Beijing, China.&#xD;Department of Automation, MOE Key Laboratory of Bioinformatics, Bioinformatics Division and Center for Synthetic and Systems Biology, BNRist, Tsinghua University, Beijing, China.&#xD;State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences, Beijing Institute of Life Omics, Beijing, China.&#xD;Annoroad Gene Technology (Beijing) Co., Ltd., Beijing, China.&#xD;School of Life Sciences, Tsinghua University, Beijing, China.&#xD;Beijing Key Laboratory for Immunological Research on Chronic Diseases, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-cell profiling highlight pathogenic myeloid features in house dust mite-induced murine model of airway inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1478-1481</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/05/13</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38738468</style></accession-num><notes><style face="normal" font="default" size="100%">Liu, Jiachen&#xD;Lv, Jiaoyan&#xD;Chen, Sijie&#xD;Ma, Jie&#xD;Yao, Jiaying&#xD;Yuan, Zan&#xD;Yang, Chunyuan&#xD;Li, Xiao&#xD;Zhang, Xuegong&#xD;Zhu, Yunping&#xD;Zhang, Jianhong&#xD;Wu, Li&#xD;eng&#xD;National Natural Science Foundation of China (Grants 81971476 to J.Z., 91642207 and 31991174 to L.W., 62250005 to X.Z.)/&#xD;the Ministry of Science and Technology of China (National Key Research Project 2019YFA0508502 and 2022YFC2505001 to L.W.)/&#xD;the National Basic Research Center of China (82388101 to L.W.)/&#xD;Tsinghua-Peking Center for Life Sciences (to L.W.)/&#xD;the National Key Research and Development Program of China (2021YFA1301603 to Y. Z.)/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1478-1481. doi: 10.1111/all.16156. Epub 2024 May 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38738468</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16156</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3173</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3173</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cai, S.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Yao, S.</style></author><author><style face="normal" font="default" size="100%">Zhang, P.</style></author><author><style face="normal" font="default" size="100%">Lou, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of New Medicine and Diagnostic Technology Research for Nasal Disease, Beijing, China.&#xD;Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children, Rare Disease Center, Beijing Children&apos;s Hospital, Capital Medical University, National Center for Children&apos;s Health, Beijing, China.&#xD;Department of Otolaryngology, Eye &amp; ENT Hospital, Fudan University, Shanghai, China.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-Cell Profiling Identifies TNF-Responsive Circulating Eosinophils in Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/05</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 4</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41189294</style></accession-num><notes><style face="normal" font="default" size="100%">Cai, Shiru&#xD;Zhao, Yan&#xD;Yao, Shuang&#xD;Zhang, Peng&#xD;Lou, Hongfei&#xD;Zhang, Luo&#xD;eng&#xD;2022YFC2504100/National Key R&amp;D Program of China/&#xD;82271139/National Natural Science Foundation of China/&#xD;82471139/National Natural Science Foundation of China/&#xD;82371115/National Natural Science Foundation of China/&#xD;IRT13082/Program for Changjiang Scholars and Innovative Research Team/&#xD;20230484476/Beijing Nova Program/&#xD;Lingjunrencai-02-09/High-Level Public Health Technical Talent Training Plan/&#xD;JYY2023-1/Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes, Beijing Municipal Health Commission/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov 4. doi: 10.1111/all.70142.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41189294</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70142</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1573</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1573</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beken, B.</style></author><author><style face="normal" font="default" size="100%">Arcolaci, A.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Allergy &amp; Immunology, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.&#xD;Asthma Center &amp; Allergy Unit, Borgo Roma University &amp; General Hospital, Verona, Italy.&#xD;Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;Department of Pathology and Molecular Medicine, McMaster Immunology Research Centre (MIRC), McMaster University, Hamilton, ON, Canada.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-cell RNA analysis: Guiding the treatment of DiHS/DRESS</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2713-2715</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2020/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Rna</style></keyword><keyword><style face="normal" font="default" size="100%">drug reaction with eosinophilia and systemic symptoms</style></keyword><keyword><style face="normal" font="default" size="100%">drug-induced hypersensitivity syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">severe cutaneous adverse reaction</style></keyword><keyword><style face="normal" font="default" size="100%">single-cell RNA sequencing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32638393</style></accession-num><notes><style face="normal" font="default" size="100%">Beken, Burcin&#xD;Arcolaci, Alessandra&#xD;Jimenez-Saiz, Rodrigo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Oct;75(10):2713-2715. doi: 10.1111/all.14487. Epub 2020 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32638393</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14487</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2594</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2594</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rodrigo-Munoz, J. M.</style></author><author><style face="normal" font="default" size="100%">Naharro-Gonzalez, S.</style></author><author><style face="normal" font="default" size="100%">Callejas, S.</style></author><author><style face="normal" font="default" size="100%">Relano-Ruperez, C.</style></author><author><style face="normal" font="default" size="100%">Torroja, C.</style></author><author><style face="normal" font="default" size="100%">Benguria, A.</style></author><author><style face="normal" font="default" size="100%">Lorente-Sorolla, C.</style></author><author><style face="normal" font="default" size="100%">Gil-Martinez, M.</style></author><author><style face="normal" font="default" size="100%">Garcia de Castro, Z.</style></author><author><style face="normal" font="default" size="100%">Canas, J. A.</style></author><author><style face="normal" font="default" size="100%">Valverde-Monge, M.</style></author><author><style face="normal" font="default" size="100%">Bernaola, J.</style></author><author><style face="normal" font="default" size="100%">Pinillos-Robles, E. J.</style></author><author><style face="normal" font="default" size="100%">Betancor, D.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Nieto, M.</style></author><author><style face="normal" font="default" size="100%">Dopazo, A.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Cabo, F.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Pernaute, O.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Nieto, M. J.</style></author><author><style face="normal" font="default" size="100%">Sastre, J.</style></author><author><style face="normal" font="default" size="100%">Del Pozo, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunoallergy Laboratory, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD, UAM), Madrid, Spain.&#xD;CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.&#xD;Genomics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.&#xD;Bioinformatics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.&#xD;Allergy Department, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.&#xD;Pulmonology Unit, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.&#xD;CIBER de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.&#xD;Rheumatology Department, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.&#xD;Hospital Universitario General de Villalba, Madrid, Spain.&#xD;Universidad Autonoma de Madrid, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-cell RNA sequencing of human blood eosinophils reveals plasticity and absence of canonical cell subsets</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">570-574</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/06/27</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38934897</style></accession-num><notes><style face="normal" font="default" size="100%">Rodrigo-Munoz, Jose Manuel&#xD;Naharro-Gonzalez, Sara&#xD;Callejas, Sergio&#xD;Relano-Ruperez, Carlos&#xD;Torroja, Carlos&#xD;Benguria, Alberto&#xD;Lorente-Sorolla, Clara&#xD;Gil-Martinez, Marta&#xD;Garcia de Castro, Zahara&#xD;Canas, Jose Antonio&#xD;Valverde-Monge, Marcela&#xD;Bernaola, Jaime&#xD;Pinillos-Robles, Erwin Javier&#xD;Betancor, Diana&#xD;Fernandez-Nieto, Mar&#xD;Dopazo, Ana&#xD;Sanchez-Cabo, Fatima&#xD;Sanchez-Pernaute, Olga&#xD;Rodriguez-Nieto, Maria Jesus&#xD;Sastre, Joaquin&#xD;Del Pozo, Victoria&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):570-574. doi: 10.1111/all.16213. Epub 2024 Jun 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38934897</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804299 Zeneca and GSK. D-B reports having been under contract with the Instituto de Salud Carlos III (Rio Hortega Research Contract). MJR-N reports receiving research grant support from AstraZeneca, and having received payments for lectures from AstraZeneca and SANOFI. MV-M reports receiving payments for lectures and support for attending meetings and/or travel by AstraZeneca, GSK, Gebro, and Organon S.A.; as well as having received grant support for research from Organon S.A. VdP has received honoraria (advisory board, speaker) and/or institutional grant/research support from AstraZeneca and GSK and has held an unpaid leadership or fiduciary role in committees belonging to the EAACI. The rest of authors declare no conflicts of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16213</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>553</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">553</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, Z.</style></author><author><style face="normal" font="default" size="100%">Feng, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, H.</style></author><author><style face="normal" font="default" size="100%">Yang, H.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Pang, J.</style></author><author><style face="normal" font="default" size="100%">Yang, P.</style></author><author><style face="normal" font="default" size="100%">Zhao, H.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Department of Pathophysiology, Peking Union Medical College, Beijing, China.&#xD;Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.&#xD;State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Department of Physiology, Peking Union Medical College, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-cell transcriptomics of mouse lung reveal inflammatory memory neutrophils in allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1911-1915</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/03/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style face="normal" font="default" size="100%">*Neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">Ovalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35315082</style></accession-num><notes><style face="normal" font="default" size="100%">Li, Zhiwei&#xD;Feng, Yufan&#xD;Liu, Haitao&#xD;Yang, Hongqin&#xD;Li, Jinqiu&#xD;Zhou, Yitian&#xD;Pang, Junling&#xD;Yang, Peiran&#xD;Zhao, Hongmei&#xD;Wang, Jing&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1911-1915. doi: 10.1111/all.15286. Epub 2022 Mar 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35315082</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15286</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1130</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1130</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prieto, A.</style></author><author><style face="normal" font="default" size="100%">Munoz, C.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Palomares, F.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Paediatrics Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA-ARADyAL, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-ARADyAL, Malaga, Spain.&#xD;Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.&#xD;Medicine Department, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-dose prolonged drug provocation test, without previous skin testing, is safe for diagnosing children with mild non-immediate reactions to beta-lactams</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2544-2554</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/03/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">*Pharmaceutical Preparations</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">beta-Lactams/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">amoxicillin</style></keyword><keyword><style face="normal" font="default" size="100%">beta-lactam</style></keyword><keyword><style face="normal" font="default" size="100%">drug provocation test</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default" size="100%">non-immediate reaction</style></keyword><keyword><style face="normal" font="default" size="100%">skin test</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33650109</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Mild non-immediate reactions (NIRs) to beta-lactams (BLs) are the most frequent manifestation of drug allergy in children. The diagnostic approach is complex as the utility of skin tests (STs) and lymphocyte transformation tests (LTTs) is controversial. Drug provocation test (DPT) is the gold standard, although no standardized protocols exist. We aimed to investigate the utility of DPT in a unique dose without previous STs, and LTTs in the diagnosis of NIRs to BLs in children. METHODS: We prospectively evaluated children 0-14 years old referred to the Regional University Hospital of Malaga during 2017-2020 reporting NIRs to BLs. We performed a DPT with a unique dose followed by regular treatment at home. If positive, STs and LTTs were done after the reaction had disappeared. RESULTS: We included 194 children, having 24 (12.4%) a positive DPT. The main culprit was AX (70.1%) followed by AX-clavulanic acid (CLV) (26.8%) and the main symptoms maculopapular exanthema (MPE) (49.5%) and delayed-urticaria (48.5%). A decrease (p = 0.013) in the interval of days between drug administration and onset of symptoms was observed in positive DPT compared with the original reaction (3.5 vs 6 days), with no differences in the overall percentage of MPE and delayed-appearing urticaria (p = 0.551). No severe reactions occurred during DPT. Moreover, STs were positive in 13.33% and LTTs in 52.9%. CONCLUSIONS: Single-dose DPT without previous STs is a safe and useful way to assess NIRs to BLs in children. LTT has shown to be useful, confirming a T-cell mechanism involved in these reactions.</style></abstract><notes><style face="normal" font="default" size="100%">Prieto, Ana&#xD;Munoz, Candelaria&#xD;Bogas, Gador&#xD;Fernandez-Santamaria, Ruben&#xD;Palomares, Francisca&#xD;Mayorga, Cristobalina&#xD;Salas, Maria&#xD;Dona, Inmaculada&#xD;Torres, Maria Jose&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2544-2554. doi: 10.1111/all.14800. Epub 2021 Mar 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33650109</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14800</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2130</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2130</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schwartz, B. S.</style></author><author><style face="normal" font="default" size="100%">Pollak, J. S.</style></author><author><style face="normal" font="default" size="100%">Bandeen-Roche, K.</style></author><author><style face="normal" font="default" size="100%">Hirsch, A. G.</style></author><author><style face="normal" font="default" size="100%">Lehmann, A. E.</style></author><author><style face="normal" font="default" size="100%">Kern, R. C.</style></author><author><style face="normal" font="default" size="100%">Tan, B. K.</style></author><author><style face="normal" font="default" size="100%">Kato, A.</style></author><author><style face="normal" font="default" size="100%">Schleimer, R. P.</style></author><author><style face="normal" font="default" size="100%">Peters, A. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Environmental Health and Engineering, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.&#xD;Department of Population Health Sciences, Geisinger, Danville, Pennsylvania, USA.&#xD;Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.&#xD;Department of Otolaryngology, Geisinger, Danville, Pennsylvania, USA.&#xD;Department of Otolaryngology Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sinus inflammation and chronic rhinosinusitis are associated with a diagnosis of new onset asthma in the following year</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2659-2668</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/05/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/diagnosis/epidemiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/diagnosis/epidemiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Paranasal Sinuses</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/complications</style></keyword><keyword><style face="normal" font="default" size="100%">asthma etiology</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">risk factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37195236</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chronic rhinosinusitis (CRS) and asthma commonly co-occur. No studies have leveraged large samples needed to formally address whether preexisting CRS is associated with new onset asthma over time. METHODS: We evaluated whether prevalent CRS [identified in two ways: validated text algorithm applied to sinus computerized tomography (CT) scan or two diagnoses] was associated with new onset adult asthma in the following year. We used electronic health record data from Geisinger from 2008 to 2019. For each year we removed persons with any evidence of asthma through the end of the year, then identified those with new diagnosis of asthma in the following year. Complementary log-log regression was used to adjust for confounding variables (e.g., sociodemographic, contact with the health system, comorbidities), and hazard ratios (HRs) and 95% confidence intervals (CI) were calculated. RESULTS: A total of 35,441 persons were diagnosed with new onset asthma and were compared to 890,956 persons who did not develop asthma. Persons with new onset asthma tended to be female (69.6%) and younger (mean [SD] age 45.9 [17.0] years). Both CRS definitions were associated (HR, 95% CI) with new onset asthma, with 2.21 (1.93, 2.54) and 1.48 (1.38, 1.59) for CRS based on sinus CT scan and two diagnoses, respectively. New onset asthma was uncommonly observed in persons with a history of sinus surgery. CONCLUSION: Prevalent CRS identified with two complementary approaches was associated with a diagnosis of new onset asthma in the following year. The findings may have clinical implications for the prevention of asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Schwartz, Brian S&#xD;Pollak, Jonathan S&#xD;Bandeen-Roche, Karen&#xD;Hirsch, Annemarie G&#xD;Lehmann, Ashton E&#xD;Kern, Robert C&#xD;Tan, Bruce K&#xD;Kato, Atsushi&#xD;Schleimer, Robert P&#xD;Peters, Anju T&#xD;eng&#xD;P01 AI106683/AI/NIAID NIH HHS/&#xD;P01 AI145818/AI/NIAID NIH HHS/&#xD;R01 AI137174/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2659-2668. doi: 10.1111/all.15771. Epub 2023 May 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37195236</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10543467</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15771</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2843</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2843</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zielen, S.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Sturm, G. J.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Resonate Investigator Group</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Mosges, R.</style></author><author><style face="normal" font="default" size="100%">Berger, M.</style></author><author><style face="normal" font="default" size="100%">Berger, U. E.</style></author><author><style face="normal" font="default" size="100%">DuBuske, L.</style></author><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Skinner, M. A.</style></author><author><style face="normal" font="default" size="100%">Kramer, M. F.</style></author><author><style face="normal" font="default" size="100%">de Kam, P. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, University Hospital, Goethe University, Frankfurt, Germany.&#xD;Respiratory Research Center Medaimun GmbH, Frankfurt, Germany.&#xD;Division of Rheumatology, Allergy and Immunology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Bernstein Clinical Research Center, Cincinnati, Ohio, USA.&#xD;Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.&#xD;Department of Clinical Immunology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;IMSB, Medical Faculty University at Cologne, Cologne, Germany.&#xD;ClinCompetence Cologne GmbH, Cologne, Germany.&#xD;Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Klinik Landstrasse, Wiener Gesundheitsverbund, Vienna, Austria.&#xD;Allergy Centre Vienna West, Vienna, Austria.&#xD;Sigmund Freud Private University Vienna, Vienna, Austria.&#xD;Department of Botany, University of Innsbruck, Innsbruck, Austria.&#xD;George Washington University Hospital, Washington, DC, USA.&#xD;Center for Rhinology and Allergy, Wiesbaden, Germany.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.&#xD;Allergy Therapeutics (UK) Plc, Worthing, UK.&#xD;Bencard Allergie GmbH, Munchen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1982-1994</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/02/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/immunology/therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">*Poaceae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Adjuvants, Immunologic/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">grass pollen allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pivotal Phase III clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">short-course treatment</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Ingelheim, Allergy Therapeutics, AstraZeneca, SanofiAventis, EryDel SpA and</style></keyword><keyword><style face="normal" font="default" size="100%">Lofarma during the last 3 years. J.A.B. is acting as consultant and PI for:</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics, Stallergens, ALK, Eli Lilly, Novartis, Genentech, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, AZ, GSK, Amgen. G.J.S. reports grants from ALK-Abello, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from ALK-Abello, personal fees from Allergopharma, personal fees from Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">and personal fees from Stallergenes-Greer, outside the submitted work. M.J.</style></keyword><keyword><style face="normal" font="default" size="100%">reports personal fees from ALK-Abello, Allergopharma, Stallergenes, Anergis,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics, Leti, HAL, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from GSK, Novartis, Teva, Takeda, Chiesi outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and is the</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Journal Deputy Editor. O.P. reports grants for his institution as</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial unit for RESONATE from Allergy Therapeutics Plc, UK, and he</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants and/or personal fees and/or travel support from ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard Allergie GmbH/Allergy Therapeutics, Laboratorios LETI/LETI Pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, ROXALL Medizin, Novartis, Sanofi-Aventis and Sanofi-Genzyme, Med</style></keyword><keyword><style face="normal" font="default" size="100%">Update Europe GmbH, streamedup! GmbH, Pohl-Boskamp, Inmunotek S.L., John Wiley</style></keyword><keyword><style face="normal" font="default" size="100%">and Sons/AS, Paul-Martini-Stiftung (PMS), Regeneron Pharmaceuticals Inc., RG</style></keyword><keyword><style face="normal" font="default" size="100%">Aerztefortbildung, Institut fur Disease Management, Springer GmbH, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">IQVIA Commercial, Ingress Health, Wort &amp; Bild Verlag, Verlag ME, Procter &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Gamble, ALTAMIRA, Meinhardt Congress GmbH, Deutsche Forschungsgemeinschaft,</style></keyword><keyword><style face="normal" font="default" size="100%">Thieme, Deutsche AllergieLiga e.V., AeDA, Alfried-Krupp Krankenhaus, Red Maple</style></keyword><keyword><style face="normal" font="default" size="100%">Trials Inc., Koniglich Danisches Generalkonsulat, Medizinische Hochschule</style></keyword><keyword><style face="normal" font="default" size="100%">Hannover, ECM Expro &amp; Conference Management, Technical University Dresden, Lilly,</style></keyword><keyword><style face="normal" font="default" size="100%">Japanese Society of Allergy, Forum fur Medizinische Fortbildung, Dustri-Verlag,</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumolive, ASIT Biotech, LOFARMA, Almirall, Paul-Ehrlich-Institut, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and he is Vice President of the EAACI and member of EAACI Excom,</style></keyword><keyword><style face="normal" font="default" size="100%">member of ext. board of directors DGAKI</style></keyword><keyword><style face="normal" font="default" size="100%">coordinator, main- or co-author of</style></keyword><keyword><style face="normal" font="default" size="100%">different position papers and guidelines in rhinology, allergology and</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">he is associate editor (AE) of Allergy and Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Translational Allergy. R.M. reports grants and personal fees from Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics Ltd., during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from ALK,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from ASIT biotech, personal fees from allergopharma, grants and personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Bencard, grants from Leti, grants, personal fees and non-financial</style></keyword><keyword><style face="normal" font="default" size="100%">support from Lofarma, non-financial support from Roxall, grants and personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Stallergenes, grants from Optima, personal fees from Friulchem, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Hexal, personal fees from Servier, personal fees from Klosterfrau,</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from Atmos, personal fees from Bayer, non-financial support</style></keyword><keyword><style face="normal" font="default" size="100%">from Bionorica, personal fees from FAES, personal fees from GSK, personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from MSD, personal fees from Johnson &amp; Johnson, personal fees from Meda, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees and non-financial support from Novartis, non-financial support from Otonomy,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Stada, personal fees from UCB, non-financial support from</style></keyword><keyword><style face="normal" font="default" size="100%">Ferrero, grants from Hulka, personal fees from Nuvo, grants and personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Ursapharm, personal fees from Menarini, personal fees from Mundipharma,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Pohl-Boskamp, grants from Inmunotek, grants from Cassella-med</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH &amp; Co. KG, personal fees from Laboratoire de la Mer, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Sidroga, grants and personal fees from HAL BV, personal fees from Lek, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from PRO-AdWise, personal fees from Angelini Pharma, grants and</style></keyword><keyword><style face="normal" font="default" size="100%">non-financial support from JGL, grants and personal fees from bitop, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, grants and personal fees from Probelte Pharma, grants from Diater,</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Worg Pharmaceuticals, outside the submitted work. M.H.S.</style></keyword><keyword><style face="normal" font="default" size="100%">reports research grants from Immune Tolerance Network, Medical Research Council,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics, LETI Laboratorios, Rovolo Biotherapeutics and lecture fees</style></keyword><keyword><style face="normal" font="default" size="100%">from Allergy Therapeutics and Leti Laboratorios, all outside the submitted work.</style></keyword><keyword><style face="normal" font="default" size="100%">M.B. and U.E.B. reports grants and/or personal fees and/or travel support from AZ</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen Research GmbH, outside the submitted work. L.D. acts as a consultant for</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics and a Consultant and/or Speakers Bureau for GSK, Sanofi,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Astra Zeneca, ALK-Abello, Amgen, Bryn Pharm, Areteia. J.A.L. reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants via Biomedical Research Funding (Imperial College BRC), all outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. L.K. has received research grants from Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics/Bencard, Great Britain/Germany</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Germany</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune, USA</style></keyword><keyword><style face="normal" font="default" size="100%">ASIT Biotech, Belgium</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Sweden, Bionorica,</style></keyword><keyword><style face="normal" font="default" size="100%">Germany</style></keyword><keyword><style face="normal" font="default" size="100%">BioNTech, Germany, Biomay, Austria, Boehringer Ingelheim, Germany,</style></keyword><keyword><style face="normal" font="default" size="100%">Circassia, USA</style></keyword><keyword><style face="normal" font="default" size="100%">Chiesi, Italy</style></keyword><keyword><style face="normal" font="default" size="100%">Cytos, Switzerland</style></keyword><keyword><style face="normal" font="default" size="100%">Curalogic, Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">HAL,</style></keyword><keyword><style face="normal" font="default" size="100%">Netherlands</style></keyword><keyword><style face="normal" font="default" size="100%">Lofarma, Italy</style></keyword><keyword><style face="normal" font="default" size="100%">Menarini, Italy</style></keyword><keyword><style face="normal" font="default" size="100%">Viatris/Mylan, USA</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Switzerland, Leti, Spain</style></keyword><keyword><style face="normal" font="default" size="100%">ROXALL, Germany</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline (GSK), Great Britain</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi, France</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes, France</style></keyword><keyword><style face="normal" font="default" size="100%">Thermofisher, USA and/or has served on the</style></keyword><keyword><style face="normal" font="default" size="100%">speaker&apos;s bureau or was consulting for the above mentioned pharmaceutical</style></keyword><keyword><style face="normal" font="default" size="100%">companies. L.K. is the current President of German Society of Allergology AeDA,</style></keyword><keyword><style face="normal" font="default" size="100%">Governance Committee Board Member of the European Academy for Allergy and</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Immunology (EAACI), Vice-President of German Academy for Allergy and</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Medicine and Editor-in-Chief of AllergoJournal and AllergoJournal</style></keyword><keyword><style face="normal" font="default" size="100%">International. M.O. received personal fees and/or speakers&apos; honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics/Bencard Allergie GmbH, Thermo Fisher Scientific, Hycor</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostics, as well as grants from the European Commission, the National</style></keyword><keyword><style face="normal" font="default" size="100%">Research Fund Luxembourg (FNR) and Angany, all outside the submitted work. M.S.,</style></keyword><keyword><style face="normal" font="default" size="100%">M.F.K., and P.-J.K. are employees of Allergy Therapeutics (UK) Plc. and are named</style></keyword><keyword><style face="normal" font="default" size="100%">inventors on patents related to PQ Grass.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39905623</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: PQ Grass 27600 SU (PQ Grass) cumulative dose is a pre-seasonal, six-injection, aluminium-free, modified subcutaneous immunotherapy product under development for the treatment of allergic rhinitis (AR). A pivotal Phase III randomised double-blind, placebo-controlled clinical trial was performed to evaluate the efficacy and safety of PQ Grass in subjects with seasonal AR. METHODS: An adaptive group sequential trial PQGrass306 (G306) with one pre-defined interim analysis was designed, using 2 parallel groups applying a 1:1 active versus placebo randomisation of patients aged 18-65. The primary efficacy endpoint was the EAACI (European Academy of Allergy and Clinical Immunology) Combined Symptom and Medication Score (EAACI-CSMS(0-6)) averaged over the peak grass pollen season (GPS). RESULTS: 858 subjects were screened and 555 subjects were randomised. Based on the results of the pre-defined interim analysis, the trial was stopped for success showing superiority in favour of PQ Grass. The primary endpoint EAACI-CSMS(0-6) (peak GPS) demonstrated a highly significant and clinically meaningful point difference of PQ Grass over placebo of -0.27 points (95% CI: -0.42 to -0.12), corresponding to a relative difference of -20.3% (p = 0.0005). Highly consistent and beneficial results were obtained for PQ Grass for all key secondary endpoints. Significant induction of blocking IgG4 and IgA antibody subclasses occurred. PQ Grass was well tolerated, and no unexpected safety signals occurred. CONCLUSIONS: This pivotal Phase III trial demonstrated a significant and clinically meaningful effect on the primary endpoint as well as highly consistent secondary endpoint results and a supportive safety profile.</style></abstract><notes><style face="normal" font="default" size="100%">Zielen, Stefan&#xD;Bernstein, Jonathan A&#xD;Sturm, Gunter J&#xD;Jutel, Marek&#xD;Pfaar, Oliver&#xD;Shamji, Mohamed H&#xD;Mosges, Ralph&#xD;Berger, Markus&#xD;Berger, Uwe E&#xD;DuBuske, Lawrence&#xD;Layhadi, Janice A&#xD;Klimek, Ludger&#xD;Ollert, Markus&#xD;Skinner, Murray A&#xD;Kramer, Matthias F&#xD;de Kam, Pieter-Jan&#xD;eng&#xD;Allergy Therapeutics/&#xD;Clinical Trial, Phase III&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1982-1994. doi: 10.1111/all.16491. Epub 2025 Feb 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39905623</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261879</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16491</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1166</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1166</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hou, T.</style></author><author><style face="normal" font="default" size="100%">Tsang, M. S.</style></author><author><style face="normal" font="default" size="100%">Chu, I. M.</style></author><author><style face="normal" font="default" size="100%">Kan, L. L.</style></author><author><style face="normal" font="default" size="100%">Hon, K. L.</style></author><author><style face="normal" font="default" size="100%">Leung, T. F.</style></author><author><style face="normal" font="default" size="100%">Lam, C. W.</style></author><author><style face="normal" font="default" size="100%">Wong, C. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemical Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.&#xD;Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China.&#xD;Department of Paediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.&#xD;Faculty of Medicine and State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Skewed inflammation is associated with aberrant interleukin-37 signaling pathway in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2102-2114</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-1</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukins</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Il-37</style></keyword><keyword><style face="normal" font="default" size="100%">allergic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">involucrin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33569791</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is a severe global burden on physical, physiological, and mental health. The role of IL-37, a fundamental inhibitor of immunity, in AD was herein explored. METHOD: Serum levels of IL-37 and T helper (Th) 2-related inflammatory mediators were quantified in subjects with or without AD. The expression of IL-37 receptors was determined by flow cytometry. Proteomics was employed to explore the serum protein profile and novel biomarkers. In vitro cell model, 3D-keratinocytes mimicking skin model, and the serum of subjects with or without AD were investigated to verify the proteomic results. RESULTS: AD patients were found to present with higher levels of total and specific IgE as well as Th2 inflammatory mediators compared with healthy controls (HC). IL-37 level and its receptor IL18Ra expression in AD patients were significantly decreased, together with increased population of eosinophils, indicating that the signaling of IL37/IL18Ra was dampened. In addition, proteomic analysis revealed a significantly differential protein profile of AD patients compared with HC. IL-37 showed the strongest negative correlation with involucrin, a keratinizing epithelia protein. IL-37 was verified to suppress induced involucrin expression in in vitro skin cell models. AD patients show a significantly higher serum concentration of involucrin compared with HC. Together, our results demonstrated that IL-37 plays a regulatory role in AD. Its deficiency may lead to the aberrant involucrin expression in AD. CONCLUSIONS: The dysregulation of serum protein and skin disruption in AD is related to the insufficiency of IL-37 and its attenuated anti-inflammatory signaling.</style></abstract><notes><style face="normal" font="default" size="100%">Hou, Tianheng&#xD;Tsang, Miranda Sin-Man&#xD;Chu, Ida Miu-Ting&#xD;Kan, Lea Ling-Yu&#xD;Hon, Kam-Lun&#xD;Leung, Ting-Fan&#xD;Lam, Christopher Wai-Kei&#xD;Wong, Chun-Kwok&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2102-2114. doi: 10.1111/all.14769. Epub 2021 Mar 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33569791</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14769</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>288</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">288</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rinnov, M. R.</style></author><author><style face="normal" font="default" size="100%">Halling, A. S.</style></author><author><style face="normal" font="default" size="100%">Gerner, T.</style></author><author><style face="normal" font="default" size="100%">Ravn, N. H.</style></author><author><style face="normal" font="default" size="100%">Knudgaard, M. H.</style></author><author><style face="normal" font="default" size="100%">Trautner, S.</style></author><author><style face="normal" font="default" size="100%">Goorden, S. M. I.</style></author><author><style face="normal" font="default" size="100%">Ghauharali-van der Vlugt, K. J. M.</style></author><author><style face="normal" font="default" size="100%">Stet, F. S.</style></author><author><style face="normal" font="default" size="100%">Skov, L.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author><author><style face="normal" font="default" size="100%">Egeberg, A.</style></author><author><style face="normal" font="default" size="100%">Rosted, A. L. L.</style></author><author><style face="normal" font="default" size="100%">Petersen, T.</style></author><author><style face="normal" font="default" size="100%">Jakasa, I.</style></author><author><style face="normal" font="default" size="100%">Riethmuller, C.</style></author><author><style face="normal" font="default" size="100%">Kezic, S.</style></author><author><style face="normal" font="default" size="100%">Thyssen, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.&#xD;Department of Dermatology and Venereology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Neonatology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.&#xD;Laboratory Genetic Metabolic Diseases, Department of Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark.&#xD;Laboratory for Analytical Chemistry, Department of Chemistry and Biochemistry, Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.&#xD;Serend-ip GmbH, Centre for Nanotechnology, Munster, Germany.&#xD;Amsterdam Public Health research institute, Department of Public and Occupational Health Amsterdam UMC, Department of Public and Occupational Health, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Skin biomarkers predict development of atopic dermatitis in infancy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">791-802</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/09/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Chemokine CCL17</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Ceramides</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">birth cohort</style></keyword><keyword><style face="normal" font="default" size="100%">prediction</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36112082</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: There is currently no insight into biomarkers that can predict the onset of pediatric atopic dermatitis (AD). METHODS: Nested in a prospective birth cohort study that examined the occurrence of physician-diagnosed AD in 300 children, 44 random children with onset of AD in the first year of life were matched on sex and season of birth with 44 children who did not develop AD. Natural moisturizing factor (NMF), corneocyte surface protrusions, cytokines, free sphingoid bases (SBs) of different chain lengths and their ceramides were analyzed from tape strips collected at 2 months of age before onset of AD using liquid chromatography, atomic force microscopy, multiplex immunoassay, and liquid chromatography mass spectrometry, respectively. RESULTS: Significant alterations were observed for four lipid markers, with phytosphingosine ([P]) levels being significantly lower in children who developed AD compared with children who did not (median 240 pmol/mg vs. 540 pmol/mg, p &lt; 0.001). The two groups of children differed in the relative amounts of SB of different chain lengths (C17, C18 and C20). Thymus- and activation-regulated chemokine (TARC/CCL17) was slightly higher in children who developed AD, whereas NMF and corneocyte surface texture were similar. AD severity assessed by the eczema area and severity index (EASI) at disease onset was 4.2 (2.0;7.2). [P] had the highest prediction accuracy among the biomarkers (75.6%), whereas the combination of 5 lipid ratios gave an accuracy of 89.4%. CONCLUSION: This study showed that levels and SB chain length were altered in infants who later developed AD, and that TARC/CCL17 levels were higher.</style></abstract><notes><style face="normal" font="default" size="100%">Rinnov, Maria Rasmussen&#xD;Halling, Anne-Sofie&#xD;Gerner, Trine&#xD;Ravn, Nina Haarup&#xD;Knudgaard, Mette Hjorslev&#xD;Trautner, Simon&#xD;Goorden, Susan M I&#xD;Ghauharali-van der Vlugt, Karen J M&#xD;Stet, Femke S&#xD;Skov, Lone&#xD;Thomsen, Simon Francis&#xD;Egeberg, Alexander&#xD;Rosted, Aske L L&#xD;Petersen, Troels&#xD;Jakasa, Ivone&#xD;Riethmuller, Christoph&#xD;Kezic, Sanja&#xD;Thyssen, Jacob P&#xD;eng&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):791-802. doi: 10.1111/all.15518. Epub 2022 Sep 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36112082</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15518</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3022</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3022</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bhattacharyya, M.</style></author><author><style face="normal" font="default" size="100%">Lauffer, F.</style></author><author><style face="normal" font="default" size="100%">Jargosch, M.</style></author><author><style face="normal" font="default" size="100%">Frey, K.</style></author><author><style face="normal" font="default" size="100%">Dadras, M. S.</style></author><author><style face="normal" font="default" size="100%">Raunegger, T.</style></author><author><style face="normal" font="default" size="100%">Wasserer, S.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Biedermann, T.</style></author><author><style face="normal" font="default" size="100%">Eyerich, K.</style></author><author><style face="normal" font="default" size="100%">Eyerich, S.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Klose, C.</style></author><author><style face="normal" font="default" size="100%">Reiger, M.</style></author><author><style face="normal" font="default" size="100%">Garzorz-Stark, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environmental Medicine - Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg and University Hospital of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Center Munich, German Research Center for Environmental Health, Augsburg, Germany.&#xD;Department of Dermatology and Allergy, LMU Hospital Munich, Munich, Germany.&#xD;Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.&#xD;ZAUM - Center of Allergy and Environment, Technical University of Munich and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.&#xD;Department of Dermatology and Venerology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.&#xD;Division of Dermatology and Venereology, Department of Medicine Solna, and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Lipotype GmbH, Dresden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Skin Lipid-Microbe Interplay Links Staphylococcus hominis to Barrier Control in Adult Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/08/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Staphylococcus hominis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">lipidomics</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 28</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40874637</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Skin surface lipids and commensal microbes are essential for the epidermal barrier, but their mutual interactions remain poorly understood. METHODS: We conducted high-resolution shotgun lipidomics of tape strips from lesional and non-lesional atopic dermatitis (AD) skin and healthy controls. Lipidomic data were integrated with 16S amplicon sequencing to construct lipid-microbe interaction networks. RESULTS: AD skin showed disease-specific lipid-microbe correlations, with less diverse interactions in lesional compared to non-lesional and healthy skin. Staphylococcus hominis (S. hominis) negatively correlated with non-hydroxy-dehydrosphingosine (NdS) 18:0;2/24:0;0 and positively with diacylglycerol (DAG) 18:1;0_18:1;0 and DAG 16:0;0_18:1;0. In vitro co-cultures of reconstructed human epidermis (RHE) with AD skin-derived T cell supernatant (TCS) and S. hominis reduced RHE thickness, spongiosis, and NdS 18:0;2/24:0;0 levels. Furthermore, S. hominis directly lowered NdS 18:0;2/24:0;0 levels in lesional AD skin tape samples, and reversed type 2 inflammation and lipid metabolism gene expression in TCS-stimulated RHE. CONCLUSIONS: These findings identify S. hominis as a key regulator of lipid-microbe interactions in AD, influencing epidermal inflammation and differentiation.</style></abstract><notes><style face="normal" font="default" size="100%">Bhattacharyya, Madhumita&#xD;Lauffer, Felix&#xD;Jargosch, Manja&#xD;Frey, Kristina&#xD;Dadras, Mahsa Shahidi&#xD;Raunegger, Theresa&#xD;Wasserer, Sophia&#xD;Schmidt-Weber, Carsten B&#xD;Biedermann, Tilo&#xD;Eyerich, Kilian&#xD;Eyerich, Stefanie&#xD;Traidl-Hoffmann, Claudia&#xD;Klose, Christian&#xD;Reiger, Matthias&#xD;Garzorz-Stark, Natalie&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Aug 28. doi: 10.1111/all.70028.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40874637</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70028</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2420</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2420</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tham, E. H.</style></author><author><style face="normal" font="default" size="100%">Chia, M.</style></author><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Nagarajan, N.</style></author><author><style face="normal" font="default" size="100%">Common, J. E. A.</style></author><author><style face="normal" font="default" size="100%">Kong, H. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Khoo Teck Puat-National University Children&apos;s Medical Institute, National University Health System (NUHS), Singapore City, Singapore.&#xD;Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore City, Singapore.&#xD;Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.&#xD;A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.&#xD;National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The skin microbiome in pediatric atopic dermatitis and food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1470-1484</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/02/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/microbiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/microbiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin/microbiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">skin microbiome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38308490</style></accession-num><abstract><style face="normal" font="default" size="100%">The skin microbiome is an extensive community of bacteria, fungi, mites, viruses and archaea colonizing the skin. Fluctuations in the composition of the skin microbiome have been observed in atopic dermatitis (AD) and food allergy (FA), particularly in early life, established disease, and associated with therapeutics. However, AD is a multifactorial disease characterized by skin barrier aberrations modulated by genetics, immunology, and environmental influences, thus the skin microbiome is not the sole feature of this disease. Future research should focus on mechanistic understanding of how early-life skin microbial shifts may influence AD and FA onset, to guide potential early intervention strategies or as microbial biomarkers to identify high-risk infants who may benefit from possible microbiome-based biotherapeutic strategies. Harnessing skin microbes as AD biotherapeutics is an emerging field, but more work is needed to investigate whether this approach can lead to sustained clinical responses.</style></abstract><notes><style face="normal" font="default" size="100%">Tham, Elizabeth Huiwen&#xD;Chia, Minghao&#xD;Riggioni, Carmen&#xD;Nagarajan, Niranjan&#xD;Common, John E A&#xD;Kong, Heidi H&#xD;eng&#xD;Z99 AR999999/ImNIH/Intramural NIH HHS/&#xD;Agency for Science, Technology and Research/&#xD;National Medical Research Council/&#xD;NH/NIH HHS/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1470-1484. doi: 10.1111/all.16044. Epub 2024 Feb 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38308490</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11142881</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16044</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1934</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1934</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rapin, A.</style></author><author><style face="normal" font="default" size="100%">Rehbinder, E. M.</style></author><author><style face="normal" font="default" size="100%">Macowan, M.</style></author><author><style face="normal" font="default" size="100%">Pattaroni, C.</style></author><author><style face="normal" font="default" size="100%">Lodrup Carlsen, K. C.</style></author><author><style face="normal" font="default" size="100%">Harris, N. L.</style></author><author><style face="normal" font="default" size="100%">Jonassen, C. M.</style></author><author><style face="normal" font="default" size="100%">Landro, L.</style></author><author><style face="normal" font="default" size="100%">Lossius, A. H.</style></author><author><style face="normal" font="default" size="100%">Nordlund, B.</style></author><author><style face="normal" font="default" size="100%">Rudi, K.</style></author><author><style face="normal" font="default" size="100%">Skjerven, H. O.</style></author><author><style face="normal" font="default" size="100%">Cathrine Staff, A.</style></author><author><style face="normal" font="default" size="100%">Soderhall, C.</style></author><author><style face="normal" font="default" size="100%">Ubags, N.</style></author><author><style face="normal" font="default" size="100%">Vettukattil, R.</style></author><author><style face="normal" font="default" size="100%">Marsland, B. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Global Health Institute, Ecole Polytechnique Federale de Lausanne (EPFL), Lausanne, Switzerland.&#xD;Service de Pneumologie, Departement de Medecine, Centre Hospitalier Universitaire Vaudois (CHUV), Epalinges, Switzerland.&#xD;Department of Dermatology, Oslo University Hospital, Oslo, Norway.&#xD;Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.&#xD;Department of Immunology, Monash University, Melbourne, Victoria, Australia.&#xD;Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.&#xD;Genetic Unit, Centre for Laboratory Medicine, Ostfold Hospital Trust, Kalnes, Norway.&#xD;Astrid Lindgren Children&apos;s Hospital, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Women&apos;s and Children&apos;s Health, Karolinska Institutet, Stockholm, Sweden.&#xD;Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, As, Norway.&#xD;Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The skin microbiome in the first year of life and its association with atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1949-1963</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Cesarean Section</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Water</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">cohort study</style></keyword><keyword><style face="normal" font="default" size="100%">infancy</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36779606</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Early-life microbial colonization of the skin may modulate the immune system and impact the development of atopic dermatitis (AD) and allergic diseases later in life. To address this question, we assessed the association between the skin microbiome and AD, skin barrier integrity and allergic diseases in the first year of life. We further explored the evolution of the skin microbiome with age and its possible determinants, including delivery mode. METHODS: Skin microbiome was sampled from the lateral upper arm on the first day of life, and at 3, 6, and 12 months of age. Bacterial communities were assessed by 16S rRNA gene amplicon sequencing in 346 infants from the PreventADALL population-based birth cohort study, representing 970 samples. Clinical investigations included skin examination and skin barrier function measured as trans-epidermal water loss (TEWL) at the site and time of microbiome sampling at 3, 6, and 12 months. Parental background information was recorded in electronic questionnaires, and delivery mode (including vaginal delivery (VD), VD in water, elective caesarean section (CS) and emergency CS) was obtained from maternal hospital charts. RESULTS: Strong temporal variations in skin bacterial community composition were found in the first year of life, with distinct patterns associated with different ages. Confirming our hypothesis, skin bacterial community composition in the first year of life was associated with skin barrier integrity and later onsets of AD. Delivery mode had a strong impact on the microbiome composition at birth, with each mode leading to distinct patterns of colonization. Other possible determinants of the skin microbiome were identified, including environmental and parental factors as well as breastfeeding. CONCLUSION: Skin microbiome composition during infancy is defined by age, transiently influenced by delivery mode as well as environmental, parental factors and breastfeeding. The microbiome is also associated with skin barrier integrity and the onset of AD.</style></abstract><notes><style face="normal" font="default" size="100%">Rapin, Alexis&#xD;Rehbinder, Eva Maria&#xD;Macowan, Matthew&#xD;Pattaroni, Celine&#xD;Lodrup Carlsen, Karin C&#xD;Harris, Nicola L&#xD;Jonassen, Christine M&#xD;Landro, Linn&#xD;Lossius, Astrid H&#xD;Nordlund, Bjorn&#xD;Rudi, Knut&#xD;Skjerven, Havard O&#xD;Cathrine Staff, Anne&#xD;Soderhall, Cilla&#xD;Ubags, Niki&#xD;Vettukattil, Riyas&#xD;Marsland, Benjamin J&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):1949-1963. doi: 10.1111/all.15671. Epub 2023 Feb 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36779606</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15671</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1638</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1638</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hulpusch, C.</style></author><author><style face="normal" font="default" size="100%">Tremmel, K.</style></author><author><style face="normal" font="default" size="100%">Hammel, G.</style></author><author><style face="normal" font="default" size="100%">Bhattacharyya, M.</style></author><author><style face="normal" font="default" size="100%">de Tomassi, A.</style></author><author><style face="normal" font="default" size="100%">Nussbaumer, T.</style></author><author><style face="normal" font="default" size="100%">Neumann, A. U.</style></author><author><style face="normal" font="default" size="100%">Reiger, M.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum Munchen, Augsburg, Germany.&#xD;CK CARE - Christine Kuhne Center for Allergy research and Education, Davos, Switzerland.&#xD;ZIEL, Technical University of Munich, Freising, Germany.&#xD;Outpatient Clinic for Environmental Medicine, Universitatsklinikum Augsburg, Augsburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Skin pH-dependent Staphylococcus aureus abundance as predictor for increasing atopic dermatitis severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2888-2898</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2020/06/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrogen-Ion Concentration</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">pH</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32562575</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic eczema (atopic dermatitis, AD) is characterized by disrupted skin barrier associated with elevated skin pH and skin microbiome dysbiosis, due to high Staphylococcus aureus loads, especially during flares. Since S aureus shows optimal growth at neutral pH, we investigated the longitudinal interplay between these factors and AD severity in a pilot study. METHOD: Emollient (with either basic pH 8.5 or pH 5.5) was applied double-blinded twice daily to 6 AD patients and 6 healthy (HE) controls for 8 weeks. Weekly, skin swabs for microbiome analysis (deep sequencing) were taken, AD severity was assessed, and skin physiology (pH, hydration, transepidermal water loss) was measured. RESULTS: Physiological, microbiome, and clinical results were not robustly related to the pH of applied emollient. In contrast to longitudinally stable microbiome in HE, S aureus frequency significantly increased in AD over 8 weeks. High S aureus abundance was associated with skin pH 5.7-6.2. High baseline S aureus frequency predicted both increase in S aureus and in AD severity (EASI and local SCORAD) after 8 weeks. CONCLUSION: Skin pH is tightly regulated by intrinsic factors and limits the abundance of S aureus. High baseline S aureus abundance in turn predicts an increase in AD severity over the study period. This underlines the importance and potential of sustained intervention regarding the skin pH and urges for larger studies linking skin pH and skin S aureus abundance to understand driving factors of disease progression.</style></abstract><notes><style face="normal" font="default" size="100%">Hulpusch, Claudia&#xD;Tremmel, Karolina&#xD;Hammel, Gertrud&#xD;Bhattacharyya, Madhumita&#xD;de Tomassi, Amedeo&#xD;Nussbaumer, Thomas&#xD;Neumann, Avidan U&#xD;Reiger, Matthias&#xD;Traidl-Hoffmann, Claudia&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Nov;75(11):2888-2898. doi: 10.1111/all.14461. Epub 2020 Jul 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32562575</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14461</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2495</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2495</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rothenberg-Lausell, C.</style></author><author><style face="normal" font="default" size="100%">David, E.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Da Rosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Dahabreh, D.</style></author><author><style face="normal" font="default" size="100%">Gomez-Arias, P. J.</style></author><author><style face="normal" font="default" size="100%">Catlin, E.</style></author><author><style face="normal" font="default" size="100%">Nandymazumdar, M.</style></author><author><style face="normal" font="default" size="100%">Jarvinen, K. M.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;University of Puerto Rico School of Medicine, San Juan, Puerto Rico.&#xD;Department of Dermatology, University of La Sapienza, Rome, Italy.&#xD;Department of Dermatology and Immune-Mediated Inflammatory Skin Diseases Research Group, IMIBIC/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.&#xD;Department of Pediatrics, Division of Allergy and Immunology, Center for Food Allergy, University of Rochester School of Medicine, Rochester, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Skin tape-strips in old order Mennonite toddlers reveal upregulated barrier markers and low T-helper inflammatory tone</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2012-2015</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/05/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Helper-Inducer/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/immunology/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38814244</style></accession-num><notes><style face="normal" font="default" size="100%">Rothenberg-Lausell, Camille&#xD;David, Eden&#xD;Del Duca, Ester&#xD;Da Rosa, Joel Correa&#xD;Dahabreh, Dante&#xD;Gomez-Arias, Pedro Jesus&#xD;Catlin, Elizabeth&#xD;Nandymazumdar, Monali&#xD;Jarvinen, Kirsi M&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;P30 ES001247/ES/NIEHS NIH HHS/&#xD;U01 AI131344/AI/NIAID NIH HHS/&#xD;U19 AI175113/AI/NIAID NIH HHS/&#xD;This work was supported in part by funding from NIAID U01AI131344 and U19AI175113./&#xD;P30 AR079200/AR/NIAMS NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):2012-2015. doi: 10.1111/all.16154. Epub 2024 May 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38814244</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11236509</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16154</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1068</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1068</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bianchi, L.</style></author><author><style face="normal" font="default" size="100%">Biondi, F.</style></author><author><style face="normal" font="default" size="100%">Hansel, K.</style></author><author><style face="normal" font="default" size="100%">Murgia, N.</style></author><author><style face="normal" font="default" size="100%">Tramontana, M.</style></author><author><style face="normal" font="default" size="100%">Stingeni, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine and Surgery, Section of Dermatology, University of Perugia, Perugia, Italy.&#xD;Department of Medicine and Surgery, Section of Occupational Medicine, Respiratory Diseases and Toxicology, University of Perugia, Perugia, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2605-2607</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/04/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Angioedema/chemically induced/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2 vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">intradermal test</style></keyword><keyword><style face="normal" font="default" size="100%">skin test</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33811344</style></accession-num><notes><style face="normal" font="default" size="100%">Bianchi, Leonardo&#xD;Biondi, Filippo&#xD;Hansel, Katharina&#xD;Murgia, Nicola&#xD;Tramontana, Marta&#xD;Stingeni, Luca&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2605-2607. doi: 10.1111/all.14839. Epub 2021 Apr 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33811344</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8251329</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14839</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2995</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2995</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kida, M.</style></author><author><style face="normal" font="default" size="100%">Nakamura, T.</style></author><author><style face="normal" font="default" size="100%">Maeda, S.</style></author><author><style face="normal" font="default" size="100%">Nagata, N.</style></author><author><style face="normal" font="default" size="100%">Enomoto, H.</style></author><author><style face="normal" font="default" size="100%">Murata, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Animal Radiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.&#xD;Division of Bioscience and Bioindustry, Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Japan.&#xD;Veterinary Pharmacology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.&#xD;Food and Animal Systemics, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Skin-Derived PGD(2) Promotes Antigen-Specific IgE Production via CRTH2 Signaling</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2674-2677</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/07/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacology and pharmacogenomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40605522</style></accession-num><notes><style face="normal" font="default" size="100%">Kida, Misato&#xD;Nakamura, Tatsuro&#xD;Maeda, Shingo&#xD;Nagata, Nanae&#xD;Enomoto, Hirofumi&#xD;Murata, Takahisa&#xD;eng&#xD;JPMJTR22UF/Japan Science and Technology Agency/&#xD;20H05678/Japan Society for the Promotion of Science/&#xD;25H00430/Japan Society for the Promotion of Science/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2674-2677. doi: 10.1111/all.16635. Epub 2025 Jul 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40605522</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12444815</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16635</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2449</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2449</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Berni Canani, R.</style></author><author><style face="normal" font="default" size="100%">Caminati, M.</style></author><author><style face="normal" font="default" size="100%">Carucci, L.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medical Science, University of Naples Federico II, Naples, Italy.&#xD;CEINGE Advanced Biotechnologies, University of Naples Federico II, Naples, Italy.&#xD;Allergy Unit and Asthma Centre, Verona Integrated University Hospital and Department of Medicine, University of Verona, Verona, Italy.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Allergy Group, Biomedical Research Institute of Malaga (IBIMA)-BIONAND Platform, RICORS Inflammatory Diseases, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Skin, gut, and lung barrier: Physiological interface and target of intervention for preventing and treating allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1485-1500</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/03/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Microbiome/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Lung/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Barrier Function/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Il-25</style></keyword><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">Tslp</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">tight junctions</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38439599</style></accession-num><abstract><style face="normal" font="default" size="100%">The epithelial barriers of the skin, gut, and respiratory tract are critical interfaces between the environment and the host, and they orchestrate both homeostatic and pathogenic immune responses. The mechanisms underlying epithelial barrier dysfunction in allergic and inflammatory conditions, such as atopic dermatitis, food allergy, eosinophilic oesophagitis, allergic rhinitis, chronic rhinosinusitis, and asthma, are complex and influenced by the exposome, microbiome, individual genetics, and epigenetics. Here, we review the role of the epithelial barriers of the skin, digestive tract, and airways in maintaining homeostasis, how they influence the occurrence and progression of allergic and inflammatory conditions, how current treatments target the epithelium to improve symptoms of these disorders, and what the unmet needs are in the identification and treatment of epithelial disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Berni Canani, Roberto&#xD;Caminati, Marco&#xD;Carucci, Laura&#xD;Eguiluz-Gracia, Ibon&#xD;eng&#xD;Amgen/&#xD;AstraZeneca/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1485-1500. doi: 10.1111/all.16092. Epub 2024 Mar 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38439599</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16092</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2952</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2952</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mak, H. W. F.</style></author><author><style face="normal" font="default" size="100%">Lee, E.</style></author><author><style face="normal" font="default" size="100%">Wong, J. C. Y.</style></author><author><style face="normal" font="default" size="100%">Li, P. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.&#xD;Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Hong Kong-Shenzhen Hospital, Hong Kong, Guangdong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sleep Disturbance Mediates the Association Between Disease Activity and Work Productivity Impairments in Chronic Urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2395-2397</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/06/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">CU-Q2oL</style></keyword><keyword><style face="normal" font="default" size="100%">Wpai</style></keyword><keyword><style face="normal" font="default" size="100%">chronic urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">mediation analysis</style></keyword><keyword><style face="normal" font="default" size="100%">patient-reported outcome</style></keyword><keyword><style face="normal" font="default" size="100%">quality-of-life</style></keyword><keyword><style face="normal" font="default" size="100%">sleep</style></keyword><keyword><style face="normal" font="default" size="100%">work productivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40560683</style></accession-num><notes><style face="normal" font="default" size="100%">Mak, Hugo W F&#xD;Lee, Elaine&#xD;Wong, Jane C Y&#xD;Li, Philip H&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2395-2397. doi: 10.1111/all.16629. Epub 2025 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40560683</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368741</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16629</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2481</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2481</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lam, L. H.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Wu, W. C.</style></author><author><style face="normal" font="default" size="100%">Chow, K. C.</style></author><author><style face="normal" font="default" size="100%">Au, W. Y. D.</style></author><author><style face="normal" font="default" size="100%">Xu, G.</style></author><author><style face="normal" font="default" size="100%">Wang, G.</style></author><author><style face="normal" font="default" size="100%">Qian, X.</style></author><author><style face="normal" font="default" size="100%">Ng, K. M.</style></author><author><style face="normal" font="default" size="100%">Nawabjan, S. A.</style></author><author><style face="normal" font="default" size="100%">Gandhi Sethuraman, M. I.</style></author><author><style face="normal" font="default" size="100%">Choi, W. Y.</style></author><author><style face="normal" font="default" size="100%">Chow, B. K. C.</style></author><author><style face="normal" font="default" size="100%">Leung, S. O.</style></author><author><style face="normal" font="default" size="100%">Hui, C. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">SinoMab BioScience Limited, Hong Kong, China.&#xD;MediNexus Pharma (Suzhou) Limited, Suzhou, Jiangsu, China.&#xD;School of Biological Sciences, The University of Hong Kong, Hong Kong, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">SM17, a new IL-17RB-targeting antibody, ameliorates disease progression in a mouse model of atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1625-1628</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/04/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/immunology/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Interleukin-17/immunology/antagonists &amp; inhibitors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38590291</style></accession-num><notes><style face="normal" font="default" size="100%">Lam, Lik Hang&#xD;Li, Weimin&#xD;Wu, Wai Chung&#xD;Chow, Kai Cheung&#xD;Au, Wai Yin Dennis&#xD;Xu, Guolin&#xD;Wang, Ge&#xD;Qian, Xuchen&#xD;Ng, Ka Man&#xD;Nawabjan, Shaik Abdullah&#xD;Gandhi Sethuraman, Muthu Iswarya&#xD;Choi, Wai Yan&#xD;Chow, Billy Kwok Chong&#xD;Leung, Shui On&#xD;Hui, Chin Wai&#xD;eng&#xD;SinoMab BioScience Limited/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1625-1628. doi: 10.1111/all.16120. Epub 2024 Apr 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38590291</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16120</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3256</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3256</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kumar, Akshi</style></author><author><style face="normal" font="default" size="100%">Chan, Rory</style></author><author><style face="normal" font="default" size="100%">Zounemat-Kermani, Nazanin</style></author><author><style face="normal" font="default" size="100%">Quek, Eleanor</style></author><author><style face="normal" font="default" size="100%">Adcock, Ian M.</style></author><author><style face="normal" font="default" size="100%">Beghe, Bianca</style></author><author><style face="normal" font="default" size="100%">Brightling, Christopher</style></author><author><style face="normal" font="default" size="100%">Singh, Dave</style></author><author><style face="normal" font="default" size="100%">Kocks, Janwillem</style></author><author><style face="normal" font="default" size="100%">Papi, Alberto</style></author><author><style face="normal" font="default" size="100%">Rabe, Klaus F.</style></author><author><style face="normal" font="default" size="100%">Scaffidi-Argentina, Ulrica</style></author><author><style face="normal" font="default" size="100%">van den Berge, Maarten</style></author><author><style face="normal" font="default" size="100%">Kraft, Monica</style></author><author><style face="normal" font="default" size="100%">Siddiqui, Salman</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Small Airways Dysfunction and Remission in Adults With Asthma: A Longitudinal Exploratory Analysis of the AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS) Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Asthma remission is a feasible treatment goal. However, remission definitions vary, and predictive biomarkers remain underexplored. Methods We conducted a post hoc analysis of ATLANTIS (NCT02123667), a multinational prospective study including 684 adult asthmatics. Remission was defined by 3-component (3C) and 4-component (4C) criteria. 3C remission included: (1) ACQ-6 &lt; 1.5, (2) no maintenance oral corticosteroids, (3) no exacerbations. An absolute decline &lt; 10% in pre-bronchodilator FEV1% predicted, was added for the 4C definition. Multivariate logistic regression identified remission predictors. A novel Low Disease Activity (LDA) score was developed using factor analysis of five clinical variables (ACQ-6, FeNO, BEC, and FEV1) including an innovative small airways dysfunction questionnaire tool (SADT). Nasal transcriptomics were analysed for differential gene expression and pathway enrichment and were replicated in U-BIOPRED (NCT01976767) using sputum transcriptomics. U-BIOPRED was included only to study omics replication of remission pathways identified in ATLANTIS. Findings Remission occurred in 48% (3C) and 45% (4C) of patients. Predictors included male sex, better lung function, fewer previous exacerbations, and higher SADT (fewer small airways symptoms). LDA identified milder disease and was associated with remission [OR 3C 4.43 (2.80, 7.10) and 4C 3.46 (2.23, 5.43)], improved QoL [OR 2.07 (1.65, 2.60)], and fewer future exacerbations [OR 0.43 (0.22, 0.85)]. Transcriptomic analyses revealed remission-associated upregulation of interleukin 4/13 signalling and downregulation of coagulation pathways, in both ATLANTIS and U-BIOPRED. Interpretation SAD was associated with reduced asthma remission. A novel LDA tool demonstrated clinical utility in stratifying prospective asthma risk. Key immunologic and haemostatic pathways may underpin remission, offering potential targets for future intervention.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70264</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70264</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1322</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1322</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Greening, N. J.</style></author><author><style face="normal" font="default" size="100%">Larsson, P.</style></author><author><style face="normal" font="default" size="100%">Ljungstrom, E.</style></author><author><style face="normal" font="default" size="100%">Siddiqui, S.</style></author><author><style face="normal" font="default" size="100%">Olin, A. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Sciences, University of Leicester, Leicester, UK.&#xD;Institute for Lung Health, NIHR Biomedical Research Centre, Glenfield Hospital, Leicester, UK.&#xD;Unit of Occupational and Environmental Medicine, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.&#xD;Atmospheric science, Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Small droplet emission in exhaled breath during different breathing manoeuvres: Implications for clinical lung function testing during COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">915-917</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/09/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Breath Tests</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Exhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Function Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32966612</style></accession-num><notes><style face="normal" font="default" size="100%">Greening, Neil J&#xD;Larsson, Per&#xD;Ljungstrom, Evert&#xD;Siddiqui, Salman&#xD;Olin, Anna-Carin&#xD;eng&#xD;PDF-2017-10-052/DH_/Department of Health/United Kingdom&#xD;20130279/The Swedish Heart Lung Foundation/&#xD;pdf-2017-10-052/National Institute for Health Research/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):915-917. doi: 10.1111/all.14596. Epub 2020 Oct 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32966612</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7537081 associated with the PEXA(R) method (Patent number: wo2009045163). SS has received grants for PEXA research from the Chiesi Onulus foundation. No other conflict of interest is declared by the authors.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14596</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3054</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3054</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Watanabe, S.</style></author><author><style face="normal" font="default" size="100%">Sato, A.</style></author><author><style face="normal" font="default" size="100%">Shibuya, K.</style></author><author><style face="normal" font="default" size="100%">Kusuda, R.</style></author><author><style face="normal" font="default" size="100%">Yauchi, T.</style></author><author><style face="normal" font="default" size="100%">Fukuie, T.</style></author><author><style face="normal" font="default" size="100%">Yamamoto-Hanada, K.</style></author><author><style face="normal" font="default" size="100%">Ohya, Y.</style></author><author><style face="normal" font="default" size="100%">Nomura, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gastroenterology, Soka Municipal Hospital, Saitama, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.&#xD;Department of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.&#xD;Division of Eosinophilic Gastrointestinal Disorders, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Department of Environmental and Occupational Health, Nagoya City University Graduate School of Medicine, Aichi, Japan.&#xD;Division of General Allergy, Bantane Hospital, Fujita Health University, Aichi, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Small Intestinal Dilation Is Associated With Severe Abdominal Symptoms of Food-Protein-Induced Enterocolitis Syndrome in Adults</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Fpies</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">food-protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">small intestine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41020299</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Food-Protein-Induced Enterocolitis Syndrome (FPIES) is a non-IgE-mediated food allergy that causes gastrointestinal symptoms, though its anatomical origin and pathogenesis remain unclear. Abdominal distention is common in adult FPIES, but symptoms vary among patients. This study aimed to establish objective criteria for assessing abdominal distention and to clarify the pathophysiology and anatomical origin of FPIES. METHODS: This study targeted 26 adult FPIES patients. Abdominal distention was broken down into eight factors, and an evaluation algorithm was developed based on items with high positivity rates. Clinical characteristics, blood, and imaging analyses were performed before and after OFC (oral food challenge) to investigate the pathophysiology. RESULTS: Among 14 adult FPIES patients who underwent OFC, seven showed positive results. The latency period was 1.5 h, with the most frequent symptoms being abdominal distention (100%), abdominal pain, and nausea (71.4%). All patients received treatment with intravenous extracellular fluid infusion and ondansetron, which resulted in reduced symptom duration. In an evaluation of blood test data, there were no specific serological markers of FPIES, except in the severe case. Image analysis with computed tomography revealed significant dilation and edema of the small intestine during the FPIES event, suggesting that dilation of the small intestine is associated with adult FPIES. CONCLUSION: These results are expected to aid in the early and appropriate diagnosis of FPIES based on medical interviews, blood test data, and imaging findings when adult patients present to medical institutions with severe acute gastroenteritis symptoms.</style></abstract><notes><style face="normal" font="default" size="100%">Watanabe, Sho&#xD;Sato, Ayako&#xD;Shibuya, Keitaro&#xD;Kusuda, Rina&#xD;Yauchi, Tsunehito&#xD;Fukuie, Tatsuki&#xD;Yamamoto-Hanada, Kiwako&#xD;Ohya, Yukihiro&#xD;Nomura, Ichiro&#xD;eng&#xD;The Japan Health Foundation/&#xD;JSA WAO 2020 Memorial Research Grant Program/&#xD;Denmark&#xD;Allergy. 2025 Sep 29. doi: 10.1111/all.70081.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41020299</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70081</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2143</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2143</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sitaru, S.</style></author><author><style face="normal" font="default" size="100%">Wecker, H.</style></author><author><style face="normal" font="default" size="100%">Buters, J.</style></author><author><style face="normal" font="default" size="100%">Biedermann, T.</style></author><author><style face="normal" font="default" size="100%">Zink, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Center Allergy &amp; Environment (ZAUM), Technical University Munich/Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.&#xD;Division of Dermatology and Venereology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Social media to monitor prevalent diseases: Hay fever and Twitter activity in Germany</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2777-2780</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/06/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal</style></keyword><keyword><style face="normal" font="default" size="100%">*Social Media</style></keyword><keyword><style face="normal" font="default" size="100%">Germany/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37317626</style></accession-num><notes><style face="normal" font="default" size="100%">Sitaru, Sebastian&#xD;Wecker, Hannah&#xD;Buters, Jeroen&#xD;Biedermann, Tilo&#xD;Zink, Alexander&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2777-2780. doi: 10.1111/all.15787. Epub 2023 Jun 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37317626</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15787</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>455</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">455</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Watanabe, M.</style></author><author><style face="normal" font="default" size="100%">Nakamoto, K.</style></author><author><style face="normal" font="default" size="100%">Inui, T.</style></author><author><style face="normal" font="default" size="100%">Sada, M.</style></author><author><style face="normal" font="default" size="100%">Chibana, K.</style></author><author><style face="normal" font="default" size="100%">Miyaoka, C.</style></author><author><style face="normal" font="default" size="100%">Yoshida, Y.</style></author><author><style face="normal" font="default" size="100%">Aso, J.</style></author><author><style face="normal" font="default" size="100%">Nunokawa, H.</style></author><author><style face="normal" font="default" size="100%">Honda, K.</style></author><author><style face="normal" font="default" size="100%">Nakamura, M.</style></author><author><style face="normal" font="default" size="100%">Tamura, M.</style></author><author><style face="normal" font="default" size="100%">Hirata, A.</style></author><author><style face="normal" font="default" size="100%">Oda, M.</style></author><author><style face="normal" font="default" size="100%">Takata, S.</style></author><author><style face="normal" font="default" size="100%">Saraya, T.</style></author><author><style face="normal" font="default" size="100%">Kurai, D.</style></author><author><style face="normal" font="default" size="100%">Ishii, H.</style></author><author><style face="normal" font="default" size="100%">Takizawa, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, Kyorin University School of Medicine, Tokyo, Japan.&#xD;Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Tochigi, Japan.&#xD;Department of General Medicine, Kyorin University School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Soluble ST2 enhances IL-33-induced neutrophilic and pro-type 2 inflammation in the lungs</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3137-3141</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/06/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-1 Receptor-Like 1 Protein</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-33</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">Copd</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma-COPD overlap</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophil</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35661175</style></accession-num><notes><style face="normal" font="default" size="100%">Watanabe, Masato&#xD;Nakamoto, Keitaro&#xD;Inui, Toshiya&#xD;Sada, Mitsuru&#xD;Chibana, Kazuyuki&#xD;Miyaoka, Chika&#xD;Yoshida, Yuki&#xD;Aso, Jumpei&#xD;Nunokawa, Hiroki&#xD;Honda, Kojiro&#xD;Nakamura, Masuo&#xD;Tamura, Masaki&#xD;Hirata, Aya&#xD;Oda, Miku&#xD;Takata, Saori&#xD;Saraya, Takeshi&#xD;Kurai, Daisuke&#xD;Ishii, Haruyuki&#xD;Takizawa, Hajime&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3137-3141. doi: 10.1111/all.15401. Epub 2022 Jun 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35661175</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9796337</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15401</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1935</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1935</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Contreras, N.</style></author><author><style face="normal" font="default" size="100%">Macias-Camero, A.</style></author><author><style face="normal" font="default" size="100%">Delgado-Dolset, M. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Metabolomics and Bioanalysis (CEMBIO), Department of Chemistry and Biochemistry, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanizacion Monteprincipe, Madrid, Spain.&#xD;Instituto de Medicina Molecular Aplicada Nemesio Diez (IMMA-NM), Departamento de Ciencias Medicas Basicas, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Urbanizacion Monteprincipe, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Some OPA once told me &quot;LKB1 is going to rule me&quot;: The OPA1-LKB1 axis in immune response</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1400-1402</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/02/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">GTP Phosphohydrolases</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">*Protein Serine-Threonine Kinases</style></keyword><keyword><style face="normal" font="default" size="100%">AMP-Activated Protein Kinase Kinases/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36785923</style></accession-num><notes><style face="normal" font="default" size="100%">Contreras, Nuria&#xD;Macias-Camero, Andrea&#xD;Delgado-Dolset, Maria Isabel&#xD;eng&#xD;Comment&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1400-1402. doi: 10.1111/all.15672. Epub 2023 Feb 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36785923</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15672</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>60</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">60</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gauvreau, G. M.</style></author><author><style face="normal" font="default" size="100%">Bergeron, C.</style></author><author><style face="normal" font="default" size="100%">Boulet, L. P.</style></author><author><style face="normal" font="default" size="100%">Cockcroft, D. W.</style></author><author><style face="normal" font="default" size="100%">Cote, A.</style></author><author><style face="normal" font="default" size="100%">Davis, B. E.</style></author><author><style face="normal" font="default" size="100%">Leigh, R.</style></author><author><style face="normal" font="default" size="100%">Myers, I.</style></author><author><style face="normal" font="default" size="100%">O&apos;Byrne, P. M.</style></author><author><style face="normal" font="default" size="100%">Sehmi, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;Centre for Lung Health, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada.&#xD;Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada.&#xD;Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.&#xD;Department of Medicine, Cumming School of Medicine, Calgary, Alberta, Canada.&#xD;Division of Pulmonary Medicine, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sounding the alarmins-The role of alarmin cytokines in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">402-417</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Alarmins/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-1 Receptor-Like 1 Protein</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Thymic Stromal Lymphopoietin</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">alarmin cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trials</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">this work, GMG reports receiving consulting or speaker fees from AstraZeneca.</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Regeneron and research grants from Biohaven, Genentech, BioGaia, Novartis</style></keyword><keyword><style face="normal" font="default" size="100%">CB reports receiving consulting or speaker fees from Valeo, AstraZeneca, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">Grifols, Takeda, and research grants (clinical trials paid to Vancouver Coastal</style></keyword><keyword><style face="normal" font="default" size="100%">Health Research Institute/University of British Columbia) from Biohaven,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Regeneron, GSK, Novartis, Sanofi, Teva</style></keyword><keyword><style face="normal" font="default" size="100%">LPB reports receiving</style></keyword><keyword><style face="normal" font="default" size="100%">consulting or speaker fees from AstraZeneca, Covis, Cipla, GlaxoSmithKline,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Merck, Sanofi-Regeneron, and research grants from Amgen, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Merck, Novartis, Sanofi-Regeneron, Biohaven</style></keyword><keyword><style face="normal" font="default" size="100%">DWC reports</style></keyword><keyword><style face="normal" font="default" size="100%">receiving research grants from Department of Medicine University of Saskatchewan,</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Biohaven, Novartis, CSACI, and AllerGen NCE</style></keyword><keyword><style face="normal" font="default" size="100%">AC reports receiving</style></keyword><keyword><style face="normal" font="default" size="100%">consulting or speaker fees from AstraZeneca, Covis, Valeo pharma,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Sanofi-Regeneron, and research grants from GlaxoSmithKline</style></keyword><keyword><style face="normal" font="default" size="100%">RL</style></keyword><keyword><style face="normal" font="default" size="100%">reports receiving consulting or speaker fees from Novartis, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Sanofi Genzyme, and Valeo Pharma Inc research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Biohaven</style></keyword><keyword><style face="normal" font="default" size="100%">POB reports personal fees for consulting or speaker fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, GSK, Medimmune, Chiesi, Menarini, and Covis and research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Medimmune, Biohaven, Merck, and Bayer. RL reports receiving</style></keyword><keyword><style face="normal" font="default" size="100%">consulting or speaker fees from AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi</style></keyword><keyword><style face="normal" font="default" size="100%">Genzyme and Valeo Pharma Inc. RS reports speaker fees from AstraZeneca, Teva,</style></keyword><keyword><style face="normal" font="default" size="100%">Genentech and Grants-In Aid from AstraZeneca, GlaxoSmithKline, Teva, Genentech.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36463491</style></accession-num><abstract><style face="normal" font="default" size="100%">The alarmin cytokines thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, and IL-25 are epithelial cell-derived mediators that contribute to the pathobiology and pathophysiology of asthma. Released from airway epithelial cells exposed to environmental triggers, the alarmins drive airway inflammation through the release of predominantly T2 cytokines from multiple effector cells. The upstream positioning of the alarmins is an attractive pharmacological target to block multiple T2 pathways important in asthma. Blocking the function of TSLP inhibits allergen-induced responses including bronchoconstriction, airway hyperresponsiveness, and inflammation, and subsequent clinical trials of an anti-TSLP monoclonal antibody, tezepelumab, in asthma patients demonstrated improvements in lung function, airway responsiveness, inflammation, and importantly, a reduction in the rate of exacerbations. Notably, these improvements were observed in patients with T2-high and with T2-low asthma. Clinical trials blocking IL-33 and its receptor ST2 have also shown improvements in lung function and exacerbation rates; however, the impact of blocking the IL-33/ST2 axis in T2-high versus T2-low asthma is unclear. To date, there is no evidence that IL-25 blockade is beneficial in asthma. Despite the considerable overlap in the cellular functions of IL-25, IL-33, and TSLP, they appear to have distinct roles in the immunopathology of asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Gauvreau, Gail M&#xD;Bergeron, Celine&#xD;Boulet, Louis-Philippe&#xD;Cockcroft, Donald W&#xD;Cote, Andreanne&#xD;Davis, Beth E&#xD;Leigh, Richard&#xD;Myers, Irvin&#xD;O&apos;Byrne, Paul M&#xD;Sehmi, Roma&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):402-417. doi: 10.1111/all.15609. Epub 2022 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36463491</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10108333</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15609</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2767</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2767</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karabacak, D. E.</style></author><author><style face="normal" font="default" size="100%">Arzt-Gradwohl, L.</style></author><author><style face="normal" font="default" size="100%">Binder, B.</style></author><author><style face="normal" font="default" size="100%">Schadelbauer, E.</style></author><author><style face="normal" font="default" size="100%">Vallant, C.</style></author><author><style face="normal" font="default" size="100%">Laipold, K.</style></author><author><style face="normal" font="default" size="100%">Sturm, G. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergic Diseases, Department of Internal Medicine, Faculty of Medicine, Istanbul University, Istanbul, Turkiye.&#xD;Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Soybean Oil in Propofol Is Not Able to Induce Allergic Reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2398-2400</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/12/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anesthesia</style></keyword><keyword><style face="normal" font="default" size="100%">birch pollen allergy</style></keyword><keyword><style face="normal" font="default" size="100%">propofol</style></keyword><keyword><style face="normal" font="default" size="100%">skin prick test</style></keyword><keyword><style face="normal" font="default" size="100%">soy</style></keyword><keyword><style face="normal" font="default" size="100%">soybean oil</style></keyword><keyword><style face="normal" font="default" size="100%">soymilk</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose. Dr. Barbara Binder has nothing to disclose. Dr. Eva</style></keyword><keyword><style face="normal" font="default" size="100%">Schadelbauer has nothing to disclose. Dr. Christina Vallant has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Ms. Karin Laipold has nothing to disclose. Dr. Gunter J. Sturm reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants from ALK-Abello, personal fees from ALK-Abello, personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, personal fees from Novartis, and personal fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes-Greer, outside the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39736042</style></accession-num><notes><style face="normal" font="default" size="100%">Karabacak, Deniz Eyice&#xD;Arzt-Gradwohl, Lisa&#xD;Binder, Barbara&#xD;Schadelbauer, Eva&#xD;Vallant, Christina&#xD;Laipold, Karin&#xD;Sturm, Gunter J&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2398-2400. doi: 10.1111/all.16454. Epub 2024 Dec 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39736042</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368747</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16454</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2142</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2142</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Reiger, M.</style></author><author><style face="normal" font="default" size="100%">Kim, J.</style></author><author><style face="normal" font="default" size="100%">Xiao, Y.</style></author><author><style face="normal" font="default" size="100%">Zhakparov, D.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Ruckert, B.</style></author><author><style face="normal" font="default" size="100%">Rinaldi, A. O.</style></author><author><style face="normal" font="default" size="100%">Baerenfaller, K.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Brunner, P. M.</style></author><author><style face="normal" font="default" size="100%">Roqueiro, D.</style></author><author><style face="normal" font="default" size="100%">Traidl-Hoffmann, C.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;CK CARE - Christine Kuhne Center for Allergy Research and Education, Davos, Switzerland.&#xD;Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;Institute of Environmental Medicine, Helmholtz Zentrum Munchen, Augsburg, Germany.&#xD;Swiss Institute of Bioinformatics (SIB), Davos, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University Zurich, Zurich, Switzerland.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, California, USA.&#xD;Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, California, USA.&#xD;Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.&#xD;ZIEL, Technical University of Munich, Freising, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Spatial transcriptomics combined with single-cell RNA-sequencing unravels the complex inflammatory cell network in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2215-2231</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/06/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, CCR7</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">RNA/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">single-cell transcriptomics</style></keyword><keyword><style face="normal" font="default" size="100%">spatial transcriptomics</style></keyword><keyword><style face="normal" font="default" size="100%">targeted proteomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37312623</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease with complex pathogenesis for which the cellular and molecular crosstalk in AD skin has not been fully understood. METHODS: Skin tissues examined for spatial gene expression were derived from the upper arm of 6 healthy control (HC) donors and 7 AD patients (lesion and nonlesion). We performed spatial transcriptomics sequencing to characterize the cellular infiltrate in lesional skin. For single-cell analysis, we analyzed the single-cell data from suction blister material from AD lesions and HC skin at the antecubital fossa skin (4 ADs and 5 HCs) and full-thickness skin biopsies (4 ADs and 2 HCs). The multiple proximity extension assays were performed in the serum samples from 36 AD patients and 28 HCs. RESULTS: The single-cell analysis identified unique clusters of fibroblasts, dendritic cells, and macrophages in the lesional AD skin. Spatial transcriptomics analysis showed the upregulation of COL6A5, COL4A1, TNC, and CCL19 in COL18A1-expressing fibroblasts in the leukocyte-infiltrated areas in AD skin. CCR7-expressing dendritic cells (DCs) showed a similar distribution in the lesions. Additionally, M2 macrophages expressed CCL13 and CCL18 in this area. Ligand-receptor interaction analysis of the spatial transcriptome identified neighboring infiltration and interaction between activated COL18A1-expressing fibroblasts, CCL13- and CCL18-expressing M2 macrophages, CCR7- and LAMP3-expressing DCs, and T cells. As observed in skin lesions, serum levels of TNC and CCL18 were significantly elevated in AD, and correlated with clinical disease severity. CONCLUSION: In this study, we show the unknown cellular crosstalk in leukocyte-infiltrated area in lesional skin. Our findings provide a comprehensive in-depth knowledge of the nature of AD skin lesions to guide the development of better treatments.</style></abstract><notes><style face="normal" font="default" size="100%">Mitamura, Yasutaka&#xD;Reiger, Matthias&#xD;Kim, Juno&#xD;Xiao, Yi&#xD;Zhakparov, Damir&#xD;Tan, Ge&#xD;Ruckert, Beate&#xD;Rinaldi, Arturo O&#xD;Baerenfaller, Katja&#xD;Akdis, Mubeccel&#xD;Bruggen, Marie-Charlotte&#xD;Nadeau, Kari C&#xD;Brunner, Patrick M&#xD;Roqueiro, Damian&#xD;Traidl-Hoffmann, Claudia&#xD;Akdis, Cezmi A&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2215-2231. doi: 10.1111/all.15781. Epub 2023 Jun 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37312623</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15781</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2616</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2616</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jabeen, M. F.</style></author><author><style face="normal" font="default" size="100%">Sanderson, N. D.</style></author><author><style face="normal" font="default" size="100%">Tine, M.</style></author><author><style face="normal" font="default" size="100%">Donachie, G.</style></author><author><style face="normal" font="default" size="100%">Barber, C.</style></author><author><style face="normal" font="default" size="100%">Azim, A.</style></author><author><style face="normal" font="default" size="100%">Lau, L. C. K.</style></author><author><style face="normal" font="default" size="100%">Brown, T.</style></author><author><style face="normal" font="default" size="100%">Pavord, I. D.</style></author><author><style face="normal" font="default" size="100%">Chauhan, A.</style></author><author><style face="normal" font="default" size="100%">Klenerman, P.</style></author><author><style face="normal" font="default" size="100%">Street, T. L.</style></author><author><style face="normal" font="default" size="100%">Marchi, E.</style></author><author><style face="normal" font="default" size="100%">Howarth, P. H.</style></author><author><style face="normal" font="default" size="100%">Hinks, T. S. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Nuffield Department of Medicine, Experimental Medicine Division, Respiratory Medicine Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK.&#xD;Nuffield Department of Clinical Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.&#xD;National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.&#xD;Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.&#xD;Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories and NIHR Southampton Respiratory Biomedical Research Unit, Southampton University, Southampton, UK.&#xD;Portsmouth Hospitals NHS Trust, Portsmouth, UK.&#xD;Nuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research and Translational Gastroenterology Unit, University of Oxford, Oxford, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Species-level, metagenomic and proteomic analysis of microbe-immune interactions in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2966-2980</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/08/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/immunology/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Metagenomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum/microbiology/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Metagenome</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bacteria</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">sputum</style></keyword><keyword><style face="normal" font="default" size="100%">and the National Institute for Health Research (NIHR) Oxford Biomedical Research</style></keyword><keyword><style face="normal" font="default" size="100%">Centre. Clair Barber, and Adnan Azim are employees of AstraZeneca, Ian D Pavord</style></keyword><keyword><style face="normal" font="default" size="100%">has received funding from Merck, from Chiesi and consultancy fees from</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, Teva, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi/Regeneron, Menarini, GSK, Circassia, Knopp outside the submitted work.</style></keyword><keyword><style face="normal" font="default" size="100%">Anoop Chauhan has received funding from Airsonett and consultancy fees from</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi Genzyme, Novartis, XIM, Glyconics and Exhalation Technology. Mariaenrica</style></keyword><keyword><style face="normal" font="default" size="100%">Tine, Gillian Donachie, Laurie CK Lau, Thomas Brown and Paul Klenerman declare</style></keyword><keyword><style face="normal" font="default" size="100%">they have no conflict of interest. Nicholas D Sanderson and Teresa L Street</style></keyword><keyword><style face="normal" font="default" size="100%">received funding from the National Institute for Health Research (NIHR) Oxford</style></keyword><keyword><style face="normal" font="default" size="100%">Biomedical Research Centre. Emanuele Marchi has received funding from Asthma+Lung</style></keyword><keyword><style face="normal" font="default" size="100%">UK. Peter H Howarth is an employee of GSK. Timothy SC Hinks reports grants from</style></keyword><keyword><style face="normal" font="default" size="100%">The Wellcome Trust, grants from The Guardians of the Beit Fellowship, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer, grants from NIHR Oxford BRC, grants from University of Oxford, grants</style></keyword><keyword><style face="normal" font="default" size="100%">from Kymab, grants from Arcturis, grants from Asthma+Lung UK, during the conduct</style></keyword><keyword><style face="normal" font="default" size="100%">of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from Astra Zeneca, personal fees from TEVA, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Peer Voice, personal fees from AZ Pieris, outside the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39127908</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The airway microbiome in severe asthma has not been characterised at species-level by metagenomic sequencing, nor have the relationships between specific species and mucosal immune responses in &apos;type-2 low&apos;, neutrophilic asthma been defined. We performed an integrated species-level metagenomic data with inflammatory mediators to characterise prevalence of dominant potentially pathogenic organisms and host immune responses. METHODS: Sputum and nasal lavage samples were analysed using long-read metagenomic sequencing with Nanopore and qPCR in two cross-sectional adult severe asthma cohorts, Wessex (n = 66) and Oxford (n = 30). We integrated species-level data with clinical parameters and 39 selected airway proteins measured by immunoassay and O-link. RESULTS: The sputum microbiome in health and mild asthma displayed comparable microbial diversity. By contrast, 23% (19/81) of severe asthma microbiomes were dominated by a single respiratory pathogen, namely H. influenzae (n = 10), M. catarrhalis (n = 4), S. pneumoniae (n = 4) and P. aeruginosa (n = 1). Neutrophilic asthma was associated with H. influenzae, M. catarrhalis, S. pneumoniae and T. whipplei with elevated type-1 cytokines and proteases; eosinophilic asthma with higher M. catarrhalis, but lower H. influenzae, and S. pneumoniae abundance. H. influenzae load correlated with Eosinophil Cationic Protein, elastase and IL-10. R. mucilaginosa associated positively with IL-6 and negatively with FGF. Bayesian network analysis also revealed close and distinct relationships of H. influenzae and M. catarrhalis with type-1 airway inflammation. The microbiomes and cytokine milieu were distinct between upper and lower airways. CONCLUSIONS: This species-level integrated analysis reveals central, but distinct associations between potentially pathogenic bacteria and airways inflammation in severe asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Jabeen, Maisha F&#xD;Sanderson, Nicholas D&#xD;Tine, Mariaenrica&#xD;Donachie, Gillian&#xD;Barber, Clair&#xD;Azim, Adnan&#xD;Lau, Laurie C K&#xD;Brown, Thomas&#xD;Pavord, Ian D&#xD;Chauhan, Anoop&#xD;Klenerman, Paul&#xD;Street, Teresa L&#xD;Marchi, Emanuele&#xD;Howarth, Peter H&#xD;Hinks, Timothy S C&#xD;eng&#xD;MRC_/Medical Research Council/United Kingdom&#xD;211050/WT_/Wellcome Trust/United Kingdom&#xD;National Institute for Health Research Southampton Biomedical Research Centre/&#xD;NIHR Oxford Biomedical Research Centre/&#xD;NIHR Primary Care Research Network/&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):2966-2980. doi: 10.1111/all.16269. Epub 2024 Aug 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39127908</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7617782</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16269</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>254</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">254</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walsemann, T.</style></author><author><style face="normal" font="default" size="100%">Bottger, M.</style></author><author><style face="normal" font="default" size="100%">Traidl, S.</style></author><author><style face="normal" font="default" size="100%">Schwager, C.</style></author><author><style face="normal" font="default" size="100%">Gulsen, A.</style></author><author><style face="normal" font="default" size="100%">Freimooser, S.</style></author><author><style face="normal" font="default" size="100%">Roesner, L. M.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Jappe, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Clinical and Molecular Allergology, Priority Area Asthma and Allergy, Research Center Borstel, German Center for Lung Research (DZL) Airway Research Center North (ARCN), Borstel, Germany.&#xD;Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University of Luebeck, Luebeck, Germany.&#xD;Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Specific IgE against the house dust mite allergens Der p 5, 20 and 21 influences the phenotype and severity of atopic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">731-742</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/10/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">allergens and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36239002</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: House dust mites (HDM) are among the most important sources for airborne allergens with high relevance for atopic diseases. Routine tests contain only 4 of 32 registered allergens of Dermatophagoides pteronyssinus. Clinical relevance and pathomechanistic properties of many allergens are not well understood. OBJECTIVE: The association of several HDM allergens with allergic rhinitis, allergic asthma, and atopic dermatitis was investigated to identify allergens with biomarker potential and to transfer them into diagnostics. METHODS: Eight out of nine D. pteronyssinus allergens (nDer p 1, rDer p 2, rDer p 5, rDer p 7, rDer p 10, rDer p 13, rDer p 20, rDer p 21, rDer p 23) were recombinantly expressed and purified. Sensitization patterns of 384 HDM-allergic individuals exhibiting different clinical phenotypes were analyzed with a serum-saving multiplex array. RESULTS: Sensitization to more than three mite allergens (sensitization count) was associated with allergic asthma and/or atopic dermatitis. Reactions to Der p 5 and Der p 21 were more frequent in allergic asthma compared to allergic rhinitis. Atopic dermatitis patients were more often sensitized to Der p 5, Der p 20, and Der p 21 among others. Der p 20-IgE &gt; 80 kU/L was associated with severe atopic dermatitis in 75% of patients. CONCLUSION: This study demonstrates the clinical importance of the sensitization count and of certain allergens (Der p 5, Der p 20, and Der p 21) not available for routine diagnostics yet. Implementing them as well as the sensitization count in diagnostic measures will improve diagnosis and risk assessment of HDM-allergic patients.</style></abstract><notes><style face="normal" font="default" size="100%">Walsemann, Theresa&#xD;Bottger, Marisa&#xD;Traidl, Stephan&#xD;Schwager, Christian&#xD;Gulsen, Askin&#xD;Freimooser, Sina&#xD;Roesner, Lennart Matthias&#xD;Werfel, Thomas&#xD;Jappe, Uta&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):731-742. doi: 10.1111/all.15553. Epub 2022 Oct 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36239002</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15553</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>761</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">761</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Farag, A. K.</style></author><author><style face="normal" font="default" size="100%">Roesner, L. M.</style></author><author><style face="normal" font="default" size="100%">Wieschowski, S.</style></author><author><style face="normal" font="default" size="100%">Heratizadeh, A.</style></author><author><style face="normal" font="default" size="100%">Eiz-Vesper, B.</style></author><author><style face="normal" font="default" size="100%">Kwok, W. W.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Dermatology and Allergy, Department of Immunodermatology and Allergy Research, Hannover Medical School, Hannover, Germany.&#xD;Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.&#xD;Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.&#xD;Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA.&#xD;Department of Medicine, University of Washington, Seattle, Washington, USA.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;NRC Institute of Immunology FMBA of Russia, Moscow, Russia.&#xD;Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Specific T cells targeting Staphylococcus aureus fibronectin-binding protein 1 induce a type 2/type 1 inflammatory response in sensitized atopic dermatitis patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1245-1253</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/10/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Carrier Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Fibronectins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">*Staphylococcal Infections/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">antigen-specific T cells</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">fibronectin-binding protein 1</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34601735</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is one of the most common inflammatory skin diseases worldwide and Staphylococcus aureus colonization and secondary infections occur in the majority of AD patients. Allergic sensitizations against microbial antigens have been discussed as possible trigger factors of AD. Recently, we reported IgE sensitization against fibronectin-binding protein 1 (FBP1), an essential virulence component in S. aureus, in a subgroup of patients suffering from AD. To expand these findings by investigating delayed-type immune reactions, the objective of this study was to detect and phenotypically characterize FBP1-specific T cells as possible trigger factors in AD. METHODS: Immunodominant T-cell epitopes were mapped by proliferation testing of patient-derived FBP1-specific T-cell lines after stimulation with single 15mer peptides, which were derived from different functional domains of the FBP1 sequence. Major histocompatibility complex class II tetramers carrying immunodominant epitopes successfully stained T helper cells in 8 out of 8 HLA-matched, IgE-sensitized AD patients. RESULTS: Cytokine profiling of multimer-sorted cells revealed that predominantly the type 2 cytokines IL-13 and IL-4 were secreted by these cells. In contrast, IL-17, the marker cytokine for response to extracellular pathogens, was scarcely detectable. CONCLUSIONS: We demonstrate that FBP1 contains immunodominant peptides that induce a specific pro-inflammatory T helper cell response with increased Th2 levels that can drive an allergic inflammation in sensitized AD patients.</style></abstract><notes><style face="normal" font="default" size="100%">Farag, Ahmed K&#xD;Roesner, Lennart M&#xD;Wieschowski, Susanne&#xD;Heratizadeh, Annice&#xD;Eiz-Vesper, Britta&#xD;Kwok, William W&#xD;Valenta, Rudolf&#xD;Werfel, Thomas&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1245-1253. doi: 10.1111/all.15120. Epub 2021 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34601735</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11497299</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15120</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2295</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2295</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Checa, A.</style></author><author><style face="normal" font="default" size="100%">Zhang, P.</style></author><author><style face="normal" font="default" size="100%">Huang, M.</style></author><author><style face="normal" font="default" size="100%">Kelly, R. S.</style></author><author><style face="normal" font="default" size="100%">Kim, M.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. S.</style></author><author><style face="normal" font="default" size="100%">Lee-Sarwar, K. A.</style></author><author><style face="normal" font="default" size="100%">Prince, N.</style></author><author><style face="normal" font="default" size="100%">Mendez, K. M.</style></author><author><style face="normal" font="default" size="100%">Begum, S.</style></author><author><style face="normal" font="default" size="100%">Kachroo, P.</style></author><author><style face="normal" font="default" size="100%">Chu, S. H.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Litonjua, A. A.</style></author><author><style face="normal" font="default" size="100%">Bisgaard, H.</style></author><author><style face="normal" font="default" size="100%">Weiss, S. T.</style></author><author><style face="normal" font="default" size="100%">Chawes, B. L.</style></author><author><style face="normal" font="default" size="100%">Wheelock, C. E.</style></author><author><style face="normal" font="default" size="100%">Lasky-Su, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Channing Division of Network Medicine, Department of Medicine, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.&#xD;Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.&#xD;Gunma University Initiative for Advanced Research (GIAR), Gunma University, Maebashi, Gunma, Japan.&#xD;Copenhagen Prospective Studies on Asthma in Childhood (COPSAC), Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark.&#xD;Division of Allergy and Clinical Immunology, Brigham and Women&apos;s Hospital and Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Pediatric Pulmonary Medicine, Department of Pediatrics, Golisano Children&apos;s Hospital and University of Rochester Medical Center, Rochester, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sphingolipid classes and the interrelationship with pediatric asthma and asthma risk factors</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">404-418</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/11/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sphingolipids/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Chromatography, Liquid</style></keyword><keyword><style face="normal" font="default" size="100%">Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">Ceramides/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">asthma risk factors</style></keyword><keyword><style face="normal" font="default" size="100%">childhood asthma</style></keyword><keyword><style face="normal" font="default" size="100%">lung function</style></keyword><keyword><style face="normal" font="default" size="100%">metabolomic epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">sphingolipids</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostic, Inc. STW receives royalties from UpToDate and is on the Board of</style></keyword><keyword><style face="normal" font="default" size="100%">Histolix. The authors have no relevant competing interests to disclose. K.L.S is</style></keyword><keyword><style face="normal" font="default" size="100%">employed by and owns stock in Vertex Pharmaceuticals.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38014461</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: While dysregulated sphingolipid metabolism has been associated with risk of childhood asthma, the specific sphingolipid classes and/or mechanisms driving this relationship remain unclear. We aimed to understand the multifaceted role between sphingolipids and other established asthma risk factors that complicate this relationship. METHODS: We performed targeted LC-MS/MS-based quantification of 77 sphingolipids in plasma from 997 children aged 6 years from two independent cohorts (VDAART and COPSAC(2010) ). We examined associations of circulatory sphingolipids with childhood asthma, lung function, and three asthma risk factors: functional SNPs in ORMDL3, low vitamin D levels, and reduced gut microbial maturity. Given racial differences between these cohorts, association analyses were performed separately and then meta-analyzed together. RESULTS: We observed elevations in circulatory sphingolipids with asthma phenotypes and risk factors; however, there were differential associations of sphingolipid classes with clinical outcomes and/or risk factors. While elevations from metabolites involved in ceramide recycling and catabolic pathways were associated with asthma and worse lung function [meta p-value range: 1.863E-04 to 2.24E-3], increased ceramide levels were associated with asthma risk factors [meta p-value range: 7.75E-5 to .013], but not asthma. Further investigation identified that some ceramides acted as mediators while some interacted with risk factors in the associations with asthma outcomes. CONCLUSION: This study demonstrates the differential role that sphingolipid subclasses may play in asthma and its risk factors. While overall elevations in sphingolipids appeared to be deleterious overall; elevations in ceramides were uniquely associated with increases in asthma risk factors only; while elevations in asthma phenotypes were associated with recycling sphingolipids. Modification of asthma risk factors may play an important role in regulating sphingolipid homeostasis via ceramides to affect asthma. Further function work may validate the observed associations.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Yulu&#xD;Checa, Antonio&#xD;Zhang, Pei&#xD;Huang, Mengna&#xD;Kelly, Rachel S&#xD;Kim, Min&#xD;Chen, Yih-Chieh S&#xD;Lee-Sarwar, Kathleen A&#xD;Prince, Nicole&#xD;Mendez, Kevin M&#xD;Begum, Sofina&#xD;Kachroo, Priyadarshini&#xD;Chu, Su H&#xD;Stokholm, Jakob&#xD;Bonnelykke, Klaus&#xD;Litonjua, Augusto A&#xD;Bisgaard, Hans&#xD;Weiss, Scott T&#xD;Chawes, Bo L&#xD;Wheelock, Craig E&#xD;Lasky-Su, Jessica A&#xD;eng&#xD;U01 HL091528/HL/NHLBI NIH HHS/&#xD;K01 HL153941/HL/NHLBI NIH HHS/&#xD;R01 HL155742/HL/NHLBI NIH HHS/&#xD;K08 HL148178/HL/NHLBI NIH HHS/&#xD;K01 HL146980/HL/NHLBI NIH HHS/&#xD;T32 HL007427/HL/NHLBI NIH HHS/&#xD;R01 HL091528/HL/NHLBI NIH HHS/&#xD;R01 HL123915/HL/NHLBI NIH HHS/&#xD;K99 HL159234/HL/NHLBI NIH HHS/&#xD;R01 HL141826/HL/NHLBI NIH HHS/&#xD;ERC_/European Research Council/International&#xD;T32 AI007306/AI/NIAID NIH HHS/&#xD;P30 ES001247/ES/NIEHS NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):404-418. doi: 10.1111/all.15942. Epub 2023 Nov 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38014461</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11175620</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15942</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3305</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3305</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yamamura, Kazuhiko</style></author><author><style face="normal" font="default" size="100%">Garcet, Sandra</style></author><author><style face="normal" font="default" size="100%">Gonzalez, Juana</style></author><author><style face="normal" font="default" size="100%">Zhou, Jerry</style></author><author><style face="normal" font="default" size="100%">Fiedler, Jacob</style></author><author><style face="normal" font="default" size="100%">Miura, Shunsuke</style></author><author><style face="normal" font="default" size="100%">Williams, Samuel C.</style></author><author><style face="normal" font="default" size="100%">Hur, Hong Beom</style></author><author><style face="normal" font="default" size="100%">Murai-Yamamura, Mika</style></author><author><style face="normal" font="default" size="100%">Li, Xuan</style></author><author><style face="normal" font="default" size="100%">Renert-Yuval, Yael</style></author><author><style face="normal" font="default" size="100%">Estrada, Yeriel</style></author><author><style face="normal" font="default" size="100%">Krueger, James G.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, Emma</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Sphingosine 1-Phosphate Receptor 1 and 5 Reciprocally Regulate IL-13 and IL-9 Production in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Atopic dermatitis (AD) is a common inflammatory skin disease associated with Th2, Th9, and Th22 skewing. Recent studies have implicated various lipid mediators in modulating T helper cell responses. However, the relationship between lipid mediators and Th skewing in AD is not fully understood. Objective We sought to identify lipid mediators that modulate cytokine production involved in Th skewing in AD. Methods RNA-sequencing was performed in CD3+ T cells and CD3– non-T cells from AD patients and healthy subjects. Differentially expressed genes were analyzed to detect candidate lipid mediators. Intracellular cytokine staining (ICS) was used to evaluate production of polarizing cytokines in CD4+ T cells cultured in vitro with various lipid mediators. Results Several lipid mediator-related genes, including sphingosine 1-phosphate receptor 5 (S1PR5), were differentially expressed in CD3+ and CD3– cells from AD patients. ICS revealed markedly increased IL-13 and IL-9 production in the presence of S1P, with AD patients expressing higher levels of S1P in serum compared to healthy controls. Further mechanistic studies using siRNA knockdown for S1PR5 and S1PR1 revealed that IL-13 and IL-9 production are suppressed via S1PR5 and enhanced via S1PR1 signaling. Conclusions S1P signaling contributes to Th2/Th9-driven inflammation in AD by reciprocally regulating IL-13 and IL-9 production via S1PR5 and S1PR1.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70299</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70299</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1281</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1281</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weidner, J.</style></author><author><style face="normal" font="default" size="100%">Bartel, S.</style></author><author><style face="normal" font="default" size="100%">Kilic, A.</style></author><author><style face="normal" font="default" size="100%">Zissler, U. M.</style></author><author><style face="normal" font="default" size="100%">Renz, H.</style></author><author><style face="normal" font="default" size="100%">Schwarze, J.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Maes, T.</style></author><author><style face="normal" font="default" size="100%">Rebane, A.</style></author><author><style face="normal" font="default" size="100%">Krauss-Etschmann, S.</style></author><author><style face="normal" font="default" size="100%">Radinger, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine and Clinical Nutrition, Krefting Research Centre, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.&#xD;Department of Pathology and Medical Biology, GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;Channing Division of Network Medicine, Brigham and Women&apos;s Hospital, Boston, MA, USA.&#xD;Center for Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany.&#xD;Institut fur Laboratoriumsmedizin und Pathobiochemie, Philipps University of Marburg, Marburg, Germany.&#xD;Centre for Inflammation Research, The University of Edinburgh, Edinburgh, UK.&#xD;Department of Respiratory Medicine, Ghent University, Ghent, Belgium.&#xD;Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.&#xD;Research Center Borstel, Borstel, Germany.&#xD;Institute of Experimental Medicine, Christian-Albrechts University Kiel, Kiel, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Spotlight on microRNAs in allergy and asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1661-1678</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*MicroRNAs/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory System</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">allergic disease</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">experimental models</style></keyword><keyword><style face="normal" font="default" size="100%">microRNA</style></keyword><keyword><style face="normal" font="default" size="100%">pollution</style></keyword><keyword><style face="normal" font="default" size="100%">from Bencard Allergie GmbH, outside the submitted work. Dr Kilic has nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. Dr Zissler has nothing to disclose. Dr Renz has nothing to disclose. Dr</style></keyword><keyword><style face="normal" font="default" size="100%">Schwarze reports personal fees from MYLAN, personal fees from F2F events, outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and Industry support to educational activities of the</style></keyword><keyword><style face="normal" font="default" size="100%">Scottish Allergy and Respiratory Academy and of the Children&apos;s and Young people&apos;s</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Network Scotland. Industry support to EAACI, he is EAACI Secretary</style></keyword><keyword><style face="normal" font="default" size="100%">General 2019-2021. Prof. Schmidt-Weber reports grants from DFG, grants from BMBF,</style></keyword><keyword><style face="normal" font="default" size="100%">grants from EIT Health, and grants from German Center of lung research, outside</style></keyword><keyword><style face="normal" font="default" size="100%">the submitted work. Dr Maes reports grants from Ghent University, grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Fund for Scientific Research in Flanders, during the conduct of the study</style></keyword><keyword><style face="normal" font="default" size="100%">personal fees from GlaxoSmithKline, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and is</style></keyword><keyword><style face="normal" font="default" size="100%">shareholder from Oryzon Genomics and Mendelion Lifesciences SL. Dr Rebane has</style></keyword><keyword><style face="normal" font="default" size="100%">nothing to disclose. Dr Krauss-Etschmann has nothing to disclose. Dr Radinger</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants and personal fees from AstraZeneca outside the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33128813</style></accession-num><abstract><style face="normal" font="default" size="100%">In past 10 years, microRNAs (miRNAs) have gained scientific attention due to their importance in the pathophysiology of allergic diseases and their potential as biomarkers in liquid biopsies. They act as master post-transcriptional regulators that control most cellular processes. As one miRNA can target several mRNAs, often within the same pathway, dysregulated expression of miRNAs may alter particular cellular responses and contribute, or lead, to the development of various diseases. In this review, we give an overview of the current research on miRNAs in allergic diseases, including atopic dermatitis, allergic rhinitis, and asthma. Specifically, we discuss how individual miRNAs function in the regulation of immune responses in epithelial cells and specialized immune cells in response to different environmental factors and respiratory viruses. In addition, we review insights obtained from experiments with murine models of allergic airway and skin inflammation and offer an overview of studies focusing on miRNA discovery using profiling techniques and bioinformatic modeling of the network effect of multiple miRNAs. In conclusion, we highlight the importance of research into miRNA function in allergy and asthma to improve our knowledge of the molecular mechanisms involved in the pathogenesis of this heterogeneous group of diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Weidner, Julie&#xD;Bartel, Sabine&#xD;Kilic, Ayse&#xD;Zissler, Ulrich M&#xD;Renz, Harald&#xD;Schwarze, Jurgen&#xD;Schmidt-Weber, Carsten B&#xD;Maes, Tania&#xD;Rebane, Ana&#xD;Krauss-Etschmann, Susanne&#xD;Radinger, Madeleine&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1661-1678. doi: 10.1111/all.14646. Epub 2020 Nov 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33128813</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8246745</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14646</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2262</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2262</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gautam, S.</style></author><author><style face="normal" font="default" size="100%">Chu, J. H.</style></author><author><style face="normal" font="default" size="100%">Cohen, A. J.</style></author><author><style face="normal" font="default" size="100%">Kaur, R.</style></author><author><style face="normal" font="default" size="100%">Lee, S.</style></author><author><style face="normal" font="default" size="100%">Wilson, G.</style></author><author><style face="normal" font="default" size="100%">Liu, Q.</style></author><author><style face="normal" font="default" size="100%">Gomez, J.</style></author><author><style face="normal" font="default" size="100%">Rajaveen, H.</style></author><author><style face="normal" font="default" size="100%">Yan, X.</style></author><author><style face="normal" font="default" size="100%">Cohn, L.</style></author><author><style face="normal" font="default" size="100%">Clark, B. J.</style></author><author><style face="normal" font="default" size="100%">Chupp, G. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, Connecticut, USA.&#xD;Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.&#xD;Department of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, Yale School of Medicine, New Haven, Connecticut, USA.&#xD;Yale Center for Medical Informatics, Yale School of Medicine, New Haven, Connecticut, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sputum alarmins delineate distinct T2 cytokine pathways and unique subtypes of patients with asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3274-3277</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/10/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Alarmins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37874609</style></accession-num><notes><style face="normal" font="default" size="100%">Gautam, Samir&#xD;Chu, Jen-Hwa&#xD;Cohen, Avi J&#xD;Kaur, Ravdeep&#xD;Lee, Seohyuk&#xD;Wilson, Gabriella&#xD;Liu, Qing&#xD;Gomez, Jose&#xD;Rajaveen, Haseena&#xD;Yan, Xiting&#xD;Cohn, Lauren&#xD;Clark, Brian J&#xD;Chupp, Geoffrey L&#xD;eng&#xD;R21 LM012884/LM/NLM NIH HHS/&#xD;U24 HL138998/HL/NHLBI NIH HHS/&#xD;T32 HL007778/HL/NHLBI NIH HHS/&#xD;R01 LM014087/LM/NLM NIH HHS/&#xD;UM1 AI114271/AI/NIAID NIH HHS/&#xD;R01 HL161362/HL/NHLBI NIH HHS/&#xD;UL1 TR000142/TR/NCATS NIH HHS/&#xD;K08 HL159422/HL/NHLBI NIH HHS/&#xD;R03 HL154275/HL/NHLBI NIH HHS/&#xD;F32 HL154641/HL/NHLBI NIH HHS/&#xD;DDCF/Doris Duke Charitable Foundation/&#xD;R01 HL153604/HL/NHLBI NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3274-3277. doi: 10.1111/all.15915. Epub 2023 Oct 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37874609</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10842366</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15915</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>815</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">815</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Luu, Q. Q.</style></author><author><style face="normal" font="default" size="100%">Cao, T. B. T.</style></author><author><style face="normal" font="default" size="100%">Shin, Y. S.</style></author><author><style face="normal" font="default" size="100%">Yang, E. M.</style></author><author><style face="normal" font="default" size="100%">Moon, J. Y.</style></author><author><style face="normal" font="default" size="100%">Park, H. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.&#xD;Department of Biomedical Sciences, Ajou University School of Medicine, Suwon, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sputum antinuclear antibody serves as a biomarker for severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3832-3835</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/09/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Antibodies, Antinuclear</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34528264</style></accession-num><notes><style face="normal" font="default" size="100%">Luu, Quoc Quang&#xD;Cao, Thi Bich Tra&#xD;Shin, Yoo Seob&#xD;Yang, Eun-Mi&#xD;Moon, Ji-Young&#xD;Park, Hae-Sim&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3832-3835. doi: 10.1111/all.15086. Epub 2021 Sep 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34528264</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15086</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2378</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2378</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hekking, P. P.</style></author><author><style face="normal" font="default" size="100%">Zhang, K.</style></author><author><style face="normal" font="default" size="100%">Garrido, C. P. V.</style></author><author><style face="normal" font="default" size="100%">Lopez-Rodriguez, R.</style></author><author><style face="normal" font="default" size="100%">Kjarsgaard, M.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Respirology, Department of Medicine, St. Joseph&apos;s Healthcare Hamilton, McMaster University, Hamilton, Ontario, Canada.&#xD;Department of Respiratory Diseases, STZ Centre of Excellence for Asthma &amp; COPD, Franciscus Gasthuis &amp; Vlietland Hospital, Rotterdam, The Netherlands.&#xD;Department of Allergy, Lucus Augusti Hospital, Lugo, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sputum cytokines associated with raised FeNO after anti-IL5 biologic therapy in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2244-2247</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/01/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-5/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Therapy/methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38197516</style></accession-num><notes><style face="normal" font="default" size="100%">Hekking, Pieter-Paul&#xD;Zhang, Kayla&#xD;Garrido, Carmen Paz Venegas&#xD;Lopez-Rodriguez, Raquel&#xD;Kjarsgaard, Melanie&#xD;Mukherjee, Manali&#xD;Nair, Parameswaran&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2244-2247. doi: 10.1111/all.16011. Epub 2024 Jan 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38197516</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16011</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1374</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1374</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tiotiu, A.</style></author><author><style face="normal" font="default" size="100%">Zounemat Kermani, N.</style></author><author><style face="normal" font="default" size="100%">Badi, Y.</style></author><author><style face="normal" font="default" size="100%">Pavlidis, S.</style></author><author><style face="normal" font="default" size="100%">Hansbro, P. M.</style></author><author><style face="normal" font="default" size="100%">Guo, Y. K.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">U. Biopred consortium project team</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Pulmonology, University Hospital of Nancy, Nancy, France.&#xD;Department of Computing, Data Science Institute, Imperial College London, London, UK.&#xD;Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia.&#xD;Centre for Inflammation, Centenary Institute and University of Technology Sydney, Sydney, NSW, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sputum macrophage diversity and activation in asthma: Role of severity and inflammatory phenotype</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">775-788</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/08/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophage Activation</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">gene set variation analysis</style></keyword><keyword><style face="normal" font="default" size="100%">macrophage subtypes</style></keyword><keyword><style face="normal" font="default" size="100%">sputum</style></keyword><keyword><style face="normal" font="default" size="100%">tissue-resident</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32740964</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Macrophages control innate and acquired immunity, but their role in severe asthma remains ill-defined. We investigated gene signatures of macrophage subtypes in the sputum of 104 asthmatics and 16 healthy volunteers from the U-BIOPRED cohort. METHODS: Forty-nine gene signatures (modules) for differentially stimulated macrophages, one to assess lung tissue-resident cells (TR-Mphi) and two for their polarization (classically and alternatively activated macrophages: M1 and M2, respectively) were studied using gene set variation analysis. We calculated enrichment scores (ES) across severity and previously identified asthma transcriptome-associated clusters (TACs). RESULTS: Macrophage numbers were significantly decreased in severe asthma compared to mild-moderate asthma and healthy volunteers. The ES for most modules were also significantly reduced in severe asthma except for 3 associated with inflammatory responses driven by TNF and Toll-like receptors via NF-kappaB, eicosanoid biosynthesis via the lipoxygenase pathway and IL-2 biosynthesis (all P &lt; .01). Sputum macrophage number and the ES for most macrophage signatures were higher in the TAC3 group compared to TAC1 and TAC2 asthmatics. However, a high enrichment was found in TAC1 for 3 modules showing inflammatory pathways linked to Toll-like and TNF receptor activation and arachidonic acid metabolism (P &lt; .001) and in TAC2 for the inflammasome and interferon signalling pathways (P &lt; .001). Data were validated in the ADEPT cohort. Module analysis provides additional information compared to conventional M1 and M2 classification. TR-Mphi were enriched in TAC3 and associated with mitochondrial function. CONCLUSIONS: Macrophage activation is attenuated in severe granulocytic asthma highlighting defective innate immunity except for specific subsets characterized by distinct inflammatory pathways.</style></abstract><notes><style face="normal" font="default" size="100%">Tiotiu, Angelica&#xD;Zounemat Kermani, Nazanin&#xD;Badi, Yusef&#xD;Pavlidis, Stelios&#xD;Hansbro, Philip M&#xD;Guo, Yi-Ke&#xD;Chung, Kian Fan&#xD;Adcock, Ian M&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):775-788. doi: 10.1111/all.14535. Epub 2020 Aug 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32740964</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14535</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1641</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1641</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Diver, S.</style></author><author><style face="normal" font="default" size="100%">Richardson, M.</style></author><author><style face="normal" font="default" size="100%">Haldar, K.</style></author><author><style face="normal" font="default" size="100%">Ghebre, M. A.</style></author><author><style face="normal" font="default" size="100%">Ramsheh, M. Y.</style></author><author><style face="normal" font="default" size="100%">Bafadhel, M.</style></author><author><style face="normal" font="default" size="100%">Desai, D.</style></author><author><style face="normal" font="default" size="100%">Cohen, E. S.</style></author><author><style face="normal" font="default" size="100%">Newbold, P.</style></author><author><style face="normal" font="default" size="100%">Rapley, L.</style></author><author><style face="normal" font="default" size="100%">Rugman, P.</style></author><author><style face="normal" font="default" size="100%">Pavord, I. D.</style></author><author><style face="normal" font="default" size="100%">May, R. D.</style></author><author><style face="normal" font="default" size="100%">Barer, M.</style></author><author><style face="normal" font="default" size="100%">Brightling, C. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Lung Health, NIHR Leicester Biomedical Research Centre, Department of Respiratory Sciences, College of Life Sciences, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK.&#xD;hVIVO Services Limited, London, UK.&#xD;Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.&#xD;AstraZeneca, Cambridge, UK.&#xD;AstraZeneca, Gaithersburg, MD, USA.&#xD;GlaxoSmithKline, Stevenage, UK.&#xD;Sosei Heptares, Cambridge, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilus-predominant subgroup</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">808-817</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2019/09/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cluster Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Haemophilus/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Ribosomal, 16S/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">Copd</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">sputum</style></keyword><keyword><style face="normal" font="default" size="100%">from AstraZeneca, Boehringer Ingelheim and Chiesi, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">MBaf reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi,</style></keyword><keyword><style face="normal" font="default" size="100%">GlaxoSmithKline, Novartis and Pfizer, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">ESC, PN and PR</style></keyword><keyword><style face="normal" font="default" size="100%">are employees of AstraZeneca, which supported the study</style></keyword><keyword><style face="normal" font="default" size="100%">IDP reports personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees and nonfinancial support from AstraZeneca and Boehringer Ingelheim, personal</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Aerocrine, Almirall, Novartis, GlaxoSmithKline, Genentech, Regeneron,</style></keyword><keyword><style face="normal" font="default" size="100%">Merck &amp; Co., Schering-Plough, Mylan Speciality (Dey Pharma), Napp Pharmaceuticals</style></keyword><keyword><style face="normal" font="default" size="100%">and Respivert, outside the submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">RDM and LR are former employees of</style></keyword><keyword><style face="normal" font="default" size="100%">AstraZeneca, which supported the study</style></keyword><keyword><style face="normal" font="default" size="100%">CEB has received grants and personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">paid to his institution from AstraZeneca, GlaxoSmithKline, Roche/Genentech,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, Chiesi, Pfizer, Teva, Sanofi/Regeneron, Glenmark, Mologic, PreP and</style></keyword><keyword><style face="normal" font="default" size="100%">Vectura, outside the submitted work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31556120</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Airway ecology is altered in asthma and chronic obstructive pulmonary disease (COPD). Anti-microbial interventions might have benefit in subgroups of airway disease. Differences in sputum microbial profiles at acute exacerbation of airways disease are reflected by the gammaProteobacteria:Firmicutes (gammaP:F) ratio. We hypothesized that sputum microbiomic clusters exist in stable airways disease, which can be differentiated by the sputum gammaP:F ratio. METHODS: Sputum samples were collected from 63 subjects with severe asthma and 78 subjects with moderate-to-severe COPD in a prospective single centre trial. Microbial profiles were obtained through 16S rRNA gene sequencing. Topological data analysis was used to visualize the data set and cluster analysis performed at genus level. Clinical characteristics and sputum inflammatory mediators were compared across the clusters. RESULTS: Two ecological clusters were identified across the combined airways disease population. The smaller cluster was predominantly COPD and was characterized by dominance of Haemophilus at genus level (n = 20), high gammaP:F ratio, increased H influenzae, low diversity measures and increased pro-inflammatory mediators when compared to the larger Haemophilus-low cluster (n = 121), in which Streptococcus demonstrated the highest relative abundance at the genus level. Similar clusters were identified within disease groups individually and the gammaP:F ratio consistently differentiated between clusters. CONCLUSION: Cluster analysis by airway ecology of asthma and COPD in stable state identified two subgroups differentiated according to dominance of Haemophilus. The gammaP:F ratio was able to distinguish the Haemophilus-high versus Haemophilus-low subgroups, whether the Haemophilus-high group might benefit from treatment strategies to modulate the airway ecology warrants further investigation.</style></abstract><notes><style face="normal" font="default" size="100%">Diver, Sarah&#xD;Richardson, Matt&#xD;Haldar, Koirobi&#xD;Ghebre, Michael A&#xD;Ramsheh, Mohammadali Y&#xD;Bafadhel, Mona&#xD;Desai, Dhananjay&#xD;Cohen, Emma Suzanne&#xD;Newbold, Paul&#xD;Rapley, Laura&#xD;Rugman, Paul&#xD;Pavord, Ian D&#xD;May, Richard D&#xD;Barer, Michael&#xD;Brightling, Christopher E&#xD;eng&#xD;WT_/Wellcome Trust/United Kingdom&#xD;G0601369/MRC_/Medical Research Council/United Kingdom&#xD;G0801980/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Apr;75(4):808-817. doi: 10.1111/all.14058. Epub 2019 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31556120</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7217013</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14058</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1167</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1167</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Niessen, N. M.</style></author><author><style face="normal" font="default" size="100%">Gibson, P. G.</style></author><author><style face="normal" font="default" size="100%">Baines, K. J.</style></author><author><style face="normal" font="default" size="100%">Barker, D.</style></author><author><style face="normal" font="default" size="100%">Yang, I. A.</style></author><author><style face="normal" font="default" size="100%">Upham, J. W.</style></author><author><style face="normal" font="default" size="100%">Reynolds, P. N.</style></author><author><style face="normal" font="default" size="100%">Hodge, S.</style></author><author><style face="normal" font="default" size="100%">James, A. L.</style></author><author><style face="normal" font="default" size="100%">Jenkins, C.</style></author><author><style face="normal" font="default" size="100%">Peters, M. J.</style></author><author><style face="normal" font="default" size="100%">Marks, G. B.</style></author><author><style face="normal" font="default" size="100%">Baraket, M.</style></author><author><style face="normal" font="default" size="100%">Simpson, J. L.</style></author><author><style face="normal" font="default" size="100%">Fricker, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Health and Medicine and Priority Research Centre for Healthy Lungs, School of Medicine and Public Health, The University of Newcastle, Newcastle, NSW, Australia.&#xD;National Health and Medical Research Council Centre for Excellence in Severe Asthma, Newcastle, NSW, Australia.&#xD;Hunter Medical Research Institute, Newcastle, NSW, Australia.&#xD;Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW, Australia.&#xD;Faculty of Medicine, Department of Thoracic Medicine, The Prince Charles Hospital, The University of Queensland, Brisbane, Qld, Australia.&#xD;Diamantina Institute, The University of Queensland, Brisbane, Qld, Australia.&#xD;Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Qld, Australia.&#xD;Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.&#xD;Lung Research Laboratory, Hanson Institute, Adelaide, SA, Australia.&#xD;School of Medicine, University of Adelaide, Adelaide, SA, Australia.&#xD;Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia.&#xD;Medical School, The University of Western Australia, Perth, WA, Australia.&#xD;Respiratory Trials, The George Institute for Global Health, Sydney, NSW, Australia.&#xD;Department of Thoracic Medicine, Concord General Hospital, Sydney, NSW, Australia.&#xD;Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.&#xD;Woolcock Institute of Medical Research, Sydney, NSW, Australia.&#xD;South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia.&#xD;Medicine Faculty, Respiratory Medicine Department and Ingham Institute Liverpool Hospital, University of New South Wales, Sydney, NSW, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2090-2101</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Azithromycin/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">macrolide</style></keyword><keyword><style face="normal" font="default" size="100%">serum</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33569770</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The AMAZES randomized controlled trial demonstrated that long-term low-dose azithromycin treatment reduces exacerbations of poorly controlled asthma, but the therapeutic mechanisms remain unclear. Dysregulation of the inflammatory tumour necrosis factor (TNF) pathway is implicated in asthma and could be suppressed by azithromycin. We aimed to determine the inflammatory and clinical associations of soluble TNF signalling proteins (TNF receptors [TNFR] 1 and 2, TNF) in sputum and serum, and to test the effect of 48 weeks of azithromycin vs placebo on TNF markers. METHODS: Sputum supernatant and serum TNFR1, TNFR2 (n = 142; 75 azithromycin-treated, 67 placebo-treated) and TNF (n = 48; 22 azithromycin-treated, 26 placebo-treated) were measured by ELISA in an AMAZES trial sub-population at baseline and end of treatment. Baseline levels were compared between sputum inflammatory phenotypes, severe/non-severe asthma and frequent/non-frequent exacerbators. Effect of azithromycin on markers was tested using linear mixed models. RESULTS: Baseline sputum TNFR1 and TNFR2 were significantly increased in neutrophilic vs non-neutrophilic asthma phenotypes, while serum markers did not differ. Sputum TNFR1 and TNFR2 were increased in severe asthma and correlated with poorer lung function, worse asthma control and increasing age. Serum TNFR1 was also increased in severe asthma. Sputum and serum TNFR2 were increased in frequent exacerbators. Azithromycin treatment significantly reduced sputum TNFR2 and TNF relative to placebo, specifically in non-eosinophilic participants. CONCLUSIONS: We demonstrate dysregulation of TNF markers, particularly in the airways, that relates to clinically important phenotypes of asthma including neutrophilic and severe asthma. Suppression of dysregulated TNF signalling by azithromycin could contribute to its therapeutic mechanism.</style></abstract><notes><style face="normal" font="default" size="100%">Niessen, Natalie M&#xD;Gibson, Peter G&#xD;Baines, Katherine J&#xD;Barker, Daniel&#xD;Yang, Ian A&#xD;Upham, John W&#xD;Reynolds, Paul N&#xD;Hodge, Sandra&#xD;James, Alan L&#xD;Jenkins, Christine&#xD;Peters, Matthew J&#xD;Marks, Guy B&#xD;Baraket, Melissa&#xD;Simpson, Jodie L&#xD;Fricker, Michael&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2090-2101. doi: 10.1111/all.14768. Epub 2021 Mar 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33569770</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14768</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>330</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">330</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mastalerz, L.</style></author><author><style face="normal" font="default" size="100%">Kacorzyk, R.</style></author><author><style face="normal" font="default" size="100%">Jakiela, B.</style></author><author><style face="normal" font="default" size="100%">Cmiel, A.</style></author><author><style face="normal" font="default" size="100%">Sanak, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">II Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.&#xD;Department of Applied Mathematics, AGH University of Science and Technology, Krakow, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sputum transcriptome analysis of co-regulated genes related to arachidonic acid metabolism in N-ERD</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">553-555</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/09/02</style></edition><section><style face="normal" font="default" size="100%">553</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Arachidonic Acid/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Sputum/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36048968</style></accession-num><notes><style face="normal" font="default" size="100%">Mastalerz, Lucyna&#xD;Kacorzyk, Radoslaw&#xD;Jakiela, Bogdan&#xD;Cmiel, Adam&#xD;Sanak, Marek&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):553-555. doi: 10.1111/all.15501. Epub 2022 Sep 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36048968</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15501</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3140</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3140</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Just, J.</style></author><author><style face="normal" font="default" size="100%">Nolte, H.</style></author><author><style face="normal" font="default" size="100%">Hels, O. H.</style></author><author><style face="normal" font="default" size="100%">Emeryk, A.</style></author><author><style face="normal" font="default" size="100%">Vidal, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The David Hide Asthma and Allergy Centre, St Mary&apos;s Hospital, Newport, Isle of Wight, UK.&#xD;NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;University of Southampton Faculty of Medicine and University Hospital Southampton, Southampton, UK.&#xD;Unite d&apos;Allergologie, Hopital Americain de Paris, Neuilly sur Seine, France.&#xD;Sorbonne Universite, Paris, France.&#xD;CRESS, Inserm, INRAE, HERA Team, Universite Paris Cite, Paris, France.&#xD;ALK-Abello A/S, Horsholm, Denmark.&#xD;Department of Pulmonary Diseases and Children Rheumatology, Medical University of Lublin, Lublin, Poland.&#xD;Servicio de Alergologia, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruna, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3401-3411</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroglyphidae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Dermatophagoides/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">a consultant/speaker for ALK-Abello A/S, a consultant for AstraZeneca, an author</style></keyword><keyword><style face="normal" font="default" size="100%">of the British Thoracic Society/Scottish Intercollegiate Guidelines Network</style></keyword><keyword><style face="normal" font="default" size="100%">(SIGN) guideline, Past President of the British Society for Allergy and Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Immunology (BSACI), and has received research funding from the National Institute</style></keyword><keyword><style face="normal" font="default" size="100%">for Health and Care Research (NIHR), National Institutes of Health (NIH), the EU,</style></keyword><keyword><style face="normal" font="default" size="100%">the Medical Research Council (MRC), and Action Medicine Research. A.E. has</style></keyword><keyword><style face="normal" font="default" size="100%">received lecture fees from ALK-Abello A/S. H.N. and O.H.H. are employees of</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello A/S. J.J. is a member of the ALK-Abello Paediatric Advisory Board and</style></keyword><keyword><style face="normal" font="default" size="100%">has received fees for lectures and consulting activities from ALK-Abello A/S,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes-Greer, GSK, Novartis, AstraZeneca, and Zambon. C.V. has received</style></keyword><keyword><style face="normal" font="default" size="100%">funding for educational and research activities from ALK-Abello A/S, Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, AstraZeneca, GSK, HAL, Industry Roxal, Leti, and</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes-Greer.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41064908</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In children, house dust mite (HDM) sensitisation is a contributing factor for developing allergic asthma. HDM allergen immunotherapy has demonstrated efficacy and safety in adults with allergic asthma; however, evidence for its use in children is limited. MT-11 evaluated the efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT) tablet in children (5-17 years) with HDM allergic asthma. METHODS: This phase III, randomised, double-blind, placebo-controlled trial randomised 533 children with a recent history of asthma exacerbations, despite treatment with inhaled corticosteroids and/or long-acting beta-agonists, to daily treatment with SQ HDM SLIT-tablet or placebo for 24-30 months. The primary endpoint was the annualised rate of clinically relevant asthma exacerbations. Adverse events (AEs) were reported throughout the trial. RESULTS: The rate ratio for the annualised rate of clinically relevant asthma exacerbations was 0.89 (95% CI: 0.60, 1.31), in favour of the SQ HDM-SLIT tablet; superiority over placebo was not established. Most treatment-related AEs (TRAEs) were of mild or moderate severity, and few subjects discontinued due to TRAEs (&lt; 2%). The most common TRAEs were local application site reactions (oral pruritus, throat irritation, ear pruritus, and upper abdominal pain). There was no increased incidence of asthma-related events, and no anaphylaxis or adrenaline use in the SQ HDM SLIT-tablet group. CONCLUSION: As a result of the coronavirus disease 2019 pandemic, asthma exacerbation rates were much lower than expected, contributing to the primary endpoint not being met. The SQ HDM SLIT-tablet was well tolerated in a paediatric population with inadequately controlled HDM allergic asthma. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT03654976; EudraCT number: 2016-004363-39.</style></abstract><notes><style face="normal" font="default" size="100%">Roberts, Graham&#xD;Just, Jocelyne&#xD;Nolte, Hendrik&#xD;Hels, Ole Holm&#xD;Emeryk, Andrzej&#xD;Vidal, Carmen&#xD;eng&#xD;ALK-Abello A/S/&#xD;Clinical Trial, Phase III&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3401-3411. doi: 10.1111/all.70073. Epub 2025 Oct 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41064908</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666737</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70073</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2727</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2727</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gappa, M.</style></author><author><style face="normal" font="default" size="100%">Gagnon, R.</style></author><author><style face="normal" font="default" size="100%">Horak, F.</style></author><author><style face="normal" font="default" size="100%">Cichocka-Jarosz, E.</style></author><author><style face="normal" font="default" size="100%">Dalgaard, T.</style></author><author><style face="normal" font="default" size="100%">Hargreaves, K.</style></author><author><style face="normal" font="default" size="100%">Mikler, J.</style></author><author><style face="normal" font="default" size="100%">Emeryk, A.</style></author><author><style face="normal" font="default" size="100%">Hansen, K. S.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Paediatric and Adolescent Medicine, Evangelic Hospital Dusseldorf, Dusseldorf, Germany.&#xD;Clinique specialisee en allergie de la capitale, Quebec City, Quebec, Canada.&#xD;Allergiezentrum Wien West, Vienna, Austria.&#xD;Department of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.&#xD;ALK-Abello, Horsholm, Denmark.&#xD;Pediatric clinic, University hospital in Martin and Jessenius medical faculty in Martin, Commenius University, Bratislava, Slovakia.&#xD;Department of Pulmonary Disease and Children Rheumatology, Medical University of Lublin, Lublin, Poland.&#xD;Allergy Clinic &amp; Department of Paediatrics, Herlev-Gentofte Hospital, Hellerup, Denmark.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">795-806</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/11/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Tablets</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Trees/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Betula/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual immunotherapy tablet</style></keyword><keyword><style face="normal" font="default" size="100%">tree pollen</style></keyword><keyword><style face="normal" font="default" size="100%">research and/or personal fees from ALK-Abello, AstraZeneca, BerlinChemie,</style></keyword><keyword><style face="normal" font="default" size="100%">Infectopharm, Nestle and Sanofi/Regeneron. Remi Gagnon is a consultant for</style></keyword><keyword><style face="normal" font="default" size="100%">Bausch-Health, Takeda and Sanofi Genzyme</style></keyword><keyword><style face="normal" font="default" size="100%">is involved in clinical research for</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, GlaxoSmithKline, AstraZeneca, ALK-Abello, Sanofi, Amgen, Moderna,</style></keyword><keyword><style face="normal" font="default" size="100%">Allakos and DBV-Technologies</style></keyword><keyword><style face="normal" font="default" size="100%">is a speaker for Bausch-Health. Fritz Horak reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants and/or personal fees and/or travel support from LETI, Bencard, MEDA,</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, Novartis, Allergopharma, Stallergenes Greer, HAL Allergy outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. Ewa Cichocka-Jarosz reports lecture fees and honoraria from</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, Thermo Fisher, Allergopharma, Stallergenes Greer, and GSK. Terrie</style></keyword><keyword><style face="normal" font="default" size="100%">Dalgaard and Kate Hargreaves are employees at ALK-Abello at the time of trial</style></keyword><keyword><style face="normal" font="default" size="100%">conduct. Jan Mikler was clinical investigator in ALK-Abello trials (MT-12, MT-18,</style></keyword><keyword><style face="normal" font="default" size="100%">TT-06), and YOBI-SL79.22. Andrzej Emeryk reports lecture fee for ALK-Abello.</style></keyword><keyword><style face="normal" font="default" size="100%">Kirsten Skamstrup Hansen has nothing to disclose. Oliver Pfaar reports grants for</style></keyword><keyword><style face="normal" font="default" size="100%">his institution as clinical trial unit for TT-06 from ALK-Abello, and he reports</style></keyword><keyword><style face="normal" font="default" size="100%">grants and/or personal fees and/or travel support from ALK-Abello, Allergopharma,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH/Allergy Therapeutics, Laboratorios LETI/LETI Pharma, GlaxoSmithKline, ROXALL</style></keyword><keyword><style face="normal" font="default" size="100%">Medizin, Novartis, Sanofi-Aventis and Sanofi-Genzyme, Med Update Europe GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">streamedup! GmbH, Pohl-Boskamp, Inmunotek S.L., John Wiley and Sons/AS,</style></keyword><keyword><style face="normal" font="default" size="100%">Paul-Martini-Stiftung (PMS), Regeneron Pharmaceuticals Inc., RG</style></keyword><keyword><style face="normal" font="default" size="100%">Aerztefortbildung, Institut fur Disease Management, Springer GmbH, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">IQVIA Commercial, Ingress Health, Wort&amp;Bild Verlag, Verlag ME, Procter&amp;Gamble,</style></keyword><keyword><style face="normal" font="default" size="100%">ALTAMIRA, Meinhardt Congress GmbH, Deutsche Forschungsgemeinschaft, Thieme,</style></keyword><keyword><style face="normal" font="default" size="100%">Deutsche AllergieLiga e.V., AeDA, Alfried-Krupp Krankenhaus, Red Maple Trials</style></keyword><keyword><style face="normal" font="default" size="100%">Inc., Koniglich Danisches Generalkonsulat, Medizinische Hochschule Hannover, ECM</style></keyword><keyword><style face="normal" font="default" size="100%">Expo&amp;Conference Management GmbH, Technical University Dresden, Lilly, Japanese</style></keyword><keyword><style face="normal" font="default" size="100%">Society of Allergy, Forum fur Medizinische Fortbildung, Dustri-Verlag,</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumolive, ASIT Biotech, LOFARMA, Almirall, Paul-Ehrlich-Institut, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and he is Vice President of the EAACI and member of EAACI Excom,</style></keyword><keyword><style face="normal" font="default" size="100%">member of ext. board of directors DGAKI</style></keyword><keyword><style face="normal" font="default" size="100%">coordinator, main- or co-author of</style></keyword><keyword><style face="normal" font="default" size="100%">different position papers and guidelines in rhinology, allergology and</style></keyword><keyword><style face="normal" font="default" size="100%">allergen-immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">he is associate editor (AE) of Allergy and Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Translational Allergy.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39495086</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic rhinitis and/or conjunctivitis (AR/C) induced by tree pollen is common and negatively impacts quality of life in children and adolescents. This phase III trial investigated the efficacy and safety of the SQ tree SLIT-tablet in a paediatric population (5-17 years) with moderate-to-severe AR/C induced by pollen from birch and trees in the birch homologous group. METHODS: Nine hundred and fifty-two subjects were randomized (1:1) to daily treatment with SQ tree SLIT-tablet or placebo for up to 52 weeks and had free access to AR/C symptom-relieving medications. The primary endpoint was the average total combined score (TCS); sum of average daily symptom score (DSS) and average daily medication score (DMS) during the birch pollen season (BPS). Key secondary endpoints included average DSS and DMS during BPS and average TCS, DSS and DMS during tree pollen season (TPS). RESULTS: SQ tree SLIT-tablet demonstrated a statistically significant and clinically relevant treatment effect compared with placebo for the TCS during BPS with an absolute treatment difference of 1.29 (95% CI: 0.58, 2.00; p = .0004) and a relative reduction of 21.9% (95% CI: 10.6, 31.9). Results were substantiated by reductions in both DSS and DMS versus placebo during the BPS and in DSS, DMS and TCS during the TPS. Treatment was generally well tolerated. Most treatment-related adverse events were mild or moderate local administration site reactions. CONCLUSION: This is the first paediatric trial to provide robust evidence of efficacy and safety of the SQ tree SLIT-tablet in tree pollen-induced AR/C in a paediatric population (5-17 years).</style></abstract><notes><style face="normal" font="default" size="100%">Gappa, Monika&#xD;Gagnon, Remi&#xD;Horak, Fritz&#xD;Cichocka-Jarosz, Ewa&#xD;Dalgaard, Terrie&#xD;Hargreaves, Kate&#xD;Mikler, Jan&#xD;Emeryk, Andrzej&#xD;Hansen, Kirsten Skamstrup&#xD;Pfaar, Oliver&#xD;eng&#xD;The study and manuscript writing were funded by ALK-Abello, Horsholm, Denmark/&#xD;Clinical Trial, Phase III&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):795-806. doi: 10.1111/all.16363. Epub 2024 Nov 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39495086</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891417</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16363</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1636</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1636</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kaur, D.</style></author><author><style face="normal" font="default" size="100%">Chachi, L.</style></author><author><style face="normal" font="default" size="100%">Gomez, E.</style></author><author><style face="normal" font="default" size="100%">Sylvius, N.</style></author><author><style face="normal" font="default" size="100%">Singh, S. R.</style></author><author><style face="normal" font="default" size="100%">Ramsheh, M. Y.</style></author><author><style face="normal" font="default" size="100%">Saunders, R.</style></author><author><style face="normal" font="default" size="100%">Brightling, C. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK.&#xD;Genomic Core Facility, Department of Genetics, University of Leicester, Leicester, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">ST2 expression and release by the bronchial epithelium is downregulated in asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3184-3194</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2020/06/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchi</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">*Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">St2</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32516479</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The airway epithelium plays an important role in wound repair, host defense and is involved in the immunopathogenesis of asthma. Genome wide association studies have described associations between ST2/Interleukin (IL)-33 genes in asthma, but its role in bronchial epithelium is unclear. METHODS: ST2 expression was examined in subjects with asthma and healthy controls in bronchial epithelium from biopsies (n = 27 versus n = 9) and brushings (n = 34 versus n = 20) by immunohistochemistry and RNA-Seq. In human primary bronchial epithelial cells ST2 mRNA and protein expression were assessed by qPCR, flow cytometry, Western blotting, and immunofluorescence. IL-33 function in epithelial cells was examined by intracellular calcium measurements, wound healing assays, and synthetic activation by gene array and ELISA. RESULTS: Bronchial epithelial ST2 protein expression was significantly decreased in biopsies in subjects with asthma compared to healthy controls (P = .039). IL1RL1 gene expression in bronchial brushes was not different between health and disease. In vitro primary bronchial epithelial cells expressed ST2 and IL-33 stimulation led to an increase in intracellular calcium, altered gene expression, but had no effect upon wound repair. Epithelial cells released sST2 spontaneously, which was reduced following stimulation with TNFalpha or poly-IC. Stimulation by TNFalpha or poly-IC did not affect the total ST2 expression by epithelial cell whereas surface ST2 decreased in response to TNFalpha, but not poly-IC. CONCLUSION: In asthma, bronchial epithelium protein expression of ST2 is decreased. Our in vitro findings suggest that this decrease might be a consequence of the pro-inflammatory environment in asthma or in response to viral infection.</style></abstract><notes><style face="normal" font="default" size="100%">Kaur, Davinder&#xD;Chachi, Latifa&#xD;Gomez, Edith&#xD;Sylvius, Nicolas&#xD;Singh, Shailendra R&#xD;Ramsheh, Mohammadali Y&#xD;Saunders, Ruth&#xD;Brightling, Christopher E&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Dec;75(12):3184-3194. doi: 10.1111/all.14436. Epub 2020 Jul 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32516479</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14436</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>913</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">913</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zimmer, J.</style></author><author><style face="normal" font="default" size="100%">Schmidt, S.</style></author><author><style face="normal" font="default" size="100%">Kaul, S.</style></author><author><style face="normal" font="default" size="100%">Costanzo, A.</style></author><author><style face="normal" font="default" size="100%">Buchheit, K. H.</style></author><author><style face="normal" font="default" size="100%">Brown, S.</style></author><author><style face="normal" font="default" size="100%">Carnes, J.</style></author><author><style face="normal" font="default" size="100%">Chapman, M.</style></author><author><style face="normal" font="default" size="100%">Chen, A.</style></author><author><style face="normal" font="default" size="100%">De Neergaard, M.</style></author><author><style face="normal" font="default" size="100%">Doring, S.</style></author><author><style face="normal" font="default" size="100%">Hindley, J. P.</style></author><author><style face="normal" font="default" size="100%">Holzhauser, T.</style></author><author><style face="normal" font="default" size="100%">Jorajuria, S.</style></author><author><style face="normal" font="default" size="100%">Le Tallec, D.</style></author><author><style face="normal" font="default" size="100%">Lombardero, M.</style></author><author><style face="normal" font="default" size="100%">Iacovacci, P.</style></author><author><style face="normal" font="default" size="100%">Reese, G.</style></author><author><style face="normal" font="default" size="100%">Sander, I.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author><author><style face="normal" font="default" size="100%">Strecker, D.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author><author><style face="normal" font="default" size="100%">Zebina, M.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Paul-Ehrlich-Institut, Langen, Germany.&#xD;European Directorate for the Quality of Medicines &amp; HealthCare (EDQM), Strasbourg, France.&#xD;Jubilant HollisterStier, Spokane, WA, USA.&#xD;R&amp;D Unit Allergy &amp; Immunology. LETI Pharma, Madrid, Spain.&#xD;Indoor Biotechnologies, Charlottesville, VA, USA.&#xD;Food and Drug Administration, Silver Spring, MD, USA.&#xD;ALK-Abello A/S, Horsholm, Denmark.&#xD;Indoor Biotechnologies Ltd, Cardiff, UK.&#xD;ALK-Abello S.A, Madrid, Spain.&#xD;ISS CNCF, Roma, Italy.&#xD;Allergopharma GmbH &amp; Co. KG, Reinbek, Germany.&#xD;Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr-Universitat Bochum, Bochum, Germany.&#xD;Departments of Experimental Immunology and of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.&#xD;Stallergenes Greer, Antony Cedex, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Standardisation of allergen products: 4. Validation of a candidate European Pharmacopoeia standard method for quantification of major grass pollen allergen Phl p 5</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">633-642</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/07/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Phleum/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Poaceae</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Standards</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Standardisation Programme</style></keyword><keyword><style face="normal" font="default" size="100%">Elisa</style></keyword><keyword><style face="normal" font="default" size="100%">Phl p 5</style></keyword><keyword><style face="normal" font="default" size="100%">Timothy grass</style></keyword><keyword><style face="normal" font="default" size="100%">major allergen</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34241919</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The aim of the BSP090 project is the establishment of European Pharmacopoeia Chemical Reference Substances (CRSs) in combination with corresponding standard ELISA methods for quantification of major allergens in allergen products. Here, we present data of a Phl p 5-specific sandwich ELISA that proved suitable for the quantification of Phl p 5, one of the major Timothy grass (Phleum pratense) pollen allergens. METHODS: A Phl p 5-specific ELISA system was assessed with respect to accuracy, precision, inter-assay (within laboratory) and inter-laboratory variations, in a ring trial including 14 laboratories in Europe and the USA. Model samples containing recombinant Phl p 5a CRS as well as native grass pollen extracts were analysed. Each participant was instructed to perform at least one preliminary assay to familiarise with the protocol, followed by three independent assays. RESULTS: The candidate standard ELISA proved suitable to quantify recombinant and native Phl p 5 with satisfactory precision (93% of results within +/-30% acceptance range). Inter-assay variation (max. GCV 24%) and especially inter-laboratory variation (max. GCV 13%) showed conclusive results. When assessing accuracy by means of recovery of recombinant spikes from a grass pollen extract matrix, similarly satisfactory spike recovery results were observed for the two spikes with higher concentrations (all within +/-30% acceptance range), whereas recovery of the lowest concentration spike was slightly poorer with mean results of six laboratories exceeding acceptance range. CONCLUSIONS: Based on the collaborative study results, the assessed Phl p 5-specific immunoassay is appropriate to be proposed as European Pharmacopoeia standard method.</style></abstract><notes><style face="normal" font="default" size="100%">Zimmer, Julia&#xD;Schmidt, Sandra&#xD;Kaul, Susanne&#xD;Costanzo, Angele&#xD;Buchheit, Karl-Heinz&#xD;Brown, Shannon&#xD;Carnes, Jeronimo&#xD;Chapman, Martin&#xD;Chen, Aaron&#xD;De Neergaard, Michalade&#xD;Doring, Sascha&#xD;Hindley, James Phillip&#xD;Holzhauser, Thomas&#xD;Jorajuria, Sylvie&#xD;Le Tallec, David&#xD;Lombardero, Manuel&#xD;Iacovacci, Patrizia&#xD;Reese, Gerald&#xD;Sander, Ingrid&#xD;Smith, Bryan&#xD;Strecker, Daniel&#xD;van Ree, Ronald&#xD;Zebina, Myriam&#xD;Vieths, Stefan&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):633-642. doi: 10.1111/all.15003. Epub 2021 Jul 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34241919</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15003</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2196</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2196</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kappen, J.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Guibas, G. V.</style></author><author><style face="normal" font="default" size="100%">Hamelmann, E.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Zieglmayer, P.</style></author><author><style face="normal" font="default" size="100%">Gerth van Wijk, R.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pulmonology, STZ Centre of Excellence for Asthma, COPD and Respiratory Allergy, Franciscus Gasthuis &amp; Vlietland, Rotterdam, The Netherlands.&#xD;Department of National Heart and Lung Institute, Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Imperial College London, London, UK.&#xD;Departmentt of Microbiology Immunology &amp; Transplantation, KU Leuven, Catholic University of Leuven, Leuven, Belgium.&#xD;Department of Respiratory Medicine &amp; Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.&#xD;Department of Clinical Pharmacy &amp; Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.&#xD;Transylvania University, Brasov, Romania.&#xD;Department of Cardiovascular and Thoracic Sciences, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;Department of Clinical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.&#xD;Charite Universitatsmedizin Berlin Campus Berlin Buch, MASK-air, Montpellier, France.&#xD;Personalized Medicine Asthma &amp; Allergy Clinic Humanitas University &amp; Research Hospital-IRCCS, Milan, Italy.&#xD;MRC &amp; Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Department of Allergy and Clinical Immunology, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.&#xD;School of Biological Sciences, Medicine and Health, University of Manchester, Manchester, UK.&#xD;Children&apos;s Center Bethel, University Hospital Bielefeld, University Bielefeld, Bielefeld, Germany.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Newport, UK.&#xD;NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Paediatric Allergy and Respiratory Medicine (MP803), Clinical &amp; Experimental Sciences &amp; Human Development in Health Academic Units University of Southampton Faculty of Medicine &amp; University Hospital Southampton, Southampton, UK.&#xD;Karl Landsteiner University, Competence Center for Allergology and Immunology, Krems, Austria.&#xD;Section of Allergology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2835-2850</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/07/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Standards</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">clinical outcomes</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">sublingual</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37449468</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: In allergic asthma patients, one of the more common phenotypes might benefit from allergen immunotherapy (AIT) as add-on intervention to pharmacological treatment. AIT is a treatment with disease-modifying modalities, the evidence for efficacy is based on controlled clinical trials following standardized endpoint measures. However, so far there is a lack of a consensus for asthma endpoints in AIT trials. The aim of a task force (TF) of the European Academy of Allergy and Clinical Immunology (EAACI) is evaluating several outcome measures for AIT in allergic asthma. METHODS: The following domains of outcome measures in asthmatic patients have been evaluated for this position paper (PP): (i) exacerbation rate, (ii) lung function, (iii) ICS withdrawal, (iv) symptoms and rescue medication use, (v) questionnaires (PROMS), (vi) bronchial/nasal provocation, (vii) allergen exposure chambers (AEC) and (viii) biomarkers. RESULTS: Exacerbation rate can be used as a reliable objective primary outcome; however, there is limited evidence due to different definitions of exacerbation. The time after ICS withdrawal to first exacerbation is considered a primary outcome measure. Besides, the advantages and disadvantages and clinical implications of further domains of asthma endpoints in AIT trials are elaborated in this PP. CONCLUSION: This EAACI-PP aims to highlight important aspects of current asthma measures by critically evaluating their applicability for controlled trials of AIT.</style></abstract><notes><style face="normal" font="default" size="100%">Kappen, Jasper&#xD;Diamant, Zuzana&#xD;Agache, Ioana&#xD;Bonini, Matteo&#xD;Bousquet, Jean&#xD;Canonica, G Walter&#xD;Durham, Stephen R&#xD;Guibas, George V&#xD;Hamelmann, Eckard&#xD;Jutel, Marek&#xD;Papadopoulos, Nikolaos G&#xD;Roberts, Graham&#xD;Shamji, Mohamed H&#xD;Zieglmayer, Petra&#xD;Gerth van Wijk, Roy&#xD;Pfaar, Oliver&#xD;eng&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2835-2850. doi: 10.1111/all.15817. Epub 2023 Jul 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37449468</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15817</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3319</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3319</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gluud, Maria</style></author><author><style face="normal" font="default" size="100%">Pallesen, Emil M.</style></author><author><style face="normal" font="default" size="100%">Zeng, Ziao</style></author><author><style face="normal" font="default" size="100%">Namini, Martin R. J.</style></author><author><style face="normal" font="default" size="100%">Vadivel, Chella Krishna</style></author><author><style face="normal" font="default" size="100%">Gjerdrum, Lise Mette Rahbek</style></author><author><style face="normal" font="default" size="100%">Yan, Lang</style></author><author><style face="normal" font="default" size="100%">Ahmad, Sana</style></author><author><style face="normal" font="default" size="100%">Lindahl, Lise M.</style></author><author><style face="normal" font="default" size="100%">Bzorek, Michael</style></author><author><style face="normal" font="default" size="100%">Kamstrup, Maria R.</style></author><author><style face="normal" font="default" size="100%">Dey, Saptaswa</style></author><author><style face="normal" font="default" size="100%">Ostrowski, Sisse Rye</style></author><author><style face="normal" font="default" size="100%">Sørensen, Erik</style></author><author><style face="normal" font="default" size="100%">Rantakari, Pia</style></author><author><style face="normal" font="default" size="100%">Bonefeld, Charlotte Menne</style></author><author><style face="normal" font="default" size="100%">Geisler, Carsten</style></author><author><style face="normal" font="default" size="100%">Woetmann, Anders</style></author><author><style face="normal" font="default" size="100%">Lahesmaa, Riitta</style></author><author><style face="normal" font="default" size="100%">Iversen, Lars</style></author><author><style face="normal" font="default" size="100%">Wolf, Peter</style></author><author><style face="normal" font="default" size="100%">Litman, Thomas</style></author><author><style face="normal" font="default" size="100%">Buus, Terkild B.</style></author><author><style face="normal" font="default" size="100%">Ødum, Niels</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Staphylococcus aureus Augments Epithelial Skin Barrier Damage Through T Cell Activation in Cutaneous T Cell Lymphoma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Skin barrier dysfunction is central to inflammation and susceptibility to infection in atopic dermatitis (AD). Cutaneous T-cell lymphoma (CTCL) shares clinical similarities with AD and is also associated with a high prevalence of Staphylococcus aureus (S. aureus) colonisation. However, the mechanisms driving skin barrier damage in CTCL and the contribution of bacteria remain poorly understood. Methods We investigate how the interplay between S. aureus (and staphylococcal enterotoxins (SEs)) and primary malignant- and non-malignant T cells affects keratinocyte expression of skin barrier proteins; in vitro, in an EL4 murine lymphoma model of bacteria-driven tumour progression, and in CTCL patient lesions colonised with SE-producing S. aureus before and after bacterial eradication by antibiotic treatment. Results S. aureus and SEs activate malignant and non-malignant T cells to release barrier-repressing cytokines, including IL-4, IL-13, IL-22, and OSM, and JAK-dependent downregulation of filaggrin and loricrin in keratinocytes. In the EL4 model, bacteria-colonised tumour-bearing mice show significant filaggrin loss in tumour-adjacent epidermis, whereas antibiotic-treated mice maintain near-normal expression. Clinically, antibiotic eradication of SE-producing S. aureus partially restores filaggrin and loricrin expression in three of four patients, paralleling reduced inflammatory signalling. Conclusions SE-producing S. aureus promotes skin barrier impairment in CTCL through cytokine-driven, JAK-dependent repression of structural proteins in keratinocytes. These findings identify microbial–immune crosstalk as a contributor to CTCL skin pathology and provide mechanistic rationale for strategies targeting S. aureus colonisation as adjunctive therapy in CTCL.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70292</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70292</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>22</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">22</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, J.</style></author><author><style face="normal" font="default" size="100%">Kim, B. E.</style></author><author><style face="normal" font="default" size="100%">Berdyshev, E.</style></author><author><style face="normal" font="default" size="100%">Bronova, I.</style></author><author><style face="normal" font="default" size="100%">Bin, L.</style></author><author><style face="normal" font="default" size="100%">Bae, J.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Kim, H. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, U. H.</style></author><author><style face="normal" font="default" size="100%">Kim, M. S.</style></author><author><style face="normal" font="default" size="100%">Kim, H.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author><author><style face="normal" font="default" size="100%">Hall, C. F.</style></author><author><style face="normal" font="default" size="100%">Hui-Beckman, J.</style></author><author><style face="normal" font="default" size="100%">Chang, Y.</style></author><author><style face="normal" font="default" size="100%">Bronoff, A. S.</style></author><author><style face="normal" font="default" size="100%">Hwang, D.</style></author><author><style face="normal" font="default" size="100%">Lee, H. Y.</style></author><author><style face="normal" font="default" size="100%">Goleva, E.</style></author><author><style face="normal" font="default" size="100%">Ahn, K.</style></author><author><style face="normal" font="default" size="100%">Leung, D. Y. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, National Jewish Health, Denver, Colorado, USA.&#xD;Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.&#xD;Department of Medicine, National Jewish Health, Denver, Colorado, USA.&#xD;R&amp;D Institute, BioEleven Co., Ltd., Seoul, Korea.&#xD;Department of Pediatrics, Medical Research Institute of Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.&#xD;Department of Dermatology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.&#xD;Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, Wonju, Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Staphylococcus aureus causes aberrant epidermal lipid composition and skin barrier dysfunction</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1292-1306</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">*Methicillin-Resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-6</style></keyword><keyword><style face="normal" font="default" size="100%">*Staphylococcal Infections</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Lipids</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">ceramides</style></keyword><keyword><style face="normal" font="default" size="100%">elongase</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier</style></keyword><keyword><style face="normal" font="default" size="100%">and Leo Pharma. EB had research contracts from LEO Pharma and SANOFI. The</style></keyword><keyword><style face="normal" font="default" size="100%">remaining authors do not have any conflicts to report.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36609802</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Staphylococcus (S) aureus colonization is known to cause skin barrier disruption in atopic dermatitis (AD) patients. However, it has not been studied how S. aureus induces aberrant epidermal lipid composition and skin barrier dysfunction. METHODS: Skin tape strips (STS) and swabs were obtained from 24 children with AD (6.0 +/- 4.4 years) and 16 healthy children (7.0 +/- 4.5 years). Lipidomic analysis of STS samples was performed by mass spectrometry. Skin levels of methicillin-sensitive and methicillin-resistant S. aureus (MSSA and MRSA) were evaluated. The effects of MSSA and MRSA were evaluated in primary human keratinocytes (HEKs) and organotypic skin cultures. RESULTS: AD and organotypic skin colonized with MRSA significantly increased the proportion of lipid species with nonhydroxy fatty acid sphingosine ceramide with palmitic acid ([N-16:0 NS-CER], sphingomyelins [16:0-18:0 SM]), and lysophosphatidylcholines [16:0-18:0 LPC], but significantly reduced the proportion of corresponding very long-chain fatty acids (VLCFAs) species (C22-28) compared to the skin without S. aureus colonization. Significantly increased transepidermal water loss (TEWL) was found in MRSA-colonized AD skin. S. aureus indirectly through interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, IL-6, and IL-33 inhibited expression of fatty acid elongase enzymes (ELOVL3 and ELOVL4) in HEKs. ELOVL inhibition was more pronounced by MRSA and resulted in TEWL increase in organotypic skin. CONCLUSION: Aberrant skin lipid profiles and barrier dysfunction are associated with S. aureus colonization in AD patients. These effects are attributed to the inhibition of ELOVLs by S. aureus-induced IL-1beta, TNF-alpha, IL-6, and IL-33 seen in keratinocyte models and are more prominent in MRSA than MSSA.</style></abstract><notes><style face="normal" font="default" size="100%">Kim, Jihyun&#xD;Kim, Byung Eui&#xD;Berdyshev, Evgeny&#xD;Bronova, Irina&#xD;Bin, Lianghua&#xD;Bae, Jaewoong&#xD;Kim, Seokjin&#xD;Kim, Hye-Young&#xD;Lee, Un Ha&#xD;Kim, Myoung Shin&#xD;Kim, Hyunmi&#xD;Lee, Jinyoung&#xD;Hall, Clifton F&#xD;Hui-Beckman, Jessica&#xD;Chang, Yunhee&#xD;Bronoff, Anna Sofia&#xD;Hwang, Dasom&#xD;Lee, Hae-Young&#xD;Goleva, Elena&#xD;Ahn, Kangmo&#xD;Leung, Donald Y M&#xD;eng&#xD;R01 AR041256/AR/NIAMS NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 May;78(5):1292-1306. doi: 10.1111/all.15640. Epub 2023 Jan 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36609802</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12727050</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15640</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1232</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1232</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Biggs, T. C.</style></author><author><style face="normal" font="default" size="100%">Abadalkareem, R. S.</style></author><author><style face="normal" font="default" size="100%">Hayes, S. M.</style></author><author><style face="normal" font="default" size="100%">Holding, R. E.</style></author><author><style face="normal" font="default" size="100%">Lau, L. C.</style></author><author><style face="normal" font="default" size="100%">Harries, P. G.</style></author><author><style face="normal" font="default" size="100%">Allan, R. N.</style></author><author><style face="normal" font="default" size="100%">Pender, S. L. F.</style></author><author><style face="normal" font="default" size="100%">Walls, A. F.</style></author><author><style face="normal" font="default" size="100%">Salib, R. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Southampton NIHR Respiratory Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Department of Otorhinolaryngology / Head &amp; Neck Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;Faculty of Environmental &amp; Life Sciences, Department of Biological Sciences, University of Southampton, Southampton, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Staphylococcus aureus internalisation enhances bacterial survival through modulation of host immune responses and mast cell activation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1893-1896</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/12/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antigen Presentation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Staphylococcal Infections</style></keyword><keyword><style face="normal" font="default" size="100%">*Staphylococcus aureus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33314209</style></accession-num><notes><style face="normal" font="default" size="100%">Biggs, Timothy C&#xD;Abadalkareem, Rana S&#xD;Hayes, Stephen M&#xD;Holding, Rebecca E&#xD;Lau, Laurie C&#xD;Harries, Philip G&#xD;Allan, Raymond N&#xD;Pender, Sylvia L F&#xD;Walls, Andrew F&#xD;Salib, Rami J&#xD;eng&#xD;G0500729/MRC_/Medical Research Council/United Kingdom&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1893-1896. doi: 10.1111/all.14701. Epub 2020 Dec 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33314209</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14701</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3277</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3277</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rozumbetov, Ramazan</style></author><author><style face="normal" font="default" size="100%">Ogulur, Ismail</style></author><author><style face="normal" font="default" size="100%">Heider, Anja</style></author><author><style face="normal" font="default" size="100%">Globinska, Anna</style></author><author><style face="normal" font="default" size="100%">Chanishvili, Nina</style></author><author><style face="normal" font="default" size="100%">Kakabadze, Elene</style></author><author><style face="normal" font="default" size="100%">Goderdzishvili, Marina</style></author><author><style face="normal" font="default" size="100%">Grdzelishvili, Nino</style></author><author><style face="normal" font="default" size="100%">Bakuradze, Nata</style></author><author><style face="normal" font="default" size="100%">Yu, Moelong</style></author><author><style face="normal" font="default" size="100%">Aripova, Tamara</style></author><author><style face="normal" font="default" size="100%">Ismailova, Adolat</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, Nikolaos</style></author><author><style face="normal" font="default" size="100%">Akdis, Mubeccel</style></author><author><style face="normal" font="default" size="100%">Akdis, Cezmi A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Staphylococcus aureus Sb-1 Bacteriophage Alters Frequency and Subset Distribution of Human Innate Lymphoid Cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70212</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70212</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2310</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2310</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ordak, M.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Paoletti, G.</style></author><author><style face="normal" font="default" size="100%">Brussino, L.</style></author><author><style face="normal" font="default" size="100%">Carvalho, D.</style></author><author><style face="normal" font="default" size="100%">Di Bona, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milan, Italy.&#xD;SCDU Immunologia e Allergologia, AO Ordine Mauriziano di Torino, Torino, Italy.&#xD;Dipartimento di Scienze Mediche, Universita degli Studi di Torino, Torino, Italy.&#xD;NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal.&#xD;Department of Medical and Surgical Sciences, School of Allergology and Clinical Immunology, University of Foggia, Foggia, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Statistical advice provided by ChatGPT regarding an accepted article in Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">748-751</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/11/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37985460</style></accession-num><notes><style face="normal" font="default" size="100%">Ordak, Michal&#xD;Canonica, Giorgio Walter&#xD;Paoletti, Giovanni&#xD;Brussino, Liusa&#xD;Carvalho, Daniela&#xD;Di Bona, Danilo&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):748-751. doi: 10.1111/all.15956. Epub 2023 Nov 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37985460</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15956</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3025</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3025</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ordak, M.</style></author><author><style face="normal" font="default" size="100%">Paoletti, G.</style></author><author><style face="normal" font="default" size="100%">Di Bona, D.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Martini, M.</style></author><author><style face="normal" font="default" size="100%">Bognanni, A.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Biomedical Sciences, Humanitas University, Milan, Italy.&#xD;Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milan, Italy.&#xD;Department of Medical and Surgical Sciences, School of Allergology and Clinical Immunology, University of Foggia, Foggia, Italy.&#xD;MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences; Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE - Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Allergy Unit, Department of Internal Medicine, University Hospital AOU Delle Marche, Ancona, Italy.&#xD;Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.&#xD;Department of Health Research Methods, Evidence, and Impact &amp; Department of Medicine, Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada.&#xD;Clinical Epidemiology and Research Center (CERC), IRCCS Humanitas Research Hospital, Milan, Italy.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Berlin, Germany.&#xD;Aria, Montpellier, France.&#xD;MASK-Air, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Statistical Analysis in Allergy and Immunology: A Review With Practical Examples</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2755-2766</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/08/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergy and Immunology/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Data Interpretation, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Biomedical Research</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunology</style></keyword><keyword><style face="normal" font="default" size="100%">statistical analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40847684</style></accession-num><abstract><style face="normal" font="default" size="100%">Statistical analysis plays a critical role in biomedical research, ensuring that data are interpreted appropriately and that conclusions are both valid and reproducible. In allergy and immunology, where studies increasingly rely on complex data structures and analytical approaches, clarity on biostatistical methods is essential to support transparency and scientific rigor. However, inconsistent statistical reporting and misuse of analytical techniques remain persistent challenges in the field. This review provides a structured and practice-oriented overview of key statistical aspects relevant to research in allergy and immunology Drawing upon recent peer-reviewed articles in these disciplines, we highlight best practices in the transparent reporting of statistical methods, verification of underlying assumptions, and interpretation of statistical significance in the context of clinical relevance. Each section is illustrated with practical examples to demonstrate sound analytical reasoning and to guide researchers, reviewers, and educators in improving statistical standards across the field.</style></abstract><notes><style face="normal" font="default" size="100%">Ordak, Michal&#xD;Paoletti, Giovanni&#xD;Di Bona, Danilo&#xD;Sousa-Pinto, Bernardo&#xD;Martini, Matteo&#xD;Bognanni, Antonio&#xD;Bousquet, Jean&#xD;Canonica, Giorgio Walter&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2755-2766. doi: 10.1111/all.70013. Epub 2025 Aug 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40847684</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70013</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>616</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">616</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barker-Tejeda, T. C.</style></author><author><style face="normal" font="default" size="100%">Zubeldia-Varela, E.</style></author><author><style face="normal" font="default" size="100%">Obeso, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centro de Metabolomica y Bioanalisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanizacion Monteprincipe, Madrid, Espana.&#xD;Instituto de Medicina Molecular Aplicada (IMMA), Departamento de Ciencias Medicas Basicas. Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Espana.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A step closer to understanding the relationship between host and gut microbiota metabolism</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1638-1640</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">genomics</style></keyword><keyword><style face="normal" font="default" size="100%">gut microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">metabolonomy</style></keyword><keyword><style face="normal" font="default" size="100%">phylogeny</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35122270</style></accession-num><notes><style face="normal" font="default" size="100%">Barker-Tejeda, Tomas C&#xD;Zubeldia-Varela, Elisa&#xD;Obeso, David&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1638-1640. doi: 10.1111/all.15246. Epub 2022 Feb 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35122270</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15246</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1897</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1897</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barker-Tejeda, T. C.</style></author><author><style face="normal" font="default" size="100%">Zubeldia-Varela, E.</style></author><author><style face="normal" font="default" size="100%">Obeso, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centro de Metabolomica y Bioanalisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanizacion Monteprincipe, Madrid, Espana.&#xD;Instituto de Medicina Molecular Aplicada (IMMA), Departamento de Ciencias Medicas Basicas. Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Espana.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A step closer to understanding the relationship between host and gut microbiota metabolism</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1638-1640</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/02/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">genomics</style></keyword><keyword><style face="normal" font="default" size="100%">gut microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">metabolonomy</style></keyword><keyword><style face="normal" font="default" size="100%">phylogeny</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35122270</style></accession-num><notes><style face="normal" font="default" size="100%">Barker-Tejeda, Tomas C&#xD;Zubeldia-Varela, Elisa&#xD;Obeso, David&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1638-1640. doi: 10.1111/all.15246. Epub 2022 Feb 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35122270</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15246</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2111</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2111</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nocerino, R.</style></author><author><style face="normal" font="default" size="100%">Coppola, S.</style></author><author><style face="normal" font="default" size="100%">Carucci, L.</style></author><author><style face="normal" font="default" size="100%">de Giovanni di Santa Severina, A. F.</style></author><author><style face="normal" font="default" size="100%">Oglio, F.</style></author><author><style face="normal" font="default" size="100%">de Michele, R.</style></author><author><style face="normal" font="default" size="100%">di Sessa, I.</style></author><author><style face="normal" font="default" size="100%">Masino, A.</style></author><author><style face="normal" font="default" size="100%">Bedogni, G.</style></author><author><style face="normal" font="default" size="100%">Berni Canani, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Translational Medical Science, University of Naples Federico II, Naples, Italy.&#xD;ImmunoNutritionLab at CEINGE Advanced Biotechnologies, University of Naples Federico II, Naples, Italy.&#xD;Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.&#xD;Department of Primary Health Care, Internal Medicine Unit addressed to Frailty and Aging, S. Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy.&#xD;European Laboratory for the Investigation of Food-Induced Diseases, University of Naples Federico II, Naples, Italy.&#xD;Task Force on Microbiome Studies, University of Naples Federico II, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The step-down approach in children with cow&apos;s milk allergy: Results of a randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2477-2486</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">*Milk Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Caseins</style></keyword><keyword><style face="normal" font="default" size="100%">*Lacticaseibacillus rhamnosus</style></keyword><keyword><style face="normal" font="default" size="100%">Milk Proteins/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">diet therapy</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">hypoallergenic formula</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">probiotics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37087638</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The Step-Down Approach for Cow&apos;s Milk Allergy (SDACMA) trial evaluated the tolerability and the rate of immune tolerance acquisition in CMA children starting dietary treatment with amino acid-based formula (AAF) and then switching to EHCF containing the probiotic Lacticaseibacillus rhamnosus GG (EHCF + LGG). METHODS: Randomized controlled trial involving IgE-mediated CMA children receiving AAF from at least 4 weeks. EHCF + LGG tolerance was evaluated by the results of double-blind placebo-controlled food challenge (DBPCFC). Subjects tolerating EHCF + LGG were randomly allocated to remain on AAF, or to switch to EHCF + LGG. Immune tolerance acquisition to cow&apos;s milk proteins was evaluated with DBPCFC after 12 months of treatment. Allergy screening tests and body growth were also monitored. RESULTS: Sixty IgE-mediated CMA children were enrolled. The proportion of children treated with AAF who resulted tolerant to the first exposure of EHCF + LGG was 0.98 (exact 95% CI 0.91-0.99). The rate of the immune tolerance acquisition to cow milk proteins after 12 months treatment was higher in the EHCF + LGG (0.48, 95% exact CI 0.29-0.67, n/N = 14/29) than in the AAF group (0.03, 95% exact CI 0.001-0.17, n/N = 1/30). There was an absolute benefit increase (ABI) of tolerance rate equal to 0.45 (95% CI 0.23-0.63, Newcombe method 10) for EHCF + LGG versus AAF, corresponding to a NNT of 2 (2-4, Bender&apos;s method). A normal body growth pattern was observed in the two study groups. CONCLUSION: In IgE-mediated CMA children the step-down from AAF to EHCF + LGG is well tolerated and could facilitate the immune tolerance acquisition.</style></abstract><notes><style face="normal" font="default" size="100%">Nocerino, Rita&#xD;Coppola, Serena&#xD;Carucci, Laura&#xD;de Giovanni di Santa Severina, Anna Fiorenza&#xD;Oglio, Franca&#xD;de Michele, Roberta&#xD;di Sessa, Ilaria&#xD;Masino, Antonio&#xD;Bedogni, Giorgio&#xD;Berni Canani, Roberto&#xD;eng&#xD;Randomized Controlled Trial&#xD;Randomized Controlled Trial, Veterinary&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2477-2486. doi: 10.1111/all.15750. Epub 2023 May 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37087638</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15750</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2132</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2132</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Falduto, G. H.</style></author><author><style face="normal" font="default" size="100%">Schwartz, D. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stepping off the beaten path: A multiomic atlas uncovers novel trajectories of T-cell exhaustion</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2802-2804</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/05/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Cell Exhaustion</style></keyword><keyword><style face="normal" font="default" size="100%">*Multiomics</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">bioinformatics</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37191851</style></accession-num><notes><style face="normal" font="default" size="100%">Falduto, Guido H&#xD;Schwartz, Daniella M&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2802-2804. doi: 10.1111/all.15770. Epub 2023 May 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37191851</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15770</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>264</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">264</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Goretzki, A.</style></author><author><style face="normal" font="default" size="100%">Lin, Y. J.</style></author><author><style face="normal" font="default" size="100%">Meier, C.</style></author><author><style face="normal" font="default" size="100%">Dorn, B.</style></author><author><style face="normal" font="default" size="100%">Wolfheimer, S.</style></author><author><style face="normal" font="default" size="100%">Jamin, A.</style></author><author><style face="normal" font="default" size="100%">Schott, M.</style></author><author><style face="normal" font="default" size="100%">Wangorsch, A.</style></author><author><style face="normal" font="default" size="100%">Vieths, S.</style></author><author><style face="normal" font="default" size="100%">Jakob, T.</style></author><author><style face="normal" font="default" size="100%">Scheurer, S.</style></author><author><style face="normal" font="default" size="100%">Schulke, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular Allergology, Paul-Ehrlich-Institut, Langen, Germany.&#xD;Department of Dermatology and Allergology, University Medical Center, Justus Liebig University, Giessen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stimulation of naive B cells with a fusion protein consisting of FlaA and Bet v 1 induces regulatory B cells ex vivo</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">663-681</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2022/10/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-10</style></keyword><keyword><style face="normal" font="default" size="100%">*B-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Myeloid Differentiation Factor 88/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Flagellin/chemistry/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">TOR Serine-Threonine Kinases</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin M</style></keyword><keyword><style face="normal" font="default" size="100%">Ait</style></keyword><keyword><style face="normal" font="default" size="100%">MyD88</style></keyword><keyword><style face="normal" font="default" size="100%">flagellin</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory B cell</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36196479</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The experimental fusion protein rFlaA:Betv1 was shown to efficiently suppress allergen-specific sensitization in mice. However, the detailed mechanism of rFlaA:Betv1-mediated immune modulation is not fully understood. In this study, we investigated the effect of rFlaA:Betv1 on naive murine B cells. METHODS: Immune modulating capacity of rFlaA:Betv1 was screened in IL-10 reporter mice. B cells were isolated from spleens of naive C57Bl/6, TLR5(-/-) , or MyD88(-/-) mice, stimulated with rFlaA:Betv1 and controls, and monitored for the expression of the regulatory B cell markers CD1d, CD24, CD38, and surface IgM by flow cytometry. Secreted cytokines, antibodies, and reactivity of the induced antibodies were investigated by ELISA and intracellular flow cytometry. Suppressive capacity of rFlaA:Betv1-stimulated B cells was tested in mDC:CD4(+) T cell:B cell triple cultures. RESULTS: Upon in vivo application of rFlaA:Betv1 into IL-10-GFP reporter mice, CD19(+) B cells were shown to produce anti-inflammatory IL-10, suggesting B cells to contribute to the immune-modulatory properties of rFlaA:Betv1. rFlaA:Betv1-induced IL-10 secretion was confirmed in human B cells isolated from buffy coats. In vitro stimulation of naive murine B cells with rFlaA:Betv1 resulted in an mTOR- and MyD88-dependent production of IL-10 and rFlaA:Betv1 induced Bet v 1-reactive IgG production, which was not observed for IgA. rFlaA:Betv1-stimulated B cells formed a CD19(+) CD24(+) CD1d(+) IgM(+) CD38(+) Breg subpopulation capable of suppressing Bet v 1-induced TH2 cytokine secretion in vitro. CONCLUSION: rFlaA:Betv1 can act as a thymus-independent B cell antigen, stimulating the mTOR- and MyD88-dependent differentiation of B cells displaying a regulatory phenotype, IL-10 secretion, antigen-binding antibody production, and a suppressive capacity in vitro.</style></abstract><notes><style face="normal" font="default" size="100%">Goretzki, Alexandra&#xD;Lin, Yen-Ju&#xD;Meier, Clara&#xD;Dorn, Britta&#xD;Wolfheimer, Sonja&#xD;Jamin, Annette&#xD;Schott, Maike&#xD;Wangorsch, Andrea&#xD;Vieths, Stefan&#xD;Jakob, Thilo&#xD;Scheurer, Stephan&#xD;Schulke, Stefan&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Mar;78(3):663-681. doi: 10.1111/all.15542. Epub 2022 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36196479</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15542</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2540</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2540</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nikolouli, E.</style></author><author><style face="normal" font="default" size="100%">Mommert, S.</style></author><author><style face="normal" font="default" size="100%">Dawodu, D. M.</style></author><author><style face="normal" font="default" size="100%">Schaper-Gerhardt, K.</style></author><author><style face="normal" font="default" size="100%">Stark, H.</style></author><author><style face="normal" font="default" size="100%">Dittrich-Breiholz, O.</style></author><author><style face="normal" font="default" size="100%">Gutzmer, R.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum Campus Minden, Minden, Germany.&#xD;Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Dusseldorf, Dusseldorf, Germany.&#xD;Research Core Unit Genomics, Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The stimulation of TH2 cells results in increased IL-5 and IL-13 production via the H(4) receptor</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2186-2196</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/06/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-13/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-5/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Histamine H4/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocyte Activation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">H4 receptor</style></keyword><keyword><style face="normal" font="default" size="100%">Il-13</style></keyword><keyword><style face="normal" font="default" size="100%">Il-5</style></keyword><keyword><style face="normal" font="default" size="100%">TH2-lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">histamine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38853666</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease resulting in decreased quality of life. Histamine and specifically the H(4) receptor play a key role in the inflammatory process in AD and serve as targets for novel therapeutic approaches. OBJECTIVE: In the present study we aimed to elucidate the immunopathological mechanisms with which the H(4) receptor impacts TH2 cells and contributes to AD pathophysiology. METHODS: Total CD4(+) T cells obtained from healthy or AD individuals and in vitro differentiated TH2 cells were cultured under different conditions and the mRNA expression or protein production of target molecules were determined using quantitative real-time PCR and ELISA. RESULTS: H(4) receptor mRNA expression was upregulated concentration dependent upon IL-4 stimulation in in vitro differentiated TH2 cells progressively during the differentiation. Transcriptomic analysis of in vitro differentiated TH2 versus TH1 cells revealed that the H(4) receptor among other genes represents one of the highly upregulated genes in TH2 cells. Most importantly, increased amounts of IL-5 and IL-13 mRNA expression were detected in in vitro differentiated TH2 cells as well as protein secretion in the presence of histamine or of the H(4) receptor-selective-agonist when compared to the untreated control. CONCLUSION: We show for the first time an H(4) receptor dependent upregulation of the pro-inflammatory cytokines IL-5 and IL-13 in human TH2 cells by histamine. This suggests that the blockade of the H(4) receptor may lead to downregulation of these cytokines and amelioration of AD symptoms as reported in first clinical studies.</style></abstract><notes><style face="normal" font="default" size="100%">Nikolouli, Eirini&#xD;Mommert, Susanne&#xD;Dawodu, Damilola Modupe&#xD;Schaper-Gerhardt, Katrin&#xD;Stark, Holger&#xD;Dittrich-Breiholz, Oliver&#xD;Gutzmer, Ralf&#xD;Werfel, Thomas&#xD;eng&#xD;Novartis Pharma AG/&#xD;Deutsche Forschungsgemeinschaft/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2186-2196. doi: 10.1111/all.16182. Epub 2024 Jun 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38853666</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16182</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3137</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3137</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vega Castro, A.</style></author><author><style face="normal" font="default" size="100%">Breynaert, C.</style></author><author><style face="normal" font="default" size="100%">Alfaya, T.</style></author><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Fassio, F.</style></author><author><style face="normal" font="default" size="100%">Karabacak, D. E.</style></author><author><style face="normal" font="default" size="100%">Martini, M.</style></author><author><style face="normal" font="default" size="100%">Sahiner, U. M.</style></author><author><style face="normal" font="default" size="100%">Ruiz-Leon, B.</style></author><author><style face="normal" font="default" size="100%">Spriggs, K.</style></author><author><style face="normal" font="default" size="100%">Sturm, G.</style></author><author><style face="normal" font="default" size="100%">Boni, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, University Hospital of Guadalajara, Guadalajara, Spain.&#xD;IDISCAM (Instituto de Investigacion de Castilla la Mancha), Toledo, Spain.&#xD;KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, Leuven, Belgium.&#xD;Department of General Internal Medicine, Division of Allergy and Clinical Immunology, UZ Leuven, Leuven, Belgium.&#xD;Allergy Unit, Hospital Universitario Fundacion Alcorcon, Madrid, Spain.&#xD;Department of Clinical and Molecular Science (DISCLIMO), Marche Politechnic University, Ancona, Italy.&#xD;Allergy Unit, Department of Internal Medicine, AOU Delle Marche, Ancona, Italy.&#xD;Allergy Clinic, Pisa, Italy.&#xD;Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.&#xD;Hacettepe University School of Medicine, Ankara, Turkey.&#xD;Allergy Department, Reina Sofia University Hospital, Cordoba, Spain.&#xD;Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.&#xD;Department of Allergy and Immunology, Monash Health, Clayton, Victoria, Australia.&#xD;Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Department of Allergy and Immunology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.&#xD;Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.&#xD;Clinical Immunology Unit, Maggiore Hospital, Bologna, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Sting Challenge Test: An EAACI Position Paper on Hymenoptera Venom Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3251-3259</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Hymenoptera/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthropod Venoms/immunology/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Insect Bites and Stings/immunology/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Anaphylaxis/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunologic Tests/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Hymenoptera</style></keyword><keyword><style face="normal" font="default" size="100%">Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">sting challenge test</style></keyword><keyword><style face="normal" font="default" size="100%">venom immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41074684</style></accession-num><abstract><style face="normal" font="default" size="100%">A Sting Challenge Test (SCT) is the only reliable method to verify the effectiveness of venom immunotherapy (VIT) in patients allergic to Hymenoptera venom, a leading cause of anaphylaxis in adults. This European Academy of Allergy and Clinical Immunology (EAACI) position paper provides an in-depth analysis of the SCT&apos;s key applications, risks, and outcomes in clinical practice, focusing on its role in monitoring VIT efficacy, improving patient quality of life, and ensuring appropriate therapeutic interventions. The SCT is primarily used to assess VIT protection, adjust VIT dosage, and confirm patient safety but is not recommended for routine diagnosis due to the risk of provoking systemic allergic reactions. This position paper also offers practical considerations for performing the SCT, including insect handling, patient preparation, and risk management. While SCT is a valuable tool in personalized allergy treatment, it requires careful handling of live insects and patient preparation to ensure safety. This position paper reviews the literature and presents the expert experience of the Insect Venom Hypersensitivity Working Group of the European Academy of Allergy and Clinical Immunology.</style></abstract><notes><style face="normal" font="default" size="100%">Vega Castro, Arantza&#xD;Breynaert, Christine&#xD;Alfaya, Teresa&#xD;Bilo, Maria Beatrice&#xD;Fassio, Filippo&#xD;Karabacak, Deniz Eyice&#xD;Martini, Matteo&#xD;Sahiner, Umit Murat&#xD;Ruiz-Leon, Berta&#xD;Spriggs, Kymble&#xD;Sturm, Gunter&#xD;Boni, Elisa&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Consensus Development Conference&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3251-3259. doi: 10.1111/all.70096. Epub 2025 Oct 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41074684</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70096</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2669</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2669</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Messaoud-Nacer, Y.</style></author><author><style face="normal" font="default" size="100%">Culerier, E.</style></author><author><style face="normal" font="default" size="100%">Rose, S.</style></author><author><style face="normal" font="default" size="100%">Maillet, I.</style></author><author><style face="normal" font="default" size="100%">Boussad, R.</style></author><author><style face="normal" font="default" size="100%">Veront, C.</style></author><author><style face="normal" font="default" size="100%">Savigny, F.</style></author><author><style face="normal" font="default" size="100%">Malissen, B.</style></author><author><style face="normal" font="default" size="100%">Radzikowska, U.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">da Silva, G. V. L.</style></author><author><style face="normal" font="default" size="100%">Edwards, M. R.</style></author><author><style face="normal" font="default" size="100%">Jackson, D. J.</style></author><author><style face="normal" font="default" size="100%">Johnston, S. L.</style></author><author><style face="normal" font="default" size="100%">Ryffel, B.</style></author><author><style face="normal" font="default" size="100%">Quesniaux, V. F.</style></author><author><style face="normal" font="default" size="100%">Togbe, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Experimental and Molecular Immunology and Neurogenetics, INEM UMR7355 University of Orleans and CNRS, Orleans, France.&#xD;Centre d&apos;Immunophenomique (CIPHE), Aix Marseille Universite, INSERM, CNRS, Marseille, France.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Herman- Burchard-Strasse 1, Davos, Switzerland.&#xD;Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil.&#xD;National Heart and Lung Institute, Imperial College Londont, London, UK.&#xD;Asthma UK Centre in Allergic Mechanism of Asthma, London, UK.&#xD;Imperial College Healthcare NHS Trust, London, UK.&#xD;Guy&apos;s Severe Asthma Centre, Guy&apos;s &amp; St Thomas&apos; NHS Trust, London, UK.&#xD;School of Immunology &amp; Microbial Sciences, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">STING-dependent induction of neutrophilic asthma exacerbation in response to house dust mite</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">715-737</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/10/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/immunology/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroglyphidae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Neutrophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Membrane Proteins/metabolism/genetics/agonists</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">DNA sensing</style></keyword><keyword><style face="normal" font="default" size="100%">asthma exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">cGAMP</style></keyword><keyword><style face="normal" font="default" size="100%">cell death</style></keyword><keyword><style face="normal" font="default" size="100%">diABZI</style></keyword><keyword><style face="normal" font="default" size="100%">with inserts</style></keyword><keyword><style face="normal" font="default" size="100%">310030_189334/1), Novartis Foundation for Medical-Biological Research, GSK, and</style></keyword><keyword><style face="normal" font="default" size="100%">Stiftung vorm. Buendner Heilstaette Arosa</style></keyword><keyword><style face="normal" font="default" size="100%">speaker&apos;s fee from AstraZeneca</style></keyword><keyword><style face="normal" font="default" size="100%">voluntary positions in the European Academy of Allergy and Clinical Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">(EAACI) as Executive Board member and Basic and Clinical Immunology Section</style></keyword><keyword><style face="normal" font="default" size="100%">Chair. S.L.J. reports grants/contracts from European Research Council ERC FP7</style></keyword><keyword><style face="normal" font="default" size="100%">grant number 233015, Chair from Asthma UK CH11SJ, Medical Research Council Centre</style></keyword><keyword><style face="normal" font="default" size="100%">grant number G1000758, NIHR Biomedical Research Centre grant number P26095,</style></keyword><keyword><style face="normal" font="default" size="100%">Predicta FP7 Collaborative Project grant number 260895, NIHR Emeritus NIHR Senior</style></keyword><keyword><style face="normal" font="default" size="100%">Investigator</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Lallemand Pharma, Bioforce, resTORbio, Gerson</style></keyword><keyword><style face="normal" font="default" size="100%">Lehrman Group, Boehringer Ingelheim, Novartis, Bayer, Myelo Therapeutics GmbH</style></keyword><keyword><style face="normal" font="default" size="100%">patents issued/licensed: Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus</style></keyword><keyword><style face="normal" font="default" size="100%">therapy for respiratory diseases. UK patent application No. GB 0405634.7, 12March</style></keyword><keyword><style face="normal" font="default" size="100%">2004. Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-Beta for Anti-Virus</style></keyword><keyword><style face="normal" font="default" size="100%">Therapy for Respiratory Diseases. International Patent Application No.</style></keyword><keyword><style face="normal" font="default" size="100%">PCT/GB05/50031, 12 March 2004. Davies DE, Wark PA, Holgate ST, Johnston SL.</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon Lambda therapy for the treatment of respiratory disease. UK patent</style></keyword><keyword><style face="normal" font="default" size="100%">application No. 6779645.9, granted15th August 2012</style></keyword><keyword><style face="normal" font="default" size="100%">Participation on a data</style></keyword><keyword><style face="normal" font="default" size="100%">safety monitory board or advisory board: Enanta Chair of DSMB, Virtus Respiratory</style></keyword><keyword><style face="normal" font="default" size="100%">Research Ltd. Shareholder and Board membership. All other authors declare no</style></keyword><keyword><style face="normal" font="default" size="100%">competing interests.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39466641</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Severe refractory, neutrophilic asthma remains an unsolved clinical problem. STING agonists induce a neutrophilic response in the airways, suggesting that STING activation may contribute to the triggering of neutrophilic exacerbations. We aim to determine whether STING-induced neutrophilic lung inflammation mimics severe asthma. METHODS: We developed new models of neutrophilic lung inflammation induced by house dust mite (HDM) plus STING agonists diamidobenzimidazole (diABZI) or cGAMP in wild-type, and conditional-STING-deficient mice. We measured DNA damage, cell death, NETs, cGAS/STING pathway activation by immunoblots, N1/N2 balance by flow cytometry, lung function by plethysmography, and Th1/Th2 cytokines by multiplex. We evaluated diABZI effects on human airway epithelial cells from healthy or patients with asthma, and validated the results by transcriptomic analyses of rhinovirus infected healthy controls vs patients with asthma. RESULTS: DiABZI administration during HDM challenge increased airway hyperresponsiveness, neutrophil recruitment with prominent NOS2(+)ARG1(-) type 1 neutrophils, protein extravasation, cell death by PANoptosis, NETs formation, extracellular dsDNA release, DNA sensors activation, IFNgamma, IL-6 and CXCL10 release. Functionally, STING agonists exacerbated airway hyperresponsiveness. DiABZI caused DNA and epithelial barrier damage, STING pathway activation in human airway epithelial cells exposed to HDM, in line with DNA-sensing and PANoptosis pathways upregulation and tight-junction downregulation induced by rhinovirus challenge in patients with asthma. CONCLUSIONS: Our study identifies that triggering STING in the context of asthma induces cell death by PANoptosis, fueling the flame of inflammation through a mixed Th1/Th2 immune response recapitulating the features of severe asthma with a prognostic signature of type 1 neutrophils.</style></abstract><notes><style face="normal" font="default" size="100%">Messaoud-Nacer, Yasmine&#xD;Culerier, Elodie&#xD;Rose, Stephanie&#xD;Maillet, Isabelle&#xD;Boussad, Rania&#xD;Veront, Chloe&#xD;Savigny, Florence&#xD;Malissen, Bernard&#xD;Radzikowska, Urszula&#xD;Sokolowska, Milena&#xD;da Silva, Gabriel V L&#xD;Edwards, Michael R&#xD;Jackson, David J&#xD;Johnston, Sebastian L&#xD;Ryffel, Bernhard&#xD;Quesniaux, Valerie F&#xD;Togbe, Dieudonnee&#xD;eng&#xD;Fondation pour la Recherche Medicale/&#xD;Conseil Regional du Centre-Val de Loire/&#xD;N degrees 2024-00012066Exposome&amp;Inflammation/European Regional Development Fund in Region Centre Val de Loire/&#xD;ANR-10-INSB-07 and CIPHE/&#xD;SNSF grant nr 310030_189334/1/&#xD;investissement d&apos;avenir programme PHENOMIN/&#xD;Chair from Asthma UK/&#xD;NIHR Biomedical Research Centre at Imperial College London/&#xD;National Institute for Health and Care Research/&#xD;ERC_/European Research Council/International&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):715-737. doi: 10.1111/all.16369. Epub 2024 Oct 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39466641</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11891437</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16369</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2491</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2491</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tsuji, M.</style></author><author><style face="normal" font="default" size="100%">Kondo, M.</style></author><author><style face="normal" font="default" size="100%">Nishiyama, A.</style></author><author><style face="normal" font="default" size="100%">Tamura, T.</style></author><author><style face="normal" font="default" size="100%">Nakamura-Ishizu, A.</style></author><author><style face="normal" font="default" size="100%">Koizumi, M.</style></author><author><style face="normal" font="default" size="100%">Honda, H.</style></author><author><style face="normal" font="default" size="100%">Tagaya, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, Tokyo Women&apos;s Medical University, Tokyo, Japan.&#xD;Department of Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.&#xD;Department of Microscopic and Developmental Anatomy, Tokyo Women&apos;s Medical University, Tokyo, Japan.&#xD;Field of Human Disease Models, Major in Advanced Life Sciences and Medicine, Institute of Laboratory Animals, Tokyo Women&apos;s Medical University, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">STING/RANTES pathway in airway epithelium enhances Der p1-induced airway inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2008-2011</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">*Membrane Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Mucosa/metabolism/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Dermatophagoides/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthropod Proteins/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cysteine Endopeptidases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38837714</style></accession-num><notes><style face="normal" font="default" size="100%">Tsuji, Mayoko&#xD;Kondo, Mitsuko&#xD;Nishiyama, Akira&#xD;Tamura, Tomohiko&#xD;Nakamura-Ishizu, Ayako&#xD;Koizumi, Miho&#xD;Honda, Hiroaki&#xD;Tagaya, Etsuko&#xD;eng&#xD;JP20K17198/Japan Society for the promotion of science KAKENHI/&#xD;JP22K08244/Japan Society for the promotion of science KAKENHI/&#xD;JPMXP0622717006/Ministry of Education, Culture, Sports, Science and Technology Promotion of Distinctive Joint Research Center Program/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):2008-2011. doi: 10.1111/all.16173. Epub 2024 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38837714</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16173</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2546</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2546</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tsuji, M.</style></author><author><style face="normal" font="default" size="100%">Kondo, M.</style></author><author><style face="normal" font="default" size="100%">Nishiyama, A.</style></author><author><style face="normal" font="default" size="100%">Tamura, T.</style></author><author><style face="normal" font="default" size="100%">Nakamura-Ishizu, A.</style></author><author><style face="normal" font="default" size="100%">Koizumi, M.</style></author><author><style face="normal" font="default" size="100%">Honda, H.</style></author><author><style face="normal" font="default" size="100%">Tagaya, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, Tokyo Women&apos;s Medical University, Tokyo, Japan.&#xD;Department of Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.&#xD;Department of Microscopic and Developmental Anatomy, Tokyo Women&apos;s Medical University, Tokyo, Japan.&#xD;Field of Human Disease Models, Major in Advanced Life Sciences and Medicine, Institute of Laboratory Animals, Tokyo Women&apos;s Medical University, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">STING/RANTES pathway in airway epithelium enhances Der p1-induced airway inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2008-2011</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">*Membrane Proteins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Mucosa/metabolism/immunology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Dermatophagoides/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthropod Proteins/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Cysteine Endopeptidases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38837714</style></accession-num><notes><style face="normal" font="default" size="100%">Tsuji, Mayoko&#xD;Kondo, Mitsuko&#xD;Nishiyama, Akira&#xD;Tamura, Tomohiko&#xD;Nakamura-Ishizu, Ayako&#xD;Koizumi, Miho&#xD;Honda, Hiroaki&#xD;Tagaya, Etsuko&#xD;eng&#xD;JP20K17198/Japan Society for the promotion of science KAKENHI/&#xD;JP22K08244/Japan Society for the promotion of science KAKENHI/&#xD;JPMXP0622717006/Ministry of Education, Culture, Sports, Science and Technology Promotion of Distinctive Joint Research Center Program/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):2008-2011. doi: 10.1111/all.16173. Epub 2024 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38837714</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16173</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2097</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2097</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tomei, L.</style></author><author><style face="normal" font="default" size="100%">Cespedes, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Allergy Research Group, IBIMA Plataforma BIONAND, Malaga, Spain.&#xD;Department of Medicine, University of Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stk4, a key regulator in regulatory T cells homeostasis activity?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2329-2330</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2023/04/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocytes, Regulatory/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphorylation</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">*Forkhead Transcription Factors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Foxp3</style></keyword><keyword><style face="normal" font="default" size="100%">Stk4</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37017139</style></accession-num><notes><style face="normal" font="default" size="100%">Tomei, Leonardo&#xD;Cespedes, Jose Antonio&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Aug;78(8):2329-2330. doi: 10.1111/all.15735. Epub 2023 Apr 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37017139</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15735</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3165</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3165</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arzt-Gradwohl, L.</style></author><author><style face="normal" font="default" size="100%">Schadelbauer, E.</style></author><author><style face="normal" font="default" size="100%">Cerpes, U.</style></author><author><style face="normal" font="default" size="100%">Pregartner, G.</style></author><author><style face="normal" font="default" size="100%">Herzog, S. A.</style></author><author><style face="normal" font="default" size="100%">Jungwirth, E.</style></author><author><style face="normal" font="default" size="100%">Laipold, K.</style></author><author><style face="normal" font="default" size="100%">Binder, B.</style></author><author><style face="normal" font="default" size="100%">Sturm, G. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.&#xD;Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Straightforward Algorithm for Diagnosing Hymenoptera Venom Allergy and Identifying the Relevant Venom for Immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="default" size="100%">intradermal test</style></keyword><keyword><style face="normal" font="default" size="100%">specific IgE</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 12</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41229167</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Routine allergy diagnostic assessment relies on the patient&apos;s medical history, skin testing, and the detection of specific IgE (sIgE) in the serum. In addition, molecular allergy diagnostics and the basophil activation test (BAT) can be used; however, these additional tests are costly and sometimes time-consuming. Therefore, our objective was to identify the test with the highest sensitivity, determine the most effective combination of tests to enhance sensitivity, and develop a simple IgE ratio to distinguish between bee and vespid venom allergy in cases of double positivity. METHODS: We retrospectively analyzed data from 190 bee venom-allergic and 809 vespid venom-allergic patients, along with 61 non-allergic subjects. Sensitivity and specificity were assessed for sIgE (ImmunoCAP), the intradermal test (IDT), and the BAT. RESULTS: Applying a lower cut-off of 0.1 kU/L in patients with total IgE &lt; 30 kU/L (while keeping the standard cut-off of 0.35 kU/L otherwise) increased sensitivity for sIgE to bee venom from 85.7% to 94.6% and for vespid venom from 92.2% to 97.0%. The highest sensitivity (100%) was achieved by combining this sIgE dual cut-off approach with the intradermal test for bee venom allergy, while sensitivity for vespid venom allergy reached 98.5%. A vespid/bee ratio &gt;/= 2.68 indicated vespid venom allergy with 59.3% sensitivity, while a bee/vespid ratio &gt;/= 5.33 identified bee venom allergy with 50.6% sensitivity, both with 100% specificity. CONCLUSIONS: Conventional tests, such as sIgE determination or intradermal testing, are usually sufficient. Combining both increases sensitivity, while additional tests provide no further benefit. Double-positive findings may often be clarified using a simple sIgE ratio, though sensitivity remains limited.</style></abstract><notes><style face="normal" font="default" size="100%">Arzt-Gradwohl, Lisa&#xD;Schadelbauer, Eva&#xD;Cerpes, Urban&#xD;Pregartner, Gudrun&#xD;Herzog, Sereina Annik&#xD;Jungwirth, Elisabeth&#xD;Laipold, Karin&#xD;Binder, Barbara&#xD;Sturm, Gunter J&#xD;eng&#xD;Austrian Science Fund/&#xD;Denmark&#xD;Allergy. 2025 Nov 12. doi: 10.1111/all.70154.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41229167</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70154</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2880</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2880</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ardicli, O.</style></author><author><style face="normal" font="default" size="100%">Lopez, J. F.</style></author><author><style face="normal" font="default" size="100%">Starrenburg, M. E.</style></author><author><style face="normal" font="default" size="100%">Buergi, L.</style></author><author><style face="normal" font="default" size="100%">Carli, T. K.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Division of Food Processing, Milk and Dairy Products Technology Program, Karacabey Vocational School, Bursa Uludag University, Bursa, Turkey.&#xD;Department of Dermatology, Center of Pediatric Dermatology, Erasmus University Medical Center-Sophia Children&apos;s Hospital, Rotterdam, the Netherlands.&#xD;Department of Microbiology, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Strategies for Flow Cytometric Profiling of BCR IgH Isotypes: A Comparative Assessment of FcR Blocking Agents</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2898-2901</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">b cells</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">European Union (EU CURE, EU Syn-Air-G), Novartis Research Institutes (Basel,</style></keyword><keyword><style face="normal" font="default" size="100%">Switzerland), Stanford University (Redwood City, Calif), Seed Health (Boston,</style></keyword><keyword><style face="normal" font="default" size="100%">USA) and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">is the Co-Chair for EAACI Guidelines on</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Science in Allergic diseases and Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">is on the Advisory Boards</style></keyword><keyword><style face="normal" font="default" size="100%">of Sanofi/Regeneron (Bern, Switzerland, New York, USA), Stanford University Sean</style></keyword><keyword><style face="normal" font="default" size="100%">Parker Asthma Allergy Center (CA, USA), Novartis (Basel, Switzerland), Glaxo</style></keyword><keyword><style face="normal" font="default" size="100%">Smith Kline (Zurich, Switzerland), Bristol-Myers Squibb (New York, USA), Seed</style></keyword><keyword><style face="normal" font="default" size="100%">Health (Boston, USA), and SciBase (Stockholm, Sweden)</style></keyword><keyword><style face="normal" font="default" size="100%">and is the Editor-in-Chief</style></keyword><keyword><style face="normal" font="default" size="100%">of Allergy. M.A. has received research grants from the Swiss National Science</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, Bern</style></keyword><keyword><style face="normal" font="default" size="100%">research grant from Stanford University</style></keyword><keyword><style face="normal" font="default" size="100%">Leading House for the</style></keyword><keyword><style face="normal" font="default" size="100%">Latin American Region, Seed Money Grant. She is the Scientific Advisory Board</style></keyword><keyword><style face="normal" font="default" size="100%">member of Stanford University Sean Parker Asthma Allergy Center, CA</style></keyword><keyword><style face="normal" font="default" size="100%">Advisory</style></keyword><keyword><style face="normal" font="default" size="100%">Board member of LEO Foundation Skin Immunology Research Center, Copenhagen</style></keyword><keyword><style face="normal" font="default" size="100%">and</style></keyword><keyword><style face="normal" font="default" size="100%">Scientific Co-Chair of World Allergy Congress (WAC) Istanbul, 2022, Scientific</style></keyword><keyword><style face="normal" font="default" size="100%">Programme Committee Chair, EAACI. The other authors declare no conflicts of</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40501435</style></accession-num><notes><style face="normal" font="default" size="100%">Ardicli, Ozge&#xD;Lopez, Juan Felipe&#xD;Starrenburg, Margot E&#xD;Buergi, Laura&#xD;Carli, Tayfun K&#xD;Akdis, Cezmi A&#xD;Akdis, Mubeccel&#xD;van de Veen, Willem&#xD;eng&#xD;1515/M/ProMedica/&#xD;Novartis/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2898-2901. doi: 10.1111/all.16624. Epub 2025 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40501435</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486338</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16624</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2800</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2800</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maehara, E.</style></author><author><style face="normal" font="default" size="100%">Kido-Nakahara, M.</style></author><author><style face="normal" font="default" size="100%">Fujita, Y.</style></author><author><style face="normal" font="default" size="100%">Kato, K.</style></author><author><style face="normal" font="default" size="100%">Kido, S.</style></author><author><style face="normal" font="default" size="100%">Yamasaki, R.</style></author><author><style face="normal" font="default" size="100%">Nagata, S.</style></author><author><style face="normal" font="default" size="100%">Kishimoto, J.</style></author><author><style face="normal" font="default" size="100%">Watanabe, H.</style></author><author><style face="normal" font="default" size="100%">Harada, E.</style></author><author><style face="normal" font="default" size="100%">Nagashima, Y.</style></author><author><style face="normal" font="default" size="100%">Umeno, E.</style></author><author><style face="normal" font="default" size="100%">Tsuji, G.</style></author><author><style face="normal" font="default" size="100%">Esaki, H.</style></author><author><style face="normal" font="default" size="100%">Nakahara, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.&#xD;Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.&#xD;Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.&#xD;Clinical Education Center, Kyushu University Hospital, Fukuoka, Japan.&#xD;Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.&#xD;Department of Nursing, Kyushu University Hospital, Fukuoka, Japan.&#xD;Medical Corporation Umeno Pediatric and Internal Medicine Clinic, Fukuoka, Japan.&#xD;Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, Fukuoka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stratum Corneum Interleukin-2 in Facial Eczema at 1-Month-Old Predicts Later Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2401-2404</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2025/01/15</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39812143</style></accession-num><notes><style face="normal" font="default" size="100%">Maehara, Eriko&#xD;Kido-Nakahara, Makiko&#xD;Fujita, Yasuyuki&#xD;Kato, Kiyoko&#xD;Kido, Saki&#xD;Yamasaki, Ryo&#xD;Nagata, Satoshi&#xD;Kishimoto, Junji&#xD;Watanabe, Hiroko&#xD;Harada, Eri&#xD;Nagashima, Yumiko&#xD;Umeno, Eisuke&#xD;Tsuji, Gaku&#xD;Esaki, Hitokazu&#xD;Nakahara, Takeshi&#xD;eng&#xD;JP22K08383/JSPS KAKENHI/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Aug;80(8):2401-2404. doi: 10.1111/all.16474. Epub 2025 Jan 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39812143</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12368750</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16474</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3003</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3003</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boussand, M.</style></author><author><style face="normal" font="default" size="100%">Castaing-Lasvignottes, M. E.</style></author><author><style face="normal" font="default" size="100%">Leopold, K.</style></author><author><style face="normal" font="default" size="100%">Bourgoin, P.</style></author><author><style face="normal" font="default" size="100%">Busnel, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Global Research Organization, Beckman Coulter Life Sciences, Marseille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Streamlined Miniaturized and Multi-Allergen Basophil Activation Test Platform Amenable to Population-Based Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3458-3460</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/09/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">population-based study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40910560</style></accession-num><notes><style face="normal" font="default" size="100%">Boussand, Maud&#xD;Castaing-Lasvignottes, Marie-Elise&#xD;Leopold, Kevin&#xD;Bourgoin, Penelope&#xD;Busnel, Jean-Marc&#xD;eng&#xD;Food Allergy Research and Education/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3458-3460. doi: 10.1111/all.70040. Epub 2025 Sep 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40910560</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70040</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3094</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3094</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boussand, M.</style></author><author><style face="normal" font="default" size="100%">Castaing-Lasvignottes, M. E.</style></author><author><style face="normal" font="default" size="100%">Leopold, K.</style></author><author><style face="normal" font="default" size="100%">Bourgoin, P.</style></author><author><style face="normal" font="default" size="100%">Busnel, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Global Research Organization, Beckman Coulter Life Sciences, Marseille, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Streamlined Miniaturized and Multi-Allergen Basophil Activation Test Platform Amenable to Population-Based Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3458-3460</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/09/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">population-based study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40910560</style></accession-num><notes><style face="normal" font="default" size="100%">Boussand, Maud&#xD;Castaing-Lasvignottes, Marie-Elise&#xD;Leopold, Kevin&#xD;Bourgoin, Penelope&#xD;Busnel, Jean-Marc&#xD;eng&#xD;Food Allergy Research and Education/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3458-3460. doi: 10.1111/all.70040. Epub 2025 Sep 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40910560</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70040</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1308</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1308</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Z. Z.</style></author><author><style face="normal" font="default" size="100%">Song, J.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Li, J. X.</style></author><author><style face="normal" font="default" size="100%">Xiao, Q.</style></author><author><style face="normal" font="default" size="100%">Yu, Z.</style></author><author><style face="normal" font="default" size="100%">Wang, Z. C.</style></author><author><style face="normal" font="default" size="100%">Liu, J. X.</style></author><author><style face="normal" font="default" size="100%">Pan, L.</style></author><author><style face="normal" font="default" size="100%">Yao, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, C. L.</style></author><author><style face="normal" font="default" size="100%">Lu, X.</style></author><author><style face="normal" font="default" size="100%">Liu, C.</style></author><author><style face="normal" font="default" size="100%">Gao, P.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Pathogen Biology, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan, China.&#xD;Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stromal cells and B cells orchestrate ectopic lymphoid tissue formation in nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1416-1431</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">B-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelial Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">Stromal Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Tertiary Lymphoid Structures</style></keyword><keyword><style face="normal" font="default" size="100%">B cell</style></keyword><keyword><style face="normal" font="default" size="100%">chemokine (C-X-C motif) ligand 13</style></keyword><keyword><style face="normal" font="default" size="100%">ectopic lymphoid tissue</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 17A</style></keyword><keyword><style face="normal" font="default" size="100%">lymphotoxin</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">stromal cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33022771</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Although the importance of ectopic lymphoid tissues (eLTs) in the pathophysiology of nasal polyps (NPs) is increasingly appreciated, the mechanisms underlying their formation remain unclear. OBJECTIVE: To study the role of interleukin (IL)-17A, C-X-C motif chemokine ligand 13 (CXCL13) and lymphotoxin (LT) in eLT formation in NPs. METHODS: The expression levels of CXCL13 and LT and their receptors, in addition to the phenotypes of stromal cells in NPs, were studied by flow cytometry, immunostaining, and real-time reverse transcription-polymerase chain reaction (RT-PCR). Purified nasal stromal cells and B cells were cultured, and a murine model of nasal type 17 inflammation was established by intranasal curdlan challenge for the mechanistic study. RESULTS: The excessive CXCL13 production in NPs correlated with enhanced IL-17A expression. Stromal cells, with CD31(-) Pdpn(+) fibroblastic reticular cell (FRC) expansion, were the major source of CXCL13 in NPs without eLTs. IL-17A induced FRC expansion and CXCL13 production in nasal stromal cells. In contrast, B cells were the main source of CXCL13 and LTalpha(1) beta(2) in NPs with eLTs. CXCL13 upregulated LTalpha(1) beta(2) expression on B cells, which in turn promoted CXCL13 production in nasal B cells and stromal cells. LTalpha(1) beta(2) induced expansion of FRCs and CD31(+) Pdpn(+) lymphoid endothelial cells, which were the predominant stromal cell types in NPs with eLTs. IL-17A knockout and CXCL13 and LTbetaR blockage diminished nasal eLT formation in the murine model. CONCLUSION: We identified an important role of IL-17A-induced stromal cell remodeling in the initiation and crosstalk between B and stromal cells via CXCL13 and LTalpha(1) beta(2) in the enlargement of eLTs in NPs.</style></abstract><notes><style face="normal" font="default" size="100%">Wang, Zhe-Zheng&#xD;Song, Jia&#xD;Wang, Hai&#xD;Li, Jing-Xian&#xD;Xiao, Qiao&#xD;Yu, Ze&#xD;Wang, Zhi-Chao&#xD;Liu, Jin-Xin&#xD;Pan, Li&#xD;Yao, Yin&#xD;Chen, Cai-Ling&#xD;Lu, Xiang&#xD;Liu, Chaohong&#xD;Gao, Peisong&#xD;Liu, Zheng&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1416-1431. doi: 10.1111/all.14612. Epub 2020 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33022771</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14612</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>245</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">245</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alvarado, D.</style></author><author><style face="normal" font="default" size="100%">Lu, Y.</style></author><author><style face="normal" font="default" size="100%">Shoda, T.</style></author><author><style face="normal" font="default" size="100%">Caldwell, J. M.</style></author><author><style face="normal" font="default" size="100%">Keler, T.</style></author><author><style face="normal" font="default" size="100%">Rothenberg, M. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Celldex Therapeutics, Hampton, New Jersey, USA.&#xD;Division of Allergy and Immunology, University of Cincinnati College of Medicine and Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Strong association of mast cells with eosinophilic esophagitis-specific signatures</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">583-586</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Enteritis</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastritis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36278970</style></accession-num><notes><style face="normal" font="default" size="100%">Alvarado, Diego&#xD;Lu, Yufang&#xD;Shoda, Tetsuo&#xD;Caldwell, Julie M&#xD;Keler, Tibor&#xD;Rothenberg, Marc E&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):583-586. doi: 10.1111/all.15562. Epub 2022 Nov 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36278970</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10098655 M.E.R. is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, Nextstone One, Bristol Myers Squibb, Astra Zeneca, Ellodi Pharma, GlaxoSmith Kline, Regeneron/Sanofi, Revolo Biotherapeutics, and Guidepoint and has an equity interest in the first seven listed, and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust) and UpToDate. M.E.R. is an inventor of patents owned by Cincinnati Children&apos;s Hospital.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15562</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>730</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">730</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Munera, M.</style></author><author><style face="normal" font="default" size="100%">Martinez, D.</style></author><author><style face="normal" font="default" size="100%">Wortmann, J.</style></author><author><style face="normal" font="default" size="100%">Zakzuk, J.</style></author><author><style face="normal" font="default" size="100%">Keller, W.</style></author><author><style face="normal" font="default" size="100%">Caraballo, L.</style></author><author><style face="normal" font="default" size="100%">Puerta, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Immunological Research, University of Cartagena, Cartagena, Colombia.&#xD;Institute of Molecular Biosciences, BioTechMed Graz, University of Graz, Graz, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Structural and allergenic properties of the fatty acid binding protein from shrimp Litopenaeus vannamei</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1534-1544</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/10/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Chromatography, Liquid</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acid-Binding Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Penaeidae</style></keyword><keyword><style face="normal" font="default" size="100%">Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">Allergen and epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">basophils</style></keyword><keyword><style face="normal" font="default" size="100%">bioinformatics</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34695231</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The shrimp Litopenaeus vannamei is an important source of food allergens but its allergenic repertoire is poorly characterized. Cross-reactivity between crustacean and mites has been reported, with tropomyosin, the most relevant allergen involved. The aim of this study was to investigate the structural and immunological properties of a recombinant Fatty Acid Binding Protein (FABP) family from L. vannamei (LvFABP). METHODS: ELISA, skin prick test (SPT) and basophil activation assays were performed to determine IgE reactivity and allergenic activity of LvFABP. LC-MS/MS and Circular Dichroism experiments were done for structural analysis. B-cell epitope mapping with overlapping peptides, and cross-inhibition studies using human sera were done to identify antigenic regions and cross-reactivity. RESULTS: The recombinant LvFABP bound serum IgE from 27% of 36 shrimp allergic patients and showed allergenic activity when tested for basophil activation and SPT in a selected number of them. CD-spectroscopy of LvFABP revealed that the protein is folded with a secondary structure composed of mainly beta-strands and a smaller fraction of alpha helices. This is consistent with molecular modelling results, which exhibit a typical beta barrel fold with two alpha-helices and ten beta-strands. Epitope mapping identified two IgE-binding antigenic regions and inhibition assays found high cross-reactivity between LvFABP and Blo t 13, mediated by the antigenic region involving amino acids 54 to 72. CONCLUSIONS: Our results show that LvFABP is a shrimp allergen that cross reacts with the house dust mite allergen Blo t 13 and has allergenic activity, which suggest that it could be clinically relevant in case of shellfish allergy. This new allergen, named Lit v 13, will also help to understand basic mechanisms of sensitization to shrimp.</style></abstract><notes><style face="normal" font="default" size="100%">Munera, Marlon&#xD;Martinez, Dalgys&#xD;Wortmann, Judith&#xD;Zakzuk, Josefina&#xD;Keller, Walter&#xD;Caraballo, Luis&#xD;Puerta, Leonardo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1534-1544. doi: 10.1111/all.15154. Epub 2021 Oct 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34695231</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15154</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>427</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">427</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Plum, M.</style></author><author><style face="normal" font="default" size="100%">Tjerrild, L.</style></author><author><style face="normal" font="default" size="100%">Raiber, T.</style></author><author><style face="normal" font="default" size="100%">Bantleon, F.</style></author><author><style face="normal" font="default" size="100%">Bantleon, S.</style></author><author><style face="normal" font="default" size="100%">Miehe, M.</style></author><author><style face="normal" font="default" size="100%">Jabs, F.</style></author><author><style face="normal" font="default" size="100%">Seismann, H.</style></author><author><style face="normal" font="default" size="100%">Mobs, C.</style></author><author><style face="normal" font="default" size="100%">Pfutzner, W.</style></author><author><style face="normal" font="default" size="100%">Jakob, T.</style></author><author><style face="normal" font="default" size="100%">Andersen, G. R.</style></author><author><style face="normal" font="default" size="100%">Spillner, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunological Biotechnology, Department of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.&#xD;Division of Clinical and Molecular Allergology, Research Center Borstel, Leibniz Lung Center, German Center for Lung Research (DZL), Borstel, Germany.&#xD;Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.&#xD;Institute of Biochemistry and Molecular Biology, Department of Chemistry, University of Hamburg, Hamburg, Germany.&#xD;Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.&#xD;Clinical &amp; Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany.&#xD;Department of Dermatology and Allergy, University Medical Center Giessen, Justus Liebig University, Giessen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Structural and functional analyses of antibodies specific for modified core N-glycans suggest a role in T(H) 2 responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">121-130</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/06/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Polysaccharides</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Carbohydrates</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Epitopes</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">IgE and IgG</style></keyword><keyword><style face="normal" font="default" size="100%">N-glycan</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">glycotopes</style></keyword><keyword><style face="normal" font="default" size="100%">recognition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35726192</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Immune responses to N-glycan structures from allergens and parasites are often associated with pronounced, high affinity IgE reactivities. Cross-reactive carbohydrate determinants (CCDs) are constituted by modified N-glycan core structures and represent the most frequently recognized epitopes in allergic immune responses. Although recently accepted as potentially allergenic epitopes, the biological and clinical relevance as well as structural and functional characteristics of CCD-specific antibodies remain elusive. METHODS: In order to gain structural insights into the recognition of CCDs, two specific antibody fragments were isolated from a leporid immune repertoire library and converted into human/leporid IgE and IgG formats. The antibody formats were assessed by ELISA and surface plasmon resonance, structural and functional analyses were performed by X-ray crystallography, mediator release, and ELIFAB assays. RESULTS: The recombinant IgE exhibited highly specific interactions with different types of CCDs on numerous CCD-carrying glycoproteins. Crystal structures of two CCD-specific antibodies, one of which in complex with a CCD-derived disaccharide emphasize that mechanisms of core glycan epitope recognition are as specific as those governing protein epitope recognition. The rIgE triggered immediate cellular responses via FcepsilonRI cross-linking and mediated facilitated antigen presentation by binding of IgE/antigen complexes to CD23, a process that also could be blocked by IgG of allergic patients. CONCLUSIONS: Our study provides evidence for the relevance of N-glycan recognition in T(H) 2 responses and corroborates that IgE and IgG antibodies to ubiquitous carbohydrate epitopes can be equivalent to those directed against proteinaceous epitopes with implications for diagnostic and immunotherapeutic concepts.</style></abstract><notes><style face="normal" font="default" size="100%">Plum, Melanie&#xD;Tjerrild, Luna&#xD;Raiber, Tim&#xD;Bantleon, Frank&#xD;Bantleon, Sara&#xD;Miehe, Michaela&#xD;Jabs, Frederic&#xD;Seismann, Henning&#xD;Mobs, Christian&#xD;Pfutzner, Wolfgang&#xD;Jakob, Thilo&#xD;Andersen, Gregers R&#xD;Spillner, Edzard&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):121-130. doi: 10.1111/all.15417. Epub 2022 Jul 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35726192</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10083920</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15417</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3257</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3257</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parkkinen, Tarja</style></author><author><style face="normal" font="default" size="100%">Heiniluoto, Heidi</style></author><author><style face="normal" font="default" size="100%">Jänis, Janne</style></author><author><style face="normal" font="default" size="100%">Takkinen, Kristiina</style></author><author><style face="normal" font="default" size="100%">Rouvinen, Juha</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Structural Basis for Trivalent Cross-Linking of a Patient-Derived IgE Antibody by the Major Peanut Allergen Ara h 2.0201</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Peanut allergy is a serious form of food allergy that can lead to anaphylactic reactions. Research has shown that the Ara h 2 allergen is immunodominant and associated with fatal systemic reactions. Methods We determined the crystal structure of recombinant Ara h 2.0201 in a complex with the human-derived PA12P3D08 (D08) IgE Fab fragment at 3.2 Å resolution. In addition, native mass spectrometry was used to study interactions of D08 with Ara h 2 and its peptides. Results The structure revealed that D08 Fab binds to a long loop of Ara h 2.0201, which contains three repeated DPYSPS motifs. The immunocomplex structure illustrated how three copies of D08 Fabs can bind simultaneously to Ara h 2.0201 in close proximity. Native mass spectrometry studies of D08 Fab with Ara h 2.0201 and peptides containing 2–3 motifs demonstrated cross-linking of Ara h 2.0201 in solution and the propensity of D08 Fab to self-associate. Motif peptides from Ara h 2.0201 highlighted the importance of proline hydroxylation for binding affinity. D08 Fab also bound to hydroxyproline-containing peptides from Ara h 1 and 3. Conclusions The trivalent binding is effective in forming large allergen-IgE complexes on mast cell or basophil surfaces and contributes to the potency of Ara h 2 in triggering allergic reactions and highlighting its role in anaphylaxis. Proline hydroxylation considerably enhances D08 binding affinity and contributes to cross-reactivity among Ara h 1–3 allergens.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70258</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70258</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3283</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3283</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">O&apos;Malley, Andrea</style></author><author><style face="normal" font="default" size="100%">Borders, Brooke T.</style></author><author><style face="normal" font="default" size="100%">Wilson, Jeffrey M.</style></author><author><style face="normal" font="default" size="100%">Smith, Scott A.</style></author><author><style face="normal" font="default" size="100%">Chruszcz, Maksymilian</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Structural Determination of a Human IgE Epitope on Major Birch Allergen Bet v 1</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70240</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70240</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2597</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2597</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ziadlou, R.</style></author><author><style face="normal" font="default" size="100%">Pandian, G. N.</style></author><author><style face="normal" font="default" size="100%">Hafner, J.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Stingl, G.</style></author><author><style face="normal" font="default" size="100%">Maverakis, E.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, University of Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Christine Kuhne Center for Allergy Research and Education CK-CARE, Davos, Switzerland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland.&#xD;Institute for Integrated Cell-Material Science (WPI-iCeMS), Kyoto University, Kyoto, Japan.&#xD;Department of Dermatology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Dermatology, University of California, Davis, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Subcutaneous adipose tissue: Implications in dermatological diseases and beyond</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3310-3325</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/08/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin Diseases/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Subcutaneous Fat/immunology/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/immunology/pathology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">interleukins</style></keyword><keyword><style face="normal" font="default" size="100%">macrophages</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39206504</style></accession-num><abstract><style face="normal" font="default" size="100%">Subcutaneous adipose tissue (SAT) is the deepest component of the three-layered cutaneous integument. While mesenteric adipose tissue-based immune processes have gained recognition in the context of the metabolic syndrome, SAT has been traditionally considered primarily for energy storage, with less attention to its immune functions. SAT harbors a reservoir of immune and stromal cells that significantly impact metabolic and immunologic processes not only in the skin, but even on a systemic level. These processes include wound healing, cutaneous and systemic infections, immunometabolic, and autoimmune diseases, inflammatory skin diseases, as well as neoplastic conditions. A better understanding of SAT immune functions in different processes, could open avenues for novel therapeutic interventions. Targeting SAT may not only address SAT-specific diseases but also offer potential treatments for cutaneous or even systemic conditions. This review aims to provide a comprehensive overview on SAT&apos;s structure and functions, highlight recent advancements in understanding its role in both homeostatic and pathological conditions within and beyond the skin, and discuss the main questions for future research in the field.</style></abstract><notes><style face="normal" font="default" size="100%">Ziadlou, Reihane&#xD;Pandian, Ganesh N&#xD;Hafner, Jurg&#xD;Akdis, Cezmi A&#xD;Stingl, Georg&#xD;Maverakis, Emanual&#xD;Bruggen, Marie-Charlotte&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3310-3325. doi: 10.1111/all.16295. Epub 2024 Aug 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39206504</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657049</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16295</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3076</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3076</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bachert, C.</style></author><author><style face="normal" font="default" size="100%">Hoogeveen, H.</style></author><author><style face="normal" font="default" size="100%">Ten Have, R.</style></author><author><style face="normal" font="default" size="100%">Yu, D.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Distler, A.</style></author><author><style face="normal" font="default" size="100%">Bozek, A.</style></author><author><style face="normal" font="default" size="100%">Opstelten, D. J.</style></author><author><style face="normal" font="default" size="100%">Narkus, A.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ENT-Dep, University of Muenster, Muenster, Germany.&#xD;HAL Allergy B.V., Leiden, the Netherlands.&#xD;Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Department of Clinical Immunology, Faculty of Medicine of Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.&#xD;HAL Allergy GmbH, Dusseldorf, Germany.&#xD;Clinical Department of Internal Diseases, Dermatology and Allergology in Zabrze, Medical University of Silesia, Katowice, Poland.&#xD;OLSC B.V., Oegstgeest, the Netherlands.&#xD;Fa. MC Narkus GmbH Medical Consulting &amp; Services, Bleckede, Germany.&#xD;Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3391-3400</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/09/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroglyphidae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Subcutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Dermatophagoides/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy (AIT)</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">combined symptom and medication score (CSMS)</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mites (HDM)</style></keyword><keyword><style face="normal" font="default" size="100%">pivotal phase III trial</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">subcutaneous immunotherapy (SCIT)</style></keyword><keyword><style face="normal" font="default" size="100%">D.Y., A.D. are employees of HAL. Allergy Holding B.V/HAL Allergie GmbH. M.W.</style></keyword><keyword><style face="normal" font="default" size="100%">reports honoraria and/or consulting fees from AbbVie, Aimmune Therapeutics,</style></keyword><keyword><style face="normal" font="default" size="100%">ALK-Abello, Allergopharma, Almirall, Amgen, Biotest, Boehringer Ingelheim, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Genzyme, Kymab, LEO Pharma, Eli Lilly, Mylan, Novartis, Pfizer,</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron Pharmaceuticals Inc., Sanofi, Stallergenes Greer, Worg Pharmaceutics</style></keyword><keyword><style face="normal" font="default" size="100%">Orcid ID: 0000-0002-3449-1245. Oliver Pfaar reports grants and/or personal fees</style></keyword><keyword><style face="normal" font="default" size="100%">and/or travel support from AEDA, Alfried Krupp Krankenhaus, ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">Allergopharma, Almirall, Altamira Therapeutics, ASIT Biotech, AstraZeneca,</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard Allergie GmbH/Allergy Therapeutics, Deutsche AllergieLiga e.V., Deutsche</style></keyword><keyword><style face="normal" font="default" size="100%">Forschungsgemeinschaft, Dustri-Verlag, ECM Expro&amp;Conference Management GmBH,</style></keyword><keyword><style face="normal" font="default" size="100%">Forum fur Medizinische Fortbildung, GSK, HAL Allergy Holding B.V./HAL Allergie</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, Immunotek, Ingress Health, Institut fur Disease Management (Essen,</style></keyword><keyword><style face="normal" font="default" size="100%">Germany), IQVIA Commercial, Japanese Society of Allergology, Koniglich Danisches</style></keyword><keyword><style face="normal" font="default" size="100%">Generalkonsulat, Laboratorios LETI/LETI Pharma, Lilly, Lofarma, Medizinische</style></keyword><keyword><style face="normal" font="default" size="100%">Hochschule Hannover, med update europe GmbH, Meinhardt Congress GmbH, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Paul-Ehrlich-Institut, Paul-Martini-Stiftung, PneumoLive, Pohl-Boskamp, Procter &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">Gamble, Red Maple Trials Inc., Regeneron Pharmaceuticals, RG Aerztefortbildung,</style></keyword><keyword><style face="normal" font="default" size="100%">ROXALL Medizin, Sanofi Aventis, Sanofi Genzyme, Springer GmbH, Stallergenes</style></keyword><keyword><style face="normal" font="default" size="100%">Greer, streamedup! GmbH, Technical University Dresden, Thieme Medical Publishers,</style></keyword><keyword><style face="normal" font="default" size="100%">Wiley Publishers, Wort &amp; Bild Verlag, Verlag ME</style></keyword><keyword><style face="normal" font="default" size="100%">outside the submitted work,</style></keyword><keyword><style face="normal" font="default" size="100%">Oliver Pfaar is Vice President of the European Academy of Allergy and Clinical</style></keyword><keyword><style face="normal" font="default" size="100%">Immunology (EAACI), a member of EAACI Excom as well as a member of the external</style></keyword><keyword><style face="normal" font="default" size="100%">board of directors of the German Society of Allergy and Clinical Immunology</style></keyword><keyword><style face="normal" font="default" size="100%">(DGAKI)</style></keyword><keyword><style face="normal" font="default" size="100%">coordinator, main or co-author of different position papers and</style></keyword><keyword><style face="normal" font="default" size="100%">guidelines in rhinology, allergology, and allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">and he is</style></keyword><keyword><style face="normal" font="default" size="100%">Editor-in-Chief of Clinical Translational Allergy and Associate Editor of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy. M.J. reports grants and personal fees from Allergopharma, ALK-Abello,</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes, Anergis, Allergy Therapeutics, Eli Lilly, Inmunotek, Leti, HAL,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, Novartis, Teva, Takeda, Chiesi, Pfizer, Regeneron, Sanofi, AstraZeneka,</style></keyword><keyword><style face="normal" font="default" size="100%">Lallemand, Shire, Celltrion Inc., Genentech, Roche, Upstream Bio, Verona, Lek</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Arcutis Biotherapeutics, FAES FARMA, outside of submitted work</style></keyword><keyword><style face="normal" font="default" size="100%">and he is deputy editor in chief of Allergy. A.B. reports grants and research</style></keyword><keyword><style face="normal" font="default" size="100%">support from Stallergenes greer, AstraZeneca, HAL Allergy, GSK, Novartis, ALK</style></keyword><keyword><style face="normal" font="default" size="100%">Abello, and lectures for or advisory board fees from Merck, Stallergenes Greer,</style></keyword><keyword><style face="normal" font="default" size="100%">HAL Allergy, Dieter, Allergopharma, AstraZeneca, Polpharma. A.N.: No conflict of</style></keyword><keyword><style face="normal" font="default" size="100%">interest. D.-J.O. was an employee of HAL Allergy B.V. at the time of the study</style></keyword><keyword><style face="normal" font="default" size="100%">conducted. D.-J.O. reports consultancy fees from HAL Allergy B.V. and from</style></keyword><keyword><style face="normal" font="default" size="100%">Desentum Oy. R.R. reports consultancies for HAL Allergy BV, Citeq BV, Angany</style></keyword><keyword><style face="normal" font="default" size="100%">Inc., AB Enzymes GmbH, The Protein Brewery, Mission MightyMe, Reacta Healthcare</style></keyword><keyword><style face="normal" font="default" size="100%">Ltd.</style></keyword><keyword><style face="normal" font="default" size="100%">speaker fees from HAL Allergy BV, Thermo Fisher Scientific, ALK</style></keyword><keyword><style face="normal" font="default" size="100%">stock</style></keyword><keyword><style face="normal" font="default" size="100%">options from Angany Inc.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40965045</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Subcutaneous allergen immunotherapy (SCIT) has a longstanding history as a safe and effective treatment. Nevertheless, to meet the European Medicines Agency&apos;s regulatory requirements for continued market authorization, its efficacy and safety must be confirmed in a pivotal Phase III trial. OBJECTIVE: Based on a successful Phase II dose-finding study, the aim was to confirm the safety and efficacy of a subcutaneous house dust mites (HDM) preparation in a randomized controlled trial using an optimal higher dose than the current maintenance dose. METHOD: Seven hundred sixty-seven subjects were randomized in a 1:1 ratio to 1-year treatment with SCIT-product at a dose of 50,000 AUeq/mL or placebo. Out of these, 682 subjects completed the study. The primary endpoint was assessed using the combined symptom and medication score (CSMS(n)), which focuses on nasal symptoms, as specified by the European Academy of Allergy and Clinical Immunology (EAACI). RESULTS: The primary endpoint showed a trend (p = 0.0767) with a mean treatment effect of -0.12 (95% CI, -0.3 to 0) toward a favorable change in mean CSMS(n) for active compared to placebo treatment. This treatment effect of 0.12 points did however not meet the prespecified minimal clinically relevant difference of 0.25 points. Among the 767 randomized patients, 539 had mild symptoms and 228 patients had moderate to severe HDM allergic symptoms, defined by a mean baseline daily symptom score (dSS(n)) of at least 2. Post hoc analysis of the clinical data, focusing on this subgroup of patients with moderate to severe symptoms, revealed a significant treatment effect for the primary endpoint, with a clinically meaningful reduction of -0.39 points (95% CI, -0.64 to -0.13; p = 0.0031) thereby surpassing the minimal prespecified difference of 0.25 points. No additional safety concerns were observed in the moderate to severe symptom group compared with the minor symptom group. CONCLUSION: Treatment with the tested SCIT-product at a dose of 50,000 AUeq/mL was safe and well tolerated. The primary outcome was not met, with no significant difference observed between the active and placebo groups. A likely explanation might be the inclusion of mainly patients with mild symptoms of rhino conjunctivitis (539 of in total 767 randomized subjects). Post hoc analysis, however, indicated that SCIT was effective in the subgroup of patients with moderate to severe disease, suggesting that the overall study outcome may have been influenced by the inclusion of a large proportion of patients with only mild symptoms of HDM-induced rhino-conjunctivitis. As a consequence, reconfirming efficacy requires adequate baseline symptom severity, especially in HDM allergic patients.</style></abstract><notes><style face="normal" font="default" size="100%">Bachert, Claus&#xD;Hoogeveen, Hans&#xD;Ten Have, Rimko&#xD;Yu, Donghui&#xD;Worm, Margitta&#xD;Pfaar, Oliver&#xD;Jutel, Marek&#xD;Distler, Andreas&#xD;Bozek, Andrzej&#xD;Opstelten, Dirk-Jan&#xD;Narkus, Annemie&#xD;van Ree, Ronald&#xD;eng&#xD;HAL Allergy/&#xD;Clinical Trial, Phase III&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3391-3400. doi: 10.1111/all.70063. Epub 2025 Sep 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40965045</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666762</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70063</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2904</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2904</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aglas, L.</style></author><author><style face="normal" font="default" size="100%">Tannert, L. K.</style></author><author><style face="normal" font="default" size="100%">Versteeg, S. A.</style></author><author><style face="normal" font="default" size="100%">Smith, S. A.</style></author><author><style face="normal" font="default" size="100%">Bartko, E. A.</style></author><author><style face="normal" font="default" size="100%">Wenger, M.</style></author><author><style face="normal" font="default" size="100%">Kraiem, A.</style></author><author><style face="normal" font="default" size="100%">Widauer, H.</style></author><author><style face="normal" font="default" size="100%">Nunes, N.</style></author><author><style face="normal" font="default" size="100%">Sinkunaite, S.</style></author><author><style face="normal" font="default" size="100%">Stolz, F.</style></author><author><style face="normal" font="default" size="100%">Jongejan, L.</style></author><author><style face="normal" font="default" size="100%">Neubauer, A.</style></author><author><style face="normal" font="default" size="100%">Blom, L. H.</style></author><author><style face="normal" font="default" size="100%">Ferreira, F.</style></author><author><style face="normal" font="default" size="100%">Poulsen, L. K.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">van Ree, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Biosciences and Medical Biology, University of Salzburg, Austria.&#xD;Odense Research Center for Anaphylaxis, Odense University Hospital, Odense, Denmark.&#xD;Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.&#xD;Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Department of Dermatology and Allergy, Allergy Clinic, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.&#xD;Vienna Competence Center, Biomay AG, Vienna, Austria.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Dermatology and Allergy Center, Odense University Hospital, Odense, Denmark.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Subcutaneous Allergen Immunotherapy With Hypoallergenic Bet v 1 Compared to Conventional Extract: Poorer Blocking Antibody Capacity Dominated by IgG(1) Instead of IgG(4)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2018-2030</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/06/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin G/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, Plant/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/immunology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Blocking/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Plant Extracts/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Betula/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Subcutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Ait</style></keyword><keyword><style face="normal" font="default" size="100%">Bet v 1</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4</style></keyword><keyword><style face="normal" font="default" size="100%">birch</style></keyword><keyword><style face="normal" font="default" size="100%">hypoallergen</style></keyword><keyword><style face="normal" font="default" size="100%">that the research was conducted in the absence of any commercial or financial</style></keyword><keyword><style face="normal" font="default" size="100%">relationships that could be construed as potential conflicts of interest. Ronald</style></keyword><keyword><style face="normal" font="default" size="100%">van Ree received consulting fees and/or speaker fees from Angany Inc., HAL</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy BV, Citeq BV, ThermoFisher Scientific, ALK Abello, Reacta Healthcare</style></keyword><keyword><style face="normal" font="default" size="100%">Ltd., Mission MightyMe, and The Protein Brewery and has stock options from Angany</style></keyword><keyword><style face="normal" font="default" size="100%">Inc.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40452413</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hypoallergenic recombinant fold-variants of major allergens have been suggested as safer and more effective AIT candidates. The Bet v 1-fold variant BM41, with confirmed preclinical hypoallergenicity and increased immunogenicity, was proposed for the treatment of birch pollen allergy. METHODS: We performed a 6-month randomized, double-blind, placebo-controlled first-in-human clinical trial with BM41, a licensed birch pollen extract-based treatment, as the active comparator (AC), and placebo (n = 16, n = 16, and n = 15, respectively). The primary endpoint was safety. Secondary outcomes were Bet v 1-specific (s)IgE, IgG, IgG(1), and IgG(4) responses measured by ImmunoCAP, and sIgE-blocking activity using mediator release and facilitated antigen binding assays. RESULTS: Despite SPT-confirmed hypoallergenicity (~50% compared to natural Bet v 1), more adverse events occurred in response to BM41. Although similar sIgG and sIgG(1) levels were induced, sIgG(4) levels increased 3-fold more in AC compared to the BM41 group. In AC, the sIgG(4)/sIgG(1) ratio tripled over time, whereas for BM41 it stagnated. BM41 induced efficient serum inhibitory activity for sIgE compared to placebo but was 12%-32% less efficient than AC. Both sIgG(4) and sIgG(1) contributed to the blocking effect in AC, while in BM41 both sIgG subclasses showed a lowered functional capacity. CONCLUSION: Preclinically established hypoallergenicity of BM41 did not result in a lower number of adverse events. The reduced induction of sIgG(4) by the fold variant in the course of the treatment was less efficient in blocking sIgE-mediated responses. This is the first study providing evidence that, instead of a Th1-favored IgG(1)-dominated response, &quot;modified Th2&quot;-skewed IgG(4)-dominated humoral responses are beneficial in AIT vaccine design.</style></abstract><notes><style face="normal" font="default" size="100%">Aglas, Lorenz&#xD;Tannert, Line Kring&#xD;Versteeg, Serge A&#xD;Smith, Scott A&#xD;Bartko, Ewa A&#xD;Wenger, Mario&#xD;Kraiem, Amin&#xD;Widauer, Hannah&#xD;Nunes, Natalia&#xD;Sinkunaite, Sibile&#xD;Stolz, Frank&#xD;Jongejan, Laurian&#xD;Neubauer, Angela&#xD;Blom, Lars H&#xD;Ferreira, Fatima&#xD;Poulsen, Lars K&#xD;Bindslev-Jensen, Carsten&#xD;van Ree, Ronald&#xD;eng&#xD;Austrian Science Funds/&#xD;the European Union&apos;s Seventh Framework Program FP7/&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2018-2030. doi: 10.1111/all.16606. Epub 2025 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40452413</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261870</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16606</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2277</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2277</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nakamura, K.</style></author><author><style face="normal" font="default" size="100%">Kouzaki, H.</style></author><author><style face="normal" font="default" size="100%">Murao, T.</style></author><author><style face="normal" font="default" size="100%">Kawakita, K.</style></author><author><style face="normal" font="default" size="100%">Arai, H.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, K.</style></author><author><style face="normal" font="default" size="100%">Kubo, Y.</style></author><author><style face="normal" font="default" size="100%">Tojima, I.</style></author><author><style face="normal" font="default" size="100%">Shimizu, S.</style></author><author><style face="normal" font="default" size="100%">Ogawa, Y.</style></author><author><style face="normal" font="default" size="100%">Yuta, A.</style></author><author><style face="normal" font="default" size="100%">Sakai, R.</style></author><author><style face="normal" font="default" size="100%">Ohno, H.</style></author><author><style face="normal" font="default" size="100%">Kido, H.</style></author><author><style face="normal" font="default" size="100%">Shimizu, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology-Head and Neck Surgery, Shiga University of Medical Science, Otsu, Japan.&#xD;Yuta Clinic, Tsu, Japan.&#xD;Division of Enzyme Chemistry, Institute for Enzyme Research, Tokushima University, Tokushima, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sublingual immunotherapy decreases the avidity of antigen-specific IgE in patients with Japanese cedar pollinosis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3268-3271</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Cryptomeria</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37807665</style></accession-num><notes><style face="normal" font="default" size="100%">Nakamura, Keigo&#xD;Kouzaki, Hideaki&#xD;Murao, Takuya&#xD;Kawakita, Kento&#xD;Arai, Hiroyuki&#xD;Matsumoto, Koji&#xD;Kubo, Yoshihito&#xD;Tojima, Ichiro&#xD;Shimizu, Shino&#xD;Ogawa, Yukiko&#xD;Yuta, Atsushi&#xD;Sakai, Rika&#xD;Ohno, Hitoshi&#xD;Kido, Hiroshi&#xD;Shimizu, Takeshi&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3268-3271. doi: 10.1111/all.15900. Epub 2023 Oct 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37807665</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15900</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>854</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">854</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tomsitz, D.</style></author><author><style face="normal" font="default" size="100%">Biedermann, T.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munchen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sublingual immunotherapy reduces reaction threshold in three patients with wheat-dependent exercise-induced anaphylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3804-3806</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/08/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Gliadin</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Wheat Hypersensitivity/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34392539</style></accession-num><notes><style face="normal" font="default" size="100%">Tomsitz, Dirk&#xD;Biedermann, Tilo&#xD;Brockow, Knut&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3804-3806. doi: 10.1111/all.15053. Epub 2021 Aug 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34392539</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15053</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>660</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">660</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cahill, J. A.</style></author><author><style face="normal" font="default" size="100%">Kan, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fraser Health Authority, Langley, BC, Canada.&#xD;Fraser Allergy, Langley, BC, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Successful administration of second dose of BNT162b2 COVID-19 vaccine in two patients with potential anaphylaxis to first dose</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">337-338</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2021/12/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34965310</style></accession-num><notes><style face="normal" font="default" size="100%">Cahill, Julia A&#xD;Kan, Manstein&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Jan;77(1):337-338. doi: 10.1111/all.14996.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34965310</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14996</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3252</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3252</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Céspedes, Jose A.</style></author><author><style face="normal" font="default" size="100%">Lebrón-Martín, Clara</style></author><author><style face="normal" font="default" size="100%">Vallecillos-Azor, Lucía</style></author><author><style face="normal" font="default" size="100%">Torres, Pablo</style></author><author><style face="normal" font="default" size="100%">Ayane, Amene Tesfaye</style></author><author><style face="normal" font="default" size="100%">Bogas, Gádor</style></author><author><style face="normal" font="default" size="100%">Salas, María</style></author><author><style face="normal" font="default" size="100%">Ariza, Adriana</style></author><author><style face="normal" font="default" size="100%">Montañez, María Isabel</style></author><author><style face="normal" font="default" size="100%">Torres, María José</style></author><author><style face="normal" font="default" size="100%">Aranda, Carlos José</style></author><author><style face="normal" font="default" size="100%">Mayorga, Cristobalina</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Successful Application of the Mast Cell Activation Test in Immediate Hypersensitivity to Amoxicillin</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Immediate drug allergic reactions (IDAR) to betalactams are frequent, yet mislabelling remains common and negatively impacts clinical decisions. Conventional diagnostics such as STs and drug provocation are effective but limited by time, risk, and contraindications in severe cases. In vitro alternatives—sIgEquantification and basophil activation tests (BAT)—offer safer options, although performance may be affected by biological variability and suboptimal sensitivity with an important drawback for the latter in patients with non-releaser basophils. This study aimed to evaluate a mast cell activation test (MAT) based on human CD34+-derived mast cells (dMCs) for IDAR diagnosis to amoxicillin (AX) using both free AX and dendrimeric amoxicilloyl conjugates (G4/G5-AXO). Methods CD34+ cells were cultured for 10–12 weeks to generate dMCs. After passive sensitization with sera from AX-allergic patients (N = 28) or tolerant controls (N = 11), dMCs were stimulated with free AX, G4-AXO, or G5-AXO. Activation was quantified by CD63 expression via flow cytometry. Diagnostic performance was compared with BAT and sIgE determination by ImmunoCAP. Results MAT with free AX achieved 53.57% sensitivity, G4/G5-AXO reached 46.43%, and all methods maintained 100% specificity. Combining results with AX or dendrimeric stimuli increased sensitivity to 75% while preserving specificity. Importantly, MAT identified positive cases among BAT non-releasers and patients with undetectable sIgE. Conclusions Under optimized conditions, MAT using dMCs and different AX determinants reached 75% sensitivity and 100% specificity. The complementary use of free AX and dendrimeric conjugates expands detection across heterogeneous IgE reactivity profiles from AX-allergic patients, reinforcing the diagnostic value of advanced cellular models and engineered allergens.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70267</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70267</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>954</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">954</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hutten, E. M.</style></author><author><style face="normal" font="default" size="100%">Lambeck, A. J. A.</style></author><author><style face="normal" font="default" size="100%">Dijkstra, H.</style></author><author><style face="normal" font="default" size="100%">Nuver, J.</style></author><author><style face="normal" font="default" size="100%">Oude Elberink, H. N. G.</style></author><author><style face="normal" font="default" size="100%">Van de Ven, Aajm</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine and Allergology, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Department of Laboratory Medicine, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.&#xD;Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Successful rapid desensitization in a glioma patient with procarbazine-mediated anaphylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1932-1933</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/06/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/chemically induced/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Glioma/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Procarbazine</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">desensitization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34128560</style></accession-num><notes><style face="normal" font="default" size="100%">Hutten, Evelien M&#xD;Lambeck, Annechien J A&#xD;Dijkstra, Hilda&#xD;Nuver, Janine&#xD;Oude Elberink, Hanneke N G&#xD;Van de Ven, Annick A J M&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1932-1933. doi: 10.1111/all.14698.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34128560</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14698</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1976</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1976</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schneider, S.</style></author><author><style face="normal" font="default" size="100%">Gasteiger, C.</style></author><author><style face="normal" font="default" size="100%">Wecker, H.</style></author><author><style face="normal" font="default" size="100%">Hobenreich, J.</style></author><author><style face="normal" font="default" size="100%">Biedermann, T.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Zink, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany.&#xD;Technical University of Munich, Department of Informatics, Munich, Germany.&#xD;Division of Dermatology and Venereology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Successful usage of a chatbot to standardize and automate history taking in Hymenoptera venom allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2526-2528</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/03/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthropod Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">*Hymenoptera</style></keyword><keyword><style face="normal" font="default" size="100%">*Venom Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Medical History Taking</style></keyword><keyword><style face="normal" font="default" size="100%">*Insect Bites and Stings</style></keyword><keyword><style face="normal" font="default" size="100%">*Bee Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">Wasp Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36946258</style></accession-num><notes><style face="normal" font="default" size="100%">Schneider, Simon&#xD;Gasteiger, Christine&#xD;Wecker, Hannah&#xD;Hobenreich, Jonas&#xD;Biedermann, Tilo&#xD;Brockow, Knut&#xD;Zink, Alexander&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2526-2528. doi: 10.1111/all.15720. Epub 2023 Mar 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36946258</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15720</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2503</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2503</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tan, J.</style></author><author><style face="normal" font="default" size="100%">Potier-Villette, C.</style></author><author><style face="normal" font="default" size="100%">Ni, D.</style></author><author><style face="normal" font="default" size="100%">Hoeckh, M.</style></author><author><style face="normal" font="default" size="100%">Taitz, J.</style></author><author><style face="normal" font="default" size="100%">Simpson, S. J.</style></author><author><style face="normal" font="default" size="100%">Nanan, R.</style></author><author><style face="normal" font="default" size="100%">Macia, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.&#xD;School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Sydney Medical School Nepean, The University of Sydney, Sydney, New South Wales, Australia.&#xD;School of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales, Australia.&#xD;Sydney Cytometry Core Research Facility, Charles Perkins Centre, The University of Sydney and Centenary Institute, Sydney, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Succinate induces a Th2 environment in the small intestine but does not exacerbate food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2853-2855</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Intestine, Small/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38747065</style></accession-num><notes><style face="normal" font="default" size="100%">Tan, Jian&#xD;Potier-Villette, Camille&#xD;Ni, Duan&#xD;Hoeckh, Maike&#xD;Taitz, Jemma&#xD;Simpson, Stephen J&#xD;Nanan, Ralph&#xD;Macia, Laurence&#xD;eng&#xD;Australian Research Council/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2853-2855. doi: 10.1111/all.16155. Epub 2024 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38747065</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16155</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2972</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2972</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Utami, F. A.</style></author><author><style face="normal" font="default" size="100%">Nguyen, N. N.</style></author><author><style face="normal" font="default" size="100%">Huang, S. Y.</style></author><author><style face="normal" font="default" size="100%">Huang, S. W.</style></author><author><style face="normal" font="default" size="100%">Weng, C. M.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Nutrition and Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.&#xD;International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Family Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.&#xD;Department of Family Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.&#xD;School of Nutrition and Health Sciences, Taipei Medical University, Taipei, Taiwan.&#xD;Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei, Taiwan.&#xD;Nutrition Research Center, Taipei Medical University Hospital, Taipei, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sugar Intake and Respiratory Consequences: Deciphering the Link Between Drink Choice and Asthma Risk</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/07/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 19</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40682324</style></accession-num><notes><style face="normal" font="default" size="100%">Utami, Fasty Arum&#xD;Nguyen, Nam Nhat&#xD;Huang, Shih-Yi&#xD;Huang, Shiu-Wen&#xD;Weng, Chih-Ming&#xD;Chen, Yang-Ching&#xD;eng&#xD;Wan Fang Hospital/&#xD;Taipei Medical University Hospital/&#xD;Taipei Medical University/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul 19. doi: 10.1111/all.16667.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40682324</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16667</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2479</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2479</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Achour, J.</style></author><author><style face="normal" font="default" size="100%">Reche, M.</style></author><author><style face="normal" font="default" size="100%">Valbuena, T.</style></author><author><style face="normal" font="default" size="100%">Chapuis, C.</style></author><author><style face="normal" font="default" size="100%">Guillon, B.</style></author><author><style face="normal" font="default" size="100%">Galet, O.</style></author><author><style face="normal" font="default" size="100%">Adel-Patient, K.</style></author><author><style face="normal" font="default" size="100%">Bernard, H.</style></author><author><style face="normal" font="default" size="100%">Hazebrouck, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite Paris Saclay, CEA, INRAE, Departement Medicaments et Technologies pour la Sante, Gif-sur-Yvette, France.&#xD;Hospital Universitario Infanta Sofia, San Sebastian de los Reyes, Madrid, Spain.&#xD;Avril SCA 11/13, rue de Monceau, Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sunflower seed allergy: Identification of novel 2S-albumins as potential marker allergens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2273-2276</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/04/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Helianthus/immunology/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Seeds/adverse effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">2S Albumins, Plant/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38619510</style></accession-num><notes><style face="normal" font="default" size="100%">Achour, J&#xD;Reche, M&#xD;Valbuena, T&#xD;Chapuis, C&#xD;Guillon, B&#xD;Galet, O&#xD;Adel-Patient, K&#xD;Bernard, H&#xD;Hazebrouck, S&#xD;eng&#xD;SOFIPROTEOL/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2273-2276. doi: 10.1111/all.16124. Epub 2024 Apr 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38619510</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16124</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3164</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3164</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vonk, P. E.</style></author><author><style face="normal" font="default" size="100%">Otten, J. J.</style></author><author><style face="normal" font="default" size="100%">Elzinga, H. B. E.</style></author><author><style face="normal" font="default" size="100%">van der Lans, R. J. L.</style></author><author><style face="normal" font="default" size="100%">Adriaensen, Gfjp</style></author><author><style face="normal" font="default" size="100%">Benoist, L. B. L.</style></author><author><style face="normal" font="default" size="100%">Hoven, D. R.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Poly, R. E. G. Consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">&quot;Super-Responders&quot; to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">tapering</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 12</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41221560</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dupilumab is effective in treating patients with type-2 dominant chronic rhinosinusitis with nasal polyps (T2-CRSwNP). Dosing starts at an interval of 1x/2 weeks (Q2W) with possible tapering upon disease control. Prolonging the interdose interval reduces patient burden and side effects and improves cost-effectiveness. OBJECTIVES: (1) Analyze how many patients successfully reach and maintain extended tapering of at least 1x/12 weeks (Q12W), (2) evaluate differences in baseline characteristics and clinical measurements between patients who maintain disease control on &gt;/= Q12W (&quot;super-responders&quot;) and patients who do not; (3) compare characteristics of &quot;super-responders&quot; to patients reaching Q12W but losing disease control on that dose (&quot;excellent responders&quot;). METHOD: Prospective cohort study including dupilumab-treated T2-CRSwNP patients with a minimum follow-up of 2.5 years. RESULTS: From a total of 198 patients, 28 (14%) were &quot;super-responders&quot;, and 26 (13%) &quot;excellent responders.&quot; &quot;super-responders&quot; had less comorbid asthma (60.7% vs. 85.9%, p &lt; 0.001), lower baseline immunoglobulin E levels (median [Q1: Q3]: 145 [58.7; 485] vs. 313 [135.5; 746]; p = 0.007) and a shorter time since last sinus surgery (2.5 years [1; 4.8] vs. 4 years [2; 7]; p = 0.026) compared to others. No differences were observed between &quot;excellent&quot; and &quot;super-responders&quot; at baseline, nor at the start of the Q12W interval. &quot;excellent responders&quot; showed worsening of clinical outcomes as well as increases in T2 markers in blood between start and stop of the Q12W interval. CONCLUSION: Tapering of dupilumab to once every 12 weeks (Q12W) can be applied to super-responding patients. No clear predisposing factors were identified predicting the feasibility of extended tapering.</style></abstract><notes><style face="normal" font="default" size="100%">Vonk, P E&#xD;Otten, J J&#xD;Elzinga, H B E&#xD;van der Lans, R J L&#xD;Adriaensen, G F J P&#xD;Benoist, L B L&#xD;Hoven, D R&#xD;Fokkens, W J&#xD;Reitsma, S&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Nov 12. doi: 10.1111/all.70151.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41221560</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70151</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1528</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1528</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author><author><style face="normal" font="default" size="100%">Schmidt-Weber, C. B.</style></author><author><style face="normal" font="default" size="100%">Blank, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.&#xD;Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Member of the German Center of Lung Research (DZL), Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Supporting allergen-specific immunotherapy by inhibition of Janus kinases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1814-1816</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2019/04/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens/administration &amp; dosage/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/etiology/metabolism/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Janus Kinase Inhibitors/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Janus Kinases/*antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30953592</style></accession-num><notes><style face="normal" font="default" size="100%">Gutermuth, Jan&#xD;Schmidt-Weber, Carsten B&#xD;Blank, Simon&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2019 Sep;74(9):1814-1816. doi: 10.1111/all.13808. Epub 2019 May 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30953592</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13808</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2448</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2448</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Valk, A. M.</style></author><author><style face="normal" font="default" size="100%">Keijser, J. B. D.</style></author><author><style face="normal" font="default" size="100%">van Dam, K. P. J.</style></author><author><style face="normal" font="default" size="100%">Stalman, E. W.</style></author><author><style face="normal" font="default" size="100%">Wieske, L.</style></author><author><style face="normal" font="default" size="100%">Steenhuis, M.</style></author><author><style face="normal" font="default" size="100%">Kummer, L. Y. L.</style></author><author><style face="normal" font="default" size="100%">Spuls, P. I.</style></author><author><style face="normal" font="default" size="100%">Bekkenk, M. W.</style></author><author><style face="normal" font="default" size="100%">Musters, A. H.</style></author><author><style face="normal" font="default" size="100%">Post, N. F.</style></author><author><style face="normal" font="default" size="100%">Bosma, A. L.</style></author><author><style face="normal" font="default" size="100%">Horvath, B.</style></author><author><style face="normal" font="default" size="100%">Hijnen, D. J.</style></author><author><style face="normal" font="default" size="100%">Schreurs, C. R. G.</style></author><author><style face="normal" font="default" size="100%">van Kempen, Z. L. E.</style></author><author><style face="normal" font="default" size="100%">Killestein, J.</style></author><author><style face="normal" font="default" size="100%">Volkers, A. G.</style></author><author><style face="normal" font="default" size="100%">Tas, S. W.</style></author><author><style face="normal" font="default" size="100%">Boekel, L.</style></author><author><style face="normal" font="default" size="100%">Wolbink, G. J.</style></author><author><style face="normal" font="default" size="100%">Keijzer, S.</style></author><author><style face="normal" font="default" size="100%">Derksen, N. I. L.</style></author><author><style face="normal" font="default" size="100%">van Deelen, M.</style></author><author><style face="normal" font="default" size="100%">van Mierlo, G.</style></author><author><style face="normal" font="default" size="100%">Kuijpers, T. W.</style></author><author><style face="normal" font="default" size="100%">Eftimov, F.</style></author><author><style face="normal" font="default" size="100%">van Ham, S. M.</style></author><author><style face="normal" font="default" size="100%">Ten Brinke, A.</style></author><author><style face="normal" font="default" size="100%">Rispens, T.</style></author><author><style face="normal" font="default" size="100%">T. B. Immunity against SARS-CoV-2 study group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, The Netherlands.&#xD;Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.&#xD;Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Clinical Neurophysiology, St. Antonius Hospital, Nieuwegein, The Netherlands.&#xD;Department of Dermatology, Amsterdam Public Health/Infection and Immunology, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Dermatology, UMCG Expertise Center for Blistering Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.&#xD;Department of Dermatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.&#xD;Department of Neurology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands.&#xD;Department of Gastroenterology and Hepatology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands.&#xD;Department of Pediatric Immunology, Rheumatology and Infectious Disease, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1952-1961</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/03/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin G/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin Class Switching</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor Inhibitors/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/prevention &amp; control/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA Vaccines/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Viral/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">IgG4 class switching</style></keyword><keyword><style face="normal" font="default" size="100%">TNFi</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">tolerance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38439527</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The noninflammatory immunoglobulin G4 (IgG4) is linked to tolerance and is unique to humans. Although poorly understood, prolonged antigenic stimulation and IL-4-signaling along the T helper 2-axis may be instrumental in IgG4 class switching. Recently, repeated SARS-CoV-2 mRNA vaccination has been linked to IgG4 skewing. Although widely used immunosuppressive drugs have been shown to only moderately affect humoral responses to SARS-CoV-2 mRNA vaccination, the effect on IgG4 switching has not been investigated. METHODS: Here we study the impact of such immunosuppressive drugs, including the IL-4 receptor-blocking antibody dupilumab, on IgG4 skewing upon repeated SARS-CoV-2 mRNA vaccination. Receptor-binding domain (RBD) specific antibody responses were longitudinally measured in 600 individuals, including patients with immune-mediated inflammatory diseases treated with a TNF inhibitor (TNFi) and/or methotrexate (MTX), dupilumab, and healthy/untreated controls, after repeated mRNA vaccination. RESULTS: We observed a substantial increase in the proportion of RBD-specific IgG4 antibodies (median 21%) in healthy/untreated controls after third vaccination. This IgG4 skewing was profoundly reduced in dupilumab-treated patients (&lt;1%). Unexpectedly, an equally strong suppression of IgG4 skewing was observed in TNFi-treated patients (&lt;1%), whereas MTX caused a modest reduction (7%). RBD-specific total IgG levels were hardly affected by these immunosuppressive drugs. Minimal skewing was observed, when primary vaccination was adenoviral vector-based. CONCLUSIONS: Our results imply a critical role for IL-4/IL-13 as well as TNF in vivo IgG4 class switching. These novel findings advance our understanding of IgG4 class switch dynamics, and may benefit humoral tolerance induction strategies, treatment of IgG4 pathologies and mRNA vaccine optimization.</style></abstract><notes><style face="normal" font="default" size="100%">Valk, Anika M&#xD;Keijser, Jim B D&#xD;van Dam, Koos P J&#xD;Stalman, Eileen W&#xD;Wieske, Luuk&#xD;Steenhuis, Maurice&#xD;Kummer, Laura Y L&#xD;Spuls, Phyllis I&#xD;Bekkenk, Marcel W&#xD;Musters, Annelie H&#xD;Post, Nicoline F&#xD;Bosma, Angela L&#xD;Horvath, Barbara&#xD;Hijnen, Dirk-Jan&#xD;Schreurs, Corine R G&#xD;van Kempen, Zoe L E&#xD;Killestein, Joep&#xD;Volkers, Adriaan G&#xD;Tas, Sander W&#xD;Boekel, Laura&#xD;Wolbink, Gerrit J&#xD;Keijzer, Sofie&#xD;Derksen, Ninotska I L&#xD;van Deelen, Melanie&#xD;van Mierlo, Gerard&#xD;Kuijpers, Taco W&#xD;Eftimov, Filip&#xD;van Ham, S Marieke&#xD;Ten Brinke, Anja&#xD;Rispens, Theo&#xD;eng&#xD;ZONMW_/ZonMw/Netherlands&#xD;Samenwerkende Gezondheidsfondsen/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1952-1961. doi: 10.1111/all.16089. Epub 2024 Mar 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38439527</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16089</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3188</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3188</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bakirtas, A.</style></author><author><style face="normal" font="default" size="100%">Kiykim, A.</style></author><author><style face="normal" font="default" size="100%">Baskin, A. K.</style></author><author><style face="normal" font="default" size="100%">Anil, H.</style></author><author><style face="normal" font="default" size="100%">Bozkurt, H. B.</style></author><author><style face="normal" font="default" size="100%">Cimen, S. S.</style></author><author><style face="normal" font="default" size="100%">Demirkale, Z. H.</style></author><author><style face="normal" font="default" size="100%">Esenboga, S.</style></author><author><style face="normal" font="default" size="100%">Ogulur, I.</style></author><author><style face="normal" font="default" size="100%">Ardicli, S.</style></author><author><style face="normal" font="default" size="100%">Cagdas, D.</style></author><author><style face="normal" font="default" size="100%">Kistler, W.</style></author><author><style face="normal" font="default" size="100%">Yuksel, H.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine Department of Pediatric Allergy and Immunology, Gazi University, Ankara, Turkiye.&#xD;Cerrahpasa School of Medicine, Pediatric Allergy and Immunology, Istanbul University-Cerrahpasa, Istanbul, Turkiye.&#xD;Pediatric Allergy and Immunology, Osmangazi University, Eskisehir, Turkiye.&#xD;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Umraniye Training and Research Hospital, Istanbul, Turkiye.&#xD;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Sisli Etfal Training and Research Hospital, Istanbul, Turkiye.&#xD;Department of Immunology, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkiye.&#xD;Institute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Turkiye.&#xD;Ihsan Dogramaci Children&apos;s Hospital, Department of Pediatrics, Division of Pediatric Immunology, Hacettepe University Medical School, Ankara, Turkiye.&#xD;Department of Pediatric Basic Sciences, Division of Immunology, Hacettepe University, Institute of Child Health, Ankara, Turkey.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Department of Sports Medicine, Davos Hospital, Davos, Switzerland.&#xD;Swiss Research Institute for Sports Medicine (SRISM), Davos, Switzerland.&#xD;Medical Committee International Ice Hockey Federation (IIHF), Zurich, Switzerland.&#xD;Medical Faculty, Department of Pediatric Allergy and Immunology, Celal Bayar University, Manisa, Turkiye.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Survey on Environmental Protective and Risk Factors and Awareness Related to Epithelial Barrier Integrity, Microbiome and Allergic Diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">detergents</style></keyword><keyword><style face="normal" font="default" size="100%">environmental pollutants</style></keyword><keyword><style face="normal" font="default" size="100%">food processed</style></keyword><keyword><style face="normal" font="default" size="100%">plastics</style></keyword><keyword><style face="normal" font="default" size="100%">survey</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41431830</style></accession-num><notes><style face="normal" font="default" size="100%">Bakirtas, Arzu&#xD;Kiykim, Ayca&#xD;Baskin, A Kubra&#xD;Anil, Hulya&#xD;Bozkurt, Hayrunnisa Bekis&#xD;Cimen, Sevgi Sipahi&#xD;Demirkale, Zeynep Hizli&#xD;Esenboga, Saliha&#xD;Ogulur, Ismail&#xD;Ardicli, Sena&#xD;Cagdas, Deniz&#xD;Kistler, Walter&#xD;Yuksel, Hasan&#xD;Akdis, Cezmi A&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec 23. doi: 10.1111/all.70190.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41431830</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70190</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2209</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2209</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moreno-Sanchez, P. M.</style></author><author><style face="normal" font="default" size="100%">Scafidi, A.</style></author><author><style face="normal" font="default" size="100%">Salvato, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">NORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.&#xD;Faculty of Science, Technology and Medicine (FSTM), University of Luxembourg, Belvaux, Luxembourg.&#xD;Neuro-Immunology Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.</style></auth-address><titles><title><style face="normal" font="default" size="100%">SUSD2-IL-2 receptor interaction hinders antitumoral CD8(+) T-cell activity: Implications for cancer immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3035-3037</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/07/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Interleukin-2</style></keyword><keyword><style face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Neoplasms/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy, Adoptive</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Glycoproteins</style></keyword><keyword><style face="normal" font="default" size="100%">CAR T cells</style></keyword><keyword><style face="normal" font="default" size="100%">CD8+ T cells</style></keyword><keyword><style face="normal" font="default" size="100%">Il-2</style></keyword><keyword><style face="normal" font="default" size="100%">Susd2</style></keyword><keyword><style face="normal" font="default" size="100%">cancer immunotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37401528</style></accession-num><notes><style face="normal" font="default" size="100%">Moreno-Sanchez, Pilar M&#xD;Scafidi, Andrea&#xD;Salvato, Ilaria&#xD;eng&#xD;Action LIONS Vaincre le Cancer/&#xD;Fonds De La Recherche Scientifique - FNRS/&#xD;Fonds National de la Recherche Luxembourg/&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):3035-3037. doi: 10.1111/all.15804. Epub 2023 Jul 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37401528</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15804</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1269</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1269</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spergel, J. M.</style></author><author><style face="normal" font="default" size="100%">Muir, A. B.</style></author><author><style face="normal" font="default" size="100%">Liacouras, C. A.</style></author><author><style face="normal" font="default" size="100%">Burke, D.</style></author><author><style face="normal" font="default" size="100%">Lewis, M. O.</style></author><author><style face="normal" font="default" size="100%">Brown-Whitehorn, T.</style></author><author><style face="normal" font="default" size="100%">Cianferoni, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, The Children&apos;s Hospital of Philadelphia, Philadelphia, PA, USA.&#xD;Department of Pediatrics, The Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, USA.&#xD;Division of Gastroenterology, Hepatology, and Nutrition, The Children&apos;s Hospital of Philadelphia, PA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sustained milk consumption after 2 years post-milk epicutaneous immunotherapy for eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1573-1576</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/11/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Milk</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">milk food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33202086</style></accession-num><notes><style face="normal" font="default" size="100%">Spergel, Jonathan M&#xD;Muir, Amanda B&#xD;Liacouras, Chris A&#xD;Burke, Deirdre&#xD;Lewis, Megan O&#xD;Brown-Whitehorn, Terri&#xD;Cianferoni, Antonella&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1573-1576. doi: 10.1111/all.14659. Epub 2020 Nov 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33202086</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14659</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>698</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">698</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Chu, C. Y.</style></author><author><style face="normal" font="default" size="100%">Danilycheva, I.</style></author><author><style face="normal" font="default" size="100%">Hide, M.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Metz, M.</style></author><author><style face="normal" font="default" size="100%">Savic, S.</style></author><author><style face="normal" font="default" size="100%">Sitz, K.</style></author><author><style face="normal" font="default" size="100%">Soong, W.</style></author><author><style face="normal" font="default" size="100%">Staubach, P.</style></author><author><style face="normal" font="default" size="100%">Sussman, G.</style></author><author><style face="normal" font="default" size="100%">Barve, A.</style></author><author><style face="normal" font="default" size="100%">Burciu, A.</style></author><author><style face="normal" font="default" size="100%">Hua, E.</style></author><author><style face="normal" font="default" size="100%">Janocha, R.</style></author><author><style face="normal" font="default" size="100%">Severin, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Dermatology Department, Hospital del Mar, IMIM Universitat Autonoma Barcelona, Barcelona, Spain.&#xD;University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati, Ohio, USA.&#xD;Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.&#xD;National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow, Russia.&#xD;Department of Dermatology, Hiroshima University, Hiroshima, Japan.&#xD;Allergy Unit, 2nd Department of Dermatology and Venereology, National and Kapodistrian University, &quot;Attikon&quot; University Hospital, Athens, Greece.&#xD;Leeds Biomedical Research Centre, Department of Clinical Immunology and Allergy, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), St James&apos;s University Hospital, Leeds, UK.&#xD;Little Rock Allergy and Asthma Clinic, Little Rock, Arkansas, USA.&#xD;Alabama Allergy &amp; Asthma Center - AllerVie Health, Clinical Research Center of Alabama, Birmingham, Alabama, USA.&#xD;Department of Dermatology, University Medical Center, Mainz, Germany.&#xD;Division of Allergy and Clinical Immunology, University of Toronto, Canada.&#xD;Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.&#xD;Novartis Pharma AG, Basel, Switzerland.&#xD;China Novartis Institutes for Biomedical Research Co. Ltd, Shanghai, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2175-2184</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/11/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">ligelizumab</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34773261</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Ligelizumab, a next-generation, humanized anti-immunoglobulin E (IgE) monoclonal antibody is in development as a treatment for patients with chronic spontaneous urticaria, whose symptoms are inadequately controlled with standard-of-care therapy. OBJECTIVE: To evaluate the long-term safety and re-treatment efficacy of ligelizumab 240 mg in patients who completed the core study and extension study. METHODS: This open-label, single-arm, long-term Phase 2b extension study was designed to assess patients who were previously administered various doses of ligelizumab, omalizumab or placebo in the Phase 2b, dose-finding core study and who presented with active disease after Week 32. In the extension study, patients received ligelizumab 240 mg subcutaneously every 4 weeks, for 52 weeks and were monitored post-treatment for 48 weeks. RESULTS: Overall, ligelizumab was well-tolerated with no newly identified safety signals. A total of 95.4% (226/237) screened patients received ligelizumab 240 mg in the extension study; 84.1% (190/226) of patients experienced at least one treatment-emergent adverse event. Most reported events were mild (41.6%) or moderate (35.8%) and mostly unrelated to the study treatment. At Week 12, 46.5% of patients had a complete response increasing to 53.1% after 52 weeks. Following 52 weeks of extension study treatment, 75.8% (95% confidence interval, 69.9, 81.3) of patients had cumulative complete responses. The median time to relapse in complete responders was 38 weeks. CONCLUSION: The long-term safety profile of ligelizumab 240 mg in patients with chronic spontaneous urticaria was consistent with the core study and re-treatment efficacy was shown. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02477332 and NCT02649218.</style></abstract><notes><style face="normal" font="default" size="100%">Maurer, Marcus&#xD;Gimenez-Arnau, Ana&#xD;Bernstein, Jonathan A&#xD;Chu, Chia-Yu&#xD;Danilycheva, Inna&#xD;Hide, Michihiro&#xD;Makris, Michael&#xD;Metz, Martin&#xD;Savic, Sinisa&#xD;Sitz, Karl&#xD;Soong, Weily&#xD;Staubach, Petra&#xD;Sussman, Gordon&#xD;Barve, Avantika&#xD;Burciu, Alis&#xD;Hua, Eva&#xD;Janocha, Reinhold&#xD;Severin, Thomas&#xD;eng&#xD;Clinical Trial, Phase II&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2175-2184. doi: 10.1111/all.15175. Epub 2021 Nov 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34773261</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15175</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>934</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">934</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Darrigade, A. S.</style></author><author><style face="normal" font="default" size="100%">Theophile, H.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Pena, P.</style></author><author><style face="normal" font="default" size="100%">Milpied, B.</style></author><author><style face="normal" font="default" size="100%">Colbert, M.</style></author><author><style face="normal" font="default" size="100%">Pedeboscq, S.</style></author><author><style face="normal" font="default" size="100%">Pistone, T.</style></author><author><style face="normal" font="default" size="100%">Jullie, M. L.</style></author><author><style face="normal" font="default" size="100%">Seneschal, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Adult and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France.&#xD;Department of Pharmacovigilancy, Bordeaux University Hospitals, Bordeaux, France.&#xD;Department of Geriatry, Clinic Bordeaux Nord, Bordeaux, France.&#xD;Department of Pharmacology, Bordeaux University Hospitals, Bordeaux, France.&#xD;Department of Infectious Disease, Bordeaux University Hospitals, Bordeaux, France.&#xD;Department of Anatomopathology, Bordeaux University Hospitals, Bordeaux, France.&#xD;Research Unit INSERM U1035, Bordeaux, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3194-3196</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/06/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Sweet Syndrome/chemically induced/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Pfizer-BioNTech mRNA vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">delayed hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">intradermal test</style></keyword><keyword><style face="normal" font="default" size="100%">sweet syndrome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34143448</style></accession-num><notes><style face="normal" font="default" size="100%">Darrigade, Anne-Sophie&#xD;Theophile, Helene&#xD;Sanchez-Pena, Paola&#xD;Milpied, Brigitte&#xD;Colbert, Marianne&#xD;Pedeboscq, Stephane&#xD;Pistone, Thierry&#xD;Jullie, Marie-Laure&#xD;Seneschal, Julien&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3194-3196. doi: 10.1111/all.14981. Epub 2021 Jul 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34143448</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8441847</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14981</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1937</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1937</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kiatiwat, P.</style></author><author><style face="normal" font="default" size="100%">Sangasapaviliya, A.</style></author><author><style face="normal" font="default" size="100%">Pradubpongsa, P.</style></author><author><style face="normal" font="default" size="100%">Sangkanjanavanich, S.</style></author><author><style face="normal" font="default" size="100%">Chiewchalermsri, C.</style></author><author><style face="normal" font="default" size="100%">Jacquet, A.</style></author><author><style face="normal" font="default" size="100%">Jaisupa, N.</style></author><author><style face="normal" font="default" size="100%">Jindarat, S.</style></author><author><style face="normal" font="default" size="100%">Boonpiyathad, T.</style></author><author><style face="normal" font="default" size="100%">Mitthamsiri, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Clinical Immunology, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand.&#xD;Department of Medicine, Bangkok Metropolitan Administration Latkrabang Hospital, Bangkok, Thailand.&#xD;Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Medicine, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, Thailand.&#xD;Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.&#xD;Department of Pharmacology, Phramongkutklao College of Medicine, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Switching from subcutaneous to sublingual immunotherapy during the maintenance phase in patients with house dust mite allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2019-2021</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Sublingual Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Dust Mite Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Hdm</style></keyword><keyword><style face="normal" font="default" size="100%">Scit</style></keyword><keyword><style face="normal" font="default" size="100%">SLIT tablets</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36754574</style></accession-num><notes><style face="normal" font="default" size="100%">Kiatiwat, Ploykarn&#xD;Sangasapaviliya, Atik&#xD;Pradubpongsa, Panitan&#xD;Sangkanjanavanich, Sasipa&#xD;Chiewchalermsri, Chirawat&#xD;Jacquet, Alain&#xD;Jaisupa, Nattapol&#xD;Jindarat, Sarawut&#xD;Boonpiyathad, Tadech&#xD;Mitthamsiri, Wat&#xD;eng&#xD;Phramongkutklao Hospital/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2019-2021. doi: 10.1111/all.15669. Epub 2023 Feb 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36754574</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15669</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3308</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3308</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Riedl, Marc A.</style></author><author><style face="normal" font="default" size="100%">Bernstein, Jonathan A.</style></author><author><style face="normal" font="default" size="100%">Jacobs, Joshua S.</style></author><author><style face="normal" font="default" size="100%">Craig, Timothy</style></author><author><style face="normal" font="default" size="100%">Lumry, William R.</style></author><author><style face="normal" font="default" size="100%">Wedner, H. James</style></author><author><style face="normal" font="default" size="100%">Banerji, Aleena</style></author><author><style face="normal" font="default" size="100%">Gierer, Selina</style></author><author><style face="normal" font="default" size="100%">Smith, Andrew</style></author><author><style face="normal" font="default" size="100%">Manning, Michael E.</style></author><author><style face="normal" font="default" size="100%">Perego, Francesca</style></author><author><style face="normal" font="default" size="100%">Bordone, Laura</style></author><author><style face="normal" font="default" size="100%">Treadwell, Sabrina</style></author><author><style face="normal" font="default" size="100%">Lin, Tao</style></author><author><style face="normal" font="default" size="100%">Newman, Kenneth B.</style></author><author><style face="normal" font="default" size="100%">Yarlas, Aaron</style></author><author><style face="normal" font="default" size="100%">Cohn, Danny M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Switching Long-Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1-Year OASISplus Results</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Donidalorsen is an antisense oligonucleotide designed to reduce plasma prekallikrein in patients with hereditary angioedema (HAE). The Switch cohort of the OASISplus study (NCT05392114) evaluated the long-term safety and efficacy of donidalorsen in patients who switched from a long-term prophylactic treatment (LTP) to donidalorsen with 1-year outcomes. Methods This study enrolled patients with HAE aged ≥ 12 years previously on stable doses of an LTP (lanadelumab, berotralstat, C1 inhibitor). Patients directly switched from an LTP to donidalorsen 80 mg administered subcutaneously once every 4 weeks. Endpoints included incidence and severity of treatment-emergent adverse events (TEAEs; primary endpoint), monthly HAE attack rate, Angioedema Quality of Life (AE-QoL), and Angioedema Control Test (AECT) measured at baseline and Week 52. Results Sixty-five patients enrolled, and 54 (83.1%) completed 1 year. Eleven (16.9%) patients discontinued treatment during the first year, and one discontinued treatment after 1 year. Donidalorsen reduced HAE attack rates from baseline on the prior LTP by 67.6% over 52 weeks. Fifty-six of 64 (87.5%) dosed patients experienced a TEAE; most reported mild to moderate events. The most common treatment-related TEAEs were injection-site erythema (10.9%) and injection-site pruritus (10.9%). One patient had a serious adverse event that was not treatment-related. AE-QoL total score improved by 12.2 points (clinically meaningful ≥ 6 points) from baseline to Week 52, and 90.4% of patients had well-controlled disease (AECT ≥ 10) at Week 52. Conclusion In patients who switched from another LTP, donidalorsen was well tolerated and improved long-term HAE attack rates, quality of life, and disease control.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70294</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70294</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>827</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">827</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Inomata, T.</style></author><author><style face="normal" font="default" size="100%">Nakamura, M.</style></author><author><style face="normal" font="default" size="100%">Iwagami, M.</style></author><author><style face="normal" font="default" size="100%">Sung, J.</style></author><author><style face="normal" font="default" size="100%">Nakamura, M.</style></author><author><style face="normal" font="default" size="100%">Ebihara, N.</style></author><author><style face="normal" font="default" size="100%">Fujisawa, K.</style></author><author><style face="normal" font="default" size="100%">Muto, K.</style></author><author><style face="normal" font="default" size="100%">Nojiri, S.</style></author><author><style face="normal" font="default" size="100%">Ide, T.</style></author><author><style face="normal" font="default" size="100%">Okano, M.</style></author><author><style face="normal" font="default" size="100%">Okumura, Y.</style></author><author><style face="normal" font="default" size="100%">Fujio, K.</style></author><author><style face="normal" font="default" size="100%">Fujimoto, K.</style></author><author><style face="normal" font="default" size="100%">Nagao, M.</style></author><author><style face="normal" font="default" size="100%">Hirosawa, K.</style></author><author><style face="normal" font="default" size="100%">Akasaki, Y.</style></author><author><style face="normal" font="default" size="100%">Murakami, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Department of Digital Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Department of Strategic Operating Room Management and Improvement, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Department of Hospital Administration, Juntendo University Graduate School of Medicine, Tokyo, Japan.&#xD;Precision Health, Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.&#xD;Department of Health Services Research, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan.&#xD;Department of Ophthalmology, Juntendo University Urayasu Hospital, Chiba, Japan.&#xD;Department of Public Policy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.&#xD;Department of Medical Technology Innovation Center, Juntendo University, Tokyo, Japan.&#xD;Department of Otorhinolaryngology, International University of Health and Welfare, Chiba, Japan.&#xD;Department of Orthopedic Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan.&#xD;Graduate School of Health and Sports Science, Juntendo University, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Symptom-based stratification for hay fever: A crowdsourced study using the smartphone application AllerSearch</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3820-3824</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/09/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Crowdsourcing</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mobile Applications</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Smartphone</style></keyword><keyword><style face="normal" font="default" size="100%">ResearchKit</style></keyword><keyword><style face="normal" font="default" size="100%">hay fever</style></keyword><keyword><style face="normal" font="default" size="100%">mobile health</style></keyword><keyword><style face="normal" font="default" size="100%">smartphone application</style></keyword><keyword><style face="normal" font="default" size="100%">stratification</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34480802</style></accession-num><notes><style face="normal" font="default" size="100%">Inomata, Takenori&#xD;Nakamura, Masahiro&#xD;Iwagami, Masao&#xD;Sung, Jaemyoung&#xD;Ebihara, Nobuyuki&#xD;Fujisawa, Kumiko&#xD;Muto, Kaori&#xD;Nojiri, Shuko&#xD;Ide, Takuma&#xD;Okano, Mitsuhiro&#xD;Okumura, Yuichi&#xD;Fujio, Kenta&#xD;Fujimoto, Keiichi&#xD;Nagao, Masashi&#xD;Hirosawa, Kunihiko&#xD;Akasaki, Yasutsugu&#xD;Murakami, Akira&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3820-3824. doi: 10.1111/all.15078. Epub 2021 Sep 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34480802</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15078</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>469</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">469</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Santamaria, R.</style></author><author><style face="normal" font="default" size="100%">Bogas, G.</style></author><author><style face="normal" font="default" size="100%">Montanez, M. I.</style></author><author><style face="normal" font="default" size="100%">Ariza, A.</style></author><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Cespedes, J. A.</style></author><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Paris, J. L.</style></author><author><style face="normal" font="default" size="100%">Perez-Sanchez, N.</style></author><author><style face="normal" font="default" size="100%">Perez-Inestrosa, E.</style></author><author><style face="normal" font="default" size="100%">Vida, Y.</style></author><author><style face="normal" font="default" size="100%">Fernandez, T. D.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA-ARADyAL, Malaga, Spain.&#xD;Departmento de Medicina, Universidad de Malaga-UMA, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga-HRUM, Malaga, Spain.&#xD;Departamento de Quimica Organica, Universidad de Malaga-UMA, Malaga, Spain.&#xD;Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Centro Andaluz de Nanomedicina y Biotecnologia-BIONAND, Malaga, Spain.&#xD;Departamento de Biologia Celular, Genetica y Fisiologia, Universidad de Malaga-UMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Synthetic antigenic determinants of clavulanic acid induce dendritic cell maturation and specific T cell proliferation in patients with immediate hypersensitivity reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3070-3083</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/05/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Amoxicillin</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">Clavulanic Acid/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Epitopes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">antigenic determinants</style></keyword><keyword><style face="normal" font="default" size="100%">clavulanic acid</style></keyword><keyword><style face="normal" font="default" size="100%">immediate drug hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default" size="100%">maturation</style></keyword><keyword><style face="normal" font="default" size="100%">proliferation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35611454</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Immediate drug hypersensitivity reactions (IDHRs) to clavulanic acid (CLV) have increased in the last decades due to a higher consumption alongside amoxicillin (AX). Due to its chemical instability, diagnostic procedures to evaluate IDHRs to CLV are difficult, and current in vitro assays do not have an optimal sensitivity. The inclusion of the specific metabolites after CLV degradation, which are efficiently recognised by the immune system, could help to improve sensitivity of in vitro tests. METHODS: Recognition by dendritic cells (DCs) of CLV and the synthetic analogues of two of its hypothesised antigenic determinants (ADs) was evaluated by flow cytometry in 27 allergic patients (AP) and healthy controls (HC). Their ability to trigger the proliferation of T cells was also analysed by flow cytometry. RESULTS: The inclusion of synthetic analogues of CLV ADs, significantly increased the expression of maturation markers on DCs from AP compared to HC. A different recognition pattern could be observed with each AD, and, therefore, the inclusion of both ADs achieves an improved sensitivity. The addition of synthetic ADs analogues increased the proliferative response of CD4(+) Th2 compared to the addition of native CLV. The combination of results from both ADs increased the sensitivity of proliferative assays from 19% to 65% with a specificity higher than 90%. CONCLUSIONS: Synthetic ADs from CLV are efficiently recognised by DCs with ability to activate CD4(+) Th2 cells from AP. The combination of analogues from both ADs, significantly increased the sensitivity of DC maturation and T-cell proliferation compared to native CLV.</style></abstract><notes><style face="normal" font="default" size="100%">Fernandez-Santamaria, Ruben&#xD;Bogas, Gador&#xD;Montanez, Maria Isabel&#xD;Ariza, Adriana&#xD;Salas, Maria&#xD;Cespedes, Jose Antonio&#xD;Labella, Marina&#xD;Paris, Juan Luis&#xD;Perez-Sanchez, Natalia&#xD;Perez-Inestrosa, Ezequiel&#xD;Vida, Yolanda&#xD;Fernandez, Tahia D&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3070-3083. doi: 10.1111/all.15383. Epub 2022 Jun 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35611454</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9796838</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15383</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2297</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2297</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Riggioni, C.</style></author><author><style face="normal" font="default" size="100%">Ricci, C.</style></author><author><style face="normal" font="default" size="100%">Moya, B.</style></author><author><style face="normal" font="default" size="100%">Wong, D.</style></author><author><style face="normal" font="default" size="100%">van Goor, E.</style></author><author><style face="normal" font="default" size="100%">Bartha, I.</style></author><author><style face="normal" font="default" size="100%">Buyuktiryaki, B.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Jayasinghe, S.</style></author><author><style face="normal" font="default" size="100%">Jaumdally, H.</style></author><author><style face="normal" font="default" size="100%">Marques-Mejias, A.</style></author><author><style face="normal" font="default" size="100%">Piletta-Zanin, A.</style></author><author><style face="normal" font="default" size="100%">Berbenyuk, A.</style></author><author><style face="normal" font="default" size="100%">Andreeva, M.</style></author><author><style face="normal" font="default" size="100%">Levina, D.</style></author><author><style face="normal" font="default" size="100%">Iakovleva, E.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Chu, D.</style></author><author><style face="normal" font="default" size="100%">Peters, R.</style></author><author><style face="normal" font="default" size="100%">du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Skypala, I.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.&#xD;Khoo Teck Puat-National University Children&apos;s Medical Institute, National University Hospital, National University Health System, Singapore City, Singapore.&#xD;Africa Unit for Transdisciplinary Health Research (AUTHeR), North-WEst University, Potchefstroom, South Africa.&#xD;Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain.&#xD;Instituto de Investigacion Sanitaria, Hospital 12 de Octubre (imas12), Madrid, Spain.&#xD;Department of Women and Children&apos;s Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, London, UK.&#xD;Elkerliek Hospital, Helmond, The Netherlands.&#xD;Children&apos;s Allergy Service, Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Division of Pediatric Allergy, Department of Pediatrics, Koc University School of Medicine, Istanbul, Turkey.&#xD;Allergy Unit, Meyer Children&apos;s Hospital IRCCS, Florence, Italy.&#xD;Department of Health Sciences, University of Florence, Florence, Italy.&#xD;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Division of Pediatric Specialties, Department of Women, Children and Adolescents, Geneva University Hospitals, Geneva, Switzerland.&#xD;Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child&apos;s Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.&#xD;Clinical and Experimental Sciences and Human Development in Health, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Newport, UK.&#xD;Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;Murdoch Children&apos;s Research Institute Melbourne, Melbourne, Victoria, Australia.&#xD;Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.&#xD;National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Department of Allergy &amp; Clinical Immunology, Royal Brompton &amp; Harefield NHS Foundation Trust, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systematic review and meta-analyses on the accuracy of diagnostic tests for IgE-mediated food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">324-352</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/11/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Egg Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostic Tests, Routine</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-mediated</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">component-resolved diagnostics</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostic tests</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">skin prick test</style></keyword><keyword><style face="normal" font="default" size="100%">specific IgE</style></keyword><keyword><style face="normal" font="default" size="100%">specificity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38009299</style></accession-num><abstract><style face="normal" font="default" size="100%">The European Academy of Allergy and Clinical Immunology (EAACI) is updating the Guidelines on Food Allergy Diagnosis. We aimed to undertake a systematic review of the literature with meta-analyses to assess the accuracy of diagnostic tests for IgE-mediated food allergy. We searched three databases (Cochrane CENTRAL (Trials), MEDLINE (OVID) and Embase (OVID)) for diagnostic test accuracy studies published between 1 October 2012 and 30 June 2021 according to a previously published protocol (CRD42021259186). We independently screened abstracts, extracted data from full texts and assessed risk of bias with QUADRAS 2 tool in duplicate. Meta-analyses were undertaken for food-test combinations for which three or more studies were available. A total of 149 studies comprising 24,489 patients met the inclusion criteria and they were generally heterogeneous. 60.4% of studies were in children &lt;/=12 years of age, 54.3% were undertaken in Europe, &gt;/=95% were conducted in a specialized paediatric or allergy clinical setting and all included oral food challenge in at least a percentage of enrolled patients, in 21.5% double-blind placebo-controlled food challenges. Skin prick test (SPT) with fresh cow&apos;s milk and raw egg had high sensitivity (90% and 94%) for milk and cooked egg allergies. Specific IgE (sIgE) to individual components had high specificity: Ara h 2-sIgE had 92%, Cor a 14-sIgE 95%, Ana o 3-sIgE 94%, casein-sIgE 93%, ovomucoid-sIgE 92/91% for the diagnosis of peanut, hazelnut, cashew, cow&apos;s milk and raw/cooked egg allergies, respectively. The basophil activation test (BAT) was highly specific for the diagnosis of peanut (90%) and sesame (93%) allergies. In conclusion, SPT and specific IgE to extracts had high sensitivity whereas specific IgE to components and BAT had high specificity to support the diagnosis of individual food allergies.</style></abstract><notes><style face="normal" font="default" size="100%">Riggioni, Carmen&#xD;Ricci, Cristian&#xD;Moya, Beatriz&#xD;Wong, Dominic&#xD;van Goor, Evi&#xD;Bartha, Irene&#xD;Buyuktiryaki, Betul&#xD;Giovannini, Mattia&#xD;Jayasinghe, Sashini&#xD;Jaumdally, Hannah&#xD;Marques-Mejias, Andreina&#xD;Piletta-Zanin, Alexandre&#xD;Berbenyuk, Anna&#xD;Andreeva, Margarita&#xD;Levina, Daria&#xD;Iakovleva, Ekaterina&#xD;Roberts, Graham&#xD;Chu, Derek&#xD;Peters, Rachel&#xD;du Toit, George&#xD;Skypala, Isabel&#xD;Santos, Alexandra F&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MC_PC_18052/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 Feb;79(2):324-352. doi: 10.1111/all.15939. Epub 2023 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38009299</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15939</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2501</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2501</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vassilopoulou, E.</style></author><author><style face="normal" font="default" size="100%">Comotti, A.</style></author><author><style face="normal" font="default" size="100%">Douladiris, N.</style></author><author><style face="normal" font="default" size="100%">Konstantinou, GNu</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Alberti, I.</style></author><author><style face="normal" font="default" size="100%">Agostoni, C.</style></author><author><style face="normal" font="default" size="100%">Berni Canani, R.</style></author><author><style face="normal" font="default" size="100%">Bocsan, I. C.</style></author><author><style face="normal" font="default" size="100%">Corsello, A.</style></author><author><style face="normal" font="default" size="100%">De Cosmi, V.</style></author><author><style face="normal" font="default" size="100%">Feketea, G.</style></author><author><style face="normal" font="default" size="100%">Laitinen, K.</style></author><author><style face="normal" font="default" size="100%">Mazzocchi, A.</style></author><author><style face="normal" font="default" size="100%">Monzani, N. A.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Peroni, D. G.</style></author><author><style face="normal" font="default" size="100%">Pitsios, C.</style></author><author><style face="normal" font="default" size="100%">Roth-Walter, F.</style></author><author><style face="normal" font="default" size="100%">Skypala, I.</style></author><author><style face="normal" font="default" size="100%">Tsabouri, S.</style></author><author><style face="normal" font="default" size="100%">Baldeh, A. K.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Milani, G. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece.&#xD;Pediatric Area, Fondazione IRCCS Ca&apos; Granda-Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Occupational Medicine Unit, Fondazione IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.&#xD;Institute of Allergology, Charite - Universitatsmedizin Berlin, Berlin, Germany.&#xD;Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany.&#xD;Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy.&#xD;Department of Translational Medical Science, University of Naples &quot;Federico II&quot;, Naples, Italy.&#xD;Department of Pharmacology, Toxicology and Clinical Pharmacology, &quot;luliu Hatieganu&quot; University of Medicine and Pharmacy, Cluj-Napoca, Romania.&#xD;Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanita - Italian National Institute of Health, Rome, Italy.&#xD;Department of Pediatrics, &quot;Karamandaneio&quot; Children&apos;s Hospital of Patra, Patras, Greece.&#xD;Faculty of Medicine, Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology and Nutrition and Food Research Center, University of Turku, Turku, Finland.&#xD;Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Medical School, University of Cyprus, Nicosia, Cyprus.&#xD;Department of Interdisciplinary Life Sciences, Messerli Research Institute, University of Veterinary Medicine, Vienna, Austria.&#xD;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Royal Brompton &amp; Harefield Hospitals, Part of Guys &amp; St Thomas NHS Foundation Trust, London, UK.&#xD;Department of Inflammation &amp; Repaid, Imperial College of London, London, UK.&#xD;Child Health Department, University of Ioannina School of Medicine, Ioannina, Greece.&#xD;Department of Public Health and Community Medicine, Sahlgrenska Academy, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.&#xD;APC Microbiome Ireland, Department of Medicine, School of Microbiology, University College Cork, Cork, Ireland.&#xD;Pediatric Allergy and Clinical Immunology, Children&apos;s Hospital Colorado/University of Colorado, Aurora, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A systematic review and meta-analysis of nutritional and dietary interventions in randomized controlled trials for skin symptoms in children with atopic dermatitis and without food allergy: An EAACI task force report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1708-1724</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/05/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diet therapy/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Prebiotics/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">childhood</style></keyword><keyword><style face="normal" font="default" size="100%">diet</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">nutrient</style></keyword><keyword><style face="normal" font="default" size="100%">oils</style></keyword><keyword><style face="normal" font="default" size="100%">postbiotics</style></keyword><keyword><style face="normal" font="default" size="100%">prebiotics</style></keyword><keyword><style face="normal" font="default" size="100%">probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">synbiotics</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38783644</style></accession-num><abstract><style face="normal" font="default" size="100%">This systematic review and meta-analysis aimed to consolidate evidence on dietary interventions for atopic eczema/dermatitis (AD) skin symptoms in children without food allergies, following PRISMA 2020 guidelines. Systematic review updates were conducted in May 2022 and June 2023, focusing on randomized placebo-controlled trials (RCTs) involving children with AD but without food allergies. Specific diets or supplements, such as vitamins, minerals, probiotics, prebiotics, symbiotics, or postbiotics, were explored in these trials. Exclusions comprised descriptive studies, systematic reviews, meta-analyses, letters, case reports, studies involving elimination diets, and those reporting on food allergens in children and adolescents. Additionally, studies assessing exacerbation of AD due to food allergy/sensitization and those evaluating elimination diets&apos; effects on AD were excluded. Nutritional supplementation studies were eligible regardless of sensitization profile. Evaluation of their impact on AD clinical expression was performed using SCORAD scores, and a meta-analysis of SCORAD outcomes was conducted using random-effect models (CRD42022328702). The review encompassed 27 RCTs examining prebiotics, Vitamin D, evening primrose oil, and substituting cow&apos;s milk formula with partially hydrolyzed whey milk formula. A meta-analysis of 20 RCTs assessing probiotics, alone or combined with prebiotics, revealed a significant reduction in SCORAD scores, suggesting a consistent trend in alleviating AD symptoms in children without food allergies. Nonetheless, evidence for other dietary interventions remains limited, underscoring the necessity for well-designed intervention studies targeting multiple factors to understand etiological interactions and propose reliable manipulation strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Vassilopoulou, Emilia&#xD;Comotti, Anna&#xD;Douladiris, Nikolaos&#xD;Konstantinou, George Nu&#xD;Zuberbier, Torsten&#xD;Alberti, Ilaria&#xD;Agostoni, Carlo&#xD;Berni Canani, Roberto&#xD;Bocsan, Ioana Corina&#xD;Corsello, Antonio&#xD;De Cosmi, Valentina&#xD;Feketea, Gavriela&#xD;Laitinen, Kirsi&#xD;Mazzocchi, Alessandra&#xD;Monzani, Nicola A&#xD;Papadopoulos, Nikolaos G&#xD;Peroni, Diego G&#xD;Pitsios, Constantinos&#xD;Roth-Walter, Franziska&#xD;Skypala, Isabel&#xD;Tsabouri, Sophia&#xD;Baldeh, Abdoulie K&#xD;O&apos;Mahony, Liam&#xD;Venter, Carina&#xD;Milani, Gregorio Paolo&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1708-1724. doi: 10.1111/all.16160. Epub 2024 May 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38783644</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16160</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3092</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3092</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rosser, S. A.</style></author><author><style face="normal" font="default" size="100%">Lloyd, M.</style></author><author><style face="normal" font="default" size="100%">Tang, P.</style></author><author><style face="normal" font="default" size="100%">Walsh, A. M.</style></author><author><style face="normal" font="default" size="100%">Peters, R. L.</style></author><author><style face="normal" font="default" size="100%">Wijesuriya, R.</style></author><author><style face="normal" font="default" size="100%">Hornung, C. J.</style></author><author><style face="normal" font="default" size="100%">Koplin, J. J.</style></author><author><style face="normal" font="default" size="100%">Karahalios, A.</style></author><author><style face="normal" font="default" size="100%">Tang, M. L. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Immunology, Murdoch Children&apos;s Research Institute, Parkville, Australia.&#xD;Department of Paediatrics, The University of Melbourne, Parkville, Australia.&#xD;National Allergy Centre of Excellence (NACE), Parkville, Australia.&#xD;Health Economics and Policy Evaluation Research Group, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.&#xD;Population Allergy, Murdoch Children&apos;s Research Institute, Parkville, Australia.&#xD;Centre for Food Allergy Research, Murdoch Children&apos;s Research Institute, Parkville, Australia.&#xD;Clinical Epidemiology and Biostatistics Unit, Murdoch Children&apos;s Research Institute, Parkville, Australia.&#xD;Child Health Research Centre, The University of Queensland, Brisbane, Australia.&#xD;Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, Australia.&#xD;Department of Allergy and Immunology, Royal Children&apos;s Hospital, Parkville, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systematic Review and Meta-Analysis of Oral Immunotherapy Effect on Food Allergy-Related Quality of Life</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2767-2780</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">shares/options in Prota Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">is a member of the Medical Advisory Board</style></keyword><keyword><style face="normal" font="default" size="100%">of Allergy &amp; Anaphylaxis Australia</style></keyword><keyword><style face="normal" font="default" size="100%">is a member of the Board of Directors of Asia</style></keyword><keyword><style face="normal" font="default" size="100%">Pacific Association of Allergy Asthma and Clinical Immunology, AllergyPal and</style></keyword><keyword><style face="normal" font="default" size="100%">Prota Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">is a member of expert committees of the American Academy of</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy, Asthma &amp; Immunology, Asia Pacific Association of Allergy Asthma and</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Immunology, Australasian Society of Clinical Immunology and Allergy, and</style></keyword><keyword><style face="normal" font="default" size="100%">World Allergy Organisation. J.J.K. and R.L.P. have received a prize from the</style></keyword><keyword><style face="normal" font="default" size="100%">Stallergenes Greer Foundation paid to their institution outside the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work and R.L.P. received speaker fees from Stallergenes Greer, outside the</style></keyword><keyword><style face="normal" font="default" size="100%">submitted work. M.L. has received consulting fees from the National Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Centre of Excellence Australia. M.L.K.T. and M.L. were investigators on the</style></keyword><keyword><style face="normal" font="default" size="100%">PPOIT-001 and/or PPOIT-003 randomised trials that were included in this review,</style></keyword><keyword><style face="normal" font="default" size="100%">with contributions to the conduct, analysis and publication of findings. As such,</style></keyword><keyword><style face="normal" font="default" size="100%">these authors were not included in the process of determining</style></keyword><keyword><style face="normal" font="default" size="100%">inclusion/exclusion, data extraction, or risk of bias assessments in relation to</style></keyword><keyword><style face="normal" font="default" size="100%">any publications related to these trials. The other authors declare no relevant</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts of interest for this work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40919791</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Uncertainty exists regarding the health-related quality of life (HRQL) benefits of food allergen oral immunotherapy (OIT). Up-to-date meta-analyses incorporating HRQL data from recent randomised trials are lacking. METHODS: Systematic searches of MEDLINE, Embase, CENTRAL and Google Scholar were conducted for food OIT randomised trials (versus any comparator) that measured HRQL with a validated instrument (27 July 2023). Hedges&apos; g standardised mean differences in HRQL between OIT and comparator were analysed by allergen, reporting perspective, and treatment/post-treatment periods, and synthesised using random-effects meta-analysis models when results from multiple trials were available. RESULTS: Ten trials (nine peanut, one baked milk; N = 1330) were included. No between-group differences were observed in parent-reported child HRQL (g = -0.07, 95% CI: -0.19 to 0.04, 9 trials, N = 1259), self-reported child HRQL (g = -0.23, 95% CI: -0.73 to 0.27, 5 trials, N = 435), or self-reported teenager HRQL (g = 0.00, 95% CI: -0.41 to 0.40, 3 trials, N = 209) during peanut OIT treatment. However, 12 months post-treatment, improved parent-reported child HRQL was observed (g = -0.51, 95% CI: -0.84 to -0.19, 3 comparisons from 2 trials, N = 213). No between-group differences were observed in the baked milk OIT trial in children (g = 0.118, 95% CI: -0.63 to 0.87, N = 26). CONCLUSION: HRQL benefits were observed after OIT protocol completion, with limited evidence of benefit during active treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Rosser, Sophie A&#xD;Lloyd, Melanie&#xD;Tang, Ping&#xD;Walsh, Audrey M&#xD;Peters, Rachel L&#xD;Wijesuriya, Rushani&#xD;Hornung, Catherine J&#xD;Koplin, Jennifer J&#xD;Karahalios, Amalia&#xD;Tang, Mimi L K&#xD;eng&#xD;Australian Commonwealth Government Research Training Program (RTP)/&#xD;National Allergy Centre of Excellence (NACE) Postgraduate Scholarship/&#xD;Centre for Food Allergy Research Postdoctoral Fellowship/&#xD;Victorian Government&apos;s Operational Infrastructure Program/&#xD;Meta-Analysis&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2767-2780. doi: 10.1111/all.70046. Epub 2025 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40919791</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486368</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70046</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2387</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2387</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Milani, G. P.</style></author><author><style face="normal" font="default" size="100%">Alberti, I.</style></author><author><style face="normal" font="default" size="100%">Abodi, M.</style></author><author><style face="normal" font="default" size="100%">Lakoumentas, J.</style></author><author><style face="normal" font="default" size="100%">Konstantinou, G. N.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Pop, R. M.</style></author><author><style face="normal" font="default" size="100%">Bocsan, I. C.</style></author><author><style face="normal" font="default" size="100%">Cassimos, D.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author><author><style face="normal" font="default" size="100%">Bettocchi, S.</style></author><author><style face="normal" font="default" size="100%">Corsello, A.</style></author><author><style face="normal" font="default" size="100%">Cugliari, M.</style></author><author><style face="normal" font="default" size="100%">Ciliberti, L.</style></author><author><style face="normal" font="default" size="100%">Spolidoro, G. C. I.</style></author><author><style face="normal" font="default" size="100%">Agostoni, C.</style></author><author><style face="normal" font="default" size="100%">Vlieg Boerstra, B.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Vassilopoulou, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Unit, Foundation IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Department of Clinical Science and Community Health, University of Milan, Milan, Italy.&#xD;Department of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece.&#xD;Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.&#xD;Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.&#xD;Department of Pharmacology, Toxicology and Clinical Pharmacology, &quot;Iuliu Hatieganu&quot; University of Medicine and Pharmacy, Cluj Napoca, Romania.&#xD;Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.&#xD;Department of Clinical Science and Education Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Sachs&apos; Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.&#xD;Department of Pediatrics, OLVG Hospital, Amsterdam, The Netherlands.&#xD;Rijnstate Allergy Centre, Rijnstate Hospital, Arnhem, The Netherlands.&#xD;Section of Allergy and Immunology, Department of Pediatrics, Children&apos;s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Department of Medicine and School of Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A systematic review and meta-analysis on nutritional and dietary interventions for the treatment of acute respiratory infection in pediatric patients: An EAACI taskforce</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1687-1707</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/01/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="default" size="100%">*Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamins/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">acute respiratory tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">childhood</style></keyword><keyword><style face="normal" font="default" size="100%">diet</style></keyword><keyword><style face="normal" font="default" size="100%">nutrients</style></keyword><keyword><style face="normal" font="default" size="100%">supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38174413</style></accession-num><abstract><style face="normal" font="default" size="100%">Acute respiratory infections are a major cause of morbidity and mortality in children worldwide. Dietary and nutritional interventions, including minerals and vitamin supplementation, have been explored as potential treatments for these infections. However, the evidence on their efficacy is limited and inconclusive. This systematic review and meta-analysis aim to provide a comprehensive summary of the available evidence on the effectiveness of dietary and nutritional interventions for treating acute respiratory tract infections in children. A systematic review was conducted according to the PRISMA 2020 guidelines in April 2022 and updated in April 2023. Clinical trials focusing on dietary or nutritional interventions, including supplementations, in children with acute respiratory tract infections were included. The selection of interventions and outcomes was based on biological plausibility. Data were extracted using a standardized form, and the risk of bias was assessed using the Cochrane Risk of Bias Tool. Meta-analysis was performed using random-effect models. A total of 50 studies were included in the review. Four trials were conducted in low, 32 in lower-middle, 12 in upper-middle, and only two in high-income countries. The studies evaluated various dietary interventions, including zinc, vitamin A, vitamin E, vitamin D, and probiotics. The results of individual studies on the efficacy of these interventions were mixed, with some showing positive effects on clinical outcomes such as duration of symptoms, while others showed no significant impact. Meta-analysis was conducted for zinc supplementation in children with pneumonia, and the pooled results suggested a potential limited benefit in terms of reduced hospital length of stay but not time to recovery. Meta-analyses on vitamin D did not show any effect in children with pneumonia. This systematic review fills a critical gap in the literature by synthesizing the available evidence on the efficacy and safety of nutritional or dietary interventions for acute respiratory tract infections in children. The findings indicate no dietary or nutritional intervention can currently be recommended for the routine treatment of respiratory tract infections in children based on single supplement studies. The metanalysis suggests that zinc supplementation might have a beneficial effect on length of hospitalization in children with pneumonia. New studies are needed to establish more conclusive evidence for pediatric acute respiratory diseases especially for children living in a context of high-income countries.</style></abstract><notes><style face="normal" font="default" size="100%">Milani, Gregorio P&#xD;Alberti, Ilaria&#xD;Abodi, Martina&#xD;Lakoumentas, John&#xD;Konstantinou, George N&#xD;Papadopoulos, Nikolaos G&#xD;Pop, Raluca M&#xD;Bocsan, Ioana C&#xD;Cassimos, Dimitrios&#xD;Kull, Inger&#xD;Bettocchi, Silvia&#xD;Corsello, Antonio&#xD;Cugliari, Marco&#xD;Ciliberti, Letizia&#xD;Spolidoro, Giulia C I&#xD;Agostoni, Carlo&#xD;Vlieg Boerstra, Berber&#xD;Venter, Carina&#xD;O&apos;Mahony, Liam&#xD;Vassilopoulou, Emilia&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1687-1707. doi: 10.1111/all.15997. Epub 2024 Jan 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38174413</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15997</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3198</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3198</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rossi, C. M.</style></author><author><style face="normal" font="default" size="100%">Terreehorst, I.</style></author><author><style face="normal" font="default" size="100%">Apostolidou, E.</style></author><author><style face="normal" font="default" size="100%">Votto, M.</style></author><author><style face="normal" font="default" size="100%">Bakirtas, A.</style></author><author><style face="normal" font="default" size="100%">Cianferroni, A.</style></author><author><style face="normal" font="default" size="100%">Konstantinou, G. N.</style></author><author><style face="normal" font="default" size="100%">Pantavou, K.</style></author><author><style face="normal" font="default" size="100%">Antolin-Amerigo, D.</style></author><author><style face="normal" font="default" size="100%">Heffler, E.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Perea, A.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rivas, M.</style></author><author><style face="normal" font="default" size="100%">Nikolopoulos, G. K.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Pitsios, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, IRCCS San Matteo Hospital Foundation, Pavia, Italy.&#xD;Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.&#xD;ENT Department, Amsterdam University Medical Centre, Amsterdam, the Netherlands.&#xD;Department of Internal Medicine, &quot;Hippocrateion&quot; General Hospital of Thessaloniki, Thessaloniki, Greece.&#xD;Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.&#xD;Department of Pediatric Allergy, Faculty of Medicine, Gazi University, Ankara, Turkiye.&#xD;Children&apos;s Hospital of Philadelphia, University of Pennsylvania Medical School, Philadelphia, Pennsylvania, USA.&#xD;Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.&#xD;Medical School, University of Cyprus, Nicosia, Cyprus.&#xD;Allergy Department, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Madrid, Spain.&#xD;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.&#xD;Personalized Medicine, Asthma and Allergy, Humanitas Research Hospital, Rozzano, Italy.&#xD;Allergy Service, Hospital General Universitario Gregorio Maranon, Madrid, Spain.&#xD;Allergy Department, Hospital Clinico San Carlos, Madrid, Spain.&#xD;Facultad de Medicina, Universidad Complutense, IdISSC, ARADyAL, Madrid, Spain.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Allergy Outpatient Clinic, General Hospital of Nicosia, Nicosia, Cyprus.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Systematic Review and Meta-Analysis on the Induction of Confirmed Eosinophilic Esophagitis as a Side Effect of Allergen Immunotherapy: An EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">food desensitization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 16</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41403138</style></accession-num><abstract><style face="normal" font="default" size="100%">The European Academy of Allergy and Clinical Immunology (EAACI) established a Task Force to assess the existing data on the relationship between eosinophilic esophagitis (EoE) and allergen immunotherapy (AIT). This systematic review and meta-analysis aimed to study the incidence of confirmed EoE, developing as a side effect of AIT to food or airborne allergens, following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines. The literature search was performed in three databases (PubMed, Embase and Scopus). Databases were searched from inception to March 31st, 2023. A total of 17 studies met the criteria for inclusion in the review. Fifteen studies, comprising 3,302 patients, were on food desensitization, and the overall estimate of EoE incidence, combining the results of these individual studies, was 2.31% (95% CI 1.45, 3.36). Registered data reported de novo cases of eosinophilic esophagitis, and its diagnosis was usually made during the maintenance phase of food desensitization. With the adopted searching strategy, only two studies on sublingual immunotherapy with aeroallergens meeting the inclusion criteria were retrieved, comprising 1,436 patients and not reporting cases of EoE. The meta-analysis showed that the development of EoE is a common adverse effect of oral immunotherapy with food allergens, whereas it is uncommon during sublingual immunotherapy with aeroallergens. Trial Registration: PROSPERO: CRD42023425917.</style></abstract><notes><style face="normal" font="default" size="100%">Rossi, Carlo Maria&#xD;Terreehorst, Ingrid&#xD;Apostolidou, Evaggelia&#xD;Votto, Martina&#xD;Bakirtas, Arzu&#xD;Cianferroni, Antonella&#xD;Konstantinou, George N&#xD;Pantavou, Katerina&#xD;Antolin-Amerigo, Dario&#xD;Heffler, Enrico&#xD;Alvarez-Perea, Alberto&#xD;Fernandez-Rivas, Montserrat&#xD;Nikolopoulos, Georgios K&#xD;Pfaar, Oliver&#xD;Pitsios, Constantinos&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Dec 16. doi: 10.1111/all.70183.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41403138</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70183</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3155</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3155</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, D.</style></author><author><style face="normal" font="default" size="100%">Shu, L.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Yan, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of New Medicine and Diagnostic Technology Research for Nasal Disease, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China.&#xD;Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.&#xD;Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Systematic Review of Multidimensional Predictors for Refractory Chronic Rhinosinusitis: Clinical, Systemic and Local Insights</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/11/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">clinical characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">multi-marker panel</style></keyword><keyword><style face="normal" font="default" size="100%">refractory chronic rhinosinusitis with nasal polyps</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41251197</style></accession-num><abstract><style face="normal" font="default" size="100%">The identification of predictive markers for refractory chronic rhinosinusitis with nasal polyps (RCRSwNP) is essential for advancing precision medicine. In this review, we systematically reviewed the literature on the predictive value of clinical characteristics and biomarkers for RCRSwNP, aiming to better understand current findings and support medical therapy for these patients. PubMed, EMBASE, The Cochrane Library, and Web of Science were searched from data inception until June 2024. The titles and abstracts of 6934 publications were screened, and finally, 54 eligible studies encompassing 450 markers, with categories including clinical characteristics, biomarkers, and multi-marker panels (combinations of multiple markers to predict outcomes of CRSwNP) were evaluated. Data extraction and quality control were performed by two authors independently. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool was used to assess the risk of bias of included studies. Markers were categorized by specimen type (systemic [in blood] vs. local [in nasal polyp tissues vs. in noninvasive samplings]) and analysis method (receiver operating characteristic-based vs. group comparison-based). Most markers demonstrated satisfactory diagnostic performance. Among demographic and clinical characteristics, the E/M ratio showed the highest diagnostic accuracy (area under the curve [AUC] = 0.947). Biomarkers derived from nasal polyp tissues-particularly Charcot-Leyden crystals (CLCs), and eosinophil counts or percentages, achieved high AUCs (up to 0.973). Noninvasive local markers, including cystatin SN and galectin-10 protein levels in nasal secretions and CLC mRNA levels in nasal brushings, also showed strong predictive potential (AUCs &gt; 0.930). Over 90% of the multi-marker panels that integrated multiple markers demonstrated moderate to high predictive accuracy (AUCs &gt; 0.700). This systematic review highlights critical predictors and their implications for the diagnosis and management of RCRSwNP, and emphasizes the need for standardized methodologies, larger cohorts, and validation studies to refine the predictive utility of these markers. Future advances in multi-omics technologies and noninvasive sampling methods may further enhance the precision of RCRSwNP prediction, paving the way for improved therapeutic strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Wu, Di&#xD;Shu, Linping&#xD;Wang, Chengshuo&#xD;Wang, Xiaomo&#xD;Zhang, Luo&#xD;Yan, Bing&#xD;eng&#xD;IRT13082/Changjiang Scholar Program, Ministry of Education/&#xD;Z211100002921057/Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park/&#xD;2022YFC2504100/National Key Research and Development Program of China/&#xD;82371115/National Natural Science Foundation of China/&#xD;82171108/National Natural Science Foundation of China/&#xD;82025010/National Natural Science Foundation of China/&#xD;82201252/National Natural Science Foundation of China/&#xD;CFH2022-1-1091/Capital&apos;s Funds for Health Improvement and Research/&#xD;YGLX202303/Beijing Municipal Administration of Hospitals&apos; Yangfan plan/&#xD;A2306/Talent Program of Capital Medical University/&#xD;Lingjunrencai-02-09/Special Funds for the Construction of High-level Public Health Technical Talents/&#xD;JYY2021-2/Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes/&#xD;JYY2023-1/Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes/&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Nov 18. doi: 10.1111/all.70155.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41251197</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70155</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>743</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">743</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Proctor, K. B.</style></author><author><style face="normal" font="default" size="100%">Tison, K.</style></author><author><style face="normal" font="default" size="100%">H. Estrem H</style></author><author><style face="normal" font="default" size="100%">Park, J.</style></author><author><style face="normal" font="default" size="100%">Scahill, L.</style></author><author><style face="normal" font="default" size="100%">Vickery, B. P.</style></author><author><style face="normal" font="default" size="100%">Sharp, W. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Children&apos;s Healthcare of Atlanta, Atlanta, GA, USA.&#xD;Emory University, Atlanta, GA, USA.&#xD;University of North Carolina Wilmington, Wilmington, NC, USA.&#xD;Boston College, Chestnut Hill, MA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A systematic review of parent report measures assessing the psychosocial impact of food allergy on patients and families</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1347-1359</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/10/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">food hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34647344</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Reducing the psychosocial impact of food allergy (FA) represents a top patient-centered research priority. This priority recognizes that psychosocial impact is an important outcome of current FA therapies (eg, oral immunotherapy), as well as interventions aimed at improving overall quality of life and illness adaptation. Reliable and valid measurement is a necessary prerequisite to developing and evaluating current and emerging FA therapies and potential changes in psychosocial impact. METHODS: In this systematic review, we applied the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to evaluate available parent report measures assessing the psychosocial impact of pediatric IgE-mediated FA. RESULTS: The systematic search yielded 64 articles involving 13 unique measures. Measures were evaluated through the lens of the Patient Reported Outcomes Measurement Information System (PROMIS) guidelines. Findings indicated that available measures show some evidence of reliability and validity; however, none completely adhere to PROMIS guidelines for measure development. CONCLUSION: Results highlight a continued need to dedicate research to develop a measurement approach that assesses the full range of psychosocial impact that parents and families may experience as a result of FA, as well as serve as a research outcome as the field continues to develop effective treatments, including immunotherapy.</style></abstract><notes><style face="normal" font="default" size="100%">Proctor, Kaitlin B&#xD;Tison, Katherine&#xD;H Estrem, Hayley&#xD;Park, Jinhee&#xD;Scahill, Lawrence&#xD;Vickery, Brian P&#xD;Sharp, William G&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1347-1359. doi: 10.1111/all.15140. Epub 2021 Oct 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34647344</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15140</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1216</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1216</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kaegi, C.</style></author><author><style face="normal" font="default" size="100%">Steiner, U. C.</style></author><author><style face="normal" font="default" size="100%">Wuest, B.</style></author><author><style face="normal" font="default" size="100%">Crowley, C.</style></author><author><style face="normal" font="default" size="100%">Boyman, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2673-2683</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2020/12/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immune System Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Lupus Erythematosus, Systemic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">B cell</style></keyword><keyword><style face="normal" font="default" size="100%">B cell-activating factor</style></keyword><keyword><style face="normal" font="default" size="100%">Sjogren&apos;s syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">belimumab</style></keyword><keyword><style face="normal" font="default" size="100%">immune-mediated disease</style></keyword><keyword><style face="normal" font="default" size="100%">monoclonal antibody</style></keyword><keyword><style face="normal" font="default" size="100%">rheumatoid arthritis</style></keyword><keyword><style face="normal" font="default" size="100%">systemic lupus erythematosus</style></keyword><keyword><style face="normal" font="default" size="100%">vasculitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33368349</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Biologic agents (also termed biologics or biologicals) are becoming increasingly important in the treatment of immune-mediated diseases. However, the diversity of clinical trials along with the fast pace of publication makes it difficult to determine the level of evidence for the use of a biologic for a given disorder. To address this challenge, we are publishing a series of systematic reviews evaluating the safety and efficacy of B cell-targeting biologics for the treatment of immune-mediated diseases. In this article, we have assessed the safety and efficacy of belimumab, a fully human IgG1 monoclonal antibody targeting the cytokine B cell-activating factor (BAFF). OBJECTIVE: To evaluate belimumab&apos;s safety and efficacy for the treatment of immune-mediated disorders compared to placebo, conventional treatment or other biologics. METHODS: The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) checklist guided the reporting of the data. We searched the PubMed database between October 4, 2016, and June 23, 2019, concentrating on immune-mediated disorders. RESULTS: The literature search identified 583 articles. After screening titles and abstracts against the inclusion and exclusion criteria and assessing full texts, 17 articles were finally included in a narrative synthesis. CONCLUSIONS: Belimumab is both safe and effective for the treatment of systemic lupus erythematosus. Results were further promising for the use of belimumab in patients with rheumatoid arthritis and Sjogren&apos;s syndrome. Conversely, results using belimumab in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and myasthenia gravis were rather disappointing.</style></abstract><notes><style face="normal" font="default" size="100%">Kaegi, Celine&#xD;Steiner, Urs C&#xD;Wuest, Benjamin&#xD;Crowley, Catherine&#xD;Boyman, Onur&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2673-2683. doi: 10.1111/all.14704. Epub 2020 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33368349</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14704</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2396</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2396</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sasaki, M.</style></author><author><style face="normal" font="default" size="100%">Suaini, N. H. A.</style></author><author><style face="normal" font="default" size="100%">Afghani, J.</style></author><author><style face="normal" font="default" size="100%">Heye, K. N.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Venter, C.</style></author><author><style face="normal" font="default" size="100%">Lauener, R.</style></author><author><style face="normal" font="default" size="100%">Frei, R.</style></author><author><style face="normal" font="default" size="100%">Roduit, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Children&apos;s Hospital Zurich, Zurich, Switzerland.&#xD;Division of Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, University of Bern, Bern, Switzerland.&#xD;Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.&#xD;Environmental Medicine Faculty of Medicine, University of Augsburg, Augsburg, Germany.&#xD;ZIEL-Institute for Food and Health, Technical University of Munich, Freising, Germany.&#xD;Institute of Environmental Medicine, Environmental Health Centre, Helmholtz Munich - German Research Centre for Environmental Health (GmbH), Neuherberg, Germany.&#xD;Children&apos;s Hospital of Eastern Switzerland, St. Gallen, Switzerland.&#xD;Department of Medicine, University College Cork, National University of Ireland, Cork, Ireland.&#xD;APC Microbiome Ireland, University College Cork, National University of Ireland, Cork, Ireland.&#xD;School of Microbiology, University College Cork, National University of Ireland, Cork, Ireland.&#xD;Pediatric Allergy and Immunology, University of Colorado/Childrens Hospital Colorado, Aurora, Colorado, USA.&#xD;Christine Kuhne Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Biomedical Research, University of Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systematic review of the association between short-chain fatty acids and allergic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1789-1811</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/02/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Fatty Acids, Volatile/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">allergic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">butyrate</style></keyword><keyword><style face="normal" font="default" size="100%">gut microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">propionate</style></keyword><keyword><style face="normal" font="default" size="100%">short chain fatty acids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38391245</style></accession-num><abstract><style face="normal" font="default" size="100%">We performed a systematic review to investigate the current evidence on the association between allergic diseases and short chain fatty acids (SCFAs), which are microbially produced and suggested as one mechanism on how gut microbiome affects the risk of allergic diseases. Medline, Embase and Web of Science were searched from data inception until September 2022. We identified 37 papers, of which 17 investigated prenatal or early childhood SCFAs and the development of allergic diseases in childhood, and 20 assessed SCFAs in patients with pre-existing allergic diseases. Study design, study populations, outcome definition, analysis method and reporting of the results varied between papers. Overall, there was some evidence showing that the three main SCFAs (acetate, propionate and butyrate) in the first few years of life had a protective effect against allergic diseases, especially for atopic dermatitis, wheeze or asthma and IgE-mediated food allergy in childhood. The association between each SCFA and allergic disease appeared to be different by disease and the age of assessment. Further research that can determine the potentially timing specific effect of each SCFA will be useful to investigate how SCFAs can be used in treatment or in prevention against allergic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Sasaki, Mari&#xD;Suaini, Noor H A&#xD;Afghani, Jamie&#xD;Heye, Kristina N&#xD;O&apos;Mahony, Liam&#xD;Venter, Carina&#xD;Lauener, Roger&#xD;Frei, Remo&#xD;Roduit, Caroline&#xD;eng&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1789-1811. doi: 10.1111/all.16065. Epub 2024 Feb 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38391245</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16065</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1291</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1291</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Asero, R.</style></author><author><style face="normal" font="default" size="100%">Ariano, R.</style></author><author><style face="normal" font="default" size="100%">Aruanno, A.</style></author><author><style face="normal" font="default" size="100%">Barzaghi, C.</style></author><author><style face="normal" font="default" size="100%">Borrelli, P.</style></author><author><style face="normal" font="default" size="100%">Busa, M.</style></author><author><style face="normal" font="default" size="100%">Celi, G.</style></author><author><style face="normal" font="default" size="100%">Cinquini, M.</style></author><author><style face="normal" font="default" size="100%">Cortellini, G.</style></author><author><style face="normal" font="default" size="100%">D&apos;Auria, F.</style></author><author><style face="normal" font="default" size="100%">De Carli, M.</style></author><author><style face="normal" font="default" size="100%">Di Paolo, C.</style></author><author><style face="normal" font="default" size="100%">Garzi, G.</style></author><author><style face="normal" font="default" size="100%">Lodi Rizzini, F.</style></author><author><style face="normal" font="default" size="100%">Magnani, M.</style></author><author><style face="normal" font="default" size="100%">Manzotti, G.</style></author><author><style face="normal" font="default" size="100%">Marra, A.</style></author><author><style face="normal" font="default" size="100%">Miceli Sopo, S.</style></author><author><style face="normal" font="default" size="100%">Murzilli, F.</style></author><author><style face="normal" font="default" size="100%">Nucera, E.</style></author><author><style face="normal" font="default" size="100%">Pinter, E.</style></author><author><style face="normal" font="default" size="100%">Pravettoni, V.</style></author><author><style face="normal" font="default" size="100%">Rivolta, F.</style></author><author><style face="normal" font="default" size="100%">Rizzi, A.</style></author><author><style face="normal" font="default" size="100%">Saporiti, N.</style></author><author><style face="normal" font="default" size="100%">Scala, E.</style></author><author><style face="normal" font="default" size="100%">Villalta, D.</style></author><author><style face="normal" font="default" size="100%">Yacoub, M. R.</style></author><author><style face="normal" font="default" size="100%">Zisa, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ambulatorio di Allergologia, Clinica san Carlo, Paderno Dugnano (MI), Italia.&#xD;Private Practice, Liguria, Italy.&#xD;Fondazione Policlinico Universitario A. Gemelli- IRCCS Universita Cattolica del Sacro Cuore, Roma, Italy.&#xD;Ambulatorio di Allergologia, UOC Medicina, ASST Rhodenese, P.O Rho, Rho, Italia.&#xD;SSD Dermatologia e Allergologia - Ospedale Beauregard, Aosta, Italia.&#xD;Ambulatorio di Allergologia U.O.S. Dermatologia Ospedale di Mirano (VE), Mirano, Italia.&#xD;Ambulatorio di Allergologia Ospedale di Bassano del Grappa (VI), Bassano del Grappa, Italia.&#xD;Clinica Villa Pia, Roma, Italy.&#xD;SSVD Allergologia, Spedali Civili Brescia, Italia.&#xD;UOD Allergologia, Az Sanitaria della Romagna, Rimini, Italia.&#xD;ASST Bergamo Ovest, Bergamo, Italia.&#xD;S.O.C Medicina 2, Presidio Ospedaliero &quot;Santa Maria della Misericordia&quot;, Udine, Italy.&#xD;Ambulatorio di Allergologia, UOC Medicina Interna ed Immunologia Clinica, Policlinico Umberto I, Roma, Italia.&#xD;Dipartimento Scienze Cliniche e Sperimentali, Universita Studi Brescia / SSVD Allergologia, Spedali Civili Brescia, Italy.&#xD;Allergologia U.O.C.P.S. AUSL Bologna, Bologna, Italia.&#xD;Ambulatorio di Allergologia, Casa di Cura Beato Palazzolo, Bergamo, Italia.&#xD;Pediatric Allergy Unit, Pediatrics Area, Department of Life Sciences and Public Health, Policlinico Gemelli Fondazione Universitaria IRCCS, Universita Cattolica del Sacro Cuore, Roma, Italia.&#xD;U.O.S.D. di Allergologia, Ospedale S.S. Filippo e Nicola, Avezzano (AQ), Italy.&#xD;UOC General Medicine Immunology and Allergology - IRCCS Foudation Ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Italy.&#xD;Istituto Dermopatico dell&apos;Immacolata, Rome, Italy.&#xD;Immunologia e Allergologia, Ospedale S. Maria degli Angeli, Pordenone, Italia.&#xD;S.S. Allergologia e Immunologia Clinica, S.C.D.U. Medicina Interna I - A.O.U. Maggiore della Carita di Novara, Novara, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systemic allergic reactions induced by labile plant-food allergens: Seeking potential cofactors. A multicenter study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1473-1479</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2020/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Proteins/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">pollen allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33080053</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Heat-and-pepsin-sensitive plant food allergens (PR-10 and profilin) sometimes cause systemic reaction. OBJECTIVE: To detect the risk factors for systemic reactions induced by labile food allergens. METHODS: A retrospective multicenter study was performed on patients with a documented history of systemic allergic reaction to labile plant food allergens and on age-matched controls with a history of oral allergy syndrome (OAS) induced by the same foods. Offending foods, their amount, and state (solid or liquid), and potential cofactors (nonsteroidal anti-inflammatory drugs, protonic pump inhibitors, exercise, alcohol, and fasting) were considered. RESULTS: We studied 89 patients and 81 controls. Sensitization to PR-10 or profilin, IgE to Bet v 1 and/or Bet v 2, and foods causing OAS were similar in the two groups. Twenty patients experienced &gt;1 systemic allergic reaction. Tree nuts, Rosaceae, Apiaceae, and soymilk were the main offending foods. Seventeen (19%) patients were taking a PPI when the systemic reaction occurred (vs 5% in controls; P &lt; .025). The ingestion of the offending food in liquid form (soymilk) was frequent among patients (15%) but unusual among controls (2%; P &lt; .025). Soy milk-induced systemic reactions were independent of PPI treatment. Fasting and excess of allergen, but not NSAID and exercise, were other relevant cofactors for systemic reactions. Systemic reactions occurred without any identifiable cofactor in 39 (44%) cases. CONCLUSION: PR-10- and profilin-induced systemic reactions are facilitated by PPI, ingestion of large amounts of unprocessed foods, and fasting. Soybean beverages represent a risk for PR-10 hypersensitive patients and should be avoided.</style></abstract><notes><style face="normal" font="default" size="100%">Asero, Riccardo&#xD;Ariano, Renato&#xD;Aruanno, Arianna&#xD;Barzaghi, Claudio&#xD;Borrelli, Paolo&#xD;Busa, Moira&#xD;Celi, Giorgio&#xD;Cinquini, Massimo&#xD;Cortellini, Gabriele&#xD;D&apos;Auria, Francesca&#xD;De Carli, Marco&#xD;Di Paolo, Camilla&#xD;Garzi, Giulia&#xD;Lodi Rizzini, Fabio&#xD;Magnani, Monica&#xD;Manzotti, Giuseppina&#xD;Marra, Alessandro&#xD;Miceli Sopo, Stefano&#xD;Murzilli, Francesco&#xD;Nucera, Eleonora&#xD;Pinter, Elena&#xD;Pravettoni, Valerio&#xD;Rivolta, Federica&#xD;Rizzi, Angela&#xD;Saporiti, Nicoletta&#xD;Scala, Enrico&#xD;Villalta, Danilo&#xD;Yacoub, Mona-Rita&#xD;Zisa, Giuliana&#xD;eng&#xD;Multicenter Study&#xD;Denmark&#xD;Allergy. 2021 May;76(5):1473-1479. doi: 10.1111/all.14634. Epub 2020 Nov 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33080053</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14634</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>65</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">65</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ndika, J.</style></author><author><style face="normal" font="default" size="100%">Suojalehto, H.</style></author><author><style face="normal" font="default" size="100%">Lindstrom, I.</style></author><author><style face="normal" font="default" size="100%">Airaksinen, L.</style></author><author><style face="normal" font="default" size="100%">Wisgrill, L.</style></author><author><style face="normal" font="default" size="100%">Alenius, H.</style></author><author><style face="normal" font="default" size="100%">Karisola, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Human Microbiome Research Program, University of Helsinki, Helsinki, Finland.&#xD;Occupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland.&#xD;Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.&#xD;Institute of Environmental Medicine (IMM), Karolinska Institutet, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systemic gene signature of inhaled corticosteroid treatment in allergic asthma to flour</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">592-595</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/12/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Flour</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36453834</style></accession-num><notes><style face="normal" font="default" size="100%">Ndika, Joseph&#xD;Suojalehto, Hille&#xD;Lindstrom, Irmeli&#xD;Airaksinen, Liisa&#xD;Wisgrill, Lukas&#xD;Alenius, Harri&#xD;Karisola, Piia&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):592-595. doi: 10.1111/all.15605. Epub 2022 Dec 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36453834</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15605</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2553</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2553</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, Q.</style></author><author><style face="normal" font="default" size="100%">Jia, J.</style></author><author><style face="normal" font="default" size="100%">Lin, H.</style></author><author><style face="normal" font="default" size="100%">Liang, D.</style></author><author><style face="normal" font="default" size="100%">Chen, H.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Gao, X.</style></author><author><style face="normal" font="default" size="100%">Liao, W.</style></author><author><style face="normal" font="default" size="100%">Chen, G.</style></author><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Zhou, Q.</style></author><author><style face="normal" font="default" size="100%">Bai, J.</style></author><author><style face="normal" font="default" size="100%">Xie, Z.</style></author><author><style face="normal" font="default" size="100%">Shan, L.</style></author><author><style face="normal" font="default" size="100%">Zhu, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.&#xD;Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central South University, Changsha, China.&#xD;Department of Allergy, The Affiliated Hospital of Qingdao University, Qingdao, China.&#xD;Department of Allergy, Chengdu First People&apos;s Hospital, Chengdu, China.&#xD;Department of Pediatrics, Foshan Maternal and Children&apos;s Hospital, Foshan, China.&#xD;Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.&#xD;National Clinical Research Center for Geriatric Disorders, Xiangya Hospital of Central South University, Changsha, China.&#xD;Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systemic reactions to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis and/or asthma: A real-life, multi-center study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1506-1508</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/07/26</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39056450</style></accession-num><notes><style face="normal" font="default" size="100%">Xu, Qingxiu&#xD;Jia, Jiaxin&#xD;Lin, Hang&#xD;Liang, Dan&#xD;Chen, Hao&#xD;Wang, Yin&#xD;Gao, Xiang&#xD;Liao, Wang&#xD;Chen, Guohua&#xD;Yang, Lihong&#xD;Zhou, Qianlan&#xD;Bai, Jun&#xD;Xie, Zhihai&#xD;Shan, Lishen&#xD;Zhu, Rongfei&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1506-1508. doi: 10.1111/all.16254. Epub 2024 Jul 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39056450</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105055</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16254</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1294</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1294</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Siegels, D.</style></author><author><style face="normal" font="default" size="100%">Heratizadeh, A.</style></author><author><style face="normal" font="default" size="100%">Abraham, S.</style></author><author><style face="normal" font="default" size="100%">Binnmyr, J.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Irvine, A. D.</style></author><author><style face="normal" font="default" size="100%">Halken, S.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Flohr, C.</style></author><author><style face="normal" font="default" size="100%">Schmid-Grendelmeier, P.</style></author><author><style face="normal" font="default" size="100%">Van der Poel, L. A.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Weidinger, S.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author><author><style face="normal" font="default" size="100%">Schmitt, J.</style></author><author><style face="normal" font="default" size="100%">European Academy of Allergy, Clinical Immunology Atopic Dermatitis Guideline group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Evidence-Based Healthcare, University Hospital Dresden, Dresden, Germany.&#xD;Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy Hannover Medical School, Hannover, Germany.&#xD;Department of Dermatology, Medical Faculty Carl Gustav Carus, University Allergy Center, TU Dresden, Dresden, Germany.&#xD;The Swedish Asthma- and Allergy Association, Stockholm, Sweden.&#xD;The Swedish Asthma- and Allergy Research Foundation, Stockholm, Sweden.&#xD;Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.&#xD;Department of Clinical Medicine, Trinity College Dublin, Ireland.&#xD;Dermatology, Children&apos;s Health Ireland, National Children&apos;s Research Centre, Dublin, Ireland.&#xD;Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Odense, Denmark.&#xD;Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.&#xD;Unit for Population-Based Dermatology Research, St John&apos;s Institute of Dermatology, Guy&apos;s &amp; St Thomas&apos; NHS Foundation Trust and King&apos;s College London, London, UK.&#xD;Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich.&#xD;Christine-Kuehne Center for Allergy Research and Education CK_CARE, Davos, Switzerland.&#xD;Department of Paediatric Allergy, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, UK.&#xD;Department of Woman and Child Health, Food Allergy Referral Centre, Padua University Hospital, Padua, Italy.&#xD;Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1053-1076</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/10/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Cutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclosporine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33074565</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: As an evidence resource for the currently planned European Academy of Allergy and Clinical Immunology (EAACI) clinical practice guideline &quot;systemic treatment of atopic dermatitis (AD),&quot; we critically appraised evidence on systemic treatments for moderate-to-severe AD. METHODS: We systematically identified randomized controlled trials (RCTs) investigating the safety and efficacy of systemic treatments for AD up to February 2020. Primary efficacy outcomes were clinical signs, AD symptoms and health-related quality of life. Primary safety outcomes included cumulative incidence rates for (serious) adverse events. Trial quality was assessed applying the Cochrane Risk of Bias Tool 2.0. Meta-analyses were conducted where appropriate. RESULTS: 50 RCTs totalling 6681 patients were included. Trial evidence was identified for apremilast, azathioprine (AZA), baricitinib, ciclosporin A (CSA), corticosteroids, dupilumab, interferon-gamma, intravenous immunoglobulins (IVIG), mepolizumab, methotrexate (MTX), omalizumab, upadacitinib and ustekinumab. Meta-analyses were indicated for the efficacy of baricitinib [EASI75 RD 0.16, 95% CI (0.10;0.23)] and dupilumab [EASI75, RD 0.37, 95% CI (0.32;0.42)] indicating short-term (ie 16-week treatment) superiority over placebo. Furthermore, efficacy analyses of AZA and CSA indicated short-term superiority over placebo; however, nonvalidated scores were used and can therefore not be compared to EASI. CONCLUSION: The most robust, replicated high-quality trial evidence is present for the efficacy and safety of dupilumab for up to 1 year in adults. Robust trial evidence was further revealed for AZA, baricitinib and CSA. Methodological restrictions led to limited evidence-based conclusions for all other systemic treatments. Head-to-head trials with novel systemic treatments are required to clarify the future role of conventional therapies.</style></abstract><notes><style face="normal" font="default" size="100%">Siegels, Doreen&#xD;Heratizadeh, Annice&#xD;Abraham, Susanne&#xD;Binnmyr, Jonas&#xD;Brockow, Knut&#xD;Irvine, Alan D&#xD;Halken, Susanne&#xD;Mortz, Charlotte G&#xD;Flohr, Carsten&#xD;Schmid-Grendelmeier, Peter&#xD;Van der Poel, Lauri-Ann&#xD;Muraro, Antonella&#xD;Weidinger, Stephan&#xD;Werfel, Thomas&#xD;Schmitt, Jochen&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1053-1076. doi: 10.1111/all.14631. Epub 2020 Nov 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33074565</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14631</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3023</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3023</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jafari, M.</style></author><author><style face="normal" font="default" size="100%">Hjalmarsson, E.</style></author><author><style face="normal" font="default" size="100%">Paziou, E.</style></author><author><style face="normal" font="default" size="100%">Petro, M.</style></author><author><style face="normal" font="default" size="100%">Karlsson, A.</style></author><author><style face="normal" font="default" size="100%">Winqvist, O.</style></author><author><style face="normal" font="default" size="100%">Kumlien Georen, S.</style></author><author><style face="normal" font="default" size="100%">Cardell, L. O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of ENT Diseases, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Otorhinolaryngology, Karolinska University Hospital, Stockholm, Sweden.&#xD;ABC Labs, Biomedicum, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">T Cell Subsets Are Altered Off Season in Patients With Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3438-3440</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/08/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">ENT (rhinitis, sinusitis, nasal polyps...)</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">basic mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy and tolerance induction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40847674</style></accession-num><notes><style face="normal" font="default" size="100%">Jafari, Maryam&#xD;Hjalmarsson, Eric&#xD;Paziou, Eirini&#xD;Petro, Marianne&#xD;Karlsson, Agnetha&#xD;Winqvist, Ola&#xD;Kumlien Georen, Susanna&#xD;Cardell, Lars-Olaf&#xD;eng&#xD;Center for Innovative Medicine (CIMED), Karolinska Institutet/&#xD;Konsul Berghs Stiftelse/&#xD;ALF funding from Region Stockholm/&#xD;Vetenskapsradet/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3438-3440. doi: 10.1111/all.16668. Epub 2025 Aug 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40847674</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666747</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16668</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>346</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">346</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gallais Serezal, I.</style></author><author><style face="normal" font="default" size="100%">Tajpara, P.</style></author><author><style face="normal" font="default" size="100%">Schonfeldt, T.</style></author><author><style face="normal" font="default" size="100%">Ignatov, B.</style></author><author><style face="normal" font="default" size="100%">Sortebech, D.</style></author><author><style face="normal" font="default" size="100%">Hoffer, E.</style></author><author><style face="normal" font="default" size="100%">Zhang, T.</style></author><author><style face="normal" font="default" size="100%">Rooijackers, E.</style></author><author><style face="normal" font="default" size="100%">Ehrstrom, M.</style></author><author><style face="normal" font="default" size="100%">Nylen, S.</style></author><author><style face="normal" font="default" size="100%">Matura, M.</style></author><author><style face="normal" font="default" size="100%">Melican, K.</style></author><author><style face="normal" font="default" size="100%">Eidsmo, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.&#xD;PO Rheumatology/Dermatology/Gastroenterology, Karolinska University Hospital, Stockholm, Sweden.&#xD;INSERM UMR 1098, Besancon, France.&#xD;Leo Foundation Skin Immunology Center, Department of Microbiology and Immunology, Copenhagen University, Copenhagen, Denmark.&#xD;Department of Neuroscience, Karolinska Institutet, Solna, Sweden.&#xD;AIMES-Center for the Advancement of Integrated Medical and Engineering Sciences, Karolinska Institutet and KTH Royal Institute of Technology, Stockholm, Sweden.&#xD;Department of Reconstructive Plastic Surgery, Karolinska University Hospital Solna, Stockholm, Sweden.&#xD;Nordiska Kliniken, Stockholm, Sweden.&#xD;Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Solna, Sweden.&#xD;Department of Dermatology, Skaraborgs sjukhus Skovde, Skovde, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">T cells in resolved allergic contact dermatitis steer tissue inflammation and MMP-12-driven tissue modulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3680-3683</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/08/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Matrix Metalloproteinase 12</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35984563</style></accession-num><notes><style face="normal" font="default" size="100%">Gallais Serezal, Irene&#xD;Tajpara, Poojabahen&#xD;Schonfeldt, Trine&#xD;Ignatov, Borislav&#xD;Sortebech, Daniel&#xD;Hoffer, Elena&#xD;Zhang, Tianqi&#xD;Rooijackers, Elin&#xD;Ehrstrom, Marcus&#xD;Nylen, Susanne&#xD;Matura, Mihaly&#xD;Melican, Keira&#xD;Eidsmo, Liv&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3680-3683. doi: 10.1111/all.15484. Epub 2022 Sep 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35984563</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10086995</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15484</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2750</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2750</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vaher, H.</style></author><author><style face="normal" font="default" size="100%">Gadsboll, A. O.</style></author><author><style face="normal" font="default" size="100%">Seibel, A. T.</style></author><author><style face="normal" font="default" size="100%">Kongsbak-Wismann, M.</style></author><author><style face="normal" font="default" size="100%">Lohmann, R. K. D.</style></author><author><style face="normal" font="default" size="100%">Mraz, V.</style></author><author><style face="normal" font="default" size="100%">Funch, A. B.</style></author><author><style face="normal" font="default" size="100%">Jee, M. H.</style></author><author><style face="normal" font="default" size="100%">Odum, N.</style></author><author><style face="normal" font="default" size="100%">Woetmann, A.</style></author><author><style face="normal" font="default" size="100%">Geisler, C.</style></author><author><style face="normal" font="default" size="100%">Bonefeld, C. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">T Cells Induce Prolonged Downregulation of Barrier Molecules in a Mouse Model of Allergic Contact Dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1956-1966</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/12/14 20:06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact/immunology/metabolism/etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Keratinocytes/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*CD8-Positive T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Down-Regulation</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Interferon-gamma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Dinitrofluorobenzene</style></keyword><keyword><style face="normal" font="default" size="100%">CD8+ T cells</style></keyword><keyword><style face="normal" font="default" size="100%">IFN-gamma</style></keyword><keyword><style face="normal" font="default" size="100%">allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier molecules</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39673368</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dysfunction of the skin barrier is regarded as a key event in the initiation and progression of inflammatory skin diseases. In many cases of allergic contact dermatitis (ACD), epidermal-resident memory CD8(+) T (T(RM)) cells play a central role in the immune response to contact allergens. However, if and how allergen-specific CD8(+) T(RM) cells affect the expression of skin barrier molecules is not known. METHODS: The expression level of skin barrier molecules was determined by RT-qPCR and immunofluorescence in a mouse model of ACD. The role of CD8(+) T cells on the expression of skin barrier molecules was investigated by depletion of CD8(+) cells. Human primary keratinocytes were used to assess the direct effect of IFN-gamma and contact allergen on their expression of skin barrier molecules. RESULTS: Sensitization with the contact allergen 1-fluoro-2,4-dinitrobenzene (DNFB) resulted in epidermal accumulation of CD8(+) T(RM) cells and prolonged upregulation of Ifng and downregulation of keratin 5 (Krt5) and Krt14 even after complete macroscopic remission of the inflammatory response. Challenge with DNFB lead to an additionally rapid downregulation of Krt5 and Krt14 and the downregulation of several other skin barrier molecules. Depletion of CD8(+) cells abolished both the prolonged and rapid downregulation of skin barrier molecules. In keratinocytes, IFN-gamma and contact allergen synergistically down-regulated the expression of KRT5 and KRT14. CONCLUSION: CD8(+) T(RM) cells contribute to a prolonged reduction in the expression of skin barrier molecules, which might exacerbate allergen permeation and the inflammatory response during succeeding exposures of the skin to allergens and antigens.</style></abstract><notes><style face="normal" font="default" size="100%">Vaher, Helen&#xD;Gadsboll, Anne-Sofie O&#xD;Seibel, Alexandra T&#xD;Kongsbak-Wismann, Martin&#xD;Lohmann, Rebecca K D&#xD;Mraz, Veronika&#xD;Funch, Anders B&#xD;Jee, Mia H&#xD;Odum, Niels&#xD;Woetmann, Anders&#xD;Geisler, Carsten&#xD;Bonefeld, Charlotte M&#xD;eng&#xD;The LEO Foundation/&#xD;Danmarks Frie Forskningsfond/&#xD;European Academy of Dermatology and Venereology/&#xD;Eesti Teadusagentuur/&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1956-1966. doi: 10.1111/all.16421. Epub 2024 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39673368</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16421</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>679</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">679</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jansen, K.</style></author><author><style face="normal" font="default" size="100%">Satitsuksanoa, P.</style></author><author><style face="normal" font="default" size="100%">Wirz, O. F.</style></author><author><style face="normal" font="default" size="100%">Schneider, S. R.</style></author><author><style face="normal" font="default" size="100%">van de Veen, W.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Message, S. D.</style></author><author><style face="normal" font="default" size="100%">Kebadze, T.</style></author><author><style face="normal" font="default" size="100%">Glanville, N.</style></author><author><style face="normal" font="default" size="100%">Mallia, P.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Moniuszko, M.</style></author><author><style face="normal" font="default" size="100%">Johnston, S. L.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Functional Genomics Center Zurich, ETH Zurich/University of Zurich, Zurich, Switzerland.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.&#xD;Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">T regulatory cells from atopic asthmatic individuals show a Th2-like phenotype</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1320-1324</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34862792</style></accession-num><notes><style face="normal" font="default" size="100%">Jansen, Kirstin&#xD;Satitsuksanoa, Pattraporn&#xD;Wirz, Oliver F&#xD;Schneider, Stephan R&#xD;van de Veen, Willem&#xD;Tan, Ge&#xD;Sokolowska, Milena&#xD;Message, Simon D&#xD;Kebadze, Tatiana&#xD;Glanville, Nicholas&#xD;Mallia, Patrick&#xD;Akdis, Cezmi A&#xD;Moniuszko, Marcin&#xD;Johnston, Sebastian L&#xD;Nadeau, Kari&#xD;Akdis, Mubeccel&#xD;eng&#xD;063717/WT_/Wellcome Trust/United Kingdom&#xD;083567/Z/07/Z/WT_/Wellcome Trust/United Kingdom&#xD;DH_/Department of Health/United Kingdom&#xD;G1000758/MRC_/Medical Research Council/United Kingdom&#xD;U19 AI104209/AI/NIAID NIH HHS/&#xD;U01 AI140498/AI/NIAID NIH HHS/&#xD;R01 AI140134/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1320-1324. doi: 10.1111/all.15193. Epub 2021 Dec 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34862792</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15193</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1116</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salas, M.</style></author><author><style face="normal" font="default" size="100%">Berciano-Guerrero, M. A.</style></author><author><style face="normal" font="default" size="100%">Palomares, F.</style></author><author><style face="normal" font="default" size="100%">Rueda, A.</style></author><author><style face="normal" font="default" size="100%">Fernandez, T. D.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Allergy Clinical Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;Unidad de Gestion Clinica Intercentros de Oncologia Medica. Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Centro Andaluz de Nanomedicina y Biotecnologia-BIONAND, Malaga, Spain.&#xD;Medicine Department, Universidad de Malaga-UMA, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">T-cell changes induced by desensitisation to BRAF inhibitors in two patients with DRESS</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2285-2288</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity Syndrome/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Kinase Inhibitors/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Proto-Oncogene Proteins B-raf/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33682162</style></accession-num><notes><style face="normal" font="default" size="100%">Salas, Maria&#xD;Berciano-Guerrero, Miguel-Angel&#xD;Palomares, Francisca&#xD;Rueda, Antonio&#xD;Fernandez, Tahia D&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;eng&#xD;Case Reports&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2285-2288. doi: 10.1111/all.14807. Epub 2021 Mar 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33682162</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14807</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2421</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2421</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez-Pons, A.</style></author><author><style face="normal" font="default" size="100%">Teodosio, C.</style></author><author><style face="normal" font="default" size="100%">Jara-Acevedo, M.</style></author><author><style face="normal" font="default" size="100%">Henriques, A.</style></author><author><style face="normal" font="default" size="100%">Navarro-Navarro, P.</style></author><author><style face="normal" font="default" size="100%">Garcia-Montero, A. C.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Twose, I.</style></author><author><style face="normal" font="default" size="100%">Lecrevisse, Q.</style></author><author><style face="normal" font="default" size="100%">Fluxa, R.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Munoz, L.</style></author><author><style face="normal" font="default" size="100%">Caldas, C.</style></author><author><style face="normal" font="default" size="100%">Pozo, J.</style></author><author><style face="normal" font="default" size="100%">Martin, S.</style></author><author><style face="normal" font="default" size="100%">Sanfeliciano, T. C.</style></author><author><style face="normal" font="default" size="100%">Pedreira, C. E.</style></author><author><style face="normal" font="default" size="100%">Botafogo, V.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Lopez, O.</style></author><author><style face="normal" font="default" size="100%">Mayado, A.</style></author><author><style face="normal" font="default" size="100%">Orfao, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine and Cytometry Service (NUCLEUS), Cancer Research Center (IBMCC, USAL-CSIC), Universidad de Salamanca, Salamanca, Spain.&#xD;Biomedical Research Networking Center Consortium (CIBERONC; CB16/12/00400), Madrid, Spain.&#xD;Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain.&#xD;Spanish Network on Mastocytosis (REMA), Toledo, Salamanca, Spain.&#xD;Sequencing Service (NUCLEUS), Universidad de Salamanca, Salamanca, Spain.&#xD;Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Virgen del Valle Hospital, CIBERONC, Toledo, Madrid, Spain.&#xD;Cytognos SL, Salamanca, Spain.&#xD;Department of Biochemistry, University Hospital of Salamanca, Salamanca, Spain.&#xD;Systems and Computing Department (PESC), COPPE, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.&#xD;Department of Hematology and Hemotherapy, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">T-cell immune profile in blood of systemic mastocytosis: Association with disease features</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1921-1937</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/02/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mastocytosis, Systemic/immunology/diagnosis/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocyte Subsets/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Immunophenotyping</style></keyword><keyword><style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-kit/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Killer Cells, Natural/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">cytotoxic T cells</style></keyword><keyword><style face="normal" font="default" size="100%">helper T cells</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">systemic mastocytosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38299742</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Systemic mastocytosis (SM) is a heterogeneous disease characterized by an expansion of KIT-mutated mast cells (MC). KIT-mutated MC display activated features and release MC mediators that might act on the tumour microenvironment and other immune cells. Here, we investigated the distribution of lymphocyte subsets in blood of patients with distinct subtypes of SM and determined its association with other disease features. METHODS: We studied the distribution of TCD4(+) and TCD4(-) cytotoxic cells and their subsets, as well as total NK- and B cells, in blood of 115 SM patients-38 bone marrow mastocytosis (BMM), 67 indolent SM (ISM), 10 aggressive SM (ASM)- and 83 age-matched healthy donors (HD), using spectral flow cytometry and the EuroFlow Immunomonitoring panel, and correlated it with multilineage KIT(D816V), the alpha-tryptasemia genotype (HalphaT) and the clinical manifestations of the disease. RESULTS: SM patients showed decreased counts (vs. HD) of TCD4(-) cytotoxic cells, NK cells and several functional subsets of TCD4(+) cells (total Th1, Th2-effector memory, Th22-terminal effector and Th1-like Tregs), together with increased T-follicular-helper and Th1/Th17-like Treg counts, associated with different immune profiles per diagnostic subtype of SM, in multilineal versus MC-restricted KIT(D816V) and in cases with a HalphaT(+) versus HalphaT(-) genotype. Unique immune profiles were found among BMM and ISM patients with MC-restricted KIT(D816V) who displayed HalphaT, anaphylaxis, hymenoptera venom allergy, bone disease, pruritus, flushing and GI symptoms. CONCLUSION: Our results reveal altered T- and NK-cell immune profiles in blood of SM, which vary per disease subtype, the pattern of involvement of haematopoiesis by KIT(D816V), the HalphaT genotype and specific clinical manifestations of the disease.</style></abstract><notes><style face="normal" font="default" size="100%">Perez-Pons, Alba&#xD;Teodosio, Cristina&#xD;Jara-Acevedo, Maria&#xD;Henriques, Ana&#xD;Navarro-Navarro, Paula&#xD;Garcia-Montero, Andres C&#xD;Alvarez-Twose, Ivan&#xD;Lecrevisse, Quentin&#xD;Fluxa, Rafael&#xD;Sanchez-Munoz, Laura&#xD;Caldas, Carolina&#xD;Pozo, Julio&#xD;Martin, Silvia&#xD;Sanfeliciano, Teresa Contreras&#xD;Pedreira, Carlos E&#xD;Botafogo, Vitor&#xD;Gonzalez-Lopez, Oscar&#xD;Mayado, Andrea&#xD;Orfao, Alberto&#xD;eng&#xD;HORIZON EUROPE Marie Sklodowska-Curie Actions/&#xD;Junta de Castilla y Leon/&#xD;European Regional Development Fund/&#xD;Centro de Investigacion Biomedica en Red de Cancer/&#xD;Instituto de Salud Carlos III/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1921-1937. doi: 10.1111/all.16043. Epub 2024 Feb 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38299742</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16043</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1568</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1568</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author><author><style face="normal" font="default" size="100%">Lodi, L.</style></author><author><style face="normal" font="default" size="100%">Ricci, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Health Sciences, Anna Meyer Children&apos;s University Hospital, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">T-cell immunomodulation by bile acid metabolites</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1833-1834</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/02/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Bile Acids and Salts</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Th17 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Treg cells</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunological disorder</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32037593</style></accession-num><notes><style face="normal" font="default" size="100%">Giovannini, Mattia&#xD;Lodi, Lorenzo&#xD;Ricci, Silvia&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2020 Jul;75(7):1833-1834. doi: 10.1111/all.14223. Epub 2020 Apr 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32037593</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14223</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>576</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">576</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roesner, L. M.</style></author><author><style face="normal" font="default" size="100%">Farag, A. K.</style></author><author><style face="normal" font="default" size="100%">Pospich, R.</style></author><author><style face="normal" font="default" size="100%">Traidl, S.</style></author><author><style face="normal" font="default" size="100%">Werfel, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.&#xD;Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">T-cell receptor sequencing specifies psoriasis as a systemic and atopic dermatitis as a skin-focused, allergen-driven disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2737-2747</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/03/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Differentiation, T-Lymphocyte</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Membrane Glycoproteins</style></keyword><keyword><style face="normal" font="default" size="100%">*Psoriasis</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Antigen, T-Cell/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Lymphocyte Homing</style></keyword><keyword><style face="normal" font="default" size="100%">T cell</style></keyword><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">clone</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35255168</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) and psoriasis represent two of the most common inflammatory skin diseases in developed countries. A hallmark of both diseases is T-cell infiltration into the skin. However, it is still not clarified to what extent these infiltrating T cells are antigen-specific skin-homing T cells or unspecific heterogeneous bystander cells. METHODS: To elucidate this, T cells from lesional skin and from blood of 9 AD and 10 psoriasis patients were compared by receptor (TCR) sequencing. Therefore, peripheral blood mononuclear cells (PBMC) were cell-sorted according to expression of the cutaneous leukocyte antigen (CLA) into skin-homing (CLA(+) ) and non-skin-homing (CLA(-) ) subfractions. Aeroallergen-specific T-cell lines were grown from AD patients&apos; PBMC in parallel. RESULTS: Intra-individual comparison of TCRB CDR3 regions revealed that clonally expanded T cells in skin lesions of both AD and psoriasis patients corresponded to skin-homing circulating T cells. However, in psoriasis patients, these T-cell clones were also detectable to a larger extent among CLA(-) circulating T cells. Up to 28% of infiltrating cells in AD skin were identified as allergen-specific by overlapping TCR sequences. CONCLUSIONS: Our data show that in line with the systemic nature of psoriasis, T-cell clones that infiltrate psoriatic skin lesions do not exclusively possess skin-homing ability and are therefore most probably specific to antigens that are not exclusively expressed or located in the skin. T cells driving AD skin inflammation appear to home nearly exclusively to the skin and are, to a certain extent, specific to aeroallergens.</style></abstract><notes><style face="normal" font="default" size="100%">Roesner, Lennart M&#xD;Farag, Ahmed K&#xD;Pospich, Rebecca&#xD;Traidl, Stephan&#xD;Werfel, Thomas&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2737-2747. doi: 10.1111/all.15272. Epub 2022 Mar 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35255168</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15272</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>501</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">501</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Taeschler, P.</style></author><author><style face="normal" font="default" size="100%">Adamo, S.</style></author><author><style face="normal" font="default" size="100%">Deng, Y.</style></author><author><style face="normal" font="default" size="100%">Cervia, C.</style></author><author><style face="normal" font="default" size="100%">Zurbuchen, Y.</style></author><author><style face="normal" font="default" size="100%">Chevrier, S.</style></author><author><style face="normal" font="default" size="100%">Raeber, M. E.</style></author><author><style face="normal" font="default" size="100%">Hasler, S.</style></author><author><style face="normal" font="default" size="100%">Bachli, E.</style></author><author><style face="normal" font="default" size="100%">Rudiger, A.</style></author><author><style face="normal" font="default" size="100%">Stussi-Helbling, M.</style></author><author><style face="normal" font="default" size="100%">Huber, L. C.</style></author><author><style face="normal" font="default" size="100%">Bodenmiller, B.</style></author><author><style face="normal" font="default" size="100%">Boyman, O.</style></author><author><style face="normal" font="default" size="100%">Nilsson, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.&#xD;Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.&#xD;Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.&#xD;Clinic for Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland.&#xD;Department of Medicine, Limmattal Hospital, Schlieren, Switzerland.&#xD;Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University of Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">T-cell recovery and evidence of persistent immune activation 12 months after severe COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2468-2481</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphopenia/etiology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">follow-up</style></keyword><keyword><style face="normal" font="default" size="100%">recovery</style></keyword><keyword><style face="normal" font="default" size="100%">Stussi-Helbling, Dr. Huber, and Dr. Deng have nothing to disclose. Dr. Adamo</style></keyword><keyword><style face="normal" font="default" size="100%">reports grants from Swiss Academy of Medical Sciences and University of Zurich,</style></keyword><keyword><style face="normal" font="default" size="100%">during the conduct of the study. Dr. Cervia reports grants from Swiss Academy of</style></keyword><keyword><style face="normal" font="default" size="100%">Medical Sciences, during the conduct of the study. Mr. Zurbuchen reports grants</style></keyword><keyword><style face="normal" font="default" size="100%">from Swiss Academy of Medical Sciences, during the conduct of the study. Dr.</style></keyword><keyword><style face="normal" font="default" size="100%">Raeber reports a Young Talents in Clinical Research Project Grant by the Swiss</style></keyword><keyword><style face="normal" font="default" size="100%">Academy of Medical Sciences and the G. &amp; J. Bangerter-Rhyner Foundation, during</style></keyword><keyword><style face="normal" font="default" size="100%">the conduct of the study. Dr. Bodenmiller reports grants from Swiss National</style></keyword><keyword><style face="normal" font="default" size="100%">Science Foundation, grants from Pandemic Fund of the University of Zurich, during</style></keyword><keyword><style face="normal" font="default" size="100%">the conduct of the study. Dr. Boyman reports grants from Swiss National Science</style></keyword><keyword><style face="normal" font="default" size="100%">Foundation, grants from Clinical Research Priority Program of University of</style></keyword><keyword><style face="normal" font="default" size="100%">Zurich, and an Innovation grant of University Hospital Zurich, during the conduct</style></keyword><keyword><style face="normal" font="default" size="100%">of the study. Dr. Nilsson reports grants from Swiss National Science Foundation,</style></keyword><keyword><style face="normal" font="default" size="100%">during the conduct of the study.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35567391</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: T-cell lymphopenia and functional impairment is a hallmark of severe acute coronavirus disease 2019 (COVID-19). How T-cell numbers and function evolve at later timepoints after clinical recovery remains poorly investigated. METHODS: We prospectively enrolled and longitudinally sampled 173 individuals with asymptomatic to critical COVID-19 and analyzed phenotypic and functional characteristics of T cells using flow cytometry, 40-parameter mass cytometry, targeted proteomics, and functional assays. RESULTS: The extensive T-cell lymphopenia observed particularly in patients with severe COVID-19 during acute infection had recovered 6 months after infection, which was accompanied by a normalization of functional T-cell responses to common viral antigens. We detected persisting CD4(+) and CD8(+) T-cell activation up to 12 months after infection, in patients with mild and severe COVID-19, as measured by increased HLA-DR and CD38 expression on these cells. Persistent T-cell activation after COVID-19 was independent of administration of a COVID-19 vaccine post-infection. Furthermore, we identified a subgroup of patients with severe COVID-19 that presented with persistently low CD8(+) T-cell counts at follow-up and exhibited a distinct phenotype during acute infection consisting of a dysfunctional T-cell response and signs of excessive pro-inflammatory cytokine production. CONCLUSION: Our study suggests that T-cell numbers and function recover in most patients after COVID-19. However, we find evidence of persistent T-cell activation up to 12 months after infection and describe a subgroup of severe COVID-19 patients with persistently low CD8(+) T-cell counts exhibiting a dysregulated immune response during acute infection.</style></abstract><notes><style face="normal" font="default" size="100%">Taeschler, Patrick&#xD;Adamo, Sarah&#xD;Deng, Yun&#xD;Cervia, Carlo&#xD;Zurbuchen, Yves&#xD;Chevrier, Stephane&#xD;Raeber, Miro E&#xD;Hasler, Sara&#xD;Bachli, Esther&#xD;Rudiger, Alain&#xD;Stussi-Helbling, Melina&#xD;Huber, Lars C&#xD;Bodenmiller, Bernd&#xD;Boyman, Onur&#xD;Nilsson, Jakob&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2468-2481. doi: 10.1111/all.15372. Epub 2022 Jun 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35567391</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9347640</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15372</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>806</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">806</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kortekaas Krohn, I.</style></author><author><style face="normal" font="default" size="100%">Aerts, J. L.</style></author><author><style face="normal" font="default" size="100%">Breckpot, K.</style></author><author><style face="normal" font="default" size="100%">Goyvaerts, C.</style></author><author><style face="normal" font="default" size="100%">Knol, E.</style></author><author><style face="normal" font="default" size="100%">Van Wijk, F.</style></author><author><style face="normal" font="default" size="100%">Gutermuth, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Vrije Universiteit Brussel (VUB), Skin Immunology &amp; Immune Tolerance (SKIN) Research Group, Brussels, Belgium.&#xD;Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Dermatology, Universitair Ziekenhuis Brussel, Brussels, Belgium.&#xD;Vrije Universiteit Brussel (VUB), Neuro-Aging and Viro-Immunotherapy (NAVI) Research Group, Brussels, Belgium.&#xD;Vrije Universiteit Brussel (VUB), Laboratory for Molecular and Cellular Therapy (LMCT), Department of Biomedical Sciences, Brussels, Belgium.&#xD;Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Department Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">T-cell subsets in the skin and their role in inflammatory skin disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">827-842</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2021/09/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin Diseases/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*T-Lymphocyte Subsets</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">T-cell subsets</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory skin disorders</style></keyword><keyword><style face="normal" font="default" size="100%">skin diseases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34559894</style></accession-num><abstract><style face="normal" font="default" size="100%">T lymphocytes (T cells) are major players of the adaptive immune response. Naive T cells are primed in the presence of cytokines, leading to polarization into distinct T-cell subsets with specific functions. These subsets are classified based on their T-cell receptor profile, expression of transcription factors, surface cytokine and chemokine receptors, and their cytokine production, which together determine their specific function. This review provides an overview of the various T-cell subsets and their function in several inflammatory skin disorders ranging from allergic inflammation to skin tumors. Moreover, we highlight similarities of T-cell responses across different skin disorders, demonstrating the presence of similar and opposing functions for the different T-cell subsets. Finally, we discuss the effects of currently available and promising therapeutic approaches to harness T cells in inflammatory skin diseases for which efficacy next to unwanted side effects provide new insights into the pathophysiology of skin disorders.</style></abstract><notes><style face="normal" font="default" size="100%">Kortekaas Krohn, Inge&#xD;Aerts, Joeri L&#xD;Breckpot, Karine&#xD;Goyvaerts, Cleo&#xD;Knol, Edward&#xD;Van Wijk, Femke&#xD;Gutermuth, Jan&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Mar;77(3):827-842. doi: 10.1111/all.15104. Epub 2021 Oct 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34559894</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15104</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>868</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">868</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Murai-Yamamura, M.</style></author><author><style face="normal" font="default" size="100%">Garcet, S.</style></author><author><style face="normal" font="default" size="100%">Yamamura, K.</style></author><author><style face="normal" font="default" size="100%">Gonzalez, J.</style></author><author><style face="normal" font="default" size="100%">Miura, S.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Hur, H.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY, USA.&#xD;Department of Dermatology, Icahn School of Medicine at the Mount Sinai Medical Center, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">T(H) 2 cytokines and Staphylococcus aureus cooperatively induce atopic dermatitis-like transcriptomes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3534-3537</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cytokines/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Keratinocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Staphylococcal Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">infections</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34358351</style></accession-num><notes><style face="normal" font="default" size="100%">Murai-Yamamura, Mika&#xD;Garcet, Sandra&#xD;Yamamura, Kazuhiko&#xD;Gonzalez, Juana&#xD;Miura, Shunsuke&#xD;Li, Xuan&#xD;Hur, Hong&#xD;Guttman-Yassky, Emma&#xD;Krueger, James G&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3534-3537. doi: 10.1111/all.15035. Epub 2021 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34358351</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15035</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1141</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1141</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hox, V.</style></author><author><style face="normal" font="default" size="100%">Beyaert, S.</style></author><author><style face="normal" font="default" size="100%">Bullens, D.</style></author><author><style face="normal" font="default" size="100%">Couto, M.</style></author><author><style face="normal" font="default" size="100%">Langer, D.</style></author><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author><author><style face="normal" font="default" size="100%">Huart, C.</style></author><author><style face="normal" font="default" size="100%">Rombaux, P.</style></author><author><style face="normal" font="default" size="100%">Seys, S. F.</style></author><author><style face="normal" font="default" size="100%">Surda, P.</style></author><author><style face="normal" font="default" size="100%">Walker, A.</style></author><author><style face="normal" font="default" size="100%">Steelant, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.&#xD;Institute of Experimental and Clinical Research, Pole of Pulmonology, Otorhinolaryngology and Dermatology, UCLouvain, Brussels, Belgium.&#xD;Clinical Division of Pediatrics, University Hospitals, Leuven, Belgium.&#xD;Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium.&#xD;Allergy Unit, Hospital CUF Descobertas, Lisbon, Portugal, Lisbon, Portugal.&#xD;Respiratory Rehabilitation and Respiratory Division, University Hospitals Leuven, KU Leuven, Leuven, Belgium.&#xD;Clinical Division of Ear, Nose and Throat Disease, Head and Neck Surgery, University Hospitals, Leuven, Belgium.&#xD;Department of Otorhinolaryngology, Guy&apos;s and St-Thomas&apos; University Hospital, London, UK.&#xD;Department of Ear, Nose and Throat Disease, St-George Hospital, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tackling nasal symptoms in athletes: Moving towards personalized medicine</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2716-2729</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Athletes</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Precision Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Sports</style></keyword><keyword><style face="normal" font="default" size="100%">Ent</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">sports</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33605430</style></accession-num><abstract><style face="normal" font="default" size="100%">Adequate nasal breathing is indispensable for athletes, and nasal symptoms have been shown to interfere with their subjective feeling of comfortable breathing and quality of life. Nasal symptoms are caused by either structural abnormalities or mucosal pathology. Structural pathologies are managed differently from mucosal disease, and therefore, adequate diagnosis is of utmost importance in athletes in order to choose the correct treatment option for the individual. Literature suggests that nasal symptoms are more prevalent in athletes compared to the general population and certain sports environments might even trigger the development of symptoms. Given the high demands of respiratory function in athletes, insight into triggering factors is of high importance for disease prevention. Also, it has been suggested that athletes are more neglectful to their symptoms and hence remain undertreated, meaning that special attention should be paid to education of athletes and their caregivers. This review aims at giving an overview of nasal physiology in exercise as well as the possible types of nasal pathology. Additionally, diagnostic and treatment options are discussed and we focus on unmet needs for the management and prevention of these symptoms in athletes within the concept of precision medicine.</style></abstract><notes><style face="normal" font="default" size="100%">Hox, Valerie&#xD;Beyaert, Simon&#xD;Bullens, Dominique&#xD;Couto, Mariana&#xD;Langer, Daniel&#xD;Hellings, Peter-Willem&#xD;Huart, Caroline&#xD;Rombaux, Philippe&#xD;Seys, Sven F&#xD;Surda, Pavol&#xD;Walker, Abigail&#xD;Steelant, Brecht&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2716-2729. doi: 10.1111/all.14786. Epub 2021 Mar 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33605430</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14786</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>417</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">417</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Renert-Yuval, Y.</style></author><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Bose, S.</style></author><author><style face="normal" font="default" size="100%">Gomez-Arias, P. J.</style></author><author><style face="normal" font="default" size="100%">Rangel, S. M.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y. D.</style></author><author><style face="normal" font="default" size="100%">Paller, A. S.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Laboratory for Investigative Dermatology, Rockefeller University, New York, New York, USA.&#xD;Department of Biomedical Engineering, University of Mississippi, Oxford, Mississippi, USA.&#xD;Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tape strips capture atopic dermatitis-related changes in nonlesional skin throughout maturation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3445-3447</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35775320</style></accession-num><notes><style face="normal" font="default" size="100%">Renert-Yuval, Yael&#xD;Pavel, Ana B&#xD;Bose, Swaroop&#xD;Gomez-Arias, Pedro J&#xD;Rangel, Stephanie M&#xD;Estrada, Yeriel D&#xD;Paller, Amy S&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;UL1 TR001866/TR/NCATS NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3445-3447. doi: 10.1111/all.15423. Epub 2022 Jul 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35775320</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11344220</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15423</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1405</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1405</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Renert-Yuval, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, J.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Diaz, A.</style></author><author><style face="normal" font="default" size="100%">Lefferdink, R.</style></author><author><style face="normal" font="default" size="100%">Fang, M. M.</style></author><author><style face="normal" font="default" size="100%">Canter, T.</style></author><author><style face="normal" font="default" size="100%">Rangel, S. M.</style></author><author><style face="normal" font="default" size="100%">Zhang, N.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author><author><style face="normal" font="default" size="100%">Paller, A. S.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Biomedical Engineering, University of Mississippi, MS, USA.&#xD;Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.&#xD;College of Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA.&#xD;Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.&#xD;Ponce Health Sciences University School of Medicine, Ponce, PR, USA.&#xD;Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">314-325</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Epidermis</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier</style></keyword><keyword><style face="normal" font="default" size="100%">tape strips</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32639640</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Skin biopsies promote our understanding of atopic dermatitis/AD pathomechanisms in infants/toddlers with early-onset AD, but are not feasible in pediatric populations. Tape strips are an emerging, minimally invasive alternative, but global transcriptomic profiling in early pediatric AD is lacking. We aimed to provide global lesional and nonlesional skin profiles of infants/toddlers with recent-onset, moderate-to-severe AD using tape strips. METHODS: Sixteen tape strips were collected for RNA-seq profiling from 19 infants/toddlers (&lt;5 years old; lesional and nonlesional) with early-onset moderate-to-severe AD (&lt;/=6 months) and 17 healthy controls. RESULTS: We identified 1829 differentially expressed genes/DEGs in lesional AD and 662 DEGs in nonlesional AD, vs healthy skin (fold-change &gt;/=2, FDR &lt;0.05), with 100% sample recovery. Both lesional and nonlesional skin showed significant dysregulations of Th2 (CCL17 and IL4R) and Th22/Th17 (IL36G, CCL20, and S100As)-related genes, largely lacking significant Th1-skewing. Significant down-regulation of terminal differentiation (FLG and FLG2), lipid synthesis/metabolism (ELOVL3 and FA2H), and tight junction (CLDN8) genes were primarily seen in lesional AD. Significant negative correlations were identified between Th2 measures and epidermal barrier gene-subsets and individual genes (FLG with IL-4R and CCL17; r &lt; -0.4, P &lt; .05). Significant correlations were also identified between clinical measures (body surface area/BSA, pruritus ADQ, and transepidermal water loss/TEWL) with immune and barrier mRNAs in lesional and/or nonlesional AD (FLG/FLG2 with TEWL; r &lt; -0.4, P &lt; .05). CONCLUSION: RNA-seq profiling using tape strips in early-onset pediatric AD captures immune and barrier alterations in both lesional and nonlesional skin. Tape strips provide insight into disease pathomechanisms and cutaneous disease activity.</style></abstract><notes><style face="normal" font="default" size="100%">Pavel, Ana B&#xD;Renert-Yuval, Yael&#xD;Wu, Jianni&#xD;Del Duca, Ester&#xD;Diaz, Aisleen&#xD;Lefferdink, Rachel&#xD;Fang, Milie M&#xD;Canter, Talia&#xD;Rangel, Stephanie M&#xD;Zhang, Ning&#xD;Krueger, James G&#xD;Paller, Amy S&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;P30 AR075049/AR/NIAMS NIH HHS/&#xD;NUCATS U19 069526/TR/NCATS NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):314-325. doi: 10.1111/all.14490. Epub 2020 Aug 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32639640</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9285647</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14490</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1602</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1602</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Renert-Yuval, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, J.</style></author><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Diaz, A.</style></author><author><style face="normal" font="default" size="100%">Lefferdink, R.</style></author><author><style face="normal" font="default" size="100%">Fang, M. M.</style></author><author><style face="normal" font="default" size="100%">Canter, T.</style></author><author><style face="normal" font="default" size="100%">Rangel, S. M.</style></author><author><style face="normal" font="default" size="100%">Zhang, N.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author><author><style face="normal" font="default" size="100%">Paller, A. S.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Biomedical Engineering, University of Mississippi, MS, USA.&#xD;Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.&#xD;College of Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA.&#xD;Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.&#xD;Ponce Health Sciences University School of Medicine, Ponce, PR, USA.&#xD;Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">314-325</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Epidermis</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric</style></keyword><keyword><style face="normal" font="default" size="100%">skin barrier</style></keyword><keyword><style face="normal" font="default" size="100%">tape strips</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32639640</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Skin biopsies promote our understanding of atopic dermatitis/AD pathomechanisms in infants/toddlers with early-onset AD, but are not feasible in pediatric populations. Tape strips are an emerging, minimally invasive alternative, but global transcriptomic profiling in early pediatric AD is lacking. We aimed to provide global lesional and nonlesional skin profiles of infants/toddlers with recent-onset, moderate-to-severe AD using tape strips. METHODS: Sixteen tape strips were collected for RNA-seq profiling from 19 infants/toddlers (&lt;5 years old; lesional and nonlesional) with early-onset moderate-to-severe AD (&lt;/=6 months) and 17 healthy controls. RESULTS: We identified 1829 differentially expressed genes/DEGs in lesional AD and 662 DEGs in nonlesional AD, vs healthy skin (fold-change &gt;/=2, FDR &lt;0.05), with 100% sample recovery. Both lesional and nonlesional skin showed significant dysregulations of Th2 (CCL17 and IL4R) and Th22/Th17 (IL36G, CCL20, and S100As)-related genes, largely lacking significant Th1-skewing. Significant down-regulation of terminal differentiation (FLG and FLG2), lipid synthesis/metabolism (ELOVL3 and FA2H), and tight junction (CLDN8) genes were primarily seen in lesional AD. Significant negative correlations were identified between Th2 measures and epidermal barrier gene-subsets and individual genes (FLG with IL-4R and CCL17; r &lt; -0.4, P &lt; .05). Significant correlations were also identified between clinical measures (body surface area/BSA, pruritus ADQ, and transepidermal water loss/TEWL) with immune and barrier mRNAs in lesional and/or nonlesional AD (FLG/FLG2 with TEWL; r &lt; -0.4, P &lt; .05). CONCLUSION: RNA-seq profiling using tape strips in early-onset pediatric AD captures immune and barrier alterations in both lesional and nonlesional skin. Tape strips provide insight into disease pathomechanisms and cutaneous disease activity.</style></abstract><notes><style face="normal" font="default" size="100%">Pavel, Ana B&#xD;Renert-Yuval, Yael&#xD;Wu, Jianni&#xD;Del Duca, Ester&#xD;Diaz, Aisleen&#xD;Lefferdink, Rachel&#xD;Fang, Milie M&#xD;Canter, Talia&#xD;Rangel, Stephanie M&#xD;Zhang, Ning&#xD;Krueger, James G&#xD;Paller, Amy S&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;P30 AR075049/AR/NIAMS NIH HHS/&#xD;NUCATS U19 069526/TR/NCATS NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):314-325. doi: 10.1111/all.14490. Epub 2020 Aug 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32639640</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9285647</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14490</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2544</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2544</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Upton, J.</style></author><author><style face="normal" font="default" size="100%">Elizur, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.&#xD;Yitzhak Shamir Medical Center, Institute of Allergy, Immunology and Pediatric Pulmonology, Zerifin, and Department of Pediatrics, Tel Aviv University, Tel Aviv, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Target maintenance dose for peanut oral immunotherapy is 300 mg protein (or less): Pros and cons</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2305-2306</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/06/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">*Arachis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38841823</style></accession-num><notes><style face="normal" font="default" size="100%">Upton, Julia&#xD;Elizur, Arnon&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2305-2306. doi: 10.1111/all.16188. Epub 2024 Jun 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38841823</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16188</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">5</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paolucci, M.</style></author><author><style face="normal" font="default" size="100%">Wuillemin, N.</style></author><author><style face="normal" font="default" size="100%">Homere, V.</style></author><author><style face="normal" font="default" size="100%">Bieli, D.</style></author><author><style face="normal" font="default" size="100%">Kohli, A.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B.</style></author><author><style face="normal" font="default" size="100%">Waeckerle-Men, Y.</style></author><author><style face="normal" font="default" size="100%">Pengo, N.</style></author><author><style face="normal" font="default" size="100%">Kundig, T. M.</style></author><author><style face="normal" font="default" size="100%">Sonati, T.</style></author><author><style face="normal" font="default" size="100%">Johansen, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, University of Zurich, Zurich, Switzerland.&#xD;Mabylon AG, Schlieren, Switzerland.&#xD;Division of Allergology, University Children&apos;s Hospital Zurich, Zurich, Switzerland.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1605-1614</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts</style></keyword><keyword><style face="normal" font="default" size="100%">2S Albumins, Plant/chemistry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36704937</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Peanut allergy is a type-I hypersensitivity immune reaction mediated by the binding of peanut allergens to IgE-FcepsilonRI complexes on mast cells and basophils and by their subsequent cellular degranulation. Of all major peanut allergens, Ara h 2 is considered the most anaphylactic. With few options but allergen avoidance, effective treatment of allergic patients is needed. Passive immunotherapy (herein called PIT) based on prophylactic administration of peanut-specific monoclonal antibodies (mAbs) may present a promising treatment option for this under-served disease. METHOD: Fully human recombinant anti-peanut IgG mAbs were tested in mice sensitized to peanut allergen extract. Allergic mice received intravenous immunotherapy with anti-peanut Ara h 2-specific IgG1 or IgG4 mAbs cocktails, and were then challenged by a systemic injection of high-dose peanut allergen extract. The protection from allergic anaphylaxis was measured by monitoring the core body temperature. RESULTS: PIT with peanut-specific mAbs was associated with a significant and dose-dependent reduction of anaphylactic reactions in peanut-sensitized mice challenged with peanut allergen extract. Complete protection was observed at doses approximately 0.3-0.6 mg mAbs. Mixtures of mAbs were more effective than single mAbs, and effective treatment could be obtained with mAbs of both IgG1 and IgG4 subclasses. The therapeutic effect of anti-Ara h 2 mAbs was based on allergen neutralization and independent of the Fcgamma receptor and mast-cell inhibition. CONCLUSION: This is the first report that shows that human-derived anti-peanut mAbs can prevent allergic anaphylaxis in mice. The study demonstrates that neutralizing allergenic epitopes on Ara h 2 by mAbs may represent a promising treatment option in peanut-allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Paolucci, Marta&#xD;Wuillemin, Natascha&#xD;Homere, Valentine&#xD;Bieli, Dimitri&#xD;Kohli, Alice&#xD;Ballmer-Weber, Barbara&#xD;Waeckerle-Men, Ying&#xD;Pengo, Niccolo&#xD;Kundig, Thomas M&#xD;Sonati, Tiziana&#xD;Johansen, Pal&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1605-1614. doi: 10.1111/all.15659. Epub 2023 Feb 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36704937</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15659</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2490</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2490</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Kabashima, K.</style></author><author><style face="normal" font="default" size="100%">Staumont-Salle, D.</style></author><author><style face="normal" font="default" size="100%">Nahm, W. K.</style></author><author><style face="normal" font="default" size="100%">Pauser, S.</style></author><author><style face="normal" font="default" size="100%">Da Rosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Martel, B. C.</style></author><author><style face="normal" font="default" size="100%">Madsen, D. E.</style></author><author><style face="normal" font="default" size="100%">Ropke, M.</style></author><author><style face="normal" font="default" size="100%">Arlert, P.</style></author><author><style face="normal" font="default" size="100%">Steffensen, L.</style></author><author><style face="normal" font="default" size="100%">Blauvelt, A.</style></author><author><style face="normal" font="default" size="100%">Reich, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.&#xD;Department of Dermatology, University Hospital of Lille, INFINITE (Institute for Translational Research) U1286 Inserm, University of Lille, Lille, France.&#xD;University of California, San Diego School of Medicine, San Diego, California, USA.&#xD;Klinische Forschung Osnabruck, Osnabruck, Germany.&#xD;Mount Sinai Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;LEO Pharma A/S, Ballerup, Denmark.&#xD;Oregon Medical Research Center, Portland, Oregon, USA.&#xD;Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1560-1572</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/04/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-13/metabolism/antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology/metabolism/immunology/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">tralokinumab</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38563683</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tralokinumab is a monoclonal antibody that specifically neutralizes interleukin (IL)-13, a key driver of skin inflammation and barrier abnormalities in atopic dermatitis (AD). This study evaluated early and 2-year impacts of IL-13 neutralization on skin and serum biomarkers following tralokinumab treatment in adults with moderate-to-severe AD. METHODS: Skin biopsies and blood samples were evaluated from a subset of patients enrolled in the Phase 3 ECZTRA 1 (NCT03131648) and the long-term extension ECZTEND (NCT03587805) trials. Gene expression was assessed by RNA sequencing; protein expression was assessed by immunohistochemistry and immunoassay. RESULTS: Tralokinumab improved the transcriptomic profile of lesional skin by Week 4. Mean improvements in the expression of genes dysregulated in AD were 39% at Week 16 and 85% at 2 years with tralokinumab, with 15% worsening at Week 16 with placebo. At Week 16, tralokinumab significantly decreased type 2 serum biomarkers (CCL17/TARC, periostin, and IgE), reduced epidermal thickness versus placebo, and increased loricrin coverage versus baseline. Two years of tralokinumab treatment significantly reduced expression of genes in the Th2 (IL4R, IL31, CCL17, and CCL26), Th1 (IFNG), and Th17/Th22 (IL22, S100A7, S100A8, and S100A9) pathways as well as increased expression of epidermal differentiation and barrier genes (CLDN1 and LOR). Tralokinumab also shifted atherosclerosis signaling pathway genes (SELE, IL-37, and S100A8) toward non-lesional expression. CONCLUSION: Tralokinumab treatment improved epidermal pathology, reduced systemic markers of type 2 inflammation, and shifted expression of key AD biomarkers in skin towards non-lesional levels, further highlighting the key role of IL-13 in the pathogenesis of AD. CLINICAL TRIAL REGISTRATION: NCT03131648, NCT03587805.</style></abstract><notes><style face="normal" font="default" size="100%">Guttman-Yassky, Emma&#xD;Kabashima, Kenji&#xD;Staumont-Salle, Delphine&#xD;Nahm, Walter K&#xD;Pauser, Sylvia&#xD;Da Rosa, Joel Correa&#xD;Martel, Britta Cathrina&#xD;Madsen, Daniel Elenius&#xD;Ropke, Mads&#xD;Arlert, Petra&#xD;Steffensen, Louise&#xD;Blauvelt, Andrew&#xD;Reich, Kristian&#xD;eng&#xD;LEO Pharma A/S/&#xD;Clinical Trial, Phase III&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1560-1572. doi: 10.1111/all.16108. Epub 2024 Apr 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38563683</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16108</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3222</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3222</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wilson-Morkeh, H.</style></author><author><style face="normal" font="default" size="100%">Seluk, L.</style></author><author><style face="normal" font="default" size="100%">Bosch, P.</style></author><author><style face="normal" font="default" size="100%">Aguiar, C.</style></author><author><style face="normal" font="default" size="100%">Thiel, J.</style></author><author><style face="normal" font="default" size="100%">Hellmich, B.</style></author><author><style face="normal" font="default" size="100%">Wechsler, M. E.</style></author><author><style face="normal" font="default" size="100%">Siddiqui, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado, USA.&#xD;Division of Rheumatology and Clinical Immunology, Medical University of Graz, Graz, Austria.&#xD;Global Medical Affairs, GSK, Rio de Janeiro, Brazil.&#xD;Department of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Freiburg, Germany.&#xD;Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology, and Diabetology, Medius Klinik Kirchheim, Academic Teaching Hospital, University of Tubingen, Tubingen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">vasculitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41574554</style></accession-num><abstract><style face="normal" font="default" size="100%">Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life-threatening systemic, inflammatory disease with multi-organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type-2 immune response driving predominantly eosinophilic inflammation, B-cell mediated autoimmunity, neutrophil activation, and the generation of pathogenic anti-neutrophil cytoplasmic antibodies, all of which can contribute to tissue/organ damage. High-dose glucocorticoids are the mainstay treatment for EGPA, but over the past two decades the development of biologic treatments targeting interleukin (IL)-5, eosinophils and B-cells has revitalized the treatment landscape. Mepolizumab, a humanized monoclonal antibody that specifically targets IL-5, and benralizumab, which targets the IL-5 receptor (IL-5Ralpha), are both approved for the treatment of patients with non-severe relapsing or refractory EGPA. In Phase III trials, these biologics have demonstrated favorable safety profiles and efficacy, with treatment leading to remission induction, remission maintenance, and oral glucocorticoid sparing benefits. However, as understanding of the full complexity of EGPA pathogenesis improves, new treatment targets are emerging. Consequently, understanding key pathogenic mechanisms at the patient level, enabling a more tailored treatment approach, is an important goal for future research.</style></abstract><notes><style face="normal" font="default" size="100%">Wilson-Morkeh, Harold&#xD;Seluk, Lior&#xD;Bosch, Philipp&#xD;Aguiar, Carolina&#xD;Thiel, Jens&#xD;Hellmich, Bernhard&#xD;Wechsler, Michael E&#xD;Siddiqui, Salman&#xD;eng&#xD;GlaxoSmithKline/&#xD;Review&#xD;Denmark&#xD;Allergy. 2026 Jan 23. doi: 10.1111/all.70215.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41574554</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70215</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>566</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">566</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maverakis, E.</style></author><author><style face="normal" font="default" size="100%">Ji-Xu, A.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, University of California, Davis, Sacramento, California, USA.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Christine Kuhne Center for Allergy Research and Education CK-CARE, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Targeting interleukin-5 with benralizumab: A novel treatment for drug rash with eosinophilia and systemic symptoms</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2287-2289</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2022/03/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilia/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Exanthema/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-5</style></keyword><keyword><style face="normal" font="default" size="100%">Il-5</style></keyword><keyword><style face="normal" font="default" size="100%">benralizumab</style></keyword><keyword><style face="normal" font="default" size="100%">drug rash with eosinophilia and systemic symptoms</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">reslizumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35285038</style></accession-num><notes><style face="normal" font="default" size="100%">Maverakis, Emanual&#xD;Ji-Xu, Antonio&#xD;Bruggen, Marie-Charlotte&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2022 Aug;77(8):2287-2289. doi: 10.1111/all.15283.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35285038</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15283</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2821</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2821</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, C.</style></author><author><style face="normal" font="default" size="100%">Pang, B.</style></author><author><style face="normal" font="default" size="100%">Luo, Y.</style></author><author><style face="normal" font="default" size="100%">Cao, Z.</style></author><author><style face="normal" font="default" size="100%">Qiao, P.</style></author><author><style face="normal" font="default" size="100%">Zhu, Z.</style></author><author><style face="normal" font="default" size="100%">Fang, H.</style></author><author><style face="normal" font="default" size="100%">Yang, J.</style></author><author><style face="normal" font="default" size="100%">Dang, E.</style></author><author><style face="normal" font="default" size="100%">Shen, S.</style></author><author><style face="normal" font="default" size="100%">Kang, P.</style></author><author><style face="normal" font="default" size="100%">Jiao, Q.</style></author><author><style face="normal" font="default" size="100%">Hasegawa, A.</style></author><author><style face="normal" font="default" size="100%">Abe, R.</style></author><author><style face="normal" font="default" size="100%">Qiao, H.</style></author><author><style face="normal" font="default" size="100%">Wang, G.</style></author><author><style face="normal" font="default" size="100%">Fu, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi&apos;an, China.&#xD;Department of Health Education and Management and the Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi&apos;an, China.&#xD;Department.of Dermatology, The First Affiliated Hospital of Soochow University Central Research Laboratory, Suzhou, China.&#xD;Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Targeting the Galectin-7/TRPM2/Zn(2+)/DRP-1 Signaling Pathway: A Potential Therapeutic Intervention in the Pathogenesis of SJS/TEN</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1358-1376</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2025/03/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Galectins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*TRPM Cation Channels/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Exosomes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Keratinocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Stevens-Johnson syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Trpm2</style></keyword><keyword><style face="normal" font="default" size="100%">Zn2+</style></keyword><keyword><style face="normal" font="default" size="100%">exosomes</style></keyword><keyword><style face="normal" font="default" size="100%">galectin-7</style></keyword><keyword><style face="normal" font="default" size="100%">mitochondria</style></keyword><keyword><style face="normal" font="default" size="100%">mitochondrial fission</style></keyword><keyword><style face="normal" font="default" size="100%">toxic epidermal necrolysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40042066</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) represent a spectrum of severe drug-induced cutaneous reactions. These conditions are characterized by widespread and confluent keratinocyte apoptosis, which differentiates them from erythema multiforme (EM). Mounting evidence has implicated the mitochondrial-dependent apoptosis pathway in the pathogenesis of SJS/TEN, but the potential roles and specific mechanisms of these pathways in SJS/TEN remain largely unexplored. METHODS: Proteomic analyses were conducted to investigate differential protein expression in blister fluid (BF)-derived exosomes from suction surgery in healthy individuals (Con Exo) or patients with EM (EM Exo) or SJS/TEN (TEN Exo). Further analysis involved glutathione S-transferase (GST) pull-down assay, liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, and validation of MS results through proximity ligation assay (PLA) and coimmunoprecipitation (co-IP). Phenotypic and mechanistic analyses were performed using immunohistochemistry (IHC) staining, enzyme-linked immunosorbent assay (ELISA), western blotting, reverse transcription-polymerase chain reaction (RT-PCR), co-IP, CCK-8 assay, adenosine triphosphate (ATP) level measurements, and flow cytometry. RESULTS: Galectin-7 was markedly upregulated in BF-derived exosomes from SJS/TEN patients and showed a correlation with disease severity. Further analysis confirmed the interaction between galectin-7 and transient receptor potential (melastatin) 2 (TRPM2). BF-derived exosomes from SJS/TEN patients induced an imbalance in mitochondrial dynamics via galectin-7/TRPM2 upregulation. Activation of TRPM2 led to an elevation in mitochondrial Zn(2+), which facilitated the recruitment of the fission factor dynamin-related protein-1 (DRP-1) to mitochondria to trigger mitochondrial fission in the keratinocyte. In addition, the recruitment of DRP-1-dependent mitochondrial fission via the voltage-dependent anion channel 1 (VDAC1)/hexokinase 2 (HK2)-mediated opening of the mitochondrial permeability transition pore (mPTP)-triggered cytochrome c release. These effects ultimately induce activation of the intrinsic mitochondrial apoptotic pathway and contribute to the pathogenesis of SJS/TEN. CONCLUSIONS: Targeting the galectin-7/TRPM2/Zn(2+)/DRP-1 signaling pathway in keratinocytes presents a prospective therapeutic strategy for mitigating SJS/TEN in the future.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Chen&#xD;Pang, BingYu&#xD;Luo, YiXin&#xD;Cao, Zipeng&#xD;Qiao, Pei&#xD;Zhu, ZhenLai&#xD;Fang, Hui&#xD;Yang, JianKang&#xD;Dang, ErLe&#xD;Shen, ShengXian&#xD;Kang, Pan&#xD;Jiao, Qingqing&#xD;Hasegawa, Akito&#xD;Abe, Riichiro&#xD;Qiao, HongJiang&#xD;Wang, Gang&#xD;Fu, Meng&#xD;eng&#xD;National Natural Science Foundation of China/&#xD;Denmark&#xD;Allergy. 2025 May;80(5):1358-1376. doi: 10.1111/all.16510. Epub 2025 Mar 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40042066</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12105064</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16510</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2689</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2689</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jackson, D. J.</style></author><author><style face="normal" font="default" size="100%">Wechsler, M. E.</style></author><author><style face="normal" font="default" size="100%">Brusselle, G.</style></author><author><style face="normal" font="default" size="100%">Buhl, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Guy&apos;s Severe Asthma Centre, Guy&apos;s and St Thomas&apos; NHS Trust, London, UK.&#xD;School of Immunology &amp; Microbial Sciences, King&apos;s College London, London, UK.&#xD;Department of Medicine, National Jewish Health, Denver, Colorado, USA.&#xD;Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.&#xD;Pulmonary Department, Mainz University Hospital, Mainz, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Targeting the IL-5 pathway in eosinophilic asthma: A comparison of anti-IL-5 versus anti-IL-5 receptor agents</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2943-2952</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/10/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-5/antagonists &amp; inhibitors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Interleukin-5/antagonists &amp; inhibitors/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Targeted Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophilia/drug therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Il-5</style></keyword><keyword><style face="normal" font="default" size="100%">Il-5r</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">benralizumab</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">reslizumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39396109</style></accession-num><abstract><style face="normal" font="default" size="100%">Eosinophilic asthma is characterized by frequent exacerbations, poor symptom control and accelerated lung function decline. It is now recognized that the immune response underlying eosinophilic asthma involves a complex network of interconnected pathways from both the adaptive and innate immune systems. Within this response, interleukin-5 (IL-5) plays a central role in eosinophil differentiation, activation and survival and has emerged as a key target for therapies treating severe asthma. The monoclonal antibodies mepolizumab and reslizumab target the ligand IL-5, preventing its interaction with eosinophils; in contrast, benralizumab binds to the IL-5 receptor (IL-5R), preventing IL-5 from binding and leading to substantially greater eosinophil reduction by enhanced antibody-dependent cell-mediated cytotoxicity. Although no direct head-to-head clinical trials of asthma have been published to formally evaluate the clinical significance of these different therapeutic approaches, the potential benefits of partial versus complete eosinophil depletion continue to remain an important area of study and debate. Here, we review the existing real-world and clinical study data of anti-IL-5/anti-IL-5R therapies in severe eosinophilic asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Jackson, David J&#xD;Wechsler, Michael E&#xD;Brusselle, Guy&#xD;Buhl, Roland&#xD;eng&#xD;AstraZeneca/&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):2943-2952. doi: 10.1111/all.16346. Epub 2024 Oct 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39396109</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16346</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1162</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1162</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Messina, A.</style></author><author><style face="normal" font="default" size="100%">Palmigiano, A.</style></author><author><style face="normal" font="default" size="100%">Tosto, C.</style></author><author><style face="normal" font="default" size="100%">Romeo, D. A.</style></author><author><style face="normal" font="default" size="100%">Sturiale, L.</style></author><author><style face="normal" font="default" size="100%">Garozzo, D.</style></author><author><style face="normal" font="default" size="100%">Leonardi, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Consiglio Nazionale delle Ricerche (CNR), Istituto per i Polimeri, Compositi e Biomateriali, (IPCB) Catania, Catania, Italy.&#xD;Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tear N-glycomics in vernal and atopic keratoconjunctivitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2500-2509</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/02/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Conjunctivitis, Allergic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Glycomics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">Polysaccharides</style></keyword><keyword><style face="normal" font="default" size="100%">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</style></keyword><keyword><style face="normal" font="default" size="100%">Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">Tears</style></keyword><keyword><style face="normal" font="default" size="100%">atopic keratoconjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">mass spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">vernal keratocojunctivitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33583051</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: Tear fluid N-Glycome from patients affected with vernal (VKC) and atopic keratoconjunctivitis (AKC) was investigated to identify specific changes in tears and to recognize possible glyco-biomarkers. METHODS: The analysis of the N-glycans was performed using matrix-assisted laser desorption ionization mass spectrometry on single tear samples. Tears from control normal subjects (CTRL), VKC and AKC patients were processed and treated with peptide N-glycosidase F (PNGase F) to deglycosylate N-glycoproteins. Released N-glycans were purified, permethylated, and analyzed by matrix-assisted laser desorption/ionization-time of flight mass spectrometry and tandem mass spectrometry (MALDI-TOF MS and MALDI-TOF MS/MS). RESULTS: More than 150 complex N-glycans, including highly fucosylated biantennary, triantennary, tetra-antennary, and bisecting species, were observed in our spectra. Three distinct patterns for CTRL, VKC, and AKC patients were identified in terms of relative intensities for some N-glycans structures. Major variations involved bisecting and hyperfucosylated glycoforms. The most intense ions were associated with species at m/z 1907.0 (asialo, agalacto, bisected, biantennary structure-NGA2B) in CTRL MS profiles, at m/z 2605.3 and 2966.5 in VKC, and at m/z 2792.4 in AKC corresponding to a well-known biantennary, disialylated N-glycan. Several peaks were associated with structures bearing one or two Lewis X epitopes. Structures were confirmed by MS/MS analysis. Quantitative differences among the three groups were statistically significant. CONCLUSIONS: Tear MS profiles are rich in specific glycoforms, particularly those with a high fucosylation degree, indicating both core and peripheral decoration. Tear N-glycome analysis provided important information for a better comprehension of VKC and AKC alterations at the molecular level.</style></abstract><notes><style face="normal" font="default" size="100%">Messina, Angela&#xD;Palmigiano, Angelo&#xD;Tosto, Claudia&#xD;Romeo, Donata Agata&#xD;Sturiale, Luisa&#xD;Garozzo, Domenico&#xD;Leonardi, Andrea&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2500-2509. doi: 10.1111/all.14775. Epub 2021 Mar 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33583051</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14775</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>974</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">974</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Bergmann, K. C.</style></author><author><style face="normal" font="default" size="100%">Bonini, S.</style></author><author><style face="normal" font="default" size="100%">Compalati, E.</style></author><author><style face="normal" font="default" size="100%">Domis, N.</style></author><author><style face="normal" font="default" size="100%">de Blay, F.</style></author><author><style face="normal" font="default" size="100%">de Kam, P. J.</style></author><author><style face="normal" font="default" size="100%">Devillier, P.</style></author><author><style face="normal" font="default" size="100%">Durham, S. R.</style></author><author><style face="normal" font="default" size="100%">Ellis, A. K.</style></author><author><style face="normal" font="default" size="100%">Gherasim, A.</style></author><author><style face="normal" font="default" size="100%">Haya, L.</style></author><author><style face="normal" font="default" size="100%">Hohlfeld, J. M.</style></author><author><style face="normal" font="default" size="100%">Horak, F.</style></author><author><style face="normal" font="default" size="100%">Iinuma, T.</style></author><author><style face="normal" font="default" size="100%">Jacobs, R. L.</style></author><author><style face="normal" font="default" size="100%">Jacobi, H. H.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Kaul, S.</style></author><author><style face="normal" font="default" size="100%">Kelly, S.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Larche, M.</style></author><author><style face="normal" font="default" size="100%">Lemell, P.</style></author><author><style face="normal" font="default" size="100%">Mahler, V.</style></author><author><style face="normal" font="default" size="100%">Nolte, H.</style></author><author><style face="normal" font="default" size="100%">Okamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Patel, P.</style></author><author><style face="normal" font="default" size="100%">Rabin, R. L.</style></author><author><style face="normal" font="default" size="100%">Rather, C.</style></author><author><style face="normal" font="default" size="100%">Sager, A.</style></author><author><style face="normal" font="default" size="100%">Salapatek, A. M.</style></author><author><style face="normal" font="default" size="100%">Sigsgaard, T.</style></author><author><style face="normal" font="default" size="100%">Togias, A.</style></author><author><style face="normal" font="default" size="100%">Willers, C.</style></author><author><style face="normal" font="default" size="100%">Yang, W. H.</style></author><author><style face="normal" font="default" size="100%">Zieglmayer, R.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Zieglmayer, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Department of Dermatology and Allergy, Allergy Centre Charite, Berlin, Germany.&#xD;Institute of Translational Medicine, Italian National Research Council, Rome, Italy.&#xD;Medical Department, Lofarma S.p.A, Milan, Italy.&#xD;ALYATEC Environmental Exposure Chamber, Strasbourg, France.&#xD;Chest Diseases Department, Strasbourg University Hospital, Strasbourg, France.&#xD;Allergy Therapeutics Ltd, Worthing, UK.&#xD;Department of Airway Diseases, Pharmacology Research Laboratory-VIM Suresnes, Exhalomics Platform, Hopital Foch, University Paris-Saclay, Suresnes, France.&#xD;National Heart and Lung Institute, Imperial College London, UK.&#xD;Departments of Medicine and Biomedical &amp; Molecular Sciences, Queen&apos;s University, Kingston, ON, Canada.&#xD;Allergy Research Unit, Kingston General Health Research Institute, Kingston, ON, Canada.&#xD;Red Maple Trials Inc, Ottawa, ON, Canada.&#xD;Fraunhofer Institute for Toxicology and Experimental Medicine and Department of Respiratory Medicine, Hannover Medical School, Member of the German Center for Lung Research, Hannover, Germany.&#xD;Allergy Center Vienna West, Vienna, Austria.&#xD;Chiba University and Chiba Rosai Hospital, Chiba, Japan.&#xD;Biogenics Research Institute, San Antonio, TX, USA.&#xD;ALK, Horsholm, Denmark.&#xD;Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;All-MED Medical Research Institute, Wroclaw, Poland.&#xD;Paul-Ehrlich-Institut, Langen, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Allergy Center Rhineland-Palatinate, Mainz University Medical Center, Mainz, Germany.&#xD;Divisions of Clinical Immunology &amp; Allergy, and Respirology, Department of Medicine and Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.&#xD;Vienna Challenge Chamber, Vienna, Austria.&#xD;Cliantha Research Limited, Mississauga, ON, Canada.&#xD;Providence Therapeutics, Toronto, ON, Canada.&#xD;Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.&#xD;LETI Pharma, Witten, Germany.&#xD;Department of Public Health, Section for Environment Occupation and Health, Danish Ramazzini Centre, Aarhus University, Aarhus, Denmark.&#xD;Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.&#xD;Allergopharma GmbH &amp; Co KG, Reinbek, Germany.&#xD;Karl Landsteiner University, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3589-3612</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/25</style></edition><section><style face="normal" font="default" size="100%">3589</style></section><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pollen</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergen exposure chambers</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trials</style></keyword><keyword><style face="normal" font="default" size="100%">technical standards</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34028057</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non-allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose-finding Phase II trials is emphasized. Although methodologically insulated from the variability of natural pollen exposure, chamber models remain confined to supporting secondary, rather than primary, endpoints in Phase III registration trials. The need for further validation in comparison with field exposure is clearly mandated. On this basis, the European Academy of Allergy and Clinical Immunology (EAACI) initiated a Task Force in 2015 charged to gain a better understanding of how AECs can generate knowledge about respiratory allergies and can contribute to the clinical development of treatments. Researchers working with AECs worldwide were asked to provide technical information in eight sections: (i) dimensions and structure of the AEC, (ii) AEC staff, (iii) airflow, air processing, and operating conditions, (iv) particle dispersal, (v) pollen/particle counting, (vi) safety and non-contamination measures, (vii) procedures for symptom assessments, (viii) tested allergens/substances and validation procedures. On this basis, a minimal set of technical requirements for AECs applied to the field of allergology is proposed.</style></abstract><notes><style face="normal" font="default" size="100%">Pfaar, Oliver&#xD;Bergmann, Karl-Christian&#xD;Bonini, Sergio&#xD;Compalati, Enrico&#xD;Domis, Nathalie&#xD;de Blay, Frederic&#xD;de Kam, Pieter-Jan&#xD;Devillier, Philippe&#xD;Durham, Stephen R&#xD;Ellis, Anne K&#xD;Gherasim, Alina&#xD;Haya, Laura&#xD;Hohlfeld, Jens M&#xD;Horak, Friedrich&#xD;Iinuma, Tomohisa&#xD;Jacobs, Robert L&#xD;Jacobi, Henrik Hugo&#xD;Jutel, Marek&#xD;Kaul, Susanne&#xD;Kelly, Suzanne&#xD;Klimek, Ludger&#xD;Larche, Mark&#xD;Lemell, Patrick&#xD;Mahler, Vera&#xD;Nolte, Hendrik&#xD;Okamoto, Yoshitaka&#xD;Patel, Piyush&#xD;Rabin, Ronald L&#xD;Rather, Cynthia&#xD;Sager, Angelika&#xD;Salapatek, Anne Marie&#xD;Sigsgaard, Torben&#xD;Togias, Alkis&#xD;Willers, Christoph&#xD;Yang, William H&#xD;Zieglmayer, Rene&#xD;Zuberbier, Torsten&#xD;Zieglmayer, Petra&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3589-3612. doi: 10.1111/all.14957.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34028057</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14957</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2350</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2350</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sullivan, M. O.</style></author><author><style face="normal" font="default" size="100%">Curtin, M.</style></author><author><style face="normal" font="default" size="100%">Flynn, R.</style></author><author><style face="normal" font="default" size="100%">Cronin, C.</style></author><author><style face="normal" font="default" size="100%">Mahony, J. O.</style></author><author><style face="normal" font="default" size="100%">Trujillo, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University College Cork, Cork, Ireland.&#xD;Cork University Hospital, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Telehealth interventions for transition to self-management in adolescents with allergic conditions: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">861-883</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/12/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Telemedicine</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Self-Management/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">mobile applications</style></keyword><keyword><style face="normal" font="default" size="100%">self-management</style></keyword><keyword><style face="normal" font="default" size="100%">telemedicine</style></keyword><keyword><style face="normal" font="default" size="100%">transition to adult care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38041398</style></accession-num><abstract><style face="normal" font="default" size="100%">Telehealth is an emerging approach that uses technology to provide healthcare remotely. Recent publications have outlined the importance of supporting the transition to self-management of adolescents with allergic conditions. However, no synthesis of the evidence base on the use and impact of telehealth interventions for this purpose has been conducted to date. This review achieves these aims, in addition to exploring the language use surrounding these interventions, and their implementation. Four databases were searched systematically. References were independently screened by two reviewers. Methodological quality was assessed using the Mixed Methods Appraisal Tool. A narrative synthesis was undertaken. Eighteen articles were included, reporting on 15 telehealth interventions. A total of 86% targeted adolescents with asthma. Mobile applications were the most common telehealth modality used, followed by video-conferencing, web-based, virtual reality and artificial intelligence. Five intervention content categories were identified; educational, monitoring, behavioural, psychosocial and healthcare navigational. Peer and/or healthcare professional interaction, gamification and tailoring may increase engagement. The studies showed positive effects of the interventions or no difference from active controls, in self-management outcomes such as knowledge, health outcomes such as quality-of-life, and economic outcomes such as healthcare utilization. The most common implementation outcomes reported were acceptability, appropriateness, feasibility and fidelity.</style></abstract><notes><style face="normal" font="default" size="100%">Sullivan, Meg O&apos;&#xD;Curtin, Margaret&#xD;Flynn, Rachel&#xD;Cronin, Caoimhe&#xD;Mahony, James O&apos;&#xD;Trujillo, Juan&#xD;eng&#xD;Systematic Review&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):861-883. doi: 10.1111/all.15963. Epub 2023 Dec 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38041398</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15963</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1417</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1417</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Hagemann, J.</style></author><author><style face="normal" font="default" size="100%">Alali, A.</style></author><author><style face="normal" font="default" size="100%">Spielhaupter, M.</style></author><author><style face="normal" font="default" size="100%">Huppertz, T.</style></author><author><style face="normal" font="default" size="100%">Hormann, K.</style></author><author><style face="normal" font="default" size="100%">Stielow, S.</style></author><author><style face="normal" font="default" size="100%">Freudelsperger, L.</style></author><author><style face="normal" font="default" size="100%">Matthias, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Universitatsmedizin der Johannes Gutenberg-Universitat Mainz.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center, Mainz, Germany.&#xD;Mannheim University Hospital, Mannheim, Germany.&#xD;COVID-19 Test Center Wiesbaden, Wiesbaden, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Telemedicine allows quantitative measuring of olfactory dysfunction in COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">868-870</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/06/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*complications</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Olfaction Disorders/*diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Telemedicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32569393</style></accession-num><notes><style face="normal" font="default" size="100%">Klimek, Ludger&#xD;Hagemann, Jan&#xD;Alali, Ali&#xD;Spielhaupter, Magdalena&#xD;Huppertz, Tilman&#xD;Hormann, Karl&#xD;Stielow, Sabine&#xD;Freudelsperger, Laura&#xD;Matthias, Christoph&#xD;eng&#xD;HSP 2020/03-1/Hessische Stiftung fur Pravention, Wiesbaden, Germany/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):868-870. doi: 10.1111/all.14467. Epub 2020 Jul 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32569393</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7361410 Stielow, Dr Freudelsperger and Dr Matthias have nothing to disclose.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14467</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2351</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2351</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Smolinska, S.</style></author><author><style face="normal" font="default" size="100%">Popescu, F. D.</style></author><author><style face="normal" font="default" size="100%">Izquierdo, E.</style></author><author><style face="normal" font="default" size="100%">Antolin-Amerigo, D.</style></author><author><style face="normal" font="default" size="100%">Price, O. J.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Perea, A.</style></author><author><style face="normal" font="default" size="100%">Eguiluz Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Fassio, F.</style></author><author><style face="normal" font="default" size="100%">Hoffmann-Sommergruber, K.</style></author><author><style face="normal" font="default" size="100%">Dramburg, S.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Angier, E.</style></author><author><style face="normal" font="default" size="100%">Boccabella, C.</style></author><author><style face="normal" font="default" size="100%">Bonini, M.</style></author><author><style face="normal" font="default" size="100%">Dunn Galvin, A.</style></author><author><style face="normal" font="default" size="100%">Gibson, P. G.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Hannachi, F.</style></author><author><style face="normal" font="default" size="100%">Kalayci, O.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Knibb, R.</style></author><author><style face="normal" font="default" size="100%">Matricardi, P.</style></author><author><style face="normal" font="default" size="100%">Chivato, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;Department of Allergology, Nicolae Malaxa Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.&#xD;Department of Basic Medical Sciences, Facultad de Medicina, Institute of Applied Molecular Medicine Instituto de Medicina Molecular Aplicada Nemesio Diez (IMMA), Universidad San Pablo-CEU, CEU Universities, Urbanizacion Monteprincipe, Madrid, Spain.&#xD;Servicio de Alergia, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Madrid, Spain.&#xD;School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, UK.&#xD;Allergy Service, Hospital General Universitario Gregorio Maranon, Madrid, Spain.&#xD;Gregorio Maranon Health Research Institute, Madrid, Spain.&#xD;Allergy Department, Hospital Regional Universitario de Malaga and Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA-Plataforma BIONAND). RICORS &quot;Inflammatory Diseases&quot;, Malaga, Spain.&#xD;Allergy Department, 2nd Pediatric Clinic, National Kapodistrian University of Athens, Athens, Greece.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.&#xD;Centro Studi Allergie, Pistoia, Italy.&#xD;Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.&#xD;Department of Pediatric Respiratory Care, Immunology and Intensive Care Medicine, Charite Universitatsmedizin, Berlin, Germany.&#xD;Allergy and Clinical Immunology at Transylvania University, Brasov, Romania.&#xD;&quot;ALL-MED&quot; Medical Research Institute, Wroclaw, Poland.&#xD;Children&apos;s Allergy Service, Evelina Children&apos;s Hospital, Guy&apos;s and St. Thomas&apos; Hospital, London, UK.&#xD;Department of Women and Children&apos;s Health, School of Life Course Sciences, King&apos;s College London, London, UK.&#xD;CINTESIS@RISE, MEDCIDS, Faculty of Medicine of the University of Porto, Porto, Portugal.&#xD;Primary Care, Population Science and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;Department of Cardiovascular and Thoracic Sciences, Universita Cattolica del Sacro Cuore, Rome, Italy.&#xD;Department of Clinical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.&#xD;National Heart and Lung Institute (NHLI), Imperial College London, London, UK.&#xD;School of Applied Psychology, University College Cork, Cork, Ireland.&#xD;John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, Australia.&#xD;Department of Internal Medicine, Allergology and Clinical Immunology, Medical University of Silesia, Katowice, Poland.&#xD;Immuno-Allergology Unit, Hospital Centre of Luxembourg, Luxembourg City, Luxembourg.&#xD;Hacettepe University School of Medicine, Ankara, Turkey.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;School of Psychology, College of Health and Life Sciences, Aston University, Birmingham, UK.&#xD;Department of Clinical Medical Sciences, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Urbanizacion Monteprincipe, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Telemedicine with special focus on allergic diseases and asthma-Status 2022: An EAACI position paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">777-792</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/12/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">*Telemedicine/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Confidentiality</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">e-health</style></keyword><keyword><style face="normal" font="default" size="100%">m-health</style></keyword><keyword><style face="normal" font="default" size="100%">telecare</style></keyword><keyword><style face="normal" font="default" size="100%">telehealth</style></keyword><keyword><style face="normal" font="default" size="100%">telemedicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38041429</style></accession-num><abstract><style face="normal" font="default" size="100%">Efficacious, effective and efficient communication between healthcare professionals (HCP) and patients is essential to achieve a successful therapeutic alliance. Telemedicine (TM) has been used for decades but during the COVID-19 pandemic its use has become widespread. This position paper aims to describe the terminology and most important forms of TM among HCP and patients and review the existing studies on the uses of TM for asthma and allergy. Besides, the advantages and risks of TM are discussed, concluding that TM application reduces costs and time for both, HCP and patients, but cannot completely replace face-to-face visits for physical examinations and certain tests that are critical in asthma and allergy. From an ethical point of view, it is important to identify those involved in the TM process, ensure confidentiality and use communication channels that fully guarantee the security of the information. Unmet needs and directions for the future regarding implementation, data protection, privacy regulations, methodology and efficacy are described.</style></abstract><notes><style face="normal" font="default" size="100%">Smolinska, Sylwia&#xD;Popescu, Florin-Dan&#xD;Izquierdo, Elena&#xD;Antolin-Amerigo, Dario&#xD;Price, Oliver J&#xD;Alvarez-Perea, Alberto&#xD;Eguiluz Gracia, Ibon&#xD;Papadopoulos, Nikolaos G&#xD;Pfaar, Oliver&#xD;Fassio, Filippo&#xD;Hoffmann-Sommergruber, Karin&#xD;Dramburg, Stephanie&#xD;Agache, Ioana&#xD;Jutel, Marek&#xD;Brough, Helen A&#xD;Fonseca, Joao A&#xD;Angier, Elizabeth&#xD;Boccabella, Cristina&#xD;Bonini, Matteo&#xD;Dunn Galvin, Audrey&#xD;Gibson, Peter G&#xD;Gawlik, Radoslaw&#xD;Hannachi, Farah&#xD;Kalayci, Omer&#xD;Klimek, Ludger&#xD;Knibb, Rebecca&#xD;Matricardi, Paolo&#xD;Chivato, Tomas&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology/&#xD;Consensus Development Conference&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Apr;79(4):777-792. doi: 10.1111/all.15964. Epub 2023 Dec 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38041429</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15964</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2114</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2114</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liao, W.</style></author><author><style face="normal" font="default" size="100%">Chen, G.</style></author><author><style face="normal" font="default" size="100%">Song, L.</style></author><author><style face="normal" font="default" size="100%">Xu, M.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Ye, J.</style></author><author><style face="normal" font="default" size="100%">Ren, M.</style></author><author><style face="normal" font="default" size="100%">Kuang, X.</style></author><author><style face="normal" font="default" size="100%">Tang, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, S.</style></author><author><style face="normal" font="default" size="100%">Ning, X.</style></author><author><style face="normal" font="default" size="100%">Xie, J.</style></author><author><style face="normal" font="default" size="100%">Yang, Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The State Key Laboratory of Respiratory Disease, Department of Otolaryngology, Head and Neck Surgery, Laboratory of ENT-HNS Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.&#xD;Innovation and Transformation Platform of Upper Airway Disease in Guangdong Province, Guangzhou, China.&#xD;Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.&#xD;Department of Otolaryngology, Head and Neck Surgery, Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Temperature regulates Rab3a and mast cell-derived exosomal FcepsilonRI to inhibit mast cell activation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1707-1710</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/04/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, IgE</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Degranulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37069491</style></accession-num><notes><style face="normal" font="default" size="100%">Liao, Wenjing&#xD;Chen, Gui&#xD;Song, Lijuan&#xD;Xu, Meiqian&#xD;Li, Hao&#xD;Wang, Yiyan&#xD;Wang, Xiaofen&#xD;Ye, Jinfeng&#xD;Ren, Mei&#xD;Kuang, Xiaoxuan&#xD;Tang, Yaqiang&#xD;Yang, Saixuan&#xD;Ning, Xiaoping&#xD;Xie, Jianlei&#xD;Yang, Zhaowei&#xD;Zhang, Xiaowen&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1707-1710. doi: 10.1111/all.15744. Epub 2023 Apr 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37069491</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15744</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2225</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2225</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dahal, A.</style></author><author><style face="normal" font="default" size="100%">Chang, W. C.</style></author><author><style face="normal" font="default" size="100%">Almasri, C.</style></author><author><style face="normal" font="default" size="100%">Johansson, E.</style></author><author><style face="normal" font="default" size="100%">Hurd, M.</style></author><author><style face="normal" font="default" size="100%">Velasquez, V.</style></author><author><style face="normal" font="default" size="100%">Grashel, B.</style></author><author><style face="normal" font="default" size="100%">Spagna, D.</style></author><author><style face="normal" font="default" size="100%">Jenkins, S.</style></author><author><style face="normal" font="default" size="100%">Morgan, D.</style></author><author><style face="normal" font="default" size="100%">Satish, L.</style></author><author><style face="normal" font="default" size="100%">Martin, L. J.</style></author><author><style face="normal" font="default" size="100%">Biagini, J. M.</style></author><author><style face="normal" font="default" size="100%">Khurana Hershey, G. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Asthma Research, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.&#xD;Medical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;Division of Human Genetics, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, Ohio, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Temporal relationships between Staphylococcus aureus colonization, filaggrin expression, and pediatric atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">104-115</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/08/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Staphylococcus aureus/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Acuity</style></keyword><keyword><style face="normal" font="default" size="100%">*Filaggrin Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">filaggrin expression</style></keyword><keyword><style face="normal" font="default" size="100%">longitudinal colonization</style></keyword><keyword><style face="normal" font="default" size="100%">mediation analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37650296</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is characterized by Staphylococcus aureus (S. aureus) colonization. Longitudinal early life data delineating relationships of S. aureus colonization, barrier function, and AD outcomes are lacking. We define longitudinal S. aureus endotypes and AD pathogenesis in early life. METHODS: We defined longitudinal S. aureus skin colonization phenotypes across two annual visits (non-colonized: V1(-) V2(-) , early transient: V1(+) V2(-) , late-onset: V1(-) V2(+) , persistent: V1(+) V2(+) ) in the Mechanisms of Progression of Atopic Dermatitis to Asthma in Children cohort. We analyzed AD severity, sensitization, and skin barrier function across phenotypes, and performed mediation analyses between colonization and FLG expression. RESULTS: Persistent S. aureus colonization was associated with increased SCORAD at V1 (33.5 vs. 19.0, p = .004) and V2 (40.1 vs.16.9, p &lt; .001), and lower non-lesional (NL) FLG at V2 (1.77 vs. 4.09, p = .029) compared to the non-colonized phenotype, with early transient and late-onset colonization as intermediate phenotypes. Children colonized at V2 demonstrated a decrease in NL-FLG expression from V1 to V2 compared to those non-colonized at V2 (p = .0012), who maintained expression. This effect remained significant even after adjusting for V1 colonization and SCORAD (p = .011). CONCLUSIONS: Our findings are the first to present longitudinal quantitative FLG expression and S. aureus skin colonization in early life and suggest that a decrease in NL-FLG drives later colonization. Hence, therapies to maintain NL-FLG expression may prevent S. aureus colonization. Further, a longitudinal AD endotype of persistent colonization is characterized by increased AD severity, sensitization, and decreasing NL-FLG.</style></abstract><notes><style face="normal" font="default" size="100%">Dahal, Arya&#xD;Chang, Wan Chi&#xD;Almasri, Cassandra&#xD;Johansson, Elisabet&#xD;Hurd, Makenna&#xD;Velasquez, Veronica&#xD;Grashel, Brittany&#xD;Spagna, Daniel&#xD;Jenkins, Seth&#xD;Morgan, David&#xD;Satish, Latha&#xD;Martin, Lisa J&#xD;Biagini, Jocelyn M&#xD;Khurana Hershey, Gurjit K&#xD;eng&#xD;T32 GM063483/GM/NIGMS NIH HHS/&#xD;U19AI070235/NH/NIH HHS/&#xD;R01 AI127392/NH/NIH HHS/&#xD;R01 AI127392/AI/NIAID NIH HHS/&#xD;U19 AI070235/AI/NIAID NIH HHS/&#xD;T32 GM063483/NH/NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):104-115. doi: 10.1111/all.15871. Epub 2023 Aug 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37650296</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11190941</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15871</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>639</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">639</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parr, C. L.</style></author><author><style face="normal" font="default" size="100%">Nystad, W.</style></author><author><style face="normal" font="default" size="100%">Karlstad, O.</style></author><author><style face="normal" font="default" size="100%">Oymar, K.</style></author><author><style face="normal" font="default" size="100%">Langhammer, A.</style></author><author><style face="normal" font="default" size="100%">Nafstad, P.</style></author><author><style face="normal" font="default" size="100%">Wisloff, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Norwegian Scientific Committee for Food and Environment, Norwegian Institute of Public Health, Oslo, Norway.&#xD;Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway.&#xD;Department of Pediatrics, Stavanger University Hospital, Stavanger, Norway.&#xD;Department of Clinical Science, University of Bergen, Norway.&#xD;Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.&#xD;Department of Community Medicine and Public Health, University of Oslo, Oslo, Norway.&#xD;Health Services Research Unit, Akershus University Hospital, Lorenskog, Norway.&#xD;Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ten-year trends of national healthcare costs of asthma, allergic rhinitis, and atopic eczema in 3 million Norwegians</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1614-1616</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/01/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Health Care Costs</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Norway</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35048378</style></accession-num><notes><style face="normal" font="default" size="100%">Parr, Christine Louise&#xD;Nystad, Wenche&#xD;Karlstad, Oystein&#xD;Oymar, Knut&#xD;Langhammer, Arnulf&#xD;Nafstad, Per&#xD;Wisloff, Torbjorn&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1614-1616. doi: 10.1111/all.15225. Epub 2022 Feb 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35048378</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9303559 Nordisk and LEO Pharma, all regulator-mandated phase IV-studies, all with funds paid to his institution (no personal fees) and with no relation to the work reported in this paper. Arnulf Langhammer has been PI of the Lung Study in HUNT that was partially funded by non-demanding grants from AstraZeneca. He has participated in some advisory boards for AstraZeneca and GlaxoSmithKline and has given lectures for medical doctors paid by AZ, GSK and Boehringer Ingelheim. He has not received any payment related to the work reported in this paper. Torbjorn Wisloff has done consulting for completely unrelated project on varicella and herpes zoster vaccine for MSD. Christine Louise Parr, Wenche Nystad, Knut Oymar, and Per Nafstad reports no conflicts of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15225</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>385</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">385</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, P.</style></author><author><style face="normal" font="default" size="100%">Qin, D.</style></author><author><style face="normal" font="default" size="100%">Deng, Z.</style></author><author><style face="normal" font="default" size="100%">Tong, X.</style></author><author><style face="normal" font="default" size="100%">Liu, K.</style></author><author><style face="normal" font="default" size="100%">Fan, W.</style></author><author><style face="normal" font="default" size="100%">Huang, J.</style></author><author><style face="normal" font="default" size="100%">Zhou, H.</style></author><author><style face="normal" font="default" size="100%">Gong, W.</style></author><author><style face="normal" font="default" size="100%">Jin, J.</style></author><author><style face="normal" font="default" size="100%">Lv, H.</style></author><author><style face="normal" font="default" size="100%">Chen, S.</style></author><author><style face="normal" font="default" size="100%">Tao, Z.</style></author><author><style face="normal" font="default" size="100%">Xu, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China.&#xD;Research Institute of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">TET2 deficiency exacerbates nasal polypogenesis by inducing epithelial-to-mesenchymal transition</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3452-3455</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial-Mesenchymal Transition/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">DNA-Binding Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Dioxygenases</style></keyword><keyword><style face="normal" font="default" size="100%">Crs</style></keyword><keyword><style face="normal" font="default" size="100%">Emt</style></keyword><keyword><style face="normal" font="default" size="100%">PPAR-gamma</style></keyword><keyword><style face="normal" font="default" size="100%">Tet2</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35844041</style></accession-num><notes><style face="normal" font="default" size="100%">Liu, Peiqiang&#xD;Qin, Danxue&#xD;Deng, Zhifeng&#xD;Tong, Xiaoting&#xD;Liu, Kunyu&#xD;Fan, Wenjun&#xD;Huang, Jingyu&#xD;Zhou, Huiqin&#xD;Gong, Wanyang&#xD;Jin, Jing&#xD;Lv, Hao&#xD;Chen, Siyuan&#xD;Tao, Zezhang&#xD;Xu, Yu&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3452-3455. doi: 10.1111/all.15446. Epub 2022 Jul 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35844041</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15446</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2757</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2757</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hsu, A. T.</style></author><author><style face="normal" font="default" size="100%">Bugajev, V.</style></author><author><style face="normal" font="default" size="100%">Gottschalk, T. A.</style></author><author><style face="normal" font="default" size="100%">Demkova, L.</style></author><author><style face="normal" font="default" size="100%">Potuckova, L.</style></author><author><style face="normal" font="default" size="100%">Draberova, L.</style></author><author><style face="normal" font="default" size="100%">Bambouskova, M.</style></author><author><style face="normal" font="default" size="100%">Hagemann, P.</style></author><author><style face="normal" font="default" size="100%">O&apos;Brien, C. A.</style></author><author><style face="normal" font="default" size="100%">Riecan, M.</style></author><author><style face="normal" font="default" size="100%">Kuda, O.</style></author><author><style face="normal" font="default" size="100%">Tsantikos, E.</style></author><author><style face="normal" font="default" size="100%">Draber, P.</style></author><author><style face="normal" font="default" size="100%">Wright, M. D.</style></author><author><style face="normal" font="default" size="100%">van Spriel, A. B.</style></author><author><style face="normal" font="default" size="100%">Hibbs, M. L.</style></author><author><style face="normal" font="default" size="100%">Halova, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Alfred Research Alliance, Monash University, Melbourne, Victoria, Australia.&#xD;Laboratory of Signal Transduction, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.&#xD;Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.&#xD;Laboratory of Metabolism of Bioactive Lipids, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tetraspanin CD53 Promotes Inflammation but Restrains Mucus Production in a Mouse Model of Allergic Airway Inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1127-1131</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/09</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39651606</style></accession-num><notes><style face="normal" font="default" size="100%">Hsu, Amy T&#xD;Bugajev, Viktor&#xD;Gottschalk, Timothy A&#xD;Demkova, Livia&#xD;Potuckova, Lucie&#xD;Draberova, Lubica&#xD;Bambouskova, Monika&#xD;Hagemann, Philipp&#xD;O&apos;Brien, Caitlin A&#xD;Riecan, Martin&#xD;Kuda, Ondrej&#xD;Tsantikos, Evelyn&#xD;Draber, Petr&#xD;Wright, Mark D&#xD;van Spriel, Annemiek B&#xD;Hibbs, Margaret L&#xD;Halova, Ivana&#xD;eng&#xD;KWF Kankerbestrijding/&#xD;Ministerstvo Skolstvi, Mladeze a Telovychovy/&#xD;Grantova Agentura Ceske Republiky/&#xD;Nederlandse Organisatie voor Wetenschappelijk Onderzoek/&#xD;APP1141208/National Health and Medical Research Council/&#xD;H2020 European Research Council/&#xD;Australian Research Training Program/&#xD;Ustav Molekularni Genetiky/&#xD;School of Translational Medicine, Monash University/&#xD;Lekarska fakulta Univerzity Karlovy/&#xD;Czech Science Foundation/&#xD;68378050/Czech Academy of Sciences/&#xD;14726/Dutch Cancer Society/&#xD;12949/Dutch Cancer Society/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1127-1131. doi: 10.1111/all.16426. Epub 2024 Dec 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39651606</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969303</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16426</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2267</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2267</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sverrild, A.</style></author><author><style face="normal" font="default" size="100%">Cerps, S.</style></author><author><style face="normal" font="default" size="100%">Nieto-Fontarigo, J. J.</style></author><author><style face="normal" font="default" size="100%">Ramu, S.</style></author><author><style face="normal" font="default" size="100%">Hvidtfeldt, M.</style></author><author><style face="normal" font="default" size="100%">Menzel, M.</style></author><author><style face="normal" font="default" size="100%">Kearley, J.</style></author><author><style face="normal" font="default" size="100%">Griffiths, J. M.</style></author><author><style face="normal" font="default" size="100%">Parnes, J. R.</style></author><author><style face="normal" font="default" size="100%">Porsbjerg, C.</style></author><author><style face="normal" font="default" size="100%">Uller, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, University Hospital Bispebjerg, Copenhagen, Denmark.&#xD;Department of Experimental Medicine, Lund University, Lund, Sweden.&#xD;BioLympho Research group, Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.&#xD;Translational Research in Airway Diseases Group (TRIAD), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.&#xD;Bioscience, Research &amp; Early Development, Respiratory &amp; Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, Maryland, USA.&#xD;Translational Science and Experimental Medicine, Research &amp; Early Development, Respiratory &amp; Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, Maryland, USA.&#xD;Translational Medicine, Amgen, Thousand Oaks, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">656-666</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/10/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchi</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33</style></keyword><keyword><style face="normal" font="default" size="100%">*Virus Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">airway epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">tezepelumab</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37846599</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Respiratory virus infections are main triggers of asthma exacerbations. Tezepelumab, an anti-TSLP mAb, reduces exacerbations in patients with asthma, but the effect of blocking TSLP on host epithelial resistance and tolerance to virus infection is not known. AIM: To examine effects of blocking TSLP in patients with asthma on host resistance (IFNbeta, IFNlambda, and viral load) and on the airway epithelial inflammatory response to viral challenge. METHODS: Bronchoalveolar lavage fluid (BALF, n = 39) and bronchial epithelial cells (BECs) were obtained from patients with uncontrolled asthma before and after 12 weeks of tezepelumab treatment (n = 13) or placebo (n = 13). BECs were cultured in vitro and exposed to the viral infection mimic poly(I:C) or infected by rhinovirus (RV). Alarmins, T2- and pro-inflammatory cytokines, IFNbeta IFNlambda, and viral load were analyzed by RT-qPCR and multiplex ELISA before and after stimulation. RESULTS: IL-33 expression in unstimulated BECs and IL-33 protein levels in BALF were reduced after 12 weeks of tezepelumab. Further, IL-33 gene and protein levels decreased in BECs challenged with poly(I:C) after tezepelumab whereas TSLP gene expression remained unaffected. Poly(I:C)-induced IL-4, IL-13, and IL-17A release from BECs was also reduced with tezepelumab whereas IFNbeta and IFNlambda expression and viral load were unchanged. CONCLUSION: Blocking TSLP with tezepelumab in vivo in asthma reduced the airway epithelial inflammatory response including IL-33 and T2 cytokines to viral challenge without affecting anti-viral host resistance. Our results suggest that blocking TSLP stabilizes the bronchial epithelial immune response to respiratory viruses.</style></abstract><notes><style face="normal" font="default" size="100%">Sverrild, A&#xD;Cerps, S&#xD;Nieto-Fontarigo, J J&#xD;Ramu, S&#xD;Hvidtfeldt, M&#xD;Menzel, M&#xD;Kearley, J&#xD;Griffiths, J M&#xD;Parnes, J R&#xD;Porsbjerg, C&#xD;Uller, L&#xD;eng&#xD;Capital region of Copenhagen Foundation/&#xD;Interreg foundation/&#xD;Lundbeck Foundation/&#xD;Medicinska Forskningsradet/&#xD;Swedish Heart and Lung foundation/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):656-666. doi: 10.1111/all.15918. Epub 2023 Oct 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37846599</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15918</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2328</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2328</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caminati, M.</style></author><author><style face="normal" font="default" size="100%">Buhl, R.</style></author><author><style face="normal" font="default" size="100%">Corren, J.</style></author><author><style face="normal" font="default" size="100%">Hanania, N. A.</style></author><author><style face="normal" font="default" size="100%">Kim, H.</style></author><author><style face="normal" font="default" size="100%">Korn, S.</style></author><author><style face="normal" font="default" size="100%">Lommatzsch, M.</style></author><author><style face="normal" font="default" size="100%">Martin, N.</style></author><author><style face="normal" font="default" size="100%">Matucci, A.</style></author><author><style face="normal" font="default" size="100%">Nasser, S. M.</style></author><author><style face="normal" font="default" size="100%">Pavord, I. D.</style></author><author><style face="normal" font="default" size="100%">Domingo, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Asthma Center and Allergy Unit, Verona Integrated University Hospital &amp; Department of Medicine, University of Verona, Verona, Italy.&#xD;Pulmonary Department, Mainz University Hospital, Mainz, Germany.&#xD;David Geffen School of Medicine, University of California, Los Angeles, California, USA.&#xD;Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas, USA.&#xD;Department of Medicine, Western University, London, Ontario, Canada.&#xD;Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;IKF Pneumologie Mainz, Mainz, Germany.&#xD;Thoraxklinik Heidelberg, Heidelberg, Germany.&#xD;Department of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.&#xD;Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.&#xD;University of Leicester, Leicester, UK.&#xD;Immunoallergology Unit, Careggi University Hospital, Florence, Italy.&#xD;Department of Allergy, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.&#xD;Respiratory Medicine, NIHR Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.&#xD;Servei de Pneumologia, Corporacio Sanitaria Parc Tauli, Sabadell, Universitat Autonoma de Barcelona (UAB), Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tezepelumab in patients with allergic and eosinophilic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1134-1145</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2023/12/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophilia/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">tezepelumab</style></keyword><keyword><style face="normal" font="default" size="100%">thymic stromal lymphopoietin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38146651</style></accession-num><abstract><style face="normal" font="default" size="100%">Asthma is a heterogeneous disease commonly driven by allergic and/or eosinophilic inflammation, both of which may be present in severe disease. Most approved biologics for severe asthma are indicated for specific phenotypes and target individual downstream type 2 components of the inflammatory cascade. Tezepelumab, a human monoclonal antibody (immunoglobulin G2lambda), binds specifically to thymic stromal lymphopoietin (TSLP), an epithelial cytokine that initiates and sustains allergic and eosinophilic inflammation in asthma. By blocking TSLP, tezepelumab has demonstrated efficacy across known asthma phenotypes and acts upstream of all current clinically used biomarkers. In a pooled analysis of the phase 2b PATHWAY (NCT02054130) and phase 3 NAVIGATOR (NCT03347279) studies, compared with placebo, tezepelumab reduced the annualized asthma exacerbation rate over 52 weeks by 62% (95% confidence interval [CI]: 53, 70) in patients with perennial aeroallergen sensitization (allergic asthma); by 71% (95% CI: 62, 78) in patients with a baseline blood eosinophil count &gt;/=300 cells/muL; and by 71% (95% CI: 59, 79) in patients with allergic asthma and a baseline blood eosinophil count &gt;/=300 cells/muL. This review examines the efficacy and mode of action of tezepelumab in patients with allergic asthma, eosinophilic asthma and coexisting allergic and eosinophilic phenotypes.</style></abstract><notes><style face="normal" font="default" size="100%">Caminati, Marco&#xD;Buhl, Roland&#xD;Corren, Jonathan&#xD;Hanania, Nicola A&#xD;Kim, Harold&#xD;Korn, Stephanie&#xD;Lommatzsch, Marek&#xD;Martin, Neil&#xD;Matucci, Andrea&#xD;Nasser, Shuaib M&#xD;Pavord, Ian D&#xD;Domingo, Christian&#xD;eng&#xD;AstraZeneca/&#xD;Amgen/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1134-1145. doi: 10.1111/all.15986. Epub 2023 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38146651</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15986</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3057</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3057</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hirai, K.</style></author><author><style face="normal" font="default" size="100%">Uehara, S.</style></author><author><style face="normal" font="default" size="100%">Shirai, T.</style></author><author><style face="normal" font="default" size="100%">Akamatsu, T.</style></author><author><style face="normal" font="default" size="100%">Itoh, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Pharmacology and Therapeutics, Shinshu University Graduate School of Medicine, Matsumoto, Japan.&#xD;Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan.&#xD;Department of Clinical Pharmacology &amp; Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.&#xD;Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.&#xD;Laboratory of Clinical Pharmacogenomics, Shizuoka General Hospital, Shizuoka, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tezepelumab Targeting Thymic Stromal Lymphopoietin Enhances Steroid Sensitivity in Patients With Severe Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">277-280</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/09/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">steroid sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">thymic stromal lymphopoietin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41014145</style></accession-num><notes><style face="normal" font="default" size="100%">Hirai, Keita&#xD;Uehara, Sekiko&#xD;Shirai, Toshihiro&#xD;Akamatsu, Taisuke&#xD;Itoh, Kunihiko&#xD;eng&#xD;Japan Society for the Promotion of Science/&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):277-280. doi: 10.1111/all.70083. Epub 2025 Sep 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41014145</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773678</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70083</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>641</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">641</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Theofani, E.</style></author><author><style face="normal" font="default" size="100%">Semitekolou, M.</style></author><author><style face="normal" font="default" size="100%">Samitas, K.</style></author><author><style face="normal" font="default" size="100%">Mais, A.</style></author><author><style face="normal" font="default" size="100%">Galani, I. E.</style></author><author><style face="normal" font="default" size="100%">Triantafyllia, V.</style></author><author><style face="normal" font="default" size="100%">Lama, J.</style></author><author><style face="normal" font="default" size="100%">Morianos, I.</style></author><author><style face="normal" font="default" size="100%">Stavropoulos, A.</style></author><author><style face="normal" font="default" size="100%">Jeong, S. J.</style></author><author><style face="normal" font="default" size="100%">Andreakos, E.</style></author><author><style face="normal" font="default" size="100%">Razani, B.</style></author><author><style face="normal" font="default" size="100%">Rovina, N.</style></author><author><style face="normal" font="default" size="100%">Xanthou, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece.&#xD;1st Department of Respiratory Medicine, Medical School, &apos;Sotiria&apos; Athens Chest Diseases Hospital, National Kapodistrian University of Athens, Athens, Greece.&#xD;7th Respiratory Clinic and Asthma Center of the &apos;Sotiria&apos; Athens Chest Hospital, Athens, Greece.&#xD;Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, BRFAA, Athens, Greece.&#xD;Department of Medicine, Cardiovascular Division, and Department of Pathology &amp; Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.&#xD;John Cochran VA Medical Center, St. Louis, Missouri, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">TFEB signaling attenuates NLRP3-driven inflammatory responses in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2131-2146</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/01/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Autophagy</style></keyword><keyword><style face="normal" font="default" size="100%">*Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammasomes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mechanistic Target of Rapamycin Complex 1/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*NLR Family, Pyrin Domain-Containing 3 Protein/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nlrp3</style></keyword><keyword><style face="normal" font="default" size="100%">Tfeb</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">monocytes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35038351</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: NLRP3-driven inflammatory responses by circulating and lung-resident monocytes are critical drivers of asthma pathogenesis. Autophagy restrains NLRP3-induced monocyte activation in asthma models. Yet, the effects of autophagy and its master regulator, transcription factor EB (TFEB), on monocyte responses in human asthma remain unexplored. Here, we investigated whether activation of autophagy and TFEB signaling suppress inflammatory monocyte responses in asthmatic individuals. METHODS: Peripheral blood CD14(+) monocytes from asthmatic patients (n = 83) and healthy controls (n = 46) were stimulated with LPS/ATP to induce NLRP3 activation with or without the autophagy inducer, rapamycin. ASC specks, caspase-1 activation, IL-1beta and IL-18 levels, mitochondrial function, ROS release, and mTORC1 signaling were examined. Autophagy was evaluated by LC3 puncta formation, p62/SQSTM1 degradation and TFEB activation. In a severe asthma (SA) model, we investigated the role of NLRP3 signaling using Nlrp3(-/-) mice and/or MCC950 administration, and the effects of TFEB activation using myeloid-specific TFEB-overexpressing mice or administration of the TFEB activator, trehalose. RESULTS: We observed increased NLRP3 inflammasome activation, concomitant with impaired autophagy in circulating monocytes that correlated with asthma severity. SA patients also exhibited mitochondrial dysfunction and ROS accumulation. Autophagy failed to inhibit NLRP3-driven monocyte responses, due to defective TFEB activation and excessive mTORC1 signaling. NLRP3 blockade restrained inflammatory cytokine release and linked airway disease. TFEB activation restored impaired autophagy, attenuated NLRP3-driven pulmonary inflammation, and ameliorated SA phenotype. CONCLUSIONS: Our studies uncover a crucial role for TFEB-mediated reprogramming of monocyte inflammatory responses, raising the prospect that this pathway can be therapeutically harnessed for the management of SA.</style></abstract><notes><style face="normal" font="default" size="100%">Theofani, Efthymia&#xD;Semitekolou, Maria&#xD;Samitas, Konstantinos&#xD;Mais, Annie&#xD;Galani, Ioanna E&#xD;Triantafyllia, Vasiliki&#xD;Lama, Joanna&#xD;Morianos, Ioannis&#xD;Stavropoulos, Athanasios&#xD;Jeong, Se-Jin&#xD;Andreakos, Evangelos&#xD;Razani, Babak&#xD;Rovina, Nikoletta&#xD;Xanthou, Georgina&#xD;eng&#xD;R01 DK131188/DK/NIDDK NIH HHS/&#xD;R01 HL125838/GF/NIH HHS/&#xD;I01 BX003415/BX/BLRD VA/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2131-2146. doi: 10.1111/all.15221. Epub 2022 Jan 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35038351</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15221</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>969</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">969</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garcia de Durango, C. R.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author><author><style face="normal" font="default" size="100%">Rosace, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">DKTK Research Group, Oncogenic Signalling Pathways of Colorectal Cancer, Institute of Pathology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany.&#xD;Institute of Applied Molecular Medicine (IMMA), Department of Basic Medical Sciences, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, UrbanizacionMonteprincipe, Boadilla del Monte, Madrid, Spain.&#xD;Centro De Investigacion Del Cancer and Instituto De Biologia Molecular Y Celular Del Cancer, Consejo Superior De Investigaciones Cientificas (CSIC)-Universidadde Salamanca, Salamanca, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The TGF-beta-Th2 axis: A new target for cancer therapy?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3563-3565</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">*Neoplasms/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="default" size="100%">Il-4</style></keyword><keyword><style face="normal" font="default" size="100%">TGF-beta</style></keyword><keyword><style face="normal" font="default" size="100%">cancer</style></keyword><keyword><style face="normal" font="default" size="100%">hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34047361</style></accession-num><notes><style face="normal" font="default" size="100%">Garcia de Durango, Cira Rosario&#xD;Escribese, Maria M&#xD;Rosace, Domenico&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3563-3565. doi: 10.1111/all.14965. Epub 2021 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34047361</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14965</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1910</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1910</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garcia de Durango, C. R.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author><author><style face="normal" font="default" size="100%">Rosace, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">DKTK Research Group, Oncogenic Signalling Pathways of Colorectal Cancer, Institute of Pathology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany.&#xD;Institute of Applied Molecular Medicine (IMMA), Department of Basic Medical Sciences, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, UrbanizacionMonteprincipe, Boadilla del Monte, Madrid, Spain.&#xD;Centro De Investigacion Del Cancer and Instituto De Biologia Molecular Y Celular Del Cancer, Consejo Superior De Investigaciones Cientificas (CSIC)-Universidadde Salamanca, Salamanca, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The TGF-beta-Th2 axis: A new target for cancer therapy?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3563-3565</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2021/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">*Neoplasms/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="default" size="100%">Il-4</style></keyword><keyword><style face="normal" font="default" size="100%">TGF-beta</style></keyword><keyword><style face="normal" font="default" size="100%">cancer</style></keyword><keyword><style face="normal" font="default" size="100%">hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34047361</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract The innate and adaptive immune responses are critical for the recognition and removal of pathogens. Moreover, in the last two decades it has been demonstrated that immune cells are also key cells in the cancer-related immune response.1Ideally, the immune system should eradicate the tumor cells to maintain homeostasis.However,it has been demonstrated that adysregulationof the innate and adaptive immune responsescould lead totumorigenesis, inhibition of T- and B-cell activation, and stimulation oftumor proliferation and metastasis.</style></abstract><notes><style face="normal" font="default" size="100%">Garcia de Durango, Cira Rosario&#xD;Escribese, Maria M&#xD;Rosace, Domenico&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Nov;76(11):3563-3565. doi: 10.1111/all.14965. Epub 2021 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34047361</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14965</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1372</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1372</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shrestha Palikhe, N.</style></author><author><style face="normal" font="default" size="100%">Wu, Y.</style></author><author><style face="normal" font="default" size="100%">Konrad, E.</style></author><author><style face="normal" font="default" size="100%">Gandhi, V. D.</style></author><author><style face="normal" font="default" size="100%">Rowe, B. H.</style></author><author><style face="normal" font="default" size="100%">Vliagoftis, H.</style></author><author><style face="normal" font="default" size="100%">Cameron, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary Medicine, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.&#xD;Alberta Respiratory Centre, University of Alberta, Edmonton, AB, Canada.&#xD;Department of Emergency Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.&#xD;School of Public Health, University of Alberta, Edmonton, AB, Canada.&#xD;Department of Pathology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Th2 cell markers in peripheral blood increase during an acute asthma exacerbation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">281-290</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/08/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32750154</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergic asthma is characterized by type 2 inflammation. We have shown the presence of increased type 2 inflammation in patients with severe asthma and those with frequent exacerbations. However, it is not known whether increased type 2 inflammation drives asthma exacerbations. This study aims to determine Th2 immune parameters in patients presenting to the emergency department (ED) with an acute asthma exacerbation and correlate these parameters with clinical and physiological measures of asthma. METHODS: Sixteen adults presenting to the ED with acute asthma exacerbations were recruited after giving informed consent. Ten patients returned 2 weeks later for follow-up. Physiological parameters, asthma control (ACQ6), asthma quality of life (AQLQ) questionnaires, and venous blood were collected during both visits. An immune cell profiling was performed by whole blood flow cytometry: CD4(+) T cells, Th2 cells (CD4(+) CRTh2(+) T cells and % of CD4(+) T cells expressing CRTh2), eosinophils and innate lymphoid cells (ILC2). RESULTS: During exacerbation, peripheral blood Th2 cell numbers correlated with ACQ6 and AQLQ scores, while ILC2 and eosinophil numbers did not. Subjects had higher % of CD4(+) T cells expressing CRTh2 and worse FEV(1) during exacerbation compared with the follow-up. The decrease in the % of CD4(+) T cells expressing CRTh2 seen during the follow-up visit correlated with the improvement in lung function. CONCLUSIONS: These data suggest that Th2 cells in peripheral blood may be a sensitive measure of increasing symptoms in patients with asthma exacerbations and may serve as a biomarker of an asthma exacerbation.</style></abstract><notes><style face="normal" font="default" size="100%">Shrestha Palikhe, Nami&#xD;Wu, Yingqi&#xD;Konrad, Emily&#xD;Gandhi, Vivek Dipak&#xD;Rowe, Brian H&#xD;Vliagoftis, Harissios&#xD;Cameron, Lisa&#xD;eng&#xD;CIHR/Canada&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):281-290. doi: 10.1111/all.14543. Epub 2020 Aug 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32750154</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14543</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3123</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3123</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scala, E.</style></author><author><style face="normal" font="default" size="100%">Abeni, D.</style></author><author><style face="normal" font="default" size="100%">Giani, M.</style></author><author><style face="normal" font="default" size="100%">Villella, V.</style></author><author><style face="normal" font="default" size="100%">Caprini, E.</style></author><author><style face="normal" font="default" size="100%">Brusca, I.</style></author><author><style face="normal" font="default" size="100%">Cecchi, L.</style></author><author><style face="normal" font="default" size="100%">Villalta, D.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fondazione Luigi Maria Monti, IDI-IRCCS, Rome, Italy.&#xD;U.O.C of Clinical Pathology, Buccheri La Ferla Hospital, Palermo, Italy.&#xD;Allergy and Clinical Immunology Unit, San Giovanni di Dio Hospital, Florence, Italy.&#xD;S.C. di Immunologia e Allergologia di Laboratorio, PO S. Maria Degli Angeli, Pordenone, Italy.&#xD;Ambulatorio di Allergologia, Clinica San Carlo, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thaumatin-Like Proteins in Molecular Allergy Diagnostics: Uncommon, Co-Sensitized, and Clinically Inconspicuous? Insights From an Italian Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41121597</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Thaumatin-like proteins (TLPs) are conserved plant pathogenesis-related proteins with IgE-binding capacity, but their clinical relevance remains poorly defined. Unlike well-characterized panallergens, TLPs are underrepresented in diagnostic panels, and their role in food allergy is largely unexplored. OBJECTIVE: To assess the prevalence, quantitative IgE levels, co-sensitization patterns, and clinical significance of IgE reactivity to two TLPs-Act d 2 (kiwi) and Mal d 2 (apple)-in a large Italian allergic cohort. METHODS: We conducted a cross-sectional study of 7176 consecutive patients referred to Italian tertiary allergy centers. Specific IgE to TLPs and other plant allergens was measured using ALEX(2). Clinical outcomes were evaluated, and associations with IgE levels and co-sensitizations were examined using multivariate models. ROC analyses were applied to evaluate the discriminatory ability of Act d 2 IgE for clinical severity. RESULTS: TLP sensitization occurred in 137 patients (1.9%), predominantly to Act d 2. Isolated TLP sensitization was rare (n = 20) and associated with low IgE levels (mean 0.61 +/- 0.98 kUA/L) and minimal symptoms. Co-sensitized patients (n = 117) had higher and more variable IgE levels (mean 1.41 +/- 3.49 kUA/L) and experienced more clinically relevant reactions, including oral allergy syndrome and food-dependent exercise-induced anaphylaxis. ROC analyses indicated limited discriminatory power of Act d 2 IgE for predicting reaction severity (AUC 0.51-0.61). Multivariate adjustment confirmed no independent association between TLP-specific IgE and moderate or severe symptoms. CONCLUSIONS: TLP sensitization is uncommon and generally clinically silent when isolated. Co-sensitization with other panallergens appears to drive allergic manifestations. Quantitative TLP-specific IgE alone provides limited predictive value, emphasizing the importance of integrating molecular diagnostics with clinical phenotyping in precision allergy management.</style></abstract><notes><style face="normal" font="default" size="100%">Scala, Enrico&#xD;Abeni, Damiano&#xD;Giani, Mauro&#xD;Villella, Valeria&#xD;Caprini, Elisabetta&#xD;Brusca, Ignazio&#xD;Cecchi, Lorenzo&#xD;Villalta, Danilo&#xD;Asero, Riccardo&#xD;eng&#xD;Ministero della Salute/&#xD;Denmark&#xD;Allergy. 2025 Oct 21. doi: 10.1111/all.70114.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41121597</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70114</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3115</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3115</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Korkmaz, R. U.</style></author><author><style face="normal" font="default" size="100%">Omony, J.</style></author><author><style face="normal" font="default" size="100%">Tan, X.</style></author><author><style face="normal" font="default" size="100%">Klotz, M.</style></author><author><style face="normal" font="default" size="100%">Dragunas, G.</style></author><author><style face="normal" font="default" size="100%">Chen, S.</style></author><author><style face="normal" font="default" size="100%">Shankhwar, S.</style></author><author><style face="normal" font="default" size="100%">Ertuz, Z.</style></author><author><style face="normal" font="default" size="100%">Muller, C.</style></author><author><style face="normal" font="default" size="100%">Ragab, M.</style></author><author><style face="normal" font="default" size="100%">Jeridi, A.</style></author><author><style face="normal" font="default" size="100%">Augustin, R.</style></author><author><style face="normal" font="default" size="100%">Nawroth, J.</style></author><author><style face="normal" font="default" size="100%">Kapellos, T. S.</style></author><author><style face="normal" font="default" size="100%">Rankl, B.</style></author><author><style face="normal" font="default" size="100%">Yildirim, A. O.</style></author><author><style face="normal" font="default" size="100%">von Mutius, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Helmholtz Zentrum Munchen, Research Center for Environmental Health, Institute of Asthma and Allergy Prevention, Neuherberg, Germany.&#xD;Comprehensive Pneumology Center (CPC-M), Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Munich, Germany.&#xD;Department of Pharmacy-Center for Drug Research, Ludwig-Maximilians Universitat Munchen, Munich, Germany.&#xD;Department of Internal Medicine II, TUM University Hospital, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.&#xD;German Center for Lung Research (DZL), Munich, Germany.&#xD;Helmholtz Pioneer Campus, Helmholtz Zentrum Munchen, Neuherberg, Germany.&#xD;Institute of Biological and Medical Imaging, Bioengineering Center, Helmholtz Zentrum Munchen, Neuherberg, Germany.&#xD;Chair of Biological Imaging at the Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, Technical University of Munich, Munich, Germany.&#xD;Faculty of Engineering Sciences, University of Heidelberg, Heidelberg, Germany.&#xD;Institute of Experimental Pneumology, LMU University Hospital, Ludwig-Maximilian&apos;s University, Munich, Germany.&#xD;Ludwig-Maximilians University, Dr. von Hauner Children&apos;s Hospital, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Therapeutic Potential of Farm Dust Extracts in a Mouse Model of Eosinophilic Inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Th2 inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">farm dust extract</style></keyword><keyword><style face="normal" font="default" size="100%">prophylactic intervention</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41123048</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma affects over 355 million people globally and poses a major healthcare burden. While corticosteroids remain a cornerstone of treatment, their side effects highlight the need for additional therapeutic strategies. Environmental exposures such as traditional farm dust have been linked to protection against asthma and allergies. This study investigated the therapeutic potential of farm dust extract (FDE) in a murine model of allergic asthma when administered after sensitization and during allergen challenge, mimicking a secondary prevention or early interventional treatment approach. METHODS: We used an ovalbumin (OVA)-induced asthma model to evaluate FDE effects on airway eosinophilia, airway hyperresponsiveness (AHR), mucus production, and IgE levels. Mechanistic studies assessed regulatory T cells (Tregs), dendritic cell phenotype, epithelial barrier integrity, and cytokine signaling. Complementary experiments were performed in peripheral blood mononuclear cells (PBMCs) from asthmatic donors. RESULTS: FDE significantly reduced airway inflammation and AHR, with secondary prevention effects comparable to systemic dexamethasone. FDE enhanced Treg frequency and CTLA-4 expression, modulated dendritic cell MHC-II and PD-L1 expression, and promoted an immunoregulatory environment. It also restored epithelial barrier integrity and increased IL-33 release, supporting Treg activation. In asthmatic PBMCs, FDE increased Tregs, reduced Th2 cells, and suppressed CIITA, suggesting similar immune-regulatory effects. Interactions among IL-33, amphiregulin (AREG), and Tregs highlighted a mechanism reinforcing immune-epithelial homeostasis. CONCLUSION: FDE administered after sensitization and during allergen challenge mitigated key asthma features in mice and showed translational potential in human cells, supporting its development as a novel, environmentally derived immunomodulatory strategy.</style></abstract><notes><style face="normal" font="default" size="100%">Korkmaz, Rabia Ulku&#xD;Omony, Jimmy&#xD;Tan, Xiaomei&#xD;Klotz, Markus&#xD;Dragunas, Guilherme&#xD;Chen, Sirui&#xD;Shankhwar, Soni&#xD;Ertuz, Zeynep&#xD;Muller, Christoph&#xD;Ragab, Mohab&#xD;Jeridi, Aicha&#xD;Augustin, Romina&#xD;Nawroth, Janna&#xD;Kapellos, Theodore S&#xD;Rankl, Bettina&#xD;Yildirim, Ali Onder&#xD;von Mutius, Erika&#xD;eng&#xD;German Center for Lung Research (DZL)/&#xD;Federal Ministry of Education and Research/&#xD;ERC_/European Research Council/International&#xD;German Center for Lung Research/&#xD;Denmark&#xD;Allergy. 2025 Oct 22. doi: 10.1111/all.70121.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41123048</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70121</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2548</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2548</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rupani, H.</style></author><author><style face="normal" font="default" size="100%">Busse, W. W.</style></author><author><style face="normal" font="default" size="100%">Howarth, P. H.</style></author><author><style face="normal" font="default" size="100%">Bardin, P. G.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Konno, S.</style></author><author><style face="normal" font="default" size="100%">Jackson, D. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, UK.&#xD;Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK.&#xD;Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.&#xD;Global Medical, Global Specialty and Primary Care, GSK, Brentford, Middlesex, UK.&#xD;Monash Lung Sleep Allergy and Immunology, Monash University and Medical Centre and Hudson Institute, Melbourne, Victoria, Australia.&#xD;Airway Disease Section, National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.&#xD;Guy&apos;s Severe Asthma Centre, Guy&apos;s and St Thomas&apos; Hospitals, London, UK.&#xD;School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Therapeutic relevance of eosinophilic inflammation and airway viral interactions in severe asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2589-2604</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/08/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/immunology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Inflammation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Virus Diseases/immunology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Tract Infections/immunology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophilia/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biologic</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39087443</style></accession-num><abstract><style face="normal" font="default" size="100%">The role of eosinophils in airway inflammation and asthma pathogenesis is well established, with raised eosinophil counts in blood and sputum associated with increased disease severity and risk of asthma exacerbation. Conversely, there is also preliminary evidence suggesting antiviral properties of eosinophils in the airways. These dual roles for eosinophils are particularly pertinent as respiratory virus infections contribute to asthma exacerbations. Biologic therapies targeting key molecules implicated in eosinophil-associated pathologies have been approved in patients with severe asthma and, therefore, the effects of depleting eosinophils in a clinical setting are of considerable interest. This review discusses the pathological and antiviral roles of eosinophils in asthma and exacerbations. We also highlight the significant reduction in asthma exacerbations seen with biologic therapies, even at the height of the respiratory virus season. Furthermore, we discuss the implications of these findings in relation to the role of eosinophils in inflammation and antiviral responses to respiratory virus infection in asthma.</style></abstract><notes><style face="normal" font="default" size="100%">Rupani, Hitasha&#xD;Busse, William W&#xD;Howarth, Peter H&#xD;Bardin, Philip G&#xD;Adcock, Ian M&#xD;Konno, Satoshi&#xD;Jackson, David J&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2589-2604. doi: 10.1111/all.16242. Epub 2024 Aug 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39087443</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16242</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2224</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2224</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Taki, A. C.</style></author><author><style face="normal" font="default" size="100%">Ruethers, T.</style></author><author><style face="normal" font="default" size="100%">Nugraha, R.</style></author><author><style face="normal" font="default" size="100%">Karnaneedi, S.</style></author><author><style face="normal" font="default" size="100%">Williamson, N. A.</style></author><author><style face="normal" font="default" size="100%">Nie, S.</style></author><author><style face="normal" font="default" size="100%">Leeming, M. G.</style></author><author><style face="normal" font="default" size="100%">Mehr, S. S.</style></author><author><style face="normal" font="default" size="100%">Campbell, D. E.</style></author><author><style face="normal" font="default" size="100%">Lopata, A. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Molecular Allergy Research Laboratory, Discipline of Molecular and Cell Biology, College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, Queensland, Australia.&#xD;Department of Veterinary Biosciences, Melbourne Veterinary School, Faculty of Science, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Tropical Futures Institute, James Cook University, Singapore City, Singapore.&#xD;Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia.&#xD;Centre for Food and Allergy Research, Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;Department of Aquatic Product Technology, Faculty of Fisheries and Marine Science, IPB University, Bogor, Indonesia.&#xD;Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria, Australia.&#xD;Department of Allergy and Immunology, The Royal Children&apos;s Hospital, Parkville, Victoria, Australia.&#xD;Department of Allergy and Immunology, The Children&apos;s Hospital at Westmead, Westmead, New South Wales, Australia.&#xD;Discipline of Paediatrics and Child Health, The University of Sydney, Westmead, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thermostable allergens in canned fish: Evaluating risks for fish allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3221-3234</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/08/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Tropomyosin</style></keyword><keyword><style face="normal" font="default" size="100%">Fishes</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies</style></keyword><keyword><style face="normal" font="default" size="100%">Salmon</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Fish Products/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Parvalbumins</style></keyword><keyword><style face="normal" font="default" size="100%">Collagen</style></keyword><keyword><style face="normal" font="default" size="100%">canned fish</style></keyword><keyword><style face="normal" font="default" size="100%">fish allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy management</style></keyword><keyword><style face="normal" font="default" size="100%">parvalbumin</style></keyword><keyword><style face="normal" font="default" size="100%">thermostable allergen</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37650248</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Major fish allergens, including parvalbumin (PV), are heat stable and can withstand extensive cooking processes. Thus, the management of fish allergy generally relies on complete avoidance. Fish-allergic patients may be advised to consume canned fish, as some fish-allergic individuals have reported tolerance to canned fish. However, the safety of consuming canned fish has not been evaluated with comprehensive immunological and molecular analysis of canned fish products. METHODS: We characterized the in vitro immunoreactivity of serum obtained from fish-allergic subjects to canned fish. Seventeen canned fish products (salmon n = 8; tuna n = 7; sardine n = 2) were assessed for the content and integrity of PV using allergen-specific antibodies. Subsequently, the sIgE binding of five selected products was evaluated for individual fish-allergic patients (n = 53). Finally, sIgE-binding proteins were identified by mass spectrometry. RESULTS: The canned fish showed a markedly reduced PV content and binding to PV-specific antibodies compared with conventionally cooked fish. However, PV and other heat-stable fish allergens, including tropomyosin and collagen, still maintained their sIgE-binding capacity. Of 53 patients, 66% showed sIgE binding to canned fish proteins. The canned sardine contained proteins bound to sIgE from 51% of patients, followed by canned salmon (43%-45%) and tuna (8%-17%). PV was the major allergen in canned salmon and sardine. Tropomyosin and/or collagen also showed sIgE binding. CONCLUSION: We showed that canned fish products may not be safe for all fish-allergic patients. Canned fish products should only be considered into the diet of individuals with fish allergy, after detailed evaluation which may include in vitro diagnostics to various heat-stable fish allergens and food challenge conducted in suitable environments.</style></abstract><notes><style face="normal" font="default" size="100%">Taki, Aya C&#xD;Ruethers, Thimo&#xD;Nugraha, Roni&#xD;Karnaneedi, Shaymaviswanathan&#xD;Williamson, Nicholas A&#xD;Nie, Shuai&#xD;Leeming, Michael G&#xD;Mehr, Sam S&#xD;Campbell, Dianne E&#xD;Lopata, Andreas L&#xD;eng&#xD;Centre for Food and Allergy Research/&#xD;National Health and Medical Research Council/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3221-3234. doi: 10.1111/all.15864. Epub 2023 Aug 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37650248</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10952748</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15864</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1378</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1378</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Gallego, N.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Madrid, F.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Inmunologia, Hospital Universitario La Princesa, Instituto Investigacion Sanitaria Princesa (IIS-IP), Universidad Autonoma de Madrid (UAM), Madrid, Spain.&#xD;Vascular Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.&#xD;CIBER de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.&#xD;Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;McMaster Immunology Research Centre (MIRC), Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thinking small: Zinc sensing by the gut epithelium</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">411-413</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Digestive System</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Mucosal</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Zinc</style></keyword><keyword><style face="normal" font="default" size="100%">antigen presentation</style></keyword><keyword><style face="normal" font="default" size="100%">enterocytes</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">nutrient sensing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32738826</style></accession-num><notes><style face="normal" font="default" size="100%">Fernandez-Gallego, Nieves&#xD;Sanchez-Madrid, Francisco&#xD;Jimenez-Saiz, Rodrigo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):411-413. doi: 10.1111/all.14531. Epub 2020 Aug 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32738826</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14531</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1622</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1622</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Gallego, N.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Madrid, F.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Inmunologia, Hospital Universitario La Princesa, Instituto Investigacion Sanitaria Princesa (IIS-IP), Universidad Autonoma de Madrid (UAM), Madrid, Spain.&#xD;Vascular Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.&#xD;CIBER de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.&#xD;Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;McMaster Immunology Research Centre (MIRC), Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thinking small: Zinc sensing by the gut epithelium</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">411-413</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Digestive System</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Mucosal</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Zinc</style></keyword><keyword><style face="normal" font="default" size="100%">antigen presentation</style></keyword><keyword><style face="normal" font="default" size="100%">enterocytes</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">nutrient sensing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32738826</style></accession-num><notes><style face="normal" font="default" size="100%">Fernandez-Gallego, Nieves&#xD;Sanchez-Madrid, Francisco&#xD;Jimenez-Saiz, Rodrigo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):411-413. doi: 10.1111/all.14531. Epub 2020 Aug 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32738826</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14531</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1911</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1911</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez-Gallego, N.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Madrid, F.</style></author><author><style face="normal" font="default" size="100%">Jimenez-Saiz, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Inmunologia, Hospital Universitario La Princesa, Instituto Investigacion Sanitaria Princesa (IIS-IP), Universidad Autonoma de Madrid (UAM), Madrid, Spain.&#xD;Vascular Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.&#xD;CIBER de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.&#xD;Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain.&#xD;McMaster Immunology Research Centre (MIRC), Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.&#xD;Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thinking small: Zinc sensing by the gut epithelium</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">411-413</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Digestive System</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Mucosal</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Zinc</style></keyword><keyword><style face="normal" font="default" size="100%">antigen presentation</style></keyword><keyword><style face="normal" font="default" size="100%">enterocytes</style></keyword><keyword><style face="normal" font="default" size="100%">immune tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">nutrient sensing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32738826</style></accession-num><notes><style face="normal" font="default" size="100%">Fernandez-Gallego, Nieves&#xD;Sanchez-Madrid, Francisco&#xD;Jimenez-Saiz, Rodrigo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):411-413. doi: 10.1111/all.14531. Epub 2020 Aug 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32738826</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14531</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1332</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1332</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D. E.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Monroy, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medica Sur, Clinical Foundation and Hospital, Mexico D.F., Mexico.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thirty-six COVID-19 cases preventively vaccinated with mumps-measles-rubella vaccine: All mild course</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">910-914</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/09/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/immunology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Measles-Mumps-Rubella Vaccine/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">MMR vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">measles vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32894782</style></accession-num><notes><style face="normal" font="default" size="100%">Larenas-Linnemann, Desiree E&#xD;Rodriguez-Monroy, Fernanda&#xD;eng&#xD;Letter&#xD;Observational Study&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):910-914. doi: 10.1111/all.14584. Epub 2020 Sep 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32894782</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14584</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>762</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">762</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tang, X.</style></author><author><style face="normal" font="default" size="100%">Rabin, R. L.</style></author><author><style face="normal" font="default" size="100%">Yan, L. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland, USA.&#xD;Office of Vaccines Research and Review, CBER, FDA, Silver Spring, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A three-stage design for allergen immunotherapy trials</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1835-1842</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/10/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">allergen immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">delayed introduction</style></keyword><keyword><style face="normal" font="default" size="100%">discontinue treatment</style></keyword><keyword><style face="normal" font="default" size="100%">placebo-crossover</style></keyword><keyword><style face="normal" font="default" size="100%">sustained response</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34599605</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Clinical trials of allergen immunotherapy (AIT) may require up to 5 years to complete. These lengthy trials may be complicated by high and potentially differential dropouts, especially among participants who perceive that they are receiving placebo. We propose a three-stage design in which the placebo group in Stage 1 crosses over to receive active treatment in Stage 2. In Stage 3, AIT is discontinued to determine whether benefit is maintained post-treatment. We apply inferential statistics to support the three-stage design for clinical trials to determine clinical efficacy, treatment response over time, and sustained response to AIT. METHODS: The proposed framework constitutes a series of hypothesis tests for comparing treatment responses at the end of each stage. A simulation study was performed to illustrate the statistical properties under varying statistical missing mechanisms and effect sizes. RESULTS: The statistical properties in terms of bias and statistical power were consistent with what are expected from conventional analyses. Specifically, the extent of bias depended on the missing mechanism and magnitude. The statistical powers were largely driven by effect and sample sizes as well as prespecified success margins. As an illustration, assuming relative treatment differences of 25% and stagewise dropout rate of 15%, a sample size of 200 per group may achieve 93% power to demonstrate a treatment effect and 60% power to demonstrate a maintained response post-treatment. CONCLUSIONS: Inferential statistics support our proposed study design for evaluating benefits of AIT over time and inform clinical understanding and decisions.</style></abstract><notes><style face="normal" font="default" size="100%">Tang, Xinyu&#xD;Rabin, Ronald L&#xD;Yan, Lihan K&#xD;eng&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1835-1842. doi: 10.1111/all.15117. Epub 2021 Oct 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34599605</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15117</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3251</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3251</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yamamoto-Hanada, Kiwako</style></author><author><style face="normal" font="default" size="100%">Saito-Abe, Mayako</style></author><author><style face="normal" font="default" size="100%">Sato, Miori</style></author><author><style face="normal" font="default" size="100%">Ishikawa, Fumi</style></author><author><style face="normal" font="default" size="100%">Toyokuni, Kenji</style></author><author><style face="normal" font="default" size="100%">Inuzuka, Yusuke</style></author><author><style face="normal" font="default" size="100%">Yaguchi, Tomoki</style></author><author><style face="normal" font="default" size="100%">Ogasawara, Hisako</style></author><author><style face="normal" font="default" size="100%">Shimada, Mami</style></author><author><style face="normal" font="default" size="100%">Kabashima, Shigenori</style></author><author><style face="normal" font="default" size="100%">Iikura, Katsuhito</style></author><author><style face="normal" font="default" size="100%">Tsuchiya, Kunihiko</style></author><author><style face="normal" font="default" size="100%">Morimoto, Mariko</style></author><author><style face="normal" font="default" size="100%">Tamagawa-Mineoka, Risa</style></author><author><style face="normal" font="default" size="100%">Masuda, Koji</style></author><author><style face="normal" font="default" size="100%">Hosoi, Hajime</style></author><author><style face="normal" font="default" size="100%">Katoh, Norito</style></author><author><style face="normal" font="default" size="100%">Kameda, Makoto</style></author><author><style face="normal" font="default" size="100%">Takaoka, Yuri</style></author><author><style face="normal" font="default" size="100%">Shigekawa, Amane</style></author><author><style face="normal" font="default" size="100%">Takemura, Yutaka</style></author><author><style face="normal" font="default" size="100%">Xu, Alexandre</style></author><author><style face="normal" font="default" size="100%">Sato, Sakura</style></author><author><style face="normal" font="default" size="100%">Ebisawa, Motohiro</style></author><author><style face="normal" font="default" size="100%">Itonaga, Takaaki</style></author><author><style face="normal" font="default" size="100%">Hasegawa, Shunji</style></author><author><style face="normal" font="default" size="100%">Wakiguchi, Hiroyuki</style></author><author><style face="normal" font="default" size="100%">Fujisawa, Takao</style></author><author><style face="normal" font="default" size="100%">Kanai, Rei</style></author><author><style face="normal" font="default" size="100%">Yamaide, Fumiya</style></author><author><style face="normal" font="default" size="100%">Nakano, Taiji</style></author><author><style face="normal" font="default" size="100%">Natsume, Osamu</style></author><author><style face="normal" font="default" size="100%">Yasuoka, Ryuhei</style></author><author><style face="normal" font="default" size="100%">Kondo, Yasuto</style></author><author><style face="normal" font="default" size="100%">Mori, Yuji</style></author><author><style face="normal" font="default" size="100%">Kawaguchi, Takahiro</style></author><author><style face="normal" font="default" size="100%">Futamura, Masaki</style></author><author><style face="normal" font="default" size="100%">Sugiura, Kazumitsu</style></author><author><style face="normal" font="default" size="100%">Kitazawa, Hiroshi</style></author><author><style face="normal" font="default" size="100%">Hamahata, Yuko</style></author><author><style face="normal" font="default" size="100%">Akiyama, Masashi</style></author><author><style face="normal" font="default" size="100%">Kono, Michihiro</style></author><author><style face="normal" font="default" size="100%">Pak, Kyongsun</style></author><author><style face="normal" font="default" size="100%">Fukuie, Tatsuki</style></author><author><style face="normal" font="default" size="100%">Kobayashi, Tohru</style></author><author><style face="normal" font="default" size="100%">Saito, Hirohisa</style></author><author><style face="normal" font="default" size="100%">Williams, Hywel C.</style></author><author><style face="normal" font="default" size="100%">Ohya, Yukihiro</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Three-Year Follow-Up of the PACI Randomized Controlled Trial (PACI-ON): Effects of Early Intervention for Atopic Dermatitis on Atopic March</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background The Prevention of Allergy via Cutaneous Intervention (PACI) randomized controlled trial (RCT) demonstrated that early enhanced topical corticosteroid (TCS) therapy modestly reduced food allergy (FA) at 28 weeks of age. The present prospective follow-up study (PACI-ON) evaluated whether these effects persisted to age 3 years. Methods Participants were randomized in infancy to early enhanced (proactive) or early conventional (reactive) TCS treatment (1:1) for atopic dermatitis (AD) until 28 weeks. A total of 590 (91%) children who completed the PACI RCT were followed to age 3 years. During follow-up, no protocolized interventions were given; all participants received usual care. Main outcomes included physician-diagnosed FA, AD severity (EASI, POEM), sensitization profiles, allergic comorbidities, and growth parameters as safety outcomes. Results At age 3 years, the prevalence of any FA remained lower in the early enhanced group than in the conventional group (47.4% vs. 58.8%, p = 0.006), mainly driven by a reduced prevalence of raw egg allergy (30.4% vs. 40.5%, p = 0.013). No between-group differences were observed for wheeze, asthma, or rhinitis. Japanese cedar sensitization at age 2 was lower in the enhanced group (6.1% vs. 12.2%, p = 0.02 6) but not at age 3. AD control and quality of life were well maintained and similar across groups, with &gt; 90% achieving mild or less disease. Early growth suppression at 1 year resolved by age 3. Conclusion Early enhanced AD intervention was associated with a sustained modest reduction in its planned primary follow-up outcome of FA and safety (growth) up to age 3. Although most differences were small and may reflect early diagnosis and good overall management in both groups, the findings support early AD treatment as a potential strategy to modify allergic disease trajectories.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70262</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70262</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>653</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">653</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, Y.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Zhu, L.</style></author><author><style face="normal" font="default" size="100%">Huang, C.</style></author><author><style face="normal" font="default" size="100%">Chen, W.</style></author><author><style face="normal" font="default" size="100%">Ling, Z.</style></author><author><style face="normal" font="default" size="100%">Zhu, S.</style></author><author><style face="normal" font="default" size="100%">Feng, X.</style></author><author><style face="normal" font="default" size="100%">Yi, C.</style></author><author><style face="normal" font="default" size="100%">Gu, W.</style></author><author><style face="normal" font="default" size="100%">Yan, C.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Ma, L.</style></author><author><style face="normal" font="default" size="100%">Su, X.</style></author><author><style face="normal" font="default" size="100%">Dai, R.</style></author><author><style face="normal" font="default" size="100%">Shi, G.</style></author><author><style face="normal" font="default" size="100%">Sun, B.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.&#xD;Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.&#xD;Unit of Respiratory Infection and Immunity, Chinese Academy of Sciences, Institute Pasteur of Shanghai, Shanghai, China.&#xD;Department of Respiratory Medicine, First Affiliated Hospital of Xinjiang Medical University, Wulumuqi, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thrombin cleaves IL-33 and modulates IL-33-activated allergic lung inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2104-2120</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Alveolitis, Extrinsic Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Heparin, Low-Molecular-Weight/metabolism/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombin/metabolism/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Il-33</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">group 2 innate lymphoid cell</style></keyword><keyword><style face="normal" font="default" size="100%">thrombin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34995358</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Organisms have orchestrated coagulation and immune systems. Although a link between inflammation and haemostasis has been reported in asthma, the interaction mechanism has not been completely elucidated. Here, we investigated the direct link between the mammalian immune and coagulation systems. METHODS: Mice were administered protease or antigens intranasally to induce airway inflammation with or without thrombin inhibitors treatment. The effects of thrombin and its inhibitors on interleukin (IL)-33 were investigated both in vivo and in vitro. Peripheral blood mononuclear cells (PBMCs) and plasma from asthma patients are collected to verify the correlation between thrombin and group 2 innate lymphocytes (ILC2s). RESULTS: Low-molecular-weight heparin (LMWH, an indirect inhibitor of thrombin) restrained both papain- and fungus-induced type 2 immune responses in mice by inhibiting IL-33 cleavage. Upon examining the potential thrombin protease consensus sites, we found that IL-33 was directly cleaved by thrombin at specific amino acids (R48 and R106) to generate a mature form of IL-33 with potent biological activity. In addition, we found that bivalirudin TFA (a direct inhibitor of thrombin) inhibited a variety of type 2 inflammatory responses, such as those in house dust mite (HDM)- and ovalbumin (OVA)-mediated pulmonary inflammation models. We found that plasma thrombin-antithrombin complex (TATc) levels in asthma patients were positively associated with the number and function of IL-33-responder group 2 innate lymphocytes (ILC2s) among peripheral blood mononuclear cells (PBMCs) from asthma patients. CONCLUSION: The data suggested that thrombin inhibitors administration could be effective in treating lung inflammation by regulating ILC2s via IL-33 maturation, indicating that targeting thrombin is a potential way to treat allergic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Huang, Yuying&#xD;Li, Xuezhen&#xD;Zhu, Lin&#xD;Huang, Chunrong&#xD;Chen, Wen&#xD;Ling, Zhiyang&#xD;Zhu, SongLing&#xD;Feng, Xintong&#xD;Yi, Chunyan&#xD;Gu, Wangpeng&#xD;Yan, Chenghua&#xD;Wang, Jing&#xD;Ma, Liyan&#xD;Su, Xiao&#xD;Dai, Ranran&#xD;Shi, Guochao&#xD;Sun, Bing&#xD;Zhang, Yaguang&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2104-2120. doi: 10.1111/all.15210. Epub 2022 Jan 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34995358</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15210</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2657</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2657</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thien, F.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Eastern Health &amp; Monash University, Melbourne, Victoria, Australia.&#xD;IDESP, INSERM and University of Montpellier &amp; Department of Pulmonology, Allergy and Thoracic Oncology, University Hospital of Montpellier, Montpellier, France.&#xD;Division of Respiratory and Allergic Diseases, High Speciality Hospital &apos;A. Cardarelli&apos;, Professor of Respiratory Allergy School of Specialization in Respiratory Diseases, Federico II University of Naples, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thunderstorm-related respiratory symptoms: An old story with a new ending?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">377-379</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/09/02</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39221480</style></accession-num><notes><style face="normal" font="default" size="100%">Thien, Francis&#xD;Annesi-Maesano, Isabella&#xD;D&apos;Amato, Gennaro&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):377-379. doi: 10.1111/all.16308. Epub 2024 Sep 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39221480</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16308</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2379</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2379</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wilson, J. M.</style></author><author><style face="normal" font="default" size="100%">Erickson, L.</style></author><author><style face="normal" font="default" size="100%">Levin, M.</style></author><author><style face="normal" font="default" size="100%">Ailsworth, S. M.</style></author><author><style face="normal" font="default" size="100%">Commins, S. P.</style></author><author><style face="normal" font="default" size="100%">Platts-Mills, T. A. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, University of Virginia, Charlottesville, Virginia, USA.&#xD;Department of Microbiology, Immunology, and Cancer Biology and Beirne Carter Center for Immunology Research, University of Virginia, Charlottesville, Virginia, USA.&#xD;University of Cape Town, Rondebosch, South Africa.&#xD;Division of Rheumatology, Allergy and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tick bites, IgE to galactose-alpha-1,3-galactose and urticarial or anaphylactic reactions to mammalian meat: The alpha-gal syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1440-1454</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/01/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/immunology/etiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Disaccharides/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mammals/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Meat/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">*Tick Bites/immunology/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Ticks/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Tick-Borne Diseases/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-gal</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">mammalian meat allergy</style></keyword><keyword><style face="normal" font="default" size="100%">ticks</style></keyword><keyword><style face="normal" font="default" size="100%">the alpha-gal IgE assay. J.W. and TP-M have received assay support from</style></keyword><keyword><style face="normal" font="default" size="100%">Thermo-Fisher/Phadia. S.C. is the recipient of a grant from Revivicor, Inc. and</style></keyword><keyword><style face="normal" font="default" size="100%">has received royalties from UpToDate Inc., honoraria from Genentech for</style></keyword><keyword><style face="normal" font="default" size="100%">participation in educational events and Regeneron for participation in an</style></keyword><keyword><style face="normal" font="default" size="100%">advisory meeting. The remaining authors do not have relevant disclosures.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38193233</style></accession-num><abstract><style face="normal" font="default" size="100%">The recent recognition of a syndrome of tick-acquired mammalian meat allergy has transformed the previously held view that mammalian meat is an uncommon allergen. The syndrome, mediated by IgE antibodies against the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal), can also involve reactions to visceral organs, dairy, gelatin and other products, including medications sourced from non-primate mammals. Thus, fittingly, this allergic disorder is now called the alpha-gal syndrome (AGS). The syndrome is strikingly regional, reflecting the important role of tick bites in sensitization, and is more common in demographic groups at risk of tick exposure. Reactions in AGS are delayed, often by 2-6 h after ingestion of mammalian meat. In addition to classic allergic symptomatology such as urticaria and anaphylaxis, AGS is increasingly recognized as a cause of isolated gastrointestinal morbidity and alpha-gal sensitization has also been linked with cardiovascular disease. The unusual link with tick bites may be explained by the fact that allergic cells and mediators are mobilized to the site of tick bites and play a role in resistance against ticks and tick-borne infections. IgE directed to alpha-gal is likely an incidental consequence of what is otherwise an adaptive immune strategy for host defense against endo- and ectoparasites, including ticks.</style></abstract><notes><style face="normal" font="default" size="100%">Wilson, Jeffrey M&#xD;Erickson, Loren&#xD;Levin, Michael&#xD;Ailsworth, Samuel M&#xD;Commins, Scott P&#xD;Platts-Mills, Thomas A E&#xD;eng&#xD;R01 AI135049/AI/NIAID NIH HHS/&#xD;R21 AI166861/AI/NIAID NIH HHS/&#xD;NH/NIH HHS/&#xD;R01 AI172112/AI/NIAID NIH HHS/&#xD;R37 AI020565/AI/NIAID NIH HHS/&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1440-1454. doi: 10.1111/all.16003. Epub 2024 Jan 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38193233</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11142869</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16003</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1025</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1025</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koidl, L.</style></author><author><style face="normal" font="default" size="100%">Rohrhofer, J.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Time matters: The circadian rhythm in intestinal homeostasis and food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2931-2933</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/04/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Circadian Rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intestines</style></keyword><keyword><style face="normal" font="default" size="100%">circadian rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">intermittent fasting</style></keyword><keyword><style face="normal" font="default" size="100%">intestinal barrier function</style></keyword><keyword><style face="normal" font="default" size="100%">oral tolerance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33914931</style></accession-num><notes><style face="normal" font="default" size="100%">Koidl, Larissa&#xD;Rohrhofer, Johanna&#xD;Untersmayr, Eva&#xD;eng&#xD;JPI HDHL KP project &quot;Intestinal microbiomics&quot;/&#xD;Comment&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2931-2933. doi: 10.1111/all.14887. Epub 2021 May 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33914931</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14887</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1615</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1615</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koidl, L.</style></author><author><style face="normal" font="default" size="100%">Rohrhofer, J.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Time matters: The circadian rhythm in intestinal homeostasis and food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2931-2933</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/04/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Circadian Rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intestines</style></keyword><keyword><style face="normal" font="default" size="100%">circadian rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">intermittent fasting</style></keyword><keyword><style face="normal" font="default" size="100%">intestinal barrier function</style></keyword><keyword><style face="normal" font="default" size="100%">oral tolerance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33914931</style></accession-num><notes><style face="normal" font="default" size="100%">Koidl, Larissa&#xD;Rohrhofer, Johanna&#xD;Untersmayr, Eva&#xD;eng&#xD;JPI HDHL KP project &quot;Intestinal microbiomics&quot;/&#xD;Comment&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2931-2933. doi: 10.1111/all.14887. Epub 2021 May 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33914931</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14887</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1907</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1907</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koidl, L.</style></author><author><style face="normal" font="default" size="100%">Rohrhofer, J.</style></author><author><style face="normal" font="default" size="100%">Untersmayr, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Time matters: The circadian rhythm in intestinal homeostasis and food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2931-2933</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2021/04/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Circadian Rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intestines</style></keyword><keyword><style face="normal" font="default" size="100%">circadian rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">intermittent fasting</style></keyword><keyword><style face="normal" font="default" size="100%">intestinal barrier function</style></keyword><keyword><style face="normal" font="default" size="100%">oral tolerance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33914931</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract Intestinal immune homeostasis and well-balanced oral tolerance mechanisms are essential for defending the host against pathogens and toxic substances while simultaneously absorbing essential nutrients to nourish the human body.</style></abstract><notes><style face="normal" font="default" size="100%">Koidl, Larissa&#xD;Rohrhofer, Johanna&#xD;Untersmayr, Eva&#xD;eng&#xD;JPI HDHL KP project &quot;Intestinal microbiomics&quot;/&#xD;Comment&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Sep;76(9):2931-2933. doi: 10.1111/all.14887. Epub 2021 May 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33914931</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14887</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2303</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2303</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abbasi, Kamran</style></author><author><style face="normal" font="default" size="100%">Ali, Parveen</style></author><author><style face="normal" font="default" size="100%">Barbour, Virginia</style></author><author><style face="normal" font="default" size="100%">Benfield, Thomas</style></author><author><style face="normal" font="default" size="100%">Bibbins‐Domingo, Kirsten</style></author><author><style face="normal" font="default" size="100%">Hancocks, Stephen</style></author><author><style face="normal" font="default" size="100%">Horton, Richard</style></author><author><style face="normal" font="default" size="100%">Laybourn‐Langton, Laurie</style></author><author><style face="normal" font="default" size="100%">Mash, Robert</style></author><author><style face="normal" font="default" size="100%">Sahni, Peush</style></author><author><style face="normal" font="default" size="100%">Sharief, Wadeia Mohammad</style></author><author><style face="normal" font="default" size="100%">Yonga, Paul</style></author><author><style face="normal" font="default" size="100%">Zielinski, Chris</style></author><author><style face="normal" font="default" size="100%">Erhabor, Gregory E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">BMJ, London, UK.&#xD;International Nursing Review, Sheffield, UK.&#xD;Medical Journal of Australia, Brisbane, Australia.&#xD;Danish Medical Journal, Copenhagen, Denmark.&#xD;JAMA, San Fransico, USA.&#xD;British Dental Journal, London, UK.&#xD;The Lancet, London, UK.&#xD;University of Exeter, Exeter, UK.&#xD;African Journal of Primary Health Care &amp; Family Medicine, Stellenbosch, South Africa.&#xD;National Medical Journal of India, New Delhi, India.&#xD;Dubai Medical Journal, Dubai, UAE.&#xD;East African Medical Journal, Nairobi, Kenya.&#xD;University of Winchester, Winchester, England.&#xD;West African Journal of Medicine, Nigeria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Time to treat the climate and nature crisis as one indivisible global health emergency</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">286-289</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2023/11/21</style></edition><section><style face="normal" font="default" size="100%">286</style></section><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 20</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538&#xD;1398-9995</style></isbn><accession-num><style face="normal" font="default" size="100%">37984455</style></accession-num><notes><style face="normal" font="default" size="100%">Abbasi, Kamran&#xD;Ali, Parveen&#xD;Barbour, Virginia&#xD;Benfield, Thomas&#xD;Bibbins-Domingo, Kirsten&#xD;Hancocks, Stephen&#xD;Horton, Richard&#xD;Laybourn-Langton, Laurie&#xD;Mash, Robert&#xD;Sahni, Peush&#xD;Sharief, Wadeia Mohammad&#xD;Yonga, Paul&#xD;Zielinski, Chris&#xD;Erhabor, Gregory E&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2023 Nov 20. doi: 10.1111/all.15944.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37984455</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15944</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3073</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3073</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Worrall, W. P. M.</style></author><author><style face="normal" font="default" size="100%">Serhan, N.</style></author><author><style face="normal" font="default" size="100%">Karrich, J. J.</style></author><author><style face="normal" font="default" size="100%">El Samrout, C.</style></author><author><style face="normal" font="default" size="100%">Ekren, R.</style></author><author><style face="normal" font="default" size="100%">Kamphuis, J. B. J.</style></author><author><style face="normal" font="default" size="100%">Hateb, C.</style></author><author><style face="normal" font="default" size="100%">Leveque, E.</style></author><author><style face="normal" font="default" size="100%">Loste, A.</style></author><author><style face="normal" font="default" size="100%">Apoil, P. A.</style></author><author><style face="normal" font="default" size="100%">Gaudenzio, N.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 - CNRS UMR5051 - University of Toulouse, Toulouse, France.&#xD;Institut Federatif de Biologie, University Hospital Centre of Toulouse, Toulouse, France.&#xD;Genoskin SAS, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tissue Distribution and Phenotype of Human Mast Cells in BRGSF and NSG-SGM3-IL15 Humanized Mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3212-3216</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/09/20</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40974102</style></accession-num><notes><style face="normal" font="default" size="100%">Worrall, William P M&#xD;Serhan, Nadine&#xD;Karrich, Julien J&#xD;El Samrout, Celine&#xD;Ekren, Ruchan&#xD;Kamphuis, Jasper B J&#xD;Hateb, Charlotte&#xD;Leveque, Edouard&#xD;Loste, Alexia&#xD;Apoil, Pol Andre&#xD;Gaudenzio, Nicolas&#xD;Reber, Laurent L&#xD;eng&#xD;Argenx/&#xD;Agence Nationale de la Recherche/&#xD;Fondation du Souffle/&#xD;Region Occitanie Pyrenees-Mediterranee/&#xD;Institut National de la Sante et de la Recherche Medicale/&#xD;Fondation pour la Recherche Medicale/&#xD;ARCDOC42022120005713/Fondation ARC for cancer research/&#xD;ERC_/European Research Council/International&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3212-3216. doi: 10.1111/all.70058. Epub 2025 Sep 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40974102</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590321 was a speaker and/or advisor for and/or has received research funding from Argenx, Novartis, Ceva, and Neovacs. Nicolas Gaudenzio is (or was) collaborating or consulting or a member of the scientific advisory board for Genoskin (CSO, shareholder), Escient Pharmaceuticals, Aikium, CEVA, MaxiVax, Boehringer Ingelheim, Novartis, Sanofi, and ArgenX. The rest of the authors declare that they have no relevant conflicts of interest.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70058</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>754</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">754</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Uchida, A. M.</style></author><author><style face="normal" font="default" size="100%">Lenehan, P. J.</style></author><author><style face="normal" font="default" size="100%">Vimalathas, P.</style></author><author><style face="normal" font="default" size="100%">Miller, K. C.</style></author><author><style face="normal" font="default" size="100%">Valencia-Yang, M.</style></author><author><style face="normal" font="default" size="100%">Qiang, L.</style></author><author><style face="normal" font="default" size="100%">Canha, L. A.</style></author><author><style face="normal" font="default" size="100%">Ali, L. R.</style></author><author><style face="normal" font="default" size="100%">Dougan, M.</style></author><author><style face="normal" font="default" size="100%">Garber, J. J.</style></author><author><style face="normal" font="default" size="100%">Dougan, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.&#xD;Department of Medicine, Harvard Medical School, Boston, MA, USA.&#xD;Cancer Immunology and Virology, Dana Farber Cancer Institute, Boston, MA, USA.&#xD;Department of Immunology, Harvard Medical School, Boston, MA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tissue eosinophils express the IL-33 receptor ST2 and type 2 cytokines in patients with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">656-660</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Enteritis</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophilic Esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Gastritis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-1 Receptor-Like 1 Protein</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-33</style></keyword><keyword><style face="normal" font="default" size="100%">clinical immunology</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">interleukins</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. MD receives research support from Novartis and Eli Lilly, consulting</style></keyword><keyword><style face="normal" font="default" size="100%">fees from Partner Therapeutics, Tillotts Pharma, ORIC Pharmaceuticals, AzurRx,</style></keyword><keyword><style face="normal" font="default" size="100%">SQZ, Moderna, WebMD, and Experts at Your Fingertips, and Genentech, and is a</style></keyword><keyword><style face="normal" font="default" size="100%">member of the Scientific Advisory Board for Neoleukin Therapeutics. JJG reports</style></keyword><keyword><style face="normal" font="default" size="100%">no conflicts of interest related to this study but has received research support</style></keyword><keyword><style face="normal" font="default" size="100%">from Takeda and the American Partnership for Eosinophilic Disorders. SKD reports</style></keyword><keyword><style face="normal" font="default" size="100%">no conflicts of interest related to this study, but has received research support</style></keyword><keyword><style face="normal" font="default" size="100%">from Novartis, BMS, and Eli Lilly, is a co-founder and SAB member for Kojin, and</style></keyword><keyword><style face="normal" font="default" size="100%">received consulting fees from GSK.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34614218</style></accession-num><notes><style face="normal" font="default" size="100%">Uchida, Amiko M&#xD;Lenehan, Patrick J&#xD;Vimalathas, Praveen&#xD;Miller, Kaia C&#xD;Valencia-Yang, Mabel&#xD;Qiang, Li&#xD;Canha, Lauren A&#xD;Ali, Lestat R&#xD;Dougan, Michael&#xD;Garber, John J&#xD;Dougan, Stephanie K&#xD;eng&#xD;U01 CA224146/CA/NCI NIH HHS/&#xD;T32 DK007191/DK/NIDDK NIH HHS/&#xD;P30 DK043351/DK/NIDDK NIH HHS/&#xD;T32 GM007753/GM/NIGMS NIH HHS/&#xD;K08 DK114563/DK/NIDDK NIH HHS/&#xD;T32 CA207021/CA/NCI NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):656-660. doi: 10.1111/all.15127. Epub 2021 Oct 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34614218</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9052372</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15127</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2654</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2654</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Miyabe, Y.</style></author><author><style face="normal" font="default" size="100%">Abe, T.</style></author><author><style face="normal" font="default" size="100%">Yamada, T.</style></author><author><style face="normal" font="default" size="100%">Endo, T.</style></author><author><style face="normal" font="default" size="100%">Kawasaki, Y.</style></author><author><style face="normal" font="default" size="100%">Suzuki, S.</style></author><author><style face="normal" font="default" size="100%">Arima, M.</style></author><author><style face="normal" font="default" size="100%">Ueki, S.</style></author><author><style face="normal" font="default" size="100%">Yamada, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Akita University, Akita, Japan.&#xD;Department of General Internal Medicine and Clinical Laboratory Medicine, Graduate School of Medicine, Akita University, Akita, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tissue levels of Alternaria allergen Alt a 1 reflect recurrence of refractory airway diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">587-589</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/09/08 22:44</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39244710</style></accession-num><notes><style face="normal" font="default" size="100%">Miyabe, Yui&#xD;Abe, Tomoe&#xD;Yamada, Toshiki&#xD;Endo, Tentaro&#xD;Kawasaki, Yohei&#xD;Suzuki, Shinsuke&#xD;Arima, Misaki&#xD;Ueki, Shigeharu&#xD;Yamada, Takechiyo&#xD;eng&#xD;JP17K11356/Japan Society for the Promotion of Science (JSPS) Grant Numbers/&#xD;JP25293348/Japan Society for the Promotion of Science (JSPS) Grant Numbers/&#xD;JP21H02707/Japan Society for the Promotion of Science (JSPS) Grant Numbers/&#xD;JP21K19368/Japan Society for the Promotion of Science (JSPS) Grant Numbers/&#xD;JP20H03832/Japan Society for the Promotion of Science (JSPS) Grant Numbers/&#xD;24K11593/Japan Society for the Promotion of Science (JSPS) Grant Numbers/&#xD;24K23305/Japan Society for the Promotion of Science (JSPS) Grant Numbers/&#xD;JSA WAO Memorial Research Grant Program/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):587-589. doi: 10.1111/all.16294. Epub 2024 Sep 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39244710</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804301 and grant support from Sanofi. S.U. is an advisory board member of GlaxoSmithKline K.K. (GSK), received honoraria for lectures from AstraZeneca K.K. AZ received honoraria from GSK and Sanofi, and grant support from AZ, Novartis Pharma K.K., and Maruho Co. Ltd.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16294</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3270</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3270</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liang, Yibo</style></author><author><style face="normal" font="default" size="100%">Li, Zhili</style></author><author><style face="normal" font="default" size="100%">Zhang, Chenting</style></author><author><style face="normal" font="default" size="100%">Liu, Jiarui</style></author><author><style face="normal" font="default" size="100%">Zhang, Kai</style></author><author><style face="normal" font="default" size="100%">Zhang, Guimin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tissue-Serum Metabolomics Identifies Lipid Signatures in Eosinophilic Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70239</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70239</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2360</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2360</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cait, A.</style></author><author><style face="normal" font="default" size="100%">Woods, K.</style></author><author><style face="normal" font="default" size="100%">Naidoo, K.</style></author><author><style face="normal" font="default" size="100%">Gell, K.</style></author><author><style face="normal" font="default" size="100%">Schmidt, A.</style></author><author><style face="normal" font="default" size="100%">Jackson, R.</style></author><author><style face="normal" font="default" size="100%">Grooby, A.</style></author><author><style face="normal" font="default" size="100%">O&apos;Sullivan, D.</style></author><author><style face="normal" font="default" size="100%">Gasser, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Malaghan Institute of Medical Research, Wellington, New Zealand.&#xD;High-Value Nutrition National Science Challenge, Auckland, New Zealand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tissue-specific contribution of mucosal-associated invariant T cells to allergic airway inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1962-1965</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/01/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Mucosal-Associated Invariant T Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Organ Specificity/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Hypersensitivity/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38269416</style></accession-num><notes><style face="normal" font="default" size="100%">Cait, Alissa&#xD;Woods, Katherine&#xD;Naidoo, Karmella&#xD;Gell, Katie&#xD;Schmidt, Alfonso&#xD;Jackson, Rosemary&#xD;Grooby, Alix&#xD;O&apos;Sullivan, David&#xD;Gasser, Olivier&#xD;eng&#xD;Ministry for Business Innovation and Employment/&#xD;Health Research Council of New Zealand/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1962-1965. doi: 10.1111/all.16038. Epub 2024 Jan 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38269416</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16038</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2227</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2227</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gupta, R. K.</style></author><author><style face="normal" font="default" size="100%">Miller, J.</style></author><author><style face="normal" font="default" size="100%">Croft, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.&#xD;Department of Medicine, University of California San Diego, La Jolla, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">TNF-like weak inducer of apoptosis inhibition is comparable to IL-13 blockade in ameliorating atopic dermatitis inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">116-127</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/08/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">TWEAK Receptor/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Tweak</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37650473</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Targeting IL-13 is highly efficacious in patients with Th2-biased atopic dermatitis (AD), but inhibition of other inflammatory molecules might also limit disease. We investigated the importance of the TNF family cytokine TNF-like weak inducer of apoptosis (TWEAK; TNFSF12) to keratinocyte dysregulation and the pathogenesis of AD in mice and also tested if blocking TWEAK has a similar therapeutic effect as targeting IL-13. METHODS: Conditional knockout mice lacking Fn14 (TNFRSF12A), the receptor for TWEAK, only in keratinocytes, were repetitively sensitized with house dust mite allergen and analyzed for AD-like skin inflammation. To determine the translational potential, wild-type mice with AD were therapeutically treated with anti-TWEAK and/or anti-IL-13 antibodies, and skin inflammation was assessed. RESULTS: Mice deficient in Fn14 in keratinocytes were resistant to developing maximal clinical features of AD, exhibiting reduced epidermal hyperplasia and dermal thickening, less skin infiltration of immune cells, and downregulated inflammatory gene expression. Moreover, therapeutic neutralization of TWEAK in wild-type mice with AD reduced all of the pathological features to a comparable extent as blocking IL-13. CONCLUSIONS: The activity of TWEAK in keratinocytes contributes to AD development, and neutralizing TWEAK represents a future potential therapeutic option in human AD similar to targeting IL-13.</style></abstract><notes><style face="normal" font="default" size="100%">Gupta, Rinkesh K&#xD;Miller, Jacqueline&#xD;Croft, Michael&#xD;eng&#xD;R01 AR072640/AR/NIAMS NIH HHS/&#xD;NH/NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):116-127. doi: 10.1111/all.15879. Epub 2023 Aug 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37650473</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10840791</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15879</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2522</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2522</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Camacho, I.</style></author><author><style face="normal" font="default" size="100%">Caeiro, E.</style></author><author><style face="normal" font="default" size="100%">Camacho, R.</style></author><author><style face="normal" font="default" size="100%">Grinn-Gofron, A.</style></author><author><style face="normal" font="default" size="100%">Strzelczak, A.</style></author><author><style face="normal" font="default" size="100%">Ferreira, M. B.</style></author><author><style face="normal" font="default" size="100%">Carreiro-Martins, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculdade de Ciencias da Vida, Campus Universitario da Penteada, Madeira University, Funchal, Portugal.&#xD;SPAIC-Sociedade Portuguesa de Alergologia e Imunologia Clinica, Lisbon, Portugal.&#xD;MED-Mediterranean Institute for Agriculture, Environment and Development &amp; CHANGE-Global Change and Sustainability Institute, Institute for Advanced Studies and Research, Universidade de Evora, Evora, Portugal.&#xD;Escola Superior de Tecnologias e Gestao, Campus Universitario da Penteada, Madeira University, Funchal, Portugal.&#xD;Institute of Biology, University of Szczecin, Szczecin, Poland.&#xD;West Pomeranian University of Technology in Szczecin, Szczecin, Poland.&#xD;Centro Hospitalar Universitario Lisboa Norte, Lisbon, Portugal.&#xD;Faculdade de Medicina da Universidade de Lisboa, Clinica Universitaria Imunoalergologia, Lisbon, Portugal.&#xD;Servico de Imunoalergologia, Centro Hospitalar Universitario de Lisboa Central, Lisbon, Portugal.&#xD;CHRC, NOVA Medical School | Faculdade de Ciencias Medicas, NMS|FCM Universidade Nova de Lisboa, Lisbon, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">To what extent can wildfires in the Mediterranean influence pollen abundance?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2287-2289</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2024/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mediterranean Region</style></keyword><keyword><style face="normal" font="default" size="100%">*Wildfires</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38923532</style></accession-num><notes><style face="normal" font="default" size="100%">Camacho, Irene&#xD;Caeiro, Elsa&#xD;Camacho, Roberto&#xD;Grinn-Gofron, Agnieszka&#xD;Strzelczak, Agnieszka&#xD;Ferreira, Manuel Branco&#xD;Carreiro-Martins, Pedro&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Aug;79(8):2287-2289. doi: 10.1111/all.16211. Epub 2024 Jun 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38923532</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16211</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1222</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1222</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jorg, L.</style></author><author><style face="normal" font="default" size="100%">Gschwend, A.</style></author><author><style face="normal" font="default" size="100%">Fricker, M.</style></author><author><style face="normal" font="default" size="100%">Helbling, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergology, Department of Rheumatology, Immunology and Allergology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tolerance of an immunotherapy switch between two aqueous hymenoptera venoms</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2211-2214</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/12/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthropod Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">*Bee Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hymenoptera</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Insect Bites and Stings</style></keyword><keyword><style face="normal" font="default" size="100%">Wasp Venoms</style></keyword><keyword><style face="normal" font="default" size="100%">aluminium</style></keyword><keyword><style face="normal" font="default" size="100%">honey bee</style></keyword><keyword><style face="normal" font="default" size="100%">hymenoptera</style></keyword><keyword><style face="normal" font="default" size="100%">wasp</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33326622</style></accession-num><notes><style face="normal" font="default" size="100%">Jorg, Lukas&#xD;Gschwend, Anna&#xD;Fricker, Michael&#xD;Helbling, Arthur&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2211-2214. doi: 10.1111/all.14712. Epub 2020 Dec 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33326622</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14712</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>373</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">373</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hanif, T.</style></author><author><style face="normal" font="default" size="100%">Ivaska, L. E.</style></author><author><style face="normal" font="default" size="100%">Ahmad, F.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Mikola, E.</style></author><author><style face="normal" font="default" size="100%">Puhakka, T.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author><author><style face="normal" font="default" size="100%">Jartti, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics and Adolescent Medicine, University of Turku, Turku, Finland.&#xD;Haartman Institute, University of Helsinki, Helsinki, Finland.&#xD;Department of Otorhinolaryngology - Head and Neck Surgery, Turku University Hospital and University of Turku, Turku, Finland.&#xD;Department of Biology University of Turku, Turku, Finland.&#xD;Functional Genomics Center Zurich, ETH Zurich/University of Zurich, Zurich, Switzerland.&#xD;Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.&#xD;Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.&#xD;Department of Otorhinolaryngology, Satakunta Central Hospital, Pori, Finland.&#xD;Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.&#xD;Haartman Institute, University of Helsinki &amp; Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.&#xD;PEDEGO Research Unit, Medical Research Center, University of Oulu, Oulu, Finland.&#xD;Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tonsillar transcriptional profiles in atopic and non-atopic subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">522-536</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2022/07/29</style></edition><section><style face="normal" font="default" size="100%">522</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Palatine Tonsil</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Chemokines</style></keyword><keyword><style face="normal" font="default" size="100%">Il-17</style></keyword><keyword><style face="normal" font="default" size="100%">aeroallergen</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">tonsil</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35899482</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Emerging research suggests that local lymphatic tissue such as tonsils have important role in regulating the immune responses. However, allergen sensitization-induced alterations in transcriptome of tonsils are not known. OBJECTIVES: To examine the key differences in tonsillar gene expression between atopic and non-atopic subjects and further by type of sensitization. METHODS: RNA-sequencing was performed on 52 tonsillar samples from atopic and non-atopic tonsillectomy patients. Sensitization to common food- and aero-allergen was defined by allergen specific IgE. Following groups were studied: (1) aero- and food-allergen sensitized (AS+FS) versus non-sensitized (NS), (2) aeroallergen-sensitized (AS) versus food-allergen sensitized (FS), (3) AS versus NS, (4) FS versus NS. Bioinformatics analysis was done using DESeq2(v3.10.2), WGCNA and GATK pipeline in R software (v3.3.1). Protein-protein interaction network was made from String database. RESULTS: We studied 13 aeroallergen-sensitized, 6 food-allergen sensitized, 4 both food-and aero-allergen-sensitized and 29 non-sensitized tonsillectomy patients. Overall, 697 unique differentially expressed genes (DEGs) were detected in all sensitized subgroups including chemokines (CXCL2, CXCL8, CXCL10, CXCL11), IL-20RA, MUC1 and MUC20. When comparing different groups, the gene expression profiles overlapped except the AS versus FS group comparison, suggesting significantly different gene expression between the two sensitization subgroups. Furthermore, aeroallergen-sensitized subjects had more prominent immune responses compared with non-sensitized and food-allergen sensitized subjects including gene expression for IL-17 pathway and Toll-like receptor signalling pathway. CONCLUSION: Allergic sensitization is associated with extensive tonsillar transcriptomic alterations and changes in immune related genes and pathways. Distinct differences were found between aero-allergen and food-allergen sensitization.</style></abstract><notes><style face="normal" font="default" size="100%">Hanif, Tanzeela&#xD;Ivaska, Lotta E&#xD;Ahmad, Freed&#xD;Tan, Ge&#xD;Mikola, Emilia&#xD;Puhakka, Tuomo&#xD;Palomares, Oscar&#xD;Akdis, Cezmi A&#xD;Toppila-Salmi, Sanna&#xD;Jartti, Tuomas&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Feb;78(2):522-536. doi: 10.1111/all.15458. Epub 2022 Aug 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35899482</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087516</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15458</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>658</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">658</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author><author><style face="normal" font="default" size="100%">Baumert, J. L.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Brooke-Taylor, S.</style></author><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author><author><style face="normal" font="default" size="100%">Crevel, R. W. R.</style></author><author><style face="normal" font="default" size="100%">Gerdts, J. D.</style></author><author><style face="normal" font="default" size="100%">Hazel Gowland, M.</style></author><author><style face="normal" font="default" size="100%">Houben, G. F.</style></author><author><style face="normal" font="default" size="100%">Hourihane, J. O.</style></author><author><style face="normal" font="default" size="100%">Konstantinou, G. N.</style></author><author><style face="normal" font="default" size="100%">La Vieille, S.</style></author><author><style face="normal" font="default" size="100%">Moya, B.</style></author><author><style face="normal" font="default" size="100%">Muraro, A.</style></author><author><style face="normal" font="default" size="100%">Mills, E. N. C.</style></author><author><style face="normal" font="default" size="100%">Patel, N.</style></author><author><style face="normal" font="default" size="100%">Podesta, M.</style></author><author><style face="normal" font="default" size="100%">Popping, B.</style></author><author><style face="normal" font="default" size="100%">Reese, I.</style></author><author><style face="normal" font="default" size="100%">Roberts, G.</style></author><author><style face="normal" font="default" size="100%">Said, M.</style></author><author><style face="normal" font="default" size="100%">Santos, A. F.</style></author><author><style face="normal" font="default" size="100%">Schnadt, S.</style></author><author><style face="normal" font="default" size="100%">Taylor, S. L.</style></author><author><style face="normal" font="default" size="100%">Vlieg-Boerstra, B.</style></author><author><style face="normal" font="default" size="100%">Remington, B. C.</style></author><author><style face="normal" font="default" size="100%">Eaaci Taskforce on Food allergen thresholds</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Department of Food Science and Technology, Food Allergy Research and Resource Program, University of Nebraska, Lincoln, Nebraska, USA.&#xD;Department of Paediatric Respiratory Medicine, Immunology and Intensive Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Brooke-Taylor &amp; Co Pty Ltd, Milawa, Victoria, Australia.&#xD;Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Rene Crevel Consulting Limited, Bedford, UK.&#xD;Food Allergy Canada, Toronto, Ontario, Canada.&#xD;Allergy Action, St Albans, UK.&#xD;Netherlands Organisation for Applied Scientific Research TNO, Utrecht, The Netherlands.&#xD;Royal College of Surgeons in Ireland and Children&apos;s Health Ireland Temple St Hospital Dublin, Dublin, Ireland.&#xD;Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.&#xD;Food Directorate, Health Canada, Ottawa, Ontario, Canada.&#xD;Allergy Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.&#xD;Department of Woman and Child Health, Food Allergy Referral Centre Veneto Region, Padua University Hospital, Padua, Italy.&#xD;Division of Infection, Immunity and Respiratory Medicine, Manchester Institute of Biotechnology, University of Manchester, Manchester, UK.&#xD;Food Allergy Italia, Padua, Italy.&#xD;FOCOS-Food Consulting Strategically, Alzenau, Germany.&#xD;Nutrition Therapy, Munich, Germany.&#xD;NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;The David Hide Asthma and Allergy Research Centre, St Mary&apos;s Hospital, Isle of Wight, UK.&#xD;Allergy &amp; Anaphylaxis Australia, Castle Hill, Hornsby, New South Wales, Australia.&#xD;Department of Women and Children&apos;s Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King&apos;s College London, Children&apos;s Allergy Service, Evelina London, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Deutscher Allergie- und Asthmabund (DAAB), Monchengladbach, Germany.&#xD;Department of Paediatrics, OLVG Hospital, Amsterdam, The Netherlands.&#xD;Remington Consulting Group BV, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">&apos;Too high, too low&apos;: The complexities of using thresholds in isolation to inform precautionary allergen (&apos;may contain&apos;) labels</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1661-1666</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/12/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allergens/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Food Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">eliciting dose</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">precautionary allergen labelling</style></keyword><keyword><style face="normal" font="default" size="100%">reference dose</style></keyword><keyword><style face="normal" font="default" size="100%">thresholds</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34967036</style></accession-num><notes><style face="normal" font="default" size="100%">Turner, Paul J&#xD;Baumert, Joseph L&#xD;Beyer, Kirsten&#xD;Brooke-Taylor, Simon&#xD;Comberiati, Pasquale&#xD;Crevel, Rene W R&#xD;Gerdts, Jennifer D&#xD;Hazel Gowland, M&#xD;Houben, Geert F&#xD;Hourihane, Jonathan O&apos;B&#xD;Konstantinou, George N&#xD;La Vieille, Sebastien&#xD;Moya, Beatriz&#xD;Muraro, Antonella&#xD;Mills, E N Clare&#xD;Patel, Nandinee&#xD;Podesta, Marcia&#xD;Popping, Bert&#xD;Reese, Imke&#xD;Roberts, Graham&#xD;Said, Maria&#xD;Santos, Alexandra F&#xD;Schnadt, Sabine&#xD;Taylor, Steve L&#xD;Vlieg-Boerstra, Berber&#xD;Remington, Benjamin C&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;DH_/Department of Health/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/K010468/1/MRC_/Medical Research Council/United Kingdom&#xD;Editorial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1661-1666. doi: 10.1111/all.15202.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34967036</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15202</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2874</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2874</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cho, J.</style></author><author><style face="normal" font="default" size="100%">Jo, H.</style></author><author><style face="normal" font="default" size="100%">Park, J.</style></author><author><style face="normal" font="default" size="100%">Oh, J.</style></author><author><style face="normal" font="default" size="100%">Kim, T. H.</style></author><author><style face="normal" font="default" size="100%">Lee, K.</style></author><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Jeong, J.</style></author><author><style face="normal" font="default" size="100%">Lee, S.</style></author><author><style face="normal" font="default" size="100%">Miligkos, M.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Yon, D. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Medicine, CHA University School of Medicine, Seongnam, South Korea.&#xD;Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.&#xD;Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Department of Electronics and Information Convergence Engineering, Kyung Hee University, Yongin, South Korea.&#xD;Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.&#xD;Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.&#xD;Lydia Becker Institute, University of Manchester, Manchester, UK.&#xD;Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">TOP10-SCAR: A Global Pharmacovigilance Study on Medications Most Frequently Related to Severe Cutaneous Adverse Reactions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3181-3184</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/04/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacology and pharmacogenomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40171941</style></accession-num><notes><style face="normal" font="default" size="100%">Cho, Jaehyeong&#xD;Jo, Hyesu&#xD;Park, Jaeyu&#xD;Oh, Jeongseon&#xD;Kim, Tae Hyeon&#xD;Lee, Kyeongmin&#xD;Lee, Hayeon&#xD;Jeong, Jinyoung&#xD;Lee, Sooji&#xD;Miligkos, Michael&#xD;Papadopoulos, Nikolaos G&#xD;Yon, Dong Keon&#xD;eng&#xD;National Research Foundation of Korea/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3181-3184. doi: 10.1111/all.16544. Epub 2025 Apr 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40171941</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16544</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2176</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2176</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ono, E.</style></author><author><style face="normal" font="default" size="100%">Lenief, V.</style></author><author><style face="normal" font="default" size="100%">Lefevre, M. A.</style></author><author><style face="normal" font="default" size="100%">Cuzin, R.</style></author><author><style face="normal" font="default" size="100%">Guironnet-Paquet, A.</style></author><author><style face="normal" font="default" size="100%">Mosnier, A.</style></author><author><style face="normal" font="default" size="100%">Nosbaum, A.</style></author><author><style face="normal" font="default" size="100%">Nicolas, J. F.</style></author><author><style face="normal" font="default" size="100%">Vocanson, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CIRI-Centre International de Recherche en Infectiologie, INSERM, U1111, Universite Lyon, Universite Claude Bernard Lyon 1, Ecole Normale Superieure de Lyon, CNRS UMR 5308, Lyon, France.&#xD;Etablissement Francais du Sang (EFS) Auvergne Rhone-Alpes, Apheresis Unit, Hopital Lyon Sud, Pierre Benite, France.&#xD;Allergology and Clinical Immunology Department, Lyon Sud University Hospital, Pierre Benite, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Topical corticosteroids inhibit allergic skin inflammation but are ineffective in impeding the formation and expansion of resident memory T cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">52-64</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/08/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Memory T Cells</style></keyword><keyword><style face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatologic Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Haptens</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Memory</style></keyword><keyword><style face="normal" font="default" size="100%">allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">chronicity</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroids</style></keyword><keyword><style face="normal" font="default" size="100%">eczemas</style></keyword><keyword><style face="normal" font="default" size="100%">resident memory T cells</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37539746</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tissue-resident memory T (T(RM) ) cells are detrimental in allergic contact dermatitis (ACD), in which they contribute to the chronicity and severity of the disease. METHODS: We assessed the impact of a standard topical corticosteroid (TCS) treatment, triamcinolone acetonide (TA), on the formation, maintenance and reactivation of epidermal T(RM) cells in a preclinical model of ACD to 2,4-dinitrofluorobenzene. TA 0.01% was applied at different time points of ACD response and we monitored skin inflammation and tracked CD8+ CD69+ CD103+ T(RM) by flow cytometry and RNA sequencing. RESULTS: The impact of TA on T(RM) formation depended on treatment regimen: (i) in a preventive mode, that is, in sensitized mice before challenge, TA transiently inhibited the infiltration of effector T cells and the accumulation of T(RM) upon hapten challenge. In contrast, (ii) in a curative mode, that is, at the peak of the ACD response, TA blocked skin inflammation but failed to prevent the formation of T(RM) . Finally, (iii) in a proactive mode, that is, on previous eczema lesions, TA had no effect on the survival of skin T(RM) , but transiently inhibited their reactivation program upon allergen reexposure. Indeed, specific T(RM) progressively regained proliferative functions upon TA discontinuation and expanded in the tissue, leading to exaggerated iterative responses. Interestingly, T(RM) re-expansion correlated with the decreased clearance of hapten moieties from the skin induced by repeated TA applications. CONCLUSIONS: Our results demonstrate that TCS successfully treat ACD inflammation, but are mostly ineffective in impeding the formation and expansion of allergen-specific T(RM) , which certainly restricts the induction of lasting tolerance in patients with chronic dermatitis.</style></abstract><notes><style face="normal" font="default" size="100%">Ono, Emi&#xD;Lenief, Vanina&#xD;Lefevre, Marine-Alexia&#xD;Cuzin, Roxane&#xD;Guironnet-Paquet, Aurelie&#xD;Mosnier, Amandine&#xD;Nosbaum, Audrey&#xD;Nicolas, Jean-Francois&#xD;Vocanson, Marc&#xD;eng&#xD;institutional grants from the Institut national de la sante et de la recherche medicale (Inserm) and the Japanese Society of Allergology Overseas Research Study Abroad Grant/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):52-64. doi: 10.1111/all.15819. Epub 2023 Aug 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37539746</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15819</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2710</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2710</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Babayev, H.</style></author><author><style face="normal" font="default" size="100%">Sahin, A.</style></author><author><style face="normal" font="default" size="100%">Ardicli, S.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Faculty of Medicine, Selcuk University, Konya, Turkey.&#xD;Department of Genetics, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tracing the evolutionary pathway of IgG4: Implications for immune tolerance and regulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">346-348</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/11/16 20:04</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39548796</style></accession-num><notes><style face="normal" font="default" size="100%">Babayev, Huseyn&#xD;Sahin, Ali&#xD;Ardicli, Sena&#xD;Akdis, Mubeccel&#xD;Akdis, Cezmi A&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):346-348. doi: 10.1111/all.16383. Epub 2024 Nov 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39548796</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724249</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16383</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1304</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1304</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wanka, L.</style></author><author><style face="normal" font="default" size="100%">Jappe, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Clinical and Molecular Allergology, Research Center Borstel - Leibniz Lung Center, Priority Area Asthma and Allergy, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany.&#xD;Interdisciplinary Allergy Outpatient Clinic, MK III, Airway Research Center North (ARCN), German Center for Lung Research (DZL), University of Lubeck, Lubeck, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trained immunity and allergy: State of the art and future perspectives</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1265-1267</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/10/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33037616</style></accession-num><notes><style face="normal" font="default" size="100%">Wanka, Lizzy&#xD;Jappe, Uta&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1265-1267. doi: 10.1111/all.14617. Epub 2020 Oct 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33037616</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14617</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1978</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1978</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, T.</style></author><author><style face="normal" font="default" size="100%">Pham, J.</style></author><author><style face="normal" font="default" size="100%">Denton, E.</style></author><author><style face="normal" font="default" size="100%">Lee, J.</style></author><author><style face="normal" font="default" size="100%">Hore-Lacy, F.</style></author><author><style face="normal" font="default" size="100%">Sverrild, A.</style></author><author><style face="normal" font="default" size="100%">Stojanovic, S.</style></author><author><style face="normal" font="default" size="100%">Tay, T. R.</style></author><author><style face="normal" font="default" size="100%">Murthee, K. G.</style></author><author><style face="normal" font="default" size="100%">Radhakrishna, N.</style></author><author><style face="normal" font="default" size="100%">Dols, M.</style></author><author><style face="normal" font="default" size="100%">Bondarenko, J.</style></author><author><style face="normal" font="default" size="100%">Mahoney, J.</style></author><author><style face="normal" font="default" size="100%">O&apos;Hehir, R. E.</style></author><author><style face="normal" font="default" size="100%">Dabscheck, E.</style></author><author><style face="normal" font="default" size="100%">Hew, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy, Asthma &amp; Clinical Immunology Service, Alfred Health, Melbourne, Victoria, Australia.&#xD;School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.&#xD;Department of Respiratory Medicine, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.&#xD;Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore City, Singapore.&#xD;Department of Internal Medicine, Singapore General Hospital, Singapore City, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trait profiles in difficult-to-treat asthma: Clinical impact and response to systematic assessment</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2418-2427</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/03/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Respiration</style></keyword><keyword><style face="normal" font="default" size="100%">Anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">asthma phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">difficult-to-treat asthma</style></keyword><keyword><style face="normal" font="default" size="100%">latent class analysis</style></keyword><keyword><style face="normal" font="default" size="100%">treatable traits</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36940306</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Multidisciplinary systematic assessment improves outcomes in difficult-to-treat asthma, but without clear response predictors. Using a treatable-traits framework, we stratified patients by trait profile, examining clinical impact and treatment responsiveness to systematic assessment. METHODS: We performed latent class analysis using 12 traits on difficult-to-treat asthma patients undergoing systematic assessment at our institution. We examined Asthma Control Questionnaire (ACQ-6) and Asthma Quality of Life Questionnaire (AQLQ) scores, FEV(1) , exacerbation frequency, and maintenance oral corticosteroid (mOCS) dose, at baseline and following systematic assessment. RESULTS: Among 241 patients, two airway-centric profiles were characterized by early-onset with allergic rhinitis (n = 46) and adult onset with eosinophilia/chronic rhinosinusitis (n = 60), respectively, with minimal comorbid or psychosocial traits; three non-airway-centric profiles exhibited either comorbid (obesity, vocal cord dysfunction, dysfunctional breathing) dominance (n = 51), psychosocial (anxiety, depression, smoking, unemployment) dominance (n = 72), or multi-domain impairment (n = 12). Compared to airway-centric profiles, non-airway-centric profiles had worse baseline ACQ-6 (2.7 vs. 2.2, p &lt; .001) and AQLQ (3.8 vs. 4.5, p &lt; .001) scores. Following systematic assessment, the cohort showed overall improvements across all outcomes. However, airway-centric profiles had more FEV(1) improvement (5.6% vs. 2.2% predicted, p &lt; .05) while non-airway-centric profiles trended to greater exacerbation reduction (1.7 vs. 1.0, p = .07); mOCS dose reduction was similar (3.1 mg vs. 3.5 mg, p = .782). CONCLUSION: Distinct trait profiles in difficult-to-treat asthma are associated with different clinical outcomes and treatment responsiveness to systematic assessment. These findings yield clinical and mechanistic insights into difficult-to-treat asthma, offer a conceptual framework to address disease heterogeneity, and highlight areas responsive to targeted intervention.</style></abstract><notes><style face="normal" font="default" size="100%">Lin, Tiffany&#xD;Pham, Jonathan&#xD;Denton, Eve&#xD;Lee, Joy&#xD;Hore-Lacy, Fiona&#xD;Sverrild, Asger&#xD;Stojanovic, Stephanie&#xD;Tay, Tunn Ren&#xD;Murthee, Kavitha Garuna&#xD;Radhakrishna, Naghmeh&#xD;Dols, Monique&#xD;Bondarenko, Janet&#xD;Mahoney, Janine&#xD;O&apos;Hehir, Robyn E&#xD;Dabscheck, Eli&#xD;Hew, Mark&#xD;eng&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2418-2427. doi: 10.1111/all.15719. Epub 2023 Mar 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36940306</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15719</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>831</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">831</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Forster, F.</style></author><author><style face="normal" font="default" size="100%">Ege, M. J.</style></author><author><style face="normal" font="default" size="100%">Gerlich, J.</style></author><author><style face="normal" font="default" size="100%">Weinmann, T.</style></author><author><style face="normal" font="default" size="100%">Kreissl, S.</style></author><author><style face="normal" font="default" size="100%">Weinmayr, G.</style></author><author><style face="normal" font="default" size="100%">Genuneit, J.</style></author><author><style face="normal" font="default" size="100%">Nowak, D.</style></author><author><style face="normal" font="default" size="100%">von Mutius, E.</style></author><author><style face="normal" font="default" size="100%">Vogelberg, C.</style></author><author><style face="normal" font="default" size="100%">Radon, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany.&#xD;Comprehensive Pneumology Center (CPC) Munich, member, German Center for Lung Research (DZL), Munich, Germany.&#xD;Dr. v. Hauner Children&apos;s Hospital, University Hospital, LMU Munich, Munich, Germany.&#xD;Paediatric Department, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany.&#xD;Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.&#xD;Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trajectories of asthma and allergy symptoms from childhood to adulthood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1192-1203</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/09/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Sounds/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">latent class analysis</style></keyword><keyword><style face="normal" font="default" size="100%">rhinoconjunctivitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34473346</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Phenotypes of asthma and allergic diseases are mainly studied separately for children and adults. To explore the role of adolescence and young adulthood, we investigated symptom trajectories at the transition from childhood into adulthood. METHODS: Latent class analysis (LCA) was conducted in a population initially recruited for the German arm of Phase II of the International Study of Asthma and Allergies in Childhood and followed-up three times until their early 30s (N=2267). Indicators included in LCA were 12-month prevalences of symptoms of wheeze, rhinoconjunctivitis, and eczema. Latent classes were further characterised regarding important traits such as skin prick tests. Logistic regression models were used to investigate associations with environmental determinants such as smoking and occupational exposures. RESULTS: Six latent classes were identified: an asymptomatic one as well as three with single and two with co-occurring symptoms. All trajectories essentially established between baseline assessment at around 10 years and the first follow-up at around 17 years. Probabilities for symptoms increased from childhood to adolescence, especially for wheeze-related latent classes, while they remained constant in adulthood. Wheeze-related latent classes were also positively associated with exposures during adolescence (e.g. active smoking). CONCLUSION: Distinct trajectories of asthma and allergy symptoms establish from childhood through adolescence and stabilize during early adulthood. This pattern was most notable in wheeze-related latent classes which also showed the strongest positive associations with environmental exposures in adolescence/young adulthood. Therefore, not only childhood but also adolescence is relevant for disease development and offers considerable potential for prevention and health promotion.</style></abstract><notes><style face="normal" font="default" size="100%">Forster, Felix&#xD;Ege, Markus Johannes&#xD;Gerlich, Jessica&#xD;Weinmann, Tobias&#xD;Kreissl, Sylvia&#xD;Weinmayr, Gudrun&#xD;Genuneit, Jon&#xD;Nowak, Dennis&#xD;von Mutius, Erika&#xD;Vogelberg, Christian&#xD;Radon, Katja&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1192-1203. doi: 10.1111/all.15075. Epub 2021 Sep 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34473346</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15075</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2549</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2549</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nakamura, T.</style></author><author><style face="normal" font="default" size="100%">Nakano, T.</style></author><author><style face="normal" font="default" size="100%">Simpson, A.</style></author><author><style face="normal" font="default" size="100%">Kono, M.</style></author><author><style face="normal" font="default" size="100%">Curtin, J. A.</style></author><author><style face="normal" font="default" size="100%">Kobayashi, T.</style></author><author><style face="normal" font="default" size="100%">Murray, C. S.</style></author><author><style face="normal" font="default" size="100%">Akiyama, M.</style></author><author><style face="normal" font="default" size="100%">Imanishi, M.</style></author><author><style face="normal" font="default" size="100%">Mikuriya, M.</style></author><author><style face="normal" font="default" size="100%">Custovic, A.</style></author><author><style face="normal" font="default" size="100%">Shimojo, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Showa University, Tokyo, Japan.&#xD;Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.&#xD;Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.&#xD;Department of Dermatology and Plastic Surgery, Akita University Graduate School of Medicine, Akita, Japan.&#xD;Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.&#xD;Research and development, Duskin co., LTD, Osaka, Japan.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Center for Preventive Medical Sciences, Chiba University, Chiba, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trajectories of egg sensitization in childhood: Two birth cohorts in Asia and Europe</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">193-204</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/08/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Egg Hypersensitivity/epidemiology/immunology/genetics/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Europe/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Asia/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Birth Cohort</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">childhood</style></keyword><keyword><style face="normal" font="default" size="100%">egg exposure</style></keyword><keyword><style face="normal" font="default" size="100%">filaggrin</style></keyword><keyword><style face="normal" font="default" size="100%">food hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39087444</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hen&apos;s egg exposure through impaired skin barrier is considered a major mechanism of sensitization to eggs. However, the impact of filaggrin (FLG) gene loss-of-function mutations on the natural history of egg sensitization lacks consensus among studies. OBJECTIVE: To evaluate the association between the natural course of egg sensitization and FLG mutations. METHODS: We used Japanese and the UK birth cohorts (CHIBA and MAAS) to identify the longitudinal patterns of egg sensitization until mid-school age and examined the relationship between the identified patterns and FLG mutations. Sensitization was assessed using egg white-specific IgE levels or skin prick tests (SPTs). Egg allergy was confirmed by parental reports and sensitization. Latent class growth analysis identified longitudinal patterns. RESULTS: Three similar patterns of egg sensitization (persistent, early-onset remitting, and no/low grade classes) were identified in both cohorts, with differing prevalence estimates. The proportion of children with egg allergy in the persistent class at 7 or 8 years of age was 23% (CHIBA) and 20% (MAAS). Consistently in both cohorts, FLG mutations were significantly associated only with the persistent class. Children with FLG mutations had an approximately four-fold increased risk of being in the persistent sensitization class (RRRs: 4.3, 95%C.I. (1.2-16.0), p = .03 in CHIBA; 4.3 (1.3-14.7), p = .02 in MAAS). CONCLUSION: FLG loss-of-function mutations are associated with persistent egg sensitization in both Japanese and European ethnicities, and the mutations might be a potential biomarker for identifying the risk of persistent egg sensitization/allergy in early infancy. Future studies should incorporate oral food challenges to confirm this relationship.</style></abstract><notes><style face="normal" font="default" size="100%">Nakamura, Toshinori&#xD;Nakano, Taiji&#xD;Simpson, Angela&#xD;Kono, Michihiro&#xD;Curtin, John A&#xD;Kobayashi, Tomoko&#xD;Murray, Clare S&#xD;Akiyama, Masashi&#xD;Imanishi, Masahiro&#xD;Mikuriya, Masayuki&#xD;Custovic, Adnan&#xD;Shimojo, Naoki&#xD;eng&#xD;The North West Lung Centre Charity/&#xD;British Medical Association James Trust/&#xD;JP Moulton Charitable Foundation/&#xD;the Asthma UK Grants/&#xD;Japan Agency for Medical Research and Development/&#xD;MRC_/Medical Research Council/United Kingdom&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):193-204. doi: 10.1111/all.16264. Epub 2024 Aug 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39087444</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16264</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>929</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">929</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Siroux, V.</style></author><author><style face="normal" font="default" size="100%">Boudier, A.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Dumas, O.</style></author><author><style face="normal" font="default" size="100%">Just, J.</style></author><author><style face="normal" font="default" size="100%">Le Moual, N.</style></author><author><style face="normal" font="default" size="100%">Nadif, R.</style></author><author><style face="normal" font="default" size="100%">Varraso, R.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Pin, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Team of Environmental Epidemiology applied to the Development and Respiratory Health, IAB, Inserm, Univ. Grenoble Alpes, CNRS, Grenoble, France.&#xD;MACVIA-France, Montpellier, France.&#xD;UVSQ, INSERM, Equipe d&apos;Epidemiologie respiratoire integrative, CESP, Universite Paris-Saclay, Univ. Paris-Sud, Villejuif, France.&#xD;Department of Allergology, France Hopital d&apos;Enfants Armand Trousseau, Sorbonne Universite Paris, Paris, France.&#xD;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;NRC Institute of Immunology FMBA of Russia, Moscow, Russia.&#xD;Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Karl Landsteiner University of Health Sciences, Krems, Austria.&#xD;Pediatric Department, CHU Grenoble Alpes, Grenoble, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trajectories of IgE sensitization to allergen molecules from childhood to adulthood and respiratory health in the EGEA cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">609-618</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/06/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34169532</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Longitudinal studies assessing the association of profiles of allergen-specific IgE (sIgE) sensitization to a large range of allergen molecules and respiratory health are rare. We aimed to assess trajectories of molecular sIgE sensitization profiles from childhood to adulthood and their associations with respiratory health. METHODS: IgE reactivity to microarrayed allergen molecules were measured in childhood (EGEA1) and 12 years later in adult life (EGEA2) among 291 EGEA participants (152 with asthma). At each time point, sIgE sensitization profiles were identified by latent class analysis (LCA) by considering IgE-reactivity to the 38 most prevalent respiratory allergens. The LCA-defined profiles were then studied in association with respiratory health. RESULTS: At baseline, the mean (min-max) age of the population was 11 (4.5-16) years. The LCA identified four sIgE sensitization profiles which were very similar at both time points (% at EGEA1 and EGEA2); A: &quot;no/few allergen(s)&quot; (48%, 39%), B: &quot;pollen/animal allergens&quot; (18%, 21%), C: &quot;most prevalent house dust mite allergens&quot; (22%, 27%) and D: &quot;many allergens&quot; (12%, 13%). Overall, 73% of the participants remained in the same profile from childhood to adulthood. The profiles were associated with asthma and rhinitis phenotypes. Participants of profiles C and D had lower FEV(1) % and FEF(25-75) % as compared to profile A. Similar patterns of associations were observed for participants with asthma. There was no association with change in lung function. CONCLUSION: Using high-resolution sIgE longitudinal data, the LCA identified four molecular sensitization profiles, mainly stable from childhood to adulthood, that were associated with respiratory health.</style></abstract><notes><style face="normal" font="default" size="100%">Siroux, Valerie&#xD;Boudier, Anne&#xD;Bousquet, Jean&#xD;Dumas, Orianne&#xD;Just, Jocelyne&#xD;Le Moual, Nicole&#xD;Nadif, Rachel&#xD;Varraso, Raphaelle&#xD;Valenta, Rudolf&#xD;Pin, Isabelle&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):609-618. doi: 10.1111/all.14987. Epub 2021 Jul 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34169532</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14987</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3176</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3176</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Asamoah, K.</style></author><author><style face="normal" font="default" size="100%">Yang, F.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Vuckovic, D.</style></author><author><style face="normal" font="default" size="100%">Uddin, M.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Chadeau-Hyam, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MRC Centre for Environment and Health &amp; Department of Epidemiology and Biostatistics, Faculty of Medicine, School of Public Health, Imperial College London, London, UK.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Data Science Institute, Department of Computing, Imperial College London, London, UK.&#xD;AstraZeneca, BioPharmaceuticals R&amp;D, Gothenburg, Sweden.&#xD;Royal Brompton and Harefield Hospital, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trajectory-Based Clustering to Identify Asthma Subgroups Responsive to the Selective CXCR2 Antagonist, AZD5069</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">297-299</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/11/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma treatment</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, AZ, Novartis, Roche, Merck, Trevi, Nocion, Shionogi and Rickett-Beckinson</style></keyword><keyword><style face="normal" font="default" size="100%">and has also been renumerated for speaking engagements for GSK, Novartis and AZ.</style></keyword><keyword><style face="normal" font="default" size="100%">He holds research grants from GSK and Merck, paid to his institution. F.Y. has</style></keyword><keyword><style face="normal" font="default" size="100%">received honoraria for attending meetings and speaker fees from AZ and GSK, and</style></keyword><keyword><style face="normal" font="default" size="100%">is a member of the British Thoracic Society Asthma Advisory Group. M.U. is an</style></keyword><keyword><style face="normal" font="default" size="100%">employee and holds shares in AstraZeneca. M.C.-H. holds shares in the O-SMOSE</style></keyword><keyword><style face="normal" font="default" size="100%">company and has no conflicts of interest to disclose. Consulting activities</style></keyword><keyword><style face="normal" font="default" size="100%">conducted by the company are independent of the present work. The other authors</style></keyword><keyword><style face="normal" font="default" size="100%">declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41177856</style></accession-num><notes><style face="normal" font="default" size="100%">Asamoah, Khezia&#xD;Yang, Freda&#xD;Adcock, Ian M&#xD;Vuckovic, Dragana&#xD;Uddin, Mohib&#xD;Chung, Kian Fan&#xD;Chadeau-Hyam, Marc&#xD;eng&#xD;NCT01704495/AstraZeneca/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):297-299. doi: 10.1111/all.70140. Epub 2025 Nov 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41177856</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12773661</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70140</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2193</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2193</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Simpson, E. L.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Eichenfield, L. F.</style></author><author><style face="normal" font="default" size="100%">Boguniewicz, M.</style></author><author><style face="normal" font="default" size="100%">Bieber, T.</style></author><author><style face="normal" font="default" size="100%">Schneider, S.</style></author><author><style face="normal" font="default" size="100%">Guana, A.</style></author><author><style face="normal" font="default" size="100%">Silverberg, J. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA.&#xD;Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Departments of Dermatology and Pediatrics, University of California San Diego and Rady Children&apos;s Hospital San Diego, San Diego, California, USA.&#xD;Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, Colorado, USA.&#xD;Department of Dermatology and Allergy, Christine Kuhne-Center for Allergy Research and Education (CK-CARE), University Hospital Bonn, Bonn, Germany.&#xD;LEO Pharma, Madison, New Jersey, USA.&#xD;Department of Dermatology, George Washington University School of Medicine, Washington, DC, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2875-2891</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/07/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Subcutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">tralokinumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37455359</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopic dermatitis (AD) is a chronic, inflammatory, intensely pruritic skin disorder associated with significant patient burden. Interleukin (IL)-13 is a cytokine that acts as a driver of immune dysregulation, skin-barrier dysfunction, and microbiome dysbiosis that characterizes AD, and is consistently overexpressed in AD skin. Tralokinumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody that binds specifically to IL-13 with high affinity, thereby inhibiting subsequent downstream IL-13 signaling. Three pivotal phase 3 clinical trials demonstrated that tralokinumab 300 mg every other week, as monotherapy or in combination with topical corticosteroids as needed, provides significant improvements in signs and symptoms of moderate-to-severe AD, as measured by Investigator&apos;s Global Assessment 0/1 (clear/almost clear) and Eczema Area and Severity Index-75 at Week 16. Improvements were observed soon after tralokinumab initiation and were maintained over 52 weeks of therapy. Tralokinumab significantly improved patient-reported outcomes such as itch and sleep, and demonstrated a safety profile comparable with placebo; conjunctivitis during tralokinumab therapy was generally mild. Similar results were observed in a phase 3 adolescent trial. The role of IL-13 in the pathophysiology of AD justifies a targeted approach and a wealth of clinical data supports tralokinumab as a new therapeutic option for people with moderate-to-severe AD.</style></abstract><notes><style face="normal" font="default" size="100%">Simpson, Eric L&#xD;Guttman-Yassky, Emma&#xD;Eichenfield, Lawrence F&#xD;Boguniewicz, Mark&#xD;Bieber, Thomas&#xD;Schneider, Shannon&#xD;Guana, Adriana&#xD;Silverberg, Jonathan I&#xD;eng&#xD;LEO Pharma Inc./&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):2875-2891. doi: 10.1111/all.15811. Epub 2023 Jul 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37455359</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15811</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2748</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2748</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dekkers, C.</style></author><author><style face="normal" font="default" size="100%">Zuithoff, N.</style></author><author><style face="normal" font="default" size="100%">Bakker, D.</style></author><author><style face="normal" font="default" size="100%">Knol, E.</style></author><author><style face="normal" font="default" size="100%">Wevers, A.</style></author><author><style face="normal" font="default" size="100%">Touwslager, W.</style></author><author><style face="normal" font="default" size="100%">Christoffers, W.</style></author><author><style face="normal" font="default" size="100%">Prosje, P.</style></author><author><style face="normal" font="default" size="100%">van Lynden-van Nes, A.</style></author><author><style face="normal" font="default" size="100%">van Lumig, P.</style></author><author><style face="normal" font="default" size="100%">Kamsteeg, M.</style></author><author><style face="normal" font="default" size="100%">Oosting, A. J.</style></author><author><style face="normal" font="default" size="100%">Schuttelaar, M. L. A.</style></author><author><style face="normal" font="default" size="100%">Haeck, I.</style></author><author><style face="normal" font="default" size="100%">de Graaf, M.</style></author><author><style face="normal" font="default" size="100%">van Wijk, F.</style></author><author><style face="normal" font="default" size="100%">de Bruin-Weller, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.&#xD;Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Catharina Hospital Eindhoven, Eindhoven, The Netherlands.&#xD;Isala Hospital Zwolle, Zwolle, The Netherlands.&#xD;Medical Center Leeuwarden, Leeuwarden, The Netherlands.&#xD;Meander Medical Center Amersfoort, Amersfoort, The Netherlands.&#xD;Maastricht University Medical Center, Maastricht, The Netherlands.&#xD;Radboud University Medical Center, Nijmegen, The Netherlands.&#xD;Spaarne Gasthuis Hoofddorp, Hoofddorp, The Netherlands.&#xD;University Medical Center Groningen, Groningen, The Netherlands.&#xD;Reinier de Graaf Hospital Delft, Delft, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1060-1073</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2024/12/14 20:06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy/blood/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal/therapeutic use/adverse effects/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">*Blood Proteins/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">tralokinumab</style></keyword><keyword><style face="normal" font="default" size="100%">Lynden-van Nes, P. van Lumig, M. Kamsteeg, and B. Oosting have nothing to</style></keyword><keyword><style face="normal" font="default" size="100%">disclose. D.S. Bakker is a speaker for Sanofi and LEO Pharma. E.F. Knol is a</style></keyword><keyword><style face="normal" font="default" size="100%">speaker for Sanofi and GSK. has W.A. Christoffers is a consultant, advisory board</style></keyword><keyword><style face="normal" font="default" size="100%">member, and/or speaker for Genzyme, Abbvie and LEO Pharma. M.L.A. Schuttelaar is</style></keyword><keyword><style face="normal" font="default" size="100%">an advisor, consultant, speaker and/or investigator for AbbVie, Pfizer, LEO</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma, Regeneron, Sanofi, Eli Lilly and Galderma. She has received grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Regeneron, Sanofi and Pfizer. I.M Haeck is a consultant, advisory board member,</style></keyword><keyword><style face="normal" font="default" size="100%">and/or speaker for Sanofi and Regeneron Pharmaceuticals, LEO Pharma, AbbVie,</style></keyword><keyword><style face="normal" font="default" size="100%">Janssen and Eli Lilly. Dr. M. de Graaf is a consultant, advisory board member,</style></keyword><keyword><style face="normal" font="default" size="100%">and/or speaker for Sanofi and Regeneron Pharmaceuticals, AbbVie, Almirall,</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis, LEO Pharma, Pfizer and Eli Lilly. Prof. M. S. de Bruin-Weller is a</style></keyword><keyword><style face="normal" font="default" size="100%">consultant, advisory board member, and/or speaker for AbbVie, Almirall, Aslan,</style></keyword><keyword><style face="normal" font="default" size="100%">Arena, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39673366</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION AND OBJECTIVES: Tralokinumab-a biological that specifically targets interleukin-13-is one of the newer advanced systemic treatments for patients with moderate-to-severe atopic dermatitis (AD). Although safety and efficacy have been shown in phase-III clinical trials, daily practice data are needed. Therefore, the aim of this study was to evaluate 28-week safety and effectiveness, serum proteins and total IgE levels in adult AD patients treated with tralokinumab in daily practice. MATERIALS AND METHODS: Data of all adult AD patients who started treatment with tralokinumab and participated in the BioDay registry were collected at baseline, and after 4,16 and 28 weeks of treatment. Clinical efficacy was evaluated by clinical outcome measures, such as the Eczema Area and Severity Index (EASI) as well as patient-reported outcome measures, such as the numerical rating scale (NRS) for pruritus. Adverse events were evaluated. In a subgroup of patients, 18 proteins as well as total IgE levels were measured in serum. RESULTS: A total of 84 patients were included, of whom 39 were dupilumab-naive (D-naive) and 45 were dupilumab non-naive (D-non-naive) patients. All primary outcomes significantly improved during 28 weeks of tralokinumab treatment and the probability of achieving EASI &lt;/= 7 and NRS-pruritis &lt;/= 4 was 75.8% (56.9-88.2) and 51.4% (28.0-74.2), respectively. The disease severity-associated proteins TARC/CCL17 and PARC/CCL18 decreased during treatment, and total IgE levels significantly decreased in the D-naive patients. The most reported adverse events were eye disorders (n = 24, 28.6%). A total of 23 patients (27.4%) discontinued treatment due to adverse events and/or ineffectiveness, with hair loss being the most common adverse event leading to treatment discontinuation (n = 6). CONCLUSION: Tralokinumab is an effective treatment for moderate-to-severe AD in adult patients, in both dupilumab-naive patients and patients who previously failed on dupilumab treatment. The clinical effect is supported by the biological data.</style></abstract><notes><style face="normal" font="default" size="100%">Dekkers, Coco&#xD;Zuithoff, Nicolaas&#xD;Bakker, Daphne&#xD;Knol, Edward&#xD;Wevers, Anne&#xD;Touwslager, Wouter&#xD;Christoffers, Wianda&#xD;Prosje, Petra&#xD;van Lynden-van Nes, Anneke&#xD;van Lumig, Paula&#xD;Kamsteeg, Marijke&#xD;Oosting, Albert Jan&#xD;Schuttelaar, Marie L A&#xD;Haeck, Inge&#xD;de Graaf, Marlies&#xD;van Wijk, Femke&#xD;de Bruin-Weller, Marjolein&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1060-1073. doi: 10.1111/all.16414. Epub 2024 Dec 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39673366</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11969312</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16414</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1214</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1214</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, J.</style></author><author><style face="normal" font="default" size="100%">Scicluna, B. P.</style></author><author><style face="normal" font="default" size="100%">van Engelen, T. S. R.</style></author><author><style face="normal" font="default" size="100%">Bonta, P. I.</style></author><author><style face="normal" font="default" size="100%">Majoor, C. J.</style></author><author><style face="normal" font="default" size="100%">Van&apos;t Veer, C.</style></author><author><style face="normal" font="default" size="100%">de Vos, A. F.</style></author><author><style face="normal" font="default" size="100%">Bel, E. H.</style></author><author><style face="normal" font="default" size="100%">van der Poll, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.&#xD;Division of Infectious Disease, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcriptional changes in alveolar macrophages from adults with asthma after allergen challenge</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2218-2222</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/12/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages, Alveolar</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33368438</style></accession-num><notes><style face="normal" font="default" size="100%">Yang, Jack&#xD;Scicluna, Brendon P&#xD;van Engelen, Tjitske S R&#xD;Bonta, Peter I&#xD;Majoor, Christof J&#xD;Van&apos;t Veer, Cornelis&#xD;de Vos, Alex F&#xD;Bel, Elisabeth H&#xD;van der Poll, Tom&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2218-2222. doi: 10.1111/all.14719. Epub 2021 Jan 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33368438</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8359176</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14719</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1413</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1413</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hara, M.</style></author><author><style face="normal" font="default" size="100%">Morimoto, N.</style></author><author><style face="normal" font="default" size="100%">Suzuki, N.</style></author><author><style face="normal" font="default" size="100%">Tsuchihashi, N.</style></author><author><style face="normal" font="default" size="100%">Komori, M.</style></author><author><style face="normal" font="default" size="100%">Yoshihama, K.</style></author><author><style face="normal" font="default" size="100%">Fujii, K.</style></author><author><style face="normal" font="default" size="100%">Yamaguchi, S.</style></author><author><style face="normal" font="default" size="100%">Tsunoda, M.</style></author><author><style face="normal" font="default" size="100%">Tomisato, S.</style></author><author><style face="normal" font="default" size="100%">Takahashi, N.</style></author><author><style face="normal" font="default" size="100%">Oyake, K.</style></author><author><style face="normal" font="default" size="100%">Okuba, Y.</style></author><author><style face="normal" font="default" size="100%">Fujieda, M.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Department of Otolaryngology, National Center for Child Health and Development, Tokyo, Japan.&#xD;Department of Pediatrics, Kochi Medical School, Kochi University, Kochi, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcriptome analysis reveals two distinct endotypes and putative immune pathways in tonsils from children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">359-363</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/06/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphadenitis/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Palatine Tonsil</style></keyword><keyword><style face="normal" font="default" size="100%">*Pharyngitis/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Stomatitis, Aphthous/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">PFAPA syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">endotype</style></keyword><keyword><style face="normal" font="default" size="100%">innate immune response</style></keyword><keyword><style face="normal" font="default" size="100%">phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">tonsil</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32593215</style></accession-num><notes><style face="normal" font="default" size="100%">Hara, Mariko&#xD;Morimoto, Noriko&#xD;Suzuki, Noriomi&#xD;Tsuchihashi, Nana&#xD;Komori, Manabu&#xD;Yoshihama, Keisuke&#xD;Fujii, Kae&#xD;Yamaguchi, Sota&#xD;Tsunoda, Mayumi&#xD;Tomisato, Syuta&#xD;Takahashi, Nozomi&#xD;Oyake, Koichiro&#xD;Okuba, Yuzuru&#xD;Fujieda, Mikiya&#xD;Matsumoto, Kenji&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):359-363. doi: 10.1111/all.14477. Epub 2020 Jul 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32593215</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14477</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1113</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1113</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Matsushita, K.</style></author><author><style face="normal" font="default" size="100%">Jackson, J.</style></author><author><style face="normal" font="default" size="100%">Numata, T.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, G.</style></author><author><style face="normal" font="default" size="100%">Tsai, M.</style></author><author><style face="normal" font="default" size="100%">Galli, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcriptome programming of IL-3-dependent bone marrow-derived cultured mast cells by stem cell factor (SCF)</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2288-2291</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bone Marrow</style></keyword><keyword><style face="normal" font="default" size="100%">Bone Marrow Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-3/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">*Stem Cell Factor/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">basic immunology</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">stem cell factor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33683709</style></accession-num><notes><style face="normal" font="default" size="100%">Wang, Ying&#xD;Matsushita, Kazufumi&#xD;Jackson, Jennifer&#xD;Numata, Takafumi&#xD;Zhang, Yue&#xD;Zhou, Gao&#xD;Tsai, Mindy&#xD;Galli, Stephen J&#xD;eng&#xD;R01 AI132494/AI/NIAID NIH HHS/&#xD;R01 AR067145/AR/NIAMS NIH HHS/&#xD;T32 AI007290/AI/NIAID NIH HHS/&#xD;Letter&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2288-2291. doi: 10.1111/all.14808. Epub 2021 Mar 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33683709</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8274682</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14808</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>733</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">733</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lefevre-Utile, A.</style></author><author><style face="normal" font="default" size="100%">Saichi, M.</style></author><author><style face="normal" font="default" size="100%">Olah, P.</style></author><author><style face="normal" font="default" size="100%">Delord, M.</style></author><author><style face="normal" font="default" size="100%">Homey, B.</style></author><author><style face="normal" font="default" size="100%">Soumelis, V.</style></author><author><style face="normal" font="default" size="100%">Maars consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">U976 HIPI Unit, Institut de Recherche Saint-Louis, Universite de Paris, Inserm, Paris, France.&#xD;General Pediatrics and Pediatric Emergency Department, Jean Verdier Hospital, Assistance Publique-Hopitaux de Paris (APHP), Bondy, France.&#xD;Universite Paris Saclay, Gif-sur-Yvette, France.&#xD;Department of Dermatology, University of Duesseldorf, Duesseldorf, Germany.&#xD;Department of Dermatology, Venereology, and Oncodermatology, Medical Faculty, University of Pecs, Pecs, Hungary.&#xD;Clinical Research Center, Centre Hospitalier de Versailles, Le Chesnay, France.&#xD;Laboratoire d&apos;Immunologie et histocompatibilite, Hopital Saint-Louis, Assistance Publique-Hopitaux de Paris (AP-HP), Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcriptome-based identification of novel endotypes in adult atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1486-1498</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2021/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">clustering</style></keyword><keyword><style face="normal" font="default" size="100%">endotype</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34689335</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Atopic dermatitis (AD) is a frequent and heterogeneous inflammatory skin disease, for which personalized medicine remains a challenge. High-throughput approaches have improved understanding of the complex pathophysiology of AD. However, a purely data-driven AD classification is still lacking. METHODS: To address this question, we applied an original unsupervised approach on the largest available transcriptome dataset of AD lesional (n = 82) and healthy (n = 213) skin biopsies. RESULTS: Taking into account pathological and physiological state, a variance-based filtering revealed 222 AD-specific hyper-variable genes that efficiently classified the AD samples into 4 clusters that turned out to be clinically and biologically distinct. Comparison of gene expressions between clusters identified 3 sets of upregulated genes used to derive metagenes (MGs): MG-I (19 genes) was associated with IL-1 family signaling (including IL-36A and 36G) and skin remodeling, MG-II (23 genes) with negative immune regulation (including IL-34 and 37) and skin architecture, and MG-III (17 genes) with B lymphocyte immunity. Sample clusters differed in terms of disease severity (p = .02) and S. aureus (SA) colonization (p = .02). Cluster 1 contained the most severe AD, highest SA colonization, and overexpressed MG-I. Cluster 2 was characterized by less severe AD, low SA colonization, and high MG-II expression. Cluster 3 included mild AD, mild SA colonization, and mild expression of all MGs. Cluster 4 had the same clinical features as cluster 3 but had hyper-expression of MG-III. Last, we successfully validated our method and results in an independent cohort. CONCLUSION: Our study revealed unrecognized AD endotypes with specific underlying biological pathways, highlighting novel pathophysiological mechanisms. These data could provide new insights into personalized treatment strategies.</style></abstract><notes><style face="normal" font="default" size="100%">Lefevre-Utile, Alain&#xD;Saichi, Melissa&#xD;Olah, Peter&#xD;Delord, Marc&#xD;Homey, Bernhard&#xD;Soumelis, Vassili&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1486-1498. doi: 10.1111/all.15150. Epub 2021 Nov 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34689335</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15150</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2987</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2987</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pesque, D.</style></author><author><style face="normal" font="default" size="100%">Andrades, E.</style></author><author><style face="normal" font="default" size="100%">Berenguer-Molins, P.</style></author><author><style face="normal" font="default" size="100%">Perera-Bel, J.</style></author><author><style face="normal" font="default" size="100%">Claros, M.</style></author><author><style face="normal" font="default" size="100%">Bodalo-Torruella, M.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Farre, M.</style></author><author><style face="normal" font="default" size="100%">Gallardo, F.</style></author><author><style face="normal" font="default" size="100%">Pujol, R. M.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Universitat Autonoma de Barcelona (UAB), Barcelona, Spain.&#xD;Department of Dermatology, Hospital del Mar Research Institute, Barcelona, Spain.&#xD;Department of Medicine, Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;MARData, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain.&#xD;MARGenomics, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain.&#xD;Department of Pathology, Hospital del Mar Research Institute, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcriptomic Analysis of Allergic Patch Test Reactions in Non-Atopic Patients: A Comparative Study Across Multiple Allergens</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3043-3054</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Patch Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact/immunology/genetics/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">allergic</style></keyword><keyword><style face="normal" font="default" size="100%">contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">immune</style></keyword><keyword><style face="normal" font="default" size="100%">patch test</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomic</style></keyword><keyword><style face="normal" font="default" size="100%">speaker and/or advisor for and has received research funding or participated in</style></keyword><keyword><style face="normal" font="default" size="100%">research from Almirall, Amgen, AstraZeneca, Avene, Blue Print, Celldex, Escient</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals, Genentech, GSK, Harmonic Bio, Incyte, Instituto Carlos</style></keyword><keyword><style face="normal" font="default" size="100%">III-FEDER, Jaspers, Leo Pharma, Menarini, Mitsubishi Tanabe Pharma, Novartis,</style></keyword><keyword><style face="normal" font="default" size="100%">Sanofi-Regeneron, Septerna, Servier, Thermo Fisher Scientific, Uriach</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma/Neucor, outside the submitted work. All other authors declare no conflicts</style></keyword><keyword><style face="normal" font="default" size="100%">of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40632077</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Immune mechanisms underlying elicitation in allergic contact dermatitis (ACD) have yet to be fully elucidated. Previous studies have shown a double-faceted nature of ACD with both common biomarkers among different allergens and allergen-specific imprinting, albeit with discordance in terms of relevant pathways involved. Several factors, including co-existing atopic dermatitis, may influence immune reactions. We aim to characterize molecular signatures and their immune mechanisms of different relevant allergens (nickel, 2-hydroxyethylmethacrylate [2-HEMA], methylisothiazolinone [MIT], formaldehyde) in strong and extreme positive (2/3+) patch test reactions of patients without atopic dermatitis. METHODS: A transcriptomic analysis of 40 skin biopsies of ACD reactions (11 nickel, 10 MIT, 10 2-HEMA, 9 formaldehyde) and 19 controls (petrolatum-occluded skin) was performed using RNA sequencing. Differentially expressed genes (DEG) were assessed, and enriched functional pathways were obtained with an over-representation analysis for allergens. RESULTS: ACD molecular profiling revealed a strong, common imprinting of DEG among allergens versus controls (n = 814), with further partially shared DEG among allergens (n = 664) and allergen-specific DEG (n = 430). The most relevant shared pathways were associated with immune adaptive and innate responses. All allergens exhibited mixed effector immune responses, mainly type 1 and 3 immunity, and, to a lesser extent, type 2 immunity. Furthermore, partially shared and unique DEG were associated with further inflammatory pathways, particularly for nickel and 2-HEMA. CONCLUSIONS: This study confirms shared ACD imprinting among different allergens and shared pathways&apos; predominant role in ACD elicitation in patients without atopic dermatitis, alongside allergen-specific immune processes and mixed effector responses (type 1, 3 and 2).</style></abstract><notes><style face="normal" font="default" size="100%">Pesque, David&#xD;Andrades, Evelyn&#xD;Berenguer-Molins, Pau&#xD;Perera-Bel, Julia&#xD;Claros, Miquel&#xD;Bodalo-Torruella, Marta&#xD;Gonzalez-Farre, Monica&#xD;Gallardo, Fernando&#xD;Pujol, Ramon M&#xD;Gimenez-Arnau, Ana M&#xD;eng&#xD;LEO Fondet/&#xD;Comparative Study&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):3043-3054. doi: 10.1111/all.16642. Epub 2025 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40632077</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12590323</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16642</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2400</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2400</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Del Duca, E.</style></author><author><style face="normal" font="default" size="100%">Dahabreh, D.</style></author><author><style face="normal" font="default" size="100%">Kim, M.</style></author><author><style face="normal" font="default" size="100%">Bar, J.</style></author><author><style face="normal" font="default" size="100%">Da Rosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Rabinowitz, G.</style></author><author><style face="normal" font="default" size="100%">Facheris, P.</style></author><author><style face="normal" font="default" size="100%">Gomez-Arias, P. J.</style></author><author><style face="normal" font="default" size="100%">Chang, A.</style></author><author><style face="normal" font="default" size="100%">Utti, V.</style></author><author><style face="normal" font="default" size="100%">Chowdhury, A.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y. D.</style></author><author><style face="normal" font="default" size="100%">Laculiceanu, A.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Icahn School of Medicine at the Mount Sinai, New York, New York, USA.&#xD;Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.&#xD;Department of Dermatology, IRCCS Humanitas Research Hospital, Milan, Italy.&#xD;Department of Dermatology, Reina Sofia University Hospital, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.&#xD;Department of Allergy and Clinical Immunology, Transylvania University, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcriptomic evaluation of skin tape-strips in children with allergic asthma uncovers epidermal barrier dysfunction and asthma-associated biomarkers abnormalities</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1516-1530</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics/diagnosis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">*Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Filaggrin Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Epidermis/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">airway remodeling</style></keyword><keyword><style face="normal" font="default" size="100%">allergic asthma</style></keyword><keyword><style face="normal" font="default" size="100%">asthma-related outcomes</style></keyword><keyword><style face="normal" font="default" size="100%">atopic march</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier</style></keyword><keyword><style face="normal" font="default" size="100%">tape-strips</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomic biomarkers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38375886</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Tape-strips, a minimally invasive method validated for the evaluation of several skin diseases, may help identify asthma-specific biomarkers in the skin of children with allergic asthma. METHODS: Skin tape-strips were obtained and analyzed with RNA-Seq from children with moderate allergic asthma (MAA) (n = 11, mean age 7.00; SD = 1.67), severe allergic asthma (SAA) (n = 9, mean age 9.11; SD = 2.37), and healthy controls (HCs) (n = 12, mean age 7.36; SD = 2.03). Differentially expressed genes (DEGs) were identified by fold change &gt;/=2 with a false discovery rate &lt;0.05. Transcriptomic biomarkers were analyzed for their accuracy in distinguishing asthma from HCs, their relationships with asthma-related outcomes (exacerbation rate, lung function-FEV1, IOS-R5-20, and lung inflammation-FeNO), and their links to skin (barrier and immune response) and lung (remodeling, metabolism, aging) pathogenetic pathways. RESULTS: RNA-Seq captured 1113 in MAA and 2117 DEGs in SAA. Epidermal transcriptomic biomarkers for terminal differentiation (FLG/filaggrin), cell adhesion (CDH19, JAM2), lipid biosynthesis/metabolism (ACOT2, LOXL2) were significantly downregulated. Gene set variation analysis revealed enrichment of Th1/IFNgamma pathways (p &lt; .01). MAA and SAA shared downregulation of G-protein-coupled receptor (OR4A16, TAS1R3), upregulation of TGF-beta/ErbB signaling-related (ACVR1B, EGFR, ID1/2), and upregulation of mitochondrial-related (HIGD2A, VDAC3, NDUFB9) genes. Skin transcriptomic biomarkers correlated with the annualized exacerbation rate and with lung function parameters. A two-gene classifier (TSSC4-FAM212B) was able to differentiate asthma from HCs with 100% accuracy. CONCLUSION: Tape-strips detected epithelial barrier and asthma-associated signatures in normal-appearing skin from children with allergic asthma and may serve as an alternative to invasive approaches for evaluating asthma endotypes.</style></abstract><notes><style face="normal" font="default" size="100%">Del Duca, Ester&#xD;Dahabreh, Dante&#xD;Kim, Madeline&#xD;Bar, Jonathan&#xD;Da Rosa, Joel Correa&#xD;Rabinowitz, Grace&#xD;Facheris, Paola&#xD;Gomez-Arias, Pedro Jesus&#xD;Chang, Annie&#xD;Utti, Vivian&#xD;Chowdhury, Amira&#xD;Liu, Ying&#xD;Estrada, Yeriel D&#xD;Laculiceanu, Alexandru&#xD;Agache, Ioana&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;P30 AR079200/AR/NIAMS NIH HHS/&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1516-1530. doi: 10.1111/all.16060. Epub 2024 Feb 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38375886</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11247382</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16060</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2683</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2683</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tran, N. Q. V.</style></author><author><style face="normal" font="default" size="100%">Kobayashi, Y.</style></author><author><style face="normal" font="default" size="100%">Nakamura, Y.</style></author><author><style face="normal" font="default" size="100%">Ishimaru, K.</style></author><author><style face="normal" font="default" size="100%">Izuhara, K.</style></author><author><style face="normal" font="default" size="100%">Nakao, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.&#xD;Division of Allergy, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.&#xD;Yamanashi GLIA Center, University of Yamanashi, Yamanashi, Japan.&#xD;Atopy Research Center, Juntendo University School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcriptomic evidence for T cell-fibroblast-keratinocyte axis via IL-13-periostin-integrin in atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3521-3525</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/10/18</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39418111</style></accession-num><notes><style face="normal" font="default" size="100%">Tran, Nguyen Quoc Vuong&#xD;Kobayashi, Yoshiaki&#xD;Nakamura, Yuki&#xD;Ishimaru, Kayoko&#xD;Izuhara, Kenji&#xD;Nakao, Atsuhito&#xD;eng&#xD;(22K19427)/The Ministry of Education, Culture, Sports, Science and Technology of Japan/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3521-3525. doi: 10.1111/all.16352. Epub 2024 Oct 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39418111</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657014</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16352</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2660</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2660</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ordak, M.</style></author><author><style face="normal" font="default" size="100%">Di Bona, D.</style></author><author><style face="normal" font="default" size="100%">Serviddio, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcriptomic in allergy-statistical recommendations</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">598-601</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/08/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">RNA-seq</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39215541</style></accession-num><notes><style face="normal" font="default" size="100%">Ordak, Michal&#xD;Di Bona, Danilo&#xD;Serviddio, Gaetano&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):598-601. doi: 10.1111/all.16306. Epub 2024 Aug 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39215541</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16306</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2776</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2776</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sudharson, S.</style></author><author><style face="normal" font="default" size="100%">Eckl-Dorna, J.</style></author><author><style face="normal" font="default" size="100%">Meshcheryakova, A.</style></author><author><style face="normal" font="default" size="100%">Basilio, J.</style></author><author><style face="normal" font="default" size="100%">Derdak, S.</style></author><author><style face="normal" font="default" size="100%">Kalic, T.</style></author><author><style face="normal" font="default" size="100%">Lengger, N.</style></author><author><style face="normal" font="default" size="100%">Schweitzer, N.</style></author><author><style face="normal" font="default" size="100%">Mechtcheriakova, D.</style></author><author><style face="normal" font="default" size="100%">Breiteneder, H.</style></author><author><style face="normal" font="default" size="100%">Hafner, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, St. Poelten, Austria.&#xD;Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.&#xD;INESC ID, Instituto Superior Tecnico, Universidade de Lisboa, Lisboa, Portugal.&#xD;Core Facilities, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcriptomic Profiles of the Nasal Mucosa Following Birch Pollen Provocation Differ Between Birch Pollen-Allergic and Non-Allergic Individuals</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1757-1769</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/12/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Betula/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Mucosa/metabolism/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/immunology/genetics/metabolism/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">birch pollen allergy</style></keyword><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">differentially expressed genes</style></keyword><keyword><style face="normal" font="default" size="100%">nasal mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">nasal provocation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39717878</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Birch pollen (BP) interacts with airway epithelial cells to cause allergic sensitization and allergy in predisposed individuals. However, the basic mechanisms underlying the clinical effects are poorly understood. Changes in gene expression and cytokine secretion in nasal mucosal cells upon BP exposure were determined in BP-allergic and non-allergic individuals. METHODS: BP-allergic (n = 11) and non-allergic individuals (n = 12) participated in nasal provocations with saline and aqueous BP solution. Nasal scrapings and secretions were obtained at baseline and after BP provocation. Bulk RNA sequencing of the nasal scrapings was performed, and cytokines in nasal secretions were quantified. RESULTS: After BP challenge, we identified 160 differentially expressed genes (DEGs) in the nasal scrapings of allergic individuals and 44 in non-allergic individuals. DEGs encoding S100 proteins, keratins, small proline-rich repeat proteins, and cytokines were predominantly identified, with proinflammatory cytokine transcripts being upregulated only in the allergic cohort. The top canonical pathways in allergic individuals included granulocyte and agranulocyte adhesion and diapedesis, wound healing, IL-8 signaling, and IL-17-related pathways. Enriched pathways in allergic participants were associated with granulocyte chemotaxis, humoral cell responses, and IL-10, IL-4, and IL-13 signaling and were absent in non-allergic individuals. At baseline and after BP challenge, higher amounts of CCL17, CCL20, CCL26, IL-7, IL-16, and IL-33 were detected in nasal secretions of allergic compared to non-allergic individuals. CONCLUSION: Our results highlight the activation of important cellular signaling pathways specific to BP-allergic individuals after BP exposure offering new perspectives for studying key players in BP allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Sudharson, Srinidhi&#xD;Eckl-Dorna, Julia&#xD;Meshcheryakova, Anastasia&#xD;Basilio, Jose&#xD;Derdak, Sophia&#xD;Kalic, Tanja&#xD;Lengger, Nina&#xD;Schweitzer, Nina&#xD;Mechtcheriakova, Diana&#xD;Breiteneder, Heimo&#xD;Hafner, Christine&#xD;eng&#xD;Danube Allergy Research Cluster Projects P06 and P09 funded by the Federal State of Lower Austria, Austria/&#xD;951970/FCT PhD Scholarship 2020.09166.BD, European Union&apos;s Horizon 2020 research and innovation programme/&#xD;UIDB/50021/2020/INESC-ID Plurianual project/&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1757-1769. doi: 10.1111/all.16448. Epub 2024 Dec 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39717878</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186594</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16448</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2620</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2620</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marrocco, A.</style></author><author><style face="normal" font="default" size="100%">Mitchel, J. A.</style></author><author><style face="normal" font="default" size="100%">Parker, M.</style></author><author><style face="normal" font="default" size="100%">McGill, M.</style></author><author><style face="normal" font="default" size="100%">Chase, R. P.</style></author><author><style face="normal" font="default" size="100%">Weiss, S. T.</style></author><author><style face="normal" font="default" size="100%">Gold, D. R.</style></author><author><style face="normal" font="default" size="100%">Castaldi, P. J.</style></author><author><style face="normal" font="default" size="100%">Israel, E.</style></author><author><style face="normal" font="default" size="100%">Park, J. A.</style></author><author><style face="normal" font="default" size="100%">Sordillo, J. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Channing Division of Network Medicine, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Pulmonary and Critical Care Medicine, Allergy &amp; Immunology, Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, Massachusetts, USA.&#xD;Division of Chronic Disease Research Across the Lifecourse (CoRAL), Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcriptomic profiles of well-differentiated airway epithelial cells in response to environmental triggers of asthma exacerbation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3501-3505</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/08/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">RNAseq</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bronchial epithelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">disclose.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39109392</style></accession-num><notes><style face="normal" font="default" size="100%">Marrocco, Antonella&#xD;Mitchel, Jennifer A&#xD;Parker, Margaret&#xD;McGill, Maureen&#xD;Chase, Robert P&#xD;Weiss, Scott T&#xD;Gold, Diane R&#xD;Castaldi, Peter J&#xD;Israel, Elliot&#xD;Park, Jin-Ah&#xD;Sordillo, Joanne E&#xD;eng&#xD;P30 ES000002/ES/NIEHS NIH HHS/&#xD;R01 HL148152/HL/NHLBI NIH HHS/&#xD;T32 HL007118/HL/NHLBI NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3501-3505. doi: 10.1111/all.16226. Epub 2024 Aug 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39109392</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11984455</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16226</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>567</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">567</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ong, H. H.</style></author><author><style face="normal" font="default" size="100%">Andiappan, A. K.</style></author><author><style face="normal" font="default" size="100%">Duan, K.</style></author><author><style face="normal" font="default" size="100%">Lum, J.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Tan, K. S.</style></author><author><style face="normal" font="default" size="100%">Howland, S.</style></author><author><style face="normal" font="default" size="100%">Lee, B.</style></author><author><style face="normal" font="default" size="100%">Ong, Y. K.</style></author><author><style face="normal" font="default" size="100%">Thong, M.</style></author><author><style face="normal" font="default" size="100%">Chow, V. T.</style></author><author><style face="normal" font="default" size="100%">Wang, D. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.&#xD;Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.&#xD;Biosafety level 3 Core Facility, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, Singapore, Singapore.&#xD;Department of Otolaryngology - Head &amp; Neck Surgery, National University Health System, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcriptomics of rhinovirus persistence reveals sustained expression of RIG-I and interferon-stimulated genes in nasal epithelial cells in vitro</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2778-2793</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/03/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antiviral Agents</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interferons</style></keyword><keyword><style face="normal" font="default" size="100%">Nasal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">RNA/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Retinoic Acid/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinovirus/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Rig-i</style></keyword><keyword><style face="normal" font="default" size="100%">innate immune responses</style></keyword><keyword><style face="normal" font="default" size="100%">interferon-stimulated genes</style></keyword><keyword><style face="normal" font="default" size="100%">nasal epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">rhinovirus persistence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35274302</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Human rhinoviruses (HRVs) are frequently associated with asthma exacerbations, and have been found in the airways of asthmatic patients. While HRV-induced acute infection is well-documented, it is less clear whether the nasal epithelium sustains prolonged HRV infections along with the associated activation of host immune responses. OBJECTIVE: To investigate sustainably regulated host responses of human nasal epithelial cells (hNECs) during HRV persistence. METHODS: Using a time-course study, HRV16 persistence and viral replication dynamics were established using an in vitro infection model of hNECs. RNA sequencing was performed on hNECs in the early and late stages of infection at 3 and 14 days post-infection (dpi), respectively. The functional enrichment of differentially expressed genes (DEGs) was evaluated using gene ontology (GO) and Ingenuity pathway analysis. RESULTS: HRV RNA and protein expression persisted throughout prolonged infections, even after decreased production of infectious virus progeny. GO analysis of unique DEGs indicated altered regulation of pathways related to ciliary function and airway remodeling at 3 dpi and serine-type endopeptidase activity at 14 dpi. The functional enrichment of shared DEGs between the two time-points was related to interferon (IFN) and cytoplasmic pattern recognition receptor (PRR) signaling pathways. Validation of the sustained regulation of candidate genes confirmed the persistent expression of RIG-I and revealed its close co-regulation with interferon-stimulated genes (ISGs) during HRV persistence. CONCLUSIONS: The persistence of HRV RNA does not necessarily indicate an active infection during prolonged infection. The sustained expression of RIG-I and ISGs in response to viral RNA persistence highlights the importance of assessing how immune-activating host factors can change during active HRV infection and the immune regulation that persists thereafter.</style></abstract><notes><style face="normal" font="default" size="100%">Ong, Hsiao Hui&#xD;Andiappan, Anand Kumar&#xD;Duan, Kaibo&#xD;Lum, Josephine&#xD;Liu, Jing&#xD;Tan, Kai Sen&#xD;Howland, Shanshan&#xD;Lee, Bernett&#xD;Ong, Yew Kwang&#xD;Thong, Mark&#xD;Chow, Vincent T&#xD;Wang, De-Yun&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2778-2793. doi: 10.1111/all.15280. Epub 2022 Mar 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35274302</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15280</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2232</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2232</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Estravis, M.</style></author><author><style face="normal" font="default" size="100%">Perez-Pazos, J.</style></author><author><style face="normal" font="default" size="100%">Moreno-Jimenez, E.</style></author><author><style face="normal" font="default" size="100%">Trivino, J. C.</style></author><author><style face="normal" font="default" size="100%">Garcia-Sanchez, A.</style></author><author><style face="normal" font="default" size="100%">Gomez-Garcia, M.</style></author><author><style face="normal" font="default" size="100%">Morgado, N.</style></author><author><style face="normal" font="default" size="100%">Ramos-Gonzalez, J.</style></author><author><style face="normal" font="default" size="100%">Gil-Melcon, M.</style></author><author><style face="normal" font="default" size="100%">Martin-Garcia, C.</style></author><author><style face="normal" font="default" size="100%">Munoz-Bellido, F.</style></author><author><style face="normal" font="default" size="100%">Sanz, C.</style></author><author><style face="normal" font="default" size="100%">Isidoro-Garcia, M.</style></author><author><style face="normal" font="default" size="100%">Davila, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain.&#xD;Red de Enfermedades Inflamatorias - Instituto de Salud Carlos III, Madrid, Spain.&#xD;Clinical Biochemistry Department Salamanca, Pharmacogenetics and Precision Medicine Unit, Hospital Universitario de Salamanca, Salamanca, Spain.&#xD;Microbiology and Genetics Department Salamanca, Universidad de Salamanca, Salamanca, Spain.&#xD;Synlab Group, Sistemas Genomicos SL, Valencia, Spain.&#xD;Biomedical and Diagnostics Sciences Department, Universidad de Salamanca, Salamanca, Spain.&#xD;Pneumology Department, Hospital Universitario de Salamanca, Salamanca, Spain.&#xD;Otorhinolaryngology and Head and Neck Surgery Department, Hospital Universitario de Salamanca, Salamanca, Spain.&#xD;Allergy Department, Hospital Universitario de Salamanca, Salamanca, Spain.&#xD;Medicine Department, Universidad de Salamanca, Salamanca, Spain.&#xD;Clinical Biochemistry Department, Hospital Universitario de Salamanca, Salamanca, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transcriptomics reveals new regulatory mechanisms involved in benralizumab response</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3023-3026</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2023/08/29</style></edition><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37641395</style></accession-num><notes><style face="normal" font="default" size="100%">Estravis, Miguel&#xD;Perez-Pazos, Jacqueline&#xD;Moreno-Jimenez, Emma&#xD;Trivino, Juan Carlos&#xD;Garcia-Sanchez, Asuncion&#xD;Gomez-Garcia, Manuel&#xD;Morgado, Natalia&#xD;Ramos-Gonzalez, Jacinto&#xD;Gil-Melcon, Maria&#xD;Martin-Garcia, Cristina&#xD;Munoz-Bellido, Francisco&#xD;Sanz, Catalina&#xD;Isidoro-Garcia, Maria&#xD;Davila, Ignacio&#xD;eng&#xD;Consejeria de Educacion, Junta de Castilla y Leon/&#xD;Instituto de Salud Carlos III/&#xD;Ministerio de Ciencia e Innovacion/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Nov;78(11):3023-3026. doi: 10.1111/all.15869. Epub 2023 Aug 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37641395</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15869</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>926</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">926</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Urbano, A.</style></author><author><style face="normal" font="default" size="100%">Plaza, J.</style></author><author><style face="normal" font="default" size="100%">Turon, S.</style></author><author><style face="normal" font="default" size="100%">Pujol, A.</style></author><author><style face="normal" font="default" size="100%">Costa-Farre, C.</style></author><author><style face="normal" font="default" size="100%">Marco, A.</style></author><author><style face="normal" font="default" size="100%">Picado, C.</style></author><author><style face="normal" font="default" size="100%">Torres, R.</style></author><author><style face="normal" font="default" size="100%">de Mora, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, Therapeutics and Toxicology, Universitat Autonoma de Barcelona, Barcelona, Spain.&#xD;Transgenic Animal Unit, Center of Animal Biotechnology and Gene Therapy, Universitat Autonoma de Barcelona, Bellaterra (Barcelona), Spain.&#xD;Department of Surgery and Animals Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.&#xD;Department of Pneumology and Respiratory Allergy, Hospital Clinic, IDIBAPS (Institut d&apos;Investigacions Biomediques August Pi i Sunyer), Universitat de Barcelona, Barcelona, Spain.&#xD;CIBERES (Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias), Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transgenic mice overexpressing the PGE(2) receptor EP(2) on mast cells exhibit a protective phenotype in a model of allergic asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3196-3199</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Dinoprostone</style></keyword><keyword><style face="normal" font="default" size="100%">Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34173237</style></accession-num><notes><style face="normal" font="default" size="100%">Urbano, Adrian&#xD;Plaza, Judith&#xD;Turon, Sandra&#xD;Pujol, Anna&#xD;Costa-Farre, Cristina&#xD;Marco, Alberto&#xD;Picado, Cesar&#xD;Torres, Rosa&#xD;de Mora, Fernando&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3196-3199. doi: 10.1111/all.14988. Epub 2021 Jul 10.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34173237</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14988</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2414</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2414</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Odling, M.</style></author><author><style face="normal" font="default" size="100%">Lagercrantz, B.</style></author><author><style face="normal" font="default" size="100%">Goksor, E.</style></author><author><style face="normal" font="default" size="100%">Sandelowsky, H.</style></author><author><style face="normal" font="default" size="100%">Janson, C.</style></author><author><style face="normal" font="default" size="100%">Kull, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Women&apos;s and Children&apos;s Health, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Paediatrics, Queen Silvia Children&apos;s Hospital, University of Gothenburg, Gothenburg, Sweden.&#xD;Department of Medicine, Solna, Division of Clinical Epidemiology, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, Stockholm, Sweden.&#xD;Academic Primary Healthcare Centre, Stockholm, Sweden.&#xD;Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.&#xD;Sachs&apos; Children and Youth Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transitional care of adolescents and young adults with asthma and allergy-The healthcare professional perspective</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1972-1974</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/02/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/therapy/epidemiology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Transitional Care</style></keyword><keyword><style face="normal" font="default" size="100%">Health Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38334163</style></accession-num><notes><style face="normal" font="default" size="100%">Odling, Maria&#xD;Lagercrantz, Birgitta&#xD;Goksor, Emma&#xD;Sandelowsky, Hanna&#xD;Janson, Christer&#xD;Kull, Inger&#xD;eng&#xD;the Asthma, Allergy and COPD Nursing Association/&#xD;Sallskapet Barnavard/&#xD;Konsul Th C Berghs Stiftelse/&#xD;Hjart-Lungfonden/&#xD;Astma- och Allergiforbundet/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1972-1974. doi: 10.1111/all.16047. Epub 2024 Feb 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38334163</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16047</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>628</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">628</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Della Bella, E.</style></author><author><style face="normal" font="default" size="100%">Koch, J.</style></author><author><style face="normal" font="default" size="100%">Baerenfaller, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">AO Research Institute Davos (ARI), Davos, Switzerland.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Swiss Institute of Bioinformatics (SIB), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Translation and emerging functions of non-coding RNAs in inflammation and immunity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2025-2037</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/01/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Circular</style></keyword><keyword><style face="normal" font="default" size="100%">*RNA, Long Noncoding/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">immunology</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">non-coding RNA</style></keyword><keyword><style face="normal" font="default" size="100%">regulation</style></keyword><keyword><style face="normal" font="default" size="100%">translation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35094406</style></accession-num><abstract><style face="normal" font="default" size="100%">Regulatory non-coding RNAs (ncRNAs) including small non-coding RNAs (sRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) have gained considerable attention in the last few years. This is mainly due to their condition- and tissue-specific expression and their various modes of action, which suggests them as promising biomarkers and therapeutic targets. One important mechanism of ncRNAs to regulate gene expression is through translation of short open reading frames (sORFs). These sORFs can be located in lncRNAs, in non-translated regions of mRNAs where upstream ORFs (uORFs) represent the majority, or in circRNAs. Regulation of their translation can function as a quick way to adapt protein production to changing cellular or environmental cues, and can either depend solely on the initiation and elongation of translation, or on the roles of the produced functional peptides. Due to the experimental challenges to pinpoint translation events and to detect the produced peptides, translational regulation through regulatory RNAs is not well studied yet. In the case of circRNAs, they have only recently started to be recognized as regulatory molecules instead of mere artifacts of RNA biosynthesis. Of the many roles described for regulatory ncRNAs, we will focus here on their regulation during inflammation and in immunity.</style></abstract><notes><style face="normal" font="default" size="100%">Della Bella, Elena&#xD;Koch, Jana&#xD;Baerenfaller, Katja&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2025-2037. doi: 10.1111/all.15234. Epub 2022 Feb 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35094406</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9302665</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15234</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1366</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1366</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thomas, W. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Translation of experimental immunotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">12-13</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Neoplasms</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32761982</style></accession-num><notes><style face="normal" font="default" size="100%">Thomas, Wayne Robert&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):12-13. doi: 10.1111/all.14544.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32761982</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14544</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3180</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3180</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hong, X.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K. C.</style></author><author><style face="normal" font="default" size="100%">Frischmeyer-Guerrerio, P.</style></author><author><style face="normal" font="default" size="100%">Wang, G.</style></author><author><style face="normal" font="default" size="100%">Jernbom, A. F.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Zhao, N.</style></author><author><style face="normal" font="default" size="100%">Morgenlander, W. R.</style></author><author><style face="normal" font="default" size="100%">Angkeow, J. W.</style></author><author><style face="normal" font="default" size="100%">Thakar, M.</style></author><author><style face="normal" font="default" size="100%">Pearson, C.</style></author><author><style face="normal" font="default" size="100%">Adams, W. G.</style></author><author><style face="normal" font="default" size="100%">Larman, H. B.</style></author><author><style face="normal" font="default" size="100%">Ji, H.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center on the Early Life Origins of Disease, Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.&#xD;Division of Immunology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.&#xD;Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden.&#xD;Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.&#xD;Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.&#xD;Division of General Pediatrics &amp; Adolescent Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transplacental Antimicrobial Antibodies and Childhood Asthma: Maternal Nativity as an Upstream Factor</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">197-208</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2025/11/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/immunology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Fetal Blood/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">*Prenatal Exposure Delayed Effects/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Maternal-Fetal Exchange/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Bacterial/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">IgG antibody</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">maternal nativity</style></keyword><keyword><style face="normal" font="default" size="100%">microbe</style></keyword><keyword><style face="normal" font="default" size="100%">prospective birth cohort</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41307260</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Early-life microbial exposure to microbes may play a role in asthma development. This study tests the hypothesis that mothers born in low-income countries might have been exposed to diverse microbes-leading to greater diversity and higher levels of transplacental anti-microbial antibodies, thereby conferring protection against asthma in offspring. METHODS: In the prospective Boston Birth Cohort, IgG antibody reactome against microbes (2740 species; 1311 genera) was profiled in cord blood, using Phage ImmunoPrecipitation Sequencing. Multinomial regression models were applied to examine the associations of cord blood IgG reactome with child risk of physician-diagnosed atopy and asthma. Mediation analysis was performed to examine the inter-relationships among maternal nativity, IgG reactome and risk of developing childhood asthma. RESULTS: This report included 943 mother-child dyads enrolled at birth and followed prospectively. Compared to children of US-born mothers, children of foreign-born mothers had a lower prevalence of asthma (17.5% vs. 30.5%) and greater diversity of cord blood IgG antibodies against hundreds of microbes (FDR &lt; 0.05). Cord blood seropositivity to peptides or proteins from 6 microbes was inversely associated with the risk of asthma in children, and children with more seropositivity to these microbes were at a lower risk of developing asthma (p &lt; 0.001). IgG seropositivity to A. actinomycetemcomitans, H. pylori, S. flexneri, and T. parva each mediated 17%-62% of the association between maternal nativity and child risk of asthma. CONCLUSION: In this US prospective birth cohort, maternal transplacental IgG reactivity to four microbes (A. actinomycetemcomitans, H. pylori, S. flexneri and T. parva) was associated with a lower risk of childhood asthma, and partly explains the lower risk of asthma in children of mothers born outside the US.</style></abstract><notes><style face="normal" font="default" size="100%">Hong, Xiumei&#xD;Nadeau, Kari C&#xD;Frischmeyer-Guerrerio, Pamela&#xD;Wang, Guoying&#xD;Jernbom, August F&#xD;Li, Shuai&#xD;Zhao, Ni&#xD;Morgenlander, William R&#xD;Angkeow, Julia W&#xD;Thakar, Manju&#xD;Pearson, Colleen&#xD;Adams, William G&#xD;Larman, H Benjamin&#xD;Ji, Hongkai&#xD;Wang, Xiaobin&#xD;eng&#xD;NH/NIH HHS/&#xD;Maternal and Child Health Bureau/&#xD;Denmark&#xD;Allergy. 2026 Jan;81(1):197-208. doi: 10.1111/all.70167. Epub 2025 Nov 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41307260</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70167</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1397</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1397</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bilo, M. B.</style></author><author><style face="normal" font="default" size="100%">Pravettoni, V.</style></author><author><style face="normal" font="default" size="100%">Mauro, M.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.&#xD;Ancona and Allergy Unit, Department of Internal Medicine, University Hospital of Ancona, Ancona, Italy.&#xD;U.O.C. General Medicine - Immunology and Allergology, Foundation IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico, Milan, Italy.&#xD;U.O.S. Allergology - Sant&apos;Anna Hospital, ASST Lariana, Como, Italy.&#xD;U.S.D. Allergy Unit, Integrated University-Hospital of Verona, Verona, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treating venom allergy during COVID-19 pandemic</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">949-950</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/07/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bee Venoms/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/*epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32677059</style></accession-num><notes><style face="normal" font="default" size="100%">Bilo, Maria Beatrice&#xD;Pravettoni, Valerio&#xD;Mauro, Marina&#xD;Bonadonna, Patrizia&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):949-950. doi: 10.1111/all.14473. Epub 2020 Jul 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32677059</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7404889</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14473</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1523</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1523</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">O&apos;Konek, J. J.</style></author><author><style face="normal" font="default" size="100%">Baker, J. R., Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Mary H. Weiser Food Allergy Center, University of Michigan, Ann Arbor, MI, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of allergic disease with nanoemulsion adjuvant vaccines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">246-249</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2019/07/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adjuvants, Immunologic/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Intranasal</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Emulsions</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypersensitivity/*therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Nanotechnology/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Patents as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines/immunology/*therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">31298741</style></accession-num><notes><style face="normal" font="default" size="100%">O&apos;Konek, Jessica J&#xD;Baker, James R Jr&#xD;eng&#xD;HHSN272200900031C/AI/NIAID NIH HHS/&#xD;Food Allergy Research and Education/International&#xD;W81XWH-14-PRMRP-DA/U.S. Department of Defense/International&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2020 Jan;75(1):246-249. doi: 10.1111/all.13977. Epub 2019 Aug 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31298741</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC6952560</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.13977</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2382</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2382</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muller, S.</style></author><author><style face="normal" font="default" size="100%">Maintz, L.</style></author><author><style face="normal" font="default" size="100%">Bieber, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.&#xD;Christine Kuhne Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.&#xD;Davos BioSciences, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1501-1515</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2024/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Approval</style></keyword><keyword><style face="normal" font="default" size="100%">Janus Kinase Inhibitors/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Development</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biological therapy</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38186219</style></accession-num><abstract><style face="normal" font="default" size="100%">Atopic dermatitis (AD) represents the most common skin disease characterized by heterogeneous endophenotypes and a high disease burden. In Europe, six new systemic therapies for AD have been approved: the biologics dupilumab (anti-interleukin-4 receptor (IL-4R) alpha in 2017), tralokinumab (anti-IL-13 in 2021), lebrikizumab (anti-IL-13 in 2023), and the oral janus kinase (JAK) inhibitors (JAKi) targeting JAK1/2 (baricitinib in 2020 in the EU) or JAK1 (upadacitinib in 2021 and abrocitinib in 2022). Herein, we give an update on new approvals, long-term safety, and efficacy. Upadacitinib and abrocitinib have the highest short-term efficacy among the approved systemic therapies. In responders, dupilumab and tralokinumab catch up regarding long-term efficacy and incremental clinical benefit within continuous use. Recently, the European Medicines Agency has released recommendations for the use of JAKi in patients at risk (cardiovascular and thromboembolic diseases, malignancies, (former) smoking, and age &gt;/=65 years). Furthermore, we give an overview on emerging therapies currently in Phase III trials. Among the topical therapies, tapinarof (aryl hydrocarbon receptor), ruxolitinib (JAK1/2i), delgocitinib (pan-JAKi), asivatrep (anti-transient receptor potential vanilloid), and phosphodiesterase-4-inhibitors (roflumilast, difamilast) are discussed. Among systemic therapies, current data on cord-blood-derived mesenchymal stem cells, CM310 (anti IL-4Ralpha), nemolizumab (anti-IL-31RA), anti-OX40/OX40L-antibodies, neurokinin-receptor-1-antagonists, and difelikefalin (kappa-opioid-R) are reported.</style></abstract><notes><style face="normal" font="default" size="100%">Muller, Svenja&#xD;Maintz, Laura&#xD;Bieber, Thomas&#xD;eng&#xD;This article was funded by the Christine Kuhne-Center for Allergy Research and Education (CK-CARE)/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 Jun;79(6):1501-1515. doi: 10.1111/all.16009. Epub 2024 Jan 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38186219</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16009</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1223</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1223</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Singh, U.</style></author><author><style face="normal" font="default" size="100%">Rao, M. B.</style></author><author><style face="normal" font="default" size="100%">Berendts, K.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Mutasim, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Cincinnati College of Medicine, Cincinnati, OH, USA.&#xD;Bernstein Clinical Research Center, Cincinnati, OH, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of chronic spontaneous urticaria with benralizumab: Report of primary endpoint per-protocol analysis and exploratory endpoints</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1277-1280</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/12/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Il-5</style></keyword><keyword><style face="normal" font="default" size="100%">basophil</style></keyword><keyword><style face="normal" font="default" size="100%">biologics</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33326617</style></accession-num><notes><style face="normal" font="default" size="100%">Bernstein, Jonathan A&#xD;Singh, Umesh&#xD;Rao, Marepalli B&#xD;Berendts, Karen&#xD;Zhang, Xiang&#xD;Mutasim, Diya&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1277-1280. doi: 10.1111/all.14713. Epub 2020 Dec 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33326617</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14713</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1662</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1662</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khaitov, M.</style></author><author><style face="normal" font="default" size="100%">Nikonova, A.</style></author><author><style face="normal" font="default" size="100%">Kofiadi, I.</style></author><author><style face="normal" font="default" size="100%">Shilovskiy, I.</style></author><author><style face="normal" font="default" size="100%">Smirnov, V.</style></author><author><style face="normal" font="default" size="100%">Elisytina, O.</style></author><author><style face="normal" font="default" size="100%">Maerle, A.</style></author><author><style face="normal" font="default" size="100%">Shatilov, A.</style></author><author><style face="normal" font="default" size="100%">Shatilova, A.</style></author><author><style face="normal" font="default" size="100%">Andreev, S.</style></author><author><style face="normal" font="default" size="100%">Sergeev, I.</style></author><author><style face="normal" font="default" size="100%">Trofimov, D.</style></author><author><style face="normal" font="default" size="100%">Latysheva, T.</style></author><author><style face="normal" font="default" size="100%">Ilyna, N.</style></author><author><style face="normal" font="default" size="100%">Martynov, A.</style></author><author><style face="normal" font="default" size="100%">Rabdano, S.</style></author><author><style face="normal" font="default" size="100%">Ruzanova, E.</style></author><author><style face="normal" font="default" size="100%">Savelev, N.</style></author><author><style face="normal" font="default" size="100%">Pletiukhina, I.</style></author><author><style face="normal" font="default" size="100%">Safi, A.</style></author><author><style face="normal" font="default" size="100%">Ratnikov, V.</style></author><author><style face="normal" font="default" size="100%">Gorelov, V.</style></author><author><style face="normal" font="default" size="100%">Kaschenko, V.</style></author><author><style face="normal" font="default" size="100%">Kucherenko, N.</style></author><author><style face="normal" font="default" size="100%">Umarova, I.</style></author><author><style face="normal" font="default" size="100%">Moskaleva, S.</style></author><author><style face="normal" font="default" size="100%">Fabrichnikov, S.</style></author><author><style face="normal" font="default" size="100%">Zuev, O.</style></author><author><style face="normal" font="default" size="100%">Pavlov, N.</style></author><author><style face="normal" font="default" size="100%">Kruchko, D.</style></author><author><style face="normal" font="default" size="100%">Berzin, I.</style></author><author><style face="normal" font="default" size="100%">Goryachev, D.</style></author><author><style face="normal" font="default" size="100%">Merkulov, V.</style></author><author><style face="normal" font="default" size="100%">Shipulin, G.</style></author><author><style face="normal" font="default" size="100%">Udin, S.</style></author><author><style face="normal" font="default" size="100%">Trukhin, V.</style></author><author><style face="normal" font="default" size="100%">Valenta, R.</style></author><author><style face="normal" font="default" size="100%">Skvortsova, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Research Center (NRC) Institute of Immunology Federal Medical-Biological Agency (FMBA) of Russia, Moscow, Russia.&#xD;Pirogov Russian National Research Medical University, Moscow, Russia.&#xD;RUDN University, Moscow, Russia.&#xD;I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.&#xD;Federal State Unitary Enterprise &quot;The Saint Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations&quot; of Federal Medical and Biologic Agency (FSUE SPbSRIVS FMBA of Russia), St. Petersburg, Russia.&#xD;North-West District Scientific and Clinical Center named after L.G. Sokolov Federal Medical and Biological Agency, St. Petersburg, Russia.&#xD;Federal Clinical Center of High Medical Technologies of the Federal Medical and Biological Agency of Russia, Moscow, Russia.&#xD;Federal Medico-biological Agency of Russia (FMBA Russia), Moscow, Russia.&#xD;Centre for Evaluation and Control of Finished Pharmaceutical Products, Federal State Budgetary Institution &quot;Scientific Centre for Expert Evaluation of Medicinal Products&quot; of the Ministry of Health of the Russian Federation, Moscow, Russia.&#xD;Centre for Strategic Planning of FMBA of Russia Federal State Budgetary Institution &quot;Centre for Strategic Planning and Management of Biomedical Health Risks&quot; of the Federal Medical Biological Agency, Moscow, Russia.&#xD;Medical University of Vienna, Vienna, Austria.&#xD;Karl Landsteiner University of Healthcare, Krems, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of COVID-19 patients with a SARS-CoV-2-specific siRNA-peptide dendrimer formulation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1639-1653</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/02/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">*Dendrimers</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">siRNA</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36721963</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Severe acute respiratory syndrome corona virus (SARS-CoV-2) infection frequently causes severe and prolonged disease but only few specific treatments are available. We aimed to investigate safety and efficacy of a SARS-CoV-2-specific siRNA-peptide dendrimer formulation MIR 19(R) (siR-7-EM/KK-46) targeting a conserved sequence in known SARS-CoV-2 variants for treatment of COVID-19. METHODS: We conducted an open-label, randomized, controlled multicenter phase II trial (NCT05184127) evaluating safety and efficacy of inhaled siR-7-EM/KK-46 (3.7 mg and 11.1 mg/day: low and high dose, respectively) in comparison with standard etiotropic drug treatment (control group) in patients hospitalized with moderate COVID-19 (N = 52 for each group). The primary endpoint was the time to clinical improvement according to predefined criteria within 14 days of randomization. RESULTS: Patients from the low-dose group achieved the primary endpoint defined by simultaneous achievement of relief of fever, normalization of respiratory rate, reduction of coughing, and oxygen saturation of &gt;95% for 48 h significantly earlier (median 6 days; 95% confidence interval [CI]: 5-7, HR 1.75, p = .0005) than patients from the control group (8 days; 95% CI: 7-10). No significant clinical efficacy was observed for the high-dose group. Adverse events were reported in 26 (50.00%), 25 (48.08%), and 28 (53.85%) patients from the low-, high-dose and control group, respectively. None of them were associated with siR-7-EM/KK-46. CONCLUSIONS: siR-7-EM/KK-46, a SARS-CoV-2-specific siRNA-peptide dendrimer formulation is safe, well tolerated and significantly reduces time to clinical improvement in patients hospitalized with moderate COVID-19 compared to standard therapy in a randomized controlled trial.</style></abstract><notes><style face="normal" font="default" size="100%">Khaitov, Musa&#xD;Nikonova, Alexandra&#xD;Kofiadi, Ilya&#xD;Shilovskiy, Igor&#xD;Smirnov, Valeriy&#xD;Elisytina, Olga&#xD;Maerle, Artem&#xD;Shatilov, Artem&#xD;Shatilova, Anastasia&#xD;Andreev, Sergey&#xD;Sergeev, Ilya&#xD;Trofimov, Dmitry&#xD;Latysheva, Tatyana&#xD;Ilyna, Natalia&#xD;Martynov, Alexander&#xD;Rabdano, Sevastyan&#xD;Ruzanova, Ellina&#xD;Savelev, Nikita&#xD;Pletiukhina, Iuliia&#xD;Safi, Ariana&#xD;Ratnikov, Vyacheslav&#xD;Gorelov, Viktor&#xD;Kaschenko, Viktor&#xD;Kucherenko, Natalya&#xD;Umarova, Irina&#xD;Moskaleva, Svetlana&#xD;Fabrichnikov, Sergei&#xD;Zuev, Oleg&#xD;Pavlov, Nikolai&#xD;Kruchko, Daria&#xD;Berzin, Igor&#xD;Goryachev, Dmitriy&#xD;Merkulov, Vadim&#xD;Shipulin, German&#xD;Udin, Sergey&#xD;Trukhin, Victor&#xD;Valenta, Rudolf&#xD;Skvortsova, Veronica&#xD;eng&#xD;Clinical Trial, Phase II&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1639-1653. doi: 10.1111/all.15663. Epub 2023 Feb 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36721963</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15663</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1310</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1310</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, X.</style></author><author><style face="normal" font="default" size="100%">Liu, M.</style></author><author><style face="normal" font="default" size="100%">Wu, S.</style></author><author><style face="normal" font="default" size="100%">Huang, Z.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Lai, X.</style></author><author><style face="normal" font="default" size="100%">Bao, H.</style></author><author><style face="normal" font="default" size="100%">Huang, J.</style></author><author><style face="normal" font="default" size="100%">Chang, L.</style></author><author><style face="normal" font="default" size="100%">Zhang, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.&#xD;Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment-emergent adverse events in dupilumab-treated patients with allergic diseases: A meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">593-596</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/10/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic</style></keyword><keyword><style face="normal" font="default" size="100%">ENT (rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy treament</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy clinical</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps...)</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33017860</style></accession-num><notes><style face="normal" font="default" size="100%">Chen, Xiaohong&#xD;Liu, Menghui&#xD;Wu, Shuo&#xD;Huang, Zizhen&#xD;Li, Xia&#xD;Lai, Xiaoping&#xD;Bao, Hongwei&#xD;Huang, Jiancong&#xD;Chang, Lihong&#xD;Zhang, Gehua&#xD;eng&#xD;Letter&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Feb;76(2):593-596. doi: 10.1111/all.14610. Epub 2020 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33017860</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14610</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2285</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2285</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saarimaki, L.</style></author><author><style face="normal" font="default" size="100%">Kivisto, J.</style></author><author><style face="normal" font="default" size="100%">Palmu, S.</style></author><author><style face="normal" font="default" size="100%">Protudjer, J. L. P.</style></author><author><style face="normal" font="default" size="100%">Huhtala, H.</style></author><author><style face="normal" font="default" size="100%">Karjalainen, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Tampere University Hospital, Tampere, Finland.&#xD;Allergy Centre, Tampere University Hospital, Tampere, Finland.&#xD;Center for Child, Adolescent and Maternal Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.&#xD;Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.&#xD;Faculty of Social Sciences, Tampere University, Tampere, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trends in severe allergic reactions of adults in Finland between 1999 and 2020: A national population study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">252-254</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Finland/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37902169</style></accession-num><notes><style face="normal" font="default" size="100%">Saarimaki, Lasse&#xD;Kivisto, Juho&#xD;Palmu, Sauli&#xD;Protudjer, Jennifer L P&#xD;Huhtala, Heini&#xD;Karjalainen, Jussi&#xD;eng&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):252-254. doi: 10.1111/all.15929. Epub 2023 Oct 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37902169</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15929</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>550</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">550</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grilo, J.</style></author><author><style face="normal" font="default" size="100%">Vollmann, U.</style></author><author><style face="normal" font="default" size="100%">Aumayr, M.</style></author><author><style face="normal" font="default" size="100%">Sturm, G. J.</style></author><author><style face="normal" font="default" size="100%">Bohle, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.&#xD;MacroArray Diagnostics, Vienna, Austria.&#xD;Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.&#xD;Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tropomyosin is no accurate marker allergen for diagnosis of shrimp allergy in Central Europe</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1921-1923</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/03/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Tropomyosin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35322447</style></accession-num><notes><style face="normal" font="default" size="100%">Grilo, Joao&#xD;Vollmann, Ute&#xD;Aumayr, Martina&#xD;Sturm, Gunter J&#xD;Bohle, Barbara&#xD;eng&#xD;P 32953/FWF_/Austrian Science Fund FWF/Austria&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1921-1923. doi: 10.1111/all.15290. Epub 2022 Apr 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35322447</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9321988 Novartis, Bencard, and Allergopharma, during the conduct of the study. BB reports grants from Austrian Science Funds, Austrian Jubilaumsfonds, and Medical University of Vienna, during the conduct of the study and personal fees from AllergenOnline outside the submitted work. MA is employed by MacroArray Diagnostics, Vienna, Austria. The other authors have nothing to declare.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15290</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>502</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">502</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Slot, M. C.</style></author><author><style face="normal" font="default" size="100%">Claessen, L. H. J.</style></author><author><style face="normal" font="default" size="100%">Bons, J. A. P.</style></author><author><style face="normal" font="default" size="100%">Menheere, Ppca</style></author><author><style face="normal" font="default" size="100%">Nieuwhof, C. M. G.</style></author><author><style face="normal" font="default" size="100%">de Boer, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergology and Clinical Immunology, Maastricht UMC+, Maastricht, The Netherlands.&#xD;Central Diagnostic Laboratory, Maastricht UMC+, Maastricht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tryptase reference ranges are age-dependent in a large population-based cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2833-2834</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2022/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Values</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35567344</style></accession-num><notes><style face="normal" font="default" size="100%">Slot, Marjan C&#xD;Claessen, Luuk H J&#xD;Bons, Judith A P&#xD;Menheere, Paul P C A&#xD;Nieuwhof, Chris M G&#xD;de Boer, Douwe&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2022 Sep;77(9):2833-2834. doi: 10.1111/all.15369. Epub 2022 May 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35567344</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9544703</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15369</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2346</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2346</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gander-Bui, H. T. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Experimental Pathology, Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Turning nature&apos;s experiment into a cure</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">767-769</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2023/12/12</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38084776</style></accession-num><notes><style face="normal" font="default" size="100%">Gander-Bui, Hang Thi Thuy&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Mar;79(3):767-769. doi: 10.1111/all.15981. Epub 2023 Dec 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38084776</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15981</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2912</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2912</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elzinga, H. B. E.</style></author><author><style face="normal" font="default" size="100%">Otten, J. J.</style></author><author><style face="normal" font="default" size="100%">Cornet, M. E.</style></author><author><style face="normal" font="default" size="100%">Rinia, A. B.</style></author><author><style face="normal" font="default" size="100%">Van Der Lans, R. J. L.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Poly, R. E. G. Consortium</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.&#xD;Department of Otorhinolaryngology, Alrijne Hospital, Leiden, the Netherlands.&#xD;Department of Otorhinolaryngology, Isala Hospital, Zwolle, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Two-Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1737-1745</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/05/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/drug therapy/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Monoclonal, Humanized/therapeutic use/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy/diagnosis/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Inflammatory Agents, Non-Steroidal/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">NSAID intolerance</style></keyword><keyword><style face="normal" font="default" size="100%">NSAID-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default" size="100%">aspirine-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">as a consultant and/or advisory board member for Sanofi, GSK, and Novartis.</style></keyword><keyword><style face="normal" font="default" size="100%">M.E.C. has acted as a consultant and/or advisory board member for Sanofi, GSK,</style></keyword><keyword><style face="normal" font="default" size="100%">ALK, Mylan, and Medtronic. A.B.R. has acted as a consultant and/or advisory board</style></keyword><keyword><style face="normal" font="default" size="100%">member for Sanofi. The department of Otorhinolaryngology and Head/Neck Surgery of</style></keyword><keyword><style face="normal" font="default" size="100%">the Amsterdam UMC has received research funding from Sanofi, GSK, and Novartis.</style></keyword><keyword><style face="normal" font="default" size="100%">The other authors declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40377347</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Patients with Non-steroidal anti-inflammatory drugs (NSAID)-Exacerbated Respiratory Disease (N-ERD) can suffer from difficult-to-treat primary diffuse type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). This study evaluates dupilumab effectiveness and dose tapering in CRSwNP patients with N-ERD compared to those without. METHODS: A real-world prospective cohort with CRSwNP patients, with N-ERD or without (CRSwNP-NOS; not otherwise specified), aged &gt;/= 18 treated with dupilumab 300 mg subcutaneously every 2 weeks. In case of clinical control, the interdose interval was prolonged every 6 months with steps of 2 weeks. (Clinical) data were collected at baseline, 24 weeks, and 2 years of treatment. RESULTS: Most baseline characteristics, including Nasal Polyp Score (NPS), Sino-Nasal Outcome Test-22 (SNOT-22), and Sniffin&apos; sticks-12 test (SSIT-12) were comparable between groups (N-ERD n = 105, CRSwNP-NOS n = 293). There was a higher prevalence (91.5% vs. 71.1%, p &lt; 0.001) but comparable control of asthma in N-ERD patients (asthma control test [ACT]: N-ERD 66.7% less controlled/uncontrolled vs. CRSwNP-NOS 58.3%, p = 0.21). All outcomes improved significantly with dupilumab treatment at 24 weeks and remained improved after 2 years, without intergroup differences (median scores at 24 weeks for N-ERD patients vs. CRSwNP-NOS, respectively: NPS: 2 vs. 1, p = 0.65; SNOT-22: 18 vs. 19, p = 0.27; SSIT-12: 7 vs. 8, p = 0.02; ACT: 21 vs. 22, p = 0.11). Dose tapering was possible in the majority of patients, with almost half at an 8-12 weeks interval in both groups after 2 years. CONCLUSION: Dupilumab shows comparable effectiveness and taper feasibility between CRSwNP N-ERD patients and CRSwNP-NOS patients.</style></abstract><notes><style face="normal" font="default" size="100%">Elzinga, H B E&#xD;Otten, J J&#xD;Cornet, M E&#xD;Rinia, A B&#xD;Van Der Lans, R J L&#xD;Fokkens, W J&#xD;Reitsma, S&#xD;eng&#xD;Amsterdam UMC/&#xD;AERO/&#xD;GlaxoSmithKline foundation/&#xD;Novartis/&#xD;Sanofi/&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1737-1745. doi: 10.1111/all.16579. Epub 2025 May 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40377347</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186595</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16579</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2625</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2625</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Loke, P.</style></author><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Lloyd, M.</style></author><author><style face="normal" font="default" size="100%">Ashley, S. E.</style></author><author><style face="normal" font="default" size="100%">Lozinsky, A. C.</style></author><author><style face="normal" font="default" size="100%">Gold, M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Sullivan, M. D.</style></author><author><style face="normal" font="default" size="100%">Quinn, P.</style></author><author><style face="normal" font="default" size="100%">Robinson, M.</style></author><author><style face="normal" font="default" size="100%">Galvin, A. D.</style></author><author><style face="normal" font="default" size="100%">Orsini, F.</style></author><author><style face="normal" font="default" size="100%">Ppoit- study group</style></author><author><style face="normal" font="default" size="100%">Tang, M. L. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Murdoch Children&apos;s Research Institute, Parkville, Victoria, Australia.&#xD;Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia.&#xD;Monash Children&apos;s Hospital, Monash Health, Clayton, Victoria, Australia.&#xD;Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.&#xD;Department of Allergy and Immunology, Royal Children&apos;s Hospital, Parkville, Victoria, Australia.&#xD;Department of Paediatrics, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.&#xD;Women&apos;s and Children&apos;s Hospital Adelaide, North Adelaide, South Australia, Australia.&#xD;Immunology Department, Perth Children&apos;s Hospital, Child and Adolescent Health Service, Nedlands, Western Australia, Australia.&#xD;Discipline of Paediatrics, Medical School, The University of Western Australia, Perth, Western Australia, Australia.&#xD;Telethon Kids Institute, Nedlands, Western Australia, Australia.&#xD;School of Applied Psychology, Cork University Hospital, University College Cork, Cork, Ireland.&#xD;Allergy Research Network, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Two-year post-treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy-003 Long-Term (PPOIT-003LT) study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2759-2774</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/08/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/therapy/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Probiotics/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">*Arachis/immunology/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">desensitization</style></keyword><keyword><style face="normal" font="default" size="100%">health-related quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">probiotic</style></keyword><keyword><style face="normal" font="default" size="100%">remission</style></keyword><keyword><style face="normal" font="default" size="100%">sustained unresponsiveness</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39099231</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Few studies have examined long-term outcomes following oral immunotherapy (OIT); none have examined long-term risks and benefits associated with distinct clinical outcomes (desensitization, remission). METHODS: Participants completing the probiotic and peanut oral immunotherapy (PPOIT) -003 randomized trial were enrolled in a follow-on study, PPOIT-003LT. Peanut ingestion, reactions, and health-related quality of life (HRQOL) were monitored prospectively. Outcomes at 1-year and 2-years post-treatment were examined by treatment group and by post-OIT clinical outcome (remission, desensitization without remission [DWR], allergic). RESULTS: 86% (151/176) of eligible children enrolled. Post-treatment peanut ingestion at 2-years post-treatment were similar for PPOIT (86.7%) and OIT (78.7%) groups, both higher than placebo (10.3%). Reactions reduced over time for all treatment and clinical outcome groups (PPOIT 31.7% to 23.3%, OIT 37.7% to 19.7%, placebo 13.8% to 6.9%; remission 27.5% to 15.9%; DWR 57.9% to 36.8%; allergic 11.6% to 7%). At 2-years post-treatment, similar proportions of remission and allergic participants reported reactions (RD 0.09 (95%CI -0.03, 0.20), p = .127), whereas more DWR participants reported reactions than remission (remission vs DWR: RD -0.21 (95%CI -0.39; -0.03), p = .02) and allergic (DWR vs allergic: RD 0.30 (95%CI 0.13, 0.47), p = .001) participants. At 2-years post-treatment, 0% remission versus 5.3% DWR versus 2.3% allergic participants reported adrenaline injector usage. Remission participants had significantly greater HRQOL improvement (adjusted for baseline) compared with both DWR (MD -0.54 (95%CI -0.99, -0.10), p = .017) and allergic (MD -0.82 (95%CI -1.25, -0.38), p &lt; .001). CONCLUSION: By 2-years post-treatment, remission participants reported fewer reactions, less severe reactions and greater HRQOL improvement compared with DWR and allergic participants, indicating that remission is the patient-preferred treatment outcome over desensitization or remaining allergic.</style></abstract><notes><style face="normal" font="default" size="100%">Loke, Paxton&#xD;Wang, Xiaofang&#xD;Lloyd, Melanie&#xD;Ashley, Sarah E&#xD;Lozinsky, Adriana C&#xD;Gold, Michael&#xD;O&apos;Sullivan, Michael D&#xD;Quinn, Patrick&#xD;Robinson, Marnie&#xD;Galvin, Audrey Dunn&#xD;Orsini, Francesca&#xD;Tang, Mimi L K&#xD;eng&#xD;Murdoch Children&apos;s Research Institute/&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2759-2774. doi: 10.1111/all.16262. Epub 2024 Aug 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39099231</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16262</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2211</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2211</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van der Lans, R. J. L.</style></author><author><style face="normal" font="default" size="100%">Otten, J. J.</style></author><author><style face="normal" font="default" size="100%">Adriaensen, Gfjpm</style></author><author><style face="normal" font="default" size="100%">Hoven, D. R.</style></author><author><style face="normal" font="default" size="100%">Benoist, L. B.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2684-2697</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/07/03</style></edition><section><style face="normal" font="default" size="100%">2684</style></section><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">biological therapy</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">long term</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">observational study</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37394895</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dupilumab is an anti-T2-inflammatory biological registered for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), indicated by integrated CRS-care pathways when optimal medico-surgical treatment yields insufficient CRS control. This study aims to evaluate long-term results with focus on established therapeutic efficacy while tapering dupilumab. METHODS: Real-life, prospective observational cohort study in single tertiary referral center with add-on dupilumab as primary biological treatment in adult (&gt;/=18 years) biological-naive CRSwNP patients per the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS)2020-indication with a 2-year follow-up. Tapering (increasing interdose interval) applied every 24 weeks, conditional to sufficient treatment response and CRS control. RESULTS: Mean scores (s.d.) of all co-primary outcomes improved significantly from baseline ( 228) to the 48 ( 214) and 96-weeks ( 99) timepoints: Nasal Polyp Score (0-8) improved from 5,3 (1,9) to 1,4 (1,8) and 1,3 (1,7); SinoNasal Outcome Test (SNOT)-22 (0-110) improved from 53,6 (19,6) to 20,2 (15,4) and 21,2 (15,6); Sniffin&apos;Sticks-12 identification test (0-12; 0-6 anosmia, 7-10 hyposmia, 11-12 normosmia) improved from 3,7 (2,4) to 7,7 (2,9) and 7,3 (3,04); Asthma Control Test (5-25; &gt;19 indicating well-controlled asthma) improved from 18,5 (4,8) to 21,8 (3,8) and 21,4 (3,9). Tapering was feasible in 79,5% of the patients at the 24-weeks timepoint, and in 93,7% and 95,8% at the 48- and 96-weeks timepoints, respectively. One-way repeated-measures ANOVA demonstrated no significant alterations of individual co-primary outcome mean-scores from 24 weeks onward. CONCLUSION: This first long-term real-life prospective observational cohort study shows high therapeutic efficacy of dupilumab for severe CRswNP in the first 2 years. Therapeutic efficacy is principally established within 24 weeks and endures while tapering dupilumab conditional to treatment response and CRS control.</style></abstract><notes><style face="normal" font="default" size="100%">van der Lans, Rik Johannes Leonardus&#xD;Otten, Josje Janna&#xD;Adriaensen, Gwijde Flavius Jacobus Petrus Maria&#xD;Hoven, Dinand Rienk&#xD;Benoist, Linda Berendina&#xD;Fokkens, Wytske Johanna&#xD;Reitsma, Sietze&#xD;eng&#xD;Observational Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2684-2697. doi: 10.1111/all.15796. Epub 2023 Jul 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37394895</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15796</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3012</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3012</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">De Corso, E.</style></author><author><style face="normal" font="default" size="100%">Montuori, C.</style></author><author><style face="normal" font="default" size="100%">Pipolo, C.</style></author><author><style face="normal" font="default" size="100%">La Mantia, I.</style></author><author><style face="normal" font="default" size="100%">Pasquini, E.</style></author><author><style face="normal" font="default" size="100%">Ghidini, A.</style></author><author><style face="normal" font="default" size="100%">Seccia, V.</style></author><author><style face="normal" font="default" size="100%">Ottaviano, G.</style></author><author><style face="normal" font="default" size="100%">Cantone, E.</style></author><author><style face="normal" font="default" size="100%">Dane, G.</style></author><author><style face="normal" font="default" size="100%">Garzaro, M.</style></author><author><style face="normal" font="default" size="100%">Fadda, G. L.</style></author><author><style face="normal" font="default" size="100%">Torretta, S.</style></author><author><style face="normal" font="default" size="100%">Anastasi, F.</style></author><author><style face="normal" font="default" size="100%">Canevari, F. R. M.</style></author><author><style face="normal" font="default" size="100%">Pagella, F.</style></author><author><style face="normal" font="default" size="100%">Lucidi, D.</style></author><author><style face="normal" font="default" size="100%">Cavaliere, C.</style></author><author><style face="normal" font="default" size="100%">Pagliuca, G.</style></author><author><style face="normal" font="default" size="100%">Maffei, M.</style></author><author><style face="normal" font="default" size="100%">Bussu, F.</style></author><author><style face="normal" font="default" size="100%">Corbo, M.</style></author><author><style face="normal" font="default" size="100%">D. Auria LM</style></author><author><style face="normal" font="default" size="100%">De Maio, G.</style></author><author><style face="normal" font="default" size="100%">Loperfido, A.</style></author><author><style face="normal" font="default" size="100%">Gallo, S.</style></author><author><style face="normal" font="default" size="100%">D. Agostino G</style></author><author><style face="normal" font="default" size="100%">Giannarelli, D.</style></author><author><style face="normal" font="default" size="100%">Galli, J.</style></author><author><style face="normal" font="default" size="100%">Dupireal Italian Study Group</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Otorhinolaryngology Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.&#xD;Department of Head, Neck and Sensory Organs, Catholic University of the Sacred Heart, Rome, Italy.&#xD;Otorhinolaryngology Unit, Department of Health Sciences, ASST Santi Paolo e Carlo Hospital, Universita Degli Studi di Milano, Milan, Italy.&#xD;Department of Medical and Surgical Sciences and Advanced Technologies &quot;GF Ingrassia&quot;, ENT Section, University of Catania, Catania, Italy.&#xD;ENT Unit, Bellaria Hospital, Azienda USL Bologna, Bologna, Italy.&#xD;Otorhinolaryngology Head and Neck Surgery Department, IRCCS Arcispedale Santamaria Nuova, Reggio Emilia, Italy.&#xD;Otolaryngology, Audiology and Phoniatric Operative Unit, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Pisa, Italy.&#xD;Otolaryngology Section, Department of Neurosciences, University of Padova, Padova, Italy.&#xD;Department of Neuroscience, Reproductive and Odontostomatological Sciences-ENT Section, University of Naples Federico II, Naples, Italy.&#xD;Head and Neck Department-ENT Section, AOU Federico II, Naples, Italy.&#xD;Otorhinolaryngology Unit, Head and Neck Department, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.&#xD;Department of Otorhinolaryngology, Rhinology Unit, Eastern Piedmont University - Maggiore Hospital, Novara, Italy.&#xD;Department of Otorhinolaryngology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.&#xD;Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico&quot;, University of Milan, Milan, Italy.&#xD;Otorhinolaryngology Unit, Ospedale San Giovanni Evangelista, Tivoli, Rome, Italy.&#xD;Otorhinolaryngology Unit, IRCCS Policlinico San Martino Genova, Dipartimento DISC Universita di Genova, Genova, Italy.&#xD;Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.&#xD;Department of Otolaryngology - Head and Neck Surgery, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.&#xD;Department of Sense Organs, Sapienza University of Rome, Rome, Italy.&#xD;Otolaryngology University Unit, &quot;S. M. Goretti Hospital&quot;, Latina, Italy.&#xD;Otolaryngology Head and Neck Surgery Unit, AORN Ospedali Della Colli, Naples, Italy.&#xD;Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.&#xD;Division of Otolaryngology, Azienda Ospedaliera Universitaria di Sassari, Sassari, Italy.&#xD;Otolaryngology Unit, San Camillo Forlanini Hospital, Rome, Italy.&#xD;Unit of Otorhinolaryngology, Head and Neck Department, ASST Sette Laghi, Varese, Italy.&#xD;UPLOAD (Upper and Lower Airways Diseases) Research Centre, Varese, Italy.&#xD;Design and Analysis of Clinical Trials Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Two-Year Turning Point With Dupilumab in CRSwNP: Control, Remission, and Tapering Dosage</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/08/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">CRSwNP</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">dupilumab</style></keyword><keyword><style face="normal" font="default" size="100%">late response</style></keyword><keyword><style face="normal" font="default" size="100%">long term</style></keyword><keyword><style face="normal" font="default" size="100%">remission</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40884177</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Dupilumab is an effective treatment for severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Most real-life studies have been conducted on small patient cohorts for up to 1 year. METHODS: This ambispective, multicentric, 2-year-long study evaluated dupilumab effectiveness (including treatment response, disease control, and remission) and safety in severe, uncontrolled CRSwNP patients from the DUPIREAL Italian study centers. RESULTS: The study involved 926 patients. At 24 months, median nasal polyp score (NPS), nasal obstruction visual analogue scale (VAS), Sino-nasal Outcome Test-22 (SNOT-22), and olfaction improved from baseline (all p &lt; 0.0001). Patients with NPS &gt; 4, and/or SNOT-22 &gt; 30, and/or Sniffin&apos; Sticks Identification Test-16 (SSIT-16) &lt; 12 at 12 months demonstrated improvements in these outcomes over the second year. Overall, 18.7% of patients extended the dupilumab interdose interval to every 4 weeks (q4w). Notably, 91.2% of patients were &quot;good-to-excellent&quot; responders based on EPOS/Euforea criteria. Given the absence of standardized definitions for disease control and remission, we proposed different sets of criteria reporting results from different scenarios. Remission analysis is clinically important as it helps define treatment success and long-term therapeutic goals. Most adverse events were mild-to-moderate; 2.4% of patients discontinued treatment due to safety concerns. CONCLUSIONS: This is the largest real-life study evaluating dupilumab in CRSwNP over 2 years. Dupilumab showed sustained effectiveness, with progressive improvements across all clinical outcomes. Dupilumab tapering did not compromise outcomes; treatment continuation allowed meaningful clinical benefits in late responders. Two-year rates of disease control and remission are clinically relevant, although standardized criteria to assess these outcomes are needed.</style></abstract><notes><style face="normal" font="default" size="100%">De Corso, Eugenio&#xD;Montuori, Claudio&#xD;Pipolo, Carlotta&#xD;La Mantia, Ignazio&#xD;Pasquini, Ernesto&#xD;Ghidini, Angelo&#xD;Seccia, Veronica&#xD;Ottaviano, Giancarlo&#xD;Cantone, Elena&#xD;Dane, Giulia&#xD;Garzaro, Massimiliano&#xD;Fadda, Gian Luca&#xD;Torretta, Sara&#xD;Anastasi, Francesca&#xD;Canevari, Frank Rikki Mauritz&#xD;Pagella, Fabio&#xD;Lucidi, Daniela&#xD;Cavaliere, Carlo&#xD;Pagliuca, Giulio&#xD;Maffei, Marianna&#xD;Bussu, Francesco&#xD;Corbo, Marco&#xD;D Auria, Leandro Maria&#xD;De Maio, Gabriele&#xD;Loperfido, Antonella&#xD;Gallo, Stefania&#xD;D Agostino, Giuseppe&#xD;Giannarelli, Diana&#xD;Galli, Jacopo&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Aug 30. doi: 10.1111/all.70032.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40884177</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70032</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2446</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2446</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rha, M. S.</style></author><author><style face="normal" font="default" size="100%">Kim, G.</style></author><author><style face="normal" font="default" size="100%">Lee, S.</style></author><author><style face="normal" font="default" size="100%">Jung, C. M.</style></author><author><style face="normal" font="default" size="100%">Lee, Y. W.</style></author><author><style face="normal" font="default" size="100%">Noh, H. E.</style></author><author><style face="normal" font="default" size="100%">Jeong, Y.</style></author><author><style face="normal" font="default" size="100%">Cho, H. J.</style></author><author><style face="normal" font="default" size="100%">Kim, C. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea.&#xD;Department of Biomedical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea.&#xD;The Airway Mucus Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Type 1/17 CD103(+)CD4(+) nasal-resident memory T cells in non-eosinophilic chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1996-1999</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2024/03/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/immunology/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Antigens, CD/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Integrin alpha Chains/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Memory T Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Th17 Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Th1 Cells/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Immunologic Memory</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocyte Subsets/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">CD4-Positive T-Lymphocytes/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Rhinosinusitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38445758</style></accession-num><notes><style face="normal" font="default" size="100%">Rha, Min-Seok&#xD;Kim, Gyeongyeob&#xD;Lee, Sol&#xD;Jung, Chan Min&#xD;Lee, Young-Woo&#xD;Noh, Hae Eun&#xD;Jeong, Yeonsu&#xD;Cho, Hyung-Ju&#xD;Kim, Chang-Hoon&#xD;eng&#xD;2021R1I1A1A01047571/The National Research Foundation of Korea/&#xD;HI23C1464/The Ministry of Health &amp;amp; Welfare, Republic of Korea/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2024 Jul;79(7):1996-1999. doi: 10.1111/all.16094. Epub 2024 Mar 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38445758</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16094</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>917</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">917</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lommatzsch, M.</style></author><author><style face="normal" font="default" size="100%">Klein, M.</style></author><author><style face="normal" font="default" size="100%">Stoll, P.</style></author><author><style face="normal" font="default" size="100%">Virchow, J. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3199-3202</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/07/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Exhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34216489</style></accession-num><notes><style face="normal" font="default" size="100%">Lommatzsch, Marek&#xD;Klein, Maria&#xD;Stoll, Paul&#xD;Virchow, Johann Christian&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3199-3202. doi: 10.1111/all.14997. Epub 2021 Jul 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34216489</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14997</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3196</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3196</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pham, D. D.</style></author><author><style face="normal" font="default" size="100%">Kwon, H. S.</style></author><author><style face="normal" font="default" size="100%">Song, W. J.</style></author><author><style face="normal" font="default" size="100%">Cho, Y. S.</style></author><author><style face="normal" font="default" size="100%">Lee, S. W.</style></author><author><style face="normal" font="default" size="100%">Ban, G. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, T.</style></author><author><style face="normal" font="default" size="100%">Park, S. Y.</style></author><author><style face="normal" font="default" size="100%">Nam, Y. H.</style></author><author><style face="normal" font="default" size="100%">Lee, B. J.</style></author><author><style face="normal" font="default" size="100%">An, J.</style></author><author><style face="normal" font="default" size="100%">Park, C. S.</style></author><author><style face="normal" font="default" size="100%">Rhyou, H. I.</style></author><author><style face="normal" font="default" size="100%">Kim, J. H.</style></author><author><style face="normal" font="default" size="100%">Park, H. K.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Yang, M. S.</style></author><author><style face="normal" font="default" size="100%">Kim, M. H.</style></author><author><style face="normal" font="default" size="100%">Ahn, K. M.</style></author><author><style face="normal" font="default" size="100%">Shim, J. S.</style></author><author><style face="normal" font="default" size="100%">Choi, J. H.</style></author><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Jung, J. W.</style></author><author><style face="normal" font="default" size="100%">Park, H. K.</style></author><author><style face="normal" font="default" size="100%">Kim, B. K.</style></author><author><style face="normal" font="default" size="100%">Lee, J. H.</style></author><author><style face="normal" font="default" size="100%">Kim, Y. C.</style></author><author><style face="normal" font="default" size="100%">Lee, S. M.</style></author><author><style face="normal" font="default" size="100%">Kang, S. Y.</style></author><author><style face="normal" font="default" size="100%">Kwon, J. W.</style></author><author><style face="normal" font="default" size="100%">Hur, G. Y.</style></author><author><style face="normal" font="default" size="100%">Moon, J. Y.</style></author><author><style face="normal" font="default" size="100%">Sohn, K. H.</style></author><author><style face="normal" font="default" size="100%">Kim, M. A.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Yoon, S.</style></author><author><style face="normal" font="default" size="100%">Jang, A. S.</style></author><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Park, S. Y.</style></author><author><style face="normal" font="default" size="100%">Jin, H. J.</style></author><author><style face="normal" font="default" size="100%">Kim, S. R.</style></author><author><style face="normal" font="default" size="100%">Lee, J. H.</style></author><author><style face="normal" font="default" size="100%">Bhavsar, P. K.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Dixey, P.</style></author><author><style face="normal" font="default" size="100%">Zounemat-Kermani, N.</style></author><author><style face="normal" font="default" size="100%">Yang, F.</style></author><author><style face="normal" font="default" size="100%">Patel, P. H.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Kim, T. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.&#xD;Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.&#xD;Department of Pulmonary, Allergy and Critical Care Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.&#xD;Department of Internal Medicine, Division of Pulmonology, Allergy and Critical Care Medicine, Chung-Ang University Gwangmyeong Hospital, Korea.&#xD;Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.&#xD;Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.&#xD;Department of Pulmonary, Allergy and Critical Care Medicine, College of Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University, Seoul, Republic of Korea.&#xD;Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.&#xD;Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.&#xD;Department of Internal Medicine, Pusan National University Hospital, Pusan National University College of Medicine, Busan, Korea.&#xD;Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.&#xD;Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.&#xD;Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.&#xD;Department of Pulmonology and Allergy, Hallym University Dongtan Sacred Heart Hospital, Korea.&#xD;Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.&#xD;Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.&#xD;Department of Allergy and Clinical Immunology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea.&#xD;Department of Internal Medicine, Korea University Medical Center Anam Hospital, Seoul, Korea.&#xD;Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.&#xD;Department of Internal Medicine, Division of Respiratory Diseases and Allergy, Dankook University College of Medicine, Cheonan, Korea.&#xD;Department of Internal Medicine, Division of Pulmonology and Allergy, Gachon University Gil Medical Center, Incheon, Republic of Korea.&#xD;Department of Allergy and Clinical Immunology, School of Medicine, Kangwon National University, Chuncheon, Korea.&#xD;Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.&#xD;Department of Internal Medicine, Division of Pulmonary and Allergy, Konkuk University School of Medicine, Konkuk University Medical Center, Seoul, Republic of Korea.&#xD;Department of Internal Medicine, Kyung Hee University Medical Center, Seoul, Korea.&#xD;Department of Pulmonology, Allergy and Critical Care Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.&#xD;Department of Internal Medicine, Division of Allergy and Clinical Immunology, Seoul National University Bundang Hospital, Seongnam, Korea.&#xD;Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.&#xD;Department of Internal Medicine, Division of Allergy and Respiratory Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.&#xD;Department of Internal Medicine, Eulji University School of Medicine, Nowon Eulji Hospital, Seoul, Korea.&#xD;Department of Internal Medicine Department of Pathology, Regional Center for Respiratory Disease, College of Medicine, Yeungnam University Medical Center, Yeungnam University, Daegu, Republic of Korea.&#xD;Department of Internal Medicine, Division of Respiratory Medicine and Allergy, Jeonju, Korea.&#xD;Department of Internal Medicine, Division of Allergy and Immunology, Yonsei University College of Medicine, Seoul, Korea.&#xD;National Heart and Lung Institute, Imperial College London, UK.&#xD;Royal Brompton and Harefield Hospital, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Type 2 Biomarkers as Mediators of Clinical Remission With Biologics in Severe Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">T2-biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">mediation effect</style></keyword><keyword><style face="normal" font="default" size="100%">remission</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41410200</style></accession-num><notes><style face="normal" font="default" size="100%">Pham, Duong Duc&#xD;Kwon, Hyouk-Soo&#xD;Song, Woo-Jung&#xD;Cho, You Sook&#xD;Lee, Sei Won&#xD;Ban, Ga-Young&#xD;Lee, Taehoon&#xD;Park, So-Young&#xD;Nam, Young-Hee&#xD;Lee, Byung-Jae&#xD;An, Jin&#xD;Park, Chan Sun&#xD;Rhyou, Hyo-In&#xD;Kim, Joo-Hee&#xD;Park, Hye-Kyung&#xD;Kim, Sang-Ha&#xD;Yang, Min-Suk&#xD;Kim, Min-Hye&#xD;Ahn, Kyung-Min&#xD;Shim, Ji-Su&#xD;Choi, Jeong-Hee&#xD;Kim, Sujeong&#xD;Jung, Jae-Woo&#xD;Park, Han Ki&#xD;Kim, Byung Keun&#xD;Lee, Ji-Hyang&#xD;Kim, Young-Chan&#xD;Lee, Sang Min&#xD;Kang, Sung-Yoon&#xD;Kwon, Jae-Woo&#xD;Hur, Gyu Young&#xD;Moon, Ji-Yong&#xD;Sohn, Kyoung-Hee&#xD;Kim, Mi-Ae&#xD;Kim, Sae-Hoon&#xD;Yoon, Sunyoung&#xD;Jang, An-Soo&#xD;Kim, Sang Hoon&#xD;Park, So Young&#xD;Jin, Hyun Jung&#xD;Kim, So Ri&#xD;Lee, Jae-Hyun&#xD;Bhavsar, Pankaj K&#xD;Adcock, Ian M&#xD;Dixey, Piers&#xD;Zounemat-Kermani, Nazanin&#xD;Yang, Freda&#xD;Patel, Pujan H&#xD;Chung, Kian Fan&#xD;Kim, Tae-Bum&#xD;eng&#xD;Korea Health Industry Development Institute/&#xD;Ministry of Health/&#xD;MRC_/Medical Research Council/United Kingdom&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec 18. doi: 10.1111/all.70186.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41410200</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70186</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2894</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2894</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liao, C. C.</style></author><author><style face="normal" font="default" size="100%">Chiu, C. J.</style></author><author><style face="normal" font="default" size="100%">Chiang, B. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.&#xD;Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.&#xD;Genome and Systems Biology Degree Program, College of Life Science, National Taiwan University, Taipei, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Type 2 Immunity Promotes Neonatal Lung Progenitor Developmental Activity Through the STAT6 Signaling Axis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1807-1810</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/05/22</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40401397</style></accession-num><notes><style face="normal" font="default" size="100%">Liao, Chien-Chia&#xD;Chiu, Chiao-Juno&#xD;Chiang, Bor-Luen&#xD;eng&#xD;NSTC112-2314-B-002-295/National Science and Technology Council/&#xD;NTUH-111-CGN0008/National Taiwan University Hospital/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1807-1810. doi: 10.1111/all.16604. Epub 2025 May 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40401397</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16604</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2534</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2534</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cook, D. P.</style></author><author><style face="normal" font="default" size="100%">Wu, A. Y.</style></author><author><style face="normal" font="default" size="100%">Thomas, C. M.</style></author><author><style face="normal" font="default" size="100%">Hamilton, R. G.</style></author><author><style face="normal" font="default" size="100%">Peebles, R. S., Jr.</style></author><author><style face="normal" font="default" size="100%">Kerchberger, V. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Department of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.&#xD;Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.&#xD;Tennessee Valley Healthcare System, United States Department of Veterans Affairs, Nashville, Tennessee, USA.&#xD;Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Type 2 inflammation in cystic fibrosis is a predictor of mortality and targeted with CFTR modulator therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3528-3533</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2024/06/17</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38881035</style></accession-num><notes><style face="normal" font="default" size="100%">Cook, Daniel P&#xD;Wu, Ashley Y&#xD;Thomas, Christopher M&#xD;Hamilton, Robert G&#xD;Peebles, Ray Stokes Jr&#xD;Kerchberger, Vern Eric&#xD;eng&#xD;National Institute of Allergy and Infectious Diseases/&#xD;Cystic Fibrosis Foundation/&#xD;U.S. Department of Veterans Affairs/&#xD;K08 AI181763/AI/NIAID NIH HHS/&#xD;UL1 TR002243/TR/NCATS NIH HHS/&#xD;K01 HL157755/HL/NHLBI NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Dec;79(12):3528-3533. doi: 10.1111/all.16198. Epub 2024 Jun 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38881035</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11657065 personal relationships that could have appeared to influence the work reported in this manuscript.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16198</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1266</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1266</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Higham, A.</style></author><author><style face="normal" font="default" size="100%">Beech, A.</style></author><author><style face="normal" font="default" size="100%">Wolosianka, S.</style></author><author><style face="normal" font="default" size="100%">Jackson, N.</style></author><author><style face="normal" font="default" size="100%">Long, G.</style></author><author><style face="normal" font="default" size="100%">Kolsum, U.</style></author><author><style face="normal" font="default" size="100%">Southworth, T.</style></author><author><style face="normal" font="default" size="100%">Pham, T. H.</style></author><author><style face="normal" font="default" size="100%">Sridhar, S.</style></author><author><style face="normal" font="default" size="100%">McCrae, C.</style></author><author><style face="normal" font="default" size="100%">Newbold, P.</style></author><author><style face="normal" font="default" size="100%">Singh, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester University NHS Foundations Trust, Manchester, UK.&#xD;Medicines Evaluation Unit, Manchester, UK.&#xD;Translational Science &amp; Experimental Medicine, Early Respiratory &amp; Immunology, Research and Early Development, AstraZeneca, Gaithersburg, MD, USA.&#xD;Translational Science, Oncology R&amp;D, AstraZeneca, Gaithersburg, MD, USA.&#xD;Biopharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1861-1864</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2020/11/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Disease, Chronic Obstructive/diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33206402</style></accession-num><notes><style face="normal" font="default" size="100%">Higham, Andrew&#xD;Beech, Augusta&#xD;Wolosianka, Sophie&#xD;Jackson, Natalie&#xD;Long, Gabriella&#xD;Kolsum, Umme&#xD;Southworth, Thomas&#xD;Pham, Tuyet-Hang&#xD;Sridhar, Sriram&#xD;McCrae, Christopher&#xD;Newbold, Paul&#xD;Singh, Dave&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jun;76(6):1861-1864. doi: 10.1111/all.14661. Epub 2020 Dec 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33206402</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8247000 conflicts of interest. T-HP, SS, CM and PN are employees of AstraZeneca. DS has received personal fess from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Therevance and Verona.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14661</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3306</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3306</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, Ying</style></author><author><style face="normal" font="default" size="100%">Liang, Shuang</style></author><author><style face="normal" font="default" size="100%">Wang, Huiqing</style></author><author><style face="normal" font="default" size="100%">Cui, Bangyu</style></author><author><style face="normal" font="default" size="100%">Cao, Jiayu</style></author><author><style face="normal" font="default" size="100%">Chen, Zhen</style></author><author><style face="normal" font="default" size="100%">Yan, Yun</style></author><author><style face="normal" font="default" size="100%">Li, Ying</style></author><author><style face="normal" font="default" size="100%">Wang, Yang</style></author><author><style face="normal" font="default" size="100%">Wang, Chengshuo</style></author><author><style face="normal" font="default" size="100%">Zhang, Luo</style></author><author><style face="normal" font="default" size="100%">Yan, Bing</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Type 2 Inflammation-Biased Arachidonic Acid Metabolite Regulates Mucosal Remodeling of Chronic Rhinosinusitis With Nasal Polyps</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common inflammatory respiratory disease. Its eosinophilic subtype (ECRSwNP), characterized by pronounced type 2 inflammation, mucosal edema and stromal remodeling, presents particular therapeutic challenges. Emerging evidence suggests metabolic dysregulation may contribute to its pathogenesis, but the underlying mechanisms remain unclear. Methods Untargeted metabolomics was performed using plasma and nasal mucosa from mouse models of CRSwNP with type 2 inflammation; targeted metabolomics was applied to plasma from patients with CRSwNP and healthy controls. Murine models, primary cells derived from nasal polyps, and samples from patients who had received anti-IL-4Rα monoclonal antibody were used to evaluate the role of 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE] in CRSwNP. Results (1) Mechanistically: The arachidonate 15-lipoxygenase (ALOX15)-dependent metabolite 15(S)-HETE, derived from arachidonic acid and induced by interleukin (IL)-4 and IL-13, correlated with CRSwNP severity. 15(S)-HETE reduced transforming growth factor-β1 (TGF-β1) through peroxisome proliferator-activated receptor gamma (PPAR-γ) activation, thereby impairing collagen production and exacerbating mucosal edema. (2) Therapeutically: In mouse models of CRSwNP, ALOX15 inhibition improved mucosal remodeling, reduced polyp size, and attenuated type 2 inflammation. Post hoc analysis of a clinical trial demonstrated that anti-IL-4Rα treatment reversed this metabolic axis and improved mucosal remodeling. Conclusion This work establishes the type 2 inflammation–ALOX15–15(S)-HETE–PPAR-γ axis as a key driver of impaired tissue remodeling in ECRSwNP through TGF-β1 suppression. These findings provide novel mechanistic insights into the inflammation–metabolism–remodeling interplay in CRSwNP and highlight promising therapeutic targets for this refractory condition.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70301</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70301</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2614</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2614</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mulder, J.</style></author><author><style face="normal" font="default" size="100%">Dvorscek, A. R.</style></author><author><style face="normal" font="default" size="100%">Ding, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Monash University, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Type 2 memory B cells: The repository of allergic memory?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3173-3175</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2024/08/16</style></edition><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39148401</style></accession-num><notes><style face="normal" font="default" size="100%">Mulder, Jesse&#xD;Dvorscek, Alexandra R&#xD;Ding, Zhoujie&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Nov;79(11):3173-3175. doi: 10.1111/all.16278. Epub 2024 Aug 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39148401</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16278</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1340</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1340</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zounemat Kermani, N.</style></author><author><style face="normal" font="default" size="100%">Saqi, M.</style></author><author><style face="normal" font="default" size="100%">Agapow, P.</style></author><author><style face="normal" font="default" size="100%">Pavlidis, S.</style></author><author><style face="normal" font="default" size="100%">Kuo, C.</style></author><author><style face="normal" font="default" size="100%">Tan, K. S.</style></author><author><style face="normal" font="default" size="100%">Mumby, S.</style></author><author><style face="normal" font="default" size="100%">Sun, K.</style></author><author><style face="normal" font="default" size="100%">Loza, M.</style></author><author><style face="normal" font="default" size="100%">Baribaud, F.</style></author><author><style face="normal" font="default" size="100%">Sousa, A. R.</style></author><author><style face="normal" font="default" size="100%">Riley, J.</style></author><author><style face="normal" font="default" size="100%">Wheelock, A. M.</style></author><author><style face="normal" font="default" size="100%">Wheelock, C. E.</style></author><author><style face="normal" font="default" size="100%">De Meulder, B.</style></author><author><style face="normal" font="default" size="100%">Schofield, J.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Ovando, S.</style></author><author><style face="normal" font="default" size="100%">Simpson, J. L.</style></author><author><style face="normal" font="default" size="100%">Baines, K. J.</style></author><author><style face="normal" font="default" size="100%">Wark, P. A.</style></author><author><style face="normal" font="default" size="100%">Auffray, C.</style></author><author><style face="normal" font="default" size="100%">Dahlen, S. E.</style></author><author><style face="normal" font="default" size="100%">Sterk, P. J.</style></author><author><style face="normal" font="default" size="100%">Djukanovic, R.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Guo, Y. K.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">U. Biopred Project Team</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Computing &amp; Data Science Institute, Imperial College London, London, UK.&#xD;National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Department of Otolaryngology, National University of Singapore, Singapore, Singapore.&#xD;Janssen Research and Development, High Wycombe, UK.&#xD;Respiratory Therapeutic Unit, GSK, Stockley Park, UK.&#xD;Department of Medicine Solna &amp; Center for Molecular Medicine &amp; Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.&#xD;European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France.&#xD;Faculty of Medicine, Southampton University, Southampton, UK.&#xD;NIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK.&#xD;Priority Research Centre for Healthy Lungs, Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW, Australia.&#xD;Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Type 2-low asthma phenotypes by integration of sputum transcriptomics and serum proteomics</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">380-383</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/09/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Sputum</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bioinformatics</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword><keyword><style face="normal" font="default" size="100%">systems biology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32865817</style></accession-num><notes><style face="normal" font="default" size="100%">Zounemat Kermani, Nazanin&#xD;Saqi, Mansoor&#xD;Agapow, Paul&#xD;Pavlidis, Stelios&#xD;Kuo, Chihhsi&#xD;Tan, Kai Sen&#xD;Mumby, Sharon&#xD;Sun, Kai&#xD;Loza, Matthew&#xD;Baribaud, Frederic&#xD;Sousa, Ana R&#xD;Riley, John&#xD;Wheelock, Asa M&#xD;Wheelock, Craig E&#xD;De Meulder, Bertrand&#xD;Schofield, Jim&#xD;Sanchez-Ovando, Stephany&#xD;Simpson, Jodie Louise&#xD;Baines, Katherine Joanne&#xD;Wark, Peter A&#xD;Auffray, Charles&#xD;Dahlen, Sven-Erik&#xD;Sterk, Peter J&#xD;Djukanovic, Ratko&#xD;Adcock, Ian M&#xD;Guo, Yi-Ke&#xD;Chung, Kian Fan&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jan;76(1):380-383. doi: 10.1111/all.14573. Epub 2020 Sep 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32865817</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14573</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3192</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3192</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hwang, S.</style></author><author><style face="normal" font="default" size="100%">Sepahpour, T.</style></author><author><style face="normal" font="default" size="100%">Kortchak, S.</style></author><author><style face="normal" font="default" size="100%">Sivakumar, K. K.</style></author><author><style face="normal" font="default" size="100%">Karaiskos, S.</style></author><author><style face="normal" font="default" size="100%">Pham, N.</style></author><author><style face="normal" font="default" size="100%">Jang, Y.</style></author><author><style face="normal" font="default" size="100%">Puig, M.</style></author><author><style face="normal" font="default" size="100%">Norcross, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.&#xD;Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T-Cell Enhancement in Immunocompetent HLA-Transgenic Mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Hla-b*57:01</style></keyword><keyword><style face="normal" font="default" size="100%">IFN-alpha</style></keyword><keyword><style face="normal" font="default" size="100%">IFN-gamma</style></keyword><keyword><style face="normal" font="default" size="100%">abacavir hypersensitivity reaction (AHR)</style></keyword><keyword><style face="normal" font="default" size="100%">plasmacytoid DC</style></keyword><keyword><style face="normal" font="default" size="100%">regulatory T-cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 19</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41416656</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Abacavir (ABC)-induced hypersensitivity is associated with HLA-B*57:01, with tolerance maintained by regulatory T cells (Treg). This study hypothesized that the balance between Treg and CD8(+) T-cells is influenced by the level of human leucocyte antigen (HLA) expression to determine hypersensitivity versus tolerance to abacavir. METHODS: HLA-B*57:01 transgenic (Tg) mice and Tg mice lacking H2-K(b)D(b) (Tg/KO) were treated with ABC with or without IFN-alpha or IFN-gamma blockade. Immune cell phenotype and functions were assessed via flow cytometry, and splenic transcriptomic profiles were analyzed to evaluate gene expression changes associated with treatment. RESULTS: ABC treatment of Tg/KO mice, which only express HLA-B*57:01 as an MHC-I allele, led to the expansion of drug-specific CD8(+) T-cells, enhanced antigen presenting cell (APC) activity, and reduction in Tregs. These changes were accompanied by increased IFN-alpha levels and plasmacytoid dendritic cell (pDC) maturation. Depletion of pDCs or blocking of IFN-alphaR, in contrast to IFN-gamma blockade, restored Treg populations and diminished CD8(+) T-cell responses. These findings demonstrate that IFN-alpha, primarily produced by pDCs, disrupts Treg expansion, whereas IFN-gamma predominantly enhances APC maturation and activation. Transcriptomic analysis revealed key genes regulated exclusively by ABC treatment in the presence of both IFN-alpha and IFN-gamma signaling and demonstrated that IFN-alpha signaling predominantly modulates innate and adaptive immune genes while supporting the downregulation of Treg-related genes. CONCLUSIONS: In vivo upregulation of HLA expression modulates the balance between drug-specific and regulatory T cells, thereby promoting optimal pDC expansion and enhancing IFN-alpha production, which counteracts Treg-mediated ABC tolerance. IFN-gamma secretion by drug-specific CD8(+) T-cells promoted APC and effector T-cell function that led to the development of ABC-associated hypersensitivity reactions in immunocompetent HLA Tg mice.</style></abstract><notes><style face="normal" font="default" size="100%">Hwang, SuJin&#xD;Sepahpour, Telly&#xD;Kortchak, Stephanie&#xD;Sivakumar, Kirthiram Krishnaveni&#xD;Karaiskos, Spyros&#xD;Pham, Ngoc&#xD;Jang, Yura&#xD;Puig, Montserrat&#xD;Norcross, Michael&#xD;eng&#xD;U.S. Food and Drug Administration/&#xD;Oak Ridge Institute for Science and Education (ORISE)/&#xD;Denmark&#xD;Allergy. 2025 Dec 19. doi: 10.1111/all.70189.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41416656</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70189</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2231</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2231</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Samolinski, B.</style></author><author><style face="normal" font="default" size="100%">Kaidashev, I.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author><author><style face="normal" font="default" size="100%">Roche, N.</style></author><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Kurchenko, A.</style></author><author><style face="normal" font="default" size="100%">Stepanenko, R.</style></author><author><style face="normal" font="default" size="100%">Tsaryk, V.</style></author><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Ventura, M. T.</style></author><author><style face="normal" font="default" size="100%">Bedbrook, A.</style></author><author><style face="normal" font="default" size="100%">Czarlewski, W.</style></author><author><style face="normal" font="default" size="100%">Lysanets, Y.</style></author><author><style face="normal" font="default" size="100%">Kupczyk, M.</style></author><author><style face="normal" font="default" size="100%">Skolimowski, L.</style></author><author><style face="normal" font="default" size="100%">Kulus, M.</style></author><author><style face="normal" font="default" size="100%">Del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Ollert, M.</style></author><author><style face="normal" font="default" size="100%">Garcia-Aymerich, J.</style></author><author><style face="normal" font="default" size="100%">Robalo Cordeiro, C.</style></author><author><style face="normal" font="default" size="100%">Yorgancioglu, A.</style></author><author><style face="normal" font="default" size="100%">Schlapbach, C.</style></author><author><style face="normal" font="default" size="100%">Amaral, R.</style></author><author><style face="normal" font="default" size="100%">Bonaglia, C.</style></author><author><style face="normal" font="default" size="100%">Bosse, I.</style></author><author><style face="normal" font="default" size="100%">Buquicchio, R.</style></author><author><style face="normal" font="default" size="100%">Christou, D.</style></author><author><style face="normal" font="default" size="100%">Fedoruk, G.</style></author><author><style face="normal" font="default" size="100%">Fontanesi, P.</style></author><author><style face="normal" font="default" size="100%">Gemicioglu, B.</style></author><author><style face="normal" font="default" size="100%">Giuliano, A. F. M.</style></author><author><style face="normal" font="default" size="100%">Lepore, P.</style></author><author><style face="normal" font="default" size="100%">Nakonechna, A.</style></author><author><style face="normal" font="default" size="100%">Neisinger, S.</style></author><author><style face="normal" font="default" size="100%">Pereira, A. M.</style></author><author><style face="normal" font="default" size="100%">Ramanauskaite, A.</style></author><author><style face="normal" font="default" size="100%">Raciborski, F.</style></author><author><style face="normal" font="default" size="100%">Sitkauskiene, B.</style></author><author><style face="normal" font="default" size="100%">Sokhatska, O.</style></author><author><style face="normal" font="default" size="100%">Stepanenko, V.</style></author><author><style face="normal" font="default" size="100%">Stevanovic, K.</style></author><author><style face="normal" font="default" size="100%">Syzon, O.</style></author><author><style face="normal" font="default" size="100%">Kvedariene, V.</style></author><author><style face="normal" font="default" size="100%">de Vries, G.</style></author><author><style face="normal" font="default" size="100%">van Eerd, M.</style></author><author><style face="normal" font="default" size="100%">Valiulis, A.</style></author><author><style face="normal" font="default" size="100%">Fonseca, J. A.</style></author><author><style face="normal" font="default" size="100%">Anto, J. M.</style></author><author><style face="normal" font="default" size="100%">Haahtela, T.</style></author><author><style face="normal" font="default" size="100%">Schunemann, H.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;MASK-air, Montpellier, France.&#xD;Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland.&#xD;Poltava State Medical University, Poltava, Ukraine.&#xD;Pneumologie, AP-HP Centre Universite de Paris Cite, Hopital Cochin, Paris, France.&#xD;UMR 1016, Institut Cochin, Paris, France.&#xD;MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS@RISE- Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;Department of Clinical Immunology and Allergology with section of Medical Genetic, Bogomolets National Medical University, Kiev, Ukraine.&#xD;Department of Dermatology and Venereology with Cosmetology Course, Bogomolets National Medical University, Kiev, Ukraine.&#xD;Department of Otolaryngology, Head and Neck Surgery, Universitatsmedizin Mainz, Mainz, Germany.&#xD;Center for Rhinology and Allergology, Wiesbaden, Germany.&#xD;Allergy and Clinical Immunology, University of Bari Medical School, Bari, Italy.&#xD;Institute of Sciences of Food Production, National Research Council (ISPA-CNR), Bari, Italy.&#xD;ARIA, Montpellier, France.&#xD;Medical Consulting Czarlewski, Levallois, France.&#xD;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.&#xD;Polish Society of Allergology, Warsaw, Poland.&#xD;Department of Pediatric Respiratory Diseases and Allergology, Medical University of Warsaw, Warsaw, Poland.&#xD;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital &apos;Duilio Casula&apos;, University of Cagliari, Cagliari, Italy.&#xD;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.&#xD;Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.&#xD;ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.&#xD;Universitat Pompeu Fabra (UPF), Barcelona, Spain.&#xD;Department of Pneumology, Coimbra University Hospital, Faculty of Medicine, Coimbra, Portugal.&#xD;Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey.&#xD;Bern University Hospital, Bern, Switzerland.&#xD;Institute &apos;Bona Sforza&apos;, University for Linguistic Mediators, Bari, Italy.&#xD;Allergist, La Rochelle, France.&#xD;Department of Dermatology, Perrino Hospital, Brindisi, Italy.&#xD;Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.&#xD;Department of Internal Medicine &apos;A. Murri&apos;, University of Bari Medical School, Bari, Italy.&#xD;Rotary Club Bari Mediterranean RY23/24, Bari, Italy.&#xD;Clinical Immunology and Allergy Unit, Sheffield Teaching Hospitals, Sheffield, UK.&#xD;University of Liverpool, Liverpool, UK.&#xD;Department of Immunology and Allergology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.&#xD;Basic &amp; Clinical Immunology Unit, Department of Pathology, Faculty of Medicine of the University of Porto, Porto, Portugal.&#xD;Department of Dermatology, Venereology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.&#xD;Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.&#xD;Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania.&#xD;Peercode BV, Geldermalsen, The Netherlands.&#xD;Interdisciplinary Research Group of Human Ecology, Institute of Clinical Medicine and Institute of Health Sciences, Medical Faculty of Vilnius University, Vilnius, Lithuania.&#xD;European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium.&#xD;CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.&#xD;Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.&#xD;Department of Health Research Methods, Evidence, and Impact &amp; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2581-2595</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2023/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Ukrainian refugees</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">mHealth</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37641384</style></accession-num><abstract><style face="normal" font="default" size="100%">Eight million Ukrainians have taken refuge in the European Union. Many have asthma and/or allergic rhinitis and/or urticaria, and around 100,000 may have a severe disease. Cultural and language barriers are a major obstacle to appropriate management. Two widely available mHealth apps, MASK-air(R) (Mobile Airways Sentinel NetworK) for the management of rhinitis and asthma and CRUSE(R) (Chronic Urticaria Self Evaluation) for patients with chronic spontaneous urticaria, were updated to include Ukrainian versions that make the documented information available to treating physicians in their own language. The Ukrainian patients fill in the questionnaires and daily symptom-medication scores for asthma, rhinitis (MASK-air) or urticaria (CRUSE) in Ukrainian. Then, following the GDPR, patients grant their physician access to the app by scanning a QR code displayed on the physician&apos;s computer enabling the physician to read the app contents in his/her own language. This service is available freely. It takes less than a minute to show patient data to the physician in the physician&apos;s web browser. UCRAID-developed by ARIA (Allergic Rhinitis and its Impact on Asthma) and UCARE (Urticaria Centers of Reference and Excellence)-is under the auspices of the Ukraine Ministry of Health as well as European (European Academy of Allergy and Clinical immunology, EAACI, European Respiratory Society, ERS, European Society of Dermatologic Research, ESDR) and national societies.</style></abstract><notes><style face="normal" font="default" size="100%">Bousquet, Jean&#xD;Samolinski, Boleslaw&#xD;Kaidashev, Igor&#xD;Maurer, Marcus&#xD;Roche, Nicolas&#xD;Sousa-Pinto, Bernardo&#xD;Kurchenko, Andrii&#xD;Stepanenko, Roman&#xD;Tsaryk, Vladyslav&#xD;Klimek, Ludger&#xD;Ventura, Maria Teresa&#xD;Bedbrook, Anna&#xD;Czarlewski, Wienczyslawa&#xD;Lysanets, Yuliia&#xD;Kupczyk, Maciej&#xD;Skolimowski, Lukasz&#xD;Kulus, Marek&#xD;Del Giacco, Stefano&#xD;Ollert, Markus&#xD;Garcia-Aymerich, Judith&#xD;Robalo Cordeiro, Carlos&#xD;Yorgancioglu, Arzu&#xD;Schlapbach, Christoph&#xD;Amaral, Rita&#xD;Bonaglia, Cristina&#xD;Bosse, Isabelle&#xD;Buquicchio, Rosalba&#xD;Christou, Demetrios&#xD;Fedoruk, Galyna&#xD;Fontanesi, Pietro&#xD;Gemicioglu, Bilun&#xD;Giuliano, Antonio F M&#xD;Lepore, Paolo&#xD;Nakonechna, Alla&#xD;Neisinger, Sophia&#xD;Pereira, Ana M&#xD;Ramanauskaite, Aiste&#xD;Raciborski, Filip&#xD;Sitkauskiene, Brigita&#xD;Sokhatska, Oksana&#xD;Stepanenko, Viktor&#xD;Stevanovic, Katarina&#xD;Syzon, Orysya&#xD;Kvedariene, Violeta&#xD;de Vries, Govert&#xD;van Eerd, Michiel&#xD;Valiulis, Arunas&#xD;Fonseca, Joao A&#xD;Anto, Josep M&#xD;Haahtela, Tari&#xD;Schunemann, Holger&#xD;Zuberbier, Torsten&#xD;eng&#xD;MASK-air SAS/&#xD;MOXIE/&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Oct;78(10):2581-2595. doi: 10.1111/all.15855. Epub 2023 Aug 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37641384</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15855</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2878</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2878</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shibuya, K.</style></author><author><style face="normal" font="default" size="100%">Balasubramanyam, S.</style></author><author><style face="normal" font="default" size="100%">Verma, D.</style></author><author><style face="normal" font="default" size="100%">Holm, K. E.</style></author><author><style face="normal" font="default" size="100%">Nair, L. G.</style></author><author><style face="normal" font="default" size="100%">Manczak, E.</style></author><author><style face="normal" font="default" size="100%">DePrince, A. P.</style></author><author><style face="normal" font="default" size="100%">Alam, R.</style></author><author><style face="normal" font="default" size="100%">Wang, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Jewish Health, Denver, Colorado, USA.&#xD;University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Houston Methodist Hospital, Houston, Texas, USA.&#xD;University of Denver, Denver, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Uncontrolled Asthma, Intimate Partner Violence, and Inflammatory Pathways: Surprising Insights From Cytokine Profiles</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2084-2087</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">chronic stress</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory pathways</style></keyword><keyword><style face="normal" font="default" size="100%">intimate partner violence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40501370</style></accession-num><notes><style face="normal" font="default" size="100%">Shibuya, Kelly&#xD;Balasubramanyam, Sadhana&#xD;Verma, Divya&#xD;Holm, Kristen E&#xD;Nair, Lakshmi Gopalakrishnan&#xD;Manczak, Erika&#xD;DePrince, Anne P&#xD;Alam, Rafeul&#xD;Wang, Eileen&#xD;eng&#xD;National Jewish Health/&#xD;University of Denver/&#xD;NCT04724278/Genentech/&#xD;NCT04462224/GlaxoSmithKline/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2084-2087. doi: 10.1111/all.16621. Epub 2025 Jun 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40501370</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16621</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1321</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1321</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Uncovering the immunological properties of isolated lymphoid follicles</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1292-1293</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/09/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin A</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphoid Tissue</style></keyword><keyword><style face="normal" font="default" size="100%">*Peyer&apos;s Patches</style></keyword><keyword><style face="normal" font="default" size="100%">Galt</style></keyword><keyword><style face="normal" font="default" size="100%">Ilf</style></keyword><keyword><style face="normal" font="default" size="100%">adaptive immunity</style></keyword><keyword><style face="normal" font="default" size="100%">intestine</style></keyword><keyword><style face="normal" font="default" size="100%">secretory IgA</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32969038</style></accession-num><notes><style face="normal" font="default" size="100%">Layhadi, Janice A&#xD;Shamji, Mohamed H&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1292-1293. doi: 10.1111/all.14598. Epub 2020 Oct 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32969038</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14598</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1558</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1558</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Layhadi, J. A.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Uncovering the immunological properties of isolated lymphoid follicles</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1292-1293</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/09/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin A</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphoid Tissue</style></keyword><keyword><style face="normal" font="default" size="100%">*Peyer&apos;s Patches</style></keyword><keyword><style face="normal" font="default" size="100%">Galt</style></keyword><keyword><style face="normal" font="default" size="100%">Ilf</style></keyword><keyword><style face="normal" font="default" size="100%">adaptive immunity</style></keyword><keyword><style face="normal" font="default" size="100%">intestine</style></keyword><keyword><style face="normal" font="default" size="100%">secretory IgA</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32969038</style></accession-num><notes><style face="normal" font="default" size="100%">Layhadi, Janice A&#xD;Shamji, Mohamed H&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1292-1293. doi: 10.1111/all.14598. Epub 2020 Oct 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32969038</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14598</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1165</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1165</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Obeso, D.</style></author><author><style face="normal" font="default" size="100%">Zubeldia-Varela, E.</style></author><author><style face="normal" font="default" size="100%">Villasenor, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Facultad de Farmacia, Centro de Metabolomica y Bioanalisis (CEMBIO, Universidad San Pablo-CEU, CEU Universities, Urbanizacion Monteprincipe, Madrid, Espana.&#xD;Facultad de Medicina, Departamento de Ciencias Medicas Basicas, Instituto de Medicina Molecular Aplicada (IMMA, Universidad San Pablo-CEU, CEU Universities, Madrid, Espana.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Uncovering the influence of diet and gut microbiota in human serum metabolome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2306-2308</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/02/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolome</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">serum</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33570758</style></accession-num><notes><style face="normal" font="default" size="100%">Obeso, David&#xD;Zubeldia-Varela, Elisa&#xD;Villasenor, Alma&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2306-2308. doi: 10.1111/all.14770. Epub 2021 Mar 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33570758</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14770</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1661</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1661</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anderson, J.</style></author><author><style face="normal" font="default" size="100%">Do, L. A. H.</style></author><author><style face="normal" font="default" size="100%">Wurzel, D.</style></author><author><style face="normal" font="default" size="100%">Licciardi, P. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infection and Immunity, Murdoch Children&apos;s Research Institute, Melbourne, Victoria, Australia.&#xD;Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.&#xD;Department of Respiratory and Sleep Medicine, The Royal Children&apos;s Hospital, Melbourne, Victoria, Australia.&#xD;Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Understanding the increased susceptibility to asthma development in preterm infants</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">928-939</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2023/02/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Premature</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Premature Birth</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/etiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Immediate</style></keyword><keyword><style face="normal" font="default" size="100%">Rsv</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">preterm infant</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36719074</style></accession-num><abstract><style face="normal" font="default" size="100%">Preterm birth is associated with aberrant pulmonary development and increased susceptibility to a range of chronic lung diseases. Even in healthy preterms, the prevalence of physician-diagnosed asthma is far higher than in infants born at term. While physiological, environmental, and genetic factors have been studied extensively, few studies have investigated the immunological factors underpinning this increased susceptibility. Lower rates of atopy and allergic sensitization in preterm compared to term infants suggests non-allergic mechanisms may be driving asthma development in preterms. Preterm infants are more likely to develop severe RSV and HRV disease and have altered microbiomes compared to term infants. Therefore, investigating the differences in immunological interactions (e.g., response to viral infections, microbiome) between children born preterm and term will aid in understanding the immunological basis for their increased susceptibility to asthma development. This is critical to inform the development of interventions to reduce the burden of asthma in this highly vulnerable demographic.</style></abstract><notes><style face="normal" font="default" size="100%">Anderson, Jeremy&#xD;Do, Lien Anh Ha&#xD;Wurzel, Danielle&#xD;Licciardi, Paul V&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Apr;78(4):928-939. doi: 10.1111/all.15662. Epub 2023 Feb 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36719074</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15662</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2969</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2969</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arnau-Soler, A.</style></author><author><style face="normal" font="default" size="100%">Ashley, S. E.</style></author><author><style face="normal" font="default" size="100%">Ghauri, A.</style></author><author><style face="normal" font="default" size="100%">Jeanrenaud, Acsn</style></author><author><style face="normal" font="default" size="100%">Marenholz, I.</style></author><author><style face="normal" font="default" size="100%">Blumchen, K.</style></author><author><style face="normal" font="default" size="100%">Cibin, P.</style></author><author><style face="normal" font="default" size="100%">Iakupova, A.</style></author><author><style face="normal" font="default" size="100%">Hubner, N.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Lee, Y. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Max-Delbruck-Center for Molecular Medicine, Berlin, Germany.&#xD;Clinic for Pediatric Allergy, Experimental and Clinical Research Center of Max-Delbruck-Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;German Center for Child and Adolescent Health (DZKJ) partner site Berlin, Berlin, Germany.&#xD;Division of Pneumology, Allergology, Infectious Diseases and Gastroenterology, Department of Pediatrics, Goethe University Frankfurt, Frankfurt am Main, Germany.&#xD;Department of Pediatric Respiratory Medicine, Immunology, and Intensive Care Medicine, Charite-Universitatsmedizin Berlin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Understanding the Variability of Peanut-Oral Immunotherapy Responses by Multi-Omics Profiling of Immune Cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3342-3358</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/07/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity/immunology/therapy/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Desensitization, Immunologic/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Arachis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Allergens/immunology/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">Multiomics</style></keyword><keyword><style face="normal" font="default" size="100%">DNA methylome</style></keyword><keyword><style face="normal" font="default" size="100%">oral immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">peanut allergy</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptome</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics, Bencard, Danone/Nutricia, DBV, Hycor, Infectopharm, Mabylon, Meda</style></keyword><keyword><style face="normal" font="default" size="100%">Pharma/Mylan, Nestle, Novartis, and ThermoFisher</style></keyword><keyword><style face="normal" font="default" size="100%">and research grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune, ALK, Danone/Nutricia, DBV Technologies, Hipp, Hycor, Infectopharm, and</style></keyword><keyword><style face="normal" font="default" size="100%">Novartis outside the submitted work. KBl or her institution received grants from</style></keyword><keyword><style face="normal" font="default" size="100%">Aimmune therapeutics, DBV Technologies, Novartis Pharma GmbH, Hipp GmbH,</style></keyword><keyword><style face="normal" font="default" size="100%">consulting fees from Aimmune therapeutics, DBV Technologies, Novartis Pharma</style></keyword><keyword><style face="normal" font="default" size="100%">GmbH, Bencard Allergie, honoraria for lectures from Aimmune therapeutics, DBV</style></keyword><keyword><style face="normal" font="default" size="100%">Technologies, Novartis Pharma GmbH, HAL Allergy, Allergopharma, Nestle, Thermo</style></keyword><keyword><style face="normal" font="default" size="100%">Fisher Scientific, Viatris Healthcare GmbH, payment for expert testimony from</style></keyword><keyword><style face="normal" font="default" size="100%">Nestle, support for travel/meetings from Aimmune therapeutics, DBV Technologies,</style></keyword><keyword><style face="normal" font="default" size="100%">Bencard Allergie, and ALK. She is on the safety board of an</style></keyword><keyword><style face="normal" font="default" size="100%">investigator-initiated study on peanut allergy at Charite, Berlin, and is a board</style></keyword><keyword><style face="normal" font="default" size="100%">member of the Westgerman Society of Pediatric Allergology. The other authors</style></keyword><keyword><style face="normal" font="default" size="100%">declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40693699</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Oral immunotherapy (OIT) induces desensitization in peanut allergy, yet 15%-30% of patients do not respond, and a significant risk of anaphylaxis due to treatment remains. In a placebo-controlled peanut OIT trial, this study identifies molecular drivers of OIT responsiveness through multi-omics profiling in immune cells. METHODS: Immunoglobulins, cytokines, transcriptome, and DNA methylome profiles were analyzed in peanut-stimulated and unstimulated peripheral blood mononuclear cells isolated from peanut-allergic children before and after treatment. Multi-omics profiling focused on OIT responsiveness within the active treatment arm. Additional subgroup analyses were performed to further elucidate molecular mechanisms and potential biomarkers. RESULTS: Complete responders, tolerating 4500 mg of peanut protein, exhibited lower pre-treatment peanut-specific IgE and Th2 cytokine production (IL-4, IL-5) compared to incomplete responders who tolerated &lt;/= 1000 mg of peanut protein after treatment. Our primary analysis identified 184 differentially expressed genes and 1001 differentially methylated genes, enriched for innate (ILC3) and adaptive (CD8alphaalpha subset of CD8(+) T cells) immune cells, alongside gammadelta T cells and exosomes, highlighting gastrointestinal regulatory processes as central to OIT success. We found a marked downregulation of immunoglobulin genes in patients receiving peanut compared to placebo, suggesting OIT-induced modulation of B-cell activity. Functional networks revealed a marked imbalance contrasting regulatory T-cell responses and B-cell suppression in the complete responders with innate immune signaling and metabolic stress in the incomplete responders. CONCLUSION: This multi-omics approach underscores the importance of gastrointestinal immune mechanisms underlying the variation in peanut oral immunotherapy responses and offers potential biomarkers for improving treatment strategies. TRIAL REGISTRATION: German Clinical Trials Register DRKS00004553.</style></abstract><notes><style face="normal" font="default" size="100%">Arnau-Soler, Aleix&#xD;Ashley, Sarah E&#xD;Ghauri, Ahla&#xD;Jeanrenaud, Alexander C S N&#xD;Marenholz, Ingo&#xD;Blumchen, Katharina&#xD;Cibin, Penelope&#xD;Iakupova, Alisa&#xD;Hubner, Norbert&#xD;Beyer, Kirsten&#xD;Lee, Young-Ae&#xD;eng&#xD;Foundation for the Treatment of Peanut Allergic Patients (Bea Stiftung)/&#xD;The Berlin Sparkasse Foundation for Medicine/&#xD;Nutricia Research Foundation/&#xD;BMBF01GL1742C/German Federal Ministry for Education and Research grant (CHAMP - CHildhood Allergy and Tolerance: bioMarkers and Predictors)/&#xD;01GL2401B/German Center for Child and Adolescent Health (DZKJ)/&#xD;01GL2401A/German Center for Child and Adolescent Health (DZKJ)/&#xD;409525714/German Research Foundation/&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3342-3358. doi: 10.1111/all.16627. Epub 2025 Jul 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40693699</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12666752</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16627</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>682</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">682</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Delgado-Dolset, M. I.</style></author><author><style face="normal" font="default" size="100%">Obeso, D.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Coira, J.</style></author><author><style face="normal" font="default" size="100%">Tarin, C.</style></author><author><style face="normal" font="default" size="100%">Tan, G.</style></author><author><style face="normal" font="default" size="100%">Cumplido, J. A.</style></author><author><style face="normal" font="default" size="100%">Cabrera, A.</style></author><author><style face="normal" font="default" size="100%">Angulo, S.</style></author><author><style face="normal" font="default" size="100%">Barbas, C.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Barber, D.</style></author><author><style face="normal" font="default" size="100%">Carrillo, T.</style></author><author><style face="normal" font="default" size="100%">Villasenor, A.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Applied Molecular Medicine (IMMA), Department of Basic Medical Sciences, Facultad de Medicina, Universidad San Pablo CEU, CEU Universities, Urbanizacion Monteprincipe, Madrid, Spain.&#xD;Centre for Metabolomics and Bioanalysis (CEMBIO), Department of Chemistry and Biochemistry, Facultad de Farmacia, Universidad San Pablo CEU, CEU Universities, Urbanizacion Monteprincipe, Madrid, Spain.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland.&#xD;Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain.&#xD;Department of Applied Mathematics and Statistics, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Understanding uncontrolled severe allergic asthma by integration of omic and clinical data</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1772-1785</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2021/11/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">machine learning</style></keyword><keyword><style face="normal" font="default" size="100%">metabolomics</style></keyword><keyword><style face="normal" font="default" size="100%">proteomics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34839541</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Asthma is a complex, multifactorial disease often linked with sensitization to house dust mites (HDM). There is a subset of patients that does not respond to available treatments, who present a higher number of exacerbations and a worse quality of life. To understand the mechanisms of poor asthma control and disease severity, we aim to elucidate the metabolic and immunologic routes underlying this specific phenotype and the associated clinical features. METHODS: Eighty-seven patients with a clinical history of asthma were recruited and stratified in 4 groups according to their response to treatment: corticosteroid-controlled (ICS), immunotherapy-controlled (IT), biologicals-controlled (BIO) or uncontrolled (UC). Serum samples were analysed by metabolomics and proteomics; and classifiers were built using machine-learning algorithms. RESULTS: Metabolomic analysis showed that ICS and UC groups cluster separately from one another and display the highest number of significantly different metabolites among all comparisons. Metabolite identification and pathway enrichment analysis highlighted increased levels of lysophospholipids related to inflammatory pathways in the UC patients. Likewise, 8 proteins were either upregulated (CCL13, ARG1, IL15 and TNFRSF12A) or downregulated (sCD4, CCL19 and IFNgamma) in UC patients compared to ICS, suggesting a significant activation of T cells in these patients. Finally, the machine-learning model built including metabolomic and clinical data was able to classify the patients with an 87.5% accuracy. CONCLUSIONS: UC patients display a unique fingerprint characterized by inflammatory-related metabolites and proteins, suggesting a pro-inflammatory environment. Moreover, the integration of clinical and experimental data led to a deeper understanding of the mechanisms underlying UC phenotype.</style></abstract><notes><style face="normal" font="default" size="100%">Delgado-Dolset, Maria Isabel&#xD;Obeso, David&#xD;Rodriguez-Coira, Juan&#xD;Tarin, Carlos&#xD;Tan, Ge&#xD;Cumplido, Jose A&#xD;Cabrera, Ana&#xD;Angulo, Santiago&#xD;Barbas, Coral&#xD;Sokolowska, Milena&#xD;Barber, Domingo&#xD;Carrillo, Teresa&#xD;Villasenor, Alma&#xD;Escribese, Maria M&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1772-1785. doi: 10.1111/all.15192. Epub 2021 Dec 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34839541</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15192</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3093</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3093</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Han, A.</style></author><author><style face="normal" font="default" size="100%">Deng, S.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Zheng, J.</style></author><author><style face="normal" font="default" size="100%">Wu, L.</style></author><author><style face="normal" font="default" size="100%">Zeng, H.</style></author><author><style face="normal" font="default" size="100%">Xu, J.</style></author><author><style face="normal" font="default" size="100%">Ma, Z.</style></author><author><style face="normal" font="default" size="100%">Huang, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ministry of Education-Shanghai Key Laboratory of Children&apos;s Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.&#xD;Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China.&#xD;Shenzhen Health Development Research and Data Management Center, Shenzhen, China.&#xD;Vanke School of Public Health, Tsinghua University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Uneven Risks of Childhood Asthma Under Extreme Temperatures and Its Interactions With Environmental Factors</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/09/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">environment and hygiene hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 5</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40910650</style></accession-num><notes><style face="normal" font="default" size="100%">Han, Azhu&#xD;Deng, Shizhou&#xD;Wang, Shuang&#xD;Zheng, Jing&#xD;Wu, Liqun&#xD;Zeng, Huatang&#xD;Xu, Jiayu&#xD;Ma, Zhao&#xD;Huang, Cunrui&#xD;eng&#xD;This work was supported by the National Key R&amp;D Program of China/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Sep 5. doi: 10.1111/all.70023.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40910650</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70023</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3116</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, P. H.</style></author><author><style face="normal" font="default" size="100%">Sabato, V.</style></author><author><style face="normal" font="default" size="100%">Khan, D. A.</style></author><author><style face="normal" font="default" size="100%">Lucas, M.</style></author><author><style face="normal" font="default" size="100%">Meng, J.</style></author><author><style face="normal" font="default" size="100%">Peter, J.</style></author><author><style face="normal" font="default" size="100%">Trubiano, J. A.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, SAR, China.&#xD;Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China.&#xD;Immunology Allergology Rheumatology, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium.&#xD;Division of Allergy and Immunology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.&#xD;Department of Immunology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.&#xD;Medical School, The University of Western Australia, Nedlands, Western Australia, Australia.&#xD;Allergy Center, West China Hospital, Sichuan University, Sichuan, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Sichuan, China.&#xD;Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town, Cape Town, South Africa.&#xD;Allergy and Immunology Unit, Lung Institute, University of Cape Town, Cape Town, South Africa.&#xD;Department of Infectious Diseases and Immunology, Austin Health, Melbourne, Victoria, Australia.&#xD;Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Allergy Unit, IBIMA-BIONAND, Regional University Hospital of Malaga, Malaga University, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Unifying Global Drug Allergy: Clarifying Concepts and Defining Low-Risk Penicillin Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2949-2952</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2025/10/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">nomenclature</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41123075</style></accession-num><notes><style face="normal" font="default" size="100%">Li, Philip H&#xD;Sabato, Vito&#xD;Khan, David A&#xD;Lucas, Michaela&#xD;Meng, Juan&#xD;Peter, Jonny&#xD;Trubiano, Jason A&#xD;Shamji, Mohamed H&#xD;Torres, Maria Jose&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Nov;80(11):2949-2952. doi: 10.1111/all.70125. Epub 2025 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41123075</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70125</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>337</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">337</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Riedel, F.</style></author><author><style face="normal" font="default" size="100%">Aparicio-Soto, M.</style></author><author><style face="normal" font="default" size="100%">Curato, C.</style></author><author><style face="normal" font="default" size="100%">Munch, L.</style></author><author><style face="normal" font="default" size="100%">Abbas, A.</style></author><author><style face="normal" font="default" size="100%">Thierse, H. J.</style></author><author><style face="normal" font="default" size="100%">Peitsch, W. K.</style></author><author><style face="normal" font="default" size="100%">Luch, A.</style></author><author><style face="normal" font="default" size="100%">Siewert, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dermatotoxicology Study Centre, German Federal Institute for Risk Assessment, Berlin, Germany.&#xD;Department of Chemical and Product Safety, German Federal Institute for Risk Assessment, Berlin, Germany.&#xD;Institute of Pharmacy, Freie Universitat Berlin, Berlin, Germany.&#xD;German Rheumatism Research Center (DRFZ), Berlin, Germany.&#xD;Department of Dermatology and Phlebology, Vivantes Klinikum im Friedrichshain, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Unique and common TCR repertoire features of Ni(2+) -, Co(2+) -, and Pd(2+) -specific human CD154 + CD4+ T cells</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">270-282</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/08/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*CD4-Positive T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Antigen, T-Cell, alpha-beta/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytes, Mononuclear/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Histidine/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Complementarity Determining Regions/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">CD154 upregulation assay</style></keyword><keyword><style face="normal" font="default" size="100%">T cell receptor (TCR) repertoire</style></keyword><keyword><style face="normal" font="default" size="100%">TCR alpha-chain segment TRAV9-2</style></keyword><keyword><style face="normal" font="default" size="100%">complementarity determining region 3 (CDR3) histidine</style></keyword><keyword><style face="normal" font="default" size="100%">metal allergens Ni2+, Co2+, Pd2+</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36005389</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Apart from Ni(2+) , Co(2+) , and Pd(2+) ions commonly trigger T cell-mediated allergic contact dermatitis. However, in vitro frequencies of metal-specific T cells and the mechanisms of antigen recognition remain unclear. METHODS: Here, we utilized a CD154 upregulation assay to quantify Ni(2+) -, Co(2+) -, and Pd(2+) -specific CD4+ T cells in peripheral blood mononuclear cells (PBMC). Involved alphabeta T cell receptor (TCR) repertoires were analyzed by high-throughput sequencing. RESULTS: Peripheral blood mononuclear cells incubation with NiSO(4) , CoCl(2) , and PdCl(2) increased frequencies of CD154 + CD4+ memory T cells that peaked at ~400 muM. Activation was TCR-mediated as shown by the metal-specific restimulation of T cell clones. Most abundant were Pd(2+) -specific T cells (mean 3.5%, n = 19), followed by Co(2+) - and Ni(2+) -specific cells (0.6%, n = 18 and 0.3%, n = 20) in both allergic and non-allergic individuals. A strong overrepresentation of the gene segment TRAV9-2 was unique for Ni(2+) -specific TCR (28% of TCR) while Co(2+) and Pd(2+) -specific TCR favorably expressed TRAV2 (8%) and the TRBV4 gene segment family (21%), respectively. As a second, independent mechanism of metal ion recognition, all analyzed metal-specific TCR showed a common overrepresentation of a histidine in the complementarity determining region 3 (CDR3; 15% of alpha-chains, 34% of beta-chains). The positions of the CDR3 histidine among metal-specific TCR mirrored those in random repertoires and were conserved among cross-reactive clonotypes. CONCLUSIONS: Induced CD154 expression allows a fast and comprehensive detection of Ni(2+) -, Co(2+) -, and Pd(2+) -specific CD4+ T cells. Distinct TCR repertoire features underlie the frequent activation and cross-reactivity of human metal-specific T cells.</style></abstract><notes><style face="normal" font="default" size="100%">Riedel, Franziska&#xD;Aparicio-Soto, Marina&#xD;Curato, Caterina&#xD;Munch, Lucas&#xD;Abbas, Amro&#xD;Thierse, Hermann-Josef&#xD;Peitsch, Wiebke K&#xD;Luch, Andreas&#xD;Siewert, Katherina&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):270-282. doi: 10.1111/all.15494. Epub 2022 Sep 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36005389</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15494</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>925</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">925</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lefevre, M. A.</style></author><author><style face="normal" font="default" size="100%">Nosbaum, A.</style></author><author><style face="normal" font="default" size="100%">Rozieres, A.</style></author><author><style face="normal" font="default" size="100%">Lenief, V.</style></author><author><style face="normal" font="default" size="100%">Mosnier, A.</style></author><author><style face="normal" font="default" size="100%">Cortial, A.</style></author><author><style face="normal" font="default" size="100%">Prieux, M.</style></author><author><style face="normal" font="default" size="100%">De Bernard, S.</style></author><author><style face="normal" font="default" size="100%">Nourikyan, J.</style></author><author><style face="normal" font="default" size="100%">Jouve, P. E.</style></author><author><style face="normal" font="default" size="100%">Buffat, L.</style></author><author><style face="normal" font="default" size="100%">Hacard, F.</style></author><author><style face="normal" font="default" size="100%">Ferrier-Lebouedec, M. C.</style></author><author><style face="normal" font="default" size="100%">Pralong, P.</style></author><author><style face="normal" font="default" size="100%">Dzviga, C.</style></author><author><style face="normal" font="default" size="100%">Herman, A.</style></author><author><style face="normal" font="default" size="100%">Baeck, M.</style></author><author><style face="normal" font="default" size="100%">Nicolas, J. F.</style></author><author><style face="normal" font="default" size="100%">Vocanson, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CIRI, Centre International de Recherche en Infectiologie, (Team Epidermal Immunity and Allergy), INSERM, U1111, Univ Lyon, Universite de Lyon 1, Ecole Normale Superieure de Lyon, CNRS, UMR 5308, Lyon, France.&#xD;Department of Dermatology and Allergology, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Priest-en-Jarez, France.&#xD;Department of Allergy and Clinical Immunology, Centre Hospitalier Lyon-Sud, Pierre-Benite, France.&#xD;Altrabio, Lyon, France.&#xD;Department of Dermatology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.&#xD;Department of Dermatology, Allergology and Photobiology, Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, France.&#xD;Department of Dermatology, Cliniques universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Unique molecular signatures typify skin inflammation induced by chemical allergens and irritants</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3697-3712</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Allergic Contact/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Irritant/etiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Irritants/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Patch Tests</style></keyword><keyword><style face="normal" font="default" size="100%">allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">chemical allergens</style></keyword><keyword><style face="normal" font="default" size="100%">chemical irritants</style></keyword><keyword><style face="normal" font="default" size="100%">transcriptomic profiling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34174113</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Skin exposure to chemicals may induce an inflammatory disease known as contact dermatitis (CD). Distinguishing the allergic and irritant forms of CD often proves challenging in the clinic. METHODS: To characterize the molecular signatures of chemical-induced skin inflammation, we conducted a comprehensive transcriptomic analysis on the skin lesions of 47 patients with positive patch tests to reference contact allergens and nonallergenic irritants. RESULTS: A clear segregation was observed between allergen- and irritant-induced gene profiles. Distinct modules pertaining to the epidermal compartment, metabolism, and proliferation were induced by both contact allergens and irritants; whereas only contact allergens prompted strong activation of adaptive immunity, notably of cytotoxic T-cell responses. Our results also confirmed that: (a) unique pathways characterize allergen- and irritant-induced dermatitis; (b) the intensity of the clinical reaction correlates with the magnitude of immune activation. Finally, using a machine-learning approach, we identified and validated several minimal combinations of biomarkers to distinguish contact allergy from irritation. CONCLUSION: These results highlight the value of molecular profiling of chemical-induced skin inflammation for improving the diagnosis of allergic versus irritant contact dermatitis.</style></abstract><notes><style face="normal" font="default" size="100%">Lefevre, Marine-Alexia&#xD;Nosbaum, Audrey&#xD;Rozieres, Aurore&#xD;Lenief, Vanina&#xD;Mosnier, Amandine&#xD;Cortial, Angele&#xD;Prieux, Margaux&#xD;De Bernard, Simon&#xD;Nourikyan, Julien&#xD;Jouve, Pierre-Emmanuel&#xD;Buffat, Laurent&#xD;Hacard, Florence&#xD;Ferrier-Lebouedec, Marie-Christine&#xD;Pralong, Pauline&#xD;Dzviga, Charles&#xD;Herman, Anne&#xD;Baeck, Marie&#xD;Nicolas, Jean-Francois&#xD;Vocanson, Marc&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3697-3712. doi: 10.1111/all.14989. Epub 2021 Jul 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34174113</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14989</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2221</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2221</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ecrement, A.</style></author><author><style face="normal" font="default" size="100%">Barnig, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite de Franche-Comte, EFS, INSERM, UMR RIGHT, Besancon, France.&#xD;CHU Besancon, Department of Chest Disease, Besancon, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Unlocking the potential of NK cells: NgR1-mediated modulation of immunological synapse stability</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3285-3286</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2023/09/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunological Synapses</style></keyword><keyword><style face="normal" font="default" size="100%">*Killer Cells, Natural</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37661661</style></accession-num><notes><style face="normal" font="default" size="100%">Ecrement, Alexandre&#xD;Barnig, Cindy&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2023 Dec;78(12):3285-3286. doi: 10.1111/all.15873. Epub 2023 Sep 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37661661</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15873</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2934</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2934</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tourlakopoulos, K.</style></author><author><style face="normal" font="default" size="100%">Mavrovounis, G.</style></author><author><style face="normal" font="default" size="100%">Kontopoulou, L.</style></author><author><style face="normal" font="default" size="100%">Polyzois, S.</style></author><author><style face="normal" font="default" size="100%">Pantazopoulos, I.</style></author><author><style face="normal" font="default" size="100%">Kirgou, P.</style></author><author><style face="normal" font="default" size="100%">Daniil, Z.</style></author><author><style face="normal" font="default" size="100%">Gourgoulianis, K. I.</style></author><author><style face="normal" font="default" size="100%">Kotsiou, O. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.&#xD;Department of Nursing, School of Health Sciences, University of Thessaly, Larissa, Greece.&#xD;Laboratory of Hygiene and Environmental Protection, Democritus University of Thrace, Alexandroupolis, Greece.&#xD;Laboratory of Human Pathophysiology, Department of Nursing, School of Health Sciences, University of Thessaly, Larissa, Greece.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Unmasking Convergent Inflammatory and Oxidative Pathways in Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1801-1806</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/05/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40326823</style></accession-num><notes><style face="normal" font="default" size="100%">Tourlakopoulos, Konstantinos&#xD;Mavrovounis, Georgios&#xD;Kontopoulou, Lamprini&#xD;Polyzois, Spyros&#xD;Pantazopoulos, Ioannis&#xD;Kirgou, Paraskevi&#xD;Daniil, Zoe&#xD;Gourgoulianis, Konstantinos I&#xD;Kotsiou, Ourania S&#xD;eng&#xD;Hellenic Thoracic Society/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1801-1806. doi: 10.1111/all.16575. Epub 2025 May 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40326823</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12186591</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16575</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3279</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3279</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klimek, L.</style></author><author><style face="normal" font="default" size="100%">Mullol, J.</style></author><author><style face="normal" font="default" size="100%">Hummel, Th.</style></author><author><style face="normal" font="default" size="100%">del Giacco, S.</style></author><author><style face="normal" font="default" size="100%">Georgalas, C.</style></author><author><style face="normal" font="default" size="100%">Rondon, C.</style></author><author><style face="normal" font="default" size="100%">Schiappoli, M.</style></author><author><style face="normal" font="default" size="100%">Gevaert, P.</style></author><author><style face="normal" font="default" size="100%">Bozkurt, B.</style></author><author><style face="normal" font="default" size="100%">Chaker, A.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">van Gerven, L.</style></author><author><style face="normal" font="default" size="100%">Maza-Solano, J.</style></author><author><style face="normal" font="default" size="100%">Lundberg, M.</style></author><author><style face="normal" font="default" size="100%">Becker, S.</style></author><author><style face="normal" font="default" size="100%">Bärhold, F.</style></author><author><style face="normal" font="default" size="100%">Karavelia, A.</style></author><author><style face="normal" font="default" size="100%">Cuevas, M.</style></author><author><style face="normal" font="default" size="100%">Gröger, M.</style></author><author><style face="normal" font="default" size="100%">Huber, P.</style></author><author><style face="normal" font="default" size="100%">Arasi, S.</style></author><author><style face="normal" font="default" size="100%">Cingi, C.</style></author><author><style face="normal" font="default" size="100%">Rojas-Lechuga, M. Jesús</style></author><author><style face="normal" font="default" size="100%">Izquierdo-Domínguez, A.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Gawlik, R.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Celik, G.</style></author><author><style face="normal" font="default" size="100%">Escribese, M.</style></author><author><style face="normal" font="default" size="100%">Walusiak-Skorupa, J.</style></author><author><style face="normal" font="default" size="100%">Betz, C.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Moreira, A.</style></author><author><style face="normal" font="default" size="100%">Bonadonna, P.</style></author><author><style face="normal" font="default" size="100%">Shamji, M.</style></author><author><style face="normal" font="default" size="100%">Torres Jaen, M. J.</style></author><author><style face="normal" font="default" size="100%">Akdis, C.</style></author><author><style face="normal" font="default" size="100%">Hagemann, J.</style></author><author><style face="normal" font="default" size="100%">Hox, V.</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Unmet Need of Olfactory Testing in Inflammatory Disorders of the Upper Airways—An EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT The sense of smell, with its extensive evolutionary history, is highly prone to disorders that can have a profound impact on daily life. Anosmia affects approximately 5% of the population, with an additional 15% exhibiting reduced olfactory function. The prevalence of olfactory dysfunction (OD) varies by population and age group, and standardized testing reveals a broad range of impacts. OD includes various causes, most commonly aging, inflammation of the olfactory epithelium, upper respiratory tract infections (URTI), traumatic brain injury, and neurological conditions. The recent COVID-19 pandemic has highlighted the association between viral infections and olfactory dysfunction, with severe hyposmia/anosmia being an early marker of infection. Despite its importance, the assessment of olfactory function remains inconsistent across clinical practices. Psychophysical smell tests, while vital for diagnosis and patient management, are underutilized, especially outside of specialized centers. Standardized testing methods are crucial for objective diagnosis, but significant challenges, including test variability, lack of comparability, and healthcare reimbursement issues, persist. The European Academy of Allergy and Immunology (EAACI) advocates for improvements in the quality and standardization of chemosensory assessments. Future efforts must prioritize education, incentives for better testing, and the integration of digital tools to expand access to olfactory testing and diagnosis in remote or quarantine situations. However, office-based testing remains irreplaceable, even with advancements in telemedicine.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70219</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70219</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3236</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3236</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kolkhir, P.</style></author><author><style face="normal" font="default" size="100%">Salameh, P.</style></author><author><style face="normal" font="default" size="100%">Zajac, M.</style></author><author><style face="normal" font="default" size="100%">Kasperska-Zajac, A.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A.</style></author><author><style face="normal" font="default" size="100%">Puertolas, M.</style></author><author><style face="normal" font="default" size="100%">Bonnekoh, H.</style></author><author><style face="normal" font="default" size="100%">Vera Ayala, C.</style></author><author><style face="normal" font="default" size="100%">Makris, M.</style></author><author><style face="normal" font="default" size="100%">Chatzidimitriou, E.</style></author><author><style face="normal" font="default" size="100%">Gregoriou, S.</style></author><author><style face="normal" font="default" size="100%">Kulthanan, K.</style></author><author><style face="normal" font="default" size="100%">Bauer, A.</style></author><author><style face="normal" font="default" size="100%">Bizjak-Suran, M.</style></author><author><style face="normal" font="default" size="100%">Fomina, D.</style></author><author><style face="normal" font="default" size="100%">Bocquet, A.</style></author><author><style face="normal" font="default" size="100%">Dissemond, J.</style></author><author><style face="normal" font="default" size="100%">Abuzakouk, M.</style></author><author><style face="normal" font="default" size="100%">Raftery, T.</style></author><author><style face="normal" font="default" size="100%">Chapman-Rothe, N.</style></author><author><style face="normal" font="default" size="100%">Kocaturk, E.</style></author><author><style face="normal" font="default" size="100%">Grattan, C.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author><author><style face="normal" font="default" size="100%">Peter, J. G.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author><author><style face="normal" font="default" size="100%">Weller, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;School of Medicine, Lebanese American University, Byblos, Lebanon.&#xD;Institut National de Sante Publique D&apos;epidemiologie Clinique et de Toxicologie-Liban (INSPECT-LB), Beirut, Lebanon.&#xD;Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.&#xD;Faculty of Pharmacy, Lebanese University, Hadat, Lebanon.&#xD;European Center for Diagnosis and Treatment of Urticaria, Medical University of Silesia, Katowice, Poland.&#xD;Department of Dermatology, Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain.&#xD;Allergy Unit &quot;D. Kalogeromitros&quot;, 2nd Department, Dermatology and Venereology, National and Kapodistrian University of Athens, &quot;Attikon&quot; University Hospital, Athens, Greece.&#xD;National and Kapodistrian University of Athens, 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, Athens, Greece.&#xD;Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.&#xD;Division of Allergy, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.&#xD;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.&#xD;Faculty of Maribor, University of Maribor, Maribor, Slovenia.&#xD;Moscow City Research and Practical Center of Allergy and Immunology, State Budgetary Healthcare Institution &quot;Moscow Clinical Science and Research Hospital 52 of Moscow Healthcare Department&quot;, Moscow, Russian Federation.&#xD;Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russian Federation.&#xD;Department of Pulmonology, Astana Medical University, Astana, Kazakhstan.&#xD;Department of Internal Medicine and Clinical Immunology, CHU Grenobles Alpes, Grenoble, France.&#xD;Department of Dermatology, Venerology and Allergology, University of Essen, Essen, Germany.&#xD;Allergy &amp; Immunology Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.&#xD;Novartis Ireland Ltd., Dublin, Ireland.&#xD;Novartis Pharma AG, Basel, Switzerland.&#xD;Bahcesehir University School of Medicine, Department of Dermatology, Istanbul, Turkey.&#xD;Guy&apos;s Hospital, St John&apos;s Institute of Dermatology, London, UK.&#xD;Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Milan, Italy.&#xD;Allergy and Immunology Unit, UCT Lung Institute, Cape Town, South Africa.&#xD;Division of Allergy and Clinical Immunology, Groote Schuur Hospital, University of Cape Town (UCT), Cape Town, South Africa.&#xD;Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.&#xD;Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2026/01/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">antihistamine</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">chronic urticaria registry (CURE)</style></keyword><keyword><style face="normal" font="default" size="100%">real-world practice</style></keyword><keyword><style face="normal" font="default" size="100%">treatment escalation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 14</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41532642</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Many patients with chronic spontaneous urticaria (CSU) remain symptomatic despite receiving second-generation H(1)-antihistamines (sgH(1)-AH). This data analysis from the Chronic Urticaria Registry (CURE) aimed to describe treatment patterns and identify unmet needs in real-world practice. METHODS: CURE is an international, prospective registry of patients with chronic urticaria. Treatment responses were categorized as Urticaria Control Test (UCT) changes from baseline (BL) to 6-month follow-up (FU). Complete response was defined as UCT = 16 with a &gt;/= 3-point increase. RESULTS: Data were available from 3995 adult patients with CSU at BL and 1288 at FU with evaluable UCT. After treatment escalation from BL to FU, 5.3% (no treatment to licensed-dose sgH(1)-AH), 6.0% (licensed-dose sgH(1)-AH to up-dosed sgH(1)-AH), and 28.4% (any dose sgH(1)-AH to omalizumab) achieved complete response. Factors associated with a lower probability of treatment escalation at FU were UCT &gt;/= 12 and omalizumab treatment at BL (both p &lt; 0.0001). About one-third (28.6%) of patients clinically eligible for escalation at BL (UCT &lt; 12) did not receive step-up treatment (18.0%) or were even stepped down (10.6%) and remained poorly controlled at FU. Factors associated with lack of escalation in this group included younger age (p = 0.014), shorter disease duration (p = 0.071), presence of wheals and angioedema (p = 0.002), better quality of life (p = 0.001), and treatment with up-dosed sgH(1)-AH (p = 0.031). CONCLUSION: Appropriate treatment escalation improves CSU control, although only about a quarter of patients achieve a complete response, indicating the need for novel treatments. Many patients with poorly controlled CSU do not receive guideline-recommended treatment escalation and remain symptomatic on their current treatments, which deserves further attention.</style></abstract><notes><style face="normal" font="default" size="100%">Kolkhir, Pavel&#xD;Salameh, Pascale&#xD;Zajac, Magdalena&#xD;Kasperska-Zajac, Alicja&#xD;Gimenez-Arnau, Ana&#xD;Puertolas, Maria&#xD;Bonnekoh, Hanna&#xD;Vera Ayala, Carolina&#xD;Makris, Michael&#xD;Chatzidimitriou, Eleni&#xD;Gregoriou, Stamatios&#xD;Kulthanan, Kanokvalai&#xD;Bauer, Andrea&#xD;Bizjak-Suran, Mojca&#xD;Fomina, Daria&#xD;Bocquet, Alexis&#xD;Dissemond, Joachim&#xD;Abuzakouk, Mohamed&#xD;Raftery, Tara&#xD;Chapman-Rothe, Nadine&#xD;Kocaturk, Emek&#xD;Grattan, Clive&#xD;Asero, Riccardo&#xD;Peter, Jonny G&#xD;Thomsen, Simon Francis&#xD;Weller, Karsten&#xD;eng&#xD;Novartis Pharma/&#xD;Denmark&#xD;Allergy. 2026 Jan 14. doi: 10.1111/all.70199.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41532642</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70199</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3021</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3021</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Larsen, L. D.</style></author><author><style face="normal" font="default" size="100%">Kian, A.</style></author><author><style face="normal" font="default" size="100%">Falta, N. A.</style></author><author><style face="normal" font="default" size="100%">Fox, B.</style></author><author><style face="normal" font="default" size="100%">Spencer, L. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.&#xD;Gastrointestinal Eosinophilic Diseases Program, Digestive Health Institute, Children&apos;s Hospital Colorado, Aurora, Colorado, USA.&#xD;GI and Liver Innate Immune Programs (GALIIP), University of Colorado School of Medicine, Aurora, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Unsupervised Clustering Reveals Intestine-Adapted Eosinophil Subsets Shaped by Local Inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2921-2925</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/08/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">animal models</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">mucosal immunity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40878357</style></accession-num><notes><style face="normal" font="default" size="100%">Larsen, Leigha D&#xD;Kian, Arman&#xD;Falta, Natalie A&#xD;Fox, Barbara&#xD;Spencer, Lisa A&#xD;eng&#xD;R01 AI168134/AI/NIAID NIH HHS/&#xD;R56 AI121186/AI/NIAID NIH HHS/&#xD;Crohn&apos;s and Colitis Foundation/&#xD;National Institute of Allergy and Infectious Diseases/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2921-2925. doi: 10.1111/all.70010. Epub 2025 Aug 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40878357</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12486345</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70010</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3208</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3208</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Margaglione, M.</style></author><author><style face="normal" font="default" size="100%">D&apos;Apolito, M.</style></author><author><style face="normal" font="default" size="100%">Santacroce, R.</style></author><author><style face="normal" font="default" size="100%">Cordisco, G.</style></author><author><style face="normal" font="default" size="100%">Arcoleo, F.</style></author><author><style face="normal" font="default" size="100%">De Pasquale, T.</style></author><author><style face="normal" font="default" size="100%">Puxeddu, I.</style></author><author><style face="normal" font="default" size="100%">Zanichelli, A.</style></author><author><style face="normal" font="default" size="100%">Cancian, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.&#xD;UOC di Patologia Clinica e Immunologia, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.&#xD;Department of Allergology, University Hospital &quot;Maggiore Della Carita&quot; of Novara, Novara, Italy.&#xD;Immuno-Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.&#xD;Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.&#xD;Operative Unit of Medicine, IRCCS Policlinico San Donato, Milan, Italy.&#xD;Department of Systems Medicine, University Hospital of Padua, Padua, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Unveiling Rare Genetic Variants in DAB2IP: New Insights Into the Pathogenesis of Recurrent Angioedema</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/12/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">angioedema</style></keyword><keyword><style face="normal" font="default" size="100%">endotypes</style></keyword><keyword><style face="normal" font="default" size="100%">genetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41351466</style></accession-num><notes><style face="normal" font="default" size="100%">Margaglione, Maurizio&#xD;D&apos;Apolito, Maria&#xD;Santacroce, Rosa&#xD;Cordisco, Giorgia&#xD;Arcoleo, Francesco&#xD;De Pasquale, Tiziana&#xD;Puxeddu, Ilaria&#xD;Zanichelli, Andrea&#xD;Cancian, Mauro&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Dec 6. doi: 10.1111/all.70184.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41351466</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70184</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2645</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2645</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Bernaola, J.</style></author><author><style face="normal" font="default" size="100%">Nolasco, S.</style></author><author><style face="normal" font="default" size="100%">Kjarsgaard, M.</style></author><author><style face="normal" font="default" size="100%">Xie, Y.</style></author><author><style face="normal" font="default" size="100%">Radford, K.</style></author><author><style face="normal" font="default" size="100%">Alotaibi, B.</style></author><author><style face="normal" font="default" size="100%">Garrido, C. V.</style></author><author><style face="normal" font="default" size="100%">Nair, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, McMaster University, Hamilton, Ontario, Canada.&#xD;Research Institute of St. Joe&apos;s. St Joseph&apos;s Healthcare, Hamilton, Ontario, Canada.&#xD;Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Up-dosing of reslizumab in severe asthmatics with persistent sputum eosinophilia: A feasibility study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">605-608</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/09/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anti-IL-5 biologic</style></keyword><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">reslizumab</style></keyword><keyword><style face="normal" font="default" size="100%">severe asthma</style></keyword><keyword><style face="normal" font="default" size="100%">sputum</style></keyword><keyword><style face="normal" font="default" size="100%">Pharamceuticals and Mirimus, consulting fees from AstraZeneca, Sanofi, Respiplus,</style></keyword><keyword><style face="normal" font="default" size="100%">GSK, Mirimus. PN reports research grants from AstraZeneca, Teva, Sanofi, Foresee</style></keyword><keyword><style face="normal" font="default" size="100%">and consulting fees from AstraZeneca, Teva, Sanofi, Equillium, Arrowhead pharma.</style></keyword><keyword><style face="normal" font="default" size="100%">All other authors have no conflict of interest within the scope of the submitted</style></keyword><keyword><style face="normal" font="default" size="100%">work.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39286951</style></accession-num><notes><style face="normal" font="default" size="100%">Mukherjee, Manali&#xD;Bernaola, Jaime&#xD;Nolasco, Santi&#xD;Kjarsgaard, Melanie&#xD;Xie, Yinglan&#xD;Radford, Katherine&#xD;Alotaibi, Bashayr&#xD;Garrido, Carmen Venegas&#xD;Nair, Parameswaran&#xD;eng&#xD;Teva Canada Innovation/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):605-608. doi: 10.1111/all.16322. Epub 2024 Sep 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39286951</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804305</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16322</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1406</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1406</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Morais-Almeida, M.</style></author><author><style face="normal" font="default" size="100%">Barbosa, M. T.</style></author><author><style face="normal" font="default" size="100%">Sousa, C. S.</style></author><author><style face="normal" font="default" size="100%">Aguiar, R.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Centre, CUF Descobertas Hospital, Lisbon, Portugal.&#xD;Portuguese Association of Asthmatics (APA), Porto, Portugal.&#xD;Charite, Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin Institute of Health, Berlin, Germany.&#xD;MACVIA-France, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Update on asthma prevalence in severe COVID-19 patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">953-954</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2020/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32639631</style></accession-num><notes><style face="normal" font="default" size="100%">Morais-Almeida, Mario&#xD;Barbosa, Miguel T&#xD;Sousa, Claudia S&#xD;Aguiar, Rita&#xD;Bousquet, Jean&#xD;eng&#xD;Comment&#xD;Letter&#xD;Denmark&#xD;Allergy. 2021 Mar;76(3):953-954. doi: 10.1111/all.14482. Epub 2020 Jul 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32639631</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC7361842</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14482</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3269</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3269</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roth-Walter, F.</style></author><author><style face="normal" font="default" size="100%">Adcock, I. M.</style></author><author><style face="normal" font="default" size="100%">Benito-Villalvilla, C.</style></author><author><style face="normal" font="default" size="100%">Bianchini, R.</style></author><author><style face="normal" font="default" size="100%">Bjermer, L.</style></author><author><style face="normal" font="default" size="100%">Caramori, G.</style></author><author><style face="normal" font="default" size="100%">Cari, L.</style></author><author><style face="normal" font="default" size="100%">Chung, K. F.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Knol, E. F.</style></author><author><style face="normal" font="default" size="100%">Jesenak, M.</style></author><author><style face="normal" font="default" size="100%">Levi-Schaffer, F.</style></author><author><style face="normal" font="default" size="100%">Nocentini, G.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Palomares, O.</style></author><author><style face="normal" font="default" size="100%">Redegeld, F.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Van Esch, B.</style></author><author><style face="normal" font="default" size="100%">Zurlo, M.</style></author><author><style face="normal" font="default" size="100%">Stellato, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Update on Non-Biological and RNA-Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal antibodies—a deeper understanding of how inflammatory and immune pathways are configured in disease-specific patterns. In this biomarker-driven approach, synthetic small molecule drugs (SMDs) were perceived as lagging behind in innovation for their relative lack of specificity. This was, however, mostly due to a shift in focus towards biologics rather than true obsolescence of SMDs. In the same timeframe, in fact, advances in structural biology and medicinal chemistry, bioinformatics and artificial intelligence held steadily SMDs&apos; innovation and relevance. The use of kinase inhibitors, well established in the treatment of cancer and rheumatological diseases, is now approved for some allergic skin diseases and is approaching asthma and COPD with several clinical trials; moreover, new therapeutics targeting mast cell receptors and molecules involved in innate immunity are entering preclinical and clinical testing. Alongside, the portfolio of biologics is harboring the expansion of RNA therapeutics, which gained global recognition during the COVID-19 pandemic due to RNA vaccines. Different types of RNA therapeutics, including those based on different non-coding RNAs, are advancing to agency approval and market, thanks to improvements in molecule stability and delivery systems. In summary, the evidence presented in this position paper illustrates that precision medicine is becoming a goal shared between synthetic SMDs and biologics, both protein/antibody-based and RNA therapeutics. We review the current state, unmet needs and opportunities within this evolving landscape, highlighting how small molecular species, both synthetic as SMDs and biologic in nature as RNA, can contribute to the precision medicine approach along with protein and antibody-based biologics and cell therapies.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70235</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70235</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>377</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">377</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Lan, F.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.&#xD;Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.&#xD;Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Update on pathomechanisms and treatments in allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3309-3319</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2022/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">immune cells</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">mechanisms</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35892225</style></accession-num><abstract><style face="normal" font="default" size="100%">Allergic rhinitis (AR) is a global health problem with increasing prevalence and association with an enormous medical and socioeconomic burden. New recognition of immune cells such as type 2 innate lymphocytes (ILC2s), T helper (Th2) 2 cells, follicular helper T cells, follicular regulatory T cells, regulatory T cells, B cells, dendritic cells, and epithelial cells in AR pathogenesis has been updated in this review paper. An in-depth understanding of the mechanisms underlying AR will aid the identification of biomarkers associated with disease and ultimately provide valuable parameters critical to guide personalized targeted therapy. As the only etiological treatment option for AR, allergen-specific immunotherapy (AIT) has attracted increasing attention, with evidence for effectiveness of AIT recently demonstrated in several randomized controlled trials and long-term real-life studies. The exploration of biologics as therapeutic options has only involved anti-IgE and anti-type 2 inflammatory agents; however, the cost-effectiveness of these agents remains to be elucidated precisely. In the midst of the currently on-going COVID-19 pandemic, a global life-threatening disease, although some studies have indicated that AR is not a risk factor for severity and mortality of COVID-19, this needs to be confirmed in multi-centre, real-life studies of AR patients from different parts of the world.</style></abstract><notes><style face="normal" font="default" size="100%">Zhang, Yuan&#xD;Lan, Feng&#xD;Zhang, Luo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Nov;77(11):3309-3319. doi: 10.1111/all.15454. Epub 2022 Aug 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35892225</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15454</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2126</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2126</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Locke, A.</style></author><author><style face="normal" font="default" size="100%">Hung, L.</style></author><author><style face="normal" font="default" size="100%">Upton, J. E. M.</style></author><author><style face="normal" font="default" size="100%">O&apos;Mahony, L.</style></author><author><style face="normal" font="default" size="100%">Hoang, J.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medicine, University of Galway, Galway, Ireland.&#xD;Translational Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Division of Immunology and Allergy, SickKids Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Toronto, Ontario, Canada.&#xD;Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.&#xD;Departments of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland.&#xD;Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.&#xD;Department of Pediatric and Adolescent Medicine, University Hospital St. Polten, St. Polten, Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An update on recent developments and highlights in food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2344-2360</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2023/04/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Food</style></keyword><keyword><style face="normal" font="default" size="100%">*Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Desensitization, Immunologic</style></keyword><keyword><style face="normal" font="default" size="100%">barrier function</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">mouse models</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37087637</style></accession-num><abstract><style face="normal" font="default" size="100%">While both the incidence and general awareness of food allergies is increasing, the variety and clinical availability of therapeutics remain limited. Therefore, investigations into the potential factors contributing to the development of food allergy (FA) and the mechanisms of natural tolerance or induced desensitization are required. In addition, a detailed understanding of the pathophysiology of food allergies is needed to generate compelling, enduring, and safe treatment options. New findings regarding the contribution of barrier function, the effect of emollient interventions, mechanisms of allergen recognition, and the contributions of specific immune cell subsets through rodent models and human clinical studies provide novel insights. With the first approved treatment for peanut allergy, the clinical management of FA is evolving toward less intensive, alternative approaches involving fixed doses, lower maintenance dose targets, coadministration of biologicals, adjuvants, and tolerance-inducing formulations. The ultimate goal is to improve immunotherapy and develop precision-based medicine via risk phenotyping allowing optimal treatment for each food-allergic patient.</style></abstract><notes><style face="normal" font="default" size="100%">Locke, Arielle&#xD;Hung, Lisa&#xD;Upton, Julia E M&#xD;O&apos;Mahony, Liam&#xD;Hoang, Jennifer&#xD;Eiwegger, Thomas&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Sep;78(9):2344-2360. doi: 10.1111/all.15749. Epub 2023 May 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37087637</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15749</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2403</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2403</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, Z. Q.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Sun, L. Y.</style></author><author><style face="normal" font="default" size="100%">Ong, H. H.</style></author><author><style face="normal" font="default" size="100%">Ye, J.</style></author><author><style face="normal" font="default" size="100%">Xu, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, D. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China.&#xD;Department of Otolaryngology, Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore.&#xD;First School of Clinical Medicine, Renmin Hospital of Wuhan University, Wuhan, China.&#xD;Department of Otolaryngology-Head and Neck Surgery, The 1st Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Updated epithelial barrier dysfunction in chronic rhinosinusitis: Targeting pathophysiology and treatment response of tight junctions</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1146-1165</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2024/02/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Mucosa/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinosinusitis/physiopathology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Tight Junctions/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">epithelial barrier theory</style></keyword><keyword><style face="normal" font="default" size="100%">nasal epithelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword><keyword><style face="normal" font="default" size="100%">tight junctions</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38372149</style></accession-num><abstract><style face="normal" font="default" size="100%">Tight junction (TJ) proteins establish a physical barrier between epithelial cells, playing a crucial role in maintaining tissue homeostasis by safeguarding host tissues against pathogens, allergens, antigens, irritants, etc. Recently, an increasing number of studies have demonstrated that abnormal expression of TJs plays an essential role in the development and progression of inflammatory airway diseases, including chronic obstructive pulmonary disease, asthma, allergic rhinitis, and chronic rhinosinusitis (CRS) with or without nasal polyps. Among them, CRS with nasal polyps is a prevalent chronic inflammatory disease that affects the nasal cavity and paranasal sinuses, leading to a poor prognosis and significantly impacting patients&apos; quality of life. Its pathogenesis primarily involves dysfunction of the nasal epithelial barrier, impaired mucociliary clearance, disordered immune response, and excessive tissue remodeling. Numerous studies have elucidated the pivotal role of TJs in both the pathogenesis and response to traditional therapies in CRS. We therefore to review and discuss potential factors contributing to impair and repair of TJs in the nasal epithelium based on their structure, function, and formation process.</style></abstract><notes><style face="normal" font="default" size="100%">Huang, Zhi-Qun&#xD;Liu, Jing&#xD;Sun, Li-Ying&#xD;Ong, Hsiao Hui&#xD;Ye, Jing&#xD;Xu, Yu&#xD;Wang, De-Yun&#xD;eng&#xD;National Medical Research Council of Singapore/&#xD;National Natural Science Foundation of China/&#xD;China Scholarship Council/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2024 May;79(5):1146-1165. doi: 10.1111/all.16064. Epub 2024 Feb 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38372149</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16064</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>506</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">506</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turner, P. J.</style></author><author><style face="normal" font="default" size="100%">Gretzinger, M.</style></author><author><style face="normal" font="default" size="100%">Patel, N.</style></author><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Chinthrajah, R. S.</style></author><author><style face="normal" font="default" size="100%">Ebisawa, M.</style></author><author><style face="normal" font="default" size="100%">Elizur, A.</style></author><author><style face="normal" font="default" size="100%">Koplin, J. J.</style></author><author><style face="normal" font="default" size="100%">Peters, R. L.</style></author><author><style face="normal" font="default" size="100%">Purington, N.</style></author><author><style face="normal" font="default" size="100%">Nowak-Wegrzyn, A.</style></author><author><style face="normal" font="default" size="100%">Saf, S.</style></author><author><style face="normal" font="default" size="100%">Sampson, H. A.</style></author><author><style face="normal" font="default" size="100%">Westerhout, J.</style></author><author><style face="normal" font="default" size="100%">Blom, W. M.</style></author><author><style face="normal" font="default" size="100%">Baumert, J. L.</style></author><author><style face="normal" font="default" size="100%">Houben, G. F.</style></author><author><style face="normal" font="default" size="100%">Remington, B. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart &amp; Lung Institute, Imperial College London, London, UK.&#xD;Children&apos;s Allergy Service, Evelina Children&apos;s Hospital, Guy&apos;s and St. Thomas&apos; NHS Foundation Hospital, London, UK.&#xD;Department of Paediatric Allergy, King&apos;s College London, London, UK.&#xD;Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.&#xD;Institute of Allergy, Immunology and Pediatric Pulmonology, Yitzhak Shamir Medical Center, Zerifin, Israel.&#xD;Department of Pediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.&#xD;Population Health, The Murdoch Children&apos;s Research Institute, Melbourne, Victoria, Australia.&#xD;Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.&#xD;Department of Medicine, Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.&#xD;Allergy and Immunology, Department of Pediatrics, New York University Langone Health, New York, NY, USA.&#xD;Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.&#xD;Division of Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Allergology-Centre de l&apos;Asthme et des Allergies, Hopital d&apos;Enfants Armand Trousseau, Paris, France.&#xD;TNO, The Netherlands Organisation of Applied Scientific Research, Utrecht, The Netherlands.&#xD;Food Allergy Research and Resource Program, University of Nebraska, Lincoln, Nebraska, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Updated threshold dose-distribution data for sesame</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3124-3162</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2022/05/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sesamum/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35531634</style></accession-num><notes><style face="normal" font="default" size="100%">Turner, Paul J&#xD;Gretzinger, Magdalena&#xD;Patel, Nandinee&#xD;Brough, Helen A&#xD;Chinthrajah, R Sharon&#xD;Ebisawa, Motohiro&#xD;Elizur, Arnon&#xD;Koplin, Jennifer J&#xD;Peters, Rachel L&#xD;Purington, Natasha&#xD;Nowak-Wegrzyn, Anna&#xD;Saf, Sarah&#xD;Sampson, Hugh A&#xD;Westerhout, Joost&#xD;Blom, W Marty&#xD;Baumert, Joseph L&#xD;Houben, Geert F&#xD;Remington, Benjamin C&#xD;eng&#xD;DH_/Department of Health/United Kingdom&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Oct;77(10):3124-3162. doi: 10.1111/all.15364. Epub 2022 May 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35531634</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9790362 Aquestive, and UK Food Standards Agency pe; grants from NIHR/Imperial BRC, UK Medical Research Council, UK Food Standards Agency, Jon Moulton Charity Trust, outside the submitted work. H. Brough declares speaker fees from DBV Technologies and Sanofi, and research grants from NIH (NAIAD), DBV Technologies and Aimmune Therapeutics. S. Chinthrajah reports grants from NIAID, CoFAR, Aimmune Therapeutics, DBV Technologies, Astellas, Regeneron, FARE, Stanford Maternal and Child Health Research Institute (MCHRI); other support from Alladapt Therapeutics, Novartis, Genentech, Sanofi, Allergenis, Nutricia, outside the submitted work. M. Ebisawa reports personal fees from DBV Technologies, Mylan, ARS Pharmaceuticals, outside the submitted work. J. Koplin and R. Peters receive research support from the National Health and Medical Research Council of Australia. A. Nowak-Wegrzyn reports royalty payments from UpToDate; personal fees from the American College of Allergy, Asthma, and Immunology as Deputy Editor of the Annals of Allergy, Asthma, and Immunology; consulting fees from Nestle, Nutricia, Novartis, and Aimmune outside of the submitted work. H. Sampson reports grants from Immune Tolerance Network, NIAID/NIH, personal fees and other support from N-Fold Therapeutics, DBV Technologies, and personal fees from Siolta Therapeutics, outside the submitted work. J Westerhout, WM Blom and GF Houben report financial support from Dutch Governmental TNO Research Cooperation Funds, Netherlands, and the Food Allergy Research and Resource Program (FARRP) of the University of Nebraska, USA. BC Remington reports grants from FARRP, grants and personal fees from DBV Technologies, and travel support from ILSI Europe, outside the submitted work. The other authors declare no competing interests.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15364</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3273</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3273</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Çelik, Gülfem E.</style></author><author><style face="normal" font="default" size="100%">Makowska, Joanna S.</style></author><author><style face="normal" font="default" size="100%">Torres, Maria Jose</style></author><author><style face="normal" font="default" size="100%">Mayorga, Cristobalina</style></author><author><style face="normal" font="default" size="100%">Laidlaw, Tanya M.</style></author><author><style face="normal" font="default" size="100%">Vultaggio, Alessandra</style></author><author><style face="normal" font="default" size="100%">Toppila-Salmi, Sanna</style></author><author><style face="normal" font="default" size="100%">Klimek, Ludger</style></author><author><style face="normal" font="default" size="100%">Gelincik, Aslı</style></author><author><style face="normal" font="default" size="100%">Barbaud, Annick</style></author><author><style face="normal" font="default" size="100%">Garvey, Lene H.</style></author><author><style face="normal" font="default" size="100%">Aydın, Ömür</style></author><author><style face="normal" font="default" size="100%">Eiwegger, Thomas</style></author><author><style face="normal" font="default" size="100%">Woessner, Katharine M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Updated Treatment of Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><dates></dates><isbn><style face="normal" font="default" size="100%">0105-4538</style></isbn><abstract><style face="normal" font="default" size="100%">ABSTRACT Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NSAID-ERD) is a heterogeneous condition characterized by chronic eosinophilic airway inflammation in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma whose symptoms are aggravated after ingestion of aspirin and other NSAIDs. As a unique treatment, aspirin treatment after desensitization (ATAD) has been in use for several years after showing the inhibitory effect on CRS symptoms and nasal polyp growth as well as severe asthma. However, in recent years, biologics have also shown to cause a decrease in polyp size as well as associated outcomes such as quality of life. In this manuscript, considerations on choosing the best treatment of NSAID–ERD are laid out based on current literature.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.70243</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">https://doi.org/10.1111/all.70243</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>325</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">325</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, X.</style></author><author><style face="normal" font="default" size="100%">Reitsma, S.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Fokkens, W. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Otolaryngology - Head &amp; Neck Surgery, National University Hospital, Singapore, Singapore.&#xD;Department of Otorhinolaryngology, Amsterdam University Medical Centers, location AMC, Amsterdam, The Netherlands.&#xD;Department of Otolaryngology, Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and NSAID-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3593-3605</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2022/09/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Nasal Polyps/drug therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis/drug therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Sinusitis/drug therapy/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Respiration Disorders/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">NSAID-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default" size="100%">biologicals</style></keyword><keyword><style face="normal" font="default" size="100%">chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">nasal polyps</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36067036</style></accession-num><abstract><style face="normal" font="default" size="100%">Chronic rhinosinusitis with nasal polyps (CRSwNP) associated with type 2 inflammation and non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) can be difficult to control with standard medical therapy and sinus surgery. In this group, biologicals are potentially promising treatment options. The phase III clinical trials for omalizumab, dupilumab, mepolizumab and benralizumab in CRSwNP have demonstrated favourable outcomes. Moving forward, direct comparisons among biologicals, refining patient selection criteria for specific biologicals, determining optimal treatment duration and monitoring long-term outcomes are areas of emerging interest. This review summarizes the clinical evidence from the recent 2 years on the role of biologicals in severe CRSwNP and N-ERD, and proposes an approach towards decision-making in their use.</style></abstract><notes><style face="normal" font="default" size="100%">Xu, Xinni&#xD;Reitsma, Sietze&#xD;Wang, De Yun&#xD;Fokkens, Wytske J&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Dec;77(12):3593-3605. doi: 10.1111/all.15507. Epub 2022 Sep 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36067036</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15507</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2914</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2914</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Umezawa, K.</style></author><author><style face="normal" font="default" size="100%">Nagata, N.</style></author><author><style face="normal" font="default" size="100%">Kabashima, S.</style></author><author><style face="normal" font="default" size="100%">Inuzuka, Y.</style></author><author><style face="normal" font="default" size="100%">Ogasawara, H.</style></author><author><style face="normal" font="default" size="100%">Shimada, M.</style></author><author><style face="normal" font="default" size="100%">Hamaguchi, S.</style></author><author><style face="normal" font="default" size="100%">Natsume, O.</style></author><author><style face="normal" font="default" size="100%">Fukuie, T.</style></author><author><style face="normal" font="default" size="100%">Shimosawa, T.</style></author><author><style face="normal" font="default" size="100%">Ohya, Y.</style></author><author><style face="normal" font="default" size="100%">Murata, T.</style></author><author><style face="normal" font="default" size="100%">Yamamoto-Hanada, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Center, National Center for Child Health and Development, Tokyo, Japan.&#xD;Department of Animal Radiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.&#xD;Department of Pediatrics, Hamamatsu University School of Medicine, Shizuoka, Japan.&#xD;Department of Clinical Laboratory, International University of Health and Welfare, Chiba, Japan.&#xD;Department of Occupational and Environmental Health, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Alchi, Japan.&#xD;Department of Veterinary Pharmacology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary Prostaglandin Metabolites as Potential Biomarkers for Differentiating IgE-Mediated Food Allergy and Food Protein-Induced Enterocolitis Syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2890-2893</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2025/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">mast cell</style></keyword><keyword><style face="normal" font="default" size="100%">prostaglandin D2</style></keyword><keyword><style face="normal" font="default" size="100%">prostaglandin E2</style></keyword><keyword><style face="normal" font="default" size="100%">prostaglandin F2alpha</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40371994</style></accession-num><notes><style face="normal" font="default" size="100%">Umezawa, Kotaro&#xD;Nagata, Nanae&#xD;Kabashima, Shigenori&#xD;Inuzuka, Yusuke&#xD;Ogasawara, Hisako&#xD;Shimada, Mami&#xD;Hamaguchi, Sayaka&#xD;Natsume, Osamu&#xD;Fukuie, Tatsuki&#xD;Shimosawa, Tatsuo&#xD;Ohya, Yukihiro&#xD;Murata, Takahisa&#xD;Yamamoto-Hanada, Kiwako&#xD;eng&#xD;20H05678/Japan Society for the Promotion of Science/&#xD;25H00430/Japan Society for the Promotion of Science/&#xD;22K08575/Japan Society for the Promotion of Science/&#xD;23K24424/Japan Society for the Promotion of Science/&#xD;National Center for Child Health and Development/&#xD;Nipponham Foundation for the Future of Food/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Oct;80(10):2890-2893. doi: 10.1111/all.16589. Epub 2025 May 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40371994</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16589</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>349</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">349</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Makiya, M. A.</style></author><author><style face="normal" font="default" size="100%">Khoury, P.</style></author><author><style face="normal" font="default" size="100%">Kuang, F. L.</style></author><author><style face="normal" font="default" size="100%">Mata, A. D.</style></author><author><style face="normal" font="default" size="100%">Mahmood, S.</style></author><author><style face="normal" font="default" size="100%">Bowman, A.</style></author><author><style face="normal" font="default" size="100%">Espinoza, D.</style></author><author><style face="normal" font="default" size="100%">Kovacs, N.</style></author><author><style face="normal" font="default" size="100%">Brown, T.</style></author><author><style face="normal" font="default" size="100%">Holland, N.</style></author><author><style face="normal" font="default" size="100%">Wetzler, L.</style></author><author><style face="normal" font="default" size="100%">Ware, J. M.</style></author><author><style face="normal" font="default" size="100%">Dyer, A. M.</style></author><author><style face="normal" font="default" size="100%">Akuthota, P.</style></author><author><style face="normal" font="default" size="100%">Bochner, B. S.</style></author><author><style face="normal" font="default" size="100%">Chinchilli, V. M.</style></author><author><style face="normal" font="default" size="100%">Gleich, G. J.</style></author><author><style face="normal" font="default" size="100%">Langford, C.</style></author><author><style face="normal" font="default" size="100%">Merkel, P. A.</style></author><author><style face="normal" font="default" size="100%">Specks, U.</style></author><author><style face="normal" font="default" size="100%">Weller, P. F.</style></author><author><style face="normal" font="default" size="100%">Wechsler, M. E.</style></author><author><style face="normal" font="default" size="100%">Prussin, C.</style></author><author><style face="normal" font="default" size="100%">Fay, M. P.</style></author><author><style face="normal" font="default" size="100%">Klion, A. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Human Eosinophil Section, LPD, NIAID, NIH, Bethesda, Maryland, USA.&#xD;Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.&#xD;Clinical Parasitology Section, LPD, NIAID, NIH, Bethesda, Maryland, USA.&#xD;Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.&#xD;Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla, California, USA.&#xD;Departments of Dermatology and Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.&#xD;Rheumatologic and Immunologic Disease, Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA.&#xD;Division of Rheumatology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.&#xD;Department of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.&#xD;Department of Medicine, National Jewish Health, Denver, Colorado, USA.&#xD;Knopp Biosciences, Pittsburgh, Pennsylvania, USA.&#xD;Biostatistical Research Branch, NIAID, NIH, Bethesda, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urine eosinophil-derived neurotoxin: A potential marker of activity in select eosinophilic disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">258-269</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/08/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophil-Derived Neurotoxin</style></keyword><keyword><style face="normal" font="default" size="100%">*Churg-Strauss Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Prednisone</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">*Granulomatosis with Polyangiitis</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">benralizumab</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil granule protein</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">hypereosinophilic syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35971862</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Biomarkers of eosinophilic disease activity, especially in the context of novel therapies that reduce blood eosinophil counts, are an unmet need. Absolute eosinophil count (AEC) does not accurately reflect tissue eosinophilia or eosinophil activation. Therefore, the aims of this study were to compare the reliability of plasma and urine eosinophil major basic protein 1, eosinophil cationic protein, eosinophil-derived neurotoxin (EDN), and eosinophil peroxidase measurement and to evaluate the usefulness of eosinophil granule protein (EGP) measurement for the assessment of disease activity in patients with eosinophil-associated diseases treated with mepolizumab, benralizumab, or dexpramipexole. METHODS: Eosinophil granule protein concentrations were measured in serum, plasma, and urine from healthy volunteers and patients with hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA), and eosinophilic asthma using a multiplex assay. RESULTS: Urine EGP concentrations remained stable, whereas serum and plasma EGP concentrations increased significantly with delayed processing. Plasma (p) EDN, but not urine (u) EDN, concentration correlated with AEC and negatively correlated with prednisone dose. Both pEDN and uEDN decreased significantly following treatment of HES patients with benralizumab and EGPA patients with mepolizumab. uEDN appeared to increase with clinical relapse in both patient groups. CONCLUSIONS: Measurement of EGP in urine is noninvasive and unaffected by cellular lysis. Although plasma and urine EDN concentrations showed a similar pattern following benralizumab and mepolizumab treatment, the lack of correlation between AEC or prednisone dose and uEDN concentrations suggests that measurement of uEDN may provide a potential biomarker of disease activity in patients with HES and EGPA.</style></abstract><notes><style face="normal" font="default" size="100%">Makiya, Michelle A&#xD;Khoury, Paneez&#xD;Kuang, Fei Li&#xD;Mata, Alexis Dominique&#xD;Mahmood, Sana&#xD;Bowman, Abbie&#xD;Espinoza, David&#xD;Kovacs, Nicholas&#xD;Brown, Thomas&#xD;Holland, Nicole&#xD;Wetzler, Lauren&#xD;Ware, JeanAnne M&#xD;Dyer, Anne-Marie&#xD;Akuthota, Praveen&#xD;Bochner, Bruce S&#xD;Chinchilli, Vernon M&#xD;Gleich, Gerald J&#xD;Langford, Carol&#xD;Merkel, Peter A&#xD;Specks, Ulrich&#xD;Weller, Peter F&#xD;Wechsler, Michael E&#xD;Prussin, Calman&#xD;Fay, Michael P&#xD;Klion, Amy D&#xD;eng&#xD;R21 AI159586/AI/NIAID NIH HHS/&#xD;U01 AI097073/AI/NIAID NIH HHS/&#xD;U19 AI136443/AI/NIAID NIH HHS/&#xD;ZIA AI001130/ImNIH/Intramural NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):258-269. doi: 10.1111/all.15481. Epub 2022 Sep 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35971862</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11452843</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15481</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>386</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">386</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anvari, S.</style></author><author><style face="normal" font="default" size="100%">Samarakoon, U.</style></author><author><style face="normal" font="default" size="100%">Fu, X.</style></author><author><style face="normal" font="default" size="100%">Jaggers, J.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Estrada, A.</style></author><author><style face="normal" font="default" size="100%">Chong, H. J.</style></author><author><style face="normal" font="default" size="100%">Van Meerbeke, S. W.</style></author><author><style face="normal" font="default" size="100%">Petrov, A. A.</style></author><author><style face="normal" font="default" size="100%">Khan, D. A.</style></author><author><style face="normal" font="default" size="100%">Freeman, E. E.</style></author><author><style face="normal" font="default" size="100%">Banerji, A.</style></author><author><style face="normal" font="default" size="100%">Blumenthal, K. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Immunology, Allergy, and Retrovirology, Department of Pediatrics, Baylor College of Medicine, Texas Children&apos;s Hospital, Houston, Texas, USA.&#xD;Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;Division of Pulmonary, Allergy, and Sleep Medicine, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.&#xD;Division of Allergy and Immunology, University of Pittsburgh Medical Center Children&apos;s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.&#xD;Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.&#xD;Division of Allergy and Immunology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.&#xD;Harvard Medical School, Boston, Massachusetts, USA.&#xD;Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.&#xD;The Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urticaria and/or angioedema secondary to mRNA COVID-19 vaccines: Updates from a United States case registry</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">283-286</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/07/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Angioedema/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35842747</style></accession-num><notes><style face="normal" font="default" size="100%">Anvari, Sara&#xD;Samarakoon, Upeka&#xD;Fu, Xiaoqing&#xD;Jaggers, Jordan&#xD;Gonzalez-Estrada, Alexei&#xD;Chong, Hey Jin&#xD;Van Meerbeke, Sara W&#xD;Petrov, Andrej A&#xD;Khan, David A&#xD;Freeman, Esther E&#xD;Banerji, Aleena&#xD;Blumenthal, Kimberly G&#xD;eng&#xD;K01 AI125631/AI/NIAID NIH HHS/&#xD;UM2 AI130836/AI/NIAID NIH HHS/&#xD;R01 HS025375/HS/AHRQ HHS/&#xD;R01 AI150295/AI/NIAID NIH HHS/&#xD;R01 AI135197/AI/NIAID NIH HHS/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):283-286. doi: 10.1111/all.15447. Epub 2022 Aug 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35842747</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9349391</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15447</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2197</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2197</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salameh, P.</style></author><author><style face="normal" font="default" size="100%">Gutsche, A.</style></author><author><style face="normal" font="default" size="100%">Aulenbacher, F.</style></author><author><style face="normal" font="default" size="100%">Buttgereit, T.</style></author><author><style face="normal" font="default" size="100%">Weller, K.</style></author><author><style face="normal" font="default" size="100%">Siebenhaar, F.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.&#xD;School of Medicine, Lebanese American University, Byblos, Lebanon.&#xD;Institut National de Sante Publique d&apos;Epidemiologie Clinique et de Toxicologie-Liban (INSPECT-LB), Beirut, Lebanon.&#xD;Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urticaria Control Test real-world performance: A post-hoc analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">229-232</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2023/07/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/diagnosis/etiology/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37439320</style></accession-num><notes><style face="normal" font="default" size="100%">Salameh, Pascale&#xD;Gutsche, Annika&#xD;Aulenbacher, Felix&#xD;Buttgereit, Thomas&#xD;Weller, Karsten&#xD;Siebenhaar, Frank&#xD;Maurer, Marcus&#xD;eng&#xD;Letter&#xD;Denmark&#xD;Allergy. 2024 Jan;79(1):229-232. doi: 10.1111/all.15813. Epub 2023 Jul 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37439320</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15813</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2469</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2469</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alkotob, S.</style></author><author><style face="normal" font="default" size="100%">Begin, P.</style></author><author><style face="normal" font="default" size="100%">Anagnostou, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Section of Immunology Allergy and Retrovirology, Texas Children&apos;s Hospital, Houston, Texas, USA.&#xD;Section of Allergy Immunology &amp; Retrovirology, Baylor College of Medicine, Houston, Texas, USA.&#xD;Department of Pediatrics, Section of Allergy, CHU Sainte-Justine, Montreal, Quebec, Canada.&#xD;Department of Medicine, Division of Allergy &amp; Immunology, Centre Hospitalier de l&apos;Universite de Montreal, Montreal, Quebec, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The use of omalizumab in food allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2888-2889</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2024/04/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/immunology/blood</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food challenge</style></keyword><keyword><style face="normal" font="default" size="100%">multifood</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword><keyword><style face="normal" font="default" size="100%">threshold</style></keyword><keyword><style face="normal" font="default" size="100%">tolerance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">38676406</style></accession-num><notes><style face="normal" font="default" size="100%">Alkotob, Shifaa&#xD;Begin, Philippe&#xD;Anagnostou, Aikaterini&#xD;eng&#xD;News&#xD;Denmark&#xD;Allergy. 2024 Oct;79(10):2888-2889. doi: 10.1111/all.16145. Epub 2024 Apr 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/38676406</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16145</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2997</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2997</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tontini, C.</style></author><author><style face="normal" font="default" size="100%">Radzikowska, U.</style></author><author><style face="normal" font="default" size="100%">Aranda, C. J.</style></author><author><style face="normal" font="default" size="100%">Tynecka, M.</style></author><author><style face="normal" font="default" size="100%">Dolset, M. I. D.</style></author><author><style face="normal" font="default" size="100%">Eljaszewicz, A.</style></author><author><style face="normal" font="default" size="100%">Cornejo-Garcia, J. A.</style></author><author><style face="normal" font="default" size="100%">Villasenor, A.</style></author><author><style face="normal" font="default" size="100%">Ariza, A.</style></author><author><style face="normal" font="default" size="100%">Contreras, N.</style></author><author><style face="normal" font="default" size="100%">Lopez-Rodriguez, J. C.</style></author><author><style face="normal" font="default" size="100%">Karaguzel, D.</style></author><author><style face="normal" font="default" size="100%">Lozano-Ojalvo, D.</style></author><author><style face="normal" font="default" size="100%">Castagnoli, R.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Sokolowska, M.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Hilger, C.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Pfaar, O.</style></author><author><style face="normal" font="default" size="100%">Barber, D.</style></author><author><style face="normal" font="default" size="100%">Escribese, M. M.</style></author><author><style face="normal" font="default" size="100%">Karaaslan, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.&#xD;Allergy Unit and Research Group, Hospital Regional Universitario de Malaga and IBIMA-Plataforma BIONAND, RICORS Inflammatory Diseases, Malaga, Spain.&#xD;Centre of Regenerative Medicine, Medical University of Bialystok, Bialystok, Poland.&#xD;Centro de Metabolomica y Bioanalisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain.&#xD;Departamento de Ciencias Medicas Basicas, Facultad de Medicina, Instituto de Medicina Molecular Aplicada-Nemesio Diez (IMMA-ND), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.&#xD;Molecular Biology Section, Department of Biology, Faculty of Science, Hacettepe University, Ankara, Turkey.&#xD;Instituto de Investigacion en Ciencias de la Alimentacion (CIAL, CSIC), Madrid, Spain.&#xD;Pediatric Unit, Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.&#xD;Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.&#xD;Department of Infection &amp; Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.&#xD;Department of Dermatology and Allergy Center, Odense University Hospital, University of Southern Denmark, Odense, Denmark.&#xD;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universitat Marburg, Marburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Use of Omics Sciences in Allergic Diseases From Bench to Bedside: An EAACI Position Paper</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2442-2483</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2025/07/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/diagnosis/metabolism/therapy/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Metabolomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Genomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Translational Research, Biomedical</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">drug allergy</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">omics</style></keyword><keyword><style face="normal" font="default" size="100%">precision medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40600338</style></accession-num><abstract><style face="normal" font="default" size="100%">Omics have revolutionized our understanding of allergic diseases, with increasingly more studies adopting techniques like genomics, proteomics, and metabolomics over the years. Integrating high-dimensional omics data with clinical features can enable more precise disease classification and biomarker identification, leading to improved disease management and the development of novel therapies. However, translating these discoveries into clinical practice remains a challenge. In this European Academy of Allergy and Clinical Immunology (EAACI) Position Paper, the Task Force (TF) &quot;The Use of Omics Sciences in Asthma and Allergy Clinical Practice&quot; performed a broad review of recent papers where omics technologies were used in the context of clinical studies and provided a summary of relevant findings in the field of asthma, atopic dermatitis, allergic rhinitis, food allergy and drug hypersensitivity reactions. Particular attention was dedicated to studies investigating overlapping diseases/co-morbidities, revealing unique and shared signatures that could guide future therapeutic and research efforts. Furthermore, current hurdles in translating findings from bench to bedside were explained, and possible solutions were offered. With this position paper, the TF aims to assist researchers and clinicians by providing an overview of the investigations performed to date, highlighting gaps in research, limitations, and avenues for further exploration in clinical practice.</style></abstract><notes><style face="normal" font="default" size="100%">Tontini, Chiara&#xD;Radzikowska, Urszula&#xD;Aranda, Carlos J&#xD;Tynecka, Marlena&#xD;Dolset, Maria Isabel Delgado&#xD;Eljaszewicz, Andrzej&#xD;Cornejo-Garcia, Jose Antonio&#xD;Villasenor, Alma&#xD;Ariza, Adriana&#xD;Contreras, Nuria&#xD;Lopez-Rodriguez, Juan C&#xD;Karaguzel, Dilara&#xD;Lozano-Ojalvo, Daniel&#xD;Castagnoli, Riccardo&#xD;Eguiluz-Gracia, Ibon&#xD;Sokolowska, Milena&#xD;Mayorga, Cristobalina&#xD;Hilger, Christiane&#xD;Mortz, Charlotte G&#xD;Pfaar, Oliver&#xD;Barber, Domingo&#xD;Escribese, Maria M&#xD;Karaaslan, Cagatay&#xD;eng&#xD;European Academy of Allergy and Clinical Immunology (EAACI) under the EAACI Task Force &quot;The Use of Omics Sciences in Asthma and Allergy Clinical Practice&quot;/&#xD;Consensus Development Conference&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Sep;80(9):2442-2483. doi: 10.1111/all.16638. Epub 2025 Jul 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40600338</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16638</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1251</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1251</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alvarado-Vazquez, P. A.</style></author><author><style face="normal" font="default" size="100%">Mendez-Enriquez, E.</style></author><author><style face="normal" font="default" size="100%">Hallgren, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Use of spirometry-like measurements to monitor house dust mite-induced experimental asthma in mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2204-2207</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/12/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Mites</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Spirometry</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite</style></keyword><keyword><style face="normal" font="default" size="100%">lung function</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">mouse model</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33263946</style></accession-num><notes><style face="normal" font="default" size="100%">Alvarado-Vazquez, Perla A&#xD;Mendez-Enriquez, Erika&#xD;Hallgren, Jenny&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2204-2207. doi: 10.1111/all.14681. Epub 2020 Dec 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33263946</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8359446</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14681</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1355</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1355</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kraft, M.</style></author><author><style face="normal" font="default" size="100%">Gebauer, J.</style></author><author><style face="normal" font="default" size="100%">Dolle-Bierke, S.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.&#xD;adesso SE, Dortumund, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Usefulness of an artificial neural network to assess anaphylaxis severity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1244-1246</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/08/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">*Anaphylaxis/diagnosis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Networks, Computer</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">anaphylaxis severity</style></keyword><keyword><style face="normal" font="default" size="100%">artificial intelligence</style></keyword><keyword><style face="normal" font="default" size="100%">artificial neuronal network</style></keyword><keyword><style face="normal" font="default" size="100%">machine learning</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32789872</style></accession-num><notes><style face="normal" font="default" size="100%">Kraft, Magdalena&#xD;Gebauer, Johannes&#xD;Dolle-Bierke, Sabine&#xD;Worm, Margitta&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1244-1246. doi: 10.1111/all.14560. Epub 2020 Sep 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32789872</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14560</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2698</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2698</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sicherer, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, Jaffe Food Allergy Institute, Kravis Children&apos;s Hospital, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ushering in a new era in food allergy management with EAACI guidelines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7-8</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/10/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anti-IgE</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">management</style></keyword><keyword><style face="normal" font="default" size="100%">threshold</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39367658</style></accession-num><notes><style face="normal" font="default" size="100%">Sicherer, Scott H&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):7-8. doi: 10.1111/all.16350. Epub 2024 Oct 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39367658</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16350</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1944</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1944</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lamanna, E.</style></author><author><style face="normal" font="default" size="100%">Conde, E.</style></author><author><style face="normal" font="default" size="100%">Mougel, A.</style></author><author><style face="normal" font="default" size="100%">Bonnefoy, J.</style></author><author><style face="normal" font="default" size="100%">Colaone, F.</style></author><author><style face="normal" font="default" size="100%">Godon, O.</style></author><author><style face="normal" font="default" size="100%">Hamdi, S.</style></author><author><style face="normal" font="default" size="100%">Kamphuis, J. B. J.</style></author><author><style face="normal" font="default" size="100%">Drouet, B.</style></author><author><style face="normal" font="default" size="100%">Serra, V.</style></author><author><style face="normal" font="default" size="100%">Bruhns, P.</style></author><author><style face="normal" font="default" size="100%">Reber, L. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut Pasteur, Universite de Paris Cite, Inserm UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris, France.&#xD;Neovacs SA, Suresnes, France.&#xD;Sorbonne Universite, College Doctoral, Paris, France.&#xD;Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A vaccine targeting human IL-4 and IL-13 protects against asthma in humanized mice</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2028-2031</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/02/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-13</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-4</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36799426</style></accession-num><notes><style face="normal" font="default" size="100%">Lamanna, Emma&#xD;Conde, Eva&#xD;Mougel, Aurelie&#xD;Bonnefoy, Jonathan&#xD;Colaone, Fabien&#xD;Godon, Ophelie&#xD;Hamdi, Samir&#xD;Kamphuis, Jasper B J&#xD;Drouet, Beatrice&#xD;Serra, Vincent&#xD;Bruhns, Pierre&#xD;Reber, Laurent L&#xD;eng&#xD;ERC_/European Research Council/International&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2028-2031. doi: 10.1111/all.15680. Epub 2023 Mar 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36799426</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15680</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2870</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2870</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gharailoo, Z.</style></author><author><style face="normal" font="default" size="100%">Vogel, M.</style></author><author><style face="normal" font="default" size="100%">Engeroff, P.</style></author><author><style face="normal" font="default" size="100%">Bachmann, M. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, University Clinic for Rheumatology and Immunology, University of Bern, Bern, Switzerland.&#xD;Department of Biomedical Research Bern (DBMR), University of Bern, Bern, Switzerland.&#xD;Graduate School for Cellular and Biomedical Sciences (GCB), Bern, Switzerland.&#xD;Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vaccine-Induced Anti-IgE Antibodies Neutralize Free IgE but Fail to Bind and Activate Mast Cell-Displayed IgE</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1995-2007</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/04/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin E/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Mast Cells/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Anti-Idiotypic/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccines/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">*Antibodies, Neutralizing/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgE/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Binding</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, IgG/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">VLPs</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">anti-IgE IgG</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">M.F.B. is a co-founder of Saiba AG, which has out-licensed vaccine development of</style></keyword><keyword><style face="normal" font="default" size="100%">CuMV(TT) to ATLp within allergy and other disease indications. All other authors</style></keyword><keyword><style face="normal" font="default" size="100%">declare no conflicts of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40192411</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In Type I hypersensitivity, IgE is the antibody that contributes to the onset of anaphylaxis through the activation of effector cells, causing the release of allergic mediators. Blocking IgE activity with anti-IgE autoantibodies induced by active immunization could potentially offer an efficient and cost-effective method to treat allergic disorders. We recently developed an effective and safe anti-IgE vaccine in mice, but the mechanisms by which the vaccine protects and the explanation for its safety remained largely unknown. Here, our objective was to better understand those mechanisms. METHODS: CuMV(TT)-Cepsilon3-Cepsilon4 is a virus-like particles (VLP)-based vaccine designed to target domains 3 and 4 of IgE. Here, we studied the role of FcgammaRIIb and CD23 in vaccine-mediated protection from allergy using FcgammaRIIb KO and CD23 KO mice. Moreover, vaccine-induced IgGs were purified for passive immunization studies and for in vitro experiments with murine bone marrow-derived mast cells (BMMCs). RESULTS: Immunized mice generated high titers of IgG antibodies specific for IgE that conferred protection against allergic responses, independently of FcgammaRIIb and CD23. Sera of immunized mice blocked IgE binding to BMMC FcepsilonRI and suppressed degranulation, independent of FcgammaRIIb. Purified anti-IgE antibodies did not provoke an anaphylactic response when transferred into allergic mice but protected against subsequent allergen challenge. Interestingly, the purified IgG antibodies were unable to recognize receptor-bound IgE in BMMCs, explained by the finding that recognition by these anti-IgEs depends on the same mannose moieties on IgE that are essential for FcepsilonRI binding and thus hidden when receptor-bound. CONCLUSIONS: In conclusion, the CuMV(TT)-Cepsilon3-Cepsilon4 vaccine induces high titers of anti-IgE IgGs that confer protection by neutralizing IgE through its glycan epitopes, without causing FcepsilonRI cross-linking. Our results imply that an anti-IgE vaccine may represent a promising therapeutic strategy, offering effective protection while minimizing the risk of adverse reactions similar to the monoclonal antibody omalizumab.</style></abstract><notes><style face="normal" font="default" size="100%">Gharailoo, Zahra&#xD;Vogel, Monique&#xD;Engeroff, Paul&#xD;Bachmann, Martin F&#xD;eng&#xD;Novartis Stiftung fur Medizinisch-Biologische Forschung/&#xD;310030_185114/Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung/&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):1995-2007. doi: 10.1111/all.16530. Epub 2025 Apr 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40192411</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261873</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16530</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>347</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">347</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zemelka-Wiacek, M.</style></author><author><style face="normal" font="default" size="100%">Kosowska, A.</style></author><author><style face="normal" font="default" size="100%">Winiarska, E.</style></author><author><style face="normal" font="default" size="100%">Sobanska, E.</style></author><author><style face="normal" font="default" size="100%">Jutel, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.&#xD;ALL-MED Medical Research Institute, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Validated allergen exposure chamber is plausible tool for the assessment of house dust mite-triggered allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">168-177</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/08/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Perennial/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Pyroglyphidae</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Dust</style></keyword><keyword><style face="normal" font="default" size="100%">acoustic rhinometry</style></keyword><keyword><style face="normal" font="default" size="100%">allergen challenge</style></keyword><keyword><style face="normal" font="default" size="100%">allergen exposure chamber</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">house dust mite</style></keyword><keyword><style face="normal" font="default" size="100%">Allergy Therapeutics, Leti, HAL, GSK, Novartis, Teva, Takeda, and Chiesi. All</style></keyword><keyword><style face="normal" font="default" size="100%">other authors declare no conflict of interest.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35980665</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allergen exposure chamber (AEC) is a clinical facility that allows exposure to allergenic airborne particles in controlled environment. Although AECs offer stable levels of airborne allergens, the validation of symptoms and other endpoints induced by allergen challenge is key for their recommendation as a plausible tool for the assessment of patients, especially in clinical research. This study aimed to demonstrate the reproducibility of defined clinical endpoints after AEC house dust mite (HDM) challenge under optimal conditions in patients with allergic rhinitis (AR). METHOD: HDM was distributed at different concentrations. The assessment was subjective by the patients: total nasal symptom score (TNSS), visual analog scale (VAS), and objective by the investigator: acoustic rhinometry, peak nasal inspiratory flow (PNIF), and nasal secretion weight. Safety was assessed clinically and by peak expiratory flow rate (PEFR) and forced expiratory volume in the first second (FEV(1) ). RESULTS: Constant environment: temperature, humidity, and carbon dioxide (CO(2) ) concentration were maintained during all challenges. The concentration of HDM on average remained stable within the targeted values: 1000, 3000, 5000, 7000 particles (p)/m(3) . Most symptoms were observed at concentrations 3000 p/m(3) or higher. The symptoms severity and other endpoints results were reproducible. 5000 p/m(3) , and challenge duration of 120 min were found optimal. The procedure was safe with no lung function abnormalities due to challenge. CONCLUSION: HDM challenge in ALL-MED AEC offers a safe and reliable method for inducing symptoms in AR patients for the use in controlled clinical studies including allergen immunotherapy.</style></abstract><notes><style face="normal" font="default" size="100%">Zemelka-Wiacek, Magdalena&#xD;Kosowska, Anna&#xD;Winiarska, Ewa&#xD;Sobanska, Ewa&#xD;Jutel, Marek&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):168-177. doi: 10.1111/all.15485. Epub 2022 Sep 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35980665</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC10087469</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15485</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2989</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2989</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Seys, S. F.</style></author><author><style face="normal" font="default" size="100%">Gherasim, A.</style></author><author><style face="normal" font="default" size="100%">Odul, F.</style></author><author><style face="normal" font="default" size="100%">Dietsch, F.</style></author><author><style face="normal" font="default" size="100%">Diamant, Z.</style></author><author><style face="normal" font="default" size="100%">Gevaert, P.</style></author><author><style face="normal" font="default" size="100%">Hellings, P. W.</style></author><author><style face="normal" font="default" size="100%">Loeckx, D.</style></author><author><style face="normal" font="default" size="100%">Gorris, S.</style></author><author><style face="normal" font="default" size="100%">de Blay, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hippo Dx, Aarschot, Belgium.&#xD;Centre de Recherche Clinique ALYATEC, Strasbourg, France.&#xD;Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology &amp; Transplantation, KU Leuven, Leuven, Belgium.&#xD;Department of Clinical Pharmacy and Pharmacology, Univ Groningen, Univ Med Ctr Groningen, Groningen, the Netherlands.&#xD;Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.&#xD;Department of Otorhinolaryngology, Upper Airways Research Laboratory, Ghent University, Ghent, Belgium.&#xD;Department of Otorhinolaryngology-Head and Neck Surgery, UZ Leuven, Leuven, Belgium.&#xD;Department of Otorhinolaryngology, AZ Herentals, Herentals, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Validation of the Skin Prick Automated Test (SPAT) Cut-Off Value in Birch Pollen and House Dust Mite Allergic Rhinitis Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3302-3309</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2025/07/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Skin Tests/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Betula/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyroglyphidae/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Pollen/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Allergens/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/diagnosis/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">IgE-mediated hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Spat</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Prick Automated Test</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">skin prick test</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40631983</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: A novel device, Skin Prick Automated Test (SPAT), previously showed reduced variability and more consistent test results compared to conventional skin prick test (SPT) to identify allergic sensitisation. This study aimed to clinically validate the adjusted SPAT cut-off in patients with confirmed birch or house dust mite (HDM) allergy. METHODS: Seventy-five adults were included: 25 non-allergic subjects (confirmed by lack of allergy history and negative SPT), 25 birch and 25 HDM allergic rhinitis patients (both confirmed by positive SPT and nasal allergen challenge [NAC]). All subjects received a conventional SPT and an automated SPT for B ver, D pter, D far and control solutions. RESULTS: A cut-off of 4.2 and 4.1 mm, respectively, resulted in the highest accuracy to detect birch or HDM allergy using SPAT. Referring to previous study results suggesting a reliable cut-off value of 4.5 mm, it was decided to maintain 4.5 mm as SPAT cut-off indicating allergic sensitisation. Accuracy did not significantly differ between SPAT (96% using &gt;/= 4.5 mm) and conventional SPT (98% using &gt;/= 3.0 mm) to detect HDM allergy or to detect birch pollen allergy (100% for SPAT and SPT). SPAT wheal measurements performed through a ruler on the forearm or through digital measurement on a composite image did not significantly differ for any of the patient groups analysed. CONCLUSION: SPAT showed an equivalent accuracy to detect birch pollen or HDM allergy compared to conventional SPT, using the adjusted 4.5 mm SPAT cut-off in patients with confirmed allergic rhinitis. The SPAT web viewer can be used easily and effectively for digital wheal measurement on a composite image.</style></abstract><notes><style face="normal" font="default" size="100%">Seys, Sven F&#xD;Gherasim, Alina&#xD;Odul, Florian&#xD;Dietsch, Frank&#xD;Diamant, Zuzana&#xD;Gevaert, Philippe&#xD;Hellings, Peter W&#xD;Loeckx, Dirk&#xD;Gorris, Senne&#xD;de Blay, Frederic&#xD;eng&#xD;Hippo Dx/&#xD;Validation Study&#xD;Denmark&#xD;Allergy. 2025 Dec;80(12):3302-3309. doi: 10.1111/all.16645. Epub 2025 Jul 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40631983</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16645</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2676</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2676</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sousa-Pinto, B.</style></author><author><style face="normal" font="default" size="100%">Ramanauskaite, A.</style></author><author><style face="normal" font="default" size="100%">Neisinger, S.</style></author><author><style face="normal" font="default" size="100%">Witte-Handel, E.</style></author><author><style face="normal" font="default" size="100%">Gimenez-Arnau, A. M.</style></author><author><style face="normal" font="default" size="100%">Guillet, C.</style></author><author><style face="normal" font="default" size="100%">Parisi, C. A. S.</style></author><author><style face="normal" font="default" size="100%">Katelaris, C. H.</style></author><author><style face="normal" font="default" size="100%">Fomina, D.</style></author><author><style face="normal" font="default" size="100%">Larenas-Linnemann, D.</style></author><author><style face="normal" font="default" size="100%">Garcia, E.</style></author><author><style face="normal" font="default" size="100%">Kocaturk, E.</style></author><author><style face="normal" font="default" size="100%">Siebenhaar, F.</style></author><author><style face="normal" font="default" size="100%">Lima, H.</style></author><author><style face="normal" font="default" size="100%">Kaidashev, I.</style></author><author><style face="normal" font="default" size="100%">Nasr, I.</style></author><author><style face="normal" font="default" size="100%">Canales, I. O.</style></author><author><style face="normal" font="default" size="100%">Ojeda, I. C.</style></author><author><style face="normal" font="default" size="100%">Hebert, J.</style></author><author><style face="normal" font="default" size="100%">Bousquet, J.</style></author><author><style face="normal" font="default" size="100%">Bernstein, J. A.</style></author><author><style face="normal" font="default" size="100%">Peter, J.</style></author><author><style face="normal" font="default" size="100%">Sanchez, J.</style></author><author><style face="normal" font="default" size="100%">Sousa, J. I. L.</style></author><author><style face="normal" font="default" size="100%">Kulthanan, K.</style></author><author><style face="normal" font="default" size="100%">Weller, K.</style></author><author><style face="normal" font="default" size="100%">Godse, K.</style></author><author><style face="normal" font="default" size="100%">Rutkowski, K.</style></author><author><style face="normal" font="default" size="100%">Lapina, L.</style></author><author><style face="normal" font="default" size="100%">Bouillet, L.</style></author><author><style face="normal" font="default" size="100%">Han, L. L.</style></author><author><style face="normal" font="default" size="100%">Ensina, L. F.</style></author><author><style face="normal" font="default" size="100%">Goncalo, M.</style></author><author><style face="normal" font="default" size="100%">Magerl, M.</style></author><author><style face="normal" font="default" size="100%">van Doorn, M.</style></author><author><style face="normal" font="default" size="100%">Metz, M.</style></author><author><style face="normal" font="default" size="100%">Khoshkhui, M.</style></author><author><style face="normal" font="default" size="100%">Hide, M.</style></author><author><style face="normal" font="default" size="100%">Turk, M.</style></author><author><style face="normal" font="default" size="100%">Kurjane, N.</style></author><author><style face="normal" font="default" size="100%">Conlon, N.</style></author><author><style face="normal" font="default" size="100%">Salameh, P.</style></author><author><style face="normal" font="default" size="100%">Kolkhir, P.</style></author><author><style face="normal" font="default" size="100%">Asero, R.</style></author><author><style face="normal" font="default" size="100%">Stepanenko, R.</style></author><author><style face="normal" font="default" size="100%">Altrichter, S.</style></author><author><style face="normal" font="default" size="100%">Gil-Mata, S.</style></author><author><style face="normal" font="default" size="100%">Thomsen, S. F.</style></author><author><style face="normal" font="default" size="100%">Zuberbier, T.</style></author><author><style face="normal" font="default" size="100%">Tsaryk, V.</style></author><author><style face="normal" font="default" size="100%">Ye, Y. M.</style></author><author><style face="normal" font="default" size="100%">Brzoza, Z.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z.</style></author><author><style face="normal" font="default" size="100%">Maurer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.&#xD;CINTESIS-Center for Health Technology and Services Research, University of Porto, Porto, Portugal.&#xD;RISE-Health Research Network, University of Porto, Porto, Portugal.&#xD;Institute of Allergology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.&#xD;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.&#xD;Department of Dermatology, Urticaria Center of Reference, and Excellence (UCARE), Hospital del Mar, IMIM, Universitat Pompeu Fabra, Barcelona, Spain.&#xD;Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Adult and Pediatric Allergy Sections of the Italian Hospital of Buenos Aires, Buenos Aires, Argentina.&#xD;Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney, New South Wales, Australia.&#xD;Moscow City Research and Practical Center of Allergoloy and Immunology, Clinical Hospital No 52, Moscow Healthcare Department, Angioedema/Urticaria Center of Reference and Excellence (ACARE, UCARE), Moscow, Russia.&#xD;Department of Clinical Immunology and Allergology, I.M., Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.&#xD;Department of Pulmonology, Astana Medical University, Astana, Kazakhstan.&#xD;Center of Excellence in Asthma and Allergy Larenas Hospital Medica Sur, Mexico City, Mexico.&#xD;Faculty of Medicine, Universidad de los Andes, Allergy Section, Fundacion Santa Fe de Bogota, UNIMEQ ORL, Bogota, Colombia.&#xD;Department of Dermatology, Urticaria Center of Reference, and Excellence (UCARE), Koc University School of Medicine, Istanbul, Turkey.&#xD;LEADER Research Inc. and Division of Allergy and Clinic Immunology (UCARE), Medicine Department, McMaster University, Hamilton, Ontario, Canada.&#xD;Poltava State Medical University, Poltava, Ukraine.&#xD;Department of Clinical Immunology and Allergy, Royal Hospital, Muscat, Oman.&#xD;Department of Dermatology, Faculty of Medicine, Pontifical Catholic University of Chile, Santiago, Chile.&#xD;University Dermatological Center (DermaCDU), Las Condes, Chile.&#xD;Unit of Dermatology, Rancagua Regional Hospital, Rancagua, Chile.&#xD;Universidad Espiritu Santo, Samborondon, Ecuador, Respiralab Research Center, Guayaquil, Ecuador.&#xD;Service d&apos;allergie, Centre Hospitalier Universite Laval/Centre Hospitalier Universitaire de Quebec, Quebec, Quebec, Canada.&#xD;Division of Rheumatology, Allergy and Immunology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.&#xD;ACARE Centre, Division of Allergy and Clinical Immunology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.&#xD;Allergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa.&#xD;Group of Clinical and Experimental Allergy, Hospital &quot;Alma Mater de Antioquia,&quot; University of Antioquia, Medellin, Colombia.&#xD;Department of Allergy, UCARE, Clinica San Felipe, Lima, Peru.&#xD;Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Department of Dermatology, Dr D Y Patil Medical College and Hospital, Navi Mumbai, India.&#xD;Urticaria Clinic, St John&apos;s Institute of Dermatology, Guy&apos;s and St Thomas&apos; Hospital, London, UK.&#xD;Allergic Diseases Diagnosis and Treatment Center, Riga Stradins University, Pauls Stradins Clinical University Hospital, Riga, Latvia.&#xD;French national Reference Center for Angioedema (CREAK), Internal Medicine Department, Grenoble University Hospital, Grenoble, France.&#xD;Greater Bay Area Institute of Precision Medicine (Guangzhou), School of Life Sciences, Fudan University, Shanghai, China.&#xD;Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil.&#xD;Dermatology, Faculty of Medicine, University of Coimbra and University Hospital, Coimbra Local health Unit, Coimbra, Portugal.&#xD;Department of Dermatology, UCARE, Erasmus MC, Rotterdam, The Netherlands.&#xD;Allergy Research Center, Mashhad University Of Medical Sciences, Mashhad, Iran.&#xD;Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Department of Dermatology, Hiroshima University, Hiroshima, Japan.&#xD;Division of Allergy and Clinical Immunology, Erciyes University School of Medicine, Kayseri, Turkey.&#xD;Pauls Stradins Clinical University Hospital, Children Clinical University Hospital, Riga Stradins University, Riga, Latvia.&#xD;School of Medicine, Trinity College Dublin, St James&apos;s Hospital Dublin, Dublin, Ireland.&#xD;Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos, Lebanon.&#xD;Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.&#xD;Institut National de Sante Publique d&apos;Epidemiologie Clinique et de Toxicologie-Liban (INSPECT-LB), Beirut, Lebanon.&#xD;Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano (MI), Italy.&#xD;Department of Clinical and Laboratory Immunology, Allergology and Medical Genetics, Bogomolets National Medical University, Kyiv, Ukraine.&#xD;Department of Dermatology and Venerology, UCARE, Kepler University Hospital, Linz, Austria.&#xD;Faculty of Medicine, Center for Medical Research, Johannes Kepler University, Linz, Austria.&#xD;Department of Biomedical Sciences, Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.&#xD;Division of Allergology, Department of Internal Diseases, Institute of Medical Sciences, University of Opole, Opole, Poland.&#xD;Department of Dermatology and Venerology, Peking University First Hospital, Beijing Key Laboratory of molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE(R) mobile health study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">750-761</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2024/10/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">*Visual Analog Scale</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Mobile Applications</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Telemedicine</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">mHealth</style></keyword><keyword><style face="normal" font="default" size="100%">patient-reported outcome measures</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria, chronic spontaneous urticaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39445583</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: CRUSE(R) is an app that allows patients with chronic spontaneous urticaria (CSU) to monitor their daily disease activity through the use of visual analogue scales (VASs). We aimed to determine the concurrent validity, reliability, responsiveness and minimal important difference (MID) of CRUSE(R) VASs. METHODS: We evaluated the properties of three daily VASs: VAS for how much patients were affected by their CSU (&apos;VAS urticaria&apos;), VAS for the impact of urticaria on work/school productivity (&apos;VAS productivity&apos;) and the VAS of EQ-5D. Concurrent validity was assessed by measuring the association between each VAS and the Urticaria Activity Score (UAS). Intra-rater reliability was determined based on the data of users providing multiple daily questionnaires within the same day. Test-retest reliability and responsiveness (ability to change), respectively, were tested in clinically stable and clinically unstable users. MIDs were determined using distribution-based methods. RESULTS: We included 5938 patients (67,380 days). Concurrent validity was high, with VAS urticaria being more strongly associated with the UAS score than the remaining VASs. Intra-rater reliability was also high, with intraclass correlation coefficients (ICC) being above 0.950 for all VASs. Moderate-high test-retest reliability and responsiveness were observed, with reliability ICC being highest for VAS EQ-5D and responsiveness being highest for VAS urticaria. The MID for VAS urticaria was 17 (out of 100) units, compared to 15 units for VAS productivity and 11 units for VAS EQ-5D. CONCLUSION: Daily VASs for CSU available in the CRUSE(R) app display high concurrent validity and intra-rater reliability and moderate-high test-retest reliability and responsiveness.</style></abstract><notes><style face="normal" font="default" size="100%">Sousa-Pinto, Bernardo&#xD;Ramanauskaite, Aiste&#xD;Neisinger, Sophia&#xD;Witte-Handel, Ellen&#xD;Gimenez-Arnau, Ana M&#xD;Guillet, Carole&#xD;Parisi, Claudio Alberto S&#xD;Katelaris, Constance H&#xD;Fomina, Daria&#xD;Larenas-Linnemann, Desiree&#xD;Garcia, Elizabeth&#xD;Kocaturk, Emek&#xD;Siebenhaar, Frank&#xD;Lima, Hermenio&#xD;Kaidashev, Igor&#xD;Nasr, Iman&#xD;Canales, Isabel Ogueta&#xD;Ojeda, Ivan Cherrez&#xD;Hebert, Jacques&#xD;Bousquet, Jean&#xD;Bernstein, Jonathan A&#xD;Peter, Jonny&#xD;Sanchez, Jorge&#xD;Sousa, Jose Ignacio Larco&#xD;Kulthanan, Kanokvalai&#xD;Weller, Karsten&#xD;Godse, Kiran&#xD;Rutkowski, Krzysztof&#xD;Lapina, Lasma&#xD;Bouillet, Laurence&#xD;Han, Leo Lianyi&#xD;Ensina, Luis Felipe&#xD;Goncalo, Margarida&#xD;Magerl, Markus&#xD;van Doorn, Martijn&#xD;Metz, Martin&#xD;Khoshkhui, Maryam&#xD;Hide, Michihiro&#xD;Turk, Murat&#xD;Kurjane, Natalja&#xD;Conlon, Niall&#xD;Salameh, Pascale&#xD;Kolkhir, Pavel&#xD;Asero, Riccardo&#xD;Stepanenko, Roman&#xD;Altrichter, Sabine&#xD;Gil-Mata, Sara&#xD;Thomsen, Simon Francis&#xD;Zuberbier, Torsten&#xD;Tsaryk, Vladyslav&#xD;Ye, Young-Min&#xD;Brzoza, Zenon&#xD;Zhao, Zuotao&#xD;Maurer, Marcus&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Mar;80(3):750-761. doi: 10.1111/all.16371. Epub 2024 Oct 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39445583</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16371</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>732</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">732</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Labella, M.</style></author><author><style face="normal" font="default" size="100%">Cespedes, J. A.</style></author><author><style face="normal" font="default" size="100%">Dona, I.</style></author><author><style face="normal" font="default" size="100%">Shamji, M. H.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Mayorga, C.</style></author><author><style face="normal" font="default" size="100%">Torres, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Research Group, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain.&#xD;Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.&#xD;National Heart and Lung Institute, Imperial College London, London, UK.&#xD;NIHR Imperial Biomedical Research Centre, London, UK.&#xD;Faculty of Medicine, Transylvania University, Brasov, Romania.&#xD;Departamento de Medicina, Universidad de Malaga, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2067-2079</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2021/10/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">Basophil Degranulation Test/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/diagnosis/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style face="normal" font="default" size="100%">BNT162b2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">allergic reactions</style></keyword><keyword><style face="normal" font="default" size="100%">basophil activation test</style></keyword><keyword><style face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34689351</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: mRNA-based COVID-19 vaccines have been reported to induce hypersensitivity reactions (HSR) in a small number of individuals. We aimed to evaluate the real-world incidence of the BNT162b2 mRNA COVID-19 vaccine HSR and to determine the value of the basophil activation test (BAT) in the allergological workup of patients reporting these reactions. METHODS: We prospectively enrolled patients with a clinical history indicative of HSR to the BNT162b2 mRNA COVID-19 vaccine. The allergological workup included skin testing (STs) and BAT with polyethylene glycol (PEG) and the vaccine. In those with negative allergy assessments, the administration of the second dose of the BNT162b2 mRNA COVID-19 vaccine was offered. RESULTS: Seventeen adults were included. Eleven cases (64.7%) tested negative in the allergological workup and tolerated the re-administration of the second dose of the vaccine and considered non-allergic. Six cases (35.3%) were considered allergic and classified into three groups: 2 subjects displayed positive STs and/or BAT to PEG (Group A), two individuals displayed positive BAT to the vaccine (Group B), and in 2 patients with moderate or severe reactions, the culprit was not identified, tested negative to STs and BAT to both PEG and vaccine (Group C). We further evaluated the value of BAT when the results were positive to the vaccine and negative to PEG by performing BAT in controls groups, finding positive BAT results in 50% of controls, all of them recovered from COVID-19 infection. In contrast, BAT was negative in patients who had not suffered from COVID-19 disease. CONCLUSIONS: BAT can be used as a potential diagnostic tool for confirming allergy to PEG excipient but not to the vaccine as a positive result in BAT may indicate a past COVID-19 infection instead of an allergy.</style></abstract><notes><style face="normal" font="default" size="100%">Labella, Marina&#xD;Cespedes, Jose Antonio&#xD;Dona, Inmaculada&#xD;Shamji, Mohamed H&#xD;Agache, Ioana&#xD;Mayorga, Cristobalina&#xD;Torres, Maria Jose&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2067-2079. doi: 10.1111/all.15148. Epub 2021 Oct 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34689351</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8653141</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15148</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2213</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2213</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Bent, R.</style></author><author><style face="normal" font="default" size="100%">Biedermann, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Value of vaccine and vaccine excipient skin testing to COVID-19 vaccines</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2064-2065</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2023/06/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccine Excipients</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">37389865</style></accession-num><notes><style face="normal" font="default" size="100%">Brockow, Knut&#xD;Bent, Rebekka&#xD;Biedermann, Tilo&#xD;eng&#xD;Bayerisches Staatsministerium fur Wissenschaft und Kunst/&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jul;78(7):2064-2065. doi: 10.1111/all.15732.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/37389865</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15732</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>579</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">579</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Q.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Cheng, Z.</style></author><author><style face="normal" font="default" size="100%">Luo, L.</style></author><author><style face="normal" font="default" size="100%">Sun, J.</style></author><author><style face="normal" font="default" size="100%">Fu, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Food Safety Key Laboratory of Zhejiang Province, School of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou, China.&#xD;Laboratory of Food Oral Processing, School of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou, China.&#xD;Allergy Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Variations in oral microbiota and salivary proteomics reveal distinct patterns in polysensitized individuals</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1899-1902</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/03/05</style></edition><section><style face="normal" font="default" size="100%">1899</style></section><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">*Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Saliva</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35243648</style></accession-num><notes><style face="normal" font="default" size="100%">Wang, Yanbo&#xD;Zhang, Qiaozhi&#xD;Wang, Chong&#xD;Chen, Jianshe&#xD;Cheng, Zhouzhou&#xD;Luo, Lichun&#xD;Sun, Jinlyu&#xD;Fu, Linglin&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1899-1902. doi: 10.1111/all.15268. Epub 2022 Mar 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35243648</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15268</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>14</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">14</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paciencia, I.</style></author><author><style face="normal" font="default" size="100%">Rantala, A. K.</style></author><author><style face="normal" font="default" size="100%">Antikainen, H.</style></author><author><style face="normal" font="default" size="100%">Hugg, T. T.</style></author><author><style face="normal" font="default" size="100%">Jaakkola, M. S.</style></author><author><style face="normal" font="default" size="100%">Jaakkola, J. J. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Environmental and Respiratory Health Research (CERH), Population Health, University of Oulu, Oulu, Finland.&#xD;Biocenter Oulu, University of Oulu, Oulu, Finland.&#xD;Geography Research Unit, University of Oulu, Oulu, Finland.&#xD;Finnish Meteorological Institute, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Varying effects of greenness in the spring and summer on the development of allergic rhinitis up to 27 years of age: The Espoo Cohort Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1680-1682</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2023/01/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Rhinitis, Allergic, Seasonal/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">allergic rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">early life</style></keyword><keyword><style face="normal" font="default" size="100%">greenspaces</style></keyword><keyword><style face="normal" font="default" size="100%">population-based cohort study</style></keyword><keyword><style face="normal" font="default" size="100%">season</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36661482</style></accession-num><notes><style face="normal" font="default" size="100%">Paciencia, Ines&#xD;Rantala, Aino K&#xD;Antikainen, Harri&#xD;Hugg, Timo T&#xD;Jaakkola, Maritta S&#xD;Jaakkola, Jouni J K&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2023 Jun;78(6):1680-1682. doi: 10.1111/all.15649. Epub 2023 Jan 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36661482</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15649</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1043</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1043</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Villani, A. P.</style></author><author><style face="normal" font="default" size="100%">Pavel, A. B.</style></author><author><style face="normal" font="default" size="100%">Wu, J.</style></author><author><style face="normal" font="default" size="100%">Fernandes, M.</style></author><author><style face="normal" font="default" size="100%">Maari, C.</style></author><author><style face="normal" font="default" size="100%">Saint-Cyr Proulx, E.</style></author><author><style face="normal" font="default" size="100%">Jack, C.</style></author><author><style face="normal" font="default" size="100%">Glickman, J.</style></author><author><style face="normal" font="default" size="100%">Choi, S.</style></author><author><style face="normal" font="default" size="100%">He, H.</style></author><author><style face="normal" font="default" size="100%">Ungar, B.</style></author><author><style face="normal" font="default" size="100%">Estrada, Y.</style></author><author><style face="normal" font="default" size="100%">Kameyama, N.</style></author><author><style face="normal" font="default" size="100%">Zhang, N.</style></author><author><style face="normal" font="default" size="100%">Gonzales, J.</style></author><author><style face="normal" font="default" size="100%">Tardif, J. C.</style></author><author><style face="normal" font="default" size="100%">Krueger, J. G.</style></author><author><style face="normal" font="default" size="100%">Bissonnette, R.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Biomedical Engineering, University of Mississippi, University, MS, USA.&#xD;College of Medicine, State University of New York Downstate Medical Center, Brooklyn, New York, USA.&#xD;Innovaderm Research, Montreal, QC, Canada.&#xD;Montreal Heart Institute, Faculty of Medicine, Universite de Montreal, Montreal, QC, Canada.&#xD;Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3107-3121</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/04/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Positron Emission Tomography Computed Tomography</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Skin</style></keyword><keyword><style face="normal" font="default" size="100%">atherosclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular</style></keyword><keyword><style face="normal" font="default" size="100%">microparticles</style></keyword><keyword><style face="normal" font="default" size="100%">vascular inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33866573</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In atopic dermatitis (AD), some studies have shown an association with increased cardiovascular disease in certain populations. However, other investigations found modest or no association. Despite conflicting results, molecular profiling studies in both AD skin and blood have demonstrated upregulation of atherosclerosis and cardiovascular risk-related markers. However, the underlying mechanisms connecting AD to vascular inflammation/atherosclerosis are unknown. In this study, we aim to determine factors associated with vascular inflammation/atherosclerosis in AD patients. METHODS: We used 18-FDG PET-CT to characterize vascular inflammation in AD patients and healthy subjects. In parallel, we assessed their skin and blood immune profiles to determine AD-related immune biomarkers associated with vascular inflammation. We also assessed levels of circulating microparticles, which are known to be associated with increased cardiovascular risk. RESULTS: We found significant correlations between vascular inflammation and Th2-related products in skin and blood of AD patients as well as atherosclerosis-related markers that were modulated by dupilumab. Circulating levels of endothelial microparticles were significantly higher in severe AD patients and tended to correlate with vascular inflammation assessed by PET-CT. CONCLUSION: Vascular inflammation in AD is associated with enhanced Th2 response and clinical severity, which may explain cardiovascular comorbidities observed in select AD populations. Larger prospective studies are needed to further evaluate vascular inflammation and cardiovascular events and mortality in AD patients. Finally, as dupilumab treatment demonstrated significant modulation of atherosclerosis-related genes in AD patients compared to placebo, these data suggest that modulation of vascular inflammation with systemic treatment should be explored in patients with AD.</style></abstract><notes><style face="normal" font="default" size="100%">Villani, Axel P&#xD;Pavel, Ana B&#xD;Wu, Jianni&#xD;Fernandes, Marie&#xD;Maari, Catherine&#xD;Saint-Cyr Proulx, Etienne&#xD;Jack, Carolyn&#xD;Glickman, Jacob&#xD;Choi, Seulah&#xD;He, Helen&#xD;Ungar, Benjamin&#xD;Estrada, Yeriel&#xD;Kameyama, Naoya&#xD;Zhang, Ning&#xD;Gonzales, Juana&#xD;Tardif, Jean-Claude&#xD;Krueger, James G&#xD;Bissonnette, Robert&#xD;Guttman-Yassky, Emma&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3107-3121. doi: 10.1111/all.14859. Epub 2021 May 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33866573</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14859</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1338</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1338</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rijavec, M.</style></author><author><style face="normal" font="default" size="100%">Kosnik, M.</style></author><author><style face="normal" font="default" size="100%">Koren, A.</style></author><author><style face="normal" font="default" size="100%">Kopac, P.</style></author><author><style face="normal" font="default" size="100%">Selb, J.</style></author><author><style face="normal" font="default" size="100%">Vantur, R.</style></author><author><style face="normal" font="default" size="100%">Kogovsek, Z.</style></author><author><style face="normal" font="default" size="100%">Bizjak, M.</style></author><author><style face="normal" font="default" size="100%">Bajrovic, N.</style></author><author><style face="normal" font="default" size="100%">Zidarn, M.</style></author><author><style face="normal" font="default" size="100%">Korosec, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.&#xD;Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia.&#xD;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A very low number of circulating basophils is predictive of a poor response to omalizumab in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1254-1257</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/09/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anti-Allergic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Basophils</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Chronic Urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Omalizumab/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Urticaria/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">FcepsilonRI</style></keyword><keyword><style face="normal" font="default" size="100%">chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">omalizumab</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32876979</style></accession-num><notes><style face="normal" font="default" size="100%">Rijavec, Matija&#xD;Kosnik, Mitja&#xD;Koren, Ana&#xD;Kopac, Peter&#xD;Selb, Julij&#xD;Vantur, Romana&#xD;Kogovsek, Zan&#xD;Bizjak, Mojca&#xD;Bajrovic, Nissera&#xD;Zidarn, Mihaela&#xD;Korosec, Peter&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1254-1257. doi: 10.1111/all.14577. Epub 2020 Sep 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32876979</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14577</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>249</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">249</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pichler, W. J.</style></author><author><style face="normal" font="default" size="100%">Bruggen, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ADR-AC GmbH, Bern, Switzerland.&#xD;Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Faculty of Medicine, University Zurich, Zurich, Switzerland.&#xD;Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Viral infections and drug hypersensitivity</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">60-70</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2022/10/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug-Related Side Effects and Adverse Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity, Delayed</style></keyword><keyword><style face="normal" font="default" size="100%">*Virus Diseases/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Hypersensitivity Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">exanthems</style></keyword><keyword><style face="normal" font="default" size="100%">hapten</style></keyword><keyword><style face="normal" font="default" size="100%">p-i concept</style></keyword><keyword><style face="normal" font="default" size="100%">sulfa allergy</style></keyword><keyword><style face="normal" font="default" size="100%">virus infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36264263</style></accession-num><abstract><style face="normal" font="default" size="100%">Virus infections and T-cell-mediated drug hypersensitivity reactions (DHR) can influence each other. In most instances, systemic virus infections appear first. They may prime the reactivity to drugs in two ways: First, by virus-induced second signals: certain drugs like beta-lactam antibiotics are haptens and covalently bind to various soluble and tissue proteins, thereby forming novel antigens. Under homeostatic conditions, these neo-antigens do not induce an immune reaction, probably because co-stimulation is missing. During a virus infection, the hapten-modified peptides are presented in an immune-stimulatory environment with co-stimulation. A drug-specific immune reaction may develop and manifest as exanthema. Second, by increased pharmacological interactions with immune receptors (p-i): drugs tend to bind to proteins and may even bind to immune receptors. Without viral infections, this low affine binding may be insufficient to elicit T-cell activation. During a viral infection, immune receptors are more abundantly expressed and allow more interactions to occur. This increases the overall avidity of p-i reactions and may even be sufficient for T-cell activation and symptoms. There is a situation where the virus-DHR sequence of events is inversed: in drug reaction with eosinophilia and systemic symptoms (DRESS), a severe DHR can precede reactivation and viremia of various herpes viruses. One could explain this phenomenon by the massive p-i mediated immune stimulation during acute DRESS, which coincidentally activates many herpes virus-specific T cells. Through p-i stimulation, they develop a cytotoxic activity by killing herpes peptide-expressing cells and releasing herpes viruses. These concepts could explain the often transient nature of DHR occurring during viral infections and the often asymptomatic herpes-virus viraemia after DRESS.</style></abstract><notes><style face="normal" font="default" size="100%">Pichler, Werner J&#xD;Bruggen, Marie-Charlotte&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2023 Jan;78(1):60-70. doi: 10.1111/all.15558. Epub 2022 Nov 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36264263</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15558</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>749</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">749</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jitthamstaporn, S.</style></author><author><style face="normal" font="default" size="100%">Sander, A. F.</style></author><author><style face="normal" font="default" size="100%">Jacquet, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center of Excellence in Vaccine Research and Development, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.&#xD;Centre for Medical Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Virus-like particles displaying recombinant Der p 1 zymogen to optimize IgG blocking antibody response</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">664-667</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2021/10/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antibody Formation</style></keyword><keyword><style face="normal" font="default" size="100%">Antigens, Dermatophagoides</style></keyword><keyword><style face="normal" font="default" size="100%">Arthropod Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Cysteine Endopeptidases</style></keyword><keyword><style face="normal" font="default" size="100%">*Enzyme Precursors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunoglobulin G</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34617292</style></accession-num><notes><style face="normal" font="default" size="100%">Jitthamstaporn, Sirikarn&#xD;Sander, Adam F&#xD;Jacquet, Alain&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Feb;77(2):664-667. doi: 10.1111/all.15129. Epub 2021 Oct 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34617292</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15129</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>542</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">542</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hara, M.</style></author><author><style face="normal" font="default" size="100%">Morimoto, N.</style></author><author><style face="normal" font="default" size="100%">Watabe, T.</style></author><author><style face="normal" font="default" size="100%">Inoue, T.</style></author><author><style face="normal" font="default" size="100%">Takada, N.</style></author><author><style face="normal" font="default" size="100%">Amari, Y.</style></author><author><style face="normal" font="default" size="100%">Morita, H.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.&#xD;Department of Otorhinolaryngology, National Center for Child Health and Development, Tokyo, Japan.&#xD;Allergy Center, National Center for Child Health and Development, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Virus-related stimuli modulate SARS-CoV-2 entry factor expression in pediatric tonsillar epithelial cells in vitro</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2240-2242</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2022/03/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme 2</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Peptidyl-Dipeptidase A/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2 entry factor</style></keyword><keyword><style face="normal" font="default" size="100%">full-length ACE2</style></keyword><keyword><style face="normal" font="default" size="100%">tonsillar epithelial cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35347742</style></accession-num><notes><style face="normal" font="default" size="100%">Hara, Mariko&#xD;Morimoto, Noriko&#xD;Watabe, Takahisa&#xD;Inoue, Takeshi&#xD;Takada, Natsuki&#xD;Amari, Yasunobu&#xD;Morita, Hideaki&#xD;Matsumoto, Kenji&#xD;eng&#xD;Letter&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jul;77(7):2240-2242. doi: 10.1111/all.15296. Epub 2022 Apr 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35347742</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9111194</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15296</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1331</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1331</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scholz, J.</style></author><author><style face="normal" font="default" size="100%">Kuhrau, J.</style></author><author><style face="normal" font="default" size="100%">Heinrich, F.</style></author><author><style face="normal" font="default" size="100%">Heinz, G. A.</style></author><author><style face="normal" font="default" size="100%">Hutloff, A.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Heine, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergy, Charite - Universitatsmedizin Berlin, Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health, Berlin, Germany.&#xD;Deutsches Rheuma-Forschungszentrum, A Leibniz Institute, Berlin, Germany.&#xD;Institute of Immunology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.&#xD;Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.&#xD;Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vitamin A controls the allergic response through T follicular helper cell as well as plasmablast differentiation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1109-1122</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/09/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">Germinal Center</style></keyword><keyword><style face="normal" font="default" size="100%">*Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">T Follicular Helper Cells</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes, Helper-Inducer</style></keyword><keyword><style face="normal" font="default" size="100%">*Vitamin A</style></keyword><keyword><style face="normal" font="default" size="100%">9-cis retinoic acid</style></keyword><keyword><style face="normal" font="default" size="100%">Rar</style></keyword><keyword><style face="normal" font="default" size="100%">Tfh cells</style></keyword><keyword><style face="normal" font="default" size="100%">allergy</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin A</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32895937</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Vitamin A regulates the adaptive immune response and a modulatory impact on type I allergy is discussed. The cellular mechanisms are largely unknown. OBJECTIVE: To determine the vitamin A-responding specific lymphocyte reaction in vivo. METHODS: Antigen-specific B and T lymphocytes were analyzed in an adoptive transfer airway inflammation mouse model in response to 9-cis retinoic acid (9cRA) and after lymphocyte-specific genetic targeting of the receptor RARalpha. Flow cytometry, quantitative PCR, next-generation sequencing, and specific Ig-ELISA were used to characterize the cells functionally. RESULTS: Systemic 9cRA profoundly enhanced the specific IgA-secreting B-cell frequencies in the lung tissue and serum IgA while reducing serum IgE concentrations. RARalpha overexpression in antigen-specific B cells promoted differentiation into plasmablasts at the expense of germinal center B cells. In antigen-specific T cells, RARalpha strongly promoted the differentiation of T follicular helper cells followed by an enhanced germinal center response. CONCLUSIONS: 9cRA signaling via RARalpha impacts the allergen-specific immunoglobulin response directly by the differentiation of B cells and indirectly by promoting T follicular helper cells.</style></abstract><notes><style face="normal" font="default" size="100%">Scholz, Josephine&#xD;Kuhrau, Julia&#xD;Heinrich, Frederik&#xD;Heinz, Gitta Anne&#xD;Hutloff, Andreas&#xD;Worm, Margitta&#xD;Heine, Guido&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Apr;76(4):1109-1122. doi: 10.1111/all.14581. Epub 2020 Sep 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32895937</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14581</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2684</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2684</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brustad, N.</style></author><author><style face="normal" font="default" size="100%">Kyvsgaard, J. N.</style></author><author><style face="normal" font="default" size="100%">Pedersen, C. T.</style></author><author><style face="normal" font="default" size="100%">Hesselberg, L. M.</style></author><author><style face="normal" font="default" size="100%">Eliasen, A. U.</style></author><author><style face="normal" font="default" size="100%">Jensen, S. K.</style></author><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Vahman, N.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Chawes, B. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Food Science, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vitamin D in early life and risk of daily registered childhood infection episodes</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">332-335</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2024/10/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">infections</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">pneumology</style></keyword><keyword><style face="normal" font="default" size="100%">regarding the content of this manuscript.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39412486</style></accession-num><notes><style face="normal" font="default" size="100%">Brustad, Nicklas&#xD;Kyvsgaard, Julie Nyholm&#xD;Pedersen, Casper-Emil Tingskov&#xD;Hesselberg, Laura Marie&#xD;Eliasen, Anders U&#xD;Jensen, Signe Kjeldgaard&#xD;Yang, Luo&#xD;Vahman, Nilofar&#xD;Stokholm, Jakob&#xD;Bonnelykke, Klaus&#xD;Chawes, Bo L&#xD;eng&#xD;Lundbeck Foundation/&#xD;Region Hovedstaden/&#xD;H2020 European Research Council/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jan;80(1):332-335. doi: 10.1111/all.16354. Epub 2024 Oct 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39412486</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11724260</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16354</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1571</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1571</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author><author><style face="normal" font="default" size="100%">Peroni, D. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vitamin D supplementation in pregnancy does not prevent school-age asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2143-2144</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/04/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Asthma/epidemiology/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Sounds</style></keyword><keyword><style face="normal" font="default" size="100%">Schools</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">wheezing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">32335931</style></accession-num><notes><style face="normal" font="default" size="100%">Comberiati, Pasquale&#xD;Peroni, Diego G&#xD;eng&#xD;Denmark&#xD;Allergy. 2020 Aug;75(8):2143-2144. doi: 10.1111/all.14337. Epub 2020 May 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32335931</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14337</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2550</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2550</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brustad, N.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Chawes, B. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Food Science, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vitamin D-FUT2 interaction and risk of lower respiratory tract infections in childhood</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">582-584</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2024/07/30</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39075834</style></accession-num><notes><style face="normal" font="default" size="100%">Brustad, Nicklas&#xD;Stokholm, Jakob&#xD;Bonnelykke, Klaus&#xD;Chawes, Bo L&#xD;eng&#xD;H2020 European Research Council/&#xD;Region Hovedstaden/&#xD;Lundbeck Foundation/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Feb;80(2):582-584. doi: 10.1111/all.16266. Epub 2024 Jul 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39075834</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC11804297 this manuscript.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16266</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1217</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1217</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brulefert, A.</style></author><author><style face="normal" font="default" size="100%">Hoste, A.</style></author><author><style face="normal" font="default" size="100%">Muller, Q.</style></author><author><style face="normal" font="default" size="100%">Fauny, J. D.</style></author><author><style face="normal" font="default" size="100%">Mueller, C. G.</style></author><author><style face="normal" font="default" size="100%">Flacher, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory CNRS UPR3572 Immunology, Immunopathology and Therapeutic Chemistry (I2CT) / LabEx Medalis, Institut de Biologie Moleculaire et Cellulaire, Universite de Strasbourg, Strasbourg, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vitamin D3-elicited CD14+ human skin dendritic cells promote thymic stromal lymphopoietin-independent type 2 T-helper responses</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2044-2056</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2020/12/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Cholecalciferol/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Langerhans Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style face="normal" font="default" size="100%">Thymic Stromal Lymphopoietin</style></keyword><keyword><style face="normal" font="default" size="100%">T helper 2</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dendritic cell</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D3</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33368331</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Immune modulation by vitamin D3 through dendritic cells (DCs) remains controversial. Human DCs exposed in vitro counteract type-1 T-helper (Th1) differentiation and induce regulatory T cells. However, cutaneous application on mice promotes Th2-driven inflammation resembling atopic dermatitis and relying on thymic stromal lymphopoietin (TSLP) from keratinocytes and T-cell orientation by TSLP-stimulated skin DCs. We studied the effects of vitamin D3 in human skin, focusing on TSLP production and the role of skin DCs in T-cell differentiation. METHODS: Human healthy skin explants were exposed in vitro to vitamin D3 analogs. Migrating DCs were analyzed and TSLP quantified in the supernatant. Allogeneic naive CD4+ T cells were cocultured with DCs to assess their proliferation and cytokine production. RESULTS: Vitamin D3 induced skin DCs to differentiate Th2 cells producing IL-4 and IL-13. Vitamin D3 triggered TSLP release in ~30% of skin explants, correlating with IL-13 detection in Th2 cells. In these donors, blocking TSLP receptor during skin explant cultures abrogated IL-13 production, yet IL-4+ Th2 cells were unaffected. Among skin DCs emerged CD14+ cells that had responded directly to vitamin D3 and differed from classical CD14+ dermal emigrants. Vitamin D3-elicited CD14+ DCs sufficed to promote IL-4+ Th2 cells in a TSLP-independent manner. CONCLUSION: Vitamin D3, despite inducing TSLP in some donors, had a direct influence on skin DCs, affecting their phenotype and ability to drive Th2 responses independently of TSLP. Our findings pave the way toward in vitro systems that accurately model human cutaneous Th2 responses, notably involved in atopic dermatitis.</style></abstract><notes><style face="normal" font="default" size="100%">Brulefert, Adrien&#xD;Hoste, Astrid&#xD;Muller, Quentin&#xD;Fauny, Jean-Daniel&#xD;Mueller, Christopher G&#xD;Flacher, Vincent&#xD;eng&#xD;I 4229/FWF_/Austrian Science Fund FWF/Austria&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Jul;76(7):2044-2056. doi: 10.1111/all.14718. Epub 2021 Jan 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33368331</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14718</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2902</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2902</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fuertes, E.</style></author><author><style face="normal" font="default" size="100%">Konstantinoudis, G.</style></author><author><style face="normal" font="default" size="100%">van der Plaat, D.</style></author><author><style face="normal" font="default" size="100%">Koczoski, A.</style></author><author><style face="normal" font="default" size="100%">Sofiev, M.</style></author><author><style face="normal" font="default" size="100%">Agnew, P.</style></author><author><style face="normal" font="default" size="100%">Neal, L.</style></author><author><style face="normal" font="default" size="100%">Jarvis, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Heart and Lung Institute, Imperial College London, London, UK.&#xD;Grantham Institute for Climate Change and the Environment, Imperial College London, London, UK.&#xD;Finnish Meteorological Institute, Helsinki, Finland.&#xD;Met Office, Exeter, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vulnerability to Pollen-Related Asthma Hospital Admissions in the UK Biobank: A Case-Crossover Study</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2081-2083</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2025/06/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">case-crossover</style></keyword><keyword><style face="normal" font="default" size="100%">cohort</style></keyword><keyword><style face="normal" font="default" size="100%">pollen</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40462398</style></accession-num><notes><style face="normal" font="default" size="100%">Fuertes, Elaine&#xD;Konstantinoudis, Garyfallos&#xD;van der Plaat, Diana&#xD;Koczoski, Adam&#xD;Sofiev, Mikhail&#xD;Agnew, Paul&#xD;Neal, Lucy&#xD;Jarvis, Debbie&#xD;eng&#xD;HORIZON EUROPE European Research Council/&#xD;Strategic Priorities Fund Clean Air Project/&#xD;Imperial College Research Fellowships/&#xD;Letter&#xD;Denmark&#xD;Allergy. 2025 Jul;80(7):2081-2083. doi: 10.1111/all.16612. Epub 2025 Jun 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40462398</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC12261866</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16612</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>802</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">802</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maggi, E.</style></author><author><style face="normal" font="default" size="100%">Azzarone, B. G.</style></author><author><style face="normal" font="default" size="100%">Canonica, G. W.</style></author><author><style face="normal" font="default" size="100%">Moretta, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, Bambino Gesu Children&apos;s Hospital, IRCCS, Rome, Italy.&#xD;Asthma &amp; Allergy Clinic, Humanitas University &amp; Research Hospital, IRCCS, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">What we know and still ignore on COVID-19 immune pathogenesis and a proposal based on the experience of allergic disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1114-1128</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2021/09/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adaptive Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">endo-types</style></keyword><keyword><style face="normal" font="default" size="100%">innate and adaptive Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34582050</style></accession-num><abstract><style face="normal" font="default" size="100%">The coronavirus disease 2019 (COVID-19) pandemic started in March 2020 and caused over 5 million confirmed deaths worldwide as far August 2021. We have been recently overwhelmed by a wide literature on how the immune system recognizes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and contributes to COVID-19 pathogenesis. Although originally considered a respiratory viral disease, COVID-19 is now recognized as a far more complex, multi-organ-, immuno-mediated-, and mostly heterogeneous disorder. Though efficient innate and adaptive immunity may control infection, when the patient fails to mount an adequate immune response at the start, or in advanced disease, a high innate-induced inflammation can lead to different clinical outcomes through heterogeneous compensatory mechanisms. The variability of viral load and persistence, the genetic alterations of virus-driven receptors/signaling pathways and the plasticity of innate and adaptive responses may all account for the extreme heterogeneity of pathogenesis and clinical patterns. As recently applied to some inflammatory disorders as asthma, rhinosinusitis with polyposis, and atopic dermatitis, herein we suggest defining different endo-types and the related phenotypes along COVID-19. Patients should be stratified for evolving symptoms and tightly monitored for surrogate biomarkers of innate and adaptive immunity. This would allow to preventively identify each endo-type (and its related phenotype) and to treat patients precisely with agents targeting pathogenic mechanisms.</style></abstract><notes><style face="normal" font="default" size="100%">Maggi, Enrico&#xD;Azzarone, Bruno Giuseppe&#xD;Canonica, Giorgio Walter&#xD;Moretta, Lorenzo&#xD;eng&#xD;RC-2020/Ministero della Salute/&#xD;5x1000 2018 Id 21147/Associazione Italiana per la Ricerca sul Cancro/&#xD;IG 2017 Id 19920/Associazione Italiana per la Ricerca sul Cancro/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Denmark&#xD;Allergy. 2022 Apr;77(4):1114-1128. doi: 10.1111/all.15112. Epub 2021 Oct 12.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34582050</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8652765</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15112</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>930</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">930</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Santos, A.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.&#xD;Children&apos;s Allergy Service Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, Paediatric Allergy Group, School of Life Course Sciences &amp; School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University Munich, Munich, Germany.&#xD;Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Allergy and Immunology, Deprtment of Dermatology, Venerology and Allergy, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Allergy Unit, Clinic for Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">When and how to evaluate for immediate type food allergy in children with atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3845-3848</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/06/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34157156</style></accession-num><notes><style face="normal" font="default" size="100%">Mortz, Charlotte G&#xD;du Toit, George&#xD;Beyer, Kirsten&#xD;Bindslev-Jensen, Carsten&#xD;Brockow, Knut&#xD;Brough, Helen Annaruth&#xD;Comberiati, Pasquale&#xD;Eiwegger, Thomas&#xD;Santos, Alexandra&#xD;Worm, Margitta&#xD;Ballmer-Weber, Barbara K&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3845-3848. doi: 10.1111/all.14982. Epub 2021 Jul 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34157156</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14982</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1853</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1853</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">du Toit, G.</style></author><author><style face="normal" font="default" size="100%">Beyer, K.</style></author><author><style face="normal" font="default" size="100%">Bindslev-Jensen, C.</style></author><author><style face="normal" font="default" size="100%">Brockow, K.</style></author><author><style face="normal" font="default" size="100%">Brough, H. A.</style></author><author><style face="normal" font="default" size="100%">Comberiati, P.</style></author><author><style face="normal" font="default" size="100%">Eiwegger, T.</style></author><author><style face="normal" font="default" size="100%">Santos, A.</style></author><author><style face="normal" font="default" size="100%">Worm, M.</style></author><author><style face="normal" font="default" size="100%">Ballmer-Weber, B. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.&#xD;Children&apos;s Allergy Service Evelina London Children&apos;s Hospital, Guy&apos;s and St Thomas&apos; NHS Foundation Trust, Paediatric Allergy Group, School of Life Course Sciences &amp; School of Immunology and Microbial Sciences, King&apos;s College London, London, UK.&#xD;Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany.&#xD;Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University Munich, Munich, Germany.&#xD;Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.&#xD;Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada.&#xD;Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.&#xD;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.&#xD;Allergy and Immunology, Deprtment of Dermatology, Venerology and Allergy, Charite-Universitatsmedizin Berlin, Berlin, Germany.&#xD;Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.&#xD;Allergy Unit, Clinic for Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">When and how to evaluate for immediate type food allergy in children with atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3845-3848</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/06/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Eczema</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity/complications/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">allergy diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">food allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34157156</style></accession-num><notes><style face="normal" font="default" size="100%">Mortz, Charlotte G&#xD;du Toit, George&#xD;Beyer, Kirsten&#xD;Bindslev-Jensen, Carsten&#xD;Brockow, Knut&#xD;Brough, Helen Annaruth&#xD;Comberiati, Pasquale&#xD;Eiwegger, Thomas&#xD;Santos, Alexandra&#xD;Worm, Margitta&#xD;Ballmer-Weber, Barbara K&#xD;eng&#xD;G0902018/MRC_/Medical Research Council/United Kingdom&#xD;MR/M008517/1/MRC_/Medical Research Council/United Kingdom&#xD;MR/T032081/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3845-3848. doi: 10.1111/all.14982. Epub 2021 Jul 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34157156</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14982</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>635</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">635</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bulut, O.</style></author><author><style face="normal" font="default" size="100%">Geckin, B.</style></author><author><style face="normal" font="default" size="100%">Dominguez-Andres, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">When platelets meet candidalysin: &quot;We just Wnt to have fun&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1927-1928</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/01/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Blood Platelets</style></keyword><keyword><style face="normal" font="default" size="100%">Candida albicans</style></keyword><keyword><style face="normal" font="default" size="100%">*Fungal Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">candida</style></keyword><keyword><style face="normal" font="default" size="100%">candidalysin</style></keyword><keyword><style face="normal" font="default" size="100%">platelets</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35067950</style></accession-num><notes><style face="normal" font="default" size="100%">Bulut, Ozlem&#xD;Geckin, Busranur&#xD;Dominguez-Andres, Jorge&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1927-1928. doi: 10.1111/all.15228. Epub 2022 Jan 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35067950</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15228</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1895</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1895</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bulut, O.</style></author><author><style face="normal" font="default" size="100%">Geckin, B.</style></author><author><style face="normal" font="default" size="100%">Dominguez-Andres, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">When platelets meet candidalysin: &quot;We just Wnt to have fun&quot;</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1927-1928</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2022/01/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Blood Platelets</style></keyword><keyword><style face="normal" font="default" size="100%">Candida albicans</style></keyword><keyword><style face="normal" font="default" size="100%">*Fungal Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">T cells</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">candida</style></keyword><keyword><style face="normal" font="default" size="100%">candidalysin</style></keyword><keyword><style face="normal" font="default" size="100%">platelets</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35067950</style></accession-num><notes><style face="normal" font="default" size="100%">Bulut, Ozlem&#xD;Geckin, Busranur&#xD;Dominguez-Andres, Jorge&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 Jun;77(6):1927-1928. doi: 10.1111/all.15228. Epub 2022 Jan 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35067950</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15228</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1172</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1172</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bin, L.</style></author><author><style face="normal" font="default" size="100%">Malley, C.</style></author><author><style face="normal" font="default" size="100%">Taylor, P.</style></author><author><style face="normal" font="default" size="100%">Preethi Boorgula, M.</style></author><author><style face="normal" font="default" size="100%">Chavan, S.</style></author><author><style face="normal" font="default" size="100%">Daya, M.</style></author><author><style face="normal" font="default" size="100%">Mathias, M.</style></author><author><style face="normal" font="default" size="100%">Shankar, G.</style></author><author><style face="normal" font="default" size="100%">Rafaels, N.</style></author><author><style face="normal" font="default" size="100%">Vergara, C.</style></author><author><style face="normal" font="default" size="100%">Potee, J.</style></author><author><style face="normal" font="default" size="100%">Campbell, M.</style></author><author><style face="normal" font="default" size="100%">Hanifin, J. M.</style></author><author><style face="normal" font="default" size="100%">Simpson, E.</style></author><author><style face="normal" font="default" size="100%">Schneider, L. C.</style></author><author><style face="normal" font="default" size="100%">Gallo, R. L.</style></author><author><style face="normal" font="default" size="100%">Hata, T.</style></author><author><style face="normal" font="default" size="100%">Paller, A. S.</style></author><author><style face="normal" font="default" size="100%">De Benedetto, A.</style></author><author><style face="normal" font="default" size="100%">Beck, L. A.</style></author><author><style face="normal" font="default" size="100%">Ong, P. Y.</style></author><author><style face="normal" font="default" size="100%">Guttman-Yassky, E.</style></author><author><style face="normal" font="default" size="100%">Richers, B.</style></author><author><style face="normal" font="default" size="100%">Baraghoshi, D.</style></author><author><style face="normal" font="default" size="100%">Ruczinski, I.</style></author><author><style face="normal" font="default" size="100%">Barnes, K. C.</style></author><author><style face="normal" font="default" size="100%">Leung, D. Y. M.</style></author><author><style face="normal" font="default" size="100%">Mathias, R. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, National Jewish Health, Denver, CO, USA.&#xD;Division of Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, MD, USA.&#xD;Department of Medicine, University of Colorado, Aurora, CO, USA.&#xD;Johns Hopkins University, School of Medicine, Baltimore, MD, USA.&#xD;Precision for Medicine, Frederick, MD, USA.&#xD;Oregon Health &amp; Science University, Portland, OR, USA.&#xD;Boston Children&apos;s Hospital, Boston, MA, USA.&#xD;Department of Dermatology, University of California, San Diego, CA, USA.&#xD;Northwestern University Feinberg School of Medicine, Chicago, IL, USA.&#xD;University of Rochester Medical Center, Rochester, NY, USA.&#xD;Children&apos;s Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA.&#xD;Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Division of Biostatistics, National Jewish Health, Denver, CO, USA.&#xD;Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2510-2523</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2021/02/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Glutathione Transferase</style></keyword><keyword><style face="normal" font="default" size="100%">*Herpesvirus 1, Human/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Kaposi Varicelliform Eruption/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">*Nucleotide Transport Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Whole Genome Sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">Sidt2</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">eczema herpeticum</style></keyword><keyword><style face="normal" font="default" size="100%">genetics</style></keyword><keyword><style face="normal" font="default" size="100%">herpes simplex virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Print)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33548076</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Eczema herpeticum (EH) is a rare complication of atopic dermatitis (AD) caused by disseminated herpes simplex virus (HSV) infection. The role of rare and/or deleterious genetic variants in disease etiology is largely unknown. This study aimed to identify genes that harbor damaging genetic variants associated with HSV infection in AD with a history of recurrent eczema herpeticum (ADEH+). METHODS: Whole genome sequencing (WGS) was performed on 49 recurrent ADEH+ (&gt;/=3 EH episodes), 491 AD without a history of eczema herpeticum (ADEH-) and 237 non-atopic control (NA) subjects. Variants were annotated, and a gene-based approach (SKAT-O) was used to identify genes harboring damaging genetic variants associated with ADEH+. Genes identified through WGS were studied for effects on HSV responses and keratinocyte differentiation. RESULTS: Eight genes were identified in the comparison of recurrent ADEH+to ADEH-and NA subjects: SIDT2, CLEC7A, GSTZ1, TPSG1, SP110, RBBP8NL, TRIM15, and FRMD3. Silencing SIDT2 and RBBP8NL in normal human primary keratinocytes (NHPKs) led to significantly increased HSV-1 replication. SIDT2-silenced NHPKs had decreased gene expression of IFNk and IL1b in response to HSV-1 infection. RBBP8NL-silenced NHPKs had decreased gene expression of IFNk, but increased IL1b. Additionally, silencing SIDT2 and RBBP8NL also inhibited gene expression of keratinocyte differentiation markers keratin 10 (KRT10) and loricrin (LOR). CONCLUSION: SIDT2 and RBBP8NL participate in keratinocyte&apos;s response to HSV-1 infection. SIDT2 and RBBP8NL also regulate expression of keratinocyte differentiation genes of KRT10 and LOR.</style></abstract><notes><style face="normal" font="default" size="100%">Bin, Lianghua&#xD;Malley, Claire&#xD;Taylor, Patricia&#xD;Preethi Boorgula, Meher&#xD;Chavan, Sameer&#xD;Daya, Michelle&#xD;Mathias, Malaika&#xD;Shankar, Gautam&#xD;Rafaels, Nicholas&#xD;Vergara, Candelaria&#xD;Potee, Joseph&#xD;Campbell, Monica&#xD;Hanifin, Jon M&#xD;Simpson, Eric&#xD;Schneider, Lynda C&#xD;Gallo, Richard L&#xD;Hata, Tissa&#xD;Paller, Amy S&#xD;De Benedetto, Anna&#xD;Beck, Lisa A&#xD;Ong, Peck Y&#xD;Guttman-Yassky, Emma&#xD;Richers, Brittany&#xD;Baraghoshi, David&#xD;Ruczinski, Ingo&#xD;Barnes, Kathleen C&#xD;Leung, Donald Y M&#xD;Mathias, Rasika A&#xD;eng&#xD;UL1 RR025780/RR/NCRR NIH HHS/&#xD;1U19AI117673-01/National Institute of Allergy and Infectious Diseases/&#xD;UL1 TR000154/TR/NCATS NIH HHS/&#xD;U01 AI152011/AI/NIAID NIH HHS/&#xD;1UM1AI151958/National Institute of Allergy and Infectious Diseases/&#xD;U19 AI117673/AI/NIAID NIH HHS/&#xD;UM1 AI151958/AI/NIAID NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2510-2523. doi: 10.1111/all.14762. Epub 2021 Mar 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33548076</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8978872</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14762</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2803</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2803</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ryser, F. S.</style></author><author><style face="normal" font="default" size="100%">Iype, J.</style></author><author><style face="normal" font="default" size="100%">Christ, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Rheumatology and Immunology, University Hospital Bern, Inselspital, University of Bern, Bern, Switzerland.&#xD;Graduate School for Health Sciences, University Bern, Bern, Switzerland.&#xD;Clinical Cytomics Facility, University Institute of Clinical Chemistry, University Hospital Bern, Inselspital, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Why Anti-IL-17 Therapy Fails: The Role of Autonomous IL-17R Signaling in Autoimmune Inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1190-1191</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2025/01/29</style></edition><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">39878040</style></accession-num><notes><style face="normal" font="default" size="100%">Ryser, Fabio S&#xD;Iype, Joseena&#xD;Christ, Lisa&#xD;eng&#xD;Denmark&#xD;Allergy. 2025 Apr;80(4):1190-1191. doi: 10.1111/all.16487. Epub 2025 Jan 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/39878040</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16487</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3113</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">3113</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ha, A.</style></author><author><style face="normal" font="default" size="100%">Balmes, J. R.</style></author><author><style face="normal" font="default" size="100%">Wei, M. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Public Health, University of California, Berkeley, Berkeley, California, USA.&#xD;Dermatology Service, San Francisco VA Health Care System, San Francisco, California, USA.&#xD;Department of Medicine, University of California, San Francisco, San Francisco, California, USA.&#xD;Department of Dermatology, University of California, San Francisco, San Francisco, California, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Wildfires and Atopic Diseases: A Review</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">n/a</style></volume><number><style face="normal" font="default" size="100%">n/a</style></number><edition><style face="normal" font="default" size="100%">2025/10/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">air pollution</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">wildfire</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">41128291</style></accession-num><abstract><style face="normal" font="default" size="100%">Wildfire smoke is a major environmental health threat that has increased in frequency and severity in recent years. A hazardous component of wildfire smoke is particulate matter &lt;/= 2.5 mum (PM(2.5)). There is evidence to suggest that exposure to wildfire PM(2.5) may increase the risk of developing or exacerbating atopic diseases, such as asthma, allergic rhinitis, and atopic dermatitis. Certain communities may be disproportionately affected due to a lack of access to resources and information about how to protect themselves. This review highlights the negative impacts of wildfire smoke on atopic diseases and effects on specific communities. Further research is needed to better understand factors that contribute to the impact of wildfire smoke and to develop strategies and policy interventions for mitigation.</style></abstract><notes><style face="normal" font="default" size="100%">Ha, Alex&#xD;Balmes, John R&#xD;Wei, Maria L&#xD;eng&#xD;Review&#xD;Denmark&#xD;Allergy. 2025 Oct 23. doi: 10.1111/all.70116.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/41128291</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.70116</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2809</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">2809</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">D&apos;Amato, G.</style></author><author><style face="normal" font="default" size="100%">Agache, I.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Sampath, V.</style></author><author><style face="normal" font="default" size="100%">Akdis, C.</style></author><author><style face="normal" font="default" size="100%">Annesi-Maesano, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Respiratory and Allergic Diseases, Department of Chest Diseases, High Specialty A, Cardarelli Hospital, and Medical School of Respiratory Diseases, University of Naples Federico II, Naples, Italy.&#xD;Allergy &amp; Clinical Immunology Transylvania University, Brasov, Romania.&#xD;Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.&#xD;Swiss Institute of Allergy and Asthma Research (SIAF) and University of Zurich, Zurich, Switzerland.&#xD;Desbrest Institute of Epidemiology and Public Health, University of Montpellier, INSERM, Montpellier, France.&#xD;Division of Respiratory Medicine, Allergology, and Thoracic Oncology, University Hospital of Montpellier, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Wildfires and Respiratory Allergy</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1569-1571</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2025/03/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Los Angeles wildfires</style></keyword><keyword><style face="normal" font="default" size="100%">airborne pollutants</style></keyword><keyword><style face="normal" font="default" size="100%">wildfires and airways hyperreactivity</style></keyword><keyword><style face="normal" font="default" size="100%">wildfires and airways inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">wildfires and asthma</style></keyword><keyword><style face="normal" font="default" size="100%">wildfires and respiratory allergy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">40105042</style></accession-num><notes><style face="normal" font="default" size="100%">D&apos;Amato, Gennaro&#xD;Agache, Ioana&#xD;Nadeau, Kari&#xD;Sampath, Vanitha&#xD;Akdis, Cezmi&#xD;Annesi-Maesano, Isabella&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2025 Jun;80(6):1569-1571. doi: 10.1111/all.16527. Epub 2025 Mar 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/40105042</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.16527</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1245</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1245</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bourdin, A.</style></author><author><style face="normal" font="default" size="100%">Charriot, J.</style></author><author><style face="normal" font="default" size="100%">Boissin, C.</style></author><author><style face="normal" font="default" size="100%">Ahmed, E.</style></author><author><style face="normal" font="default" size="100%">Suehs, C.</style></author><author><style face="normal" font="default" size="100%">De Sevin, A.</style></author><author><style face="normal" font="default" size="100%">Volpato, M.</style></author><author><style face="normal" font="default" size="100%">Pahus, L.</style></author><author><style face="normal" font="default" size="100%">Gras, D.</style></author><author><style face="normal" font="default" size="100%">Vachier, I.</style></author><author><style face="normal" font="default" size="100%">Halimi, L.</style></author><author><style face="normal" font="default" size="100%">Hamerlijnck, D.</style></author><author><style face="normal" font="default" size="100%">Chanez, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Diseases, Univ Montpellier, CHU Montpellier, Montpellier, France.&#xD;PhyMedExp, Univ Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France.&#xD;Department of Medical Information, Univ Montpellier, CHU Montpellier, Montpellier, France.&#xD;Aix Marseille Univ, APHM, Hopital NORD, CIC 9502, Clinique des bronches allergies et sommeil, Chemin des Bourrely, 13015, Marseille, France.&#xD;Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France.&#xD;Aix Marseille Univ, INSERM U1263, INRA 1260 (C2VN), Marseille, France.&#xD;Dutch Lung Foundation, Amersfoort, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Will the asthma revolution fostered by biologics also benefit adult ICU patients?</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2395-2406</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/12/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-Asthmatic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Products/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intensive Care Units</style></keyword><keyword><style face="normal" font="default" size="100%">Lung</style></keyword><keyword><style face="normal" font="default" size="100%">IL4Ralpha</style></keyword><keyword><style face="normal" font="default" size="100%">Il5</style></keyword><keyword><style face="normal" font="default" size="100%">T2 airway inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">severe exacerbation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33283296</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: Asthma exacerbations are inflammatory events that rarely result in full hospitalization following an ER visit. Unfortunately, certain patients require prolonged support, including occasional external lung support through ECMO or ECCOR (with subsequent further exposure to other life-threatening issues), and some die. In parallel, biologics are revolutionizing severe asthma management, mostly in T2 high patients. METHODS: We extensively reviewed the current unmet needs surrounding ICU-admitted asthma exacerbations, with a focus on currently available drugs and the underlying biological processes involved. We explored whether currently available T2-targeting drugs can reasonably be seen as potential players not only for relapse prevention but also as candidate drugs for a faster resolution of such episodes. The patient&apos;s perspective was also sought. RESULTS: About 30% of asthma exacerbations admitted to the ICU do not resolve within five days. Persistent severe airway obstruction despite massive doses of corticosteroids and maximal pharmacologically induced bronchodilation is the main cause of treatment failure. Previous ICU admission is the main risk factor for such episodes and may eventually be considered as a T2 surrogate marker. Fatal asthma cases are hallmarked by poorly steroid-sensitive T2-inflammation associated with severe mucus plugging. New, fast-acting T2-targeting biologics (already used for preventing asthma exacerbations) have the potential to circumvent steroid sensitivity pathways and decrease mucus plugging. This unmet need was confirmed by patients who reported highly negative, traumatizing experiences. CONCLUSIONS: There is room for improvement in the management of ICU-admitted severe asthma episodes. Clinical trials assessing how biologics might improve ICU outcomes are direly needed.</style></abstract><notes><style face="normal" font="default" size="100%">Bourdin, Arnaud&#xD;Charriot, Jeremy&#xD;Boissin, Clement&#xD;Ahmed, Engi&#xD;Suehs, Carey&#xD;De Sevin, Arthur&#xD;Volpato, Mathilde&#xD;Pahus, Laurie&#xD;Gras, Delphine&#xD;Vachier, Isabelle&#xD;Halimi, Laurence&#xD;Hamerlijnck, Dominic&#xD;Chanez, Pascal&#xD;eng&#xD;Denmark&#xD;Allergy. 2021 Aug;76(8):2395-2406. doi: 10.1111/all.14688. Epub 2020 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33283296</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14688</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>965</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">965</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pawankar, R.</style></author><author><style face="normal" font="default" size="100%">Castells, M.</style></author><author><style face="normal" font="default" size="100%">Akdis, M.</style></author><author><style face="normal" font="default" size="100%">Nadeau, K.</style></author><author><style face="normal" font="default" size="100%">Leung, A. S. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Div of Allergy, Dept. of Pediatrics, Nippon Medical School, Tokyo, Japan.&#xD;Drug Hypersensitivity Desensitization Center, Brigham &amp; Women&apos;s Hospital, Boston, MA, USA.&#xD;Dept. of Medicine, Harvard Medical School, Boston, MA, USA.&#xD;Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.&#xD;Sean. N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA, USA.&#xD;Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Women in science and medicine</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3578-3580</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2021/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34047393</style></accession-num><notes><style face="normal" font="default" size="100%">Pawankar, Ruby&#xD;Castells, Mariana&#xD;Akdis, Mubeccel&#xD;Nadeau, Kari&#xD;Leung, Agnes Sze Yin&#xD;eng&#xD;Editorial&#xD;Denmark&#xD;Allergy. 2021 Dec;76(12):3578-3580. doi: 10.1111/all.14967.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34047393</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14967</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1542</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1542</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Delgado-Dolset, M. I.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Coira, J.</style></author><author><style face="normal" font="default" size="100%">Sanchez-Solares, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Instituto de Medicina Molecular Aplicada (IMMA), Departamento de Ciencias Medicas Basicas, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Word of mouth: Oral mucosa composition in health and immune disease</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1641-1643</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2022/01/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immune System Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*Mouth Mucosa</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35030265</style></accession-num><abstract><style face="normal" font="default" size="100%">Abstract -</style></abstract><notes><style face="normal" font="default" size="100%">Delgado-Dolset, Maria Isabel&#xD;Rodriguez-Coira, Juan&#xD;Sanchez-Solares, Javier&#xD;eng&#xD;News&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2022 May;77(5):1641-1643. doi: 10.1111/all.15219. Epub 2022 Jan 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35030265</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.15219</style></electronic-resource-num></record><record><database name="My EndNote Library-April 2026.enl" path="C:\Users\Work account\Desktop\My EndNote Library-April 2026.enl">My EndNote Library-April 2026.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1564</rec-number><foreign-keys><key app="EN" db-id="srpsap5w60zzxhesx0oxrxdh92sxrp5zsxev">1564</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">de Las Vecillas, L.</style></author><author><style face="normal" font="default" size="100%">Eguiluz-Gracia, I.</style></author><author><style face="normal" font="default" size="100%">Giovannini, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Allergy Department, Marques de Valdecilla University Hospital-Instituto de Investigacion Marques de Valdecilla (IDIVAL), Santander, Spain.&#xD;Allergy Unit, ARADyAL, IBIMA-Hospital Regional Universitario de Malaga-UMA, Malaga, Spain.&#xD;Allergy Unit, Department of Pediatrics, Meyer Children&apos;s University Hospital, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">You might owe your mother more than you think</style></title><secondary-title><style face="normal" font="default" size="100%">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3236-3237</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2021/04/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mothers</style></keyword><keyword><style face="normal" font="default" size="100%">IgE</style></keyword><keyword><style face="normal" font="default" size="100%">mast cells</style></keyword><keyword><style face="normal" font="default" size="100%">protection</style></keyword><keyword><style face="normal" font="default" size="100%">toxin hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">transplacental transfer</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1398-9995 (Electronic)&#xD;0105-4538 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33840097</style></accession-num><notes><style face="normal" font="default" size="100%">de Las Vecillas, Leticia&#xD;Eguiluz-Gracia, Ibon&#xD;Giovannini, Mattia&#xD;eng&#xD;Comment&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Denmark&#xD;Allergy. 2021 Oct;76(10):3236-3237. doi: 10.1111/all.14855. Epub 2021 Apr 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33840097</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/all.14855</style></electronic-resource-num></record></records></xml>